Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
LIHC	cis	rs11718455	0.591	rs6765212	chr3:43931484	C/T	cg08738300	chr3:44038990	NA	0.37	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.92	-0.3	7.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg03934865	chr2:198174659	NA	0.43	6.09	0.31	3.01e-9	Intracranial aneurysm;
LIHC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00152838	chr16:24741724	TNRC6A	0.46	6.45	0.33	3.78e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.54	9.36	0.45	1.08e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.11e-35	White blood cell count (basophil);
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.14e-11	Alzheimer's disease;
LIHC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.4	7.24	0.36	2.96e-12	Psoriasis;
LIHC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.5	9.03	0.44	1.25e-17	Height;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.58	-8.31	-0.41	2.24e-15	Lymphocyte counts;
LIHC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.32	-8.54	-0.42	4.48e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3112357	1.000	rs3112355	chr7:135394680	C/T	cg20392616	chr7:135392013	SLC13A4	0.39	6.53	0.33	2.38e-10	Plantar warts;
LIHC	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14154082	chr13:112174009	NA	0.29	6.21	0.32	1.52e-9	Menarche (age at onset);
LIHC	cis	rs6466055	0.720	rs1204066	chr7:104971987	G/T	cg04380332	chr7:105027541	SRPK2	0.38	7.28	0.37	2.26e-12	Schizophrenia;
LIHC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	6.04	0.31	4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.15	-0.55	1.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.68	-0.42	1.69e-16	Lymphocyte counts;
LIHC	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	0.95	12.16	0.55	1.6e-28	Economic and political preferences (immigration/crime);
LIHC	cis	rs1165668	1.000	rs1165668	chr12:104317996	G/A	cg21863207	chr12:104234989	NT5DC3	0.39	6.2	0.32	1.62e-9	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.14	-0.36	5.64e-12	Renal cell carcinoma;
LIHC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.53	-9.28	-0.45	1.93e-18	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.79	0.34	4.99e-11	Breast cancer;
LIHC	cis	rs713477	0.678	rs4901566	chr14:55912663	C/A	cg13175173	chr14:55914753	NA	-0.29	-6.6	-0.34	1.53e-10	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.68	13.4	0.59	3.38e-33	High light scatter reticulocyte count;
LIHC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.69	-7.72	-0.39	1.27e-13	Neuroticism;
LIHC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.57	8.75	0.43	1.01e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg18357645	chr12:58087776	OS9	-0.45	-6.97	-0.35	1.61e-11	Multiple sclerosis;
LIHC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg18357645	chr12:58087776	OS9	-0.48	-7.24	-0.36	3.08e-12	Multiple sclerosis;
LIHC	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.73	10.24	0.48	1.2e-21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.39	-0.49	3.79e-22	Chronic sinus infection;
LIHC	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.34	-0.32	7.31e-10	Height;
LIHC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.28	0.37	2.35e-12	Vitiligo;
LIHC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.78	12.96	0.57	1.55e-31	Anterior chamber depth;
LIHC	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg03037974	chr15:76606532	NA	-0.63	-10.95	-0.51	4.07e-24	Blood metabolite levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02594498	chr15:22893147	CYFIP1	-0.38	-6.12	-0.31	2.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg23435118	chr5:141488016	NDFIP1	-0.44	-6.12	-0.31	2.61e-9	Crohn's disease;
LIHC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.49	-7.53	-0.38	4.48e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs12464559	0.522	rs11676866	chr2:152628858	G/C	cg01189475	chr2:152685088	ARL5A	0.72	9.21	0.45	3.27e-18	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg00035636	chr13:21900591	NA	0.37	6.05	0.31	3.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg16434002	chr17:42200994	HDAC5	0.55	7.96	0.4	2.49e-14	Total body bone mineral density;
LIHC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.65	12.85	0.57	4.28e-31	Schizophrenia;
LIHC	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.9	12.67	0.57	2.05e-30	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-12.13	-0.55	2.17e-28	Type 2 diabetes;
LIHC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.36	-0.37	1.35e-12	Bipolar disorder;
LIHC	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.8	-0.35	4.61e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.29	-6.65	-0.34	1.15e-10	Menarche (age at onset);
LIHC	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.42	6.39	0.33	5.44e-10	Alzheimer's disease (survival time);
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.69	9.44	0.45	6.05e-19	Aortic root size;
LIHC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs9918079	0.560	rs4698409	chr4:15659766	G/A	cg04067612	chr4:15429572	C1QTNF7	-0.27	-5.76	-0.3	1.88e-8	Obesity-related traits;
LIHC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.33	0.58	6.18e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.53	-8.05	-0.4	1.36e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.52	0.53	3.59e-26	Monocyte percentage of white cells;
LIHC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.65	8.95	0.44	2.24e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg18306943	chr3:40428807	ENTPD3	0.39	6.51	0.33	2.63e-10	Renal cell carcinoma;
LIHC	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21659725	chr3:3221576	CRBN	0.56	8.16	0.4	6.32e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg08888203	chr3:10149979	C3orf24	0.54	6.67	0.34	1.04e-10	Alzheimer's disease;
LIHC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.42	-5.96	-0.31	6.43e-9	Dental caries;
LIHC	cis	rs12765878	0.675	rs3752946	chr10:105670849	A/T	cg11005552	chr10:105648138	OBFC1	0.38	6.0	0.31	5.1e-9	Coronary artery disease;
LIHC	cis	rs3790844	0.876	rs3790845	chr1:200006861	C/T	cg07208853	chr1:200005219	NR5A2	0.42	9.12	0.44	6.64e-18	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg24069376	chr3:38537580	EXOG	0.42	7.72	0.39	1.3e-13	Electrocardiographic conduction measures;
LIHC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.6	-0.56	3.51e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4586057	0.514	rs7896973	chr10:92650797	A/G	cg14313238	chr10:92632228	RPP30	0.37	6.22	0.32	1.48e-9	Economic and political preferences (time);
LIHC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.39	5.86	0.3	1.09e-8	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.85	0.3	1.14e-8	Aortic root size;
LIHC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg05555928	chr11:63887634	MACROD1	0.56	7.4	0.37	1.08e-12	Mean platelet volume;
LIHC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.47	-7.68	-0.38	1.68e-13	Menarche (age at onset);
LIHC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.56	-16.35	-0.66	8.71e-45	Breast cancer;
LIHC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg04083430	chr16:4736063	MGRN1	0.43	5.88	0.3	9.8e-9	Schizophrenia;
LIHC	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.39	-5.78	-0.3	1.67e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.17	-0.44	4.56e-18	Bipolar disorder;
LIHC	cis	rs11991744	0.681	rs11784192	chr8:124664167	T/C	cg22342100	chr8:124666123	KLHL38	-0.39	-6.19	-0.32	1.74e-9	Electrocardiographic traits;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.44	8.17	0.4	6.08e-15	Prudent dietary pattern;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-0.53	-7.69	-0.38	1.56e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-10.33	-0.49	5.79e-22	Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03150409	chr4:1892317	WHSC1	-0.63	-8.87	-0.43	4.02e-17	Lung function (FEV1/FVC);
LIHC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02251663	chr11:14281053	SPON1	0.46	6.34	0.32	7.34e-10	Mitochondrial DNA levels;
LIHC	cis	rs11212737	0.714	rs2640768	chr11:108520632	C/A	cg22776369	chr11:108536276	DDX10	0.38	6.21	0.32	1.56e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg21373526	chr11:82782794	RAB30	0.4	6.65	0.34	1.15e-10	Longevity;
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.58	8.55	0.42	4.15e-16	Obesity-related traits;
LIHC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02985541	chr2:219472218	PLCD4	0.43	7.82	0.39	6.76e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-7.57	-0.38	3.58e-13	Breast cancer;
LIHC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.65	9.85	0.47	2.63e-20	Testicular germ cell tumor;
LIHC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-0.73	-10.44	-0.49	2.5e-22	White blood cell count;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg20607798	chr8:58055168	NA	0.66	8.34	0.41	1.86e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.34e-24	Subjective well-being;
LIHC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.65	0.34	1.15e-10	Schizophrenia;
LIHC	cis	rs3770081	1.000	rs2241437	chr2:86360573	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.43	6.06	0.31	3.67e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-10.8	-0.5	1.41e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.26	-0.32	1.17e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg14671364	chr1:107599128	PRMT6	-0.45	-6.46	-0.33	3.6e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.4	6.36	0.33	6.58e-10	Red blood cell count;
LIHC	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg10820045	chr2:198174542	NA	0.56	9.11	0.44	7.29e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12463550	chr7:65579703	CRCP	0.59	5.93	0.31	7.32e-9	Diabetic kidney disease;
LIHC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.44	0.37	8.01e-13	Glycated hemoglobin levels;
LIHC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg22676075	chr6:135203613	NA	0.38	6.24	0.32	1.32e-9	Red blood cell count;
LIHC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.59	-8.47	-0.42	7.29e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg05110241	chr16:68378359	PRMT7	-0.63	-6.85	-0.35	3.34e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02290350	chr8:58132656	NA	0.5	10.22	0.48	1.43e-21	Developmental language disorder (linguistic errors);
LIHC	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-7.99	-0.4	2.15e-14	Vitamin D levels;
LIHC	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.67	12.22	0.55	1.01e-28	Obesity-related traits;
LIHC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.54	-0.38	4.32e-13	Chronic sinus infection;
LIHC	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	9.49	0.46	4.07e-19	Morning vs. evening chronotype;
LIHC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.12	-0.44	6.77e-18	Bipolar disorder;
LIHC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg16586182	chr3:47516702	SCAP	-0.54	-9.83	-0.47	2.93e-20	Colorectal cancer;
LIHC	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.9	-0.39	3.79e-14	Vitamin D levels;
LIHC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.34	5.89	0.3	9.04e-9	Body mass index;
LIHC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.33	-6.15	-0.32	2.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.04	21.33	0.76	8.26e-65	Schizophrenia;
LIHC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.75	6.32	0.32	8.16e-10	Type 2 diabetes;
LIHC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	7.23	0.36	3.11e-12	Platelet count;
LIHC	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.63	-8.75	-0.43	9.67e-17	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.41	-6.18	-0.32	1.85e-9	Height;
LIHC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg25039879	chr17:56429692	SUPT4H1	0.77	9.0	0.44	1.63e-17	Cognitive test performance;
LIHC	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg26138937	chr11:71823887	C11orf51	1.1	9.53	0.46	2.92e-19	Severe influenza A (H1N1) infection;
LIHC	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.46	-7.12	-0.36	6.57e-12	Waist circumference;Body mass index;
LIHC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg23485639	chr6:28045615	ZNF165	0.38	5.8	0.3	1.47e-8	Cardiac Troponin-T levels;
LIHC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg14450231	chr5:172199425	DUSP1	0.4	6.06	0.31	3.53e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14395634	chr11:65626208	CFL1	0.42	6.04	0.31	4.04e-9	Cognitive function;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.42	8.51	0.42	5.4e-16	Renal cell carcinoma;
LIHC	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.62	-9.54	-0.46	2.88e-19	Obesity-related traits;
LIHC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg13468214	chr4:1046988	NA	-0.36	-6.68	-0.34	9.75e-11	Recombination rate (males);
LIHC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.58	-7.56	-0.38	3.86e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.93	10.72	0.5	2.51e-23	Triglycerides;
LIHC	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.58	7.79	0.39	8.18e-14	Economic and political preferences (feminism/equality);
LIHC	trans	rs4644158	1.000	rs4644158	chr7:101536726	G/T	cg09627607	chr7:23028562	FAM126A	0.59	6.23	0.32	1.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.52	-8.63	-0.42	2.3e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg10932868	chr11:921992	NA	0.31	5.8	0.3	1.52e-8	Alzheimer's disease (late onset);
LIHC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.37	5.94	0.31	7.05e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg01864836	chr14:55583639	NA	-0.43	-8.46	-0.42	7.86e-16	Protein biomarker;
LIHC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.96	12.33	0.55	3.75e-29	Bladder cancer;
LIHC	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg04610667	chr7:75704037	NA	-0.32	-5.97	-0.31	5.9e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.81	13.56	0.59	7.91e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.76	11.4	0.52	1.02e-25	Subjective well-being;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.37	6.11	0.31	2.66e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg03037974	chr15:76606532	NA	0.79	15.99	0.65	2.33e-43	Blood metabolite levels;
LIHC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-7.19	-0.36	4.06e-12	Vitiligo;
LIHC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.04	0.31	3.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg20587970	chr11:113659929	NA	-0.58	-6.64	-0.34	1.26e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.25	6.54	0.33	2.18e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs11229555	0.609	rs7927730	chr11:58187906	G/A	cg15696309	chr11:58395628	NA	-0.64	-7.47	-0.37	6.57e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.93	-12.67	-0.57	2.02e-30	Post bronchodilator FEV1;
LIHC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg08392591	chr16:89556376	ANKRD11	0.4	5.99	0.31	5.31e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.59	-5.71	-0.3	2.43e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs8056893	0.885	rs7199750	chr16:68351859	C/G	cg02226672	chr16:68398533	SMPD3	0.41	5.87	0.3	1.02e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.4	6.41	0.33	4.74e-10	Red blood cell count;
LIHC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-9.76	-0.47	5.02e-20	Asthma;
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.45	-7.25	-0.37	2.77e-12	Testicular germ cell tumor;
LIHC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.51	-7.56	-0.38	3.67e-13	Total body bone mineral density;
LIHC	cis	rs12101261	1.000	rs12101261	chr14:81451229	C/T	cg06600135	chr14:81408086	NA	0.36	6.05	0.31	3.83e-9	Graves' disease;
LIHC	cis	rs9503598	0.644	rs9503593	chr6:3430787	T/C	cg00476032	chr6:3446245	SLC22A23	0.34	6.44	0.33	4.13e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.51	8.13	0.4	7.84e-15	Testicular germ cell tumor;
LIHC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.46	-7.84	-0.39	5.97e-14	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.49	-0.59	1.55e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.66	11.79	0.54	3.63e-27	High light scatter reticulocyte count;
LIHC	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.26	-6.56	-0.33	1.96e-10	Mean corpuscular volume;
LIHC	cis	rs1494950	1.000	rs2643082	chr4:14995227	C/T	cg12377275	chr4:15005593	CPEB2	-0.79	-6.68	-0.34	9.6e-11	Political ideology;
LIHC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg06238570	chr21:40685208	BRWD1	0.59	7.03	0.36	1.12e-11	Cognitive function;
LIHC	cis	rs17152411	0.895	rs61872119	chr10:126583534	A/G	cg07906193	chr10:126599966	NA	0.43	6.94	0.35	1.93e-11	Height;
LIHC	trans	rs1814175	0.571	rs12294066	chr11:49738287	C/T	cg03929089	chr4:120376271	NA	-0.86	-16.84	-0.67	9.09e-47	Height;
LIHC	cis	rs7116495	1.000	rs675185	chr11:71775572	T/G	cg26138937	chr11:71823887	C11orf51	-0.79	-7.81	-0.39	6.89e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.37	-5.89	-0.3	9.22e-9	Mortality in heart failure;
LIHC	trans	rs6600671	1.000	rs1986111	chr1:121204788	C/T	cg09829573	chr1:144692074	NBPF9	-0.41	-7.33	-0.37	1.72e-12	Hip geometry;
LIHC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.48	-6.93	-0.35	2.08e-11	Ulcerative colitis;
LIHC	cis	rs17021463	0.673	rs1426566	chr4:95292086	T/G	cg11021082	chr4:95130006	SMARCAD1	0.44	7.59	0.38	3e-13	Testicular germ cell tumor;
LIHC	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.72	-13.47	-0.59	1.86e-33	Mean platelet volume;
LIHC	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg25182066	chr10:30743637	MAP3K8	0.43	7.02	0.36	1.18e-11	Inflammatory bowel disease;
LIHC	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.18	0.52	5.88e-25	Lung cancer in ever smokers;
LIHC	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg00792783	chr2:198669748	PLCL1	-0.43	-6.26	-0.32	1.15e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.47	7.18	0.36	4.5e-12	Triglyceride levels;
LIHC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.16	0.36	4.97e-12	Lung cancer in ever smokers;
LIHC	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg22842854	chr12:123319900	HIP1R	-0.65	-8.57	-0.42	3.5e-16	Schizophrenia;
LIHC	cis	rs4834770	1.000	rs878374	chr4:120237564	A/G	cg09307838	chr4:120376055	NA	0.42	6.24	0.32	1.33e-9	Blood protein levels;
LIHC	cis	rs3106136	0.678	rs28437833	chr4:95280510	A/T	cg11021082	chr4:95130006	SMARCAD1	0.34	5.87	0.3	1.04e-8	Capecitabine sensitivity;
LIHC	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg16586182	chr3:47516702	SCAP	0.51	8.95	0.44	2.33e-17	Colorectal cancer;
LIHC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.77	-10.93	-0.51	4.88e-24	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.5	7.42	0.37	9.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.66	11.19	0.52	5.49e-25	Diisocyanate-induced asthma;
LIHC	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.31	7.01	0.35	1.29e-11	Corneal astigmatism;
LIHC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.34	8.91	0.43	3.02e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.59	-0.38	3.1400000000000003e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.61e-14	Prudent dietary pattern;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg02993280	chr1:107599747	PRMT6	0.62	9.22	0.45	3.22e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	1.05	21.54	0.76	1.19e-65	Breast cancer;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.8	-0.35	4.62e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.27	-0.45	2.09e-18	Bipolar disorder;
LIHC	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.68	7.91	0.39	3.55e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg15448220	chr1:150897856	SETDB1	0.43	6.74	0.34	6.71e-11	Tonsillectomy;
LIHC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.63	12.23	0.55	8.81e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.48	-7.08	-0.36	8.05e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.68	-7.31	-0.37	1.89e-12	Schizophrenia;
LIHC	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	6.97	0.35	1.68e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg03037974	chr15:76606532	NA	-0.63	-11.06	-0.51	1.65e-24	Blood metabolite levels;
LIHC	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg26536354	chr8:144654954	C8orf73	0.56	6.1	0.31	2.91e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-10.42	-0.49	3.03e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.76	0.34	5.8e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.81	11.99	0.54	6.6e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs1814175	0.645	rs10769605	chr11:49713723	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-20.66	-0.75	4.12e-62	Height;
LIHC	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.4	6.01	0.31	4.72e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.71	0.5	2.81e-23	Alzheimer's disease;
LIHC	cis	rs4934494	0.681	rs34591435	chr10:91481448	A/G	cg19698084	chr10:91461284	KIF20B	-0.47	-6.35	-0.32	6.84e-10	Red blood cell count;
LIHC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.5	-8.24	-0.41	3.83e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.51	-6.95	-0.35	1.87e-11	Aortic root size;
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.6	0.53	1.85e-26	Alzheimer's disease;
LIHC	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.49	9.46	0.46	5.24e-19	Testicular germ cell tumor;
LIHC	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg13753209	chr17:57696993	CLTC	0.76	12.15	0.55	1.75e-28	Hemoglobin concentration;
LIHC	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.68	11.21	0.52	4.66e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.31	-7.04	-0.36	1.05e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6087685	1.000	rs10747514	chr20:33775369	G/A	cg08999081	chr20:33150536	PIGU	0.39	5.71	0.3	2.42e-8	Venous thromboembolism;
LIHC	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.56	-0.38	3.66e-13	Tuberculosis;
LIHC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.51	7.96	0.4	2.48e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.46	7.32	0.37	1.8e-12	Mortality in heart failure;
LIHC	cis	rs847649	0.621	rs2222539	chr7:102674786	G/A	cg18108683	chr7:102477205	FBXL13	0.39	5.9	0.3	8.63e-9	Morning vs. evening chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14450231	chr5:172199425	DUSP1	0.47	6.71	0.34	8.31e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.77	13.18	0.58	2.42e-32	Anterior chamber depth;
LIHC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.33	-0.41	1.98e-15	Bladder cancer;
LIHC	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.82	-13.54	-0.59	9.4e-34	Morning vs. evening chronotype;
LIHC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg25894440	chr7:65020034	NA	-0.53	-6.04	-0.31	4.05e-9	Diabetic kidney disease;
LIHC	trans	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.43	0.33	4.19e-10	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01198024	chr21:33672713	MRAP	-0.45	-6.11	-0.31	2.78e-9	Lung function (FEV1/FVC);
LIHC	cis	rs831571	0.955	rs35837	chr3:64013249	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.56	-6.96	-0.35	1.8e-11	Type 2 diabetes;
LIHC	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.54	8.51	0.42	5.7e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.44	0.37	8.26e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14318942	chr4:114683204	CAMK2D	0.45	6.25	0.32	1.21e-9	Migraine with aura;
LIHC	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-9.34	-0.45	1.27e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.39	-5.91	-0.3	8.37e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.71	0.38	1.37e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.5	8.92	0.43	2.84e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.43	-9.22	-0.45	3.04e-18	Rheumatoid arthritis;
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	10.19	0.48	1.78e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.48	-5.86	-0.3	1.09e-8	Parkinson's disease;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg03721293	chr16:90014378	DEF8	0.36	6.25	0.32	1.19e-9	Skin colour saturation;
LIHC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.77	0.3	1.82e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9948	1.000	rs62152793	chr2:97484948	C/T	cg01990225	chr2:97406019	LMAN2L	-0.66	-6.24	-0.32	1.32e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg04317338	chr11:64019027	PLCB3	0.49	6.74	0.34	6.73e-11	Platelet count;
LIHC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.64	-12.06	-0.55	3.91e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.4	6.52	0.33	2.52e-10	Mean corpuscular volume;
LIHC	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	0.94	17.06	0.68	1.14e-47	Coronary artery disease;
LIHC	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.02	-0.35	1.2e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.84	-16.28	-0.66	1.57e-44	Coronary artery disease;
LIHC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.52	8.54	0.42	4.54e-16	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg03929089	chr4:120376271	NA	-0.4	-6.09	-0.31	3.02e-9	HDL cholesterol;
LIHC	cis	rs7619427	1.000	rs7624393	chr3:44066045	C/A	cg24966902	chr3:44043705	NA	0.56	7.76	0.39	9.6e-14	Schizophrenia;
LIHC	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.56	-0.5	9.76e-23	Total cholesterol levels;
LIHC	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg17130504	chr10:102756923	LZTS2	0.45	6.05	0.31	3.9e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.39	6.17	0.32	1.96e-9	Testicular germ cell tumor;
LIHC	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.42e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.56	-0.73	1.06e-57	Coronary artery disease;
LIHC	cis	rs10503871	0.690	rs7812836	chr8:30352258	A/G	cg26383811	chr8:30366931	RBPMS	-0.39	-6.98	-0.35	1.52e-11	Metabolite levels  (X-11787);
LIHC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	10.89	0.51	6.48e-24	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.34	8.44	0.42	9.13e-16	Weight;
LIHC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs17106184	0.892	rs59318346	chr1:51190932	C/A	cg07174182	chr1:51127561	FAF1	-0.64	-7.3	-0.37	2.04e-12	Type 2 diabetes;
LIHC	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.65	12.72	0.57	1.24e-30	Endometriosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16978263	chr3:160118452	SMC4;IFT80	0.49	7.28	0.37	2.37e-12	Cognitive function;
LIHC	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg05623727	chr3:50126028	RBM5	0.35	5.88	0.3	9.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg10127483	chr1:110009974	SYPL2	0.5	6.23	0.32	1.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.49	9.3	0.45	1.74e-18	Testicular germ cell tumor;
LIHC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.39	-6.03	-0.31	4.21e-9	Mortality in heart failure;
LIHC	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.55	-6.14	-0.31	2.34e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.6	0.34	1.56e-10	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg16822855	chr3:40428330	ENTPD3	0.35	6.4	0.33	4.99e-10	Renal cell carcinoma;
LIHC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.32	-0.32	8.31e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.54	-8.34	-0.41	1.86e-15	Height;
LIHC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.44	0.53	7.27e-26	Motion sickness;
LIHC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.67	-0.34	1.01e-10	Hepatocellular carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02132458	chr4:57333267	SRP72	0.5	6.61	0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.32	6.26	0.32	1.14e-9	Monocyte count;
LIHC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21467203	chr3:49911342	NA	0.4	6.88	0.35	2.83e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11671005	0.572	rs11669127	chr19:59003830	A/G	cg25952890	chr19:58913133	NA	-0.65	-6.45	-0.33	3.91e-10	Mean platelet volume;
LIHC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	trans	rs1814175	0.571	rs12294066	chr11:49738287	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.59	-0.74	7.56e-62	Height;
LIHC	cis	rs77861329	1.000	rs9841469	chr3:52166596	C/A	cg08692210	chr3:52188851	WDR51A	0.83	7.85	0.39	5.47e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7902334	1.000	rs7902334	chr10:12645941	A/C	cg09958065	chr10:12648526	CAMK1D	-0.64	-7.46	-0.37	7.07e-13	Coronary artery aneurysm in Kawasaki disease;
LIHC	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.41	-7.3	-0.37	2e-12	Crohn's disease;
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg21486233	chr12:29375141	FAR2	0.31	6.25	0.32	1.22e-9	QT interval;
LIHC	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.2e-22	Cognitive function;
LIHC	trans	rs2359714	0.935	rs7526525	chr1:118807059	T/C	cg19861078	chr7:7936962	NA	-0.31	-6.16	-0.32	2.05e-9	Breast size;
LIHC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg12798992	chr6:167411361	FGFR1OP	0.46	7.19	0.36	4.2e-12	Crohn's disease;
LIHC	cis	rs67981189	0.593	rs8005160	chr14:71446494	G/T	cg15816911	chr14:71606274	NA	0.4	6.53	0.33	2.34e-10	Schizophrenia;
LIHC	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.4	0.33	5.23e-10	Rheumatoid arthritis;
LIHC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.44	6.6	0.34	1.59e-10	Personality dimensions;
LIHC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.29	-0.68	1.4e-48	Body mass index;
LIHC	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-6.19	-0.32	1.7e-9	Coronary artery disease;
LIHC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.37	5.98	0.31	5.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.86	-13.19	-0.58	2.1e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg11091909	chr13:33640726	NA	-0.33	-6.06	-0.31	3.61e-9	Coronary artery disease;
LIHC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.75	11.22	0.52	4.42e-25	Obesity-related traits;
LIHC	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.58	9.49	0.46	3.93e-19	Corneal astigmatism;
LIHC	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.77	0.34	5.6e-11	Ileal carcinoids;
LIHC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs11955398	0.625	rs11745077	chr5:59955716	C/T	cg02684056	chr5:59996105	DEPDC1B	0.42	5.92	0.3	7.97e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	1.02	17.85	0.69	7.7e-51	Monocyte percentage of white cells;
LIHC	cis	rs7095607	0.606	rs7913133	chr10:69961470	A/G	cg18986048	chr10:69913749	MYPN	0.39	5.92	0.31	7.67e-9	Lung function (FVC);
LIHC	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.69	15.31	0.64	1.13e-40	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06825153	chr1:90287453	LRRC8D	-0.45	-6.36	-0.33	6.44e-10	Pancreatic cancer;
LIHC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.57	0.59	7.69e-34	Lung cancer in ever smokers;
LIHC	cis	rs903552	0.932	rs1587108	chr15:102006825	G/A	cg19295451	chr15:102010161	PCSK6	-0.48	-6.64	-0.34	1.26e-10	Diabetic kidney disease;
LIHC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.43	6.17	0.32	1.95e-9	Longevity;Endometriosis;
LIHC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.74	-0.34	6.65e-11	Psoriasis;
LIHC	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.51	8.04	0.4	1.51e-14	HDL cholesterol;
LIHC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.84	-0.39	5.95e-14	Gut microbiome composition (summer);
LIHC	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.03	21.04	0.75	1.16e-63	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.4e-30	Menopause (age at onset);
LIHC	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.92	0.51	5.31e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	8.76	0.43	9.08e-17	Height;
LIHC	trans	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.5	0.33	2.88e-10	Endometrial cancer;
LIHC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23640757	chr6:7889014	TXNDC5	-0.45	-7.15	-0.36	5.41e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg16970926	chr12:29381810	FAR2	0.27	5.72	0.3	2.33e-8	QT interval;
LIHC	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	1.13	8.79	0.43	7.28e-17	Arsenic metabolism;
LIHC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.88	14.75	0.62	1.82e-38	Schizophrenia;
LIHC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-1.09	-17.39	-0.69	5.58e-49	Urate levels;
LIHC	trans	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg21139485	chr7:99987584	PILRA	-0.27	-6.06	-0.31	3.5e-9	Body mass index;
LIHC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.27	-7.11	-0.36	6.9e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg26031613	chr14:104095156	KLC1	0.79	9.69	0.46	9.14e-20	Body mass index;
LIHC	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.75	9.82	0.47	3.15e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.71	-12.66	-0.56	2.19e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.01	20.59	0.74	7.45e-62	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.68	13.23	0.58	1.46e-32	High light scatter reticulocyte count;
LIHC	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg23250157	chr14:64679961	SYNE2	0.4	5.92	0.3	8.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.46	-6.77	-0.34	5.63e-11	Corneal structure;
LIHC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.6	7.84	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10733682	0.659	rs3861879	chr9:129464856	A/G	cg00232160	chr9:129468157	NA	0.35	6.28	0.32	1.06e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg01843034	chr6:37503916	NA	0.42	6.67	0.34	1.02e-10	Cognitive performance;
LIHC	trans	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.11e-31	Sense of smell;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23808061	chr1:179923593	CEP350	0.45	6.44	0.33	4e-10	Pancreatic cancer;
LIHC	cis	rs6782228	0.565	rs67445542	chr3:128330526	T/C	cg16766828	chr3:128327626	NA	-0.41	-6.49	-0.33	3.05e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.36	-0.45	1.06e-18	Gut microbiome composition (summer);
LIHC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.75	10.01	0.48	7.28e-21	Body mass index;
LIHC	trans	rs13202860	1.000	rs35782874	chr6:87186506	G/A	cg27326224	chr7:950474	ADAP1	-0.57	-6.32	-0.32	8.05e-10	Sexual dysfunction (female);
LIHC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.29	0.45	1.85e-18	Platelet count;
LIHC	cis	rs1865721	0.728	rs7232269	chr18:73219023	G/A	cg26385618	chr18:73139727	C18orf62	-0.27	-6.98	-0.35	1.54e-11	Intelligence;
LIHC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.5	7.92	0.39	3.44e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.82	7.21	0.36	3.57e-12	Uric acid levels;
LIHC	trans	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	6.88	0.35	2.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.51	-0.38	5.16e-13	Morning vs. evening chronotype;
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg06951627	chr6:26196580	NA	0.55	6.43	0.33	4.39e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.34	-0.41	1.79e-15	Body mass index (adult);
LIHC	trans	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg10756647	chr7:56101905	PSPH	1.02	11.74	0.54	5.57e-27	Diabetic kidney disease;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.64	7.89	0.39	4.03e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs918629	0.798	rs7724599	chr5:95323378	T/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.29	-0.32	9.51e-10	IgG glycosylation;
LIHC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.58	-10.77	-0.5	1.8e-23	Vitamin D levels;
LIHC	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.53	8.35	0.41	1.66e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10570662	chr22:19159548	NA	-0.44	-6.15	-0.32	2.15e-9	Triglycerides;
LIHC	cis	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg01231543	chr16:68741748	NA	0.39	5.77	0.3	1.76e-8	Colorectal cancer;
LIHC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.48	6.98	0.35	1.59e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.39	6.57	0.33	1.83e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.41	-0.33	4.74e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.97	13.54	0.59	9.77e-34	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg10411590	chr13:21900810	NA	0.45	7.49	0.38	5.9e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.56	-8.8	-0.43	6.69e-17	Waist circumference;Body mass index;
LIHC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21467203	chr3:49911342	NA	-0.45	-7.81	-0.39	6.94e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.62	9.57	0.46	2.17e-19	Longevity;Endometriosis;
LIHC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.03e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg08345082	chr10:99160200	RRP12	-0.37	-6.11	-0.31	2.67e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg12751644	chr20:60527061	NA	-0.36	-5.99	-0.31	5.41e-9	Body mass index;
LIHC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.03e-19	Hemoglobin concentration;
LIHC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26897989	chr16:1907736	C16orf73	-0.5	-6.18	-0.32	1.84e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.17	-30.11	-0.85	3.42e-98	IgG glycosylation;
LIHC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.51	0.56	7.82e-30	Total body bone mineral density;
LIHC	cis	rs3981351	0.797	rs61866462	chr10:115464690	C/T	cg24846397	chr10:115438155	CASP7	-0.46	-7.13	-0.36	5.84e-12	Obesity-related traits;
LIHC	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	6.57	0.33	1.89e-10	Response to antipsychotic treatment;
LIHC	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.98	0.47	9.69e-21	Corneal astigmatism;
LIHC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg05973401	chr12:123451056	ABCB9	0.41	6.3	0.32	9.22e-10	Platelet count;
LIHC	trans	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.93	-0.35	2.05e-11	Aortic root size;
LIHC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.57	10.15	0.48	2.44e-21	Height;
LIHC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25046584	chr21:32932016	TIAM1	0.33	6.04	0.31	4.02e-9	Cognitive function;
LIHC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg03146154	chr1:46216737	IPP	0.46	7.39	0.37	1.11e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.41	-6.73	-0.34	7.09e-11	Red blood cell count;
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg00091569	chr3:40428383	ENTPD3	0.4	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	cis	rs2422052	0.639	rs11676728	chr2:118654927	T/C	cg22545206	chr2:118617499	NA	0.38	6.27	0.32	1.07e-9	Mosquito bite size;
LIHC	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.56	-8.39	-0.41	1.31e-15	White matter hyperintensity burden;
LIHC	cis	rs6442522	0.780	rs13095978	chr3:15441110	G/T	cg16303742	chr3:15540471	COLQ	0.38	5.99	0.31	5.28e-9	Uric acid levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04145193	chr17:38083691	ORMDL3	0.48	6.62	0.34	1.4e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-8.94	-0.44	2.4e-17	Height;
LIHC	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg09572067	chr16:29127029	RRN3P2	0.51	8.14	0.4	7.53e-15	Menopause (age at onset);
LIHC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.64	0.46	1.34e-19	Bladder cancer;
LIHC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.39	-6.7	-0.34	8.42e-11	Coronary artery disease;
LIHC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg12568669	chr8:11666485	FDFT1	0.29	5.89	0.3	9.19e-9	Myopia (pathological);
LIHC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.74	-0.3	2.12e-8	Tonsillectomy;
LIHC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.28	-5.97	-0.31	6.04e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.58	6.27	0.32	1.07e-9	Gut microbiome composition (summer);
LIHC	trans	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg26939375	chr7:64535504	NA	0.4	6.42	0.33	4.54e-10	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04197313	chr15:67547198	IQCH;AAGAB	-0.51	-6.97	-0.35	1.64e-11	Pancreatic cancer;
LIHC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-5.94	-0.31	7.07e-9	Longevity;
LIHC	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg25364880	chr3:44379878	C3orf23	0.59	8.22	0.41	4.39e-15	Depressive symptoms;
LIHC	cis	rs6960043	0.584	rs2189724	chr7:15041822	G/A	cg19272540	chr7:15055459	NA	0.25	6.68	0.34	9.83e-11	Type 2 diabetes;
LIHC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.75	10.72	0.5	2.6e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg24693881	chr1:107596107	NA	0.53	9.31	0.45	1.54e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg25828445	chr12:7781288	NA	0.43	6.64	0.34	1.26e-10	HDL cholesterol levels;
LIHC	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg26149184	chr10:133730230	NA	0.47	7.48	0.37	6.46e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-9.73	-0.47	6.39e-20	Electroencephalogram traits;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08219700	chr8:58056026	NA	0.52	7.15	0.36	5.24e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg07424592	chr7:64974309	NA	0.72	7.46	0.37	7.2e-13	Gout;
LIHC	cis	rs10861342	0.892	rs7966106	chr12:105615272	C/G	cg23923672	chr12:105501055	KIAA1033	-0.64	-7.16	-0.36	5.1e-12	IgG glycosylation;
LIHC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.87	-0.47	2.27e-20	Chronic sinus infection;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13099829	chr1:2237991	SKI	0.43	6.22	0.32	1.47e-9	Longevity;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.94	0.39	2.89e-14	Renal cell carcinoma;
LIHC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.69	11.44	0.53	6.89e-26	Menopause (age at onset);
LIHC	trans	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg10756647	chr7:56101905	PSPH	1.12	16.83	0.67	9.77e-47	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26706201	chr11:57103334	SSRP1	0.48	6.19	0.32	1.68e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.6	10.17	0.48	2.06e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.31	7.38	0.37	1.2e-12	Corneal astigmatism;
LIHC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	1.03	13.79	0.6	1.01e-34	Body mass index;
LIHC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg20487152	chr13:99095054	FARP1	-0.39	-6.6	-0.34	1.54e-10	Longevity;
LIHC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.86	0.57	3.97e-31	Schizophrenia;
LIHC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.17	-0.36	4.75e-12	Response to antipsychotic treatment;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	11.96	0.54	8.84e-28	Prudent dietary pattern;
LIHC	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-8.44	-0.42	9.07e-16	Total cholesterol levels;
LIHC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.89	0.3	9.32e-9	Menopause (age at onset);
LIHC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-8.34	-0.41	1.9e-15	Body mass index;
LIHC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.43	-6.49	-0.33	3.06e-10	Height;
LIHC	cis	rs9871864	1.000	rs9871864	chr3:20352766	A/G	cg00235661	chr3:20228976	SGOL1	-0.31	-5.94	-0.31	6.86e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.51	0.38	5.15e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.43e-11	IgG glycosylation;
LIHC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.1	-0.31	2.81e-9	Mean corpuscular volume;
LIHC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg03037974	chr15:76606532	NA	-0.64	-11.21	-0.52	4.74e-25	Blood metabolite levels;
LIHC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.58e-13	Bone mineral density;
LIHC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.37	-6.12	-0.31	2.51e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg05267444	chr8:11627012	NEIL2	-0.48	-5.94	-0.31	6.89e-9	Monocyte count;
LIHC	cis	rs3015497	0.586	rs12587821	chr14:51092554	A/G	cg09863266	chr14:51125203	SAV1	-0.39	-6.17	-0.32	1.88e-9	Mean platelet volume;
LIHC	cis	rs4650994	0.509	rs7519794	chr1:178542390	G/T	cg05350800	chr1:178550844	NA	-0.35	-7.64	-0.38	2.26e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-7.99	-0.4	2.14e-14	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.33	-0.41	1.97e-15	Exhaled nitric oxide output;
LIHC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg18016565	chr1:150552671	MCL1	-0.52	-9.64	-0.46	1.31e-19	Tonsillectomy;
LIHC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.12	0.4	8.79e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg25214090	chr10:38739885	LOC399744	0.44	7.02	0.35	1.17e-11	Educational attainment;
LIHC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.64	-16.58	-0.67	1.01e-45	Breast cancer;
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.49	6.99	0.35	1.41e-11	Longevity;Endometriosis;
LIHC	cis	rs13394619	0.562	rs34532804	chr2:11746003	G/A	cg07314298	chr2:11723111	GREB1	0.36	6.07	0.31	3.4e-9	Endometriosis;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.55	0.53	2.81e-26	Prudent dietary pattern;
LIHC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg15691649	chr6:25882328	NA	-0.62	-8.35	-0.41	1.67e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07148452	chr15:90176987	KIF7	0.42	6.07	0.31	3.47e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	0.78	8.5	0.42	5.88e-16	Mitochondrial DNA levels;
LIHC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.51	-8.64	-0.42	2.21e-16	White blood cell count;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.71	0.38	1.37e-13	Bipolar disorder;
LIHC	cis	rs9915021	0.623	rs9890191	chr17:33964539	C/G	cg20932281	chr17:33905541	PEX12	0.6	7.43	0.37	8.53e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.31	-6.45	-0.33	3.72e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.69	12.12	0.55	2.28e-28	Iron status biomarkers;
LIHC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.32	7.86	0.39	5e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1419980	0.730	rs7137180	chr12:7745614	C/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09527731	chr5:132097228	SEPT8	0.42	6.2	0.32	1.66e-9	Pancreatic cancer;
LIHC	cis	rs11645898	0.504	rs118034653	chr16:71922944	T/C	cg03805757	chr16:71968109	PKD1L3	-0.82	-8.44	-0.42	8.93e-16	Blood protein levels;
LIHC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.76	-0.34	5.84e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.65	10.37	0.49	4.27e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.64	-5.89	-0.3	9.08e-9	Red cell distribution width;
LIHC	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg03929089	chr4:120376271	NA	-0.45	-6.8	-0.35	4.63e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.05	-0.31	3.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.69	-7.71	-0.38	1.37e-13	Exhaled nitric oxide output;
LIHC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg11764359	chr7:65958608	NA	0.58	6.12	0.31	2.54e-9	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg10755058	chr3:40428713	ENTPD3	0.41	6.89	0.35	2.77e-11	Renal cell carcinoma;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg16103275	chr6:290800	DUSP22	0.5	6.56	0.33	1.99e-10	Menopause (age at onset);
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.25	-0.32	1.25e-9	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20087917	chr14:77924039	C14orf133;AHSA1	0.44	7.56	0.38	3.8e-13	Cognitive function;
LIHC	cis	rs965469	1.000	rs1040726	chr20:3264267	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.59e-11	IFN-related cytopenia;
LIHC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.52	8.12	0.4	8.6e-15	Resting heart rate;
LIHC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.77	12.0	0.54	6.54e-28	Psoriasis;
LIHC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg08029281	chr1:67600428	NA	0.38	6.42	0.33	4.44e-10	Psoriasis;
LIHC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg18912006	chr12:123335444	HIP1R	-0.64	-7.67	-0.38	1.78e-13	Schizophrenia;
LIHC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.63	-8.65	-0.42	2.1e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg20651018	chr11:3035856	CARS	-0.35	-5.92	-0.31	7.68e-9	Longevity;
LIHC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.43	7.07	0.36	8.58e-12	Response to temozolomide;
LIHC	cis	rs1823913	1.000	rs7574570	chr2:192098516	G/A	cg12404831	chr2:192114017	MYO1B	-0.34	-6.71	-0.34	8.34e-11	Obesity-related traits;
LIHC	cis	rs425535	0.619	rs9291189	chr4:74832037	A/C	cg02530824	chr4:74847766	PF4	0.35	5.96	0.31	6.4e-9	Blood protein levels;
LIHC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.46	-7.54	-0.38	4.19e-13	Response to temozolomide;
LIHC	cis	rs965469	0.779	rs6037566	chr20:3331414	A/C	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	0.66	7.38	0.37	1.19e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg16989086	chr20:62203971	PRIC285	0.57	8.21	0.41	4.49e-15	Glioblastoma;
LIHC	cis	rs965469	0.779	rs6051785	chr20:3339199	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-6.27	-0.32	1.06e-9	IFN-related cytopenia;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.75	13.7	0.6	2.43e-34	Prudent dietary pattern;
LIHC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.78	11.79	0.54	3.65e-27	Response to antineoplastic agents;
LIHC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	10.73	0.5	2.43e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.71	11.63	0.53	1.45e-26	Night sleep phenotypes;
LIHC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.92	0.31	7.65e-9	Neuroticism;
LIHC	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.36	6.26	0.32	1.14e-9	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.63	-10.96	-0.51	3.71e-24	Breast cancer;
LIHC	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.63	-6.85	-0.35	3.46e-11	Type 2 diabetes;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01162549	chr5:141367464	RNF14	0.38	6.05	0.31	3.73e-9	Immature fraction of reticulocytes;
LIHC	trans	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-6.32	-0.32	8.06e-10	Mosquito bite size;
LIHC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.56	-9.09	-0.44	8.38e-18	Obesity-related traits;
LIHC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.45	7.66	0.38	1.95e-13	Electroencephalogram traits;
LIHC	cis	rs2637266	0.756	rs2583063	chr10:78558048	T/C	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.96e-9	Pulmonary function;
LIHC	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg12253828	chr6:101329408	ASCC3	-0.41	-6.35	-0.32	6.89e-10	Neuroticism;
LIHC	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg10978503	chr1:24200527	CNR2	-0.38	-9.0	-0.44	1.64e-17	Immature fraction of reticulocytes;
LIHC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg24209194	chr3:40518798	ZNF619	0.46	6.55	0.33	2.15e-10	Renal cell carcinoma;
LIHC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs8108269	1.000	rs10404142	chr19:46160698	C/A	cg13320842	chr19:46175254	GIPR	0.43	8.05	0.4	1.37e-14	Type 2 diabetes;
LIHC	cis	rs16912059	0.661	rs12293486	chr11:24296391	T/G	ch.11.24196551F	chr11:24239977	NA	0.8	7.64	0.38	2.21e-13	Thrombin-antithrombin complex levels in ischemic stroke;
LIHC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.33	0.41	1.98e-15	Body mass index;
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg14393609	chr7:65229607	NA	0.44	6.56	0.33	2.04e-10	Calcium levels;
LIHC	cis	rs10792665	0.671	rs4076574	chr11:82667726	C/T	cg24227371	chr11:82718527	RAB30	-0.3	-6.61	-0.34	1.49e-10	Obesity-related traits;
LIHC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.43	-7.05	-0.36	9.96e-12	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.5	-8.09	-0.4	1.05e-14	Mononucleosis;
LIHC	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.6	8.93	0.43	2.6e-17	Recombination rate (females);
LIHC	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.4	8.52	0.42	5.14e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.52e-9	Schizophrenia;
LIHC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.79	-9.86	-0.47	2.32e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.35	5.77	0.3	1.81e-8	Type 2 diabetes;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20762182	chr15:69727293	KIF23	0.42	6.44	0.33	4.09e-10	Immature fraction of reticulocytes;
LIHC	cis	rs11098699	0.750	rs1500122	chr4:124220060	A/C	cg09941581	chr4:124220074	SPATA5	0.33	6.57	0.33	1.92e-10	Mosquito bite size;
LIHC	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.61	-9.75	-0.47	5.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.07	-0.4	1.22e-14	Response to antipsychotic treatment;
LIHC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.47	7.54	0.38	4.19e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg04691961	chr3:161091175	C3orf57	-0.33	-5.71	-0.3	2.41e-8	Morning vs. evening chronotype;
LIHC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.45	7.14	0.36	5.48e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg25894440	chr7:65020034	NA	0.53	6.07	0.31	3.34e-9	Diabetic kidney disease;
LIHC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	0.96	10.0	0.48	8.24e-21	Vitiligo;
LIHC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.88	-0.3	9.58e-9	Schizophrenia;
LIHC	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.68	0.38	1.73e-13	Systemic lupus erythematosus;
LIHC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.71	12.15	0.55	1.72e-28	Menopause (age at onset);
LIHC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.41	0.49	3.08e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.54	-7.88	-0.39	4.3e-14	Total body bone mineral density;
LIHC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-6.13	-0.31	2.46e-9	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg23782820	chr8:58130467	NA	0.33	5.86	0.3	1.1e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg15691649	chr6:25882328	NA	-0.63	-8.64	-0.42	2.24e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.61e-9	Schizophrenia;
LIHC	cis	rs4934494	0.768	rs12571918	chr10:91434677	G/T	cg19698084	chr10:91461284	KIF20B	-0.49	-6.49	-0.33	2.93e-10	Red blood cell count;
LIHC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.59	6.59	0.34	1.64e-10	Axial length;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27390425	chr1:212964975	TATDN3;NSL1	-0.44	-6.39	-0.33	5.54e-10	Pancreatic cancer;
LIHC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.96	17.17	0.68	4.27e-48	Intelligence (multi-trait analysis);
LIHC	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.5	6.65	0.34	1.18e-10	Glioblastoma;Glioma;
LIHC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.64	11.56	0.53	2.49e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg14146966	chr2:61757674	XPO1	0.46	7.94	0.39	2.91e-14	Tuberculosis;
LIHC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.35	6.38	0.33	5.9e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.43	0.33	4.27e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg18898632	chr2:242989856	NA	-0.56	-7.53	-0.38	4.44e-13	Obesity-related traits;
LIHC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.37	0.52	1.29e-25	Alzheimer's disease (late onset);
LIHC	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg06096015	chr1:231504339	EGLN1	-0.45	-7.43	-0.37	8.5e-13	Red blood cell count;
LIHC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.47	7.27	0.37	2.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg04160030	chr1:24195659	FUCA1	-0.37	-6.14	-0.32	2.31e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.11	0.52	1.04e-24	Platelet count;
LIHC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.5	9.04	0.44	1.17e-17	Height;
LIHC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg13393036	chr8:95962371	TP53INP1	-0.32	-5.97	-0.31	5.91e-9	Type 2 diabetes;
LIHC	cis	rs12744310	0.887	rs34152153	chr1:41801408	T/C	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6442522	0.933	rs6442518	chr3:15422050	C/G	cg16303742	chr3:15540471	COLQ	0.35	5.82	0.3	1.38e-8	Uric acid levels;
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg05185784	chr16:90016020	DEF8	-0.48	-6.33	-0.32	7.84e-10	Skin colour saturation;
LIHC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.67	11.87	0.54	1.84e-27	Iron status biomarkers;
LIHC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg26149184	chr10:133730230	NA	0.46	7.21	0.36	3.71e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.72	10.77	0.5	1.79e-23	Corneal astigmatism;
LIHC	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	0.98	6.47	0.33	3.34e-10	Mitochondrial DNA levels;
LIHC	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg15448220	chr1:150897856	SETDB1	0.42	6.48	0.33	3.17e-10	Tonsillectomy;
LIHC	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	0.9	7.28	0.37	2.29e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.59	-8.04	-0.4	1.49e-14	Gut microbiome composition (summer);
LIHC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.64	10.6	0.5	7.06e-23	Breast cancer;
LIHC	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.93	0.51	4.56e-24	Colorectal cancer;
LIHC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-8.75	-0.43	9.75e-17	Chronic sinus infection;
LIHC	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.54	8.61	0.42	2.68e-16	Dialysis-related mortality;
LIHC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.26	-18.66	-0.71	4.38e-54	Ulcerative colitis;
LIHC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.57	10.97	0.51	3.41e-24	Coronary artery disease;
LIHC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.12	0.31	2.59e-9	Glycated hemoglobin levels;
LIHC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.41	8.2	0.41	4.95e-15	Cardiovascular disease risk factors;
LIHC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.19	13.18	0.58	2.25e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.57	11.67	0.53	1e-26	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-9.43	-0.45	6.3e-19	Initial pursuit acceleration;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.35	0.59	5.02e-33	Prudent dietary pattern;
LIHC	trans	rs10411161	0.702	rs10424202	chr19:52387297	G/A	cg22319618	chr22:45562946	NUP50	-0.61	-8.42	-0.41	1.06e-15	Breast cancer;
LIHC	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg01843034	chr6:37503916	NA	-0.46	-7.9	-0.39	3.82e-14	Cognitive performance;
LIHC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	7.24	0.36	2.92e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.92	15.43	0.64	3.78e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg08499158	chr17:42289980	UBTF	-0.48	-7.81	-0.39	7.16e-14	Total body bone mineral density;
LIHC	cis	rs7129220	0.512	rs12279871	chr11:10228196	G/A	cg01453529	chr11:10209919	SBF2	-0.43	-7.87	-0.39	4.77e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg03721293	chr16:90014378	DEF8	0.39	6.53	0.33	2.32e-10	Skin colour saturation;
LIHC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.94	15.9	0.65	5.07e-43	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.82	13.59	0.59	5.99e-34	Multiple sclerosis;
LIHC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	1.04	20.83	0.75	8.28e-63	Breast cancer;
LIHC	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg03934865	chr2:198174659	NA	0.47	7.06	0.36	9.38e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg20129853	chr10:51489980	NA	-0.39	-8.57	-0.42	3.6e-16	Prostate-specific antigen levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19550733	chr1:25869992	LDLRAP1	-0.51	-6.39	-0.33	5.56e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg25649188	chr17:73499917	CASKIN2	0.39	6.44	0.33	4.14e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs629922	0.642	rs531831	chr11:114071814	A/G	cg01914181	chr11:114070210	ZBTB16	-0.52	-7.52	-0.38	4.78e-13	Paneth cell defects in Crohn's disease;
LIHC	cis	rs17428076	0.793	rs3765167	chr2:172693944	A/G	cg13550731	chr2:172543902	DYNC1I2	0.37	6.14	0.32	2.32e-9	Myopia;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg22528358	chr1:107598549	PRMT6	-0.62	-9.51	-0.46	3.4e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.45	6.13	0.31	2.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.34	6.07	0.31	3.4e-9	Colorectal cancer;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.59	8.51	0.42	5.42e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.35	-6.52	-0.33	2.46e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.69	7.48	0.38	6.25e-13	Testicular germ cell tumor;
LIHC	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.25	12.79	0.57	6.83e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg22153463	chr1:85462885	MCOLN2	0.54	6.48	0.33	3.22e-10	Serum sulfate level;
LIHC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.4	5.77	0.3	1.76e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg07451762	chr16:28383216	NA	0.39	6.93	0.35	2.05e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg12800803	chr20:60717299	PSMA7	-0.47	-6.09	-0.31	3e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	1.07	16.1	0.66	8.42e-44	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-8.45	-0.42	8.7e-16	Height;
LIHC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.44	-7.39	-0.37	1.17e-12	Platelet distribution width;
LIHC	cis	rs11971779	0.625	rs10260850	chr7:139003602	G/T	cg07862535	chr7:139043722	LUC7L2	0.43	6.13	0.31	2.41e-9	Diisocyanate-induced asthma;
LIHC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.51	-7.72	-0.39	1.27e-13	Crohn's disease;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.73	-11.2	-0.52	5.1e-25	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.67	0.5	4.01e-23	Vitiligo;
LIHC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.51	-7.69	-0.38	1.55e-13	Total body bone mineral density;
LIHC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.46	-7.21	-0.36	3.6e-12	Insulin-like growth factors;
LIHC	trans	rs10411161	0.810	rs77082285	chr19:52387583	G/A	cg22319618	chr22:45562946	NUP50	-0.63	-7.38	-0.37	1.21e-12	Breast cancer;
LIHC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	12.35	0.56	3.24e-29	Menopause (age at onset);
LIHC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.4	6.08	0.31	3.23e-9	Childhood ear infection;
LIHC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07305463	chr2:136567211	LCT	-0.39	-7.54	-0.38	4.14e-13	Mosquito bite size;
LIHC	cis	rs7238033	0.624	rs10432193	chr18:43307072	A/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.49	0.33	3.03e-10	Bladder cancer;
LIHC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.81	10.43	0.49	2.66e-22	Resting heart rate;
LIHC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24110177	chr3:50126178	RBM5	-0.44	-6.76	-0.34	6.02e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg21395723	chr22:39101663	GTPBP1	-0.38	-6.34	-0.32	7.09e-10	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.33	0.41	2.04e-15	Renal cell carcinoma;
LIHC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.33	6.39	0.33	5.58e-10	Alcohol dependence;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg06812651	chr1:234746099	IRF2BP2	-0.44	-6.1	-0.31	2.8e-9	Alopecia areata;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01089589	chr2:10920095	ATP6V1C2	0.47	6.28	0.32	1.05e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-12.63	-0.56	2.76e-30	Primary sclerosing cholangitis;
LIHC	cis	rs57502260	0.680	rs7104806	chr11:68222188	C/T	cg16797656	chr11:68205561	LRP5	0.6	8.0	0.4	1.99e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.59	9.58	0.46	2.03e-19	Response to antidepressants and depression;
LIHC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg21466736	chr12:48725269	NA	0.33	5.95	0.31	6.81e-9	Plateletcrit;
LIHC	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.45	6.58	0.34	1.8e-10	Hepatocellular carcinoma;
LIHC	cis	rs3770081	0.590	rs60838463	chr2:86443532	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.73	-7.65	-0.38	2.06e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs6564851	0.508	rs7199144	chr16:81251846	A/T	cg00908271	chr16:81254010	PKD1L2	-0.3	-6.31	-0.32	8.58e-10	Carotenoid and tocopherol levels;
LIHC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-10.22	-0.48	1.37e-21	Tonsillectomy;
LIHC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.0	0.4	1.99e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.72	12.0	0.54	6.21e-28	Testicular germ cell tumor;
LIHC	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.36	-0.37	1.42e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.58	11.42	0.53	8.57e-26	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg11764359	chr7:65958608	NA	0.57	5.82	0.3	1.39e-8	Diabetic kidney disease;
LIHC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23043544	chr7:2124092	MAD1L1	0.37	5.77	0.3	1.81e-8	Bipolar disorder;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.28	6.97	0.35	1.6e-11	Schizophrenia;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg05484376	chr2:27715224	FNDC4	0.37	6.41	0.33	4.8e-10	Total body bone mineral density;
LIHC	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg20578329	chr17:80767326	TBCD	0.59	6.3	0.32	9.33e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs17106184	1.000	rs11205771	chr1:51276490	A/G	cg07174182	chr1:51127561	FAF1	-0.64	-7.07	-0.36	8.58e-12	Type 2 diabetes;
LIHC	cis	rs17106184	1.000	rs1846522	chr1:50981205	G/A	cg07174182	chr1:51127561	FAF1	-0.66	-6.96	-0.35	1.76e-11	Type 2 diabetes;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.68	-9.91	-0.47	1.64e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.46	8.49	0.42	6.6e-16	Testicular germ cell tumor;
LIHC	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.96	-0.4	2.51e-14	Response to antipsychotic treatment;
LIHC	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.88	0.35	2.9e-11	Type 2 diabetes;
LIHC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.49	-6.96	-0.35	1.71e-11	Prostate cancer;
LIHC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	cis	rs7238033	0.686	rs3819177	chr18:43316110	T/C	cg20610511	chr18:43302872	SLC14A1	0.4	6.61	0.34	1.43e-10	Bladder cancer;
LIHC	cis	rs72843506	0.722	rs74255387	chr17:20101383	G/A	cg12065943	chr17:19881925	AKAP10	-0.39	-6.18	-0.32	1.8e-9	Schizophrenia;
LIHC	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.8	-13.14	-0.58	3.17e-32	Oral cavity cancer;
LIHC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg02290350	chr8:58132656	NA	0.31	6.9	0.35	2.57e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.04	-0.44	1.19e-17	Bipolar disorder and schizophrenia;
LIHC	trans	rs783540	1.000	rs783531	chr15:83249119	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.79	-0.34	4.83e-11	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.42	-9.45	-0.46	5.54e-19	Arsenic metabolism;
LIHC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	8.79	0.43	7.61e-17	Schizophrenia;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.65	-9.7	-0.46	8.19e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3791556	0.581	rs6543514	chr2:240096690	T/C	cg03281426	chr2:240109471	HDAC4	0.39	6.12	0.31	2.57e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg12863693	chr15:85201151	NMB	0.44	6.34	0.32	7.18e-10	Schizophrenia;
LIHC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.81	15.49	0.64	2.22e-41	Blood protein levels;
LIHC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg05044414	chr3:183734942	ABCC5	0.34	5.99	0.31	5.34e-9	Anterior chamber depth;
LIHC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.64	-0.38	2.21e-13	Bipolar disorder;
LIHC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.67	11.05	0.51	1.82e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.5	8.72	0.43	1.19e-16	Total body bone mineral density;
LIHC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.34	-0.49	5.46e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-8.75	-0.43	1.01e-16	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.34	-0.45	1.28e-18	Colorectal cancer;
LIHC	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.42	-6.93	-0.35	2.05e-11	Schizophrenia;
LIHC	cis	rs17286411	0.750	rs2288030	chr16:71914107	G/A	cg06353428	chr16:71660113	MARVELD3	0.56	7.06	0.36	9.2e-12	Blood protein levels;
LIHC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24110177	chr3:50126178	RBM5	-0.44	-6.8	-0.35	4.71e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.41	6.96	0.35	1.76e-11	Alcohol dependence;
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg22663859	chr13:21900854	NA	0.5	8.17	0.4	5.87e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.45	-8.73	-0.43	1.14e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.66	-6.18	-0.32	1.77e-9	Menopause (age at onset);
LIHC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	19.43	0.72	3.44e-57	Nonalcoholic fatty liver disease;
LIHC	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.61	-0.38	2.77e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4908768	0.906	rs11584261	chr1:8560366	C/A	cg25722041	chr1:8623473	RERE	0.41	5.88	0.3	1e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.3	7.55	0.38	3.92e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.04	0.31	4.1e-9	Electroencephalogram traits;
LIHC	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.66	10.08	0.48	4.43e-21	Height;
LIHC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.16e-9	Menopause (age at onset);
LIHC	cis	rs1165668	0.755	rs10735390	chr12:104311731	A/G	cg21863207	chr12:104234989	NT5DC3	0.46	8.01	0.4	1.76e-14	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.79	-0.3	1.62e-8	Personality dimensions;
LIHC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.31	-6.03	-0.31	4.15e-9	Colorectal cancer;
LIHC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.16	17.99	0.7	2.16e-51	Gut microbiome composition (summer);
LIHC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg13647721	chr17:30228624	UTP6	0.8	7.65	0.38	2.07e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.67	-6.26	-0.32	1.14e-9	Urate levels in lean individuals;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00162751	chr1:220921532	MOSC2	0.38	6.19	0.32	1.74e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11958404	0.932	rs10045597	chr5:157451963	T/C	cg05962755	chr5:157440814	NA	0.9	10.6	0.5	6.7e-23	IgG glycosylation;
LIHC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.95	-12.37	-0.56	2.64e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.64	9.44	0.45	6.05e-19	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	cis	rs7756236	0.521	rs6907793	chr6:36625206	A/G	cg08179530	chr6:36648295	CDKN1A	0.42	6.35	0.32	7e-10	QRS duration;
LIHC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.23e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.89	-0.3	9.23e-9	Menopause (age at onset);
LIHC	trans	rs875971	0.964	rs778735	chr7:65814809	C/A	cg10756647	chr7:56101905	PSPH	0.44	6.49	0.33	3.09e-10	Aortic root size;
LIHC	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg27432699	chr2:27873401	GPN1	-0.57	-8.3	-0.41	2.46e-15	Total body bone mineral density;
LIHC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	5.96	0.31	6.44e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs3736485	0.966	rs28428679	chr15:51913040	A/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.56e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.44	6.16	0.32	1.99e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20887711	chr4:1340912	KIAA1530	0.6	9.34	0.45	1.23e-18	Obesity-related traits;
LIHC	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.26	6.34	0.32	7.21e-10	Schizophrenia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01782320	chr10:27443404	YME1L1;MASTL	-0.43	-6.5	-0.33	2.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.91	16.53	0.67	1.58e-45	Bone mineral density;
LIHC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg25179470	chr10:102756915	LZTS2	0.44	6.1	0.31	2.91e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-8.12	-0.4	8.59e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03736562	chr6:100016731	CCNC	-0.43	-6.25	-0.32	1.24e-9	Pancreatic cancer;
LIHC	cis	rs507080	0.922	rs12577485	chr11:118547503	C/A	cg04173919	chr11:118528438	PHLDB1	0.31	5.84	0.3	1.21e-8	Serum metabolite levels;
LIHC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.25	-0.45	2.55e-18	Bipolar disorder;
LIHC	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.37	-5.85	-0.3	1.13e-8	Hypospadias;
LIHC	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg26138144	chr22:38071188	LGALS1	0.71	10.43	0.49	2.63e-22	Fat distribution (HIV);
LIHC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.64	9.69	0.46	8.58e-20	Corneal astigmatism;
LIHC	cis	rs7116495	0.881	rs7930544	chr11:71737354	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-8.04	-0.4	1.43e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg02418909	chr7:4811322	NA	-0.46	-6.16	-0.32	1.99e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.94	0.51	4.41e-24	Personality dimensions;
LIHC	trans	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg16088116	chr21:44841560	SIK1	-0.41	-6.37	-0.33	6.25e-10	Coronary artery disease;
LIHC	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.33	6.82	0.35	4.12e-11	Sitting height ratio;
LIHC	cis	rs11018874	0.709	rs10830428	chr11:89894294	C/G	cg05041596	chr11:89867385	NAALAD2	-0.39	-6.35	-0.32	6.91e-10	White blood cell types;
LIHC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.59	-5.92	-0.31	7.69e-9	IgG glycosylation;
LIHC	cis	rs10503871	0.690	rs4147357	chr8:30344444	T/C	cg26383811	chr8:30366931	RBPMS	0.43	7.48	0.37	6.46e-13	Metabolite levels  (X-11787);
LIHC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.33	0.32	7.88e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.37	-5.99	-0.31	5.35e-9	Menopause (age at onset);
LIHC	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.78	11.05	0.51	1.79e-24	Response to hepatitis C treatment;
LIHC	cis	rs55665837	0.540	rs1007392	chr11:14774591	A/G	cg00085434	chr11:14927489	NA	0.41	5.82	0.3	1.37e-8	Vitamin D levels;
LIHC	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.57	7.86	0.39	4.9e-14	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.13e-9	Total body bone mineral density;
LIHC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	15.93	0.65	4.13e-43	Platelet count;
LIHC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg08499158	chr17:42289980	UBTF	-0.53	-9.25	-0.45	2.58e-18	Total body bone mineral density;
LIHC	trans	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg01596870	chr19:55963115	NA	-0.62	-7.38	-0.37	1.23e-12	Obesity-related traits;
LIHC	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg10932868	chr11:921992	NA	0.33	6.16	0.32	2.05e-9	Alzheimer's disease (late onset);
LIHC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.81	0.54	3.2e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg03689076	chr20:33865952	NA	0.58	6.65	0.34	1.16e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.55	-6.96	-0.35	1.73e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs12086130	0.892	rs72904788	chr1:51415247	T/G	cg07174182	chr1:51127561	FAF1	-0.75	-7.9	-0.39	3.96e-14	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736485	0.966	rs7177471	chr15:51911232	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.73	-0.34	7.21e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.58	7.6	0.38	2.94e-13	Migraine;
LIHC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.72	-0.3	2.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.66	-0.42	1.92e-16	Heart rate;
LIHC	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-20.78	-0.75	1.27e-62	Exhaled nitric oxide output;
LIHC	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.81	0.47	3.63e-20	Corneal astigmatism;
LIHC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.47	6.26	0.32	1.17e-9	High light scatter reticulocyte count;
LIHC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.41	6.59	0.34	1.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.38	6.56	0.33	2.04e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg26831259	chr4:1366826	KIAA1530	0.36	6.0	0.31	5.14e-9	Obesity-related traits;
LIHC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	9.73	0.47	6.35e-20	Lung cancer;
LIHC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.64	11.51	0.53	3.76e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-6.25	-0.32	1.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs332507	0.673	rs2242426	chr3:124398031	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.07	0.36	8.83e-12	Plateletcrit;
LIHC	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.77	10.08	0.48	4.37e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.37	-0.37	1.26e-12	Personality dimensions;
LIHC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg14067834	chr17:29058358	SUZ12P	0.67	6.54	0.33	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.7	-8.33	-0.41	2.01e-15	Vitiligo;
LIHC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.51	6.18	0.32	1.82e-9	Menarche (age at onset);
LIHC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.74	0.3	2.12e-8	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.28	-0.49	8.59e-22	Blood metabolite levels;
LIHC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg12798992	chr6:167411361	FGFR1OP	0.48	7.19	0.36	4.22e-12	Crohn's disease;
LIHC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.57	6.4	0.33	5.1e-10	Eosinophil percentage of granulocytes;
LIHC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20135002	chr11:47629003	NA	-0.53	-8.99	-0.44	1.73e-17	Subjective well-being;
LIHC	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg16309518	chr5:176445507	NA	-0.58	-11.49	-0.53	4.46e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg17764715	chr19:33622953	WDR88	0.54	7.21	0.36	3.73e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.73	-11.87	-0.54	1.93e-27	Systemic lupus erythematosus;
LIHC	cis	rs2257205	0.667	rs7220884	chr17:56743948	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.79	0.39	8.05e-14	Pancreatic cancer;
LIHC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg10932868	chr11:921992	NA	0.37	6.84	0.35	3.76e-11	Alzheimer's disease (late onset);
LIHC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.63	0.38	2.39e-13	Bipolar disorder;
LIHC	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.74	-8.79	-0.43	7.29e-17	Migraine;
LIHC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.73	-6.94	-0.35	1.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.05	0.6	1.02e-35	Chronic sinus infection;
LIHC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.42	-7.77	-0.39	9.12e-14	Schizophrenia;
LIHC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.69	-0.46	8.83e-20	Electroencephalogram traits;
LIHC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.98	22.82	0.78	1.07e-70	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg19680672	chr10:131412579	MGMT	-0.45	-6.8	-0.35	4.63e-11	Response to temozolomide;
LIHC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg26138937	chr11:71823887	C11orf51	-1.28	-10.28	-0.49	8.92e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg12373951	chr3:133503437	NA	0.5	7.3	0.37	1.99e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs11229555	0.645	rs11229463	chr11:58210147	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.96	-13.14	-0.58	3.22e-32	Post bronchodilator FEV1;
LIHC	cis	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.56e-11	Atopic dermatitis;
LIHC	cis	rs7810240	0.762	rs10282108	chr7:150082610	A/G	cg10018233	chr7:150070692	REPIN1	-0.41	-6.38	-0.33	5.75e-10	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LIHC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.7	-10.8	-0.5	1.39e-23	Urate levels in obese individuals;
LIHC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.43	7.26	0.37	2.58e-12	Hemoglobin concentration;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.42	7.51	0.38	5.16e-13	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.56	5.92	0.3	7.86e-9	IgG glycosylation;
LIHC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.03e-11	Ileal carcinoids;
LIHC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg14067834	chr17:29058358	SUZ12P	0.69	6.65	0.34	1.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08280861	chr8:58055591	NA	0.53	6.57	0.33	1.87e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.25	0.36	2.87e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19623624	chr10:135278901	LOC619207	-0.45	-6.99	-0.35	1.45e-11	Systemic lupus erythematosus;
LIHC	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-7.63	-0.38	2.31e-13	Pediatric bone mineral density (spine);
LIHC	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.67	13.31	0.58	7.28e-33	Leprosy;
LIHC	cis	rs61160187	0.503	rs248911	chr5:59847538	T/C	cg02684056	chr5:59996105	DEPDC1B	0.39	5.98	0.31	5.53e-9	Educational attainment (years of education);Educational attainment (college completion);
LIHC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.62	-0.34	1.38e-10	Personality dimensions;
LIHC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.37e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.75e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1355223	0.902	rs11603774	chr11:34732891	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.5	7.29	0.37	2.22e-12	Obesity-related traits;
LIHC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg03859395	chr2:55845619	SMEK2	0.83	13.68	0.59	2.85e-34	Metabolic syndrome;
LIHC	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.39	-0.33	5.4e-10	Ulcerative colitis;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.76	-11.48	-0.53	4.99e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg27386326	chr11:61587980	NA	0.64	13.6	0.59	5.78e-34	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg02951883	chr7:2050386	MAD1L1	0.6	8.24	0.41	3.83e-15	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-5.79	-0.3	1.61e-8	Tonsillectomy;
LIHC	cis	rs7487075	0.619	rs10785629	chr12:46854727	G/A	cg23829395	chr12:46796953	NA	0.34	5.94	0.31	6.95e-9	Itch intensity from mosquito bite;
LIHC	cis	rs8141529	0.551	rs34578331	chr22:29347215	G/T	cg15103426	chr22:29168792	CCDC117	0.44	6.2	0.32	1.63e-9	Lymphocyte counts;
LIHC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-10.57	-0.5	8.77e-23	Diastolic blood pressure;
LIHC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.58	10.61	0.5	6.24e-23	Diastolic blood pressure;
LIHC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.48	5.92	0.3	7.94e-9	Morning vs. evening chronotype;
LIHC	cis	rs7188697	0.922	rs37053	chr16:58558707	T/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.21	-0.36	3.65e-12	QT interval;
LIHC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.45	-7.41	-0.37	1.02e-12	Testicular germ cell tumor;
LIHC	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.49	7.74	0.39	1.11e-13	Alzheimer's disease (survival time);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18580865	chr12:93323267	EEA1	-0.38	-6.1	-0.31	2.82e-9	Pancreatic cancer;
LIHC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.48	-0.33	3.24e-10	Heart rate;
LIHC	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg25783544	chr11:47291846	MADD	0.41	5.85	0.3	1.16e-8	HDL cholesterol;
LIHC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.82	0.47	3.16e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg27555944	chr3:49056208	DALRD3	-0.45	-6.23	-0.32	1.37e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.81	13.56	0.59	7.91e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.23	-0.41	4.06e-15	Glycated hemoglobin levels;
LIHC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg08923669	chr16:420230	MRPL28	-0.47	-6.2	-0.32	1.67e-9	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08628601	chr15:52861409	ARPP19	0.48	6.32	0.32	7.97e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs4908768	0.906	rs12409937	chr1:8538302	G/C	cg20416874	chr1:8611966	RERE	0.57	9.07	0.44	9.19e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg14222797	chr10:16859974	RSU1	0.54	6.42	0.33	4.51e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.36	-0.45	1.07e-18	Gut microbiome composition (summer);
LIHC	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	0.92	22.69	0.78	3.35e-70	Multiple myeloma;
LIHC	trans	rs2211698	0.881	rs4817655	chr21:35841020	C/G	cg18044562	chr7:50468399	IKZF1	0.52	7.29	0.37	2.18e-12	Cancer;
LIHC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg01657329	chr11:68192670	LRP5	-0.46	-5.99	-0.31	5.25e-9	Total body bone mineral density;
LIHC	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.53	7.74	0.39	1.15e-13	Corneal astigmatism;
LIHC	cis	rs4934494	0.768	rs17126269	chr10:91454731	C/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.51	-0.33	2.69e-10	Red blood cell count;
LIHC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Obesity-related traits;
LIHC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.6	-11.73	-0.54	6.28e-27	Urate levels in overweight individuals;
LIHC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg03854865	chr6:26224070	HIST1H3E	0.63	7.07	0.36	8.82e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.7	0.43	1.45e-16	Initial pursuit acceleration;
LIHC	cis	rs4141404	0.781	rs4820945	chr22:31549155	T/C	cg07713946	chr22:31675144	LIMK2	-0.34	-5.79	-0.3	1.58e-8	Paclitaxel-induced neuropathy;
LIHC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.77	12.18	0.55	1.32e-28	Corneal astigmatism;
LIHC	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.63	-7.94	-0.39	3.03e-14	QRS complex (12-leadsum);
LIHC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Corneal astigmatism;
LIHC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.04	0.4	1.5e-14	Motion sickness;
LIHC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.72	11.83	0.54	2.58e-27	Body mass index;
LIHC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.31	0.37	1.85e-12	Morning vs. evening chronotype;
LIHC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.6	0.53	1.87e-26	Alzheimer's disease;
LIHC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-7.4	-0.37	1.09e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.2	-0.32	1.67e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07677032	chr17:61819896	STRADA	0.41	5.86	0.3	1.12e-8	Prudent dietary pattern;
LIHC	cis	rs7075426	0.669	rs11202042	chr10:88237104	T/C	cg07322936	chr10:88137208	NA	0.48	6.29	0.32	9.59e-10	Migraine without aura;
LIHC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.83	8.71	0.43	1.34e-16	Platelet count;
LIHC	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg09752223	chr19:15281200	NOTCH3	-0.36	-6.26	-0.32	1.18e-9	Pulse pressure;
LIHC	trans	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg10756647	chr7:56101905	PSPH	0.44	6.43	0.33	4.25e-10	Aortic root size;
LIHC	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.77	11.45	0.53	6.32e-26	Coronary artery disease;
LIHC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.51	7.14	0.36	5.74e-12	Mean corpuscular volume;
LIHC	trans	rs9641123	0.639	rs2677086	chr7:93208570	G/T	cg09745688	chr16:2908918	PRSS22	-0.36	-6.33	-0.32	7.77e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs7914558	0.646	rs11191459	chr10:104662118	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.16	-0.36	5.12e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.45	-5.78	-0.3	1.72e-8	Schizophrenia;
LIHC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.62	-8.69	-0.43	1.57e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14503165	chr17:2202686	SMG6	0.41	6.09	0.31	3.01e-9	Immature fraction of reticulocytes;
LIHC	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg22951263	chr5:87985283	NA	-0.37	-6.53	-0.33	2.34e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg03934865	chr2:198174659	NA	0.55	8.38	0.41	1.42e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg19680672	chr10:131412579	MGMT	-0.44	-6.86	-0.35	3.33e-11	Response to temozolomide;
LIHC	cis	rs7707921	0.723	rs73138787	chr5:81568934	G/A	cg15871215	chr5:81402204	ATG10	-0.7	-8.2	-0.41	5.06e-15	Breast cancer;
LIHC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.89	-18.71	-0.71	2.82e-54	Height;
LIHC	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	0.87	14.21	0.61	2.47e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg10820045	chr2:198174542	NA	0.49	7.44	0.37	8.27e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11031096	0.738	rs2923950	chr11:4042069	G/C	cg18678763	chr11:4115507	RRM1	0.42	6.26	0.32	1.18e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.08	0.58	5.66e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg16479474	chr6:28041457	NA	0.42	6.6	0.34	1.61e-10	Parkinson's disease;
LIHC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.47	-7.46	-0.37	7.27e-13	Cognitive function;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg12435611	chr17:59941052	BRIP1	-0.43	-6.27	-0.32	1.09e-9	Bipolar disorder;
LIHC	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.57	-8.32	-0.41	2.11e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.58	-10.11	-0.48	3.34e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs12464559	0.649	rs4233654	chr2:152596011	C/G	cg01189475	chr2:152685088	ARL5A	-0.63	-7.4	-0.37	1.04e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.82	0.3	1.38e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg03859395	chr2:55845619	SMEK2	0.85	15.1	0.63	7.58e-40	Metabolic syndrome;
LIHC	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.46	-6.29	-0.32	9.85e-10	Obesity-related traits;
LIHC	cis	rs600806	0.888	rs461200	chr1:109855404	G/A	cg16275483	chr1:110013120	SYPL2	-0.51	-6.26	-0.32	1.14e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.86	-0.39	5.07e-14	Primary biliary cholangitis;
LIHC	cis	rs6450176	0.633	rs389525	chr5:53333075	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.5	-0.59	1.4e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.15	-0.58	3.05e-32	Bipolar disorder and schizophrenia;
LIHC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.01	-9.58	-0.46	2.13e-19	Diabetic retinopathy;
LIHC	cis	rs74544699	1.000	rs11574452	chr4:74846661	A/C	cg15398841	chr4:74847761	PF4	-0.59	-6.08	-0.31	3.22e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.5	-9.3	-0.45	1.72e-18	Asthma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02892961	chr21:34863959	DNAJC28	-0.5	-6.08	-0.31	3.16e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg21724239	chr8:58056113	NA	0.49	6.28	0.32	1.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.89	15.37	0.64	6.58e-41	Monocyte percentage of white cells;
LIHC	cis	rs10792665	0.640	rs10898055	chr11:82628257	G/C	cg24227371	chr11:82718527	RAB30	-0.27	-6.25	-0.32	1.26e-9	Obesity-related traits;
LIHC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.63	9.82	0.47	3.21e-20	Corneal astigmatism;
LIHC	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.49	9.3	0.45	1.68e-18	Testicular germ cell tumor;
LIHC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.68	-8.49	-0.42	6.52e-16	Gut microbiome composition (summer);
LIHC	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg19338460	chr6:170058176	WDR27	-0.9	-9.03	-0.44	1.28e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs72960926	0.744	rs77045321	chr6:74915572	T/C	cg07247405	chr1:2484626	LOC115110	0.52	6.04	0.31	4.09e-9	Metabolite levels (MHPG);
LIHC	cis	rs4789452	0.538	rs2627207	chr17:75353160	A/G	cg05865280	chr17:75406074	SEPT9	-0.33	-6.75	-0.34	6.48e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.32	-0.37	1.76e-12	Breast cancer;
LIHC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.42	0.37	9.12e-13	Mean platelet volume;
LIHC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg26138144	chr22:38071188	LGALS1	0.75	14.09	0.61	7.25e-36	Fat distribution (HIV);
LIHC	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.94	-0.31	7.2e-9	Tuberculosis;
LIHC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.82	8.24	0.41	3.62e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs868943	0.582	rs12209373	chr6:116488925	G/A	cg08036074	chr6:116424633	NT5DC1	-0.61	-6.6	-0.34	1.57e-10	Total cholesterol levels;
LIHC	cis	rs611744	0.967	rs660065	chr8:109191932	G/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.45	8.15	0.4	6.72e-15	Prudent dietary pattern;
LIHC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg15208524	chr1:10270712	KIF1B	0.38	5.79	0.3	1.62e-8	Hepatocellular carcinoma;
LIHC	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-10.23	-0.48	1.35e-21	Asthma;
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.47	0.33	3.38e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs800082	0.839	rs17282884	chr3:144319905	C/T	cg24215973	chr2:240111563	HDAC4	0.49	6.87	0.35	2.99e-11	Smoking behavior;
LIHC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.49	8.07	0.4	1.21e-14	Type 2 diabetes;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.15	-0.48	2.46e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs7616330	0.836	rs73118214	chr3:71047396	A/C	cg01511742	chr3:71112437	FOXP1	-0.45	-6.05	-0.31	3.78e-9	QT interval;
LIHC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06050784	chr16:88016603	BANP	0.39	6.76	0.34	5.95e-11	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs1712517	0.771	rs11191654	chr10:105077124	C/A	cg05636881	chr10:105038444	INA	0.48	7.58	0.38	3.19e-13	Migraine;
LIHC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.77	12.84	0.57	4.59e-31	Total cholesterol levels;
LIHC	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.84	0.3	1.22e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.61	-9.57	-0.46	2.27e-19	Height;
LIHC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.35	5.72	0.3	2.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12101261	0.580	rs4411444	chr14:81445108	A/G	cg06600135	chr14:81408086	NA	0.44	7.74	0.39	1.11e-13	Graves' disease;
LIHC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg25039879	chr17:56429692	SUPT4H1	0.77	8.91	0.43	3e-17	Cognitive test performance;
LIHC	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	7.9	0.39	3.91e-14	Response to antipsychotic treatment;
LIHC	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-8.14	-0.4	7.27e-15	Morning vs. evening chronotype;
LIHC	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg20240347	chr1:204465584	NA	-0.35	-7.53	-0.38	4.64e-13	Schizophrenia;
LIHC	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02985541	chr2:219472218	PLCD4	0.43	7.8	0.39	7.5e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.68	8.52	0.42	5.06e-16	Corneal astigmatism;
LIHC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg12658694	chr1:38397304	INPP5B	0.52	7.73	0.39	1.23e-13	Coronary artery disease;
LIHC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.85	0.54	2.32e-27	Colorectal cancer;
LIHC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg18016565	chr1:150552671	MCL1	0.56	10.79	0.5	1.48e-23	Melanoma;
LIHC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.51	7.0	0.35	1.34e-11	Aortic root size;
LIHC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.38	-6.18	-0.32	1.78e-9	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.28	-6.37	-0.33	6.01e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg19680672	chr10:131412579	MGMT	-0.42	-6.5	-0.33	2.89e-10	Response to temozolomide;
LIHC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	10.41	0.49	3.03e-22	Monocyte percentage of white cells;
LIHC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-6.07	-0.31	3.46e-9	Bipolar disorder;
LIHC	cis	rs7914558	0.646	rs10883799	chr10:104663310	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.09	-0.36	7.9e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs722599	0.501	rs2286914	chr14:75387012	T/C	cg08847533	chr14:75593920	NEK9	-0.6	-10.28	-0.49	8.81e-22	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.77	0.54	4.4e-27	Motion sickness;
LIHC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg14067834	chr17:29058358	SUZ12P	0.67	6.6	0.34	1.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.5	-6.09	-0.31	2.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.43	-7.11	-0.36	6.74e-12	IgG glycosylation;
LIHC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg10360323	chr17:41437877	NA	0.41	5.96	0.31	6.2e-9	Menopause (age at onset);
LIHC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.57	8.74	0.43	1.06e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-9.15	-0.44	5.08e-18	Asthma;
LIHC	cis	rs7106204	0.514	rs34587986	chr11:24253053	T/C	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.86	0.3	1.12e-8	Aortic root size;
LIHC	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22857957	chr1:146697082	FMO5	-0.38	-6.2	-0.32	1.63e-9	Myopia (pathological);
LIHC	trans	rs800082	0.802	rs2717380	chr3:144256908	A/T	cg24215973	chr2:240111563	HDAC4	0.44	6.26	0.32	1.15e-9	Smoking behavior;
LIHC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.58	0.34	1.78e-10	Platelet count;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17789012	chr17:13972896	COX10	-0.54	-6.18	-0.32	1.87e-9	Systolic blood pressure;
LIHC	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.48	6.48	0.33	3.13e-10	Inflammatory skin disease;
LIHC	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.76	-6.14	-0.32	2.25e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg11062466	chr8:58055876	NA	0.42	6.12	0.31	2.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg07424592	chr7:64974309	NA	0.82	9.58	0.46	2.09e-19	Diabetic kidney disease;
LIHC	cis	rs36051895	0.530	rs7036833	chr9:5226484	G/A	cg02405213	chr9:5042618	JAK2	-0.61	-9.19	-0.45	3.91e-18	Pediatric autoimmune diseases;
LIHC	cis	rs743757	1.000	rs762897	chr3:50428766	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.42	6.27	0.32	1.12e-9	Diastolic blood pressure;
LIHC	cis	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg15105060	chr4:7024189	TBC1D14	-0.72	-6.07	-0.31	3.44e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs55665837	0.701	rs10766188	chr11:14660826	T/C	cg19336497	chr11:14380999	RRAS2	-0.36	-6.03	-0.31	4.26e-9	Vitamin D levels;
LIHC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.42	0.33	4.62e-10	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08280861	chr8:58055591	NA	0.55	6.12	0.31	2.59e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1144333	0.655	rs1417402	chr1:76437196	C/T	cg22875332	chr1:76189707	ACADM	0.43	6.27	0.32	1.1e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.58	-6.91	-0.35	2.38e-11	Metabolite levels;
LIHC	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.2	-0.32	1.6e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.65	-12.19	-0.55	1.24e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.04	0.31	3.94e-9	Eosinophil percentage of white cells;
LIHC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.99	-0.31	5.3300000000000004e-09	Bipolar disorder and schizophrenia;
LIHC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs7937890	0.593	rs2597189	chr11:14512060	C/T	cg02886208	chr11:14281011	SPON1	-0.49	-6.61	-0.34	1.46e-10	Mitochondrial DNA levels;
LIHC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.64	8.98	0.44	1.89e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg11792281	chr17:26443366	NLK	0.6	6.33	0.32	7.58e-10	Mean platelet volume;
LIHC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.74	-0.57	1.07e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18898632	chr2:242989856	NA	-0.47	-6.5	-0.33	2.86e-10	Obesity-related traits;
LIHC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	1.02	10.14	0.48	2.72e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.48	8.34	0.41	1.88e-15	Tuberculosis;
LIHC	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	6.2	0.32	1.59e-9	Blood protein levels;
LIHC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	8.92	0.43	2.83e-17	Schizophrenia;
LIHC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg23109721	chr2:106886537	NA	-0.65	-6.29	-0.32	9.47e-10	Facial morphology (factor 23);
LIHC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.7	9.53	0.46	2.95e-19	Aortic root size;
LIHC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.73	-9.99	-0.48	8.47e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.73	-12.08	-0.55	3.08e-28	Systemic lupus erythematosus;
LIHC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	9.73	0.47	6.31e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.43	-0.56	1.53e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.56	7.18	0.36	4.37e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.23	-0.41	3.97e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.57	-11.0	-0.51	2.67e-24	Mean corpuscular volume;
LIHC	cis	rs35160687	0.623	rs2276625	chr2:86481835	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.37	-6.13	-0.31	2.36e-9	Night sleep phenotypes;
LIHC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	1.05	15.71	0.65	2.87e-42	Breast cancer;
LIHC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.53	0.56	6.83e-30	Electrocardiographic conduction measures;
LIHC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.24e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs11724903	0.935	rs11732877	chr4:183206596	A/G	cg16239906	chr20:35724590	RBL1	-0.62	-6.15	-0.32	2.21e-9	Smoking initiation;
LIHC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.73	0.34	7.11e-11	Lung cancer in ever smokers;
LIHC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg14440974	chr22:39074834	NA	-0.36	-6.06	-0.31	3.56e-9	Menopause (age at onset);
LIHC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.24	0.61	1.91e-36	Chronic sinus infection;
LIHC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.88	9.96	0.47	1.14e-20	Initial pursuit acceleration;
LIHC	cis	rs74233809	1.000	rs10883835	chr10:104884208	T/C	cg03493300	chr10:104813866	CNNM2	0.47	6.34	0.32	7.15e-10	Birth weight;
LIHC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-6.58	-0.34	1.77e-10	Height;
LIHC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg14393609	chr7:65229607	NA	-0.38	-6.04	-0.31	4.07e-9	Aortic root size;
LIHC	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.49	-6.32	-0.32	7.97e-10	Pursuit maintenance gain;
LIHC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg19635926	chr16:89946313	TCF25	0.55	7.39	0.37	1.11e-12	Skin colour saturation;
LIHC	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.69	-10.31	-0.49	6.91e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.83	0.43	5.6e-17	Lung cancer in ever smokers;
LIHC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.46	7.1	0.36	7.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg13409248	chr3:40428643	ENTPD3	0.38	5.9	0.3	8.59e-9	Renal cell carcinoma;
LIHC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	9.74	0.47	6.04e-20	Platelet count;
LIHC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.44	5.86	0.3	1.09e-8	Panic disorder;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg20273358	chr20:56100118	CTCFL	0.48	6.34	0.32	7.36e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.7	-10.21	-0.48	1.49e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.65	-12.3	-0.55	4.98e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.58	9.42	0.45	7.06e-19	Lymphocyte counts;
LIHC	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg17507749	chr15:85114479	UBE2QP1	0.62	6.61	0.34	1.52e-10	Schizophrenia;
LIHC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	7.75	0.39	1.08e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg17750252	chr2:136567154	LCT	0.33	5.93	0.31	7.44e-9	Mosquito bite size;
LIHC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.78	11.94	0.54	1.08e-27	Total body bone mineral density;
LIHC	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.28	0.52	2.73e-25	Coffee consumption (cups per day);
LIHC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg00750074	chr16:89608354	SPG7	-0.38	-5.79	-0.3	1.59e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs3099143	0.901	rs1611866	chr15:77236291	A/C	cg21673338	chr15:77095150	SCAPER	-0.5	-6.83	-0.35	3.86e-11	Recalcitrant atopic dermatitis;
LIHC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-1.03	-17.48	-0.69	2.42e-49	Metabolic syndrome;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg24879335	chr3:133465180	TF	0.29	6.46	0.33	3.56e-10	Iron status biomarkers;
LIHC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.48	5.72	0.3	2.34e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.8	10.15	0.48	2.5e-21	Morning vs. evening chronotype;
LIHC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg11812906	chr14:75593930	NEK9	0.4	6.06	0.31	3.67e-9	IgG glycosylation;
LIHC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.41e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17554472	chr22:41940697	POLR3H	0.56	6.04	0.31	3.98e-9	Vitiligo;
LIHC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.45	5.91	0.3	8.31e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-5.86	-0.3	1.08e-8	Alzheimer's disease (late onset);
LIHC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.73	-13.26	-0.58	1.2e-32	Mortality in heart failure;
LIHC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.68	11.44	0.53	6.89e-26	Birth weight;
LIHC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.61	-0.5	6.32e-23	Chronic sinus infection;
LIHC	trans	rs867371	0.820	rs12443224	chr15:82495610	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.46	-7.98	-0.4	2.31e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg12751644	chr20:60527061	NA	-0.37	-6.14	-0.32	2.31e-9	Body mass index;
LIHC	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.76	12.53	0.56	6.59e-30	Anterior chamber depth;
LIHC	cis	rs6669384	0.774	rs4844623	chr1:208035434	T/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.84	-0.3	1.21e-8	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs6782228	0.606	rs2001703	chr3:128383097	A/G	cg16766828	chr3:128327626	NA	-0.4	-6.39	-0.33	5.54e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.5	7.63	0.38	2.36e-13	Obesity-related traits;
LIHC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-9.84	-0.47	2.77e-20	Glaucoma (primary open-angle);
LIHC	cis	rs7551222	0.752	rs12130686	chr1:204554057	G/C	cg20240347	chr1:204465584	NA	-0.31	-6.28	-0.32	1.01e-9	Schizophrenia;
LIHC	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg10756647	chr7:56101905	PSPH	1.02	12.11	0.55	2.53e-28	Diabetic kidney disease;
LIHC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.81	-12.39	-0.56	2.25e-29	Total body bone mineral density;
LIHC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.74	-10.58	-0.5	8.1e-23	Pancreatic cancer;
LIHC	trans	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg10756647	chr7:56101905	PSPH	1.15	13.01	0.58	1.02e-31	Diabetic kidney disease;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.27	0.55	6.38e-29	Prudent dietary pattern;
LIHC	cis	rs74181299	0.684	rs6756585	chr2:65340070	G/A	cg05010058	chr2:65284262	CEP68	-0.41	-6.89	-0.35	2.63e-11	Pulse pressure;
LIHC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg24296786	chr1:45957014	TESK2	-0.39	-5.76	-0.3	1.92e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg02269571	chr22:50332266	NA	-0.65	-8.83	-0.43	5.68e-17	Schizophrenia;
LIHC	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg26138937	chr11:71823887	C11orf51	-1.32	-10.9	-0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.14	0.4	7.35e-15	Electrocardiographic conduction measures;
LIHC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.57	11.14	0.52	8.65e-25	Coronary artery disease;
LIHC	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.35	-6.98	-0.35	1.52e-11	Testicular germ cell tumor;
LIHC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-5.95	-0.31	6.64e-9	Prostate cancer;
LIHC	cis	rs6120849	0.707	rs3746448	chr20:33572979	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.33	0.37	1.64e-12	Protein C levels;
LIHC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.95	10.46	0.49	2.07e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	7.76	0.39	1.01e-13	Adiposity;
LIHC	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.68	8.14	0.4	7.54e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.11	-0.36	6.88e-12	Monocyte percentage of white cells;
LIHC	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-5.94	-0.31	6.99e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00975115	chr16:30958403	FBXL19	0.45	6.45	0.33	3.8e-10	Longevity;
LIHC	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-11.91	-0.54	1.39e-27	Pediatric autoimmune diseases;
LIHC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.9	8.19	0.41	5.11e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg00656387	chr3:40428638	ENTPD3	0.43	7.18	0.36	4.51e-12	Renal cell carcinoma;
LIHC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.65	8.87	0.43	4.17e-17	Asthma;
LIHC	cis	rs34540877	1.000	rs34377680	chr19:33121874	C/A	cg22980127	chr19:33182716	NUDT19	1.01	6.75	0.34	6.37e-11	Red cell distribution width;
LIHC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.71	10.9	0.51	6.27e-24	Corneal astigmatism;
LIHC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg11764359	chr7:65958608	NA	0.57	6.09	0.31	3.09e-9	Diabetic kidney disease;
LIHC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.39	-6.01	-0.31	4.72e-9	Glioblastoma;
LIHC	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg21605333	chr4:119757512	SEC24D	0.82	6.81	0.35	4.28e-11	Cannabis dependence symptom count;
LIHC	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg03146154	chr1:46216737	IPP	-0.4	-6.55	-0.33	2.11e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-6.53	-0.33	2.45e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg13919466	chr1:32135498	COL16A1	0.34	6.39	0.33	5.38e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg23091122	chr1:110024289	SYPL2	0.45	6.14	0.31	2.32e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg10360323	chr17:41437877	NA	0.39	5.84	0.3	1.24e-8	Menopause (age at onset);
LIHC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.34	0.41	1.84e-15	Birth weight;
LIHC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.94	12.11	0.55	2.55e-28	HIV-1 control;
LIHC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.74	-10.61	-0.5	6.46e-23	Pancreatic cancer;
LIHC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.45	-8.73	-0.43	1.14e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.55	7.72	0.39	1.33e-13	Crohn's disease;
LIHC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg19645103	chr12:69753606	YEATS4	-0.4	-6.07	-0.31	3.49e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.55	0.53	2.74e-26	Menopause (age at onset);
LIHC	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.38	-6.04	-0.31	4.02e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg06466757	chr4:1255808	NA	0.34	5.8	0.3	1.53e-8	Obesity-related traits;
LIHC	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg17135325	chr3:160939158	NMD3	0.59	8.47	0.42	7.36e-16	Parkinson's disease;
LIHC	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-9.03	-0.44	1.26e-17	Exhaled nitric oxide levels;
LIHC	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.57	8.97	0.44	2.03e-17	Corneal astigmatism;
LIHC	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.84	9.03	0.44	1.26e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.68	-0.34	9.95e-11	Metabolite levels;
LIHC	cis	rs2292096	0.850	rs6663728	chr1:200815179	G/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-5.96	-0.31	6.35e-9	Epilepsy;
LIHC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.35	0.41	1.67e-15	Schizophrenia;
LIHC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg03945807	chr20:60948434	NA	-0.36	-6.47	-0.33	3.37e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg07424592	chr7:64974309	NA	0.79	9.12	0.44	6.72e-18	Diabetic kidney disease;
LIHC	trans	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg10756647	chr7:56101905	PSPH	0.47	6.95	0.35	1.86e-11	Aortic root size;
LIHC	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-12.72	-0.57	1.27e-30	Coffee consumption (cups per day);
LIHC	cis	rs1144333	0.655	rs1146649	chr1:76268803	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.16	-0.32	2.06e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	1.03	15.33	0.64	9.68e-41	Breast cancer;
LIHC	cis	rs74233809	1.000	rs77180047	chr10:104666757	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.02	0.31	4.57e-9	Birth weight;
LIHC	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.38	7.73	0.39	1.21e-13	Obesity (extreme);
LIHC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.81	0.3	1.43e-8	Axial length;
LIHC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg03264133	chr6:25882463	NA	-0.4	-6.01	-0.31	4.72e-9	Height;
LIHC	trans	rs983392	0.709	rs4939320	chr11:59981801	T/C	cg17275991	chr19:58003312	ZNF419	0.43	6.16	0.32	2.09e-9	Alzheimer's disease (late onset);
LIHC	cis	rs17094222	0.812	rs10786600	chr10:102435521	A/G	cg26540559	chr10:102447443	NA	0.32	6.14	0.32	2.24e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs16858210	0.520	rs35586421	chr3:183544607	G/A	cg25686905	chr3:183603175	PARL	-0.44	-7.22	-0.36	3.31e-12	Menopause (age at onset);
LIHC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.46	-6.27	-0.32	1.11e-9	Coronary artery disease;
LIHC	cis	rs1865721	0.804	rs35653478	chr18:73212546	C/T	cg26385618	chr18:73139727	C18orf62	-0.29	-7.38	-0.37	1.18e-12	Intelligence;
LIHC	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.87	-0.35	3.14e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.72	-11.25	-0.52	3.43e-25	White matter hyperintensity burden;
LIHC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-22.74	-0.78	2.13e-70	Height;
LIHC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18867708	chr6:26865862	GUSBL1	0.54	8.09	0.4	1.05e-14	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.07	-0.44	9.29e-18	Gut microbiome composition (summer);
LIHC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.13	-0.44	6.13e-18	Bipolar disorder;
LIHC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg23262073	chr20:60523788	NA	-0.28	-5.77	-0.3	1.74e-8	Body mass index;
LIHC	cis	rs2286503	0.839	rs4722189	chr7:22860474	G/A	cg11367502	chr7:22862612	TOMM7	0.45	7.58	0.38	3.22e-13	Fibrinogen;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.36	0.45	1.08e-18	Height;
LIHC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-8.47	-0.42	7.38e-16	Primary biliary cholangitis;
LIHC	cis	rs67981189	0.593	rs1558097	chr14:71557267	T/A	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.76	11.85	0.54	2.28e-27	Corneal astigmatism;
LIHC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	0.95	18.28	0.7	1.51e-52	Bone mineral density;
LIHC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg00129232	chr17:37814104	STARD3	0.36	5.96	0.31	6.44e-9	Self-reported allergy;
LIHC	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.49	6.72	0.34	7.7e-11	Morning vs. evening chronotype;
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.99	-0.35	1.46e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg00612595	chr21:47717864	NA	-0.35	-5.78	-0.3	1.71e-8	Testicular germ cell tumor;
LIHC	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.04	-0.31	3.92e-9	Blood pressure;
LIHC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.75	13.72	0.6	1.93e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1555399	0.934	rs10133618	chr14:67981403	G/C	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.82	-0.3	1.37e-8	Parkinson's disease;
LIHC	cis	rs6088813	1.000	rs1406947	chr20:33969530	C/T	cg14752227	chr20:34000481	UQCC	-0.4	-5.79	-0.3	1.61e-8	Height;
LIHC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.52	7.35	0.37	1.46e-12	Colorectal cancer;
LIHC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.94	-0.47	1.29e-20	Response to antipsychotic treatment;
LIHC	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.88	0.35	2.8e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.48	7.09	0.36	7.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg20435097	chr10:126320824	FAM53B	0.38	6.3	0.32	9.36e-10	Asthma;
LIHC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg05941027	chr17:61774174	LIMD2	-0.32	-6.3	-0.32	9.18e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.47	-8.57	-0.42	3.7e-16	Colorectal cancer;
LIHC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.51	-8.64	-0.42	2.19e-16	White blood cell count;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08264122	chr7:1882997	MAD1L1	0.4	6.04	0.31	4.01e-9	Longevity;
LIHC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.88	-12.36	-0.56	3.02e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.59	-6.86	-0.35	3.28e-11	Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.48	-0.37	6.33e-13	Schizophrenia;
LIHC	cis	rs244293	0.965	rs244310	chr17:53212655	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	trans	rs6934970	1.000	rs28623201	chr6:113083939	G/C	cg19071452	chr2:152146944	NMI	-0.57	-6.08	-0.31	3.21e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.53	-0.49	1.17e-22	Alzheimer's disease;
LIHC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.01	0.44	1.47e-17	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03442064	chr6:41515050	FOXP4	0.47	7.12	0.36	6.56e-12	Pancreatic cancer;
LIHC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg11812906	chr14:75593930	NEK9	-0.45	-7.13	-0.36	5.85e-12	IgG glycosylation;
LIHC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.5	6.57	0.33	1.88e-10	Major depressive disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22276571	chr20:17549599	DSTN	0.39	6.44	0.33	4.02e-10	Cognitive function;
LIHC	cis	rs7187994	0.848	rs16974560	chr16:84788425	A/G	cg07647771	chr16:84786436	USP10	-0.31	-6.02	-0.31	4.44e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.47	6.42	0.33	4.57e-10	Obesity-related traits;
LIHC	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg00204512	chr16:28754710	NA	0.34	6.1	0.31	2.79e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.38	-5.86	-0.3	1.08e-8	Testicular germ cell tumor;
LIHC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.32	-0.32	8.05e-10	Axial length;
LIHC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.43	5.84	0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg15691649	chr6:25882328	NA	-0.39	-6.14	-0.32	2.23e-9	Height;
LIHC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.51e-11	Type 2 diabetes;
LIHC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.49	-7.05	-0.36	9.68e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7937890	0.532	rs2575827	chr11:14475515	A/G	cg02886208	chr11:14281011	SPON1	-0.46	-6.58	-0.34	1.75e-10	Mitochondrial DNA levels;
LIHC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg21466736	chr12:48725269	NA	-0.7	-10.73	-0.5	2.33e-23	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg15017067	chr4:17643749	FAM184B	-0.34	-5.72	-0.3	2.34e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17106184	1.000	rs72902736	chr1:51239976	A/G	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.18e-10	Type 2 diabetes;
LIHC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.32	0.41	2.08e-15	Schizophrenia;
LIHC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.4	-5.92	-0.3	8.03e-9	Lung cancer;
LIHC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.6	-0.38	2.81e-13	Bipolar disorder;
LIHC	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.28	0.55	6.02e-29	Eye color traits;
LIHC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.78	-8.67	-0.42	1.76e-16	Vitiligo;
LIHC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.51	7.96	0.4	2.48e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.53	-7.7	-0.38	1.5e-13	Uric acid levels;
LIHC	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg10241871	chr14:102965420	TECPR2	-0.41	-6.04	-0.31	4.05e-9	Plateletcrit;
LIHC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.6	7.45	0.37	7.73e-13	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg02290350	chr8:58132656	NA	0.42	7.96	0.4	2.6e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs4934494	0.911	rs7081788	chr10:91408756	G/A	cg19698084	chr10:91461284	KIF20B	-0.45	-6.15	-0.32	2.19e-9	Red blood cell count;
LIHC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	cis	rs611744	0.901	rs2348801	chr8:109167337	C/T	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.14e-10	Dupuytren's disease;
LIHC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.5	3.78e-23	Chronic sinus infection;
LIHC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.61	-7.73	-0.39	1.22e-13	Gut microbiome composition (summer);
LIHC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.4	-6.51	-0.33	2.67e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg00800038	chr16:89945340	TCF25	-0.67	-10.53	-0.49	1.16e-22	Skin colour saturation;
LIHC	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.62	9.95	0.47	1.19e-20	Anterior chamber depth;
LIHC	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.65	7.85	0.39	5.23e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	6.29	0.32	9.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.74	-0.34	6.81e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.39	-5.84	-0.3	1.18e-8	Menarche (age at onset);
LIHC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.89	0.65	5.82e-43	White blood cell count;
LIHC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.87	-12.24	-0.55	8.17e-29	Diastolic blood pressure;
LIHC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.68	-12.72	-0.57	1.24e-30	Refractive error;
LIHC	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg09795085	chr6:101329169	ASCC3	-0.54	-7.62	-0.38	2.5e-13	Neuroticism;
LIHC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	0.99	9.86	0.47	2.35e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	10.19	0.48	1.85e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.69	12.24	0.55	8.46e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.49	8.78	0.43	7.98e-17	Tuberculosis;
LIHC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.55	-8.14	-0.4	7.36e-15	Blood metabolite levels;
LIHC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.95	-0.35	1.85e-11	Neuroticism;
LIHC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.35	5.79	0.3	1.61e-8	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10857712	0.851	rs7913420	chr10:135213854	C/T	cg19623624	chr10:135278901	LOC619207	-0.41	-6.33	-0.32	7.59e-10	Systemic lupus erythematosus;
LIHC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg19774624	chr17:42201019	HDAC5	-0.45	-6.32	-0.32	8.12e-10	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg21486233	chr12:29375141	FAR2	0.31	5.94	0.31	6.9e-9	QT interval;
LIHC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.95e-9	Menopause (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg10038085	chr1:165797905	UCK2	-0.42	-6.4	-0.33	5.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25916527	chr5:72292534	FCHO2	0.51	8.01	0.4	1.78e-14	Bilirubin levels;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg22528358	chr1:107598549	PRMT6	0.72	11.91	0.54	1.35e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.8	-18.23	-0.7	2.41e-52	Urate levels in lean individuals;
LIHC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.3	0.32	9.13e-10	Cognitive test performance;
LIHC	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	7.14	0.36	5.7e-12	Migraine;Coronary artery disease;
LIHC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg09835421	chr16:68378352	PRMT7	-0.55	-6.26	-0.32	1.16e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.78	12.24	0.55	8.09e-29	Resting heart rate;
LIHC	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	0.39	6.15	0.32	2.2e-9	Coronary artery disease;
LIHC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.1	13.42	0.59	2.83e-33	Primary sclerosing cholangitis;
LIHC	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.79	11.85	0.54	2.27e-27	Response to antineoplastic agents;
LIHC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.5	-6.17	-0.32	1.93e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.11	24.65	0.8	8.07e-78	Cortisol levels (saliva);
LIHC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.78	11.71	0.54	7.24e-27	Dental caries;
LIHC	cis	rs564343	0.560	rs11227384	chr11:65799332	G/T	cg08986711	chr11:66045560	CNIH2	0.37	5.71	0.3	2.42e-8	Obesity (early onset extreme);
LIHC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg16797656	chr11:68205561	LRP5	0.54	8.61	0.42	2.63e-16	Total body bone mineral density;
LIHC	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg00864860	chr1:7907996	UTS2	0.6	5.93	0.31	7.29e-9	Inflammatory bowel disease;
LIHC	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.54	8.38	0.41	1.41e-15	Noise-induced hearing loss;
LIHC	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg08539965	chr1:21396338	EIF4G3	0.34	5.93	0.31	7.37e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.56	-7.7	-0.38	1.45e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	12.29	0.55	5.45e-29	Longevity;
LIHC	cis	rs10419226	0.625	rs12974777	chr19:18765663	C/T	cg14292368	chr19:18793705	CRTC1	-0.54	-9.1	-0.44	7.8e-18	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.71	-0.3	2.41e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg19752551	chr11:57585705	CTNND1	-0.52	-7.34	-0.37	1.56e-12	Schizophrenia;
LIHC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.37	-0.49	4.5e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	11.93	0.54	1.11e-27	High light scatter reticulocyte count;
LIHC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.74	0.34	6.56e-11	Ileal carcinoids;
LIHC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.23	-7.3	-0.37	2.09e-12	Mean corpuscular volume;
LIHC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.85	0.39	5.36e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.22	-0.32	1.46e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12463550	chr7:65579703	CRCP	-0.6	-6.32	-0.32	8.39e-10	Diabetic kidney disease;
LIHC	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.45	-6.76	-0.34	5.83e-11	Schizophrenia;
LIHC	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.37	-6.47	-0.33	3.37e-10	IgG glycosylation;
LIHC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.9	19.29	0.72	1.23e-56	Blood protein levels;
LIHC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg08888203	chr3:10149979	C3orf24	0.44	5.73	0.3	2.16e-8	Alzheimer's disease;
LIHC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.66	13.06	0.58	6.68e-32	Schizophrenia;
LIHC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.25	11.04	0.51	2e-24	Uric acid levels;
LIHC	cis	rs11888559	0.655	rs4675315	chr2:204018529	C/T	cg24605529	chr2:203879461	NBEAL1	0.78	5.92	0.31	7.62e-9	Height;
LIHC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.21	0.52	4.87e-25	Coronary artery disease;
LIHC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.83	-0.3	1.3e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs12464559	0.649	rs3922996	chr2:152609668	A/G	cg01189475	chr2:152685088	ARL5A	0.61	7.19	0.36	4.22e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7188697	0.882	rs37054	chr16:58558989	C/T	cg02549819	chr16:58548995	SETD6	-0.46	-7.21	-0.36	3.65e-12	QT interval;
LIHC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.66	10.69	0.5	3.41e-23	Response to diuretic therapy;
LIHC	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.41	6.55	0.33	2.14e-10	Anterior chamber depth;
LIHC	cis	rs6882046	0.513	rs34320	chr5:88021527	T/G	cg22951263	chr5:87985283	NA	-0.38	-6.5	-0.33	2.84e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.71	8.28	0.41	2.86e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.78	12.71	0.57	1.43e-30	Corneal astigmatism;
LIHC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.6	-10.05	-0.48	5.52e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	13.85	0.6	6.27e-35	Lung cancer in ever smokers;
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.48	9.22	0.45	3.06e-18	Endometriosis;
LIHC	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.19	0.48	1.83e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.75	-9.95	-0.47	1.19e-20	Coronary artery disease;
LIHC	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg23461800	chr14:103021989	NA	-0.39	-5.9	-0.3	8.95e-9	Platelet count;
LIHC	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.33	0.55	3.71e-29	Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.42	7.0	0.35	1.33e-11	Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.54e-9	Alzheimer's disease;
LIHC	cis	rs9828933	0.577	rs832194	chr3:63857071	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.84	11.13	0.52	8.99e-25	Type 2 diabetes;
LIHC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg24130564	chr14:104152367	KLC1	0.56	9.78	0.47	4.45e-20	Reticulocyte count;
LIHC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.73	5.95	0.31	6.78e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.19	0.41	5.08e-15	Lymphocyte counts;
LIHC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.43	6.51	0.33	2.67e-10	Post bronchodilator FEV1;
LIHC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.64	0.46	1.34e-19	Platelet count;
LIHC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg24585782	chr17:78113791	EIF4A3	-0.43	-5.75	-0.3	1.95e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.46	6.65	0.34	1.16e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-7.16	-0.36	5.02e-12	Hepatocellular carcinoma;
LIHC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19904058	chr10:135279010	LOC619207	-0.35	-5.71	-0.3	2.46e-8	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg18279126	chr7:2041391	MAD1L1	-0.37	-6.08	-0.31	3.19e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.61	6.99	0.35	1.44e-11	Axial length;
LIHC	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.33	6.56	0.33	1.94e-10	Blood protein levels;
LIHC	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.25	6.17	0.32	1.96e-9	Menarche (age at onset);
LIHC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg18357645	chr12:58087776	OS9	0.42	6.12	0.31	2.62e-9	Multiple sclerosis;
LIHC	trans	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.21	-0.32	1.54e-9	Pulmonary function;
LIHC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.29	-5.9	-0.3	8.69e-9	QRS complex (12-leadsum);
LIHC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.45	8.28	0.41	2.83e-15	Platelet distribution width;
LIHC	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.95	10.45	0.49	2.37e-22	Neuroticism;
LIHC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.92	-0.7	4.26e-51	Gut microbiome composition (summer);
LIHC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg09238746	chr17:78121135	EIF4A3	-0.49	-6.87	-0.35	3.01e-11	Yeast infection;
LIHC	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg27205649	chr11:78285834	NARS2	0.43	6.35	0.32	6.85e-10	Alzheimer's disease (survival time);
LIHC	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.5	-7.82	-0.39	6.65e-14	Schizophrenia;
LIHC	cis	rs7129220	0.858	rs61878630	chr11:10132815	A/T	cg01453529	chr11:10209919	SBF2	-0.38	-6.88	-0.35	2.92e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-7.25	-0.36	2.79e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.3	-0.45	1.73e-18	Breast cancer;
LIHC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	0.93	21.3	0.76	1.1e-64	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.05	-0.36	9.88e-12	Reticulocyte count;
LIHC	cis	rs6693567	0.826	rs1260387	chr1:150371448	T/C	cg18016565	chr1:150552671	MCL1	-0.37	-6.11	-0.31	2.66e-9	Migraine;
LIHC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	10.53	0.49	1.2e-22	Personality dimensions;
LIHC	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg06664874	chr5:179499304	RNF130	0.58	7.08	0.36	8.06e-12	LDL cholesterol;
LIHC	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg03999872	chr20:62272968	STMN3	-0.45	-6.8	-0.35	4.72e-11	Atopic dermatitis;
LIHC	cis	rs7712401	0.686	rs246305	chr5:122199606	A/T	cg18764291	chr5:122110994	SNX2	0.33	5.82	0.3	1.37e-8	Mean platelet volume;
LIHC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.71	0.34	8.11e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67981189	0.593	rs221925	chr14:71579629	T/G	cg15816911	chr14:71606274	NA	-0.42	-6.75	-0.34	6.31e-11	Schizophrenia;
LIHC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17507749	chr15:85114479	UBE2QP1	0.66	7.54	0.38	4.21e-13	Schizophrenia;
LIHC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.75	0.3	2.01e-8	Schizophrenia;
LIHC	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.78	11.15	0.52	7.64e-25	Pediatric areal bone mineral density (radius);
LIHC	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.13	-0.44	5.97e-18	Exhaled nitric oxide output;
LIHC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-12.72	-0.57	1.27e-30	Height;
LIHC	trans	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg17675199	chr6:35436792	RPL10A	-0.45	-9.17	-0.44	4.52e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.19	0.36	4.08e-12	Electroencephalogram traits;
LIHC	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	0.72	7.9	0.39	3.82e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.24	0.81	4.27e-80	Prudent dietary pattern;
LIHC	cis	rs965469	0.779	rs6037546	chr20:3298697	G/T	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	trans	rs10411161	0.702	rs10420224	chr19:52398955	A/G	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.78e-13	Chronic sinus infection;
LIHC	cis	rs425535	0.588	rs6810940	chr4:74842189	A/G	cg02530824	chr4:74847766	PF4	0.37	6.07	0.31	3.46e-9	Blood protein levels;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.75	0.8	3.17e-78	Prudent dietary pattern;
LIHC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg02344993	chr17:57696989	CLTC	0.7	11.74	0.54	5.5e-27	Hemoglobin concentration;
LIHC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-6.88	-0.35	2.84e-11	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg08888203	chr3:10149979	C3orf24	0.59	6.57	0.33	1.92e-10	Alzheimer's disease;
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.64	9.44	0.45	6.15e-19	Lymphocyte counts;
LIHC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg05697976	chr12:29376483	FAR2	0.31	6.3	0.32	9.28e-10	QT interval;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02438054	chr19:4791315	FEM1A	-0.58	-6.78	-0.34	5.14e-11	Systolic blood pressure;
LIHC	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.45	-7.01	-0.35	1.29e-11	Type 2 diabetes;
LIHC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.59	-6.0	-0.31	5.1e-9	Rheumatoid arthritis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05391628	chr12:49463937	RHEBL1	0.44	6.5	0.33	2.83e-10	Cognitive function;
LIHC	cis	rs1419980	0.730	rs12229540	chr12:7776578	A/C	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg19773385	chr1:10388646	KIF1B	-0.47	-8.03	-0.4	1.58e-14	Hepatocellular carcinoma;
LIHC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07305463	chr2:136567211	LCT	-0.38	-7.24	-0.36	2.99e-12	Mosquito bite size;
LIHC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.88	-17.01	-0.68	1.81e-47	Height;
LIHC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg09137382	chr11:130731461	NA	0.39	5.85	0.3	1.16e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg13647721	chr17:30228624	UTP6	0.69	6.72	0.34	7.39e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.17	-0.32	1.89e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.42	5.94	0.31	7.11e-9	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-8.44	-0.42	8.96e-16	Parkinson's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04309227	chr1:26561027	CCDC21	0.5	7.14	0.36	5.55e-12	Pancreatic cancer;
LIHC	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.47	-6.95	-0.35	1.86e-11	Plateletcrit;
LIHC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-8.28	-0.41	2.73e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.74	-9.77	-0.47	4.64e-20	Schizophrenia;
LIHC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.98	0.44	1.78e-17	Platelet count;
LIHC	cis	rs4908760	0.827	rs11121210	chr1:8708529	T/C	cg20416874	chr1:8611966	RERE	-0.64	-12.78	-0.57	7.53e-31	Vitiligo;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25632300	chr5:174905618	SFXN1	0.59	7.71	0.38	1.4e-13	Lung function (FEV1/FVC);
LIHC	cis	rs11958404	0.929	rs72816533	chr5:157413352	G/T	cg05962755	chr5:157440814	NA	0.96	10.52	0.49	1.28e-22	IgG glycosylation;
LIHC	cis	rs7919006	1.000	rs6480766	chr10:76803880	G/A	cg01390419	chr10:76803856	DUPD1	0.5	7.82	0.39	6.68e-14	Weight;
LIHC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg03013999	chr17:37608204	MED1	-0.35	-5.82	-0.3	1.38e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.02	0.4	1.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.21	0.36	3.69e-12	Height;
LIHC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02634712	chr18:19750909	GATA6	0.45	6.06	0.31	3.67e-9	Pancreatic cancer;
LIHC	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.36	-5.72	-0.3	2.33e-8	Hypospadias;
LIHC	cis	rs12464559	0.579	rs2293221	chr2:152653380	C/T	cg01189475	chr2:152685088	ARL5A	0.62	7.33	0.37	1.65e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg08499158	chr17:42289980	UBTF	-0.52	-8.52	-0.42	5.11e-16	Total body bone mineral density;
LIHC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg09835421	chr16:68378352	PRMT7	-0.63	-7.96	-0.4	2.5e-14	Schizophrenia;
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.27	6.29	0.32	9.88e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.49	6.69	0.34	9.11e-11	Morning vs. evening chronotype;
LIHC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs11229555	0.645	rs11229450	chr11:58201629	G/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.62	10.1	0.48	3.55e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26695837	chr4:37688098	RELL1	-0.51	-6.5	-0.33	2.85e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.8	-0.3	1.48e-8	Ulcerative colitis;
LIHC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.39	-6.01	-0.31	4.72e-9	Glioblastoma;
LIHC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg06046430	chr4:77819534	ANKRD56	0.51	6.26	0.32	1.12e-9	Emphysema distribution in smoking;
LIHC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg07424592	chr7:64974309	NA	0.81	9.47	0.46	4.62e-19	Diabetic kidney disease;
LIHC	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.47	7.61	0.38	2.64e-13	Metabolite levels;
LIHC	cis	rs7546668	1.000	rs1129347	chr1:15817334	G/A	cg11706911	chr1:15910989	AGMAT	0.4	6.04	0.31	3.95e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11905131	chr22:24372483	LOC391322	-0.78	-12.24	-0.55	8.29e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg06627628	chr2:24431161	ITSN2	-0.64	-7.39	-0.37	1.16e-12	Lymphocyte counts;
LIHC	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.88	11.08	0.51	1.38e-24	Blood protein levels;
LIHC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.46	-0.37	7.12e-13	Body mass index;
LIHC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.59	8.09	0.4	1.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg13271783	chr10:134563150	INPP5A	-0.56	-7.07	-0.36	8.51e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	18.45	0.71	3.04e-53	Testicular germ cell tumor;
LIHC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-22.76	-0.78	1.8e-70	Myeloid white cell count;
LIHC	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.45	7.28	0.37	2.35e-12	Corneal astigmatism;
LIHC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.56	0.38	3.67e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.64	-0.34	1.25e-10	Type 2 diabetes;
LIHC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-8.55	-0.42	4.04e-16	Bipolar disorder;
LIHC	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.72	-0.39	1.26e-13	Obesity-related traits;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.92	14.08	0.61	8.22e-36	Skin colour saturation;
LIHC	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.75	-0.71	1.96e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-0.74	-8.45	-0.42	8.62e-16	Hip circumference adjusted for BMI;
LIHC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.39	0.56	2.28e-29	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-19.96	-0.73	2.55e-59	Height;
LIHC	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg05714579	chr10:131428358	MGMT	0.41	6.52	0.33	2.54e-10	Response to temozolomide;
LIHC	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.99	0.48	8.49e-21	Corneal astigmatism;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	6.97	0.35	1.65e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.4	-0.33	5e-10	Total body bone mineral density;
LIHC	cis	rs3748682	1.000	rs3748682	chr1:38279987	C/T	cg12658694	chr1:38397304	INPP5B	-0.46	-6.29	-0.32	9.53e-10	Hypothyroidism;
LIHC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.98	0.65	2.62e-43	White blood cell count;
LIHC	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.5	8.87	0.43	4.04e-17	Coronary artery disease;
LIHC	trans	rs1814175	0.618	rs7483546	chr11:49714784	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.18e-11	Height;
LIHC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.8	-0.3	1.51e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.74	-0.3	2.04e-8	Colorectal cancer;
LIHC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.76	11.47	0.53	5.31e-26	Coronary artery disease;
LIHC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.73	5.76	0.3	1.88e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-7.01	-0.35	1.29e-11	Electroencephalogram traits;
LIHC	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.1	0.44	7.66e-18	Platelet count;
LIHC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.92	0.43	2.94e-17	Multiple sclerosis;
LIHC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.69	0.34	8.86e-11	Mean corpuscular volume;
LIHC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.09	-0.31	3.05e-9	Tonsillectomy;
LIHC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.52	7.88	0.39	4.47e-14	Menarche (age at onset);
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg24693881	chr1:107596107	NA	0.56	9.87	0.47	2.22e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.39	6.16	0.32	2.01e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.6	-8.51	-0.42	5.35e-16	Blood metabolite levels;
LIHC	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.43	5.87	0.3	1.01e-8	Plateletcrit;
LIHC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg21573476	chr21:45109991	RRP1B	-0.53	-9.94	-0.47	1.25e-20	Mean corpuscular volume;
LIHC	cis	rs2412488	0.853	rs12507739	chr4:54352768	C/T	cg22241045	chr4:54363911	LNX1	-0.44	-7.05	-0.36	9.9e-12	DNA methylation (variation);
LIHC	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.62	-6.72	-0.34	7.72e-11	Prostate cancer;
LIHC	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.46	-7.2	-0.36	3.76e-12	Type 2 diabetes;
LIHC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.54	8.06	0.4	1.28e-14	HIV-1 control;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17524854	chr12:67663046	CAND1	0.48	7.83	0.39	5.99e-14	Cognitive function;
LIHC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.57	8.22	0.41	4.29e-15	Emphysema distribution in smoking;
LIHC	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg26694713	chr4:57773883	REST	0.67	9.01	0.44	1.44e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.2	0.32	1.61e-9	Prudent dietary pattern;
LIHC	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	6.65	0.34	1.19e-10	Response to antipsychotic treatment;
LIHC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.53	7.56	0.38	3.75e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-8.2	-0.41	4.88e-15	Gut microbiome composition (summer);
LIHC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-6.5	-0.33	2.78e-10	Height;
LIHC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.71	7.21	0.36	3.53e-12	Vitiligo;
LIHC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-8.69	-0.43	1.52e-16	Vitiligo;
LIHC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.73	-0.43	1.12e-16	Heart rate;
LIHC	cis	rs1198430	0.636	rs2156087	chr1:23743581	C/G	cg13183780	chr1:23809682	ASAP3	0.35	6.3	0.32	9.34e-10	Total cholesterol levels;
LIHC	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg14930904	chr10:32216787	ARHGAP12	0.39	6.92	0.35	2.21e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25184507	chr17:7760147	CYB5D1;LSMD1	0.47	6.8	0.35	4.69e-11	Pancreatic cancer;
LIHC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-0.84	-9.29	-0.45	1.86e-18	Exhaled nitric oxide output;
LIHC	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.43	-6.4	-0.33	5.11e-10	Dementia with Lewy bodies;
LIHC	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.39	-5.82	-0.3	1.34e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04317338	chr11:64019027	PLCB3	0.48	6.57	0.33	1.91e-10	Platelet count;
LIHC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg25894440	chr7:65020034	NA	0.52	5.94	0.31	7.16e-9	Diabetic kidney disease;
LIHC	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Corneal astigmatism;
LIHC	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.63	9.29	0.45	1.82e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.29	0.32	9.72e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.36	6.3	0.32	8.94e-10	Metabolite levels;
LIHC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.55	-9.7	-0.46	7.95e-20	Coronary artery disease;
LIHC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	1.05	21.17	0.75	3.6e-64	Breast cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25310909	chr1:165738087	TMCO1	-0.52	-6.24	-0.32	1.26e-9	Systolic blood pressure;
LIHC	cis	rs1866706	0.739	rs7116989	chr11:12856087	G/A	cg25843174	chr11:12811716	TEAD1	-0.32	-6.69	-0.34	8.89e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.57	7.81	0.39	7.06e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.31	-0.32	8.63e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18864164	chr10:115934049	MIR2110;C10orf118	0.42	6.21	0.32	1.54e-9	Pancreatic cancer;
LIHC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.38	6.06	0.31	3.67e-9	Menopause (age at onset);
LIHC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.84	16.07	0.66	1.06e-43	Height;
LIHC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.96	-0.35	1.78e-11	Diabetic kidney disease;
LIHC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.3	7.51	0.38	5.34e-13	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06185204	chr15:80351985	ZFAND6	0.42	6.96	0.35	1.75e-11	Pancreatic cancer;
LIHC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.53	-6.7	-0.34	8.63e-11	Prostate cancer;
LIHC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.09	0.4	1.02e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.69	9.32	0.45	1.49e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.66	10.72	0.5	2.54e-23	Schizophrenia;
LIHC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.69	-10.59	-0.5	7.67e-23	Longevity;
LIHC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-9.44	-0.45	5.85e-19	Schizophrenia;
LIHC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.59	0.38	3.03e-13	Bipolar disorder;
LIHC	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.52	-7.35	-0.37	1.48e-12	Obesity-related traits;
LIHC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-10.57	-0.5	8.92e-23	Personality dimensions;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg14671364	chr1:107599128	PRMT6	0.48	6.96	0.35	1.71e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.12	0.55	2.27e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.56	7.76	0.39	9.92e-14	Neuroblastoma;
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.32	-7.05	-0.36	9.7e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.44	7.32	0.37	1.81e-12	Endometrial cancer;
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.86	-0.39	5.09e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.43e-11	Height;
LIHC	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.71	-10.99	-0.51	2.85e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.81	13.04	0.58	7.7e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg08992911	chr2:238395768	MLPH	0.67	6.98	0.35	1.58e-11	Prostate cancer;
LIHC	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.94	-16.48	-0.67	2.58e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.87	0.47	2.2e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg24693881	chr1:107596107	NA	-0.55	-9.72	-0.47	6.99e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.73	-9.13	-0.44	5.99e-18	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs7296418	0.961	rs61955196	chr12:123451018	G/C	cg06742321	chr12:123595122	PITPNM2	0.33	5.99	0.31	5.32e-9	Platelet count;
LIHC	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.4	-6.42	-0.33	4.69e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.47	0.37	6.67e-13	Aortic root size;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg11557530	chr8:9911760	MSRA	-0.52	-6.42	-0.33	4.51e-10	Monocyte count;
LIHC	cis	rs10792665	0.512	rs10431163	chr11:82641500	G/A	cg24227371	chr11:82718527	RAB30	-0.3	-7.02	-0.35	1.19e-11	Obesity-related traits;
LIHC	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg15208524	chr1:10270712	KIF1B	0.44	6.5	0.33	2.77e-10	Hepatocellular carcinoma;
LIHC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.73	-12.09	-0.55	2.84e-28	Systemic lupus erythematosus;
LIHC	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg26138937	chr11:71823887	C11orf51	-1.31	-10.43	-0.49	2.7e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.79	15.51	0.64	1.81e-41	Longevity;
LIHC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.31e-20	Menopause (age at onset);
LIHC	cis	rs17106184	1.000	rs72898966	chr1:50969571	A/G	cg07174182	chr1:51127561	FAF1	-0.58	-6.32	-0.32	8.21e-10	Type 2 diabetes;
LIHC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg00204512	chr16:28754710	NA	0.42	7.12	0.36	6.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.52	6.92	0.35	2.19e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.18	-0.55	1.37e-28	Alzheimer's disease;
LIHC	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07080220	chr10:102295463	HIF1AN	0.44	5.95	0.31	6.7e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg17796960	chr10:135278976	LOC619207	-0.35	-5.74	-0.3	2.1e-8	Systemic lupus erythematosus;
LIHC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.9	0.3	8.79e-9	Self-reported allergy;
LIHC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.45	7.44	0.37	8.25e-13	Response to temozolomide;
LIHC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.96	18.31	0.7	1.11e-52	Ewing sarcoma;
LIHC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.44	0.53	7.27e-26	Motion sickness;
LIHC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.9	-18.73	-0.71	2.22e-54	Height;
LIHC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.14	-28.66	-0.84	6.41e-93	IgG glycosylation;
LIHC	cis	rs8053891	0.756	rs12708922	chr16:72001629	A/G	cg01557791	chr16:72042693	DHODH	-0.47	-6.84	-0.35	3.7e-11	Coronary artery disease;
LIHC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg03037974	chr15:76606532	NA	0.81	16.67	0.67	4.37e-46	Blood metabolite levels;
LIHC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.48	-8.21	-0.41	4.57e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.1	0.55	2.66e-28	Cognitive test performance;
LIHC	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg20387954	chr3:183756860	HTR3D	0.28	5.98	0.31	5.57e-9	Anterior chamber depth;
LIHC	cis	rs10924970	0.649	rs4659763	chr1:235447779	T/C	cg26050004	chr1:235667680	B3GALNT2	0.4	5.77	0.3	1.8e-8	Asthma;
LIHC	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg09003973	chr2:102972529	NA	0.81	7.09	0.36	7.59e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs11673344	0.764	rs1644643	chr19:37463171	G/A	cg27390819	chr19:37464633	NA	-0.53	-6.29	-0.32	9.74e-10	Obesity-related traits;
LIHC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg04450456	chr4:17643702	FAM184B	0.34	5.74	0.3	2.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.75	-10.72	-0.5	2.67e-23	Mosquito bite size;
LIHC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg12798992	chr6:167411361	FGFR1OP	0.46	7.19	0.36	4.2e-12	Crohn's disease;
LIHC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.82	-15.66	-0.65	4.84e-42	Height;
LIHC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7074356	0.915	rs1870146	chr10:82210379	A/G	cg00277334	chr10:82204260	NA	-0.75	-6.47	-0.33	3.33e-10	Borderline personality disorder;
LIHC	cis	rs3741798	1.000	rs61922054	chr12:12499472	A/G	cg08615371	chr12:12503544	MANSC1	0.9	7.28	0.37	2.29e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.82	13.59	0.59	5.96e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.67	8.61	0.42	2.8e-16	Corneal astigmatism;
LIHC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.59	-11.77	-0.54	4.34e-27	Coronary artery disease;
LIHC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.7	7.89	0.39	4.18e-14	Migraine;Coronary artery disease;
LIHC	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-1.03	-15.49	-0.64	2.33e-41	Dilated cardiomyopathy;
LIHC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.66	-11.03	-0.51	2.04e-24	Bipolar disorder;
LIHC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.48	0.33	3.27e-10	Alzheimer's disease (late onset);
LIHC	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.34	5.89	0.3	9.4e-9	Mean corpuscular volume;
LIHC	trans	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg09872104	chr7:134855509	C7orf49	-0.79	-6.33	-0.32	7.48e-10	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14067834	chr17:29058358	SUZ12P	0.6	6.29	0.32	9.74e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg03441853	chr15:73075003	ADPGK	0.28	5.8	0.3	1.5e-8	Triglyceride levels;
LIHC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg14393609	chr7:65229607	NA	0.37	5.84	0.3	1.22e-8	Aortic root size;
LIHC	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.01	20.59	0.74	7.62e-62	Schizophrenia;
LIHC	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs8084351	0.577	rs9949928	chr18:50608590	A/G	cg24270629	chr18:50823537	DCC	0.46	6.94	0.35	2.02e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.16	-0.36	5.13e-12	Metabolite levels;
LIHC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg04155231	chr12:9217510	LOC144571	0.31	5.9	0.3	8.77e-9	Sjögren's syndrome;
LIHC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg16479474	chr6:28041457	NA	0.38	6.25	0.32	1.19e-9	Parkinson's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08655493	chr21:33765248	URB1;C21orf119	0.47	6.68	0.34	9.51e-11	Pancreatic cancer;
LIHC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg10935138	chr17:73851978	WBP2	0.49	7.3	0.37	2.01e-12	White matter hyperintensity burden;
LIHC	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.8	-8.58	-0.42	3.26e-16	Vitiligo;
LIHC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.15	0.36	5.14e-12	Protein C levels;
LIHC	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.55	-8.58	-0.42	3.43e-16	White matter hyperintensity burden;
LIHC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17467752	chr17:38218738	THRA	0.4	6.05	0.31	3.79e-9	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.34	-6.74	-0.34	6.71e-11	Body mass index;
LIHC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.76	-9.91	-0.47	1.62e-20	Type 2 diabetes;
LIHC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg07150772	chr14:90864620	CALM1	-0.42	-5.95	-0.31	6.5e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19671926	chr4:122722719	EXOSC9	0.46	6.69	0.34	9.39e-11	Type 2 diabetes;
LIHC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.39	0.61	4.75e-37	Myeloid white cell count;
LIHC	cis	rs2723064	0.516	rs17849707	chr2:65298839	A/G	cg05010058	chr2:65284262	CEP68	0.37	5.87	0.3	1.02e-8	Atrial fibrillation;
LIHC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg22834771	chr12:69754056	YEATS4	-0.37	-5.96	-0.31	6.19e-9	Blood protein levels;
LIHC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg00343986	chr7:65444356	GUSB	-0.39	-5.83	-0.3	1.31e-8	Aortic root size;
LIHC	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	0.94	13.54	0.59	1.01e-33	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17554472	chr22:41940697	POLR3H	0.56	6.23	0.32	1.34e-9	Vitiligo;
LIHC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg26149184	chr10:133730230	NA	0.47	7.49	0.38	5.75e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	0.81	14.22	0.61	2.18e-36	Eosinophil percentage of white cells;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.89	-0.3	9.01e-9	Total body bone mineral density;
LIHC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	10.4	0.49	3.4e-22	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.59	9.04	0.44	1.22e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.18	0.32	1.77e-9	Renal cell carcinoma;
LIHC	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.4	-5.73	-0.3	2.24e-8	Plateletcrit;
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.38	7.55	0.38	3.96e-13	Renal cell carcinoma;
LIHC	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-6.96	-0.35	1.75e-11	Response to antipsychotic treatment;
LIHC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.94	-0.31	7.07e-9	Colorectal cancer;
LIHC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.88	16.22	0.66	2.85e-44	Coronary artery disease;
LIHC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.06	-0.31	3.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-1.02	-19.52	-0.73	1.47e-57	Breast cancer;
LIHC	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.8	10.51	0.49	1.37e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs12464559	0.649	rs7557801	chr2:152586658	G/A	cg01189475	chr2:152685088	ARL5A	0.67	7.78	0.39	8.52e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs4788570	0.584	rs6499534	chr16:71755278	C/G	cg06353428	chr16:71660113	MARVELD3	1.38	15.03	0.63	1.45e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.72	-8.74	-0.43	1.07e-16	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.36	6.51	0.33	2.61e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg14784868	chr12:69753453	YEATS4	0.56	7.92	0.39	3.35e-14	Response to diuretic therapy;
LIHC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.26	-0.32	1.15e-9	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.08	13.0	0.57	1.16e-31	Primary sclerosing cholangitis;
LIHC	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.66	-0.34	1.1e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.51	7.98	0.4	2.24e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	0.53	10.05	0.48	5.28e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	1.01	14.13	0.61	5.2e-36	Breast cancer;
LIHC	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.35	-7.37	-0.37	1.3e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-1.0	-16.77	-0.67	1.79e-46	Body mass index;
LIHC	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg09003973	chr2:102972529	NA	0.82	7.15	0.36	5.19e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.57	6.84	0.35	3.72e-11	Alzheimer's disease;
LIHC	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.46	8.45	0.42	8.7e-16	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.49	6.96	0.35	1.7e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	1.03	18.16	0.7	4.44e-52	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.57	-0.5	8.81e-23	Hemoglobin concentration;
LIHC	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg01557791	chr16:72042693	DHODH	-0.49	-7.03	-0.36	1.09e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LIHC	cis	rs2710642	0.611	rs1527959	chr2:62867413	T/C	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs5015933	0.815	rs13297440	chr9:128087200	C/G	cg14078157	chr9:128172775	NA	-0.37	-5.85	-0.3	1.13e-8	Body mass index;
LIHC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.73	-0.43	1.12e-16	Hemoglobin concentration;
LIHC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.97e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.0	14.61	0.62	6.55e-38	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	9.45	0.45	5.67e-19	Platelet count;
LIHC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-6.52	-0.33	2.57e-10	Neuroticism;
LIHC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.43	-7.85	-0.39	5.51e-14	Schizophrenia;
LIHC	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.36	7.19	0.36	4.12e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.8	-17.92	-0.7	4.12e-51	Urate levels in lean individuals;
LIHC	cis	rs11871801	0.915	rs647397	chr17:40679398	G/A	cg14558262	chr17:40713999	COASY	0.56	7.65	0.38	2.11e-13	Crohn's disease;
LIHC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.34	-0.56	3.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.53	-6.97	-0.35	1.68e-11	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.78	-13.02	-0.58	9.62e-32	Coronary artery disease;
LIHC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg14067834	chr17:29058358	SUZ12P	0.74	7.49	0.38	5.96e-13	Body mass index;
LIHC	cis	rs2834188	0.883	rs16997869	chr21:34696867	C/T	cg04842828	chr21:34696676	IFNAR1	-0.46	-6.22	-0.32	1.47e-9	Narcolepsy;
LIHC	trans	rs7668874	0.779	rs9997910	chr4:116754123	C/A	cg08917878	chr5:172668965	NA	-0.3	-6.05	-0.31	3.89e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.91	-18.02	-0.7	1.61e-51	Coronary artery disease;
LIHC	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.5e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.68	-8.79	-0.43	7.44e-17	Aortic root size;
LIHC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.26	-0.37	2.63e-12	Platelet count;
LIHC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.93	-15.87	-0.65	6.71e-43	Electrocardiographic conduction measures;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg21458073	chr7:35840614	SEPT7	-0.43	-6.5	-0.33	2.91e-10	Eotaxin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12580275	chr1:205744413	RAB7L1	0.51	7.01	0.35	1.26e-11	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.86	15.55	0.64	1.35e-41	Menopause (age at onset);
LIHC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg05555928	chr11:63887634	MACROD1	0.5	6.6	0.34	1.62e-10	Mean platelet volume;
LIHC	cis	rs7129556	0.520	rs4945185	chr11:77318142	G/A	cg03570279	chr11:77446074	RSF1	-0.35	-6.64	-0.34	1.2e-10	Weight loss (gastric bypass surgery);
LIHC	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.37	-6.16	-0.32	2.06e-9	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg24296786	chr1:45957014	TESK2	0.42	6.37	0.33	6.25e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	0.8	13.44	0.59	2.34e-33	Total cholesterol levels;
LIHC	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.57	-0.33	1.83e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.43	5.75	0.3	1.99e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00809820	chr17:80708513	TBCD;FN3K	-0.39	-6.94	-0.35	1.93e-11	Glycated hemoglobin levels;
LIHC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg08210727	chr20:33865349	NA	0.51	5.89	0.3	9.43e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.53	7.88	0.39	4.37e-14	Longevity;
LIHC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.48	6.41	0.33	4.93e-10	Mean platelet volume;
LIHC	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.17e-24	Eye color traits;
LIHC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.23	0.32	1.37e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg19623624	chr10:135278901	LOC619207	-0.41	-6.31	-0.32	8.86e-10	Systemic lupus erythematosus;
LIHC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.72	9.24	0.45	2.63e-18	Gut microbiome composition (summer);
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg14828511	chr1:107599125	PRMT6	0.42	6.03	0.31	4.15e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.23	-0.32	1.38e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.72	-14.0	-0.6	1.6e-35	Height;
LIHC	cis	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg03342759	chr3:160939853	NMD3	0.56	7.31	0.37	1.87e-12	Morning vs. evening chronotype;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.46	5.86	0.3	1.08e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.28	16.98	0.68	2.52e-47	Diabetic kidney disease;
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.77	-0.3	1.75e-8	Total body bone mineral density;
LIHC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.29	-0.78	1.57e-72	Height;
LIHC	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.32	0.61	8.9e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	11.17	0.52	6.5e-25	Prudent dietary pattern;
LIHC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs2758596	1.000	rs2842875	chr1:156161794	T/C	cg24450063	chr1:156163899	SLC25A44	0.98	9.96	0.47	1.07e-20	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg14440974	chr22:39074834	NA	-0.45	-7.35	-0.37	1.49e-12	Menopause (age at onset);
LIHC	trans	rs72632736	0.881	rs72632727	chr1:4442940	T/A	cg21153040	chr19:13985688	MIR181D	-0.47	-6.24	-0.32	1.27e-9	Systemic juvenile idiopathic arthritis;
LIHC	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	10.31	0.49	6.92e-22	Obesity-related traits;
LIHC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.25	6.03	0.31	4.32e-9	Crohn's disease;
LIHC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.49	9.18	0.44	4.06e-18	Hemoglobin concentration;
LIHC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	17.37	0.68	6.68e-49	Lung cancer in ever smokers;
LIHC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08219700	chr8:58056026	NA	0.51	6.93	0.35	2.07e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg15105060	chr4:7024189	TBC1D14	-0.77	-6.38	-0.33	5.87e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.37	5.84	0.3	1.21e-8	Coronary artery disease;
LIHC	trans	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21659725	chr3:3221576	CRBN	0.57	8.19	0.4	5.34e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2273156	0.706	rs7144617	chr14:35498059	C/T	cg16230307	chr14:35515116	FAM177A1	-0.44	-6.29	-0.32	9.76e-10	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.44	7.32	0.37	1.76e-12	Corneal astigmatism;
LIHC	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.36	0.45	1.08e-18	Corneal astigmatism;
LIHC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.67	10.03	0.48	6.3e-21	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.84	0.35	3.73e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	12.08	0.55	3.32e-28	Cognitive test performance;
LIHC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	10.07	0.48	4.79e-21	Multiple sclerosis;
LIHC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.38	6.18	0.32	1.82e-9	Menopause (age at onset);
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04498913	chr7:1135747	C7orf50	0.44	6.94	0.35	2.03e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10651618	chr6:90122152	RRAGD	0.48	6.82	0.35	4.1e-11	Hepatitis;
LIHC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.1	0.36	7.06e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.54	-8.22	-0.41	4.31e-15	Schizophrenia;
LIHC	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.32	7.27	0.37	2.45e-12	Blood metabolite ratios;
LIHC	cis	rs8081395	0.836	rs2150879	chr17:57859210	G/A	cg02344993	chr17:57696989	CLTC	-0.43	-7.16	-0.36	5.07e-12	White blood cell count;
LIHC	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg16070018	chr6:26224392	HIST1H3E	0.42	5.89	0.3	9.11e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg25179470	chr10:102756915	LZTS2	0.45	6.26	0.32	1.17e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	9.92	0.47	1.5e-20	Chronic sinus infection;
LIHC	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg14067834	chr17:29058358	SUZ12P	0.61	6.27	0.32	1.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.6	-8.51	-0.42	5.7e-16	Lung cancer in ever smokers;
LIHC	cis	rs7945718	0.905	rs7949728	chr11:12728595	C/G	cg25843174	chr11:12811716	TEAD1	0.35	7.96	0.4	2.52e-14	Educational attainment (years of education);
LIHC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.37	-6.6	-0.34	1.56e-10	Coronary artery disease;
LIHC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02985541	chr2:219472218	PLCD4	0.4	6.22	0.32	1.41e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.85	13.68	0.59	2.7200000000000002e-34	Glomerular filtration rate (creatinine);
LIHC	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.54e-11	Type 2 diabetes;
LIHC	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.37	-5.94	-0.31	7.07e-9	Lewy body disease;
LIHC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.42	0.33	4.58e-10	Morning vs. evening chronotype;
LIHC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	8.91	0.43	3.18e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.5	7.18	0.36	4.44e-12	High light scatter reticulocyte count;
LIHC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.45	7.36	0.37	1.42e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.53	7.7	0.38	1.5e-13	Schizophrenia;
LIHC	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.5	8.98	0.44	1.88e-17	Leprosy;
LIHC	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.33	0.55	3.71e-29	Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09060823	chr12:56862504	SPRYD4	0.56	7.79	0.39	8.2e-14	Pancreatic cancer;
LIHC	cis	rs2257205	0.667	rs78253932	chr17:56804101	C/G	cg12560992	chr17:57184187	TRIM37	0.72	7.9	0.39	3.98e-14	Pancreatic cancer;
LIHC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-8.55	-0.42	4.24e-16	Morning vs. evening chronotype;
LIHC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04498913	chr7:1135747	C7orf50	0.41	6.56	0.33	2.02e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.93	-0.31	7.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.91	0.35	2.39e-11	Vitiligo;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05062814	chr6:39083007	C6orf64	0.43	6.11	0.31	2.73e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.1	-0.31	2.87e-9	Total body bone mineral density;
LIHC	cis	rs79149102	0.737	rs75128970	chr15:75181397	C/T	cg16226627	chr15:75307476	SCAMP5	0.43	6.1	0.31	2.9e-9	Lung cancer;
LIHC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.8	12.72	0.57	1.27e-30	Longevity;
LIHC	cis	rs7818688	0.745	rs73271178	chr8:95907230	C/T	cg16049864	chr8:95962084	TP53INP1	0.58	6.64	0.34	1.25e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs783540	1.000	rs1259180	chr15:83244680	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.7	-0.34	8.5e-11	Schizophrenia;
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	7.93	0.39	3.23e-14	Height;
LIHC	trans	rs16962242	1.000	rs10220266	chr13:104049586	G/C	cg12071008	chr17:76457640	DNAH17	0.46	6.09	0.31	3.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.67	10.61	0.5	6.29e-23	Longevity;
LIHC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27189623	chr16:705930	WDR90	0.43	7.04	0.36	1.06e-11	Height;
LIHC	cis	rs10508774	1.000	rs1333221	chr10:32903423	G/C	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.75	10.55	0.5	1.04e-22	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.41e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-0.42	-6.6	-0.34	1.58e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg14393609	chr7:65229607	NA	-0.42	-6.03	-0.31	4.27e-9	Aortic root size;
LIHC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.51	-7.64	-0.38	2.19e-13	Total body bone mineral density;
LIHC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-8.4	-0.41	1.22e-15	Morning vs. evening chronotype;
LIHC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg09835421	chr16:68378352	PRMT7	-0.83	-9.98	-0.47	9.6e-21	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.26	0.58	1.15e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.33	7.01	0.35	1.27e-11	Ulcerative colitis;
LIHC	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-7.06	-0.36	9.57e-12	Neuroticism;
LIHC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg03013999	chr17:37608204	MED1	-0.36	-6.12	-0.31	2.49e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	9.93	0.47	1.38e-20	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.13	0.4	7.9e-15	Motion sickness;
LIHC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.71	-0.3	2.45e-8	Subjective well-being;
LIHC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg09835421	chr16:68378352	PRMT7	-0.74	-8.29	-0.41	2.58e-15	Magnesium levels;
LIHC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.35e-8	Bladder cancer;
LIHC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.48	7.23	0.36	3.19e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.53	-8.89	-0.43	3.56e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.85	10.04	0.48	6.01e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.4	7.58	0.38	3.39e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-0.96	-8.89	-0.43	3.6e-17	Diabetic retinopathy;
LIHC	cis	rs2282802	0.685	rs11750229	chr5:139559014	T/G	cg26211634	chr5:139558579	C5orf32	-0.38	-5.92	-0.3	7.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg16797656	chr11:68205561	LRP5	0.4	5.9	0.3	8.53e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.9	-0.3	8.64e-9	Longevity;
LIHC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-8.53	-0.42	4.65e-16	Heart rate;
LIHC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.84	0.35	3.73e-11	Bladder cancer;
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg08916839	chr5:415575	AHRR	0.29	6.31	0.32	8.64e-10	Cystic fibrosis severity;
LIHC	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg27523141	chr10:43048294	ZNF37B	0.4	6.76	0.34	6.02e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12928939	0.859	rs11670	chr16:71679027	G/T	cg03805757	chr16:71968109	PKD1L3	-0.67	-7.35	-0.37	1.43e-12	Post bronchodilator FEV1;
LIHC	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg17385448	chr1:15911702	AGMAT	0.4	6.73	0.34	7.25e-11	Systolic blood pressure;
LIHC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.57	-0.33	1.89e-10	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.2	0.36	3.91e-12	Morning vs. evening chronotype;
LIHC	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	1.0	19.08	0.72	8.79e-56	Breast cancer;
LIHC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.42	6.78	0.34	5.37e-11	Height;
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.61	-0.5	6.33e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.44	-0.56	1.43e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg06453172	chr10:134556979	INPP5A	0.54	7.71	0.38	1.41e-13	Migraine;
LIHC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.44	-5.86	-0.3	1.08e-8	Obesity-related traits;
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02711726	chr17:80685570	FN3KRP	-0.49	-9.06	-0.44	1.03e-17	Glycated hemoglobin levels;
LIHC	trans	rs783540	0.967	rs55972423	chr15:83258954	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.68	-0.34	9.8e-11	Schizophrenia;
LIHC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg03037974	chr15:76606532	NA	0.79	16.09	0.66	8.87e-44	Blood metabolite levels;
LIHC	cis	rs7395581	0.959	rs326222	chr11:47259668	A/G	cg25783544	chr11:47291846	MADD	-0.43	-6.37	-0.33	5.94e-10	HDL cholesterol;
LIHC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.67	0.38	1.81e-13	Electroencephalogram traits;
LIHC	cis	rs6466055	0.777	rs2237613	chr7:104845253	G/C	cg04380332	chr7:105027541	SRPK2	-0.36	-6.73	-0.34	7.2e-11	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03993166	chr15:101817914	SELS	-0.54	-6.37	-0.33	6.18e-10	Systolic blood pressure;
LIHC	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.68	11.25	0.52	3.39e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg12626036	chr5:134662980	NA	0.41	6.21	0.32	1.5e-9	Cannabis use (initiation);
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.31	-7.92	-0.39	3.44e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs240764	0.644	rs4329121	chr6:101087507	G/C	cg09795085	chr6:101329169	ASCC3	0.4	5.83	0.3	1.25e-8	Neuroticism;
LIHC	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.54	-8.15	-0.4	6.92e-15	Coronary artery disease;
LIHC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-11.73	-0.54	6.2e-27	Platelet distribution width;
LIHC	cis	rs72627123	0.867	rs78496651	chr14:74480070	C/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.65	5.98	0.31	5.64e-9	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.91	-9.7	-0.46	8.16e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.29e-24	Subjective well-being;
LIHC	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.38	6.38	0.33	5.62e-10	Menopause (age at onset);
LIHC	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.4	-9.73	-0.47	6.5e-20	Cutaneous nevi;
LIHC	cis	rs7953508	0.741	rs1498706	chr12:93996980	C/T	cg18151635	chr12:93972918	NA	-0.42	-6.17	-0.32	1.91e-9	Pubertal anthropometrics;
LIHC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.2	0.52	4.99e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs11157436	0.918	rs12586393	chr14:22618769	G/A	cg13567813	chr19:50879636	NR1H2	0.42	6.1	0.31	2.82e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.93	-17.77	-0.69	1.72e-50	Height;
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.22	0.36	3.39e-12	Bipolar disorder;
LIHC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.8e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23640757	chr6:7889014	TXNDC5	0.4	6.06	0.31	3.65e-9	Longevity;
LIHC	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.28	-6.46	-0.33	3.52e-10	Educational attainment (years of education);
LIHC	cis	rs1198430	0.925	rs487859	chr1:23801101	T/C	cg19827787	chr1:23763612	ASAP3	0.38	6.68	0.34	9.55e-11	Total cholesterol levels;
LIHC	cis	rs12022452	0.591	rs12049435	chr1:40990560	C/T	cg25568243	chr1:40974465	DEM1	0.46	6.17	0.32	1.91e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	7.68	0.38	1.69e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.56	8.66	0.42	1.88e-16	Multiple sclerosis;
LIHC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg06766960	chr11:133703094	NA	-0.4	-6.04	-0.31	4.07e-9	Childhood ear infection;
LIHC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.8	13.41	0.59	3.01e-33	Psoriasis;
LIHC	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.61	-9.68	-0.46	9.53e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.87	-0.35	3.05e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg01864836	chr14:55583639	NA	-0.38	-6.51	-0.33	2.74e-10	Protein biomarker;
LIHC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg10932868	chr11:921992	NA	0.39	7.26	0.37	2.71e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.08	9.42	0.45	6.98e-19	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.32	-5.99	-0.31	5.3e-9	Aortic root size;
LIHC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	8.12	0.4	8.42e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs17286411	0.750	rs4788450	chr16:71955400	T/G	cg06353428	chr16:71660113	MARVELD3	0.54	6.66	0.34	1.1e-10	Blood protein levels;
LIHC	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg02811702	chr13:24901961	NA	0.24	5.79	0.3	1.6e-8	Obesity-related traits;
LIHC	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-6.26	-0.32	1.13e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.21	-0.32	1.53e-9	Coronary artery disease;
LIHC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.78	12.98	0.57	1.38e-31	Anterior chamber depth;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.17	-0.4	5.9e-15	Longevity;Endometriosis;
LIHC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.75	12.46	0.56	1.27e-29	Menarche (age at onset);
LIHC	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg23435118	chr5:141488016	NDFIP1	-0.44	-6.05	-0.31	3.89e-9	Crohn's disease;
LIHC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg01557791	chr16:72042693	DHODH	-0.42	-6.97	-0.35	1.63e-11	Fibrinogen levels;
LIHC	cis	rs11098699	0.821	rs13141181	chr4:124212126	G/A	cg09941581	chr4:124220074	SPATA5	0.33	6.61	0.34	1.47e-10	Mosquito bite size;
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02290350	chr8:58132656	NA	0.51	10.45	0.49	2.28e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.68	-9.97	-0.47	1.01e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.65	-7.76	-0.39	9.81e-14	Cognitive function;
LIHC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.73	-0.69	2.35e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.87	0.35	3.05e-11	Monocyte percentage of white cells;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13976866	chr7:128696069	LOC286016;TNPO3	0.37	6.1	0.31	2.91e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.83	0.39	6.11e-14	Bladder cancer;
LIHC	trans	rs8113308	1.000	rs6509600	chr19:52442589	G/T	cg14959425	chr7:20447707	ITGB8	-0.44	-6.09	-0.31	3.03e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.38	6.16	0.32	2.05e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-5.85	-0.3	1.13e-8	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.47	7.01	0.35	1.24e-11	Cystic fibrosis severity;
LIHC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21467203	chr3:49911342	NA	-0.44	-7.84	-0.39	5.69e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.74	11.2	0.52	5.17e-25	Metabolite levels;
LIHC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.59	0.5	7.71e-23	Hip circumference adjusted for BMI;
LIHC	trans	rs73389468	1	rs73389468	chr10:134295815	C/T	cg14435695	chr11:71950660	PHOX2A	-0.78	-6.1	-0.31	2.85e-9	Periodontitis (CDC/AAP);
LIHC	cis	rs6723226	0.503	rs4952262	chr2:32597234	G/A	cg02381751	chr2:32503542	YIPF4	-0.54	-7.45	-0.37	7.88e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.44	-5.79	-0.3	1.59e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg08800856	chr11:64428347	NRXN2	0.39	6.13	0.31	2.48e-9	Body mass index;Urate levels;
LIHC	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg04455712	chr21:45112962	RRP1B	0.44	7.4	0.37	1.07e-12	Mean corpuscular volume;
LIHC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.41	-5.78	-0.3	1.64e-8	Height;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	0.94	10.32	0.49	6.35e-22	Breast cancer;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	23.08	0.78	1.03e-71	Height;
LIHC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	4.13e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg09137382	chr11:130731461	NA	0.42	6.35	0.32	6.9e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.16	-0.32	2.04e-9	Resting heart rate;
LIHC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg00800038	chr16:89945340	TCF25	-0.62	-9.01	-0.44	1.47e-17	Skin colour saturation;
LIHC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.77	-11.2	-0.52	5.09e-25	Diastolic blood pressure;
LIHC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg18357526	chr6:26021779	HIST1H4A	0.81	10.96	0.51	3.72e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs963731	0.579	rs6739568	chr2:39287550	G/T	cg04010122	chr2:39346883	SOS1	-0.68	-6.16	-0.32	2.07e-9	Corticobasal degeneration;
LIHC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg02640540	chr1:67518911	SLC35D1	0.45	6.19	0.32	1.69e-9	Lymphocyte percentage of white cells;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg17512779	chr8:17104072	CNOT7;VPS37A	-0.61	-6.39	-0.33	5.27e-10	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7209700	0.614	rs7225927	chr17:45323934	A/G	cg18085866	chr17:45331354	ITGB3	-0.4	-5.83	-0.3	1.27e-8	IgG glycosylation;
LIHC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.4	6.03	0.31	4.2e-9	Menarche (age at onset);
LIHC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.28	-0.45	1.92e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21099776	chr17:17739742	SREBF1	0.47	6.33	0.32	7.51e-10	Lung function (FEV1/FVC);
LIHC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg23806715	chr17:73775811	H3F3B	0.7	6.78	0.34	5.45e-11	Psoriasis;
LIHC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.56e-13	Bone mineral density;
LIHC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.33	-5.81	-0.3	1.4e-8	Headache;
LIHC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg14580859	chr9:123691850	NA	0.4	6.82	0.35	4.24e-11	Rheumatoid arthritis;
LIHC	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg01028140	chr2:1542097	TPO	-0.44	-6.99	-0.35	1.46e-11	IgG glycosylation;
LIHC	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.76	11.45	0.53	6.58e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg08847533	chr14:75593920	NEK9	0.48	7.0	0.35	1.32e-11	IgG glycosylation;
LIHC	cis	rs1355223	0.902	rs1773908	chr11:34743380	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1712517	0.771	rs2008530	chr10:105058839	G/A	cg05636881	chr10:105038444	INA	0.46	7.12	0.36	6.56e-12	Migraine;
LIHC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.43	-6.88	-0.35	2.93e-11	Neurofibrillary tangles;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01711272	chr12:56122120	CD63	-0.4	-6.54	-0.33	2.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.12	-0.55	2.19e-28	Colorectal cancer;
LIHC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg26149184	chr10:133730230	NA	0.46	7.21	0.36	3.71e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.58	-8.84	-0.43	5.02e-17	Cerebrospinal P-tau181p levels;
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13301601	chr7:774633	HEATR2	-0.41	-5.86	-0.3	1.07e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.45	8.32	0.41	2.12e-15	Prudent dietary pattern;
LIHC	cis	rs12365397	0.748	rs1845821	chr11:43258997	T/C	cg16667275	chr11:43333495	API5	0.4	5.95	0.31	6.63e-9	Migraine;
LIHC	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-9.07	-0.44	9.59e-18	Body mass index;
LIHC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.53	7.72	0.39	1.26e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2574704	0.851	rs2574723	chr3:11659592	C/T	cg15876825	chr3:11651881	VGLL4	0.49	7.9	0.39	3.94e-14	Body mass index;
LIHC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.48	6.88	0.35	2.89e-11	Height;
LIHC	cis	rs6429082	0.509	rs2803846	chr1:235521054	C/G	cg26050004	chr1:235667680	B3GALNT2	0.41	6.17	0.32	1.89e-9	Adiposity;
LIHC	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.49	7.73	0.39	1.25e-13	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg17724175	chr1:150552817	MCL1	0.47	9.08	0.44	9.03e-18	Melanoma;
LIHC	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg14061069	chr19:46274453	DMPK	-0.55	-8.49	-0.42	6.37e-16	Coronary artery disease;
LIHC	trans	rs2073499	0.935	rs2526396	chr3:50188309	C/T	cg21659725	chr3:3221576	CRBN	0.6	6.38	0.33	5.71e-10	Schizophrenia;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg07725925	chr16:89976287	TCF25	0.43	5.95	0.31	6.58e-9	Skin colour saturation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26576155	chr15:85201829	NMB	0.47	6.26	0.32	1.17e-9	Lung function (FEV1/FVC);
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	7.12	0.36	6.28e-12	Height;
LIHC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg08213375	chr14:104286397	PPP1R13B	0.48	9.16	0.44	5.06e-18	Schizophrenia;
LIHC	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg19752551	chr11:57585705	CTNND1	0.5	7.14	0.36	5.79e-12	Schizophrenia;
LIHC	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.36	-6.11	-0.31	2.75e-9	Coronary artery disease;
LIHC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.02	-0.51	2.28e-24	Chronic sinus infection;
LIHC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.99	-10.26	-0.49	1.02e-21	Breast cancer;
LIHC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20011983	chr2:74347215	NA	-0.39	-5.77	-0.3	1.79e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.87	13.22	0.58	1.6e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg05896524	chr21:47604654	C21orf56	0.44	6.61	0.34	1.49e-10	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.54	7.69	0.38	1.54e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.26	-0.32	1.18e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg02782426	chr3:40428986	ENTPD3	0.33	6.17	0.32	1.94e-9	Renal cell carcinoma;
LIHC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.47	-6.23	-0.32	1.37e-9	Vitiligo;
LIHC	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	23.94	0.79	4.53e-75	Schizophrenia;
LIHC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.97	-0.4	2.43e-14	Body mass index;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	20.68	0.75	3.41e-62	Prudent dietary pattern;
LIHC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.43	6.04	0.31	3.98e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.32	-6.05	-0.31	3.79e-9	Type 1 diabetes;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg03721293	chr16:90014378	DEF8	0.42	6.98	0.35	1.5e-11	Skin colour saturation;
LIHC	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.37	0.37	1.29e-12	Mood instability;
LIHC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg03037974	chr15:76606532	NA	0.74	14.57	0.62	9.41e-38	Blood metabolite levels;
LIHC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.08	-0.36	8.3e-12	Breast cancer;
LIHC	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.55	0.5	1e-22	Hypertriglyceridemia;
LIHC	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.43	-0.37	8.63e-13	QT interval;
LIHC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.55	8.7	0.43	1.43e-16	Neuroticism;
LIHC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.41	-0.49	3.08e-22	Chronic sinus infection;
LIHC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.7	-11.31	-0.52	2e-25	Mean platelet volume;
LIHC	cis	rs7914558	0.621	rs12219346	chr10:104657300	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.38	-0.37	1.22e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01717636	chr1:46216399	IPP	-0.56	-6.69	-0.34	9.19e-11	Systolic blood pressure;
LIHC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.36	6.78	0.34	5.16e-11	Total body bone mineral density;
LIHC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.93	-0.35	2.07e-11	Menarche (age at onset);
LIHC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.94	0.54	1.02e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	8.8	0.43	6.96e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg07636037	chr3:49044803	WDR6	-0.84	-8.52	-0.42	5.33e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.33	-7.2	-0.36	3.87e-12	Ulcerative colitis;
LIHC	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg15123519	chr2:136567270	LCT	-0.4	-6.0	-0.31	4.93e-9	Corneal structure;
LIHC	cis	rs11888559	0.655	rs7601146	chr2:203950592	G/A	cg24605529	chr2:203879461	NBEAL1	0.75	5.78	0.3	1.66e-8	Height;
LIHC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg20417195	chr1:21767127	NBPF3	0.38	5.89	0.3	9.28e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs600626	0.588	rs72997616	chr11:75474195	C/A	cg24262691	chr11:75473276	NA	0.4	5.89	0.3	9.02e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.55	0.33	2.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg19318889	chr4:1322082	MAEA	0.4	5.77	0.3	1.81e-8	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	11.73	0.54	5.98e-27	Prudent dietary pattern;
LIHC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.21	-0.45	3.37e-18	Ulcerative colitis;
LIHC	trans	rs6489882	0.867	rs2384073	chr12:113367595	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.15	0.52	7.49e-25	Hemoglobin concentration;
LIHC	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg09695851	chr17:3907499	NA	-0.49	-6.34	-0.32	7.41e-10	Type 2 diabetes;
LIHC	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.57	8.97	0.44	2.03e-17	Corneal astigmatism;
LIHC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.31	-0.37	1.9e-12	Platelet count;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.41	-5.72	-0.3	2.27e-8	Total body bone mineral density;
LIHC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.56	-7.86	-0.39	5.08e-14	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg25344623	chr2:136566232	LCT	0.44	8.85	0.43	4.78e-17	Mosquito bite size;
LIHC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02886208	chr11:14281011	SPON1	-0.55	-8.15	-0.4	6.81e-15	Mitochondrial DNA levels;
LIHC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg07713946	chr22:31675144	LIMK2	0.42	7.59	0.38	3.03e-13	Colorectal cancer;
LIHC	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg10820045	chr2:198174542	NA	-0.57	-9.61	-0.46	1.64e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg12218747	chr21:37451666	NA	-0.41	-6.64	-0.34	1.24e-10	Mitral valve prolapse;
LIHC	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.64	10.25	0.48	1.15e-21	White matter hyperintensity burden;
LIHC	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.58	-8.63	-0.42	2.29e-16	Blood protein levels;
LIHC	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-11.4	-0.52	9.78e-26	Morning vs. evening chronotype;
LIHC	cis	rs2279817	0.820	rs924686	chr1:18027726	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.41	6.24	0.32	1.33e-9	Neuroticism;
LIHC	cis	rs11673344	0.832	rs11084871	chr19:37532925	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.16	-0.32	2.02e-9	Obesity-related traits;
LIHC	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.5	6.91	0.35	2.37e-11	Aortic root size;
LIHC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg14132834	chr19:41945861	ATP5SL	-0.4	-5.82	-0.3	1.36e-8	Height;
LIHC	cis	rs6596100	0.538	rs17166268	chr5:132180990	C/T	cg02081065	chr5:132209139	LEAP2	-0.26	-5.94	-0.31	7.17e-9	Breast cancer;
LIHC	cis	rs6750047	0.549	rs151096	chr2:38316571	A/C	cg19753864	chr2:38320028	NA	-0.34	-6.06	-0.31	3.6e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg04865290	chr3:52927548	TMEM110	-0.51	-5.89	-0.3	9.01e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.26	0.37	2.63e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg23978390	chr7:1156363	C7orf50	0.59	6.88	0.35	2.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-6.43	-0.33	4.28e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-8.62	-0.42	2.48e-16	Bipolar disorder;
LIHC	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.27	0.32	1.1e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	0.98	10.53	0.49	1.23e-22	Vitiligo;
LIHC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.32	-8.03	-0.4	1.54e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.68	0.53	9.41e-27	Platelet count;
LIHC	cis	rs17106184	1.000	rs12065210	chr1:50942784	C/T	cg07174182	chr1:51127561	FAF1	-0.57	-6.55	-0.33	2.09e-10	Type 2 diabetes;
LIHC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg23625390	chr15:77176239	SCAPER	0.36	5.84	0.3	1.2e-8	Blood metabolite levels;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.49	8.42	0.41	1.03e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.63	11.29	0.52	2.48e-25	Breast cancer;
LIHC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.5	7.73	0.39	1.22e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.22	0.32	1.42e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.44	6.74	0.34	6.66e-11	Fibroblast growth factor basic levels;
LIHC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg06466757	chr4:1255808	NA	0.35	5.78	0.3	1.64e-8	Obesity-related traits;
LIHC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg16970926	chr12:29381810	FAR2	-0.28	-6.02	-0.31	4.57e-9	QT interval;
LIHC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.62	-9.22	-0.45	3.05e-18	Platelet count;
LIHC	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg00387323	chr7:6746715	ZNF12	0.65	7.29	0.37	2.2e-12	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.59	6.78	0.34	5.41e-11	Menarche (age at onset);
LIHC	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg10820045	chr2:198174542	NA	0.49	7.26	0.37	2.57e-12	Dermatomyositis;
LIHC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.59	7.51	0.38	5.35e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.45	-0.49	2.29e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.6	9.22	0.45	3.01e-18	Height;
LIHC	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg22705602	chr4:152727874	NA	-0.3	-6.12	-0.31	2.51e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.36	-8.26	-0.41	3.34e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.2	0.55	1.19e-28	Platelet count;
LIHC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.98	-0.35	1.53e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.5	-7.65	-0.38	2e-13	Lymphocyte counts;
LIHC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.16	-0.32	2.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg23091122	chr1:110024289	SYPL2	-0.48	-6.67	-0.34	1.04e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg20991723	chr1:152506922	NA	0.53	8.76	0.43	9.49e-17	Hair morphology;
LIHC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.14	0.31	2.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.38	6.66	0.34	1.11e-10	HIV-1 susceptibility;
LIHC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	7.87	0.39	4.78e-14	Parkinson's disease;
LIHC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	1.01	11.16	0.52	7.11e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs9513627	0.833	rs112671387	chr13:100123073	A/G	cg25919922	chr13:100150906	NA	-0.79	-6.95	-0.35	1.86e-11	Obesity-related traits;
LIHC	cis	rs4917300	0.650	rs4917218	chr8:143072470	G/A	cg06573787	chr8:143070187	NA	0.28	5.82	0.3	1.38e-8	Amyotrophic lateral sclerosis;
LIHC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.68	0.53	9.06e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.29	-0.32	9.84e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1823913	1.000	rs1454749	chr2:192105635	C/T	cg12404831	chr2:192114017	MYO1B	0.34	6.7	0.34	8.82e-11	Obesity-related traits;
LIHC	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.89	10.97	0.51	3.51e-24	Coronary artery disease;
LIHC	cis	rs611744	0.870	rs423940	chr8:109093578	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.52	0.42	5e-16	Dupuytren's disease;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.63	10.73	0.5	2.46e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-14.26	-0.61	1.58e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.44	-6.11	-0.31	2.65e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.65	8.21	0.41	4.69e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.9	10.77	0.5	1.76e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs9649465	1.000	rs1506635	chr7:123317184	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.02e-15	Migraine;
LIHC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.44	0.37	8.27e-13	Lung cancer;
LIHC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.86	-0.35	3.26e-11	Schizophrenia;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.74	14.48	0.62	2.09e-37	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.58e-32	Colorectal cancer;
LIHC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.1	-0.36	7.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg14558262	chr17:40713999	COASY	0.62	9.51	0.46	3.55e-19	Crohn's disease;
LIHC	cis	rs151997	0.925	rs27260	chr5:50166696	C/T	cg06027927	chr5:50259733	NA	0.57	7.57	0.38	3.47e-13	Callous-unemotional behaviour;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08251337	chr16:81040389	C16orf61;CENPN	-0.5	-6.77	-0.34	5.69e-11	Systolic blood pressure;
LIHC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.82	0.43	6.15e-17	Menarche (age at onset);
LIHC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs507080	0.961	rs543327	chr11:118549985	G/T	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.16	-0.32	2.04e-9	Resting heart rate;
LIHC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.64	-12.71	-0.57	1.42e-30	Sense of smell;
LIHC	trans	rs6600671	1.000	rs10794671	chr1:121168242	A/C	cg09829573	chr1:144692074	NBPF9	-0.42	-7.64	-0.38	2.17e-13	Hip geometry;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.29	-0.32	9.67e-10	Renal cell carcinoma;
LIHC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.55	10.3	0.49	7.74e-22	Total body bone mineral density;
LIHC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	5.87	0.3	1.02e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.83	0.3	1.31e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.6	9.17	0.44	4.62e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg07450219	chr17:78428858	NA	-0.43	-6.36	-0.33	6.29e-10	Alopecia areata;
LIHC	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.23	-0.41	3.95e-15	Exhaled nitric oxide output;
LIHC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg10820045	chr2:198174542	NA	-0.58	-9.64	-0.46	1.29e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.69	7.22	0.36	3.4e-12	Alzheimer's disease;
LIHC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.65	0.46	1.21e-19	Tonsillectomy;
LIHC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.79	12.06	0.55	3.92e-28	Dental caries;
LIHC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.89	13.12	0.58	3.95e-32	Metabolic syndrome;
LIHC	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg20568497	chr10:133558893	NA	0.45	6.98	0.35	1.52e-11	Survival in rectal cancer;
LIHC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	8.01	0.4	1.79e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19443418	chr4:39482010	LOC401127	0.41	6.83	0.35	3.94e-11	Bilirubin levels;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.02	0.44	1.42e-17	Platelet count;
LIHC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.71	-12.13	-0.55	2.03e-28	Menopause (age at onset);
LIHC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.66	13.13	0.58	3.67e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg12863693	chr15:85201151	NMB	0.44	5.87	0.3	1.02e-8	Schizophrenia;
LIHC	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg05197062	chr11:11642011	GALNTL4	0.42	6.08	0.31	3.17e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.78	11.57	0.53	2.42e-26	Metabolic syndrome;
LIHC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Inflammatory skin disease;
LIHC	cis	rs8049040	0.609	rs7188858	chr16:71468895	T/C	cg06353428	chr16:71660113	MARVELD3	-0.67	-7.06	-0.36	9.54e-12	Blood protein levels;
LIHC	cis	rs7116495	1.000	rs482013	chr11:71803962	G/A	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.26	-13.75	-0.6	1.51e-34	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.48	6.91	0.35	2.35e-11	Lung cancer;
LIHC	cis	rs10861342	1.000	rs10861342	chr12:105458797	C/T	cg23923672	chr12:105501055	KIAA1033	-0.67	-7.66	-0.38	1.98e-13	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.37	6.03	0.31	4.14e-9	Cystic fibrosis severity;
LIHC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.5	-6.28	-0.32	1.05e-9	Body mass index;
LIHC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.54	-10.95	-0.51	3.98e-24	Tonsillectomy;
LIHC	cis	rs867186	0.541	rs77173268	chr20:33288002	G/A	cg08999081	chr20:33150536	PIGU	0.57	5.95	0.31	6.59e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs10508774	1.000	rs11008974	chr10:32844014	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.44	8.14	0.4	7.19e-15	Prudent dietary pattern;
LIHC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.15	-0.4	6.97e-15	Body mass index;
LIHC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	6.98e-25	Corneal astigmatism;
LIHC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.25	0.48	1.14e-21	Bladder cancer;
LIHC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.66	6.96	0.35	1.72e-11	Schizophrenia;
LIHC	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.58	7.56	0.38	3.77e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.24	-0.41	3.72e-15	Exhaled nitric oxide output;
LIHC	cis	rs7224685	0.569	rs12942513	chr17:4016721	C/A	cg09695851	chr17:3907499	NA	0.6	6.81	0.35	4.42e-11	Type 2 diabetes;
LIHC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-6.82	-0.35	4.09e-11	Morning vs. evening chronotype;
LIHC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.84	0.57	4.73e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.63	-9.6	-0.46	1.79e-19	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.78	12.1	0.55	2.78e-28	Breast cancer;
LIHC	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.58	-8.72	-0.43	1.22e-16	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.83	0.54	2.59e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg16586182	chr3:47516702	SCAP	-0.5	-9.02	-0.44	1.4e-17	Colorectal cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22658129	chr5:49962507	PARP8	0.51	6.59	0.34	1.64e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg16736954	chr20:23401023	NAPB	0.7	8.08	0.4	1.15e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg07636037	chr3:49044803	WDR6	-0.73	-7.5	-0.38	5.68e-13	Cognitive function;
LIHC	cis	rs34540877	1.000	rs71351186	chr19:33164583	C/T	cg22980127	chr19:33182716	NUDT19	0.9	6.19	0.32	1.72e-9	Red cell distribution width;
LIHC	trans	rs9531686	0.967	rs7994341	chr13:85546229	T/G	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.25	0.32	1.24e-9	Anorexia nervosa;
LIHC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg22633049	chr21:46681294	NA	0.33	5.92	0.3	8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.53	-8.84	-0.43	5.07e-17	Blood metabolite levels;
LIHC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-13.4	-0.59	3.3e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.33	-6.54	-0.33	2.19e-10	DNA methylation (variation);
LIHC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.58	11.22	0.52	4.27e-25	Coronary artery disease;
LIHC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.82	-13.06	-0.58	6.88e-32	Colorectal cancer;
LIHC	cis	rs12980942	0.591	rs11879435	chr19:41757603	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.96	0.35	1.72e-11	Coronary artery disease;
LIHC	cis	rs7703744	0.747	rs6896277	chr5:118678721	C/T	cg10911160	chr5:118691794	TNFAIP8	-0.49	-5.79	-0.3	1.56e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.13	-0.58	3.45e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.59	6.8	0.34	4.76e-11	Iron status biomarkers;
LIHC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.06	-0.31	3.54e-9	Type 2 diabetes;
LIHC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.48	-18.17	-0.7	4.09e-52	Breast cancer;
LIHC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.78	0.5	1.62e-23	Bladder cancer;
LIHC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	7.89	0.39	4.23e-14	Motion sickness;
LIHC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg20651018	chr11:3035856	CARS	-0.35	-5.96	-0.31	6.34e-9	Longevity;
LIHC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.59	8.61	0.42	2.64e-16	Breast cancer;
LIHC	cis	rs7818688	0.697	rs77402106	chr8:95970484	C/T	cg16049864	chr8:95962084	TP53INP1	0.57	6.33	0.32	7.64e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.26	0.32	1.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg26338869	chr17:61819248	STRADA	0.53	7.18	0.36	4.33e-12	Height;
LIHC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.9	-11.78	-0.54	4.15e-27	Schizophrenia;
LIHC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.48	-7.73	-0.39	1.21e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.6	0.56	3.51e-30	Cognitive test performance;
LIHC	cis	rs72781680	0.566	rs6713865	chr2:23899807	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	6.18	0.32	1.85e-9	Lymphocyte counts;
LIHC	trans	rs668210	0.947	rs610497	chr11:65765551	C/T	cg17712092	chr4:129076599	LARP1B	0.59	7.42	0.37	9.19e-13	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03535439	chr6:42981950	MEA1;KLHDC3	-0.41	-6.34	-0.32	7.35e-10	Pancreatic cancer;
LIHC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.43	7.28	0.37	2.36e-12	Breast cancer;
LIHC	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.79	0.3	1.59e-8	Bipolar disorder;
LIHC	cis	rs12365397	1.000	rs10838074	chr11:43233816	A/G	cg16667275	chr11:43333495	API5	0.44	6.11	0.31	2.67e-9	Migraine;
LIHC	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.32	-5.74	-0.3	2.09e-8	Lewy body disease;
LIHC	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.62	6.14	0.32	2.27e-9	Carotid intima media thickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23964739	chr19:45909864	CD3EAP;PPP1R13L	0.51	6.86	0.35	3.26e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.52	-6.68	-0.34	9.89e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg12798992	chr6:167411361	FGFR1OP	0.6	9.95	0.47	1.18e-20	Crohn's disease;
LIHC	trans	rs6489882	0.779	rs57484342	chr12:113371973	A/G	cg10175203	chr3:128143634	NA	0.38	6.13	0.31	2.41e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-8.08	-0.4	1.1e-14	Putamen volume;
LIHC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.44	-0.37	8.31e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg05973401	chr12:123451056	ABCB9	0.47	6.02	0.31	4.43e-9	Neutrophil percentage of white cells;
LIHC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg05697976	chr12:29376483	FAR2	0.31	6.2	0.32	1.62e-9	QT interval;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23522508	chr19:11287505	KANK2	0.4	6.18	0.32	1.8e-9	Bilirubin levels;
LIHC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.33	6.43	0.33	4.32e-10	Renal cell carcinoma;
LIHC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.5	0.53	4.14e-26	Coronary artery disease;
LIHC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.5	7.9	0.39	3.86e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg02811702	chr13:24901961	NA	0.26	6.34	0.32	7.35e-10	Obesity-related traits;
LIHC	cis	rs11229555	0.645	rs6591475	chr11:58193551	G/T	cg15696309	chr11:58395628	NA	0.66	7.85	0.39	5.24e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-0.88	-10.54	-0.5	1.09e-22	Mitochondrial DNA levels;
LIHC	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-9.04	-0.44	1.17e-17	Schizophrenia;
LIHC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.53	-0.49	1.24e-22	Chronic sinus infection;
LIHC	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg21466736	chr12:48725269	NA	0.54	7.26	0.37	2.57e-12	Glycated hemoglobin levels;
LIHC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.65	-9.36	-0.45	1.11e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.95	-0.4	2.66e-14	Response to antipsychotic treatment;
LIHC	cis	rs1419980	0.730	rs7965446	chr12:7747134	C/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs2412488	0.888	rs7698792	chr4:54319911	C/T	cg22241045	chr4:54363911	LNX1	-0.42	-6.78	-0.34	5.27e-11	DNA methylation (variation);
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07677032	chr17:61819896	STRADA	-0.41	-5.81	-0.3	1.46e-8	Prudent dietary pattern;
LIHC	cis	rs6466055	0.669	rs1142	chr7:104756326	C/T	cg04380332	chr7:105027541	SRPK2	-0.3	-6.0	-0.31	5.12e-9	Schizophrenia;
LIHC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Electroencephalogram traits;
LIHC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.74	0.3	2.11e-8	Bladder cancer;
LIHC	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.39	-7.2	-0.36	3.95e-12	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-12.78	-0.57	7.85e-31	Primary sclerosing cholangitis;
LIHC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.54	-7.38	-0.37	1.2e-12	Body mass index;
LIHC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg12863693	chr15:85201151	NMB	0.41	5.74	0.3	2.09e-8	Schizophrenia;
LIHC	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.5	7.84	0.39	5.74e-14	Alzheimer's disease (survival time);
LIHC	cis	rs73191547	0.706	rs1905634	chr8:10051748	C/G	cg21625330	chr8:9911636	MSRA	0.39	6.02	0.31	4.48e-9	Schizophrenia;
LIHC	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg10820045	chr2:198174542	NA	0.47	7.03	0.36	1.12e-11	Dermatomyositis;
LIHC	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.54	0.5	1.12e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs16958440	0.867	rs79712753	chr18:44676727	C/A	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	trans	rs2270927	0.510	rs34596551	chr5:75577143	C/T	cg13563193	chr19:33072644	PDCD5	0.97	9.09	0.44	8.16e-18	Mean corpuscular volume;
LIHC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.16	18.04	0.7	1.36e-51	Gut microbiome composition (summer);
LIHC	cis	rs4759375	1.000	rs12366872	chr12:123804721	G/C	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg27433088	chr4:174089019	GALNT7	0.4	6.89	0.35	2.73e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg00977110	chr5:151150581	G3BP1	0.56	7.04	0.36	1.08e-11	Preschool internalizing problems;
LIHC	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.45	-6.76	-0.34	5.97e-11	Diastolic blood pressure;
LIHC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.76	0.43	9.46e-17	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg05926928	chr17:57297772	GDPD1	-0.52	-7.72	-0.39	1.26e-13	Schizophrenia;
LIHC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.7	10.47	0.49	1.99e-22	Obesity-related traits;
LIHC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.52	6.52	0.33	2.59e-10	Total body bone mineral density;
LIHC	cis	rs15676	0.947	rs2997922	chr9:131580744	C/T	cg00228799	chr9:131580591	ENDOG	0.47	7.15	0.36	5.24e-12	Blood metabolite levels;
LIHC	cis	rs16828019	0.777	rs2300658	chr1:41505022	G/A	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	12.3	0.55	4.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9918079	0.560	rs6414767	chr4:15655721	A/G	cg21123203	chr4:15471301	CC2D2A	-0.46	-7.35	-0.37	1.48e-12	Obesity-related traits;
LIHC	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.61	9.87	0.47	2.18e-20	Corneal astigmatism;
LIHC	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg07424592	chr7:64974309	NA	0.76	8.62	0.42	2.49e-16	Diabetic kidney disease;
LIHC	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.54	-6.72	-0.34	7.54e-11	Mean platelet volume;
LIHC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.26	-0.52	3.07e-25	Diastolic blood pressure;
LIHC	cis	rs3736485	0.934	rs17609812	chr15:51879260	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.42	-7.17	-0.36	4.62e-12	Squamous cell lung carcinoma;
LIHC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg11070056	chr1:107600091	PRMT6	-0.63	-10.6	-0.5	6.9e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.42	0.56	1.8e-29	Prudent dietary pattern;
LIHC	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.48	7.38	0.37	1.24e-12	Triglyceride levels;
LIHC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.34	-0.32	7.08e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-1.02	-19.48	-0.73	2.17e-57	Breast cancer;
LIHC	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.63	11.35	0.52	1.55e-25	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.44	6.28	0.32	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-6.35	-0.32	6.96e-10	Colorectal cancer;
LIHC	cis	rs17106184	0.892	rs116692933	chr1:51136273	T/C	cg07174182	chr1:51127561	FAF1	-0.76	-8.12	-0.4	8.47e-15	Type 2 diabetes;
LIHC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.74	12.01	0.54	5.62e-28	Body mass index;
LIHC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.57	-9.22	-0.45	3.16e-18	Menarche (age at onset);
LIHC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.17e-9	Height;
LIHC	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.87	-0.35	3.14e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.61	-11.41	-0.53	9.22e-26	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24675879	chr17:28444056	MIR423;CCDC55	0.41	6.24	0.32	1.31e-9	Cognitive function;
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.81	14.58	0.62	8.65e-38	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.46	-7.97	-0.4	2.46e-14	Survival in pancreatic cancer;
LIHC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg18016565	chr1:150552671	MCL1	0.55	10.21	0.48	1.5e-21	Melanoma;
LIHC	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.53	-8.1	-0.4	9.58e-15	Blood protein levels;
LIHC	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.31	7.12	0.36	6.58e-12	Blood metabolite ratios;
LIHC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.57	7.71	0.38	1.35e-13	Blood metabolite levels;
LIHC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-18.49	-0.71	2.06e-53	Ulcerative colitis;
LIHC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg11062466	chr8:58055876	NA	0.4	5.91	0.3	8.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.53	-0.33	2.42e-10	Fear of minor pain;
LIHC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg13145458	chr22:31556086	RNF185	0.46	6.44	0.33	4.09e-10	Paclitaxel-induced neuropathy;
LIHC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.14	-13.48	-0.59	1.66e-33	Vitiligo;
LIHC	cis	rs1816752	0.749	rs77832754	chr13:24990154	G/A	cg22771759	chr13:24902376	NA	0.3	6.02	0.31	4.43e-9	Obesity-related traits;
LIHC	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.59	8.76	0.43	9.11e-17	Recombination rate (females);
LIHC	cis	rs12744310	0.887	rs35807669	chr1:41801652	C/T	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs6489882	0.867	rs4988618	chr12:113363178	G/A	cg10175203	chr3:128143634	NA	0.39	6.38	0.33	5.72e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg23933602	chr10:16859644	RSU1	0.59	5.76	0.3	1.83e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.31	0.45	1.57e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.75	0.34	6.37e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	1.05	12.55	0.56	5.55e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.98	0.35	1.56e-11	Lung cancer in ever smokers;
LIHC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.45	-6.16	-0.32	2.04e-9	Initial pursuit acceleration;
LIHC	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg02023728	chr11:77925099	USP35	0.36	6.32	0.32	8.31e-10	Alzheimer's disease (survival time);
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.65	9.77	0.47	4.93e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.06e-8	Coronary artery disease;
LIHC	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.4	-5.83	-0.3	1.27e-8	Red blood cell traits;
LIHC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.38	-0.33	5.64e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.3	-6.11	-0.31	2.7e-9	Blood metabolite levels;
LIHC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.54	-7.94	-0.39	2.99e-14	Prostate cancer;
LIHC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14067834	chr17:29058358	SUZ12P	0.64	6.28	0.32	1.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.71	-12.82	-0.57	5.63e-31	Obesity-related traits;
LIHC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-6.94	-0.35	2.01e-11	Bipolar disorder;
LIHC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg07451762	chr16:28383216	NA	0.39	7.05	0.36	9.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	5.92	0.3	8.04e-9	Bipolar disorder;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04305677	chr7:2281541	NUDT1;FTSJ2	0.41	6.39	0.33	5.3e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4407350	0.837	rs5765707	chr22:44909507	A/T	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.16	-0.32	2.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.33	7.6	0.38	2.84e-13	Blood metabolite ratios;
LIHC	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg22705602	chr4:152727874	NA	-0.29	-5.95	-0.31	6.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg04083430	chr16:4736063	MGRN1	-0.42	-6.05	-0.31	3.84e-9	Schizophrenia;
LIHC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg20818283	chr2:191399100	TMEM194B	0.46	6.19	0.32	1.75e-9	Pulse pressure;
LIHC	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.66	-0.42	1.88e-16	Atrioventricular conduction;
LIHC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.07	16.04	0.66	1.47e-43	Cognitive function;
LIHC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.99	16.22	0.66	2.8e-44	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.71	12.04	0.55	4.57e-28	Menopause (age at onset);
LIHC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.41	-6.13	-0.31	2.38e-9	Iron status biomarkers;
LIHC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.47	7.24	0.36	3.01e-12	Height;
LIHC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg20933634	chr6:27740509	NA	0.46	6.06	0.31	3.53e-9	Parkinson's disease;
LIHC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg19006947	chr11:64034861	PLCB3	-0.45	-6.26	-0.32	1.17e-9	Body mass index;
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg00280220	chr17:61926910	NA	0.41	6.67	0.34	1.02e-10	Prudent dietary pattern;
LIHC	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg00601450	chr5:74908170	NA	0.58	7.1	0.36	7.09e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg14515779	chr1:101123966	NA	-0.68	-13.21	-0.58	1.81e-32	Monocyte count;
LIHC	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.51	-6.52	-0.33	2.49e-10	Type 2 diabetes;
LIHC	cis	rs7534824	0.625	rs12565777	chr1:101485794	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	7.03	0.36	1.13e-11	Refractive astigmatism;
LIHC	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.43	7.88	0.39	4.32e-14	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.28	16.95	0.68	3.23e-47	Diabetic kidney disease;
LIHC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg25344623	chr2:136566232	LCT	-0.37	-6.06	-0.31	3.66e-9	Corneal structure;
LIHC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.73	-10.48	-0.49	1.82e-22	Pancreatic cancer;
LIHC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.58	9.63	0.46	1.42e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	trans	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.58e-32	Colorectal cancer;
LIHC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs2304456	1.000	rs2304456	chr3:186445052	G/T	cg12454167	chr3:186435060	KNG1	-0.35	-6.31	-0.32	8.54e-10	Blood protein levels;
LIHC	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.46	6.78	0.34	5.42e-11	Dermatomyositis;
LIHC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg18357526	chr6:26021779	HIST1H4A	0.62	8.73	0.43	1.18e-16	Blood metabolite levels;
LIHC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.41	6.64	0.34	1.2e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.37	6.66	0.34	1.08e-10	Aortic root size;
LIHC	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs611744	0.935	rs661036	chr8:109213088	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.01	-9.18	-0.44	4.2e-18	Diabetic retinopathy;
LIHC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13482356	chr1:118148519	FAM46C	0.47	6.92	0.35	2.23e-11	Pancreatic cancer;
LIHC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.88	16.29	0.66	1.46e-44	Coronary artery disease;
LIHC	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.5	8.16	0.4	6.69e-15	Corneal astigmatism;
LIHC	cis	rs12744310	1.000	rs12030762	chr1:41766761	T/C	cg03962019	chr1:41807865	NA	0.38	6.22	0.32	1.46e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.4	-6.16	-0.32	2.04e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17776563	0.887	rs58548047	chr15:89123073	T/C	cg05013243	chr15:89149849	MIR1179	0.37	6.06	0.31	3.5e-9	Thyroid hormone levels;
LIHC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.7	10.95	0.51	4.17e-24	Corneal astigmatism;
LIHC	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.01	-0.31	4.81e-9	Blood metabolite levels;
LIHC	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.6	7.27	0.37	2.48e-12	Interstitial lung disease;
LIHC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.44	5.91	0.3	8.44e-9	Initial pursuit acceleration;
LIHC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg10587741	chr22:38071170	LGALS1	0.72	12.43	0.56	1.64e-29	Fat distribution (HIV);
LIHC	cis	rs6429082	0.875	rs2291688	chr1:235594250	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.4	-6.28	-0.32	1e-9	Adiposity;
LIHC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.73	12.2	0.55	1.17e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.49	-8.44	-0.42	8.83e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	5.93e-33	Diabetic kidney disease;
LIHC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.47	7.52	0.38	4.71e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg15848620	chr12:58087721	OS9	-0.55	-7.44	-0.37	8.41e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg01652190	chr22:50026171	C22orf34	-0.34	-7.43	-0.37	8.63e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs3736485	0.934	rs2414105	chr15:51868373	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.06	-0.31	3.5e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.51	-6.4	-0.33	5.1e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06656553	chr16:89960601	TCF25	-0.49	-6.26	-0.32	1.13e-9	Skin colour saturation;
LIHC	cis	rs3823572	0.542	rs10224226	chr7:133626662	G/A	cg03336402	chr7:133662267	EXOC4	0.49	5.98	0.31	5.58e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-9.84	-0.47	2.87e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.52	6.71	0.34	8.1e-11	Alzheimer's disease;
LIHC	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg01843034	chr6:37503916	NA	-0.37	-6.06	-0.31	3.66e-9	Cognitive performance;
LIHC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg02269571	chr22:50332266	NA	-0.64	-8.36	-0.41	1.59e-15	Schizophrenia;
LIHC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-14.02	-0.6	1.38e-35	Height;
LIHC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs12980942	1.000	rs12984160	chr19:41815713	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.84	0.35	3.72e-11	Coronary artery disease;
LIHC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.4	-6.0	-0.31	4.89e-9	Lung cancer;
LIHC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.66	12.93	0.57	2.14e-31	Schizophrenia;
LIHC	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	7.51	0.38	5.3e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4742903	0.904	rs966390	chr9:106944031	A/G	cg14250997	chr9:106856677	SMC2	0.35	5.94	0.31	7.01e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg18867708	chr6:26865862	GUSBL1	0.51	7.97	0.4	2.44e-14	Schizophrenia;
LIHC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg12661370	chr5:149340060	SLC26A2	-0.5	-6.13	-0.31	2.42e-9	HIV-1 control;
LIHC	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.52	7.43	0.37	8.78e-13	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg00292662	chr22:38071168	LGALS1	0.65	10.28	0.49	9.01e-22	Fat distribution (HIV);
LIHC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.65	-9.66	-0.46	1.13e-19	Coronary artery disease;
LIHC	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.46	-6.71	-0.34	8.2e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.42	-0.37	9.23e-13	Adiposity;
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.54	8.19	0.4	5.44e-15	Height;
LIHC	cis	rs11627756	0.846	rs1190336	chr14:103108478	A/G	cg12046867	chr14:103022105	NA	0.37	5.8	0.3	1.48e-8	Mean platelet volume;
LIHC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg14440974	chr22:39074834	NA	0.36	6.24	0.32	1.27e-9	Menopause (age at onset);
LIHC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.12	13.03	0.58	8.92e-32	Vitiligo;
LIHC	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.47	9.61	0.46	1.61e-19	Immature fraction of reticulocytes;
LIHC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.55	-8.58	-0.42	3.47e-16	Menarche (age at onset);
LIHC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.71	0.5	2.86e-23	Smoking initiation;
LIHC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.3300000000000004e-09	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.1e-34	Gastritis;
LIHC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20135002	chr11:47629003	NA	-0.54	-9.17	-0.44	4.7e-18	Subjective well-being;
LIHC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	7.61	0.38	2.63e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.77	11.25	0.52	3.28e-25	Menarche (age at onset);
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	7.19	0.36	4.13e-12	Prudent dietary pattern;
LIHC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.87	-0.3	1.04e-8	Heart rate;
LIHC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg15123519	chr2:136567270	LCT	0.43	8.95	0.44	2.29e-17	Mosquito bite size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19787033	chr11:77850962	ALG8	0.41	6.27	0.32	1.1e-9	Cognitive function;
LIHC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.35	6.84	0.35	3.65e-11	Renal cell carcinoma;
LIHC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.73	-6.94	-0.35	1.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg08824895	chr13:115047677	UPF3A	0.45	6.55	0.33	2.08e-10	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	1.11	12.64	0.56	2.57e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.6	8.75	0.43	1.02e-16	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs4704846	0.660	rs72805202	chr5:156553390	A/C	cg02632742	chr2:60187357	NA	-0.6	-6.04	-0.31	3.99e-9	Blood protein levels;
LIHC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.86	-10.59	-0.5	7.73e-23	Schizophrenia;
LIHC	cis	rs652260	0.967	rs569175	chr19:7901160	T/G	cg26014689	chr19:7917955	EVI5L	-0.67	-11.67	-0.53	1.03e-26	Menarche (age at onset);
LIHC	cis	rs7017914	0.905	rs2639956	chr8:71924091	A/G	cg27618939	chr8:71581788	XKR9;LACTB2	-0.37	-5.76	-0.3	1.83e-8	Bone mineral density;
LIHC	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg14515779	chr1:101123966	NA	0.49	6.84	0.35	3.64e-11	Monocyte count;
LIHC	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.57	-8.3	-0.41	2.5e-15	Prostate cancer;
LIHC	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg07636037	chr3:49044803	WDR6	-0.56	-6.32	-0.32	8.37e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-7.16	-0.36	4.88e-12	Dental caries;
LIHC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20135002	chr11:47629003	NA	-0.58	-10.14	-0.48	2.58e-21	Subjective well-being;
LIHC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.48	7.45	0.37	7.7e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.58	7.33	0.37	1.63e-12	Corneal astigmatism;
LIHC	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg14593290	chr7:50529359	DDC	0.62	9.78	0.47	4.43e-20	Malaria;
LIHC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.59	0.38	2.99e-13	Electroencephalogram traits;
LIHC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs7707921	0.752	rs2406910	chr5:81308719	C/T	cg15871215	chr5:81402204	ATG10	0.66	7.14	0.36	5.75e-12	Breast cancer;
LIHC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.79	12.32	0.55	4.18e-29	Resting heart rate;
LIHC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.21	-0.36	3.52e-12	Personality dimensions;
LIHC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-11.59	-0.53	2.04e-26	Dental caries;
LIHC	cis	rs3981351	0.797	rs12777332	chr10:115458936	A/G	cg24846397	chr10:115438155	CASP7	-0.45	-6.99	-0.35	1.44e-11	Obesity-related traits;
LIHC	cis	rs35150201	0.838	rs6959832	chr7:135289854	G/A	cg23117316	chr7:135346802	PL-5283	-0.27	-5.73	-0.3	2.19e-8	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LIHC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.36	-0.37	1.35e-12	Tonsillectomy;
LIHC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.55	9.97	0.47	9.96e-21	Schizophrenia;
LIHC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg23387056	chr11:14280742	SPON1	0.45	6.17	0.32	1.9e-9	Mitochondrial DNA levels;
LIHC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.56	-7.81	-0.39	7.21e-14	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs7976838	0.831	rs17120243	chr12:60206636	A/G	cg02574734	chr1:116369351	NA	0.49	6.21	0.32	1.55e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg07952391	chr2:88470173	THNSL2	0.77	7.15	0.36	5.27e-12	Plasma clusterin levels;
LIHC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.25	-0.32	1.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.82	14.54	0.62	1.27e-37	Aortic root size;
LIHC	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.7	11.59	0.53	1.98e-26	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs116248771	0.739	rs73156451	chr3:158365449	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.28	0.32	1.04e-9	diarrhoeal disease at age 2;
LIHC	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg10820045	chr2:198174542	NA	-0.59	-9.84	-0.47	2.85e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs507080	0.922	rs493834	chr11:118567444	A/G	cg04173919	chr11:118528438	PHLDB1	0.36	6.68	0.34	9.53e-11	Serum metabolite levels;
LIHC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.16e-9	Tonsillectomy;
LIHC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.56	-8.64	-0.42	2.25e-16	Breast size;
LIHC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg15691649	chr6:25882328	NA	-0.59	-7.59	-0.38	3.12e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	7.12	0.36	6.39e-12	Menarche (age at onset);
LIHC	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg03721293	chr16:90014378	DEF8	-0.4	-6.79	-0.34	4.96e-11	Skin colour saturation;
LIHC	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.5	-7.88	-0.39	4.34e-14	Schizophrenia;
LIHC	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7587476	0.548	rs35982594	chr2:215706075	G/A	cg04004882	chr2:215674386	BARD1	0.5	5.93	0.31	7.6e-9	Neuroblastoma;
LIHC	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.48	-7.52	-0.38	4.9e-13	Graves' disease;
LIHC	cis	rs4742903	1.000	rs3818625	chr9:106856452	G/A	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs7238033	0.602	rs3819178	chr18:43310845	G/C	cg20610511	chr18:43302872	SLC14A1	0.39	6.49	0.33	3.01e-10	Bladder cancer;
LIHC	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg22771759	chr13:24902376	NA	0.32	6.8	0.35	4.62e-11	Obesity-related traits;
LIHC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	0.81	11.9	0.54	1.53e-27	Vitamin D levels;
LIHC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.83	-15.93	-0.65	4.11e-43	Height;
LIHC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	8.73	0.43	1.13e-16	Platelet count;
LIHC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.31	6.43	0.33	4.17e-10	QRS complex (12-leadsum);
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.2	0.41	4.93e-15	Renal cell carcinoma;
LIHC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.71	-0.34	8.17e-11	Psoriasis;
LIHC	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg24069376	chr3:38537580	EXOG	0.43	7.9	0.39	3.93e-14	Electrocardiographic conduction measures;
LIHC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.09	16.35	0.66	8.22e-45	Cognitive function;
LIHC	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg16309518	chr5:176445507	NA	-0.5	-9.32	-0.45	1.45e-18	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.92	0.51	5.28e-24	Heart rate;
LIHC	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.24	-0.32	1.29e-9	Diastolic blood pressure;
LIHC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg14067834	chr17:29058358	SUZ12P	0.64	6.16	0.32	2.02e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg08847533	chr14:75593920	NEK9	0.5	7.51	0.38	5.22e-13	IgG glycosylation;
LIHC	cis	rs903552	1.000	rs12903048	chr15:102006325	G/T	cg19295451	chr15:102010161	PCSK6	-0.44	-6.12	-0.31	2.6e-9	Diabetic kidney disease;
LIHC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-6.97	-0.35	1.62e-11	Morning vs. evening chronotype;
LIHC	cis	rs17106184	0.892	rs12084054	chr1:51242141	C/T	cg07174182	chr1:51127561	FAF1	-0.61	-6.69	-0.34	8.86e-11	Type 2 diabetes;
LIHC	cis	rs6442522	0.640	rs6762964	chr3:15527445	G/C	cg16303742	chr3:15540471	COLQ	0.39	6.19	0.32	1.72e-9	Uric acid levels;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	10.27	0.49	9.91e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg10587741	chr22:38071170	LGALS1	0.44	7.93	0.39	3.22e-14	Fat distribution (HIV);
LIHC	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-17.32	-0.68	1.03e-48	Schizophrenia;
LIHC	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg15123519	chr2:136567270	LCT	-0.38	-5.87	-0.3	1.02e-8	Corneal structure;
LIHC	trans	rs6058796	1.000	rs6141333	chr20:31263324	C/A	cg02600331	chr11:130417168	NA	0.36	7.86	0.39	4.98e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.06	-17.37	-0.68	7.03e-49	Dilated cardiomyopathy;
LIHC	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.51	-6.94	-0.35	1.97e-11	Interleukin-18 levels;
LIHC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.41	-6.9	-0.35	2.57e-11	Monocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21558545	chr12:71834859	LGR5	0.42	6.2	0.32	1.63e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02290350	chr8:58132656	NA	0.4	8.39	0.41	1.29e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.7	-11.59	-0.53	2.03e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs17711722	0.583	rs11768292	chr7:65474801	G/T	cg18876405	chr7:65276391	NA	-0.52	-7.8	-0.39	7.46e-14	Calcium levels;
LIHC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg05343316	chr1:45956843	TESK2	0.48	7.16	0.36	4.82e-12	High light scatter reticulocyte count;
LIHC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg20090690	chr10:134436459	INPP5A	0.45	6.07	0.31	3.45e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs3015497	0.646	rs2934693	chr14:51101641	C/T	cg09863266	chr14:51125203	SAV1	-0.42	-5.76	-0.3	1.91e-8	Mean platelet volume;
LIHC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.49	-0.59	1.55e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.61	-10.17	-0.48	2.04e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg15123519	chr2:136567270	LCT	-0.38	-5.98	-0.31	5.75e-9	Corneal structure;
LIHC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	8.07	0.4	1.22e-14	Platelet count;
LIHC	cis	rs1190552	0.846	rs4906212	chr14:102981595	A/G	cg10241871	chr14:102965420	TECPR2	0.47	7.26	0.37	2.57e-12	Blood protein levels;
LIHC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.14e-14	Mean platelet volume;
LIHC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.1	0.44	7.64e-18	Menarche (age at onset);
LIHC	cis	rs1712517	0.844	rs1163087	chr10:105043289	G/A	cg05636881	chr10:105038444	INA	0.42	6.43	0.33	4.38e-10	Migraine;
LIHC	cis	rs1190552	0.761	rs11626217	chr14:102866362	G/A	cg10241871	chr14:102965420	TECPR2	0.39	5.92	0.3	7.95e-9	Blood protein levels;
LIHC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg03037974	chr15:76606532	NA	0.75	14.74	0.62	2.14e-38	Blood metabolite levels;
LIHC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	8.38	0.41	1.35e-15	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.42	6.74	0.34	6.58e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs7823896	0.605	rs6989795	chr8:110086377	C/T	cg11277220	chr19:9271193	ZNF317	0.64	6.17	0.32	1.94e-9	Myopia (pathological);
LIHC	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg02248941	chr16:2239361	CASKIN1	0.34	6.51	0.33	2.64e-10	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14490972	chr6:43484812	POLR1C;YIPF3	-0.5	-6.17	-0.32	1.89e-9	Lung function (FEV1/FVC);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg15617548	chr2:171785815	GORASP2	-0.4	-6.41	-0.33	4.9e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg21548813	chr6:291882	DUSP22	-0.55	-7.33	-0.37	1.68e-12	Menopause (age at onset);
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg06876404	chr16:30941527	FBXL19	0.42	6.62	0.34	1.4e-10	Bipolar disorder;
LIHC	trans	rs1814175	0.616	rs6486011	chr11:49740230	C/T	cg03929089	chr4:120376271	NA	-0.85	-16.54	-0.67	1.44e-45	Height;
LIHC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.52	6.08	0.31	3.27e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.26e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg15123519	chr2:136567270	LCT	0.36	5.87	0.3	1.01e-8	Corneal structure;
LIHC	cis	rs11229555	0.645	rs56228632	chr11:58187444	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg16586182	chr3:47516702	SCAP	0.5	8.82	0.43	6.12e-17	Colorectal cancer;
LIHC	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg20991723	chr1:152506922	NA	0.54	9.22	0.45	3.2e-18	Hair morphology;
LIHC	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.14	0.36	5.55e-12	Diastolic blood pressure;
LIHC	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg20335179	chr10:1068567	C10orf110;IDI2	-0.61	-6.73	-0.34	7.32e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.44e-28	Height;
LIHC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.44	-0.49	2.4e-22	Total cholesterol levels;
LIHC	cis	rs9596863	1.000	rs9536557	chr13:54433190	A/G	ch.13.53330881F	chr13:54432880	NA	-0.45	-6.43	-0.33	4.18e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.43	7.97	0.4	2.46e-14	Prudent dietary pattern;
LIHC	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.95	0.35	1.83e-11	Exhaled nitric oxide output;
LIHC	cis	rs2257205	0.667	rs8076021	chr17:56694646	T/G	cg05425664	chr17:57184151	TRIM37	-0.61	-6.69	-0.34	8.94e-11	Pancreatic cancer;
LIHC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.73	-12.35	-0.56	3.21e-29	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.75	-0.39	1.02e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.64	8.96	0.44	2.12e-17	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg16822855	chr3:40428330	ENTPD3	0.33	5.93	0.31	7.32e-9	Renal cell carcinoma;
LIHC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.29	-6.73	-0.34	7.19e-11	Menarche (age at onset);
LIHC	cis	rs8016947	0.583	rs12891895	chr14:35827557	A/C	cg03549618	chr14:35838977	NA	0.43	6.94	0.35	1.97e-11	Psoriasis;
LIHC	cis	rs2997447	0.846	rs12069719	chr1:26411918	A/G	cg19633962	chr1:26362018	EXTL1	-0.61	-7.16	-0.36	5.05e-12	QRS complex (12-leadsum);
LIHC	trans	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg26939375	chr7:64535504	NA	0.42	6.82	0.35	4.26e-11	Aortic root size;
LIHC	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs6663390	0.510	rs73072979	chr1:208072057	G/A	cg03990033	chr1:208084030	CD34	0.48	5.8	0.3	1.53e-8	Facial morphology (factor 18);
LIHC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.35	5.71	0.3	2.45e-8	Menopause (age at onset);
LIHC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg24693881	chr1:107596107	NA	0.55	9.61	0.46	1.64e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.42	-0.33	4.6e-10	Mean corpuscular volume;
LIHC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.63	10.69	0.5	3.22e-23	Colorectal cancer;
LIHC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.97	18.13	0.7	5.68e-52	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs2694632	chr2:61558682	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.79	0.3	1.56e-8	Tuberculosis;
LIHC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg03013999	chr17:37608204	MED1	0.35	5.8	0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs3814244	0.528	rs7306466	chr12:68408722	G/A	cg15249341	chr12:68405565	NA	-0.32	-6.27	-0.32	1.09e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs7712401	0.755	rs13172043	chr5:122184759	G/A	cg18764291	chr5:122110994	SNX2	0.35	5.91	0.3	8.16e-9	Mean platelet volume;
LIHC	cis	rs3762637	0.941	rs75344200	chr3:122073421	C/T	cg24169773	chr3:122142474	KPNA1	-0.49	-9.64	-0.46	1.3e-19	LDL cholesterol levels;
LIHC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.1e-17	Bipolar disorder;
LIHC	cis	rs10508774	1.000	rs72782254	chr10:32963332	C/A	cg01819863	chr10:32635814	EPC1	0.63	5.79	0.3	1.62e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15397725	chr14:53019133	TXNDC16;GPR137C	0.43	6.33	0.32	7.73e-10	Pancreatic cancer;
LIHC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg11764359	chr7:65958608	NA	0.57	6.0	0.31	4.9e-9	Diabetic kidney disease;
LIHC	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg23435118	chr5:141488016	NDFIP1	-0.44	-6.02	-0.31	4.6e-9	Crohn's disease;
LIHC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.73	0.3	2.16e-8	Schizophrenia;
LIHC	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.71	11.43	0.53	7.95e-26	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.12	0.44	6.4e-18	Cognitive ability;
LIHC	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	6.57	0.33	1.86e-10	Homocysteine levels;
LIHC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.67	6.46	0.33	3.68e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.46	-8.29	-0.41	2.54e-15	Vitamin D levels;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.85	-0.35	3.36e-11	Menopause (age at onset);
LIHC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.81	17.19	0.68	3.47e-48	Gestational age at birth (maternal effect);
LIHC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	8.15	0.4	6.94e-15	Lymphocyte counts;
LIHC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.32	5.89	0.3	9.15e-9	Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17340548	chr19:46185070	GIPR	-0.41	-6.33	-0.32	7.49e-10	Pancreatic cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26708280	chr2:190649305	PMS1;ORMDL1	0.44	6.23	0.32	1.41e-9	Pancreatic cancer;
LIHC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.28	-0.45	2.05e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs6442522	0.933	rs7622657	chr3:15411892	C/G	cg16303742	chr3:15540471	COLQ	-0.34	-5.76	-0.3	1.83e-8	Uric acid levels;
LIHC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.54	-10.07	-0.48	4.6e-21	Asthma;
LIHC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.3	0.32	9.39e-10	Tonsillectomy;
LIHC	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs7914558	0.621	rs7896290	chr10:104656015	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-7.38	-0.37	1.22e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.13	0.48	2.88e-21	Melanoma;
LIHC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg13047869	chr3:10149882	C3orf24	0.41	5.76	0.3	1.87e-8	Alzheimer's disease;
LIHC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.0	-0.31	4.9e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs4930561	0.714	rs11228151	chr11:67949371	C/G	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.75	-0.3	1.96e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LIHC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	0.88	12.21	0.55	1.01e-28	Skin colour saturation;
LIHC	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg26138937	chr11:71823887	C11orf51	1.31	10.43	0.49	2.7e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.73	7.56	0.38	3.68e-13	Vitiligo;
LIHC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.8	17.45	0.69	3.24e-49	Gestational age at birth (maternal effect);
LIHC	cis	rs1144333	0.655	rs76612182	chr1:76451889	C/T	cg03433033	chr1:76189801	ACADM	0.55	7.79	0.39	8.24e-14	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2412488	0.893	rs7691892	chr4:54360381	A/G	cg22241045	chr4:54363911	LNX1	0.46	7.65	0.38	2.07e-13	DNA methylation (variation);
LIHC	cis	rs4563143	0.514	rs112651366	chr19:29299704	A/T	cg14983838	chr19:29218262	NA	0.44	6.34	0.32	7.44e-10	Methadone dose in opioid dependence;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg17859187	chr1:168147929	TIPRL	0.6	7.64	0.38	2.18e-13	Schizophrenia;
LIHC	cis	rs7546668	1.000	rs4646068	chr1:15828704	T/C	cg11706911	chr1:15910989	AGMAT	0.44	6.8	0.35	4.68e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg00938859	chr5:1591904	SDHAP3	0.58	6.86	0.35	3.34e-11	Breast cancer;
LIHC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.66	8.42	0.41	1.05e-15	Initial pursuit acceleration;
LIHC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg22961513	chr11:14280813	SPON1	0.49	7.64	0.38	2.21e-13	Mitochondrial DNA levels;
LIHC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.16e-11	Aortic root size;
LIHC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.82	16.95	0.68	3.17e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg03237606	chr10:63212265	TMEM26	0.33	7.39	0.37	1.11e-12	Night sleep phenotypes;
LIHC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg20607798	chr8:58055168	NA	0.49	6.23	0.32	1.34e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	1.1	12.95	0.57	1.73e-31	Eosinophil percentage of granulocytes;
LIHC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.95	20.39	0.74	5e-61	Blood protein levels;
LIHC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.56	7.81	0.39	6.85e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22827060	chr13:30424359	UBL3	0.44	6.44	0.33	3.98e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.4	0.52	9.72e-26	Coffee consumption (cups per day);
LIHC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.82	-13.91	-0.6	3.69e-35	Aortic root size;
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.43	6.14	0.32	2.32e-9	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.74	11.18	0.52	5.92e-25	Corneal astigmatism;
LIHC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.6	7.39	0.37	1.1e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg26939375	chr7:64535504	NA	-0.42	-7.22	-0.36	3.32e-12	Calcium levels;
LIHC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg03959625	chr15:84868606	LOC388152	0.43	6.07	0.31	3.43e-9	Schizophrenia;
LIHC	cis	rs611744	0.967	rs686251	chr8:109198907	C/A	cg18478394	chr8:109455254	TTC35	0.4	6.89	0.35	2.64e-11	Dupuytren's disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00322698	chr6:41069048	NFYA;LOC221442	0.4	6.24	0.32	1.26e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.67	8.97	0.44	1.99e-17	Blood metabolite levels;
LIHC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.48	-0.53	5.13e-26	Type 2 diabetes;
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04025307	chr7:1156635	C7orf50	0.55	7.33	0.37	1.73e-12	Bronchopulmonary dysplasia;
LIHC	trans	rs72960926	0.744	rs11754468	chr6:74932522	C/T	cg07247405	chr1:2484626	LOC115110	0.55	6.58	0.34	1.75e-10	Metabolite levels (MHPG);
LIHC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.01	0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13821173	chr7:98591120	TRRAP	-0.4	-6.06	-0.31	3.67e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.59	8.31	0.41	2.27e-15	Platelet count;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg09033563	chr22:24373618	LOC391322	-0.47	-6.57	-0.33	1.84e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	16.23	0.66	2.46e-44	Nonalcoholic fatty liver disease;
LIHC	trans	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg01311341	chr22:25575246	KIAA1671	0.43	6.64	0.34	1.27e-10	Prostate cancer;
LIHC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.35	8.82	0.43	6.11e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.55	0.33	2.11e-10	Mean corpuscular volume;
LIHC	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.0	-0.35	1.37e-11	Blood pressure;
LIHC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg13264159	chr8:625131	ERICH1	-0.62	-6.29	-0.32	9.62e-10	IgG glycosylation;
LIHC	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.79	0.71	1.31e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-10.47	-0.49	2.03e-22	Schizophrenia;
LIHC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.96	17.17	0.68	4.27e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.26	0.64	1.81e-40	Chronic sinus infection;
LIHC	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.48	-6.74	-0.34	6.5500000000000006e-11	Depression and alcohol dependence;
LIHC	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.32	8.06	0.4	1.32e-14	Gut microbiome composition (winter);
LIHC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.21	0.45	3.34e-18	Platelet count;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.52	6.99	0.35	1.44e-11	Menopause (age at onset);
LIHC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.17	0.58	2.51e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-0.72	-10.12	-0.48	3.23e-21	White blood cell count;
LIHC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs1892700	0.730	rs2834232	chr21:34892896	C/T	cg14850771	chr21:34775459	IFNGR2	-0.45	-5.98	-0.31	5.51e-9	Educational attainment;
LIHC	cis	rs3736485	0.966	rs17609917	chr15:51911487	G/C	cg08986416	chr15:51914746	DMXL2	-0.47	-6.99	-0.35	1.49e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Corneal astigmatism;
LIHC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.3	-0.41	2.43e-15	Longevity;
LIHC	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.52	0.38	4.95e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	1.08	11.83	0.54	2.63e-27	Eosinophil percentage of granulocytes;
LIHC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02732134	chr10:101732382	DNMBP	-0.37	-6.6	-0.34	1.59e-10	Height;
LIHC	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.64	-9.24	-0.45	2.78e-18	White matter hyperintensity burden;
LIHC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.1	-10.33	-0.49	5.84e-22	Breast cancer;
LIHC	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.59	-9.97	-0.47	9.88e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs1419980	0.730	rs116906540	chr12:7751202	A/C	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	trans	rs6600671	1.000	rs6600671	chr1:121200490	T/G	cg09829573	chr1:144692074	NBPF9	0.39	6.43	0.33	4.27e-10	Hip geometry;
LIHC	cis	rs10426930	0.607	rs877287	chr19:5041989	G/A	cg18473234	chr19:5097819	KDM4B	0.57	6.63	0.34	1.33e-10	Monocyte percentage of white cells;
LIHC	cis	rs4919087	0.683	rs7074896	chr10:99071282	T/C	cg25902810	chr10:99078978	FRAT1	-0.6	-7.23	-0.36	3.16e-12	Monocyte count;
LIHC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	8.36	0.41	1.57e-15	Platelet count;
LIHC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg04013166	chr16:89971882	TCF25	0.5	6.21	0.32	1.51e-9	Skin colour saturation;
LIHC	trans	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg26939375	chr7:64535504	NA	-0.39	-6.2	-0.32	1.63e-9	Aortic root size;
LIHC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.89	8.44	0.42	9.23e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-6.0	-0.31	5.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs783540	0.967	rs1864699	chr15:83323318	A/G	cg18393722	chr15:85113863	UBE2QP1	0.39	6.78	0.34	5.17e-11	Schizophrenia;
LIHC	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg15704280	chr7:45808275	SEPT13	-0.5	-7.63	-0.38	2.31e-13	Pediatric bone mineral density (spine);
LIHC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg06212747	chr3:49208901	KLHDC8B	0.45	5.92	0.3	7.8e-9	Resting heart rate;
LIHC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.54	7.33	0.37	1.63e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg05185784	chr16:90016020	DEF8	-0.45	-5.88	-0.3	9.64e-9	Skin colour saturation;
LIHC	cis	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg05315874	chr8:20054693	ATP6V1B2	-0.61	-6.7	-0.34	8.42e-11	Preeclampsia;
LIHC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.32	7.32	0.37	1.75e-12	Crohn's disease;
LIHC	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg13974409	chr11:65292307	SCYL1	-0.38	-5.99	-0.31	5.46e-9	Bone mineral density;
LIHC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.45	-0.49	2.26e-22	Chronic sinus infection;
LIHC	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.26	-0.32	1.16e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9942416	0.586	rs111745049	chr5:75037761	T/A	cg19683494	chr5:74908142	NA	0.52	5.85	0.3	1.12e-8	Age-related disease endophenotypes;
LIHC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg26441486	chr22:50317300	CRELD2	-0.35	-6.32	-0.32	7.96e-10	Schizophrenia;
LIHC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.39	-6.47	-0.33	3.4e-10	Age at first birth;
LIHC	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.8	-7.47	-0.37	6.58e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.37	0.52	1.23e-25	Height;
LIHC	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.33	5.71	0.3	2.42e-8	Mean corpuscular volume;
LIHC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.66e-12	Height;
LIHC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.51	5.74	0.3	2.11e-8	Primary sclerosing cholangitis;
LIHC	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg18912006	chr12:123335444	HIP1R	-0.62	-7.38	-0.37	1.18e-12	Schizophrenia;
LIHC	cis	rs4668356	0.687	rs16859206	chr2:172043803	A/G	cg13882835	chr2:172017928	TLK1	0.44	5.99	0.31	5.25e-9	Cognitive performance;
LIHC	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.57	-7.21	-0.36	3.69e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs2524276	1	rs2524276	chr6:31408265	C/A	cg15633609	chr6:31324621	HLA-B	0.77	6.2	0.32	1.61e-9	Capecitabine sensitivity;
LIHC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.26	0.41	3.32e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.62	9.0	0.44	1.57e-17	Monocyte count;
LIHC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.51	7.95	0.4	2.67e-14	Lymphocyte counts;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg14780466	chr2:20870812	GDF7	0.39	8.77	0.43	8.8e-17	Abdominal aortic aneurysm;
LIHC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	12.0	0.54	6.38e-28	Response to antipsychotic treatment;
LIHC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.27	0.41	3.05e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10768122	0.642	rs4756214	chr11:35365938	C/T	cg13971030	chr11:35366721	SLC1A2	-0.35	-5.76	-0.3	1.9e-8	Vitiligo;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.42	0.41	1.01e-15	Platelet count;
LIHC	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.32	6.75	0.34	6.43e-11	Ulcerative colitis;
LIHC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg06565975	chr8:143823917	SLURP1	-0.44	-8.04	-0.4	1.44e-14	Urinary tract infection frequency;
LIHC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.34	-5.78	-0.3	1.7e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3015497	0.753	rs4643225	chr14:51122205	G/C	cg09863266	chr14:51125203	SAV1	-0.43	-6.86	-0.35	3.24e-11	Mean platelet volume;
LIHC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg00677901	chr16:88017247	BANP	0.52	8.02	0.4	1.74e-14	Menopause (age at onset);
LIHC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.93	-17.04	-0.68	1.48e-47	Colorectal cancer;
LIHC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.37	-0.33	6.02e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg06085875	chr4:83937413	NA	0.38	6.84	0.35	3.73e-11	Oropharynx cancer;
LIHC	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.61	-11.87	-0.54	1.89e-27	Prudent dietary pattern;
LIHC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg01200585	chr1:228362443	C1orf69	0.42	6.44	0.33	4.08e-10	Diastolic blood pressure;
LIHC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.5	-7.44	-0.37	8.04e-13	Asthma;
LIHC	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-9.53	-0.46	3.12e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.52e-14	Platelet count;
LIHC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.34	-6.32	-0.32	7.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.69	10.36	0.49	4.72e-22	Lung cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06363214	chr1:90228963	NA	0.39	6.09	0.31	3.02e-9	Cognitive function;
LIHC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg21573476	chr21:45109991	RRP1B	-0.54	-10.37	-0.49	4.2e-22	Mean corpuscular volume;
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.63	8.0	0.4	1.89e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09698166	chr20:21106763	PLK1S1	0.49	7.96	0.4	2.48e-14	Pancreatic cancer;
LIHC	cis	rs12079745	0.793	rs78266198	chr1:169346615	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg15841412	chr13:111365552	ING1	0.47	5.93	0.31	7.54e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.56	-7.48	-0.38	6.26e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.45	0.49	2.24e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.32	-5.99	-0.31	5.43e-9	Body mass index;
LIHC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.58	0.53	2.17e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-9.06	-0.44	1.06e-17	Bipolar disorder;
LIHC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg21724239	chr8:58056113	NA	0.49	6.4	0.33	5.14e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.41	6.85	0.35	3.51e-11	Lewy body disease;
LIHC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.42	0.33	4.69e-10	Menopause (age at onset);
LIHC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	8.96	0.44	2.1e-17	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	0.51	6.51	0.33	2.66e-10	Lung cancer;
LIHC	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.45	-6.98	-0.35	1.56e-11	Multiple sclerosis;
LIHC	cis	rs17152411	0.895	rs66531168	chr10:126586908	T/A	cg07906193	chr10:126599966	NA	0.44	6.89	0.35	2.74e-11	Height;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.21e-14	Prudent dietary pattern;
LIHC	cis	rs61712019	0.563	rs11885676	chr2:77732482	T/C	cg11252801	chr2:77748917	LRRTM4	0.46	6.36	0.33	6.44e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14208070	chr17:4685804	TM4SF5	0.41	6.2	0.32	1.66e-9	Cognitive function;
LIHC	trans	rs8033655	0.925	rs7180182	chr15:50310295	A/G	cg10099229	chr12:6960622	USP5;CDCA3	0.42	6.08	0.31	3.2e-9	Skin pigmentation;
LIHC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.81	-6.59	-0.34	1.63e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.73	-0.6	1.82e-34	Coffee consumption (cups per day);
LIHC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17507749	chr15:85114479	UBE2QP1	0.68	7.89	0.39	4.17e-14	Schizophrenia;
LIHC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg14580859	chr9:123691850	NA	0.38	6.55	0.33	2.08e-10	Rheumatoid arthritis;
LIHC	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.4	0.37	1.07e-12	Diastolic blood pressure;
LIHC	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.22	0.32	1.48e-9	Mean corpuscular volume;
LIHC	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg14515779	chr1:101123966	NA	0.49	6.79	0.34	4.86e-11	Monocyte count;
LIHC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg12661370	chr5:149340060	SLC26A2	0.51	6.17	0.32	1.92e-9	HIV-1 control;
LIHC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17554472	chr22:41940697	POLR3H	0.56	6.23	0.32	1.34e-9	Vitiligo;
LIHC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11645453	chr3:52864694	ITIH4	0.22	5.74	0.3	2.13e-8	Bipolar disorder;
LIHC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.52	-6.61	-0.34	1.44e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.85	13.35	0.59	5.11e-33	Obesity-related traits;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	0.6	8.61	0.42	2.73e-16	Prudent dietary pattern;
LIHC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.78e-10	Menarche (age at onset);
LIHC	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.77	-13.37	-0.59	4.39e-33	Height;
LIHC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.42	12.92	0.57	2.22e-31	Uric acid levels;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.17	-0.36	4.62e-12	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15655138	chr6:37139981	PIM1	0.48	6.82	0.35	4.2e-11	Pancreatic cancer;
LIHC	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-5.75	-0.3	2e-8	Inflammatory biomarkers;
LIHC	cis	rs78545713	0.892	rs76182849	chr6:26257950	C/T	cg16070018	chr6:26224392	HIST1H3E	0.66	7.25	0.36	2.85e-12	Iron status biomarkers (total iron binding capacity);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12317515	chr5:74063363	GFM2;NSA2	0.44	6.39	0.33	5.54e-10	Pancreatic cancer;
LIHC	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.37	-6.08	-0.31	3.25e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	9.28	0.45	2.04e-18	Schizophrenia;
LIHC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.42	-5.9	-0.3	8.55e-9	Type 1 diabetes;
LIHC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg01081584	chr15:40268610	EIF2AK4	-0.53	-6.19	-0.32	1.69e-9	Corneal curvature;
LIHC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.53	7.18	0.36	4.49e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.39	6.15	0.32	2.15e-9	Melanoma;
LIHC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.6	8.69	0.43	1.5e-16	Platelet count;
LIHC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.54	7.68	0.38	1.71e-13	Height;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15979172	chr19:15490570	AKAP8	0.47	6.28	0.32	1.01e-9	Hepatitis;
LIHC	trans	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.35	6.48	0.33	3.24e-10	Blood metabolite levels;
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg07002622	chr6:118822466	C6orf204;BRD7P3	0.5	5.94	0.31	6.83e-9	Diastolic blood pressure;
LIHC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.69	-7.78	-0.39	8.92e-14	Neuroticism;
LIHC	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg23367146	chr19:21773418	NA	0.38	5.79	0.3	1.56e-8	Pain;
LIHC	trans	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg01596870	chr19:55963115	NA	-0.63	-7.52	-0.38	4.78e-13	Obesity-related traits;
LIHC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg18512352	chr11:47633146	NA	0.28	6.19	0.32	1.72e-9	Subjective well-being;
LIHC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.73	-0.34	7.29e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.72	10.9	0.51	6.07e-24	Breast cancer;
LIHC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.96	17.77	0.69	1.73e-50	Breast cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15708001	chr12:54673887	CBX5;HNRNPA1;HNRPA1L-2	0.33	6.09	0.31	3.1e-9	Calcium levels;
LIHC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.23	0.32	1.37e-9	Schizophrenia;
LIHC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	6.13	0.31	2.49e-9	Schizophrenia;
LIHC	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg27205649	chr11:78285834	NARS2	0.46	7.13	0.36	5.96e-12	Alzheimer's disease (survival time);
LIHC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3823572	0.564	rs2953618	chr7:133672476	G/C	cg03336402	chr7:133662267	EXOC4	-0.5	-5.71	-0.3	2.41e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-6.98	-0.35	1.56e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg27432699	chr2:27873401	GPN1	-0.5	-7.17	-0.36	4.62e-12	Total body bone mineral density;
LIHC	cis	rs2637266	1.000	rs7474960	chr10:78359021	C/T	cg18941641	chr10:78392320	NA	0.29	6.21	0.32	1.55e-9	Pulmonary function;
LIHC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-5.99	-0.31	5.28e-9	Diabetic kidney disease;
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.45	-0.33	3.79e-10	Schizophrenia;
LIHC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.73	10.55	0.5	1.01e-22	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.95	-0.31	6.62e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs700651	0.789	rs892514	chr2:198905270	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.55	0.33	2.06e-10	Intracranial aneurysm;
LIHC	cis	rs2292096	1.000	rs35045998	chr1:200719186	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.12	-0.31	2.57e-9	Epilepsy;
LIHC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-7.31	-0.37	1.95e-12	Mean platelet volume;
LIHC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.64	0.38	2.23e-13	Diastolic blood pressure;
LIHC	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.72	-0.47	7.19e-20	Ulcerative colitis;
LIHC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.38	-6.51	-0.33	2.66e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.85e-13	Lymphocyte counts;
LIHC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.77	6.15	0.32	2.21e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.73	11.78	0.54	3.98e-27	Oral cavity cancer;
LIHC	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.86	-13.02	-0.58	9.33e-32	Obesity-related traits;
LIHC	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	6.84	0.35	3.63e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs11031096	0.535	rs10767886	chr11:4218391	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-6.28	-0.32	1.03e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs903552	0.673	rs4965878	chr15:102009589	C/T	cg04789225	chr15:102009795	PCSK6	-0.45	-5.84	-0.3	1.19e-8	Diabetic kidney disease;
LIHC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.59	-8.18	-0.4	5.52e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs847649	1.000	rs9718453	chr7:102594976	T/G	cg18108683	chr7:102477205	FBXL13	0.48	7.5	0.38	5.45e-13	Morning vs. evening chronotype;
LIHC	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs67981189	0.574	rs2526848	chr14:71419742	T/C	cg15816911	chr14:71606274	NA	-0.42	-6.67	-0.34	1.03e-10	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-7.0	-0.35	1.33e-11	Neuroticism;
LIHC	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg13397359	chr6:42928475	GNMT	0.47	6.59	0.34	1.63e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg01364799	chr7:75623366	TMEM120A	-0.47	-7.13	-0.36	5.84e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-9.16	-0.44	4.72e-18	Total body bone mineral density;
LIHC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.77	11.56	0.53	2.67e-26	Coronary artery disease;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.56	-8.31	-0.41	2.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs5015933	0.966	rs1965342	chr9:128133661	T/A	cg14078157	chr9:128172775	NA	-0.38	-6.58	-0.34	1.79e-10	Body mass index;
LIHC	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.75	9.73	0.47	6.53e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs9628987	0.569	rs3765972	chr1:8425798	C/T	cg20416874	chr1:8611966	RERE	0.49	5.96	0.31	6.22e-9	Breast cancer;
LIHC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.91	-0.35	2.41e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg14146966	chr2:61757674	XPO1	-0.43	-7.19	-0.36	4.17e-12	Tuberculosis;
LIHC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg09314803	chr17:79180344	AZI1	-0.41	-7.22	-0.36	3.32e-12	Frontotemporal dementia;
LIHC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	10.32	0.49	6.35e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11718455	0.582	rs6763436	chr3:43913653	A/G	cg08738300	chr3:44038990	NA	-0.41	-6.94	-0.35	1.96e-11	Coronary artery disease;
LIHC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.44	-0.74	2.99e-61	Height;
LIHC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.29	-0.32	9.84e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18252515	chr7:66147081	NA	-0.44	-6.39	-0.33	5.48e-10	Aortic root size;
LIHC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.16	-0.52	7.35e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.42	-6.77	-0.34	5.53e-11	Mortality in heart failure;
LIHC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.77	13.15	0.58	2.9e-32	Menarche (age at onset);
LIHC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg20933634	chr6:27740509	NA	0.47	6.24	0.32	1.28e-9	Parkinson's disease;
LIHC	cis	rs7106204	0.514	rs1443043	chr11:24251991	A/G	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.91	11.51	0.53	4e-26	Dilated cardiomyopathy;
LIHC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.93	-0.31	7.29e-9	Menarche (age at onset);
LIHC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.58	-8.62	-0.42	2.51e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg00825309	chr19:58991885	ZNF446	-0.41	-6.0	-0.31	5e-9	Uric acid clearance;
LIHC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.78	-12.79	-0.57	6.97e-31	Oral cavity cancer;
LIHC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.3	0.32	9.1e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.11	-0.44	6.82e-18	Type 2 diabetes;
LIHC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-11.6	-0.53	1.84e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.41	6.34	0.32	7.39e-10	Height;
LIHC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	7.82	0.39	6.76e-14	Schizophrenia;
LIHC	cis	rs1256061	0.624	rs1152578	chr14:64697037	T/C	cg23250157	chr14:64679961	SYNE2	0.42	6.03	0.31	4.21e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg09222892	chr1:25734099	RHCE	-0.42	-7.65	-0.38	2.1e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.4	6.33	0.32	7.78e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs1144333	0.655	rs75578876	chr1:76395586	A/C	cg10523679	chr1:76189770	ACADM	0.47	6.36	0.33	6.47e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.62	-8.73	-0.43	1.12e-16	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2569991	0.636	rs361221	chr3:12922767	A/C	cg22481960	chr3:13008800	IQSEC1	0.4	6.88	0.35	2.83e-11	Periodontitis (DPAL);
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	0.58	8.49	0.42	6.43e-16	Prudent dietary pattern;
LIHC	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.46	-7.56	-0.38	3.67e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs6934970	1.000	rs28510827	chr6:113101492	T/A	cg09308777	chr6:169852575	NA	0.6	6.26	0.32	1.13e-9	Bipolar disorder (body mass index interaction);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16256065	chr11:68216328	LRP5	0.42	6.26	0.32	1.16e-9	Longevity;
LIHC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.38	1.4e-13	Glioblastoma;
LIHC	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.45	0.33	3.84e-10	Resting heart rate;
LIHC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	ch.11.42038R	chr11:967971	AP2A2	0.55	10.03	0.48	6.14e-21	Alzheimer's disease (late onset);
LIHC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.74	13.64	0.59	3.84e-34	Height;
LIHC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	9.3	0.45	1.66e-18	Response to antipsychotic treatment;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.23	0.81	4.46e-80	Prudent dietary pattern;
LIHC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.44	-8.65	-0.42	1.97e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.96	0.51	3.56e-24	Monocyte percentage of white cells;
LIHC	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.94	16.44	0.66	3.8e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.42	7.69	0.38	1.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.43	-6.01	-0.31	4.75e-9	Total body bone mineral density;
LIHC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.5	0.53	4.42e-26	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05246190	chr22:50330022	NA	0.47	6.23	0.32	1.4e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2737618	0.674	rs2260033	chr1:200086074	G/A	cg21825944	chr1:200113062	NR5A2	-0.49	-8.34	-0.41	1.83e-15	Uric acid levels;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01171360	chr6:293285	DUSP22	-0.46	-6.66	-0.34	1.11e-10	Menopause (age at onset);
LIHC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.88	-0.35	2.85e-11	Hepatocellular carcinoma;
LIHC	cis	rs151997	0.671	rs493507	chr5:50219675	G/T	cg06027927	chr5:50259733	NA	-0.43	-6.4	-0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg19442470	chr8:27470225	CLU	0.35	6.22	0.32	1.47e-9	Myopia (pathological);
LIHC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.32	-5.85	-0.3	1.14e-8	Diastolic blood pressure;
LIHC	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.38	9.04	0.44	1.22e-17	Blood metabolite ratios;
LIHC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.32	-6.38	-0.33	5.68e-10	Platelet distribution width;
LIHC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg09835421	chr16:68378352	PRMT7	-0.49	-5.98	-0.31	5.59e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.83	-9.32	-0.45	1.45e-18	Alzheimer's disease (late onset);
LIHC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg18270830	chr10:32634957	EPC1	0.53	6.44	0.33	4.04e-10	Sexual dysfunction (female);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26434225	chr8:80942688	MRPS28	0.54	8.26	0.41	3.34e-15	Cognitive function;
LIHC	cis	rs11628318	0.614	rs4906254	chr14:103209153	C/T	cg23461800	chr14:103021989	NA	-0.39	-5.86	-0.3	1.12e-8	Platelet count;
LIHC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.23e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.83	-0.3	1.28e-8	Fibrinogen levels;
LIHC	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.37	-6.2	-0.32	1.67e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	trans	rs9217	0.776	rs11650977	chr17:7392341	A/G	cg08566640	chr11:64091735	NA	-0.42	-7.33	-0.37	1.73e-12	Height;
LIHC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.53	8.72	0.43	1.25e-16	Schizophrenia;
LIHC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.55	7.36	0.37	1.38e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	1.02	19.69	0.73	3.16e-58	Breast cancer;
LIHC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	0.67	6.66	0.34	1.09e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.32	0.52	1.85e-25	Prudent dietary pattern;
LIHC	trans	rs7022054	0.502	rs2770771	chr9:7216426	G/A	cg26740341	chr6:22874184	NA	0.27	6.14	0.32	2.3e-9	Schizophrenia;
LIHC	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.35	-5.76	-0.3	1.9e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.6	11.91	0.54	1.36e-27	Plateletcrit;Platelet count;
LIHC	cis	rs7534824	0.582	rs61780297	chr1:101400855	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.65	0.38	2.07e-13	Refractive astigmatism;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.69	-9.92	-0.47	1.47e-20	Initial pursuit acceleration;
LIHC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.61	11.61	0.53	1.75e-26	Neuroticism;
LIHC	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-6.11	-0.31	2.76e-9	Coronary artery disease;
LIHC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg10755058	chr3:40428713	ENTPD3	0.42	7.12	0.36	6.3e-12	Renal cell carcinoma;
LIHC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-10.43	-0.49	2.65e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6504950	0.720	rs7216138	chr17:52995664	G/A	cg10237252	chr17:52977213	TOM1L1	-0.36	-6.32	-0.32	8.02e-10	Breast cancer;
LIHC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	1.01	19.32	0.72	9.73e-57	Breast cancer;
LIHC	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.6	-0.46	1.73e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.0	-0.31	5.02e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22442454	chr1:209979470	IRF6	0.4	5.94	0.31	7.07e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg07636037	chr3:49044803	WDR6	-0.55	-6.39	-0.33	5.38e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.57	8.46	0.42	7.85e-16	White matter hyperintensity burden;
LIHC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.52	7.54	0.38	4.36e-13	Obesity-related traits;
LIHC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.65	11.61	0.53	1.74e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9543976	1.000	rs1535724	chr13:76183273	G/C	cg01531495	chr13:76123901	UCHL3	0.48	5.76	0.3	1.87e-8	Diabetic retinopathy;
LIHC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg04469686	chr1:162760199	HSD17B7	0.38	6.18	0.32	1.83e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg14515779	chr1:101123966	NA	-0.67	-12.44	-0.56	1.47e-29	Monocyte count;
LIHC	cis	rs55702914	0.712	rs12619296	chr2:198148767	A/G	cg10820045	chr2:198174542	NA	-0.37	-5.75	-0.3	2.01e-8	Major depression and alcohol dependence;
LIHC	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.68	6.81	0.35	4.52e-11	Migraine;Coronary artery disease;
LIHC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg14092571	chr14:90743983	NA	-0.38	-6.06	-0.31	3.5e-9	Mortality in heart failure;
LIHC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.36e-11	Protein C levels;
LIHC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.4e-8	Heart rate;
LIHC	cis	rs12493885	0.818	rs7641039	chr3:153768638	A/C	cg10247383	chr3:153839028	SGEF	-0.65	-6.1	-0.31	2.89e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg13443165	chr9:33130375	B4GALT1	-0.34	-5.94	-0.31	6.93e-9	IgG glycosylation;
LIHC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.64	12.98	0.57	1.4e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.67	9.35	0.45	1.16e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	6.02	0.31	4.42e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.44	-0.37	8.13e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg23625390	chr15:77176239	SCAPER	0.36	5.95	0.31	6.48e-9	Blood metabolite levels;
LIHC	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.85	-0.35	3.48e-11	Metabolite levels;
LIHC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.92	-16.02	-0.65	1.72e-43	Tonsillectomy;
LIHC	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-0.8	-9.28	-0.45	1.93e-18	Alzheimer's disease (late onset);
LIHC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-10.12	-0.48	3.05e-21	Parkinson's disease;
LIHC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.78	10.87	0.51	7.51e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.45	0.53	6.42e-26	Colorectal cancer;
LIHC	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	0.81	11.5	0.53	4.29e-26	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.39	-5.82	-0.3	1.35e-8	Menarche (age at onset);
LIHC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.43	7.91	0.39	3.71e-14	Schizophrenia;
LIHC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-9.33	-0.45	1.41e-18	Blood metabolite levels;
LIHC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.82	0.39	6.52e-14	Morning vs. evening chronotype;
LIHC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.54	-8.38	-0.41	1.44e-15	Crohn's disease;
LIHC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg02344993	chr17:57696989	CLTC	0.7	11.89	0.54	1.66e-27	Hemoglobin concentration;
LIHC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg14779329	chr11:130786720	SNX19	0.43	6.52	0.33	2.6e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.4	7.77	0.39	9.09e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg24130564	chr14:104152367	KLC1	0.43	7.05	0.36	9.65e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-8.37	-0.41	1.54e-15	Morning vs. evening chronotype;
LIHC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.44	8.03	0.4	1.61e-14	Prudent dietary pattern;
LIHC	cis	rs17125944	0.686	rs3818453	chr14:53326454	C/A	cg00686598	chr14:53173677	PSMC6	-0.75	-8.51	-0.42	5.49e-16	Alzheimer's disease (late onset);
LIHC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs16958440	0.867	rs75287977	chr18:44686823	G/A	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.45	6.57	0.33	1.89e-10	Retinal vascular caliber;
LIHC	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.81	-9.72	-0.47	6.83e-20	Mean platelet volume;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06873352	chr17:61820015	STRADA	0.52	7.56	0.38	3.63e-13	Height;
LIHC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.38	-6.29	-0.32	9.44e-10	Obesity-related traits;
LIHC	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.99	-0.44	1.66e-17	Obesity-related traits;
LIHC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.64	9.97	0.47	1e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs911119	0.955	rs12625716	chr20:23606845	A/G	cg16589663	chr20:23618590	CST3	-0.78	-8.24	-0.41	3.81e-15	Chronic kidney disease;
LIHC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.94	15.14	0.63	5.24e-40	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg16011679	chr1:85725395	C1orf52	0.46	6.01	0.31	4.79e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.67	-11.6	-0.53	1.83e-26	Platelet distribution width;
LIHC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.73	14.04	0.6	1.1e-35	N-glycan levels;
LIHC	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg20435097	chr10:126320824	FAM53B	-0.45	-6.71	-0.34	7.85e-11	Cocaine dependence;
LIHC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.63	8.01	0.4	1.76e-14	Morning vs. evening chronotype;
LIHC	cis	rs939574	0.512	rs2276638	chr2:220145286	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.59	7.08	0.36	8.04e-12	Platelet distribution width;
LIHC	cis	rs7224685	0.569	rs12942513	chr17:4016721	C/A	cg09597638	chr17:3907349	NA	0.54	6.45	0.33	3.83e-10	Type 2 diabetes;
LIHC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-10.11	-0.48	3.36e-21	Parkinson's disease;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg07599136	chr5:415885	AHRR	0.39	6.75	0.34	6.32e-11	Cystic fibrosis severity;
LIHC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.74	12.65	0.56	2.3e-30	Menopause (age at onset);
LIHC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.73	-0.43	1.13e-16	Crohn's disease;
LIHC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg10790698	chr19:18539756	SSBP4	-0.34	-7.16	-0.36	4.89e-12	Breast cancer;
LIHC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.33	6.94	0.35	1.99e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.58	9.24	0.45	2.63e-18	High light scatter reticulocyte count;
LIHC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.57	-8.9	-0.43	3.44e-17	Dental caries;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20276947	chr17:80056775	FASN	0.49	6.04	0.31	4.13e-9	Hepatitis;
LIHC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.37	0.45	1e-18	Bipolar disorder;
LIHC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19451033	chr5:141276143	LOC729080	0.41	6.2	0.32	1.66e-9	Hepatitis;
LIHC	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg09182678	chr22:50328711	NA	0.46	6.0	0.31	5.01e-9	Schizophrenia;
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12016809	chr21:47604291	C21orf56	0.42	6.21	0.32	1.58e-9	Testicular germ cell tumor;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27347728	chr4:17578864	LAP3	0.47	6.04	0.31	4.08e-9	Lung function (FEV1/FVC);
LIHC	cis	rs918629	0.679	rs12055287	chr5:95272428	G/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.24	-0.32	1.28e-9	IgG glycosylation;
LIHC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.1	0.51	1.19e-24	Platelet count;
LIHC	cis	rs58785573	0.624	rs337605	chr4:38647753	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.43	6.13	0.31	2.39e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg00656387	chr3:40428638	ENTPD3	0.41	6.91	0.35	2.32e-11	Renal cell carcinoma;
LIHC	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg04610667	chr7:75704037	NA	-0.35	-6.25	-0.32	1.23e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.37	5.86	0.3	1.11e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.51	0.49	1.36e-22	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.59e-14	Parkinson's disease;
LIHC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.95	15.74	0.65	2.17e-42	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs546131	0.642	rs11603640	chr11:34832907	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.62	-0.34	1.36e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	0.9	6.59	0.34	1.65e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg18279126	chr7:2041391	MAD1L1	0.36	6.02	0.31	4.6e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.39	5.95	0.31	6.75e-9	Longevity;Endometriosis;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.5	-0.62	1.79e-37	Longevity;
LIHC	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg06664874	chr5:179499304	RNF130	0.57	7.01	0.35	1.3e-11	LDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10373645	chr2:74007265	DUSP11	0.51	6.65	0.34	1.13e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.34	0.58	5.91e-33	Cognitive test performance;
LIHC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.87	16.15	0.66	5.16e-44	Smoking behavior;
LIHC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.78	0.3	1.69e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7238033	0.624	rs12455090	chr18:43313367	A/G	cg20610511	chr18:43302872	SLC14A1	-0.38	-6.4	-0.33	4.99e-10	Bladder cancer;
LIHC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27297192	chr10:134578999	INPP5A	0.51	7.78	0.39	8.43e-14	Migraine;
LIHC	cis	rs4407350	0.870	rs4823329	chr22:44910117	T/C	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.06	-0.31	3.69e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg22903471	chr2:27725779	GCKR	-0.44	-6.59	-0.34	1.71e-10	Blood metabolite levels;
LIHC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.36	6.23	0.32	1.37e-9	Schizophrenia;
LIHC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg12437481	chr16:420112	MRPL28	-0.59	-7.8	-0.39	7.69e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	9.36	0.45	1.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4907240	0.961	rs7580048	chr2:97304180	G/C	cg26665480	chr2:98280029	ACTR1B	-0.4	-5.96	-0.31	6.34e-9	Event-related brain oscillations;
LIHC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.03e-19	Height;
LIHC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	8.38	0.41	1.35e-15	HIV-1 control;
LIHC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-7.02	-0.36	1.17e-11	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg18081818	chr7:23246105	NA	-0.46	-7.07	-0.36	8.79e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00338116	chr13:43566313	EPSTI1	0.43	6.12	0.31	2.53e-9	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	0.57	8.19	0.41	5.15e-15	Prudent dietary pattern;
LIHC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-8.52	-0.42	5.21e-16	Chronic sinus infection;
LIHC	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.11	0.61	5.99e-36	Bipolar disorder;
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.57	11.18	0.52	6.19e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.66	0.65	4.89e-42	Chronic sinus infection;
LIHC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.47	-7.78	-0.39	8.76e-14	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14011500	chr6:126101974	NA	-0.45	-6.58	-0.34	1.79e-10	Pancreatic cancer;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg24209194	chr3:40518798	ZNF619	0.63	9.66	0.46	1.13e-19	Renal cell carcinoma;
LIHC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.46	7.71	0.38	1.41e-13	Extrinsic epigenetic age acceleration;
LIHC	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.56	-6.76	-0.34	5.92e-11	Breast cancer;
LIHC	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.46	-0.37	6.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.35	5.96	0.31	6.16e-9	Colorectal cancer;
LIHC	cis	rs4908768	0.501	rs7530745	chr1:8557691	A/C	cg20416874	chr1:8611966	RERE	-0.66	-13.46	-0.59	2.02e-33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg23749163	chr14:77563968	KIAA1737	-0.39	-6.13	-0.31	2.41e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.47	7.09	0.36	7.77e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg19000871	chr14:103996768	TRMT61A	-0.4	-6.43	-0.33	4.36e-10	Reticulocyte count;
LIHC	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.37	6.37	0.33	6.09e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.56	10.41	0.49	3.26e-22	Mean corpuscular volume;
LIHC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.46	8.85	0.43	4.95e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg16434002	chr17:42200994	HDAC5	-0.52	-7.64	-0.38	2.25e-13	Total body bone mineral density;
LIHC	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.92	-0.3	8.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18357526	chr6:26021779	HIST1H4A	0.49	7.24	0.36	2.97e-12	Height;
LIHC	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg22771759	chr13:24902376	NA	0.32	6.7	0.34	8.43e-11	Obesity-related traits;
LIHC	trans	rs743793	0.818	rs137364	chr22:33576488	T/C	cg20274824	chr1:36638199	MAP7D1	0.45	6.38	0.33	5.92e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg16479474	chr6:28041457	NA	0.45	6.78	0.34	5.41e-11	Parkinson's disease;
LIHC	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg16797656	chr11:68205561	LRP5	0.58	7.84	0.39	5.68e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs7116495	0.737	rs475959	chr11:71605332	A/G	cg26138937	chr11:71823887	C11orf51	0.68	6.68	0.34	9.69e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.56	9.74	0.47	6.08e-20	Systemic lupus erythematosus;
LIHC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	0.87	11.95	0.54	9.72e-28	Skin colour saturation;
LIHC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.33	7.64	0.38	2.15e-13	Blood metabolite ratios;
LIHC	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.32	5.81	0.3	1.44e-8	DNA methylation (variation);
LIHC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.83	-0.35	3.91e-11	Diabetic kidney disease;
LIHC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.77	-12.77	-0.57	8.33e-31	Breast cancer;
LIHC	cis	rs9427116	0.740	rs11264230	chr1:154608418	G/T	cg17218026	chr1:154582156	ADAR	0.34	6.51	0.33	2.65e-10	Blood protein levels;
LIHC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.42	-6.37	-0.33	6e-10	Height;
LIHC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.47	7.86	0.39	5.02e-14	Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.41	0.33	4.8e-10	Prudent dietary pattern;
LIHC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg10932868	chr11:921992	NA	0.32	5.74	0.3	2.06e-8	Alzheimer's disease (late onset);
LIHC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.31	6.44	0.33	3.95e-10	Blood metabolite levels;
LIHC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg03037974	chr15:76606532	NA	0.75	14.48	0.62	2.07e-37	Blood metabolite levels;
LIHC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.49	-7.63	-0.38	2.42e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg17294928	chr15:75287854	SCAMP5	-0.53	-6.45	-0.33	3.86e-10	Blood trace element (Zn levels);
LIHC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.5	-7.78	-0.39	8.91e-14	Cocaine dependence;
LIHC	cis	rs2834188	0.889	rs8134026	chr21:34671098	T/A	cg04842828	chr21:34696676	IFNAR1	0.47	6.23	0.32	1.39e-9	Narcolepsy;
LIHC	cis	rs1816752	0.633	rs8002387	chr13:24990444	A/G	cg22771759	chr13:24902376	NA	0.31	6.06	0.31	3.57e-9	Obesity-related traits;
LIHC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-6.95	-0.35	1.9e-11	Vitiligo;
LIHC	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-10.1	-0.48	3.77e-21	Morning vs. evening chronotype;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23054166	chr20:5986708	CRLS1	-0.46	-6.24	-0.32	1.32e-9	Systolic blood pressure;
LIHC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg00656387	chr3:40428638	ENTPD3	-0.45	-7.6	-0.38	2.92e-13	Renal cell carcinoma;
LIHC	trans	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04565464	chr8:145669602	NFKBIL2	0.41	6.86	0.35	3.14e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.67	-11.3	-0.52	2.21e-25	Pediatric autoimmune diseases;
LIHC	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg16589663	chr20:23618590	CST3	0.75	7.66	0.38	1.98e-13	Chronic kidney disease;
LIHC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg13607699	chr17:42295918	UBTF	0.75	15.31	0.64	1.16e-40	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg08499158	chr17:42289980	UBTF	-0.49	-7.94	-0.39	2.91e-14	Red cell distribution width;Reticulocyte count;
LIHC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.59	7.68	0.38	1.71e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.76	11.03	0.51	2.02e-24	Obesity-related traits;
LIHC	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.18	0.61	3.24e-36	Bipolar disorder;
LIHC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg12365402	chr11:9010492	NRIP3	0.29	7.46	0.37	7.28e-13	Hemoglobin concentration;
LIHC	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg05347473	chr6:146136440	FBXO30	-0.36	-5.77	-0.3	1.81e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.84	-0.65	9.44e-43	Chronic sinus infection;
LIHC	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.2	0.36	3.84e-12	Exhaled nitric oxide output;
LIHC	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-0.8	-9.28	-0.45	1.93e-18	Exhaled nitric oxide output;
LIHC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg06951627	chr6:26196580	NA	0.55	6.19	0.32	1.71e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.72	7.09	0.36	7.94e-12	Vitiligo;
LIHC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.67	0.53	1.05e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1461503	0.903	rs7124683	chr11:122834036	A/G	cg25161029	chr11:122845972	NA	-0.43	-7.38	-0.37	1.21e-12	Menarche (age at onset);
LIHC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.82	-0.3	1.36e-8	Subjective well-being;
LIHC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.48	11.82	0.54	2.9e-27	Alzheimer's disease (late onset);
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.77	-0.39	9.16e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs965469	0.779	rs2236088	chr20:3256342	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.68	-0.34	9.87e-11	IFN-related cytopenia;
LIHC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-0.95	-20.89	-0.75	5.02e-63	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.0	-0.35	1.34e-11	Aortic root size;
LIHC	cis	rs4690686	0.769	rs7660827	chr4:177274542	T/C	cg17059388	chr4:177262070	NA	0.36	6.69	0.34	9.24e-11	Essential tremor;
LIHC	cis	rs7165170	0.549	rs6496689	chr15:91096915	C/T	cg26821196	chr15:91095069	CRTC3	-0.35	-6.2	-0.32	1.58e-9	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1035144	0.546	rs2215981	chr14:81444967	G/A	cg06600135	chr14:81408086	NA	-0.44	-7.61	-0.38	2.64e-13	Male sexual orientation;
LIHC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.35	7.33	0.37	1.7e-12	Cancer;
LIHC	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg10820045	chr2:198174542	NA	-0.47	-7.19	-0.36	4.07e-12	Dermatomyositis;
LIHC	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg10127483	chr1:110009974	SYPL2	0.47	5.98	0.31	5.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.63	9.24	0.45	2.71e-18	Menarche (age at onset);
LIHC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg14593290	chr7:50529359	DDC	-0.48	-7.97	-0.4	2.37e-14	Malaria;
LIHC	trans	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.88	0.35	2.84e-11	Endometrial cancer;
LIHC	cis	rs1144333	0.655	rs1146602	chr1:76239309	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-7.73	-0.39	1.19e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg04756594	chr16:24857601	SLC5A11	0.37	5.92	0.3	7.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.41	6.32	0.32	8.18e-10	Resting heart rate;
LIHC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.61	10.5	0.49	1.53e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.29	0.52	2.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.32	-0.32	8.15e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.82	6.88	0.35	2.87e-11	Body mass index;
LIHC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.58	9.99	0.48	8.77e-21	Blood metabolite levels;
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	0.81	12.07	0.55	3.47e-28	Menarche (age at onset);
LIHC	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.49	-6.19	-0.32	1.68e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs11779988	0.528	rs208029	chr8:17840987	A/C	cg01800426	chr8:17659068	MTUS1	-0.41	-5.89	-0.3	9.37e-9	Breast cancer;
LIHC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.79	11.42	0.53	8.51e-26	Coronary artery disease;
LIHC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.49	0.49	1.63e-22	Colorectal cancer;
LIHC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02034447	chr16:89574710	SPG7	0.48	7.31	0.37	1.93e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg09003973	chr2:102972529	NA	0.82	8.41	0.41	1.1e-15	Blood protein levels;
LIHC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.81	-0.5	1.22e-23	Response to antipsychotic treatment;
LIHC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg13264159	chr8:625131	ERICH1	-0.62	-6.28	-0.32	1.06e-9	IgG glycosylation;
LIHC	cis	rs1144333	0.655	rs968018	chr1:76395662	G/A	cg10523679	chr1:76189770	ACADM	0.47	6.36	0.33	6.47e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.61	9.65	0.46	1.2e-19	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.54	-6.35	-0.32	6.69e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.3	-0.32	9.03e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg18964960	chr10:1102726	WDR37	0.7	6.6	0.34	1.55e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2334880	0.678	rs6499520	chr16:71458100	C/T	cg06353428	chr16:71660113	MARVELD3	-0.81	-8.01	-0.4	1.87e-14	Malaria;
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.75	0.39	1.07e-13	Prudent dietary pattern;
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.48	6.36	0.33	6.61e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.72	0.3	2.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	13.38	0.59	3.93e-33	Primary sclerosing cholangitis;
LIHC	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg01864069	chr14:103024347	NA	0.35	5.8	0.3	1.48e-8	Platelet count;
LIHC	cis	rs16828019	0.852	rs12729448	chr1:41509834	G/A	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.68	13.1	0.58	4.79e-32	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06115741	chr20:33292138	TP53INP2	0.42	5.95	0.31	6.77e-9	Coronary artery disease;
LIHC	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.74	-0.47	6.22e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg02269571	chr22:50332266	NA	-0.69	-9.28	-0.45	2.03e-18	Schizophrenia;
LIHC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.81	7.75	0.39	1.06e-13	Plasma clusterin levels;
LIHC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	trans	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg24036039	chr1:3397125	ARHGEF16	0.39	6.43	0.33	4.3e-10	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.86	-0.3	1.1e-8	Colorectal cancer;
LIHC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg21100191	chr22:23484243	RTDR1	0.73	8.22	0.41	4.24e-15	Bone mineral density;
LIHC	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.77	7.68	0.38	1.73e-13	Diabetic retinopathy;
LIHC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	8.44	0.42	9.2e-16	Platelet count;
LIHC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.38	-6.4	-0.33	5.04e-10	Educational attainment;
LIHC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.77	-11.42	-0.53	8.61e-26	Response to antineoplastic agents;
LIHC	cis	rs959260	1.000	rs7211915	chr17:73379872	A/G	cg20590849	chr17:73267439	MIF4GD	-0.53	-5.76	-0.3	1.85e-8	Systemic lupus erythematosus;
LIHC	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg20140201	chr2:241835670	C2orf54	-0.53	-8.22	-0.41	4.32e-15	Urinary metabolites;
LIHC	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.37	-6.12	-0.31	2.58e-9	Obesity-related traits;
LIHC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	8.58	0.42	3.44e-16	Blood metabolite levels;
LIHC	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg15816464	chr17:2026533	SMG6	0.49	9.47	0.46	4.81e-19	Total body bone mineral density;
LIHC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.17	0.4	6e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.61	9.62	0.46	1.5700000000000001e-19	White matter hyperintensity burden;
LIHC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.46	8.09	0.4	1.04e-14	IgG glycosylation;
LIHC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-5.93	-0.31	7.31e-9	Mood instability;
LIHC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.16	0.4	6.31e-15	Lymphocyte counts;
LIHC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.07	-0.31	3.4e-9	Tonsillectomy;
LIHC	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Colorectal cancer;
LIHC	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.41	7.2	0.36	3.76e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.46	6.61	0.34	1.48e-10	Pulse pressure;
LIHC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg05361325	chr10:32636312	EPC1	-0.52	-6.41	-0.33	4.77e-10	Sexual dysfunction (female);
LIHC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.84	9.81	0.47	3.38e-20	Red cell distribution width;
LIHC	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	0.72	6.21	0.32	1.58e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg10450322	chr1:51434373	CDKN2C	0.41	6.07	0.31	3.48e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.85	-13.45	-0.59	2.21e-33	Schizophrenia;
LIHC	cis	rs2737618	0.651	rs2816975	chr1:200081159	A/G	cg21825944	chr1:200113062	NR5A2	-0.45	-8.13	-0.4	8.1e-15	Uric acid levels;
LIHC	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	8.76	0.43	9.08e-17	Height;
LIHC	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.63	9.8	0.47	3.69e-20	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg03342759	chr3:160939853	NMD3	0.56	7.38	0.37	1.25e-12	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg03037974	chr15:76606532	NA	-0.6	-9.87	-0.47	2.28e-20	Blood metabolite levels;
LIHC	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	1.0	12.48	0.56	1.05e-29	Heart rate;
LIHC	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg21231739	chr4:1642635	FAM53A	-0.38	-6.0	-0.31	4.9e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg16736954	chr20:23401023	NAPB	0.53	5.91	0.3	8.15e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	16.26	0.66	1.84e-44	Tonsillectomy;
LIHC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.38	-8.66	-0.42	1.87e-16	Type 2 diabetes;
LIHC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-9.37	-0.45	1.02e-18	Crohn's disease;
LIHC	trans	rs1034394	0.775	rs5999350	chr22:34818544	A/G	cg02641517	chr3:54169983	CACNA2D3	-0.24	-6.1	-0.31	2.93e-9	Major depressive disorder;
LIHC	trans	rs654384	0.866	rs13224870	chr7:4172006	C/T	cg26675336	chr15:86133334	AKAP13	0.29	6.24	0.32	1.29e-9	Positive affect;
LIHC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-8.89	-0.43	3.57e-17	Parkinson's disease;
LIHC	cis	rs700651	0.789	rs1147169	chr2:198901395	C/T	cg10820045	chr2:198174542	NA	-0.44	-6.36	-0.33	6.48e-10	Intracranial aneurysm;
LIHC	cis	rs2273156	1.000	rs12050390	chr14:35461079	A/C	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.02	0.48	6.67e-21	Crohn's disease;
LIHC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg24209194	chr3:40518798	ZNF619	0.56	7.97	0.4	2.33e-14	Renal cell carcinoma;
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg26570765	chr4:1273065	NA	0.3	5.75	0.3	2.01e-8	Obesity-related traits;
LIHC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.64	-8.35	-0.41	1.71e-15	Initial pursuit acceleration;
LIHC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.56	0.59	7.95e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.41	-9.14	-0.44	5.49e-18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.49	-0.38	6.04e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.71	12.59	0.56	3.89e-30	Monocyte count;
LIHC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.06	9.35	0.45	1.21e-18	Diabetic retinopathy;
LIHC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg00204512	chr16:28754710	NA	0.41	7.22	0.36	3.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.26e-9	Menopause (age at onset);
LIHC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.52	-7.34	-0.37	1.54e-12	Body mass index;
LIHC	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.59	8.91	0.43	3.01e-17	Leprosy;
LIHC	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg23250157	chr14:64679961	SYNE2	0.4	5.92	0.3	8.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.44	7.14	0.36	5.75e-12	Dementia with Lewy bodies;
LIHC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.46	8.23	0.41	3.99e-15	IgG glycosylation;
LIHC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-6.15	-0.32	2.16e-9	Schizophrenia;
LIHC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.29	-0.45	1.85e-18	Ulcerative colitis;
LIHC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.01e-25	Corneal astigmatism;
LIHC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.69	-0.38	1.59e-13	Lymphocyte counts;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01078248	chr7:123197661	NDUFA5	0.45	7.04	0.36	1.08e-11	Cognitive function;
LIHC	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.65	-8.4	-0.41	1.21e-15	Initial pursuit acceleration;
LIHC	cis	rs1387259	0.759	rs7960122	chr12:48777000	C/T	cg21466736	chr12:48725269	NA	0.6	8.79	0.43	7.59e-17	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.4	6.29	0.32	9.51e-10	Alzheimer's disease (survival time);
LIHC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.08	0.31	3.24e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.38	-5.94	-0.31	7.18e-9	Mortality in heart failure;
LIHC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs600806	0.821	rs417270	chr1:109849144	T/C	cg16275483	chr1:110013120	SYPL2	-0.51	-6.22	-0.32	1.47e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.87	16.52	0.67	1.74e-45	Blood protein levels;
LIHC	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg02023728	chr11:77925099	USP35	-0.35	-6.29	-0.32	9.8e-10	Alzheimer's disease (survival time);
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13409248	chr3:40428643	ENTPD3	0.49	8.24	0.41	3.61e-15	Renal cell carcinoma;
LIHC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg01028140	chr2:1542097	TPO	-0.49	-5.95	-0.31	6.8e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.97	-0.31	5.84e-9	IgG glycosylation;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.55	-7.89	-0.39	4.02e-14	Lymphocyte counts;
LIHC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.16	-8.65	-0.42	2.07e-16	Body mass index;
LIHC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.94	-0.35	2e-11	IgG glycosylation;
LIHC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg02640540	chr1:67518911	SLC35D1	0.41	6.39	0.33	5.56e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13409248	chr3:40428643	ENTPD3	0.48	8.18	0.4	5.67e-15	Renal cell carcinoma;
LIHC	cis	rs2108622	0.683	rs56228205	chr19:15981973	A/C	cg13772218	chr19:15982569	NA	0.37	7.83	0.39	6.17e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg14515779	chr1:101123966	NA	-0.66	-12.4	-0.56	2.04e-29	Monocyte count;
LIHC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	6.4	0.33	5.22e-10	Renal cell carcinoma;
LIHC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.96	-0.31	6.39e-9	Mean corpuscular volume;
LIHC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.66	-6.93	-0.35	2.1e-11	Neuroticism;
LIHC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.41	-0.45	7.59e-19	Schizophrenia;
LIHC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05300132	chr14:69676275	EXD2	0.39	6.21	0.32	1.54e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.51	7.25	0.37	2.72e-12	Asthma;
LIHC	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.14	-0.4	7.63e-15	Capecitabine sensitivity;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.91	-0.3	8.17e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.71	-11.51	-0.53	3.92e-26	Fibrinogen levels;
LIHC	cis	rs7503168	1.000	rs16971217	chr17:33944055	C/G	cg20932281	chr17:33905541	PEX12	0.55	7.15	0.36	5.39e-12	Plateletcrit;
LIHC	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.28	6.62	0.34	1.4e-10	Educational attainment (years of education);
LIHC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.84	12.98	0.57	1.29e-31	Total body bone mineral density;
LIHC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	1.07	12.08	0.55	3.31e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.42	6.55	0.33	2.16e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.68	10.46	0.49	2.17e-22	Height;
LIHC	cis	rs11888559	0.655	rs4673243	chr2:204019844	G/A	cg24605529	chr2:203879461	NBEAL1	0.77	5.82	0.3	1.34e-8	Height;
LIHC	cis	rs74405815	0.510	rs6780441	chr3:126447838	A/G	cg16285380	chr3:126373980	NA	-0.66	-7.89	-0.39	4e-14	Response to paliperidone in schizophrenia (positive Marder score);
LIHC	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg01864069	chr14:103024347	NA	0.35	5.95	0.31	6.68e-9	Platelet count;
LIHC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4759375	1.000	rs12317452	chr12:123788246	C/T	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg24826892	chr11:71159390	DHCR7	0.47	6.16	0.32	2.06e-9	Vitamin D levels;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.54	5.86	0.3	1.06e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.79	0.3	1.56e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg19773385	chr1:10388646	KIF1B	-0.33	-5.98	-0.31	5.57e-9	Hepatocellular carcinoma;
LIHC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.45	-6.44	-0.33	4.04e-10	Cognitive ability;
LIHC	cis	rs11800820	0.555	rs6661155	chr1:246628943	C/G	cg16700716	chr1:246684329	NA	-0.41	-7.16	-0.36	4.97e-12	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.81	13.01	0.58	9.99e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.75	-11.63	-0.53	1.38e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.06	-0.44	9.91e-18	Heart rate;
LIHC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.5e-9	Aortic root size;
LIHC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.33	-6.57	-0.33	1.9e-10	Body mass index;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	8.87e-33	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.58	8.63	0.42	2.34e-16	Prudent dietary pattern;
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg14671364	chr1:107599128	PRMT6	0.47	6.86	0.35	3.17e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg14289826	chr9:140003911	NA	-0.35	-5.85	-0.3	1.13e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-8.97	-0.44	2.04e-17	Heart rate;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20929545	chr11:118958046	HMBS	0.43	6.74	0.34	6.58e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.49	7.1	0.36	7.28e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.56	-9.62	-0.46	1.5700000000000001e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.75	-0.34	6.35e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17106184	0.892	rs72900982	chr1:51190459	C/T	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg08847533	chr14:75593920	NEK9	-0.56	-9.02	-0.44	1.37e-17	IgG glycosylation;
LIHC	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg12661370	chr5:149340060	SLC26A2	-0.56	-7.55	-0.38	3.97e-13	HIV-1 control;
LIHC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg20607798	chr8:58055168	NA	0.69	7.41	0.37	1.01e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.6	-8.96	-0.44	2.16e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	trans	rs10847980	0.623	rs28501453	chr12:123877312	A/G	cg07919128	chr17:18022025	MYO15A	-0.75	-7.5	-0.38	5.62e-13	Adiponectin levels;
LIHC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg03060546	chr3:49711283	APEH	0.4	6.15	0.32	2.21e-9	Menarche (age at onset);
LIHC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.36	-5.8	-0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.76	11.09	0.51	1.31e-24	Dental caries;
LIHC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.52	-0.38	4.99e-13	Body mass index;
LIHC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.1e-10	Bipolar disorder;
LIHC	cis	rs16958440	0.867	rs77348110	chr18:44674167	T/C	cg17192377	chr18:44677553	HDHD2	0.61	6.67	0.34	1.03e-10	Sitting height ratio;
LIHC	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.34	-13.99	-0.6	1.79e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.63	9.95	0.47	1.23e-20	Corneal structure;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05214676	chr4:141005085	MAML3	0.45	6.69	0.34	9.17e-11	Longevity;
LIHC	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21821726	chr22:50170866	BRD1	-0.38	-6.21	-0.32	1.52e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs58785573	0.504	rs11947292	chr4:38634749	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.54	0.38	4.25e-13	Lymphocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.23	-0.36	3.19e-12	Renal cell carcinoma;
LIHC	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.62	-8.6	-0.42	2.95e-16	Vitamin D levels;
LIHC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg07636037	chr3:49044803	WDR6	-0.81	-8.44	-0.42	9.01e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.33	-18.17	-0.7	3.94e-52	Diabetic kidney disease;
LIHC	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07169764	chr2:136633963	MCM6	-0.68	-9.78	-0.47	4.41e-20	Mosquito bite size;
LIHC	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.53	7.73	0.39	1.18e-13	Schizophrenia;
LIHC	cis	rs3770081	1.000	rs78646493	chr2:86283195	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.58	9.34	0.45	1.32e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	11.46	0.53	5.76e-26	Platelet count;
LIHC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg10096929	chr1:156261403	TMEM79	0.36	5.84	0.3	1.2e-8	Tonsillectomy;
LIHC	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.62	-0.34	1.43e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.57	-0.46	2.16e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs509477	0.718	rs273356	chr18:32597462	A/T	cg23791764	chr18:32556832	MAPRE2	0.45	6.1	0.31	2.81e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.57	-7.47	-0.37	6.87e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg03146154	chr1:46216737	IPP	-0.41	-6.3	-0.32	9.12e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg26939375	chr7:64535504	NA	0.4	6.43	0.33	4.37e-10	Aortic root size;
LIHC	cis	rs17106184	1.000	rs1474784	chr1:50944634	C/G	cg07174182	chr1:51127561	FAF1	-0.53	-6.11	-0.31	2.76e-9	Type 2 diabetes;
LIHC	trans	rs116095464	0.558	rs6962	chr5:256509	G/A	cg00938859	chr5:1591904	SDHAP3	0.58	6.57	0.33	1.83e-10	Breast cancer;
LIHC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.48	7.93	0.39	3.21e-14	Breast cancer;
LIHC	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.33	7.64	0.38	2.15e-13	Blood metabolite ratios;
LIHC	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	0.97	14.09	0.61	7.13e-36	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg03945807	chr20:60948434	NA	-0.39	-7.11	-0.36	6.78e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.83	0.35	3.86e-11	Melanoma;
LIHC	cis	rs16828019	0.929	rs12037037	chr1:41698256	C/T	cg03387723	chr1:41708464	SCMH1	-0.44	-7.23	-0.36	3.16e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4575098	0.652	rs11576058	chr1:161111446	C/A	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.43	7.78	0.39	8.83e-14	Monocyte percentage of white cells;
LIHC	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.52	8.72	0.43	1.24e-16	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.56	0.33	1.95e-10	Renal cell carcinoma;
LIHC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.16e-16	Motion sickness;
LIHC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.45	8.14	0.4	7.68e-15	Tuberculosis;
LIHC	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg03934865	chr2:198174659	NA	0.45	6.54	0.33	2.23e-10	Dermatomyositis;
LIHC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.68	10.03	0.48	6.56e-21	Testicular germ cell tumor;
LIHC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.02	-0.48	6.69e-21	Total cholesterol levels;
LIHC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	19.16	0.72	4.36e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg04865290	chr3:52927548	TMEM110	-0.54	-6.04	-0.31	3.95e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18357526	chr6:26021779	HIST1H4A	0.48	6.98	0.35	1.5e-11	Iron status biomarkers;
LIHC	cis	rs15676	0.947	rs2977999	chr9:131579807	G/A	cg00228799	chr9:131580591	ENDOG	0.47	7.15	0.36	5.24e-12	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01506766	chr13:46626746	ZC3H13	0.57	7.44	0.37	8.02e-13	Lung function (FEV1/FVC);
LIHC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.56	-8.96	-0.44	2.15e-17	Menarche (age at onset);
LIHC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-9.76	-0.47	5.02e-20	Asthma;
LIHC	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.73	-11.25	-0.52	3.46e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg05697976	chr12:29376483	FAR2	0.31	6.27	0.32	1.1e-9	QT interval;
LIHC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.78	-0.67	1.55e-46	Ulcerative colitis;
LIHC	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg03477792	chr4:77819574	ANKRD56	0.6	8.79	0.43	7.59e-17	Emphysema distribution in smoking;
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.59	-8.58	-0.42	3.42e-16	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-8.13	-0.4	8.08e-15	Crohn's disease;
LIHC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg24130564	chr14:104152367	KLC1	-0.34	-5.74	-0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg12798992	chr6:167411361	FGFR1OP	0.47	6.93	0.35	2.07e-11	Rheumatoid arthritis;
LIHC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.77	-0.3	1.76e-8	Subjective well-being;
LIHC	cis	rs7224737	0.750	rs12325861	chr17:40289412	T/C	cg20291162	chr17:40259547	DHX58	-0.42	-5.9	-0.3	8.8e-9	Fibrinogen levels;
LIHC	cis	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg14515779	chr1:101123966	NA	-0.7	-14.11	-0.61	6e-36	Monocyte count;
LIHC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.49	5.85	0.3	1.18e-8	Schizophrenia;
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg15382696	chr6:118971807	C6orf204	0.63	6.37	0.33	6.05e-10	Diastolic blood pressure;
LIHC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.18e-31	Sense of smell;
LIHC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.43	-8.04	-0.4	1.43e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg08345082	chr10:99160200	RRP12	-0.39	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.66	10.63	0.5	5.27e-23	Diisocyanate-induced asthma;
LIHC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg12297030	chr17:43662878	NA	-0.65	-6.24	-0.32	1.27e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.68	-0.46	9.29e-20	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-8.96	-0.44	2.18e-17	Total body bone mineral density;
LIHC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.51	1.09e-24	Crohn's disease;
LIHC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.46	7.01	0.35	1.31e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.76	10.97	0.51	3.3e-24	Coronary artery disease;
LIHC	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.56	-9.11	-0.44	6.87e-18	Colorectal cancer;
LIHC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.71	0.34	8.06e-11	Bipolar disorder;
LIHC	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg00128877	chr1:47070178	MKNK1	-0.49	-6.42	-0.33	4.43e-10	Facial morphology (factor 20);
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg03354898	chr7:1950403	MAD1L1	-0.36	-5.71	-0.3	2.4e-8	Bipolar disorder and schizophrenia;
LIHC	trans	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg17675199	chr6:35436792	RPL10A	-0.45	-9.33	-0.45	1.39e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05972000	chr8:67525501	MYBL1	-0.46	-6.34	-0.32	7.47e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08677398	chr8:58056175	NA	-0.39	-6.1	-0.31	2.83e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-16.8	-0.67	1.27e-46	Systemic lupus erythematosus;
LIHC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.41	-6.31	-0.32	8.58e-10	Iron status biomarkers;
LIHC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.43	-7.45	-0.37	7.54e-13	Aortic root size;
LIHC	cis	rs7546668	1.000	rs4233534	chr1:15842329	C/T	cg11706911	chr1:15910989	AGMAT	0.45	6.96	0.35	1.7e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg16836995	chr17:43662488	NA	-0.76	-7.78	-0.39	8.76e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg20026190	chr17:76395443	PGS1	0.39	5.82	0.3	1.37e-8	HDL cholesterol levels;
LIHC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.44	-7.19	-0.36	4.22e-12	Menarche (age at onset);
LIHC	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg09597638	chr17:3907349	NA	-0.5	-6.04	-0.31	3.92e-9	Type 2 diabetes;
LIHC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.81	0.57	6.12e-31	Airflow obstruction;
LIHC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.63	8.1	0.4	9.82e-15	Blood metabolite levels;
LIHC	cis	rs1198430	1.000	rs1198432	chr1:23756155	C/T	cg13183780	chr1:23809682	ASAP3	0.54	7.73	0.39	1.23e-13	Total cholesterol levels;
LIHC	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg07424592	chr7:64974309	NA	0.78	8.95	0.44	2.26e-17	Diabetic kidney disease;
LIHC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.23	0.36	3.09e-12	Electroencephalogram traits;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg07725925	chr16:89976287	TCF25	0.41	5.77	0.3	1.74e-8	Skin colour saturation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01078248	chr7:123197661	NDUFA5	0.46	6.34	0.32	7.37e-10	Pancreatic cancer;
LIHC	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.37	-0.33	5.97e-10	Metabolite levels;
LIHC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.25	6.02	0.31	4.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.52	-7.26	-0.37	2.55e-12	Menopause (age at onset);
LIHC	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.36	5.99	0.31	5.27e-9	Mean corpuscular volume;
LIHC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.64	-7.34	-0.37	1.57e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.77	0.47	4.63e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.46	7.33	0.37	1.72e-12	Mortality in heart failure;
LIHC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.8	0.65	1.34e-42	Chronic sinus infection;
LIHC	cis	rs74181299	0.750	rs12472718	chr2:65327620	G/A	cg05010058	chr2:65284262	CEP68	-0.39	-6.6	-0.34	1.6e-10	Pulse pressure;
LIHC	cis	rs8067354	0.540	rs1051424	chr17:58024324	A/G	cg02344993	chr17:57696989	CLTC	0.66	10.24	0.48	1.26e-21	Hemoglobin concentration;
LIHC	cis	rs7000551	0.778	rs2469760	chr8:22365945	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	7.01	0.35	1.3e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg03146154	chr1:46216737	IPP	-0.41	-6.52	-0.33	2.48e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	13.48	0.59	1.61e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg13152130	chr6:118910203	C6orf204	0.59	7.32	0.37	1.84e-12	Diastolic blood pressure;
LIHC	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	8.01	0.4	1.78e-14	Triglyceride levels;
LIHC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.43	-6.01	-0.31	4.83e-9	Schizophrenia;
LIHC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-5.8	-0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-9.53	-0.46	3.01e-19	Hemoglobin concentration;
LIHC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg06096015	chr1:231504339	EGLN1	0.49	9.14	0.44	5.73e-18	Hemoglobin concentration;
LIHC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13647721	chr17:30228624	UTP6	0.7	6.93	0.35	2.14e-11	Hip circumference adjusted for BMI;
LIHC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg01098656	chr10:1095069	IDI1	0.44	6.17	0.32	1.9e-9	Positive affect;
LIHC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.94	-0.35	2e-11	IgG glycosylation;
LIHC	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.5	5.73	0.3	2.2e-8	Weight;
LIHC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.35	7.72	0.39	1.28e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-11.79	-0.54	3.61e-27	Vitiligo;
LIHC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg20607798	chr8:58055168	NA	0.45	6.25	0.32	1.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	13.04	0.58	7.89e-32	Colorectal cancer;
LIHC	cis	rs12602486	1.000	rs74635090	chr17:42219267	G/A	cg08193365	chr17:42277699	NA	1.08	7.74	0.39	1.12e-13	Glycated hemoglobin levels;
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg14222432	chr12:29376421	FAR2	-0.36	-6.95	-0.35	1.89e-11	QT interval;
LIHC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.64	-0.38	2.18e-13	Body mass index;
LIHC	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	0.54	10.19	0.48	1.76e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg00204748	chr12:29376779	FAR2	0.38	7.02	0.35	1.2e-11	QT interval;
LIHC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.27	-6.65	-0.34	1.17e-10	Mean corpuscular volume;
LIHC	cis	rs4700695	0.925	rs414001	chr5:65383259	C/G	cg21114390	chr5:65439923	SFRS12	-0.46	-6.02	-0.31	4.39e-9	Facial morphology (factor 19);
LIHC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg03645007	chr3:50255295	SLC38A3	0.52	6.36	0.33	6.5e-10	Schizophrenia;
LIHC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg17980119	chr2:219472607	PLCD4	0.34	5.88	0.3	9.92e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg20019720	chr6:154832845	CNKSR3	0.44	6.49	0.33	2.97e-10	Lipoprotein (a) levels;
LIHC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-6.2	-0.32	1.64e-9	Total body bone mineral density;
LIHC	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.6	8.82	0.43	6.08e-17	Recombination rate (females);
LIHC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.71	13.02	0.58	9.36e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg04610667	chr7:75704037	NA	-0.35	-6.3	-0.32	8.94e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10411936	0.626	rs8109817	chr19:16587889	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	6.81	0.35	4.36e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.71	0.38	1.43e-13	Bipolar disorder;
LIHC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.34	-6.2	-0.32	1.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	9.7e-13	Putamen volume;
LIHC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	12.92	0.57	2.24e-31	Cognitive test performance;
LIHC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.75	-8.79	-0.43	7.64e-17	Mean platelet volume;
LIHC	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.04	-19.32	-0.72	9.92e-57	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.95	0.31	6.49e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg05110241	chr16:68378359	PRMT7	0.6	6.5	0.33	2.8e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs783540	0.867	rs10906984	chr15:83366296	A/C	cg18393722	chr15:85113863	UBE2QP1	0.39	6.84	0.35	3.65e-11	Schizophrenia;
LIHC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	0.77	7.09	0.36	7.55e-12	Plateletcrit;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11995801	chr2:232826275	DIS3L2	-0.5	-6.47	-0.33	3.45e-10	Systolic blood pressure;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02290350	chr8:58132656	NA	0.46	9.17	0.44	4.46e-18	Developmental language disorder (linguistic errors);
LIHC	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-9.72	-0.47	6.79e-20	Red cell distribution width;
LIHC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg22777020	chr22:31556080	RNF185	0.55	6.38	0.33	5.81e-10	Colorectal cancer;
LIHC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.91	16.41	0.66	4.78e-45	Colorectal cancer;
LIHC	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg01320579	chr17:75405842	SEPT9	0.51	8.91	0.43	2.98e-17	Airflow obstruction;
LIHC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.74	14.71	0.62	2.82e-38	Menopause (age at onset);
LIHC	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-7.89	-0.39	4.24e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs2569991	0.588	rs2596909	chr3:12928672	G/C	cg22481960	chr3:13008800	IQSEC1	-0.42	-7.29	-0.37	2.23e-12	Periodontitis (DPAL);
LIHC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.65	-9.85	-0.47	2.68e-20	Subjective well-being;
LIHC	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.37	-7.2	-0.36	3.86e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17554472	chr22:41940697	POLR3H	-0.55	-5.95	-0.31	6.47e-9	Vitiligo;
LIHC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg17764715	chr19:33622953	WDR88	0.54	7.19	0.36	4.22e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg13957321	chr17:43675089	NA	0.45	7.24	0.36	3.07e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-14.69	-0.62	3.22e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.42	7.34	0.37	1.53e-12	Mean corpuscular volume;
LIHC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg21573476	chr21:45109991	RRP1B	-0.53	-10.03	-0.48	6.12e-21	Mean corpuscular volume;
LIHC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg17980119	chr2:219472607	PLCD4	0.35	6.02	0.31	4.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.35	0.41	1.74e-15	Educational attainment;
LIHC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.36	0.52	1.32e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.7	-10.52	-0.49	1.32e-22	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs61332075	0.518	rs72994950	chr2:239422993	T/C	cg01134436	chr17:81009848	B3GNTL1	0.76	6.53	0.33	2.44e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.95	0.47	1.22e-20	Alzheimer's disease;
LIHC	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg09835421	chr16:68378352	PRMT7	0.47	5.78	0.3	1.72e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.56	-7.64	-0.38	2.18e-13	Coronary artery disease;
LIHC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.52	-7.84	-0.39	5.66e-14	Tonsillectomy;
LIHC	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.39	-6.64	-0.34	1.21e-10	Coronary artery disease;
LIHC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg24004478	chr7:855632	UNC84A	0.49	8.05	0.4	1.41e-14	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.69	-10.63	-0.5	5.56e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs61990749	0.511	rs2052444	chr14:78312918	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.49	7.9	0.39	3.89e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.69	-0.38	1.54e-13	Response to antipsychotic treatment;
LIHC	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg10820045	chr2:198174542	NA	0.42	6.15	0.32	2.18e-9	Dermatomyositis;
LIHC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-15.52	-0.64	1.65e-41	Tonsillectomy;
LIHC	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.75	15.96	0.65	3.13e-43	Urate levels in lean individuals;
LIHC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.02	-0.4	1.66e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.62	-8.88	-0.43	3.86e-17	Blood metabolite levels;
LIHC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg18270830	chr10:32634957	EPC1	-0.54	-6.67	-0.34	1.05e-10	Sexual dysfunction (female);
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06420487	chr17:61919686	SMARCD2	0.42	5.76	0.3	1.88e-8	Height;
LIHC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg16479474	chr6:28041457	NA	0.45	6.49	0.33	3.07e-10	Parkinson's disease;
LIHC	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.93	0.39	3.07e-14	Tonsillectomy;
LIHC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.12	-8.4	-0.41	1.17e-15	Body mass index;
LIHC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg17135325	chr3:160939158	NMD3	0.52	7.29	0.37	2.17e-12	Parkinson's disease;
LIHC	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.43	7.3	0.37	2.06e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.36e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.17	13.02	0.58	9.42e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs943466	0.793	rs59137082	chr6:33732365	C/T	cg25922239	chr6:33757077	LEMD2	-0.46	-5.73	-0.3	2.24e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg00204512	chr16:28754710	NA	0.34	6.3	0.32	9.35e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	1.06	14.92	0.63	3.95e-39	Heart rate;
LIHC	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.19	0.32	1.7e-9	Mean corpuscular volume;
LIHC	trans	rs7867456	0.546	rs10757178	chr9:21046674	A/G	cg08478193	chr16:27561459	GTF3C1;KIAA0556	0.47	6.67	0.34	1.02e-10	Axial length;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.43	-7.02	-0.35	1.23e-11	Testicular germ cell tumor;
LIHC	cis	rs2637030	0.559	rs549131	chr5:52902238	T/C	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.26e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs72653721	0.877	rs72653723	chr6:10976218	G/A	cg13562911	chr6:11044106	ELOVL2	0.51	7.1	0.36	7.37e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg12798992	chr6:167411361	FGFR1OP	0.48	7.37	0.37	1.32e-12	Crohn's disease;
LIHC	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.88	0.35	2.92e-11	Nonalcoholic fatty liver disease;
LIHC	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.64	10.23	0.48	1.36e-21	Obesity-related traits;
LIHC	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.62	11.7	0.53	7.92e-27	Schizophrenia;
LIHC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.71	11.33	0.52	1.7e-25	Oral cavity cancer;
LIHC	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg14593290	chr7:50529359	DDC	-0.39	-6.51	-0.33	2.72e-10	Malaria;
LIHC	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.03	0.31	4.17e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-9.52	-0.46	3.2e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	6.18	0.32	1.85e-9	Lymphocyte counts;
LIHC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.91	0.65	4.59e-43	White blood cell count;
LIHC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.84	13.51	0.59	1.24e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.17	13.02	0.58	9.42e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1144333	0.510	rs12408897	chr1:76448102	T/C	cg10523679	chr1:76189770	ACADM	0.44	5.91	0.3	8.5e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.54	8.65	0.42	1.99e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.5	-0.62	1.81e-37	Electrocardiographic conduction measures;
LIHC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.6	7.19	0.36	4e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.7	-9.78	-0.47	4.5e-20	Mosquito bite size;
LIHC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg07451762	chr16:28383216	NA	0.41	7.05	0.36	9.65e-12	Body mass index;
LIHC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg18944383	chr4:111397179	ENPEP	0.27	6.96	0.35	1.78e-11	Height;
LIHC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.96	11.79	0.54	3.72e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.83	10.01	0.48	7.48e-21	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01185801	chr11:65265397	MALAT1	0.44	6.36	0.33	6.56e-10	Pancreatic cancer;
LIHC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-7.6	-0.38	2.92e-13	Initial pursuit acceleration;
LIHC	cis	rs11958404	0.860	rs72818136	chr5:157462866	C/T	cg05962755	chr5:157440814	NA	1.01	11.11	0.52	1.05e-24	IgG glycosylation;
LIHC	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.28	6.01	0.31	4.71e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20870372	chr13:99867982	UBAC2	0.37	6.32	0.32	8.25e-10	Bilirubin levels;
LIHC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg12463550	chr7:65579703	CRCP	0.68	7.05	0.36	9.9e-12	Diabetic kidney disease;
LIHC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.69	-9.52	-0.46	3.16e-19	Longevity;
LIHC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12463550	chr7:65579703	CRCP	0.67	7.03	0.36	1.15e-11	Diabetic kidney disease;
LIHC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg02711726	chr17:80685570	FN3KRP	-0.38	-7.16	-0.36	5.02e-12	Glycated hemoglobin levels;
LIHC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.16	0.4	6.61e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.63	-16.46	-0.66	2.95e-45	Breast cancer;
LIHC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.41	0.33	4.82e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.6	10.47	0.49	1.92e-22	Dupuytren's disease;
LIHC	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.43	9.2	0.45	3.55e-18	Migraine;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg22528358	chr1:107598549	PRMT6	-0.71	-11.82	-0.54	2.78e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11212260	0.655	rs7122872	chr11:107340702	C/G	cg25435332	chr11:107328525	CWF19L2	0.84	8.24	0.41	3.8e-15	IgG glycosylation;
LIHC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.47	-7.54	-0.38	4.33e-13	Platelet distribution width;
LIHC	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.62	10.06	0.48	4.84e-21	Red blood cell count;
LIHC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.64	-0.34	1.24e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.3	0.41	2.52e-15	Lung cancer;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.27	-6.39	-0.33	5.58e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.75	-7.8	-0.39	7.39e-14	Vitiligo;
LIHC	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg23280166	chr11:118938394	VPS11	-0.51	-7.08	-0.36	7.98e-12	Coronary artery disease;
LIHC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.44	5.87	0.3	1.04e-8	Osteoporosis;
LIHC	cis	rs2637030	0.533	rs2607511	chr5:52930471	G/A	cg06476337	chr5:52856530	NDUFS4	0.43	6.82	0.35	4.25e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.9	-0.3	8.72e-9	Life satisfaction;
LIHC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.32	0.45	1.45e-18	Hemoglobin concentration;
LIHC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.16	-0.32	2.06e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs732505	1.000	rs8111720	chr19:5585823	A/G	cg26242866	chr19:5711310	LONP1	0.86	6.31	0.32	8.52e-10	vWF and FVIII levels;
LIHC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-6.73	-0.34	7.12e-11	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg05555928	chr11:63887634	MACROD1	-0.52	-6.48	-0.33	3.24e-10	Body mass index;
LIHC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.43	-0.76	3.5e-65	Height;
LIHC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.79	6.79	0.34	4.85e-11	Body mass index;
LIHC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.61	8.99	0.44	1.72e-17	Recombination rate (females);
LIHC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.86	0.57	3.97e-31	Schizophrenia;
LIHC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.77	13.28	0.58	9.45e-33	Platelet distribution width;
LIHC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04317338	chr11:64019027	PLCB3	0.48	6.72	0.34	7.41e-11	Platelet count;
LIHC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.7	-0.5	3.02e-23	Monocyte percentage of white cells;
LIHC	cis	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg19680485	chr15:31195859	MTMR15	-0.55	-6.07	-0.31	3.46e-9	Hypertriglyceridemia;
LIHC	cis	rs67981189	0.593	rs221926	chr14:71579135	A/C	cg15816911	chr14:71606274	NA	-0.41	-6.58	-0.34	1.76e-10	Schizophrenia;
LIHC	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg09537434	chr19:41945824	ATP5SL	1.02	21.05	0.75	1.07e-63	Height;
LIHC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.9	8.47	0.42	7.52e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26897989	chr16:1907736	C16orf73	-0.46	-5.77	-0.3	1.82e-8	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg09182678	chr22:50328711	NA	0.44	6.38	0.33	5.72e-10	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.3	-5.72	-0.3	2.35e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-6.94	-0.35	1.99e-11	Neuroticism;
LIHC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.34	6.04	0.31	4.06e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg13844804	chr7:814759	HEATR2	0.44	5.95	0.31	6.72e-9	Cerebrospinal P-tau181p levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24378253	chr1:1017383	C1orf159	0.43	6.51	0.33	2.69e-10	Bilirubin levels;
LIHC	cis	rs2334880	0.678	rs12922830	chr16:71447270	C/T	cg06353428	chr16:71660113	MARVELD3	-0.78	-7.87	-0.39	4.87e-14	Malaria;
LIHC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg11839771	chr15:80205821	ST20	-0.32	-6.92	-0.35	2.21e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg02886208	chr11:14281011	SPON1	0.57	8.36	0.41	1.61e-15	Mitochondrial DNA levels;
LIHC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-0.97	-22.79	-0.78	1.36e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.25	-0.36	2.8e-12	Renal cell carcinoma;
LIHC	cis	rs6442522	0.678	rs924813	chr3:15512799	A/T	cg16303742	chr3:15540471	COLQ	0.44	7.31	0.37	1.89e-12	Uric acid levels;
LIHC	cis	rs903552	0.935	rs12907726	chr15:102003626	C/G	cg00659931	chr15:102010125	PCSK6	-0.44	-6.04	-0.31	4.03e-9	Diabetic kidney disease;
LIHC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.33	-0.32	7.86e-10	Height;
LIHC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg03959625	chr15:84868606	LOC388152	0.44	6.12	0.31	2.54e-9	Schizophrenia;
LIHC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.75	11.24	0.52	3.59e-25	Monocyte percentage of white cells;
LIHC	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg12698662	chr3:15914712	MIR563	0.4	7.34	0.37	1.54e-12	Mean platelet volume;
LIHC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg17085576	chr10:5658249	NA	-0.35	-6.2	-0.32	1.66e-9	Breast cancer;
LIHC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg08528486	chr13:113648767	MCF2L	-0.38	-5.77	-0.3	1.79e-8	Systolic blood pressure;
LIHC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.4	8.67	0.42	1.81e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.67	-10.44	-0.49	2.46e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs116248771	0.690	rs116470672	chr3:158337762	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.28	0.32	1.04e-9	diarrhoeal disease at age 2;
LIHC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.0	-0.31	5.11e-9	Heart rate;
LIHC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg18944383	chr4:111397179	ENPEP	0.25	6.2	0.32	1.66e-9	Coronary artery disease;
LIHC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.52	-8.37	-0.41	1.54e-15	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg07424592	chr7:64974309	NA	0.79	8.55	0.42	4.11e-16	Diabetic kidney disease;
LIHC	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.09	0.48	3.87e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9503598	0.644	rs10498663	chr6:3430439	C/T	cg00476032	chr6:3446245	SLC22A23	-0.35	-6.56	-0.33	2.05e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg00750074	chr16:89608354	SPG7	-0.46	-7.5	-0.38	5.6e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	7.86	0.39	5.11e-14	HDL cholesterol;
LIHC	cis	rs9658691	0.607	rs12415680	chr10:90780737	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.93	-6.71	-0.34	8.01e-11	Mosquito bite size;
LIHC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg03959625	chr15:84868606	LOC388152	0.38	5.84	0.3	1.24e-8	Schizophrenia;
LIHC	cis	rs4907240	0.961	rs60959055	chr2:97313450	C/G	cg26665480	chr2:98280029	ACTR1B	-0.4	-5.95	-0.31	6.82e-9	Event-related brain oscillations;
LIHC	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.49	9.18	0.44	4.19e-18	Testicular germ cell tumor;
LIHC	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.66	8.31	0.41	2.35e-15	Corneal astigmatism;
LIHC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.33	5.95	0.31	6.68e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg14671364	chr1:107599128	PRMT6	0.49	7.29	0.37	2.19e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	0.85	10.88	0.51	7.23e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.7	-10.21	-0.48	1.59e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.75	13.27	0.58	1.08e-32	Eosinophil percentage of white cells;
LIHC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.78	0.43	8.07e-17	Platelet count;
LIHC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.9	8.79	0.43	7.65e-17	Inflammatory bowel disease;
LIHC	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.6	8.93	0.43	2.6e-17	Recombination rate (females);
LIHC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg02297831	chr4:17616191	MED28	0.45	7.1	0.36	7.21e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg19000871	chr14:103996768	TRMT61A	-0.38	-6.26	-0.32	1.15e-9	Reticulocyte count;
LIHC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.63	8.82	0.43	5.8e-17	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs4234798	1.000	rs4234798	chr4:7219933	G/T	cg12632249	chr4:7449638	SORCS2	0.29	5.73	0.3	2.17e-8	Insulin-like growth factors;
LIHC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg22777020	chr22:31556080	RNF185	-0.55	-6.35	-0.32	6.77e-10	Colorectal cancer;
LIHC	cis	rs2074193	0.951	rs215344	chr12:47733024	A/G	cg02516419	chr12:47771422	NA	-0.42	-5.82	-0.3	1.38e-8	Migraine with aura;
LIHC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.42	0.33	4.61e-10	Alzheimer's disease;
LIHC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.53	-7.59	-0.38	2.98e-13	Metabolic syndrome;
LIHC	cis	rs5769765	0.740	rs138838	chr22:50180951	C/G	cg02269571	chr22:50332266	NA	-0.75	-6.95	-0.35	1.85e-11	Schizophrenia;
LIHC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	0.75	7.97	0.4	2.43e-14	Testicular germ cell tumor;
LIHC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.5	7.78	0.39	8.81e-14	Total body bone mineral density;
LIHC	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.77	0.3	1.75e-8	Tonsillectomy;
LIHC	cis	rs9328573	1.000	rs9920711	chr15:100510478	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.5	-7.7	-0.38	1.48e-13	Urate levels in lean individuals;
LIHC	cis	rs7512552	0.525	rs2298161	chr1:150237624	A/G	cg15654264	chr1:150340011	RPRD2	0.49	8.15	0.4	6.82e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.5	8.83	0.43	5.57e-17	Total body bone mineral density;
LIHC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg16102536	chr7:156981717	UBE3C	0.35	5.87	0.3	1.02e-8	Body mass index;
LIHC	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.39	-7.76	-0.39	1.01e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.51	8.27	0.41	3.1e-15	Height;
LIHC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	9.18	0.44	4.25e-18	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.45	0.33	3.75e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.72	11.61	0.53	1.73e-26	Oral cavity cancer;
LIHC	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg12140854	chr5:148520817	ABLIM3	0.45	6.08	0.31	3.19e-9	Breast cancer;
LIHC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.49	5.78	0.3	1.72e-8	Serum sulfate level;
LIHC	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg14473756	chr11:122847823	NA	-0.37	-6.65	-0.34	1.18e-10	Menarche (age at onset);
LIHC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.2	-0.41	4.97e-15	Obesity-related traits;
LIHC	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.12	-0.36	6.31e-12	Migraine;Coronary artery disease;
LIHC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.6	-8.36	-0.41	1.56e-15	Coronary artery disease;
LIHC	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	0.97	14.86	0.63	6.81e-39	Corneal structure;
LIHC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg19318889	chr4:1322082	MAEA	0.44	5.95	0.31	6.61e-9	Obesity-related traits;
LIHC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-10.85	-0.51	9.06e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.45	7.6	0.38	2.81e-13	Mean corpuscular volume;
LIHC	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.5	-7.7	-0.38	1.47e-13	Superior crus of antihelix expression;
LIHC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	7.1	0.36	7.04e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg14784868	chr12:69753453	YEATS4	0.55	7.85	0.39	5.51e-14	Response to diuretic therapy;
LIHC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg19635926	chr16:89946313	TCF25	0.49	6.21	0.32	1.5e-9	Skin colour saturation;
LIHC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.69	-12.32	-0.55	3.98e-29	Iron status biomarkers;
LIHC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.86	0.35	3.28e-11	Ileal carcinoids;
LIHC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.27	-7.1	-0.36	7.23e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.86	7.71	0.38	1.36e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.24	0.36	3.03e-12	Aortic root size;
LIHC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.43	0.37	8.59e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.48	0.46	4.3e-19	Tonsillectomy;
LIHC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.03	-0.4	1.59e-14	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08347471	chr19:36297670	PRODH2	0.43	6.95	0.35	1.85e-11	Pancreatic cancer;
LIHC	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.58	8.05	0.4	1.39e-14	Neuroticism;
LIHC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg16226627	chr15:75307476	SCAMP5	0.54	9.6	0.46	1.7e-19	Lung cancer;
LIHC	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg22903471	chr2:27725779	GCKR	-0.43	-6.08	-0.31	3.22e-9	Blood metabolite levels;
LIHC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.26	6.36	0.33	6.45e-10	Primary biliary cholangitis;
LIHC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg07599136	chr5:415885	AHRR	0.58	9.49	0.46	4.23e-19	Fat distribution (HIV);
LIHC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.34	0.41	1.82e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3753275	0.568	rs1812457	chr1:8685520	C/T	cg20416874	chr1:8611966	RERE	-0.52	-6.38	-0.33	5.64e-10	Educational attainment;
LIHC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.93	0.31	7.39e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.87	13.22	0.58	1.58e-32	Vitamin D levels;
LIHC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	5.86e-12	Diabetic kidney disease;
LIHC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg18769074	chr3:133464867	TF	0.27	5.98	0.31	5.56e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs600806	0.821	rs3879448	chr1:109891423	C/G	cg08911820	chr1:110026001	ATXN7L2	-0.52	-6.73	-0.34	7.23e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3981351	0.624	rs12415607	chr10:115438204	A/C	cg24846397	chr10:115438155	CASP7	0.43	6.67	0.34	1.06e-10	Obesity-related traits;
LIHC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.17	0.44	4.42e-18	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.38	-0.68	6.12e-49	Gut microbiome composition (summer);
LIHC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.76	-9.61	-0.46	1.67e-19	Primary sclerosing cholangitis;
LIHC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.47	7.26	0.37	2.7e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.46	8.33	0.41	2.01e-15	Platelet distribution width;
LIHC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg06026331	chr20:60912101	LAMA5	0.49	6.47	0.33	3.43e-10	Colorectal cancer;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.32	7.59	0.38	3.04e-13	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.93	12.83	0.57	4.98e-31	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.53	0.56	6.98e-30	Alzheimer's disease;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg14835113	chr13:111303423	CARS2	0.51	6.33	0.32	7.49e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.64	9.97	0.47	9.9e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.5	0.53	4.36e-26	Tonsillectomy;
LIHC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg07636037	chr3:49044803	WDR6	-0.83	-8.47	-0.42	7.51e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.63	0.62	5.66e-38	Prudent dietary pattern;
LIHC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.43	8.0	0.4	1.98e-14	Electrocardiographic conduction measures;
LIHC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.68	-0.5	3.48e-23	Alzheimer's disease;
LIHC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.73	-0.3	2.21e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.8	11.88	0.54	1.7e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.18	-0.36	4.26e-12	Inflammatory bowel disease;
LIHC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.74	12.1	0.55	2.67e-28	Body mass index;
LIHC	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.79	-0.39	8.19e-14	QT interval;
LIHC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.93	8.51	0.42	5.35e-16	Type 2 diabetes;
LIHC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.54	-7.06	-0.36	9.42e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg23352942	chr3:46931381	PTH1R	-0.33	-8.84	-0.43	4.97e-17	Birth weight;
LIHC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.79	9.68	0.46	9.64e-20	Morning vs. evening chronotype;
LIHC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.15	0.4	7e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs57590327	0.679	rs35754586	chr3:81601765	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-6.5	-0.33	2.93e-10	Extraversion;
LIHC	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.55	0.42	4.29e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	1.02	19.59	0.73	8.04e-58	Breast cancer;
LIHC	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.9e-25	Intelligence (multi-trait analysis);
LIHC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.56	-7.62	-0.38	2.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.06e-34	Gastritis;
LIHC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg14393609	chr7:65229607	NA	-0.35	-5.78	-0.3	1.72e-8	Aortic root size;
LIHC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.55	-7.1	-0.36	7.14e-12	Breast cancer;
LIHC	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg13753209	chr17:57696993	CLTC	0.59	9.03	0.44	1.28e-17	Hemoglobin concentration;
LIHC	cis	rs3770081	1.000	rs12624126	chr2:86342366	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-7.9	-0.39	3.9e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-0.84	-9.29	-0.45	1.86e-18	Exhaled nitric oxide output;
LIHC	cis	rs17310467	0.541	rs78522696	chr20:33182159	G/C	cg08999081	chr20:33150536	PIGU	0.59	6.13	0.31	2.42e-9	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.57	6.34	0.32	7.24e-10	Axial length;
LIHC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.41	-5.83	-0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs2574704	0.886	rs7614263	chr3:11650269	T/C	cg15876825	chr3:11651881	VGLL4	-0.5	-8.2	-0.41	4.88e-15	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26164735	chr4:71768712	MOBKL1A	0.42	6.11	0.31	2.76e-9	Pancreatic cancer;
LIHC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.57	-9.15	-0.44	5.25e-18	Lymphocyte counts;
LIHC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.38	-6.04	-0.31	3.98e-9	Smoking behavior;
LIHC	cis	rs2997447	0.761	rs17184884	chr1:26446565	G/A	cg19633962	chr1:26362018	EXTL1	-0.64	-5.88	-0.3	9.64e-9	QRS complex (12-leadsum);
LIHC	cis	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg22544144	chr8:26435318	DPYSL2	0.66	5.96	0.31	6.17e-9	Musician's dystonia;
LIHC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.69	-10.28	-0.49	8.75e-22	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg10360323	chr17:41437877	NA	0.41	6.04	0.31	4.09e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.47	6.6	0.34	1.59e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.45	6.41	0.33	4.82e-10	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg03037974	chr15:76606532	NA	-0.61	-10.2	-0.48	1.7e-21	Blood metabolite levels;
LIHC	cis	rs7551222	0.646	rs4951382	chr1:204451495	T/C	cg20240347	chr1:204465584	NA	-0.32	-6.7	-0.34	8.54e-11	Schizophrenia;
LIHC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg18944383	chr4:111397179	ENPEP	0.33	7.48	0.37	6.44e-13	Coronary artery disease;
LIHC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.66	0.65	4.59e-42	Electrocardiographic conduction measures;
LIHC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.55	-7.33	-0.37	1.63e-12	Pancreatic cancer;
LIHC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	6.34	0.32	7.44e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.83	0.57	4.79e-31	Prudent dietary pattern;
LIHC	cis	rs3112357	1.000	rs3112357	chr7:135396896	A/G	cg20392616	chr7:135392013	SLC13A4	0.41	6.79	0.34	5.12e-11	Plantar warts;
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.96	-0.54	8.63e-28	Schizophrenia;
LIHC	cis	rs903552	1.000	rs11634912	chr15:102005510	A/G	cg00659931	chr15:102010125	PCSK6	-0.46	-6.19	-0.32	1.7e-9	Diabetic kidney disease;
LIHC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.63	11.98	0.54	7.74e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.58	-6.22	-0.32	1.46e-9	Hair shape;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.4	-8.03	-0.4	1.54e-14	Renal cell carcinoma;
LIHC	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	5.86	0.3	1.09e-8	Lipoprotein (a) levels;
LIHC	cis	rs3540	0.538	rs2074585	chr15:91009484	G/A	cg22089800	chr15:90895588	ZNF774	0.5	6.52	0.33	2.51e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.85	7.04	0.36	1.05e-11	Arsenic metabolism;
LIHC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.57	-8.14	-0.4	7.57e-15	Lung cancer;
LIHC	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-0.88	-18.38	-0.7	5.83e-53	Height;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06420487	chr17:61919686	SMARCD2	0.44	6.14	0.32	2.26e-9	Height;
LIHC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg10587741	chr22:38071170	LGALS1	0.73	12.8	0.57	6.38e-31	Fat distribution (HIV);
LIHC	cis	rs4759375	1.000	rs10773004	chr12:123788758	G/A	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.93	-0.35	2.04e-11	Obesity-related traits;
LIHC	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.88	0.39	4.38e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs11662586	1.000	rs8093291	chr18:77701294	G/A	cg20368463	chr18:77673604	PQLC1	0.41	6.24	0.32	1.29e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.51	-18.77	-0.71	1.57e-54	Breast cancer;
LIHC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.8	10.12	0.48	3.19e-21	Cognitive function;
LIHC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.45	7.16	0.36	5.1e-12	Height;
LIHC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	0.77	6.32	0.32	8.14e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.42	5.86	0.3	1.1e-8	Tonsillectomy;
LIHC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	8.1	0.4	9.5e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.44	7.39	0.37	1.16e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.1	-0.36	7.26e-12	Personality dimensions;
LIHC	cis	rs7707921	1.000	rs1543911	chr5:81504841	C/T	cg15871215	chr5:81402204	ATG10	0.59	5.82	0.3	1.38e-8	Breast cancer;
LIHC	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg07689907	chr11:61582574	FADS1	0.39	5.83	0.3	1.27e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	trans	rs993804	0.527	rs7630907	chr3:25122044	G/C	cg25259296	chr21:43235862	PRDM15	-0.41	-6.03	-0.31	4.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.94	0.65	3.74e-43	Electrocardiographic conduction measures;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg10553204	chr2:20871195	GDF7	-0.41	-7.52	-0.38	4.88e-13	Abdominal aortic aneurysm;
LIHC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.88	0.6	4.62e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.7	6.85	0.35	3.35e-11	Vitiligo;
LIHC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.97	13.44	0.59	2.33e-33	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg12042659	chr19:58951599	ZNF132	0.38	6.33	0.32	7.59e-10	Uric acid clearance;
LIHC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.48	-0.49	1.81e-22	Chronic sinus infection;
LIHC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.36	6.46	0.33	3.55e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	6.29	0.32	9.71e-10	Renal cell carcinoma;
LIHC	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.89	15.1	0.63	7.73e-40	Gastritis;
LIHC	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg10820045	chr2:198174542	NA	0.41	6.03	0.31	4.23e-9	Intracranial aneurysm;
LIHC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.33	-6.38	-0.33	5.6e-10	Homoarginine levels;
LIHC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.27e-12	Bipolar disorder;
LIHC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.45	0.82	1.05e-84	Cognitive ability;
LIHC	cis	rs7192750	0.586	rs8054111	chr16:71990651	A/G	cg06353428	chr16:71660113	MARVELD3	0.76	8.79	0.43	7.19e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.62	-0.42	2.56e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.52	6.84	0.35	3.67e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67981189	0.593	rs10145824	chr14:71447732	T/C	cg15816911	chr14:71606274	NA	0.41	6.63	0.34	1.33e-10	Schizophrenia;
LIHC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs11644362	1.000	rs35325771	chr16:12985138	A/C	cg06890432	chr16:12997467	SHISA9	-0.4	-6.73	-0.34	6.96e-11	Positive affect;Subjective well-being;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23274123	chr1:229478617	C1orf96	-0.46	-6.82	-0.35	4.25e-11	Cognitive function;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06528150	chr2:61293470	KIAA1841	0.42	6.04	0.31	3.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.42	-6.83	-0.35	3.8e-11	Schizophrenia;
LIHC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.82	0.35	4.02e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg07713946	chr22:31675144	LIMK2	-0.42	-7.4	-0.37	1.04e-12	Colorectal cancer;
LIHC	cis	rs2412488	1.000	rs10017903	chr4:54267009	C/T	cg22241045	chr4:54363911	LNX1	-0.47	-7.51	-0.38	5.16e-13	DNA methylation (variation);
LIHC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs2637030	0.559	rs6881928	chr5:52988609	C/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.77	0.34	5.57e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.63	-8.87	-0.43	4.19e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-1.02	-19.56	-0.73	1.01e-57	Breast cancer;
LIHC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.68	0.5	3.73e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs7534824	0.556	rs61780323	chr1:101433407	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.85	0.35	3.43e-11	Refractive astigmatism;
LIHC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.81	-0.43	6.55e-17	Type 2 diabetes;
LIHC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.05	16.04	0.66	1.41e-43	Breast cancer;
LIHC	cis	rs7395581	0.959	rs35879051	chr11:47275882	C/G	cg25783544	chr11:47291846	MADD	0.45	6.66	0.34	1.06e-10	HDL cholesterol;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.41	-7.02	-0.36	1.18e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.06e-25	Tonsillectomy;
LIHC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.4	7.65	0.38	2.13e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-30.49	-0.85	1.55e-99	Myeloid white cell count;
LIHC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.74	-0.3	2.06e-8	Ulcerative colitis;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs7187994	0.806	rs12445172	chr16:84747016	C/G	cg07647771	chr16:84786436	USP10	-0.32	-6.14	-0.31	2.33e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-9.54	-0.46	2.85e-19	Cognitive function;
LIHC	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.58	-6.44	-0.33	3.96e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.88	15.8	0.65	1.25e-42	Aortic root size;
LIHC	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg03934865	chr2:198174659	NA	0.54	8.3	0.41	2.46e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs59901009	0.569	rs12280005	chr11:10228452	G/A	cg01453529	chr11:10209919	SBF2	-0.43	-7.87	-0.39	4.77e-14	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	12.36	0.56	2.79e-29	Response to bleomycin (chromatid breaks);
LIHC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.55	9.26	0.45	2.36e-18	Blood metabolite levels;
LIHC	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.6	10.03	0.48	6.14e-21	HDL cholesterol;
LIHC	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.73	-15.08	-0.63	9.44e-40	Urate levels in lean individuals;
LIHC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.56	-0.5	9.37e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.94	18.01	0.7	1.79e-51	Menopause (age at onset);
LIHC	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	14.01	0.6	1.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.04	9.47	0.46	4.9e-19	Diabetic retinopathy;
LIHC	cis	rs926392	0.932	rs6513589	chr20:37686585	A/G	cg16355469	chr20:37678765	NA	0.37	5.9	0.3	8.89e-9	Dialysis-related mortality;
LIHC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.38	8.39	0.41	1.31e-15	Prostate-specific antigen levels;
LIHC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.83	9.52	0.46	3.24e-19	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18501264	chr19:33555827	RHPN2	-0.43	-6.54	-0.33	2.19e-10	Pancreatic cancer;
LIHC	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg26031613	chr14:104095156	KLC1	0.89	9.01	0.44	1.46e-17	Body mass index;
LIHC	cis	rs7238033	0.663	rs17675121	chr18:43318185	T/C	cg20610511	chr18:43302872	SLC14A1	0.4	6.77	0.34	5.65e-11	Bladder cancer;
LIHC	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.62	-10.13	-0.48	2.9e-21	Malaria;
LIHC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.52	-15.89	-0.65	5.89e-43	Breast cancer;
LIHC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.5	9.14	0.44	5.69e-18	Hemoglobin concentration;
LIHC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.05e-8	Menopause (age at onset);
LIHC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg17834443	chr8:19674713	INTS10	-0.49	-7.45	-0.37	7.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.4	5.85	0.3	1.15e-8	Arsenic metabolism;
LIHC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg08807892	chr2:162101083	NA	0.45	7.64	0.38	2.25e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.33	0.37	1.63e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.74	13.03	0.58	8.81e-32	Prudent dietary pattern;
LIHC	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.18	-0.32	1.84e-9	Schizophrenia;
LIHC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.38	-11.7	-0.53	8.09e-27	Hip circumference adjusted for BMI;
LIHC	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.52	7.96	0.4	2.55e-14	Corneal astigmatism;
LIHC	cis	rs2176862	1.000	rs73073734	chr3:46620518	T/C	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.3	-0.32	9.3e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	0.52	5.73	0.3	2.18e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.69	0.38	1.53e-13	Nonalcoholic fatty liver disease;
LIHC	cis	rs2574704	0.683	rs6793495	chr3:11647942	G/A	cg15876825	chr3:11651881	VGLL4	0.41	6.45	0.33	3.81e-10	Body mass index;
LIHC	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg01864836	chr14:55583639	NA	-0.4	-7.48	-0.38	6.13e-13	Protein biomarker;
LIHC	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg24225360	chr4:15471699	CC2D2A	-0.41	-6.69	-0.34	9.09e-11	Obesity-related traits;
LIHC	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.19	0.32	1.77e-9	Rheumatoid arthritis;
LIHC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.12	-0.36	6.31e-12	Diabetic kidney disease;
LIHC	cis	rs7192750	0.562	rs9921412	chr16:71988106	C/T	cg06353428	chr16:71660113	MARVELD3	0.77	8.89	0.43	3.46e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.61	-7.43	-0.37	8.73e-13	Mean platelet volume;
LIHC	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg02272795	chr19:15279244	NOTCH3	-0.31	-6.38	-0.33	5.67e-10	Pulse pressure;
LIHC	cis	rs72653721	0.838	rs3756962	chr6:11006861	C/T	cg13562911	chr6:11044106	ELOVL2	0.5	7.22	0.36	3.36e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.84	-0.39	5.62e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.95	-12.57	-0.56	4.62e-30	Post bronchodilator FEV1;
LIHC	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg25952890	chr19:58913133	NA	0.71	7.75	0.39	1.09e-13	Mean platelet volume;
LIHC	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.56	-8.31	-0.41	2.23e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-9.28	-0.45	2.03e-18	Response to antipsychotic treatment;
LIHC	cis	rs7534824	0.625	rs61780286	chr1:101359898	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	6.55	0.33	2.15e-10	Refractive astigmatism;
LIHC	cis	rs490234	0.932	rs577026	chr9:128341023	C/T	cg14078157	chr9:128172775	NA	-0.35	-5.94	-0.31	6.83e-9	Mean arterial pressure;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.78	11.96	0.54	8.59e-28	Longevity;
LIHC	cis	rs903552	0.932	rs9806551	chr15:102008206	C/T	cg19295451	chr15:102010161	PCSK6	-0.54	-7.65	-0.38	2.1e-13	Diabetic kidney disease;
LIHC	cis	rs67981189	0.593	rs2097975	chr14:71480404	G/A	cg15816911	chr14:71606274	NA	0.39	6.22	0.32	1.48e-9	Schizophrenia;
LIHC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.11	-0.31	2.75e-9	Headache;
LIHC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	0.95	8.89	0.43	3.47e-17	Alzheimer's disease;
LIHC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.85	0.35	3.44e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.59	-9.34	-0.45	1.29e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.71	-8.92	-0.43	2.85e-17	Gut microbiome composition (summer);
LIHC	cis	rs12960505	0.506	rs9964174	chr18:51010181	A/C	cg24270629	chr18:50823537	DCC	-0.47	-6.44	-0.33	3.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.31	0.32	8.5e-10	Prudent dietary pattern;
LIHC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-23.93	-0.79	5e-75	Height;
LIHC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	cis	rs4853036	0.904	rs2278934	chr2:70121197	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.87	-0.35	3.02e-11	Colorectal or endometrial cancer;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.99	-0.4	2.14e-14	Lymphocyte counts;
LIHC	trans	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.26	7.0	0.35	1.33e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg03037974	chr15:76606532	NA	-0.75	-14.66	-0.62	4.18e-38	Blood metabolite levels;
LIHC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.45	7.68	0.38	1.66e-13	Schizophrenia;
LIHC	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.57	-8.52	-0.42	5.29e-16	Blood protein levels;
LIHC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-16.64	-0.67	5.81e-46	Primary sclerosing cholangitis;
LIHC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.0	-0.44	1.64e-17	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	1.06	15.99	0.65	2.22e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.8	-0.57	6.34e-31	Type 2 diabetes;
LIHC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.77	9.97	0.47	9.88e-21	Body mass index;
LIHC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.42	6.8	0.35	4.66e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10207060	0.500	rs7585903	chr2:240682481	A/C	cg07506560	chr2:240697449	NA	0.41	6.15	0.32	2.2e-9	Obesity-related traits;
LIHC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-10.39	-0.49	3.75e-22	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07721005	chr5:87564621	TMEM161B	0.45	6.55	0.33	2.07e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16755220	chr16:12070685	RUNDC2A	-0.42	-6.43	-0.33	4.36e-10	Pancreatic cancer;
LIHC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.65	6.45	0.33	3.78e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.87	12.39	0.56	2.17e-29	Menarche (age at onset);
LIHC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08219700	chr8:58056026	NA	0.52	6.39	0.33	5.41e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg11764359	chr7:65958608	NA	0.59	6.01	0.31	4.63e-9	Diabetic kidney disease;
LIHC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg18016565	chr1:150552671	MCL1	-0.51	-10.49	-0.49	1.72e-22	Tonsillectomy;
LIHC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.87	0.3	1.02e-8	Body mass index;
LIHC	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg06640241	chr16:89574553	SPG7	0.56	8.58	0.42	3.45e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.61	-10.17	-0.48	2.11e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs7116495	1.000	rs7931941	chr11:71667604	C/T	cg26138937	chr11:71823887	C11orf51	-0.67	-6.83	-0.35	3.92e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.86	0.35	3.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg04719120	chr6:96025338	MANEA	0.47	5.72	0.3	2.37e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg23495837	chr4:3480318	DOK7	-0.38	-6.81	-0.35	4.3e-11	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.48	7.36	0.37	1.42e-12	Alzheimer's disease (survival time);
LIHC	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.58	7.08	0.36	8.15e-12	Breast cancer;
LIHC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.65	0.34	1.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.65	-9.49	-0.46	4.17e-19	White matter hyperintensity burden;
LIHC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.54	8.46	0.42	7.66e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.85	-0.3	1.16e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg18944383	chr4:111397179	ENPEP	0.26	6.3	0.32	9.32e-10	Coronary artery disease;
LIHC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg19680672	chr10:131412579	MGMT	-0.42	-6.52	-0.33	2.46e-10	Response to temozolomide;
LIHC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg18357526	chr6:26021779	HIST1H4A	0.62	8.69	0.43	1.58e-16	Blood metabolite levels;
LIHC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.17	-15.58	-0.64	9.57e-42	Ulcerative colitis;
LIHC	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.53	-5.78	-0.3	1.67e-8	Blood protein levels;
LIHC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	7.09	0.36	7.71e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1144333	0.737	rs1144331	chr1:76272357	G/A	cg10523679	chr1:76189770	ACADM	-0.46	-6.75	-0.34	6.26e-11	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.44	8.92	0.43	2.97e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg02415029	chr1:110025642	ATXN7L2	-0.53	-6.8	-0.35	4.54e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg12560992	chr17:57184187	TRIM37	-0.52	-7.3	-0.37	2.03e-12	Cognitive test performance;
LIHC	cis	rs61990749	0.571	rs2364841	chr14:78284036	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.56	7.45	0.37	7.89e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.82	13.77	0.6	1.29e-34	Monocyte count;
LIHC	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.58	10.26	0.49	1.05e-21	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.84	0.3	1.24e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-6.97	-0.35	1.65e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.83	-8.85	-0.43	4.94e-17	Facial morphology (factor 23);
LIHC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.88	0.39	4.43e-14	Lung cancer;
LIHC	trans	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg18335740	chr13:41363409	SLC25A15	0.35	6.06	0.31	3.57e-9	Lewy body disease;
LIHC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.24	6.09	0.31	3.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.12	13.51	0.59	1.26e-33	Gut microbiome composition (summer);
LIHC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg26149184	chr10:133730230	NA	0.47	7.47	0.37	6.73e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.46	8.77	0.43	8.69e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.37	5.91	0.3	8.06e-9	Menopause (age at onset);
LIHC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.65	-9.37	-0.45	1.05e-18	Obesity-related traits;
LIHC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.59	7.77	0.39	9.29e-14	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.21	-0.36	3.69e-12	Reticulocyte count;
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.44	-5.98	-0.31	5.62e-9	Total body bone mineral density;
LIHC	cis	rs1043515	0.935	rs2338115	chr17:36929578	C/T	cg09592244	chr17:37024020	NA	0.37	6.01	0.31	4.88e-9	Height;
LIHC	cis	rs2625529	0.761	rs8028532	chr15:72348054	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.92	-0.3	7.89e-9	Red blood cell count;
LIHC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.38	5.98	0.31	5.68e-9	Menopause (age at onset);
LIHC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.65	11.64	0.53	1.38e-26	Total body bone mineral density;
LIHC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.85	-14.12	-0.61	5.42e-36	Headache;
LIHC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.36	-6.04	-0.31	4.11e-9	IgG glycosylation;
LIHC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.12	13.54	0.59	9.92e-34	Gut microbiome composition (summer);
LIHC	trans	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg18335740	chr13:41363409	SLC25A15	0.36	6.34	0.32	7.17e-10	Lewy body disease;
LIHC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.54	-7.88	-0.39	4.36e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.02	-0.4	1.66e-14	Type 2 diabetes;
LIHC	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.72	-11.21	-0.52	4.6e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.21	-0.32	1.53e-9	Coronary artery disease;
LIHC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	10.6	0.5	6.72e-23	Coronary artery disease;
LIHC	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-11.12	-0.52	1.01e-24	Eye color traits;
LIHC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.44	-6.01	-0.31	4.64e-9	Height;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.6	8.59	0.42	3.02e-16	Blood metabolite levels;
LIHC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.53	-9.09	-0.44	8.02e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.52	7.14	0.36	5.67e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg23485639	chr6:28045615	ZNF165	0.38	5.96	0.31	6.31e-9	Parkinson's disease;
LIHC	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.75	11.45	0.53	6.52e-26	Eye color traits;
LIHC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-17.52	-0.69	1.73e-49	Height;
LIHC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.81	13.14	0.58	3.19e-32	Colorectal cancer;
LIHC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg18225595	chr11:63971243	STIP1	-0.68	-8.45	-0.42	8.27e-16	Mean platelet volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02653728	chr5:132165751	NA	0.45	6.78	0.34	5.18e-11	Lung function (FEV1/FVC);
LIHC	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.11	-0.36	6.92e-12	QT interval;
LIHC	cis	rs939574	0.512	rs10194278	chr2:220138408	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.61	7.42	0.37	9.22e-13	Platelet distribution width;
LIHC	cis	rs986417	0.901	rs7157458	chr14:60999852	C/T	cg27398547	chr14:60952738	C14orf39	0.83	9.59	0.46	1.95e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.58	8.18	0.4	5.53e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.39	6.36	0.33	6.53e-10	Red blood cell count;
LIHC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.58	-0.46	2.13e-19	Gut microbiome composition (summer);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06441968	chr1:40627537	RLF	0.43	6.43	0.33	4.39e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.45	6.3	0.32	8.95e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-0.62	-8.05	-0.4	1.36e-14	Lung cancer;
LIHC	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.78	11.43	0.53	7.37e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg07689907	chr11:61582574	FADS1	-0.37	-5.72	-0.3	2.3e-8	Trans fatty acid levels;
LIHC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02886208	chr11:14281011	SPON1	-0.55	-8.12	-0.4	8.39e-15	Mitochondrial DNA levels;
LIHC	cis	rs7258015	0.909	rs2304237	chr19:10446568	T/C	cg13981319	chr19:10446556	ICAM3	0.47	7.14	0.36	5.66e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs7616330	0.887	rs2100142	chr3:71112560	A/G	cg01511742	chr3:71112437	FOXP1	-0.57	-7.85	-0.39	5.51e-14	QT interval;
LIHC	cis	rs3736485	0.966	rs8042221	chr15:51774613	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.16	-0.32	2.08e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	18.21	0.7	2.91e-52	Tonsillectomy;
LIHC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg07636037	chr3:49044803	WDR6	-0.84	-8.52	-0.42	5.33e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg10932868	chr11:921992	NA	0.32	6.05	0.31	3.87e-9	Alzheimer's disease (late onset);
LIHC	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg19773385	chr1:10388646	KIF1B	-0.48	-8.29	-0.41	2.64e-15	Hepatocellular carcinoma;
LIHC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19671926	chr4:122722719	EXOSC9	0.54	8.51	0.42	5.73e-16	Type 2 diabetes;
LIHC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.65	7.92	0.39	3.46e-14	Heart rate;
LIHC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.71	11.14	0.52	8.4e-25	Corneal astigmatism;
LIHC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg09835421	chr16:68378352	PRMT7	-0.6	-7.01	-0.35	1.24e-11	Schizophrenia;
LIHC	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.89	0.43	3.55e-17	Exhaled nitric oxide output;
LIHC	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.85	-14.65	-0.62	4.54e-38	Oral cavity cancer;
LIHC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.26	-5.9	-0.3	8.73e-9	Longevity;Endometriosis;
LIHC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.45	0.37	7.81e-13	Parkinson's disease;
LIHC	trans	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg03874509	chr1:107600012	PRMT6	0.73	11.65	0.53	1.26e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.37	5.9	0.3	8.55e-9	Mean corpuscular volume;
LIHC	cis	rs6582630	0.555	rs7956782	chr12:38603641	C/G	cg26384229	chr12:38710491	ALG10B	0.87	10.03	0.48	6.16e-21	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.81	-0.3	1.41e-8	Arsenic metabolism;
LIHC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg23791538	chr6:167370224	RNASET2	-0.51	-7.81	-0.39	6.86e-14	Crohn's disease;
LIHC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.71	-6.87	-0.35	2.97e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs7721647	0.853	rs6867266	chr5:90873294	T/C	cg11567849	chr6:111751012	REV3L	-0.49	-6.08	-0.31	3.14e-9	Breast cancer;
LIHC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.37	-8.42	-0.41	1.05e-15	Ulcerative colitis;
LIHC	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.45	7.54	0.38	4.19e-13	Crohn's disease;
LIHC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-11.25	-0.52	3.48e-25	Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.29	0.49	8.41e-22	Alzheimer's disease;
LIHC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.9	10.56	0.5	9.14e-23	Primary sclerosing cholangitis;
LIHC	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.78	-11.67	-0.53	1.01e-26	Personality dimensions;
LIHC	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.38	6.04	0.31	4.05e-9	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12463550	chr7:65579703	CRCP	0.69	7.27	0.37	2.42e-12	Diabetic kidney disease;
LIHC	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-7.01	-0.35	1.31e-11	Metabolite levels;
LIHC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.7	0.43	1.4e-16	Lung cancer in ever smokers;
LIHC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.38	6.97	0.35	1.61e-11	Obesity-related traits;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg08837587	chr8:30601672	UBXN8	-0.66	-6.92	-0.35	2.24e-11	Obesity-related traits;
LIHC	cis	rs34245846	0.704	rs11264280	chr1:154862952	C/T	cg03351412	chr1:154909251	PMVK	-0.59	-7.23	-0.36	3.22e-12	Atrial fibrillation;
LIHC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.7	-0.62	3.07e-38	Alzheimer's disease (late onset);
LIHC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.8	-12.89	-0.57	2.97e-31	Colorectal cancer;
LIHC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.36	-6.09	-0.31	2.97e-9	Schizophrenia;
LIHC	cis	rs35883536	1.000	rs12410168	chr1:101115321	G/A	cg14515779	chr1:101123966	NA	-0.67	-13.36	-0.59	4.66e-33	Monocyte count;
LIHC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg19682013	chr15:45996608	NA	0.39	6.67	0.34	1.01e-10	Waist circumference;Weight;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.74	10.89	0.51	6.79e-24	Menarche (age at onset);
LIHC	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg05110241	chr16:68378359	PRMT7	0.53	6.29	0.32	9.74e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.65	-10.48	-0.49	1.84e-22	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24419099	chr11:47270565	NR1H3;ACP2	0.49	6.89	0.35	2.77e-11	Pancreatic cancer;
LIHC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.44	7.05	0.36	9.71e-12	Total body bone mineral density;
LIHC	cis	rs6429082	0.509	rs2789362	chr1:235521235	A/G	cg26050004	chr1:235667680	B3GALNT2	0.42	6.33	0.32	7.79e-10	Adiposity;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19482537	chr5:156692823	CYFIP2	0.46	7.23	0.36	3.18e-12	Calcium levels;
LIHC	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg03934865	chr2:198174659	NA	0.46	6.61	0.34	1.47e-10	Dermatomyositis;
LIHC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.42	6.21	0.32	1.52e-9	Diastolic blood pressure;
LIHC	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.78	10.73	0.5	2.44e-23	Personality dimensions;
LIHC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs9503598	0.502	rs6938209	chr6:3430487	G/A	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.86	-0.3	1.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.37	6.21	0.32	1.52e-9	White matter hyperintensity burden;
LIHC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.86	13.01	0.58	9.87e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	6.54	0.33	2.19e-10	Schizophrenia;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg20349687	chr2:88927127	EIF2AK3	-0.43	-6.54	-0.33	2.22e-10	Body mass index;
LIHC	trans	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17183009	chr3:120277827	NA	0.52	6.09	0.31	3.02e-9	Corneal astigmatism;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs10512049	0.655	rs11521830	chr9:78290840	A/C	cg02083989	chr12:65153459	GNS	0.86	6.77	0.34	5.63e-11	Total ventricular volume (Alzheimer's disease interaction);
LIHC	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.63	-9.51	-0.46	3.57e-19	Schizophrenia;
LIHC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.39	6.23	0.32	1.34e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.34	-5.77	-0.3	1.82e-8	Educational attainment;
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.85	0.35	3.42e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.22e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg13409248	chr3:40428643	ENTPD3	0.5	8.35	0.41	1.74e-15	Renal cell carcinoma;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.7	10.01	0.48	7.71e-21	Lymphocyte counts;
LIHC	trans	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg10756647	chr7:56101905	PSPH	-1.08	-13.29	-0.58	8.75e-33	Diabetic kidney disease;
LIHC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg03013999	chr17:37608204	MED1	0.34	5.75	0.3	2.03e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7707921	0.881	rs4391141	chr5:81263522	T/A	cg15871215	chr5:81402204	ATG10	-0.61	-5.82	-0.3	1.35e-8	Breast cancer;
LIHC	cis	rs12744310	0.887	rs12047161	chr1:41807528	G/T	cg03387723	chr1:41708464	SCMH1	-0.32	-5.9	-0.3	8.91e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.92	14.84	0.63	8.3e-39	Tonsillectomy;
LIHC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.95e-9	Menopause (age at onset);
LIHC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-10.07	-0.48	4.59e-21	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg02290350	chr8:58132656	NA	0.41	8.7	0.43	1.43e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.66	0.53	1.09e-26	Motion sickness;
LIHC	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.52	8.94	0.44	2.54e-17	Coronary artery disease;
LIHC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-8.88	-0.43	3.9e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.91	-0.3	8.48e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-9.42	-0.45	6.71e-19	Chronic sinus infection;
LIHC	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.56	-0.38	3.63e-13	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10345131	chr15:91475918	UNC45A;HDDC3	0.45	6.51	0.33	2.63e-10	Lung function (FEV1/FVC);
LIHC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.25	13.58	0.59	6.5e-34	Opioid sensitivity;
LIHC	cis	rs9783347	0.857	rs2124374	chr11:18313911	A/C	cg15585147	chr11:18324498	HPS5	0.45	6.88	0.35	2.92e-11	Pancreatic cancer;
LIHC	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.24	-6.29	-0.32	9.54e-10	Menarche (age at onset);
LIHC	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg25019722	chr6:37503610	NA	-0.31	-5.74	-0.3	2.09e-8	Cognitive performance;
LIHC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.55	-8.81	-0.43	6.4e-17	Menarche (age at onset);
LIHC	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.48	-6.56	-0.33	2.03e-10	Educational attainment;
LIHC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg22633049	chr21:46681294	NA	-0.37	-6.46	-0.33	3.6e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.57	0.53	2.44e-26	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg07424592	chr7:64974309	NA	0.83	9.54	0.46	2.85e-19	Diabetic kidney disease;
LIHC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-8.15	-0.4	7.18e-15	Ulcerative colitis;
LIHC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.11e-18	Bipolar disorder;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg01339444	chr6:118972232	C6orf204	0.59	5.82	0.3	1.32e-8	Diastolic blood pressure;
LIHC	cis	rs600626	0.529	rs2008476	chr11:75470813	C/T	cg24262691	chr11:75473276	NA	0.43	6.37	0.33	6e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.91	11.37	0.52	1.23e-25	Coronary artery disease;
LIHC	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	0.96	8.01	0.4	1.84e-14	Lymphocyte counts;
LIHC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.69	-8.98	-0.44	1.8e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs986417	1.000	rs11845369	chr14:60944959	A/G	cg27398547	chr14:60952738	C14orf39	0.8	9.07	0.44	9.75e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.31e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.54	-7.16	-0.36	5.06e-12	Lung cancer;
LIHC	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.52	-9.41	-0.45	7.66e-19	Total body bone mineral density;
LIHC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.77	12.8	0.57	6.22e-31	Psoriasis;
LIHC	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.68	-0.34	9.55e-11	Schizophrenia;
LIHC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg03037974	chr15:76606532	NA	-0.59	-10.19	-0.48	1.76e-21	Blood metabolite levels;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.6	0.38	2.91e-13	Prudent dietary pattern;
LIHC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.89	-18.62	-0.71	6.08e-54	Height;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.2	0.32	1.66e-9	Cognitive ability;
LIHC	cis	rs6973256	0.637	rs12539993	chr7:133418799	C/T	cg03336402	chr7:133662267	EXOC4	-0.38	-5.89	-0.3	9.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg13660082	chr14:53194042	PSMC6	-0.45	-7.77	-0.39	9.3e-14	Alzheimer's disease (late onset);
LIHC	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg18289306	chr13:113640169	MCF2L	0.41	6.58	0.34	1.75e-10	Systolic blood pressure;
LIHC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.68	-8.77	-0.43	8.46e-17	Initial pursuit acceleration;
LIHC	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	1.09	7.82	0.39	6.53e-14	Arsenic metabolism;
LIHC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg27478167	chr7:817139	HEATR2	-0.41	-5.83	-0.3	1.32e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg16586182	chr3:47516702	SCAP	0.5	8.72	0.43	1.21e-16	Colorectal cancer;
LIHC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.77	-8.68	-0.43	1.59e-16	Initial pursuit acceleration;
LIHC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.55	8.55	0.42	4.02e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	0.73	7.88	0.39	4.46e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-0.91	-10.92	-0.51	5.23e-24	Mitochondrial DNA levels;
LIHC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-1.17	-13.04	-0.58	8.22e-32	White matter hyperintensity burden;
LIHC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.6	-11.57	-0.53	2.35e-26	Neuroticism;
LIHC	cis	rs15676	0.783	rs7860949	chr9:131586883	C/T	cg00228799	chr9:131580591	ENDOG	-0.48	-6.93	-0.35	2.16e-11	Blood metabolite levels;
LIHC	cis	rs55665837	0.540	rs12290926	chr11:14695046	A/G	cg00085434	chr11:14927489	NA	0.41	5.86	0.3	1.07e-8	Vitamin D levels;
LIHC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg14222432	chr12:29376421	FAR2	0.36	6.96	0.35	1.72e-11	QT interval;
LIHC	trans	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg16088116	chr21:44841560	SIK1	-0.42	-6.52	-0.33	2.59e-10	Coronary artery disease;
LIHC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg16586182	chr3:47516702	SCAP	-0.47	-8.5	-0.42	6.1e-16	Colorectal cancer;
LIHC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg03037974	chr15:76606532	NA	0.74	14.54	0.62	1.27e-37	Blood metabolite levels;
LIHC	cis	rs244293	1.000	rs2628313	chr17:53235352	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.08	-0.36	8.38e-12	Menarche (age at onset);
LIHC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.78e-23	Hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.26	-16.63	-0.67	6.04e-46	Diabetic kidney disease;
LIHC	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.6	8.96	0.44	2.09e-17	Recombination rate (females);
LIHC	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg14011486	chr1:26737247	LIN28	-0.62	-8.89	-0.43	3.45e-17	Atrial fibrillation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25733613	chr11:111637437	PPP2R1B	0.44	6.16	0.32	2.07e-9	Lung function (FEV1/FVC);
LIHC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg07599136	chr5:415885	AHRR	-0.39	-6.77	-0.34	5.55e-11	Cystic fibrosis severity;
LIHC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.89	-19.7	-0.73	2.86e-58	Height;
LIHC	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.33	-0.32	7.83e-10	Colorectal cancer;
LIHC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	0.906	rs12405049	chr1:8626117	C/T	cg20416874	chr1:8611966	RERE	0.57	8.72	0.43	1.22e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.52	-7.75	-0.39	1.05e-13	Total body bone mineral density;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06090383	chr4:174292579	SAP30	-0.5	-6.33	-0.32	7.71e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg15691649	chr6:25882328	NA	0.45	5.77	0.3	1.78e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.43	7.08	0.36	8.36e-12	Mean corpuscular volume;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg16479474	chr6:28041457	NA	0.4	5.76	0.3	1.86e-8	Parkinson's disease;
LIHC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg13753209	chr17:57696993	CLTC	0.73	11.56	0.53	2.62e-26	Hemoglobin concentration;
LIHC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-6.24	-0.32	1.28e-9	Schizophrenia;
LIHC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg06096015	chr1:231504339	EGLN1	0.48	8.78	0.43	7.71e-17	Hemoglobin concentration;
LIHC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.41	-7.06	-0.36	9.22e-12	Schizophrenia;
LIHC	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.57	-8.93	-0.43	2.59e-17	White matter hyperintensity burden;
LIHC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.68e-19	Hemoglobin concentration;
LIHC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg00204512	chr16:28754710	NA	0.41	7.16	0.36	4.9e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.53	-9.43	-0.45	6.37e-19	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg14160804	chr18:12703040	PSMG2;CEP76	-0.49	-6.09	-0.31	3.11e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg18404041	chr3:52824283	ITIH1	0.39	5.81	0.3	1.43e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2637266	0.686	rs1660915	chr10:78525318	T/A	cg18941641	chr10:78392320	NA	0.28	6.05	0.31	3.77e-9	Pulmonary function;
LIHC	trans	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg17675199	chr6:35436792	RPL10A	-0.41	-8.56	-0.42	3.98e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.41	0.45	7.45e-19	Mean platelet volume;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17935035	chr15:40763388	CHST14	-0.48	-6.21	-0.32	1.51e-9	Systolic blood pressure;
LIHC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.75	-14.39	-0.61	4.74e-37	Mortality in heart failure;
LIHC	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.36	-0.49	4.8e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	0.8	11.47	0.53	5.69e-26	Left atrial antero-posterior diameter;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11599998	chr3:160283537	KPNA4	-0.46	-6.42	-0.33	4.47e-10	Bilirubin levels;
LIHC	trans	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg23605328	chr1:201951606	RNPEP	0.39	6.1	0.31	2.92e-9	Monocyte percentage of white cells;
LIHC	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg07706471	chr12:123319906	HIP1R	0.72	8.13	0.4	7.75e-15	Adiponectin levels;
LIHC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg16479474	chr6:28041457	NA	0.38	6.34	0.32	7.08e-10	Cardiac Troponin-T levels;
LIHC	cis	rs937213	0.573	rs12592831	chr15:40302441	G/A	cg16127683	chr15:40268777	EIF2AK4	-0.36	-5.89	-0.3	9.23e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.65	-8.93	-0.44	2.59e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.45	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.76	0.34	5.96e-11	Axial length;
LIHC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg24634471	chr8:143751801	JRK	-0.43	-5.92	-0.3	7.86e-9	Urinary tract infection frequency;
LIHC	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg03934865	chr2:198174659	NA	0.46	6.79	0.34	5.08e-11	Dermatomyositis;
LIHC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.25	-5.74	-0.3	2.12e-8	Inflammatory skin disease;
LIHC	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.31	0.32	8.68e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.94	0.39	3.03e-14	Tonsillectomy;
LIHC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.58	9.33	0.45	1.33e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg24391279	chr8:1708526	NA	-0.35	-5.85	-0.3	1.14e-8	Systolic blood pressure;
LIHC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.95	-0.35	1.88e-11	Body mass index;
LIHC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.43	-6.55	-0.33	2.15e-10	Height;
LIHC	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-20.09	-0.74	7.73e-60	Exhaled nitric oxide output;
LIHC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.51	7.21	0.36	3.71e-12	Height;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.33	0.41	1.94e-15	Height;
LIHC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.57	7.35	0.37	1.43e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg04756594	chr16:24857601	SLC5A11	-0.46	-7.26	-0.37	2.64e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg10820045	chr2:198174542	NA	0.55	8.95	0.44	2.22e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.39	-6.3	-0.32	8.97e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.09	-0.31	2.99e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.1	11.26	0.52	3.23e-25	Opioid sensitivity;
LIHC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12463550	chr7:65579703	CRCP	0.68	7.14	0.36	5.69e-12	Diabetic kidney disease;
LIHC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04221910	chr5:616842	CEP72	-0.42	-7.34	-0.37	1.53e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.73	7.48	0.38	6.15e-13	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.52	7.7	0.38	1.45e-13	Renal cell carcinoma;
LIHC	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25632853	chr15:73088954	NA	0.36	5.94	0.31	6.95e-9	Triglyceride levels;
LIHC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-6.38	-0.33	5.86e-10	Bipolar disorder;
LIHC	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4586057	0.514	rs12246757	chr10:92634383	A/G	cg14313238	chr10:92632228	RPP30	0.37	6.08	0.31	3.22e-9	Economic and political preferences (time);
LIHC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.58	5.87	0.3	1.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	0.58	5.99	0.31	5.29e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.49	7.14	0.36	5.5e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.96	-0.31	6.22e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2224391	1.000	rs9504370	chr6:5261601	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.42	-6.28	-0.32	1.02e-9	Height;
LIHC	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg03934865	chr2:198174659	NA	0.48	6.9	0.35	2.57e-11	Dermatomyositis;
LIHC	cis	rs903552	1.000	rs8043379	chr15:102005837	A/G	cg06707286	chr15:102010195	PCSK6	-0.44	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.79	13.92	0.6	3.27e-35	Coronary artery disease;
LIHC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	12.98	0.57	1.38e-31	Cognitive test performance;
LIHC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.34	-6.21	-0.32	1.57e-9	Aortic root size;
LIHC	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.48	-0.33	3.26e-10	Body mass index;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.6	0.53	1.85e-26	Alzheimer's disease;
LIHC	trans	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg09045935	chr12:6379348	NA	0.83	6.85	0.35	3.36e-11	Blood metabolite levels;
LIHC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.68	0.34	9.43e-11	Bipolar disorder;
LIHC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg23533926	chr12:111358616	MYL2	-0.35	-6.78	-0.34	5.43e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.06	-0.31	3.54e-9	Type 2 diabetes;
LIHC	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg04374321	chr14:90722782	PSMC1	-0.75	-14.2	-0.61	2.6e-36	Mortality in heart failure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20264566	chr11:10316295	SBF2	0.46	6.31	0.32	8.71e-10	Lung function (FEV1/FVC);
LIHC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.47e-8	Aortic root size;
LIHC	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg22951263	chr5:87985283	NA	-0.41	-7.18	-0.36	4.42e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.6	10.45	0.49	2.26e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg02023728	chr11:77925099	USP35	-0.33	-5.9	-0.3	8.97e-9	Alzheimer's disease (survival time);
LIHC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.58	-0.38	3.34e-13	Chronic sinus infection;
LIHC	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.03	0.31	4.21e-9	Educational attainment;
LIHC	cis	rs1113500	0.814	rs1592282	chr1:108601365	T/C	cg06207961	chr1:108661230	NA	0.31	5.71	0.3	2.44e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs6782228	0.606	rs2811500	chr3:128366256	C/T	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.33	-8.47	-0.42	7.27e-16	Gut microbiome composition (winter);
LIHC	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.48	7.41	0.37	1.03e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg16736954	chr20:23401023	NAPB	0.52	5.84	0.3	1.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.96	-0.31	6.15e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14067834	chr17:29058358	SUZ12P	0.62	6.08	0.31	3.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.57	-7.91	-0.39	3.65e-14	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-6.3	-0.32	9.4e-10	Vitiligo;
LIHC	cis	rs600806	0.854	rs367586	chr1:109850122	C/A	cg16275483	chr1:110013120	SYPL2	-0.51	-6.22	-0.32	1.47e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-16.05	-0.66	1.27e-43	Height;
LIHC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.67	11.52	0.53	3.57e-26	Lymphocyte counts;
LIHC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.64	0.34	1.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.46	-0.37	7.12e-13	Body mass index;
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg16970926	chr12:29381810	FAR2	0.33	7.24	0.36	2.91e-12	QT interval;
LIHC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	cis	rs3820500	0.543	rs1146297	chr1:117910682	A/G	cg20383390	chr1:117909022	MAN1A2	-0.46	-5.97	-0.31	5.96e-9	Pneumonia;
LIHC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.63	11.33	0.52	1.7e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.72	13.74	0.6	1.62e-34	Mortality in heart failure;
LIHC	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg27205649	chr11:78285834	NARS2	0.39	6.15	0.32	2.14e-9	Alzheimer's disease (survival time);
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.73	0.47	6.32e-20	Corneal astigmatism;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15889976	chr12:124432796	CCDC92	-0.39	-6.52	-0.33	2.56e-10	Systolic blood pressure;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg00280220	chr17:61926910	NA	0.43	6.85	0.35	3.35e-11	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15688767	chr3:125093330	ZNF148	0.49	6.97	0.35	1.68e-11	Pancreatic cancer;
LIHC	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.7	-10.82	-0.51	1.14e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.32	-6.5	-0.33	2.91e-10	Testicular germ cell tumor;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17683632	chr2:210883371	RPE	-0.27	-6.29	-0.32	9.85e-10	Calcium levels;
LIHC	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.68	-6.54	-0.33	2.21e-10	Bipolar disorder;
LIHC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-9.45	-0.46	5.47e-19	Body mass index;
LIHC	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg20129853	chr10:51489980	NA	-0.42	-9.16	-0.44	4.9e-18	Prostate-specific antigen levels;
LIHC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.72	-10.93	-0.51	4.85e-24	Aortic root size;
LIHC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg02640540	chr1:67518911	SLC35D1	0.41	6.38	0.33	5.76e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9596863	0.898	rs9568901	chr13:54321748	A/C	ch.13.53330881F	chr13:54432880	NA	0.42	5.73	0.3	2.19e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.63	-9.52	-0.46	3.25e-19	Aortic root size;
LIHC	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.43	7.18	0.36	4.29e-12	Crohn's disease;
LIHC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.75	12.68	0.57	1.77e-30	Aortic root size;
LIHC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.57	8.92	0.43	2.94e-17	Uric acid clearance;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	9.04e-33	Prudent dietary pattern;
LIHC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg24069376	chr3:38537580	EXOG	0.38	6.87	0.35	3.12e-11	Electrocardiographic conduction measures;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.53	6.15	0.32	2.11e-9	Alzheimer's disease;
LIHC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-8.03	-0.4	1.56e-14	Cognitive function;
LIHC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg26149184	chr10:133730230	NA	0.47	7.49	0.38	5.75e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.45	-8.96	-0.44	2.12e-17	LDL cholesterol levels;
LIHC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg07424592	chr7:64974309	NA	-0.79	-9.51	-0.46	3.47e-19	Diabetic kidney disease;
LIHC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.79	10.09	0.48	4.12e-21	Body mass index;
LIHC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.5	-8.97	-0.44	1.93e-17	Longevity;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg07133347	chr1:107600762	PRMT6	0.43	6.34	0.32	7.27e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24023618	chr6:114292459	HDAC2	0.47	6.83	0.35	3.79e-11	Pancreatic cancer;
LIHC	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg22951263	chr5:87985283	NA	-0.39	-6.84	-0.35	3.67e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.07	-12.47	-0.56	1.15e-29	Vitiligo;
LIHC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.57	9.83	0.47	3.11e-20	Colorectal cancer;
LIHC	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.45	6.79	0.34	5.04e-11	Night sleep phenotypes;
LIHC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.57	10.99	0.51	2.93e-24	Coronary artery disease;
LIHC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.41	1.35e-15	Morning vs. evening chronotype;
LIHC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.58	-8.09	-0.4	1.05e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.56	-0.33	2e-10	Fear of minor pain;
LIHC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.56	9.36	0.45	1.12e-18	Mortality in heart failure;
LIHC	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.84	11.67	0.53	1.02e-26	Menopause (age at onset);
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg13271783	chr10:134563150	INPP5A	0.56	6.93	0.35	2.1e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.57	9.82	0.47	3.37e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg05868516	chr6:26286170	HIST1H4H	-0.38	-5.96	-0.31	6.29e-9	Educational attainment;
LIHC	cis	rs2274273	0.870	rs10145203	chr14:55784458	A/C	cg01864836	chr14:55583639	NA	-0.37	-6.61	-0.34	1.49e-10	Protein biomarker;
LIHC	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.49	8.58	0.42	3.26e-16	Narcolepsy;
LIHC	cis	rs7577696	0.512	rs212736	chr2:32473126	T/C	cg02381751	chr2:32503542	YIPF4	0.44	5.77	0.3	1.74e-8	Inflammatory biomarkers;
LIHC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03352830	chr11:487213	PTDSS2	0.79	6.36	0.33	6.32e-10	Body mass index;
LIHC	cis	rs1144333	0.655	rs76612182	chr1:76451889	C/T	cg10523679	chr1:76189770	ACADM	0.45	6.09	0.31	3.08e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.1	23.27	0.78	1.82e-72	Cortisol levels (saliva);
LIHC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.35	6.45	0.33	3.85e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.6	6.55	0.33	2.17e-10	Alzheimer's disease;
LIHC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.53	9.26	0.45	2.24e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.64	0.56	2.6e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.33	0.32	7.81e-10	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16828019	0.852	rs10489520	chr1:41511755	C/A	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.91e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.64	-0.74	4.81e-62	Height;
LIHC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg09911534	chr15:67153556	NA	0.44	6.8	0.35	4.62e-11	Lung cancer (smoking interaction);
LIHC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.54	-9.55	-0.46	2.62e-19	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.37	-6.32	-0.32	8.23e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.47	7.69	0.38	1.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.82	-9.1	-0.44	7.44e-18	Coronary artery disease;
LIHC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.59	-0.5	7.54e-23	Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg00280220	chr17:61926910	NA	0.44	7.06	0.36	9.25e-12	Prudent dietary pattern;
LIHC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-6.29	-0.32	9.47e-10	Subjective well-being;
LIHC	cis	rs17776563	1.000	rs11638818	chr15:89119711	C/T	cg05013243	chr15:89149849	MIR1179	0.44	7.28	0.37	2.28e-12	Thyroid hormone levels;
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04025307	chr7:1156635	C7orf50	0.53	6.92	0.35	2.22e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg00339695	chr16:24857497	SLC5A11	-0.32	-5.83	-0.3	1.31e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.63	6.92	0.35	2.19e-11	Homocysteine levels;
LIHC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.24	-7.29	-0.37	2.2e-12	Motion sickness;
LIHC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg12365402	chr11:9010492	NRIP3	-0.33	-8.46	-0.42	7.72e-16	Hemoglobin concentration;
LIHC	cis	rs1023500	0.956	rs1894713	chr22:42335621	G/A	cg04733989	chr22:42467013	NAGA	-0.51	-5.9	-0.3	8.82e-9	Schizophrenia;
LIHC	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.5	8.37	0.41	1.53e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg22676075	chr6:135203613	NA	0.38	6.29	0.32	9.78e-10	Red blood cell count;
LIHC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	0.95	9.27	0.45	2.13e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.47	8.58	0.42	3.27e-16	Testicular germ cell tumor;
LIHC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	7.74	0.39	1.12e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.67	10.06	0.48	4.99e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.27	-5.88	-0.3	9.96e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07305463	chr2:136567211	LCT	0.4	7.39	0.37	1.1e-12	Mosquito bite size;
LIHC	trans	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg07393940	chr7:158741817	NA	-0.55	-6.53	-0.33	2.35e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg00564555	chr16:1970112	NA	0.26	6.0	0.31	5.13e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg19318889	chr4:1322082	MAEA	0.49	6.77	0.34	5.73e-11	Obesity-related traits;
LIHC	cis	rs2422052	0.614	rs13004599	chr2:118647505	G/A	cg22545206	chr2:118617499	NA	0.36	6.08	0.31	3.25e-9	Mosquito bite size;
LIHC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.7	0.34	8.79e-11	Bladder cancer;
LIHC	trans	rs11689435	0.925	rs17807893	chr2:218351373	A/C	cg13544946	chr9:35729779	TLN1	-0.41	-6.1	-0.31	2.82e-9	Metabolite levels (MHPG);
LIHC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	0.93	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.41	6.44	0.33	4.14e-10	Menopause (age at onset);
LIHC	cis	rs4773330	0.925	rs7331226	chr13:111814205	A/G	cg26911804	chr13:111806221	ARHGEF7	0.61	6.02	0.31	4.54e-9	Bilirubin levels;
LIHC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.42	-0.37	9.63e-13	Psoriasis;
LIHC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.94	-0.35	1.97e-11	Vitiligo;
LIHC	trans	rs1474747	0.931	rs965358	chr1:159140349	A/T	cg00587465	chr19:45429910	APOC1P1	0.34	6.08	0.31	3.24e-9	Select biomarker traits;
LIHC	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg20636351	chr8:55087400	NA	-0.38	-7.73	-0.39	1.2e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg12560992	chr17:57184187	TRIM37	-0.71	-9.15	-0.44	5.07e-18	Vitamin D levels;
LIHC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.56	7.01	0.35	1.26e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.42	-6.47	-0.33	3.31e-10	Post bronchodilator FEV1;
LIHC	cis	rs2108622	0.727	rs12609900	chr19:15982414	G/A	cg13772218	chr19:15982569	NA	0.37	7.8	0.39	7.46e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.41	8.27	0.41	3.08e-15	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11388866	chr21:40752116	WRB	-0.43	-6.4	-0.33	5.18e-10	Pancreatic cancer;
LIHC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg20399509	chr21:47717575	C21orf57	-0.4	-6.13	-0.31	2.39e-9	Testicular germ cell tumor;
LIHC	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.49	7.49	0.38	5.74e-13	Adiposity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17139369	chr19:8478169	MARCH2	0.49	6.39	0.33	5.43e-10	Lung function (FEV1/FVC);
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	7.67	0.38	1.86e-13	Obesity-related traits;
LIHC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg01181863	chr3:195395398	SDHAP2	-0.9	-8.19	-0.4	5.32e-15	Pancreatic cancer;
LIHC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.73	0.39	1.21e-13	Lymphocyte counts;
LIHC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg09911534	chr15:67153556	NA	-0.46	-6.11	-0.31	2.7e-9	Lung cancer (smoking interaction);
LIHC	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	trans	rs983392	0.709	rs1820428	chr11:59986333	A/T	cg17275991	chr19:58003312	ZNF419	0.44	6.27	0.32	1.08e-9	Alzheimer's disease (late onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.45	6.59	0.34	1.63e-10	Pancreatic cancer;
LIHC	cis	rs7211079	0.719	rs2289535	chr17:78111449	A/C	cg09238746	chr17:78121135	EIF4A3	-0.5	-7.19	-0.36	4.21e-12	Myocardial infarction;
LIHC	trans	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg01134436	chr17:81009848	B3GNTL1	0.8	6.64	0.34	1.27e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.65	8.87	0.43	4.17e-17	Initial pursuit acceleration;
LIHC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg12903224	chr12:29470962	FAR2	0.4	6.61	0.34	1.5e-10	QT interval;
LIHC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.27	6.06	0.31	3.59e-9	Type 2 diabetes;
LIHC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.58	8.01	0.4	1.8e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.2	5.89	0.3	9.09e-9	Motion sickness;
LIHC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.75	0.47	5.42e-20	Mean platelet volume;
LIHC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21467203	chr3:49911342	NA	-0.58	-10.66	-0.5	4.16e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg04455712	chr21:45112962	RRP1B	0.4	6.58	0.34	1.73e-10	Mean corpuscular volume;
LIHC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg23485639	chr6:28045615	ZNF165	0.39	6.05	0.31	3.78e-9	Cardiac Troponin-T levels;
LIHC	cis	rs55702914	0.742	rs34555121	chr2:198166053	C/T	cg03934865	chr2:198174659	NA	0.4	5.73	0.3	2.16e-8	Major depression and alcohol dependence;
LIHC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.44	6.32	0.32	7.94e-10	Longevity;Endometriosis;
LIHC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	15.39	0.64	5.49e-41	IgG glycosylation;
LIHC	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.68	11.6	0.53	1.82e-26	Monocyte count;
LIHC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.7	6.85	0.35	3.35e-11	Vitiligo;
LIHC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.17	0.48	2.19e-21	Personality dimensions;
LIHC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg18306943	chr3:40428807	ENTPD3	-0.35	-6.16	-0.32	2.03e-9	Renal cell carcinoma;
LIHC	cis	rs11671005	0.696	rs73066211	chr19:58997079	C/T	cg25952890	chr19:58913133	NA	0.73	7.45	0.37	7.64e-13	Mean platelet volume;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05969148	chr19:51307846	C19orf48	-0.48	-6.2	-0.32	1.63e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.56	-8.43	-0.41	9.7e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs17854409	0.764	rs73613593	chr20:61471582	T/C	cg06598544	chr20:61472147	COL9A3	-0.91	-7.86	-0.39	4.97e-14	Obesity-related traits;
LIHC	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.25	0.32	1.25e-9	Lymphocyte counts;
LIHC	trans	rs259842	0.800	rs6725456	chr2:180718419	C/T	cg16168311	chr1:156561947	APOA1BP	0.41	6.49	0.33	2.99e-10	Blood protein levels;
LIHC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.87	-0.65	6.88e-43	Height;
LIHC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.82e-13	Bipolar disorder;
LIHC	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	12.11	0.55	2.48e-28	Eye color traits;
LIHC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	0.92	17.13	0.68	6.07e-48	Bone mineral density;
LIHC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.43	-7.56	-0.38	3.83e-13	Aortic root size;
LIHC	trans	rs7448169	1.000	rs7705200	chr5:99147531	C/G	cg11015893	chr7:135433540	FAM180A	0.25	6.11	0.31	2.72e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.4	7.33	0.37	1.66e-12	Glaucoma;
LIHC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.92	-0.3	7.9e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.14.1056569F	chr14:73577815	RBM25	-0.39	-6.47	-0.33	3.42e-10	Hepatitis;
LIHC	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04530015	chr2:215796436	ABCA12	0.41	6.53	0.33	2.32e-10	Neuroblastoma;
LIHC	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-7.99	-0.4	2.14e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.8	-0.35	4.54e-11	Vitiligo;
LIHC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	7.27	0.37	2.51e-12	Osteoporosis;
LIHC	cis	rs75064307	0.834	rs4855561	chr3:108116331	T/C	cg03329597	chr3:108125523	MYH15	0.5	6.63	0.34	1.32e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.45	0.42	8.3e-16	Menarche (age at onset);
LIHC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.58	11.21	0.52	4.79e-25	Type 2 diabetes;
LIHC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.77	12.27	0.55	6.06e-29	Corneal astigmatism;
LIHC	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg13444538	chr7:158905317	VIPR2	-0.31	-5.77	-0.3	1.74e-8	Facial morphology (factor 20);
LIHC	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00938859	chr5:1591904	SDHAP3	0.57	7.07	0.36	8.57e-12	Breast cancer;
LIHC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.43	-0.59	2.64e-33	Vitiligo;
LIHC	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg08539965	chr1:21396338	EIF4G3	0.32	5.72	0.3	2.27e-8	Superior frontal gyrus grey matter volume;
LIHC	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	0.55	7.22	0.36	3.49e-12	Opioid sensitivity;
LIHC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.35	6.46	0.33	3.65e-10	Aortic root size;
LIHC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	9.0	0.44	1.64e-17	Multiple sclerosis;
LIHC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.72	-13.95	-0.6	2.61e-35	Height;
LIHC	cis	rs72772090	1.000	rs72772095	chr5:96053853	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-6.76	-0.34	5.9e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.73	10.8	0.5	1.33e-23	Corneal astigmatism;
LIHC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg25039879	chr17:56429692	SUPT4H1	0.77	8.91	0.43	3e-17	Cognitive test performance;
LIHC	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Intracranial aneurysm;
LIHC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.94	0.35	1.95e-11	Morning vs. evening chronotype;
LIHC	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.6	-5.98	-0.31	5.59e-9	Carotid intima media thickness;
LIHC	cis	rs10792665	0.724	rs11233398	chr11:82691952	A/G	cg24227371	chr11:82718527	RAB30	-0.36	-8.68	-0.42	1.64e-16	Obesity-related traits;
LIHC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.81	0.54	3.25e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.38	-0.37	1.19e-12	Total body bone mineral density;
LIHC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-0.64	-7.41	-0.37	9.95e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.46	-7.36	-0.37	1.37e-12	Cognitive function;
LIHC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.78	-0.76	1.34e-66	Height;
LIHC	cis	rs7534824	0.625	rs7514731	chr1:101449675	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	7.69	0.38	1.54e-13	Refractive astigmatism;
LIHC	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg26138144	chr22:38071188	LGALS1	0.42	7.83	0.39	6.21e-14	Fat distribution (HIV);
LIHC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	8.88	0.43	3.86e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg03983715	chr16:68378420	PRMT7	-0.51	-6.03	-0.31	4.27e-9	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.92	0.47	1.54e-20	Platelet count;
LIHC	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg26138937	chr11:71823887	C11orf51	1.34	10.79	0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs8108269	1.000	rs7258890	chr19:46159609	T/C	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.47	-7.61	-0.38	2.71e-13	Mean corpuscular volume;
LIHC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg16586182	chr3:47516702	SCAP	-0.59	-11.48	-0.53	5.15e-26	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.6	0.56	3.6e-30	Alzheimer's disease;
LIHC	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.8	-10.87	-0.51	8.03e-24	Blood pressure (smoking interaction);
LIHC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.36	6.0	0.31	4.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17427986	chr1:154402922	IL6R	-0.42	-6.4	-0.33	5.01e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs7945718	0.870	rs3890064	chr11:12758766	C/A	cg25843174	chr11:12811716	TEAD1	0.33	7.39	0.37	1.12e-12	Educational attainment (years of education);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18115022	chr15:65822705	PTPLAD1	-0.54	-7.1	-0.36	7.41e-12	Systolic blood pressure;
LIHC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.83	-15.94	-0.65	3.68e-43	Height;
LIHC	cis	rs7937890	0.559	rs2034480	chr11:14466923	G/A	cg02886208	chr11:14281011	SPON1	-0.46	-6.46	-0.33	3.58e-10	Mitochondrial DNA levels;
LIHC	cis	rs12431939	1.000	rs4567626	chr14:51647640	A/T	cg23942311	chr14:51606299	NA	0.35	5.9	0.3	8.75e-9	Cancer;
LIHC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg12798992	chr6:167411361	FGFR1OP	0.5	7.61	0.38	2.69e-13	Crohn's disease;
LIHC	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg00129232	chr17:37814104	STARD3	-0.5	-9.21	-0.45	3.47e-18	Asthma;
LIHC	cis	rs34245846	0.704	rs11264278	chr1:154845534	G/C	cg03351412	chr1:154909251	PMVK	-0.58	-7.1	-0.36	7.47e-12	Atrial fibrillation;
LIHC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.6	10.38	0.49	4.14e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-1.01	-20.97	-0.75	2.29e-63	Height;
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg26338869	chr17:61819248	STRADA	0.52	6.91	0.35	2.33e-11	Height;
LIHC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg08888203	chr3:10149979	C3orf24	0.44	5.8	0.3	1.48e-8	Alzheimer's disease;
LIHC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.78	-0.3	1.64e-8	Life satisfaction;
LIHC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.4	6.17	0.32	1.94e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.89	-0.35	2.77e-11	Alcohol dependence;
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.62	-9.07	-0.44	9.26e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs55702914	1.000	rs55702914	chr2:198214396	C/G	cg10820045	chr2:198174542	NA	0.38	5.83	0.3	1.31e-8	Major depression and alcohol dependence;
LIHC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg03859395	chr2:55845619	SMEK2	-0.48	-7.69	-0.38	1.56e-13	Metabolic syndrome;
LIHC	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.4	-7.28	-0.37	2.27e-12	Hepatocellular carcinoma;
LIHC	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.66	11.27	0.52	2.97e-25	Diisocyanate-induced asthma;
LIHC	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.51	-0.38	5.11e-13	Mean platelet volume;
LIHC	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg24344662	chr13:114018021	GRTP1	-0.44	-6.59	-0.34	1.65e-10	Mean platelet volume;
LIHC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.39	5.86	0.3	1.08e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-7.73	-0.39	1.22e-13	Gut microbiome composition (summer);
LIHC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17554472	chr22:41940697	POLR3H	0.53	5.81	0.3	1.44e-8	Vitiligo;
LIHC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.79	9.1	0.44	7.43e-18	Vitiligo;
LIHC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.67	9.79	0.47	4.03e-20	Schizophrenia;
LIHC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.66	0.42	1.89e-16	Motion sickness;
LIHC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.56	-9.5	-0.46	3.79e-19	Blood metabolite levels;
LIHC	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.25	0.37	2.71e-12	Cervical cancer;
LIHC	cis	rs6466055	0.669	rs10953468	chr7:104741842	A/T	cg04380332	chr7:105027541	SRPK2	-0.34	-6.32	-0.32	8.37e-10	Schizophrenia;
LIHC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21467203	chr3:49911342	NA	0.37	6.44	0.33	4.06e-10	Menarche (age at onset);
LIHC	cis	rs2932538	0.583	rs2932537	chr1:113230394	C/T	cg22162597	chr1:113214053	CAPZA1	0.64	7.97	0.4	2.34e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.77	-9.45	-0.46	5.46e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.23	-0.45	2.99e-18	Type 2 diabetes;
LIHC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg07061783	chr6:25882402	NA	0.47	6.63	0.34	1.34e-10	Blood metabolite levels;
LIHC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.38	-6.51	-0.33	2.65e-10	Facial morphology (factor 20);
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg16970926	chr12:29381810	FAR2	-0.3	-6.38	-0.33	5.78e-10	QT interval;
LIHC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	0.96	17.25	0.68	2.07e-48	IgG glycosylation;
LIHC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.8	18.18	0.7	3.59e-52	Urate levels in lean individuals;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26446827	chr20:18268978	ZNF133	-0.49	-6.19	-0.32	1.73e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7487075	0.619	rs9669404	chr12:46798963	A/G	cg23829395	chr12:46796953	NA	-0.35	-6.25	-0.32	1.25e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.64e-16	Motion sickness;
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-8.07	-0.4	1.24e-14	Lymphocyte counts;
LIHC	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg25251204	chr11:14927456	NA	0.42	6.03	0.31	4.32e-9	Vitamin D levels;
LIHC	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg22777020	chr22:31556080	RNF185	-0.52	-5.84	-0.3	1.21e-8	Paclitaxel-induced neuropathy;
LIHC	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.45	5.98	0.31	5.5e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.66	10.51	0.49	1.4e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.46	8.72	0.43	1.24e-16	Atrioventricular conduction;
LIHC	cis	rs8064024	0.582	rs2660241	chr16:4940023	T/C	cg08329684	chr16:4932620	PPL	0.34	5.88	0.3	1e-8	Cancer;
LIHC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.08e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.75	8.37	0.41	1.53e-15	Initial pursuit acceleration;
LIHC	cis	rs243505	0.691	rs243480	chr7:148452905	G/T	cg09806900	chr7:148480153	CUL1	-0.43	-6.09	-0.31	3.01e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.67	-8.08	-0.4	1.14e-14	Mean platelet volume;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.87	0.78	6.99e-71	Height;
LIHC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.58	6.98	0.35	1.56e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg12698662	chr3:15914712	MIR563	-0.39	-7.16	-0.36	5.03e-12	Mean platelet volume;
LIHC	cis	rs75920871	0.557	rs7123336	chr11:116782819	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-5.93	-0.31	7.23e-9	Subjective well-being;
LIHC	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg00564555	chr16:1970112	NA	0.27	6.29	0.32	9.59e-10	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	8.03	0.4	1.57e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg14146966	chr2:61757674	XPO1	0.48	8.28	0.41	2.73e-15	Tuberculosis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02951695	chr10:134400351	INPP5A	0.47	6.16	0.32	2.04e-9	Hepatitis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11933116	chr6:139349681	C6orf115	0.37	6.43	0.33	4.2e-10	Cognitive function;
LIHC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.76	13.98	0.6	1.96e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.58	9.25	0.45	2.47e-18	Corneal astigmatism;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.7	0.38	1.51e-13	Height;
LIHC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.69	-8.98	-0.44	1.9e-17	Asthma;
LIHC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.27	-0.37	2.5e-12	Total body bone mineral density;
LIHC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.25	-0.32	1.22e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.5	-7.16	-0.36	4.84e-12	Metabolic syndrome;
LIHC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.7	11.65	0.53	1.22e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08377569	chr16:30538014	ZNF768	0.45	6.52	0.33	2.46e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs9473924	0.505	rs4111288	chr6:50908094	G/A	cg14470998	chr6:50812995	TFAP2B	0.91	10.51	0.49	1.39e-22	Body mass index;
LIHC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.65	-7.66	-0.38	1.99e-13	Vitiligo;
LIHC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.36	5.93	0.31	7.39e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.19	-5.92	-0.3	7.95e-9	Cutaneous nevi;
LIHC	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	trans	rs7226229	0.950	rs2291037	chr17:20924523	C/T	ch.21.43742285F	chr21:44917857	NA	-0.41	-6.06	-0.31	3.69e-9	Blood trace element (Se levels);
LIHC	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.42	-6.9	-0.35	2.45e-11	Schizophrenia;
LIHC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg05714579	chr10:131428358	MGMT	0.41	6.62	0.34	1.42e-10	Response to temozolomide;
LIHC	cis	rs8081395	0.576	rs1292032	chr17:57992343	A/C	cg13753209	chr17:57696993	CLTC	0.38	5.9	0.3	8.64e-9	White blood cell count;
LIHC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-5.89	-0.3	9.41e-9	Cognitive function;
LIHC	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.14	0.48	2.63e-21	Fibroblast growth factor basic levels;
LIHC	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.5	9.27	0.45	2.17e-18	Leprosy;
LIHC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.55	6.11	0.31	2.76e-9	Vitiligo;
LIHC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.26	-16.63	-0.67	6.04e-46	Diabetic kidney disease;
LIHC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg21724239	chr8:58056113	NA	0.49	6.38	0.33	5.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.55	9.94	0.47	1.24e-20	Platelet distribution width;
LIHC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.81	12.96	0.57	1.6e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.74	14.57	0.62	9.4e-38	Mortality in heart failure;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07466437	chr6:8086756	EEF1E1;SCARNA27	0.4	6.41	0.33	4.86e-10	Longevity;
LIHC	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg14146966	chr2:61757674	XPO1	0.49	8.82	0.43	5.82e-17	Tuberculosis;
LIHC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.5	5.75	0.3	1.96e-8	Alzheimer's disease;
LIHC	cis	rs2635047	0.699	rs2247578	chr18:44745056	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.87	0.3	1.01e-8	Educational attainment;
LIHC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg18912006	chr12:123335444	HIP1R	-0.64	-7.68	-0.38	1.69e-13	Schizophrenia;
LIHC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.24	0.32	1.32e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.04	0.51	1.86e-24	Coronary artery disease;
LIHC	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.41	-6.89	-0.35	2.69e-11	Squamous cell lung carcinoma;
LIHC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg18944383	chr4:111397179	ENPEP	0.31	7.27	0.37	2.46e-12	Coronary artery disease;
LIHC	cis	rs67981189	0.555	rs11623266	chr14:71365940	A/T	cg15816911	chr14:71606274	NA	-0.42	-6.72	-0.34	7.84e-11	Schizophrenia;
LIHC	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs8014671	0.553	rs34866539	chr14:70873763	T/C	cg25576086	chr14:70833871	SYNJ2BP	-0.45	-7.09	-0.36	7.65e-12	Prostate cancer;
LIHC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.98	-0.4	2.21e-14	Total body bone mineral density;
LIHC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.36	-0.64	7.28e-41	Headache;
LIHC	trans	rs6058796	0.901	rs6087966	chr20:31255035	C/G	cg02600331	chr11:130417168	NA	0.35	7.6	0.38	2.82e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.28	0.41	2.76e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12744310	0.887	rs12757611	chr1:41808972	C/T	cg03387723	chr1:41708464	SCMH1	-0.33	-6.06	-0.31	3.66e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg01596870	chr19:55963115	NA	-0.63	-7.51	-0.38	5.05e-13	Obesity-related traits;
LIHC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.12	-0.55	2.19e-28	Colorectal cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg13551243	chr8:146052742	ZNF7	-0.41	-6.26	-0.32	1.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs365132	0.905	rs353463	chr5:176403170	A/C	cg16309518	chr5:176445507	NA	-0.53	-10.06	-0.48	5.09e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.48	6.51	0.33	2.66e-10	Blood metabolite levels;
LIHC	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.66	0.5	4.09e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.42	6.03	0.31	4.36e-9	Breast cancer;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg15382696	chr6:118971807	C6orf204	0.62	6.45	0.33	3.75e-10	Diastolic blood pressure;
LIHC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.47	7.85	0.39	5.34e-14	Mean corpuscular volume;
LIHC	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.57	9.86	0.47	2.31e-20	Dupuytren's disease;
LIHC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.52	0.53	3.63e-26	Alzheimer's disease;
LIHC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.48	-0.37	6.33e-13	Schizophrenia;
LIHC	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.81	-0.39	7.3e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg10820045	chr2:198174542	NA	0.43	6.55	0.33	2.16e-10	Intracranial aneurysm;
LIHC	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.86	-0.35	3.19e-11	Schizophrenia;
LIHC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.86	0.51	8.19e-24	Personality dimensions;
LIHC	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.7	6.12	0.31	2.55e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11792649	chr11:68664631	MRPL21	0.43	6.55	0.33	2.14e-10	Bilirubin levels;
LIHC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.1	10.25	0.48	1.15e-21	Diabetic retinopathy;
LIHC	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.34	-0.32	7.38e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.55	7.48	0.38	6.21e-13	Bone properties (heel);
LIHC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg22079354	chr11:130786696	SNX19	0.42	6.11	0.31	2.78e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.41	6.66	0.34	1.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2412488	0.850	rs6828559	chr4:54235363	A/C	cg22241045	chr4:54363911	LNX1	-0.37	-5.93	-0.31	7.4e-9	DNA methylation (variation);
LIHC	cis	rs16944613	0.510	rs17180057	chr15:91155834	G/A	cg26821196	chr15:91095069	CRTC3	0.35	6.23	0.32	1.34e-9	Colorectal cancer;
LIHC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.64	7.34	0.37	1.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.62	10.53	0.49	1.21e-22	HDL cholesterol;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27247225	chr6:26970382	C6orf41	0.47	6.31	0.32	8.42e-10	Hepatitis;
LIHC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.12	-0.31	2.57e-9	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.27	16.79	0.67	1.38e-46	Diabetic kidney disease;
LIHC	cis	rs4700695	0.841	rs251294	chr5:65261848	A/G	cg21114390	chr5:65439923	SFRS12	0.44	5.75	0.3	1.94e-8	Facial morphology (factor 19);
LIHC	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg10820045	chr2:198174542	NA	0.46	6.92	0.35	2.24e-11	Dermatomyositis;
LIHC	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	15.73	0.65	2.44e-42	Lung cancer in ever smokers;
LIHC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.75	-0.3	1.93e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-18.14	-0.7	5.44e-52	Schizophrenia;
LIHC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.94	15.33	0.64	9.51e-41	Metabolic syndrome;
LIHC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05735659	chr12:48099394	RPAP3	-0.4	-6.33	-0.32	7.64e-10	Calcium levels;
LIHC	cis	rs1144333	1.000	rs17097841	chr1:76462641	T/A	cg03433033	chr1:76189801	ACADM	0.51	7.48	0.38	6.2800000000000005e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.8	-12.4	-0.56	2.06e-29	Obesity-related traits;
LIHC	trans	rs7874142	0.616	rs4072883	chr9:137686906	C/T	cg18109838	chr5:88185987	MEF2C	-0.36	-7.14	-0.36	5.56e-12	Longevity;
LIHC	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.47	6.35	0.32	6.75e-10	Blood metabolite levels;
LIHC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.24	0.55	7.96e-29	Mean platelet volume;
LIHC	cis	rs2637030	0.559	rs256087	chr5:52895233	G/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.01	0.51	2.5e-24	Personality dimensions;
LIHC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.87	0.3	1e-8	Bipolar disorder;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg12538369	chr19:40932019	SERTAD1	0.37	6.04	0.31	4.12e-9	Alopecia areata;
LIHC	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.54	9.56	0.46	2.32e-19	Systemic lupus erythematosus;
LIHC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-7.14	-0.36	5.69e-12	Alzheimer's disease (late onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09997638	chr19:17530742	FAM125A	-0.47	-7.02	-0.35	1.22e-11	Cognitive function;
LIHC	trans	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg06832677	chr2:119976764	NA	0.56	6.18	0.32	1.8e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.65	9.29	0.45	1.82e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg21395723	chr22:39101663	GTPBP1	-0.42	-7.3	-0.37	2.03e-12	Menopause (age at onset);
LIHC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.47	-7.7	-0.38	1.49e-13	Alzheimer's disease (late onset);
LIHC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.09	12.91	0.57	2.49e-31	Vitiligo;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.8	12.76	0.57	8.91e-31	Longevity;
LIHC	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.62	11.08	0.51	1.43e-24	Breast cancer;
LIHC	cis	rs72843506	0.656	rs78408002	chr17:19985914	A/G	cg12065943	chr17:19881925	AKAP10	-0.33	-5.76	-0.3	1.9e-8	Schizophrenia;
LIHC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.73	-10.69	-0.5	3.32e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.06e-25	Corneal astigmatism;
LIHC	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.64	11.08	0.51	1.44e-24	Diisocyanate-induced asthma;
LIHC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.52	-8.48	-0.42	7.01e-16	Cognitive function;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg20607798	chr8:58055168	NA	0.62	7.87	0.39	4.63e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.54	-0.38	4.36e-13	Platelet count;
LIHC	trans	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-7.66	-0.38	1.93e-13	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.31	6.43	0.33	4.17e-10	QRS complex (12-leadsum);
LIHC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg02640540	chr1:67518911	SLC35D1	0.44	6.06	0.31	3.5e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.24	-0.32	1.27e-9	Total body bone mineral density;
LIHC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg11212589	chr17:38028394	ZPBP2	0.32	6.44	0.33	4.06e-10	Self-reported allergy;
LIHC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.51	0.62	1.6e-37	Prudent dietary pattern;
LIHC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.42	6.48	0.33	3.25e-10	Height;
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.62	6.93	0.35	2.15e-11	Alzheimer's disease;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.52	-0.42	5.08e-16	Obesity-related traits;
LIHC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.15	-0.58	3.05e-32	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00699235	chr12:49962218	MCRS1	0.45	6.92	0.35	2.27e-11	Cognitive function;
LIHC	cis	rs8017423	0.967	rs61989980	chr14:90727635	C/T	cg14092571	chr14:90743983	NA	-0.38	-6.02	-0.31	4.54e-9	Mortality in heart failure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg22487209	chr8:27950625	ELP3	-0.57	-6.39	-0.33	5.31e-10	Systolic blood pressure;
LIHC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg20607798	chr8:58055168	NA	0.64	8.2	0.41	4.94e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.62	-10.53	-0.49	1.17e-22	Alcohol dependence;
LIHC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.62	0.53	1.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17106184	1.000	rs72902755	chr1:51250908	G/T	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.18e-10	Type 2 diabetes;
LIHC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg15123519	chr2:136567270	LCT	0.45	9.22	0.45	3.04e-18	Mosquito bite size;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.76	0.43	9.47e-17	Prudent dietary pattern;
LIHC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg17279839	chr7:150038598	RARRES2	0.51	10.68	0.5	3.68e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	6.97e-29	Eye color traits;
LIHC	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.64	-8.18	-0.4	5.76e-15	Corneal structure;
LIHC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.36	7.03	0.36	1.1e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	6.88	0.35	2.93e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LIHC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg06289844	chr6:126071538	HEY2	0.38	6.64	0.34	1.24e-10	Brugada syndrome;
LIHC	cis	rs7551222	0.681	rs10900595	chr1:204511602	C/A	cg20240347	chr1:204465584	NA	-0.37	-7.85	-0.39	5.51e-14	Schizophrenia;
LIHC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.38	5.87	0.3	1.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.36	-0.64	7.55e-41	Chronic sinus infection;
LIHC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.73	-9.71	-0.46	7.43e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg16479474	chr6:28041457	NA	0.38	6.32	0.32	8.32e-10	Parkinson's disease;
LIHC	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.01	-0.4	1.79e-14	Vitamin D levels;
LIHC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg13047869	chr3:10149882	C3orf24	0.5	6.07	0.31	3.46e-9	Alzheimer's disease;
LIHC	cis	rs2997447	0.846	rs3008430	chr1:26390328	A/G	cg19633962	chr1:26362018	EXTL1	-0.58	-6.53	-0.33	2.43e-10	QRS complex (12-leadsum);
LIHC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	13.24	0.58	1.39e-32	Psoriasis;
LIHC	cis	rs258324	0.790	rs2162944	chr16:89717670	G/C	cg04240660	chr16:89714849	CHMP1A	-0.57	-7.28	-0.37	2.29e-12	Height;
LIHC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.45	-6.58	-0.34	1.8e-10	P wave terminal force;
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg14004847	chr7:1930337	MAD1L1	0.42	5.92	0.31	7.66e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs2710642	0.611	rs1534418	chr2:62883920	A/G	cg17519650	chr2:63277830	OTX1	-0.5	-7.39	-0.37	1.11e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.75	15.06	0.63	1.09e-39	Menopause (age at onset);
LIHC	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	6.97e-29	Eye color traits;
LIHC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.11	0.4	9.27e-15	Alzheimer's disease;
LIHC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-10.63	-0.5	5.34e-23	Body mass index (adult);
LIHC	cis	rs611744	0.967	rs627019	chr8:109222544	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-6.53	-0.33	2.43e-10	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.54	0.8	2.06e-77	Prudent dietary pattern;
LIHC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs918629	0.679	rs3822750	chr5:95276260	C/A	cg10483112	chr5:95245456	ELL2	-0.35	-5.91	-0.3	8.46e-9	IgG glycosylation;
LIHC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.83	13.82	0.6	8.14e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.44	6.56	0.33	1.97e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg18887096	chr2:219472410	PLCD4	0.38	6.88	0.35	2.79e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.19	0.36	4.05e-12	Schizophrenia;
LIHC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg16102536	chr7:156981717	UBE3C	-0.36	-6.11	-0.31	2.77e-9	Body mass index;
LIHC	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04709771	chr16:646395	RAB40C	0.43	7.97	0.4	2.39e-14	Height;
LIHC	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.35	3.39e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs807029	0.533	rs67692077	chr10:102740271	T/C	cg17130504	chr10:102756923	LZTS2	0.56	7.77	0.39	9.27e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg17135325	chr3:160939158	NMD3	0.55	7.62	0.38	2.55e-13	Parkinson's disease;
LIHC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg16102536	chr7:156981717	UBE3C	0.36	6.07	0.31	3.34e-9	Body mass index;
LIHC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.03	0.36	1.16e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.52	-7.98	-0.4	2.26e-14	Systemic lupus erythematosus;
LIHC	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.33	-0.41	1.94e-15	Exhaled nitric oxide output;
LIHC	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg03934865	chr2:198174659	NA	0.45	6.32	0.32	8.2e-10	Dermatomyositis;
LIHC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.06	-0.31	3.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12986413	1.000	rs12459350	chr19:2176586	A/G	cg09261902	chr19:2140048	AP3D1	0.39	6.67	0.34	1.01e-10	Height;
LIHC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.56	8.27	0.41	3.08e-15	Bone properties (heel);
LIHC	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.44	-6.0	-0.31	5.08e-9	Obesity-related traits;
LIHC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.45	6.96	0.35	1.73e-11	Heart rate;
LIHC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.7	-8.98	-0.44	1.91e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg10756647	chr7:56101905	PSPH	0.62	8.5	0.42	6.09e-16	Corneal structure;
LIHC	cis	rs11031096	0.655	rs1822289	chr11:4212184	T/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.91	-0.3	8.4e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.5	7.28	0.37	2.36e-12	Obesity-related traits;
LIHC	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg27205649	chr11:78285834	NARS2	0.45	6.72	0.34	7.79e-11	Alzheimer's disease (survival time);
LIHC	cis	rs4920343	0.698	rs591009	chr1:19086869	A/G	cg26220594	chr1:19110978	NA	0.28	5.72	0.3	2.38e-8	Knee osteoarthritis;
LIHC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	6.17	0.32	1.91e-9	Resting heart rate;
LIHC	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.32	-6.34	-0.32	7.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	cis	rs4908760	0.827	rs10864362	chr1:8732454	A/C	cg20416874	chr1:8611966	RERE	-0.66	-13.5	-0.59	1.4e-33	Vitiligo;
LIHC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg12310025	chr6:25882481	NA	-0.42	-6.32	-0.32	8.09e-10	Height;
LIHC	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.48	7.4	0.37	1.05e-12	Longevity;Endometriosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12447188	chr16:4743522	NUDT16L1	-0.5	-6.7	-0.34	8.6e-11	Pancreatic cancer;
LIHC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.51	9.36	0.45	1.07e-18	Temperament;
LIHC	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.29	-6.43	-0.33	4.31e-10	DNA methylation (variation);
LIHC	cis	rs9625935	0.518	rs5752972	chr22:30250312	A/T	cg01021169	chr22:30184971	ASCC2	0.34	5.92	0.31	7.71e-9	Tonsillectomy;
LIHC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21293397	chr19:35454992	ZNF792	0.49	6.51	0.33	2.6200000000000003e-10	Hepatitis;
LIHC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-1.01	-13.22	-0.58	1.64e-32	Intelligence (multi-trait analysis);
LIHC	cis	rs937213	0.573	rs12592831	chr15:40302441	G/A	cg01081584	chr15:40268610	EIF2AK4	-0.36	-6.05	-0.31	3.75e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.75	-0.43	1.02e-16	Gut microbiome composition (summer);
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.34	0.32	7.29e-10	Prudent dietary pattern;
LIHC	cis	rs3736485	0.966	rs4775965	chr15:51908251	A/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.97	-0.35	1.64e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.11	-0.31	2.64e-9	Bipolar disorder;
LIHC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg10374813	chr17:38183790	MED24;SNORD124	-0.32	-5.84	-0.3	1.22e-8	White blood cell count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19552494	chr11:60674271	PRPF19	0.5	7.22	0.36	3.38e-12	Pancreatic cancer;
LIHC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.45	6.09	0.31	2.96e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg27478167	chr7:817139	HEATR2	-0.51	-6.82	-0.35	4.1e-11	Cerebrospinal P-tau181p levels;
LIHC	trans	rs8056893	0.610	rs3803650	chr16:68344696	C/T	cg18587063	chr11:122940457	NA	0.37	6.67	0.34	1.02e-10	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.72	-10.09	-0.48	3.9e-21	Colorectal cancer;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	6.74	0.34	6.8e-11	Obesity-related traits;
LIHC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.56	9.03	0.44	1.25e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg03264133	chr6:25882463	NA	-0.38	-5.74	-0.3	2.14e-8	Height;
LIHC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs12915845	0.584	rs7403482	chr15:89062709	A/T	cg05013243	chr15:89149849	MIR1179	-0.39	-7.1	-0.36	7.47e-12	Menarche (age at onset);
LIHC	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg24148817	chr6:37461033	C6orf129	-0.37	-5.71	-0.3	2.44e-8	Cognitive performance;
LIHC	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-7.74	-0.39	1.15e-13	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg24209194	chr3:40518798	ZNF619	0.56	8.12	0.4	8.41e-15	Renal cell carcinoma;
LIHC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-6.0	-0.31	4.89e-9	Schizophrenia;
LIHC	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.47	7.32	0.37	1.81e-12	Menopause (age at onset);
LIHC	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.83	-0.3	1.29e-8	Prostate cancer;
LIHC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg14593290	chr7:50529359	DDC	-0.5	-8.41	-0.41	1.16e-15	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.53	8.6	0.42	2.93e-16	Prudent dietary pattern;
LIHC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.65	11.6	0.53	1.83e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-16.49	-0.67	2.23e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00612595	chr21:47717864	NA	-0.42	-6.61	-0.34	1.49e-10	Testicular germ cell tumor;
LIHC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	8.37	0.41	1.5e-15	Type 2 diabetes;
LIHC	cis	rs7116495	0.737	rs634829	chr11:71555128	G/A	cg26138937	chr11:71823887	C11orf51	0.64	5.93	0.31	7.44e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.41	7.55	0.38	4.1e-13	Schizophrenia;
LIHC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	7.49	0.38	5.94e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.27	13.03	0.58	8.96e-32	Eosinophil percentage of granulocytes;
LIHC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.88	16.66	0.67	4.72e-46	Blood protein levels;
LIHC	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.57	-14.06	-0.61	9.04e-36	White blood cell count (basophil);
LIHC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.77	0.47	4.85e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg06664874	chr5:179499304	RNF130	-0.58	-7.12	-0.36	6.37e-12	LDL cholesterol;
LIHC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.17e-9	Height;
LIHC	cis	rs11229555	0.645	rs12269928	chr11:58184358	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.64	0.34	1.24e-10	Dupuytren's disease;
LIHC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.71	-0.5	2.78e-23	Primary sclerosing cholangitis;
LIHC	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.35	6.77	0.34	5.68e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg27432699	chr2:27873401	GPN1	-0.5	-7.14	-0.36	5.69e-12	Total body bone mineral density;
LIHC	cis	rs11688816	1.000	rs11688816	chr2:63053048	G/A	cg17519650	chr2:63277830	OTX1	-0.5	-7.61	-0.38	2.63e-13	Body mass index;
LIHC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg14067834	chr17:29058358	SUZ12P	0.69	6.82	0.35	4.05e-11	Body mass index;
LIHC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.07	16.08	0.66	1.01e-43	Cognitive function;
LIHC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.52	-9.0	-0.44	1.56e-17	White blood cell count;
LIHC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.92	0.51	5.28e-24	Heart rate;
LIHC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg10360323	chr17:41437877	NA	0.4	6.05	0.31	3.83e-9	Menopause (age at onset);
LIHC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.87	0.3	1.01e-8	Self-reported allergy;
LIHC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.47	5.95	0.31	6.6e-9	Obesity (extreme);
LIHC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg05343316	chr1:45956843	TESK2	0.42	6.16	0.32	2.04e-9	High light scatter reticulocyte count;
LIHC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg20417195	chr1:21767127	NBPF3	0.38	5.91	0.3	8.49e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs77637988	0.631	rs7587385	chr2:48600691	T/G	cg00032884	chr2:48540671	FOXN2	0.41	6.43	0.33	4.38e-10	Joint mobility (Beighton score);
LIHC	cis	rs600806	0.742	rs12753439	chr1:110015519	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.55	-7.04	-0.36	1.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-6.06	-0.31	3.56e-9	IgG glycosylation;
LIHC	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.35	-6.06	-0.31	3.69e-9	Menopause (age at onset);
LIHC	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00149659	chr3:10157352	C3orf10	0.52	5.79	0.3	1.56e-8	Alzheimer's disease;
LIHC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	12.25	0.55	7.7e-29	Colorectal cancer;
LIHC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.31	0.37	1.91e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.67	-0.53	1.02e-26	Total cholesterol levels;
LIHC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.59	-11.23	-0.52	4.11e-25	Body mass index;
LIHC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.54	8.88	0.43	3.98e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05741837	chr8:27632005	ESCO2	-0.54	-6.25	-0.32	1.22e-9	Systolic blood pressure;
LIHC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg16070018	chr6:26224392	HIST1H3E	0.55	6.52	0.33	2.6e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs9427116	0.702	rs9427108	chr1:154607914	G/A	cg17218026	chr1:154582156	ADAR	0.34	6.51	0.33	2.65e-10	Blood protein levels;
LIHC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.86	0.43	4.46e-17	Cognitive test performance;
LIHC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-6.52	-0.33	2.6e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg01843034	chr6:37503916	NA	-0.48	-8.26	-0.41	3.26e-15	Cognitive performance;
LIHC	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg00228799	chr9:131580591	ENDOG	0.47	7.1	0.36	7.14e-12	Blood metabolite levels;
LIHC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.82e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	7.89	0.39	4.18e-14	Lymphocyte counts;
LIHC	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	cis	rs11958404	0.789	rs72800604	chr5:157502940	C/T	cg05962755	chr5:157440814	NA	1.02	11.77	0.54	4.45e-27	IgG glycosylation;
LIHC	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg04837898	chr3:45731254	SACM1L	0.35	5.72	0.3	2.28e-8	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	16.72	0.67	2.64e-46	Lung cancer in ever smokers;
LIHC	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14154082	chr13:112174009	NA	0.29	6.09	0.31	3.03e-9	Menarche (age at onset);
LIHC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	0.58	11.18	0.52	6.04e-25	Fat distribution (HIV);
LIHC	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg08992911	chr2:238395768	MLPH	0.55	6.42	0.33	4.5e-10	Prostate cancer;
LIHC	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.54	-8.41	-0.41	1.16e-15	Extraversion;
LIHC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.59	-9.72	-0.47	7.04e-20	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs9993613	0.935	rs17775434	chr4:73525567	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.39	-5.87	-0.3	1.05e-8	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.71	0.34	8.15e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.4	-0.71	4.84e-53	Height;
LIHC	cis	rs4684776	0.935	rs3816380	chr3:11381973	A/C	cg00170343	chr3:11313890	ATG7	-0.49	-6.61	-0.34	1.45e-10	Small vessel stroke;
LIHC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg08890338	chr13:113700818	MCF2L	-0.36	-5.89	-0.3	9.01e-9	Systolic blood pressure;
LIHC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg03959625	chr15:84868606	LOC388152	0.47	6.62	0.34	1.38e-10	Schizophrenia;
LIHC	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg01843034	chr6:37503916	NA	-0.51	-8.23	-0.41	4.1e-15	Cognitive performance;
LIHC	cis	rs74233809	1.000	rs11191582	chr10:104913653	G/A	cg03493300	chr10:104813866	CNNM2	0.47	5.88	0.3	9.74e-9	Birth weight;
LIHC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.55	8.75	0.43	9.62e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-9.44	-0.45	6.11e-19	Alzheimer's disease;
LIHC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.65	-6.6	-0.34	1.57e-10	Vitiligo;
LIHC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.57	9.74	0.47	5.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.71e-15	Body mass index;
LIHC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.13	0.31	2.4e-9	Alzheimer's disease;
LIHC	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.68	12.02	0.55	5.23e-28	Obesity-related traits;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.63	9.19	0.44	4.03e-18	Menarche (age at onset);
LIHC	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7523273	0.565	rs11118451	chr1:207887493	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	7.91	0.39	3.54e-14	Schizophrenia;
LIHC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	trans	rs6693295	0.793	rs2788016	chr1:246244622	A/T	cg13514129	chr1:39547527	MACF1	0.4	6.09	0.31	3.02e-9	Migraine - clinic-based;Migraine with aura;
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.62	8.7	0.43	1.37e-16	Skin colour saturation;
LIHC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.39	-0.33	5.58e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.39	6.29	0.32	9.51e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.55	-10.17	-0.48	2.04e-21	Coronary artery disease;
LIHC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11164142	chr4:141565589	TBC1D9	0.51	6.99	0.35	1.45e-11	Pancreatic cancer;
LIHC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.67	-9.33	-0.45	1.34e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs3780378	0.967	rs7023146	chr9:5040163	G/A	cg02405213	chr9:5042618	JAK2	-0.56	-9.87	-0.47	2.27e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs11822910	0.911	rs2250887	chr11:57202184	G/A	cg00522883	chr11:57194120	SLC43A3	0.68	9.01	0.44	1.48e-17	Platelet distribution width;
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg17372223	chr3:52568218	NT5DC2	0.37	5.71	0.3	2.41e-8	Bipolar disorder;
LIHC	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg08824895	chr13:115047677	UPF3A	0.51	7.36	0.37	1.38e-12	Schizophrenia;
LIHC	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.57	-11.2	-0.52	5.17e-25	Schizophrenia;
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.96	-0.31	6.12e-9	Total body bone mineral density;
LIHC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.44	6.16	0.32	2.02e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3736485	0.868	rs8034197	chr15:51922506	C/G	cg08986416	chr15:51914746	DMXL2	-0.42	-5.9	-0.3	8.86e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.69	-10.7	-0.5	3.08e-23	Urate levels in obese individuals;
LIHC	cis	rs243505	0.660	rs7785022	chr7:148533384	C/T	cg09806900	chr7:148480153	CUL1	0.42	6.03	0.31	4.26e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.72	-10.95	-0.51	3.88e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.56	8.38	0.41	1.42e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.28	22.06	0.77	1.09e-67	Corneal structure;
LIHC	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg27205649	chr11:78285834	NARS2	0.39	5.95	0.31	6.6e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.73	-0.5	2.32e-23	Inflammatory bowel disease;
LIHC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg14222432	chr12:29376421	FAR2	0.34	6.28	0.32	1.03e-9	QT interval;
LIHC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.31	6.49	0.33	2.97e-10	Blood metabolite levels;
LIHC	cis	rs611744	0.967	rs684904	chr8:109199417	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.95	14.44	0.62	3.05e-37	Skin colour saturation;
LIHC	cis	rs10916814	0.704	rs4655221	chr1:20899265	C/A	cg24502330	chr1:20914028	CDA	-0.3	-6.7	-0.34	8.63e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	14.01	0.6	1.51e-35	Multiple sclerosis;
LIHC	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.32	0.72	9.13e-57	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.12	-0.48	3.16e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.54	7.87	0.39	4.87e-14	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.38	6.38	0.33	5.86e-10	Lewy body disease;
LIHC	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.57	-7.83	-0.39	6.27e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.61	-0.59	5.27e-34	Coffee consumption (cups per day);
LIHC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.92	16.97	0.68	2.79e-47	Coronary artery disease;
LIHC	trans	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17183009	chr3:120277827	NA	0.52	6.23	0.32	1.38e-9	Corneal astigmatism;
LIHC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.55	-9.98	-0.47	9.62e-21	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg17644776	chr2:200775616	C2orf69	0.52	6.02	0.31	4.41e-9	LDL cholesterol to HDL cholesterol ratio;
LIHC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.66	9.52	0.46	3.33e-19	Schizophrenia;
LIHC	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	0.85	11.13	0.52	9.19e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.32	-8.21	-0.41	4.56e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-11.8	-0.54	3.38e-27	Platelet count;
LIHC	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.79	8.21	0.41	4.49e-15	Schizophrenia;
LIHC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.43	0.45	6.3e-19	Melanoma;
LIHC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg05425664	chr17:57184151	TRIM37	0.53	7.59	0.38	3.07e-13	Cognitive test performance;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg22528358	chr1:107598549	PRMT6	0.63	10.08	0.48	4.4e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg13385521	chr17:29058706	SUZ12P	-0.6	-5.92	-0.31	7.69e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.45	5.99	0.31	5.18e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.74	0.34	6.75e-11	Renal cell carcinoma;
LIHC	cis	rs36051895	0.623	rs7870536	chr9:5245493	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-10.52	-0.49	1.28e-22	Pediatric autoimmune diseases;
LIHC	cis	rs10792665	0.844	rs7130899	chr11:82644904	G/A	cg24227371	chr11:82718527	RAB30	-0.31	-7.42	-0.37	9.15e-13	Obesity-related traits;
LIHC	cis	rs2412488	0.927	rs7691578	chr4:54311275	C/T	cg22241045	chr4:54363911	LNX1	-0.42	-6.79	-0.34	4.97e-11	DNA methylation (variation);
LIHC	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16684958	chr7:75615977	POR	-0.5	-8.45	-0.42	8.79e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.65	-0.38	2e-13	Schizophrenia;
LIHC	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.61	7.52	0.38	4.92e-13	Coronary artery disease;
LIHC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21016266	chr12:122356598	WDR66	0.51	7.12	0.36	6.23e-12	Mean corpuscular volume;
LIHC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg18357526	chr6:26021779	HIST1H4A	0.45	6.74	0.34	6.82e-11	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15231902	chr12:56618064	OBFC2B	-0.46	-6.42	-0.33	4.67e-10	Pancreatic cancer;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg24805985	chr8:25045589	DOCK5	-0.31	-6.2	-0.32	1.6e-9	Monocyte count;
LIHC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.61	-0.42	2.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.67	-0.38	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18867708	chr6:26865862	GUSBL1	0.56	8.5	0.42	5.94e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-15.09	-0.63	8.57e-40	Height;
LIHC	cis	rs2710642	0.611	rs6705835	chr2:62870408	C/T	cg17519650	chr2:63277830	OTX1	0.52	7.52	0.38	4.73e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Alcohol dependence;
LIHC	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.17	17.26	0.68	1.82e-48	Corneal structure;
LIHC	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg20240347	chr1:204465584	NA	-0.36	-7.68	-0.38	1.64e-13	Schizophrenia;
LIHC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-9.56	-0.46	2.4e-19	Bronchopulmonary dysplasia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27056175	chr8:141556352	EIF2C2	-0.43	-6.62	-0.34	1.36e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.85	0.3	1.14e-8	Calcium levels;
LIHC	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.43	6.17	0.32	1.93e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.37	5.99	0.31	5.46e-9	Menopause (age at onset);
LIHC	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.37	5.93	0.31	7.22e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.15	-0.58	3.05e-32	Bipolar disorder and schizophrenia;
LIHC	cis	rs11644362	1.000	rs976243	chr16:12991679	A/T	cg06890432	chr16:12997467	SHISA9	-0.39	-6.63	-0.34	1.34e-10	Positive affect;Subjective well-being;
LIHC	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.74	7.6	0.38	2.79e-13	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.52	0.56	7.34e-30	Prudent dietary pattern;
LIHC	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.78	-14.61	-0.62	6.92e-38	Mortality in heart failure;
LIHC	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg10381502	chr11:71823885	C11orf51	-0.95	-8.2	-0.41	5.03e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	5.95	0.31	6.54e-9	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	6.62	0.34	1.37e-10	Renal cell carcinoma;
LIHC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.47	7.93	0.39	3.22e-14	Response to temozolomide;
LIHC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.24	-15.92	-0.65	4.31e-43	Diabetic kidney disease;
LIHC	trans	rs11088226	0.692	rs8127603	chr21:33886658	T/C	cg09050820	chr6:167586206	TCP10L2	0.45	6.76	0.34	5.88e-11	Gastritis;
LIHC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.79	12.32	0.55	4.18e-29	Resting heart rate;
LIHC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.37	-0.41	1.44e-15	Chronic sinus infection;
LIHC	trans	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.68e-10	Educational attainment (years of education);
LIHC	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg01843034	chr6:37503916	NA	-0.46	-8.06	-0.4	1.3e-14	Cognitive performance;
LIHC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.16	-0.4	6.45e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.77	6.52	0.33	2.49e-10	Type 2 diabetes;
LIHC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.96	9.51	0.46	3.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg09137382	chr11:130731461	NA	0.41	6.26	0.32	1.15e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg03962019	chr1:41807865	NA	0.53	7.64	0.38	2.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.43	-7.41	-0.37	1.03e-12	Schizophrenia;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg14709524	chr16:89940631	TCF25	0.58	7.44	0.37	8.46e-13	Skin colour saturation;
LIHC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.95	0.51	3.91e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs1034435	0.547	rs5767174	chr22:48898857	A/G	cg05992904	chr22:48892994	FAM19A5	-0.46	-8.33	-0.41	2.04e-15	Late-onset Alzheimer's disease;
LIHC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.67	-0.42	1.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	9.03	0.44	1.23e-17	Post bronchodilator FEV1;
LIHC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.37e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg15103426	chr22:29168792	CCDC117	0.43	5.74	0.3	2.12e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.49	-6.39	-0.33	5.58e-10	Breast cancer;
LIHC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.91	-0.54	1.38e-27	Chronic sinus infection;
LIHC	cis	rs17106184	1.000	rs72902785	chr1:51290830	G/A	cg07174182	chr1:51127561	FAF1	-0.6	-6.47	-0.33	3.47e-10	Type 2 diabetes;
LIHC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-9.73	-0.47	6.39e-20	Vitiligo;
LIHC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.02	0.48	6.67e-21	Crohn's disease;
LIHC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.37	0.49	4.17e-22	Resting heart rate;
LIHC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.61	-0.42	2.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg14784868	chr12:69753453	YEATS4	0.51	7.12	0.36	6.25e-12	Response to diuretic therapy;
LIHC	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.67	9.82	0.47	3.25e-20	Monocyte count;
LIHC	cis	rs920590	0.679	rs4577973	chr8:19658017	A/G	cg03894339	chr8:19674705	INTS10	0.54	8.41	0.41	1.13e-15	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg02782426	chr3:40428986	ENTPD3	0.33	6.15	0.32	2.14e-9	Renal cell carcinoma;
LIHC	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	0.89	9.79	0.47	4.14e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20999901	chr10:105615046	SH3PXD2A	-0.39	-6.24	-0.32	1.28e-9	Calcium levels;
LIHC	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.18	0.61	3.24e-36	Bipolar disorder;
LIHC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.63	-9.1	-0.44	7.75e-18	White matter hyperintensity burden;
LIHC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.69	9.38	0.45	9.44e-19	Mean platelet volume;
LIHC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.64	-8.7	-0.43	1.39e-16	Asthma;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04454426	chr16:70507104	FUK	0.45	6.75	0.34	6.49e-11	Longevity;
LIHC	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg14675211	chr2:100938903	LONRF2	0.52	7.75	0.39	1.08e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.69	10.57	0.5	8.65e-23	Lung disease severity in cystic fibrosis;
LIHC	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg18887096	chr2:219472410	PLCD4	0.4	6.84	0.35	3.59e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs12699921	0.599	rs6973480	chr7:17978129	C/T	cg23563507	chr2:44001149	DYNC2LI1	0.34	6.24	0.32	1.32e-9	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.34	-7.99	-0.4	2.14e-14	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg10756647	chr7:56101905	PSPH	-0.45	-6.8	-0.35	4.81e-11	Aortic root size;
LIHC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.29	0.45	1.8e-18	Schizophrenia;
LIHC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.91	11.48	0.53	5.09e-26	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.72	-0.39	1.33e-13	Monocyte percentage of white cells;
LIHC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.78	15.26	0.64	1.75e-40	Mortality in heart failure;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06656553	chr16:89960601	TCF25	-0.49	-6.19	-0.32	1.71e-9	Skin colour saturation;
LIHC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26897989	chr16:1907736	C16orf73	-0.49	-6.14	-0.32	2.25e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.63	-8.51	-0.42	5.61e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs16912285	0.748	rs7104550	chr11:24345162	A/G	ch.11.24196551F	chr11:24239977	NA	0.58	6.13	0.31	2.37e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.95	-0.35	1.81e-11	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07761912	chr1:179846929	TOR1AIP2	0.48	6.46	0.33	3.52e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.72	-13.99	-0.6	1.75e-35	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11644362	1.000	rs4505301	chr16:12989467	A/G	cg06890432	chr16:12997467	SHISA9	-0.4	-6.86	-0.35	3.34e-11	Positive affect;Subjective well-being;
LIHC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg17724175	chr1:150552817	MCL1	0.43	8.61	0.42	2.71e-16	Melanoma;
LIHC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	0.79	11.74	0.54	5.51e-27	Monocyte percentage of white cells;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11015505	chr11:64645556	EHD1	0.43	6.11	0.31	2.68e-9	Hepatitis;
LIHC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.61	-10.14	-0.48	2.58e-21	Post bronchodilator FEV1;
LIHC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.31e-22	Colorectal cancer;
LIHC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.62	7.45	0.37	7.92e-13	Bipolar disorder (body mass index interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12580275	chr1:205744413	RAB7L1	0.41	6.15	0.32	2.13e-9	Cognitive function;
LIHC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.67	0.38	1.84e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-7.57	-0.38	3.55e-13	Hepatocellular carcinoma;
LIHC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.46	-5.97	-0.31	5.87e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg15269541	chr15:43626905	ADAL	-0.3	-5.91	-0.3	8.21e-9	Lung cancer in ever smokers;
LIHC	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.01	-19.45	-0.72	2.87e-57	Exhaled nitric oxide output;
LIHC	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.85	-8.87	-0.43	4.05e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs965469	1.000	rs2236092	chr20:3258188	G/C	cg25506879	chr20:3388711	C20orf194	-0.6	-7.17	-0.36	4.77e-12	IFN-related cytopenia;
LIHC	cis	rs4699052	0.963	rs4698890	chr4:104181878	T/C	cg16532752	chr4:104119610	CENPE	-0.4	-6.33	-0.32	7.56e-10	Testicular germ cell tumor;
LIHC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.78	0.34	5.43e-11	Aortic root size;
LIHC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg19682013	chr15:45996608	NA	0.41	7.25	0.37	2.78e-12	Waist circumference;Weight;
LIHC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.26	0.45	2.39e-18	Hemoglobin concentration;
LIHC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.61	0.42	2.64e-16	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-5.72	-0.3	2.34e-8	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg19635926	chr16:89946313	TCF25	0.52	6.54	0.33	2.24e-10	Skin colour saturation;
LIHC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.16e-8	Menopause (age at onset);
LIHC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.68	12.24	0.55	8.15e-29	Breast cancer;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.46	8.31	0.41	2.24e-15	Prudent dietary pattern;
LIHC	cis	rs3018712	0.508	rs4930581	chr11:68411093	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-5.83	-0.3	1.28e-8	Total body bone mineral density;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02853322	chr7:39989723	CDK13	-0.48	-6.19	-0.32	1.74e-9	Lung function (FEV1);
LIHC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg19680672	chr10:131412579	MGMT	-0.41	-6.44	-0.33	3.98e-10	Response to temozolomide;
LIHC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.79	6.68	0.34	9.53e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.41	-6.42	-0.33	4.48e-10	Height;
LIHC	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.32	7.17	0.36	4.54e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.79	12.29	0.55	5.25e-29	Eye color traits;
LIHC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	-0.39	-5.78	-0.3	1.68e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.77	11.7	0.53	8.12e-27	Coronary artery disease;
LIHC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.23	-0.32	1.39e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg20607798	chr8:58055168	NA	0.49	6.07	0.31	3.33e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.74	11.98	0.54	7.37e-28	Colorectal cancer;
LIHC	cis	rs11951515	0.508	rs7706431	chr5:43582423	C/T	cg01983248	chr5:43482804	C5orf28	-0.37	-6.06	-0.31	3.64e-9	Metabolite levels  (X-11787);
LIHC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg12641515	chr19:46296257	DMWD	0.46	7.03	0.36	1.16e-11	Coronary artery disease;
LIHC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.38	-6.39	-0.33	5.34e-10	Hepatocellular carcinoma;
LIHC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.35	-5.79	-0.3	1.63e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.42	7.85	0.39	5.34e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.43	6.29	0.32	9.83e-10	Neutrophil percentage of white cells;
LIHC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.04	-0.36	1.07e-11	Monocyte percentage of white cells;
LIHC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.54	-9.08	-0.44	8.92e-18	Colorectal cancer;
LIHC	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.91	0.35	2.32e-11	Dermatomyositis;
LIHC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.42	-6.7	-0.34	8.59e-11	Schizophrenia;
LIHC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.35	5.93	0.31	7.61e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.61	-0.38	2.63e-13	Coronary artery disease;
LIHC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.2	0.32	1.65e-9	Schizophrenia;
LIHC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-8.46	-0.42	7.96e-16	Diastolic blood pressure;
LIHC	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.52	-6.38	-0.33	5.84e-10	Schizophrenia;
LIHC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.95	0.31	6.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.56	9.74	0.47	6.01e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.12	0.31	2.54e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.0	-0.31	4.98e-9	Blood metabolite levels;
LIHC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	8.93	0.43	2.72e-17	Lung cancer in ever smokers;
LIHC	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg03934865	chr2:198174659	NA	0.47	6.74	0.34	6.87e-11	Dermatomyositis;
LIHC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-10.37	-0.49	4.36e-22	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg00612595	chr21:47717864	NA	0.34	5.85	0.3	1.17e-8	Testicular germ cell tumor;
LIHC	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.26	6.11	0.31	2.79e-9	Heart rate;
LIHC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.56	7.78	0.39	8.61e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.49	0.56	9.6e-30	Prudent dietary pattern;
LIHC	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.76	11.71	0.54	7.21e-27	Eye color traits;
LIHC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.5e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.65	-9.63	-0.46	1.42e-19	Subjective well-being;
LIHC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.41	-5.84	-0.3	1.21e-8	Height;
LIHC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg13877915	chr19:58951672	ZNF132	0.54	6.18	0.32	1.87e-9	Mean platelet volume;
LIHC	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-7.42	-0.37	9.58e-13	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.48	6.1	0.31	2.81e-9	Alzheimer's disease;
LIHC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.33	-0.55	3.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.46	-7.03	-0.36	1.14e-11	Multiple myeloma;
LIHC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.41	8.82	0.43	5.95e-17	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	5.75	0.3	2e-8	Response to antipsychotic treatment;
LIHC	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg22153463	chr1:85462885	MCOLN2	0.49	5.87	0.3	1.03e-8	Serum sulfate level;
LIHC	cis	rs1789	0.872	rs4333182	chr4:15684712	G/A	cg24225360	chr4:15471699	CC2D2A	-0.38	-5.82	-0.3	1.37e-8	Blood protein levels;
LIHC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg02290350	chr8:58132656	NA	0.38	7.9	0.39	3.9e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2257205	0.588	rs77430462	chr17:56804085	C/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.56	-0.33	2e-10	Pancreatic cancer;
LIHC	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.25	-13.18	-0.58	2.36e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20887711	chr4:1340912	KIAA1530	0.81	12.35	0.56	3.16e-29	Longevity;
LIHC	cis	rs2574704	0.851	rs2251175	chr3:11661600	G/A	cg15876825	chr3:11651881	VGLL4	-0.49	-7.93	-0.39	3.12e-14	Body mass index;
LIHC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg15017067	chr4:17643749	FAM184B	0.34	5.84	0.3	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.62	7.79	0.39	8.1e-14	Macular telangiectasia type 2;
LIHC	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.16e-11	Ileal carcinoids;
LIHC	cis	rs9918079	0.560	rs10008376	chr4:15623955	A/G	cg24225360	chr4:15471699	CC2D2A	0.38	6.0	0.31	4.97e-9	Obesity-related traits;
LIHC	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.73	0.3	2.18e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17286411	0.750	rs11075910	chr16:71936733	A/G	cg03805757	chr16:71968109	PKD1L3	0.43	6.06	0.31	3.53e-9	Blood protein levels;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.41	7.03	0.36	1.13e-11	Pulse pressure;
LIHC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.27	-0.37	2.54e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	trans	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.71	-9.46	-0.46	5.2e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.6	-9.65	-0.46	1.21e-19	Waist circumference;Body mass index;
LIHC	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg10820045	chr2:198174542	NA	0.49	7.4	0.37	1.05e-12	Dermatomyositis;
LIHC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17554472	chr22:41940697	POLR3H	0.57	6.4	0.33	5.03e-10	Vitiligo;
LIHC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.51	-8.15	-0.4	6.91e-15	Fibrinogen levels;
LIHC	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg27124370	chr19:33622961	WDR88	0.52	7.32	0.37	1.75e-12	Bone properties (heel);
LIHC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.9	-0.39	3.86e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.65	-0.38	2.05e-13	Chronic sinus infection;
LIHC	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.9	14.89	0.63	5.5e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.45	-6.9	-0.35	2.54e-11	Glycated hemoglobin levels;
LIHC	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.76	-11.83	-0.54	2.63e-27	Eosinophil percentage of white cells;
LIHC	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.52	7.89	0.39	4.08e-14	Corneal astigmatism;
LIHC	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.51	-8.5	-0.42	6.12e-16	Urate levels in overweight individuals;
LIHC	trans	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg25214090	chr10:38739885	LOC399744	0.4	6.58	0.34	1.72e-10	Educational attainment;
LIHC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.55	9.32	0.45	1.53e-18	Mean corpuscular volume;
LIHC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.12	-0.58	4.01e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.47	-0.37	6.61e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.56	10.96	0.51	3.78e-24	Intelligence (multi-trait analysis);
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21843114	chr4:26334859	RBPJ	0.47	6.81	0.35	4.33e-11	Thyroid stimulating hormone;
LIHC	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg12458913	chr13:53173898	NA	0.51	8.39	0.41	1.3e-15	Lewy body disease;
LIHC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.69	10.58	0.5	8e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2997447	0.846	rs3008230	chr1:26401331	A/G	cg19633962	chr1:26362018	EXTL1	-0.52	-5.94	-0.31	6.97e-9	QRS complex (12-leadsum);
LIHC	trans	rs7120489	0.643	rs6485725	chr11:12446262	A/G	cg08537300	chr5:179058959	NA	0.57	6.18	0.32	1.84e-9	Mortality in heart failure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02926110	chr15:72411069	MYO9A;SENP8	0.44	6.35	0.32	6.96e-10	Cognitive function;
LIHC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.71	10.63	0.5	5.35e-23	Aortic root size;
LIHC	cis	rs8053891	0.756	rs12708921	chr16:71999589	G/A	cg01557791	chr16:72042693	DHODH	-0.46	-6.75	-0.34	6.37e-11	Coronary artery disease;
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.15	-0.32	2.14e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.72	13.96	0.6	2.39e-35	Menopause (age at onset);
LIHC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.42e-17	Lung cancer in ever smokers;
LIHC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	8.03	0.4	1.58e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg03013999	chr17:37608204	MED1	0.34	5.75	0.3	2.03e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.28	17.42	0.69	4.2e-49	Diabetic kidney disease;
LIHC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg05343316	chr1:45956843	TESK2	0.44	6.51	0.33	2.63e-10	High light scatter reticulocyte count;
LIHC	cis	rs66569888	0.633	rs11680226	chr2:106745044	A/G	cg16099169	chr2:106886729	NA	0.63	6.75	0.34	6.44e-11	Facial morphology (factor 23);
LIHC	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.4	-7.3	-0.37	2.02e-12	Hepatocellular carcinoma;
LIHC	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg09467607	chr2:36825704	FEZ2	0.51	7.48	0.37	6.36e-13	Height;
LIHC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.8	12.1	0.55	2.62e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg14092571	chr14:90743983	NA	-0.4	-6.3	-0.32	8.9e-10	Mortality in heart failure;
LIHC	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-12.86	-0.57	3.77e-31	Alzheimer's disease;
LIHC	cis	rs28830936	0.966	rs4924576	chr15:42119593	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.07	-0.31	3.48e-9	Diastolic blood pressure;
LIHC	trans	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg25214090	chr10:38739885	LOC399744	0.39	6.51	0.33	2.75e-10	Diastolic blood pressure;
LIHC	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.6	-7.36	-0.37	1.38e-12	QRS complex (12-leadsum);
LIHC	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.62	6.25	0.32	1.25e-9	Lymphocyte counts;
LIHC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.96	-11.2	-0.52	5.16e-25	Vitiligo;
LIHC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.97	13.1	0.58	4.65e-32	Heart rate;
LIHC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.41	0.37	9.8e-13	Morning vs. evening chronotype;
LIHC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.41	-7.93	-0.39	3.16e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.52	-0.38	4.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10620530	chr9:139922595	C9orf139;ABCA2	0.4	6.43	0.33	4.38e-10	Pancreatic cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08128889	chr17:80828176	TBCD	-0.37	-6.27	-0.32	1.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.43	6.07	0.31	3.49e-9	Height;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg09951433	chr7:101843287	CUX1	0.37	6.27	0.32	1.06e-9	Calcium levels;
LIHC	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg18887096	chr2:219472410	PLCD4	0.34	5.8	0.3	1.54e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg24130564	chr14:104152367	KLC1	-0.35	-5.74	-0.3	2.07e-8	Schizophrenia;
LIHC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.42	7.32	0.37	1.79e-12	Aortic root size;
LIHC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	1.03	12.24	0.55	8.27e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.61	-10.35	-0.49	5.05e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg08847533	chr14:75593920	NEK9	-0.47	-7.46	-0.37	7.3e-13	IgG glycosylation;
LIHC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.59	-11.55	-0.53	2.8e-26	Asthma;
LIHC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.65	8.95	0.44	2.24e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs4908760	0.792	rs11121215	chr1:8733128	T/C	cg20416874	chr1:8611966	RERE	-0.63	-12.27	-0.55	6.37e-29	Vitiligo;
LIHC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.67	8.61	0.42	2.62e-16	Initial pursuit acceleration;
LIHC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg07959070	chr22:50026188	C22orf34	-0.33	-8.7	-0.43	1.47e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.65	-0.38	2.01e-13	Vitiligo;
LIHC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs868943	0.582	rs12196141	chr6:116489550	C/T	cg08036074	chr6:116424633	NT5DC1	0.58	6.15	0.32	2.18e-9	Total cholesterol levels;
LIHC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.71	-8.97	-0.44	1.97e-17	Gut microbiome composition (summer);
LIHC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.61	-0.53	1.76e-26	Total cholesterol levels;
LIHC	cis	rs4788570	0.584	rs8051968	chr16:71761978	C/A	cg06353428	chr16:71660113	MARVELD3	1.42	15.9	0.65	5.23e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.73	0.3	2.21e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg03934865	chr2:198174659	NA	0.45	6.54	0.33	2.22e-10	Intracranial aneurysm;
LIHC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.55	8.59	0.42	3.08e-16	White matter hyperintensity burden;
LIHC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.5	-0.38	5.7e-13	Aortic root size;
LIHC	cis	rs9473924	0.542	rs2744504	chr6:50798668	G/C	cg14470998	chr6:50812995	TFAP2B	0.98	11.01	0.51	2.45e-24	Body mass index;
LIHC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-1.01	-12.33	-0.55	3.63e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.25	0.52	3.29e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-1.0	-16.82	-0.67	1.07e-46	Monocyte percentage of white cells;
LIHC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.83	10.86	0.51	8.58e-24	Cognitive function;
LIHC	cis	rs10744422	0.800	rs6489240	chr12:123275030	T/C	cg22842854	chr12:123319900	HIP1R	-0.64	-8.02	-0.4	1.68e-14	Schizophrenia;
LIHC	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.01	-0.4	1.83e-14	Colorectal cancer;
LIHC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	6.74	0.34	6.86e-11	Renal function-related traits (BUN);
LIHC	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.37	-5.75	-0.3	2e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg05973401	chr12:123451056	ABCB9	0.41	6.29	0.32	9.5e-10	Platelet count;
LIHC	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.45	7.51	0.38	5.3e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg12152193	chr5:175954583	RNF44	0.42	6.22	0.32	1.47e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.79	-14.23	-0.61	2e-36	Refractive error;
LIHC	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs2073300	1.000	rs6114126	chr20:23452127	A/T	cg12062639	chr20:23401060	NAPB	0.81	9.62	0.46	1.56e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.59	-8.88	-0.43	3.85e-17	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.66	-13.01	-0.58	1.08e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.38	6.1	0.31	2.85e-9	Menopause (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21044577	chr13:111364847	ING1	0.47	6.84	0.35	3.68e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.93	-0.31	7.22e-9	Red blood cell count;
LIHC	cis	rs12464559	1.000	rs12464559	chr2:152597660	G/A	cg01189475	chr2:152685088	ARL5A	0.67	6.77	0.34	5.68e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.44	6.17	0.32	1.93e-9	Height;
LIHC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.1	-0.44	7.39e-18	Bipolar disorder;
LIHC	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.5	-7.26	-0.37	2.64e-12	Mortality in heart failure;
LIHC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.61	7.79	0.39	8.19e-14	Height;
LIHC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.75	-15.34	-0.64	8.83e-41	Menopause (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05264915	chr2:210867333	RPE	0.55	6.69	0.34	9.21e-11	Hepatitis;
LIHC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.45	6.13	0.31	2.48e-9	Initial pursuit acceleration;
LIHC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg03013999	chr17:37608204	MED1	0.35	5.93	0.31	7.47e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.61	-0.34	1.52e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs6977660	1.000	rs4719584	chr7:19823388	T/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.85	0.3	1.13e-8	Thyroid stimulating hormone;
LIHC	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.74	-8.63	-0.42	2.37e-16	Exhaled nitric oxide levels;
LIHC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.39	-5.94	-0.31	7.02e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.22e-11	Body mass index;
LIHC	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg20991723	chr1:152506922	NA	0.57	10.25	0.48	1.13e-21	Hair morphology;
LIHC	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.92	11.74	0.54	5.69e-27	Coronary artery disease;
LIHC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.62	-10.78	-0.5	1.64e-23	Dental caries;
LIHC	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-5.99	-0.31	5.32e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03634887	chr16:66730948	CMTM4	0.46	6.41	0.33	4.9e-10	Pancreatic cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13131519	chr7:127032423	ZNF800	0.45	6.31	0.32	8.73e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg14092571	chr14:90743983	NA	-0.38	-6.04	-0.31	4.12e-9	Mortality in heart failure;
LIHC	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.59	-0.42	3.07e-16	Obesity-related traits;
LIHC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.35	5.87	0.3	1.03e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2997447	0.761	rs2783637	chr1:26439226	C/T	cg19633962	chr1:26362018	EXTL1	-0.51	-5.74	-0.3	2.06e-8	QRS complex (12-leadsum);
LIHC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.68	13.4	0.59	3.38e-33	High light scatter reticulocyte count;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12830327	chr11:85339628	TMEM126B;DLG2	-0.45	-6.59	-0.34	1.67e-10	Triglycerides;
LIHC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	1.09	11.36	0.52	1.33e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.4	7.31	0.37	1.95e-12	Arsenic metabolism;
LIHC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg17279839	chr7:150038598	RARRES2	0.59	11.97	0.54	7.99e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	8.68	0.42	1.68e-16	Response to bleomycin (chromatid breaks);
LIHC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg04359351	chr2:3481828	TTC15	0.29	6.17	0.32	1.88e-9	Neurofibrillary tangles;
LIHC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg14393609	chr7:65229607	NA	-0.35	-5.71	-0.3	2.4e-8	Aortic root size;
LIHC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	9.79	0.47	4.13e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs6885147	1.000	rs16893468	chr5:64467770	A/G	cg27019278	chr4:101438804	EMCN	0.68	6.4	0.33	5.17e-10	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;
LIHC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.55	-10.83	-0.51	1.07e-23	Blood protein levels;
LIHC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	1.02e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.88	0.35	2.9100000000000002e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.4	6.58	0.34	1.76e-10	Lewy body disease;
LIHC	cis	rs2070433	0.904	rs8130209	chr21:47925984	T/C	cg12379764	chr21:47803548	PCNT	0.6	8.76	0.43	9.25e-17	Lymphocyte counts;
LIHC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.46	-0.33	3.65e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg23254163	chr1:152506842	NA	0.23	5.95	0.31	6.79e-9	Hair morphology;
LIHC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.91	-0.43	3.01e-17	Bipolar disorder;
LIHC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.52	7.05	0.36	9.94e-12	Lung cancer;
LIHC	cis	rs17106184	1.000	rs112780433	chr1:51401419	C/T	cg07174182	chr1:51127561	FAF1	-0.74	-7.94	-0.39	2.99e-14	Type 2 diabetes;
LIHC	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.49	8.06	0.4	1.28e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.16	0.48	2.3e-21	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg08015704	chr19:12868765	BEST2	-0.47	-6.18	-0.32	1.83e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	6.77	0.34	5.55e-11	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.35	-0.41	1.74e-15	Chronic sinus infection;
LIHC	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg17074339	chr11:11642133	GALNTL4	0.4	6.09	0.31	3.09e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.49	7.76	0.39	9.95e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg12798992	chr6:167411361	FGFR1OP	0.49	7.5	0.38	5.51e-13	Crohn's disease;
LIHC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg03543861	chr21:44258195	NA	0.52	8.63	0.42	2.35e-16	Information processing speed;
LIHC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.33e-18	Bipolar disorder;
LIHC	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.87	0.6	5.03e-35	Coffee consumption (cups per day);
LIHC	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.37	-5.74	-0.3	2.07e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg01864069	chr14:103024347	NA	-0.49	-7.4	-0.37	1.04e-12	Platelet count;
LIHC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1664789	0.743	rs1694104	chr5:53263103	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.44	6.63	0.34	1.28e-10	Waist circumference adjusted for body mass index;
LIHC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-1.02	-11.32	-0.52	1.91e-25	Triglycerides;
LIHC	cis	rs861318	0.702	rs6940	chr1:159024668	A/T	cg11003133	chr1:159046391	AIM2	-0.33	-6.38	-0.33	5.77e-10	Obesity-related traits;
LIHC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs546131	0.642	rs11600239	chr11:34821699	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.36	-0.33	6.29e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg15902774	chr15:75289873	SCAMP5	0.34	5.96	0.31	6.21e-9	Systemic lupus erythematosus;
LIHC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.98	-18.7	-0.71	3.06e-54	Breast cancer;
LIHC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.73	0.34	7.34e-11	Lung cancer;
LIHC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.96	15.09	0.63	8.93e-40	Skin colour saturation;
LIHC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg16836995	chr17:43662488	NA	-0.77	-7.89	-0.39	4.06e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25387593	chr11:118927868	HYOU1	0.51	6.88	0.35	2.88e-11	Lung function (FEV1/FVC);
LIHC	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg00204512	chr16:28754710	NA	-0.35	-6.14	-0.32	2.29e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg07599136	chr5:415885	AHRR	0.39	6.66	0.34	1.1e-10	Cystic fibrosis severity;
LIHC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.64	-10.16	-0.48	2.31e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.65	6.42	0.33	4.46e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.95	0.44	2.35e-17	Exhaled nitric oxide output;
LIHC	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.05e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg03859395	chr2:55845619	SMEK2	0.92	15.71	0.65	3.07e-42	Metabolic syndrome;
LIHC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	7.95	0.39	2.82e-14	Schizophrenia;
LIHC	cis	rs3814244	0.528	rs10878723	chr12:68399273	A/G	cg15249341	chr12:68405565	NA	-0.32	-6.24	-0.32	1.33e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg00280220	chr17:61926910	NA	0.43	6.69	0.34	9.03e-11	Prudent dietary pattern;
LIHC	cis	rs4663866	0.901	rs35713061	chr2:239183774	C/T	cg16914508	chr2:239161102	PER2	0.8	5.84	0.3	1.23e-8	Irritable bowel syndrome;
LIHC	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.39	6.36	0.33	6.33e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.94	19.28	0.72	1.38e-56	Height;
LIHC	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-0.79	-8.86	-0.43	4.48e-17	Exhaled nitric oxide output;
LIHC	cis	rs10794720	0.748	rs11250275	chr10:1171823	A/G	cg08668510	chr10:1095578	IDI1	-0.82	-5.83	-0.3	1.29e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
LIHC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.87	-0.35	3.1e-11	Bipolar disorder;
LIHC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.61	0.34	1.45e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22588542	chr2:228190772	MFF	-0.43	-6.06	-0.31	3.59e-9	Pancreatic cancer;
LIHC	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.33	6.54	0.33	2.19e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg17294928	chr15:75287854	SCAMP5	-0.46	-5.83	-0.3	1.3e-8	Lung cancer;
LIHC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	cis	rs4845459	0.967	rs1886734	chr1:152591142	A/C	cg20634798	chr1:152595351	LCE3A	-0.32	-6.2	-0.32	1.63e-9	Psoriasis;
LIHC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-6.95	-0.35	1.87e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg12661370	chr5:149340060	SLC26A2	0.51	6.13	0.31	2.49e-9	HIV-1 control;
LIHC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.72	-0.3	2.33e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.64	-0.38	2.16e-13	Ulcerative colitis;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.25	0.41	3.48e-15	Renal cell carcinoma;
LIHC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.23	6.06	0.31	3.59e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.56	-7.97	-0.4	2.43e-14	Facial morphology (factor 19);
LIHC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.13	0.4	8.12e-15	Morning vs. evening chronotype;
LIHC	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.59	10.11	0.48	3.27e-21	HDL cholesterol;
LIHC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.51	8.54	0.42	4.38e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	6.34	0.32	7.22e-10	Initial pursuit acceleration;
LIHC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.87	6.74	0.34	6.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-9.59	-0.46	1.93e-19	Coronary artery disease;
LIHC	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg05197062	chr11:11642011	GALNTL4	0.44	6.45	0.33	3.74e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.78	12.34	0.56	3.41e-29	Resting heart rate;
LIHC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.47	-7.62	-0.38	2.58e-13	Fibrinogen levels;
LIHC	cis	rs72627123	0.656	rs117129791	chr14:74520871	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	8.7	0.43	1.38e-16	Morning vs. evening chronotype;
LIHC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.53	-0.42	4.75e-16	Schizophrenia;
LIHC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg20933634	chr6:27740509	NA	0.47	6.19	0.32	1.69e-9	Parkinson's disease;
LIHC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	trans	rs7657257	1.000	rs16892283	chr4:15731534	A/G	cg17675199	chr6:35436792	RPL10A	-0.42	-6.57	-0.33	1.85e-10	Blood protein levels;
LIHC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1144333	1.000	rs17097841	chr1:76462641	T/A	cg22875332	chr1:76189707	ACADM	0.4	6.24	0.32	1.26e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg05185784	chr16:90016020	DEF8	-0.46	-5.72	-0.3	2.27e-8	Skin colour saturation;
LIHC	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg25182066	chr10:30743637	MAP3K8	-0.5	-8.05	-0.4	1.37e-14	Inflammatory bowel disease;
LIHC	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.35	-7.39	-0.37	1.1e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.76	7.89	0.39	4.07e-14	Schizophrenia;
LIHC	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.68	8.14	0.4	7.54e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.62	0.69	6.85e-50	Smoking behavior;
LIHC	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-0.72	-7.97	-0.4	2.33e-14	Coronary artery disease;
LIHC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-12.17	-0.55	1.47e-28	Electrocardiographic conduction measures;
LIHC	cis	rs365132	1.000	rs353467	chr5:176445698	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.34	-0.52	1.62e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg22633049	chr21:46681294	NA	0.36	6.22	0.32	1.46e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg08210727	chr20:33865349	NA	-0.51	-5.9	-0.3	8.9e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.32	-0.37	1.75e-12	Tuberculosis;
LIHC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg14440974	chr22:39074834	NA	-0.41	-6.65	-0.34	1.13e-10	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.39	7.91	0.39	3.67e-14	Renal cell carcinoma;
LIHC	cis	rs35661897	0.764	rs67648943	chr2:227259665	C/A	cg03426602	chr2:227312417	NA	-0.56	-5.95	-0.31	6.58e-9	Urinary tract infection frequency;
LIHC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.56	9.83	0.47	3.12e-20	Platelet distribution width;
LIHC	cis	rs7487075	0.823	rs34472481	chr12:46836348	C/G	cg11331445	chr12:47219877	SLC38A4	0.26	5.73	0.3	2.18e-8	Itch intensity from mosquito bite;
LIHC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.35	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.28	0.37	2.25e-12	Vitiligo;
LIHC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.44	-6.18	-0.32	1.8e-9	Diastolic blood pressure;
LIHC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	7.64	0.38	2.24e-13	Eosinophil percentage of white cells;
LIHC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-6.91	-0.35	2.34e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.78	11.01	0.51	2.56e-24	Monocyte percentage of white cells;
LIHC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.77	-8.5	-0.42	6.16e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.6	9.23	0.45	2.82e-18	Mean corpuscular volume;
LIHC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.7	12.6	0.56	3.78e-30	Lewy body disease;
LIHC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.43	0.41	1.01e-15	Lung cancer in ever smokers;
LIHC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	10.09	0.48	3.86e-21	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.57	0.33	1.82e-10	Renal cell carcinoma;
LIHC	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg08807101	chr21:30365312	RNF160	0.52	7.53	0.38	4.66e-13	Dental caries;
LIHC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	trans	rs10411161	0.810	rs76098421	chr19:52404645	T/C	cg22319618	chr22:45562946	NUP50	-0.61	-7.18	-0.36	4.32e-12	Breast cancer;
LIHC	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.81	0.57	6.08e-31	Monocyte count;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.59	-8.48	-0.42	6.94e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-9.17	-0.44	4.4e-18	Body mass index;
LIHC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.56	-7.37	-0.37	1.33e-12	Body mass index;
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.06	0.31	3.68e-9	Aortic root size;
LIHC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg20607798	chr8:58055168	NA	-0.44	-6.47	-0.33	3.42e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.33	0.41	1.98e-15	Body mass index;
LIHC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.75	9.83	0.47	2.94e-20	Eosinophilic esophagitis;
LIHC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg10978503	chr1:24200527	CNR2	0.38	8.97	0.44	1.93e-17	Immature fraction of reticulocytes;
LIHC	trans	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg07424592	chr7:64974309	NA	0.65	7.92	0.39	3.35e-14	Diabetic kidney disease;
LIHC	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.6	-0.38	2.92e-13	Response to antipsychotic treatment;
LIHC	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.68	-0.34	9.73e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-9.12	-0.44	6.46e-18	Gut microbiome composition (summer);
LIHC	trans	rs4714291	1.000	rs847752	chr6:40034557	T/C	cg02267698	chr19:7991119	CTXN1	0.4	6.33	0.32	7.66e-10	Strep throat;
LIHC	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	10.94	0.51	4.28e-24	Myopia (pathological);
LIHC	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.11	-0.4	8.96e-15	Response to antipsychotic treatment;
LIHC	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-7.69	-0.38	1.58e-13	Exhaled nitric oxide output;
LIHC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.3	0.41	2.45e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7534824	0.625	rs12568338	chr1:101500622	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	7.23	0.36	3.18e-12	Refractive astigmatism;
LIHC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.55	0.33	2.08e-10	Lung cancer;
LIHC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.84	15.18	0.63	3.78e-40	Multiple myeloma (IgH translocation);
LIHC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.57	7.78	0.39	8.78e-14	Bladder cancer;
LIHC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	8.03	0.4	1.63e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.76	12.78	0.57	7.43e-31	Aortic root size;
LIHC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg04719120	chr6:96025338	MANEA	0.64	6.77	0.34	5.48e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.3	-6.93	-0.35	2.07e-11	Educational attainment (years of education);
LIHC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.64	8.7	0.43	1.43e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.46	0.37	7.21e-13	Corneal astigmatism;
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.69	-11.58	-0.53	2.1e-26	Prudent dietary pattern;
LIHC	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.42	6.57	0.33	1.9e-10	Resting heart rate;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg16103275	chr6:290800	DUSP22	0.5	6.44	0.33	4.07e-10	Menopause (age at onset);
LIHC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.51	7.39	0.37	1.15e-12	Obesity-related traits;
LIHC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg02404636	chr22:31891804	SFI1	0.34	6.02	0.31	4.45e-9	Colorectal cancer;
LIHC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	7.9	0.39	3.85e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.85	-16.75	-0.67	2.06e-46	Height;
LIHC	cis	rs6466055	0.669	rs2299304	chr7:104771857	T/C	cg04380332	chr7:105027541	SRPK2	-0.33	-6.3	-0.32	8.99e-10	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13077517	chr20:2082435	STK35	0.41	6.12	0.31	2.59e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-8.7	-0.43	1.44e-16	Gut microbiome composition (summer);
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.64	0.38	2.16e-13	Prudent dietary pattern;
LIHC	cis	rs7523273	0.925	rs6540443	chr1:208002010	T/A	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.59	-0.5	7.74e-23	Schizophrenia;
LIHC	cis	rs2479724	0.870	rs7766817	chr6:41918104	T/A	cg17623882	chr6:41773611	USP49	-0.5	-7.4	-0.37	1.09e-12	Menarche (age at onset);
LIHC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.92	-0.3	7.91e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs273218	0.590	rs156828	chr5:53364230	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.56	9.86	0.47	2.36e-20	Migraine;
LIHC	trans	rs71658797	0.536	rs9324162	chr1:77954804	A/G	cg04606550	chr5:14226569	TRIO	0.41	6.18	0.32	1.83e-9	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
LIHC	cis	rs12744310	0.943	rs7521544	chr1:41772126	G/A	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.6	-8.46	-0.42	8.07e-16	Dialysis-related mortality;
LIHC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Body mass index;
LIHC	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.29	-8.35	-0.41	1.67e-15	Intelligence;
LIHC	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.45	8.65	0.42	2.05e-16	Testicular germ cell tumor;
LIHC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.53	-0.46	2.98e-19	Type 2 diabetes;
LIHC	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg14580859	chr9:123691850	NA	0.35	6.17	0.32	1.95e-9	Rheumatoid arthritis;
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.67	11.68	0.53	9.55e-27	Longevity;Endometriosis;
LIHC	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.95	-10.85	-0.51	9.18e-24	Neuroticism;
LIHC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.39	6.25	0.32	1.22e-9	Melanoma;
LIHC	cis	rs59901009	0.863	rs2278634	chr11:10184463	C/A	cg01453529	chr11:10209919	SBF2	-0.33	-6.49	-0.33	2.99e-10	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.73	-9.49	-0.46	4.15e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.83	8.67	0.42	1.78e-16	Platelet count;
LIHC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.66	10.71	0.5	2.83e-23	Colorectal cancer;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg25461793	chr19:17212553	MYO9B	0.42	6.5	0.33	2.87e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7258015	1.000	rs7250300	chr19:10448660	C/A	cg13981319	chr19:10446556	ICAM3	0.45	6.57	0.33	1.9e-10	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg02990361	chr1:107599529	PRMT6	0.64	10.66	0.5	4.15e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs988712	0.705	rs4923461	chr11:27656910	A/G	cg18117895	chr11:27722066	BDNF	0.45	6.14	0.32	2.3e-9	Obesity;
LIHC	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.37	5.98	0.31	5.66e-9	Prostate cancer;
LIHC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.45	6.72	0.34	7.4e-11	Gout;
LIHC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg06289844	chr6:126071538	HEY2	0.34	5.96	0.31	6.33e-9	Brugada syndrome;
LIHC	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs332507	0.830	rs3772789	chr3:124395607	A/G	cg05980111	chr3:124395277	KALRN	0.45	6.99	0.35	1.49e-11	Plateletcrit;
LIHC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.56	0.53	2.55e-26	Personality dimensions;
LIHC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.06	-0.36	9.28e-12	Myeloid white cell count;
LIHC	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg04756594	chr16:24857601	SLC5A11	0.48	7.5	0.38	5.38e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.93	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.49	6.62	0.34	1.36e-10	Red cell distribution width;
LIHC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg22532475	chr10:104410764	TRIM8	-0.37	-6.5	-0.33	2.93e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	1.05	17.36	0.68	7.23e-49	Metabolic syndrome;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00802484	chr4:39773226	UBE2K	0.46	6.74	0.34	6.82e-11	Bilirubin levels;
LIHC	cis	rs3770081	1.000	rs60479377	chr2:86283948	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.57	8.85	0.43	4.86e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg07424592	chr7:64974309	NA	0.75	8.79	0.43	7.66e-17	Diabetic kidney disease;
LIHC	cis	rs3736485	0.932	rs4775966	chr15:51913788	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.15	-0.32	2.19e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2637266	0.875	rs2395409	chr10:78381004	A/G	cg18941641	chr10:78392320	NA	0.27	5.73	0.3	2.2e-8	Pulmonary function;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07466437	chr6:8086756	EEF1E1;SCARNA27	0.37	6.07	0.31	3.49e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.28	-0.41	2.75e-15	Gut microbiome composition (summer);
LIHC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.46	6.28	0.32	1.02e-9	Initial pursuit acceleration;
LIHC	cis	rs655641	0.953	rs472618	chr11:85662839	T/G	cg09030501	chr11:85779252	PICALM	-0.49	-5.94	-0.31	6.86e-9	Platelet count;
LIHC	trans	rs1875517	0.510	rs11721241	chr3:117329656	A/C	cg23682007	chr1:167523064	CREG1	0.34	6.29	0.32	9.87e-10	Waist circumference;
LIHC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg25124228	chr12:125621409	AACS	-0.44	-7.06	-0.36	9.1e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg25894440	chr7:65020034	NA	-0.53	-6.17	-0.32	1.93e-9	Diabetic kidney disease;
LIHC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.61	-10.79	-0.5	1.53e-23	Body mass index;
LIHC	cis	rs887797	0.518	rs8075979	chr17:64576138	C/T	cg27019712	chr17:64599478	PRKCA	-0.34	-5.92	-0.3	7.9e-9	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.58e-21	Diabetic retinopathy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14197205	chr17:28256862	EFCAB5;SSH2	0.42	6.12	0.31	2.6e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs965469	0.724	rs6037527	chr20:3254412	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-6.46	-0.33	3.58e-10	IFN-related cytopenia;
LIHC	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.36	5.79	0.3	1.62e-8	Monocyte percentage of white cells;
LIHC	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-0.42	-6.66	-0.34	1.08e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg12374095	chr12:54320830	NA	0.44	6.36	0.33	6.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs831571	0.695	rs73120926	chr3:64036950	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.51	-5.87	-0.3	1.04e-8	Type 2 diabetes;
LIHC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg14779329	chr11:130786720	SNX19	0.38	5.88	0.3	9.87e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-11.29	-0.52	2.55e-25	Primary sclerosing cholangitis;
LIHC	cis	rs116248771	0.549	rs9811858	chr3:158443093	T/C	cg16708174	chr3:158430962	RARRES1	0.71	9.47	0.46	4.69e-19	diarrhoeal disease at age 2;
LIHC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.76	14.06	0.61	9.19e-36	Crohn's disease;
LIHC	cis	rs332507	0.601	rs13064734	chr3:124374940	C/T	cg05980111	chr3:124395277	KALRN	0.32	6.21	0.32	1.57e-9	Plateletcrit;
LIHC	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.35	7.34	0.37	1.55e-12	Sitting height ratio;
LIHC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-8.67	-0.42	1.81e-16	Lung cancer in ever smokers;
LIHC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.97	0.51	3.47e-24	Lung cancer in ever smokers;
LIHC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.91	-16.94	-0.68	3.63e-47	Aortic root size;
LIHC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg13844804	chr7:814759	HEATR2	0.44	5.95	0.31	6.72e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7095607	0.606	rs10998015	chr10:69959624	A/G	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.66e-9	Lung function (FVC);
LIHC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.4	-6.05	-0.31	3.79e-9	Menarche (age at onset);
LIHC	cis	rs704795	0.651	rs11693959	chr2:27574159	T/C	cg27432699	chr2:27873401	GPN1	-0.63	-6.11	-0.31	2.64e-9	Menopause (age at onset);
LIHC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-9.89	-0.47	1.95e-20	Chronic sinus infection;
LIHC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-6.32	-0.32	8.07e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.68	0.57	1.91e-30	Alzheimer's disease;
LIHC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.44	-6.12	-0.31	2.62e-9	Initial pursuit acceleration;
LIHC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-0.97	-9.78	-0.47	4.4e-20	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03261162	chr17:79791653	DYSFIP1;FAM195B	0.46	6.28	0.32	1.05e-9	Pancreatic cancer;
LIHC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg05973401	chr12:123451056	ABCB9	0.41	6.31	0.32	8.89e-10	Platelet count;
LIHC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.66	9.77	0.47	4.67e-20	Testicular germ cell tumor;
LIHC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-7.04	-0.36	1.05e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.39	5.86	0.3	1.08e-8	Melanoma;
LIHC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	1.09	7.67	0.38	1.8e-13	Height;
LIHC	cis	rs9513627	0.831	rs9582301	chr13:100125814	C/T	cg25919922	chr13:100150906	NA	-0.76	-6.66	-0.34	1.07e-10	Obesity-related traits;
LIHC	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	0.55	8.54	0.42	4.46e-16	Atopic dermatitis;
LIHC	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.49	-7.34	-0.37	1.58e-12	Diastolic blood pressure;
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.6	0.53	1.85e-26	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.32	0.37	1.74e-12	Diabetic kidney disease;
LIHC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.03e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.69	7.23	0.36	3.17e-12	Bipolar disorder;
LIHC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.77	11.88	0.54	1.75e-27	Corneal astigmatism;
LIHC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.71	10.58	0.5	8.06e-23	Corneal astigmatism;
LIHC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.8	-10.88	-0.51	7.16e-24	Response to metformin (IC50);
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg00815214	chr21:47717953	NA	-0.36	-6.11	-0.31	2.77e-9	Testicular germ cell tumor;
LIHC	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.37	7.47	0.37	6.65e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.18	0.32	1.77e-9	Renal cell carcinoma;
LIHC	cis	rs9596863	1.000	rs9568941	chr13:54419426	A/G	ch.13.53330881F	chr13:54432880	NA	0.44	5.97	0.31	5.84e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.77	-0.3	1.82e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.56	-0.33	1.94e-10	Metabolite levels;
LIHC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	4.12e-15	Schizophrenia;
LIHC	cis	rs244293	0.831	rs11654268	chr17:53151290	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.41	0.37	9.92e-13	Menarche (age at onset);
LIHC	cis	rs990171	0.607	rs871659	chr2:102771855	C/T	cg22835712	chr2:102737379	NA	0.51	7.34	0.37	1.61e-12	Lymphocyte counts;
LIHC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.43	6.45	0.33	3.87e-10	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05739825	chr11:125439882	EI24	0.41	6.04	0.31	4.12e-9	Pancreatic cancer;
LIHC	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.86	16.84	0.67	9.26e-47	Testicular germ cell tumor;
LIHC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.57	7.94	0.39	2.96e-14	Parkinson's disease;
LIHC	cis	rs6066825	0.644	rs761271	chr20:47315637	A/G	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.76e-12	Colorectal cancer;
LIHC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.47	7.15	0.36	5.35e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.5	-6.39	-0.33	5.34e-10	Pursuit maintenance gain;
LIHC	cis	rs716804	0.703	rs4910115	chr11:10269375	A/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.89	-0.3	9.21e-9	Neuroticism;
LIHC	cis	rs1144333	1.000	rs5745327	chr1:76270040	A/T	cg10523679	chr1:76189770	ACADM	-0.44	-6.5	-0.33	2.76e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3106136	0.807	rs7657805	chr4:95273659	C/T	cg11021082	chr4:95130006	SMARCAD1	0.43	7.46	0.37	7.08e-13	Capecitabine sensitivity;
LIHC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg14515779	chr1:101123966	NA	-0.68	-13.21	-0.58	1.81e-32	Monocyte count;
LIHC	trans	rs10411161	0.810	rs77458785	chr19:52384295	T/G	cg22319618	chr22:45562946	NUP50	-0.6	-7.09	-0.36	7.95e-12	Breast cancer;
LIHC	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08893839	chr5:154027129	NA	0.49	6.69	0.34	9.21e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg02640540	chr1:67518911	SLC35D1	0.44	6.08	0.31	3.29e-9	Lymphocyte percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20697630	chr1:20960374	PINK1	0.52	7.36	0.37	1.34e-12	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02290350	chr8:58132656	NA	0.41	8.59	0.42	3.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.49	0.38	6.04e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg16586182	chr3:47516702	SCAP	-0.57	-11.05	-0.51	1.77e-24	Colorectal cancer;
LIHC	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.26	-0.37	2.68e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.95	0.31	6.6e-9	Tonsillectomy;
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg05484376	chr2:27715224	FNDC4	0.39	6.5	0.33	2.78e-10	Menopause (age at onset);
LIHC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.59	7.03	0.36	1.13e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs3736485	0.932	rs2278988	chr15:51915234	A/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.15	-0.32	2.22e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.66	0.34	1.12e-10	Response to antipsychotic treatment;
LIHC	cis	rs67981189	0.593	rs221918	chr14:71588415	C/G	cg15816911	chr14:71606274	NA	-0.44	-6.98	-0.35	1.51e-11	Schizophrenia;
LIHC	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.59	-0.46	1.85e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg03785755	chr6:26196794	NA	0.53	5.76	0.3	1.89e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg24826892	chr11:71159390	DHCR7	0.51	6.64	0.34	1.22e-10	Vitamin D levels;
LIHC	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.6	7.83	0.39	6.17e-14	Exhaled nitric oxide output;
LIHC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.28	0.41	2.77e-15	Morning vs. evening chronotype;
LIHC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.8	-14.74	-0.62	2.02e-38	Refractive error;
LIHC	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.34	-0.32	7.24e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.5	7.33	0.37	1.66e-12	Tonsillectomy;
LIHC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-7.71	-0.38	1.37e-13	Gut microbiome composition (summer);
LIHC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.32	7.04	0.36	1.04e-11	Multiple sclerosis;
LIHC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.89	-0.35	2.63e-11	Fear of minor pain;
LIHC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg08499158	chr17:42289980	UBTF	-0.51	-8.96	-0.44	2.15e-17	Total body bone mineral density;
LIHC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg02376097	chr19:46275166	DMPK	-0.44	-6.91	-0.35	2.33e-11	Coronary artery disease;
LIHC	cis	rs7131987	0.675	rs1436322	chr12:29554805	A/G	cg14222432	chr12:29376421	FAR2	-0.31	-6.1	-0.31	2.95e-9	QT interval;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18185028	chr3:154042079	DHX36	0.39	6.18	0.32	1.83e-9	Calcium levels;
LIHC	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg14146966	chr2:61757674	XPO1	0.47	8.17	0.4	6.05e-15	Tuberculosis;
LIHC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg05555928	chr11:63887634	MACROD1	0.54	7.21	0.36	3.64e-12	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.54	6.41	0.33	4.82e-10	Alzheimer's disease;
LIHC	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	-0.41	-6.56	-0.33	2.04e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4919087	0.683	rs1687371	chr10:98978183	T/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.32	-0.32	8.02e-10	Monocyte count;
LIHC	trans	rs10213084	1.000	rs13147096	chr4:147495321	A/G	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.28	0.32	1e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.62	9.48	0.46	4.43e-19	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05663655	chr7:107532014	DLD	0.43	6.55	0.33	2.16e-10	Cognitive function;
LIHC	trans	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.48	-0.37	6.23e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg14067834	chr17:29058358	SUZ12P	0.6	6.32	0.32	7.98e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12744310	1.000	rs12032191	chr1:41769218	A/G	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12016809	chr21:47604291	C21orf56	0.41	6.03	0.31	4.27e-9	Testicular germ cell tumor;
LIHC	trans	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg25214090	chr10:38739885	LOC399744	0.43	7.17	0.36	4.59e-12	Diastolic blood pressure;
LIHC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-9.21	-0.45	3.35e-18	Gut microbiome composition (summer);
LIHC	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.4	-6.55	-0.33	2.11e-10	Lung cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03160445	chr3:100120349	LNP1;TOMM70A	0.36	6.06	0.31	3.64e-9	Cognitive function;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.17	-0.32	1.91e-9	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg16449302	chr5:108744973	PJA2	0.36	6.27	0.32	1.09e-9	Calcium levels;
LIHC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.96	19.09	0.72	7.83e-56	Breast cancer;
LIHC	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg20636351	chr8:55087400	NA	-0.39	-7.89	-0.39	4.05e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.54	0.38	4.13e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.47	0.49	1.9e-22	Dupuytren's disease;
LIHC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.36	7.23	0.36	3.09e-12	Alcohol dependence;
LIHC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg00612595	chr21:47717864	NA	-0.35	-5.77	-0.3	1.81e-8	Testicular germ cell tumor;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.68	9.69	0.46	8.89e-20	Body mass index;
LIHC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg10820045	chr2:198174542	NA	-0.57	-9.68	-0.46	9.35e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-13.52	-0.59	1.14e-33	Primary sclerosing cholangitis;
LIHC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.48	7.82	0.39	6.52e-14	Lung cancer;
LIHC	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.1	-0.4	9.8e-15	Response to antipsychotic treatment;
LIHC	cis	rs6750047	0.546	rs2082255	chr2:38273758	C/A	cg07380506	chr2:38303506	CYP1B1	0.6	7.72	0.39	1.28e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.35	5.95	0.31	6.79e-9	Height;
LIHC	cis	rs10949834	0.689	rs2269081	chr7:73519887	T/G	cg07137043	chr7:73588983	EIF4H	-0.63	-6.48	-0.33	3.17e-10	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg14930904	chr10:32216787	ARHGAP12	0.37	6.4	0.33	5.1e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.35	6.07	0.31	3.31e-9	Metabolic traits;
LIHC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg06096015	chr1:231504339	EGLN1	-0.47	-8.79	-0.43	7.46e-17	Hemoglobin concentration;
LIHC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.83	11.97	0.54	7.86e-28	Hemoglobin concentration;Hematocrit;
LIHC	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	6.79	0.34	5.03e-11	Exhaled nitric oxide output;
LIHC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Life satisfaction;
LIHC	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg18081818	chr7:23246105	NA	-0.4	-5.98	-0.31	5.71e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11605275	1.000	rs77993017	chr11:20031388	C/G	cg14835545	chr11:20032148	NAV2	-0.8	-7.39	-0.37	1.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg11212589	chr17:38028394	ZPBP2	0.36	7.32	0.37	1.73e-12	Self-reported allergy;
LIHC	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg03945807	chr20:60948434	NA	0.35	6.09	0.31	3.03e-9	Colorectal cancer;
LIHC	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.67	-0.34	1.05e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs400736	0.800	rs225095	chr1:8102801	T/C	cg25007680	chr1:8021821	PARK7	0.63	9.77	0.47	4.77e-20	Response to antidepressants and depression;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.34	0.37	1.58e-12	Renal cell carcinoma;
LIHC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.34	-0.56	3.41e-29	Primary sclerosing cholangitis;
LIHC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs10420951	0.579	rs75445489	chr19:18571150	G/A	cg10790698	chr19:18539756	SSBP4	-0.42	-6.03	-0.31	4.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.45	6.51	0.33	2.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02985541	chr2:219472218	PLCD4	-0.38	-6.47	-0.33	3.47e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs26949	0.511	rs11740327	chr5:59899413	G/A	cg02684056	chr5:59996105	DEPDC1B	0.4	5.99	0.31	5.32e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.45	8.32	0.41	2.08e-15	Testicular germ cell tumor;
LIHC	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg27005118	chr17:13972210	COX10	-0.36	-6.63	-0.34	1.32e-10	Temperament;
LIHC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.95	0.54	9.43e-28	Colorectal cancer;
LIHC	cis	rs12464559	0.522	rs4316939	chr2:152525120	C/T	cg01189475	chr2:152685088	ARL5A	-0.71	-9.2	-0.45	3.49e-18	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg07148914	chr20:33460835	GGT7	0.43	5.94	0.31	6.9e-9	Height;
LIHC	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	0.77	8.96	0.44	2.12e-17	Exhaled nitric oxide output;
LIHC	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.86	-9.99	-0.48	8.71e-21	Alzheimer's disease (late onset);
LIHC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.45	7.72	0.39	1.29e-13	Mean corpuscular volume;
LIHC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.6	-10.3	-0.49	7.81e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.55	8.62	0.42	2.44e-16	Height;
LIHC	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.59	10.04	0.48	5.95e-21	Dupuytren's disease;
LIHC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg12798992	chr6:167411361	FGFR1OP	0.42	6.61	0.34	1.48e-10	Primary biliary cholangitis;
LIHC	cis	rs1403694	0.966	rs1648715	chr3:186439618	A/G	cg12454167	chr3:186435060	KNG1	0.29	7.17	0.36	4.62e-12	Blood protein levels;
LIHC	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.44	6.22	0.32	1.44e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-10.13	-0.48	2.81e-21	Renal cell carcinoma;
LIHC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	0.92	17.13	0.68	6.07e-48	Bone mineral density;
LIHC	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg07636037	chr3:49044803	WDR6	-0.56	-6.45	-0.33	3.85e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22456539	chr1:11741693	MAD2L2	0.42	6.23	0.32	1.39e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.39	-6.27	-0.32	1.09e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.21	0.32	1.52e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.66	-12.48	-0.56	1.02e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.45	-7.27	-0.37	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7523273	0.597	rs2761437	chr1:207923081	A/G	cg22525895	chr1:207977042	MIR29B2	0.64	7.52	0.38	4.85e-13	Schizophrenia;
LIHC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17286411	0.750	rs4788575	chr16:71931126	T/G	cg06353428	chr16:71660113	MARVELD3	0.54	6.82	0.35	4.02e-11	Blood protein levels;
LIHC	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.72	-0.43	1.26e-16	Type 2 diabetes;
LIHC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg09182678	chr22:50328711	NA	-0.39	-5.82	-0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs6449957	0.590	rs6881033	chr5:67529191	A/G	cg23036683	chr5:67512108	NA	-0.4	-5.8	-0.3	1.5e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.28	-0.32	1.03e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg03037974	chr15:76606532	NA	0.74	14.44	0.62	3.1e-37	Blood metabolite levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14485789	chr2:236586744	AGAP1	0.41	6.05	0.31	3.76e-9	Longevity;
LIHC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.32	6.11	0.31	2.71e-9	Renal cell carcinoma;
LIHC	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg02023728	chr11:77925099	USP35	-0.36	-6.29	-0.32	9.63e-10	Alzheimer's disease (survival time);
LIHC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg07636037	chr3:49044803	WDR6	-0.8	-8.17	-0.4	6.25e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.65	9.53	0.46	3.02e-19	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.43	7.85	0.39	5.26e-14	Prudent dietary pattern;
LIHC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.47e-37	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.4	7.67	0.38	1.77e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg09417038	chr21:47716443	C21orf57	0.46	7.03	0.36	1.11e-11	Testicular germ cell tumor;
LIHC	cis	rs988712	0.705	rs10501087	chr11:27670108	C/T	cg18117895	chr11:27722066	BDNF	-0.5	-6.91	-0.35	2.33e-11	Obesity;
LIHC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.72	-0.43	1.26e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Coronary artery disease;
LIHC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg27211696	chr2:191398769	TMEM194B	-0.51	-6.57	-0.33	1.87e-10	Diastolic blood pressure;
LIHC	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg01364799	chr7:75623366	TMEM120A	0.54	8.42	0.41	1.09e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.32	7.03	0.36	1.14e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13409248	chr3:40428643	ENTPD3	0.39	6.17	0.32	1.94e-9	Renal cell carcinoma;
LIHC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.75	8.32	0.41	2.13e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-7.75	-0.39	1.07e-13	Chronic sinus infection;
LIHC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.77	8.62	0.42	2.6e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.08	-0.31	3.13e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.17	-0.32	1.91e-9	Schizophrenia;
LIHC	cis	rs611744	0.934	rs609102	chr8:109227406	A/G	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.41	-6.38	-0.33	5.85e-10	Systemic sclerosis;
LIHC	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg06664874	chr5:179499304	RNF130	-0.58	-7.12	-0.36	6.37e-12	LDL cholesterol;
LIHC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	8.42	0.41	1.04e-15	Platelet count;
LIHC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26031613	chr14:104095156	KLC1	1.03	13.02	0.58	9.24e-32	Body mass index;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg26939375	chr7:64535504	NA	-0.46	-6.97	-0.35	1.6e-11	Corneal structure;
LIHC	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.72	6.87	0.35	3.09e-11	Inflammatory bowel disease;
LIHC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.53	-6.91	-0.35	2.42e-11	Pancreatic cancer;
LIHC	cis	rs4788570	0.566	rs72791974	chr16:71478574	A/T	cg06353428	chr16:71660113	MARVELD3	-1.11	-10.04	-0.48	6.1e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg03037974	chr15:76606532	NA	0.74	14.63	0.62	5.72e-38	Blood metabolite levels;
LIHC	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08754654	chr5:154026448	NA	-0.32	-7.2	-0.36	3.8e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs116248771	0.739	rs114379619	chr3:158338781	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.28	0.32	1.04e-9	diarrhoeal disease at age 2;
LIHC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg18709589	chr6:96969512	KIAA0776	-0.47	-5.76	-0.3	1.83e-8	Migraine;Coronary artery disease;
LIHC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.6	12.6	0.56	3.64e-30	Fat distribution (HIV);
LIHC	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.26	6.56	0.33	2e-10	Menarche (age at onset);
LIHC	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.25	-0.32	1.22e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg15282417	chr9:129245246	FAM125B	0.39	6.28	0.32	1.01e-9	Intraocular pressure;
LIHC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg26395211	chr5:140044315	WDR55	-0.41	-6.0	-0.31	4.91e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg17385448	chr1:15911702	AGMAT	0.34	6.03	0.31	4.2e-9	Systolic blood pressure;
LIHC	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.23	0.61	2.02e-36	Bipolar disorder;
LIHC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.84	-15.86	-0.65	7.39e-43	Height;
LIHC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg02836325	chr17:76403955	PGS1	0.34	6.62	0.34	1.36e-10	HDL cholesterol levels;
LIHC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02034447	chr16:89574710	SPG7	0.49	7.38	0.37	1.25e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.1	-0.31	2.91e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.4	0.45	8.03e-19	Melanoma;
LIHC	cis	rs11671005	0.656	rs11672609	chr19:59006924	C/T	cg25952890	chr19:58913133	NA	0.68	6.55	0.33	2.08e-10	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-1.04	-17.61	-0.69	7.19e-50	Monocyte percentage of white cells;
LIHC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.65	11.14	0.52	8.5e-25	Response to diuretic therapy;
LIHC	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.76	8.81	0.43	6.58e-17	Mitochondrial DNA levels;
LIHC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.64	8.35	0.41	1.72e-15	Motion sickness;
LIHC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	12.24	0.55	8.24e-29	Platelet count;
LIHC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.58	7.84	0.39	5.89e-14	Bone mineral density (spine);
LIHC	trans	rs10411161	1.000	rs4514789	chr19:52365654	A/G	cg22319618	chr22:45562946	NUP50	-0.49	-6.84	-0.35	3.7e-11	Breast cancer;
LIHC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg25039879	chr17:56429692	SUPT4H1	0.78	8.84	0.43	5.15e-17	Cognitive test performance;
LIHC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.29	-6.02	-0.31	4.43e-9	Blood metabolite levels;
LIHC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.48	-7.02	-0.35	1.22e-11	Urate levels in obese individuals;
LIHC	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.46	-0.37	6.98e-13	Prevalent atrial fibrillation;
LIHC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.76	10.9	0.51	6.19e-24	Coronary artery disease;
LIHC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.35	0.32	6.93e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6466055	0.748	rs10266871	chr7:104812129	G/A	cg04380332	chr7:105027541	SRPK2	-0.35	-6.56	-0.33	2e-10	Schizophrenia;
LIHC	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg07424592	chr7:64974309	NA	0.75	8.73	0.43	1.16e-16	Diabetic kidney disease;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.38	-0.49	4.05e-22	Longevity;Endometriosis;
LIHC	cis	rs1986734	0.597	rs4859684	chr4:77419107	C/T	cg24201034	chr4:77507246	SHROOM3	-0.38	-6.0	-0.31	5.16e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs4979906	1.000	rs4979906	chr10:79444753	A/G	cg07817648	chr10:79422355	NA	-0.28	-6.05	-0.31	3.8e-9	Mortality in heart failure;
LIHC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg14779329	chr11:130786720	SNX19	0.42	6.36	0.33	6.33e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-10.99	-0.51	2.84e-24	Personality dimensions;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08595667	chr16:89445453	ANKRD11	0.43	6.05	0.31	3.82e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.4	8.55	0.42	4.13e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg27386326	chr11:61587980	NA	0.69	14.85	0.63	7.29e-39	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg04025307	chr7:1156635	C7orf50	0.55	7.19	0.36	4.2e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs116248771	0.739	rs10276	chr3:158415166	C/T	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.43e-10	diarrhoeal disease at age 2;
LIHC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.74	0.43	1.08e-16	Motion sickness;
LIHC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg17085576	chr10:5658249	NA	-0.34	-6.18	-0.32	1.83e-9	Breast cancer;
LIHC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.28	0.32	1.03e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg14709524	chr16:89940631	TCF25	0.51	6.9	0.35	2.59e-11	Interleukin-17 levels;
LIHC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.65	-12.42	-0.56	1.74e-29	Schizophrenia;
LIHC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.47	-0.33	3.45e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.73	-9.55	-0.46	2.67e-19	Type 2 diabetes;
LIHC	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg20697417	chr1:41786797	NA	0.31	5.91	0.3	8.23e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4908768	0.906	rs12409937	chr1:8538302	G/C	cg25722041	chr1:8623473	RERE	0.41	6.02	0.31	4.5e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-1.09	-13.71	-0.6	2.13e-34	Blood protein levels;
LIHC	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.94	17.91	0.7	4.47e-51	Menopause (age at onset);
LIHC	cis	rs9527	0.518	rs11191487	chr10:104734623	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-5.98	-0.31	5.6e-9	Arsenic metabolism;
LIHC	trans	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg16011800	chr17:1958478	HIC1	0.51	7.37	0.37	1.26e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.24	6.0	0.31	5e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.29	-0.32	9.92e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	1.04	11.8	0.54	3.42e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg19645103	chr12:69753606	YEATS4	-0.39	-5.87	-0.3	1.02e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg17623882	chr6:41773611	USP49	-0.43	-5.76	-0.3	1.91e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.86	-17.03	-0.68	1.55e-47	Height;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-0.42	-6.6	-0.34	1.61e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg24203234	chr3:128598194	ACAD9	0.43	5.95	0.31	6.79e-9	IgG glycosylation;
LIHC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.57	-0.38	3.54e-13	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.43	-0.33	4.24e-10	Longevity;
LIHC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.95	-18.25	-0.7	1.86e-52	Breast cancer;
LIHC	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.64	9.17	0.44	4.53e-18	Bipolar disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22246692	chr19:2475189	GADD45B	0.45	6.25	0.32	1.23e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-8.41	-0.41	1.14e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.47	-6.13	-0.31	2.48e-9	Coronary artery calcification;
LIHC	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg25179470	chr10:102756915	LZTS2	0.45	6.23	0.32	1.36e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.6	9.28	0.45	1.96e-18	Height;
LIHC	cis	rs332507	0.830	rs879535	chr3:124400107	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.07	0.36	8.83e-12	Plateletcrit;
LIHC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.34	-7.49	-0.38	5.95e-13	Type 2 diabetes;
LIHC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.59	-0.46	1.86e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg19633962	chr1:26362018	EXTL1	-0.76	-6.75	-0.34	6.25e-11	QRS complex (12-leadsum);
LIHC	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.33	20.83	0.75	8.23e-63	Corneal structure;
LIHC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.51	7.48	0.37	6.44e-13	Height;
LIHC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg18357645	chr12:58087776	OS9	-0.51	-7.78	-0.39	8.63e-14	Multiple sclerosis;
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.64	7.89	0.39	4.03e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.52	9.13	0.44	6.32e-18	Total body bone mineral density;
LIHC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	1.06	16.14	0.66	5.7e-44	Breast cancer;
LIHC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.35	0.49	5.15e-22	Dupuytren's disease;
LIHC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.47	-0.42	7.3e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.06	-0.31	3.69e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.48	7.51	0.38	5.23e-13	Methadone dose in opioid dependence;
LIHC	cis	rs34540877	1.000	rs117920513	chr19:33147520	C/T	cg22980127	chr19:33182716	NUDT19	0.87	6.07	0.31	3.49e-9	Red cell distribution width;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.83	-13.65	-0.59	3.62e-34	Morning vs. evening chronotype;
LIHC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.58	5.76	0.3	1.88e-8	Urate levels in lean individuals;
LIHC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-6.72	-0.34	7.57e-11	Bipolar disorder;
LIHC	cis	rs249954	0.512	rs35634	chr16:23697679	C/T	cg09867953	chr16:23706666	ERN2	0.35	5.88	0.3	9.91e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.5	-9.09	-0.44	8.33e-18	Glycated hemoglobin levels;
LIHC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.78	13.62	0.59	4.71e-34	Aortic root size;
LIHC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.31	-0.32	8.81e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.73	11.78	0.54	4.22e-27	Oral cavity cancer;
LIHC	cis	rs9309473	0.528	rs11126396	chr2:73565143	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.33	-0.37	1.67e-12	Metabolite levels;
LIHC	cis	rs9918079	0.542	rs1789	chr4:15664535	G/A	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.09	-0.36	7.61e-12	Obesity-related traits;
LIHC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg12374095	chr12:54320830	NA	0.4	5.86	0.3	1.08e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.59	7.5	0.38	5.55e-13	Morning vs. evening chronotype;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg04632378	chr13:21900426	NA	0.37	6.13	0.31	2.48e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.43	6.16	0.32	2.08e-9	Aortic root size;
LIHC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.45	-0.37	7.71e-13	Urate levels in overweight individuals;
LIHC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.8	11.94	0.54	1.04e-27	Coronary artery disease;
LIHC	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.54	-8.13	-0.4	7.72e-15	P wave terminal force;
LIHC	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-9.95	-0.47	1.15e-20	Mosquito bite size;
LIHC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg24209194	chr3:40518798	ZNF619	0.42	5.97	0.31	6.06e-9	Renal cell carcinoma;
LIHC	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.52	0.46	3.18e-19	Intelligence (multi-trait analysis);
LIHC	trans	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg01596870	chr19:55963115	NA	-0.65	-9.5	-0.46	3.64e-19	Obesity-related traits;
LIHC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg04374321	chr14:90722782	PSMC1	0.44	6.08	0.31	3.23e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg03934865	chr2:198174659	NA	0.54	8.27	0.41	3.03e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg15691649	chr6:25882328	NA	-0.51	-7.38	-0.37	1.22e-12	Blood metabolite levels;
LIHC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.87	-12.58	-0.56	4.33e-30	Blood metabolite levels;
LIHC	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.31	7.04	0.36	1.07e-11	Blood metabolite ratios;
LIHC	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.43	-6.01	-0.31	4.86e-9	QT interval;
LIHC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg16797656	chr11:68205561	LRP5	0.52	8.27	0.41	2.96e-15	Total body bone mineral density;
LIHC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.28	0.45	1.98e-18	Bipolar disorder;
LIHC	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs9649465	1.000	rs7803287	chr7:123354807	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-7.96	-0.4	2.58e-14	Migraine;
LIHC	cis	rs2834188	0.924	rs6517160	chr21:34683512	A/G	cg14352951	chr21:34696688	IFNAR1	0.46	6.39	0.33	5.51e-10	Narcolepsy;
LIHC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg24879335	chr3:133465180	TF	0.28	6.35	0.32	6.74e-10	Iron status biomarkers;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.61	-10.08	-0.48	4.32e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.32	6.56	0.33	1.97e-10	Blood metabolite levels;
LIHC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg05941027	chr17:61774174	LIMD2	0.37	7.75	0.39	1.07e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.92	0.54	1.23e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.85	-0.3	1.17e-8	Coronary artery disease;
LIHC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.33	6.25	0.32	1.21e-9	Alcohol dependence;
LIHC	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	0.66	7.26	0.37	2.57e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.46	-7.35	-0.37	1.47e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.63	12.68	0.57	1.89e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.43	-7.73	-0.39	1.24e-13	Aortic root size;
LIHC	cis	rs716804	0.819	rs716803	chr11:10247283	C/A	cg01453529	chr11:10209919	SBF2	-0.3	-5.92	-0.3	7.89e-9	Neuroticism;
LIHC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.39	-6.06	-0.31	3.52e-9	Cognitive function;
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.94	14.48	0.62	2.22e-37	Skin colour saturation;
LIHC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-7.29	-0.37	2.13e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.58	0.34	1.76e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1789	0.868	rs4631041	chr4:15673395	A/T	cg24225360	chr4:15471699	CC2D2A	-0.38	-5.91	-0.3	8.24e-9	Blood protein levels;
LIHC	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.62	-7.39	-0.37	1.15e-12	Vitiligo;
LIHC	trans	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg10756647	chr7:56101905	PSPH	-1.07	-13.17	-0.58	2.44e-32	Diabetic kidney disease;
LIHC	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.68	11.31	0.52	2.09e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg14440974	chr22:39074834	NA	-0.36	-6.05	-0.31	3.78e-9	Menopause (age at onset);
LIHC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg16486109	chr11:613632	IRF7	0.61	6.81	0.35	4.44e-11	Systemic lupus erythematosus;
LIHC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.53	0.56	6.58e-30	Menopause (age at onset);
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.82	-0.35	4.15e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs11958404	0.932	rs112683473	chr5:157437819	T/C	cg05962755	chr5:157440814	NA	0.99	11.5	0.53	4.32e-26	IgG glycosylation;
LIHC	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg18887096	chr2:219472410	PLCD4	0.39	6.74	0.34	6.62e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg20195005	chr22:42527684	CYP2D6	0.31	5.89	0.3	9.43e-9	Birth weight;
LIHC	cis	rs7818688	0.697	rs78777150	chr8:95984411	C/G	cg16049864	chr8:95962084	TP53INP1	0.6	6.55	0.33	2.08e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg07061783	chr6:25882402	NA	-0.47	-6.48	-0.33	3.29e-10	Blood metabolite levels;
LIHC	cis	rs74544699	1.000	rs57274239	chr4:74789027	A/G	cg02530824	chr4:74847766	PF4	0.64	6.68	0.34	9.72e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16828019	0.929	rs11209734	chr1:41698074	C/T	cg20697417	chr1:41786797	NA	0.34	6.51	0.33	2.61e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16512924	chr15:28394682	HERC2	0.47	7.35	0.37	1.5e-12	Longevity;
LIHC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	1.02	18.05	0.7	1.27e-51	Tonsillectomy;
LIHC	cis	rs3823572	0.564	rs2953624	chr7:133659125	C/G	cg03336402	chr7:133662267	EXOC4	-0.49	-5.93	-0.31	7.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.46	-7.15	-0.36	5.35e-12	Type 2 diabetes;
LIHC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.45	-0.37	7.82e-13	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27180563	chr19:13056485	RAD23A	-0.41	-6.35	-0.32	6.99e-10	Pancreatic cancer;
LIHC	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg05110241	chr16:68378359	PRMT7	0.48	5.76	0.3	1.91e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6442522	1.000	rs9847430	chr3:15449640	G/T	cg16303742	chr3:15540471	COLQ	0.41	6.95	0.35	1.91e-11	Uric acid levels;
LIHC	cis	rs1403694	0.695	rs11924390	chr3:186433099	T/C	cg12454167	chr3:186435060	KNG1	0.4	9.06	0.44	1.01e-17	Blood protein levels;
LIHC	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.45	-9.07	-0.44	9.84e-18	Plateletcrit;Platelet count;
LIHC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg21395723	chr22:39101663	GTPBP1	0.39	6.72	0.34	7.71e-11	Menopause (age at onset);
LIHC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.56	9.84	0.47	2.69e-20	Alcohol dependence;
LIHC	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg15871215	chr5:81402204	ATG10	0.68	8.24	0.41	3.82e-15	Breast cancer;
LIHC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg14440974	chr22:39074834	NA	-0.37	-5.84	-0.3	1.2e-8	Menopause (age at onset);
LIHC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.08	-14.97	-0.63	2.54e-39	Chronic sinus infection;
LIHC	cis	rs713477	0.654	rs12886848	chr14:55911138	G/A	cg13175173	chr14:55914753	NA	-0.31	-6.74	-0.34	6.64e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs1190552	0.747	rs1190538	chr14:102890919	T/C	cg10241871	chr14:102965420	TECPR2	0.41	6.09	0.31	2.96e-9	Blood protein levels;
LIHC	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.52	-8.24	-0.41	3.72e-15	Menopause (age at onset);
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg08916839	chr5:415575	AHRR	0.29	6.27	0.32	1.09e-9	Cystic fibrosis severity;
LIHC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.48	7.59	0.38	3.07e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21211367	chr2:162094118	NA	0.37	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.47	10.23	0.48	1.31e-21	Abdominal aortic aneurysm;
LIHC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	7.36	0.37	1.4e-12	Platelet count;
LIHC	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg09795085	chr6:101329169	ASCC3	-0.52	-7.25	-0.36	2.82e-12	Neuroticism;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.69	9.4	0.45	8.19e-19	Calcium levels;
LIHC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.49	7.45	0.37	7.58e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.89	-13.32	-0.58	6.91e-33	Sudden cardiac arrest;
LIHC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.94	13.39	0.59	3.63e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.41	-0.37	1.03e-12	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12639422	chr2:64069082	UGP2	0.43	6.14	0.32	2.25e-9	Pancreatic cancer;
LIHC	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-5.73	-0.3	2.17e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.6	-0.56	3.81e-30	Response to antipsychotic treatment;
LIHC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg17135325	chr3:160939158	NMD3	0.62	9.17	0.44	4.65e-18	Parkinson's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09097040	chr12:68726427	MDM1	-0.42	-6.46	-0.33	3.54e-10	Cognitive function;
LIHC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg16070123	chr10:51489643	NA	-0.38	-5.97	-0.31	6.05e-9	Prostate-specific antigen levels;
LIHC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	1.07	12.04	0.55	4.32e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.9	-0.3	8.92e-9	Resting heart rate;
LIHC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg02640540	chr1:67518911	SLC35D1	0.44	6.83	0.35	3.83e-11	Lymphocyte percentage of white cells;
LIHC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg16836995	chr17:43662488	NA	-0.73	-7.2	-0.36	3.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg10820045	chr2:198174542	NA	-0.47	-7.19	-0.36	4.07e-12	Dermatomyositis;
LIHC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18357526	chr6:26021779	HIST1H4A	0.61	9.11	0.44	7.09e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg25952890	chr19:58913133	NA	0.69	7.4	0.37	1.07e-12	Mean platelet volume;
LIHC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg27121462	chr16:89883253	FANCA	-0.37	-5.95	-0.31	6.54e-9	Vitiligo;
LIHC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg09182678	chr22:50328711	NA	0.46	6.0	0.31	5.01e-9	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.72	-10.75	-0.5	2e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg01864836	chr14:55583639	NA	-0.42	-8.19	-0.4	5.21e-15	Protein biomarker;
LIHC	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.3	0.41	2.49e-15	Corneal astigmatism;
LIHC	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.62	11.63	0.53	1.45e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.49	7.16	0.36	4.87e-12	Educational attainment;
LIHC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.64	-10.03	-0.48	6.44e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs546131	0.642	rs508062	chr11:34843820	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.65	9.31	0.45	1.64e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.52	0.71	1.52e-53	Tonsillectomy;
LIHC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	10.41	0.49	3.27e-22	Chronic sinus infection;
LIHC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.55	-6.01	-0.31	4.81e-9	Menarche (age at onset);
LIHC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.03	-0.31	4.3e-9	Total body bone mineral density;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.76	11.79	0.54	3.75e-27	Longevity;
LIHC	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.36	7.66	0.38	1.95e-13	Optic cup area;
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs72627123	0.656	rs77660260	chr14:74569573	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	8.36	0.41	1.65e-15	Morning vs. evening chronotype;
LIHC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.85	9.71	0.46	7.86e-20	Initial pursuit acceleration;
LIHC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.38e-12	Bipolar disorder;
LIHC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg18357645	chr12:58087776	OS9	-0.44	-6.82	-0.35	4.17e-11	Multiple sclerosis;
LIHC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.25	-0.37	2.79e-12	Response to antipsychotic treatment;
LIHC	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	9.6	0.46	1.76e-19	Red blood cell count;
LIHC	cis	rs600806	0.893	rs370088	chr1:109858119	T/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.93	-0.31	7.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9649465	0.967	rs1005568	chr7:123306470	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.56e-14	Migraine;
LIHC	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.58e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg17371911	chr8:10683139	PINX1;MIR1322	-0.47	-6.06	-0.31	3.52e-9	Monocyte count;
LIHC	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.47	6.27	0.32	1.08e-9	Mean platelet volume;
LIHC	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.62	10.41	0.49	3.16e-22	Recombination rate (males);
LIHC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.5	-6.3	-0.32	8.97e-10	Menarche (age at onset);
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.89	-0.3	9.32e-9	Menopause (age at onset);
LIHC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.75	-0.39	1.09e-13	Schizophrenia;
LIHC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg15448220	chr1:150897856	SETDB1	-0.38	-5.91	-0.3	8.22e-9	Blood protein levels;
LIHC	cis	rs9513627	1.000	rs3928270	chr13:100184268	A/G	cg25919922	chr13:100150906	NA	0.78	7.13	0.36	5.91e-12	Obesity-related traits;
LIHC	cis	rs12602486	1.000	rs78867692	chr17:42263873	G/C	cg13607699	chr17:42295918	UBTF	-0.74	-6.4	-0.33	5.05e-10	Glycated hemoglobin levels;
LIHC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.62	-0.38	2.59e-13	Type 2 diabetes;
LIHC	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.12	-9.88	-0.47	2.02e-20	Schizophrenia;
LIHC	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg05340658	chr4:99064831	C4orf37	0.7	10.67	0.5	3.88e-23	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.21e-9	Mean corpuscular volume;
LIHC	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.53	0.42	4.82e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.67e-12	Bipolar disorder;
LIHC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.5	8.92	0.43	2.77e-17	Height;
LIHC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.27	-0.58	1.06e-32	Primary sclerosing cholangitis;
LIHC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.34	-0.41	1.88e-15	Gut microbiome composition (summer);
LIHC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.38	-8.65	-0.42	2.09e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg21573476	chr21:45109991	RRP1B	-0.47	-9.16	-0.44	4.95e-18	Mean corpuscular volume;
LIHC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.36	5.82	0.3	1.34e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg25179470	chr10:102756915	LZTS2	0.45	6.32	0.32	8.06e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.48	7.66	0.38	1.95e-13	Blood protein levels;
LIHC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	8.01	0.4	1.88e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.43	6.3	0.32	9.04e-10	Dementia with Lewy bodies;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs34540877	1.000	rs35017666	chr19:33161314	G/A	cg22980127	chr19:33182716	NUDT19	0.86	5.98	0.31	5.74e-9	Red cell distribution width;
LIHC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.12	-0.36	6.3e-12	Response to antipsychotic treatment;
LIHC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.35	-0.37	1.46e-12	Breast cancer;
LIHC	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.73	10.21	0.48	1.49e-21	Left atrial antero-posterior diameter;
LIHC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.58	6.88	0.35	2.9100000000000002e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg14393609	chr7:65229607	NA	0.39	6.47	0.33	3.37e-10	Aortic root size;
LIHC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	0.9	15.02	0.63	1.55e-39	Left atrial antero-posterior diameter;
LIHC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.04	21.14	0.75	4.79e-64	Schizophrenia;
LIHC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.48	-5.8	-0.3	1.51e-8	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg09045935	chr12:6379348	NA	0.84	7.17	0.36	4.54e-12	Blood metabolite levels;
LIHC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg08847533	chr14:75593920	NEK9	-0.39	-6.54	-0.33	2.28e-10	Caffeine consumption;
LIHC	cis	rs55665837	0.540	rs12788030	chr11:14764684	C/T	cg25251204	chr11:14927456	NA	0.4	5.74	0.3	2.11e-8	Vitamin D levels;
LIHC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.03e-26	Chronic sinus infection;
LIHC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.97	-0.31	5.82e-9	Heart rate;
LIHC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.56	10.86	0.51	8.42e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	1.01	14.44	0.62	3.14e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.21	-0.41	4.47e-15	Total cholesterol levels;
LIHC	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.7	-9.43	-0.45	6.54e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.57	5.88	0.3	9.8e-9	IgG glycosylation;
LIHC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg18357645	chr12:58087776	OS9	-0.44	-6.89	-0.35	2.69e-11	Multiple sclerosis;
LIHC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-6.85	-0.35	3.49e-11	Migraine;Coronary artery disease;
LIHC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18357526	chr6:26021779	HIST1H4A	0.44	6.43	0.33	4.17e-10	Height;
LIHC	cis	rs2073300	1.000	rs6036418	chr20:23449698	A/G	cg12062639	chr20:23401060	NAPB	0.61	7.34	0.37	1.6e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.79	-10.75	-0.5	2.11e-23	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7432375	0.901	rs7616204	chr3:136444589	C/T	cg21827317	chr3:136751795	NA	-0.44	-5.83	-0.3	1.27e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg05484376	chr2:27715224	FNDC4	0.4	6.61	0.34	1.52e-10	Total body bone mineral density;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.71	-10.71	-0.5	2.83e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.61	9.52	0.46	3.33e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg00864860	chr1:7907996	UTS2	0.6	5.93	0.31	7.29e-9	Inflammatory bowel disease;
LIHC	cis	rs61677309	0.638	rs58162302	chr11:118146199	A/T	cg06090739	chr11:118230722	UBE4A	0.32	6.04	0.31	3.98e-9	Lung cancer in ever smokers;
LIHC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.48	6.38	0.33	5.82e-10	Major depressive disorder;
LIHC	cis	rs6545883	0.894	rs6545845	chr2:61437044	G/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.25	-0.36	2.8e-12	Tuberculosis;
LIHC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg17724175	chr1:150552817	MCL1	0.46	9.13	0.44	6.32e-18	Melanoma;
LIHC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg16586182	chr3:47516702	SCAP	-0.54	-9.89	-0.47	1.96e-20	Colorectal cancer;
LIHC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	6.24	0.32	1.3e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg20368463	chr18:77673604	PQLC1	-0.36	-6.32	-0.32	8.1e-10	Schizophrenia;
LIHC	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.39	8.34	0.41	1.85e-15	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.28	-6.04	-0.31	3.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg10096929	chr1:156261403	TMEM79	0.41	6.77	0.34	5.47e-11	Tonsillectomy;
LIHC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.33	0.52	1.75e-25	Platelet count;
LIHC	cis	rs36051895	0.632	rs7849717	chr9:5170080	G/A	cg02405213	chr9:5042618	JAK2	-0.69	-10.5	-0.49	1.54e-22	Pediatric autoimmune diseases;
LIHC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.29	-5.73	-0.3	2.21e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg10820045	chr2:198174542	NA	0.49	7.76	0.39	1.02e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3731896	1.000	rs3731896	chr2:220146402	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.59	7.08	0.36	8.04e-12	Educational attainment;
LIHC	cis	rs16828019	0.929	rs10524	chr1:41726473	T/C	cg20697417	chr1:41786797	NA	0.34	6.53	0.33	2.31e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2092850	1	rs2092850	chr6:88100419	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.38	-5.82	-0.3	1.36e-8	Itch intensity from mosquito bite;
LIHC	cis	rs7487075	0.558	rs7959095	chr12:46633328	G/T	cg15584813	chr12:47219626	SLC38A4	0.32	5.83	0.3	1.26e-8	Itch intensity from mosquito bite;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.45	-6.24	-0.32	1.26e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-12.18	-0.55	1.37e-28	Chronic sinus infection;
LIHC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.38	8.17	0.4	5.92e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.75	0.47	5.77e-20	Bipolar disorder;
LIHC	trans	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.66	-10.95	-0.51	4.08e-24	Bipolar disorder;
LIHC	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.64	8.18	0.4	5.57e-15	Blood metabolite levels;
LIHC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.93	9.54	0.46	2.9e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg00647820	chr17:40259828	DHX58	-0.29	-5.82	-0.3	1.39e-8	Fibrinogen levels;
LIHC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.49	-7.85	-0.39	5.29e-14	Electroencephalogram traits;
LIHC	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.3	-7.85	-0.39	5.35e-14	Intelligence;
LIHC	cis	rs12286929	0.644	rs12099024	chr11:115082142	A/G	cg04055981	chr11:115044050	NA	0.46	6.76	0.34	6.05e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05030077	chr16:2255199	MLST8	0.47	6.54	0.33	2.31e-10	Lung function (FEV1/FVC);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08882882	chr6:84937375	KIAA1009	0.42	6.35	0.32	6.81e-10	Cognitive function;
LIHC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.56	-0.5	9.22e-23	Breast cancer;
LIHC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg03037974	chr15:76606532	NA	0.8	16.57	0.67	1.05e-45	Blood metabolite levels;
LIHC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg22676075	chr6:135203613	NA	0.38	6.23	0.32	1.4e-9	Red blood cell count;
LIHC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.67	13.22	0.58	1.57e-32	High light scatter reticulocyte count;
LIHC	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.65	6.57	0.33	1.86e-10	Lymphocyte counts;
LIHC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	0.89	7.89	0.39	4.06e-14	Lymphocyte counts;
LIHC	cis	rs7487075	0.619	rs4768717	chr12:46831561	C/T	cg23829395	chr12:46796953	NA	0.34	6.05	0.31	3.81e-9	Itch intensity from mosquito bite;
LIHC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.95	22.44	0.77	3.39e-69	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1432089	0.773	rs62344305	chr4:171787203	C/T	cg02328223	chr3:127541927	MGLL	-0.42	-6.09	-0.31	3.02e-9	Endometriosis;
LIHC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.67	0.42	1.82e-16	Menarche (age at onset);
LIHC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-9.99	-0.48	8.48e-21	Obesity-related traits;
LIHC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg25894440	chr7:65020034	NA	-0.58	-6.27	-0.32	1.08e-9	Diabetic kidney disease;
LIHC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.32	0.41	2.15e-15	Platelet count;
LIHC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-9.45	-0.46	5.47e-19	Body mass index;
LIHC	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.65	-6.85	-0.35	3.5e-11	Hair shape;
LIHC	cis	rs1775715	0.870	rs1419168	chr10:32257332	A/C	cg14930904	chr10:32216787	ARHGAP12	0.4	7.1	0.36	7.47e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.6	9.04	0.44	1.16e-17	Menopause (age at onset);
LIHC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg12373951	chr3:133503437	NA	0.43	7.09	0.36	7.95e-12	Iron status biomarkers;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.52	-0.33	2.58e-10	Longevity;Endometriosis;
LIHC	cis	rs16922576	0.640	rs12343727	chr9:5215926	A/G	cg02405213	chr9:5042618	JAK2	-0.59	-9.4	-0.45	7.97e-19	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.34	-0.45	1.31e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs12980942	0.872	rs10421990	chr19:41797099	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.18	0.32	1.83e-9	Coronary artery disease;
LIHC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.69	10.52	0.49	1.28e-22	Height;
LIHC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.5	6.48	0.33	3.16e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg10402321	chr1:26617780	UBXN11	-0.38	-5.78	-0.3	1.65e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.55	-0.46	2.52e-19	Initial pursuit acceleration;
LIHC	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg10241871	chr14:102965420	TECPR2	-0.43	-6.69	-0.34	9.13e-11	Plateletcrit;
LIHC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.64	-0.38	2.27e-13	Total body bone mineral density;
LIHC	cis	rs1401454	0.967	rs11023881	chr11:16246700	T/A	cg02656851	chr11:16430247	SOX6	-0.32	-6.11	-0.31	2.66e-9	Blood pressure;
LIHC	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg07856975	chr6:36356162	ETV7	-0.35	-5.78	-0.3	1.69e-8	Platelet distribution width;
LIHC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.82	-0.35	4.02e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.67	0.38	1.75e-13	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.81	-14.37	-0.61	5.58e-37	Schizophrenia;
LIHC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.5	8.92	0.43	2.77e-17	Height;
LIHC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.32	-0.32	8.19e-10	Total cholesterol levels;
LIHC	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.49	8.18	0.4	5.6e-15	Schizophrenia;
LIHC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.53	7.14	0.36	5.62e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.93	17.09	0.68	9.35e-48	Breast cancer;
LIHC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.47	-6.86	-0.35	3.24e-11	Aortic root size;
LIHC	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.54e-11	Type 2 diabetes;
LIHC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.27	-6.68	-0.34	9.98e-11	Mean corpuscular volume;
LIHC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.88	-0.3	9.64e-9	Schizophrenia;
LIHC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.42	-5.76	-0.3	1.87e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg21522988	chr12:29376872	FAR2	0.27	6.17	0.32	1.98e-9	QT interval;
LIHC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	1.03	18.4	0.71	4.71e-53	Multiple system atrophy;
LIHC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.27	0.37	2.41e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg03932398	chr20:1206703	RAD21L1	0.44	7.22	0.36	3.45e-12	Multiple sclerosis;
LIHC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.55	7.77	0.39	9.38e-14	Lung cancer;
LIHC	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.02	-0.31	4.53e-9	Mean corpuscular volume;
LIHC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.09	-0.31	3.08e-9	Alzheimer's disease (late onset);
LIHC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.25e-12	Bipolar disorder;
LIHC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.57	-10.48	-0.49	1.82e-22	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg03721293	chr16:90014378	DEF8	0.41	6.89	0.35	2.62e-11	Skin colour saturation;
LIHC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg18016565	chr1:150552671	MCL1	-0.5	-10.31	-0.49	6.9e-22	Tonsillectomy;
LIHC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg14440974	chr22:39074834	NA	-0.39	-6.24	-0.32	1.28e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.43	0.56	1.58e-29	Prudent dietary pattern;
LIHC	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg03934865	chr2:198174659	NA	0.54	8.37	0.41	1.51e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.89	0.3	9.32e-9	Menopause (age at onset);
LIHC	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg14146966	chr2:61757674	XPO1	0.48	8.46	0.42	7.73e-16	Tuberculosis;
LIHC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.32	0.32	8.22e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7258015	1.000	rs3176767	chr19:10449751	A/C	cg13981319	chr19:10446556	ICAM3	0.39	6.34	0.32	7.06e-10	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.6	10.02	0.48	6.61e-21	HDL cholesterol;
LIHC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg16102536	chr7:156981717	UBE3C	-0.35	-5.9	-0.3	8.69e-9	Body mass index;
LIHC	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.89	-10.22	-0.48	1.44e-21	Breast cancer;
LIHC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17467752	chr17:38218738	THRA	-0.5	-8.62	-0.42	2.53e-16	White blood cell count;
LIHC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.34	7.29	0.37	2.21e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.66	0.53	1.15e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.09	0.58	5.25e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.37	-6.0	-0.31	4.96e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.68	-11.03	-0.51	2.15e-24	Lung cancer;
LIHC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-16.72	-0.67	2.81e-46	Gut microbiome composition (summer);
LIHC	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.78	10.38	0.49	4e-22	Post bronchodilator FEV1;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01704976	chr3:52273381	TWF2	-0.42	-6.55	-0.33	2.16e-10	Cognitive function;
LIHC	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.85	-0.3	1.18e-8	Biliary atresia;
LIHC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.37	7.02	0.35	1.19e-11	Type 2 diabetes;
LIHC	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg07451762	chr16:28383216	NA	-0.38	-6.43	-0.33	4.24e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.74	6.97	0.35	1.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14968603	chr10:102046143	BLOC1S2	-0.39	-6.06	-0.31	3.67e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs79389047	1.000	rs76212864	chr4:157669091	A/T	cg18148021	chr14:56616059	PELI2	0.42	6.28	0.32	1.04e-9	Plateletcrit;
LIHC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.69	-0.34	9.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3764618	1.000	rs2303049	chr19:49494812	C/T	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.73	-5.95	-0.31	6.8e-9	Follicule stimulating hormone;
LIHC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.65	0.38	2e-13	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg00280220	chr17:61926910	NA	0.42	6.73	0.34	7.18e-11	Prudent dietary pattern;
LIHC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.33	7.42	0.37	9.44e-13	Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg20891283	chr12:69753455	YEATS4	0.48	6.98	0.35	1.55e-11	Response to diuretic therapy;
LIHC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg20946044	chr11:1010712	AP2A2	-0.34	-5.97	-0.31	6.11e-9	Alzheimer's disease (late onset);
LIHC	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.54	9.51	0.46	3.46e-19	Systemic lupus erythematosus;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10102242	chr16:4422216	VASN;CORO7	-0.48	-6.71	-0.34	8.06e-11	Pancreatic cancer;
LIHC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.9	-0.3	8.98e-9	Menarche (age at onset);
LIHC	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.6	10.03	0.48	6.14e-21	HDL cholesterol;
LIHC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.23	-0.36	3.09e-12	Bipolar disorder;
LIHC	cis	rs4478037	0.822	rs9875140	chr3:33117068	T/A	cg27203090	chr3:33138513	GLB1;TMPPE	-0.58	-7.42	-0.37	9.39e-13	Major depressive disorder;
LIHC	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg20991723	chr1:152506922	NA	0.59	10.48	0.49	1.85e-22	Hair morphology;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.59	10.33	0.49	6.08e-22	Longevity;Endometriosis;
LIHC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg16836995	chr17:43662488	NA	0.61	6.46	0.33	3.53e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12922040	1.000	rs2075516	chr16:15869525	C/T	cg27174420	chr16:15820903	MYH11	0.36	6.13	0.31	2.48e-9	Serum uric acid levels in response to allopurinol in gout;
LIHC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.81	-13.72	-0.6	2.01e-34	Dental caries;
LIHC	trans	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg17675199	chr6:35436792	RPL10A	0.41	8.42	0.41	1.06e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6504622	0.537	rs197918	chr17:45003080	A/G	cg16759221	chr17:45003025	GOSR2	-0.33	-5.74	-0.3	2.07e-8	Orofacial clefts;
LIHC	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg14473756	chr11:122847823	NA	-0.37	-6.79	-0.34	4.99e-11	Menarche (age at onset);
LIHC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg20933634	chr6:27740509	NA	0.46	6.2	0.32	1.64e-9	Parkinson's disease;
LIHC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg15691649	chr6:25882328	NA	-0.39	-6.22	-0.32	1.44e-9	Height;
LIHC	cis	rs7715806	0.500	rs77544433	chr5:75001025	C/A	cg00601450	chr5:74908170	NA	0.49	6.24	0.32	1.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.27e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-6.85	-0.35	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.92	-0.3	8e-9	Total body bone mineral density;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.71	-0.34	8.05e-11	Total body bone mineral density;
LIHC	cis	rs74233809	1.000	rs11191499	chr10:104764271	A/G	cg03493300	chr10:104813866	CNNM2	0.47	6.48	0.33	3.15e-10	Birth weight;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14108394	chr12:62997291	MIRLET7I;C12orf61	-0.44	-6.52	-0.33	2.51e-10	Pancreatic cancer;
LIHC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.59	10.51	0.49	1.41e-22	Dupuytren's disease;
LIHC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.42	7.71	0.38	1.4e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.54	-10.3	-0.49	7.38e-22	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25525087	chr17:17743565	NA	-0.46	-6.46	-0.33	3.63e-10	Pancreatic cancer;
LIHC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg00409905	chr10:38381863	ZNF37A	0.44	7.04	0.36	1.07e-11	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.36	-7.66	-0.38	1.98e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-6.77	-0.34	5.61e-11	Response to antipsychotic treatment;
LIHC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.95	-10.89	-0.51	6.74e-24	Vitiligo;
LIHC	cis	rs7188697	0.922	rs37060	chr16:58566304	C/T	cg02549819	chr16:58548995	SETD6	-0.43	-6.84	-0.35	3.6e-11	QT interval;
LIHC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-6.49	-0.33	2.94e-10	Personality dimensions;
LIHC	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.57	9.39	0.45	9.01e-19	Corneal astigmatism;
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg02990361	chr1:107599529	PRMT6	0.65	11.07	0.51	1.48e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs875971	0.660	rs801190	chr7:66033033	C/T	cg26939375	chr7:64535504	NA	-0.43	-6.94	-0.35	2.02e-11	Aortic root size;
LIHC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	13.11	0.58	4.31e-32	Chronic sinus infection;
LIHC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg01557791	chr16:72042693	DHODH	-0.45	-7.52	-0.38	4.95e-13	Fibrinogen levels;
LIHC	cis	rs7319311	0.565	rs9588148	chr13:111021081	G/T	cg05272587	chr13:111038400	COL4A2	0.36	7.37	0.37	1.31e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.66	-7.88	-0.39	4.4e-14	LDL cholesterol to HDL cholesterol ratio;
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg20090690	chr10:134436459	INPP5A	0.45	5.99	0.31	5.44e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg16479474	chr6:28041457	NA	0.43	6.65	0.34	1.15e-10	Parkinson's disease;
LIHC	cis	rs7395581	0.959	rs901746	chr11:47260319	A/G	cg26139080	chr11:47293733	MADD	-0.48	-8.03	-0.4	1.63e-14	HDL cholesterol;
LIHC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-9.6	-0.46	1.79e-19	Heart rate;
LIHC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.72	10.6	0.5	6.95e-23	Prostate cancer;
LIHC	cis	rs12286929	0.669	rs11606837	chr11:115042837	C/T	cg04055981	chr11:115044050	NA	0.53	8.51	0.42	5.53e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.91e-23	Colorectal cancer;
LIHC	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg02290350	chr8:58132656	NA	0.47	9.11	0.44	7.19e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.58	8.73	0.43	1.16e-16	Testicular germ cell tumor;
LIHC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg15208524	chr1:10270712	KIF1B	0.37	5.71	0.3	2.46e-8	Hepatocellular carcinoma;
LIHC	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.78e-10	Obesity-related traits;
LIHC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	trans	rs4332037	0.619	rs78443464	chr7:1970229	C/T	cg11693508	chr17:37793320	STARD3	0.78	7.98	0.4	2.19e-14	Bipolar disorder;
LIHC	trans	rs1875517	0.510	rs11721241	chr3:117329656	A/C	cg18115495	chr7:65579946	CRCP	-0.41	-6.36	-0.33	6.58e-10	Waist circumference;
LIHC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.59	8.57	0.42	3.54e-16	Obesity-related traits;
LIHC	cis	rs2073300	1.000	rs6048827	chr20:23458080	T/C	cg12062639	chr20:23401060	NAPB	0.82	10.06	0.48	4.89e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.57	9.35	0.45	1.15e-18	Corneal astigmatism;
LIHC	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.47	6.85	0.35	3.41e-11	Smoking behavior;
LIHC	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.72	-11.39	-0.52	1.11e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4917833	0.738	rs7067713	chr10:100221120	T/C	cg19043522	chr10:100227446	HPSE2	0.4	5.76	0.3	1.83e-8	Pediatric bone mineral density (femoral neck);
LIHC	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg11693508	chr17:37793320	STARD3	0.66	7.0	0.35	1.4e-11	Bipolar disorder;
LIHC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.46	-0.33	3.57e-10	HDL cholesterol;
LIHC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.61	0.67	7.88e-46	Smoking behavior;
LIHC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.94	-0.39	2.89e-14	Type 2 diabetes;
LIHC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.49	5.95	0.31	6.5e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4407350	0.870	rs4823329	chr22:44910117	T/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.56	0.33	1.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.66	9.12	0.44	6.78e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.46	-0.46	5.22e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg04310649	chr10:35416472	CREM	0.42	5.75	0.3	1.95e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02985541	chr2:219472218	PLCD4	0.43	6.95	0.35	1.84e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg00343986	chr7:65444356	GUSB	0.39	5.85	0.3	1.14e-8	Aortic root size;
LIHC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg17980119	chr2:219472607	PLCD4	0.34	5.74	0.3	2.08e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.82	-0.43	5.91e-17	Total cholesterol levels;
LIHC	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg24579218	chr15:68104479	NA	-0.34	-5.77	-0.3	1.81e-8	Restless legs syndrome;
LIHC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.39	0.45	8.48e-19	Lung disease severity in cystic fibrosis;
LIHC	trans	rs3960554	0.600	rs2302429	chr7:75614777	G/A	cg19862616	chr7:65841803	NCRNA00174	0.53	6.84	0.35	3.65e-11	Eotaxin levels;
LIHC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	trans	rs916888	0.821	rs199499	chr17:44865498	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.76	-6.27	-0.32	1.11e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.39	-0.49	3.73e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs600806	0.683	rs10857789	chr1:110012293	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.48	-0.38	6.2e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.68	12.32	0.55	4.25e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg10381502	chr11:71823885	C11orf51	-1.02	-8.51	-0.42	5.38e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.56	-6.5	-0.33	2.87e-10	Metabolite levels;
LIHC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-7.15	-0.36	5.16e-12	Vitiligo;
LIHC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg08816869	chr17:79829959	ARHGDIA	0.49	6.08	0.31	3.18e-9	Morning vs. evening chronotype;
LIHC	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.49	7.07	0.36	8.72e-12	Asthma;
LIHC	trans	rs4604234	0.803	rs73463522	chr6:80979758	A/G	cg08069338	chr6:160207898	SNORA29;TCP1	0.64	6.2	0.32	1.63e-9	Cancer;
LIHC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.83	-0.47	3.09e-20	Height;
LIHC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	10.65	0.5	4.46e-23	Hemoglobin concentration;
LIHC	cis	rs655641	1.000	rs547767	chr11:85743449	A/G	cg09030501	chr11:85779252	PICALM	-0.54	-6.22	-0.32	1.45e-9	Platelet count;
LIHC	cis	rs3770081	1.000	rs17026854	chr2:86280496	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-8.88	-0.43	3.77e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-6.81	-0.35	4.5e-11	Hepatocellular carcinoma;
LIHC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.94	-0.31	6.83e-9	Tonsillectomy;
LIHC	cis	rs4919087	0.590	rs1253396	chr10:99045230	C/T	cg25902810	chr10:99078978	FRAT1	-0.6	-6.79	-0.34	4.92e-11	Monocyte count;
LIHC	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.65	10.79	0.5	1.54e-23	Breast cancer;
LIHC	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9896052	0.614	rs4073989	chr17:73450862	G/A	cg25649188	chr17:73499917	CASKIN2	0.46	6.92	0.35	2.21e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.45	5.82	0.3	1.36e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.83	13.13	0.58	3.52e-32	Height;
LIHC	cis	rs965469	0.779	rs3746630	chr20:3320902	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-6.63	-0.34	1.33e-10	IFN-related cytopenia;
LIHC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.59	9.12	0.44	6.8e-18	Ulcerative colitis;
LIHC	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-9.36	-0.45	1.08e-18	Morning vs. evening chronotype;
LIHC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.56	-7.35	-0.37	1.45e-12	Initial pursuit acceleration;
LIHC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.69	10.58	0.5	8e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg17675199	chr6:35436792	RPL10A	0.34	6.76	0.34	6.06e-11	Coronary artery disease;
LIHC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-12.11	-0.55	2.38e-28	Blood metabolite levels;
LIHC	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg14515779	chr1:101123966	NA	-0.45	-6.38	-0.33	5.67e-10	Monocyte count;
LIHC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.56	-7.24	-0.36	3.03e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17756712	0.528	rs2073007	chr6:638267	C/T	cg14374089	chr6:596013	EXOC2	-0.44	-5.74	-0.3	2.14e-8	Vertical cup-disc ratio;
LIHC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.99	-19.67	-0.73	3.83e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.54	7.94	0.39	2.92e-14	Information processing speed;
LIHC	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-9.33	-0.45	1.33e-18	Type 2 diabetes;
LIHC	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.78	13.23	0.58	1.48e-32	Coronary artery disease;
LIHC	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.61	-9.96	-0.47	1.09e-20	Breast cancer;
LIHC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-14.43	-0.62	3.3e-37	Systemic lupus erythematosus;
LIHC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.61	6.34	0.32	7.31e-10	Gut microbiome composition (summer);
LIHC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.39	-8.32	-0.41	2.17e-15	Cancer;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.68	10.12	0.48	3.11e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs11888559	0.655	rs13397552	chr2:203969436	C/T	cg24605529	chr2:203879461	NBEAL1	0.78	5.92	0.3	7.94e-9	Height;
LIHC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.92	-16.02	-0.65	1.72e-43	Tonsillectomy;
LIHC	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg19752551	chr11:57585705	CTNND1	-0.49	-6.76	-0.34	6.14e-11	Schizophrenia;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.65	-11.42	-0.53	8.01e-26	Prudent dietary pattern;
LIHC	cis	rs151997	1.000	rs32483	chr5:50205230	C/T	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-7.08	-0.36	8.34e-12	Cognitive function;
LIHC	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg02415029	chr1:110025642	ATXN7L2	0.45	5.73	0.3	2.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.2	0.36	3.92e-12	Parkinson's disease;
LIHC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	5.99	0.31	5.25e-9	Lung cancer in ever smokers;
LIHC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02985541	chr2:219472218	PLCD4	-0.4	-6.46	-0.33	3.59e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg25019722	chr6:37503610	NA	-0.32	-5.74	-0.3	2.07e-8	Cognitive performance;
LIHC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.38	6.11	0.31	2.67e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.92	-10.7	-0.5	3.15e-23	Childhood ear infection;
LIHC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.63	10.9	0.51	5.98e-24	Longevity;Endometriosis;
LIHC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	6.98	0.35	1.59e-11	Bone mineral density;
LIHC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.68	10.47	0.49	1.89e-22	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.93	-0.47	1.42e-20	Crohn's disease;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01125608	chr5:646071	CEP72	0.42	6.16	0.32	2.08e-9	Bilirubin levels;
LIHC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.67	-0.5	3.98e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.88	10.95	0.51	4.09e-24	Prostate cancer;
LIHC	trans	rs975809	0.966	rs11004607	chr10:56622686	G/T	cg09782621	chr19:56653147	ZNF444	0.39	6.16	0.32	2.09e-9	Carotid intima media thickness;
LIHC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg05110241	chr16:68378359	PRMT7	-0.64	-5.72	-0.3	2.29e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.64	-9.18	-0.44	4.09e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-8.33	-0.41	2.02e-15	Morning vs. evening chronotype;
LIHC	cis	rs17106184	1.000	rs12096626	chr1:51286155	G/A	cg07174182	chr1:51127561	FAF1	-0.65	-7.21	-0.36	3.53e-12	Type 2 diabetes;
LIHC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	5.84	0.3	1.24e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs783540	0.934	rs4779050	chr15:83368738	T/G	cg18393722	chr15:85113863	UBE2QP1	0.37	6.45	0.33	3.72e-10	Schizophrenia;
LIHC	cis	rs332507	0.830	rs35816663	chr3:124405513	G/T	cg05980111	chr3:124395277	KALRN	0.45	6.88	0.35	2.9100000000000002e-11	Plateletcrit;
LIHC	cis	rs3736485	0.966	rs12441167	chr15:51850652	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.74	-0.3	2.12e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.36	0.33	6.41e-10	Platelet distribution width;
LIHC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.55	-9.37	-0.45	9.77e-19	Bipolar disorder;
LIHC	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.27	-0.32	1.1e-9	Response to antipsychotic treatment;
LIHC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.71	-12.15	-0.55	1.7e-28	Height;
LIHC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.66	6.42	0.33	4.55e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.42	7.92	0.39	3.41e-14	Schizophrenia;
LIHC	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	trans	rs4596713	0.508	rs59620993	chr9:71771911	C/T	cg16512924	chr15:28394682	HERC2	0.4	6.47	0.33	3.43e-10	Headache;
LIHC	trans	rs1814175	0.588	rs7481648	chr11:49754910	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-20.37	-0.74	5.91e-61	Height;
LIHC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.72	10.95	0.51	4.14e-24	Aortic root size;
LIHC	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	trans	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg26939375	chr7:64535504	NA	-0.39	-6.12	-0.31	2.57e-9	Aortic root size;
LIHC	cis	rs2637266	0.626	rs2588329	chr10:78552782	C/T	cg18941641	chr10:78392320	NA	0.3	6.55	0.33	2.14e-10	Pulmonary function;
LIHC	cis	rs738321	0.756	rs11089863	chr22:38512402	G/A	cg25457927	chr22:38595422	NA	-0.29	-6.47	-0.33	3.49e-10	Breast cancer;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.66	13.14	0.58	3.42e-32	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg20283391	chr11:68216788	NA	0.36	5.74	0.3	2.12e-8	Total body bone mineral density;
LIHC	trans	rs17586843	0.528	rs13119466	chr4:116805008	C/G	cg25881869	chr10:114609298	LOC143188	0.41	6.15	0.32	2.18e-9	Age-related macular degeneration;
LIHC	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg09445902	chr10:555545	DIP2C	-0.4	-6.48	-0.33	3.17e-10	Psychosis in Alzheimer's disease;
LIHC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg16398128	chr5:16465888	ZNF622	0.39	6.24	0.32	1.33e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs8056893	0.842	rs1111571	chr16:68363181	A/G	cg02226672	chr16:68398533	SMPD3	-0.43	-6.17	-0.32	1.89e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs965469	0.779	rs2236112	chr20:3294983	C/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg23978390	chr7:1156363	C7orf50	0.42	6.16	0.32	2.02e-9	Longevity;Endometriosis;
LIHC	trans	rs2363709	1.000	rs2363714	chr3:67421846	C/G	cg25028035	chr6:42016671	CCND3	0.83	6.16	0.32	2.04e-9	IgE levels;
LIHC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.53	9.29	0.45	1.79e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.51	7.69	0.38	1.59e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.65	-9.37	-0.45	1.05e-18	Obesity-related traits;
LIHC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.49	7.65	0.38	2.12e-13	Triglyceride levels;
LIHC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	8.14	0.4	7.44e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg06359132	chr10:99160096	RRP12	0.41	6.38	0.33	5.64e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.25	-17.87	-0.69	6.28e-51	Ulcerative colitis;
LIHC	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.44	-6.12	-0.31	2.59e-9	QT interval;
LIHC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg03983715	chr16:68378420	PRMT7	-0.53	-6.45	-0.33	3.8e-10	Schizophrenia;
LIHC	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.6	-9.41	-0.45	7.76e-19	Red cell distribution width;
LIHC	cis	rs11212260	0.655	rs11212234	chr11:107306877	C/A	cg25435332	chr11:107328525	CWF19L2	0.82	8.3	0.41	2.4e-15	IgG glycosylation;
LIHC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.54	6.04	0.31	4.01e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs12286929	0.646	rs12805914	chr11:115019739	T/A	cg04055981	chr11:115044050	NA	0.38	5.72	0.3	2.39e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.55	0.53	2.91e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.13	-0.36	6.08e-12	Migraine;Coronary artery disease;
LIHC	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.92	0.39	3.35e-14	Corneal astigmatism;
LIHC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-8.79	-0.43	7.66e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-7.76	-0.39	1.01e-13	Morning vs. evening chronotype;
LIHC	cis	rs3106136	0.772	rs2865353	chr4:95270878	T/C	cg11021082	chr4:95130006	SMARCAD1	0.41	7.32	0.37	1.73e-12	Capecitabine sensitivity;
LIHC	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	0.9	16.89	0.67	5.5e-47	Eosinophil percentage of white cells;
LIHC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.2	-0.41	4.94e-15	Body mass index;
LIHC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.53	-0.49	1.17e-22	Hemoglobin concentration;
LIHC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.94	13.55	0.59	8.74e-34	Coronary artery disease;
LIHC	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.52	-6.5	-0.33	2.9e-10	Schizophrenia;
LIHC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-5.78	-0.3	1.66e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	19.26	0.72	1.67e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs26949	0.511	rs1562235	chr5:59877538	T/G	cg02684056	chr5:59996105	DEPDC1B	0.4	5.93	0.31	7.57e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg23682824	chr7:23144976	KLHL7	0.39	5.83	0.3	1.26e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.34	6.21	0.32	1.53e-9	Aortic root size;
LIHC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-8.07	-0.4	1.22e-14	Putamen volume;
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.45	-7.18	-0.36	4.3e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs6442522	0.640	rs13095087	chr3:15518841	A/G	cg16303742	chr3:15540471	COLQ	-0.41	-6.63	-0.34	1.3e-10	Uric acid levels;
LIHC	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.24	0.32	1.27e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-7.93	-0.39	3.24e-14	Morning vs. evening chronotype;
LIHC	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.46	7.05	0.36	1.02e-11	Diastolic blood pressure;
LIHC	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs9921222	0.542	rs9926968	chr16:381561	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	7.01	0.35	1.27e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.69	12.4	0.56	2.1e-29	Height;
LIHC	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.57	-9.27	-0.45	2.1e-18	Pulse pressure;
LIHC	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg10920230	chr7:150757210	SLC4A2	0.54	6.31	0.32	8.79e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs72843506	0.722	rs117096120	chr17:20167693	G/A	cg12065943	chr17:19881925	AKAP10	-0.38	-6.34	-0.32	7.14e-10	Schizophrenia;
LIHC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.14	-0.32	2.23e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.35	-6.94	-0.35	1.95e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.01	-0.4	1.77e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.6	8.43	0.41	1.01e-15	Aortic root size;
LIHC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.71	7.74	0.39	1.17e-13	Gut microbiome composition (summer);
LIHC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.68	10.67	0.5	3.83e-23	Response to diuretic therapy;
LIHC	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.96	17.52	0.69	1.76e-49	Breast cancer;
LIHC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.59	-0.71	8.2e-54	Ulcerative colitis;
LIHC	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.99	11.8	0.54	3.46e-27	Red blood cell traits;
LIHC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.9	10.79	0.5	1.52e-23	Primary sclerosing cholangitis;
LIHC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.35	5.78	0.3	1.66e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg26939375	chr7:64535504	NA	0.42	7.03	0.36	1.13e-11	Aortic root size;
LIHC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg25894440	chr7:65020034	NA	-0.53	-6.17	-0.32	1.93e-9	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03402805	chr12:2921865	ITFG2	-0.46	-6.49	-0.33	2.99e-10	Pancreatic cancer;
LIHC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.25	0.41	3.52e-15	Lymphocyte counts;
LIHC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg18912006	chr12:123335444	HIP1R	-0.58	-7.11	-0.36	6.8e-12	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.58	0.59	6.97e-34	Prudent dietary pattern;
LIHC	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg10820045	chr2:198174542	NA	0.46	7.18	0.36	4.27e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.45	-7.4	-0.37	1.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.66	8.28	0.41	2.77e-15	Gut microbiome composition (summer);
LIHC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4934494	0.768	rs11330	chr10:91394079	G/T	cg19698084	chr10:91461284	KIF20B	0.47	6.43	0.33	4.31e-10	Red blood cell count;
LIHC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.96	0.44	2.2e-17	Lung cancer in ever smokers;
LIHC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.44	-6.96	-0.35	1.75e-11	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08674093	chr3:182697846	DCUN1D1	0.44	6.07	0.31	3.43e-9	Hepatitis;
LIHC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg03859395	chr2:55845619	SMEK2	0.94	17.02	0.68	1.66e-47	Metabolic syndrome;
LIHC	trans	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg23114964	chr1:42217077	HIVEP3	-0.43	-6.71	-0.34	8.26e-11	Chronic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20449327	chr14:59951241	C14orf149;JKAMP	0.48	6.22	0.32	1.42e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4788570	0.615	rs7206470	chr16:71668800	G/A	cg06353428	chr16:71660113	MARVELD3	1.44	15.41	0.64	4.85e-41	Intelligence (multi-trait analysis);
LIHC	trans	rs7690819	0.589	rs12505855	chr4:112131601	A/C	cg06972903	chr1:6580525	PLEKHG5	0.37	6.32	0.32	7.95e-10	Medication adherence in chronic diseases;
LIHC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.88	16.95	0.68	3.41e-47	Blood protein levels;
LIHC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg06917634	chr15:78832804	PSMA4	-0.58	-7.24	-0.36	3.03e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.36	1.17e-11	Diabetic kidney disease;
LIHC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01200585	chr1:228362443	C1orf69	-0.41	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LIHC	trans	rs2273156	0.929	rs4573843	chr14:35391769	A/G	cg20620338	chr15:102077239	NA	-0.41	-6.04	-0.31	3.97e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.28	5.99	0.31	5.45e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02290350	chr8:58132656	NA	0.51	11.04	0.51	1.9e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.98	9.92	0.47	1.56e-20	Plasma clusterin levels;
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.21	0.32	1.51e-9	Renal cell carcinoma;
LIHC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.44	6.15	0.32	2.18e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.44	6.94	0.35	1.93e-11	Mortality in heart failure;
LIHC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.62	10.4	0.49	3.54e-22	Alcohol dependence;
LIHC	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.65	10.02	0.48	6.9e-21	Longevity;Endometriosis;
LIHC	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07151155	chr5:1473589	LPCAT1	-0.4	-6.15	-0.32	2.21e-9	Breast cancer;
LIHC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-6.0	-0.31	4.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs611744	0.905	rs408506	chr8:109154233	A/C	cg21045802	chr8:109455806	TTC35	-0.47	-8.17	-0.4	6.13e-15	Dupuytren's disease;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.06	-0.31	3.57e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.61	12.64	0.56	2.53e-30	Fat distribution (HIV);
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	0.6	8.75	0.43	9.91e-17	Prudent dietary pattern;
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg11161837	chr1:110010384	SYPL2	0.44	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.53	-0.38	4.56e-13	Bipolar disorder;
LIHC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.82	0.39	6.77e-14	Lymphocyte counts;
LIHC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg15352829	chr14:105391018	PLD4	0.44	8.88	0.43	3.98e-17	Rheumatoid arthritis;
LIHC	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.44	-7.36	-0.37	1.41e-12	Mean arterial pressure;
LIHC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.67	8.42	0.41	1.06e-15	Mean platelet volume;
LIHC	cis	rs3770081	1.000	rs2289237	chr2:86266274	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.86	9.03	0.44	1.32e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.82	-0.3	1.36e-8	Systemic lupus erythematosus;
LIHC	cis	rs1664789	0.844	rs1694062	chr5:53278982	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.5	7.87	0.39	4.63e-14	Waist circumference adjusted for body mass index;
LIHC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg18964960	chr10:1102726	WDR37	-0.71	-6.55	-0.33	2.13e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg10820045	chr2:198174542	NA	0.4	5.92	0.3	7.95e-9	Dermatomyositis;
LIHC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.78	11.75	0.54	5.43e-27	Coronary artery disease;
LIHC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg26395211	chr5:140044315	WDR55	-0.44	-6.48	-0.33	3.25e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg17724175	chr1:150552817	MCL1	0.4	8.0	0.4	1.93e-14	Melanoma;
LIHC	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	7.18	0.36	4.26e-12	Mean corpuscular volume;
LIHC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-8.19	-0.4	5.23e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.46	-6.91	-0.35	2.45e-11	Cognitive function;
LIHC	cis	rs4742903	0.967	rs4743690	chr9:106909577	T/C	cg14250997	chr9:106856677	SMC2	0.4	7.19	0.36	4.21e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.82	8.5	0.42	6.01e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.65	0.46	1.24e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.43	6.59	0.34	1.69e-10	Asthma (sex interaction);
LIHC	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg19773385	chr1:10388646	KIF1B	-0.37	-6.79	-0.34	4.95e-11	Hepatocellular carcinoma;
LIHC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.53	9.71	0.47	7.38e-20	Systemic lupus erythematosus;
LIHC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.43	7.09	0.36	7.64e-12	Red blood cell count;
LIHC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.4	6.8	0.34	4.8e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg10820045	chr2:198174542	NA	0.56	9.02	0.44	1.35e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.94	13.39	0.59	3.54e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.6	0.56	3.78e-30	Menopause (age at onset);
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.57	0.5	8.58e-23	Lymphocyte counts;
LIHC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.27	-6.62	-0.34	1.41e-10	Cutaneous nevi;
LIHC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg16434002	chr17:42200994	HDAC5	0.5	7.26	0.37	2.64e-12	Total body bone mineral density;
LIHC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.82	-12.18	-0.55	1.3e-28	Blood metabolite levels;
LIHC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.0	-0.35	1.35e-11	Bipolar disorder;
LIHC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg03037974	chr15:76606532	NA	0.74	14.39	0.61	4.85e-37	Blood metabolite levels;
LIHC	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.4	7.34	0.37	1.62e-12	Monocyte count;
LIHC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	11.1	0.51	1.13e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.63	9.73	0.47	6.66e-20	Renal cell carcinoma;
LIHC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg16479474	chr6:28041457	NA	-0.45	-6.68	-0.34	9.49e-11	Parkinson's disease;
LIHC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.57	-7.76	-0.39	9.98e-14	Lung cancer;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.38	-0.37	1.19e-12	Total body bone mineral density;
LIHC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.83	-0.3	1.28e-8	Pulse pressure;
LIHC	cis	rs11663156	1.000	rs1010360	chr18:50928441	A/C	cg24270629	chr18:50823537	DCC	-0.49	-6.76	-0.34	6.02e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.79	-0.3	1.63e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg02344993	chr17:57696989	CLTC	-0.57	-9.29	-0.45	1.78e-18	Hemoglobin concentration;
LIHC	trans	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg10756647	chr7:56101905	PSPH	-1.1	-13.4	-0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.79	8.38	0.41	1.42e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.49	7.6	0.38	2.95e-13	Alzheimer's disease (survival time);
LIHC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg27211696	chr2:191398769	TMEM194B	-0.69	-8.91	-0.43	3.16e-17	Diastolic blood pressure;
LIHC	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.21	-6.59	-0.34	1.69e-10	Motion sickness;
LIHC	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	0.77	8.77	0.43	8.38e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.19e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.99	18.54	0.71	1.32e-53	Breast cancer;
LIHC	trans	rs12752401	0.717	rs34542611	chr1:103028047	C/T	cg24921808	chr19:740313	PALM	0.48	6.31	0.32	8.9e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.27	-16.34	-0.66	9.2e-45	Diabetic kidney disease;
LIHC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg11212589	chr17:38028394	ZPBP2	0.39	8.09	0.4	1.03e-14	Self-reported allergy;
LIHC	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg16070123	chr10:51489643	NA	0.38	5.92	0.3	7.8e-9	Prostate-specific antigen levels;
LIHC	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg10820045	chr2:198174542	NA	0.42	6.13	0.31	2.43e-9	Dermatomyositis;
LIHC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.52	8.12	0.4	8.73e-15	Lymphocyte counts;
LIHC	cis	rs12702595	0.509	rs2159191	chr7:7266939	A/G	cg04827551	chr7:7268805	C1GALT1	0.33	6.18	0.32	1.84e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg15382696	chr6:118971807	C6orf204	0.64	6.24	0.32	1.28e-9	Diastolic blood pressure;
LIHC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.34	7.34	0.37	1.59e-12	Bone mineral density;
LIHC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.52	7.42	0.37	9.28e-13	Post bronchodilator FEV1;
LIHC	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg16558253	chr16:72132732	DHX38	-0.45	-6.04	-0.31	4.01e-9	Coronary artery disease;
LIHC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.65	6.61	0.34	1.47e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg23485639	chr6:28045615	ZNF165	0.38	5.87	0.3	1.03e-8	Parkinson's disease;
LIHC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	7.93	0.39	3.18e-14	Parkinson's disease;
LIHC	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.68	-6.58	-0.34	1.75e-10	Pulmonary function in asthmatics;
LIHC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.56	8.59	0.42	3.08e-16	Height;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.65	-6.96	-0.35	1.7e-11	Diastolic blood pressure;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.82	12.99	0.57	1.22e-31	Longevity;
LIHC	cis	rs3748682	0.821	rs12751325	chr1:38289383	T/C	cg12658694	chr1:38397304	INPP5B	0.43	5.92	0.3	7.76e-9	Hypothyroidism;
LIHC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg00292662	chr22:38071168	LGALS1	0.64	10.16	0.48	2.34e-21	Fat distribution (HIV);
LIHC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.44	5.72	0.3	2.27e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.81	-16.32	-0.66	1.06e-44	Height;
LIHC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.02	13.88	0.6	4.91e-35	Cognitive function;
LIHC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.38	0.64	6.23e-41	Breast cancer;
LIHC	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.46	-7.78	-0.39	8.54e-14	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02073427	chr10:15252052	NA	0.46	7.01	0.35	1.28e-11	Pancreatic cancer;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.7	0.34	8.37e-11	Exhaled nitric oxide output;
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.76	11.97	0.54	8.4e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.1	0.31	2.83e-9	Blood metabolite levels;
LIHC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg18887096	chr2:219472410	PLCD4	0.34	5.77	0.3	1.74e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6782228	0.675	rs4443194	chr3:128383446	T/A	cg16766828	chr3:128327626	NA	-0.43	-6.8	-0.35	4.66e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.36	-7.38	-0.37	1.22e-12	Renal cell carcinoma;
LIHC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg13753209	chr17:57696993	CLTC	0.74	11.66	0.53	1.11e-26	Obesity-related traits;
LIHC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.62	10.42	0.49	2.82e-22	Menopause (age at onset);
LIHC	cis	rs11229555	0.645	rs7116847	chr11:58178478	C/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg14061069	chr19:46274453	DMPK	-0.55	-8.58	-0.42	3.39e-16	Coronary artery disease;
LIHC	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg00277334	chr10:82204260	NA	-0.54	-6.68	-0.34	9.51e-11	Post bronchodilator FEV1;
LIHC	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.74	-0.3	2.11e-8	Alcohol dependence;
LIHC	cis	rs17776563	0.959	rs13329353	chr15:89113877	A/G	cg05013243	chr15:89149849	MIR1179	0.46	7.68	0.38	1.69e-13	Thyroid hormone levels;
LIHC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.49	-0.53	4.52e-26	Type 2 diabetes;
LIHC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.85	0.54	2.26e-27	Cognitive test performance;
LIHC	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.48	8.71	0.43	1.34e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs9993613	1.000	rs7697556	chr4:73515313	C/T	cg15102770	chr4:73434591	ADAMTS3	0.38	6.06	0.31	3.69e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs17106184	1.000	rs12085022	chr1:51269018	T/C	cg07174182	chr1:51127561	FAF1	-0.64	-7.03	-0.36	1.09e-11	Type 2 diabetes;
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.18	-0.36	4.4e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.47	7.19	0.36	4.18e-12	Longevity;Endometriosis;
LIHC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.6	8.99	0.44	1.67e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.57	-9.27	-0.45	2.21e-18	Lymphocyte counts;
LIHC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.89	0.39	4.06e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs611744	0.658	rs2443774	chr8:109064957	T/C	cg21045802	chr8:109455806	TTC35	0.43	7.22	0.36	3.4e-12	Dupuytren's disease;
LIHC	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg16589663	chr20:23618590	CST3	0.73	7.41	0.37	1.03e-12	Chronic kidney disease;
LIHC	cis	rs1593	0.565	rs10025152	chr4:187225304	C/T	cg14349977	chr4:187219430	NA	0.42	6.8	0.35	4.67e-11	Activated partial thromboplastin time;
LIHC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.86	-0.3	1.07e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.54	-10.07	-0.48	4.6e-21	Asthma;
LIHC	cis	rs10129255	0.576	rs2157616	chr14:107176045	T/C	cg07958169	chr14:107095056	NA	-0.33	-5.71	-0.3	2.43e-8	Kawasaki disease;
LIHC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	19.54	0.73	1.28e-57	Smoking behavior;
LIHC	cis	rs7238033	0.663	rs11082468	chr18:43321028	A/G	cg20610511	chr18:43302872	SLC14A1	0.37	6.15	0.32	2.17e-9	Bladder cancer;
LIHC	trans	rs10411161	0.702	rs7247017	chr19:52391769	T/C	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.87	13.09	0.58	4.92e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg15155738	chr12:121454335	C12orf43	0.45	6.54	0.33	2.27e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg20302533	chr7:39170763	POU6F2	-0.37	-6.75	-0.34	6.34e-11	IgG glycosylation;
LIHC	cis	rs17152411	1.000	rs17152374	chr10:126592644	T/C	cg07906193	chr10:126599966	NA	0.46	6.94	0.35	1.99e-11	Height;
LIHC	trans	rs4865875	0.792	rs6891667	chr5:54139679	C/T	cg04079215	chr1:95095221	NA	-0.41	-6.07	-0.31	3.43e-9	Sense of smell;
LIHC	trans	rs10411161	0.702	rs7251689	chr19:52389117	A/T	cg22319618	chr22:45562946	NUP50	-0.62	-8.49	-0.42	6.32e-16	Breast cancer;
LIHC	cis	rs4684776	0.935	rs11713733	chr3:11400552	G/A	cg00170343	chr3:11313890	ATG7	-0.46	-6.27	-0.32	1.06e-9	Small vessel stroke;
LIHC	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25632853	chr15:73088954	NA	0.37	6.17	0.32	1.93e-9	Triglyceride levels;
LIHC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg16797656	chr11:68205561	LRP5	0.51	8.1	0.4	9.54e-15	Total body bone mineral density;
LIHC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.46	-7.61	-0.38	2.72e-13	Cognitive function;
LIHC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg24203234	chr3:128598194	ACAD9	0.46	6.43	0.33	4.19e-10	IgG glycosylation;
LIHC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.6	8.16	0.4	6.29e-15	Blood metabolite levels;
LIHC	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	0.95	14.54	0.62	1.28e-37	Corneal structure;
LIHC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.67	-10.97	-0.51	3.32e-24	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.61	8.9	0.43	3.37e-17	Prudent dietary pattern;
LIHC	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.7	9.68	0.46	9.36e-20	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	1.07	16.08	0.66	9.77e-44	Breast cancer;
LIHC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-6.75	-0.34	6.39e-11	Colorectal cancer;
LIHC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.19	0.52	5.7e-25	Personality dimensions;
LIHC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.89	-9.17	-0.44	4.48e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg15902774	chr15:75289873	SCAMP5	0.43	6.56	0.33	2.04e-10	Lung cancer;
LIHC	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.57	-13.94	-0.6	2.75e-35	White blood cell count (basophil);
LIHC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg21522988	chr12:29376872	FAR2	-0.26	-5.91	-0.3	8.23e-9	QT interval;
LIHC	cis	rs2997447	0.846	rs3008417	chr1:26403470	G/A	cg19633962	chr1:26362018	EXTL1	-0.53	-6.05	-0.31	3.79e-9	QRS complex (12-leadsum);
LIHC	cis	rs7602441	0.521	rs74742552	chr2:14773375	G/T	cg06545361	chr2:14773388	FAM84A	0.52	5.84	0.3	1.22e-8	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.95	-0.31	6.51e-9	Body mass index;
LIHC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.93	-0.39	3.15e-14	Monocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.72	-0.43	1.24e-16	Renal cell carcinoma;
LIHC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.27	-0.41	3.08e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.37	6.08	0.31	3.3e-9	Monobrow;
LIHC	cis	rs25645	0.502	rs17609240	chr17:38110689	T/G	cg17467752	chr17:38218738	THRA	0.4	5.85	0.3	1.12e-8	Myeloid white cell count;
LIHC	cis	rs2292864	0.764	rs36046953	chr17:45381791	A/G	cg18085866	chr17:45331354	ITGB3	-0.64	-6.68	-0.34	9.87e-11	Left atrial antero-posterior diameter;
LIHC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.22	0.32	1.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.89	18.14	0.7	5.21e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.36	-5.72	-0.3	2.32e-8	Platelet count;
LIHC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02290350	chr8:58132656	NA	0.41	8.59	0.42	3.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg09445902	chr10:555545	DIP2C	-0.39	-6.3	-0.32	9.15e-10	Psychosis in Alzheimer's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg02995680	chr14:103430766	CDC42BPB	0.47	7.11	0.36	6.86e-12	Longevity;
LIHC	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.48	6.94	0.35	1.96e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.6	-8.46	-0.42	8.01e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs8141529	0.551	rs16986864	chr22:29350911	G/T	cg15103426	chr22:29168792	CCDC117	0.44	6.15	0.32	2.14e-9	Lymphocyte counts;
LIHC	trans	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.53	6.1	0.31	2.93e-9	Alzheimer's disease;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg16318947	chr17:78355466	RNF213;LOC100294362	0.44	6.58	0.34	1.78e-10	Alopecia areata;
LIHC	cis	rs9513627	1.000	rs2147625	chr13:100140645	G/T	cg25919922	chr13:100150906	NA	0.79	7.14	0.36	5.57e-12	Obesity-related traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19355919	chr18:48346593	MRO	-0.46	-6.09	-0.31	3.1e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9658691	0.607	rs12411483	chr10:90780910	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.93	-6.71	-0.34	8.01e-11	Mosquito bite size;
LIHC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.69	-6.41	-0.33	4.77e-10	Breast cancer;
LIHC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs17017235	0.649	rs6845910	chr4:91481236	A/C	cg17163168	chr1:3600735	TP73	-0.58	-6.08	-0.31	3.15e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-28.17	-0.84	3.99e-91	Myeloid white cell count;
LIHC	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg09795085	chr6:101329169	ASCC3	0.46	6.66	0.34	1.08e-10	Neuroticism;
LIHC	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg27205649	chr11:78285834	NARS2	0.4	6.2	0.32	1.6e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.13	0.36	6.07e-12	Lung cancer in ever smokers;
LIHC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.53e-11	Urinary metabolites;
LIHC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	1.0	18.45	0.71	2.99e-53	Monocyte percentage of white cells;
LIHC	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg18964960	chr10:1102726	WDR37	0.65	5.86	0.3	1.1e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs507080	0.922	rs514143	chr11:118558449	G/A	cg04173919	chr11:118528438	PHLDB1	0.35	6.6	0.34	1.56e-10	Serum metabolite levels;
LIHC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.33	7.38	0.37	1.19e-12	Inflammatory bowel disease;Ulcerative colitis;
LIHC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.99	19.71	0.73	2.65e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs12079745	0.793	rs12081030	chr1:169350003	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-15.52	-0.64	1.77e-41	Gut microbiome composition (summer);
LIHC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg16586182	chr3:47516702	SCAP	0.6	11.59	0.53	2.08e-26	Colorectal cancer;
LIHC	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg10820045	chr2:198174542	NA	-0.55	-8.82	-0.43	5.83e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.71	7.06	0.36	9.26e-12	Vitiligo;
LIHC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.18	0.4	5.81e-15	Coronary artery disease;
LIHC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg05484376	chr2:27715224	FNDC4	0.34	5.75	0.3	2.03e-8	Total body bone mineral density;
LIHC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.56	8.62	0.42	2.44e-16	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg18944383	chr4:111397179	ENPEP	0.26	6.31	0.32	8.62e-10	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.03	0.36	1.1e-11	Renal cell carcinoma;
LIHC	cis	rs7729447	0.804	rs4867471	chr5:32693456	A/T	cg16267343	chr5:32710456	NPR3	0.47	5.78	0.3	1.71e-8	Blood pressure;
LIHC	cis	rs253664	0.898	rs1624314	chr3:138084976	T/C	cg25188949	chr3:137893707	DBR1	-0.56	-5.72	-0.3	2.36e-8	Body mass index;
LIHC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.01	0.31	4.74e-9	Tonsillectomy;
LIHC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.56	-9.61	-0.46	1.63e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21467203	chr3:49911342	NA	-0.41	-7.09	-0.36	7.66e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.99	-0.31	5.44e-9	Iron status biomarkers;
LIHC	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg24169773	chr3:122142474	KPNA1	0.45	8.91	0.43	2.98e-17	LDL cholesterol levels;
LIHC	cis	rs12144094	0.882	rs1441011	chr1:120245374	T/C	cg20995928	chr1:120229863	NA	0.42	7.23	0.36	3.14e-12	Height;
LIHC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.66	12.96	0.57	1.6e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-12.09	-0.55	2.86e-28	Glomerular filtration rate (creatinine);
LIHC	trans	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg10208301	chr11:6592745	DNHD1	0.47	6.75	0.34	6.31e-11	Coronary artery calcification;
LIHC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.99	-15.84	-0.65	9.03e-43	Breast cancer;
LIHC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs6782228	0.527	rs2712371	chr3:128346214	G/A	cg16766828	chr3:128327626	NA	-0.41	-6.51	-0.33	2.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.49	-7.52	-0.38	4.89e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg22153463	chr1:85462885	MCOLN2	0.52	6.17	0.32	1.93e-9	Serum sulfate level;
LIHC	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.51	-6.87	-0.35	2.99e-11	Schizophrenia;
LIHC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.45	-6.22	-0.32	1.47e-9	Initial pursuit acceleration;
LIHC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.36	6.81	0.35	4.4e-11	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00166722	chr3:10149974	C3orf24	0.46	5.8	0.3	1.53e-8	Alzheimer's disease;
LIHC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.37	6.68	0.34	9.57e-11	Aortic root size;
LIHC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.7	13.9	0.6	4.06e-35	Menopause (age at onset);
LIHC	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg10820045	chr2:198174542	NA	0.56	9.02	0.44	1.35e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.24	-15.89	-0.65	5.57e-43	Diabetic kidney disease;
LIHC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.95	17.63	0.69	5.92e-50	Menopause (age at onset);
LIHC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg14773178	chr5:1868261	NA	0.26	6.67	0.34	1.01e-10	Cardiovascular disease risk factors;
LIHC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-10.86	-0.51	8.27e-24	Neuroticism;
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.68	10.19	0.48	1.85e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.88	0.3	9.93e-9	Birth weight;
LIHC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg15123519	chr2:136567270	LCT	0.35	6.72	0.34	7.75e-11	Mosquito bite size;
LIHC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.67	7.06	0.36	9.27e-12	Diabetic kidney disease;
LIHC	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.28	-13.83	-0.6	7.33e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.23	0.52	4.11e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	1.07	14.42	0.61	3.64e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.37	9.6	0.46	1.71e-19	Asthma (sex interaction);
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg10774155	chr7:65338427	VKORC1L1	-0.44	-6.58	-0.34	1.78e-10	Calcium levels;
LIHC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.34	-0.32	7.13e-10	Height;
LIHC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.37	5.96	0.31	6.29e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Urate levels;
LIHC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.01	0.65	1.98e-43	Electrocardiographic conduction measures;
LIHC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	0.94	9.28	0.45	1.95e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.43	0.33	4.36e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.59	6.95	0.35	1.86e-11	Bipolar disorder;
LIHC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.41	-7.06	-0.36	9.18e-12	Colorectal or endometrial cancer;
LIHC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.34	-0.59	5.58e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.37	-5.8	-0.3	1.5e-8	Mood instability;
LIHC	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.75	-15.55	-0.64	1.24e-41	Body mass index;
LIHC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.22	0.52	4.26e-25	Platelet count;
LIHC	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.64	-7.51	-0.38	5.05e-13	Body mass index;
LIHC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg07424592	chr7:64974309	NA	0.8	9.08	0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.47	0.33	3.39e-10	Mean platelet volume;
LIHC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg26441486	chr22:50317300	CRELD2	0.34	6.08	0.31	3.14e-9	Schizophrenia;
LIHC	cis	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg21605333	chr4:119757512	SEC24D	0.97	8.11	0.4	9.41e-15	Cannabis dependence symptom count;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.73	-0.3	2.25e-8	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg11764359	chr7:65958608	NA	-0.58	-6.04	-0.31	3.97e-9	Diabetic kidney disease;
LIHC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.6	7.3	0.37	1.98e-12	Cognitive function;
LIHC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02376097	chr19:46275166	DMPK	0.51	8.98	0.44	1.9e-17	Coronary artery disease;
LIHC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg27432699	chr2:27873401	GPN1	-0.6	-8.65	-0.42	1.99e-16	Total body bone mineral density;
LIHC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.86	10.34	0.49	5.57e-22	Cognitive function;
LIHC	cis	rs12464559	0.522	rs6715027	chr2:152626657	T/C	cg01189475	chr2:152685088	ARL5A	0.66	8.12	0.4	8.31e-15	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.42	6.27	0.32	1.06e-9	Height;
LIHC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg09904177	chr6:26538194	HMGN4	0.49	6.81	0.35	4.39e-11	Small cell lung carcinoma;
LIHC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-6.37	-0.33	6.15e-10	Subjective well-being;
LIHC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg05896524	chr21:47604654	C21orf56	-0.4	-6.34	-0.32	7.18e-10	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	1.13	9.34	0.45	1.31e-18	Alzheimer's disease;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.79	9.9	0.47	1.7e-20	Cognitive function;
LIHC	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg20636351	chr8:55087400	NA	-0.38	-7.71	-0.38	1.41e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.26	-0.41	3.22e-15	Gut microbiome composition (summer);
LIHC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.36	-0.37	1.36e-12	Personality dimensions;
LIHC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg27494647	chr7:150038898	RARRES2	0.3	5.79	0.3	1.63e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4934494	0.911	rs34486602	chr10:91415652	T/C	cg19698084	chr10:91461284	KIF20B	-0.45	-6.18	-0.32	1.85e-9	Red blood cell count;
LIHC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.85	10.27	0.49	9.85e-22	Cognitive function;
LIHC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-11.77	-0.54	4.44e-27	Total cholesterol levels;
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.16	-0.44	4.79e-18	Aortic root size;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11958404	0.615	rs7737601	chr5:157448269	C/T	cg05962755	chr5:157440814	NA	-0.61	-8.12	-0.4	8.43e-15	IgG glycosylation;
LIHC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg15848620	chr12:58087721	OS9	-0.54	-7.31	-0.37	1.96e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-7.85	-0.39	5.54e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.41	-0.49	3.17e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg13409248	chr3:40428643	ENTPD3	-0.44	-7.45	-0.37	7.75e-13	Renal cell carcinoma;
LIHC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.8	0.35	4.71e-11	Lung cancer;
LIHC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.46	-6.21	-0.32	1.56e-9	Serum sulfate level;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.8	11.85	0.54	2.2e-27	Menarche (age at onset);
LIHC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.65	11.32	0.52	1.84e-25	Colorectal cancer;
LIHC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	8.54	0.42	4.53e-16	Diastolic blood pressure;
LIHC	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.82	-13.5	-0.59	1.33e-33	Morning vs. evening chronotype;
LIHC	cis	rs600806	0.854	rs3768496	chr1:109866569	T/A	cg23091122	chr1:110024289	SYPL2	-0.45	-5.93	-0.31	7.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.68	0.5	3.61e-23	Colorectal cancer;
LIHC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.66	0.38	1.92e-13	Bipolar disorder;
LIHC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.58	8.33	0.41	2.04e-15	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs10503871	0.740	rs13249960	chr8:30417532	C/G	cg26383811	chr8:30366931	RBPMS	0.45	7.47	0.37	6.94e-13	Metabolite levels  (X-11787);
LIHC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg07636037	chr3:49044803	WDR6	-0.66	-6.17	-0.32	1.95e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	0.69	8.3	0.41	2.53e-15	Corneal curvature;
LIHC	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.54	8.77	0.43	8.31e-17	Menopause (age at onset);
LIHC	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.59	-10.17	-0.48	2.15e-21	Diisocyanate-induced asthma;
LIHC	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.76	-11.46	-0.53	5.97e-26	Personality dimensions;
LIHC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	8.85	0.43	4.63e-17	Response to antipsychotic treatment;
LIHC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.7	12.96	0.57	1.54e-31	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05871582	chr8:648014	ERICH1	0.44	6.29	0.32	9.84e-10	Bilirubin levels;
LIHC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.02	12.83	0.57	5.14e-31	Iron status biomarkers;
LIHC	cis	rs9918079	0.560	rs10008975	chr4:15624571	C/T	cg21329975	chr4:15471214	CC2D2A	-0.41	-6.16	-0.32	2.06e-9	Obesity-related traits;
LIHC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg16822855	chr3:40428330	ENTPD3	0.34	6.18	0.32	1.82e-9	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20390613	chr1:12678355	DHRS3	0.43	6.04	0.31	4.03e-9	Pancreatic cancer;
LIHC	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	1.11	12.06	0.55	3.7e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg08847533	chr14:75593920	NEK9	0.48	7.31	0.37	1.88e-12	IgG glycosylation;
LIHC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.4	6.48	0.33	3.14e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.41	-6.56	-0.33	2.04e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.43	8.0	0.4	1.98e-14	Electrocardiographic conduction measures;
LIHC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.18	-0.48	2e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.84	0.3	1.24e-8	Bladder cancer;
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.55	6.95	0.35	1.82e-11	Alzheimer's disease;
LIHC	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.6	6.21	0.32	1.56e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg19633962	chr1:26362018	EXTL1	-0.64	-5.91	-0.3	8.34e-9	QRS complex (12-leadsum);
LIHC	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.75	0.39	1.03e-13	Alzheimer's disease;
LIHC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.29	0.41	2.57e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00137585	chr16:3450828	ZNF174;ZNF434	0.49	6.18	0.32	1.83e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.73	11.09	0.51	1.23e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.71	13.27	0.58	1.06e-32	Coronary artery disease;
LIHC	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.75	-6.56	-0.33	1.94e-10	Alzheimer's disease;
LIHC	cis	rs1401454	1.000	rs1519125	chr11:16244588	G/C	cg02656851	chr11:16430247	SOX6	-0.32	-6.14	-0.32	2.23e-9	Blood pressure;
LIHC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.63	11.07	0.51	1.56e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.52	0.33	2.5e-10	Renal cell carcinoma;
LIHC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.04e-10	Menopause (age at onset);
LIHC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.12	0.52	1.02e-24	Hip circumference adjusted for BMI;
LIHC	trans	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg26939375	chr7:64535504	NA	0.4	6.25	0.32	1.24e-9	Aortic root size;
LIHC	cis	rs4908768	1.000	rs11121203	chr1:8648240	T/C	cg20416874	chr1:8611966	RERE	0.54	6.93	0.35	2.15e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.54	-8.31	-0.41	2.21e-15	White matter hyperintensity burden;
LIHC	trans	rs7714584	1.000	rs73284141	chr5:150266086	A/G	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg03934865	chr2:198174659	NA	0.43	6.23	0.32	1.33e-9	Intracranial aneurysm;
LIHC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.93	-0.31	7.47e-9	Ulcerative colitis;
LIHC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.66	-11.07	-0.51	1.48e-24	Pulse pressure;
LIHC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.39	-0.33	5.31e-10	Gut microbiome composition (summer);
LIHC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg13047869	chr3:10149882	C3orf24	0.41	5.76	0.3	1.87e-8	Alzheimer's disease;
LIHC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.01	-0.4	1.77e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg12798992	chr6:167411361	FGFR1OP	0.6	9.93	0.47	1.36e-20	Crohn's disease;
LIHC	cis	rs2242420	0.920	rs829413	chr1:21956050	C/G	cg18150885	chr1:21978612	RAP1GAP	-0.46	-5.73	-0.3	2.25e-8	Hematological and biochemical traits;
LIHC	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.23	-5.89	-0.3	9.47e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg01629716	chr15:45996671	NA	0.52	9.6	0.46	1.77e-19	Waist circumference;Weight;
LIHC	cis	rs11955398	0.716	rs1379114	chr5:59997798	A/G	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.56	9.75	0.47	5.44e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.39	0.33	5.51e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg07424592	chr7:64974309	NA	0.78	8.94	0.44	2.44e-17	Diabetic kidney disease;
LIHC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.35	6.24	0.32	1.32e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.66	10.91	0.51	5.54e-24	Menopause (age at onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13559217	chr19:5119331	KDM4B	0.49	6.41	0.33	4.7e-10	Systolic blood pressure;
LIHC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.63	-10.11	-0.48	3.46e-21	Obesity-related traits;
LIHC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg03037974	chr15:76606532	NA	0.63	11.16	0.52	7.43e-25	Blood metabolite levels;
LIHC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg18887096	chr2:219472410	PLCD4	0.36	6.31	0.32	8.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.66	0.46	1.12e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.47	5.75	0.3	1.94e-8	Alzheimer's disease;
LIHC	cis	rs7818688	0.697	rs75349998	chr8:95990918	G/A	cg16049864	chr8:95962084	TP53INP1	0.59	6.37	0.33	6.09e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.6	9.02	0.44	1.36e-17	Recombination rate (females);
LIHC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs7937890	0.559	rs2597217	chr11:14532883	A/G	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.39	7.62	0.38	2.54e-13	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg14393609	chr7:65229607	NA	-0.43	-6.36	-0.33	6.33e-10	Aortic root size;
LIHC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg14440974	chr22:39074834	NA	0.43	6.71	0.34	8.11e-11	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg07424592	chr7:64974309	NA	0.82	9.55	0.46	2.54e-19	Diabetic kidney disease;
LIHC	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg00291366	chr1:12616550	NA	0.44	8.97	0.44	1.95e-17	Optic cup area;
LIHC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg24163568	chr5:669837	TPPP	0.39	8.21	0.41	4.7e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg02023728	chr11:77925099	USP35	0.35	6.29	0.32	9.61e-10	Alzheimer's disease (survival time);
LIHC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.03e-14	Motion sickness;
LIHC	cis	rs1664789	0.935	rs1694055	chr5:53276568	G/A	ch.5.1024479R	chr5:53302184	ARL15	0.5	8.09	0.4	1.06e-14	Waist circumference adjusted for body mass index;
LIHC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.63	10.23	0.48	1.29e-21	Monocyte count;
LIHC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.44	-0.37	8.21e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.63	5.84	0.3	1.23e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.54	0.42	4.55e-16	Initial pursuit acceleration;
LIHC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.64	8.91	0.43	3.17e-17	Sudden cardiac arrest;
LIHC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.81	15.06	0.63	1.13e-39	Multiple myeloma (IgH translocation);
LIHC	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.37	-6.48	-0.33	3.29e-10	Asthma;
LIHC	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg25344623	chr2:136566232	LCT	-0.39	-6.04	-0.31	3.95e-9	Corneal structure;
LIHC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.33	-6.95	-0.35	1.89e-11	Blood metabolite levels;
LIHC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.42	6.38	0.33	5.61e-10	Mean platelet volume;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.44	0.59	2.25e-33	Prudent dietary pattern;
LIHC	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg26811252	chr16:29126840	RRN3P2	0.42	6.8	0.35	4.59e-11	Menopause (age at onset);
LIHC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg08800856	chr11:64428347	NRXN2	0.38	5.9	0.3	8.6e-9	Body mass index;Urate levels;
LIHC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.55	0.38	3.95e-13	Electroencephalogram traits;
LIHC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.51	7.99	0.4	2.09e-14	Lymphocyte counts;
LIHC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.39	6.19	0.32	1.73e-9	Menopause (age at onset);
LIHC	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg01864836	chr14:55583639	NA	-0.43	-8.44	-0.42	9.04e-16	Protein biomarker;
LIHC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg07636037	chr3:49044803	WDR6	-0.81	-8.4	-0.41	1.2e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.63	5.8	0.3	1.5e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg11657440	chr19:46296263	DMWD	0.67	12.33	0.55	3.64e-29	Coronary artery disease;
LIHC	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.76	-0.39	9.97e-14	Response to antipsychotic treatment;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg15910486	chr5:142783621	NR3C1	-0.46	-6.12	-0.31	2.62e-9	Longevity;
LIHC	trans	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg18393722	chr15:85113863	UBE2QP1	0.41	7.0	0.35	1.39e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.23	-5.73	-0.3	2.17e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.6	0.53	1.79e-26	Body mass index;
LIHC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-8.45	-0.42	8.65e-16	Morning vs. evening chronotype;
LIHC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg02297831	chr4:17616191	MED28	0.4	6.56	0.33	1.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.61	-9.46	-0.46	5.24e-19	Blood trace element (Zn levels);
LIHC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.89	10.69	0.5	3.45e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.85	19.65	0.73	4.55e-58	Gestational age at birth (maternal effect);
LIHC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.48	6.82	0.35	4.18e-11	Response to diuretic therapy;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.03	-0.31	4.34e-9	Total body bone mineral density;
LIHC	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg20991723	chr1:152506922	NA	0.53	9.23	0.45	2.89e-18	Hair morphology;
LIHC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.2	0.32	1.67e-9	Tonsillectomy;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg12311636	chr6:118886798	C6orf204	-0.52	-6.23	-0.32	1.35e-9	Diastolic blood pressure;
LIHC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg00990874	chr7:1149470	C7orf50	-0.7	-9.36	-0.45	1.1e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.33	-6.36	-0.33	6.35e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	9.14	0.44	5.59e-18	Exhaled nitric oxide output;
LIHC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.71	-0.65	3.04e-42	Chronic sinus infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20743544	chr7:32982957	RP9P	0.45	6.34	0.32	7.26e-10	Pancreatic cancer;
LIHC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.14	-0.36	5.71e-12	Monocyte percentage of white cells;
LIHC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	8.4	0.41	1.19e-15	Initial pursuit acceleration;
LIHC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.41	-7.57	-0.38	3.39e-13	IgG glycosylation;
LIHC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.03	-9.32	-0.45	1.46e-18	Diabetic retinopathy;
LIHC	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-12.4	-0.56	2e-29	Pediatric autoimmune diseases;
LIHC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.33	8.52	0.42	5.22e-16	Schizophrenia;
LIHC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.37	-5.87	-0.3	1.04e-8	Mortality in heart failure;
LIHC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.24	0.32	1.32e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.42	-6.29	-0.32	9.9e-10	Calcium levels;
LIHC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.49	6.93	0.35	2.13e-11	Uric acid levels;
LIHC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.67	9.68	0.46	9.29e-20	Monocyte percentage of white cells;
LIHC	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg17771515	chr6:154831774	CNKSR3	0.59	6.27	0.32	1.1e-9	Lipoprotein (a) levels;
LIHC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg00149659	chr3:10157352	C3orf10	0.66	6.49	0.33	2.94e-10	Alzheimer's disease;
LIHC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg02158880	chr13:53174818	NA	0.38	5.91	0.3	8.14e-9	Lewy body disease;
LIHC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.62	0.34	1.38e-10	Renal cell carcinoma;
LIHC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg04034577	chr2:241836375	C2orf54	-0.49	-11.5	-0.53	4.35e-26	Urinary metabolites;
LIHC	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.16	0.32	2.03e-9	Schizophrenia;
LIHC	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg05425664	chr17:57184151	TRIM37	-0.46	-5.75	-0.3	1.93e-8	Vitamin D levels;
LIHC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.22	-0.32	1.46e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg09592244	chr17:37024020	NA	-0.4	-6.74	-0.34	6.89e-11	Height;
LIHC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg09222892	chr1:25734099	RHCE	0.41	7.3	0.37	2.05e-12	Plateletcrit;Mean corpuscular volume;
LIHC	trans	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg10756647	chr7:56101905	PSPH	1.03	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-8.1	-0.4	9.64e-15	Body mass index (adult);
LIHC	cis	rs10840270	0.672	rs12273601	chr11:9636854	C/T	cg26541003	chr11:9594436	WEE1	-0.42	-5.78	-0.3	1.7e-8	Bacteremia;
LIHC	cis	rs965469	0.779	rs967366	chr20:3266935	T/G	cg25506879	chr20:3388711	C20orf194	-0.54	-6.63	-0.34	1.3e-10	IFN-related cytopenia;
LIHC	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	0.96	20.32	0.74	9.35e-61	Bone mineral density;
LIHC	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-9.7	-0.46	8.36e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.57	7.83	0.39	6.11e-14	Bladder cancer;
LIHC	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.52	-8.06	-0.4	1.25e-14	Retinal vascular caliber;
LIHC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.82	13.71	0.6	2.09e-34	Monocyte count;
LIHC	cis	rs1144333	0.655	rs968018	chr1:76395662	G/A	cg03433033	chr1:76189801	ACADM	0.53	7.55	0.38	4.02e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.55	5.76	0.3	1.87e-8	IgG glycosylation;
LIHC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.8	-14.12	-0.61	5.66e-36	Body mass index;
LIHC	cis	rs74233809	1.000	rs10883806	chr10:104713076	C/T	cg03493300	chr10:104813866	CNNM2	0.45	5.91	0.3	8.45e-9	Birth weight;
LIHC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.0	0.35	1.36e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.66	0.42	1.91e-16	Motion sickness;
LIHC	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.67	11.22	0.52	4.36e-25	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06970076	chr16:1560791	IFT140	0.45	6.48	0.33	3.25e-10	Longevity;
LIHC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.96	-0.35	1.69e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.96	20.75	0.75	1.74e-62	Height;
LIHC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg11764359	chr7:65958608	NA	0.58	6.02	0.31	4.53e-9	Diabetic kidney disease;
LIHC	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.66	8.45	0.42	8.31e-16	Exhaled nitric oxide output;
LIHC	cis	rs79387448	0.810	rs75218113	chr2:103239356	C/G	cg09003973	chr2:102972529	NA	0.86	6.22	0.32	1.49e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.59	-8.46	-0.42	7.85e-16	Facial morphology (factor 19);
LIHC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.52	-9.11	-0.44	6.93e-18	Dental caries;
LIHC	cis	rs3736485	0.966	rs7170217	chr15:51890678	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.37	-0.33	5.94e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08280861	chr8:58055591	NA	0.52	6.16	0.32	2.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26734620	chr12:56694298	CS	-1.21	-10.41	-0.49	3.22e-22	Psoriasis vulgaris;
LIHC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.8	0.35	4.71e-11	Lung cancer;
LIHC	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg19752551	chr11:57585705	CTNND1	-0.53	-7.44	-0.37	8.4e-13	Schizophrenia;
LIHC	cis	rs6746896	0.959	rs58361269	chr2:97403110	G/A	cg26665480	chr2:98280029	ACTR1B	0.45	5.84	0.3	1.21e-8	Bipolar disorder;
LIHC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	8.05	0.4	1.37e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.71	-0.38	1.41e-13	Coronary artery disease;
LIHC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.23	-0.41	3.96e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-9.31	-0.45	1.62e-18	Morning vs. evening chronotype;
LIHC	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg09165964	chr15:75287851	SCAMP5	0.52	7.5	0.38	5.72e-13	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.46	-7.4	-0.37	1.07e-12	Menarche (age at onset);
LIHC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.59	8.88	0.43	3.93e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs151997	0.671	rs395557	chr5:50215832	G/T	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.86	15.65	0.65	5.1e-42	Dental caries;
LIHC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.34	5.9	0.3	8.78e-9	Platelet distribution width;
LIHC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.5	7.18	0.36	4.44e-12	High light scatter reticulocyte count;
LIHC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.47	-6.46	-0.33	3.56e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.57	-10.06	-0.48	4.98e-21	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs1075232	1.000	rs34959140	chr15:31725223	G/A	cg17859187	chr1:168147929	TIPRL	0.75	6.04	0.31	3.96e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg03721293	chr16:90014378	DEF8	0.39	6.52	0.33	2.48e-10	Skin colour saturation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13961709	chr14:74486189	C14orf45;ENTPD5	0.44	6.59	0.34	1.69e-10	Cognitive function;
LIHC	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08893839	chr5:154027129	NA	0.49	6.74	0.34	6.64e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs546131	0.642	rs35617374	chr11:34832373	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.62	-0.34	1.36e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.36	-6.24	-0.32	1.28e-9	Schizophrenia;
LIHC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	7.99	0.4	2.03e-14	Menarche (age at onset);
LIHC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.3	-0.32	9.23e-10	Aortic root size;
LIHC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg14906510	chr12:7781169	NA	-0.43	-6.58	-0.34	1.81e-10	HDL cholesterol levels;
LIHC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.94	-0.31	6.83e-9	Tonsillectomy;
LIHC	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	8.39	0.41	1.29e-15	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.53	0.42	4.66e-16	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg02290350	chr8:58132656	NA	0.32	7.09	0.36	7.94e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.08	-0.31	3.3e-9	Total body bone mineral density;
LIHC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.52	0.33	2.51e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg04067612	chr4:15429572	C1QTNF7	0.3	6.4	0.33	4.99e-10	Obesity-related traits;
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17280350	chr2:20853360	NA	-0.43	-6.32	-0.32	8.14e-10	Gut microbiome composition (summer);
LIHC	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg14146966	chr2:61757674	XPO1	-0.44	-7.48	-0.38	6.25e-13	Tuberculosis;
LIHC	cis	rs7546	0.504	rs2075636	chr16:4938321	A/T	cg08329684	chr16:4932620	PPL	-0.42	-7.34	-0.37	1.53e-12	Cancer;
LIHC	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.38	5.78	0.3	1.72e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	6.92	0.35	2.27e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.33	-0.37	1.64e-12	Lymphocyte counts;
LIHC	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-9.11	-0.44	7.02e-18	Brugada syndrome;
LIHC	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.58	-7.44	-0.37	8.11e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	11.25	0.52	3.38e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.65	-9.85	-0.47	2.68e-20	Subjective well-being;
LIHC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.65	9.23	0.45	2.86e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.63	-0.34	1.33e-10	Fear of minor pain;
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.61	7.28	0.37	2.33e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.51	6.66	0.34	1.07e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.58	-8.18	-0.4	5.5e-15	Neuroblastoma;
LIHC	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.52	8.33	0.41	1.95e-15	Fuchs's corneal dystrophy;
LIHC	cis	rs7106204	0.748	rs6484024	chr11:24210079	T/C	ch.11.24196551F	chr11:24239977	NA	0.76	10.01	0.48	7.62e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs7818688	0.697	rs77805255	chr8:95983566	G/A	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.74	13.56	0.59	7.94e-34	Blood protein levels;
LIHC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.51	8.46	0.42	7.74e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-1.19	-10.49	-0.49	1.66e-22	Breast cancer;
LIHC	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.48	-0.33	3.29e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg14092571	chr14:90743983	NA	-0.37	-5.79	-0.3	1.59e-8	Mortality in heart failure;
LIHC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.97	-0.31	5.91e-9	Mean corpuscular volume;
LIHC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.84	11.15	0.52	7.6e-25	Orofacial clefts;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.1	0.4	9.76e-15	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13425677	chr5:56112090	MAP3K1	-0.54	-7.15	-0.36	5.14e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13552506	chr1:946444	NA	0.47	6.84	0.35	3.67e-11	Bilirubin levels;
LIHC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.3	-7.04	-0.36	1.06e-11	Menarche (age at onset);
LIHC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-10.05	-0.48	5.31e-21	Mean corpuscular volume;
LIHC	cis	rs990171	0.607	rs2192752	chr2:102769373	A/C	cg22835712	chr2:102737379	NA	-0.52	-7.61	-0.38	2.72e-13	Lymphocyte counts;
LIHC	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.44	0.33	3.97e-10	Ulcerative colitis;
LIHC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg14779329	chr11:130786720	SNX19	0.39	5.95	0.31	6.72e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.89	-17.88	-0.7	6.17e-51	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.99	0.6	1.8e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs546131	0.614	rs12791769	chr11:34834268	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.34	1.66e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs55665837	0.701	rs12286408	chr11:14579376	G/A	cg25251204	chr11:14927456	NA	0.44	6.14	0.31	2.35e-9	Vitamin D levels;
LIHC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.62	-8.91	-0.43	3.19e-17	Total body bone mineral density;
LIHC	cis	rs882732	1.000	rs10139745	chr14:95035374	C/T	cg14866387	chr14:95027382	SERPINA4	-0.43	-5.95	-0.31	6.5e-9	Blood protein levels;
LIHC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.02	0.31	4.48e-9	Eosinophil percentage of white cells;
LIHC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-8.32	-0.41	2.09e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.84	14.95	0.63	3.09e-39	Aortic root size;
LIHC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.27	-6.78	-0.34	5.29e-11	Mean corpuscular volume;
LIHC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.68	-11.3	-0.52	2.2e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17258537	chr5:179401804	RNF130	-0.48	-7.14	-0.36	5.5e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.58	7.85	0.39	5.57e-14	Bone mineral density (spine);
LIHC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.85	-12.39	-0.56	2.3e-29	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs194045	0.609	rs252344	chr16:29184882	G/A	cg16691023	chr16:29205632	NA	-0.58	-8.67	-0.42	1.72e-16	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg23791538	chr6:167370224	RNASET2	-0.52	-7.84	-0.39	5.63e-14	Crohn's disease;
LIHC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.72	-13.0	-0.58	1.11e-31	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10556349	chr10:835070	NA	0.65	5.75	0.3	1.94e-8	Eosinophil percentage of granulocytes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04578738	chr17:34136331	TAF15	0.39	6.21	0.32	1.5e-9	Cognitive function;
LIHC	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.62	0.34	1.36e-10	Type 2 diabetes;
LIHC	trans	rs6600671	1.000	rs4844380	chr1:121193620	A/T	cg09829573	chr1:144692074	NBPF9	-0.41	-7.27	-0.37	2.5e-12	Hip geometry;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02092906	chr6:83903419	PGM3;RWDD2A	0.49	6.54	0.33	2.26e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.43	-9.23	-0.45	2.83e-18	Rheumatoid arthritis;
LIHC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.8	11.62	0.53	1.57e-26	Coronary artery disease;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg12903224	chr12:29470962	FAR2	-0.4	-6.42	-0.33	4.56e-10	QT interval;
LIHC	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.5	-7.63	-0.38	2.3e-13	Extraversion;
LIHC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.06	15.39	0.64	5.35e-41	Cognitive function;
LIHC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.68	10.72	0.5	2.59e-23	Colorectal adenoma (advanced);
LIHC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.46	16.73	0.67	2.42e-46	Eosinophil percentage of granulocytes;
LIHC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.98	0.31	5.61e-9	Obesity-related traits;
LIHC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.65	12.61	0.56	3.24e-30	High light scatter reticulocyte count;
LIHC	cis	rs611744	0.967	rs689256	chr8:109186398	T/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/A	cg07918374	chr16:82182319	MPHOSPH6	0.35	7.02	0.35	1.19e-11	Lung adenocarcinoma;
LIHC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg10765909	chr12:53715428	AAAS	0.43	6.56	0.33	1.98e-10	Platelet distribution width;
LIHC	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.53	6.15	0.32	2.19e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LIHC	cis	rs6586163	1.000	rs7072828	chr10:90754953	T/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.56	-8.22	-0.41	4.2e-15	Chronic lymphocytic leukemia;
LIHC	trans	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg10756647	chr7:56101905	PSPH	0.47	6.95	0.35	1.86e-11	Aortic root size;
LIHC	cis	rs7572733	0.536	rs6732517	chr2:198912902	G/C	cg03934865	chr2:198174659	NA	0.45	6.5	0.33	2.83e-10	Dermatomyositis;
LIHC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.2e-22	Cognitive function;
LIHC	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg09795085	chr6:101329169	ASCC3	0.53	7.54	0.38	4.18e-13	Neuroticism;
LIHC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.34	-7.2	-0.36	3.96e-12	Bone mineral density;
LIHC	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.34	8.06	0.4	1.33e-14	Weight;
LIHC	trans	rs9836270	1.000	rs9836270	chr3:131916996	G/T	cg14990970	chr19:58967158	ZNF324B	-0.39	-6.18	-0.32	1.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.38	0.49	3.89e-22	Post bronchodilator FEV1;
LIHC	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.49	-7.96	-0.4	2.55e-14	Malaria;
LIHC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.38	6.04	0.31	3.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.31	6.54	0.33	2.23e-10	Bone mineral density;
LIHC	cis	rs9948	1.000	rs9973492	chr2:97498481	T/A	cg01990225	chr2:97406019	LMAN2L	-0.57	-5.89	-0.3	9.12e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg02269571	chr22:50332266	NA	-0.65	-8.62	-0.42	2.55e-16	Schizophrenia;
LIHC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.45	-0.37	7.74e-13	Type 2 diabetes;
LIHC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.79	13.78	0.6	1.16e-34	Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg20636351	chr8:55087400	NA	-0.34	-7.09	-0.36	7.97e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg25801113	chr15:45476975	SHF	0.36	6.01	0.31	4.63e-9	Uric acid levels;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.47	-6.6	-0.34	1.58e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-6.9	-0.35	2.48e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg19645103	chr12:69753606	YEATS4	-0.46	-6.28	-0.32	1e-9	Response to diuretic therapy;
LIHC	cis	rs244293	0.965	rs244334	chr17:53204055	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.46	6.81	0.35	4.33e-11	Menarche (age at onset);
LIHC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.08	9.8	0.47	3.68e-20	Diabetic retinopathy;
LIHC	cis	rs11673344	0.796	rs16971886	chr19:37487975	G/A	cg27390819	chr19:37464633	NA	-0.5	-6.05	-0.31	3.82e-9	Obesity-related traits;
LIHC	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.88	-0.35	2.95e-11	Mean corpuscular volume;
LIHC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.22	-6.09	-0.31	2.97e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.28	-0.41	2.9e-15	Blood protein levels;
LIHC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.67	-12.53	-0.56	6.71e-30	Body mass index;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26816438	chr1:45139524	TMEM53;C1orf228	-0.38	-6.09	-0.31	2.99e-9	Triglycerides;
LIHC	trans	rs4290604	0.748	rs10929216	chr2:238080938	C/T	cg15676719	chr1:167598521	RCSD1	-0.46	-6.19	-0.32	1.77e-9	Asthma;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg23625390	chr15:77176239	SCAPER	0.35	5.8	0.3	1.49e-8	Blood metabolite levels;
LIHC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.58	0.34	1.78e-10	Platelet count;
LIHC	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.42	5.91	0.3	8.41e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.09	-0.4	1.06e-14	Response to antipsychotic treatment;
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.13	0.4	8.12e-15	Height;
LIHC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.72	0.54	6.88e-27	Motion sickness;
LIHC	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.34	-6.44	-0.33	4.01e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9378688	0.872	rs3800185	chr6:2212169	A/C	cg12303981	chr6:2244766	GMDS	-0.44	-5.84	-0.3	1.2e-8	Caudate nucleus volume;
LIHC	trans	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-9.42	-0.45	7.08e-19	Skin colour saturation;
LIHC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-6.83	-0.35	3.79e-11	Reticulocyte count;
LIHC	cis	rs2574704	0.816	rs2616555	chr3:11661114	T/A	cg15876825	chr3:11651881	VGLL4	0.49	7.92	0.39	3.36e-14	Body mass index;
LIHC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.47	8.46	0.42	7.78e-16	Colorectal cancer;
LIHC	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.73	11.01	0.51	2.45e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.69	12.1	0.55	2.64e-28	Colorectal cancer;
LIHC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.72	13.01	0.58	1.05e-31	Prostate cancer;
LIHC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.79	0.3	1.6e-8	Tonsillectomy;
LIHC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg07706471	chr12:123319906	HIP1R	-0.6	-7.97	-0.4	2.4e-14	Schizophrenia;
LIHC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11781535	chr10:38893821	NA	0.4	7.09	0.36	7.57e-12	Electrocardiographic conduction measures;
LIHC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.33	7.06	0.36	9.23e-12	Ulcerative colitis;
LIHC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.41	-6.84	-0.35	3.55e-11	Facial morphology (factor 20);
LIHC	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.61	0.34	1.45e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4908768	0.906	rs10492966	chr1:8598005	C/T	cg20416874	chr1:8611966	RERE	0.58	9.41	0.45	7.38e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg08132940	chr7:1081526	C7orf50	-0.77	-6.47	-0.33	3.47e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	0.51	9.03	0.44	1.26e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg10820045	chr2:198174542	NA	0.47	7.03	0.36	1.12e-11	Dermatomyositis;
LIHC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	12.08	0.55	3.15e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs10861342	0.892	rs11112378	chr12:105514033	A/G	cg23923672	chr12:105501055	KIAA1033	0.66	7.75	0.39	1.08e-13	IgG glycosylation;
LIHC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.1	-12.96	-0.57	1.57e-31	Vitiligo;
LIHC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	10.25	0.48	1.16e-21	Multiple sclerosis;
LIHC	cis	rs1421811	0.630	rs72740637	chr5:32710486	G/A	cg16267343	chr5:32710456	NPR3	0.65	6.56	0.33	2.03e-10	Blood pressure;
LIHC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.84	0.65	9.42e-43	Nonalcoholic fatty liver disease;
LIHC	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.53	-6.73	-0.34	7.36e-11	Schizophrenia;
LIHC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.51	9.04	0.44	1.16e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.74	-12.07	-0.55	3.42e-28	Breast cancer;
LIHC	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	7.82	0.39	6.42e-14	Blood protein levels;
LIHC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg22961513	chr11:14280813	SPON1	-0.45	-6.8	-0.35	4.6e-11	Mitochondrial DNA levels;
LIHC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.73	-11.97	-0.54	7.94e-28	Body mass index;
LIHC	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg03934865	chr2:198174659	NA	0.52	7.99	0.4	2.09e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg26831259	chr4:1366826	KIAA1530	-0.36	-5.99	-0.31	5.27e-9	Obesity-related traits;
LIHC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	0.61	6.11	0.31	2.68e-9	Obesity-related traits;
LIHC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.5	7.94	0.39	2.99e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg02269571	chr22:50332266	NA	-0.59	-8.01	-0.4	1.85e-14	Schizophrenia;
LIHC	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.35	13.29	0.58	8.96e-33	Psoriasis vulgaris;
LIHC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.91	-12.14	-0.55	1.97e-28	Orofacial clefts;
LIHC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.9	0.35	2.6e-11	Bipolar disorder;
LIHC	trans	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg26939375	chr7:64535504	NA	0.41	6.49	0.33	2.98e-10	Aortic root size;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21448741	chr8:58168803	NA	0.35	6.51	0.33	2.73e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.04	-0.31	4.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs79387448	0.683	rs7571985	chr2:103147561	G/A	cg09003973	chr2:102972529	NA	0.85	7.4	0.37	1.04e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg04374321	chr14:90722782	PSMC1	0.47	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg22705602	chr4:152727874	NA	-0.34	-7.3	-0.37	2.03e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.31	-5.73	-0.3	2.26e-8	Sitting height ratio;
LIHC	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg25237894	chr2:233734115	C2orf82	-0.4	-7.22	-0.36	3.42e-12	Coronary artery disease;
LIHC	cis	rs4478037	0.822	rs4528891	chr3:33121392	G/T	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.07	-0.36	9e-12	Major depressive disorder;
LIHC	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg08126542	chr6:37504118	NA	-0.4	-6.46	-0.33	3.63e-10	Cognitive performance;
LIHC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.5	0.33	2.86e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.1	-0.31	2.79e-9	Total body bone mineral density;
LIHC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.48	6.31	0.32	8.84e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.54	7.3	0.37	2.01e-12	Neuroblastoma;
LIHC	cis	rs9322817	0.691	rs2499659	chr6:105286124	A/T	cg02098413	chr6:105308735	HACE1	0.45	8.41	0.41	1.16e-15	Thyroid stimulating hormone;
LIHC	cis	rs903552	0.736	rs2412008	chr15:102006841	C/T	cg06707286	chr15:102010195	PCSK6	-0.52	-7.42	-0.37	9.5e-13	Diabetic kidney disease;
LIHC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg09182678	chr22:50328711	NA	-0.43	-6.09	-0.31	2.99e-9	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.6	8.64	0.42	2.25e-16	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg00656387	chr3:40428638	ENTPD3	0.42	6.95	0.35	1.81e-11	Renal cell carcinoma;
LIHC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.6	9.48	0.46	4.34e-19	Crohn's disease;
LIHC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg22834771	chr12:69754056	YEATS4	-0.48	-8.39	-0.41	1.3e-15	Blood protein levels;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.75	11.85	0.54	2.17e-27	Longevity;
LIHC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg23978390	chr7:1156363	C7orf50	0.49	7.53	0.38	4.62e-13	Longevity;Endometriosis;
LIHC	cis	rs9648428	0.731	rs11496028	chr7:36203759	A/G	cg14708893	chr7:36124863	NA	-0.65	-8.42	-0.41	1.03e-15	Obesity-related traits;
LIHC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.59	0.56	4.07e-30	Electrocardiographic conduction measures;
LIHC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.75	-11.43	-0.53	7.65e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.59	0.5	7.49e-23	Vitiligo;
LIHC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.57	6.32	0.32	8.19e-10	Axial length;
LIHC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.45	-6.26	-0.32	1.15e-9	Longevity;
LIHC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg13844804	chr7:814759	HEATR2	0.44	5.95	0.31	6.72e-9	Cerebrospinal P-tau181p levels;
LIHC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.37	0.49	4.17e-22	Resting heart rate;
LIHC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-8.12	-0.4	8.43e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10426930	0.844	rs56386046	chr19:5037230	C/T	cg18473234	chr19:5097819	KDM4B	0.54	6.79	0.34	5.11e-11	Monocyte percentage of white cells;
LIHC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.47	0.33	3.33e-10	Multiple sclerosis;
LIHC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-7.54	-0.38	4.27e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.46	-5.78	-0.3	1.7e-8	Breast cancer;
LIHC	cis	rs10845606	0.581	rs11055015	chr12:12836679	T/G	cg04607235	chr12:12878440	APOLD1	-0.46	-6.35	-0.32	6.88e-10	Systemic lupus erythematosus;
LIHC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.83	11.45	0.53	6.63e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg02491457	chr7:128862824	NA	-0.59	-8.82	-0.43	6.01e-17	White matter hyperintensity burden;
LIHC	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.61	10.4	0.49	3.53e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.58	8.61	0.42	2.79e-16	Diastolic blood pressure;
LIHC	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.52	0.42	5.1e-16	Exhaled nitric oxide output;
LIHC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.41	6.14	0.32	2.24e-9	Menarche (age at onset);
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg04709771	chr16:646395	RAB40C	0.47	8.33	0.41	1.99e-15	Height;
LIHC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.33	8.6	0.42	2.86e-16	Schizophrenia;
LIHC	trans	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg18335740	chr13:41363409	SLC25A15	-0.37	-6.47	-0.33	3.46e-10	Lewy body disease;
LIHC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.96e-11	Rheumatoid arthritis;
LIHC	cis	rs11955398	0.521	rs4298206	chr5:60012235	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.41	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-7.99	-0.4	2.08e-14	Gut microbiome composition (summer);
LIHC	cis	rs3015497	0.904	rs3015501	chr14:51108524	C/T	cg09863266	chr14:51125203	SAV1	-0.39	-6.34	-0.32	7.3e-10	Mean platelet volume;
LIHC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.37	-6.01	-0.31	4.67e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg15848620	chr12:58087721	OS9	-0.43	-5.92	-0.31	7.69e-9	Rheumatoid arthritis;
LIHC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.11	0.44	6.98e-18	Schizophrenia;
LIHC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.58	-11.11	-0.51	1.13e-24	Mean corpuscular volume;
LIHC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-0.95	-19.65	-0.73	4.32e-58	Height;
LIHC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg22356347	chr1:167427500	CD247	0.39	6.43	0.33	4.4e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.41	-6.91	-0.35	2.33e-11	Breast cancer;
LIHC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.16	0.36	4.95e-12	Self-reported allergy;
LIHC	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.23e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7635838	0.819	rs2454481	chr3:11535178	C/T	cg00170343	chr3:11313890	ATG7	0.4	6.19	0.32	1.67e-9	HDL cholesterol;
LIHC	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.47	-0.42	7.18e-16	Response to antipsychotic treatment;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg24129382	chr3:119529158	NR1I2	-0.22	-6.22	-0.32	1.49e-9	Pain;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11642254	chr7:156684974	LMBR1	0.48	6.98	0.35	1.52e-11	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02315113	chr1:173684045	KLHL20	0.41	6.41	0.33	4.71e-10	Cognitive function;
LIHC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09695851	chr17:3907499	NA	0.67	11.13	0.52	8.99e-25	Type 2 diabetes;
LIHC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.28e-9	Menopause (age at onset);
LIHC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.63	-0.38	2.38e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.59	10.14	0.48	2.61e-21	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21448741	chr8:58168803	NA	0.38	6.23	0.32	1.35e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.47	-7.88	-0.39	4.53e-14	IgG glycosylation;
LIHC	cis	rs12611088	0.571	rs2599447	chr19:44007012	G/A	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.38	-0.33	5.61e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs735860	0.726	rs209507	chr6:53194768	T/A	cg10236188	chr6:53219634	NA	0.41	7.41	0.37	1.01e-12	Glaucoma;
LIHC	cis	rs7937890	0.559	rs2597221	chr11:14527075	C/T	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.75	8.44	0.42	9.31e-16	Obesity-related traits;
LIHC	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg25364880	chr3:44379878	C3orf23	0.59	8.1	0.4	9.87e-15	Depressive symptoms;
LIHC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-0.84	-10.68	-0.5	3.74e-23	Blood pressure (smoking interaction);
LIHC	cis	rs67981189	0.593	rs2240341	chr14:71373580	T/C	cg15816911	chr14:71606274	NA	-0.41	-6.51	-0.33	2.6200000000000003e-10	Schizophrenia;
LIHC	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg08847533	chr14:75593920	NEK9	0.4	6.67	0.34	1.03e-10	Caffeine consumption;
LIHC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-9.0	-0.44	1.59e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.46	-6.86	-0.35	3.28e-11	Menopause (age at onset);
LIHC	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.24	-0.41	3.72e-15	Exhaled nitric oxide output;
LIHC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.3	-16.67	-0.67	4.52e-46	Diabetic kidney disease;
LIHC	cis	rs3736485	0.932	rs4774592	chr15:51778879	C/T	cg08986416	chr15:51914746	DMXL2	-0.4	-6.05	-0.31	3.78e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.75	-6.19	-0.32	1.69e-9	IgG glycosylation;
LIHC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.71	10.55	0.5	1.02e-22	Aortic root size;
LIHC	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.58	0.5	8.16e-23	Obesity-related traits;
LIHC	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17125944	0.686	rs7155860	chr14:53335229	G/C	cg00686598	chr14:53173677	PSMC6	-0.74	-8.52	-0.42	5.34e-16	Alzheimer's disease (late onset);
LIHC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg22834771	chr12:69754056	YEATS4	-0.47	-8.0	-0.4	1.95e-14	Response to diuretic therapy;
LIHC	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.34	5.84	0.3	1.2e-8	Metabolite levels;
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.26	0.75	1.62e-64	Height;
LIHC	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	0.8	11.22	0.52	4.32e-25	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21408716	chr3:52279700	PPM1M	-0.46	-6.16	-0.32	2.01e-9	Hepatitis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18827097	chr2:3522506	ADI1	0.41	6.59	0.34	1.65e-10	Cognitive function;
LIHC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.45	6.1	0.31	2.91e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg24947615	chr21:44515479	U2AF1	0.41	6.08	0.31	3.28e-9	Alopecia areata;
LIHC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.34	-0.32	7.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.49	-0.38	5.86e-13	Platelet distribution width;
LIHC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg08499158	chr17:42289980	UBTF	-0.49	-8.1	-0.4	9.85e-15	Total body bone mineral density;
LIHC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.49	8.16	0.4	6.68e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg07451762	chr16:28383216	NA	0.34	6.47	0.33	3.31e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg09445902	chr10:555545	DIP2C	0.36	5.75	0.3	1.96e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg15105060	chr4:7024189	TBC1D14	-0.71	-6.02	-0.31	4.41e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg25344623	chr2:136566232	LCT	-0.34	-5.92	-0.3	7.92e-9	Corneal structure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00116058	chr5:154320652	MRPL22	0.43	6.08	0.31	3.16e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.35	0.49	4.97e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17507749	chr15:85114479	UBE2QP1	0.67	6.39	0.33	5.38e-10	Schizophrenia;
LIHC	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.57	7.45	0.37	7.55e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg19683494	chr5:74908142	NA	0.54	7.16	0.36	5.12e-12	Age-related disease endophenotypes;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg23933339	chr15:57731055	CGNL1	0.56	6.6	0.34	1.54e-10	Mean platelet volume;
LIHC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.12	0.36	6.48e-12	Renal cell carcinoma;
LIHC	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg06108461	chr20:60628389	TAF4	-0.53	-7.18	-0.36	4.31e-12	Body mass index;
LIHC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.49	7.73	0.39	1.25e-13	Diastolic blood pressure;
LIHC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.51	6.66	0.34	1.13e-10	Alzheimer's disease;
LIHC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.89	-0.57	2.93e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.69	0.46	9.11e-20	Coffee consumption (cups per day);
LIHC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.9	14.0	0.6	1.66e-35	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.03	16.24	0.66	2.33e-44	Breast cancer;
LIHC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.1	0.58	4.59e-32	Lung cancer in ever smokers;
LIHC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg12160578	chr15:63334699	TPM1	-0.6	-8.66	-0.42	1.93e-16	Platelet count;
LIHC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg08499158	chr17:42289980	UBTF	-0.52	-9.04	-0.44	1.16e-17	Total body bone mineral density;
LIHC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.89	10.12	0.48	3.02e-21	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	1.04	15.21	0.64	3.01e-40	Breast cancer;
LIHC	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg14515779	chr1:101123966	NA	-0.45	-6.38	-0.33	5.67e-10	Monocyte count;
LIHC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.87	-0.54	1.88e-27	Type 2 diabetes;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg18279126	chr7:2041391	MAD1L1	-0.36	-6.0	-0.31	4.9e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.47	8.45	0.42	8.36e-16	IgG glycosylation;
LIHC	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.54	8.06	0.4	1.27e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14379462	chr9:136234288	SURF4	0.46	6.1	0.31	2.83e-9	Systolic blood pressure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04015759	chr2:27718181	FNDC4	0.39	6.27	0.32	1.1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.57	8.05	0.4	1.34e-14	Lymphocyte percentage of white cells;
LIHC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg15448220	chr1:150897856	SETDB1	-0.43	-6.63	-0.34	1.33e-10	Urate levels;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.35	6.69	0.34	8.99e-11	Tonsillectomy;
LIHC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.99	0.35	1.44e-11	Axial length;
LIHC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.09	-0.55	2.85e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.84	-13.87	-0.6	4.92e-35	Breast cancer;
LIHC	cis	rs17106184	0.892	rs17106175	chr1:50904241	G/A	cg07174182	chr1:51127561	FAF1	-0.62	-6.88	-0.35	2.88e-11	Type 2 diabetes;
LIHC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.61	7.28	0.37	2.36e-12	Cognitive function;
LIHC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.43	6.49	0.33	3.09e-10	Personality dimensions;
LIHC	cis	rs2574704	0.701	rs1561073	chr3:11642114	T/A	cg15876825	chr3:11651881	VGLL4	-0.47	-6.99	-0.35	1.47e-11	Body mass index;
LIHC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.37	-5.72	-0.3	2.29e-8	Lung cancer;
LIHC	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg05425664	chr17:57184151	TRIM37	-0.47	-5.89	-0.3	9.43e-9	Vitamin D levels;
LIHC	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.03e-11	Ileal carcinoids;
LIHC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.63	9.39	0.45	8.71e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14396892	chr9:96623032	NA	-0.33	-6.3	-0.32	9.26e-10	DNA methylation (variation);
LIHC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.97	9.8	0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.65	-0.38	2.08e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.72	13.55	0.59	8.78e-34	Mortality in heart failure;
LIHC	cis	rs11229555	0.645	rs12294062	chr11:58175603	G/T	cg15696309	chr11:58395628	NA	-0.63	-7.49	-0.38	5.92e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg15704280	chr7:45808275	SEPT13	0.7	7.16	0.36	5.01e-12	Body mass index;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13126279	chr21:47581558	C21orf56	-0.46	-7.22	-0.36	3.35e-12	Testicular germ cell tumor;
LIHC	cis	rs12744310	0.830	rs4406620	chr1:41792765	A/G	cg03962019	chr1:41807865	NA	0.39	6.38	0.33	5.89e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07080220	chr10:102295463	HIF1AN	0.45	6.15	0.32	2.12e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.74	-11.56	-0.53	2.59e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.6	-0.38	2.79e-13	Blood metabolite levels;
LIHC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.45	-12.12	-0.55	2.26e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00339695	chr16:24857497	SLC5A11	0.48	7.38	0.37	1.19e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg20011983	chr2:74347215	NA	-0.39	-5.83	-0.3	1.31e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.6	7.15	0.36	5.22e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg22153463	chr1:85462885	MCOLN2	0.52	6.26	0.32	1.16e-9	Serum sulfate level;
LIHC	cis	rs963731	0.737	rs6544197	chr2:39315388	T/C	cg04010122	chr2:39346883	SOS1	-0.68	-6.03	-0.31	4.15e-9	Corticobasal degeneration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23250374	chr4:57253573	AASDH	-0.5	-6.05	-0.31	3.84e-9	Systolic blood pressure;
LIHC	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg03934865	chr2:198174659	NA	0.48	6.96	0.35	1.78e-11	Dermatomyositis;
LIHC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.57	-5.87	-0.3	1.02e-8	Schizophrenia;
LIHC	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.61	-10.07	-0.48	4.75e-21	Waist circumference;Body mass index;
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.87	13.12	0.58	3.91e-32	Skin colour saturation;
LIHC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-9.84	-0.47	2.89e-20	Schizophrenia;
LIHC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.58	6.47	0.33	3.44e-10	Axial length;
LIHC	cis	rs965469	1.000	rs6037590	chr20:3374085	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.63	-0.34	1.3e-10	IFN-related cytopenia;
LIHC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.6	8.43	0.41	9.62e-16	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.54	6.07	0.31	3.45e-9	Alzheimer's disease;
LIHC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27297192	chr10:134578999	INPP5A	0.54	7.87	0.39	4.76e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.59	-8.63	-0.42	2.4e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs34540877	1.000	rs35413309	chr19:33167837	C/T	cg22980127	chr19:33182716	NUDT19	0.97	6.06	0.31	3.68e-9	Red cell distribution width;
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.26	-6.2	-0.32	1.62e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.78	14.69	0.62	3.25e-38	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.41	-6.77	-0.34	5.62e-11	Schizophrenia;
LIHC	cis	rs1198430	1.000	rs1198431	chr1:23755716	C/T	cg13183780	chr1:23809682	ASAP3	0.55	8.1	0.4	9.75e-15	Total cholesterol levels;
LIHC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.75	-13.88	-0.6	4.5e-35	Height;
LIHC	cis	rs860295	0.580	rs12032720	chr1:155274960	G/C	cg02153340	chr1:155202674	NA	-0.35	-6.16	-0.32	2.08e-9	Body mass index;
LIHC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4908768	0.906	rs55830087	chr1:8681550	C/T	cg25722041	chr1:8623473	RERE	0.43	5.75	0.3	2.01e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.66	13.22	0.58	1.58e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.62	-0.34	1.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.49	-8.13	-0.4	7.91e-15	Schizophrenia;
LIHC	trans	rs8012283	0.591	rs72683631	chr14:51261114	C/A	cg07338119	chr7:157211683	NA	-0.67	-6.08	-0.31	3.2e-9	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs4660306	0.614	rs1007859	chr1:45911906	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	6.86	0.35	3.31e-11	Homocysteine levels;
LIHC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.38	5.75	0.3	1.98e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2386661	0.736	rs11818357	chr10:5661667	C/T	cg17085576	chr10:5658249	NA	-0.36	-6.44	-0.33	4.05e-10	Breast cancer;
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.35	-6.87	-0.35	2.97e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.42	0.41	1.09e-15	Lung cancer in ever smokers;
LIHC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.23	6.57	0.33	1.87e-10	Blood protein levels;
LIHC	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.6	9.98	0.47	9.71e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18252515	chr7:66147081	NA	0.43	5.98	0.31	5.63e-9	Aortic root size;
LIHC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg12317470	chr15:67143691	NA	-0.6	-7.32	-0.37	1.77e-12	Lung cancer (smoking interaction);
LIHC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.66	-0.46	1.13e-19	Bipolar disorder;
LIHC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg18867708	chr6:26865862	GUSBL1	0.52	8.1	0.4	9.8e-15	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.68	6.93	0.35	2.11e-11	Alzheimer's disease;
LIHC	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.94	0.51	4.35e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	1.02	19.7	0.73	2.9e-58	Breast cancer;
LIHC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg21734168	chr11:67353974	GSTP1	-0.28	-6.78	-0.34	5.17e-11	Mean corpuscular volume;
LIHC	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.62	0.38	2.46e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.52	8.21	0.41	4.63e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4517514	0.509	rs10830434	chr11:89912652	T/C	cg05041596	chr11:89867385	NAALAD2	0.42	6.77	0.34	5.49e-11	Trans fatty acid levels;
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	23.22	0.78	2.96e-72	Prudent dietary pattern;
LIHC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.53	-0.33	2.37e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07327967	chr16:87926682	CA5A	0.4	6.13	0.31	2.38e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	ch.11.42038R	chr11:967971	AP2A2	0.55	9.83	0.47	3.11e-20	Alzheimer's disease (late onset);
LIHC	trans	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg16290275	chr1:208042910	NA	-0.53	-6.09	-0.31	3.08e-9	Type 2 diabetes;
LIHC	cis	rs11671005	0.735	rs12981875	chr19:58935130	A/C	cg25952890	chr19:58913133	NA	0.68	7.26	0.37	2.62e-12	Mean platelet volume;
LIHC	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg26211634	chr5:139558579	C5orf32	0.4	6.18	0.32	1.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.72	9.71	0.46	7.42e-20	Body mass index;
LIHC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.86	-0.35	3.27e-11	Migraine;Coronary artery disease;
LIHC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.56	-8.55	-0.42	4.11e-16	Coronary artery disease;
LIHC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.15	0.52	8.09e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14416316	chr13:111145583	COL4A2	0.4	7.35	0.37	1.44e-12	Cognitive function;
LIHC	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02886208	chr11:14281011	SPON1	0.63	9.21	0.45	3.48e-18	Mitochondrial DNA levels;
LIHC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16024904	chr19:17905718	B3GNT3	0.44	6.25	0.32	1.25e-9	Tumor biomarkers;
LIHC	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.7	-0.43	1.43e-16	Blood metabolite levels;
LIHC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.34	-5.82	-0.3	1.38e-8	IgG glycosylation;
LIHC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.38	-0.56	2.37e-29	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg07424592	chr7:64974309	NA	0.84	9.58	0.46	2.05e-19	Diabetic kidney disease;
LIHC	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.47	6.92	0.35	2.27e-11	Schizophrenia;
LIHC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-6.31	-0.32	8.56e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.87	13.09	0.58	4.92e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg25039879	chr17:56429692	SUPT4H1	0.75	8.41	0.41	1.1e-15	Cognitive test performance;
LIHC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	1.03	11.77	0.54	4.55e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.63	-6.5	-0.33	2.83e-10	Migraine;Coronary artery disease;
LIHC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.44	-7.16	-0.36	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.2	-0.41	4.88e-15	Response to antipsychotic treatment;
LIHC	cis	rs11233413	0.508	rs10792666	chr11:82650000	A/T	cg24227371	chr11:82718527	RAB30	-0.29	-6.51	-0.33	2.6200000000000003e-10	Economic and political preferences (feminism/equality);
LIHC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.35	5.76	0.3	1.9e-8	Colorectal cancer;
LIHC	cis	rs10792665	0.510	rs7116170	chr11:82630702	G/A	cg24227371	chr11:82718527	RAB30	-0.28	-6.59	-0.34	1.66e-10	Obesity-related traits;
LIHC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.6	9.48	0.46	4.34e-19	Lung cancer;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg14257396	chr1:107603778	NA	-0.37	-6.15	-0.32	2.17e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22719782	chr11:114310057	REXO2	0.52	6.52	0.33	2.59e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.66	-12.67	-0.57	2.05e-30	Age at first birth;
LIHC	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.73	-9.0	-0.44	1.64e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.49	8.29	0.41	2.6e-15	Total cholesterol levels;
LIHC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.44	-7.16	-0.36	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.46	8.81	0.43	6.43e-17	Testicular germ cell tumor;
LIHC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.46	9.69e-20	Bipolar disorder;
LIHC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.39	-6.06	-0.31	3.56e-9	Height;
LIHC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg07451762	chr16:28383216	NA	0.39	7.08	0.36	8.46e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.6	8.18	0.4	5.74e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs80282103	0.618	rs74117848	chr10:1160974	T/G	cg08668510	chr10:1095578	IDI1	0.64	6.13	0.31	2.37e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs12493885	0.725	rs11718315	chr3:153724197	A/G	cg10247383	chr3:153839028	SGEF	0.65	6.1	0.31	2.89e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-6.06	-0.31	3.52e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08219700	chr8:58056026	NA	0.5	6.31	0.32	8.65e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27498675	chr19:41945691	ATP5SL	0.4	6.05	0.31	3.79e-9	Cognitive function;
LIHC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.54	8.82	0.43	6e-17	Body mass index;
LIHC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	7.49	0.38	5.97e-13	Schizophrenia;
LIHC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.69	10.59	0.5	7.39e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Vitiligo;
LIHC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-6.02	-0.31	4.48e-9	Bronchopulmonary dysplasia;
LIHC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.79	0.34	5.09e-11	Morning vs. evening chronotype;
LIHC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.52	-7.06	-0.36	9.42e-12	Pancreatic cancer;
LIHC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.21	-0.36	3.61e-12	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.32	7.55	0.38	3.88e-13	Blood metabolite ratios;
LIHC	cis	rs7119038	0.774	rs7945144	chr11:118608716	A/G	cg19308663	chr11:118741387	NA	0.42	6.47	0.33	3.3e-10	Sjögren's syndrome;
LIHC	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg25024717	chr12:54324583	NA	-0.32	-6.3	-0.32	8.9e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-8.69	-0.43	1.49e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.32	7.89	0.39	4.23e-14	Corneal astigmatism;
LIHC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.49	9.35	0.45	1.14e-18	Atrioventricular conduction;
LIHC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg22079354	chr11:130786696	SNX19	0.42	6.02	0.31	4.43e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.16	-14.99	-0.63	2.16e-39	Ulcerative colitis;
LIHC	cis	rs4853525	0.522	rs62179715	chr2:191570072	C/T	cg10560079	chr2:191398806	TMEM194B	-0.42	-5.96	-0.31	6.45e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.54	-9.53	-0.46	3.02e-19	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.42	0.45	7.02e-19	Bipolar disorder;
LIHC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg12798992	chr6:167411361	FGFR1OP	0.52	8.05	0.4	1.37e-14	Crohn's disease;
LIHC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.69	-9.95	-0.47	1.23e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.33	6.06	0.31	3.52e-9	Height;
LIHC	cis	rs17021463	0.673	rs4699459	chr4:95292702	G/A	cg11021082	chr4:95130006	SMARCAD1	0.44	7.59	0.38	3e-13	Testicular germ cell tumor;
LIHC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg16926213	chr1:1841314	NA	0.32	5.9	0.3	8.86e-9	Body mass index;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10687131	chr2:20871002	GDF7	0.33	6.71	0.34	8.07e-11	Abdominal aortic aneurysm;
LIHC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.24	6.09	0.31	3.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.37	-8.16	-0.4	6.35e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.67	-11.24	-0.52	3.68e-25	Childhood ear infection;
LIHC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-9.05	-0.44	1.1e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.26	-6.29	-0.32	9.9e-10	Mean corpuscular volume;
LIHC	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.67	-0.34	1.04e-10	Neuroticism;
LIHC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.59	7.93	0.39	3.08e-14	Mean platelet volume;
LIHC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.41	-7.24	-0.36	2.9e-12	Height;
LIHC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-7.91	-0.39	3.5e-14	Uric acid levels;
LIHC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.39	-0.49	3.69e-22	Hemoglobin concentration;
LIHC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.81	-8.92	-0.43	2.78e-17	Schizophrenia;
LIHC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.05	-0.4	1.37e-14	Monocyte percentage of white cells;
LIHC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.48	-7.67	-0.38	1.76e-13	Diastolic blood pressure;
LIHC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.21	-0.45	3.27e-18	Bipolar disorder;
LIHC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.51	7.07	0.36	8.59e-12	Morning vs. evening chronotype;
LIHC	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	7.06	0.36	9.54e-12	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.32	-5.96	-0.31	6.38e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs703410	0.545	rs242962	chr10:119313030	G/T	cg10846980	chr10:119306025	EMX2;EMX2OS	-0.56	-8.52	-0.42	5.19e-16	Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.42	-7.37	-0.37	1.29e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.46	6.88	0.35	2.92e-11	Asthma (sex interaction);
LIHC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-6.35	-0.32	7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.7	10.34	0.49	5.29e-22	Prostate cancer;
LIHC	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-9.75	-0.47	5.44e-20	Platelet count;
LIHC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	11.25	0.52	3.43e-25	Platelet count;
LIHC	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.53	-7.42	-0.37	9.25e-13	Body mass index;
LIHC	cis	rs918629	0.798	rs2548595	chr5:95284341	C/T	cg10483112	chr5:95245456	ELL2	-0.36	-6.3	-0.32	9.17e-10	IgG glycosylation;
LIHC	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.89	11.15	0.52	8.01e-25	Coronary artery disease;
LIHC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-0.95	-19.82	-0.73	8.91e-59	Height;
LIHC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.49	5.82	0.3	1.39e-8	Alzheimer's disease;
LIHC	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.53	9.98	0.48	9.08e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.04	0.48	5.83e-21	Colorectal cancer;
LIHC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	8.11	0.4	9.37e-15	Lymphocyte counts;
LIHC	cis	rs744487	1.000	rs744487	chr1:234726012	A/C	cg09691134	chr1:234734475	NA	0.39	6.59	0.34	1.67e-10	LDL cholesterol;
LIHC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.77	9.55	0.46	2.55e-19	Morning vs. evening chronotype;
LIHC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.89	12.6	0.56	3.55e-30	Blood metabolite levels;
LIHC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.57	10.65	0.5	4.52e-23	Mean corpuscular volume;
LIHC	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	0.54	7.08	0.36	8.09e-12	Pulse pressure;
LIHC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-26.0	-0.81	5.29e-83	Myeloid white cell count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02726883	chr17:29421732	NF1	0.48	6.55	0.33	2.09e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg22951263	chr5:87985283	NA	-0.38	-6.62	-0.34	1.42e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-8.58	-0.42	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.16e-9	Menopause (age at onset);
LIHC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.66	-12.0	-0.54	6.23e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.87	-0.35	3.1e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg26939375	chr7:64535504	NA	0.4	6.43	0.33	4.35e-10	Aortic root size;
LIHC	trans	rs3783890	0.887	rs35803481	chr14:93803409	G/A	cg02802420	chr16:69363236	PDF;COG8	0.34	6.47	0.33	3.44e-10	Body mass index;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg15382696	chr6:118971807	C6orf204	0.63	6.37	0.33	6.05e-10	Diastolic blood pressure;
LIHC	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.44	-6.18	-0.32	1.77e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.52	-0.49	1.28e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.52	9.08	0.44	8.79e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-6.13	-0.31	2.4e-9	Ulcerative colitis;
LIHC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg16586182	chr3:47516702	SCAP	-0.57	-10.91	-0.51	5.7e-24	Colorectal cancer;
LIHC	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	1.08	12.48	0.56	9.9e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.46	7.1	0.36	7.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.5	6.96	0.35	1.71e-11	Height;
LIHC	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-5.94	-0.31	7.01e-9	Response to antipsychotic treatment;
LIHC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.93	-0.43	2.6e-17	Blood metabolite levels;
LIHC	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.92	10.57	0.5	8.6e-23	IgG glycosylation;
LIHC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	7.25	0.37	2.78e-12	Height;
LIHC	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.33	-5.95	-0.31	6.81e-9	Lewy body disease;
LIHC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.77	10.41	0.49	3.11e-22	Coronary artery disease;
LIHC	cis	rs4908768	0.501	rs6577492	chr1:8575064	C/A	cg20416874	chr1:8611966	RERE	-0.66	-13.86	-0.6	5.69e-35	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.6	10.08	0.48	4.41e-21	Height;
LIHC	cis	rs3018712	0.532	rs28551086	chr11:68400739	G/A	cg20283391	chr11:68216788	NA	-0.52	-6.24	-0.32	1.3e-9	Total body bone mineral density;
LIHC	trans	rs6600671	0.932	rs6600663	chr1:121222437	A/T	cg09829573	chr1:144692074	NBPF9	-0.39	-6.94	-0.35	1.92e-11	Hip geometry;
LIHC	cis	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg16296745	chr17:78355552	RNF213;LOC100294362	0.39	5.82	0.3	1.37e-8	Electroencephalogram traits;
LIHC	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	0.58	7.9	0.39	3.82e-14	Obesity-related traits;
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.29	0.55	5.29e-29	Prudent dietary pattern;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06083525	chr1:27216957	GPN2	-0.49	-6.23	-0.32	1.33e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.59	7.2	0.36	3.75e-12	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.52	7.09	0.36	7.61e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	trans	rs2270927	0.510	rs2937750	chr5:75571511	C/T	cg13563193	chr19:33072644	PDCD5	0.85	8.05	0.4	1.4e-14	Mean corpuscular volume;
LIHC	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.64	9.77	0.47	4.68e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg25382214	chr1:3105252	PRDM16	-0.26	-5.84	-0.3	1.19e-8	Migraine;
LIHC	cis	rs17106184	0.892	rs72900979	chr1:51190314	T/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-7.04	-0.36	1.08e-11	Chronic sinus infection;
LIHC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.83	-0.43	5.68e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.41	-7.21	-0.36	3.59e-12	Tuberculosis;
LIHC	cis	rs600806	0.745	rs12136063	chr1:110014170	A/G	cg02415029	chr1:110025642	ATXN7L2	0.46	6.3	0.32	9.27e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.47	-7.39	-0.37	1.11e-12	Dental caries;
LIHC	cis	rs6442522	0.799	rs4395387	chr3:15503055	G/A	cg16303742	chr3:15540471	COLQ	0.49	8.32	0.41	2.14e-15	Uric acid levels;
LIHC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.51	8.65	0.42	1.98e-16	Response to temozolomide;
LIHC	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	0.68	12.98	0.57	1.29e-31	Systemic lupus erythematosus;
LIHC	cis	rs12744310	0.887	rs36040148	chr1:41801448	T/C	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg15691649	chr6:25882328	NA	-0.53	-7.62	-0.38	2.55e-13	Blood metabolite levels;
LIHC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.33	-0.37	1.63e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.65	10.24	0.48	1.23e-21	Menopause (age at onset);
LIHC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	8.15	0.4	7.18e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs1555399	0.905	rs12879556	chr14:67980074	G/C	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.82	-0.3	1.37e-8	Parkinson's disease;
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-12.29	-0.55	5.18e-29	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.9	-0.39	3.95e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.68	0.34	9.53e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.52	-8.09	-0.4	1.07e-14	Extraversion;
LIHC	trans	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg01596870	chr19:55963115	NA	-0.67	-9.61	-0.46	1.58e-19	Obesity-related traits;
LIHC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.52	-0.38	4.9e-13	Breast cancer;
LIHC	cis	rs6466055	0.645	rs4730073	chr7:104855871	A/C	cg04380332	chr7:105027541	SRPK2	-0.31	-6.03	-0.31	4.21e-9	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg14067834	chr17:29058358	SUZ12P	0.72	7.17	0.36	4.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.49	0.38	5.77e-13	Aortic root size;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.81	14.8	0.62	1.22e-38	Prudent dietary pattern;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.93	-0.35	2.13e-11	Obesity-related traits;
LIHC	cis	rs11031096	0.711	rs10767882	chr11:4205841	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.86	-0.3	1.08e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.13	-0.44	5.97e-18	Exhaled nitric oxide output;
LIHC	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg12165864	chr7:66369176	NA	-0.45	-6.42	-0.33	4.63e-10	Corneal structure;
LIHC	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.69	-10.46	-0.49	2.11e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg04998671	chr14:104000505	TRMT61A	0.42	5.76	0.3	1.86e-8	Coronary artery disease;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.57	8.57	0.42	3.65e-16	Testicular germ cell tumor;
LIHC	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg18121669	chr1:26560928	CCDC21	-0.49	-7.24	-0.36	3.02e-12	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.57	-8.39	-0.41	1.34e-15	Prostate cancer;
LIHC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg03013999	chr17:37608204	MED1	-0.35	-5.78	-0.3	1.71e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-12.06	-0.55	3.7e-28	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.75	0.39	1.07e-13	Prudent dietary pattern;
LIHC	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg03934865	chr2:198174659	NA	0.46	6.54	0.33	2.25e-10	Intracranial aneurysm;
LIHC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.24	19.18	0.72	3.64e-56	Type 1 diabetes nephropathy;
LIHC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg00612595	chr21:47717864	NA	-0.36	-5.86	-0.3	1.1e-8	Testicular germ cell tumor;
LIHC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-8.89	-0.43	3.62e-17	Chronic sinus infection;
LIHC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.61	-0.46	1.65e-19	Bipolar disorder;
LIHC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.43	7.38	0.37	1.24e-12	Aortic root size;
LIHC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-5.84	-0.3	1.2e-8	Aortic root size;
LIHC	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.46	-0.37	6.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.5	8.18	0.4	5.7e-15	Corneal astigmatism;
LIHC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.9	11.17	0.52	6.86e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.57	-9.55	-0.46	2.63e-19	Cognitive function;
LIHC	cis	rs12493885	0.818	rs11928425	chr3:153773565	G/T	cg10247383	chr3:153839028	SGEF	0.65	6.13	0.31	2.41e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.81	0.39	7.04e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4979906	1.000	rs2395494	chr10:79458340	C/T	cg07817648	chr10:79422355	NA	-0.34	-7.4	-0.37	1.1e-12	Mortality in heart failure;
LIHC	cis	rs1823913	0.892	rs35596292	chr2:192111616	C/T	cg12404831	chr2:192114017	MYO1B	0.33	6.51	0.33	2.67e-10	Obesity-related traits;
LIHC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg17279839	chr7:150038598	RARRES2	0.51	10.68	0.5	3.68e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.97	-0.35	1.67e-11	Hepatocellular carcinoma;
LIHC	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	14.67	0.62	4.02e-38	Nonalcoholic fatty liver disease;
LIHC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.34	-5.84	-0.3	1.25e-8	Prostate cancer;
LIHC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	10.0	0.48	8.11e-21	Platelet count;
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08219700	chr8:58056026	NA	0.52	7.15	0.36	5.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4788570	0.615	rs4788550	chr16:71720523	C/T	cg06353428	chr16:71660113	MARVELD3	1.41	14.74	0.62	2.12e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.39	0.37	1.16e-12	Vitiligo;
LIHC	cis	rs7192750	0.586	rs11648353	chr16:71986764	G/A	cg06353428	chr16:71660113	MARVELD3	0.77	8.89	0.43	3.46e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.62	-9.9	-0.47	1.77e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	0.91	6.6	0.34	1.58e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.48	-8.69	-0.43	1.55e-16	Colorectal cancer;
LIHC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.48	-0.59	1.66e-33	Vitiligo;
LIHC	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-6.36	-0.33	6.56e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.46	8.54	0.42	4.63e-16	Testicular germ cell tumor;
LIHC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg21573476	chr21:45109991	RRP1B	-0.49	-9.48	-0.46	4.54e-19	Mean corpuscular volume;
LIHC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg21724239	chr8:58056113	NA	0.46	6.2	0.32	1.64e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.02	-0.4	1.7e-14	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.3	-16.7	-0.67	3.38e-46	Diabetic kidney disease;
LIHC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg03037974	chr15:76606532	NA	-0.6	-9.99	-0.48	8.46e-21	Blood metabolite levels;
LIHC	cis	rs337161	0.604	rs11118593	chr1:220878164	C/T	cg06786860	chr1:220876396	NA	-0.46	-7.45	-0.37	7.75e-13	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13922166	chr19:54693569	MBOAT7;TSEN34	0.4	6.24	0.32	1.32e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08667777	chr3:51422532	MANF	0.49	7.22	0.36	3.32e-12	Pancreatic cancer;
LIHC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.67	0.46	9.99e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg12365402	chr11:9010492	NRIP3	0.32	7.86	0.39	5.04e-14	Hemoglobin concentration;
LIHC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.29	6.93	0.35	2.04e-11	Primary biliary cholangitis;
LIHC	trans	rs12752401	1.000	rs35190459	chr1:103089554	T/A	cg03332897	chr19:740442	PALM	0.5	6.15	0.32	2.2e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs4716602	0.596	rs28451598	chr7:156158974	G/A	cg16983916	chr7:156159713	NA	-0.32	-5.87	-0.3	1.02e-8	Anti-saccade response;
LIHC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg26566898	chr11:117069891	TAGLN	0.45	7.12	0.36	6.47e-12	Blood protein levels;
LIHC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg20255370	chr15:40268687	EIF2AK4	-0.62	-8.1	-0.4	9.64e-15	Response to haloperidol in psychosis;
LIHC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.32	0.41	2.15e-15	Platelet count;
LIHC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg00656387	chr3:40428638	ENTPD3	0.4	6.35	0.32	6.8e-10	Renal cell carcinoma;
LIHC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg00204748	chr12:29376779	FAR2	0.38	7.0	0.35	1.4e-11	QT interval;
LIHC	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.45	8.14	0.4	7.48e-15	Resting heart rate;
LIHC	cis	rs240764	0.746	rs240141	chr6:101084946	G/A	cg09795085	chr6:101329169	ASCC3	0.51	7.22	0.36	3.3e-12	Neuroticism;
LIHC	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-8.06	-0.4	1.25e-14	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00777555	chr3:57583074	ARF4	0.42	7.03	0.36	1.13e-11	Cognitive function;
LIHC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	7.72	0.39	1.3e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.48	7.41	0.37	1.03e-12	Ulcerative colitis;
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.51	-6.52	-0.33	2.54e-10	Schizophrenia;
LIHC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06634786	chr22:41940651	POLR3H	0.57	6.36	0.33	6.55e-10	Vitiligo;
LIHC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.9	0.3	8.57e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7937890	0.532	rs2575832	chr11:14488810	A/G	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.3	0.61	1.06e-36	Prudent dietary pattern;
LIHC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17554472	chr22:41940697	POLR3H	0.55	5.89	0.3	9.21e-9	Vitiligo;
LIHC	trans	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg10756647	chr7:56101905	PSPH	0.63	8.75	0.43	9.95e-17	Corneal structure;
LIHC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.32	7.19	0.36	4.24e-12	Crohn's disease;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.83	0.3	1.29e-8	Birth weight;
LIHC	trans	rs4714291	0.698	rs9296321	chr6:40118352	C/T	cg02267698	chr19:7991119	CTXN1	-0.37	-6.2	-0.32	1.59e-9	Strep throat;
LIHC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.2	0.36	3.93e-12	Lung cancer in ever smokers;
LIHC	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg21466736	chr12:48725269	NA	-0.63	-9.28	-0.45	2e-18	Glycated hemoglobin levels;
LIHC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.57	8.11	0.4	9.3e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg12160578	chr15:63334699	TPM1	0.67	8.87	0.43	4.13e-17	Orofacial clefts;
LIHC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	0.97	8.25	0.41	3.56e-15	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21819024	chr1:52344978	NRD1	0.53	7.57	0.38	3.56e-13	Pancreatic cancer;
LIHC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.58	-7.63	-0.38	2.32e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg24209194	chr3:40518798	ZNF619	0.49	7.26	0.37	2.71e-12	Renal cell carcinoma;
LIHC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.55	0.42	4.08e-16	Menarche (age at onset);
LIHC	cis	rs12602486	0.744	rs12603404	chr17:42223914	G/A	cg08193365	chr17:42277699	NA	1.08	7.74	0.39	1.12e-13	Glycated hemoglobin levels;
LIHC	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-6.21	-0.32	1.51e-9	IFN-related cytopenia;
LIHC	cis	rs13088318	0.504	rs55759062	chr3:101202152	C/T	cg19452782	chr3:101232218	SENP7	0.41	6.12	0.31	2.5e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg24044564	chr13:99115944	STK24	0.49	6.93	0.35	2.07e-11	Obesity-related traits;
LIHC	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	0.78	8.77	0.43	8.75e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.91	0.35	2.32e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.13	0.55	2e-28	Prudent dietary pattern;
LIHC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	13.24	0.58	1.39e-32	Psoriasis;
LIHC	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.55	-8.24	-0.41	3.66e-15	Blood protein levels;
LIHC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.57	9.82	0.47	3.34e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10792665	0.575	rs10736756	chr11:82560810	A/G	cg24227371	chr11:82718527	RAB30	0.26	6.18	0.32	1.81e-9	Obesity-related traits;
LIHC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-7.79	-0.39	8.26e-14	Electroencephalogram traits;
LIHC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg24826892	chr11:71159390	DHCR7	0.49	6.23	0.32	1.39e-9	Vitamin D levels;
LIHC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg17980119	chr2:219472607	PLCD4	0.36	6.14	0.31	2.34e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	13.88	0.6	4.66e-35	Primary sclerosing cholangitis;
LIHC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.39	-6.89	-0.35	2.67e-11	Aortic root size;
LIHC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.89	0.54	1.65e-27	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02996269	chr4:106394692	PPA2	0.43	6.56	0.33	2.01e-10	Lung function (FEV1/FVC);
LIHC	cis	rs60515486	0.702	rs11039197	chr11:47378399	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-5.74	-0.3	2.03e-8	Lymphocyte counts;
LIHC	cis	rs10499694	0.697	rs3779074	chr7:50612202	A/G	cg14593290	chr7:50529359	DDC	-0.41	-6.83	-0.35	3.81e-11	Body mass index;
LIHC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg08469215	chr1:156261351	TMEM79	0.39	6.25	0.32	1.21e-9	Tonsillectomy;
LIHC	cis	rs15676	0.561	rs10739736	chr9:131577981	A/T	cg00228799	chr9:131580591	ENDOG	0.47	7.14	0.36	5.51e-12	Blood metabolite levels;
LIHC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg03859395	chr2:55845619	SMEK2	0.92	15.84	0.65	9.33e-43	Metabolic syndrome;
LIHC	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.62	11.86	0.54	2.07e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.47	6.89	0.35	2.67e-11	Aortic root size;
LIHC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.41	7.7	0.38	1.52e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.69	10.68	0.5	3.71e-23	Corneal astigmatism;
LIHC	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg11812906	chr14:75593930	NEK9	0.38	5.94	0.31	7.21e-9	IgG glycosylation;
LIHC	trans	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg01596870	chr19:55963115	NA	-0.65	-9.5	-0.46	3.68e-19	Obesity-related traits;
LIHC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.22e-11	Height;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.76	10.14	0.48	2.64e-21	Selective IgA deficiency;
LIHC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.43	-6.01	-0.31	4.71e-9	Height;
LIHC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	11.64	0.53	1.32e-26	Cognitive test performance;
LIHC	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.9	-0.39	3.79e-14	Vitamin D levels;
LIHC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.57	8.81	0.43	6.63e-17	Multiple sclerosis;
LIHC	cis	rs2637030	0.559	rs370594	chr5:52955554	C/T	cg06476337	chr5:52856530	NDUFS4	0.43	6.76	0.34	5.88e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	0.79	11.4	0.52	9.42e-26	Monocyte percentage of white cells;
LIHC	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg00204512	chr16:28754710	NA	0.36	6.49	0.33	2.98e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg03146154	chr1:46216737	IPP	0.5	8.54	0.42	4.4e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.0	-0.51	2.78e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.21	6.49	0.33	3.1e-10	Motion sickness;
LIHC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.25	-0.37	2.77e-12	Cognitive test performance;
LIHC	trans	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg26939375	chr7:64535504	NA	0.4	6.39	0.33	5.4e-10	Aortic root size;
LIHC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.59	7.87	0.39	4.73e-14	Blood metabolite levels;
LIHC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.53	-9.29	-0.45	1.84e-18	Myeloid white cell count;
LIHC	cis	rs11627756	0.957	rs6575929	chr14:103149447	T/G	cg12046867	chr14:103022105	NA	0.39	5.95	0.31	6.78e-9	Mean platelet volume;
LIHC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	9.93	0.47	1.39e-20	Colorectal cancer;
LIHC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.36	5.99	0.31	5.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.34	13.9	0.6	3.84e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs4450131	0.522	rs4962680	chr10:126358833	C/T	cg20435097	chr10:126320824	FAM53B	0.67	12.33	0.55	3.71e-29	White blood cell count (basophil);
LIHC	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg10820045	chr2:198174542	NA	0.48	7.47	0.37	6.93e-13	Dermatomyositis;
LIHC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg05941027	chr17:61774174	LIMD2	0.35	7.47	0.37	6.95e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.89e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg16724585	chr3:197361211	NA	-0.44	-6.37	-0.33	5.95e-10	Pancreatic cancer;
LIHC	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	0.55	8.56	0.42	3.82e-16	Atopic dermatitis;
LIHC	cis	rs4006360	0.646	rs8080447	chr17:39301276	T/A	cg20663846	chr17:39254439	KRTAP4-8	0.2	5.8	0.3	1.48e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.93	-0.47	1.36e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.79	-0.3	1.61e-8	Pulse pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25936770	chr7:122321411	CADPS2	0.42	6.41	0.33	4.95e-10	Pancreatic cancer;
LIHC	trans	rs7668874	0.779	rs1992270	chr4:116806638	C/T	cg08917878	chr5:172668965	NA	-0.31	-6.03	-0.31	4.17e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.98	-0.35	1.5e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21583412	chr17:27621436	NUFIP2	0.38	6.07	0.31	3.35e-9	Lung function (FEV1/FVC);
LIHC	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.53	-8.17	-0.4	6.25e-15	Coronary artery disease;
LIHC	cis	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-7.27	-0.37	2.39e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg03037974	chr15:76606532	NA	0.66	12.17	0.55	1.53e-28	Blood metabolite levels;
LIHC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.65	0.34	1.19e-10	Bladder cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13671128	chr19:1612344	TCF3	0.5	6.26	0.32	1.16e-9	Systolic blood pressure;
LIHC	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.1	-0.31	2.86e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg20195005	chr22:42527684	CYP2D6	0.32	6.23	0.32	1.39e-9	Birth weight;
LIHC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.63	0.34	1.33e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.55	6.5	0.33	2.83e-10	Alzheimer's disease;
LIHC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.61	0.5	6.33e-23	Colorectal cancer;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07697189	chr5:171766855	SH3PXD2B	0.38	6.15	0.32	2.21e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg03735888	chr19:58951602	ZNF132	0.36	5.95	0.31	6.5e-9	Uric acid clearance;
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.83	12.2	0.55	1.1e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.97	16.89	0.67	5.92e-47	Subjective well-being;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg19635926	chr16:89946313	TCF25	0.55	7.39	0.37	1.11e-12	Skin colour saturation;
LIHC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.97	9.8	0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.56	10.28	0.49	9.19e-22	Vitamin D levels;
LIHC	cis	rs3736485	0.966	rs9920124	chr15:51908942	T/A	cg08986416	chr15:51914746	DMXL2	-0.47	-6.97	-0.35	1.64e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-15.07	-0.63	1.01e-39	Alzheimer's disease (late onset);
LIHC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs7129556	0.520	rs4945185	chr11:77318142	G/A	cg21573582	chr11:77300763	AQP11	0.38	5.71	0.3	2.45e-8	Weight loss (gastric bypass surgery);
LIHC	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.22e-24	Breast cancer;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.19e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.52	-7.74	-0.39	1.14e-13	Total body bone mineral density;
LIHC	cis	rs77633900	0.772	rs284903	chr15:76744813	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-6.1	-0.31	2.79e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-14.08	-0.61	8.16e-36	Systemic lupus erythematosus;
LIHC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg22903471	chr2:27725779	GCKR	-0.43	-6.32	-0.32	7.98e-10	Blood metabolite levels;
LIHC	cis	rs1355223	0.902	rs836462	chr11:34743263	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.95	0.31	6.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg12863693	chr15:85201151	NMB	0.45	6.33	0.32	7.53e-10	Schizophrenia;
LIHC	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.71	10.51	0.49	1.36e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9322817	0.691	rs17680345	chr6:105337409	A/T	cg02098413	chr6:105308735	HACE1	0.39	7.48	0.38	6.25e-13	Thyroid stimulating hormone;
LIHC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg03647239	chr10:116582469	FAM160B1	0.46	6.77	0.34	5.47e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg03934865	chr2:198174659	NA	0.47	6.99	0.35	1.42e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.69	0.46	9.2e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02006803	chr2:128990870	NA	-0.46	-6.06	-0.31	3.52e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.53	8.5	0.42	5.98e-16	Blood protein levels;
LIHC	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	6.99	0.35	1.43e-11	Total cholesterol levels;
LIHC	cis	rs4671400	0.571	rs6738482	chr2:61494901	A/G	cg14146966	chr2:61757674	XPO1	-0.36	-5.75	-0.3	2.01e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.2	0.48	1.73e-21	Alzheimer's disease (late onset);
LIHC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg18867708	chr6:26865862	GUSBL1	0.52	8.1	0.4	9.8e-15	Schizophrenia;
LIHC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.57	0.46	2.25e-19	Mean platelet volume;
LIHC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.44	7.63	0.38	2.42e-13	Mean corpuscular volume;
LIHC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.87e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg25356066	chr3:128598488	ACAD9	0.55	7.36	0.37	1.4e-12	IgG glycosylation;
LIHC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.67	11.59	0.53	1.95e-26	Menopause (age at onset);
LIHC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.43	-6.49	-0.33	3.07e-10	HDL cholesterol;
LIHC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	10.55	0.5	1.03e-22	Systolic blood pressure;
LIHC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.43	0.37	8.76e-13	Glycated hemoglobin levels;
LIHC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg27129171	chr3:47204927	SETD2	0.48	7.67	0.38	1.79e-13	Birth weight;
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.44	7.08	0.36	8.02e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs4788570	0.667	rs8052910	chr16:71790221	A/G	cg06353428	chr16:71660113	MARVELD3	1.38	14.61	0.62	6.7e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg24296786	chr1:45957014	TESK2	-0.47	-6.46	-0.33	3.58e-10	Platelet count;
LIHC	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg24203234	chr3:128598194	ACAD9	0.44	6.02	0.31	4.46e-9	IgG glycosylation;
LIHC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.51	6.98	0.35	1.52e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01111842	chr9:140444966	PNPLA7;MRPL41	-0.53	-6.85	-0.35	3.54e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.59	8.28	0.41	2.72e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.71	-9.04	-0.44	1.18e-17	Systemic lupus erythematosus;
LIHC	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg26138144	chr22:38071188	LGALS1	0.42	7.81	0.39	7.3e-14	Fat distribution (HIV);
LIHC	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2758596	1.000	rs2758596	chr1:156189286	C/T	cg25208724	chr1:156163844	SLC25A44	0.74	7.79	0.39	8.02e-14	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.34	-0.37	1.54e-12	Systolic blood pressure;
LIHC	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.4	6.45	0.33	3.83e-10	Red blood cell count;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg17385448	chr1:15911702	AGMAT	0.4	6.74	0.34	6.62e-11	Systolic blood pressure;
LIHC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg06046430	chr4:77819534	ANKRD56	0.53	6.55	0.33	2.13e-10	Emphysema distribution in smoking;
LIHC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.24	0.41	3.73e-15	Schizophrenia;
LIHC	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.29	0.32	9.72e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.38	-7.65	-0.38	2e-13	Obesity-related traits;
LIHC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg08923669	chr16:420230	MRPL28	-0.45	-5.88	-0.3	9.97e-9	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.77	12.18	0.55	1.32e-28	Corneal astigmatism;
LIHC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg17279839	chr7:150038598	RARRES2	0.49	10.02	0.48	6.78e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-7.65	-0.38	2.08e-13	Initial pursuit acceleration;
LIHC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.71	-8.79	-0.43	7.44e-17	Systemic lupus erythematosus;
LIHC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.82	0.43	5.9e-17	Cognitive test performance;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg23174392	chr13:114009751	GRTP1	-0.39	-6.65	-0.34	1.19e-10	Pain;
LIHC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.73	0.54	6.22e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.64e-11	Aortic root size;
LIHC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.13	-0.44	5.98e-18	Obesity-related traits;
LIHC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24110177	chr3:50126178	RBM5	0.48	7.9	0.39	3.86e-14	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg16558208	chr1:156270281	VHLL	0.53	10.01	0.48	7.3e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs78062588	0.892	rs6680410	chr1:154550724	C/T	cg24304309	chr1:154577895	ADAR	-0.56	-6.3	-0.32	9.35e-10	Lung cancer;
LIHC	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	0.78	8.57	0.42	3.61e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.29	-6.01	-0.31	4.74e-9	Blood metabolite levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27010136	chr7:1131122	GPER;C7orf50	0.42	6.52	0.33	2.59e-10	Longevity;
LIHC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.15	0.55	1.74e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.82	16.82	0.67	1.06e-46	Gestational age at birth (maternal effect);
LIHC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.48	-7.7	-0.38	1.43e-13	Cognitive function;
LIHC	cis	rs1775715	0.870	rs11008702	chr10:32244818	T/G	cg14930904	chr10:32216787	ARHGAP12	0.39	7.01	0.35	1.31e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.53	-8.05	-0.4	1.39e-14	Response to antidepressants and depression;
LIHC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.21e-53	Height;
LIHC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.22	-0.45	3.13e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.89	-0.3	9.12e-9	Dental caries;
LIHC	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.65	6.92	0.35	2.19e-11	Type 2 diabetes;
LIHC	cis	rs11628318	0.515	rs8009257	chr14:103155594	A/G	cg01864069	chr14:103024347	NA	0.36	5.88	0.3	9.68e-9	Platelet count;
LIHC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.23	0.55	8.67e-29	Cognitive test performance;
LIHC	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg04306507	chr14:55594613	LGALS3	0.33	6.05	0.31	3.79e-9	Protein biomarker;
LIHC	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.49	-7.72	-0.39	1.26e-13	Ulcerative colitis;
LIHC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.27	-0.41	3.08e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6717918	0.781	rs4640379	chr2:233141377	A/G	ch.2.233013039R	chr2:233304795	NA	-0.49	-5.81	-0.3	1.46e-8	Height;
LIHC	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.57	-8.57	-0.42	3.54e-16	Body mass index;
LIHC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg12046867	chr14:103022105	NA	-0.59	-8.57	-0.42	3.55e-16	Platelet count;
LIHC	cis	rs7684253	0.550	rs4566710	chr4:57745463	G/A	cg26694713	chr4:57773883	REST	-0.41	-5.84	-0.3	1.19e-8	Migraine;
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.19	-0.32	1.73e-9	Total body bone mineral density;
LIHC	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.35	-6.38	-0.33	5.75e-10	Blood pressure (smoking interaction);
LIHC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	8.07	0.4	1.17e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.78	-12.8	-0.57	6.17e-31	Gut microbiota (bacterial taxa);
LIHC	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.67	6.48	0.33	3.19e-10	Carotid intima media thickness;
LIHC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.71	-0.34	8e-11	Menarche (age at onset);
LIHC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18252515	chr7:66147081	NA	0.45	6.59	0.34	1.69e-10	Aortic root size;
LIHC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.94	-0.31	6.88e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.44	0.66	3.67e-45	Smoking behavior;
LIHC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.37	6.02	0.31	4.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6442522	0.673	rs1869855	chr3:15501142	G/T	cg16303742	chr3:15540471	COLQ	0.43	7.25	0.36	2.81e-12	Uric acid levels;
LIHC	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.23	6.38	0.33	5.83e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	1.0	11.73	0.54	6.05e-27	IgG glycosylation;
LIHC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.43	-6.33	-0.32	7.66e-10	Gout;
LIHC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.58	-6.84	-0.35	3.59e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.27	0.37	2.44e-12	Prudent dietary pattern;
LIHC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.4	-8.77	-0.43	8.65e-17	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21448741	chr8:58168803	NA	0.36	6.5	0.33	2.8e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.79	-0.3	1.56e-8	Life satisfaction;
LIHC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.78	-0.3	1.64e-8	Life satisfaction;
LIHC	cis	rs77633900	0.881	rs80003765	chr15:76657075	T/A	cg21673338	chr15:77095150	SCAPER	-0.53	-5.93	-0.31	7.22e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg09417038	chr21:47716443	C21orf57	0.46	6.86	0.35	3.2e-11	Testicular germ cell tumor;
LIHC	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.31	6.07	0.31	3.43e-9	DNA methylation (variation);
LIHC	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.57	7.53	0.38	4.44e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg04904834	chr1:179851103	TOR1AIP1	0.4	6.1	0.31	2.87e-9	Morning vs. evening chronotype;
LIHC	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-14.69	-0.62	3.22e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.63	0.34	1.3e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs922107	0.967	rs922104	chr1:90041899	C/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.77	-0.39	9.52e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.56	-10.05	-0.48	5.43e-21	Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.18e-23	Hemoglobin concentration;
LIHC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.49	6.79	0.34	5e-11	Asthma (bronchodilator response);
LIHC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.89	7.13	0.36	6.2e-12	Type 2 diabetes nephropathy;
LIHC	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg14146966	chr2:61757674	XPO1	0.47	8.18	0.4	5.8e-15	Tuberculosis;
LIHC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg21724239	chr8:58056113	NA	0.5	6.68	0.34	9.98e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.24	0.36	3e-12	Height;
LIHC	cis	rs7523273	0.565	rs34355011	chr1:207887322	T/G	cg22525895	chr1:207977042	MIR29B2	0.52	7.72	0.39	1.33e-13	Schizophrenia;
LIHC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-6.15	-0.32	2.19e-9	Testicular germ cell tumor;
LIHC	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.67	-0.34	1.02e-10	Homocysteine levels;
LIHC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	0.71	10.91	0.51	5.6e-24	Blood trace element (Zn levels);
LIHC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.37	-6.2	-0.32	1.63e-9	Educational attainment;
LIHC	cis	rs988712	0.705	rs4923457	chr11:27648580	A/T	cg18117895	chr11:27722066	BDNF	0.45	6.2	0.32	1.63e-9	Obesity;
LIHC	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg07382826	chr16:28625726	SULT1A1	0.5	7.86	0.39	5.17e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg06064525	chr11:970664	AP2A2	-0.44	-10.79	-0.5	1.53e-23	Alzheimer's disease (late onset);
LIHC	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg03934865	chr2:198174659	NA	0.45	6.56	0.33	1.97e-10	Dermatomyositis;
LIHC	cis	rs2997447	0.761	rs55815920	chr1:26457662	A/C	cg19633962	chr1:26362018	EXTL1	-0.65	-5.76	-0.3	1.87e-8	QRS complex (12-leadsum);
LIHC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.47	9.74	0.47	5.99e-20	Tonsillectomy;
LIHC	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.52	6.34	0.32	7.2e-10	Crohn's disease;
LIHC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	1.02	14.32	0.61	9.09e-37	Breast cancer;
LIHC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.61	9.14	0.44	5.63e-18	Recombination rate (females);
LIHC	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.58	9.69	0.46	8.63e-20	Dupuytren's disease;
LIHC	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg03894339	chr8:19674705	INTS10	-0.49	-7.93	-0.39	3.07e-14	Breast cancer;
LIHC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.02	16.27	0.66	1.67e-44	Breast cancer;
LIHC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.6	0.59	5.67e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg18478394	chr8:109455254	TTC35	0.37	6.26	0.32	1.15e-9	Dupuytren's disease;
LIHC	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg20991723	chr1:152506922	NA	0.53	9.06	0.44	1.05e-17	Hair morphology;
LIHC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.35	5.73	0.3	2.15e-8	Bipolar disorder;
LIHC	trans	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg12798992	chr6:167411361	FGFR1OP	0.39	6.14	0.32	2.28e-9	Crohn's disease;
LIHC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	6.0	0.31	4.93e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	9.02	0.44	1.39e-17	Multiple sclerosis;
LIHC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.03e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg12798992	chr6:167411361	FGFR1OP	0.47	7.3	0.37	2.04e-12	Crohn's disease;
LIHC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	6.09	0.31	3.09e-9	Height;
LIHC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.46	-5.94	-0.31	7.2e-9	Parkinson's disease;
LIHC	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.08	-0.36	8.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18252515	chr7:66147081	NA	0.45	6.47	0.33	3.42e-10	Aortic root size;
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.26	-0.52	3.17e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.5	10.07	0.48	4.53e-21	Melanoma;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10553204	chr2:20871195	GDF7	0.39	7.9	0.39	3.97e-14	Abdominal aortic aneurysm;
LIHC	cis	rs6584283	0.846	rs10883370	chr10:101291472	T/C	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.13	-0.31	2.44e-9	Ulcerative colitis;
LIHC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.25	-0.32	1.24e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.44	7.5	0.38	5.37e-13	Bipolar disorder;
LIHC	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.43	6.44	0.33	4.02e-10	Schizophrenia;
LIHC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.9	-19.49	-0.73	2.02e-57	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20228115	chr3:167813730	GOLIM4	0.43	6.23	0.32	1.34e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg15282417	chr9:129245246	FAM125B	0.41	6.77	0.34	5.52e-11	Intraocular pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27574168	chr18:54318782	WDR7	0.51	7.58	0.38	3.34e-13	Cognitive function;
LIHC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.48	8.22	0.41	4.35e-15	Mean corpuscular volume;
LIHC	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg14515779	chr1:101123966	NA	0.55	7.59	0.38	3.12e-13	Monocyte count;
LIHC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.64	-8.93	-0.43	2.72e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg07234388	chr1:156261841	TMEM79	0.52	8.93	0.44	2.59e-17	Tonsillectomy;
LIHC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.59	9.0	0.44	1.64e-17	Longevity;
LIHC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	15.76	0.65	1.93e-42	Tonsillectomy;
LIHC	cis	rs546131	0.614	rs7106579	chr11:34835502	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.34	1.66e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.6	-7.7	-0.38	1.47e-13	Obesity-related traits;
LIHC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.08e-14	Mean platelet volume;
LIHC	cis	rs600806	0.889	rs585545	chr1:109841662	A/T	cg08911820	chr1:110026001	ATXN7L2	-0.52	-6.09	-0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg08847533	chr14:75593920	NEK9	0.54	8.16	0.4	6.38e-15	IgG glycosylation;
LIHC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.53	9.21	0.45	3.29e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.92	0.35	2.18e-11	Diabetic kidney disease;
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-7.73	-0.39	1.22e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1144333	1.000	rs12410724	chr1:76459134	A/G	cg22875332	chr1:76189707	ACADM	0.4	6.27	0.32	1.11e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg00656387	chr3:40428638	ENTPD3	0.5	8.29	0.41	2.68e-15	Renal cell carcinoma;
LIHC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01200585	chr1:228362443	C1orf69	-0.4	-5.95	-0.31	6.54e-9	Diastolic blood pressure;
LIHC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.39	-6.85	-0.35	3.47e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-10.54	-0.5	1.15e-22	Vitiligo;
LIHC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.42	-6.62	-0.34	1.36e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13673319	chr1:174968334	CACYBP	0.45	6.85	0.35	3.53e-11	Cognitive function;
LIHC	trans	rs6732426	0.792	rs3901678	chr2:43587451	A/C	cg10773526	chr4:143327279	INPP4B	-0.35	-6.1	-0.31	2.93e-9	Hair morphology;
LIHC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.66	8.28	0.41	2.87e-15	Mean platelet volume;
LIHC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.46	7.72	0.39	1.27e-13	Mean corpuscular volume;
LIHC	cis	rs17125944	0.556	rs11625479	chr14:53354172	A/C	cg00686598	chr14:53173677	PSMC6	-0.78	-8.8	-0.43	6.93e-17	Alzheimer's disease (late onset);
LIHC	trans	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.24e-10	Coronary artery calcification;
LIHC	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg25182066	chr10:30743637	MAP3K8	0.6	9.48	0.46	4.52e-19	Inflammatory bowel disease;
LIHC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.53	6.87	0.35	3.01e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	1.01	19.31	0.72	1.04e-56	Breast cancer;
LIHC	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08584230	chr13:113666091	MCF2L	0.44	6.89	0.35	2.62e-11	Calcium levels;
LIHC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.87	-0.3	1.02e-8	Gout;
LIHC	cis	rs7192750	0.586	rs2335714	chr16:71897926	A/G	cg06353428	chr16:71660113	MARVELD3	0.79	8.9	0.43	3.23e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.75	-15.36	-0.64	7.53e-41	Body mass index;
LIHC	cis	rs55783344	1.000	rs3999410	chr12:121445427	G/A	cg02403541	chr12:121454288	C12orf43	-0.71	-5.73	-0.3	2.2e-8	Type 2 diabetes;
LIHC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.51	0.33	2.66e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.72	-7.25	-0.36	2.88e-12	Vitiligo;
LIHC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.42	-0.33	4.57e-10	Diabetic kidney disease;
LIHC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	6.76	0.34	5.95e-11	IgG glycosylation;
LIHC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.67	12.33	0.55	3.73e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.64	10.47	0.49	1.89e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-6.77	-0.34	5.77e-11	Personality dimensions;
LIHC	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg03543861	chr21:44258195	NA	0.53	8.63	0.42	2.29e-16	Information processing speed;
LIHC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.02	0.44	1.38e-17	Platelet count;
LIHC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg00800038	chr16:89945340	TCF25	-0.62	-9.28	-0.45	1.94e-18	Skin colour saturation;
LIHC	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.51e-22	Colorectal cancer;
LIHC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.73	12.2	0.55	1.17e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.63	12.49	0.56	9.32e-30	Schizophrenia;
LIHC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.42	-7.17	-0.36	4.58e-12	Platelet distribution width;
LIHC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.96	16.31	0.66	1.25e-44	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-7.33	-0.37	1.63e-12	Obesity (extreme);
LIHC	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.43	-7.73	-0.39	1.2e-13	Platelet distribution width;
LIHC	cis	rs6442522	0.867	rs12637268	chr3:15500248	T/C	cg16303742	chr3:15540471	COLQ	0.5	8.34	0.41	1.86e-15	Uric acid levels;
LIHC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg04958157	chr13:113748321	MCF2L	-0.35	-5.74	-0.3	2.09e-8	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg25894440	chr7:65020034	NA	0.53	6.12	0.31	2.53e-9	Diabetic kidney disease;
LIHC	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.38	-7.79	-0.39	7.83e-14	Squamous cell lung carcinoma;
LIHC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.42	6.66	0.34	1.11e-10	Red blood cell count;
LIHC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg06026331	chr20:60912101	LAMA5	0.61	8.98	0.44	1.89e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs3812111	0.676	rs958738	chr6:116470561	A/G	cg08036074	chr6:116424633	NT5DC1	-0.48	-8.06	-0.4	1.31e-14	Age-related macular degeneration;
LIHC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-5.96	-0.31	6.21e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	9.03	0.44	1.27e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.76	0.54	4.95e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.57	8.38	0.41	1.4e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.03	-0.31	4.19e-9	Tuberculosis;
LIHC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-7.94	-0.39	2.89e-14	Crohn's disease;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.62	0.38	2.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.84	10.05	0.48	5.24e-21	Cognitive function;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg11073931	chr20:57269626	NPEPL1	0.44	6.31	0.32	8.55e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.36	-6.47	-0.33	3.31e-10	Aortic root size;
LIHC	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.61	-9.75	-0.47	5.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.85	12.82	0.57	5.2e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg18809830	chr7:99032528	PTCD1	-0.82	-6.37	-0.33	5.95e-10	Blood metabolite levels;
LIHC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.44	6.66	0.34	1.12e-10	Cognitive test performance;
LIHC	cis	rs3744061	0.520	rs4322697	chr17:74648642	C/T	cg02128979	chr17:74682217	MXRA7	0.33	5.82	0.3	1.33e-8	Retinal arteriolar caliber;
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg26939375	chr7:64535504	NA	-0.47	-7.04	-0.36	1.08e-11	Calcium levels;
LIHC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.71	10.74	0.5	2.28e-23	Breast cancer;
LIHC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg25356066	chr3:128598488	ACAD9	0.53	7.47	0.37	6.95e-13	IgG glycosylation;
LIHC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.84	12.57	0.56	4.6e-30	Vitamin D levels;
LIHC	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.23	13.26	0.58	1.14e-32	Opioid sensitivity;
LIHC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg03037974	chr15:76606532	NA	0.8	16.71	0.67	2.93e-46	Blood metabolite levels;
LIHC	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.49	-6.73	-0.34	7.04e-11	Corneal structure;
LIHC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.69	10.73	0.5	2.45e-23	Response to diuretic therapy;
LIHC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.64	9.68	0.46	9.72e-20	Height;
LIHC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.0	-0.35	1.4e-11	Bipolar disorder;
LIHC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.51	-8.0	-0.4	1.93e-14	Educational attainment;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg11598736	chr3:195384522	SDHAP2	-0.72	-8.58	-0.42	3.47e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.48	7.06	0.36	9.15e-12	Personality dimensions;
LIHC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg18887096	chr2:219472410	PLCD4	0.36	6.46	0.33	3.52e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11673344	0.542	rs1667380	chr19:37492750	C/T	cg27390819	chr19:37464633	NA	-0.47	-6.26	-0.32	1.13e-9	Obesity-related traits;
LIHC	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.44	7.26	0.37	2.71e-12	Menopause (age at onset);
LIHC	trans	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg04013166	chr16:89971882	TCF25	0.51	6.39	0.33	5.51e-10	Skin colour saturation;
LIHC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.31	7.09	0.36	7.82e-12	Crohn's disease;
LIHC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.92	15.12	0.63	6.59e-40	Cognitive ability;
LIHC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.83	16.96	0.68	2.94e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.57	-10.12	-0.48	3.08e-21	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg15123519	chr2:136567270	LCT	0.44	8.68	0.42	1.63e-16	Mosquito bite size;
LIHC	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.06	-0.31	3.51e-9	Tuberculosis;
LIHC	trans	rs3783890	1.000	rs61375994	chr14:93758073	G/A	cg02802420	chr16:69363236	PDF;COG8	0.33	6.29	0.32	9.7e-10	Body mass index;
LIHC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.69	-11.23	-0.52	3.87e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg14222432	chr12:29376421	FAR2	0.36	6.86	0.35	3.2e-11	QT interval;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06925236	chr11:68039653	C11orf24	0.47	6.96	0.35	1.76e-11	Pancreatic cancer;
LIHC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8081395	0.836	rs2063353	chr17:57889192	T/G	cg02344993	chr17:57696989	CLTC	-0.46	-7.61	-0.38	2.77e-13	White blood cell count;
LIHC	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.44	7.28	0.37	2.26e-12	Corneal astigmatism;
LIHC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg07424592	chr7:64974309	NA	0.87	9.34	0.45	1.26e-18	Diabetic kidney disease;
LIHC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.45	-8.73	-0.43	1.14e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg05110241	chr16:68378359	PRMT7	-0.61	-6.77	-0.34	5.71e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.45	-8.82	-0.43	5.76e-17	Schizophrenia;
LIHC	cis	rs911119	0.955	rs6048946	chr20:23602307	G/T	cg16589663	chr20:23618590	CST3	0.74	7.78	0.39	8.48e-14	Chronic kidney disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08585897	chr16:75680535	KARS;TERF2IP	0.44	6.69	0.34	9.36e-11	Longevity;
LIHC	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg14515779	chr1:101123966	NA	0.64	12.18	0.55	1.36e-28	Monocyte count;
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.88	-0.39	4.39e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs9641123	0.639	rs2528521	chr7:93204544	C/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.35	-0.32	6.93e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.48	-8.06	-0.4	1.28e-14	Cocaine dependence;
LIHC	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.62	-12.58	-0.56	4.45e-30	Plateletcrit;Platelet count;
LIHC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	7.3	0.37	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-9.43	-0.45	6.22e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.56	-10.55	-0.5	9.98e-23	Asthma;
LIHC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.53	6.9	0.35	2.56e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.6	6.34	0.32	7.18e-10	Hip geometry;
LIHC	cis	rs7700895	0.691	rs3777183	chr5:95263735	G/A	cg10483112	chr5:95245456	ELL2	-0.38	-6.63	-0.34	1.33e-10	IgG glycosylation;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.59	10.16	0.48	2.22e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg07423050	chr13:99094983	FARP1	0.35	5.78	0.3	1.68e-8	Longevity;
LIHC	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg23112188	chr14:24563095	PCK2	-0.31	-6.1	-0.31	2.89e-9	IgG glycosylation;
LIHC	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.47	-7.85	-0.39	5.25e-14	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.35	5.8	0.3	1.5e-8	Height;
LIHC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.61	-5.83	-0.3	1.27e-8	Vitiligo;
LIHC	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	5.01e-12	Educational attainment;
LIHC	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.66	-6.14	-0.32	2.31e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs2033908	0.620	rs1440271	chr11:12852068	A/G	cg25843174	chr11:12811716	TEAD1	-0.33	-7.67	-0.38	1.78e-13	Sitting height ratio;
LIHC	cis	rs35160687	0.623	rs718292	chr2:86473740	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.39	-6.32	-0.32	8.36e-10	Night sleep phenotypes;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.46	-5.74	-0.3	2.05e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg13264159	chr8:625131	ERICH1	0.58	6.3	0.32	9.18e-10	IgG glycosylation;
LIHC	cis	rs965469	0.779	rs6037571	chr20:3334322	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg12463550	chr7:65579703	CRCP	0.68	7.05	0.36	9.9e-12	Diabetic kidney disease;
LIHC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg12458913	chr13:53173898	NA	0.52	8.5	0.42	5.89e-16	Lewy body disease;
LIHC	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	0.91	7.34	0.37	1.54e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.34	-0.45	1.28e-18	Schizophrenia;
LIHC	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg26138937	chr11:71823887	C11orf51	-1.27	-10.41	-0.49	3.03e-22	Severe influenza A (H1N1) infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02326931	chr13:37572901	ALG5	0.47	6.39	0.33	5.47e-10	Pancreatic cancer;
LIHC	cis	rs12602486	1.000	rs79296687	chr17:42262067	C/T	cg13607699	chr17:42295918	UBTF	-0.78	-6.64	-0.34	1.24e-10	Glycated hemoglobin levels;
LIHC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.76	0.39	9.83e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	0.54	10.28	0.49	8.88e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs526231	0.819	rs366437	chr5:102605601	T/C	cg05225461	chr5:102596755	C5orf30	0.38	5.93	0.31	7.22e-9	Primary biliary cholangitis;
LIHC	cis	rs10838687	0.800	rs3729805	chr11:47352757	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.83	-0.3	1.27e-8	Proinsulin levels;
LIHC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg23539780	chr8:10696689	PINX1	0.41	6.09	0.31	3.02e-9	Myopia (pathological);
LIHC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.41	6.34	0.32	7.18e-10	Melanoma;
LIHC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.41	6.87	0.35	3.05e-11	Type 2 diabetes;
LIHC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02985541	chr2:219472218	PLCD4	0.43	7.99	0.4	2.14e-14	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.84	-15.93	-0.65	3.87e-43	Height;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg03721293	chr16:90014378	DEF8	0.36	6.24	0.32	1.26e-9	Skin colour saturation;
LIHC	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.1	-0.48	3.69e-21	Chronic sinus infection;
LIHC	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.6	0.46	1.82e-19	Corneal astigmatism;
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg20607798	chr8:58055168	NA	0.62	7.91	0.39	3.52e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.63	-7.93	-0.39	3.15e-14	Response to metformin (IC50);
LIHC	cis	rs400736	0.894	rs226253	chr1:8027706	T/C	cg25007680	chr1:8021821	PARK7	0.61	9.64	0.46	1.25e-19	Response to antidepressants and depression;
LIHC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.65	12.86	0.57	3.97e-31	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.3	5.71	0.3	2.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg08935021	chr1:28832541	SNHG3-RCC1;SNHG3	0.43	6.07	0.31	3.31e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03157738	chr19:11308118	KANK2	0.46	6.87	0.35	3.01e-11	Pancreatic cancer;
LIHC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg12310025	chr6:25882481	NA	-0.42	-6.34	-0.32	7.27e-10	Height;
LIHC	cis	rs7508	0.511	rs208026	chr8:17878155	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-6.08	-0.31	3.22e-9	Atrial fibrillation;
LIHC	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg08668510	chr10:1095578	IDI1	0.69	6.7	0.34	8.81e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.32	7.75	0.39	1.08e-13	Corneal astigmatism;
LIHC	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.42	-6.5	-0.33	2.85e-10	Metabolite levels;
LIHC	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.42	-0.33	4.44e-10	Schizophrenia;
LIHC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.49	7.11	0.36	6.62e-12	Neutrophil percentage of white cells;
LIHC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg22633049	chr21:46681294	NA	-0.35	-6.25	-0.32	1.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.33	7.17	0.36	4.62e-12	Ulcerative colitis;
LIHC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.66	11.68	0.53	9.19e-27	Lewy body disease;
LIHC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.44	7.1	0.36	7.46e-12	Total body bone mineral density;
LIHC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.61	9.02	0.44	1.37e-17	Cognitive ability;
LIHC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg10932868	chr11:921992	NA	0.35	6.57	0.33	1.93e-10	Alzheimer's disease (late onset);
LIHC	cis	rs249954	0.512	rs703767	chr16:23661639	G/C	cg01460202	chr16:23706506	ERN2	0.35	5.93	0.31	7.24e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-7.72	-0.39	1.31e-13	Hip circumference adjusted for BMI;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23434193	chr8:74884752	TCEB1	0.45	6.9	0.35	2.5e-11	Cognitive function;
LIHC	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg09795085	chr6:101329169	ASCC3	0.52	7.4	0.37	1.06e-12	Neuroticism;
LIHC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.18	-0.48	1.98e-21	Primary biliary cholangitis;
LIHC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.41	7.3	0.37	2.03e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.02	0.58	9.58e-32	Cognitive test performance;
LIHC	cis	rs986417	0.901	rs1884094	chr14:61016933	C/G	cg27398547	chr14:60952738	C14orf39	0.66	7.5	0.38	5.66e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.31	7.54	0.38	4.32e-13	Gut microbiome composition (winter);
LIHC	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-5.71	-0.3	2.46e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.04	-0.31	3.97e-9	Longevity;
LIHC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.55	8.23	0.41	4.03e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03076246	chr16:67906784	EDC4	0.39	6.74	0.34	6.63e-11	Cognitive function;
LIHC	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.39	6.25	0.32	1.22e-9	Metabolite levels;
LIHC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.31	0.45	1.56e-18	Electroencephalogram traits;
LIHC	cis	rs911119	0.657	rs2104005	chr20:23630761	G/A	cg16589663	chr20:23618590	CST3	0.67	6.32	0.32	7.98e-10	Chronic kidney disease;
LIHC	cis	rs7106204	0.514	rs7126508	chr11:24255147	G/A	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	0.99	14.54	0.62	1.29e-37	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.09	0.31	3.07e-9	Obesity-related traits;
LIHC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.91	-0.39	3.49e-14	Heart rate;
LIHC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg07332563	chr6:291687	DUSP22	-0.47	-6.79	-0.34	5.03e-11	Menopause (age at onset);
LIHC	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-0.91	-10.15	-0.48	2.47e-21	Post bronchodilator FEV1;
LIHC	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg19752551	chr11:57585705	CTNND1	-0.5	-6.9	-0.35	2.53e-11	Schizophrenia;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg09417038	chr21:47716443	C21orf57	0.45	7.02	0.35	1.24e-11	Testicular germ cell tumor;
LIHC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.44	-6.01	-0.31	4.75e-9	Iron status biomarkers;
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.36	-7.84	-0.39	5.77e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.01e-25	Corneal astigmatism;
LIHC	cis	rs735860	0.763	rs2817111	chr6:53125700	G/C	cg10236188	chr6:53219634	NA	-0.4	-7.29	-0.37	2.14e-12	Glaucoma;
LIHC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.43	6.21	0.32	1.51e-9	Facial emotion recognition (sad faces);
LIHC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.04	21.39	0.76	4.96e-65	IgG glycosylation;
LIHC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.64	10.83	0.51	1.07e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	5.88	0.3	9.77e-9	Putamen volume;
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg14709524	chr16:89940631	TCF25	0.55	7.23	0.36	3.15e-12	Skin colour saturation;
LIHC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.72	-10.75	-0.5	2.11e-23	Aortic root size;
LIHC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.24	6.17	0.32	1.93e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	21.23	0.75	2.06e-64	Chronic sinus infection;
LIHC	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg09904177	chr6:26538194	HMGN4	-0.37	-5.95	-0.31	6.82e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.24	-0.36	3.06e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg10217327	chr6:118973057	C6orf204	0.7	7.26	0.37	2.67e-12	Diastolic blood pressure;
LIHC	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.69	11.19	0.52	5.54e-25	Diisocyanate-induced asthma;
LIHC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.71	11.53	0.53	3.42e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.66	-0.38	1.89e-13	Body mass index;
LIHC	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.03	0.31	4.17e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs72960926	0.744	rs72954314	chr6:74939737	A/G	cg07247405	chr1:2484626	LOC115110	0.53	6.38	0.33	5.78e-10	Metabolite levels (MHPG);
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.54	-0.42	4.56e-16	Renal cell carcinoma;
LIHC	trans	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg19894588	chr14:64061835	NA	-0.47	-7.44	-0.37	8.1e-13	Fat distribution (HIV);
LIHC	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg14593290	chr7:50529359	DDC	0.62	9.68	0.46	9.37e-20	Malaria;
LIHC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.24e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-6.9	-0.35	2.52e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.32	-6.49	-0.33	3.02e-10	Platelet distribution width;
LIHC	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg08847533	chr14:75593920	NEK9	0.53	8.17	0.4	6.15e-15	IgG glycosylation;
LIHC	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17554472	chr22:41940697	POLR3H	0.56	6.06	0.31	3.53e-9	Vitiligo;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16595246	chr2:48009933	MSH6	0.45	6.3	0.32	8.98e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg03037974	chr15:76606532	NA	-0.6	-9.96	-0.47	1.14e-20	Blood metabolite levels;
LIHC	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.62	6.36	0.33	6.59e-10	Type 2 diabetes;
LIHC	cis	rs6782228	0.606	rs9828893	chr3:128332925	T/C	cg16766828	chr3:128327626	NA	-0.41	-6.42	-0.33	4.54e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.0	20.05	0.74	1.12e-59	Schizophrenia;
LIHC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00684032	chr4:1343700	KIAA1530	-0.35	-5.79	-0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.44	6.19	0.32	1.68e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.67	7.2	0.36	3.79e-12	Blood protein levels;
LIHC	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12516959	chr21:47718080	NA	-0.36	-6.0	-0.31	4.99e-9	Testicular germ cell tumor;
LIHC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	1.05	21.66	0.76	4.03e-66	Breast cancer;
LIHC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg07090678	chr1:91966139	CDC7	0.51	7.01	0.35	1.29e-11	Breast cancer;
LIHC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.82	-0.3	1.36e-8	Colorectal cancer;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12379764	chr21:47803548	PCNT	-0.57	-8.4	-0.41	1.18e-15	Testicular germ cell tumor;
LIHC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	0.94	16.18	0.66	3.95e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.39	-9.61	-0.46	1.65e-19	Cutaneous nevi;
LIHC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	9.78	0.47	4.59e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.48	7.93	0.39	3.23e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.2	10.01	0.48	7.28e-21	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg08694578	chr2:241835147	C2orf54	-0.52	-8.03	-0.4	1.55e-14	Urinary metabolites;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09920427	chr19:12777674	MORG1;MAN2B1	0.49	7.48	0.37	6.2800000000000005e-13	Pancreatic cancer;
LIHC	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg19920283	chr7:105172520	RINT1	0.49	6.08	0.31	3.16e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs12602486	1.000	rs2285953	chr17:42268255	G/C	cg13607699	chr17:42295918	UBTF	-0.76	-6.42	-0.33	4.65e-10	Glycated hemoglobin levels;
LIHC	cis	rs4700695	0.841	rs152996	chr5:65256506	A/G	cg21114390	chr5:65439923	SFRS12	0.44	5.77	0.3	1.8e-8	Facial morphology (factor 19);
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg16132339	chr22:24313637	DDTL;DDT	0.7	12.83	0.57	5.08e-31	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12744310	0.887	rs12024263	chr1:41820949	A/G	cg03962019	chr1:41807865	NA	0.39	6.18	0.32	1.86e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.39	-5.95	-0.31	6.71e-9	Lymphocyte counts;
LIHC	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.25	-6.86	-0.35	3.18e-11	Type 2 diabetes;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-6.76	-0.34	6.05e-11	Lymphocyte counts;
LIHC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.84	10.19	0.48	1.86e-21	Mean platelet volume;
LIHC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.82	-0.35	4.09e-11	Response to antipsychotic treatment;
LIHC	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7944735	0.508	rs4752783	chr11:47558220	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.76	-0.3	1.91e-8	Intraocular pressure;
LIHC	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.44	6.62	0.34	1.38e-10	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg23517279	chr6:96025343	MANEA	0.57	6.3	0.32	9.19e-10	Behavioural disinhibition (generation interaction);
LIHC	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.26	-0.32	1.12e-9	Corneal astigmatism;
LIHC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.18	-0.32	1.82e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.29	-6.62	-0.34	1.36e-10	Hip circumference;Waist circumference;
LIHC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.69	12.02	0.54	5.37e-28	Menopause (age at onset);
LIHC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.42	7.32	0.37	1.79e-12	Aortic root size;
LIHC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.57	8.81	0.43	6.63e-17	Multiple sclerosis;
LIHC	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg23091122	chr1:110024289	SYPL2	-0.5	-6.66	-0.34	1.09e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-15.73	-0.65	2.38e-42	Refractive error;
LIHC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.5	-0.38	5.56e-13	Schizophrenia;
LIHC	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg08345082	chr10:99160200	RRP12	-0.4	-6.91	-0.35	2.39e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg15902774	chr15:75289873	SCAMP5	0.41	6.08	0.31	3.2e-9	Lung cancer;
LIHC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	trans	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.44	-6.13	-0.31	2.45e-9	Type 2 diabetes;
LIHC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg18306943	chr3:40428807	ENTPD3	0.38	6.36	0.33	6.38e-10	Renal cell carcinoma;
LIHC	cis	rs7534824	0.507	rs7518380	chr1:101451262	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	7.63	0.38	2.34e-13	Refractive astigmatism;
LIHC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-8.85	-0.43	4.9e-17	Blood metabolite levels;
LIHC	cis	rs963731	0.522	rs297128	chr2:39298403	C/G	cg04010122	chr2:39346883	SOS1	-0.68	-6.02	-0.31	4.46e-9	Corticobasal degeneration;
LIHC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.3	-0.32	9.41e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.54	0.5	1.12e-22	Colorectal cancer;
LIHC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg26138144	chr22:38071188	LGALS1	0.75	13.96	0.6	2.28e-35	Fat distribution (HIV);
LIHC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.46	0.46	5.3e-19	Platelet count;
LIHC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.86	-14.81	-0.63	1.06e-38	Height;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14828511	chr1:107599125	PRMT6	0.41	6.0	0.31	4.95e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12249377	0.519	rs11186320	chr10:92576448	C/T	cg14313238	chr10:92632228	RPP30	-0.38	-6.53	-0.33	2.39e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	7.72	0.39	1.33e-13	Lung cancer in ever smokers;
LIHC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg16070018	chr6:26224392	HIST1H3E	0.48	6.53	0.33	2.32e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg14222432	chr12:29376421	FAR2	0.34	6.69	0.34	9.16e-11	QT interval;
LIHC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.84	0.3	1.21e-8	Bipolar disorder;
LIHC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.62	6.96	0.35	1.76e-11	Menarche (age at onset);
LIHC	cis	rs4728302	0.838	rs10224828	chr7:133591071	G/A	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.8	0.39	7.36e-14	Motion sickness;
LIHC	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.39e-35	White blood cell count (basophil);
LIHC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-8.46	-0.42	8.17e-16	Electroencephalogram traits;
LIHC	cis	rs26949	0.511	rs2898287	chr5:59884233	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.39	-5.95	-0.31	6.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.33	-0.32	7.84e-10	Longevity;Endometriosis;
LIHC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.57	8.19	0.41	5.15e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.43	-5.83	-0.3	1.26e-8	Longevity;
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg23262073	chr20:60523788	NA	-0.29	-6.18	-0.32	1.87e-9	Body mass index;
LIHC	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04530015	chr2:215796436	ABCA12	-0.37	-5.91	-0.3	8.2e-9	Neuroblastoma;
LIHC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	7.77	0.39	9.04e-14	Platelet count;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg02782426	chr3:40428986	ENTPD3	0.35	6.48	0.33	3.23e-10	Renal cell carcinoma;
LIHC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.62	9.64	0.46	1.32e-19	Lymphocyte counts;
LIHC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.95	0.35	1.83e-11	Morning vs. evening chronotype;
LIHC	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.47	-10.29	-0.49	7.91e-22	Response to paliperidone in schizophrenia (CGI-S score);
LIHC	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.7	-12.22	-0.55	9.79e-29	Monocyte count;
LIHC	cis	rs1075232	0.826	rs12438813	chr15:31705913	C/T	cg01030201	chr15:31746330	NA	-0.86	-6.64	-0.34	1.22e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.66	-0.56	2.17e-30	Alzheimer's disease;
LIHC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.49	-8.84	-0.43	5.22e-17	Colorectal cancer;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.54	0.38	4.19e-13	Prudent dietary pattern;
LIHC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.13	0.36	6.13e-12	Height;
LIHC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.5	-0.46	3.75e-19	Obesity-related traits;
LIHC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.31	0.55	4.54e-29	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.55	9.8	0.47	3.86e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg14779329	chr11:130786720	SNX19	0.42	6.41	0.33	4.72e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-10.72	-0.5	2.54e-23	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06451949	chr17:48942959	NA	0.48	7.45	0.37	7.54e-13	Pancreatic cancer;
LIHC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.99e-16	Motion sickness;
LIHC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.54	8.81	0.43	6.41e-17	Body mass index;
LIHC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.68	10.4	0.49	3.49e-22	Longevity;
LIHC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg21531657	chr3:10005747	TMEM111	0.39	5.83	0.3	1.28e-8	Alzheimer's disease;
LIHC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg03854865	chr6:26224070	HIST1H3E	0.56	6.36	0.33	6.64e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.34	5.82	0.3	1.34e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.4	6.76	0.34	6.01e-11	Bipolar disorder;
LIHC	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.39	5.84	0.3	1.23e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.86	-0.3	1.07e-8	Systemic lupus erythematosus;
LIHC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg12560992	chr17:57184187	TRIM37	0.73	10.84	0.51	9.51e-24	Cognitive test performance;
LIHC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.83	0.35	4.01e-11	Morning vs. evening chronotype;
LIHC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg07117364	chr1:16154769	NA	-0.39	-7.03	-0.36	1.09e-11	Dilated cardiomyopathy;
LIHC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.22	0.41	4.32e-15	Motion sickness;
LIHC	trans	rs10242455	0.571	rs11972210	chr7:99206943	A/C	cg09045935	chr12:6379348	NA	0.8	6.76	0.34	6.1e-11	Blood metabolite levels;
LIHC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.92	12.12	0.55	2.31e-28	Heart rate;
LIHC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg00656387	chr3:40428638	ENTPD3	0.4	6.48	0.33	3.27e-10	Renal cell carcinoma;
LIHC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.56	-8.28	-0.41	2.89e-15	Ulcerative colitis;
LIHC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.49	-8.01	-0.4	1.86e-14	Cognitive function;
LIHC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.95	0.39	2.73e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.56	-6.69	-0.34	8.95e-11	IFN-related cytopenia;
LIHC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.24	0.41	3.84e-15	Motion sickness;
LIHC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg16070018	chr6:26224392	HIST1H3E	0.62	7.5	0.38	5.6e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs600626	0.588	rs10793124	chr11:75452267	C/G	cg24262691	chr11:75473276	NA	0.4	5.88	0.3	9.98e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg03854865	chr6:26224070	HIST1H3E	0.62	6.86	0.35	3.24e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.44	6.94	0.35	2.01e-11	Height;
LIHC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.5	9.12	0.44	6.5e-18	Height;
LIHC	cis	rs2073300	1.000	rs61080017	chr20:23457569	A/G	cg12062639	chr20:23401060	NAPB	0.78	9.7	0.46	8.37e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg20607798	chr8:58055168	NA	0.46	5.88	0.3	9.96e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-8.97	-0.44	1.94e-17	Chronic sinus infection;
LIHC	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg20826740	chr17:37024042	NA	-0.39	-6.68	-0.34	9.76e-11	Height;
LIHC	cis	rs6540556	0.517	rs11807619	chr1:209881373	G/T	cg05527609	chr1:210001259	C1orf107	-0.54	-7.56	-0.38	3.8e-13	Red blood cell count;
LIHC	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.41	5.96	0.31	6.35e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs4788570	0.667	rs8053186	chr16:71790166	G/A	cg06353428	chr16:71660113	MARVELD3	1.36	14.03	0.6	1.21e-35	Intelligence (multi-trait analysis);
LIHC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.57	6.34	0.32	7.24e-10	Axial length;
LIHC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.9	-14.86	-0.63	6.84e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.6	8.17	0.4	6.1e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7224685	0.569	rs10521129	chr17:4008820	C/T	cg09597638	chr17:3907349	NA	0.55	7.08	0.36	8.18e-12	Type 2 diabetes;
LIHC	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.6	8.72	0.43	1.19e-16	Menopause (age at onset);
LIHC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg08847533	chr14:75593920	NEK9	-0.37	-6.24	-0.32	1.28e-9	Caffeine consumption;
LIHC	cis	rs16828019	0.777	rs12047657	chr1:41461513	G/C	cg03387723	chr1:41708464	SCMH1	-0.45	-6.66	-0.34	1.07e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg02702477	chr5:179499311	RNF130	0.89	11.71	0.53	7.31e-27	LDL cholesterol;
LIHC	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.1	9.18	0.44	4.1e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.69	13.8	0.6	9.3e-35	Coronary artery disease;
LIHC	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg12560992	chr17:57184187	TRIM37	-0.81	-12.41	-0.56	1.93e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.76	-10.88	-0.51	6.99e-24	Obesity-related traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08664849	chr16:2546474	TBC1D24	-0.36	-6.13	-0.31	2.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs12986413	1.000	rs12983458	chr19:2168612	A/G	cg09261902	chr19:2140048	AP3D1	0.37	6.24	0.32	1.26e-9	Height;
LIHC	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.63	-9.03	-0.44	1.26e-17	Monocyte count;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-7.07	-0.36	8.55e-12	Total body bone mineral density;
LIHC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg15123519	chr2:136567270	LCT	0.45	9.45	0.45	5.73e-19	Mosquito bite size;
LIHC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.2	0.41	4.96e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg08992911	chr2:238395768	MLPH	0.52	6.34	0.32	7.29e-10	Prostate cancer;
LIHC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.65	0.46	1.17e-19	Mean platelet volume;
LIHC	trans	rs875971	1.000	rs778696	chr7:65870813	C/G	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg10815395	chr12:49237807	DDX23	0.45	6.27	0.32	1.09e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.62	-8.66	-0.42	1.9e-16	Menopause (age at onset);
LIHC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10454142	0.807	rs13399936	chr2:48654126	T/G	cg15846641	chr2:48541264	FOXN2	0.46	6.06	0.31	3.54e-9	Sex hormone-binding globulin levels;
LIHC	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.28	-0.32	1.05e-9	Osteoarthritis;
LIHC	trans	rs3758911	0.796	rs10890720	chr11:107206018	C/T	cg21068293	chr15:74496576	STRA6	-0.27	-6.31	-0.32	8.86e-10	Coronary artery disease;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	9.97	0.47	9.89e-21	Lymphocyte counts;
LIHC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.14e-23	Hemoglobin concentration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18906815	chr12:124996063	NCOR2	-0.4	-6.08	-0.31	3.26e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.47	7.65	0.38	2.01e-13	Caffeine consumption;
LIHC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.66	9.05	0.44	1.14e-17	Chronic sinus infection;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.28	0.32	1.03e-9	Prudent dietary pattern;
LIHC	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.68	11.23	0.52	4.18e-25	Diisocyanate-induced asthma;
LIHC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.59	10.08	0.48	4.36e-21	Height;
LIHC	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	0.78	7.9	0.39	3.79e-14	Arsenic metabolism;
LIHC	cis	rs4407350	0.870	rs5764877	chr22:44915530	T/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.35	-0.32	6.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.38	-7.02	-0.35	1.19e-11	Abdominal aortic aneurysm;
LIHC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18252515	chr7:66147081	NA	-0.41	-5.76	-0.3	1.86e-8	Aortic root size;
LIHC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.25	0.48	1.16e-21	Melanoma;
LIHC	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.61	9.19	0.44	4.04e-18	Lymphocyte counts;
LIHC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.76	12.3	0.55	4.72e-29	Corneal astigmatism;
LIHC	cis	rs4759375	1.000	rs28410096	chr12:123880862	T/C	cg00376283	chr12:123451042	ABCB9	0.49	6.1	0.31	2.93e-9	HDL cholesterol;
LIHC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.2	15.24	0.64	2.21e-40	Alzheimer's disease (late onset);
LIHC	cis	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg01231543	chr16:68741748	NA	0.4	6.15	0.32	2.11e-9	Colorectal cancer;
LIHC	trans	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg10756647	chr7:56101905	PSPH	0.59	7.84	0.39	5.64e-14	Corneal structure;
LIHC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg01629716	chr15:45996671	NA	0.52	9.56	0.46	2.41e-19	Waist circumference;Weight;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.62	7.88	0.39	4.46e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.39	6.43	0.33	4.24e-10	Red blood cell count;
LIHC	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	12.2	0.55	1.15e-28	Coffee consumption (cups per day);
LIHC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.23	-6.35	-0.32	6.66e-10	Type 2 diabetes;
LIHC	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-1.09	-13.71	-0.6	2.13e-34	Blood protein levels;
LIHC	cis	rs2108622	0.958	rs56340170	chr19:15981877	G/C	cg13772218	chr19:15982569	NA	0.42	8.58	0.42	3.34e-16	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg10932868	chr11:921992	NA	0.38	7.34	0.37	1.59e-12	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs6466055	0.720	rs12668097	chr7:104996472	A/G	cg04380332	chr7:105027541	SRPK2	0.35	6.65	0.34	1.19e-10	Schizophrenia;
LIHC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.46	0.66	3.08e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.85	0.43	4.79e-17	Height;
LIHC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.82	-8.94	-0.44	2.48e-17	Vitiligo;
LIHC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.83	9.78	0.47	4.26e-20	Iron status biomarkers;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05573837	chr3:42696434	ZBTB47	-0.54	-6.24	-0.32	1.32e-9	Systolic blood pressure;
LIHC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.43	5.87	0.3	1.03e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.41	-0.53	9.08e-26	Chronic sinus infection;
LIHC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.3	-0.32	9.17e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.45	-6.98	-0.35	1.57e-11	Birth weight;
LIHC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.77	0.3	1.75e-8	Height;
LIHC	cis	rs2274273	0.661	rs2147964	chr14:55564395	T/G	cg01864836	chr14:55583639	NA	-0.35	-6.64	-0.34	1.26e-10	Protein biomarker;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.42	-0.41	1.02e-15	Lymphocyte counts;
LIHC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg19016816	chr7:1267987	NA	0.26	5.74	0.3	2.05e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs4653663	0.533	rs12081218	chr1:225903098	G/A	cg20799095	chr1:225924665	NA	0.38	5.76	0.3	1.9e-8	Neuroticism;
LIHC	cis	rs861318	0.646	rs3768513	chr1:159012217	A/T	cg11003133	chr1:159046391	AIM2	-0.35	-6.86	-0.35	3.32e-11	Obesity-related traits;
LIHC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg14092571	chr14:90743983	NA	-0.38	-6.16	-0.32	2.09e-9	Mortality in heart failure;
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.86	12.54	0.56	6.28e-30	Menarche (age at onset);
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg09033563	chr22:24373618	LOC391322	-0.47	-6.71	-0.34	7.95e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03587843	chr5:1885516	NA	0.37	7.15	0.36	5.26e-12	Cognitive function;
LIHC	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.08	-0.36	8.06e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg06046430	chr4:77819534	ANKRD56	0.5	6.18	0.32	1.82e-9	Emphysema distribution in smoking;
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg16970926	chr12:29381810	FAR2	0.34	7.41	0.37	9.7e-13	QT interval;
LIHC	trans	rs11165623	0.624	rs11165665	chr1:97007925	T/C	cg10631902	chr5:14652156	NA	-0.25	-6.28	-0.32	9.99e-10	Hip circumference;Waist circumference;
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.71	-10.48	-0.49	1.74e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.45	-0.37	7.76e-13	Obesity-related traits;
LIHC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.71	12.09	0.55	2.96e-28	Menopause (age at onset);
LIHC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.23e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.83	-15.84	-0.65	8.89e-43	Height;
LIHC	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.35	23.43	0.78	4.43e-73	Corneal structure;
LIHC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.45	6.83	0.35	3.89e-11	Post bronchodilator FEV1;
LIHC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.58	-8.64	-0.42	2.11e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs17152411	0.625	rs12265337	chr10:126618620	G/A	cg07906193	chr10:126599966	NA	-0.3	-5.86	-0.3	1.06e-8	Height;
LIHC	trans	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg16011800	chr17:1958478	HIC1	0.51	7.35	0.37	1.5e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.46	5.82	0.3	1.34e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.59	8.71	0.43	1.37e-16	Recombination rate (females);
LIHC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.53	6.91	0.35	2.45e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.44e-19	Bipolar disorder;
LIHC	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg27205649	chr11:78285834	NARS2	0.39	5.98	0.31	5.63e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.51	-5.8	-0.3	1.48e-8	Corneal curvature;
LIHC	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.14	-15.18	-0.63	3.67e-40	Ulcerative colitis;
LIHC	cis	rs244293	0.864	rs244374	chr17:53183754	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.52	0.38	4.85e-13	Menarche (age at onset);
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.57	8.7	0.43	1.44e-16	Height;
LIHC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.62	-10.87	-0.51	7.96e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.51	7.6	0.38	2.89e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs5769765	0.773	rs7410304	chr22:50316835	T/C	cg09182678	chr22:50328711	NA	-0.39	-5.79	-0.3	1.61e-8	Schizophrenia;
LIHC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.47	7.51	0.38	5.31e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.39	8.65	0.42	2.08e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.74	13.01	0.58	1.05e-31	Platelet count;
LIHC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.57	-8.18	-0.4	5.78e-15	Testicular germ cell tumor;
LIHC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.1	7.87	0.39	4.78e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg13409248	chr3:40428643	ENTPD3	-0.51	-8.63	-0.42	2.29e-16	Renal cell carcinoma;
LIHC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.54	9.09	0.44	8.33e-18	Mean corpuscular volume;
LIHC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.45	-7.5	-0.38	5.49e-13	Blood pressure (smoking interaction);
LIHC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.1	23.48	0.79	2.81e-73	Cognitive ability;
LIHC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.3	-17.27	-0.68	1.73e-48	Diabetic kidney disease;
LIHC	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.9	-14.86	-0.63	6.84e-39	Gut microbiota (bacterial taxa);
LIHC	trans	rs6011368	0.840	rs6062361	chr20:62904542	C/T	cg13869341	chr1:15865	WASH5P	-0.38	-6.67	-0.34	1.01e-10	Clozapine-induced cytotoxicity;
LIHC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.1e-31	Sense of smell;
LIHC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-7.06	-0.36	9.21e-12	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs10411161	0.721	rs10401778	chr19:52384315	C/T	cg22319618	chr22:45562946	NUP50	-0.6	-8.17	-0.4	6.12e-15	Breast cancer;
LIHC	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.63	9.1	0.44	7.59e-18	Schizophrenia;
LIHC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.7	-0.34	8.45e-11	Multiple sclerosis;
LIHC	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-13.49	-0.59	1.54e-33	Vitiligo;
LIHC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.66	-10.98	-0.51	3.27e-24	Childhood ear infection;
LIHC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg08807892	chr2:162101083	NA	0.45	7.64	0.38	2.25e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.39	7.07	0.36	8.85e-12	Obesity;
LIHC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.77	13.12	0.58	3.93e-32	Anterior chamber depth;
LIHC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.42	5.78	0.3	1.67e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-6.38	-0.33	5.61e-10	Body mass index;
LIHC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.9	0.3	8.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.33	-6.28	-0.32	1.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.5	7.8	0.39	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-14.36	-0.61	6.23e-37	Lymphocyte percentage of white cells;
LIHC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.89	-0.43	3.45e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3823572	0.542	rs2971974	chr7:133644598	C/T	cg03336402	chr7:133662267	EXOC4	0.49	6.18	0.32	1.79e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	9.45	0.46	5.4e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.6	11.85	0.54	2.27e-27	Plateletcrit;Platelet count;
LIHC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs244293	0.965	rs244363	chr17:53188893	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.47	-0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02290350	chr8:58132656	NA	0.37	7.63	0.38	2.32e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10792665	0.512	rs2127363	chr11:82641001	C/A	cg24227371	chr11:82718527	RAB30	-0.28	-6.59	-0.34	1.67e-10	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.43	-6.45	-0.33	3.89e-10	Cognitive function;
LIHC	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg09003973	chr2:102972529	NA	-0.91	-7.31	-0.37	1.94e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02290350	chr8:58132656	NA	-0.43	-8.75	-0.43	9.56e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg14930904	chr10:32216787	ARHGAP12	0.36	6.29	0.32	9.94e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg24849736	chr1:201084428	NA	-0.31	-6.1	-0.31	2.93e-9	Permanent tooth development;
LIHC	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.49	-0.33	2.93e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg15841412	chr13:111365552	ING1	0.47	5.93	0.31	7.54e-9	Coronary artery disease;
LIHC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.61	0.5	6.31e-23	Vitiligo;
LIHC	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg03934865	chr2:198174659	NA	0.46	6.67	0.34	1.03e-10	Dermatomyositis;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.13	-0.31	2.46e-9	Aortic root size;
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.62	0.38	2.5e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg26570765	chr4:1273065	NA	0.3	5.95	0.31	6.67e-9	Obesity-related traits;
LIHC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.9	-16.66	-0.67	4.73e-46	Aortic root size;
LIHC	cis	rs903552	1.000	rs12908310	chr15:102003635	A/G	cg25677261	chr15:102009856	PCSK6	-0.43	-5.92	-0.3	7.76e-9	Diabetic kidney disease;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.41	0.33	4.8e-10	Total body bone mineral density;
LIHC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.49	-0.33	2.99e-10	Mood instability;
LIHC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.54	8.68	0.43	1.61e-16	Anterior chamber depth;
LIHC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.53	8.68	0.42	1.67e-16	Blood metabolite levels;
LIHC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.07	-20.41	-0.74	4.11e-61	Multiple system atrophy;
LIHC	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.97	-8.49	-0.42	6.33e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.93	0.35	2.11e-11	Alzheimer's disease;
LIHC	cis	rs74181299	0.717	rs11893423	chr2:65350949	G/A	cg05010058	chr2:65284262	CEP68	-0.42	-6.91	-0.35	2.4e-11	Pulse pressure;
LIHC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.78	12.7	0.57	1.55e-30	Oral cavity cancer;
LIHC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.56	9.44	0.45	5.83e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg16836995	chr17:43662488	NA	-0.75	-7.61	-0.38	2.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.56	9.74	0.47	6.01e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg18887096	chr2:219472410	PLCD4	0.36	6.39	0.33	5.46e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.77	0.54	4.25e-27	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01586524	chr8:67341819	RRS1	0.47	6.99	0.35	1.43e-11	Pancreatic cancer;
LIHC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.8	0.3	1.5e-8	Tonsillectomy;
LIHC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.12	0.55	2.36e-28	Menopause (age at onset);
LIHC	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	6.64	0.34	1.27e-10	Eye color traits;
LIHC	cis	rs6586163	0.872	rs1926200	chr10:90746533	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.53	-7.76	-0.39	1.02e-13	Chronic lymphocytic leukemia;
LIHC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.49	7.78	0.39	8.54e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.25	0.48	1.14e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-0.8	-8.77	-0.43	8.43e-17	Alzheimer's disease (late onset);
LIHC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-6.73	-0.34	7.05e-11	Schizophrenia;
LIHC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-8.69	-0.43	1.55e-16	Gut microbiome composition (summer);
LIHC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg00750074	chr16:89608354	SPG7	-0.54	-8.72	-0.43	1.22e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.12	12.8	0.57	6.57e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.44	-5.81	-0.3	1.44e-8	Subjective well-being;
LIHC	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.76	-13.02	-0.58	9.81e-32	Platelet distribution width;
LIHC	cis	rs6001982	0.541	rs17002067	chr22:41050306	C/G	cg14879645	chr22:41048474	NA	0.4	5.91	0.3	8.13e-9	Breast cancer;
LIHC	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	5.94	0.31	6.92e-9	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03172837	chr2:236949449	AGAP1	0.41	6.34	0.32	7.11e-10	Pancreatic cancer;
LIHC	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.64	9.64	0.46	1.34e-19	Lymphocyte counts;
LIHC	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg08694578	chr2:241835147	C2orf54	-0.63	-10.16	-0.48	2.3e-21	Urinary metabolites;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16451004	chr11:27494421	LGR4	0.45	6.35	0.32	7.02e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.66	8.37	0.41	1.54e-15	Corneal astigmatism;
LIHC	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18898632	chr2:242989856	NA	-0.47	-6.5	-0.33	2.86e-10	Obesity-related traits;
LIHC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg06565975	chr8:143823917	SLURP1	-0.33	-6.29	-0.32	9.6e-10	Urinary tract infection frequency;
LIHC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	10.94	0.51	4.5e-24	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14195458	chr4:89381447	HERC5	0.27	6.49	0.33	3e-10	Cognitive function;
LIHC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.58	8.18	0.4	5.67e-15	Aortic root size;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.63	-0.42	2.41e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	13.3	0.58	8.25e-33	Coffee consumption (cups per day);
LIHC	cis	rs963731	0.649	rs297150	chr2:39326164	C/T	cg04010122	chr2:39346883	SOS1	-0.67	-6.07	-0.31	3.31e-9	Corticobasal degeneration;
LIHC	trans	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.51	-6.19	-0.32	1.68e-9	Ulcerative colitis;
LIHC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.8	11.86	0.54	2e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.5	7.81	0.39	6.97e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg05082376	chr22:42548792	NA	-0.4	-5.89	-0.3	9.43e-9	Schizophrenia;
LIHC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.98	11.98	0.54	7.58e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg19508488	chr2:152266495	RIF1	0.5	6.83	0.35	3.97e-11	Lung cancer;
LIHC	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.86	-0.39	4.91e-14	Response to antipsychotic treatment;
LIHC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	1.06	22.64	0.77	5.25e-70	Breast cancer;
LIHC	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.51	9.4	0.45	8.16e-19	Testicular germ cell tumor;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01052087	chr20:10414899	C20orf94;MKKS	0.42	6.32	0.32	8.37e-10	Calcium levels;
LIHC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.81	0.39	6.86e-14	Alzheimer's disease;
LIHC	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.43	6.0	0.31	5e-9	Tuberculosis;
LIHC	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg08824895	chr13:115047677	UPF3A	0.48	6.89	0.35	2.73e-11	Schizophrenia;
LIHC	cis	rs10751667	0.557	rs4077531	chr11:1013167	G/A	cg10932868	chr11:921992	NA	0.32	5.88	0.3	9.97e-9	Alzheimer's disease (late onset);
LIHC	cis	rs1865721	1.000	rs62089509	chr18:73194519	G/A	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.4	-6.34	-0.32	7.21e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.23	0.32	1.38e-9	Menarche (age at onset);
LIHC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-7.57	-0.38	3.5e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.28	-0.37	2.3e-12	Body mass index;
LIHC	trans	rs2579103	0.767	rs2579096	chr12:90662255	C/G	cg00091569	chr3:40428383	ENTPD3	0.37	6.08	0.31	3.19e-9	Body mass index;
LIHC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.13e-9	Tonsillectomy;
LIHC	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.49	7.64	0.38	2.2e-13	P wave terminal force;
LIHC	trans	rs2096176	0.581	rs7895318	chr10:26423091	A/G	cg01396774	chr2:218299024	DIRC3	-0.31	-6.09	-0.31	3.04e-9	Obesity-related traits;
LIHC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.99	-0.31	5.19e-9	Menarche (age at onset);
LIHC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg18867708	chr6:26865862	GUSBL1	0.52	8.07	0.4	1.19e-14	Schizophrenia;
LIHC	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	7.4	0.37	1.05e-12	Adiposity;
LIHC	cis	rs2625529	0.824	rs12901886	chr15:72408069	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.86	-0.3	1.06e-8	Red blood cell count;
LIHC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.16	-0.58	2.7e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.94	-0.31	6.95e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-6.0	-0.31	5.01e-9	Life satisfaction;
LIHC	cis	rs4845459	0.933	rs11205044	chr1:152593437	T/C	cg20634798	chr1:152595351	LCE3A	-0.31	-6.02	-0.31	4.48e-9	Psoriasis;
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.66	12.8	0.57	6.45e-31	Schizophrenia;
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.7	11.58	0.53	2.27e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.33	7.08	0.36	8e-12	Ulcerative colitis;
LIHC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg16736954	chr20:23401023	NAPB	0.71	8.48	0.42	6.86e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg16102536	chr7:156981717	UBE3C	-0.35	-5.9	-0.3	8.56e-9	Body mass index;
LIHC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg16486109	chr11:613632	IRF7	0.6	6.48	0.33	3.28e-10	Systemic lupus erythematosus;
LIHC	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.44	6.53	0.33	2.41e-10	Menopause (age at onset);
LIHC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.59	-10.2	-0.48	1.73e-21	Diisocyanate-induced asthma;
LIHC	cis	rs11212737	0.765	rs2640764	chr11:108511063	G/A	cg22776369	chr11:108536276	DDX10	0.35	5.88	0.3	9.82e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04784546	chr15:50646617	GABPB1;FLJ10038;LOC100129387	-0.5	-6.29	-0.32	9.85e-10	Systolic blood pressure;
LIHC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	8.91	0.43	3e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7927771	0.507	rs3740699	chr11:47504075	G/T	cg20307385	chr11:47447363	PSMC3	0.74	10.55	0.5	1.04e-22	Subjective well-being;
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.33	-0.37	1.73e-12	Lymphocyte counts;
LIHC	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.61	-9.76	-0.47	5.08e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg26536354	chr8:144654954	C8orf73	0.55	6.19	0.32	1.72e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	11.23	0.52	4.18e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.76	12.9	0.57	2.74e-31	Anterior chamber depth;
LIHC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.89	-8.61	-0.42	2.8e-16	Mean corpuscular hemoglobin;
LIHC	trans	rs13381277	1.000	rs9956431	chr18:74329251	G/T	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.4	-0.33	5e-10	Dental caries;
LIHC	cis	rs12594515	0.694	rs2068294	chr15:45985548	G/T	cg19682013	chr15:45996608	NA	0.4	6.85	0.35	3.34e-11	Waist circumference;Weight;
LIHC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	1.02	18.35	0.7	7.4e-53	Tonsillectomy;
LIHC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg25281562	chr12:121454272	C12orf43	0.34	5.98	0.31	5.66e-9	N-glycan levels;
LIHC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.57	-8.74	-0.43	1.07e-16	Corneal astigmatism;
LIHC	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.37	-8.71	-0.43	1.3e-16	Resting heart rate;
LIHC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.8	0.69	1.24e-50	Smoking behavior;
LIHC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.59	6.78	0.34	5.41e-11	Menarche (age at onset);
LIHC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg13798912	chr7:905769	UNC84A	0.44	5.81	0.3	1.45e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.28	6.55	0.33	2.1e-10	Primary biliary cholangitis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.45	7.14	0.36	5.75e-12	Pancreatic cancer;
LIHC	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.34	-7.69	-0.38	1.59e-13	Breast cancer;
LIHC	cis	rs10454142	0.700	rs17037289	chr2:48587198	A/G	cg15846641	chr2:48541264	FOXN2	0.5	6.09	0.31	3.12e-9	Sex hormone-binding globulin levels;
LIHC	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.29	21.47	0.76	2.32e-65	Corneal structure;
LIHC	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	6.79	0.34	4.98e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	trans	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg01596870	chr19:55963115	NA	-0.64	-9.37	-0.45	1.03e-18	Obesity-related traits;
LIHC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.38	-9.69	-0.46	8.99e-20	Asthma (sex interaction);
LIHC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg20129853	chr10:51489980	NA	-0.4	-8.72	-0.43	1.21e-16	Prostate-specific antigen levels;
LIHC	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.66	10.52	0.49	1.33e-22	Obesity-related traits;
LIHC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.49	7.61	0.38	2.77e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.39	-6.4	-0.33	4.99e-10	Tuberculosis;
LIHC	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg04306507	chr14:55594613	LGALS3	0.32	5.96	0.31	6.31e-9	Protein biomarker;
LIHC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.6e-13	Bone mineral density;
LIHC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.53	-8.69	-0.43	1.56e-16	Cognitive function;
LIHC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	9.47	0.46	4.71e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	16.13	0.66	6.44e-44	Platelet count;
LIHC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	13.84	0.6	6.87e-35	Chronic sinus infection;
LIHC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg25894440	chr7:65020034	NA	-0.55	-6.33	-0.32	7.79e-10	Diabetic kidney disease;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg14828511	chr1:107599125	PRMT6	-0.46	-6.58	-0.34	1.79e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.53	10.01	0.48	7.45e-21	Testicular germ cell tumor;
LIHC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg06565975	chr8:143823917	SLURP1	0.34	6.66	0.34	1.1e-10	Urinary tract infection frequency;
LIHC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.87	-11.73	-0.54	5.98e-27	Cognitive function;
LIHC	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	0.88	14.17	0.61	3.41e-36	Testicular germ cell tumor;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg05309934	chr10:5855475	GDI2	-0.53	-6.2	-0.32	1.62e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg27121462	chr16:89883253	FANCA	0.42	6.63	0.34	1.3e-10	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23104823	chr14:45553408	PRPF39	0.44	6.54	0.33	2.29e-10	Pancreatic cancer;
LIHC	cis	rs713477	0.817	rs55868790	chr14:55913275	T/C	cg13175173	chr14:55914753	NA	-0.35	-8.1	-0.4	9.62e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.32	21.74	0.76	2.04e-66	Corneal structure;
LIHC	cis	rs11951515	0.508	rs11958046	chr5:43583389	T/C	cg01983248	chr5:43482804	C5orf28	-0.37	-6.1	-0.31	2.9e-9	Metabolite levels  (X-11787);
LIHC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg21573476	chr21:45109991	RRP1B	-0.48	-8.7	-0.43	1.45e-16	Mean corpuscular volume;
LIHC	trans	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg10208301	chr11:6592745	DNHD1	0.45	6.45	0.33	3.73e-10	Coronary artery calcification;
LIHC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.6	7.48	0.38	6.18e-13	Heart rate;
LIHC	trans	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16471864	chr4:38666270	KLF3;FLJ13197	0.42	6.05	0.31	3.75e-9	Type 2 diabetes;
LIHC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg03013999	chr17:37608204	MED1	0.35	5.78	0.3	1.71e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg16797656	chr11:68205561	LRP5	0.52	8.25	0.41	3.4e-15	Total body bone mineral density;
LIHC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.4	7.95e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.66	10.12	0.48	3.15e-21	Height;
LIHC	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1165668	0.785	rs1165681	chr12:104325111	A/G	cg21863207	chr12:104234989	NT5DC3	-0.41	-6.87	-0.35	3.03e-11	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.32	7.07	0.36	8.81e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg11812906	chr14:75593930	NEK9	-0.4	-6.18	-0.32	1.85e-9	IgG glycosylation;
LIHC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.52e-14	Platelet count;
LIHC	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.25	-0.32	1.21e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.53	8.58	0.42	3.45e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.49	-0.33	2.94e-10	Prevalent atrial fibrillation;
LIHC	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg08345082	chr10:99160200	RRP12	-0.39	-6.72	-0.34	7.76e-11	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17712092	chr4:129076599	LARP1B	-0.71	-10.38	-0.49	4.11e-22	Eosinophil percentage of white cells;
LIHC	cis	rs7903847	0.612	rs72838764	chr10:99142107	T/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.05	-0.31	3.71e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg15412446	chr2:106886593	NA	-0.69	-6.87	-0.35	3.07e-11	Facial morphology (factor 23);
LIHC	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.49	8.14	0.4	7.41e-15	Uric acid levels;
LIHC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.61	9.47	0.46	4.92e-19	Crohn's disease;
LIHC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.24	-15.92	-0.65	4.31e-43	Diabetic kidney disease;
LIHC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.5e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.55	0.33	2.15e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.58	6.14	0.31	2.32e-9	Hip geometry;
LIHC	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg01864069	chr14:103024347	NA	0.36	5.99	0.31	5.22e-9	Platelet count;
LIHC	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg06359132	chr10:99160096	RRP12	-0.38	-5.97	-0.31	6.01e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg18887096	chr2:219472410	PLCD4	-0.39	-6.69	-0.34	9.17e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.35	7.73	0.39	1.2e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18252515	chr7:66147081	NA	0.43	6.24	0.32	1.27e-9	Aortic root size;
LIHC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg21724239	chr8:58056113	NA	0.42	5.71	0.3	2.39e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.35	5.76	0.3	1.91e-8	Blood metabolite levels;
LIHC	trans	rs4799915	1.000	rs4799915	chr18:34928639	A/G	cg11874882	chr17:31910113	ACCN1	0.27	6.38	0.33	5.61e-10	Response to iloperidone treatment (QT prolongation);
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg26570765	chr4:1273065	NA	0.31	6.15	0.32	2.16e-9	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg07424592	chr7:64974309	NA	0.79	9.02	0.44	1.37e-17	Diabetic kidney disease;
LIHC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.96	-0.31	6.38e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.86	0.47	2.39e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg20991723	chr1:152506922	NA	0.53	8.88	0.43	3.78e-17	Hair morphology;
LIHC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.55	-0.38	4.07e-13	Initial pursuit acceleration;
LIHC	trans	rs78049276	0.688	rs73855809	chr4:148380348	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-7.67	-0.38	1.76e-13	Pulse pressure;
LIHC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.53	-8.43	-0.41	9.54e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00828616	chr10:81838587	LOC219347;C10orf57	0.41	6.07	0.31	3.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.34	-6.43	-0.33	4.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	6.0	0.31	5.04e-9	Tonsillectomy;
LIHC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs600806	0.888	rs444387	chr1:109851127	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.48	-5.97	-0.31	6.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg19635926	chr16:89946313	TCF25	0.54	7.33	0.37	1.65e-12	Skin colour saturation;
LIHC	trans	rs6489882	0.867	rs6489874	chr12:113367895	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.83	14.9	0.63	5.03e-39	Adiposity;
LIHC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.92	-15.37	-0.64	6.67e-41	Longevity;
LIHC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.45	6.14	0.32	2.26e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.26	-16.93	-0.68	3.82e-47	Diabetic kidney disease;
LIHC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.59	7.96	0.4	2.5e-14	Blood metabolite levels;
LIHC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-0.71	-10.13	-0.48	2.87e-21	Initial pursuit acceleration;
LIHC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00498163	chr2:242821619	NA	0.37	6.24	0.32	1.29e-9	Cognitive function;
LIHC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.46	-7.72	-0.39	1.32e-13	Mean corpuscular volume;
LIHC	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.25	-13.18	-0.58	2.36e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.64	5.89	0.3	9.33e-9	Schizophrenia;
LIHC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg17724175	chr1:150552817	MCL1	0.46	9.16	0.44	4.94e-18	Melanoma;
LIHC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.62	8.13	0.4	7.76e-15	Motion sickness;
LIHC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.54	-0.38	4.31e-13	Schizophrenia;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg00800038	chr16:89945340	TCF25	-0.59	-9.61	-0.46	1.58e-19	Interleukin-17 levels;
LIHC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.6	8.64	0.42	2.24e-16	Blood metabolite levels;
LIHC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg07117364	chr1:16154769	NA	-0.4	-5.9	-0.3	8.51e-9	Dilated cardiomyopathy;
LIHC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.56	7.52	0.38	4.94e-13	Vitiligo;
LIHC	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg09238746	chr17:78121135	EIF4A3	-0.67	-11.03	-0.51	2.16e-24	Yeast infection;
LIHC	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.41	7.41	0.37	9.96e-13	Testicular germ cell tumor;
LIHC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg09779027	chr19:7224513	INSR	0.31	6.73	0.34	7.14e-11	Hypothyroidism;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21635948	chr2:53994617	LOC100302652;ASB3;CHAC2	0.3	6.13	0.31	2.47e-9	Calcium levels;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.01	-0.35	1.26e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.79	-0.3	1.58e-8	Ulcerative colitis;
LIHC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.55	-8.31	-0.41	2.27e-15	Multiple sclerosis;
LIHC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.37	-8.39	-0.41	1.32e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.68	0.38	1.68e-13	Height;
LIHC	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg20607764	chr19:44506953	ZNF230	-0.43	-7.02	-0.35	1.19e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.39	0.33	5.52e-10	Ileal carcinoids;
LIHC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.48	-8.81	-0.43	6.61e-17	Body mass index;
LIHC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.88	0.43	3.71e-17	Multiple sclerosis;
LIHC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.41	1.36e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.63	-7.32	-0.37	1.73e-12	Mosquito bite size;
LIHC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-7.87	-0.39	4.79e-14	Vitiligo;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg26939375	chr7:64535504	NA	0.44	7.48	0.38	6.18e-13	Calcium levels;
LIHC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg12863693	chr15:85201151	NMB	-0.41	-5.78	-0.3	1.68e-8	Schizophrenia;
LIHC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.85	14.95	0.63	2.96e-39	Headache;
LIHC	cis	rs16828019	0.852	rs12729586	chr1:41522377	C/A	cg03962019	chr1:41807865	NA	0.49	7.06	0.36	9.32e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.24	0.58	1.36e-32	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	1.04	8.3	0.41	2.41e-15	Arsenic metabolism;
LIHC	cis	rs10878977	0.586	rs732214	chr12:69815826	T/C	cg17330252	chr12:69809627	NA	0.37	5.88	0.3	9.79e-9	Colorectal cancer;
LIHC	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.3	0.61	1.12e-36	Bipolar disorder;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02228635	chr1:93298093	RPL5	-0.51	-6.48	-0.33	3.19e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.51	-7.4	-0.37	1.05e-12	Breast size;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg17512779	chr8:17104072	CNOT7;VPS37A	-0.52	-6.12	-0.31	2.63e-9	Obesity-related traits;
LIHC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-8.09	-0.4	1.05e-14	Parkinson's disease;
LIHC	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.64	-10.29	-0.49	8.2e-22	Pediatric autoimmune diseases;
LIHC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.59	-5.8	-0.3	1.53e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs4252707	1	rs4252707	chr1:204508147	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.4	-6.27	-0.32	1.06e-9	Glioma;Non-glioblastoma glioma;
LIHC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.53	9.26	0.45	2.24e-18	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7668874	0.731	rs4339279	chr4:116751046	T/A	cg08917878	chr5:172668965	NA	-0.31	-6.15	-0.32	2.12e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.95	-8.41	-0.41	1.09e-15	White matter integrity;
LIHC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	5.87e-9	Menopause (age at onset);
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.5	-8.62	-0.42	2.62e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs3820500	0.543	rs1290539	chr1:118029601	T/G	cg20383390	chr1:117909022	MAN1A2	0.46	5.93	0.31	7.33e-9	Pneumonia;
LIHC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs7923837	0.651	rs11187096	chr10:94369588	G/T	cg25506282	chr10:94462361	NA	0.34	5.76	0.3	1.85e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.66	-6.57	-0.33	1.93e-10	Multiple sclerosis;
LIHC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	1.0	13.27	0.58	1.01e-32	Breast cancer;
LIHC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.46	7.29	0.37	2.11e-12	HDL cholesterol levels;
LIHC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-0.85	-10.5	-0.49	1.5e-22	Blood pressure (smoking interaction);
LIHC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg05896524	chr21:47604654	C21orf56	0.43	6.13	0.31	2.43e-9	Testicular germ cell tumor;
LIHC	trans	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.49	6.11	0.31	2.65e-9	Ulcerative colitis;
LIHC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg11812906	chr14:75593930	NEK9	0.41	6.67	0.34	1.03e-10	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.25	-16.5	-0.67	2.19e-45	Diabetic kidney disease;
LIHC	cis	rs4407350	0.788	rs5764879	chr22:44920771	T/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.16	-0.32	2.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-6.7	-0.34	8.58e-11	Chronic sinus infection;
LIHC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.35	6.05	0.31	3.85e-9	Schizophrenia;
LIHC	cis	rs12744310	1.000	rs12038924	chr1:41760317	C/T	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.53	-10.69	-0.5	3.46e-23	Prostate cancer;
LIHC	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.67	8.54	0.42	4.35e-16	Exhaled nitric oxide output;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.67	0.42	1.81e-16	Lymphocyte counts;
LIHC	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.31	7.82	0.39	6.64e-14	Resting heart rate;
LIHC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.21	-0.36	3.61e-12	Response to antipsychotic treatment;
LIHC	cis	rs992157	0.764	rs2891077	chr2:219184430	A/C	cg00012203	chr2:219082015	ARPC2	0.75	10.52	0.49	1.33e-22	Colorectal cancer;
LIHC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	1.02	19.53	0.73	1.36e-57	Breast cancer;
LIHC	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg15103426	chr22:29168792	CCDC117	-0.48	-6.34	-0.32	7.29e-10	Red cell distribution width;
LIHC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-6.55	-0.33	2.14e-10	Blood metabolite levels;
LIHC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg17750252	chr2:136567154	LCT	0.35	6.23	0.32	1.36e-9	Mosquito bite size;
LIHC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.55	-10.35	-0.49	5.06e-22	Coronary artery disease;
LIHC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg25364880	chr3:44379878	C3orf23	0.46	6.63	0.34	1.28e-10	Depressive symptoms;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03130149	chr11:3819041	PGAP2;NUP98	0.44	6.46	0.33	3.56e-10	Pancreatic cancer;
LIHC	cis	rs4407350	0.655	rs135623	chr22:44890672	C/T	cg26276947	chr22:44892394	LDOC1L	0.33	6.22	0.32	1.45e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.61	0.42	2.73e-16	Prudent dietary pattern;
LIHC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-6.48	-0.33	3.17e-10	Bipolar disorder;
LIHC	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.72	-11.29	-0.52	2.39e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.45	6.24	0.32	1.28e-9	Height;
LIHC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg17980119	chr2:219472607	PLCD4	-0.37	-6.24	-0.32	1.3e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg08694578	chr2:241835147	C2orf54	-0.51	-7.16	-0.36	4.88e-12	Urinary metabolites;
LIHC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.76	-11.65	-0.53	1.17e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.41	-0.49	3.04e-22	Platelet count;
LIHC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.32	5.98	0.31	5.52e-9	Height;
LIHC	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg15282417	chr9:129245246	FAM125B	0.41	6.75	0.34	6.28e-11	Intraocular pressure;
LIHC	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.02	-0.31	4.52e-9	Blood pressure;
LIHC	cis	rs57590327	0.679	rs13071810	chr3:81618478	T/C	cg07356753	chr3:81810745	GBE1	-0.49	-6.69	-0.34	9.09e-11	Extraversion;
LIHC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs11673344	0.830	rs3745770	chr19:37488565	C/G	cg27390819	chr19:37464633	NA	-0.5	-6.05	-0.31	3.82e-9	Obesity-related traits;
LIHC	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg17507749	chr15:85114479	UBE2QP1	0.69	7.81	0.39	6.89e-14	Schizophrenia;
LIHC	trans	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg10208301	chr11:6592745	DNHD1	0.47	6.76	0.34	5.93e-11	Coronary artery calcification;
LIHC	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.53	-7.6	-0.38	2.8e-13	Neuroticism;
LIHC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.64	6.84	0.35	3.58e-11	Type 2 diabetes;
LIHC	cis	rs735860	0.712	rs6909592	chr6:53163090	C/G	cg10236188	chr6:53219634	NA	0.41	7.48	0.37	6.36e-13	Glaucoma;
LIHC	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.45	6.36	0.33	6.46e-10	Asthma;
LIHC	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.42	-6.79	-0.34	5.01e-11	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.51	0.53	3.97e-26	Motion sickness;
LIHC	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg23117778	chr20:1206693	RAD21L1	0.37	6.34	0.32	7.29e-10	Multiple sclerosis;
LIHC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.66	12.88	0.57	3.24e-31	Schizophrenia;
LIHC	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.61	-0.42	2.81e-16	Colorectal cancer;
LIHC	cis	rs6442522	0.772	rs2278962	chr3:15492786	A/T	cg16303742	chr3:15540471	COLQ	0.43	7.25	0.37	2.76e-12	Uric acid levels;
LIHC	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.58	-0.38	3.36e-13	Homocysteine levels;
LIHC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg02269571	chr22:50332266	NA	-0.61	-8.71	-0.43	1.29e-16	Schizophrenia;
LIHC	cis	rs74233809	1.000	rs74444347	chr10:104769275	A/C	cg03493300	chr10:104813866	CNNM2	0.45	6.06	0.31	3.69e-9	Birth weight;
LIHC	trans	rs983392	0.709	rs4492839	chr11:59986399	T/A	cg17275991	chr19:58003312	ZNF419	0.44	6.27	0.32	1.08e-9	Alzheimer's disease (late onset);
LIHC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.79	11.04	0.51	1.98e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.88	0.43	3.97e-17	Coffee consumption (cups per day);
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg00960700	chr17:80709150	TBCD	0.36	5.98	0.31	5.73e-9	Glycated hemoglobin levels;
LIHC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.65	-9.37	-0.45	1.05e-18	Obesity-related traits;
LIHC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.36	0.32	6.65e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg03037974	chr15:76606532	NA	-0.57	-9.54	-0.46	2.74e-19	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.97	0.31	6.06e-9	Renal cell carcinoma;
LIHC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.42	-6.13	-0.31	2.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.44	6.47	0.33	3.46e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11673344	0.864	rs12151313	chr19:37563211	C/T	cg27390819	chr19:37464633	NA	-0.51	-6.25	-0.32	1.23e-9	Obesity-related traits;
LIHC	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.77	-11.42	-0.53	8.63e-26	Personality dimensions;
LIHC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.98	0.54	7.29e-28	Coffee consumption (cups per day);
LIHC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.53	-8.23	-0.41	4e-15	P wave terminal force;
LIHC	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	28.29	0.84	1.44e-91	Schizophrenia;
LIHC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.41	0.37	1.02e-12	Lung cancer;
LIHC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg16479474	chr6:28041457	NA	0.38	6.43	0.33	4.2e-10	Cardiac Troponin-T levels;
LIHC	cis	rs509477	0.962	rs562412	chr18:32576305	T/C	cg23791764	chr18:32556832	MAPRE2	-0.53	-7.53	-0.38	4.44e-13	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.26	0.45	2.33e-18	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25397718	chr9:140317786	EXD3;NOXA1	0.44	6.41	0.33	4.94e-10	Pancreatic cancer;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.55	-9.94	-0.47	1.29e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs7937890	0.598	rs10734225	chr11:14442994	C/G	cg23387056	chr11:14280742	SPON1	-0.46	-6.01	-0.31	4.74e-9	Mitochondrial DNA levels;
LIHC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.58	8.57	0.42	3.74e-16	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11411107	chr3:160473611	PPM1L	0.47	6.86	0.35	3.21e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.4e-11	Diabetic kidney disease;
LIHC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.45	5.85	0.3	1.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.45	8.13	0.4	7.75e-15	Prudent dietary pattern;
LIHC	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg09795085	chr6:101329169	ASCC3	0.46	6.65	0.34	1.14e-10	Neuroticism;
LIHC	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg02811702	chr13:24901961	NA	0.25	6.42	0.33	4.48e-10	Obesity-related traits;
LIHC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.97	-0.44	1.96e-17	Skin colour saturation;
LIHC	cis	rs4684776	0.867	rs11706990	chr3:11343663	G/A	cg00170343	chr3:11313890	ATG7	-0.52	-7.21	-0.36	3.53e-12	Small vessel stroke;
LIHC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.53	-6.32	-0.32	8.09e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-9.0	-0.44	1.58e-17	Arsenic metabolism;
LIHC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.87	-10.8	-0.5	1.39e-23	Bladder cancer;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.78	11.96	0.54	8.59e-28	Longevity;
LIHC	cis	rs12602486	1.000	rs2285954	chr17:42232938	T/G	cg08193365	chr17:42277699	NA	1.05	7.39	0.37	1.16e-12	Glycated hemoglobin levels;
LIHC	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.23	6.34	0.32	7.08e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs72653721	0.838	rs17764592	chr6:11003144	G/T	cg13562911	chr6:11044106	ELOVL2	-0.5	-7.27	-0.37	2.51e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs700651	0.789	rs2196176	chr2:198904914	A/G	cg03934865	chr2:198174659	NA	0.47	6.56	0.33	1.95e-10	Intracranial aneurysm;
LIHC	cis	rs11605275	1.000	rs73434177	chr11:20023995	G/A	cg14835545	chr11:20032148	NAV2	-0.85	-7.68	-0.38	1.73e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg14393609	chr7:65229607	NA	0.44	6.58	0.34	1.81e-10	Aortic root size;
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12379764	chr21:47803548	PCNT	-0.58	-8.46	-0.42	7.96e-16	Testicular germ cell tumor;
LIHC	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg00825309	chr19:58991885	ZNF446	-0.69	-10.71	-0.5	2.72e-23	Uric acid clearance;
LIHC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.57	-5.79	-0.3	1.55e-8	Rheumatoid arthritis;
LIHC	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.73	10.63	0.5	5.51e-23	Obesity-related traits;
LIHC	cis	rs2412488	0.893	rs2271559	chr4:54362676	A/G	cg22241045	chr4:54363911	LNX1	0.46	7.64	0.38	2.15e-13	DNA methylation (variation);
LIHC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	0.98	15.37	0.64	6.88e-41	Type 1 diabetes nephropathy;
LIHC	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.56	-13.77	-0.6	1.21e-34	White blood cell count (basophil);
LIHC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.2	-0.32	1.63e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.7	10.46	0.49	2.16e-22	Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.47	7.09	0.36	7.78e-12	Thyroid stimulating hormone;
LIHC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.84	-15.41	-0.64	4.78e-41	Height;
LIHC	cis	rs918629	0.761	rs3777166	chr5:95291056	G/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.22	-0.32	1.42e-9	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.5	5.79	0.3	1.61e-8	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.72	8.07	0.4	1.19e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	10.02	0.48	6.87e-21	Cognitive test performance;
LIHC	cis	rs1866706	1.000	rs2099744	chr11:12866146	A/G	cg25843174	chr11:12811716	TEAD1	0.3	6.31	0.32	8.53e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg13251533	chr12:132286017	NA	0.48	8.81	0.43	6.25e-17	Migraine;
LIHC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07308232	chr7:1071921	C7orf50	-0.38	-6.12	-0.31	2.61e-9	Longevity;Endometriosis;
LIHC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.86	11.04	0.51	1.9e-24	Cognitive function;
LIHC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.71	0.65	2.87e-42	Breast cancer;
LIHC	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.58	8.02	0.4	1.7e-14	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.46	-5.82	-0.3	1.37e-8	Mean platelet volume;
LIHC	cis	rs2579500	0.807	rs11891926	chr2:97339781	A/G	cg26665480	chr2:98280029	ACTR1B	-0.42	-5.84	-0.3	1.22e-8	Eosinophil counts;Eosinophil percentage of white cells;
LIHC	cis	rs9649465	0.967	rs11765790	chr7:123293152	A/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.04	-0.4	1.49e-14	Migraine;
LIHC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg06046430	chr4:77819534	ANKRD56	0.48	6.41	0.33	4.97e-10	Emphysema distribution in smoking;
LIHC	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg15208524	chr1:10270712	KIF1B	0.38	5.86	0.3	1.09e-8	Hepatocellular carcinoma;
LIHC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.59	8.28	0.41	2.77e-15	Morning vs. evening chronotype;
LIHC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.75	0.43	9.6e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.08	0.51	1.43e-24	Colorectal cancer;
LIHC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.85	0.3	1.12e-8	Birth weight;
LIHC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.86	10.46	0.49	2.13e-22	Alzheimer's disease;
LIHC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.42	-6.53	-0.33	2.44e-10	Schizophrenia;
LIHC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-7.01	-0.35	1.26e-11	Response to antipsychotic treatment;
LIHC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.06	-0.36	9.33e-12	Aortic root size;
LIHC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.52	8.43	0.41	9.46e-16	Vitiligo;
LIHC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17554472	chr22:41940697	POLR3H	0.53	5.88	0.3	9.54e-9	Vitiligo;
LIHC	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.37	-6.46	-0.33	3.57e-10	Breast cancer;
LIHC	cis	rs7818688	0.697	rs11782818	chr8:95978221	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	6.33	0.32	7.76e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.45	8.26	0.41	3.22e-15	Testicular germ cell tumor;
LIHC	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16346588	chr10:242978	ZMYND11	0.38	5.88	0.3	9.97e-9	Psychosis in Alzheimer's disease;
LIHC	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.78	0.34	5.17e-11	Resting heart rate;
LIHC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg21395723	chr22:39101663	GTPBP1	0.37	6.19	0.32	1.7e-9	Menopause (age at onset);
LIHC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.51	-7.71	-0.38	1.41e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08050352	chr16:46864715	C16orf87	0.42	6.42	0.33	4.58e-10	Lung function (FEV1/FVC);
LIHC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.33	-6.2	-0.32	1.66e-9	Body mass index;
LIHC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.47	-6.94	-0.35	1.93e-11	Psoriasis;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17707966	chr8:144718525	ZNF623	-0.48	-6.11	-0.31	2.67e-9	Lung function (FEV1);
LIHC	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	trans	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg26939375	chr7:64535504	NA	0.39	6.12	0.31	2.63e-9	Aortic root size;
LIHC	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.52	-0.33	2.5e-10	Prevalent atrial fibrillation;
LIHC	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.65	8.25	0.41	3.45e-15	Blood pressure (smoking interaction);
LIHC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.97	17.74	0.69	2.19e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.53	6.95	0.35	1.85e-11	Hip circumference adjusted for BMI;
LIHC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.7	10.26	0.49	1.06e-21	Height;
LIHC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.75	0.47	5.57e-20	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06742493	chr19:13056745	RAD23A	-0.44	-6.16	-0.32	2.08e-9	Pancreatic cancer;
LIHC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-6.92	-0.35	2.26e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.55	6.42	0.33	4.68e-10	Mammographic density (dense area);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21012729	chr14:51297401	NIN	0.42	6.35	0.32	6.99e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2060793	0.506	rs10741658	chr11:14924736	T/C	cg25251204	chr11:14927456	NA	0.42	5.94	0.31	6.84e-9	Vitamin D levels;
LIHC	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09597638	chr17:3907349	NA	0.63	8.28	0.41	2.83e-15	Type 2 diabetes;
LIHC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.11	16.42	0.66	4.34e-45	Sexual dysfunction (female);
LIHC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg02297831	chr4:17616191	MED28	0.48	7.46	0.37	7.18e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.58	-8.55	-0.42	4.04e-16	Body mass index;
LIHC	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.54	8.08	0.4	1.11e-14	Platelet count;
LIHC	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.66	-9.91	-0.47	1.63e-20	Monocyte count;
LIHC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.22	0.32	1.42e-9	Blood metabolite levels;
LIHC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.78	-0.47	4.28e-20	Mean platelet volume;
LIHC	cis	rs7633770	0.643	rs58413466	chr3:46689154	G/T	cg11219411	chr3:46661640	NA	-0.36	-5.95	-0.31	6.55e-9	Coronary artery disease;
LIHC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.45	-7.32	-0.37	1.75e-12	Morning vs. evening chronotype;
LIHC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.64	-12.74	-0.57	1.08e-30	Schizophrenia;
LIHC	cis	rs244293	1.000	rs244316	chr17:53215223	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.45	-0.37	7.67e-13	Menarche (age at onset);
LIHC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	0.67	6.66	0.34	1.09e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26115276	chr5:178977181	RUFY1	-0.52	-6.84	-0.35	3.76e-11	Myopia (pathological);
LIHC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.57	7.81	0.39	6.92e-14	Neuroblastoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07280387	chr12:120763487	PLA2G1B	0.49	7.13	0.36	5.9e-12	Cognitive function;
LIHC	cis	rs151997	0.925	rs27847	chr5:50176197	G/T	cg06027927	chr5:50259733	NA	0.57	7.57	0.38	3.59e-13	Callous-unemotional behaviour;
LIHC	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg06096015	chr1:231504339	EGLN1	0.51	9.2	0.45	3.52e-18	Hemoglobin concentration;
LIHC	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.69	10.73	0.5	2.47e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.2e-13	Breast cancer;
LIHC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-9.44	-0.45	6.01e-19	Platelet distribution width;
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg10756647	chr7:56101905	PSPH	0.47	6.95	0.35	1.81e-11	Aortic root size;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.55	-10.55	-0.5	1.04e-22	Prudent dietary pattern;
LIHC	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg01206211	chr2:36825736	FEZ2	0.45	7.29	0.37	2.14e-12	Height;
LIHC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.65	11.58	0.53	2.16e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.33	-7.02	-0.35	1.21e-11	Bone mineral density;
LIHC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.06	-0.36	9.52e-12	Bipolar disorder;
LIHC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.96	-17.88	-0.7	5.74e-51	Breast cancer;
LIHC	cis	rs3106136	0.843	rs1991316	chr4:95268272	G/T	cg11021082	chr4:95130006	SMARCAD1	0.41	7.63	0.38	2.41e-13	Capecitabine sensitivity;
LIHC	cis	rs2997447	0.669	rs61776624	chr1:26474580	A/C	cg19633962	chr1:26362018	EXTL1	-0.69	-6.47	-0.33	3.44e-10	QRS complex (12-leadsum);
LIHC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.66	9.11	0.44	7.16e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg03037974	chr15:76606532	NA	0.79	16.05	0.66	1.36e-43	Blood metabolite levels;
LIHC	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg27386326	chr11:61587980	NA	-0.68	-14.17	-0.61	3.61e-36	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.69	0.8	5.26e-78	Prudent dietary pattern;
LIHC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-11.19	-0.52	5.8e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	7.99	0.4	2.16e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg25686905	chr3:183603175	PARL	-0.48	-9.02	-0.44	1.35e-17	Menopause (age at onset);
LIHC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16684958	chr7:75615977	POR	0.51	8.59	0.42	3.18e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.93	19.36	0.72	6.34e-57	Bone mineral density;
LIHC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-6.17	-0.32	1.91e-9	Menarche (age at onset);
LIHC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.71	10.95	0.51	3.9e-24	Body mass index;
LIHC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-6.38	-0.33	5.63e-10	Blood pressure (smoking interaction);
LIHC	cis	rs360798	0.512	rs6545973	chr2:63089434	C/T	cg17519650	chr2:63277830	OTX1	0.45	7.1	0.36	7.43e-12	Coronary artery disease;
LIHC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02034447	chr16:89574710	SPG7	0.47	7.38	0.37	1.25e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg13245912	chr11:63449340	RTN3	-0.43	-6.79	-0.34	5.07e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
LIHC	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg16684958	chr7:75615977	POR	0.5	8.57	0.42	3.56e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.57	-0.33	1.86e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg02527881	chr3:46936655	PTH1R	0.32	6.42	0.33	4.68e-10	Colorectal cancer;
LIHC	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg02886208	chr11:14281011	SPON1	-0.47	-6.64	-0.34	1.23e-10	Mitochondrial DNA levels;
LIHC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg19680672	chr10:131412579	MGMT	-0.44	-6.66	-0.34	1.1e-10	Response to temozolomide;
LIHC	cis	rs8027181	0.682	rs4777546	chr15:73104435	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.44	-6.84	-0.35	3.67e-11	Triglyceride levels;
LIHC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.6	11.06	0.51	1.62e-24	Menopause (age at onset);
LIHC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.44	6.34	0.32	7.07e-10	Asthma;
LIHC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg00409905	chr10:38381863	ZNF37A	0.46	7.25	0.36	2.8e-12	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03120789	chr1:20208808	OTUD3	0.44	6.63	0.34	1.29e-10	Cognitive function;
LIHC	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.08	-0.31	3.19e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg08499158	chr17:42289980	UBTF	0.47	7.73	0.39	1.18e-13	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.48	8.24	0.41	3.64e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs861318	0.640	rs2793844	chr1:159016967	A/G	cg11003133	chr1:159046391	AIM2	0.32	6.27	0.32	1.08e-9	Obesity-related traits;
LIHC	cis	rs3770081	1.000	rs58898686	chr2:86216909	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.52	-0.42	5.32e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12016809	chr21:47604291	C21orf56	0.45	6.63	0.34	1.34e-10	Testicular germ cell tumor;
LIHC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.48	7.97	0.4	2.43e-14	Diastolic blood pressure;
LIHC	trans	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg11693508	chr17:37793320	STARD3	0.61	6.23	0.32	1.41e-9	Bipolar disorder;
LIHC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-9.03	-0.44	1.26e-17	Platelet distribution width;
LIHC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.52	6.11	0.31	2.75e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.7	-0.34	8.52e-11	Mood instability;
LIHC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.38	5.98	0.31	5.6e-9	Melanoma;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg04013166	chr16:89971882	TCF25	0.56	7.37	0.37	1.3e-12	Skin colour saturation;
LIHC	cis	rs4788570	0.625	rs4788810	chr16:71621637	C/T	cg06353428	chr16:71660113	MARVELD3	-1.35	-12.76	-0.57	9.25e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.5e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs918629	0.567	rs1841010	chr5:95251911	G/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.72	-0.34	7.41e-11	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.82	0.35	4.07e-11	Gut microbiome composition (summer);
LIHC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg06781209	chr11:61594997	FADS2	-0.63	-5.86	-0.3	1.08e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg04498913	chr7:1135747	C7orf50	0.45	7.24	0.36	2.9e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.55	0.38	4.03e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.32	0.32	8.3e-10	Response to antipsychotic treatment;
LIHC	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg03146154	chr1:46216737	IPP	-0.4	-6.54	-0.33	2.27e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.45	6.83	0.35	3.99e-11	Cognitive test performance;
LIHC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20135002	chr11:47629003	NA	-0.57	-9.85	-0.47	2.63e-20	Subjective well-being;
LIHC	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs11958404	0.615	rs7704746	chr5:157450601	C/G	cg05962755	chr5:157440814	NA	0.59	7.83	0.39	6.15e-14	IgG glycosylation;
LIHC	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.04	-0.4	1.5e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	trans	rs800082	0.734	rs1726536	chr3:144249504	G/T	cg24215973	chr2:240111563	HDAC4	0.44	6.43	0.33	4.29e-10	Smoking behavior;
LIHC	cis	rs55702914	0.742	rs34555121	chr2:198166053	C/T	cg10820045	chr2:198174542	NA	0.41	6.19	0.32	1.76e-9	Major depression and alcohol dependence;
LIHC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg14393609	chr7:65229607	NA	0.38	5.91	0.3	8.22e-9	Aortic root size;
LIHC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.35	0.41	1.77e-15	Motion sickness;
LIHC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg05325390	chr16:23464715	COG7	-0.46	-7.19	-0.36	4.01e-12	Body mass index;
LIHC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-7.61	-0.38	2.7e-13	Cognitive function;
LIHC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Urate levels;
LIHC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.45	7.76	0.39	1.01e-13	Mean corpuscular volume;
LIHC	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.15	-0.32	2.18e-9	Bipolar disorder;
LIHC	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.73	11.2	0.52	5.32e-25	Metabolite levels;
LIHC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.42e-14	Morning vs. evening chronotype;
LIHC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.46	6.77	0.34	5.78e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg27572855	chr1:25598939	RHD	0.4	8.68	0.43	1.59e-16	Erythrocyte sedimentation rate;
LIHC	trans	rs75804782	0.521	rs72993033	chr2:239382882	A/G	cg01134436	chr17:81009848	B3GNTL1	0.86	7.2	0.36	3.82e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs11663156	0.921	rs67915568	chr18:50921507	C/T	cg24270629	chr18:50823537	DCC	-0.49	-6.69	-0.34	9.18e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg22481606	chr17:56429567	SUPT4H1	-0.4	-6.65	-0.34	1.19e-10	Oropharynx cancer;
LIHC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs7523273	0.517	rs2985106	chr1:207892033	T/G	cg22525895	chr1:207977042	MIR29B2	-0.53	-7.72	-0.39	1.28e-13	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg10756647	chr7:56101905	PSPH	-1.1	-13.4	-0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg06935464	chr4:38784597	TLR10	0.48	7.44	0.37	8.27e-13	Breast cancer;
LIHC	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg07075026	chr17:47091521	IGF2BP1	0.42	5.84	0.3	1.24e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LIHC	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.3	6.35	0.32	6.81e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs611744	0.967	rs671139	chr8:109191260	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24141115	chr1:52831603	CC2D1B	0.45	6.33	0.32	7.65e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.25e-8	Bladder cancer;
LIHC	cis	rs1211375	0.628	rs3859141	chr16:245079	T/C	cg08400316	chr16:204221	HBZ	0.38	5.96	0.31	6.42e-9	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg11057378	chr10:81107060	PPIF	0.36	5.84	0.3	1.23e-8	Height;
LIHC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.79	-0.43	7.58e-17	Motion sickness;
LIHC	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg07862535	chr7:139043722	LUC7L2	0.58	10.03	0.48	6.38e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg05361325	chr10:32636312	EPC1	-0.52	-6.41	-0.33	4.77e-10	Sexual dysfunction (female);
LIHC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg12046867	chr14:103022105	NA	0.49	6.96	0.35	1.73e-11	Platelet count;
LIHC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.85	-0.3	1.17e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	14.65	0.62	4.81e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.44	-6.2	-0.32	1.6e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs7474896	1.000	rs35258216	chr10:38018220	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-6.29	-0.32	9.83e-10	Obesity (extreme);
LIHC	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-7.87	-0.39	4.67e-14	Morning vs. evening chronotype;
LIHC	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.32	-5.88	-0.3	9.94e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.63	0.56	2.74e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.71	-11.11	-0.52	1.06e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs6442522	0.772	rs2278961	chr3:15492807	G/A	cg16303742	chr3:15540471	COLQ	0.43	7.24	0.36	2.97e-12	Uric acid levels;
LIHC	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06108461	chr20:60628389	TAF4	-0.53	-6.93	-0.35	2.08e-11	Body mass index;
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04025307	chr7:1156635	C7orf50	0.53	6.94	0.35	1.99e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13378865	chr6:26660005	ZNF322A	0.41	6.11	0.31	2.78e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	0.79	7.86	0.39	5.13e-14	Arsenic metabolism;
LIHC	cis	rs12744310	0.887	rs12047439	chr1:41809640	A/T	cg03962019	chr1:41807865	NA	0.38	6.17	0.32	1.96e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.49	9.17	0.44	4.55e-18	Hemoglobin concentration;
LIHC	trans	rs4290604	0.748	rs4621125	chr2:238080214	G/A	cg15676719	chr1:167598521	RCSD1	-0.48	-6.23	-0.32	1.33e-9	Asthma;
LIHC	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.34	0.32	7.28e-10	Schizophrenia;
LIHC	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	1.03	16.41	0.66	4.83e-45	Nonalcoholic fatty liver disease;
LIHC	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.4	-6.21	-0.32	1.51e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg07713946	chr22:31675144	LIMK2	-0.44	-7.91	-0.39	3.52e-14	Colorectal cancer;
LIHC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18867708	chr6:26865862	GUSBL1	0.55	8.3	0.41	2.37e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11690462	0.817	rs7571948	chr2:26542155	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.48	6.82	0.35	4.11e-11	Coronary artery disease;
LIHC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.82	-8.91	-0.43	3.12e-17	Vitiligo;
LIHC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg18887096	chr2:219472410	PLCD4	0.36	6.32	0.32	8.27e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs36051895	0.623	rs7025005	chr9:5261794	T/C	cg02405213	chr9:5042618	JAK2	-0.57	-9.22	-0.45	3.02e-18	Pediatric autoimmune diseases;
LIHC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	8.38	0.41	1.38e-15	Diastolic blood pressure;
LIHC	cis	rs8081395	0.711	rs1292034	chr17:57989860	G/A	cg13753209	chr17:57696993	CLTC	0.38	5.82	0.3	1.33e-8	White blood cell count;
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.61	8.9	0.43	3.37e-17	Prudent dietary pattern;
LIHC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.13	0.31	2.41e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg10130564	chr11:117069849	TAGLN	0.35	5.97	0.31	5.91e-9	Blood protein levels;
LIHC	cis	rs818427	0.896	rs351770	chr5:112199199	C/A	cg07820702	chr5:112228657	REEP5	0.36	5.76	0.3	1.92e-8	Total body bone mineral density;
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	5.99	0.31	5.41e-9	Calcium levels;
LIHC	cis	rs903552	0.800	rs6598479	chr15:102005913	A/C	cg06707286	chr15:102010195	PCSK6	-0.48	-6.72	-0.34	7.56e-11	Diabetic kidney disease;
LIHC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02732134	chr10:101732382	DNMBP	0.4	6.98	0.35	1.5e-11	Cognitive function;
LIHC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.47	6.32	0.32	8.15e-10	Height;
LIHC	cis	rs11080107	0.542	rs894606	chr17:27909352	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	7.14	0.36	5.56e-12	Coronary artery disease;
LIHC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.25	-0.36	2.83e-12	Ulcerative colitis;
LIHC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg06598544	chr20:61472147	COL9A3	-0.81	-7.65	-0.38	2.01e-13	Obesity-related traits;
LIHC	cis	rs2257205	0.667	rs7221142	chr17:56758786	A/G	cg12560992	chr17:57184187	TRIM37	0.71	7.79	0.39	8.05e-14	Pancreatic cancer;
LIHC	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg10820045	chr2:198174542	NA	0.55	8.83	0.43	5.41e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs258324	0.790	rs2162944	chr16:89717670	G/C	cg03597607	chr16:89714999	CHMP1A	-0.46	-5.98	-0.31	5.51e-9	Height;
LIHC	cis	rs760762	0.636	rs12480916	chr20:39932356	T/G	cg06424997	chr20:39929561	ZHX3	0.36	5.94	0.31	6.86e-9	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LIHC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.37	6.74	0.34	6.65e-11	IgG glycosylation;
LIHC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.77	12.51	0.56	7.9e-30	Colorectal cancer;
LIHC	cis	rs244293	0.965	rs244365	chr17:53187401	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.47	-0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.56	7.83	0.39	6.23e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs9993613	0.967	rs35631249	chr4:73443865	C/A	cg15102770	chr4:73434591	ADAMTS3	0.38	6.15	0.32	2.11e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.39	-7.63	-0.38	2.42e-13	Platelet distribution width;
LIHC	cis	rs9503598	0.502	rs6939192	chr6:3430282	C/T	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.86	-0.3	1.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg13047869	chr3:10149882	C3orf24	0.51	5.84	0.3	1.23e-8	Alzheimer's disease;
LIHC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.57	6.31	0.32	8.6e-10	Axial length;
LIHC	trans	rs6600671	0.934	rs11249431	chr1:121286203	A/G	cg09829573	chr1:144692074	NBPF9	0.42	7.03	0.36	1.16e-11	Hip geometry;
LIHC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	10.57	0.5	8.8e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.9e-9	Aortic root size;
LIHC	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.6	9.82	0.47	3.28e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg03037974	chr15:76606532	NA	-0.6	-9.93	-0.47	1.38e-20	Blood metabolite levels;
LIHC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.63	10.48	0.49	1.8e-22	Inflammatory bowel disease;
LIHC	cis	rs9596863	0.851	rs1379832	chr13:54429818	C/T	ch.13.53330881F	chr13:54432880	NA	0.45	5.98	0.31	5.65e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.39	9.46	0.46	5.12e-19	Breast cancer;
LIHC	trans	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.47	-6.31	-0.32	8.81e-10	Mean corpuscular volume;
LIHC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	0.97	9.55	0.46	2.49e-19	Diabetic retinopathy;
LIHC	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.35	-6.19	-0.32	1.73e-9	Lewy body disease;
LIHC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	13.24	0.58	1.37e-32	Response to antipsychotic treatment;
LIHC	cis	rs7116495	1.000	rs3886589	chr11:71669487	G/T	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg02640540	chr1:67518911	SLC35D1	0.43	5.96	0.31	6.44e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.87	0.39	4.83e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.79	-9.72	-0.47	7.2e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg03264133	chr6:25882463	NA	0.39	5.74	0.3	2.07e-8	Height;
LIHC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg03013999	chr17:37608204	MED1	-0.35	-5.88	-0.3	9.53e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.92	0.35	2.29e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.41	6.62	0.34	1.37e-10	Smoking behavior;
LIHC	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.85	0.57	4.17e-31	Monocyte count;
LIHC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	9.53	0.46	3.07e-19	Mean platelet volume;
LIHC	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.5	0.49	1.59e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg07959070	chr22:50026188	C22orf34	-0.35	-8.49	-0.42	6.29e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.2e-10	Aortic root size;
LIHC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.3	-6.77	-0.34	5.75e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.63	0.56	2.74e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.92	0.51	5.13e-24	Monocyte percentage of white cells;
LIHC	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.71	-10.95	-0.51	3.86e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.44	-0.49	2.4e-22	Chronic sinus infection;
LIHC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.51	8.38	0.41	1.37e-15	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07501049	chr1:981392	AGRN	0.48	7.34	0.37	1.6e-12	Cognitive function;
LIHC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.54	-0.33	2.21e-10	Personality dimensions;
LIHC	cis	rs7129220	0.588	rs7950718	chr11:10086624	C/A	cg01453529	chr11:10209919	SBF2	-0.41	-7.44	-0.37	8.44e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.79	12.74	0.57	1.1e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.42e-17	Lung cancer in ever smokers;
LIHC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg24209194	chr3:40518798	ZNF619	0.43	6.24	0.32	1.31e-9	Renal cell carcinoma;
LIHC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	11.96	0.54	8.55e-28	Post bronchodilator FEV1;
LIHC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.42	-8.84	-0.43	5.19e-17	Obesity-related traits;
LIHC	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.61	7.0	0.35	1.32e-11	Blood protein levels;
LIHC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg21395723	chr22:39101663	GTPBP1	0.34	5.73	0.3	2.16e-8	Menopause (age at onset);
LIHC	cis	rs4891159	0.724	rs690401	chr18:74108576	C/T	cg24786174	chr18:74118243	ZNF516	0.79	14.02	0.6	1.38e-35	Longevity;
LIHC	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.73	11.2	0.52	5.32e-25	Metabolite levels;
LIHC	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.22	6.0	0.31	5.1e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06620762	chr15:76136437	UBE2Q2	0.41	6.35	0.32	6.82e-10	Cognitive function;
LIHC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.51	9.79	0.47	4.25e-20	Testicular germ cell tumor;
LIHC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.31	0.55	4.45e-29	Cognitive test performance;
LIHC	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.96	-0.31	6.17e-9	Diisocyanate-induced asthma;
LIHC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.56	9.48	0.46	4.43e-19	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10283155	chr3:42642604	NKTR	0.45	6.4	0.33	5.11e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg00825309	chr19:58991885	ZNF446	-0.44	-6.52	-0.33	2.54e-10	Uric acid clearance;
LIHC	trans	rs6058796	1.000	rs6057614	chr20:31255800	C/T	cg02600331	chr11:130417168	NA	0.35	7.51	0.38	5.18e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg15017067	chr4:17643749	FAM184B	0.34	5.85	0.3	1.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.69	11.24	0.52	3.71e-25	Diisocyanate-induced asthma;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.63	-8.74	-0.43	1.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs116248771	0.739	rs4680454	chr3:158377913	C/T	cg16708174	chr3:158430962	RARRES1	0.48	6.38	0.33	5.61e-10	diarrhoeal disease at age 2;
LIHC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.71	7.12	0.36	6.44e-12	Vitiligo;
LIHC	trans	rs11165623	0.602	rs7527155	chr1:97016690	T/C	cg10631902	chr5:14652156	NA	-0.25	-6.28	-0.32	1.04e-9	Hip circumference;Waist circumference;
LIHC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.66	-9.21	-0.45	3.36e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13819586	chr14:24685205	MDP1	0.5	7.23	0.36	3.28e-12	Lung function (FEV1/FVC);
LIHC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs3785309	0.519	rs7197253	chr16:276549	C/T	cg14162552	chr9:139744532	PHPT1	0.61	6.54	0.33	2.21e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.37	-6.48	-0.33	3.29e-10	Asthma;
LIHC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.78	-13.64	-0.59	4.13e-34	Aortic root size;
LIHC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.77	0.34	5.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.77	-12.52	-0.56	7.04e-30	Height;
LIHC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.38	-5.79	-0.3	1.62e-8	Menarche (age at onset);
LIHC	trans	rs4596713	0.538	rs10114369	chr9:71799697	T/A	cg16512924	chr15:28394682	HERC2	0.39	6.23	0.32	1.33e-9	Headache;
LIHC	cis	rs116248771	0.739	rs116045655	chr3:158335368	G/A	cg16708174	chr3:158430962	RARRES1	0.47	6.28	0.32	1.04e-9	diarrhoeal disease at age 2;
LIHC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.87	14.18	0.61	3.16e-36	Gut microbiota (bacterial taxa);
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-7.92	-0.39	3.38e-14	Total body bone mineral density;
LIHC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Electroencephalogram traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16404460	chr10:89622595	PTEN;KILLIN	0.48	6.51	0.33	2.6200000000000003e-10	Pancreatic cancer;
LIHC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.32	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs288342	0.832	rs288306	chr2:183652286	C/T	cg02625481	chr2:183667124	NA	-0.29	-6.11	-0.31	2.67e-9	Recurrent major depressive disorder;
LIHC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.29	0.52	2.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.04	-0.31	4.09e-9	Longevity;
LIHC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.26	-0.37	2.62e-12	Migraine;Coronary artery disease;
LIHC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg05110241	chr16:68378359	PRMT7	0.71	8.36	0.41	1.62e-15	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18964732	chr1:165737775	TMCO1	0.46	6.62	0.34	1.41e-10	Cognitive function;
LIHC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.93	-0.39	3.04e-14	Capecitabine sensitivity;
LIHC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.13	-0.55	2.01e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-7.99	-0.4	2.05e-14	Obesity-related traits;
LIHC	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg20578329	chr17:80767326	TBCD	-0.66	-6.64	-0.34	1.24e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.64e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg20302533	chr7:39170763	POU6F2	0.33	6.08	0.31	3.17e-9	IgG glycosylation;
LIHC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.51	-0.53	3.96e-26	Coronary artery disease;
LIHC	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.24	-0.32	1.29e-9	Coronary artery disease;
LIHC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-8.69	-0.43	1.58e-16	Vitiligo;
LIHC	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	0.64	10.61	0.5	6.26e-23	Yeast infection;
LIHC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-7.69	-0.38	1.55e-13	HDL cholesterol;
LIHC	cis	rs4788570	0.615	rs2032918	chr16:71703436	T/G	cg06353428	chr16:71660113	MARVELD3	1.39	14.48	0.62	2.14e-37	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11668638	chr6:42952412	PPP2R5D	0.48	7.1	0.36	7.46e-12	Pancreatic cancer;
LIHC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.67	-8.69	-0.43	1.53e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07677032	chr17:61819896	STRADA	-0.39	-5.73	-0.3	2.18e-8	Prudent dietary pattern;
LIHC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.93	-0.35	2.1e-11	Response to antipsychotic treatment;
LIHC	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg09537434	chr19:41945824	ATP5SL	-1.01	-20.37	-0.74	5.93e-61	Height;
LIHC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg25801113	chr15:45476975	SHF	0.37	6.37	0.33	6.28e-10	Uric acid levels;
LIHC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg23109721	chr2:106886537	NA	0.71	6.83	0.35	3.99e-11	Facial morphology (factor 23);
LIHC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.73	7.39	0.37	1.15e-12	Vitiligo;
LIHC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.63	10.19	0.48	1.83e-21	Monocyte count;
LIHC	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	7.67	0.38	1.81e-13	Blood protein levels;
LIHC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.6	8.2	0.41	4.8e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs116248771	0.690	rs73156439	chr3:158359462	G/C	cg16708174	chr3:158430962	RARRES1	0.48	6.42	0.33	4.46e-10	diarrhoeal disease at age 2;
LIHC	trans	rs73389468	1	rs73389468	chr10:134295815	C/T	cg20713102	chr15:85144157	ZSCAN2	-0.85	-6.27	-0.32	1.11e-9	Periodontitis (CDC/AAP);
LIHC	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg03945807	chr20:60948434	NA	0.37	6.27	0.32	1.11e-9	Colorectal cancer;
LIHC	cis	rs3758785	0.737	rs12270338	chr11:94147464	A/C	cg21580213	chr11:94231278	ANKRD49	0.36	6.27	0.32	1.11e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LIHC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg03146154	chr1:46216737	IPP	-0.41	-6.63	-0.34	1.3100000000000001e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.99	23.08	0.78	1.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.56	-7.52	-0.38	4.77e-13	Menopause (age at onset);
LIHC	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg27523141	chr10:43048294	ZNF37B	-0.37	-6.3	-0.32	8.92e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6788895	1.000	rs73006998	chr3:150464271	G/A	cg09723797	chr3:150481914	SIAH2	0.78	9.87	0.47	2.17e-20	Breast cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03350042	chr15:40733177	BAHD1	0.45	6.59	0.34	1.63e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21767703	chr1:236444768	ERO1LB	-0.51	-6.67	-0.34	1.05e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs2096176	0.606	rs11819592	chr10:26422407	G/A	cg01396774	chr2:218299024	DIRC3	-0.31	-6.09	-0.31	3.04e-9	Obesity-related traits;
LIHC	cis	rs9918079	0.560	rs4698402	chr4:15629803	G/A	cg21329975	chr4:15471214	CC2D2A	-0.38	-5.77	-0.3	1.75e-8	Obesity-related traits;
LIHC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.69	-8.11	-0.4	9.08e-15	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.59	-9.42	-0.45	6.98e-19	HDL cholesterol;
LIHC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.38	-6.18	-0.32	1.77e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.62	0.34	1.37e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg04756594	chr16:24857601	SLC5A11	-0.47	-7.33	-0.37	1.73e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.56	0.62	1.09e-37	Prudent dietary pattern;
LIHC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11444135	chr17:72428287	GPRC5C	0.47	6.88	0.35	2.94e-11	Lung function (FEV1/FVC);
LIHC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.07	25.2	0.81	6.09e-80	IgG glycosylation;
LIHC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.65	13.65	0.59	3.68e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01669482	chr16:25043131	NA	0.5	6.91	0.35	2.31e-11	Pancreatic cancer;
LIHC	cis	rs1144333	0.850	rs1144342	chr1:76284364	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.63	-0.34	1.29e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18252515	chr7:66147081	NA	0.43	5.71	0.3	2.45e-8	Aortic root size;
LIHC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.74	9.77	0.47	4.79e-20	Coronary artery disease;
LIHC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.88	9.85	0.47	2.52e-20	Triglycerides;
LIHC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.28	0.37	2.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg04727924	chr7:799746	HEATR2	-0.61	-8.55	-0.42	4.2e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.69	6.86	0.35	3.22e-11	Breast cancer;
LIHC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.36	-0.37	1.4e-12	Body mass index;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-7.0	-0.35	1.37e-11	Menopause (age at onset);
LIHC	cis	rs9649465	0.967	rs2402666	chr7:123285478	A/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.24	-0.41	3.79e-15	Migraine;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12315363	chr17:34136012	TAF15	-0.42	-6.43	-0.33	4.34e-10	Systolic blood pressure;
LIHC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.63	-9.02	-0.44	1.33e-17	Blood metabolite levels;
LIHC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.23	6.12	0.31	2.55e-9	Calcium levels;
LIHC	cis	rs2108622	0.545	rs59140933	chr19:15975308	C/T	cg13772218	chr19:15982569	NA	0.34	7.23	0.36	3.19e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.58	0.59	7.01e-34	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg25344623	chr2:136566232	LCT	0.38	7.3	0.37	1.98e-12	Mosquito bite size;
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg13395646	chr4:1353034	KIAA1530	0.41	5.86	0.3	1.08e-8	Longevity;
LIHC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg10360323	chr17:41437877	NA	0.41	6.09	0.31	3.1e-9	Menopause (age at onset);
LIHC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.92	0.3	7.91e-9	Body mass index;
LIHC	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg12373951	chr3:133503437	NA	0.45	7.29	0.37	2.21e-12	Iron status biomarkers;
LIHC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg07061783	chr6:25882402	NA	-0.49	-6.23	-0.32	1.41e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.46	-7.68	-0.38	1.7e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.95	-9.26	-0.45	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-8.53	-0.42	4.81e-16	Neuroticism;
LIHC	cis	rs507080	0.922	rs582630	chr11:118562799	C/A	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.77e-10	Serum metabolite levels;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg14671364	chr1:107599128	PRMT6	-0.54	-7.93	-0.39	3.08e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.48	6.95	0.35	1.81e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.47	-7.56	-0.38	3.74e-13	Diastolic blood pressure;
LIHC	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	0.95	13.92	0.6	3.3e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs1204798	0.589	rs6909133	chr6:116601532	A/G	cg23214565	chr6:116600728	DSE;TSPYL1	-0.42	-6.16	-0.32	2e-9	Dental caries;
LIHC	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.55	8.23	0.41	4.09e-15	Response to antidepressants and depression;
LIHC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg19645103	chr12:69753606	YEATS4	-0.45	-6.15	-0.32	2.17e-9	Response to diuretic therapy;
LIHC	cis	rs17125944	0.615	rs1998779	chr14:53295950	T/A	cg00686598	chr14:53173677	PSMC6	-0.82	-9.68	-0.46	9.22e-20	Alzheimer's disease (late onset);
LIHC	cis	rs2797369	0.546	rs11963911	chr6:101308421	T/C	cg12253828	chr6:101329408	ASCC3	0.44	6.37	0.33	6.13e-10	Renal function-related traits (eGRFcrea);
LIHC	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.78	-0.39	8.9e-14	Coronary artery disease;
LIHC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.98	0.54	7.74e-28	Colorectal cancer;
LIHC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.04	-0.48	5.98e-21	Response to antipsychotic treatment;
LIHC	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-10.88	-0.51	6.85e-24	Myopia (pathological);
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.74	13.21	0.58	1.74e-32	Prudent dietary pattern;
LIHC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.11	-0.36	6.68e-12	Personality dimensions;
LIHC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	6.82	0.35	4.02e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg11062466	chr8:58055876	NA	0.39	5.72	0.3	2.34e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.72	-0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	6.86	0.35	3.3e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.62	0.38	2.44e-13	Prudent dietary pattern;
LIHC	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.47	-0.37	6.61e-13	Response to antipsychotic treatment;
LIHC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	8.07	0.4	1.18e-14	Platelet count;
LIHC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg04310649	chr10:35416472	CREM	-0.43	-5.9	-0.3	8.97e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	11.55	0.53	2.9e-26	Coronary artery disease;
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg16070018	chr6:26224392	HIST1H3E	0.59	7.45	0.37	7.55e-13	Gout;Renal underexcretion gout;
LIHC	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg16724585	chr3:197361211	NA	-0.46	-6.44	-0.33	4.17e-10	Pancreatic cancer;
LIHC	trans	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.37	-0.33	6.01e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.84e-10	Diabetic kidney disease;
LIHC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.9e-10	Menarche (age at onset);
LIHC	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg00935119	chr6:36647544	CDKN1A	0.46	6.56	0.33	1.94e-10	QRS duration;
LIHC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.84	0.3	1.19e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.35	-0.37	1.52e-12	Body mass index;
LIHC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24110177	chr3:50126178	RBM5	0.42	6.49	0.33	3.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.73	-8.91	-0.43	3.1e-17	Body mass index;
LIHC	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.0	19.33	0.72	8.35e-57	Exhaled nitric oxide output;
LIHC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.82	9.83	0.47	3.08e-20	Bladder cancer;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.41	0.8	6.42e-77	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11102324	chr15:49658865	C15orf33	0.41	6.09	0.31	3.11e-9	Pancreatic cancer;
LIHC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.57	-0.38	3.57e-13	Alzheimer's disease;
LIHC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.43	5.9	0.3	8.51e-9	Iron status biomarkers;
LIHC	cis	rs12611088	0.600	rs12978269	chr19:44004419	T/C	cg13740135	chr19:44006432	PHLDB3	-0.43	-6.24	-0.32	1.28e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.58	6.42	0.33	4.49e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.76	-8.12	-0.4	8.74e-15	Putamen volume;
LIHC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.35	-7.15	-0.36	5.46e-12	Bone mineral density;
LIHC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.72	-14.01	-0.6	1.41e-35	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.78	-7.26	-0.37	2.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2257205	0.667	rs6503872	chr17:56696008	C/T	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.8	-0.35	4.72e-11	Response to antipsychotic treatment;
LIHC	cis	rs6448317	0.556	rs6814108	chr4:24904781	C/T	cg21108841	chr4:24914750	CCDC149	0.52	6.39	0.33	5.45e-10	Heschl's gyrus morphology;
LIHC	cis	rs2257205	0.667	rs8070007	chr17:56709169	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.43	7.7	0.38	1.46e-13	Capecitabine sensitivity;
LIHC	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.53	-0.33	2.36e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.38	-6.0	-0.31	4.93e-9	Testicular germ cell tumor;
LIHC	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.87	15.81	0.65	1.15e-42	Body mass index;
LIHC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.98	-18.68	-0.71	3.49e-54	Breast cancer;
LIHC	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg03689076	chr20:33865952	NA	0.57	6.7	0.34	8.63e-11	Attention deficit hyperactivity disorder;
LIHC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.28	-0.49	8.82e-22	Type 2 diabetes;
LIHC	cis	rs151997	0.538	rs62367392	chr5:50270298	T/C	cg06027927	chr5:50259733	NA	0.54	6.41	0.33	4.87e-10	Callous-unemotional behaviour;
LIHC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.86	0.35	3.29e-11	Diabetic kidney disease;
LIHC	trans	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg04702396	chr17:15466718	FAM18B2	0.44	6.65	0.34	1.18e-10	Educational attainment (years of education);
LIHC	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.6	9.57	0.46	2.3e-19	White matter hyperintensity burden;
LIHC	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg00277334	chr10:82204260	NA	-0.51	-6.3	-0.32	9.21e-10	Post bronchodilator FEV1;
LIHC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg26441486	chr22:50317300	CRELD2	0.39	6.64	0.34	1.21e-10	Schizophrenia;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.67	10.06	0.48	5.03e-21	Menarche (age at onset);
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg26338869	chr17:61819248	STRADA	0.52	6.89	0.35	2.61e-11	Height;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.28	-0.32	1.01e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs1144333	0.655	rs76612182	chr1:76451889	C/T	cg10154597	chr10:134910271	GPR123	0.31	6.11	0.31	2.72e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.44	-0.45	5.93e-19	Bipolar disorder;
LIHC	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.67	13.33	0.58	6e-33	Leprosy;
LIHC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.0	-0.44	1.55e-17	Obesity-related traits;
LIHC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg18016565	chr1:150552671	MCL1	0.52	9.7	0.46	8.02e-20	Melanoma;
LIHC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.26	-0.37	2.68e-12	Body mass index;
LIHC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.83	6.98	0.35	1.55e-11	Body mass index;
LIHC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.51	8.75	0.43	1.02e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.66	-13.85	-0.6	6.4e-35	Brugada syndrome;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.99	-0.31	5.41e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs59901009	1.000	rs59901009	chr11:10178437	T/C	cg01453529	chr11:10209919	SBF2	-0.3	-5.89	-0.3	9.4e-9	Hematocrit;Hemoglobin concentration;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg05904041	chr7:4802774	FOXK1	0.61	6.29	0.32	9.48e-10	Mean platelet volume;
LIHC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.65	-0.42	2.09e-16	Primary biliary cholangitis;
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.35	-7.53	-0.38	4.51e-13	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs903552	1.000	rs4965872	chr15:102004002	C/T	cg00659931	chr15:102010125	PCSK6	-0.45	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.79	9.51	0.46	3.56e-19	Cognitive function;
LIHC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg00204512	chr16:28754710	NA	0.37	6.64	0.34	1.2e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg01843034	chr6:37503916	NA	-0.37	-5.95	-0.31	6.61e-9	Cognitive performance;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg06853376	chr5:125937059	PHAX	0.42	6.64	0.34	1.24e-10	Calcium levels;
LIHC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg09417038	chr21:47716443	C21orf57	-0.5	-7.36	-0.37	1.35e-12	Testicular germ cell tumor;
LIHC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.28	0.37	2.37e-12	Lung cancer in ever smokers;
LIHC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.72	12.26	0.55	6.95e-29	Menopause (age at onset);
LIHC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.57	6.35	0.32	6.75e-10	Axial length;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26512142	chr11:2554198	KCNQ1	0.4	6.36	0.33	6.51e-10	Pancreatic cancer;
LIHC	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg00204512	chr16:28754710	NA	-0.36	-6.78	-0.34	5.34e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.44	5.81	0.3	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.09	-0.48	3.82e-21	Response to antipsychotic treatment;
LIHC	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg08126542	chr6:37504118	NA	-0.39	-6.15	-0.32	2.16e-9	Cognitive performance;
LIHC	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.96	0.31	6.2e-9	Rheumatoid arthritis;
LIHC	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg01864836	chr14:55583639	NA	-0.44	-8.26	-0.41	3.22e-15	Protein biomarker;
LIHC	trans	rs783540	1.000	rs803688	chr15:83216793	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.46	-0.37	6.98e-13	Schizophrenia;
LIHC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.99	-0.51	2.9e-24	Mean corpuscular volume;
LIHC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.49	-7.3	-0.37	2.08e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.4	-5.74	-0.3	2.14e-8	Longevity;
LIHC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs4407350	0.870	rs5765712	chr22:44914711	A/G	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.2	-0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.91	0.35	2.31e-11	Alzheimer's disease;
LIHC	cis	rs9596863	0.898	rs9568904	chr13:54330100	A/G	ch.13.53330881F	chr13:54432880	NA	0.44	6.04	0.31	4e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.94	14.88	0.63	5.99e-39	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.73	-12.33	-0.55	3.76e-29	Systemic lupus erythematosus;
LIHC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.75	0.39	1.03e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1789	0.786	rs6414768	chr4:15695363	A/G	cg16509355	chr4:15471240	CC2D2A	-0.46	-6.92	-0.35	2.29e-11	Blood protein levels;
LIHC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.07	25.66	0.81	1.04e-81	IgG glycosylation;
LIHC	cis	rs1983891	0.874	rs1326322	chr6:41512462	G/T	cg20194872	chr6:41519635	FOXP4	0.41	6.64	0.34	1.23e-10	Prostate cancer;
LIHC	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07305463	chr2:136567211	LCT	-0.38	-5.88	-0.3	9.67e-9	Corneal structure;
LIHC	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.6	0.34	1.59e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.74	13.37	0.59	4.2e-33	Ewing sarcoma;
LIHC	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.19	-0.36	4.04e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.46	-7.7	-0.38	1.45e-13	Lung cancer;
LIHC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.37	0.45	9.83e-19	Hemoglobin concentration;
LIHC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.72	-10.36	-0.49	4.68e-22	IgG glycosylation;
LIHC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg06012730	chr15:75315579	PPCDC	-0.32	-5.94	-0.31	7.02e-9	Blood trace element (Zn levels);
LIHC	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.65	6.57	0.33	1.86e-10	Lymphocyte counts;
LIHC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg12661370	chr5:149340060	SLC26A2	-0.5	-5.97	-0.31	5.81e-9	HIV-1 control;
LIHC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.74	14.44	0.62	2.96e-37	Mortality in heart failure;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19687152	chr14:102968497	TECPR2	0.43	6.16	0.32	2.02e-9	Myopia (pathological);
LIHC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	8.29	0.41	2.58e-15	Mean platelet volume;
LIHC	cis	rs2274273	0.624	rs8015211	chr14:55841447	A/G	cg01864836	chr14:55583639	NA	-0.35	-5.87	-0.3	1.03e-8	Protein biomarker;
LIHC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-6.67	-0.34	1.03e-10	Fear of minor pain;
LIHC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg14067834	chr17:29058358	SUZ12P	0.6	6.21	0.32	1.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.37	6.57	0.33	1.91e-10	Smoking behavior;
LIHC	cis	rs9918079	0.560	rs4557256	chr4:15626647	A/C	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.17	-0.36	4.71e-12	Obesity-related traits;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg19635926	chr16:89946313	TCF25	0.48	6.71	0.34	8.23e-11	Skin colour saturation;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17662584	chr22:40440687	TNRC6B	0.44	6.21	0.32	1.53e-9	Pancreatic cancer;
LIHC	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg16275483	chr1:110013120	SYPL2	-0.48	-5.94	-0.31	6.99e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.58	11.8	0.54	3.41e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg11764359	chr7:65958608	NA	0.57	5.82	0.3	1.39e-8	Diabetic kidney disease;
LIHC	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.29	-0.37	2.13e-12	Tuberculosis;
LIHC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.49	-8.78	-0.43	7.8e-17	Colorectal cancer;
LIHC	cis	rs8056893	0.714	rs1110570	chr16:68408119	G/C	cg02226672	chr16:68398533	SMPD3	0.42	5.9	0.3	8.72e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg03859395	chr2:55845619	SMEK2	-0.49	-8.18	-0.4	5.71e-15	Metabolic syndrome;
LIHC	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg19920283	chr7:105172520	RINT1	0.47	5.96	0.31	6.26e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.86	10.95	0.51	4.13e-24	Cognitive function;
LIHC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.45	-7.42	-0.37	9.54e-13	Menarche (age at onset);
LIHC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg17391518	chr19:59028285	ZBTB45	0.47	6.77	0.34	5.59e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.18	-0.44	4.1e-18	Bladder cancer;
LIHC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.5	8.58	0.42	3.41e-16	Methadone dose in opioid dependence;
LIHC	cis	rs2637266	0.626	rs846603	chr10:78570793	A/G	cg18941641	chr10:78392320	NA	-0.3	-6.33	-0.32	7.57e-10	Pulmonary function;
LIHC	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg02290350	chr8:58132656	NA	0.47	9.18	0.44	4.31e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg24693881	chr1:107596107	NA	0.56	9.71	0.46	7.52e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.51	-7.39	-0.37	1.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.58	0.46	2.13e-19	Bipolar disorder;
LIHC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.52	-6.84	-0.35	3.62e-11	Pancreatic cancer;
LIHC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.93	0.65	3.95e-43	Lymphocyte percentage of white cells;
LIHC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.88e-9	Body mass index;
LIHC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.65	10.83	0.51	1.09e-23	Smoking initiation;
LIHC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.03	14.59	0.62	7.75e-38	Cognitive function;
LIHC	cis	rs2073300	1.000	rs6114144	chr20:23462022	A/T	cg12062639	chr20:23401060	NAPB	0.78	9.75	0.47	5.71e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11056748	chr11:66036038	RAB1B	-0.54	-6.05	-0.31	3.73e-9	Systolic blood pressure;
LIHC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Body mass index;
LIHC	cis	rs7124681	0.505	rs7126378	chr11:47585348	G/T	cg20307385	chr11:47447363	PSMC3	0.8	12.07	0.55	3.5e-28	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg14440974	chr22:39074834	NA	-0.35	-6.04	-0.31	4.09e-9	Menopause (age at onset);
LIHC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.4	6.45	0.33	3.78e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg12379764	chr21:47803548	PCNT	0.73	10.45	0.49	2.21e-22	Lymphocyte counts;
LIHC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.57	10.49	0.49	1.7e-22	Alzheimer's disease (late onset);
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07424592	chr7:64974309	NA	-0.44	-6.72	-0.34	7.5e-11	Calcium levels;
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.67	-12.34	-0.56	3.32e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.55	10.17	0.48	2.04e-21	Lewy body disease;
LIHC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.06	-0.44	1e-17	Ulcerative colitis;
LIHC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.65	6.1	0.31	2.95e-9	Menopause (age at onset);
LIHC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.44	0.37	8.29e-13	Lung cancer in ever smokers;
LIHC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg04719120	chr6:96025338	MANEA	0.64	6.78	0.34	5.19e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	0.65	9.37	0.45	1e-18	Left atrial antero-posterior diameter;
LIHC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.36	-7.04	-0.36	1.03e-11	Body mass index;
LIHC	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	7.01	0.35	1.31e-11	Blood protein levels;
LIHC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	5.73	0.3	2.24e-8	Schizophrenia;
LIHC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.27	0.41	2.94e-15	Schizophrenia;
LIHC	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.49	6.08	0.31	3.22e-9	Interleukin-17 levels;
LIHC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg00409905	chr10:38381863	ZNF37A	0.42	6.4	0.33	5.14e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg10621924	chr7:39171070	POU6F2	0.42	6.51	0.33	2.67e-10	IgG glycosylation;
LIHC	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.25	13.63	0.59	4.42e-34	Opioid sensitivity;
LIHC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.67	9.47	0.46	4.64e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07677032	chr17:61819896	STRADA	0.44	6.35	0.32	6.89e-10	Prudent dietary pattern;
LIHC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg24879335	chr3:133465180	TF	0.26	5.89	0.3	9.49e-9	Iron status biomarkers;
LIHC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.83	-0.3	1.26e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.86	-0.43	4.32e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.84	-0.35	3.73e-11	Personality dimensions;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg03721293	chr16:90014378	DEF8	0.37	6.47	0.33	3.37e-10	Interleukin-17 levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19102404	chr1:116941269	C1orf203;ATP1A1	-0.36	-6.3	-0.32	9.36e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-6.25	-0.32	1.19e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.98	-0.31	5.63e-9	Colorectal cancer;
LIHC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg24849736	chr1:201084428	NA	-0.38	-7.41	-0.37	1.01e-12	Permanent tooth development;
LIHC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.72	-10.09	-0.48	3.9e-21	Colorectal cancer;
LIHC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.01	0.31	4.66e-9	Resting heart rate;
LIHC	cis	rs7091068	0.566	rs1326220	chr10:95486155	G/A	cg20715218	chr10:95462985	C10orf4	0.58	6.18	0.32	1.86e-9	Urinary tract infection frequency;
LIHC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.2	-0.32	1.67e-9	Schizophrenia;
LIHC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.59	10.46	0.49	2.08e-22	Dupuytren's disease;
LIHC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.53	7.69	0.38	1.58e-13	Type 2 diabetes;
LIHC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-13.43	-0.59	2.64e-33	Vitiligo;
LIHC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.48	-8.15	-0.4	6.74e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.35	-7.06	-0.36	9.56e-12	Body mass index;
LIHC	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.52	-7.17	-0.36	4.66e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14067834	chr17:29058358	SUZ12P	-0.59	-6.34	-0.32	7.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg12064134	chr16:90016061	DEF8	0.35	5.86	0.3	1.11e-8	Squamous cell carcinoma;
LIHC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.32	-11.06	-0.51	1.68e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg20607798	chr8:58055168	NA	0.5	6.16	0.32	2.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.45	5.96	0.31	6.11e-9	Alzheimer's disease;
LIHC	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.81	0.54	3.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.15	0.52	7.72e-25	Colorectal cancer;
LIHC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18357526	chr6:26021779	HIST1H4A	0.81	11.32	0.52	1.89e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.59	9.4	0.45	8.27e-19	Crohn's disease;
LIHC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.79	-0.34	4.84e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.94	-0.39	2.94e-14	Pulse pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19787033	chr11:77850962	ALG8	0.45	6.26	0.32	1.13e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.65	0.62	4.57e-38	Prudent dietary pattern;
LIHC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg25356066	chr3:128598488	ACAD9	0.52	7.21	0.36	3.68e-12	IgG glycosylation;
LIHC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg06598544	chr20:61472147	COL9A3	0.8	7.97	0.4	2.46e-14	Obesity-related traits;
LIHC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.38	-0.33	5.61e-10	Menarche (age at onset);
LIHC	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.73	-0.3	2.16e-8	Red blood cell count;
LIHC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	0.99	6.93	0.35	2.11e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs10915437	0.531	rs4233259	chr1:4197842	G/A	cg23269655	chr10:75541687	CHCHD1	0.41	6.04	0.31	3.99e-9	Migraine - clinic-based;
LIHC	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.08	0.31	3.13e-9	Protein biomarker;
LIHC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.9	12.45	0.56	1.36e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg10018233	chr7:150070692	REPIN1	0.56	8.61	0.42	2.75e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.08e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24294857	chr1:20812821	CAMK2N1	0.4	6.12	0.31	2.53e-9	Lung function (FEV1/FVC);
LIHC	trans	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg09872104	chr7:134855509	C7orf49	-0.78	-6.18	-0.32	1.84e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs9596863	0.898	rs34617186	chr13:54370594	A/G	ch.13.53330881F	chr13:54432880	NA	0.43	5.79	0.3	1.63e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg20487152	chr13:99095054	FARP1	-0.39	-6.3	-0.32	9.4e-10	Neuroticism;
LIHC	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg03146154	chr1:46216737	IPP	-0.4	-6.55	-0.33	2.11e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.94	-11.68	-0.53	9.75e-27	Body mass index;
LIHC	trans	rs13405020	0.578	rs1453290	chr2:138219404	T/C	cg10008445	chr10:105630969	NA	-0.37	-6.09	-0.31	2.99e-9	Non-small cell lung cancer;
LIHC	cis	rs365132	0.875	rs187114	chr5:176364039	A/G	cg16309518	chr5:176445507	NA	-0.53	-9.84	-0.47	2.76e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	cis	rs1863824	0.625	rs10887600	chr10:88169072	C/T	cg07322936	chr10:88137208	NA	-0.47	-5.99	-0.31	5.43e-9	Schizophrenia;
LIHC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.51	7.75	0.39	1.03e-13	Obesity-related traits;
LIHC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.37	-6.73	-0.34	7.2e-11	Aortic root size;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.4	-5.94	-0.31	7.06e-9	Longevity;Endometriosis;
LIHC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg09222892	chr1:25734099	RHCE	-0.44	-8.1	-0.4	9.96e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg02640540	chr1:67518911	SLC35D1	-0.48	-7.47	-0.37	6.83e-13	Lymphocyte percentage of white cells;
LIHC	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.8	12.06	0.55	3.89e-28	Subjective well-being;
LIHC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg21522988	chr12:29376872	FAR2	0.3	7.0	0.35	1.33e-11	QT interval;
LIHC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	6.37	0.33	6.04e-10	Height;
LIHC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg25344623	chr2:136566232	LCT	0.42	8.59	0.42	3.11e-16	Mosquito bite size;
LIHC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.57	-9.53	-0.46	3.09e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	8.5	0.42	6.15e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.33	5.74	0.3	2.08e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.32	-5.91	-0.3	8.38e-9	Lewy body disease;
LIHC	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	10.45	0.49	2.24e-22	Response to antipsychotic treatment;
LIHC	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.76	-8.61	-0.42	2.67e-16	Exhaled nitric oxide output;
LIHC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.49	8.09	0.4	1.06e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.51	9.02	0.44	1.35e-17	Coronary artery disease;
LIHC	trans	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.79	12.8	0.57	6.35e-31	Longevity;
LIHC	cis	rs17286411	0.671	rs8062477	chr16:71803974	A/G	cg06353428	chr16:71660113	MARVELD3	-0.42	-6.18	-0.32	1.83e-9	Blood protein levels;
LIHC	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.49	8.93	0.43	2.72e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.37	-0.45	1.05e-18	Alzheimer's disease;
LIHC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg23791538	chr6:167370224	RNASET2	0.4	6.45	0.33	3.84e-10	Primary biliary cholangitis;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.75	13.41	0.59	2.94e-33	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.72	-0.3	2.32e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.54	-9.81	-0.47	3.59e-20	Total body bone mineral density;
LIHC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.58	0.56	4.5e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12315590	chr3:128997497	C3orf37	0.42	6.63	0.34	1.3100000000000001e-10	Cognitive function;
LIHC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.53	-7.35	-0.37	1.45e-12	Body mass index;
LIHC	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.6	9.82	0.47	3.28e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.73	14.04	0.6	1.08e-35	Mortality in heart failure;
LIHC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.53	7.38	0.37	1.25e-12	Height;
LIHC	cis	rs3780378	0.840	rs10119004	chr9:5071049	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.21	-0.45	3.25e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.55	7.18	0.36	4.48e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-9.47	-0.46	4.91e-19	Longevity;Endometriosis;
LIHC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-6.56	-0.33	2.05e-10	Chronic sinus infection;
LIHC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs7173389	0.530	rs6495062	chr15:73682691	T/C	cg01796676	chr15:73680284	NA	0.53	8.69	0.43	1.56e-16	Resting heart rate;
LIHC	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.64	-10.91	-0.51	5.46e-24	Coronary artery disease;
LIHC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.79	0.39	8.01e-14	Mean platelet volume;
LIHC	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.89	-10.0	-0.48	8.11e-21	Facial emotion recognition (sad faces);
LIHC	cis	rs1865721	1.000	rs11659761	chr18:73186974	A/G	cg26385618	chr18:73139727	C18orf62	-0.26	-6.66	-0.34	1.08e-10	Intelligence;
LIHC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-9.08	-0.44	8.78e-18	Parkinson's disease;
LIHC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.74	13.42	0.59	2.82e-33	Platelet count;
LIHC	cis	rs10878977	0.565	rs7295234	chr12:69811369	A/C	cg17330252	chr12:69809627	NA	0.37	5.82	0.3	1.34e-8	Colorectal cancer;
LIHC	cis	rs911119	0.913	rs12710327	chr20:23569689	C/T	cg16589663	chr20:23618590	CST3	0.68	7.12	0.36	6.6e-12	Chronic kidney disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22843129	chr8:669177	ERICH1	0.4	6.18	0.32	1.83e-9	Longevity;
LIHC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.0	-0.35	1.39e-11	Vitiligo;
LIHC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg17294928	chr15:75287854	SCAMP5	0.47	6.27	0.32	1.1e-9	Lung cancer;
LIHC	cis	rs3733606	0.538	rs11734099	chr4:6891435	G/A	cg05012661	chr4:6891264	NA	0.39	6.22	0.32	1.46e-9	Platelet count;
LIHC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.47	7.34	0.37	1.59e-12	Blood protein levels;
LIHC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.52	0.71	1.52e-53	Tonsillectomy;
LIHC	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.81	10.85	0.51	8.82e-24	Menopause (age at onset);
LIHC	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.64	-7.76	-0.39	1.01e-13	Body mass index;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.97	-0.35	1.6e-11	Diastolic blood pressure;
LIHC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.59	7.76	0.39	9.77e-14	Parkinson's disease;
LIHC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.43	6.29	0.32	9.83e-10	Height;
LIHC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg07706471	chr12:123319906	HIP1R	-0.63	-8.28	-0.41	2.88e-15	Schizophrenia;
LIHC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg03859395	chr2:55845619	SMEK2	0.92	15.71	0.65	3.07e-42	Metabolic syndrome;
LIHC	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.53	-8.59	-0.42	3.15e-16	Cocaine dependence;
LIHC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.65	-16.58	-0.67	9.67e-46	Breast cancer;
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.56	-9.77	-0.47	4.71e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1823913	0.927	rs35339956	chr2:192126394	C/T	cg12404831	chr2:192114017	MYO1B	0.33	6.69	0.34	9.35e-11	Obesity-related traits;
LIHC	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg03934865	chr2:198174659	NA	0.49	6.95	0.35	1.89e-11	Dermatomyositis;
LIHC	cis	rs4689642	0.756	rs4689089	chr4:7225587	C/G	cg21353189	chr4:7228343	SORCS2	0.38	6.46	0.33	3.51e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg19318889	chr4:1322082	MAEA	0.4	5.77	0.3	1.81e-8	Obesity-related traits;
LIHC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.68	8.5	0.42	5.94e-16	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	0.53	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.41	6.07	0.31	3.43e-9	Post bronchodilator FEV1;
LIHC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.64	10.52	0.49	1.31e-22	Resting heart rate;
LIHC	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	0.86	11.16	0.52	7.22e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.46	0.33	3.64e-10	Cervical cancer;
LIHC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg02269571	chr22:50332266	NA	-0.65	-8.73	-0.43	1.17e-16	Schizophrenia;
LIHC	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.41	-0.33	4.88e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.52	-0.33	2.55e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg03934865	chr2:198174659	NA	0.46	6.64	0.34	1.25e-10	Dermatomyositis;
LIHC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg07451762	chr16:28383216	NA	0.31	5.94	0.31	7.12e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-0.95	-22.99	-0.78	2.31e-71	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.86	0.6	5.82e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.48	5.9	0.3	8.57e-9	Neuroblastoma;
LIHC	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.48	7.67	0.38	1.8e-13	Corneal astigmatism;
LIHC	cis	rs483180	0.512	rs866321	chr1:120224469	T/C	cg19096424	chr1:120255104	PHGDH	0.62	7.62	0.38	2.54e-13	Macular telangiectasia type 2;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.69	8.23	0.41	3.93e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09597638	chr17:3907349	NA	0.61	10.74	0.5	2.17e-23	Type 2 diabetes;
LIHC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.27	-0.41	3.08e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.9	-0.3	8.6e-9	Personality dimensions;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.35	1.23e-11	Diabetic kidney disease;
LIHC	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.51	6.17	0.32	1.9e-9	Economic and political preferences (feminism/equality);
LIHC	trans	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg15676719	chr1:167598521	RCSD1	-0.37	-6.65	-0.34	1.18e-10	Systemic lupus erythematosus;
LIHC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.69	-12.41	-0.56	1.86e-29	Obesity-related traits;
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.1	-0.31	2.92e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	0.85	11.76	0.54	4.68e-27	Skin colour saturation;
LIHC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.81	0.39	6.99e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.74	0.34	6.57e-11	Heart rate;
LIHC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.6	10.07	0.48	4.76e-21	Resting heart rate;
LIHC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.8	7.82	0.39	6.44e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg19318889	chr4:1322082	MAEA	0.47	6.55	0.33	2.13e-10	Obesity-related traits;
LIHC	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.73	-9.04	-0.44	1.23e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.23	0.81	4.46e-80	Prudent dietary pattern;
LIHC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.79	10.34	0.49	5.46e-22	Body mass index;
LIHC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg16586182	chr3:47516702	SCAP	0.61	11.95	0.54	9.64e-28	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.5	0.56	8.65e-30	Electrocardiographic conduction measures;
LIHC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.17	12.95	0.57	1.73e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.15	-0.32	2.13e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.08	24.35	0.8	1.1e-76	IgG glycosylation;
LIHC	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg22771759	chr13:24902376	NA	0.31	6.47	0.33	3.49e-10	Obesity-related traits;
LIHC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg23533926	chr12:111358616	MYL2	-0.32	-6.23	-0.32	1.39e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12744310	0.887	rs12724625	chr1:41782270	G/C	cg03962019	chr1:41807865	NA	0.39	6.23	0.32	1.38e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.74	12.32	0.55	4.17e-29	Aortic root size;
LIHC	cis	rs13161895	0.887	rs863231	chr5:179409613	C/T	cg06664874	chr5:179499304	RNF130	0.49	6.35	0.32	6.84e-10	LDL cholesterol;
LIHC	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg20991723	chr1:152506922	NA	0.54	9.36	0.45	1.12e-18	Hair morphology;
LIHC	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.95	-0.44	2.37e-17	Coffee consumption (cups per day);
LIHC	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg18081818	chr7:23246105	NA	-0.46	-7.08	-0.36	8.25e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.69	12.04	0.55	4.33e-28	Colorectal cancer;
LIHC	cis	rs12744310	0.887	rs35807669	chr1:41801652	C/T	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.44	-7.26	-0.37	2.63e-12	IgG glycosylation;
LIHC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.38e-17	Recombination rate (females);
LIHC	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.23	6.33	0.32	7.68e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.42	-7.07	-0.36	8.8e-12	Breast cancer;
LIHC	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.4	5.84	0.3	1.19e-8	Life satisfaction;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02290350	chr8:58132656	NA	0.5	10.4	0.49	3.31e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs35883536	1.000	rs12409831	chr1:101107670	A/T	cg14515779	chr1:101123966	NA	-0.67	-13.22	-0.58	1.65e-32	Monocyte count;
LIHC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.24	0.52	3.71e-25	Monocyte percentage of white cells;
LIHC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	11.39	0.52	1.05e-25	Menarche (age at onset);
LIHC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.94	-10.98	-0.51	3.04e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.71	0.34	8.1e-11	Red blood cell count;
LIHC	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg23422044	chr7:1970798	MAD1L1	-0.54	-8.95	-0.44	2.24e-17	Bipolar disorder;
LIHC	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.15	0.36	5.43e-12	Breast cancer;
LIHC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.23	-0.36	3.08e-12	Migraine;Coronary artery disease;
LIHC	cis	rs244293	0.965	rs244352	chr17:53195478	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.51	7.52	0.38	4.77e-13	Menarche (age at onset);
LIHC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.52	8.21	0.41	4.63e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.92	17.07	0.68	1.09e-47	Menopause (age at onset);
LIHC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg20026190	chr17:76395443	PGS1	0.45	7.04	0.36	1.09e-11	HDL cholesterol levels;
LIHC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.64	0.38	2.14e-13	IgG glycosylation;
LIHC	cis	rs11212737	0.765	rs2624146	chr11:108520716	G/C	cg22776369	chr11:108536276	DDX10	0.38	6.32	0.32	8.28e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	0.67	6.61	0.34	1.46e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg00792783	chr2:198669748	PLCL1	-0.44	-6.39	-0.33	5.42e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.93	-0.31	7.49e-9	Coronary artery disease;
LIHC	cis	rs10744422	0.800	rs6489240	chr12:123275030	T/C	cg25930673	chr12:123319894	HIP1R	-0.83	-10.27	-0.49	9.91e-22	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg05590025	chr7:65112418	INTS4L2	-0.53	-5.75	-0.3	2.01e-8	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg18306943	chr3:40428807	ENTPD3	0.37	6.47	0.33	3.44e-10	Renal cell carcinoma;
LIHC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	7.85	0.39	5.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.51	-0.53	3.76e-26	Coronary artery disease;
LIHC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs7395581	0.959	rs2167079	chr11:47270255	C/T	cg25783544	chr11:47291846	MADD	0.43	6.34	0.32	7.42e-10	HDL cholesterol;
LIHC	cis	rs10838687	0.736	rs11039144	chr11:47264044	G/A	cg25783544	chr11:47291846	MADD	0.46	5.78	0.3	1.64e-8	Proinsulin levels;
LIHC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg12798992	chr6:167411361	FGFR1OP	0.53	8.29	0.41	2.58e-15	Crohn's disease;
LIHC	trans	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg26939375	chr7:64535504	NA	-0.4	-6.27	-0.32	1.08e-9	Aortic root size;
LIHC	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.71	-12.63	-0.56	2.79e-30	Height;
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg07234388	chr1:156261841	TMEM79	0.51	9.21	0.45	3.42e-18	Tonsillectomy;
LIHC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.35	-0.37	1.47e-12	Body mass index;
LIHC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.44	-0.33	4.09e-10	Colorectal cancer;
LIHC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.76	15.25	0.64	1.91e-40	Mortality in heart failure;
LIHC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.84	14.14	0.61	4.57e-36	Coronary artery disease;
LIHC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.35	-6.37	-0.33	6.12e-10	Aortic root size;
LIHC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26913058	chr16:419975	MRPL28	0.5	7.76	0.39	9.8e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.41	-6.76	-0.34	5.8200000000000003e-11	Mean corpuscular volume;
LIHC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.58	9.58	0.46	2.05e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.51	8.22	0.41	4.13e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg18478394	chr8:109455254	TTC35	0.41	7.1	0.36	7.08e-12	Dupuytren's disease;
LIHC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.6	-7.41	-0.37	1.01e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.79	0.39	8.37e-14	Prudent dietary pattern;
LIHC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg15017067	chr4:17643749	FAM184B	-0.33	-5.84	-0.3	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-0.84	-15.35	-0.64	7.87e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.36	6.16	0.32	2.09e-9	Cognitive performance;
LIHC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.47	7.4	0.37	1.07e-12	Longevity;
LIHC	cis	rs526821	0.595	rs504661	chr11:55312683	A/G	cg04317927	chr11:55418816	OR4S2	0.47	9.04	0.44	1.17e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs1198430	0.683	rs7551124	chr1:23785760	C/T	cg19827787	chr1:23763612	ASAP3	0.31	6.68	0.34	9.89e-11	Total cholesterol levels;
LIHC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.59	-10.95	-0.51	4.18e-24	Menopause (age at onset);
LIHC	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.45	6.92	0.35	2.2e-11	Thyroid stimulating hormone;
LIHC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.84	14.14	0.61	4.52e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1030268	0.546	rs12707100	chr7:133274376	T/C	cg10665199	chr7:133106180	EXOC4	0.5	5.98	0.31	5.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	6.02e-12	Diabetic kidney disease;
LIHC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg18912006	chr12:123335444	HIP1R	-0.56	-6.69	-0.34	8.9e-11	Schizophrenia;
LIHC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.43	6.35	0.32	6.72e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.07e-8	Electroencephalogram traits;
LIHC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.45e-11	Height;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg09623986	chr2:74753896	AUP1;DQX1	0.44	6.67	0.34	1.03e-10	Alopecia areata;
LIHC	trans	rs7668874	0.779	rs9784432	chr4:116742879	A/C	cg08917878	chr5:172668965	NA	-0.3	-6.05	-0.31	3.89e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.02	0.51	2.26e-24	Coffee consumption (cups per day);
LIHC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	8.08	0.4	1.1e-14	Platelet count;
LIHC	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17467752	chr17:38218738	THRA	-0.55	-9.24	-0.45	2.75e-18	Myeloid white cell count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18615184	chr17:61678500	TACO1	0.5	7.14	0.36	5.74e-12	Lung function (FEV1/FVC);
LIHC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.3	-6.88	-0.35	2.88e-11	Menarche (age at onset);
LIHC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.02e-11	Red blood cell count;
LIHC	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.62	-9.69	-0.46	9.19e-20	Schizophrenia;
LIHC	cis	rs12602486	1.000	rs76913347	chr17:42267048	C/T	cg13607699	chr17:42295918	UBTF	-0.76	-6.42	-0.33	4.65e-10	Glycated hemoglobin levels;
LIHC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.53	-6.87	-0.35	3.13e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.44	6.46	0.33	3.67e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg20607798	chr8:58055168	NA	0.49	6.3	0.32	9.41e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.78	-0.43	8.15e-17	Monocyte count;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08219700	chr8:58056026	NA	-0.5	-6.84	-0.35	3.72e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.97	-0.7	2.53e-51	Schizophrenia;
LIHC	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.63	-6.78	-0.34	5.27e-11	Bipolar disorder;
LIHC	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.42	-0.37	9.23e-13	Adiposity;
LIHC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.71	-6.43	-0.33	4.3e-10	Mean corpuscular hemoglobin;
LIHC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.4	-6.12	-0.31	2.5e-9	Longevity;Endometriosis;
LIHC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.82	-0.3	1.33e-8	Mean corpuscular volume;
LIHC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.79	12.23	0.55	9.12e-29	Multiple system atrophy;
LIHC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.56	8.23	0.41	4.1e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.03	-0.31	4.36e-9	Obesity-related traits;
LIHC	cis	rs9378688	0.654	rs12191002	chr6:2362070	A/G	cg12303981	chr6:2244766	GMDS	0.45	6.28	0.32	1.05e-9	Caudate nucleus volume;
LIHC	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg14393609	chr7:65229607	NA	-0.36	-5.86	-0.3	1.09e-8	Aortic root size;
LIHC	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.6	0.38	2.88e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	11.76	0.54	4.85e-27	Post bronchodilator FEV1;
LIHC	trans	rs6934970	1.000	rs12190989	chr6:113093127	C/T	cg09308777	chr6:169852575	NA	0.62	6.16	0.32	2.08e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.78e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.75	13.68	0.59	2.85e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.76	-15.54	-0.64	1.45e-41	Refractive error;
LIHC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.39	-6.3	-0.32	9.2e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg22771759	chr13:24902376	NA	0.32	6.76	0.34	5.8e-11	Obesity-related traits;
LIHC	cis	rs62179067	0.708	rs17363057	chr2:179936172	A/C	cg27622325	chr2:179545785	TTN	0.66	5.75	0.3	1.95e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg04160030	chr1:24195659	FUCA1	-0.36	-5.88	-0.3	9.82e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9309473	0.950	rs13391258	chr2:73848933	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.65	-0.34	1.13e-10	Metabolite levels;
LIHC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.9	-0.35	2.55e-11	Personality dimensions;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg13152130	chr6:118910203	C6orf204	-0.62	-6.59	-0.34	1.63e-10	Diastolic blood pressure;
LIHC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.51	7.76	0.39	1e-13	Cognitive function;
LIHC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.86	16.22	0.66	2.69e-44	Coronary artery disease;
LIHC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.9	-0.3	8.53e-9	Systemic lupus erythematosus;
LIHC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.7	0.34	8.77e-11	Mean corpuscular volume;
LIHC	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.86	0.35	3.21e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs4908768	0.501	rs6677736	chr1:8552804	A/T	cg20416874	chr1:8611966	RERE	-0.68	-14.36	-0.61	6.45e-37	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	0.8	7.53	0.38	4.68e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs7534824	0.582	rs61780297	chr1:101400855	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.41	0.37	1.02e-12	Refractive astigmatism;
LIHC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.86	14.45	0.62	2.9e-37	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.81	-9.74	-0.47	5.84e-20	Mean platelet volume;
LIHC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg25894440	chr7:65020034	NA	-0.54	-6.27	-0.32	1.08e-9	Diabetic kidney disease;
LIHC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.47	0.82	8.62e-85	Cognitive ability;
LIHC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.77	12.35	0.56	3.23e-29	Psoriasis;
LIHC	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.91	0.51	5.56e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.53	5.74	0.3	2.12e-8	Menopause (age at onset);
LIHC	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-9.77	-0.47	4.93e-20	Capecitabine sensitivity;
LIHC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	7.23	0.36	3.17e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg17623882	chr6:41773611	USP49	-0.44	-5.87	-0.3	1.04e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	1.03	15.33	0.64	9.68e-41	Breast cancer;
LIHC	cis	rs1144333	0.655	rs76992868	chr1:76418916	G/A	cg03433033	chr1:76189801	ACADM	0.53	7.56	0.38	3.79e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.19	-0.36	3.98e-12	Body mass index;
LIHC	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.31	5.72	0.3	2.34e-8	Body mass index;
LIHC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg25344623	chr2:136566232	LCT	-0.38	-6.1	-0.31	2.88e-9	Corneal structure;
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08280861	chr8:58055591	NA	0.49	6.14	0.31	2.35e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.33	2.39e-10	Vitiligo;
LIHC	trans	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.95	-0.35	1.91e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.64	8.63	0.42	2.37e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.47	6.85	0.35	3.37e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.06	-0.51	1.66e-24	Primary sclerosing cholangitis;
LIHC	cis	rs1144333	0.655	rs75578876	chr1:76395586	A/C	cg22875332	chr1:76189707	ACADM	0.42	6.29	0.32	9.69e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg18866267	chr4:3310044	NA	0.36	6.07	0.31	3.33e-9	Oropharynx cancer;
LIHC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.3	-0.32	9.19e-10	Tonsillectomy;
LIHC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	15.84	0.65	9.42e-43	Nonalcoholic fatty liver disease;
LIHC	cis	rs75908454	1.000	rs77344335	chr6:169948501	G/A	cg19338460	chr6:170058176	WDR27	-0.8	-7.48	-0.37	6.42e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs12744310	1.000	rs12722758	chr1:41757015	G/A	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.82e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.56	-5.92	-0.3	7.82e-9	Vitiligo;
LIHC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg08896387	chr1:24191740	FUCA1	0.38	6.05	0.31	3.89e-9	Immature fraction of reticulocytes;
LIHC	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg14515779	chr1:101123966	NA	-0.45	-6.38	-0.33	5.67e-10	Monocyte count;
LIHC	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.48	6.38	0.33	5.84e-10	Blood metabolite levels;
LIHC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.65	9.53	0.46	2.92e-19	Corneal astigmatism;
LIHC	cis	rs8010715	0.816	rs8015168	chr14:24599872	A/T	cg23112188	chr14:24563095	PCK2	-0.29	-6.08	-0.31	3.25e-9	IgG glycosylation;
LIHC	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-6.58	-0.34	1.73e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg24163568	chr5:669837	TPPP	0.39	8.26	0.41	3.2e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg15841412	chr13:111365552	ING1	0.51	6.46	0.33	3.53e-10	Coronary artery disease;
LIHC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.45	7.08	0.36	8.24e-12	Height;
LIHC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.57	-8.46	-0.42	7.89e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9309473	0.950	rs10189885	chr2:73877055	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.25	-0.32	1.23e-9	Metabolite levels;
LIHC	trans	rs983392	0.679	rs72920867	chr11:60005424	T/C	cg17275991	chr19:58003312	ZNF419	0.43	6.1	0.31	2.87e-9	Alzheimer's disease (late onset);
LIHC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg12373951	chr3:133503437	NA	0.45	7.25	0.36	2.84e-12	Iron status biomarkers (transferrin levels);
LIHC	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.58	-6.44	-0.33	3.96e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.6	-9.63	-0.46	1.41e-19	Lymphocyte counts;
LIHC	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.59	-6.33	-0.32	7.77e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.81	-0.35	4.5e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-1.03	-10.62	-0.5	5.67e-23	Schizophrenia;
LIHC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02985541	chr2:219472218	PLCD4	-0.42	-6.78	-0.34	5.31e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.51	0.62	1.6e-37	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08219700	chr8:58056026	NA	0.52	7.12	0.36	6.34e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.5	9.2	0.45	3.59e-18	Hemoglobin concentration;
LIHC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg06766960	chr11:133703094	NA	-0.61	-9.57	-0.46	2.2e-19	Childhood ear infection;
LIHC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.6	9.33	0.45	1.42e-18	Tonsillectomy;
LIHC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	0.96	20.63	0.74	5.47e-62	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21551704	chr5:80550860	RNU5E;RNU5D;CKMT2	0.44	6.19	0.32	1.77e-9	Hepatitis;
LIHC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg20283391	chr11:68216788	NA	-0.53	-8.12	-0.4	8.65e-15	Total body bone mineral density;
LIHC	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.4	5.78	0.3	1.64e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.76	13.44	0.59	2.3e-33	Prudent dietary pattern;
LIHC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-6.2	-0.32	1.63e-9	Type 2 diabetes;
LIHC	cis	rs7116495	1.000	rs12283462	chr11:71835406	T/G	cg26138937	chr11:71823887	C11orf51	0.82	8.33	0.41	2.03e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-6.08	-0.31	3.16e-9	Coronary artery disease;
LIHC	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg26939375	chr7:64535504	NA	0.43	6.82	0.35	4.11e-11	Aortic root size;
LIHC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27297192	chr10:134578999	INPP5A	0.54	8.24	0.41	3.74e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.74	0.3	2.07e-8	Height;
LIHC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg01069141	chr11:67398826	TBX10;NUDT8	0.36	6.34	0.32	7.21e-10	Mean corpuscular volume;
LIHC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.59	0.56	3.89e-30	Colorectal cancer;
LIHC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.56	8.47	0.42	7.22e-16	Platelet count;
LIHC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.51	-8.05	-0.4	1.38e-14	Educational attainment;
LIHC	cis	rs965469	1.000	rs6037526	chr20:3251248	T/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.84	-0.35	3.75e-11	IFN-related cytopenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09658576	chr7:139477957	TBXAS1;HIPK2	0.37	6.24	0.32	1.27e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.72	13.18	0.58	2.28e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12826209	chr6:26865740	GUSBL1	0.57	5.84	0.3	1.2e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.74	8.98	0.44	1.92e-17	Cognitive function;
LIHC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.63	5.82	0.3	1.35e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg24069376	chr3:38537580	EXOG	0.42	7.65	0.38	2.1e-13	Electrocardiographic conduction measures;
LIHC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg10986814	chr5:109025713	MAN2A1	-0.48	-6.51	-0.33	2.69e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.67	-8.39	-0.41	1.28e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6584283	0.716	rs10786558	chr10:101287610	G/A	cg17888390	chr10:101282816	NA	-0.31	-5.83	-0.3	1.31e-8	Ulcerative colitis;
LIHC	cis	rs7106204	0.609	rs12791360	chr11:24286239	T/G	ch.11.24196551F	chr11:24239977	NA	0.66	6.44	0.33	4.03e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02985541	chr2:219472218	PLCD4	0.43	7.96	0.4	2.57e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2257205	0.667	rs16943200	chr17:56829611	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.64	-0.34	1.21e-10	Pancreatic cancer;
LIHC	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.28	6.54	0.33	2.24e-10	Heart rate;
LIHC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.27	16.79	0.67	1.38e-46	Diabetic kidney disease;
LIHC	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg20634798	chr1:152595351	LCE3A	-0.31	-6.13	-0.31	2.44e-9	Psoriasis;
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg09417038	chr21:47716443	C21orf57	-0.46	-6.76	-0.34	5.8200000000000003e-11	Testicular germ cell tumor;
LIHC	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.67	-10.45	-0.49	2.33e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg20435097	chr10:126320824	FAM53B	-0.35	-5.86	-0.3	1.09e-8	Asthma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03352657	chr17:26684557	POLDIP2;TMEM199	-0.45	-6.78	-0.34	5.41e-11	Pancreatic cancer;
LIHC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.84	0.39	5.73e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.7	11.49	0.53	4.66e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.69e-11	Blood pressure;
LIHC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg23262073	chr20:60523788	NA	-0.29	-5.99	-0.31	5.42e-9	Body mass index;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.69	10.05	0.48	5.52e-21	Lymphocyte counts;
LIHC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	1.02	21.29	0.75	1.19e-64	Height;
LIHC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	1.0	16.28	0.66	1.57e-44	Metabolic syndrome;
LIHC	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.27	-14.1	-0.61	6.28e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25916527	chr5:72292534	FCHO2	-0.41	-6.34	-0.32	7.31e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.29	7.75	0.39	1.07e-13	Skin aging (microtopography measurement);
LIHC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.55	-0.38	3.91e-13	Response to antipsychotic treatment;
LIHC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-1.01	-21.86	-0.76	6.73e-67	Height;
LIHC	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.85	-0.3	1.17e-8	Coronary artery disease;
LIHC	cis	rs7707921	0.752	rs2897554	chr5:81276241	C/T	cg15871215	chr5:81402204	ATG10	0.6	6.93	0.35	2.17e-11	Breast cancer;
LIHC	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.37	5.95	0.31	6.5e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.1e-13	Prudent dietary pattern;
LIHC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-9.0	-0.44	1.6e-17	Coronary artery disease;
LIHC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg16479474	chr6:28041457	NA	0.39	6.68	0.34	9.59e-11	Cardiac Troponin-T levels;
LIHC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.8	0.34	4.81e-11	Primary biliary cholangitis;
LIHC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.53	5.77	0.3	1.82e-8	Menopause (age at onset);
LIHC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.12	0.31	2.57e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11110643	chr11:72929135	P2RY2	0.39	6.04	0.31	3.92e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.59	0.42	3.02e-16	Lung cancer in ever smokers;
LIHC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.42	6.3	0.32	9.2e-10	Menarche (age at onset);
LIHC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.71	-0.34	8e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Schizophrenia;
LIHC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.72	0.3	2.32e-8	Self-reported allergy;
LIHC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.47	7.4	0.37	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg23587288	chr2:27483067	SLC30A3	0.3	5.87	0.3	1.03e-8	Blood metabolite levels;
LIHC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg03517284	chr6:25882590	NA	-0.44	-6.64	-0.34	1.21e-10	Height;
LIHC	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.81	-10.66	-0.5	4.21e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	5.79	0.3	1.57e-8	Lung function (FEV1/FVC);
LIHC	trans	rs10411161	0.702	rs8110461	chr19:52383569	A/C	cg22319618	chr22:45562946	NUP50	-0.6	-8.08	-0.4	1.13e-14	Breast cancer;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21448741	chr8:58168803	NA	0.37	6.87	0.35	3.11e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.77	-0.39	9.02e-14	Response to antipsychotic treatment;
LIHC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.5	7.63	0.38	2.36e-13	Obesity-related traits;
LIHC	cis	rs16958440	0.867	rs74346439	chr18:44677467	G/C	cg17192377	chr18:44677553	HDHD2	0.93	8.68	0.42	1.66e-16	Sitting height ratio;
LIHC	cis	rs1144333	0.655	rs76532097	chr1:76320759	G/C	cg03433033	chr1:76189801	ACADM	0.58	8.65	0.42	1.97e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.39	6.14	0.32	2.24e-9	Melanoma;
LIHC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.74	-0.34	6.65e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-9.88	-0.47	2.07e-20	Body mass index (adult);
LIHC	cis	rs7945718	0.591	rs7102432	chr11:12700132	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.59	0.38	3.11e-13	Educational attainment (years of education);
LIHC	cis	rs7187994	0.848	rs34923260	chr16:84773460	A/G	cg07647771	chr16:84786436	USP10	-0.33	-5.73	-0.3	2.16e-8	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.97	-0.47	1.04e-20	Response to antipsychotic treatment;
LIHC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg25281562	chr12:121454272	C12orf43	0.34	5.92	0.3	7.73e-9	N-glycan levels;
LIHC	cis	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg18809830	chr7:99032528	PTCD1	-0.82	-6.37	-0.33	5.95e-10	Blood metabolite levels;
LIHC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	7.21	0.36	3.58e-12	Protein C levels;
LIHC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.69	-9.61	-0.46	1.67e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs10411161	1.000	rs8108583	chr19:52364977	C/A	cg22319618	chr22:45562946	NUP50	-0.51	-6.91	-0.35	2.31e-11	Breast cancer;
LIHC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.8	-10.47	-0.49	1.9e-22	Systemic lupus erythematosus;
LIHC	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.44	7.21	0.36	3.63e-12	Corneal astigmatism;
LIHC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.08	-0.48	4.45e-21	Response to antipsychotic treatment;
LIHC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg05590025	chr7:65112418	INTS4L2	0.66	7.29	0.37	2.21e-12	Diabetic kidney disease;
LIHC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg03934865	chr2:198174659	NA	-0.59	-9.6	-0.46	1.74e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.76	7.5	0.38	5.53e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.65	0.73	4.7e-58	Smoking behavior;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24174984	chr2:29117731	WDR43	-0.46	-6.44	-0.33	4.09e-10	Pancreatic cancer;
LIHC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.56	-11.21	-0.52	4.68e-25	Tonsillectomy;
LIHC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.42	6.3	0.32	9.07e-10	Obesity-related traits;
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.16	-0.32	2.03e-9	Longevity;
LIHC	cis	rs9443189	1.000	rs1280047	chr6:76527791	A/G	cg01950844	chr6:76311363	SENP6	0.52	6.45	0.33	3.76e-10	Prostate cancer;
LIHC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.79	9.94	0.47	1.29e-20	Body mass index;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg13409248	chr3:40428643	ENTPD3	-0.42	-6.95	-0.35	1.81e-11	Renal cell carcinoma;
LIHC	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.45	7.21	0.36	3.57e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08219700	chr8:58056026	NA	0.5	6.13	0.31	2.49e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.76	16.6	0.67	8e-46	Systemic lupus erythematosus;
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.51	7.87	0.39	4.79e-14	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-11.32	-0.52	1.9e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-7.03	-0.36	1.15e-11	Response to antipsychotic treatment;
LIHC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	11.85	0.54	2.19e-27	Lung cancer in ever smokers;
LIHC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.2	-0.41	4.92e-15	Chronic sinus infection;
LIHC	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.57	8.58	0.42	3.35e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg18769074	chr3:133464867	TF	0.26	5.82	0.3	1.32e-8	Iron status biomarkers (transferrin levels);
LIHC	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg08754654	chr5:154026448	NA	-0.28	-5.87	-0.3	1.05e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.45	-7.26	-0.37	2.61e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6442522	0.809	rs17041143	chr3:15485845	C/G	cg16303742	chr3:15540471	COLQ	0.39	6.15	0.32	2.11e-9	Uric acid levels;
LIHC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.35	5.75	0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	6.58	0.33	1.82e-10	Monocyte percentage of white cells;
LIHC	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.37	7.29	0.37	2.18e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs77633900	0.772	rs166933	chr15:76736265	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-5.92	-0.3	7.98e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.59	-11.37	-0.52	1.22e-25	Coronary artery disease;
LIHC	cis	rs2274273	0.682	rs1201378	chr14:55493408	A/G	cg01864836	chr14:55583639	NA	0.34	5.88	0.3	9.74e-9	Protein biomarker;
LIHC	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg22771759	chr13:24902376	NA	-0.32	-6.81	-0.35	4.43e-11	Obesity-related traits;
LIHC	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg06265175	chr8:121136014	COL14A1	0.48	7.72	0.39	1.34e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg14515779	chr1:101123966	NA	-0.67	-13.11	-0.58	4.4e-32	Monocyte count;
LIHC	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.57	7.67	0.38	1.79e-13	Type 2 diabetes;
LIHC	cis	rs4450131	0.522	rs3781455	chr10:126347688	T/C	cg20435097	chr10:126320824	FAM53B	0.68	12.41	0.56	1.85e-29	White blood cell count (basophil);
LIHC	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-0.88	-8.92	-0.43	2.97e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	7.26	0.37	2.61e-12	IgG glycosylation;
LIHC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg13753209	chr17:57696993	CLTC	0.76	12.15	0.55	1.75e-28	Hemoglobin concentration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08031094	chr2:54013912	LOC100302652;ASB3;ERLEC1	0.46	6.25	0.32	1.22e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-7.16	-0.36	4.89e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.29e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	6.08	0.31	3.17e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.59	10.21	0.48	1.6e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	1.07	12.48	0.56	9.98e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.63	10.2	0.48	1.63e-21	Resting heart rate;
LIHC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.68	10.31	0.49	7.18e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg18887096	chr2:219472410	PLCD4	0.36	6.46	0.33	3.52e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.11	16.43	0.66	3.99e-45	Sexual dysfunction (female);
LIHC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.36	5.76	0.3	1.89e-8	Menopause (age at onset);
LIHC	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg02023728	chr11:77925099	USP35	0.35	6.29	0.32	9.61e-10	Alzheimer's disease (survival time);
LIHC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.93	0.39	3.1e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg20129853	chr10:51489980	NA	-0.41	-9.04	-0.44	1.2e-17	Prostate-specific antigen levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06116495	chr3:112280886	ATG3;SLC35A5	-0.5	-6.3	-0.32	9.09e-10	Systolic blood pressure;
LIHC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.73	-0.43	1.13e-16	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.06	0.58	6.74e-32	Prudent dietary pattern;
LIHC	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.41	-0.33	4.83e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.34	-0.32	7.28e-10	Metabolite levels;
LIHC	cis	rs12464559	0.649	rs9287998	chr2:152621356	C/T	cg01189475	chr2:152685088	ARL5A	0.63	7.46	0.37	7.1e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10625758	chr17:73851514	WBP2	0.45	6.14	0.32	2.31e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.57	10.29	0.49	7.98e-22	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22828804	chr20:3140466	UBOX5;FASTKD5	0.39	6.06	0.31	3.57e-9	Parkinson's disease;
LIHC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs600626	0.636	rs10899110	chr11:75452342	C/G	cg24262691	chr11:75473276	NA	0.39	5.91	0.3	8.34e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.55	-7.95	-0.4	2.69e-14	Asthma;
LIHC	cis	rs12079745	0.793	rs12092506	chr1:169405517	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-6.87	-0.35	2.99e-11	QT interval;
LIHC	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.65	8.98	0.44	1.83e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1475718	0.563	rs1041608	chr9:137116205	C/T	cg21243944	chr9:137118148	NA	-0.57	-8.14	-0.4	7.24e-15	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	6.4	0.33	5.13e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-11.24	-0.52	3.81e-25	Bipolar disorder and schizophrenia;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg21784052	chr20:47835958	DDX27	0.52	6.23	0.32	1.34e-9	Glycated hemoglobin levels;
LIHC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.48	0.56	1.05e-29	Colorectal cancer;
LIHC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.81	-12.98	-0.57	1.34e-31	Colorectal cancer;
LIHC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13647721	chr17:30228624	UTP6	0.79	7.44	0.37	8.4e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.11	0.55	2.4e-28	Menopause (age at onset);
LIHC	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.79	-7.14	-0.36	5.57e-12	Arsenic metabolism;
LIHC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.35	-7.06	-0.36	9.2e-12	Body mass index;
LIHC	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.79	0.71	1.31e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs244293	0.730	rs2332314	chr17:53033007	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.07	-0.31	3.48e-9	Menarche (age at onset);
LIHC	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg12140854	chr5:148520817	ABLIM3	0.45	6.11	0.31	2.64e-9	Breast cancer;
LIHC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Blood protein levels;
LIHC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.44	-7.1	-0.36	7.13e-12	Multiple myeloma;
LIHC	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.41	-0.37	9.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.91	16.81	0.67	1.25e-46	Aortic root size;
LIHC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.96	11.79	0.54	3.72e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.56	5.94	0.31	7.12e-9	Hip geometry;
LIHC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.75	14.41	0.61	4.2e-37	Mortality in heart failure;
LIHC	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.69	7.27	0.37	2.52e-12	Exhaled nitric oxide output;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg20957396	chr2:135062876	MGAT5	0.35	6.35	0.32	6.78e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.78	12.12	0.55	2.34e-28	Resting heart rate;
LIHC	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.15	10.34	0.49	5.55e-22	Schizophrenia;
LIHC	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.52	-7.49	-0.38	6.09e-13	Obesity-related traits;
LIHC	trans	rs10242455	0.571	rs55830753	chr7:99292222	A/G	cg09045935	chr12:6379348	NA	0.74	6.16	0.32	2.03e-9	Blood metabolite levels;
LIHC	cis	rs7534824	0.582	rs17448827	chr1:101421407	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	7.48	0.38	6.25e-13	Refractive astigmatism;
LIHC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.71	9.32	0.45	1.5e-18	Body mass index;
LIHC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg27490568	chr2:178487706	NA	0.38	6.03	0.31	4.34e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-10.74	-0.5	2.25e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg11812906	chr14:75593930	NEK9	-0.68	-12.07	-0.55	3.38e-28	Height;
LIHC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06897120	chr16:4613204	LOC342346	0.37	6.39	0.33	5.33e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg20016023	chr10:99160130	RRP12	0.38	5.96	0.31	6.31e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6504950	0.800	rs9891704	chr17:53010755	A/G	cg10237252	chr17:52977213	TOM1L1	-0.34	-5.99	-0.31	5.22e-9	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13095604	chr12:12966124	DDX47	0.43	6.46	0.33	3.7e-10	Cognitive function;
LIHC	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.5	7.17	0.36	4.71e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.9	-0.3	8.84e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04317338	chr11:64019027	PLCB3	0.5	6.84	0.35	3.68e-11	Platelet count;
LIHC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.39	6.45	0.33	3.92e-10	Bipolar disorder;
LIHC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg22834771	chr12:69754056	YEATS4	-0.49	-8.47	-0.42	7.15e-16	Blood protein levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18088712	chr1:16810147	CROCCL2	-0.43	-6.6	-0.34	1.53e-10	Calcium levels;
LIHC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.49e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.72	0.43	1.24e-16	Lymphocyte counts;
LIHC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.51	8.61	0.42	2.62e-16	Obesity-related traits;
LIHC	cis	rs965469	0.779	rs6051746	chr20:3307290	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-6.33	-0.32	7.55e-10	IFN-related cytopenia;
LIHC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.4	-6.38	-0.33	5.87e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.24	-6.1	-0.31	2.86e-9	Schizophrenia;
LIHC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs903552	0.935	rs4965871	chr15:102003810	A/T	cg00659931	chr15:102010125	PCSK6	-0.45	-6.31	-0.32	8.74e-10	Diabetic kidney disease;
LIHC	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	6.87	0.35	3.04e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.7	11.94	0.54	1.07e-27	Prudent dietary pattern;
LIHC	trans	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg18335740	chr13:41363409	SLC25A15	0.36	6.37	0.33	6.11e-10	Lewy body disease;
LIHC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.67	9.58	0.46	2.05e-19	Schizophrenia;
LIHC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.66	9.12	0.44	6.48e-18	Menopause (age at onset);
LIHC	cis	rs13161895	1.000	rs394616	chr5:179418134	T/G	cg02702477	chr5:179499311	RNF130	0.75	10.3	0.49	7.38e-22	LDL cholesterol;
LIHC	cis	rs1775715	0.835	rs11008701	chr10:32241096	A/G	cg14930904	chr10:32216787	ARHGAP12	0.39	7.05	0.36	1.02e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.35	0.52	1.46e-25	Coronary artery disease;
LIHC	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg02702477	chr5:179499311	RNF130	0.83	11.48	0.53	4.88e-26	LDL cholesterol;
LIHC	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg07451762	chr16:28383216	NA	0.32	6.59	0.34	1.62e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06420487	chr17:61919686	SMARCD2	0.42	5.78	0.3	1.69e-8	Height;
LIHC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.85	-9.53	-0.46	3.03e-19	Triglycerides;
LIHC	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg14092571	chr14:90743983	NA	0.47	7.24	0.36	2.98e-12	Mortality in heart failure;
LIHC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.11	18.51	0.71	1.7e-53	IgG glycosylation;
LIHC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.62	-10.04	-0.48	5.96e-21	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09477292	chr4:6577027	MAN2B2	0.52	7.27	0.37	2.47e-12	Lung function (FEV1/FVC);
LIHC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.71	7.17	0.36	4.8e-12	Vitiligo;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.62	10.36	0.49	4.65e-22	Glycated hemoglobin levels;
LIHC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.45	6.8	0.34	4.82e-11	Height;
LIHC	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg26384229	chr12:38710491	ALG10B	0.4	6.08	0.31	3.29e-9	Morning vs. evening chronotype;
LIHC	trans	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg26939375	chr7:64535504	NA	0.42	6.63	0.34	1.32e-10	Aortic root size;
LIHC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	5.85	0.3	1.14e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.38	-7.69	-0.38	1.59e-13	Obesity-related traits;
LIHC	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.23	-0.32	1.37e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.78	0.69	1.5e-50	Gut microbiome composition (summer);
LIHC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg14440974	chr22:39074834	NA	-0.37	-6.17	-0.32	1.98e-9	Menopause (age at onset);
LIHC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.88	16.91	0.67	4.65e-47	Blood protein levels;
LIHC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.44	6.46	0.33	3.66e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.51	-7.15	-0.36	5.41e-12	High light scatter reticulocyte count;
LIHC	cis	rs4700695	0.614	rs153387	chr5:65422236	G/A	cg21114390	chr5:65439923	SFRS12	-0.54	-6.04	-0.31	4.07e-9	Facial morphology (factor 19);
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg14709524	chr16:89940631	TCF25	0.57	7.28	0.37	2.27e-12	Skin colour saturation;
LIHC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.54	-8.16	-0.4	6.28e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.45	-6.66	-0.34	1.09e-10	Dermatomyositis;
LIHC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04013166	chr16:89971882	TCF25	0.48	6.02	0.31	4.62e-9	Interleukin-17 levels;
LIHC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.72	8.0	0.4	2e-14	Testicular germ cell tumor;
LIHC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.84	14.44	0.62	3.23e-37	Colorectal cancer;
LIHC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.76	0.6	1.32e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg05110241	chr16:68378359	PRMT7	0.61	6.89	0.35	2.74e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg05425664	chr17:57184151	TRIM37	-0.46	-5.88	-0.3	9.65e-9	Vitamin D levels;
LIHC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24229701	chr12:130821962	PIWIL1	0.4	5.82	0.3	1.37e-8	Menopause (age at onset);
LIHC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.51	5.87	0.3	1.03e-8	Gut microbiome composition (summer);
LIHC	trans	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.43	-6.11	-0.31	2.76e-9	Type 2 diabetes;
LIHC	cis	rs655641	0.823	rs2458493	chr11:85783875	A/G	cg09030501	chr11:85779252	PICALM	-0.5	-5.89	-0.3	9.43e-9	Platelet count;
LIHC	trans	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg26939375	chr7:64535504	NA	-0.43	-6.98	-0.35	1.57e-11	Aortic root size;
LIHC	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.16	16.23	0.66	2.6e-44	Corneal structure;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg09774412	chr22:50902130	SBF1	0.39	6.5	0.33	2.81e-10	Eotaxin levels;
LIHC	trans	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg10756647	chr7:56101905	PSPH	-1.08	-13.18	-0.58	2.26e-32	Diabetic kidney disease;
LIHC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.76	7.75	0.39	1.03e-13	Schizophrenia;
LIHC	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.45	6.41	0.33	4.73e-10	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.73	8.86	0.43	4.42e-17	Body mass index;
LIHC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.43	-6.85	-0.35	3.45e-11	Blood pressure (smoking interaction);
LIHC	cis	rs3812111	0.899	rs9488836	chr6:116435795	C/T	cg08036074	chr6:116424633	NT5DC1	-0.66	-11.48	-0.53	5.16e-26	Age-related macular degeneration;
LIHC	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg14515779	chr1:101123966	NA	0.5	6.9	0.35	2.49e-11	Monocyte count;
LIHC	cis	rs918629	0.679	rs72656689	chr5:95270872	A/G	cg10483112	chr5:95245456	ELL2	-0.37	-6.32	-0.32	8.28e-10	IgG glycosylation;
LIHC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.82	0.69	1.01e-50	Smoking behavior;
LIHC	trans	rs214034	0.825	rs2710675	chr2:17848189	T/C	cg09061216	chr1:1558936	MIB2	0.51	6.04	0.31	4.01e-9	Response to amphetamines;
LIHC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.49	17.34	0.68	8.86e-49	Eosinophil percentage of granulocytes;
LIHC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.53	7.43	0.37	8.67e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.04	0.51	1.93e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16262614	chr3:133464971	TF	0.28	6.48	0.33	3.29e-10	Iron status biomarkers;
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.55	-7.92	-0.39	3.25e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.32	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs6466055	0.720	rs62484712	chr7:105005741	G/A	cg04380332	chr7:105027541	SRPK2	-0.37	-6.9	-0.35	2.52e-11	Schizophrenia;
LIHC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.5	8.9	0.43	3.35e-17	HDL cholesterol levels;
LIHC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.88	12.12	0.55	2.3e-28	Diastolic blood pressure;
LIHC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.67	-10.82	-0.51	1.12e-23	Lung cancer;
LIHC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.18	0.44	4.07e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.53	5.84	0.3	1.23e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.65	-10.93	-0.51	4.88e-24	Childhood ear infection;
LIHC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.47	0.33	3.3e-10	Morning vs. evening chronotype;
LIHC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.65	9.85	0.47	2.6e-20	Height;
LIHC	cis	rs1198430	0.599	rs946269	chr1:23769359	T/C	cg19827787	chr1:23763612	ASAP3	0.28	6.15	0.32	2.22e-9	Total cholesterol levels;
LIHC	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.78	-9.44	-0.45	6.04e-19	Mean platelet volume;
LIHC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-0.84	-10.37	-0.49	4.23e-22	Blood pressure (smoking interaction);
LIHC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.65	-10.44	-0.49	2.5e-22	Lung cancer;
LIHC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.26	-5.86	-0.3	1.08e-8	Menarche (age at onset);
LIHC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.5	8.16	0.4	6.38e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	9.6	0.46	1.74e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	trans	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg01596870	chr19:55963115	NA	-0.67	-9.5	-0.46	3.67e-19	Obesity-related traits;
LIHC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.59	8.37	0.41	1.49e-15	Blood metabolite levels;
LIHC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.39	6.37	0.33	6.02e-10	Red blood cell count;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.05	0.58	7.39e-32	Prudent dietary pattern;
LIHC	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	7.79	0.39	8.15e-14	Blood protein levels;
LIHC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.38	6.33	0.32	7.67e-10	Red blood cell count;
LIHC	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg18081818	chr7:23246105	NA	0.41	6.34	0.32	7.16e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.87	15.78	0.65	1.55e-42	Dental caries;
LIHC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16466278	chr15:43429893	TMEM62	0.41	6.73	0.34	7.12e-11	Longevity;
LIHC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg07424592	chr7:64974309	NA	0.76	8.84	0.43	5.28e-17	Diabetic kidney disease;
LIHC	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04055981	chr11:115044050	NA	0.53	8.55	0.42	4.25e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.44	-7.05	-0.36	9.71e-12	Menarche (age at onset);
LIHC	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg13753209	chr17:57696993	CLTC	0.77	12.28	0.55	6.02e-29	Hemoglobin concentration;
LIHC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg16226627	chr15:75307476	SCAMP5	0.51	8.81	0.43	6.34e-17	Lung cancer;
LIHC	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.29	6.19	0.32	1.74e-9	Pulmonary function;
LIHC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.13	-0.44	5.98e-18	Obesity-related traits;
LIHC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16346588	chr10:242978	ZMYND11	0.38	5.84	0.3	1.22e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	5.87	0.3	1.05e-8	Longevity;
LIHC	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-6.42	-0.33	4.67e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.41	0.52	9.38e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.46	0.33	3.62e-10	Heart rate;
LIHC	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	0.93	12.13	0.55	2.12e-28	Post bronchodilator FEV1;
LIHC	cis	rs9880406	0.833	rs938389	chr3:126058762	C/T	cg15490784	chr3:126061950	KLF15	0.41	5.78	0.3	1.68e-8	Macular telangiectasia type 2;
LIHC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.7	-0.34	8.76e-11	Diabetic kidney disease;
LIHC	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-8.3	-0.41	2.46e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.71	-0.38	1.37e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.4	5.81	0.3	1.42e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.33	-0.37	1.71e-12	Bipolar disorder;
LIHC	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.58e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs11628318	0.515	rs4906245	chr14:103088182	G/C	cg12046867	chr14:103022105	NA	-0.37	-5.72	-0.3	2.28e-8	Platelet count;
LIHC	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.53	8.79	0.43	7.35e-17	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19671926	chr4:122722719	EXOSC9	0.49	7.16	0.36	4.87e-12	Type 2 diabetes;
LIHC	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.45	6.76	0.34	5.98e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.61	-8.57	-0.42	3.56e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.39	0.45	8.53e-19	Platelet count;
LIHC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.13	-0.36	6.08e-12	Migraine;Coronary artery disease;
LIHC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg15848620	chr12:58087721	OS9	-0.55	-7.49	-0.38	5.89e-13	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.98	10.2	0.48	1.72e-21	Mean corpuscular volume;
LIHC	cis	rs57244997	0.725	rs7746243	chr6:162436437	G/C	cg17173639	chr6:162384350	PARK2	-0.49	-6.42	-0.33	4.48e-10	Mosquito bite size;
LIHC	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.36	-6.93	-0.35	2.14e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	1.01	20.73	0.75	2.04e-62	Breast cancer;
LIHC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.4	6.47	0.33	3.49e-10	Red blood cell count;
LIHC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.7	-0.5	3.03e-23	Chronic sinus infection;
LIHC	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs11673344	0.764	rs474017	chr19:37454119	A/G	cg27390819	chr19:37464633	NA	-0.53	-6.38	-0.33	5.61e-10	Obesity-related traits;
LIHC	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	0.93	7.5	0.38	5.39e-13	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.44	6.3	0.32	9.38e-10	Schizophrenia;
LIHC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02985541	chr2:219472218	PLCD4	0.44	8.46	0.42	7.9e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	0.66	7.32	0.37	1.81e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg03013999	chr17:37608204	MED1	-0.36	-5.97	-0.31	5.89e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs12986413	0.967	rs2108524	chr19:2170764	A/G	cg09261902	chr19:2140048	AP3D1	0.38	6.34	0.32	7.28e-10	Height;
LIHC	cis	rs16912285	0.535	rs7936178	chr11:24252515	G/T	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg13175981	chr1:150552382	MCL1	-0.43	-5.97	-0.31	5.98e-9	Melanoma;
LIHC	trans	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg26113512	chr3:38035601	VILL	0.55	6.41	0.33	4.8e-10	Alzheimer's disease;
LIHC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.43	7.48	0.37	6.44e-13	Aortic root size;
LIHC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.61	9.31	0.45	1.58e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	cis	rs17286411	0.750	rs2288030	chr16:71914107	G/A	cg03805757	chr16:71968109	PKD1L3	0.41	5.85	0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs611744	0.967	rs636399	chr8:109235569	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs1419980	0.730	rs1833148	chr12:7774680	C/T	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02038173	chr21:34852701	TMEM50B	0.48	6.42	0.33	4.67e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.11	-0.36	6.64e-12	Vitiligo;
LIHC	cis	rs3789045	0.774	rs12031912	chr1:204476113	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.39	-5.93	-0.31	7.24e-9	Educational attainment (college completion);
LIHC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	10.14	0.48	2.71e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	18.14	0.7	5.62e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg16103275	chr6:290800	DUSP22	-0.49	-6.48	-0.33	3.16e-10	Menopause (age at onset);
LIHC	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.67	-10.58	-0.5	8.2000000000000006e-23	White matter hyperintensity burden;
LIHC	cis	rs17106184	1.000	rs12083647	chr1:51314649	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.62	-0.34	1.43e-10	Type 2 diabetes;
LIHC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.65	11.41	0.52	9.35e-26	Menopause (age at onset);
LIHC	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.56	10.98	0.51	3.03e-24	Multiple myeloma;
LIHC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	8.32	0.41	2.07e-15	Nonalcoholic fatty liver disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26105702	chr2:209120195	IDH1	-0.43	-6.04	-0.31	4.04e-9	Pancreatic cancer;
LIHC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.8	-12.49	-0.56	9.23e-30	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.56	-7.93	-0.39	3.2e-14	Platelet count;
LIHC	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.47	8.1	0.4	9.64e-15	Hepatocellular carcinoma;
LIHC	cis	rs9473924	0.542	rs9473928	chr6:50842003	G/A	cg14470998	chr6:50812995	TFAP2B	0.93	10.68	0.5	3.66e-23	Body mass index;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg00656387	chr3:40428638	ENTPD3	0.5	8.42	0.41	1.07e-15	Renal cell carcinoma;
LIHC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.61e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-8.36	-0.41	1.58e-15	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.41	6.32	0.32	8.35e-10	Post bronchodilator FEV1;
LIHC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg10360323	chr17:41437877	NA	0.4	5.95	0.31	6.7e-9	Menopause (age at onset);
LIHC	cis	rs876084	0.505	rs7459865	chr8:121115611	A/T	cg06265175	chr8:121136014	COL14A1	0.44	7.09	0.36	7.9e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs546131	0.614	rs35953213	chr11:34848769	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.55	-0.33	2.17e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2997447	0.761	rs17184891	chr1:26447557	A/T	cg19633962	chr1:26362018	EXTL1	-0.64	-5.88	-0.3	9.64e-9	QRS complex (12-leadsum);
LIHC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	7.2	0.36	3.91e-12	Protein C levels;
LIHC	cis	rs1144333	1.000	rs5745542	chr1:76365073	C/G	cg10523679	chr1:76189770	ACADM	0.45	6.47	0.33	3.38e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.1	23.58	0.79	1.08e-73	Cortisol levels (saliva);
LIHC	trans	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg19894588	chr14:64061835	NA	-0.65	-9.18	-0.44	4.16e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg05590025	chr7:65112418	INTS4L2	-0.54	-6.24	-0.32	1.28e-9	Diabetic kidney disease;
LIHC	cis	rs6726292	0.500	rs1822617	chr2:55227231	C/G	cg09592903	chr2:55203963	RTN4	-0.48	-7.43	-0.37	8.65e-13	Obesity (extreme);
LIHC	cis	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg01231543	chr16:68741748	NA	0.39	6.21	0.32	1.54e-9	Colorectal cancer;
LIHC	cis	rs7945718	0.621	rs10831887	chr11:12665436	A/C	cg25843174	chr11:12811716	TEAD1	0.33	7.71	0.38	1.41e-13	Educational attainment (years of education);
LIHC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4e-19	Bipolar disorder;
LIHC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.9	0.43	3.36e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.75e-9	Aortic root size;
LIHC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg19318889	chr4:1322082	MAEA	-0.48	-7.99	-0.4	2.05e-14	Obesity-related traits;
LIHC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.6	10.58	0.5	7.9e-23	Dupuytren's disease;
LIHC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.91	0.6	3.63e-35	Primary sclerosing cholangitis;
LIHC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.56	-5.92	-0.3	7.82e-9	Vitiligo;
LIHC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg00343986	chr7:65444356	GUSB	-0.39	-5.84	-0.3	1.2e-8	Aortic root size;
LIHC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.48	7.7	0.38	1.53e-13	Multiple sclerosis;
LIHC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.61	-7.78	-0.39	8.75e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg00292662	chr22:38071168	LGALS1	0.65	8.48	0.42	6.78e-16	Fat distribution (HIV);
LIHC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg03854865	chr6:26224070	HIST1H3E	0.59	6.42	0.33	4.67e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.53	5.77	0.3	1.82e-8	Menopause (age at onset);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg22867288	chr6:57086716	RAB23	0.42	6.13	0.31	2.48e-9	Migraine with aura;
LIHC	trans	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.6e-9	Coronary artery disease;
LIHC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg10621924	chr7:39171070	POU6F2	0.39	6.09	0.31	2.98e-9	IgG glycosylation;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.61	9.81	0.47	3.47e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.5	-7.82	-0.39	6.49e-14	Cognitive function;
LIHC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.67	-9.64	-0.46	1.33e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.61	9.76	0.47	5.35e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-6.22	-0.32	1.45e-9	Ulcerative colitis;
LIHC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.4	-6.1	-0.31	2.85e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.36	6.15	0.32	2.12e-9	Schizophrenia;
LIHC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.58	7.99	0.4	2.1e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg10820045	chr2:198174542	NA	0.55	8.78	0.43	7.88e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.67	0.5	4.01e-23	Vitiligo;
LIHC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.31	0.52	2.05e-25	Colorectal cancer;
LIHC	cis	rs2302190	0.882	rs11650105	chr17:56588072	C/T	cg12560992	chr17:57184187	TRIM37	0.7	8.9	0.43	3.38e-17	Vitamin D levels;
LIHC	trans	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg10756647	chr7:56101905	PSPH	0.63	8.68	0.42	1.62e-16	Corneal structure;
LIHC	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.43	7.09	0.36	7.54e-12	Schizophrenia;
LIHC	cis	rs3736485	0.966	rs2305708	chr15:51909960	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.56e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-1.12	-11.01	-0.51	2.51e-24	Breast cancer;
LIHC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg26338869	chr17:61819248	STRADA	0.52	6.99	0.35	1.46e-11	Height;
LIHC	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.43	-7.08	-0.36	8.26e-12	QT interval (drug interaction);
LIHC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	6.0	0.31	5.07e-9	Response to antipsychotic treatment;
LIHC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.67	-9.2	-0.45	3.5e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.99	0.35	1.44e-11	Dupuytren's disease;
LIHC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.77	-0.34	5.78e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs2820292	0.967	rs2820290	chr1:201783682	A/G	cg11586189	chr1:201857591	SHISA4	0.39	5.76	0.3	1.89e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LIHC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.93	17.2	0.68	3.13e-48	Menopause (age at onset);
LIHC	cis	rs965469	0.779	rs6051752	chr20:3310452	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-6.14	-0.32	2.28e-9	IFN-related cytopenia;
LIHC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	0.62	6.24	0.32	1.28e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs11212737	0.765	rs2128243	chr11:108509754	A/G	cg22776369	chr11:108536276	DDX10	0.37	6.04	0.31	4.05e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.47	-6.67	-0.34	1.03e-10	Tonsillectomy;
LIHC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	0.94	21.3	0.76	1.11e-64	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs79387448	0.745	rs9677607	chr2:103149520	A/T	cg09003973	chr2:102972529	NA	0.85	7.47	0.37	6.82e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.42	10.58	0.5	7.93e-23	Cutaneous nevi;
LIHC	trans	rs4604234	0.803	rs76568328	chr6:80977101	T/C	cg08069338	chr6:160207898	SNORA29;TCP1	0.63	6.16	0.32	2.07e-9	Cancer;
LIHC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13047869	chr3:10149882	C3orf24	0.41	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg00277334	chr10:82204260	NA	-0.53	-6.63	-0.34	1.29e-10	Post bronchodilator FEV1;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.57	-7.94	-0.39	2.99e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg01364799	chr7:75623366	TMEM120A	0.46	6.96	0.35	1.7e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.5	5.78	0.3	1.69e-8	Coronary artery disease;
LIHC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.01	-0.44	1.43e-17	Bipolar disorder;
LIHC	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-8.77	-0.43	8.67e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.29	0.37	2.16e-12	Diastolic blood pressure;
LIHC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.97	17.94	0.7	3.35e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs2121661	chr2:61561658	A/G	cg15711740	chr2:61764176	XPO1	0.43	5.86	0.3	1.08e-8	Tuberculosis;
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.97	-0.44	1.96e-17	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg10167378	chr1:228756711	NA	0.59	5.88	0.3	9.82e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	10.52	0.49	1.33e-22	Obesity-related traits;
LIHC	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.61	7.33	0.37	1.71e-12	Interstitial lung disease;
LIHC	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg07150772	chr14:90864620	CALM1	-0.42	-5.88	-0.3	9.62e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.29	-6.73	-0.34	7.2e-11	Breast cancer;
LIHC	cis	rs3748682	0.821	rs12030690	chr1:38258007	G/C	cg12658694	chr1:38397304	INPP5B	0.48	6.72	0.34	7.72e-11	Hypothyroidism;
LIHC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-22.16	-0.77	4.26e-68	Coronary artery disease;
LIHC	cis	rs10744422	1.000	rs2061101	chr12:123348925	C/A	cg25930673	chr12:123319894	HIP1R	-0.79	-9.13	-0.44	6.01e-18	Schizophrenia;
LIHC	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.56	-8.39	-0.41	1.33e-15	Colorectal cancer;
LIHC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.08	0.31	3.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs8081395	0.580	rs180515	chr17:58024275	A/G	cg02344993	chr17:57696989	CLTC	0.45	7.51	0.38	5.31e-13	White blood cell count;
LIHC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.33e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01566283	chr6:28109239	ZNF192	0.36	6.64	0.34	1.26e-10	Calcium levels;
LIHC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg22532475	chr10:104410764	TRIM8	-0.3	-5.94	-0.31	6.86e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.45	6.9	0.35	2.5e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00152838	chr16:24741724	TNRC6A	-0.46	-6.16	-0.32	2.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-1.1	-11.22	-0.52	4.28e-25	Breast cancer;
LIHC	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.77	8.33	0.41	2.02e-15	Alzheimer's disease (late onset);
LIHC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.51	9.33	0.45	1.34e-18	Systemic lupus erythematosus;
LIHC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg03146154	chr1:46216737	IPP	-0.46	-7.26	-0.37	2.66e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg07713946	chr22:31675144	LIMK2	0.42	7.53	0.38	4.67e-13	Colorectal cancer;
LIHC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg17980119	chr2:219472607	PLCD4	0.35	6.02	0.31	4.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07874155	chr5:138089656	CTNNA1	0.46	6.68	0.34	9.93e-11	Pancreatic cancer;
LIHC	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.84	13.58	0.59	6.56e-34	Colorectal cancer;
LIHC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.9	-15.76	-0.65	1.88e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.51	8.25	0.41	3.56e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.48	-6.96	-0.35	1.78e-11	Psoriasis;
LIHC	cis	rs3814244	0.528	rs7952790	chr12:68406452	C/T	cg15249341	chr12:68405565	NA	-0.31	-6.12	-0.31	2.59e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.88	-16.66	-0.67	4.74e-46	Coronary artery disease;
LIHC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.79	12.59	0.56	4.04e-30	Breast cancer;
LIHC	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg09572067	chr16:29127029	RRN3P2	0.5	7.93	0.39	3.09e-14	Menopause (age at onset);
LIHC	cis	rs16912285	0.688	rs7109312	chr11:24338974	G/A	ch.11.24196551F	chr11:24239977	NA	0.69	7.7	0.38	1.45e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.5	0.53	4.42e-26	Motion sickness;
LIHC	cis	rs16858210	0.913	rs1879255	chr3:183609445	C/A	cg25686905	chr3:183603175	PARL	-0.49	-9.09	-0.44	8.39e-18	Menopause (age at onset);
LIHC	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.34	-5.83	-0.3	1.28e-8	Mean platelet volume;
LIHC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg27205649	chr11:78285834	NARS2	0.38	5.71	0.3	2.4e-8	Alzheimer's disease (survival time);
LIHC	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	0.96	14.78	0.62	1.46e-38	Corneal structure;
LIHC	cis	rs16828019	0.777	rs12023079	chr1:41470111	G/A	cg03387723	chr1:41708464	SCMH1	-0.45	-6.91	-0.35	2.37e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.29	6.75	0.34	6.23e-11	Primary biliary cholangitis;
LIHC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-7.88	-0.39	4.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.89	-17.75	-0.69	2.04e-50	Height;
LIHC	cis	rs13161895	1.000	rs35973843	chr5:179466502	T/C	cg02702477	chr5:179499311	RNF130	0.8	11.17	0.52	6.67e-25	LDL cholesterol;
LIHC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.51	8.63	0.42	2.33e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg02869306	chr7:64672164	INTS4L1	-0.29	-6.41	-0.33	4.84e-10	Calcium levels;
LIHC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.61	11.32	0.52	1.86e-25	Systemic lupus erythematosus;
LIHC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.43	6.31	0.32	8.62e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.49	5.81	0.3	1.44e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.44	-6.88	-0.35	2.84e-11	Multiple myeloma;
LIHC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.84	12.76	0.57	9.4e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.06	-0.36	9.2e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.78	-7.27	-0.37	2.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21467203	chr3:49911342	NA	0.43	7.65	0.38	2.09e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1866706	1.000	rs6486066	chr11:12871127	A/G	cg25843174	chr11:12811716	TEAD1	0.29	6.21	0.32	1.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.66	7.1	0.36	7.33e-12	Type 2 diabetes;
LIHC	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.97	-0.31	6.06e-9	Blood pressure;
LIHC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.37	6.01	0.31	4.84e-9	Menopause (age at onset);
LIHC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-0.53	-5.76	-0.3	1.83e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.59	-8.24	-0.41	3.65e-15	Obesity-related traits;
LIHC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.88e-10	Uric acid levels;
LIHC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.67	-9.64	-0.46	1.31e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.57	-7.19	-0.36	4.02e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9921222	0.565	rs1805105	chr16:396264	A/G	cg12437481	chr16:420112	MRPL28	-0.51	-7.52	-0.38	5e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.38e-26	Corneal astigmatism;
LIHC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg06096015	chr1:231504339	EGLN1	-0.51	-9.5	-0.46	3.67e-19	Hemoglobin concentration;
LIHC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.58	7.54	0.38	4.35e-13	Morning vs. evening chronotype;
LIHC	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg03037974	chr15:76606532	NA	0.74	14.44	0.62	3.06e-37	Blood metabolite levels;
LIHC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.13	0.61	5.14e-36	Chronic sinus infection;
LIHC	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.52	6.43	0.33	4.4e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.39	6.16	0.32	2e-9	Menopause (age at onset);
LIHC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.21	0.32	1.56e-9	Schizophrenia;
LIHC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.55	-6.92	-0.35	2.3e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09417774	chr12:112037791	ATXN2	0.48	6.31	0.32	8.54e-10	Pancreatic cancer;
LIHC	cis	rs903552	0.935	rs4965387	chr15:102003209	G/A	cg06707286	chr15:102010195	PCSK6	-0.45	-6.42	-0.33	4.43e-10	Diabetic kidney disease;
LIHC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg08847533	chr14:75593920	NEK9	-0.35	-5.73	-0.3	2.21e-8	Caffeine consumption;
LIHC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.89	-18.09	-0.7	8.17e-52	Height;
LIHC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-7.26	-0.37	2.56e-12	Uric acid levels;
LIHC	cis	rs1185460	0.565	rs2276060	chr11:118919132	G/A	cg01677386	chr11:118938358	VPS11	0.43	5.75	0.3	1.97e-8	Coronary artery disease;
LIHC	trans	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg19894588	chr14:64061835	NA	-0.6	-8.02	-0.4	1.65e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.35	0.37	1.48e-12	Lung cancer;
LIHC	trans	rs36715	0.953	rs36700	chr5:127551273	A/G	cg16011800	chr17:1958478	HIC1	-0.41	-6.11	-0.31	2.74e-9	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05902063	chr12:96794315	CDK17	-0.48	-6.63	-0.34	1.33e-10	Pancreatic cancer;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-8.89	-0.43	3.49e-17	Lymphocyte counts;
LIHC	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.9	-0.3	8.7e-9	Coronary artery disease;
LIHC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.36	-5.83	-0.3	1.29e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.59	9.55	0.46	2.51e-19	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21821726	chr22:50170866	BRD1	0.39	6.22	0.32	1.44e-9	Bilirubin levels;
LIHC	cis	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg20045696	chr14:77926864	AHSA1	-0.82	-7.71	-0.38	1.41e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LIHC	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.43	-6.69	-0.34	8.95e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.94	-0.31	7.04e-9	Neuroticism;
LIHC	cis	rs9425766	0.640	rs9425756	chr1:173816586	C/T	cg06124660	chr1:173389066	NA	-0.34	-6.61	-0.34	1.44e-10	Life satisfaction;
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.55	9.42	0.45	7.17e-19	Calcium levels;
LIHC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.54	7.61	0.38	2.67e-13	Prostate cancer;
LIHC	cis	rs4919087	0.683	rs11189121	chr10:99072036	T/C	cg25902810	chr10:99078978	FRAT1	-0.6	-7.23	-0.36	3.16e-12	Monocyte count;
LIHC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.64	-9.96	-0.47	1.1e-20	QT interval;
LIHC	cis	rs2257205	0.667	rs8081074	chr17:56836596	G/A	cg12560992	chr17:57184187	TRIM37	0.68	7.44	0.37	8.24e-13	Pancreatic cancer;
LIHC	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.45	7.27	0.37	2.49e-12	Corneal astigmatism;
LIHC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.57	-8.27	-0.41	3.09e-15	Glaucoma (primary open-angle);
LIHC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.47	-5.88	-0.3	9.54e-9	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25423225	chr7:935108	C7orf20	0.42	6.36	0.33	6.38e-10	Bilirubin levels;
LIHC	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-6.47	-0.33	3.45e-10	Response to antipsychotic treatment;
LIHC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg04013166	chr16:89971882	TCF25	-0.48	-5.76	-0.3	1.91e-8	Skin colour saturation;
LIHC	cis	rs57244997	0.652	rs78477696	chr6:162428316	C/T	cg17173639	chr6:162384350	PARK2	-0.54	-6.76	-0.34	6.14e-11	Mosquito bite size;
LIHC	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg20435097	chr10:126320824	FAM53B	0.38	6.4	0.33	5.03e-10	Asthma;
LIHC	trans	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg14222797	chr10:16859974	RSU1	-0.53	-6.2	-0.32	1.63e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.85	0.3	1.12e-8	Systolic blood pressure;
LIHC	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-9.58	-0.46	2.05e-19	Colorectal cancer;
LIHC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg17074339	chr11:11642133	GALNTL4	0.41	6.1	0.31	2.81e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.68	-10.89	-0.51	6.66e-24	Lung cancer;
LIHC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.6	6.57	0.33	1.91e-10	Alzheimer's disease;
LIHC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.72	0.43	1.23e-16	Cognitive test performance;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.63	-8.93	-0.43	2.66e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02179239	chr10:23002514	PIP4K2A	0.42	6.21	0.32	1.55e-9	Pancreatic cancer;
LIHC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.9	-0.35	2.47e-11	IgG glycosylation;
LIHC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08822215	chr16:89438651	ANKRD11	0.44	6.87	0.35	3.05e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.44	-0.37	8.05e-13	Obesity-related traits;
LIHC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.37	-6.97	-0.35	1.6e-11	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.19e-16	Motion sickness;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12963096	chr13:39612675	NHLRC3;C13orf23	-0.44	-6.31	-0.32	8.52e-10	Triglycerides;
LIHC	cis	rs9649465	0.905	rs3757504	chr7:123391750	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.04	-0.4	1.5e-14	Migraine;
LIHC	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.57	-13.94	-0.6	2.8e-35	White blood cell count (basophil);
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.71	0.34	7.92e-11	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21902160	chr7:29689075	LOC646762	0.43	6.1	0.31	2.86e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.69	9.7	0.46	8.46e-20	Menarche (age at onset);
LIHC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.89	0.6	4.28e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Vitiligo;
LIHC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.34	0.32	7.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.71	13.66	0.59	3.41e-34	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg05697976	chr12:29376483	FAR2	0.31	6.24	0.32	1.33e-9	QT interval;
LIHC	cis	rs4788570	0.624	rs9929985	chr16:71838458	A/G	cg06353428	chr16:71660113	MARVELD3	1.29	12.98	0.57	1.4e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg18700516	chr19:44507157	ZNF230	-0.35	-5.76	-0.3	1.84e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg11952622	chr19:58962976	ZNF324B	-0.49	-7.57	-0.38	3.47e-13	Uric acid clearance;
LIHC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.67	-8.47	-0.42	7.61e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.66	11.89	0.54	1.59e-27	Colorectal cancer;
LIHC	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.37	2.22e-12	Migraine;Coronary artery disease;
LIHC	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.71	0.38	1.35e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs6708331	0.517	rs7599072	chr2:70360006	C/T	cg01613454	chr2:70366299	NA	0.38	6.11	0.31	2.75e-9	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg00656387	chr3:40428638	ENTPD3	-0.44	-7.42	-0.37	9.64e-13	Renal cell carcinoma;
LIHC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg18016565	chr1:150552671	MCL1	-0.5	-9.54	-0.46	2.73e-19	Melanoma;
LIHC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.18	-0.68	3.93e-48	Gut microbiome composition (summer);
LIHC	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16684958	chr7:75615977	POR	0.51	8.59	0.42	3.18e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg12698662	chr3:15914712	MIR563	-0.34	-6.22	-0.32	1.49e-9	Inflammatory skin disease;
LIHC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21467203	chr3:49911342	NA	-0.43	-7.87	-0.39	4.85e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07305463	chr2:136567211	LCT	-0.39	-5.98	-0.31	5.48e-9	Corneal structure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06387028	chr7:72395397	POM121	0.44	6.35	0.32	6.77e-10	Pancreatic cancer;
LIHC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-6.46	-0.33	3.62e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg23043544	chr7:2124092	MAD1L1	-0.45	-7.33	-0.37	1.64e-12	Neuroticism;
LIHC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.32	6.69	0.34	9.24e-11	Blood metabolite levels;
LIHC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.66	0.53	1.08e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.21	0.36	3.71e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.55	-0.33	2.06e-10	Personality dimensions;
LIHC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg20568497	chr10:133558893	NA	-0.4	-6.03	-0.31	4.31e-9	Survival in rectal cancer;
LIHC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.8	-18.05	-0.7	1.24e-51	Urate levels in lean individuals;
LIHC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.18	-10.63	-0.5	5.45e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg06742321	chr12:123595122	PITPNM2	0.31	5.75	0.3	1.98e-8	Platelet count;
LIHC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg04359351	chr2:3481828	TTC15	0.29	6.04	0.31	3.92e-9	Neurofibrillary tangles;
LIHC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	1.07	12.48	0.56	9.98e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.29	-0.45	1.83e-18	Bipolar disorder;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.48	0.56	1.07e-29	Alzheimer's disease;
LIHC	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-16.97	-0.68	2.62e-47	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20686432	chr4:184365613	CDKN2AIP	0.52	6.73	0.34	7.26e-11	Hepatitis;
LIHC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-11.89	-0.54	1.59e-27	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.45	0.56	1.35e-29	Prudent dietary pattern;
LIHC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.35	-0.7	7.66e-53	Ulcerative colitis;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg16396417	chr19:59085259	MZF1;LOC100131691	-0.54	-6.15	-0.32	2.16e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.41	0.45	7.5e-19	Coffee consumption (cups per day);
LIHC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.55	-8.78	-0.43	7.71e-17	Body mass index;
LIHC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg18944383	chr4:111397179	ENPEP	-0.35	-8.1	-0.4	9.97e-15	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.18	0.32	1.82e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-6.43	-0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.36	-6.03	-0.31	4.36e-9	Corneal structure;
LIHC	trans	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.49	6.18	0.32	1.88e-9	Ulcerative colitis;
LIHC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.59	-12.73	-0.57	1.18e-30	Obesity-related traits;
LIHC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.55	-14.76	-0.62	1.69e-38	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.8	-17.87	-0.69	6.82e-51	Urate levels in lean individuals;
LIHC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11645453	chr3:52864694	ITIH4	0.23	6.0	0.31	4.94e-9	Bipolar disorder;
LIHC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.76	-0.5	1.85e-23	Mean corpuscular volume;
LIHC	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19671926	chr4:122722719	EXOSC9	0.56	8.61	0.42	2.64e-16	Type 2 diabetes;
LIHC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs965469	1.000	rs2236107	chr20:3285821	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.54	-0.33	2.27e-10	IFN-related cytopenia;
LIHC	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.42	7.83	0.39	6.26e-14	Glaucoma;
LIHC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.86	-13.49	-0.59	1.55e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg14440974	chr22:39074834	NA	-0.36	-6.07	-0.31	3.36e-9	Menopause (age at onset);
LIHC	cis	rs75908454	1.000	rs75712439	chr6:169982682	T/A	cg19338460	chr6:170058176	WDR27	-0.79	-7.58	-0.38	3.35e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.43	8.33	0.41	2.02e-15	Testicular germ cell tumor;
LIHC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.3	-0.58	8.13e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs5753037	0.543	rs140122	chr22:30138908	C/G	cg01021169	chr22:30184971	ASCC2	-0.32	-5.97	-0.31	5.83e-9	Type 1 diabetes;
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg12034118	chr1:209979487	IRF6	0.38	5.8	0.3	1.52e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.28	-0.37	2.34e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.41	-0.37	9.97e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.64	6.17	0.32	1.95e-9	Inflammatory bowel disease;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.96e-16	Prudent dietary pattern;
LIHC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-9.36	-0.45	1.13e-18	Mean corpuscular volume;
LIHC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.52	8.39	0.41	1.32e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.44	-0.45	6.15e-19	Mood instability;
LIHC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.75	0.3	1.95e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.43	-6.25	-0.32	1.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	10.36	0.49	4.63e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17507749	chr15:85114479	UBE2QP1	0.68	7.71	0.38	1.36e-13	Schizophrenia;
LIHC	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg25019722	chr6:37503610	NA	0.38	6.37	0.33	5.95e-10	Cognitive performance;
LIHC	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.91	0.39	3.5e-14	Refractive astigmatism;
LIHC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.59	5.82	0.3	1.32e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.25	-6.92	-0.35	2.21e-11	Type 2 diabetes;
LIHC	trans	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.78	-8.55	-0.42	4.1e-16	Vitiligo;
LIHC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.47	6.41	0.33	4.95e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.54	-9.96	-0.47	1.07e-20	Coronary artery disease;
LIHC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.27	-0.78	1.83e-72	Height;
LIHC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.44	-7.65	-0.38	2e-13	Alzheimer's disease (late onset);
LIHC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	6.14	0.32	2.24e-9	Lung cancer;
LIHC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.69	-10.81	-0.5	1.24e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.9	16.03	0.65	1.61e-43	Parkinson's disease;
LIHC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	11.62	0.53	1.6e-26	Cognitive test performance;
LIHC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.99	0.48	9e-21	Lung cancer;
LIHC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	10.28	0.49	8.81e-22	Multiple sclerosis;
LIHC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.71	12.52	0.56	7e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06212747	chr3:49208901	KLHDC8B	0.63	8.61	0.42	2.74e-16	Menarche (age at onset);
LIHC	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.63	0.59	4.53e-34	Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12187049	chr5:70882888	MCCC2	0.48	6.63	0.34	1.28e-10	Pancreatic cancer;
LIHC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.5	-6.25	-0.32	1.19e-9	Pancreatic cancer;
LIHC	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.71	7.84	0.39	5.67e-14	Schizophrenia;
LIHC	cis	rs785830	0.689	rs1536608	chr9:223613	T/G	cg14500300	chr9:211689	NA	0.3	6.74	0.34	6.76e-11	Platelet distribution width;
LIHC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.56	-8.67	-0.42	1.81e-16	Corneal astigmatism;
LIHC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.92	16.75	0.67	2.14e-46	Colorectal cancer;
LIHC	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg22138327	chr13:27999177	GTF3A	0.64	10.13	0.48	2.84e-21	Weight;
LIHC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.57	-8.6	-0.42	2.97e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.43	7.0	0.35	1.37e-11	Red blood cell count;
LIHC	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg14515779	chr1:101123966	NA	0.48	6.95	0.35	1.83e-11	Monocyte count;
LIHC	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.57	8.26	0.41	3.18e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	trans	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg26939375	chr7:64535504	NA	-0.43	-6.97	-0.35	1.65e-11	Aortic root size;
LIHC	cis	rs600806	0.665	rs1368988	chr1:110012123	A/T	cg11161837	chr1:110010384	SYPL2	0.46	6.46	0.33	3.6e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.76	0.34	5.99e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.42	5.89	0.3	9.18e-9	Tonsillectomy;
LIHC	cis	rs17152411	1.000	rs1807099	chr10:126593774	C/T	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07649862	chr16:88897202	GALNS	0.44	6.56	0.33	2.03e-10	Immature fraction of reticulocytes;
LIHC	cis	rs2108622	0.727	rs62106157	chr19:15980448	G/A	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.74	0.34	6.9e-11	Gut microbiome composition (summer);
LIHC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.46	10.36	0.49	4.53e-22	Iron status biomarkers (transferrin levels);
LIHC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.01	-0.48	7.6e-21	Aortic root size;
LIHC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg16586182	chr3:47516702	SCAP	0.48	8.63	0.42	2.29e-16	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08535411	chr7:151826219	NA	0.41	6.49	0.33	3.06e-10	Cognitive function;
LIHC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg18944383	chr4:111397179	ENPEP	0.35	8.19	0.4	5.35e-15	Coronary artery disease;
LIHC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.69	-0.34	9.06e-11	Fear of minor pain;
LIHC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.55	9.14	0.44	5.75e-18	Dupuytren's disease;
LIHC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.61	10.26	0.48	1.08e-21	Red blood cell count;
LIHC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-9.08	-0.44	8.53e-18	Chronic sinus infection;
LIHC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg03037974	chr15:76606532	NA	0.74	14.58	0.62	8.72e-38	Blood metabolite levels;
LIHC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-12.05	-0.55	3.99e-28	Alzheimer's disease (late onset);
LIHC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.21	-0.32	1.55e-9	Menarche (age at onset);
LIHC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.62	7.88	0.39	4.48e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6061231	0.958	rs2379126	chr20:60953005	C/A	cg24112000	chr20:60950667	NA	-0.6	-8.34	-0.41	1.78e-15	Colorectal cancer;
LIHC	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	trans	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg16088116	chr21:44841560	SIK1	0.41	6.46	0.33	3.58e-10	Coronary artery disease;
LIHC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.43	-7.0	-0.35	1.35e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg23485639	chr6:28045615	ZNF165	0.39	6.02	0.31	4.39e-9	Cardiac Troponin-T levels;
LIHC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-7.2	-0.36	3.74e-12	Total body bone mineral density;
LIHC	cis	rs17152411	1.000	rs61873263	chr10:126589202	G/A	cg07906193	chr10:126599966	NA	0.42	6.61	0.34	1.48e-10	Height;
LIHC	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.56	7.28	0.37	2.32e-12	Economic and political preferences (feminism/equality);
LIHC	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.45	6.43	0.33	4.25e-10	Smoking behavior;
LIHC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	ch.11.42038R	chr11:967971	AP2A2	0.54	9.88	0.47	2.02e-20	Alzheimer's disease (late onset);
LIHC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23043544	chr7:2124092	MAD1L1	-0.45	-7.31	-0.37	1.87e-12	Neuroticism;
LIHC	trans	rs7668874	0.731	rs9990651	chr4:116814979	A/G	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	1.02	19.53	0.73	1.36e-57	Breast cancer;
LIHC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg16822855	chr3:40428330	ENTPD3	0.35	6.38	0.33	5.91e-10	Renal cell carcinoma;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07424592	chr7:64974309	NA	-0.44	-6.69	-0.34	8.93e-11	Calcium levels;
LIHC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.66	-0.38	1.88e-13	Electroencephalogram traits;
LIHC	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.53	-6.03	-0.31	4.21e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.33	0.49	5.93e-22	Dupuytren's disease;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25043602	chr13:113489734	ATP11A	0.43	6.21	0.32	1.55e-9	Bilirubin levels;
LIHC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg18944383	chr4:111397179	ENPEP	0.27	7.06	0.36	9.47e-12	Height;
LIHC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg11812906	chr14:75593930	NEK9	-0.43	-6.99	-0.35	1.47e-11	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.84	0.63	8.46e-39	Prudent dietary pattern;
LIHC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.35e-16	Motion sickness;
LIHC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg12373951	chr3:133503437	NA	0.47	7.88	0.39	4.54e-14	Iron status biomarkers;
LIHC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.85	-9.91	-0.47	1.57e-20	Schizophrenia;
LIHC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg15691649	chr6:25882328	NA	0.5	7.07	0.36	8.51e-12	Blood metabolite levels;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	20.86	0.75	6.63e-63	Prudent dietary pattern;
LIHC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.63	13.25	0.58	1.25e-32	Breast size;
LIHC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.49	0.42	6.56e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.46	6.18	0.32	1.84e-9	Initial pursuit acceleration;
LIHC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.64e-16	Motion sickness;
LIHC	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.5	6.5	0.33	2.83e-10	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.71	-12.63	-0.56	2.9e-30	Prudent dietary pattern;
LIHC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.59	10.77	0.5	1.69e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.68	11.1	0.51	1.2e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.5	5.73	0.3	2.23e-8	Coronary artery disease;
LIHC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg10018233	chr7:150070692	REPIN1	0.5	8.42	0.41	1.08e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg14393609	chr7:65229607	NA	0.37	5.84	0.3	1.22e-8	Aortic root size;
LIHC	cis	rs10276381	0.579	rs73072543	chr7:28146850	A/G	cg23620719	chr7:28220237	JAZF1	0.63	7.04	0.36	1.05e-11	Crohn's disease;
LIHC	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg08085267	chr17:45401833	C17orf57	-0.61	-8.17	-0.4	6.16e-15	Coronary artery disease;
LIHC	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.47	7.09	0.36	7.74e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.5	-10.86	-0.51	8.1e-24	Birth weight;
LIHC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.61	-9.46	-0.46	5.24e-19	Blood trace element (Zn levels);
LIHC	trans	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.33	0.32	7.57e-10	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06589161	chr5:180618230	NA	0.41	6.35	0.32	7e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.6	9.12	0.44	6.67e-18	Gout;
LIHC	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.35	-0.61	6.85e-37	Systemic lupus erythematosus;
LIHC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	12.51	0.56	7.93e-30	Platelet count;
LIHC	trans	rs944289	0.746	rs7145546	chr14:36558246	G/C	cg15660807	chr2:220381734	ACCN4	-0.26	-6.3	-0.32	8.94e-10	Thyroid cancer;
LIHC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.12	-0.48	3.03e-21	Response to antipsychotic treatment;
LIHC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.55	-0.53	2.75e-26	Chronic sinus infection;
LIHC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg11764359	chr7:65958608	NA	-0.56	-5.86	-0.3	1.09e-8	Diabetic kidney disease;
LIHC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.15	10.7	0.5	3.08e-23	Diabetic retinopathy;
LIHC	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.51	-7.51	-0.38	5.14e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.5	-8.31	-0.41	2.3e-15	Longevity;Endometriosis;
LIHC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	6.18	0.32	1.8e-9	IgG glycosylation;
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.43	7.15	0.36	5.39e-12	Testicular germ cell tumor;
LIHC	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.89	0.57	2.91e-31	Coffee consumption (cups per day);
LIHC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.3	0.37	2.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11673344	0.764	rs529468	chr19:37446200	T/G	cg27390819	chr19:37464633	NA	-0.53	-6.38	-0.33	5.79e-10	Obesity-related traits;
LIHC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.69	-8.11	-0.4	9.08e-15	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.35	6.41	0.33	4.8e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.39	5.8	0.3	1.51e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.37	-5.96	-0.31	6.4e-9	Orofacial clefts;
LIHC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.63	0.46	1.45e-19	Hemoglobin concentration;
LIHC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	13.46	0.59	2.04e-33	Cognitive test performance;
LIHC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.94	-0.31	7.15e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.89	15.98	0.65	2.56e-43	Aortic root size;
LIHC	cis	rs847649	0.842	rs11976237	chr7:102641383	A/G	cg18108683	chr7:102477205	FBXL13	0.44	6.6	0.34	1.57e-10	Morning vs. evening chronotype;
LIHC	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.67	13.37	0.59	4.49e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-7.24	-0.36	3.05e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.39	-6.21	-0.32	1.55e-9	Hypospadias;
LIHC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg11212589	chr17:38028394	ZPBP2	0.36	7.25	0.37	2.75e-12	Self-reported allergy;
LIHC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.73	-14.38	-0.61	5.39e-37	Height;
LIHC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.94	-0.31	7.14e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.77	-10.24	-0.48	1.22e-21	Systemic lupus erythematosus;
LIHC	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg15595755	chr5:1867978	NA	0.34	6.13	0.31	2.4e-9	Cardiovascular disease risk factors;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11011602	chr9:136215029	SNORD24;MED22;RPL7A	-0.52	-6.67	-0.34	1.04e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.98	-0.4	2.17e-14	Lymphocyte counts;
LIHC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg15123519	chr2:136567270	LCT	0.44	8.69	0.43	1.52e-16	Mosquito bite size;
LIHC	cis	rs9628987	0.569	rs11121176	chr1:8437032	T/C	cg20416874	chr1:8611966	RERE	0.49	5.84	0.3	1.19e-8	Breast cancer;
LIHC	cis	rs78062588	1.000	rs73001420	chr1:154586759	C/G	cg24304309	chr1:154577895	ADAR	-0.5	-5.86	-0.3	1.11e-8	Lung cancer;
LIHC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.59	-0.34	1.65e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7903847	0.600	rs2275582	chr10:99128983	G/A	cg06359132	chr10:99160096	RRP12	-0.4	-5.82	-0.3	1.35e-8	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.62	0.34	1.36e-10	Morning vs. evening chronotype;
LIHC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00152838	chr16:24741724	TNRC6A	-0.45	-6.1	-0.31	2.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg05760424	chr2:242988095	NA	-0.48	-6.76	-0.34	5.96e-11	Obesity-related traits;
LIHC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.54	8.05	0.4	1.38e-14	Prostate cancer;
LIHC	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.46	8.42	0.41	1.07e-15	Platelet distribution width;
LIHC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.03	-0.4	1.55e-14	Type 2 diabetes;
LIHC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.93	14.06	0.61	9.61e-36	Sudden cardiac arrest;
LIHC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-10.63	-0.5	5.33e-23	Schizophrenia;
LIHC	cis	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17862404	chr13:45009330	TSC22D1	0.41	5.74	0.3	2.05e-8	Leprosy;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg26634121	chr16:88897219	GALNS	0.43	6.54	0.33	2.29e-10	Electroencephalogram traits;
LIHC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.84	-14.05	-0.61	9.87e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.48	7.63	0.38	2.3e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.51	-8.21	-0.41	4.73e-15	Coronary artery disease;
LIHC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.36	7.16	0.36	4.98e-12	Alcohol dependence;
LIHC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.26	-6.09	-0.31	3.01e-9	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.22	-0.41	4.26e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.21	0.55	1.08e-28	Prudent dietary pattern;
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	5.91	0.3	8.42e-9	Height;
LIHC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg25039879	chr17:56429692	SUPT4H1	0.6	7.83	0.39	6.21e-14	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg00529422	chr1:16285251	ZBTB17	0.33	6.13	0.31	2.42e-9	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12463550	chr7:65579703	CRCP	0.71	7.44	0.37	8.23e-13	Diabetic kidney disease;
LIHC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.64	-11.79	-0.54	3.71e-27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.47	-6.35	-0.32	6.85e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27001534	chr5:443220	C5orf55;EXOC3	0.55	7.09	0.36	7.61e-12	Lung function (FEV1/FVC);
LIHC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.94	0.35	1.92e-11	Personality dimensions;
LIHC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.75	13.04	0.58	7.78e-32	Mean platelet volume;
LIHC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg17135325	chr3:160939158	NMD3	0.53	7.58	0.38	3.17e-13	Parkinson's disease;
LIHC	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	8.63	0.42	2.43e-16	Eotaxin levels;
LIHC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	0.97	9.37	0.45	1.01e-18	Midgestational circulating levels of PBDEs (fetal genetic effect);
LIHC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg26395211	chr5:140044315	WDR55	0.41	5.97	0.31	5.94e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg19006947	chr11:64034861	PLCB3	-0.47	-7.36	-0.37	1.35e-12	Body mass index;
LIHC	cis	rs6693567	0.874	rs698915	chr1:150388318	C/T	cg18016565	chr1:150552671	MCL1	0.36	6.17	0.32	1.97e-9	Migraine;
LIHC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.41	-5.94	-0.31	7.18e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-6.3	-0.32	9.22e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg00280220	chr17:61926910	NA	0.43	6.93	0.35	2.13e-11	Prudent dietary pattern;
LIHC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.7	-13.17	-0.58	2.47e-32	Body mass index;
LIHC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.65	9.53	0.46	3.01e-19	Monocyte percentage of white cells;
LIHC	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.58	-8.99	-0.44	1.77e-17	White matter hyperintensity burden;
LIHC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg01677386	chr11:118938358	VPS11	0.45	5.92	0.3	7.94e-9	Coronary artery disease;
LIHC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg03013999	chr17:37608204	MED1	0.35	5.74	0.3	2.09e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg14709524	chr16:89940631	TCF25	0.52	7.08	0.36	8.05e-12	Skin colour saturation;
LIHC	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg14146966	chr2:61757674	XPO1	0.46	8.01	0.4	1.81e-14	Tuberculosis;
LIHC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.63	6.2	0.32	1.62e-9	Plasma clusterin levels;
LIHC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	0.92	16.54	0.67	1.44e-45	Parkinson's disease;
LIHC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.33	6.13	0.31	2.36e-9	Platelet distribution width;
LIHC	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.85	0.3	1.14e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg11657440	chr19:46296263	DMWD	-0.53	-8.35	-0.41	1.76e-15	Coronary artery disease;
LIHC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.54	0.46	2.87e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.3	-5.78	-0.3	1.73e-8	Red blood cell count;
LIHC	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.34	5.87	0.3	1.04e-8	Metabolite levels;
LIHC	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.36	-5.75	-0.3	2.02e-8	Hypospadias;
LIHC	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg07451762	chr16:28383216	NA	0.41	7.03	0.36	1.16e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.86	-0.35	3.33e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	cis	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg14984255	chr18:11908827	MPPE1	0.33	5.77	0.3	1.8e-8	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs1555399	0.967	rs7161368	chr14:67983868	C/T	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.91	-0.3	8.43e-9	Parkinson's disease;
LIHC	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg07959070	chr22:50026188	C22orf34	-0.3	-7.19	-0.36	4.03e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.73	-13.33	-0.58	6.34e-33	Height;
LIHC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.12	-0.4	8.57e-15	Type 2 diabetes;
LIHC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.56	7.71	0.38	1.4e-13	Morning vs. evening chronotype;
LIHC	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.31	0.45	1.64e-18	Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	8.05	0.4	1.43e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.74	-11.76	-0.54	4.69e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.08	0.44	9.16e-18	Platelet count;
LIHC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.49	6.51	0.33	2.68e-10	Major depressive disorder;
LIHC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.52	-7.28	-0.37	2.26e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg14440974	chr22:39074834	NA	-0.35	-6.01	-0.31	4.79e-9	Menopause (age at onset);
LIHC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.57e-15	Bladder cancer;
LIHC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.54	-7.35	-0.37	1.51e-12	Body mass index;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10071602	chr16:2028740	TBL3	0.5	7.62	0.38	2.44e-13	Longevity;
LIHC	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg23280166	chr11:118938394	VPS11	-0.51	-6.95	-0.35	1.87e-11	Coronary artery disease;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg11070056	chr1:107600091	PRMT6	-0.66	-11.17	-0.52	6.77e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.44	7.14	0.36	5.58e-12	Red blood cell count;
LIHC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-8.66	-0.42	1.96e-16	Vitiligo;
LIHC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.76	-11.44	-0.53	6.98e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.7	11.96	0.54	8.91e-28	Blood protein levels;
LIHC	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg12064134	chr16:90016061	DEF8	-0.47	-6.15	-0.32	2.19e-9	Skin colour saturation;
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	7.02	0.35	1.2e-11	Prudent dietary pattern;
LIHC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.79	-6.51	-0.33	2.68e-10	IgG glycosylation;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12516959	chr21:47718080	NA	-0.36	-5.96	-0.31	6.14e-9	Testicular germ cell tumor;
LIHC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg02297831	chr4:17616191	MED28	0.43	6.75	0.34	6.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.16	0.36	4.83e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.87	-9.77	-0.47	4.65e-20	Facial emotion recognition (sad faces);
LIHC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.28	0.32	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.38	-6.32	-0.32	8.14e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg12365402	chr11:9010492	NRIP3	0.29	7.54	0.38	4.21e-13	Hemoglobin concentration;
LIHC	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg27205649	chr11:78285834	NARS2	0.4	6.2	0.32	1.65e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.9	16.53	0.67	1.53e-45	Bone mineral density;
LIHC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.66	-0.38	1.93e-13	Morning vs. evening chronotype;
LIHC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.75	11.85	0.54	2.2e-27	Corneal astigmatism;
LIHC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-8.99	-0.44	1.67e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg21252483	chr19:49399788	TULP2	-0.46	-7.67	-0.38	1.85e-13	Red cell distribution width;
LIHC	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.61	-10.95	-0.51	4.15e-24	Breast cancer;
LIHC	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.56	-0.42	3.94e-16	Brugada syndrome;
LIHC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg11632617	chr15:75315747	PPCDC	-0.43	-6.26	-0.32	1.15e-9	Blood trace element (Zn levels);
LIHC	cis	rs2455799	0.593	rs13078487	chr3:15929590	G/T	cg12698662	chr3:15914712	MIR563	-0.36	-6.82	-0.35	4.07e-11	Mean platelet volume;
LIHC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.57	5.87	0.3	1.04e-8	Gut microbiome composition (summer);
LIHC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.72	0.5	2.64e-23	Bladder cancer;
LIHC	trans	rs800082	1.000	rs7613909	chr3:144308606	A/G	cg24215973	chr2:240111563	HDAC4	0.51	7.56	0.38	3.76e-13	Smoking behavior;
LIHC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.03e-32	Psoriasis;
LIHC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.29	15.79	0.65	1.44e-42	Alzheimer's disease (late onset);
LIHC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg22079354	chr11:130786696	SNX19	0.41	5.76	0.3	1.84e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.47	6.97	0.35	1.62e-11	Aortic root size;
LIHC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.28	6.82	0.35	4.09e-11	Primary biliary cholangitis;
LIHC	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg25783544	chr11:47291846	MADD	0.43	6.27	0.32	1.1e-9	HDL cholesterol;
LIHC	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.32	-7.61	-0.38	2.64e-13	Resting heart rate;
LIHC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.55	7.04	0.36	1.04e-11	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.34	0.41	1.81e-15	Renal cell carcinoma;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.19	-0.32	1.71e-9	Total body bone mineral density;
LIHC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-8.44	-0.42	9.2e-16	Alzheimer's disease;
LIHC	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg04317338	chr11:64019027	PLCB3	-0.55	-7.48	-0.37	6.53e-13	Platelet count;
LIHC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.07	15.39	0.64	5.41e-41	Cognitive function;
LIHC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.49	6.07	0.31	3.45e-9	Alzheimer's disease;
LIHC	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.79	13.49	0.59	1.48e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.3	-5.73	-0.3	2.24e-8	Red blood cell count;
LIHC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.4	-6.16	-0.32	2.01e-9	Cognitive function;
LIHC	trans	rs792448	0.743	rs351379	chr1:212423789	G/T	cg20223728	chr6:6006398	NRN1	0.35	6.12	0.31	2.51e-9	White blood cell count (basophil);
LIHC	cis	rs4936323	0.504	rs10891812	chr11:115096431	T/C	cg04055981	chr11:115044050	NA	0.37	5.91	0.3	8.27e-9	Response to cytadine analogues (cytosine arabinoside);
LIHC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.18	30.04	0.85	5.97e-98	IgG glycosylation;
LIHC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.6	9.08	0.44	9.03e-18	Testicular germ cell tumor;
LIHC	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.94e-10	Metabolite levels;
LIHC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.44	-0.33	4e-10	Blood metabolite levels;
LIHC	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg20368463	chr18:77673604	PQLC1	0.55	6.85	0.35	3.45e-11	Opioid sensitivity;
LIHC	cis	rs16828019	0.777	rs35044078	chr1:41474400	C/G	cg03387723	chr1:41708464	SCMH1	-0.4	-6.25	-0.32	1.25e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.18	0.32	1.88e-9	Melanoma;
LIHC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.53	-8.51	-0.42	5.69e-16	Schizophrenia;
LIHC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.44	-0.45	5.88e-19	Testicular germ cell tumor;
LIHC	cis	rs7712401	0.791	rs4836244	chr5:122116232	A/G	cg18764291	chr5:122110994	SNX2	0.37	6.36	0.33	6.38e-10	Mean platelet volume;
LIHC	cis	rs11663156	1.000	rs72933414	chr18:50929489	C/T	cg24270629	chr18:50823537	DCC	-0.48	-6.59	-0.34	1.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs244293	0.965	rs244290	chr17:53231231	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.33	-0.37	1.65e-12	Menarche (age at onset);
LIHC	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	23.98	0.79	3.01e-75	Chronic sinus infection;
LIHC	cis	rs7075426	0.716	rs11598718	chr10:88294484	G/A	cg07322936	chr10:88137208	NA	0.49	6.31	0.32	8.75e-10	Migraine without aura;
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.48	7.4	0.37	1.03e-12	Testicular germ cell tumor;
LIHC	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.0	-0.31	5.15e-9	Blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11087358	chr12:57940980	DCTN2	0.43	6.15	0.32	2.2e-9	Pancreatic cancer;
LIHC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-6.71	-0.34	8.33e-11	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.54	0.8	2.06e-77	Prudent dietary pattern;
LIHC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.68	-0.34	9.6e-11	Multiple sclerosis;
LIHC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.6	10.11	0.48	3.5e-21	Height;
LIHC	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg07862535	chr7:139043722	LUC7L2	0.58	10.01	0.48	7.65e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.31	0.32	8.7e-10	HDL cholesterol;
LIHC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.47	-7.42	-0.37	9.14e-13	HDL cholesterol;
LIHC	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.07	-0.31	3.45e-9	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.23	0.36	3.24e-12	Diabetic kidney disease;
LIHC	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.33	-5.8	-0.3	1.5e-8	Mean corpuscular volume;
LIHC	cis	rs3736485	0.808	rs28485410	chr15:51949885	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.02	-0.31	4.4e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg00204512	chr16:28754710	NA	0.4	6.92	0.35	2.29e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg20302533	chr7:39170763	POU6F2	0.36	6.67	0.34	1.01e-10	IgG glycosylation;
LIHC	cis	rs2574704	0.781	rs2616556	chr3:11659990	T/C	cg15876825	chr3:11651881	VGLL4	0.49	7.9	0.39	3.94e-14	Body mass index;
LIHC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.5	-8.76	-0.43	9.11e-17	Longevity;
LIHC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-11.77	-0.54	4.56e-27	Chronic sinus infection;
LIHC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg04083430	chr16:4736063	MGRN1	0.41	5.74	0.3	2.12e-8	Schizophrenia;
LIHC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.53	8.38	0.41	1.34e-15	Adiponectin levels;
LIHC	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg15208524	chr1:10270712	KIF1B	0.45	6.44	0.33	4.13e-10	Hepatocellular carcinoma;
LIHC	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.25	6.76	0.34	6.04e-11	Type 2 diabetes;
LIHC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.71	11.14	0.52	8.4e-25	Corneal astigmatism;
LIHC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.54	-8.12	-0.4	8.63e-15	Colorectal cancer;
LIHC	trans	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg26939375	chr7:64535504	NA	0.4	6.43	0.33	4.37e-10	Aortic root size;
LIHC	trans	rs13325613	0.834	rs13092160	chr3:46254791	A/G	cg24700663	chr4:77172643	FAM47E	0.54	6.15	0.32	2.12e-9	Monocyte count;
LIHC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.41	-6.82	-0.35	4.16e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12464559	0.522	rs4414677	chr2:152624932	A/C	cg01189475	chr2:152685088	ARL5A	-0.65	-7.84	-0.39	5.76e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg03387723	chr1:41708464	SCMH1	-0.43	-6.95	-0.35	1.8e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg14067834	chr17:29058358	SUZ12P	0.57	6.04	0.31	3.99e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.66	0.53	1.09e-26	Motion sickness;
LIHC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.58	9.65	0.46	1.23e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.45	8.76	0.43	9.18e-17	Testicular germ cell tumor;
LIHC	cis	rs2412488	0.927	rs7689981	chr4:54314828	A/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.79	-0.34	4.97e-11	DNA methylation (variation);
LIHC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg13866156	chr1:1669148	SLC35E2	-0.66	-12.42	-0.56	1.77e-29	Body mass index;
LIHC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.74	9.18	0.44	4.2e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.88	13.16	0.58	2.85e-32	Lymphocyte percentage of white cells;
LIHC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.55	7.07	0.36	8.95e-12	Parkinson's disease;
LIHC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.4	-5.94	-0.31	7.09e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs9503598	0.644	rs4959240	chr6:3430674	C/T	cg00476032	chr6:3446245	SLC22A23	0.34	6.46	0.33	3.53e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg26308932	chr13:114088860	ADPRHL1	0.42	6.19	0.32	1.7e-9	Longevity;
LIHC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.49	-7.3	-0.37	2.08e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	1.06	14.36	0.61	6.26e-37	Body mass index;
LIHC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg17771515	chr6:154831774	CNKSR3	0.58	6.08	0.31	3.14e-9	Lipoprotein (a) levels;
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.33	6.29	0.32	9.57e-10	Tonsillectomy;
LIHC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.54	-8.77	-0.43	8.66e-17	Prudent dietary pattern;
LIHC	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-6.58	-0.34	1.72e-10	Metabolite levels;
LIHC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.78	-0.3	1.68e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs4714291	0.832	rs1524087	chr6:40057504	A/G	cg02267698	chr19:7991119	CTXN1	-0.4	-6.85	-0.35	3.5e-11	Strep throat;
LIHC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.66	-9.07	-0.44	9.23e-18	Schizophrenia;
LIHC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.5	9.31	0.45	1.54e-18	Hemoglobin concentration;
LIHC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.66	10.45	0.49	2.22e-22	Diisocyanate-induced asthma;
LIHC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.59	9.06	0.44	1.03e-17	Uric acid clearance;
LIHC	trans	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.58e-9	Childhood ear infection;
LIHC	cis	rs1401454	1.000	rs1837095	chr11:16245692	T/A	cg02656851	chr11:16430247	SOX6	-0.32	-6.11	-0.31	2.66e-9	Blood pressure;
LIHC	cis	rs9783347	1.000	rs9783386	chr11:18386625	G/A	cg15585147	chr11:18324498	HPS5	0.43	6.55	0.33	2.09e-10	Pancreatic cancer;
LIHC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	11.31	0.52	2.13e-25	Colorectal cancer;
LIHC	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg06766960	chr11:133703094	NA	-0.46	-6.95	-0.35	1.89e-11	Childhood ear infection;
LIHC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.35	0.32	6.88e-10	Total body bone mineral density;
LIHC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.67	10.26	0.49	1e-21	Height;
LIHC	cis	rs7116495	0.881	rs680150	chr11:71605507	T/A	cg26138937	chr11:71823887	C11orf51	0.68	6.85	0.35	3.52e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs2625529	0.824	rs35167572	chr15:72378960	A/G	cg16672083	chr15:72433130	SENP8	-0.31	-5.86	-0.3	1.06e-8	Red blood cell count;
LIHC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-7.63	-0.38	2.36e-13	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16527491	chr14:38065127	FOXA1	0.48	6.5	0.33	2.85e-10	Lung function (FEV1/FVC);
LIHC	trans	rs6058796	1.000	rs13036962	chr20:31239010	T/C	cg02600331	chr11:130417168	NA	0.38	7.38	0.37	1.25e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg18912006	chr12:123335444	HIP1R	0.62	7.28	0.37	2.31e-12	Schizophrenia;
LIHC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.07	0.51	1.47e-24	Type 2 diabetes;
LIHC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.71	0.38	1.39e-13	Total body bone mineral density;
LIHC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20135002	chr11:47629003	NA	-0.55	-9.17	-0.44	4.67e-18	Subjective well-being;
LIHC	trans	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg01596870	chr19:55963115	NA	-0.69	-10.46	-0.49	2.19e-22	Obesity-related traits;
LIHC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.59	8.29	0.41	2.69e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg24879335	chr3:133465180	TF	0.28	6.36	0.33	6.59e-10	Iron status biomarkers;
LIHC	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg06359132	chr10:99160096	RRP12	-0.42	-6.6	-0.34	1.57e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.55	8.86	0.43	4.3e-17	Birth weight;
LIHC	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.57	9.86	0.47	2.31e-20	Dupuytren's disease;
LIHC	trans	rs875971	0.895	rs778700	chr7:65866450	C/T	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg19680672	chr10:131412579	MGMT	0.41	6.4	0.33	5.26e-10	Response to temozolomide;
LIHC	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg27209729	chr11:64428925	NRXN2	0.35	6.57	0.33	1.9e-10	Body mass index;Urate levels;
LIHC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.69	-0.34	8.98e-11	Gut microbiome composition (summer);
LIHC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.12	-0.31	2.57e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs10411161	0.810	rs57171871	chr19:52385332	T/C	cg22319618	chr22:45562946	NUP50	-0.59	-7.01	-0.35	1.28e-11	Breast cancer;
LIHC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg12374095	chr12:54320830	NA	0.42	6.06	0.31	3.67e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.02	-0.31	4.58e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg12863693	chr15:85201151	NMB	0.48	7.01	0.35	1.27e-11	Schizophrenia;
LIHC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg22800045	chr5:56110881	MAP3K1	-0.58	-6.91	-0.35	2.33e-11	Initial pursuit acceleration;
LIHC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	9.06	0.44	1.04e-17	Platelet count;
LIHC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg03959625	chr15:84868606	LOC388152	-0.44	-6.47	-0.33	3.31e-10	Schizophrenia;
LIHC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-12.35	-0.56	3.21e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg18367735	chr17:79674897	NA	0.64	7.61	0.38	2.66e-13	Dental caries;
LIHC	cis	rs713477	0.617	rs11627405	chr14:55911657	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.73	-0.34	7.38e-11	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs1814175	0.616	rs10839349	chr11:49753748	C/A	cg18944383	chr4:111397179	ENPEP	0.28	7.07	0.36	8.67e-12	Height;
LIHC	cis	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg03342759	chr3:160939853	NMD3	0.56	7.33	0.37	1.63e-12	Morning vs. evening chronotype;
LIHC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg06238570	chr21:40685208	BRWD1	-0.38	-6.09	-0.31	3.05e-9	Menarche (age at onset);
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg03874509	chr1:107600012	PRMT6	0.67	9.92	0.47	1.47e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.56	0.5	9.87e-23	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.24	-0.36	2.92e-12	Bipolar disorder;
LIHC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg09182678	chr22:50328711	NA	-0.39	-5.82	-0.3	1.34e-8	Schizophrenia;
LIHC	cis	rs3823572	0.564	rs2971983	chr7:133652537	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.76	-0.3	1.89e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.46	-7.24	-0.36	2.96e-12	Vitiligo;
LIHC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.44	7.1	0.36	7.46e-12	Total body bone mineral density;
LIHC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.74	0.57	1.07e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.38	7.48	0.37	6.47e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.22	-0.32	1.47e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6952808	0.743	rs10266703	chr7:1918941	C/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.0	-0.4	1.97e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.29	-0.68	1.44e-48	Body mass index;
LIHC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg20283391	chr11:68216788	NA	-0.53	-8.05	-0.4	1.35e-14	Total body bone mineral density;
LIHC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-0.99	-10.44	-0.49	2.57e-22	Vitiligo;
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.73	10.31	0.49	7.04e-22	Menarche (age at onset);
LIHC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.56	10.03	0.48	6.55e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.67	-8.2	-0.41	4.95e-15	Gut microbiome composition (summer);
LIHC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.47	-7.41	-0.37	9.73e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.41	6.37	0.33	5.99e-10	Height;
LIHC	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	0.77	8.6	0.42	2.82e-16	Mitochondrial DNA levels;
LIHC	cis	rs6723226	0.593	rs176401	chr2:32636511	A/T	cg02381751	chr2:32503542	YIPF4	-0.7	-10.71	-0.5	2.86e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg14146966	chr2:61757674	XPO1	0.47	8.29	0.41	2.54e-15	Tuberculosis;
LIHC	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.59	-9.8	-0.47	3.93e-20	Corneal astigmatism;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.77	11.41	0.53	8.73e-26	Menarche (age at onset);
LIHC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-18.41	-0.71	4.36e-53	Ulcerative colitis;
LIHC	cis	rs1866706	0.896	rs4757955	chr11:12876492	C/A	cg25843174	chr11:12811716	TEAD1	-0.28	-6.01	-0.31	4.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg06359132	chr10:99160096	RRP12	-0.42	-6.47	-0.33	3.3e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.03	9.23	0.45	2.94e-18	Diabetic retinopathy;
LIHC	cis	rs116975820	0.601	rs11181393	chr12:42657902	A/G	cg01256987	chr12:42539512	GXYLT1	-0.53	-5.75	-0.3	2e-8	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.36	6.89	0.35	2.71e-11	Multiple system atrophy;
LIHC	trans	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg16088116	chr21:44841560	SIK1	-0.41	-6.39	-0.33	5.52e-10	Coronary artery disease;
LIHC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.34	-0.58	5.73e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg18016565	chr1:150552671	MCL1	0.49	9.49	0.46	4.11e-19	Melanoma;
LIHC	trans	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg18393722	chr15:85113863	UBE2QP1	0.44	7.66	0.38	1.91e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg10096929	chr1:156261403	TMEM79	0.37	6.01	0.31	4.73e-9	Tonsillectomy;
LIHC	trans	rs13381277	0.850	rs9948412	chr18:74329454	A/C	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.4	-0.33	5e-10	Dental caries;
LIHC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.05e-17	Bipolar disorder;
LIHC	cis	rs5753037	0.676	rs6006267	chr22:30216982	C/A	cg01021169	chr22:30184971	ASCC2	-0.41	-8.2	-0.41	4.74e-15	Type 1 diabetes;
LIHC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.6	-6.53	-0.33	2.37e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg20283391	chr11:68216788	NA	-0.38	-6.05	-0.31	3.85e-9	Total body bone mineral density;
LIHC	cis	rs7937890	0.504	rs2575847	chr11:14471172	C/T	cg02886208	chr11:14281011	SPON1	-0.46	-6.58	-0.34	1.75e-10	Mitochondrial DNA levels;
LIHC	cis	rs8028182	0.583	rs9944207	chr15:75912889	A/T	cg20655648	chr15:75932815	IMP3	0.46	6.51	0.33	2.67e-10	Sudden cardiac arrest;
LIHC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.51	6.95	0.35	1.87e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	11.11	0.51	1.11e-24	Prudent dietary pattern;
LIHC	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.47	-6.38	-0.33	5.75e-10	Breast cancer;
LIHC	cis	rs57244997	0.582	rs73030429	chr6:162438902	A/G	cg17173639	chr6:162384350	PARK2	-0.52	-6.79	-0.34	5.09e-11	Mosquito bite size;
LIHC	cis	rs28830936	0.966	rs28373318	chr15:42126725	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.8	-0.3	1.51e-8	Diastolic blood pressure;
LIHC	cis	rs11673344	0.523	rs10420330	chr19:37602171	G/A	cg27390819	chr19:37464633	NA	-0.43	-5.79	-0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.61	0.34	1.51e-10	Ileal carcinoids;
LIHC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.57	9.3	0.45	1.72e-18	Breast cancer;
LIHC	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg03934865	chr2:198174659	NA	0.43	6.04	0.31	3.95e-9	Dermatomyositis;
LIHC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.54	-0.33	2.22e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.42	7.14	0.36	5.61e-12	Methadone dose in opioid dependence;
LIHC	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.06	-0.4	1.31e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17253792	0.545	rs12886406	chr14:56027605	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-6.58	-0.34	1.72e-10	Putamen volume;
LIHC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg00204512	chr16:28754710	NA	0.34	6.26	0.32	1.15e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.56	-0.33	1.99e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.33	6.14	0.32	2.3e-9	Mean corpuscular volume;
LIHC	cis	rs909002	0.772	rs6681414	chr1:32070234	G/A	cg13919466	chr1:32135498	COL16A1	-0.32	-6.15	-0.32	2.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.84	16.17	0.66	4.19e-44	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.71	-0.3	2.43e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.53	6.13	0.31	2.36e-9	Axial length;
LIHC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg22563815	chr15:78856949	CHRNA5	0.35	6.26	0.32	1.13e-9	Sudden cardiac arrest;
LIHC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.71	-9.72	-0.47	6.89e-20	Response to metformin (IC50);
LIHC	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.31	-5.75	-0.3	1.98e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01381637	chr19:50902842	POLD1	0.4	6.39	0.33	5.57e-10	Pancreatic cancer;
LIHC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.63	6.86	0.35	3.24e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.36	5.73	0.3	2.16e-8	Schizophrenia;
LIHC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.47	8.23	0.41	3.97e-15	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs3853824	0.898	rs6503767	chr17:54900047	C/T	cg13675837	chr17:54910204	DGKE	0.42	5.93	0.31	7.59e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.47	8.33	0.41	2.02e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.45	0.33	3.82e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	9.06	0.44	1.03e-17	Multiple sclerosis;
LIHC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.67	9.47	0.46	4.65e-19	Coronary artery disease;
LIHC	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.32	0.55	4.05e-29	Coffee consumption (cups per day);
LIHC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.1	0.4	1.01e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.53	-0.79	1.77e-73	Height;
LIHC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20887711	chr4:1340912	KIAA1530	0.45	6.02	0.31	4.48e-9	Obesity-related traits;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.72	-11.91	-0.54	1.32e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.69	14.07	0.61	8.35e-36	Coronary artery disease;
LIHC	trans	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg10756647	chr7:56101905	PSPH	1.11	13.27	0.58	1.06e-32	Diabetic kidney disease;
LIHC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-0.88	-8.45	-0.42	8.25e-16	Alzheimer's disease;
LIHC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-8.92	-0.43	2.8e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.53	0.56	6.56e-30	Prudent dietary pattern;
LIHC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.51	-7.13	-0.36	5.86e-12	Height;
LIHC	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg02187348	chr16:89574699	SPG7	0.44	6.43	0.33	4.2e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg13919466	chr1:32135498	COL16A1	-0.37	-6.9	-0.35	2.48e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg02811702	chr13:24901961	NA	0.26	6.64	0.34	1.25e-10	Obesity-related traits;
LIHC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg07061783	chr6:25882402	NA	-0.46	-6.38	-0.33	5.67e-10	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.23	0.55	8.54e-29	Prudent dietary pattern;
LIHC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.09	-0.4	1.06e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg02503808	chr4:7069936	GRPEL1	-0.43	-6.69	-0.34	9.3e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.14	-0.4	7.28e-15	Exhaled nitric oxide output;
LIHC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.76	-8.28	-0.41	2.81e-15	Exhaled nitric oxide output;
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26240231	chr7:1148101	C7orf50	-0.39	-5.85	-0.3	1.18e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs3736594	0.513	rs1881396	chr2:27844601	G/T	cg27432699	chr2:27873401	GPN1	-0.46	-6.82	-0.35	4.17e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.17e-8	Pulmonary function;
LIHC	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.54	-9.51	-0.46	3.55e-19	Systemic lupus erythematosus;
LIHC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.46	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.09	-0.31	3.02e-9	Total body bone mineral density;
LIHC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg26395211	chr5:140044315	WDR55	0.41	5.92	0.31	7.66e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg18898632	chr2:242989856	NA	-0.7	-8.76	-0.43	9.26e-17	Obesity-related traits;
LIHC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07737236	chr3:161089327	C3orf57	0.49	7.0	0.35	1.35e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-6.1	-0.31	2.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	6.47	0.33	3.32e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs55883249	0.957	rs16867083	chr2:9767441	C/T	cg23886495	chr2:9695866	ADAM17	-0.72	-6.89	-0.35	2.63e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LIHC	cis	rs1865721	1.000	rs8091890	chr18:73197242	T/C	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.16e-13	Intelligence;
LIHC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.4	0.52	9.72e-26	Alzheimer's disease (late onset);
LIHC	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	0.51	9.28	0.45	2.02e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	1.08	14.49	0.62	1.89e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-6.58	-0.34	1.72e-10	Type 2 diabetes;
LIHC	cis	rs2286503	0.839	rs1054471	chr7:22852643	T/A	cg11367502	chr7:22862612	TOMM7	0.43	7.16	0.36	4.96e-12	Fibrinogen;
LIHC	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.9e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.8	9.89	0.47	1.85e-20	Morning vs. evening chronotype;
LIHC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.85	0.3	1.13e-8	Resting heart rate;
LIHC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.63	-8.7	-0.43	1.44e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg09324706	chr12:114395457	RBM19	0.42	6.42	0.33	4.68e-10	Alopecia areata;
LIHC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.63	-0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.49	-6.04	-0.31	4.07e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.41	-7.05	-0.36	9.67e-12	Schizophrenia;
LIHC	cis	rs7260329	0.507	rs71358958	chr19:41530883	G/A	cg10403441	chr19:41533888	NA	0.49	6.45	0.33	3.74e-10	Smoking behavior;
LIHC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg18912006	chr12:123335444	HIP1R	-0.59	-6.79	-0.34	5.03e-11	Schizophrenia;
LIHC	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.49	-9.44	-0.45	5.8e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.43	6.15	0.32	2.12e-9	Longevity;Endometriosis;
LIHC	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg16684958	chr7:75615977	POR	0.37	6.02	0.31	4.59e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.73	-11.01	-0.51	2.42e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.82	-0.35	4.19e-11	Response to antipsychotic treatment;
LIHC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.53	9.49	0.46	3.96e-19	Type 2 diabetes;
LIHC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.17	0.36	4.68e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg04719120	chr6:96025338	MANEA	0.58	6.21	0.32	1.51e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs77861329	1.000	rs352147	chr3:52208285	A/G	cg08692210	chr3:52188851	WDR51A	0.84	8.06	0.4	1.26e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-7.93	-0.39	3.24e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.8	12.51	0.56	7.98e-30	Coronary artery disease;
LIHC	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.75	-0.34	6.46e-11	IFN-related cytopenia;
LIHC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.36	6.13	0.31	2.47e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01818597	chr11:63741913	COX8A	0.46	7.27	0.37	2.4e-12	Cognitive function;
LIHC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.16	0.32	2.01e-9	Menopause (age at onset);
LIHC	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.11	-0.4	9.46e-15	Exhaled nitric oxide output;
LIHC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.0	0.31	4.99e-9	Menopause (age at onset);
LIHC	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg25356066	chr3:128598488	ACAD9	0.54	6.99	0.35	1.49e-11	IgG glycosylation;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg18294483	chr11:96123194	JRKL;CCDC82	-0.43	-6.09	-0.31	3.05e-9	Eotaxin levels;
LIHC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.98	-14.73	-0.62	2.31e-38	Breast cancer;
LIHC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.45	6.33	0.32	7.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.44	6.28	0.32	1.04e-9	Height;
LIHC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.25	-5.87	-0.3	1.02e-8	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.7	7.1	0.36	7.09e-12	Alzheimer's disease;
LIHC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.27	7.09	0.36	7.89e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.37	5.95	0.31	6.49e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098699	0.821	rs6830451	chr4:124230386	G/A	cg09941581	chr4:124220074	SPATA5	0.33	6.59	0.34	1.68e-10	Mosquito bite size;
LIHC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.51	7.77	0.39	9.55e-14	Cognitive function;
LIHC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.13	-0.44	6.06e-18	Morning vs. evening chronotype;
LIHC	cis	rs244293	0.730	rs12165058	chr17:53022049	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.03	-0.31	4.32e-9	Menarche (age at onset);
LIHC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg22563815	chr15:78856949	CHRNA5	0.35	6.4	0.33	5.07e-10	Sudden cardiac arrest;
LIHC	cis	rs2279817	0.731	rs78474704	chr1:18010154	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.76	-0.39	9.68e-14	Neuroticism;
LIHC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.83	-11.72	-0.54	6.47e-27	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7546	0.504	rs2075637	chr16:4938280	T/C	cg08329684	chr16:4932620	PPL	-0.42	-7.35	-0.37	1.43e-12	Cancer;
LIHC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.29	6.75	0.34	6.23e-11	Primary biliary cholangitis;
LIHC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.77	12.48	0.56	1.07e-29	Corneal astigmatism;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.86	0.43	4.47e-17	Height;
LIHC	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.65	5.97	0.31	6.04e-9	Blood protein levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19049344	chr2:166095825	SCN2A	-0.34	-6.74	-0.34	6.82e-11	Cognitive function;
LIHC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.17	-0.48	2.04e-21	Chronic sinus infection;
LIHC	cis	rs1712517	0.744	rs4293063	chr10:105052976	G/T	cg05636881	chr10:105038444	INA	0.46	7.01	0.35	1.31e-11	Migraine;
LIHC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-5.78	-0.3	1.64e-8	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.9	10.72	0.5	2.52e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg06050784	chr16:88016603	BANP	0.38	6.94	0.35	1.93e-11	Menopause (age at onset);
LIHC	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.54	10.46	0.49	2.08e-22	Testicular germ cell tumor;
LIHC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.45	0.33	3.88e-10	Renal cell carcinoma;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	cis	rs8084351	0.577	rs4578737	chr18:50664300	C/T	cg24270629	chr18:50823537	DCC	-0.44	-6.49	-0.33	3.1e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.3	-6.48	-0.33	3.28e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23868672	chr14:35344258	BAZ1A	0.42	6.37	0.33	5.96e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.04e-24	Crohn's disease;
LIHC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs12744310	1.000	rs56409354	chr1:41772971	G/A	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2834188	0.538	rs2026253	chr21:34687966	A/T	cg14352951	chr21:34696688	IFNAR1	0.45	6.38	0.33	5.76e-10	Narcolepsy;
LIHC	trans	rs11671005	0.504	rs2305119	chr19:59067623	C/T	cg22037779	chr5:139682734	PFDN1	-0.52	-6.16	-0.32	2.07e-9	Mean platelet volume;
LIHC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.55	-11.31	-0.52	2.06e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs7129220	0.588	rs61878581	chr11:10083808	C/T	cg01453529	chr11:10209919	SBF2	-0.4	-7.04	-0.36	1.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs7818688	0.697	rs77055525	chr8:95980583	G/A	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg02023728	chr11:77925099	USP35	0.35	6.14	0.32	2.26e-9	Alzheimer's disease (survival time);
LIHC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.42	6.13	0.31	2.48e-9	Bipolar disorder;
LIHC	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.58	5.82	0.3	1.34e-8	IgG glycosylation;
LIHC	cis	rs7119038	0.818	rs10892280	chr11:118611817	C/T	cg19308663	chr11:118741387	NA	0.43	5.81	0.3	1.4e-8	Sjögren's syndrome;
LIHC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg19635926	chr16:89946313	TCF25	0.54	6.74	0.34	6.74e-11	Skin colour saturation;
LIHC	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26734620	chr12:56694298	CS	-1.23	-11.01	-0.51	2.5300000000000002e-24	Psoriasis vulgaris;
LIHC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20135002	chr11:47629003	NA	0.54	8.62	0.42	2.55e-16	Subjective well-being;
LIHC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	6.9	0.35	2.55e-11	Menarche (age at onset);
LIHC	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg16309518	chr5:176445507	NA	-0.57	-10.94	-0.51	4.24e-24	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg15123519	chr2:136567270	LCT	-0.37	-5.97	-0.31	5.9e-9	Corneal structure;
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.84	-0.54	2.51e-27	Alzheimer's disease;
LIHC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.61	5.87	0.3	1.02e-8	Vitiligo;
LIHC	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs8192917	1.000	rs10909625	chr14:25101629	A/G	cg03875678	chr14:25103546	GZMB	0.43	7.63	0.38	2.34e-13	Vitiligo;
LIHC	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.7	0.38	1.46e-13	Systemic lupus erythematosus;
LIHC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs7187994	0.848	rs7498187	chr16:84770570	G/A	cg07647771	chr16:84786436	USP10	-0.34	-6.17	-0.32	1.9e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg23461800	chr14:103021989	NA	-0.42	-5.87	-0.3	1.03e-8	Platelet count;
LIHC	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.4	0.41	1.25e-15	Eosinophil percentage of white cells;
LIHC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.44	-7.05	-0.36	9.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6967414	0.786	rs7804259	chr7:6755448	C/G	cg00387323	chr7:6746715	ZNF12	0.67	7.31	0.37	1.88e-12	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg02990361	chr1:107599529	PRMT6	0.58	9.71	0.46	7.79e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.58	-8.73	-0.43	1.13e-16	QRS duration;
LIHC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg16479474	chr6:28041457	NA	0.39	6.39	0.33	5.56e-10	Parkinson's disease;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-7.77	-0.39	9.34e-14	Lymphocyte counts;
LIHC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg24826892	chr11:71159390	DHCR7	0.53	6.76	0.34	6.09e-11	Vitamin D levels;
LIHC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.68	11.26	0.52	3.26e-25	Menopause (age at onset);
LIHC	cis	rs847851	0.617	rs73403805	chr6:34964724	C/T	cg13137465	chr6:34857473	ANKS1A	0.67	7.39	0.37	1.12e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.33	6.86	0.35	3.23e-11	Sitting height ratio;
LIHC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.81	-0.3	1.43e-8	Subjective well-being;
LIHC	cis	rs36051895	0.587	rs16922785	chr9:5200409	C/G	cg02405213	chr9:5042618	JAK2	-0.62	-9.7	-0.46	8.32e-20	Pediatric autoimmune diseases;
LIHC	cis	rs965469	1.000	rs6051713	chr20:3265779	C/T	cg25506879	chr20:3388711	C20orf194	0.57	6.96	0.35	1.79e-11	IFN-related cytopenia;
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.37	5.71	0.3	2.44e-8	Prostate cancer;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03076246	chr16:67906784	EDC4	0.4	6.23	0.32	1.37e-9	Pancreatic cancer;
LIHC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg18478394	chr8:109455254	TTC35	0.44	7.67	0.38	1.76e-13	Dupuytren's disease;
LIHC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.48	6.08	0.31	3.3e-9	Mean platelet volume;
LIHC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg04865290	chr3:52927548	TMEM110	-0.49	-5.73	-0.3	2.22e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.28	0.55	5.77e-29	Electrocardiographic conduction measures;
LIHC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.48	-7.73	-0.39	1.21e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg06026331	chr20:60912101	LAMA5	-0.51	-8.63	-0.42	2.36e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2971970	0.519	rs2346270	chr7:133647033	G/A	cg03336402	chr7:133662267	EXOC4	-0.46	-5.74	-0.3	2.06e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01534608	chr4:187646364	FAT1	0.48	6.82	0.35	4.18e-11	Pancreatic cancer;
LIHC	cis	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg05084668	chr3:125655381	ALG1L	-0.34	-6.27	-0.32	1.11e-9	Blood pressure (smoking interaction);
LIHC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.6	0.56	3.78e-30	Cognitive test performance;
LIHC	trans	rs78049276	0.512	rs7659823	chr4:148398877	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.68	-10.74	-0.5	2.29e-23	Pulse pressure;
LIHC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.48	-7.88	-0.39	4.28e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.46	0.33	3.62e-10	Aortic root size;
LIHC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.37	0.37	1.3e-12	Renal cell carcinoma;
LIHC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-6.93	-0.35	2.13e-11	Chronic sinus infection;
LIHC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.58	-0.5	8.01e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg16970926	chr12:29381810	FAR2	0.29	5.97	0.31	5.96e-9	QT interval;
LIHC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.26	-17.06	-0.68	1.18e-47	Diabetic kidney disease;
LIHC	cis	rs6973256	0.605	rs7792396	chr7:133345526	T/C	cg10665199	chr7:133106180	EXOC4	0.34	5.86	0.3	1.1e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.49	7.16	0.36	4.89e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9322817	0.691	rs2486141	chr6:105299930	G/A	cg02098413	chr6:105308735	HACE1	0.43	8.14	0.4	7.25e-15	Thyroid stimulating hormone;
LIHC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg07061783	chr6:25882402	NA	-0.47	-6.48	-0.33	3.29e-10	Blood metabolite levels;
LIHC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20135002	chr11:47629003	NA	-0.56	-9.59	-0.46	1.98e-19	Subjective well-being;
LIHC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.79	11.27	0.52	2.85e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.75	-11.47	-0.53	5.38e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.38	-6.45	-0.33	3.76e-10	Hepatocellular carcinoma;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.4	0.33	5e-10	Renal cell carcinoma;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.66	10.44	0.49	2.55e-22	Longevity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03705947	chr1:68152081	GADD45A	0.4	7.1	0.36	7.47e-12	Cognitive function;
LIHC	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.89	-0.35	2.64e-11	Blood protein levels;
LIHC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg18912006	chr12:123335444	HIP1R	0.56	6.77	0.34	5.6e-11	Schizophrenia;
LIHC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.34	6.07	0.31	3.39e-9	Body mass index;
LIHC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.83	0.39	6.31e-14	Bladder cancer;
LIHC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.27e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.59	-8.46	-0.42	8.05e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.7	11.21	0.52	4.79e-25	Colorectal adenoma (advanced);
LIHC	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg25356066	chr3:128598488	ACAD9	0.55	7.36	0.37	1.4e-12	IgG glycosylation;
LIHC	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-20.79	-0.75	1.17e-62	Exhaled nitric oxide output;
LIHC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.38	5.87	0.3	1.01e-8	Longevity;
LIHC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.77	0.39	9.04e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.46	-7.57	-0.38	3.41e-13	Multiple myeloma;
LIHC	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.93	-0.65	4.13e-43	Chronic sinus infection;
LIHC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-12.32	-0.55	3.99e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.81	-0.35	4.53e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg03934865	chr2:198174659	NA	0.47	7.06	0.36	9.38e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	9.25	0.45	2.54e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	cis	rs61677309	0.964	rs55815657	chr11:118155074	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01635816	chr20:2082448	STK35	0.45	6.18	0.32	1.81e-9	Pancreatic cancer;
LIHC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.29	-17.35	-0.68	8.27e-49	Diabetic kidney disease;
LIHC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	0.82	6.21	0.32	1.58e-9	IgG glycosylation;
LIHC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.87	0.3	1.01e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs600806	0.854	rs3768496	chr1:109866569	T/A	cg16275483	chr1:110013120	SYPL2	-0.49	-6.11	-0.31	2.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-7.04	-0.36	1.04e-11	Monocyte percentage of white cells;
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.52	8.0	0.4	1.91e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.82	17.05	0.68	1.3e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-1.01	-19.24	-0.72	1.97e-56	Breast cancer;
LIHC	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.52	0.46	3.32e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.39	0.37	1.14e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09745873	chr9:130653159	ST6GALNAC6	0.4	6.47	0.33	3.35e-10	Cognitive function;
LIHC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.4	7.58	0.38	3.35e-13	IgG glycosylation;
LIHC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg07451762	chr16:28383216	NA	0.4	6.99	0.35	1.42e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs16877106	0.661	rs16877005	chr4:25313994	A/G	cg04796973	chr4:25314218	ZCCHC4	0.54	5.8	0.3	1.54e-8	Weight;
LIHC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.39	-6.31	-0.32	8.72e-10	Monocyte count;
LIHC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg06064525	chr11:970664	AP2A2	0.43	10.36	0.49	4.87e-22	Alzheimer's disease (late onset);
LIHC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10454142	0.666	rs11678403	chr2:48550497	G/A	cg15846641	chr2:48541264	FOXN2	0.49	5.75	0.3	1.97e-8	Sex hormone-binding globulin levels;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07677032	chr17:61819896	STRADA	0.41	6.05	0.31	3.91e-9	Prudent dietary pattern;
LIHC	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	8.77	0.43	8.36e-17	Post bronchodilator FEV1;
LIHC	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg12160578	chr15:63334699	TPM1	0.68	8.88	0.43	3.8e-17	Orofacial clefts;
LIHC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.46	-6.32	-0.32	8.38e-10	Longevity;
LIHC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.33	-6.28	-0.32	1e-9	Body mass index;
LIHC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.23	6.52	0.33	2.58e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg25952890	chr19:58913133	NA	0.66	6.81	0.35	4.31e-11	Mean platelet volume;
LIHC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.7	-9.9	-0.47	1.71e-20	Monocyte percentage of white cells;
LIHC	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.61	7.49	0.38	6.11e-13	Exhaled nitric oxide output;
LIHC	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.06	-0.36	9.58e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs1464321	0.951	rs7488867	chr12:103699685	C/T	cg15403093	chr12:133312361	ANKLE2	0.39	6.14	0.32	2.26e-9	Body mass index;
LIHC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-6.37	-0.33	5.99e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.6	6.91	0.35	2.34e-11	Menarche (age at onset);
LIHC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.2e-13	Heart rate;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17187048	chr2:122407283	CLASP1	0.51	8.0	0.4	2.01e-14	Cognitive function;
LIHC	cis	rs903552	1.000	rs4965873	chr15:102004023	A/G	cg00659931	chr15:102010125	PCSK6	0.46	6.35	0.32	6.91e-10	Diabetic kidney disease;
LIHC	cis	rs4605213	0.686	rs8076111	chr17:49302782	C/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.45	-5.94	-0.31	6.91e-9	Height;
LIHC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg07061783	chr6:25882402	NA	-0.47	-6.48	-0.33	3.29e-10	Blood metabolite levels;
LIHC	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.4	0.45	7.96e-19	Coffee consumption (cups per day);
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.65	9.93	0.47	1.34e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg20487152	chr13:99095054	FARP1	-0.4	-6.47	-0.33	3.41e-10	Neuroticism;
LIHC	cis	rs10984561	0.588	rs1412055	chr9:122249965	G/A	cg14242995	chr9:122249943	NA	0.38	6.03	0.31	4.3e-9	Pulmonary function decline;
LIHC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.6	7.67	0.38	1.83e-13	Morning vs. evening chronotype;
LIHC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg08499158	chr17:42289980	UBTF	0.52	8.51	0.42	5.47e-16	Total body bone mineral density;
LIHC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.38	-5.9	-0.3	8.94e-9	Platelet count;
LIHC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg10402321	chr1:26617780	UBXN11	-0.38	-5.8	-0.3	1.48e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.64	-11.61	-0.53	1.76e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.81	11.12	0.52	1.02e-24	Skin colour saturation;
LIHC	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.48	-6.65	-0.34	1.17e-10	QT interval;
LIHC	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.71	-8.03	-0.4	1.59e-14	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.75	13.88	0.6	4.5e-35	Crohn's disease;
LIHC	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg25952890	chr19:58913133	NA	0.71	7.75	0.39	1.09e-13	Mean platelet volume;
LIHC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg18016565	chr1:150552671	MCL1	-0.49	-9.32	-0.45	1.51e-18	Melanoma;
LIHC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17554472	chr22:41940697	POLR3H	0.54	5.8	0.3	1.48e-8	Vitiligo;
LIHC	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.39	-7.55	-0.38	3.9e-13	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7212590	0.655	rs16943969	chr17:58031153	A/G	cg10252138	chr17:58120427	NA	-0.58	-5.87	-0.3	1.01e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.57	9.92	0.47	1.52e-20	Mean corpuscular volume;
LIHC	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg00977110	chr5:151150581	G3BP1	-0.58	-7.22	-0.36	3.29e-12	Preschool internalizing problems;
LIHC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-0.35	-5.72	-0.3	2.37e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg13516796	chr16:5122251	ALG1	0.42	6.13	0.31	2.47e-9	Morning vs. evening chronotype;
LIHC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.57	-9.53	-0.46	3e-19	Cognitive function;
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.4	8.25	0.41	3.44e-15	Renal cell carcinoma;
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.63	9.24	0.45	2.71e-18	Menarche (age at onset);
LIHC	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.81	-10.6	-0.5	6.61e-23	Blood pressure (smoking interaction);
LIHC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.74	0.69	2.14e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs3736485	0.934	rs17609924	chr15:51911592	G/A	cg08986416	chr15:51914746	DMXL2	-0.47	-6.99	-0.35	1.49e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs72627509	0.638	rs78272732	chr4:57870537	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.63	-8.97	-0.44	2e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.88e-10	Total body bone mineral density;
LIHC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.52	-7.47	-0.37	6.67e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	8.99	0.44	1.71e-17	Schizophrenia;
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.59	8.75	0.43	1.01e-16	Menarche (age at onset);
LIHC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.79	-0.3	1.56e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.69	6.76	0.34	6.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.45	-9.01	-0.44	1.51e-17	Immature fraction of reticulocytes;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13492291	chr12:133312126	ANKLE2	0.36	6.54	0.33	2.24e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg13628971	chr7:2884303	GNA12	0.41	6.54	0.33	2.29e-10	Height;
LIHC	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.45	8.4	0.41	1.18e-15	Testicular germ cell tumor;
LIHC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg12046867	chr14:103022105	NA	-0.5	-7.2	-0.36	3.94e-12	Platelet count;
LIHC	cis	rs12744310	0.887	rs35464028	chr1:41800474	T/G	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg17372223	chr3:52568218	NT5DC2	0.35	5.83	0.3	1.28e-8	Bipolar disorder;
LIHC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.46	7.35	0.37	1.49e-12	Platelet count;
LIHC	cis	rs17106184	0.892	rs12063007	chr1:51166302	G/T	cg07174182	chr1:51127561	FAF1	-0.6	-6.77	-0.34	5.75e-11	Type 2 diabetes;
LIHC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.64	-11.5	-0.53	4.35e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.95	15.5	0.64	2.06e-41	Obesity;Body mass index;
LIHC	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.79	12.66	0.56	2.23e-30	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LIHC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.38	0.37	1.21e-12	Protein C levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg16280946	chr22:20716554	NA	0.42	6.07	0.31	3.48e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs838721	0.574	rs13014016	chr2:234257454	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	5.85	0.3	1.12e-8	Total body bone mineral density;
LIHC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg18944383	chr4:111397179	ENPEP	0.28	6.55	0.33	2.14e-10	Coronary artery disease;
LIHC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.04	0.55	4.36e-28	Alzheimer's disease;
LIHC	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.79	-8.82	-0.43	5.87e-17	Exhaled nitric oxide output;
LIHC	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.86	0.39	5.2e-14	Refractive astigmatism;
LIHC	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.27	-0.32	1.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.52	8.19	0.41	5.16e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.78	-0.34	5.44e-11	Ulcerative colitis;
LIHC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.51	-0.33	2.73e-10	Mean corpuscular volume;
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-12.09	-0.55	2.86e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs959260	1.000	rs4789184	chr17:73383314	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.8	-0.3	1.51e-8	Systemic lupus erythematosus;
LIHC	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.65	-0.46	1.19e-19	LDL cholesterol levels;
LIHC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg21518248	chr2:162101506	NA	0.39	5.81	0.3	1.4e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.85	10.22	0.48	1.41e-21	Mean platelet volume;
LIHC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	13.14	0.58	3.26e-32	Psoriasis;
LIHC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg18016565	chr1:150552671	MCL1	0.49	9.4	0.45	8.09e-19	Melanoma;
LIHC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg12903224	chr12:29470962	FAR2	-0.42	-6.79	-0.34	4.9e-11	QT interval;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.43	-6.05	-0.31	3.77e-9	Longevity;
LIHC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.38	-7.01	-0.35	1.3e-11	Response to antipsychotic treatment;
LIHC	cis	rs6466055	0.777	rs2299319	chr7:104877916	C/T	cg04380332	chr7:105027541	SRPK2	-0.36	-6.74	-0.34	6.6e-11	Schizophrenia;
LIHC	cis	rs11671005	0.656	rs73066226	chr19:59008213	T/C	cg25952890	chr19:58913133	NA	0.67	6.44	0.33	4.15e-10	Mean platelet volume;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg00280220	chr17:61926910	NA	0.42	6.51	0.33	2.71e-10	Prudent dietary pattern;
LIHC	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.51	9.49	0.46	3.99e-19	Testicular germ cell tumor;
LIHC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.62e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg24693881	chr1:107596107	NA	-0.52	-9.16	-0.44	5e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.08e-11	Alzheimer's disease;
LIHC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.53	8.58	0.42	3.26e-16	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23685580	chr15:43940867	CATSPER2	-0.44	-6.4	-0.33	5.2400000000000005e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.77	-0.43	8.46e-17	Cognitive function;
LIHC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg03146154	chr1:46216737	IPP	-0.48	-8.1	-0.4	9.55e-15	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.88	-0.35	2.9100000000000002e-11	Metabolite levels;
LIHC	cis	rs11098699	0.821	rs6811839	chr4:124222326	G/A	cg09941581	chr4:124220074	SPATA5	0.34	6.79	0.34	4.84e-11	Mosquito bite size;
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.58	7.23	0.36	3.14e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs7487075	0.619	rs10785627	chr12:46824229	G/A	cg23829395	chr12:46796953	NA	0.35	6.17	0.32	1.97e-9	Itch intensity from mosquito bite;
LIHC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg19645103	chr12:69753606	YEATS4	-0.46	-6.28	-0.32	1e-9	Response to diuretic therapy;
LIHC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.99	-0.4	2.13e-14	Lymphocyte counts;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05002041	chr16:23652837	DCTN5;PALB2	-0.34	-6.3	-0.32	9.18e-10	Bilirubin levels;
LIHC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg27478167	chr7:817139	HEATR2	-0.41	-5.89	-0.3	9.18e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.47	-7.64	-0.38	2.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.43	6.09	0.31	3.11e-9	Tuberculosis;
LIHC	cis	rs6977660	1.000	rs5017193	chr7:19820103	G/A	cg07541023	chr7:19748670	TWISTNB	0.36	5.74	0.3	2.1e-8	Thyroid stimulating hormone;
LIHC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg23485639	chr6:28045615	ZNF165	0.39	5.94	0.31	7.13e-9	Parkinson's disease;
LIHC	cis	rs3770081	1.000	rs6718632	chr2:86176084	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.79	0.3	1.64e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.72	-10.77	-0.5	1.73e-23	Aortic root size;
LIHC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	2.97e-30	Menopause (age at onset);
LIHC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-7.64	-0.38	2.19e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	cis	rs6831352	0.673	rs1154403	chr4:100009590	C/T	cg12011299	chr4:100065546	ADH4	0.49	7.88	0.39	4.54e-14	Alcohol dependence;
LIHC	cis	rs6001982	0.541	rs5995890	chr22:41051302	G/C	cg14879645	chr22:41048474	NA	0.4	5.8	0.3	1.53e-8	Breast cancer;
LIHC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	8.93	0.43	2.72e-17	Lung cancer in ever smokers;
LIHC	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.76	-5.98	-0.31	5.47e-9	Mosquito bite size;
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg06497051	chr1:156261200	TMEM79	0.38	6.05	0.31	3.83e-9	Tonsillectomy;
LIHC	trans	rs10915437	0.536	rs6663939	chr1:4197256	C/T	cg23269655	chr10:75541687	CHCHD1	0.4	6.04	0.31	4.06e-9	Migraine - clinic-based;
LIHC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.43	-5.78	-0.3	1.7e-8	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.95	19.27	0.72	1.55e-56	Height;
LIHC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg15605315	chr1:45957053	TESK2	0.44	5.95	0.31	6.59e-9	Platelet count;
LIHC	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg06533319	chr4:3265114	C4orf44	0.34	6.35	0.32	6.9e-10	Parental longevity (mother's age at death);
LIHC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.4	7.13	0.36	6.19e-12	Testicular germ cell tumor;
LIHC	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.54	0.33	2.25e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	0.76	8.07	0.4	1.19e-14	Testicular germ cell tumor;
LIHC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg03859395	chr2:55845619	SMEK2	0.85	15.05	0.63	1.22e-39	Metabolic syndrome;
LIHC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.37	5.78	0.3	1.64e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs17683430	0.614	rs2006253	chr22:32530256	A/C	cg19942213	chr7:117476040	CTTNBP2	0.69	6.11	0.31	2.67e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg16836995	chr17:43662488	NA	-0.77	-7.92	-0.39	3.28e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.8	-11.81	-0.54	3.2e-27	Motion sickness;
LIHC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.68	0.38	1.65e-13	Blood metabolite levels;
LIHC	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg15192750	chr16:69999425	NA	0.45	6.86	0.35	3.22e-11	IgE levels;
LIHC	cis	rs11671005	0.651	rs10402325	chr19:58913507	A/G	cg25952890	chr19:58913133	NA	0.69	7.08	0.36	8.04e-12	Mean platelet volume;
LIHC	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg03146154	chr1:46216737	IPP	-0.36	-6.01	-0.31	4.78e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.32	-0.32	8.19e-10	Dental caries;
LIHC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.53	-8.36	-0.41	1.64e-15	Uric acid clearance;
LIHC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.45	7.38	0.37	1.2e-12	Caffeine consumption;
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20570016	chr1:156261298	TMEM79	0.38	6.08	0.31	3.22e-9	Tonsillectomy;
LIHC	trans	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg26939375	chr7:64535504	NA	0.42	6.63	0.34	1.32e-10	Aortic root size;
LIHC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.34	-0.49	5.5e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.43	-6.08	-0.31	3.14e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	8.87e-33	Prudent dietary pattern;
LIHC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.03	-0.4	1.58e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.52	-0.42	5.34e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.84	-0.3	1.21e-8	Biliary atresia;
LIHC	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg09065629	chr16:1709722	CRAMP1L	0.33	5.75	0.3	1.98e-8	Coronary artery disease;
LIHC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-5.84	-0.3	1.19e-8	Neuroticism;
LIHC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.36	-7.23	-0.36	3.18e-12	Renal cell carcinoma;
LIHC	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg13616963	chr3:57583610	ARF4	-0.41	-6.43	-0.33	4.29e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs365132	0.846	rs812246	chr5:176327644	G/A	cg16309518	chr5:176445507	NA	-0.51	-9.69	-0.46	8.59e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs9649465	0.967	rs2286831	chr7:123303477	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.59e-14	Migraine;
LIHC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	5.86	0.3	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.68	0.34	9.67e-11	Bipolar disorder;
LIHC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.63	-8.86	-0.43	4.45e-17	Blood metabolite levels;
LIHC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.62	10.08	0.48	4.18e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs10857712	0.950	rs11101744	chr10:135226041	G/C	cg01444801	chr10:135216882	MTG1	-0.67	-10.36	-0.49	4.7e-22	Systemic lupus erythematosus;
LIHC	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg08345082	chr10:99160200	RRP12	-0.39	-6.41	-0.33	4.72e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.77	-14.66	-0.62	4.39e-38	Mortality in heart failure;
LIHC	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg05110241	chr16:68378359	PRMT7	-0.54	-6.51	-0.33	2.67e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.56	0.42	3.83e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg25039879	chr17:56429692	SUPT4H1	0.76	8.79	0.43	7.19e-17	Cognitive test performance;
LIHC	cis	rs6445975	0.715	rs4681835	chr3:58263351	T/G	cg23715586	chr3:58305044	RPP14	-0.37	-6.21	-0.32	1.52e-9	Systemic lupus erythematosus;
LIHC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.74	0.6	1.59e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg20607798	chr8:58055168	NA	0.51	6.37	0.33	5.93e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.6	0.38	2.91e-13	Tonsillectomy;
LIHC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20135002	chr11:47629003	NA	-0.58	-10.01	-0.48	7.32e-21	Subjective well-being;
LIHC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.55	9.26	0.45	2.26e-18	Vitiligo;
LIHC	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.86	14.87	0.63	6.41e-39	Headache;
LIHC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.49	-8.26	-0.41	3.32e-15	Menarche (age at onset);
LIHC	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.87	10.9	0.51	6.08e-24	Prostate cancer;
LIHC	cis	rs4407350	0.870	rs5765714	chr22:44915203	T/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.39	0.33	5.35e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11871801	0.846	rs4792923	chr17:40690118	G/C	cg14558262	chr17:40713999	COASY	-0.51	-6.97	-0.35	1.6e-11	Crohn's disease;
LIHC	trans	rs792448	0.743	rs351373	chr1:212426631	G/T	cg20223728	chr6:6006398	NRN1	0.34	6.2	0.32	1.66e-9	White blood cell count (basophil);
LIHC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.62	9.83	0.47	3.01e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.65	-7.18	-0.36	4.5e-12	Putamen volume;
LIHC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.37	0.41	1.48e-15	Birth weight;
LIHC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.39	7.32	0.37	1.74e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg25364880	chr3:44379878	C3orf23	0.72	10.45	0.49	2.36e-22	Depressive symptoms;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21144940	chr19:1993265	BTBD2	0.44	6.46	0.33	3.51e-10	Cognitive function;
LIHC	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg02569219	chr17:2266849	SGSM2	0.42	6.35	0.32	6.92e-10	Proinsulin levels;
LIHC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.44	-6.77	-0.34	5.63e-11	Dental caries;
LIHC	cis	rs1198430	0.636	rs2811963	chr1:23824242	A/C	cg13183780	chr1:23809682	ASAP3	-0.59	-8.09	-0.4	1.04e-14	Total cholesterol levels;
LIHC	trans	rs9375946	0.512	rs12191555	chr6:99537716	A/G	cg01500633	chr6:86387148	SNORD50A;SNHG5	-0.45	-6.22	-0.32	1.46e-9	Depressive symptoms;
LIHC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.08	9.83	0.47	3.04e-20	Diabetic retinopathy;
LIHC	trans	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg01596870	chr19:55963115	NA	-0.62	-7.33	-0.37	1.68e-12	Obesity-related traits;
LIHC	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.49	-6.86	-0.35	3.31e-11	Life satisfaction;
LIHC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.2e-13	Electroencephalogram traits;
LIHC	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.77	8.7	0.43	1.45e-16	Height;
LIHC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.42	-6.84	-0.35	3.61e-11	Alcohol dependence;
LIHC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.89	-0.3	9.31e-9	Body mass index;
LIHC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.66	13.79	0.6	1.01e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-10.69	-0.5	3.39e-23	Platelet count;
LIHC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.51	7.41	0.37	9.72e-13	Response to diuretic therapy;
LIHC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg03037974	chr15:76606532	NA	0.74	14.52	0.62	1.54e-37	Blood metabolite levels;
LIHC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	8.47	0.42	7.11e-16	IgG glycosylation;
LIHC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.49	8.32	0.41	2.18e-15	Mean corpuscular volume;
LIHC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.41e-23	Personality dimensions;
LIHC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-6.66	-0.34	1.13e-10	Blood pressure (smoking interaction);
LIHC	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.43	6.31	0.32	8.83e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs12464559	0.826	rs10196143	chr2:152599229	C/T	cg01189475	chr2:152685088	ARL5A	0.65	6.56	0.33	2.05e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-7.1	-0.36	7.09e-12	Mortality in heart failure;
LIHC	cis	rs3748682	0.821	rs71642605	chr1:38256427	T/C	cg12658694	chr1:38397304	INPP5B	0.45	6.11	0.31	2.75e-9	Hypothyroidism;
LIHC	cis	rs600806	0.778	rs4970731	chr1:109995459	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-5.9	-0.3	8.91e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.57	-7.5	-0.38	5.57e-13	Itch intensity from mosquito bite;
LIHC	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg04727924	chr7:799746	HEATR2	0.53	6.76	0.34	5.98e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.54	10.53	0.49	1.24e-22	Testicular germ cell tumor;
LIHC	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.22	6.0	0.31	5.1e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15640707	chr5:89705759	CETN3	0.4	6.24	0.32	1.29e-9	Calcium levels;
LIHC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.64	-9.06	-0.44	9.93e-18	Blood metabolite levels;
LIHC	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-18.94	-0.72	3.09e-55	Schizophrenia;
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08682334	chr16:737214	WDR24	-0.44	-6.27	-0.32	1.11e-9	Gut microbiome composition (summer);
LIHC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.2	-0.32	1.66e-9	Menarche (age at onset);
LIHC	cis	rs5762813	0.566	rs4055	chr22:29352495	A/C	cg15103426	chr22:29168792	CCDC117	0.44	6.09	0.31	2.96e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.35	-0.78	8.99e-73	Height;
LIHC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	0.55	10.36	0.49	4.85e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.47	5.93	0.31	7.4e-9	Pancreatic cancer;
LIHC	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg08847533	chr14:75593920	NEK9	-0.36	-5.99	-0.31	5.23e-9	Caffeine consumption;
LIHC	cis	rs1866706	1.000	rs10734205	chr11:12861267	C/T	cg25843174	chr11:12811716	TEAD1	-0.31	-6.56	-0.33	1.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg22771759	chr13:24902376	NA	0.33	6.79	0.34	4.98e-11	Obesity-related traits;
LIHC	cis	rs9596863	0.898	rs9568902	chr13:54324954	G/A	ch.13.53330881F	chr13:54432880	NA	0.44	6.08	0.31	3.2e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.22	-0.41	4.23e-15	Vitamin D levels;
LIHC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.29	0.41	2.59e-15	Birth weight;
LIHC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.52	9.16	0.44	4.88e-18	N-glycan levels;
LIHC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21467203	chr3:49911342	NA	-0.38	-6.48	-0.33	3.18e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg03999872	chr20:62272968	STMN3	-0.46	-6.81	-0.35	4.41e-11	Atopic dermatitis;
LIHC	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.56	6.52	0.33	2.51e-10	Eye color traits;
LIHC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg24879335	chr3:133465180	TF	-0.33	-6.81	-0.35	4.47e-11	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.46	6.82	0.35	4.1e-11	Dermatomyositis;
LIHC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.78	-13.42	-0.59	2.76e-33	Aortic root size;
LIHC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.52	7.4	0.37	1.05e-12	Asthma;
LIHC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	6.13	0.31	2.48e-9	Rheumatoid arthritis;
LIHC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.69	-8.18	-0.4	5.63e-15	Behavioural disinhibition (generation interaction);
LIHC	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg09572067	chr16:29127029	RRN3P2	0.54	8.21	0.41	4.55e-15	Menopause (age at onset);
LIHC	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	0.98	13.75	0.6	1.46e-34	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.88	-10.95	-0.51	4.08e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27297192	chr10:134578999	INPP5A	0.55	8.08	0.4	1.1e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.04	19.22	0.72	2.37e-56	Subjective well-being;
LIHC	cis	rs10916814	0.632	rs4439331	chr1:20897091	T/C	cg24502330	chr1:20914028	CDA	-0.31	-6.82	-0.35	4.1e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.38	6.25	0.32	1.22e-9	Alzheimer's disease (late onset);
LIHC	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg18081818	chr7:23246105	NA	-0.38	-5.83	-0.3	1.3e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg05590025	chr7:65112418	INTS4L2	-0.51	-6.2	-0.32	1.59e-9	Diabetic kidney disease;
LIHC	cis	rs3736485	0.934	rs11634999	chr15:51871461	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.05e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.37	-9.77	-0.47	4.66e-20	Asthma (sex interaction);
LIHC	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg19302996	chr17:73780495	UNK	-0.59	-9.41	-0.45	7.44e-19	White matter hyperintensity burden;
LIHC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.79	-12.41	-0.56	1.83e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.8e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2997447	0.669	rs61776584	chr1:26438455	T/C	cg19633962	chr1:26362018	EXTL1	-0.5	-5.75	-0.3	1.97e-8	QRS complex (12-leadsum);
LIHC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg00292662	chr22:38071168	LGALS1	0.63	9.97	0.47	1.03e-20	Fat distribution (HIV);
LIHC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.73	5.99	0.31	5.45e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.91	-0.39	3.58e-14	Schizophrenia;
LIHC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.08	12.81	0.57	6.14e-31	Vitiligo;
LIHC	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg10820045	chr2:198174542	NA	0.47	7.07	0.36	8.78e-12	Dermatomyositis;
LIHC	trans	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg13698153	chr12:118541722	VSIG10	0.58	6.26	0.32	1.12e-9	Vitiligo;
LIHC	cis	rs55665837	0.540	rs10832299	chr11:14769392	G/A	cg00085434	chr11:14927489	NA	0.4	5.77	0.3	1.78e-8	Vitamin D levels;
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg21486233	chr12:29375141	FAR2	0.3	5.85	0.3	1.14e-8	QT interval;
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg02782426	chr3:40428986	ENTPD3	-0.33	-6.24	-0.32	1.29e-9	Renal cell carcinoma;
LIHC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs743757	1.000	rs762897	chr3:50428766	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.43	5.9	0.3	8.95e-9	Diastolic blood pressure;
LIHC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.94	17.54	0.69	1.39e-49	Menopause (age at onset);
LIHC	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg13753209	chr17:57696993	CLTC	-0.76	-12.25	-0.55	7.28e-29	Hemoglobin concentration;
LIHC	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.64	-10.2	-0.48	1.69e-21	Rheumatoid arthritis;
LIHC	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs4596713	0.538	rs10869961	chr9:71787071	C/T	cg16512924	chr15:28394682	HERC2	0.38	6.22	0.32	1.45e-9	Headache;
LIHC	cis	rs9596863	0.950	rs9563182	chr13:54395310	T/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.08e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.35	7.34	0.37	1.55e-12	Sitting height ratio;
LIHC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-19.92	-0.73	3.7e-59	Coronary artery disease;
LIHC	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.4	-0.33	5.09e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.72	-0.34	7.6e-11	Psoriasis;
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06420487	chr17:61919686	SMARCD2	0.43	5.85	0.3	1.16e-8	Height;
LIHC	cis	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05901451	chr6:126070800	HEY2	-0.45	-8.06	-0.4	1.25e-14	Endometrial cancer;
LIHC	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.02	-0.35	1.22e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.01e-22	Hypertriglyceridemia;
LIHC	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg20194872	chr6:41519635	FOXP4	0.4	6.33	0.32	7.78e-10	Prostate cancer;
LIHC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.75	-0.39	1.07e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.61	9.02	0.44	1.33e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4589502	0.528	rs8039656	chr15:67208848	G/A	cg12317470	chr15:67143691	NA	-0.45	-5.88	-0.3	9.79e-9	Lung cancer (smoking interaction);
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06656553	chr16:89960601	TCF25	-0.49	-6.2	-0.32	1.6e-9	Skin colour saturation;
LIHC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg05501817	chr11:14380813	RRAS2	-0.45	-6.29	-0.32	9.56e-10	Sense of smell;
LIHC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.22	0.32	1.46e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.54	7.02	0.35	1.19e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.73	0.3	2.21e-8	Nonalcoholic fatty liver disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02429622	chr10:30024742	SVIL	-0.53	-6.16	-0.32	2.06e-9	Systolic blood pressure;
LIHC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.57	11.03	0.51	2.06e-24	Coronary artery disease;
LIHC	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.49	-6.54	-0.33	2.19e-10	Neuroblastoma;
LIHC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.5	-7.52	-0.38	4.86e-13	Total body bone mineral density;
LIHC	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.49	-0.42	6.42e-16	Renal cell carcinoma;
LIHC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg07424592	chr7:64974309	NA	0.83	9.5	0.46	3.78e-19	Diabetic kidney disease;
LIHC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.39	5.91	0.3	8.48e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.71	0.38	1.43e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.51	7.96	0.4	2.49e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.81	0.35	4.42e-11	Height;
LIHC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.67	6.86	0.35	3.16e-11	Gout;
LIHC	cis	rs7116495	1.000	rs2511114	chr11:71792147	T/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.08	7.83	0.39	6.23e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg25329415	chr6:28076851	NA	0.27	5.71	0.3	2.41e-8	Cardiac Troponin-T levels;
LIHC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.56	-6.12	-0.31	2.55e-9	Menarche (age at onset);
LIHC	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg25344623	chr2:136566232	LCT	-0.34	-5.89	-0.3	9e-9	Corneal structure;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg05185784	chr16:90016020	DEF8	-0.45	-5.84	-0.3	1.21e-8	Skin colour saturation;
LIHC	cis	rs9513627	0.510	rs4365162	chr13:100212614	G/C	cg25919922	chr13:100150906	NA	0.78	7.03	0.36	1.13e-11	Obesity-related traits;
LIHC	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg20991723	chr1:152506922	NA	0.53	8.88	0.43	3.78e-17	Hair morphology;
LIHC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.19	-0.36	4.12e-12	Psoriasis;
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg12153709	chr19:56196971	EPN1	0.42	6.04	0.31	4e-9	Bilirubin levels;
LIHC	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23598886	chr18:12777645	NA	0.48	6.48	0.33	3.27e-10	Inflammatory skin disease;
LIHC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.89	12.94	0.57	1.93e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.45	6.14	0.32	2.3e-9	High light scatter reticulocyte count;
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.0	-11.0	-0.51	2.63e-24	Platelet count;
LIHC	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg00142150	chr22:38071001	LGALS1	0.44	7.53	0.38	4.5e-13	Fat distribution (HIV);
LIHC	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.72	-12.63	-0.56	2.81e-30	Intelligence (multi-trait analysis);
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13773083	chr2:220197274	RESP18	-0.38	-6.22	-0.32	1.44e-9	Lung cancer in ever smokers;
LIHC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs9942416	0.533	rs12109685	chr5:75024066	A/G	cg19683494	chr5:74908142	NA	0.58	6.25	0.32	1.2e-9	Age-related disease endophenotypes;
LIHC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.27	0.37	2.53e-12	Electroencephalogram traits;
LIHC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.44	8.25	0.41	3.35e-15	Schizophrenia;
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.55	-0.33	2.16e-10	Menopause (age at onset);
LIHC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.39	6.14	0.32	2.29e-9	Multiple sclerosis;
LIHC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg17834443	chr8:19674713	INTS10	0.48	7.02	0.35	1.2e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg24296786	chr1:45957014	TESK2	-0.47	-6.79	-0.34	5.09e-11	Platelet count;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg02990361	chr1:107599529	PRMT6	-0.67	-11.17	-0.52	6.58e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.71	-11.09	-0.51	1.24e-24	White matter hyperintensity burden;
LIHC	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.71	-8.73	-0.43	1.11e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-5.73	-0.3	2.23e-8	Personality dimensions;
LIHC	cis	rs3736485	0.934	rs4775955	chr15:51873449	C/T	cg08986416	chr15:51914746	DMXL2	0.42	6.28	0.32	1.04e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.06	-19.15	-0.72	4.8e-56	Testicular germ cell tumor;
LIHC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.4	0.45	8.18e-19	Platelet count;
LIHC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg01629716	chr15:45996671	NA	0.52	9.48	0.46	4.49e-19	Waist circumference;Weight;
LIHC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.42	-6.94	-0.35	1.98e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.85	-17.99	-0.7	2.14e-51	Height;
LIHC	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.92	-0.54	1.2e-27	Birth weight;
LIHC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg18964960	chr10:1102726	WDR37	0.72	6.63	0.34	1.32e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.88	-0.35	2.89e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.97	-18.17	-0.7	4.14e-52	Breast cancer;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg03785755	chr6:26196794	NA	0.51	5.97	0.31	5.8e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.64	-0.34	1.27e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.5	-6.94	-0.35	1.97e-11	Morning vs. evening chronotype;
LIHC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.2	0.41	5.04e-15	IgG glycosylation;
LIHC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.77	8.55	0.42	4.13e-16	Bipolar disorder (body mass index interaction);
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg14630369	chr13:100803190	PCCA	-0.38	-6.41	-0.33	4.83e-10	Pain;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.18	-0.32	1.78e-9	Total body bone mineral density;
LIHC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.9	8.69	0.43	1.54e-16	Eosinophil percentage of granulocytes;
LIHC	trans	rs10411161	0.752	rs8107388	chr19:52407286	C/A	cg22319618	chr22:45562946	NUP50	-0.56	-7.0	-0.35	1.37e-11	Breast cancer;
LIHC	cis	rs12286929	0.617	rs11607928	chr11:115102224	A/G	cg04055981	chr11:115044050	NA	0.43	6.14	0.32	2.31e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.87	11.29	0.52	2.49e-25	Coronary artery disease;
LIHC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg00656387	chr3:40428638	ENTPD3	0.43	6.96	0.35	1.75e-11	Renal cell carcinoma;
LIHC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.7	-0.5	3.03e-23	Chronic sinus infection;
LIHC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	11.42	0.53	8.18e-26	Menarche (age at onset);
LIHC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.94	0.31	7.05e-9	Tonsillectomy;
LIHC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-8.61	-0.42	2.76e-16	Bipolar disorder;
LIHC	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg00750074	chr16:89608354	SPG7	-0.4	-6.32	-0.32	8.04e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.33	0.41	2.02e-15	Motion sickness;
LIHC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.48	-7.79	-0.39	8.26e-14	Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09844907	chr16:15489619	MPV17L	0.65	8.74	0.43	1.04e-16	Lung function (FEV1/FVC);
LIHC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.37	-5.77	-0.3	1.78e-8	Glioblastoma;
LIHC	trans	rs13113376	0.517	rs9307624	chr4:131242185	A/G	cg22022747	chr1:209237649	NA	0.28	6.04	0.31	3.94e-9	Intelligence;
LIHC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg22676075	chr6:135203613	NA	0.41	6.5	0.33	2.93e-10	Red blood cell count;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.6	9.28	0.45	1.99e-18	Height;
LIHC	cis	rs7192750	0.586	rs4788585	chr16:71993638	A/G	cg06353428	chr16:71660113	MARVELD3	0.81	9.13	0.44	6.3e-18	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.49	-0.46	4.07e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs16828019	0.852	rs12729586	chr1:41522377	C/A	cg03387723	chr1:41708464	SCMH1	-0.4	-6.46	-0.33	3.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4908768	0.906	rs11121182	chr1:8522553	G/T	cg20416874	chr1:8611966	RERE	0.56	8.72	0.43	1.25e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs17106184	1.000	rs12085666	chr1:51391569	A/G	cg07174182	chr1:51127561	FAF1	-0.75	-8.32	-0.41	2.05e-15	Type 2 diabetes;
LIHC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.97	0.35	1.59e-11	Breast cancer;
LIHC	cis	rs7116495	1.000	rs2511076	chr11:71783827	A/G	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.54	-8.22	-0.41	4.17e-15	Menarche (age at onset);
LIHC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg16102536	chr7:156981717	UBE3C	-0.35	-5.88	-0.3	9.69e-9	Body mass index;
LIHC	cis	rs7116495	0.609	rs501308	chr11:71581325	C/G	cg26138937	chr11:71823887	C11orf51	1.25	9.95	0.47	1.18e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.75	7.79	0.39	7.89e-14	Vitiligo;
LIHC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.69	13.69	0.59	2.65e-34	Coronary artery disease;
LIHC	cis	rs6448317	0.556	rs4697076	chr4:24908601	G/A	cg21108841	chr4:24914750	CCDC149	0.53	6.57	0.33	1.92e-10	Heschl's gyrus morphology;
LIHC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20135002	chr11:47629003	NA	-0.57	-10.06	-0.48	5.2e-21	Subjective well-being;
LIHC	trans	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg09045935	chr12:6379348	NA	0.83	6.85	0.35	3.36e-11	Blood metabolite levels;
LIHC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14067834	chr17:29058358	SUZ12P	0.62	6.24	0.32	1.28e-9	Body mass index;
LIHC	cis	rs240764	0.658	rs1336251	chr6:101247698	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.83	-0.3	1.31e-8	Neuroticism;
LIHC	cis	rs918629	0.798	rs6898399	chr5:95289398	A/G	cg10483112	chr5:95245456	ELL2	-0.37	-6.41	-0.33	4.82e-10	IgG glycosylation;
LIHC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00628130	chr8:95908808	CCNE2	-0.44	-6.32	-0.32	7.98e-10	Cognitive function;
LIHC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.13	-0.36	6.07e-12	Ulcerative colitis;
LIHC	cis	rs7131987	0.509	rs11050173	chr12:29441473	T/A	cg00204748	chr12:29376779	FAR2	0.37	6.31	0.32	8.87e-10	QT interval;
LIHC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.72	-0.5	2.57e-23	Monocyte percentage of white cells;
LIHC	cis	rs4908768	0.501	rs35865480	chr1:8603777	C/T	cg20416874	chr1:8611966	RERE	-0.7	-15.08	-0.63	9.46e-40	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.56	10.17	0.48	2.16e-21	Methadone dose in opioid dependence;
LIHC	cis	rs903552	0.736	rs9806369	chr15:102008430	A/C	cg19295451	chr15:102010161	PCSK6	-0.57	-7.96	-0.4	2.64e-14	Diabetic kidney disease;
LIHC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-5.95	-0.31	6.7e-9	Vitiligo;
LIHC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.59	-0.64	9.19e-42	Headache;
LIHC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.57	7.63	0.38	2.4e-13	Mean corpuscular volume;
LIHC	cis	rs6808694	0.568	rs3913938	chr3:20221698	G/A	cg00235661	chr3:20228976	SGOL1	0.37	6.51	0.33	2.74e-10	Ischemic stroke;
LIHC	cis	rs965469	1.000	rs6037547	chr20:3299228	C/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.83	-0.35	3.86e-11	IFN-related cytopenia;
LIHC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.81	0.39	6.86e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg16434002	chr17:42200994	HDAC5	-0.4	-5.87	-0.3	1.03e-8	Bone mineral density (hip);Bone mineral density;
LIHC	trans	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg27615363	chr5:174120078	NA	0.41	6.08	0.31	3.17e-9	Cannabis use (initiation);
LIHC	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.45	-7.04	-0.36	1.03e-11	Glioblastoma;
LIHC	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg14473756	chr11:122847823	NA	-0.37	-6.67	-0.34	1.02e-10	Menarche (age at onset);
LIHC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.3	-0.32	9.02e-10	Total body bone mineral density;
LIHC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.58	-9.8	-0.47	3.94e-20	Colorectal cancer;
LIHC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.72	0.3	2.32e-8	Menopause (age at onset);
LIHC	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.51	-0.38	5.11e-13	Mean platelet volume;
LIHC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.23	0.45	2.8e-18	IgG glycosylation;
LIHC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg10932868	chr11:921992	NA	0.33	6.26	0.32	1.16e-9	Alzheimer's disease (late onset);
LIHC	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	6.36	0.33	6.32e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	11.02	0.51	2.34e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.48	-7.57	-0.38	3.58e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-9.68	-0.46	9.26e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.32	6.09	0.31	3e-9	Sitting height ratio;
LIHC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.65	-0.38	2.08e-13	Chronic sinus infection;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11600697	chr3:37034814	EPM2AIP1;MLH1	-0.48	-6.1	-0.31	2.92e-9	Systolic blood pressure;
LIHC	cis	rs4407350	0.756	rs131158	chr22:44891873	A/G	cg26276947	chr22:44892394	LDOC1L	0.32	6.1	0.31	2.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs4780401	0.933	rs11075010	chr16:11826013	C/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-6.04	-0.31	4.13e-9	Rheumatoid arthritis;
LIHC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.56	9.06	0.44	1.03e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.62	9.58	0.46	2.06e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	12.38	0.56	2.49e-29	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.55	-0.33	2.1e-10	Response to antipsychotic treatment;
LIHC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.74	13.69	0.59	2.56e-34	Iron status biomarkers;
LIHC	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg18898632	chr2:242989856	NA	-0.56	-7.47	-0.37	6.72e-13	Obesity-related traits;
LIHC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg20487152	chr13:99095054	FARP1	-0.36	-6.11	-0.31	2.72e-9	Longevity;
LIHC	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.76	0.34	5.98e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26915774	chr2:162094867	NA	-0.48	-6.08	-0.31	3.17e-9	Systolic blood pressure;
LIHC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.8	12.02	0.54	5.38e-28	Obesity-related traits;
LIHC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg10621924	chr7:39171070	POU6F2	0.43	6.6	0.34	1.57e-10	IgG glycosylation;
LIHC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg16558253	chr16:72132732	DHX38	-0.4	-6.75	-0.34	6.34e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.4	-5.83	-0.3	1.3e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.32	-5.86	-0.3	1.08e-8	Aortic root size;
LIHC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg02297831	chr4:17616191	MED28	0.44	6.05	0.31	3.83e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.42	5.88	0.3	9.5e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23809679	chr4:71554125	UTP3	-0.46	-6.04	-0.31	3.96e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.5	7.05	0.36	9.94e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.68	8.6	0.42	2.87e-16	Initial pursuit acceleration;
LIHC	cis	rs7619427	1.000	rs6804901	chr3:44066663	G/A	cg24966902	chr3:44043705	NA	0.55	7.79	0.39	8.19e-14	Schizophrenia;
LIHC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.64	11.01	0.51	2.46e-24	Colorectal cancer;
LIHC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.4	6.41	0.33	4.74e-10	Reticulocyte count;High light scatter reticulocyte count;
LIHC	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.2	-0.48	1.67e-21	Ear protrusion;
LIHC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.69	-9.92	-0.47	1.45e-20	Mosquito bite size;
LIHC	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg11783602	chr8:55087084	NA	-0.31	-6.15	-0.32	2.19e-9	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.65	10.42	0.49	2.98e-22	Obesity-related traits;
LIHC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.49	7.72	0.39	1.32e-13	Platelet count;
LIHC	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.34	-6.04	-0.31	4.07e-9	Lewy body disease;
LIHC	cis	rs12220238	0.915	rs10824197	chr10:76282793	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.05	0.31	3.85e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs72960926	0.744	rs11755740	chr6:74934131	C/T	cg07247405	chr1:2484626	LOC115110	0.56	6.7	0.34	8.8e-11	Metabolite levels (MHPG);
LIHC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.03	0.31	4.29e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.5	8.96	0.44	2.21e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.75e-12	IgG glycosylation;
LIHC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.72	-12.96	-0.57	1.61e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.67	13.47	0.59	1.73e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg10546459	chr2:36825355	FEZ2	0.49	5.86	0.3	1.07e-8	Height;
LIHC	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.06	-0.44	1.02e-17	Type 2 diabetes;
LIHC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	9.28	0.45	1.98e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.85	0.3	1.14e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg00529422	chr1:16285251	ZBTB17	0.33	6.34	0.32	7.35e-10	Systolic blood pressure;
LIHC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.45	-6.72	-0.34	7.63e-11	Cognitive function;
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg00091569	chr3:40428383	ENTPD3	0.38	6.58	0.34	1.82e-10	Renal cell carcinoma;
LIHC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg04498913	chr7:1135747	C7orf50	0.39	5.72	0.3	2.27e-8	Bronchopulmonary dysplasia;
LIHC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.47	7.25	0.36	2.82e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.59	6.39	0.33	5.54e-10	Vitiligo;
LIHC	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg17218026	chr1:154582156	ADAR	0.34	6.55	0.33	2.18e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21467203	chr3:49911342	NA	-0.41	-7.09	-0.36	7.66e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28489187	0.683	rs233093	chr1:85823120	C/T	cg16011679	chr1:85725395	C1orf52	0.45	5.81	0.3	1.42e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs332507	0.830	rs10804562	chr3:124377196	C/T	cg05980111	chr3:124395277	KALRN	0.37	6.17	0.32	1.97e-9	Plateletcrit;
LIHC	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.55	8.51	0.42	5.65e-16	Corneal astigmatism;
LIHC	cis	rs2540917	0.657	rs11125840	chr2:60627402	G/C	cg00543073	chr2:60773386	BCL11A	-0.33	-6.57	-0.33	1.87e-10	Mean corpuscular volume;
LIHC	cis	rs7712401	0.791	rs10063253	chr5:122128711	T/C	cg18764291	chr5:122110994	SNX2	0.37	6.28	0.32	1.01e-9	Mean platelet volume;
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg12034118	chr1:209979487	IRF6	0.38	5.76	0.3	1.85e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-10.99	-0.51	2.84e-24	Personality dimensions;
LIHC	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.22	-5.88	-0.3	9.86e-9	Hepatitis;
LIHC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg27490568	chr2:178487706	NA	0.37	5.8	0.3	1.52e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.47	6.62	0.34	1.36e-10	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg13957321	chr17:43675089	NA	0.5	7.69	0.38	1.62e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3758785	0.679	rs13447595	chr11:94222690	A/G	cg21580213	chr11:94231278	ANKRD49	-0.36	-6.23	-0.32	1.36e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LIHC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg01652190	chr22:50026171	C22orf34	-0.31	-6.99	-0.35	1.42e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg10208301	chr11:6592745	DNHD1	0.48	6.35	0.32	6.68e-10	Coronary artery calcification;
LIHC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.69	-12.86	-0.57	3.75e-31	Refractive error;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	0.6	8.34	0.41	1.89e-15	Prudent dietary pattern;
LIHC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.38	5.75	0.3	1.93e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs3121446	0.889	rs3104041	chr6:107141728	A/G	cg26014185	chr6:10033784	NA	0.2	6.18	0.32	1.83e-9	Daytime sleep phenotypes;
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.65	9.77	0.47	4.93e-20	Height;
LIHC	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg05425664	chr17:57184151	TRIM37	-0.46	-5.79	-0.3	1.58e-8	Vitamin D levels;
LIHC	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.24	12.8	0.57	6.47e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.59	8.96	0.44	2.21e-17	Corneal astigmatism;
LIHC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.13	-0.31	2.36e-9	Type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.21	-0.36	3.58e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.14	0.55	1.85e-28	Prudent dietary pattern;
LIHC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	trans	rs6011368	0.840	rs2427638	chr20:62900717	C/T	cg13869341	chr1:15865	WASH5P	0.43	7.48	0.37	6.26e-13	Clozapine-induced cytotoxicity;
LIHC	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.3	-7.57	-0.38	3.49e-13	Primary biliary cholangitis;
LIHC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.31	7.28	0.37	2.35e-12	Crohn's disease;
LIHC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01200585	chr1:228362443	C1orf69	-0.4	-5.82	-0.3	1.34e-8	Diastolic blood pressure;
LIHC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.62	0.59	4.85e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20036162	chr8:67404651	C8orf46	-0.39	-7.24	-0.36	2.92e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.35	0.32	6.81e-10	Gut microbiome composition (summer);
LIHC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.85	-0.3	1.18e-8	Breast cancer;
LIHC	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg10820045	chr2:198174542	NA	-0.47	-7.2	-0.36	3.92e-12	Dermatomyositis;
LIHC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.58	9.31	0.45	1.63e-18	Lymphocyte counts;
LIHC	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.4	6.24	0.32	1.33e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9649465	1.000	rs3807635	chr7:123382152	A/C	cg03229431	chr7:123269106	ASB15	-0.37	-7.89	-0.39	4.16e-14	Migraine;
LIHC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.47	7.72	0.39	1.27e-13	Blood metabolite levels;
LIHC	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg10845886	chr2:3471009	TTC15	-0.52	-8.95	-0.44	2.38e-17	Neurofibrillary tangles;
LIHC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.62	9.89	0.47	1.93e-20	Corneal astigmatism;
LIHC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.71	13.53	0.59	1.03e-33	Mortality in heart failure;
LIHC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs11229555	0.645	rs11229462	chr11:58209931	A/T	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.52e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.43	-7.63	-0.38	2.36e-13	Height;
LIHC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.9e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600626	0.636	rs11236516	chr11:75451668	C/T	cg24262691	chr11:75473276	NA	-0.41	-6.04	-0.31	4e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg03037974	chr15:76606532	NA	0.72	13.98	0.6	1.88e-35	Blood metabolite levels;
LIHC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg22325292	chr17:80708367	FN3K	0.39	6.13	0.31	2.49e-9	Glycated hemoglobin levels;
LIHC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg24296786	chr1:45957014	TESK2	0.41	5.72	0.3	2.39e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1144333	1.000	rs1340684	chr1:76471146	T/C	cg22875332	chr1:76189707	ACADM	0.4	6.26	0.32	1.18e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.61	6.76	0.34	5.94e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	1.02	19.55	0.73	1.15e-57	Breast cancer;
LIHC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.51	9.32	0.45	1.43e-18	Hemoglobin concentration;
LIHC	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.44	8.15	0.4	7.11e-15	Testicular germ cell tumor;
LIHC	cis	rs2637266	0.756	rs846609	chr10:78551718	A/G	cg18941641	chr10:78392320	NA	0.27	5.85	0.3	1.14e-8	Pulmonary function;
LIHC	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.59	0.59	6.14e-34	Coffee consumption (cups per day);
LIHC	cis	rs1986734	0.576	rs4493564	chr4:77420407	A/G	cg24201034	chr4:77507246	SHROOM3	-0.37	-5.88	-0.3	9.68e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.7	6.74	0.34	6.64e-11	Migraine;Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.41	8.27	0.41	2.99e-15	Renal cell carcinoma;
LIHC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.65	9.91	0.47	1.6e-20	Height;
LIHC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.65	-7.01	-0.35	1.3e-11	Alzheimer's disease;
LIHC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.7	10.28	0.49	8.98e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.25	5.81	0.3	1.43e-8	Heart rate;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.9	-0.3	8.7e-9	Total body bone mineral density;
LIHC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.74	7.67	0.38	1.78e-13	Vitiligo;
LIHC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.64e-11	Aortic root size;
LIHC	cis	rs17106184	1.000	rs2105211	chr1:51299810	G/C	cg07174182	chr1:51127561	FAF1	-0.63	-7.19	-0.36	4.13e-12	Type 2 diabetes;
LIHC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.8	0.5	1.35e-23	Chronic sinus infection;
LIHC	cis	rs9783347	1.000	rs59150578	chr11:18340862	G/A	cg15585147	chr11:18324498	HPS5	0.38	6.06	0.31	3.69e-9	Pancreatic cancer;
LIHC	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg03999872	chr20:62272968	STMN3	0.41	6.08	0.31	3.19e-9	Prostate cancer;
LIHC	cis	rs922107	0.664	rs1459637	chr1:90040758	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26072250	chr5:443457	EXOC3;C5orf55	0.47	7.07	0.36	8.74e-12	Cystic fibrosis severity;
LIHC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.55	8.24	0.41	3.7e-15	HIV-1 control;
LIHC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg12903224	chr12:29470962	FAR2	-0.41	-6.67	-0.34	1.01e-10	QT interval;
LIHC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg16070018	chr6:26224392	HIST1H3E	0.6	7.2	0.36	3.79e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.3	-16.7	-0.67	3.38e-46	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.37	7.42	0.37	9.12e-13	Renal cell carcinoma;
LIHC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.6	6.58	0.33	1.82e-10	Alzheimer's disease;
LIHC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg07895657	chr22:50616420	PANX2	-0.39	-6.94	-0.35	1.99e-11	Obesity-related traits;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg00091569	chr3:40428383	ENTPD3	-0.4	-6.79	-0.34	4.83e-11	Renal cell carcinoma;
LIHC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.05	-16.92	-0.68	4.2e-47	Dilated cardiomyopathy;
LIHC	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.32	-6.7	-0.34	8.49e-11	Ulcerative colitis;
LIHC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg06466757	chr4:1255808	NA	0.35	5.93	0.31	7.24e-9	Obesity-related traits;
LIHC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.43	-8.0	-0.4	1.92e-14	Total body bone mineral density;
LIHC	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.42	6.44	0.33	3.98e-10	Neuroticism;
LIHC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg24634471	chr8:143751801	JRK	-0.43	-5.97	-0.31	5.92e-9	Urinary tract infection frequency;
LIHC	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg05425664	chr17:57184151	TRIM37	-0.46	-5.79	-0.3	1.58e-8	Vitamin D levels;
LIHC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.66	13.06	0.58	6.55e-32	High light scatter reticulocyte count;
LIHC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg18944383	chr4:111397179	ENPEP	0.33	7.52	0.38	4.93e-13	Coronary artery disease;
LIHC	cis	rs4742903	0.935	rs10820618	chr9:106960503	T/A	cg14250997	chr9:106856677	SMC2	0.35	5.87	0.3	1.01e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg02795151	chr17:7402630	POLR2A	0.52	5.9	0.3	8.95e-9	Androgen levels;
LIHC	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.93	8.68	0.42	1.64e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs7429990	0.896	rs7427648	chr3:48158239	C/T	cg11946769	chr3:48343235	NME6	-0.47	-6.23	-0.32	1.35e-9	Educational attainment (years of education);
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.06	0.55	3.69e-28	Prudent dietary pattern;
LIHC	trans	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg15676719	chr1:167598521	RCSD1	-0.37	-6.65	-0.34	1.18e-10	Systemic lupus erythematosus;
LIHC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-7.63	-0.38	2.36e-13	Melanoma;
LIHC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11645453	chr3:52864694	ITIH4	0.21	5.71	0.3	2.46e-8	Electroencephalogram traits;
LIHC	cis	rs9783347	1.000	rs1520884	chr11:18309700	C/T	cg15585147	chr11:18324498	HPS5	-0.42	-6.65	-0.34	1.17e-10	Pancreatic cancer;
LIHC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.6	8.83	0.43	5.64e-17	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg10756647	chr7:56101905	PSPH	-1.03	-12.6	-0.56	3.61e-30	Diabetic kidney disease;
LIHC	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.78	-10.99	-0.51	2.79e-24	Ear protrusion;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg00656387	chr3:40428638	ENTPD3	0.48	8.05	0.4	1.36e-14	Renal cell carcinoma;
LIHC	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.27	0.32	1.11e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.55	9.82	0.47	3.2e-20	Coronary heart disease;
LIHC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.77	10.49	0.49	1.68e-22	Coronary artery disease;
LIHC	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg07148914	chr20:33460835	GGT7	0.56	8.63	0.42	2.38e-16	Height;
LIHC	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.66	-6.75	-0.34	6.43e-11	Putamen volume;
LIHC	trans	rs10411161	0.752	rs4584941	chr19:52392141	C/T	cg22319618	chr22:45562946	NUP50	-0.65	-8.52	-0.42	5.07e-16	Breast cancer;
LIHC	cis	rs7487075	0.554	rs7967629	chr12:46628607	C/T	cg15584813	chr12:47219626	SLC38A4	0.31	5.79	0.3	1.63e-8	Itch intensity from mosquito bite;
LIHC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.62	8.22	0.41	4.22e-15	Motion sickness;
LIHC	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.82	8.45	0.42	8.78e-16	Schizophrenia;
LIHC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg08499158	chr17:42289980	UBTF	-0.51	-8.45	-0.42	8.48e-16	Total body bone mineral density;
LIHC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-28.66	-0.84	6.08e-93	Myeloid white cell count;
LIHC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg18944383	chr4:111397179	ENPEP	0.24	6.14	0.32	2.31e-9	Height;
LIHC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg06050784	chr16:88016603	BANP	0.36	6.57	0.33	1.93e-10	Menopause (age at onset);
LIHC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.81	15.31	0.64	1.21e-40	Blood protein levels;
LIHC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.62	-9.59	-0.46	1.87e-19	Uric acid clearance;
LIHC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.64	5.82	0.3	1.34e-8	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7674212	0.541	rs2720458	chr4:104052963	C/G	cg16532752	chr4:104119610	CENPE	-0.42	-6.61	-0.34	1.48e-10	Type 2 diabetes;
LIHC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.81	-0.47	3.57e-20	Response to antipsychotic treatment;
LIHC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.41	6.49	0.33	3.05e-10	Huntington's disease progression;
LIHC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg00343986	chr7:65444356	GUSB	0.41	6.21	0.32	1.5e-9	Aortic root size;
LIHC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.89	-14.15	-0.61	4.18e-36	Body mass index;
LIHC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.3	0.41	2.45e-15	Lung cancer in ever smokers;
LIHC	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.59	-11.7	-0.53	7.97e-27	Schizophrenia;
LIHC	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.8	-0.39	7.78e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7238033	0.624	rs9304323	chr18:43308315	A/G	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs78545713	1.000	rs78661760	chr6:26250033	A/T	cg16070018	chr6:26224392	HIST1H3E	0.67	7.14	0.36	5.72e-12	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.7	-9.81	-0.47	3.57e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.45	8.2	0.41	4.88e-15	Capecitabine sensitivity;
LIHC	trans	rs910316	0.737	rs175045	chr14:75475275	A/C	cg10152585	chr3:50297680	NA	-0.46	-6.22	-0.32	1.43e-9	Height;
LIHC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.43	7.36	0.37	1.34e-12	Aortic root size;
LIHC	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.48	-11.7	-0.53	7.69e-27	Diastolic blood pressure;
LIHC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg03013999	chr17:37608204	MED1	0.35	5.93	0.31	7.32e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.12e-23	Crohn's disease;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.45	8.06	0.4	1.26e-14	Prudent dietary pattern;
LIHC	trans	rs4146653	0.706	rs10904328	chr10:4772604	G/A	cg25345178	chr8:72459908	NA	-0.32	-6.08	-0.31	3.26e-9	Major depressive disorder;
LIHC	cis	rs72627123	0.656	rs17096314	chr14:74567952	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.85	8.21	0.41	4.66e-15	Morning vs. evening chronotype;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg14246617	chr3:69788840	MITF	-0.46	-6.14	-0.32	2.33e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11630290	0.736	rs2197259	chr15:64154156	T/C	cg12036633	chr15:63758958	NA	0.64	6.12	0.31	2.53e-9	Iris characteristics;
LIHC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	cis	rs17817600	0.866	rs12290316	chr11:85644998	T/C	cg03102841	chr11:85646010	NA	-0.48	-6.27	-0.32	1.06e-9	Alzheimer's disease;
LIHC	cis	rs1355223	0.867	rs11821793	chr11:34681462	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.76	-0.3	1.83e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs903552	0.736	rs9806369	chr15:102008430	A/C	cg00659931	chr15:102010125	PCSK6	-0.53	-7.22	-0.36	3.45e-12	Diabetic kidney disease;
LIHC	cis	rs3770081	1.000	rs735737	chr2:86177101	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.82	-0.43	6.02e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-12.91	-0.57	2.54e-31	Dental caries;
LIHC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg23205692	chr1:25664452	TMEM50A	0.41	6.62	0.34	1.37e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.81	12.84	0.57	4.73e-31	Longevity;
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg07133347	chr1:107600762	PRMT6	0.46	6.9	0.35	2.5e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.45e-25	Eye color traits;
LIHC	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.18	-0.52	5.9e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.6e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs34540877	1.000	rs12985259	chr19:33139230	T/G	cg22980127	chr19:33182716	NUDT19	1.0	6.63	0.34	1.3e-10	Red cell distribution width;
LIHC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.48	0.42	6.79e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.79	0.3	1.59e-8	Bipolar disorder;
LIHC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.48	-7.36	-0.37	1.38e-12	Morning vs. evening chronotype;
LIHC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.54	-7.84	-0.39	5.69e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.69	9.55	0.46	2.63e-19	Schizophrenia;
LIHC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg18306943	chr3:40428807	ENTPD3	0.34	5.86	0.3	1.07e-8	Renal cell carcinoma;
LIHC	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg18289306	chr13:113640169	MCF2L	0.42	6.67	0.34	1.02e-10	Systolic blood pressure;
LIHC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-8.4	-0.41	1.24e-15	Gut microbiome composition (summer);
LIHC	cis	rs3820500	0.585	rs1289954	chr1:117914309	G/A	cg20383390	chr1:117909022	MAN1A2	0.44	5.77	0.3	1.79e-8	Pneumonia;
LIHC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.88	0.6	4.52e-35	Chronic sinus infection;
LIHC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg03146154	chr1:46216737	IPP	-0.47	-7.54	-0.38	4.18e-13	Red blood cell count;Reticulocyte count;
LIHC	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg15704280	chr7:45808275	SEPT13	0.64	6.11	0.31	2.72e-9	Myopia (pathological);
LIHC	cis	rs918629	0.798	rs7705279	chr5:95324375	C/T	cg10483112	chr5:95245456	ELL2	-0.36	-6.36	-0.33	6.3e-10	IgG glycosylation;
LIHC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.38	-6.44	-0.33	4.06e-10	Facial morphology (factor 20);
LIHC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.83	10.28	0.49	8.84e-22	Bladder cancer;
LIHC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.76	7.74	0.39	1.14e-13	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22542420	chr17:43183176	NMT1	0.45	6.05	0.31	3.71e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-8.51	-0.42	5.64e-16	Total body bone mineral density;
LIHC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.78	0.3	1.72e-8	Schizophrenia;
LIHC	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg14092571	chr14:90743983	NA	0.42	6.07	0.31	3.47e-9	Mortality in heart failure;
LIHC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.37e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.34	0.32	7.32e-10	Menopause (age at onset);
LIHC	cis	rs2710642	0.721	rs12328837	chr2:62896544	G/A	cg17519650	chr2:63277830	OTX1	0.48	7.15	0.36	5.33e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg00091569	chr3:40428383	ENTPD3	0.4	6.73	0.34	7.09e-11	Renal cell carcinoma;
LIHC	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23598886	chr18:12777645	NA	0.46	6.28	0.32	1.01e-9	Inflammatory skin disease;
LIHC	trans	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs360798	0.553	rs360804	chr2:62939397	C/T	cg17519650	chr2:63277830	OTX1	-0.57	-8.98	-0.44	1.82e-17	Coronary artery disease;
LIHC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.47	-7.42	-0.37	9.06e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.77	11.93	0.54	1.14e-27	Corneal astigmatism;
LIHC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg02297831	chr4:17616191	MED28	0.48	7.3	0.37	2e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-7.12	-0.36	6.35e-12	Mean platelet volume;
LIHC	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.05	-0.66	1.26e-43	Electrocardiographic conduction measures;
LIHC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg13393036	chr8:95962371	TP53INP1	-0.3	-5.86	-0.3	1.11e-8	Type 2 diabetes;
LIHC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	6.93	0.35	2.07e-11	Acylcarnitine levels;
LIHC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg07706471	chr12:123319906	HIP1R	-0.61	-8.12	-0.4	8.33e-15	Schizophrenia;
LIHC	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg20384732	chr3:195601375	TNK2	-0.4	-6.43	-0.33	4.39e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.47	8.58	0.42	3.34e-16	Tuberculosis;
LIHC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04476341	chr5:669733	TPPP	-0.41	-9.0	-0.44	1.62e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	1.05	21.66	0.76	4.03e-66	Breast cancer;
LIHC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.67	-11.31	-0.52	2.06e-25	Childhood ear infection;
LIHC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg03037974	chr15:76606532	NA	-0.64	-11.4	-0.52	1.01e-25	Blood metabolite levels;
LIHC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.4	-6.37	-0.33	6.17e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Corneal astigmatism;
LIHC	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg16511985	chr3:153974050	SGEF	0.41	8.78	0.43	7.86e-17	Coronary artery disease;
LIHC	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-6.19	-0.32	1.71e-9	IFN-related cytopenia;
LIHC	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.3	6.52	0.33	2.5e-10	Pulmonary function;
LIHC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.48	7.59	0.38	3.02e-13	Systemic lupus erythematosus;
LIHC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg07541023	chr7:19748670	TWISTNB	0.41	6.2	0.32	1.67e-9	Thyroid stimulating hormone;
LIHC	cis	rs11630290	0.592	rs8028348	chr15:64156465	A/G	cg12036633	chr15:63758958	NA	0.57	6.09	0.31	3.03e-9	Iris characteristics;
LIHC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-9.26	-0.45	2.39e-18	Gut microbiome composition (summer);
LIHC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	6.38	0.33	5.91e-10	Parkinson's disease;
LIHC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-11.37	-0.52	1.22e-25	Dental caries;
LIHC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.26	-0.32	1.12e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg03645007	chr3:50255295	SLC38A3	0.53	6.59	0.34	1.66e-10	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.76	-0.3	1.86e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.44	0.53	7.27e-26	Motion sickness;
LIHC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.51	7.53	0.38	4.69e-13	Total body bone mineral density;
LIHC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg21559469	chr19:19431446	KIAA0892;SF4	0.41	5.74	0.3	2.09e-8	Tonsillectomy;
LIHC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-12.28	-0.55	5.86e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.46	7.39	0.37	1.13e-12	Mean corpuscular volume;
LIHC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.1e-13	Lung cancer;
LIHC	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg00012203	chr2:219082015	ARPC2	-0.83	-13.05	-0.58	7.16e-32	Colorectal cancer;
LIHC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.66	10.0	0.48	7.83e-21	Body mass index;
LIHC	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg14784868	chr12:69753453	YEATS4	0.66	6.27	0.32	1.09e-9	Response to diuretic therapy;
LIHC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10838687	0.736	rs3781619	chr11:47255317	C/T	cg25783544	chr11:47291846	MADD	0.47	5.98	0.31	5.6e-9	Proinsulin levels;
LIHC	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.69	-0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.74	12.78	0.57	7.66e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg11952622	chr19:58962976	ZNF324B	0.47	7.12	0.36	6.31e-12	Uric acid clearance;
LIHC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.68	5.86	0.3	1.1e-8	Body mass index;
LIHC	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.36	7.64	0.38	2.26e-13	Obesity (extreme);
LIHC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs4668356	0.773	rs60091560	chr2:172031406	T/C	cg13882835	chr2:172017928	TLK1	0.45	6.01	0.31	4.76e-9	Cognitive performance;
LIHC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.42	6.68	0.34	9.55e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg14440974	chr22:39074834	NA	0.44	7.04	0.36	1.06e-11	Menopause (age at onset);
LIHC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.24	7.39	0.37	1.17e-12	Mean corpuscular volume;
LIHC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg25356066	chr3:128598488	ACAD9	-0.53	-7.59	-0.38	3.15e-13	IgG glycosylation;
LIHC	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg14146966	chr2:61757674	XPO1	0.47	8.24	0.41	3.71e-15	Tuberculosis;
LIHC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-0.62	-6.41	-0.33	4.93e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs9649465	0.935	rs7780086	chr7:123378471	C/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.16	-0.4	6.39e-15	Migraine;
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08677398	chr8:58056175	NA	0.39	6.02	0.31	4.39e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.15	-0.36	5.35e-12	Vitiligo;
LIHC	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-1.22	-10.23	-0.48	1.34e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.5	-6.52	-0.33	2.56e-10	Initial pursuit acceleration;
LIHC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg26149184	chr10:133730230	NA	0.47	7.48	0.37	6.46e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.94	-0.31	6.88e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.43	7.26	0.37	2.61e-12	Breast cancer;
LIHC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg16434002	chr17:42200994	HDAC5	0.45	5.77	0.3	1.73e-8	Bone mineral density (hip);Bone mineral density (spine);
LIHC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg18016565	chr1:150552671	MCL1	-0.57	-11.25	-0.52	3.45e-25	Tonsillectomy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20786246	chr2:72377174	NA	0.42	6.48	0.33	3.29e-10	Cognitive function;
LIHC	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg00142150	chr22:38071001	LGALS1	0.43	7.14	0.36	5.52e-12	Fat distribution (HIV);
LIHC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.19	-0.32	1.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.24	-0.32	1.28e-9	Bipolar disorder;
LIHC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg14440974	chr22:39074834	NA	0.39	6.05	0.31	3.86e-9	Menopause (age at onset);
LIHC	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.77	-12.77	-0.57	8.69e-31	Body mass index;
LIHC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.27	0.32	1.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg19752551	chr11:57585705	CTNND1	-0.46	-6.42	-0.33	4.45e-10	Schizophrenia;
LIHC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.76	-17.95	-0.7	3.19e-51	Brugada syndrome;
LIHC	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.6	-8.35	-0.41	1.68e-15	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.56	8.6	0.42	2.92e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.61	-8.73	-0.43	1.16e-16	Obesity-related traits;
LIHC	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.5	7.69	0.38	1.5700000000000001e-13	Urate levels in overweight individuals;
LIHC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg07424592	chr7:64974309	NA	0.79	9.11	0.44	7.25e-18	Diabetic kidney disease;
LIHC	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg00792783	chr2:198669748	PLCL1	0.41	5.97	0.31	5.97e-9	Dermatomyositis;
LIHC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.79	-0.3	1.61e-8	Uric acid levels;
LIHC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.54	7.91	0.39	3.72e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs77861329	1.000	rs72964044	chr3:52092670	G/C	cg08692210	chr3:52188851	WDR51A	0.85	7.73	0.39	1.22e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.63	-0.38	2.4e-13	Glioblastoma;
LIHC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg23262073	chr20:60523788	NA	-0.28	-5.89	-0.3	9.17e-9	Body mass index;
LIHC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.42	7.74	0.39	1.16e-13	Platelet distribution width;
LIHC	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.46	6.14	0.32	2.34e-9	Glioblastoma;Glioma;
LIHC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01200585	chr1:228362443	C1orf69	-0.39	-5.85	-0.3	1.17e-8	Diastolic blood pressure;
LIHC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-8.87	-0.43	4.15e-17	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21937244	chr14:103406412	CDC42BPB	0.45	7.16	0.36	5e-12	Cognitive function;
LIHC	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02985541	chr2:219472218	PLCD4	-0.39	-6.48	-0.33	3.18e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.75	-0.34	6.32e-11	Bipolar disorder;
LIHC	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.44	6.48	0.33	3.18e-10	Schizophrenia;
LIHC	cis	rs918629	0.798	rs2161318	chr5:95288576	C/T	cg10483112	chr5:95245456	ELL2	0.37	6.5	0.33	2.81e-10	IgG glycosylation;
LIHC	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.66	-13.2	-0.58	1.87e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02290350	chr8:58132656	NA	0.47	9.55	0.46	2.57e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-12.28	-0.55	5.94e-29	Breast cancer;
LIHC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg16479474	chr6:28041457	NA	0.44	6.67	0.34	1.03e-10	Parkinson's disease;
LIHC	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.41	-6.77	-0.34	5.62e-11	Schizophrenia;
LIHC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg23485639	chr6:28045615	ZNF165	0.4	6.3	0.32	9.03e-10	Cardiac Troponin-T levels;
LIHC	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.91	10.32	0.49	6.65e-22	Neuroticism;
LIHC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.71	0.43	1.34e-16	Schizophrenia;
LIHC	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.76	11.64	0.53	1.36e-26	Vitamin D levels;
LIHC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg21734168	chr11:67353974	GSTP1	-0.27	-6.57	-0.33	1.92e-10	Mean corpuscular volume;
LIHC	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.36	-0.59	4.92e-33	Coffee consumption (cups per day);
LIHC	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	7.32	0.37	1.75e-12	Breast cancer;
LIHC	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.95e-50	Schizophrenia;
LIHC	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg08992911	chr2:238395768	MLPH	0.5	6.01	0.31	4.86e-9	Prostate cancer;
LIHC	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg03934865	chr2:198174659	NA	0.46	6.81	0.35	4.35e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-7.66	-0.38	1.91e-13	Chronic sinus infection;
LIHC	cis	rs7534824	0.507	rs7518380	chr1:101451262	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.91	0.39	3.59e-14	Refractive astigmatism;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19569686	chr19:1555141	MEX3D	0.4	6.08	0.31	3.21e-9	Bilirubin levels;
LIHC	trans	rs783540	0.934	rs36109438	chr15:83264459	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.66	-0.34	1.09e-10	Schizophrenia;
LIHC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.59	10.17	0.48	2.07e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26734620	chr12:56694298	CS	1.29	11.3	0.52	2.28e-25	Psoriasis vulgaris;
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg25894440	chr7:65020034	NA	0.4	6.32	0.32	8.19e-10	Calcium levels;
LIHC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08219700	chr8:58056026	NA	0.46	5.78	0.3	1.71e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg21231739	chr4:1642635	FAM53A	0.37	6.16	0.32	2.08e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs17102423	0.859	rs34184001	chr14:65596027	T/C	cg11161011	chr14:65562177	MAX	-0.41	-5.97	-0.31	5.95e-9	Obesity-related traits;
LIHC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.79	12.43	0.56	1.53e-29	Breast cancer;
LIHC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.42	6.65	0.34	1.15e-10	Red blood cell count;
LIHC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg07713946	chr22:31675144	LIMK2	-0.43	-7.72	-0.39	1.25e-13	Colorectal cancer;
LIHC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.37	18.17	0.7	3.95e-52	Breast cancer;
LIHC	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	0.78	11.03	0.51	2.18e-24	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4450131	0.902	rs10794174	chr10:126357981	T/C	cg20435097	chr10:126320824	FAM53B	-0.49	-8.99	-0.44	1.68e-17	White blood cell count (basophil);
LIHC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg10360323	chr17:41437877	NA	0.39	5.71	0.3	2.44e-8	Menopause (age at onset);
LIHC	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-7.25	-0.36	2.83e-12	Mortality in heart failure;
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg20607798	chr8:58055168	NA	0.62	7.92	0.39	3.38e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	6.02	0.31	4.5e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.76	11.34	0.52	1.65e-25	Menarche (age at onset);
LIHC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.27	-5.9	-0.3	8.73e-9	Menarche (age at onset);
LIHC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg05044414	chr3:183734942	ABCC5	0.34	6.02	0.31	4.46e-9	Anterior chamber depth;
LIHC	cis	rs7919006	1.000	rs2395127	chr10:76772778	A/T	cg01390419	chr10:76803856	DUPD1	0.44	6.84	0.35	3.59e-11	Weight;
LIHC	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-0.71	-8.02	-0.4	1.74e-14	Gut microbiota (bacterial taxa);
LIHC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-23.92	-0.79	5.38e-75	Height;
LIHC	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.38	-5.96	-0.31	6.19e-9	Coronary artery disease;
LIHC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg11764359	chr7:65958608	NA	0.56	5.96	0.31	6.14e-9	Diabetic kidney disease;
LIHC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg20283391	chr11:68216788	NA	0.36	5.73	0.3	2.16e-8	Total body bone mineral density;
LIHC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.58	9.37	0.45	1.03e-18	Bipolar disorder;
LIHC	cis	rs10420951	0.542	rs2303693	chr19:18557673	A/G	cg10790698	chr19:18539756	SSBP4	0.43	6.06	0.31	3.58e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.67	-10.1	-0.48	3.57e-21	Parkinson's disease;
LIHC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg06664874	chr5:179499304	RNF130	0.67	7.72	0.39	1.3e-13	LDL cholesterol;
LIHC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg15534755	chr11:117069859	TAGLN	-0.37	-6.25	-0.32	1.25e-9	Blood protein levels;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.41	-0.33	4.78e-10	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.16	-0.36	5.11e-12	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.87	-0.35	3e-11	Diabetic kidney disease;
LIHC	trans	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg07393940	chr7:158741817	NA	-0.57	-6.76	-0.34	5.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.62	-7.77	-0.39	9.51e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.36	-7.2	-0.36	3.88e-12	Body mass index;
LIHC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11871801	0.750	rs7216927	chr17:40651497	T/A	cg14558262	chr17:40713999	COASY	0.49	6.83	0.35	3.88e-11	Crohn's disease;
LIHC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg17750252	chr2:136567154	LCT	-0.34	-6.13	-0.31	2.47e-9	Mosquito bite size;
LIHC	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.86	7.93	0.39	3.16e-14	LDL cholesterol;
LIHC	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.75	10.83	0.51	1.04e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-13.8	-0.6	9.43e-35	Height;
LIHC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.55	7.12	0.36	6.57e-12	Parkinson's disease;
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.57	-8.6	-0.42	2.95e-16	Testicular germ cell tumor;
LIHC	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.36	-5.87	-0.3	1.02e-8	Cancer;
LIHC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.52	-7.05	-0.36	9.95e-12	Systolic blood pressure;
LIHC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg20135002	chr11:47629003	NA	-0.5	-8.67	-0.42	1.78e-16	Subjective well-being;
LIHC	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.36	-0.33	6.47e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.63	0.53	1.38e-26	Motion sickness;
LIHC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.41	-6.49	-0.33	2.95e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-1.04	-22.17	-0.77	3.79e-68	Height;
LIHC	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg27255678	chr10:102756921	LZTS2	0.51	7.31	0.37	1.89e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.53e-9	Childhood ear infection;
LIHC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.7	-0.5	3.15e-23	Breast cancer;
LIHC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	4.12e-15	Schizophrenia;
LIHC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.48	6.63	0.34	1.28e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.81	-11.84	-0.54	2.39e-27	Motion sickness;
LIHC	cis	rs1030268	0.651	rs12707118	chr7:133474900	C/T	cg03336402	chr7:133662267	EXOC4	0.47	6.08	0.31	3.21e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-6.65	-0.34	1.15e-10	Lung cancer in ever smokers;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg16070018	chr6:26224392	HIST1H3E	0.59	7.45	0.37	7.55e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.9	0.3	8.67e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs74544699	1.000	rs7666671	chr4:74807007	G/A	cg16072462	chr4:74847758	PF4	0.59	6.02	0.31	4.45e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	0.93	15.89	0.65	5.65e-43	Testicular germ cell tumor;
LIHC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs1865721	1.000	rs72977879	chr18:73193696	T/C	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.39	-0.41	1.29e-15	Blood protein levels;
LIHC	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.66	0.34	1.1e-10	Dupuytren's disease;
LIHC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg15691649	chr6:25882328	NA	0.5	7.23	0.36	3.17e-12	Blood metabolite levels;
LIHC	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.81	-11.91	-0.54	1.39e-27	Response to antineoplastic agents;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-7.64	-0.38	2.17e-13	Lymphocyte counts;
LIHC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	7.55	0.38	3.96e-13	Parkinson's disease;
LIHC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.98	-0.31	5.67e-9	Breast cancer;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.83	13.13	0.58	3.52e-32	Height;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-5.83	-0.3	1.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs11603020	0.950	rs28362947	chr11:57369008	C/G	cg19752551	chr11:57585705	CTNND1	-0.54	-6.73	-0.34	7.15e-11	Blood protein levels;
LIHC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg03859395	chr2:55845619	SMEK2	0.89	15.32	0.64	1.04e-40	Metabolic syndrome;
LIHC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.26	-15.71	-0.65	2.88e-42	Diabetic kidney disease;
LIHC	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.4	7.41	0.37	9.69e-13	Height;
LIHC	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.41	-6.67	-0.34	1.02e-10	Lewy body disease;
LIHC	cis	rs4728302	0.869	rs13231079	chr7:133604373	C/G	cg10665199	chr7:133106180	EXOC4	0.39	6.81	0.35	4.51e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-13.65	-0.59	3.51e-34	Headache;
LIHC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.98	12.83	0.57	4.89e-31	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.52	7.34	0.37	1.54e-12	Body mass index;
LIHC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.46	-5.74	-0.3	2.05e-8	Breast cancer;
LIHC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.6	6.62	0.34	1.36e-10	Alzheimer's disease;
LIHC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg06951627	chr6:26196580	NA	0.55	6.43	0.33	4.39e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg04592579	chr7:75616294	TMEM120A	0.41	6.98	0.35	1.52e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4742903	0.935	rs4742907	chr9:106968226	G/A	cg14250997	chr9:106856677	SMC2	0.35	5.87	0.3	1.04e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.86	-0.35	3.23e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg03945807	chr20:60948434	NA	-0.38	-6.9	-0.35	2.5e-11	Colorectal cancer;
LIHC	cis	rs546131	0.571	rs11601422	chr11:34793759	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-6.23	-0.32	1.4e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.62	7.52	0.38	4.77e-13	Cognitive function;
LIHC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	10.67	0.5	3.76e-23	Body mass index (adult);
LIHC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg07424592	chr7:64974309	NA	0.8	9.15	0.44	5.17e-18	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.83	0.54	2.59e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.42	-6.76	-0.34	6.13e-11	Blood protein levels;
LIHC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.45	-6.41	-0.33	4.95e-10	Height;
LIHC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.37	6.82	0.35	4.12e-11	Schizophrenia;
LIHC	trans	rs6717918	0.517	rs2853362	chr2:233122412	A/G	cg19760917	chr1:2411643	PLCH2	-0.41	-6.41	-0.33	4.69e-10	Height;
LIHC	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	7.14	0.36	5.52e-12	Exhaled nitric oxide output;
LIHC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg04006266	chr11:66300458	BBS1	-0.33	-5.75	-0.3	2e-8	HIV-1 susceptibility;
LIHC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.33	7.18	0.36	4.26e-12	Ulcerative colitis;
LIHC	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.44	6.68	0.34	9.75e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs17135159	0.625	rs11251873	chr10:3436109	A/G	cg20417998	chr20:34252789	CPNE1;RBM12	-0.5	-6.11	-0.31	2.7e-9	Reading and spelling;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.29	0.52	2.46e-25	Prudent dietary pattern;
LIHC	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.3	6.26	0.32	1.16e-9	Menarche (age at onset);
LIHC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg06064525	chr11:970664	AP2A2	-0.44	-10.55	-0.5	9.97e-23	Alzheimer's disease (late onset);
LIHC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.47	7.65	0.38	2.12e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.37	-5.89	-0.3	9.22e-9	Mortality in heart failure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06625838	chr5:162865006	CCNG1	0.45	6.18	0.32	1.81e-9	Pancreatic cancer;
LIHC	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.7	-6.39	-0.33	5.43e-10	Blood protein levels;
LIHC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.76	-9.68	-0.46	9.89e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.08	20.28	0.74	1.34e-60	IgG glycosylation;
LIHC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.79	-0.34	4.85e-11	Body mass index;
LIHC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.02	0.35	1.21e-11	Lung cancer;
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.69	-10.96	-0.51	3.81e-24	Skin colour saturation;
LIHC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.35	-9.19	-0.44	4e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-9.37	-0.45	1.02e-18	Crohn's disease;
LIHC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02424695	chr17:17399795	RASD1	0.45	6.6	0.34	1.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.46	-11.85	-0.54	2.34e-27	Hip circumference adjusted for BMI;
LIHC	trans	rs3785309	0.519	rs7197253	chr16:276549	C/T	cg04806177	chr16:1991447	SEPX1	0.42	6.08	0.31	3.2e-9	Immature fraction of reticulocytes;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg15160873	chr2:128471243	WDR33	0.41	6.4	0.33	5.12e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.67	12.29	0.55	5.33e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12016809	chr21:47604291	C21orf56	0.4	5.85	0.3	1.16e-8	Testicular germ cell tumor;
LIHC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.5	7.9	0.39	3.86e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg22842854	chr12:123319900	HIP1R	-0.65	-8.39	-0.41	1.28e-15	Schizophrenia;
LIHC	cis	rs903552	0.736	rs9806495	chr15:102008059	G/A	cg19295451	chr15:102010161	PCSK6	-0.55	-7.7	-0.38	1.53e-13	Diabetic kidney disease;
LIHC	cis	rs9630089	0.622	rs4919083	chr10:98958738	T/C	cg25902810	chr10:99078978	FRAT1	0.42	5.86	0.3	1.1e-8	Neutrophil percentage of white cells;
LIHC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.52	-7.32	-0.37	1.73e-12	Body mass index;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.51e-13	Prudent dietary pattern;
LIHC	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14154082	chr13:112174009	NA	0.29	6.14	0.32	2.28e-9	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10139015	chr11:47448256	PSMC3	0.37	6.1	0.31	2.91e-9	Pancreatic cancer;
LIHC	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.38	8.12	0.4	8.58e-15	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg00612595	chr21:47717864	NA	-0.39	-6.34	-0.32	7.47e-10	Testicular germ cell tumor;
LIHC	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.44	-7.89	-0.39	4.26e-14	Inhibitory control;
LIHC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.6	-8.59	-0.42	3.09e-16	Blood pressure (smoking interaction);
LIHC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.58	0.38	3.2e-13	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	0.906	rs6678982	chr1:8577185	C/A	cg20416874	chr1:8611966	RERE	0.58	9.11	0.44	6.9e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg04610667	chr7:75704037	NA	-0.35	-6.25	-0.32	1.23e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg07713946	chr22:31675144	LIMK2	-0.43	-7.8	-0.39	7.68e-14	Colorectal cancer;
LIHC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.4	6.55	0.33	2.13e-10	Red blood cell count;
LIHC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.65	10.67	0.5	3.83e-23	Type 2 diabetes;
LIHC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.86	-12.44	-0.56	1.4e-29	Tonsillectomy;
LIHC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.45	-7.88	-0.39	4.48e-14	Aortic root size;
LIHC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.66	8.73	0.43	1.16e-16	Motion sickness;
LIHC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg11764359	chr7:65958608	NA	0.57	6.0	0.31	4.9e-9	Diabetic kidney disease;
LIHC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-7.79	-0.39	7.91e-14	Crohn's disease;
LIHC	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	trans	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg10756647	chr7:56101905	PSPH	1.11	13.23	0.58	1.43e-32	Diabetic kidney disease;
LIHC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20091523	chr11:58909996	FAM111A	0.44	6.57	0.33	1.89e-10	Calcium levels;
LIHC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	24.53	0.8	2.3e-77	Chronic sinus infection;
LIHC	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.64	0.34	1.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.59	-10.02	-0.48	6.64e-21	Red blood cell count;
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg14222432	chr12:29376421	FAR2	0.38	7.19	0.36	4.1e-12	QT interval;
LIHC	cis	rs4700695	0.686	rs27075	chr5:65370379	C/T	cg21114390	chr5:65439923	SFRS12	-0.47	-6.04	-0.31	3.91e-9	Facial morphology (factor 19);
LIHC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.48	0.38	6.29e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs4006360	0.646	rs8080164	chr17:39292845	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.2	5.77	0.3	1.78e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.67	-0.46	1.04e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.73	9.72	0.47	7.02e-20	Fat distribution (HIV);
LIHC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.73	0.3	2.17e-8	Self-reported allergy;
LIHC	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25632853	chr15:73088954	NA	-0.4	-6.66	-0.34	1.07e-10	Triglyceride levels;
LIHC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-11.36	-0.52	1.39e-25	Platelet distribution width;
LIHC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-8.98	-0.44	1.87e-17	Bipolar disorder;
LIHC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.71	12.2	0.55	1.19e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	8.66	0.42	1.92e-16	Multiple sclerosis;
LIHC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.79	10.32	0.49	6.46e-22	Body mass index;
LIHC	cis	rs11630290	0.575	rs7169210	chr15:64165069	T/C	cg12036633	chr15:63758958	NA	0.57	5.79	0.3	1.59e-8	Iris characteristics;
LIHC	cis	rs12744310	0.887	rs12045979	chr1:41809477	A/G	cg03387723	chr1:41708464	SCMH1	-0.32	-5.71	-0.3	2.4e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.88	14.57	0.62	9.52e-38	Schizophrenia;
LIHC	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	0.72	6.21	0.32	1.57e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs9649465	0.967	rs11769381	chr7:123264804	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-9.15	-0.44	5.34e-18	Migraine;
LIHC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.89	11.02	0.51	2.3e-24	Prostate cancer;
LIHC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.45	-6.34	-0.32	7.38e-10	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.67	-9.21	-0.45	3.31e-18	Coronary artery disease;
LIHC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.44	6.39	0.33	5.28e-10	Platelet count;
LIHC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4407350	1.000	rs9626478	chr22:44923619	A/G	cg26276947	chr22:44892394	LDOC1L	0.33	6.08	0.31	3.12e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.08	-0.44	9.06e-18	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16012478	chr7:98609764	TRRAP	0.39	6.54	0.33	2.29e-10	Longevity;
LIHC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17554472	chr22:41940697	POLR3H	0.56	6.23	0.32	1.34e-9	Vitiligo;
LIHC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg11062466	chr8:58055876	NA	0.4	5.82	0.3	1.36e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.63	-0.46	1.43e-19	Response to antipsychotic treatment;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg11070056	chr1:107600091	PRMT6	0.68	11.54	0.53	3.02e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06320982	chr16:58718767	SLC38A7	0.35	6.3	0.32	9.41e-10	Cognitive function;
LIHC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.66	10.57	0.5	9.03e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.72	11.23	0.52	4.11e-25	Phospholipid levels (plasma);
LIHC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg25344623	chr2:136566232	LCT	0.35	7.14	0.36	5.72e-12	Mosquito bite size;
LIHC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.77	-0.3	1.77e-8	Menopause (age at onset);
LIHC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.93	0.65	3.95e-43	Lymphocyte percentage of white cells;
LIHC	trans	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg20587970	chr11:113659929	NA	-0.57	-7.14	-0.36	5.56e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.72	11.27	0.52	2.89e-25	Corneal astigmatism;
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.35	-7.01	-0.35	1.31e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.04e-10	Menopause (age at onset);
LIHC	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.54	8.32	0.41	2.2e-15	HDL cholesterol;
LIHC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-23.11	-0.78	7.6e-72	Height;
LIHC	cis	rs3096299	0.754	rs3096296	chr16:89411010	C/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.82	-0.35	4.18e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg24296786	chr1:45957014	TESK2	0.41	5.81	0.3	1.43e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.69	9.05	0.44	1.08e-17	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.55	8.42	0.41	1.03e-15	Longevity;
LIHC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.26	6.11	0.31	2.65e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg10820045	chr2:198174542	NA	0.48	7.31	0.37	1.91e-12	Dermatomyositis;
LIHC	cis	rs17106184	0.892	rs72900903	chr1:51053585	A/G	cg07174182	chr1:51127561	FAF1	-0.67	-7.1	-0.36	7.38e-12	Type 2 diabetes;
LIHC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-8.18	-0.4	5.53e-15	Blood protein levels;
LIHC	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.28	-0.41	2.73e-15	Blood protein levels;
LIHC	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg25356066	chr3:128598488	ACAD9	0.46	6.22	0.32	1.44e-9	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23803311	chr5:147763284	FBXO38	0.43	6.27	0.32	1.11e-9	Cognitive function;
LIHC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.41	0.33	4.83e-10	Schizophrenia;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.46	7.38	0.37	1.21e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg16394018	chr11:14927549	NA	0.4	5.72	0.3	2.27e-8	Vitamin D levels;
LIHC	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.07	-22.47	-0.77	2.53e-69	Schizophrenia;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.46	0.62	2.68e-37	Prudent dietary pattern;
LIHC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-7.7	-0.38	1.5e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.91	11.52	0.53	3.48e-26	Coronary artery disease;
LIHC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04530015	chr2:215796436	ABCA12	-0.4	-6.55	-0.33	2.12e-10	Neuroblastoma;
LIHC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.59	-9.62	-0.46	1.5700000000000001e-19	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs539514	0.637	rs552030	chr13:76322065	G/T	cg04757411	chr13:76259545	LMO7	-0.42	-7.13	-0.36	5.87e-12	Type 1 diabetes;
LIHC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.05	0.58	7.58e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg11946769	chr3:48343235	NME6	-0.48	-6.17	-0.32	1.96e-9	Educational attainment (years of education);
LIHC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.75	14.71	0.62	2.72e-38	Mortality in heart failure;
LIHC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.67	10.29	0.49	8.05e-22	Corneal astigmatism;
LIHC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.65	0.42	2.04e-16	Schizophrenia;
LIHC	trans	rs72960926	0.744	rs3897895	chr6:74917550	C/T	cg07247405	chr1:2484626	LOC115110	0.52	6.17	0.32	1.93e-9	Metabolite levels (MHPG);
LIHC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.56	6.06	0.31	3.69e-9	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.54	7.69	0.38	1.61e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.87	10.6	0.5	6.69e-23	Mean platelet volume;
LIHC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.44	6.95	0.35	1.88e-11	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs5756813	1.000	rs1074407	chr22:38156183	T/A	cg19894588	chr14:64061835	NA	0.65	9.94	0.47	1.23e-20	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.54	7.26	0.37	2.62e-12	Blood protein levels;
LIHC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.8	8.85	0.43	4.81e-17	Vitiligo;
LIHC	cis	rs17106184	1.000	rs72902729	chr1:51231935	A/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.82	14.59	0.62	7.86e-38	Multiple myeloma (IgH translocation);
LIHC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.65	9.91	0.47	1.61e-20	Mosquito bite size;
LIHC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	1.02	19.46	0.72	2.57e-57	Breast cancer;
LIHC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.5	12.5	0.56	8.99e-30	Alzheimer's disease (late onset);
LIHC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.5	6.27	0.32	1.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs61542988	0.606	rs4722185	chr7:22832711	G/A	cg11367502	chr7:22862612	TOMM7	0.58	9.37	0.45	9.77e-19	Fibrinogen levels;
LIHC	trans	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.75	-0.34	6.31e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.28	0.41	2.77e-15	Eotaxin levels;
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.66	9.91	0.47	1.57e-20	Menarche (age at onset);
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04701394	chr12:92489468	NA	0.43	6.23	0.32	1.38e-9	Myopia (pathological);
LIHC	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.36	-0.33	6.49e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg05941027	chr17:61774174	LIMD2	0.33	6.71	0.34	8.24e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.46	7.45	0.37	7.5e-13	Corneal astigmatism;
LIHC	cis	rs1144333	1.000	rs75399471	chr1:76339092	A/T	cg22875332	chr1:76189707	ACADM	0.44	6.44	0.33	4.14e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg20090690	chr10:134436459	INPP5A	0.44	5.77	0.3	1.76e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs3852053	1.000	rs3852053	chr3:186937200	A/C	cg12634932	chr5:43397230	CCL28	0.45	6.25	0.32	1.25e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.24e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs546131	0.642	rs566798	chr11:34852277	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.56	-7.17	-0.36	4.58e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.59	-0.46	1.87e-19	Initial pursuit acceleration;
LIHC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	0.84	10.93	0.51	4.91e-24	Skin colour saturation;
LIHC	cis	rs2274273	0.684	rs2340921	chr14:55563705	A/G	cg01864836	chr14:55583639	NA	-0.36	-6.68	-0.34	9.45e-11	Protein biomarker;
LIHC	cis	rs10916814	0.610	rs1890005	chr1:20899016	T/C	cg24502330	chr1:20914028	CDA	-0.3	-6.7	-0.34	8.63e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.13	0.48	2.88e-21	Alzheimer's disease (late onset);
LIHC	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.87	13.54	0.59	9.67e-34	Migraine;
LIHC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.9	-0.3	8.94e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	8.04	0.4	1.49e-14	Platelet count;
LIHC	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14154082	chr13:112174009	NA	0.29	6.15	0.32	2.13e-9	Menarche (age at onset);
LIHC	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.75	13.27	0.58	1.08e-32	Eosinophil percentage of white cells;
LIHC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.66	-13.04	-0.58	7.95e-32	Type 2 diabetes;
LIHC	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.47	-8.61	-0.42	2.72e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg05484376	chr2:27715224	FNDC4	-0.38	-6.46	-0.33	3.63e-10	Total body bone mineral density;
LIHC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg03735888	chr19:58951602	ZNF132	0.39	6.59	0.34	1.67e-10	Uric acid clearance;
LIHC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg03264133	chr6:25882463	NA	-0.41	-6.22	-0.32	1.48e-9	Height;
LIHC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	1.06	13.86	0.6	5.48e-35	Red blood cell traits;
LIHC	cis	rs860295	0.627	rs11264410	chr1:155745349	G/A	cg02153340	chr1:155202674	NA	-0.36	-6.54	-0.33	2.26e-10	Body mass index;
LIHC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.38	7.4	0.37	1.09e-12	Body mass index;
LIHC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	0.98	17.59	0.69	9.08e-50	Monocyte percentage of white cells;
LIHC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.51	8.32	0.41	2.06e-15	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.58	6.82	0.35	4.24e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01398529	chr4:26322459	RBPJ	0.49	6.31	0.32	8.73e-10	Lung function (FEV1/FVC);
LIHC	trans	rs412658	0.812	rs17554725	chr19:22317759	A/G	cg17074339	chr11:11642133	GALNTL4	-0.48	-7.1	-0.36	7.41e-12	Telomere length;
LIHC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	13.02	0.58	9.61e-32	Birth weight;
LIHC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.81	13.16	0.58	2.86e-32	Fat distribution (HIV);
LIHC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	2.97e-23	Bladder cancer;
LIHC	trans	rs903027	0.752	rs11774171	chr8:62477247	C/T	cg25338577	chr2:201391149	SGOL2	0.47	7.12	0.36	6.22e-12	Whole-brain volume;
LIHC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00152838	chr16:24741724	TNRC6A	-0.51	-6.96	-0.35	1.72e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.5	0.77	1.96e-69	Height;
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05665937	chr4:1216051	CTBP1	0.39	6.2	0.32	1.59e-9	Obesity-related traits;
LIHC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.58	7.73	0.39	1.18e-13	Emphysema distribution in smoking;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg16246252	chr11:119535621	PVRL1	0.36	6.17	0.32	1.92e-9	Calcium levels;
LIHC	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.49	5.86	0.3	1.07e-8	Interleukin-17 levels;
LIHC	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.83	-0.51	1.09e-23	Eye color traits;
LIHC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.74	9.48	0.46	4.39e-19	Selective IgA deficiency;
LIHC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.49	8.19	0.41	5.13e-15	Mean corpuscular volume;
LIHC	cis	rs3917254	0.543	rs11123911	chr2:102761538	C/T	cg22835712	chr2:102737379	NA	-0.47	-5.81	-0.3	1.42e-8	Blood protein levels;
LIHC	cis	rs61160187	0.522	rs2045356	chr5:59947354	C/T	cg02684056	chr5:59996105	DEPDC1B	0.42	5.9	0.3	8.62e-9	Educational attainment (years of education);Educational attainment (college completion);
LIHC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.52	-6.63	-0.34	1.34e-10	Coronary artery calcification;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.36	6.1	0.31	2.85e-9	Height;
LIHC	cis	rs9896052	0.580	rs8078577	chr17:73464294	G/T	cg25649188	chr17:73499917	CASKIN2	0.48	7.16	0.36	5.1e-12	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.5	-0.38	5.73e-13	Uric acid levels;
LIHC	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.47	7.71	0.38	1.4e-13	Tuberculosis;
LIHC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg07061783	chr6:25882402	NA	-0.43	-6.05	-0.31	3.77e-9	Blood metabolite levels;
LIHC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.67	-7.15	-0.36	5.13e-12	Neuroticism;
LIHC	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.38	0.33	5.61e-10	Hepatocellular carcinoma;
LIHC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.32	-5.71	-0.3	2.43e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs8067354	0.507	rs72840511	chr17:57806011	G/T	cg02344993	chr17:57696989	CLTC	0.72	12.1	0.55	2.68e-28	Hemoglobin concentration;
LIHC	cis	rs838721	0.574	rs11679046	chr2:234258101	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.4	5.71	0.3	2.4e-8	Total body bone mineral density;
LIHC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg16797656	chr11:68205561	LRP5	0.51	8.04	0.4	1.47e-14	Total body bone mineral density;
LIHC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.59	6.91	0.35	2.36e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.52	9.85	0.47	2.52e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.41	-6.66	-0.34	1.08e-10	Menarche (age at onset);
LIHC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.47	-7.33	-0.37	1.65e-12	Alcohol dependence;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg07133347	chr1:107600762	PRMT6	0.45	6.73	0.34	6.98e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.57	7.62	0.38	2.58e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.15	-0.58	3.05e-32	Bipolar disorder and schizophrenia;
LIHC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.97	17.27	0.68	1.7e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.22	5.78	0.3	1.66e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg01864069	chr14:103024347	NA	-0.54	-8.97	-0.44	2.02e-17	Platelet count;
LIHC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.88	-0.57	3.09e-31	Breast cancer;
LIHC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.47	7.36	0.37	1.34e-12	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.67	-10.87	-0.51	7.54e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.46	-6.37	-0.33	6.21e-10	Ulcerative colitis;
LIHC	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.7	11.78	0.54	4.2e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg00935119	chr6:36647544	CDKN1A	0.41	5.94	0.31	7.14e-9	QRS duration;
LIHC	cis	rs332507	0.830	rs3772781	chr3:124387439	G/T	cg05980111	chr3:124395277	KALRN	0.46	7.11	0.36	6.65e-12	Plateletcrit;
LIHC	cis	rs4742903	0.904	rs7047747	chr9:106939922	G/A	cg14250997	chr9:106856677	SMC2	0.35	5.94	0.31	7.03e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19259030	chr15:76553926	ETFA;TYRO3P	-0.35	-6.15	-0.32	2.15e-9	Calcium levels;
LIHC	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.4	6.01	0.31	4.76e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg01528321	chr10:82214614	TSPAN14	1.14	15.15	0.63	4.96e-40	Post bronchodilator FEV1;
LIHC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	13.2	0.58	1.95e-32	Hip circumference adjusted for BMI;
LIHC	cis	rs7619427	0.908	rs9682281	chr3:44082811	A/T	cg24966902	chr3:44043705	NA	0.43	6.17	0.32	1.95e-9	Schizophrenia;
LIHC	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg03934865	chr2:198174659	NA	0.51	7.86	0.39	4.97e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg22951263	chr5:87985283	NA	-0.41	-7.18	-0.36	4.38e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg14004847	chr7:1930337	MAD1L1	-0.48	-7.18	-0.36	4.37e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.42	0.41	1.05e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.38	7.64	0.38	2.27e-13	Type 2 diabetes;
LIHC	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-7.76	-0.39	9.72e-14	Morning vs. evening chronotype;
LIHC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-6.61	-0.34	1.44e-10	Ileal carcinoids;
LIHC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20135002	chr11:47629003	NA	-0.59	-9.99	-0.48	8.61e-21	Subjective well-being;
LIHC	cis	rs7116495	1.000	rs2508858	chr11:71805405	C/G	cg26138937	chr11:71823887	C11orf51	0.8	7.88	0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.4	0.77	4.86e-69	Chronic sinus infection;
LIHC	trans	rs17034615	0.510	rs17034560	chr1:10229158	A/G	cg13617753	chr19:58096512	ZIK1	-0.5	-6.09	-0.31	3.09e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.3	0.45	1.74e-18	Bipolar disorder;
LIHC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.4	6.39	0.33	5.36e-10	Menopause (age at onset);
LIHC	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.07	0.36	8.67e-12	Exhaled nitric oxide output;
LIHC	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.51e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-7.17	-0.36	4.67e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.56	8.23	0.41	3.98e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.69e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.94	17.9	0.7	5.08e-51	Menopause (age at onset);
LIHC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg03037974	chr15:76606532	NA	-0.81	-18.16	-0.7	4.36e-52	Blood metabolite levels;
LIHC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg16586182	chr3:47516702	SCAP	-0.58	-10.97	-0.51	3.32e-24	Colorectal cancer;
LIHC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.52	-8.05	-0.4	1.39e-14	Lymphocyte counts;
LIHC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-6.46	-0.33	3.61e-10	Blood metabolite levels;
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg00612595	chr21:47717864	NA	-0.4	-6.76	-0.34	5.88e-11	Testicular germ cell tumor;
LIHC	cis	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg11619707	chr19:22235551	ZNF257	-0.32	-5.82	-0.3	1.37e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.64	9.55	0.46	2.62e-19	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15459742	chr9:111775564	CTNNAL1	0.41	6.34	0.32	7.39e-10	Pancreatic cancer;
LIHC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.6	9.23	0.45	2.98e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg09835421	chr16:68378352	PRMT7	-0.82	-9.6	-0.46	1.8e-19	Schizophrenia;
LIHC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg27494647	chr7:150038898	RARRES2	0.34	6.15	0.32	2.16e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg10790698	chr19:18539756	SSBP4	-0.36	-7.25	-0.36	2.8e-12	Breast cancer;
LIHC	cis	rs8081395	0.711	rs11368	chr17:58031412	A/G	cg02344993	chr17:57696989	CLTC	0.36	5.85	0.3	1.14e-8	White blood cell count;
LIHC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.82	0.51	1.12e-23	Bladder cancer;
LIHC	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.42	-5.71	-0.3	2.45e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs477895	0.941	rs35692796	chr11:64110805	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.76	0.34	6.01e-11	Mean platelet volume;
LIHC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.21	19.87	0.73	5.66e-59	Primary sclerosing cholangitis;
LIHC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.01	0.31	4.66e-9	Resting heart rate;
LIHC	cis	rs12744310	1.000	rs12739950	chr1:41759891	C/T	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg04592579	chr7:75616294	TMEM120A	-0.4	-7.0	-0.35	1.32e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.37	-5.81	-0.3	1.41e-8	Bipolar disorder;
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.74e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.57	15.02	0.63	1.62e-39	Airflow obstruction;
LIHC	cis	rs2710642	0.576	rs6545968	chr2:62871184	C/A	cg17519650	chr2:63277830	OTX1	0.5	7.27	0.37	2.39e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1144333	0.655	rs77244403	chr1:76304872	A/G	cg10523679	chr1:76189770	ACADM	0.44	5.95	0.31	6.73e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg03146154	chr1:46216737	IPP	-0.36	-5.94	-0.31	7.06e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg06466757	chr4:1255808	NA	0.34	5.8	0.3	1.53e-8	Obesity-related traits;
LIHC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.48	7.59	0.38	3.01e-13	Schizophrenia;
LIHC	cis	rs28830936	0.966	rs2241522	chr15:42127734	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.86	-0.3	1.11e-8	Diastolic blood pressure;
LIHC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.75	10.49	0.49	1.65e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.27	15.78	0.65	1.51e-42	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg08847533	chr14:75593920	NEK9	0.52	8.73	0.43	1.12e-16	IgG glycosylation;
LIHC	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.46	-0.33	3.5e-10	Neuroticism;
LIHC	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.93	-0.35	2.05e-11	Hepatocellular carcinoma;
LIHC	cis	rs4407350	0.933	rs5765732	chr22:44922761	A/G	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.22	-0.32	1.47e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.53	8.52	0.42	5.02e-16	Bipolar disorder;
LIHC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.48	7.59	0.38	3.01e-13	Schizophrenia;
LIHC	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.85	-16.17	-0.66	4.54e-44	Nonalcoholic fatty liver disease;
LIHC	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg14345882	chr6:26364793	BTN3A2	0.39	5.76	0.3	1.88e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.51	6.1	0.31	2.92e-9	Serum sulfate level;
LIHC	cis	rs3770081	1.000	rs111295372	chr2:86283357	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.95	-11.58	-0.53	2.24e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg03342759	chr3:160939853	NMD3	0.54	7.19	0.36	4.05e-12	Morning vs. evening chronotype;
LIHC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.3	-0.32	9.3e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.47	8.83	0.43	5.41e-17	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.71	12.65	0.56	2.48e-30	Prudent dietary pattern;
LIHC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.56	9.49	0.46	4.11e-19	Colorectal cancer;
LIHC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.49	-5.88	-0.3	9.51e-9	Parkinson's disease;
LIHC	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.83	-16.79	-0.67	1.47e-46	Longevity;
LIHC	cis	rs965469	1.000	rs6051751	chr20:3310049	G/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.83	-0.35	3.86e-11	IFN-related cytopenia;
LIHC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.25	-0.32	1.21e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.41	5.75	0.3	1.93e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg05848834	chr11:43543746	NA	0.31	6.25	0.32	1.21e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg03934865	chr2:198174659	NA	0.46	6.61	0.34	1.44e-10	Dermatomyositis;
LIHC	cis	rs7395581	0.879	rs3758673	chr11:47278917	C/T	cg26139080	chr11:47293733	MADD	-0.5	-8.53	-0.42	4.94e-16	HDL cholesterol;
LIHC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.7	10.58	0.5	8.1e-23	Height;
LIHC	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.75	-11.62	-0.53	1.55e-26	Coronary artery disease;
LIHC	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.67	10.82	0.51	1.14e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg03721293	chr16:90014378	DEF8	0.36	6.31	0.32	8.77e-10	Skin colour saturation;
LIHC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-9.2	-0.45	3.75e-18	Body mass index;
LIHC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg18357645	chr12:58087776	OS9	-0.47	-7.1	-0.36	7.22e-12	Multiple sclerosis;
LIHC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00802000	chr16:706648	WDR90	-0.39	-6.29	-0.32	9.45e-10	Height;
LIHC	cis	rs1204798	0.617	rs6909152	chr6:116601557	A/G	cg23214565	chr6:116600728	DSE;TSPYL1	-0.41	-6.07	-0.31	3.45e-9	Dental caries;
LIHC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	1.06	15.49	0.64	2.27e-41	Breast cancer;
LIHC	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg07895657	chr22:50616420	PANX2	-0.34	-5.73	-0.3	2.25e-8	Obesity-related traits;
LIHC	trans	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg17830980	chr10:43048298	ZNF37B	0.42	7.91	0.39	3.5e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg24203234	chr3:128598194	ACAD9	0.45	6.29	0.32	9.67e-10	IgG glycosylation;
LIHC	cis	rs17428076	0.831	rs3736499	chr2:172690418	C/T	cg13550731	chr2:172543902	DYNC1I2	0.38	6.22	0.32	1.47e-9	Myopia;
LIHC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.04	-0.48	5.96e-21	Platelet count;
LIHC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg07148914	chr20:33460835	GGT7	-0.56	-8.41	-0.41	1.12e-15	Height;
LIHC	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg13753209	chr17:57696993	CLTC	0.77	12.28	0.55	6.02e-29	Hemoglobin concentration;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.95	14.44	0.62	3.05e-37	Skin colour saturation;
LIHC	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.82	-12.26	-0.55	6.88e-29	Obesity-related traits;
LIHC	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg07424592	chr7:64974309	NA	0.77	8.87	0.43	4.13e-17	Diabetic kidney disease;
LIHC	cis	rs17095355	1.000	rs13377169	chr10:111729414	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.96	-0.31	6.35e-9	Biliary atresia;
LIHC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.44	6.02	0.31	4.43e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.67e-9	Mortality in heart failure;
LIHC	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg15841412	chr13:111365552	ING1	0.53	6.46	0.33	3.6e-10	Coronary artery disease;
LIHC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.83	-0.35	3.84e-11	Gut microbiome composition (summer);
LIHC	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.49	-11.29	-0.52	2.46e-25	Urinary metabolites;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-8.68	-0.42	1.67e-16	Lymphocyte counts;
LIHC	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.34	7.78	0.39	8.88e-14	Blood metabolite ratios;
LIHC	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg25930673	chr12:123319894	HIP1R	-0.87	-10.46	-0.49	2.1e-22	Schizophrenia;
LIHC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	7.05	0.36	1.02e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.81	-8.95	-0.44	2.26e-17	Vitiligo;
LIHC	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.68	7.84	0.39	5.76e-14	Height;
LIHC	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.34	-0.32	7.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg21734168	chr11:67353974	GSTP1	-0.26	-6.49	-0.33	3.07e-10	Mean corpuscular volume;
LIHC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg15208524	chr1:10270712	KIF1B	0.37	5.72	0.3	2.3e-8	Hepatocellular carcinoma;
LIHC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.92	0.3	8.01e-9	HDL cholesterol;
LIHC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.57	8.24	0.41	3.74e-15	Response to diuretic therapy;
LIHC	cis	rs6695567	0.902	rs6588469	chr1:53630705	C/T	cg20326410	chr1:53600821	SLC1A7	0.3	6.34	0.32	7.22e-10	Systemic lupus erythematosus;
LIHC	cis	rs151997	1.000	rs152690	chr5:50213584	A/T	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.68	6.93	0.35	2.11e-11	Alzheimer's disease;
LIHC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-22.29	-0.77	1.37e-68	Myeloid white cell count;
LIHC	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.45	6.13	0.31	2.39e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.55	7.15	0.36	5.36e-12	Economic and political preferences (feminism/equality);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16466278	chr15:43429893	TMEM62	0.38	6.16	0.32	2.02e-9	Bilirubin levels;
LIHC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.11	-0.44	6.94e-18	Bipolar disorder;
LIHC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.75	-0.34	6.37e-11	Longevity;Endometriosis;
LIHC	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.36	-5.84	-0.3	1.2e-8	Body mass index;
LIHC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.46	-7.72	-0.39	1.32e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.39	-6.2	-0.32	1.61e-9	Monobrow;
LIHC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg08847533	chr14:75593920	NEK9	-0.38	-6.4	-0.33	5.15e-10	Caffeine consumption;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04335562	chr19:2945000	ZNF77	0.49	6.9	0.35	2.53e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.4	-7.12	-0.36	6.46e-12	Crohn's disease;
LIHC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.54	-10.38	-0.49	4.12e-22	Coronary artery disease;
LIHC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.58	-0.38	3.24e-13	Morning vs. evening chronotype;
LIHC	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.89	-11.7	-0.53	8.16e-27	Schizophrenia;
LIHC	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.55	10.16	0.48	2.32e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg26138937	chr11:71823887	C11orf51	-1.25	-10.59	-0.5	7.2e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	5.75	0.3	1.96e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg17372223	chr3:52568218	NT5DC2	0.36	5.78	0.3	1.7e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg14132834	chr19:41945861	ATP5SL	-0.41	-5.94	-0.31	6.99e-9	Height;
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02290350	chr8:58132656	NA	0.38	7.79	0.39	8.16e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.7	6.42	0.33	4.62e-10	Cognitive function;
LIHC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.53	8.17	0.4	6.17e-15	Glycated hemoglobin levels;
LIHC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.04	0.31	4.08e-9	Menopause (age at onset);
LIHC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.1	-0.31	2.85e-9	Breast cancer;
LIHC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg18306943	chr3:40428807	ENTPD3	0.33	5.88	0.3	9.6e-9	Renal cell carcinoma;
LIHC	cis	rs797680	0.856	rs6680107	chr1:93770880	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.97	-0.31	5.84e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02985541	chr2:219472218	PLCD4	0.44	8.35	0.41	1.7e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.75	14.45	0.62	2.74e-37	Mortality in heart failure;
LIHC	cis	rs8084351	0.539	rs6508193	chr18:50584544	A/G	cg24270629	chr18:50823537	DCC	0.45	6.89	0.35	2.62e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs1075232	1.000	rs66581165	chr15:31743767	A/G	cg01030201	chr15:31746330	NA	-0.8	-6.32	-0.32	8.37e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.67	8.46	0.42	8.07e-16	Initial pursuit acceleration;
LIHC	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg06359132	chr10:99160096	RRP12	-0.4	-6.37	-0.33	6.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2334880	0.678	rs12444714	chr16:71452606	C/T	cg06353428	chr16:71660113	MARVELD3	-0.86	-8.15	-0.4	6.78e-15	Malaria;
LIHC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.48	7.7	0.38	1.52e-13	Cognitive function;
LIHC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.94	-15.69	-0.65	3.5e-42	Metabolic syndrome;
LIHC	cis	rs16828019	0.852	rs12408956	chr1:41651952	G/A	cg03387723	chr1:41708464	SCMH1	-0.45	-7.23	-0.36	3.13e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.46	8.31	0.41	2.24e-15	Prudent dietary pattern;
LIHC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	1.03	10.42	0.49	2.85e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs3790844	0.667	rs3790843	chr1:200010824	A/G	cg13229857	chr1:200006247	NR5A2	-0.41	-6.84	-0.35	3.57e-11	Pancreatic cancer;
LIHC	cis	rs10847980	0.590	rs75794148	chr12:123287329	C/G	cg07706471	chr12:123319906	HIP1R	0.75	8.16	0.4	6.55e-15	Adiponectin levels;
LIHC	cis	rs61677309	0.964	rs56020103	chr11:118172132	C/T	cg06090739	chr11:118230722	UBE4A	0.34	6.32	0.32	8.33e-10	Lung cancer in ever smokers;
LIHC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.43	-6.91	-0.35	2.44e-11	Menarche (age at onset);
LIHC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.78	-0.39	8.93e-14	Neuroticism;
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.64	9.61	0.46	1.66e-19	Renal cell carcinoma;
LIHC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg19302996	chr17:73780495	UNK	-0.46	-6.52	-0.33	2.57e-10	White matter hyperintensity burden;
LIHC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs1865721	0.958	rs72977878	chr18:73193037	T/G	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs3762637	0.941	rs6788746	chr3:122106743	G/A	cg24169773	chr3:122142474	KPNA1	-0.47	-9.23	-0.45	2.87e-18	LDL cholesterol levels;
LIHC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.66	-9.29	-0.45	1.89e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg05941027	chr17:61774174	LIMD2	0.35	7.43	0.37	8.8e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3018712	0.532	rs55761963	chr11:68402629	G/T	cg16797656	chr11:68205561	LRP5	0.5	6.22	0.32	1.45e-9	Total body bone mineral density;
LIHC	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-0.76	-8.38	-0.41	1.42e-15	Exhaled nitric oxide output;
LIHC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.83	-0.51	1.04e-23	Mean corpuscular volume;
LIHC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.42	-6.26	-0.32	1.16e-9	Cognitive function;
LIHC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.12	-0.31	2.6e-9	IgG glycosylation;
LIHC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg21531657	chr3:10005747	TMEM111	0.39	5.72	0.3	2.28e-8	Alzheimer's disease;
LIHC	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.88	15.46	0.64	2.85e-41	Parkinson's disease;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02016892	chr7:22122612	NA	-0.52	-6.24	-0.32	1.3e-9	Lung function (FEV1);
LIHC	trans	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg01530962	chr3:9027157	SRGAP3	0.35	6.07	0.31	3.33e-9	Rheumatoid arthritis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23088989	chr10:38301786	ZNF33A	0.42	6.29	0.32	9.48e-10	Longevity;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3018712	0.532	rs2510399	chr11:68421458	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-5.81	-0.3	1.41e-8	Total body bone mineral density;
LIHC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg12373951	chr3:133503437	NA	0.47	7.88	0.39	4.54e-14	Iron status biomarkers;
LIHC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.44	6.78	0.34	5.13e-11	Methadone dose in opioid dependence;
LIHC	trans	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg10756647	chr7:56101905	PSPH	-0.44	-6.38	-0.33	5.64e-10	Aortic root size;
LIHC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.59	-11.11	-0.51	1.12e-24	Body mass index;
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg14709524	chr16:89940631	TCF25	0.52	7.08	0.36	8.05e-12	Skin colour saturation;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.38	-6.78	-0.34	5.17e-11	Alzheimer's disease;
LIHC	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.41	6.82	0.35	4.14e-11	Menopause (age at onset);
LIHC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.89	-0.3	9.39e-9	Pulse pressure;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	-0.61	-8.82	-0.43	5.75e-17	Prudent dietary pattern;
LIHC	cis	rs7546668	0.947	rs10803391	chr1:15876578	A/G	cg11706911	chr1:15910989	AGMAT	0.44	6.71	0.34	8.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.45	-6.03	-0.31	4.23e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.44	6.12	0.31	2.5e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.36	7.37	0.37	1.31e-12	Cancer;
LIHC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.25	-0.32	1.2e-9	Mood instability;
LIHC	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.91	6.85	0.35	3.55e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.27	-0.32	1.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg21747090	chr2:27597821	SNX17	-0.41	-5.97	-0.31	6e-9	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03383553	chr7:5349072	TNRC18	0.42	6.15	0.32	2.14e-9	Pancreatic cancer;
LIHC	cis	rs17094222	0.812	rs10883519	chr10:102435648	T/C	cg26540559	chr10:102447443	NA	0.32	6.17	0.32	1.96e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg02023728	chr11:77925099	USP35	0.34	6.18	0.32	1.83e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.74	13.42	0.59	2.89e-33	Ewing sarcoma;
LIHC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.63	11.29	0.52	2.48e-25	Breast cancer;
LIHC	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.48	7.04	0.36	1.07e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12079745	0.793	rs12094791	chr1:169387911	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.8	-7.11	-0.36	7e-12	QT interval;
LIHC	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.5	-8.15	-0.4	6.92e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	11.58	0.53	2.19e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04688917	chr3:179040469	ZNF639	0.43	6.6	0.34	1.58e-10	Pancreatic cancer;
LIHC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg22532475	chr10:104410764	TRIM8	-0.41	-7.21	-0.36	3.58e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg18478394	chr8:109455254	TTC35	0.37	6.16	0.32	1.99e-9	Dupuytren's disease;
LIHC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg05941027	chr17:61774174	LIMD2	0.33	6.71	0.34	8.24e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.51	8.28	0.41	2.72e-15	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.09	0.55	3.01e-28	Prudent dietary pattern;
LIHC	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.44	-7.29	-0.37	2.22e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.52	-8.47	-0.42	7.51e-16	Longevity;Endometriosis;
LIHC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg22563815	chr15:78856949	CHRNA5	0.35	6.4	0.33	5.07e-10	Sudden cardiac arrest;
LIHC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.39	6.18	0.32	1.78e-9	Melanoma;
LIHC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.52	9.81	0.47	3.46e-20	Testicular germ cell tumor;
LIHC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	6.9	0.35	2.57e-11	Hip circumference adjusted for BMI;
LIHC	trans	rs1464321	1.000	rs1464321	chr12:103656233	A/C	cg15403093	chr12:133312361	ANKLE2	0.38	6.05	0.31	3.78e-9	Body mass index;
LIHC	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg01864836	chr14:55583639	NA	-0.44	-8.65	-0.42	2.05e-16	Protein biomarker;
LIHC	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.71	-8.18	-0.4	5.77e-15	Urate levels in lean individuals;
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937890	0.559	rs2597196	chr11:14491601	C/T	cg02886208	chr11:14281011	SPON1	0.44	6.13	0.31	2.44e-9	Mitochondrial DNA levels;
LIHC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.48	7.46	0.37	7.4e-13	Methadone dose in opioid dependence;
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04498913	chr7:1135747	C7orf50	0.44	6.98	0.35	1.51e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.33	5.79	0.3	1.61e-8	Osteoporosis;
LIHC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.24	-0.41	3.62e-15	Heart rate;
LIHC	trans	rs875971	0.545	rs316323	chr7:65610989	C/T	cg26939375	chr7:64535504	NA	-0.41	-6.47	-0.33	3.32e-10	Aortic root size;
LIHC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	6.53	0.33	2.44e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2274273	0.901	rs7147136	chr14:55826688	G/C	cg01864836	chr14:55583639	NA	-0.38	-6.58	-0.34	1.72e-10	Protein biomarker;
LIHC	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.41	7.37	0.37	1.33e-12	Testicular germ cell tumor;
LIHC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.44	7.3	0.37	1.97e-12	Smoking behavior;
LIHC	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg03462622	chr3:195777018	TFRC	-0.33	-5.71	-0.3	2.4e-8	Mean corpuscular volume;
LIHC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19671926	chr4:122722719	EXOSC9	0.54	8.32	0.41	2.15e-15	Type 2 diabetes;
LIHC	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg20636351	chr8:55087400	NA	-0.34	-7.1	-0.36	7.46e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7534824	0.625	rs2391574	chr1:101373298	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.61	0.34	1.52e-10	Refractive astigmatism;
LIHC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.08	0.31	3.24e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	1.03	20.91	0.75	3.97e-63	Breast cancer;
LIHC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.0	15.32	0.64	1.06e-40	Breast cancer;
LIHC	trans	rs7668874	0.779	rs7688219	chr4:116814062	T/C	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	9.58	0.46	2.09e-19	Personality dimensions;
LIHC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.9	0.3	8.95e-9	Menopause (age at onset);
LIHC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-10.95	-0.51	4.14e-24	Vitiligo;
LIHC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.56	-9.39	-0.45	8.75e-19	Colorectal cancer;
LIHC	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg17074339	chr11:11642133	GALNTL4	0.47	7.38	0.37	1.25e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg16970926	chr12:29381810	FAR2	0.31	6.71	0.34	8.23e-11	QT interval;
LIHC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.46	6.24	0.32	1.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.07	0.31	3.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg12501888	chr15:85177176	SCAND2	-0.5	-7.79	-0.39	7.99e-14	P wave terminal force;
LIHC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-6.86	-0.35	3.17e-11	Morning vs. evening chronotype;
LIHC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.63	10.74	0.5	2.31e-23	Uric acid clearance;
LIHC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg07713946	chr22:31675144	LIMK2	-0.43	-7.81	-0.39	7.12e-14	Colorectal cancer;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.67	-9.77	-0.47	4.87e-20	Menarche (age at onset);
LIHC	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.93	-16.06	-0.66	1.26e-43	Lymphocyte percentage of white cells;
LIHC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.89	-13.72	-0.6	1.87e-34	Body mass index;
LIHC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg24693881	chr1:107596107	NA	-0.53	-9.13	-0.44	6.24e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.82e-10	Fibrinogen levels;
LIHC	cis	rs15676	0.783	rs10988121	chr9:131564926	A/T	cg00228799	chr9:131580591	ENDOG	-0.48	-6.8	-0.34	4.79e-11	Blood metabolite levels;
LIHC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.58	8.54	0.42	4.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.83	10.09	0.48	4.04e-21	Cognitive function;
LIHC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg02376097	chr19:46275166	DMPK	-0.44	-6.88	-0.35	2.87e-11	Coronary artery disease;
LIHC	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.62	-11.21	-0.52	4.59e-25	Breast cancer;
LIHC	trans	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.4	0.33	5.23e-10	Mean corpuscular volume;
LIHC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg07661805	chr8:143867942	LY6D	-0.27	-5.92	-0.3	7.8e-9	Urinary tract infection frequency;
LIHC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.38	6.7	0.34	8.73e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.74	9.04	0.44	1.17e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs16854884	0.632	rs60505453	chr3:143643864	C/G	cg06585982	chr3:143692056	C3orf58	0.63	8.79	0.43	7.66e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg23517279	chr6:96025343	MANEA	0.57	5.78	0.3	1.68e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4700695	0.614	rs446618	chr5:65210062	G/A	cg21114390	chr5:65439923	SFRS12	0.46	5.83	0.3	1.3e-8	Facial morphology (factor 19);
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.46	-7.39	-0.37	1.11e-12	Type 2 diabetes;
LIHC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-0.98	-22.77	-0.78	1.69e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.75	11.33	0.52	1.79e-25	Corneal astigmatism;
LIHC	trans	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg26939375	chr7:64535504	NA	0.41	6.51	0.33	2.63e-10	Aortic root size;
LIHC	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg25533220	chr19:2328480	SPPL2B;LSM7	-0.46	-6.05	-0.31	3.8e-9	Facial morphology (factor 20);
LIHC	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg20129853	chr10:51489980	NA	-0.41	-8.93	-0.43	2.64e-17	Prostate-specific antigen levels;
LIHC	cis	rs903552	1.000	rs4965386	chr15:102003207	G/A	cg00659931	chr15:102010125	PCSK6	-0.45	-6.15	-0.32	2.2e-9	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16439512	chr15:57598924	LOC283663	0.44	6.22	0.32	1.48e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.03	0.36	1.15e-11	Alzheimer's disease;
LIHC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.53	-8.05	-0.4	1.43e-14	High light scatter reticulocyte count;
LIHC	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-9.03	-0.44	1.3e-17	Corneal astigmatism;
LIHC	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18573204	chr11:798458	NA	-0.5	-6.22	-0.32	1.49e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-9.31	-0.45	1.62e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.65	-10.52	-0.49	1.34e-22	Schizophrenia;
LIHC	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg03805757	chr16:71968109	PKD1L3	-0.67	-7.66	-0.38	1.97e-13	Post bronchodilator FEV1;
LIHC	trans	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg10208301	chr11:6592745	DNHD1	0.45	6.42	0.33	4.58e-10	Coronary artery calcification;
LIHC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.37	-0.33	6.02e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07305463	chr2:136567211	LCT	0.39	7.54	0.38	4.34e-13	Mosquito bite size;
LIHC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.55	0.53	2.78e-26	Platelet count;
LIHC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.73	0.34	7.22e-11	Mean corpuscular volume;
LIHC	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-6.77	-0.34	5.66e-11	Endometrial cancer;
LIHC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.34	-5.89	-0.3	9.24e-9	Prostate cancer;
LIHC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.46	-6.27	-0.32	1.09e-9	Initial pursuit acceleration;
LIHC	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-19.26	-0.72	1.68e-56	Schizophrenia;
LIHC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-7.6	-0.38	2.81e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg20240347	chr1:204465584	NA	-0.35	-7.42	-0.37	9.64e-13	Schizophrenia;
LIHC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.53	-8.11	-0.4	9.35e-15	Total body bone mineral density;
LIHC	trans	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg26939375	chr7:64535504	NA	0.41	6.15	0.32	2.15e-9	Aortic root size;
LIHC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.81	0.39	6.88e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs4407350	0.870	rs5765712	chr22:44914711	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.39	0.33	5.35e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03260790	chr12:56211718	ORMDL2;SARNP	0.5	7.5	0.38	5.65e-13	Pancreatic cancer;
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.68	10.29	0.49	8.11e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.41	0.45	7.58e-19	Corneal astigmatism;
LIHC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.3	8.53e-9	Obesity (extreme);
LIHC	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg11764359	chr7:65958608	NA	0.5	6.65	0.34	1.19e-10	Corneal structure;
LIHC	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.79	-7.32	-0.37	1.81e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg22509189	chr2:225307070	NA	-0.53	-6.35	-0.32	6.96e-10	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.82	0.3	1.38e-8	Putamen volume;
LIHC	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.57	-8.19	-0.41	5.19e-15	Schizophrenia;
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.22	-0.36	3.32e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.91	0.65	4.79e-43	Lymphocyte percentage of white cells;
LIHC	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.45	8.83	0.43	5.37e-17	Testicular germ cell tumor;
LIHC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg07706471	chr12:123319906	HIP1R	0.58	7.32	0.37	1.79e-12	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.48	-12.05	-0.55	3.99e-28	Alzheimer's disease (late onset);
LIHC	cis	rs12079745	0.793	rs10800445	chr1:169374793	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.96	-0.35	1.74e-11	QT interval;
LIHC	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.49	8.84	0.43	5.32e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.56	9.43	0.45	6.19e-19	Blood metabolite levels;
LIHC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.4	8.61	0.42	2.66e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.85	0.39	5.3e-14	Motion sickness;
LIHC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	0.71	5.99	0.31	5.37e-9	Blood metabolite levels;
LIHC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	7.56	0.38	3.72e-13	Parkinson's disease;
LIHC	cis	rs5753037	0.653	rs131272	chr22:30153655	A/G	cg01021169	chr22:30184971	ASCC2	-0.31	-5.75	-0.3	1.96e-8	Type 1 diabetes;
LIHC	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.37	-0.33	5.97e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.55	9.06	0.44	9.99e-18	Breast cancer;
LIHC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.71	-8.83	-0.43	5.7e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs16958440	0.867	rs78720782	chr18:44664015	A/T	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13126279	chr21:47581558	C21orf56	-0.4	-5.91	-0.3	8.11e-9	Testicular germ cell tumor;
LIHC	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg27205649	chr11:78285834	NARS2	0.39	5.96	0.31	6.31e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.72	-9.64	-0.46	1.33e-19	Platelet distribution width;
LIHC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27297192	chr10:134578999	INPP5A	0.55	7.7	0.38	1.52e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.6	9.72	0.47	7.01e-20	Corneal astigmatism;
LIHC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs16828019	0.929	rs35813191	chr1:41742800	T/C	cg03387723	chr1:41708464	SCMH1	-0.44	-7.06	-0.36	9.06e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.53	8.78	0.43	7.99e-17	Obesity-related traits;
LIHC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg06634786	chr22:41940651	POLR3H	-0.52	-5.73	-0.3	2.26e-8	Neuroticism;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg01032570	chr8:22224534	SLC39A14	-0.46	-6.36	-0.33	6.4e-10	Monocyte count;
LIHC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.64	10.93	0.51	4.64e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.53	7.56	0.38	3.75e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.65	-6.81	-0.35	4.46e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs600806	0.676	rs2781553	chr1:110026989	G/T	cg08911820	chr1:110026001	ATXN7L2	0.55	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.98	0.31	5.65e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.49	-0.33	3.03e-10	Prevalent atrial fibrillation;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03578013	chr3:24145718	LOC152024	-0.4	-6.5	-0.33	2.86e-10	Systolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19280121	chr17:21117780	TMEM11	0.4	6.32	0.32	8.29e-10	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25887850	chr20:44509743	ZSWIM1	0.48	6.66	0.34	1.07e-10	Pancreatic cancer;
LIHC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.88	0.35	2.9100000000000002e-11	Aortic root size;
LIHC	cis	rs611744	0.659	rs669584	chr8:109138107	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.59	0.42	3.15e-16	Dupuytren's disease;
LIHC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02034447	chr16:89574710	SPG7	0.38	5.83	0.3	1.29e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs7546668	1.000	rs10803394	chr1:15909480	G/C	cg11706911	chr1:15910989	AGMAT	0.47	7.16	0.36	4.97e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.63	0.42	2.31e-16	Menarche (age at onset);
LIHC	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.7	-10.65	-0.5	4.56e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.7	-10.74	-0.5	2.27e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21467203	chr3:49911342	NA	-0.59	-10.75	-0.5	1.99e-23	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.6	-0.46	1.73e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.42	-6.58	-0.34	1.81e-10	Lung cancer;
LIHC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.92	-0.31	7.64e-9	Mean corpuscular volume;
LIHC	cis	rs10420951	0.617	rs77852139	chr19:18606526	T/G	cg10790698	chr19:18539756	SSBP4	-0.42	-5.86	-0.3	1.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.7	-0.53	8.18e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg05590025	chr7:65112418	INTS4L2	-0.61	-6.78	-0.34	5.22e-11	Diabetic kidney disease;
LIHC	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.88	15.9	0.65	5.36e-43	Body mass index;
LIHC	cis	rs9464760	0.527	rs13194276	chr6:15158452	G/C	cg15799072	chr6:15248335	JARID2	0.59	5.92	0.3	7.97e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11673344	0.864	rs56208574	chr19:37498745	C/T	cg27390819	chr19:37464633	NA	-0.51	-6.21	-0.32	1.57e-9	Obesity-related traits;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.7	11.5	0.53	4.21e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.89	-0.3	9.45e-9	Blood protein levels;
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg27432699	chr2:27873401	GPN1	-0.49	-6.9	-0.35	2.47e-11	Menopause (age at onset);
LIHC	trans	rs6489882	0.703	rs11066451	chr12:113361443	G/A	cg10175203	chr3:128143634	NA	0.4	6.41	0.33	4.85e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	7.67	0.38	1.78e-13	Aortic root size;
LIHC	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.23	6.23	0.32	1.35e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs959260	1.000	rs2117563	chr17:73368985	A/G	cg20590849	chr17:73267439	MIF4GD	-0.53	-5.75	-0.3	1.96e-8	Systemic lupus erythematosus;
LIHC	cis	rs6137287	0.668	rs6047258	chr20:21098277	A/C	cg04219410	chr20:21106687	PLK1S1	0.34	6.02	0.31	4.43e-9	Height;
LIHC	cis	rs16828019	0.852	rs12408956	chr1:41651952	G/A	cg20697417	chr1:41786797	NA	0.35	6.65	0.34	1.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.3	-5.76	-0.3	1.92e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-7.24	-0.36	3.01e-12	Coronary artery disease;
LIHC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.68	9.83	0.47	2.93e-20	Obesity-related traits;
LIHC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.97	16.94	0.68	3.52e-47	Breast cancer;
LIHC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	0.94	6.69	0.34	9.3e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.24	-0.55	7.9e-29	Primary sclerosing cholangitis;
LIHC	cis	rs11212260	0.512	rs77832235	chr11:107149713	T/C	cg25435332	chr11:107328525	CWF19L2	0.73	6.79	0.34	4.93e-11	IgG glycosylation;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.59	10.66	0.5	4.22e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg14067834	chr17:29058358	SUZ12P	0.67	6.5	0.33	2.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg21573476	chr21:45109991	RRP1B	-0.53	-9.99	-0.48	8.99e-21	Mean corpuscular volume;
LIHC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.56	-8.6	-0.42	2.92e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg18944383	chr4:111397179	ENPEP	-0.35	-8.1	-0.4	9.97e-15	Coronary artery disease;
LIHC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08754654	chr5:154026448	NA	-0.32	-7.06	-0.36	9.17e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.51	8.27	0.41	3.02e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs12249377	0.528	rs11186299	chr10:92513343	C/A	cg12165685	chr19:47288109	SLC1A5	-0.53	-6.1	-0.31	2.81e-9	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-8.58	-0.42	3.31e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs244293	0.965	rs244360	chr17:53191703	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.54	-0.38	4.36e-13	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	8.56	0.42	3.92e-16	Total cholesterol levels;
LIHC	cis	rs36051895	0.623	rs12720	chr9:5231712	T/A	cg02405213	chr9:5042618	JAK2	-0.69	-11.02	-0.51	2.26e-24	Pediatric autoimmune diseases;
LIHC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.54	-7.7	-0.38	1.5e-13	Body mass index;
LIHC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13495025	chr9:130230056	LRSAM1	0.46	6.31	0.32	8.56e-10	Hepatitis;
LIHC	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.23	-0.48	1.3e-21	Eye color traits;
LIHC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.46	-6.37	-0.33	6e-10	Vitiligo;
LIHC	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.57	-8.45	-0.42	8.6e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.47	-0.33	3.32e-10	Height;
LIHC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.85	10.16	0.48	2.26e-21	Cognitive function;
LIHC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs263063	0.834	rs11673509	chr19:5080647	A/G	cg18473234	chr19:5097819	KDM4B	-0.57	-7.17	-0.36	4.73e-12	Periodontitis (CDC/AAP);
LIHC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg19752551	chr11:57585705	CTNND1	-0.48	-5.87	-0.3	1.02e-8	Schizophrenia;
LIHC	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.58	10.69	0.5	3.33e-23	Leprosy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24125890	chr12:21654287	RECQL;GOLT1B	0.47	6.91	0.35	2.42e-11	Pancreatic cancer;
LIHC	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.64	-11.0	-0.51	2.67e-24	Pediatric autoimmune diseases;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.64	-0.42	2.21e-16	Total cholesterol levels;
LIHC	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs67981189	0.537	rs917067	chr14:71371904	C/T	cg15816911	chr14:71606274	NA	-0.41	-6.5	-0.33	2.83e-10	Schizophrenia;
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg02711726	chr17:80685570	FN3KRP	-0.43	-7.84	-0.39	5.72e-14	Glycated hemoglobin levels;
LIHC	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.44	-0.33	4.01e-10	Subjective well-being;
LIHC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.71	10.45	0.49	2.38e-22	Menarche (age at onset);
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg05185784	chr16:90016020	DEF8	-0.47	-6.13	-0.31	2.37e-9	Skin colour saturation;
LIHC	cis	rs1823913	1.000	rs12623832	chr2:192125644	A/C	cg12404831	chr2:192114017	MYO1B	-0.33	-6.81	-0.35	4.5e-11	Obesity-related traits;
LIHC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.75	13.71	0.6	2.07e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.8e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.49	-6.13	-0.31	2.37e-9	Pancreatic cancer;
LIHC	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.43	6.2	0.32	1.59e-9	Longevity;Endometriosis;
LIHC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.96	17.48	0.69	2.53e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.27	-6.18	-0.32	1.78e-9	Menarche (age at onset);
LIHC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.1	0.4	9.9e-15	Electrocardiographic conduction measures;
LIHC	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg02023728	chr11:77925099	USP35	0.37	6.35	0.32	7.04e-10	Alzheimer's disease (survival time);
LIHC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg18357526	chr6:26021779	HIST1H4A	0.6	8.53	0.42	4.77e-16	Blood metabolite levels;
LIHC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.03	-0.31	4.17e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg24203234	chr3:128598194	ACAD9	0.46	6.47	0.33	3.43e-10	IgG glycosylation;
LIHC	cis	rs1494950	0.661	rs10433859	chr4:15072329	C/G	cg12377275	chr4:15005593	CPEB2	-0.81	-7.23	-0.36	3.21e-12	Political ideology;
LIHC	cis	rs787274	1.000	rs1361720	chr9:115535579	G/A	cg13803584	chr9:115635662	SNX30	-0.54	-6.04	-0.31	4.12e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03170881	chr6:136571050	FAM54A	-0.52	-6.15	-0.32	2.15e-9	Systolic blood pressure;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.69	-0.62	3.11e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.71	8.66	0.42	1.96e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7129220	0.512	rs57618276	chr11:10129276	C/T	cg01453529	chr11:10209919	SBF2	-0.39	-6.8	-0.35	4.7e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-7.51	-0.38	5.17e-13	Cognitive test performance;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg24846343	chr22:24311635	DDTL	0.68	13.29	0.58	8.94e-33	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs526821	0.595	rs532278	chr11:55344983	A/G	cg04317927	chr11:55418816	OR4S2	0.47	8.98	0.44	1.87e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.78	-0.76	1.34e-66	Height;
LIHC	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.44	-6.11	-0.31	2.64e-9	Blood protein levels;
LIHC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.5	5.92	0.3	7.77e-9	Schizophrenia;
LIHC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg03517284	chr6:25882590	NA	-0.38	-5.72	-0.3	2.27e-8	Height;
LIHC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.99	-0.7	2.08e-51	Coronary artery disease;
LIHC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.53	0.33	2.34e-10	Hemoglobin concentration;
LIHC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.91	-0.35	2.37e-11	Axial length;
LIHC	cis	rs2933343	0.818	rs6764681	chr3:128568380	G/C	cg25356066	chr3:128598488	ACAD9	-0.52	-6.78	-0.34	5.27e-11	IgG glycosylation;
LIHC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.55	-7.12	-0.36	6.56e-12	Coronary artery calcification;
LIHC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.67	11.37	0.52	1.29e-25	Lymphocyte counts;
LIHC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-6.19	-0.32	1.71e-9	Hemoglobin concentration;
LIHC	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.01	-0.51	2.56e-24	Coffee consumption (cups per day);
LIHC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.07	-0.36	8.52e-12	Height;
LIHC	cis	rs943466	1.000	rs2395400	chr6:33770076	G/A	cg25922239	chr6:33757077	LEMD2	-0.5	-6.29	-0.32	9.86e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg07061783	chr6:25882402	NA	-0.43	-6.03	-0.31	4.14e-9	Blood metabolite levels;
LIHC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.38e-17	Recombination rate (females);
LIHC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.75	17.42	0.69	4.11e-49	Brugada syndrome;
LIHC	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.45	6.76	0.34	5.84e-11	Fibroblast growth factor basic levels;
LIHC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.66	9.79	0.47	4.16e-20	Menopause (age at onset);
LIHC	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-9.1	-0.44	7.46e-18	Morning vs. evening chronotype;
LIHC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg03945807	chr20:60948434	NA	-0.35	-6.26	-0.32	1.17e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.71	10.65	0.5	4.53e-23	Urinary electrolytes (magnesium/calcium ratio);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24980700	chr20:30410739	MYLK2	0.44	6.14	0.32	2.27e-9	Lung function (FEV1/FVC);
LIHC	cis	rs3736485	0.903	rs750162	chr15:51907153	A/C	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.57e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-10.83	-0.51	1.03e-23	Morning vs. evening chronotype;
LIHC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.57	-9.77	-0.47	4.76e-20	Colorectal cancer;
LIHC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.66	12.83	0.57	4.78e-31	Schizophrenia;
LIHC	cis	rs8192917	0.895	rs2236338	chr14:25100282	A/G	cg03875678	chr14:25103546	GZMB	0.4	7.33	0.37	1.63e-12	Vitiligo;
LIHC	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.11e-35	White blood cell count (basophil);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01218756	chr4:48695242	FRYL	0.3	6.06	0.31	3.56e-9	Pancreatic cancer;
LIHC	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.28	-0.32	1.04e-9	Coronary artery disease;
LIHC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.64	-0.34	1.23e-10	Vitiligo;
LIHC	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg23091122	chr1:110024289	SYPL2	0.48	6.5	0.33	2.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-14.24	-0.61	1.88e-36	Primary sclerosing cholangitis;
LIHC	cis	rs9590974	0.705	rs9526209	chr13:47219780	A/G	cg04092803	chr13:47240378	LRCH1	0.28	6.01	0.31	4.76e-9	PR segment;
LIHC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.62	-8.95	-0.44	2.34e-17	Aortic root size;
LIHC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01028844	chr5:122736986	CEP120	-0.41	-6.64	-0.34	1.23e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	0.67	12.06	0.55	3.93e-28	Pediatric autoimmune diseases;
LIHC	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.06	0.4	1.29e-14	Alzheimer's disease;
LIHC	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.54	8.24	0.41	3.59e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	0.59	8.69	0.43	1.5e-16	Prudent dietary pattern;
LIHC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.58	0.34	1.76e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg21171335	chr12:122356390	WDR66	-0.41	-6.73	-0.34	7.08e-11	Mean corpuscular volume;
LIHC	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg10381502	chr11:71823885	C11orf51	1.04	9.61	0.46	1.62e-19	Severe influenza A (H1N1) infection;
LIHC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.59	-10.83	-0.51	1.05e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.54	-8.61	-0.42	2.68e-16	Colorectal cancer;
LIHC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-11.53	-0.53	3.33e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs17095355	1.000	rs61614979	chr10:111743994	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.85	-0.3	1.15e-8	Biliary atresia;
LIHC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-0.96	-10.28	-0.49	8.78e-22	Vitiligo;
LIHC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.22	-0.36	3.3e-12	Response to antipsychotic treatment;
LIHC	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg17218026	chr1:154582156	ADAR	0.34	6.51	0.33	2.65e-10	Blood protein levels;
LIHC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	7.01	0.35	1.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.85	-0.35	3.39e-11	Diabetic kidney disease;
LIHC	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg20991723	chr1:152506922	NA	0.59	10.39	0.49	3.62e-22	Hair morphology;
LIHC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-7.99	-0.4	2.16e-14	Schizophrenia;
LIHC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg10932868	chr11:921992	NA	0.39	7.27	0.37	2.53e-12	Alzheimer's disease (late onset);
LIHC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-11.25	-0.52	3.48e-25	Coronary artery disease;
LIHC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg18357645	chr12:58087776	OS9	-0.41	-6.28	-0.32	1.05e-9	Multiple sclerosis;
LIHC	cis	rs6060717	0.553	rs2590958	chr20:34616590	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.91	-0.39	3.49e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg18809830	chr7:99032528	PTCD1	-0.83	-6.45	-0.33	3.76e-10	Blood metabolite levels;
LIHC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	1.02	19.48	0.73	2.12e-57	Breast cancer;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg07332563	chr6:291687	DUSP22	-0.52	-7.19	-0.36	4e-12	Menopause (age at onset);
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.66	9.55	0.46	2.6e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.52	6.93	0.35	2.08e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.92	-0.31	7.69e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.43	0.45	6.43e-19	Morning vs. evening chronotype;
LIHC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg04517722	chr19:17905589	B3GNT3	0.45	6.97	0.35	1.59e-11	Tumor biomarkers;
LIHC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.6	8.4	0.41	1.2e-15	Blood metabolite levels;
LIHC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.84	-12.65	-0.56	2.4e-30	Multiple sclerosis;
LIHC	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.91	13.78	0.6	1.18e-34	Obesity-related traits;
LIHC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg23625390	chr15:77176239	SCAPER	-0.35	-5.86	-0.3	1.08e-8	Blood metabolite levels;
LIHC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-7.19	-0.36	4.11e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.67	-0.34	1e-10	Total cholesterol levels;
LIHC	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.84	17.43	0.69	3.78e-49	Longevity;
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.45	5.98	0.31	5.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.46	6.83	0.35	3.94e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.3	-6.22	-0.32	1.42e-9	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg05590025	chr7:65112418	INTS4L2	0.58	6.43	0.33	4.21e-10	Diabetic kidney disease;
LIHC	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.96	-0.31	6.13e-9	Systemic lupus erythematosus;
LIHC	cis	rs9318086	0.534	rs17338049	chr13:24382148	G/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.35	-5.89	-0.3	9.42e-9	Myopia (pathological);
LIHC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.39	7.15	0.36	5.17e-12	Response to antipsychotic treatment;
LIHC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	5.84	0.3	1.24e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg00677901	chr16:88017247	BANP	0.51	7.85	0.39	5.52e-14	Menopause (age at onset);
LIHC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg07148914	chr20:33460835	GGT7	-0.5	-7.14	-0.36	5.77e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-0.58	-7.1	-0.36	7.31e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.25	-6.27	-0.32	1.07e-9	Cutaneous nevi;
LIHC	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	0.74	8.26	0.41	3.28e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg02491457	chr7:128862824	NA	0.5	7.87	0.39	4.64e-14	White matter hyperintensity burden;
LIHC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.2	-0.41	4.94e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg23485639	chr6:28045615	ZNF165	0.39	5.94	0.31	7.13e-9	Parkinson's disease;
LIHC	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.37	-6.2	-0.32	1.58e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg00684032	chr4:1343700	KIAA1530	0.38	6.45	0.33	3.75e-10	Obesity-related traits;
LIHC	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.62	0.34	1.42e-10	Schizophrenia;
LIHC	cis	rs4794202	0.629	rs7214694	chr17:45895353	C/T	cg10638573	chr17:45915098	SCRN2	0.56	5.95	0.31	6.47e-9	Alzheimer's disease (cognitive decline);
LIHC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-6.1	-0.31	2.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04565464	chr8:145669602	NFKBIL2	0.4	6.72	0.34	7.64e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.57	-8.07	-0.4	1.24e-14	Coronary artery disease;
LIHC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.57	-7.32	-0.37	1.75e-12	Body mass index;
LIHC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs7635838	0.964	rs7624086	chr3:11412620	C/G	cg00170343	chr3:11313890	ATG7	0.45	7.24	0.36	2.91e-12	HDL cholesterol;
LIHC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.49	-0.49	1.66e-22	Hemoglobin concentration;
LIHC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg22800045	chr5:56110881	MAP3K1	0.59	7.06	0.36	9.36e-12	Type 2 diabetes;
LIHC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg05973401	chr12:123451056	ABCB9	-0.42	-6.23	-0.32	1.34e-9	Platelet count;
LIHC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg14580859	chr9:123691850	NA	0.37	6.55	0.33	2.07e-10	Rheumatoid arthritis;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.53	6.86	0.35	3.24e-11	Alzheimer's disease;
LIHC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	1.02	19.7	0.73	2.9e-58	Breast cancer;
LIHC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.52	9.46	0.46	5.04e-19	Systemic lupus erythematosus;
LIHC	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.38	6.78	0.34	5.19e-11	Total cholesterol levels;
LIHC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.92	-0.3	8.03e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.59	-9.4	-0.45	8.16e-19	Breast cancer;
LIHC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.61	8.83	0.43	5.48e-17	Aortic root size;
LIHC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.36	6.0	0.31	5.03e-9	Type 2 diabetes;
LIHC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.15	0.36	5.37e-12	Axial length;
LIHC	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.74	0.34	6.68e-11	Mean corpuscular volume;
LIHC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.84	12.63	0.56	2.91e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17258537	chr5:179401804	RNF130	0.46	6.72	0.34	7.68e-11	Longevity;
LIHC	cis	rs11955398	0.716	rs56191602	chr5:59954444	T/A	cg02684056	chr5:59996105	DEPDC1B	0.4	5.91	0.3	8.27e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.64	8.91	0.43	3.17e-17	Sudden cardiac arrest;
LIHC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.44	-6.69	-0.34	9.4e-11	Lung cancer in ever smokers;
LIHC	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.36	-8.26	-0.41	3.34e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.42	5.74	0.3	2.07e-8	Life satisfaction;
LIHC	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg04155231	chr12:9217510	LOC144571	0.31	5.85	0.3	1.12e-8	Sjögren's syndrome;
LIHC	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-8.15	-0.4	6.71e-15	Hepatocellular carcinoma;
LIHC	trans	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg01596870	chr19:55963115	NA	-0.62	-8.17	-0.4	5.86e-15	Obesity-related traits;
LIHC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.59	0.34	1.68e-10	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02181963	chr13:111358803	CARS2	0.48	6.05	0.31	3.73e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.82	0.35	4.1e-11	Dermatomyositis;
LIHC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg12798992	chr6:167411361	FGFR1OP	0.41	6.47	0.33	3.49e-10	Primary biliary cholangitis;
LIHC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.49	8.16	0.4	6.5e-15	Blood metabolite levels;
LIHC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.58	7.64	0.38	2.2e-13	Pancreatic cancer;
LIHC	cis	rs7923837	0.687	rs1111875	chr10:94462882	C/T	cg25506282	chr10:94462361	NA	0.37	6.64	0.34	1.24e-10	Body mass index;Multiple sclerosis;
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg09417038	chr21:47716443	C21orf57	-0.52	-7.99	-0.4	2.03e-14	Testicular germ cell tumor;
LIHC	cis	rs9473924	0.580	rs58105163	chr6:50832730	C/T	cg14470998	chr6:50812995	TFAP2B	0.89	10.22	0.48	1.42e-21	Body mass index;
LIHC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg03037974	chr15:76606532	NA	0.74	14.52	0.62	1.54e-37	Blood metabolite levels;
LIHC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.4	15.14	0.63	5.6e-40	Eosinophil percentage of granulocytes;
LIHC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg22079354	chr11:130786696	SNX19	0.42	5.95	0.31	6.74e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg08687515	chr19:58661962	ZNF329	0.47	6.16	0.32	2e-9	Breast cancer;
LIHC	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.46	-6.69	-0.34	9.28e-11	Life satisfaction;
LIHC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.48	-18.06	-0.7	1.11e-51	Breast cancer;
LIHC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.63	10.09	0.48	4.09e-21	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg13175981	chr1:150552382	MCL1	0.51	7.2	0.36	3.96e-12	Blood protein levels;
LIHC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.58	-0.38	3.23e-13	Glioblastoma;
LIHC	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.45	-5.94	-0.31	7.19e-9	Psoriasis;
LIHC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-19.96	-0.73	2.55e-59	Height;
LIHC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.59	-9.38	-0.45	9.64e-19	Childhood ear infection;
LIHC	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg22961513	chr11:14280813	SPON1	-0.44	-6.43	-0.33	4.28e-10	Mitochondrial DNA levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09637470	chr11:109963583	ZC3H12C	0.48	6.71	0.34	8.24e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.99	0.44	1.72e-17	Corneal astigmatism;
LIHC	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.53	6.95	0.35	1.85e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg05185784	chr16:90016020	DEF8	-0.46	-5.95	-0.31	6.75e-9	Skin colour saturation;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02878701	chr21:47706221	MCM3AP;C21orf57	0.43	6.15	0.32	2.18e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-8.98	-0.44	1.78e-17	Tonsillectomy;
LIHC	trans	rs2073499	0.872	rs7642692	chr3:50222693	T/C	cg21659725	chr3:3221576	CRBN	0.67	8.08	0.4	1.16e-14	Schizophrenia;
LIHC	trans	rs1920116	0.778	rs4352416	chr3:169554084	G/A	cg00669760	chr2:44735195	C2orf34	0.38	6.05	0.31	3.79e-9	Glioma (high-grade);
LIHC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.59	6.78	0.34	5.41e-11	Menarche (age at onset);
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.0	-0.44	1.6e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.95	-0.4	2.68e-14	Lymphocyte counts;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14417382	chr12:64616000	C12orf66	-0.4	-6.19	-0.32	1.71e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.59	-7.7	-0.38	1.48e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00594016	chr16:19721831	C16orf88	0.39	6.72	0.34	7.41e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25618672	chr7:65939712	NA	0.42	6.43	0.33	4.18e-10	Immature fraction of reticulocytes;
LIHC	cis	rs965469	0.779	rs6037515	chr20:3233091	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-6.24	-0.32	1.3e-9	IFN-related cytopenia;
LIHC	cis	rs17106184	1.000	rs1015085	chr1:51260668	C/A	cg07174182	chr1:51127561	FAF1	-0.64	-6.93	-0.35	2.1e-11	Type 2 diabetes;
LIHC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.49	6.95	0.35	1.88e-11	Body mass index;
LIHC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg02297831	chr4:17616191	MED28	0.42	6.56	0.33	1.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.52	7.23	0.36	3.13e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.85	0.3	1.17e-8	Rheumatoid arthritis;
LIHC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.97e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.37	6.01	0.31	4.72e-9	Height;
LIHC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.28	-6.01	-0.31	4.74e-9	Bronchopulmonary dysplasia;
LIHC	trans	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg23605328	chr1:201951606	RNPEP	0.38	6.07	0.31	3.35e-9	Monocyte percentage of white cells;
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00166722	chr3:10149974	C3orf24	0.51	5.84	0.3	1.19e-8	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg00091569	chr3:40428383	ENTPD3	0.41	6.78	0.34	5.36e-11	Renal cell carcinoma;
LIHC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.65	-0.34	1.18e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.45	-0.37	7.86e-13	Response to antipsychotic treatment;
LIHC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.41	-0.41	1.12e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.59	9.75	0.47	5.42e-20	HDL cholesterol;
LIHC	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00938859	chr5:1591904	SDHAP3	0.54	6.59	0.34	1.63e-10	Breast cancer;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.85	-0.35	3.48e-11	Longevity;Endometriosis;
LIHC	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs907683	0.584	rs2070927	chr2:220282955	C/T	cg15015639	chr2:220282977	DES	0.36	8.53	0.42	4.88e-16	Resting heart rate;
LIHC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.25	0.45	2.51e-18	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg02415029	chr1:110025642	ATXN7L2	0.45	5.95	0.31	6.75e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.08	0.66	9.77e-44	Breast cancer;
LIHC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.86	12.99	0.57	1.26e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.77e-13	Bone mineral density;
LIHC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs77861329	1.000	rs57335685	chr3:52098458	C/T	cg08692210	chr3:52188851	WDR51A	0.79	6.99	0.35	1.44e-11	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs10847980	0.590	rs12319654	chr12:123327160	C/T	cg25930673	chr12:123319894	HIP1R	1.14	12.88	0.57	3.08e-31	Adiponectin levels;
LIHC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.55	7.72	0.39	1.28e-13	Neuroticism;
LIHC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	trans	rs7714584	1.000	rs11955172	chr5:150254378	T/C	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs78545713	1.000	rs77281308	chr6:26250029	C/T	cg16070018	chr6:26224392	HIST1H3E	0.67	7.14	0.36	5.72e-12	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.61	-10.93	-0.51	4.8e-24	Breast cancer;
LIHC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.55	-9.05	-0.44	1.12e-17	Obesity-related traits;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.23	-0.32	1.39e-9	Total body bone mineral density;
LIHC	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.49	9.39	0.45	8.68e-19	Testicular germ cell tumor;
LIHC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	12.11	0.55	2.56e-28	Cognitive test performance;
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.91	0.35	2.44e-11	Renal cell carcinoma;
LIHC	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg20194872	chr6:41519635	FOXP4	0.41	6.5	0.33	2.78e-10	Prostate cancer;
LIHC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.75	-0.43	9.96e-17	Total cholesterol levels;
LIHC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.95	0.31	6.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7106204	1.000	rs7106204	chr11:24236096	C/T	ch.11.24196551F	chr11:24239977	NA	-0.6	-6.61	-0.34	1.47e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.44	-6.04	-0.31	4.12e-9	Coronary artery calcification;
LIHC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.64	9.64	0.46	1.32e-19	Corneal astigmatism;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.65	-9.85	-0.47	2.62e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19671926	chr4:122722719	EXOSC9	0.56	8.52	0.42	5.25e-16	Type 2 diabetes;
LIHC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg24634471	chr8:143751801	JRK	-0.43	-5.99	-0.31	5.35e-9	Urinary tract infection frequency;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg27433088	chr4:174089019	GALNT7	0.41	7.0	0.35	1.39e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.34	8.85	0.43	4.91e-17	Schizophrenia;
LIHC	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.7	13.13	0.58	3.49e-32	Pediatric autoimmune diseases;
LIHC	trans	rs3758911	0.796	rs56753250	chr11:107209225	T/A	cg21068293	chr15:74496576	STRA6	0.26	6.19	0.32	1.74e-9	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.7	7.14	0.36	5.55e-12	Alzheimer's disease;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08331733	chr4:113332969	ALPK1	0.46	6.8	0.35	4.6e-11	Bilirubin levels;
LIHC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.99	-19.64	-0.73	4.88e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.23	6.19	0.32	1.68e-9	Calcium levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21942256	chr3:156892528	NA	0.46	6.09	0.31	2.99e-9	Lung function (FEV1/FVC);
LIHC	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg09454613	chr16:77233327	SYCE1L;MON1B	-0.4	-6.06	-0.31	3.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.61	8.97	0.44	1.94e-17	Recombination rate (females);
LIHC	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.48	6.2	0.32	1.64e-9	Interleukin-18 levels;
LIHC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.53	8.09	0.4	1.02e-14	Lymphocyte counts;
LIHC	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg01843034	chr6:37503916	NA	-0.39	-6.22	-0.32	1.48e-9	Cognitive performance;
LIHC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-21.89	-0.76	4.92e-67	Height;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg07332563	chr6:291687	DUSP22	-0.52	-7.24	-0.36	3.05e-12	Menopause (age at onset);
LIHC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.96	-12.76	-0.57	9.14e-31	Schizophrenia;
LIHC	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	11.84	0.54	2.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.82	7.72	0.39	1.31e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.64	8.54	0.42	4.51e-16	Motion sickness;
LIHC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.37	5.81	0.3	1.4e-8	Menopause (age at onset);
LIHC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.5	6.8	0.35	4.71e-11	Aortic root size;
LIHC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.51	-8.91	-0.43	2.99e-17	Total body bone mineral density;
LIHC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.53	-0.33	2.32e-10	Response to antipsychotic treatment;
LIHC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	8.47	0.42	7.14e-16	Blood metabolite levels;
LIHC	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.57	-10.0	-0.48	7.99e-21	Colorectal cancer;
LIHC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.57	-10.63	-0.5	5.57e-23	Neurofibrillary tangles;
LIHC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg18306943	chr3:40428807	ENTPD3	-0.34	-6.12	-0.31	2.62e-9	Renal cell carcinoma;
LIHC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.4	6.15	0.32	2.2e-9	Neutrophil percentage of white cells;
LIHC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg06565975	chr8:143823917	SLURP1	-0.46	-8.43	-0.41	1.01e-15	Urinary tract infection frequency;
LIHC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.5	7.93	0.39	3.1e-14	Multiple sclerosis;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg03874509	chr1:107600012	PRMT6	0.76	12.17	0.55	1.44e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs244293	0.965	rs244333	chr17:53204178	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.46	-6.75	-0.34	6.25e-11	Menarche (age at onset);
LIHC	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.4	-6.25	-0.32	1.2e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.45	6.14	0.32	2.31e-9	Tonsillectomy;
LIHC	cis	rs13161895	1.000	rs35135297	chr5:179469532	T/C	cg02702477	chr5:179499311	RNF130	0.8	11.17	0.52	6.67e-25	LDL cholesterol;
LIHC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.63	10.83	0.51	1.03e-23	Colorectal cancer;
LIHC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-8.3	-0.41	2.43e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.5	8.92	0.43	2.77e-17	Height;
LIHC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.46	6.07	0.31	3.48e-9	Obesity-related traits;
LIHC	cis	rs151997	0.569	rs10035173	chr5:50276059	C/G	cg06027927	chr5:50259733	NA	0.54	6.6	0.34	1.61e-10	Callous-unemotional behaviour;
LIHC	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.91	0.35	2.36e-11	Bipolar disorder;
LIHC	cis	rs2273156	0.706	rs7155696	chr14:35496754	G/A	cg16230307	chr14:35515116	FAM177A1	-0.43	-6.19	-0.32	1.72e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.37	0.66	6.68e-45	Smoking behavior;
LIHC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	1.02	10.2	0.48	1.68e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.94	-16.48	-0.67	2.41e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6442522	0.533	rs2100544	chr3:15521665	G/A	cg16303742	chr3:15540471	COLQ	0.36	5.76	0.3	1.87e-8	Uric acid levels;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg14393609	chr7:65229607	NA	0.44	6.55	0.33	2.09e-10	Calcium levels;
LIHC	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16684958	chr7:75615977	POR	0.52	8.53	0.42	4.68e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.58	0.34	1.76e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.47	6.07	0.31	3.48e-9	Panic disorder;
LIHC	cis	rs6920965	0.545	rs614031	chr6:126165720	A/C	cg05901451	chr6:126070800	HEY2	-0.36	-6.29	-0.32	9.9e-10	High light scatter reticulocyte count;
LIHC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.88	0.39	4.54e-14	Lung cancer;
LIHC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.54	0.46	2.87e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.83	8.06	0.4	1.29e-14	Plasma clusterin levels;
LIHC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.55	9.47	0.46	4.84e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7188697	0.775	rs8056620	chr16:58604387	T/A	cg02549819	chr16:58548995	SETD6	0.48	7.56	0.38	3.8e-13	QT interval;
LIHC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.01e-8	Tonsillectomy;
LIHC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.52	-7.04	-0.36	1.04e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.02e-10	Metabolite levels (Pyroglutamine);
LIHC	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.79	-7.4	-0.37	1.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01995718	chr19:53913889	ZNF765	0.41	6.22	0.32	1.44e-9	Thyroid stimulating hormone;
LIHC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg13385521	chr17:29058706	SUZ12P	0.69	6.61	0.34	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.46	-6.15	-0.32	2.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.79	6.54	0.33	2.25e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	5.97	0.31	5.84e-9	Iron status biomarkers;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.59	0.56	4.01e-30	Prudent dietary pattern;
LIHC	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg12046867	chr14:103022105	NA	0.44	6.78	0.34	5.21e-11	Platelet count;
LIHC	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg07322936	chr10:88137208	NA	-0.47	-6.04	-0.31	3.96e-9	Schizophrenia;
LIHC	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.87	-0.3	1.04e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.45	-7.06	-0.36	9.56e-12	Multiple sclerosis;
LIHC	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.97	10.89	0.51	6.51e-24	IgG glycosylation;
LIHC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.4	6.79	0.34	5e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.76e-11	IgG glycosylation;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.25	-0.32	1.25e-9	Menopause (age at onset);
LIHC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.77	9.97	0.47	9.88e-21	Body mass index;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg14694896	chr8:104427370	SLC25A32;DCAF13	-0.45	-6.12	-0.31	2.53e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg15208524	chr1:10270712	KIF1B	0.44	6.39	0.33	5.34e-10	Hepatocellular carcinoma;
LIHC	cis	rs2421770	0.530	rs10836375	chr11:35353842	C/T	cg13971030	chr11:35366721	SLC1A2	-0.4	-6.79	-0.34	4.83e-11	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.76	8.85	0.43	4.72e-17	Exhaled nitric oxide levels;
LIHC	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg00977110	chr5:151150581	G3BP1	-0.54	-6.86	-0.35	3.22e-11	Preschool internalizing problems;
LIHC	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.34	-12.2	-0.55	1.1e-28	Psoriasis vulgaris;
LIHC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.3	0.32	9.31e-10	Schizophrenia;
LIHC	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-7.26	-0.37	2.71e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.72	0.3	2.33e-8	Electroencephalogram traits;
LIHC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	12.56	0.56	5.04e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06544989	chr22:39130855	UNC84B	-0.35	-5.86	-0.3	1.07e-8	Menopause (age at onset);
LIHC	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.72	-10.68	-0.5	3.55e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg12792011	chr19:58661915	ZNF329	0.95	7.77	0.39	9.44e-14	Cholesterol, total;
LIHC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg06742321	chr12:123595122	PITPNM2	0.31	5.83	0.3	1.31e-8	Platelet count;
LIHC	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.66	0.5	4.19e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.67	0.5	3.86e-23	Bladder cancer;
LIHC	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.61	-11.04	-0.51	1.86e-24	Neurofibrillary tangles;
LIHC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	8.45	0.42	8.67e-16	Lymphocyte counts;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04125373	chr11:65430610	RELA	0.48	6.12	0.31	2.6e-9	Hepatitis;
LIHC	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg15782153	chr7:917662	C7orf20	0.41	5.94	0.31	6.95e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg13263691	chr18:77568018	NA	0.24	6.73	0.34	7.32e-11	Schizophrenia;
LIHC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg25828445	chr12:7781288	NA	0.44	6.82	0.35	4.27e-11	HDL cholesterol levels;
LIHC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.56	7.61	0.38	2.67e-13	Multiple sclerosis;
LIHC	cis	rs864643	1.000	rs1340224	chr3:39549563	C/A	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg15696662	chr1:46669221	C1orf190;POMGNT1	-0.43	-6.65	-0.34	1.17e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.5	16.55	0.67	1.29e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg21724239	chr8:58056113	NA	0.47	6.34	0.32	7.19e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.64	-11.19	-0.52	5.72e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3736485	0.966	rs7161973	chr15:51854163	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.3	-0.32	9.35e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.48	6.45	0.33	3.84e-10	Resting heart rate;
LIHC	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.32	-5.71	-0.3	2.44e-8	Lewy body disease;
LIHC	cis	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg01231543	chr16:68741748	NA	0.39	6.09	0.31	2.99e-9	Colorectal cancer;
LIHC	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg26395211	chr5:140044315	WDR55	0.38	5.77	0.3	1.8e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.53	-6.25	-0.32	1.2e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06466203	chr10:89623360	PTEN;KILLIN	0.38	6.5	0.33	2.78e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2108622	0.727	rs62106156	chr19:15980424	C/T	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.73e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.2	-13.38	-0.59	4.14e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.51	-8.16	-0.4	6.62e-15	Multiple myeloma (IgH translocation);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg04486506	chr20:62577863	UCKL1	0.4	6.22	0.32	1.49e-9	Alopecia areata;
LIHC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.77	8.64	0.42	2.17e-16	Vitiligo;
LIHC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.98	-0.31	5.61e-9	Diabetic kidney disease;
LIHC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg19680672	chr10:131412579	MGMT	-0.42	-6.59	-0.34	1.67e-10	Response to temozolomide;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20859525	chr6:80714300	TTK	0.53	7.5	0.38	5.46e-13	Pancreatic cancer;
LIHC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.1	11.26	0.52	3.23e-25	Opioid sensitivity;
LIHC	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.78	-10.63	-0.5	5.23e-23	Response to hepatitis C treatment;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24842223	chr10:1129728	WDR37	-0.38	-6.11	-0.31	2.74e-9	Calcium levels;
LIHC	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg19752551	chr11:57585705	CTNND1	-0.51	-7.17	-0.36	4.8e-12	Schizophrenia;
LIHC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg15744005	chr10:104629667	AS3MT	0.38	8.17	0.4	5.87e-15	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs10916814	0.959	rs2101731	chr1:20901922	G/A	cg24502330	chr1:20914028	CDA	-0.28	-5.86	-0.3	1.07e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg18850929	chr19:1828978	REXO1	0.39	6.25	0.32	1.24e-9	Bipolar disorder;
LIHC	cis	rs10838687	0.867	rs2633082	chr11:47248050	C/G	cg26139080	chr11:47293733	MADD	0.42	6.01	0.31	4.67e-9	Proinsulin levels;
LIHC	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg06046430	chr4:77819534	ANKRD56	0.49	6.51	0.33	2.71e-10	Emphysema distribution in smoking;
LIHC	cis	rs4919087	0.590	rs2861877	chr10:99053316	C/A	cg25902810	chr10:99078978	FRAT1	-0.63	-6.98	-0.35	1.57e-11	Monocyte count;
LIHC	cis	rs2273156	0.929	rs8017225	chr14:35470049	G/A	cg16230307	chr14:35515116	FAM177A1	-0.4	-5.87	-0.3	1.05e-8	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.67	-10.02	-0.48	6.84e-21	Mosquito bite size;
LIHC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.83	0.35	3.93e-11	Height;
LIHC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.46	5.79	0.3	1.6e-8	Total body bone mineral density;
LIHC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.79	-0.34	4.93e-11	Aortic root size;
LIHC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.91	-8.95	-0.44	2.36e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9341808	0.586	rs3805869	chr6:81045917	T/C	cg08355045	chr6:80787529	NA	0.34	6.83	0.35	3.92e-11	Sitting height ratio;
LIHC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.75	11.33	0.52	1.79e-25	Corneal astigmatism;
LIHC	trans	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg26939375	chr7:64535504	NA	0.42	6.75	0.34	6.45e-11	Aortic root size;
LIHC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.65	-7.8	-0.39	7.55e-14	Heart rate;
LIHC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.26	6.68	0.34	9.55e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7635838	0.819	rs2454482	chr3:11534031	C/T	cg00170343	chr3:11313890	ATG7	0.4	6.19	0.32	1.68e-9	HDL cholesterol;
LIHC	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg12046867	chr14:103022105	NA	-0.43	-6.78	-0.34	5.22e-11	Platelet count;
LIHC	cis	rs7945718	0.621	rs11022463	chr11:12685395	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.55	-7.56	-0.38	3.78e-13	Pancreatic cancer;
LIHC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.42	7.67	0.38	1.79e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08280861	chr8:58055591	NA	0.49	6.05	0.31	3.9e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg05425664	chr17:57184151	TRIM37	-0.43	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LIHC	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-7.97	-0.4	2.4e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-0.96	-22.67	-0.77	4.29e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.31	7.56	0.38	3.64e-13	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23337289	chr2:27603239	ZNF513	0.42	6.34	0.32	7.3e-10	Pancreatic cancer;
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.29	-0.32	9.81e-10	Menopause (age at onset);
LIHC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.44	7.01	0.35	1.24e-11	Height;
LIHC	trans	rs10411161	0.810	rs17778661	chr19:52383288	C/G	cg22319618	chr22:45562946	NUP50	-0.6	-7.02	-0.35	1.24e-11	Breast cancer;
LIHC	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.55	-8.44	-0.42	8.92e-16	White matter hyperintensity burden;
LIHC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg18306943	chr3:40428807	ENTPD3	0.35	5.85	0.3	1.13e-8	Renal cell carcinoma;
LIHC	trans	rs11174436	0.571	rs11174401	chr12:62655061	T/A	cg14249155	chr9:124976040	LHX6	0.46	6.09	0.31	3.03e-9	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.5	7.6	0.38	2.89e-13	Liver enzyme levels;
LIHC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.02	-11.4	-0.52	9.83e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg09417038	chr21:47716443	C21orf57	-0.5	-7.27	-0.37	2.49e-12	Testicular germ cell tumor;
LIHC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.19	-0.36	4.2e-12	Migraine;Coronary artery disease;
LIHC	cis	rs12744310	0.778	rs61477144	chr1:41771793	A/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs8192282	0.739	rs9427415	chr1:154508437	A/T	cg16683920	chr1:154474344	TDRD10;SHE	0.45	5.72	0.3	2.34e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LIHC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.54	8.03	0.4	1.64e-14	High light scatter reticulocyte count;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg11598736	chr3:195384522	SDHAP2	0.71	8.55	0.42	4.15e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.35	13.72	0.6	1.87e-34	Psoriasis vulgaris;
LIHC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg12373951	chr3:133503437	NA	-0.49	-6.89	-0.35	2.61e-11	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.83	-0.3	1.25e-8	Tonsillectomy;
LIHC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.04	-0.31	4.07e-9	Height;
LIHC	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg01864836	chr14:55583639	NA	-0.41	-7.86	-0.39	4.89e-14	Protein biomarker;
LIHC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.56	-8.12	-0.4	8.28e-15	Asthma;
LIHC	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.46	6.08	0.31	3.21e-9	Glioblastoma;Glioma;
LIHC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg05110241	chr16:68378359	PRMT7	-0.86	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg23682824	chr7:23144976	KLHL7	0.4	5.93	0.31	7.21e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg07713946	chr22:31675144	LIMK2	-0.28	-6.16	-0.32	2.05e-9	Paclitaxel-induced neuropathy;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7712401	0.791	rs154507	chr5:122200907	C/G	cg18764291	chr5:122110994	SNX2	-0.36	-6.12	-0.31	2.54e-9	Mean platelet volume;
LIHC	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.74	12.98	0.57	1.38e-31	Eosinophil percentage of white cells;
LIHC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg04013166	chr16:89971882	TCF25	0.49	6.01	0.31	4.68e-9	Skin colour saturation;
LIHC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.55	9.66	0.46	1.1e-19	Age at first birth;
LIHC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03352830	chr11:487213	PTDSS2	0.81	6.12	0.31	2.5e-9	Body mass index;
LIHC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.38	-0.33	5.9e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17433710	0.543	rs12024691	chr1:162654790	G/A	cg01063088	chr1:162760584	HSD17B7	0.43	5.97	0.31	6.08e-9	Dupuytren's disease;
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	0.98	15.17	0.63	4.19e-40	Skin colour saturation;
LIHC	trans	rs6489882	0.671	rs4767028	chr12:113359188	A/G	cg10175203	chr3:128143634	NA	0.39	6.4	0.33	5.08e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs861318	0.702	rs3754460	chr1:159006846	T/C	cg11003133	chr1:159046391	AIM2	-0.35	-6.72	-0.34	7.84e-11	Obesity-related traits;
LIHC	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.28	-0.45	1.96e-18	Diabetic kidney disease;
LIHC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.44	6.34	0.32	7.48e-10	Aortic root size;
LIHC	trans	rs7849581	1	rs7849581	chr9:9924724	A/G	cg01301323	chr12:77252588	CSRP2	0.52	6.1	0.31	2.85e-9	Myopia (pathological);
LIHC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	cis	rs2279817	0.863	rs34820073	chr1:18010535	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.76	-0.39	9.68e-14	Neuroticism;
LIHC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.21	5.76	0.3	1.92e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.73	11.07	0.51	1.54e-24	Corneal astigmatism;
LIHC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.12	0.31	2.56e-9	Cognitive ability;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25454546	chr8:17781589	PCM1	0.46	6.46	0.33	3.54e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.03	-0.36	1.16e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg11764359	chr7:65958608	NA	0.56	5.74	0.3	2.04e-8	Diabetic kidney disease;
LIHC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg00677901	chr16:88017247	BANP	0.58	8.47	0.42	7.32e-16	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02290350	chr8:58132656	NA	0.49	10.6	0.5	6.68e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg07424592	chr7:64974309	NA	-0.8	-9.23	-0.45	2.9e-18	Diabetic kidney disease;
LIHC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.83	-9.59	-0.46	1.86e-19	Initial pursuit acceleration;
LIHC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.59	-6.82	-0.35	4.11e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20444381	chr8:109456000	TTC35	-0.44	-6.38	-0.33	5.74e-10	Systolic blood pressure;
LIHC	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg21280719	chr6:42927975	GNMT	-0.31	-7.26	-0.37	2.69e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-12.49	-0.56	9.48e-30	Obesity-related traits;
LIHC	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.27	-6.09	-0.31	3.05e-9	Graves' disease;
LIHC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4407350	1.000	rs5765745	chr22:44924894	A/G	cg26276947	chr22:44892394	LDOC1L	0.33	6.05	0.31	3.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg05527609	chr1:210001259	C1orf107	-0.54	-7.39	-0.37	1.1e-12	Red blood cell count;
LIHC	cis	rs787274	0.850	rs7862183	chr9:115529696	C/T	cg13803584	chr9:115635662	SNX30	-0.56	-6.18	-0.32	1.79e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.84	13.13	0.58	3.57e-32	Breast cancer;
LIHC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-6.83	-0.35	3.93e-11	Homocysteine levels;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg03874509	chr1:107600012	PRMT6	0.73	11.29	0.52	2.45e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.25	0.32	1.25e-9	Lymphocyte counts;
LIHC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg26536354	chr8:144654954	C8orf73	-0.45	-5.81	-0.3	1.45e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg07636037	chr3:49044803	WDR6	-0.83	-7.1	-0.36	7.41e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.4	-5.92	-0.3	7.79e-9	Tonsillectomy;
LIHC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.78	-11.83	-0.54	2.62e-27	Corneal astigmatism;
LIHC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	7.73	0.39	1.21e-13	Lymphocyte counts;
LIHC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-8.21	-0.41	4.46e-15	Longevity;
LIHC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.76	0.43	9.13e-17	Height;
LIHC	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg14930904	chr10:32216787	ARHGAP12	0.36	6.29	0.32	9.98e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.45	5.87	0.3	1.02e-8	Subjective well-being;
LIHC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.04	0.51	1.88e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.22	-0.48	1.37e-21	Schizophrenia;
LIHC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15506890	chr2:3487001	NA	-0.54	-8.54	-0.42	4.58e-16	Neurofibrillary tangles;
LIHC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.54	-7.06	-0.36	9.08e-12	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11207507	chr13:80915118	SPRY2	0.44	6.35	0.32	6.93e-10	Pancreatic cancer;
LIHC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg21573476	chr21:45109991	RRP1B	0.53	8.9	0.43	3.43e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg15871215	chr5:81402204	ATG10	-0.69	-8.31	-0.41	2.36e-15	Breast cancer;
LIHC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27297192	chr10:134578999	INPP5A	0.54	7.58	0.38	3.3e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.65	0.42	2.09e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.58	-0.34	1.72e-10	Metabolite levels;
LIHC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.57	-6.44	-0.33	4e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	trans	rs7714584	1.000	rs7705542	chr5:150228318	G/A	cg20675040	chr8:143813288	C8orf55	0.34	6.13	0.31	2.41e-9	Crohn's disease;
LIHC	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.43	6.06	0.31	3.53e-9	Tuberculosis;
LIHC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.75	-10.71	-0.5	2.88e-23	Pancreatic cancer;
LIHC	cis	rs4759375	0.598	rs11060725	chr12:123399478	G/T	cg25930673	chr12:123319894	HIP1R	0.63	7.12	0.36	6.31e-12	HDL cholesterol;
LIHC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.27	0.41	2.94e-15	Schizophrenia;
LIHC	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.71	0.46	7.58e-20	Corneal astigmatism;
LIHC	trans	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.33	-0.32	7.66e-10	Selective IgA deficiency;
LIHC	cis	rs965469	0.779	rs6037543	chr20:3289505	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg03959625	chr15:84868606	LOC388152	0.45	6.35	0.32	7.05e-10	Schizophrenia;
LIHC	cis	rs288342	0.832	rs208393	chr2:183649428	C/T	cg02625481	chr2:183667124	NA	-0.29	-5.95	-0.31	6.48e-9	Recurrent major depressive disorder;
LIHC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg07061783	chr6:25882402	NA	-0.47	-6.48	-0.33	3.29e-10	Blood metabolite levels;
LIHC	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.31	7.19	0.36	4.24e-12	Blood metabolite ratios;
LIHC	cis	rs600626	0.529	rs10899113	chr11:75468464	T/A	cg24262691	chr11:75473276	NA	0.39	5.82	0.3	1.36e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	11.04	0.51	1.88e-24	Alzheimer's disease (late onset);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg13572638	chr1:227173653	CABC1	0.42	6.09	0.31	3.11e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg21518248	chr2:162101506	NA	0.42	6.26	0.32	1.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.62	6.93	0.35	2.15e-11	Alzheimer's disease;
LIHC	cis	rs16828019	0.929	rs111309254	chr1:41736000	A/G	cg03387723	chr1:41708464	SCMH1	-0.44	-7.17	-0.36	4.74e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg04998671	chr14:104000505	TRMT61A	0.59	7.86	0.39	5.15e-14	Coronary artery disease;
LIHC	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-6.1	-0.31	2.86e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06438815	chr21:46292710	PTTG1IP	0.37	6.12	0.31	2.53e-9	Cognitive function;
LIHC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.56	7.24	0.36	3.06e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg14473756	chr11:122847823	NA	-0.37	-6.74	-0.34	6.82e-11	Menarche (age at onset);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg03533979	chr22:47097306	CERK	0.39	6.34	0.32	7.36e-10	Alopecia areata;
LIHC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	7.96	0.4	2.57e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11207507	chr13:80915118	SPRY2	0.4	6.27	0.32	1.06e-9	Cognitive function;
LIHC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.54	8.12	0.4	8.47e-15	Platelet count;
LIHC	cis	rs2286503	0.839	rs2270105	chr7:22862467	G/A	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02359409	chr6:42947317	PEX6	-0.48	-6.8	-0.35	4.69e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.13	0.52	9.28e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.93	17.47	0.69	2.79e-49	Menopause (age at onset);
LIHC	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.53	8.29	0.41	2.59e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg02829992	chr2:10710499	NA	-0.38	-6.05	-0.31	3.75e-9	Prostate cancer;
LIHC	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg25124228	chr12:125621409	AACS	-0.39	-6.62	-0.34	1.35e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.21	-0.32	1.49e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7818688	0.697	rs76215523	chr8:95987015	T/C	cg16049864	chr8:95962084	TP53INP1	0.59	6.42	0.33	4.5e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg26138144	chr22:38071188	LGALS1	0.42	7.83	0.39	6.21e-14	Fat distribution (HIV);
LIHC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.91	0.7	4.42e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	14.19	0.61	3.04e-36	Coffee consumption (cups per day);
LIHC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.38	6.11	0.31	2.67e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg15506890	chr2:3487001	NA	-0.44	-6.6	-0.34	1.58e-10	Neurofibrillary tangles;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08219700	chr8:58056026	NA	0.53	6.36	0.33	6.6e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.76	-7.63	-0.38	2.28e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.9	15.98	0.65	2.55e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs74233809	1.000	rs12217501	chr10:104851889	T/C	cg03493300	chr10:104813866	CNNM2	0.46	6.11	0.31	2.71e-9	Birth weight;
LIHC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.51	9.39	0.45	8.59e-19	Hemoglobin concentration;
LIHC	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.49	7.44	0.37	8.42e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.84	-0.3	1.22e-8	Colorectal cancer;
LIHC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.47	-0.37	6.89e-13	Total body bone mineral density;
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.53	7.88	0.39	4.46e-14	Longevity;
LIHC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	cis	rs7546668	1.000	rs6429746	chr1:15815579	A/G	cg11706911	chr1:15910989	AGMAT	-0.39	-5.82	-0.3	1.39e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs712039	0.652	rs8069062	chr17:35829306	C/T	cg16670864	chr17:35848621	DUSP14	0.34	5.73	0.3	2.19e-8	Tuberculosis;
LIHC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	0.67	7.05	0.36	9.86e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04232466	chr8:21988724	HR	0.45	6.58	0.34	1.72e-10	Pancreatic cancer;
LIHC	trans	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg07393940	chr7:158741817	NA	-0.56	-6.59	-0.34	1.66e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg02972257	chr16:68554789	NA	0.61	6.45	0.33	3.74e-10	Ulcerative colitis;
LIHC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.6	7.07	0.36	8.73e-12	Cognitive function;
LIHC	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-8.14	-0.4	7.19e-15	Blood pressure (smoking interaction);
LIHC	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg20240347	chr1:204465584	NA	-0.34	-7.13	-0.36	5.89e-12	Schizophrenia;
LIHC	cis	rs2637030	0.559	rs31303	chr5:52942197	C/T	cg06476337	chr5:52856530	NDUFS4	-0.42	-6.73	-0.34	7.19e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs10916814	0.632	rs6691041	chr1:20898650	A/G	cg24502330	chr1:20914028	CDA	-0.3	-6.7	-0.34	8.63e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-7.64	-0.38	2.26e-13	Diabetic kidney disease;
LIHC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.4	-0.33	5.07e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs72781680	0.533	rs34668726	chr2:23895901	C/G	cg08917208	chr2:24149416	ATAD2B	0.92	7.8	0.39	7.56e-14	Lymphocyte counts;
LIHC	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg13919466	chr1:32135498	COL16A1	-0.36	-6.65	-0.34	1.18e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.95	0.35	1.83e-11	Blood protein levels;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg09074113	chr2:20870087	GDF7	-0.52	-10.35	-0.49	5.22e-22	Abdominal aortic aneurysm;
LIHC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26031613	chr14:104095156	KLC1	-0.73	-9.24	-0.45	2.61e-18	Body mass index;
LIHC	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.42	-7.01	-0.35	1.27e-11	Platelet distribution width;
LIHC	trans	rs1974653	0.813	rs1974652	chr22:20134147	A/G	cg20152630	chr19:46405944	MYPOP	0.51	6.64	0.34	1.25e-10	Schizophrenia;
LIHC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg25457927	chr22:38595422	NA	-0.32	-7.34	-0.37	1.52e-12	Breast cancer;
LIHC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg00792783	chr2:198669748	PLCL1	0.46	6.86	0.35	3.19e-11	Dermatomyositis;
LIHC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	11.41	0.52	9.39e-26	Cognitive test performance;
LIHC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg00990874	chr7:1149470	C7orf50	-0.43	-6.44	-0.33	3.93e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.84	18.46	0.71	2.84e-53	Gestational age at birth (maternal effect);
LIHC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs918629	0.716	rs3777178	chr5:95273915	G/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.28	-0.32	1.04e-9	IgG glycosylation;
LIHC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.64	-9.17	-0.44	4.62e-18	Blood metabolite levels;
LIHC	trans	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg16011800	chr17:1958478	HIC1	0.52	7.31	0.37	1.96e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.56	7.07	0.36	8.9e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.99	0.4	2.14e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.14e-8	Pulmonary function;
LIHC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.37	5.89	0.3	9.48e-9	Lung cancer;
LIHC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.08	-0.48	4.45e-21	Response to antipsychotic treatment;
LIHC	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg17120908	chr11:65337727	SSSCA1	0.46	6.52	0.33	2.53e-10	Bone mineral density;
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.57	7.54	0.38	4.31e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs903552	1.000	rs12906575	chr15:102003617	G/A	cg25677261	chr15:102009856	PCSK6	-0.44	-5.99	-0.31	5.4e-9	Diabetic kidney disease;
LIHC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	9.69	0.46	8.64e-20	Platelet count;
LIHC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg12365402	chr11:9010492	NRIP3	-0.26	-6.65	-0.34	1.17e-10	Hemoglobin concentration;
LIHC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.46	7.12	0.36	6.45e-12	Blood protein levels;
LIHC	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.63	-0.42	2.28e-16	Waist circumference;Body mass index;
LIHC	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.82	11.65	0.53	1.17e-26	Body mass index;
LIHC	cis	rs11971779	0.680	rs4732379	chr7:139122814	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	9.7	0.46	8.15e-20	Diisocyanate-induced asthma;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.54	-7.11	-0.36	6.83e-12	Menopause (age at onset);
LIHC	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.36	6.43	0.33	4.21e-10	HIV-1 susceptibility;
LIHC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.47	-7.82	-0.39	6.84e-14	IgG glycosylation;
LIHC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.25	15.27	0.64	1.6e-40	Psoriasis vulgaris;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg20786246	chr2:72377174	NA	-0.5	-6.3	-0.32	9.39e-10	Facial morphology (factor 20);
LIHC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.73	0.34	7.32e-11	Schizophrenia;
LIHC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.66	-7.47	-0.37	6.67e-13	Bipolar disorder;
LIHC	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg18190219	chr22:46762943	CELSR1	0.72	6.69	0.34	9.02e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.08e-8	Coronary artery disease;
LIHC	cis	rs151997	0.893	rs27607	chr5:50228977	A/G	cg06027927	chr5:50259733	NA	-0.57	-7.68	-0.38	1.69e-13	Callous-unemotional behaviour;
LIHC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.14	0.48	2.72e-21	Calcium levels;
LIHC	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg02023728	chr11:77925099	USP35	0.32	5.85	0.3	1.14e-8	Alzheimer's disease (survival time);
LIHC	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.0	0.31	4.92e-9	Morning vs. evening chronotype;
LIHC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.49	-7.87	-0.39	4.68e-14	Diastolic blood pressure;
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.46	5.73	0.3	2.21e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.97	11.78	0.54	4.14e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs7619427	0.544	rs58289556	chr3:44034726	C/T	cg24966902	chr3:44043705	NA	0.53	8.23	0.41	4.07e-15	Schizophrenia;
LIHC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.38	6.45	0.33	3.86e-10	Type 2 diabetes;
LIHC	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.15	-0.32	2.2e-9	Response to antipsychotic treatment;
LIHC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-13.58	-0.59	6.77e-34	Primary sclerosing cholangitis;
LIHC	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.49	8.33	0.41	2e-15	Schizophrenia;
LIHC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	0.91	17.01	0.68	1.88e-47	Bone mineral density;
LIHC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.24	-0.32	1.29e-9	Fear of minor pain;
LIHC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.38	5.77	0.3	1.77e-8	Multiple sclerosis;
LIHC	cis	rs13161895	0.646	rs75894617	chr5:179499854	G/C	cg02702477	chr5:179499311	RNF130	0.96	11.78	0.54	4.13e-27	LDL cholesterol;
LIHC	cis	rs11673344	0.864	rs8106386	chr19:37503899	C/T	cg27390819	chr19:37464633	NA	0.5	6.1	0.31	2.87e-9	Obesity-related traits;
LIHC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.35	7.26	0.37	2.69e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13240253	chr3:71245529	FOXP1	0.45	7.25	0.36	2.86e-12	Longevity;
LIHC	cis	rs1000083	0.748	rs3108530	chr5:96628139	C/G	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs7818688	0.653	rs16893774	chr8:95895976	C/G	cg16049864	chr8:95962084	TP53INP1	-0.52	-6.04	-0.31	4.07e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs17818399	0.684	rs62134759	chr2:46791849	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.51	7.42	0.37	9.47e-13	Height;
LIHC	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.45	6.22	0.32	1.48e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.14	0.68	5.42e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4728302	0.869	rs2059298	chr7:133603245	C/G	cg10665199	chr7:133106180	EXOC4	0.39	6.82	0.35	4.1e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg03970086	chr16:88974840	CBFA2T3	0.33	6.37	0.33	6.17e-10	Social autistic-like traits;
LIHC	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.44	7.01	0.35	1.28e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.27	-0.55	6.47e-29	Alzheimer's disease;
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.7	-11.35	-0.52	1.51e-25	Skin colour saturation;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15725733	chr2:236949415	AGAP1	-0.34	-6.31	-0.32	8.51e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.03	16.27	0.66	1.75e-44	Breast cancer;
LIHC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.82	0.69	1.04e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.25	-0.41	3.51e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.49	-7.6	-0.38	2.93e-13	P wave terminal force;
LIHC	cis	rs6988985	0.560	rs2078674	chr8:143928233	G/T	cg23373978	chr8:143916136	GML	-0.29	-6.12	-0.31	2.56e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LIHC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-6.05	-0.31	3.73e-9	Vitiligo;
LIHC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg10820045	chr2:198174542	NA	0.56	9.01	0.44	1.46e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.74	7.56	0.38	3.64e-13	Chronic kidney disease;
LIHC	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.48	-0.37	6.42e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs72627509	0.523	rs12650282	chr4:57733604	A/G	cg26694713	chr4:57773883	REST	-0.42	-5.82	-0.3	1.35e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.85	12.19	0.55	1.26e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.72	-11.07	-0.51	1.49e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.53	12.44	0.56	1.46e-29	White blood cell count (basophil);
LIHC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.46	-7.67	-0.38	1.86e-13	Blood metabolite levels;
LIHC	cis	rs600806	0.888	rs444387	chr1:109851127	A/G	cg16275483	chr1:110013120	SYPL2	-0.5	-6.13	-0.31	2.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02290350	chr8:58132656	NA	0.48	9.39	0.45	8.97e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg04306507	chr14:55594613	LGALS3	0.32	6.17	0.32	1.94e-9	Protein biomarker;
LIHC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.74	-9.05	-0.44	1.1e-17	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.04	0.31	3.93e-9	Bipolar disorder;
LIHC	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg05197062	chr11:11642011	GALNTL4	0.42	6.08	0.31	3.17e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.95	-14.87	-0.63	6.08e-39	Orofacial clefts;
LIHC	cis	rs3812111	0.677	rs1204849	chr6:116525269	C/T	cg08036074	chr6:116424633	NT5DC1	-0.39	-6.31	-0.32	8.7e-10	Age-related macular degeneration;
LIHC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.43	6.12	0.31	2.51e-9	Menarche (age at onset);
LIHC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.37	6.39	0.33	5.47e-10	Monocyte percentage of white cells;
LIHC	trans	rs75804782	0.581	rs55931535	chr2:239372632	A/G	cg01134436	chr17:81009848	B3GNTL1	0.86	7.2	0.36	3.75e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.44	7.46	0.37	6.98e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.22	-0.45	3.18e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.51	8.21	0.41	4.64e-15	Blood protein levels;
LIHC	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.04e-10	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.49	0.76	2.02e-65	Height;
LIHC	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.89	10.75	0.5	2.11e-23	Prostate cancer;
LIHC	cis	rs4450131	0.898	rs3824804	chr10:126326606	C/T	cg20435097	chr10:126320824	FAM53B	0.53	9.7	0.46	8.51e-20	White blood cell count (basophil);
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.3	0.55	4.83e-29	Prudent dietary pattern;
LIHC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.79e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg15848620	chr12:58087721	OS9	-0.54	-7.41	-0.37	9.97e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4919087	0.561	rs34288920	chr10:99083483	C/T	cg25902810	chr10:99078978	FRAT1	-0.59	-6.96	-0.35	1.75e-11	Monocyte count;
LIHC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.78	-12.6	-0.56	3.76e-30	Resting heart rate;
LIHC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.77	7.44	0.37	7.95e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs600806	0.745	rs12136063	chr1:110014170	A/G	cg08911820	chr1:110026001	ATXN7L2	0.55	7.22	0.36	3.32e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.38	-7.0	-0.35	1.35e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.37	6.24	0.32	1.27e-9	Obesity-related traits;
LIHC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg19635926	chr16:89946313	TCF25	0.49	6.3	0.32	9.24e-10	Skin colour saturation;
LIHC	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg00204512	chr16:28754710	NA	0.36	6.43	0.33	4.28e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.35	7.1	0.36	7.45e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LIHC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-9.35	-0.45	1.18e-18	Primary sclerosing cholangitis;
LIHC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.14e-14	Neuroticism;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	0.61	8.91	0.43	3.16e-17	Prudent dietary pattern;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11897690	chr12:111051732	TCTN1	0.38	6.1	0.31	2.86e-9	Immature fraction of reticulocytes;
LIHC	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	0.71	7.69	0.38	1.61e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.76	12.2	0.55	1.15e-28	Colorectal cancer;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.68	-0.34	9.87e-11	Total body bone mineral density;
LIHC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.6	9.22	0.45	3.01e-18	Height;
LIHC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-6.1	-0.31	2.9e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	15.16	0.63	4.74e-40	Prudent dietary pattern;
LIHC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg00091569	chr3:40428383	ENTPD3	0.36	5.73	0.3	2.18e-8	Renal cell carcinoma;
LIHC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	6.92	0.35	2.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.11	-0.31	2.76e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.33	7.37	0.37	1.27e-12	Blood metabolite ratios;
LIHC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-0.77	-12.05	-0.55	4.03e-28	Platelet distribution width;
LIHC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.53	7.81	0.39	6.92e-14	Type 2 diabetes;
LIHC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.49	-7.87	-0.39	4.68e-14	Diastolic blood pressure;
LIHC	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.42	0.41	1.09e-15	Lung cancer in ever smokers;
LIHC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.6	5.77	0.3	1.81e-8	Cannabis dependence symptom count;
LIHC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg17306686	chr7:157230923	NA	0.39	8.51	0.42	5.73e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg21522988	chr12:29376872	FAR2	0.28	6.38	0.33	5.81e-10	QT interval;
LIHC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.63	-0.34	1.29e-10	Mean corpuscular volume;
LIHC	cis	rs797680	0.927	rs1000607	chr1:93772001	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.97	-0.31	5.84e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-6.84	-0.35	3.65e-11	Eye color traits;
LIHC	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.5	6.97	0.35	1.63e-11	Parkinson's disease;
LIHC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.21	-15.29	-0.64	1.45e-40	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.82	0.39	6.79e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg05555928	chr11:63887634	MACROD1	0.55	7.41	0.37	1.03e-12	Mean platelet volume;
LIHC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg05361325	chr10:32636312	EPC1	-0.51	-6.24	-0.32	1.31e-9	Sexual dysfunction (female);
LIHC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg09835421	chr16:68378352	PRMT7	-0.54	-6.05	-0.31	3.78e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.65	9.18	0.44	4.29e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9918079	0.542	rs12499412	chr4:15602252	G/C	cg21123203	chr4:15471301	CC2D2A	0.45	7.23	0.36	3.24e-12	Obesity-related traits;
LIHC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg18270830	chr10:32634957	EPC1	0.53	6.44	0.33	4.04e-10	Sexual dysfunction (female);
LIHC	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.39	5.97	0.31	6.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg20283391	chr11:68216788	NA	-0.39	-6.23	-0.32	1.34e-9	Total body bone mineral density;
LIHC	cis	rs4853036	0.951	rs13393656	chr2:70119255	C/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.87	-0.35	2.95e-11	Colorectal or endometrial cancer;
LIHC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg15208524	chr1:10270712	KIF1B	0.41	6.16	0.32	2.03e-9	Hepatocellular carcinoma;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.56	-7.86	-0.39	5.16e-14	Total body bone mineral density;
LIHC	cis	rs7534824	0.543	rs6577221	chr1:101420406	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.33	0.37	1.66e-12	Refractive astigmatism;
LIHC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-8.6	-0.42	2.84e-16	Facial morphology (factor 19);
LIHC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	11.26	0.52	3.23e-25	Lung cancer in ever smokers;
LIHC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12463550	chr7:65579703	CRCP	0.68	7.09	0.36	7.69e-12	Diabetic kidney disease;
LIHC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.06	0.36	9.53e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.58	-11.39	-0.52	1.1e-25	Coronary artery disease;
LIHC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg05941027	chr17:61774174	LIMD2	0.38	7.88	0.39	4.54e-14	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg19338460	chr6:170058176	WDR27	-0.39	-5.98	-0.31	5.58e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs7777677	0.925	rs2156964	chr7:142372587	C/T	cg21680980	chr1:221069572	NA	-0.48	-6.08	-0.31	3.27e-9	Alcoholic chronic pancreatitis;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.21	-0.32	1.5e-9	Total body bone mineral density;
LIHC	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-7.24	-0.36	2.93e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg06565975	chr8:143823917	SLURP1	0.33	6.16	0.32	2.07e-9	Urinary tract infection frequency;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00137585	chr16:3450828	ZNF174;ZNF434	-0.49	-6.37	-0.33	6.02e-10	Pancreatic cancer;
LIHC	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21467203	chr3:49911342	NA	-0.59	-10.62	-0.5	5.81e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.73	11.94	0.54	1.05e-27	Body mass index;
LIHC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.45	-7.5	-0.38	5.52e-13	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	24.89	0.8	9.36e-79	Chronic sinus infection;
LIHC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.51	-8.03	-0.4	1.61e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.96	-0.44	2.15e-17	Ulcerative colitis;
LIHC	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg19773385	chr1:10388646	KIF1B	-0.32	-5.73	-0.3	2.19e-8	Hepatocellular carcinoma;
LIHC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.44	-10.2	-0.48	1.67e-21	Type 2 diabetes;
LIHC	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg01320579	chr17:75405842	SEPT9	0.51	8.57	0.42	3.64e-16	Airflow obstruction;
LIHC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg01320579	chr17:75405842	SEPT9	0.54	7.72	0.39	1.31e-13	Airflow obstruction;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg08556938	chr17:58512855	NA	0.41	6.43	0.33	4.21e-10	Immature fraction of reticulocytes;
LIHC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.92	0.3	7.91e-9	Obesity-related traits;
LIHC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.6	8.29	0.41	2.71e-15	Bladder cancer;
LIHC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.6	-8.4	-0.41	1.24e-15	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08219700	chr8:58056026	NA	0.51	6.89	0.35	2.73e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma;
LIHC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.44	0.45	6.09e-19	Bipolar disorder;
LIHC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21747090	chr2:27597821	SNX17	-0.4	-5.82	-0.3	1.36e-8	Total body bone mineral density;
LIHC	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg09829573	chr1:144692074	NBPF9	0.42	7.11	0.36	6.93e-12	Hip geometry;
LIHC	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.4	-6.02	-0.31	4.38e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.43	-9.64	-0.46	1.34e-19	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs4878497	0.646	rs10511906	chr9:32442492	A/G	cg14296220	chr9:32431791	ACO1	0.6	10.43	0.49	2.59e-22	Inflammatory skin disease;
LIHC	cis	rs1865721	0.848	rs12966327	chr18:73208445	C/T	cg26385618	chr18:73139727	C18orf62	-0.29	-7.3	-0.37	1.99e-12	Intelligence;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.44	-6.12	-0.31	2.63e-9	Total body bone mineral density;
LIHC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.63	0.42	2.42e-16	Lung cancer in ever smokers;
LIHC	cis	rs4908768	0.539	rs1809332	chr1:8656434	C/T	cg20416874	chr1:8611966	RERE	-0.62	-11.27	-0.52	2.9e-25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.52	9.36	0.45	1.05e-18	Mean corpuscular volume;
LIHC	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.71	-10.68	-0.5	3.68e-23	Subjective well-being;
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg26939375	chr7:64535504	NA	0.47	7.19	0.36	4.13e-12	Calcium levels;
LIHC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.45	6.06	0.31	3.66e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-9.35	-0.45	1.15e-18	Crohn's disease;
LIHC	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.73	-11.35	-0.52	1.52e-25	Gastritis;
LIHC	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg01864069	chr14:103024347	NA	0.45	7.03	0.36	1.13e-11	Platelet count;
LIHC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.34	-0.32	7.16e-10	Blood metabolite levels;
LIHC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	8.53	0.42	4.77e-16	Blood metabolite levels;
LIHC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.7	13.6	0.59	5.91e-34	Menopause (age at onset);
LIHC	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.13	-0.44	5.97e-18	Exhaled nitric oxide output;
LIHC	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg09572067	chr16:29127029	RRN3P2	0.53	8.55	0.42	4.2e-16	Menopause (age at onset);
LIHC	cis	rs1494373	0.722	rs6659246	chr1:220931227	A/C	cg06786860	chr1:220876396	NA	0.38	5.82	0.3	1.32e-8	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.42	0.33	4.62e-10	Response to antipsychotic treatment;
LIHC	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.63	-6.98	-0.35	1.52e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg22771759	chr13:24902376	NA	0.32	6.59	0.34	1.71e-10	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs16828019	0.777	rs16911	chr1:41498021	C/T	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.69	-11.21	-0.52	4.68e-25	Itch intensity from mosquito bite;
LIHC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	1.06	22.31	0.77	1.12e-68	Breast cancer;
LIHC	trans	rs10411161	0.810	rs59911578	chr19:52385597	G/C	cg22319618	chr22:45562946	NUP50	-0.59	-7.05	-0.36	9.8e-12	Breast cancer;
LIHC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.8	0.3	1.54e-8	Tonsillectomy;
LIHC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.39	6.39	0.33	5.57e-10	Red blood cell count;
LIHC	cis	rs10508774	0.810	rs12252927	chr10:32726139	G/T	cg01819863	chr10:32635814	EPC1	0.61	5.88	0.3	9.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.53	8.55	0.42	4.12e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs7714584	0.590	rs115823027	chr5:150265951	G/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.06	-0.36	9.1e-12	Schizophrenia;
LIHC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg27121462	chr16:89883253	FANCA	0.46	7.18	0.36	4.39e-12	Vitiligo;
LIHC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.87	0.54	1.9e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.42	6.03	0.31	4.31e-9	Breast cancer;
LIHC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg01864069	chr14:103024347	NA	0.47	7.18	0.36	4.29e-12	Platelet count;
LIHC	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-9.69	-0.46	9.18e-20	Ulcerative colitis;
LIHC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.62	-11.07	-0.51	1.45e-24	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2018683	0.932	rs4386882	chr7:28989270	C/T	cg19402173	chr7:128379420	CALU	-0.41	-6.3	-0.32	8.91e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.7	10.06	0.48	5.15e-21	Lymphocyte counts;
LIHC	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg06533319	chr4:3265114	C4orf44	0.38	7.5	0.38	5.55e-13	Parental longevity (mother's age at death);
LIHC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6669384	0.737	rs882198	chr1:208036509	A/G	cg22525895	chr1:207977042	MIR29B2	0.51	6.08	0.31	3.15e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.81	-13.34	-0.59	5.67e-33	Morning vs. evening chronotype;
LIHC	trans	rs983392	0.680	rs11230201	chr11:59996994	C/G	cg17275991	chr19:58003312	ZNF419	0.43	6.19	0.32	1.7e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg25356066	chr3:128598488	ACAD9	0.56	7.56	0.38	3.76e-13	IgG glycosylation;
LIHC	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.3	6.6	0.34	1.58e-10	Ulcerative colitis;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02290350	chr8:58132656	NA	0.51	11.04	0.51	1.9e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.76	0.39	9.83e-14	Triglyceride levels;
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.64	-9.46	-0.46	4.96e-19	Lymphocyte counts;
LIHC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs6435862	0.517	rs6757091	chr2:215672793	G/C	cg04530015	chr2:215796436	ABCA12	0.49	9.01	0.44	1.46e-17	Neuroblastoma (high-risk);
LIHC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.35	0.37	1.44e-12	Lung cancer;
LIHC	cis	rs2279817	0.863	rs871089	chr1:18017704	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.68	8.05	0.4	1.36e-14	Neuroticism;
LIHC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.54	8.67	0.42	1.78e-16	Total body bone mineral density;
LIHC	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg04267008	chr7:1944627	MAD1L1	0.43	5.77	0.3	1.81e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.45	-7.93	-0.39	3.07e-14	Aortic root size;
LIHC	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.33	7.35	0.37	1.48e-12	Blood metabolite ratios;
LIHC	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg19000871	chr14:103996768	TRMT61A	-0.4	-6.86	-0.35	3.3e-11	Coronary artery disease;
LIHC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.02	11.8	0.54	3.5e-27	Vitiligo;
LIHC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.04	0.36	1.06e-11	Neutrophil percentage of white cells;
LIHC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.86	-0.35	3.29e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.52	8.02	0.4	1.66e-14	Blood trace element (Zn levels);
LIHC	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.66	0.65	4.59e-42	Electrocardiographic conduction measures;
LIHC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg19682013	chr15:45996608	NA	0.4	7.09	0.36	7.7e-12	Waist circumference;Weight;
LIHC	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-16.66	-0.67	4.74e-46	Schizophrenia;
LIHC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.71e-15	Body mass index;
LIHC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23262073	chr20:60523788	NA	0.28	5.91	0.3	8.22e-9	Body mass index;
LIHC	cis	rs2574704	1.000	rs2574704	chr3:11655381	T/C	cg15876825	chr3:11651881	VGLL4	0.5	8.2	0.41	4.88e-15	Body mass index;
LIHC	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.45	0.37	7.66e-13	Endometrial cancer;
LIHC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.78	13.71	0.6	2.06e-34	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06586915	chr7:65958596	NA	0.44	6.25	0.32	1.24e-9	Pancreatic cancer;
LIHC	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.43	-8.23	-0.41	3.9e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.51	9.06	0.44	1.04e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.3	-0.32	9.31e-10	Coronary artery disease;
LIHC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.85	0.3	1.15e-8	Self-reported allergy;
LIHC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.44	-8.61	-0.42	2.79e-16	Tuberculosis;
LIHC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg04691961	chr3:161091175	C3orf57	-0.33	-5.73	-0.3	2.23e-8	Morning vs. evening chronotype;
LIHC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg10935138	chr17:73851978	WBP2	0.48	7.09	0.36	7.83e-12	White matter hyperintensity burden;
LIHC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.4	-6.9	-0.35	2.52e-11	Type 2 diabetes;
LIHC	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	0.92	22.57	0.77	1.05e-69	Multiple myeloma;
LIHC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.88	0.39	4.48e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.5	-8.03	-0.4	1.56e-14	Total body bone mineral density;
LIHC	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.44	6.64	0.34	1.26e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11627756	0.957	rs7144340	chr14:103128777	G/T	cg12046867	chr14:103022105	NA	0.39	5.87	0.3	1.02e-8	Mean platelet volume;
LIHC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.62	9.49	0.46	3.93e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.94	-0.7	3.35e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02359409	chr6:42947317	PEX6	-0.48	-6.79	-0.34	4.99e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.45	-7.16	-0.36	4.98e-12	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.45	-7.55	-0.38	3.94e-13	IgG glycosylation;
LIHC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.4	6.65	0.34	1.15e-10	Red blood cell count;
LIHC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg10360323	chr17:41437877	NA	0.39	5.71	0.3	2.44e-8	Menopause (age at onset);
LIHC	trans	rs1624005	0.933	rs1667657	chr14:43398628	T/C	cg11960719	chr5:1510684	LPCAT1	-0.36	-6.26	-0.32	1.16e-9	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LIHC	cis	rs970821	1.000	rs17258588	chr8:124746618	C/T	cg00283535	chr8:124749564	ANXA13	0.35	5.91	0.3	8.29e-9	Breast cancer;
LIHC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.68	-8.92	-0.43	2.88e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11098699	0.821	rs4833890	chr4:124217864	G/C	cg09941581	chr4:124220074	SPATA5	0.33	6.72	0.34	7.55e-11	Mosquito bite size;
LIHC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.3	0.32	8.96e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.58	11.69	0.53	8.52e-27	Glycated hemoglobin levels;
LIHC	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.08	-0.31	3.18e-9	Tuberculosis;
LIHC	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-9.17	-0.44	4.46e-18	Colorectal cancer;
LIHC	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.55	0.46	2.51e-19	Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	trans	rs17154702	0.506	rs2427	chr8:8641125	A/G	cg06710121	chr8:12235606	FAM66A	-0.52	-6.09	-0.31	3.04e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	0.96	14.01	0.6	1.46e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.41	7.33	0.37	1.69e-12	Monocyte percentage of white cells;
LIHC	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.4	7.36	0.37	1.39e-12	Platelet distribution width;
LIHC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.85	15.64	0.65	5.69e-42	Multiple myeloma (IgH translocation);
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.47	0.62	2.37e-37	Prudent dietary pattern;
LIHC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.39	-5.77	-0.3	1.81e-8	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7209395	0.700	rs17690171	chr17:64202857	C/T	cg27381822	chr6:149304457	UST	-0.32	-6.08	-0.31	3.17e-9	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LIHC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-15.77	-0.65	1.66e-42	Tonsillectomy;
LIHC	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-7.77	-0.39	8.98e-14	Putamen volume;
LIHC	cis	rs903552	1.000	rs12907048	chr15:102003873	G/T	cg25677261	chr15:102009856	PCSK6	-0.44	-6.0	-0.31	5.1e-9	Diabetic kidney disease;
LIHC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.5	-0.42	6.02e-16	Total cholesterol levels;
LIHC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg05665937	chr4:1216051	CTBP1	0.44	5.83	0.3	1.29e-8	Obesity-related traits;
LIHC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg12863693	chr15:85201151	NMB	0.44	6.09	0.31	3.03e-9	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.41	0.33	4.82e-10	Alzheimer's disease;
LIHC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.46	-7.22	-0.36	3.3e-12	Multiple sclerosis;
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.13	13.45	0.59	2.2e-33	Diabetic kidney disease;
LIHC	cis	rs3736485	0.966	rs7182977	chr15:51854130	C/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.85	-0.3	1.14e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.6	7.7	0.38	1.49e-13	Parkinson's disease;
LIHC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.63	6.86	0.35	3.27e-11	Alzheimer's disease;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.71	0.76	2.62e-66	Height;
LIHC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-5.88	-0.3	1e-8	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.2	0.36	3.84e-12	Exhaled nitric oxide output;
LIHC	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg09065629	chr16:1709722	CRAMP1L	0.34	5.88	0.3	9.66e-9	Coronary artery disease;
LIHC	trans	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg26939375	chr7:64535504	NA	-0.43	-6.94	-0.35	2.02e-11	Aortic root size;
LIHC	cis	rs2540917	0.728	rs11125841	chr2:60627565	A/G	cg00543073	chr2:60773386	BCL11A	-0.34	-6.7	-0.34	8.8e-11	Mean corpuscular volume;
LIHC	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg25174290	chr11:3078921	CARS	0.58	8.7	0.43	1.38e-16	Longevity;
LIHC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg08085267	chr17:45401833	C17orf57	-0.6	-8.77	-0.43	8.67e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs9322817	0.691	rs4591886	chr6:105249970	G/C	cg02098413	chr6:105308735	HACE1	-0.41	-7.68	-0.38	1.68e-13	Thyroid stimulating hormone;
LIHC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.78	0.43	8.18e-17	Motion sickness;
LIHC	cis	rs1982963	0.585	rs77091361	chr14:52486961	C/T	cg10843707	chr14:52510701	NID2	0.39	6.08	0.31	3.3e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs7635838	0.892	rs34830847	chr3:11437798	A/C	cg00170343	chr3:11313890	ATG7	0.45	7.02	0.35	1.23e-11	HDL cholesterol;
LIHC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.4	8.64	0.42	2.23e-16	Plateletcrit;Mean corpuscular volume;
LIHC	trans	rs2460905	0.867	rs2466273	chr8:12866004	A/C	cg05956521	chr1:157668115	FCRL3	-0.44	-6.45	-0.33	3.74e-10	Post-traumatic stress disorder;
LIHC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.07	-0.31	3.38e-9	Alzheimer's disease (late onset);
LIHC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.69	-9.08	-0.44	8.83e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-7.32	-0.37	1.75e-12	Testicular germ cell tumor;
LIHC	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.18e-41	Mortality in heart failure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08749122	chr1:150459996	TARS2	0.42	6.21	0.32	1.5e-9	Pancreatic cancer;
LIHC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.0	-0.31	4.95e-9	Blood metabolite levels;
LIHC	cis	rs10216189	1.000	rs7799665	chr7:5527501	G/A	cg05318486	chr7:5553423	FBXL18	-0.56	-8.12	-0.4	8.47e-15	Relative hand skill in reading disability;
LIHC	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	0.97	8.16	0.4	6.38e-15	Lymphocyte counts;
LIHC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.72	9.25	0.45	2.55e-18	Eosinophilic esophagitis;
LIHC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.05	-0.31	3.81e-9	Headache;
LIHC	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.82	-8.92	-0.43	2.86e-17	Vitiligo;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.9	-0.35	2.49e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.57	-9.35	-0.45	1.17e-18	Obesity-related traits;
LIHC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-8.61	-0.42	2.77e-16	Blood metabolite levels;
LIHC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.66	-0.34	1.13e-10	Schizophrenia;
LIHC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17554472	chr22:41940697	POLR3H	0.56	6.01	0.31	4.84e-9	Vitiligo;
LIHC	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.45	-7.98	-0.4	2.28e-14	Inhibitory control;
LIHC	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.62	-8.2	-0.41	5.05e-15	Colorectal cancer;
LIHC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.38	6.04	0.31	4.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg25364880	chr3:44379878	C3orf23	0.45	6.33	0.32	7.77e-10	Depressive symptoms;
LIHC	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.0	-0.35	1.37e-11	Blood pressure;
LIHC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.78	-12.1	-0.55	2.58e-28	Blood metabolite levels;
LIHC	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg03805757	chr16:71968109	PKD1L3	-0.51	-5.86	-0.3	1.07e-8	Post bronchodilator FEV1;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.42	-0.41	1.04e-15	Lymphocyte counts;
LIHC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.02	-0.35	1.23e-11	Bipolar disorder;
LIHC	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	trans	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg01134436	chr17:81009848	B3GNTL1	0.83	7.3	0.37	2.04e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs2625529	0.824	rs4131630	chr15:72355398	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.92	-0.3	7.89e-9	Red blood cell count;
LIHC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg18887096	chr2:219472410	PLCD4	-0.38	-6.7	-0.34	8.8e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg11005552	chr10:105648138	OBFC1	0.38	6.08	0.31	3.26e-9	Coronary artery disease;
LIHC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.76	-0.34	6.01e-11	Coronary artery disease;
LIHC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg05697976	chr12:29376483	FAR2	0.32	6.44	0.33	4.12e-10	QT interval;
LIHC	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.76	-8.39	-0.41	1.34e-15	Exhaled nitric oxide output;
LIHC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.86	-0.3	1.11e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	10.56	0.5	9.22e-23	Blood protein levels;
LIHC	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg03962019	chr1:41807865	NA	0.5	7.36	0.37	1.35e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.05	-0.31	3.75e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	7.32	0.37	1.81e-12	Total body bone mineral density;
LIHC	cis	rs7116495	0.541	rs579320	chr11:71794954	G/T	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.43	-6.5	-0.33	2.77e-10	Coronary artery disease;
LIHC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	5.9	0.3	8.88e-9	Tonsillectomy;
LIHC	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.44	6.77	0.34	5.56e-11	Alzheimer's disease (survival time);
LIHC	cis	rs9899728	0.572	rs9915968	chr17:73059616	G/C	cg27626185	chr17:73056755	KCTD2	-0.66	-11.83	-0.54	2.78e-27	Alzheimer's disease or small vessel stroke;
LIHC	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.82	-0.54	2.95e-27	Coffee consumption (cups per day);
LIHC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.47	7.03	0.36	1.1e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.69	12.56	0.56	5.2e-30	Iron status biomarkers;
LIHC	cis	rs757110	0.590	rs7484027	chr11:17368381	T/A	cg15432903	chr11:17409602	KCNJ11	-0.56	-8.57	-0.42	3.66e-16	Type 2 diabetes;
LIHC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-10.95	-0.51	3.91e-24	Personality dimensions;
LIHC	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.32	-5.71	-0.3	2.44e-8	Lewy body disease;
LIHC	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.57	-7.63	-0.38	2.28e-13	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg11764359	chr7:65958608	NA	-0.56	-5.87	-0.3	1.03e-8	Diabetic kidney disease;
LIHC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-12.33	-0.55	3.73e-29	Refractive error;
LIHC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.5	16.55	0.67	1.29e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg19680672	chr10:131412579	MGMT	-0.39	-5.9	-0.3	8.73e-9	Response to temozolomide;
LIHC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.59	-0.34	1.64e-10	Diastolic blood pressure;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.67	-9.84	-0.47	2.83e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.86	0.47	2.37e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg03464473	chr7:72343742	NA	-0.3	-6.06	-0.31	3.53e-9	Migraine with aura;
LIHC	cis	rs1355223	0.752	rs286893	chr11:34674882	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.47	0.33	3.44e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.55	-0.42	4.12e-16	Total body bone mineral density;
LIHC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.54	-9.1	-0.44	7.46e-18	Obesity-related traits;
LIHC	cis	rs3736485	0.966	rs12102203	chr15:51791559	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.15	-0.32	2.18e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.25	0.52	3.29e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.5	-7.26	-0.37	2.56e-12	Uric acid levels;
LIHC	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.74	11.47	0.53	5.53e-26	Metabolite levels;
LIHC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.25	-0.48	1.15e-21	Hemoglobin concentration;
LIHC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.1	-0.31	2.94e-9	Ulcerative colitis;
LIHC	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.63	-8.12	-0.4	8.65e-15	Body mass index;
LIHC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.3	0.45	1.65e-18	Melanoma;
LIHC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-9.91	-0.47	1.59e-20	Coronary artery disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19143760	chr3:148709578	GYG1	0.43	6.06	0.31	3.67e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg27523141	chr10:43048294	ZNF37B	0.37	6.4	0.33	5.12e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.39	6.37	0.33	5.98e-10	Red blood cell count;
LIHC	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9918079	0.506	rs7696127	chr4:15642953	T/A	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.23	-0.32	1.4e-9	Obesity-related traits;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg04727924	chr7:799746	HEATR2	0.41	6.36	0.33	6.53e-10	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg15691649	chr6:25882328	NA	0.51	7.34	0.37	1.58e-12	Blood metabolite levels;
LIHC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg19000871	chr14:103996768	TRMT61A	-0.55	-9.08	-0.44	9.02e-18	Coronary artery disease;
LIHC	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.78	11.45	0.53	6.52e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs16958440	1.000	rs62096474	chr18:44647504	G/A	cg17192377	chr18:44677553	HDHD2	0.6	6.74	0.34	6.88e-11	Sitting height ratio;
LIHC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.3	-0.37	2.09e-12	Platelet count;
LIHC	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg04610667	chr7:75704037	NA	0.34	6.15	0.32	2.2e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.06	0.36	9.44e-12	Glycated hemoglobin levels;
LIHC	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.51	7.72	0.39	1.27e-13	Corneal astigmatism;
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg26939375	chr7:64535504	NA	0.48	7.29	0.37	2.1e-12	Aortic root size;
LIHC	cis	rs13161895	0.938	rs594202	chr5:179417335	C/T	cg06664874	chr5:179499304	RNF130	0.57	7.02	0.35	1.21e-11	LDL cholesterol;
LIHC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.15e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.9	10.77	0.5	1.76e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs10792665	0.934	rs11233383	chr11:82659498	T/C	cg24227371	chr11:82718527	RAB30	-0.29	-6.81	-0.35	4.53e-11	Obesity-related traits;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.69	11.62	0.53	1.57e-26	Prudent dietary pattern;
LIHC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.38	5.77	0.3	1.78e-8	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.85	0.3	1.18e-8	Height;
LIHC	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.65	-0.34	1.14e-10	Neuroticism;
LIHC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg09137382	chr11:130731461	NA	0.41	6.16	0.32	2.07e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2834188	1.000	rs2843994	chr21:34706870	G/A	cg04842828	chr21:34696676	IFNAR1	0.48	6.26	0.32	1.14e-9	Narcolepsy;
LIHC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.53	8.03	0.4	1.63e-14	Systemic sclerosis;
LIHC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.56	11.06	0.51	1.65e-24	Schizophrenia;
LIHC	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.4	7.37	0.37	1.32e-12	Height;
LIHC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg15105060	chr4:7024189	TBC1D14	-0.85	-6.71	-0.34	7.95e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.03e-19	Hemoglobin concentration;
LIHC	cis	rs72843506	1.000	rs7223910	chr17:19982768	G/A	cg13482628	chr17:19912719	NA	0.48	6.29	0.32	9.74e-10	Schizophrenia;
LIHC	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.55	-10.31	-0.49	7.25e-22	Sense of smell;
LIHC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.69	11.97	0.54	8.45e-28	Menopause (age at onset);
LIHC	trans	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22867288	chr6:57086716	RAB23	0.49	6.84	0.35	3.62e-11	Lung function (FEV1/FVC);
LIHC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.52	7.25	0.36	2.84e-12	Height;
LIHC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.91	-0.39	3.48e-14	Monocyte percentage of white cells;
LIHC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.49	7.59	0.38	3.11e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.75	-0.43	1.02e-16	Total cholesterol levels;
LIHC	trans	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-8.99	-0.44	1.73e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg23262073	chr20:60523788	NA	-0.28	-5.76	-0.3	1.89e-8	Body mass index;
LIHC	cis	rs1866706	0.896	rs1866711	chr11:12875301	C/T	cg25843174	chr11:12811716	TEAD1	-0.29	-6.08	-0.31	3.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs6960043	0.560	rs7811965	chr7:15041076	A/T	cg19272540	chr7:15055459	NA	0.24	6.56	0.33	2.02e-10	Type 2 diabetes;
LIHC	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg19539972	chr4:7069911	GRPEL1	-0.7	-7.62	-0.38	2.54e-13	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01744729	chr13:113474194	ATP11A	0.42	6.05	0.31	3.79e-9	Longevity;
LIHC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.73	-11.08	-0.51	1.42e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7165170	0.549	rs10775250	chr15:91099156	T/C	cg26821196	chr15:91095069	CRTC3	0.39	7.09	0.36	7.92e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13559217	chr19:5119331	KDM4B	-0.4	-6.21	-0.32	1.55e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.81	0.39	7.29e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.9	-0.3	8.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg00387323	chr7:6746715	ZNF12	0.64	7.01	0.35	1.28e-11	Hematocrit;Hemoglobin concentration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08655493	chr21:33765248	URB1;C21orf119	0.4	6.25	0.32	1.2e-9	Cognitive function;
LIHC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg16970926	chr12:29381810	FAR2	0.28	5.91	0.3	8.13e-9	QT interval;
LIHC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.64	11.5	0.53	4.37e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg16586182	chr3:47516702	SCAP	0.58	10.71	0.5	2.8e-23	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15188491	chr1:146644106	PRKAB2	0.39	6.06	0.31	3.65e-9	Cognitive function;
LIHC	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg25237894	chr2:233734115	C2orf82	-0.38	-7.34	-0.37	1.57e-12	Coronary artery disease;
LIHC	cis	rs6466055	0.720	rs13239067	chr7:105011629	T/A	cg04380332	chr7:105027541	SRPK2	-0.37	-6.9	-0.35	2.52e-11	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.79	0.5	1.49e-23	Platelet count;
LIHC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.63	-7.33	-0.37	1.65e-12	Schizophrenia;
LIHC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.91	-0.3	8.45e-9	Fibrinogen levels;
LIHC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.94	-0.31	6.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg27426351	chr10:43362370	NA	0.47	5.75	0.3	1.95e-8	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.61	9.09	0.44	8.13e-18	Renal cell carcinoma;
LIHC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg13395646	chr4:1353034	KIAA1530	-0.65	-8.95	-0.44	2.34e-17	Obesity-related traits;
LIHC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.68	-11.75	-0.54	5.28e-27	Crohn's disease;
LIHC	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.59	-9.01	-0.44	1.47e-17	Neuroblastoma (high-risk);
LIHC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.13	0.4	7.9e-15	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.52	-7.6	-0.38	2.93e-13	Mortality in heart failure;
LIHC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-8.48	-0.42	6.81e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	1.11	9.33	0.45	1.38e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-9.0	-0.44	1.62e-17	Cognitive function;
LIHC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.43	7.51	0.38	5.15e-13	Educational attainment;
LIHC	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	19.23	0.72	2.29e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg20636351	chr8:55087400	NA	-0.4	-8.06	-0.4	1.31e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg09417038	chr21:47716443	C21orf57	-0.46	-6.88	-0.35	2.9100000000000002e-11	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.36	8.32	0.41	2.16e-15	Crohn's disease;
LIHC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.3	0.41	2.45e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	9.69	0.46	9.01e-20	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.75	-0.34	6.48e-11	Fear of minor pain;
LIHC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-10.11	-0.48	3.36e-21	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.46	-7.02	-0.35	1.22e-11	Diastolic blood pressure;
LIHC	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.67	-12.99	-0.57	1.28e-31	Multiple myeloma;
LIHC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg10360323	chr17:41437877	NA	0.41	6.06	0.31	3.58e-9	Menopause (age at onset);
LIHC	trans	rs9940464	0.901	rs12597147	chr16:83367049	G/A	cg13016115	chr14:23388406	RBM23	0.39	6.26	0.32	1.18e-9	Malaria;
LIHC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.5	-10.22	-0.48	1.47e-21	Birth weight;
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg06497051	chr1:156261200	TMEM79	-0.36	-5.73	-0.3	2.21e-8	Tonsillectomy;
LIHC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.74	-0.3	2.07e-8	Schizophrenia;
LIHC	cis	rs600806	1.000	rs600806	chr1:109840629	A/G	cg08911820	chr1:110026001	ATXN7L2	0.5	6.01	0.31	4.66e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg12560992	chr17:57184187	TRIM37	0.69	8.91	0.43	3.17e-17	Vitamin D levels;
LIHC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.88	-0.3	9.64e-9	Subjective well-being;
LIHC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.76	11.62	0.53	1.52e-26	Corneal astigmatism;
LIHC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg23533926	chr12:111358616	MYL2	-0.35	-6.51	-0.33	2.63e-10	Breast cancer;
LIHC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.3	5.96	0.31	6.4e-9	Body mass index;
LIHC	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.42	8.83	0.43	5.6e-17	Optic cup area;
LIHC	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.5	9.29	0.45	1.84e-18	Testicular germ cell tumor;
LIHC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.16	21.94	0.76	3.11e-67	Triglycerides;
LIHC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg15691649	chr6:25882328	NA	-0.54	-7.08	-0.36	8.5e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.88	0.3	9.82e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.49	-8.48	-0.42	6.86e-16	Total body bone mineral density;
LIHC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.74	12.14	0.55	1.93e-28	Anterior chamber depth;
LIHC	cis	rs611744	0.967	rs584555	chr8:109218612	C/G	cg21045802	chr8:109455806	TTC35	0.52	8.87	0.43	4.22e-17	Dupuytren's disease;
LIHC	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.52	8.83	0.43	5.45e-17	Schizophrenia;
LIHC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.1	-0.7	7.56e-52	Tonsillectomy;
LIHC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.68	-0.5	3.57e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.36	7.95	0.39	2.74e-14	Blood metabolite ratios;
LIHC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg22079354	chr11:130786696	SNX19	-0.46	-6.33	-0.32	7.77e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11630290	0.649	rs1036910	chr15:64157015	T/C	cg12036633	chr15:63758958	NA	0.62	6.6	0.34	1.59e-10	Iris characteristics;
LIHC	cis	rs2412488	0.893	rs35978987	chr4:54358819	A/G	cg22241045	chr4:54363911	LNX1	0.46	7.66	0.38	1.93e-13	DNA methylation (variation);
LIHC	cis	rs17854409	0.764	rs8114722	chr20:61478492	G/A	cg06598544	chr20:61472147	COL9A3	-0.84	-7.24	-0.36	3.07e-12	Obesity-related traits;
LIHC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.34	0.41	1.84e-15	Birth weight;
LIHC	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-6.01	-0.31	4.78e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04498913	chr7:1135747	C7orf50	0.44	7.04	0.36	1.03e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02475777	chr4:1388615	CRIPAK	0.55	8.1	0.4	9.84e-15	Longevity;
LIHC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.38	-5.74	-0.3	2.06e-8	Iron status biomarkers;
LIHC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg14580859	chr9:123691850	NA	0.38	6.58	0.34	1.79e-10	Rheumatoid arthritis;
LIHC	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.69	7.79	0.39	7.91e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.68	10.84	0.51	1.01e-23	Type 2 diabetes;
LIHC	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg06697600	chr4:7070879	GRPEL1	0.74	8.91	0.43	3.01e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.41	-6.52	-0.33	2.49e-10	Mortality in heart failure;
LIHC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.59	8.54	0.42	4.33e-16	Platelet count;
LIHC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18252515	chr7:66147081	NA	0.42	6.03	0.31	4.37e-9	Aortic root size;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00166836	chr6:149721425	MAP3K7IP2;SUMO4	0.41	6.05	0.31	3.78e-9	Longevity;
LIHC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	0.97	13.01	0.58	1.05e-31	Cognitive function;
LIHC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.62	8.38	0.41	1.39e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.72	7.46	0.37	7.03e-13	Vitiligo;
LIHC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.05	17.2	0.68	3.19e-48	Testicular germ cell tumor;
LIHC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.59	-11.12	-0.52	9.71e-25	Body mass index;
LIHC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.65	8.77	0.43	8.35e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.89	0.47	1.86e-20	Menopause (age at onset);
LIHC	cis	rs4728302	0.869	rs10224575	chr7:133590875	G/A	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.77	-0.3	1.8e-8	Crohn's disease;
LIHC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-0.91	-13.45	-0.59	2.22e-33	Post bronchodilator FEV1;
LIHC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.39	6.23	0.32	1.34e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	7.31	0.37	1.95e-12	Lung cancer in ever smokers;
LIHC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23485639	chr6:28045615	ZNF165	0.45	6.03	0.31	4.28e-9	Depression;
LIHC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.92	16.59	0.67	9.39e-46	Colorectal cancer;
LIHC	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.1	-0.31	2.9e-9	Intraocular pressure;
LIHC	cis	rs7503168	0.908	rs9907772	chr17:34000628	G/A	cg05299278	chr17:33885742	SLFN14	-0.25	-5.77	-0.3	1.82e-8	Plateletcrit;
LIHC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.45	-6.93	-0.35	2.08e-11	Myopia (pathological);
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg14709524	chr16:89940631	TCF25	0.51	6.82	0.35	4.18e-11	Skin colour saturation;
LIHC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.26	-16.8	-0.67	1.31e-46	Diabetic kidney disease;
LIHC	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.49	7.79	0.39	8e-14	HDL cholesterol;
LIHC	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg26536354	chr8:144654954	C8orf73	0.56	6.23	0.32	1.35e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs16958440	0.867	rs16948928	chr18:44675821	C/T	cg17192377	chr18:44677553	HDHD2	0.56	6.46	0.33	3.6e-10	Sitting height ratio;
LIHC	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg02811702	chr13:24901961	NA	0.25	6.33	0.32	7.79e-10	Obesity-related traits;
LIHC	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.09	-0.31	2.97e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.09	-0.75	7.8e-64	Height;
LIHC	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.42	6.32	0.32	8.13e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.68	-9.88	-0.47	1.99e-20	Initial pursuit acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg19497325	chr3:43121668	C3orf39	0.42	6.09	0.31	3e-9	Longevity;
LIHC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg11764359	chr7:65958608	NA	-0.58	-6.04	-0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.97	-16.23	-0.66	2.63e-44	Breast cancer;
LIHC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.39	-6.49	-0.33	3.08e-10	Blood metabolite levels;
LIHC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.7	0.73	2.92e-58	Smoking behavior;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27654529	chr19:35418345	ZNF30	0.41	6.91	0.35	2.37e-11	Cognitive function;
LIHC	cis	rs77637988	0.604	rs6722246	chr2:48597045	T/G	cg15846641	chr2:48541264	FOXN2	0.58	7.77	0.39	9.18e-14	Joint mobility (Beighton score);
LIHC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg00204512	chr16:28754710	NA	0.36	6.43	0.33	4.28e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.87	13.18	0.58	2.4e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.47	-7.7	-0.38	1.43e-13	Testicular germ cell tumor;
LIHC	trans	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg25214090	chr10:38739885	LOC399744	0.44	7.38	0.37	1.18e-12	Diastolic blood pressure;
LIHC	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.3	6.29	0.32	9.6e-10	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.6	9.77	0.47	4.71e-20	Breast cancer;
LIHC	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-9.24	-0.45	2.7e-18	Morning vs. evening chronotype;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg20349687	chr2:88927127	EIF2AK3	-0.4	-6.3	-0.32	9.23e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.94	20.44	0.74	3.16e-61	Blood protein levels;
LIHC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg18912006	chr12:123335444	HIP1R	-0.6	-7.29	-0.37	2.18e-12	Schizophrenia;
LIHC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.19	-0.63	3.57e-40	Coronary artery disease;
LIHC	cis	rs611744	0.934	rs682954	chr8:109210559	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04169830	chr2:88471460	THNSL2	0.42	5.71	0.3	2.4e-8	Response to metformin (IC50);
LIHC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg14067834	chr17:29058358	SUZ12P	0.62	6.38	0.33	5.64e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.7	6.89	0.35	2.65e-11	Vitiligo;
LIHC	cis	rs61542988	0.532	rs12673996	chr7:22833400	C/T	cg11367502	chr7:22862612	TOMM7	0.54	8.68	0.42	1.67e-16	Fibrinogen levels;
LIHC	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.72	-0.47	7.19e-20	Ulcerative colitis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13272430	chr14:67708475	MPP5	-0.49	-7.34	-0.37	1.58e-12	Cognitive function;
LIHC	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.49	0.38	6.02e-13	Electroencephalogram traits;
LIHC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.33	6.5	0.33	2.83e-10	Renal cell carcinoma;
LIHC	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg12698662	chr3:15914712	MIR563	-0.38	-7.09	-0.36	7.59e-12	Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs72653721	0.689	rs17697071	chr6:11052580	C/T	cg13562911	chr6:11044106	ELOVL2	0.52	7.41	0.37	1.03e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs6504950	0.720	rs9895901	chr17:52984885	A/G	cg10237252	chr17:52977213	TOM1L1	-0.38	-6.64	-0.34	1.23e-10	Breast cancer;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.0	-0.4	1.89e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.5	9.49	0.46	4.13e-19	Testicular germ cell tumor;
LIHC	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg01652190	chr22:50026171	C22orf34	-0.34	-7.61	-0.38	2.65e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.29	6.5	0.33	2.81e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	0.74	8.02	0.4	1.71e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg08469215	chr1:156261351	TMEM79	0.4	6.62	0.34	1.39e-10	Tonsillectomy;
LIHC	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.3	-0.49	7.3e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.66	-6.42	-0.33	4.57e-10	Urate levels in lean individuals;
LIHC	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg06102954	chr21:42741788	MX2	0.36	6.27	0.32	1.07e-9	Melanoma;
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.62	0.34	1.38e-10	Obesity-related traits;
LIHC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg09238746	chr17:78121135	EIF4A3	-0.51	-7.23	-0.36	3.22e-12	Yeast infection;
LIHC	cis	rs2997447	0.761	rs61776620	chr1:26457980	T/C	cg19633962	chr1:26362018	EXTL1	-0.67	-6.07	-0.31	3.37e-9	QRS complex (12-leadsum);
LIHC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.23	-7.26	-0.37	2.67e-12	Mean corpuscular volume;
LIHC	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg16724585	chr3:197361211	NA	-0.47	-6.62	-0.34	1.4e-10	Pancreatic cancer;
LIHC	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.98	18.66	0.71	4.27e-54	Platelet distribution width;
LIHC	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-9.11	-0.44	7.25e-18	Brugada syndrome;
LIHC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.33	-8.46	-0.42	7.86e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-9.89	-0.47	1.92e-20	Parkinson's disease;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.89	-0.3	9.32e-9	Menopause (age at onset);
LIHC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.36	6.04	0.31	3.98e-9	Urate levels in obese individuals;
LIHC	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg05197062	chr11:11642011	GALNTL4	0.45	6.7	0.34	8.85e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.48	6.07	0.31	3.46e-9	Mean platelet volume;
LIHC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.82	-9.5	-0.46	3.69e-19	Schizophrenia;
LIHC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.47e-9	Aortic root size;
LIHC	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs4407350	0.748	rs131170	chr22:44901601	C/A	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.54	-0.33	2.27e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.89	-0.3	9.26e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs17854409	0.764	rs3761301	chr20:61494021	C/T	cg05147244	chr20:61493195	TCFL5	1.28	10.3	0.49	7.83e-22	Obesity-related traits;
LIHC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.57	-7.34	-0.37	1.56e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.67	-11.18	-0.52	6.09e-25	Pediatric autoimmune diseases;
LIHC	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.74	-11.16	-0.52	6.95e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg09417038	chr21:47716443	C21orf57	-0.49	-7.14	-0.36	5.51e-12	Testicular germ cell tumor;
LIHC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07305463	chr2:136567211	LCT	0.39	7.22	0.36	3.4e-12	Mosquito bite size;
LIHC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.81e-9	Blood metabolite levels;
LIHC	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg02344993	chr17:57696989	CLTC	0.7	11.66	0.53	1.16e-26	Hemoglobin concentration;
LIHC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.47	-0.56	1.16e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg06951627	chr6:26196580	NA	0.55	6.39	0.33	5.5e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.31	-0.37	1.84e-12	Response to antipsychotic treatment;
LIHC	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.2	-0.48	1.71e-21	Ulcerative colitis;
LIHC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg11062466	chr8:58055876	NA	0.42	6.12	0.31	2.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.33	-0.52	1.78e-25	Response to antipsychotic treatment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06162493	chr17:34900563	GGNBP2	0.48	6.41	0.33	4.96e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg25039879	chr17:56429692	SUPT4H1	0.42	5.81	0.3	1.44e-8	Cognitive test performance;
LIHC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.85	-0.65	8.31e-43	Chronic sinus infection;
LIHC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.25	-0.52	3.46e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs74544699	1.000	rs4082827	chr4:74831180	A/C	cg02530824	chr4:74847766	PF4	-0.66	-7.51	-0.38	5.17e-13	Growth-regulated protein alpha levels;
LIHC	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	0.85	7.27	0.37	2.44e-12	Uric acid levels;
LIHC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.69	10.43	0.49	2.75e-22	Height;Educational attainment;Head circumference (infant);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02381965	chr2:3418480	TTC15	0.53	6.6	0.34	1.57e-10	Lung function (FEV1);
LIHC	cis	rs7635838	0.827	rs4273358	chr3:11415160	T/G	cg00170343	chr3:11313890	ATG7	0.44	7.03	0.36	1.1e-11	HDL cholesterol;
LIHC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.33	0.41	1.98e-15	Body mass index;
LIHC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10556349	chr10:835070	NA	0.67	5.85	0.3	1.13e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	7.73	0.39	1.19e-13	Lymphocyte counts;
LIHC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.61	-7.77	-0.39	9.01e-14	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg15691649	chr6:25882328	NA	-0.62	-7.83	-0.39	5.98e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg25894440	chr7:65020034	NA	0.4	6.27	0.32	1.12e-9	Calcium levels;
LIHC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	5.73	0.3	2.15e-8	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09311052	chr1:154531418	UBE2Q1	0.41	7.09	0.36	7.5e-12	Cognitive function;
LIHC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg00990874	chr7:1149470	C7orf50	-0.66	-9.19	-0.45	3.86e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	10.03	0.48	6.31e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.9	8.69	0.43	1.54e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.53	7.79	0.39	8.06e-14	Type 2 diabetes;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg15641998	chr4:88312323	HSD17B11	-0.28	-6.17	-0.32	1.88e-9	Oropharynx cancer;
LIHC	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	12.08	0.55	3.14e-28	Post bronchodilator FEV1;
LIHC	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	1.01	20.35	0.74	6.81e-61	Height;
LIHC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.2	-18.07	-0.7	1e-51	Ulcerative colitis;
LIHC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.42	-6.31	-0.32	8.58e-10	Calcium levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22596738	chr1:236688128	LGALS8	0.51	7.71	0.38	1.41e-13	Cognitive function;
LIHC	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	0.4	7.71	0.38	1.38e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.19e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg24579218	chr15:68104479	NA	-0.34	-5.94	-0.31	7.12e-9	Restless legs syndrome;
LIHC	cis	rs918629	0.530	rs3777192	chr5:95246867	G/A	cg10483112	chr5:95245456	ELL2	-0.37	-6.89	-0.35	2.77e-11	IgG glycosylation;
LIHC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.54	7.15	0.36	5.15e-12	Body mass index;
LIHC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.24	0.36	3.06e-12	IgG glycosylation;
LIHC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg24296786	chr1:45957014	TESK2	0.4	5.75	0.3	1.99e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.36	9.36	0.45	1.09e-18	Schizophrenia;
LIHC	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg00601450	chr5:74908170	NA	-0.57	-6.96	-0.35	1.72e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.41	6.11	0.31	2.68e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.75	-0.71	1.96e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.38	6.16	0.32	2e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8067354	0.958	rs2333563	chr17:57839568	A/G	cg13753209	chr17:57696993	CLTC	0.58	8.76	0.43	9.51e-17	Hemoglobin concentration;
LIHC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.73	11.07	0.51	1.5e-24	Corneal astigmatism;
LIHC	cis	rs2281558	0.793	rs6115227	chr20:25591377	A/C	cg13962466	chr20:25176127	ENTPD6	-0.41	-5.84	-0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LIHC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.67	-10.11	-0.48	3.36e-21	Parkinson's disease;
LIHC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.45	6.17	0.32	1.89e-9	Height;
LIHC	cis	rs17711722	0.690	rs116823227	chr7:65331001	A/G	cg11764359	chr7:65958608	NA	0.7	8.57	0.42	3.59e-16	Calcium levels;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg09033563	chr22:24373618	LOC391322	-0.48	-6.79	-0.34	4.93e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17554472	chr22:41940697	POLR3H	-0.56	-6.11	-0.31	2.77e-9	Vitiligo;
LIHC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-13.51	-0.59	1.28e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2279817	0.863	rs871088	chr1:18017558	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.68	8.05	0.4	1.36e-14	Neuroticism;
LIHC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg07061783	chr6:25882402	NA	-0.48	-6.73	-0.34	7.1e-11	Blood metabolite levels;
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-7.57	-0.38	3.5e-13	Lymphocyte counts;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.63	0.46	1.44e-19	Height;
LIHC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22509189	chr2:225307070	NA	-0.5	-7.46	-0.37	7.2e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.25	-6.85	-0.35	3.53e-11	Type 2 diabetes;
LIHC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg11212589	chr17:38028394	ZPBP2	0.38	7.98	0.4	2.22e-14	Self-reported allergy;
LIHC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	1.03	20.53	0.74	1.35e-61	Breast cancer;
LIHC	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg25182066	chr10:30743637	MAP3K8	-0.43	-6.93	-0.35	2.06e-11	Inflammatory bowel disease;
LIHC	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.46	6.96	0.35	1.71e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg06533319	chr4:3265114	C4orf44	0.31	5.76	0.3	1.9e-8	Mean platelet volume;
LIHC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-5.92	-0.3	7.72e-9	Cognitive function;
LIHC	cis	rs28735056	0.584	rs11664834	chr18:77644876	G/T	cg20368463	chr18:77673604	PQLC1	0.57	8.08	0.4	1.14e-14	Schizophrenia;
LIHC	cis	rs10847980	0.590	rs2292131	chr12:123332354	C/T	cg18912006	chr12:123335444	HIP1R	0.76	7.79	0.39	8.13e-14	Adiponectin levels;
LIHC	cis	rs611744	0.837	rs399131	chr8:109105285	C/T	cg21045802	chr8:109455806	TTC35	-0.46	-7.9	-0.39	3.76e-14	Dupuytren's disease;
LIHC	cis	rs4919087	0.561	rs61861844	chr10:99064171	G/A	cg25902810	chr10:99078978	FRAT1	-0.63	-7.39	-0.37	1.13e-12	Monocyte count;
LIHC	trans	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg26939375	chr7:64535504	NA	0.4	6.29	0.32	9.67e-10	Aortic root size;
LIHC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.56	7.53	0.38	4.43e-13	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.34	8.06	0.4	1.33e-14	Immature fraction of reticulocytes;
LIHC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg18944383	chr4:111397179	ENPEP	0.31	6.86	0.35	3.24e-11	Coronary artery disease;
LIHC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.48e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9649465	1.000	rs9641715	chr7:123348623	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-8.0	-0.4	1.96e-14	Migraine;
LIHC	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.43	8.22	0.41	4.21e-15	Testicular germ cell tumor;
LIHC	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.49	8.88	0.43	3.95e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs11673344	0.734	rs496872	chr19:37439481	C/T	cg27390819	chr19:37464633	NA	-0.52	-6.22	-0.32	1.42e-9	Obesity-related traits;
LIHC	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.45	6.7	0.34	8.84e-11	Dermatomyositis;
LIHC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.14	-0.32	2.27e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.79	12.29	0.55	5.29e-29	Longevity;
LIHC	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.75	-11.32	-0.52	1.84e-25	Subjective well-being;
LIHC	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.45	7.48	0.37	6.21e-13	Corneal astigmatism;
LIHC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	8.02	0.4	1.73e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.06	0.36	9.55e-12	Height;
LIHC	cis	rs1868673	0.503	rs4129188	chr3:150241673	C/T	cg10752315	chr3:150238463	NA	0.3	5.92	0.3	7.73e-9	Waist circumference;
LIHC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-8.86	-0.43	4.49e-17	Personality dimensions;
LIHC	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.8	-10.87	-0.51	8.03e-24	Blood pressure (smoking interaction);
LIHC	trans	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.49	-0.33	3.03e-10	Aortic root size;
LIHC	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.4	0.33	5.2e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.55	7.62	0.38	2.53e-13	Pancreatic cancer;
LIHC	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.74	-0.39	1.13e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9513627	1.000	rs7334844	chr13:100121047	G/C	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.54	0.5	1.15e-22	Hypertriglyceridemia;
LIHC	trans	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.04	0.31	4.11e-9	Coronary artery calcification;
LIHC	cis	rs9649465	1.000	rs1006764	chr7:123337873	C/T	cg03229431	chr7:123269106	ASB15	-0.37	-7.99	-0.4	2.04e-14	Migraine;
LIHC	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.37	-6.01	-0.31	4.67e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.7	0.69	3.05e-50	Gut microbiome composition (summer);
LIHC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.53	8.6	0.42	2.93e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.87	13.06	0.58	6.74e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2834188	1.000	rs2834188	chr21:34689253	A/G	cg14352951	chr21:34696688	IFNAR1	0.47	6.53	0.33	2.35e-10	Narcolepsy;
LIHC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.75	12.65	0.56	2.3e-30	Mean platelet volume;
LIHC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.81	0.3	1.39e-8	Menopause (age at onset);
LIHC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.5	-6.52	-0.33	2.56e-10	Initial pursuit acceleration;
LIHC	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.34	-5.78	-0.3	1.72e-8	Red blood cell traits;
LIHC	cis	rs72653721	0.617	rs57940154	chr6:11035425	C/T	cg13562911	chr6:11044106	ELOVL2	0.39	5.79	0.3	1.56e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.74	11.29	0.52	2.39e-25	Body mass index;
LIHC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-9.35	-0.45	1.21e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs629922	0.671	rs1184748	chr11:114037061	A/G	cg01914181	chr11:114070210	ZBTB16	0.41	5.92	0.3	7.93e-9	Paneth cell defects in Crohn's disease;
LIHC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.87	13.17	0.58	2.48e-32	Cognitive ability;
LIHC	cis	rs911119	0.908	rs8114619	chr20:23601813	G/T	cg16589663	chr20:23618590	CST3	0.73	7.67	0.38	1.75e-13	Chronic kidney disease;
LIHC	cis	rs595982	0.661	rs606400	chr19:49371498	T/C	cg21252483	chr19:49399788	TULP2	-0.45	-7.54	-0.38	4.28e-13	Red cell distribution width;
LIHC	cis	rs11673344	0.704	rs484001	chr19:37422222	C/T	cg27390819	chr19:37464633	NA	-0.5	-6.09	-0.31	3.05e-9	Obesity-related traits;
LIHC	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.43	7.33	0.37	1.7e-12	Lung cancer;
LIHC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.86	9.82	0.47	3.36e-20	Primary sclerosing cholangitis;
LIHC	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-9.78	-0.47	4.54e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1863824	0.625	rs11202024	chr10:88168024	C/A	cg07322936	chr10:88137208	NA	-0.47	-5.99	-0.31	5.43e-9	Schizophrenia;
LIHC	cis	rs9918079	0.542	rs6414765	chr4:15626493	G/A	cg04067612	chr4:15429572	C1QTNF7	-0.27	-5.75	-0.3	2.03e-8	Obesity-related traits;
LIHC	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.79	8.97	0.44	1.94e-17	Exhaled nitric oxide levels;
LIHC	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.52	8.4	0.41	1.23e-15	Obesity-related traits;
LIHC	cis	rs858239	0.863	rs274058	chr7:23391509	C/G	cg00469287	chr7:23338798	C7orf30	0.48	6.48	0.33	3.25e-10	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.49	-6.71	-0.34	8.13e-11	Life satisfaction;
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.37	-5.72	-0.3	2.34e-8	Obesity-related traits;
LIHC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg14067834	chr17:29058358	SUZ12P	0.62	6.25	0.32	1.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.96	-0.31	6.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.57	-8.38	-0.41	1.43e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-8.26	-0.41	3.21e-15	Schizophrenia;
LIHC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.77	-0.5	1.68e-23	Platelet count;
LIHC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04374321	chr14:90722782	PSMC1	0.71	13.52	0.59	1.11e-33	Mortality in heart failure;
LIHC	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.82	-0.3	1.39e-8	Red blood cell count;
LIHC	trans	rs4720750	0.502	rs4140803	chr7:7710369	A/C	cg27619457	chr5:1298761	NA	0.42	6.54	0.33	2.24e-10	Neuroticism;
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.25	-0.37	2.77e-12	Coronary artery disease;
LIHC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.06	18.38	0.7	5.89e-53	Triglycerides;
LIHC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	cis	rs12594515	0.694	rs2068295	chr15:45985546	T/C	cg01629716	chr15:45996671	NA	0.51	9.24	0.45	2.66e-18	Waist circumference;Weight;
LIHC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg11764359	chr7:65958608	NA	0.57	5.85	0.3	1.13e-8	Diabetic kidney disease;
LIHC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.35	5.86	0.3	1.08e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.68	6.93	0.35	2.11e-11	Alzheimer's disease;
LIHC	cis	rs3770081	1.000	rs2278086	chr2:86281905	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.95	-11.58	-0.53	2.24e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.42	-8.48	-0.42	7.01e-16	Obesity-related traits;
LIHC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	0.79	11.81	0.54	3.14e-27	Monocyte percentage of white cells;
LIHC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.07	-0.31	3.4e-9	Colorectal cancer;
LIHC	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg01364799	chr7:75623366	TMEM120A	0.48	7.22	0.36	3.33e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg07451762	chr16:28383216	NA	0.32	6.12	0.31	2.56e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.08	-15.36	-0.64	7.54e-41	Chronic sinus infection;
LIHC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.44	6.74	0.34	6.88e-11	Survival in rectal cancer;
LIHC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	13.98	0.6	1.85e-35	Multiple sclerosis;
LIHC	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg27386326	chr11:61587980	NA	0.69	14.12	0.61	5.62e-36	Trans fatty acid levels;
LIHC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg25344623	chr2:136566232	LCT	-0.37	-5.92	-0.3	7.94e-9	Corneal structure;
LIHC	cis	rs2304069	0.826	rs184960	chr5:149343370	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.69	-9.01	-0.44	1.51e-17	HIV-1 control;
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.95	0.57	1.78e-31	Prudent dietary pattern;
LIHC	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.91	-13.05	-0.58	7.02e-32	Post bronchodilator FEV1;
LIHC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg16558253	chr16:72132732	DHX38	-0.5	-8.16	-0.4	6.65e-15	Fibrinogen levels;
LIHC	cis	rs288342	0.832	rs288299	chr2:183657289	C/T	cg02625481	chr2:183667124	NA	-0.29	-5.99	-0.31	5.43e-9	Recurrent major depressive disorder;
LIHC	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.63	-10.77	-0.5	1.69e-23	Menopause (age at onset);
LIHC	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02985541	chr2:219472218	PLCD4	0.44	8.12	0.4	8.52e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.55	5.83	0.3	1.3e-8	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs12220238	0.822	rs7919517	chr10:76111355	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs3820500	0.543	rs1290543	chr1:118036420	A/G	cg20383390	chr1:117909022	MAN1A2	-0.46	-6.03	-0.31	4.33e-9	Pneumonia;
LIHC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.34	-5.87	-0.3	1.06e-8	Schizophrenia;
LIHC	cis	rs61712019	0.599	rs17595137	chr2:77728001	G/C	cg11252801	chr2:77748917	LRRTM4	0.45	6.31	0.32	8.65e-10	Schizophrenia;
LIHC	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Intracranial aneurysm;
LIHC	cis	rs9993613	1.000	rs753944	chr4:73449917	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.38	-6.06	-0.31	3.58e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg27432699	chr2:27873401	GPN1	-0.54	-7.84	-0.39	5.98e-14	Total body bone mineral density;
LIHC	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg20503657	chr10:835505	NA	1.0	10.97	0.51	3.33e-24	Eosinophil percentage of granulocytes;
LIHC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg03959625	chr15:84868606	LOC388152	0.44	6.08	0.31	3.13e-9	Schizophrenia;
LIHC	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.93	0.31	7.21e-9	Educational attainment;
LIHC	cis	rs3015497	0.616	rs34061700	chr14:51084860	G/A	cg09863266	chr14:51125203	SAV1	-0.39	-6.18	-0.32	1.8e-9	Mean platelet volume;
LIHC	cis	rs8084351	0.512	rs11664776	chr18:50797415	T/C	cg24270629	chr18:50823537	DCC	-0.52	-7.96	-0.4	2.63e-14	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.67	-9.23	-0.45	2.84e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01357671	chr17:3626806	ITGAE;GSG2	0.43	6.27	0.32	1.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.76	11.71	0.54	7.22e-27	Corneal astigmatism;
LIHC	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg04865290	chr3:52927548	TMEM110	-0.59	-6.69	-0.34	9.1e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg19318889	chr4:1322082	MAEA	0.43	5.95	0.31	6.65e-9	Obesity-related traits;
LIHC	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.23	-0.48	1.35e-21	Blood metabolite levels;
LIHC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.79	-11.69	-0.53	8.82e-27	Height;
LIHC	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.44	-6.82	-0.35	4.07e-11	Blood metabolite levels;
LIHC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.59	8.71	0.43	1.36e-16	Obesity-related traits;
LIHC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.83	-0.43	5.66e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.68	-0.53	9.81e-27	Chronic sinus infection;
LIHC	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	1.17	10.73	0.5	2.37e-23	Type 2 diabetes;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.32	-0.32	8.17e-10	Diastolic blood pressure;
LIHC	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg14092571	chr14:90743983	NA	0.45	6.36	0.33	6.62e-10	Mortality in heart failure;
LIHC	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.5	-7.14	-0.36	5.69e-12	Height;
LIHC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.85	-12.99	-0.57	1.27e-31	Obesity-related traits;
LIHC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.53	7.89	0.39	4.22e-14	Cognitive function;
LIHC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.5	-6.52	-0.33	2.56e-10	Initial pursuit acceleration;
LIHC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.67	10.26	0.49	1.05e-21	Corneal astigmatism;
LIHC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.41	-6.61	-0.34	1.45e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg04240660	chr16:89714849	CHMP1A	-0.51	-8.54	-0.42	4.5e-16	Hemoglobin concentration;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.08	0.58	5.59e-32	Prudent dietary pattern;
LIHC	cis	rs9392556	0.600	rs2326408	chr6:4119516	A/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.24	5.77	0.3	1.82e-8	Blood metabolite levels;
LIHC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.59	-0.34	1.67e-10	Gut microbiome composition (summer);
LIHC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15044384	chr19:18118666	ARRDC2	-0.52	-6.21	-0.32	1.54e-9	Systolic blood pressure;
LIHC	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.77	0.39	9.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7116495	1.000	rs7930721	chr11:71737481	C/A	cg26138937	chr11:71823887	C11orf51	-0.81	-8.04	-0.4	1.43e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs7520050	0.872	rs1707308	chr1:46604315	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.45	6.74	0.34	6.94e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	7.99	0.4	2.07e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.88	-0.47	2.04e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.74	-11.65	-0.53	1.25e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.63	-8.86	-0.43	4.45e-17	Blood metabolite levels;
LIHC	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg03959625	chr15:84868606	LOC388152	0.45	6.28	0.32	1.06e-9	Schizophrenia;
LIHC	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.44	8.49	0.42	6.61e-16	Testicular germ cell tumor;
LIHC	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.15e-10	Putamen volume;
LIHC	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.36	-5.8	-0.3	1.5e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.46	6.22	0.32	1.43e-9	Major depressive disorder;
LIHC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.56	10.84	0.51	1.02e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.57	7.67	0.38	1.76e-13	Blood metabolite levels;
LIHC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg09990169	chr2:241835740	C2orf54	-0.66	-9.36	-0.45	1.06e-18	Urinary metabolites;
LIHC	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.26	6.19	0.32	1.72e-9	Heart rate;
LIHC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.65	8.69	0.43	1.56e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-0.71	-8.29	-0.41	2.54e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs2574704	0.781	rs2574721	chr3:11660035	A/G	cg15876825	chr3:11651881	VGLL4	0.49	7.9	0.39	3.94e-14	Body mass index;
LIHC	cis	rs4908768	0.906	rs11121213	chr1:8728187	C/A	cg20416874	chr1:8611966	RERE	0.5	7.11	0.36	6.92e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs10838687	0.736	rs4647726	chr11:47245494	A/T	cg25783544	chr11:47291846	MADD	0.49	6.15	0.32	2.11e-9	Proinsulin levels;
LIHC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	0.84	7.15	0.36	5.14e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg13819250	chr17:41560934	DHX8	-0.41	-6.08	-0.31	3.25e-9	Calcium levels;
LIHC	trans	rs875971	0.545	rs316306	chr7:65618674	G/A	cg26939375	chr7:64535504	NA	-0.41	-6.47	-0.33	3.36e-10	Aortic root size;
LIHC	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.55	-0.38	3.89e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg19635926	chr16:89946313	TCF25	0.55	7.44	0.37	8.03e-13	Skin colour saturation;
LIHC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.52	-7.32	-0.37	1.79e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg02990361	chr1:107599529	PRMT6	0.64	10.45	0.49	2.24e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg14092571	chr14:90743983	NA	-0.37	-5.82	-0.3	1.37e-8	Mortality in heart failure;
LIHC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.57	-0.46	2.3e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.61	10.14	0.48	2.65e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	10.88	0.51	7.22e-24	Colorectal cancer;
LIHC	cis	rs36051895	0.623	rs2208685	chr9:5251758	T/C	cg02405213	chr9:5042618	JAK2	-0.62	-9.89	-0.47	1.84e-20	Pediatric autoimmune diseases;
LIHC	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.59	9.5	0.46	3.65e-19	Corneal astigmatism;
LIHC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.41	6.09	0.31	3.01e-9	Monobrow;
LIHC	cis	rs5753037	0.809	rs2057882	chr22:30217827	A/T	cg01021169	chr22:30184971	ASCC2	-0.36	-6.74	-0.34	6.72e-11	Type 1 diabetes;
LIHC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.55	-9.21	-0.45	3.4e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg07689907	chr11:61582574	FADS1	0.39	5.77	0.3	1.78e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.56	0.64	1.18e-41	Breast cancer;
LIHC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg25344623	chr2:136566232	LCT	0.4	7.63	0.38	2.42e-13	Mosquito bite size;
LIHC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.5	7.03	0.36	1.09e-11	Tonsillectomy;
LIHC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	20.48	0.74	2.02e-61	Smoking behavior;
LIHC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.99	19.71	0.73	2.65e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.821	rs417270	chr1:109849144	T/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.71	-0.3	2.44e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.74	0.76	1.99e-66	Prudent dietary pattern;
LIHC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.38	6.14	0.31	2.32e-9	Multiple sclerosis;
LIHC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.36	-7.17	-0.36	4.78e-12	Body mass index;
LIHC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.6	9.93	0.47	1.35e-20	HDL cholesterol;
LIHC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.42	5.89	0.3	9.18e-9	Tonsillectomy;
LIHC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15326801	chr14:94596007	IFI27L2	-0.55	-6.36	-0.33	6.53e-10	Systolic blood pressure;
LIHC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.59	-8.74	-0.43	1.09e-16	Prostate cancer;
LIHC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg10932868	chr11:921992	NA	0.34	6.42	0.33	4.67e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg02811702	chr13:24901961	NA	-0.25	-6.33	-0.32	7.65e-10	Obesity-related traits;
LIHC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.68	-13.73	-0.6	1.85e-34	Pulse pressure;
LIHC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.58	8.71	0.43	1.29e-16	Response to diuretic therapy;
LIHC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.37	0.33	5.95e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.49	7.76	0.39	9.79e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg16102536	chr7:156981717	UBE3C	0.35	5.82	0.3	1.38e-8	Body mass index;
LIHC	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.03	20.76	0.75	1.6e-62	Schizophrenia;
LIHC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.5	0.42	6e-16	Motion sickness;
LIHC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.57	9.83	0.47	3.09e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.46	-7.43	-0.37	8.54e-13	Cognitive function;
LIHC	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg22138327	chr13:27999177	GTF3A	0.8	6.07	0.31	3.32e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.78	-10.85	-0.51	8.75e-24	Coronary artery disease;
LIHC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg14558262	chr17:40713999	COASY	0.61	9.39	0.45	8.98e-19	Crohn's disease;
LIHC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.93	15.16	0.63	4.39e-40	Metabolic syndrome;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.66	-9.94	-0.47	1.32e-20	Menarche (age at onset);
LIHC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.35	14.76	0.62	1.75e-38	Eosinophil percentage of granulocytes;
LIHC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.38	-0.33	5.89e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.74	0.3	2.1e-8	Height;
LIHC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.47	6.47	0.33	3.45e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.8	11.42	0.53	8.65e-26	Coronary artery disease;
LIHC	cis	rs17106184	0.892	rs111779227	chr1:51328987	A/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg02990361	chr1:107599529	PRMT6	-0.66	-10.88	-0.51	7.07e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.74	0.39	1.17e-13	Prudent dietary pattern;
LIHC	trans	rs1075232	0.510	rs78884938	chr15:31510885	C/T	cg04373760	chr16:53404718	NA	0.69	6.96	0.35	1.79e-11	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.63	9.29	0.45	1.84e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11673344	0.764	rs13345491	chr19:37473099	G/T	cg27390819	chr19:37464633	NA	-0.49	-5.91	-0.3	8.23e-9	Obesity-related traits;
LIHC	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.5	-9.0	-0.44	1.59e-17	Itch intensity from mosquito bite;
LIHC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.46	-0.46	5.02e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.36	5.83	0.3	1.28e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.01	-0.31	4.86e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.78	15.8	0.65	1.3e-42	Height;
LIHC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg03854865	chr6:26224070	HIST1H3E	0.57	6.42	0.33	4.54e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.52	7.74	0.39	1.15e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7116495	1.000	rs1541306	chr11:71708013	G/A	cg26138937	chr11:71823887	C11orf51	-0.71	-7.3	-0.37	1.97e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs925946	0.518	rs7107410	chr11:27551388	T/C	cg18117895	chr11:27722066	BDNF	0.44	5.72	0.3	2.33e-8	Body mass index;Weight;
LIHC	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	1.09	7.79	0.39	8.36e-14	Arsenic metabolism;
LIHC	cis	rs1046896	0.961	rs7208565	chr17:80696692	C/T	cg02711726	chr17:80685570	FN3KRP	-0.57	-11.05	-0.51	1.74e-24	Glycated hemoglobin levels;
LIHC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-8.25	-0.41	3.46e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg16049864	chr8:95962084	TP53INP1	-0.53	-9.29	-0.45	1.86e-18	Type 2 diabetes;
LIHC	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.48	9.03	0.44	1.28e-17	Testicular germ cell tumor;
LIHC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg06565975	chr8:143823917	SLURP1	0.34	6.69	0.34	8.92e-11	Urinary tract infection frequency;
LIHC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.05	0.51	1.73e-24	Personality dimensions;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00834988	chr7:70060153	AUTS2	0.36	6.22	0.32	1.44e-9	Cognitive function;
LIHC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.1	0.31	2.89e-9	Renal cell carcinoma;
LIHC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.72	-0.5	2.62e-23	Chronic sinus infection;
LIHC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.73	0.39	1.23e-13	Prudent dietary pattern;
LIHC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.54	0.42	4.46e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.43	-6.94	-0.35	1.96e-11	Response to temozolomide;
LIHC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg03854865	chr6:26224070	HIST1H3E	-0.62	-7.09	-0.36	7.5e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.86	-0.3	1.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg22325292	chr17:80708367	FN3K	0.38	6.04	0.31	4.02e-9	Glycated hemoglobin levels;
LIHC	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Colorectal cancer;
LIHC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg07952391	chr2:88470173	THNSL2	-0.41	-5.73	-0.3	2.26e-8	Response to metformin (IC50);
LIHC	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg25179470	chr10:102756915	LZTS2	0.45	6.23	0.32	1.36e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.43	8.37	0.41	1.47e-15	Testicular germ cell tumor;
LIHC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg18306943	chr3:40428807	ENTPD3	0.34	5.92	0.3	7.9e-9	Renal cell carcinoma;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11871801	0.517	rs34855406	chr17:40731411	G/C	cg14558262	chr17:40713999	COASY	0.52	6.82	0.35	4.24e-11	Crohn's disease;
LIHC	cis	rs782590	0.687	rs62165255	chr2:55932585	G/A	cg18811423	chr2:55921094	PNPT1	0.88	13.49	0.59	1.56e-33	Metabolic syndrome;
LIHC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.56	9.3	0.45	1.7e-18	Colorectal cancer;
LIHC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg06092702	chr1:163392909	NA	0.19	6.01	0.31	4.74e-9	Motion sickness;
LIHC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg02297831	chr4:17616191	MED28	0.46	7.08	0.36	7.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs6058796	1.000	rs6141781	chr20:31263342	C/T	cg02600331	chr11:130417168	NA	0.36	7.86	0.39	4.98e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs16828019	0.852	rs12048187	chr1:41616183	A/G	cg03387723	chr1:41708464	SCMH1	-0.45	-7.22	-0.36	3.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.43	0.41	1e-15	Lymphocyte counts;
LIHC	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg16558208	chr1:156270281	VHLL	0.53	10.11	0.48	3.29e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg13976866	chr7:128696069	LOC286016;TNPO3	-0.38	-6.17	-0.32	1.94e-9	Pain;
LIHC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.77	12.66	0.56	2.13e-30	Anterior chamber depth;
LIHC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	1.0	15.93	0.65	3.93e-43	Metabolic syndrome;
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.08	0.31	3.19e-9	Renal cell carcinoma;
LIHC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	8.0	0.4	2.01e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.74	-0.34	6.68e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.42	7.32	0.37	1.79e-12	Aortic root size;
LIHC	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	10.47	0.49	1.89e-22	Obesity-related traits;
LIHC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-6.07	-0.31	3.49e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg10820045	chr2:198174542	NA	-0.59	-9.89	-0.47	1.85e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.5	7.8	0.39	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05400618	chr7:2128721	MAD1L1	0.62	7.5	0.38	5.55e-13	Systolic blood pressure;
LIHC	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	7.39	0.37	1.12e-12	Lung cancer;
LIHC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.77	-0.39	9.19e-14	Type 2 diabetes;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.46	-6.1	-0.31	2.82e-9	Serum sulfate level;
LIHC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.9	19.55	0.73	1.18e-57	Blood protein levels;
LIHC	trans	rs528418	0.651	rs77111222	chr6:145542401	C/G	cg09173621	chr13:111773936	ARHGEF7	0.52	6.04	0.31	4.03e-9	Methadone dose in opioid dependence;
LIHC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.4	0.45	7.89e-19	Hemoglobin concentration;
LIHC	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg18898632	chr2:242989856	NA	-0.5	-7.05	-0.36	9.66e-12	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.89	13.62	0.59	4.7e-34	Vitamin D levels;
LIHC	cis	rs7119038	0.818	rs10892279	chr11:118611781	G/A	cg19308663	chr11:118741387	NA	0.41	6.31	0.32	8.52e-10	Sjögren's syndrome;
LIHC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.43	-10.12	-0.48	3.14e-21	Type 2 diabetes;
LIHC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.31e-22	Colorectal cancer;
LIHC	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.58e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.57	8.51	0.42	5.67e-16	Platelet count;
LIHC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-18.9	-0.71	4.62e-55	Height;
LIHC	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.23	6.6	0.34	1.53e-10	Monocyte percentage of white cells;Monocyte count;
LIHC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.96e-16	Prudent dietary pattern;
LIHC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.14	-0.78	6.05e-72	Height;
LIHC	trans	rs3858145	0.588	rs61854837	chr10:70042370	C/G	cg04882175	chr6:131122610	NA	-0.5	-6.22	-0.32	1.48e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.57	7.11	0.36	6.9e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg02505535	chr3:195703920	SDHAP1	0.35	6.39	0.33	5.45e-10	Longevity;
LIHC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg19678392	chr7:94953810	PON1	-0.45	-5.9	-0.3	8.71e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.86	-0.3	1.09e-8	Alzheimer's disease (late onset);
LIHC	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg10820045	chr2:198174542	NA	0.48	7.28	0.37	2.36e-12	Dermatomyositis;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06972615	chr5:77081292	NA	0.51	6.78	0.34	5.23e-11	Lung function (FEV1);
LIHC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.53	-8.12	-0.4	8.34e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.22	0.55	9.92e-29	Prudent dietary pattern;
LIHC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.64	7.18	0.36	4.25e-12	Eosinophil percentage of granulocytes;
LIHC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07305463	chr2:136567211	LCT	0.4	7.34	0.37	1.57e-12	Mosquito bite size;
LIHC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs62179067	0.708	rs16866624	chr2:179936770	C/G	cg07532576	chr2:179544947	TTN	0.58	5.73	0.3	2.18e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.06	0.4	1.32e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.58	11.74	0.54	5.48e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.48	-0.33	3.2e-10	Personality dimensions;
LIHC	cis	rs861318	0.702	rs3018316	chr1:159017958	G/T	cg11003133	chr1:159046391	AIM2	0.32	6.21	0.32	1.51e-9	Obesity-related traits;
LIHC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.39	6.28	0.32	1.04e-9	Red blood cell count;
LIHC	cis	rs9372498	0.505	rs1690655	chr6:118653045	A/T	cg01339444	chr6:118972232	C6orf204	0.71	6.24	0.32	1.26e-9	Diastolic blood pressure;
LIHC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	6.95	0.35	1.88e-11	Lung cancer in ever smokers;
LIHC	cis	rs7818688	0.697	rs58314911	chr8:95985111	G/A	cg16049864	chr8:95962084	TP53INP1	0.6	6.51	0.33	2.69e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.57	7.17	0.36	4.75e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.57	-0.33	1.92e-10	Mean corpuscular volume;
LIHC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.68	10.45	0.49	2.29e-22	Height;
LIHC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.32	-6.1	-0.31	2.94e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.81	9.71	0.46	7.72e-20	Mean platelet volume;
LIHC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.08	0.31	3.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg01231543	chr16:68741748	NA	0.39	6.28	0.32	1.05e-9	Colorectal cancer;
LIHC	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.37	7.29	0.37	2.1e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.31	0.32	8.5e-10	Prudent dietary pattern;
LIHC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	0.91	7.14	0.36	5.67e-12	IgG glycosylation;
LIHC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.45	9.1	0.44	7.49e-18	Birth weight;
LIHC	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg16309518	chr5:176445507	NA	-0.53	-10.05	-0.48	5.22e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs8056893	0.686	rs3826167	chr16:68397530	T/G	cg02226672	chr16:68398533	SMPD3	0.43	6.06	0.31	3.58e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.55	-0.38	4.11e-13	Initial pursuit acceleration;
LIHC	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg22705602	chr4:152727874	NA	-0.4	-7.39	-0.37	1.15e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.29	12.34	0.55	3.55e-29	Psoriasis vulgaris;
LIHC	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.51	9.49	0.46	4.15e-19	Testicular germ cell tumor;
LIHC	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.37	5.86	0.3	1.11e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.19	0.58	2.13e-32	Cognitive test performance;
LIHC	cis	rs74233809	1.000	rs12219901	chr10:104840967	A/G	cg03493300	chr10:104813866	CNNM2	0.48	6.4	0.33	5.23e-10	Birth weight;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.12	0.4	8.4e-15	Height;
LIHC	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.41	-7.99	-0.4	2.08e-14	Type 1 diabetes;
LIHC	cis	rs4699052	0.927	rs1870888	chr4:104169326	G/C	cg16532752	chr4:104119610	CENPE	-0.39	-6.24	-0.32	1.31e-9	Testicular germ cell tumor;
LIHC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.52	7.2	0.36	3.82e-12	Aortic root size;
LIHC	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.73	-11.49	-0.53	4.78e-26	White matter hyperintensity burden;
LIHC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg18016565	chr1:150552671	MCL1	-0.5	-10.34	-0.49	5.31e-22	Tonsillectomy;
LIHC	cis	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg03999872	chr20:62272968	STMN3	-0.45	-6.78	-0.34	5.24e-11	Atopic dermatitis;
LIHC	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.49	-7.6	-0.38	2.86e-13	Blood pressure (smoking interaction);
LIHC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	9.32	0.45	1.52e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg25214090	chr10:38739885	LOC399744	0.38	6.27	0.32	1.09e-9	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11595794	chr4:186317094	ANKRD37	0.45	6.3	0.32	9.17e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02290350	chr8:58132656	NA	0.37	7.99	0.4	2.13e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg10546562	chr7:5390491	TNRC18	0.51	7.07	0.36	9.02e-12	Hip circumference;
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07781247	chr5:93954443	ANKRD32;C5orf36	0.42	6.25	0.32	1.2e-9	Gut microbiome composition (summer);
LIHC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.75	-14.96	-0.63	2.78e-39	Height;
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.77	13.94	0.6	2.81e-35	Bipolar disorder and schizophrenia;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07175572	chr10:89310145	MINPP1	-0.29	-6.37	-0.33	6.28e-10	Calcium levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg12716232	chr8:43001931	HGSNAT	-0.32	-6.31	-0.32	8.54e-10	Calcium levels;
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg18769074	chr3:133464867	TF	0.27	6.09	0.31	3.02e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs55665837	0.540	rs4144487	chr11:14750451	C/G	cg19336497	chr11:14380999	RRAS2	-0.34	-5.74	-0.3	2.13e-8	Vitamin D levels;
LIHC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.43	7.1	0.36	7.45e-12	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg11764359	chr7:65958608	NA	0.58	6.03	0.31	4.29e-9	Diabetic kidney disease;
LIHC	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.53	0.33	2.44e-10	Bipolar disorder;
LIHC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.59	10.23	0.48	1.37e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.56	7.34	0.37	1.53e-12	Parkinson's disease;
LIHC	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.37	-8.56	-0.42	3.93e-16	Blood protein levels;
LIHC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.65	9.6	0.46	1.74e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs16944613	0.541	rs4566137	chr15:91097964	A/G	cg26821196	chr15:91095069	CRTC3	0.51	8.78	0.43	7.94e-17	Colorectal cancer;
LIHC	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.73	-0.5	2.44e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.04	-0.36	1.08e-11	Vitiligo;
LIHC	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.12	-0.44	6.35e-18	Type 2 diabetes;
LIHC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.64	-9.04	-0.44	1.23e-17	Body mass index;
LIHC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.0	15.51	0.64	1.82e-41	Breast cancer;
LIHC	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.07	0.36	8.51e-12	Bipolar disorder;
LIHC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.58	-10.29	-0.49	8e-22	Platelet distribution width;
LIHC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.63	10.78	0.5	1.63e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg27433088	chr4:174089019	GALNT7	0.33	5.77	0.3	1.76e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg03843852	chr15:55611099	PIGB	-0.57	-6.16	-0.32	2.05e-9	Bronchial neuroendocrine tumor;
LIHC	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.67	6.77	0.34	5.65e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs2629751	0.512	rs2583271	chr12:104440855	C/T	cg14987745	chr12:104360022	TDG	-0.66	-6.38	-0.33	5.81e-10	Hepatitis C induced liver fibrosis;
LIHC	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.68	-0.38	1.68e-13	Schizophrenia;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg04234412	chr22:24373322	LOC391322	-0.73	-11.14	-0.52	8.78e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg24296786	chr1:45957014	TESK2	-0.49	-7.13	-0.36	6.04e-12	Platelet count;
LIHC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg16822855	chr3:40428330	ENTPD3	0.34	6.12	0.31	2.56e-9	Renal cell carcinoma;
LIHC	cis	rs151997	0.671	rs152099	chr5:50210091	A/G	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs10426930	0.816	rs2602728	chr19:5046318	C/T	cg18473234	chr19:5097819	KDM4B	0.53	6.72	0.34	7.64e-11	Monocyte percentage of white cells;
LIHC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.74	-11.35	-0.52	1.46e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg24112000	chr20:60950667	NA	0.48	7.41	0.37	1.01e-12	Colorectal cancer;
LIHC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.72	10.74	0.5	2.22e-23	Selective IgA deficiency;
LIHC	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.34	6.54	0.33	2.26e-10	Cancer;
LIHC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.37	0.37	1.33e-12	Bipolar disorder;
LIHC	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.45	-7.03	-0.36	1.12e-11	Lung cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25629694	chr17:62657497	SMURF2	-0.45	-6.52	-0.33	2.54e-10	Bilirubin levels;
LIHC	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.42	7.1	0.36	7.42e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	0.72	8.22	0.41	4.29e-15	Testicular germ cell tumor;
LIHC	cis	rs2997447	0.761	rs17257107	chr1:26448447	A/G	cg19633962	chr1:26362018	EXTL1	-0.64	-5.88	-0.3	9.64e-9	QRS complex (12-leadsum);
LIHC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg05896524	chr21:47604654	C21orf56	0.44	6.64	0.34	1.25e-10	Testicular germ cell tumor;
LIHC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.54	0.46	2.89e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.77	-14.81	-0.63	1.08e-38	Mortality in heart failure;
LIHC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.58	9.48	0.46	4.31e-19	Resting heart rate;
LIHC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	6.24	0.32	1.3e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.32	11.94	0.54	1.03e-27	Uric acid levels;
LIHC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.62	-0.59	4.57e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.59	5.92	0.3	7.98e-9	Smoking initiation;
LIHC	cis	rs13177718	0.908	rs7713158	chr5:108179300	G/A	cg20423064	chr5:108166851	FER	-0.59	-6.46	-0.33	3.59e-10	Height;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03047724	chr7:139477895	TBXAS1;HIPK2	0.42	6.39	0.33	5.34e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.65	-8.27	-0.41	3.07e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.25e-12	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.29	-16.99	-0.68	2.36e-47	Diabetic kidney disease;
LIHC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.65	-7.54	-0.38	4.39e-13	Lymphocyte counts;
LIHC	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg26395211	chr5:140044315	WDR55	-0.41	-5.93	-0.31	7.45e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22496380	chr5:211416	CCDC127	-1.04	-9.77	-0.47	4.91e-20	Breast cancer;
LIHC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.33	-0.32	7.83e-10	Colorectal cancer;
LIHC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.77	5.85	0.3	1.17e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.37	0.37	1.26e-12	Bipolar disorder;
LIHC	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-7.42	-0.37	9.3e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg03874509	chr1:107600012	PRMT6	0.77	12.67	0.57	1.91e-30	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10256972	0.640	rs10271082	chr7:1081562	G/C	cg23978390	chr7:1156363	C7orf50	0.46	6.62	0.34	1.36e-10	Longevity;Endometriosis;
LIHC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.97	18.22	0.7	2.54e-52	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg16586182	chr3:47516702	SCAP	-0.58	-11.19	-0.52	5.73e-25	Colorectal cancer;
LIHC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.8	13.08	0.58	5.65e-32	Body mass index (adult);
LIHC	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16684958	chr7:75615977	POR	0.51	8.49	0.42	6.26e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	3.07e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs611744	0.967	rs597649	chr8:109187718	T/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs4407350	0.870	rs4823327	chr22:44908708	T/C	cg11695653	chr22:44894386	LDOC1L	-0.35	-6.02	-0.31	4.52e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs922107	0.738	rs12140018	chr1:90025689	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.75	-0.39	1.05e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg18357645	chr12:58087776	OS9	-0.4	-5.97	-0.31	5.88e-9	Multiple sclerosis;
LIHC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.94	-0.39	2.92e-14	Total cholesterol levels;
LIHC	cis	rs6732160	0.574	rs7557055	chr2:73472670	G/A	cg24220031	chr2:73402428	NA	-0.28	-6.0	-0.31	5.16e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09820084	chr6:18387507	RNF144B	0.47	7.22	0.36	3.5e-12	Pancreatic cancer;
LIHC	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg24848339	chr3:12840334	CAND2	0.32	6.32	0.32	8.04e-10	QRS complex (12-leadsum);
LIHC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.55	-0.33	2.14e-10	Mean corpuscular volume;
LIHC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg18944383	chr4:111397179	ENPEP	0.28	6.42	0.33	4.47e-10	Coronary artery disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13674483	chr17:37212827	NA	-0.39	-6.82	-0.35	4.26e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg14393609	chr7:65229607	NA	0.45	6.59	0.34	1.63e-10	Aortic root size;
LIHC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	1.01	10.14	0.48	2.67e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg27211696	chr2:191398769	TMEM194B	-0.54	-6.98	-0.35	1.53e-11	Diastolic blood pressure;
LIHC	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-11.42	-0.53	8.29e-26	Coffee consumption (cups per day);
LIHC	trans	rs9914544	0.564	rs11868520	chr17:18770367	A/G	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.73	-0.34	7.38e-11	Educational attainment (years of education);
LIHC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg23625390	chr15:77176239	SCAPER	0.33	5.73	0.3	2.24e-8	Blood metabolite levels;
LIHC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg02079420	chr8:82753780	SNX16	-0.36	-6.59	-0.34	1.69e-10	Diastolic blood pressure;
LIHC	cis	rs10503871	0.545	rs7822088	chr8:30498193	G/A	cg26383811	chr8:30366931	RBPMS	0.42	6.41	0.33	4.72e-10	Metabolite levels  (X-11787);
LIHC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg20195005	chr22:42527684	CYP2D6	0.32	6.01	0.31	4.68e-9	Birth weight;
LIHC	cis	rs4407350	0.870	rs131172	chr22:44902759	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.62	0.34	1.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg12365402	chr11:9010492	NRIP3	-0.29	-7.8	-0.39	7.62e-14	Hemoglobin concentration;
LIHC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.35	0.41	1.67e-15	Lung cancer in ever smokers;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12832228	chr8:28244096	ZNF395	0.47	6.13	0.31	2.44e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.23	0.36	3.16e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.47e-14	Bladder cancer;
LIHC	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg22771759	chr13:24902376	NA	0.32	6.64	0.34	1.22e-10	Obesity-related traits;
LIHC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.44	-6.71	-0.34	8.26e-11	Asthma;
LIHC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg05555928	chr11:63887634	MACROD1	0.55	7.47	0.37	6.77e-13	Mean platelet volume;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg15604507	chr11:19263433	E2F8	0.44	6.05	0.31	3.86e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.94	0.31	6.94e-9	Alzheimer's disease;
LIHC	cis	rs7780883	1.000	rs6946471	chr7:77062284	G/A	cg12876866	chr7:77025528	PION	-0.45	-5.71	-0.3	2.46e-8	Cervical cancer;
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg24693881	chr1:107596107	NA	-0.55	-9.68	-0.46	9.49e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.74	13.04	0.58	8.06e-32	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg22842854	chr12:123319900	HIP1R	-0.64	-8.39	-0.41	1.26e-15	Schizophrenia;
LIHC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.63	10.06	0.48	4.84e-21	Bipolar disorder and schizophrenia;
LIHC	trans	rs875971	0.964	rs778708	chr7:65856319	T/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg04610667	chr7:75704037	NA	-0.33	-6.0	-0.31	5.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.49	-0.33	3.08e-10	Fear of minor pain;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.4	0.45	7.99e-19	Lymphocyte counts;
LIHC	trans	rs6489882	0.836	rs12322160	chr12:113368505	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.41	6.64	0.34	1.22e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.41	6.71	0.34	8.11e-11	Red blood cell count;
LIHC	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg00792783	chr2:198669748	PLCL1	0.43	6.26	0.32	1.15e-9	Intracranial aneurysm;
LIHC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.97	0.31	5.99e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg17771515	chr6:154831774	CNKSR3	0.58	6.19	0.32	1.77e-9	Lipoprotein (a) levels;
LIHC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-11.04	-0.51	1.87e-24	Type 2 diabetes;
LIHC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-5.89	-0.3	9.09e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.57	8.97	0.44	1.96e-17	Red cell distribution width;
LIHC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.36e-11	Protein C levels;
LIHC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-5.94	-0.31	7.12e-9	Menarche (age at onset);
LIHC	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.22e-24	Breast cancer;
LIHC	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg13482628	chr17:19912719	NA	0.4	6.68	0.34	9.93e-11	Schizophrenia;
LIHC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.19	-0.32	1.74e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02900441	chr1:15911134	AGMAT	-0.52	-6.17	-0.32	1.89e-9	Systolic blood pressure;
LIHC	cis	rs2236918	0.687	rs851778	chr1:242037110	A/G	cg17736920	chr1:242011382	EXO1	0.41	5.95	0.31	6.51e-9	Menopause (age at onset);
LIHC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.49	-6.11	-0.31	2.72e-9	Breast cancer;
LIHC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.47	9.54	0.46	2.7e-19	Immature fraction of reticulocytes;
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.42	8.46	0.42	7.64e-16	Renal cell carcinoma;
LIHC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.2e-18	Hemoglobin concentration;
LIHC	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg09795085	chr6:101329169	ASCC3	-0.53	-7.38	-0.37	1.24e-12	Neuroticism;
LIHC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	trans	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.49	0.59	1.56e-33	Diabetic kidney disease;
LIHC	cis	rs4478037	0.822	rs3924696	chr3:33122013	T/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.52	-6.51	-0.33	2.6e-10	Major depressive disorder;
LIHC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.47	7.69	0.38	1.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1461503	0.534	rs7123283	chr11:122809055	C/T	cg25161029	chr11:122845972	NA	0.34	5.81	0.3	1.4e-8	Menarche (age at onset);
LIHC	cis	rs74181299	0.571	rs12990465	chr2:65281401	C/T	cg05010058	chr2:65284262	CEP68	0.37	5.88	0.3	9.76e-9	Pulse pressure;
LIHC	cis	rs17152411	1.000	rs12569940	chr10:126592684	T/C	cg07906193	chr10:126599966	NA	0.47	7.25	0.37	2.75e-12	Height;
LIHC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.51	-0.56	8.09e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg07713946	chr22:31675144	LIMK2	-0.4	-6.96	-0.35	1.74e-11	Paclitaxel-induced neuropathy;
LIHC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-10.77	-0.5	1.74e-23	Colorectal cancer;
LIHC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.86	0.39	5.18e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.53	9.39	0.45	8.69e-19	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14579516	chr2:135677120	CCNT2	-0.42	-6.27	-0.32	1.11e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs875971	0.543	rs801191	chr7:66032955	G/A	cg26939375	chr7:64535504	NA	-0.44	-7.46	-0.37	7.43e-13	Aortic root size;
LIHC	cis	rs79387448	0.745	rs723292	chr2:103166804	A/G	cg09003973	chr2:102972529	NA	0.88	7.77	0.39	9.15e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg25801113	chr15:45476975	SHF	0.37	6.28	0.32	1.05e-9	Uric acid levels;
LIHC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.46	8.85	0.43	4.66e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg10621924	chr7:39171070	POU6F2	0.42	6.51	0.33	2.67e-10	IgG glycosylation;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg05874655	chr5:40798723	PRKAA1	-0.44	-6.56	-0.33	1.99e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-9.46	-0.46	4.94e-19	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg02782426	chr3:40428986	ENTPD3	0.33	6.04	0.31	4.03e-9	Renal cell carcinoma;
LIHC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg15691649	chr6:25882328	NA	0.48	6.67	0.34	1.03e-10	Blood metabolite levels;
LIHC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.23	-6.59	-0.34	1.7e-10	Blood protein levels;
LIHC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.39	-7.0	-0.35	1.34e-11	Hepatocellular carcinoma;
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09256448	chr16:638327	NA	0.39	6.82	0.35	4.1e-11	Height;
LIHC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg03146154	chr1:46216737	IPP	-0.37	-6.16	-0.32	1.99e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.63	10.03	0.48	6.2e-21	Longevity;
LIHC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.37	5.84	0.3	1.21e-8	Menopause (age at onset);
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.48	0.56	1.07e-29	Alzheimer's disease;
LIHC	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-6.21	-0.32	1.51e-9	IFN-related cytopenia;
LIHC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-7.1	-0.36	7.11e-12	Hemoglobin concentration;
LIHC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.42	6.76	0.34	6.12e-11	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2026037	1.000	rs2026037	chr9:23762529	C/T	cg18828137	chr12:52968145	KRT74	-0.22	-6.07	-0.31	3.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-10.64	-0.5	5.03e-23	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg07424592	chr7:64974309	NA	-0.66	-7.57	-0.38	3.52e-13	Diabetic kidney disease;
LIHC	cis	rs9543976	0.858	rs8192763	chr13:76179170	A/T	cg01531495	chr13:76123901	UCHL3	0.48	5.76	0.3	1.87e-8	Diabetic retinopathy;
LIHC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.58	9.22	0.45	3.13e-18	Multiple sclerosis;
LIHC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-8.34	-0.41	1.86e-15	Vitiligo;
LIHC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.75	-0.39	1.09e-13	Schizophrenia;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	trans	rs2122469	0.655	rs17576178	chr8:20581162	T/C	cg20211604	chr17:11632341	DNAH9	0.47	6.27	0.32	1.11e-9	Serum tamsulosin hydrochloride concentration;
LIHC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs225245	0.610	rs321608	chr17:33880636	A/G	cg05299278	chr17:33885742	SLFN14	0.23	6.06	0.31	3.62e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.73	11.1	0.51	1.2e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.67	-9.87	-0.47	2.21e-20	Lymphocyte counts;
LIHC	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.15	16.07	0.66	1.08e-43	Corneal structure;
LIHC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25833597	chr17:30823145	MYO1D	-0.49	-6.0	-0.31	4.91e-9	Schizophrenia;
LIHC	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg07423050	chr13:99094983	FARP1	0.35	5.78	0.3	1.68e-8	Longevity;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.43	-6.47	-0.33	3.36e-10	Diastolic blood pressure;
LIHC	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.35	-0.32	6.74e-10	Morning vs. evening chronotype;
LIHC	cis	rs882732	1.000	rs10146582	chr14:95037778	G/A	cg14866387	chr14:95027382	SERPINA4	-0.49	-6.66	-0.34	1.08e-10	Blood protein levels;
LIHC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-16.07	-0.66	1.14e-43	Coronary artery disease;
LIHC	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg24391279	chr8:1708526	NA	0.38	6.11	0.31	2.77e-9	Systolic blood pressure;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.48	-8.22	-0.41	4.17e-15	Total body bone mineral density;
LIHC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-8.09	-0.4	1.08e-14	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21515243	chr18:21033072	RIOK3	0.42	7.0	0.35	1.34e-11	Cognitive function;
LIHC	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.55	-9.62	-0.46	1.55e-19	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.67	6.77	0.34	5.65e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.44	6.73	0.34	6.95e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg00656387	chr3:40428638	ENTPD3	0.49	8.31	0.41	2.24e-15	Renal cell carcinoma;
LIHC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.53	-0.33	2.41e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.66	-0.5	4.18e-23	Breast cancer;
LIHC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.58	-0.5	8.09e-23	Total cholesterol levels;
LIHC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.75	-0.6	1.47e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.62	-8.78	-0.43	8.07e-17	Blood metabolite levels;
LIHC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.96	0.31	6.19e-9	Eosinophil percentage of white cells;
LIHC	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.51	8.25	0.41	3.48e-15	Corneal astigmatism;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.79	-0.3	1.56e-8	Total body bone mineral density;
LIHC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-11.66	-0.53	1.13e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.42	6.4	0.33	4.98e-10	Bladder cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02706910	chr19:24269975	ZNF254	0.46	6.4	0.33	5.25e-10	Hepatitis;
LIHC	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.91	0.35	2.36e-11	Bipolar disorder;
LIHC	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.36	6.4	0.33	5.1e-10	Mean corpuscular volume;
LIHC	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	5.99	0.31	5.35e-9	Asthma;
LIHC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.54	-6.68	-0.34	9.5e-11	Menarche (age at onset);
LIHC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.33	-6.16	-0.32	1.99e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.65	-10.52	-0.49	1.28e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg18944383	chr4:111397179	ENPEP	0.35	8.19	0.4	5.35e-15	Coronary artery disease;
LIHC	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.39	5.97	0.31	6.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28489187	0.706	rs233095	chr1:85824816	T/C	cg16011679	chr1:85725395	C1orf52	0.46	5.82	0.3	1.33e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg24209194	chr3:40518798	ZNF619	0.41	5.9	0.3	8.8e-9	Renal cell carcinoma;
LIHC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.48	6.06	0.31	3.69e-9	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg00091569	chr3:40428383	ENTPD3	-0.37	-6.34	-0.32	7.31e-10	Renal cell carcinoma;
LIHC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.5	-6.03	-0.31	4.29e-9	Blood metabolite levels;
LIHC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.26	-0.32	1.15e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.08	-0.36	8.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.18	-0.32	1.86e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.59	-0.34	1.66e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.87	-0.3	1.05e-8	Vitiligo;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg00280220	chr17:61926910	NA	0.43	6.79	0.34	4.99e-11	Prudent dietary pattern;
LIHC	cis	rs10423674	0.526	rs34482977	chr19:18824038	C/G	cg16673477	chr19:18812017	CRTC1	-0.41	-6.5	-0.33	2.82e-10	Menarche (age at onset);
LIHC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.26	-0.41	3.25e-15	Gut microbiome composition (summer);
LIHC	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg06854084	chr10:101292507	NKX2-3	-0.34	-6.09	-0.31	2.96e-9	Dental caries;
LIHC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.87	15.58	0.64	9.5e-42	Aortic root size;
LIHC	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg17074339	chr11:11642133	GALNTL4	0.4	6.07	0.31	3.37e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.28	20.79	0.75	1.25e-62	Corneal structure;
LIHC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg17724175	chr1:150552817	MCL1	0.47	9.23	0.45	2.9e-18	Melanoma;
LIHC	cis	rs910316	0.712	rs10131894	chr14:75446879	C/G	cg11812906	chr14:75593930	NEK9	0.73	13.49	0.59	1.47e-33	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19775406	chr17:5390252	MIS12;DERL2	0.42	6.31	0.32	8.82e-10	Cognitive function;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg22649068	chr1:150552352	MCL1	-0.54	-6.36	-0.33	6.35e-10	Systolic blood pressure;
LIHC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.42	0.37	9.53e-13	Gut microbiome composition (summer);
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg21565150	chr10:90751097	FAS;ACTA2	-0.48	-6.3	-0.32	9.16e-10	Electroencephalogram traits;
LIHC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.9	15.97	0.65	2.79e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg22951263	chr5:87985283	NA	-0.39	-6.8	-0.35	4.61e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs8016982	0.662	rs1951616	chr14:81671752	T/C	cg01989461	chr14:81687754	GTF2A1	0.53	9.25	0.45	2.52e-18	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.12	0.31	2.5e-9	Menarche (age at onset);
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.14e-13	Total body bone mineral density;
LIHC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.29	15.79	0.65	1.44e-42	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.44e-11	IgG glycosylation;
LIHC	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-7.9	-0.39	3.89e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg14515779	chr1:101123966	NA	0.46	6.6	0.34	1.61e-10	Monocyte count;
LIHC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg24130564	chr14:104152367	KLC1	-0.35	-5.82	-0.3	1.34e-8	Schizophrenia;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05106659	chr4:152682899	PET112L	-0.36	-6.43	-0.33	4.39e-10	Calcium levels;
LIHC	cis	rs3736757	0.603	rs10911631	chr1:184651867	A/C	cg07817967	chr1:184721222	EDEM3	0.36	5.76	0.3	1.84e-8	Obesity-related traits;
LIHC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.89	0.35	2.77e-11	Schizophrenia;
LIHC	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.31	6.5	0.33	2.9e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs9921222	0.500	rs12917907	chr16:405866	C/T	cg08923669	chr16:420230	MRPL28	-0.45	-6.18	-0.32	1.79e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.43	6.05	0.31	3.87e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.67	-10.09	-0.48	3.91e-21	Mosquito bite size;
LIHC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg20607798	chr8:58055168	NA	0.67	7.7	0.38	1.48e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26755928	chr19:10363173	MRPL4	0.44	6.19	0.32	1.68e-9	Pancreatic cancer;
LIHC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	14.67	0.62	3.87e-38	Menopause (age at onset);
LIHC	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg23112188	chr14:24563095	PCK2	-0.32	-6.35	-0.32	6.94e-10	IgG glycosylation;
LIHC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.42	-6.52	-0.33	2.56e-10	Schizophrenia;
LIHC	cis	rs17106184	1.000	rs12089041	chr1:51381594	C/T	cg07174182	chr1:51127561	FAF1	-0.75	-8.06	-0.4	1.32e-14	Type 2 diabetes;
LIHC	cis	rs1982963	1.000	rs3818187	chr14:52509788	A/G	cg10843707	chr14:52510701	NID2	0.46	8.36	0.41	1.55e-15	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	0.74	8.02	0.4	1.71e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg24955406	chr1:100503596	HIAT1	0.6	5.99	0.31	5.44e-9	Carotid intima media thickness;
LIHC	cis	rs8113613	0.656	rs1059840	chr19:10370490	A/T	cg01850179	chr19:10340795	S1PR2	0.54	6.45	0.33	3.88e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg05484376	chr2:27715224	FNDC4	0.4	6.67	0.34	1.02e-10	Total body bone mineral density;
LIHC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.77	15.18	0.63	3.75e-40	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-11.34	-0.52	1.57e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.55	-10.35	-0.49	5.08e-22	Vitamin D levels;
LIHC	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.03	0.31	4.27e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.51	7.55	0.38	3.95e-13	Longevity;Endometriosis;
LIHC	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg16736954	chr20:23401023	NAPB	0.52	5.82	0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16346588	chr10:242978	ZMYND11	-0.39	-5.95	-0.31	6.61e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.87	10.96	0.51	3.84e-24	Mean platelet volume;
LIHC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.61	-5.9	-0.3	8.67e-9	Urate levels in lean individuals;
LIHC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.37	-5.98	-0.31	5.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1419980	0.730	rs11525576	chr12:7752041	A/G	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.71	-0.3	2.45e-8	Subjective well-being;
LIHC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.9	19.49	0.73	1.94e-57	Blood protein levels;
LIHC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.57	7.94	0.39	2.94e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.5	-7.99	-0.4	2.07e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.58	9.58	0.46	2.03e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7712401	0.791	rs1531340	chr5:122108017	G/A	cg18764291	chr5:122110994	SNX2	0.36	6.12	0.31	2.54e-9	Mean platelet volume;
LIHC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.87	7.86	0.39	4.95e-14	Type 2 diabetes;
LIHC	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.72	10.84	0.51	1.03e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.94	0.44	2.39e-17	Platelet count;
LIHC	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg22842854	chr12:123319900	HIP1R	0.82	9.22	0.45	3.08e-18	Adiponectin levels;
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.61	6.88	0.35	2.78e-11	Alzheimer's disease;
LIHC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-13.58	-0.59	6.77e-34	Primary sclerosing cholangitis;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	0.59	8.72	0.43	1.25e-16	Prudent dietary pattern;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg24693881	chr1:107596107	NA	0.47	7.88	0.39	4.5e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6752107	0.935	rs10929326	chr2:234151045	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.89	0.35	2.75e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs903552	0.800	rs6598478	chr15:102001696	A/T	cg25677261	chr15:102009856	PCSK6	-0.45	-5.88	-0.3	9.92e-9	Diabetic kidney disease;
LIHC	cis	rs903552	0.736	rs2412008	chr15:102006841	C/T	cg04789225	chr15:102009795	PCSK6	-0.44	-5.76	-0.3	1.88e-8	Diabetic kidney disease;
LIHC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.08	12.74	0.57	1.13e-30	Vitiligo;
LIHC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.03	-0.44	1.31e-17	Bipolar disorder;
LIHC	cis	rs61712019	0.563	rs34996456	chr2:77731311	G/A	cg11252801	chr2:77748917	LRRTM4	0.45	6.21	0.32	1.57e-9	Schizophrenia;
LIHC	cis	rs1198430	0.683	rs1198433	chr1:23756695	A/G	cg13183780	chr1:23809682	ASAP3	-0.39	-6.72	-0.34	7.78e-11	Total cholesterol levels;
LIHC	cis	rs12960505	0.506	rs9950293	chr18:51055233	C/A	cg24270629	chr18:50823537	DCC	-0.46	-6.28	-0.32	1.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.75	11.29	0.52	2.42e-25	Corneal astigmatism;
LIHC	trans	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.68e-10	Educational attainment (years of education);
LIHC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.73	-0.3	2.16e-8	Mortality in heart failure;
LIHC	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.43	-9.21	-0.45	3.33e-18	White blood cell count (basophil);
LIHC	cis	rs2108622	0.727	rs8104311	chr19:15982760	T/C	cg13772218	chr19:15982569	NA	0.37	7.75	0.39	1.06e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.52	-8.07	-0.4	1.21e-14	Schizophrenia;
LIHC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg12798992	chr6:167411361	FGFR1OP	-0.48	-7.79	-0.39	8.26e-14	Crohn's disease;
LIHC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg17135325	chr3:160939158	NMD3	0.57	8.13	0.4	7.9e-15	Parkinson's disease;
LIHC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.69	-14.51	-0.62	1.58e-37	Brugada syndrome;
LIHC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.55	8.32	0.41	2.12e-15	Platelet count;
LIHC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-6.85	-0.35	3.55e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	7.71	0.38	1.37e-13	Schizophrenia;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs9896052	0.580	rs6416847	chr17:73468434	G/A	cg25649188	chr17:73499917	CASKIN2	0.5	7.43	0.37	8.98e-13	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.85	-0.39	5.27e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.6	-7.19	-0.36	4.18e-12	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.65	10.0	0.48	7.98e-21	Renal cell carcinoma;
LIHC	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.35	5.72	0.3	2.3e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4788570	0.655	rs1392484	chr16:71822101	T/A	cg06353428	chr16:71660113	MARVELD3	1.33	14.27	0.61	1.38e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.36	5.82	0.3	1.39e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.73	0.3	2.25e-8	Electroencephalogram traits;
LIHC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.56e-8	Bladder cancer;
LIHC	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.49	-7.4	-0.37	1.1e-12	Urate levels in overweight individuals;
LIHC	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg04065206	chr12:109973212	UBE3B	-0.49	-6.02	-0.31	4.51e-9	Neuroticism;
LIHC	cis	rs797680	0.856	rs7540025	chr1:93759228	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	0.34	6.12	0.31	2.6e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg21877656	chr19:58662188	ZNF329	1.07	8.34	0.41	1.83e-15	Cholesterol, total;
LIHC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg18357645	chr12:58087776	OS9	-0.43	-6.83	-0.35	3.82e-11	Multiple sclerosis;
LIHC	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.42	12.22	0.55	9.43e-29	Uric acid levels;
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.66	9.78	0.47	4.36e-20	Menarche (age at onset);
LIHC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.19e-13	Bipolar disorder;
LIHC	cis	rs6695567	1.000	rs6672276	chr1:53629901	C/A	cg20326410	chr1:53600821	SLC1A7	0.3	6.34	0.32	7.26e-10	Systemic lupus erythematosus;
LIHC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.73	11.96	0.54	8.98e-28	Mean platelet volume;
LIHC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.63	0.42	2.41e-16	Prudent dietary pattern;
LIHC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.49	6.96	0.35	1.76e-11	Schizophrenia;
LIHC	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.49	6.43	0.33	4.3e-10	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.75	-11.85	-0.54	2.34e-27	Colorectal cancer;
LIHC	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.73	11.15	0.52	7.68e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.54	-0.5	1.11e-22	Response to antipsychotic treatment;
LIHC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.74	-0.3	2.06e-8	Ulcerative colitis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14166846	chr1:220268091	IARS2	0.49	7.58	0.38	3.38e-13	Pancreatic cancer;
LIHC	cis	rs860295	0.812	rs11264413	chr1:155788656	G/A	cg02153340	chr1:155202674	NA	-0.34	-6.12	-0.31	2.52e-9	Body mass index;
LIHC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg10621924	chr7:39171070	POU6F2	0.41	6.45	0.33	3.86e-10	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10198271	chr20:55966838	RBM38	-0.46	-6.76	-0.34	5.81e-11	Cognitive function;
LIHC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-6.51	-0.33	2.63e-10	Schizophrenia;
LIHC	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.56	-6.8	-0.35	4.55e-11	Breast cancer;
LIHC	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.1	-0.31	2.85e-9	Breast cancer;
LIHC	cis	rs7165170	0.549	rs11635656	chr15:91103096	A/G	cg26821196	chr15:91095069	CRTC3	0.4	7.08	0.36	8.28e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08280861	chr8:58055591	NA	0.5	6.06	0.31	3.5e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.72	-0.34	7.52e-11	Metabolite levels;
LIHC	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg03945807	chr20:60948434	NA	0.46	5.81	0.3	1.41e-8	Colorectal cancer;
LIHC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	0.92	6.53	0.33	2.33e-10	Height;
LIHC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.24	-6.03	-0.31	4.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-8.28	-0.41	2.84e-15	Schizophrenia;
LIHC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.73	-0.3	2.15e-8	Uric acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27209117	chr17:58469727	USP32	0.48	6.98	0.35	1.52e-11	Pancreatic cancer;
LIHC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	7.88	0.39	4.31e-14	Menarche (age at onset);
LIHC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.12	0.55	2.35e-28	Cognitive test performance;
LIHC	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg06565975	chr8:143823917	SLURP1	0.3	5.77	0.3	1.74e-8	Urinary tract infection frequency;
LIHC	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.5	0.33	2.87e-10	Ileal carcinoids;
LIHC	cis	rs7923837	0.616	rs12778642	chr10:94464307	G/T	cg25506282	chr10:94462361	NA	0.43	7.59	0.38	2.97e-13	Body mass index;Multiple sclerosis;
LIHC	cis	rs12286929	0.839	rs12803174	chr11:115023159	T/C	cg04055981	chr11:115044050	NA	0.45	6.7	0.34	8.7e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.55	-8.82	-0.43	5.86e-17	Crohn's disease;
LIHC	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.68	-0.46	9.67e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.06	8.42	0.41	1.05e-15	Arsenic metabolism;
LIHC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg02269571	chr22:50332266	NA	0.58	8.24	0.41	3.71e-15	Schizophrenia;
LIHC	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.5	-7.34	-0.37	1.58e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs10861342	1.000	rs11112380	chr12:105526695	C/T	cg23923672	chr12:105501055	KIAA1033	0.66	7.7	0.38	1.44e-13	IgG glycosylation;
LIHC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2971970	0.539	rs2971972	chr7:133644200	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.8	-0.3	1.52e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4705952	1.000	rs4705952	chr5:131839618	A/G	cg02551604	chr5:131831745	NA	0.39	6.16	0.32	1.99e-9	C-reactive protein levels;
LIHC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.05	12.79	0.57	7.01e-31	Primary sclerosing cholangitis;
LIHC	cis	rs3015497	0.789	rs8003372	chr14:51102351	G/A	cg09863266	chr14:51125203	SAV1	-0.43	-6.85	-0.35	3.53e-11	Mean platelet volume;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.0	-0.31	5.01e-9	Diastolic blood pressure;
LIHC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg17135325	chr3:160939158	NMD3	0.57	8.22	0.41	4.39e-15	Parkinson's disease;
LIHC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg17980119	chr2:219472607	PLCD4	0.36	6.08	0.31	3.14e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg26939375	chr7:64535504	NA	-0.41	-6.5	-0.33	2.79e-10	Aortic root size;
LIHC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.45	6.27	0.32	1.07e-9	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg07423050	chr13:99094983	FARP1	0.35	5.77	0.3	1.8e-8	Longevity;
LIHC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.65	-0.5	4.68e-23	Hemoglobin concentration;
LIHC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.32	-5.85	-0.3	1.16e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-11.17	-0.52	6.71e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg26441486	chr22:50317300	CRELD2	0.37	6.08	0.31	3.19e-9	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.32e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.69	8.45	0.42	8.6e-16	Morning vs. evening chronotype;
LIHC	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.51	-7.4	-0.37	1.08e-12	Mortality in heart failure;
LIHC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	8.94	0.44	2.52e-17	Multiple sclerosis;
LIHC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.8	16.11	0.66	7.72e-44	White blood cell count;
LIHC	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.65	10.72	0.5	2.72e-23	Pediatric autoimmune diseases;
LIHC	cis	rs2273156	0.706	rs8015622	chr14:35487100	G/A	cg16230307	chr14:35515116	FAM177A1	-0.43	-6.19	-0.32	1.68e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12090654	chr8:6424636	MCPH1	0.46	6.78	0.34	5.21e-11	Longevity;
LIHC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.68	0.59	2.81e-34	Lung cancer in ever smokers;
LIHC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.53	-0.38	4.53e-13	Initial pursuit acceleration;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg27313007	chr17:78617750	RPTOR	0.46	6.12	0.31	2.52e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.6	12.77	0.57	8.28e-31	Fat distribution (HIV);
LIHC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.49	6.36	0.33	6.32e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs73186030	0.920	rs73186060	chr3:122052354	T/G	cg13973942	chr17:977984	ABR	0.47	6.06	0.31	3.6e-9	Serum parathyroid hormone levels;
LIHC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.79	0.3	1.63e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.94	-15.35	-0.64	8.07e-41	Platelet count;
LIHC	cis	rs999943	0.739	rs62407633	chr6:33609244	C/T	cg14003231	chr6:33640908	ITPR3	0.43	6.97	0.35	1.64e-11	Obesity (extreme);
LIHC	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg23091122	chr1:110024289	SYPL2	-0.48	-6.54	-0.33	2.3e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.71	12.2	0.55	1.17e-28	Menopause (age at onset);
LIHC	cis	rs3812111	0.506	rs1204837	chr6:116514792	G/A	cg08036074	chr6:116424633	NT5DC1	-0.41	-6.51	-0.33	2.63e-10	Age-related macular degeneration;
LIHC	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg15192750	chr16:69999425	NA	0.44	6.62	0.34	1.42e-10	IgE levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12484590	chr1:156475177	NA	0.5	6.93	0.35	2.1e-11	Pancreatic cancer;
LIHC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg26149184	chr10:133730230	NA	0.48	7.52	0.38	4.79e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.92	0.43	2.9e-17	Prudent dietary pattern;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.72	-10.92	-0.51	4.96e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.33	0.45	1.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs11708189	1.000	rs11708189	chr3:140175360	A/G	cg21073520	chr19:19648991	CILP2	0.35	6.11	0.31	2.65e-9	Sudden cardiac arrest;
LIHC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg19338460	chr6:170058176	WDR27	-0.41	-6.19	-0.32	1.69e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.72	0.34	7.76e-11	Melanoma;
LIHC	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg00277334	chr10:82204260	NA	-0.54	-6.68	-0.34	9.51e-11	Post bronchodilator FEV1;
LIHC	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	0.95	6.93	0.35	2.14e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.65	10.9	0.51	6.12e-24	Psoriasis;
LIHC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg13047869	chr3:10149882	C3orf24	0.51	6.55	0.33	2.05e-10	Alzheimer's disease;
LIHC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg10360323	chr17:41437877	NA	0.41	6.21	0.32	1.52e-9	Menopause (age at onset);
LIHC	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23598886	chr18:12777645	NA	0.48	6.48	0.33	3.27e-10	Inflammatory skin disease;
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.58	-8.5	-0.42	5.96e-16	Blood metabolite levels;
LIHC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-7.18	-0.36	4.5e-12	Crohn's disease;
LIHC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.04	14.97	0.63	2.54e-39	Cognitive function;
LIHC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26734620	chr12:56694298	CS	-1.18	-10.53	-0.49	1.23e-22	Psoriasis vulgaris;
LIHC	trans	rs10777288	0.561	rs4842747	chr12:91400720	G/A	cg03760490	chr1:35245996	GJB3	-0.33	-6.09	-0.31	3e-9	Pulmonary function (smoking interaction);
LIHC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.92	-0.39	3.27e-14	Type 2 diabetes;
LIHC	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.15	-0.48	2.51e-21	Ear protrusion;
LIHC	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-7.99	-0.4	2.13e-14	Pediatric bone mineral density (spine);
LIHC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.67	9.54	0.46	2.87e-19	Coronary artery disease;
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	0.45	8.17	0.4	5.93e-15	Prudent dietary pattern;
LIHC	cis	rs11229555	0.645	rs11229460	chr11:58208343	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg24209194	chr3:40518798	ZNF619	0.56	8.13	0.4	8.15e-15	Renal cell carcinoma;
LIHC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.63	-0.5	5.4e-23	Total cholesterol levels;
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.51	-8.23	-0.41	3.91e-15	Testicular germ cell tumor;
LIHC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.32	-15.3	-0.64	1.29e-40	Diabetic kidney disease;
LIHC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21467203	chr3:49911342	NA	0.53	9.55	0.46	2.58e-19	Body mass index;
LIHC	trans	rs3112255	1.000	rs3112255	chr2:101317260	C/A	cg06958034	chr1:23346203	KDM1A	-0.46	-6.05	-0.31	3.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	0.57	10.45	0.49	2.25e-22	Fat distribution (HIV);
LIHC	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.61	-11.01	-0.51	2.52e-24	Breast cancer;
LIHC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	1.04	14.7	0.62	3.06e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-1.06	-16.34	-0.66	9.22e-45	Uric acid levels;
LIHC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.96	-0.31	6.37e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.51	-0.42	5.56e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg24585782	chr17:78113791	EIF4A3	-0.46	-6.27	-0.32	1.06e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	trans	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg19894588	chr14:64061835	NA	-0.69	-10.02	-0.48	7.07e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.99	0.31	5.44e-9	Educational attainment;
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.72	-0.34	7.62e-11	Lymphocyte counts;
LIHC	trans	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg01134436	chr17:81009848	B3GNTL1	0.76	6.36	0.33	6.62e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.39	-0.49	3.83e-22	Platelet count;
LIHC	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.92	-0.3	7.85e-9	Colorectal cancer;
LIHC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.29	-0.37	2.13e-12	Breast cancer;
LIHC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.96	9.07	0.44	9.55e-18	Cognitive function;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.45	6.51	0.33	2.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.44	7.02	0.35	1.22e-11	Morning vs. evening chronotype;
LIHC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3736594	0.513	rs59876138	chr2:27792323	A/C	cg27432699	chr2:27873401	GPN1	0.46	6.76	0.34	6.12e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs4919087	0.748	rs701814	chr10:98975719	C/T	cg25902810	chr10:99078978	FRAT1	-0.53	-6.21	-0.32	1.55e-9	Monocyte count;
LIHC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.98	-18.34	-0.7	8.37e-53	Breast cancer;
LIHC	cis	rs17776563	0.887	rs72763807	chr15:89131572	T/C	cg05013243	chr15:89149849	MIR1179	0.41	6.81	0.35	4.45e-11	Thyroid hormone levels;
LIHC	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.5	-7.53	-0.38	4.55e-13	Diastolic blood pressure;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16202803	chr2:240014758	HDAC4	0.43	6.37	0.33	6.07e-10	Bilirubin levels;
LIHC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.48	7.84	0.39	5.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2224391	0.822	rs2773321	chr6:5262220	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-5.96	-0.31	6.36e-9	Height;
LIHC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs911119	0.954	rs2254635	chr20:23622758	G/T	cg16589663	chr20:23618590	CST3	0.71	7.58	0.38	3.25e-13	Chronic kidney disease;
LIHC	cis	rs11955398	0.716	rs2409792	chr5:59998236	A/G	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.44	6.26	0.32	1.18e-9	Aortic root size;
LIHC	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-6.81	-0.35	4.51e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg16070018	chr6:26224392	HIST1H3E	0.57	6.81	0.35	4.47e-11	Gout;Renal underexcretion gout;
LIHC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	0.6	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs79976124	0.797	rs2226266	chr6:66617302	C/T	cg07460842	chr6:66804631	NA	0.62	6.18	0.32	1.85e-9	Type 2 diabetes;
LIHC	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.24	-0.45	2.68e-18	Red blood cell count;
LIHC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.52	6.54	0.33	2.2e-10	Coronary artery calcification;
LIHC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.44	-6.11	-0.31	2.74e-9	Initial pursuit acceleration;
LIHC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.96	-16.56	-0.67	1.22e-45	Schizophrenia;
LIHC	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg08916839	chr5:415575	AHRR	0.5	10.55	0.5	1.06e-22	Fat distribution (HIV);
LIHC	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs4766646	0.757	rs4766641	chr12:110301492	T/A	cg12870014	chr12:110450643	ANKRD13A	0.36	6.22	0.32	1.42e-9	Metabolite levels (MHPG);
LIHC	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.56	8.78	0.43	7.72e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.34	-7.4	-0.37	1.03e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.46	8.07	0.4	1.23e-14	N-glycan levels;
LIHC	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.87	10.9	0.51	6.08e-24	Prostate cancer;
LIHC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.36	5.71	0.3	2.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg21747090	chr2:27597821	SNX17	-0.41	-5.92	-0.31	7.64e-9	Total body bone mineral density;
LIHC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-6.18	-0.32	1.82e-9	Testicular germ cell tumor;
LIHC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.46	6.27	0.32	1.09e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.18	-0.36	4.24e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.83	0.54	2.7e-27	Motion sickness;
LIHC	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.76	13.09	0.58	5.31e-32	Eosinophil percentage of white cells;
LIHC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.12	24.6	0.8	1.17e-77	Cognitive ability;
LIHC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg00277334	chr10:82204260	NA	-0.53	-6.76	-0.34	6.08e-11	Post bronchodilator FEV1;
LIHC	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.6	9.98	0.48	9.08e-21	HDL cholesterol;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg14257396	chr1:107603778	NA	-0.37	-6.1	-0.31	2.79e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg03207436	chr5:125937141	PHAX	0.4	6.09	0.31	3.04e-9	Morning vs. evening chronotype;
LIHC	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-0.86	-7.94	-0.39	2.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.57	-8.69	-0.43	1.56e-16	Blood protein levels;
LIHC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg26138144	chr22:38071188	LGALS1	0.71	13.26	0.58	1.16e-32	Fat distribution (HIV);
LIHC	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg05315195	chr6:109294784	ARMC2	-0.53	-5.75	-0.3	1.99e-8	Prostate cancer;
LIHC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.08	-0.31	3.23e-9	Menarche (age at onset);
LIHC	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg16586182	chr3:47516702	SCAP	0.51	9.01	0.44	1.45e-17	Colorectal cancer;
LIHC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-14.73	-0.62	2.22e-38	Refractive error;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.58	-0.34	1.77e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.55	-13.21	-0.58	1.75e-32	White blood cell count (basophil);
LIHC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.11	-0.31	2.79e-9	Aortic root size;
LIHC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.7	6.31	0.32	8.68e-10	Mean corpuscular hemoglobin;
LIHC	cis	rs733592	0.599	rs12819124	chr12:48409054	G/T	cg21466736	chr12:48725269	NA	-0.34	-5.74	-0.3	2.13e-8	Plateletcrit;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg25970120	chr1:39325951	RRAGC	-0.41	-6.07	-0.31	3.45e-9	Body mass index;
LIHC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.61	5.72	0.3	2.38e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	-0.63	-9.99	-0.48	8.8e-21	Inflammatory bowel disease;
LIHC	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs1914816	0.878	rs2456078	chr15:76558870	T/C	cg03037974	chr15:76606532	NA	-0.61	-6.36	-0.33	6.48e-10	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.68	10.19	0.48	1.78e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7575217	0.697	rs796067	chr2:101707009	C/T	cg23907051	chr2:101730305	TBC1D8	-0.25	-5.8	-0.3	1.51e-8	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-7.07	-0.36	8.87e-12	Type 2 diabetes;
LIHC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-8.88	-0.43	3.73e-17	Pancreatic cancer;
LIHC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.28	0.32	1e-9	Schizophrenia;
LIHC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17507749	chr15:85114479	UBE2QP1	0.62	7.09	0.36	7.9e-12	Schizophrenia;
LIHC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.47	-7.55	-0.38	3.9e-13	Neurofibrillary tangles;
LIHC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg13319975	chr6:146136371	FBXO30	-0.35	-5.84	-0.3	1.23e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4930561	0.714	rs6591335	chr11:67976812	T/C	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.75	-0.3	1.97e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LIHC	trans	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg17675199	chr6:35436792	RPL10A	0.35	6.88	0.35	2.81e-11	Coronary artery disease;
LIHC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg12798992	chr6:167411361	FGFR1OP	0.49	7.54	0.38	4.33e-13	Crohn's disease;
LIHC	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.5	-7.39	-0.37	1.12e-12	Mortality in heart failure;
LIHC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-5.98	-0.31	5.48e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1144333	1.000	rs12410724	chr1:76459134	A/G	cg03433033	chr1:76189801	ACADM	0.51	7.58	0.38	3.18e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.73	0.43	1.11e-16	Platelet count;
LIHC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08392591	chr16:89556376	ANKRD11	0.45	6.8	0.35	4.62e-11	Multiple myeloma (IgH translocation);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04174309	chr11:117102980	RNF214;PCSK7	0.49	6.32	0.32	8.34e-10	Lung function (FEV1/FVC);
LIHC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.23	0.64	2.5e-40	Menopause (age at onset);
LIHC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg23461800	chr14:103021989	NA	-0.43	-5.96	-0.31	6.39e-9	Platelet count;
LIHC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	5.73	0.3	2.19e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs16944613	0.588	rs6496697	chr15:91131832	C/T	cg26821196	chr15:91095069	CRTC3	-0.45	-7.78	-0.39	8.81e-14	Colorectal cancer;
LIHC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.37	6.87	0.35	3.11e-11	Testicular germ cell tumor;
LIHC	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-6.08	-0.31	3.19e-9	IFN-related cytopenia;
LIHC	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.76	0.3	1.91e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs539514	0.690	rs585233	chr13:76317973	A/G	cg04757411	chr13:76259545	LMO7	0.45	7.92	0.39	3.41e-14	Type 1 diabetes;
LIHC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.36	-0.37	1.35e-12	Diabetic kidney disease;
LIHC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.57	8.62	0.42	2.49e-16	Lymphocyte counts;
LIHC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.25	-0.36	2.82e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.44	7.23	0.36	3.16e-12	Red blood cell count;
LIHC	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg03263716	chr11:64435066	NRXN2	0.32	6.82	0.35	4.03e-11	Body mass index;Urate levels;
LIHC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.08	0.51	1.43e-24	Hemoglobin concentration;
LIHC	cis	rs4699052	0.928	rs2866642	chr4:104213866	T/G	cg16532752	chr4:104119610	CENPE	-0.4	-6.3	-0.32	9.07e-10	Testicular germ cell tumor;
LIHC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg25364880	chr3:44379878	C3orf23	0.43	6.15	0.32	2.13e-9	Depressive symptoms;
LIHC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.05e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg26338869	chr17:61819248	STRADA	0.43	6.15	0.32	2.13e-9	Prudent dietary pattern;
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.93	16.1	0.66	8.23e-44	Longevity;
LIHC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.59	0.5	7.35e-23	Personality dimensions;
LIHC	cis	rs17106184	1.000	rs57412341	chr1:51310327	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.52	-0.33	2.47e-10	Type 2 diabetes;
LIHC	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.46	7.11	0.36	6.82e-12	Diastolic blood pressure;
LIHC	cis	rs8056893	0.714	rs4783554	chr16:68384010	A/G	cg02226672	chr16:68398533	SMPD3	0.44	6.31	0.32	8.55e-10	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.24	-0.32	1.33e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs17401966	0.522	rs7368073	chr1:10314962	G/T	cg19773385	chr1:10388646	KIF1B	-0.34	-6.13	-0.31	2.44e-9	Hepatocellular carcinoma;
LIHC	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg18898632	chr2:242989856	NA	-0.47	-6.51	-0.33	2.7e-10	Obesity-related traits;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.9	-0.3	8.51e-9	Menopause (age at onset);
LIHC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.27	-6.79	-0.34	4.91e-11	Mean corpuscular volume;
LIHC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.59	9.85	0.47	2.65e-20	Lung cancer;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg24115593	chr5:169010705	CCDC99	-0.55	-6.33	-0.32	7.92e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg16479474	chr6:28041457	NA	0.4	6.22	0.32	1.48e-9	Parkinson's disease;
LIHC	cis	rs77861329	1.000	rs9843852	chr3:52132029	C/G	cg08692210	chr3:52188851	WDR51A	0.82	8.02	0.4	1.65e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.18	0.55	1.41e-28	Height;
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg08469215	chr1:156261351	TMEM79	0.4	6.55	0.33	2.1e-10	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.52	8.44	0.41	9.43e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.13	-0.31	2.36e-9	Aortic root size;
LIHC	cis	rs77861329	1.000	rs9817653	chr3:52148233	T/G	cg08692210	chr3:52188851	WDR51A	0.83	7.85	0.39	5.47e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs1256061	0.533	rs2357479	chr14:64792764	G/T	cg23250157	chr14:64679961	SYNE2	0.42	6.2	0.32	1.6e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg22777020	chr22:31556080	RNF185	0.56	6.41	0.33	4.78e-10	Colorectal cancer;
LIHC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.76	7.38	0.37	1.17e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.66	12.8	0.57	6.17e-31	Lymphocyte percentage of white cells;
LIHC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.72	11.15	0.52	7.79e-25	Eye color traits;
LIHC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.64	12.97	0.57	1.43e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.57	7.88	0.39	4.45e-14	Aortic root size;
LIHC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.24	-0.36	2.96e-12	Reticulocyte count;
LIHC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.58	0.38	3.36e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg20487152	chr13:99095054	FARP1	-0.37	-6.17	-0.32	1.96e-9	Neuroticism;
LIHC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	1.13	13.99	0.6	1.79e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.06	-0.4	1.3e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.77	0.34	5.55e-11	Menopause (age at onset);
LIHC	cis	rs10420951	0.617	rs75245298	chr19:18581227	T/C	cg10790698	chr19:18539756	SSBP4	-0.42	-5.83	-0.3	1.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	9.5	0.46	3.88e-19	Lung cancer;
LIHC	cis	rs611744	0.967	rs650437	chr8:109210927	T/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.42	6.6	0.34	1.58e-10	Menopause (age at onset);
LIHC	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-10.17	-0.48	2.14e-21	Coronary artery disease;
LIHC	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.53	8.44	0.42	8.86e-16	Dialysis-related mortality;
LIHC	cis	rs2070433	0.851	rs10854484	chr21:47926702	T/C	cg12379764	chr21:47803548	PCNT	0.6	8.76	0.43	9.25e-17	Lymphocyte counts;
LIHC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg14092571	chr14:90743983	NA	0.42	6.52	0.33	2.52e-10	Mortality in heart failure;
LIHC	cis	rs9513627	0.834	rs73556197	chr13:100128479	A/G	cg25919922	chr13:100150906	NA	-0.77	-6.89	-0.35	2.74e-11	Obesity-related traits;
LIHC	cis	rs9473924	0.542	rs56240592	chr6:50815514	T/A	cg14470998	chr6:50812995	TFAP2B	0.98	11.12	0.52	9.6e-25	Body mass index;
LIHC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.5	-0.49	1.53e-22	Coronary artery disease;
LIHC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.4	7.18	0.36	4.42e-12	Psoriasis;
LIHC	trans	rs6934970	1.000	rs12196593	chr6:113022033	T/A	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg06289844	chr6:126071538	HEY2	0.36	6.15	0.32	2.2e-9	Brugada syndrome;
LIHC	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.26	0.37	2.6e-12	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.87	-12.17	-0.55	1.44e-28	Diastolic blood pressure;
LIHC	cis	rs1000083	0.748	rs4413553	chr5:96621221	A/G	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.62	-11.33	-0.52	1.76e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.57	-9.78	-0.47	4.48e-20	Colorectal cancer;
LIHC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20011983	chr2:74347215	NA	-0.39	-5.86	-0.3	1.08e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.6	-10.51	-0.49	1.41e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.56	-13.91	-0.6	3.75e-35	White blood cell count (basophil);
LIHC	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.43	6.45	0.33	3.91e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs12644436	0.576	rs13151968	chr4:88784874	T/C	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg10820045	chr2:198174542	NA	0.56	8.88	0.43	3.78e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7534824	0.625	rs61780288	chr1:101389945	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	7.07	0.36	8.96e-12	Refractive astigmatism;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.17	-0.32	1.91e-9	Total body bone mineral density;
LIHC	cis	rs4908768	0.501	rs11121201	chr1:8632791	A/T	cg20416874	chr1:8611966	RERE	-0.69	-14.54	-0.62	1.22e-37	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.81	0.39	7.04e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7091068	0.671	rs517785	chr10:95403973	G/A	cg20715218	chr10:95462985	C10orf4	-0.62	-6.81	-0.35	4.3e-11	Urinary tract infection frequency;
LIHC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.51	0.33	2.68e-10	Mean corpuscular volume;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg06850467	chr2:110371607	SEPT10;ANKRD57	0.36	6.15	0.32	2.14e-9	Electroencephalogram traits;
LIHC	cis	rs2607426	0.579	rs2644917	chr19:41287007	G/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-6.18	-0.32	1.77e-9	Blood protein levels;
LIHC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.78	12.96	0.57	1.55e-31	Coronary artery disease;
LIHC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.08	-0.31	3.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg22395253	chr7:104941898	SRPK2	0.44	6.38	0.33	5.7e-10	Immature fraction of reticulocytes;
LIHC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.57	8.98	0.44	1.85e-17	Height;
LIHC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.35	-7.16	-0.36	5.02e-12	Colorectal cancer;
LIHC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.35	5.77	0.3	1.82e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.26	-0.37	2.7e-12	Schizophrenia;
LIHC	cis	rs12079745	0.793	rs12071630	chr1:169421023	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.75	-6.78	-0.34	5.28e-11	QT interval;
LIHC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.41	-0.37	9.78e-13	Response to antipsychotic treatment;
LIHC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-0.79	-7.0	-0.35	1.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.84	0.51	9.48e-24	Lung cancer in ever smokers;
LIHC	cis	rs3780378	0.967	rs7043371	chr9:5040203	T/A	cg02405213	chr9:5042618	JAK2	-0.56	-9.87	-0.47	2.18e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg26395211	chr5:140044315	WDR55	-0.4	-5.96	-0.31	6.39e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.97	-17.95	-0.7	3.2e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs10197940	0.901	rs2290367	chr2:152266731	T/A	cg19508488	chr2:152266495	RIF1	0.74	12.6	0.56	3.68e-30	Lung cancer;
LIHC	cis	rs72627509	0.587	rs17087401	chr4:57901155	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-7.29	-0.37	2.23e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-0.79	-9.04	-0.44	1.22e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg10360323	chr17:41437877	NA	0.41	6.09	0.31	3.1e-9	Menopause (age at onset);
LIHC	trans	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg10756647	chr7:56101905	PSPH	-1.07	-13.17	-0.58	2.44e-32	Diabetic kidney disease;
LIHC	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs860295	0.812	rs10908481	chr1:155713650	T/G	cg02153340	chr1:155202674	NA	-0.35	-6.3	-0.32	9.36e-10	Body mass index;
LIHC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg21252483	chr19:49399788	TULP2	-0.84	-9.78	-0.47	4.41e-20	Red cell distribution width;
LIHC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg23625390	chr15:77176239	SCAPER	0.36	5.93	0.31	7.52e-9	Blood metabolite levels;
LIHC	cis	rs4970966	0.904	rs12131809	chr1:150544640	C/T	cg18016565	chr1:150552671	MCL1	-0.43	-6.26	-0.32	1.14e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg21452805	chr1:244014465	NA	0.42	5.75	0.3	1.96e-8	RR interval (heart rate);
LIHC	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.64	7.39	0.37	1.14e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.86	-0.47	2.47e-20	Tonsillectomy;
LIHC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.77	-0.39	9.35e-14	Tonsillectomy;
LIHC	cis	rs2016586	0.561	rs5755929	chr22:36118302	G/A	cg26342177	chr22:36113512	APOL5	-0.35	-5.82	-0.3	1.32e-8	Body mass index;
LIHC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.61	9.31	0.45	1.58e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.39	7.03	0.36	1.16e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.73	-0.39	1.2e-13	Bipolar disorder;
LIHC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-5.74	-0.3	2.04e-8	Systolic blood pressure;
LIHC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	0.78	13.12	0.58	3.8e-32	Total cholesterol levels;
LIHC	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-6.18	-0.32	1.81e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.34	0.32	7.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.66	0.34	1.11e-10	Lung cancer in ever smokers;
LIHC	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.66	-0.42	1.92e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg10241871	chr14:102965420	TECPR2	0.43	6.77	0.34	5.46e-11	Plateletcrit;
LIHC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.69	6.8	0.35	4.72e-11	Plasma clusterin levels;
LIHC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06634786	chr22:41940651	POLR3H	0.57	6.26	0.32	1.12e-9	Vitiligo;
LIHC	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25632853	chr15:73088954	NA	0.39	6.47	0.33	3.38e-10	Triglyceride levels;
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg00656387	chr3:40428638	ENTPD3	-0.43	-7.43	-0.37	8.99e-13	Renal cell carcinoma;
LIHC	cis	rs7502590	1.000	rs7502590	chr17:79082081	A/G	cg02064366	chr17:79045526	BAIAP2	0.53	6.25	0.32	1.19e-9	Neuroticism;
LIHC	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.16	-0.36	4.88e-12	Diabetic kidney disease;
LIHC	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg08992911	chr2:238395768	MLPH	0.49	5.95	0.31	6.48e-9	Prostate cancer;
LIHC	cis	rs2412488	0.927	rs10021541	chr4:54286095	G/A	cg22241045	chr4:54363911	LNX1	-0.42	-6.87	-0.35	3.02e-11	DNA methylation (variation);
LIHC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.46	-6.12	-0.31	2.5e-9	Major depressive disorder;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21448741	chr8:58168803	NA	0.35	6.45	0.33	3.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg09033563	chr22:24373618	LOC391322	0.44	6.35	0.32	6.88e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg01364799	chr7:75623366	TMEM120A	0.52	7.84	0.39	5.66e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.04	0.36	1.08e-11	HDL cholesterol;
LIHC	cis	rs7238033	0.624	rs9946998	chr18:43312822	C/T	cg20610511	chr18:43302872	SLC14A1	0.37	6.24	0.32	1.31e-9	Bladder cancer;
LIHC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.87	14.28	0.61	1.25e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.51	7.93	0.39	3.14e-14	Pulse pressure;
LIHC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.4	0.52	1.01e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3015497	0.789	rs11621971	chr14:51124527	C/T	cg09863266	chr14:51125203	SAV1	0.41	6.58	0.34	1.81e-10	Mean platelet volume;
LIHC	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg07952391	chr2:88470173	THNSL2	0.76	7.15	0.36	5.22e-12	Plasma clusterin levels;
LIHC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.62	-10.23	-0.48	1.35e-21	Obesity-related traits;
LIHC	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.15e-10	Putamen volume;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17042098	chr1:61519631	NA	0.44	6.84	0.35	3.66e-11	Bilirubin levels;
LIHC	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.44	-7.41	-0.37	1.01e-12	Schizophrenia;
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg21877656	chr19:58662188	ZNF329	1.07	8.24	0.41	3.82e-15	Cholesterol, total;
LIHC	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg20129853	chr10:51489980	NA	0.39	8.81	0.43	6.29e-17	Prostate-specific antigen levels;
LIHC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.6	-0.38	2.8e-13	Glioblastoma;
LIHC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.59	-0.42	3.06e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg05941027	chr17:61774174	LIMD2	0.32	6.61	0.34	1.52e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg09597638	chr17:3907349	NA	-0.46	-6.41	-0.33	4.88e-10	Type 2 diabetes;
LIHC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.12	0.4	8.57e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.55	7.12	0.36	6.57e-12	Parkinson's disease;
LIHC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.64	11.16	0.52	7.27e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs2016586	0.894	rs4821432	chr22:36100896	G/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.24	-0.32	1.3e-9	Body mass index;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06420487	chr17:61919686	SMARCD2	0.43	5.79	0.3	1.6e-8	Height;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12516959	chr21:47718080	NA	-0.39	-6.18	-0.32	1.77e-9	Testicular germ cell tumor;
LIHC	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.35	-6.01	-0.31	4.63e-9	HIV-1 susceptibility;
LIHC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.49e-29	Menopause (age at onset);
LIHC	cis	rs75908454	1.000	rs79951072	chr6:169830051	C/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.77	-0.39	9.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg21734168	chr11:67353974	GSTP1	-0.28	-6.85	-0.35	3.37e-11	Mean corpuscular volume;
LIHC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.73e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.26	-6.88	-0.35	2.9100000000000002e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.52	6.25	0.32	1.25e-9	Alzheimer's disease;
LIHC	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.54	-0.33	2.29e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03239638	chr21:37529510	NA	-0.44	-6.14	-0.32	2.29e-9	Cognitive function;
LIHC	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	9.5	0.46	3.64e-19	Mean platelet volume;
LIHC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.64	-10.84	-0.51	1.02e-23	Menopause (age at onset);
LIHC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.59	-10.36	-0.49	4.57e-22	Platelet distribution width;
LIHC	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.32	-0.32	7.99e-10	Coronary artery disease;
LIHC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.98	-11.29	-0.52	2.41e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.89	-17.31	-0.68	1.19e-48	Height;
LIHC	cis	rs6967414	0.605	rs7786706	chr7:6747267	C/T	cg00387323	chr7:6746715	ZNF12	0.52	6.05	0.31	3.81e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-13.42	-0.59	2.69e-33	Coffee consumption (cups per day);
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12016809	chr21:47604291	C21orf56	-0.43	-6.44	-0.33	4.17e-10	Testicular germ cell tumor;
LIHC	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.58	0.42	3.3e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.69	-10.94	-0.51	4.22e-24	Cognitive test performance;
LIHC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg25024717	chr12:54324583	NA	-0.31	-6.16	-0.32	2.03e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.48	6.81	0.35	4.28e-11	Blood metabolite levels;
LIHC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.51	7.46	0.37	7.02e-13	Total body bone mineral density;
LIHC	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg03146154	chr1:46216737	IPP	-0.39	-6.41	-0.33	4.79e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9649465	0.967	rs6966470	chr7:123299855	C/T	cg03229431	chr7:123269106	ASB15	0.36	7.56	0.38	3.81e-13	Migraine;
LIHC	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-7.55	-0.38	4.02e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04243181	chr16:15951195	MYH11	-0.35	-6.12	-0.31	2.58e-9	Immature fraction of reticulocytes;
LIHC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.48	6.68	0.34	9.95e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.58	7.47	0.37	6.87e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.85	8.09	0.4	1.04e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg03645007	chr3:50255295	SLC38A3	0.52	6.91	0.35	2.42e-11	Schizophrenia;
LIHC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.57	11.2	0.52	5.05e-25	Coronary artery disease;
LIHC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.4	7.62	0.38	2.52e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.29	-5.99	-0.31	5.36e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	7.76	0.39	1.01e-13	Adiposity;
LIHC	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg00292662	chr22:38071168	LGALS1	0.39	6.63	0.34	1.35e-10	Fat distribution (HIV);
LIHC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.56	8.72	0.43	1.21e-16	White matter hyperintensity burden;
LIHC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg16070018	chr6:26224392	HIST1H3E	-0.57	-7.12	-0.36	6.51e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.38	6.28	0.32	1.06e-9	Lewy body disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19701416	chr10:28592092	NA	0.43	7.1	0.36	7.28e-12	Cognitive function;
LIHC	cis	rs8053891	0.673	rs35338546	chr16:72022156	C/T	cg01557791	chr16:72042693	DHODH	-0.45	-6.64	-0.34	1.2e-10	Coronary artery disease;
LIHC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.5	10.53	0.49	1.2e-22	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.58	8.16	0.4	6.31e-15	Aortic root size;
LIHC	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg06533319	chr4:3265114	C4orf44	0.33	5.92	0.3	7.81e-9	Parental longevity (mother's age at death);
LIHC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.22	-10.2	-0.48	1.65e-21	Hip circumference adjusted for BMI;
LIHC	cis	rs2302190	0.882	rs3744111	chr17:56607959	G/A	cg12560992	chr17:57184187	TRIM37	0.69	8.88	0.43	3.9e-17	Vitamin D levels;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs7116495	1.000	rs541022	chr11:71783056	G/A	cg26138937	chr11:71823887	C11orf51	-0.7	-6.95	-0.35	1.85e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.84	-9.85	-0.47	2.51e-20	Primary sclerosing cholangitis;
LIHC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.58	10.36	0.49	4.68e-22	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg07541023	chr7:19748670	TWISTNB	0.41	6.09	0.31	3.03e-9	Thyroid stimulating hormone;
LIHC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.5	8.58	0.42	3.41e-16	Methadone dose in opioid dependence;
LIHC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.34	7.51	0.38	5.22e-13	Ulcerative colitis;
LIHC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.79	12.79	0.57	6.86e-31	Cognitive test performance;
LIHC	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg03934865	chr2:198174659	NA	-0.53	-8.06	-0.4	1.29e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg01148741	chr2:96811453	DUSP2	0.38	6.12	0.31	2.51e-9	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs2191566	0.664	rs7251083	chr19:44551866	G/T	cg20607764	chr19:44506953	ZNF230	-0.37	-6.25	-0.32	1.21e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.41	-7.38	-0.37	1.18e-12	Aortic root size;
LIHC	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.55	8.37	0.41	1.54e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg07451762	chr16:28383216	NA	-0.36	-6.36	-0.33	6.5e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.61	7.49	0.38	6.11e-13	Exhaled nitric oxide output;
LIHC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.03e-32	Psoriasis;
LIHC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg04013166	chr16:89971882	TCF25	0.53	6.67	0.34	1.04e-10	Skin colour saturation;
LIHC	cis	rs992157	0.730	rs2891078	chr2:219184432	C/T	cg00012203	chr2:219082015	ARPC2	0.75	10.52	0.49	1.33e-22	Colorectal cancer;
LIHC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.09	-0.36	7.75e-12	Personality dimensions;
LIHC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.11	0.52	1.04e-24	Platelet count;
LIHC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.47	7.11	0.36	6.62e-12	Personality dimensions;
LIHC	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.32	7.67	0.38	1.81e-13	Corneal astigmatism;
LIHC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.56	9.15	0.44	5.27e-18	Lymphocyte counts;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24136288	chr17:43183150	NMT1	0.44	6.6	0.34	1.57e-10	Longevity;
LIHC	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	19.53	0.73	1.31e-57	Colorectal cancer;
LIHC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.64	9.97	0.47	1.04e-20	Tonsillectomy;
LIHC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-10.74	-0.5	2.2e-23	Alzheimer's disease;
LIHC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.75	0.3	1.93e-8	Menopause (age at onset);
LIHC	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg10523679	chr1:76189770	ACADM	0.46	6.69	0.34	9.02e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.42	7.67	0.38	1.79e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.25	19.27	0.72	1.53e-56	Type 1 diabetes nephropathy;
LIHC	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.52	9.68	0.46	9.28e-20	Testicular germ cell tumor;
LIHC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.46	-6.54	-0.33	2.3e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg14930904	chr10:32216787	ARHGAP12	0.4	7.02	0.35	1.21e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.09	0.36	7.92e-12	Self-reported allergy;
LIHC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-7.6	-0.38	2.81e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.75	-8.53	-0.42	4.65e-16	Vitiligo;
LIHC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg23461800	chr14:103021989	NA	-0.45	-6.16	-0.32	2.03e-9	Platelet count;
LIHC	cis	rs611744	0.752	rs609197	chr8:109234035	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs7619427	0.544	rs9872047	chr3:43991630	C/T	cg24966902	chr3:44043705	NA	0.44	6.67	0.34	1.03e-10	Schizophrenia;
LIHC	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.81	-0.3	1.45e-8	Alcohol dependence;
LIHC	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg06359132	chr10:99160096	RRP12	-0.37	-5.93	-0.31	7.28e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4728302	0.838	rs7798804	chr7:133584085	C/T	cg10665199	chr7:133106180	EXOC4	0.36	6.28	0.32	1.04e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg25344623	chr2:136566232	LCT	0.39	7.26	0.37	2.66e-12	Mosquito bite size;
LIHC	cis	rs4650994	0.517	rs2761473	chr1:178609758	A/C	cg05350800	chr1:178550844	NA	-0.28	-6.02	-0.31	4.6e-9	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26949087	chr2:26467503	HADHB;HADHA	0.5	6.62	0.34	1.42e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.47	-6.85	-0.35	3.52e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.47e-18	Bipolar disorder;
LIHC	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	11.08	0.51	1.35e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs77637988	0.578	rs12328506	chr2:48623184	C/T	cg00032884	chr2:48540671	FOXN2	0.37	5.77	0.3	1.77e-8	Joint mobility (Beighton score);
LIHC	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.51	9.78	0.47	4.46e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg03013999	chr17:37608204	MED1	0.35	5.8	0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg02503808	chr4:7069936	GRPEL1	-0.73	-10.36	-0.49	4.54e-22	Monocyte percentage of white cells;
LIHC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.79	-0.34	5e-11	Menarche (age at onset);
LIHC	cis	rs1664789	1.000	rs1664786	chr5:53281711	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.68	0.42	1.61e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.65	7.92	0.39	3.46e-14	Heart rate;
LIHC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.56	7.64	0.38	2.23e-13	Coronary artery disease;
LIHC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.58	11.28	0.52	2.63e-25	Coronary artery disease;
LIHC	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg01864836	chr14:55583639	NA	-0.37	-6.7	-0.34	8.37e-11	Protein biomarker;
LIHC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.89	-17.53	-0.69	1.56e-49	Height;
LIHC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg07636037	chr3:49044803	WDR6	-0.79	-8.19	-0.4	5.34e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.29	-7.26	-0.37	2.65e-12	Longevity;Endometriosis;
LIHC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.88	0.3	9.88e-9	Electroencephalogram traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20777956	chr18:60987812	BCL2	0.46	6.77	0.34	5.6e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02905964	chr19:29704262	UQCRFS1	0.5	6.81	0.35	4.42e-11	Lung function (FEV1/FVC);
LIHC	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.35	0.32	6.93e-10	Hepatocellular carcinoma;
LIHC	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg03989125	chr22:38214979	NA	-0.43	-5.99	-0.31	5.38e-9	Glioblastoma;Glioma;
LIHC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.31	-6.7	-0.34	8.83e-11	Longevity;
LIHC	cis	rs2997447	0.846	rs3008226	chr1:26394997	A/C	cg19633962	chr1:26362018	EXTL1	-0.58	-6.53	-0.33	2.37e-10	QRS complex (12-leadsum);
LIHC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.61	8.84	0.43	5.27e-17	Mood instability;
LIHC	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.44	0.64	3.5e-41	Electrocardiographic conduction measures;
LIHC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg16736954	chr20:23401023	NAPB	-0.7	-8.4	-0.41	1.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg11264863	chr20:43835661	SEMG1	-0.47	-5.8	-0.3	1.51e-8	Blood protein levels;
LIHC	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg22705602	chr4:152727874	NA	-0.3	-6.15	-0.32	2.17e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg03934865	chr2:198174659	NA	-0.62	-10.19	-0.48	1.88e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg03859395	chr2:55845619	SMEK2	0.78	13.22	0.58	1.57e-32	Metabolic syndrome;
LIHC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.5	-7.22	-0.36	3.4e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.06	-0.31	3.65e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02290350	chr8:58132656	NA	0.5	9.72	0.47	7.22e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-8.03	-0.4	1.59e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.44	0.42	9.04e-16	Lung cancer in ever smokers;
LIHC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.49	9.09	0.44	8.42e-18	Hemoglobin concentration;
LIHC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7945718	0.621	rs6485992	chr11:12697359	C/T	cg25843174	chr11:12811716	TEAD1	0.35	8.06	0.4	1.31e-14	Educational attainment (years of education);
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-11.84	-0.54	2.5e-27	Prudent dietary pattern;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-9.74	-0.47	5.95e-20	Skin colour saturation;
LIHC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17554472	chr22:41940697	POLR3H	0.57	6.4	0.33	5.26e-10	Vitiligo;
LIHC	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.04	-0.36	1.05e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	12.96	0.57	1.6e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.52	-6.95	-0.35	1.85e-11	Vitiligo;
LIHC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.31	-0.32	8.82e-10	Bipolar disorder;
LIHC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg06289844	chr6:126071538	HEY2	0.39	6.79	0.34	5.05e-11	Brugada syndrome;
LIHC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	8.02	0.4	1.66e-14	Mean platelet volume;
LIHC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg07599136	chr5:415885	AHRR	-0.55	-8.68	-0.42	1.61e-16	Fat distribution (HIV);
LIHC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.58	6.47	0.33	3.44e-10	Axial length;
LIHC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.52	6.47	0.33	3.34e-10	Body mass index;
LIHC	cis	rs1823913	1.000	rs4853568	chr2:192126190	G/A	cg12404831	chr2:192114017	MYO1B	-0.34	-6.72	-0.34	7.51e-11	Obesity-related traits;
LIHC	cis	rs1823913	1.000	rs4853561	chr2:192107706	T/C	cg12404831	chr2:192114017	MYO1B	-0.34	-6.83	-0.35	3.85e-11	Obesity-related traits;
LIHC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.41	6.31	0.32	8.62e-10	Educational attainment;
LIHC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-10.89	-0.51	6.62e-24	Chronic sinus infection;
LIHC	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.16	-0.4	6.51e-15	Body mass index;
LIHC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.4	-6.18	-0.32	1.78e-9	Menarche (age at onset);
LIHC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.61	10.14	0.48	2.74e-21	Lymphocyte counts;
LIHC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.89	-0.3	9.44e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-6.35	-0.32	6.89e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	1.14	13.45	0.59	2.16e-33	Eosinophil percentage of granulocytes;
LIHC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.23e-16	Schizophrenia;
LIHC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	18.33	0.7	8.9e-53	Tonsillectomy;
LIHC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.18	0.44	4.13e-18	Bipolar disorder;
LIHC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg03037974	chr15:76606532	NA	0.7	13.64	0.59	4.13e-34	Blood metabolite levels;
LIHC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.54	7.49	0.38	6.12e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.93	16.94	0.68	3.74e-47	Parkinson's disease;
LIHC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.91	16.74	0.67	2.23e-46	Bone mineral density;
LIHC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.76	-6.31	-0.32	8.76e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.39	9.57	0.46	2.29e-19	Blood metabolite ratios;
LIHC	cis	rs17711722	0.583	rs11768292	chr7:65474801	G/T	cg26939375	chr7:64535504	NA	-0.44	-6.04	-0.31	4e-9	Calcium levels;
LIHC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.81	12.18	0.55	1.31e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7224685	0.569	rs28481302	chr17:4011527	T/G	cg09695851	chr17:3907499	NA	0.61	6.94	0.35	2.02e-11	Type 2 diabetes;
LIHC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.57	8.0	0.4	2e-14	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.75	6.38	0.33	5.71e-10	Uric acid levels;
LIHC	cis	rs17152411	0.625	rs10751611	chr10:126658893	A/G	cg07906193	chr10:126599966	NA	-0.3	-5.94	-0.31	7.03e-9	Height;
LIHC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.49	7.27	0.37	2.4e-12	Asthma (sex interaction);
LIHC	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg20891283	chr12:69753455	YEATS4	0.48	6.78	0.34	5.35e-11	Response to diuretic therapy;
LIHC	cis	rs611744	0.935	rs679077	chr8:109244742	G/T	cg21045802	chr8:109455806	TTC35	0.5	8.65	0.42	1.99e-16	Dupuytren's disease;
LIHC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.51	-7.47	-0.37	6.56e-13	Type 2 diabetes;
LIHC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.85	0.43	4.64e-17	Cognitive ability;
LIHC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg25281562	chr12:121454272	C12orf43	0.34	5.92	0.3	7.73e-9	N-glycan levels;
LIHC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.06e-19	Renal cell carcinoma;
LIHC	cis	rs8108269	0.868	rs10421566	chr19:46159123	C/T	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg17724175	chr1:150552817	MCL1	0.41	7.93	0.39	3.18e-14	Melanoma;
LIHC	cis	rs7534824	0.583	rs6577225	chr1:101506126	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	6.97	0.35	1.61e-11	Refractive astigmatism;
LIHC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.51	7.28	0.37	2.33e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8005677	0.828	rs712486	chr14:23425041	A/G	cg25600027	chr14:23388339	RBM23	-0.4	-5.78	-0.3	1.72e-8	Cognitive ability (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13410609	chr19:50291885	AP2A1	0.43	6.48	0.33	3.23e-10	Longevity;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg27432699	chr2:27873401	GPN1	0.5	7.2	0.36	3.95e-12	Total body bone mineral density;
LIHC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.76	0.57	9.25e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.39	5.82	0.3	1.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg00280220	chr17:61926910	NA	0.4	6.25	0.32	1.23e-9	Prudent dietary pattern;
LIHC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.45	6.61	0.34	1.5e-10	Aortic root size;
LIHC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg18887096	chr2:219472410	PLCD4	0.37	5.78	0.3	1.64e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.84	-5.83	-0.3	1.29e-8	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg23280166	chr11:118938394	VPS11	0.53	7.0	0.35	1.35e-11	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14832358	chr2:45837811	SRBD1	0.5	7.49	0.38	6.07e-13	Pancreatic cancer;
LIHC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-8.33	-0.41	2.04e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.46	-6.69	-0.34	9.19e-11	Asthma (sex interaction);
LIHC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg22633049	chr21:46681294	NA	-0.38	-6.32	-0.32	8.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6876835	0.511	rs58514300	chr5:6598022	C/T	cg04204831	chr5:6583394	LOC255167	0.42	6.44	0.33	4.04e-10	Visceral fat;
LIHC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.85	0.39	5.37e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.43	-6.54	-0.33	2.29e-10	Menarche (age at onset);
LIHC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.63	8.12	0.4	8.25e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10150615	chr22:24372951	LOC391322	0.46	6.81	0.35	4.41e-11	Cognitive function;
LIHC	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.49	-8.81	-0.43	6.6e-17	Vitamin D levels;
LIHC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.41	-7.44	-0.37	8.34e-13	Hepatocellular carcinoma;
LIHC	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg18912006	chr12:123335444	HIP1R	0.72	7.44	0.37	8.06e-13	Adiponectin levels;
LIHC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06002616	chr8:101225028	SPAG1	0.34	5.76	0.3	1.87e-8	Atrioventricular conduction;
LIHC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	8.95	0.44	2.24e-17	Response to bleomycin (chromatid breaks);
LIHC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg21466736	chr12:48725269	NA	0.36	6.32	0.32	8.02e-10	Plateletcrit;
LIHC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	2.99e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.62	0.34	1.36e-10	Cognitive ability;
LIHC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.87	14.13	0.61	4.81e-36	Parkinson's disease;
LIHC	trans	rs78049276	0.562	rs55965782	chr4:148378442	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-8.27	-0.41	2.96e-15	Pulse pressure;
LIHC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.59	-8.9	-0.43	3.26e-17	Bone properties (heel);
LIHC	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.53	8.15	0.4	6.97e-15	Smoking behavior;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27402845	chr11:1000533	AP2A2	0.42	6.1	0.31	2.86e-9	Longevity;
LIHC	cis	rs36051895	0.623	rs28872016	chr9:5253558	T/G	cg02405213	chr9:5042618	JAK2	-0.62	-10.06	-0.48	4.95e-21	Pediatric autoimmune diseases;
LIHC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19671926	chr4:122722719	EXOSC9	0.56	8.63	0.42	2.3e-16	Type 2 diabetes;
LIHC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16262614	chr3:133464971	TF	0.29	6.38	0.33	5.9e-10	Iron status biomarkers;
LIHC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.69	-0.43	1.56e-16	Cognitive function;
LIHC	cis	rs4908768	0.579	rs12137865	chr1:8868406	A/G	cg20416874	chr1:8611966	RERE	0.44	6.66	0.34	1.12e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg09165964	chr15:75287851	SCAMP5	0.42	5.89	0.3	9.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.38	-11.72	-0.54	6.87e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs1800973	0.536	rs11177576	chr12:69671660	A/G	cg20891283	chr12:69753455	YEATS4	-0.52	-5.96	-0.31	6.44e-9	Monocyte percentage of white cells;Monocyte count;Blood protein levels;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg00656387	chr3:40428638	ENTPD3	0.39	6.42	0.33	4.57e-10	Renal cell carcinoma;
LIHC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg14779329	chr11:130786720	SNX19	0.42	6.34	0.32	7.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg18887096	chr2:219472410	PLCD4	0.36	6.39	0.33	5.41e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	trans	rs2363709	1.000	rs6770280	chr3:67416712	T/C	cg13681781	chr9:139102396	QSOX2	0.81	6.33	0.32	7.66e-10	IgE levels;
LIHC	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02985541	chr2:219472218	PLCD4	-0.38	-6.57	-0.33	1.83e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg07424592	chr7:64974309	NA	0.81	9.45	0.45	5.58e-19	Diabetic kidney disease;
LIHC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-6.94	-0.35	1.96e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-8.32	-0.41	2.12e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11229555	0.645	rs11229430	chr11:58181104	G/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-12.6	-0.56	3.74e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.96	-0.44	2.21e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.45	5.99	0.31	5.46e-9	Menopause (age at onset);
LIHC	cis	rs1198430	0.683	rs1077514	chr1:23766233	A/G	cg13183780	chr1:23809682	ASAP3	0.37	6.4	0.33	5.27e-10	Total cholesterol levels;
LIHC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	12.6	0.56	3.76e-30	HIV-1 control;
LIHC	trans	rs7714584	1.000	rs6579804	chr5:150255931	T/C	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs713477	0.692	rs10146713	chr14:55911597	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.64	-0.34	1.24e-10	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg07451762	chr16:28383216	NA	0.32	6.12	0.31	2.56e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.85e-9	Total body bone mineral density;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27037990	chr4:184427250	ING2	0.43	6.09	0.31	3.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6600671	0.967	rs4844613	chr1:121173773	T/C	cg09829573	chr1:144692074	NBPF9	-0.47	-8.57	-0.42	3.54e-16	Hip geometry;
LIHC	cis	rs16828019	0.852	rs12044539	chr1:41661732	A/C	cg20697417	chr1:41786797	NA	0.34	6.51	0.33	2.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg06466757	chr4:1255808	NA	0.34	5.8	0.3	1.53e-8	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg10360323	chr17:41437877	NA	0.4	5.95	0.31	6.7e-9	Menopause (age at onset);
LIHC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg01364799	chr7:75623366	TMEM120A	-0.42	-6.25	-0.32	1.26e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.98	0.31	5.76e-9	Menopause (age at onset);
LIHC	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.58	-0.38	3.25e-13	QT interval;
LIHC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.81	-0.35	4.49e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.98	-0.31	5.56e-9	Response to antipsychotic treatment;
LIHC	cis	rs9326778	0.520	rs10042130	chr5:108818528	C/A	cg17395555	chr5:108820864	NA	-0.35	-5.98	-0.31	5.56e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.82	-14.9	-0.63	4.89e-39	Height;
LIHC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.66	10.05	0.48	5.27e-21	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg03959625	chr15:84868606	LOC388152	0.44	6.11	0.31	2.64e-9	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.33	-6.64	-0.34	1.21e-10	Renal cell carcinoma;
LIHC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.16	-0.44	4.85e-18	Schizophrenia;
LIHC	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.98	16.75	0.67	2.13e-46	Cognitive ability;
LIHC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.55	-7.1	-0.36	7.14e-12	Breast cancer;
LIHC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg03037974	chr15:76606532	NA	0.73	14.39	0.61	5.01e-37	Blood metabolite levels;
LIHC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg23690444	chr14:81902736	NA	-0.45	-6.21	-0.32	1.52e-9	Night sleep phenotypes;
LIHC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.78	13.8	0.6	9.9e-35	Coronary artery disease;
LIHC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg25344623	chr2:136566232	LCT	-0.37	-5.96	-0.31	6.45e-9	Corneal structure;
LIHC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.53	-8.58	-0.42	3.33e-16	Blood protein levels;
LIHC	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.61	8.27	0.41	2.92e-15	Breast cancer;
LIHC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.64	7.39	0.37	1.11e-12	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.45e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg25922239	chr6:33757077	LEMD2	0.43	6.25	0.32	1.2e-9	Crohn's disease;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg00091569	chr3:40428383	ENTPD3	-0.4	-6.79	-0.34	4.83e-11	Renal cell carcinoma;
LIHC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.33	-6.4	-0.33	4.98e-10	Body mass index;
LIHC	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg06495728	chr3:187462459	BCL6	-0.49	-6.47	-0.33	3.41e-10	DNA methylation (variation);
LIHC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	8.86	0.43	4.34e-17	Menarche (age at onset);
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.37	6.03	0.31	4.14e-9	Cystic fibrosis severity;
LIHC	cis	rs713477	1.000	rs7142204	chr14:55908436	G/T	cg13175173	chr14:55914753	NA	0.35	8.15	0.4	7.17e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg03934865	chr2:198174659	NA	-0.57	-8.88	-0.43	3.92e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs861318	0.702	rs7532207	chr1:159024424	A/T	cg11003133	chr1:159046391	AIM2	-0.33	-6.38	-0.33	5.77e-10	Obesity-related traits;
LIHC	cis	rs918629	0.761	rs7705720	chr5:95280033	T/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.1	-0.31	2.85e-9	IgG glycosylation;
LIHC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.09	-0.44	8.29e-18	Bipolar disorder;
LIHC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.53	8.54	0.42	4.59e-16	Corneal astigmatism;
LIHC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23422044	chr7:1970798	MAD1L1	-0.55	-8.76	-0.43	9.2e-17	Neuroticism;
LIHC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.92	12.12	0.55	2.31e-28	Heart rate;
LIHC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.85	10.22	0.48	1.41e-21	Mean platelet volume;
LIHC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.49	7.61	0.38	2.64e-13	Height;
LIHC	cis	rs11822910	0.911	rs11828218	chr11:57196223	C/G	cg00522883	chr11:57194120	SLC43A3	0.65	8.97	0.44	1.98e-17	Platelet distribution width;
LIHC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.79	-14.23	-0.61	2e-36	Refractive error;
LIHC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.17e-22	Cognitive function;
LIHC	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.48	5.97	0.31	5.82e-9	Pancreatic cancer;
LIHC	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10838687	0.736	rs326224	chr11:47255598	T/C	cg25783544	chr11:47291846	MADD	-0.47	-5.86	-0.3	1.11e-8	Proinsulin levels;
LIHC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.59	-9.14	-0.44	5.47e-18	Multiple sclerosis;
LIHC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.5	7.6	0.38	2.84e-13	Adiposity;
LIHC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.41	7.53	0.38	4.48e-13	Electrocardiographic conduction measures;
LIHC	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.52	9.08	0.44	9.01e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs600806	0.778	rs4970731	chr1:109995459	T/C	cg11161837	chr1:110010384	SYPL2	0.44	5.8	0.3	1.55e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg09222892	chr1:25734099	RHCE	-0.48	-8.71	-0.43	1.31e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	13.76	0.6	1.35e-34	Cognitive test performance;
LIHC	cis	rs10792665	0.934	rs10898063	chr11:82672020	A/G	cg24227371	chr11:82718527	RAB30	-0.3	-6.93	-0.35	2.07e-11	Obesity-related traits;
LIHC	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.43	7.09	0.36	7.5e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.27	0.41	3.1e-15	Bladder cancer;
LIHC	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg19676328	chr12:49525230	TUBA1B	-0.4	-6.55	-0.33	2.11e-10	Total cholesterol levels;
LIHC	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.61	-7.0	-0.35	1.39e-11	Urinary tract infection frequency;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09250149	chr16:85684353	KIAA0182	-0.42	-6.45	-0.33	3.91e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.78	12.22	0.55	9.56e-29	Longevity;
LIHC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.57	-8.73	-0.43	1.16e-16	Blood trace element (Zn levels);
LIHC	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.82	8.99	0.44	1.76e-17	Vitiligo;
LIHC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.41	6.91	0.35	2.32e-11	Aortic root size;
LIHC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.39	-6.24	-0.32	1.27e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs4908768	0.596	rs4908516	chr1:8879610	G/C	cg20416874	chr1:8611966	RERE	0.46	6.23	0.32	1.34e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-9.15	-0.44	5.24e-18	Coronary artery disease;
LIHC	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-6.91	-0.35	2.35e-11	Blood protein levels;
LIHC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.17	-0.4	6.17e-15	Gut microbiome composition (summer);
LIHC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.16	-0.32	1.99e-9	Schizophrenia;
LIHC	trans	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg26939375	chr7:64535504	NA	-0.46	-6.9	-0.35	2.6e-11	Aortic root size;
LIHC	cis	rs4853525	0.522	rs7574840	chr2:191584236	C/G	cg10560079	chr2:191398806	TMEM194B	-0.42	-6.04	-0.31	4.1e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg15257755	chr8:22225668	SLC39A14	-0.38	-6.12	-0.31	2.62e-9	Height;
LIHC	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.7	-0.34	8.57e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	7.81	0.39	6.86e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs6499244	0.530	rs4275849	chr16:69832105	G/A	cg15192750	chr16:69999425	NA	0.35	5.72	0.3	2.3e-8	Menarche (age at onset);
LIHC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg08132940	chr7:1081526	C7orf50	-0.75	-6.86	-0.35	3.27e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg19676328	chr12:49525230	TUBA1B	-0.44	-6.42	-0.33	4.6e-10	Total cholesterol levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03621406	chr19:9930365	FBXL12	-0.5	-6.15	-0.32	2.17e-9	Systolic blood pressure;
LIHC	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.79	-0.39	7.93e-14	Response to antipsychotic treatment;
LIHC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.77	0.3	1.82e-8	Schizophrenia;
LIHC	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	9.02	0.44	1.34e-17	Exhaled nitric oxide output;
LIHC	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg08539965	chr1:21396338	EIF4G3	0.34	5.93	0.31	7.44e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2421770	0.530	rs6484784	chr11:35368347	A/C	cg13971030	chr11:35366721	SLC1A2	0.44	7.5	0.38	5.59e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg13957321	chr17:43675089	NA	0.5	7.97	0.4	2.46e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4934494	0.768	rs67111731	chr10:91419285	C/G	cg19698084	chr10:91461284	KIF20B	-0.5	-6.52	-0.33	2.47e-10	Red blood cell count;
LIHC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg03037974	chr15:76606532	NA	0.71	13.51	0.59	1.28e-33	Blood metabolite levels;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.49	-6.36	-0.33	6.42e-10	Coronary artery calcification;
LIHC	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.96	-0.4	2.62e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs4759375	0.850	rs28503862	chr12:123867106	C/T	cg00376283	chr12:123451042	ABCB9	0.5	6.35	0.32	6.89e-10	HDL cholesterol;
LIHC	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg22802111	chr1:160068614	IGSF8	0.43	6.2	0.32	1.65e-9	Response to antipsychotic treatment;
LIHC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.61	9.13	0.44	6.05e-18	Longevity;
LIHC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.57	10.06	0.48	5.02e-21	Mean corpuscular volume;
LIHC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.05	0.31	3.91e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23376870	chr14:90422459	TDP1;C14orf143	0.41	6.41	0.33	4.84e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg02527881	chr3:46936655	PTH1R	0.33	6.34	0.32	7.38e-10	Colorectal cancer;
LIHC	trans	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg09872104	chr7:134855509	C7orf49	-0.77	-6.25	-0.32	1.26e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.82	0.3	1.38e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.92	-0.35	2.18e-11	IgG glycosylation;
LIHC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.59	-0.5	7.59e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.39	5.87	0.3	1.04e-8	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg26566898	chr11:117069891	TAGLN	0.43	6.74	0.34	6.91e-11	Blood protein levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11646757	chr7:128095699	C7orf68	0.41	6.21	0.32	1.54e-9	Cognitive function;
LIHC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.38	-6.18	-0.32	1.8e-9	Menopause (age at onset);
LIHC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.65	0.42	2.04e-16	Lung cancer in ever smokers;
LIHC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg12798992	chr6:167411361	FGFR1OP	0.47	6.97	0.35	1.63e-11	Crohn's disease;
LIHC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.34	0.55	3.52e-29	Alzheimer's disease;
LIHC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.43	7.36	0.37	1.34e-12	Aortic root size;
LIHC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg18306943	chr3:40428807	ENTPD3	0.34	6.09	0.31	2.96e-9	Renal cell carcinoma;
LIHC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.7	10.06	0.48	4.84e-21	Pancreatic cancer;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg03874509	chr1:107600012	PRMT6	0.76	12.1	0.55	2.79e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.49	7.48	0.37	6.49e-13	White matter hyperintensity burden;
LIHC	cis	rs11673344	0.764	rs472226	chr19:37458713	A/C	cg27390819	chr19:37464633	NA	-0.52	-6.21	-0.32	1.52e-9	Obesity-related traits;
LIHC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg18305652	chr10:134549665	INPP5A	0.37	6.11	0.31	2.73e-9	Migraine;
LIHC	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg02811702	chr13:24901961	NA	0.25	6.35	0.32	6.74e-10	Obesity-related traits;
LIHC	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg20435097	chr10:126320824	FAM53B	0.38	6.38	0.33	5.7e-10	Asthma;
LIHC	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.7	11.62	0.53	1.51e-26	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs12644436	0.628	rs9991148	chr4:88781760	G/T	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs7945718	0.621	rs4606460	chr11:12687781	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.5	-0.38	5.56e-13	Schizophrenia;
LIHC	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.46	-6.73	-0.34	7.11e-11	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.87	0.78	6.99e-71	Height;
LIHC	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.45	6.79	0.34	5e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-11.63	-0.53	1.41e-26	Platelet count;
LIHC	cis	rs818427	0.865	rs1093611	chr5:112218476	A/T	cg07820702	chr5:112228657	REEP5	0.37	5.93	0.31	7.4e-9	Total body bone mineral density;
LIHC	cis	rs8084351	0.569	rs876553	chr18:50776747	C/T	cg24270629	chr18:50823537	DCC	-0.46	-6.84	-0.35	3.68e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.6	-6.06	-0.31	3.56e-9	Urate levels in lean individuals;
LIHC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	ch.8.33884649F	chr8:33765107	NA	0.4	6.59	0.34	1.68e-10	Body mass index;
LIHC	cis	rs11630290	0.566	rs4777395	chr15:64161693	T/G	cg12036633	chr15:63758958	NA	0.63	6.82	0.35	4.14e-11	Iris characteristics;
LIHC	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.47	7.52	0.38	4.96e-13	Mean corpuscular volume;
LIHC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg18016565	chr1:150552671	MCL1	0.52	9.67	0.46	1.03e-19	Melanoma;
LIHC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg08668510	chr10:1095578	IDI1	0.71	7.06	0.36	9.46e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg15123519	chr2:136567270	LCT	-0.38	-5.82	-0.3	1.38e-8	Corneal structure;
LIHC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.8	12.32	0.55	4.16e-29	Breast cancer;
LIHC	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.73	5.97	0.31	6.08e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	6.88	0.35	2.8e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg15595755	chr5:1867978	NA	0.42	8.61	0.42	2.66e-16	Cardiovascular disease risk factors;
LIHC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.36	-8.25	-0.41	3.45e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs1401454	1.000	rs2351958	chr11:16248020	C/A	cg10927848	chr11:16298618	SOX6	-0.33	-6.26	-0.32	1.18e-9	Blood pressure;
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg21486233	chr12:29375141	FAR2	0.31	6.25	0.32	1.22e-9	QT interval;
LIHC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-6.81	-0.35	4.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.41	-6.59	-0.34	1.64e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.17	-0.32	1.94e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.37	5.87	0.3	1.01e-8	Height;
LIHC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg10978503	chr1:24200527	CNR2	0.29	6.8	0.35	4.59e-11	Immature fraction of reticulocytes;
LIHC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.3	6.01	0.31	4.74e-9	Body mass index;
LIHC	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.64	-0.34	1.2e-10	Homocysteine levels;
LIHC	trans	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg10208301	chr11:6592745	DNHD1	0.47	6.68	0.34	9.96e-11	Coronary artery calcification;
LIHC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.29	-0.32	9.75e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg17130504	chr10:102756923	LZTS2	0.56	7.77	0.39	9.27e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8067354	0.681	rs76856339	chr17:57800966	G/A	cg13753209	chr17:57696993	CLTC	0.78	12.34	0.56	3.34e-29	Hemoglobin concentration;
LIHC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27297192	chr10:134578999	INPP5A	0.55	7.7	0.38	1.52e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.87	15.12	0.63	6.55e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.43	6.78	0.34	5.3e-11	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24262715	chr15:44038991	PDIA3;CATSPER2P1	0.44	6.14	0.32	2.26e-9	Lung function (FEV1/FVC);
LIHC	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9322817	0.902	rs9322812	chr6:105194651	A/G	cg02098413	chr6:105308735	HACE1	-0.38	-6.13	-0.31	2.38e-9	Thyroid stimulating hormone;
LIHC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg24296786	chr1:45957014	TESK2	0.43	6.25	0.32	1.2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.54	-0.33	2.22e-10	Total body bone mineral density;
LIHC	cis	rs11800820	0.517	rs12022808	chr1:246659163	C/A	cg16700716	chr1:246684329	NA	0.43	7.22	0.36	3.31e-12	Obesity-related traits;
LIHC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.92	17.02	0.68	1.74e-47	Menopause (age at onset);
LIHC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.54	0.42	4.58e-16	Menarche (age at onset);
LIHC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.59	6.92	0.35	2.23e-11	Cognitive function;
LIHC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02290350	chr8:58132656	NA	0.49	9.15	0.44	5.44e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs10949834	0.652	rs2269082	chr7:73519875	A/G	cg07137043	chr7:73588983	EIF4H	-0.61	-7.24	-0.36	2.99e-12	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.49	6.36	0.33	6.37e-10	Large artery stroke;
LIHC	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06420487	chr17:61919686	SMARCD2	0.46	6.22	0.32	1.48e-9	Height;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.69	9.95	0.47	1.17e-20	Menarche (age at onset);
LIHC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	1.19	9.31	0.45	1.6e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs77861329	1.000	rs9809977	chr3:52166147	T/C	cg08692210	chr3:52188851	WDR51A	0.83	7.85	0.39	5.47e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg16226627	chr15:75307476	SCAMP5	0.54	9.83	0.47	3.01e-20	Lung cancer;
LIHC	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21659725	chr3:3221576	CRBN	0.56	8.23	0.41	4.04e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.96	13.62	0.59	4.63e-34	Breast cancer;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg00612595	chr21:47717864	NA	-0.37	-6.08	-0.31	3.21e-9	Testicular germ cell tumor;
LIHC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.45	-7.26	-0.37	2.55e-12	Fibrinogen levels;
LIHC	cis	rs797680	0.856	rs569414	chr1:93784901	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.04	-0.31	3.95e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs10761482	0.566	rs10159663	chr10:62208417	A/G	cg10096035	chr12:96392698	NA	-0.4	-6.34	-0.32	7.26e-10	Schizophrenia;
LIHC	cis	rs2412459	0.803	rs7165105	chr15:40273788	A/G	cg02712587	chr15:40268421	EIF2AK4	0.55	5.79	0.3	1.63e-8	Response to haloperidol in psychosis;
LIHC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg17724175	chr1:150552817	MCL1	0.38	7.5	0.38	5.42e-13	Melanoma;
LIHC	cis	rs7716219	0.580	rs1396611	chr5:54878771	T/C	cg14753740	chr5:54468940	CDC20B;MIR449C	0.43	5.9	0.3	8.93e-9	Height;
LIHC	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.1	-0.31	2.87e-9	Coronary artery disease;
LIHC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	6.86	0.35	3.24e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg04824913	chr4:887549	GAK	0.57	6.94	0.35	1.94e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.3	0.32	9.42e-10	Heart rate;
LIHC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.76e-9	Menopause (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05904041	chr7:4802774	FOXK1	0.45	6.54	0.33	2.27e-10	Longevity;
LIHC	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.45	-6.13	-0.31	2.42e-9	Tuberculosis;
LIHC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.53	0.53	3.33e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.02	-0.44	1.42e-17	Bipolar disorder;
LIHC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.22	0.48	1.38e-21	Alzheimer's disease (late onset);
LIHC	cis	rs10838687	0.673	rs2290148	chr11:47346145	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.82	-0.3	1.39e-8	Proinsulin levels;
LIHC	trans	rs9914544	0.545	rs35911764	chr17:18782582	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.62e-10	Educational attainment (years of education);
LIHC	cis	rs7116495	0.609	rs2885661	chr11:71588331	C/G	cg26138937	chr11:71823887	C11orf51	1.17	9.03	0.44	1.25e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17158424	chr11:33095023	TCP11L1	-0.27	-6.16	-0.32	2.09e-9	Calcium levels;
LIHC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.73	7.39	0.37	1.15e-12	Vitiligo;
LIHC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.58	0.42	3.3e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4716602	0.596	rs4997808	chr7:156158734	C/G	cg16983916	chr7:156159713	NA	-0.33	-5.91	-0.3	8.43e-9	Anti-saccade response;
LIHC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-7.54	-0.38	4.25e-13	Mean corpuscular volume;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg03854865	chr6:26224070	HIST1H3E	0.63	7.23	0.36	3.28e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.52	-9.21	-0.45	3.28e-18	Blood protein levels;
LIHC	cis	rs611744	0.905	rs421695	chr8:109117403	T/C	cg21045802	chr8:109455806	TTC35	0.5	8.44	0.42	8.98e-16	Dupuytren's disease;
LIHC	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.58	-10.72	-0.5	2.53e-23	Urate levels in overweight individuals;
LIHC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.47	8.51	0.42	5.69e-16	Colorectal cancer;
LIHC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg03037974	chr15:76606532	NA	0.73	14.24	0.61	1.94e-36	Blood metabolite levels;
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg04013166	chr16:89971882	TCF25	0.62	8.2	0.41	4.97e-15	Skin colour saturation;
LIHC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.51	7.07	0.36	8.59e-12	Morning vs. evening chronotype;
LIHC	cis	rs965469	1.000	rs6051715	chr20:3266548	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.96	-0.35	1.79e-11	IFN-related cytopenia;
LIHC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg27166718	chr6:118880109	PLN;C6orf204	0.53	7.04	0.36	1.07e-11	Diastolic blood pressure;
LIHC	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.6	-8.4	-0.41	1.18e-15	Blood pressure (smoking interaction);
LIHC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.27	0.58	1.01e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.97	0.35	1.59e-11	Breast cancer;
LIHC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg11062466	chr8:58055876	NA	0.4	5.82	0.3	1.37e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.4	7.52	0.38	4.99e-13	Monocyte count;
LIHC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.58	7.85	0.39	5.26e-14	Bone mineral density (spine);
LIHC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg08392591	chr16:89556376	ANKRD11	0.41	6.12	0.31	2.59e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.75	0.39	1.03e-13	Obesity-related traits;
LIHC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.59	10.21	0.48	1.5e-21	Colorectal cancer;
LIHC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.57	-9.24	-0.45	2.78e-18	Longevity;Endometriosis;
LIHC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.46	-7.79	-0.39	8.33e-14	Prevalent atrial fibrillation;
LIHC	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.43	6.46	0.33	3.59e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.59	0.59	6.27e-34	Lung cancer in ever smokers;
LIHC	cis	rs55665837	0.701	rs12286408	chr11:14579376	G/A	cg16394018	chr11:14927549	NA	0.42	5.9	0.3	8.89e-9	Vitamin D levels;
LIHC	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.72	0.5	2.69e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs847851	0.617	rs9394267	chr6:34960760	C/T	cg13137465	chr6:34857473	ANKS1A	-0.67	-7.49	-0.38	6.1e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs365132	0.875	rs353476	chr5:176424035	A/G	cg16309518	chr5:176445507	NA	-0.53	-10.11	-0.48	3.39e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg16652328	chr3:33138982	GLB1;TMPPE	0.54	7.08	0.36	8.33e-12	Major depressive disorder;
LIHC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.43	7.97	0.4	2.39e-14	Electrocardiographic conduction measures;
LIHC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.47	7.85	0.39	5.34e-14	Mean corpuscular volume;
LIHC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-8.51	-0.42	5.47e-16	Gut microbiome composition (summer);
LIHC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg17135325	chr3:160939158	NMD3	0.51	7.64	0.38	2.24e-13	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-8.94	-0.44	2.56e-17	Total body bone mineral density;
LIHC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg13844804	chr7:814759	HEATR2	0.43	5.75	0.3	1.95e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.69	0.43	1.51e-16	Response to antipsychotic treatment;
LIHC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	14.01	0.6	1.53e-35	Cognitive test performance;
LIHC	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg18809830	chr7:99032528	PTCD1	-0.83	-6.45	-0.33	3.72e-10	Blood metabolite levels;
LIHC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.53	7.45	0.37	7.49e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.13	-0.31	2.47e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.46	-7.78	-0.39	8.59e-14	IgG glycosylation;
LIHC	cis	rs72653721	0.838	rs3798710	chr6:11002783	C/G	cg13562911	chr6:11044106	ELOVL2	0.5	7.24	0.36	2.97e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.74	12.05	0.55	4.28e-28	Body mass index;
LIHC	cis	rs9503598	0.502	rs9405203	chr6:3433846	G/T	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.8	-0.3	1.52e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs6973256	0.605	rs13237435	chr7:133347570	C/T	cg10665199	chr7:133106180	EXOC4	-0.34	-5.83	-0.3	1.29e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.04	0.36	1.08e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.74	0.34	6.56e-11	Ileal carcinoids;
LIHC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02290350	chr8:58132656	NA	0.42	8.58	0.42	3.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.85	0.35	3.39e-11	Height;
LIHC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	8.79	0.43	7.16e-17	Platelet count;
LIHC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	9.11	0.44	6.88e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg00280220	chr17:61926910	NA	0.43	6.83	0.35	3.79e-11	Prudent dietary pattern;
LIHC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.97	-19.09	-0.72	7.74e-56	Intelligence (multi-trait analysis);
LIHC	cis	rs13161895	1.000	rs27018	chr5:179405144	A/G	cg02702477	chr5:179499311	RNF130	0.75	10.39	0.49	3.62e-22	LDL cholesterol;
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg19318889	chr4:1322082	MAEA	0.39	6.36	0.33	6.59e-10	Obesity-related traits;
LIHC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg25329415	chr6:28076851	NA	0.27	5.71	0.3	2.44e-8	Cardiac Troponin-T levels;
LIHC	cis	rs7534824	0.543	rs72734254	chr1:101382039	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.06	0.36	9.27e-12	Refractive astigmatism;
LIHC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.48	0.67	2.63e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.88	-0.39	4.44e-14	Monocyte percentage of white cells;
LIHC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg19774624	chr17:42201019	HDAC5	0.45	6.4	0.33	5.02e-10	Total body bone mineral density;
LIHC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.37	-6.53	-0.33	2.41e-10	Aortic root size;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg23782820	chr8:58130467	NA	0.33	5.95	0.31	6.66e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.87	15.63	0.65	6.4e-42	Dental caries;
LIHC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	6.62	0.34	1.36e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.7	-9.16	-0.44	4.91e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-6.86	-0.35	3.28e-11	Neuroticism;
LIHC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.35	5.98	0.31	5.54e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.47	-6.93	-0.35	2.15e-11	Psoriasis;
LIHC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.69	6.4	0.33	5.12e-10	Breast cancer;
LIHC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.68	13.52	0.59	1.12e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.32	5.9	0.3	8.77e-9	Response to antipsychotic treatment;
LIHC	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.69	10.45	0.49	2.36e-22	Schizophrenia;
LIHC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.8	9.89	0.47	1.85e-20	Morning vs. evening chronotype;
LIHC	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.84	-0.3	1.24e-8	Red blood cell count;
LIHC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.12	12.8	0.57	6.57e-31	Vitiligo;
LIHC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.08	0.31	3.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.71	9.82	0.47	3.3e-20	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs2479724	0.870	rs6913232	chr6:41915143	C/T	cg17623882	chr6:41773611	USP49	0.51	7.6	0.38	2.81e-13	Menarche (age at onset);
LIHC	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.54	-7.76	-0.39	9.98e-14	Neuroticism;
LIHC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg26692224	chr17:62915920	LRRC37A3	-0.72	-6.82	-0.35	4.04e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.38	-6.37	-0.33	6.1e-10	Educational attainment;
LIHC	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.46	0.42	8e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.72	9.38	0.45	9.41e-19	Dilated cardiomyopathy;
LIHC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	7.3	0.37	2e-12	Personality dimensions;
LIHC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.37e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17428076	0.836	rs57718990	chr2:172662614	T/G	cg13550731	chr2:172543902	DYNC1I2	0.41	6.7	0.34	8.7e-11	Myopia;
LIHC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.15	-0.32	2.14e-9	Total body bone mineral density;
LIHC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	1.02	19.55	0.73	1.15e-57	Breast cancer;
LIHC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg12798992	chr6:167411361	FGFR1OP	0.45	6.94	0.35	2.01e-11	Crohn's disease;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.63	9.71	0.46	7.86e-20	Renal cell carcinoma;
LIHC	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.46	-5.73	-0.3	2.17e-8	Exhaled nitric oxide output;
LIHC	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.73	-11.04	-0.51	1.94e-24	Morning vs. evening chronotype;
LIHC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-1.05	-19.69	-0.73	3.11e-58	Migraine;
LIHC	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.31	-7.15	-0.36	5.16e-12	Hip circumference;Waist circumference;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg07998290	chr8:9912305	MSRA	-0.56	-6.19	-0.32	1.7e-9	Preeclampsia;
LIHC	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.83	0.43	5.5e-17	Exhaled nitric oxide levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11427898	chr15:38544983	SPRED1	-0.43	-6.44	-0.33	4.09e-10	Pancreatic cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25300318	chr2:200527297	NA	0.43	6.54	0.33	2.24e-10	Immature fraction of reticulocytes;
LIHC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.72	-0.34	7.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.02e-25	Corneal astigmatism;
LIHC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.63	-0.5	5.24e-23	Coronary artery disease;
LIHC	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.75	-0.34	6.43e-11	Metabolite levels;
LIHC	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	6.94	0.35	2.03e-11	Type 2 diabetes;
LIHC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.15	-10.76	-0.5	1.93e-23	Breast cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12960782	chr5:59996455	DEPDC1B	-0.43	-6.87	-0.35	3.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.41	8.94	0.44	2.41e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.81	-0.3	1.41e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7119038	0.730	rs10790269	chr11:118729456	C/T	cg19308663	chr11:118741387	NA	-0.46	-6.01	-0.31	4.8e-9	Sjögren's syndrome;
LIHC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.67	10.26	0.49	1.01e-21	Longevity;
LIHC	cis	rs4800452	0.871	rs9961220	chr18:20733201	G/T	cg26136497	chr18:20735537	CABLES1	-0.45	-5.97	-0.31	5.94e-9	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-13.08	-0.58	5.8e-32	Morning vs. evening chronotype;
LIHC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.61	0.56	3.35e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.36	0.59	4.89e-33	Prudent dietary pattern;
LIHC	trans	rs743793	0.875	rs5998786	chr22:33575643	G/A	cg20274824	chr1:36638199	MAP7D1	0.45	6.38	0.33	5.92e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.49	8.99	0.44	1.78e-17	Testicular germ cell tumor;
LIHC	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.02	-16.58	-0.67	1.02e-45	Mitochondrial DNA levels;
LIHC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.29	-5.72	-0.3	2.38e-8	Prostate cancer;
LIHC	cis	rs4478037	0.822	rs3924695	chr3:33122085	C/T	cg27203090	chr3:33138513	GLB1;TMPPE	-0.5	-6.27	-0.32	1.08e-9	Major depressive disorder;
LIHC	cis	rs79149102	0.737	rs12593975	chr15:75189591	G/A	cg16226627	chr15:75307476	SCAMP5	0.43	6.09	0.31	2.95e-9	Lung cancer;
LIHC	cis	rs12144094	0.882	rs55806106	chr1:120232539	T/A	cg20995928	chr1:120229863	NA	0.37	6.17	0.32	1.92e-9	Height;
LIHC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.58	8.41	0.41	1.13e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	8.66	0.42	1.87e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.45	-0.37	7.93e-13	Tuberculosis;
LIHC	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.36	5.98	0.31	5.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg10935138	chr17:73851978	WBP2	0.72	9.38	0.45	9.27e-19	Psoriasis;
LIHC	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg04998671	chr14:104000505	TRMT61A	0.57	7.81	0.39	7.23e-14	Coronary artery disease;
LIHC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.42	6.17	0.32	1.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.62	0.5	5.84e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg21142257	chr8:20054699	ATP6V1B2	-0.56	-5.98	-0.31	5.58e-9	Preeclampsia;
LIHC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	2.97e-11	Renal cell carcinoma;
LIHC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.51	8.39	0.41	1.3e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.57	9.24	0.45	2.68e-18	Pulse pressure;
LIHC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.55	-9.12	-0.44	6.75e-18	Colorectal cancer;
LIHC	cis	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg17459225	chr2:239074497	NA	-0.36	-5.83	-0.3	1.26e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.49	-8.39	-0.41	1.29e-15	Neuroticism;
LIHC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.85	-0.51	8.78e-24	Platelet count;
LIHC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.82	0.47	3.25e-20	Alzheimer's disease;
LIHC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.52	6.84	0.35	3.63e-11	Gut microbiome composition (summer);
LIHC	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	0.98	7.84	0.39	5.9e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	11.48	0.53	5.1e-26	Gut microbiome composition (summer);
LIHC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	8.71	0.43	1.35e-16	Schizophrenia;
LIHC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.36	-7.05	-0.36	9.96e-12	Multiple system atrophy;
LIHC	cis	rs600806	0.778	rs10494040	chr1:110015732	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.44	-5.75	-0.3	1.95e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.79	15.09	0.63	8.58e-40	Testicular germ cell tumor;
LIHC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.96	0.35	1.77e-11	Gout;
LIHC	trans	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.69	0.59	2.59e-34	Diabetic kidney disease;
LIHC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.11	0.44	7.22e-18	Schizophrenia;
LIHC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg20933634	chr6:27740509	NA	0.45	5.78	0.3	1.64e-8	Parkinson's disease;
LIHC	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.5	-7.39	-0.37	1.11e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg27386326	chr11:61587980	NA	-0.69	-14.72	-0.62	2.36e-38	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.43	0.53	7.55e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9641123	0.639	rs2528529	chr7:93232328	C/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.41	-0.33	4.76e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.5	6.33	0.32	7.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	6.45	0.33	3.83e-10	Mean corpuscular hemoglobin;
LIHC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.65	-0.38	2.03e-13	Morning vs. evening chronotype;
LIHC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.99	0.31	5.29e-9	Self-reported allergy;
LIHC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.37	0.33	6.1e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	5.97	0.31	6.04e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.35	-0.45	1.18e-18	Bipolar disorder;
LIHC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.5	-8.51	-0.42	5.35e-16	Menopause (age at onset);
LIHC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.91	0.39	3.61e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs1712517	0.771	rs11191666	chr10:105127278	A/G	cg05636881	chr10:105038444	INA	0.48	7.53	0.38	4.62e-13	Migraine;
LIHC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.94	-12.26	-0.55	6.68e-29	HIV-1 control;
LIHC	cis	rs12744310	0.887	rs67483852	chr1:41784465	C/T	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.92e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.35	8.96	0.44	2.08e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16828019	0.852	rs11209545	chr1:41576357	T/G	cg03962019	chr1:41807865	NA	0.5	7.22	0.36	3.33e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	cis	rs4934494	0.768	rs34993776	chr10:91441689	C/T	cg19698084	chr10:91461284	KIF20B	-0.49	-6.33	-0.32	7.54e-10	Red blood cell count;
LIHC	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	8.96	0.44	2.2e-17	Platelet count;
LIHC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.75	7.57	0.38	3.48e-13	Vitiligo;
LIHC	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg00204748	chr12:29376779	FAR2	0.38	6.76	0.34	6.12e-11	QT interval;
LIHC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02985541	chr2:219472218	PLCD4	0.45	8.43	0.41	1.01e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.76	9.66	0.46	1.08e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.29	-0.52	2.45e-25	Type 2 diabetes;
LIHC	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.34	-0.32	7.28e-10	Metabolite levels;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.62	8.43	0.41	9.62e-16	Skin colour saturation;
LIHC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.66	-10.43	-0.49	2.66e-22	Lung cancer;
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.7	-11.13	-0.52	9.55e-25	Skin colour saturation;
LIHC	cis	rs11614062	0.761	rs11107115	chr12:93972987	A/G	cg18151635	chr12:93972918	NA	-0.53	-8.78	-0.43	8.12e-17	Height;
LIHC	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg10820045	chr2:198174542	NA	0.56	9.11	0.44	7.29e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg15123519	chr2:136567270	LCT	0.44	8.69	0.43	1.52e-16	Mosquito bite size;
LIHC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.36	-0.49	4.51e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs4586057	0.514	rs7905446	chr10:92619161	T/G	cg14313238	chr10:92632228	RPP30	0.36	5.99	0.31	5.4e-9	Economic and political preferences (time);
LIHC	cis	rs2412488	1.000	rs11734039	chr4:54264428	T/C	cg22241045	chr4:54363911	LNX1	-0.41	-6.71	-0.34	8.19e-11	DNA methylation (variation);
LIHC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.39	-6.97	-0.35	1.66e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg13318129	chr22:45737514	FAM118A	0.54	7.86	0.39	5.11e-14	Tonsillectomy;
LIHC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.38	8.15	0.4	6.96e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.51	7.99	0.4	2.03e-14	Pulse pressure;
LIHC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.62	9.47	0.46	4.67e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12493885	0.818	rs61791544	chr3:153767504	T/A	cg10247383	chr3:153839028	SGEF	0.65	6.13	0.31	2.41e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.29	-0.41	2.56e-15	Schizophrenia;
LIHC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.48	-6.98	-0.35	1.55e-11	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.43	6.49	0.33	2.97e-10	Height;
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.42	-7.04	-0.36	1.08e-11	Paraoxonase activity;
LIHC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg02269571	chr22:50332266	NA	0.61	8.64	0.42	2.24e-16	Schizophrenia;
LIHC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02711726	chr17:80685570	FN3KRP	-0.4	-7.41	-0.37	1.01e-12	Glycated hemoglobin levels;
LIHC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.88	8.29	0.41	2.69e-15	Lymphocyte counts;
LIHC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.3	-6.23	-0.32	1.34e-9	Blood metabolite levels;
LIHC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.02	-0.31	4.55e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.63	-8.48	-0.42	6.94e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1419980	0.730	rs11054886	chr12:7772948	C/A	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	1.06	14.59	0.62	7.64e-38	Heart rate;
LIHC	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.38	6.28	0.32	1.04e-9	Longevity;
LIHC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	1.02	14.47	0.62	2.36e-37	Breast cancer;
LIHC	cis	rs4407350	0.870	rs131172	chr22:44902759	A/G	cg04154583	chr22:44889756	LDOC1L	0.29	5.75	0.3	1.97e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.62	-7.17	-0.36	4.77e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.5	8.13	0.4	7.9e-15	Corneal astigmatism;
LIHC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.54	-8.36	-0.41	1.62e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.27	0.32	1.08e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.21	0.41	4.7e-15	Renal cell carcinoma;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg05185784	chr16:90016020	DEF8	-0.48	-6.43	-0.33	4.38e-10	Skin colour saturation;
LIHC	trans	rs12752401	0.717	rs12751268	chr1:103002533	C/T	cg24921808	chr19:740313	PALM	0.48	6.35	0.32	6.81e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.36	9.36	0.45	1.09e-18	Schizophrenia;
LIHC	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.33	6.8	0.35	4.66e-11	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.39	0.52	1.11e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-9.11	-0.44	7e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.33	-0.45	1.37e-18	Schizophrenia;
LIHC	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-0.73	-5.71	-0.3	2.39e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LIHC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.38	6.06	0.31	3.69e-9	Coronary artery disease;
LIHC	cis	rs7945718	0.591	rs4515952	chr11:12690200	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.55	0.33	2.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg07451762	chr16:28383216	NA	-0.32	-6.13	-0.31	2.47e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.85	0.35	3.37e-11	Bipolar disorder;
LIHC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.48	7.87	0.39	4.59e-14	Methadone dose in opioid dependence;
LIHC	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg03037974	chr15:76606532	NA	0.91	19.73	0.73	2.06e-58	Blood metabolite levels;
LIHC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.3	-5.87	-0.3	1.04e-8	Colorectal cancer;
LIHC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	7.05	0.36	1.02e-11	Monocyte percentage of white cells;
LIHC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.45	-7.11	-0.36	6.75e-12	Total body bone mineral density;
LIHC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.47	6.62	0.34	1.38e-10	High light scatter reticulocyte count;
LIHC	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.69	11.26	0.52	3.09e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-0.73	-8.32	-0.41	2.12e-15	Hip circumference adjusted for BMI;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01390039	chr16:89315293	NA	0.43	6.14	0.32	2.25e-9	Bilirubin levels;
LIHC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg20933634	chr6:27740509	NA	0.47	6.34	0.32	7.46e-10	Parkinson's disease;
LIHC	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.46	6.35	0.32	7.05e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.72	8.35	0.41	1.74e-15	Bipolar disorder lithium response (categorical) or schizophrenia;
LIHC	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.57	-9.07	-0.44	9.85e-18	Menarche (age at onset);
LIHC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg03037974	chr15:76606532	NA	-0.64	-11.92	-0.54	1.24e-27	Blood metabolite levels;
LIHC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs2070433	0.749	rs718496	chr21:47904585	A/C	cg12379764	chr21:47803548	PCNT	0.6	8.8	0.43	6.94e-17	Lymphocyte counts;
LIHC	trans	rs3960554	0.709	rs56163935	chr7:75788744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.61	8.31	0.41	2.31e-15	Eotaxin levels;
LIHC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	9.88	0.47	1.98e-20	Post bronchodilator FEV1;
LIHC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.93	12.42	0.56	1.67e-29	Post bronchodilator FEV1;
LIHC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.57	11.04	0.51	1.86e-24	Coronary artery disease;
LIHC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.57	-10.51	-0.49	1.45e-22	Prostate cancer;
LIHC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.63	9.55	0.46	2.51e-19	Blood protein levels;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.18	-0.36	4.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2257205	0.588	rs7219856	chr17:56941020	C/T	cg12560992	chr17:57184187	TRIM37	0.67	7.28	0.37	2.36e-12	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21467203	chr3:49911342	NA	-0.5	-8.86	-0.43	4.39e-17	Body mass index;
LIHC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg27170947	chr2:26402098	FAM59B	-0.66	-8.21	-0.41	4.43e-15	Gut microbiome composition (summer);
LIHC	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-10.59	-0.5	7.56e-23	Body mass index;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.31	0.52	2.11e-25	Prudent dietary pattern;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg08122386	chr6:26195954	NA	0.54	5.98	0.31	5.6e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02969873	chr4:1330999	MAEA	-0.41	-6.3	-0.32	9.07e-10	Longevity;
LIHC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.46	10.69	0.5	3.32e-23	Iron status biomarkers (transferrin levels);
LIHC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.81	-12.62	-0.56	3.08e-30	Total body bone mineral density;
LIHC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.79	9.1	0.44	7.43e-18	Vitiligo;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.2	0.32	1.62e-9	Prudent dietary pattern;
LIHC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.66	-11.04	-0.51	1.94e-24	Childhood ear infection;
LIHC	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.52	-7.88	-0.39	4.46e-14	Extraversion;
LIHC	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.5	6.03	0.31	4.19e-9	Serum sulfate level;
LIHC	cis	rs7937890	0.559	rs1548074	chr11:14534825	A/G	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg02953397	chr1:1238678	ACAP3	0.3	6.27	0.32	1.07e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.47	-6.93	-0.35	2.09e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.37	-5.82	-0.3	1.36e-8	Tonsillectomy;
LIHC	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.5	-9.68	-0.46	9.57e-20	Endometriosis;
LIHC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	0.78	5.96	0.31	6.3e-9	IgG glycosylation;
LIHC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg14067834	chr17:29058358	SUZ12P	0.74	7.49	0.38	5.97e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.64	10.41	0.49	3.23e-22	Longevity;
LIHC	cis	rs11991744	0.510	rs7464171	chr8:124660335	G/A	cg22342100	chr8:124666123	KLHL38	-0.37	-5.93	-0.31	7.28e-9	Electrocardiographic traits;
LIHC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg14580859	chr9:123691850	NA	0.38	6.9	0.35	2.6e-11	Rheumatoid arthritis;
LIHC	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	6.02	0.31	4.52e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs1712517	0.771	rs7921655	chr10:105113701	C/T	cg05636881	chr10:105038444	INA	0.49	7.59	0.38	3e-13	Migraine;
LIHC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.81	-0.3	1.45e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg10360323	chr17:41437877	NA	0.4	5.95	0.31	6.7e-9	Menopause (age at onset);
LIHC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.13	-0.4	8.04e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	0.97	10.19	0.48	1.76e-21	Vitiligo;
LIHC	cis	rs2279817	0.863	rs13376033	chr1:18016590	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-7.99	-0.4	2.06e-14	Neuroticism;
LIHC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.71	-10.76	-0.5	1.87e-23	Prostate cancer;
LIHC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18252515	chr7:66147081	NA	-0.43	-6.02	-0.31	4.43e-9	Aortic root size;
LIHC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.22e-9	Fibrinogen levels;
LIHC	cis	rs7534824	0.625	rs61780321	chr1:101428304	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	6.73	0.34	7.3e-11	Refractive astigmatism;
LIHC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.35	0.56	3.17e-29	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.24	-0.36	3.08e-12	Diabetic kidney disease;
LIHC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg01657329	chr11:68192670	LRP5	-0.46	-5.97	-0.31	6.09e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.24	-0.32	1.29e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs12980942	0.810	rs8103839	chr19:41781493	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.57	7.01	0.35	1.27e-11	Coronary artery disease;
LIHC	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.58	-0.42	3.28e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.4	-7.36	-0.37	1.4e-12	Hepatocellular carcinoma;
LIHC	cis	rs17213078	0.505	rs737101	chr2:106732545	C/T	cg16099169	chr2:106886729	NA	0.41	6.33	0.32	7.55e-10	Facial morphology (factor 23);
LIHC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.95	-0.31	6.46e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-9.41	-0.45	7.5e-19	Coffee consumption (cups per day);
LIHC	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.62	6.36	0.33	6.65e-10	Axial length;
LIHC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.51	-7.03	-0.36	1.1e-11	Menarche (age at onset);
LIHC	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.61	-0.34	1.49e-10	Neuroticism;
LIHC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.63	8.01	0.4	1.76e-14	Morning vs. evening chronotype;
LIHC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.56	-0.33	2.02e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.71	-11.03	-0.51	2.12e-24	Corneal astigmatism;
LIHC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.16	0.36	4.94e-12	Axial length;
LIHC	cis	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg18809830	chr7:99032528	PTCD1	0.66	6.05	0.31	3.89e-9	Blood metabolite levels;
LIHC	cis	rs2257205	0.667	rs16943134	chr17:56681389	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-6.69	-0.34	8.94e-11	Pancreatic cancer;
LIHC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.48	-0.53	5.13e-26	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs9470361	0.506	rs4568449	chr6:36621143	A/G	cg08179530	chr6:36648295	CDKN1A	0.42	6.29	0.32	9.6e-10	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
LIHC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg12798992	chr6:167411361	FGFR1OP	0.43	6.6	0.34	1.59e-10	Primary biliary cholangitis;
LIHC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg12863693	chr15:85201151	NMB	0.47	6.76	0.34	5.88e-11	Schizophrenia;
LIHC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.58	6.89	0.35	2.62e-11	Bladder cancer;
LIHC	cis	rs12744310	0.887	rs17362424	chr1:41794403	A/C	cg03962019	chr1:41807865	NA	-0.4	-6.04	-0.31	4.06e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	10.24	0.48	1.22e-21	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7078219	0.505	rs41290504	chr10:101293035	C/A	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.09	-0.31	3.11e-9	Dental caries;
LIHC	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.74	0.3	2.07e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg03037974	chr15:76606532	NA	0.74	14.63	0.62	5.72e-38	Blood metabolite levels;
LIHC	trans	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg10756647	chr7:56101905	PSPH	0.47	7.06	0.36	9.12e-12	Aortic root size;
LIHC	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.56	-8.58	-0.42	3.32e-16	Platelet distribution width;
LIHC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg15691649	chr6:25882328	NA	-0.53	-7.65	-0.38	2.07e-13	Blood metabolite levels;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg18279126	chr7:2041391	MAD1L1	0.36	6.04	0.31	4.12e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.79	-0.3	1.58e-8	Alzheimer's disease (late onset);
LIHC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.42	6.7	0.34	8.72e-11	Height;
LIHC	cis	rs6788895	1.000	rs41354246	chr3:150524636	G/T	cg09723797	chr3:150481914	SIAH2	0.57	7.11	0.36	6.67e-12	Breast cancer;
LIHC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.6	7.29	0.37	2.21e-12	Heart rate;
LIHC	cis	rs4586057	0.533	rs4933618	chr10:92652571	C/T	cg14313238	chr10:92632228	RPP30	0.36	6.06	0.31	3.55e-9	Economic and political preferences (time);
LIHC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.71	-0.43	1.34e-16	Atrioventricular conduction;
LIHC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.01	0.44	1.44e-17	Height;
LIHC	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.44	8.06	0.4	1.28e-14	Resting heart rate;
LIHC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Blood protein levels;
LIHC	trans	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg17135325	chr3:160939158	NMD3	0.53	7.5	0.38	5.58e-13	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.64	10.93	0.51	4.87e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.44	-5.89	-0.3	9.03e-9	Major depressive disorder;
LIHC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.72	0.47	7.13e-20	Tonsillectomy;
LIHC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.53	-9.32	-0.45	1.45e-18	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg20607798	chr8:58055168	NA	0.64	7.95	0.39	2.75e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.72	-11.87	-0.54	1.92e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.72	8.81	0.43	6.49e-17	Gut microbiome composition (summer);
LIHC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.36	5.95	0.31	6.75e-9	Blood metabolite levels;
LIHC	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.06	-0.31	3.58e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.48	7.48	0.38	6.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.5	-0.38	5.41e-13	Initial pursuit acceleration;
LIHC	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg26395211	chr5:140044315	WDR55	-0.43	-6.32	-0.32	8.19e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.58	8.87	0.43	4.25e-17	Height;
LIHC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.05	0.31	3.91e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	trans	rs6489882	0.867	rs7958379	chr12:113363284	A/G	cg10175203	chr3:128143634	NA	0.38	6.1	0.31	2.83e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs926392	1.000	rs926392	chr20:37690464	A/G	cg16355469	chr20:37678765	NA	0.37	5.95	0.31	6.53e-9	Dialysis-related mortality;
LIHC	cis	rs12602486	1.000	rs60684277	chr17:42281307	G/A	cg13607699	chr17:42295918	UBTF	-0.78	-6.63	-0.34	1.29e-10	Glycated hemoglobin levels;
LIHC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.51	8.34	0.41	1.8e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg05110241	chr16:68378359	PRMT7	-0.66	-7.52	-0.38	5.01e-13	Schizophrenia;
LIHC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.28	-0.37	2.29e-12	IgG glycosylation;
LIHC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.47	6.03	0.31	4.21e-9	Initial pursuit acceleration;
LIHC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.01	19.13	0.72	5.34e-56	Monocyte percentage of white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18827097	chr2:3522506	ADI1	0.5	7.41	0.37	1.03e-12	Pancreatic cancer;
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg16060761	chr17:80687452	NA	-0.48	-7.19	-0.36	4.03e-12	Glycated hemoglobin levels;
LIHC	cis	rs1355223	0.902	rs35032224	chr11:34698154	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.03	-0.31	4.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.45	-0.37	7.76e-13	Obesity-related traits;
LIHC	cis	rs4930561	1.000	rs4930561	chr11:67931761	C/T	cg04465784	chr11:67976953	SUV420H1	-0.26	-5.94	-0.31	7.14e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
LIHC	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.5	7.28	0.37	2.31e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11827097	chr2:231280903	SP100	0.44	6.13	0.31	2.46e-9	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg24209194	chr3:40518798	ZNF619	-0.51	-7.52	-0.38	4.77e-13	Renal cell carcinoma;
LIHC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	8.33	0.41	2.03e-15	Platelet count;
LIHC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-5.72	-0.3	2.31e-8	Bipolar disorder;
LIHC	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg23682824	chr7:23144976	KLHL7	0.4	6.0	0.31	4.94e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.9	0.35	2.58e-11	Lung cancer;
LIHC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.57	-7.38	-0.37	1.2e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg16558253	chr16:72132732	DHX38	-0.38	-6.36	-0.33	6.44e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg21174375	chr14:64681225	SYNE2	0.38	6.1	0.31	2.86e-9	Atrial fibrillation;
LIHC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.96	0.44	2.09e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.76	7.97	0.4	2.44e-14	Chronic kidney disease;
LIHC	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg14558262	chr17:40713999	COASY	0.63	9.7	0.46	8.39e-20	Crohn's disease;
LIHC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.82	0.43	5.98e-17	Eosinophil percentage of white cells;
LIHC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.32	-6.48	-0.33	3.13e-10	Platelet distribution width;
LIHC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg04756594	chr16:24857601	SLC5A11	0.48	7.46	0.37	7.15e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1062177	1.000	rs12653926	chr5:151250248	C/A	cg00977110	chr5:151150581	G3BP1	0.51	6.34	0.32	7.45e-10	Preschool internalizing problems;
LIHC	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-0.81	-8.38	-0.41	1.35e-15	Blood pressure (smoking interaction);
LIHC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.73	0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.64	12.93	0.57	2.11e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg16673477	chr19:18812017	CRTC1	-0.41	-6.64	-0.34	1.26e-10	Menarche (age at onset);
LIHC	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg10820045	chr2:198174542	NA	0.48	7.49	0.38	5.73e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.52	7.08	0.36	8.02e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.31	0.52	2.11e-25	Lung cancer in ever smokers;
LIHC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-6.01	-0.31	4.69e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.45	6.9	0.35	2.53e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.48	6.73	0.34	6.98e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	0.83	10.83	0.51	1.07e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.71	-7.61	-0.38	2.76e-13	Vitiligo;
LIHC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.49	-0.42	6.46e-16	Putamen volume;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08677398	chr8:58056175	NA	0.4	6.05	0.31	3.89e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	9.68	0.46	9.89e-20	Lymphocyte counts;
LIHC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.65	12.87	0.57	3.42e-31	Schizophrenia;
LIHC	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.53	8.95	0.44	2.31e-17	Coronary artery disease;
LIHC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.42	-6.56	-0.33	2.05e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.89	12.96	0.57	1.58e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs4407350	1.000	rs5765724	chr22:44921575	G/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.11	-0.31	2.64e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg03013999	chr17:37608204	MED1	0.36	6.03	0.31	4.18e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.12	-0.55	2.19e-28	Colorectal cancer;
LIHC	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.72	11.26	0.52	3.11e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs7260329	0.507	rs1552222	chr19:41525904	T/A	cg10403441	chr19:41533888	NA	0.46	6.12	0.31	2.58e-9	Smoking behavior;
LIHC	cis	rs6429082	0.902	rs704708	chr1:235620134	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	6.11	0.31	2.77e-9	Adiposity;
LIHC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.53	5.78	0.3	1.68e-8	Menopause (age at onset);
LIHC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.39	0.45	8.39e-19	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.37	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg26338869	chr17:61819248	STRADA	0.54	7.17	0.36	4.67e-12	Height;
LIHC	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.62	-6.76	-0.34	6.02e-11	Putamen volume;
LIHC	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.2	5.74	0.3	2.13e-8	Mean corpuscular volume;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg03874509	chr1:107600012	PRMT6	0.73	11.65	0.53	1.26e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs937213	0.676	rs8042456	chr15:40290476	G/T	cg16127683	chr15:40268777	EIF2AK4	-0.44	-6.7	-0.34	8.53e-11	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	trans	rs6489882	0.867	rs7316586	chr12:113365828	C/T	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.95	0.76	2.86e-67	Prudent dietary pattern;
LIHC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.91	10.06	0.48	5.21e-21	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.43	-6.08	-0.31	3.14e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.69	-10.45	-0.49	2.24e-22	Longevity;
LIHC	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.41	-6.01	-0.31	4.66e-9	Life satisfaction;
LIHC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08893839	chr5:154027129	NA	-0.5	-6.86	-0.35	3.3e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.82	-6.6	-0.34	1.53e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg05110241	chr16:68378359	PRMT7	-0.92	-9.38	-0.45	9.61e-19	Schizophrenia;
LIHC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg05535760	chr7:792225	HEATR2	-0.49	-6.74	-0.34	6.85e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.68	10.27	0.49	9.42e-22	Response to diuretic therapy;
LIHC	cis	rs16958440	0.581	rs72907280	chr18:44681130	C/T	cg17192377	chr18:44677553	HDHD2	0.71	7.79	0.39	8.32e-14	Sitting height ratio;
LIHC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.36	-6.74	-0.34	6.81e-11	Sudden cardiac arrest;
LIHC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.1	0.36	7.4e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.64	-11.32	-0.52	1.86e-25	Dental caries;
LIHC	trans	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg25214090	chr10:38739885	LOC399744	-0.38	-6.2	-0.32	1.65e-9	Diastolic blood pressure;
LIHC	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.44	7.06	0.36	9.32e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01117833	chr14:94547303	DDX24;IFI27L1	0.37	6.23	0.32	1.37e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6466055	0.720	rs4730080	chr7:105001133	T/C	cg04380332	chr7:105027541	SRPK2	-0.37	-6.89	-0.35	2.66e-11	Schizophrenia;
LIHC	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.02	-19.93	-0.73	3.41e-59	Exhaled nitric oxide output;
LIHC	cis	rs2580764	0.517	rs2972070	chr2:55301691	G/A	cg09592903	chr2:55203963	RTN4	0.62	11.27	0.52	2.79e-25	Mean platelet volume;
LIHC	cis	rs1982963	0.627	rs61971554	chr14:52491583	A/G	cg10843707	chr14:52510701	NID2	0.36	5.84	0.3	1.18e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg16405210	chr4:1374714	KIAA1530	0.41	6.07	0.31	3.46e-9	Obesity-related traits;
LIHC	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.78	8.98	0.44	1.88e-17	Exhaled nitric oxide levels;
LIHC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.57	11.54	0.53	2.97e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.53	6.77	0.34	5.69e-11	Schizophrenia;
LIHC	trans	rs8113308	0.688	rs7259507	chr19:52445728	A/G	cg14959425	chr7:20447707	ITGB8	-0.47	-6.1	-0.31	2.87e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs12079745	0.793	rs12092952	chr1:169389715	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.82	-7.17	-0.36	4.62e-12	QT interval;
LIHC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.96	11.55	0.53	2.78e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-16.31	-0.66	1.22e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.43	6.49	0.33	3.07e-10	Coronary artery disease;
LIHC	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.23	6.22	0.32	1.45e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.07	0.36	8.94e-12	Diabetic kidney disease;
LIHC	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.61	-9.09	-0.44	8.15e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs7577696	0.597	rs6756085	chr2:32336522	A/G	cg02381751	chr2:32503542	YIPF4	-0.45	-6.36	-0.33	6.44e-10	Inflammatory biomarkers;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.89	0.57	2.96e-31	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg05590025	chr7:65112418	INTS4L2	-0.54	-5.91	-0.3	8.45e-9	Diabetic kidney disease;
LIHC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg16989086	chr20:62203971	PRIC285	0.56	8.07	0.4	1.2e-14	Glioblastoma;
LIHC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.38	6.27	0.32	1.07e-9	Height;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.1	0.55	2.65e-28	Height;
LIHC	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg03146154	chr1:46216737	IPP	-0.38	-6.29	-0.32	9.94e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.59	-8.33	-0.41	1.97e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.42	0.41	1.05e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.36	-8.44	-0.42	9.08e-16	Immature fraction of reticulocytes;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.13	-0.52	9.51e-25	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.25	-7.83	-0.39	6.11e-14	Mean corpuscular volume;
LIHC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.75	11.44	0.53	7.26e-26	Corneal astigmatism;
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.73	0.43	1.17e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg10820045	chr2:198174542	NA	-0.43	-6.53	-0.33	2.35e-10	Intracranial aneurysm;
LIHC	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.47	6.69	0.34	9.13e-11	Lung cancer;
LIHC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.71	-12.56	-0.56	5.15e-30	Prudent dietary pattern;
LIHC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.56	7.15	0.36	5.31e-12	Parkinson's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17127132	chr2:85788382	GGCX	0.4	6.14	0.32	2.31e-9	Pancreatic cancer;
LIHC	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.76	10.16	0.48	2.22e-21	Post bronchodilator FEV1;
LIHC	cis	rs72653721	0.730	rs56074859	chr6:11044089	C/T	cg13562911	chr6:11044106	ELOVL2	0.52	7.45	0.37	7.45e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04498913	chr7:1135747	C7orf50	0.43	6.9	0.35	2.52e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.51	0.59	1.31e-33	Colorectal cancer;
LIHC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.83	10.86	0.51	8.58e-24	Cognitive function;
LIHC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-6.42	-0.33	4.58e-10	Urate levels in lean individuals;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.49	-6.27	-0.32	1.08e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6815814	0.731	rs11734342	chr4:38773109	A/G	cg06935464	chr4:38784597	TLR10	0.37	5.93	0.31	7.47e-9	Breast cancer;
LIHC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16576597	chr16:28551801	NUPR1	0.47	6.99	0.35	1.43e-11	Body mass index;
LIHC	cis	rs16944613	0.510	rs10520692	chr15:91154471	A/G	cg26821196	chr15:91095069	CRTC3	0.31	5.91	0.3	8.06e-9	Colorectal cancer;
LIHC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.57	11.02	0.51	2.3e-24	Coronary artery disease;
LIHC	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.11e-35	White blood cell count (basophil);
LIHC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.39	5.71	0.3	2.41e-8	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs792448	0.743	rs351378	chr1:212425196	T/C	cg20223728	chr6:6006398	NRN1	0.35	6.2	0.32	1.65e-9	White blood cell count (basophil);
LIHC	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.76	-12.77	-0.57	8.35e-31	Coronary artery disease;
LIHC	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.07	0.36	8.67e-12	Exhaled nitric oxide output;
LIHC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.97	-0.31	6.01e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.94	-0.35	1.96e-11	Acylcarnitine levels;
LIHC	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.0	0.48	8.3e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs611744	1.000	rs611744	chr8:109228008	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-5.86	-0.3	1.08e-8	Alzheimer's disease (late onset);
LIHC	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	11.71	0.53	7.6e-27	Schizophrenia;
LIHC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.35	-0.37	1.51e-12	Platelet count;
LIHC	cis	rs2191566	0.664	rs62115482	chr19:44554083	C/A	cg20607764	chr19:44506953	ZNF230	-0.37	-6.14	-0.32	2.24e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.09	-0.55	2.81e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.91	-0.39	3.48e-14	Monocyte percentage of white cells;
LIHC	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2.1e-12	Exhaled nitric oxide output;
LIHC	cis	rs6442522	1.000	rs13075694	chr3:15450400	C/T	cg16303742	chr3:15540471	COLQ	0.41	6.95	0.35	1.91e-11	Uric acid levels;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02290350	chr8:58132656	NA	0.5	10.21	0.48	1.49e-21	Developmental language disorder (linguistic errors);
LIHC	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.9	11.02	0.51	2.34e-24	Prostate cancer;
LIHC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.09	13.07	0.58	6.34e-32	Vitiligo;
LIHC	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg20991723	chr1:152506922	NA	0.55	9.44	0.45	6.15e-19	Hair morphology;
LIHC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs3099143	0.901	rs76036665	chr15:77232720	A/G	cg21673338	chr15:77095150	SCAPER	-0.54	-7.34	-0.37	1.57e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg05527609	chr1:210001259	C1orf107	-0.58	-7.83	-0.39	6.22e-14	Red blood cell count;
LIHC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg21724239	chr8:58056113	NA	0.49	6.36	0.33	6.38e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.56	5.92	0.3	7.86e-9	IgG glycosylation;
LIHC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.24	11.03	0.51	2.16e-24	Uric acid levels;
LIHC	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02290350	chr8:58132656	NA	0.49	10.45	0.49	2.26e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.42	-0.41	1.04e-15	Lymphocyte counts;
LIHC	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.49	8.97	0.44	1.96e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11645453	chr3:52864694	ITIH4	0.21	5.82	0.3	1.38e-8	Bipolar disorder;
LIHC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-6.93	-0.35	2.06e-11	Lung cancer;
LIHC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.5	7.95	0.39	2.75e-14	Alzheimer's disease;
LIHC	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.23	0.61	2.02e-36	Bipolar disorder;
LIHC	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg20240347	chr1:204465584	NA	-0.34	-7.13	-0.36	5.89e-12	Schizophrenia;
LIHC	cis	rs8038465	0.615	rs6495074	chr15:73959013	A/G	cg15420318	chr15:73925796	NPTN	0.44	6.75	0.34	6.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.98	-0.31	5.63e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg17675199	chr6:35436792	RPL10A	0.34	6.63	0.34	1.32e-10	Coronary artery disease;
LIHC	cis	rs12079745	0.793	rs78967023	chr1:169419543	C/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.72	-6.62	-0.34	1.37e-10	QT interval;
LIHC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.35	-6.52	-0.33	2.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-6.13	-0.31	2.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.4	-0.41	1.23e-15	Renal cell carcinoma;
LIHC	cis	rs3018712	0.532	rs55761963	chr11:68402629	G/T	cg20283391	chr11:68216788	NA	-0.5	-5.99	-0.31	5.23e-9	Total body bone mineral density;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg06820907	chr2:242122206	PPP1R7	0.42	6.62	0.34	1.37e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.85	-0.3	1.14e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg22771759	chr13:24902376	NA	0.32	6.6	0.34	1.54e-10	Obesity-related traits;
LIHC	cis	rs4934494	0.727	rs2418929	chr10:91501477	C/G	cg19698084	chr10:91461284	KIF20B	-0.45	-6.02	-0.31	4.44e-9	Red blood cell count;
LIHC	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.5	8.04	0.4	1.51e-14	Corneal astigmatism;
LIHC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	6.71	0.34	8.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	9.19	0.45	3.83e-18	Platelet count;
LIHC	cis	rs2637266	0.783	rs7900420	chr10:78476543	T/C	cg18941641	chr10:78392320	NA	0.27	5.81	0.3	1.45e-8	Pulmonary function;
LIHC	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg09572067	chr16:29127029	RRN3P2	0.5	7.88	0.39	4.55e-14	Menopause (age at onset);
LIHC	cis	rs7534824	0.625	rs17525507	chr1:101430504	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	7.0	0.35	1.34e-11	Refractive astigmatism;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg07133347	chr1:107600762	PRMT6	0.46	6.83	0.35	3.87e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.51	8.57	0.42	3.55e-16	Coronary artery disease;
LIHC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg16736954	chr20:23401023	NAPB	0.72	8.44	0.42	9.01e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	1.21	11.07	0.51	1.47e-24	Obesity-related traits;
LIHC	trans	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg10756647	chr7:56101905	PSPH	1.11	13.6	0.59	5.63e-34	Diabetic kidney disease;
LIHC	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.72	10.82	0.5	1.19e-23	Subjective well-being;
LIHC	cis	rs6449957	0.607	rs251394	chr5:67512000	C/G	cg23036683	chr5:67512108	NA	0.53	7.75	0.39	1.05e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.54	-7.83	-0.39	6.27e-14	Initial pursuit acceleration;
LIHC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.68	13.8	0.6	9.85e-35	Coronary artery disease;
LIHC	cis	rs7296418	0.961	rs61955196	chr12:123451018	G/C	cg05973401	chr12:123451056	ABCB9	0.46	6.97	0.35	1.67e-11	Platelet count;
LIHC	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.51	6.12	0.31	2.57e-9	Metabolite levels;
LIHC	cis	rs7674212	0.540	rs2711897	chr4:104023567	C/T	cg16532752	chr4:104119610	CENPE	-0.43	-6.86	-0.35	3.31e-11	Type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.69	-7.3	-0.37	2.05e-12	Alzheimer's disease;
LIHC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.3	0.45	1.65e-18	Melanoma;
LIHC	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-10.46	-0.49	2.06e-22	Colorectal cancer;
LIHC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg03037974	chr15:76606532	NA	-0.59	-10.09	-0.48	4.02e-21	Blood metabolite levels;
LIHC	trans	rs7657257	1.000	rs11931532	chr4:15725766	A/G	cg17675199	chr6:35436792	RPL10A	-0.39	-6.26	-0.32	1.12e-9	Blood protein levels;
LIHC	cis	rs4407350	0.756	rs135622	chr22:44890658	T/C	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.45	-0.33	3.88e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03255221	chr20:57617810	SLMO2	0.45	6.03	0.31	4.15e-9	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.48	0.37	6.39e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	7.34	0.37	1.6e-12	Menarche (age at onset);
LIHC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02290350	chr8:58132656	NA	0.4	8.44	0.42	9.38e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-7.07	-0.36	8.67e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.95	-12.4	-0.56	2.1e-29	Obesity-related traits;
LIHC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.45	9.93e-19	Bipolar disorder;
LIHC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.94	-0.35	2.02e-11	Total cholesterol levels;
LIHC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.22	-0.36	3.29e-12	Bipolar disorder;
LIHC	cis	rs11955398	0.716	rs3857236	chr5:59909529	G/A	cg02684056	chr5:59996105	DEPDC1B	0.41	6.09	0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.45	-0.53	6.54e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.8	-0.47	3.77e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.33	6.29	0.32	9.45e-10	Renal cell carcinoma;
LIHC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.63	8.59	0.42	3.11e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.94	9.63	0.46	1.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.57	7.89	0.39	4.22e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.71	11.05	0.51	1.77e-24	Corneal astigmatism;
LIHC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.43	6.78	0.34	5.3e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg00334542	chr7:100209784	MOSPD3	-0.72	-7.41	-0.37	1.01e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2599510	0.783	rs2710626	chr2:32758754	G/C	cg02381751	chr2:32503542	YIPF4	0.48	6.66	0.34	1.07e-10	Interleukin-18 levels;
LIHC	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.33	-0.32	7.62e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17152411	1.000	rs7914110	chr10:126599886	C/G	cg07906193	chr10:126599966	NA	0.49	7.4	0.37	1.05e-12	Height;
LIHC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs75064307	0.834	rs7636575	chr3:108115862	C/T	cg03329597	chr3:108125523	MYH15	-0.49	-6.58	-0.34	1.79e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2710642	0.611	rs1534419	chr2:62883936	C/A	cg17519650	chr2:63277830	OTX1	0.52	7.51	0.38	5.26e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.0	15.32	0.64	1.06e-40	Breast cancer;
LIHC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.48	7.47	0.37	6.65e-13	Fibrinogen levels;
LIHC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg10130564	chr11:117069849	TAGLN	-0.37	-6.21	-0.32	1.51e-9	Blood protein levels;
LIHC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	cis	rs10426930	0.763	rs7257002	chr19:5043527	G/T	cg18473234	chr19:5097819	KDM4B	0.54	6.79	0.34	4.86e-11	Monocyte percentage of white cells;
LIHC	trans	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg10756647	chr7:56101905	PSPH	0.64	8.81	0.43	6.36e-17	Corneal structure;
LIHC	cis	rs6782228	0.527	rs7426806	chr3:128412930	G/A	cg16766828	chr3:128327626	NA	-0.37	-5.77	-0.3	1.74e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg12698662	chr3:15914712	MIR563	-0.39	-7.32	-0.37	1.74e-12	Mean platelet volume;
LIHC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.73	-10.0	-0.48	7.94e-21	Monocyte percentage of white cells;
LIHC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.27	-6.61	-0.34	1.51e-10	Cutaneous nevi;
LIHC	trans	rs71658797	0.536	rs12034334	chr1:77954397	G/C	cg04606550	chr5:14226569	TRIO	0.41	6.25	0.32	1.19e-9	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
LIHC	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.86	-6.53	-0.33	2.43e-10	Mosquito bite size;
LIHC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.36	-6.08	-0.31	3.12e-9	IgG glycosylation;
LIHC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.72	-14.47	-0.62	2.26e-37	Body mass index;
LIHC	trans	rs4146653	0.671	rs4639834	chr10:4768818	C/T	cg25345178	chr8:72459908	NA	-0.32	-6.12	-0.31	2.51e-9	Major depressive disorder;
LIHC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27297192	chr10:134578999	INPP5A	-0.52	-8.26	-0.41	3.33e-15	Migraine;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.19	0.55	1.25e-28	Height;
LIHC	cis	rs611744	0.967	rs641820	chr8:109190717	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.43	-6.68	-0.34	9.8e-11	Dental caries;
LIHC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.6	8.3	0.41	2.48e-15	Lung cancer;
LIHC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.83	0.39	6.12e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.41	6.69	0.34	9.19e-11	Cleft lip with or without cleft palate;
LIHC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.8	-0.3	1.51e-8	Menopause (age at onset);
LIHC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.58	11.84	0.54	2.36e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.46	-6.16	-0.32	2.07e-9	Large artery stroke;
LIHC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.98	0.31	5.59e-9	Eosinophil percentage of white cells;
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg00280220	chr17:61926910	NA	0.43	6.87	0.35	3.04e-11	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00767560	chr19:19887256	LOC284440	0.5	7.91	0.39	3.53e-14	Cognitive function;
LIHC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02985541	chr2:219472218	PLCD4	-0.42	-6.83	-0.35	3.99e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.68	-13.73	-0.6	1.85e-34	Pulse pressure;
LIHC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg14067834	chr17:29058358	SUZ12P	-0.6	-5.86	-0.3	1.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.52	0.53	3.51e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.32	-5.82	-0.3	1.33e-8	Calcium levels;
LIHC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.4	6.75	0.34	6.2e-11	Blood metabolite levels;
LIHC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.01	-0.35	1.26e-11	Bipolar disorder;
LIHC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.32	0.58	6.47e-33	Cognitive test performance;
LIHC	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.45	-8.0	-0.4	1.9e-14	Inhibitory control;
LIHC	cis	rs2274273	0.870	rs11851169	chr14:55815932	G/A	cg01864836	chr14:55583639	NA	-0.37	-6.59	-0.34	1.66e-10	Protein biomarker;
LIHC	cis	rs918629	0.716	rs6881355	chr5:95274795	C/T	cg10483112	chr5:95245456	ELL2	-0.35	-6.02	-0.31	4.47e-9	IgG glycosylation;
LIHC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.53	0.46	3.02e-19	Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.37	7.2	0.36	3.89e-12	Renal cell carcinoma;
LIHC	cis	rs507080	0.883	rs12798453	chr11:118561410	T/G	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.78e-10	Serum metabolite levels;
LIHC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.75	13.46	0.59	1.94e-33	Platelet count;
LIHC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.67	8.4	0.41	1.18e-15	Gut microbiome composition (summer);
LIHC	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.87	-0.39	4.77e-14	Morning vs. evening chronotype;
LIHC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg06050784	chr16:88016603	BANP	0.35	6.33	0.32	7.66e-10	Menopause (age at onset);
LIHC	trans	rs7219021	1.000	rs11657371	chr17:46843873	T/C	cg14968300	chr8:23585186	NA	-0.35	-6.44	-0.33	3.97e-10	Schizophrenia or bipolar disorder;
LIHC	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.77	9.18	0.44	4.23e-18	Coronary artery disease;
LIHC	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-0.58	-7.1	-0.36	7.31e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg08345082	chr10:99160200	RRP12	-0.39	-6.43	-0.33	4.33e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.84	11.0	0.51	2.62e-24	Coronary artery disease;
LIHC	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.84	-0.35	3.61e-11	Metabolite levels;
LIHC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.06	-0.51	1.58e-24	Hemoglobin concentration;
LIHC	cis	rs611744	0.934	rs604698	chr8:109238721	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs17756712	0.527	rs1193742	chr6:635629	T/C	cg14374089	chr6:596013	EXOC2	0.42	5.88	0.3	9.56e-9	Vertical cup-disc ratio;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg00958676	chr8:9911641	MSRA	0.54	6.23	0.32	1.36e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.77	11.49	0.53	4.54e-26	Corneal astigmatism;
LIHC	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-0.73	-8.47	-0.42	7.54e-16	Exhaled nitric oxide output;
LIHC	cis	rs10861342	1.000	rs73395802	chr12:105588718	T/C	cg23923672	chr12:105501055	KIAA1033	0.64	7.58	0.38	3.22e-13	IgG glycosylation;
LIHC	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.74	11.55	0.53	2.81e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10792665	0.649	rs4619175	chr11:82741029	G/A	cg24227371	chr11:82718527	RAB30	-0.38	-9.25	-0.45	2.49e-18	Obesity-related traits;
LIHC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.61	-8.61	-0.42	2.66e-16	Motion sickness;
LIHC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.52	7.23	0.36	3.2e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.72	0.54	6.76e-27	Motion sickness;
LIHC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.59	0.38	3.12e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg27205649	chr11:78285834	NARS2	-0.38	-5.89	-0.3	9.24e-9	Alzheimer's disease (survival time);
LIHC	cis	rs797680	0.856	rs6703310	chr1:93788740	A/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.06	-0.31	3.6e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	10.99	0.51	3.01e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.58	11.21	0.52	4.87e-25	Coronary artery disease;
LIHC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.69	11.81	0.54	3.16e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.43	-6.69	-0.34	8.95e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg24955955	chr5:415729	AHRR	0.32	6.63	0.34	1.28e-10	Cystic fibrosis severity;
LIHC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.56	9.25	0.45	2.48e-18	Longevity;Endometriosis;
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg17691542	chr6:26056736	HIST1H1C	0.44	6.54	0.33	2.27e-10	Height;
LIHC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-9.61	-0.46	1.67e-19	Asthma;
LIHC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg19302996	chr17:73780495	UNK	-0.54	-6.71	-0.34	8.24e-11	Psoriasis;
LIHC	cis	rs1395	0.634	rs62130713	chr2:27525661	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-5.9	-0.3	8.7e-9	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	5.87e-9	Menopause (age at onset);
LIHC	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg04374321	chr14:90722782	PSMC1	-0.49	-6.86	-0.35	3.23e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	16.09	0.66	8.95e-44	Electrocardiographic conduction measures;
LIHC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.56	7.98	0.4	2.16e-14	Parkinson's disease;
LIHC	cis	rs6604026	0.740	rs10782946	chr1:93352669	G/A	cg17283838	chr1:93427260	FAM69A	-0.42	-5.8	-0.3	1.48e-8	Multiple sclerosis;
LIHC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	1.04	21.69	0.76	3.13e-66	Breast cancer;
LIHC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.43	6.39	0.33	5.3e-10	Neuroticism;
LIHC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.16	-13.14	-0.58	3.16e-32	White matter hyperintensity burden;
LIHC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7523273	0.927	rs1891423	chr1:207931913	G/A	cg22525895	chr1:207977042	MIR29B2	0.69	10.64	0.5	4.98e-23	Schizophrenia;
LIHC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.62	0.34	1.36e-10	Morning vs. evening chronotype;
LIHC	trans	rs7102494	1.000	rs35533964	chr11:129238527	C/A	cg00296894	chr2:3685756	COLEC11	0.68	6.07	0.31	3.39e-9	Breast cancer;
LIHC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg18944383	chr4:111397179	ENPEP	0.24	6.14	0.32	2.25e-9	Height;
LIHC	cis	rs1789	0.786	rs6414768	chr4:15695363	A/G	cg21329975	chr4:15471214	CC2D2A	-0.4	-5.89	-0.3	9.39e-9	Blood protein levels;
LIHC	trans	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg17675199	chr6:35436792	RPL10A	-0.44	-8.99	-0.44	1.74e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.76	0.3	1.89e-8	Tuberculosis;
LIHC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.55	0.59	8.81e-34	Colorectal cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01699524	chr5:7869638	MTRR;FASTKD3	-0.46	-6.14	-0.32	2.3e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.81	-0.3	1.45e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.42	6.19	0.32	1.74e-9	Height;
LIHC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg05267444	chr8:11627012	NEIL2	0.54	6.96	0.35	1.79e-11	Myopia (pathological);
LIHC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg03517284	chr6:25882590	NA	-0.38	-5.72	-0.3	2.27e-8	Height;
LIHC	cis	rs6545883	0.860	rs6545848	chr2:61461183	G/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.22	-0.36	3.31e-12	Tuberculosis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08711378	chr8:11471054	NA	0.28	6.29	0.32	9.86e-10	Hepatitis;
LIHC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.63	6.3	0.32	9.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18382599	chr1:43124310	PPIH	0.43	6.51	0.33	2.6e-10	Lung function (FEV1/FVC);
LIHC	cis	rs911119	0.913	rs3004139	chr20:23578674	C/T	cg16589663	chr20:23618590	CST3	-0.69	-7.33	-0.37	1.71e-12	Chronic kidney disease;
LIHC	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg26913058	chr16:419975	MRPL28	-0.5	-6.99	-0.35	1.49e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	13.87	0.6	4.98e-35	Multiple sclerosis;
LIHC	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.74	-0.47	6.22e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2882877	0.560	rs11568351	chr2:190445194	C/G	cg10752008	chr2:190445175	SLC40A1	-0.63	-7.89	-0.39	4.23e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.64	-10.58	-0.5	7.81e-23	Pediatric autoimmune diseases;
LIHC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.28	6.19	0.32	1.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.9	0.3	8.83e-9	Bladder cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09720207	chr12:54400125	NA	0.46	6.23	0.32	1.36e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.73	0.6	1.84e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.66	8.05	0.4	1.35e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg11764359	chr7:65958608	NA	0.6	6.38	0.33	5.71e-10	Diabetic kidney disease;
LIHC	cis	rs8084351	0.546	rs11664095	chr18:50763183	A/G	cg24270629	chr18:50823537	DCC	-0.46	-6.7	-0.34	8.41e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.11	12.98	0.57	1.32e-31	Vitiligo;
LIHC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.64	9.88	0.47	2.1e-20	Height;
LIHC	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg19680672	chr10:131412579	MGMT	0.42	6.38	0.33	5.85e-10	Response to temozolomide;
LIHC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.86	20.08	0.74	8.69e-60	Gestational age at birth (maternal effect);
LIHC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.8	0.54	3.41e-27	Cognitive ability;
LIHC	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.49	-9.86	-0.47	2.35e-20	Left ventricular obstructive tract defect (inherited effect);
LIHC	cis	rs1144333	0.655	rs4949681	chr1:76409828	C/T	cg10523679	chr1:76189770	ACADM	0.46	6.29	0.32	9.93e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs17433710	0.543	rs10799865	chr1:162651824	C/G	cg01063088	chr1:162760584	HSD17B7	0.45	6.19	0.32	1.76e-9	Dupuytren's disease;
LIHC	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.58	0.42	3.45e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg25356066	chr3:128598488	ACAD9	0.53	7.4	0.37	1.08e-12	IgG glycosylation;
LIHC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.44	5.76	0.3	1.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.39	-6.15	-0.32	2.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg27386326	chr11:61587980	NA	0.71	15.31	0.64	1.16e-40	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.2	-0.36	3.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.23	-0.36	3.2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg07645718	chr20:61493192	TCFL5	0.79	6.54	0.33	2.28e-10	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00958927	chr1:175162553	KIAA0040	-0.37	-6.22	-0.32	1.48e-9	Alcohol dependence;
LIHC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.46	6.65	0.34	1.17e-10	Schizophrenia;
LIHC	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-5.87	-0.3	1.03e-8	Vitiligo;
LIHC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	1.05	12.79	0.57	7.17e-31	Vitiligo;
LIHC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	12.5	0.56	8.71e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.6	-10.37	-0.49	4.42e-22	Diisocyanate-induced asthma;
LIHC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.87	-0.3	1.01e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.35	-6.0	-0.31	5.14e-9	Mean platelet volume;
LIHC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	1.2	13.91	0.6	3.69e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26897989	chr16:1907736	C16orf73	-0.47	-5.83	-0.3	1.31e-8	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg02079420	chr8:82753780	SNX16	-0.37	-6.65	-0.34	1.17e-10	Diastolic blood pressure;
LIHC	cis	rs9814567	0.858	rs4955548	chr3:134341060	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-9.98	-0.47	9.67e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.06	-0.31	3.63e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7116495	1.000	rs607446	chr11:71789252	G/A	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs965469	1.000	rs6051747	chr20:3307945	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg23149560	chr2:74406255	MOBKL1B	0.41	5.75	0.3	2.02e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg09795085	chr6:101329169	ASCC3	-0.52	-7.17	-0.36	4.63e-12	Neuroticism;
LIHC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.81	-0.39	7.2e-14	Body mass index;
LIHC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.4	6.28	0.32	1.04e-9	Resting heart rate;
LIHC	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-7.99	-0.4	2.15e-14	Vitamin D levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25506325	chr7:2093962	MAD1L1	0.43	6.4	0.33	5.19e-10	Longevity;
LIHC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.8	-12.07	-0.55	3.42e-28	Coronary artery disease;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg23752198	chr20:30311963	BCL2L1	-0.55	-6.7	-0.34	8.84e-11	Bronchial neuroendocrine tumor;
LIHC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.26	-6.07	-0.31	3.45e-9	Subjective well-being;
LIHC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.44	-0.37	8.35e-13	Response to antipsychotic treatment;
LIHC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.05	16.49	0.67	2.21e-45	Breast cancer;
LIHC	cis	rs2279817	0.863	rs13375960	chr1:18016687	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-7.99	-0.4	2.06e-14	Neuroticism;
LIHC	cis	rs75920871	0.588	rs688456	chr11:116722551	G/T	cg04087571	chr11:116723030	SIK3	-0.29	-5.72	-0.3	2.34e-8	Subjective well-being;
LIHC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.54	-0.86	3e-103	Myeloid white cell count;
LIHC	cis	rs10861342	1.000	rs703683	chr12:105567135	T/C	cg23923672	chr12:105501055	KIAA1033	0.64	7.64	0.38	2.26e-13	IgG glycosylation;
LIHC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	1.05	12.28	0.55	5.87e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs9649465	0.967	rs13225110	chr7:123340849	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.18e-15	Migraine;
LIHC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.67e-9	Schizophrenia;
LIHC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.27e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2574704	0.603	rs3856802	chr3:11667714	C/T	cg15876825	chr3:11651881	VGLL4	-0.41	-6.73	-0.34	7.34e-11	Body mass index;
LIHC	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.53	-5.93	-0.31	7.57e-9	Ulcerative colitis;
LIHC	trans	rs9641123	0.643	rs6975603	chr7:93206375	A/C	cg09745688	chr16:2908918	PRSS22	-0.37	-6.38	-0.33	5.87e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg09594475	chr20:60884601	LAMA5	-0.53	-6.28	-0.32	1.06e-9	Colorectal cancer;
LIHC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21467203	chr3:49911342	NA	-0.58	-10.57	-0.5	8.47e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.35	-7.38	-0.37	1.2e-12	Longevity;
LIHC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-1.03	-20.55	-0.74	1.15e-61	Breast cancer;
LIHC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.78	0.39	8.7e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs787274	1.000	rs787298	chr9:115542206	C/T	cg13803584	chr9:115635662	SNX30	-0.57	-6.31	-0.32	8.49e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg05848834	chr11:43543746	NA	-0.3	-6.07	-0.31	3.49e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.82	-9.03	-0.44	1.25e-17	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	14.26	0.61	1.52e-36	Chronic sinus infection;
LIHC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.63	10.29	0.49	8.39e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.74	11.27	0.52	2.83e-25	Urate levels in overweight individuals;
LIHC	cis	rs2204008	0.642	rs11169812	chr12:37995530	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.01	-0.35	1.28e-11	Bladder cancer;
LIHC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.57	10.29	0.49	7.98e-22	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg03037974	chr15:76606532	NA	0.74	14.33	0.61	8.31e-37	Blood metabolite levels;
LIHC	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.44	8.72	0.43	1.26e-16	Testicular germ cell tumor;
LIHC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17507749	chr15:85114479	UBE2QP1	0.72	8.32	0.41	2.12e-15	Schizophrenia;
LIHC	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.78	11.05	0.51	1.79e-24	Response to hepatitis C treatment;
LIHC	cis	rs9596863	0.898	rs67601073	chr13:54322196	A/T	ch.13.53330881F	chr13:54432880	NA	0.42	5.73	0.3	2.19e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.13	-0.44	6.13e-18	Bipolar disorder;
LIHC	cis	rs12744310	1.000	rs56096486	chr1:41771230	A/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg10756647	chr7:56101905	PSPH	1.1	13.62	0.59	4.65e-34	Diabetic kidney disease;
LIHC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.22e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2292096	0.636	rs6658395	chr1:200748760	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.55	-10.56	-0.5	9.47e-23	Epilepsy;
LIHC	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg05760424	chr2:242988095	NA	-0.54	-7.28	-0.37	2.37e-12	Obesity-related traits;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs2979489	0.773	rs2915617	chr8:30272310	C/G	cg26383811	chr8:30366931	RBPMS	0.47	7.71	0.38	1.41e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg02951883	chr7:2050386	MAD1L1	-0.56	-8.45	-0.42	8.44e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs903552	0.673	rs4965878	chr15:102009589	C/T	cg06707286	chr15:102010195	PCSK6	-0.55	-7.78	-0.39	8.54e-14	Diabetic kidney disease;
LIHC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.47	7.24	0.36	3.01e-12	Height;
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27297192	chr10:134578999	INPP5A	0.52	7.81	0.39	6.95e-14	Migraine;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.57	0.42	3.6e-16	Corneal astigmatism;
LIHC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	0.97	10.23	0.48	1.33e-21	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.46	8.51	0.42	5.74e-16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg00529422	chr1:16285251	ZBTB17	0.34	6.54	0.33	2.22e-10	Systolic blood pressure;
LIHC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.49	6.51	0.33	2.66e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-6.65	-0.34	1.14e-10	Vitiligo;
LIHC	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.42	7.63	0.38	2.42e-13	Glaucoma;
LIHC	cis	rs116248771	0.739	rs73156489	chr3:158414026	C/T	cg16708174	chr3:158430962	RARRES1	0.49	6.48	0.33	3.25e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.02	-0.35	1.22e-11	Post bronchodilator FEV1;
LIHC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.84	-9.3	-0.45	1.71e-18	Vitiligo;
LIHC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.87e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.52	0.53	3.67e-26	Motion sickness;
LIHC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.59	-7.09	-0.36	7.59e-12	Bladder cancer;
LIHC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg02352945	chr3:38496316	LOC100128640;ACVR2B	0.41	5.83	0.3	1.29e-8	Electrocardiographic conduction measures;
LIHC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.19	-0.32	1.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12744310	1.000	rs7513682	chr1:41772167	T/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.25	-0.32	1.22e-9	Longevity;Endometriosis;
LIHC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-7.8	-0.39	7.41e-14	Longevity;Endometriosis;
LIHC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13047869	chr3:10149882	C3orf24	0.43	6.03	0.31	4.17e-9	Alzheimer's disease;
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.51	8.21	0.41	4.46e-15	Migraine;
LIHC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.54	-8.72	-0.43	1.23e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.4	5.74e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg19413766	chr7:29689036	LOC646762	-0.62	-6.36	-0.33	6.62e-10	Facial emotion recognition (angry faces);
LIHC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	9.23	0.45	2.93e-18	Lung cancer;
LIHC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.72	-10.79	-0.5	1.54e-23	Aortic root size;
LIHC	cis	rs832190	1	rs832190	chr3:63842629	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.55	8.09	0.4	1.02e-14	Schizophrenia;
LIHC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.8	9.65	0.46	1.16e-19	Cognitive function;
LIHC	trans	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.12	-0.36	6.54e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15001132	chr13:25875890	NUPL1	-0.46	-6.38	-0.33	5.79e-10	Pancreatic cancer;
LIHC	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.27	0.32	1.08e-9	Mean corpuscular volume;
LIHC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.2	0.32	1.67e-9	Tonsillectomy;
LIHC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.44	6.22	0.32	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs990171	0.607	rs10153578	chr2:102764609	C/T	cg22835712	chr2:102737379	NA	-0.51	-7.23	-0.36	3.27e-12	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01506766	chr13:46626746	ZC3H13	-0.47	-6.2	-0.32	1.61e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg20991723	chr1:152506922	NA	0.49	8.34	0.41	1.78e-15	Hair morphology;
LIHC	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.38	-0.45	9.44e-19	Eye color traits;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.51	5.85	0.3	1.17e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.22	0.32	1.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs75908454	1.000	rs117148598	chr6:169832846	G/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.77	-0.39	9.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.92	-0.3	7.81e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.84	9.16	0.44	4.88e-18	Vitiligo;
LIHC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.68	-12.4	-0.56	1.97e-29	Dental caries;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg27220681	chr17:685915	RNMTL1;GLOD4	-0.41	-6.38	-0.33	5.68e-10	Triglycerides;
LIHC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs7091068	0.707	rs829107	chr10:95418102	C/T	cg20715218	chr10:95462985	C10orf4	-0.55	-5.78	-0.3	1.71e-8	Urinary tract infection frequency;
LIHC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.86	8.15	0.4	6.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.6	9.59	0.46	1.85e-19	Menarche (age at onset);
LIHC	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.11	-0.31	2.64e-9	Ulcerative colitis;
LIHC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg24209194	chr3:40518798	ZNF619	0.44	6.28	0.32	1.05e-9	Renal cell carcinoma;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg08168689	chr14:76455272	C14orf179	0.45	6.81	0.35	4.28e-11	Alopecia areata;
LIHC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-10.81	-0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.96	-15.13	-0.63	5.85e-40	Body mass index;
LIHC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs655641	0.859	rs648270	chr11:85726818	T/C	cg09030501	chr11:85779252	PICALM	-0.52	-6.14	-0.32	2.23e-9	Platelet count;
LIHC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.43	-8.96	-0.44	2.17e-17	Immature fraction of reticulocytes;
LIHC	cis	rs3736757	0.627	rs9425338	chr1:184646229	T/C	cg07817967	chr1:184721222	EDEM3	0.36	5.8	0.3	1.5e-8	Obesity-related traits;
LIHC	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg06533319	chr4:3265114	C4orf44	0.31	5.76	0.3	1.86e-8	Mean platelet volume;
LIHC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg00204512	chr16:28754710	NA	0.36	6.71	0.34	7.92e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg22961513	chr11:14280813	SPON1	-0.43	-6.62	-0.34	1.42e-10	Mitochondrial DNA levels;
LIHC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.57	10.03	0.48	6.57e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg01596870	chr19:55963115	NA	-0.63	-7.54	-0.38	4.17e-13	Obesity-related traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16895464	chr15:91415119	FURIN	-0.49	-6.2	-0.32	1.65e-9	Systolic blood pressure;
LIHC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.72	-6.86	-0.35	3.28e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4453791	0.872	rs62244134	chr3:38888764	G/A	cg02254461	chr3:39195904	CSRNP1	0.64	5.76	0.3	1.84e-8	Social communication problems;
LIHC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.43	-6.75	-0.34	6.53e-11	Schizophrenia;
LIHC	cis	rs7258950	0.751	rs2738464	chr19:11242307	G/C	cg07962303	chr19:11253944	NA	-0.64	-7.99	-0.4	2.02e-14	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg03037974	chr15:76606532	NA	0.9	23.51	0.79	2.01e-73	Blood metabolite levels;
LIHC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.52	8.07	0.4	1.17e-14	Tonsillectomy;
LIHC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.71	11.25	0.52	3.29e-25	Corneal astigmatism;
LIHC	cis	rs3106136	0.649	rs4699411	chr4:95299347	T/C	cg11021082	chr4:95130006	SMARCAD1	0.36	6.13	0.31	2.43e-9	Capecitabine sensitivity;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.46	0.62	2.68e-37	Prudent dietary pattern;
LIHC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.92	0.47	1.48e-20	Multiple sclerosis;
LIHC	cis	rs1400745	0.812	rs72678789	chr14:35348201	T/G	cg05294307	chr14:35346193	BAZ1A	0.45	7.54	0.38	4.27e-13	Monocyte count;
LIHC	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	0.67	8.54	0.42	4.42e-16	Corneal structure;
LIHC	cis	rs10847980	0.590	rs2292131	chr12:123332354	C/T	cg25930673	chr12:123319894	HIP1R	1.14	12.88	0.57	3.08e-31	Adiponectin levels;
LIHC	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.44	-5.96	-0.31	6.43e-9	Waist circumference;Body mass index;
LIHC	cis	rs2997447	0.894	rs55722280	chr1:26412684	T/C	cg19633962	chr1:26362018	EXTL1	-0.59	-6.9	-0.35	2.52e-11	QRS complex (12-leadsum);
LIHC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.01	0.4	1.81e-14	Body mass index;
LIHC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-8.95	-0.44	2.23e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.55	8.64	0.42	2.24e-16	Menarche (age at onset);
LIHC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.57	-7.88	-0.39	4.49e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02985541	chr2:219472218	PLCD4	-0.36	-6.36	-0.33	6.34e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg00204512	chr16:28754710	NA	0.41	6.75	0.34	6.46e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.83	-8.85	-0.43	4.94e-17	Facial morphology (factor 23);
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-6.07	-0.31	3.45e-9	Systemic lupus erythematosus;
LIHC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.25	-6.63	-0.34	1.29e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-18.87	-0.71	6.25e-55	Coronary artery disease;
LIHC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.75	-11.94	-0.54	1.03e-27	Breast cancer;
LIHC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-12.51	-0.56	7.85e-30	Refractive error;
LIHC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02251663	chr11:14281053	SPON1	0.45	6.3	0.32	9e-10	Mitochondrial DNA levels;
LIHC	cis	rs17152411	0.817	rs4478950	chr10:126596425	T/C	cg07906193	chr10:126599966	NA	0.46	7.09	0.36	7.76e-12	Height;
LIHC	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg08992911	chr2:238395768	MLPH	0.47	5.73	0.3	2.23e-8	Prostate cancer;
LIHC	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.08	0.31	3.26e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.56	0.62	1.09e-37	Prudent dietary pattern;
LIHC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.19	0.36	4.22e-12	Bipolar disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11932640	chr4:4861200	MSX1	0.44	6.07	0.31	3.35e-9	Lung function (FEV1/FVC);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg08021833	chr19:5785663	PRR22;DUS3L	0.4	6.11	0.31	2.65e-9	Immature fraction of reticulocytes;
LIHC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.6	9.12	0.44	6.67e-18	Gout;
LIHC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	5.97	0.31	6.03e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg16070018	chr6:26224392	HIST1H3E	0.53	6.47	0.33	3.33e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.6	0.34	1.53e-10	Renal cell carcinoma;
LIHC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.87	-0.35	3.06e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.38	0.8	8.94e-77	Prudent dietary pattern;
LIHC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.79	11.72	0.54	6.68e-27	Dental caries;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.34	-7.03	-0.36	1.12e-11	Asthma (sex interaction);
LIHC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.8	0.3	1.54e-8	Menopause (age at onset);
LIHC	cis	rs1823913	0.927	rs13025919	chr2:192124901	T/C	cg12404831	chr2:192114017	MYO1B	0.32	6.52	0.33	2.46e-10	Obesity-related traits;
LIHC	cis	rs10508774	1.000	rs1984071	chr10:32910806	G/T	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.65	-10.92	-0.51	5.15e-24	Childhood ear infection;
LIHC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs4700695	0.841	rs251608	chr5:65247893	C/T	cg21114390	chr5:65439923	SFRS12	0.49	6.63	0.34	1.3e-10	Facial morphology (factor 19);
LIHC	trans	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg10756647	chr7:56101905	PSPH	1.06	13.26	0.58	1.11e-32	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg18306943	chr3:40428807	ENTPD3	0.34	6.06	0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.82	11.59	0.53	2.05e-26	Body mass index;
LIHC	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.27	-0.32	1.12e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.83	-0.39	6.33e-14	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.3.96438232F	chr3:94955542	NA	-0.36	-6.79	-0.34	5e-11	Cognitive function;
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.69	0.46	9.05e-20	Bipolar disorder;
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.52	-0.33	2.58e-10	Longevity;Endometriosis;
LIHC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-5.97	-0.31	5.97e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23485639	chr6:28045615	ZNF165	0.45	6.03	0.31	4.28e-9	Depression;
LIHC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.89	0.3	9.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.63	-7.79	-0.39	8.3e-14	Gut microbiome composition (summer);
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.47	8.07	0.4	1.18e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	trans	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg04373760	chr16:53404718	NA	-0.59	-7.92	-0.39	3.31e-14	Hypertriglyceridemia;
LIHC	cis	rs600806	0.888	rs443345	chr1:109849254	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.49	-5.94	-0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.7	-6.69	-0.34	8.91e-11	Red cell distribution width;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.71	-0.34	8.29e-11	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg25894440	chr7:65020034	NA	-0.51	-5.97	-0.31	5.96e-9	Diabetic kidney disease;
LIHC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.83	0.35	3.87e-11	Coronary artery disease;
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.77	-12.58	-0.56	4.43e-30	Longevity;
LIHC	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.49	7.73	0.39	1.19e-13	HDL cholesterol;
LIHC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.59	-8.73	-0.43	1.12e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.68	11.1	0.51	1.15e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs11864453	0.682	rs10852509	chr16:72026010	G/A	cg01557791	chr16:72042693	DHODH	-0.41	-6.45	-0.33	3.8e-10	Fibrinogen levels;
LIHC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.62	10.31	0.49	6.98e-22	Platelet count;
LIHC	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.44	-5.72	-0.3	2.33e-8	Obesity (extreme);
LIHC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg16576597	chr16:28551801	NUPR1	0.37	6.11	0.31	2.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg26939375	chr7:64535504	NA	0.39	6.21	0.32	1.57e-9	Aortic root size;
LIHC	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg01028140	chr2:1542097	TPO	-0.62	-8.01	-0.4	1.85e-14	Placebo response in major depressive disorder (% change in symptom score);
LIHC	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.2	0.41	4.76e-15	Corneal astigmatism;
LIHC	cis	rs7534824	0.625	rs55693426	chr1:101466859	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	7.29	0.37	2.2e-12	Refractive astigmatism;
LIHC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.63	0.34	1.33e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg09445902	chr10:555545	DIP2C	-0.36	-5.71	-0.3	2.44e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.05	-0.31	3.81e-9	Headache;
LIHC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg06951627	chr6:26196580	NA	0.54	5.92	0.3	7.89e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg20697417	chr1:41786797	NA	0.31	5.86	0.3	1.09e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg17724175	chr1:150552817	MCL1	0.4	7.78	0.39	8.7e-14	Melanoma;
LIHC	cis	rs72653721	0.689	rs4435941	chr6:11061518	C/T	cg13562911	chr6:11044106	ELOVL2	0.51	7.51	0.38	5.15e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.91	11.6	0.53	1.83e-26	Coronary artery disease;
LIHC	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg20891283	chr12:69753455	YEATS4	0.61	5.96	0.31	6.39e-9	Response to diuretic therapy;
LIHC	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg08741688	chr4:3415352	RGS12	-0.45	-7.15	-0.36	5.2e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg00101154	chr16:420108	MRPL28	-0.57	-8.26	-0.41	3.23e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.75	11.36	0.52	1.39e-25	Coronary artery disease;
LIHC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06420487	chr17:61919686	SMARCD2	0.43	5.84	0.3	1.2e-8	Height;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.65	-0.34	1.13e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.96	9.22	0.45	3.12e-18	Eosinophil percentage of granulocytes;
LIHC	cis	rs8010715	0.816	rs762093	chr14:24591918	G/C	cg23112188	chr14:24563095	PCK2	-0.29	-5.96	-0.31	6.21e-9	IgG glycosylation;
LIHC	cis	rs7700895	0.737	rs1043381	chr5:95221337	C/T	cg10483112	chr5:95245456	ELL2	-0.33	-5.95	-0.31	6.67e-9	IgG glycosylation;
LIHC	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.42	6.92	0.35	2.18e-11	Menopause (age at onset);
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.42	7.23	0.36	3.2e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg04162153	chr10:124029871	BTBD16	0.42	5.82	0.3	1.33e-8	Total body bone mineral density;
LIHC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.48	8.49	0.42	6.22e-16	IgG glycosylation;
LIHC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.26	-6.08	-0.31	3.18e-9	Subjective well-being;
LIHC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg15448220	chr1:150897856	SETDB1	-0.39	-6.2	-0.32	1.59e-9	Tonsillectomy;
LIHC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	7.3	0.37	1.97e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg06766960	chr11:133703094	NA	-0.41	-6.14	-0.32	2.31e-9	Childhood ear infection;
LIHC	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.45	6.11	0.31	2.74e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.54	-8.11	-0.4	8.96e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.89	0.57	2.82e-31	Prudent dietary pattern;
LIHC	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg05197062	chr11:11642011	GALNTL4	0.46	6.68	0.34	9.74e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg03037974	chr15:76606532	NA	0.75	15.1	0.63	7.91e-40	Blood metabolite levels;
LIHC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.3	-0.37	2e-12	Heart rate;
LIHC	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.34	-6.49	-0.33	3.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-1.08	-11.28	-0.52	2.6e-25	Dilated cardiomyopathy;
LIHC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.47	6.15	0.32	2.13e-9	Alzheimer's disease;
LIHC	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.84	0.54	2.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.42	6.71	0.34	7.87e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7129556	0.520	rs6592737	chr11:77322619	A/T	cg21573582	chr11:77300763	AQP11	0.38	5.72	0.3	2.27e-8	Weight loss (gastric bypass surgery);
LIHC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.74	-9.6	-0.46	1.74e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.32	6.49	0.33	2.98e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7487075	0.619	rs4768710	chr12:46808104	G/A	cg23829395	chr12:46796953	NA	0.35	6.26	0.32	1.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg06012730	chr15:75315579	PPCDC	-0.32	-5.91	-0.3	8.11e-9	Blood trace element (Zn levels);
LIHC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg23625390	chr15:77176239	SCAPER	-0.35	-6.06	-0.31	3.54e-9	Blood metabolite levels;
LIHC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.71	10.26	0.49	1.01e-21	Coronary artery disease;
LIHC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.45	7.4	0.37	1.04e-12	Breast cancer;
LIHC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg20135002	chr11:47629003	NA	-0.52	-9.14	-0.44	5.78e-18	Subjective well-being;
LIHC	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.49	6.1	0.31	2.87e-9	Interleukin-17 levels;
LIHC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs561341	0.843	rs56389115	chr17:30237308	T/C	cg20587970	chr11:113659929	NA	-0.61	-7.23	-0.36	3.15e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.44	-5.94	-0.31	6.86e-9	Coronary artery calcification;
LIHC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg09238746	chr17:78121135	EIF4A3	-0.68	-10.44	-0.49	2.54e-22	Yeast infection;
LIHC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.73	-0.57	1.23e-30	Breast cancer;
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.28	0.41	2.88e-15	Height;
LIHC	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.49	7.61	0.38	2.65e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.42	7.35	0.37	1.52e-12	Aortic root size;
LIHC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.23e-9	Blood pressure;
LIHC	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-7.97	-0.4	2.43e-14	Alzheimer's disease;
LIHC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.8	12.22	0.55	1e-28	Resting heart rate;
LIHC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.84e-10	Diabetic kidney disease;
LIHC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg11062466	chr8:58055876	NA	0.39	5.73	0.3	2.23e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.54	7.97	0.4	2.45e-14	Height;
LIHC	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg09238746	chr17:78121135	EIF4A3	-0.75	-11.89	-0.54	1.57e-27	Yeast infection;
LIHC	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.5	-7.33	-0.37	1.71e-12	Coffee consumption (cups per day);
LIHC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.37	-0.41	1.51e-15	Chronic sinus infection;
LIHC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-0.95	-20.93	-0.75	3.29e-63	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.5	8.79	0.43	7.66e-17	Total body bone mineral density;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	9.44	0.45	5.93e-19	Lymphocyte counts;
LIHC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.33	-12.63	-0.56	2.91e-30	Plateletcrit;
LIHC	cis	rs12464559	0.649	rs4664496	chr2:152522556	T/C	cg01189475	chr2:152685088	ARL5A	-0.7	-9.18	-0.44	4.21e-18	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-8.56	-0.42	4.01e-16	Fibrinogen levels;
LIHC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg07952391	chr2:88470173	THNSL2	-0.41	-5.72	-0.3	2.29e-8	Response to metformin (IC50);
LIHC	cis	rs4453791	0.932	rs78329075	chr3:38868431	C/T	cg02254461	chr3:39195904	CSRNP1	0.66	5.83	0.3	1.26e-8	Social communication problems;
LIHC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg27211696	chr2:191398769	TMEM194B	-0.49	-6.45	-0.33	3.85e-10	Diastolic blood pressure;
LIHC	cis	rs6815814	0.731	rs4504266	chr4:38773754	G/A	cg06935464	chr4:38784597	TLR10	0.38	5.96	0.31	6.18e-9	Breast cancer;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.57	8.61	0.42	2.64e-16	Longevity;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07348706	chr3:112709771	GTPBP8	0.43	6.2	0.32	1.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.72	0.47	6.83e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.8	11.36	0.52	1.4e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg17980119	chr2:219472607	PLCD4	0.36	6.21	0.32	1.55e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	7.6	0.38	2.93e-13	Tonsillectomy;
LIHC	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg09795085	chr6:101329169	ASCC3	-0.41	-6.05	-0.31	3.82e-9	Neuroticism;
LIHC	trans	rs983392	0.709	rs11601689	chr11:59996266	G/C	cg17275991	chr19:58003312	ZNF419	0.43	6.16	0.32	2.06e-9	Alzheimer's disease (late onset);
LIHC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg12297030	chr17:43662878	NA	-0.64	-6.09	-0.31	2.98e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	10.77	0.5	1.71e-23	HIV-1 control;
LIHC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.69	-8.58	-0.42	3.32e-16	Gut microbiome composition (summer);
LIHC	cis	rs12744310	0.832	rs12027990	chr1:41764437	T/C	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs10411161	1.000	rs10412080	chr19:52373508	A/C	cg22319618	chr22:45562946	NUP50	-0.54	-7.31	-0.37	1.93e-12	Breast cancer;
LIHC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.45	8.57	0.42	3.63e-16	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg18306943	chr3:40428807	ENTPD3	-0.35	-6.01	-0.31	4.82e-9	Renal cell carcinoma;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg27411370	chr8:25316735	KCTD9;CDCA2	0.48	6.3	0.32	9.26e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-5.83	-0.3	1.27e-8	Vitiligo;
LIHC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg04691961	chr3:161091175	C3orf57	-0.41	-6.53	-0.33	2.37e-10	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.56	9.39	0.45	9.02e-19	Aortic root size;
LIHC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.46	0.33	3.57e-10	Bipolar disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04132851	chr1:85155548	SSX2IP	0.49	7.46	0.37	7.33e-13	Cognitive function;
LIHC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.28	0.41	2.72e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.36	3.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.54	-8.56	-0.42	3.82e-16	Waist circumference;Body mass index;
LIHC	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.52	9.75	0.47	5.65e-20	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs10949834	0.824	rs2285026	chr7:73530404	C/T	cg07137043	chr7:73588983	EIF4H	-0.6	-6.01	-0.31	4.74e-9	Verbal memory performance (residualized delayed recall change);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26940751	chr1:143467856	NA	-0.39	-7.64	-0.38	2.24e-13	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.78	-13.49	-0.59	1.5e-33	Aortic root size;
LIHC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.84	13.64	0.59	4e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.4	-7.28	-0.37	2.37e-12	Asthma;
LIHC	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	0.85	11.02	0.51	2.3e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs965469	1.000	rs1331215	chr20:3376565	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.7	-0.34	8.8e-11	IFN-related cytopenia;
LIHC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.46	-7.55	-0.38	3.89e-13	IgG glycosylation;
LIHC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.55	-8.12	-0.4	8.55e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.58	9.3	0.45	1.77e-18	High light scatter reticulocyte count;
LIHC	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.51	-8.61	-0.42	2.64e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.73	-0.34	7.11e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.45	8.65	0.42	2.07e-16	Testicular germ cell tumor;
LIHC	trans	rs7142002	1.000	rs7145448	chr14:102361064	A/C	cg18984499	chr17:8286166	RPL26	0.65	6.19	0.32	1.77e-9	Autism;
LIHC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.63	-9.4	-0.45	8.02e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.46	7.35	0.37	1.47e-12	Monocyte count;
LIHC	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.56	7.13	0.36	6.05e-12	Eye color traits;
LIHC	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.3	-6.42	-0.33	4.43e-10	Weight;
LIHC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-0.96	-21.11	-0.75	6.53e-64	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg11642891	chr2:3452563	TTC15	-0.45	-7.2	-0.36	3.8e-12	Obesity-related traits;
LIHC	cis	rs6750047	0.868	rs1431332	chr2:38280253	G/A	cg07380506	chr2:38303506	CYP1B1	0.56	6.92	0.35	2.23e-11	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.77	-0.3	1.78e-8	Bladder cancer;
LIHC	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.29	6.39	0.33	5.33e-10	Pulmonary function;
LIHC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	6.02e-12	Diabetic kidney disease;
LIHC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg11812906	chr14:75593930	NEK9	0.4	6.52	0.33	2.56e-10	IgG glycosylation;
LIHC	cis	rs965469	0.817	rs16988490	chr20:3335431	C/T	cg25506879	chr20:3388711	C20orf194	0.52	6.09	0.31	3.07e-9	IFN-related cytopenia;
LIHC	cis	rs965469	0.779	rs2207994	chr20:3294304	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg09795085	chr6:101329169	ASCC3	0.52	7.4	0.37	1.06e-12	Neuroticism;
LIHC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.54	5.82	0.3	1.39e-8	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.67	13.47	0.59	1.87e-33	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs55665837	0.701	rs2007361	chr11:14662722	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-6.07	-0.31	3.4e-9	Vitamin D levels;
LIHC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.3	8.53e-9	Obesity (extreme);
LIHC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.22	5.76	0.3	1.91e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	1.03	19.85	0.73	6.84e-59	Breast cancer;
LIHC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg13628971	chr7:2884303	GNA12	0.48	8.44	0.42	9.06e-16	Height;
LIHC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.84	0.47	2.7e-20	Crohn's disease;
LIHC	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.36	9.83	0.47	3.06e-20	Weight;
LIHC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.72	10.29	0.49	7.88e-22	Coronary artery disease;
LIHC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg05941027	chr17:61774174	LIMD2	0.32	6.74	0.34	6.7e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	10.37	0.49	4.49e-22	Menarche (age at onset);
LIHC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.07	-0.44	9.45e-18	Bipolar disorder;
LIHC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg08392591	chr16:89556376	ANKRD11	0.41	6.14	0.32	2.31e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg16970926	chr12:29381810	FAR2	0.28	5.97	0.31	6.02e-9	QT interval;
LIHC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg07451762	chr16:28383216	NA	0.34	6.32	0.32	8.09e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.66	7.74	0.39	1.1e-13	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.26	6.11	0.31	2.76e-9	Heart rate;
LIHC	trans	rs8108034	0.920	rs30480	chr19:39807213	A/G	cg03482411	chr20:62572509	UCKL1	-0.56	-6.09	-0.31	3.02e-9	Lung adenocarcinoma;
LIHC	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.44	-0.33	4.15e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.44	5.81	0.3	1.45e-8	Resting heart rate;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg14709524	chr16:89940631	TCF25	0.55	7.23	0.36	3.15e-12	Skin colour saturation;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.15	0.32	2.12e-9	Prudent dietary pattern;
LIHC	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.49	-0.33	3.02e-10	Metabolite levels;
LIHC	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.3	6.72	0.34	7.57e-11	DNA methylation (variation);
LIHC	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.3	-0.32	9.09e-10	Bipolar disorder;
LIHC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.09	-0.36	7.72e-12	Schizophrenia;
LIHC	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.57	6.92	0.35	2.27e-11	Crohn's disease;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18202627	chr2:200776533	C2orf69	0.4	6.13	0.31	2.44e-9	Metabolic traits;
LIHC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	7.04	0.36	1.04e-11	Longevity;
LIHC	cis	rs74233809	1.000	rs79082900	chr10:104877302	T/C	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.44	-0.33	3.95e-10	Bipolar disorder;
LIHC	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.85	12.96	0.57	1.54e-31	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg06718696	chr17:78121285	EIF4A3	-0.42	-5.74	-0.3	2.09e-8	Yeast infection;
LIHC	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg02405213	chr9:5042618	JAK2	-0.46	-7.84	-0.39	5.96e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.51	6.33	0.32	7.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.05e-17	Bipolar disorder;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11473911	chr4:140005743	ELF2	0.44	6.22	0.32	1.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg09222892	chr1:25734099	RHCE	-0.47	-8.78	-0.43	7.69e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.71	-7.3	-0.37	1.98e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LIHC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.57	-0.33	1.84e-10	Personality dimensions;
LIHC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.07	0.36	8.63e-12	Diastolic blood pressure;
LIHC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-6.74	-0.34	6.86e-11	Body mass index;
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.51	7.09	0.36	7.72e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs1704198	1.000	rs830335	chr1:213898743	G/T	cg02442787	chr4:139230014	NA	0.4	6.16	0.32	2.02e-9	Obesity;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg11235426	chr6:292522	DUSP22	-0.53	-7.09	-0.36	7.64e-12	Menopause (age at onset);
LIHC	trans	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17183009	chr3:120277827	NA	0.52	6.31	0.32	8.5e-10	Corneal astigmatism;
LIHC	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg05714579	chr10:131428358	MGMT	0.4	6.47	0.33	3.47e-10	Response to temozolomide;
LIHC	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg21559469	chr19:19431446	KIAA0892;SF4	-0.45	-5.73	-0.3	2.2e-8	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs55702914	0.746	rs7588530	chr2:198146698	A/C	cg03934865	chr2:198174659	NA	-0.4	-5.71	-0.3	2.42e-8	Major depression and alcohol dependence;
LIHC	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-6.08	-0.31	3.25e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.29	-0.41	2.71e-15	Obesity-related traits;
LIHC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.81	-0.35	4.41e-11	Personality dimensions;
LIHC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-8.36	-0.41	1.6e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg22834771	chr12:69754056	YEATS4	-0.46	-7.81	-0.39	7.28e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4407350	0.837	rs5765710	chr22:44914354	C/T	cg04154583	chr22:44889756	LDOC1L	-0.29	-5.78	-0.3	1.64e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9503598	0.543	rs913536	chr6:3432608	G/A	cg00476032	chr6:3446245	SLC22A23	-0.33	-6.0	-0.31	4.96e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg09033563	chr22:24373618	LOC391322	-0.46	-6.25	-0.32	1.25e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg07356753	chr3:81810745	GBE1	0.46	6.85	0.35	3.4e-11	Extraversion;
LIHC	cis	rs798766	0.904	rs13142863	chr4:1755549	T/G	cg21231739	chr4:1642635	FAM53A	-0.37	-5.81	-0.3	1.41e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.36	7.4	0.37	1.09e-12	Renal cell carcinoma;
LIHC	cis	rs1555399	0.868	rs7160654	chr14:67983491	C/T	cg16224230	chr14:67978224	TMEM229B	-0.25	-6.04	-0.31	4.02e-9	Parkinson's disease;
LIHC	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.73	-0.39	1.19e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.97	0.44	1.99e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.89	11.14	0.52	8.2e-25	Coronary artery disease;
LIHC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.73	8.36	0.41	1.59e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.88e-12	Growth-regulated protein alpha levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07077115	chr13:28024429	MTIF3	0.48	7.42	0.37	9.32e-13	Cognitive function;
LIHC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.29	17.34	0.68	9.06e-49	Diabetic kidney disease;
LIHC	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.58	11.51	0.53	3.98e-26	Myopia (pathological);
LIHC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	7.63	0.38	2.3e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.63	11.24	0.52	3.83e-25	Dupuytren's disease;
LIHC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.58	9.06	0.44	1.02e-17	Longevity;
LIHC	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.58	-0.34	1.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.54	7.68	0.38	1.74e-13	Ulcerative colitis;
LIHC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.5	-0.49	1.57e-22	Total cholesterol levels;
LIHC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg12798992	chr6:167411361	FGFR1OP	0.45	7.25	0.36	2.86e-12	Crohn's disease;
LIHC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.42	-0.33	4.67e-10	Menarche (age at onset);
LIHC	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg08126542	chr6:37504118	NA	-0.37	-6.33	-0.32	7.52e-10	Cognitive performance;
LIHC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.55	7.22	0.36	3.47e-12	Body mass index;
LIHC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.4	-6.46	-0.33	3.69e-10	Red blood cell count;
LIHC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20135002	chr11:47629003	NA	-0.54	-9.14	-0.44	5.58e-18	Subjective well-being;
LIHC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.47	7.24	0.36	3.01e-12	Height;
LIHC	cis	rs6466055	0.777	rs3801285	chr7:104837801	C/A	cg04380332	chr7:105027541	SRPK2	-0.36	-6.73	-0.34	7.2e-11	Schizophrenia;
LIHC	cis	rs4450131	0.522	rs17152232	chr10:126398927	A/G	cg20435097	chr10:126320824	FAM53B	0.65	11.79	0.54	3.88e-27	White blood cell count (basophil);
LIHC	cis	rs739401	0.582	rs7932369	chr11:2958468	A/G	cg25174290	chr11:3078921	CARS	-0.57	-8.56	-0.42	3.78e-16	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23837253	chr19:47759802	CCDC9	0.48	6.97	0.35	1.65e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.98	-0.4	2.26e-14	Coronary artery disease;
LIHC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	14.29	0.61	1.24e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.51	9.55	0.46	2.68e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg19500275	chr17:80737654	TBCD	0.49	7.03	0.36	1.14e-11	Glycated hemoglobin levels;
LIHC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.87	0.35	3.04e-11	Lung cancer in ever smokers;
LIHC	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg12798992	chr6:167411361	FGFR1OP	0.39	5.9	0.3	8.66e-9	Primary biliary cholangitis;
LIHC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.36	0.33	6.54e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg08539965	chr1:21396338	EIF4G3	0.34	5.96	0.31	6.37e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.48	0.49	1.75e-22	LDL cholesterol;
LIHC	trans	rs6934970	1.000	rs7745564	chr6:113101580	G/A	cg09308777	chr6:169852575	NA	0.59	6.29	0.32	9.63e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.69	9.24	0.45	2.67e-18	Psoriasis;
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27297192	chr10:134578999	INPP5A	0.52	7.07	0.36	8.91e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-5.92	-0.3	8.01e-9	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.19e-12	HDL cholesterol levels;
LIHC	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-0.72	-7.9	-0.39	3.75e-14	Coronary artery disease;
LIHC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.34e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.08	-0.36	8.34e-12	Heart rate;
LIHC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.91	16.88	0.67	6.34e-47	Menopause (age at onset);
LIHC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.65	12.71	0.57	1.41e-30	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23477849	chr19:5698492	LONP1	-0.45	-6.77	-0.34	5.55e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.58	8.74	0.43	1.05e-16	Noise-induced hearing loss;
LIHC	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.57	-8.62	-0.42	2.49e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-0.83	-9.59	-0.46	1.88e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-14.59	-0.62	8.14e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12463199	chr20:49126897	PTPN1	0.41	6.44	0.33	4.13e-10	Pancreatic cancer;
LIHC	cis	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg01364799	chr7:75623366	TMEM120A	-0.54	-7.63	-0.38	2.41e-13	Eotaxin levels;
LIHC	cis	rs2524276	1	rs2524276	chr6:31408265	C/A	cg12985770	chr6:31324627	HLA-B	0.79	6.09	0.31	3.01e-9	Capecitabine sensitivity;
LIHC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.62	5.86	0.3	1.1e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg09417038	chr21:47716443	C21orf57	-0.46	-7.05	-0.36	1.01e-11	Testicular germ cell tumor;
LIHC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg00204512	chr16:28754710	NA	0.4	6.95	0.35	1.83e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.18	-0.36	4.26e-12	Inflammatory bowel disease;
LIHC	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.5	-9.49	-0.46	3.98e-19	Endometriosis;
LIHC	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	12.01	0.54	5.85e-28	Response to antipsychotic treatment;
LIHC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.39	-6.05	-0.31	3.8e-9	Neurofibrillary tangles;
LIHC	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.33	-5.74	-0.3	2.12e-8	Schizophrenia;
LIHC	cis	rs2412488	0.927	rs2412447	chr4:54277516	C/T	cg22241045	chr4:54363911	LNX1	-0.41	-6.71	-0.34	8.15e-11	DNA methylation (variation);
LIHC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg25039879	chr17:56429692	SUPT4H1	0.79	8.95	0.44	2.37e-17	Cognitive test performance;
LIHC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.52	-9.24	-0.45	2.74e-18	Total body bone mineral density;
LIHC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.68	9.89	0.47	1.82e-20	Monocyte percentage of white cells;
LIHC	trans	rs4714291	0.963	rs847777	chr6:40055754	C/T	cg02267698	chr19:7991119	CTXN1	0.38	6.15	0.32	2.17e-9	Strep throat;
LIHC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg11812906	chr14:75593930	NEK9	-0.46	-7.3	-0.37	1.97e-12	IgG glycosylation;
LIHC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.66	10.1	0.48	3.73e-21	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs72843506	0.722	rs74658636	chr17:20197982	A/G	cg12065943	chr17:19881925	AKAP10	-0.36	-6.11	-0.31	2.75e-9	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.48	-17.96	-0.7	2.77e-51	Breast cancer;
LIHC	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.48	7.37	0.37	1.33e-12	Triglyceride levels;
LIHC	cis	rs72653721	0.838	rs3798709	chr6:11001276	A/G	cg13562911	chr6:11044106	ELOVL2	0.5	7.19	0.36	4.14e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs7961581	0.719	rs1705256	chr12:71601657	T/G	cg05756094	chr12:71608604	NA	0.41	6.66	0.34	1.12e-10	Type 2 diabetes;
LIHC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.49	0.56	9.12e-30	Menopause (age at onset);
LIHC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.5	-7.79	-0.39	7.91e-14	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LIHC	cis	rs4908768	0.501	rs6702060	chr1:8607024	G/A	cg20416874	chr1:8611966	RERE	-0.7	-15.08	-0.63	9.46e-40	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.41	0.59	3.07e-33	Airflow obstruction;
LIHC	cis	rs6088813	1.000	rs6142369	chr20:33973315	T/G	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.56	7.97	0.4	2.45e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	6.89	0.35	2.73e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg17675199	chr6:35436792	RPL10A	0.32	6.32	0.32	8.08e-10	Coronary artery disease;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg23601095	chr6:26197514	HIST1H3D	0.53	5.74	0.3	2.1e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.57	-10.37	-0.49	4.25e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.9	0.54	1.54e-27	Cognitive test performance;
LIHC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.84	8.01	0.4	1.88e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.58	0.59	6.97e-34	Prudent dietary pattern;
LIHC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.5	6.32	0.32	8.13e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.57	8.84	0.43	5.2e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.39	-6.5	-0.33	2.86e-10	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg14393609	chr7:65229607	NA	0.44	6.55	0.33	2.08e-10	Aortic root size;
LIHC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg02297831	chr4:17616191	MED28	0.41	6.58	0.34	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.64	10.01	0.48	7.38e-21	Height;
LIHC	trans	rs6600671	0.967	rs11249347	chr1:121188347	G/T	cg09829573	chr1:144692074	NBPF9	-0.43	-7.83	-0.39	6.27e-14	Hip geometry;
LIHC	cis	rs17228178	0.961	rs7172386	chr15:31467352	C/T	cg01030201	chr15:31746330	NA	-0.43	-5.92	-0.3	7.91e-9	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);
LIHC	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.94	19.24	0.72	2.06e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.6	8.66	0.42	1.95e-16	Coronary artery disease;
LIHC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.7	13.2	0.58	1.96e-32	Systemic lupus erythematosus;
LIHC	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.81	-0.35	4.37e-11	Blood pressure;
LIHC	cis	rs9783347	0.961	rs4150588	chr11:18360131	G/A	cg15585147	chr11:18324498	HPS5	0.42	6.7	0.34	8.6e-11	Pancreatic cancer;
LIHC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg00343986	chr7:65444356	GUSB	0.42	6.29	0.32	9.6e-10	Aortic root size;
LIHC	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	10.91	0.51	5.59e-24	Diisocyanate-induced asthma;
LIHC	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.34	-0.37	1.59e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.84	0.3	1.21e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.39	7.62	0.38	2.54e-13	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.24	-6.63	-0.34	1.34e-10	Type 2 diabetes;
LIHC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7212590	0.748	rs73315252	chr17:57854855	A/G	cg10252138	chr17:58120427	NA	-0.61	-6.21	-0.32	1.5e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.54	-6.44	-0.33	4.01e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.41	6.19	0.32	1.74e-9	Schizophrenia;
LIHC	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	5.76	0.3	1.87e-8	Schizophrenia;
LIHC	cis	rs1664789	1.000	rs1664788	chr5:53282416	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.56	0.42	3.76e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.51	-0.33	2.68e-10	Blood metabolite levels;
LIHC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14774288	chr8:30669556	PPP2CB	-0.59	-7.15	-0.36	5.46e-12	Systolic blood pressure;
LIHC	cis	rs1198430	1.000	rs1198434	chr1:23758134	A/G	cg13183780	chr1:23809682	ASAP3	-0.56	-7.8	-0.39	7.68e-14	Total cholesterol levels;
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.39	-6.03	-0.31	4.35e-9	Testicular germ cell tumor;
LIHC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg03037974	chr15:76606532	NA	0.91	23.48	0.79	2.82e-73	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg19346786	chr7:2764209	NA	-0.41	-5.98	-0.31	5.5e-9	Height;
LIHC	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg16724696	chr11:118992527	HINFP	-0.5	-6.53	-0.33	2.43e-10	Plateletcrit;
LIHC	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg14393609	chr7:65229607	NA	-0.43	-6.45	-0.33	3.72e-10	Aortic root size;
LIHC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.75e-9	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.56	7.0	0.35	1.37e-11	Alzheimer's disease;
LIHC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.58	7.85	0.39	5.57e-14	Bone mineral density (spine);
LIHC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.95	0.31	6.6e-9	Tonsillectomy;
LIHC	cis	rs9616064	0.812	rs5767288	chr22:46996254	G/A	cg05621596	chr22:47072043	GRAMD4	-0.47	-6.47	-0.33	3.48e-10	Urate levels in obese individuals;
LIHC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.85	-0.39	5.42e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg06026331	chr20:60912101	LAMA5	-0.39	-5.76	-0.3	1.85e-8	Colorectal cancer;
LIHC	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg17130504	chr10:102756923	LZTS2	0.55	7.41	0.37	1.03e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.75	0.39	1.07e-13	Prudent dietary pattern;
LIHC	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-9.75	-0.47	5.76e-20	Pediatric autoimmune diseases;
LIHC	cis	rs2108622	0.727	rs62107763	chr19:15982598	T/C	cg13772218	chr19:15982569	NA	0.37	7.75	0.39	1.06e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg14067834	chr17:29058358	SUZ12P	0.68	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.56	-0.5	9.13e-23	Hemoglobin concentration;
LIHC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-9.61	-0.46	1.67e-19	Asthma;
LIHC	trans	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg15676719	chr1:167598521	RCSD1	-0.37	-6.65	-0.34	1.18e-10	Systemic lupus erythematosus;
LIHC	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.82	-0.39	6.67e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.54	-8.19	-0.41	5.16e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg04592579	chr7:75616294	TMEM120A	-0.41	-7.1	-0.36	7.22e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.5	7.47	0.37	6.85e-13	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.6	7.51	0.38	5.32e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.81e-10	Obesity-related traits;
LIHC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.8	-8.7	-0.43	1.43e-16	Schizophrenia;
LIHC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.35	0.45	1.17e-18	Bipolar disorder;
LIHC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.8	12.66	0.56	2.11e-30	Breast cancer;
LIHC	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-9.6	-0.46	1.77e-19	Platelet distribution width;
LIHC	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg25952890	chr19:58913133	NA	0.69	7.4	0.37	1.07e-12	Mean platelet volume;
LIHC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.16	-0.52	7.15e-25	Hemoglobin concentration;
LIHC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	15.84	0.65	9.35e-43	Platelet count;
LIHC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.79	12.59	0.56	3.89e-30	Corneal astigmatism;
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11466908	chr9:94123704	AUH	-0.54	-6.93	-0.35	2.15e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2274273	0.870	rs11625423	chr14:55795913	G/A	cg01864836	chr14:55583639	NA	-0.37	-6.57	-0.33	1.9e-10	Protein biomarker;
LIHC	cis	rs7534824	0.625	rs7521668	chr1:101491108	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-6.83	-0.35	3.99e-11	Refractive astigmatism;
LIHC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.52	-7.39	-0.37	1.15e-12	Body mass index;
LIHC	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.49	7.36	0.37	1.4e-12	Height;
LIHC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.86	0.65	7.5e-43	Myeloid white cell count;
LIHC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.69	10.45	0.49	2.24e-22	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.43	-6.13	-0.31	2.37e-9	Body mass index;
LIHC	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.64	8.74	0.43	1.03e-16	Coronary artery disease;
LIHC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg05425664	chr17:57184151	TRIM37	0.49	6.67	0.34	1.04e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.39	-0.37	1.15e-12	Tonsillectomy;
LIHC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.52	-6.23	-0.32	1.41e-9	Menarche (age at onset);
LIHC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.56	9.87	0.47	2.2e-20	Alcohol dependence;
LIHC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.66e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.49	8.51	0.42	5.55e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg06565975	chr8:143823917	SLURP1	-0.43	-8.24	-0.41	3.83e-15	Urinary tract infection frequency;
LIHC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.13	0.48	2.79e-21	Schizophrenia;
LIHC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.99	17.27	0.68	1.7e-48	Breast cancer;
LIHC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg10932868	chr11:921992	NA	0.39	7.29	0.37	2.22e-12	Alzheimer's disease (late onset);
LIHC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07305463	chr2:136567211	LCT	-0.4	-7.98	-0.4	2.23e-14	Mosquito bite size;
LIHC	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg00012203	chr2:219082015	ARPC2	-0.84	-13.32	-0.58	6.49e-33	Colorectal cancer;
LIHC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg22633049	chr21:46681294	NA	-0.37	-6.46	-0.33	3.6e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.92	13.44	0.59	2.36e-33	Psoriasis;
LIHC	cis	rs12744310	0.887	rs1316274	chr1:41793658	G/A	cg03962019	chr1:41807865	NA	0.39	6.38	0.33	5.89e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.56	9.47	0.46	4.75e-19	Vitiligo;
LIHC	cis	rs6867032	1.000	rs4254943	chr5:2009878	C/T	cg26168224	chr5:2018326	NA	0.31	7.76	0.39	9.92e-14	Gut microbiome composition (winter);
LIHC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	0.51	6.44	0.33	3.95e-10	Myopia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18294483	chr11:96123194	JRKL;CCDC82	0.44	6.09	0.31	3.02e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.51	7.36	0.37	1.38e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20307385	chr11:47447363	PSMC3	-0.45	-5.92	-0.3	7.87e-9	Neuroticism;
LIHC	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.31	-5.93	-0.31	7.31e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.42	-6.79	-0.34	4.84e-11	Menarche (age at onset);
LIHC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.47	-6.33	-0.32	7.65e-10	Initial pursuit acceleration;
LIHC	cis	rs9443189	1.000	rs1280048	chr6:76529583	C/T	cg01950844	chr6:76311363	SENP6	0.52	6.42	0.33	4.57e-10	Prostate cancer;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1982963	1.000	rs2749876	chr14:52504397	T/G	cg10843707	chr14:52510701	NID2	-0.44	-7.49	-0.38	5.74e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.65	12.67	0.57	2e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11332131	1	rs11332131	chr17:57926391	GT/G	cg13753209	chr17:57696993	CLTC	0.47	7.19	0.36	4.14e-12	Platelet distribution width;
LIHC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg10096929	chr1:156261403	TMEM79	0.39	6.33	0.32	7.66e-10	Tonsillectomy;
LIHC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.44	6.44	0.33	4.17e-10	Crohn's disease;
LIHC	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.08	0.36	8.15e-12	Breast cancer;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg20908993	chr14:67826378	EIF2S1;ATP6V1D	-0.59	-6.48	-0.33	3.22e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.58	9.84	0.47	2.83e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.49	-0.49	1.66e-22	Hemoglobin concentration;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg00280220	chr17:61926910	NA	0.41	6.5	0.33	2.91e-10	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.92	17.05	0.68	1.3e-47	Menopause (age at onset);
LIHC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	cis	rs1823913	1.000	rs10445783	chr2:192101498	C/T	cg12404831	chr2:192114017	MYO1B	-0.35	-6.85	-0.35	3.41e-11	Obesity-related traits;
LIHC	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.37	-6.38	-0.33	5.77e-10	Lewy body disease;
LIHC	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.69	11.18	0.52	6.16e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.51	5.98	0.31	5.61e-9	Pancreatic cancer;
LIHC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.48	-0.46	4.36e-19	Bipolar disorder;
LIHC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.55	0.38	3.92e-13	Lymphocyte counts;
LIHC	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs672413	0.739	rs500390	chr5:78283656	C/T	cg04677158	chr5:78279841	ARSB	0.37	6.26	0.32	1.14e-9	Blood and toenail selenium levels;Blood protein levels;
LIHC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.59	9.33	0.45	1.32e-18	High light scatter reticulocyte count;
LIHC	trans	rs783540	1.000	rs6603033	chr15:83335875	A/C	cg18393722	chr15:85113863	UBE2QP1	0.38	6.59	0.34	1.68e-10	Schizophrenia;
LIHC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.25	-5.87	-0.3	1.05e-8	Subjective well-being;
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.63	-9.78	-0.47	4.42e-20	Uric acid clearance;
LIHC	cis	rs12915845	0.529	rs7175106	chr15:89088724	G/C	cg05013243	chr15:89149849	MIR1179	-0.38	-6.79	-0.34	4.94e-11	Menarche (age at onset);
LIHC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.9	-0.39	3.9e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.4	7.24	0.36	3.01e-12	Monocyte percentage of white cells;
LIHC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg12046867	chr14:103022105	NA	-0.55	-8.15	-0.4	6.87e-15	Platelet count;
LIHC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.31	0.55	4.45e-29	Electrocardiographic conduction measures;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27329737	chr3:150930072	P2RY14;MED12L	0.39	6.78	0.34	5.28e-11	Hepatitis;
LIHC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.59	9.71	0.46	7.66e-20	Colorectal cancer;
LIHC	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.4	-6.5	-0.33	2.8e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.32	-0.32	8.03e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.39	-6.6	-0.34	1.56e-10	Menopause (age at onset);
LIHC	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.29	6.23	0.32	1.34e-9	Pulmonary function;
LIHC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.58	-0.42	3.39e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.5	-8.81	-0.43	6.48e-17	Total body bone mineral density;
LIHC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.45	0.33	3.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.42	-6.04	-0.31	4.11e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.74	11.3	0.52	2.16e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-6.49	-0.33	3.09e-10	Height;
LIHC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.79	10.84	0.51	1e-23	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.85	13.77	0.6	1.22e-34	Colorectal cancer;
LIHC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.62	11.09	0.51	1.26e-24	Dupuytren's disease;
LIHC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg05590025	chr7:65112418	INTS4L2	0.58	6.43	0.33	4.21e-10	Diabetic kidney disease;
LIHC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.89	0.6	4.28e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.06	-0.31	3.58e-9	Type 2 diabetes;
LIHC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-0.94	-21.98	-0.77	2.26e-67	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg27523141	chr10:43048294	ZNF37B	-0.37	-6.3	-0.32	8.92e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	trans	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg26939375	chr7:64535504	NA	0.4	6.36	0.33	6.44e-10	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10168434	chr2:71295172	NAGK	0.47	6.51	0.33	2.63e-10	Lung function (FEV1/FVC);
LIHC	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.74	0.3	2.08e-8	Rheumatoid arthritis;
LIHC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg09904177	chr6:26538194	HMGN4	0.47	6.75	0.34	6.22e-11	Small cell lung carcinoma;
LIHC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.48	0.46	4.57e-19	Bipolar disorder;
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.18	-0.36	4.32e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg20932281	chr17:33905541	PEX12	0.42	5.76	0.3	1.9e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg21856205	chr7:94953877	PON1	-0.48	-6.17	-0.32	1.95e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg18306943	chr3:40428807	ENTPD3	0.36	5.93	0.31	7.51e-9	Renal cell carcinoma;
LIHC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	7.1	0.36	7.1e-12	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.41	5.73	0.3	2.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-0.66	-6.75	-0.34	6.43e-11	Putamen volume;
LIHC	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.31	0.32	8.87e-10	Renal cell carcinoma;
LIHC	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg27205649	chr11:78285834	NARS2	-0.38	-5.81	-0.3	1.42e-8	Testicular germ cell tumor;
LIHC	trans	rs800082	1.000	rs1405596	chr3:144314033	C/G	cg24215973	chr2:240111563	HDAC4	-0.5	-7.44	-0.37	8.47e-13	Smoking behavior;
LIHC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.62	7.58	0.38	3.3e-13	Cognitive function;
LIHC	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	9.74	0.47	6.02e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.61	10.09	0.48	4.11e-21	Recombination rate (males);
LIHC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.48	-0.73	2.22e-57	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-16.75	-0.67	2.06e-46	Gut microbiome composition (summer);
LIHC	cis	rs903552	1.000	rs8043205	chr15:102005749	A/G	cg19295451	chr15:102010161	PCSK6	-0.46	-6.32	-0.32	8.18e-10	Diabetic kidney disease;
LIHC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.56	-7.97	-0.4	2.43e-14	Coronary artery disease;
LIHC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.36	0.45	1.05e-18	Melanoma;
LIHC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg14067834	chr17:29058358	SUZ12P	0.71	7.03	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg04605084	chr1:91487590	ZNF644	-0.37	-6.07	-0.31	3.44e-9	Eotaxin levels;
LIHC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.3	-0.32	9.02e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.35	-6.97	-0.35	1.63e-11	Body mass index;
LIHC	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	9.7	0.46	8.47e-20	Response to antipsychotic treatment;
LIHC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.51	-8.25	-0.41	3.54e-15	Colorectal cancer;
LIHC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.51	0.46	3.49e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs970821	0.667	rs7013258	chr8:124745441	T/C	cg00283535	chr8:124749564	ANXA13	-0.42	-7.47	-0.37	6.82e-13	Breast cancer;
LIHC	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg03934865	chr2:198174659	NA	0.43	6.09	0.31	3.01e-9	Dermatomyositis;
LIHC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	7.84	0.39	5.89e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs2422052	0.614	rs13033724	chr2:118644670	C/T	cg22545206	chr2:118617499	NA	0.36	6.12	0.31	2.61e-9	Mosquito bite size;
LIHC	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.41	7.41	0.37	1e-12	IgG glycosylation;
LIHC	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.9	11.84	0.54	2.46e-27	Breast cancer;
LIHC	cis	rs4908768	0.906	rs56305243	chr1:8725420	T/C	cg20416874	chr1:8611966	RERE	0.45	6.39	0.33	5.43e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg04013166	chr16:89971882	TCF25	0.61	8.54	0.42	4.6e-16	Skin colour saturation;
LIHC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.51	0.33	2.75e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs28830936	0.966	rs3179542	chr15:42118123	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.9	-0.3	8.75e-9	Diastolic blood pressure;
LIHC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg03983715	chr16:68378420	PRMT7	-0.51	-6.22	-0.32	1.44e-9	Magnesium levels;
LIHC	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.59	9.15	0.44	5.36e-18	Multiple sclerosis;
LIHC	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.07	0.61	8.73e-36	Bipolar disorder;
LIHC	cis	rs74544699	1.000	rs77149208	chr4:74768731	C/A	cg16072462	chr4:74847758	PF4	0.59	6.03	0.31	4.29e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.3	-0.32	9.01e-10	Longevity;Endometriosis;
LIHC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-0.61	-8.2	-0.41	4.95e-15	Lung cancer;
LIHC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-9.85	-0.47	2.61e-20	Mean corpuscular volume;
LIHC	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.55	-7.81	-0.39	6.9e-14	Body mass index;
LIHC	cis	rs7937890	0.572	rs2597202	chr11:14484645	C/T	cg23387056	chr11:14280742	SPON1	-0.47	-6.11	-0.31	2.69e-9	Mitochondrial DNA levels;
LIHC	trans	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg19862616	chr7:65841803	NCRNA00174	0.51	7.85	0.39	5.37e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.83	10.64	0.5	4.86e-23	Small cell lung carcinoma;
LIHC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.47	9.71	0.46	7.47e-20	Immature fraction of reticulocytes;
LIHC	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg01028140	chr2:1542097	TPO	-0.45	-7.16	-0.36	4.98e-12	IgG glycosylation;
LIHC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.14	0.32	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs244293	0.965	rs2058027	chr17:53204859	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.28	6.93	0.35	2.09e-11	Migraine;
LIHC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg05044414	chr3:183734942	ABCC5	0.34	5.94	0.31	6.87e-9	Anterior chamber depth;
LIHC	cis	rs748404	0.578	rs2584701	chr15:43684939	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.64	0.42	2.16e-16	Lung cancer;
LIHC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg05555928	chr11:63887634	MACROD1	0.56	7.6	0.38	2.93e-13	Mean platelet volume;
LIHC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.4	-6.17	-0.32	1.94e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg12560992	chr17:57184187	TRIM37	0.69	8.82	0.43	6.14e-17	Vitamin D levels;
LIHC	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.42	6.81	0.35	4.46e-11	Menopause (age at onset);
LIHC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.47	-7.01	-0.35	1.25e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.5	0.77	1.86e-69	Chronic sinus infection;
LIHC	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.43	6.94	0.35	1.99e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.75	-11.92	-0.54	1.2100000000000001e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs7707921	0.767	rs3739	chr5:81569311	A/G	cg15871215	chr5:81402204	ATG10	-0.7	-8.35	-0.41	1.7e-15	Breast cancer;
LIHC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-5.74	-0.3	2.06e-8	Vitiligo;
LIHC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.06	0.31	3.67e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.62	-0.38	2.57e-13	Prevalent atrial fibrillation;
LIHC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-0.82	-9.65	-0.46	1.24e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25005279	chr10:135113451	TUBGCP2	0.43	6.41	0.33	4.7e-10	Bilirubin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17322444	chr19:33572249	GPATCH1	0.43	7.11	0.36	6.68e-12	Cognitive function;
LIHC	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.51	-0.71	1.72e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.94	13.48	0.59	1.58e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg18306943	chr3:40428807	ENTPD3	-0.35	-5.95	-0.31	6.52e-9	Renal cell carcinoma;
LIHC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.8	11.32	0.52	1.89e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg05941027	chr17:61774174	LIMD2	0.34	7.26	0.37	2.67e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg03874509	chr1:107600012	PRMT6	-0.72	-11.25	-0.52	3.45e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	0.81	9.45	0.46	5.55e-19	Opioid sensitivity;
LIHC	cis	rs4788570	0.538	rs72797713	chr16:71534208	G/A	cg06353428	chr16:71660113	MARVELD3	-1.12	-10.11	-0.48	3.32e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.45	6.59	0.34	1.62e-10	Aortic root size;
LIHC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.64	7.62	0.38	2.59e-13	Heart rate;
LIHC	cis	rs7872515	1.000	rs7852067	chr9:94815594	A/G	cg01248375	chr9:94877805	SPTLC1	0.54	7.5	0.38	5.5e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.83	-0.3	1.3e-8	Total body bone mineral density;
LIHC	cis	rs11229555	0.645	rs12802819	chr11:58174747	T/G	cg15696309	chr11:58395628	NA	-0.64	-7.47	-0.37	6.61e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4794202	0.629	rs7212099	chr17:45925890	A/G	cg10638573	chr17:45915098	SCRN2	0.58	5.78	0.3	1.69e-8	Alzheimer's disease (cognitive decline);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03578541	chr16:72128063	TXNL4B;DHX38	0.48	7.21	0.36	3.67e-12	Pancreatic cancer;
LIHC	trans	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg10756647	chr7:56101905	PSPH	-1.07	-13.17	-0.58	2.44e-32	Diabetic kidney disease;
LIHC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.48	-0.33	3.13e-10	Obesity-related traits;
LIHC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	5.78	0.3	1.64e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg24296786	chr1:45957014	TESK2	-0.52	-7.63	-0.38	2.32e-13	Platelet count;
LIHC	trans	rs2206405	0.565	rs6117903	chr20:7622942	C/T	cg22883290	chr2:127800646	NA	0.49	6.04	0.31	4.06e-9	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg20090690	chr10:134436459	INPP5A	0.41	5.77	0.3	1.75e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.49	7.36	0.37	1.39e-12	Mean platelet volume;
LIHC	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	0.93	5.93	0.31	7.49e-9	Mitochondrial DNA levels;
LIHC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg13628971	chr7:2884303	GNA12	0.42	6.57	0.33	1.93e-10	Height;
LIHC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.37	6.72	0.34	7.71e-11	Height;
LIHC	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.09	0.31	3.02e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.02e-11	Red blood cell count;
LIHC	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.84	15.56	0.64	1.18e-41	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.62	7.58	0.38	3.3e-13	Cognitive function;
LIHC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.77	-0.3	1.78e-8	Personality dimensions;
LIHC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.62	9.58	0.46	2.08e-19	Tonsillectomy;
LIHC	cis	rs3736485	0.934	rs2899476	chr15:51903874	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.21	-0.32	1.54e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.9e-9	Aortic root size;
LIHC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-8.26	-0.41	3.34e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg01864069	chr14:103024347	NA	-0.34	-5.72	-0.3	2.32e-8	Platelet count;
LIHC	cis	rs151997	1.000	rs26063	chr5:50216718	G/A	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	9.91e-21	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.41	6.09	0.31	3.04e-9	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06778680	chr14:21979519	METTL3	0.46	6.18	0.32	1.84e-9	Lung function (FEV1/FVC);
LIHC	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.43	6.18	0.32	1.79e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.58	9.97	0.47	1.04e-20	Alcohol dependence;
LIHC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	5.92	0.3	7.76e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.56	8.63	0.42	2.35e-16	Pulse pressure;
LIHC	cis	rs918629	0.724	rs10515232	chr5:95310985	A/G	cg10483112	chr5:95245456	ELL2	0.36	6.12	0.31	2.63e-9	IgG glycosylation;
LIHC	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg08539965	chr1:21396338	EIF4G3	-0.32	-5.73	-0.3	2.26e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg02415029	chr1:110025642	ATXN7L2	0.48	6.1	0.31	2.94e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg25344623	chr2:136566232	LCT	-0.38	-6.37	-0.33	6.24e-10	Corneal structure;
LIHC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.48e-11	Gut microbiome composition (summer);
LIHC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.52	6.56	0.33	1.96e-10	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.05e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg04082016	chr2:20871401	NA	-0.38	-6.69	-0.34	9.21e-11	Abdominal aortic aneurysm;
LIHC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.68	0.53	9.51e-27	Alzheimer's disease;
LIHC	cis	rs11871801	0.517	rs34138141	chr17:40781561	G/T	cg14558262	chr17:40713999	COASY	0.54	6.95	0.35	1.83e-11	Crohn's disease;
LIHC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.34	0.52	1.59e-25	Coronary artery disease;
LIHC	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.74	-0.34	6.91e-11	Bladder cancer;
LIHC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.47	-0.33	3.42e-10	Fear of minor pain;
LIHC	cis	rs10861342	1.000	rs11112403	chr12:105586649	A/G	cg23923672	chr12:105501055	KIAA1033	0.64	7.65	0.38	2.03e-13	IgG glycosylation;
LIHC	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-12.59	-0.56	4e-30	Alzheimer's disease;
LIHC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-10.87	-0.51	7.69e-24	Lung cancer;
LIHC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.2	0.32	1.66e-9	Cognitive ability;
LIHC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.74	0.54	5.88e-27	Motion sickness;
LIHC	cis	rs6141769	0.542	rs28523897	chr20:31301248	C/T	cg13636640	chr20:31349939	DNMT3B	-0.32	-5.74	-0.3	2.09e-8	Subjective well-being;
LIHC	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg03934865	chr2:198174659	NA	0.47	6.84	0.35	3.75e-11	Dermatomyositis;
LIHC	cis	rs295140	0.743	rs1729412	chr2:201083598	T/C	cg23649088	chr2:200775458	C2orf69	0.44	5.88	0.3	9.55e-9	QT interval;
LIHC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg07451762	chr16:28383216	NA	0.32	6.14	0.31	2.33e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.36	-0.49	4.8e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.23	-5.74	-0.3	2.14e-8	Schizophrenia;
LIHC	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.72	-0.3	2.3e-8	Neuroticism;
LIHC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.55	-7.59	-0.38	3.02e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.66	8.05	0.4	1.35e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.14	0.44	5.78e-18	IgG glycosylation;
LIHC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.66	6.62	0.34	1.37e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg00292662	chr22:38071168	LGALS1	0.39	6.63	0.34	1.35e-10	Fat distribution (HIV);
LIHC	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-9.19	-0.45	3.83e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg17980119	chr2:219472607	PLCD4	0.35	6.02	0.31	4.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	5.8	0.3	1.52e-8	Schizophrenia;
LIHC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-6.87	-0.35	3.12e-11	Waist circumference;Hip circumference;
LIHC	cis	rs1401454	0.967	rs11023881	chr11:16246700	T/A	cg10927848	chr11:16298618	SOX6	-0.33	-6.08	-0.31	3.24e-9	Blood pressure;
LIHC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.76	0.54	4.69e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07305463	chr2:136567211	LCT	0.38	7.25	0.36	2.83e-12	Mosquito bite size;
LIHC	trans	rs875971	0.528	rs801213	chr7:66014918	C/T	cg26939375	chr7:64535504	NA	-0.4	-6.31	-0.32	8.63e-10	Aortic root size;
LIHC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.73	0.3	2.18e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg00656387	chr3:40428638	ENTPD3	0.5	8.41	0.41	1.16e-15	Renal cell carcinoma;
LIHC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.55	8.51	0.42	5.55e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg02503808	chr4:7069936	GRPEL1	-0.77	-10.76	-0.5	1.86e-23	Monocyte percentage of white cells;
LIHC	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg03585969	chr10:35415529	CREM	0.76	10.95	0.51	3.88e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg15688767	chr3:125093330	ZNF148	-0.43	-6.17	-0.32	1.94e-9	Urinary tract infection frequency;
LIHC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg17724175	chr1:150552817	MCL1	-0.39	-7.88	-0.39	4.26e-14	Tonsillectomy;
LIHC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg27432699	chr2:27873401	GPN1	0.51	7.69	0.38	1.62e-13	Total body bone mineral density;
LIHC	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.7	14.5	0.62	1.88e-37	Schizophrenia;
LIHC	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg11783602	chr8:55087084	NA	-0.3	-6.11	-0.31	2.73e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.82	17.05	0.68	1.3e-47	Gestational age at birth (maternal effect);
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04282497	chr4:82350883	RASGEF1B	0.42	6.11	0.31	2.67e-9	Myopia (pathological);
LIHC	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.57	-0.42	3.66e-16	Body mass index;
LIHC	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg09003973	chr2:102972529	NA	0.84	7.11	0.36	6.73e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.88	17.88	0.69	6.24e-51	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.25e-9	Mean corpuscular volume;
LIHC	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg17385448	chr1:15911702	AGMAT	0.4	6.7	0.34	8.78e-11	Systolic blood pressure;
LIHC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.41	-5.71	-0.3	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.79	6.07	0.31	3.39e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.46	-0.37	7.34e-13	Response to antipsychotic treatment;
LIHC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.66	13.89	0.6	4.3e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.98	11.93	0.54	1.18e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.41	7.95	0.39	2.78e-14	Testicular germ cell tumor;
LIHC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.46	9.5e-20	Bipolar disorder;
LIHC	cis	rs4407350	0.729	rs9819	chr22:44889386	C/T	cg26276947	chr22:44892394	LDOC1L	-0.31	-5.73	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4920343	0.645	rs685300	chr1:19067368	C/T	cg19637330	chr1:19110922	NA	0.31	5.89	0.3	9.21e-9	Knee osteoarthritis;
LIHC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg12826209	chr6:26865740	GUSBL1	0.49	5.9	0.3	8.61e-9	Small cell lung carcinoma;
LIHC	cis	rs6752107	0.512	rs1372097	chr2:234227047	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.39	5.84	0.3	1.2e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.01	0.44	1.52e-17	IgG glycosylation;
LIHC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.4	8.48	0.42	6.74e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.9	-0.35	2.56e-11	Longevity;Endometriosis;
LIHC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.64	-0.38	2.23e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.15	0.36	5.31e-12	Self-reported allergy;
LIHC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.34	-0.59	5.58e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.84	0.35	3.75e-11	Gut microbiome composition (summer);
LIHC	trans	rs2352908	1.000	rs12897476	chr14:49453299	G/T	cg01449224	chr4:123073775	NA	-0.47	-6.3	-0.32	9.26e-10	Social communication problems;
LIHC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.06	-0.31	3.55e-9	Colorectal cancer;
LIHC	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.62	-10.85	-0.51	9.07e-24	Inflammatory bowel disease;
LIHC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.05	0.36	9.72e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	6.04	0.31	3.93e-9	Type 2 diabetes;
LIHC	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg15816464	chr17:2026533	SMG6	0.5	9.7	0.46	8.02e-20	Total body bone mineral density;
LIHC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	0.98	10.31	0.49	7.06e-22	Vitiligo;
LIHC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.22	-0.7	2.49e-52	Height;
LIHC	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.52	-9.37	-0.45	9.84e-19	Atrioventricular conduction;
LIHC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.8	-0.43	7e-17	Cognitive function;
LIHC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.56	9.61	0.46	1.65e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.61	9.12	0.44	6.66e-18	Recombination rate (females);
LIHC	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.51	-0.42	5.57e-16	Blood pressure (smoking interaction);
LIHC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-10.48	-0.49	1.83e-22	Monocyte percentage of white cells;
LIHC	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.4	7.77	0.39	9.11e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21467203	chr3:49911342	NA	-0.44	-7.99	-0.4	2.11e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.5	-0.38	5.55e-13	Uric acid levels;
LIHC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg14132834	chr19:41945861	ATP5SL	0.43	6.24	0.32	1.27e-9	Height;
LIHC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.43	-9.71	-0.46	7.75e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg20607798	chr8:58055168	NA	0.58	6.77	0.34	5.5e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg15254632	chr17:4843418	SLC25A11;RNF167	-0.46	-7.27	-0.37	2.53e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.84	-0.3	1.22e-8	Mean corpuscular volume;
LIHC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.62	9.81	0.47	3.56e-20	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09256448	chr16:638327	NA	0.38	6.25	0.32	1.25e-9	Height;
LIHC	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.46	-0.37	7.07e-13	QT interval;
LIHC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04530015	chr2:215796436	ABCA12	-0.38	-6.23	-0.32	1.38e-9	Neuroblastoma;
LIHC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.56	-0.5	9.45e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs12644436	0.711	rs12646494	chr4:88788205	A/G	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-12.26	-0.55	6.64e-29	Prudent dietary pattern;
LIHC	cis	rs10216189	1.000	rs9986884	chr7:5527211	C/T	cg05318486	chr7:5553423	FBXL18	-0.57	-8.47	-0.42	7.31e-16	Relative hand skill in reading disability;
LIHC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.5	-7.95	-0.39	2.83e-14	Educational attainment;
LIHC	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.58	7.12	0.36	6.47e-12	Morning vs. evening chronotype;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.65	-0.42	2.02e-16	Renal cell carcinoma;
LIHC	cis	rs7523273	0.526	rs12132176	chr1:207884287	A/T	cg22525895	chr1:207977042	MIR29B2	0.49	7.14	0.36	5.67e-12	Schizophrenia;
LIHC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg18306943	chr3:40428807	ENTPD3	0.39	6.63	0.34	1.33e-10	Renal cell carcinoma;
LIHC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.36	2.88e-12	Educational attainment;
LIHC	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	6.62	0.34	1.4e-10	Menarche (age at onset);
LIHC	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.83	11.48	0.53	5.01e-26	Body mass index;
LIHC	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.57	-13.99	-0.6	1.79e-35	White blood cell count (basophil);
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.84	10.61	0.5	6.44e-23	Cognitive function;
LIHC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.18	0.32	1.83e-9	Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.76	-0.5	1.95e-23	Hemoglobin concentration;
LIHC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg03854865	chr6:26224070	HIST1H3E	0.59	6.5	0.33	2.88e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.7	0.43	1.39e-16	Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26918957	chr8:22926800	TNFRSF10B	0.48	7.53	0.38	4.6e-13	Lung function (FEV1/FVC);
LIHC	cis	rs3770081	1.000	rs76052260	chr2:86328727	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.11	0.31	2.74e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.37	7.39	0.37	1.1e-12	Immature fraction of reticulocytes;
LIHC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.74	12.69	0.57	1.75e-30	Menopause (age at onset);
LIHC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg20140201	chr2:241835670	C2orf54	-0.46	-6.41	-0.33	4.95e-10	Urinary metabolites;
LIHC	cis	rs903552	1.000	rs12908310	chr15:102003635	A/G	cg00659931	chr15:102010125	PCSK6	-0.44	-6.04	-0.31	4.03e-9	Diabetic kidney disease;
LIHC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-8.94	-0.44	2.46e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-15.01	-0.63	1.76e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.6	0.46	1.71e-19	Asthma (sex interaction);
LIHC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.84	-13.33	-0.58	5.97e-33	Colorectal cancer;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg14828511	chr1:107599125	PRMT6	-0.43	-6.01	-0.31	4.79e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg15871215	chr5:81402204	ATG10	0.68	8.21	0.41	4.57e-15	Breast cancer;
LIHC	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.42	-6.09	-0.31	3.06e-9	Blood protein levels;
LIHC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.63e-9	Aortic root size;
LIHC	cis	rs1816752	0.901	rs28600047	chr13:25041108	T/C	cg22771759	chr13:24902376	NA	0.32	6.56	0.33	1.99e-10	Obesity-related traits;
LIHC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.95	0.31	6.49e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14154082	chr13:112174009	NA	0.3	6.26	0.32	1.16e-9	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.26e-27	Motion sickness;
LIHC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg10381502	chr11:71823885	C11orf51	0.97	8.22	0.41	4.21e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.5e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg15605315	chr1:45957053	TESK2	0.45	5.9	0.3	8.75e-9	High light scatter reticulocyte count;
LIHC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.12	11.56	0.53	2.54e-26	Opioid sensitivity;
LIHC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg15691649	chr6:25882328	NA	-0.53	-6.55	-0.33	2.16e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.54	7.01	0.35	1.24e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.55	-7.65	-0.38	2.01e-13	Multiple sclerosis;
LIHC	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg00469287	chr7:23338798	C7orf30	0.44	5.92	0.3	8.03e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.95	-0.31	6.74e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.41	6.62	0.34	1.41e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.57	-7.6	-0.38	2.89e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg00656387	chr3:40428638	ENTPD3	0.44	7.32	0.37	1.8e-12	Renal cell carcinoma;
LIHC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.68	11.67	0.53	9.94e-27	Crohn's disease;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg00280220	chr17:61926910	NA	0.44	7.12	0.36	6.29e-12	Prudent dietary pattern;
LIHC	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.55	0.62	1.15e-37	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07044724	chr16:30406465	ZNF48	0.46	6.58	0.34	1.82e-10	Pancreatic cancer;
LIHC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.72	10.39	0.49	3.7e-22	Diastolic blood pressure;
LIHC	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.23	-0.32	1.39e-9	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.77e-28	Motion sickness;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg26149184	chr10:133730230	NA	0.49	7.83	0.39	6.16e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.46	6.77	0.34	5.79e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10150615	chr22:24372951	LOC391322	-0.64	-9.67	-0.46	1e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.6	9.12	0.44	6.57e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.24	-0.41	3.72e-15	Chronic sinus infection;
LIHC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.1	10.01	0.48	7.28e-21	Diabetic retinopathy;
LIHC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	7.98	0.4	2.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.75	11.18	0.52	6.09e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.66	-10.16	-0.48	2.25e-21	Mosquito bite size;
LIHC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.55	9.82	0.47	3.32e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19040702	chr17:22023833	NA	-0.33	-6.48	-0.33	3.11e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg00800038	chr16:89945340	TCF25	-0.62	-9.35	-0.45	1.2e-18	Skin colour saturation;
LIHC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.12	-0.31	2.55e-9	Menarche (age at onset);
LIHC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.5	8.71	0.43	1.35e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg19645103	chr12:69753606	YEATS4	-0.46	-6.04	-0.31	3.96e-9	Response to diuretic therapy;
LIHC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.6	5.99	0.31	5.27e-9	Lymphocyte counts;
LIHC	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg20240347	chr1:204465584	NA	0.37	7.87	0.39	4.71e-14	Schizophrenia;
LIHC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.83	-15.84	-0.65	8.89e-43	Height;
LIHC	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.68	-10.78	-0.5	1.67e-23	Pediatric autoimmune diseases;
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg08469215	chr1:156261351	TMEM79	0.39	6.31	0.32	8.44e-10	Tonsillectomy;
LIHC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg15841412	chr13:111365552	ING1	0.5	6.23	0.32	1.37e-9	Coronary artery disease;
LIHC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.28	-0.32	1.02e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.27	-6.36	-0.33	6.28e-10	Alcohol dependence;
LIHC	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg02702477	chr5:179499311	RNF130	0.75	10.29	0.49	7.91e-22	LDL cholesterol;
LIHC	cis	rs2421770	0.530	rs3858470	chr11:35365444	T/C	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.59	-0.38	3.02e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs7818688	0.697	rs11784212	chr8:95976995	G/A	cg16049864	chr8:95962084	TP53INP1	0.62	6.78	0.34	5.18e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg23422044	chr7:1970798	MAD1L1	-0.6	-6.82	-0.35	4.1e-11	Bipolar disorder;
LIHC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.45e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02985541	chr2:219472218	PLCD4	-0.41	-6.55	-0.33	2.13e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.7	0.38	1.51e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg17623882	chr6:41773611	USP49	-0.43	-5.78	-0.3	1.68e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg10820045	chr2:198174542	NA	0.46	7.02	0.35	1.21e-11	Dermatomyositis;
LIHC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg14580859	chr9:123691850	NA	0.37	6.53	0.33	2.41e-10	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg26939375	chr7:64535504	NA	0.39	6.11	0.31	2.69e-9	Aortic root size;
LIHC	cis	rs864643	1.000	rs1768262	chr3:39553276	A/G	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06781563	chr16:85646914	KIAA0182	0.46	6.58	0.34	1.76e-10	Lung function (FEV1/FVC);
LIHC	cis	rs16828019	0.852	rs12729448	chr1:41509834	G/A	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg01256987	chr12:42539512	GXYLT1	0.41	6.89	0.35	2.69e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg14580859	chr9:123691850	NA	0.39	6.96	0.35	1.73e-11	Rheumatoid arthritis;
LIHC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.83	10.63	0.5	5.55e-23	Bladder cancer;
LIHC	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.92	-0.35	2.19e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01301323	chr12:77252588	CSRP2	0.54	7.7	0.38	1.47e-13	Systolic blood pressure;
LIHC	cis	rs11605275	1.000	rs11603592	chr11:20023522	C/T	cg14835545	chr11:20032148	NAV2	-0.81	-7.58	-0.38	3.31e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.2	0.32	1.62e-9	Schizophrenia;
LIHC	cis	rs3736594	0.513	rs60854669	chr2:27786929	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.75	0.34	6.44e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.43	-8.2	-0.41	4.96e-15	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.54	6.11	0.31	2.67e-9	Urinary tract infection frequency;
LIHC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg12463550	chr7:65579703	CRCP	0.71	7.26	0.37	2.63e-12	Diabetic kidney disease;
LIHC	trans	rs875971	0.929	rs778692	chr7:65872449	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.37	6.67	0.34	1.04e-10	Aortic root size;
LIHC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.75	14.44	0.62	3e-37	Mortality in heart failure;
LIHC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg03037974	chr15:76606532	NA	0.71	13.86	0.6	5.53e-35	Blood metabolite levels;
LIHC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-9.13	-0.44	6.11e-18	Parkinson's disease;
LIHC	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.54	8.08	0.4	1.09e-14	Body mass index;
LIHC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.58e-21	Diabetic retinopathy;
LIHC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.55	-11.03	-0.51	2.16e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs9596863	0.898	rs7983436	chr13:54388598	T/A	ch.13.53330881F	chr13:54432880	NA	0.43	5.73	0.3	2.21e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.71	11.01	0.51	2.46e-24	Selective IgA deficiency;
LIHC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.92	11.39	0.52	1.1e-25	Coronary artery disease;
LIHC	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg11812906	chr14:75593930	NEK9	0.43	6.51	0.33	2.63e-10	IgG glycosylation;
LIHC	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-5.98	-0.31	5.5e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	14.5	0.62	1.75e-37	Schizophrenia;
LIHC	trans	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg10208301	chr11:6592745	DNHD1	0.47	6.68	0.34	9.96e-11	Coronary artery calcification;
LIHC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg12798992	chr6:167411361	FGFR1OP	0.49	7.43	0.37	8.73e-13	Crohn's disease;
LIHC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.22	-0.55	9.39e-29	Colorectal cancer;
LIHC	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.93	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.65	-9.58	-0.46	2.07e-19	Coronary artery disease;
LIHC	cis	rs11800820	0.557	rs12045741	chr1:246664634	A/T	cg16700716	chr1:246684329	NA	-0.44	-7.84	-0.39	5.67e-14	Obesity-related traits;
LIHC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.51	8.17	0.4	6.11e-15	Platelet count;
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg05697976	chr12:29376483	FAR2	0.32	6.44	0.33	4.12e-10	QT interval;
LIHC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.67	11.91	0.54	1.38e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg20636351	chr8:55087400	NA	-0.4	-8.16	-0.4	6.43e-15	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.5	5.82	0.3	1.33e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7546668	1.000	rs10803388	chr1:15850097	G/A	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs3962382	1	rs3962382	chr1:68165693	A/C	cg10178795	chr1:68298432	GNG12	-0.44	-6.36	-0.33	6.33e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.79	11.26	0.52	3.02e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs1030268	0.828	rs1362735	chr7:133398605	A/G	cg03336402	chr7:133662267	EXOC4	-0.46	-6.51	-0.33	2.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.26e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.21	-0.58	1.83e-32	Type 2 diabetes;
LIHC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.93	0.65	3.95e-43	Lymphocyte percentage of white cells;
LIHC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	5.8	0.3	1.48e-8	Handedness;
LIHC	trans	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg07817883	chr1:32538562	TMEM39B	1.08	8.92	0.43	2.93e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.95	-0.31	6.64e-9	Diisocyanate-induced asthma;
LIHC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg01657329	chr11:68192670	LRP5	-0.6	-6.77	-0.34	5.69e-11	Total body bone mineral density (age 45-60);
LIHC	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg02811702	chr13:24901961	NA	0.24	6.02	0.31	4.6e-9	Obesity-related traits;
LIHC	trans	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04565464	chr8:145669602	NFKBIL2	0.37	6.19	0.32	1.73e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.38	-6.32	-0.32	8.18e-10	Lung cancer;
LIHC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	13.63	0.59	4.19e-34	Multiple sclerosis;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.67	9.89	0.47	1.84e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.3	0.68	1.31e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg03713592	chr11:72463424	ARAP1	0.59	6.53	0.33	2.31e-10	Type 2 diabetes;
LIHC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.87	0.3	1.03e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg10130564	chr11:117069849	TAGLN	0.35	5.9	0.3	8.53e-9	Blood protein levels;
LIHC	cis	rs8010715	0.596	rs12435995	chr14:24589464	A/C	cg23112188	chr14:24563095	PCK2	-0.32	-6.46	-0.33	3.5e-10	IgG glycosylation;
LIHC	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.26	-6.55	-0.33	2.08e-10	Mean corpuscular volume;
LIHC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02359409	chr6:42947317	PEX6	-0.47	-6.5	-0.33	2.77e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1789	0.903	rs6850422	chr4:15682437	C/T	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.89	-0.3	9.34e-9	Blood protein levels;
LIHC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg09911534	chr15:67153556	NA	-0.5	-6.08	-0.31	3.18e-9	Lung cancer (smoking interaction);
LIHC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.8	0.35	4.68e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg15257565	chr10:42644887	NA	0.31	6.04	0.31	3.99e-9	Ulcerative colitis;
LIHC	cis	rs7944735	0.564	rs58357937	chr11:47692160	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-5.89	-0.3	9.23e-9	Intraocular pressure;
LIHC	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg25457927	chr22:38595422	NA	-0.39	-9.46	-0.46	4.97e-19	Cutaneous nevi;
LIHC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.81	0.35	4.49e-11	Menopause (age at onset);
LIHC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	6.08	0.31	3.29e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg19920283	chr7:105172520	RINT1	0.75	6.01	0.31	4.64e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.45	-0.56	1.32e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.41	-6.71	-0.34	8.25e-11	Schizophrenia;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00612595	chr21:47717864	NA	0.41	6.5	0.33	2.87e-10	Testicular germ cell tumor;
LIHC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.44	-7.02	-0.35	1.21e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.77	12.18	0.55	1.32e-28	Corneal astigmatism;
LIHC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg05973401	chr12:123451056	ABCB9	0.43	6.42	0.33	4.48e-10	Platelet count;
LIHC	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg07998840	chr16:88851295	FAM38A	0.49	7.02	0.36	1.17e-11	Glycated hemoglobin levels;
LIHC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg04310649	chr10:35416472	CREM	-0.44	-5.94	-0.31	7.05e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg05090150	chr14:56047923	C14orf33;KTN1	-0.49	-6.66	-0.34	1.11e-10	QT interval;
LIHC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg03037974	chr15:76606532	NA	-0.61	-10.37	-0.49	4.39e-22	Blood metabolite levels;
LIHC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	0.85	11.09	0.51	1.32e-24	Skin colour saturation;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.89	-14.48	-0.62	2.09e-37	Longevity;
LIHC	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.32	-0.45	1.52e-18	Capecitabine sensitivity;
LIHC	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.22	0.66	2.74e-44	Electrocardiographic conduction measures;
LIHC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg19318889	chr4:1322082	MAEA	0.49	6.77	0.34	5.73e-11	Obesity-related traits;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04902049	chr1:36622448	MAP7D1	0.38	6.14	0.32	2.32e-9	Cognitive function;
LIHC	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.86	15.37	0.64	6.91e-41	Bone mineral density;
LIHC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.19	-0.32	1.73e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20135002	chr11:47629003	NA	0.56	9.53	0.46	3.03e-19	Subjective well-being;
LIHC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.47	7.66	0.38	1.88e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg13409248	chr3:40428643	ENTPD3	-0.48	-7.99	-0.4	2.02e-14	Renal cell carcinoma;
LIHC	cis	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg01231543	chr16:68741748	NA	0.39	6.19	0.32	1.71e-9	Colorectal cancer;
LIHC	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.5	-7.39	-0.37	1.12e-12	Mortality in heart failure;
LIHC	cis	rs600806	0.888	rs680434	chr1:109842271	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.53	-6.17	-0.32	1.98e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg08847533	chr14:75593920	NEK9	-0.47	-7.46	-0.37	7.3e-13	IgG glycosylation;
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.38	0.33	5.88e-10	Renal cell carcinoma;
LIHC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.61	-0.53	1.76e-26	Total cholesterol levels;
LIHC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.78	-0.3	1.71e-8	Schizophrenia;
LIHC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.83	0.43	5.6e-17	Cognitive ability;
LIHC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg08528486	chr13:113648767	MCF2L	-0.39	-6.35	-0.32	6.69e-10	Systolic blood pressure;
LIHC	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.24	-0.68	2.16e-48	Primary sclerosing cholangitis;
LIHC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.77	-8.22	-0.41	4.36e-15	Vitiligo;
LIHC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg05941027	chr17:61774174	LIMD2	0.36	7.06	0.36	9.16e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.66	0.38	1.93e-13	Mean platelet volume;
LIHC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.86	-0.43	4.36e-17	Type 2 diabetes;
LIHC	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.45	-7.76	-0.39	9.84e-14	Prevalent atrial fibrillation;
LIHC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.73	13.36	0.59	4.87e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10423674	0.526	rs757317	chr19:18819984	C/T	cg16673477	chr19:18812017	CRTC1	-0.41	-6.56	-0.33	2.04e-10	Menarche (age at onset);
LIHC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.71	6.25	0.32	1.26e-9	Mean corpuscular hemoglobin;
LIHC	cis	rs9980664	1.000	rs9984973	chr21:34739174	G/C	cg04842828	chr21:34696676	IFNAR1	0.48	6.35	0.32	6.92e-10	Cognitive decline (age-related);
LIHC	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.6	-11.91	-0.54	1.3e-27	Plateletcrit;Platelet count;
LIHC	cis	rs918629	0.601	rs889302	chr5:95264652	A/C	cg10483112	chr5:95245456	ELL2	-0.38	-6.99	-0.35	1.43e-11	IgG glycosylation;
LIHC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02290350	chr8:58132656	NA	0.45	8.73	0.43	1.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2997447	0.761	rs17257127	chr1:26452386	C/T	cg19633962	chr1:26362018	EXTL1	-0.62	-6.16	-0.32	2.04e-9	QRS complex (12-leadsum);
LIHC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg01864069	chr14:103024347	NA	0.45	7.04	0.36	1.05e-11	Platelet count;
LIHC	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	trans	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-7.73	-0.39	1.17e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.44	6.04	0.31	4.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.44	-8.18	-0.4	5.81e-15	Prudent dietary pattern;
LIHC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.46	6.71	0.34	8.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11663156	0.764	rs10853629	chr18:50889886	A/G	cg24270629	chr18:50823537	DCC	0.48	6.53	0.33	2.33e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.8	6.76	0.34	5.98e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.93	0.39	3.1e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.66	10.66	0.5	4.41e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.39	0.37	1.15e-12	Obesity-related traits;
LIHC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.56	-0.46	2.47e-19	Mean platelet volume;
LIHC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.61	9.92	0.47	1.53e-20	Bipolar disorder;
LIHC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg25344623	chr2:136566232	LCT	0.43	8.51	0.42	5.58e-16	Mosquito bite size;
LIHC	cis	rs712039	0.617	rs60118041	chr17:35803252	G/A	cg16670864	chr17:35848621	DUSP14	0.33	5.74	0.3	2.15e-8	Tuberculosis;
LIHC	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg02023728	chr11:77925099	USP35	0.39	7.02	0.36	1.17e-11	Testicular germ cell tumor;
LIHC	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-7.04	-0.36	1.04e-11	Pancreatic cancer;
LIHC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.26	0.41	3.23e-15	Motion sickness;
LIHC	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.04	0.36	1.09e-11	Diastolic blood pressure;
LIHC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.88	0.6	4.52e-35	Chronic sinus infection;
LIHC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg18081818	chr7:23246105	NA	-0.4	-5.84	-0.3	1.18e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg18081818	chr7:23246105	NA	-0.41	-6.12	-0.31	2.57e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg12863693	chr15:85201151	NMB	0.48	6.83	0.35	3.9e-11	Schizophrenia;
LIHC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg16586182	chr3:47516702	SCAP	0.49	8.64	0.42	2.15e-16	Colorectal cancer;
LIHC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.41	6.92	0.35	2.3e-11	Alcohol dependence;
LIHC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.75	-11.44	-0.53	7.18e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.64e-11	Aortic root size;
LIHC	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.38	-6.31	-0.32	8.84e-10	Schizophrenia;
LIHC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.94	-0.31	6.96e-9	Morning vs. evening chronotype;
LIHC	cis	rs9543976	1.000	rs55927305	chr13:76135349	A/G	cg01531495	chr13:76123901	UCHL3	-0.51	-5.98	-0.31	5.68e-9	Diabetic retinopathy;
LIHC	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.43	6.53	0.33	2.44e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-9.63	-0.46	1.41e-19	Alzheimer's disease (late onset);
LIHC	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14154082	chr13:112174009	NA	0.29	6.08	0.31	3.26e-9	Menarche (age at onset);
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg14709524	chr16:89940631	TCF25	0.56	7.05	0.36	9.75e-12	Skin colour saturation;
LIHC	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg25251204	chr11:14927456	NA	0.41	5.93	0.31	7.23e-9	Vitamin D levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21224049	chr4:668623	ATP5I	0.48	7.62	0.38	2.56e-13	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.1	-0.31	2.84e-9	Diabetic kidney disease;
LIHC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.57	0.33	1.83e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4605213	0.605	rs41524846	chr17:49252238	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	0.45	6.17	0.32	1.93e-9	Height;
LIHC	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg14593290	chr7:50529359	DDC	0.49	7.86	0.39	5.03e-14	Malaria;
LIHC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	7.34	0.37	1.62e-12	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27289501	chr12:77378460	NA	0.4	6.17	0.32	1.91e-9	Longevity;
LIHC	cis	rs17756712	0.666	rs6911663	chr6:633382	G/C	cg14374089	chr6:596013	EXOC2	0.4	5.71	0.3	2.42e-8	Vertical cup-disc ratio;
LIHC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg15691649	chr6:25882328	NA	-0.44	-7.01	-0.35	1.26e-11	Height;
LIHC	cis	rs864643	1.000	rs602527	chr3:39568784	A/G	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg20932281	chr17:33905541	PEX12	0.42	5.73	0.3	2.23e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.82	9.53	0.46	3.1e-19	Vitiligo;
LIHC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.34	-5.82	-0.3	1.39e-8	Prostate cancer;
LIHC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg02290350	chr8:58132656	NA	0.42	7.96	0.4	2.6e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.61	7.61	0.38	2.68e-13	Diastolic blood pressure;
LIHC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.61	11.47	0.53	5.46e-26	Alzheimer's disease (late onset);
LIHC	cis	rs713477	0.967	rs10483642	chr14:55920460	A/G	cg13175173	chr14:55914753	NA	0.32	7.26	0.37	2.68e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg07061783	chr6:25882402	NA	0.42	5.85	0.3	1.16e-8	Blood metabolite levels;
LIHC	cis	rs1494950	1.000	rs4698308	chr4:14988190	C/T	cg12377275	chr4:15005593	CPEB2	-0.79	-6.62	-0.34	1.35e-10	Political ideology;
LIHC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.79	9.91	0.47	1.65e-20	Body mass index;
LIHC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg16558253	chr16:72132732	DHX38	-0.44	-6.3	-0.32	9.07e-10	Fibrinogen levels;
LIHC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg02640540	chr1:67518911	SLC35D1	0.45	6.13	0.31	2.41e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs8083850	0.698	rs6508229	chr18:50874503	G/C	cg24270629	chr18:50823537	DCC	0.53	8.03	0.4	1.53e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg15017067	chr4:17643749	FAM184B	0.36	6.02	0.31	4.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg03859395	chr2:55845619	SMEK2	0.92	16.44	0.66	3.59e-45	Metabolic syndrome;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.38	-5.75	-0.3	2.03e-8	Total body bone mineral density;
LIHC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.47	7.36	0.37	1.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.57	-8.14	-0.4	7.19e-15	Blood pressure (smoking interaction);
LIHC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg12373951	chr3:133503437	NA	0.42	6.93	0.35	2.15e-11	Iron status biomarkers;
LIHC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.4	7.94	0.39	2.95e-14	Cardiovascular disease risk factors;
LIHC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.71	0.34	8.09e-11	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06513149	chr13:33002431	N4BP2L1	0.45	6.13	0.31	2.36e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg22842854	chr12:123319900	HIP1R	-0.64	-8.24	-0.41	3.59e-15	Schizophrenia;
LIHC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg02344993	chr17:57696989	CLTC	0.58	9.4	0.45	7.78e-19	Hemoglobin concentration;
LIHC	cis	rs611744	0.934	rs672591	chr8:109192453	T/A	cg18478394	chr8:109455254	TTC35	0.4	6.87	0.35	3.09e-11	Dupuytren's disease;
LIHC	cis	rs16828019	0.852	rs71648534	chr1:41613747	G/T	cg20697417	chr1:41786797	NA	0.35	6.64	0.34	1.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.45	-0.53	6.66e-26	Total cholesterol levels;
LIHC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.59	9.77	0.47	4.76e-20	Type 2 diabetes;
LIHC	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg16558208	chr1:156270281	VHLL	-0.48	-9.04	-0.44	1.17e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.34	-6.79	-0.34	4.86e-11	Platelet distribution width;
LIHC	cis	rs1555399	0.934	rs4902477	chr14:67989097	G/A	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.74	-0.3	2.04e-8	Parkinson's disease;
LIHC	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg06795125	chr2:108905320	SULT1C2	0.31	6.33	0.32	7.88e-10	Blood pressure;
LIHC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.77	13.18	0.58	2.42e-32	Anterior chamber depth;
LIHC	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.86	14.84	0.63	8.69e-39	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.17	-0.4	6.17e-15	Gut microbiome composition (summer);
LIHC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	8.59	0.42	3.12e-16	Platelet count;
LIHC	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	10.29	0.49	8.26e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-6.27	-0.32	1.07e-9	Morning vs. evening chronotype;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg07805724	chr3:69062774	C3orf64	-0.45	-6.85	-0.35	3.55e-11	Eotaxin levels;
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.43	0.33	4.22e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.75	13.9	0.6	4.04e-35	Iron status biomarkers;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg11342453	chr6:26196699	NA	0.52	5.8	0.3	1.55e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg13628971	chr7:2884303	GNA12	0.44	6.96	0.35	1.71e-11	Height;
LIHC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.43	-8.19	-0.4	5.34e-15	Birth weight;
LIHC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.71	0.43	1.34e-16	Motion sickness;
LIHC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.38	6.16	0.32	2e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg02290350	chr8:58132656	NA	0.33	7.04	0.36	1.06e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	1.12	14.83	0.63	9.49e-39	Blood protein levels;
LIHC	cis	rs4700695	0.925	rs11958597	chr5:65417038	G/A	cg21114390	chr5:65439923	SFRS12	-0.46	-6.02	-0.31	4.46e-9	Facial morphology (factor 19);
LIHC	cis	rs16858210	0.874	rs55666767	chr3:183573235	C/T	cg25686905	chr3:183603175	PARL	-0.52	-9.57	-0.46	2.27e-19	Menopause (age at onset);
LIHC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg09182678	chr22:50328711	NA	-0.41	-6.07	-0.31	3.48e-9	Schizophrenia;
LIHC	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.4	5.93	0.31	7.32e-9	Menopause (age at onset);
LIHC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21467203	chr3:49911342	NA	-0.53	-9.65	-0.46	1.16e-19	Body mass index;
LIHC	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg20737812	chr15:86336631	KLHL25	-0.44	-6.1	-0.31	2.83e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.69	13.02	0.58	9.69e-32	Systemic lupus erythematosus;
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.9	-15.26	-0.64	1.75e-40	Longevity;
LIHC	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.42e-11	Intracranial aneurysm;
LIHC	cis	rs17854409	0.764	rs73613593	chr20:61471582	T/C	cg07645718	chr20:61493192	TCFL5	0.79	5.98	0.31	5.7e-9	Obesity-related traits;
LIHC	cis	rs611744	0.934	rs673356	chr8:109185159	A/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs7116495	1.000	rs947932	chr11:71656705	A/G	cg26138937	chr11:71823887	C11orf51	-0.81	-7.95	-0.39	2.76e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	9.08	0.44	8.57e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.47	8.19	0.4	5.22e-15	Pubertal anthropometrics;
LIHC	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg21448741	chr8:58168803	NA	0.34	6.1	0.31	2.94e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1144333	0.655	rs946164	chr1:76383286	A/T	cg03433033	chr1:76189801	ACADM	0.52	7.28	0.37	2.26e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	5.75	0.3	1.97e-8	Resting heart rate;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03538922	chr16:87737870	LOC100129637	0.39	6.08	0.31	3.22e-9	Longevity;
LIHC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg05425664	chr17:57184151	TRIM37	0.43	6.07	0.31	3.43e-9	Testicular germ cell tumor;
LIHC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.56	7.82	0.39	6.8e-14	Lung cancer;
LIHC	trans	rs17384439	1.000	rs17024030	chr4:96399606	A/G	cg27488279	chr7:117864698	ANKRD7	-0.52	-6.1	-0.31	2.87e-9	Obsessive-compulsive symptoms;
LIHC	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg01364799	chr7:75623366	TMEM120A	0.51	7.79	0.39	8.37e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.54	-8.72	-0.43	1.24e-16	Cocaine dependence;
LIHC	cis	rs2292096	1.000	rs2029751	chr1:200698286	A/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-6.02	-0.31	4.41e-9	Epilepsy;
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg10755058	chr3:40428713	ENTPD3	-0.34	-5.81	-0.3	1.42e-8	Renal cell carcinoma;
LIHC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg27284194	chr4:1044797	NA	0.38	5.82	0.3	1.33e-8	Obesity-related traits;
LIHC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.98	-0.4	2.21e-14	Monocyte percentage of white cells;
LIHC	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	0.95	6.95	0.35	1.85e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.54	8.59	0.42	3.03e-16	Height;
LIHC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	1.0	9.71	0.46	7.65e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.48	0.46	4.49e-19	Alzheimer's disease;
LIHC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.53	-0.38	4.56e-13	Bipolar disorder;
LIHC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.86	-0.35	3.23e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.09	-0.63	8.65e-40	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.45	8.27	0.41	2.96e-15	Prudent dietary pattern;
LIHC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg21395723	chr22:39101663	GTPBP1	0.35	6.04	0.31	3.95e-9	Menopause (age at onset);
LIHC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.21	13.44	0.59	2.28e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg12310025	chr6:25882481	NA	-0.45	-6.73	-0.34	7.05e-11	Height;
LIHC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.18	10.27	0.49	9.72e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.32	-0.32	8.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.59	10.16	0.48	2.26e-21	Height;
LIHC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg25801113	chr15:45476975	SHF	0.41	7.04	0.36	1.05e-11	Uric acid levels;
LIHC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.79	7.52	0.38	4.77e-13	Plasma clusterin levels;
LIHC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	8.47	0.42	7.25e-16	Obesity-related traits;
LIHC	cis	rs288342	0.832	rs13509	chr2:183642878	G/A	cg02625481	chr2:183667124	NA	-0.29	-6.06	-0.31	3.53e-9	Recurrent major depressive disorder;
LIHC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.33	7.13	0.36	5.86e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	9.75	0.47	5.53e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.42	-6.74	-0.34	6.64e-11	Menarche (age at onset);
LIHC	cis	rs2929278	0.617	rs3087657	chr15:44063859	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.37	6.11	0.31	2.72e-9	Schizophrenia;
LIHC	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-7.4	-0.37	1.09e-12	Blood pressure;
LIHC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1789	0.839	rs9997068	chr4:15650990	T/C	cg16509355	chr4:15471240	CC2D2A	-0.47	-7.21	-0.36	3.51e-12	Blood protein levels;
LIHC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.17	0.32	1.89e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	6.96	0.35	1.78e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14828511	chr1:107599125	PRMT6	0.42	5.91	0.3	8.33e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.62	-11.21	-0.52	4.84e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.62	-0.53	1.57e-26	Platelet distribution width;
LIHC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg12046867	chr14:103022105	NA	-0.49	-7.23	-0.36	3.16e-12	Platelet count;
LIHC	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg15208524	chr1:10270712	KIF1B	0.45	6.5	0.33	2.82e-10	Hepatocellular carcinoma;
LIHC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs34563280	1	rs34563280	chr11:47811496	CT/C	cg20307385	chr11:47447363	PSMC3	0.74	10.81	0.5	1.26e-23	Plateletcrit;
LIHC	cis	rs244293	0.730	rs3213757	chr17:53041857	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.13	-0.31	2.47e-9	Menarche (age at onset);
LIHC	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.66	-10.55	-0.5	1.04e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	8.12	0.4	8.8e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.34	5.86	0.3	1.11e-8	Permanent tooth development;
LIHC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg18016565	chr1:150552671	MCL1	0.54	10.11	0.48	3.36e-21	Melanoma;
LIHC	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.59	-0.42	3.07e-16	Obesity-related traits;
LIHC	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.4	6.16	0.32	2.09e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.59	11.96	0.54	9e-28	Coronary artery disease;
LIHC	cis	rs6449957	0.966	rs73126520	chr5:67475425	C/T	cg23036683	chr5:67512108	NA	0.48	7.05	0.36	1e-11	Cleft lip with or without cleft palate;
LIHC	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.42	0.49	2.8e-22	Fuchs's corneal dystrophy;
LIHC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.98	0.44	1.87e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.27	0.66	1.75e-44	Smoking behavior;
LIHC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	7.08	0.36	8.26e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.25	-6.42	-0.33	4.68e-10	Hip circumference;Waist circumference;
LIHC	cis	rs7737355	0.773	rs32103	chr5:131030961	T/C	cg06307176	chr5:131281290	NA	0.4	5.79	0.3	1.56e-8	Life satisfaction;
LIHC	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg10381502	chr11:71823885	C11orf51	1.07	9.57	0.46	2.22e-19	Severe influenza A (H1N1) infection;
LIHC	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.33	-6.85	-0.35	3.52e-11	Testicular germ cell tumor;
LIHC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-14.45	-0.62	2.82e-37	Alzheimer's disease (late onset);
LIHC	cis	rs3790844	0.876	rs61486545	chr1:200008337	G/A	cg13229857	chr1:200006247	NR5A2	0.44	7.19	0.36	3.99e-12	Pancreatic cancer;
LIHC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.72	0.34	7.49e-11	Gut microbiome composition (summer);
LIHC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.85	-0.3	1.17e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	6.58	0.34	1.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg27432699	chr2:27873401	GPN1	-0.46	-6.53	-0.33	2.4e-10	Total body bone mineral density;
LIHC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg24130564	chr14:104152367	KLC1	-0.53	-8.43	-0.41	9.84e-16	Reticulocyte count;
LIHC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg03970086	chr16:88974840	CBFA2T3	-0.34	-6.71	-0.34	8.25e-11	Social autistic-like traits;
LIHC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.64	0.34	1.2e-10	Height;
LIHC	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.48	7.87	0.39	4.85e-14	Corneal astigmatism;
LIHC	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	0.69	8.97	0.44	2.01e-17	Body mass index;
LIHC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg10621924	chr7:39171070	POU6F2	0.42	6.41	0.33	4.94e-10	IgG glycosylation;
LIHC	cis	rs11229555	0.598	rs12269888	chr11:58184336	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg09990169	chr2:241835740	C2orf54	-0.66	-9.09	-0.44	8.22e-18	Urinary metabolites;
LIHC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.85	-15.03	-0.63	1.49e-39	Aortic root size;
LIHC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.32	1.29e-9	Aortic root size;
LIHC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.59	-11.16	-0.52	7.41e-25	Mean corpuscular volume;
LIHC	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg20283391	chr11:68216788	NA	-0.5	-6.04	-0.31	4.09e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.54	-8.39	-0.41	1.31e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3736485	0.932	rs28795073	chr15:51927562	C/T	cg08986416	chr15:51914746	DMXL2	-0.44	-6.33	-0.32	7.52e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg15382696	chr6:118971807	C6orf204	0.62	6.03	0.31	4.36e-9	Diastolic blood pressure;
LIHC	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg06046430	chr4:77819534	ANKRD56	0.49	6.51	0.33	2.66e-10	Emphysema distribution in smoking;
LIHC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-6.86	-0.35	3.33e-11	Schizophrenia;
LIHC	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.58	-0.38	3.22e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs11098699	0.821	rs11942230	chr4:124199453	A/G	cg09941581	chr4:124220074	SPATA5	0.31	6.2	0.32	1.6e-9	Mosquito bite size;
LIHC	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	6.35	0.32	6.85e-10	Iron status biomarkers;
LIHC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.85	10.99	0.51	2.87e-24	Heart rate;
LIHC	cis	rs13401104	0.796	rs1466207	chr2:237121350	C/T	cg19324714	chr2:237145437	ASB18	0.37	5.85	0.3	1.13e-8	Educational attainment;
LIHC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.02	-0.31	4.55e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg07424592	chr7:64974309	NA	-0.76	-8.54	-0.42	4.52e-16	Diabetic kidney disease;
LIHC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg19680672	chr10:131412579	MGMT	-0.45	-6.88	-0.35	2.89e-11	Response to temozolomide;
LIHC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg15105060	chr4:7024189	TBC1D14	-0.66	-5.96	-0.31	6.11e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14751398	chr6:20402153	E2F3	0.42	6.67	0.34	1.04e-10	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20261243	chr20:44718728	NCOA5	0.43	6.99	0.35	1.47e-11	Cognitive function;
LIHC	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.88	0.3	9.71e-9	Height;
LIHC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-5.81	-0.3	1.4e-8	IgG glycosylation;
LIHC	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-9.22	-0.45	3.15e-18	Platelet distribution width;
LIHC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.48	-5.74	-0.3	2.05e-8	Blood metabolite levels;
LIHC	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.83	-0.6	7.2e-35	Coffee consumption (cups per day);
LIHC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg03854865	chr6:26224070	HIST1H3E	0.66	7.48	0.37	6.5e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg25011176	chr20:3776985	CDC25B	-0.47	-6.5	-0.33	2.83e-10	Bipolar disorder;
LIHC	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.2	6.25	0.32	1.25e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs4917833	0.789	rs10786427	chr10:100218382	G/A	cg19043522	chr10:100227446	HPSE2	0.4	5.78	0.3	1.65e-8	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.75	-7.71	-0.38	1.35e-13	Vitiligo;
LIHC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.73	-9.76	-0.47	5.17e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1355223	0.872	rs12802798	chr11:34747434	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.5	-0.33	2.86e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08893839	chr5:154027129	NA	0.49	6.68	0.34	9.57e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg18016565	chr1:150552671	MCL1	0.5	9.46	0.46	5.19e-19	Melanoma;
LIHC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-9.2	-0.45	3.52e-18	Chronic sinus infection;
LIHC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg21724239	chr8:58056113	NA	0.42	5.87	0.3	1.04e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.83	12.43	0.56	1.65e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg05425664	chr17:57184151	TRIM37	-0.46	-5.79	-0.3	1.58e-8	Vitamin D levels;
LIHC	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.74e-11	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg20607798	chr8:58055168	NA	0.49	5.91	0.3	8.09e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.42	-6.15	-0.32	2.19e-9	Cognitive ability;
LIHC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.74	0.34	6.87e-11	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg02290350	chr8:58132656	NA	0.32	7.07	0.36	8.87e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg04632378	chr13:21900426	NA	0.37	6.13	0.31	2.48e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.25	0.58	1.22e-32	Psoriasis;
LIHC	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.24	-12.96	-0.57	1.55e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs72843506	0.656	rs58313980	chr17:19940050	A/G	cg12065943	chr17:19881925	AKAP10	-0.41	-6.93	-0.35	2.14e-11	Schizophrenia;
LIHC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.67	10.93	0.51	4.79e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.81	0.3	1.46e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.57	-8.75	-0.43	9.98e-17	Extraversion;
LIHC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.74e-11	Ileal carcinoids;
LIHC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.66	0.34	1.1e-10	Renal cell carcinoma;
LIHC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg15472797	chr10:135243109	NA	-0.38	-5.73	-0.3	2.22e-8	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.37	6.08	0.31	3.24e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.33	-6.31	-0.32	8.65e-10	Abdominal aortic aneurysm;
LIHC	cis	rs12744310	0.887	rs35690915	chr1:41797999	T/C	cg03962019	chr1:41807865	NA	0.38	6.17	0.32	1.88e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg01117627	chr14:100150713	CYP46A1	-0.49	-6.37	-0.33	6.01e-10	Electroencephalogram traits;
LIHC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.62	0.34	1.38e-10	Renal cell carcinoma;
LIHC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.9	-0.3	8.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7116495	1.000	rs529522	chr11:71580562	C/G	cg26138937	chr11:71823887	C11orf51	0.69	6.83	0.35	3.94e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.58	-8.22	-0.41	4.35e-15	Response to antineoplastic agents;
LIHC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.46	6.85	0.35	3.54e-11	Aortic root size;
LIHC	cis	rs9473924	1.000	rs9473932	chr6:50857995	G/A	cg14470998	chr6:50812995	TFAP2B	0.49	7.26	0.37	2.57e-12	Body mass index;
LIHC	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg26550851	chr1:3701203	LRRC47	-0.42	-6.97	-0.35	1.68e-11	Mean corpuscular volume;
LIHC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.95	12.37	0.56	2.58e-29	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.45	0.37	7.57e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg22079354	chr11:130786696	SNX19	-0.4	-5.79	-0.3	1.61e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.57	7.77	0.39	9.03e-14	Eotaxin levels;
LIHC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.6	-9.15	-0.44	5.4e-18	Height;
LIHC	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	9.51	0.46	3.59e-19	Red blood cell count;
LIHC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg23205692	chr1:25664452	TMEM50A	0.4	6.5	0.33	2.81e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17507749	chr15:85114479	UBE2QP1	0.61	6.87	0.35	3.04e-11	Schizophrenia;
LIHC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.32	-7.91	-0.39	3.49e-14	Schizophrenia;
LIHC	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg01652190	chr22:50026171	C22orf34	-0.34	-7.57	-0.38	3.46e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.16	0.77	4.33e-68	Chronic sinus infection;
LIHC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.86	-0.3	1.1e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.33	0.55	3.63e-29	Menopause (age at onset);
LIHC	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.23	12.6	0.56	3.64e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.09	21.08	0.75	8.37e-64	Triglycerides;
LIHC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	0.54	5.77	0.3	1.75e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-1.08	-13.65	-0.59	3.69e-34	Dilated cardiomyopathy;
LIHC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.97	15.57	0.64	1.04e-41	Metabolic syndrome;
LIHC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg15704280	chr7:45808275	SEPT13	-0.45	-6.64	-0.34	1.23e-10	HDL cholesterol;
LIHC	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.72	-0.3	2.33e-8	Diastolic blood pressure;
LIHC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg12373951	chr3:133503437	NA	0.49	8.15	0.4	7.14e-15	Iron status biomarkers;
LIHC	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.86	-0.39	4.99e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.03	0.31	4.22e-9	Renal cell carcinoma;
LIHC	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.78	9.03	0.44	1.31e-17	Exhaled nitric oxide output;
LIHC	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.38	-0.33	5.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7546668	1.000	rs6686890	chr1:15835414	C/G	cg11706911	chr1:15910989	AGMAT	0.45	6.91	0.35	2.41e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.46	-8.23	-0.41	4.03e-15	N-glycan levels;
LIHC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg00343986	chr7:65444356	GUSB	0.41	6.24	0.32	1.28e-9	Aortic root size;
LIHC	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.04	-0.31	4.12e-9	Resting heart rate;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22603710	chr3:134514098	EPHB1	0.49	6.55	0.33	2.11e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	0.99	15.31	0.64	1.13e-40	Skin colour saturation;
LIHC	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.3	-6.65	-0.34	1.15e-10	DNA methylation (variation);
LIHC	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	5.77	0.3	1.82e-8	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs12431939	1.000	rs11845886	chr14:51635873	G/A	cg23942311	chr14:51606299	NA	-0.35	-5.85	-0.3	1.14e-8	Cancer;
LIHC	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.64	6.21	0.32	1.56e-9	Plasma clusterin levels;
LIHC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.37	-6.35	-0.32	6.86e-10	Schizophrenia;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-11.19	-0.52	5.63e-25	Longevity;Endometriosis;
LIHC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.75	0.34	6.38e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.56	0.33	2.02e-10	Renal cell carcinoma;
LIHC	cis	rs7707921	0.767	rs6880209	chr5:81574182	C/T	cg15871215	chr5:81402204	ATG10	-0.66	-8.03	-0.4	1.63e-14	Breast cancer;
LIHC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.37	-6.08	-0.31	3.2e-9	Height;
LIHC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg25329415	chr6:28076851	NA	0.27	5.71	0.3	2.44e-8	Cardiac Troponin-T levels;
LIHC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.47	-6.8	-0.35	4.7e-11	Corneal structure;
LIHC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg25039879	chr17:56429692	SUPT4H1	0.76	8.75	0.43	1.02e-16	Cognitive test performance;
LIHC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.34	-0.32	7.46e-10	Personality dimensions;
LIHC	cis	rs950169	0.690	rs12901166	chr15:84699113	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	6.78	0.34	5.26e-11	Schizophrenia;
LIHC	cis	rs10838687	0.736	rs76832686	chr11:47247287	C/T	cg25783544	chr11:47291846	MADD	0.49	6.18	0.32	1.84e-9	Proinsulin levels;
LIHC	cis	rs7635838	0.859	rs34621655	chr3:11530121	T/C	cg00170343	chr3:11313890	ATG7	0.39	6.03	0.31	4.35e-9	HDL cholesterol;
LIHC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.55	8.57	0.42	3.52e-16	Red cell distribution width;
LIHC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Corneal astigmatism;
LIHC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-6.08	-0.31	3.17e-9	Fear of minor pain;
LIHC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.38	-9.81	-0.47	3.41e-20	Longevity;Endometriosis;
LIHC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.53	-9.69	-0.46	8.91e-20	Lung cancer in ever smokers;
LIHC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	0.97	10.23	0.48	1.33e-21	Vitiligo;
LIHC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.36	-5.94	-0.31	6.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17739167	0.550	rs1426890	chr15:42226125	G/A	cg20935245	chr15:42234343	EHD4	0.4	7.34	0.37	1.58e-12	Monocyte count;
LIHC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-1.0	-17.33	-0.68	9.86e-49	Monocyte percentage of white cells;
LIHC	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4700695	0.841	rs152935	chr5:65358593	A/G	cg21114390	chr5:65439923	SFRS12	-0.46	-5.86	-0.3	1.1e-8	Facial morphology (factor 19);
LIHC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.84	10.13	0.48	2.88e-21	Cognitive function;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg10219037	chr11:111750118	C11orf1;FDXACB1	0.42	6.16	0.32	2.06e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.62	11.15	0.52	7.58e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs797680	0.786	rs10874772	chr1:93787770	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.03	-0.31	4.37e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.69	11.19	0.52	5.58e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.43	-6.38	-0.33	5.63e-10	Gut microbiome composition (summer);
LIHC	cis	rs244293	0.801	rs7225949	chr17:53096771	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.48	7.09	0.36	7.88e-12	Menarche (age at onset);
LIHC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.93	-0.47	1.36e-20	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.02	0.44	1.38e-17	Platelet count;
LIHC	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.36	-7.58	-0.38	3.38e-13	Sitting height ratio;
LIHC	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg08668510	chr10:1095578	IDI1	0.65	6.63	0.34	1.28e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs965469	0.779	rs6051830	chr20:3373397	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-6.34	-0.32	7.07e-10	IFN-related cytopenia;
LIHC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.57	-7.91	-0.39	3.72e-14	Lung cancer;
LIHC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.91	0.47	1.66e-20	Tonsillectomy;
LIHC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.32	7.07	0.36	8.7e-12	Ulcerative colitis;
LIHC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.94	13.39	0.59	3.54e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.86	11.16	0.52	7.1e-25	Heart rate;
LIHC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.38	6.17	0.32	1.94e-9	Red blood cell count;
LIHC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.49	9.97	0.47	9.91e-21	Tonsillectomy;
LIHC	cis	rs699	0.545	rs2478524	chr1:230836276	G/C	cg07502417	chr1:230849801	AGT	-0.31	-6.86	-0.35	3.31e-11	Coronary artery disease;
LIHC	cis	rs847649	1.000	rs4620204	chr7:102594217	T/C	cg18108683	chr7:102477205	FBXL13	0.48	7.42	0.37	9.13e-13	Morning vs. evening chronotype;
LIHC	cis	rs2016586	0.894	rs1997883	chr22:36103709	C/T	cg26342177	chr22:36113512	APOL5	0.39	6.48	0.33	3.19e-10	Body mass index;
LIHC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	9.26e-10	Aortic root size;
LIHC	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.5	7.27	0.37	2.44e-12	Asthma;
LIHC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.54	9.75	0.47	5.8e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.46	-7.46	-0.37	7.12e-13	Morning vs. evening chronotype;
LIHC	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg18898632	chr2:242989856	NA	-0.46	-6.34	-0.32	7.1e-10	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26816438	chr1:45139524	TMEM53;C1orf228	0.43	6.64	0.34	1.23e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-0.39	-6.22	-0.32	1.48e-9	Coronary artery disease;
LIHC	trans	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg10208301	chr11:6592745	DNHD1	0.46	6.23	0.32	1.36e-9	Coronary artery calcification;
LIHC	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.2	0.32	1.58e-9	Tonsillectomy;
LIHC	cis	rs963731	0.649	rs78421201	chr2:39339424	C/A	cg04010122	chr2:39346883	SOS1	0.68	6.05	0.31	3.74e-9	Corticobasal degeneration;
LIHC	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.12e-9	Coronary artery disease;
LIHC	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.69	6.25	0.32	1.22e-9	Obesity;Body mass index;
LIHC	cis	rs12079745	0.793	rs78277513	chr1:169414777	A/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-6.56	-0.33	1.97e-10	QT interval;
LIHC	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.11	9.39	0.45	9e-19	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.78	12.99	0.57	1.23e-31	Phospholipid levels (plasma);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10815395	chr12:49237807	DDX23	0.41	6.1	0.31	2.91e-9	Longevity;
LIHC	cis	rs4690686	0.769	rs7656505	chr4:177274867	A/T	cg17059388	chr4:177262070	NA	0.36	6.67	0.34	1.02e-10	Essential tremor;
LIHC	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.41	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.72	7.21	0.36	3.65e-12	Vitiligo;
LIHC	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.64	6.89	0.35	2.73e-11	Type 2 diabetes;
LIHC	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg00792783	chr2:198669748	PLCL1	0.45	6.56	0.33	2.04e-10	Dermatomyositis;
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.21e-9	Urinary tract infection frequency;
LIHC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.53	7.45	0.37	7.49e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.48	-6.37	-0.33	5.96e-10	Blood metabolite levels;
LIHC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.11	24.52	0.8	2.47e-77	Cognitive ability;
LIHC	cis	rs7224685	0.569	rs10521129	chr17:4008820	C/T	cg09695851	chr17:3907499	NA	0.61	7.44	0.37	7.96e-13	Type 2 diabetes;
LIHC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.68e-8	Height;
LIHC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.42	6.09	0.31	3.11e-9	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg16822855	chr3:40428330	ENTPD3	0.35	6.42	0.33	4.5e-10	Renal cell carcinoma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg16218610	chr6:26124417	HIST1H2AC;HIST1H2BC	-0.5	-6.19	-0.32	1.71e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.42e-23	Mean corpuscular volume;
LIHC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01200585	chr1:228362443	C1orf69	0.46	7.05	0.36	9.73e-12	Diastolic blood pressure;
LIHC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.65e-12	Breast cancer;
LIHC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.51	6.56	0.33	2e-10	Initial pursuit acceleration;
LIHC	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.74	0.34	6.67e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.45	7.15	0.36	5.33e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08989290	chr16:615782	NHLRC4	0.3	5.87	0.3	1.05e-8	Height;
LIHC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21211367	chr2:162094118	NA	0.37	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.93	-9.76	-0.47	5.04e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.45e-29	Menopause (age at onset);
LIHC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg05110241	chr16:68378359	PRMT7	-0.67	-8.19	-0.4	5.42e-15	Schizophrenia;
LIHC	cis	rs10792665	0.724	rs10898068	chr11:82710889	A/C	cg24227371	chr11:82718527	RAB30	-0.38	-9.3	-0.45	1.68e-18	Obesity-related traits;
LIHC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg20283391	chr11:68216788	NA	-0.38	-6.04	-0.31	4.03e-9	Total body bone mineral density;
LIHC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.51	-0.38	5.14e-13	Breast cancer;
LIHC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg01864069	chr14:103024347	NA	-0.48	-7.35	-0.37	1.43e-12	Platelet count;
LIHC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.48	5.71	0.3	2.42e-8	Bladder cancer;
LIHC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	11.25	0.52	3.43e-25	Platelet count;
LIHC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-20.37	-0.74	5.76e-61	Height;
LIHC	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-6.26	-0.32	1.16e-9	Coronary artery disease;
LIHC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-5.81	-0.3	1.41e-8	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.58	-8.66	-0.42	1.92e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7793919	0.691	rs4077986	chr7:4766676	A/G	cg09789173	chr7:4769017	FOXK1	0.61	9.16	0.44	4.89e-18	Mosquito bite size;
LIHC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08219700	chr8:58056026	NA	0.51	6.44	0.33	4.06e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	6.39	0.33	5.38e-10	Schizophrenia;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.5	-8.54	-0.42	4.55e-16	Total body bone mineral density;
LIHC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.16	-0.32	2.07e-9	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.02	0.31	4.58e-9	Menopause (age at onset);
LIHC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.83	-0.35	3.91e-11	Total body bone mineral density;
LIHC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19671926	chr4:122722719	EXOSC9	0.56	8.63	0.42	2.3e-16	Type 2 diabetes;
LIHC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.22	-6.95	-0.35	1.88e-11	Motion sickness;
LIHC	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.52	8.5	0.42	6.06e-16	Corneal astigmatism;
LIHC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg16226627	chr15:75307476	SCAMP5	0.54	9.71	0.46	7.62e-20	Lung cancer;
LIHC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.56	8.26	0.41	3.22e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.95	-0.35	1.82e-11	Fear of minor pain;
LIHC	cis	rs1419980	0.730	rs12229550	chr12:7745968	T/C	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.67	-7.93	-0.39	3.15e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.39e-18	Subjective well-being;
LIHC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg13647721	chr17:30228624	UTP6	0.67	6.68	0.34	9.74e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.8	-0.34	4.81e-11	Bipolar disorder;
LIHC	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.92	11.74	0.54	5.69e-27	Coronary artery disease;
LIHC	cis	rs2274273	0.648	rs58553156	chr14:55582694	T/A	cg01864836	chr14:55583639	NA	-0.38	-6.63	-0.34	1.28e-10	Protein biomarker;
LIHC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg16558253	chr16:72132732	DHX38	-0.37	-6.05	-0.31	3.83e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.66	-9.92	-0.47	1.46e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.49	9.57	0.46	2.25e-19	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03602528	chr17:19266095	B9D1	-0.47	-6.15	-0.32	2.13e-9	Systolic blood pressure;
LIHC	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg04610667	chr7:75704037	NA	-0.35	-6.21	-0.32	1.54e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10792665	0.575	rs5006164	chr11:82557595	T/C	cg24227371	chr11:82718527	RAB30	-0.25	-6.0	-0.31	5.11e-9	Obesity-related traits;
LIHC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg00800038	chr16:89945340	TCF25	-0.61	-9.42	-0.45	7.08e-19	Skin colour saturation;
LIHC	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.51	7.76	0.39	9.62e-14	Corneal astigmatism;
LIHC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00958927	chr1:175162553	KIAA0040	-0.4	-6.55	-0.33	2.08e-10	Alcohol dependence;
LIHC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-9.31	-0.45	1.61e-18	Heart rate;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	cis	rs8067354	0.958	rs8081468	chr17:57836924	A/G	cg13753209	chr17:57696993	CLTC	0.58	8.76	0.43	9.51e-17	Hemoglobin concentration;
LIHC	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.67	0.34	1.03e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs539514	0.637	rs2025354	chr13:76275577	T/C	cg04757411	chr13:76259545	LMO7	-0.45	-7.98	-0.4	2.3e-14	Type 1 diabetes;
LIHC	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg21100191	chr22:23484243	RTDR1	0.87	15.36	0.64	7.61e-41	Bone mineral density;
LIHC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs4728302	0.838	rs10225605	chr7:133591676	G/A	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.55	-0.33	2.05e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg12560992	chr17:57184187	TRIM37	0.65	8.2	0.41	4.87e-15	Vitamin D levels;
LIHC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.68	13.4	0.59	3.27e-33	High light scatter reticulocyte count;
LIHC	cis	rs3789045	0.774	rs4252733	chr1:204516918	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.41	-6.31	-0.32	8.76e-10	Educational attainment (college completion);
LIHC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs78545713	1.000	rs78545713	chr6:26248840	A/G	cg16070018	chr6:26224392	HIST1H3E	0.72	7.6	0.38	2.9e-13	Iron status biomarkers (total iron binding capacity);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11892836	chr11:64410564	NRXN2	0.4	6.09	0.31	2.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.87	-0.3	1.05e-8	Coronary artery disease;
LIHC	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg11783602	chr8:55087084	NA	-0.31	-6.19	-0.32	1.73e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.7	11.65	0.53	1.22e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.61	-10.74	-0.5	2.16e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	9.15	0.44	5.42e-18	Lung cancer in ever smokers;
LIHC	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg18367735	chr17:79674897	NA	0.64	7.48	0.37	6.34e-13	Dental caries;
LIHC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg20283391	chr11:68216788	NA	-0.52	-7.77	-0.39	9.51e-14	Total body bone mineral density;
LIHC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.84	0.3	1.21e-8	Resting heart rate;
LIHC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.47	-6.06	-0.31	3.67e-9	Vitiligo;
LIHC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.39	6.22	0.32	1.43e-9	Multiple sclerosis;
LIHC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.92	-0.47	1.55e-20	Response to antipsychotic treatment;
LIHC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg07148914	chr20:33460835	GGT7	-0.55	-8.3	-0.41	2.48e-15	Height;
LIHC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.61	0.46	1.59e-19	Mean platelet volume;
LIHC	cis	rs7581030	0.518	rs7578166	chr2:71630041	A/C	cg07678644	chr2:71558969	ZNF638	0.38	6.0	0.31	5.13e-9	Testicular germ cell tumor;
LIHC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	11.37	0.52	1.29e-25	Menarche (age at onset);
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg14671364	chr1:107599128	PRMT6	-0.54	-7.87	-0.39	4.72e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4845459	0.967	rs4085613	chr1:152550018	T/G	cg20634798	chr1:152595351	LCE3A	-0.32	-6.17	-0.32	1.91e-9	Psoriasis;
LIHC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.2	-0.32	1.64e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg04450456	chr4:17643702	FAM184B	0.34	5.73	0.3	2.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg01652190	chr22:50026171	C22orf34	-0.33	-7.47	-0.37	6.9e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.88	-0.47	2.07e-20	Height;
LIHC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.41	0.33	4.94e-10	Schizophrenia;
LIHC	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.8	9.47	0.46	4.59e-19	Iron status biomarkers;
LIHC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.39e-20	Height;
LIHC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.9	-0.35	2.46e-11	Metabolite levels;
LIHC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.53	0.38	4.66e-13	Mean platelet volume;
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02359409	chr6:42947317	PEX6	-0.49	-6.99	-0.35	1.42e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg14515779	chr1:101123966	NA	0.5	6.9	0.35	2.49e-11	Monocyte count;
LIHC	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.5	8.04	0.4	1.51e-14	Corneal astigmatism;
LIHC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16262614	chr3:133464971	TF	0.27	6.07	0.31	3.45e-9	Iron status biomarkers;
LIHC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.72	-8.99	-0.44	1.68e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.73	8.42	0.41	1.05e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs3812111	0.609	rs1204777	chr6:116494940	A/G	cg08036074	chr6:116424633	NT5DC1	-0.46	-7.55	-0.38	3.89e-13	Age-related macular degeneration;
LIHC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg16479474	chr6:28041457	NA	0.4	6.65	0.34	1.18e-10	Cardiac Troponin-T levels;
LIHC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg17279839	chr7:150038598	RARRES2	-0.5	-10.68	-0.5	3.69e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs4759375	0.920	rs7972811	chr12:123820780	G/T	cg00376283	chr12:123451042	ABCB9	0.5	6.44	0.33	4.06e-10	HDL cholesterol;
LIHC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	5.8	0.3	1.48e-8	Schizophrenia;
LIHC	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg14675211	chr2:100938903	LONRF2	0.52	7.88	0.39	4.51e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.26	6.2	0.32	1.59e-9	Heart rate;
LIHC	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg14593290	chr7:50529359	DDC	-0.35	-6.12	-0.31	2.57e-9	Systemic sclerosis;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg24068859	chr3:194392930	LSG1	0.52	6.15	0.32	2.14e-9	Glycated hemoglobin levels;
LIHC	cis	rs7945718	0.870	rs3890065	chr11:12758767	C/G	cg25843174	chr11:12811716	TEAD1	0.33	7.39	0.37	1.12e-12	Educational attainment (years of education);
LIHC	trans	rs36715	1.000	rs36702	chr5:127552723	A/T	cg16011800	chr17:1958478	HIC1	-0.4	-6.05	-0.31	3.75e-9	Breast cancer;
LIHC	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg10381502	chr11:71823885	C11orf51	1.06	9.3	0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg16836995	chr17:43662488	NA	0.6	6.26	0.32	1.17e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg00800038	chr16:89945340	TCF25	-0.62	-9.35	-0.45	1.2e-18	Skin colour saturation;
LIHC	cis	rs11212260	0.655	rs79059631	chr11:107326042	T/A	cg25435332	chr11:107328525	CWF19L2	0.82	8.43	0.41	9.83e-16	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18789337	chr6:114180353	MARCKS	0.47	7.07	0.36	8.78e-12	Cognitive function;
LIHC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg19006947	chr11:64034861	PLCB3	-0.61	-8.87	-0.43	4.07e-17	Body mass index;
LIHC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.79	-14.97	-0.63	2.62e-39	IgG glycosylation;
LIHC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-11.09	-0.51	1.32e-24	Total cholesterol levels;
LIHC	cis	rs253664	0.898	rs1199347	chr3:138083361	T/C	cg25188949	chr3:137893707	DBR1	-0.57	-5.77	-0.3	1.8e-8	Body mass index;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.46	-6.35	-0.32	6.85e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	trans	rs10744955	0.533	rs9707844	chr15:50444400	A/G	cg02452418	chr19:39056126	RYR1	0.55	6.04	0.31	4.08e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-6.04	-0.31	4.05e-9	Type 2 diabetes;
LIHC	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.32	9.52e-10	Axial length;
LIHC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.41	-6.4	-0.33	5.08e-10	Iron status biomarkers;
LIHC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.96	0.6	2.22e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg12252866	chr3:50263686	NA	-0.4	-6.42	-0.33	4.6e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg22705602	chr4:152727874	NA	0.31	6.53	0.33	2.34e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg17385448	chr1:15911702	AGMAT	0.37	6.6	0.34	1.55e-10	Systolic blood pressure;
LIHC	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.63	-6.99	-0.35	1.42e-11	Putamen volume;
LIHC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg14393609	chr7:65229607	NA	0.37	5.86	0.3	1.07e-8	Aortic root size;
LIHC	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg20991723	chr1:152506922	NA	0.5	8.49	0.42	6.21e-16	Hair morphology;
LIHC	cis	rs2279817	0.731	rs11203434	chr1:18010189	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.41	-5.86	-0.3	1.08e-8	Neuroticism;
LIHC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.45	0.37	7.9e-13	Airflow obstruction;
LIHC	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg12501888	chr15:85177176	SCAND2	-0.44	-6.49	-0.33	3.05e-10	P wave terminal force;
LIHC	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.74	13.11	0.58	4.34e-32	Eosinophil percentage of white cells;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg25894440	chr7:65020034	NA	-0.41	-6.61	-0.34	1.5e-10	Calcium levels;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.54	0.33	2.23e-10	Renal cell carcinoma;
LIHC	cis	rs17021463	0.807	rs6847989	chr4:95277099	A/C	cg11021082	chr4:95130006	SMARCAD1	0.35	6.2	0.32	1.63e-9	Testicular germ cell tumor;
LIHC	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.54	-9.51	-0.46	3.55e-19	Systemic lupus erythematosus;
LIHC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.88	-12.77	-0.57	8.48e-31	Blood metabolite levels;
LIHC	cis	rs1775715	0.870	rs7095322	chr10:32248491	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.37	-6.71	-0.34	8.1e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.01	0.4	1.79e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.97	-0.31	5.8e-9	Schizophrenia;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.29	0.41	2.64e-15	Height;
LIHC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg02187348	chr16:89574699	SPG7	-0.41	-6.0	-0.31	5.03e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg16479474	chr6:28041457	NA	0.46	6.76	0.34	6.14e-11	Depression;
LIHC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs16858210	0.647	rs67397446	chr3:183618143	C/T	cg25686905	chr3:183603175	PARL	-0.4	-6.24	-0.32	1.31e-9	Menopause (age at onset);
LIHC	cis	rs9896052	0.649	rs6501801	chr17:73447030	A/G	cg25649188	chr17:73499917	CASKIN2	-0.41	-6.45	-0.33	3.91e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs9921222	0.565	rs1805105	chr16:396264	A/G	cg00101154	chr16:420108	MRPL28	-0.43	-6.34	-0.32	7.16e-10	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs1816752	0.875	rs17384871	chr13:25059097	T/C	cg22771759	chr13:24902376	NA	0.32	6.66	0.34	1.06e-10	Obesity-related traits;
LIHC	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg18964960	chr10:1102726	WDR37	0.67	6.37	0.33	5.99e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs243505	0.559	rs734003	chr7:148505498	T/G	cg09806900	chr7:148480153	CUL1	0.41	6.09	0.31	3e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-0.86	-10.47	-0.49	2.03e-22	Blood pressure (smoking interaction);
LIHC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg20607798	chr8:58055168	NA	0.47	6.42	0.33	4.58e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg01032570	chr8:22224534	SLC39A14	-0.56	-6.47	-0.33	3.43e-10	Obesity-related traits;
LIHC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.53	8.36	0.41	1.64e-15	Height;
LIHC	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	7.78	0.39	8.52e-14	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LIHC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.03	-0.51	2.07e-24	Response to antipsychotic treatment;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22806587	chr15:75871813	PTPN9	0.47	6.93	0.35	2.09e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-7.5	-0.38	5.41e-13	Platelet count;
LIHC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg24634471	chr8:143751801	JRK	-0.42	-5.86	-0.3	1.1e-8	Urinary tract infection frequency;
LIHC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.58	-6.87	-0.35	3.06e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.22	-5.95	-0.31	6.75e-9	Hepatitis;
LIHC	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.67	-9.82	-0.47	3.24e-20	Lymphocyte counts;
LIHC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.82	0.3	1.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg10621924	chr7:39171070	POU6F2	0.41	6.28	0.32	1.03e-9	IgG glycosylation;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg03191532	chr2:237032664	AGAP1	0.38	6.44	0.33	3.97e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg09045935	chr12:6379348	NA	0.84	6.91	0.35	2.41e-11	Blood metabolite levels;
LIHC	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.55	6.8	0.34	4.81e-11	Heart rate;
LIHC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.55	-0.82	4.16e-85	Myeloid white cell count;
LIHC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg04511125	chr2:88470314	THNSL2	-0.42	-6.43	-0.33	4.23e-10	Response to metformin (IC50);
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.73	-10.85	-0.51	8.88e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.63	10.23	0.48	1.29e-21	Monocyte count;
LIHC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg00204512	chr16:28754710	NA	0.4	6.82	0.35	4.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7937890	0.507	rs4463820	chr11:14556342	A/G	cg02886208	chr11:14281011	SPON1	-0.44	-6.14	-0.32	2.3e-9	Mitochondrial DNA levels;
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg13409248	chr3:40428643	ENTPD3	-0.38	-6.28	-0.32	1.05e-9	Renal cell carcinoma;
LIHC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.52	7.34	0.37	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.33	6.07	0.31	3.31e-9	IgG glycosylation;
LIHC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.34	-0.58	5.73e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.62	5.9	0.3	8.54e-9	Inflammatory bowel disease;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg12034118	chr1:209979487	IRF6	0.37	5.82	0.3	1.38e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg20302533	chr7:39170763	POU6F2	0.38	6.79	0.34	5.08e-11	IgG glycosylation;
LIHC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.0	-0.31	4.91e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12074084	chr1:45140087	C1orf228;TMEM53	0.42	6.05	0.31	3.7e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.64	11.05	0.51	1.8e-24	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.86	0.43	4.37e-17	Exhaled nitric oxide levels;
LIHC	trans	rs4824093	0.610	rs28473584	chr22:50315413	C/T	cg09872104	chr7:134855509	C7orf49	-0.75	-6.04	-0.31	4.09e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg08668510	chr10:1095578	IDI1	-0.71	-7.06	-0.36	9.36e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21448741	chr8:58168803	NA	0.36	6.72	0.34	7.69e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	0.579	rs7520572	chr1:8871690	G/A	cg20416874	chr1:8611966	RERE	0.44	6.57	0.33	1.88e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg00792783	chr2:198669748	PLCL1	0.4	5.92	0.3	8.03e-9	Intracranial aneurysm;
LIHC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.97	17.95	0.7	3.2e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg02251663	chr11:14281053	SPON1	-0.44	-5.82	-0.3	1.34e-8	Mitochondrial DNA levels;
LIHC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.25	-0.32	1.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg12140854	chr5:148520817	ABLIM3	-0.52	-5.97	-0.31	5.92e-9	Breast cancer;
LIHC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg07424592	chr7:64974309	NA	0.81	9.12	0.44	6.81e-18	Diabetic kidney disease;
LIHC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.64	10.23	0.48	1.29e-21	Bipolar disorder;
LIHC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.11	-0.31	2.75e-9	Headache;
LIHC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.87	11.38	0.52	1.15e-25	Coronary artery disease;
LIHC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg13753209	chr17:57696993	CLTC	0.73	11.52	0.53	3.5e-26	Hemoglobin concentration;
LIHC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.43	6.04	0.31	3.98e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.89e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2744203	1.000	rs72610882	chr6:104638716	A/G	cg27088726	chr16:83171155	CDH13	-0.46	-6.06	-0.31	3.7e-9	IgG glycosylation;
LIHC	cis	rs17152411	0.895	rs7094381	chr10:126585848	G/A	cg07906193	chr10:126599966	NA	0.44	6.96	0.35	1.78e-11	Height;
LIHC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.5	6.58	0.34	1.77e-10	Menopause (age at onset);
LIHC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11645453	chr3:52864694	ITIH4	0.22	6.04	0.31	3.96e-9	Bipolar disorder;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18548523	chr11:67260961	PITPNM1	0.43	6.4	0.33	5.03e-10	Bilirubin levels;
LIHC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg07061783	chr6:25882402	NA	-0.52	-6.4	-0.33	4.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg11212589	chr17:38028394	ZPBP2	0.36	7.37	0.37	1.32e-12	Self-reported allergy;
LIHC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.42	6.21	0.32	1.53e-9	Prostate cancer;
LIHC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.45	6.81	0.35	4.36e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01777103	chr8:145550585	DGAT1	0.38	6.06	0.31	3.5e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs6565180	0.783	rs9888967	chr16:30407979	G/C	cg17640201	chr16:30407289	ZNF48	0.81	13.9	0.6	3.88e-35	Tonsillectomy;
LIHC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg18357645	chr12:58087776	OS9	-0.45	-6.98	-0.35	1.49e-11	Multiple sclerosis;
LIHC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-8.07	-0.4	1.2e-14	Total body bone mineral density;
LIHC	trans	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.86	-0.3	1.1e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.15	-0.32	2.21e-9	Tuberculosis;
LIHC	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	0.74	8.32	0.41	2.19e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.81	0.5	1.27e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.73	-13.97	-0.6	2.01e-35	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs10411161	1.000	rs8111316	chr19:52369069	A/C	cg22319618	chr22:45562946	NUP50	-0.53	-7.14	-0.36	5.77e-12	Breast cancer;
LIHC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20307385	chr11:47447363	PSMC3	-0.44	-5.74	-0.3	2.04e-8	Subjective well-being;
LIHC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.68	11.5	0.53	4.29e-26	Bipolar disorder;
LIHC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.11e-13	Lung cancer;
LIHC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02985541	chr2:219472218	PLCD4	0.46	8.73	0.43	1.18e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg07870479	chr16:1813987	MAPK8IP3	0.45	6.24	0.32	1.31e-9	Insulin-like growth factors;
LIHC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.39	6.86	0.35	3.19e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6960043	0.738	rs12540947	chr7:15059326	T/C	cg19272540	chr7:15055459	NA	0.28	7.39	0.37	1.15e-12	Type 2 diabetes;
LIHC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.89	13.85	0.6	6.12e-35	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.8	-0.39	7.35e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.6	8.84	0.43	5.24e-17	Recombination rate (females);
LIHC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg12496599	chr19:3199014	NCLN	0.4	6.23	0.32	1.38e-9	Bilirubin levels;
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg21466736	chr12:48725269	NA	-0.34	-5.94	-0.31	6.92e-9	Plateletcrit;
LIHC	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	0.93	11.79	0.54	3.65e-27	Economic and political preferences (immigration/crime);
LIHC	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg16836995	chr17:43662488	NA	0.69	7.04	0.36	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7674212	0.541	rs4699050	chr4:104114297	A/G	cg16532752	chr4:104119610	CENPE	-0.42	-6.54	-0.33	2.23e-10	Type 2 diabetes;
LIHC	cis	rs9473924	1.000	rs9463656	chr6:50859655	A/G	cg14470998	chr6:50812995	TFAP2B	0.49	7.33	0.37	1.7e-12	Body mass index;
LIHC	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.77	8.85	0.43	4.91e-17	Exhaled nitric oxide levels;
LIHC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.62	9.2	0.45	3.73e-18	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-12.06	-0.55	3.69e-28	Coffee consumption (cups per day);
LIHC	cis	rs10838687	0.736	rs11039144	chr11:47264044	G/A	cg26139080	chr11:47293733	MADD	-0.41	-5.73	-0.3	2.2e-8	Proinsulin levels;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg10932868	chr11:921992	NA	0.4	7.54	0.38	4.4e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	trans	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg10208301	chr11:6592745	DNHD1	0.46	6.19	0.32	1.7e-9	Coronary artery calcification;
LIHC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.27	-6.81	-0.35	4.28e-11	Mean corpuscular volume;
LIHC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg17980119	chr2:219472607	PLCD4	0.35	6.02	0.31	4.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg14092571	chr14:90743983	NA	0.4	6.32	0.32	8.18e-10	Mortality in heart failure;
LIHC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.44	6.83	0.35	3.94e-11	Methadone dose in opioid dependence;
LIHC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.22	0.36	3.39e-12	Bipolar disorder;
LIHC	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.61	12.19	0.55	1.23e-28	Plateletcrit;Platelet count;
LIHC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22509189	chr2:225307070	NA	-0.5	-7.41	-0.37	1.02e-12	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00232805	chr2:97779565	ANKRD36	0.44	6.67	0.34	1e-10	Cognitive function;
LIHC	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16684958	chr7:75615977	POR	0.49	8.29	0.41	2.54e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.67	-10.74	-0.5	2.28e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg27478167	chr7:817139	HEATR2	-0.41	-5.86	-0.3	1.07e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.51	6.63	0.34	1.3100000000000001e-10	Alzheimer's disease;
LIHC	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.64	-12.8	-0.57	6.69e-31	Schizophrenia;
LIHC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	1.0	11.14	0.52	8.48e-25	Triglycerides;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02475777	chr4:1388615	CRIPAK	0.39	6.02	0.31	4.43e-9	Obesity-related traits;
LIHC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.53	7.86	0.39	4.95e-14	Lymphocyte counts;
LIHC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.57	8.68	0.43	1.59e-16	Longevity;Endometriosis;
LIHC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.33	-0.45	1.41e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-9.8	-0.47	3.79e-20	Obesity-related traits;
LIHC	cis	rs6545883	0.894	rs2463102	chr2:61571295	G/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.37	-0.37	1.31e-12	Tuberculosis;
LIHC	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.86	0.51	8.71e-24	Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.76	9.87	0.47	2.28e-20	Post bronchodilator FEV1;
LIHC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg23205692	chr1:25664452	TMEM50A	0.38	6.03	0.31	4.26e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs611744	0.967	rs678387	chr8:109242730	G/C	cg18478394	chr8:109455254	TTC35	0.38	6.55	0.33	2.06e-10	Dupuytren's disease;
LIHC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.28	-5.97	-0.31	6.09e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.54	9.52	0.46	3.15e-19	Total cholesterol levels;
LIHC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg26441486	chr22:50317300	CRELD2	0.36	6.38	0.33	5.73e-10	Schizophrenia;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg26570765	chr4:1273065	NA	0.31	5.97	0.31	6.03e-9	Obesity-related traits;
LIHC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.03	22.16	0.77	4.24e-68	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.71	-0.3	2.39e-8	Resting heart rate;
LIHC	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.5	8.06	0.4	1.32e-14	Corneal astigmatism;
LIHC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	1.16	10.64	0.5	5.04e-23	Obesity-related traits;
LIHC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.37	6.03	0.31	4.29e-9	Prostate cancer;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg07133347	chr1:107600762	PRMT6	0.46	6.77	0.34	5.61e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.41	-0.49	3.07e-22	Waist circumference;Body mass index;
LIHC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.63	8.94	0.44	2.56e-17	Asthma;
LIHC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.81	7.65	0.38	2e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-9.38	-0.45	9.54e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-6.99	-0.35	1.49e-11	P wave terminal force;
LIHC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.5	8.97	0.44	1.99e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1059312	0.669	rs11059917	chr12:129287925	T/A	cg09035930	chr12:129282057	SLC15A4	0.66	12.11	0.55	2.42e-28	Systemic lupus erythematosus;
LIHC	cis	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.5	-0.38	5.7e-13	Eotaxin levels;
LIHC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs1395	0.634	rs62130713	chr2:27525661	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-5.94	-0.31	7.01e-9	Blood metabolite levels;
LIHC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.89	-0.3	9.44e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.64	-9.75	-0.47	5.57e-20	Corneal astigmatism;
LIHC	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.42	-7.72	-0.39	1.32e-13	Glaucoma;
LIHC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg15691649	chr6:25882328	NA	-0.47	-7.12	-0.36	6.4e-12	Blood metabolite levels;
LIHC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.34	-0.41	1.91e-15	Heart rate;
LIHC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-0.95	-19.96	-0.73	2.55e-59	Height;
LIHC	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	7.59	0.38	3e-13	Eosinophil percentage of white cells;
LIHC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.62	10.27	0.49	9.51e-22	Platelet count;
LIHC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	15.57	0.64	1.09e-41	Nonalcoholic fatty liver disease;
LIHC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg18944383	chr4:111397179	ENPEP	-0.32	-7.07	-0.36	8.91e-12	Coronary artery disease;
LIHC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.58	10.32	0.49	6.53e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.69	-8.99	-0.44	1.74e-17	Asthma;
LIHC	cis	rs2016586	0.929	rs4821440	chr22:36114274	T/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.58	9.41	0.45	7.54e-19	Lymphocyte counts;
LIHC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-10.43	-0.49	2.67e-22	Blood pressure (smoking interaction);
LIHC	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg15654264	chr1:150340011	RPRD2	0.49	8.18	0.4	5.54e-15	Migraine;
LIHC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	1.04	13.79	0.6	1.09e-34	Heart rate;
LIHC	cis	rs7116495	1.000	rs585228	chr11:71773289	G/C	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.78	0.3	1.67e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	0.99	13.72	0.6	1.91e-34	Body mass index;
LIHC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.81	0.3	1.42e-8	Menopause (age at onset);
LIHC	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg04552319	chr11:89519481	NA	-0.35	-5.94	-0.31	6.84e-9	White blood cell types;
LIHC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.41	9.01	0.44	1.43e-17	Prostate-specific antigen levels;
LIHC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.75	-0.3	1.98e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	6.71	0.34	8.05e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7119038	0.818	rs11217040	chr11:118680648	C/A	cg19308663	chr11:118741387	NA	0.4	6.04	0.31	3.97e-9	Sjögren's syndrome;
LIHC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg27433088	chr4:174089019	GALNT7	0.38	6.93	0.35	2.07e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.69	-11.83	-0.54	2.66e-27	Testicular germ cell tumor;
LIHC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.58	7.22	0.36	3.35e-12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12602486	1.000	rs12602486	chr17:42241929	T/G	cg08193365	chr17:42277699	NA	1.05	7.39	0.37	1.16e-12	Glycated hemoglobin levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03898802	chr21:37617652	DOPEY2	-0.39	-6.16	-0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg19513890	chr22:42538836	CYP2D7P1	0.41	8.21	0.41	4.73e-15	Cognitive function;
LIHC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg02503808	chr4:7069936	GRPEL1	-0.76	-10.62	-0.5	5.88e-23	Monocyte percentage of white cells;
LIHC	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.86	-12.76	-0.57	8.83e-31	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs11229555	0.609	rs7928676	chr11:58188022	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4407350	0.967	rs5765722	chr22:44921063	G/A	cg26276947	chr22:44892394	LDOC1L	0.34	6.32	0.32	8.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.67	-9.92	-0.47	1.45e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg03732007	chr1:2071316	PRKCZ	0.35	6.08	0.31	3.23e-9	Height;
LIHC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg03874509	chr1:107600012	PRMT6	-0.75	-11.77	-0.54	4.47e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.8	-12.61	-0.56	3.3e-30	Colorectal cancer;
LIHC	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.73	6.78	0.34	5.34e-11	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.42	-0.37	9.53e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg08499158	chr17:42289980	UBTF	-0.51	-8.41	-0.41	1.16e-15	Total body bone mineral density;
LIHC	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg16794390	chr17:18148240	FLII	0.42	6.4	0.33	5.22e-10	Parental longevity (combined parental age at death);
LIHC	cis	rs6782228	0.509	rs2811495	chr3:128359957	A/G	cg16766828	chr3:128327626	NA	-0.4	-6.34	-0.32	7.21e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-7.58	-0.38	3.18e-13	Putamen volume;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg02529035	chr2:220377885	ACCN4	-0.38	-6.1	-0.31	2.86e-9	Urinary tract infection frequency;
LIHC	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	0.97	14.97	0.63	2.64e-39	Corneal structure;
LIHC	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.85	-0.35	3.38e-11	Prevalent atrial fibrillation;
LIHC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.49	0.38	5.77e-13	Schizophrenia;
LIHC	cis	rs963731	0.649	rs10166801	chr2:39250771	C/T	cg04010122	chr2:39346883	SOS1	-0.69	-6.03	-0.31	4.3e-9	Corticobasal degeneration;
LIHC	cis	rs9896052	0.500	rs7406077	chr17:73450015	T/A	cg25649188	chr17:73499917	CASKIN2	0.46	6.91	0.35	2.34e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg04160030	chr1:24195659	FUCA1	0.37	5.84	0.3	1.2e-8	Immature fraction of reticulocytes;
LIHC	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.98	15.32	0.64	1.03e-40	Metabolic syndrome;
LIHC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-0.77	-8.98	-0.44	1.84e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg02466173	chr16:30829666	NA	0.47	7.03	0.36	1.11e-11	Dementia with Lewy bodies;
LIHC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg17724175	chr1:150552817	MCL1	0.44	8.75	0.43	9.58e-17	Melanoma;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.44	7.99	0.4	2.02e-14	Prudent dietary pattern;
LIHC	cis	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.59	-5.71	-0.3	2.43e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.67	8.4	0.41	1.21e-15	Corneal astigmatism;
LIHC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.32	0.41	2.19e-15	Motion sickness;
LIHC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.4	7.58	0.38	3.36e-13	IgG glycosylation;
LIHC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg26441486	chr22:50317300	CRELD2	0.36	6.42	0.33	4.48e-10	Schizophrenia;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.79	-8.66	-0.42	1.96e-16	Vitiligo;
LIHC	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg00204512	chr16:28754710	NA	0.34	6.92	0.35	2.22e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1712517	0.844	rs4918003	chr10:105044157	C/T	cg05636881	chr10:105038444	INA	0.45	7.13	0.36	5.88e-12	Migraine;
LIHC	cis	rs4908760	0.827	rs2401138	chr1:8704059	C/G	cg20416874	chr1:8611966	RERE	0.6	11.48	0.53	5.09e-26	Vitiligo;
LIHC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.59	7.04	0.36	1.07e-11	Heart rate;
LIHC	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.44	-6.35	-0.32	6.91e-10	Blood protein levels;
LIHC	trans	rs983392	0.678	rs1426253	chr11:59981218	A/C	cg17275991	chr19:58003312	ZNF419	0.43	6.16	0.32	2.09e-9	Alzheimer's disease (late onset);
LIHC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.34	6.21	0.32	1.53e-9	Aortic root size;
LIHC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.73	7.54	0.38	4.13e-13	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.52	6.27	0.32	1.07e-9	Alzheimer's disease;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.61	9.44	0.45	5.81e-19	Height;
LIHC	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg01858014	chr14:56050164	KTN1	-0.77	-7.65	-0.38	2.04e-13	Putamen volume;
LIHC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.66	-6.86	-0.35	3.33e-11	Opioid sensitivity;
LIHC	cis	rs7129220	0.512	rs1867137	chr11:10228809	G/A	cg01453529	chr11:10209919	SBF2	-0.43	-7.88	-0.39	4.41e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	7.07	0.36	9.01e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.23	0.36	3.22e-12	Lymphocyte counts;
LIHC	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.4	5.9	0.3	8.69e-9	Menopause (age at onset);
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.58	-5.9	-0.3	8.72e-9	Diastolic blood pressure;
LIHC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.8	-14.35	-0.61	6.9e-37	Refractive error;
LIHC	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.71	-8.69	-0.43	1.49e-16	Morning vs. evening chronotype;
LIHC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg07424592	chr7:64974309	NA	0.8	8.32	0.41	2.09e-15	Diabetic kidney disease;
LIHC	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.46	7.26	0.37	2.64e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3814244	0.540	rs2159064	chr12:68410906	A/G	cg15249341	chr12:68405565	NA	0.31	6.32	0.32	7.95e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.64	9.92	0.47	1.46e-20	Longevity;Endometriosis;
LIHC	cis	rs17433710	0.543	rs10753585	chr1:162669006	C/T	cg01063088	chr1:162760584	HSD17B7	0.41	5.97	0.31	5.92e-9	Dupuytren's disease;
LIHC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.88	0.39	4.36e-14	Motion sickness;
LIHC	cis	rs10508774	0.810	rs1987197	chr10:32830595	C/T	cg01819863	chr10:32635814	EPC1	0.6	5.78	0.3	1.66e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg12798992	chr6:167411361	FGFR1OP	0.45	6.75	0.34	6.53e-11	Crohn's disease;
LIHC	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-0.8	-9.28	-0.45	1.93e-18	Alzheimer's disease (late onset);
LIHC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	11.18	0.52	6.16e-25	Response to antipsychotic treatment;
LIHC	cis	rs34779708	0.733	rs60616028	chr10:35543802	G/A	cg03585969	chr10:35415529	CREM	0.73	10.15	0.48	2.52e-21	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11761441	1.000	rs12718067	chr7:82873	T/C	cg13828236	chr7:80970	NA	0.29	7.06	0.36	9.42e-12	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.6	7.16	0.36	4.89e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg09829573	chr1:144692074	NBPF9	0.45	8.33	0.41	2.04e-15	Hip geometry;
LIHC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.65	0.34	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.12	0.55	2.21e-28	Menopause (age at onset);
LIHC	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.42	6.9	0.35	2.56e-11	Lewy body disease;
LIHC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.36	0.41	1.55e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.5	8.54	0.42	4.44e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg11953164	chr1:23521307	HTR1D	0.29	5.78	0.3	1.68e-8	Height;
LIHC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.12	-0.55	2.19e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.5	-6.5	-0.33	2.81e-10	Pancreatic cancer;
LIHC	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-7.16	-0.36	4.84e-12	Hepatocellular carcinoma;
LIHC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.87	-0.51	7.56e-24	Hemoglobin concentration;
LIHC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.74	7.67	0.38	1.78e-13	Vitiligo;
LIHC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.66	11.39	0.52	1.07e-25	Menopause (age at onset);
LIHC	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.28	0.32	1.05e-9	Mean corpuscular volume;
LIHC	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.23	-0.48	1.3e-21	Eye color traits;
LIHC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.37	-7.42	-0.37	9.58e-13	Body mass index;
LIHC	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.91	18.3	0.7	1.27e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02290350	chr8:58132656	NA	0.49	10.55	0.5	1.07e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08219700	chr8:58056026	NA	0.52	6.22	0.32	1.43e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.49	5.86	0.3	1.11e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.99	-0.31	5.45e-9	Personality dimensions;
LIHC	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.4	-6.58	-0.34	1.74e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.62e-9	Life satisfaction;
LIHC	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	-0.44	-7.1	-0.36	7.12e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.6	-9.81	-0.47	3.57e-20	Obesity-related traits;
LIHC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg23205692	chr1:25664452	TMEM50A	-0.39	-6.25	-0.32	1.24e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.83	13.53	0.59	1.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	trans	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg26939375	chr7:64535504	NA	-0.43	-7.34	-0.37	1.62e-12	Aortic root size;
LIHC	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg19743168	chr1:23544995	NA	-0.36	-6.63	-0.34	1.3e-10	Height;
LIHC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.37	6.83	0.35	4.01e-11	Male-pattern baldness;
LIHC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.59	7.98	0.4	2.16e-14	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.16	0.44	4.81e-18	Response to antipsychotic treatment;
LIHC	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.58	10.69	0.5	3.2e-23	Leprosy;
LIHC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.74	-0.34	6.83e-11	IgG glycosylation;
LIHC	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	7.01	0.35	1.24e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2637266	0.783	rs1797500	chr10:78510400	G/A	cg18941641	chr10:78392320	NA	0.27	5.83	0.3	1.26e-8	Pulmonary function;
LIHC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.4	-5.92	-0.3	8e-9	Schizophrenia;
LIHC	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.66	-11.62	-0.53	1.6e-26	Menarche (age at onset);
LIHC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-0.81	-11.29	-0.52	2.55e-25	Urate levels;
LIHC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg25801113	chr15:45476975	SHF	0.38	6.58	0.34	1.78e-10	Uric acid levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03086376	chr16:1876114	HAGH;FAHD1	0.4	6.27	0.32	1.1e-9	Cognitive function;
LIHC	cis	rs10508774	1.000	rs72795539	chr10:32842326	G/A	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.72e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.68	-12.12	-0.55	2.35e-28	Obesity-related traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11003645	chr6:143382007	AIG1	-0.55	-6.1	-0.31	2.9e-9	Systolic blood pressure;
LIHC	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg25566285	chr7:158114605	PTPRN2	0.22	5.96	0.31	6.38e-9	Calcium levels;
LIHC	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-6.99	-0.35	1.46e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-6.2	-0.32	1.62e-9	Colorectal cancer;
LIHC	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-1.05	-11.96	-0.54	8.91e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.77	-9.44	-0.45	6.02e-19	Gut microbiome composition (summer);
LIHC	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg18151635	chr12:93972918	NA	-0.44	-6.9	-0.35	2.53e-11	Pubertal anthropometrics;
LIHC	cis	rs17433710	0.543	rs7519400	chr1:162661603	G/T	cg01063088	chr1:162760584	HSD17B7	0.44	6.22	0.32	1.43e-9	Dupuytren's disease;
LIHC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.89	-0.3	9.41e-9	Personality dimensions;
LIHC	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02985541	chr2:219472218	PLCD4	0.42	7.9	0.39	3.92e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.49	8.16	0.4	6.52e-15	Schizophrenia;
LIHC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4450131	0.522	rs4962683	chr10:126371957	C/T	cg20435097	chr10:126320824	FAM53B	0.67	12.22	0.55	9.74e-29	White blood cell count (basophil);
LIHC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.96	-0.31	6.45e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg17830980	chr10:43048298	ZNF37B	0.36	6.14	0.32	2.31e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg17675199	chr6:35436792	RPL10A	0.39	7.86	0.39	4.92e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.48	-0.46	4.55e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	8.59	0.42	3.05e-16	Platelet count;
LIHC	trans	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.67e-11	Aortic root size;
LIHC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.73	9.24	0.45	2.62e-18	Body mass index;
LIHC	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg05760424	chr2:242988095	NA	-0.55	-7.32	-0.37	1.79e-12	Obesity-related traits;
LIHC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.76	-0.39	9.65e-14	Vitiligo;
LIHC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.56	7.47	0.37	6.62e-13	Emphysema distribution in smoking;
LIHC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg19635926	chr16:89946313	TCF25	0.48	6.17	0.32	1.97e-9	Skin colour saturation;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg05896524	chr21:47604654	C21orf56	0.45	6.78	0.34	5.34e-11	Testicular germ cell tumor;
LIHC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.39	6.15	0.32	2.14e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg12365402	chr11:9010492	NRIP3	-0.25	-6.3	-0.32	9.39e-10	Hemoglobin concentration;
LIHC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg19318889	chr4:1322082	MAEA	0.47	6.59	0.34	1.71e-10	Obesity-related traits;
LIHC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.53	-7.47	-0.37	6.76e-13	Body mass index;
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.54	0.38	4.16e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.39	0.41	1.33e-15	Lung cancer in ever smokers;
LIHC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	7.69	0.38	1.62e-13	Height;
LIHC	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	1.02	9.16	0.44	4.93e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.77	-11.65	-0.53	1.23e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs992157	0.764	rs1870123	chr2:219187698	G/A	cg00012203	chr2:219082015	ARPC2	0.76	10.61	0.5	6.43e-23	Colorectal cancer;
LIHC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.95	-0.31	6.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.86	14.98	0.63	2.4e-39	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg12560992	chr17:57184187	TRIM37	0.69	8.91	0.43	3.17e-17	Vitamin D levels;
LIHC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg22601191	chr20:60968625	CABLES2	0.4	5.75	0.3	1.98e-8	Colorectal cancer;
LIHC	cis	rs57590327	0.503	rs2372906	chr3:81504673	G/A	cg07356753	chr3:81810745	GBE1	0.46	6.8	0.35	4.6e-11	Extraversion;
LIHC	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.7	8.95	0.44	2.37e-17	Exhaled nitric oxide output;
LIHC	cis	rs7116495	1.000	rs671681	chr11:71782812	T/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.47	10.94	0.51	4.29e-24	Iron status biomarkers;
LIHC	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.44	-7.16	-0.36	4.93e-12	Mean corpuscular volume;
LIHC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.44e-29	Menopause (age at onset);
LIHC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.57	8.86	0.43	4.43e-17	Uric acid clearance;
LIHC	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg07959070	chr22:50026188	C22orf34	-0.28	-6.98	-0.35	1.55e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.76	0.39	9.67e-14	Schizophrenia;
LIHC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.88	-0.43	3.84e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	11.25	0.52	3.48e-25	Alzheimer's disease (late onset);
LIHC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-5.96	-0.31	6.27e-9	Bladder cancer;
LIHC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg18016565	chr1:150552671	MCL1	-0.5	-10.44	-0.49	2.43e-22	Tonsillectomy;
LIHC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.29	6.26	0.32	1.13e-9	Height;
LIHC	trans	rs1427593	1.000	rs1896473	chr2:137533702	C/T	cg04243827	chr5:3103718	NA	0.41	6.11	0.31	2.74e-9	Pancreatic cancer;
LIHC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg24296786	chr1:45957014	TESK2	0.4	5.71	0.3	2.44e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Parkinson's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02982722	chr20:44486048	ZSWIM3;ACOT8	0.49	6.52	0.33	2.57e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.62	-9.71	-0.46	7.53e-20	Malaria;
LIHC	cis	rs11958404	1.000	rs72816528	chr5:157410949	G/A	cg05962755	chr5:157440814	NA	0.88	10.05	0.48	5.43e-21	IgG glycosylation;
LIHC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.08	-0.44	8.98e-18	Bipolar disorder;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg07489123	chr19:1812466	ATP8B3	-0.42	-6.15	-0.32	2.17e-9	Neuroblastoma;
LIHC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg11342453	chr6:26196699	NA	0.52	5.8	0.3	1.55e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.33	0.55	3.77e-29	Coffee consumption (cups per day);
LIHC	cis	rs7129220	0.588	rs7946649	chr11:10107980	G/C	cg01453529	chr11:10209919	SBF2	-0.4	-7.0	-0.35	1.33e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-0.77	-8.71	-0.43	1.28e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs546131	0.642	rs7946980	chr11:34820438	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.58	8.69	0.43	1.52e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06420487	chr17:61919686	SMARCD2	0.43	5.85	0.3	1.14e-8	Height;
LIHC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.71	7.06	0.36	9.26e-12	Vitiligo;
LIHC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg12437481	chr16:420112	MRPL28	0.51	7.9	0.39	3.82e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg20991723	chr1:152506922	NA	-0.49	-8.85	-0.43	4.69e-17	Hair morphology;
LIHC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.0	15.51	0.64	1.82e-41	Breast cancer;
LIHC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.22	0.32	1.42e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.47	-7.21	-0.36	3.65e-12	Blood protein levels;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.54	6.41	0.33	4.82e-10	Alzheimer's disease;
LIHC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.38	7.38	0.37	1.23e-12	Methadone dose in opioid dependence;
LIHC	trans	rs983392	0.709	rs7932740	chr11:59976111	G/A	cg17275991	chr19:58003312	ZNF419	0.44	6.17	0.32	1.92e-9	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08280861	chr8:58055591	NA	0.54	6.28	0.32	1.05e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.45	-8.1	-0.4	1e-14	Resting heart rate;
LIHC	cis	rs4759375	1.000	rs9669295	chr12:123842670	A/G	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.57e-10	HDL cholesterol;
LIHC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.67	0.5	4.01e-23	Vitiligo;
LIHC	trans	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.4	-0.33	5.23e-10	Endometrial cancer;
LIHC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.69	11.32	0.52	1.84e-25	Obesity-related traits;
LIHC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	12.91	0.57	2.39e-31	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.23	-0.58	1.45e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.35	5.86	0.3	1.11e-8	Height;
LIHC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg18944383	chr4:111397179	ENPEP	-0.28	-6.52	-0.33	2.55e-10	Coronary artery disease;
LIHC	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	7.14	0.36	5.52e-12	Exhaled nitric oxide output;
LIHC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg06238570	chr21:40685208	BRWD1	0.62	7.69	0.38	1.55e-13	Cognitive function;
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.56	8.17	0.4	5.85e-15	Lymphocyte counts;
LIHC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.45	8.41	0.41	1.09e-15	Prudent dietary pattern;
LIHC	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.5	7.95	0.4	2.7e-14	Blood protein levels;
LIHC	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	11.25	0.52	3.35e-25	Coronary artery disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07798295	chr16:89715839	CHMP1A	0.45	6.37	0.33	6.12e-10	Longevity;
LIHC	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.47	0.37	6.86e-13	Corneal astigmatism;
LIHC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-13.99	-0.6	1.8e-35	Systemic lupus erythematosus;
LIHC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.37	-6.27	-0.32	1.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.44	8.15	0.4	7.02e-15	Prudent dietary pattern;
LIHC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	1.06	11.8	0.54	3.33e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.73	-0.3	2.23e-8	Total body bone mineral density;
LIHC	cis	rs4407350	0.870	rs135627	chr22:44906402	A/G	cg26276947	chr22:44892394	LDOC1L	0.36	6.81	0.35	4.28e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02290350	chr8:58132656	NA	0.4	8.44	0.42	9.38e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04814990	chr13:111957387	ARHGEF7	0.39	6.23	0.32	1.37e-9	Immature fraction of reticulocytes;
LIHC	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.41	6.32	0.32	8.05e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.93	17.55	0.69	1.33e-49	Breast cancer;
LIHC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.76	-9.22	-0.45	3.09e-18	Systemic lupus erythematosus;
LIHC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.31	-6.14	-0.32	2.23e-9	Colorectal cancer;
LIHC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.8	6.67	0.34	1.05e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.52	7.33	0.37	1.69e-12	HIV-1 control;
LIHC	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-0.82	-9.65	-0.46	1.24e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	6.29	0.32	9.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09299307	chr5:86709023	CCNH	0.37	6.06	0.31	3.58e-9	Metabolic traits;
LIHC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.45	-0.33	3.82e-10	Height;
LIHC	cis	rs244293	0.965	rs2787482	chr17:53210774	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	7.32	0.37	1.81e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.53	-7.25	-0.37	2.79e-12	Ulcerative colitis;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg09033563	chr22:24373618	LOC391322	-0.43	-5.92	-0.31	7.63e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.58	-8.45	-0.42	8.51e-16	Facial morphology (factor 19);
LIHC	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.22e-24	Breast cancer;
LIHC	cis	rs2292096	1.000	rs66530019	chr1:200813692	A/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-6.07	-0.31	3.33e-9	Epilepsy;
LIHC	cis	rs16828019	0.852	rs71648540	chr1:41722295	G/A	cg20697417	chr1:41786797	NA	0.34	6.55	0.33	2.11e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs332507	0.560	rs6806224	chr3:124365803	C/T	cg05980111	chr3:124395277	KALRN	0.31	5.85	0.3	1.17e-8	Plateletcrit;
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.51	-5.83	-0.3	1.28e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.64	-8.18	-0.4	5.45e-15	Blood metabolite levels;
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12379764	chr21:47803548	PCNT	-0.57	-8.34	-0.41	1.88e-15	Testicular germ cell tumor;
LIHC	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.93	-16.58	-0.67	9.83e-46	Oral cavity cancer;
LIHC	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.01	-0.31	4.81e-9	Blood metabolite levels;
LIHC	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	trans	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.77	-0.3	1.75e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.94	0.54	1.01e-27	Eye color traits;
LIHC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.7	-12.65	-0.56	2.45e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.66	7.62	0.38	2.5e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.9	0.35	2.48e-11	Bipolar disorder;
LIHC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.56	7.21	0.36	3.56e-12	Parkinson's disease;
LIHC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	8.37	0.41	1.54e-15	Lung cancer in ever smokers;
LIHC	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.26	-0.41	3.31e-15	Chronic sinus infection;
LIHC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	9.22	0.45	3.23e-18	Lung cancer;
LIHC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.59	-10.31	-0.49	6.75e-22	Extrinsic epigenetic age acceleration;
LIHC	trans	rs975809	0.966	rs11004607	chr10:56622686	G/T	cg01052087	chr20:10414899	C20orf94;MKKS	0.44	6.23	0.32	1.4e-9	Carotid intima media thickness;
LIHC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.61	-9.42	-0.45	6.97e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.59	7.68	0.38	1.71e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	6.23	0.32	1.34e-9	Response to antipsychotic treatment;
LIHC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.67	11.78	0.54	4.19e-27	Sum eosinophil basophil counts;
LIHC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.8	8.97	0.44	1.94e-17	Cannabis dependence symptom count;
LIHC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-10.01	-0.48	7.58e-21	Dental caries;
LIHC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-6.64	-0.34	1.27e-10	Electroencephalogram traits;
LIHC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.51	-8.68	-0.43	1.59e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.4	6.32	0.32	8.03e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.37	-0.33	5.93e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg16797656	chr11:68205561	LRP5	0.52	8.25	0.41	3.4e-15	Total body bone mineral density;
LIHC	cis	rs507080	0.733	rs489126	chr11:118572747	G/A	cg04173919	chr11:118528438	PHLDB1	0.33	6.09	0.31	2.98e-9	Serum metabolite levels;
LIHC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.58	-7.63	-0.38	2.32e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.84	12.88	0.57	3.26e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs507080	0.733	rs611733	chr11:118572760	C/T	cg04173919	chr11:118528438	PHLDB1	0.32	6.01	0.31	4.86e-9	Serum metabolite levels;
LIHC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-6.89	-0.35	2.67e-11	Bipolar disorder;
LIHC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.31	-6.04	-0.31	4.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg00204748	chr12:29376779	FAR2	0.44	8.32	0.41	2.08e-15	QT interval;
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.69	9.4	0.45	8.19e-19	Calcium levels;
LIHC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-13.55	-0.59	9.17e-34	Gut microbiome composition (summer);
LIHC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.49	6.3	0.32	9.41e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.8	0.34	4.77e-11	Ileal carcinoids;
LIHC	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.6	7.74	0.39	1.13e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.58	-7.81	-0.39	7.15e-14	Vitiligo;
LIHC	cis	rs7635838	0.892	rs9310383	chr3:11491305	A/G	cg00170343	chr3:11313890	ATG7	-0.37	-5.78	-0.3	1.72e-8	HDL cholesterol;
LIHC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.6	9.2	0.45	3.49e-18	Longevity;Endometriosis;
LIHC	cis	rs10916814	0.546	rs7547998	chr1:20903192	C/T	cg24502330	chr1:20914028	CDA	-0.3	-6.6	-0.34	1.55e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.29	-6.84	-0.35	3.58e-11	Longevity;Endometriosis;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.58	8.61	0.42	2.7e-16	Prudent dietary pattern;
LIHC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg24296786	chr1:45957014	TESK2	-0.48	-5.92	-0.3	8.04e-9	Platelet count;
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg10755058	chr3:40428713	ENTPD3	0.35	6.04	0.31	4.08e-9	Renal cell carcinoma;
LIHC	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.52	-0.38	4.9e-13	Breast cancer;
LIHC	cis	rs3823572	0.504	rs2346268	chr7:133642742	G/A	cg03336402	chr7:133662267	EXOC4	-0.46	-5.71	-0.3	2.4e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15757022	chr11:71163853	NADSYN1	-0.46	-6.38	-0.33	5.7e-10	Pancreatic cancer;
LIHC	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	6.38	0.33	5.72e-10	Platelet distribution width;
LIHC	cis	rs700651	0.675	rs1371665	chr2:198942568	C/T	cg10820045	chr2:198174542	NA	0.4	6.02	0.31	4.38e-9	Intracranial aneurysm;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.73	-13.82	-0.6	7.89e-35	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21548788	chr4:77997565	CCNI	0.44	6.09	0.31	3.05e-9	Pancreatic cancer;
LIHC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.91	-0.3	8.14e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.36	0.33	6.5e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04530015	chr2:215796436	ABCA12	-0.36	-5.78	-0.3	1.71e-8	Neuroblastoma;
LIHC	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg22771759	chr13:24902376	NA	0.29	5.73	0.3	2.19e-8	Obesity-related traits;
LIHC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.23	6.36	0.33	6.38e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-7.87	-0.39	4.87e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7187994	0.848	rs12448489	chr16:84774022	G/A	cg07647771	chr16:84786436	USP10	-0.33	-5.8	-0.3	1.52e-8	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.56	0.5	9.32e-23	Platelet count;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.89	-0.3	9.14e-9	Total body bone mineral density;
LIHC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.04e-16	Motion sickness;
LIHC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.16	-13.64	-0.59	4.12e-34	White matter hyperintensity burden;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02047359	chr10:75174015	ANXA7	0.5	7.43	0.37	8.95e-13	Pancreatic cancer;
LIHC	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.49	-7.24	-0.36	3.04e-12	Obesity (extreme);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg16015499	chr1:159888603	TAGLN2	0.41	6.46	0.33	3.57e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg06766960	chr11:133703094	NA	-0.59	-9.36	-0.45	1.09e-18	Childhood ear infection;
LIHC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg16797656	chr11:68205561	LRP5	-0.48	-7.47	-0.37	6.85e-13	Bone mineral density (spine);
LIHC	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.51	-6.39	-0.33	5.38e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.81	9.63	0.46	1.41e-19	Cognitive function;
LIHC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.48	8.19	0.4	5.43e-15	Response to temozolomide;
LIHC	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	0.55	10.14	0.48	2.72e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs244293	0.899	rs2787489	chr17:53208136	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg09222892	chr1:25734099	RHCE	0.48	8.83	0.43	5.5e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs10503871	0.625	rs13275869	chr8:30310335	T/C	cg26383811	chr8:30366931	RBPMS	0.4	6.9	0.35	2.61e-11	Metabolite levels  (X-11787);
LIHC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.25	-6.23	-0.32	1.38e-9	Cutaneous nevi;
LIHC	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.15	-10.34	-0.49	5.63e-22	Schizophrenia;
LIHC	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.28	-5.94	-0.31	7.1e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg04374321	chr14:90722782	PSMC1	-0.74	-13.97	-0.6	2.06e-35	Mortality in heart failure;
LIHC	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg10820045	chr2:198174542	NA	0.41	6.03	0.31	4.23e-9	Dermatomyositis;
LIHC	trans	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg05926928	chr17:57297772	GDPD1	0.61	6.14	0.32	2.35e-9	Opioid sensitivity;
LIHC	cis	rs7577696	0.568	rs7574000	chr2:32342888	A/C	cg02381751	chr2:32503542	YIPF4	-0.45	-6.35	-0.32	6.89e-10	Inflammatory biomarkers;
LIHC	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg00204512	chr16:28754710	NA	0.43	7.48	0.37	6.44e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg03959625	chr15:84868606	LOC388152	0.44	6.47	0.33	3.31e-10	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.48	7.23	0.36	3.19e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22024783	chr19:45393916	TOMM40	0.47	6.53	0.33	2.41e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg00800038	chr16:89945340	TCF25	-0.59	-8.71	-0.43	1.33e-16	Skin colour saturation;
LIHC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02985541	chr2:219472218	PLCD4	-0.44	-7.99	-0.4	2.04e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.23	-0.32	1.39e-9	Bipolar disorder;
LIHC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.6	-8.59	-0.42	3.21e-16	Blood metabolite levels;
LIHC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.87	-0.35	3.02e-11	Bipolar disorder;
LIHC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.5	-8.76	-0.43	9.45e-17	Longevity;
LIHC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.75	10.72	0.5	2.67e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.7e-9	Blood metabolite levels;
LIHC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.8	13.19	0.58	2.11e-32	Parkinson's disease;
LIHC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.47	-7.86	-0.39	5.09e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.35	0.52	1.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs10861342	1.000	rs11112394	chr12:105551570	C/T	cg23923672	chr12:105501055	KIAA1033	-0.66	-7.93	-0.39	3.22e-14	IgG glycosylation;
LIHC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.6	8.63	0.42	2.42e-16	Blood metabolite levels;
LIHC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.87	-0.51	7.85e-24	Hemoglobin concentration;
LIHC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg16226627	chr15:75307476	SCAMP5	0.52	9.27	0.45	2.09e-18	Lung cancer;
LIHC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.12	0.31	2.56e-9	Cognitive ability;
LIHC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-8.42	-0.41	1.02e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.89	0.39	4.06e-14	Height;
LIHC	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-21.15	-0.75	4.27e-64	Colorectal cancer;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg05064044	chr6:292385	DUSP22	-0.53	-6.92	-0.35	2.22e-11	Menopause (age at onset);
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg27124293	chr6:170124346	PHF10	-0.56	-6.61	-0.34	1.49e-10	Response to hepatitis C treatment;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18305365	chr7:36007211	NA	0.39	6.08	0.31	3.17e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09379601	chr19:12992224	DNASE2	0.42	6.9	0.35	2.59e-11	Cognitive function;
LIHC	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.41	5.81	0.3	1.42e-8	Life satisfaction;
LIHC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	13.44	0.59	2.41e-33	Lung cancer in ever smokers;
LIHC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg02272795	chr19:15279244	NOTCH3	-0.34	-6.41	-0.33	4.84e-10	Pulse pressure;
LIHC	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.72	10.31	0.49	7.11e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.35	5.78	0.3	1.64e-8	Blood metabolite levels;
LIHC	cis	rs36051895	0.623	rs12349113	chr9:5254224	T/A	cg02405213	chr9:5042618	JAK2	-0.58	-9.58	-0.46	2.11e-19	Pediatric autoimmune diseases;
LIHC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.74	11.14	0.52	8.37e-25	Corneal astigmatism;
LIHC	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.69e-11	Blood pressure;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.06	-0.31	3.67e-9	Total body bone mineral density;
LIHC	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg03037974	chr15:76606532	NA	0.91	19.73	0.73	2.06e-58	Blood metabolite levels;
LIHC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg25214090	chr10:38739885	LOC399744	0.38	6.19	0.32	1.74e-9	Diastolic blood pressure;
LIHC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.83	-10.44	-0.49	2.45e-22	Cognitive function;
LIHC	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.74	-0.39	1.13e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.56	10.32	0.49	6.24e-22	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.06	-0.36	9.12e-12	Coronary artery disease;
LIHC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg18944383	chr4:111397179	ENPEP	0.25	6.31	0.32	8.46e-10	Coronary artery disease;
LIHC	cis	rs3770081	0.793	rs58186343	chr2:86218400	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.44	-0.42	8.84e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.4	-0.37	1.04e-12	Psoriasis;
LIHC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-6.16	-0.32	2.08e-9	Initial pursuit acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22098324	chr2:232645906	PDE6D	-0.36	-6.09	-0.31	3.02e-9	Cognitive function;
LIHC	cis	rs6750047	0.625	rs59363818	chr2:38261973	A/C	cg07380506	chr2:38303506	CYP1B1	-0.59	-7.45	-0.37	7.81e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.4	-0.37	1.08e-12	Obesity (extreme);
LIHC	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.2	0.48	1.72e-21	Fibroblast growth factor basic levels;
LIHC	trans	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.6e-9	Coronary artery disease;
LIHC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.73	0.3	2.26e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.35	-7.2	-0.36	3.86e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg20607798	chr8:58055168	NA	0.44	5.82	0.3	1.34e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.53	10.14	0.48	2.59e-21	Prostate cancer;
LIHC	cis	rs151997	1.000	rs152817	chr5:50230879	T/A	cg06027927	chr5:50259733	NA	-0.57	-7.71	-0.38	1.38e-13	Callous-unemotional behaviour;
LIHC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.48	6.72	0.34	7.41e-11	Response to diuretic therapy;
LIHC	cis	rs273218	0.568	rs1644814	chr5:53365452	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.56	9.07	0.44	9.37e-18	Migraine;
LIHC	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.49	6.07	0.31	3.44e-9	Serum sulfate level;
LIHC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.41	0.37	9.83e-13	Schizophrenia;
LIHC	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.41	7.26	0.37	2.66e-12	Testicular germ cell tumor;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg07133347	chr1:107600762	PRMT6	0.45	6.63	0.34	1.3e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Parkinson's disease;
LIHC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.56	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	7.84	0.39	5.95e-14	Systolic blood pressure;
LIHC	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.48	7.09	0.36	7.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.06	0.7	1.12e-51	Smoking behavior;
LIHC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.12	-0.52	9.74e-25	Crohn's disease;
LIHC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.42	6.49	0.33	3.02e-10	Red blood cell count;
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg05564831	chr3:52568323	NT5DC2	0.38	5.98	0.31	5.78e-9	Bipolar disorder;
LIHC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.69	12.39	0.56	2.33e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.08	-0.36	8.41e-12	Personality dimensions;
LIHC	cis	rs16958440	0.867	rs75934126	chr18:44679781	T/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	11.9	0.54	1.51e-27	Electrocardiographic conduction measures;
LIHC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.48	0.37	6.38e-13	Mean platelet volume;
LIHC	trans	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg14222797	chr10:16859974	RSU1	-0.56	-6.07	-0.31	3.4e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	6.52	0.33	2.58e-10	Lymphocyte counts;
LIHC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.64	11.16	0.52	7.35e-25	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14230542	chr1:110577941	FAM40A	0.44	6.38	0.33	5.72e-10	Cognitive function;
LIHC	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.41	-5.74	-0.3	2.08e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.57	7.99	0.4	2.02e-14	Total body bone mineral density;
LIHC	trans	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg10756647	chr7:56101905	PSPH	1.09	13.54	0.59	9.78e-34	Diabetic kidney disease;
LIHC	cis	rs13088318	0.504	rs535173	chr3:101055424	T/C	cg19452782	chr3:101232218	SENP7	-0.39	-5.9	-0.3	8.8e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4908768	0.906	rs12117910	chr1:8556953	A/C	cg25722041	chr1:8623473	RERE	0.41	5.85	0.3	1.18e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs12086130	0.892	rs72904790	chr1:51415652	T/C	cg07174182	chr1:51127561	FAF1	-0.72	-8.24	-0.41	3.62e-15	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.36	0.45	1.06e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.29e-12	Bipolar disorder;
LIHC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg03013999	chr17:37608204	MED1	-0.35	-5.79	-0.3	1.62e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03100511	chr19:49173757	SEC1;NTN5	0.37	6.12	0.31	2.57e-9	Pancreatic cancer;
LIHC	trans	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg01148741	chr2:96811453	DUSP2	-0.39	-6.16	-0.32	2.08e-9	Subjective well-being;Cardiovascular disease risk factors;
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg12578287	chr13:42846195	AKAP11	0.48	6.62	0.34	1.39e-10	Leprosy;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.48	-0.33	3.13e-10	Renal cell carcinoma;
LIHC	cis	rs2033908	0.620	rs1371753	chr11:12853703	G/A	cg25843174	chr11:12811716	TEAD1	-0.34	-7.73	-0.39	1.18e-13	Sitting height ratio;
LIHC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg23791538	chr6:167370224	RNASET2	0.4	6.45	0.33	3.84e-10	Primary biliary cholangitis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03621406	chr19:9930365	FBXL12	-0.51	-7.01	-0.35	1.25e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05947499	chr12:113704091	TPCN1	0.45	6.92	0.35	2.24e-11	Longevity;
LIHC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.07	-0.4	1.22e-14	Monocyte percentage of white cells;
LIHC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.45	-7.84	-0.39	5.97e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg24324837	chr19:49891574	CCDC155	0.38	5.88	0.3	9.59e-9	Multiple sclerosis;
LIHC	cis	rs970821	0.667	rs1985668	chr8:124742952	T/A	cg00283535	chr8:124749564	ANXA13	0.45	8.08	0.4	1.12e-14	Breast cancer;
LIHC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.54	-8.85	-0.43	4.75e-17	Longevity;Endometriosis;
LIHC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-0.48	-6.19	-0.32	1.71e-9	Lung cancer;
LIHC	cis	rs4759375	1.000	rs4759375	chr12:123796238	C/T	cg00376283	chr12:123451042	ABCB9	-0.54	-6.7	-0.34	8.39e-11	HDL cholesterol;
LIHC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.52	-9.89	-0.47	1.95e-20	Prudent dietary pattern;
LIHC	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg00792783	chr2:198669748	PLCL1	0.46	6.81	0.35	4.49e-11	Dermatomyositis;
LIHC	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	0.87	14.21	0.61	2.48e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.45	0.37	7.63e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.09	-0.51	1.29e-24	Response to antipsychotic treatment;
LIHC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.46	0.37	7.3e-13	Bone mineral density;
LIHC	cis	rs903552	0.736	rs11858491	chr15:102007456	C/T	cg19295451	chr15:102010161	PCSK6	0.53	7.6	0.38	2.91e-13	Diabetic kidney disease;
LIHC	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs8038465	0.615	rs62004618	chr15:73962164	A/G	cg15420318	chr15:73925796	NPTN	0.44	6.81	0.35	4.35e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.57	9.08	0.44	8.65e-18	Obesity-related traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09011732	chr2:74730507	LOC151534;LBX2	-0.4	-6.36	-0.33	6.43e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg12798992	chr6:167411361	FGFR1OP	0.58	9.52	0.46	3.29e-19	Crohn's disease;
LIHC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.59	7.64	0.38	2.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.55	-0.56	5.78e-30	Response to antipsychotic treatment;
LIHC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.87	-0.3	1.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	7.11	0.36	6.71e-12	HDL cholesterol;
LIHC	cis	rs77633900	0.772	rs75253262	chr15:76657124	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-6.15	-0.32	2.15e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.91	0.3	8.33e-9	Birth weight;
LIHC	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	trans	rs459571	0.959	rs378740	chr9:136890876	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-9.53	-0.46	3.01e-19	Platelet distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23187205	chr6:109416245	SESN1;C6orf182	0.47	6.63	0.34	1.33e-10	Pancreatic cancer;
LIHC	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg06359132	chr10:99160096	RRP12	-0.4	-6.04	-0.31	4.02e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.89	-0.35	2.64e-11	Blood protein levels;
LIHC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.42	6.82	0.35	4.24e-11	Response to temozolomide;
LIHC	cis	rs10792665	0.547	rs10736755	chr11:82559433	C/T	cg24227371	chr11:82718527	RAB30	-0.26	-6.25	-0.32	1.19e-9	Obesity-related traits;
LIHC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg24296786	chr1:45957014	TESK2	0.39	5.8	0.3	1.48e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg25894440	chr7:65020034	NA	-0.52	-5.79	-0.3	1.6e-8	Diabetic kidney disease;
LIHC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.87	0.3	1.05e-8	Tonsillectomy;
LIHC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-7.82	-0.39	6.75e-14	Obesity-related traits;
LIHC	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg24879335	chr3:133465180	TF	0.29	6.39	0.33	5.4e-10	Iron status biomarkers;
LIHC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-6.24	-0.32	1.29e-9	Testicular germ cell tumor;
LIHC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg12863693	chr15:85201151	NMB	0.41	5.83	0.3	1.27e-8	Schizophrenia;
LIHC	cis	rs4684776	0.676	rs3732941	chr3:11304575	A/G	cg00170343	chr3:11313890	ATG7	-0.49	-6.78	-0.34	5.3e-11	Small vessel stroke;
LIHC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.49	7.06	0.36	9.06e-12	Blood metabolite levels;
LIHC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.69	11.65	0.53	1.22e-26	Crohn's disease;
LIHC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg03934865	chr2:198174659	NA	-0.56	-8.67	-0.42	1.74e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg03395511	chr6:291903	DUSP22	-0.5	-6.61	-0.34	1.44e-10	Menopause (age at onset);
LIHC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.44	-6.26	-0.32	1.17e-9	Aortic root size;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.66e-17	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03337784	chr13:41768818	KBTBD7	0.39	6.25	0.32	1.2e-9	Cognitive function;
LIHC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.03	15.95	0.65	3.18e-43	Breast cancer;
LIHC	cis	rs9309473	1.000	rs2140195	chr2:73702344	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.79	-0.34	4.95e-11	Metabolite levels;
LIHC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.38	6.11	0.31	2.67e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25329296	chr4:113486062	C4orf21	0.44	6.56	0.33	2e-10	Longevity;
LIHC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg08213375	chr14:104286397	PPP1R13B	0.53	9.17	0.44	4.64e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-7.96	-0.4	2.53e-14	Morning vs. evening chronotype;
LIHC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg14393609	chr7:65229607	NA	0.37	5.71	0.3	2.42e-8	Aortic root size;
LIHC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.98	17.0	0.68	2.01e-47	Breast cancer;
LIHC	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.98	0.31	5.68e-9	Educational attainment;
LIHC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg15744005	chr10:104629667	AS3MT	-0.4	-9.05	-0.44	1.08e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.76	11.98	0.54	7.16e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.67	0.5	3.77e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.8	0.3	1.51e-8	Axial length;
LIHC	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg27386326	chr11:61587980	NA	-0.63	-13.48	-0.59	1.69e-33	Trans fatty acid levels;
LIHC	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.54	-8.36	-0.41	1.57e-15	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06745235	chr1:180471494	ACBD6	0.44	6.71	0.34	8.24e-11	Pancreatic cancer;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.52	-8.98	-0.44	1.79e-17	Total body bone mineral density;
LIHC	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.56	-10.09	-0.48	3.98e-21	Plateletcrit;Platelet count;
LIHC	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg22153463	chr1:85462885	MCOLN2	0.52	6.24	0.32	1.32e-9	Serum sulfate level;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.49	-0.38	6e-13	Lymphocyte counts;
LIHC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.79	11.85	0.54	2.34e-27	Dental caries;
LIHC	cis	rs1434579	1.000	rs1434579	chr19:44932972	C/T	cg15540054	chr19:45004280	ZNF180	0.55	7.36	0.37	1.4e-12	Tuberculosis;
LIHC	cis	rs4407350	0.756	rs131154	chr22:44890845	C/G	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.49	-0.33	3.02e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.64	12.29	0.55	5.2e-29	Schizophrenia;
LIHC	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Colorectal cancer;
LIHC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.37	-5.81	-0.3	1.43e-8	Schizophrenia;
LIHC	cis	rs2273156	1.000	rs17102970	chr14:35480569	T/G	cg16230307	chr14:35515116	FAM177A1	-0.41	-5.99	-0.31	5.17e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	6.02e-12	Diabetic kidney disease;
LIHC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg04610667	chr7:75704037	NA	0.35	6.12	0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg03146154	chr1:46216737	IPP	-0.4	-6.55	-0.33	2.11e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-9.15	-0.44	5.17e-18	Body mass index;
LIHC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg24296786	chr1:45957014	TESK2	0.4	5.73	0.3	2.26e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.49	-0.42	6.24e-16	Blood pressure (smoking interaction);
LIHC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.51	-0.79	2.04e-73	Height;
LIHC	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.53	0.46	2.94e-19	Eye color traits;
LIHC	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg25894440	chr7:65020034	NA	-0.53	-6.17	-0.32	1.93e-9	Diabetic kidney disease;
LIHC	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.21	-0.36	3.68e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.47	6.82	0.35	4.03e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs16958440	0.581	rs11873880	chr18:44692465	T/C	cg17192377	chr18:44677553	HDHD2	0.71	7.79	0.39	8.32e-14	Sitting height ratio;
LIHC	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.4	5.84	0.3	1.23e-8	Life satisfaction;
LIHC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22161983	chr8:103818636	NA	0.38	6.05	0.31	3.72e-9	Pancreatic cancer;
LIHC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.06	0.31	3.6e-9	Menopause (age at onset);
LIHC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.74	0.43	1.07e-16	Schizophrenia;
LIHC	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-0.72	-7.97	-0.4	2.33e-14	Coronary artery disease;
LIHC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04530015	chr2:215796436	ABCA12	-0.39	-6.39	-0.33	5.58e-10	Neuroblastoma;
LIHC	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.44	-5.95	-0.31	6.65e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.95	0.35	1.81e-11	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17061595	chr4:1245206	C4orf42	0.4	6.08	0.31	3.12e-9	Longevity;
LIHC	cis	rs7923452	0.688	rs117895480	chr10:30788921	A/G	cg25182066	chr10:30743637	MAP3K8	0.47	6.16	0.32	2.03e-9	Itch intensity from mosquito bite;
LIHC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.79	0.69	1.4e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	0.850	rs1251273	chr1:76288617	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-8.54	-0.42	4.51e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16434002	chr17:42200994	HDAC5	0.51	7.38	0.37	1.18e-12	Total body bone mineral density;
LIHC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.47	-8.7	-0.43	1.4e-16	Mean corpuscular volume;
LIHC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.69	0.46	9.15e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs16958440	0.708	rs57468764	chr18:44624856	T/C	cg17192377	chr18:44677553	HDHD2	0.52	6.53	0.33	2.38e-10	Sitting height ratio;
LIHC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.45	0.42	8.36e-16	Motion sickness;
LIHC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	17.31	0.68	1.2e-48	Lung cancer in ever smokers;
LIHC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-1.02	-19.48	-0.73	2.17e-57	Breast cancer;
LIHC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg26566898	chr11:117069891	TAGLN	0.39	6.05	0.31	3.79e-9	Blood protein levels;
LIHC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-9.1	-0.44	7.44e-18	Parkinson's disease;
LIHC	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.45	7.36	0.37	1.37e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg03806693	chr22:41940476	POLR3H	-0.73	-8.71	-0.43	1.34e-16	Vitiligo;
LIHC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg14067834	chr17:29058358	SUZ12P	0.71	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	6.94	0.35	1.94e-11	Migraine;Coronary artery disease;
LIHC	cis	rs4908760	0.860	rs11121202	chr1:8639357	T/C	cg20416874	chr1:8611966	RERE	-0.65	-12.94	-0.57	1.91e-31	Vitiligo;
LIHC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.41	1.56e-15	Bladder cancer;
LIHC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.64	9.52	0.46	3.19e-19	Schizophrenia;
LIHC	cis	rs10847980	0.590	rs2292131	chr12:123332354	C/T	cg22842854	chr12:123319900	HIP1R	0.92	10.44	0.49	2.49e-22	Adiponectin levels;
LIHC	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	0.95	13.92	0.6	3.3e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.48	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.03	-0.4	1.58e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.69	-9.87	-0.47	2.26e-20	Initial pursuit acceleration;
LIHC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.66	9.13	0.44	6.1e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.6	-7.9	-0.39	3.79e-14	Vitamin D levels;
LIHC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg13385521	chr17:29058706	SUZ12P	0.69	6.62	0.34	1.36e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs611744	0.967	rs595266	chr8:109193784	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04433306	chr7:129592730	UBE2H	-0.46	-6.69	-0.34	9.13e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg14067834	chr17:29058358	SUZ12P	0.61	6.18	0.32	1.8e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs62179067	0.708	rs11901918	chr2:179940077	A/G	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs6586163	1.000	rs7097572	chr10:90753260	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-8.42	-0.41	1.06e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.53	5.85	0.3	1.15e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-5.97	-0.31	5.85e-9	Coronary artery disease;
LIHC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-7.26	-0.37	2.55e-12	Cognitive function;
LIHC	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.44	6.82	0.35	4.11e-11	Alzheimer's disease (survival time);
LIHC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs11800820	0.615	rs7513288	chr1:246661679	A/G	cg16700716	chr1:246684329	NA	-0.49	-8.15	-0.4	6.87e-15	Obesity-related traits;
LIHC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-5.93	-0.31	7.32e-9	Response to antipsychotic treatment;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13735959	chr19:40949335	SERTAD3	-0.47	-6.1	-0.31	2.8e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.73	-0.34	7.29e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03050127	chr17:59413660	BCAS3	0.21	6.64	0.34	1.23e-10	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00399650	chr7:141402322	KIAA1147	0.45	6.7	0.34	8.51e-11	Pancreatic cancer;
LIHC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg26395211	chr5:140044315	WDR55	0.41	5.97	0.31	6e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.46	-6.62	-0.34	1.42e-10	Lymphocyte counts;
LIHC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.7	-13.45	-0.59	2.07e-33	Body mass index;
LIHC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg10932868	chr11:921992	NA	0.38	7.07	0.36	8.7e-12	Alzheimer's disease (late onset);
LIHC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.25	-0.74	1.8e-60	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19223106	chr19:58898630	RPS5	0.57	7.38	0.37	1.23e-12	Lung function (FEV1/FVC);
LIHC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.48	-8.23	-0.41	3.9e-15	Longevity;
LIHC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.72	-9.03	-0.44	1.27e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs288342	0.832	rs288304	chr2:183653727	C/A	cg02625481	chr2:183667124	NA	-0.29	-6.1	-0.31	2.83e-9	Recurrent major depressive disorder;
LIHC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.52	-8.15	-0.4	6.93e-15	Diastolic blood pressure;
LIHC	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.74	-0.3	2.08e-8	Blood metabolite levels;
LIHC	trans	rs2579103	0.630	rs1222611	chr12:90709661	C/T	cg07211377	chr9:34377402	KIAA1161	-0.48	-6.76	-0.34	6.1e-11	Body mass index;
LIHC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.86	0.3	1.11e-8	Menopause (age at onset);
LIHC	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg03258749	chr1:151040405	MLLT11	-0.48	-7.48	-0.37	6.49e-13	Childhood ear infection;
LIHC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.66	-0.5	4.34e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs903552	0.736	rs2132196	chr15:102007089	A/G	cg19295451	chr15:102010161	PCSK6	-0.54	-7.6	-0.38	2.78e-13	Diabetic kidney disease;
LIHC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg18016565	chr1:150552671	MCL1	0.54	10.69	0.5	3.32e-23	Tonsillectomy;
LIHC	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.48	6.65	0.34	1.19e-10	Asthma (bronchodilator response);
LIHC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.68	6.32	0.32	8.3e-10	Breast cancer;
LIHC	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.91	11.33	0.52	1.81e-25	Coronary artery disease;
LIHC	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.91	0.57	2.52e-31	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.52	8.18	0.4	5.51e-15	Total body bone mineral density;
LIHC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	8.05	0.4	1.43e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.3	6.93	0.35	2.14e-11	Crohn's disease;
LIHC	cis	rs7095607	0.521	rs2673792	chr10:69927959	T/A	cg18986048	chr10:69913749	MYPN	0.48	7.07	0.36	8.82e-12	Lung function (FVC);
LIHC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.6	5.85	0.3	1.17e-8	Type 2 diabetes nephropathy;
LIHC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.64	-9.61	-0.46	1.61e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.33	-6.28	-0.32	1.05e-9	Body mass index;
LIHC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.16	-18.52	-0.71	1.54e-53	Chronic sinus infection;
LIHC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.51	6.61	0.34	1.5e-10	Initial pursuit acceleration;
LIHC	cis	rs600806	0.813	rs4970760	chr1:109985439	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.58	-6.99	-0.35	1.45e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-0.95	-21.95	-0.76	2.98e-67	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13470557	chr20:61431876	C20orf20	0.45	6.47	0.33	3.42e-10	Hip circumference;
LIHC	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg02023728	chr11:77925099	USP35	0.32	5.82	0.3	1.34e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.77	9.23	0.45	2.99e-18	Coronary artery disease;
LIHC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-6.23	-0.32	1.38e-9	Colorectal cancer;
LIHC	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.02	0.31	4.61e-9	Heart rate;
LIHC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.68	-9.78	-0.47	4.54e-20	Initial pursuit acceleration;
LIHC	cis	rs4684776	0.867	rs13084898	chr3:11334276	C/T	cg00170343	chr3:11313890	ATG7	-0.53	-7.29	-0.37	2.2e-12	Small vessel stroke;
LIHC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-7.67	-0.38	1.76e-13	Gut microbiome composition (summer);
LIHC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.66	0.56	2.25e-30	Hip circumference adjusted for BMI;
LIHC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.43	-0.78	4.16e-73	Height;
LIHC	cis	rs7554547	0.667	rs4846072	chr1:11950391	T/C	cg07603449	chr1:11986842	KIAA2013	-0.36	-6.07	-0.31	3.32e-9	Nonsyndromic cleft lip with cleft palate;
LIHC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.51	0.53	3.97e-26	Motion sickness;
LIHC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.52	-9.8	-0.47	3.7799999999999997e-20	Mean corpuscular volume;
LIHC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.62	8.71	0.43	1.36e-16	Platelet count;
LIHC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.59	-7.89	-0.39	4.03e-14	Vitamin D levels;
LIHC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.3	-0.32	9.29e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12744310	0.887	rs12043581	chr1:41788265	C/T	cg03962019	chr1:41807865	NA	0.36	5.86	0.3	1.08e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.37	5.86	0.3	1.12e-8	Coronary artery disease;
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg13409248	chr3:40428643	ENTPD3	0.5	8.44	0.42	9.3e-16	Renal cell carcinoma;
LIHC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg04083430	chr16:4736063	MGRN1	0.44	5.96	0.31	6.25e-9	Schizophrenia;
LIHC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.82	0.3	1.37e-8	Birth weight;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.27	-0.49	9.5e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs10097731	0.901	rs10464931	chr8:82042664	A/G	cg25230327	chr8:82042993	NA	0.52	7.08	0.36	8.34e-12	Serum total protein level;
LIHC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	trans	rs6437061	0.835	rs2853361	chr2:233120923	A/G	cg19760917	chr1:2411643	PLCH2	-0.41	-6.41	-0.33	4.69e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.52	-7.88	-0.39	4.46e-14	Extraversion;
LIHC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.71	9.58	0.46	2.08e-19	Sudden cardiac arrest;
LIHC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	5.71	0.3	2.45e-8	Schizophrenia;
LIHC	cis	rs6450176	0.564	rs34360866	chr5:53332737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.5	-0.59	1.4e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.9	13.35	0.59	5.41e-33	Sudden cardiac arrest;
LIHC	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04305677	chr7:2281541	NUDT1;FTSJ2	-0.55	-7.19	-0.36	4.14e-12	Systolic blood pressure;
LIHC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.23	0.55	8.88e-29	Alzheimer's disease;
LIHC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.4	0.37	1.04e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs990171	0.506	rs4141632	chr2:102757139	A/G	cg22835712	chr2:102737379	NA	0.56	8.76	0.43	8.96e-17	Lymphocyte counts;
LIHC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.67	0.53	1.03e-26	Motion sickness;
LIHC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.91	-17.09	-0.68	8.66e-48	Menopause (age at onset);
LIHC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.26	6.74	0.34	6.56e-11	Cardiovascular disease risk factors;
LIHC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.48	7.1	0.36	7.04e-12	Height;
LIHC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.79	10.5	0.49	1.5e-22	Psoriasis;
LIHC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.28	-0.45	2.06e-18	Type 2 diabetes;
LIHC	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg22153463	chr1:85462885	MCOLN2	0.49	5.91	0.3	8.45e-9	Serum sulfate level;
LIHC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.21e-26	Motion sickness;
LIHC	cis	rs12079745	0.623	rs2982468	chr1:169090971	A/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.63	-6.46	-0.33	3.51e-10	QT interval;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736485	0.966	rs11634180	chr15:51895757	G/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.29	-0.32	9.52e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg09254047	chr11:66045564	CNIH2	-0.39	-5.8	-0.3	1.51e-8	Gout;
LIHC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.5e-9	Aortic root size;
LIHC	cis	rs986417	1.000	rs713336	chr14:60974958	T/G	cg27398547	chr14:60952738	C14orf39	0.85	9.85	0.47	2.61e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs8067354	0.574	rs1292033	chr17:57990597	A/T	cg02344993	chr17:57696989	CLTC	0.66	10.44	0.49	2.57e-22	Hemoglobin concentration;
LIHC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.93	-17.77	-0.69	1.67e-50	Coronary artery disease;
LIHC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20135002	chr11:47629003	NA	-0.54	-9.21	-0.45	3.48e-18	Neuroticism;
LIHC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.61	-6.53	-0.33	2.44e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg22079354	chr11:130786696	SNX19	-0.46	-6.9	-0.35	2.52e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.98	-0.31	5.55e-9	Schizophrenia;
LIHC	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.54	-6.11	-0.31	2.78e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg06804625	chr1:109812012	CELSR2	-0.41	-5.94	-0.31	6.91e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.43	7.17	0.36	4.72e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24656492	chr10:70940659	SUPV3L1	0.46	6.08	0.31	3.25e-9	Pancreatic cancer;
LIHC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.87	13.22	0.58	1.58e-32	Vitamin D levels;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.41	5.76	0.3	1.85e-8	Breast cancer;
LIHC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.04	0.4	1.52e-14	Lung cancer;
LIHC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.31	6.74	0.34	6.56e-11	Longevity;
LIHC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.1	10.04	0.48	5.77e-21	Diabetic retinopathy;
LIHC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.48	6.35	0.32	6.72e-10	Mean platelet volume;
LIHC	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-6.2	-0.32	1.62e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.31	0.41	2.25e-15	Height;
LIHC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg12863693	chr15:85201151	NMB	0.45	6.2	0.32	1.65e-9	Schizophrenia;
LIHC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.7	-9.65	-0.46	1.21e-19	Prostate cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24043861	chr14:73396628	DCAF4	0.44	6.51	0.33	2.71e-10	Hepatitis;
LIHC	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-6.73	-0.34	7.01e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.66	-12.35	-0.56	3.03e-29	Height;
LIHC	cis	rs10792665	0.640	rs10751082	chr11:82625273	G/A	cg24227371	chr11:82718527	RAB30	-0.27	-6.25	-0.32	1.26e-9	Obesity-related traits;
LIHC	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg27523141	chr10:43048294	ZNF37B	-0.37	-6.3	-0.32	8.92e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	8.49	0.42	6.46e-16	HIV-1 control;
LIHC	cis	rs360798	0.532	rs1022110	chr2:63046039	T/G	cg17519650	chr2:63277830	OTX1	-0.47	-7.26	-0.37	2.56e-12	Coronary artery disease;
LIHC	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	9.14	0.44	5.85e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg06565975	chr8:143823917	SLURP1	-0.39	-6.38	-0.33	5.59e-10	Urinary tract infection frequency;
LIHC	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.42	-6.16	-0.32	2.04e-9	Dementia with Lewy bodies;
LIHC	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16684958	chr7:75615977	POR	-0.51	-8.48	-0.42	6.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23967809	chr8:141647658	NA	0.47	6.85	0.35	3.38e-11	Pancreatic cancer;
LIHC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-9.02	-0.44	1.34e-17	Vitiligo;
LIHC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.88	12.38	0.56	2.37e-29	Blood metabolite levels;
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.82	14.82	0.63	1.03e-38	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.39	-6.11	-0.31	2.65e-9	Menopause (age at onset);
LIHC	cis	rs4934494	0.911	rs7098233	chr10:91422868	A/C	cg19698084	chr10:91461284	KIF20B	0.45	6.26	0.32	1.16e-9	Red blood cell count;
LIHC	cis	rs4853036	0.951	rs3755391	chr2:70141519	C/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.28	-0.32	1.05e-9	Colorectal or endometrial cancer;
LIHC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.9	0.3	8.66e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12640387	chr1:6694331	THAP3;DNAJC11	-0.42	-6.14	-0.32	2.26e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.45	-7.22	-0.36	3.36e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.17	-0.36	4.54e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg12046867	chr14:103022105	NA	0.5	7.24	0.36	3.01e-12	Platelet count;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.41	0.61	3.94e-37	Prudent dietary pattern;
LIHC	trans	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.45	-9.08	-0.44	9.1e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.83	10.86	0.51	8.58e-24	Cognitive function;
LIHC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.39	7.36	0.37	1.41e-12	Schizophrenia;
LIHC	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.56	8.5	0.42	6.1e-16	Coronary artery disease;
LIHC	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.29	-6.81	-0.35	4.31e-11	Hip circumference;Waist circumference;
LIHC	cis	rs7487075	0.619	rs4768718	chr12:46834336	G/C	cg23829395	chr12:46796953	NA	0.35	6.19	0.32	1.76e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7165170	0.678	rs2010673	chr15:91201285	C/T	cg26821196	chr15:91095069	CRTC3	-0.37	-6.84	-0.35	3.66e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.91	-0.3	8.17e-9	Total body bone mineral density;
LIHC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.46	-5.8	-0.3	1.5e-8	Blood protein levels;
LIHC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.41	6.16	0.32	2e-9	Lymphocyte counts;
LIHC	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	1.13	8.8	0.43	6.86e-17	Arsenic metabolism;
LIHC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.51	7.3	0.37	2.04e-12	Initial pursuit acceleration;
LIHC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20135002	chr11:47629003	NA	-0.55	-9.27	-0.45	2.17e-18	Subjective well-being;
LIHC	cis	rs943466	1.000	rs73412140	chr6:33757014	G/T	cg25922239	chr6:33757077	LEMD2	-0.47	-5.78	-0.3	1.66e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	0.94	13.32	0.58	6.65e-33	Mitochondrial DNA levels;
LIHC	cis	rs7539624	0.541	rs4653499	chr1:223892703	T/C	cg07395969	chr1:223900822	CAPN2	0.53	6.01	0.31	4.8e-9	Schizophrenia;
LIHC	cis	rs8056893	0.775	rs6499172	chr16:68376570	A/G	cg02226672	chr16:68398533	SMPD3	0.47	6.73	0.34	7.05e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg24097872	chr10:5724021	NA	0.79	11.37	0.52	1.24e-25	Childhood ear infection;
LIHC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.91	-16.71	-0.67	3.03e-46	Height;
LIHC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.75	9.26	0.45	2.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.38	-5.95	-0.31	6.72e-9	Platelet count;
LIHC	cis	rs7703744	0.747	rs6896277	chr5:118678721	C/T	cg04195774	chr5:118677172	TNFAIP8	-0.4	-5.72	-0.3	2.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg19680672	chr10:131412579	MGMT	-0.43	-6.62	-0.34	1.43e-10	Response to temozolomide;
LIHC	cis	rs4450131	0.569	rs3824801	chr10:126356840	T/G	cg20435097	chr10:126320824	FAM53B	0.59	10.73	0.5	2.43e-23	White blood cell count (basophil);
LIHC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.41	-0.49	3.04e-22	Platelet count;
LIHC	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.57	-7.59	-0.38	3.13e-13	Type 2 diabetes;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg21666675	chr3:14165843	TMEM43;CHCHD4	-0.43	-6.35	-0.32	6.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04347379	chr7:794485	HEATR2	-0.4	-5.78	-0.3	1.66e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9596863	0.950	rs9563183	chr13:54396931	A/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.1	0.31	2.82e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.31	-0.37	1.84e-12	Response to antipsychotic treatment;
LIHC	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.9	-0.39	3.81e-14	Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-0.84	-9.48	-0.46	4.43e-19	Mitochondrial DNA levels;
LIHC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20887711	chr4:1340912	KIAA1530	0.45	6.01	0.31	4.77e-9	Obesity-related traits;
LIHC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.86	0.43	4.4e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.26	-6.11	-0.31	2.66e-9	Longevity;Endometriosis;
LIHC	cis	rs72653721	0.627	rs57786993	chr6:11070940	T/A	cg13562911	chr6:11044106	ELOVL2	0.5	7.26	0.37	2.7e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.61	6.98	0.35	1.56e-11	Height;
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18455759	chr8:126443767	TRIB1	0.44	6.29	0.32	9.77e-10	Cognitive function;
LIHC	cis	rs61677309	0.638	rs4938493	chr11:118144804	T/G	cg06090739	chr11:118230722	UBE4A	0.32	6.03	0.31	4.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.32	7.19	0.36	4.09e-12	Blood metabolite ratios;
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	0.6	8.75	0.43	9.91e-17	Prudent dietary pattern;
LIHC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.89	-10.78	-0.5	1.6e-23	Primary sclerosing cholangitis;
LIHC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.36	5.82	0.3	1.36e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.56	8.98	0.44	1.84e-17	Menarche (age at onset);
LIHC	trans	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22867288	chr6:57086716	RAB23	-0.41	-6.05	-0.31	3.8e-9	Triglycerides;
LIHC	cis	rs1816752	0.819	rs7400583	chr13:24990054	C/T	cg22771759	chr13:24902376	NA	0.3	5.87	0.3	1.02e-8	Obesity-related traits;
LIHC	cis	rs6726292	0.539	rs2580769	chr2:55214618	A/C	cg09592903	chr2:55203963	RTN4	0.43	6.83	0.35	3.86e-11	Obesity (extreme);
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.9	12.42	0.56	1.75e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg17724175	chr1:150552817	MCL1	0.45	8.97	0.44	1.97e-17	Melanoma;
LIHC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.69	-9.39	-0.45	8.46e-19	Aortic root size;
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02244288	chr16:89573955	SPG7	-0.3	-5.77	-0.3	1.74e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs7945718	0.905	rs7935997	chr11:12728651	A/G	cg25843174	chr11:12811716	TEAD1	0.35	7.84	0.39	5.8e-14	Educational attainment (years of education);
LIHC	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg18850929	chr19:1828978	REXO1	0.39	6.36	0.33	6.4e-10	Bipolar disorder;
LIHC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg18306943	chr3:40428807	ENTPD3	-0.39	-6.54	-0.33	2.21e-10	Renal cell carcinoma;
LIHC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.94	17.89	0.7	5.39e-51	Menopause (age at onset);
LIHC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.8e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00435469	chr11:1495117	HCCA2	0.43	6.08	0.31	3.24e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg08847533	chr14:75593920	NEK9	-0.38	-6.4	-0.33	5.15e-10	Caffeine consumption;
LIHC	trans	rs13381277	0.850	rs9951590	chr18:74330117	T/C	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.4	-0.33	5e-10	Dental caries;
LIHC	cis	rs6565189	0.865	rs4350585	chr16:30505513	A/G	cg17640201	chr16:30407289	ZNF48	0.51	6.03	0.31	4.29e-9	Tonsillectomy;
LIHC	cis	rs7238033	0.624	rs4479340	chr18:43308955	C/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs9527	0.518	rs10883802	chr10:104680362	C/T	cg15744005	chr10:104629667	AS3MT	0.42	5.87	0.3	1.04e-8	Arsenic metabolism;
LIHC	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.11	-16.35	-0.66	8.02e-45	Corneal structure;
LIHC	cis	rs12493885	0.769	rs57354204	chr3:153755718	C/T	cg10247383	chr3:153839028	SGEF	0.61	5.8	0.3	1.53e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.55	-0.38	3.97e-13	Mean platelet volume;
LIHC	trans	rs800082	0.799	rs9870285	chr3:144236432	C/A	cg24215973	chr2:240111563	HDAC4	0.44	6.36	0.33	6.4e-10	Smoking behavior;
LIHC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	1.02	12.3	0.55	4.95e-29	Red blood cell traits;
LIHC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.43	-7.37	-0.37	1.31e-12	Aortic root size;
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-6.0	-0.31	5.05e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.7	-0.38	1.43e-13	Total body bone mineral density;
LIHC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.65	11.63	0.53	1.48e-26	Total body bone mineral density;
LIHC	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg01674679	chr13:27998804	GTF3A	-0.46	-6.69	-0.34	9e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-7.35	-0.37	1.45e-12	Initial pursuit acceleration;
LIHC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.59	-8.81	-0.43	6.57e-17	Lung cancer;
LIHC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg13318129	chr22:45737514	FAM118A	0.53	7.65	0.38	2.03e-13	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg07424592	chr7:64974309	NA	0.74	8.56	0.42	3.98e-16	Diabetic kidney disease;
LIHC	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.4	0.33	5.12e-10	Mammographic density (dense area);
LIHC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.37	-0.45	9.84e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.88	-16.79	-0.67	1.44e-46	Blood protein levels;
LIHC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg09182678	chr22:50328711	NA	-0.46	-6.68	-0.34	9.66e-11	Schizophrenia;
LIHC	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.82	-9.18	-0.44	4.08e-18	Alzheimer's disease (late onset);
LIHC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.64	7.04	0.36	1.06e-11	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg26939375	chr7:64535504	NA	0.4	6.31	0.32	8.63e-10	Aortic root size;
LIHC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg19680672	chr10:131412579	MGMT	0.39	5.83	0.3	1.28e-8	Response to temozolomide;
LIHC	cis	rs67981189	0.593	rs8020480	chr14:71528044	C/A	cg15816911	chr14:71606274	NA	0.42	6.82	0.35	4.07e-11	Schizophrenia;
LIHC	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.6	8.94	0.44	2.5e-17	Recombination rate (females);
LIHC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.67	-0.38	1.86e-13	Chronic sinus infection;
LIHC	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.48	-0.37	6.38e-13	Prevalent atrial fibrillation;
LIHC	cis	rs6540556	0.517	rs11119328	chr1:209885318	C/A	cg05527609	chr1:210001259	C1orf107	-0.58	-7.65	-0.38	2.01e-13	Red blood cell count;
LIHC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.87	11.56	0.53	2.65e-26	Blood metabolite levels;
LIHC	cis	rs9372498	0.505	rs1690657	chr6:118650470	C/A	cg01339444	chr6:118972232	C6orf204	0.71	6.25	0.32	1.22e-9	Diastolic blood pressure;
LIHC	cis	rs546131	0.642	rs10501136	chr11:34846516	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.52	6.42	0.33	4.46e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.81	-12.6	-0.56	3.68e-30	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs10411161	1.000	rs3764540	chr19:52380681	T/A	cg22319618	chr22:45562946	NUP50	-0.55	-7.42	-0.37	9.4e-13	Breast cancer;
LIHC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.8	-18.16	-0.7	4.62e-52	Urate levels in lean individuals;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14197205	chr17:28256862	EFCAB5;SSH2	0.4	6.2	0.32	1.6e-9	Calcium levels;
LIHC	cis	rs9322817	0.583	rs7746856	chr6:105146360	A/C	cg02098413	chr6:105308735	HACE1	0.37	6.54	0.33	2.24e-10	Thyroid stimulating hormone;
LIHC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	9.45	0.46	5.48e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	ch.8.33884649F	chr8:33765107	NA	0.37	6.23	0.32	1.41e-9	Body mass index;
LIHC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg07382826	chr16:28625726	SULT1A1	-0.49	-7.73	-0.39	1.23e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.7	-12.16	-0.55	1.61e-28	Height;
LIHC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.51	-0.33	2.7e-10	Height;
LIHC	trans	rs60752752	0.852	rs57572338	chr1:153370725	G/T	cg14901121	chr8:98817630	LAPTM4B	-0.43	-7.01	-0.35	1.27e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.37	-0.41	1.48e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg09904177	chr6:26538194	HMGN4	-0.37	-5.79	-0.3	1.57e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.41	6.19	0.32	1.75e-9	Pediatric autoimmune diseases;
LIHC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.42	6.27	0.32	1.1e-9	Height;
LIHC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.03	14.83	0.63	8.98e-39	Cognitive function;
LIHC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg21466736	chr12:48725269	NA	0.64	9.17	0.44	4.67e-18	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg27386326	chr11:61587980	NA	0.7	14.63	0.62	5.66e-38	Trans fatty acid levels;
LIHC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.48	7.97	0.4	2.42e-14	Diastolic blood pressure;
LIHC	cis	rs12365397	0.775	rs2132484	chr11:43244386	A/C	cg16667275	chr11:43333495	API5	0.41	6.13	0.31	2.36e-9	Migraine;
LIHC	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg17927777	chr20:33865990	NA	-0.54	-6.53	-0.33	2.45e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-11.28	-0.52	2.63e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.18	0.32	1.77e-9	Renal cell carcinoma;
LIHC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-11.11	-0.51	1.08e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.51	-8.14	-0.4	7.6e-15	Testicular germ cell tumor;
LIHC	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	6.24	0.32	1.28e-9	Blood protein levels;
LIHC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.56	-6.64	-0.34	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2933343	1.000	rs2933343	chr3:128658492	G/A	cg25356066	chr3:128598488	ACAD9	0.53	7.13	0.36	5.89e-12	IgG glycosylation;
LIHC	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.52	8.36	0.41	1.57e-15	Corneal astigmatism;
LIHC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.98	21.26	0.75	1.65e-64	Bone mineral density;
LIHC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.62e-15	Motion sickness;
LIHC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.54	0.38	4.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.81	10.43	0.49	2.66e-22	Morning vs. evening chronotype;
LIHC	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-6.86	-0.35	3.2e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.17	-0.32	1.91e-9	Total body bone mineral density;
LIHC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.51	-0.56	8.09e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.98	15.78	0.65	1.63e-42	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	11.5	0.53	4.2e-26	Coronary artery disease;
LIHC	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg24579218	chr15:68104479	NA	-0.35	-5.91	-0.3	8.1e-9	Restless legs syndrome;
LIHC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-7.17	-0.36	4.66e-12	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.06	-0.31	3.57e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg10096929	chr1:156261403	TMEM79	0.38	6.12	0.31	2.51e-9	Tonsillectomy;
LIHC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg15595755	chr5:1867978	NA	0.41	7.96	0.4	2.57e-14	Cardiovascular disease risk factors;
LIHC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-11.1	-0.51	1.19e-24	Body mass index (adult);
LIHC	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.58	11.46	0.53	5.97e-26	Myopia (pathological);
LIHC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg26138937	chr11:71823887	C11orf51	1.34	10.79	0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.68	0.34	9.76e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg26831259	chr4:1366826	KIAA1530	0.35	5.75	0.3	1.99e-8	Obesity-related traits;
LIHC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-1.02	-19.48	-0.73	2.17e-57	Breast cancer;
LIHC	cis	rs8114671	0.545	rs2378335	chr20:33756830	A/C	cg08999081	chr20:33150536	PIGU	0.41	5.78	0.3	1.72e-8	Height;
LIHC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.41	7.28	0.37	2.37e-12	Mean corpuscular volume;
LIHC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.4	6.09	0.31	3.05e-9	Iron status biomarkers;
LIHC	trans	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg15676719	chr1:167598521	RCSD1	-0.39	-6.95	-0.35	1.84e-11	Systemic lupus erythematosus;
LIHC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.17	-0.36	4.62e-12	Bipolar disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25048202	chr15:66993412	SMAD6	0.44	6.63	0.34	1.3e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg24130564	chr14:104152367	KLC1	-0.43	-6.98	-0.35	1.53e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg22590775	chr19:49891494	CCDC155	0.47	7.55	0.38	3.93e-13	Multiple sclerosis;
LIHC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.7	-10.02	-0.48	7.11e-21	Bronchopulmonary dysplasia;
LIHC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.35	0.52	1.51e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.39	0.37	1.13e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.78	-0.3	1.65e-8	Body mass index;
LIHC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg17724175	chr1:150552817	MCL1	0.44	9.09	0.44	8.01e-18	Melanoma;
LIHC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.72	9.78	0.47	4.54e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.55	7.07	0.36	8.98e-12	Parkinson's disease;
LIHC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.57	9.64	0.46	1.32e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.41	-0.37	9.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.39	-0.45	8.54e-19	Colorectal cancer;
LIHC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.38	0.45	9.22e-19	Bipolar disorder;
LIHC	cis	rs4908768	0.906	rs55860300	chr1:8596335	G/A	cg25722041	chr1:8623473	RERE	0.41	5.94	0.31	7.12e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03136712	chr5:140053068	DND1	0.5	6.11	0.31	2.75e-9	Lung function (FEV1);
LIHC	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.39	5.77	0.3	1.76e-8	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06009330	chr2:70485380	PCYOX1	0.61	8.12	0.4	8.45e-15	Lung function (FEV1/FVC);
LIHC	cis	rs7635838	0.785	rs7427412	chr3:11535020	G/A	cg00170343	chr3:11313890	ATG7	0.4	6.19	0.32	1.67e-9	HDL cholesterol;
LIHC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg13753209	chr17:57696993	CLTC	0.72	11.38	0.52	1.15e-25	Hemoglobin concentration;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg16132339	chr22:24313637	DDTL;DDT	-0.7	-13.58	-0.59	6.74e-34	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg24693881	chr1:107596107	NA	-0.52	-9.38	-0.45	9.34e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.07	15.4	0.64	5.23e-41	Cognitive function;
LIHC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.3	-16.95	-0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.47	0.42	7.46e-16	Lung cancer in ever smokers;
LIHC	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.88	-0.3	9.86e-9	Calcium levels;
LIHC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.71	-13.0	-0.58	1.15e-31	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2363709	1.000	rs6770280	chr3:67416712	T/C	cg15775005	chr18:9136598	ANKRD12	-0.79	-6.05	-0.31	3.71e-9	IgE levels;
LIHC	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg26441486	chr22:50317300	CRELD2	0.36	6.14	0.31	2.34e-9	Schizophrenia;
LIHC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.68	-0.34	9.61e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.92	16.54	0.67	1.44e-45	Parkinson's disease;
LIHC	cis	rs2029362	0.513	rs7931247	chr11:27746991	T/C	cg18117895	chr11:27722066	BDNF	-0.39	-5.76	-0.3	1.87e-8	Total body bone mineral density;
LIHC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.61	8.16	0.4	6.3e-15	Migraine;
LIHC	cis	rs1144333	0.655	rs3765682	chr1:76333172	T/C	cg03433033	chr1:76189801	ACADM	0.54	7.44	0.37	8.34e-13	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg18944383	chr4:111397179	ENPEP	0.27	7.06	0.36	9.34e-12	Height;
LIHC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	6.81	0.35	4.49e-11	Menopause (age at onset);
LIHC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.71	-0.38	1.37e-13	Coronary artery disease;
LIHC	cis	rs4917833	0.510	rs754586	chr10:100224362	A/G	cg19043522	chr10:100227446	HPSE2	0.4	5.96	0.31	6.35e-9	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs3015497	0.789	rs3015500	chr14:51108877	C/T	cg09863266	chr14:51125203	SAV1	-0.42	-6.82	-0.35	4.2e-11	Mean platelet volume;
LIHC	cis	rs1075232	1.000	rs56396205	chr15:31678385	G/A	cg01030201	chr15:31746330	NA	-0.79	-6.12	-0.31	2.56e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.44	6.4	0.33	5.18e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg27386326	chr11:61587980	NA	0.69	14.45	0.62	2.72e-37	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.22e-34	Aortic root size;
LIHC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.32	8.08	0.4	1.13e-14	Schizophrenia;
LIHC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg07636037	chr3:49044803	WDR6	-0.58	-6.95	-0.35	1.9e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.47	-7.63	-0.38	2.35e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.5	-8.17	-0.4	5.97e-15	Cognitive function;
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg26939375	chr7:64535504	NA	0.47	7.21	0.36	3.66e-12	Calcium levels;
LIHC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.73	13.22	0.58	1.65e-32	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.48	-7.7	-0.38	1.5e-13	Cognitive function;
LIHC	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg15704280	chr7:45808275	SEPT13	0.61	6.23	0.32	1.39e-9	Axial length;
LIHC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.99	0.7	2.16e-51	Gut microbiome composition (summer);
LIHC	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08547432	chr19:50143419	RRAS	0.46	6.75	0.34	6.21e-11	Pancreatic cancer;
LIHC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.43	-0.59	2.61e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg12863693	chr15:85201151	NMB	0.45	6.2	0.32	1.65e-9	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.5	-0.33	2.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.75	0.34	6.22e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.7	6.58	0.34	1.76e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.52	-7.76	-0.39	9.74e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.71	10.35	0.49	5.1e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.45e-11	Height;
LIHC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-7.82	-0.39	6.74e-14	Gut microbiome composition (summer);
LIHC	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.79	-7.32	-0.37	1.81e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7944735	0.508	rs4752871	chr11:47849432	C/G	cg20307385	chr11:47447363	PSMC3	-0.51	-5.75	-0.3	1.97e-8	Intraocular pressure;
LIHC	cis	rs2016586	0.522	rs66518367	chr22:36094486	G/T	cg26342177	chr22:36113512	APOL5	-0.34	-5.74	-0.3	2.14e-8	Body mass index;
LIHC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.9	0.3	8.59e-9	Height;
LIHC	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.31	6.74	0.34	6.71e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.5	-8.62	-0.42	2.54e-16	Total body bone mineral density;
LIHC	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg07382826	chr16:28625726	SULT1A1	0.47	7.21	0.36	3.6e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.53	7.8	0.39	7.47e-14	Diastolic blood pressure;
LIHC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.38	-0.56	2.44e-29	Primary sclerosing cholangitis;
LIHC	trans	rs13325613	0.915	rs34414382	chr3:46265190	C/T	cg26337592	chr1:153642686	ILF2	0.68	6.2	0.32	1.66e-9	Monocyte count;
LIHC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.57	7.17	0.36	4.75e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	10.23	0.48	1.3e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2279817	0.863	rs34430730	chr1:18015100	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-8.05	-0.4	1.36e-14	Neuroticism;
LIHC	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.49	-8.84	-0.43	5.04e-17	Leprosy;
LIHC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg04498913	chr7:1135747	C7orf50	0.38	5.84	0.3	1.18e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg17750252	chr2:136567154	LCT	0.35	6.32	0.32	8.34e-10	Mosquito bite size;
LIHC	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-10.74	-0.5	2.14e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs918629	0.798	rs2546199	chr5:95282091	A/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.46	-0.33	3.62e-10	IgG glycosylation;
LIHC	cis	rs4755351	0.504	rs12418119	chr11:33347977	G/A	cg05567920	chr11:33183001	CSTF3	0.4	5.75	0.3	1.97e-8	Lung cancer in ever smokers;
LIHC	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21545522	chr1:205238299	TMCC2	0.32	6.25	0.32	1.21e-9	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.25	6.34	0.32	7.07e-10	Migraine;
LIHC	trans	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg24637308	chr11:6592297	DNHD1	0.44	6.16	0.32	2.02e-9	Coronary artery calcification;
LIHC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg06096015	chr1:231504339	EGLN1	0.5	9.34	0.45	1.28e-18	Hemoglobin concentration;
LIHC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.04	-0.36	1.08e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg21252483	chr19:49399788	TULP2	-0.69	-5.82	-0.3	1.35e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg17608529	chr10:436626	DIP2C	0.53	6.09	0.31	3.1e-9	Colorectal cancer;
LIHC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.46	7.58	0.38	3.38e-13	Response to temozolomide;
LIHC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.22	-0.45	3.22e-18	Diabetic kidney disease;
LIHC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg10360323	chr17:41437877	NA	0.4	5.92	0.31	7.69e-9	Menopause (age at onset);
LIHC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.22	0.52	4.31e-25	Colorectal cancer;
LIHC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.5	7.8	0.39	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.45	0.59	2.07e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs57244997	0.582	rs73030432	chr6:162439864	G/A	cg17173639	chr6:162384350	PARK2	-0.52	-6.68	-0.34	9.42e-11	Mosquito bite size;
LIHC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.14	-0.78	5.71e-72	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17492891	chr22:41843204	TOB2	0.4	6.14	0.32	2.3e-9	Pancreatic cancer;
LIHC	cis	rs7619427	1.000	rs7635417	chr3:44074449	C/T	cg24966902	chr3:44043705	NA	0.5	7.08	0.36	8.07e-12	Schizophrenia;
LIHC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg14092571	chr14:90743983	NA	0.41	6.59	0.34	1.69e-10	Mortality in heart failure;
LIHC	cis	rs10744422	1.000	rs2061101	chr12:123348925	C/A	cg07706471	chr12:123319906	HIP1R	-0.57	-6.96	-0.35	1.75e-11	Schizophrenia;
LIHC	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-7.18	-0.36	4.43e-12	Exhaled nitric oxide output;
LIHC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-11.1	-0.51	1.21e-24	Morning vs. evening chronotype;
LIHC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	1.15	19.93	0.73	3.24e-59	IgG glycosylation;
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.13	-0.4	7.85e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg09137382	chr11:130731461	NA	-0.39	-5.85	-0.3	1.18e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9527	0.518	rs12771834	chr10:104655419	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-6.09	-0.31	3.01e-9	Arsenic metabolism;
LIHC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.46	-7.5	-0.38	5.6e-13	Menarche (age at onset);
LIHC	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg25364880	chr3:44379878	C3orf23	0.57	8.08	0.4	1.16e-14	Depressive symptoms;
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg26939375	chr7:64535504	NA	0.48	7.22	0.36	3.46e-12	Calcium levels;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.6	-8.52	-0.42	5.17e-16	Menopause (age at onset);
LIHC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.42	0.33	4.47e-10	Schizophrenia;
LIHC	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.23	-5.9	-0.3	8.8e-9	Schizophrenia;
LIHC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.66	6.15	0.32	2.17e-9	Urate levels in lean individuals;
LIHC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.75	-0.34	6.26e-11	Diabetic kidney disease;
LIHC	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.83	-0.35	3.8e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.76	13.09	0.58	5.08e-32	Mean platelet volume;
LIHC	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.46	8.81	0.43	6.43e-17	Testicular germ cell tumor;
LIHC	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg09904177	chr6:26538194	HMGN4	-0.37	-5.95	-0.31	6.82e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28830936	0.966	rs11635067	chr15:42124673	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.98	-0.31	5.75e-9	Diastolic blood pressure;
LIHC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.9	16.05	0.66	1.33e-43	Aortic root size;
LIHC	cis	rs6669384	0.774	rs12141901	chr1:208031234	G/A	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.91	-0.3	8.17e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs2257205	0.667	rs73996262	chr17:56784426	C/T	cg12560992	chr17:57184187	TRIM37	0.72	7.97	0.4	2.33e-14	Pancreatic cancer;
LIHC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.73	10.57	0.5	9.04e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.49	7.59	0.38	3.11e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.64	-7.51	-0.38	5.05e-13	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23634318	chr6:46097671	ENPP4	0.43	6.5	0.33	2.91e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg07599136	chr5:415885	AHRR	0.39	6.71	0.34	8.03e-11	Cystic fibrosis severity;
LIHC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.37	6.05	0.31	3.74e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06050784	chr16:88016603	BANP	0.39	6.64	0.34	1.2e-10	Menopause (age at onset);
LIHC	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.54	6.66	0.34	1.07e-10	QRS duration;
LIHC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.72	12.32	0.55	4.18e-29	Menopause (age at onset);
LIHC	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.53	8.62	0.42	2.44e-16	Blood protein levels;
LIHC	cis	rs600806	0.854	rs11102974	chr1:109886371	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.57	-6.87	-0.35	3.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg19635926	chr16:89946313	TCF25	0.49	6.38	0.33	5.81e-10	Skin colour saturation;
LIHC	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.39	7.78	0.39	8.43e-14	Obesity (extreme);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14564021	chr9:26892069	C9orf82	0.47	6.16	0.32	2.03e-9	Pancreatic cancer;
LIHC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.44	-7.29	-0.37	2.22e-12	Fibrinogen levels;
LIHC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21467203	chr3:49911342	NA	-0.41	-7.02	-0.36	1.17e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg11783602	chr8:55087084	NA	-0.33	-6.49	-0.33	2.95e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.53	7.99	0.4	2.15e-14	High light scatter reticulocyte count;
LIHC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.94	-0.35	1.96e-11	Acylcarnitine levels;
LIHC	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg19338460	chr6:170058176	WDR27	-0.74	-8.42	-0.41	1.04e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg16070123	chr10:51489643	NA	-0.38	-6.07	-0.31	3.36e-9	Prostate-specific antigen levels;
LIHC	cis	rs526231	0.853	rs377192	chr5:102603554	C/T	cg05225461	chr5:102596755	C5orf30	0.38	5.89	0.3	9.25e-9	Primary biliary cholangitis;
LIHC	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.48	7.99	0.4	2.14e-14	Schizophrenia;
LIHC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05025164	chr4:1340916	KIAA1530	-0.41	-6.24	-0.32	1.32e-9	Obesity-related traits;
LIHC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg20283391	chr11:68216788	NA	-0.38	-6.11	-0.31	2.73e-9	Total body bone mineral density;
LIHC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	6.77	0.34	5.55e-11	Menopause (age at onset);
LIHC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.26	-6.78	-0.34	5.43e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.25	-0.36	2.89e-12	Diabetic kidney disease;
LIHC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg16797656	chr11:68205561	LRP5	0.51	8.04	0.4	1.47e-14	Total body bone mineral density;
LIHC	cis	rs887797	0.557	rs8072699	chr17:64592569	T/C	cg27019712	chr17:64599478	PRKCA	-0.4	-6.86	-0.35	3.22e-11	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs847649	0.842	rs7789252	chr7:102624227	C/A	cg18108683	chr7:102477205	FBXL13	-0.46	-7.15	-0.36	5.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	6.37	0.33	5.93e-10	Coronary artery disease;
LIHC	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.38	-0.33	5.7e-10	Metabolite levels;
LIHC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg23461800	chr14:103021989	NA	-0.45	-6.36	-0.33	6.56e-10	Platelet count;
LIHC	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg22951263	chr5:87985283	NA	-0.39	-6.84	-0.35	3.67e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.4	-0.33	5.02e-10	Blood metabolite levels;
LIHC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.24	0.61	1.91e-36	Chronic sinus infection;
LIHC	cis	rs4930561	0.714	rs7122250	chr11:67946472	T/C	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.75	-0.3	1.96e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LIHC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.87	12.19	0.55	1.3e-28	Diastolic blood pressure;
LIHC	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.63	9.32	0.45	1.52e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.48e-59	Height;
LIHC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg20607798	chr8:58055168	NA	0.68	7.61	0.38	2.64e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.7	13.76	0.6	1.4e-34	Menopause (age at onset);
LIHC	cis	rs7534824	0.543	rs61780299	chr1:101403471	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.67	0.38	1.78e-13	Refractive astigmatism;
LIHC	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg00475322	chr7:917719	C7orf20	0.56	8.8	0.43	6.73e-17	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.93	13.78	0.6	1.2e-34	Primary sclerosing cholangitis;
LIHC	cis	rs507080	0.733	rs7108144	chr11:118569694	G/A	cg04173919	chr11:118528438	PHLDB1	0.33	6.2	0.32	1.64e-9	Serum metabolite levels;
LIHC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg09990169	chr2:241835740	C2orf54	-0.71	-11.61	-0.53	1.74e-26	Urinary metabolites;
LIHC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.95	-14.74	-0.62	2.03e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg14146966	chr2:61757674	XPO1	0.46	7.94	0.39	2.91e-14	Tuberculosis;
LIHC	trans	rs6467710	0.590	rs1723108	chr7:137241511	T/C	cg04467748	chr15:79760772	KIAA1024	0.41	6.26	0.32	1.18e-9	AIDS progression;
LIHC	trans	rs7668874	0.779	rs7688382	chr4:116814100	T/C	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.49e-29	Menopause (age at onset);
LIHC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg02376097	chr19:46275166	DMPK	-0.44	-6.87	-0.35	2.98e-11	Coronary artery disease;
LIHC	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.44	-6.78	-0.34	5.21e-11	Neutrophil percentage of white cells;
LIHC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg14456004	chr13:21872349	NA	-1.09	-11.94	-0.54	1.05e-27	White matter hyperintensity burden;
LIHC	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg14146966	chr2:61757674	XPO1	0.47	8.06	0.4	1.31e-14	Tuberculosis;
LIHC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.91	-0.39	3.5e-14	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13610622	chr10:11504551	USP6NL	-0.48	-7.25	-0.36	2.8e-12	Lung function (FEV1/FVC);
LIHC	trans	rs9914544	0.505	rs59633160	chr17:18761396	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.51	-0.33	2.7e-10	Educational attainment (years of education);
LIHC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17507749	chr15:85114479	UBE2QP1	0.65	7.31	0.37	1.95e-12	Schizophrenia;
LIHC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-6.02	-0.31	4.49e-9	Colorectal cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18095720	chr14:50160168	KLHDC1	-0.52	-6.15	-0.32	2.14e-9	Systolic blood pressure;
LIHC	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-6.04	-0.31	3.95e-9	Coronary artery disease;
LIHC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.82	14.12	0.61	5.43e-36	Parkinson's disease;
LIHC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg18357526	chr6:26021779	HIST1H4A	0.61	8.56	0.42	3.79e-16	Blood metabolite levels;
LIHC	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg04610667	chr7:75704037	NA	0.35	6.31	0.32	8.48e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs61677309	0.638	rs58507982	chr11:118146510	C/T	cg06090739	chr11:118230722	UBE4A	0.32	6.04	0.31	3.98e-9	Lung cancer in ever smokers;
LIHC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.24	-0.52	3.77e-25	Chronic sinus infection;
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	7.49	0.38	5.86e-13	Schizophrenia;
LIHC	cis	rs867186	0.541	rs78449612	chr20:33457367	G/A	cg08999081	chr20:33150536	PIGU	0.64	5.82	0.3	1.38e-8	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.38	0.33	5.82e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.62	-8.8	-0.43	6.77e-17	Blood metabolite levels;
LIHC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.83	8.89	0.43	3.5e-17	Vitiligo;
LIHC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.52	-9.87	-0.47	2.2e-20	Mean corpuscular volume;
LIHC	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.47	6.44	0.33	4.16e-10	Alzheimer's disease biomarkers;
LIHC	cis	rs2467099	0.679	rs2608882	chr17:73934130	G/A	cg08125733	chr17:73851984	WBP2	0.46	5.85	0.3	1.12e-8	Systolic blood pressure;
LIHC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.7	-0.38	1.43e-13	Morning vs. evening chronotype;
LIHC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-11.02	-0.51	2.21e-24	Personality dimensions;
LIHC	cis	rs151997	0.962	rs27475	chr5:50180439	A/C	cg06027927	chr5:50259733	NA	0.57	7.59	0.38	3.09e-13	Callous-unemotional behaviour;
LIHC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.72	9.6	0.46	1.73e-19	Selective IgA deficiency;
LIHC	cis	rs116248771	0.739	rs76493374	chr3:158345639	G/A	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.77e-10	diarrhoeal disease at age 2;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05348982	chr12:81331012	MIR618;LIN7A	-0.39	-6.25	-0.32	1.24e-9	Pancreatic cancer;
LIHC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.47	-7.82	-0.39	6.79e-14	Menarche (age at onset);
LIHC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.88	0.47	2e-20	Platelet count;
LIHC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.71	10.56	0.5	9.29e-23	Aortic root size;
LIHC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.65	-11.65	-0.53	1.18e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	8.56	0.42	3.88e-16	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24400517	chr7:139876520	LOC100134229;JHDM1D	0.44	6.26	0.32	1.15e-9	Pancreatic cancer;
LIHC	cis	rs4407350	1.000	rs1475991	chr22:44923160	T/C	cg26276947	chr22:44892394	LDOC1L	0.33	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.29	0.45	1.84e-18	Bipolar disorder;
LIHC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.61	-0.65	7.33e-42	Headache;
LIHC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.06	-0.31	3.55e-9	Tonsillectomy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17258551	chr19:18077791	KCNN1	0.45	6.29	0.32	9.84e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.38	-5.88	-0.3	9.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.56	-9.15	-0.44	5.2e-18	Obesity-related traits;
LIHC	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.35	8.88	0.43	3.78e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg16226627	chr15:75307476	SCAMP5	0.49	8.6	0.42	2.93e-16	Lung cancer;
LIHC	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg08469215	chr1:156261351	TMEM79	0.37	5.89	0.3	9.45e-9	Tonsillectomy;
LIHC	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.72	10.29	0.49	8.22e-22	Diisocyanate-induced asthma;
LIHC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg24296786	chr1:45957014	TESK2	0.51	7.77	0.39	9.09e-14	Platelet count;
LIHC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.64	7.76	0.39	9.75e-14	Heart rate;
LIHC	cis	rs9768139	0.935	rs10434944	chr7:158116911	C/T	cg25566285	chr7:158114605	PTPRN2	-0.25	-7.47	-0.37	6.7e-13	Calcium levels;
LIHC	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.43	-7.29	-0.37	2.11e-12	Mean arterial pressure;
LIHC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.51	0.46	3.44e-19	Corneal astigmatism;
LIHC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.5	6.56	0.33	2.05e-10	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09070522	chr4:57774717	REST	0.43	6.17	0.32	1.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.33	-5.79	-0.3	1.58e-8	Sarcoidosis;
LIHC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.13	0.48	2.99e-21	Schizophrenia;
LIHC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg21531657	chr3:10005747	TMEM111	0.39	5.76	0.3	1.92e-8	Alzheimer's disease;
LIHC	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg25364880	chr3:44379878	C3orf23	0.6	8.55	0.42	4.24e-16	Depressive symptoms;
LIHC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.22	0.36	3.4e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.68	-8.78	-0.43	7.78e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.86	-0.39	5.13e-14	Response to antipsychotic treatment;
LIHC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	trans	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg10208301	chr11:6592745	DNHD1	0.45	6.45	0.33	3.73e-10	Coronary artery calcification;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg05734877	chr13:111299462	CARS2	0.44	6.22	0.32	1.42e-9	Alopecia areata;
LIHC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.02e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg07117364	chr1:16154769	NA	-0.38	-5.72	-0.3	2.37e-8	Dilated cardiomyopathy;
LIHC	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg27203090	chr3:33138513	GLB1;TMPPE	0.52	6.5	0.33	2.76e-10	Major depressive disorder;
LIHC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	7.13	0.36	6.06e-12	Obesity-related traits;
LIHC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg05941027	chr17:61774174	LIMD2	0.31	6.0	0.31	5.12e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.41	-5.93	-0.31	7.47e-9	Menopause (age at onset);
LIHC	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg02023728	chr11:77925099	USP35	-0.37	-6.44	-0.33	4.1e-10	Alzheimer's disease (survival time);
LIHC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.53	0.53	3.24e-26	Alzheimer's disease;
LIHC	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.7	10.71	0.5	2.76e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.35	6.69	0.34	9.22e-11	HDL cholesterol;
LIHC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.45	-0.53	6.66e-26	Total cholesterol levels;
LIHC	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg02269571	chr22:50332266	NA	-0.61	-8.43	-0.41	1.01e-15	Schizophrenia;
LIHC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.64	10.12	0.48	3.23e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg14779329	chr11:130786720	SNX19	0.39	5.95	0.31	6.72e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg06935464	chr4:38784597	TLR10	0.48	7.38	0.37	1.23e-12	Breast cancer;
LIHC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.06	-0.4	1.33e-14	Mood instability;
LIHC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.64	10.52	0.49	1.31e-22	Resting heart rate;
LIHC	cis	rs963731	0.649	rs297153	chr2:39326835	C/G	cg04010122	chr2:39346883	SOS1	-0.7	-6.25	-0.32	1.25e-9	Corticobasal degeneration;
LIHC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.86	-8.29	-0.41	2.63e-15	Plasma clusterin levels;
LIHC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.78	0.3	1.68e-8	Bladder cancer;
LIHC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00934597	chr7:893267	UNC84A	-0.63	-9.09	-0.44	8e-18	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg02702477	chr5:179499311	RNF130	1.02	13.41	0.59	2.94e-33	LDL cholesterol;
LIHC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.45	5.78	0.3	1.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.64	11.59	0.53	2.03e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.61	0.64	7.81e-42	Chronic sinus infection;
LIHC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg21231739	chr4:1642635	FAM53A	-0.37	-6.07	-0.31	3.49e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	8.68	0.43	1.59e-16	Platelet count;
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.5	8.37	0.41	1.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.61	0.34	1.46e-10	Bipolar disorder;
LIHC	trans	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.38	0.59	4.07e-33	Diabetic kidney disease;
LIHC	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.23	13.28	0.58	9.61e-33	Opioid sensitivity;
LIHC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	19.2	0.72	2.97e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.44	-6.13	-0.31	2.36e-9	QT interval;
LIHC	cis	rs6545883	0.859	rs7561672	chr2:61519094	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.78	0.3	1.69e-8	Tuberculosis;
LIHC	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.79	11.75	0.54	5.18e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-23.83	-0.79	1.15e-74	Myeloid white cell count;
LIHC	cis	rs8081395	0.805	rs1295927	chr17:57929535	A/G	cg13753209	chr17:57696993	CLTC	0.45	7.08	0.36	8.43e-12	White blood cell count;
LIHC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.94	0.54	1.07e-27	Motion sickness;
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg16822855	chr3:40428330	ENTPD3	0.34	6.28	0.32	1.05e-9	Renal cell carcinoma;
LIHC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.29	7.67	0.38	1.87e-13	Bipolar disorder;
LIHC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.67	-13.44	-0.59	2.27e-33	Pulse pressure;
LIHC	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.54	8.41	0.41	1.16e-15	HDL cholesterol;
LIHC	cis	rs9942416	0.559	rs7734618	chr5:75033762	A/T	cg19683494	chr5:74908142	NA	-0.56	-6.54	-0.33	2.26e-10	Age-related disease endophenotypes;
LIHC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg04166393	chr7:2884313	GNA12	0.45	5.72	0.3	2.3e-8	Height;
LIHC	cis	rs3106136	0.649	rs4699440	chr4:95306151	T/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.63	-0.46	1.43e-19	Response to antipsychotic treatment;
LIHC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.33	-5.84	-0.3	1.19e-8	Headache;
LIHC	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg07689907	chr11:61582574	FADS1	0.4	6.02	0.31	4.62e-9	Trans fatty acid levels;
LIHC	cis	rs600806	0.888	rs461200	chr1:109855404	G/A	cg23091122	chr1:110024289	SYPL2	-0.45	-5.9	-0.3	8.75e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.46	6.19	0.32	1.76e-9	Major depressive disorder;
LIHC	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg09795085	chr6:101329169	ASCC3	0.53	7.24	0.36	3.04e-12	Neuroticism;
LIHC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.74	9.11	0.44	6.83e-18	Gut microbiome composition (summer);
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.7	0.57	1.59e-30	Alzheimer's disease;
LIHC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.28	0.32	1.01e-9	Schizophrenia;
LIHC	cis	rs4699052	0.963	rs11943325	chr4:104178393	T/C	cg16532752	chr4:104119610	CENPE	-0.38	-6.07	-0.31	3.32e-9	Testicular germ cell tumor;
LIHC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.68	10.03	0.48	6.51e-21	Coronary artery disease;
LIHC	trans	rs4714291	1.000	rs1100103	chr6:40040424	T/C	cg02267698	chr19:7991119	CTXN1	0.39	6.31	0.32	8.56e-10	Strep throat;
LIHC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg03037974	chr15:76606532	NA	-0.84	-20.67	-0.75	3.69e-62	Blood metabolite levels;
LIHC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.93	8.8	0.43	6.73e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2834188	1.000	rs2096464	chr21:34686049	G/T	cg14352951	chr21:34696688	IFNAR1	-0.47	-6.46	-0.33	3.51e-10	Narcolepsy;
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.41	8.27	0.41	3.08e-15	Renal cell carcinoma;
LIHC	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg00852783	chr1:26633632	UBXN11	0.49	8.06	0.4	1.29e-14	Obesity-related traits;
LIHC	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	0.55	10.39	0.49	3.56e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.95	-0.31	6.62e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-7.05	-0.36	9.75e-12	Diabetic kidney disease;
LIHC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg02580895	chr19:2754563	NA	-0.46	-6.76	-0.34	6.09e-11	Total cholesterol levels;
LIHC	cis	rs867186	0.614	rs116707649	chr20:33424671	G/A	cg08999081	chr20:33150536	PIGU	0.63	5.94	0.31	6.97e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07631383	chr7:131012765	MKLN1	0.45	6.38	0.33	5.84e-10	Pancreatic cancer;
LIHC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg13628971	chr7:2884303	GNA12	0.51	6.8	0.34	4.75e-11	Height;
LIHC	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.86	8.61	0.42	2.72e-16	Height;
LIHC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg07706471	chr12:123319906	HIP1R	-0.55	-6.9	-0.35	2.55e-11	Schizophrenia;
LIHC	cis	rs2412488	1.000	rs1481824	chr4:54241402	C/T	cg22241045	chr4:54363911	LNX1	-0.46	-7.24	-0.36	2.98e-12	DNA methylation (variation);
LIHC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.35	7.33	0.37	1.7e-12	Cancer;
LIHC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.25	-5.87	-0.3	1.05e-8	Subjective well-being;
LIHC	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.39	5.92	0.3	7.98e-9	Diastolic blood pressure;
LIHC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.05	0.6	1.02e-35	Chronic sinus infection;
LIHC	cis	rs747782	0.583	rs11039300	chr11:47587062	G/A	cg20307385	chr11:47447363	PSMC3	0.59	7.04	0.36	1.08e-11	Intraocular pressure;
LIHC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.05	0.6	1.02e-35	Chronic sinus infection;
LIHC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.53	0.46	2.92e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.69	12.67	0.57	1.92e-30	Coronary artery disease;
LIHC	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.57	9.86	0.47	2.31e-20	Dupuytren's disease;
LIHC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.67	9.79	0.47	4.14e-20	Breast cancer;
LIHC	cis	rs611744	0.967	rs631031	chr8:109190032	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg16262614	chr3:133464971	TF	0.35	7.98	0.4	2.26e-14	Iron status biomarkers;
LIHC	cis	rs3770081	1.000	rs2241435	chr2:86360916	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.69	-7.52	-0.38	4.84e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg07134254	chr20:33865797	NA	-0.51	-6.24	-0.32	1.27e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg05110241	chr16:68378359	PRMT7	-0.59	-6.55	-0.33	2.06e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg18944383	chr4:111397179	ENPEP	-0.35	-8.15	-0.4	7.15e-15	Coronary artery disease;
LIHC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02290350	chr8:58132656	NA	0.39	7.94	0.39	2.95e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.43	8.99	0.44	1.75e-17	White blood cell count (basophil);
LIHC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-9.3	-0.45	1.74e-18	Dental caries;
LIHC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.69	0.43	1.56e-16	Initial pursuit acceleration;
LIHC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.09	0.4	1.02e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs1974653	0.781	rs175163	chr22:20113777	T/C	cg20152630	chr19:46405944	MYPOP	0.46	6.08	0.31	3.26e-9	Schizophrenia;
LIHC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.66	11.14	0.52	8.63e-25	Lymphocyte counts;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	trans	rs2270927	0.790	rs6874435	chr5:75574855	A/G	cg13563193	chr19:33072644	PDCD5	0.89	9.63	0.46	1.42e-19	Mean corpuscular volume;
LIHC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	7.08	0.36	8.06e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.22	5.97	0.31	6.03e-9	Calcium levels;
LIHC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.42	-7.28	-0.37	2.27e-12	Aortic root size;
LIHC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.21e-16	Schizophrenia;
LIHC	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.72	11.59	0.53	1.96e-26	White matter hyperintensity burden;
LIHC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg12373951	chr3:133503437	NA	0.43	7.19	0.36	4.11e-12	Iron status biomarkers;
LIHC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg08888203	chr3:10149979	C3orf24	0.51	6.11	0.31	2.77e-9	Alzheimer's disease;
LIHC	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.67	11.5	0.53	4.25e-26	Diisocyanate-induced asthma;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.36	-7.38	-0.37	1.25e-12	Renal cell carcinoma;
LIHC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg09592244	chr17:37024020	NA	0.41	6.99	0.35	1.46e-11	Height;
LIHC	trans	rs72960926	1.000	rs72950597	chr6:74921367	T/C	cg07247405	chr1:2484626	LOC115110	0.55	6.53	0.33	2.37e-10	Metabolite levels (MHPG);
LIHC	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.23	-0.45	2.99e-18	Type 2 diabetes;
LIHC	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.45	8.14	0.4	7.46e-15	Resting heart rate;
LIHC	cis	rs10416265	0.528	rs28654374	chr19:33613610	G/A	cg27124370	chr19:33622961	WDR88	0.49	6.84	0.35	3.74e-11	Bone properties (heel);
LIHC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg16736954	chr20:23401023	NAPB	0.73	8.63	0.42	2.36e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.44	8.08	0.4	1.1e-14	Prudent dietary pattern;
LIHC	cis	rs8056893	0.686	rs10775304	chr16:68411162	C/T	cg02226672	chr16:68398533	SMPD3	0.42	5.9	0.3	8.83e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.37	10.08	0.48	4.43e-21	Weight;
LIHC	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-6.02	-0.31	4.46e-9	Cognitive function;
LIHC	trans	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg09045935	chr12:6379348	NA	0.84	6.92	0.35	2.28e-11	Blood metabolite levels;
LIHC	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.55	8.25	0.41	3.57e-15	Body mass index;
LIHC	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.22	12.75	0.57	9.9e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg18769103	chr1:236445447	ERO1LB	0.4	6.47	0.33	3.41e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.61	-10.31	-0.49	6.75e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	trans	rs4356975	0.563	rs4535394	chr4:69988453	C/T	cg18043070	chr17:72199725	RPL38	0.4	6.14	0.32	2.35e-9	Obesity-related traits;
LIHC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.4	6.47	0.33	3.48e-10	Red blood cell count;
LIHC	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.85	8.38	0.41	1.35e-15	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.8	12.14	0.55	1.92e-28	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.66	-5.94	-0.31	6.85e-9	Menopause (age at onset);
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg02993280	chr1:107599747	PRMT6	-0.69	-11.16	-0.52	6.98e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9473924	0.505	rs7738924	chr6:50850600	C/T	cg14470998	chr6:50812995	TFAP2B	0.94	10.91	0.51	5.57e-24	Body mass index;
LIHC	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.41	6.55	0.33	2.17e-10	Mean corpuscular volume;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21747090	chr2:27597821	SNX17	-0.47	-7.16	-0.36	5.01e-12	Total body bone mineral density;
LIHC	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.64	7.26	0.37	2.61e-12	Lung cancer (smoking interaction);
LIHC	cis	rs3743266	0.507	rs62003261	chr15:60761489	T/C	cg22293140	chr15:60689852	ANXA2	-0.62	-5.85	-0.3	1.14e-8	Menarche (age at onset);
LIHC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-7.11	-0.36	6.98e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11212260	0.512	rs74650296	chr11:107131138	G/A	cg25435332	chr11:107328525	CWF19L2	0.75	7.21	0.36	3.66e-12	IgG glycosylation;
LIHC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.38	5.97	0.31	5.87e-9	Response to temozolomide;
LIHC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg14067834	chr17:29058358	SUZ12P	0.64	6.24	0.32	1.28e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.09	0.36	7.92e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg08345082	chr10:99160200	RRP12	-0.4	-6.64	-0.34	1.27e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg03735888	chr19:58951602	ZNF132	0.39	6.91	0.35	2.31e-11	Uric acid clearance;
LIHC	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.54	-7.81	-0.39	7.26e-14	Neuroticism;
LIHC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.56	9.87	0.47	2.2e-20	Alcohol dependence;
LIHC	trans	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	6.94	0.35	1.94e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.51	-8.64	-0.42	2.21e-16	White blood cell count;
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.51	-7.36	-0.37	1.37e-12	Lymphocyte counts;
LIHC	trans	rs6600671	1.000	rs10903161	chr1:121178741	A/T	cg09829573	chr1:144692074	NBPF9	-0.44	-8.06	-0.4	1.26e-14	Hip geometry;
LIHC	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg10932868	chr11:921992	NA	0.36	6.77	0.34	5.46e-11	Alzheimer's disease (late onset);
LIHC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs72627123	0.656	rs6574169	chr14:74637178	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.89	-8.51	-0.42	5.4e-16	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.31	-0.45	1.65e-18	Aortic root size;
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	8.27	0.41	3.11e-15	Lymphocyte counts;
LIHC	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.16	0.44	4.93e-18	Coffee consumption (cups per day);
LIHC	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.75	14.45	0.62	2.88e-37	Testicular germ cell tumor;
LIHC	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.75	0.3	1.98e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.58	8.46	0.42	7.67e-16	Emphysema distribution in smoking;
LIHC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg14580859	chr9:123691850	NA	0.39	6.76	0.34	5.9e-11	Rheumatoid arthritis;
LIHC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg07560587	chr16:88016574	BANP	-0.42	-6.6	-0.34	1.54e-10	Menopause (age at onset);
LIHC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.71	11.6	0.53	1.87e-26	Oral cavity cancer;
LIHC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg00204512	chr16:28754710	NA	-0.39	-6.69	-0.34	9.1e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.53	-9.91	-0.47	1.59e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.44	-6.77	-0.34	5.65e-11	Neutrophil percentage of white cells;
LIHC	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18921183	chr12:6602631	NCAPD2;MRPL51	-0.49	-6.26	-0.32	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs4700695	1.000	rs111340	chr5:65420285	C/A	cg21114390	chr5:65439923	SFRS12	-0.52	-7.03	-0.36	1.14e-11	Facial morphology (factor 19);
LIHC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg02527881	chr3:46936655	PTH1R	-0.32	-6.22	-0.32	1.42e-9	Colorectal cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg22156267	chr12:110152166	C12orf34	-0.49	-6.1	-0.31	2.79e-9	Systolic blood pressure;
LIHC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg11212589	chr17:38028394	ZPBP2	0.36	7.38	0.37	1.23e-12	Self-reported allergy;
LIHC	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.85	-0.3	1.14e-8	Inflammatory bowel disease;
LIHC	cis	rs12986413	0.624	rs3786970	chr19:2141150	C/G	cg09261902	chr19:2140048	AP3D1	0.39	6.63	0.34	1.32e-10	Height;
LIHC	cis	rs12744310	0.830	rs12045184	chr1:41799611	G/A	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs72627123	0.867	rs73301485	chr14:74468643	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.63	0.42	2.42e-16	Morning vs. evening chronotype;
LIHC	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.77	-13.07	-0.58	6.09e-32	Tonsillectomy;
LIHC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	24.75	0.8	3.3e-78	Chronic sinus infection;
LIHC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.97	-17.72	-0.69	2.61e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7707921	0.881	rs7733122	chr5:81351443	C/T	cg15871215	chr5:81402204	ATG10	-0.62	-5.98	-0.31	5.48e-9	Breast cancer;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg04025307	chr7:1156635	C7orf50	0.56	7.53	0.38	4.63e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg22633049	chr21:46681294	NA	-0.37	-6.46	-0.33	3.6e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17135955	chr4:83848031	LIN54	0.32	6.17	0.32	1.95e-9	Pancreatic cancer;
LIHC	cis	rs2191566	0.959	rs7255623	chr19:44510906	G/C	cg20607764	chr19:44506953	ZNF230	-0.45	-7.51	-0.38	5.32e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.42	-6.04	-0.31	4.11e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.5	8.05	0.4	1.38e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg01843034	chr6:37503916	NA	-0.47	-7.66	-0.38	1.92e-13	Cognitive performance;
LIHC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.65	10.56	0.5	9.71e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg14343924	chr8:8086146	FLJ10661	0.51	6.46	0.33	3.52e-10	Mood instability;
LIHC	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3823572	0.542	rs11767663	chr7:133630596	T/C	cg03336402	chr7:133662267	EXOC4	0.48	5.87	0.3	1.05e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg17687970	chr8:22462467	KIAA1967	-0.49	-6.63	-0.34	1.29e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.83	7.71	0.38	1.37e-13	Lymphocyte counts;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs7129556	0.520	rs7943055	chr11:77261051	C/T	cg03570279	chr11:77446074	RSF1	-0.35	-6.55	-0.33	2.09e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg19500275	chr17:80737654	TBCD	0.51	7.29	0.37	2.18e-12	Glycated hemoglobin levels;
LIHC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.84	0.35	3.73e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg17980119	chr2:219472607	PLCD4	-0.34	-5.75	-0.3	2e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.53	8.04	0.4	1.49e-14	P wave terminal force;
LIHC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg16479474	chr6:28041457	NA	0.47	6.96	0.35	1.73e-11	Parkinson's disease;
LIHC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.9	0.3	8.52e-9	Life satisfaction;
LIHC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.41	-0.37	1.01e-12	Body mass index;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.43	7.68	0.38	1.72e-13	Prudent dietary pattern;
LIHC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.5	-7.33	-0.37	1.64e-12	Total body bone mineral density;
LIHC	trans	rs2096176	0.530	rs35769796	chr10:26303714	C/A	cg01396774	chr2:218299024	DIRC3	-0.31	-6.2	-0.32	1.58e-9	Obesity-related traits;
LIHC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.5	7.83	0.39	6.02e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.85	-16.05	-0.66	1.38e-43	Coronary artery disease;
LIHC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.8	-0.3	1.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24412469	chr1:200590040	KIF14	0.47	6.78	0.34	5.45e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14154082	chr13:112174009	NA	0.3	6.39	0.33	5.52e-10	Menarche (age at onset);
LIHC	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg00129232	chr17:37814104	STARD3	-0.51	-9.35	-0.45	1.17e-18	Asthma;
LIHC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	1.04	15.96	0.65	3.03e-43	Breast cancer;
LIHC	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg24130564	chr14:104152367	KLC1	-0.6	-10.77	-0.5	1.8e-23	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	7.81e-23	Hypertriglyceridemia;
LIHC	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.38	7.94	0.39	2.96e-14	Sitting height ratio;
LIHC	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg02527881	chr3:46936655	PTH1R	-0.45	-8.83	-0.43	5.47e-17	Birth weight;
LIHC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg04013166	chr16:89971882	TCF25	0.47	6.02	0.31	4.48e-9	Skin colour saturation;
LIHC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg24209194	chr3:40518798	ZNF619	-0.54	-8.06	-0.4	1.26e-14	Renal cell carcinoma;
LIHC	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg14515779	chr1:101123966	NA	0.42	5.75	0.3	2.01e-8	Monocyte count;
LIHC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-16.2	-0.66	3.38e-44	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19791253	chr1:203595809	ATP2B4	0.44	6.37	0.33	6e-10	Pancreatic cancer;
LIHC	cis	rs4950322	0.600	rs11240014	chr1:146852395	G/A	cg25205988	chr1:146714368	CHD1L	-0.41	-5.95	-0.31	6.75e-9	Protein quantitative trait loci;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.58	0.56	4.49e-30	Prudent dietary pattern;
LIHC	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg20291162	chr17:40259547	DHX58	-0.42	-6.17	-0.32	1.89e-9	Fibrinogen levels;
LIHC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.72	0.3	2.27e-8	Schizophrenia;
LIHC	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	7.78	0.39	8.45e-14	Blood protein levels;
LIHC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	12.11	0.55	2.49e-28	Platelet count;
LIHC	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.65	8.85	0.43	4.76e-17	Initial pursuit acceleration;
LIHC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.46	-6.23	-0.32	1.34e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.48	7.04	0.36	1.04e-11	Weight;
LIHC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Paclitaxel-induced neuropathy;
LIHC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.39e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.93	9.49	0.46	3.97e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Urate levels;
LIHC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs2284553	0.516	rs2834208	chr21:34752763	G/T	cg14850771	chr21:34775459	IFNGR2	-0.44	-6.9	-0.35	2.55e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.18	0.36	4.48e-12	Diabetic kidney disease;
LIHC	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.64	0.42	2.27e-16	Corneal astigmatism;
LIHC	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.82	-0.35	4.07e-11	Metabolite levels;
LIHC	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	trans	rs900145	0.612	rs7114573	chr11:13323498	G/T	cg01218619	chr4:25090298	NA	0.29	6.08	0.31	3.29e-9	Menarche (age at onset);
LIHC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg09752223	chr19:15281200	NOTCH3	-0.38	-5.99	-0.31	5.32e-9	Pulse pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26385779	chr5:150137906	DCTN4	0.43	6.3	0.32	9.3e-10	Cognitive function;
LIHC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg16479474	chr6:28041457	NA	0.38	6.32	0.32	8.32e-10	Parkinson's disease;
LIHC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg00292662	chr22:38071168	LGALS1	0.64	10.06	0.48	4.92e-21	Fat distribution (HIV);
LIHC	cis	rs4908768	0.906	rs55860300	chr1:8596335	G/A	cg20416874	chr1:8611966	RERE	0.59	9.61	0.46	1.68e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.63	9.63	0.46	1.44e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg12863693	chr15:85201151	NMB	-0.4	-5.8	-0.3	1.47e-8	Schizophrenia;
LIHC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.97e-14	Body mass index;
LIHC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.48	6.07	0.31	3.39e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4684776	0.867	rs7625184	chr3:11333734	C/T	cg00170343	chr3:11313890	ATG7	0.49	6.9	0.35	2.59e-11	Small vessel stroke;
LIHC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.39	6.13	0.31	2.49e-9	Menopause (age at onset);
LIHC	trans	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.89e-11	Aortic root size;
LIHC	trans	rs2122469	0.793	rs76965656	chr8:20594376	A/G	cg20211604	chr17:11632341	DNAH9	0.55	6.24	0.32	1.28e-9	Serum tamsulosin hydrochloride concentration;
LIHC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14343924	chr8:8086146	FLJ10661	0.46	6.61	0.34	1.52e-10	Systolic blood pressure;
LIHC	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.42	7.58	0.38	3.37e-13	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
LIHC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.67	11.37	0.52	1.29e-25	Lymphocyte counts;
LIHC	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg06612196	chr6:6737390	NA	0.56	10.44	0.49	2.57e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg03934865	chr2:198174659	NA	0.55	8.42	0.41	1.07e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg03037974	chr15:76606532	NA	0.72	13.59	0.59	6.05e-34	Blood metabolite levels;
LIHC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.61	-9.36	-0.45	1.11e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.89	-0.3	9.3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.51	-7.21	-0.36	3.67e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.15	0.4	6.98e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.48	8.98	0.44	1.89e-17	Hemoglobin concentration;
LIHC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.48	7.45	0.37	7.7e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.48	-0.74	2.03e-61	Coronary artery disease;
LIHC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg10217327	chr6:118973057	C6orf204	0.69	7.04	0.36	1.03e-11	Diastolic blood pressure;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.25	0.37	2.79e-12	Height;
LIHC	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.4	0.33	5.15e-10	Lymphocyte counts;
LIHC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.58	-10.77	-0.5	1.67e-23	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.56	-7.31	-0.37	1.86e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.56	-7.35	-0.37	1.45e-12	Initial pursuit acceleration;
LIHC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.43	-6.44	-0.33	3.97e-10	Height;
LIHC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.63	8.9	0.43	3.21e-17	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.56	8.35	0.41	1.7e-15	Multiple sclerosis;
LIHC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.23e-15	Bladder cancer;
LIHC	trans	rs9641123	0.639	rs2677078	chr7:93257986	C/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.4	-0.33	5.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.53	0.49	1.23e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-0.76	-10.18	-0.48	2.03e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.86	0.63	6.84e-39	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.45	6.46	0.33	3.62e-10	Aortic root size;
LIHC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.36	-0.33	6.32e-10	Obesity-related traits;
LIHC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.55	-10.37	-0.49	4.28e-22	Sense of smell;
LIHC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.89	0.35	2.65e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg07817648	chr10:79422355	NA	-0.32	-6.48	-0.33	3.21e-10	Mortality in heart failure;
LIHC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.67	-11.3	-0.52	2.18e-25	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.56	0.56	5.28e-30	Menopause (age at onset);
LIHC	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.41	6.96	0.35	1.73e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.18	0.4	5.73e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.69	12.35	0.56	3.22e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.6	8.63	0.42	2.38e-16	Blood metabolite levels;
LIHC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg03934865	chr2:198174659	NA	-0.57	-9.33	-0.45	1.32e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg01843034	chr6:37503916	NA	-0.48	-8.27	-0.41	3.1e-15	Cognitive performance;
LIHC	cis	rs812925	0.502	rs2053750	chr2:61656273	T/A	cg14146966	chr2:61757674	XPO1	-0.38	-6.19	-0.32	1.75e-9	Immature fraction of reticulocytes;
LIHC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.41	8.25	0.41	3.45e-15	Cardiovascular disease risk factors;
LIHC	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.25	6.7	0.34	8.36e-11	Type 2 diabetes;
LIHC	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.84	0.3	1.22e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-12.01	-0.54	6.03e-28	Response to antipsychotic treatment;
LIHC	trans	rs6489882	0.836	rs7967461	chr12:113369759	G/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.39	0.45	8.39e-19	IgG glycosylation;
LIHC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.59	8.25	0.41	3.55e-15	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.69	-6.41	-0.33	4.77e-10	Breast cancer;
LIHC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg20933634	chr6:27740509	NA	0.48	6.42	0.33	4.64e-10	Parkinson's disease;
LIHC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.68	10.58	0.5	8.26e-23	Platelet count;
LIHC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.54	-7.85	-0.39	5.43e-14	Coronary artery disease;
LIHC	cis	rs7712401	0.686	rs154511	chr5:122195554	T/A	cg18764291	chr5:122110994	SNX2	0.33	5.76	0.3	1.89e-8	Mean platelet volume;
LIHC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.39	7.51	0.38	5.03e-13	Methadone dose in opioid dependence;
LIHC	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	5.74	0.3	2.14e-8	Lymphocyte counts;Red cell distribution width;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27543739	chr10:94334014	IDE	0.43	6.18	0.32	1.77e-9	Longevity;
LIHC	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.76	8.85	0.43	4.72e-17	Exhaled nitric oxide levels;
LIHC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg07661805	chr8:143867942	LY6D	-0.3	-6.56	-0.33	2e-10	Urinary tract infection frequency;
LIHC	trans	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg01596870	chr19:55963115	NA	-0.66	-9.4	-0.45	8.25e-19	Obesity-related traits;
LIHC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.49	-6.47	-0.33	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.77	-0.3	1.81e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs655641	1.000	rs527162	chr11:85715736	C/T	cg09030501	chr11:85779252	PICALM	-0.5	-5.95	-0.31	6.73e-9	Platelet count;
LIHC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.03	-0.48	6.19e-21	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06665941	chr21:34602869	IFNAR2	0.37	6.44	0.33	3.99e-10	Cognitive function;
LIHC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.4	0.52	9.54e-26	Colorectal cancer;
LIHC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.25	0.41	3.41e-15	Birth weight;
LIHC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg02297831	chr4:17616191	MED28	-0.41	-5.74	-0.3	2.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg23091122	chr1:110024289	SYPL2	-0.45	-5.96	-0.31	6.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.45	6.17	0.32	1.95e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.25	-0.41	3.36e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7944735	0.506	rs10742816	chr11:47606984	C/T	cg20307385	chr11:47447363	PSMC3	0.54	6.34	0.32	7.28e-10	Intraocular pressure;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.73	13.06	0.58	6.74e-32	Prudent dietary pattern;
LIHC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-6.65	-0.34	1.17e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	7.86	0.39	5e-14	Obesity-related traits;
LIHC	cis	rs1712517	0.771	rs7074749	chr10:105116056	C/T	cg05636881	chr10:105038444	INA	0.49	7.59	0.38	3e-13	Migraine;
LIHC	trans	rs800082	1.000	rs9882503	chr3:144321296	A/T	cg24215973	chr2:240111563	HDAC4	-0.5	-7.44	-0.37	8.47e-13	Smoking behavior;
LIHC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg00277334	chr10:82204260	NA	-0.55	-6.83	-0.35	3.86e-11	Post bronchodilator FEV1;
LIHC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	1.06	16.01	0.65	1.89e-43	Breast cancer;
LIHC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	1.01	19.29	0.72	1.22e-56	Breast cancer;
LIHC	cis	rs4788570	0.545	rs8044144	chr16:71783121	T/C	cg06353428	chr16:71660113	MARVELD3	1.36	14.64	0.62	5.27e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.8	-11.15	-0.52	7.48e-25	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-6.19	-0.32	1.74e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7551222	0.752	rs12138846	chr1:204556478	T/A	cg20240347	chr1:204465584	NA	-0.32	-6.58	-0.34	1.76e-10	Schizophrenia;
LIHC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg05044414	chr3:183734942	ABCC5	0.33	5.75	0.3	1.98e-8	Anterior chamber depth;
LIHC	cis	rs459482	0.508	rs461093	chr21:42800190	C/G	cg14166395	chr21:42792516	MX1	-0.46	-6.37	-0.33	5.95e-10	IgG glycosylation;
LIHC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.08	0.58	5.66e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4979906	1.000	rs11002249	chr10:79447228	C/T	cg07817648	chr10:79422355	NA	-0.28	-6.23	-0.32	1.34e-9	Mortality in heart failure;
LIHC	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.76	0.34	5.8e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	6.82	0.35	4.14e-11	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.32	-0.32	8.25e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.55	8.54	0.42	4.48e-16	Coronary artery disease;
LIHC	cis	rs2279817	0.820	rs12754031	chr1:18006619	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-7.84	-0.39	5.76e-14	Neuroticism;
LIHC	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	9.7e-13	Putamen volume;
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.64	-0.38	2.18e-13	Testicular germ cell tumor;
LIHC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.35	-5.95	-0.31	6.51e-9	IgG glycosylation;
LIHC	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.62	-0.38	2.56e-13	Prevalent atrial fibrillation;
LIHC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.61	8.83	0.43	5.48e-17	Aortic root size;
LIHC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg23262073	chr20:60523788	NA	-0.29	-6.24	-0.32	1.33e-9	Body mass index;
LIHC	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.84	8.58	0.42	3.43e-16	Body mass index;
LIHC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg15448220	chr1:150897856	SETDB1	-0.43	-6.45	-0.33	3.83e-10	Blood protein levels;
LIHC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.42	-6.56	-0.33	2.05e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.65	12.57	0.56	4.78e-30	High light scatter reticulocyte count;
LIHC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.67	11.54	0.53	3.1e-26	Psoriasis;
LIHC	cis	rs9942416	0.585	rs253407	chr5:74926778	A/G	cg19683494	chr5:74908142	NA	-0.47	-6.11	-0.31	2.74e-9	Age-related disease endophenotypes;
LIHC	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.42	-7.19	-0.36	4.16e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.5	-6.81	-0.35	4.42e-11	Type 2 diabetes;
LIHC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg12863693	chr15:85201151	NMB	0.45	6.18	0.32	1.86e-9	Schizophrenia;
LIHC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	10.57	0.5	8.43e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.71	-13.86	-0.6	5.64e-35	Height;
LIHC	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg18908981	chr3:43732200	ABHD5	0.46	6.73	0.34	6.96e-11	Blood metabolite levels;
LIHC	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs7165170	0.549	rs11073935	chr15:91099638	A/G	cg26821196	chr15:91095069	CRTC3	0.41	7.33	0.37	1.69e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs644148	0.679	rs2204119	chr19:44970975	T/C	cg15540054	chr19:45004280	ZNF180	-0.78	-10.72	-0.5	2.66e-23	Personality dimensions;
LIHC	trans	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-17.71	-0.69	3.01e-50	Height;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.63	7.96	0.4	2.64e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.11	0.31	2.79e-9	Menopause (age at onset);
LIHC	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.62	-10.12	-0.48	3.19e-21	Malaria;
LIHC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg14092571	chr14:90743983	NA	0.46	7.14	0.36	5.6e-12	Mortality in heart failure;
LIHC	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.53	9.34	0.45	1.3e-18	Total cholesterol levels;
LIHC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17428076	0.793	rs3770448	chr2:172692265	A/G	cg13550731	chr2:172543902	DYNC1I2	0.38	6.11	0.31	2.74e-9	Myopia;
LIHC	cis	rs1461503	0.900	rs7115852	chr11:122831830	G/A	cg25161029	chr11:122845972	NA	0.41	6.7	0.34	8.41e-11	Menarche (age at onset);
LIHC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg06627628	chr2:24431161	ITSN2	-0.6	-6.95	-0.35	1.9e-11	Lymphocyte counts;
LIHC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.97	19.64	0.73	5.11e-58	Birth weight;
LIHC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.72	-11.01	-0.51	2.52e-24	Aortic root size;
LIHC	cis	rs1403694	1.000	rs1403694	chr3:186439998	T/C	cg12454167	chr3:186435060	KNG1	0.29	7.17	0.36	4.62e-12	Blood protein levels;
LIHC	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.53	-8.61	-0.42	2.72e-16	Ulcerative colitis;
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg20607798	chr8:58055168	NA	0.63	7.96	0.4	2.62e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-9.05	-0.44	1.08e-17	Mean corpuscular volume;
LIHC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.66	6.49	0.33	2.98e-10	Body mass index;
LIHC	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.31	-5.8	-0.3	1.5e-8	IgG glycosylation;
LIHC	cis	rs2906856	0.848	rs3015001	chr12:68397373	C/G	cg15249341	chr12:68405565	NA	0.34	6.88	0.35	2.82e-11	Mosquito bite size;
LIHC	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.22	0.32	1.49e-9	Mean corpuscular volume;
LIHC	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg25356066	chr3:128598488	ACAD9	0.46	6.21	0.32	1.53e-9	IgG glycosylation;
LIHC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.52	9.03	0.44	1.31e-17	Total body bone mineral density;
LIHC	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.82	-0.3	1.35e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.17e-8	Aortic root size;
LIHC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.57	8.51	0.42	5.4e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.11	-0.36	6.8e-12	Hepatocellular carcinoma;
LIHC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.44	6.82	0.35	4.13e-11	Personality dimensions;
LIHC	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.38	0.37	1.23e-12	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg24927135	chr15:63449340	RPS27L	-0.48	-6.2	-0.32	1.58e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.44	7.37	0.37	1.26e-12	Crohn's disease;
LIHC	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.45	7.36	0.37	1.36e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7091068	0.574	rs10748610	chr10:95462235	C/G	cg20715218	chr10:95462985	C10orf4	0.6	6.56	0.33	1.94e-10	Urinary tract infection frequency;
LIHC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	0.85	7.64	0.38	2.25e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.69	-8.89	-0.43	3.45e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	9.22	0.45	3.16e-18	Platelet count;
LIHC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.71	0.67	3.15e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg00656387	chr3:40428638	ENTPD3	0.44	7.38	0.37	1.24e-12	Renal cell carcinoma;
LIHC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20135002	chr11:47629003	NA	-0.52	-8.81	-0.43	6.47e-17	Subjective well-being;
LIHC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10878977	0.586	rs6581892	chr12:69817077	C/T	cg17330252	chr12:69809627	NA	-0.37	-5.8	-0.3	1.47e-8	Colorectal cancer;
LIHC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-10.0	-0.48	7.89e-21	Parkinson's disease;
LIHC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.71	-5.81	-0.3	1.46e-8	Breast cancer;
LIHC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.4	6.5	0.33	2.86e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg00280220	chr17:61926910	NA	0.43	7.02	0.35	1.19e-11	Prudent dietary pattern;
LIHC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.43	0.33	4.19e-10	Cognitive test performance;
LIHC	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.26	6.49	0.33	2.93e-10	Obesity-related traits;
LIHC	cis	rs611744	0.967	rs682007	chr8:109210326	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs7534824	0.625	rs17610202	chr1:101429724	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.71	7.55	0.38	3.96e-13	Refractive astigmatism;
LIHC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.92	11.7	0.53	7.75e-27	Coronary artery disease;
LIHC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.61	-8.1	-0.4	9.74e-15	Vitamin D levels;
LIHC	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-7.2	-0.36	3.93e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02985541	chr2:219472218	PLCD4	0.41	6.71	0.34	8.16e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.31	0.58	7.7e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18030105	chr11:3396237	ZNF195	0.41	6.13	0.31	2.49e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	0.84	9.52	0.46	3.35e-19	Mitochondrial DNA levels;
LIHC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg11212589	chr17:38028394	ZPBP2	0.36	7.3	0.37	2.05e-12	Self-reported allergy;
LIHC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg10790698	chr19:18539756	SSBP4	0.34	7.05	0.36	1.03e-11	Breast cancer;
LIHC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.58	9.36	0.45	1.12e-18	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.77	0.34	5.47e-11	Diabetic kidney disease;
LIHC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.59	6.78	0.34	5.41e-11	Menarche (age at onset);
LIHC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.23	-0.32	1.35e-9	Schizophrenia;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.64	-8.55	-0.42	4.14e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.33	-0.37	1.64e-12	Lymphocyte counts;
LIHC	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg02344993	chr17:57696989	CLTC	0.68	11.01	0.51	2.42e-24	Hemoglobin concentration;
LIHC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.91	0.65	4.75e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg23254163	chr1:152506842	NA	0.23	5.86	0.3	1.11e-8	Hair morphology;
LIHC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg16822855	chr3:40428330	ENTPD3	0.33	6.13	0.31	2.46e-9	Renal cell carcinoma;
LIHC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg25024717	chr12:54324583	NA	-0.3	-5.91	-0.3	8.5e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.61	10.64	0.5	4.85e-23	Height;
LIHC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg12374095	chr12:54320830	NA	0.4	5.81	0.3	1.42e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.95	0.31	6.71e-9	Renal cell carcinoma;
LIHC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg12560992	chr17:57184187	TRIM37	0.55	7.61	0.38	2.73e-13	Cognitive test performance;
LIHC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg20302533	chr7:39170763	POU6F2	0.39	7.24	0.36	2.89e-12	IgG glycosylation;
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.32	-5.9	-0.3	8.81e-9	Aortic root size;
LIHC	cis	rs1075232	0.826	rs12437800	chr15:31671432	A/G	cg01030201	chr15:31746330	NA	-0.78	-6.11	-0.31	2.72e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	9.8	0.47	3.74e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg05501817	chr11:14380813	RRAS2	-0.44	-6.07	-0.31	3.46e-9	Sense of smell;
LIHC	cis	rs6565681	0.760	rs9901680	chr17:78378088	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.55	-7.8	-0.39	7.74e-14	Moyamoya disease;
LIHC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.74e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	11.89	0.54	1.54e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-8.98	-0.44	1.87e-17	Body mass index;
LIHC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.46	7.33	0.37	1.65e-12	Multiple sclerosis;
LIHC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.27	0.41	2.91e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27297192	chr10:134578999	INPP5A	0.57	7.89	0.39	4.07e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.44	-6.11	-0.31	2.74e-9	Initial pursuit acceleration;
LIHC	cis	rs67981189	0.552	rs8021824	chr14:71537238	C/G	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg23091122	chr1:110024289	SYPL2	-0.5	-6.38	-0.33	5.72e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.54	-7.65	-0.38	2.1e-13	Body mass index;
LIHC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.78	-13.63	-0.59	4.46e-34	Aortic root size;
LIHC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs7633770	0.643	rs11130102	chr3:46689567	G/C	cg11219411	chr3:46661640	NA	-0.36	-6.02	-0.31	4.44e-9	Coronary artery disease;
LIHC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.43	6.14	0.31	2.35e-9	Height;
LIHC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.34	5.96	0.31	6.12e-9	Platelet distribution width;
LIHC	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.81	0.35	4.41e-11	Intracranial aneurysm;
LIHC	cis	rs1983891	0.774	rs6935446	chr6:41514372	A/G	cg20194872	chr6:41519635	FOXP4	0.41	6.47	0.33	3.39e-10	Prostate cancer;
LIHC	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.61	-8.14	-0.4	7.39e-15	Coronary artery disease;
LIHC	cis	rs992157	0.764	rs2382827	chr2:219184387	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.15	0.48	2.48e-21	Colorectal cancer;
LIHC	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.58	0.5	8.27e-23	Hypertriglyceridemia;
LIHC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.46	-9.02	-0.44	1.39e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.27	-7.11	-0.36	6.9e-12	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19262334	chr18:74631861	ZNF236	0.46	6.05	0.31	3.89e-9	Hepatitis;
LIHC	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-8.01	-0.4	1.81e-14	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24272902	chr3:178867151	PIK3CA	-0.52	-6.13	-0.31	2.43e-9	Systolic blood pressure;
LIHC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-10.4	-0.49	3.54e-22	Chronic sinus infection;
LIHC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg03859395	chr2:55845619	SMEK2	-0.76	-12.8	-0.57	6.53e-31	Metabolic syndrome;
LIHC	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.58	-0.34	1.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg26939375	chr7:64535504	NA	-0.4	-6.37	-0.33	5.94e-10	Aortic root size;
LIHC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg13628971	chr7:2884303	GNA12	0.41	6.57	0.33	1.88e-10	Height;
LIHC	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.66	-0.34	1.12e-10	Metabolite levels;
LIHC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg06697600	chr4:7070879	GRPEL1	0.6	9.19	0.45	3.84e-18	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.38	5.93	0.31	7.25e-9	Lung cancer;
LIHC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.39	5.77	0.3	1.77e-8	Melanoma;
LIHC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.52	8.21	0.41	4.53e-15	Height;
LIHC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.31	-0.32	8.76e-10	Renal cell carcinoma;
LIHC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.79	12.25	0.55	7.15e-29	Motion sickness;
LIHC	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.51	-15.27	-0.64	1.73e-40	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.88	-12.23	-0.55	8.81e-29	Diastolic blood pressure;
LIHC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.0	0.44	1.55e-17	Resting heart rate;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11060661	chr22:24314208	DDT;DDTL	-0.48	-7.04	-0.36	1.07e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs6545883	0.860	rs777589	chr2:61425621	T/C	cg14146966	chr2:61757674	XPO1	0.44	7.22	0.36	3.34e-12	Tuberculosis;
LIHC	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.54	0.42	4.49e-16	Corneal astigmatism;
LIHC	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg03037974	chr15:76606532	NA	0.72	13.97	0.6	2.11e-35	Blood metabolite levels;
LIHC	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.3	-6.65	-0.34	1.15e-10	DNA methylation (variation);
LIHC	cis	rs13126513	0.708	rs1057613	chr4:100504985	G/A	cg05468953	chr4:100565104	NA	0.32	6.05	0.31	3.76e-9	Metabolite levels (MHPG);
LIHC	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.51	8.08	0.4	1.16e-14	Brugada syndrome;
LIHC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.84	-0.35	3.71e-11	Response to antipsychotic treatment;
LIHC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.46	-6.86	-0.35	3.33e-11	Aortic root size;
LIHC	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg08847533	chr14:75593920	NEK9	-0.51	-7.81	-0.39	6.84e-14	IgG glycosylation;
LIHC	cis	rs7757419	1.000	rs7773610	chr6:34435180	C/A	cg17518776	chr6:34434842	PACSIN1	-0.3	-6.1	-0.31	2.86e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
LIHC	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.74	0.34	6.72e-11	Height;
LIHC	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.66	0.34	1.1e-10	Dupuytren's disease;
LIHC	cis	rs11229555	0.645	rs11229443	chr11:58197188	G/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.49	-6.64	-0.34	1.21e-10	Mean platelet volume;
LIHC	cis	rs11997175	0.603	rs716584	chr8:33779748	C/G	ch.8.33884649F	chr8:33765107	NA	0.37	6.42	0.33	4.61e-10	Body mass index;
LIHC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	cis	rs8081395	0.707	rs1024637	chr17:58038893	C/T	cg02344993	chr17:57696989	CLTC	-0.35	-5.73	-0.3	2.23e-8	White blood cell count;
LIHC	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.37	-6.38	-0.33	5.79e-10	Menopause (age at onset);
LIHC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.92	0.47	1.54e-20	Platelet count;
LIHC	cis	rs11696739	0.583	rs2243602	chr20:1546742	T/A	cg15722679	chr20:1638393	SIRPG	-0.37	-7.29	-0.37	2.12e-12	Mean platelet volume;
LIHC	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.78	13.12	0.58	3.85e-32	Coronary artery disease;
LIHC	cis	rs11761441	0.602	rs6963983	chr7:93176	A/C	cg25149888	chr7:81075	NA	-0.26	-5.73	-0.3	2.25e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.43	7.85	0.39	5.24e-14	Electrocardiographic conduction measures;
LIHC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.11	-0.36	7.03e-12	Diabetic kidney disease;
LIHC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-13.55	-0.59	8.72e-34	Systemic lupus erythematosus;
LIHC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.34	-7.52	-0.38	4.97e-13	Type 2 diabetes;
LIHC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.79	0.47	4.2e-20	Morning vs. evening chronotype;
LIHC	trans	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg10756647	chr7:56101905	PSPH	1.12	17.16	0.68	4.55e-48	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06136555	chr12:112123888	ACAD10;BRAP	0.46	6.54	0.33	2.18e-10	Lung function (FEV1/FVC);
LIHC	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.99	12.64	0.56	2.51e-30	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.77	12.33	0.55	3.85e-29	Corneal astigmatism;
LIHC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	7.81	0.39	7.19e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.49	8.12	0.4	8.82e-15	Blood protein levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg14392066	chr9:130497359	TOR2A	-0.4	-6.06	-0.31	3.53e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.33	6.12	0.31	2.53e-9	Platelet count;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.59	0.62	7.89e-38	Prudent dietary pattern;
LIHC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg06363034	chr20:62225388	GMEB2	-0.45	-7.6	-0.38	2.8e-13	Glioblastoma;
LIHC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.62	10.55	0.5	1e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.56	9.57	0.46	2.3e-19	Colorectal cancer;
LIHC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.07	18.89	0.71	4.96e-55	Nonalcoholic fatty liver disease;
LIHC	cis	rs2607426	0.681	rs10420651	chr19:41235038	C/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.52	-6.2	-0.32	1.67e-9	Blood protein levels;
LIHC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg19318889	chr4:1322082	MAEA	0.46	7.62	0.38	2.57e-13	Obesity-related traits;
LIHC	cis	rs4478037	0.822	rs9817393	chr3:33117069	A/G	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.01	-0.35	1.32e-11	Major depressive disorder;
LIHC	cis	rs2274273	0.967	rs10137409	chr14:55611441	A/C	cg01864836	chr14:55583639	NA	-0.36	-6.12	-0.31	2.62e-9	Protein biomarker;
LIHC	trans	rs9528384	0.927	rs9645947	chr13:62229100	A/G	cg20705804	chr7:43590176	HECW1	0.55	6.1	0.31	2.82e-9	Verbal declarative memory;
LIHC	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg15208524	chr1:10270712	KIF1B	0.43	5.8	0.3	1.53e-8	Hepatocellular carcinoma;
LIHC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.56	6.21	0.32	1.57e-9	Axial length;
LIHC	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.48	-7.55	-0.38	3.87e-13	Pubertal anthropometrics;
LIHC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.14	-0.36	5.58e-12	Bipolar disorder;
LIHC	trans	rs13113518	0.812	rs12500686	chr4:56324089	A/G	cg15358633	chr12:38710606	ALG10B	0.43	6.09	0.31	2.99e-9	Height;
LIHC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.33	0.41	2.02e-15	Lung cancer in ever smokers;
LIHC	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.91	13.17	0.58	2.45e-32	Diastolic blood pressure;Systolic blood pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10118784	chr14:65209977	PLEKHG3	-0.39	-6.04	-0.31	4.08e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.75	-11.21	-0.52	4.72e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.26	-0.52	3.07e-25	Diastolic blood pressure;
LIHC	cis	rs6788895	1.000	rs1879420	chr3:150466564	A/G	cg09723797	chr3:150481914	SIAH2	0.76	9.89	0.47	1.83e-20	Breast cancer;
LIHC	cis	rs7103648	0.966	rs11500477	chr11:47409051	T/A	cg20307385	chr11:47447363	PSMC3	0.99	16.78	0.67	1.51e-46	Diastolic blood pressure;Systolic blood pressure;
LIHC	trans	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg26939375	chr7:64535504	NA	0.4	6.29	0.32	9.67e-10	Aortic root size;
LIHC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.43	-6.03	-0.31	4.26e-9	Initial pursuit acceleration;
LIHC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.37e-11	Red blood cell count;
LIHC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.39	6.59	0.34	1.65e-10	Schizophrenia;
LIHC	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg20435097	chr10:126320824	FAM53B	-0.45	-6.35	-0.32	6.75e-10	Cocaine dependence;
LIHC	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.66	11.21	0.52	4.84e-25	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.54	8.54	0.42	4.59e-16	Total body bone mineral density;
LIHC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.35	6.11	0.31	2.73e-9	Schizophrenia;
LIHC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21211367	chr2:162094118	NA	0.37	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg25828445	chr12:7781288	NA	0.44	6.85	0.35	3.39e-11	HDL cholesterol levels;
LIHC	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.06	-0.36	9.17e-12	Blood protein levels;
LIHC	cis	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg16589663	chr20:23618590	CST3	0.66	6.47	0.33	3.47e-10	Chronic kidney disease;
LIHC	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg15208524	chr1:10270712	KIF1B	0.44	6.37	0.33	6e-10	Hepatocellular carcinoma;
LIHC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07628178	chr2:157442412	GPD2	0.39	6.41	0.33	4.9e-10	Longevity;
LIHC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.47	6.74	0.34	6.8e-11	Diastolic blood pressure;
LIHC	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.29	5.91	0.3	8.49e-9	Lupus nephritis in systemic lupus erythematosus;
LIHC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs2412488	0.720	rs28459503	chr4:54310058	C/A	cg22241045	chr4:54363911	LNX1	-0.41	-6.58	-0.34	1.72e-10	DNA methylation (variation);
LIHC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.21	0.41	4.55e-15	Body mass index;
LIHC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.83	0.39	6.29e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.54	-10.05	-0.48	5.32e-21	Total body bone mineral density;
LIHC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-6.14	-0.32	2.31e-9	Type 2 diabetes;
LIHC	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.53	9.34	0.45	1.23e-18	Total cholesterol levels;
LIHC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.59	-0.38	3.16e-13	Electroencephalogram traits;
LIHC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.43	6.26	0.32	1.15e-9	Breast cancer;
LIHC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg25237894	chr2:233734115	C2orf82	0.35	6.43	0.33	4.23e-10	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	7.01	0.35	1.28e-11	Migraine;Coronary artery disease;
LIHC	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.11	-0.44	7.04e-18	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.46e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg11621586	chr10:70884670	VPS26A	0.84	12.94	0.57	1.92e-31	Left atrial antero-posterior diameter;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.7	10.96	0.51	3.8e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.76	8.71	0.43	1.35e-16	Cognitive test performance;
LIHC	cis	rs11630290	0.589	rs12324851	chr15:64163495	G/A	cg12036633	chr15:63758958	NA	0.57	6.21	0.32	1.55e-9	Iris characteristics;
LIHC	cis	rs11958404	0.546	rs10475647	chr5:157443489	A/G	cg05962755	chr5:157440814	NA	0.62	8.19	0.41	5.09e-15	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26398333	chr1:153895721	GATAD2B	0.41	6.35	0.32	6.75e-10	Cognitive function;
LIHC	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.78	12.09	0.55	2.98e-28	Gastritis;
LIHC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.17	-0.48	2.11e-21	Hemoglobin concentration;
LIHC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.81	-0.3	1.4e-8	Blood metabolite levels;
LIHC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg07451762	chr16:28383216	NA	0.33	6.13	0.31	2.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.55	11.26	0.52	3.12e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.68	-11.01	-0.51	2.54e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.64	9.61	0.46	1.58e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11822910	1.000	rs4477456	chr11:57197781	G/A	cg00522883	chr11:57194120	SLC43A3	0.71	8.61	0.42	2.74e-16	Platelet distribution width;
LIHC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg03959625	chr15:84868606	LOC388152	0.47	6.68	0.34	9.94e-11	Schizophrenia;
LIHC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.27	-0.32	1.11e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	6.22	0.32	1.43e-9	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00480142	chr12:96046743	NA	-0.4	-6.68	-0.34	9.55e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.41	-6.23	-0.32	1.37e-9	Lymphocyte counts;
LIHC	cis	rs7572733	0.576	rs4850441	chr2:198913413	A/G	cg10820045	chr2:198174542	NA	-0.4	-5.87	-0.3	1.01e-8	Dermatomyositis;
LIHC	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.76	0.54	4.62e-27	Eye color traits;
LIHC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.76	11.0	0.51	2.74e-24	Response to antineoplastic agents;
LIHC	trans	rs9650315	0.866	rs34495936	chr8:57196273	A/G	cg22946562	chr2:1880012	MYT1L	0.36	6.07	0.31	3.37e-9	Height;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	22.18	0.77	3.52e-68	Height;
LIHC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	11.09	0.51	1.23e-24	Lymphocyte percentage of white cells;
LIHC	trans	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.24e-10	Coronary artery calcification;
LIHC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg19318889	chr4:1322082	MAEA	0.48	6.71	0.34	7.86e-11	Obesity-related traits;
LIHC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.2	0.32	1.62e-9	Electroencephalogram traits;
LIHC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.17	-0.44	4.56e-18	Bipolar disorder;
LIHC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.31	-6.08	-0.31	3.25e-9	Colorectal cancer;
LIHC	cis	rs72653721	0.793	rs9468122	chr6:10965925	T/C	cg13562911	chr6:11044106	ELOVL2	0.49	7.02	0.35	1.24e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg22223119	chr13:99095684	FARP1	-0.64	-9.99	-0.48	8.59e-21	Obesity-related traits;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09656405	chr15:69745057	RPLP1	0.39	6.39	0.33	5.34e-10	Cognitive function;
LIHC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs244293	0.965	rs2787504	chr17:53178341	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.54	0.38	4.36e-13	Menarche (age at onset);
LIHC	cis	rs911119	0.913	rs6106685	chr20:23581612	A/C	cg16589663	chr20:23618590	CST3	0.67	7.15	0.36	5.25e-12	Chronic kidney disease;
LIHC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.6	8.26	0.41	3.15e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2336384	1.000	rs4846083	chr1:12045555	G/T	cg13216073	chr1:12042593	MFN2	0.38	5.81	0.3	1.47e-8	Platelet count;
LIHC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg15691649	chr6:25882328	NA	-0.52	-6.66	-0.34	1.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07305463	chr2:136567211	LCT	0.39	7.61	0.38	2.7e-13	Mosquito bite size;
LIHC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.32	-0.66	1.07e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.73	-10.72	-0.5	2.65e-23	Smoking behavior;
LIHC	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.55	0.5	1.07e-22	Colorectal cancer;
LIHC	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.46	-7.03	-0.36	1.15e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	0.39	6.15	0.32	2.2e-9	Coronary artery disease;
LIHC	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg16583315	chr14:65563665	MAX	-0.38	-7.87	-0.39	4.86e-14	Obesity-related traits;
LIHC	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.67	-0.38	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	1.03	20.21	0.74	2.58e-60	Breast cancer;
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05665937	chr4:1216051	CTBP1	0.39	6.19	0.32	1.7e-9	Obesity-related traits;
LIHC	cis	rs3731896	0.700	rs11903211	chr2:220193434	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.56	6.52	0.33	2.58e-10	Educational attainment;
LIHC	cis	rs11786130	1.000	rs10808565	chr8:129007412	C/T	cg01765152	chr8:129005526	PVT1	-0.3	-6.39	-0.33	5.32e-10	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs2834188	1.000	rs9982088	chr21:34686841	A/G	cg14352951	chr21:34696688	IFNAR1	0.49	6.73	0.34	7.17e-11	Narcolepsy;
LIHC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.88	11.21	0.52	4.85e-25	Coronary artery disease;
LIHC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.66	-12.98	-0.57	1.32e-31	Lymphocyte percentage of white cells;
LIHC	cis	rs7078219	0.505	rs11190140	chr10:101291593	T/C	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.08	-0.31	3.14e-9	Dental caries;
LIHC	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	9.43	0.45	6.32e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-9.28	-0.45	1.98e-18	Colorectal cancer;
LIHC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.41	-6.76	-0.34	5.94e-11	Facial morphology (factor 20);
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02711726	chr17:80685570	FN3KRP	-0.42	-7.79	-0.39	7.89e-14	Glycated hemoglobin levels;
LIHC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg07451762	chr16:28383216	NA	0.39	6.88	0.35	2.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.51	5.91	0.3	8.08e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.56	9.9	0.47	1.74e-20	Platelet distribution width;
LIHC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.48	8.07	0.4	1.18e-14	Response to temozolomide;
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg00656387	chr3:40428638	ENTPD3	0.48	8.05	0.4	1.36e-14	Renal cell carcinoma;
LIHC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.33	-0.37	1.67e-12	Response to antipsychotic treatment;
LIHC	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.58	7.5	0.38	5.47e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.84	-11.13	-0.52	9.14e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.61	9.67	0.46	1.05e-19	Multiple myeloma (IgH translocation);
LIHC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.28	0.41	2.77e-15	Morning vs. evening chronotype;
LIHC	trans	rs6058796	0.892	rs35103329	chr20:31238139	G/A	cg02600331	chr11:130417168	NA	0.38	7.5	0.38	5.53e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.23e-9	Menopause (age at onset);
LIHC	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg20991723	chr1:152506922	NA	0.59	10.49	0.49	1.6400000000000001e-22	Hair morphology;
LIHC	cis	rs611744	0.819	rs424012	chr8:109154652	A/G	cg21045802	chr8:109455806	TTC35	0.46	7.52	0.38	4.86e-13	Dupuytren's disease;
LIHC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg27432699	chr2:27873401	GPN1	-0.54	-7.82	-0.39	6.6e-14	Total body bone mineral density;
LIHC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.45	-7.35	-0.37	1.49e-12	Obesity-related traits;
LIHC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	11.94	0.54	1.05e-27	Cognitive test performance;
LIHC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.54	-8.37	-0.41	1.48e-15	Coronary artery disease;
LIHC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.06	16.87	0.67	6.8e-47	Dilated cardiomyopathy;
LIHC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.38	0.37	1.23e-12	Vitiligo;
LIHC	trans	rs8030605	0.704	rs72740592	chr15:56652811	A/T	cg01710580	chr16:598674	SOLH	-0.66	-6.07	-0.31	3.41e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg16011679	chr1:85725395	C1orf52	0.92	9.64	0.46	1.28e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg00292662	chr22:38071168	LGALS1	0.64	10.15	0.48	2.48e-21	Fat distribution (HIV);
LIHC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg12798992	chr6:167411361	FGFR1OP	0.48	7.06	0.36	9.47e-12	Crohn's disease;
LIHC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.9	-12.01	-0.54	5.83e-28	Cognitive function;
LIHC	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg27433088	chr4:174089019	GALNT7	0.41	6.95	0.35	1.86e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.75	10.77	0.5	1.68e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.47	7.4	0.37	1.07e-12	Cocaine dependence;
LIHC	cis	rs16828019	0.929	rs11209734	chr1:41698074	C/T	cg03387723	chr1:41708464	SCMH1	-0.44	-7.23	-0.36	3.16e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2637030	0.586	rs1552649	chr5:52870476	A/T	cg06476337	chr5:52856530	NDUFS4	0.42	6.59	0.34	1.7e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.21	0.48	1.55e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2637266	0.626	rs2583066	chr10:78555839	T/C	cg18941641	chr10:78392320	NA	0.3	6.46	0.33	3.58e-10	Pulmonary function;
LIHC	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.85	-13.54	-0.59	9.49e-34	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg27055842	chr21:33765028	C21orf119;URB1	-0.55	-6.25	-0.32	1.24e-9	Systolic blood pressure;
LIHC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00958927	chr1:175162553	KIAA0040	-0.39	-6.5	-0.33	2.83e-10	Alcohol dependence;
LIHC	cis	rs9649465	1.000	rs11765478	chr7:123362872	A/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.06	-0.4	1.25e-14	Migraine;
LIHC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.91	-0.3	8.19e-9	Schizophrenia;
LIHC	cis	rs7326068	0.524	rs9506531	chr13:21232983	C/T	cg27234864	chr13:21295941	IL17D	-0.38	-5.89	-0.3	9.48e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-9.61	-0.46	1.59e-19	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01002995	chr12:8185077	FOXJ2	-0.45	-6.41	-0.33	4.85e-10	Pancreatic cancer;
LIHC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg15744005	chr10:104629667	AS3MT	0.37	7.88	0.39	4.39e-14	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.49	9.18	0.44	4.31e-18	Urate levels in overweight individuals;
LIHC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.74	11.17	0.52	6.36e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.57	8.73	0.43	1.17e-16	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.79	-0.39	8.36e-14	Longevity;
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-6.09	-0.31	3.06e-9	Colorectal cancer;
LIHC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.56	11.38	0.52	1.13e-25	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.69	11.23	0.52	4.11e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg25894440	chr7:65020034	NA	-0.51	-5.85	-0.3	1.13e-8	Diabetic kidney disease;
LIHC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02034447	chr16:89574710	SPG7	0.49	7.39	0.37	1.14e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.6	-10.91	-0.51	5.62e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.39	-5.94	-0.31	6.89e-9	Prudent dietary pattern;
LIHC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.47	-0.37	6.74e-13	Hemoglobin concentration;
LIHC	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg20991723	chr1:152506922	NA	0.54	9.0	0.44	1.57e-17	Hair morphology;
LIHC	trans	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.2	0.32	1.64e-9	Ulcerative colitis;
LIHC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.53	-7.47	-0.37	6.66e-13	Body mass index;
LIHC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.52	7.33	0.37	1.71e-12	Height;
LIHC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.63	11.04	0.51	1.88e-24	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.11	-0.31	2.65e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	0.97	12.98	0.57	1.38e-31	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.77	0.54	4.4e-27	Motion sickness;
LIHC	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-5.93	-0.31	7.24e-9	Cognitive function;
LIHC	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	0.95	22.69	0.78	3.56e-70	Multiple myeloma;
LIHC	cis	rs35883536	1.000	rs11586051	chr1:101096240	A/T	cg14515779	chr1:101123966	NA	0.63	12.39	0.56	2.3e-29	Monocyte count;
LIHC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.95	14.37	0.61	5.73e-37	Sudden cardiac arrest;
LIHC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg25344623	chr2:136566232	LCT	0.41	7.63	0.38	2.31e-13	Mosquito bite size;
LIHC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.6	11.05	0.51	1.78e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.28	-7.05	-0.36	1.02e-11	Mean corpuscular volume;
LIHC	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.87	9.1	0.44	7.73e-18	Body mass index;
LIHC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.4	-0.49	3.54e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.08	-14.52	-0.62	1.57e-37	Diabetic kidney disease;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg22561889	chr6:118971681	C6orf204	0.55	5.79	0.3	1.6e-8	Diastolic blood pressure;
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21448741	chr8:58168803	NA	0.38	6.83	0.35	3.84e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.51	8.43	0.41	9.66e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.42	-5.74	-0.3	2.05e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.11	0.31	2.74e-9	Aortic root size;
LIHC	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.42	-6.46	-0.33	3.51e-10	Alzheimer's disease (survival time);
LIHC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.44	5.99	0.31	5.44e-9	Initial pursuit acceleration;
LIHC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.05	-0.31	3.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.5	8.68	0.42	1.61e-16	Glomerular filtration rate (creatinine);
LIHC	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.79	-0.39	8.19e-14	QT interval;
LIHC	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.57e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.33	0.49	6.11e-22	Colorectal cancer;
LIHC	cis	rs6545883	0.894	rs2593633	chr2:61571513	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.82	0.3	1.32e-8	Tuberculosis;
LIHC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.47	-7.56	-0.38	3.83e-13	Multiple myeloma;
LIHC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.61	-10.07	-0.48	4.66e-21	Post bronchodilator FEV1;
LIHC	cis	rs6920965	0.561	rs9401851	chr6:126181956	T/C	cg05901451	chr6:126070800	HEY2	-0.36	-6.19	-0.32	1.75e-9	High light scatter reticulocyte count;
LIHC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.83	0.43	5.38e-17	Schizophrenia;
LIHC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs74181299	0.684	rs1420184	chr2:65315880	G/C	cg05010058	chr2:65284262	CEP68	-0.4	-6.66	-0.34	1.13e-10	Pulse pressure;
LIHC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.51	-8.81	-0.43	6.18e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.52	7.23	0.36	3.13e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.88	-15.36	-0.64	7.22e-41	Aortic root size;
LIHC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.48	-17.96	-0.7	2.77e-51	Breast cancer;
LIHC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	11.02	0.51	2.24e-24	Lung cancer in ever smokers;
LIHC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.6	12.58	0.56	4.31e-30	Fat distribution (HIV);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02369015	chr19:2702924	GNG7	-0.53	-6.14	-0.32	2.31e-9	Systolic blood pressure;
LIHC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.15	-0.32	2.22e-9	Total body bone mineral density;
LIHC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.91	0.65	4.82e-43	White blood cell count;
LIHC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.76	10.77	0.5	1.79e-23	Cerebrospinal P-tau181p levels;
LIHC	cis	rs992157	0.730	rs2891078	chr2:219184432	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.15	0.48	2.48e-21	Colorectal cancer;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg14988396	chr8:25316392	CDCA2;KCTD9	-0.55	-6.49	-0.33	3.06e-10	Preeclampsia;
LIHC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs2108622	1.000	rs2108622	chr19:15990431	C/T	cg13772218	chr19:15982569	NA	0.39	8.34	0.41	1.85e-15	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	0.83	11.75	0.54	5.44e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.88	-0.3	9.77e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg14393609	chr7:65229607	NA	0.37	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.61	8.97	0.44	1.95e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs1198430	0.714	rs946265	chr1:23775296	T/G	cg13183780	chr1:23809682	ASAP3	-0.38	-6.44	-0.33	4.03e-10	Total cholesterol levels;
LIHC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.57	7.02	0.35	1.22e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.62	-8.73	-0.43	1.12e-16	Blood metabolite levels;
LIHC	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.66	0.42	1.83e-16	Exhaled nitric oxide output;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23752198	chr20:30311963	BCL2L1	-0.45	-6.15	-0.32	2.18e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg25356066	chr3:128598488	ACAD9	-0.54	-7.14	-0.36	5.75e-12	IgG glycosylation;
LIHC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02034447	chr16:89574710	SPG7	0.46	7.17	0.36	4.54e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs7731783	1	rs7731783	chr5:177060312	T/C	cg17398003	chr5:175665565	C5orf25	-0.37	-6.13	-0.31	2.47e-9	Methadone dose in opioid dependence;
LIHC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.96	10.36	0.49	4.51e-22	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.43	-8.16	-0.4	6.67e-15	Neurofibrillary tangles;
LIHC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.48	8.49	0.42	6.22e-16	IgG glycosylation;
LIHC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg18887096	chr2:219472410	PLCD4	0.36	6.53	0.33	2.35e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg10978503	chr1:24200527	CNR2	0.38	9.08	0.44	9.05e-18	Immature fraction of reticulocytes;
LIHC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.45	-9.09	-0.44	8.22e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21448741	chr8:58168803	NA	0.37	5.97	0.31	5.98e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.96	-10.46	-0.49	2.05e-22	Platelet distribution width;
LIHC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.64	-0.34	1.27e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.41	-5.86	-0.3	1.11e-8	Height;
LIHC	trans	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg16011800	chr17:1958478	HIC1	-0.52	-7.42	-0.37	9.6e-13	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.02	16.75	0.67	2.13e-46	Testicular germ cell tumor;
LIHC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18252515	chr7:66147081	NA	0.42	5.93	0.31	7.46e-9	Aortic root size;
LIHC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.49	-8.78	-0.43	7.8e-17	Colorectal cancer;
LIHC	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.6	7.68	0.38	1.66e-13	Crohn's disease;
LIHC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.66	-9.04	-0.44	1.19e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.55	9.33	0.45	1.35e-18	Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19504496	chr19:36119917	RBM42	0.47	7.19	0.36	4.17e-12	Cognitive function;
LIHC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.35	0.37	1.44e-12	Lung cancer;
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.14	0.32	2.31e-9	Renal cell carcinoma;
LIHC	cis	rs9322817	0.607	rs9404572	chr6:105149439	T/C	cg02098413	chr6:105308735	HACE1	-0.41	-8.06	-0.4	1.33e-14	Thyroid stimulating hormone;
LIHC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.55	8.24	0.41	3.6e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.43	-0.49	2.67e-22	Hemoglobin concentration;
LIHC	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.55	-7.79	-0.39	8.24e-14	Neuroticism;
LIHC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	1.02	19.51	0.73	1.6e-57	Breast cancer;
LIHC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.63	-8.32	-0.41	2.11e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-7.71	-0.38	1.35e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.31	-6.93	-0.35	2.13e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9625935	0.518	rs245008	chr22:30315736	T/C	cg01021169	chr22:30184971	ASCC2	-0.35	-6.14	-0.32	2.31e-9	Tonsillectomy;
LIHC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg08132940	chr7:1081526	C7orf50	-0.78	-6.48	-0.33	3.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-6.7	-0.34	8.49e-11	Fear of minor pain;
LIHC	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.54	-8.44	-0.42	9.02e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.5	7.14	0.36	5.49e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.71	6.85	0.35	3.46e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.14	-0.32	2.31e-9	Longevity;
LIHC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.53	8.61	0.42	2.63e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs244293	0.965	rs2787487	chr17:53209382	G/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.46	-6.64	-0.34	1.21e-10	Menarche (age at onset);
LIHC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-11.81	-0.54	3.2e-27	Colorectal cancer;
LIHC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	6.99	0.35	1.42e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs2834188	1.000	rs13050445	chr21:34703597	C/T	cg04842828	chr21:34696676	IFNAR1	-0.49	-6.32	-0.32	7.97e-10	Narcolepsy;
LIHC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg12160578	chr15:63334699	TPM1	-0.61	-8.78	-0.43	8.01e-17	Platelet count;
LIHC	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.99	-0.35	1.47e-11	Blood pressure;
LIHC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.1	0.58	4.56e-32	Chronic sinus infection;
LIHC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.15	-0.32	2.22e-9	Total body bone mineral density;
LIHC	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-0.84	-9.92	-0.47	1.47e-20	Alzheimer's disease (late onset);
LIHC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.61	-8.36	-0.41	1.64e-15	Sudden cardiac arrest;
LIHC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs12079745	0.793	rs12073439	chr1:169284482	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.66	-6.3	-0.32	9.31e-10	QT interval;
LIHC	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.04	21.51	0.76	1.59e-65	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.54	5.9	0.3	8.94e-9	Alzheimer's disease;
LIHC	cis	rs1434579	0.864	rs12978167	chr19:44942628	T/C	cg15540054	chr19:45004280	ZNF180	0.57	7.97	0.4	2.39e-14	Tuberculosis;
LIHC	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.29	-0.32	9.47e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs932541	1.000	rs6111152	chr20:16456088	A/G	cg17003395	chr20:16555519	KIF16B	0.42	5.78	0.3	1.65e-8	Intelligence;
LIHC	cis	rs4689642	0.709	rs35194996	chr4:7226477	G/C	cg21353189	chr4:7228343	SORCS2	0.37	6.19	0.32	1.71e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.63	9.33	0.45	1.33e-18	Lung cancer;
LIHC	cis	rs3753275	0.690	rs6577490	chr1:8549133	G/A	cg20416874	chr1:8611966	RERE	-0.47	-5.73	-0.3	2.25e-8	Educational attainment;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg10064575	chr17:40610771	ATP6V0A1	0.45	6.08	0.31	3.17e-9	Glycated hemoglobin levels;
LIHC	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.54	0.42	4.39e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg22528358	chr1:107598549	PRMT6	0.71	11.63	0.53	1.43e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-14.23	-0.61	2e-36	Refractive error;
LIHC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.59	0.42	3.1e-16	Birth weight;
LIHC	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.2	-0.36	3.82e-12	Response to antipsychotic treatment;
LIHC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23640757	chr6:7889014	TXNDC5	0.51	6.37	0.33	5.95e-10	Lung function (FEV1);
LIHC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.17	-0.44	4.58e-18	Hemoglobin concentration;
LIHC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.5e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6723226	0.708	rs2710627	chr2:32758627	A/G	cg02381751	chr2:32503542	YIPF4	0.73	11.03	0.51	2.06e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06818126	chr11:68850279	TPCN2	0.43	7.16	0.36	4.89e-12	Hair color;
LIHC	cis	rs4407350	0.721	rs131157	chr22:44891722	A/G	cg26276947	chr22:44892394	LDOC1L	0.32	6.1	0.31	2.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.14	-0.31	2.34e-9	Alzheimer's disease (late onset);
LIHC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.48	-7.49	-0.38	5.78e-13	Bone mineral density (spine);
LIHC	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.76	-12.55	-0.56	5.68e-30	Eosinophil percentage of white cells;
LIHC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.38	7.75	0.39	1.05e-13	Ewing sarcoma;
LIHC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.76	7.75	0.39	1.03e-13	Schizophrenia;
LIHC	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.87	11.09	0.51	1.25e-24	Coronary artery disease;
LIHC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg00792783	chr2:198669748	PLCL1	0.43	6.24	0.32	1.32e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-8.26	-0.41	3.29e-15	Schizophrenia;
LIHC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.48	-7.29	-0.37	2.24e-12	Tuberculosis;
LIHC	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.9	-0.3	8.65e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23477849	chr19:5698492	LONP1	0.44	6.49	0.33	3.07e-10	Longevity;
LIHC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.47	-7.65	-0.38	2.08e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.33	0.41	2.01e-15	Eotaxin levels;
LIHC	cis	rs672413	0.739	rs500390	chr5:78283656	C/T	cg26802063	chr5:78281964	ARSB	-0.39	-6.34	-0.32	7.35e-10	Blood and toenail selenium levels;Blood protein levels;
LIHC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg21466736	chr12:48725269	NA	0.33	5.92	0.3	7.87e-9	Plateletcrit;
LIHC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.14	-0.52	8.58e-25	Crohn's disease;
LIHC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.85	-0.39	5.44e-14	Type 2 diabetes;
LIHC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg20283391	chr11:68216788	NA	0.4	6.36	0.33	6.6e-10	Total body bone mineral density;
LIHC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.77	9.97	0.47	9.88e-21	Body mass index;
LIHC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.78	-12.11	-0.55	2.41e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12379764	chr21:47803548	PCNT	0.54	7.97	0.4	2.39e-14	Testicular germ cell tumor;
LIHC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.9	-0.3	8.63e-9	Menopause (age at onset);
LIHC	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg03037974	chr15:76606532	NA	-0.56	-9.36	-0.45	1.1e-18	Blood metabolite levels;
LIHC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg03785755	chr6:26196794	NA	0.52	5.95	0.31	6.49e-9	Gout;Renal underexcretion gout;
LIHC	trans	rs11782824	1.000	rs11782824	chr8:38781040	A/C	cg24305797	chr16:9185438	C16orf72	-0.45	-6.58	-0.34	1.78e-10	Neuroticism;
LIHC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.52	8.46	0.42	7.86e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg09222892	chr1:25734099	RHCE	-0.48	-8.9	-0.43	3.36e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.72	-9.32	-0.45	1.44e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.55	8.23	0.41	3.98e-15	Platelet distribution width;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.94	-0.63	3.49e-39	Longevity;
LIHC	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	0.91	10.02	0.48	7.06e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg05623727	chr3:50126028	RBM5	0.35	5.88	0.3	9.73e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-12.96	-0.57	1.55e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	16.27	0.66	1.73e-44	Lung cancer in ever smokers;
LIHC	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.46	-7.14	-0.36	5.81e-12	Type 2 diabetes;
LIHC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.64	5.96	0.31	6.31e-9	Menopause (age at onset);
LIHC	cis	rs7091068	0.616	rs7901507	chr10:95505424	C/G	cg20715218	chr10:95462985	C10orf4	0.56	5.85	0.3	1.12e-8	Urinary tract infection frequency;
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.82	16.82	0.67	1.14e-46	Prudent dietary pattern;
LIHC	cis	rs8084351	0.599	rs4940246	chr18:50717386	T/C	cg24270629	chr18:50823537	DCC	-0.44	-6.54	-0.33	2.29e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.38	6.07	0.31	3.37e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.57e-15	Bladder cancer;
LIHC	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.62	-9.88	-0.47	2.12e-20	Schizophrenia;
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.95	15.38	0.64	6.02e-41	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9322817	0.583	rs6571202	chr6:105182644	G/T	cg02098413	chr6:105308735	HACE1	-0.43	-7.72	-0.39	1.33e-13	Thyroid stimulating hormone;
LIHC	cis	rs4934494	0.727	rs12570750	chr10:91521030	G/A	cg19698084	chr10:91461284	KIF20B	-0.44	-5.88	-0.3	9.5e-9	Red blood cell count;
LIHC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	0.97	10.4	0.49	3.29e-22	Vitiligo;
LIHC	cis	rs526231	0.819	rs35803	chr5:102606942	A/G	cg05225461	chr5:102596755	C5orf30	0.38	5.85	0.3	1.16e-8	Primary biliary cholangitis;
LIHC	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg03934865	chr2:198174659	NA	0.51	7.67	0.38	1.83e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.59	-8.55	-0.42	4.27e-16	Bladder cancer;
LIHC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.5	8.35	0.41	1.78e-15	Mean corpuscular volume;
LIHC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.16	0.77	4.33e-68	Chronic sinus infection;
LIHC	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.52	9.0	0.44	1.56e-17	Coronary artery disease;
LIHC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.86	16.97	0.68	2.81e-47	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-7.37	-0.37	1.31e-12	Fear of minor pain;
LIHC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.63	7.94	0.39	2.86e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13198984	chr17:80129470	CCDC57	-0.33	-5.8	-0.3	1.54e-8	Life satisfaction;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.74	0.39	1.13e-13	Prudent dietary pattern;
LIHC	cis	rs1823913	0.927	rs13013390	chr2:192126727	A/G	cg12404831	chr2:192114017	MYO1B	0.32	6.59	0.34	1.62e-10	Obesity-related traits;
LIHC	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.48	-11.6	-0.53	1.86e-26	Diastolic blood pressure;
LIHC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg27432699	chr2:27873401	GPN1	-0.49	-6.8	-0.35	4.62e-11	Total body bone mineral density;
LIHC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.05	14.96	0.63	2.83e-39	Cognitive function;
LIHC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	9.36	0.45	1.1e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.56	-9.73	-0.47	6.71e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg12365402	chr11:9010492	NRIP3	-0.25	-6.3	-0.32	9.39e-10	Hemoglobin concentration;
LIHC	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.41	0.41	1.13e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg03805757	chr16:71968109	PKD1L3	-0.81	-7.9	-0.39	3.84e-14	Blood protein levels;
LIHC	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.84	0.35	3.61e-11	Height;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-11.8	-0.54	3.36e-27	Longevity;
LIHC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.77	15.19	0.63	3.32e-40	Mortality in heart failure;
LIHC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg23461800	chr14:103021989	NA	-0.44	-5.97	-0.31	5.95e-9	Platelet count;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg12544020	chr12:15941292	EPS8	0.36	6.06	0.31	3.64e-9	Calcium levels;
LIHC	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.66	13.22	0.58	1.65e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.62	0.34	1.39e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg13753209	chr17:57696993	CLTC	0.58	8.93	0.43	2.68e-17	Hemoglobin concentration;
LIHC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.72	-9.82	-0.47	3.29e-20	Asthma;
LIHC	trans	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.65	-0.34	1.16e-10	Educational attainment (years of education);
LIHC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.41	-5.8	-0.3	1.55e-8	Dental caries;
LIHC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.62	-8.77	-0.43	8.61e-17	Blood metabolite levels;
LIHC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06636551	chr8:101224915	SPAG1	0.49	9.27	0.45	2.12e-18	Atrioventricular conduction;
LIHC	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.78	10.17	0.48	2.15e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.8	13.17	0.58	2.5e-32	Coronary artery disease;
LIHC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.91	13.61	0.59	5.3e-34	Metabolic syndrome;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.53	6.78	0.34	5.4e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs882732	1.000	rs1005348	chr14:95033275	T/G	cg14866387	chr14:95027382	SERPINA4	-0.46	-6.83	-0.35	3.99e-11	Blood protein levels;
LIHC	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.69	-11.98	-0.54	7.7e-28	Height;
LIHC	cis	rs10259085	0.647	rs11767988	chr7:7264359	A/C	cg04827551	chr7:7268805	C1GALT1	0.33	6.16	0.32	2.06e-9	Multiple sclerosis (severity);
LIHC	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	0.65	6.51	0.33	2.69e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14154082	chr13:112174009	NA	0.3	6.39	0.33	5.52e-10	Menarche (age at onset);
LIHC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	0.82	11.52	0.53	3.71e-26	Skin colour saturation;
LIHC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.63	0.56	2.74e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg19676328	chr12:49525230	TUBA1B	-0.42	-6.06	-0.31	3.53e-9	Total cholesterol levels;
LIHC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	0.69	8.12	0.4	8.67e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.45	6.33	0.32	7.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.47e-9	Cognitive performance;
LIHC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.42	5.74	0.3	2.04e-8	HDL cholesterol;
LIHC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	1.05	14.05	0.6	1.05e-35	Heart rate;
LIHC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05665937	chr4:1216051	CTBP1	0.46	6.19	0.32	1.71e-9	Obesity-related traits;
LIHC	cis	rs4834770	1.000	rs4834770	chr4:120241849	A/G	cg09307838	chr4:120376055	NA	0.43	6.39	0.33	5.52e-10	Blood protein levels;
LIHC	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg12253828	chr6:101329408	ASCC3	-0.39	-6.02	-0.31	4.38e-9	Neuroticism;
LIHC	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg27209729	chr11:64428925	NRXN2	0.35	6.54	0.33	2.2e-10	Body mass index;Urate levels;
LIHC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.55	-0.38	3.95e-13	Monocyte percentage of white cells;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.73	13.9	0.6	3.81e-35	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.01	-0.31	4.69e-9	Blood pressure;
LIHC	cis	rs867186	0.614	rs76163454	chr20:33451706	G/A	cg08999081	chr20:33150536	PIGU	0.64	5.79	0.3	1.61e-8	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs4934494	0.813	rs34928397	chr10:91526599	T/G	cg19698084	chr10:91461284	KIF20B	-0.44	-5.83	-0.3	1.26e-8	Red blood cell count;
LIHC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.5	8.48	0.42	6.95e-16	Response to temozolomide;
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	8.82	0.43	6.07e-17	Multiple sclerosis;
LIHC	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.51	8.44	0.42	9.43e-16	Leprosy;
LIHC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.87	0.35	3.04e-11	Lung cancer in ever smokers;
LIHC	cis	rs116248771	0.793	rs73156465	chr3:158374535	C/G	cg16708174	chr3:158430962	RARRES1	0.48	6.38	0.33	5.61e-10	diarrhoeal disease at age 2;
LIHC	cis	rs9628987	0.500	rs11121179	chr1:8455712	G/T	cg20416874	chr1:8611966	RERE	0.49	5.82	0.3	1.36e-8	Breast cancer;
LIHC	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg16511985	chr3:153974050	SGEF	0.4	8.41	0.41	1.14e-15	Coronary artery disease;
LIHC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.53	-0.46	3.03e-19	Initial pursuit acceleration;
LIHC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.67	-0.38	1.81e-13	Morning vs. evening chronotype;
LIHC	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.44	-0.33	3.98e-10	Metabolite levels;
LIHC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.5	-0.38	5.7e-13	Aortic root size;
LIHC	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg21280719	chr6:42927975	GNMT	-0.32	-7.5	-0.38	5.65e-13	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg17385448	chr1:15911702	AGMAT	0.35	5.94	0.31	7.07e-9	Systolic blood pressure;
LIHC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.04e-8	Blood metabolite levels;
LIHC	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.71	-0.34	8.07e-11	Blood pressure;
LIHC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.43	-0.56	1.64e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	11.01	0.51	2.55e-24	Lung cancer in ever smokers;
LIHC	cis	rs17854409	0.764	rs12625513	chr20:61475661	G/A	cg05147244	chr20:61493195	TCFL5	1.3	10.44	0.49	2.5e-22	Obesity-related traits;
LIHC	cis	rs10792665	0.610	rs10751081	chr11:82560697	A/G	cg24227371	chr11:82718527	RAB30	-0.25	-6.04	-0.31	4.12e-9	Obesity-related traits;
LIHC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21545522	chr1:205238299	TMCC2	-0.32	-6.17	-0.32	1.89e-9	Red blood cell count;
LIHC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.6	-9.61	-0.46	1.7e-19	Childhood ear infection;
LIHC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.21	-0.32	1.52e-9	Mean corpuscular volume;
LIHC	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.86	15.56	0.64	1.14e-41	Body mass index;
LIHC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.69	10.12	0.48	3.01e-21	Height;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22135468	chr22:20104774	TRMT2A;RANBP1	0.47	6.04	0.31	4.04e-9	Hepatitis;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24441383	chr12:19459574	PLEKHA5	0.42	6.17	0.32	1.98e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg08800856	chr11:64428347	NRXN2	0.37	5.8	0.3	1.49e-8	Body mass index;Urate levels;
LIHC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg14440974	chr22:39074834	NA	-0.36	-6.12	-0.31	2.63e-9	Menopause (age at onset);
LIHC	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg03387723	chr1:41708464	SCMH1	-0.41	-6.7	-0.34	8.63e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.78	-8.09	-0.4	1.05e-14	Vitiligo;
LIHC	cis	rs757081	0.671	rs214072	chr11:17305270	C/T	cg15432903	chr11:17409602	KCNJ11	-0.45	-5.96	-0.31	6.28e-9	Systolic blood pressure;
LIHC	cis	rs17428076	0.793	rs72881938	chr2:172628752	C/G	cg13550731	chr2:172543902	DYNC1I2	0.4	6.6	0.34	1.55e-10	Myopia;
LIHC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.36	0.37	1.35e-12	Vitiligo;
LIHC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.08	14.26	0.61	1.61e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6673480	0.541	rs67377357	chr1:51498067	G/C	cg07174182	chr1:51127561	FAF1	-0.75	-8.71	-0.43	1.31e-16	IgE grass sensitization;
LIHC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.38	-0.37	1.25e-12	Body mass index;
LIHC	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.4	6.22	0.32	1.48e-9	Neutrophil percentage of white cells;
LIHC	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.62	11.84	0.54	2.52e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg01095510	chr12:26267286	NA	0.58	6.78	0.34	5.42e-11	Inflammatory bowel disease;
LIHC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	17.38	0.68	6.24e-49	Lung cancer in ever smokers;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03425217	chr10:27443402	YME1L1;MASTL	-0.45	-6.92	-0.35	2.25e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1400745	0.756	rs3783314	chr14:35337384	T/C	cg16230307	chr14:35515116	FAM177A1	0.38	6.2	0.32	1.63e-9	Monocyte count;
LIHC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.19	-0.36	4.08e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.8	-12.34	-0.56	3.33e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.16	0.32	2.04e-9	Diastolic blood pressure;
LIHC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.42	-6.16	-0.32	2.07e-9	Narcolepsy;
LIHC	trans	rs13381277	0.850	rs1110158	chr18:74330660	A/G	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.34	-0.32	7.27e-10	Dental caries;
LIHC	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.32	-5.98	-0.31	5.66e-9	Red blood cell count;
LIHC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.93	-16.03	-0.65	1.59e-43	Tonsillectomy;
LIHC	cis	rs9378688	0.654	rs2505677	chr6:2346248	T/A	cg12303981	chr6:2244766	GMDS	-0.45	-6.07	-0.31	3.43e-9	Caudate nucleus volume;
LIHC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg21395723	chr22:39101663	GTPBP1	0.39	6.64	0.34	1.24e-10	Menopause (age at onset);
LIHC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.56	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg00343986	chr7:65444356	GUSB	0.39	5.85	0.3	1.14e-8	Aortic root size;
LIHC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.48	-8.09	-0.4	1.02e-14	Lung cancer;
LIHC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.59	-0.34	1.63e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.47	-7.35	-0.37	1.45e-12	Psoriasis;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	21.96	0.76	2.7e-67	Height;
LIHC	cis	rs926392	0.932	rs6513588	chr20:37686281	T/C	cg16355469	chr20:37678765	NA	0.37	5.99	0.31	5.37e-9	Dialysis-related mortality;
LIHC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.7	10.66	0.5	4.09e-23	Coronary artery disease;
LIHC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs3729931	0.507	rs79945102	chr3:12711975	A/C	cg23032965	chr3:12705835	RAF1	0.6	6.63	0.34	1.34e-10	Cardiac hypertrophy;
LIHC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.37	-6.01	-0.31	4.67e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.65	-9.67	-0.46	1.01e-19	Systemic lupus erythematosus;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg12823748	chr12:62654080	USP15	0.45	6.75	0.34	6.44e-11	Calcium levels;
LIHC	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.55	8.26	0.41	3.16e-15	Body mass index;
LIHC	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.65	10.0	0.48	7.84e-21	Type 2 diabetes;
LIHC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.47	6.8	0.34	4.82e-11	Blood protein levels;
LIHC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg11057378	chr10:81107060	PPIF	0.37	5.98	0.31	5.64e-9	Height;
LIHC	trans	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg01596870	chr19:55963115	NA	-0.62	-8.17	-0.4	5.86e-15	Obesity-related traits;
LIHC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.84	11.39	0.52	1.05e-25	Blood metabolite levels;
LIHC	cis	rs67981189	0.574	rs2526880	chr14:71375338	C/T	cg15816911	chr14:71606274	NA	-0.42	-6.72	-0.34	7.45e-11	Schizophrenia;
LIHC	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg21452805	chr1:244014465	NA	0.46	6.13	0.31	2.4e-9	RR interval (heart rate);
LIHC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.74	0.34	6.57e-11	Cognitive ability;
LIHC	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg03647239	chr10:116582469	FAM160B1	-0.43	-5.99	-0.31	5.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.59	7.68	0.38	1.71e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6449957	0.577	rs7707370	chr5:67529747	T/C	cg23036683	chr5:67512108	NA	0.42	6.02	0.31	4.55e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg27205649	chr11:78285834	NARS2	0.39	5.79	0.3	1.57e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.9	0.6	4.02e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.66	12.55	0.56	5.72e-30	Height;
LIHC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.64	8.66	0.42	1.85e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.83	-0.3	1.3e-8	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.67	-11.24	-0.52	3.68e-25	Childhood ear infection;
LIHC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.85	-0.65	8.31e-43	Chronic sinus infection;
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg14222432	chr12:29376421	FAR2	0.36	6.87	0.35	3.11e-11	QT interval;
LIHC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.67	-10.46	-0.49	2.04e-22	Colorectal cancer;
LIHC	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.23	-0.32	1.34e-9	Coronary artery disease;
LIHC	cis	rs611744	0.846	rs405534	chr8:109154408	T/A	cg21045802	chr8:109455806	TTC35	0.49	8.21	0.41	4.58e-15	Dupuytren's disease;
LIHC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.58	10.32	0.49	6.53e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs539514	0.563	rs7983875	chr13:76329245	T/C	cg04757411	chr13:76259545	LMO7	-0.42	-7.01	-0.35	1.25e-11	Type 1 diabetes;
LIHC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg05535760	chr7:792225	HEATR2	-0.52	-7.0	-0.35	1.33e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.55	-9.5	-0.46	3.67e-19	Reticulocyte count;
LIHC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs1408224	0.688	rs866376	chr13:47230865	A/G	cg04092803	chr13:47240378	LRCH1	-0.43	-6.8	-0.35	4.65e-11	QRS complex (12-leadsum);
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.81	11.45	0.53	6.46e-26	Menarche (age at onset);
LIHC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.43	7.22	0.36	3.33e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07152487	chr11:14665355	PDE3B;PSMA1	0.45	6.23	0.32	1.34e-9	Lung function (FEV1/FVC);
LIHC	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.53	-8.15	-0.4	7.06e-15	Corneal astigmatism;
LIHC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.56	-7.76	-0.39	1e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20022216	chr4:39700309	UBE2K	0.45	6.33	0.32	7.88e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-7.19	-0.36	4.13e-12	Total body bone mineral density;
LIHC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.48	-7.02	-0.36	1.17e-11	Total body bone mineral density;
LIHC	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg24112000	chr20:60950667	NA	0.45	7.12	0.36	6.25e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.38	-0.56	2.41e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-13.44	-0.59	2.26e-33	Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.58	-0.34	1.75e-10	Gut microbiome composition (summer);
LIHC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.58	8.66	0.42	1.91e-16	Cognitive function;
LIHC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.99	-0.44	1.66e-17	Obesity-related traits;
LIHC	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg01557791	chr16:72042693	DHODH	-0.41	-6.92	-0.35	2.27e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.34	-0.52	1.68e-25	Type 2 diabetes;
LIHC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.62	0.34	1.38e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-5.8	-0.3	1.49e-8	Diastolic blood pressure;
LIHC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.77	12.62	0.56	3.11e-30	Fat distribution (HIV);
LIHC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg11812906	chr14:75593930	NEK9	-0.44	-7.11	-0.36	6.98e-12	IgG glycosylation;
LIHC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.13	0.61	5.14e-36	Chronic sinus infection;
LIHC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.6	12.59	0.56	4.09e-30	Fat distribution (HIV);
LIHC	cis	rs2997447	0.846	rs61775430	chr1:26411109	G/A	cg19633962	chr1:26362018	EXTL1	-0.7	-6.4	-0.33	5.06e-10	QRS complex (12-leadsum);
LIHC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	1.16	9.53	0.46	3.06e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg12064134	chr16:90016061	DEF8	-0.44	-5.96	-0.31	6.44e-9	Interleukin-17 levels;
LIHC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.74	-12.03	-0.55	5.06e-28	Breast cancer;
LIHC	trans	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg13698153	chr12:118541722	VSIG10	-0.65	-6.92	-0.35	2.24e-11	Vitiligo;
LIHC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.41e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	1.13	13.37	0.59	4.36e-33	Eosinophil percentage of granulocytes;
LIHC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.65	6.56	0.33	2.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg18898632	chr2:242989856	NA	-0.58	-7.83	-0.39	6.11e-14	Obesity-related traits;
LIHC	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg26692224	chr17:62915920	LRRC37A3	-0.69	-6.77	-0.34	5.62e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9918079	0.506	rs7696127	chr4:15642953	T/A	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.86	-0.3	1.09e-8	Obesity-related traits;
LIHC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.16	-0.36	4.93e-12	Body mass index;
LIHC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.43	7.36	0.37	1.34e-12	Crohn's disease;
LIHC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.55	9.05	0.44	1.06e-17	Obesity-related traits;
LIHC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.69	8.66	0.42	1.89e-16	Initial pursuit acceleration;
LIHC	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg06664874	chr5:179499304	RNF130	-0.58	-7.13	-0.36	5.93e-12	LDL cholesterol;
LIHC	cis	rs4728302	0.869	rs6966403	chr7:133614421	A/C	cg10665199	chr7:133106180	EXOC4	-0.37	-6.55	-0.33	2.11e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.9	-18.2	-0.7	3e-52	Bone mineral density;
LIHC	cis	rs6788895	1.000	rs73008903	chr3:150465053	C/T	cg09723797	chr3:150481914	SIAH2	0.87	12.1	0.55	2.6e-28	Breast cancer;
LIHC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.1	0.4	9.55e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg02297831	chr4:17616191	MED28	0.43	5.92	0.3	7.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg03945807	chr20:60948434	NA	-0.38	-6.9	-0.35	2.49e-11	Colorectal cancer;
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	0.53	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.65	-12.83	-0.57	4.77e-31	Sense of smell;
LIHC	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.46	7.43	0.37	8.87e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs17106184	1.000	rs76852824	chr1:51121526	T/C	cg07174182	chr1:51127561	FAF1	-0.73	-7.81	-0.39	7.23e-14	Type 2 diabetes;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg19500275	chr17:80737654	TBCD	0.52	7.61	0.38	2.73e-13	Glycated hemoglobin levels;
LIHC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg15123519	chr2:136567270	LCT	0.45	8.91	0.43	3.1e-17	Mosquito bite size;
LIHC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.69	-11.27	-0.52	2.87e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.95	-0.31	6.73e-9	Response to antipsychotic treatment;
LIHC	cis	rs2737618	0.680	rs2737686	chr1:200094347	C/T	cg21825944	chr1:200113062	NR5A2	-0.4	-6.49	-0.33	3.08e-10	Uric acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15356780	chr14:90422831	TDP1	0.45	6.2	0.32	1.59e-9	Pancreatic cancer;
LIHC	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg14146966	chr2:61757674	XPO1	-0.42	-6.89	-0.35	2.75e-11	Tuberculosis;
LIHC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.97	-0.44	2.03e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg12903224	chr12:29470962	FAR2	-0.41	-6.65	-0.34	1.14e-10	QT interval;
LIHC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.82	-8.76	-0.43	9.32e-17	Vitiligo;
LIHC	cis	rs4908768	0.657	rs12144099	chr1:8816175	G/A	cg20416874	chr1:8611966	RERE	0.45	6.47	0.33	3.37e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.84	-0.35	3.61e-11	Blood pressure;
LIHC	cis	rs59901009	0.871	rs12280624	chr11:10206666	T/G	cg01453529	chr11:10209919	SBF2	-0.35	-6.69	-0.34	9.37e-11	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.14	0.44	5.5e-18	Electroencephalogram traits;
LIHC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.3e-16	Motion sickness;
LIHC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg07134254	chr20:33865797	NA	0.52	6.24	0.32	1.3e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs10916814	0.632	rs6701759	chr1:20898400	G/T	cg24502330	chr1:20914028	CDA	-0.3	-6.63	-0.34	1.34e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8081395	0.899	rs2777898	chr17:57815608	G/C	cg13753209	chr17:57696993	CLTC	-0.48	-7.3	-0.37	2e-12	White blood cell count;
LIHC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.47	6.85	0.35	3.38e-11	Corneal structure;
LIHC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.75	-7.8	-0.39	7.39e-14	Vitiligo;
LIHC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.8	-0.3	1.53e-8	Systemic lupus erythematosus;
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.51	8.31	0.41	2.2e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.61e-14	Prudent dietary pattern;
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg12064134	chr16:90016061	DEF8	-0.44	-5.97	-0.31	5.99e-9	Skin colour saturation;
LIHC	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.46	6.07	0.31	3.48e-9	Obesity-related traits;
LIHC	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.31	5.76	0.3	1.92e-8	Systemic lupus erythematosus;
LIHC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-13.77	-0.6	1.21e-34	Headache;
LIHC	cis	rs12744310	0.887	rs36040148	chr1:41801448	T/C	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.42	-6.75	-0.34	6.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.25e-16	Schizophrenia;
LIHC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.49	-7.61	-0.38	2.71e-13	Diastolic blood pressure;
LIHC	cis	rs8084351	0.599	rs12454839	chr18:50678200	A/G	cg24270629	chr18:50823537	DCC	-0.44	-6.67	-0.34	1.05e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-9.08	-0.44	8.53e-18	Chronic sinus infection;
LIHC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.5	-0.49	1.55e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.32	-0.32	8.08e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03104356	chr8:30013879	DCTN6	-0.53	-6.18	-0.32	1.8e-9	Systolic blood pressure;
LIHC	cis	rs4794202	0.534	rs6503875	chr17:45915395	T/C	cg10638573	chr17:45915098	SCRN2	0.58	5.84	0.3	1.22e-8	Alzheimer's disease (cognitive decline);
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg26338869	chr17:61819248	STRADA	0.52	6.81	0.35	4.41e-11	Height;
LIHC	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.06	-0.55	3.78e-28	Coffee consumption (cups per day);
LIHC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg19635926	chr16:89946313	TCF25	0.49	6.89	0.35	2.67e-11	Skin colour saturation;
LIHC	trans	rs78049276	0.688	rs61075980	chr4:148374767	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.61	-0.38	2.72e-13	Pulse pressure;
LIHC	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg22951263	chr5:87985283	NA	-0.41	-7.21	-0.36	3.69e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.95	14.46	0.62	2.57e-37	IgG glycosylation;
LIHC	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.69	7.93	0.39	3.21e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-10.34	-0.49	5.63e-22	Asthma;
LIHC	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg06935464	chr4:38784597	TLR10	0.44	6.79	0.34	4.93e-11	Breast cancer;
LIHC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	8.05	0.4	1.38e-14	Response to antipsychotic treatment;
LIHC	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.21	-0.32	1.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.53	7.85	0.39	5.49e-14	Type 2 diabetes;
LIHC	cis	rs77637988	0.553	rs10169629	chr2:48625044	G/T	cg15846641	chr2:48541264	FOXN2	0.53	7.11	0.36	6.65e-12	Joint mobility (Beighton score);
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg11861562	chr11:117069780	TAGLN	0.37	5.89	0.3	9.14e-9	Blood protein levels;
LIHC	cis	rs3770081	1.000	rs3770087	chr2:86267068	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-9.48	-0.46	4.51e-19	Facial emotion recognition (sad faces);
LIHC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.15e-9	Urate levels;
LIHC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.42	-10.0	-0.48	7.96e-21	Type 2 diabetes;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17652741	chr4:13629432	BOD1L	-0.55	-6.47	-0.33	3.4e-10	Systolic blood pressure;
LIHC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-8.44	-0.41	9.42e-16	Chronic sinus infection;
LIHC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg15691649	chr6:25882328	NA	0.49	7.33	0.37	1.62e-12	Blood metabolite levels;
LIHC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.47	-0.49	1.95e-22	Chronic sinus infection;
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08677398	chr8:58056175	NA	0.41	6.38	0.33	5.63e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.69	-8.46	-0.42	7.82e-16	Gut microbiome composition (summer);
LIHC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.41	-0.37	9.74e-13	Uric acid levels;
LIHC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.82	13.01	0.58	9.92e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg12798992	chr6:167411361	FGFR1OP	0.45	6.78	0.34	5.45e-11	Crohn's disease;
LIHC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.79	-0.3	1.61e-8	Extrinsic epigenetic age acceleration;
LIHC	trans	rs73389468	1	rs73389468	chr10:134295815	C/T	cg23567800	chr14:96064341	NA	-0.63	-6.06	-0.31	3.56e-9	Periodontitis (CDC/AAP);
LIHC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17554472	chr22:41940697	POLR3H	0.54	5.9	0.3	8.82e-9	Vitiligo;
LIHC	cis	rs11098699	0.848	rs4538492	chr4:124113609	A/G	cg09941581	chr4:124220074	SPATA5	0.31	5.77	0.3	1.82e-8	Mosquito bite size;
LIHC	cis	rs177542	1	rs177542	chr11:16922654	G/A	cg05701403	chr11:16947551	PLEKHA7	0.45	7.17	0.36	4.63e-12	Diastolic blood pressure;
LIHC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.31	-0.32	8.68e-10	Height;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00875911	chr4:1224246	CTBP1	0.45	6.34	0.32	7.46e-10	Bilirubin levels;
LIHC	cis	rs1144333	1.000	rs12078893	chr1:76370862	T/C	cg10523679	chr1:76189770	ACADM	0.45	6.52	0.33	2.58e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3740540	0.761	rs61870251	chr10:126284415	A/C	cg20435097	chr10:126320824	FAM53B	0.54	8.0	0.4	2e-14	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00938859	chr5:1591904	SDHAP3	0.57	7.07	0.36	8.57e-12	Breast cancer;
LIHC	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.36	-7.69	-0.38	1.61e-13	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs4907240	0.961	rs12471390	chr2:97322958	C/T	cg26665480	chr2:98280029	ACTR1B	-0.41	-6.02	-0.31	4.52e-9	Event-related brain oscillations;
LIHC	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg09003973	chr2:102972529	NA	0.52	5.83	0.3	1.31e-8	Blood protein levels;
LIHC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.58	9.45	0.45	5.66e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg15691649	chr6:25882328	NA	-0.53	-7.62	-0.38	2.55e-13	Blood metabolite levels;
LIHC	cis	rs67981189	0.593	rs7147862	chr14:71438202	T/A	cg15816911	chr14:71606274	NA	-0.4	-6.44	-0.33	4.15e-10	Schizophrenia;
LIHC	cis	rs611744	0.806	rs2440387	chr8:109067078	A/G	cg21045802	chr8:109455806	TTC35	0.47	8.02	0.4	1.71e-14	Dupuytren's disease;
LIHC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg24209194	chr3:40518798	ZNF619	-0.48	-7.11	-0.36	6.88e-12	Renal cell carcinoma;
LIHC	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg16766828	chr3:128327626	NA	-0.43	-6.88	-0.35	2.93e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06634786	chr22:41940651	POLR3H	0.54	5.8	0.3	1.47e-8	Vitiligo;
LIHC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.48e-14	Aortic root size;
LIHC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-9.74	-0.47	6.27e-20	Gut microbiome composition (summer);
LIHC	cis	rs1355223	0.902	rs704744	chr11:34736561	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg07133347	chr1:107600762	PRMT6	0.44	6.71	0.34	8.09e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg14393609	chr7:65229607	NA	-0.37	-5.85	-0.3	1.18e-8	Aortic root size;
LIHC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.79	-8.66	-0.42	1.96e-16	Vitiligo;
LIHC	cis	rs7944735	0.508	rs9666924	chr11:47540007	C/T	cg20307385	chr11:47447363	PSMC3	0.59	6.96	0.35	1.75e-11	Intraocular pressure;
LIHC	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.1	-0.36	7.46e-12	Myopia (pathological);
LIHC	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.79	0.34	5.03e-11	Dermatomyositis;
LIHC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.78	10.21	0.48	1.54e-21	Body mass index;
LIHC	cis	rs2737618	0.674	rs2816973	chr1:200084743	C/G	cg21825944	chr1:200113062	NR5A2	0.41	7.1	0.36	7.35e-12	Uric acid levels;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	25.81	0.81	2.67e-82	Prudent dietary pattern;
LIHC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.66	-0.42	1.87e-16	Longevity;
LIHC	cis	rs2637266	0.756	rs2245335	chr10:78553265	T/C	cg18941641	chr10:78392320	NA	0.28	6.01	0.31	4.85e-9	Pulmonary function;
LIHC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07208322	chr5:177027175	B4GALT7	-0.45	-6.2	-0.32	1.6e-9	Pancreatic cancer;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg06951627	chr6:26196580	NA	0.55	6.43	0.33	4.39e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.05	0.51	1.77e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	6.52	0.33	2.46e-10	Axial length;
LIHC	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.9	11.15	0.52	7.54e-25	Coronary artery disease;
LIHC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.97	21.1	0.75	6.91e-64	Bone mineral density;
LIHC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	0.6	11.32	0.52	1.94e-25	Fat distribution (HIV);
LIHC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.7	10.33	0.49	6.04e-22	Prostate cancer;
LIHC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-9.45	-0.46	5.34e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	9.32	0.45	1.46e-18	Platelet count;
LIHC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.43	-9.22	-0.45	3.04e-18	Rheumatoid arthritis;
LIHC	cis	rs888194	0.738	rs2241213	chr12:109938857	A/G	cg05360138	chr12:110035743	NA	0.4	5.74	0.3	2.07e-8	Neuroticism;
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.39	-6.67	-0.34	1.06e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs7937890	0.559	rs6486193	chr11:14437607	C/G	cg12999362	chr7:75947528	NA	-0.39	-6.88	-0.35	2.79e-11	Mitochondrial DNA levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02667081	chr16:71880439	ATXN1L	0.48	6.93	0.35	2.12e-11	Pancreatic cancer;
LIHC	cis	rs12493885	0.818	rs73158489	chr3:153757862	C/T	cg10247383	chr3:153839028	SGEF	0.61	5.78	0.3	1.65e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs10916814	0.632	rs7545313	chr1:20902728	C/T	cg24502330	chr1:20914028	CDA	-0.31	-6.81	-0.35	4.35e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	trans	rs3758911	0.765	rs687991	chr11:107320644	G/C	cg21068293	chr15:74496576	STRA6	-0.26	-6.05	-0.31	3.73e-9	Coronary artery disease;
LIHC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.94	17.6	0.69	7.83e-50	Breast cancer;
LIHC	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.41	-5.88	-0.3	9.87e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.57	-9.22	-0.45	3.2e-18	Lymphocyte counts;
LIHC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg12798992	chr6:167411361	FGFR1OP	0.43	6.73	0.34	7.25e-11	Primary biliary cholangitis;
LIHC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02034447	chr16:89574710	SPG7	0.49	7.48	0.38	6.24e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg02702477	chr5:179499311	RNF130	0.75	10.44	0.49	2.46e-22	LDL cholesterol;
LIHC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.78	-13.64	-0.59	4.13e-34	Aortic root size;
LIHC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-10.89	-0.51	6.57e-24	Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26072851	chr17:56296444	MKS1	0.47	6.2	0.32	1.65e-9	Lung function (FEV1/FVC);
LIHC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg05555928	chr11:63887634	MACROD1	-0.39	-6.48	-0.33	3.12e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg00204512	chr16:28754710	NA	0.36	6.12	0.31	2.5e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.48	-6.42	-0.33	4.64e-10	Body mass index;
LIHC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg20140201	chr2:241835670	C2orf54	-0.47	-6.45	-0.33	3.9e-10	Urinary metabolites;
LIHC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.24	-0.45	2.77e-18	Ulcerative colitis;
LIHC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.23	-0.36	3.21e-12	Schizophrenia;
LIHC	cis	rs12744310	0.887	rs12048805	chr1:41814276	G/A	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.84e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24950336	chr3:113464879	ATP6V1A;NAA50	0.45	6.03	0.31	4.15e-9	Lung function (FEV1/FVC);
LIHC	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.49	-0.33	2.94e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg18107078	chr1:162760321	HSD17B7	-0.42	-6.59	-0.34	1.66e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10508774	1.000	rs11008971	chr10:32835791	T/C	cg01819863	chr10:32635814	EPC1	0.65	6.06	0.31	3.66e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.5	8.43	0.41	9.56e-16	Obesity-related traits;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.77	11.48	0.53	5.13e-26	Menarche (age at onset);
LIHC	cis	rs7707921	0.646	rs226208	chr5:81603444	G/A	cg15871215	chr5:81402204	ATG10	0.64	7.69	0.38	1.5700000000000001e-13	Breast cancer;
LIHC	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg23533926	chr12:111358616	MYL2	0.31	6.05	0.31	3.88e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg05941027	chr17:61774174	LIMD2	0.31	6.34	0.32	7.07e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg16736954	chr20:23401023	NAPB	0.52	5.84	0.3	1.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-7.39	-0.37	1.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.72	0.39	1.27e-13	Bipolar disorder;
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	0.81	12.08	0.55	3.12e-28	Menarche (age at onset);
LIHC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-6.93	-0.35	2.11e-11	Type 2 diabetes;
LIHC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.72	-0.34	7.65e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.74	-0.43	1.08e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg10935138	chr17:73851978	WBP2	0.69	9.12	0.44	6.52e-18	Psoriasis;
LIHC	trans	rs494453	0.922	rs569504	chr1:112211777	A/G	cg13655586	chr7:111202389	IMMP2L	-0.45	-6.07	-0.31	3.49e-9	Osteoporosis-related phenotypes;
LIHC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-10.09	-0.48	3.92e-21	Platelet count;
LIHC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.47	6.72	0.34	7.75e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs17106184	0.551	rs4926859	chr1:50842123	A/T	cg07174182	chr1:51127561	FAF1	0.42	5.81	0.3	1.47e-8	Type 2 diabetes;
LIHC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.55	-9.2	-0.45	3.59e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02985541	chr2:219472218	PLCD4	0.36	6.3	0.32	9.04e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	cis	rs7674212	0.541	rs2720448	chr4:104030589	C/T	cg16532752	chr4:104119610	CENPE	-0.44	-6.89	-0.35	2.67e-11	Type 2 diabetes;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg02820958	chr19:7099040	NA	-0.49	-6.09	-0.31	2.98e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1144333	1.000	rs1586936	chr1:76366877	T/C	cg03433033	chr1:76189801	ACADM	0.54	8.06	0.4	1.26e-14	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.34	-0.49	5.55e-22	Mean corpuscular volume;
LIHC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg19635926	chr16:89946313	TCF25	0.49	6.24	0.32	1.28e-9	Skin colour saturation;
LIHC	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.72	11.74	0.54	5.55e-27	Oral cavity cancer;
LIHC	cis	rs888194	0.738	rs2241212	chr12:109939641	T/A	cg05360138	chr12:110035743	NA	0.41	5.71	0.3	2.41e-8	Neuroticism;
LIHC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg08668510	chr10:1095578	IDI1	0.65	6.32	0.32	8.19e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg01843034	chr6:37503916	NA	-0.46	-7.84	-0.39	5.95e-14	Cognitive performance;
LIHC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg12798992	chr6:167411361	FGFR1OP	0.45	6.75	0.34	6.53e-11	Crohn's disease;
LIHC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg09904177	chr6:26538194	HMGN4	0.5	7.05	0.36	1.02e-11	Small cell lung carcinoma;
LIHC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.47	7.5	0.38	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs887797	0.557	rs9900353	chr17:64575492	A/G	cg27019712	chr17:64599478	PRKCA	0.35	6.11	0.31	2.7e-9	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs963731	0.649	rs297141	chr2:39319382	T/C	cg04010122	chr2:39346883	SOS1	-0.68	-5.95	-0.31	6.6e-9	Corticobasal degeneration;
LIHC	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.67	10.48	0.49	1.76e-22	Obesity-related traits;
LIHC	cis	rs45544231	0.544	rs7193453	chr16:52565150	C/T	cg09051775	chr16:52580266	TOX3	-0.32	-5.88	-0.3	9.89e-9	Restless legs syndrome;
LIHC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.66	-0.53	1.09e-26	Platelet distribution width;
LIHC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.32	-6.72	-0.34	7.83e-11	Platelet distribution width;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.6	11.14	0.52	8.81e-25	Height;
LIHC	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.29	-6.81	-0.35	4.31e-11	Hip circumference;Waist circumference;
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02290350	chr8:58132656	NA	0.51	10.66	0.5	4.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg07424592	chr7:64974309	NA	-0.79	-9.39	-0.45	8.91e-19	Diabetic kidney disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21243150	chr15:40751171	BAHD1	0.49	6.05	0.31	3.87e-9	Systolic blood pressure;
LIHC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.99	-0.31	5.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg25952890	chr19:58913133	NA	0.7	7.64	0.38	2.23e-13	Mean platelet volume;
LIHC	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.71	10.28	0.49	9.07e-22	Selective IgA deficiency;
LIHC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.38	-9.6	-0.46	1.72e-19	Longevity;Endometriosis;
LIHC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.7	-0.38	1.45e-13	Tonsillectomy;
LIHC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg02269571	chr22:50332266	NA	-0.61	-8.66	-0.42	1.89e-16	Schizophrenia;
LIHC	cis	rs2274273	0.934	rs17740741	chr14:55762712	G/C	cg01864836	chr14:55583639	NA	-0.37	-6.46	-0.33	3.52e-10	Protein biomarker;
LIHC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.63	-9.63	-0.46	1.4e-19	Uric acid clearance;
LIHC	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01765077	chr12:122356316	WDR66	0.55	7.76	0.39	9.79e-14	Mean corpuscular volume;
LIHC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.88	-16.75	-0.67	2e-46	Coronary artery disease;
LIHC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	1.01	19.16	0.72	4.17e-56	Breast cancer;
LIHC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.68	0.34	9.43e-11	Bipolar disorder;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.24	0.81	4.27e-80	Prudent dietary pattern;
LIHC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.54	-0.59	9.67e-34	Vitiligo;
LIHC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.59	8.21	0.41	4.58e-15	Aortic root size;
LIHC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg10932868	chr11:921992	NA	0.39	7.38	0.37	1.23e-12	Alzheimer's disease (late onset);
LIHC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.62	10.08	0.48	4.3e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.46	-5.75	-0.3	1.95e-8	Coronary artery calcification;
LIHC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.47	6.26	0.32	1.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg17419623	chr1:186649559	PTGS2	-0.31	-6.11	-0.31	2.7e-9	Myopia;
LIHC	cis	rs9783347	0.961	rs12293544	chr11:18348581	T/C	cg15585147	chr11:18324498	HPS5	0.43	6.73	0.34	6.95e-11	Pancreatic cancer;
LIHC	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	trans	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg04882175	chr6:131122610	NA	-0.48	-6.05	-0.31	3.7e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.48	0.38	6.15e-13	Bipolar disorder;
LIHC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.83	-12.12	-0.55	2.31e-28	Blood metabolite levels;
LIHC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-7.33	-0.37	1.68e-12	Initial pursuit acceleration;
LIHC	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.42	6.09	0.31	3.04e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-7.8	-0.39	7.73e-14	Lymphocyte counts;
LIHC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	21.25	0.75	1.75e-64	Chronic sinus infection;
LIHC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.76	-0.57	9.05e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.49	-6.97	-0.35	1.65e-11	Lung cancer;
LIHC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.03e-26	Chronic sinus infection;
LIHC	cis	rs3853824	0.965	rs12103557	chr17:54908131	A/T	cg13675837	chr17:54910204	DGKE	0.42	5.91	0.3	8.42e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-11.11	-0.51	1.11e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.46	-6.81	-0.35	4.3e-11	Height;
LIHC	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.61	7.24	0.36	3.05e-12	Morning vs. evening chronotype;
LIHC	cis	rs11630290	0.592	rs1912049	chr15:64155606	G/T	cg12036633	chr15:63758958	NA	0.6	6.38	0.33	5.66e-10	Iris characteristics;
LIHC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs6752107	0.870	rs13418066	chr2:234145944	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.53	0.38	4.47e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.87	-0.3	1.04e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg16586182	chr3:47516702	SCAP	-0.54	-9.86	-0.47	2.43e-20	Colorectal cancer;
LIHC	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.75	13.22	0.58	1.69e-32	Eosinophil percentage of white cells;
LIHC	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.48	7.56	0.38	3.75e-13	Cocaine dependence;
LIHC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs370915	0.963	rs59452206	chr4:187816484	G/T	cg19519643	chr4:187840862	NA	-0.43	-6.9	-0.35	2.48e-11	Gout;
LIHC	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs11673344	0.864	rs7259513	chr19:37576704	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.17	-0.32	1.89e-9	Obesity-related traits;
LIHC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.1	12.74	0.57	1.04e-30	Vitiligo;
LIHC	cis	rs12986413	0.651	rs35751290	chr19:2139357	A/G	cg09261902	chr19:2140048	AP3D1	0.4	6.78	0.34	5.3e-11	Height;
LIHC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.53	10.74	0.5	2.25e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.52	0.42	5.08e-16	Menarche (age at onset);
LIHC	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.16	0.48	2.37e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02985541	chr2:219472218	PLCD4	-0.36	-6.3	-0.32	8.95e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7212590	0.748	rs55794618	chr17:57934337	G/C	cg10252138	chr17:58120427	NA	-0.62	-6.34	-0.32	7.42e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg20129853	chr10:51489980	NA	0.4	8.57	0.42	3.7e-16	Prostate-specific antigen levels;
LIHC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg27170947	chr2:26402098	FAM59B	-0.72	-8.67	-0.42	1.7e-16	Gut microbiome composition (summer);
LIHC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.41	-0.37	9.85e-13	Schizophrenia;
LIHC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.15e-11	Height;
LIHC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.44	7.1	0.36	7.46e-12	Total body bone mineral density;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg24441383	chr12:19459574	PLEKHA5	0.49	6.31	0.32	8.54e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	0.74	10.53	0.49	1.17e-22	Initial pursuit acceleration;
LIHC	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.87	-0.35	2.97e-11	Metabolite levels;
LIHC	cis	rs2016586	0.895	rs2899256	chr22:36114054	C/T	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	trans	rs528418	0.651	rs77580825	chr6:145543323	G/C	cg09173621	chr13:111773936	ARHGEF7	0.52	6.04	0.31	4.03e-9	Methadone dose in opioid dependence;
LIHC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.55	8.77	0.43	8.44e-17	Menarche (age at onset);
LIHC	cis	rs74233809	1.000	rs11191557	chr10:104864614	C/G	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg25182066	chr10:30743637	MAP3K8	0.69	9.78	0.47	4.32e-20	Itch intensity from mosquito bite;
LIHC	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.37e-9	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs3783890	1.000	rs11628538	chr14:93746562	G/A	cg02802420	chr16:69363236	PDF;COG8	0.32	6.22	0.32	1.44e-9	Body mass index;
LIHC	cis	rs74181299	0.784	rs2723082	chr2:65289623	C/T	cg05010058	chr2:65284262	CEP68	0.39	6.65	0.34	1.18e-10	Pulse pressure;
LIHC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.49	6.35	0.32	6.96e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.41	-6.41	-0.33	4.78e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1982963	0.572	rs61971551	chr14:52479975	C/G	cg10843707	chr14:52510701	NID2	0.39	5.81	0.3	1.47e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg01843034	chr6:37503916	NA	-0.48	-8.24	-0.41	3.59e-15	Cognitive performance;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.6	8.72	0.43	1.24e-16	Menarche (age at onset);
LIHC	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.56	-10.21	-0.48	1.49e-21	Urate levels in overweight individuals;
LIHC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.39	15.04	0.63	1.32e-39	Eosinophil percentage of granulocytes;
LIHC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.26	6.17	0.32	1.96e-9	Subjective well-being;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg04709771	chr16:646395	RAB40C	0.47	8.33	0.41	1.99e-15	Height;
LIHC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10508774	1.000	rs12414510	chr10:33041698	G/T	cg01819863	chr10:32635814	EPC1	0.62	5.72	0.3	2.27e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-8.43	-0.41	9.46e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.61	-0.38	2.7e-13	Homocysteine levels;
LIHC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.47	7.78	0.39	8.84e-14	Blood metabolite levels;
LIHC	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24579218	chr15:68104479	NA	0.34	5.78	0.3	1.72e-8	Restless legs syndrome;
LIHC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-8.93	-0.43	2.66e-17	Colorectal cancer;
LIHC	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.08	-0.36	8.32e-12	Inflammatory bowel disease;
LIHC	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg18081818	chr7:23246105	NA	-0.39	-5.75	-0.3	1.95e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg02931644	chr1:25747376	RHCE	0.34	7.54	0.38	4.27e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.51	7.34	0.37	1.62e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg25344623	chr2:136566232	LCT	-0.34	-6.72	-0.34	7.77e-11	Mosquito bite size;
LIHC	trans	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.67e-11	Aortic root size;
LIHC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg00204748	chr12:29376779	FAR2	0.38	6.76	0.34	5.89e-11	QT interval;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg16255150	chr14:73924775	NUMB	-0.88	-7.14	-0.36	5.53e-12	Mild influenza (H1N1) infection;
LIHC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.54	5.82	0.3	1.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.98	-0.31	5.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg04306507	chr14:55594613	LGALS3	0.32	6.22	0.32	1.46e-9	Protein biomarker;
LIHC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.71	10.3	0.49	7.86e-22	Selective IgA deficiency;
LIHC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.52	8.36	0.41	1.63e-15	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11355319	chr5:89825117	LYSMD3	0.45	6.38	0.33	5.8e-10	Pancreatic cancer;
LIHC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.71	-0.6	2.05e-34	Primary sclerosing cholangitis;
LIHC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.44	-6.74	-0.34	6.7e-11	Longevity;Endometriosis;
LIHC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05665937	chr4:1216051	CTBP1	0.46	6.09	0.31	3.11e-9	Obesity-related traits;
LIHC	cis	rs7224314	1.000	rs62085810	chr17:65372855	G/A	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.78	-0.3	1.65e-8	Diisocyanate-induced asthma;
LIHC	cis	rs2073300	1.000	rs6132629	chr20:23451251	G/A	cg12062639	chr20:23401060	NAPB	0.81	9.62	0.46	1.56e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24372485	chr19:2078331	MOBKL2A	0.41	6.06	0.31	3.62e-9	Longevity;
LIHC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs655641	1.000	rs488134	chr11:85701622	T/C	cg09030501	chr11:85779252	PICALM	-0.56	-6.47	-0.33	3.32e-10	Platelet count;
LIHC	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-6.34	-0.32	7.3e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.46	7.08	0.36	8.47e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.71	-8.14	-0.4	7.65e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs4342066	0.778	rs1870258	chr3:28390041	G/A	cg11103623	chr3:57235255	HESX1	-0.38	-6.13	-0.31	2.44e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17817600	0.866	rs7107455	chr11:85642444	C/T	cg03102841	chr11:85646010	NA	0.44	5.81	0.3	1.47e-8	Alzheimer's disease;
LIHC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg11764359	chr7:65958608	NA	0.57	5.82	0.3	1.39e-8	Diabetic kidney disease;
LIHC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.51	5.84	0.3	1.21e-8	Bladder cancer;
LIHC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg06565975	chr8:143823917	SLURP1	0.45	7.94	0.39	2.91e-14	Urinary tract infection frequency;
LIHC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.28	0.41	2.76e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.36	5.83	0.3	1.29e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19346786	chr7:2764209	NA	-0.42	-6.25	-0.32	1.22e-9	Height;
LIHC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.94	-0.44	2.53e-17	Bipolar disorder;
LIHC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.12e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.55	-6.29	-0.32	9.84e-10	Osteoarthritis;
LIHC	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	7.05	0.36	9.97e-12	Bipolar disorder;
LIHC	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg01092361	chr6:42185687	MRPS10	0.9	8.91	0.43	2.99e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.45	-7.32	-0.37	1.78e-12	Menarche (age at onset);
LIHC	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.5	-7.48	-0.38	6.12e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.68	13.05	0.58	7.41e-32	Systemic lupus erythematosus;
LIHC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.63	8.45	0.42	8.32e-16	Migraine;
LIHC	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	5.94	0.31	7.11e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.93	17.85	0.69	8.09e-51	Menopause (age at onset);
LIHC	cis	rs2257205	0.667	rs8080281	chr17:56938558	A/G	cg05425664	chr17:57184151	TRIM37	0.6	6.7	0.34	8.83e-11	Pancreatic cancer;
LIHC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.54	12.68	0.57	1.81e-30	HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.43	-0.45	6.23e-19	Bipolar disorder;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.45	6.0	0.31	4.93e-9	Obesity (extreme);
LIHC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.83	7.99	0.4	2.07e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-7.43	-0.37	8.51e-13	Migraine;Coronary artery disease;
LIHC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.89	13.73	0.6	1.82e-34	Vitamin D levels;
LIHC	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg20560298	chr2:73613845	ALMS1	0.36	5.82	0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.45	-9.09	-0.44	8.22e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg20607798	chr8:58055168	NA	0.49	6.22	0.32	1.48e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	5.89	0.3	9.48e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.12	-0.31	2.63e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.4	-5.86	-0.3	1.08e-8	Narcolepsy;
LIHC	cis	rs11951515	0.508	rs7705166	chr5:43587448	G/T	cg01983248	chr5:43482804	C5orf28	-0.37	-6.08	-0.31	3.26e-9	Metabolite levels  (X-11787);
LIHC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.65	0.42	1.99e-16	Motion sickness;
LIHC	trans	rs1349882	1.000	rs1349882	chr2:52949318	G/T	cg13127694	chr14:104656055	NA	0.32	6.07	0.31	3.33e-9	Asymmetrical dimethylarginine levels;
LIHC	trans	rs6489882	0.703	rs10774674	chr12:113361174	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.95e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs12808519	0.688	rs3740640	chr11:69587583	C/T	cg19831575	chr11:69590090	FGF4	-0.52	-7.4	-0.37	1.08e-12	Urate levels in overweight individuals;
LIHC	cis	rs7818688	0.697	rs10504939	chr8:95983354	C/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg18803079	chr1:64014643	EFCAB7;DLEU2L	0.44	6.09	0.31	3.07e-9	Myopia (pathological);
LIHC	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg08847533	chr14:75593920	NEK9	-0.35	-6.0	-0.31	5.02e-9	Caffeine consumption;
LIHC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.19	-0.36	4.24e-12	Schizophrenia;
LIHC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.56	0.53	2.57e-26	Tonsillectomy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13232119	chr14:69283484	NA	-0.48	-6.78	-0.34	5.23e-11	Systolic blood pressure;
LIHC	cis	rs490234	0.841	rs13291593	chr9:128228483	A/G	cg14078157	chr9:128172775	NA	-0.39	-6.63	-0.34	1.28e-10	Mean arterial pressure;
LIHC	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.46	6.8	0.34	4.79e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg27432699	chr2:27873401	GPN1	-0.54	-7.82	-0.39	6.44e-14	Total body bone mineral density;
LIHC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.35	7.6	0.38	2.82e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs2274273	0.773	rs10147765	chr14:55827826	G/A	cg01864836	chr14:55583639	NA	-0.38	-6.76	-0.34	6.02e-11	Protein biomarker;
LIHC	cis	rs17152411	0.895	rs7080330	chr10:126585673	A/G	cg07906193	chr10:126599966	NA	0.44	6.96	0.35	1.78e-11	Height;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.47	-0.37	6.89e-13	Total body bone mineral density;
LIHC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.8	0.3	1.47e-8	Bladder cancer;
LIHC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.95	-0.44	2.29e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	10.91	0.51	5.59e-24	Diisocyanate-induced asthma;
LIHC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg12798992	chr6:167411361	FGFR1OP	0.43	6.65	0.34	1.18e-10	Primary biliary cholangitis;
LIHC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.68	10.17	0.48	2.06e-21	Coronary artery disease;
LIHC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg25344623	chr2:136566232	LCT	0.45	9.02	0.44	1.42e-17	Cholesterol, total;
LIHC	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.83	15.0	0.63	1.88e-39	Adiposity;
LIHC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.75	13.68	0.59	2.85e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.69	-11.9	-0.54	1.47e-27	Height;
LIHC	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.53	-8.71	-0.43	1.31e-16	Fibroblast growth factor basic levels;
LIHC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.48	-7.26	-0.37	2.59e-12	Adiposity;
LIHC	cis	rs903552	0.866	rs11247296	chr15:102007919	T/C	cg25677261	chr15:102009856	PCSK6	-0.49	-6.8	-0.35	4.59e-11	Diabetic kidney disease;
LIHC	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	0.99	14.35	0.61	6.94e-37	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.72	-12.76	-0.57	9.29e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg02344993	chr17:57696989	CLTC	-0.72	-12.35	-0.56	3.14e-29	Obesity-related traits;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26949087	chr2:26467503	HADHB;HADHA	0.44	6.09	0.31	3.09e-9	Migraine with aura;
LIHC	cis	rs6732160	0.574	rs12465780	chr2:73472012	A/G	cg24220031	chr2:73402428	NA	0.27	5.82	0.3	1.38e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10508774	1.000	rs12241523	chr10:32976098	C/T	cg01819863	chr10:32635814	EPC1	0.63	5.88	0.3	9.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.22	-0.32	1.48e-9	Diastolic blood pressure;
LIHC	cis	rs911119	0.955	rs1011226	chr20:23605833	G/T	cg16589663	chr20:23618590	CST3	-0.74	-8.01	-0.4	1.76e-14	Chronic kidney disease;
LIHC	trans	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg25214090	chr10:38739885	LOC399744	0.44	6.94	0.35	2e-11	Diastolic blood pressure;
LIHC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.36	-5.77	-0.3	1.81e-8	Melanoma;
LIHC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-10.72	-0.5	2.55e-23	Platelet count;
LIHC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.48	0.46	4.54e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.39	6.4	0.33	5.2400000000000005e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.81	-0.35	4.35e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.22	0.55	9.92e-29	Prudent dietary pattern;
LIHC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	5.84	0.3	1.22e-8	Axial length;
LIHC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	15.77	0.65	1.71e-42	Lung cancer in ever smokers;
LIHC	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg18964960	chr10:1102726	WDR37	0.67	6.21	0.32	1.53e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.67	0.53	1.03e-26	Motion sickness;
LIHC	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-6.81	-0.35	4.27e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg19752551	chr11:57585705	CTNND1	-0.52	-7.34	-0.37	1.56e-12	Schizophrenia;
LIHC	cis	rs2016586	0.796	rs5750158	chr22:36101567	T/C	cg26342177	chr22:36113512	APOL5	-0.39	-6.74	-0.34	6.73e-11	Body mass index;
LIHC	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.38	-0.33	5.77e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg10360323	chr17:41437877	NA	0.4	5.92	0.31	7.69e-9	Menopause (age at onset);
LIHC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.57	-6.34	-0.32	7.34e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg01843034	chr6:37503916	NA	-0.47	-7.99	-0.4	2.12e-14	Cognitive performance;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg19635926	chr16:89946313	TCF25	0.5	7.02	0.35	1.18e-11	Skin colour saturation;
LIHC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.59e-14	Motion sickness;
LIHC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.59e-14	Morning vs. evening chronotype;
LIHC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.67	12.03	0.55	4.99e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.07	0.51	1.47e-24	Type 2 diabetes;
LIHC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	9.63	0.46	1.44e-19	Menarche (age at onset);
LIHC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-7.5	-0.38	5.63e-13	Crohn's disease;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.61	8.91	0.43	3.14e-17	Prudent dietary pattern;
LIHC	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.97	10.48	0.49	1.75e-22	Platelet distribution width;
LIHC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg03934865	chr2:198174659	NA	-0.57	-9.1	-0.44	7.61e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.78	-14.35	-0.61	6.94e-37	Longevity;
LIHC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.62	10.4	0.49	3.54e-22	Alcohol dependence;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg01320579	chr17:75405842	SEPT9	0.52	7.33	0.37	1.64e-12	Airflow obstruction;
LIHC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.54	-12.96	-0.57	1.61e-31	White blood cell count (basophil);
LIHC	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg11861562	chr11:117069780	TAGLN	0.36	5.77	0.3	1.82e-8	Blood protein levels;
LIHC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	cis	rs10508774	0.810	rs12245661	chr10:32735017	A/T	cg01819863	chr10:32635814	EPC1	0.61	5.88	0.3	9.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.49	0.38	5.77e-13	Aortic root size;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.97	-0.35	1.6e-11	Diastolic blood pressure;
LIHC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.56	9.99	0.48	8.54e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2599510	0.729	rs1135484	chr2:32749060	G/A	cg02381751	chr2:32503542	YIPF4	0.49	6.45	0.33	3.81e-10	Interleukin-18 levels;
LIHC	cis	rs12744310	1.000	rs12035353	chr1:41769337	G/A	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14298269	chr14:102689372	WDR20	0.52	6.94	0.35	1.96e-11	Hip circumference;
LIHC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.24	-0.36	2.93e-12	Personality dimensions;
LIHC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg13753209	chr17:57696993	CLTC	0.73	11.52	0.53	3.71e-26	Hemoglobin concentration;
LIHC	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.68	13.52	0.59	1.12e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	1.0	18.64	0.71	5.38e-54	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17150246	chr1:161068070	KLHDC9	0.44	6.36	0.33	6.34e-10	Pancreatic cancer;
LIHC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.7	-0.43	1.44e-16	Schizophrenia;
LIHC	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.77	8.22	0.41	4.21e-15	Chronic kidney disease;
LIHC	cis	rs35160687	0.623	rs1863060	chr2:86511456	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	5.9	0.3	8.57e-9	Night sleep phenotypes;
LIHC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.44	6.83	0.35	4e-11	Cognitive function;
LIHC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.48	-18.17	-0.7	4.09e-52	Breast cancer;
LIHC	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20982606	chr12:109535391	UNG	0.62	8.16	0.4	6.46e-15	Lung function (FEV1/FVC);
LIHC	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	0.39	6.03	0.31	4.35e-9	Coronary artery disease;
LIHC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-6.45	-0.33	3.88e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.51	5.79	0.3	1.63e-8	Primary sclerosing cholangitis;
LIHC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg18478394	chr8:109455254	TTC35	0.38	6.35	0.32	6.88e-10	Dupuytren's disease;
LIHC	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.23	5.93	0.31	7.28e-9	Hepatitis;
LIHC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg12751644	chr20:60527061	NA	-0.36	-5.87	-0.3	1.01e-8	Body mass index;
LIHC	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.41	-6.83	-0.35	3.82e-11	Facial morphology (factor 20);
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.78	-0.39	8.43e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.5	-7.46	-0.37	7.41e-13	Resting heart rate;
LIHC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-8.45	-0.42	8.28e-16	Chronic sinus infection;
LIHC	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.47	7.67	0.38	1.77e-13	Crohn's disease;
LIHC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.75	-0.47	5.79e-20	Response to antipsychotic treatment;
LIHC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.67	-10.96	-0.51	3.68e-24	Bipolar disorder;
LIHC	cis	rs8083850	0.667	rs28868998	chr18:50842731	T/C	cg24270629	chr18:50823537	DCC	-0.57	-8.56	-0.42	3.76e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.43	-0.56	1.53e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.66	8.97	0.44	1.93e-17	Initial pursuit acceleration;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg11070056	chr1:107600091	PRMT6	0.68	11.61	0.53	1.68e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07472159	chr6:116447667	COL10A1;NT5DC1	0.29	6.05	0.31	3.84e-9	Cognitive function;
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.26	0.32	1.18e-9	Calcium levels;
LIHC	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg17385448	chr1:15911702	AGMAT	0.4	6.55	0.33	2.1e-10	Systolic blood pressure;
LIHC	cis	rs9527	0.518	rs4633383	chr10:104795723	T/G	cg15744005	chr10:104629667	AS3MT	-0.47	-6.3	-0.32	9.41e-10	Arsenic metabolism;
LIHC	cis	rs360798	0.512	rs1906198	chr2:62946658	C/T	cg17519650	chr2:63277830	OTX1	0.48	7.24	0.36	3e-12	Coronary artery disease;
LIHC	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.42	7.13	0.36	5.84e-12	Mean corpuscular volume;
LIHC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.45	7.81	0.39	6.91e-14	Schizophrenia;
LIHC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.47	7.09	0.36	7.54e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg17980119	chr2:219472607	PLCD4	0.36	6.14	0.31	2.34e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.57	10.07	0.48	4.52e-21	Dupuytren's disease;
LIHC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.47	-9.62	-0.46	1.55e-19	Immature fraction of reticulocytes;
LIHC	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg12698662	chr3:15914712	MIR563	-0.41	-7.65	-0.38	2.02e-13	Mean platelet volume;
LIHC	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.47	6.24	0.32	1.3e-9	Interleukin-18 levels;
LIHC	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg11057378	chr10:81107060	PPIF	0.35	5.79	0.3	1.59e-8	Height;
LIHC	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.47	-7.15	-0.36	5.15e-12	Diastolic blood pressure;
LIHC	cis	rs8067354	0.958	rs2333563	chr17:57839568	A/G	cg02344993	chr17:57696989	CLTC	0.54	8.55	0.42	4.26e-16	Hemoglobin concentration;
LIHC	cis	rs3812111	0.676	rs9488857	chr6:116485722	C/T	cg08036074	chr6:116424633	NT5DC1	-0.52	-8.69	-0.43	1.49e-16	Age-related macular degeneration;
LIHC	cis	rs9596863	0.898	rs35359752	chr13:54364643	T/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.8	0.3	1.54e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.43	-7.47	-0.37	6.77e-13	Metabolic traits;LDL cholesterol;
LIHC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.51	-7.93	-0.39	3.14e-14	Educational attainment;
LIHC	cis	rs4906332	0.782	rs12880224	chr14:104006414	C/G	cg19000871	chr14:103996768	TRMT61A	-0.58	-9.26	-0.45	2.28e-18	Coronary artery disease;
LIHC	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.52	9.83	0.47	2.9e-20	Testicular germ cell tumor;
LIHC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	0.83	7.02	0.36	1.18e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.85	-0.3	1.16e-8	Total body bone mineral density;
LIHC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.57	8.11	0.4	8.96e-15	Aortic root size;
LIHC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg17279839	chr7:150038598	RARRES2	0.4	7.97	0.4	2.47e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.39	6.43	0.33	4.29e-10	Fibrinogen levels;
LIHC	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.78	0.54	4.01e-27	Coffee consumption (cups per day);
LIHC	cis	rs3857067	1.000	rs6532462	chr4:95026833	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.35	-0.37	1.43e-12	QT interval;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06719391	chr11:2554330	KCNQ1	0.4	6.05	0.31	3.78e-9	Cognitive function;
LIHC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.49	8.68	0.43	1.59e-16	HDL cholesterol levels;
LIHC	cis	rs7534824	0.625	rs61782084	chr1:101515298	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	7.33	0.37	1.72e-12	Refractive astigmatism;
LIHC	cis	rs1419980	0.730	rs11054868	chr12:7770601	A/T	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.67	10.56	0.5	9.86e-23	Prostate cancer;
LIHC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg25281562	chr12:121454272	C12orf43	0.33	5.78	0.3	1.68e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg17385448	chr1:15911702	AGMAT	0.37	6.1	0.31	2.87e-9	Systolic blood pressure;
LIHC	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.76	-8.08	-0.4	1.1e-14	Putamen volume;
LIHC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.47	-0.33	3.37e-10	Fear of minor pain;
LIHC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg17294928	chr15:75287854	SCAMP5	-0.54	-6.6	-0.34	1.56e-10	Lung cancer;
LIHC	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	0.7	7.66	0.38	1.88e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs17106184	1.000	rs59622625	chr1:50973264	C/T	cg07174182	chr1:51127561	FAF1	-0.58	-6.31	-0.32	8.71e-10	Type 2 diabetes;
LIHC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.69	0.46	9.15e-20	Tonsillectomy;
LIHC	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.43	-7.45	-0.37	7.62e-13	Lung cancer;
LIHC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.41	-7.29	-0.37	2.18e-12	Coronary artery disease;
LIHC	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg18898632	chr2:242989856	NA	-0.69	-8.66	-0.42	1.91e-16	Obesity-related traits;
LIHC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg18887096	chr2:219472410	PLCD4	0.4	6.97	0.35	1.67e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9902453	0.730	rs3794808	chr17:28531793	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	7.82	0.39	6.41e-14	Coffee consumption (cups per day);
LIHC	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.6	10.21	0.48	1.48e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	7.97	0.4	2.46e-14	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs7106204	0.514	rs12789549	chr11:24254726	C/G	ch.11.24196551F	chr11:24239977	NA	0.81	11.54	0.53	3.14e-26	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.24	-0.32	1.28e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25372841	chr8:145675454	CYHR1	0.42	6.49	0.33	3.05e-10	Longevity;
LIHC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.35	8.08	0.4	1.15e-14	Rheumatoid arthritis;
LIHC	cis	rs11229555	0.609	rs7128459	chr11:58179291	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.44	6.87	0.35	3.06e-11	Cognitive function;
LIHC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.04	-0.31	4.12e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.45	-8.27	-0.41	2.98e-15	Body mass index;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg24667363	chr3:158362181	GFM1	-0.39	-6.22	-0.32	1.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	9.16	0.44	4.94e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.49	7.61	0.38	2.67e-13	Testicular germ cell tumor;
LIHC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg15534755	chr11:117069859	TAGLN	-0.39	-6.56	-0.33	1.96e-10	Blood protein levels;
LIHC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.59	0.38	3.09e-13	Electroencephalogram traits;
LIHC	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.57	8.27	0.41	3.01e-15	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02290350	chr8:58132656	NA	0.5	9.72	0.47	7.22e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.4	6.17	0.32	1.92e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-7.25	-0.36	2.81e-12	Mortality in heart failure;
LIHC	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.51	7.31	0.37	1.93e-12	Asthma;
LIHC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.45	-6.9	-0.35	2.52e-11	Cognitive function;
LIHC	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg22771759	chr13:24902376	NA	0.31	6.48	0.33	3.25e-10	Obesity-related traits;
LIHC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg00204748	chr12:29376779	FAR2	0.4	7.49	0.38	5.92e-13	QT interval;
LIHC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.48	-6.31	-0.32	8.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.56	-9.58	-0.46	2.1e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.12e-9	Coronary artery disease;
LIHC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.64	-10.3	-0.49	7.28e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	trans	rs6732426	1.000	rs6732426	chr2:43587504	C/T	cg10773526	chr4:143327279	INPP4B	0.35	6.07	0.31	3.46e-9	Hair morphology;
LIHC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	trans	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg04702396	chr17:15466718	FAM18B2	0.45	6.97	0.35	1.65e-11	Educational attainment (years of education);
LIHC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg10664184	chr19:17420304	DDA1	0.46	5.81	0.3	1.41e-8	Systemic lupus erythematosus;
LIHC	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	0.54	10.31	0.49	7.15e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg16511985	chr3:153974050	SGEF	0.4	8.52	0.42	5.02e-16	Coronary artery disease;
LIHC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-8.98	-0.44	1.9e-17	Asthma;
LIHC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg03934865	chr2:198174659	NA	-0.61	-9.93	-0.47	1.34e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.84	0.35	3.7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.4	0.52	9.54e-26	Colorectal cancer;
LIHC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.18	0.36	4.49e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.77	-9.18	-0.44	4.35e-18	Exhaled nitric oxide levels;
LIHC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.49	-7.86	-0.39	5.08e-14	Longevity;Endometriosis;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05834845	chr3:195489306	MUC4	0.63	9.7	0.46	8.33e-20	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.95	-6.46	-0.33	3.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.72	-0.39	1.31e-13	Chronic sinus infection;
LIHC	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.53	-8.9	-0.43	3.31e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs963731	0.649	rs2123876	chr2:39255873	C/G	cg04010122	chr2:39346883	SOS1	-0.72	-6.07	-0.31	3.39e-9	Corticobasal degeneration;
LIHC	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.4	0.52	9.57e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.55	8.0	0.4	2.01e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg11764359	chr7:65958608	NA	0.56	5.99	0.31	5.28e-9	Diabetic kidney disease;
LIHC	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.2	0.55	1.13e-28	Coffee consumption (cups per day);
LIHC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10590442	chr11:124633181	ESAM	0.44	6.55	0.33	2.11e-10	Triglycerides;
LIHC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg09003973	chr2:102972529	NA	0.88	7.64	0.38	2.25e-13	Gut microbiota (bacterial taxa);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05619320	chr4:123653606	BBS12;LOC729338	0.32	6.17	0.32	1.94e-9	Calcium levels;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg05697976	chr12:29376483	FAR2	0.32	6.65	0.34	1.13e-10	QT interval;
LIHC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.56	-0.82	4.03e-85	Myeloid white cell count;
LIHC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.46	8.92	0.43	2.86e-17	Tuberculosis;
LIHC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.45	-6.03	-0.31	4.23e-9	Cognitive ability;
LIHC	cis	rs7786877	0.587	rs56328569	chr7:100202219	C/G	cg00334542	chr7:100209784	MOSPD3	-0.63	-5.89	-0.3	9.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25387593	chr11:118927868	HYOU1	-0.48	-6.36	-0.33	6.62e-10	Lung cancer in ever smokers;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22463517	chr17:26988906	SDF2;SUPT6H	0.44	6.58	0.34	1.78e-10	Cognitive function;
LIHC	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.46	-0.33	3.51e-10	Metabolite levels;
LIHC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg24203234	chr3:128598194	ACAD9	0.43	6.06	0.31	3.59e-9	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22524267	chr4:4543474	STX18	0.41	6.92	0.35	2.27e-11	Cognitive function;
LIHC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-7.46	-0.37	7.16e-13	Morning vs. evening chronotype;
LIHC	trans	rs75804782	0.521	rs66477197	chr2:239403832	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	6.94	0.35	1.94e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs7123876	0.717	rs58249351	chr11:72463462	G/A	cg03713592	chr11:72463424	ARAP1	0.59	6.53	0.33	2.31e-10	Body mass index;
LIHC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.45	0.56	1.38e-29	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.43	6.16	0.32	2.08e-9	Aortic root size;
LIHC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.41	-0.37	9.71e-13	Schizophrenia;
LIHC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-7.56	-0.38	3.84e-13	Morning vs. evening chronotype;
LIHC	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.36	-8.28	-0.41	2.89e-15	Educational attainment (years of education);
LIHC	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.49	9.39	0.45	8.68e-19	Testicular germ cell tumor;
LIHC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-9.21	-0.45	3.3e-18	Electroencephalogram traits;
LIHC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.55	-8.96	-0.44	2.07e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs76297747	1	rs76297747	chr18:44665657	A/G	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Response to paliperidone in schizophrenia (Multivariate);
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.36	5.93	0.31	7.35e-9	Cystic fibrosis severity;
LIHC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.44	-7.55	-0.38	3.96e-13	Educational attainment;
LIHC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-8.54	-0.42	4.57e-16	Vitiligo;
LIHC	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.69	10.64	0.5	5.03e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg14146966	chr2:61757674	XPO1	0.45	7.61	0.38	2.71e-13	Tuberculosis;
LIHC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.34	7.11	0.36	6.69e-12	Obesity-related traits;
LIHC	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.96e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.87	0.39	4.88e-14	Tonsillectomy;
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.82	12.16	0.55	1.64e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.4	-6.02	-0.31	4.52e-9	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14103574	chr5:162932455	MAT2B	0.49	7.33	0.37	1.67e-12	Pancreatic cancer;
LIHC	cis	rs611744	0.934	rs2848619	chr8:109198185	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs4728302	0.869	rs12707131	chr7:133620982	A/G	cg10665199	chr7:133106180	EXOC4	0.36	6.25	0.32	1.21e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs1805008	0.535	rs4785621	chr16:90130735	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.74	-6.79	-0.34	4.93e-11	Skin colour saturation;
LIHC	cis	rs2637266	0.597	rs846622	chr10:78543005	G/A	cg18941641	chr10:78392320	NA	0.29	6.29	0.32	9.75e-10	Pulmonary function;
LIHC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.35	6.85	0.35	3.49e-11	Alcohol dependence;
LIHC	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg16583315	chr14:65563665	MAX	-0.39	-7.94	-0.39	2.94e-14	Obesity-related traits;
LIHC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.84	0.3	1.22e-8	Bipolar disorder;
LIHC	cis	rs10878977	0.565	rs11177658	chr12:69810388	C/G	cg17330252	chr12:69809627	NA	0.38	5.88	0.3	9.93e-9	Colorectal cancer;
LIHC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.75	7.6	0.38	2.91e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg02702477	chr5:179499311	RNF130	0.76	10.52	0.49	1.27e-22	LDL cholesterol;
LIHC	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg06935464	chr4:38784597	TLR10	0.43	6.42	0.33	4.45e-10	Breast cancer;
LIHC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.22	0.32	1.43e-9	Hepatocellular carcinoma;
LIHC	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg01864836	chr14:55583639	NA	-0.41	-7.55	-0.38	4.07e-13	Protein biomarker;
LIHC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.84	13.96	0.6	2.37e-35	Breast cancer;
LIHC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	7.49	0.38	6.12e-13	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.44	-6.19	-0.32	1.68e-9	Schizophrenia;
LIHC	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg23091122	chr1:110024289	SYPL2	-0.49	-6.46	-0.33	3.51e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg21466736	chr12:48725269	NA	0.6	8.1	0.4	9.95e-15	Glycated hemoglobin levels;
LIHC	cis	rs986417	1.000	rs8021347	chr14:60952773	G/C	cg27398547	chr14:60952738	C14orf39	0.82	9.57	0.46	2.22e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.94	-0.35	2.02e-11	Total cholesterol levels;
LIHC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.67	-8.43	-0.41	9.53e-16	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3e-11	Height;
LIHC	cis	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg20932281	chr17:33905541	PEX12	0.42	5.76	0.3	1.9e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.44	8.04	0.4	1.48e-14	Prudent dietary pattern;
LIHC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.32	0.68	1.09e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg07636037	chr3:49044803	WDR6	-0.55	-6.39	-0.33	5.38e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1881396	0.947	rs4666010	chr2:27878686	T/C	cg27432699	chr2:27873401	GPN1	0.51	7.87	0.39	4.73e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs11888559	0.655	rs13431510	chr2:203989347	G/A	cg24605529	chr2:203879461	NBEAL1	0.81	6.13	0.31	2.47e-9	Height;
LIHC	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.32	-0.32	8.13e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.54	7.42	0.37	9.49e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs847649	0.731	rs13222980	chr7:102703898	A/G	cg18108683	chr7:102477205	FBXL13	0.42	6.21	0.32	1.52e-9	Morning vs. evening chronotype;
LIHC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.25	0.52	3.49e-25	Menopause (age at onset);
LIHC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.22	-0.36	3.36e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg02023728	chr11:77925099	USP35	0.34	6.11	0.31	2.67e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg20435097	chr10:126320824	FAM53B	0.38	6.4	0.33	5.03e-10	Asthma;
LIHC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg05896524	chr21:47604654	C21orf56	-0.39	-6.06	-0.31	3.54e-9	Testicular germ cell tumor;
LIHC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg12046867	chr14:103022105	NA	0.52	7.21	0.36	3.68e-12	Platelet count;
LIHC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.23	0.55	8.88e-29	Alzheimer's disease;
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-7.78	-0.39	8.45e-14	Lymphocyte counts;
LIHC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.12	9.92	0.47	1.51e-20	Diabetic retinopathy;
LIHC	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.53	8.77	0.43	8.46e-17	Coronary artery disease;
LIHC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.38	-5.87	-0.3	1.02e-8	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.67	10.14	0.48	2.69e-21	Body mass index;
LIHC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.47	-5.78	-0.3	1.66e-8	Schizophrenia;
LIHC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.88e-10	Fibrinogen levels;
LIHC	cis	rs12744310	0.895	rs1892417	chr1:41779673	T/C	cg03962019	chr1:41807865	NA	0.4	6.43	0.33	4.22e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.53	6.35	0.32	6.86e-10	Morning vs. evening chronotype;
LIHC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02359409	chr6:42947317	PEX6	-0.47	-6.66	-0.34	1.06e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.03	0.36	1.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.65	10.86	0.51	8.27e-24	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-9.68	-0.46	9.24e-20	Coronary artery disease;
LIHC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.46	6.08	0.31	3.14e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4699052	0.662	rs1516732	chr4:104251154	A/T	cg16532752	chr4:104119610	CENPE	-0.37	-5.86	-0.3	1.08e-8	Testicular germ cell tumor;
LIHC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.03e-40	Aortic root size;
LIHC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg00204512	chr16:28754710	NA	0.36	6.43	0.33	4.28e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg16226627	chr15:75307476	SCAMP5	-0.53	-9.81	-0.47	3.64e-20	Lung cancer;
LIHC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.69	9.35	0.45	1.19e-18	Mean platelet volume;
LIHC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-6.97	-0.35	1.59e-11	Bipolar disorder;
LIHC	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.93	10.45	0.49	2.21e-22	LDL cholesterol;
LIHC	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.59	-8.87	-0.43	4.01e-17	Recombination rate (females);
LIHC	cis	rs2412488	0.893	rs6840530	chr4:54359726	C/T	cg22241045	chr4:54363911	LNX1	0.47	7.65	0.38	2e-13	DNA methylation (variation);
LIHC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.27e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	8.83	0.43	5.53e-17	Schizophrenia;
LIHC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.21	0.48	1.58e-21	Lewy body disease;
LIHC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg16070123	chr10:51489643	NA	0.38	6.05	0.31	3.8e-9	Prostate-specific antigen levels;
LIHC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-1.08	-11.55	-0.53	2.92e-26	White matter hyperintensity burden;
LIHC	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	7.02	0.35	1.2e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.74	-12.53	-0.56	6.87e-30	Tonsillectomy;
LIHC	cis	rs1190552	0.761	rs3783374	chr14:102885469	C/G	cg10241871	chr14:102965420	TECPR2	-0.39	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.69	-9.96	-0.47	1.11e-20	Schizophrenia;
LIHC	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg13877915	chr19:58951672	ZNF132	0.59	9.06	0.44	9.94e-18	Uric acid clearance;
LIHC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.81	13.5	0.59	1.42e-33	Psoriasis;
LIHC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.82	14.49	0.62	1.89e-37	Body mass index (adult);
LIHC	trans	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.23	0.32	1.4e-9	Ulcerative colitis;
LIHC	trans	rs3176789	0.647	rs7295897	chr12:9920876	A/T	cg18988856	chr7:99425577	CYP3A43	0.19	6.15	0.32	2.14e-9	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LIHC	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.63	-10.59	-0.5	7.33e-23	Waist circumference;Body mass index;
LIHC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.75	-0.3	2e-8	Axial length;
LIHC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.73	0.43	1.16e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.91	-13.05	-0.58	7.02e-32	Post bronchodilator FEV1;
LIHC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.43	-6.74	-0.34	6.88e-11	Cognitive function;
LIHC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-6.24	-0.32	1.31e-9	Electroencephalogram traits;
LIHC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.17	-0.4	6.13e-15	Height;
LIHC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.47	8.27	0.41	3.09e-15	N-glycan levels;
LIHC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-10.72	-0.5	2.61e-23	Colorectal cancer;
LIHC	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg09829573	chr1:144692074	NBPF9	-0.44	-7.95	-0.39	2.67e-14	Hip geometry;
LIHC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.61	-9.27	-0.45	2.11e-18	Height;
LIHC	cis	rs2016586	0.832	rs4820209	chr22:36104647	C/T	cg26342177	chr22:36113512	APOL5	0.36	6.12	0.31	2.61e-9	Body mass index;
LIHC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.79	-13.44	-0.59	2.35e-33	Platelet distribution width;
LIHC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.74	-14.13	-0.61	4.85e-36	Mortality in heart failure;
LIHC	cis	rs1789	0.839	rs9997068	chr4:15650990	T/C	cg21123203	chr4:15471301	CC2D2A	-0.46	-7.35	-0.37	1.48e-12	Blood protein levels;
LIHC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12032009	chr15:62352934	VPS13C	-0.38	-6.04	-0.31	4.02e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.05	-0.78	1.27e-71	Height;
LIHC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.34	0.56	3.31e-29	Cognitive test performance;
LIHC	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-6.77	-0.34	5.62e-11	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.55	-9.04	-0.44	1.23e-17	Longevity;Endometriosis;
LIHC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.34	-7.3	-0.37	2.02e-12	Ulcerative colitis;
LIHC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg14829360	chr17:73884958	NA	-0.39	-6.57	-0.33	1.88e-10	White matter hyperintensity burden;
LIHC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.39	7.37	0.37	1.28e-12	Response to interferon beta in multiple sclerosis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22529720	chr7:139044624	LUC7L2	0.41	6.35	0.32	6.85e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.16	11.52	0.53	3.54e-26	Uric acid levels;
LIHC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.29	6.88	0.35	2.92e-11	Primary biliary cholangitis;
LIHC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.46	0.37	7.27e-13	Glycated hemoglobin levels;
LIHC	cis	rs12079745	0.590	rs3766092	chr1:169273400	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	1.96e-11	QT interval;
LIHC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg06334093	chr6:139094587	CCDC28A	-0.45	-6.12	-0.31	2.6e-9	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.47	8.44	0.42	9.26e-16	Testicular germ cell tumor;
LIHC	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.44	6.71	0.34	7.93e-11	Body mass index;Social communication problems;
LIHC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04025307	chr7:1156635	C7orf50	-0.55	-7.3	-0.37	2.01e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.44	-7.16	-0.36	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.15	0.44	5.3e-18	IgG glycosylation;
LIHC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-1.04	-19.85	-0.73	6.78e-59	Migraine;
LIHC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.82	-6.1	-0.31	2.82e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-11.54	-0.53	3.11e-26	Ulcerative colitis;
LIHC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.34	0.55	3.55e-29	Cognitive test performance;
LIHC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.26	5.97	0.31	5.91e-9	Crohn's disease;
LIHC	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs1400745	0.729	rs28472856	chr14:35332157	C/T	cg05294307	chr14:35346193	BAZ1A	-0.45	-7.51	-0.38	5.09e-13	Monocyte count;
LIHC	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.57	-6.51	-0.33	2.7e-10	Ulcerative colitis;
LIHC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.89	-0.3	9.01e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg21724239	chr8:58056113	NA	0.5	6.6	0.34	1.58e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.74	-0.3	2.1e-8	Coronary artery disease;
LIHC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20135002	chr11:47629003	NA	-0.52	-8.79	-0.43	7.64e-17	Subjective well-being;
LIHC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.63	8.78	0.43	7.88e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg18357526	chr6:26021779	HIST1H4A	0.62	8.59	0.42	3.19e-16	Blood metabolite levels;
LIHC	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-0.84	-10.68	-0.5	3.74e-23	Blood pressure (smoking interaction);
LIHC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.95	18.21	0.7	2.7e-52	Menopause (age at onset);
LIHC	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg25182066	chr10:30743637	MAP3K8	-0.46	-7.33	-0.37	1.73e-12	Inflammatory bowel disease;
LIHC	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.43	6.76	0.34	5.85e-11	Coronary artery disease;
LIHC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	0.73	6.8	0.35	4.72e-11	Plateletcrit;
LIHC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.42	5.99	0.31	5.21e-9	Coronary artery disease;
LIHC	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.39e-35	White blood cell count (basophil);
LIHC	cis	rs7508	0.511	rs371922	chr8:17900003	T/C	cg04898035	chr8:17640624	MTUS1	-0.34	-5.87	-0.3	1.01e-8	Atrial fibrillation;
LIHC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	9.79	0.47	4.03e-20	Resting heart rate;
LIHC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-11.33	-0.52	1.75e-25	Platelet distribution width;
LIHC	trans	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg27306034	chr1:155224863	FAM189B	0.53	6.32	0.32	7.99e-10	Inflammatory bowel disease;
LIHC	cis	rs4671400	0.543	rs10178135	chr2:61485267	T/C	cg14146966	chr2:61757674	XPO1	-0.37	-5.85	-0.3	1.15e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs9648428	0.515	rs4723485	chr7:36205242	G/T	cg14708893	chr7:36124863	NA	-0.4	-6.02	-0.31	4.38e-9	Obesity-related traits;
LIHC	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.98	-0.31	5.75e-9	Crohn's disease;
LIHC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.88	15.46	0.64	2.85e-41	Parkinson's disease;
LIHC	cis	rs11958404	0.932	rs113264420	chr5:157437779	T/C	cg05962755	chr5:157440814	NA	0.99	11.5	0.53	4.32e-26	IgG glycosylation;
LIHC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.61	-8.82	-0.43	5.83e-17	Recombination rate (females);
LIHC	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.24e-12	Post bronchodilator FEV1;
LIHC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg17771515	chr6:154831774	CNKSR3	0.54	6.05	0.31	3.8e-9	Lipoprotein (a) levels;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg14984255	chr18:11908827	MPPE1	-0.39	-6.9	-0.35	2.57e-11	Neuroblastoma;
LIHC	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg14146966	chr2:61757674	XPO1	0.47	8.17	0.4	6.2e-15	Tuberculosis;
LIHC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.72	-12.89	-0.57	3.03e-31	Crohn's disease;
LIHC	cis	rs818427	0.929	rs153550	chr5:112234957	C/T	cg07820702	chr5:112228657	REEP5	-0.36	-5.72	-0.3	2.28e-8	Total body bone mineral density;
LIHC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	0.81	6.8	0.35	4.74e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.52	8.18	0.4	5.58e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12286929	0.644	rs3793957	chr11:115095654	C/T	cg04055981	chr11:115044050	NA	0.45	6.53	0.33	2.38e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.71	-11.72	-0.54	6.94e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg17385448	chr1:15911702	AGMAT	0.35	6.11	0.31	2.78e-9	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.82	-0.35	4.26e-11	Diabetic kidney disease;
LIHC	cis	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg00455333	chr1:45205373	KIF2C	-0.38	-5.76	-0.3	1.91e-8	Eotaxin levels;
LIHC	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg14146966	chr2:61757674	XPO1	0.46	7.75	0.39	1.02e-13	Tuberculosis;
LIHC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.5	-0.46	3.7e-19	Bipolar disorder;
LIHC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-7.78	-0.39	8.42e-14	Blood metabolite levels;
LIHC	cis	rs600806	0.778	rs518697	chr1:110014778	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.44	-5.75	-0.3	1.95e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16288997	chr4:185395914	IRF2	-0.45	-6.18	-0.32	1.81e-9	Pancreatic cancer;
LIHC	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg02023728	chr11:77925099	USP35	-0.34	-5.96	-0.31	6.37e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg18016565	chr1:150552671	MCL1	0.54	10.31	0.49	7.18e-22	Melanoma;
LIHC	cis	rs3770081	1.000	rs74607112	chr2:86305534	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.58	8.72	0.43	1.21e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25978167	chr4:57301353	PAICS;PPAT	0.45	6.16	0.32	2.07e-9	Pancreatic cancer;
LIHC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-7.97	-0.4	2.4e-14	Neuroticism;
LIHC	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.64	10.31	0.49	6.75e-22	Schizophrenia;
LIHC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.98	-0.54	7.53e-28	Response to antipsychotic treatment;
LIHC	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg08126542	chr6:37504118	NA	0.41	6.6	0.34	1.61e-10	Cognitive performance;
LIHC	cis	rs243505	0.732	rs3800949	chr7:148479648	A/T	cg09806900	chr7:148480153	CUL1	-0.43	-6.51	-0.33	2.6200000000000003e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.63	-9.02	-0.44	1.35e-17	Response to antineoplastic agents;
LIHC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.89	19.14	0.72	4.92e-56	Blood protein levels;
LIHC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.5	0.77	1.86e-69	Chronic sinus infection;
LIHC	cis	rs922107	0.738	rs10922664	chr1:90032940	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.75	-0.39	1.03e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.56	8.23	0.41	3.98e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-25.41	-0.81	8.99e-81	Myeloid white cell count;
LIHC	cis	rs903552	1.000	rs12719737	chr15:101999126	C/G	cg06707286	chr15:102010195	PCSK6	-0.41	-5.78	-0.3	1.67e-8	Diabetic kidney disease;
LIHC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.4	-6.25	-0.32	1.2e-9	Iron status biomarkers;
LIHC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg13409248	chr3:40428643	ENTPD3	0.38	5.9	0.3	8.83e-9	Renal cell carcinoma;
LIHC	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.4	7.23	0.36	3.27e-12	Inflammatory bowel disease;
LIHC	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg23461800	chr14:103021989	NA	0.38	5.72	0.3	2.38e-8	Platelet count;
LIHC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.93	-16.24	-0.66	2.36e-44	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.78	15.47	0.64	2.74e-41	Mortality in heart failure;
LIHC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg00864860	chr1:7907996	UTS2	0.64	5.84	0.3	1.21e-8	Inflammatory bowel disease;
LIHC	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg15605315	chr1:45957053	TESK2	0.45	5.86	0.3	1.07e-8	High light scatter reticulocyte count;
LIHC	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.22	12.75	0.57	9.9e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.68	9.5	0.46	3.76e-19	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.43	-0.49	2.63e-22	Total cholesterol levels;
LIHC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.1	-0.31	2.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.4	6.14	0.32	2.23e-9	Height;
LIHC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.45	-7.07	-0.36	9.03e-12	Cognitive function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05178316	chr20:62661238	PRPF6	-0.39	-6.19	-0.32	1.71e-9	Calcium levels;
LIHC	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.76	14.2	0.61	2.58e-36	Mean platelet volume;
LIHC	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.35	8.12	0.4	8.77e-15	Educational attainment (years of education);
LIHC	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	9.08	0.44	8.55e-18	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.56	7.9	0.39	3.96e-14	Pancreatic cancer;
LIHC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.4	0.52	9.8e-26	Coronary artery disease;
LIHC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.16	18.07	0.7	1.04e-51	Gut microbiome composition (summer);
LIHC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14067834	chr17:29058358	SUZ12P	0.62	6.09	0.31	3.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.08	-0.4	1.13e-14	Alzheimer's disease;
LIHC	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.69	12.38	0.56	2.54e-29	Iron status biomarkers;
LIHC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08219700	chr8:58056026	NA	0.5	6.33	0.32	7.49e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg14132834	chr19:41945861	ATP5SL	0.43	6.24	0.32	1.32e-9	Height;
LIHC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs6141769	0.542	rs6119939	chr20:31315153	T/C	cg13636640	chr20:31349939	DNMT3B	-0.32	-5.74	-0.3	2.08e-8	Subjective well-being;
LIHC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg20607798	chr8:58055168	NA	0.49	6.07	0.31	3.33e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg14036092	chr11:66035641	RAB1B	0.41	6.16	0.32	2.02e-9	Gout;
LIHC	cis	rs4728302	0.934	rs4129572	chr7:133636888	T/C	cg10665199	chr7:133106180	EXOC4	-0.35	-5.86	-0.3	1.1e-8	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg03037974	chr15:76606532	NA	0.67	12.66	0.56	2.21e-30	Blood metabolite levels;
LIHC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.48	6.29	0.32	9.73e-10	Initial pursuit acceleration;
LIHC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.47	7.88	0.39	4.38e-14	Obesity-related traits;
LIHC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg13628971	chr7:2884303	GNA12	0.41	6.37	0.33	5.97e-10	Height;
LIHC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.58	-6.21	-0.32	1.53e-9	Alcohol dependence;
LIHC	trans	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg01134436	chr17:81009848	B3GNTL1	0.86	7.22	0.36	3.31e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs7707921	0.767	rs226199	chr5:81572464	G/C	cg15871215	chr5:81402204	ATG10	0.7	8.44	0.42	9.29e-16	Breast cancer;
LIHC	cis	rs3015497	0.616	rs3825571	chr14:51052118	A/G	cg09863266	chr14:51125203	SAV1	-0.37	-6.08	-0.31	3.13e-9	Mean platelet volume;
LIHC	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.73	-0.39	1.18e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.56	-7.64	-0.38	2.23e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg17724175	chr1:150552817	MCL1	0.41	7.8	0.39	7.32e-14	Melanoma;
LIHC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.47	-0.53	5.62e-26	Type 2 diabetes;
LIHC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.77	15.19	0.63	3.32e-40	Mortality in heart failure;
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg19500275	chr17:80737654	TBCD	0.52	7.58	0.38	3.2e-13	Glycated hemoglobin levels;
LIHC	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.52	7.91	0.39	3.53e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17791867	chr7:112579927	C7orf60	0.45	6.07	0.31	3.34e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.17	0.61	3.36e-36	Prudent dietary pattern;
LIHC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	19.76	0.73	1.63e-58	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.53	6.75	0.34	6.18e-11	Alzheimer's disease;
LIHC	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.95	0.31	6.82e-9	Rheumatoid arthritis;
LIHC	cis	rs787274	1.000	rs813101	chr9:115532907	C/G	cg13803584	chr9:115635662	SNX30	-0.57	-6.26	-0.32	1.15e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.9	-14.89	-0.63	5.31e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.44	8.08	0.4	1.11e-14	Prudent dietary pattern;
LIHC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-1.02	-19.52	-0.73	1.47e-57	Breast cancer;
LIHC	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.39	9.55	0.46	2.5e-19	Blood metabolite ratios;
LIHC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.72	-8.92	-0.43	2.93e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.84	13.88	0.6	4.71e-35	Colorectal cancer;
LIHC	cis	rs4589502	0.800	rs4776855	chr15:67202075	T/C	cg12317470	chr15:67143691	NA	-0.54	-6.97	-0.35	1.65e-11	Lung cancer (smoking interaction);
LIHC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.65	10.94	0.51	4.51e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.53	-6.79	-0.34	5.11e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7546668	0.947	rs4233538	chr1:15849855	G/T	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs507080	1.000	rs507080	chr11:118549582	G/A	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.76e-9	Serum metabolite levels;
LIHC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.4	6.58	0.34	1.79e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.48	-7.93	-0.39	3.16e-14	Blood metabolite levels;
LIHC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.66	8.42	0.41	1.05e-15	Initial pursuit acceleration;
LIHC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.25	0.55	7.29e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	0.9	16.03	0.65	1.61e-43	Parkinson's disease;
LIHC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	11.79	0.54	3.78e-27	Colorectal cancer;
LIHC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.74	-10.66	-0.5	4.07e-23	Coronary artery disease;
LIHC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	9.85	0.47	2.63e-20	Personality dimensions;
LIHC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.01	-0.31	4.76e-9	Tonsillectomy;
LIHC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.31	7.03	0.36	1.16e-11	Blood metabolite ratios;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04872869	chr1:28908637	SNORA16A;SNHG12	0.43	6.81	0.35	4.27e-11	Cognitive function;
LIHC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.08	-0.48	4.34e-21	Blood metabolite levels;
LIHC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.37	-0.37	1.3e-12	Cognitive test performance;
LIHC	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.32e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.46	7.34	0.37	1.59e-12	Height;
LIHC	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.73	10.55	0.5	1e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.73	0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.29	17.13	0.68	6.01e-48	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03337784	chr13:41768818	KBTBD7	0.44	6.3	0.32	9.42e-10	Pancreatic cancer;
LIHC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.47	7.19	0.36	4.12e-12	Height;
LIHC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.6	10.2	0.48	1.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	7.06	0.36	9.19e-12	Breast cancer;
LIHC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.24	-0.55	8.02e-29	Response to antipsychotic treatment;
LIHC	cis	rs7187994	0.848	rs34139611	chr16:84772473	C/T	cg07647771	chr16:84786436	USP10	-0.34	-6.12	-0.31	2.63e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.81	13.47	0.59	1.77e-33	Monocyte count;
LIHC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.73	13.82	0.6	7.8e-35	Mortality in heart failure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04277470	chr13:41707106	KBTBD6	0.5	7.07	0.36	8.54e-12	Pancreatic cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13296214	chr12:9436248	LOC642846	-0.34	-6.7	-0.34	8.54e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.35	-6.12	-0.31	2.56e-9	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Parkinson's disease;
LIHC	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.83	0.54	2.6e-27	Coffee consumption (cups per day);
LIHC	trans	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.61	0.53	1.77e-26	Tonsillectomy;
LIHC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.69	-8.39	-0.41	1.25e-15	Morning vs. evening chronotype;
LIHC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.21	0.32	1.52e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.65	-10.68	-0.5	3.58e-23	Lung cancer;
LIHC	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.93	0.31	7.33e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08367703	chr9:139304491	SDCCAG3;PMPCA	0.42	6.04	0.31	3.93e-9	Pancreatic cancer;
LIHC	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-6.49	-0.33	3.1e-10	Breast cancer;
LIHC	cis	rs922107	0.738	rs12740865	chr1:90035179	G/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.74	-0.39	1.17e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.7	0.57	1.57e-30	Total body bone mineral density;
LIHC	cis	rs8084351	0.512	rs4939727	chr18:50792914	C/T	cg24270629	chr18:50823537	DCC	-0.48	-7.24	-0.36	2.92e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.23	5.75	0.3	1.96e-8	Schizophrenia;
LIHC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.45	6.76	0.34	5.88e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs2073300	1.000	rs6114142	chr20:23461082	A/G	cg16736954	chr20:23401023	NAPB	0.49	5.73	0.3	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.57	8.97	0.44	1.98e-17	Multiple sclerosis;
LIHC	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg07424592	chr7:64974309	NA	0.78	8.94	0.44	2.44e-17	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.05	-0.31	3.91e-9	Diabetic kidney disease;
LIHC	cis	rs1866706	0.896	rs6486062	chr11:12860618	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-6.99	-0.35	1.41e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Intracranial aneurysm;
LIHC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-7.6	-0.38	2.84e-13	Lymphocyte counts;
LIHC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg16736954	chr20:23401023	NAPB	-0.71	-8.3	-0.41	2.47e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.7	0.34	8.83e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.71	0.38	1.35e-13	Platelet count;
LIHC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.77	-15.23	-0.64	2.5e-40	Height;
LIHC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.38	8.93	0.44	2.59e-17	Blood protein levels;
LIHC	trans	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.71	-6.53	-0.33	2.33e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.22	-0.32	1.43e-9	Colorectal cancer;
LIHC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg23791538	chr6:167370224	RNASET2	-0.61	-10.45	-0.49	2.32e-22	Primary biliary cholangitis;
LIHC	cis	rs9596863	0.898	rs68056413	chr13:54375907	G/T	ch.13.53330881F	chr13:54432880	NA	0.43	5.78	0.3	1.69e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11376330	chr3:49131570	QRICH1	0.47	6.24	0.32	1.27e-9	Lung function (FEV1/FVC);
LIHC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-7.82	-0.39	6.54e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg15691649	chr6:25882328	NA	-0.4	-6.22	-0.32	1.44e-9	Height;
LIHC	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.36	-5.9	-0.3	8.98e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.86	8.04	0.4	1.45e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.71	-9.41	-0.45	7.56e-19	Ankle injury;
LIHC	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.42	-6.15	-0.32	2.12e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs11229555	0.609	rs12291791	chr11:58186290	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg16586182	chr3:47516702	SCAP	-0.39	-6.63	-0.34	1.27e-10	Birth weight;
LIHC	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.4	8.66	0.42	1.96e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.04	-0.48	5.87e-21	Response to antipsychotic treatment;
LIHC	cis	rs8084351	0.512	rs4939728	chr18:50793071	C/T	cg24270629	chr18:50823537	DCC	0.51	7.72	0.39	1.3e-13	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.33	-6.28	-0.32	1.01e-9	Body mass index;
LIHC	cis	rs4845459	0.967	rs10888503	chr1:152593549	C/T	cg20634798	chr1:152595351	LCE3A	-0.3	-5.76	-0.3	1.84e-8	Psoriasis;
LIHC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-9.17	-0.44	4.55e-18	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.88	-17.6	-0.69	7.7e-50	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg14004847	chr7:1930337	MAD1L1	0.49	7.39	0.37	1.14e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.48	7.7	0.38	1.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.54	8.85	0.43	4.81e-17	Fibrinogen levels;
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg02993280	chr1:107599747	PRMT6	-0.63	-9.87	-0.47	2.26e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg14671364	chr1:107599128	PRMT6	-0.5	-7.39	-0.37	1.11e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	6.44	0.33	4e-10	Total body bone mineral density;
LIHC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.47	-0.76	2.42e-65	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16141690	chr14:23563715	C14orf119;ACIN1	0.47	7.21	0.36	3.64e-12	Cognitive function;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.95	0.4	2.66e-14	Renal cell carcinoma;
LIHC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.72	-0.62	2.56e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg10820045	chr2:198174542	NA	0.45	6.82	0.35	4.03e-11	Intracranial aneurysm;
LIHC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.73	-9.76	-0.47	5.02e-20	Asthma;
LIHC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.78e-19	Waist circumference;Weight;
LIHC	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.58	0.34	1.78e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7635838	0.859	rs9869977	chr3:11480081	C/A	cg00170343	chr3:11313890	ATG7	0.44	6.87	0.35	3.11e-11	HDL cholesterol;
LIHC	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	10.31	0.49	6.95e-22	Response to antipsychotic treatment;
LIHC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.57	7.67	0.38	1.87e-13	Ulcerative colitis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25517427	chr17:12921477	ELAC2	-0.45	-6.38	-0.33	5.61e-10	Systolic blood pressure;
LIHC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.53	7.86	0.39	5.07e-14	Diastolic blood pressure;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg12038521	chr19:2111714	AP3D1	0.43	6.36	0.33	6.61e-10	Bilirubin levels;
LIHC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.87	9.93	0.47	1.42e-20	Initial pursuit acceleration;
LIHC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg19318889	chr4:1322082	MAEA	-0.47	-7.74	-0.39	1.14e-13	Obesity-related traits;
LIHC	trans	rs1704198	1.000	rs2664689	chr1:213897431	C/T	cg02442787	chr4:139230014	NA	0.41	6.32	0.32	8.23e-10	Obesity;
LIHC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.82	0.39	6.59e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.45	6.61	0.34	1.46e-10	Retinal vascular caliber;
LIHC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26770187	chr3:14693171	C3orf19	0.48	7.18	0.36	4.31e-12	Pancreatic cancer;
LIHC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18252515	chr7:66147081	NA	-0.44	-6.39	-0.33	5.46e-10	Aortic root size;
LIHC	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.43	6.8	0.35	4.54e-11	Prostate cancer;
LIHC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.7e-9	Blood metabolite levels;
LIHC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.96	0.4	2.61e-14	Lung cancer;
LIHC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.81	-13.63	-0.59	4.22e-34	Aortic root size;
LIHC	cis	rs1165668	0.755	rs2583283	chr12:104313643	G/A	cg21863207	chr12:104234989	NT5DC3	0.46	8.02	0.4	1.69e-14	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs16828019	0.852	rs11209545	chr1:41576357	T/G	cg20697417	chr1:41786797	NA	0.32	6.12	0.31	2.52e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-8.36	-0.41	1.62e-15	Morning vs. evening chronotype;
LIHC	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.53	-0.33	2.33e-10	IFN-related cytopenia;
LIHC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.21	0.61	2.47e-36	Chronic sinus infection;
LIHC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg26395211	chr5:140044315	WDR55	0.41	5.92	0.31	7.66e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg05834845	chr3:195489306	MUC4	0.65	9.78	0.47	4.53e-20	Lung disease severity in cystic fibrosis;
LIHC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.01	0.35	1.3e-11	Height;
LIHC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-10.09	-0.48	3.81e-21	Total body bone mineral density;
LIHC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs4716602	0.596	rs12386682	chr7:156158265	C/T	cg16983916	chr7:156159713	NA	-0.32	-5.84	-0.3	1.22e-8	Anti-saccade response;
LIHC	cis	rs74544699	1.000	rs11574452	chr4:74846661	A/C	cg16072462	chr4:74847758	PF4	-0.59	-6.32	-0.32	8.28e-10	Growth-regulated protein alpha levels;
LIHC	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.31	-5.8	-0.3	1.48e-8	Red blood cell count;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.7	-10.22	-0.48	1.47e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg11057378	chr10:81107060	PPIF	0.35	5.84	0.3	1.23e-8	Height;
LIHC	trans	rs947612	0.576	rs9342991	chr6:73683775	G/A	cg13494037	chr12:24737079	C12orf67	0.36	6.04	0.31	4e-9	HIV-1 viral setpoint;Body mass index;
LIHC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.88	-12.14	-0.55	1.84e-28	Post bronchodilator FEV1;
LIHC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg22676075	chr6:135203613	NA	0.38	6.29	0.32	9.78e-10	Red blood cell count;
LIHC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.4	6.65	0.34	1.15e-10	Mean corpuscular volume;
LIHC	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.12	0.48	3.09e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.85	12.32	0.55	4.17e-29	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg06238570	chr21:40685208	BRWD1	-0.47	-7.52	-0.38	4.74e-13	Menarche (age at onset);
LIHC	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg04374321	chr14:90722782	PSMC1	-0.49	-6.85	-0.35	3.51e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.47	8.36	0.41	1.56e-15	Mean corpuscular volume;
LIHC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.71	-0.34	8.01e-11	Response to antipsychotic treatment;
LIHC	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg09795085	chr6:101329169	ASCC3	-0.52	-7.21	-0.36	3.57e-12	Neuroticism;
LIHC	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-7.28	-0.37	2.32e-12	Putamen volume;
LIHC	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs1144333	0.655	rs1361487	chr1:76430471	A/C	cg22875332	chr1:76189707	ACADM	0.4	5.94	0.31	6.85e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3731827	0.511	rs72843872	chr2:85820027	A/G	cg11108890	chr2:85811471	VAMP5	0.45	5.81	0.3	1.43e-8	Prostate cancer;
LIHC	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg09238746	chr17:78121135	EIF4A3	0.45	6.58	0.34	1.78e-10	Yeast infection;
LIHC	cis	rs17106184	0.892	rs12070594	chr1:51136876	C/A	cg07174182	chr1:51127561	FAF1	-0.74	-8.19	-0.4	5.42e-15	Type 2 diabetes;
LIHC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg13175981	chr1:150552382	MCL1	-0.44	-5.99	-0.31	5.37e-9	Tonsillectomy;
LIHC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.64	-9.14	-0.44	5.72e-18	Blood metabolite levels;
LIHC	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg06108461	chr20:60628389	TAF4	-0.96	-15.88	-0.65	6.13e-43	Body mass index;
LIHC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg23625390	chr15:77176239	SCAPER	0.36	5.79	0.3	1.59e-8	Blood metabolite levels;
LIHC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	8.79	0.43	7.68e-17	Schizophrenia;
LIHC	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-7.35	-0.37	1.51e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-6.34	-0.32	7.36e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.46	-6.72	-0.34	7.56e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.8	0.54	3.46e-27	Colorectal cancer;
LIHC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg26441486	chr22:50317300	CRELD2	0.35	6.29	0.32	9.46e-10	Schizophrenia;
LIHC	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg07541023	chr7:19748670	TWISTNB	0.4	5.97	0.31	5.9e-9	Thyroid stimulating hormone;
LIHC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.6	9.02	0.44	1.38e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.16	0.32	2.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.11	-0.31	2.64e-9	Colorectal cancer;
LIHC	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg03336402	chr7:133662267	EXOC4	-0.5	-5.97	-0.31	5.89e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-12.37	-0.56	2.74e-29	Glomerular filtration rate (creatinine);
LIHC	trans	rs3783890	1.000	rs11621025	chr14:93740831	A/G	cg02802420	chr16:69363236	PDF;COG8	0.33	6.32	0.32	8.07e-10	Body mass index;
LIHC	cis	rs2997447	0.706	rs17184877	chr1:26443908	A/T	cg19633962	chr1:26362018	EXTL1	-0.65	-5.98	-0.31	5.59e-9	QRS complex (12-leadsum);
LIHC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.71	-6.87	-0.35	2.97e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4668356	0.773	rs57335774	chr2:172031967	T/G	cg13882835	chr2:172017928	TLK1	0.45	6.02	0.31	4.41e-9	Cognitive performance;
LIHC	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-17.51	-0.69	1.92e-49	Schizophrenia;
LIHC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg11953164	chr1:23521307	HTR1D	0.29	5.78	0.3	1.68e-8	Height;
LIHC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs1664789	0.844	rs1616049	chr5:53281118	T/A	ch.5.1024479R	chr5:53302184	ARL15	0.54	8.76	0.43	9.22e-17	Waist circumference adjusted for body mass index;
LIHC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.57e-21	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-10.46	-0.49	2.16e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	7.8	0.39	7.33e-14	Lymphocyte counts;
LIHC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.64	-9.0	-0.44	1.56e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.03	14.59	0.62	7.75e-38	Cognitive function;
LIHC	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	0.92	9.45	0.46	5.52e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.28	-0.32	1.04e-9	Coronary artery disease;
LIHC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.68	9.59	0.46	1.89e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs965469	1.000	rs6051809	chr20:3352551	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.44	-0.33	4.02e-10	IFN-related cytopenia;
LIHC	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	1.03	10.06	0.48	5.03e-21	Mean corpuscular volume;
LIHC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.86	-0.39	4.92e-14	Response to antipsychotic treatment;
LIHC	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg16275483	chr1:110013120	SYPL2	-0.49	-6.04	-0.31	4.11e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.73e-12	Personality dimensions;
LIHC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.29	-7.09	-0.36	7.83e-12	Longevity;Endometriosis;
LIHC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.88	12.43	0.56	1.59e-29	Blood metabolite levels;
LIHC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg19682013	chr15:45996608	NA	0.41	7.25	0.37	2.76e-12	Waist circumference;Weight;
LIHC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.41	-0.33	4.8e-10	Height;
LIHC	trans	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg10208301	chr11:6592745	DNHD1	0.47	6.45	0.33	3.74e-10	Coronary artery calcification;
LIHC	cis	rs2637266	1.000	rs1907298	chr10:78329928	A/T	cg18941641	chr10:78392320	NA	0.28	5.96	0.31	6.31e-9	Pulmonary function;
LIHC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.06	-12.43	-0.56	1.56e-29	Vitiligo;
LIHC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21467203	chr3:49911342	NA	-0.49	-8.59	-0.42	3.2e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.35	-5.99	-0.31	5.39e-9	IgG glycosylation;
LIHC	cis	rs6586163	0.872	rs7082720	chr10:90742049	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.53	-7.78	-0.39	8.86e-14	Chronic lymphocytic leukemia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10566763	chr6:106773518	ATG5	-0.39	-6.1	-0.31	2.86e-9	Pancreatic cancer;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.54	-0.42	4.44e-16	Renal cell carcinoma;
LIHC	cis	rs4773330	1.000	rs4773330	chr13:111818832	A/G	cg26911804	chr13:111806221	ARHGEF7	0.65	6.36	0.33	6.53e-10	Bilirubin levels;
LIHC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg21100191	chr22:23484243	RTDR1	0.86	14.94	0.63	3.25e-39	Bone mineral density;
LIHC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.79	-0.34	5.07e-11	Gut microbiome composition (summer);
LIHC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.48	-0.37	6.34e-13	Prevalent atrial fibrillation;
LIHC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.85	8.13	0.4	8.16e-15	Plasma clusterin levels;
LIHC	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-9.17	-0.44	4.43e-18	Response to antipsychotic treatment;
LIHC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.31	0.68	1.13e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6596100	0.538	rs56097052	chr5:132194430	A/G	cg02081065	chr5:132209139	LEAP2	0.27	6.11	0.31	2.69e-9	Breast cancer;
LIHC	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.42	8.0	0.4	1.99e-14	Testicular germ cell tumor;
LIHC	cis	rs539514	0.587	rs7320602	chr13:76332868	A/G	cg04757411	chr13:76259545	LMO7	-0.4	-6.71	-0.34	8.23e-11	Type 1 diabetes;
LIHC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.52	8.4	0.41	1.24e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.35	6.43	0.33	4.22e-10	Mean corpuscular volume;
LIHC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.51	9.35	0.45	1.16e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg05697976	chr12:29376483	FAR2	0.33	6.76	0.34	6.05e-11	QT interval;
LIHC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.41	-6.91	-0.35	2.43e-11	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9596863	0.898	rs7328896	chr13:54334206	A/T	ch.13.53330881F	chr13:54432880	NA	0.44	6.11	0.31	2.77e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg20636351	chr8:55087400	NA	-0.4	-8.07	-0.4	1.16e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7712401	0.755	rs965821	chr5:122137708	A/G	cg18764291	chr5:122110994	SNX2	0.38	6.49	0.33	3.08e-10	Mean platelet volume;
LIHC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.86	0.57	3.77e-31	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.51	-0.38	5.16e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.52	8.25	0.41	3.51e-15	Platelet count;
LIHC	trans	rs13113518	0.812	rs12512737	chr4:56321105	A/T	cg15358633	chr12:38710606	ALG10B	0.44	6.29	0.32	9.77e-10	Height;
LIHC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.49	7.52	0.38	4.94e-13	Platelet count;
LIHC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg26138937	chr11:71823887	C11orf51	1.34	10.79	0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.81	8.29	0.41	2.69e-15	Platelet distribution width;
LIHC	cis	rs10792665	0.541	rs2170009	chr11:82641157	A/G	cg24227371	chr11:82718527	RAB30	-0.29	-6.82	-0.35	4.09e-11	Obesity-related traits;
LIHC	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.87	13.17	0.58	2.47e-32	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.73	10.37	0.49	4.21e-22	Menarche (age at onset);
LIHC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.56	-0.33	1.93e-10	Fear of minor pain;
LIHC	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.78	0.43	7.85e-17	Corneal astigmatism;
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.68	8.45	0.42	8.33e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.23	6.12	0.31	2.62e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.14	0.32	2.28e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.43	-7.72	-0.39	1.28e-13	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.74	10.73	0.5	2.5e-23	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs77633900	0.772	rs2948703	chr15:76711751	A/G	cg21673338	chr15:77095150	SCAPER	-0.52	-5.77	-0.3	1.78e-8	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.34	-6.97	-0.35	1.63e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.46	7.94	0.39	2.89e-14	Mean corpuscular volume;
LIHC	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	13.96	0.6	2.37e-35	Coffee consumption (cups per day);
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-11.11	-0.52	1.05e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.43	6.57	0.33	1.92e-10	Body mass index;Social communication problems;
LIHC	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	0.87	13.63	0.59	4.25e-34	Testicular germ cell tumor;
LIHC	trans	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	6.67	0.34	1e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7937890	0.668	rs12361851	chr11:14267668	C/T	cg22961513	chr11:14280813	SPON1	0.42	5.99	0.31	5.26e-9	Mitochondrial DNA levels;
LIHC	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg02290350	chr8:58132656	NA	0.47	9.16	0.44	4.93e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-6.28	-0.32	1.05e-9	Coronary artery disease;
LIHC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg05110241	chr16:68378359	PRMT7	-0.55	-6.38	-0.33	5.7e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.47	7.0	0.35	1.38e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.66	13.07	0.58	6.09e-32	Schizophrenia;
LIHC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.38	-0.37	1.22e-12	Pancreatic cancer;
LIHC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.67	10.53	0.49	1.19e-22	Response to diuretic therapy;
LIHC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.5	0.49	1.59e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg03342759	chr3:160939853	NMD3	0.56	7.33	0.37	1.63e-12	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09590193	chr11:105947389	KBTBD3;AASDHPPT	0.46	6.32	0.32	8e-10	Pancreatic cancer;
LIHC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.52	8.35	0.41	1.71e-15	Schizophrenia;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg00204748	chr12:29376779	FAR2	0.43	7.93	0.39	3.05e-14	QT interval;
LIHC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.78	-11.74	-0.54	5.61e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.23	5.94	0.31	7.01e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg14593290	chr7:50529359	DDC	0.4	6.69	0.34	8.93e-11	Malaria;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27113440	chr11:22214386	ANO5	0.42	6.21	0.32	1.55e-9	Calcium levels;
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg05527609	chr1:210001259	C1orf107	0.42	6.08	0.31	3.23e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.26	-0.32	1.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.59	-9.35	-0.45	1.21e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.4	5.84	0.3	1.24e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.41	5.9	0.3	8.59e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.59	8.53	0.42	4.89e-16	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.3	6.31	0.32	8.45e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.35	-6.34	-0.32	7.44e-10	Lewy body disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05315670	chr11:64037304	BAD	-0.46	-6.5	-0.33	2.87e-10	Hepatitis;
LIHC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg11764359	chr7:65958608	NA	-0.59	-6.13	-0.31	2.49e-9	Diabetic kidney disease;
LIHC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.83	11.13	0.52	8.94e-25	Coronary artery disease;
LIHC	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.36	6.95	0.35	1.91e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.34e-30	White matter hyperintensity burden;
LIHC	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.52	-6.49	-0.33	2.97e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg16511985	chr3:153974050	SGEF	0.42	9.09	0.44	8.41e-18	Coronary artery disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21244745	chr2:242665522	ING5	0.41	6.03	0.31	4.14e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.57	-9.21	-0.45	3.3e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	9.83	0.47	2.94e-20	Personality dimensions;
LIHC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-1.03	-14.71	-0.62	2.79e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.47	7.44	0.37	7.99e-13	Cognitive function;
LIHC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-0.9	-9.89	-0.47	1.95e-20	Magnesium levels;
LIHC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.95	0.31	6.78e-9	HDL cholesterol levels;
LIHC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg07636037	chr3:49044803	WDR6	-0.83	-6.99	-0.35	1.41e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.5	-7.26	-0.37	2.6e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg03934865	chr2:198174659	NA	0.55	8.84	0.43	5.12e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.24	-0.41	3.67e-15	Chronic sinus infection;
LIHC	trans	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg06453172	chr10:134556979	INPP5A	0.58	8.18	0.4	5.58e-15	Migraine;
LIHC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg00292662	chr22:38071168	LGALS1	0.64	10.15	0.48	2.4e-21	Fat distribution (HIV);
LIHC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.38	-0.68	6.12e-49	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs507080	0.961	rs600969	chr11:118545797	C/T	cg04173919	chr11:118528438	PHLDB1	0.31	5.72	0.3	2.38e-8	Serum metabolite levels;
LIHC	cis	rs1190552	0.894	rs4906203	chr14:102928991	C/T	cg10241871	chr14:102965420	TECPR2	-0.47	-7.39	-0.37	1.12e-12	Blood protein levels;
LIHC	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.57	10.45	0.49	2.29e-22	Systemic lupus erythematosus;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10463451	chr21:37432625	SETD4	-0.47	-6.9	-0.35	2.56e-11	Cognitive function;
LIHC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg22676075	chr6:135203613	NA	0.38	6.22	0.32	1.41e-9	Red blood cell count;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.43	-6.05	-0.31	3.77e-9	Longevity;
LIHC	cis	rs965469	0.708	rs80050989	chr20:3297881	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19729279	chr5:133861951	PHF15	0.42	6.21	0.32	1.52e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.4	0.33	5.15e-10	Lymphocyte counts;
LIHC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	11.34	0.52	1.57e-25	Multiple sclerosis;
LIHC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.54	-9.33	-0.45	1.33e-18	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.73	-0.34	7.04e-11	Hepatocellular carcinoma;
LIHC	cis	rs10818894	0.611	rs10117455	chr9:126692599	G/T	cg16191174	chr9:126692580	DENND1A	0.62	7.08	0.36	8.11e-12	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LIHC	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.49	-8.31	-0.41	2.36e-15	Schizophrenia;
LIHC	cis	rs7119038	0.865	rs11217044	chr11:118696022	T/C	cg19308663	chr11:118741387	NA	0.39	5.95	0.31	6.6e-9	Sjögren's syndrome;
LIHC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	1.04	12.47	0.56	1.16e-29	Red blood cell traits;
LIHC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.49	-6.01	-0.31	4.69e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10963192	chr14:100751514	NA	0.45	6.11	0.31	2.64e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4668356	0.687	rs7563109	chr2:172047280	A/C	cg13882835	chr2:172017928	TLK1	0.44	6.03	0.31	4.3e-9	Cognitive performance;
LIHC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.66	-13.16	-0.58	2.69e-32	Glomerular filtration rate (creatinine);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09430954	chr19:46236890	NA	0.5	6.97	0.35	1.66e-11	Longevity;
LIHC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.52	7.7	0.38	1.52e-13	Total body bone mineral density;
LIHC	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-6.1	-0.31	2.86e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.83	16.18	0.66	3.82e-44	Testicular germ cell tumor;
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg24955955	chr5:415729	AHRR	0.31	6.35	0.32	6.83e-10	Cystic fibrosis severity;
LIHC	cis	rs2705520	0.546	rs2705535	chr3:112208927	C/T	cg09473763	chr3:112282684	SLC35A5	-0.86	-8.8	-0.43	7.11e-17	Asthma (childhood onset);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21475434	chr5:93447410	FAM172A	0.42	6.66	0.34	1.12e-10	Calcium levels;
LIHC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.75	-11.24	-0.52	3.6e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs7818688	0.697	rs17665714	chr8:95982542	T/C	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2302190	0.882	rs12939703	chr17:56611090	G/C	cg12560992	chr17:57184187	TRIM37	0.69	8.88	0.43	3.9e-17	Vitamin D levels;
LIHC	trans	rs16962242	0.744	rs9300813	chr13:104048657	G/A	cg12071008	chr17:76457640	DNAH17	0.46	6.09	0.31	3.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.68	-12.47	-0.56	1.13e-29	Dental caries;
LIHC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.46	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.45	-6.0	-0.31	4.89e-9	Type 2 diabetes;
LIHC	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.47	-7.24	-0.36	2.95e-12	Adiposity;
LIHC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.45	6.27	0.32	1.1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg00977110	chr5:151150581	G3BP1	0.56	7.11	0.36	6.8e-12	Preschool internalizing problems;
LIHC	cis	rs986417	0.892	rs8012339	chr14:60797545	T/G	cg27398547	chr14:60952738	C14orf39	-0.74	-7.5	-0.38	5.71e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs6461503	0.644	rs916789	chr7:20572530	A/C	cg17324776	chr17:41116197	AARSD1	0.41	6.18	0.32	1.79e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.58	-8.08	-0.4	1.12e-14	Testicular germ cell tumor;
LIHC	cis	rs2033908	0.620	rs1440272	chr11:12852309	G/A	cg25843174	chr11:12811716	TEAD1	-0.31	-7.11	-0.36	6.99e-12	Sitting height ratio;
LIHC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.59	-7.98	-0.4	2.3e-14	Sudden cardiac arrest;
LIHC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.45	7.12	0.36	6.51e-12	HDL cholesterol levels;
LIHC	cis	rs288342	0.933	rs288346	chr2:183667120	G/A	cg02625481	chr2:183667124	NA	-0.28	-5.84	-0.3	1.18e-8	Recurrent major depressive disorder;
LIHC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.97	11.78	0.54	4.14e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.72	0.57	1.29e-30	Prudent dietary pattern;
LIHC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.59	-6.46	-0.33	3.57e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.49	-7.96	-0.4	2.48e-14	Crohn's disease;
LIHC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.35	-10.99	-0.51	2.87e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.75	-12.53	-0.56	6.55e-30	Breast cancer;
LIHC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg02079420	chr8:82753780	SNX16	0.34	5.83	0.3	1.28e-8	Diastolic blood pressure;
LIHC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.88	-0.3	9.8e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.57	-8.69	-0.43	1.56e-16	Blood protein levels;
LIHC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.0	-17.78	-0.69	1.57e-50	Body mass index;
LIHC	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg22771759	chr13:24902376	NA	0.32	6.57	0.33	1.9e-10	Obesity-related traits;
LIHC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.88	18.48	0.71	2.22e-53	Height;
LIHC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg23218760	chr8:16884364	EFHA2	0.48	6.27	0.32	1.11e-9	Myopia (pathological);
LIHC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.34	-0.56	3.41e-29	Primary sclerosing cholangitis;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.55	-7.35	-0.37	1.45e-12	Menopause (age at onset);
LIHC	cis	rs1144333	0.655	rs76794487	chr1:76384055	G/A	cg10523679	chr1:76189770	ACADM	0.46	6.14	0.31	2.34e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-6.51	-0.33	2.63e-10	Schizophrenia;
LIHC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.72	-10.85	-0.51	9.17e-24	Migraine;Coronary artery disease;
LIHC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg06207120	chr15:45996521	NA	0.35	6.82	0.35	4.17e-11	Waist circumference;Weight;
LIHC	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.51	-8.63	-0.42	2.28e-16	Mean corpuscular volume;
LIHC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.34	5.83	0.3	1.26e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.67	8.4	0.41	1.2e-15	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10668512	chr15:42565522	GANC;TMEM87A	0.52	7.43	0.37	8.59e-13	Pancreatic cancer;
LIHC	cis	rs4660306	0.744	rs11583290	chr1:45926363	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	6.81	0.35	4.27e-11	Homocysteine levels;
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.73	-0.3	2.22e-8	Total body bone mineral density;
LIHC	cis	rs3790645	1.000	rs657227	chr1:26892104	T/A	cg23229016	chr1:26872525	RPS6KA1	0.23	5.75	0.3	1.95e-8	Glucose homeostasis traits;
LIHC	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg11783602	chr8:55087084	NA	-0.3	-6.11	-0.31	2.73e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg15848620	chr12:58087721	OS9	-0.59	-8.1	-0.4	9.68e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg27136344	chr17:80606911	WDR45L	0.62	10.14	0.48	2.69e-21	Breast cancer;
LIHC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.78	-0.47	4.53e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.29	-0.32	9.67e-10	Renal cell carcinoma;
LIHC	cis	rs1419980	0.730	rs11559767	chr12:7748555	C/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.37	6.03	0.31	4.21e-9	Monocyte count;
LIHC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.42	-6.72	-0.34	7.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.66	6.52	0.33	2.49e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg17063962	chr7:91808500	NA	0.96	15.91	0.65	4.73e-43	Breast cancer;
LIHC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	10.19	0.48	1.83e-21	Initial pursuit acceleration;
LIHC	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.67	-9.94	-0.47	1.24e-20	Eosinophil percentage of white cells;
LIHC	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg15595755	chr5:1867978	NA	0.42	8.3	0.41	2.52e-15	Cardiovascular disease risk factors;
LIHC	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.44	8.58	0.42	3.48e-16	Testicular germ cell tumor;
LIHC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.83	14.75	0.62	1.92e-38	Aortic root size;
LIHC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.54	7.13	0.36	6.18e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.35	-0.32	6.86e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg14791747	chr16:20752902	THUMPD1	-0.49	-6.86	-0.35	3.2e-11	Dental caries;
LIHC	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg09597638	chr17:3907349	NA	0.55	7.55	0.38	4e-13	Type 2 diabetes;
LIHC	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	0.77	8.73	0.43	1.16e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg22528358	chr1:107598549	PRMT6	-0.69	-11.48	-0.53	4.96e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.44	-6.05	-0.31	3.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.44	7.07	0.36	8.52e-12	Red cell distribution width;
LIHC	trans	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg02569823	chr6:5851330	NA	0.39	6.27	0.32	1.11e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg14580859	chr9:123691850	NA	0.37	6.55	0.33	2.11e-10	Rheumatoid arthritis;
LIHC	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.36	-8.25	-0.41	3.45e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.34	6.32	0.32	8.09e-10	Total body bone mineral density;
LIHC	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-6.36	-0.33	6.32e-10	Capecitabine sensitivity;
LIHC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.68	-0.42	1.68e-16	Gut microbiome composition (summer);
LIHC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.5	-7.5	-0.38	5.4e-13	Attention deficit hyperactivity disorder;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27400282	chr2:201446673	SGOL2	-0.28	-6.63	-0.34	1.28e-10	Calcium levels;
LIHC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	5.86	0.3	1.08e-8	Schizophrenia;
LIHC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.44	-0.37	8.37e-13	Breast cancer;
LIHC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.78	-10.56	-0.5	9.39e-23	Systemic lupus erythematosus;
LIHC	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.73	-0.3	2.16e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg03859395	chr2:55845619	SMEK2	0.72	11.75	0.54	5.37e-27	Metabolic syndrome;
LIHC	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-9.52	-0.46	3.35e-19	Colorectal cancer;
LIHC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.58	-8.77	-0.43	8.32e-17	Multiple sclerosis;
LIHC	cis	rs17152411	1.000	rs12573033	chr10:126607803	T/G	cg07906193	chr10:126599966	NA	0.46	7.17	0.36	4.78e-12	Height;
LIHC	cis	rs8067354	0.574	rs1292050	chr17:57965169	T/C	cg02344993	chr17:57696989	CLTC	0.65	10.2	0.48	1.68e-21	Hemoglobin concentration;
LIHC	cis	rs860295	0.665	rs11264367	chr1:155337338	T/C	cg02153340	chr1:155202674	NA	-0.33	-5.87	-0.3	1.01e-8	Body mass index;
LIHC	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.27	-0.32	1.12e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.61	-0.34	1.48e-10	Height;
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg11070056	chr1:107600091	PRMT6	0.7	12.14	0.55	1.9e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	12.63	0.56	2.94e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.35	5.87	0.3	1.01e-8	Educational attainment;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04127825	chr1:167503222	NA	0.46	7.42	0.37	9.47e-13	Cognitive function;
LIHC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.01	0.44	1.47e-17	Lung cancer in ever smokers;
LIHC	cis	rs507080	0.961	rs656505	chr11:118549954	G/A	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.16	0.48	2.37e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.79	0.54	3.8e-27	Height;
LIHC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.5	-8.82	-0.43	6.15e-17	Total body bone mineral density;
LIHC	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12501888	chr15:85177176	SCAND2	-0.54	-8.42	-0.41	1.05e-15	P wave terminal force;
LIHC	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.29	-0.32	9.75e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.5	6.64	0.34	1.23e-10	Mean platelet volume;
LIHC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.62	-8.2	-0.41	5.05e-15	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.86	0.35	3.28e-11	Diabetic kidney disease;
LIHC	cis	rs2834256	0.884	rs11088260	chr21:35081807	G/A	cg14850771	chr21:34775459	IFNGR2	0.41	6.36	0.33	6.29e-10	Red cell distribution width;
LIHC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg10587741	chr22:38071170	LGALS1	0.74	12.88	0.57	3.09e-31	Fat distribution (HIV);
LIHC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.94	-0.47	1.26e-20	Crohn's disease;
LIHC	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.58	8.78	0.43	8.25e-17	Height;
LIHC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.36	-5.87	-0.3	1.04e-8	Height;
LIHC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.0	-9.69	-0.46	8.84e-20	Hip circumference adjusted for BMI;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg14709524	chr16:89940631	TCF25	-0.51	-6.58	-0.34	1.74e-10	Skin colour saturation;
LIHC	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	11.17	0.52	6.49e-25	Myopia (pathological);
LIHC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.61	-11.7	-0.53	8.04e-27	Mean corpuscular volume;
LIHC	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg07148914	chr20:33460835	GGT7	0.64	9.6	0.46	1.79e-19	Height;
LIHC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.52	-7.58	-0.38	3.2e-13	Platelet count;
LIHC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg15123519	chr2:136567270	LCT	-0.36	-5.77	-0.3	1.76e-8	Corneal structure;
LIHC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.38	6.55	0.33	2.07e-10	Psoriasis;
LIHC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.47	-6.66	-0.34	1.1e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg20368463	chr18:77673604	PQLC1	0.55	7.81	0.39	7.11e-14	Schizophrenia;
LIHC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.02	-0.51	2.23e-24	Crohn's disease;
LIHC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.4	0.33	5.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs11212260	0.655	rs117631524	chr11:107336026	T/C	cg25435332	chr11:107328525	CWF19L2	0.84	8.24	0.41	3.8e-15	IgG glycosylation;
LIHC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg08847533	chr14:75593920	NEK9	0.34	5.72	0.3	2.29e-8	Caffeine consumption;
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.18	0.61	3.31e-36	Prudent dietary pattern;
LIHC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	8.07	0.4	1.18e-14	Platelet count;
LIHC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg07741184	chr6:167504864	NA	-0.27	-6.05	-0.31	3.83e-9	Crohn's disease;
LIHC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-6.11	-0.31	2.78e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.25	-12.76	-0.57	9.07e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.74	12.16	0.55	1.65e-28	Mean platelet volume;
LIHC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.62	-10.55	-0.5	1e-22	Post bronchodilator FEV1;
LIHC	cis	rs507080	0.845	rs613377	chr11:118556084	C/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.8e-10	Serum metabolite levels;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.73	12.64	0.56	2.61e-30	Prudent dietary pattern;
LIHC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.61	-10.3	-0.49	7.33e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.69	12.97	0.57	1.51e-31	Mean platelet volume;
LIHC	cis	rs11212260	0.655	rs11212209	chr11:107278735	T/C	cg25435332	chr11:107328525	CWF19L2	0.81	8.77	0.43	8.76e-17	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.1	0.58	4.69e-32	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.94	17.84	0.69	8.48e-51	Menopause (age at onset);
LIHC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.81	-9.72	-0.47	6.83e-20	Mean platelet volume;
LIHC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	6.97	0.35	1.65e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg24541279	chr10:71993373	PPA1	-0.48	-6.25	-0.32	1.23e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10792665	0.512	rs4551795	chr11:82589970	A/G	cg24227371	chr11:82718527	RAB30	-0.28	-6.58	-0.34	1.78e-10	Obesity-related traits;
LIHC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg11839771	chr15:80205821	ST20	0.28	5.77	0.3	1.77e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.9	-0.35	2.47e-11	Mean corpuscular volume;
LIHC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.7	-11.32	-0.52	1.98e-25	Height;
LIHC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.45	-6.8	-0.35	4.72e-11	Cognitive function;
LIHC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.77e-9	Bipolar disorder;
LIHC	cis	rs732505	1.000	rs4807790	chr19:5584614	A/G	cg26242866	chr19:5711310	LONP1	0.83	6.22	0.32	1.44e-9	vWF and FVIII levels;
LIHC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.45	-0.42	8.23e-16	Aortic root size;
LIHC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.64	-0.34	1.25e-10	Mean corpuscular volume;
LIHC	cis	rs17106184	1.000	rs113870552	chr1:50923454	T/C	cg07174182	chr1:51127561	FAF1	-0.56	-6.01	-0.31	4.63e-9	Type 2 diabetes;
LIHC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.52	8.19	0.41	5.09e-15	Pulse pressure;
LIHC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.76	10.9	0.51	6.3e-24	Coronary artery disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25377475	chr1:236030556	LYST	-0.42	-6.27	-0.32	1.1e-9	Systolic blood pressure;
LIHC	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.41	-5.71	-0.3	2.46e-8	Blood protein levels;
LIHC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg04727924	chr7:799746	HEATR2	-0.59	-8.8	-0.43	7.07e-17	Cerebrospinal P-tau181p levels;
LIHC	cis	rs3204270	0.639	rs62080199	chr17:79627906	T/G	cg18367735	chr17:79674897	NA	0.73	8.21	0.41	4.64e-15	Dental caries;
LIHC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	8.56	0.42	3.93e-16	Platelet count;
LIHC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.86	15.04	0.63	1.41e-39	Headache;
LIHC	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg02023728	chr11:77925099	USP35	-0.33	-5.96	-0.31	6.23e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.15	0.32	2.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16684958	chr7:75615977	POR	0.52	8.57	0.42	3.5e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7578199	0.850	rs71430328	chr2:242279980	T/G	cg19372975	chr2:242212901	HDLBP	-0.62	-5.87	-0.3	1.02e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.64	10.14	0.48	2.66e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.39	6.28	0.32	1.01e-9	Menopause (age at onset);
LIHC	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg27205649	chr11:78285834	NARS2	-0.38	-5.84	-0.3	1.22e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.91	0.54	1.32e-27	Cognitive test performance;
LIHC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-0.97	-22.75	-0.78	1.95e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.49	0.67	2.29e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.46	0.46	5.31e-19	Bipolar disorder;
LIHC	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg17130504	chr10:102756923	LZTS2	0.55	7.55	0.38	4.02e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg00656387	chr3:40428638	ENTPD3	0.42	6.84	0.35	3.64e-11	Renal cell carcinoma;
LIHC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg18016565	chr1:150552671	MCL1	-0.62	-12.41	-0.56	1.91e-29	Blood protein levels;
LIHC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	9.08	0.44	8.77e-18	Motion sickness;
LIHC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg22633049	chr21:46681294	NA	-0.38	-6.41	-0.33	4.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg23262073	chr20:60523788	NA	-0.28	-5.73	-0.3	2.16e-8	Body mass index;
LIHC	trans	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10500953	chr16:346518	AXIN1	0.48	6.27	0.32	1.11e-9	Hepatitis;
LIHC	cis	rs882732	1.000	rs10139277	chr14:95035060	C/T	cg14866387	chr14:95027382	SERPINA4	-0.44	-6.34	-0.32	7.42e-10	Blood protein levels;
LIHC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.46	-6.71	-0.34	8.05e-11	Coronary artery disease;
LIHC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.96	15.47	0.64	2.62e-41	Breast cancer;
LIHC	cis	rs9513627	1.000	rs73556178	chr13:100121947	T/C	cg25919922	chr13:100150906	NA	-0.8	-7.07	-0.36	8.77e-12	Obesity-related traits;
LIHC	cis	rs7903847	0.642	rs2275581	chr10:99126249	G/A	cg06359132	chr10:99160096	RRP12	-0.39	-5.72	-0.3	2.38e-8	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg10025462	chr17:27046956	SNORD42B;RPL23A	-0.54	-6.87	-0.35	2.96e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.12	11.56	0.53	2.54e-26	Opioid sensitivity;
LIHC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg07952391	chr2:88470173	THNSL2	0.65	5.82	0.3	1.32e-8	Plasma clusterin levels;
LIHC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.44	-7.39	-0.37	1.15e-12	Mean corpuscular volume;
LIHC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.5	7.08	0.36	8.12e-12	High light scatter reticulocyte count;
LIHC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg00012203	chr2:219082015	ARPC2	-0.83	-13.16	-0.58	2.79e-32	Colorectal cancer;
LIHC	cis	rs61677309	1.000	rs1599809	chr11:118179200	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.37	0.33	5.97e-10	Lung cancer in ever smokers;
LIHC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.98	21.52	0.76	1.48e-65	Bone mineral density;
LIHC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	1.01	15.08	0.63	9.4e-40	Breast cancer;
LIHC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.68	9.93	0.47	1.36e-20	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.47	-7.66	-0.38	1.96e-13	Cognitive function;
LIHC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.37	-0.45	1.01e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg26031613	chr14:104095156	KLC1	-0.4	-5.73	-0.3	2.23e-8	Coronary artery disease;
LIHC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg17750252	chr2:136567154	LCT	0.36	6.28	0.32	1.01e-9	Corneal structure;
LIHC	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.32	7.27	0.37	2.45e-12	Blood metabolite ratios;
LIHC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.52	9.46	0.46	5.04e-19	Systemic lupus erythematosus;
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	6.48	0.33	3.17e-10	Renal cell carcinoma;
LIHC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.1	-0.31	2.87e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.45	6.7	0.34	8.85e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs5753037	0.809	rs5997530	chr22:30203599	C/G	cg01021169	chr22:30184971	ASCC2	-0.36	-6.81	-0.35	4.4e-11	Type 1 diabetes;
LIHC	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	7.72	0.39	1.25e-13	IgG glycosylation;
LIHC	cis	rs959260	1.000	rs4789193	chr17:73404796	A/T	cg20590849	chr17:73267439	MIF4GD	0.53	5.72	0.3	2.28e-8	Systemic lupus erythematosus;
LIHC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg18016565	chr1:150552671	MCL1	0.51	9.75	0.47	5.42e-20	Tonsillectomy;
LIHC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26913058	chr16:419975	MRPL28	-0.49	-7.68	-0.38	1.68e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs903552	0.800	rs12903584	chr15:101999369	G/A	cg19295451	chr15:102010161	PCSK6	-0.45	-6.28	-0.32	1.01e-9	Diabetic kidney disease;
LIHC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.69	-10.88	-0.51	7.09e-24	Cognitive test performance;
LIHC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.59	8.96	0.44	2.16e-17	Platelet count;
LIHC	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.13	26.2	0.82	8.95e-84	Schizophrenia;
LIHC	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	0.65	8.28	0.41	2.87e-15	Corneal structure;
LIHC	cis	rs3812111	0.727	rs471766	chr6:116461477	C/T	cg08036074	chr6:116424633	NT5DC1	0.47	8.1	0.4	9.93e-15	Age-related macular degeneration;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg25107268	chr6:89673349	RNGTT	-0.39	-6.1	-0.31	2.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg05697976	chr12:29376483	FAR2	0.31	6.2	0.32	1.62e-9	QT interval;
LIHC	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.56	-13.94	-0.6	2.85e-35	White blood cell count (basophil);
LIHC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.53	-0.46	2.91e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-6.52	-0.33	2.55e-10	Height;
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg18279126	chr7:2041391	MAD1L1	0.36	5.81	0.3	1.43e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.02	0.31	4.6e-9	Heart rate;
LIHC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg03037974	chr15:76606532	NA	-0.65	-11.47	-0.53	5.63e-26	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.42	-6.78	-0.34	5.33e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg01652190	chr22:50026171	C22orf34	-0.31	-7.12	-0.36	6.27e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg20435097	chr10:126320824	FAM53B	0.38	6.29	0.32	9.7e-10	Asthma;
LIHC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.45	6.03	0.31	4.22e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.67	0.42	1.73e-16	Platelet count;
LIHC	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.62	7.09	0.36	7.72e-12	Height;
LIHC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.81	17.55	0.69	1.22e-49	Gestational age at birth (maternal effect);
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.48	7.51	0.38	5.36e-13	Breast cancer;
LIHC	cis	rs4722404	0.739	rs10951044	chr7:3141147	C/T	cg19214707	chr7:3157722	NA	-0.34	-6.32	-0.32	8.01e-10	Atopic dermatitis;
LIHC	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.52	-0.33	2.53e-10	Homocysteine levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25683012	chr12:57030113	BAZ2A	0.44	6.99	0.35	1.41e-11	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.4	8.12	0.4	8.77e-15	Renal cell carcinoma;
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.49	-7.82	-0.39	6.58e-14	Testicular germ cell tumor;
LIHC	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.72	-10.39	-0.49	3.76e-22	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs3106136	0.681	rs13126976	chr4:95303472	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.66	12.76	0.57	9.24e-31	Rheumatoid arthritis;
LIHC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.5	7.84	0.39	5.77e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-9.0	-0.44	1.65e-17	Asthma;
LIHC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.94	0.31	6.9e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg05044414	chr3:183734942	ABCC5	0.34	6.07	0.31	3.33e-9	Anterior chamber depth;
LIHC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.63	11.68	0.53	9.66e-27	Coronary artery disease;
LIHC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-9.77	-0.47	4.61e-20	Schizophrenia;
LIHC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.23	6.79	0.34	4.96e-11	Blood protein levels;
LIHC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.53	8.15	0.4	6.85e-15	Resting heart rate;
LIHC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg23229984	chr5:148520753	ABLIM3	0.51	5.78	0.3	1.68e-8	Breast cancer;
LIHC	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.81	-14.6	-0.62	7.19e-38	Height;
LIHC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02290350	chr8:58132656	NA	0.38	8.02	0.4	1.66e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.62	-9.65	-0.46	1.18e-19	Smoking behavior;
LIHC	cis	rs17152411	0.895	rs11245419	chr10:126586392	A/T	cg07906193	chr10:126599966	NA	0.44	6.89	0.35	2.74e-11	Height;
LIHC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-0.58	-7.54	-0.38	4.26e-13	Lung cancer;
LIHC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11645453	chr3:52864694	ITIH4	0.21	5.71	0.3	2.39e-8	Electroencephalogram traits;
LIHC	cis	rs8084351	0.524	rs28444913	chr18:50775332	T/G	cg24270629	chr18:50823537	DCC	-0.5	-7.54	-0.38	4.3e-13	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-5.71	-0.3	2.43e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.54	-10.22	-0.48	1.38e-21	Prudent dietary pattern;
LIHC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg12310025	chr6:25882481	NA	-0.41	-6.32	-0.32	8.29e-10	Height;
LIHC	cis	rs4589502	0.512	rs4395023	chr15:67097208	G/A	cg12317470	chr15:67143691	NA	0.47	6.19	0.32	1.77e-9	Lung cancer (smoking interaction);
LIHC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.72	12.13	0.55	2.09e-28	Menopause (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16907344	chr1:16174671	SPEN;FLJ37453	0.41	6.22	0.32	1.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	trans	rs983392	0.709	rs2081547	chr11:59989430	C/T	cg17275991	chr19:58003312	ZNF419	0.43	6.16	0.32	2e-9	Alzheimer's disease (late onset);
LIHC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-9.2	-0.45	3.55e-18	Blood pressure (smoking interaction);
LIHC	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.67	10.61	0.5	6.36e-23	Type 2 diabetes;
LIHC	cis	rs9596863	0.851	rs9568913	chr13:54340500	A/G	ch.13.53330881F	chr13:54432880	NA	0.45	6.1	0.31	2.79e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs16944613	0.541	rs10852135	chr15:91106412	T/C	cg26821196	chr15:91095069	CRTC3	0.46	7.63	0.38	2.4e-13	Colorectal cancer;
LIHC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-0.99	-10.44	-0.49	2.57e-22	Vitiligo;
LIHC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.69	-0.38	1.54e-13	Monocyte percentage of white cells;
LIHC	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.43	-6.18	-0.32	1.87e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg02023728	chr11:77925099	USP35	0.32	5.82	0.3	1.38e-8	Alzheimer's disease (survival time);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26399201	chr5:132149404	ANKRD43	-0.39	-6.25	-0.32	1.19e-9	Cognitive function;
LIHC	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.61	7.52	0.38	4.83e-13	Exhaled nitric oxide output;
LIHC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22618164	chr12:122356400	WDR66	-0.51	-8.41	-0.41	1.1e-15	Mean corpuscular volume;
LIHC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg00277334	chr10:82204260	NA	-0.56	-6.87	-0.35	3.06e-11	Post bronchodilator FEV1;
LIHC	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg01843034	chr6:37503916	NA	-0.46	-7.84	-0.39	5.95e-14	Cognitive performance;
LIHC	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.55	-8.7	-0.43	1.37e-16	Waist circumference;Body mass index;
LIHC	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.8	-0.35	4.63e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.19	-0.32	1.73e-9	Ulcerative colitis;
LIHC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg03983715	chr16:68378420	PRMT7	-0.52	-6.3	-0.32	9.23e-10	Schizophrenia;
LIHC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg15902774	chr15:75289873	SCAMP5	-0.46	-6.82	-0.35	4.24e-11	Lung cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16020249	chr1:27930640	AHDC1	0.39	6.11	0.31	2.75e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.3	-0.32	8.96e-10	Arsenic metabolism;
LIHC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.41	6.51	0.33	2.74e-10	Red blood cell count;
LIHC	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	0.78	8.62	0.42	2.6e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.39	0.37	1.15e-12	Lung cancer;
LIHC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.81	11.94	0.54	1.03e-27	IgG glycosylation;
LIHC	cis	rs4407350	0.870	rs5764873	chr22:44908153	G/A	cg04154583	chr22:44889756	LDOC1L	0.3	6.0	0.31	4.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg03721293	chr16:90014378	DEF8	0.43	7.11	0.36	6.98e-12	Skin colour saturation;
LIHC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg10932868	chr11:921992	NA	0.32	5.88	0.3	9.9e-9	Alzheimer's disease (late onset);
LIHC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg22718636	chr4:961658	DGKQ	0.34	7.07	0.36	8.88e-12	Sjögren's syndrome;
LIHC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.32	7.32	0.37	1.75e-12	Crohn's disease;
LIHC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg09222892	chr1:25734099	RHCE	-0.47	-8.85	-0.43	4.77e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg06046430	chr4:77819534	ANKRD56	0.52	6.42	0.33	4.65e-10	Emphysema distribution in smoking;
LIHC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04282497	chr4:82350883	RASGEF1B	0.45	6.46	0.33	3.69e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg15691649	chr6:25882328	NA	0.51	7.0	0.35	1.35e-11	Blood metabolite levels;
LIHC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.85	0.35	3.45e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.14	0.31	2.35e-9	Bladder cancer;
LIHC	trans	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg10756647	chr7:56101905	PSPH	-1.04	-12.63	-0.56	2.87e-30	Diabetic kidney disease;
LIHC	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16684958	chr7:75615977	POR	0.48	8.04	0.4	1.5e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg19302996	chr17:73780495	UNK	-0.59	-9.44	-0.45	5.8e-19	White matter hyperintensity burden;
LIHC	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg05771511	chr15:63340396	TPM1	-0.44	-5.94	-0.31	7.01e-9	Orofacial clefts;
LIHC	cis	rs11212737	0.765	rs2640767	chr11:108518303	A/C	cg22776369	chr11:108536276	DDX10	0.38	6.3	0.32	9.31e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.5	6.37	0.33	6.05e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.43	6.43	0.33	4.27e-10	Obesity-related traits;
LIHC	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	0.57	9.91	0.47	1.67e-20	Hair morphology;
LIHC	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.69	11.4	0.52	9.57e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.03	-0.55	4.75e-28	Colorectal cancer;
LIHC	trans	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg26939375	chr7:64535504	NA	0.38	6.11	0.31	2.75e-9	Aortic root size;
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	6.36	0.33	6.37e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.88	13.13	0.58	3.53e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20913106	chr8:38324522	FGFR1	0.41	6.76	0.34	5.97e-11	Cognitive function;
LIHC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg18944383	chr4:111397179	ENPEP	0.25	6.32	0.32	8.01e-10	Height;
LIHC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.58	8.38	0.41	1.4e-15	Platelet count;
LIHC	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.5	5.82	0.3	1.33e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.47	9.54	0.46	2.7e-19	Tonsillectomy;
LIHC	cis	rs4845570	1.000	rs6681093	chr1:151755284	C/G	cg07092448	chr1:151763213	TDRKH	-0.54	-6.86	-0.35	3.27e-11	Coronary artery disease;
LIHC	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.36	7.19	0.36	3.98e-12	Blood protein levels;
LIHC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.54	-7.57	-0.38	3.39e-13	Bone properties (heel);
LIHC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.42	-0.33	4.67e-10	Menarche (age at onset);
LIHC	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.38	-5.96	-0.31	6.44e-9	Lung cancer;
LIHC	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs2625529	0.878	rs16956302	chr15:72136243	C/T	cg16672083	chr15:72433130	SENP8	-0.32	-5.95	-0.31	6.6e-9	Red blood cell count;
LIHC	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-5.88	-0.3	9.63e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.49	8.97	0.44	2.01e-17	Height;
LIHC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.45	-8.87	-0.43	4.22e-17	Height;
LIHC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.47	-0.42	7.2e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12079745	0.590	rs41272453	chr1:169412011	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.75	-6.8	-0.35	4.54e-11	QT interval;
LIHC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg06466757	chr4:1255808	NA	0.35	5.86	0.3	1.06e-8	Obesity-related traits;
LIHC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg06363034	chr20:62225388	GMEB2	-0.43	-7.32	-0.37	1.81e-12	Glioblastoma;
LIHC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.65	10.21	0.48	1.52e-21	Tonsillectomy;
LIHC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-7.91	-0.39	3.66e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20135002	chr11:47629003	NA	-0.52	-8.78	-0.43	8.09e-17	Subjective well-being;
LIHC	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.63	-13.08	-0.58	5.4e-32	Brugada syndrome;
LIHC	cis	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg16684958	chr7:75615977	POR	-0.44	-6.77	-0.34	5.69e-11	Eotaxin levels;
LIHC	cis	rs918629	0.761	rs3777175	chr5:95277555	A/G	cg10483112	chr5:95245456	ELL2	-0.36	-6.09	-0.31	3.04e-9	IgG glycosylation;
LIHC	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.51	-6.1	-0.31	2.89e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.63	-8.21	-0.41	4.59e-15	Motion sickness;
LIHC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.07	0.31	3.31e-9	Cognitive ability;
LIHC	cis	rs74233809	1.000	rs11191505	chr10:104766891	C/T	cg03493300	chr10:104813866	CNNM2	0.45	6.0	0.31	4.97e-9	Birth weight;
LIHC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.36	-6.51	-0.33	2.73e-10	Platelet distribution width;
LIHC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.58	-8.91	-0.43	3.03e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.39	-5.9	-0.3	8.76e-9	Ulcerative colitis;
LIHC	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.4	-6.14	-0.31	2.32e-9	Breast cancer;
LIHC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.33	-0.32	7.73e-10	Type 2 diabetes;
LIHC	cis	rs2710642	0.576	rs1872789	chr2:62883470	A/C	cg17519650	chr2:63277830	OTX1	0.52	7.52	0.38	4.73e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-5.98	-0.31	5.76e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.13	0.55	2e-28	Menopause (age at onset);
LIHC	cis	rs3820500	0.543	rs1290557	chr1:118064763	C/T	cg20383390	chr1:117909022	MAN1A2	-0.45	-5.82	-0.3	1.39e-8	Pneumonia;
LIHC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.57	7.14	0.36	5.53e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.54	-7.79	-0.39	8.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg24826892	chr11:71159390	DHCR7	0.47	6.1	0.31	2.86e-9	Vitamin D levels;
LIHC	cis	rs4979906	1.000	rs11002247	chr10:79446901	T/C	cg07817648	chr10:79422355	NA	-0.29	-6.34	-0.32	7.44e-10	Mortality in heart failure;
LIHC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.41	-7.18	-0.36	4.31e-12	Tuberculosis;
LIHC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-8.29	-0.41	2.53e-15	Blood metabolite levels;
LIHC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.02	-0.31	4.6e-9	Total body bone mineral density;
LIHC	cis	rs6746896	0.843	rs72809827	chr2:97390953	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	5.85	0.3	1.14e-8	Bipolar disorder;
LIHC	cis	rs11761441	0.602	rs6979396	chr7:93116	G/A	cg25149888	chr7:81075	NA	-0.26	-5.72	-0.3	2.33e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg10820045	chr2:198174542	NA	0.52	8.73	0.43	1.15e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.41	8.14	0.4	7.37e-15	Methadone dose in opioid dependence;
LIHC	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.68	-11.66	-0.53	1.1e-26	Pediatric autoimmune diseases;
LIHC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.38	-5.71	-0.3	2.42e-8	Lung cancer;
LIHC	cis	rs713477	0.654	rs7143800	chr14:55917734	A/G	cg13175173	chr14:55914753	NA	-0.31	-7.05	-0.36	9.64e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.62	9.44	0.45	5.92e-19	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.08	-0.36	8.24e-12	IgG glycosylation;
LIHC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg18709589	chr6:96969512	KIAA0776	-0.47	-5.76	-0.3	1.83e-8	Migraine;Coronary artery disease;
LIHC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.39	6.14	0.32	2.26e-9	Menopause (age at onset);
LIHC	trans	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.09e-10	Aortic root size;
LIHC	trans	rs1499280	1.000	rs1499280	chr5:52096889	C/A	cg23271318	chr20:44509620	ZSWIM1	-0.66	-6.35	-0.32	6.68e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.36	5.94	0.31	6.92e-9	Blood metabolite levels;
LIHC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	trans	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg21372672	chr17:16614065	CCDC144A	-0.29	-6.54	-0.33	2.19e-10	Educational attainment (years of education);
LIHC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg23229984	chr5:148520753	ABLIM3	0.51	5.78	0.3	1.68e-8	Breast cancer;
LIHC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.87	10.83	0.51	1.06e-23	Bladder cancer;
LIHC	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg14930904	chr10:32216787	ARHGAP12	0.36	6.27	0.32	1.07e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.79	-11.94	-0.54	1.08e-27	Coronary artery disease;
LIHC	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.38	-7.94	-0.39	2.97e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.6	8.31	0.41	2.35e-15	Coronary artery disease;
LIHC	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.79	-0.34	4.95e-11	Hip circumference;Waist circumference;
LIHC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.5	-7.61	-0.38	2.61e-13	Morning vs. evening chronotype;
LIHC	cis	rs57927100	0.734	rs1436138	chr17:75316880	A/G	cg18271897	chr17:75316784	SEPT9	0.36	7.17	0.36	4.78e-12	Systolic blood pressure;
LIHC	trans	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg26939375	chr7:64535504	NA	0.41	6.49	0.33	3.11e-10	Aortic root size;
LIHC	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.84	7.46	0.37	7.12e-13	Uric acid levels;
LIHC	cis	rs4759375	1.000	rs3088303	chr12:123779489	G/A	cg00376283	chr12:123451042	ABCB9	-0.49	-6.31	-0.32	8.53e-10	HDL cholesterol;
LIHC	cis	rs711245	0.748	rs2276671	chr2:36771701	C/A	cg15105969	chr2:36825350	FEZ2	0.49	5.86	0.3	1.08e-8	Height;
LIHC	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg01990225	chr2:97406019	LMAN2L	-0.68	-6.25	-0.32	1.23e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02244288	chr16:89573955	SPG7	-0.31	-6.12	-0.31	2.61e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-5.77	-0.3	1.82e-8	Response to antipsychotic treatment;
LIHC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.41	-0.37	1.01e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg15123519	chr2:136567270	LCT	0.45	9.22	0.45	3.04e-18	Mosquito bite size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23477257	chr7:77469577	PHTF2	0.29	6.13	0.31	2.47e-9	Cognitive function;
LIHC	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.72	-12.62	-0.56	2.99e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.69	-10.96	-0.51	3.81e-24	Skin colour saturation;
LIHC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.41	6.32	0.32	8.18e-10	Resting heart rate;
LIHC	cis	rs1419980	0.730	rs11054872	chr12:7770908	C/T	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.34	-6.7	-0.34	8.53e-11	Testicular germ cell tumor;
LIHC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.31	0.55	4.45e-29	Electrocardiographic conduction measures;
LIHC	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.43	7.21	0.36	3.5e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10411936	1.000	rs16995422	chr19:16519045	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	-0.43	-5.81	-0.3	1.41e-8	White blood cell count;Multiple sclerosis;
LIHC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.06	0.31	3.55e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg25344623	chr2:136566232	LCT	0.34	6.44	0.33	4.06e-10	Mosquito bite size;
LIHC	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.33	0.49	6.11e-22	Colorectal cancer;
LIHC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.87	-12.23	-0.55	8.6e-29	Diastolic blood pressure;
LIHC	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.75	-0.3	2.01e-8	Neuroticism;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20545544	chr12:54673867	CBX5;HNRNPA1;HNRPA1L-2	0.44	6.94	0.35	2.01e-11	Calcium levels;
LIHC	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	6.94	0.35	1.94e-11	Eotaxin levels;
LIHC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4517514	0.509	rs10830411	chr11:89865532	A/G	cg05041596	chr11:89867385	NAALAD2	0.41	6.51	0.33	2.63e-10	Trans fatty acid levels;
LIHC	cis	rs4908760	0.613	rs12028160	chr1:8812214	A/G	cg20416874	chr1:8611966	RERE	0.55	9.2	0.45	3.51e-18	Vitiligo;
LIHC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.44	6.33	0.32	7.52e-10	Aortic root size;
LIHC	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	0.89	8.0	0.4	1.93e-14	Breast cancer;
LIHC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.81	12.98	0.57	1.4e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg22771759	chr13:24902376	NA	0.31	6.47	0.33	3.49e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.81	-0.35	4.45e-11	Diabetic kidney disease;
LIHC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg18016565	chr1:150552671	MCL1	0.55	10.23	0.48	1.32e-21	Melanoma;
LIHC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	1.13	8.8	0.43	6.86e-17	Arsenic metabolism;
LIHC	trans	rs3783890	1.000	rs12884084	chr14:93762704	A/G	cg02802420	chr16:69363236	PDF;COG8	0.32	6.21	0.32	1.5e-9	Body mass index;
LIHC	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.9	-0.35	2.54e-11	Hepatocellular carcinoma;
LIHC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.52	-5.79	-0.3	1.62e-8	Gut microbiome composition (summer);
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg21003380	chr1:156261207	TMEM79	0.38	6.0	0.31	5.08e-9	Tonsillectomy;
LIHC	cis	rs919433	0.726	rs11904247	chr2:198238424	T/G	cg03934865	chr2:198174659	NA	0.54	8.14	0.4	7.24e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.44	-7.25	-0.36	2.88e-12	Fibrinogen levels;
LIHC	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs11671005	0.611	rs35138622	chr19:58912788	C/A	cg25952890	chr19:58913133	NA	0.66	6.48	0.33	3.27e-10	Mean platelet volume;
LIHC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.3	-0.74	1.06e-60	Height;
LIHC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.23	-0.45	2.79e-18	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23453437	chr7:148892747	ZNF282	0.52	6.78	0.34	5.17e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg14146966	chr2:61757674	XPO1	0.45	7.63	0.38	2.43e-13	Tuberculosis;
LIHC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02290350	chr8:58132656	NA	0.44	8.57	0.42	3.49e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg02811702	chr13:24901961	NA	0.26	6.63	0.34	1.32e-10	Obesity-related traits;
LIHC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-11.08	-0.51	1.37e-24	Chronic sinus infection;
LIHC	cis	rs11663156	1.000	rs10515961	chr18:50931238	A/G	cg24270629	chr18:50823537	DCC	-0.48	-6.62	-0.34	1.36e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-6.11	-0.31	2.68e-9	Coronary artery disease;
LIHC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg18912006	chr12:123335444	HIP1R	0.77	7.92	0.39	3.46e-14	Adiponectin levels;
LIHC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.25	-0.48	1.16e-21	Response to antipsychotic treatment;
LIHC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.67	-0.38	1.76e-13	Total body bone mineral density;
LIHC	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg25344623	chr2:136566232	LCT	0.44	8.36	0.41	1.6e-15	Mosquito bite size;
LIHC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.74	13.06	0.58	6.51e-32	Platelet count;
LIHC	cis	rs797680	0.586	rs2281525	chr1:93595306	G/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.38	-6.57	-0.33	1.85e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg01843034	chr6:37503916	NA	-0.39	-6.47	-0.33	3.36e-10	Cognitive performance;
LIHC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.47	-7.21	-0.36	3.51e-12	Longevity;Endometriosis;
LIHC	trans	rs11157436	0.830	rs61972214	chr14:22620372	T/C	cg13567813	chr19:50879636	NR1H2	0.42	6.12	0.31	2.56e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg01788221	chr16:89496183	ANKRD11	-0.43	-6.5	-0.33	2.81e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.04	0.31	4.13e-9	Tonsillectomy;
LIHC	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.75	-0.39	1.08e-13	Coronary artery disease;
LIHC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.89	-0.43	3.51e-17	Gut microbiome composition (summer);
LIHC	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-7.77	-0.39	9.35e-14	Homocysteine levels;
LIHC	cis	rs7395581	0.959	rs2279239	chr11:47281780	T/C	cg25783544	chr11:47291846	MADD	0.45	6.66	0.34	1.06e-10	HDL cholesterol;
LIHC	cis	rs4407350	0.756	rs6519877	chr22:44890192	T/G	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.41	-0.33	4.83e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.65	-10.23	-0.48	1.36e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs507080	0.922	rs525485	chr11:118555754	C/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.52	0.33	2.51e-10	Serum metabolite levels;
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg00656387	chr3:40428638	ENTPD3	0.51	8.52	0.42	5.17e-16	Renal cell carcinoma;
LIHC	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.61	9.92	0.47	1.47e-20	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.4	-7.23	-0.36	3.18e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9641123	0.669	rs2677096	chr7:93246497	T/C	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.43	7.23	0.36	3.24e-12	Crohn's disease;
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.72	-0.5	2.63e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.55	9.8	0.47	3.77e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21467203	chr3:49911342	NA	0.5	9.13	0.44	6.05e-18	Body mass index;
LIHC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.66	-0.42	1.91e-16	Gut microbiome composition (summer);
LIHC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.29	-6.7	-0.34	8.54e-11	Menarche (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01630567	chr9:26892919	C9orf82	0.42	6.09	0.31	3.08e-9	Cognitive function;
LIHC	cis	rs7703744	0.747	rs7707470	chr5:118680273	G/A	cg10911160	chr5:118691794	TNFAIP8	-0.49	-5.74	-0.3	2.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7914558	0.646	rs7909286	chr10:104658992	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-7.2	-0.36	3.87e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.81	16.59	0.67	8.76e-46	Height;
LIHC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.48	-7.65	-0.38	2.08e-13	Neurofibrillary tangles;
LIHC	cis	rs7508	0.546	rs382752	chr8:17898383	A/G	cg01800426	chr8:17659068	MTUS1	0.4	6.52	0.33	2.47e-10	Atrial fibrillation;
LIHC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.32	-0.41	2.09e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.73	-0.3	2.17e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.57	-8.3	-0.41	2.5e-15	Prostate cancer;
LIHC	cis	rs16958440	0.867	rs75901436	chr18:44689644	C/T	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.23	-0.36	3.09e-12	Reticulocyte count;
LIHC	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.27	0.41	3.06e-15	Corneal astigmatism;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg10411590	chr13:21900810	NA	0.42	6.92	0.35	2.29e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg19819135	chr1:70710422	SFRS11	0.38	6.76	0.34	6.01e-11	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.77	-12.45	-0.56	1.34e-29	Height;
LIHC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs713477	0.845	rs4898863	chr14:55910284	T/A	cg13175173	chr14:55914753	NA	-0.33	-7.53	-0.38	4.56e-13	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg00204512	chr16:28754710	NA	0.38	6.9	0.35	2.55e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.81	0.5	1.29e-23	Bladder cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11037719	chr6:2999695	NQO2	0.49	6.96	0.35	1.71e-11	Pancreatic cancer;
LIHC	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg15472797	chr10:135243109	NA	-0.39	-5.87	-0.3	1.03e-8	Systemic lupus erythematosus;
LIHC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.73	-11.14	-0.52	8.5e-25	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg14257396	chr1:107603778	NA	0.36	5.84	0.3	1.23e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.4	8.21	0.41	4.49e-15	Cardiovascular disease risk factors;
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg20295408	chr7:1910781	MAD1L1	0.42	6.27	0.32	1.09e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.43	-5.83	-0.3	1.3e-8	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.39	7.93	0.39	3.13e-14	Renal cell carcinoma;
LIHC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.84	12.81	0.57	5.68e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.55	-7.76	-0.39	9.73e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs57590327	0.679	rs34880320	chr3:81510666	T/C	cg07356753	chr3:81810745	GBE1	-0.42	-5.73	-0.3	2.15e-8	Extraversion;
LIHC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.41	6.81	0.35	4.41e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2191566	0.691	rs59086054	chr19:44549096	C/A	cg20607764	chr19:44506953	ZNF230	-0.37	-6.22	-0.32	1.45e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg00977110	chr5:151150581	G3BP1	0.54	6.88	0.35	2.9100000000000002e-11	Preschool internalizing problems;
LIHC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.48	-6.15	-0.32	2.11e-9	Subjective well-being;
LIHC	cis	rs2710642	0.721	rs6727888	chr2:62887884	T/C	cg17519650	chr2:63277830	OTX1	0.44	6.41	0.33	4.95e-10	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.63	11.24	0.52	3.83e-25	Dupuytren's disease;
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg12064134	chr16:90016061	DEF8	-0.43	-5.82	-0.3	1.34e-8	Skin colour saturation;
LIHC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	9.67	0.46	1.06e-19	Mean platelet volume;
LIHC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.83	12.9	0.57	2.73e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01565824	chr17:79361553	NA	-0.35	-6.1	-0.31	2.8e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.71	10.72	0.5	2.6e-23	Aortic root size;
LIHC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg15848620	chr12:58087721	OS9	-0.56	-7.54	-0.38	4.31e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.31	-0.61	9.82e-37	Alzheimer's disease;
LIHC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.42	6.57	0.33	1.9e-10	Resting heart rate;
LIHC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	12.48	0.56	1.05e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3789045	0.774	rs11801299	chr1:204529084	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.42	-6.49	-0.33	2.93e-10	Educational attainment (college completion);
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.81	0.5	1.26e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.7	-7.69	-0.38	1.63e-13	Exhaled nitric oxide output;
LIHC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.6	8.78	0.43	7.99e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg00677901	chr16:88017247	BANP	-0.62	-9.26	-0.45	2.26e-18	Menopause (age at onset);
LIHC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.67	11.1	0.51	1.22e-24	Menopause (age at onset);
LIHC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg08847533	chr14:75593920	NEK9	-0.37	-6.04	-0.31	3.93e-9	Caffeine consumption;
LIHC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.57	0.46	2.27e-19	Platelet count;
LIHC	cis	rs2279817	0.735	rs12075624	chr1:17991573	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.44	-5.8	-0.3	1.52e-8	Neuroticism;
LIHC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.44	-6.21	-0.32	1.55e-9	Initial pursuit acceleration;
LIHC	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.42	-0.41	1.05e-15	Response to antipsychotic treatment;
LIHC	cis	rs3099143	0.901	rs28551558	chr15:77234637	C/T	cg21673338	chr15:77095150	SCAPER	-0.49	-6.94	-0.35	1.93e-11	Recalcitrant atopic dermatitis;
LIHC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-14.45	-0.62	2.78e-37	Height;
LIHC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.56	-8.55	-0.42	4.09e-16	Ulcerative colitis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg27196102	chr16:23464713	COG7	-0.48	-6.38	-0.33	5.79e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.56	-0.46	2.36e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.29	-6.21	-0.32	1.54e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg05025164	chr4:1340916	KIAA1530	-0.53	-8.37	-0.41	1.48e-15	Obesity-related traits;
LIHC	trans	rs2270927	0.510	rs35930860	chr5:75579946	T/C	cg13563193	chr19:33072644	PDCD5	0.97	9.06	0.44	9.9e-18	Mean corpuscular volume;
LIHC	cis	rs1534166	0.507	rs8177191	chr3:133468139	A/G	cg16262614	chr3:133464971	TF	0.37	5.88	0.3	9.8e-9	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs2820292	1.000	rs2494112	chr1:201787833	G/A	cg11586189	chr1:201857591	SHISA4	0.42	6.19	0.32	1.69e-9	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.59	7.99	0.4	2.15e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg02344993	chr17:57696989	CLTC	0.7	11.9	0.54	1.51e-27	Hemoglobin concentration;
LIHC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.62	-10.92	-0.51	4.99e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.43	-6.81	-0.35	4.27e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.34	7.49	0.38	5.92e-13	Crohn's disease;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-0.63	-9.3	-0.45	1.66e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-5.81	-0.3	1.44e-8	Height;
LIHC	cis	rs4742903	0.935	rs4587392	chr9:106972508	G/A	cg14250997	chr9:106856677	SMC2	0.34	5.73	0.3	2.19e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.65	9.18	0.44	4.29e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.35	7.14	0.36	5.5e-12	Alcohol dependence;
LIHC	trans	rs800082	0.674	rs4618255	chr3:144198658	A/G	cg24215973	chr2:240111563	HDAC4	0.44	6.62	0.34	1.38e-10	Smoking behavior;
LIHC	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-5.91	-0.3	8.31e-9	Neuroticism;
LIHC	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg17640201	chr16:30407289	ZNF48	0.78	12.71	0.57	1.38e-30	Tonsillectomy;
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06420487	chr17:61919686	SMARCD2	0.45	6.14	0.32	2.31e-9	Height;
LIHC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg22777020	chr22:31556080	RNF185	-0.55	-6.31	-0.32	8.82e-10	Colorectal cancer;
LIHC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.38	-8.13	-0.4	7.79e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg02993280	chr1:107599747	PRMT6	0.6	9.04	0.44	1.16e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.37	6.83	0.35	4.01e-11	Ewing sarcoma;
LIHC	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.62	9.93	0.47	1.42e-20	Age at first birth;
LIHC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg14092571	chr14:90743983	NA	-0.41	-6.53	-0.33	2.34e-10	Mortality in heart failure;
LIHC	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg05714579	chr10:131428358	MGMT	0.44	7.07	0.36	8.92e-12	Response to temozolomide;
LIHC	cis	rs7818688	0.591	rs10098025	chr8:95989583	T/A	cg16049864	chr8:95962084	TP53INP1	0.58	6.42	0.33	4.66e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.47	6.66	0.34	1.08e-10	Post bronchodilator FEV1;
LIHC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.69	-14.61	-0.62	6.62e-38	Brugada syndrome;
LIHC	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.51	-6.92	-0.35	2.19e-11	Narcolepsy;
LIHC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg22633049	chr21:46681294	NA	0.39	6.04	0.31	4e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.94	-0.35	1.92e-11	Sudden cardiac arrest;
LIHC	cis	rs477895	0.941	rs12808002	chr11:64110932	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.76	0.34	6.01e-11	Mean platelet volume;
LIHC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.58	-0.34	1.76e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4700695	0.925	rs4700692	chr5:65396279	T/C	cg21114390	chr5:65439923	SFRS12	-0.45	-5.99	-0.31	5.4e-9	Facial morphology (factor 19);
LIHC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.36	7.27	0.37	2.53e-12	Alcohol dependence;
LIHC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.93	0.35	2.1e-11	Gout;
LIHC	trans	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs12744310	0.887	rs12046670	chr1:41809312	T/G	cg03962019	chr1:41807865	NA	0.39	6.24	0.32	1.33e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	10.13	0.48	2.98e-21	Mean platelet volume;
LIHC	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.18	-5.87	-0.3	1.05e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg03989125	chr22:38214979	NA	-0.44	-6.0	-0.31	4.9e-9	Glioblastoma;Glioma;
LIHC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.92	17.05	0.68	1.3e-47	Menopause (age at onset);
LIHC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.49	6.89	0.35	2.64e-11	Schizophrenia;
LIHC	cis	rs7238033	0.624	rs17674709	chr18:43311380	C/G	cg20610511	chr18:43302872	SLC14A1	0.38	6.34	0.32	7.44e-10	Bladder cancer;
LIHC	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.21	0.55	1.02e-28	Eye color traits;
LIHC	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.48	0.33	3.12e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.43	6.09	0.31	3.08e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg27433088	chr4:174089019	GALNT7	0.4	7.33	0.37	1.72e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.83	-0.39	6.02e-14	Type 2 diabetes;
LIHC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.8	-9.36	-0.45	1.1e-18	Red cell distribution width;
LIHC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.78	12.9	0.57	2.69e-31	Anterior chamber depth;
LIHC	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg04865290	chr3:52927548	TMEM110	-0.45	-5.81	-0.3	1.44e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.45	6.12	0.31	2.5e-9	Electroencephalographic traits in alcoholism;
LIHC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.52	-9.17	-0.44	4.65e-18	Blood protein levels;
LIHC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.8	-8.58	-0.42	3.26e-16	Vitiligo;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21606957	chr5:111753754	EPB41L4A	0.39	6.15	0.32	2.18e-9	Calcium levels;
LIHC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.66	11.07	0.51	1.53e-24	Red cell distribution width;
LIHC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.34	22.59	0.77	8.74e-70	Corneal structure;
LIHC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.87	0.54	1.96e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.39	-6.01	-0.31	4.72e-9	Iron status biomarkers;
LIHC	cis	rs12079745	0.590	rs12065030	chr1:169258201	A/G	cg09363564	chr1:169337483	NME7;BLZF1	0.78	7.16	0.36	4.87e-12	QT interval;
LIHC	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg13385521	chr17:29058706	SUZ12P	-0.64	-6.01	-0.31	4.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.33	-0.37	1.71e-12	Bipolar disorder;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21448741	chr8:58168803	NA	0.35	6.55	0.33	2.1e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16275967	chr1:161172255	NDUFS2	0.44	6.99	0.35	1.49e-11	Cognitive function;
LIHC	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.44	-6.65	-0.34	1.16e-10	Schizophrenia;
LIHC	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg16684958	chr7:75615977	POR	0.41	6.73	0.34	7.13e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.41	0.37	1.01e-12	Bipolar disorder;
LIHC	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg14765414	chr13:113652335	MCF2L	-0.31	-5.71	-0.3	2.42e-8	Systolic blood pressure;
LIHC	cis	rs7872515	1.000	rs10992221	chr9:94832043	A/G	cg01248375	chr9:94877805	SPTLC1	-0.53	-7.32	-0.37	1.78e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06932451	chr19:36869880	NA	0.52	8.06	0.4	1.29e-14	Cognitive function;
LIHC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	1.08	14.69	0.62	3.18e-38	Heart rate;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09326324	chr1:161123937	UFC1	0.43	6.71	0.34	8.01e-11	Cognitive function;
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg10755058	chr3:40428713	ENTPD3	-0.38	-6.39	-0.33	5.59e-10	Renal cell carcinoma;
LIHC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.73	0.65	2.5e-42	Tonsillectomy;
LIHC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-5.95	-0.31	6.66e-9	Pancreatic cancer;
LIHC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.51	-9.13	-0.44	6.11e-18	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-12.11	-0.55	2.45e-28	Glomerular filtration rate (creatinine);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06207460	chr9:4741011	AK3	-0.47	-6.44	-0.33	4e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.52	-8.87	-0.43	4.27e-17	Obesity-related traits;
LIHC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.66	12.76	0.57	9.24e-31	Rheumatoid arthritis;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg12064134	chr16:90016061	DEF8	-0.45	-6.09	-0.31	2.98e-9	Skin colour saturation;
LIHC	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-0.82	-9.18	-0.44	4.13e-18	Exhaled nitric oxide output;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20431080	chr7:149158239	ZNF777	0.44	6.44	0.33	4.08e-10	Cognitive function;
LIHC	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.56	10.18	0.48	1.95e-21	Lewy body disease;
LIHC	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.07	-0.4	1.22e-14	Response to antipsychotic treatment;
LIHC	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg18944383	chr4:111397179	ENPEP	0.25	6.4	0.33	5.13e-10	Height;
LIHC	cis	rs965469	0.779	rs6133031	chr20:3300857	A/C	cg25506879	chr20:3388711	C20orf194	-0.5	-6.2	-0.32	1.66e-9	IFN-related cytopenia;
LIHC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg17279839	chr7:150038598	RARRES2	0.38	7.77	0.39	9.54e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21467203	chr3:49911342	NA	-0.46	-8.54	-0.42	4.46e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.63	5.82	0.3	1.35e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26897989	chr16:1907736	C16orf73	-0.47	-5.91	-0.3	8.18e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.5	9.58	0.46	1.99e-19	Loneliness (linear analysis);
LIHC	cis	rs7209700	0.547	rs8078614	chr17:45351505	C/T	cg08085267	chr17:45401833	C17orf57	0.52	6.75	0.34	6.41e-11	IgG glycosylation;
LIHC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-14.69	-0.62	3.16e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.65	9.23	0.45	2.93e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.29	-0.32	9.53e-10	Menarche (age at onset);
LIHC	cis	rs2599510	0.811	rs2710628	chr2:32758353	A/C	cg02381751	chr2:32503542	YIPF4	0.51	7.07	0.36	8.97e-12	Interleukin-18 levels;
LIHC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-8.85	-0.43	4.79e-17	Body mass index (adult);
LIHC	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.41	-0.33	4.74e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.19	-0.36	4.16e-12	Alcohol dependence;
LIHC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.62	11.24	0.52	3.86e-25	Mean corpuscular volume;
LIHC	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.39	7.39	0.37	1.13e-12	Metabolite levels;
LIHC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.6	6.82	0.35	4.15e-11	Systemic lupus erythematosus;
LIHC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.77	9.36	0.45	1.11e-18	Bladder cancer;
LIHC	cis	rs742115	0.563	rs7762842	chr6:11303695	G/A	cg25250968	chr6:11318770	NEDD9	-0.4	-6.19	-0.32	1.69e-9	Coronary artery disease;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg00656387	chr3:40428638	ENTPD3	0.45	7.27	0.37	2.44e-12	Renal cell carcinoma;
LIHC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.63	12.15	0.55	1.73e-28	Menopause (age at onset);
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	10.72	0.5	2.66e-23	Lymphocyte counts;
LIHC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.8	0.35	4.71e-11	Lung cancer;
LIHC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg18306943	chr3:40428807	ENTPD3	0.35	5.97	0.31	6.03e-9	Renal cell carcinoma;
LIHC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00158227	chr1:6514781	ESPN	-0.27	-6.04	-0.31	3.99e-9	N-glycan levels;
LIHC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.81	9.67	0.46	1.06e-19	Cognitive function;
LIHC	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.22	0.32	1.42e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.78	0.3	1.68e-8	Bipolar disorder;
LIHC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.64	12.07	0.55	3.41e-28	Menopause (age at onset);
LIHC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg03983715	chr16:68378420	PRMT7	-0.5	-5.71	-0.3	2.45e-8	Schizophrenia;
LIHC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.55	9.75	0.47	5.52e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.23	-0.41	4.02e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.69	11.34	0.52	1.65e-25	Oral cavity cancer;
LIHC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	9.39	0.45	8.68e-19	Type 2 diabetes;
LIHC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg16736954	chr20:23401023	NAPB	0.73	8.71	0.43	1.31e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs965469	0.947	rs4611719	chr20:3228423	G/A	cg25506879	chr20:3388711	C20orf194	-0.59	-6.8	-0.35	4.69e-11	IFN-related cytopenia;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.85	0.57	4.09e-31	Prudent dietary pattern;
LIHC	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.41	-6.72	-0.34	7.79e-11	Schizophrenia;
LIHC	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.36	-6.66	-0.34	1.09e-10	Coronary artery disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19909334	chr14:53418212	FERMT2	-0.44	-6.47	-0.33	3.33e-10	Cognitive function;
LIHC	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.65	7.83	0.39	6.22e-14	Itch intensity from mosquito bite;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.56	-7.71	-0.38	1.38e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-8.46	-0.42	7.84e-16	Lung cancer;
LIHC	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg18912006	chr12:123335444	HIP1R	-0.63	-7.25	-0.36	2.86e-12	Schizophrenia;
LIHC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	9.05	0.44	1.1e-17	Cognitive test performance;
LIHC	cis	rs10916814	0.632	rs12089623	chr1:20903643	G/A	cg24502330	chr1:20914028	CDA	-0.31	-6.87	-0.35	3.04e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.04	-0.36	1.03e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	8.9	0.43	3.33e-17	Initial pursuit acceleration;
LIHC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.57	0.42	3.55e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.45	7.49	0.38	6.07e-13	Type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13294780	chr4:140005756	ELF2	-0.44	-6.12	-0.31	2.58e-9	Pancreatic cancer;
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	8.64	0.42	2.18e-16	Obesity-related traits;
LIHC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.8	0.3	1.47e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.26	6.02	0.31	4.51e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg15448220	chr1:150897856	SETDB1	-0.4	-6.36	-0.33	6.55e-10	Tonsillectomy;
LIHC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.58	10.08	0.48	4.26e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7714584	1.000	rs11167519	chr5:150265407	C/T	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	trans	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg10756647	chr7:56101905	PSPH	1.06	13.28	0.58	9.29e-33	Diabetic kidney disease;
LIHC	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg23422044	chr7:1970798	MAD1L1	-0.69	-10.6	-0.5	6.77e-23	Bipolar disorder;
LIHC	cis	rs11212737	0.694	rs2624134	chr11:108513335	C/T	cg22776369	chr11:108536276	DDX10	0.37	6.21	0.32	1.53e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.49	-5.91	-0.3	8.15e-9	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs67981189	0.593	rs6573994	chr14:71536662	G/A	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.4	-6.39	-0.33	5.36e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs4499344	0.657	rs259238	chr19:33140381	A/G	cg22980127	chr19:33182716	NUDT19	-0.52	-6.49	-0.33	3.07e-10	Mean platelet volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04516253	chr19:40596853	ZNF780A	-0.44	-6.31	-0.32	8.81e-10	Pancreatic cancer;
LIHC	trans	rs6968419	0.802	rs6978849	chr7:115809732	A/C	cg25721452	chr12:102133339	SYCP3	-0.39	-6.16	-0.32	2.1e-9	Intraocular pressure;
LIHC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.74	11.27	0.52	2.82e-25	Corneal astigmatism;
LIHC	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.5	8.08	0.4	1.12e-14	Corneal astigmatism;
LIHC	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-0.5	-5.72	-0.3	2.34e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.86	0.51	8.13e-24	Alzheimer's disease;
LIHC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.74	-0.3	2.12e-8	Melanoma;
LIHC	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg09795085	chr6:101329169	ASCC3	0.52	7.4	0.37	1.06e-12	Neuroticism;
LIHC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg23791538	chr6:167370224	RNASET2	-0.61	-10.39	-0.49	3.77e-22	Primary biliary cholangitis;
LIHC	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.77	11.58	0.53	2.15e-26	Subjective well-being;
LIHC	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.43	-6.87	-0.35	3e-11	Obesity-related traits;
LIHC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.54	6.21	0.32	1.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.01	0.44	1.47e-17	Lung cancer in ever smokers;
LIHC	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.57	8.37	0.41	1.45e-15	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs13113518	0.756	rs11939652	chr4:56398709	T/A	cg15358633	chr12:38710606	ALG10B	0.43	6.1	0.31	2.91e-9	Height;
LIHC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.55	7.72	0.39	1.27e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.47	-7.77	-0.39	9.52e-14	Menarche (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01377139	chr6:41039751	C6orf130;NFYA	-0.41	-6.09	-0.31	3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.58	8.02	0.4	1.72e-14	Coronary artery disease;
LIHC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.49	-0.59	1.51e-33	Coffee consumption (cups per day);
LIHC	cis	rs66569888	0.516	rs11681404	chr2:106736313	T/C	cg16099169	chr2:106886729	NA	-0.49	-5.8	-0.3	1.51e-8	Facial morphology (factor 23);
LIHC	cis	rs4699052	0.963	rs6533078	chr4:104212156	C/T	cg16532752	chr4:104119610	CENPE	-0.39	-6.29	-0.32	9.82e-10	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.87	10.79	0.5	1.54e-23	Bladder cancer;
LIHC	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.81	-0.3	1.42e-8	Coronary artery disease;
LIHC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	9.27	0.45	2.09e-18	Platelet count;
LIHC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg15105060	chr4:7024189	TBC1D14	-0.77	-6.38	-0.33	5.87e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.69	6.69	0.34	8.95e-11	Migraine;Coronary artery disease;
LIHC	cis	rs9783347	1.000	rs4353250	chr11:18323517	T/C	cg15585147	chr11:18324498	HPS5	0.45	6.94	0.35	2.02e-11	Pancreatic cancer;
LIHC	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.47	8.87	0.43	4.25e-17	Testicular germ cell tumor;
LIHC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg07234388	chr1:156261841	TMEM79	0.49	8.57	0.42	3.66e-16	Tonsillectomy;
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.45	0.42	8.3e-16	Lymphocyte counts;
LIHC	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.29	21.25	0.75	1.82e-64	Corneal structure;
LIHC	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.57	9.24	0.45	2.72e-18	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.44	-8.74	-0.43	1.1e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.41	5.97	0.31	5.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-8.34	-0.41	1.91e-15	Total body bone mineral density;
LIHC	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg27205649	chr11:78285834	NARS2	0.38	5.71	0.3	2.4e-8	Alzheimer's disease (survival time);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00995209	chr8:144881704	SCRIB	-0.43	-6.66	-0.34	1.07e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.42	6.55	0.33	2.16e-10	Resting heart rate;
LIHC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.8e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg19591588	chr3:45730799	SACM1L	-0.37	-6.18	-0.32	1.83e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7116495	1.000	rs6592448	chr11:71670044	C/T	cg26138937	chr11:71823887	C11orf51	0.81	8.05	0.4	1.41e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.84	-0.65	9.44e-43	Chronic sinus infection;
LIHC	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg14906510	chr12:7781169	NA	0.47	7.23	0.36	3.18e-12	HDL cholesterol levels;
LIHC	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.13	0.4	7.94e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.38	0.7	5.97e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg00277334	chr10:82204260	NA	-0.58	-7.53	-0.38	4.6e-13	Post bronchodilator FEV1;
LIHC	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg13753209	chr17:57696993	CLTC	0.69	10.45	0.49	2.29e-22	Hemoglobin concentration;
LIHC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.96	0.44	2.06e-17	Lung cancer;
LIHC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg03959625	chr15:84868606	LOC388152	0.47	6.76	0.34	6.14e-11	Schizophrenia;
LIHC	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	6.11	0.31	2.7e-9	Response to antipsychotic treatment;
LIHC	cis	rs9543976	1.000	rs2328964	chr13:76138830	G/T	cg01531495	chr13:76123901	UCHL3	0.52	6.12	0.31	2.54e-9	Diabetic retinopathy;
LIHC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg04055981	chr11:115044050	NA	0.36	5.76	0.3	1.9e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.76	0.3	1.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg20991723	chr1:152506922	NA	0.5	8.59	0.42	3.19e-16	Hair morphology;
LIHC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg18016565	chr1:150552671	MCL1	0.56	10.25	0.48	1.14e-21	Melanoma;
LIHC	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.6	-8.83	-0.43	5.59e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.64	-8.35	-0.41	1.72e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.85	-13.01	-0.58	1.04e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.22	-0.41	4.22e-15	Gut microbiome composition (summer);
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.56	8.85	0.43	4.77e-17	Longevity;Endometriosis;
LIHC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	trans	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg26939375	chr7:64535504	NA	0.4	6.37	0.33	6.17e-10	Aortic root size;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.22	-0.32	1.49e-9	Diastolic blood pressure;
LIHC	cis	rs7429990	0.932	rs936428	chr3:48167281	A/G	cg11946769	chr3:48343235	NME6	-0.48	-6.41	-0.33	4.78e-10	Educational attainment (years of education);
LIHC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.8	0.3	1.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg01596870	chr19:55963115	NA	-0.63	-7.97	-0.4	2.4e-14	Obesity-related traits;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06656553	chr16:89960601	TCF25	-0.46	-5.91	-0.3	8.17e-9	Skin colour saturation;
LIHC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.49	-7.85	-0.39	5.52e-14	Diastolic blood pressure;
LIHC	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.56	-6.42	-0.33	4.64e-10	Primary sclerosing cholangitis;
LIHC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.34	-6.21	-0.32	1.5e-9	Platelet distribution width;
LIHC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg12374095	chr12:54320830	NA	0.44	6.81	0.35	4.38e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg14222432	chr12:29376421	FAR2	0.34	6.19	0.32	1.68e-9	QT interval;
LIHC	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.49	-0.38	6.1e-13	Mean platelet volume;
LIHC	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs807029	0.577	rs701834	chr10:102761801	C/T	cg25179470	chr10:102756915	LZTS2	0.44	6.04	0.31	4.05e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg19894588	chr14:64061835	NA	-0.6	-7.73	-0.39	1.2e-13	Optic cup area;Vertical cup-disc ratio;
LIHC	trans	rs16863064	0.932	rs9817667	chr3:187887694	A/G	cg02569115	chr17:76922138	TIMP2	-0.36	-6.22	-0.32	1.41e-9	Schizophrenia;
LIHC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.78	12.93	0.57	2.07e-31	Psoriasis;
LIHC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-8.73	-0.43	1.15e-16	Schizophrenia;
LIHC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.61	9.19	0.45	3.82e-18	Longevity;
LIHC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	6.3	0.32	8.98e-10	Obesity-related traits;
LIHC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.53	-6.85	-0.35	3.36e-11	Breast cancer;
LIHC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg22079354	chr11:130786696	SNX19	0.42	5.96	0.31	6.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.96	-11.1	-0.51	1.14e-24	Neuroticism;
LIHC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs713477	1.000	rs4901562	chr14:55901373	G/A	cg13175173	chr14:55914753	NA	-0.31	-6.94	-0.35	2.01e-11	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs7899916	1.000	rs7899916	chr10:4786841	C/T	cg19819135	chr1:70710422	SFRS11	0.37	6.6	0.34	1.57e-10	Major depressive disorder;
LIHC	cis	rs4700695	0.925	rs12518262	chr5:65414004	A/G	cg21114390	chr5:65439923	SFRS12	-0.47	-6.18	-0.32	1.83e-9	Facial morphology (factor 19);
LIHC	cis	rs10503871	0.604	rs12548308	chr8:30446493	G/A	cg26383811	chr8:30366931	RBPMS	0.4	6.17	0.32	1.89e-9	Metabolite levels  (X-11787);
LIHC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.78	12.34	0.56	3.41e-29	Resting heart rate;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06796825	chr17:17140633	FLCN	0.45	6.18	0.32	1.85e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg07424592	chr7:64974309	NA	0.82	9.64	0.46	1.27e-19	Diabetic kidney disease;
LIHC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg24879335	chr3:133465180	TF	0.29	6.48	0.33	3.12e-10	Iron status biomarkers;
LIHC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.94	15.99	0.65	2.37e-43	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg01596870	chr19:55963115	NA	-0.65	-9.31	-0.45	1.54e-18	Obesity-related traits;
LIHC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg25344623	chr2:136566232	LCT	0.42	8.59	0.42	3.04e-16	Mosquito bite size;
LIHC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.38	8.89	0.43	3.7e-17	Type 2 diabetes;
LIHC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.43	5.75	0.3	2.03e-8	Colorectal cancer;
LIHC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.39	-5.78	-0.3	1.66e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.46	-6.79	-0.34	5.11e-11	Dermatomyositis;
LIHC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.87	0.35	2.95e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-6.5	-0.33	2.87e-10	Breast cancer;
LIHC	cis	rs7258465	1.000	rs34010330	chr19:18559657	G/C	cg10790698	chr19:18539756	SSBP4	-0.37	-7.7	-0.38	1.52e-13	Breast cancer;
LIHC	trans	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-7.08	-0.36	8.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.83	14.52	0.62	1.57e-37	Headache;
LIHC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.91	-0.54	1.38e-27	Chronic sinus infection;
LIHC	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	0.96	16.38	0.66	6.31e-45	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00152838	chr16:24741724	TNRC6A	-0.49	-5.78	-0.3	1.7e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.75	8.18	0.4	5.53e-15	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23182539	chr10:121355708	TIAL1	0.48	7.02	0.35	1.21e-11	Pancreatic cancer;
LIHC	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg04592579	chr7:75616294	TMEM120A	0.41	7.01	0.35	1.28e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg19743168	chr1:23544995	NA	0.4	7.31	0.37	1.89e-12	Height;
LIHC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.62	6.96	0.35	1.76e-11	Menarche (age at onset);
LIHC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg23791538	chr6:167370224	RNASET2	-0.36	-5.77	-0.3	1.77e-8	Primary biliary cholangitis;
LIHC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.72	12.2	0.55	1.15e-28	Dental caries;
LIHC	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.51	-6.94	-0.35	1.93e-11	Obesity-related traits;
LIHC	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.45	0.37	7.93e-13	Neuroticism;
LIHC	cis	rs2292096	1.000	rs6658596	chr1:200748921	A/G	cg11814564	chr1:200748674	CAMSAP1L1	0.47	6.29	0.32	9.76e-10	Epilepsy;
LIHC	cis	rs240764	0.717	rs180963	chr6:101127213	T/C	cg12253828	chr6:101329408	ASCC3	0.42	6.41	0.33	4.94e-10	Neuroticism;
LIHC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.02	-14.18	-0.61	3.13e-36	Cognitive function;
LIHC	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs9378688	1.000	rs72830184	chr6:2223930	T/C	cg12303981	chr6:2244766	GMDS	-0.49	-6.22	-0.32	1.48e-9	Caudate nucleus volume;
LIHC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg12365402	chr11:9010492	NRIP3	-0.34	-8.94	-0.44	2.54e-17	Hemoglobin concentration;
LIHC	trans	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg22319618	chr22:45562946	NUP50	-0.63	-8.51	-0.42	5.59e-16	Breast cancer;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.47	-7.57	-0.38	3.58e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.42	6.67	0.34	1.02e-10	Red blood cell count;
LIHC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.85	-12.92	-0.57	2.19e-31	Obesity-related traits;
LIHC	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.89	14.78	0.62	1.46e-38	Schizophrenia;
LIHC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg15848620	chr12:58087721	OS9	-0.54	-7.31	-0.37	1.91e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.74	-10.71	-0.5	2.87e-23	Dental caries;
LIHC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-13.48	-0.59	1.66e-33	Vitiligo;
LIHC	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.49	7.36	0.37	1.42e-12	Myeloid white cell count;
LIHC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.52	7.43	0.37	8.98e-13	Glycated hemoglobin levels;
LIHC	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.45	-6.99	-0.35	1.41e-11	Type 2 diabetes;
LIHC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.63	-0.42	2.31e-16	Heart rate;
LIHC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.16	-0.36	5e-12	Diabetic kidney disease;
LIHC	cis	rs9322817	0.691	rs4946648	chr6:105329422	G/T	cg02098413	chr6:105308735	HACE1	0.41	7.7	0.38	1.49e-13	Thyroid stimulating hormone;
LIHC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17554472	chr22:41940697	POLR3H	-0.57	-6.18	-0.32	1.78e-9	Vitiligo;
LIHC	cis	rs1982346	1.000	rs2544426	chr4:106717797	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.59	5.91	0.3	8.34e-9	Lung function (FEV1);
LIHC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-6.07	-0.31	3.38e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.41	-7.76	-0.39	9.77e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg10820045	chr2:198174542	NA	0.49	7.44	0.37	8.27e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05901451	chr6:126070800	HEY2	-0.37	-6.24	-0.32	1.29e-9	High light scatter reticulocyte count;
LIHC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	0.84	9.54	0.46	2.78e-19	Mitochondrial DNA levels;
LIHC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.44	-6.51	-0.33	2.71e-10	Aortic root size;
LIHC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.46	6.28	0.32	1.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.91	16.84	0.67	8.86e-47	Menopause (age at onset);
LIHC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.66e-17	Prudent dietary pattern;
LIHC	cis	rs1190552	0.846	rs1061924	chr14:102975655	C/T	cg10241871	chr14:102965420	TECPR2	-0.46	-6.99	-0.35	1.45e-11	Blood protein levels;
LIHC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg18357645	chr12:58087776	OS9	-0.45	-6.98	-0.35	1.49e-11	Multiple sclerosis;
LIHC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.73	0.3	2.26e-8	Parkinson's disease;
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg09417038	chr21:47716443	C21orf57	-0.5	-7.41	-0.37	9.98e-13	Testicular germ cell tumor;
LIHC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.55	8.8	0.43	7.07e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs2336384	1.000	rs2103876	chr1:12053100	C/T	cg13216073	chr1:12042593	MFN2	0.43	6.53	0.33	2.39e-10	Platelet count;
LIHC	cis	rs10508774	1.000	rs116546771	chr10:32884600	C/T	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg19894588	chr14:64061835	NA	-0.68	-10.13	-0.48	2.97e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.35	-0.32	6.76e-10	Prevalent atrial fibrillation;
LIHC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.95	10.08	0.48	4.25e-21	Schizophrenia;
LIHC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg14440974	chr22:39074834	NA	-0.34	-5.77	-0.3	1.8e-8	Menopause (age at onset);
LIHC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.81	-0.3	1.43e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.4	8.72	0.43	1.26e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.5	8.04	0.4	1.51e-14	Schizophrenia;
LIHC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg03037974	chr15:76606532	NA	-0.51	-7.94	-0.39	2.93e-14	Blood metabolite levels;
LIHC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.85	14.89	0.63	5.33e-39	Headache;
LIHC	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.54	7.25	0.37	2.78e-12	Systolic blood pressure;
LIHC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.15	0.32	2.11e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.82	8.67	0.42	1.7e-16	Platelet count;
LIHC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.84	15.53	0.64	1.61e-41	IgG glycosylation;
LIHC	cis	rs3753275	0.579	rs10779703	chr1:8596182	C/T	cg20416874	chr1:8611966	RERE	-0.49	-6.21	-0.32	1.54e-9	Educational attainment;
LIHC	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.42	8.92	0.43	2.92e-17	Coronary artery disease;
LIHC	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	19.28	0.72	1.36e-56	Colorectal cancer;
LIHC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg12042659	chr19:58951599	ZNF132	-0.37	-6.39	-0.33	5.53e-10	Uric acid clearance;
LIHC	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.13	-0.4	8.18e-15	Colorectal cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12617538	chr9:69786570	NA	0.38	6.37	0.33	5.99e-10	Longevity;
LIHC	cis	rs365132	0.517	rs7706790	chr5:176359136	C/T	cg16309518	chr5:176445507	NA	-0.49	-9.14	-0.44	5.47e-18	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.29	0.66	1.51e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.82	-0.3	1.32e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2304069	0.909	rs8073	chr5:149362400	T/G	cg12661370	chr5:149340060	SLC26A2	-0.53	-6.46	-0.33	3.53e-10	HIV-1 control;
LIHC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.08	0.48	4.35e-21	Colorectal cancer;
LIHC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.86	15.04	0.63	1.41e-39	Headache;
LIHC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-6.16	-0.32	2.03e-9	Body mass index;
LIHC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.49	7.84	0.39	5.77e-14	Schizophrenia;
LIHC	cis	rs4728302	0.838	rs755664	chr7:133596671	C/G	cg10665199	chr7:133106180	EXOC4	0.37	6.55	0.33	2.05e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg09872104	chr7:134855509	C7orf49	-0.76	-6.09	-0.31	2.99e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.55	-7.58	-0.38	3.26e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.61	12.16	0.55	1.59e-28	Plateletcrit;Platelet count;
LIHC	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg15893493	chr8:124194847	FAM83A	-0.71	-6.96	-0.35	1.79e-11	Urinary uromodulin levels;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg07133347	chr1:107600762	PRMT6	0.44	6.44	0.33	4.02e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.08	13.84	0.6	6.53e-35	Economic and political preferences (immigration/crime);
LIHC	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.57e-22	Fuchs's corneal dystrophy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13673319	chr1:174968334	CACYBP	0.48	6.47	0.33	3.45e-10	Pancreatic cancer;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-6.04	-0.31	3.92e-9	Total body bone mineral density;
LIHC	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.48	6.31	0.32	8.63e-10	Interleukin-17 levels;
LIHC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.67	-0.53	9.89e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.08	19.33	0.72	8.71e-57	Testicular germ cell tumor;
LIHC	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg05552183	chr6:42928497	GNMT	0.49	7.06	0.36	9.43e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.23	5.84	0.3	1.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.12	-0.44	6.7e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17597744	chr8:53627099	RB1CC1	0.42	6.29	0.32	9.86e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg19000871	chr14:103996768	TRMT61A	-0.54	-8.73	-0.43	1.16e-16	Coronary artery disease;
LIHC	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg10820045	chr2:198174542	NA	-0.57	-9.24	-0.45	2.73e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	6.0	0.31	5.13e-9	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs16828019	0.704	rs12031277	chr1:41491801	A/G	cg03387723	chr1:41708464	SCMH1	-0.4	-6.27	-0.32	1.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs943466	1.000	rs6940353	chr6:33752550	G/A	cg25922239	chr6:33757077	LEMD2	-0.47	-5.78	-0.3	1.66e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15813570	chr14:64854563	MTHFD1	0.39	6.13	0.31	2.41e-9	Cognitive function;
LIHC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg02079420	chr8:82753780	SNX16	0.37	6.86	0.35	3.3e-11	Diastolic blood pressure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07431748	chr10:99094531	FRAT2	-0.42	-6.08	-0.31	3.24e-9	Systolic blood pressure;
LIHC	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26734620	chr12:56694298	CS	1.27	10.89	0.51	6.57e-24	Psoriasis vulgaris;
LIHC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs2274273	1.000	rs1047556	chr14:55600282	A/T	cg01864836	chr14:55583639	NA	-0.36	-6.13	-0.31	2.43e-9	Protein biomarker;
LIHC	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.06	-0.31	3.58e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs963731	0.649	rs9679498	chr2:39218458	G/C	cg04010122	chr2:39346883	SOS1	-0.74	-6.0	-0.31	5.11e-9	Corticobasal degeneration;
LIHC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.3	-0.32	9.05e-10	Fear of minor pain;
LIHC	cis	rs9649465	1.000	rs6950659	chr7:123361910	C/T	cg03229431	chr7:123269106	ASB15	-0.37	-8.01	-0.4	1.82e-14	Migraine;
LIHC	cis	rs9577381	0.628	rs9577380	chr13:112575568	A/G	cg25344322	chr13:112575014	NA	-0.24	-6.32	-0.32	8.19e-10	Axial length;
LIHC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.76	9.91	0.47	1.65e-20	Mean platelet volume;
LIHC	cis	rs9290065	0.622	rs11705811	chr3:160643787	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-8.08	-0.4	1.13e-14	Kawasaki disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06751603	chr19:11152063	SMARCA4	0.44	6.29	0.32	9.86e-10	Longevity;
LIHC	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.71	0.38	1.36e-13	Triglyceride levels;
LIHC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.14	0.52	8.66e-25	Hemoglobin concentration;
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg08469215	chr1:156261351	TMEM79	0.4	6.59	0.34	1.68e-10	Tonsillectomy;
LIHC	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.63	9.04	0.44	1.17e-17	Monocyte count;
LIHC	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg03934865	chr2:198174659	NA	-0.46	-6.46	-0.33	3.6e-10	Intracranial aneurysm;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.49e-17	Prudent dietary pattern;
LIHC	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg01858014	chr14:56050164	KTN1	-0.57	-6.51	-0.33	2.6200000000000003e-10	Putamen volume;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.7	10.61	0.5	6.12e-23	Menarche (age at onset);
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.68	11.16	0.52	6.98e-25	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	11.02	0.51	2.24e-24	Lung cancer in ever smokers;
LIHC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.43	-5.95	-0.31	6.67e-9	Longevity;
LIHC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18252515	chr7:66147081	NA	-0.44	-6.39	-0.33	5.46e-10	Aortic root size;
LIHC	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg26138144	chr22:38071188	LGALS1	0.43	7.96	0.4	2.62e-14	Fat distribution (HIV);
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.94	0.8	5.69e-79	Prudent dietary pattern;
LIHC	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.45	8.19	0.41	5.16e-15	Testicular germ cell tumor;
LIHC	cis	rs7116495	1.000	rs2885880	chr11:71655847	A/G	cg26138937	chr11:71823887	C11orf51	-0.69	-6.93	-0.35	2.08e-11	Severe influenza A (H1N1) infection;
LIHC	trans	rs975809	0.966	rs11004607	chr10:56622686	G/T	cg10878170	chr12:12764498	CREBL2	0.4	6.13	0.31	2.41e-9	Carotid intima media thickness;
LIHC	cis	rs2710642	0.721	rs1487074	chr2:62890551	T/C	cg17519650	chr2:63277830	OTX1	0.51	7.47	0.37	6.57e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.64	-8.79	-0.43	7.59e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs74544699	1.000	rs938094	chr4:74805942	C/G	cg16072462	chr4:74847758	PF4	0.57	5.9	0.3	8.96e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.36	-7.12	-0.36	6.6e-12	Testicular germ cell tumor;
LIHC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.01	-0.4	1.84e-14	Monocyte percentage of white cells;
LIHC	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.97	17.74	0.69	2.19e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg08847533	chr14:75593920	NEK9	-0.52	-8.0	-0.4	1.95e-14	IgG glycosylation;
LIHC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	ch.11.42038R	chr11:967971	AP2A2	0.58	10.78	0.5	1.63e-23	Alzheimer's disease (late onset);
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-8.3	-0.41	2.38e-15	Lymphocyte counts;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs1559088	0.501	rs35599132	chr19:33570554	G/A	cg17764715	chr19:33622953	WDR88	0.48	6.36	0.33	6.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-0.93	-17.51	-0.69	1.78e-49	Coronary artery disease;
LIHC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.65	12.33	0.55	3.87e-29	High light scatter reticulocyte count;
LIHC	cis	rs12922317	1.000	rs12922317	chr16:12077632	A/G	cg09319797	chr16:12061715	TNFRSF17	0.4	7.09	0.36	7.68e-12	Schizophrenia;
LIHC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.44	6.01	0.31	4.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg04610667	chr7:75704037	NA	-0.35	-6.31	-0.32	8.63e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20135002	chr11:47629003	NA	-0.57	-10.06	-0.48	5.05e-21	Subjective well-being;
LIHC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.92	0.3	7.74e-9	Menopause (age at onset);
LIHC	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-6.07	-0.31	3.37e-9	Testicular germ cell tumor;
LIHC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg18944383	chr4:111397179	ENPEP	0.31	7.29	0.37	2.14e-12	Coronary artery disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg10730208	chr12:58290540	NA	0.38	6.29	0.32	9.87e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg04306507	chr14:55594613	LGALS3	0.32	6.16	0.32	2.06e-9	Protein biomarker;
LIHC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.6	7.61	0.38	2.63e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.57	6.85	0.35	3.5e-11	Alzheimer's disease;
LIHC	cis	rs244293	0.931	rs244308	chr17:53212053	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg08847533	chr14:75593920	NEK9	0.54	8.32	0.41	2.08e-15	IgG glycosylation;
LIHC	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.49	5.95	0.31	6.51e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.76	0.54	4.77e-27	Prudent dietary pattern;
LIHC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg14067834	chr17:29058358	SUZ12P	-0.66	-6.54	-0.33	2.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg27523141	chr10:43048294	ZNF37B	0.37	6.27	0.32	1.11e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg03034668	chr16:1723424	CRAMP1L	-0.37	-6.4	-0.33	5.17e-10	Coronary artery disease;
LIHC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.85	-0.3	1.15e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg00204512	chr16:28754710	NA	0.34	6.39	0.33	5.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.37	5.81	0.3	1.4e-8	Menopause (age at onset);
LIHC	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs7116495	0.881	rs7930722	chr11:71737484	C/G	cg26138937	chr11:71823887	C11orf51	-0.81	-8.04	-0.4	1.43e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs57590327	0.503	rs898763	chr3:81513408	T/C	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Extraversion;
LIHC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg05564831	chr3:52568323	NT5DC2	0.39	6.27	0.32	1.07e-9	Bipolar disorder;
LIHC	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.84	-0.3	1.2e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.41	0.37	9.76e-13	Prudent dietary pattern;
LIHC	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg03037974	chr15:76606532	NA	-0.59	-9.91	-0.47	1.68e-20	Blood metabolite levels;
LIHC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.86	0.3	1.09e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.65	-0.34	1.13e-10	Mean corpuscular volume;
LIHC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg24296786	chr1:45957014	TESK2	0.43	6.17	0.32	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs36051895	0.664	rs10815154	chr9:5095538	G/A	cg02405213	chr9:5042618	JAK2	-0.68	-11.61	-0.53	1.69e-26	Pediatric autoimmune diseases;
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.75	11.13	0.52	8.93e-25	Menarche (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27309142	chr7:32801485	NA	0.36	6.08	0.31	3.27e-9	Hepatitis;
LIHC	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg18081818	chr7:23246105	NA	-0.4	-5.98	-0.31	5.71e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.05	13.02	0.58	9.19e-32	Economic and political preferences (immigration/crime);
LIHC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.63	12.9	0.57	2.6e-31	Fat distribution (HIV);
LIHC	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg26139080	chr11:47293733	MADD	-0.48	-8.06	-0.4	1.28e-14	HDL cholesterol;
LIHC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.32	-0.32	8.2e-10	Total body bone mineral density;
LIHC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.97	-18.03	-0.7	1.54e-51	Breast cancer;
LIHC	cis	rs61925898	1	rs61925898	chr12:66779537	A/G	cg16791601	chr12:66731901	HELB	-0.48	-9.69	-0.46	8.58e-20	Basophil percentage of granulocytes;Basophil percentage of white cells;
LIHC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg09417038	chr21:47716443	C21orf57	0.52	8.16	0.4	6.37e-15	Testicular germ cell tumor;
LIHC	cis	rs7116495	0.737	rs613971	chr11:71574910	G/A	cg26138937	chr11:71823887	C11orf51	0.71	6.93	0.35	2.15e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.38	1.4e-13	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg09829573	chr1:144692074	NBPF9	-0.45	-8.3	-0.41	2.42e-15	Hip geometry;
LIHC	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg20991723	chr1:152506922	NA	0.5	8.33	0.41	1.96e-15	Hair morphology;
LIHC	cis	rs860295	0.580	rs10908461	chr1:155275727	C/T	cg02153340	chr1:155202674	NA	-0.35	-6.14	-0.31	2.35e-9	Body mass index;
LIHC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.81	-0.43	6.34e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.39	-5.72	-0.3	2.31e-8	Bronchopulmonary dysplasia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23333220	chr15:64679825	TRIP4	0.4	6.17	0.32	1.94e-9	Cognitive function;
LIHC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg14580859	chr9:123691850	NA	0.39	6.86	0.35	3.27e-11	Rheumatoid arthritis;
LIHC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.43	5.95	0.31	6.76e-9	Life satisfaction;
LIHC	cis	rs4575098	0.681	rs12727614	chr1:161097241	T/A	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.43	7.68	0.38	1.68e-13	Monocyte percentage of white cells;
LIHC	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.67	-6.6	-0.34	1.61e-10	Multiple sclerosis;
LIHC	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.61	-0.42	2.64e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Vitiligo;
LIHC	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.11	-0.55	2.39e-28	Colorectal cancer;
LIHC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.46	-0.46	5.23e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.39	-7.11	-0.36	6.72e-12	Electrocardiographic conduction measures;
LIHC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	0.75	7.86	0.39	4.95e-14	Testicular germ cell tumor;
LIHC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.54	8.69	0.43	1.47e-16	Height;
LIHC	cis	rs16828019	0.777	rs67460888	chr1:41469337	T/C	cg03387723	chr1:41708464	SCMH1	-0.45	-6.91	-0.35	2.37e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg16011800	chr17:1958478	HIC1	-0.52	-7.42	-0.37	9.6e-13	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs611744	0.967	rs673015	chr8:109191669	C/T	cg18478394	chr8:109455254	TTC35	0.44	7.69	0.38	1.58e-13	Dupuytren's disease;
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.34	-0.58	5.71e-33	Bipolar disorder and schizophrenia;
LIHC	cis	rs17106184	1.000	rs72898957	chr1:50966301	T/C	cg07174182	chr1:51127561	FAF1	-0.61	-6.54	-0.33	2.26e-10	Type 2 diabetes;
LIHC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg23109721	chr2:106886537	NA	-0.66	-6.18	-0.32	1.79e-9	Facial morphology (factor 23);
LIHC	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg22963979	chr7:1858916	MAD1L1	0.4	5.72	0.3	2.34e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.44	-7.54	-0.38	4.28e-13	Alzheimer's disease (late onset);
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg01776012	chr4:56262702	TMEM165	0.53	6.17	0.32	1.98e-9	Glycated hemoglobin levels;
LIHC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.5	-8.81	-0.43	6.29e-17	Asthma;
LIHC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.44	6.85	0.35	3.52e-11	Height;
LIHC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05665937	chr4:1216051	CTBP1	0.45	6.08	0.31	3.23e-9	Obesity-related traits;
LIHC	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.46	5.83	0.3	1.28e-8	Bipolar disorder;
LIHC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg09137382	chr11:130731461	NA	0.41	5.85	0.3	1.15e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs10213084	1.000	rs28588661	chr4:147499726	G/A	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg00428638	chr19:7224713	INSR	0.34	6.85	0.35	3.49e-11	Hypothyroidism;
LIHC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.83	-14.0	-0.6	1.65e-35	Monocyte count;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg26266098	chr10:102756795	LZTS2	0.44	6.57	0.33	1.85e-10	Alopecia areata;
LIHC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.77	15.35	0.64	8.38e-41	Mortality in heart failure;
LIHC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.67	12.15	0.55	1.72e-28	Breast cancer;
LIHC	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.46	8.52	0.42	5.3e-16	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg07424592	chr7:64974309	NA	0.8	9.21	0.45	3.38e-18	Diabetic kidney disease;
LIHC	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg20129853	chr10:51489980	NA	-0.41	-8.78	-0.43	7.83e-17	Prostate-specific antigen levels;
LIHC	cis	rs3736485	0.966	rs10220909	chr15:51762412	C/A	cg08986416	chr15:51914746	DMXL2	-0.41	-6.11	-0.31	2.7e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	7.29	0.37	2.12e-12	Total body bone mineral density;
LIHC	trans	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg24036039	chr1:3397125	ARHGEF16	0.37	6.19	0.32	1.71e-9	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.27	-0.66	1.72e-44	Diabetic kidney disease;
LIHC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18867708	chr6:26865862	GUSBL1	-0.56	-8.55	-0.42	4.13e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.21	-0.32	1.52e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.47	6.98	0.35	1.56e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs16958440	1.000	rs75800624	chr18:44633605	G/C	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.8	-0.43	6.93e-17	Cutaneous nevi;
LIHC	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.16	0.32	2.02e-9	Protein biomarker;
LIHC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21448741	chr8:58168803	NA	0.37	6.02	0.31	4.48e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.63	-10.63	-0.5	5.58e-23	Brugada syndrome;
LIHC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.78	5.82	0.3	1.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg03934865	chr2:198174659	NA	0.55	8.35	0.41	1.71e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg13385521	chr17:29058706	SUZ12P	0.75	7.6	0.38	2.85e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08677398	chr8:58056175	NA	0.36	6.1	0.31	2.81e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg03721293	chr16:90014378	DEF8	-0.34	-6.03	-0.31	4.35e-9	Skin colour saturation;
LIHC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg05110241	chr16:68378359	PRMT7	-0.62	-6.82	-0.35	4.19e-11	HDL cholesterol;
LIHC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg18887096	chr2:219472410	PLCD4	0.39	6.7	0.34	8.83e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.616	rs10839342	chr11:49742687	A/C	cg03929089	chr4:120376271	NA	-0.86	-16.84	-0.67	9.09e-47	Height;
LIHC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.54	6.27	0.32	1.06e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg21724239	chr8:58056113	NA	0.49	6.53	0.33	2.43e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg14515779	chr1:101123966	NA	0.64	12.35	0.56	3.09e-29	Monocyte count;
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.63	9.26	0.45	2.23e-18	Menarche (age at onset);
LIHC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.18	-0.4	5.63e-15	Chronic sinus infection;
LIHC	cis	rs2710642	0.721	rs6545969	chr2:62891474	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-6.97	-0.35	1.65e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs6466055	0.720	rs6466057	chr7:104952483	A/G	cg04380332	chr7:105027541	SRPK2	0.36	6.81	0.35	4.41e-11	Schizophrenia;
LIHC	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.52	0.49	1.34e-22	Hypertriglyceridemia;
LIHC	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	7.08	0.36	8.34e-12	Bipolar disorder;
LIHC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.61	9.14	0.44	5.63e-18	Recombination rate (females);
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.89e-13	Lymphocyte counts;
LIHC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-0.83	-6.87	-0.35	3.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.41	-5.94	-0.31	7.17e-9	Longevity;
LIHC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.34	6.69	0.34	9.1e-11	HDL cholesterol levels;
LIHC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.52	6.24	0.32	1.26e-9	Schizophrenia;
LIHC	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg14515779	chr1:101123966	NA	0.48	6.91	0.35	2.35e-11	Monocyte count;
LIHC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	0.79	6.09	0.31	3.03e-9	IgG glycosylation;
LIHC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg21395723	chr22:39101663	GTPBP1	0.41	6.88	0.35	2.8e-11	Menopause (age at onset);
LIHC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg18944383	chr4:111397179	ENPEP	0.25	6.23	0.32	1.41e-9	Coronary artery disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18037489	chr17:2275685	SGSM2	0.41	6.13	0.31	2.4e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg22842854	chr12:123319900	HIP1R	0.62	8.08	0.4	1.11e-14	Schizophrenia;
LIHC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.56	-7.68	-0.38	1.7e-13	Neuroblastoma;
LIHC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	0.72	8.19	0.4	5.38e-15	Testicular germ cell tumor;
LIHC	trans	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04565464	chr8:145669602	NFKBIL2	0.41	6.84	0.35	3.75e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.63	9.65	0.46	1.17e-19	Corneal astigmatism;
LIHC	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.27	-13.8	-0.6	9.37e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.77	0.34	5.6e-11	Ileal carcinoids;
LIHC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.1	-9.96	-0.47	1.1e-20	Diabetic retinopathy;
LIHC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.43	-6.99	-0.35	1.41e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.43	7.17	0.36	4.55e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.48	-0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.67	-0.34	1.06e-10	Endometrial cancer;
LIHC	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.83	10.83	0.51	1.04e-23	Menopause (age at onset);
LIHC	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.35	-6.02	-0.31	4.39e-9	Menopause (age at onset);
LIHC	cis	rs1494373	0.543	rs3806329	chr1:220863423	C/T	cg06786860	chr1:220876396	NA	0.42	6.41	0.33	4.84e-10	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.43	0.33	4.27e-10	Hepatocellular carcinoma;
LIHC	cis	rs3018712	0.532	rs7932726	chr11:68414727	T/C	cg16797656	chr11:68205561	LRP5	-0.45	-5.87	-0.3	1.04e-8	Total body bone mineral density;
LIHC	cis	rs7707921	0.881	rs74906189	chr5:81261923	A/G	cg15871215	chr5:81402204	ATG10	-0.64	-6.05	-0.31	3.73e-9	Breast cancer;
LIHC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.54	-9.08	-0.44	8.92e-18	Colorectal cancer;
LIHC	trans	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	6.88	0.35	2.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.92	-0.35	2.24e-11	Bladder cancer;
LIHC	cis	rs2637266	0.783	rs7914756	chr10:78476406	A/T	cg18941641	chr10:78392320	NA	-0.27	-5.81	-0.3	1.44e-8	Pulmonary function;
LIHC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.61	-0.34	1.5e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.47	-5.88	-0.3	9.84e-9	Schizophrenia;
LIHC	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg00792783	chr2:198669748	PLCL1	0.41	5.92	0.31	7.71e-9	Dermatomyositis;
LIHC	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs35160687	0.644	rs4832265	chr2:86488265	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.35	5.75	0.3	2.01e-8	Night sleep phenotypes;
LIHC	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.58	-0.42	3.32e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	18.74	0.71	2.05e-54	IgG glycosylation;
LIHC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg04155231	chr12:9217510	LOC144571	0.31	5.85	0.3	1.15e-8	Sjögren's syndrome;
LIHC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg08694578	chr2:241835147	C2orf54	-0.52	-7.17	-0.36	4.79e-12	Urinary metabolites;
LIHC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.57	9.74	0.47	5.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs6938574	0.672	rs6569520	chr6:128365034	C/G	cg18796704	chr6:132216033	ENPP1	-0.34	-6.65	-0.34	1.14e-10	Menarche (age at onset);
LIHC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.83	0.3	1.3e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	24.68	0.8	6.05e-78	Chronic sinus infection;
LIHC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.43	5.73	0.3	2.22e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg12903224	chr12:29470962	FAR2	-0.42	-6.8	-0.35	4.72e-11	QT interval;
LIHC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18656765	chr4:159644664	PPID	0.41	6.28	0.32	1.02e-9	Pancreatic cancer;
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.54	-0.33	2.3e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg00091569	chr3:40428383	ENTPD3	0.4	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	cis	rs7944735	0.508	rs2869531	chr11:47797402	G/C	cg20307385	chr11:47447363	PSMC3	-0.51	-5.77	-0.3	1.81e-8	Intraocular pressure;
LIHC	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02450064	chr17:40260053	DHX58	-0.3	-6.36	-0.33	6.33e-10	Fibrinogen levels;
LIHC	cis	rs28602288	1	rs28602288	chr19:41388740	C/T	cg14550611	chr19:41354682	CYP2A6	0.4	5.92	0.3	7.75e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LIHC	cis	rs6448317	0.539	rs11931422	chr4:24936925	T/C	cg21108841	chr4:24914750	CCDC149	-0.48	-6.55	-0.33	2.14e-10	Heschl's gyrus morphology;
LIHC	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg23587288	chr2:27483067	SLC30A3	-0.33	-6.0	-0.31	5.08e-9	Blood metabolite levels;
LIHC	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg17757837	chr7:157058334	UBE3C	-0.66	-9.4	-0.45	7.82e-19	Body mass index;
LIHC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg18867708	chr6:26865862	GUSBL1	-0.48	-7.33	-0.37	1.68e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.8	11.92	0.54	1.24e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg02290350	chr8:58132656	NA	-0.44	-8.95	-0.44	2.25e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.45	9.93e-19	Bipolar disorder;
LIHC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.77e-22	Hemoglobin concentration;
LIHC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.51	0.46	3.43e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.61	-7.41	-0.37	9.84e-13	Mean platelet volume;
LIHC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.44	-6.75	-0.34	6.37e-11	Height;
LIHC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	6.29	0.32	9.72e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.62	-9.98	-0.47	9.33e-21	Obesity-related traits;
LIHC	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.78	-0.5	1.56e-23	Inflammatory bowel disease;
LIHC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.74	14.52	0.62	1.53e-37	Mortality in heart failure;
LIHC	cis	rs4684776	0.676	rs2067471	chr3:11299602	A/G	cg00170343	chr3:11313890	ATG7	-0.48	-6.47	-0.33	3.31e-10	Small vessel stroke;
LIHC	trans	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg07393940	chr7:158741817	NA	0.54	6.25	0.32	1.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg03970086	chr16:88974840	CBFA2T3	0.35	7.04	0.36	1.03e-11	Social autistic-like traits;
LIHC	cis	rs244293	0.931	rs244345	chr17:53196977	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.37e-13	Menarche (age at onset);
LIHC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	7.18	0.36	4.38e-12	Schizophrenia;
LIHC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.51	-6.39	-0.33	5.33e-10	Resting heart rate;
LIHC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg05714579	chr10:131428358	MGMT	0.44	7.14	0.36	5.63e-12	Response to temozolomide;
LIHC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg01864069	chr14:103024347	NA	-0.45	-7.35	-0.37	1.52e-12	Platelet count;
LIHC	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.63	7.35	0.37	1.47e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.74	7.74	0.39	1.15e-13	Post bronchodilator FEV1;
LIHC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.75	0.39	1.08e-13	Obesity-related traits;
LIHC	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.25	-0.36	2.85e-12	Body mass index;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.56	8.11	0.4	8.97e-15	Renal cell carcinoma;
LIHC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.35	-0.37	1.47e-12	Body mass index;
LIHC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.47	6.03	0.31	4.15e-9	Mean platelet volume;
LIHC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.78	8.87	0.43	4.01e-17	Vitiligo;
LIHC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.48	6.45	0.33	3.93e-10	Pulse pressure;
LIHC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.89	-0.43	3.45e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg20240347	chr1:204465584	NA	-0.31	-6.25	-0.32	1.21e-9	Schizophrenia;
LIHC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg00071026	chr13:113650936	MCF2L	-0.38	-6.19	-0.32	1.77e-9	Systolic blood pressure;
LIHC	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-10.99	-0.51	2.79e-24	Colorectal cancer;
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.91	-0.3	8.35e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11822910	0.645	rs7122734	chr11:57190420	C/T	cg00522883	chr11:57194120	SLC43A3	-0.56	-7.24	-0.36	3.06e-12	Platelet distribution width;
LIHC	cis	rs12711979	0.509	rs882418	chr2:3820113	A/G	cg17052675	chr2:3827356	NA	-0.64	-9.65	-0.46	1.22e-19	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg24130564	chr14:104152367	KLC1	-0.43	-7.02	-0.36	1.17e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg07936541	chr2:98206095	ANKRD36B	-0.44	-6.2	-0.32	1.64e-9	Urinary tract infection frequency;
LIHC	cis	rs6596100	0.538	rs72799458	chr5:132188063	C/T	cg02081065	chr5:132209139	LEAP2	0.29	6.34	0.32	7.38e-10	Breast cancer;
LIHC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg12863693	chr15:85201151	NMB	-0.4	-5.8	-0.3	1.47e-8	Schizophrenia;
LIHC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg17980119	chr2:219472607	PLCD4	0.34	5.79	0.3	1.62e-8	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12298905	chr1:214162308	PROX1	-0.49	-6.09	-0.31	3.03e-9	Systolic blood pressure;
LIHC	trans	rs4566648	0.593	rs7356198	chr4:84173186	G/A	cg06219686	chr17:29421884	NF1	-0.5	-6.04	-0.31	4e-9	Monocyte count;
LIHC	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.36	8.92	0.43	2.77e-17	Asthma (sex interaction);
LIHC	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.38	7.45	0.37	7.62e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.1	-0.36	7.3e-12	Renal cell carcinoma;
LIHC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.68	-12.85	-0.57	4.17e-31	Body mass index;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-7.81	-0.39	6.86e-14	Crohn's disease;
LIHC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.83	12.91	0.57	2.46e-31	Glomerular filtration rate (creatinine);
LIHC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.44	6.18	0.32	1.78e-9	Morning vs. evening chronotype;
LIHC	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.881	rs642618	chr11:71788193	G/A	cg26138937	chr11:71823887	C11orf51	-0.68	-6.84	-0.35	3.56e-11	Severe influenza A (H1N1) infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25485084	chr12:118809325	TAOK3	0.37	6.2	0.32	1.59e-9	Cognitive function;
LIHC	cis	rs1144333	0.655	rs12402347	chr1:76447986	C/T	cg10523679	chr1:76189770	ACADM	0.44	5.91	0.3	8.5e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.61	-11.0	-0.51	2.6e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.5	15.23	0.64	2.46e-40	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.64	-13.2	-0.58	1.91e-32	Airflow obstruction;
LIHC	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.62	9.85	0.47	2.57e-20	Anterior chamber depth;
LIHC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	16.52	0.67	1.77e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs6058796	1.000	rs6141777	chr20:31249947	C/T	cg02600331	chr11:130417168	NA	0.35	7.44	0.37	8.33e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg22705602	chr4:152727874	NA	-0.28	-5.75	-0.3	1.99e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.38e-28	Height;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.38	5.91	0.3	8.34e-9	Lewy body disease;
LIHC	cis	rs1789	0.653	rs13142069	chr4:15593692	C/T	cg21329975	chr4:15471214	CC2D2A	0.37	5.96	0.31	6.35e-9	Blood protein levels;
LIHC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-8.97	-0.44	1.99e-17	Dental caries;
LIHC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg19680672	chr10:131412579	MGMT	-0.42	-6.42	-0.33	4.45e-10	Response to temozolomide;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05736393	chr2:74775957	LOXL3	0.45	6.1	0.31	2.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	0.93	16.95	0.68	3.21e-47	Parkinson's disease;
LIHC	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	26.37	0.82	2.15e-84	Schizophrenia;
LIHC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.32	6.3	0.32	9.34e-10	Cancer;
LIHC	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-10.02	-0.48	6.87e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.58	9.13	0.44	6.03e-18	Monocyte count;
LIHC	cis	rs17496827	0.753	rs4673024	chr2:223361153	G/A	cg25565276	chr2:223520875	FARSB	0.46	6.74	0.34	6.91e-11	Anorexia nervosa;
LIHC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.46	-6.18	-0.32	1.78e-9	Major depressive disorder;
LIHC	cis	rs13161895	0.887	rs863231	chr5:179409613	C/T	cg02702477	chr5:179499311	RNF130	0.63	9.02	0.44	1.34e-17	LDL cholesterol;
LIHC	cis	rs4478037	0.822	rs3924696	chr3:33122013	T/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.04	-0.36	1.05e-11	Major depressive disorder;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.54	0.77	1.29e-69	Prudent dietary pattern;
LIHC	cis	rs17106184	1.000	rs2137676	chr1:51217839	C/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs4407350	0.818	rs5765751	chr22:44926018	A/T	cg11695653	chr22:44894386	LDOC1L	0.39	6.44	0.33	4.06e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg18335740	chr13:41363409	SLC25A15	0.4	6.78	0.34	5.14e-11	Lewy body disease;
LIHC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10916814	0.632	rs12409100	chr1:20903207	G/A	cg24502330	chr1:20914028	CDA	-0.3	-6.6	-0.34	1.55e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.85	9.0	0.44	1.6e-17	Platelet count;
LIHC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.0	-0.68	2.14e-47	Systemic lupus erythematosus;
LIHC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.99	-19.64	-0.73	4.88e-58	Intelligence (multi-trait analysis);
LIHC	trans	rs9641123	0.607	rs2677085	chr7:93255334	T/C	cg09745688	chr16:2908918	PRSS22	-0.37	-6.46	-0.33	3.64e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.71	7.0	0.35	1.36e-11	Breast cancer;
LIHC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-15.34	-0.64	9.16e-41	Ulcerative colitis;
LIHC	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14154082	chr13:112174009	NA	0.29	6.24	0.32	1.32e-9	Menarche (age at onset);
LIHC	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.49	6.37	0.33	6.14e-10	Cognitive test performance;
LIHC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg18887096	chr2:219472410	PLCD4	0.37	6.43	0.33	4.28e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.32	-6.87	-0.35	3.02e-11	Longevity;
LIHC	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.15	-0.36	5.36e-12	Tuberculosis;
LIHC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.56	10.01	0.48	7.29e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg01364799	chr7:75623366	TMEM120A	0.51	7.6	0.38	2.91e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.71	10.52	0.49	1.36e-22	Prostate cancer;
LIHC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs11997175	0.558	rs6468207	chr8:33798095	G/A	ch.8.33884649F	chr8:33765107	NA	-0.4	-6.44	-0.33	3.96e-10	Body mass index;
LIHC	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg22705602	chr4:152727874	NA	0.33	6.96	0.35	1.75e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg12463550	chr7:65579703	CRCP	0.7	7.15	0.36	5.32e-12	Diabetic kidney disease;
LIHC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.43	6.43	0.33	4.31e-10	Mean platelet volume;
LIHC	trans	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.77	-10.74	-0.5	2.31e-23	Ear protrusion;
LIHC	cis	rs2834256	0.530	rs7281554	chr21:34928355	C/T	cg14850771	chr21:34775459	IFNGR2	0.47	7.38	0.37	1.18e-12	Red cell distribution width;
LIHC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.76	-10.06	-0.48	5.07e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.41	-8.44	-0.42	9e-16	Renal cell carcinoma;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	8.04	0.4	1.45e-14	IgG glycosylation;
LIHC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.55	-9.18	-0.44	4.34e-18	Cognitive function;
LIHC	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.25	-0.32	1.24e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.4	5.95	0.31	6.48e-9	Glycated hemoglobin levels;
LIHC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg07424592	chr7:64974309	NA	0.84	9.64	0.46	1.3e-19	Diabetic kidney disease;
LIHC	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg20697417	chr1:41786797	NA	0.31	5.91	0.3	8.23e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.49	8.8	0.43	6.84e-17	Tuberculosis;
LIHC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.95	0.39	2.73e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-0.98	-22.14	-0.77	5.34e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9888615	0.926	rs2884345	chr14:53323211	A/G	cg00686598	chr14:53173677	PSMC6	0.48	6.27	0.32	1.08e-9	Systolic blood pressure;
LIHC	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.23	-12.78	-0.57	7.71e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	0.75	8.1	0.4	9.98e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	7.57	0.38	3.51e-13	Systemic lupus erythematosus;
LIHC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.84	8.04	0.4	1.48e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg07645718	chr20:61493192	TCFL5	0.69	5.79	0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs7523273	0.565	rs2796239	chr1:207902206	G/A	cg22525895	chr1:207977042	MIR29B2	-0.54	-8.24	-0.41	3.61e-15	Schizophrenia;
LIHC	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.36	-0.49	4.78e-22	Rheumatoid arthritis;
LIHC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.63	-10.31	-0.49	6.98e-22	Malaria;
LIHC	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg19633962	chr1:26362018	EXTL1	-0.66	-5.86	-0.3	1.11e-8	QRS complex (12-leadsum);
LIHC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.5	0.33	2.87e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg09033563	chr22:24373618	LOC391322	-0.49	-6.87	-0.35	3e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.67	-9.86	-0.47	2.44e-20	Coronary artery disease;
LIHC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.94	0.31	7.05e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.82	0.43	6.02e-17	Menarche (age at onset);
LIHC	cis	rs28530618	0.603	rs4594522	chr20:31254984	T/C	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.96	-0.31	6.2e-9	Birth weight;
LIHC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg05941027	chr17:61774174	LIMD2	0.36	7.5	0.38	5.41e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs17106184	0.892	rs72900940	chr1:51124579	C/T	cg07174182	chr1:51127561	FAF1	-0.76	-8.09	-0.4	1.08e-14	Type 2 diabetes;
LIHC	cis	rs9473924	0.542	rs9473952	chr6:50921779	T/C	cg14470998	chr6:50812995	TFAP2B	0.81	7.49	0.38	5.86e-13	Body mass index;
LIHC	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.4	6.66	0.34	1.11e-10	Lewy body disease;
LIHC	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg20578329	chr17:80767326	TBCD	-0.75	-7.19	-0.36	4.11e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.33	7.14	0.36	5.5e-12	Bone mineral density;
LIHC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.5	6.86	0.35	3.29e-11	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.89	-0.35	2.76e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.25	-5.86	-0.3	1.07e-8	Subjective well-being;
LIHC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	trans	rs783540	0.933	rs2567636	chr15:83263428	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.66	-0.34	1.09e-10	Schizophrenia;
LIHC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg10556349	chr10:835070	NA	0.66	5.85	0.3	1.18e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-8.9	-0.43	3.27e-17	Atrioventricular conduction;
LIHC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg21466736	chr12:48725269	NA	0.62	9.0	0.44	1.57e-17	Glycated hemoglobin levels;
LIHC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	-0.42	-6.07	-0.31	3.39e-9	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24435866	chr1:154976595	ZBTB7B	0.46	6.52	0.33	2.57e-10	Lung function (FEV1/FVC);
LIHC	cis	rs13401104	0.796	rs1466205	chr2:237121194	A/G	cg19324714	chr2:237145437	ASB18	0.37	5.85	0.3	1.13e-8	Educational attainment;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg20841156	chr12:120652778	PXN	0.41	6.22	0.32	1.46e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs13088318	0.521	rs2553415	chr3:101095630	T/A	cg19452782	chr3:101232218	SENP7	-0.41	-6.07	-0.31	3.33e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.48	-7.2	-0.36	3.94e-12	Adiposity;
LIHC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-9.16	-0.44	5.04e-18	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.53	-5.9	-0.3	8.71e-9	Menopause (age at onset);
LIHC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.85	-0.43	4.95e-17	Blood metabolite levels;
LIHC	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-5.78	-0.3	1.65e-8	Neuroticism;
LIHC	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18252515	chr7:66147081	NA	-0.49	-6.09	-0.31	2.98e-9	Corneal structure;
LIHC	cis	rs6782228	0.606	rs2712404	chr3:128332679	C/T	cg16766828	chr3:128327626	NA	0.42	6.59	0.34	1.63e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.7	0.38	1.45e-13	Diastolic blood pressure;
LIHC	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg00792783	chr2:198669748	PLCL1	0.45	6.5	0.33	2.81e-10	Intracranial aneurysm;
LIHC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.74	-13.82	-0.6	8.21e-35	Height;
LIHC	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg25902810	chr10:99078978	FRAT1	0.69	10.43	0.49	2.68e-22	Monocyte count;
LIHC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.77	11.88	0.54	1.75e-27	Corneal astigmatism;
LIHC	trans	rs2363709	1.000	rs6770280	chr3:67416712	T/C	cg22969669	chr19:19613165	GATAD2A	0.66	6.13	0.31	2.48e-9	IgE levels;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg10755058	chr3:40428713	ENTPD3	-0.33	-5.76	-0.3	1.91e-8	Renal cell carcinoma;
LIHC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21467203	chr3:49911342	NA	0.39	6.64	0.34	1.2e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16140913	chr4:8430389	ACOX3	0.41	6.05	0.31	3.79e-9	Pancreatic cancer;
LIHC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.58	-11.39	-0.52	1.06e-25	Coronary artery disease;
LIHC	cis	rs4800452	0.778	rs35699973	chr18:20726731	G/A	cg26136497	chr18:20735537	CABLES1	-0.46	-6.14	-0.32	2.25e-9	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.72	6.92	0.35	2.27e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg09835421	chr16:68378352	PRMT7	-0.5	-5.78	-0.3	1.7e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-7.23	-0.36	3.16e-12	Fear of minor pain;
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.49	7.25	0.37	2.78e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.51e-16	Platelet count;
LIHC	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.45	8.77	0.43	8.35e-17	Testicular germ cell tumor;
LIHC	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.71	-8.75	-0.43	1.02e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.54	5.82	0.3	1.39e-8	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	6.93	0.35	2.06e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1866706	0.896	rs4757950	chr11:12861523	G/A	cg25843174	chr11:12811716	TEAD1	-0.31	-6.56	-0.33	1.96e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg10360323	chr17:41437877	NA	0.41	6.1	0.31	2.9e-9	Menopause (age at onset);
LIHC	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.44	6.69	0.34	9.32e-11	Schizophrenia;
LIHC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.57	10.1	0.48	3.79e-21	Mean corpuscular volume;
LIHC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.83	-14.05	-0.6	1.04e-35	Dental caries;
LIHC	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.55	-0.38	4.03e-13	QT interval;
LIHC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.81	17.77	0.69	1.64e-50	Gestational age at birth (maternal effect);
LIHC	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	18.31	0.7	1.15e-52	Smoking behavior;
LIHC	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.38	-6.01	-0.31	4.78e-9	Lung cancer;
LIHC	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.4	5.75	0.3	1.97e-8	Blood metabolite levels;
LIHC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg18912006	chr12:123335444	HIP1R	-0.57	-6.91	-0.35	2.31e-11	Schizophrenia;
LIHC	cis	rs7116495	1.000	rs1939247	chr11:71740521	A/T	cg26138937	chr11:71823887	C11orf51	-0.83	-8.27	-0.41	3e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.56	7.95	0.4	2.67e-14	Bone properties (heel);
LIHC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.55	10.21	0.48	1.49e-21	Educational attainment (years of education);
LIHC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.2	-0.55	1.16e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.81	-0.3	1.44e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg03959625	chr15:84868606	LOC388152	-0.44	-6.23	-0.32	1.39e-9	Schizophrenia;
LIHC	cis	rs9467160	0.511	rs796984	chr6:24440600	T/A	cg20631270	chr6:24437470	GPLD1	0.42	6.21	0.32	1.57e-9	Liver enzyme levels;
LIHC	cis	rs6967414	0.579	rs11980762	chr7:6756878	G/A	cg00387323	chr7:6746715	ZNF12	0.67	7.51	0.38	5.2e-13	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.94	20.44	0.74	3.16e-61	Blood protein levels;
LIHC	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg14515779	chr1:101123966	NA	0.45	6.37	0.33	6.24e-10	Monocyte count;
LIHC	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg22771759	chr13:24902376	NA	0.32	6.56	0.33	2.05e-10	Obesity-related traits;
LIHC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Total cholesterol levels;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.8	0.39	7.59e-14	Height;
LIHC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg01864069	chr14:103024347	NA	-0.57	-9.07	-0.44	9.18e-18	Platelet count;
LIHC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04607442	chr13:21872219	NA	-0.54	-6.77	-0.34	5.54e-11	Hepatitis;
LIHC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.76	-10.9	-0.51	6.15e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1075232	1.000	rs12437749	chr15:31649888	C/T	cg01030201	chr15:31746330	NA	-0.78	-6.11	-0.31	2.66e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.61	8.99	0.44	1.72e-17	Recombination rate (females);
LIHC	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.3	0.32	8.96e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.7	-9.81	-0.47	3.57e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.47	8.69	0.43	1.54e-16	Neurofibrillary tangles;
LIHC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.55	7.06	0.36	9.12e-12	Morning vs. evening chronotype;
LIHC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg21361702	chr7:150065534	REPIN1	0.45	6.17	0.32	1.88e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-8.54	-0.42	4.38e-16	Morning vs. evening chronotype;
LIHC	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg09795085	chr6:101329169	ASCC3	0.52	7.13	0.36	6.12e-12	Neuroticism;
LIHC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.06	0.4	1.31e-14	Morning vs. evening chronotype;
LIHC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.76	-12.07	-0.55	3.59e-28	Colorectal cancer;
LIHC	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-0.59	-5.8	-0.3	1.5e-8	Putamen volume;
LIHC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg25364880	chr3:44379878	C3orf23	0.49	6.97	0.35	1.63e-11	Depressive symptoms;
LIHC	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg05272587	chr13:111038400	COL4A2	0.37	7.56	0.38	3.66e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.44	-0.33	3.99e-10	Blood metabolite levels;
LIHC	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg18081818	chr7:23246105	NA	-0.4	-5.93	-0.31	7.36e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.81	8.1	0.4	1e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.33	-5.76	-0.3	1.88e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg21361702	chr7:150065534	REPIN1	0.46	6.24	0.32	1.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg02023728	chr11:77925099	USP35	0.36	6.33	0.32	7.49e-10	Alzheimer's disease (survival time);
LIHC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg06627628	chr2:24431161	ITSN2	-0.44	-5.89	-0.3	9.14e-9	Quantitative traits;
LIHC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.45	7.19	0.36	4.2e-12	Blood metabolite levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11056748	chr11:66036038	RAB1B	-0.46	-6.12	-0.31	2.56e-9	Bilirubin levels;
LIHC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-11.36	-0.52	1.35e-25	Alzheimer's disease;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg27322371	chr3:150329392	SELT	0.51	6.2	0.32	1.66e-9	Mean platelet volume;
LIHC	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg22903471	chr2:27725779	GCKR	-0.42	-6.07	-0.31	3.41e-9	Blood metabolite levels;
LIHC	cis	rs7487075	0.619	rs7486495	chr12:46826336	A/G	cg23829395	chr12:46796953	NA	0.35	6.13	0.31	2.45e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg25193494	chr16:90016004	DEF8	0.42	5.72	0.3	2.33e-8	Skin colour saturation;
LIHC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg03264133	chr6:25882463	NA	-0.4	-6.02	-0.31	4.42e-9	Height;
LIHC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.45	-5.94	-0.31	7.05e-9	Schizophrenia;
LIHC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.5	0.53	4.2e-26	Coronary artery disease;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg04794120	chr7:48019205	HUS1	0.48	6.13	0.31	2.36e-9	Glycated hemoglobin levels;
LIHC	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-6.39	-0.33	5.47e-10	Hepatocellular carcinoma;
LIHC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.88	-0.35	2.85e-11	Hepatocellular carcinoma;
LIHC	cis	rs4908768	0.906	rs74324642	chr1:8620172	A/C	cg20416874	chr1:8611966	RERE	0.57	8.81	0.43	6.19e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg20129853	chr10:51489980	NA	-0.41	-8.96	-0.44	2.13e-17	Prostate-specific antigen levels;
LIHC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.34	6.12	0.31	2.59e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	trans	rs12807809	0.588	rs3830078	chr11:124607535	G/A	cg14028684	chr12:48723360	H1FNT	0.43	6.6	0.34	1.58e-10	Schizophrenia;
LIHC	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-6.95	-0.35	1.85e-11	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.62	-10.19	-0.48	1.79e-21	Obesity-related traits;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.62	-8.34	-0.41	1.83e-15	Menopause (age at onset);
LIHC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg11764359	chr7:65958608	NA	-0.56	-5.84	-0.3	1.21e-8	Diabetic kidney disease;
LIHC	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs61712019	0.679	rs35195056	chr2:77719199	T/C	cg11252801	chr2:77748917	LRRTM4	0.56	7.73	0.39	1.2e-13	Schizophrenia;
LIHC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.51	8.13	0.4	8.06e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs80282103	0.618	rs74117831	chr10:1145707	A/C	cg08668510	chr10:1095578	IDI1	0.62	6.05	0.31	3.89e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs1355223	0.902	rs1258464	chr11:34731496	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-6.0	-0.31	5.05e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg19338460	chr6:170058176	WDR27	-0.38	-5.9	-0.3	8.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs507080	0.922	rs4589335	chr11:118539140	C/T	cg04173919	chr11:118528438	PHLDB1	0.32	6.02	0.31	4.54e-9	Serum metabolite levels;
LIHC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg10932868	chr11:921992	NA	-0.39	-7.35	-0.37	1.51e-12	Alzheimer's disease (late onset);
LIHC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg13535736	chr9:111863775	C9orf5	-0.4	-5.99	-0.31	5.37e-9	Menarche (age at onset);
LIHC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.82	13.59	0.59	5.99e-34	Multiple sclerosis;
LIHC	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.12	0.31	2.53e-9	Mean corpuscular volume;
LIHC	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.85	0.35	3.51e-11	Schizophrenia;
LIHC	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg19636519	chr7:99541626	NA	0.31	6.17	0.32	1.93e-9	Coronary artery disease;
LIHC	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.51	7.72	0.39	1.27e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg20607798	chr8:58055168	NA	-0.47	-6.68	-0.34	9.9e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg17675199	chr6:35436792	RPL10A	0.44	8.92	0.43	2.97e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg14930904	chr10:32216787	ARHGAP12	-0.37	-6.55	-0.33	2.07e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	0.97	14.09	0.61	7.13e-36	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs7187994	0.848	rs12922556	chr16:84784290	C/T	cg07647771	chr16:84786436	USP10	0.31	5.82	0.3	1.34e-8	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-12.41	-0.56	1.94e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.52	-0.38	4.91e-13	Psoriasis;
LIHC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.95	-0.7	3.2e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	0.86	13.59	0.59	6.18e-34	Left atrial antero-posterior diameter;
LIHC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.58	8.36	0.41	1.65e-15	Longevity;
LIHC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.37	5.75	0.3	1.95e-8	Prostate cancer;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg05760424	chr2:242988095	NA	-0.4	-6.06	-0.31	3.69e-9	Obesity-related traits;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg19837214	chr12:133402551	GOLGA3	0.42	6.34	0.32	7.25e-10	Longevity;
LIHC	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.77	-11.42	-0.53	8.63e-26	Personality dimensions;
LIHC	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7712401	0.755	rs1870560	chr5:122111210	G/C	cg18764291	chr5:122110994	SNX2	0.35	6.02	0.31	4.4e-9	Mean platelet volume;
LIHC	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	7.63	0.38	2.35e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.66	11.36	0.52	1.32e-25	Lymphocyte counts;
LIHC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	21.02	0.75	1.48e-63	Smoking behavior;
LIHC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.29e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.53e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.35	-9.28	-0.45	2.03e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.96	-0.35	1.77e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.69	8.98	0.44	1.8e-17	Exhaled nitric oxide output;
LIHC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.39	-5.93	-0.31	7.5e-9	Multiple myeloma;
LIHC	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg12698662	chr3:15914712	MIR563	-0.35	-6.54	-0.33	2.24e-10	Mean platelet volume;
LIHC	trans	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg25214090	chr10:38739885	LOC399744	0.4	6.56	0.33	2e-10	Diastolic blood pressure;
LIHC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg23791538	chr6:167370224	RNASET2	0.4	6.44	0.33	4.15e-10	Primary biliary cholangitis;
LIHC	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	7.41	0.37	1.01e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04180460	chr3:41240962	CTNNB1	0.48	7.43	0.37	9.05e-13	Pancreatic cancer;
LIHC	cis	rs6442522	0.678	rs13059607	chr3:15507408	C/T	cg16303742	chr3:15540471	COLQ	0.45	7.61	0.38	2.72e-13	Uric acid levels;
LIHC	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.61	9.29	0.45	1.79e-18	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.64	12.9	0.57	2.62e-31	Schizophrenia;
LIHC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.51	-8.33	-0.41	1.99e-15	Cognitive function;
LIHC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg16486109	chr11:613632	IRF7	0.61	6.81	0.35	4.44e-11	Systemic lupus erythematosus;
LIHC	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.39	9.55	0.46	2.5e-19	Blood metabolite ratios;
LIHC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg15691649	chr6:25882328	NA	-0.45	-5.98	-0.31	5.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.85	12.96	0.57	1.62e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02985541	chr2:219472218	PLCD4	-0.39	-6.48	-0.33	3.18e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.84	0.3	1.2e-8	Self-reported allergy;
LIHC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-7.2	-0.36	3.77e-12	Mean platelet volume;
LIHC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg15848620	chr12:58087721	OS9	-0.58	-8.0	-0.4	1.89e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg16506815	chr2:162101123	NA	-0.41	-6.25	-0.32	1.2e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg05044414	chr3:183734942	ABCC5	0.32	6.05	0.31	3.74e-9	Anterior chamber depth;
LIHC	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02985541	chr2:219472218	PLCD4	-0.36	-5.82	-0.3	1.36e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.38	0.37	1.2e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.81	14.58	0.62	8.91e-38	Breast cancer;
LIHC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.44	-9.38	-0.45	9.28e-19	Rheumatoid arthritis;
LIHC	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.57	-7.0	-0.35	1.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	12.0	0.54	6.1e-28	Mean platelet volume;
LIHC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg09222892	chr1:25734099	RHCE	-0.45	-8.21	-0.41	4.48e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.87	10.9	0.51	6.08e-24	Prostate cancer;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.45	-6.22	-0.32	1.46e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg07706471	chr12:123319906	HIP1R	-0.59	-7.84	-0.39	5.87e-14	Schizophrenia;
LIHC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.6	9.02	0.44	1.36e-17	Recombination rate (females);
LIHC	cis	rs2016586	0.802	rs5999977	chr22:36116097	T/G	cg26342177	chr22:36113512	APOL5	-0.39	-6.71	-0.34	8.13e-11	Body mass index;
LIHC	cis	rs9810089	0.814	rs696518	chr3:136120300	A/C	cg21827317	chr3:136751795	NA	0.44	6.02	0.31	4.46e-9	Gestational age at birth (child effect);
LIHC	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.06	-0.55	3.78e-28	Coffee consumption (cups per day);
LIHC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.44	7.39	0.37	1.13e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	trans	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.4	-6.23	-0.32	1.35e-9	Systemic sclerosis;
LIHC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg05590025	chr7:65112418	INTS4L2	-0.66	-7.2	-0.36	3.94e-12	Diabetic kidney disease;
LIHC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg01987224	chr1:201084466	NA	-0.33	-6.14	-0.32	2.26e-9	Permanent tooth development;
LIHC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.76	15.09	0.63	8.84e-40	Mortality in heart failure;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11989942	chr17:80067146	CCDC57	0.41	6.3	0.32	9.06e-10	Immature fraction of reticulocytes;
LIHC	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.35	-7.04	-0.36	1.06e-11	Blood protein levels;
LIHC	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg05771511	chr15:63340396	TPM1	-0.45	-6.03	-0.31	4.14e-9	Orofacial clefts;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12828819	chr4:126236816	FAT4	0.45	6.12	0.31	2.55e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.47	6.71	0.34	8.15e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	9.21	0.45	3.28e-18	Lymphocyte counts;
LIHC	trans	rs12144610	1.000	rs61806199	chr1:119450102	C/T	cg17552093	chr17:79875985	SIRT7	0.65	6.11	0.31	2.79e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg04160030	chr1:24195659	FUCA1	-0.36	-5.88	-0.3	9.82e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg01864836	chr14:55583639	NA	-0.38	-6.52	-0.33	2.49e-10	Protein biomarker;
LIHC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.12	16.75	0.67	2.08e-46	Sexual dysfunction (female);
LIHC	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.47	-6.38	-0.33	5.75e-10	Breast cancer;
LIHC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.88	-18.19	-0.7	3.42e-52	Height;
LIHC	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.64	7.87	0.39	4.67e-14	Morning vs. evening chronotype;
LIHC	cis	rs867186	0.614	rs75848331	chr20:33424989	C/G	cg08999081	chr20:33150536	PIGU	0.63	5.94	0.31	6.97e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg15448220	chr1:150897856	SETDB1	-0.37	-5.83	-0.3	1.26e-8	Urate levels;
LIHC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg22633049	chr21:46681294	NA	0.36	6.18	0.32	1.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.82	-0.63	1.03e-38	Chronic sinus infection;
LIHC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.88	-16.94	-0.68	3.45e-47	Coronary artery disease;
LIHC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.68	-10.92	-0.51	5.23e-24	Lung cancer;
LIHC	cis	rs9326778	0.520	rs4957817	chr5:108826387	C/T	cg17395555	chr5:108820864	NA	-0.35	-6.09	-0.31	3.11e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg14146966	chr2:61757674	XPO1	0.46	7.78	0.39	8.84e-14	Tuberculosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17976829	chr10:131934431	GLRX3	0.41	6.96	0.35	1.78e-11	Cognitive function;
LIHC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.64	-0.46	1.31e-19	Mean platelet volume;
LIHC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg02782426	chr3:40428986	ENTPD3	0.32	5.71	0.3	2.41e-8	Renal cell carcinoma;
LIHC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.8	-0.39	7.8e-14	Vitiligo;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.44	7.42	0.37	9.45e-13	Testicular germ cell tumor;
LIHC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.63	0.34	1.27e-10	Bipolar disorder;
LIHC	cis	rs11098699	0.769	rs6812009	chr4:124215392	A/G	cg09941581	chr4:124220074	SPATA5	0.33	6.66	0.34	1.1e-10	Mosquito bite size;
LIHC	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.29	6.22	0.32	1.43e-9	Pulmonary function;
LIHC	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-7.26	-0.37	2.71e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs80282103	0.867	rs11250231	chr10:1082040	T/C	cg20335179	chr10:1068567	C10orf110;IDI2	-0.52	-6.22	-0.32	1.45e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-8.72	-0.43	1.23e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10845606	0.581	rs10772592	chr12:12835874	A/G	cg09462578	chr12:12878428	APOLD1	-0.52	-7.68	-0.38	1.71e-13	Systemic lupus erythematosus;
LIHC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.6	-8.11	-0.4	9.37e-15	Migraine;
LIHC	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.06	-0.36	9.6e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.59	8.22	0.41	4.39e-15	Lung cancer;
LIHC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.55	-7.16	-0.36	5.05e-12	Coronary artery calcification;
LIHC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg20417195	chr1:21767127	NBPF3	0.36	5.77	0.3	1.74e-8	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.17	-0.4	5.99e-15	Brugada syndrome;
LIHC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg18944383	chr4:111397179	ENPEP	0.26	6.49	0.33	3.01e-10	Coronary artery disease;
LIHC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg15448220	chr1:150897856	SETDB1	0.43	6.77	0.34	5.77e-11	Tonsillectomy;
LIHC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg06096015	chr1:231504339	EGLN1	-0.5	-9.35	-0.45	1.22e-18	Hemoglobin concentration;
LIHC	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.67e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	1.06	12.64	0.56	2.63e-30	Vitiligo;
LIHC	cis	rs916888	0.821	rs199499	chr17:44865498	C/T	cg15921436	chr17:44337874	NA	0.7	6.12	0.31	2.51e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6732160	0.691	rs13432787	chr2:73430234	T/C	cg24220031	chr2:73402428	NA	-0.28	-6.01	-0.31	4.65e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.46e-25	Eye color traits;
LIHC	trans	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs7395581	1.000	rs830085	chr11:47251199	G/A	cg25783544	chr11:47291846	MADD	-0.47	-6.8	-0.35	4.72e-11	HDL cholesterol;
LIHC	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.53	-8.19	-0.4	5.38e-15	Coronary artery disease;
LIHC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.11	0.52	1.04e-24	Platelet count;
LIHC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.37	8.82	0.43	6.15e-17	Immature fraction of reticulocytes;
LIHC	cis	rs1075232	1.000	rs72722847	chr15:31682346	C/T	cg01030201	chr15:31746330	NA	-0.81	-6.25	-0.32	1.21e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs10861342	1.000	rs11112398	chr12:105572967	A/G	cg23923672	chr12:105501055	KIAA1033	0.63	7.66	0.38	1.94e-13	IgG glycosylation;
LIHC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.69	8.76	0.43	9.54e-17	Blood metabolite levels;
LIHC	cis	rs13343954	0.825	rs11084698	chr19:33534174	A/G	cg27124370	chr19:33622961	WDR88	0.42	5.73	0.3	2.21e-8	Colorectal cancer;
LIHC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.32	-6.38	-0.33	5.82e-10	Platelet distribution width;
LIHC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.76	11.49	0.53	4.66e-26	Corneal astigmatism;
LIHC	cis	rs2071426	0.959	rs35394919	chr10:96810972	C/T	cg09036531	chr10:96991505	NA	-0.5	-6.0	-0.31	5.08e-9	Blood metabolite levels;
LIHC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.32	-8.36	-0.41	1.55e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg23791538	chr6:167370224	RNASET2	-0.53	-8.64	-0.42	2.18e-16	Primary biliary cholangitis;
LIHC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg12751644	chr20:60527061	NA	-0.37	-6.14	-0.32	2.31e-9	Body mass index;
LIHC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.48	-6.95	-0.35	1.82e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.53	-8.36	-0.41	1.62e-15	Uric acid clearance;
LIHC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-5.81	-0.3	1.43e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-10.7	-0.5	3.12e-23	Menarche (age at onset);
LIHC	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.27	5.71	0.3	2.42e-8	Pulmonary function;
LIHC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.45	0.42	8.22e-16	Platelet count;
LIHC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.75	11.44	0.53	6.88e-26	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.59	0.56	4.01e-30	Prudent dietary pattern;
LIHC	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.34	-6.69	-0.34	9.06e-11	Platelet distribution width;
LIHC	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.99	-0.31	5.17e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.41	-7.06	-0.36	9.22e-12	Schizophrenia;
LIHC	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.15	16.41	0.66	4.97e-45	Corneal structure;
LIHC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.37	0.45	1e-18	Bipolar disorder;
LIHC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.46	0.42	7.75e-16	Resting heart rate;
LIHC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.68e-14	Mean platelet volume;
LIHC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.05e-8	Menopause (age at onset);
LIHC	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.43	-8.47	-0.42	7.19e-16	Testicular germ cell tumor;
LIHC	cis	rs4759375	1.000	rs10444439	chr12:123766437	A/G	cg00376283	chr12:123451042	ABCB9	-0.5	-6.35	-0.32	6.82e-10	HDL cholesterol;
LIHC	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg03585969	chr10:35415529	CREM	0.76	11.03	0.51	2.14e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.67	-9.99	-0.48	8.92e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs970821	0.667	rs1030590	chr8:124754410	A/G	cg00283535	chr8:124749564	ANXA13	0.46	8.6	0.42	2.99e-16	Breast cancer;
LIHC	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-6.87	-0.35	3.02e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7739232	0.920	rs6941645	chr6:53515130	A/G	cg00536792	chr6:53530503	KLHL31	-0.9	-6.71	-0.34	8.33e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs1823913	1.000	rs11681777	chr2:192121467	G/A	cg12404831	chr2:192114017	MYO1B	-0.33	-6.5	-0.33	2.9e-10	Obesity-related traits;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06656553	chr16:89960601	TCF25	-0.46	-5.91	-0.3	8.17e-9	Skin colour saturation;
LIHC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.43	0.53	7.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35955747	0.902	rs12166373	chr22:31700508	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.89	-0.3	9.31e-9	Neutrophil count;Sum basophil neutrophil counts;
LIHC	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.46	5.91	0.3	8.05e-9	Plateletcrit;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg07725925	chr16:89976287	TCF25	0.45	6.16	0.32	2e-9	Skin colour saturation;
LIHC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg25801113	chr15:45476975	SHF	0.38	6.55	0.33	2.1e-10	Uric acid levels;
LIHC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.57	-15.0	-0.63	1.96e-39	Alzheimer's disease (late onset);
LIHC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.66	-8.75	-0.43	1.01e-16	Lung cancer (smoking interaction);
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.63	9.57	0.46	2.18e-19	Renal cell carcinoma;
LIHC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.96	0.31	6.17e-9	Bipolar disorder;
LIHC	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.38	-6.7	-0.34	8.47e-11	Schizophrenia;
LIHC	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16576597	chr16:28551801	NUPR1	0.48	7.31	0.37	1.87e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.69	9.46	0.46	5.05e-19	Personality dimensions;
LIHC	cis	rs10503871	0.545	rs6991816	chr8:30487344	C/T	cg26383811	chr8:30366931	RBPMS	-0.4	-6.44	-0.33	4.04e-10	Metabolite levels  (X-11787);
LIHC	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.43	-8.72	-0.43	1.23e-16	Testicular germ cell tumor;
LIHC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.63	-10.27	-0.49	9.26e-22	Monocyte percentage of white cells;
LIHC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.69	10.71	0.5	2.95e-23	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.38	7.75	0.39	1.05e-13	Ewing sarcoma;
LIHC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.59	-8.88	-0.43	3.95e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg15192750	chr16:69999425	NA	0.46	7.03	0.36	1.12e-11	IgE levels;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.37	-7.89	-0.39	4.04e-14	Renal cell carcinoma;
LIHC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.41	-7.69	-0.38	1.53e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.42	0.56	1.76e-29	Cognitive test performance;
LIHC	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg10546459	chr2:36825355	FEZ2	0.52	6.31	0.32	8.86e-10	Height;
LIHC	cis	rs55702914	0.904	rs68062151	chr2:198230190	C/T	cg10820045	chr2:198174542	NA	0.41	6.1	0.31	2.83e-9	Major depression and alcohol dependence;
LIHC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.4	-6.0	-0.31	5.01e-9	Menarche (age at onset);
LIHC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg03929089	chr4:120376271	NA	-0.4	-6.08	-0.31	3.14e-9	HDL cholesterol;
LIHC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.33	6.43	0.33	4.32e-10	Renal cell carcinoma;
LIHC	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	1.08	7.4	0.37	1.08e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg13647721	chr17:30228624	UTP6	0.67	6.62	0.34	1.38e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.54	-10.0	-0.48	8.1899999999999992e-21	Coronary artery disease;
LIHC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.3	-0.52	2.33e-25	Electrocardiographic conduction measures;
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.54	5.77	0.3	1.79e-8	Alzheimer's disease;
LIHC	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.92	0.51	5.31e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.61	9.2	0.45	3.55e-18	Mean corpuscular volume;
LIHC	trans	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg13698153	chr12:118541722	VSIG10	0.6	6.36	0.33	6.59e-10	Vitiligo;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.55	-7.89	-0.39	4.02e-14	Lymphocyte counts;
LIHC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-7.34	-0.37	1.54e-12	Morning vs. evening chronotype;
LIHC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	11.44	0.53	6.77e-26	Cognitive test performance;
LIHC	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.39	5.91	0.3	8.16e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.08	0.58	5.75e-32	Cognitive test performance;
LIHC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg07341007	chr3:195489909	MUC4	0.45	7.92	0.39	3.37e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg14393609	chr7:65229607	NA	-0.38	-6.08	-0.31	3.24e-9	Aortic root size;
LIHC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg16479474	chr6:28041457	NA	0.39	6.38	0.33	5.78e-10	Parkinson's disease;
LIHC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg04693399	chr19:4909447	UHRF1	-0.43	-6.12	-0.31	2.5e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs1704198	1.000	rs12401447	chr1:213897230	T/C	cg02442787	chr4:139230014	NA	0.42	6.37	0.33	6.07e-10	Obesity;
LIHC	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.97e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg03543861	chr21:44258195	NA	0.48	7.68	0.38	1.74e-13	Information processing speed;
LIHC	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg24391279	chr8:1708526	NA	-0.35	-5.85	-0.3	1.14e-8	Systolic blood pressure;
LIHC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.62	0.38	2.45e-13	Lymphocyte counts;
LIHC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-7.11	-0.36	6.89e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.29	5.74	0.3	2.05e-8	Sitting height ratio;
LIHC	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg00277334	chr10:82204260	NA	0.52	6.59	0.34	1.69e-10	Post bronchodilator FEV1;
LIHC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.41	6.54	0.33	2.22e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg11783602	chr8:55087084	NA	-0.31	-6.2	-0.32	1.66e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg00800038	chr16:89945340	TCF25	-0.64	-9.34	-0.45	1.31e-18	Skin colour saturation;
LIHC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.88	10.83	0.51	1.1e-23	Bladder cancer;
LIHC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.42	-0.33	4.54e-10	Obesity-related traits;
LIHC	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.62	10.53	0.49	1.21e-22	HDL cholesterol;
LIHC	cis	rs61041384	0.661	rs75338281	chr12:123507484	G/A	cg00376283	chr12:123451042	ABCB9	-0.6	-5.71	-0.3	2.4e-8	Schizophrenia;
LIHC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg17135325	chr3:160939158	NMD3	0.61	9.01	0.44	1.52e-17	Parkinson's disease;
LIHC	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.62	11.12	0.52	9.86e-25	Schizophrenia;
LIHC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.49	7.73	0.39	1.25e-13	Diastolic blood pressure;
LIHC	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.57	-6.43	-0.33	4.29e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.94	-0.35	1.93e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.65	8.92	0.43	2.87e-17	Coronary artery disease;
LIHC	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.81	14.11	0.61	5.84e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.63	-6.38	-0.33	5.68e-10	IgG glycosylation;
LIHC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.84	-0.35	3.75e-11	Aortic root size;
LIHC	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg00792783	chr2:198669748	PLCL1	0.45	6.6	0.34	1.52e-10	Dermatomyositis;
LIHC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.47	-6.94	-0.35	1.94e-11	Psoriasis;
LIHC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.0	0.31	5.11e-9	Tonsillectomy;
LIHC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.32	-7.07	-0.36	8.7e-12	Ulcerative colitis;
LIHC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	9.98	0.48	9.14e-21	Systolic blood pressure;
LIHC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg18016565	chr1:150552671	MCL1	-0.49	-9.58	-0.46	2.09e-19	Melanoma;
LIHC	cis	rs12220238	0.915	rs11001021	chr10:76139657	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-7.61	-0.38	2.77e-13	Exhaled nitric oxide output;
LIHC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.43	6.63	0.34	1.34e-10	Methadone dose in opioid dependence;
LIHC	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg20636351	chr8:55087400	NA	-0.38	-7.77	-0.39	9.54e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg19635926	chr16:89946313	TCF25	0.54	6.76	0.34	5.85e-11	Skin colour saturation;
LIHC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-12.41	-0.56	1.94e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.65	9.87	0.47	2.23e-20	Resting heart rate;
LIHC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.71	13.15	0.58	2.99e-32	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	8.09	0.4	1.07e-14	Eotaxin levels;
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.53	0.38	4.6e-13	Renal cell carcinoma;
LIHC	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21659725	chr3:3221576	CRBN	0.73	11.46	0.53	6.07e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg03543861	chr21:44258195	NA	0.49	7.86	0.39	5.21e-14	Information processing speed;
LIHC	cis	rs11098699	0.769	rs11726870	chr4:124229175	A/G	cg09941581	chr4:124220074	SPATA5	0.33	6.59	0.34	1.68e-10	Mosquito bite size;
LIHC	cis	rs7937840	0.562	rs1047739	chr11:61919693	C/T	cg01969543	chr11:61895209	INCENP	-0.49	-6.29	-0.32	9.81e-10	Breast cancer;
LIHC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg09323728	chr8:95962352	TP53INP1	0.29	6.78	0.34	5.24e-11	Alzheimer's disease (late onset);
LIHC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.4	0.45	7.89e-19	Hemoglobin concentration;
LIHC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs4638749	0.677	rs12712018	chr2:108853505	A/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.48	-0.33	3.22e-10	Blood pressure;
LIHC	cis	rs926392	0.965	rs6129167	chr20:37689228	C/T	cg16355469	chr20:37678765	NA	-0.37	-6.01	-0.31	4.63e-9	Dialysis-related mortality;
LIHC	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg14146966	chr2:61757674	XPO1	0.49	8.62	0.42	2.6e-16	Tuberculosis;
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg03945807	chr20:60948434	NA	-0.45	-6.05	-0.31	3.75e-9	Colorectal cancer;
LIHC	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11564483	chr6:37401398	FTSJD2	0.5	6.81	0.35	4.36e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7116495	0.737	rs1791451	chr11:71570993	G/T	cg26138937	chr11:71823887	C11orf51	0.7	6.64	0.34	1.25e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.56	10.97	0.51	3.39e-24	Schizophrenia;
LIHC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg06046430	chr4:77819534	ANKRD56	0.49	6.48	0.33	3.18e-10	Emphysema distribution in smoking;
LIHC	cis	rs61712019	0.679	rs55777925	chr2:77726204	C/G	cg11252801	chr2:77748917	LRRTM4	0.55	7.83	0.39	6.25e-14	Schizophrenia;
LIHC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.39	-6.06	-0.31	3.59e-9	Lung cancer;
LIHC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.32	5.76	0.3	1.9e-8	Diastolic blood pressure;
LIHC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.55	-8.49	-0.42	6.47e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.62	11.76	0.54	4.76e-27	Menopause (age at onset);
LIHC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.64	-9.98	-0.48	9.06e-21	Glaucoma (primary open-angle);
LIHC	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.66	-8.54	-0.42	4.59e-16	Coronary artery disease;
LIHC	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.42	-6.64	-0.34	1.23e-10	Ulcerative colitis;
LIHC	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	9.74	0.47	6.02e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.49	-6.3	-0.32	9.31e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg20129853	chr10:51489980	NA	0.4	8.92	0.43	2.9e-17	Prostate-specific antigen levels;
LIHC	trans	rs1875517	0.510	rs11721241	chr3:117329656	A/C	cg23648015	chr19:49519116	RUVBL2	0.36	6.39	0.33	5.42e-10	Waist circumference;
LIHC	trans	rs2579103	0.626	rs2579099	chr12:90687355	C/T	cg02782426	chr3:40428986	ENTPD3	0.36	6.09	0.31	2.96e-9	Body mass index;
LIHC	cis	rs7911264	0.967	rs2488087	chr10:94446041	G/A	cg25506282	chr10:94462361	NA	-0.43	-7.43	-0.37	8.96e-13	Inflammatory bowel disease;
LIHC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-8.39	-0.41	1.3e-15	Longevity;Endometriosis;
LIHC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.35	8.43	0.41	9.93e-16	Crohn's disease;
LIHC	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.25e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.91	-0.3	8.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7818688	0.697	rs11780130	chr8:95976083	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.64	0.34	1.24e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	1.02	12.86	0.57	3.73e-31	Iron status biomarkers;
LIHC	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg20016023	chr10:99160130	RRP12	-0.41	-6.48	-0.33	3.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.15	0.36	5.17e-12	Self-reported allergy;
LIHC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.67	10.88	0.51	7.31e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.39	-0.45	8.81e-19	Colorectal cancer;
LIHC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg22834771	chr12:69754056	YEATS4	-0.5	-8.48	-0.42	6.72e-16	Blood protein levels;
LIHC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.51	-6.94	-0.35	2e-11	Parkinson's disease;
LIHC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.69	-9.33	-0.45	1.41e-18	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17981554	chr6:149969568	NA	0.48	6.22	0.32	1.43e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.7	-8.18	-0.4	5.49e-15	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.68	10.8	0.5	1.41e-23	Psoriasis;
LIHC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.44	6.19	0.32	1.72e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.06	15.16	0.63	4.63e-40	Cognitive function;
LIHC	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.17e-8	Pulmonary function;
LIHC	cis	rs11786130	1.000	rs10956403	chr8:129007207	A/G	cg01765152	chr8:129005526	PVT1	-0.3	-6.39	-0.33	5.32e-10	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	8.23	0.41	3.86e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg03959625	chr15:84868606	LOC388152	0.43	5.94	0.31	6.98e-9	Schizophrenia;
LIHC	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	9.69	0.46	8.94e-20	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.44	-6.7	-0.34	8.6e-11	Pubertal anthropometrics;
LIHC	cis	rs11683229	0.704	rs17850223	chr2:63283178	C/G	cg17519650	chr2:63277830	OTX1	-0.55	-6.25	-0.32	1.19e-9	Protein quantitative trait loci;
LIHC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.74	-11.62	-0.53	1.51e-26	Longevity;
LIHC	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.44	-6.12	-0.31	2.63e-9	QT interval;
LIHC	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.58	9.14	0.44	5.54e-18	Graves' disease;
LIHC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg00677901	chr16:88017247	BANP	0.57	8.38	0.41	1.41e-15	Menopause (age at onset);
LIHC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.61	-11.04	-0.51	1.99e-24	Breast cancer;
LIHC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	6.11e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.57	-10.97	-0.51	3.36e-24	Coronary artery disease;
LIHC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.3	0.45	1.65e-18	Melanoma;
LIHC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg00277334	chr10:82204260	NA	-0.55	-6.91	-0.35	2.43e-11	Post bronchodilator FEV1;
LIHC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.66	9.63	0.46	1.37e-19	Breast cancer;
LIHC	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.24	-0.32	1.27e-9	Response to antipsychotic treatment;
LIHC	cis	rs9628987	0.500	rs1443929	chr1:8457623	A/C	cg20416874	chr1:8611966	RERE	-0.5	-5.95	-0.31	6.78e-9	Breast cancer;
LIHC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.86	8.15	0.4	6.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-1.05	-22.37	-0.77	6.41e-69	Breast cancer;
LIHC	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs6708331	0.517	rs11890741	chr2:70360506	T/C	cg01613454	chr2:70366299	NA	0.38	6.11	0.31	2.75e-9	Obesity-related traits;
LIHC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg09835421	chr16:68378352	PRMT7	-0.57	-6.58	-0.34	1.81e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg16275483	chr1:110013120	SYPL2	-0.47	-5.82	-0.3	1.32e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-8.95	-0.44	2.26e-17	Gut microbiome composition (summer);
LIHC	trans	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg13698153	chr12:118541722	VSIG10	-0.61	-6.55	-0.33	2.12e-10	Vitiligo;
LIHC	cis	rs28489187	0.706	rs2300634	chr1:85791257	T/C	cg16011679	chr1:85725395	C1orf52	0.48	6.15	0.32	2.13e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.45	6.87	0.35	3.09e-11	Type 2 diabetes;
LIHC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.43	-7.19	-0.36	4.24e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	9.74	0.47	5.82e-20	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10352719	chr14:24769404	DHRS1;C14orf21	0.52	7.48	0.37	6.23e-13	Pancreatic cancer;
LIHC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs6066825	0.644	rs761272	chr20:47315581	A/G	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.51e-12	Colorectal cancer;
LIHC	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg07541023	chr7:19748670	TWISTNB	0.4	5.88	0.3	9.79e-9	Thyroid stimulating hormone;
LIHC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.88	-0.47	2.06e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.96	17.25	0.68	2.04e-48	Breast cancer;
LIHC	cis	rs9790314	0.582	rs11708813	chr3:160589852	G/A	cg03342759	chr3:160939853	NMD3	0.48	5.82	0.3	1.37e-8	Morning vs. evening chronotype;
LIHC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg20818283	chr2:191399100	TMEM194B	-0.45	-6.06	-0.31	3.62e-9	Pulse pressure;
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.62	0.42	2.52e-16	Lymphocyte counts;
LIHC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg03037974	chr15:76606532	NA	-0.63	-10.88	-0.51	7.1e-24	Blood metabolite levels;
LIHC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.85	0.3	1.16e-8	Systolic blood pressure;
LIHC	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg20435097	chr10:126320824	FAM53B	0.38	6.35	0.32	6.88e-10	Asthma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.44	7.23	0.36	3.25e-12	Cognitive function;
LIHC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.04	-0.31	4.03e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.89	13.62	0.59	4.7e-34	Vitamin D levels;
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg14222432	chr12:29376421	FAR2	0.36	7.05	0.36	9.82e-12	QT interval;
LIHC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-7.34	-0.37	1.57e-12	Ulcerative colitis;
LIHC	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.36	6.33	0.32	7.48e-10	Asthma;
LIHC	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.78	-9.49	-0.46	4.23e-19	Mean platelet volume;
LIHC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.26	-6.37	-0.33	6.13e-10	Cutaneous nevi;
LIHC	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.78	-0.39	8.77e-14	Response to antipsychotic treatment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01704976	chr3:52273381	TWF2	0.45	6.16	0.32	2.07e-9	Lung function (FEV1/FVC);
LIHC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.76	7.39	0.37	1.15e-12	Eosinophil percentage of granulocytes;
LIHC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.08	-0.44	8.66e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.07	-0.44	9.75e-18	Ulcerative colitis;
LIHC	trans	rs983392	0.679	rs764859	chr11:59978255	C/G	cg17275991	chr19:58003312	ZNF419	0.44	6.35	0.32	6.84e-10	Alzheimer's disease (late onset);
LIHC	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg07713946	chr22:31675144	LIMK2	-0.42	-7.43	-0.37	8.64e-13	Colorectal cancer;
LIHC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.11e-18	Bipolar disorder;
LIHC	cis	rs797680	0.856	rs627779	chr1:93684089	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.88	0.3	1e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.36	-0.37	1.4e-12	Body mass index;
LIHC	cis	rs151997	0.777	rs6870880	chr5:50256207	G/A	cg06027927	chr5:50259733	NA	0.6	8.31	0.41	2.35e-15	Callous-unemotional behaviour;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg05679093	chr2:86426460	MRPL35	-0.42	-6.72	-0.34	7.62e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.37	0.33	6.01e-10	Ulcerative colitis;
LIHC	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.13	0.44	6.08e-18	Coffee consumption (cups per day);
LIHC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg09361094	chr10:834503	NA	-0.53	-5.78	-0.3	1.72e-8	Eosinophil percentage of granulocytes;
LIHC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2637030	0.559	rs2637024	chr5:52993453	A/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.75	0.34	6.4e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg19683494	chr5:74908142	NA	-0.71	-8.15	-0.4	6.98e-15	Coronary artery disease;
LIHC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.77	11.55	0.53	2.86e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.87	10.8	0.5	1.32e-23	Mean platelet volume;
LIHC	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg23352942	chr3:46931381	PTH1R	-0.33	-8.84	-0.43	4.97e-17	Birth weight;
LIHC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.66	0.53	1.15e-26	Alzheimer's disease;
LIHC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.45	-7.42	-0.37	9.54e-13	Menarche (age at onset);
LIHC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12516959	chr21:47718080	NA	-0.36	-5.96	-0.31	6.14e-9	Testicular germ cell tumor;
LIHC	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-8.32	-0.41	2.1e-15	Hepatocellular carcinoma;
LIHC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.61	-11.51	-0.53	3.91e-26	Menopause (age at onset);
LIHC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.09	0.4	1.02e-14	Platelet count;
LIHC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.69	-8.98	-0.44	1.9e-17	Asthma;
LIHC	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.67	-0.38	1.85e-13	Metabolite levels;
LIHC	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04530015	chr2:215796436	ABCA12	0.4	6.49	0.33	3e-10	Neuroblastoma;
LIHC	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.73	8.54	0.42	4.6e-16	Dental caries;
LIHC	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.5	7.72	0.39	1.25e-13	Corneal astigmatism;
LIHC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.06	24.64	0.8	8.62e-78	IgG glycosylation;
LIHC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg15848620	chr12:58087721	OS9	-0.59	-8.1	-0.4	9.68e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.92	-0.3	7.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	6.36	0.32	6.65e-10	Schizophrenia;
LIHC	cis	rs2708977	0.692	rs17685766	chr2:97319534	G/C	cg01950434	chr2:97203154	ARID5A	0.5	7.13	0.36	5.93e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.84	0.54	2.44e-27	Prudent dietary pattern;
LIHC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-1.0	-11.73	-0.54	6.22e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.41	-5.83	-0.3	1.29e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.35	8.08	0.4	1.15e-14	Rheumatoid arthritis;
LIHC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.67	10.03	0.48	6.56e-21	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10847980	1.000	rs10847980	chr12:123387922	G/T	cg25930673	chr12:123319894	HIP1R	-0.67	-7.55	-0.38	4.08e-13	Adiponectin levels;
LIHC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs11955398	0.625	rs10805370	chr5:59984244	A/T	cg02684056	chr5:59996105	DEPDC1B	0.44	6.25	0.32	1.23e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.72	0.43	1.21e-16	Coffee consumption (cups per day);
LIHC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.86e-9	Aortic root size;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.82	-0.35	4.05e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.51	8.8	0.43	7.09e-17	Body mass index;
LIHC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.5	-9.49	-0.46	4.06e-19	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.47	7.48	0.38	6.2800000000000005e-13	Longevity;
LIHC	cis	rs611744	0.967	rs569701	chr8:109239207	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs4650994	0.571	rs6425486	chr1:178528822	G/A	cg05350800	chr1:178550844	NA	-0.34	-7.38	-0.37	1.19e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg16970926	chr12:29381810	FAR2	0.28	5.89	0.3	9.1e-9	QT interval;
LIHC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.47	6.71	0.34	8.08e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.01	-0.4	1.77e-14	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01056155	chr5:72794294	BTF3	-0.48	-6.2	-0.32	1.67e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.08	0.44	9.16e-18	Platelet count;
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.64	0.56	2.61e-30	Prudent dietary pattern;
LIHC	cis	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg27203090	chr3:33138513	GLB1;TMPPE	0.53	6.96	0.35	1.8e-11	Major depressive disorder;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg14671364	chr1:107599128	PRMT6	-0.53	-7.69	-0.38	1.56e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.65	10.34	0.49	5.33e-22	Obesity-related traits;
LIHC	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.31	6.21	0.32	1.58e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01073178	chr12:117537710	TESC	0.6	8.11	0.4	9.33e-15	Lung function (FEV1/FVC);
LIHC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg19635926	chr16:89946313	TCF25	0.54	6.77	0.34	5.65e-11	Skin colour saturation;
LIHC	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.58	9.65	0.46	1.23e-19	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.57	-8.36	-0.41	1.64e-15	Cerebrospinal P-tau181p levels;
LIHC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.7	0.73	2.92e-58	Smoking behavior;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.24	-0.32	1.29e-9	Total body bone mineral density;
LIHC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.44	-0.33	4.05e-10	Alzheimer's disease (late onset);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07227769	chr11:67479369	NA	0.33	6.05	0.31	3.83e-9	Bilirubin levels;
LIHC	cis	rs9810089	0.708	rs711977	chr3:136227387	G/A	cg21827317	chr3:136751795	NA	0.45	6.03	0.31	4.15e-9	Gestational age at birth (child effect);
LIHC	cis	rs4689642	0.709	rs13115404	chr4:7226101	T/G	cg21353189	chr4:7228343	SORCS2	0.37	6.24	0.32	1.29e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-11.04	-0.51	2e-24	Platelet count;
LIHC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.53	6.48	0.33	3.19e-10	Heart rate;
LIHC	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg26138937	chr11:71823887	C11orf51	-1.32	-10.43	-0.49	2.71e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg16970926	chr12:29381810	FAR2	0.34	7.4	0.37	1.05e-12	QT interval;
LIHC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg15902774	chr15:75289873	SCAMP5	0.46	6.48	0.33	3.19e-10	Lung cancer;
LIHC	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.83	0.35	3.84e-11	Bipolar disorder;
LIHC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.6	8.02	0.4	1.72e-14	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg23029597	chr12:123009494	RSRC2	-0.48	-6.89	-0.35	2.62e-11	Body mass index;
LIHC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg18887096	chr2:219472410	PLCD4	0.36	6.44	0.33	4.12e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg10944116	chr2:242448158	STK25	-0.44	-6.32	-0.32	8.19e-10	Immature fraction of reticulocytes;
LIHC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.33	-6.4	-0.33	5.2400000000000005e-10	Body mass index;
LIHC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	6.08	0.31	3.25e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05756109	chr10:103347662	POLL;RP11-529I10.4	0.44	6.24	0.32	1.32e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.02e-19	Height;
LIHC	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg15192750	chr16:69999425	NA	0.44	6.46	0.33	3.64e-10	IgE levels;
LIHC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.27	16.7	0.67	3.42e-46	Diabetic kidney disease;
LIHC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg06784218	chr1:46089804	CCDC17	0.37	5.96	0.31	6.37e-9	Platelet count;
LIHC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6489882	0.836	rs6489878	chr12:113368125	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-0.95	-21.01	-0.75	1.61e-63	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-8.22	-0.41	4.22e-15	Gut microbiome composition (summer);
LIHC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg21724239	chr8:58056113	NA	0.47	6.24	0.32	1.32e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16922576	0.623	rs2093446	chr9:5230371	G/C	cg02405213	chr9:5042618	JAK2	-0.61	-8.95	-0.44	2.35e-17	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg25356066	chr3:128598488	ACAD9	0.56	7.74	0.39	1.12e-13	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09704741	chr12:95867762	METAP2	-0.45	-6.28	-0.32	1e-9	Pancreatic cancer;
LIHC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg11812906	chr14:75593930	NEK9	-0.47	-7.93	-0.39	3.08e-14	Neuroticism;
LIHC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.3	0.41	2.48e-15	Schizophrenia;
LIHC	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.6	6.46	0.33	3.53e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.37	-6.74	-0.34	6.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg23533926	chr12:111358616	MYL2	-0.33	-6.51	-0.33	2.71e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.42	6.7	0.34	8.4e-11	Cognitive function;
LIHC	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg25182066	chr10:30743637	MAP3K8	0.68	9.68	0.46	9.69e-20	Itch intensity from mosquito bite;
LIHC	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.39	5.98	0.31	5.58e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.48	7.89	0.39	4.16e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.61	-7.16	-0.36	4.95e-12	Body mass index;
LIHC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	1.03	19.93	0.73	3.51e-59	Breast cancer;
LIHC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.41e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.71	10.38	0.49	3.94e-22	Mosquito bite size;
LIHC	cis	rs797680	0.754	rs7535214	chr1:93832565	A/AT	cg15093775	chr1:93646470	TMED5;CCDC18	0.57	8.42	0.41	1.03e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs1664789	0.904	rs1694057	chr5:53277373	T/A	ch.5.1024479R	chr5:53302184	ARL15	0.54	8.47	0.42	7.37e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.4	6.13	0.31	2.38e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg16479474	chr6:28041457	NA	0.5	5.88	0.3	9.81e-9	Depression;
LIHC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Electroencephalogram traits;
LIHC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.32	6.0	0.31	5.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg14709524	chr16:89940631	TCF25	0.59	7.57	0.38	3.43e-13	Skin colour saturation;
LIHC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.43	0.56	1.65e-29	Menopause (age at onset);
LIHC	cis	rs17001868	0.568	rs10854729	chr22:40750612	T/C	cg07138101	chr22:40742427	ADSL	0.53	6.45	0.33	3.9e-10	Mammographic density (dense area);
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.78	-0.34	5.15e-11	Lymphocyte counts;
LIHC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.82e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs860295	1.000	rs822527	chr1:155738053	A/G	cg02153340	chr1:155202674	NA	0.32	5.85	0.3	1.15e-8	Body mass index;
LIHC	cis	rs7633770	0.735	rs11719679	chr3:46687684	A/G	cg11219411	chr3:46661640	NA	-0.42	-7.26	-0.37	2.59e-12	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.67	6.81	0.35	4.45e-11	Alzheimer's disease;
LIHC	cis	rs11673344	0.734	rs1667343	chr19:37469098	G/A	cg27390819	chr19:37464633	NA	-0.5	-6.1	-0.31	2.94e-9	Obesity-related traits;
LIHC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.76	-14.89	-0.63	5.38e-39	Height;
LIHC	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.85	9.11	0.44	7.33e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.44	-5.98	-0.31	5.57e-9	Total body bone mineral density;
LIHC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.61	11.3	0.52	2.24e-25	Mean corpuscular volume;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg00809820	chr17:80708513	TBCD;FN3K	0.39	7.04	0.36	1.09e-11	Glycated hemoglobin levels;
LIHC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.09	0.44	8.32e-18	Schizophrenia;
LIHC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.9	0.51	6.28e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	12.85	0.57	4.15e-31	Birth weight;
LIHC	trans	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.5	-6.02	-0.31	4.45e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06506598	chr5:79783889	FAM151B	0.43	6.33	0.32	7.55e-10	Lung function (FEV1/FVC);
LIHC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.83	-0.43	5.53e-17	Schizophrenia;
LIHC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.24	16.17	0.66	4.22e-44	Diabetic kidney disease;
LIHC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.52	-7.71	-0.38	1.37e-13	Multiple sclerosis;
LIHC	cis	rs7619427	1.000	rs7619427	chr3:44077041	G/A	cg24966902	chr3:44043705	NA	0.5	7.05	0.36	9.76e-12	Schizophrenia;
LIHC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.88	16.68	0.67	4.15e-46	Blood protein levels;
LIHC	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.08	11.24	0.52	3.76e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.74	-0.34	6.72e-11	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07479988	chr2:39103277	MORN2;DHX57	0.46	6.6	0.34	1.55e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	6.03	0.31	4.24e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg19680672	chr10:131412579	MGMT	-0.43	-6.8	-0.34	4.8e-11	Response to temozolomide;
LIHC	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.37	-5.71	-0.3	2.42e-8	Reticulocyte fraction of red cells;
LIHC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.79	-9.95	-0.47	1.14e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg18912006	chr12:123335444	HIP1R	-0.6	-7.26	-0.37	2.56e-12	Schizophrenia;
LIHC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.97	0.6	2.02e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg08992911	chr2:238395768	MLPH	0.63	6.48	0.33	3.29e-10	Prostate cancer;
LIHC	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-0.89	-9.53	-0.46	3.06e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.45	-5.93	-0.31	7.27e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.8	11.14	0.52	8.76e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-6.98	-0.35	1.58e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg16586182	chr3:47516702	SCAP	-0.46	-8.35	-0.41	1.73e-15	Colorectal cancer;
LIHC	cis	rs10916814	0.610	rs1890004	chr1:20899066	T/C	cg24502330	chr1:20914028	CDA	-0.3	-6.7	-0.34	8.63e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.49	-7.57	-0.38	3.6e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2270927	0.510	rs6876070	chr5:75579237	T/A	cg13563193	chr19:33072644	PDCD5	0.99	9.35	0.45	1.2e-18	Mean corpuscular volume;
LIHC	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.82	14.91	0.63	4.55e-39	Adiposity;
LIHC	trans	rs6489882	0.671	rs4767026	chr12:113359132	A/G	cg10175203	chr3:128143634	NA	0.39	6.4	0.33	5.08e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.66	-9.07	-0.44	9.22e-18	Schizophrenia;
LIHC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.74	11.26	0.52	3.25e-25	Corneal astigmatism;
LIHC	trans	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.47	-0.33	3.37e-10	Educational attainment (years of education);
LIHC	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.49	-6.41	-0.33	4.73e-10	Coronary artery calcification;
LIHC	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg02023728	chr11:77925099	USP35	-0.34	-5.99	-0.31	5.41e-9	Alzheimer's disease (survival time);
LIHC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg27432699	chr2:27873401	GPN1	-0.6	-8.66	-0.42	1.88e-16	Total body bone mineral density;
LIHC	cis	rs732505	0.850	rs10412919	chr19:5586749	T/C	cg26242866	chr19:5711310	LONP1	0.89	6.52	0.33	2.59e-10	vWF and FVIII levels;
LIHC	cis	rs1198430	0.683	rs1198433	chr1:23756695	A/G	cg19827787	chr1:23763612	ASAP3	0.29	6.15	0.32	2.13e-9	Total cholesterol levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07775675	chr17:74379922	SPHK1	0.46	6.86	0.35	3.17e-11	Pancreatic cancer;
LIHC	cis	rs2834215	0.718	rs8128364	chr21:34867525	C/A	cg14850771	chr21:34775459	IFNGR2	0.42	6.07	0.31	3.39e-9	Crohn's disease;
LIHC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.59	-10.78	-0.5	1.64e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.51	7.96	0.4	2.6e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg17724175	chr1:150552817	MCL1	0.38	7.59	0.38	3.03e-13	Tonsillectomy;
LIHC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg12463550	chr7:65579703	CRCP	0.62	7.25	0.36	2.88e-12	Diabetic kidney disease;
LIHC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.58	-7.69	-0.38	1.61e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.28	0.45	2.02e-18	Lung cancer in ever smokers;
LIHC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.38	-0.37	1.18e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.38	6.12	0.31	2.63e-9	Menopause (age at onset);
LIHC	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.68	8.24	0.41	3.79e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.52	-0.38	4.99e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg00277334	chr10:82204260	NA	-0.54	-6.68	-0.34	9.51e-11	Post bronchodilator FEV1;
LIHC	cis	rs4755351	0.553	rs61887100	chr11:33170390	T/C	cg05567920	chr11:33183001	CSTF3	0.42	6.21	0.32	1.56e-9	Lung cancer in ever smokers;
LIHC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.58	7.41	0.37	1e-12	Neutrophil percentage of white cells;
LIHC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg10360323	chr17:41437877	NA	0.4	5.92	0.31	7.69e-9	Menopause (age at onset);
LIHC	trans	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg10756647	chr7:56101905	PSPH	-1.11	-13.62	-0.59	4.91e-34	Diabetic kidney disease;
LIHC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	7.73	0.39	1.24e-13	Obesity-related traits;
LIHC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg00343986	chr7:65444356	GUSB	0.4	6.05	0.31	3.88e-9	Aortic root size;
LIHC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg00277334	chr10:82204260	NA	-0.59	-7.71	-0.38	1.36e-13	Post bronchodilator FEV1;
LIHC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.93	15.46	0.64	3.05e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.77	0.3	1.77e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.46	9.03	0.44	1.25e-17	Testicular germ cell tumor;
LIHC	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg17385448	chr1:15911702	AGMAT	0.42	6.97	0.35	1.65e-11	Systolic blood pressure;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg03854865	chr6:26224070	HIST1H3E	0.63	7.23	0.36	3.28e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg14473756	chr11:122847823	NA	-0.37	-6.65	-0.34	1.18e-10	Menarche (age at onset);
LIHC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.87	-0.51	7.47e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.57	0.5	9e-23	Bladder cancer;
LIHC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.66	8.92	0.43	2.83e-17	Sudden cardiac arrest;
LIHC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	1e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.71	7.38	0.37	1.23e-12	Vitiligo;
LIHC	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-7.22	-0.36	3.44e-12	Hepatocellular carcinoma;
LIHC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.75	11.33	0.52	1.79e-25	Corneal astigmatism;
LIHC	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.7	10.5	0.49	1.56e-22	Metabolite levels;
LIHC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg08888203	chr3:10149979	C3orf24	0.56	6.45	0.33	3.89e-10	Alzheimer's disease;
LIHC	cis	rs17776563	0.887	rs8024132	chr15:89132681	G/T	cg05013243	chr15:89149849	MIR1179	0.41	6.77	0.34	5.49e-11	Thyroid hormone levels;
LIHC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg06064525	chr11:970664	AP2A2	-0.44	-10.71	-0.5	2.94e-23	Alzheimer's disease (late onset);
LIHC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07222421	chr1:155718648	MSTO2P	0.4	6.07	0.31	3.47e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08822215	chr16:89438651	ANKRD11	-0.48	-7.7	-0.38	1.48e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs3743266	0.507	rs56261931	chr15:60731618	C/T	cg22293140	chr15:60689852	ANXA2	-0.65	-6.48	-0.33	3.15e-10	Menarche (age at onset);
LIHC	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.66	-10.55	-0.5	1.04e-22	Lung cancer;
LIHC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.24	-5.71	-0.3	2.42e-8	Cutaneous nevi;
LIHC	cis	rs12019136	1	rs12019136	chr19:5835677	G/A	cg25387410	chr19:5844109	FUT3	-0.71	-8.47	-0.42	7.5e-16	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
LIHC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg00800038	chr16:89945340	TCF25	-0.62	-9.37	-0.45	9.82e-19	Skin colour saturation;
LIHC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.97	0.44	1.99e-17	Menarche (age at onset);
LIHC	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-10.26	-0.49	1.05e-21	Colorectal cancer;
LIHC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.43	6.78	0.34	5.3e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.86	-0.39	4.89e-14	Morning vs. evening chronotype;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18122802	chr7:66459960	SBDS	0.43	6.45	0.33	3.76e-10	Cognitive function;
LIHC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.9	-18.64	-0.71	5.26e-54	Height;
LIHC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	12.79	0.57	6.73e-31	Response to antipsychotic treatment;
LIHC	cis	rs12744310	0.943	rs12751511	chr1:41776403	A/T	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.77	-0.3	1.82e-8	Alzheimer's disease (late onset);
LIHC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18252515	chr7:66147081	NA	-0.43	-6.3	-0.32	9.36e-10	Aortic root size;
LIHC	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	0.84	9.45	0.45	5.66e-19	Mitochondrial DNA levels;
LIHC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.64	-0.38	2.25e-13	Calcium levels;
LIHC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-8.48	-0.42	6.74e-16	Menarche (age at onset);
LIHC	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-7.08	-0.36	8.42e-12	Homocysteine levels;
LIHC	cis	rs7781266	0.501	rs28551473	chr7:133631089	G/C	cg03336402	chr7:133662267	EXOC4	0.47	5.84	0.3	1.22e-8	Educational attainment (college completion);
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.56	-6.77	-0.34	5.51e-11	Alzheimer's disease;
LIHC	cis	rs10276381	0.579	rs58696040	chr7:28148387	A/G	cg23620719	chr7:28220237	JAZF1	0.63	6.92	0.35	2.3e-11	Crohn's disease;
LIHC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.98	15.17	0.63	4.33e-40	Metabolic syndrome;
LIHC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-8.85	-0.43	4.74e-17	Height;
LIHC	trans	rs11689435	0.925	rs3732007	chr2:218343265	A/G	cg13544946	chr9:35729779	TLN1	0.43	6.14	0.32	2.27e-9	Metabolite levels (MHPG);
LIHC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.78	8.68	0.42	1.67e-16	Vitiligo;
LIHC	cis	rs244293	0.672	rs9901526	chr17:53012379	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.56	-0.38	3.79e-13	Menarche (age at onset);
LIHC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg23172400	chr8:95962367	TP53INP1	0.33	7.05	0.36	1e-11	Type 2 diabetes;
LIHC	trans	rs12752401	1.000	rs67551785	chr1:102978472	T/C	cg24921808	chr19:740313	PALM	0.49	6.39	0.33	5.33e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg18323236	chr1:24743029	NIPAL3	0.39	7.25	0.37	2.73e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg15123519	chr2:136567270	LCT	0.45	9.45	0.45	5.65e-19	Mosquito bite size;
LIHC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.58	7.46	0.37	7.07e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-0.82	-11.46	-0.53	5.75e-26	Pediatric areal bone mineral density (radius);
LIHC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg20818283	chr2:191399100	TMEM194B	0.46	6.31	0.32	8.66e-10	Pulse pressure;
LIHC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.8	12.79	0.57	7.08e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	trans	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.47	6.74	0.34	6.6e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs61677309	1.000	rs58093803	chr11:118168156	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.41	0.33	4.89e-10	Lung cancer in ever smokers;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20707008	chr6:160210612	MRPL18;TCP1	0.42	6.19	0.32	1.7e-9	Cognitive function;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.7	0.62	2.88e-38	Prudent dietary pattern;
LIHC	cis	rs72653721	0.689	rs4711170	chr6:11070434	C/A	cg13562911	chr6:11044106	ELOVL2	0.51	7.27	0.37	2.42e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs8108269	0.955	rs55872740	chr19:46160323	A/G	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.82	10.25	0.48	1.14e-21	Bladder cancer;
LIHC	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.15	-9.94	-0.47	1.3e-20	Schizophrenia;
LIHC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.12	17.17	0.68	4.25e-48	Corneal structure;
LIHC	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.49	-6.09	-0.31	2.97e-9	Menarche (age at onset);
LIHC	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg01596870	chr19:55963115	NA	-0.66	-9.72	-0.47	7.09e-20	Obesity-related traits;
LIHC	cis	rs10242455	0.571	rs73713594	chr7:99326498	A/G	cg18809830	chr7:99032528	PTCD1	-0.85	-6.8	-0.34	4.79e-11	Blood metabolite levels;
LIHC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	1.02	21.14	0.75	4.72e-64	Height;
LIHC	cis	rs36051895	0.623	rs1830610	chr9:5260079	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-10.6	-0.5	6.92e-23	Pediatric autoimmune diseases;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13559217	chr19:5119331	KDM4B	0.43	6.68	0.34	9.76e-11	Longevity;
LIHC	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.36	5.96	0.31	6.14e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.02	0.48	6.63e-21	Post bronchodilator FEV1;
LIHC	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.55	-10.31	-0.49	6.91e-22	Sense of smell;
LIHC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg00204512	chr16:28754710	NA	0.35	6.4	0.33	4.98e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg05185784	chr16:90016020	DEF8	0.45	5.84	0.3	1.19e-8	Skin colour saturation;
LIHC	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.68	-11.72	-0.54	6.86e-27	Pediatric autoimmune diseases;
LIHC	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg16394018	chr11:14927549	NA	0.4	5.72	0.3	2.27e-8	Vitamin D levels;
LIHC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.13	0.48	2.88e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21467203	chr3:49911342	NA	-0.58	-10.76	-0.5	1.96e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg25344623	chr2:136566232	LCT	-0.37	-5.96	-0.31	6.45e-9	Corneal structure;
LIHC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.78	0.47	4.6e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg25838818	chr2:108905173	SULT1C2	0.41	7.4	0.37	1.1e-12	Blood pressure;
LIHC	cis	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg01231543	chr16:68741748	NA	0.38	5.89	0.3	9.02e-9	Colorectal cancer;
LIHC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.73	-10.96	-0.51	3.81e-24	Aortic root size;
LIHC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.51	0.49	1.45e-22	Colorectal cancer;
LIHC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.2	0.41	4.97e-15	Mean corpuscular volume;
LIHC	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg03962019	chr1:41807865	NA	0.52	7.49	0.38	6e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	3.96e-13	Electroencephalogram traits;
LIHC	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.5	-6.81	-0.35	4.47e-11	Serum thyroid-stimulating hormone levels;
LIHC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg13844804	chr7:814759	HEATR2	0.43	5.74	0.3	2.07e-8	Cerebrospinal P-tau181p levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20108328	chr21:46396156	C21orf70	-0.42	-6.26	-0.32	1.16e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg22974920	chr21:40686053	BRWD1	-0.41	-5.92	-0.3	7.72e-9	Cognitive function;
LIHC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.35	6.81	0.35	4.41e-11	Multiple system atrophy;
LIHC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.89	-17.85	-0.69	8.1e-51	Height;
LIHC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.62	-11.86	-0.54	2.01e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs80282103	0.618	rs74117849	chr10:1165425	A/G	cg08668510	chr10:1095578	IDI1	0.63	6.01	0.31	4.64e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.89	11.01	0.51	2.56e-24	Coronary artery disease;
LIHC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.2	0.55	1.19e-28	Platelet count;
LIHC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg02297831	chr4:17616191	MED28	0.47	6.98	0.35	1.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs877282	1.000	rs11253363	chr10:771891	A/G	cg22713356	chr15:30763199	NA	1.36	12.27	0.55	6.54e-29	Uric acid levels;
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.51	6.85	0.35	3.41e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.8	-0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg03934865	chr2:198174659	NA	-0.56	-8.67	-0.42	1.74e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg04865290	chr3:52927548	TMEM110	-0.42	-6.34	-0.32	7.28e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00911488	chr4:106068604	TET2	0.44	6.23	0.32	1.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.01	-0.31	4.74e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.65e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	trans	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg07341007	chr3:195489909	MUC4	0.45	7.87	0.39	4.76e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg21573476	chr21:45109991	RRP1B	-0.56	-10.64	-0.5	4.84e-23	Mean corpuscular volume;
LIHC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	13.1	0.58	4.56e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg06466757	chr4:1255808	NA	0.34	5.77	0.3	1.76e-8	Obesity-related traits;
LIHC	cis	rs6782228	0.585	rs9841161	chr3:128331870	A/G	cg16766828	chr3:128327626	NA	-0.41	-6.42	-0.33	4.62e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.04	0.31	3.94e-9	Breast cancer;
LIHC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg05484376	chr2:27715224	FNDC4	0.39	6.51	0.33	2.73e-10	Total body bone mineral density;
LIHC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg07451762	chr16:28383216	NA	0.36	6.66	0.34	1.07e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg14222432	chr12:29376421	FAR2	-0.35	-6.83	-0.35	3.79e-11	QT interval;
LIHC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.73	-0.3	2.21e-8	Body mass index;
LIHC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg09904177	chr6:26538194	HMGN4	-0.53	-5.72	-0.3	2.37e-8	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18268492	chr10:99185986	PGAM1	0.37	6.08	0.31	3.24e-9	Calcium levels;
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.53	-6.39	-0.33	5.32e-10	Alzheimer's disease;
LIHC	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.09	-0.31	3.05e-9	Tuberculosis;
LIHC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-8.23	-0.41	3.95e-15	Menarche (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19568834	chr20:34252926	CPNE1;RBM12	-0.54	-6.79	-0.34	4.9e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg17724175	chr1:150552817	MCL1	0.47	9.08	0.44	8.87e-18	Melanoma;
LIHC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.45	-0.37	7.75e-13	Bipolar disorder;
LIHC	cis	rs13190036	0.748	rs28395268	chr5:176710547	C/G	cg06733329	chr5:176740039	MXD3	-0.36	-6.17	-0.32	1.94e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs55665837	0.701	rs11023265	chr11:14616038	C/T	cg25251204	chr11:14927456	NA	0.43	6.01	0.31	4.84e-9	Vitamin D levels;
LIHC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg22777020	chr22:31556080	RNF185	-0.55	-6.31	-0.32	8.59e-10	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.34	6.94	0.35	1.97e-11	Renal cell carcinoma;
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.56	9.36	0.45	1.1e-18	Aortic root size;
LIHC	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.44	-5.72	-0.3	2.36e-8	Subjective well-being;
LIHC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.8	17.07	0.68	1.06e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs77633900	0.772	rs284897	chr15:76750722	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-5.95	-0.31	6.51e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg10756647	chr7:56101905	PSPH	0.96	12.22	0.55	9.5e-29	Diabetic kidney disease;
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg18404041	chr3:52824283	ITIH1	-0.51	-7.88	-0.39	4.32e-14	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg00656387	chr3:40428638	ENTPD3	0.5	8.39	0.41	1.34e-15	Renal cell carcinoma;
LIHC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg08499158	chr17:42289980	UBTF	0.53	8.49	0.42	6.31e-16	Total body bone mineral density;
LIHC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.38	-6.08	-0.31	3.13e-9	Menarche (age at onset);
LIHC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.98	-11.22	-0.52	4.21e-25	Vitiligo;
LIHC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.59	7.54	0.38	4.35e-13	Morning vs. evening chronotype;
LIHC	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg23387056	chr11:14280742	SPON1	0.46	6.3	0.32	9.28e-10	Mitochondrial DNA levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15742519	chr2:190627263	OSGEPL1	0.54	7.34	0.37	1.59e-12	Lung function (FEV1/FVC);
LIHC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	6.84	0.35	3.72e-11	Mood instability;
LIHC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.98	-0.31	5.74e-9	Multiple myeloma (IgH translocation);
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.53	-7.34	-0.37	1.57e-12	Menopause (age at onset);
LIHC	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.55	0.33	2.09e-10	Lymphocyte counts;
LIHC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.64	-0.71	5.02e-54	Height;
LIHC	cis	rs10847980	0.590	rs12319654	chr12:123327160	C/T	cg18912006	chr12:123335444	HIP1R	0.76	7.79	0.39	8.13e-14	Adiponectin levels;
LIHC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.38	-0.33	5.68e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10792665	0.541	rs10898050	chr11:82593525	C/T	cg24227371	chr11:82718527	RAB30	-0.28	-6.68	-0.34	9.5e-11	Obesity-related traits;
LIHC	cis	rs3815308	0.530	rs2240129	chr19:2197734	C/T	cg09261902	chr19:2140048	AP3D1	0.37	6.37	0.33	6.19e-10	Breast cancer;
LIHC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.16	0.4	6.27e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.68	0.46	9.74e-20	Morning vs. evening chronotype;
LIHC	cis	rs7487075	0.930	rs4076484	chr12:46833912	C/G	cg22049899	chr12:47219821	SLC38A4	0.32	5.8	0.3	1.5e-8	Itch intensity from mosquito bite;
LIHC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg12863693	chr15:85201151	NMB	0.4	5.86	0.3	1.08e-8	Schizophrenia;
LIHC	cis	rs4407350	0.868	rs5765719	chr22:44917849	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.4	0.33	4.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.64	0.34	1.25e-10	Bipolar disorder;
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.44	6.47	0.33	3.38e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.84	-0.39	5.64e-14	Breast cancer;
LIHC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.45	7.25	0.37	2.72e-12	Caffeine consumption;
LIHC	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.31	7.13	0.36	6.13e-12	Blood metabolite ratios;
LIHC	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.44	7.83	0.39	5.99e-14	Resting heart rate;
LIHC	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg04034577	chr2:241836375	C2orf54	-0.29	-6.07	-0.31	3.33e-9	Urinary metabolites;
LIHC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg15208524	chr1:10270712	KIF1B	0.42	6.22	0.32	1.43e-9	Hepatocellular carcinoma;
LIHC	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.57	0.46	2.14e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs732505	0.717	rs3213651	chr19:5593771	A/G	cg26242866	chr19:5711310	LONP1	0.89	6.54	0.33	2.3e-10	vWF and FVIII levels;
LIHC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.38	0.59	3.85e-33	Chronic sinus infection;
LIHC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.04	0.55	4.52e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg18357526	chr6:26021779	HIST1H4A	0.45	6.19	0.32	1.77e-9	Educational attainment;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.38	6.05	0.31	3.76e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.66	-8.22	-0.41	4.31e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.64	11.79	0.54	3.74e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12744310	1.000	rs55929643	chr1:41774212	A/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg25204440	chr1:209979598	IRF6	0.51	7.83	0.39	6.21e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.89	9.78	0.47	4.56e-20	Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.7	13.8	0.6	9.69e-35	Coronary artery disease;
LIHC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg03146154	chr1:46216737	IPP	-0.4	-6.51	-0.33	2.66e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.01	0.48	7.51e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg06115535	chr2:131100015	IMP4;CCDC115	0.43	6.06	0.31	3.55e-9	Thyroid cancer;
LIHC	cis	rs11951515	0.508	rs10065689	chr5:43604258	T/C	cg01983248	chr5:43482804	C5orf28	-0.4	-6.48	-0.33	3.12e-10	Metabolite levels  (X-11787);
LIHC	cis	rs9918079	0.560	rs4698409	chr4:15659766	G/A	cg21329975	chr4:15471214	CC2D2A	-0.4	-6.04	-0.31	4.05e-9	Obesity-related traits;
LIHC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.66	-9.97	-0.47	1.01e-20	Subjective well-being;
LIHC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.58	0.56	4.5e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02359409	chr6:42947317	PEX6	0.52	7.33	0.37	1.68e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg12560992	chr17:57184187	TRIM37	0.69	8.91	0.43	3.17e-17	Vitamin D levels;
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.94	-0.6	2.78e-35	Alzheimer's disease;
LIHC	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.97	-0.31	6.09e-9	Red blood cell count;
LIHC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-0.98	-15.91	-0.65	4.65e-43	Lymphocyte counts;
LIHC	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.5	-8.33	-0.41	2e-15	Menarche (age at onset);
LIHC	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg14515779	chr1:101123966	NA	-0.67	-12.97	-0.57	1.47e-31	Monocyte count;
LIHC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg02290350	chr8:58132656	NA	-0.33	-7.88	-0.39	4.3e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.9	-0.63	4.91e-39	Chronic sinus infection;
LIHC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.34	6.09	0.31	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.27	7.14	0.36	5.49e-12	Cardiovascular disease risk factors;
LIHC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.71	-0.3	2.42e-8	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24051152	chr8:145133159	EXOSC4	0.56	8.07	0.4	1.23e-14	Pancreatic cancer;
LIHC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.5	-6.31	-0.32	8.58e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	6.01	0.31	4.84e-9	Obesity-related traits;
LIHC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.61	-8.07	-0.4	1.23e-14	Diastolic blood pressure;
LIHC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg02023728	chr11:77925099	USP35	-0.32	-5.77	-0.3	1.82e-8	Alzheimer's disease (survival time);
LIHC	cis	rs10186029	0.648	rs13022006	chr2:213940309	A/C	cg08319019	chr2:214017104	IKZF2	0.41	5.85	0.3	1.13e-8	Systemic sclerosis;
LIHC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.95	19.21	0.72	2.72e-56	Height;
LIHC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg11062466	chr8:58055876	NA	0.39	5.72	0.3	2.34e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9649465	0.967	rs6950373	chr7:123361773	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.15e-15	Migraine;
LIHC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg07451762	chr16:28383216	NA	0.38	6.76	0.34	6.11e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.45	6.43	0.33	4.36e-10	Asthma;
LIHC	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.34	-0.49	5.53e-22	Hemoglobin concentration;
LIHC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.85	-0.43	4.65e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.57	7.68	0.38	1.73e-13	Mean corpuscular volume;
LIHC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.59	-8.47	-0.42	7.31e-16	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01774158	chr5:133562094	PPP2CA	0.6	7.76	0.39	9.76e-14	Lung function (FEV1/FVC);
LIHC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg03037974	chr15:76606532	NA	-0.73	-14.43	-0.62	3.34e-37	Blood metabolite levels;
LIHC	cis	rs918629	0.530	rs7702674	chr5:95237365	A/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.52	-0.33	2.46e-10	IgG glycosylation;
LIHC	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	6.87	0.35	2.96e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.96	0.31	6.25e-9	Menopause (age at onset);
LIHC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.35	0.32	6.99e-10	Heart rate;
LIHC	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs3770081	1.000	rs78650586	chr2:86190783	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-7.84	-0.39	5.88e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.46	-6.41	-0.33	4.94e-10	Initial pursuit acceleration;
LIHC	cis	rs6504950	0.800	rs9907961	chr17:53012927	C/G	cg10237252	chr17:52977213	TOM1L1	-0.34	-5.99	-0.31	5.22e-9	Breast cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01270466	chr14:96506401	C14orf132	-0.38	-6.08	-0.31	3.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs6578985	0.741	rs10840366	chr11:2124435	C/A	cg20230732	chr3:128721448	CCDC48	0.37	6.09	0.31	3.05e-9	Femoral neck bone geometry and menarche (age at onset);
LIHC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.69	14.53	0.62	1.37e-37	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.57	8.52	0.42	5.29e-16	Longevity;
LIHC	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg10790698	chr19:18539756	SSBP4	-0.37	-7.53	-0.38	4.47e-13	Breast cancer;
LIHC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.64	-10.5	-0.49	1.48e-22	Inflammatory bowel disease;
LIHC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22649068	chr1:150552352	MCL1	0.43	6.07	0.31	3.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.7	9.94	0.47	1.26e-20	Lymphocyte counts;
LIHC	cis	rs965469	0.947	rs6051773	chr20:3330382	C/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.49	8.49	0.42	6.48e-16	Tuberculosis;
LIHC	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-7.26	-0.37	2.71e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg10755058	chr3:40428713	ENTPD3	0.41	6.89	0.35	2.77e-11	Renal cell carcinoma;
LIHC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg15448220	chr1:150897856	SETDB1	0.42	6.47	0.33	3.44e-10	Tonsillectomy;
LIHC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.38	5.79	0.3	1.58e-8	Height;
LIHC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.7	9.83	0.47	3.1e-20	Monocyte percentage of white cells;
LIHC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg19743168	chr1:23544995	NA	0.34	5.81	0.3	1.39e-8	Height;
LIHC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg03037974	chr15:76606532	NA	-0.6	-10.09	-0.48	4.04e-21	Blood metabolite levels;
LIHC	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg21280719	chr6:42927975	GNMT	-0.32	-7.5	-0.38	5.65e-13	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4788570	0.697	rs9635524	chr16:71804956	C/G	cg06353428	chr16:71660113	MARVELD3	1.32	14.19	0.61	2.88e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.71	9.49	0.46	4.02e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.44	-6.71	-0.34	8.16e-11	Dementia with Lewy bodies;
LIHC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.48	-6.29	-0.32	9.7e-10	Initial pursuit acceleration;
LIHC	cis	rs963731	0.649	rs78510010	chr2:39348662	T/C	cg04010122	chr2:39346883	SOS1	0.69	6.06	0.31	3.62e-9	Corticobasal degeneration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01111842	chr9:140444966	PNPLA7;MRPL41	0.45	6.27	0.32	1.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.1	-0.31	2.83e-9	Pancreatic cancer;
LIHC	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.49	9.4	0.45	8.01e-19	Testicular germ cell tumor;
LIHC	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.36	5.85	0.3	1.16e-8	Blood metabolite levels;
LIHC	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.38	6.4	0.33	5.12e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-1.0	-9.98	-0.47	9.46e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2637030	0.559	rs2607501	chr5:52989545	A/T	cg06476337	chr5:52856530	NDUFS4	0.42	6.75	0.34	6.4e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20783262	chr1:68152310	GADD45A	0.46	6.38	0.33	5.72e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	5.96	0.31	6.24e-9	Schizophrenia;
LIHC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.25e-12	Bipolar disorder;
LIHC	cis	rs12986413	1.000	rs11882273	chr19:2173836	T/C	cg09261902	chr19:2140048	AP3D1	0.37	6.38	0.33	5.85e-10	Height;
LIHC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	0.82	14.6	0.62	7.36e-38	Exhaled nitric oxide output;
LIHC	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg16506815	chr2:162101123	NA	0.48	7.74	0.39	1.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.58	6.94	0.35	2e-11	Initial pursuit acceleration;
LIHC	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg00792783	chr2:198669748	PLCL1	0.45	6.63	0.34	1.33e-10	Intracranial aneurysm;
LIHC	cis	rs847649	0.692	rs10279449	chr7:102462636	T/C	cg18108683	chr7:102477205	FBXL13	-0.52	-8.04	-0.4	1.53e-14	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.37	-7.5	-0.38	5.63e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg20607798	chr8:58055168	NA	0.46	5.88	0.3	9.86e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.08	0.36	7.99e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.51	8.15	0.4	6.8e-15	Multiple myeloma (IgH translocation);
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26378183	chr14:73924401	NUMB	0.44	6.26	0.32	1.14e-9	Gut microbiome composition (summer);
LIHC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07305463	chr2:136567211	LCT	0.39	7.54	0.38	4.34e-13	Mosquito bite size;
LIHC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.33	6.3	0.32	9.38e-10	Body mass index;
LIHC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-1.0	-19.39	-0.72	4.95e-57	Breast cancer;
LIHC	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	28.2	0.84	3.06e-91	Schizophrenia;
LIHC	cis	rs7208859	0.673	rs9903862	chr17:29206433	G/A	cg14067834	chr17:29058358	SUZ12P	0.74	6.97	0.35	1.68e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.04	0.31	4.11e-9	Ulcerative colitis;
LIHC	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.84	-15.93	-0.65	3.87e-43	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09133386	chr6:20404188	E2F3	0.41	6.55	0.33	2.07e-10	Cognitive function;
LIHC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.56	-5.92	-0.3	7.82e-9	Vitiligo;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.1	0.31	2.82e-9	Prudent dietary pattern;
LIHC	cis	rs11233413	0.532	rs2374349	chr11:82670073	A/G	cg24227371	chr11:82718527	RAB30	-0.3	-6.65	-0.34	1.19e-10	Economic and political preferences (feminism/equality);
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04013166	chr16:89971882	TCF25	0.59	7.84	0.39	5.79e-14	Skin colour saturation;
LIHC	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg03934865	chr2:198174659	NA	0.43	6.23	0.32	1.34e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg07689907	chr11:61582574	FADS1	0.4	5.79	0.3	1.6e-8	Bipolar disorder;
LIHC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.37	6.58	0.34	1.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.35	6.46	0.33	3.59e-10	Testicular germ cell tumor;
LIHC	cis	rs13161895	1.000	rs27018	chr5:179405144	A/G	cg06664874	chr5:179499304	RNF130	0.57	6.99	0.35	1.48e-11	LDL cholesterol;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg16358155	chr3:195490169	MUC4	0.44	6.7	0.34	8.39e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg07061783	chr6:25882402	NA	-0.44	-6.16	-0.32	2.06e-9	Blood metabolite levels;
LIHC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	12.59	0.56	4.08e-30	Multiple sclerosis;
LIHC	cis	rs963731	0.649	rs297135	chr2:39304793	G/A	cg04010122	chr2:39346883	SOS1	-0.71	-6.33	-0.32	7.56e-10	Corticobasal degeneration;
LIHC	cis	rs8067354	0.507	rs2645478	chr17:58014712	G/A	cg13753209	chr17:57696993	CLTC	0.7	10.49	0.49	1.66e-22	Hemoglobin concentration;
LIHC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.55	11.19	0.52	5.65e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.29	-0.41	2.66e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs965469	1.000	rs6051764	chr20:3321807	A/G	cg25506879	chr20:3388711	C20orf194	0.47	5.86	0.3	1.09e-8	IFN-related cytopenia;
LIHC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.76	11.87	0.54	1.83e-27	Corneal astigmatism;
LIHC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.26	-0.32	1.16e-9	Menarche (age at onset);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg10715820	chr1:17235063	NA	0.43	6.76	0.34	6e-11	Bilirubin levels;
LIHC	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.05	-0.31	3.9e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.58	-5.81	-0.3	1.44e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.89	0.47	1.92e-20	Coffee consumption (cups per day);
LIHC	cis	rs12644436	0.628	rs10776486	chr4:88782517	A/G	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16725865	chr1:92546135	BTBD8	0.46	7.93	0.39	3.15e-14	Cognitive function;
LIHC	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg13482628	chr17:19912719	NA	0.39	6.42	0.33	4.51e-10	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01125608	chr5:646071	CEP72	0.46	6.71	0.34	8.04e-11	Longevity;
LIHC	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-6.85	-0.35	3.4e-11	Metabolite levels;
LIHC	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.46e-15	Facial morphology (factor 19);
LIHC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.42	-6.55	-0.33	2.1e-10	Schizophrenia;
LIHC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	1.01	19.44	0.72	3.13e-57	Breast cancer;
LIHC	cis	rs75908454	1.000	rs79721653	chr6:169903083	T/A	cg19338460	chr6:170058176	WDR27	-0.8	-7.26	-0.37	2.57e-12	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.65	10.58	0.5	8.38e-23	Total cholesterol levels;
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.83	-0.35	3.78e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.16	-0.48	2.32e-21	Response to antipsychotic treatment;
LIHC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-6.4	-0.33	5.26e-10	Ulcerative colitis;
LIHC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg16226627	chr15:75307476	SCAMP5	0.49	8.62	0.42	2.57e-16	Lung cancer;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.54	7.57	0.38	3.44e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.63	12.8	0.57	6.46e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.43	7.83	0.39	6.36e-14	Prudent dietary pattern;
LIHC	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg20991723	chr1:152506922	NA	0.58	10.21	0.48	1.59e-21	Hair morphology;
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.96	0.31	6.43e-9	Renal cell carcinoma;
LIHC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-6.06	-0.31	3.64e-9	Schizophrenia;
LIHC	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.35	-0.45	1.18e-18	Schizophrenia;
LIHC	cis	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg04317927	chr11:55418816	OR4S2	0.47	9.04	0.44	1.17e-17	Pediatric bone mineral density (spine);
LIHC	trans	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg06175025	chr14:78082992	SPTLC2	0.46	6.7	0.34	8.34e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LIHC	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.06	0.48	4.93e-21	Coffee consumption (cups per day);
LIHC	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.81	8.98	0.44	1.89e-17	Ulcerative colitis;
LIHC	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg13919466	chr1:32135498	COL16A1	-0.31	-5.98	-0.31	5.64e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.66	9.27	0.45	2.12e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7224737	0.750	rs13380830	chr17:40297658	C/G	cg20291162	chr17:40259547	DHX58	-0.42	-5.94	-0.31	7.2e-9	Fibrinogen levels;
LIHC	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.64	12.9	0.57	2.62e-31	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg01629716	chr15:45996671	NA	0.51	9.21	0.45	3.44e-18	Waist circumference;Weight;
LIHC	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg16583315	chr14:65563665	MAX	0.42	8.42	0.41	1.02e-15	Obesity-related traits;
LIHC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg02344993	chr17:57696989	CLTC	0.7	11.89	0.54	1.66e-27	Hemoglobin concentration;
LIHC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.83	-12.1	-0.55	2.62e-28	Diastolic blood pressure;
LIHC	cis	rs7539624	0.588	rs61823966	chr1:223895942	C/T	cg07395969	chr1:223900822	CAPN2	0.49	5.77	0.3	1.82e-8	Schizophrenia;
LIHC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg13319975	chr6:146136371	FBXO30	0.34	5.73	0.3	2.25e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.47	-8.02	-0.4	1.76e-14	Aortic root size;
LIHC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	21.47	0.76	2.25e-65	Smoking behavior;
LIHC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.6	7.09	0.36	7.97e-12	Cognitive function;
LIHC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.58	-8.24	-0.41	3.74e-15	Facial morphology (factor 19);
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg12903224	chr12:29470962	FAR2	-0.41	-6.47	-0.33	3.39e-10	QT interval;
LIHC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.33	6.24	0.32	1.32e-9	Renal cell carcinoma;
LIHC	cis	rs507080	0.922	rs12788848	chr11:118553788	C/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.24	0.32	1.33e-9	Serum metabolite levels;
LIHC	cis	rs12744310	1.000	rs60825180	chr1:41771744	A/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.48	8.64	0.42	2.17e-16	Hemoglobin concentration;
LIHC	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg03959625	chr15:84868606	LOC388152	0.42	5.76	0.3	1.87e-8	Schizophrenia;
LIHC	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.1	-0.31	2.92e-9	Metabolite levels (Pyroglutamine);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23002097	chr19:58898625	RPS5	-0.44	-6.63	-0.34	1.3e-10	Cognitive function;
LIHC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg16836995	chr17:43662488	NA	-0.74	-7.65	-0.38	2e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6442522	0.644	rs6783160	chr3:15509018	C/T	cg16303742	chr3:15540471	COLQ	0.46	7.81	0.39	6.93e-14	Uric acid levels;
LIHC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27297192	chr10:134578999	INPP5A	0.56	7.71	0.38	1.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg19559668	chr19:36105986	HAUS5	0.39	6.2	0.32	1.63e-9	Immature fraction of reticulocytes;
LIHC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.48	0.33	3.11e-10	Educational attainment;
LIHC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.66	-10.13	-0.48	2.79e-21	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6120849	0.573	rs3746429	chr20:33703607	A/G	cg24642439	chr20:33292090	TP53INP2	-0.66	-6.57	-0.33	1.9e-10	Protein C levels;
LIHC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12016809	chr21:47604291	C21orf56	0.46	6.69	0.34	9.08e-11	Testicular germ cell tumor;
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg20090690	chr10:134436459	INPP5A	0.42	5.78	0.3	1.72e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	15.05	0.63	1.27e-39	Smoking behavior;
LIHC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Alcohol dependence;
LIHC	trans	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg10756647	chr7:56101905	PSPH	1.0	12.23	0.55	9.23e-29	Diabetic kidney disease;
LIHC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.24	6.14	0.32	2.3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	13.47	0.59	1.85e-33	Coffee consumption (cups per day);
LIHC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02985541	chr2:219472218	PLCD4	-0.42	-6.83	-0.35	3.99e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.48	-7.48	-0.37	6.34e-13	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	0.44	6.38	0.33	5.62e-10	Pancreatic cancer;
LIHC	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.11	-0.55	2.39e-28	Colorectal cancer;
LIHC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.36	-6.07	-0.31	3.46e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg21361702	chr7:150065534	REPIN1	0.45	6.17	0.32	1.88e-9	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-8.96	-0.44	2.14e-17	Platelet distribution width;
LIHC	trans	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg10756647	chr7:56101905	PSPH	1.11	13.23	0.58	1.43e-32	Diabetic kidney disease;
LIHC	trans	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg17675199	chr6:35436792	RPL10A	0.31	6.08	0.31	3.13e-9	Coronary artery disease;
LIHC	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg16558253	chr16:72132732	DHX38	-0.48	-6.7	-0.34	8.46e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LIHC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23422044	chr7:1970798	MAD1L1	-0.55	-8.76	-0.43	9.2e-17	Neuroticism;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg13409248	chr3:40428643	ENTPD3	-0.49	-8.35	-0.41	1.67e-15	Renal cell carcinoma;
LIHC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.86	-0.51	8.71e-24	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.68	0.57	1.91e-30	Alzheimer's disease;
LIHC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.8	13.32	0.58	6.62e-33	Breast cancer;
LIHC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.39	-5.79	-0.3	1.56e-8	Obesity-related traits;
LIHC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	22.55	0.77	1.24e-69	Body mass index (adult);
LIHC	cis	rs12960505	0.506	rs7231042	chr18:51024692	A/G	cg24270629	chr18:50823537	DCC	-0.47	-6.27	-0.32	1.06e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.48	-7.59	-0.38	3.09e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.77	-0.3	1.77e-8	Body mass index;
LIHC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-7.93	-0.39	3.06e-14	Obesity-related traits;
LIHC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg22079354	chr11:130786696	SNX19	-0.4	-5.89	-0.3	9.32e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.48	-7.88	-0.39	4.28e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2292096	1.000	rs6660197	chr1:200703541	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.24	-0.32	1.32e-9	Epilepsy;
LIHC	cis	rs7534824	0.625	rs17448356	chr1:101345093	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	7.03	0.36	1.15e-11	Refractive astigmatism;
LIHC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.51	8.46	0.42	7.74e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg27205649	chr11:78285834	NARS2	0.4	6.35	0.32	6.83e-10	Alzheimer's disease (survival time);
LIHC	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.63	-0.38	2.31e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.53	7.13	0.36	6.01e-12	Bone properties (heel);
LIHC	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.47	9.05	0.44	1.07e-17	Testicular germ cell tumor;
LIHC	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.5	-8.46	-0.42	7.76e-16	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.87	0.35	2.98e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg04317338	chr11:64019027	PLCB3	0.84	7.67	0.38	1.77e-13	Mean platelet volume;
LIHC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.87	13.31	0.58	7.31e-33	Vitamin D levels;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07677032	chr17:61819896	STRADA	0.4	6.02	0.31	4.52e-9	Prudent dietary pattern;
LIHC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-7.62	-0.38	2.44e-13	Height;
LIHC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.36	-0.37	1.37e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs12744310	0.887	rs72667610	chr1:41794810	G/A	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.95e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9596863	0.898	rs13378524	chr13:54372390	G/A	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.1e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.69	9.45	0.46	5.39e-19	Calcium levels;
LIHC	cis	rs7927592	0.645	rs7950900	chr11:68293545	G/A	cg16797656	chr11:68205561	LRP5	0.45	7.35	0.37	1.51e-12	Total body bone mineral density;
LIHC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg16989086	chr20:62203971	PRIC285	-0.56	-8.21	-0.41	4.64e-15	Glioblastoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26035463	chr12:117627651	FBXO21	0.47	6.6	0.34	1.61e-10	Pancreatic cancer;
LIHC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.41	7.27	0.37	2.47e-12	Psoriasis;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.69	6.97	0.35	1.62e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.54	5.81	0.3	1.4e-8	Alzheimer's disease;
LIHC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.6	8.46	0.42	8.04e-16	Lymphocyte counts;
LIHC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.42	6.01	0.31	4.74e-9	Osteoporosis;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg14828511	chr1:107599125	PRMT6	-0.42	-5.98	-0.31	5.7e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg17135325	chr3:160939158	NMD3	0.51	6.89	0.35	2.73e-11	Parkinson's disease;
LIHC	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.49	7.59	0.38	3.1400000000000003e-13	Diastolic blood pressure;
LIHC	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.62	9.18	0.44	4.35e-18	Diisocyanate-induced asthma;
LIHC	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.43e-18	Coffee consumption (cups per day);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08693231	chr6:34216354	C6orf1	0.46	6.26	0.32	1.15e-9	Lung function (FEV1/FVC);
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg05481257	chr2:20870211	GDF7	-0.42	-8.08	-0.4	1.15e-14	Abdominal aortic aneurysm;
LIHC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	5.74	0.3	2.06e-8	Schizophrenia;
LIHC	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg25344623	chr2:136566232	LCT	-0.34	-5.89	-0.3	9.26e-9	Corneal structure;
LIHC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.36	5.71	0.3	2.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10916814	0.632	rs7524492	chr1:20902750	G/A	cg24502330	chr1:20914028	CDA	-0.31	-6.81	-0.35	4.35e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.63	0.46	1.43e-19	Height;
LIHC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.44	-0.37	8.12e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21448741	chr8:58168803	NA	0.36	6.28	0.32	9.99e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg05760424	chr2:242988095	NA	-0.51	-6.81	-0.35	4.43e-11	Obesity-related traits;
LIHC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.36	6.15	0.32	2.17e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg01864069	chr14:103024347	NA	0.44	6.61	0.34	1.47e-10	Platelet count;
LIHC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.48	8.0	0.4	1.9e-14	Tuberculosis;
LIHC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.57	10.65	0.5	4.58e-23	Mean corpuscular volume;
LIHC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.54	-11.02	-0.51	2.19e-24	Tonsillectomy;
LIHC	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg23112188	chr14:24563095	PCK2	-0.29	-6.04	-0.31	4.13e-9	IgG glycosylation;
LIHC	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.41	6.41	0.33	4.77e-10	Mean corpuscular volume;
LIHC	trans	rs6866721	0.791	rs34942052	chr5:116216025	C/A	cg07571379	chr11:134631427	NA	-0.29	-6.09	-0.31	2.97e-9	Body mass index;
LIHC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.83	9.74	0.47	6.26e-20	Initial pursuit acceleration;
LIHC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.72	-0.3	2.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.7	-7.8	-0.39	7.58e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg01596870	chr19:55963115	NA	-0.58	-7.88	-0.39	4.51e-14	Obesity-related traits;
LIHC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.37	9.6	0.46	1.71e-19	Asthma (sex interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26985912	chr7:76179317	LOC100133091	0.45	7.32	0.37	1.82e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.5	-8.85	-0.43	4.94e-17	Lung cancer;
LIHC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	11.75	0.54	5.35e-27	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19643841	chr6:79944399	HMGN3	0.43	6.05	0.31	3.84e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-8.31	-0.41	2.35e-15	Hepatocellular carcinoma;
LIHC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg14222432	chr12:29376421	FAR2	0.36	6.97	0.35	1.68e-11	QT interval;
LIHC	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.21	-0.36	3.67e-12	Response to antipsychotic treatment;
LIHC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	0.88	11.5	0.53	4.31e-26	Iron status biomarkers;
LIHC	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.82	0.35	4.26e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.38	5.72	0.3	2.3e-8	Uric acid clearance;
LIHC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	9.98	0.47	9.35e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.38	7.78	0.39	8.76e-14	Immature fraction of reticulocytes;
LIHC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.64	10.28	0.49	9.04e-22	Smoking initiation;
LIHC	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.57	7.84	0.39	5.81e-14	Bladder cancer;
LIHC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.93	15.43	0.64	3.98e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg12798992	chr6:167411361	FGFR1OP	0.6	9.9	0.47	1.8e-20	Crohn's disease;
LIHC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.44	7.44	0.37	8.43e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.42	6.22	0.32	1.45e-9	Prostate cancer;
LIHC	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.66	-13.73	-0.6	1.84e-34	Bipolar disorder;
LIHC	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.33	6.19	0.32	1.74e-9	Protein biomarker;
LIHC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.39	-6.15	-0.32	2.21e-9	Huntington's disease progression;
LIHC	trans	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17183009	chr3:120277827	NA	0.52	6.09	0.31	3.02e-9	Corneal astigmatism;
LIHC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.36	6.45	0.33	3.8e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs9378688	1.000	rs9378688	chr6:2235633	G/A	cg12303981	chr6:2244766	GMDS	-0.49	-6.29	-0.32	9.47e-10	Caudate nucleus volume;
LIHC	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.58	7.78	0.39	8.74e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.98	-0.57	1.31e-31	Type 2 diabetes;
LIHC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	ch.11.42038R	chr11:967971	AP2A2	0.53	9.58	0.46	2.01e-19	Alzheimer's disease (late onset);
LIHC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	11.85	0.54	2.21e-27	Total cholesterol levels;
LIHC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg06627628	chr2:24431161	ITSN2	-0.44	-5.83	-0.3	1.26e-8	Quantitative traits;
LIHC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	13.58	0.59	6.74e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg16226627	chr15:75307476	SCAMP5	0.37	7.11	0.36	6.99e-12	Blood trace element (Zn levels);
LIHC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.98	21.08	0.75	8.57e-64	Bone mineral density;
LIHC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg12798992	chr6:167411361	FGFR1OP	0.42	6.37	0.33	6.06e-10	Primary biliary cholangitis;
LIHC	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg07706471	chr12:123319906	HIP1R	-0.53	-6.41	-0.33	4.72e-10	Schizophrenia;
LIHC	cis	rs1400745	0.756	rs3783314	chr14:35337384	T/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.76	-0.39	9.72e-14	Monocyte count;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18767321	chr22:39096505	JOSD1	-0.39	-6.13	-0.31	2.41e-9	Immature fraction of reticulocytes;
LIHC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.14	15.1	0.63	8e-40	Blood protein levels;
LIHC	trans	rs9940464	0.842	rs28549904	chr16:83369972	G/A	cg02755603	chr20:18548475	LOC388789	0.34	6.17	0.32	1.94e-9	Malaria;
LIHC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.68	12.97	0.57	1.41e-31	Systemic lupus erythematosus;
LIHC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02290350	chr8:58132656	NA	0.45	8.91	0.43	3.17e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg16275483	chr1:110013120	SYPL2	-0.5	-6.22	-0.32	1.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.42	6.75	0.34	6.5e-11	Height;
LIHC	trans	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg19894588	chr14:64061835	NA	0.66	9.58	0.46	2.05e-19	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.4	0.45	8.3e-19	Bladder cancer;
LIHC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg19302996	chr17:73780495	UNK	-0.48	-6.79	-0.34	4.92e-11	White matter hyperintensity burden;
LIHC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.51	8.28	0.41	2.77e-15	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs2288327	0.673	rs6723399	chr2:179381715	G/C	cg14011486	chr1:26737247	LIN28	0.54	7.66	0.38	1.92e-13	Atrial fibrillation;
LIHC	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01893041	chr5:67583972	PIK3R1	0.5	7.27	0.37	2.46e-12	Pancreatic cancer;
LIHC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.86	0.3	1.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.42	0.33	4.48e-10	Renal cell carcinoma;
LIHC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.55	-7.67	-0.38	1.8e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2540917	0.654	rs11894442	chr2:60657018	T/C	cg00543073	chr2:60773386	BCL11A	-0.31	-6.31	-0.32	8.8e-10	Mean corpuscular volume;
LIHC	cis	rs12079745	0.793	rs75487543	chr1:169339382	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg00280220	chr17:61926910	NA	0.4	6.23	0.32	1.4e-9	Prudent dietary pattern;
LIHC	cis	rs611744	0.967	rs652485	chr8:109202696	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.69	0.34	9.31e-11	Dupuytren's disease;
LIHC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.79	-0.34	4.86e-11	Personality dimensions;
LIHC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg05110241	chr16:68378359	PRMT7	-0.55	-6.46	-0.33	3.63e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.28	-7.13	-0.36	6.09e-12	Mean corpuscular volume;
LIHC	cis	rs611744	0.967	rs597649	chr8:109187718	T/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg21724239	chr8:58056113	NA	0.49	6.53	0.33	2.43e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16684958	chr7:75615977	POR	-0.51	-8.53	-0.42	4.81e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10818894	1.000	rs10818894	chr9:126695770	A/G	cg16191174	chr9:126692580	DENND1A	-0.64	-7.36	-0.37	1.37e-12	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	0.44	6.13	0.31	2.38e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.5	7.81	0.39	6.97e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg09417038	chr21:47716443	C21orf57	-0.56	-8.22	-0.41	4.18e-15	Testicular germ cell tumor;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg16484450	chr15:100350984	NA	0.33	6.7	0.34	8.62e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.55	8.25	0.41	3.44e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs13113518	0.729	rs11133377	chr4:56279875	A/G	cg15358633	chr12:38710606	ALG10B	0.44	6.09	0.31	3.07e-9	Height;
LIHC	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.79	8.92	0.43	2.84e-17	Exhaled nitric oxide levels;
LIHC	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg00085434	chr11:14927489	NA	0.4	5.85	0.3	1.17e-8	Vitamin D levels;
LIHC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.66	-10.3	-0.49	7.77e-22	Monocyte count;
LIHC	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.75	-0.3	1.96e-8	Response to antipsychotic treatment;
LIHC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-7.92	-0.39	3.35e-14	Longevity;Endometriosis;
LIHC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.74	-12.15	-0.55	1.74e-28	Systemic lupus erythematosus;
LIHC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.64	-9.35	-0.45	1.14e-18	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.58	-8.85	-0.43	4.93e-17	Smoking behavior;
LIHC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.52	6.65	0.34	1.17e-10	Orofacial clefts;
LIHC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.56	-16.45	-0.66	3.32e-45	Breast cancer;
LIHC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.18	-0.48	1.88e-21	Response to antipsychotic treatment;
LIHC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	0.76	12.17	0.55	1.47e-28	Blood trace element (Zn levels);
LIHC	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg16583315	chr14:65563665	MAX	-0.37	-7.61	-0.38	2.74e-13	Obesity-related traits;
LIHC	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg07424592	chr7:64974309	NA	0.77	8.87	0.43	4.13e-17	Diabetic kidney disease;
LIHC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.16	0.55	1.68e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.5	-0.42	6.14e-16	Response to antipsychotic treatment;
LIHC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.78	15.27	0.64	1.69e-40	Myeloid white cell count;
LIHC	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.77	-8.53	-0.42	4.82e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs116248771	0.739	rs12630515	chr3:158346615	A/G	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.77e-10	diarrhoeal disease at age 2;
LIHC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg05185784	chr16:90016020	DEF8	-0.45	-5.9	-0.3	8.68e-9	Skin colour saturation;
LIHC	cis	rs611744	0.967	rs677330	chr8:109177572	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	14.99	0.63	2.08e-39	Menopause (age at onset);
LIHC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg00343986	chr7:65444356	GUSB	0.41	6.16	0.32	2.05e-9	Aortic root size;
LIHC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.93	0.35	2.06e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02985541	chr2:219472218	PLCD4	-0.37	-5.87	-0.3	1.05e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs757081	0.671	rs214090	chr11:17297161	C/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-5.99	-0.31	5.25e-9	Systolic blood pressure;
LIHC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.43	-6.95	-0.35	1.9e-11	Multiple myeloma;
LIHC	cis	rs6088813	0.767	rs4911179	chr20:33972899	A/C	cg14752227	chr20:34000481	UQCC	-0.41	-5.82	-0.3	1.38e-8	Height;
LIHC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	6.23	0.32	1.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.6e-18	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg05590025	chr7:65112418	INTS4L2	-0.59	-6.58	-0.34	1.81e-10	Diabetic kidney disease;
LIHC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.39	0.41	1.33e-15	Lung cancer in ever smokers;
LIHC	trans	rs72960926	0.744	rs72957983	chr6:74968228	A/G	cg07247405	chr1:2484626	LOC115110	0.53	6.35	0.32	7e-10	Metabolite levels (MHPG);
LIHC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-1.0	-10.39	-0.49	3.72e-22	Breast cancer;
LIHC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg05044414	chr3:183734942	ABCC5	0.33	5.73	0.3	2.2e-8	Anterior chamber depth;
LIHC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.55	10.59	0.5	7.63e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs151997	0.962	rs27273	chr5:50181074	G/A	cg06027927	chr5:50259733	NA	0.57	7.59	0.38	3.09e-13	Callous-unemotional behaviour;
LIHC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg17691542	chr6:26056736	HIST1H1C	0.39	5.74	0.3	2.08e-8	Height;
LIHC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.63	11.2	0.52	5.34e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.37	-6.49	-0.33	3.01e-10	Asthma;
LIHC	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.84	0.54	2.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.46	6.22	0.32	1.47e-9	Tonsillectomy;
LIHC	cis	rs882732	1.000	rs10144453	chr14:95045774	T/C	cg14866387	chr14:95027382	SERPINA4	-0.48	-6.29	-0.32	9.43e-10	Blood protein levels;
LIHC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.61	0.67	7.74e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.04	-0.31	3.96e-9	Colorectal cancer;
LIHC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.33	-5.81	-0.3	1.44e-8	Psoriasis;
LIHC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg06598544	chr20:61472147	COL9A3	-0.9	-8.42	-0.41	1.07e-15	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg03013999	chr17:37608204	MED1	0.35	5.74	0.3	2.09e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24111710	chr7:152063974	MLL3	0.42	6.47	0.33	3.33e-10	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03660134	chr7:149195865	ZNF746	-0.49	-7.13	-0.36	5.91e-12	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.51	-0.79	2.04e-73	Height;
LIHC	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg15208524	chr1:10270712	KIF1B	0.46	6.72	0.34	7.54e-11	Hepatocellular carcinoma;
LIHC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.53	7.13	0.36	6.19e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.35	-6.95	-0.35	1.9e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs7759633	0.800	rs78199196	chr6:161002749	T/C	cg06341590	chr4:57624431	NA	-0.59	-6.53	-0.33	2.35e-10	Triglycerides;
LIHC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg17750252	chr2:136567154	LCT	0.35	6.32	0.32	8.34e-10	Mosquito bite size;
LIHC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.24	-0.36	2.89e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05477027	chr19:46295590	DMWD	0.42	6.25	0.32	1.21e-9	Pancreatic cancer;
LIHC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg17623882	chr6:41773611	USP49	-0.43	-5.83	-0.3	1.27e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-8.86	-0.43	4.35e-17	Parkinson's disease;
LIHC	trans	rs2710642	0.564	rs6752597	chr2:62823444	T/C	cg23713900	chr18:615496	CLUL1	-0.24	-6.14	-0.32	2.28e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg07090678	chr1:91966139	CDC7	-0.52	-6.78	-0.34	5.44e-11	Breast cancer;
LIHC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.53	8.79	0.43	7.56e-17	Colorectal cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03919644	chr3:101443603	CEP97	-0.43	-6.84	-0.35	3.55e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs879568	0.789	rs9959091	chr18:34319676	A/G	cg16486109	chr11:613632	IRF7	0.39	6.09	0.31	3.05e-9	QRS duration;
LIHC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.99	-0.31	5.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-19.73	-0.73	2.22e-58	Height;
LIHC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.91	16.84	0.67	8.86e-47	Menopause (age at onset);
LIHC	trans	rs2073499	0.935	rs2526393	chr3:50189173	C/G	cg21659725	chr3:3221576	CRBN	-0.62	-6.66	-0.34	1.11e-10	Schizophrenia;
LIHC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.6	8.01	0.4	1.8e-14	Coronary artery disease;
LIHC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.49	6.62	0.34	1.37e-10	High light scatter reticulocyte count;
LIHC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.64e-11	Aortic root size;
LIHC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs2574704	1.000	rs2574716	chr3:11662122	A/G	cg15876825	chr3:11651881	VGLL4	-0.5	-8.36	-0.41	1.61e-15	Body mass index;
LIHC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.65	11.18	0.52	6.32e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1555399	0.901	rs12887115	chr14:67990648	C/T	cg16224230	chr14:67978224	TMEM229B	-0.25	-6.11	-0.31	2.67e-9	Parkinson's disease;
LIHC	cis	rs13088318	0.521	rs7374860	chr3:101223721	A/G	cg19452782	chr3:101232218	SENP7	0.41	6.12	0.31	2.5e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	7.28	0.37	2.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.41	7.9	0.39	3.83e-14	Testicular germ cell tumor;
LIHC	cis	rs62179067	0.655	rs11890988	chr2:179944932	G/A	cg20701897	chr2:179586761	TTN	0.56	5.74	0.3	2.05e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.54	7.01	0.35	1.26e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg13944838	chr5:179740914	GFPT2	-0.56	-8.01	-0.4	1.84e-14	Height;
LIHC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.58	7.5	0.38	5.57e-13	Morning vs. evening chronotype;
LIHC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16853953	chr19:42774803	NA	0.42	6.39	0.33	5.54e-10	Pancreatic cancer;
LIHC	cis	rs4378999	0.623	rs6796642	chr3:51091392	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.38	-5.74	-0.3	2.12e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.84	-0.3	1.22e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35883536	1.000	rs11586815	chr1:101089079	C/T	cg14515779	chr1:101123966	NA	-0.67	-13.23	-0.58	1.53e-32	Monocyte count;
LIHC	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.45	5.78	0.3	1.66e-8	Retinal vascular caliber;
LIHC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.61	9.41	0.45	7.37e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.54	-0.33	2.28e-10	Schizophrenia;
LIHC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.26	6.34	0.32	7.29e-10	DNA methylation (variation);
LIHC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-6.43	-0.33	4.29e-10	Schizophrenia;
LIHC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.49	8.19	0.4	5.37e-15	Blood metabolite levels;
LIHC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.67	6.19	0.32	1.73e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.67	7.87	0.39	4.66e-14	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg17606287	chr9:99776144	HIATL2	-0.51	-6.35	-0.32	6.67e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg12501888	chr15:85177176	SCAND2	-0.49	-7.47	-0.37	6.69e-13	P wave terminal force;
LIHC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	16.37	0.66	6.73e-45	Smoking behavior;
LIHC	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.81	0.35	4.52e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.58	-0.38	3.3e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.64	-8.25	-0.41	3.56e-15	Gut microbiome composition (summer);
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg06497051	chr1:156261200	TMEM79	0.38	6.05	0.31	3.83e-9	Tonsillectomy;
LIHC	cis	rs11229555	0.645	rs4579945	chr11:58190873	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11627756	0.958	rs2146430	chr14:103071825	G/T	cg12046867	chr14:103022105	NA	-0.4	-6.17	-0.32	1.89e-9	Mean platelet volume;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.71	10.1	0.48	3.62e-21	Menarche (age at onset);
LIHC	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.63	-0.34	1.27e-10	Metabolite levels;
LIHC	trans	rs10411161	0.657	rs67462252	chr19:52382851	T/C	cg22319618	chr22:45562946	NUP50	-0.59	-8.02	-0.4	1.72e-14	Breast cancer;
LIHC	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-0.85	-10.38	-0.49	3.95e-22	Blood pressure (smoking interaction);
LIHC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.29	-0.55	5.21e-29	Colorectal cancer;
LIHC	cis	rs2235642	0.507	rs2235643	chr16:1585115	A/G	cg03034668	chr16:1723424	CRAMP1L	0.4	6.2	0.32	1.62e-9	Coronary artery disease;
LIHC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.47	-6.36	-0.33	6.39e-10	Total body bone mineral density;
LIHC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.73	8.13	0.4	7.97e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg18912006	chr12:123335444	HIP1R	-0.64	-7.77	-0.39	9.35e-14	Schizophrenia;
LIHC	cis	rs61677309	1.000	rs58520343	chr11:118155000	A/T	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.72	7.89	0.39	4.04e-14	Gut microbiome composition (summer);
LIHC	cis	rs4853525	0.522	rs6434412	chr2:191585275	A/G	cg10560079	chr2:191398806	TMEM194B	-0.41	-5.9	-0.3	8.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.67	-11.7	-0.53	8.07e-27	Menarche (age at onset);
LIHC	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.78	11.48	0.53	4.98e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.82	-0.35	4.23e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.54	6.07	0.31	3.45e-9	Alzheimer's disease;
LIHC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.8	13.32	0.58	6.62e-33	Breast cancer;
LIHC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg05941027	chr17:61774174	LIMD2	0.34	7.03	0.36	1.15e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg00091569	chr3:40428383	ENTPD3	0.4	6.77	0.34	5.61e-11	Renal cell carcinoma;
LIHC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.74	0.3	2.06e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs253664	0.897	rs1199336	chr3:138088221	T/A	cg17918682	chr3:137893718	DBR1	-0.55	-5.77	-0.3	1.76e-8	Body mass index;
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg12903224	chr12:29470962	FAR2	-0.42	-6.73	-0.34	7.04e-11	QT interval;
LIHC	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg06265175	chr8:121136014	COL14A1	0.48	7.72	0.39	1.34e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8084351	0.599	rs72923258	chr18:50740767	A/T	cg24270629	chr18:50823537	DCC	-0.49	-7.16	-0.36	4.88e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg05590025	chr7:65112418	INTS4L2	-0.53	-5.75	-0.3	2.01e-8	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.5	7.25	0.36	2.81e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.65	11.58	0.53	2.17e-26	Mortality in heart failure;
LIHC	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.94	0.54	1.01e-27	Eye color traits;
LIHC	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.81	12.9	0.57	2.65e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.48	-7.88	-0.39	4.28e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg00529422	chr1:16285251	ZBTB17	-0.32	-6.28	-0.32	1e-9	Systolic blood pressure;
LIHC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.34	-6.29	-0.32	9.45e-10	Aortic root size;
LIHC	cis	rs12086130	0.892	rs72906805	chr1:51450445	G/A	cg07174182	chr1:51127561	FAF1	-0.92	-9.87	-0.47	2.14e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.72	9.71	0.46	7.42e-20	Body mass index;
LIHC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg26939375	chr7:64535504	NA	-0.42	-6.8	-0.35	4.54e-11	Aortic root size;
LIHC	cis	rs8067354	0.789	rs1292068	chr17:57929319	T/C	cg13753209	chr17:57696993	CLTC	0.55	8.19	0.4	5.38e-15	Hemoglobin concentration;
LIHC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-5.76	-0.3	1.92e-8	Vitiligo;
LIHC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.76	-11.65	-0.53	1.17e-26	Corneal astigmatism;
LIHC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-7.49	-0.38	5.82e-13	Gut microbiome composition (summer);
LIHC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	0.87	13.29	0.58	8.6e-33	IgG glycosylation;
LIHC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.3	6.96	0.35	1.79e-11	Primary biliary cholangitis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15985400	chr11:76091674	PRKRIR	-0.42	-6.08	-0.31	3.15e-9	Pancreatic cancer;
LIHC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.49	9.79	0.47	3.97e-20	Tonsillectomy;
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20887711	chr4:1340912	KIAA1530	0.49	7.51	0.38	5.16e-13	Obesity-related traits;
LIHC	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.82	9.14	0.44	5.56e-18	Breast cancer;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg14828511	chr1:107599125	PRMT6	0.4	5.82	0.3	1.35e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4834770	1.000	rs6857641	chr4:120243511	T/C	cg09307838	chr4:120376055	NA	0.43	6.5	0.33	2.87e-10	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.7	0.62	2.97e-38	Prudent dietary pattern;
LIHC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg20283391	chr11:68216788	NA	-0.37	-5.87	-0.3	1.04e-8	Total body bone mineral density;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.54	6.52	0.33	2.5e-10	Alzheimer's disease;
LIHC	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.34	7.76	0.39	9.76e-14	Congenital heart disease (maternal effect);
LIHC	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.89	-7.97	-0.4	2.41e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.48e-10	Aortic root size;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19579446	chr11:57335474	UBE2L6	-0.43	-6.2	-0.32	1.58e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.61	8.97	0.44	1.93e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs1144333	1.000	rs5745327	chr1:76270040	A/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.88	-0.35	2.84e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.34	-6.45	-0.33	3.83e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.34	-6.38	-0.33	5.61e-10	Ankylosing spondylitis;
LIHC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.77	0.47	4.61e-20	Corneal astigmatism;
LIHC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	0.87	13.63	0.59	4.25e-34	Testicular germ cell tumor;
LIHC	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg08738300	chr3:44038990	NA	0.38	6.09	0.31	3.1e-9	Coronary artery disease;
LIHC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.87	-0.3	1.05e-8	Colorectal cancer;
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12516959	chr21:47718080	NA	0.36	5.96	0.31	6.38e-9	Testicular germ cell tumor;
LIHC	trans	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg09872104	chr7:134855509	C7orf49	-0.76	-6.21	-0.32	1.54e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg09597638	chr17:3907349	NA	0.54	6.68	0.34	9.79e-11	Type 2 diabetes;
LIHC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.5	0.38	5.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.66	9.74	0.47	5.99e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg18016565	chr1:150552671	MCL1	0.54	10.05	0.48	5.25e-21	Melanoma;
LIHC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg15123519	chr2:136567270	LCT	-0.36	-5.81	-0.3	1.45e-8	Corneal structure;
LIHC	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.33	-5.75	-0.3	1.95e-8	Cognitive performance;
LIHC	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg01864836	chr14:55583639	NA	-0.42	-7.69	-0.38	1.58e-13	Protein biomarker;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.46	6.22	0.32	1.48e-9	Menopause (age at onset);
LIHC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.85	13.02	0.58	9.25e-32	Multiple sclerosis;
LIHC	cis	rs11229555	0.645	rs35735990	chr11:58187371	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.43	-6.77	-0.34	5.59e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg26818010	chr10:134567672	INPP5A	0.63	8.46	0.42	7.92e-16	Migraine;
LIHC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg15123519	chr2:136567270	LCT	0.42	8.7	0.43	1.39e-16	Mosquito bite size;
LIHC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.5	7.32	0.37	1.84e-12	Glycated hemoglobin levels;
LIHC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg14129931	chr18:74513950	NA	0.45	5.87	0.3	1.01e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LIHC	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.86	15.04	0.63	1.41e-39	Headache;
LIHC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.91	0.3	8.44e-9	Height;
LIHC	cis	rs963731	0.649	rs297151	chr2:39326511	A/C	cg04010122	chr2:39346883	SOS1	-0.61	-6.1	-0.31	2.83e-9	Corticobasal degeneration;
LIHC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.61	9.25	0.45	2.58e-18	Cognitive function;
LIHC	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs116248771	0.739	rs6801874	chr3:158347396	C/G	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.75e-10	diarrhoeal disease at age 2;
LIHC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.46	-7.3	-0.37	2.04e-12	Multiple myeloma;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.18	-0.36	4.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.55	8.58	0.42	3.34e-16	Systemic sclerosis;
LIHC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.4	7.71	0.38	1.38e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.54	9.24	0.45	2.69e-18	Mean corpuscular volume;
LIHC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	2.09e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg04517722	chr19:17905589	B3GNT3	0.44	6.75	0.34	6.25e-11	Tumor biomarkers;
LIHC	cis	rs1982963	0.901	rs2516589	chr14:52512610	A/G	cg10843707	chr14:52510701	NID2	-0.47	-8.46	-0.42	7.86e-16	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2274273	0.682	rs7141975	chr14:55542216	G/C	cg01864836	chr14:55583639	NA	-0.4	-6.44	-0.33	3.98e-10	Protein biomarker;
LIHC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg16102536	chr7:156981717	UBE3C	0.35	5.92	0.3	7.91e-9	Body mass index;
LIHC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.43	-5.94	-0.31	7.18e-9	Total body bone mineral density;
LIHC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg16797656	chr11:68205561	LRP5	0.49	7.71	0.38	1.39e-13	Total body bone mineral density;
LIHC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.27	7.05	0.36	1.01e-11	Cardiovascular disease risk factors;
LIHC	cis	rs7619427	0.643	rs6791785	chr3:44093101	G/A	cg24966902	chr3:44043705	NA	0.54	6.9	0.35	2.49e-11	Schizophrenia;
LIHC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.29	-0.32	9.89e-10	Body mass index;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11060661	chr22:24314208	DDT;DDTL	0.68	12.09	0.55	2.83e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-0.87	-10.39	-0.49	3.62e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.44e-28	Height;
LIHC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg05973401	chr12:123451056	ABCB9	0.42	6.35	0.32	6.75e-10	Platelet count;
LIHC	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.61	-0.42	2.75e-16	Exhaled nitric oxide output;
LIHC	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg17385448	chr1:15911702	AGMAT	0.38	6.38	0.33	5.66e-10	Systolic blood pressure;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08219700	chr8:58056026	NA	0.52	7.15	0.36	5.22e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.2	-0.41	4.9e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg15871215	chr5:81402204	ATG10	0.72	9.59	0.46	1.88e-19	Breast cancer;
LIHC	trans	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg04702396	chr17:15466718	FAM18B2	0.43	6.47	0.33	3.3e-10	Educational attainment (years of education);
LIHC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg12292205	chr6:26970375	C6orf41	0.37	6.33	0.32	7.92e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.49	5.73	0.3	2.25e-8	Alzheimer's disease;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg14828511	chr1:107599125	PRMT6	-0.42	-6.01	-0.31	4.79e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.84	0.65	9.42e-43	Nonalcoholic fatty liver disease;
LIHC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.0	-0.35	1.32e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.62	9.06	0.44	1.05e-17	Menarche (age at onset);
LIHC	trans	rs6542647	0.541	rs113341692	chr2:4971943	T/G	cg16523137	chr18:5237527	LOC339290;C18orf18	0.61	6.11	0.31	2.69e-9	Left ventricular obstructive tract defect (inherited effect);
LIHC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.49	0.38	6e-13	Schizophrenia;
LIHC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	0.88	15.59	0.64	9.16e-42	Dental caries;
LIHC	cis	rs1499280	0.920	rs975886	chr5:52101227	T/C	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02985541	chr2:219472218	PLCD4	0.43	6.95	0.35	1.84e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.58	0.34	1.75e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4755351	0.553	rs11032158	chr11:33161290	G/A	cg05567920	chr11:33183001	CSTF3	0.43	6.23	0.32	1.33e-9	Lung cancer in ever smokers;
LIHC	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg01444801	chr10:135216882	MTG1	-0.55	-8.92	-0.43	2.86e-17	Systemic lupus erythematosus;
LIHC	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.2	16.23	0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg09597638	chr17:3907349	NA	0.52	6.42	0.33	4.44e-10	Type 2 diabetes;
LIHC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-9.05	-0.44	1.1e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.43	-8.53	-0.42	4.8e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-6.1	-0.31	2.88e-9	Morning vs. evening chronotype;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22997768	chr12:11092816	TAS2R14;PRR4;PRH1	0.36	6.46	0.33	3.61e-10	Hepatitis;
LIHC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.37	5.77	0.3	1.77e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg06359132	chr10:99160096	RRP12	-0.36	-5.72	-0.3	2.28e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.51	-8.95	-0.44	2.36e-17	Longevity;
LIHC	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.36	6.99	0.35	1.41e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	trans	rs6489882	0.867	rs4767036	chr12:113369177	T/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg11062466	chr8:58055876	NA	0.39	5.73	0.3	2.2e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.55	-7.94	-0.39	2.97e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg19636519	chr7:99541626	NA	0.3	5.72	0.3	2.37e-8	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02287918	chr21:30396957	USP16	-0.47	-6.43	-0.33	4.27e-10	Pancreatic cancer;
LIHC	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	1.12	8.76	0.43	9.54e-17	Arsenic metabolism;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12379764	chr21:47803548	PCNT	0.58	8.44	0.42	8.99e-16	Testicular germ cell tumor;
LIHC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.78	-0.39	8.81e-14	Chronic sinus infection;
LIHC	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.09	0.36	7.85e-12	Exhaled nitric oxide output;
LIHC	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.29	7.01	0.35	1.28e-11	Blood protein levels;
LIHC	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.59	9.42	0.45	6.93e-19	Corneal astigmatism;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.89	13.18	0.58	2.27e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7577696	0.512	rs9789593	chr2:32381110	T/G	cg02381751	chr2:32503542	YIPF4	-0.44	-5.95	-0.31	6.75e-9	Inflammatory biomarkers;
LIHC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.15	-0.36	5.41e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.71	-0.57	1.46e-30	Alzheimer's disease;
LIHC	cis	rs9628987	0.500	rs55823627	chr1:8462079	C/T	cg20416874	chr1:8611966	RERE	0.5	5.9	0.3	8.61e-9	Breast cancer;
LIHC	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg22951263	chr5:87985283	NA	-0.38	-6.71	-0.34	8.03e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg07133347	chr1:107600762	PRMT6	0.42	6.2	0.32	1.62e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg05255149	chr17:80675120	FN3KRP	-0.44	-6.41	-0.33	4.7e-10	Glycated hemoglobin levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06791812	chr14:105677543	BRF1	0.41	6.05	0.31	3.74e-9	Longevity;
LIHC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.18	0.4	5.51e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.51	8.32	0.41	2.17e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.01	-0.4	1.84e-14	Monocyte percentage of white cells;
LIHC	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg16583315	chr14:65563665	MAX	-0.38	-7.85	-0.39	5.55e-14	Obesity-related traits;
LIHC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.91	13.86	0.6	5.73e-35	Vitamin D levels;
LIHC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg11057378	chr10:81107060	PPIF	0.36	5.76	0.3	1.89e-8	Height;
LIHC	cis	rs4700695	0.925	rs1845481	chr5:65397527	A/C	cg21114390	chr5:65439923	SFRS12	-0.5	-6.92	-0.35	2.24e-11	Facial morphology (factor 19);
LIHC	trans	rs1814175	0.564	rs12416819	chr11:49755567	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-20.37	-0.74	5.91e-61	Height;
LIHC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.58	8.4	0.41	1.24e-15	Emphysema distribution in smoking;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	24.32	0.8	1.44e-76	Prudent dietary pattern;
LIHC	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.42	6.28	0.32	1.03e-9	Menopause (age at onset);
LIHC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-10.4	-0.49	3.54e-22	Chronic sinus infection;
LIHC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.74	-0.3	2.14e-8	Mortality in heart failure;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg02993280	chr1:107599747	PRMT6	0.61	9.79	0.47	4.04e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg23485639	chr6:28045615	ZNF165	0.51	5.77	0.3	1.78e-8	Lung cancer in ever smokers;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12720424	chr1:94713229	NA	0.43	6.22	0.32	1.48e-9	Hepatitis;
LIHC	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.39	-0.33	5.58e-10	Body mass index;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.71	13.13	0.58	3.47e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.49	9.08	0.44	8.78e-18	Hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.67	13.36	0.59	4.63e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.26	-6.11	-0.31	2.67e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07897448	chr8:95907691	CCNE2	0.42	6.66	0.34	1.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg07636037	chr3:49044803	WDR6	0.61	7.41	0.37	9.73e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.47	7.85	0.39	5.34e-14	Mean corpuscular volume;
LIHC	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.96	-0.4	2.51e-14	Response to antipsychotic treatment;
LIHC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.37	6.66	0.34	1.08e-10	Aortic root size;
LIHC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.24	0.32	1.3e-9	Blood metabolite levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg11997514	chr19:40562314	ZNF780B	0.33	6.34	0.32	7.21e-10	Calcium levels;
LIHC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg10587741	chr22:38071170	LGALS1	0.72	12.65	0.56	2.46e-30	Fat distribution (HIV);
LIHC	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.63	0.65	6.13e-42	Electrocardiographic conduction measures;
LIHC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.68	-0.38	1.73e-13	Electroencephalogram traits;
LIHC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.32	6.64	0.34	1.25e-10	Blood metabolite levels;
LIHC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.12	0.31	2.56e-9	Cognitive ability;
LIHC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	7.41	0.37	1.02e-12	IgG glycosylation;
LIHC	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.62	6.16	0.32	2e-9	Carotid intima media thickness;
LIHC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.35	0.66	8.35e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	2.09e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.29e-24	Subjective well-being;
LIHC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg23485639	chr6:28045615	ZNF165	0.38	6.04	0.31	4.02e-9	Cardiac Troponin-T levels;
LIHC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	7.7	0.38	1.5e-13	Monocyte percentage of white cells;
LIHC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.82	0.35	4.23e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.77	-14.51	-0.62	1.72e-37	Height;
LIHC	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg16586182	chr3:47516702	SCAP	-0.54	-9.77	-0.47	4.62e-20	Colorectal cancer;
LIHC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-5.78	-0.3	1.65e-8	Vitiligo;
LIHC	cis	rs12960505	0.506	rs9948611	chr18:50975873	T/C	cg24270629	chr18:50823537	DCC	-0.47	-6.52	-0.33	2.57e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.3	5.72	0.3	2.31e-8	Asthma (childhood onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22779765	chr14:103369786	TRAF3	-0.43	-6.16	-0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg11062466	chr8:58055876	NA	0.5	6.9	0.35	2.56e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.48	-8.79	-0.43	7.42e-17	Body mass index;
LIHC	cis	rs7192750	0.586	rs12935795	chr16:71987452	G/C	cg06353428	chr16:71660113	MARVELD3	0.77	8.83	0.43	5.47e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	trans	rs6600671	0.934	rs11249348	chr1:121188302	T/C	cg09829573	chr1:144692074	NBPF9	-0.43	-7.81	-0.39	7.05e-14	Hip geometry;
LIHC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.45	-7.42	-0.37	9.54e-13	Menarche (age at onset);
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg23218760	chr8:16884364	EFHA2	-0.51	-6.36	-0.33	6.58e-10	Monocyte count;
LIHC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.56	9.69	0.46	9.08e-20	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg01231543	chr16:68741748	NA	0.39	6.13	0.31	2.41e-9	Colorectal cancer;
LIHC	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.07	0.31	3.36e-9	Mean corpuscular volume;
LIHC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.58	-8.32	-0.41	2.13e-15	Lung cancer;
LIHC	cis	rs10489202	0.535	rs12736786	chr1:167988283	C/G	cg24449463	chr1:168025552	DCAF6	-0.58	-8.75	-0.43	9.86e-17	Schizophrenia;
LIHC	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.35	-8.13	-0.4	7.98e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.74	-13.96	-0.6	2.33e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.68	8.42	0.41	1.04e-15	Mean platelet volume;
LIHC	cis	rs11233413	0.874	rs3793986	chr11:82704967	C/A	cg24227371	chr11:82718527	RAB30	-0.32	-6.91	-0.35	2.34e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.6	11.23	0.52	4.14e-25	Systemic lupus erythematosus;
LIHC	cis	rs7914558	0.646	rs10883795	chr10:104654577	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.38	-0.37	1.22e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg05941027	chr17:61774174	LIMD2	0.35	7.34	0.37	1.53e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.29	0.52	2.45e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08280861	chr8:58055591	NA	0.48	5.81	0.3	1.43e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.06	0.36	9.05e-12	Heart rate;
LIHC	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.32	-0.32	8.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22509189	chr2:225307070	NA	-0.56	-7.09	-0.36	7.58e-12	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.56	-13.81	-0.6	8.57e-35	White blood cell count (basophil);
LIHC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-7.52	-0.38	4.77e-13	Tonsillectomy;
LIHC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.65	-9.77	-0.47	4.92e-20	Subjective well-being;
LIHC	cis	rs13161895	0.941	rs438050	chr5:179414645	T/C	cg06664874	chr5:179499304	RNF130	0.57	7.02	0.35	1.21e-11	LDL cholesterol;
LIHC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg00277334	chr10:82204260	NA	-0.54	-6.57	-0.33	1.87e-10	Post bronchodilator FEV1;
LIHC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.73	13.25	0.58	1.21e-32	Prostate cancer;
LIHC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.3	-9.49	-0.46	4.2e-19	Body mass index;
LIHC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.04	14.86	0.63	6.67e-39	Cognitive function;
LIHC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	6.77	0.34	5.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg19645103	chr12:69753606	YEATS4	-0.4	-5.92	-0.3	7.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.75	-0.3	1.98e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.86	0.43	4.6e-17	Cognitive test performance;
LIHC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.38e-18	Subjective well-being;
LIHC	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	7.86	0.39	5.04e-14	Obesity-related traits;
LIHC	cis	rs6733011	0.622	rs12712036	chr2:99462711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.74	-0.3	2.08e-8	Bipolar disorder;
LIHC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.46	6.69	0.34	9.06e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg05941027	chr17:61774174	LIMD2	0.35	7.35	0.37	1.48e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.66	9.47	0.46	4.81e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.54	7.13	0.36	6.18e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.74	0.39	1.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.54	8.38	0.41	1.35e-15	Menarche (age at onset);
LIHC	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg23682824	chr7:23144976	KLHL7	0.4	5.98	0.31	5.7e-9	Blood protein levels;
LIHC	trans	rs1075232	0.655	rs80220087	chr15:31555817	G/A	cg04373760	chr16:53404718	NA	0.68	6.63	0.34	1.27e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg18944383	chr4:111397179	ENPEP	0.25	6.32	0.32	8.09e-10	Coronary artery disease;
LIHC	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-0.8	-12.04	-0.55	4.57e-28	Left ventricular obstructive tract defect (inherited effect);
LIHC	cis	rs35883536	0.967	rs4991930	chr1:101122755	T/C	cg14515779	chr1:101123966	NA	-0.69	-13.75	-0.6	1.45e-34	Monocyte count;
LIHC	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-6.08	-0.31	3.25e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.62	10.42	0.49	3.01e-22	Pediatric autoimmune diseases;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg15674719	chr19:1407747	DAZAP1	-0.39	-6.29	-0.32	9.95e-10	Neuroblastoma;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.01	-0.4	1.84e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.54	0.59	9.26e-34	Lung cancer in ever smokers;
LIHC	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.32	-8.71	-0.43	1.35e-16	Intelligence;
LIHC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg17980119	chr2:219472607	PLCD4	-0.34	-5.75	-0.3	2e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.63	9.32	0.45	1.52e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs6973256	0.605	rs6467499	chr7:133348922	G/T	cg10665199	chr7:133106180	EXOC4	-0.34	-5.82	-0.3	1.32e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	8.77	0.43	8.42e-17	Calcium levels;
LIHC	trans	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg17675199	chr6:35436792	RPL10A	-0.44	-9.2	-0.45	3.51e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg04607235	chr12:12878440	APOLD1	-0.5	-7.73	-0.39	1.19e-13	Pulse pressure;
LIHC	cis	rs12980942	0.935	rs2241718	chr19:41829606	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.81	0.35	4.29e-11	Coronary artery disease;
LIHC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.71	12.91	0.57	2.57e-31	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	0.6	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.1	0.58	4.53e-32	Prudent dietary pattern;
LIHC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.59	-11.32	-0.52	1.84e-25	Asthma;
LIHC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.55	0.42	4.29e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.59	0.34	1.7e-10	Height;
LIHC	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg05771511	chr15:63340396	TPM1	-0.45	-5.94	-0.31	6.83e-9	Orofacial clefts;
LIHC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.87	16.45	0.66	3.23e-45	Multiple myeloma (IgH translocation);
LIHC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg03859395	chr2:55845619	SMEK2	0.91	15.61	0.64	7.79e-42	Metabolic syndrome;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23374814	chr5:72292757	FCHO2	0.45	6.49	0.33	3.07e-10	Pancreatic cancer;
LIHC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-9.41	-0.45	7.5e-19	Schizophrenia;
LIHC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.85	-0.35	3.54e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-7.53	-0.38	4.56e-13	Brugada syndrome;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.82	0.39	6.54e-14	Prudent dietary pattern;
LIHC	cis	rs4755351	0.504	rs12225045	chr11:33346513	A/G	cg05567920	chr11:33183001	CSTF3	0.4	5.73	0.3	2.24e-8	Lung cancer in ever smokers;
LIHC	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	1.04	14.31	0.61	1.02e-36	Corneal structure;
LIHC	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.4	-13.76	-0.6	1.3600000000000001e-34	Psoriasis vulgaris;
LIHC	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	25.42	0.81	8.3e-81	Schizophrenia;
LIHC	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.58	6.66	0.34	1.09e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.9	16.7	0.67	3.24e-46	Body mass index;
LIHC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.55	8.29	0.41	2.55e-15	Longevity;Endometriosis;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	22.07	0.77	9.37e-68	Height;
LIHC	cis	rs2084898	0.891	rs2511023	chr11:120009145	A/G	cg13907859	chr11:120009124	TRIM29	-0.48	-6.36	-0.33	6.46e-10	Stroke (pediatric);
LIHC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	14.71	0.62	2.82e-38	Menopause (age at onset);
LIHC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg22951263	chr5:87985283	NA	-0.37	-6.49	-0.33	3.06e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	7.06	0.36	9.1e-12	Lung cancer in ever smokers;
LIHC	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.36	-0.37	1.42e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.47	-6.59	-0.34	1.66e-10	High light scatter reticulocyte count;
LIHC	cis	rs16858210	0.648	rs79478990	chr3:183587094	C/T	cg25686905	chr3:183603175	PARL	-0.5	-9.34	-0.45	1.31e-18	Menopause (age at onset);
LIHC	cis	rs9328573	0.967	rs873843	chr15:100510425	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.54	-8.31	-0.41	2.29e-15	Urate levels in lean individuals;
LIHC	trans	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg26939375	chr7:64535504	NA	-0.43	-6.85	-0.35	3.37e-11	Aortic root size;
LIHC	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.48	7.96	0.4	2.51e-14	Schizophrenia;
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.54	8.44	0.42	8.97e-16	Longevity;Endometriosis;
LIHC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.71	9.3	0.45	1.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg14580859	chr9:123691850	NA	0.4	7.07	0.36	8.93e-12	Rheumatoid arthritis;
LIHC	cis	rs2637266	0.905	rs60809084	chr10:78374431	A/C	cg18941641	chr10:78392320	NA	0.27	5.71	0.3	2.42e-8	Pulmonary function;
LIHC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.47	-0.37	6.92e-13	Mean platelet volume;
LIHC	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	11.14	0.52	8.22e-25	Post bronchodilator FEV1;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.76	-0.3	1.84e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	7.68	0.38	1.67e-13	Blood protein levels;
LIHC	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.45	8.77	0.43	8.5e-17	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-5.94	-0.31	7.12e-9	Menarche (age at onset);
LIHC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06002616	chr8:101225028	SPAG1	0.36	6.25	0.32	1.24e-9	Atrioventricular conduction;
LIHC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.47	6.96	0.35	1.79e-11	Other erythrocyte phenotypes;
LIHC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.35	-0.32	6.7e-10	Morning vs. evening chronotype;
LIHC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.72	9.05	0.44	1.07e-17	Body mass index;
LIHC	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.64	-6.77	-0.34	5.59e-11	Hair shape;
LIHC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.09	-8.17	-0.4	5.84e-15	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02758053	chr19:56165495	U2AF2	0.51	6.6	0.34	1.58e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10508774	0.810	rs12259710	chr10:32825870	T/C	cg01819863	chr10:32635814	EPC1	0.6	5.76	0.3	1.88e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs3112255	0.967	rs2971019	chr2:101298126	C/G	cg06958034	chr1:23346203	KDM1A	-0.46	-6.06	-0.31	3.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.61	-8.92	-0.43	2.96e-17	Blood metabolite levels;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	24.54	0.8	2.09e-77	Prudent dietary pattern;
LIHC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg13393036	chr8:95962371	TP53INP1	0.37	7.77	0.39	9.41e-14	Type 2 diabetes;
LIHC	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.69	0.38	1.62e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs7953508	0.741	rs1498707	chr12:93997128	G/A	cg18151635	chr12:93972918	NA	-0.41	-5.93	-0.31	7.34e-9	Pubertal anthropometrics;
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.3	0.32	9.29e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg14067834	chr17:29058358	SUZ12P	0.57	6.04	0.31	3.99e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg10820045	chr2:198174542	NA	-0.57	-9.35	-0.45	1.22e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11971779	0.715	rs6467856	chr7:139127299	A/C	cg07862535	chr7:139043722	LUC7L2	0.6	9.99	0.48	8.86e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg08469215	chr1:156261351	TMEM79	0.4	6.58	0.34	1.74e-10	Tonsillectomy;
LIHC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	11.72	0.54	6.56e-27	Cognitive test performance;
LIHC	cis	rs4908768	0.501	rs7520617	chr1:8573717	C/T	cg20416874	chr1:8611966	RERE	-0.66	-13.86	-0.6	5.69e-35	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	trans	rs8113308	0.810	rs8104281	chr19:52443019	G/A	cg14959425	chr7:20447707	ITGB8	-0.48	-6.15	-0.32	2.22e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg11331445	chr12:47219877	SLC38A4	0.3	6.09	0.31	3.08e-9	Itch intensity from mosquito bite;
LIHC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.6	-10.81	-0.5	1.26e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.78	6.18	0.32	1.79e-9	Body mass index;
LIHC	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg09592244	chr17:37024020	NA	0.35	5.83	0.3	1.27e-8	Height;
LIHC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-9.35	-0.45	1.18e-18	Blood protein levels;
LIHC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.71	6.8	0.35	4.68e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.58	0.53	2.1e-26	Alzheimer's disease;
LIHC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.47	-6.77	-0.34	5.57e-11	Prostate cancer;
LIHC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.22	-0.45	3.09e-18	Electroencephalogram traits;
LIHC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-15.54	-0.64	1.46e-41	Tonsillectomy;
LIHC	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.96	-10.46	-0.49	2.05e-22	Platelet distribution width;
LIHC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-5.78	-0.3	1.67e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7903847	0.656	rs12218483	chr10:99141484	C/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.05	-0.31	3.71e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg02569823	chr6:5851330	NA	0.41	6.59	0.34	1.63e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.29	21.48	0.76	2.15e-65	Corneal structure;
LIHC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-20.34	-0.74	7.59e-61	Coronary artery disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04099697	chr1:201952261	RNPEP	-0.51	-6.16	-0.32	2.03e-9	Systolic blood pressure;
LIHC	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.65	-9.06	-0.44	1.01e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.26	6.56	0.33	2.03e-10	Menarche (age at onset);
LIHC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.63	10.97	0.51	3.44e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.54	8.65	0.42	2.04e-16	Anterior chamber depth;
LIHC	trans	rs9641123	0.639	rs2677080	chr7:93256222	G/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.46	-0.33	3.71e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12697442	chr11:101981167	YAP1	0.51	6.89	0.35	2.73e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.45	6.72	0.34	7.4e-11	Gout;
LIHC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.72	-0.5	2.52e-23	Total cholesterol levels;
LIHC	cis	rs17094222	0.504	rs11190661	chr10:102452136	C/T	cg26540559	chr10:102447443	NA	0.4	7.73	0.39	1.24e-13	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs67981189	0.574	rs2526867	chr14:71395966	T/C	cg15816911	chr14:71606274	NA	-0.4	-6.32	-0.32	8.19e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25654697	chr7:7680075	RPA3	0.4	6.25	0.32	1.22e-9	Cognitive function;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg16317947	chr14:104151986	KLC1	0.4	6.08	0.31	3.19e-9	Alopecia areata;
LIHC	trans	rs4596713	0.507	rs1339546	chr9:71790297	G/A	cg16512924	chr15:28394682	HERC2	0.39	6.18	0.32	1.79e-9	Headache;
LIHC	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg20636351	chr8:55087400	NA	-0.35	-7.2	-0.36	3.97e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs611744	0.967	rs673854	chr8:109191838	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.74	0.34	6.58e-11	Dupuytren's disease;
LIHC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.03	0.36	1.11e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.75	10.91	0.51	5.57e-24	Response to antineoplastic agents;
LIHC	cis	rs860295	0.702	rs11264366	chr1:155335411	A/T	cg02153340	chr1:155202674	NA	-0.33	-5.94	-0.31	7.11e-9	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18106171	chr1:161196208	TOMM40L	0.4	6.12	0.31	2.53e-9	Pancreatic cancer;
LIHC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg16797656	chr11:68205561	LRP5	0.5	7.73	0.39	1.25e-13	Total body bone mineral density;
LIHC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg15123519	chr2:136567270	LCT	-0.41	-6.92	-0.35	2.3e-11	Corneal structure;
LIHC	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg10381502	chr11:71823885	C11orf51	-1.05	-9.21	-0.45	3.26e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.6	-9.48	-0.46	4.39e-19	Multiple myeloma (IgH translocation);
LIHC	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg14061069	chr19:46274453	DMPK	-0.54	-8.49	-0.42	6.31e-16	Coronary artery disease;
LIHC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.64	0.56	2.67e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7904368	0.524	rs7088468	chr10:16873080	C/T	cg23933602	chr10:16859644	RSU1	0.44	5.93	0.31	7.5e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.18	-0.58	2.35e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.46	7.82	0.39	6.71e-14	Mean corpuscular volume;
LIHC	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.6	9.82	0.47	3.21e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg04013166	chr16:89971882	TCF25	0.5	6.13	0.31	2.39e-9	Skin colour saturation;
LIHC	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.49	0.49	1.66e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.39	0.41	1.34e-15	Menarche (age at onset);
LIHC	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.51	-7.79	-0.39	8.27e-14	Diastolic blood pressure;
LIHC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06481639	chr22:41940642	POLR3H	-0.71	-6.65	-0.34	1.13e-10	Vitiligo;
LIHC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.39	-0.33	5.4e-10	Menarche (age at onset);
LIHC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12379764	chr21:47803548	PCNT	-0.55	-8.07	-0.4	1.18e-14	Testicular germ cell tumor;
LIHC	trans	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg26939375	chr7:64535504	NA	0.39	6.17	0.32	1.91e-9	Aortic root size;
LIHC	cis	rs7075426	1.000	rs7075426	chr10:88216402	G/A	cg07322936	chr10:88137208	NA	-0.49	-6.97	-0.35	1.61e-11	Migraine without aura;
LIHC	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.45	-6.16	-0.32	2.1e-9	Initial pursuit acceleration;
LIHC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	5.9	0.3	8.72e-9	Bipolar disorder;
LIHC	cis	rs4788570	0.584	rs6499528	chr16:71672762	T/C	cg06353428	chr16:71660113	MARVELD3	1.44	15.4	0.64	4.96e-41	Intelligence (multi-trait analysis);
LIHC	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg16558208	chr1:156270281	VHLL	0.54	9.95	0.47	1.21e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.45	-9.03	-0.44	1.3e-17	Fat distribution (HIV);
LIHC	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.39	-6.03	-0.31	4.36e-9	Multiple myeloma;
LIHC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.75	0.57	1.02e-30	Total body bone mineral density;
LIHC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	0.88	6.27	0.32	1.1e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.32	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg07884673	chr3:53033167	SFMBT1	0.68	5.72	0.3	2.27e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs2270927	0.790	rs4566770	chr5:75576313	A/G	cg13563193	chr19:33072644	PDCD5	-0.87	-9.53	-0.46	3.05e-19	Mean corpuscular volume;
LIHC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.27	0.32	1.12e-9	Rheumatoid arthritis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.3.541014R	chr3:25654052	TOP2B	-0.4	-7.04	-0.36	1.08e-11	Cognitive function;
LIHC	cis	rs611744	0.967	rs641820	chr8:109190717	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.67	-0.38	1.76e-13	Total body bone mineral density;
LIHC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	7.87	0.39	4.78e-14	Parkinson's disease;
LIHC	cis	rs867186	0.614	rs17309872	chr20:33515788	A/T	cg08999081	chr20:33150536	PIGU	0.65	6.0	0.31	5.11e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs2933343	0.553	rs35076317	chr3:128715535	T/C	cg25356066	chr3:128598488	ACAD9	0.44	5.95	0.31	6.5e-9	IgG glycosylation;
LIHC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.02e-19	Height;
LIHC	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.53	-7.75	-0.39	1.06e-13	Type 2 diabetes;
LIHC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16346588	chr10:242978	ZMYND11	-0.38	-5.95	-0.31	6.64e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg00204748	chr12:29376779	FAR2	0.38	7.0	0.35	1.36e-11	QT interval;
LIHC	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg17218026	chr1:154582156	ADAR	0.34	6.53	0.33	2.44e-10	Blood protein levels;
LIHC	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.45	-6.3	-0.32	9.08e-10	Multiple sclerosis;
LIHC	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.62	-8.5	-0.42	5.89e-16	Breast cancer;
LIHC	cis	rs4908768	0.501	rs4351668	chr1:8535818	C/T	cg20416874	chr1:8611966	RERE	-0.69	-14.74	-0.62	2.15e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.58	-0.38	3.38e-13	Body mass index;
LIHC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.52e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.77	11.14	0.52	8.36e-25	Obesity-related traits;
LIHC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.96	0.4	2.55e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg06026331	chr20:60912101	LAMA5	-0.51	-8.64	-0.42	2.16e-16	Colorectal cancer;
LIHC	cis	rs4407350	0.721	rs105248	chr22:44891399	C/G	cg26276947	chr22:44892394	LDOC1L	0.32	6.05	0.31	3.7e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.3	0.41	2.48e-15	Schizophrenia;
LIHC	cis	rs56146971	0.763	rs34854034	chr14:91870677	A/G	cg16433844	chr14:91963127	SMEK1	-0.51	-5.85	-0.3	1.14e-8	Alzheimer disease and age of onset;
LIHC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.61	8.1	0.4	1.01e-14	Platelet count;
LIHC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.54	6.56	0.33	1.97e-10	QRS duration;
LIHC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.78	-0.34	5.38e-11	Height;
LIHC	cis	rs7212590	0.748	rs7223057	chr17:57936438	G/C	cg10252138	chr17:58120427	NA	-0.64	-6.78	-0.34	5.15e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.63	-8.48	-0.42	6.94e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg05973401	chr12:123451056	ABCB9	0.52	7.49	0.38	5.93e-13	Neutrophil percentage of white cells;
LIHC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.91	0.47	1.66e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.12	-0.31	2.51e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24763869	chr17:3572311	TMEM93;TAX1BP3	0.46	6.57	0.33	1.86e-10	Lung function (FEV1/FVC);
LIHC	cis	rs16958440	0.541	rs13547	chr18:44634756	A/G	cg17192377	chr18:44677553	HDHD2	0.5	6.31	0.32	8.73e-10	Sitting height ratio;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03075561	chr2:201936709	FAM126B;NDUFB3	0.42	7.46	0.37	6.98e-13	Calcium levels;
LIHC	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06242063	chr11:67033801	ADRBK1	0.43	6.46	0.33	3.56e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.51	7.74	0.39	1.11e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15738916	chr2:102314495	MAP4K4	0.39	6.29	0.32	9.89e-10	Cognitive function;
LIHC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-9.99	-0.48	8.46e-21	Colorectal cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg18481087	chr3:160474064	PPM1L	-0.38	-6.28	-0.32	1.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.44	7.47	0.37	6.64e-13	Mean corpuscular volume;
LIHC	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.34	6.51	0.33	2.73e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.8	-12.68	-0.57	1.86e-30	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Parkinson's disease;
LIHC	cis	rs6442522	1.000	rs13075773	chr3:15450569	A/T	cg16303742	chr3:15540471	COLQ	0.41	6.95	0.35	1.91e-11	Uric acid levels;
LIHC	trans	rs12753920	0.697	rs4623754	chr1:92575278	A/G	cg15668468	chr10:118892869	VAX1	0.44	6.27	0.32	1.1e-9	Systemic lupus erythematosus;
LIHC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-8.45	-0.42	8.37e-16	Hemoglobin concentration;
LIHC	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.32	-0.37	1.81e-12	Adiposity;
LIHC	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.59	8.12	0.4	8.73e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs2920503	0.959	rs2920502	chr3:12329195	G/C	cg04748988	chr3:12329223	PPARG	0.54	6.99	0.35	1.44e-11	LDL cholesterol;
LIHC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.58	9.45	0.45	5.58e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg10756647	chr7:56101905	PSPH	0.98	11.62	0.53	1.57e-26	Gout;
LIHC	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.35	12.61	0.56	3.43e-30	Uric acid levels;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg02990361	chr1:107599529	PRMT6	-0.66	-10.94	-0.51	4.5e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.17	-0.36	4.66e-12	Response to antipsychotic treatment;
LIHC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.77	7.77	0.39	9.53e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg04374321	chr14:90722782	PSMC1	-0.46	-6.73	-0.34	7.08e-11	Mortality in heart failure;
LIHC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21467203	chr3:49911342	NA	0.42	7.25	0.36	2.85e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7091068	1.000	rs7091068	chr10:95420385	G/T	cg20715218	chr10:95462985	C10orf4	0.58	6.2	0.32	1.63e-9	Urinary tract infection frequency;
LIHC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.5	-6.65	-0.34	1.19e-10	Narcolepsy;
LIHC	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg23091122	chr1:110024289	SYPL2	-0.49	-6.46	-0.33	3.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs16958440	1.000	rs76594057	chr18:44637272	A/G	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.15e-10	Putamen volume;
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg13271783	chr10:134563150	INPP5A	-0.53	-6.74	-0.34	6.93e-11	Migraine;
LIHC	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg11783602	chr8:55087084	NA	-0.31	-6.04	-0.31	4e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg07718321	chr6:96025334	MANEA	-0.53	-5.72	-0.3	2.31e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg22079354	chr11:130786696	SNX19	0.41	5.93	0.31	7.26e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.45	0.37	7.77e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2273156	0.929	rs12894820	chr14:35435525	A/G	cg16230307	chr14:35515116	FAM177A1	0.39	5.76	0.3	1.85e-8	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.78	0.39	8.46e-14	Exhaled nitric oxide levels;
LIHC	trans	rs56292044	0.683	rs10112541	chr8:138777583	A/G	cg05886954	chr16:3631570	BTBD12	-0.31	-6.06	-0.31	3.58e-9	Post bronchodilator FEV1/FVC ratio in COPD;
LIHC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.01	-0.31	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.03	-0.31	4.29e-9	Menarche (age at onset);
LIHC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.43	5.89	0.3	9.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.5e-12	Obesity-related traits;
LIHC	cis	rs3814244	0.528	rs1468487	chr12:68390382	G/A	cg15249341	chr12:68405565	NA	0.34	6.87	0.35	2.97e-11	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-15.09	-0.63	8.65e-40	Alzheimer's disease (late onset);
LIHC	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg17074339	chr11:11642133	GALNTL4	0.4	6.09	0.31	3.09e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.24	-0.32	1.31e-9	Longevity;
LIHC	cis	rs243505	0.667	rs10249029	chr7:148576042	C/T	cg09806900	chr7:148480153	CUL1	0.45	6.75	0.34	6.2e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17106184	1.000	rs72902760	chr1:51252471	A/C	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.18e-10	Type 2 diabetes;
LIHC	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-7.15	-0.36	5.27e-12	Hepatocellular carcinoma;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.89	-14.6	-0.62	7.41e-38	Longevity;
LIHC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.2	-0.36	3.79e-12	Bipolar disorder;
LIHC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18252515	chr7:66147081	NA	-0.44	-6.38	-0.33	5.63e-10	Aortic root size;
LIHC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.67	6.76	0.34	5.87e-11	Vitiligo;
LIHC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.17	-0.48	2.11e-21	Hemoglobin concentration;
LIHC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.82e-26	Platelet count;
LIHC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.37	0.33	6.1e-10	Renal cell carcinoma;
LIHC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.01e-25	Corneal astigmatism;
LIHC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.51	8.32	0.41	2.06e-15	Schizophrenia;
LIHC	cis	rs6942756	0.747	rs691435	chr7:129097352	C/T	cg02491457	chr7:128862824	NA	0.54	8.38	0.41	1.43e-15	White matter hyperintensity burden;
LIHC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.76	9.27	0.45	2.12e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg15208524	chr1:10270712	KIF1B	0.46	6.77	0.34	5.67e-11	Hepatocellular carcinoma;
LIHC	cis	rs9322817	0.691	rs9391249	chr6:105343433	T/A	cg02098413	chr6:105308735	HACE1	0.41	7.67	0.38	1.75e-13	Thyroid stimulating hormone;
LIHC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.51	-6.61	-0.34	1.52e-10	Breast cancer;
LIHC	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.47	6.32	0.32	8.27e-10	Interleukin-18 levels;
LIHC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02290350	chr8:58132656	NA	0.46	8.74	0.43	1.09e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg22633049	chr21:46681294	NA	-0.33	-5.75	-0.3	2.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-8.3	-0.41	2.52e-15	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18357526	chr6:26021779	HIST1H4A	0.55	8.01	0.4	1.83e-14	Schizophrenia;
LIHC	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.14	-10.23	-0.48	1.3e-21	Schizophrenia;
LIHC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.44	-8.65	-0.42	1.97e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6782228	0.565	rs12695509	chr3:128417044	A/T	cg16766828	chr3:128327626	NA	-0.38	-6.01	-0.31	4.71e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.68	5.86	0.3	1.08e-8	Body mass index;
LIHC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.67	-9.14	-0.44	5.61e-18	Morning vs. evening chronotype;
LIHC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.48	-5.89	-0.3	9.04e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.63	11.38	0.52	1.14e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg09597638	chr17:3907349	NA	0.53	6.46	0.33	3.5e-10	Type 2 diabetes;
LIHC	cis	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg23923672	chr12:105501055	KIAA1033	0.7	8.54	0.42	4.64e-16	IgG glycosylation;
LIHC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.74	-8.25	-0.41	3.55e-15	Putamen volume;
LIHC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg05555928	chr11:63887634	MACROD1	0.52	6.84	0.35	3.7e-11	Mean platelet volume;
LIHC	trans	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg04373760	chr16:53404718	NA	0.58	7.28	0.37	2.29e-12	Hypertriglyceridemia;
LIHC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.07	-0.31	3.42e-9	Mean corpuscular volume;
LIHC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	9.01	0.44	1.47e-17	Initial pursuit acceleration;
LIHC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.67	10.33	0.49	5.78e-22	Corneal astigmatism;
LIHC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.58	9.86	0.47	2.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.7	-13.0	-0.58	1.09e-31	Mean platelet volume;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.12	-0.36	6.42e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg10820045	chr2:198174542	NA	0.48	7.36	0.37	1.39e-12	Dermatomyositis;
LIHC	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.49	-0.38	6.08e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.57	-8.66	-0.42	1.94e-16	QRS duration;
LIHC	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.64	-9.38	-0.45	9.06e-19	Bipolar disorder;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg22663859	chr13:21900854	NA	0.46	7.55	0.38	3.91e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.88	15.28	0.64	1.45e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg20991723	chr1:152506922	NA	0.49	8.32	0.41	2.12e-15	Hair morphology;
LIHC	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	0.97	14.81	0.63	1.14e-38	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.07	-0.31	3.42e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs116248771	0.739	rs7617983	chr3:158323716	T/A	cg16708174	chr3:158430962	RARRES1	0.47	6.27	0.32	1.12e-9	diarrhoeal disease at age 2;
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	0.61	10.49	0.49	1.69e-22	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-7.38	-0.37	1.22e-12	Cognitive function;
LIHC	cis	rs9378688	1.000	rs3800184	chr6:2211690	A/T	cg12303981	chr6:2244766	GMDS	0.48	6.2	0.32	1.65e-9	Caudate nucleus volume;
LIHC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-11.14	-0.52	8.27e-25	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.61	10.18	0.48	2.02e-21	Recombination rate (males);
LIHC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.49	-8.16	-0.4	6.35e-15	Menarche (age at onset);
LIHC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg12463550	chr7:65579703	CRCP	0.59	6.78	0.34	5.27e-11	Diabetic kidney disease;
LIHC	cis	rs10792665	0.724	rs10898069	chr11:82711209	G/A	cg24227371	chr11:82718527	RAB30	-0.38	-9.4	-0.45	8.27e-19	Obesity-related traits;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	7.69	0.38	1.59e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg19676328	chr12:49525230	TUBA1B	-0.42	-6.07	-0.31	3.48e-9	Total cholesterol levels;
LIHC	cis	rs1816752	0.819	rs7985478	chr13:24991273	C/T	cg22771759	chr13:24902376	NA	0.3	6.03	0.31	4.36e-9	Obesity-related traits;
LIHC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.54	-9.24	-0.45	2.63e-18	Reticulocyte count;
LIHC	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg04306507	chr14:55594613	LGALS3	0.32	5.97	0.31	5.83e-9	Protein biomarker;
LIHC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.67	11.53	0.53	3.2e-26	Menopause (age at onset);
LIHC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.94	12.82	0.57	5.38e-31	Blood metabolite levels;
LIHC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.56	8.67	0.42	1.72e-16	White matter hyperintensity burden;
LIHC	cis	rs807029	0.577	rs750866	chr10:102761458	A/G	cg27255678	chr10:102756921	LZTS2	0.5	6.9	0.35	2.49e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4362	0.902	rs4351	chr17:61569732	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.38	-6.18	-0.32	1.8e-9	Blood metabolite levels;
LIHC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.65	0.46	1.16e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg00280220	chr17:61926910	NA	0.43	6.75	0.34	6.18e-11	Prudent dietary pattern;
LIHC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.56	-6.64	-0.34	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.33	7.14	0.36	5.5e-12	Bone mineral density;
LIHC	cis	rs244293	0.868	rs2787490	chr17:53208051	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.43	0.37	8.65e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.14	-0.44	5.46e-18	Ulcerative colitis;
LIHC	cis	rs3770081	1.000	rs2164879	chr2:86261579	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-9.3	-0.45	1.76e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-9.0	-0.44	1.63e-17	Schizophrenia;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.87	13.12	0.58	3.91e-32	Skin colour saturation;
LIHC	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg02023728	chr11:77925099	USP35	-0.35	-6.17	-0.32	1.92e-9	Alzheimer's disease (survival time);
LIHC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.42	-6.14	-0.32	2.31e-9	Narcolepsy;
LIHC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.79	9.51	0.46	3.56e-19	Cognitive function;
LIHC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg03959625	chr15:84868606	LOC388152	0.47	6.68	0.34	9.94e-11	Schizophrenia;
LIHC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.52	-0.38	4.91e-13	Psoriasis;
LIHC	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.68	-10.6	-0.5	6.72e-23	Pediatric autoimmune diseases;
LIHC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.88	-17.06	-0.68	1.15e-47	Height;
LIHC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.53	6.8	0.35	4.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10857712	0.521	rs10857714	chr10:135235370	C/A	cg15472797	chr10:135243109	NA	-0.35	-5.85	-0.3	1.14e-8	Systemic lupus erythematosus;
LIHC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18404041	chr3:52824283	ITIH1	-0.35	-5.78	-0.3	1.69e-8	Electroencephalogram traits;
LIHC	cis	rs35883536	0.967	rs1855788	chr1:101118331	A/G	cg14515779	chr1:101123966	NA	-0.68	-13.56	-0.59	8.42e-34	Monocyte count;
LIHC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg00204512	chr16:28754710	NA	0.35	6.4	0.33	4.98e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	0.88	13.07	0.58	6.2e-32	Cisplatin-induced ototoxicity;
LIHC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.91	15.94	0.65	3.7e-43	Parkinson's disease;
LIHC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.35	0.45	1.15e-18	Bipolar disorder;
LIHC	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg09445902	chr10:555545	DIP2C	-0.39	-6.29	-0.32	9.75e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.17	-0.68	4.49e-48	Body mass index;
LIHC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.25e-11	Ileal carcinoids;
LIHC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.31e-22	Colorectal cancer;
LIHC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	11.33	0.52	1.78e-25	Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.37	-0.45	1.05e-18	Alzheimer's disease;
LIHC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.88	11.91	0.54	1.4e-27	Blood metabolite levels;
LIHC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-6.09	-0.31	2.99e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs818427	0.896	rs712663	chr5:112223594	T/C	cg07820702	chr5:112228657	REEP5	-0.39	-6.21	-0.32	1.55e-9	Total body bone mineral density;
LIHC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg05501817	chr11:14380813	RRAS2	-0.44	-6.21	-0.32	1.54e-9	Sense of smell;
LIHC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg17135325	chr3:160939158	NMD3	0.57	8.13	0.4	7.9e-15	Parkinson's disease;
LIHC	cis	rs838721	0.574	rs13003198	chr2:234257105	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.89	0.35	2.63e-11	Total body bone mineral density;
LIHC	cis	rs7106204	0.514	rs2099890	chr11:24255948	C/T	ch.11.24196551F	chr11:24239977	NA	0.84	12.17	0.55	1.5e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.56	-8.4	-0.41	1.19e-15	Renal cell carcinoma;
LIHC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Vitiligo;
LIHC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg02580895	chr19:2754563	NA	-0.46	-6.73	-0.34	6.96e-11	Total cholesterol levels;
LIHC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.49	5.85	0.3	1.14e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.56	-0.33	1.96e-10	Capecitabine sensitivity;
LIHC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg17980119	chr2:219472607	PLCD4	0.36	6.14	0.31	2.34e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.2	-0.32	1.59e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.34e-11	Cognitive function;
LIHC	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.69	11.22	0.52	4.43e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.31	7.57	0.38	3.48e-13	Gut microbiome composition (winter);
LIHC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.12e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	12.86	0.57	3.97e-31	Schizophrenia;
LIHC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg05941027	chr17:61774174	LIMD2	0.35	7.35	0.37	1.48e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.9	11.1	0.51	1.22e-24	Prostate cancer;
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg00204748	chr12:29376779	FAR2	0.42	7.89	0.39	4.23e-14	QT interval;
LIHC	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.57	9.44	0.45	6.19e-19	Corneal astigmatism;
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.55	-8.32	-0.41	2.07e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.89	-18.47	-0.71	2.57e-53	Testicular germ cell tumor;
LIHC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.5	6.35	0.32	7.05e-10	Initial pursuit acceleration;
LIHC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.45	7.29	0.37	2.18e-12	Diastolic blood pressure;
LIHC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.6	9.81	0.47	3.63e-20	Resting heart rate;
LIHC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.99	15.93	0.65	4.11e-43	Nonalcoholic fatty liver disease;
LIHC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-0.96	-9.82	-0.47	3.21e-20	Schizophrenia;
LIHC	cis	rs11212260	0.655	rs11212233	chr11:107306866	G/A	cg25435332	chr11:107328525	CWF19L2	0.82	8.3	0.41	2.4e-15	IgG glycosylation;
LIHC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.67	9.71	0.46	7.44e-20	Schizophrenia;
LIHC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.57	-7.94	-0.39	3.02e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg19635926	chr16:89946313	TCF25	0.47	6.29	0.32	9.52e-10	Skin colour saturation;
LIHC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg10820045	chr2:198174542	NA	0.46	6.91	0.35	2.4e-11	Dermatomyositis;
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.31	-7.0	-0.35	1.33e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.31	-0.32	8.59e-10	Response to antipsychotic treatment;
LIHC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.59	-6.61	-0.34	1.5e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.49	-6.86	-0.35	3.18e-11	Body mass index;
LIHC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.64	9.51	0.46	3.38e-19	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg17724175	chr1:150552817	MCL1	0.38	7.44	0.37	8.19e-13	Melanoma;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01593421	chr7:65303149	NA	0.4	6.07	0.31	3.47e-9	Immature fraction of reticulocytes;
LIHC	trans	rs10213084	1.000	rs9996620	chr4:147473314	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	-0.46	-6.16	-0.32	2.02e-9	Heart rate;
LIHC	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.64	10.73	0.5	2.46e-23	Recombination rate (males);
LIHC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg02527881	chr3:46936655	PTH1R	0.31	5.9	0.3	8.87e-9	Colorectal cancer;
LIHC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg16479474	chr6:28041457	NA	0.38	6.24	0.32	1.29e-9	Parkinson's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05202720	chr20:44486028	ACOT8;ZSWIM3	0.45	6.34	0.32	7.47e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.92	0.51	5.28e-24	Alzheimer's disease (late onset);
LIHC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.39	-0.33	5.51e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.49	8.64	0.42	2.16e-16	Reticulocyte fraction of red cells;
LIHC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.15	0.36	5.22e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg07706471	chr12:123319906	HIP1R	-0.63	-8.28	-0.41	2.88e-15	Schizophrenia;
LIHC	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg03433033	chr1:76189801	ACADM	0.55	8.26	0.41	3.14e-15	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.47	6.73	0.34	7.36e-11	Asthma;
LIHC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.34	-6.19	-0.32	1.75e-9	Platelet distribution width;
LIHC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.36	7.0	0.35	1.35e-11	Multiple system atrophy;
LIHC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.8	8.97	0.44	2e-17	Vitiligo;
LIHC	cis	rs6977660	1.000	rs12673970	chr7:19813018	T/C	cg07541023	chr7:19748670	TWISTNB	0.38	6.11	0.31	2.68e-9	Thyroid stimulating hormone;
LIHC	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg20283391	chr11:68216788	NA	-0.5	-6.0	-0.31	5.05e-9	Total body bone mineral density (age 45-60);
LIHC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs2851682	0.706	rs2727271	chr11:61603358	A/T	cg27386326	chr11:61587980	NA	0.58	9.28	0.45	2.03e-18	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg06565975	chr8:143823917	SLURP1	-0.45	-8.34	-0.41	1.84e-15	Urinary tract infection frequency;
LIHC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.89	-0.43	3.53e-17	Gut microbiome composition (summer);
LIHC	trans	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg04031134	chr7:98630788	SMURF1	-0.39	-6.05	-0.31	3.75e-9	Schizophrenia;
LIHC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.55	-10.48	-0.49	1.8e-22	Prudent dietary pattern;
LIHC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.67	0.38	1.87e-13	Mood instability;
LIHC	cis	rs240764	0.579	rs6937520	chr6:101173735	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.03	-0.31	4.17e-9	Neuroticism;
LIHC	cis	rs4788570	0.655	rs7359478	chr16:71825445	A/G	cg06353428	chr16:71660113	MARVELD3	1.33	14.27	0.61	1.38e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.66e-17	Prudent dietary pattern;
LIHC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg02269571	chr22:50332266	NA	0.69	7.94	0.39	2.89e-14	Schizophrenia;
LIHC	cis	rs9918079	0.542	rs6414765	chr4:15626493	G/A	cg24225360	chr4:15471699	CC2D2A	-0.38	-6.0	-0.31	4.96e-9	Obesity-related traits;
LIHC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg15848620	chr12:58087721	OS9	-0.56	-7.55	-0.38	3.89e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg08676812	chr11:65308423	LTBP3	1.05	7.34	0.37	1.61e-12	Height;
LIHC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.74	12.14	0.55	1.84e-28	Body mass index;
LIHC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg02640540	chr1:67518911	SLC35D1	0.43	5.9	0.3	8.77e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.55	9.38	0.45	9.09e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.21e-9	Tonsillectomy;
LIHC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	9.3	0.45	1.66e-18	Response to antipsychotic treatment;
LIHC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-7.11	-0.36	6.89e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-11.73	-0.54	6.2e-27	Platelet distribution width;
LIHC	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.33	7.51	0.38	5.11e-13	Blood metabolite ratios;
LIHC	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs4478037	0.749	rs6550204	chr3:33107645	C/T	cg27203090	chr3:33138513	GLB1;TMPPE	0.5	6.14	0.32	2.24e-9	Major depressive disorder;
LIHC	cis	rs2540917	0.765	rs243080	chr2:60614572	G/A	cg00543073	chr2:60773386	BCL11A	-0.32	-6.31	-0.32	8.43e-10	Mean corpuscular volume;
LIHC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.8	-14.76	-0.62	1.75e-38	Refractive error;
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21448741	chr8:58168803	NA	0.37	5.95	0.31	6.81e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-8.59	-0.42	3.07e-16	Primary biliary cholangitis;
LIHC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.42	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs8017423	0.967	rs11849641	chr14:90727647	T/C	cg04374321	chr14:90722782	PSMC1	0.78	15.15	0.63	4.85e-40	Mortality in heart failure;
LIHC	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg03934865	chr2:198174659	NA	-0.43	-6.22	-0.32	1.46e-9	Intracranial aneurysm;
LIHC	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg14752227	chr20:34000481	UQCC	-0.4	-5.78	-0.3	1.7e-8	Height;
LIHC	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.53	-8.56	-0.42	3.78e-16	Cocaine dependence;
LIHC	cis	rs6466055	0.720	rs7800928	chr7:105007470	T/C	cg04380332	chr7:105027541	SRPK2	-0.37	-6.85	-0.35	3.39e-11	Schizophrenia;
LIHC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.58	10.76	0.5	1.81e-23	Colorectal cancer;
LIHC	cis	rs716804	0.740	rs726102	chr11:10283978	G/A	cg01453529	chr11:10209919	SBF2	-0.3	-6.08	-0.31	3.23e-9	Neuroticism;
LIHC	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.57	-6.2	-0.32	1.67e-9	Primary sclerosing cholangitis;
LIHC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.77e-13	Alzheimer's disease (late onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24536044	chr1:244816274	PPPDE1	-0.48	-6.97	-0.35	1.62e-11	Pancreatic cancer;
LIHC	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.78	12.04	0.55	4.31e-28	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg23682824	chr7:23144976	KLHL7	0.43	6.47	0.33	3.41e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.72	-13.49	-0.59	1.49e-33	Height;
LIHC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg17135325	chr3:160939158	NMD3	0.53	7.65	0.38	2.02e-13	Parkinson's disease;
LIHC	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg02569219	chr17:2266849	SGSM2	-0.41	-6.33	-0.32	7.83e-10	Proinsulin levels;
LIHC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.7	11.65	0.53	1.22e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.99	-0.35	1.46e-11	Hepatocellular carcinoma;
LIHC	cis	rs2274273	0.870	rs8013713	chr14:55841252	A/G	cg01864836	chr14:55583639	NA	0.38	6.69	0.34	9.37e-11	Protein biomarker;
LIHC	cis	rs963731	0.649	rs2373495	chr2:39254627	C/G	cg04010122	chr2:39346883	SOS1	-0.64	-5.79	-0.3	1.56e-8	Corticobasal degeneration;
LIHC	cis	rs477692	0.637	rs2388331	chr10:131314173	G/A	cg05714579	chr10:131428358	MGMT	0.41	6.64	0.34	1.25e-10	Response to temozolomide;
LIHC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg24112000	chr20:60950667	NA	-0.61	-9.86	-0.47	2.42e-20	Colorectal cancer;
LIHC	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg10820045	chr2:198174542	NA	0.56	9.11	0.44	7.29e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.28	16.93	0.68	3.98e-47	Diabetic kidney disease;
LIHC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg25281562	chr12:121454272	C12orf43	0.36	6.28	0.32	1.02e-9	N-glycan levels;
LIHC	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.61	7.15	0.36	5.16e-12	Exhaled nitric oxide output;
LIHC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-9.94	-0.47	1.29e-20	Body mass index;
LIHC	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	9.15	0.44	5.1e-18	Schizophrenia;
LIHC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.4	-7.2	-0.36	3.75e-12	Hepatocellular carcinoma;
LIHC	trans	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg01095510	chr12:26267286	NA	0.54	6.28	0.32	9.99e-10	Inflammatory bowel disease;
LIHC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg05697976	chr12:29376483	FAR2	0.3	5.99	0.31	5.44e-9	QT interval;
LIHC	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.51	-9.35	-0.45	1.2e-18	Schizophrenia;
LIHC	trans	rs6512645	1.000	rs6512645	chr20:49087012	A/G	cg13303475	chr12:104234557	NT5DC3	0.44	6.18	0.32	1.83e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.41	6.25	0.32	1.2e-9	Neutrophil percentage of white cells;
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg04013166	chr16:89971882	TCF25	0.61	8.13	0.4	7.75e-15	Skin colour saturation;
LIHC	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	7.9	0.39	3.78e-14	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.42	-7.6	-0.38	2.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.46	0.37	7.38e-13	Monocyte percentage of white cells;
LIHC	cis	rs7192750	0.586	rs8044342	chr16:71869532	A/G	cg06353428	chr16:71660113	MARVELD3	0.74	8.24	0.41	3.8e-15	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.47	-0.37	6.66e-13	Post bronchodilator FEV1;
LIHC	cis	rs2637266	0.935	rs1907300	chr10:78325091	A/G	cg18941641	chr10:78392320	NA	0.29	5.96	0.31	6.34e-9	Pulmonary function;
LIHC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg16226627	chr15:75307476	SCAMP5	-0.52	-9.59	-0.46	1.88e-19	Lung cancer;
LIHC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	7.9	0.39	3.85e-14	Platelet count;
LIHC	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg00204512	chr16:28754710	NA	-0.35	-6.22	-0.32	1.48e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9596863	0.898	rs9568905	chr13:54330289	G/A	ch.13.53330881F	chr13:54432880	NA	0.44	6.11	0.31	2.72e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-7.09	-0.36	7.86e-12	Metabolite levels;
LIHC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.91	-11.39	-0.52	1.04e-25	Coronary artery disease;
LIHC	trans	rs7721647	0.810	rs16876880	chr5:90796839	T/A	cg10859192	chr12:54071672	ATP5G2	-0.41	-6.07	-0.31	3.32e-9	Breast cancer;
LIHC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.66	-8.49	-0.42	6.36e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	6.08	0.31	3.17e-9	Tonsillectomy;
LIHC	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	0.85	9.64	0.46	1.32e-19	Mitochondrial DNA levels;
LIHC	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.07e-8	Coronary artery disease;
LIHC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	0.9	13.15	0.58	2.99e-32	Post bronchodilator FEV1;
LIHC	trans	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg26939375	chr7:64535504	NA	0.4	6.36	0.33	6.33e-10	Aortic root size;
LIHC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	7.54	0.38	4.32e-13	Monocyte percentage of white cells;
LIHC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.7	11.97	0.54	8.2e-28	Hemoglobin concentration;
LIHC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg25801113	chr15:45476975	SHF	0.38	6.51	0.33	2.69e-10	Uric acid levels;
LIHC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg27211696	chr2:191398769	TMEM194B	-0.54	-7.07	-0.36	8.89e-12	Diastolic blood pressure;
LIHC	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs6545883	0.825	rs4672426	chr2:61457148	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.2	-0.36	3.95e-12	Tuberculosis;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2163237	0.965	rs10190131	chr2:55983605	A/G	cg18811423	chr2:55921094	PNPT1	-0.48	-6.64	-0.34	1.25e-10	IgG glycosylation;
LIHC	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg24304309	chr1:154577895	ADAR	-0.31	-5.83	-0.3	1.3e-8	Blood protein levels;
LIHC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg24296786	chr1:45957014	TESK2	-0.51	-7.6	-0.38	2.78e-13	Platelet count;
LIHC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.36	14.47	0.62	2.31e-37	White matter hyperintensity burden;
LIHC	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.93	-0.39	3.1e-14	Capecitabine sensitivity;
LIHC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.94	-10.13	-0.48	2.96e-21	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LIHC	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg23112188	chr14:24563095	PCK2	-0.29	-6.04	-0.31	4.13e-9	IgG glycosylation;
LIHC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg18887096	chr2:219472410	PLCD4	0.34	5.87	0.3	1.04e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.7	-9.52	-0.46	3.31e-19	Corneal structure;
LIHC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.94	-0.31	6.83e-9	Tonsillectomy;
LIHC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.76	12.3	0.55	4.72e-29	Corneal astigmatism;
LIHC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.5	-6.36	-0.33	6.62e-10	Coronary artery calcification;
LIHC	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.69	12.21	0.55	1.01e-28	Homoarginine levels;
LIHC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg27494647	chr7:150038898	RARRES2	0.32	5.83	0.3	1.26e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg01629716	chr15:45996671	NA	0.5	8.94	0.44	2.55e-17	Waist circumference;Weight;
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg18578343	chr6:166797258	BRP44L	-0.48	-6.46	-0.33	3.65e-10	Response to hepatitis C treatment;
LIHC	cis	rs3823572	0.564	rs2346275	chr7:133662166	G/A	cg03336402	chr7:133662267	EXOC4	-0.49	-6.07	-0.31	3.47e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.75	-0.34	6.31e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.38	6.27	0.32	1.07e-9	Corneal astigmatism;
LIHC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.11	11.42	0.53	8.64e-26	Opioid sensitivity;
LIHC	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-0.9	-8.88	-0.43	3.85e-17	Blood pressure (smoking interaction);
LIHC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs12286929	0.802	rs12787954	chr11:115020328	T/C	cg04055981	chr11:115044050	NA	0.39	5.74	0.3	2.12e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-8.41	-0.41	1.12e-15	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.43	7.36	0.37	1.34e-12	Aortic root size;
LIHC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg00277334	chr10:82204260	NA	-0.55	-6.8	-0.35	4.67e-11	Post bronchodilator FEV1;
LIHC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21467203	chr3:49911342	NA	0.43	7.67	0.38	1.85e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	0.92	22.75	0.78	2.09e-70	Multiple myeloma;
LIHC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.62	9.66	0.46	1.13e-19	Tonsillectomy;
LIHC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.88	-0.35	2.78e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg12575136	chr18:32820987	ZNF397	0.48	7.16	0.36	5.09e-12	White blood cell count;
LIHC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.77	-9.44	-0.45	6.02e-19	Gut microbiome composition (summer);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26841383	chr13:97999364	MBNL2	0.42	6.27	0.32	1.09e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	7.9	0.39	3.83e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.49	7.46	0.37	7.04e-13	Resting heart rate;
LIHC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.76	-15.2	-0.63	3.2e-40	Height;
LIHC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.73	13.49	0.59	1.45e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg13320555	chr19:33072785	PDCD5	0.49	7.33	0.37	1.69e-12	Eosinophilic esophagitis;
LIHC	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-9.02	-0.44	1.34e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.8	0.3	1.52e-8	Self-reported allergy;
LIHC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg16479474	chr6:28041457	NA	0.47	7.07	0.36	9.04e-12	Parkinson's disease;
LIHC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.51	7.32	0.37	1.75e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.79	16.18	0.66	3.92e-44	White blood cell count;
LIHC	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.9	11.22	0.52	4.37e-25	Prostate cancer;
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.45	6.44	0.33	4.14e-10	Longevity;Endometriosis;
LIHC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.6e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.23	-0.48	1.3e-21	Eye color traits;
LIHC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.57	-9.72	-0.47	6.83e-20	Blood metabolite levels;
LIHC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.81	-0.39	7.21e-14	Response to antipsychotic treatment;
LIHC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.81	-0.39	7.26e-14	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13959152	chr12:100535986	UHRF1BP1L	0.47	6.54	0.33	2.31e-10	Pancreatic cancer;
LIHC	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.61	-0.34	1.45e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.46	-9.13	-0.44	5.9e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg04998671	chr14:104000505	TRMT61A	-0.57	-7.21	-0.36	3.54e-12	Coronary artery disease;
LIHC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.13	0.4	8.23e-15	Mean corpuscular volume;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17076397	chr5:10353763	MARCH6	-0.45	-6.07	-0.31	3.4e-9	Thyroid stimulating hormone;
LIHC	cis	rs9810089	0.814	rs866758	chr3:136117870	G/C	cg21827317	chr3:136751795	NA	0.44	5.93	0.31	7.45e-9	Gestational age at birth (child effect);
LIHC	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.64e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.68	0.53	9.06e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg18944383	chr4:111397179	ENPEP	0.24	6.17	0.32	1.9e-9	Coronary artery disease;
LIHC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-6.53	-0.33	2.34e-10	Morning vs. evening chronotype;
LIHC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.9	-0.39	3.74e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.42	0.33	4.58e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.75	-0.39	1.05e-13	Total body bone mineral density;
LIHC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.86	-0.3	1.1e-8	Total body bone mineral density (age 0-15);
LIHC	cis	rs8049040	0.967	rs8050135	chr16:71472571	T/C	cg06353428	chr16:71660113	MARVELD3	-0.58	-6.17	-0.32	1.88e-9	Blood protein levels;
LIHC	cis	rs12079745	0.793	rs12061405	chr1:169208368	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-6.9	-0.35	2.59e-11	QT interval;
LIHC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.44	-7.08	-0.36	8.36e-12	Menarche (age at onset);
LIHC	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	0.74	8.02	0.4	1.71e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-7.46	-0.37	7.36e-13	Eosinophil percentage of white cells;
LIHC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.77	-11.46	-0.53	5.98e-26	Response to antineoplastic agents;
LIHC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.15	0.36	5.29e-12	Diabetic kidney disease;
LIHC	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.51	-9.11	-0.44	6.97e-18	Atrioventricular conduction;
LIHC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg13628971	chr7:2884303	GNA12	0.39	5.89	0.3	9.27e-9	Height;
LIHC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.42	-8.51	-0.42	5.39e-16	Rheumatoid arthritis;
LIHC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.37e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg05760424	chr2:242988095	NA	-0.5	-6.3	-0.32	9.04e-10	Obesity-related traits;
LIHC	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.53	6.37	0.33	6.05e-10	Plateletcrit;
LIHC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.19	0.32	1.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.17	-9.72	-0.47	7.12e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17272331	chr6:101328506	ASCC3	0.47	6.33	0.32	7.61e-10	Pancreatic cancer;
LIHC	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.6e-12	Corneal astigmatism;
LIHC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg25124228	chr12:125621409	AACS	-0.39	-6.68	-0.34	9.6e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-10.61	-0.5	6.25e-23	Vitiligo;
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.48	0.62	2.2e-37	Bipolar disorder;
LIHC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	0.62	6.53	0.33	2.39e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	7.81	0.39	6.91e-14	Response to antipsychotic treatment;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20300129	chr6:35058181	ANKS1A	0.4	6.13	0.31	2.42e-9	Lung function (FEV1);
LIHC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.53	7.43	0.37	8.67e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.78	-11.17	-0.52	6.71e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-9.3	-0.45	1.77e-18	Schizophrenia;
LIHC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg10096929	chr1:156261403	TMEM79	0.37	6.02	0.31	4.39e-9	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1144333	0.655	rs114383686	chr1:76325327	C/T	cg22875332	chr1:76189707	ACADM	0.44	6.83	0.35	3.94e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg00339695	chr16:24857497	SLC5A11	-0.36	-6.16	-0.32	2e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.61	7.5	0.38	5.64e-13	Heart rate;
LIHC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-7.56	-0.38	3.86e-13	P wave terminal force;
LIHC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	cis	rs4903214	0.895	rs1548767	chr14:74694957	C/T	cg11132536	chr14:74711944	VSX2	-0.27	-6.26	-0.32	1.14e-9	Inflammatory bowel disease;
LIHC	cis	rs12611088	0.571	rs7252955	chr19:44021766	A/T	cg13740135	chr19:44006432	PHLDB3	-0.41	-5.96	-0.31	6.23e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.34	0.32	7.38e-10	Heart rate;
LIHC	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg09060608	chr5:178986726	RUFY1	-0.41	-6.16	-0.32	2.01e-9	Lung cancer;
LIHC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg16558253	chr16:72132732	DHX38	-0.51	-8.1	-0.4	9.86e-15	Fibrinogen levels;
LIHC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.77	-14.65	-0.62	4.65e-38	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.59	11.1	0.51	1.21e-24	Systemic lupus erythematosus;
LIHC	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs1697938	0.840	rs1806513	chr5:40869406	T/C	cg01087697	chr5:40835557	RPL37	-0.49	-6.03	-0.31	4.33e-9	Multiple system atrophy;
LIHC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.65	11.42	0.53	8.59e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg00204748	chr12:29376779	FAR2	0.41	7.22	0.36	3.49e-12	QT interval;
LIHC	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg04067612	chr4:15429572	C1QTNF7	0.27	5.8	0.3	1.55e-8	Obesity-related traits;
LIHC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.29	7.67	0.38	1.87e-13	Bipolar disorder;
LIHC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.11	9.52	0.46	3.17e-19	Type 2 diabetes;
LIHC	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.32	-0.45	1.52e-18	Capecitabine sensitivity;
LIHC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.46	1.47e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.35	5.8	0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.81	-9.24	-0.45	2.62e-18	Vitiligo;
LIHC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg10587741	chr22:38071170	LGALS1	0.73	12.8	0.57	6.38e-31	Fat distribution (HIV);
LIHC	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.54	10.19	0.48	1.76e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7116495	0.786	rs2187496	chr11:71651961	G/C	cg26138937	chr11:71823887	C11orf51	-0.62	-6.47	-0.33	3.44e-10	Severe influenza A (H1N1) infection;
LIHC	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs17428076	0.831	rs3821093	chr2:172694587	C/T	cg13550731	chr2:172543902	DYNC1I2	0.37	6.01	0.31	4.89e-9	Myopia;
LIHC	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.73	-0.54	6.15e-27	Coffee consumption (cups per day);
LIHC	cis	rs2108622	0.727	rs7251296	chr19:15983736	A/G	cg13772218	chr19:15982569	NA	0.37	7.71	0.38	1.43e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg25344623	chr2:136566232	LCT	-0.38	-6.05	-0.31	3.71e-9	Corneal structure;
LIHC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.77	0.54	4.25e-27	Motion sickness;
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.75	13.62	0.59	4.83e-34	Prudent dietary pattern;
LIHC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg06238570	chr21:40685208	BRWD1	0.58	6.91	0.35	2.32e-11	Cognitive function;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.65	-8.02	-0.4	1.75e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-7.22	-0.36	3.44e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14832358	chr2:45837811	SRBD1	0.4	6.4	0.33	5.1e-10	Cognitive function;
LIHC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg15704280	chr7:45808275	SEPT13	0.62	6.49	0.33	2.96e-10	Axial length;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg16576597	chr16:28551801	NUPR1	0.37	6.1	0.31	2.86e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.32	-0.32	7.95e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.49	0.38	6.1e-13	Glycated hemoglobin levels;
LIHC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.94	17.9	0.7	5.08e-51	Menopause (age at onset);
LIHC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg03037974	chr15:76606532	NA	-0.6	-10.0	-0.48	7.96e-21	Blood metabolite levels;
LIHC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.64	-0.34	1.25e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.46	0.33	3.65e-10	Obesity-related traits;
LIHC	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg03146154	chr1:46216737	IPP	-0.36	-5.95	-0.31	6.46e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11671005	0.656	rs55652736	chr19:59007566	G/T	cg25952890	chr19:58913133	NA	0.68	6.55	0.33	2.07e-10	Mean platelet volume;
LIHC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.47	6.77	0.34	5.71e-11	Blood metabolite levels;
LIHC	cis	rs6141600	0.540	rs964786	chr20:34688491	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.51	-0.33	2.66e-10	Height;Hip circumference;
LIHC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.55	0.33	2.12e-10	Schizophrenia;
LIHC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Alcohol dependence;
LIHC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.79	-17.48	-0.69	2.37e-49	Urate levels in lean individuals;
LIHC	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.56	8.25	0.41	3.46e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-7.02	-0.36	1.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs477895	0.941	rs35692796	chr11:64110805	A/G	cg04317338	chr11:64019027	PLCB3	0.84	7.6	0.38	2.82e-13	Mean platelet volume;
LIHC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.66	8.48	0.42	6.66e-16	Initial pursuit acceleration;
LIHC	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.25	-12.76	-0.57	9.07e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs59901009	0.954	rs7129531	chr11:10174447	A/G	cg01453529	chr11:10209919	SBF2	0.29	5.75	0.3	2.02e-8	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg16576597	chr16:28551801	NUPR1	0.47	7.13	0.36	6.11e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.19	0.32	1.73e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.14e-9	Tonsillectomy;
LIHC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.91e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2073300	0.826	rs6137968	chr20:23449550	G/A	cg12062639	chr20:23401060	NAPB	0.62	7.32	0.37	1.77e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.43	-0.49	2.73e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.8	-11.96	-0.54	9.15e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.84	7.85	0.39	5.54e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.69	-10.07	-0.48	4.77e-21	Aortic root size;
LIHC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg20129853	chr10:51489980	NA	-0.39	-8.59	-0.42	3.06e-16	Prostate-specific antigen levels;
LIHC	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.58	10.58	0.5	8.23e-23	Neurofibrillary tangles;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg24693881	chr1:107596107	NA	-0.52	-9.33	-0.45	1.33e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.4	6.44	0.33	4.09e-10	Red blood cell count;
LIHC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg14067834	chr17:29058358	SUZ12P	0.64	6.73	0.34	7.16e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.52	10.27	0.49	9.96e-22	Fat distribution (HIV);
LIHC	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.54	6.36	0.33	6.45e-10	Ulcerative colitis;
LIHC	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg10820045	chr2:198174542	NA	0.55	8.96	0.44	2.12e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.3e-16	Motion sickness;
LIHC	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg13919466	chr1:32135498	COL16A1	-0.34	-6.23	-0.32	1.37e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg20487152	chr13:99095054	FARP1	-0.38	-6.35	-0.32	6.74e-10	Neuroticism;
LIHC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg05043794	chr9:111880884	C9orf5	-0.29	-6.79	-0.34	4.98e-11	Menarche (age at onset);
LIHC	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.61	-0.38	2.69e-13	Prevalent atrial fibrillation;
LIHC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	1.09	12.06	0.55	3.66e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs11212260	0.655	rs7925025	chr11:107283058	G/A	cg25435332	chr11:107328525	CWF19L2	0.8	8.71	0.43	1.36e-16	IgG glycosylation;
LIHC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg15691649	chr6:25882328	NA	-0.6	-7.75	-0.39	1.04e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs847649	0.731	rs10808120	chr7:102672234	A/G	cg18108683	chr7:102477205	FBXL13	-0.39	-5.85	-0.3	1.18e-8	Morning vs. evening chronotype;
LIHC	cis	rs7429990	0.864	rs6777081	chr3:48155569	T/C	cg11946769	chr3:48343235	NME6	-0.49	-6.23	-0.32	1.37e-9	Educational attainment (years of education);
LIHC	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.56	0.46	2.46e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.51	-8.87	-0.43	4.1e-17	Dental caries;
LIHC	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.43	7.96	0.4	2.61e-14	Height;
LIHC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg16479474	chr6:28041457	NA	0.47	6.06	0.31	3.55e-9	Depression;
LIHC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.72	-0.34	7.77e-11	Gut microbiome composition (summer);
LIHC	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	0.86	6.15	0.32	2.18e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.7	5.98	0.31	5.77e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.1	0.4	9.64e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg05941027	chr17:61774174	LIMD2	0.32	6.44	0.33	4.02e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.6	10.28	0.49	9.17e-22	Colorectal cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14280964	chr1:37940281	ZC3H12A	-0.53	-6.64	-0.34	1.23e-10	Systolic blood pressure;
LIHC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg18289306	chr13:113640169	MCF2L	0.46	7.27	0.37	2.45e-12	Systolic blood pressure;
LIHC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.95	18.06	0.7	1.16e-51	Menopause (age at onset);
LIHC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.46	-0.46	5.01e-19	Hemoglobin concentration;
LIHC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.61	-0.46	1.66e-19	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.71	-12.77	-0.57	8.34e-31	Refractive error;
LIHC	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.73	14.95	0.63	3.09e-39	Myopia (pathological);
LIHC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg00341915	chr10:119806516	CASC2;RAB11FIP2	0.55	6.57	0.33	1.84e-10	Glycated hemoglobin levels;
LIHC	cis	rs7707921	0.881	rs112413913	chr5:81359709	A/G	cg15871215	chr5:81402204	ATG10	-0.62	-5.98	-0.31	5.56e-9	Breast cancer;
LIHC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.61	7.37	0.37	1.3e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg18538332	chr22:24372958	LOC391322	-0.73	-11.2	-0.52	5.03e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.4	6.15	0.32	2.22e-9	Coronary artery disease;
LIHC	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-7.43	-0.37	8.85e-13	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.22	0.41	4.34e-15	Renal cell carcinoma;
LIHC	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg01864836	chr14:55583639	NA	-0.42	-8.17	-0.4	6.16e-15	Protein biomarker;
LIHC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.72	0.47	7.01e-20	Corneal astigmatism;
LIHC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.43	-8.55	-0.42	4.21e-16	Obesity-related traits;
LIHC	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg06265175	chr8:121136014	COL14A1	-0.49	-7.9	-0.39	3.74e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg18279126	chr7:2041391	MAD1L1	0.37	6.12	0.31	2.62e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-7.56	-0.38	3.83e-13	Ulcerative colitis;
LIHC	cis	rs8084351	0.539	rs7506784	chr18:50576221	A/T	cg24270629	chr18:50823537	DCC	0.41	6.34	0.32	7.31e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.23	-0.45	2.8e-18	Blood metabolite levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06651054	chr15:83680015	C15orf40	-0.58	-7.23	-0.36	3.23e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg16322792	chr1:120165303	ZNF697	0.46	8.45	0.42	8.77e-16	Systemic lupus erythematosus;
LIHC	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg01864836	chr14:55583639	NA	-0.43	-8.11	-0.4	9.18e-15	Protein biomarker;
LIHC	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.5	7.89	0.39	4e-14	Diastolic blood pressure;
LIHC	cis	rs6466055	0.748	rs10281422	chr7:104844519	G/A	cg04380332	chr7:105027541	SRPK2	-0.36	-6.74	-0.34	6.5500000000000006e-11	Schizophrenia;
LIHC	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.39	7.38	0.37	1.22e-12	Testicular germ cell tumor;
LIHC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.12	-0.31	2.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg13271783	chr10:134563150	INPP5A	-0.51	-6.66	-0.34	1.07e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg09297361	chr15:64444268	SNX22	-0.38	-6.12	-0.31	2.56e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.69	-12.81	-0.57	5.98e-31	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg07237590	chr20:62526788	DNAJC5	-0.51	-6.14	-0.32	2.33e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.54	-8.41	-0.41	1.13e-15	Extraversion;
LIHC	cis	rs7267979	0.565	rs6076364	chr20:25556801	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.44	-6.02	-0.31	4.47e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.24	-0.45	2.76e-18	Type 2 diabetes;
LIHC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg02290350	chr8:58132656	NA	0.38	7.37	0.37	1.28e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg10208301	chr11:6592745	DNHD1	0.45	6.13	0.31	2.41e-9	Coronary artery calcification;
LIHC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.42	-0.49	3.02e-22	Chronic sinus infection;
LIHC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	11.09	0.51	1.31e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.0	-0.4	1.89e-14	Capecitabine sensitivity;
LIHC	cis	rs4742903	0.935	rs7875929	chr9:106931408	A/G	cg14250997	chr9:106856677	SMC2	0.36	6.08	0.31	3.2e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg08847533	chr14:75593920	NEK9	-0.53	-8.27	-0.41	2.97e-15	IgG glycosylation;
LIHC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg23283495	chr1:209979779	IRF6	0.35	5.94	0.31	6.91e-9	Monobrow;
LIHC	cis	rs6450176	0.633	rs391448	chr5:53332323	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.76	-13.72	-0.6	1.87e-34	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.53	7.78	0.39	8.83e-14	Height;
LIHC	cis	rs988712	0.705	rs4923460	chr11:27656789	A/C	cg18117895	chr11:27722066	BDNF	-0.47	-6.41	-0.33	4.84e-10	Obesity;
LIHC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.41	7.05	0.36	1.02e-11	Platelet distribution width;
LIHC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.8	12.52	0.56	7.49e-30	Resting heart rate;
LIHC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.63	0.34	1.3100000000000001e-10	Bladder cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00261534	chr10:3826854	KLF6	0.42	6.26	0.32	1.17e-9	Pancreatic cancer;
LIHC	cis	rs847649	0.699	rs10271157	chr7:102527591	A/G	cg18108683	chr7:102477205	FBXL13	-0.48	-7.41	-0.37	1.03e-12	Morning vs. evening chronotype;
LIHC	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg09990169	chr2:241835740	C2orf54	-0.71	-11.49	-0.53	4.78e-26	Urinary metabolites;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03759077	chr2:153575599	ARL6IP6	0.38	6.05	0.31	3.86e-9	Cognitive function;
LIHC	cis	rs13401104	0.796	rs1466206	chr2:237121221	G/C	cg19324714	chr2:237145437	ASB18	0.37	5.85	0.3	1.13e-8	Educational attainment;
LIHC	cis	rs2279817	0.780	rs71644065	chr1:18001669	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-7.93	-0.39	3.1e-14	Neuroticism;
LIHC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00149659	chr3:10157352	C3orf10	0.49	5.85	0.3	1.12e-8	Alzheimer's disease;
LIHC	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.49	-7.22	-0.36	3.35e-12	Obesity (extreme);
LIHC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg10820045	chr2:198174542	NA	0.48	7.47	0.37	6.93e-13	Dermatomyositis;
LIHC	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.33	-0.41	1.95e-15	Colorectal cancer;
LIHC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.69	6.69	0.34	8.89e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.83	0.3	1.3e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.84	10.9	0.51	6.12e-24	Cognitive function;
LIHC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.89	0.39	4.03e-14	Heart rate;
LIHC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	0.85	11.13	0.52	9.03e-25	Iron status biomarkers;
LIHC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.64	-9.18	-0.44	4.09e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg27205649	chr11:78285834	NARS2	-0.4	-6.23	-0.32	1.38e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg02290350	chr8:58132656	NA	0.3	6.71	0.34	8.26e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23485639	chr6:28045615	ZNF165	0.44	5.74	0.3	2.08e-8	Depression;
LIHC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25632853	chr15:73088954	NA	0.36	5.96	0.31	6.41e-9	Triglyceride levels;
LIHC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20135002	chr11:47629003	NA	-0.38	-6.03	-0.31	4.19e-9	Schizophrenia;
LIHC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	16.91	0.67	4.69e-47	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.79	-0.3	1.58e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg10621924	chr7:39171070	POU6F2	0.42	6.43	0.33	4.38e-10	IgG glycosylation;
LIHC	cis	rs17106184	1.000	rs72902722	chr1:51223002	T/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.37	5.83	0.3	1.27e-8	Menopause (age at onset);
LIHC	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.4	-0.33	5.23e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.47	6.97	0.35	1.6e-11	Total body bone mineral density;
LIHC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg07959070	chr22:50026188	C22orf34	-0.3	-7.69	-0.38	1.58e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.5	-7.94	-0.39	2.97e-14	Schizophrenia;
LIHC	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.6	5.91	0.3	8.48e-9	Neutrophil percentage of white cells;
LIHC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg02290350	chr8:58132656	NA	0.41	8.54	0.42	4.62e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09610735	chr10:22609918	BMI1	0.44	6.11	0.31	2.72e-9	Pancreatic cancer;
LIHC	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg11189052	chr15:85197271	WDR73	-0.43	-6.35	-0.32	7.03e-10	P wave terminal force;
LIHC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg05941027	chr17:61774174	LIMD2	0.34	7.13	0.36	5.91e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.69	-11.4	-0.52	9.85e-26	Menopause (age at onset);
LIHC	cis	rs15676	0.947	rs1572912	chr9:131565554	T/C	cg00228799	chr9:131580591	ENDOG	-0.47	-7.1	-0.36	7.05e-12	Blood metabolite levels;
LIHC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.46	6.76	0.34	6.11e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.01	-0.4	1.87e-14	Capecitabine sensitivity;
LIHC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.56	9.15	0.44	5.27e-18	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07372840	chr5:180296196	NA	0.48	6.53	0.33	2.32e-10	Pancreatic cancer;
LIHC	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg15832292	chr6:96025679	MANEA	0.63	6.98	0.35	1.58e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.76	0.67	1.96e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.29	6.88	0.35	2.83e-11	Menarche (age at onset);
LIHC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.46	5.82	0.3	1.37e-8	Mean platelet volume;
LIHC	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg03934865	chr2:198174659	NA	0.46	6.61	0.34	1.5e-10	Intracranial aneurysm;
LIHC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg04310649	chr10:35416472	CREM	0.42	5.71	0.3	2.45e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs57590327	0.679	rs35259664	chr3:81586742	C/G	cg07356753	chr3:81810745	GBE1	-0.47	-6.49	-0.33	2.97e-10	Extraversion;
LIHC	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg02795151	chr17:7402630	POLR2A	0.54	5.85	0.3	1.13e-8	Androgen levels;
LIHC	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.7	-8.24	-0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-6.4	-0.33	5.15e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.29	-0.45	1.85e-18	Bipolar disorder;
LIHC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg04083430	chr16:4736063	MGRN1	-0.41	-5.81	-0.3	1.43e-8	Schizophrenia;
LIHC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.56	7.63	0.38	2.39e-13	Blood metabolite levels;
LIHC	cis	rs10508774	0.866	rs10827057	chr10:32731375	G/T	cg01819863	chr10:32635814	EPC1	0.66	6.18	0.32	1.84e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17106184	0.892	rs57400675	chr1:51068657	C/T	cg07174182	chr1:51127561	FAF1	-0.61	-6.23	-0.32	1.41e-9	Type 2 diabetes;
LIHC	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.26	-0.32	1.17e-9	Coronary artery disease;
LIHC	trans	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg19894588	chr14:64061835	NA	-0.65	-9.18	-0.44	4.16e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg12140854	chr5:148520817	ABLIM3	-0.44	-6.0	-0.31	4.93e-9	Breast cancer;
LIHC	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg21605333	chr4:119757512	SEC24D	0.8	6.87	0.35	3.14e-11	Cannabis dependence symptom count;
LIHC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.85	13.98	0.6	1.84e-35	Colorectal cancer;
LIHC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.62	7.46	0.37	7.14e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.88	0.35	2.88e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs10792665	0.614	rs4944423	chr11:82774606	T/C	cg24227371	chr11:82718527	RAB30	-0.39	-9.5	-0.46	3.76e-19	Obesity-related traits;
LIHC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-0.86	-10.46	-0.49	2.05e-22	Blood pressure (smoking interaction);
LIHC	cis	rs2108622	0.701	rs3093209	chr19:15988420	G/C	cg13772218	chr19:15982569	NA	0.36	7.35	0.37	1.49e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs9612	0.950	rs60649310	chr19:44269241	A/G	cg08581076	chr19:44259116	C19orf61	0.61	7.34	0.37	1.57e-12	Exhaled nitric oxide output;
LIHC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-8.87	-0.43	4.14e-17	Gut microbiome composition (summer);
LIHC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-8.59	-0.42	3.2e-16	Parkinson's disease;
LIHC	trans	rs2122469	0.655	rs74661770	chr8:20581855	G/T	cg20211604	chr17:11632341	DNAH9	0.48	6.08	0.31	3.28e-9	Serum tamsulosin hydrochloride concentration;
LIHC	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-0.76	-8.31	-0.41	2.27e-15	Exhaled nitric oxide output;
LIHC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.41	6.11	0.31	2.7e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg12317470	chr15:67143691	NA	-0.6	-7.33	-0.37	1.66e-12	Lung cancer (smoking interaction);
LIHC	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	0.84	7.15	0.36	5.14e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11229555	0.609	rs11229434	chr11:58185501	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.78	-0.3	1.67e-8	Subjective well-being;
LIHC	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg06026331	chr20:60912101	LAMA5	-0.5	-8.68	-0.42	1.7e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-7.9	-0.39	3.97e-14	Body mass index (adult);
LIHC	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg02447239	chr2:235936137	SH3BP4	-0.35	-6.05	-0.31	3.89e-9	Dialysis-related mortality;
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.64	-9.93	-0.47	1.35e-20	Bipolar disorder and schizophrenia;
LIHC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.19	13.18	0.58	2.28e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9649465	0.967	rs12537989	chr7:123308195	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.58e-14	Migraine;
LIHC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.34	-8.07	-0.4	1.23e-14	Crohn's disease;
LIHC	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.27	-5.72	-0.3	2.29e-8	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.83	-0.35	3.8e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.41	-6.44	-0.33	3.95e-10	Coronary artery disease;
LIHC	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.45	-0.37	7.59e-13	Hepatocellular carcinoma;
LIHC	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.76	-0.3	1.84e-8	Ulcerative colitis;
LIHC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg16970926	chr12:29381810	FAR2	-0.32	-6.53	-0.33	2.44e-10	QT interval;
LIHC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg12463550	chr7:65579703	CRCP	0.68	7.05	0.36	9.9e-12	Diabetic kidney disease;
LIHC	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08893839	chr5:154027129	NA	0.49	6.74	0.34	6.64e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.89	15.57	0.64	1.06e-41	Parkinson's disease;
LIHC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.29	0.66	1.46e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.83	-0.39	6.25e-14	Monocyte percentage of white cells;
LIHC	cis	rs360798	0.532	rs2421816	chr2:63075033	C/A	cg17519650	chr2:63277830	OTX1	0.45	7.03	0.36	1.11e-11	Coronary artery disease;
LIHC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg02297831	chr4:17616191	MED28	0.49	7.57	0.38	3.54e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26120584	chr12:50795366	LARP4	0.47	6.92	0.35	2.18e-11	Cognitive function;
LIHC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.43	0.37	8.94e-13	Bladder cancer;
LIHC	trans	rs875971	0.660	rs801217	chr7:66010577	C/T	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-7.74	-0.39	1.14e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.58	10.73	0.5	2.47e-23	Leprosy;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	21.0	0.75	1.71e-63	Prudent dietary pattern;
LIHC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.57	8.05	0.4	1.42e-14	Aortic root size;
LIHC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23978390	chr7:1156363	C7orf50	0.63	7.98	0.4	2.24e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.75	9.28	0.45	1.99e-18	Body mass index;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg07725925	chr16:89976287	TCF25	0.45	6.16	0.32	2e-9	Skin colour saturation;
LIHC	cis	rs3981351	0.797	rs28411397	chr10:115439530	G/C	cg24846397	chr10:115438155	CASP7	-0.45	-6.96	-0.35	1.78e-11	Obesity-related traits;
LIHC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22168489	chr12:122356033	WDR66	0.48	7.89	0.39	4.12e-14	Mean corpuscular volume;
LIHC	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg16583315	chr14:65563665	MAX	-0.4	-8.2	-0.41	5.07e-15	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08833169	chr11:810149	RPLP2	-0.4	-6.43	-0.33	4.35e-10	Pancreatic cancer;
LIHC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.43	5.8	0.3	1.49e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg05941027	chr17:61774174	LIMD2	0.31	6.5	0.33	2.84e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.59	8.08	0.4	1.11e-14	Blood metabolite levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg07495314	chr13:27845355	RASL11A	-0.52	-6.04	-0.31	4.13e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg16275483	chr1:110013120	SYPL2	-0.5	-6.22	-0.32	1.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.47	7.2	0.36	3.9e-12	Red cell distribution width;
LIHC	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.41	-5.83	-0.3	1.28e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25631650	chr19:633157	POLRMT	0.44	6.82	0.35	4.14e-11	Cognitive function;
LIHC	cis	rs9513627	1.000	rs7327068	chr13:100126965	A/G	cg25919922	chr13:100150906	NA	-0.77	-6.94	-0.35	2.01e-11	Obesity-related traits;
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.77	-13.43	-0.59	2.51e-33	Bipolar disorder and schizophrenia;
LIHC	cis	rs77633900	0.772	rs157789	chr15:76805703	T/A	cg21673338	chr15:77095150	SCAPER	-0.53	-6.09	-0.31	3.11e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs244293	0.695	rs9303360	chr17:53001456	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.52	-7.81	-0.39	6.92e-14	Menarche (age at onset);
LIHC	cis	rs10916814	0.610	rs4655222	chr1:20901418	C/T	cg24502330	chr1:20914028	CDA	-0.3	-6.73	-0.34	7.16e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	7.9	0.39	3.83e-14	Coronary artery disease;
LIHC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.31	0.58	7.13e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.57	-6.41	-0.33	4.91e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-1.16	-18.36	-0.7	7.13e-53	Urate levels;
LIHC	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.05	17.2	0.68	3.19e-48	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.88	0.54	1.7e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.79	8.79	0.43	7.49e-17	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg23205692	chr1:25664452	TMEM50A	0.38	6.15	0.32	2.1e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.83e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.87	0.39	4.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	0.53	7.11	0.36	6.93e-12	Pulse pressure;
LIHC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.61	-8.65	-0.42	2.08e-16	Blood metabolite levels;
LIHC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs201287033	1	rs201287033	chr7:150823227	TCCG/T	cg10920230	chr7:150757210	SLC4A2	-0.73	-5.92	-0.31	7.65e-9	Eyebrow thickness;
LIHC	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg13837822	chr10:26931731	LOC731789	0.38	7.42	0.37	9.28e-13	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.55	-10.21	-0.48	1.56e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.23	-0.36	3.12e-12	IgG glycosylation;
LIHC	cis	rs2273156	1.000	rs7153068	chr14:35459481	A/T	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	1.09	7.68	0.38	1.71e-13	Height;
LIHC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.55	-7.95	-0.4	2.69e-14	Asthma;
LIHC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.49	-0.38	5.8e-13	Total body bone mineral density;
LIHC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.98	0.35	1.56e-11	Lung cancer in ever smokers;
LIHC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.59	-7.64	-0.38	2.14e-13	Type 2 diabetes;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg13395646	chr4:1353034	KIAA1530	-0.48	-7.6	-0.38	2.85e-13	Obesity-related traits;
LIHC	cis	rs72843506	1.000	rs72843506	chr17:19946287	T/A	cg12065943	chr17:19881925	AKAP10	-0.33	-6.1	-0.31	2.91e-9	Schizophrenia;
LIHC	cis	rs4908768	0.539	rs7547411	chr1:8638145	A/G	cg20416874	chr1:8611966	RERE	-0.62	-12.2	-0.55	1.11e-28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs61990749	0.571	rs11628049	chr14:78308451	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.48	-7.43	-0.37	8.82e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.0	10.47	0.49	1.95e-22	Platelet distribution width;
LIHC	cis	rs1355223	0.902	rs34610590	chr11:34725440	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.43	-0.33	4.36e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg18306943	chr3:40428807	ENTPD3	0.34	5.84	0.3	1.23e-8	Renal cell carcinoma;
LIHC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.55	7.02	0.35	1.21e-11	Parkinson's disease;
LIHC	cis	rs9649465	0.967	rs598115	chr7:123402603	C/G	cg03229431	chr7:123269106	ASB15	0.39	8.27	0.41	3.06e-15	Migraine;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg14709524	chr16:89940631	TCF25	0.59	7.57	0.38	3.43e-13	Skin colour saturation;
LIHC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18867708	chr6:26865862	GUSBL1	0.54	8.16	0.4	6.42e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02985541	chr2:219472218	PLCD4	0.46	8.73	0.43	1.18e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg06238570	chr21:40685208	BRWD1	0.6	7.1	0.36	7.19e-12	Cognitive function;
LIHC	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg27205649	chr11:78285834	NARS2	0.4	6.25	0.32	1.22e-9	Alzheimer's disease (survival time);
LIHC	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.49	7.48	0.37	6.46e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.61	-0.34	1.45e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.4	7.71	0.38	1.42e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11708118	chr12:6862968	MLF2	-0.46	-6.08	-0.31	3.18e-9	Pancreatic cancer;
LIHC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	10.17	0.48	2.17e-21	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.28	0.52	2.74e-25	Motion sickness;
LIHC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.79	12.52	0.56	7.17e-30	Longevity;
LIHC	cis	rs8084351	0.524	rs1811358	chr18:50768168	G/A	cg24270629	chr18:50823537	DCC	-0.46	-6.83	-0.35	3.95e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg16989086	chr20:62203971	PRIC285	0.57	8.23	0.41	3.97e-15	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	cis	rs847649	0.842	rs4729873	chr7:102731781	G/A	cg18108683	chr7:102477205	FBXL13	0.46	6.9	0.35	2.54e-11	Morning vs. evening chronotype;
LIHC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	trans	rs10411161	0.702	rs8100716	chr19:52384061	T/C	cg22319618	chr22:45562946	NUP50	-0.6	-8.19	-0.4	5.12e-15	Breast cancer;
LIHC	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.52	-5.83	-0.3	1.32e-8	Ulcerative colitis;
LIHC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.5	7.78	0.39	8.6e-14	Cognitive function;
LIHC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.52	-8.09	-0.4	1.08e-14	Lymphocyte counts;
LIHC	cis	rs4755351	0.504	rs7945332	chr11:33188153	A/C	cg05567920	chr11:33183001	CSTF3	0.43	6.35	0.32	6.88e-10	Lung cancer in ever smokers;
LIHC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.48	7.74	0.39	1.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.65	11.73	0.54	6.4e-27	Dental caries;
LIHC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg23461800	chr14:103021989	NA	0.45	6.12	0.31	2.6e-9	Platelet count;
LIHC	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg03999872	chr20:62272968	STMN3	-0.46	-6.76	-0.34	6.08e-11	Atopic dermatitis;
LIHC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-7.73	-0.39	1.18e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7534824	0.543	rs60978318	chr1:101400413	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	7.44	0.37	8.13e-13	Refractive astigmatism;
LIHC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	8.3	0.41	2.39e-15	Schizophrenia;
LIHC	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.03	0.31	4.27e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.1	0.31	2.85e-9	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.89	-18.75	-0.71	1.95e-54	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16113047	chr5:36151301	SKP2;LMBRD2	0.42	6.08	0.31	3.26e-9	Pancreatic cancer;
LIHC	cis	rs12602486	1.000	rs76926880	chr17:42247377	C/G	cg08193365	chr17:42277699	NA	1.05	7.39	0.37	1.16e-12	Glycated hemoglobin levels;
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.66	9.79	0.47	4.08e-20	Menarche (age at onset);
LIHC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	2.97e-23	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-11.11	-0.51	1.06e-24	Coronary artery disease;
LIHC	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg21252483	chr19:49399788	TULP2	-0.78	-9.73	-0.47	6.48e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16157530	chr2:105654526	MRPS9	0.53	7.02	0.35	1.18e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.83	11.33	0.52	1.79e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.38	5.98	0.31	5.67e-9	Menopause (age at onset);
LIHC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	11.3	0.52	2.26e-25	Mood instability;
LIHC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.46	7.09	0.36	7.93e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.78	0.54	3.95e-27	Response to antipsychotic treatment;
LIHC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.08	0.58	5.66e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs611744	0.967	rs653633	chr8:109196151	T/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs4845459	0.967	rs6693105	chr1:152590663	C/T	cg20634798	chr1:152595351	LCE3A	0.29	5.74	0.3	2.09e-8	Psoriasis;
LIHC	cis	rs7258465	1.000	rs8106096	chr19:18536416	C/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.16	-0.36	4.96e-12	Breast cancer;
LIHC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.66	0.42	1.89e-16	Motion sickness;
LIHC	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.38	6.58	0.34	1.78e-10	Squamous cell lung carcinoma;
LIHC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.33	-0.52	1.73e-25	Coronary artery disease;
LIHC	cis	rs17756712	0.615	rs3823127	chr6:593841	T/C	cg14374089	chr6:596013	EXOC2	-0.5	-6.53	-0.33	2.43e-10	Vertical cup-disc ratio;
LIHC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.76	-0.34	5.92e-11	Menarche (age at onset);
LIHC	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.8	10.36	0.49	4.84e-22	Severe influenza A (H1N1) infection;
LIHC	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.17	-0.44	4.46e-18	Colorectal cancer;
LIHC	cis	rs6504950	0.745	rs12603899	chr17:53010098	T/C	cg10237252	chr17:52977213	TOM1L1	-0.34	-5.99	-0.31	5.22e-9	Breast cancer;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg05185784	chr16:90016020	DEF8	-0.45	-5.84	-0.3	1.21e-8	Skin colour saturation;
LIHC	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.33	-6.53	-0.33	2.43e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.55	-8.12	-0.4	8.75e-15	Schizophrenia;
LIHC	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.51	-7.97	-0.4	2.44e-14	Corneal astigmatism;
LIHC	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.19	-0.32	1.73e-9	Ulcerative colitis;
LIHC	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs911119	1.000	rs911119	chr20:23612737	C/T	cg16589663	chr20:23618590	CST3	-0.75	-7.96	-0.4	2.6e-14	Chronic kidney disease;
LIHC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35892873	0.703	rs7615776	chr3:126060617	G/A	cg15490784	chr3:126061950	KLF15	0.46	6.82	0.35	4.05e-11	Male-pattern baldness;
LIHC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.0	0.65	2.08e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	8.47	0.42	7.25e-16	Obesity-related traits;
LIHC	cis	rs7116495	0.881	rs673478	chr11:71799104	G/A	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	6.25	0.32	1.21e-9	Lung cancer in ever smokers;
LIHC	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg27490568	chr2:178487706	NA	0.67	8.76	0.43	9.27e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.45	-5.9	-0.3	8.85e-9	Subjective well-being;
LIHC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.27	0.32	1.1e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26705765	chr19:10252866	DNMT1	0.51	6.51	0.33	2.73e-10	Hip circumference;
LIHC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.76	11.7	0.53	8.12e-27	Corneal astigmatism;
LIHC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.78	0.39	8.95e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.55	7.71	0.38	1.43e-13	Pulse pressure;
LIHC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg26874164	chr19:58962979	ZNF324B	0.6	9.04	0.44	1.16e-17	Uric acid clearance;
LIHC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.31	-5.74	-0.3	2.08e-8	Height;
LIHC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21545522	chr1:205238299	TMCC2	0.37	6.99	0.35	1.47e-11	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs67981189	0.593	rs12896829	chr14:71463676	G/C	cg15816911	chr14:71606274	NA	0.41	6.59	0.34	1.65e-10	Schizophrenia;
LIHC	trans	rs2579103	0.767	rs1371085	chr12:90665505	T/G	cg00091569	chr3:40428383	ENTPD3	0.37	6.05	0.31	3.8e-9	Body mass index;
LIHC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-0.48	-5.89	-0.3	9.04e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-0.95	-12.18	-0.55	1.38e-28	Obesity-related traits;
LIHC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.85	-10.96	-0.51	3.66e-24	Schizophrenia;
LIHC	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.5	7.3	0.37	2e-12	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.63	11.97	0.54	8.3e-28	Menopause (age at onset);
LIHC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-7.71	-0.38	1.39e-13	Gut microbiome composition (summer);
LIHC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.7	-0.5	3.13e-23	Monocyte percentage of white cells;
LIHC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.75	7.65	0.38	2.1e-13	Alzheimer's disease;
LIHC	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.44	7.57	0.38	3.41e-13	Crohn's disease;
LIHC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg23690444	chr14:81902736	NA	-0.44	-6.38	-0.33	5.66e-10	Night sleep phenotypes;
LIHC	cis	rs17106184	0.786	rs72900944	chr1:51126914	C/T	cg07174182	chr1:51127561	FAF1	-0.76	-8.12	-0.4	8.47e-15	Type 2 diabetes;
LIHC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.32	6.61	0.34	1.46e-10	Alcohol dependence;
LIHC	cis	rs16958440	1.000	rs11082563	chr18:44659001	T/C	cg17192377	chr18:44677553	HDHD2	0.58	6.48	0.33	3.25e-10	Sitting height ratio;
LIHC	cis	rs9425766	0.546	rs6691001	chr1:173819076	T/G	cg06124660	chr1:173389066	NA	-0.34	-6.61	-0.34	1.44e-10	Life satisfaction;
LIHC	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg22705602	chr4:152727874	NA	-0.31	-6.62	-0.34	1.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.74	0.65	2.24e-42	Electrocardiographic conduction measures;
LIHC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.6	-8.4	-0.41	1.21e-15	Blood metabolite levels;
LIHC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg16797656	chr11:68205561	LRP5	0.65	8.81	0.43	6.49e-17	Total body bone mineral density (age 45-60);
LIHC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.09	0.31	3.06e-9	Schizophrenia;
LIHC	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.71	-10.89	-0.51	6.63e-24	Left atrial antero-posterior diameter;
LIHC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.31	-0.32	8.74e-10	Type 2 diabetes;
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.91	-12.63	-0.56	2.86e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9783347	0.925	rs3825025	chr11:18343822	C/G	cg15585147	chr11:18324498	HPS5	0.43	6.65	0.34	1.18e-10	Pancreatic cancer;
LIHC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	1.18	13.84	0.6	6.79e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.42	-0.37	9.63e-13	Psoriasis;
LIHC	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.78	11.05	0.51	1.79e-24	Response to hepatitis C treatment;
LIHC	trans	rs12555078	1.000	rs62542261	chr9:76085629	G/A	cg06169179	chr9:2717946	KCNV2	0.8	6.33	0.32	7.87e-10	Obesity-related traits;
LIHC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.39	-0.33	5.54e-10	Tonsillectomy;
LIHC	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg25182066	chr10:30743637	MAP3K8	-0.47	-7.66	-0.38	1.89e-13	Inflammatory bowel disease;
LIHC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20135002	chr11:47629003	NA	-0.57	-9.61	-0.46	1.58e-19	Subjective well-being;
LIHC	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.6	-9.41	-0.45	7.76e-19	Red cell distribution width;
LIHC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.82	13.76	0.6	1.37e-34	Monocyte count;
LIHC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg11764359	chr7:65958608	NA	0.57	6.03	0.31	4.16e-9	Diabetic kidney disease;
LIHC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg25801113	chr15:45476975	SHF	0.4	6.82	0.35	4.22e-11	Uric acid levels;
LIHC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.61	-10.14	-0.48	2.58e-21	Post bronchodilator FEV1;
LIHC	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg22771759	chr13:24902376	NA	0.32	6.49	0.33	3.03e-10	Obesity-related traits;
LIHC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg22563815	chr15:78856949	CHRNA5	0.35	6.26	0.32	1.13e-9	Sudden cardiac arrest;
LIHC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-8.13	-0.4	8.08e-15	Tonsillectomy;
LIHC	cis	rs7619427	1.000	rs7643455	chr3:44073001	T/C	cg24966902	chr3:44043705	NA	0.52	7.4	0.37	1.06e-12	Schizophrenia;
LIHC	cis	rs12915845	0.584	rs17196732	chr15:89069299	A/C	cg05013243	chr15:89149849	MIR1179	0.39	7.11	0.36	6.62e-12	Menarche (age at onset);
LIHC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.52	6.69	0.34	8.87e-11	Initial pursuit acceleration;
LIHC	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg13047869	chr3:10149882	C3orf24	0.53	6.83	0.35	3.97e-11	Alzheimer's disease;
LIHC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.83	-0.35	3.9e-11	Menarche (age at onset);
LIHC	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.37	8.65	0.42	1.99e-16	Blood protein levels;
LIHC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.4	6.0	0.31	4.94e-9	Glycated hemoglobin levels;
LIHC	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.3	-5.78	-0.3	1.73e-8	Red blood cell count;
LIHC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.68	8.88	0.43	3.74e-17	Motion sickness;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.44	8.25	0.41	3.48e-15	Prudent dietary pattern;
LIHC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03353000	chr22:41252913	ST13;XPNPEP3	-0.51	-7.0	-0.35	1.39e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.71	7.98	0.4	2.23e-14	Iron status biomarkers;
LIHC	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.61	7.11	0.36	6.95e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.67	13.33	0.58	6.32e-33	High light scatter reticulocyte count;
LIHC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-7.05	-0.36	9.75e-12	Diabetic kidney disease;
LIHC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.2	-0.32	1.67e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.64	7.89	0.39	4.03e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.43	8.13	0.4	8.01e-15	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.58	8.44	0.42	8.97e-16	Emphysema distribution in smoking;
LIHC	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	5.93e-33	Diabetic kidney disease;
LIHC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.11	-0.48	3.31e-21	Tonsillectomy;
LIHC	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.43	-6.55	-0.33	2.08e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	4.83e-15	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.99	0.31	5.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2637030	0.542	rs429384	chr5:52908205	A/G	cg06476337	chr5:52856530	NDUFS4	0.43	6.81	0.35	4.3e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	6.32	0.32	8.37e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.56	-0.38	3.63e-13	Coronary artery disease;
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12379764	chr21:47803548	PCNT	0.55	8.01	0.4	1.78e-14	Testicular germ cell tumor;
LIHC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.9	16.55	0.67	1.33e-45	Coronary artery disease;
LIHC	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.45	-0.49	2.36e-22	Monocyte percentage of white cells;
LIHC	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.63	8.1	0.4	9.82e-15	Blood metabolite levels;
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.99e-10	Personality dimensions;
LIHC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.45	-10.22	-0.48	1.41e-21	Urinary metabolites;
LIHC	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg16005559	chr11:120040616	NA	-0.45	-6.9	-0.35	2.56e-11	Stroke (pediatric);
LIHC	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.47	7.32	0.37	1.79e-12	Breast cancer;
LIHC	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.54	-6.39	-0.33	5.39e-10	Exhaled nitric oxide output;
LIHC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	7.04	0.36	1.03e-11	Cognitive test performance;
LIHC	trans	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.36	0.33	6.63e-10	Ulcerative colitis;
LIHC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.82	-0.35	4.07e-11	Axial length;
LIHC	cis	rs12220238	0.554	rs11001029	chr10:76154777	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.76	0.3	1.85e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.93	15.62	0.65	6.82e-42	Parkinson's disease;
LIHC	cis	rs9322817	0.691	rs2499652	chr6:105269959	G/A	cg02098413	chr6:105308735	HACE1	0.42	7.82	0.39	6.45e-14	Thyroid stimulating hormone;
LIHC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.64	-8.22	-0.41	4.31e-15	Gut microbiome composition (summer);
LIHC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9625935	0.518	rs9625870	chr22:30261219	C/T	cg01021169	chr22:30184971	ASCC2	-0.37	-6.37	-0.33	6.1e-10	Tonsillectomy;
LIHC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.76	11.65	0.53	1.25e-26	Corneal astigmatism;
LIHC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg12365402	chr11:9010492	NRIP3	-0.25	-6.3	-0.32	9.39e-10	Hemoglobin concentration;
LIHC	cis	rs7729447	0.813	rs4867121	chr5:32692548	T/C	cg16267343	chr5:32710456	NPR3	0.47	5.76	0.3	1.88e-8	Blood pressure;
LIHC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.66	-0.38	1.99e-13	Morning vs. evening chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12976413	chr7:75544151	POR	0.42	6.07	0.31	3.42e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06002616	chr8:101225028	SPAG1	-0.34	-5.81	-0.3	1.43e-8	Atrioventricular conduction;
LIHC	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.64	-6.77	-0.34	5.59e-11	Hair shape;
LIHC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-5.98	-0.31	5.55e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.85	-12.66	-0.56	2.15e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.49	6.91	0.35	2.45e-11	Parkinson's disease;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.06	0.55	3.69e-28	Prudent dietary pattern;
LIHC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.68	13.52	0.59	1.12e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs847649	0.842	rs4729860	chr7:102625567	C/T	cg18108683	chr7:102477205	FBXL13	0.47	7.06	0.36	9.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23625390	chr15:77176239	SCAPER	0.36	5.94	0.31	7.03e-9	Blood metabolite levels;
LIHC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.36	6.45	0.33	3.92e-10	Mean corpuscular volume;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.44	-0.45	6.13e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg19318889	chr4:1322082	MAEA	0.53	8.83	0.43	5.55e-17	Obesity-related traits;
LIHC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.62	8.48	0.42	6.79e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.63	0.34	1.33e-10	Alzheimer's disease;
LIHC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg13409248	chr3:40428643	ENTPD3	0.41	6.77	0.34	5.6e-11	Renal cell carcinoma;
LIHC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.64	0.42	2.21e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.94	-0.39	2.89e-14	Type 2 diabetes;
LIHC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.71	-11.24	-0.52	3.83e-25	Lung cancer;
LIHC	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.5	6.03	0.31	4.19e-9	Serum sulfate level;
LIHC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	13.38	0.59	3.93e-33	Primary sclerosing cholangitis;
LIHC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg18944383	chr4:111397179	ENPEP	0.25	6.16	0.32	1.99e-9	Coronary artery disease;
LIHC	cis	rs2737618	0.722	rs2821333	chr1:200093253	A/C	cg21825944	chr1:200113062	NR5A2	-0.41	-6.63	-0.34	1.32e-10	Uric acid levels;
LIHC	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg12858261	chr2:113808755	IL1F8	0.34	6.03	0.31	4.21e-9	Pulmonary function;
LIHC	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.46	-9.0	-0.44	1.54e-17	LDL cholesterol levels;
LIHC	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	8.5	0.42	6.13e-16	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg21100191	chr22:23484243	RTDR1	0.79	8.91	0.43	3.09e-17	Bone mineral density;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.41	9.28	0.45	2.01e-18	Abdominal aortic aneurysm;
LIHC	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg01364799	chr7:75623366	TMEM120A	0.54	8.41	0.41	1.16e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.89e-11	Aortic root size;
LIHC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.73	8.56	0.42	3.79e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.95	8.46	0.42	8.08e-16	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.4	0.33	5.04e-10	Prudent dietary pattern;
LIHC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.32e-37	Blood metabolite levels;
LIHC	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg00142150	chr22:38071001	LGALS1	0.44	7.43	0.37	8.99e-13	Fat distribution (HIV);
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.5	-6.86	-0.35	3.33e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.58	7.87	0.39	4.71e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs17152411	0.895	rs3940439	chr10:126584531	C/G	cg07906193	chr10:126599966	NA	0.43	6.94	0.35	1.93e-11	Height;
LIHC	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.63	6.76	0.34	5.97e-11	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.31	-7.23	-0.36	3.24e-12	Menarche (age at onset);
LIHC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.59	-0.38	3.15e-13	Body mass index;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05134769	chr7:2239818	MAD1L1	0.5	6.07	0.31	3.43e-9	Lung function (FEV1);
LIHC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02886208	chr11:14281011	SPON1	-0.62	-9.18	-0.44	4.24e-18	Mitochondrial DNA levels;
LIHC	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-7.22	-0.36	3.35e-12	Obesity (extreme);
LIHC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg06026331	chr20:60912101	LAMA5	-0.51	-8.54	-0.42	4.58e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.71	0.6	2.2e-34	Coffee consumption (cups per day);
LIHC	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.41	6.32	0.32	7.98e-10	Neutrophil percentage of white cells;
LIHC	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.52	-6.64	-0.34	1.2e-10	Prostate cancer;
LIHC	cis	rs8192917	0.887	rs2236337	chr14:25100247	T/C	cg03875678	chr14:25103546	GZMB	0.4	7.38	0.37	1.21e-12	Vitiligo;
LIHC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.59	-8.42	-0.41	1.08e-15	Initial pursuit acceleration;
LIHC	cis	rs11760633	0.672	rs12669620	chr7:1826878	G/C	cg23422044	chr7:1970798	MAD1L1	-0.37	-5.73	-0.3	2.26e-8	Coronary artery disease;
LIHC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs11577318	0.528	rs11247935	chr1:26698622	G/C	cg18121669	chr1:26560928	CCDC21	-0.46	-6.85	-0.35	3.49e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs428668	0.681	rs428064	chr5:150696498	G/A	cg11125805	chr5:150678162	SLC36A3	0.39	8.03	0.4	1.63e-14	Skin aging (microtopography measurement);
LIHC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.47	0.33	3.45e-10	Bipolar disorder;
LIHC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.67	0.53	1.07e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs732505	0.764	rs28528202	chr19:5583129	A/G	cg26242866	chr19:5711310	LONP1	0.83	6.11	0.31	2.65e-9	vWF and FVIII levels;
LIHC	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg23682824	chr7:23144976	KLHL7	0.4	6.08	0.31	3.27e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg21573476	chr21:45109991	RRP1B	0.48	9.32	0.45	1.42e-18	Mean corpuscular volume;
LIHC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg14393609	chr7:65229607	NA	0.37	5.71	0.3	2.42e-8	Aortic root size;
LIHC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.88	-0.3	9.96e-9	Personality dimensions;
LIHC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.44	6.34	0.32	7.48e-10	Aortic root size;
LIHC	cis	rs8081395	0.627	rs12952730	chr17:57978836	G/A	cg13753209	chr17:57696993	CLTC	0.49	7.82	0.39	6.61e-14	White blood cell count;
LIHC	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.89	7.25	0.37	2.72e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.21e-8	Menopause (age at onset);
LIHC	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.55	9.14	0.44	5.87e-18	HDL cholesterol;
LIHC	cis	rs3823572	0.564	rs2953626	chr7:133657458	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.71	-0.3	2.44e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.7	-8.34	-0.41	1.83e-15	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.65	0.46	1.17e-19	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg20638045	chr15:100107064	MEF2A	0.47	6.3	0.32	9.06e-10	Cannabis use (initiation);
LIHC	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.48	0.53	4.98e-26	Coffee consumption (cups per day);
LIHC	cis	rs507080	0.922	rs644867	chr11:118567545	A/G	cg04173919	chr11:118528438	PHLDB1	0.36	6.65	0.34	1.13e-10	Serum metabolite levels;
LIHC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.52	8.27	0.41	2.91e-15	Total body bone mineral density;
LIHC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg09990169	chr2:241835740	C2orf54	-0.67	-9.61	-0.46	1.58e-19	Urinary metabolites;
LIHC	cis	rs4407350	0.837	rs5765710	chr22:44914354	C/T	cg11695653	chr22:44894386	LDOC1L	0.35	5.92	0.3	7.73e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03514934	chr16:87731582	JPH3	-0.41	-6.08	-0.31	3.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-7.57	-0.38	3.48e-13	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg00101154	chr16:420108	MRPL28	-0.44	-6.02	-0.31	4.61e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg05555928	chr11:63887634	MACROD1	0.55	7.47	0.37	6.77e-13	Mean platelet volume;
LIHC	cis	rs611744	0.967	rs681099	chr8:109218892	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.85	0.35	3.46e-11	Dupuytren's disease;
LIHC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.66	7.46	0.37	7.28e-13	Testicular germ cell tumor;
LIHC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.6	6.15	0.32	2.22e-9	Gut microbiome composition (summer);
LIHC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg09182678	chr22:50328711	NA	-0.4	-5.92	-0.3	7.82e-9	Schizophrenia;
LIHC	cis	rs9649465	0.967	rs6944031	chr7:123299304	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.1	-0.4	9.87e-15	Migraine;
LIHC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.33	7.4	0.37	1.04e-12	Ulcerative colitis;
LIHC	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.64	6.77	0.34	5.66e-11	Type 2 diabetes;
LIHC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-0.59	-7.73	-0.39	1.17e-13	Lung cancer;
LIHC	cis	rs7188697	0.922	rs246258	chr16:58579274	A/G	cg02549819	chr16:58548995	SETD6	0.43	6.76	0.34	5.85e-11	QT interval;
LIHC	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.56	-8.28	-0.41	2.81e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg17135325	chr3:160939158	NMD3	0.6	8.73	0.43	1.12e-16	Parkinson's disease;
LIHC	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.57	8.59	0.42	3.23e-16	White matter hyperintensity burden;
LIHC	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.89	-0.3	9.44e-9	Resting heart rate;
LIHC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.41	7.11	0.36	6.62e-12	Methadone dose in opioid dependence;
LIHC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.92	10.26	0.49	1.01e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-0.99	-7.7	-0.38	1.52e-13	Body mass index;
LIHC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.55	7.6	0.38	2.78e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg18151635	chr12:93972918	NA	-0.44	-6.89	-0.35	2.74e-11	Pubertal anthropometrics;
LIHC	cis	rs4728302	0.869	rs10954434	chr7:133597864	A/G	cg10665199	chr7:133106180	EXOC4	0.38	6.64	0.34	1.21e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg03934865	chr2:198174659	NA	0.45	6.49	0.33	2.96e-10	Dermatomyositis;
LIHC	cis	rs57590327	0.503	rs6776737	chr3:81513729	T/C	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Extraversion;
LIHC	cis	rs11779988	0.501	rs3760	chr8:17886345	T/C	cg01800426	chr8:17659068	MTUS1	-0.4	-6.18	-0.32	1.78e-9	Breast cancer;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.7	-9.44	-0.45	6.08e-19	Corneal structure;
LIHC	cis	rs1178968	0.901	rs1178953	chr7:72781277	A/G	cg25889504	chr7:72793014	NA	0.36	5.74	0.3	2.08e-8	Triglyceride levels;
LIHC	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.35	-6.13	-0.31	2.42e-9	Lewy body disease;
LIHC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.47	6.54	0.33	2.24e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg18867708	chr6:26865862	GUSBL1	0.41	6.15	0.32	2.12e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.37	-6.16	-0.32	2.09e-9	IgG glycosylation;
LIHC	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.61	-9.4	-0.45	7.83e-19	Post bronchodilator FEV1;
LIHC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07305463	chr2:136567211	LCT	0.34	6.08	0.31	3.14e-9	Mosquito bite size;
LIHC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg26441486	chr22:50317300	CRELD2	0.36	6.48	0.33	3.14e-10	Schizophrenia;
LIHC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg12798992	chr6:167411361	FGFR1OP	0.47	6.86	0.35	3.19e-11	Crohn's disease;
LIHC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.51	-6.86	-0.35	3.32e-11	Blood metabolite levels;
LIHC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.42	6.97	0.35	1.65e-11	Monocyte count;
LIHC	cis	rs7635838	0.892	rs9814907	chr3:11438645	G/A	cg00170343	chr3:11313890	ATG7	0.45	7.04	0.36	1.08e-11	HDL cholesterol;
LIHC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.08	0.44	9e-18	Melanoma;
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.75	-0.3	1.96e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.38	-0.37	1.24e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2279817	0.863	rs13376020	chr1:18016402	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-7.99	-0.4	2.06e-14	Neuroticism;
LIHC	cis	rs61041384	0.661	rs77015199	chr12:123681637	G/C	cg00376283	chr12:123451042	ABCB9	-0.55	-6.14	-0.32	2.28e-9	Schizophrenia;
LIHC	trans	rs6600671	1.000	rs1856572	chr1:121169579	A/C	cg09829573	chr1:144692074	NBPF9	-0.42	-7.64	-0.38	2.17e-13	Hip geometry;
LIHC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.1	0.4	9.81e-15	Lung cancer;
LIHC	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.93	-0.35	2.07e-11	Metabolite levels;
LIHC	cis	rs611744	0.967	rs681099	chr8:109218892	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.63e-17	Dupuytren's disease;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.85	-15.49	-0.64	2.29e-41	Bipolar disorder and schizophrenia;
LIHC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.22	-0.58	1.56e-32	Primary sclerosing cholangitis;
LIHC	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg25251204	chr11:14927456	NA	0.41	5.84	0.3	1.21e-8	Vitamin D levels;
LIHC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.42	7.35	0.37	1.52e-12	Aortic root size;
LIHC	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.11	-0.4	9.46e-15	Exhaled nitric oxide output;
LIHC	cis	rs15676	0.783	rs4489410	chr9:131591649	A/C	cg00228799	chr9:131580591	ENDOG	-0.46	-6.77	-0.34	5.77e-11	Blood metabolite levels;
LIHC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.51	-0.79	2.04e-73	Height;
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.23	-0.32	1.34e-9	Longevity;
LIHC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.5	-9.36	-0.45	1.12e-18	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1419980	0.643	rs11054919	chr12:7778109	C/G	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	trans	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg05848834	chr11:43543746	NA	-0.3	-6.11	-0.31	2.64e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-8.17	-0.4	5.84e-15	Lung cancer;
LIHC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-10.27	-0.49	9.66e-22	Dental caries;
LIHC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.34	5.84	0.3	1.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04053862	chr2:179345017	MIR548N;PLEKHA3	0.43	6.12	0.31	2.55e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6141769	0.518	rs2377665	chr20:31309054	T/C	cg13636640	chr20:31349939	DNMT3B	-0.31	-5.73	-0.3	2.15e-8	Subjective well-being;
LIHC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.38	6.71	0.34	8.11e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.31	6.52	0.33	2.48e-10	Bone mineral density;
LIHC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	0.71	8.23	0.41	3.93e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.46	-8.52	-0.42	5.03e-16	Schizophrenia;
LIHC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	1.15	14.33	0.61	8.58e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs4788570	0.566	rs2052873	chr16:71505303	C/T	cg06353428	chr16:71660113	MARVELD3	-0.87	-8.03	-0.4	1.62e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs16828019	0.777	rs10489521	chr1:41508490	C/T	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg00656387	chr3:40428638	ENTPD3	0.43	6.98	0.35	1.58e-11	Renal cell carcinoma;
LIHC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.36	-0.33	6.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.15	0.36	5.42e-12	Lung cancer;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.66	6.79	0.34	5.09e-11	Alzheimer's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06759328	chr11:76572255	ACER3	0.47	6.72	0.34	7.41e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg01231543	chr16:68741748	NA	0.4	6.3	0.32	9.42e-10	Colorectal cancer;
LIHC	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.75	0.39	1.05e-13	Alzheimer's disease;
LIHC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs1347297	0.526	rs10201175	chr2:179265348	C/T	cg14011486	chr1:26737247	LIN28	0.56	8.11	0.4	9.25e-15	Alzheimer disease and age of onset;
LIHC	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg01181863	chr3:195395398	SDHAP2	-0.63	-8.0	-0.4	1.98e-14	Pancreatic cancer;
LIHC	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.39	7.21	0.36	3.68e-12	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.66	-9.73	-0.47	6.43e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.55	-6.95	-0.35	1.82e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg18357645	chr12:58087776	OS9	0.42	6.69	0.34	9.06e-11	Multiple sclerosis;
LIHC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg02297831	chr4:17616191	MED28	0.4	6.46	0.33	3.59e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.49	6.57	0.33	1.85e-10	Resting heart rate;
LIHC	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.4	-6.54	-0.33	2.31e-10	Inhibitory control;
LIHC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.69	-9.68	-0.46	9.52e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.86	17.99	0.7	2.19e-51	Testicular germ cell tumor;
LIHC	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.89	-0.3	9.38e-9	Systemic lupus erythematosus;
LIHC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.95	-0.39	2.81e-14	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg23791538	chr6:167370224	RNASET2	0.41	6.51	0.33	2.75e-10	Primary biliary cholangitis;
LIHC	cis	rs918629	0.530	rs10070197	chr5:95241868	T/C	cg10483112	chr5:95245456	ELL2	-0.38	-7.15	-0.36	5.26e-12	IgG glycosylation;
LIHC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg14440974	chr22:39074834	NA	-0.42	-6.65	-0.34	1.15e-10	Menopause (age at onset);
LIHC	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	6.97e-29	Eye color traits;
LIHC	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.21e-9	Mean corpuscular volume;
LIHC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg12863693	chr15:85201151	NMB	0.45	6.23	0.32	1.38e-9	Schizophrenia;
LIHC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.95	-0.51	4.1e-24	Lung cancer;
LIHC	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.47	-8.13	-0.4	7.91e-15	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg04373760	chr16:53404718	NA	0.59	7.7	0.38	1.48e-13	Hypertriglyceridemia;
LIHC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.43	-0.33	4.37e-10	Axial length;
LIHC	cis	rs1494373	0.504	rs796486	chr1:220885612	C/A	cg06786860	chr1:220876396	NA	-0.48	-7.1	-0.36	7.1e-12	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg17786042	chr8:19125368	NA	-0.46	-6.24	-0.32	1.26e-9	Monocyte count;
LIHC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.3	-5.89	-0.3	9.21e-9	Colorectal cancer;
LIHC	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.35	-7.85	-0.39	5.27e-14	Breast cancer;
LIHC	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.64	-8.66	-0.42	1.94e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg11062466	chr8:58055876	NA	0.48	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.13e-14	Neuroticism;
LIHC	cis	rs61677309	0.638	rs57461652	chr11:118146197	C/A	cg06090739	chr11:118230722	UBE4A	0.32	6.04	0.31	3.98e-9	Lung cancer in ever smokers;
LIHC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04904834	chr1:179851103	TOR1AIP1	0.46	7.17	0.36	4.73e-12	Cognitive function;
LIHC	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-0.77	-8.88	-0.43	3.77e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.62	-9.45	-0.46	5.48e-19	Ulcerative colitis;
LIHC	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.41	6.54	0.33	2.27e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.06	16.62	0.67	6.67e-46	Breast cancer;
LIHC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.49	-0.56	9.36e-30	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg13409248	chr3:40428643	ENTPD3	0.43	7.21	0.36	3.51e-12	Renal cell carcinoma;
LIHC	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.86	17.67	0.69	4.33e-50	Longevity;
LIHC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21747090	chr2:27597821	SNX17	-0.47	-7.19	-0.36	4.15e-12	Total body bone mineral density;
LIHC	cis	rs4699052	0.507	rs6533085	chr4:104281586	A/T	cg16532752	chr4:104119610	CENPE	-0.44	-6.08	-0.31	3.18e-9	Testicular germ cell tumor;
LIHC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg16586182	chr3:47516702	SCAP	0.35	5.82	0.3	1.34e-8	Birth weight;
LIHC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.57	9.64	0.46	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.11	-0.31	2.79e-9	Longevity;Endometriosis;
LIHC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.17	-0.32	1.9e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17939001	chr1:197871836	C1orf53	-0.46	-6.63	-0.34	1.32e-10	Alopecia areata;
LIHC	cis	rs1000083	0.748	rs1528592	chr5:96659728	T/C	ch.5.96698337R	chr5:96672581	NA	0.95	7.25	0.36	2.87e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17507749	chr15:85114479	UBE2QP1	0.69	7.89	0.39	4.08e-14	Schizophrenia;
LIHC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.39	-6.34	-0.32	7.28e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.53	0.33	2.38e-10	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.9	0.35	2.49e-11	Diabetic kidney disease;
LIHC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg08499158	chr17:42289980	UBTF	-0.52	-8.92	-0.43	2.85e-17	Total body bone mineral density;
LIHC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.25	-0.45	2.55e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11645453	chr3:52864694	ITIH4	0.21	5.75	0.3	2.01e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg19500098	chr13:21900506	NA	0.36	5.94	0.31	6.86e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9513627	1.000	rs7334274	chr13:100120801	G/A	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.46	6.76	0.34	6.11e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg03585969	chr10:35415529	CREM	0.88	13.0	0.58	1.12e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.12	0.31	2.52e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg04374321	chr14:90722782	PSMC1	0.48	6.64	0.34	1.23e-10	Gut microbiota (bacterial taxa);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27356188	chr5:637386	CEP72	0.43	6.37	0.33	6.13e-10	Migraine with aura;
LIHC	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg07884673	chr3:53033167	SFMBT1	0.9	6.59	0.34	1.63e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-8.44	-0.42	8.98e-16	Gut microbiome composition (summer);
LIHC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.76	0.65	1.93e-42	Tonsillectomy;
LIHC	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.39	6.15	0.32	2.14e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-0.92	-11.32	-0.52	1.91e-25	Post bronchodilator FEV1;
LIHC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.63	8.57	0.42	3.56e-16	Sudden cardiac arrest;
LIHC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.52	-8.41	-0.41	1.16e-15	Cognitive function;
LIHC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.68	8.73	0.43	1.18e-16	Initial pursuit acceleration;
LIHC	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.43	6.48	0.33	3.18e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-9.17	-0.44	4.43e-18	Schizophrenia;
LIHC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.51	-0.33	2.75e-10	Height;
LIHC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.94	19.94	0.73	3.03e-59	IgG glycosylation;
LIHC	trans	rs10411161	0.702	rs7251755	chr19:52388948	G/A	cg22319618	chr22:45562946	NUP50	-0.62	-8.49	-0.42	6.32e-16	Breast cancer;
LIHC	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.4	-6.97	-0.35	1.68e-11	Squamous cell lung carcinoma;
LIHC	cis	rs72772090	0.908	rs11750510	chr5:96042095	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-6.52	-0.33	2.49e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.34	6.76	0.34	5.89e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg14067834	chr17:29058358	SUZ12P	0.67	6.48	0.33	3.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs876084	0.505	rs4336644	chr8:121136128	G/C	cg06265175	chr8:121136014	COL14A1	0.42	6.58	0.34	1.79e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.16	0.44	4.82e-18	Cognitive ability;
LIHC	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg06664874	chr5:179499304	RNF130	-0.58	-7.12	-0.36	6.37e-12	LDL cholesterol;
LIHC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02290350	chr8:58132656	NA	0.41	8.46	0.42	7.71e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.4	-6.67	-0.34	1.01e-10	Menopause (age at onset);
LIHC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-10.13	-0.48	2.84e-21	Parkinson's disease;
LIHC	cis	rs1712517	0.771	rs59744322	chr10:105146692	G/T	cg05636881	chr10:105038444	INA	0.49	7.69	0.38	1.58e-13	Migraine;
LIHC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg02297831	chr4:17616191	MED28	-0.42	-5.81	-0.3	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs507080	0.883	rs527475	chr11:118563239	G/A	cg04173919	chr11:118528438	PHLDB1	0.35	6.55	0.33	2.07e-10	Serum metabolite levels;
LIHC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.92	-0.65	4.52e-43	Chronic sinus infection;
LIHC	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.23	-0.32	1.39e-9	Educational attainment (college completion);
LIHC	cis	rs77861329	0.920	rs9860982	chr3:52096432	T/C	cg08692210	chr3:52188851	WDR51A	0.84	7.93	0.39	3.05e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg20194872	chr6:41519635	FOXP4	-0.39	-6.26	-0.32	1.18e-9	Prostate cancer;
LIHC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg12501888	chr15:85177176	SCAND2	-0.49	-7.63	-0.38	2.4e-13	P wave terminal force;
LIHC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.36	6.94	0.35	1.98e-11	Multiple system atrophy;
LIHC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.89	0.6	4.46e-35	Primary sclerosing cholangitis;
LIHC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.51	8.44	0.42	9.08e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	11.3	0.52	2.24e-25	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.19	-0.44	4.04e-18	Bipolar disorder;
LIHC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.94	-0.31	7.07e-9	Colorectal cancer;
LIHC	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg06664874	chr5:179499304	RNF130	0.65	7.92	0.39	3.46e-14	LDL cholesterol;
LIHC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.38	-8.13	-0.4	7.79e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.57	-8.67	-0.42	1.79e-16	Menarche (age at onset);
LIHC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.74	-9.78	-0.47	4.42e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7534824	0.625	rs12568338	chr1:101500622	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.76	7.03	0.36	1.1e-11	Refractive astigmatism;
LIHC	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.76	8.23	0.41	3.85e-15	Alzheimer's disease (late onset);
LIHC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.45	-5.98	-0.31	5.49e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.33	8.09	0.4	1.05e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg11070056	chr1:107600091	PRMT6	-0.71	-12.16	-0.55	1.64e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.73	-0.5	2.5e-23	Hemoglobin concentration;
LIHC	cis	rs10503871	0.657	rs13248936	chr8:30316162	C/T	cg26383811	chr8:30366931	RBPMS	-0.42	-7.36	-0.37	1.36e-12	Metabolite levels  (X-11787);
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.69	0.38	1.53e-13	Height;
LIHC	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.46	7.16	0.36	4.97e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.05	0.55	4.2e-28	Menopause (age at onset);
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.4	8.65	0.42	1.97e-16	Calcium levels;
LIHC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.85	-0.3	1.16e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.68	0.38	1.7e-13	Corneal astigmatism;
LIHC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.75	0.34	6.22e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.22	12.75	0.57	9.9e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	0.9	10.56	0.5	9.71e-23	Breast cancer;
LIHC	cis	rs7587476	1.000	rs2121285	chr2:215656168	C/G	cg04530015	chr2:215796436	ABCA12	0.4	6.4	0.33	5e-10	Neuroblastoma;
LIHC	cis	rs3736485	0.932	rs10519313	chr15:51915812	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-7.01	-0.35	1.28e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	0.55	8.56	0.42	3.82e-16	Atopic dermatitis;
LIHC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.73	0.39	1.18e-13	Mean platelet volume;
LIHC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.56	8.61	0.42	2.63e-16	White matter hyperintensity burden;
LIHC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.77	13.01	0.58	1.02e-31	Menarche (age at onset);
LIHC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.24	-7.5	-0.38	5.7e-13	Motion sickness;
LIHC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.02	-0.51	2.23e-24	Crohn's disease;
LIHC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg12641515	chr19:46296257	DMWD	0.46	7.12	0.36	6.56e-12	Coronary artery disease;
LIHC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.64	-0.46	1.32e-19	Total cholesterol levels;
LIHC	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.38	-7.65	-0.38	2.09e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.7	0.46	7.92e-20	Alzheimer's disease;
LIHC	cis	rs4934494	0.768	rs12776306	chr10:91436057	T/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.49	-0.33	2.93e-10	Red blood cell count;
LIHC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.82	8.61	0.42	2.63e-16	Platelet count;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06656553	chr16:89960601	TCF25	-0.48	-6.28	-0.32	1.02e-9	Skin colour saturation;
LIHC	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.52	-6.11	-0.31	2.79e-9	Ulcerative colitis;
LIHC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.85	-0.35	3.37e-11	IgG glycosylation;
LIHC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.55	5.18e-28	Cognitive test performance;
LIHC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	6.2	0.32	1.66e-9	LDL cholesterol;
LIHC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.2e-8	Vitiligo;
LIHC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg04756594	chr16:24857601	SLC5A11	-0.49	-7.66	-0.38	1.95e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02290350	chr8:58132656	NA	0.51	11.04	0.51	1.9e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg01858014	chr14:56050164	KTN1	-0.62	-5.89	-0.3	9.46e-9	Putamen volume;
LIHC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.06	16.75	0.67	2.08e-46	Breast cancer;
LIHC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.61	10.36	0.49	4.77e-22	Alcohol dependence;
LIHC	cis	rs11628318	0.515	rs11627756	chr14:103096606	C/T	cg12046867	chr14:103022105	NA	-0.37	-5.72	-0.3	2.28e-8	Platelet count;
LIHC	cis	rs6565681	1.000	rs6565681	chr17:78348494	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.52	-7.42	-0.37	9.22e-13	Moyamoya disease;
LIHC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.77	-11.31	-0.52	2.06e-25	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg20607798	chr8:58055168	NA	0.46	5.85	0.3	1.14e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-7.31	-0.37	1.96e-12	Longevity;
LIHC	trans	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.87	-0.35	3.05e-11	Aortic root size;
LIHC	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.48	6.98	0.35	1.57e-11	Dermatomyositis;
LIHC	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg23461800	chr14:103021989	NA	-0.38	-5.84	-0.3	1.23e-8	Platelet count;
LIHC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.53	7.43	0.37	8.59e-13	Menopause (age at onset);
LIHC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.63	11.07	0.51	1.56e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs13161895	0.938	rs594202	chr5:179417335	C/T	cg02702477	chr5:179499311	RNF130	0.75	10.32	0.49	6.59e-22	LDL cholesterol;
LIHC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.57	-7.85	-0.39	5.45e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg16486109	chr11:613632	IRF7	0.58	6.23	0.32	1.36e-9	Systemic lupus erythematosus;
LIHC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.65	8.69	0.43	1.56e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.77	10.68	0.5	3.47e-23	Cerebrospinal P-tau181p levels;
LIHC	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.16	0.32	2.03e-9	Schizophrenia;
LIHC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.61	-0.46	1.59e-19	Morning vs. evening chronotype;
LIHC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg05255149	chr17:80675120	FN3KRP	-0.42	-6.26	-0.32	1.15e-9	Breast cancer;
LIHC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.83	0.3	1.26e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	12.04	0.55	4.45e-28	Cognitive test performance;
LIHC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.53	-8.62	-0.42	2.58e-16	Multiple myeloma (IgH translocation);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg27470307	chr11:61106785	DAK	0.33	6.04	0.31	4.08e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg20335179	chr10:1068567	C10orf110;IDI2	-0.56	-5.89	-0.3	9.32e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22994272	chr14:104346241	NA	0.42	7.09	0.36	7.76e-12	Cognitive function;
LIHC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg03013999	chr17:37608204	MED1	-0.36	-5.91	-0.3	8.4e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.5	8.85	0.43	4.7e-17	Total body bone mineral density;
LIHC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.59	-8.86	-0.43	4.51e-17	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19812495	chr5:71616193	MRPS27;PTCD2	0.47	6.59	0.34	1.7e-10	Lung function (FEV1/FVC);
LIHC	cis	rs903552	1.000	rs12907048	chr15:102003873	G/T	cg19295451	chr15:102010161	PCSK6	-0.44	-6.08	-0.31	3.17e-9	Diabetic kidney disease;
LIHC	cis	rs7116495	0.609	rs2885661	chr11:71588331	C/G	cg10381502	chr11:71823885	C11orf51	0.89	7.3	0.37	2.07e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg02415029	chr1:110025642	ATXN7L2	0.47	6.0	0.31	5.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.48	7.49	0.38	5.79e-13	Methadone dose in opioid dependence;
LIHC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.72	-11.03	-0.51	2.11e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00958927	chr1:175162553	KIAA0040	-0.4	-6.55	-0.33	2.08e-10	Alcohol dependence;
LIHC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg16479474	chr6:28041457	NA	0.34	5.75	0.3	2.02e-8	Cardiac Troponin-T levels;
LIHC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg27170947	chr2:26402098	FAM59B	0.67	8.4	0.41	1.19e-15	Gut microbiome composition (summer);
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.67	-0.34	1.01e-10	Obesity-related traits;
LIHC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.46	16.71	0.67	3.08e-46	Eosinophil percentage of granulocytes;
LIHC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	7.97	0.4	2.47e-14	Diastolic blood pressure;
LIHC	cis	rs17496827	0.780	rs36099214	chr2:223354888	G/A	cg25565276	chr2:223520875	FARSB	0.43	6.26	0.32	1.13e-9	Anorexia nervosa;
LIHC	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12516959	chr21:47718080	NA	-0.43	-7.04	-0.36	1.09e-11	Testicular germ cell tumor;
LIHC	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.56	-8.09	-0.4	1.09e-14	Neuroticism;
LIHC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-5.78	-0.3	1.7e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-6.66	-0.34	1.07e-10	IgG glycosylation;
LIHC	cis	rs7945718	0.533	rs10765987	chr11:12705743	C/T	cg25843174	chr11:12811716	TEAD1	0.33	7.51	0.38	5.22e-13	Educational attainment (years of education);
LIHC	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.41	6.04	0.31	3.97e-9	Thyroid stimulating hormone;
LIHC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.63	8.72	0.43	1.23e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.56	9.84	0.47	2.88e-20	Total cholesterol levels;
LIHC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.56	-6.64	-0.34	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.29	-0.45	1.83e-18	Bipolar disorder;
LIHC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.85	-0.43	4.72e-17	Gut microbiome composition (summer);
LIHC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.79	-9.6	-0.46	1.81e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.74	-0.3	2.08e-8	Blood metabolite levels;
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.43	-5.79	-0.3	1.6e-8	Total body bone mineral density;
LIHC	cis	rs11888559	0.655	rs7596118	chr2:204014655	G/A	cg24605529	chr2:203879461	NBEAL1	0.77	5.85	0.3	1.16e-8	Height;
LIHC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.61	0.38	2.76e-13	Bipolar disorder;
LIHC	cis	rs2257205	0.667	rs8077548	chr17:56690848	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs8084351	0.577	rs7235008	chr18:50632813	C/T	cg24270629	chr18:50823537	DCC	-0.41	-6.21	-0.32	1.53e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg26939375	chr7:64535504	NA	0.43	6.6	0.34	1.56e-10	Aortic root size;
LIHC	cis	rs9303280	0.934	rs8065777	chr17:38072402	C/T	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.67	-0.34	1.02e-10	Self-reported allergy;
LIHC	cis	rs12744310	1.000	rs12039767	chr1:41760860	C/T	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.37	-6.07	-0.31	3.37e-9	Alzheimer's disease (late onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03315687	chr19:40932206	SERTAD1	0.46	6.72	0.34	7.8e-11	Pancreatic cancer;
LIHC	cis	rs4700695	0.614	rs153388	chr5:65422308	G/T	cg21114390	chr5:65439923	SFRS12	-0.55	-6.14	-0.32	2.27e-9	Facial morphology (factor 19);
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.67	0.62	4.01e-38	Prudent dietary pattern;
LIHC	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-0.76	-8.35	-0.41	1.75e-15	Exhaled nitric oxide output;
LIHC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.85	0.39	5.29e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.97	9.88	0.47	1.97e-20	Plasma clusterin levels;
LIHC	cis	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24227371	chr11:82718527	RAB30	0.28	6.56	0.33	2.05e-10	Obesity-related traits;
LIHC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg09182678	chr22:50328711	NA	-0.7	-7.8	-0.39	7.52e-14	Schizophrenia;
LIHC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.57	8.94	0.44	2.43e-17	Lymphocyte counts;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.64	-9.25	-0.45	2.51e-18	Skin colour saturation;
LIHC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs1023500	1.000	rs10154646	chr22:42331409	G/C	cg04733989	chr22:42467013	NAGA	-0.52	-6.1	-0.31	2.89e-9	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.35	5.85	0.3	1.16e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.11	-0.48	3.3e-21	Response to antipsychotic treatment;
LIHC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.79	-12.07	-0.55	3.59e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.36e-11	Protein C levels;
LIHC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg20295408	chr7:1910781	MAD1L1	0.44	6.49	0.33	3.06e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.43	-6.22	-0.32	1.45e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.11	-0.68	7.46e-48	Gut microbiome composition (summer);
LIHC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg07636037	chr3:49044803	WDR6	-0.53	-6.45	-0.33	3.84e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg21782813	chr7:2030301	MAD1L1	0.37	6.32	0.32	8.28e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.7	11.11	0.51	1.1e-24	Multiple myeloma (IgH translocation);
LIHC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.45	0.42	8.19e-16	Bladder cancer;
LIHC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.67	-11.56	-0.53	2.49e-26	Crohn's disease;
LIHC	cis	rs8081395	0.775	rs2645482	chr17:57943115	T/G	cg13753209	chr17:57696993	CLTC	0.39	5.81	0.3	1.44e-8	White blood cell count;
LIHC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg21573476	chr21:45109991	RRP1B	-0.55	-10.31	-0.49	6.75e-22	Mean corpuscular volume;
LIHC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.47	-7.28	-0.37	2.3e-12	Height;
LIHC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23043544	chr7:2124092	MAD1L1	-0.43	-6.95	-0.35	1.86e-11	Neuroticism;
LIHC	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.53	8.0	0.4	2e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs75908454	1.000	rs74792903	chr6:169836217	C/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.77	-0.39	9.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21467203	chr3:49911342	NA	-0.45	-8.11	-0.4	9.27e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1892700	0.764	rs34927129	chr21:34873502	G/A	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg13263691	chr18:77568018	NA	0.25	6.76	0.34	6.13e-11	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.78	-0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.27	0.45	2.19e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07080220	chr10:102295463	HIF1AN	0.44	6.01	0.31	4.78e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.57	0.33	1.89e-10	Body mass index;
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.56	8.17	0.4	5.9e-15	Renal cell carcinoma;
LIHC	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg14146966	chr2:61757674	XPO1	0.47	8.37	0.41	1.53e-15	Tuberculosis;
LIHC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.55	0.38	3.97e-13	Nonalcoholic fatty liver disease;
LIHC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg09137382	chr11:130731461	NA	0.41	6.24	0.32	1.28e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.74	-8.81	-0.43	6.2e-17	Post bronchodilator FEV1;
LIHC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg11212589	chr17:38028394	ZPBP2	0.32	6.6	0.34	1.55e-10	Self-reported allergy;
LIHC	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-8.38	-0.41	1.38e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	9.88	0.47	1.98e-20	Post bronchodilator FEV1;
LIHC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.96	19.89	0.73	4.86e-59	Bone mineral density;
LIHC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.7	8.16	0.4	6.49e-15	Behavioural disinhibition (generation interaction);
LIHC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg14456004	chr13:21872349	NA	1.39	15.44	0.64	3.57e-41	White matter hyperintensity burden;
LIHC	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.74	0.39	1.1e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.66	7.65	0.38	2.08e-13	LDL cholesterol to HDL cholesterol ratio;
LIHC	cis	rs471756	0.523	rs574399	chr9:219875	T/A	cg14500300	chr9:211689	NA	0.25	5.81	0.3	1.45e-8	Mean platelet volume;
LIHC	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.25	0.45	2.4e-18	Schizophrenia;
LIHC	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.79	-9.62	-0.46	1.55e-19	Psoriasis vulgaris;
LIHC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg13854012	chr2:162103682	NA	-0.32	-5.71	-0.3	2.45e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.563	rs11669860	chr19:19277296	G/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-6.53	-0.33	2.43e-10	IgG glycosylation;
LIHC	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg07689907	chr11:61582574	FADS1	-0.39	-5.72	-0.3	2.3e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.71	9.11	0.44	7.26e-18	Gut microbiome composition (summer);
LIHC	trans	rs7668874	0.731	rs1835504	chr4:116790996	T/G	cg08917878	chr5:172668965	NA	-0.3	-6.04	-0.31	4e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-23.31	-0.78	1.3e-72	Height;
LIHC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg09238746	chr17:78121135	EIF4A3	-0.48	-7.2	-0.36	3.8e-12	Yeast infection;
LIHC	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg26811252	chr16:29126840	RRN3P2	0.44	6.87	0.35	3.13e-11	Menopause (age at onset);
LIHC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.49	-12.54	-0.56	6.15e-30	Hip circumference adjusted for BMI;
LIHC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.4	7.88	0.39	4.39e-14	Coronary artery disease or large artery stroke;
LIHC	cis	rs911119	1.000	rs13038305	chr20:23610262	C/T	cg16589663	chr20:23618590	CST3	0.74	7.75	0.39	1.09e-13	Chronic kidney disease;
LIHC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	11.98	0.54	7.57e-28	Cognitive test performance;
LIHC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.39	8.03	0.4	1.54e-14	Type 2 diabetes;
LIHC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.38	6.05	0.31	3.76e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.61	0.59	5.31e-34	Colorectal cancer;
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg26939375	chr7:64535504	NA	0.47	7.09	0.36	7.94e-12	Calcium levels;
LIHC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.57	8.07	0.4	1.2e-14	Mean corpuscular volume;
LIHC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.41	6.42	0.33	4.43e-10	Menopause (age at onset);
LIHC	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.04	17.95	0.7	3.13e-51	Triglycerides;
LIHC	cis	rs7248779	0.512	rs3848635	chr19:2410332	T/C	cg22729335	chr19:2427816	TIMM13	1.05	20.08	0.74	8.39e-60	Cortisol levels (saliva);
LIHC	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.1e-13	Lung cancer;
LIHC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-8.93	-0.43	2.65e-17	Body mass index (adult);
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg21486233	chr12:29375141	FAR2	0.32	6.44	0.33	4.07e-10	QT interval;
LIHC	cis	rs7818688	0.697	rs76815619	chr8:95981330	G/A	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs1814175	0.616	rs10839341	chr11:49742615	G/A	cg03929089	chr4:120376271	NA	-0.85	-16.54	-0.67	1.44e-45	Height;
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg08469215	chr1:156261351	TMEM79	0.4	6.5	0.33	2.84e-10	Tonsillectomy;
LIHC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20135002	chr11:47629003	NA	-0.51	-8.59	-0.42	3.11e-16	Subjective well-being;
LIHC	trans	rs526821	0.595	rs485555	chr11:55323570	A/G	cg03929089	chr4:120376271	NA	0.45	6.82	0.35	4.18e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.58	9.57	0.46	2.17e-19	Body mass index;
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20570016	chr1:156261298	TMEM79	0.37	5.94	0.31	7.11e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs8049603	0.524	rs36044995	chr16:23086965	T/G	cg16484020	chr16:23217411	SCNN1G	-0.24	-5.99	-0.31	5.24e-9	Multiple sclerosis;
LIHC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.65	-11.11	-0.51	1.09e-24	Childhood ear infection;
LIHC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.48	7.86	0.39	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11229555	0.645	rs12285111	chr11:58208385	T/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-8.17	-0.4	5.87e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.83	0.54	2.65e-27	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.83	-15.97	-0.65	2.6900000000000002e-43	Height;
LIHC	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg20487152	chr13:99095054	FARP1	-0.37	-6.14	-0.32	2.29e-9	Longevity;
LIHC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.67	11.37	0.52	1.29e-25	Lymphocyte counts;
LIHC	cis	rs2073499	0.872	rs7642692	chr3:50222693	T/C	cg03645007	chr3:50255295	SLC38A3	0.44	6.2	0.32	1.59e-9	Schizophrenia;
LIHC	cis	rs959260	1.000	rs4789183	chr17:73380221	G/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.8	-0.3	1.51e-8	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.14	-0.44	5.7e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs7238033	0.624	rs10460036	chr18:43311566	A/G	cg20610511	chr18:43302872	SLC14A1	0.38	6.34	0.32	7.42e-10	Bladder cancer;
LIHC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg00750074	chr16:89608354	SPG7	-0.39	-5.88	-0.3	9.79e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg09137382	chr11:130731461	NA	0.42	6.35	0.32	6.9e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs8010715	0.771	rs2277481	chr14:24587545	A/G	cg23112188	chr14:24563095	PCK2	-0.3	-6.33	-0.32	7.88e-10	IgG glycosylation;
LIHC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.21	-0.7	2.89e-52	Height;
LIHC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg18709589	chr6:96969512	KIAA0776	-0.47	-5.76	-0.3	1.83e-8	Migraine;Coronary artery disease;
LIHC	cis	rs1982963	0.950	rs1566132	chr14:52511836	C/T	cg10843707	chr14:52510701	NID2	-0.44	-8.23	-0.41	4.08e-15	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02290350	chr8:58132656	NA	0.4	8.5	0.42	6.01e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.45	8.39	0.41	1.29e-15	Platelet distribution width;
LIHC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.76	0.57	9.39e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.6	-0.5	6.66e-23	Chronic sinus infection;
LIHC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.88	15.77	0.65	1.67e-42	Coronary artery disease;
LIHC	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.52	-9.61	-0.46	1.59e-19	Endometrial cancer;
LIHC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-22.14	-0.77	5.15e-68	Coronary artery disease;
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.97	-0.31	6.04e-9	Menopause (age at onset);
LIHC	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.37	0.77	6.21e-69	Chronic sinus infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12868349	chr11:71639594	RNF121;LOC100133315	0.42	6.22	0.32	1.47e-9	Cognitive function;
LIHC	trans	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg10756647	chr7:56101905	PSPH	1.1	13.4	0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.49	7.59	0.38	3.01e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg19000871	chr14:103996768	TRMT61A	0.43	7.35	0.37	1.45e-12	Coronary artery disease;
LIHC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.5	-8.54	-0.42	4.46e-16	Response to temozolomide;
LIHC	cis	rs918629	0.530	rs11741563	chr5:95240996	C/T	cg10483112	chr5:95245456	ELL2	-0.38	-6.91	-0.35	2.34e-11	IgG glycosylation;
LIHC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.13	-0.36	5.83e-12	Vitiligo;
LIHC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	1.08	13.95	0.6	2.44e-35	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg10820045	chr2:198174542	NA	0.54	8.82	0.43	5.8e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17106184	0.786	rs113611542	chr1:51129203	T/C	cg07174182	chr1:51127561	FAF1	-0.76	-8.12	-0.4	8.47e-15	Type 2 diabetes;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg14307443	chr4:172734507	GALNTL6	0.39	7.0	0.35	1.37e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.05	14.07	0.61	8.82e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg12463550	chr7:65579703	CRCP	0.68	7.05	0.36	9.9e-12	Diabetic kidney disease;
LIHC	cis	rs11229555	0.609	rs12273517	chr11:58201094	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg05043794	chr9:111880884	C9orf5	0.29	7.13	0.36	5.83e-12	Menarche (age at onset);
LIHC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.41	-6.9	-0.35	2.49e-11	Colorectal or endometrial cancer;
LIHC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4450131	0.522	rs11245327	chr10:126358174	T/C	cg20435097	chr10:126320824	FAM53B	0.67	12.05	0.55	4.05e-28	White blood cell count (basophil);
LIHC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	5.9	0.3	8.98e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.76	6.97	0.35	1.6e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg15841412	chr13:111365552	ING1	0.46	5.84	0.3	1.2e-8	Coronary artery disease;
LIHC	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg02023728	chr11:77925099	USP35	0.35	6.19	0.32	1.69e-9	Alzheimer's disease (survival time);
LIHC	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg15893493	chr8:124194847	FAM83A	-0.77	-8.05	-0.4	1.36e-14	Urinary uromodulin levels;
LIHC	cis	rs3862030	0.510	rs11591780	chr10:104225316	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-6.99	-0.35	1.46e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	7.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	13.77	0.6	1.2e-34	Psoriasis;
LIHC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.55	9.08	0.44	9e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs244293	0.965	rs244366	chr17:53187300	G/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.47	-0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.64e-15	Motion sickness;
LIHC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg14250997	chr9:106856677	SMC2	0.42	7.45	0.37	7.54e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2637030	0.559	rs2607497	chr5:52995482	A/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.73	0.34	6.99e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg22153463	chr1:85462885	MCOLN2	0.49	5.87	0.3	1.03e-8	Serum sulfate level;
LIHC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.64	10.82	0.5	1.19e-23	Menopause (age at onset);
LIHC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs986417	0.892	rs78026410	chr14:60801142	G/A	cg27398547	chr14:60952738	C14orf39	-0.73	-7.72	-0.39	1.3e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg09182678	chr22:50328711	NA	-0.39	-5.82	-0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.39	-8.57	-0.42	3.49e-16	Prostate-specific antigen levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01506492	chr2:219232590	C2orf62	-0.44	-6.07	-0.31	3.41e-9	Longevity;
LIHC	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.37	5.9	0.3	8.77e-9	Alzheimer's disease (late onset);
LIHC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.67	9.82	0.47	3.18e-20	Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-0.95	-19.97	-0.73	2.38e-59	Height;
LIHC	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.81	10.2	0.48	1.72e-21	Type 2 diabetes;
LIHC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.62	-11.95	-0.54	9.94e-28	Neuroticism;
LIHC	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg11764359	chr7:65958608	NA	0.59	6.11	0.31	2.74e-9	Diabetic kidney disease;
LIHC	cis	rs911119	0.913	rs13038990	chr20:23589053	C/T	cg16589663	chr20:23618590	CST3	0.71	7.5	0.38	5.61e-13	Chronic kidney disease;
LIHC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.71e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs55665837	0.701	rs12286408	chr11:14579376	G/A	cg00085434	chr11:14927489	NA	0.43	6.07	0.31	3.32e-9	Vitamin D levels;
LIHC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-9.52	-0.46	3.25e-19	Schizophrenia;
LIHC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.3	-0.32	9.41e-10	Menopause (age at onset);
LIHC	cis	rs151997	0.925	rs26089	chr5:50172251	A/G	cg06027927	chr5:50259733	NA	-0.55	-7.32	-0.37	1.76e-12	Callous-unemotional behaviour;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg16606324	chr3:10149918	C3orf24	0.49	5.75	0.3	1.94e-8	Alzheimer's disease;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.28	0.52	2.61e-25	Prudent dietary pattern;
LIHC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-7.26	-0.37	2.63e-12	Uric acid levels;
LIHC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg20607798	chr8:58055168	NA	0.48	5.98	0.31	5.72e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.58	6.22	0.32	1.49e-9	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.02	-0.4	1.7e-14	Type 2 diabetes;
LIHC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.16	-0.32	2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.57	-0.33	1.83e-10	Bipolar disorder;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg09364756	chr6:160148626	WTAP	0.34	6.22	0.32	1.48e-9	Calcium levels;
LIHC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg12046867	chr14:103022105	NA	-0.5	-6.94	-0.35	1.97e-11	Platelet count;
LIHC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.43	0.53	7.93e-26	Personality dimensions;
LIHC	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.52	6.22	0.32	1.42e-9	Serum sulfate level;
LIHC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.85	0.35	3.35e-11	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.98	-0.35	1.57e-11	Diabetic kidney disease;
LIHC	cis	rs785830	0.523	rs529045	chr9:217397	C/T	cg14500300	chr9:211689	NA	0.26	5.85	0.3	1.15e-8	Platelet distribution width;
LIHC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.69	12.59	0.56	4.11e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.58	-8.09	-0.4	1.04e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.42	-0.33	4.45e-10	Longevity;Endometriosis;
LIHC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg18357645	chr12:58087776	OS9	-0.43	-6.76	-0.34	6.05e-11	Multiple sclerosis;
LIHC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.84	-12.79	-0.57	7.28e-31	Obesity-related traits;
LIHC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.88	-0.43	3.95e-17	Gut microbiome composition (summer);
LIHC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18252515	chr7:66147081	NA	0.43	6.07	0.31	3.42e-9	Aortic root size;
LIHC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.61	7.25	0.37	2.75e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.26e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02290350	chr8:58132656	NA	0.49	10.45	0.49	2.26e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs1494950	1.000	rs7667955	chr4:15084922	A/G	cg12377275	chr4:15005593	CPEB2	-0.86	-7.69	-0.38	1.5700000000000001e-13	Political ideology;
LIHC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-9.6	-0.46	1.82e-19	Parkinson's disease;
LIHC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.66	-9.78	-0.47	4.28e-20	Testicular germ cell tumor;
LIHC	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.37	-0.49	4.23e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.34	-0.32	7.3e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg03013999	chr17:37608204	MED1	0.35	5.8	0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.69	10.66	0.5	4.13e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.69	-11.43	-0.53	7.84e-26	Prudent dietary pattern;
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg25894440	chr7:65020034	NA	-0.41	-6.65	-0.34	1.17e-10	Calcium levels;
LIHC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.88	14.63	0.62	5.74e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.5	7.05	0.36	9.69e-12	Height;
LIHC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg20283391	chr11:68216788	NA	-0.36	-5.73	-0.3	2.15e-8	Total body bone mineral density;
LIHC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.04	-0.48	5.96e-21	Platelet count;
LIHC	trans	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	6.12	0.31	2.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9513627	1.000	rs9585075	chr13:100128634	G/A	cg25919922	chr13:100150906	NA	-0.77	-6.89	-0.35	2.74e-11	Obesity-related traits;
LIHC	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg25024717	chr12:54324583	NA	-0.38	-8.03	-0.4	1.63e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-6.76	-0.34	6.05e-11	Lymphocyte counts;
LIHC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.29	-0.37	2.1e-12	Body mass index;
LIHC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.28	-0.37	2.35e-12	Psoriasis;
LIHC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.66	13.79	0.6	1.01e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.4e-11	Diabetic kidney disease;
LIHC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.83	-9.2	-0.45	3.68e-18	Vitiligo;
LIHC	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.68	-6.63	-0.34	1.34e-10	Multiple sclerosis;
LIHC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20135002	chr11:47629003	NA	-0.55	-9.53	-0.46	3.1e-19	Subjective well-being;
LIHC	cis	rs2273669	0.588	rs114414265	chr6:109306489	C/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.76	-0.3	1.88e-8	Prostate cancer;
LIHC	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg06854084	chr10:101292507	NKX2-3	-0.35	-6.28	-0.32	1.05e-9	Dental caries;
LIHC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.68	-10.92	-0.51	5.23e-24	Lung cancer;
LIHC	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.61	-9.63	-0.46	1.37e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg15605315	chr1:45957053	TESK2	-0.44	-5.74	-0.3	2.08e-8	Platelet count;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17424134	chr2:27616206	FTHL3;PPM1G	0.42	6.22	0.32	1.46e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.65	-10.4	-0.49	3.35e-22	Blood trace element (Zn levels);
LIHC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg05973401	chr12:123451056	ABCB9	0.42	5.87	0.3	1.01e-8	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg17750252	chr2:136567154	LCT	-0.34	-6.06	-0.31	3.5e-9	Mosquito bite size;
LIHC	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.87e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg01596870	chr19:55963115	NA	-0.67	-9.61	-0.46	1.58e-19	Obesity-related traits;
LIHC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.49	8.86	0.43	4.61e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.54	-6.83	-0.35	3.94e-11	Blood pressure (smoking interaction);
LIHC	trans	rs3903072	0.652	rs501630	chr11:65637273	A/G	cg17712092	chr4:129076599	LARP1B	-0.63	-9.02	-0.44	1.33e-17	Breast cancer;
LIHC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.64	-12.09	-0.55	2.88e-28	Extrinsic epigenetic age acceleration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05047319	chr11:86748661	TMEM135	0.48	6.48	0.33	3.11e-10	Lung function (FEV1/FVC);
LIHC	cis	rs16958440	1.000	rs62096463	chr18:44628928	A/G	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.48	-6.88	-0.35	2.9e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.75	-0.3	2.02e-8	Tonsillectomy;
LIHC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.73	7.36	0.37	1.35e-12	Cannabis dependence symptom count;
LIHC	cis	rs4908760	0.899	rs6577496	chr1:8581227	C/A	cg20416874	chr1:8611966	RERE	-0.68	-14.37	-0.61	6.05e-37	Vitiligo;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02590972	chr2:217363392	RPL37A	0.46	6.76	0.34	6.04e-11	Cognitive function;
LIHC	trans	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10513480	chr14:21852135	SUPT16H	-0.58	-6.53	-0.33	2.44e-10	Systolic blood pressure;
LIHC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.43	-9.22	-0.45	3.04e-18	Rheumatoid arthritis;
LIHC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg21466736	chr12:48725269	NA	-0.63	-9.13	-0.44	6.08e-18	Glycated hemoglobin levels;
LIHC	cis	rs254781	0.505	rs664366	chr5:88055761	A/G	cg22951263	chr5:87985283	NA	-0.39	-6.34	-0.32	7.06e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs895636	0.898	rs10205310	chr2:45188646	A/G	cg16198908	chr2:45192207	NA	0.4	6.09	0.31	3.1e-9	Metabolite levels;Fasting plasma glucose;
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02969873	chr4:1330999	MAEA	-0.42	-6.31	-0.32	8.77e-10	Longevity;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.73	0.57	1.16e-30	Prudent dietary pattern;
LIHC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.97e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	0.76	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.36	5.78	0.3	1.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg07952391	chr2:88470173	THNSL2	0.76	6.94	0.35	1.95e-11	Plasma clusterin levels;
LIHC	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.93	15.9	0.65	5.01e-43	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11031096	0.676	rs7120125	chr11:3941264	C/T	cg18678763	chr11:4115507	RRM1	0.45	6.57	0.33	1.91e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20910303	chr4:147443095	SLC10A7	0.38	6.21	0.32	1.51e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg19635926	chr16:89946313	TCF25	0.46	6.0	0.31	5.11e-9	Skin colour saturation;
LIHC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg25894440	chr7:65020034	NA	0.56	6.48	0.33	3.21e-10	Diabetic kidney disease;
LIHC	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.32e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.67	-7.12	-0.36	6.31e-12	Vitiligo;
LIHC	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.36	6.04	0.31	4.13e-9	Platelet distribution width;
LIHC	cis	rs7116495	0.786	rs1894003	chr11:71750276	A/G	cg26138937	chr11:71823887	C11orf51	-0.81	-8.09	-0.4	1.07e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs61440199	0.818	rs59256081	chr3:20176778	G/A	cg00235661	chr3:20228976	SGOL1	-0.43	-6.04	-0.31	3.98e-9	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.91	-0.54	1.38e-27	Chronic sinus infection;
LIHC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.54	-0.86	3e-103	Myeloid white cell count;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.22	0.55	9.92e-29	Prudent dietary pattern;
LIHC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg01364799	chr7:75623366	TMEM120A	0.5	7.58	0.38	3.32e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.55	0.42	4.26e-16	Coronary artery disease;
LIHC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.01	0.31	4.73e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg25344623	chr2:136566232	LCT	0.41	8.33	0.41	1.99e-15	Mosquito bite size;
LIHC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.41	-0.53	8.75e-26	Chronic sinus infection;
LIHC	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg00469287	chr7:23338798	C7orf30	0.45	6.21	0.32	1.54e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs611744	0.806	rs2514846	chr8:109067105	C/G	cg21045802	chr8:109455806	TTC35	0.47	8.02	0.4	1.68e-14	Dupuytren's disease;
LIHC	cis	rs4853525	0.522	rs10490538	chr2:191590066	C/T	cg05765582	chr2:191677683	NA	-0.29	-5.76	-0.3	1.92e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.46	7.31	0.37	1.85e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.52	7.5	0.38	5.69e-13	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21467203	chr3:49911342	NA	-0.43	-7.41	-0.37	9.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs507080	0.885	rs533144	chr11:118559247	C/A	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.78e-10	Serum metabolite levels;
LIHC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.18	-0.48	2e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9473924	0.542	rs9463650	chr6:50822081	C/T	cg14470998	chr6:50812995	TFAP2B	0.87	9.92	0.47	1.46e-20	Body mass index;
LIHC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.5	-7.91	-0.39	3.69e-14	Morning vs. evening chronotype;
LIHC	cis	rs6466055	0.699	rs4496901	chr7:104898337	G/T	cg04380332	chr7:105027541	SRPK2	0.34	6.29	0.32	9.55e-10	Schizophrenia;
LIHC	cis	rs1775715	0.966	rs1251386	chr10:32319114	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.41	-7.38	-0.37	1.24e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.46	0.46	5.19e-19	Corneal astigmatism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01688141	chr8:23539808	NKX3-1	0.45	6.94	0.35	1.93e-11	Cognitive function;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg03874509	chr1:107600012	PRMT6	0.73	11.41	0.53	9.01e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-8.44	-0.42	9.41e-16	Morning vs. evening chronotype;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26545112	chr7:97833388	LMTK2	0.38	6.53	0.33	2.37e-10	Bilirubin levels;
LIHC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.79	-0.79	1.75e-74	Height;
LIHC	cis	rs600806	0.888	rs12046539	chr1:109875415	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.25	-0.36	2.8e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04517903	chr16:1557605	TELO2	0.43	6.55	0.33	2.09e-10	Longevity;
LIHC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg01864069	chr14:103024347	NA	-0.47	-7.31	-0.37	1.91e-12	Platelet count;
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.51	7.95	0.39	2.82e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.35	5.89	0.3	9.29e-9	Height;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg22561889	chr6:118971681	C6orf204	0.55	5.94	0.31	7.13e-9	Diastolic blood pressure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05700333	chr5:131892723	RAD50	0.49	6.38	0.33	5.62e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg25182066	chr10:30743637	MAP3K8	-0.48	-7.86	-0.39	4.93e-14	Inflammatory bowel disease;
LIHC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-6.19	-0.32	1.74e-9	Alzheimer's disease (late onset);
LIHC	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.49	-8.32	-0.41	2.06e-15	Pubertal anthropometrics;
LIHC	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.6	-0.34	1.62e-10	Body mass index;
LIHC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.73	7.56	0.38	3.67e-13	Vitiligo;
LIHC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.56	9.46	0.46	5.02e-19	Colorectal cancer;
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.72	12.12	0.55	2.32e-28	Menopause (age at onset);
LIHC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg03037974	chr15:76606532	NA	-0.6	-10.25	-0.48	1.14e-21	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	9.08	0.44	8.77e-18	Motion sickness;
LIHC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.67	-13.12	-0.58	3.82e-32	Body mass index;
LIHC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.99	0.31	5.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg20607798	chr8:58055168	NA	0.49	6.94	0.35	2.02e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.44	-6.36	-0.33	6.51e-10	Urate levels in obese individuals;
LIHC	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.42	8.46	0.42	7.64e-16	Renal cell carcinoma;
LIHC	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.52	-0.38	4.89e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs422249	0.634	rs174609	chr11:61627811	T/C	cg27386326	chr11:61587980	NA	0.33	5.86	0.3	1.07e-8	Trans fatty acid levels;
LIHC	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.39	8.38	0.41	1.39e-15	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg04592579	chr7:75616294	TMEM120A	0.41	7.06	0.36	9.23e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.54	8.07	0.4	1.17e-14	Blood protein levels;
LIHC	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.67	-10.74	-0.5	2.18e-23	Pulse pressure;
LIHC	trans	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.57	-6.01	-0.31	4.63e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs7534824	0.625	rs6676834	chr1:101463788	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	7.09	0.36	7.67e-12	Refractive astigmatism;
LIHC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.51	-8.38	-0.41	1.42e-15	Cognitive function;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.29	-0.32	9.67e-10	Renal cell carcinoma;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05459609	chr16:4689950	MGRN1	-0.4	-6.14	-0.32	2.29e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.73	-0.43	1.11e-16	Total cholesterol levels;
LIHC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.49	-0.38	5.81e-13	Schizophrenia;
LIHC	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg13919466	chr1:32135498	COL16A1	-0.35	-6.59	-0.34	1.7e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.63	0.34	1.33e-10	Axial length;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.51	7.87	0.39	4.76e-14	Longevity;Endometriosis;
LIHC	cis	rs244293	0.965	rs244305	chr17:53237843	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.19	-0.36	4.2e-12	Menarche (age at onset);
LIHC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg17724175	chr1:150552817	MCL1	0.49	9.54	0.46	2.85e-19	Melanoma;
LIHC	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.34	-5.93	-0.31	7.5e-9	Lewy body disease;
LIHC	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.3	-0.32	9.06e-10	Bipolar disorder;
LIHC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.52	-9.09	-0.44	8.05e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg23091122	chr1:110024289	SYPL2	-0.48	-6.42	-0.33	4.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg14222432	chr12:29376421	FAR2	0.37	7.23	0.36	3.27e-12	QT interval;
LIHC	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg26139080	chr11:47293733	MADD	-0.5	-8.45	-0.42	8.74e-16	HDL cholesterol;
LIHC	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.96	-0.35	1.72e-11	Neutrophil percentage of white cells;
LIHC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg17135325	chr3:160939158	NMD3	0.6	8.73	0.43	1.12e-16	Parkinson's disease;
LIHC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-7.91	-0.39	3.54e-14	Parkinson's disease;
LIHC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.83	-0.3	1.28e-8	Pulse pressure;
LIHC	cis	rs67981189	0.593	rs2526871	chr14:71385113	G/A	cg15816911	chr14:71606274	NA	-0.41	-6.44	-0.33	4.01e-10	Schizophrenia;
LIHC	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg05110241	chr16:68378359	PRMT7	-0.55	-6.46	-0.33	3.63e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.46	7.51	0.38	5.17e-13	Age at first birth;
LIHC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.37	-9.4	-0.45	7.85e-19	Longevity;Endometriosis;
LIHC	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.85	0.35	3.45e-11	Ileal carcinoids;
LIHC	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.9	12.62	0.56	3.02e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg24069376	chr3:38537580	EXOG	-0.38	-6.99	-0.35	1.41e-11	Electrocardiographic conduction measures;
LIHC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.37	7.39	0.37	1.14e-12	Alcohol dependence;
LIHC	cis	rs12079745	0.590	rs2280257	chr1:169352787	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.4	7.88	0.39	4.52e-14	Coronary artery disease or large artery stroke;
LIHC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.11	-0.61	6.26e-36	Alzheimer's disease;
LIHC	cis	rs17433710	0.516	rs11805556	chr1:162673946	C/T	cg01063088	chr1:162760584	HSD17B7	-0.44	-6.38	-0.33	5.76e-10	Dupuytren's disease;
LIHC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	8.12	0.4	8.8e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.88	14.81	0.63	1.09e-38	Schizophrenia;
LIHC	cis	rs9543976	1.000	rs9543976	chr13:76136648	G/A	cg01531495	chr13:76123901	UCHL3	0.5	6.19	0.32	1.71e-9	Diabetic retinopathy;
LIHC	cis	rs67981189	0.593	rs2810074	chr14:71378533	G/A	cg15816911	chr14:71606274	NA	-0.42	-6.75	-0.34	6.28e-11	Schizophrenia;
LIHC	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg11441379	chr12:63026424	NA	0.63	6.28	0.32	1.01e-9	IgG glycosylation;
LIHC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg04592579	chr7:75616294	TMEM120A	0.38	6.55	0.33	2.17e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2637266	0.783	rs720249	chr10:78476143	T/C	cg18941641	chr10:78392320	NA	0.28	6.04	0.31	3.98e-9	Pulmonary function;
LIHC	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.66	10.44	0.49	2.51e-22	Obesity-related traits;
LIHC	cis	rs10508774	0.925	rs11008955	chr10:32805202	G/A	cg01819863	chr10:32635814	EPC1	0.65	6.03	0.31	4.19e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4764487	0.735	rs2159521	chr12:6349328	A/G	cg08284733	chr12:6341482	CD9	0.37	6.55	0.33	2.07e-10	Mean platelet volume;
LIHC	trans	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg26939375	chr7:64535504	NA	-0.39	-6.19	-0.32	1.7e-9	Aortic root size;
LIHC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.32e-12	Migraine;Coronary artery disease;
LIHC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.76	-0.39	9.88e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	3.15e-30	Menopause (age at onset);
LIHC	cis	rs4755351	0.553	rs11032154	chr11:33155264	A/G	cg05567920	chr11:33183001	CSTF3	0.42	6.21	0.32	1.56e-9	Lung cancer in ever smokers;
LIHC	cis	rs57502260	0.764	rs3867143	chr11:68223074	A/G	cg16797656	chr11:68205561	LRP5	0.59	7.98	0.4	2.22e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs11960470	1.000	rs11960470	chr5:50328257	A/C	cg06027927	chr5:50259733	NA	0.57	8.2	0.41	4.94e-15	Breast cancer;
LIHC	trans	rs11039100	0.681	rs11039170	chr11:5845187	T/G	cg11650987	chr12:10280440	CLEC7A	0.41	6.21	0.32	1.51e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21467203	chr3:49911342	NA	-0.49	-8.59	-0.42	3.1e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.85	0.3	1.14e-8	Birth weight;
LIHC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg05941027	chr17:61774174	LIMD2	0.3	5.97	0.31	5.91e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.83	0.35	3.83e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16497277	chr3:49208875	KLHDC8B	0.48	6.07	0.31	3.47e-9	Menarche (age at onset);
LIHC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	0.98	17.99	0.7	2.1e-51	Monocyte percentage of white cells;
LIHC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	5.85	0.3	1.17e-8	Schizophrenia;
LIHC	cis	rs655641	1.000	rs548121	chr11:85675533	C/T	cg09030501	chr11:85779252	PICALM	-0.5	-5.9	-0.3	8.84e-9	Platelet count;
LIHC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg02297831	chr4:17616191	MED28	0.41	6.66	0.34	1.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg18478394	chr8:109455254	TTC35	0.41	7.18	0.36	4.44e-12	Dupuytren's disease;
LIHC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg15691649	chr6:25882328	NA	-0.55	-7.06	-0.36	9.22e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	19.82	0.73	9.57e-59	Exhaled nitric oxide output;
LIHC	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.5	-8.36	-0.41	1.55e-15	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.61	-0.38	2.62e-13	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg03037974	chr15:76606532	NA	0.75	14.57	0.62	9.92e-38	Blood metabolite levels;
LIHC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.55	-8.8	-0.43	6.67e-17	Menarche (age at onset);
LIHC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg25281562	chr12:121454272	C12orf43	0.45	7.92	0.39	3.41e-14	N-glycan levels;
LIHC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.66	9.42	0.45	6.76e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05787890	chr3:183165321	NA	0.49	6.55	0.33	2.15e-10	Lung function (FEV1/FVC);
LIHC	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg23091122	chr1:110024289	SYPL2	-0.48	-6.39	-0.33	5.44e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.62	-12.23	-0.55	8.88e-29	Schizophrenia;
LIHC	cis	rs507080	0.733	rs570949	chr11:118571911	G/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12078486	chr1:155108334	RAG1AP1	0.43	6.28	0.32	1.03e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.81	-0.63	1.06e-38	Alzheimer's disease (late onset);
LIHC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.75	-0.3	2.03e-8	Breast cancer;
LIHC	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg14092571	chr14:90743983	NA	-0.42	-6.54	-0.33	2.27e-10	Mortality in heart failure;
LIHC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.58	-9.61	-0.46	1.62e-19	Colorectal cancer;
LIHC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg19680672	chr10:131412579	MGMT	-0.46	-7.07	-0.36	8.74e-12	Response to temozolomide;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00966380	chr12:47633443	NA	-0.52	-6.96	-0.35	1.77e-11	Lung function (FEV1/FVC);
LIHC	cis	rs17433710	0.516	rs4477251	chr1:162670541	A/G	cg01063088	chr1:162760584	HSD17B7	0.43	6.15	0.32	2.22e-9	Dupuytren's disease;
LIHC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	3.07e-11	Renal cell carcinoma;
LIHC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.38	-5.82	-0.3	1.34e-8	Alzheimer's disease (late onset);
LIHC	trans	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.92e-15	Obesity-related traits;
LIHC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.97	9.8	0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.86	-0.39	5.04e-14	Coronary artery disease;
LIHC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.06	-0.48	5.08e-21	Response to antipsychotic treatment;
LIHC	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.37	5.85	0.3	1.16e-8	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.69	10.06	0.48	4.94e-21	Coronary artery disease;
LIHC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.83	-0.39	6.02e-14	Type 2 diabetes;
LIHC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.42	-6.53	-0.33	2.37e-10	Iron status biomarkers;
LIHC	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.61	-12.04	-0.55	4.49e-28	Plateletcrit;Platelet count;
LIHC	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg17623882	chr6:41773611	USP49	-0.44	-5.89	-0.3	9.01e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs61041384	1.000	rs76872194	chr12:123693363	C/A	cg00376283	chr12:123451042	ABCB9	-0.54	-5.89	-0.3	9.21e-9	Schizophrenia;
LIHC	cis	rs9896052	0.614	rs9890461	chr17:73452479	G/A	cg25649188	chr17:73499917	CASKIN2	0.46	6.91	0.35	2.34e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.5	6.25	0.32	1.19e-9	Vitiligo;
LIHC	cis	rs965469	0.901	rs6037563	chr20:3326568	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.59e-11	IFN-related cytopenia;
LIHC	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.82	-12.35	-0.56	3.06e-29	Body mass index;
LIHC	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg02290350	chr8:58132656	NA	0.44	8.95	0.44	2.3e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.49	8.73	0.43	1.16e-16	Tuberculosis;
LIHC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg02711726	chr17:80685570	FN3KRP	-0.5	-9.38	-0.45	9.09e-19	Glycated hemoglobin levels;
LIHC	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.66	0.59	3.29e-34	Coffee consumption (cups per day);
LIHC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.25	-5.8	-0.3	1.49e-8	Subjective well-being;
LIHC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs600806	0.888	rs461200	chr1:109855404	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.11	-0.36	6.85e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg07234388	chr1:156261841	TMEM79	0.51	9.08	0.44	8.56e-18	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.4	8.06	0.4	1.33e-14	Renal cell carcinoma;
LIHC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.41	-8.36	-0.41	1.56e-15	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg22281195	chr17:26989129	SUPT6H;SDF2	-0.37	-6.17	-0.32	1.96e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg16558253	chr16:72132732	DHX38	-0.51	-8.24	-0.41	3.65e-15	Fibrinogen levels;
LIHC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.29	7.05	0.36	1.02e-11	Primary biliary cholangitis;
LIHC	cis	rs4663866	0.803	rs71426511	chr2:239180200	G/A	cg16914508	chr2:239161102	PER2	0.8	5.9	0.3	8.78e-9	Irritable bowel syndrome;
LIHC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20135002	chr11:47629003	NA	-0.59	-10.11	-0.48	3.4e-21	Subjective well-being;
LIHC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.97	14.2	0.61	2.61e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg11212589	chr17:38028394	ZPBP2	0.36	7.24	0.36	3.07e-12	Self-reported allergy;
LIHC	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.22	0.32	1.49e-9	Mean corpuscular volume;
LIHC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg03146154	chr1:46216737	IPP	-0.38	-6.27	-0.32	1.11e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.76	-8.34	-0.41	1.89e-15	Exhaled nitric oxide output;
LIHC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.72	0.34	7.53e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs365132	0.875	rs353491	chr5:176432947	C/G	cg16309518	chr5:176445507	NA	-0.54	-10.26	-0.49	1.03e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg11005552	chr10:105648138	OBFC1	0.38	6.04	0.31	4.07e-9	Coronary artery disease;
LIHC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.38	-6.73	-0.34	7.05e-11	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg03146154	chr1:46216737	IPP	-0.36	-5.97	-0.31	5.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg00656387	chr3:40428638	ENTPD3	0.4	6.78	0.34	5.24e-11	Renal cell carcinoma;
LIHC	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg18809830	chr7:99032528	PTCD1	-0.83	-6.45	-0.33	3.72e-10	Blood metabolite levels;
LIHC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.52	-7.35	-0.37	1.47e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg13446199	chr8:143762866	PSCA	-0.2	-5.74	-0.3	2.05e-8	Urinary tract infection frequency;
LIHC	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg14456004	chr13:21872349	NA	-1.03	-11.33	-0.52	1.72e-25	White matter hyperintensity burden;
LIHC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.43	-6.32	-0.32	8.01e-10	Cognitive function;
LIHC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	7.99	0.4	2.12e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17467752	chr17:38218738	THRA	0.4	5.86	0.3	1.07e-8	Asthma;
LIHC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg06565975	chr8:143823917	SLURP1	0.34	6.57	0.33	1.84e-10	Urinary tract infection frequency;
LIHC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	6.63	0.34	1.3e-10	Bipolar disorder;
LIHC	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.13	-0.36	5.83e-12	Vitiligo;
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.17	-0.32	1.88e-9	Aortic root size;
LIHC	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.45	-6.68	-0.34	9.51e-11	Obesity-related traits;
LIHC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg13047869	chr3:10149882	C3orf24	0.5	5.92	0.3	7.91e-9	Alzheimer's disease;
LIHC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.66	11.71	0.53	7.54e-27	High light scatter reticulocyte count;
LIHC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-7.9	-0.39	3.93e-14	Initial pursuit acceleration;
LIHC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg18887096	chr2:219472410	PLCD4	-0.36	-6.19	-0.32	1.73e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.62	9.8	0.47	3.91e-20	Longevity;
LIHC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.79	12.39	0.56	2.31e-29	Breast cancer;
LIHC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.45	-7.89	-0.39	4.24e-14	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.11	-0.4	8.96e-15	Response to antipsychotic treatment;
LIHC	trans	rs5756813	0.646	rs875300	chr22:38157805	A/G	cg19894588	chr14:64061835	NA	0.45	6.48	0.33	3.29e-10	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.57	-7.93	-0.39	3.06e-14	Response to antineoplastic agents;
LIHC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.52	0.33	2.46e-10	Lung cancer in ever smokers;
LIHC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-0.58	-6.32	-0.32	8.31e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.72	0.57	1.29e-30	Prudent dietary pattern;
LIHC	cis	rs785830	0.523	rs2484966	chr9:216493	T/C	cg14500300	chr9:211689	NA	0.28	6.41	0.33	4.95e-10	Platelet distribution width;
LIHC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.0	22.77	0.78	1.74e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs735860	0.726	rs209517	chr6:53206989	A/T	cg10236188	chr6:53219634	NA	0.41	7.58	0.38	3.22e-13	Glaucoma;
LIHC	cis	rs2108622	0.727	rs7254940	chr19:15984508	C/T	cg13772218	chr19:15982569	NA	0.37	7.68	0.38	1.72e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg19318889	chr4:1322082	MAEA	-0.47	-7.74	-0.39	1.14e-13	Obesity-related traits;
LIHC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.68	12.69	0.57	1.75e-30	Coronary artery disease;
LIHC	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg23250157	chr14:64679961	SYNE2	0.4	5.89	0.3	9.34e-9	Atrial fibrillation;
LIHC	cis	rs11888559	0.655	rs4297863	chr2:204005877	T/C	cg24605529	chr2:203879461	NBEAL1	0.78	5.92	0.31	7.62e-9	Height;
LIHC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.53	-6.87	-0.35	3.01e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.32	-0.49	6.45e-22	Response to antipsychotic treatment;
LIHC	cis	rs7534824	0.625	rs17409422	chr1:101502386	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.73	7.28	0.37	2.38e-12	Refractive astigmatism;
LIHC	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-0.66	-11.01	-0.51	2.46e-24	Pediatric autoimmune diseases;
LIHC	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg20016023	chr10:99160130	RRP12	0.41	6.22	0.32	1.42e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.44	6.36	0.33	6.41e-10	Morning vs. evening chronotype;
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.63	10.28	0.49	8.83e-22	Longevity;
LIHC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.69	0.34	9.33e-11	Bipolar disorder;
LIHC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.74	6.33	0.32	7.53e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11671005	0.693	rs11666928	chr19:58914231	A/G	cg25952890	chr19:58913133	NA	0.7	7.19	0.36	4.02e-12	Mean platelet volume;
LIHC	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.58	10.69	0.5	3.2e-23	Leprosy;
LIHC	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.65	10.11	0.48	3.36e-21	Type 2 diabetes;
LIHC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-20.06	-0.74	1.03e-59	Height;
LIHC	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.61	-0.34	1.45e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg03859395	chr2:55845619	SMEK2	-0.47	-7.56	-0.38	3.63e-13	Metabolic syndrome;
LIHC	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.5	-5.87	-0.3	1.03e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg16576597	chr16:28551801	NUPR1	0.37	5.83	0.3	1.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.55	-9.34	-0.45	1.3e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.32	6.74	0.34	6.87e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.38	6.15	0.32	2.21e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.68	0.38	1.68e-13	Height;
LIHC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-6.72	-0.34	7.77e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg17675199	chr6:35436792	RPL10A	0.39	7.87	0.39	4.66e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-8.61	-0.42	2.65e-16	Chronic sinus infection;
LIHC	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.89	-0.47	1.87e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs8010715	0.816	rs6573572	chr14:24599230	C/A	cg23112188	chr14:24563095	PCK2	-0.29	-6.08	-0.31	3.25e-9	IgG glycosylation;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.84	0.78	8.76e-71	Height;
LIHC	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg24112000	chr20:60950667	NA	0.44	7.04	0.36	1.09e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6793245	0.845	rs4073797	chr3:38590850	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.47	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.68	-9.88	-0.47	1.99e-20	Initial pursuit acceleration;
LIHC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.43	-6.14	-0.32	2.26e-9	Blood metabolite levels;
LIHC	cis	rs11630290	0.592	rs12324556	chr15:64160951	G/A	cg12036633	chr15:63758958	NA	0.64	6.84	0.35	3.69e-11	Iris characteristics;
LIHC	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.6	-7.53	-0.38	4.49e-13	Post bronchodilator FEV1;
LIHC	cis	rs9921222	0.521	rs9935268	chr16:381562	G/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	7.01	0.35	1.27e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.25	0.61	1.74e-36	Prudent dietary pattern;
LIHC	cis	rs600806	0.778	rs4970731	chr1:109995459	T/C	cg23091122	chr1:110024289	SYPL2	-0.49	-6.43	-0.33	4.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.54	8.8	0.43	7.12e-17	Obesity-related traits;
LIHC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.69	-12.96	-0.57	1.56e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2257205	0.667	rs8070407	chr17:56709172	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-6.84	-0.35	3.67e-11	Pancreatic cancer;
LIHC	trans	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg10208301	chr11:6592745	DNHD1	0.48	6.35	0.32	6.68e-10	Coronary artery calcification;
LIHC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg25588787	chr5:154027256	NA	-0.38	-5.71	-0.3	2.42e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg25182066	chr10:30743637	MAP3K8	0.6	9.64	0.46	1.28e-19	Inflammatory bowel disease;
LIHC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg03859395	chr2:55845619	SMEK2	0.82	14.14	0.61	4.43e-36	Metabolic syndrome;
LIHC	cis	rs61677309	0.638	rs17122021	chr11:118145686	C/T	cg06090739	chr11:118230722	UBE4A	0.33	6.22	0.32	1.42e-9	Lung cancer in ever smokers;
LIHC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg18887096	chr2:219472410	PLCD4	0.36	6.32	0.32	8.27e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12022452	0.591	rs1001400	chr1:40998902	A/G	cg25568243	chr1:40974465	DEM1	0.45	5.93	0.31	7.35e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.46	0.59	2e-33	Diabetic kidney disease;
LIHC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg14580859	chr9:123691850	NA	0.36	6.22	0.32	1.45e-9	Rheumatoid arthritis;
LIHC	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg03945807	chr20:60948434	NA	0.38	6.2	0.32	1.61e-9	Colorectal cancer;
LIHC	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg20991723	chr1:152506922	NA	0.53	9.23	0.45	2.89e-18	Hair morphology;
LIHC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.4	-7.3	-0.37	2.08e-12	Aortic root size;
LIHC	cis	rs34779708	0.771	rs3867218	chr10:35527543	T/C	cg03585969	chr10:35415529	CREM	0.79	11.51	0.53	3.97e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.52	9.14	0.44	5.5e-18	Breast cancer;
LIHC	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg02891314	chr5:179741120	GFPT2	-0.45	-6.09	-0.31	3.04e-9	Height;
LIHC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.68	10.08	0.48	4.19e-21	Schizophrenia;
LIHC	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.45	6.47	0.33	3.45e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.23	0.32	1.35e-9	Tonsillectomy;
LIHC	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-9.13	-0.44	6.05e-18	Colorectal cancer;
LIHC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.43	-0.33	4.27e-10	Type 2 diabetes;
LIHC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-6.26	-0.32	1.18e-9	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg12463550	chr7:65579703	CRCP	0.67	7.06	0.36	9.33e-12	Diabetic kidney disease;
LIHC	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.48	-7.78	-0.39	8.7e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.34e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.72	13.25	0.58	1.31e-32	Height;
LIHC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg23791538	chr6:167370224	RNASET2	-0.61	-10.39	-0.49	3.77e-22	Primary biliary cholangitis;
LIHC	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	26.23	0.82	7.21e-84	Schizophrenia;
LIHC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.61	-8.65	-0.42	2.08e-16	Blood metabolite levels;
LIHC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg15123519	chr2:136567270	LCT	-0.36	-5.75	-0.3	2.01e-8	Corneal structure;
LIHC	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.2	0.41	4.76e-15	Corneal astigmatism;
LIHC	cis	rs72772090	0.614	rs10447215	chr5:96056373	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.98	-0.35	1.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.42	-7.93	-0.39	3.07e-14	Endometriosis;
LIHC	trans	rs4604234	0.803	rs73463519	chr6:80976579	C/T	cg08069338	chr6:160207898	SNORA29;TCP1	0.63	6.09	0.31	3.01e-9	Cancer;
LIHC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.09	13.05	0.58	7.36e-32	Vitiligo;
LIHC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg18305652	chr10:134549665	INPP5A	-0.37	-6.16	-0.32	2.02e-9	Migraine;
LIHC	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs8067354	0.574	rs1291947	chr17:57996336	G/T	cg02344993	chr17:57696989	CLTC	0.66	10.41	0.49	3.03e-22	Hemoglobin concentration;
LIHC	cis	rs4700695	0.841	rs251614	chr5:65228251	C/G	cg21114390	chr5:65439923	SFRS12	-0.49	-6.56	-0.33	2.01e-10	Facial morphology (factor 19);
LIHC	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.45	-8.58	-0.42	3.36e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.77	0.69	1.65e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg09863266	chr14:51125203	SAV1	-0.41	-6.58	-0.34	1.76e-10	Mean platelet volume;
LIHC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.72	-0.3	2.3e-8	Mean corpuscular volume;
LIHC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.44	-7.29	-0.37	2.22e-12	Fibrinogen levels;
LIHC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.71	0.38	1.35e-13	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.92	-0.3	7.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12915845	0.545	rs12907930	chr15:89083314	A/G	cg05013243	chr15:89149849	MIR1179	0.36	6.49	0.33	2.99e-10	Menarche (age at onset);
LIHC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.52	10.24	0.48	1.26e-21	Prostate cancer;
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-8.28	-0.41	2.81e-15	Lymphocyte counts;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05439608	chr7:156761192	NOM1	0.44	6.9	0.35	2.58e-11	Longevity;
LIHC	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg20636351	chr8:55087400	NA	-0.35	-7.24	-0.36	2.94e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs10612751	1	rs10612751	chr13:107646032	CTG/C	cg04314986	chr13:107569408	NA	0.35	6.49	0.33	3.03e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.26	0.52	3.09e-25	Colorectal cancer;
LIHC	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma;
LIHC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	0.93	12.58	0.56	4.54e-30	Cognitive function;
LIHC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	8.14	0.4	7.37e-15	Prudent dietary pattern;
LIHC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.27	-5.9	-0.3	8.82e-9	Type 2 diabetes;
LIHC	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.91	0.35	2.36e-11	Bipolar disorder;
LIHC	cis	rs2412488	0.893	rs12507563	chr4:54363194	A/G	cg22241045	chr4:54363911	LNX1	0.46	7.64	0.38	2.15e-13	DNA methylation (variation);
LIHC	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.86	-14.4	-0.61	4.41e-37	Schizophrenia;
LIHC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.51	-0.33	2.68e-10	Type 2 diabetes;
LIHC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.43	-0.41	9.55e-16	Cognitive function;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg11809123	chr19:1584870	MBD3	0.45	6.7	0.34	8.77e-11	Alopecia areata;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16627807	chr19:40596541	ZNF780A	0.47	6.76	0.34	6.02e-11	Pancreatic cancer;
LIHC	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.51	-7.4	-0.37	1.04e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs918629	0.567	rs3777196	chr5:95238160	A/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.82	-0.35	4.03e-11	IgG glycosylation;
LIHC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg19682013	chr15:45996608	NA	-0.4	-7.09	-0.36	7.6e-12	Waist circumference;Weight;
LIHC	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.27	-6.42	-0.33	4.58e-10	Menarche (age at onset);
LIHC	cis	rs847851	0.617	rs11970238	chr6:34945143	T/C	cg13137465	chr6:34857473	ANKS1A	0.67	7.45	0.37	7.92e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.57	8.74	0.43	1.07e-16	White matter hyperintensity burden;
LIHC	trans	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg17712092	chr4:129076599	LARP1B	0.58	6.24	0.32	1.29e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg19318889	chr4:1322082	MAEA	-0.48	-7.92	-0.39	3.27e-14	Obesity-related traits;
LIHC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.37	7.28	0.37	2.34e-12	Alcohol dependence;
LIHC	cis	rs2834256	0.517	rs9976290	chr21:34928329	G/A	cg14850771	chr21:34775459	IFNGR2	0.45	7.18	0.36	4.47e-12	Red cell distribution width;
LIHC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg02297831	chr4:17616191	MED28	0.43	6.94	0.35	2.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-7.13	-0.36	5.96e-12	Testicular germ cell tumor;
LIHC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.51	-6.92	-0.35	2.19e-11	Narcolepsy;
LIHC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.47	-0.37	6.92e-13	Mean platelet volume;
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg19318889	chr4:1322082	MAEA	0.4	6.63	0.34	1.32e-10	Obesity-related traits;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.49	6.84	0.35	3.63e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg05197062	chr11:11642011	GALNTL4	0.43	6.14	0.32	2.34e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.33	-6.94	-0.35	1.97e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs8081395	0.651	rs1292067	chr17:57930646	A/C	cg13753209	chr17:57696993	CLTC	-0.5	-8.08	-0.4	1.1e-14	White blood cell count;
LIHC	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.73	-13.98	-0.6	1.85e-35	Mortality in heart failure;
LIHC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.45	7.34	0.37	1.57e-12	Diastolic blood pressure;
LIHC	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.04	0.72	1.22e-55	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.47	8.03	0.4	1.64e-14	Mean corpuscular volume;
LIHC	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg20240347	chr1:204465584	NA	-0.35	-7.19	-0.36	4.04e-12	Schizophrenia;
LIHC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.46	9.09	0.44	8.17e-18	Schizophrenia;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.55	-7.75	-0.39	1.09e-13	Menopause (age at onset);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg12655621	chr3:133380788	TOPBP1	-0.41	-6.99	-0.35	1.45e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.57	8.41	0.41	1.1e-15	Osteoporosis;
LIHC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.21	0.36	3.62e-12	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.53	-0.49	1.24e-22	Chronic sinus infection;
LIHC	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.4	7.75	0.39	1.08e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17175324	chr11:64009423	FKBP2	-0.52	-6.18	-0.32	1.83e-9	Systolic blood pressure;
LIHC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.69e-10	Waist circumference;Weight;
LIHC	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.7	-9.24	-0.45	2.75e-18	HIV-1 control;
LIHC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.09	-0.36	7.51e-12	Monocyte percentage of white cells;
LIHC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.03	-0.4	1.59e-14	Total body bone mineral density;
LIHC	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.32	0.32	8.19e-10	Height;
LIHC	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.58	6.76	0.34	5.8e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg24642844	chr7:1081250	C7orf50	-0.7	-7.03	-0.36	1.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.42	6.48	0.33	3.15e-10	Mean corpuscular volume;
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27297192	chr10:134578999	INPP5A	0.53	7.55	0.38	4e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.7	11.65	0.53	1.22e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3858145	0.588	rs78041174	chr10:70038771	G/A	cg04882175	chr6:131122610	NA	-0.48	-6.07	-0.31	3.33e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg12454167	chr3:186435060	KNG1	0.32	7.68	0.38	1.73e-13	Adiponectin levels;
LIHC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.66	7.07	0.36	8.62e-12	Exhaled nitric oxide output;
LIHC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.63	10.41	0.49	3.16e-22	Resting heart rate;
LIHC	cis	rs9649465	0.934	rs7799354	chr7:123269819	A/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.94	-0.44	2.45e-17	Migraine;
LIHC	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.77	-11.42	-0.53	8.63e-26	Personality dimensions;
LIHC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.6	-0.34	1.58e-10	Type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02290350	chr8:58132656	NA	0.52	11.18	0.52	6.19e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.45	-8.09	-0.4	1.08e-14	Body mass index;
LIHC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6759839	0.716	rs6531114	chr2:16617781	T/C	cg09580478	chr2:16689509	NA	0.64	6.25	0.32	1.21e-9	Mean platelet volume;
LIHC	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.95	0.35	1.9e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg10756647	chr7:56101905	PSPH	1.06	13.26	0.58	1.11e-32	Diabetic kidney disease;
LIHC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.22	0.32	1.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11098699	1.000	rs4833884	chr4:124175208	G/A	cg09941581	chr4:124220074	SPATA5	0.33	6.27	0.32	1.09e-9	Mosquito bite size;
LIHC	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg09829573	chr1:144692074	NBPF9	-0.43	-7.87	-0.39	4.56e-14	Hip geometry;
LIHC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.46	6.71	0.34	8.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.89	0.3	9.33e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.44	-5.9	-0.3	8.54e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.71	-0.46	7.5599999999999994e-20	Electroencephalogram traits;
LIHC	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.22	0.32	1.47e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.53	8.94	0.44	2.48e-17	Coronary artery disease;
LIHC	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.74	0.71	2.14e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg01864069	chr14:103024347	NA	0.45	6.98	0.35	1.51e-11	Platelet count;
LIHC	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.84	7.5	0.38	5.72e-13	Triglycerides;
LIHC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Parkinson's disease;
LIHC	cis	rs2710642	0.564	rs6545962	chr2:62821318	G/A	cg17519650	chr2:63277830	OTX1	0.41	6.4	0.33	5.02e-10	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.61	0.34	1.5e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.42	-5.77	-0.3	1.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg07424592	chr7:64974309	NA	0.75	8.79	0.43	7.66e-17	Diabetic kidney disease;
LIHC	cis	rs7729447	0.776	rs4867472	chr5:32693566	C/T	cg16267343	chr5:32710456	NPR3	0.47	5.78	0.3	1.71e-8	Blood pressure;
LIHC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-14.39	-0.61	4.78e-37	Mortality in heart failure;
LIHC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.42	5.94	0.31	6.95e-9	Coronary artery disease;
LIHC	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.85	-0.3	1.15e-8	Tuberculosis;
LIHC	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	8.01	0.4	1.78e-14	Triglyceride levels;
LIHC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg11812906	chr14:75593930	NEK9	-0.47	-7.45	-0.37	7.94e-13	IgG glycosylation;
LIHC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-0.92	-15.47	-0.64	2.63e-41	Lymphocyte counts;
LIHC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02290350	chr8:58132656	NA	0.41	8.43	0.41	9.79e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.32	-0.58	6.78e-33	Primary sclerosing cholangitis;
LIHC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00152838	chr16:24741724	TNRC6A	-0.51	-6.3	-0.32	9.08e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs79600951	1.000	rs76233589	chr16:56769902	A/G	cg03486475	chr5:140796240	PCDHGA4;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	0.52	6.05	0.31	3.72e-9	HDL cholesterol;
LIHC	cis	rs2084898	0.891	rs477361	chr11:120000873	T/G	cg13907859	chr11:120009124	TRIM29	-0.53	-6.57	-0.33	1.86e-10	Stroke (pediatric);
LIHC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.05	22.07	0.77	9.69e-68	Platelet distribution width;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg00800038	chr16:89945340	TCF25	-0.61	-9.98	-0.48	9.06e-21	Skin colour saturation;
LIHC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.94	18.0	0.7	1.99e-51	Menopause (age at onset);
LIHC	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg20636351	chr8:55087400	NA	-0.38	-7.73	-0.39	1.2e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9596863	0.898	rs34107297	chr13:54374962	A/T	ch.13.53330881F	chr13:54432880	NA	0.43	5.8	0.3	1.53e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs4903214	0.895	rs1005740	chr14:74695332	A/G	cg11132536	chr14:74711944	VSX2	-0.26	-6.18	-0.32	1.78e-9	Inflammatory bowel disease;
LIHC	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.02	-0.31	4.61e-9	Tuberculosis;
LIHC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.42	6.53	0.33	2.32e-10	Iron status biomarkers;
LIHC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg19318889	chr4:1322082	MAEA	-0.46	-7.71	-0.38	1.34e-13	Obesity-related traits;
LIHC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.56	-7.66	-0.38	1.91e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.597	rs11771318	chr7:66062480	G/T	cg11764359	chr7:65958608	NA	-0.69	-8.92	-0.43	2.91e-17	Aortic root size;
LIHC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6489882	0.867	rs916972	chr12:113366049	G/T	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs611744	0.967	rs2597654	chr8:109221090	A/G	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.19e-10	Dupuytren's disease;
LIHC	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg25161029	chr11:122845972	NA	0.33	5.81	0.3	1.41e-8	Menarche (age at onset);
LIHC	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg00601450	chr5:74908170	NA	0.52	6.43	0.33	4.2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg03859395	chr2:55845619	SMEK2	0.74	12.29	0.55	5.25e-29	Metabolic syndrome;
LIHC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.03	0.4	1.62e-14	Body mass index;
LIHC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	7.91	0.39	3.58e-14	Platelet count;
LIHC	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs243505	0.660	rs3779037	chr7:148539323	T/C	cg09806900	chr7:148480153	CUL1	0.43	6.1	0.31	2.82e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.6	-0.38	2.86e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.82	0.43	5.94e-17	Schizophrenia;
LIHC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.72	-9.35	-0.45	1.21e-18	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23964739	chr19:45909864	CD3EAP;PPP1R13L	-0.44	-6.16	-0.32	2.09e-9	Triglycerides;
LIHC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg03647239	chr10:116582469	FAM160B1	0.47	6.83	0.35	3.85e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs35883536	1.000	rs34441740	chr1:101137046	C/G	cg14515779	chr1:101123966	NA	-0.7	-14.03	-0.6	1.21e-35	Monocyte count;
LIHC	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.79	-16.62	-0.67	6.65e-46	Longevity;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.13e-9	Total body bone mineral density;
LIHC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	9.8	0.47	3.67e-20	Personality dimensions;
LIHC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.6	0.46	1.77e-19	Alzheimer's disease;
LIHC	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	8.66	0.42	1.85e-16	LDL cholesterol;
LIHC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.88	-15.33	-0.64	9.23e-41	Colorectal cancer;
LIHC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.43	-6.13	-0.31	2.44e-9	Morning vs. evening chronotype;
LIHC	cis	rs10411936	1.000	rs11878602	chr19:16555153	A/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.42	-5.72	-0.3	2.28e-8	White blood cell count;Multiple sclerosis;
LIHC	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg14593290	chr7:50529359	DDC	-0.4	-6.59	-0.34	1.66e-10	Malaria;
LIHC	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.53	8.25	0.41	3.56e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg16434002	chr17:42200994	HDAC5	-0.53	-7.71	-0.38	1.4e-13	Total body bone mineral density;
LIHC	cis	rs7224314	1.000	rs62084079	chr17:65386917	C/T	cg01507342	chr17:65387096	PITPNC1	-0.48	-6.01	-0.31	4.63e-9	Diisocyanate-induced asthma;
LIHC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-8.6	-0.42	2.93e-16	Chronic sinus infection;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.43	7.91	0.39	3.64e-14	Prudent dietary pattern;
LIHC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	7.98	0.4	2.22e-14	Mean platelet volume;
LIHC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.03	-0.36	1.13e-11	Migraine;Coronary artery disease;
LIHC	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.67	8.64	0.42	2.13e-16	Exhaled nitric oxide output;
LIHC	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	6.99	0.35	1.46e-11	Protein C levels;
LIHC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.26	0.72	1.73e-56	Smoking behavior;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.44	8.17	0.4	6.08e-15	Prudent dietary pattern;
LIHC	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg20335179	chr10:1068567	C10orf110;IDI2	-0.61	-6.75	-0.34	6.5e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.83	9.94	0.47	1.27e-20	Bladder cancer;
LIHC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.57	-10.08	-0.48	4.17e-21	Type 2 diabetes;
LIHC	cis	rs11229555	0.645	rs4367960	chr11:58194961	C/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg19635926	chr16:89946313	TCF25	0.48	6.24	0.32	1.32e-9	Skin colour saturation;
LIHC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.14e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.35	-5.72	-0.3	2.3e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.49	0.67	2.29e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg05555928	chr11:63887634	MACROD1	0.53	7.07	0.36	8.67e-12	Mean platelet volume;
LIHC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg23625390	chr15:77176239	SCAPER	0.34	5.99	0.31	5.3300000000000004e-09	Blood metabolite levels;
LIHC	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg07424592	chr7:64974309	NA	0.78	8.84	0.43	4.99e-17	Gout;
LIHC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs8053891	0.507	rs10852510	chr16:72026041	G/A	cg01557791	chr16:72042693	DHODH	-0.4	-6.29	-0.32	9.85e-10	Coronary artery disease;
LIHC	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.46	-7.99	-0.4	2.06e-14	Survival in pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-7.64	-0.38	2.26e-13	Diabetic kidney disease;
LIHC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.82	-12.74	-0.57	1.07e-30	Total body bone mineral density;
LIHC	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.29	6.4	0.33	5.23e-10	Pulmonary function;
LIHC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg00750074	chr16:89608354	SPG7	-0.39	-5.97	-0.31	6.09e-9	Multiple myeloma (IgH translocation);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06995624	chr17:73043174	ATP5H;KCTD2	0.46	6.59	0.34	1.71e-10	Lung function (FEV1/FVC);
LIHC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg01411142	chr8:19674711	INTS10	0.5	7.72	0.39	1.28e-13	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.36	0.45	1.08e-18	Corneal astigmatism;
LIHC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.53	10.24	0.48	1.25e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg25686905	chr3:183603175	PARL	-0.48	-9.07	-0.44	9.25e-18	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05000123	chr14:20937394	PNP	0.43	6.14	0.32	2.23e-9	Pancreatic cancer;
LIHC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg15506890	chr2:3487001	NA	-0.44	-6.6	-0.34	1.58e-10	Neurofibrillary tangles;
LIHC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.62	-9.58	-0.46	2.03e-19	Smoking behavior;
LIHC	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.52	-0.38	4.9e-13	Breast cancer;
LIHC	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.49	9.51	0.46	3.63e-19	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21448741	chr8:58168803	NA	0.37	6.0	0.31	5.11e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.7	-0.69	3.13e-50	Schizophrenia;
LIHC	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26031613	chr14:104095156	KLC1	-0.42	-5.84	-0.3	1.22e-8	Coronary artery disease;
LIHC	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.41	6.1	0.31	2.91e-9	Dementia with Lewy bodies;
LIHC	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.69	-11.09	-0.51	1.24e-24	Schizophrenia;
LIHC	cis	rs9326778	0.520	rs6893387	chr5:108848237	G/A	cg17395555	chr5:108820864	NA	-0.34	-5.76	-0.3	1.92e-8	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	11.85	0.54	2.17e-27	Height;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.81	0.63	1.12e-38	Prudent dietary pattern;
LIHC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.44	-6.02	-0.31	4.41e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.12e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg19773385	chr1:10388646	KIF1B	-0.32	-5.75	-0.3	2e-8	Hepatocellular carcinoma;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20225246	chr19:2200020	DOT1L	-0.42	-6.16	-0.32	2.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.48	8.12	0.4	8.36e-15	Obesity-related traits;
LIHC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-9.2	-0.45	3.53e-18	Mean corpuscular volume;
LIHC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.58e-15	Gut microbiome composition (summer);
LIHC	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.5	9.63	0.46	1.37e-19	Testicular germ cell tumor;
LIHC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.14	0.44	5.69e-18	Hemoglobin concentration;
LIHC	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.22	-0.45	3.03e-18	Exhaled nitric oxide output;
LIHC	cis	rs7075426	0.905	rs1896514	chr10:88175881	G/A	cg07322936	chr10:88137208	NA	0.5	6.78	0.34	5.43e-11	Migraine without aura;
LIHC	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.38	6.89	0.35	2.62e-11	Obesity;
LIHC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	5.74	0.3	2.11e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.51	-7.56	-0.38	3.83e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.01e-19	Height;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.83	-0.3	1.25e-8	Total body bone mineral density;
LIHC	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.14	-10.24	-0.48	1.26e-21	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.67	13.28	0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.33	7.65	0.38	2.1e-13	Blood metabolite ratios;
LIHC	cis	rs6066825	0.554	rs4809711	chr20:47235811	T/C	cg18078177	chr20:47281410	PREX1	0.48	8.01	0.4	1.84e-14	Colorectal cancer;
LIHC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02985541	chr2:219472218	PLCD4	0.46	8.79	0.43	7.39e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.68	-0.62	3.69e-38	Electrocardiographic conduction measures;
LIHC	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.37	-0.33	6.1e-10	Breast cancer;
LIHC	cis	rs10792665	0.512	rs7112902	chr11:82589761	G/T	cg24227371	chr11:82718527	RAB30	-0.28	-6.58	-0.34	1.78e-10	Obesity-related traits;
LIHC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	20.88	0.75	5.2e-63	Smoking behavior;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.8	12.43	0.56	1.56e-29	Longevity;
LIHC	cis	rs244293	0.868	rs171510	chr17:53211527	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22879676	chr17:81009871	B3GNTL1	0.51	7.43	0.37	8.89e-13	Lung function (FEV1/FVC);
LIHC	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg20991723	chr1:152506922	NA	0.52	8.81	0.43	6.54e-17	Hair morphology;
LIHC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.33	0.37	1.64e-12	Airflow obstruction;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2273156	1.000	rs12050447	chr14:35461965	A/G	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.52	5.72	0.3	2.33e-8	Type 1 diabetes nephropathy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04139300	chr20:40247070	CHD6	0.45	6.7	0.34	8.59e-11	Cognitive function;
LIHC	cis	rs9473924	0.505	rs7756058	chr6:50904438	G/A	cg14470998	chr6:50812995	TFAP2B	0.93	10.85	0.51	9.2e-24	Body mass index;
LIHC	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	1.03	7.8	0.39	7.67e-14	Cannabis dependence symptom count;
LIHC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs2029362	0.611	rs10835215	chr11:27739949	C/T	cg18117895	chr11:27722066	BDNF	-0.4	-5.94	-0.31	6.85e-9	Total body bone mineral density;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg22018329	chr19:3116716	GNA11	0.39	6.16	0.32	2e-9	Oropharynx cancer;
LIHC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2637030	0.501	rs375956	chr5:52883715	C/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.7	0.65	3.28e-42	Lymphocyte percentage of white cells;
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.74	-8.78	-0.43	8.25e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11809123	chr19:1584870	MBD3	0.44	6.38	0.33	5.75e-10	Longevity;
LIHC	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.45	7.33	0.37	1.64e-12	Corneal astigmatism;
LIHC	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.6	-0.59	5.87e-34	Coffee consumption (cups per day);
LIHC	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.29	-0.41	2.53e-15	Vitamin D levels;
LIHC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.46	0.37	7.15e-13	Bipolar disorder;
LIHC	cis	rs988712	0.672	rs36029218	chr11:27648371	A/T	cg18117895	chr11:27722066	BDNF	0.45	6.2	0.32	1.63e-9	Obesity;
LIHC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg19774624	chr17:42201019	HDAC5	0.43	5.95	0.31	6.48e-9	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.38	0.45	9.52e-19	IgG glycosylation;
LIHC	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.32	-8.71	-0.43	1.34e-16	Intelligence;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16221841	chr14:77279127	ANGEL1	-0.46	-6.11	-0.31	2.65e-9	Systolic blood pressure;
LIHC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.82	-9.79	-0.47	4.15e-20	Mean platelet volume;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05533552	chr11:34074141	CAPRIN1	-0.48	-6.29	-0.32	9.91e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7129220	0.545	rs61520995	chr11:10139467	C/T	cg01453529	chr11:10209919	SBF2	-0.37	-6.69	-0.34	9.33e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.53	-0.42	4.71e-16	Type 2 diabetes;
LIHC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.57	6.35	0.32	6.75e-10	Axial length;
LIHC	cis	rs1434579	0.897	rs2037903	chr19:44945136	G/A	cg15540054	chr19:45004280	ZNF180	0.56	7.85	0.39	5.43e-14	Tuberculosis;
LIHC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg05590025	chr7:65112418	INTS4L2	-0.53	-5.75	-0.3	2.01e-8	Diabetic kidney disease;
LIHC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.71	0.5	2.81e-23	Alzheimer's disease;
LIHC	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.62	-9.96	-0.47	1.1e-20	Obesity-related traits;
LIHC	cis	rs16958440	0.708	rs62096477	chr18:44662310	G/A	cg17192377	chr18:44677553	HDHD2	0.51	6.36	0.33	6.31e-10	Sitting height ratio;
LIHC	cis	rs2033908	0.620	rs1992335	chr11:12851717	A/C	cg25843174	chr11:12811716	TEAD1	-0.31	-7.18	-0.36	4.41e-12	Sitting height ratio;
LIHC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.0	-0.31	5.09e-9	Blood metabolite levels;
LIHC	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.38	-7.03	-0.36	1.14e-11	Height;
LIHC	trans	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.6	0.34	1.61e-10	Coronary artery calcification;
LIHC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.63	10.34	0.49	5.59e-22	Smoking initiation;
LIHC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.63	9.59	0.46	1.9e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-11.89	-0.54	1.56e-27	Extrinsic epigenetic age acceleration;
LIHC	trans	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg17675199	chr6:35436792	RPL10A	-0.45	-9.33	-0.45	1.39e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg02640540	chr1:67518911	SLC35D1	0.44	6.89	0.35	2.65e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.4	6.46	0.33	3.53e-10	Red blood cell count;
LIHC	cis	rs6450176	0.564	rs255759	chr5:53328549	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.5	-0.59	1.4e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-6.71	-0.34	8.31e-11	Alzheimer's disease;
LIHC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	1.01	11.92	0.54	1.29e-27	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.53	7.46	0.37	7.2e-13	Prostate cancer;
LIHC	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg16000393	chr3:195602323	TNK2	-0.42	-6.88	-0.35	2.95e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.54	-6.53	-0.33	2.4e-10	Breast cancer;
LIHC	trans	rs9914544	0.545	rs8069826	chr17:18765490	G/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.68e-10	Educational attainment (years of education);
LIHC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.85	-0.43	4.86e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg19645103	chr12:69753606	YEATS4	-0.39	-5.87	-0.3	1.06e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg16970926	chr12:29381810	FAR2	0.29	6.09	0.31	3.12e-9	QT interval;
LIHC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg05973401	chr12:123451056	ABCB9	-0.41	-6.13	-0.31	2.4e-9	Platelet count;
LIHC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.77	0.39	9.29e-14	Lymphocyte counts;
LIHC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.65	0.34	1.15e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg19318889	chr4:1322082	MAEA	0.4	6.62	0.34	1.37e-10	Obesity-related traits;
LIHC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg09182678	chr22:50328711	NA	-0.43	-6.17	-0.32	1.98e-9	Schizophrenia;
LIHC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.7	10.01	0.48	7.66e-21	Monocyte percentage of white cells;
LIHC	cis	rs922107	0.713	rs10922669	chr1:90043240	A/G	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.6	-0.38	2.96e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.27e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.82	-0.39	6.67e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.48	8.2	0.41	4.97e-15	Mean corpuscular volume;
LIHC	cis	rs7364180	0.502	rs7290134	chr22:42321251	A/G	cg04733989	chr22:42467013	NAGA	-0.52	-6.01	-0.31	4.67e-9	Alzheimer's disease biomarkers;
LIHC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg15848620	chr12:58087721	OS9	-0.59	-8.1	-0.4	9.68e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.65	7.82	0.39	6.73e-14	Heart rate;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19855366	chr13:111267979	CARKD	0.41	6.2	0.32	1.6e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg17724175	chr1:150552817	MCL1	0.38	7.48	0.38	6.25e-13	Melanoma;
LIHC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.62	0.34	1.36e-10	Type 2 diabetes;
LIHC	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg06634786	chr22:41940651	POLR3H	-0.65	-7.27	-0.37	2.43e-12	Vitiligo;
LIHC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.04	0.31	4.13e-9	Tonsillectomy;
LIHC	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.51	7.57	0.38	3.53e-13	Corneal astigmatism;
LIHC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.62	-10.83	-0.51	1.11e-23	Total body bone mineral density;
LIHC	cis	rs4700695	0.764	rs27701	chr5:65377526	G/C	cg21114390	chr5:65439923	SFRS12	-0.5	-6.83	-0.35	3.91e-11	Facial morphology (factor 19);
LIHC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.71	-0.3	2.45e-8	Bipolar disorder;
LIHC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.53	-8.17	-0.4	6.25e-15	Diastolic blood pressure;
LIHC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.26	-10.72	-0.5	2.66e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.77	12.78	0.57	7.61e-31	Colorectal cancer;
LIHC	trans	rs13381277	0.850	rs1110157	chr18:74330649	G/A	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.34	-0.32	7.27e-10	Dental caries;
LIHC	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.73	12.54	0.56	6.38e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg08132940	chr7:1081526	C7orf50	-0.74	-6.36	-0.33	6.5e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg00977110	chr5:151150581	G3BP1	0.56	7.12	0.36	6.6e-12	Preschool internalizing problems;
LIHC	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.48	8.14	0.4	7.25e-15	Schizophrenia;
LIHC	cis	rs2279817	0.780	rs12737453	chr1:18006107	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.73	-0.39	1.2e-13	Neuroticism;
LIHC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.81	-14.26	-0.61	1.52e-36	Aortic root size;
LIHC	cis	rs4716602	0.596	rs1996994	chr7:156159694	A/G	cg16983916	chr7:156159713	NA	0.32	5.74	0.3	2.07e-8	Anti-saccade response;
LIHC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.84	-13.48	-0.59	1.61e-33	Colorectal cancer;
LIHC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg26692224	chr17:62915920	LRRC37A3	-0.68	-6.35	-0.32	6.79e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg11861562	chr11:117069780	TAGLN	0.37	5.85	0.3	1.14e-8	Blood protein levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18113084	chr3:5019494	NA	0.49	6.05	0.31	3.75e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17467752	chr17:38218738	THRA	0.4	6.42	0.33	4.51e-10	Asthma;
LIHC	cis	rs6429082	0.509	rs2246554	chr1:235520176	A/G	cg26050004	chr1:235667680	B3GALNT2	0.43	6.38	0.33	5.76e-10	Adiposity;
LIHC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.6	-0.5	7.13e-23	Response to antipsychotic treatment;
LIHC	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-14.0	-0.6	1.55e-35	Lymphocyte percentage of white cells;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.93	-0.35	2.08e-11	Response to antipsychotic treatment;
LIHC	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.49	7.28	0.37	2.36e-12	Thyroid stimulating hormone;
LIHC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-27.87	-0.83	5.05e-90	Myeloid white cell count;
LIHC	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg24069376	chr3:38537580	EXOG	0.43	7.71	0.38	1.37e-13	Electrocardiographic conduction measures;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10308682	chr20:5931622	MCM8;TRMT6	0.47	6.4	0.33	5.15e-10	Pancreatic cancer;
LIHC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.77	6.52	0.33	2.46e-10	Body mass index;
LIHC	cis	rs6449957	0.801	rs6449953	chr5:67456530	A/G	cg23036683	chr5:67512108	NA	0.43	6.07	0.31	3.4e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.81	13.18	0.58	2.24e-32	Chronic sinus infection;
LIHC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg16586182	chr3:47516702	SCAP	-0.58	-11.18	-0.52	6.16e-25	Colorectal cancer;
LIHC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.58	-9.16	-0.44	4.93e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.26	0.45	2.31e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg11952622	chr19:58962976	ZNF324B	0.47	7.12	0.36	6.27e-12	Uric acid clearance;
LIHC	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22509189	chr2:225307070	NA	-0.53	-7.04	-0.36	1.06e-11	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.43	-6.09	-0.31	3.06e-9	Blood protein levels;
LIHC	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg20332866	chr1:100678932	DBT	-0.36	-6.13	-0.31	2.48e-9	Pain;
LIHC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.44	6.46	0.33	3.67e-10	Gout;
LIHC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.98	0.51	3.15e-24	Personality dimensions;
LIHC	cis	rs9921222	0.521	rs9935268	chr16:381562	G/C	cg08923669	chr16:420230	MRPL28	-0.43	-5.73	-0.3	2.17e-8	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.35	-7.02	-0.36	1.17e-11	Colorectal cancer;
LIHC	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg06766960	chr11:133703094	NA	-0.53	-7.83	-0.39	6.35e-14	Childhood ear infection;
LIHC	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06544989	chr22:39130855	UNC84B	0.41	6.59	0.34	1.62e-10	Menopause (age at onset);
LIHC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg12365402	chr11:9010492	NRIP3	-0.24	-6.2	-0.32	1.65e-9	Hemoglobin concentration;
LIHC	trans	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04565464	chr8:145669602	NFKBIL2	0.4	6.69	0.34	9.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.41	-6.35	-0.32	6.9e-10	Testicular germ cell tumor;
LIHC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.7	6.58	0.34	1.76e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.99	-23.48	-0.79	2.71e-73	Prudent dietary pattern;
LIHC	cis	rs11229555	0.645	rs12289985	chr11:58185436	C/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8016982	0.662	rs2288498	chr14:81660710	T/C	cg01989461	chr14:81687754	GTF2A1	0.52	9.17	0.44	4.56e-18	Schizophrenia;
LIHC	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.43	9.13	0.44	5.95e-18	Coronary artery disease;
LIHC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg23485639	chr6:28045615	ZNF165	0.39	6.13	0.31	2.42e-9	Cardiac Troponin-T levels;
LIHC	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg09795085	chr6:101329169	ASCC3	0.46	6.64	0.34	1.26e-10	Neuroticism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21051989	chr6:90121833	RRAGD	0.5	6.58	0.34	1.73e-10	Lung function (FEV1/FVC);
LIHC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.43	7.51	0.38	5.1e-13	Dupuytren's disease;
LIHC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.73	0.39	1.19e-13	Lung cancer;
LIHC	cis	rs4919087	0.561	rs61861820	chr10:98998974	G/A	cg25902810	chr10:99078978	FRAT1	-0.53	-5.93	-0.31	7.23e-9	Monocyte count;
LIHC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.65	10.94	0.51	4.22e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.7	10.37	0.49	4.45e-22	Intelligence (multi-trait analysis);
LIHC	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.93	-19.29	-0.72	1.3e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.68	-0.34	9.87e-11	Height;
LIHC	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.4	7.77	0.39	9.14e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.43	6.86	0.35	3.26e-11	Diastolic blood pressure;
LIHC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.42	6.27	0.32	1.09e-9	Schizophrenia;
LIHC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg13385521	chr17:29058706	SUZ12P	0.57	5.76	0.3	1.83e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.37	-5.98	-0.31	5.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.46	-6.99	-0.35	1.43e-11	Cognitive function;
LIHC	cis	rs11958404	0.615	rs6884132	chr5:157437035	G/A	cg05962755	chr5:157440814	NA	0.61	7.67	0.38	1.77e-13	IgG glycosylation;
LIHC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.38	-11.72	-0.54	6.87e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg25894440	chr7:65020034	NA	0.55	6.55	0.33	2.17e-10	Diabetic kidney disease;
LIHC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.13	0.36	5.88e-12	Self-reported allergy;
LIHC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.77	7.77	0.39	9.57e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.69	-0.5	3.24e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs10508774	1.000	rs61299190	chr10:32859519	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-5.79	-0.3	1.63e-8	Renal function-related traits (BUN);
LIHC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg16836995	chr17:43662488	NA	-0.69	-7.24	-0.36	3.06e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.64	-7.89	-0.39	4e-14	QRS complex (12-leadsum);
LIHC	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg16099169	chr2:106886729	NA	0.75	8.16	0.4	6.3e-15	Facial morphology (factor 23);
LIHC	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.14	0.61	4.64e-36	Bipolar disorder;
LIHC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	13.14	0.58	3.32e-32	Lung cancer in ever smokers;
LIHC	cis	rs2273156	1.000	rs35797365	chr14:35452759	A/G	cg16230307	chr14:35515116	FAM177A1	-0.4	-5.95	-0.31	6.57e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	8.45	0.42	8.72e-16	Body mass index;
LIHC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.37	5.94	0.31	7.21e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.39	-6.08	-0.31	3.2e-9	Cognitive function;
LIHC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs972578	0.967	rs2068944	chr22:43356442	T/G	cg01576275	chr22:43409880	NA	-0.33	-5.76	-0.3	1.87e-8	Mean platelet volume;
LIHC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.47	6.14	0.32	2.27e-9	Initial pursuit acceleration;
LIHC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg16586182	chr3:47516702	SCAP	-0.58	-11.23	-0.52	4.06e-25	Colorectal cancer;
LIHC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.84	-0.3	1.19e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.84	-14.68	-0.62	3.56e-38	Coronary artery disease;
LIHC	cis	rs4517514	0.509	rs12276499	chr11:89855565	C/G	cg05041596	chr11:89867385	NAALAD2	0.41	6.37	0.33	5.92e-10	Trans fatty acid levels;
LIHC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg18478394	chr8:109455254	TTC35	0.44	7.67	0.38	1.76e-13	Dupuytren's disease;
LIHC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg16586182	chr3:47516702	SCAP	-0.52	-9.36	-0.45	1.09e-18	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.49	-0.33	2.94e-10	Diabetic kidney disease;
LIHC	cis	rs11229555	0.645	rs11601296	chr11:58423297	A/G	cg15696309	chr11:58395628	NA	-0.68	-6.4	-0.33	5.04e-10	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7095607	0.560	rs2634709	chr10:69925789	C/T	cg18986048	chr10:69913749	MYPN	0.48	7.11	0.36	6.77e-12	Lung function (FVC);
LIHC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.04	-0.51	1.98e-24	Crohn's disease;
LIHC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg12751644	chr20:60527061	NA	-0.37	-6.06	-0.31	3.59e-9	Body mass index;
LIHC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.57	8.79	0.43	7.36e-17	Corneal astigmatism;
LIHC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.34	5.94	0.31	7.21e-9	Calcium levels;
LIHC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.38	-6.66	-0.34	1.08e-10	Aortic root size;
LIHC	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.23	6.36	0.33	6.32e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.48	-0.33	3.21e-10	Mean corpuscular volume;
LIHC	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg16394018	chr11:14927549	NA	0.4	5.72	0.3	2.27e-8	Vitamin D levels;
LIHC	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.23	-5.8	-0.3	1.53e-8	Schizophrenia;
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg00204748	chr12:29376779	FAR2	0.43	8.06	0.4	1.33e-14	QT interval;
LIHC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg22777020	chr22:31556080	RNF185	-0.55	-6.35	-0.32	6.77e-10	Colorectal cancer;
LIHC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.66	-0.34	1.1e-10	Bipolar disorder;
LIHC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg11204139	chr17:3907470	NA	0.58	6.73	0.34	7.2e-11	Type 2 diabetes;
LIHC	cis	rs7872515	0.887	rs7029539	chr9:94864322	A/G	cg01248375	chr9:94877805	SPTLC1	0.54	8.16	0.4	6.26e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.45	6.06	0.31	3.66e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.6	0.46	1.72e-19	Electroencephalogram traits;
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.76	-9.13	-0.44	5.91e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	8.87	0.43	4.13e-17	Lung cancer in ever smokers;
LIHC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg23625390	chr15:77176239	SCAPER	-0.35	-6.15	-0.32	2.2e-9	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.92	0.3	7.88e-9	Menopause (age at onset);
LIHC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.75	7.82	0.39	6.76e-14	Schizophrenia;
LIHC	cis	rs16958440	1.000	rs12326600	chr18:44596497	C/T	cg17192377	chr18:44677553	HDHD2	0.57	6.11	0.31	2.72e-9	Sitting height ratio;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24258806	chr11:14380041	RRAS2	0.49	6.53	0.33	2.42e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.66	-0.53	1.09e-26	Platelet distribution width;
LIHC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.23	-5.78	-0.3	1.71e-8	Schizophrenia;
LIHC	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.74	8.23	0.41	3.88e-15	Height;
LIHC	cis	rs6722750	0.783	rs4671550	chr2:64389314	T/A	cg22352474	chr2:64371530	PELI1	0.47	6.86	0.35	3.22e-11	Neuroticism;
LIHC	cis	rs75064307	0.798	rs2290601	chr3:108112760	C/T	cg03329597	chr3:108125523	MYH15	0.5	6.68	0.34	9.97e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.84	-0.35	3.74e-11	Alzheimer's disease (late onset);
LIHC	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-8.09	-0.4	1.03e-14	Vitamin D levels;
LIHC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.4	6.44	0.33	3.96e-10	Red blood cell count;
LIHC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.48	-0.62	2.14e-37	Electrocardiographic conduction measures;
LIHC	cis	rs12086130	0.773	rs72906827	chr1:51482411	C/G	cg07174182	chr1:51127561	FAF1	-0.81	-9.0	-0.44	1.62e-17	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs7945718	0.621	rs6485977	chr11:12678387	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.87	0.39	4.59e-14	Educational attainment (years of education);
LIHC	cis	rs7429990	0.932	rs2361684	chr3:48152618	G/C	cg11946769	chr3:48343235	NME6	-0.47	-6.24	-0.32	1.28e-9	Educational attainment (years of education);
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	0.59	8.71	0.43	1.31e-16	Prudent dietary pattern;
LIHC	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg05010058	chr2:65284262	CEP68	0.4	6.82	0.35	4.1e-11	Pulse pressure;
LIHC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.57	7.38	0.37	1.2e-12	Morning vs. evening chronotype;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.54	-7.37	-0.37	1.25e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.58	10.82	0.5	1.17e-23	Leprosy;
LIHC	cis	rs244293	0.760	rs12952166	chr17:53005586	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.53	-0.33	2.32e-10	Menarche (age at onset);
LIHC	cis	rs9534288	0.552	rs2840241	chr13:46658903	T/G	cg15192986	chr13:46630673	CPB2	-0.44	-6.38	-0.33	5.79e-10	Blood protein levels;
LIHC	cis	rs911119	0.955	rs6048930	chr20:23592492	T/C	cg16589663	chr20:23618590	CST3	0.71	7.3	0.37	2.07e-12	Chronic kidney disease;
LIHC	cis	rs34638657	0.536	rs2967327	chr16:82188657	C/T	cg07918374	chr16:82182319	MPHOSPH6	0.32	6.11	0.31	2.7e-9	Lung adenocarcinoma;
LIHC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.24	0.41	3.69e-15	Height;
LIHC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.59	9.37	0.45	9.94e-19	HDL cholesterol;
LIHC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.29	-5.79	-0.3	1.58e-8	Body mass index;
LIHC	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.56	6.64	0.34	1.27e-10	Mammographic density (dense area);
LIHC	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg11783602	chr8:55087084	NA	-0.31	-6.21	-0.32	1.53e-9	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05895930	chr17:43212841	ACBD4	-0.53	-6.16	-0.32	2.08e-9	Systolic blood pressure;
LIHC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg07636037	chr3:49044803	WDR6	-0.81	-8.4	-0.41	1.2e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.91	-18.65	-0.71	4.85e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.66	11.35	0.52	1.44e-25	Type 2 diabetes;
LIHC	cis	rs11212737	0.765	rs2624144	chr11:108520134	A/T	cg22776369	chr11:108536276	DDX10	0.37	6.2	0.32	1.62e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05564831	chr3:52568323	NT5DC2	0.34	5.81	0.3	1.42e-8	Bipolar disorder;
LIHC	cis	rs10845606	0.505	rs10845604	chr12:12832734	A/G	cg04607235	chr12:12878440	APOLD1	0.43	6.24	0.32	1.31e-9	Systemic lupus erythematosus;
LIHC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-6.0	-0.31	5.12e-9	Alzheimer's disease (late onset);
LIHC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg20684491	chr1:25596433	NA	0.29	5.92	0.3	7.81e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.48	6.43	0.33	4.24e-10	Coronary artery disease;
LIHC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg27478167	chr7:817139	HEATR2	-0.4	-5.79	-0.3	1.56e-8	Cerebrospinal P-tau181p levels;
LIHC	trans	rs2565065	0.614	rs2241654	chr8:27293989	G/A	cg05556461	chr5:71018061	NA	0.3	6.1	0.31	2.83e-9	Schizophrenia;
LIHC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.88	-0.35	2.88e-11	Coronary artery disease;
LIHC	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	0.79	7.91	0.39	3.58e-14	Arsenic metabolism;
LIHC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.18	-0.48	2e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.59	-11.46	-0.53	6.21e-26	Asthma;
LIHC	trans	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.78e-9	Ulcerative colitis;
LIHC	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs62179067	0.708	rs7588765	chr2:179932838	T/G	cg20701897	chr2:179586761	TTN	0.49	5.83	0.3	1.32e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs11622475	0.580	rs36026329	chr14:104351661	T/A	cg12183467	chr14:104352244	NA	-0.5	-7.3	-0.37	2.01e-12	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.2	0.36	3.93e-12	Diabetic kidney disease;
LIHC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.45	-7.31	-0.37	1.95e-12	Fibrinogen levels;
LIHC	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg09795085	chr6:101329169	ASCC3	-0.47	-6.79	-0.34	4.83e-11	Neuroticism;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.7	0.62	3e-38	Prudent dietary pattern;
LIHC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.1	-13.13	-0.58	3.71e-32	Vitiligo;
LIHC	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16684958	chr7:75615977	POR	0.51	8.61	0.42	2.78e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.82	0.35	4.07e-11	Gut microbiome composition (summer);
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.58	10.12	0.48	3.02e-21	Longevity;Endometriosis;
LIHC	trans	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg19894588	chr14:64061835	NA	-0.46	-7.35	-0.37	1.46e-12	Fat distribution (HIV);
LIHC	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.71	0.5	2.76e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.5	-5.79	-0.3	1.6e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LIHC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	17.35	0.68	8.06e-49	Nonalcoholic fatty liver disease;
LIHC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.76	-11.66	-0.53	1.11e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6977660	1.000	rs5017196	chr7:19819983	T/C	cg07541023	chr7:19748670	TWISTNB	0.36	5.74	0.3	2.1e-8	Thyroid stimulating hormone;
LIHC	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	1.12	13.19	0.58	2.16e-32	Eosinophil percentage of granulocytes;
LIHC	cis	rs75908454	1.000	rs75667803	chr6:169998285	G/A	cg19338460	chr6:170058176	WDR27	-0.91	-8.79	-0.43	7.39e-17	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.94	17.57	0.69	1.1e-49	Menopause (age at onset);
LIHC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-8.41	-0.41	1.09e-15	Body mass index;
LIHC	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.2	-0.36	3.74e-12	Metabolite levels (Pyroglutamine);
LIHC	trans	rs10050311	0.790	rs61651372	chr4:87834056	C/T	cg04118154	chr1:45140072	C1orf228;TMEM53	-0.48	-6.18	-0.32	1.81e-9	Insulin-related traits;
LIHC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.64	-8.43	-0.41	9.73e-16	Diastolic blood pressure;
LIHC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg10820045	chr2:198174542	NA	0.52	8.68	0.42	1.7e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs74181299	0.890	rs2540950	chr2:65279223	C/T	cg05010058	chr2:65284262	CEP68	0.41	6.86	0.35	3.18e-11	Pulse pressure;
LIHC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg22563815	chr15:78856949	CHRNA5	-0.28	-5.91	-0.3	8.26e-9	Sudden cardiac arrest;
LIHC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.44	-6.65	-0.34	1.19e-10	Cognitive function;
LIHC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.26	-6.76	-0.34	5.79e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg12698662	chr3:15914712	MIR563	-0.36	-6.66	-0.34	1.1e-10	Mean platelet volume;
LIHC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg13944838	chr5:179740914	GFPT2	-0.55	-7.64	-0.38	2.14e-13	Height;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.56	8.51	0.42	5.68e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg11764359	chr7:65958608	NA	0.59	6.17	0.32	1.98e-9	Diabetic kidney disease;
LIHC	cis	rs748404	0.578	rs2012467	chr15:43690565	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	9.27	0.45	2.12e-18	Lung cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07335843	chr2:133030691	NA	0.32	6.59	0.34	1.68e-10	Bilirubin levels;
LIHC	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.5	-8.84	-0.43	5.05e-17	Uric acid levels;
LIHC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.35	0.32	7.02e-10	Schizophrenia;
LIHC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg19016816	chr7:1267987	NA	0.27	5.78	0.3	1.72e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.51	5.95	0.31	6.58e-9	Pancreatic cancer;
LIHC	cis	rs903552	1.000	rs12908406	chr15:102004046	C/T	cg00659931	chr15:102010125	PCSK6	-0.48	-6.52	-0.33	2.46e-10	Diabetic kidney disease;
LIHC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.16	0.32	2.07e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.5	-7.39	-0.37	1.11e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.95	-12.68	-0.57	1.85e-30	Schizophrenia;
LIHC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg17724175	chr1:150552817	MCL1	-0.38	-7.86	-0.39	5.21e-14	Tonsillectomy;
LIHC	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.71	-0.34	8.07e-11	Blood pressure;
LIHC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.51	-0.53	3.76e-26	Coronary artery disease;
LIHC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.54	7.55	0.38	3.92e-13	Pulse pressure;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg12331332	chr10:115439884	CASP7	0.45	6.36	0.33	6.49e-10	Alopecia areata;
LIHC	cis	rs4654748	0.507	rs10799702	chr1:21821880	A/G	cg20417195	chr1:21767127	NBPF3	-0.41	-5.92	-0.31	7.71e-9	Folate pathway vitamin levels;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg03414471	chr3:11600889	VGLL4	0.37	6.06	0.31	3.57e-9	Oropharynx cancer;
LIHC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.79	0.69	1.4e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.35	-5.93	-0.31	7.35e-9	Cisplatin-induced ototoxicity;
LIHC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-7.31	-0.37	1.88e-12	Initial pursuit acceleration;
LIHC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17691542	chr6:26056736	HIST1H1C	0.65	7.19	0.36	4.2e-12	Iron status biomarkers;
LIHC	cis	rs1816752	0.646	rs2862905	chr13:25059280	G/A	cg22771759	chr13:24902376	NA	-0.27	-5.74	-0.3	2.04e-8	Obesity-related traits;
LIHC	cis	rs2637266	0.714	rs1965156	chr10:78450559	G/A	cg18941641	chr10:78392320	NA	0.27	5.93	0.31	7.46e-9	Pulmonary function;
LIHC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.72	13.24	0.58	1.37e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.58	0.53	2.23e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.61	9.47	0.46	4.75e-19	Height;
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.79	-9.59	-0.46	1.84e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.58	9.54	0.46	2.7e-19	Resting heart rate;
LIHC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.67	-14.04	-0.6	1.12e-35	Sense of smell;
LIHC	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.55	-8.7	-0.43	1.4e-16	Rheumatoid arthritis;
LIHC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.62	-8.73	-0.43	1.12e-16	Blood metabolite levels;
LIHC	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg05163923	chr11:71159392	DHCR7	-0.56	-6.9	-0.35	2.57e-11	Vitamin D levels;
LIHC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg25801113	chr15:45476975	SHF	0.38	6.39	0.33	5.42e-10	Uric acid levels;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg20090690	chr10:134436459	INPP5A	-0.44	-5.94	-0.31	6.98e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	13.94	0.6	2.81e-35	Prudent dietary pattern;
LIHC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.88	0.39	4.45e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg03342759	chr3:160939853	NMD3	-0.58	-8.0	-0.4	1.94e-14	Morning vs. evening chronotype;
LIHC	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.18	9.36	0.45	1.08e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg04824913	chr4:887549	GAK	0.53	8.18	0.4	5.72e-15	Systemic sclerosis;
LIHC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.31	-0.32	8.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg00091569	chr3:40428383	ENTPD3	-0.35	-6.09	-0.31	2.96e-9	Renal cell carcinoma;
LIHC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.3	0.32	9.08e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-8.22	-0.41	4.32e-15	Schizophrenia;
LIHC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.32	-0.37	1.78e-12	Chronic sinus infection;
LIHC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.44	0.37	8.24e-13	Bone mineral density;
LIHC	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.49	-5.8	-0.3	1.51e-8	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg20607798	chr8:58055168	NA	0.54	6.4	0.33	5.15e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg27205649	chr11:78285834	NARS2	-0.38	-5.92	-0.3	7.93e-9	Alzheimer's disease (survival time);
LIHC	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.41	6.08	0.31	3.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg19539972	chr4:7069911	GRPEL1	0.64	9.54	0.46	2.88e-19	Monocyte percentage of white cells;
LIHC	cis	rs35160687	0.623	rs4832263	chr2:86485157	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.36	5.74	0.3	2.07e-8	Night sleep phenotypes;
LIHC	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.78	-0.3	1.66e-8	Heart rate;
LIHC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg16479474	chr6:28041457	NA	0.46	6.68	0.34	9.76e-11	Depression;
LIHC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.29	-5.83	-0.3	1.26e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.61	-0.69	7.12e-50	Body mass index;
LIHC	cis	rs17106184	1.000	rs12064411	chr1:51220291	A/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.86	-0.35	3.32e-11	Type 2 diabetes;
LIHC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.33	0.45	1.39e-18	Platelet count;
LIHC	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg25363559	chr8:143086065	NA	-0.24	-7.55	-0.38	3.99e-13	Amyotrophic lateral sclerosis;
LIHC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.54	-11.14	-0.52	8.75e-25	Tonsillectomy;
LIHC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.26	0.52	3.09e-25	Colorectal cancer;
LIHC	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.68	11.18	0.52	6.33e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7914558	0.646	rs4363528	chr10:104655515	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-7.38	-0.37	1.22e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14166365	chr9:126165469	DENND1A;MIR601	0.45	7.7	0.38	1.52e-13	Longevity;
LIHC	cis	rs9543976	1.000	rs73223968	chr13:76141721	C/A	cg01531495	chr13:76123901	UCHL3	-0.52	-6.16	-0.32	1.99e-9	Diabetic retinopathy;
LIHC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.43	6.78	0.34	5.3e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg18867708	chr6:26865862	GUSBL1	0.51	7.78	0.39	8.55e-14	Schizophrenia;
LIHC	cis	rs588177	1.000	rs588177	chr11:64024056	C/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.46	-6.83	-0.35	3.83e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	0.64	6.16	0.32	2.05e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg06565975	chr8:143823917	SLURP1	0.34	6.76	0.34	6.05e-11	Urinary tract infection frequency;
LIHC	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg21531657	chr3:10005747	TMEM111	0.4	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.39	-8.26	-0.41	3.19e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.73	13.35	0.59	5.11e-33	Blood protein levels;
LIHC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.98	0.51	3.15e-24	Personality dimensions;
LIHC	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.5	7.51	0.38	5.21e-13	Height;
LIHC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg10621924	chr7:39171070	POU6F2	0.43	6.7	0.34	8.71e-11	IgG glycosylation;
LIHC	cis	rs56146971	0.763	rs75059313	chr14:91847559	T/A	cg16433844	chr14:91963127	SMEK1	-0.56	-5.83	-0.3	1.25e-8	Alzheimer disease and age of onset;
LIHC	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.51	9.66	0.46	1.08e-19	Testicular germ cell tumor;
LIHC	cis	rs116248771	0.739	rs16829122	chr3:158312667	T/C	cg16708174	chr3:158430962	RARRES1	0.48	6.29	0.32	9.6e-10	diarrhoeal disease at age 2;
LIHC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.42e-23	Mean corpuscular volume;
LIHC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-11.91	-0.54	1.31e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.53	7.13	0.36	6.01e-12	Bone properties (heel);
LIHC	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg09795085	chr6:101329169	ASCC3	-0.52	-7.14	-0.36	5.5e-12	Neuroticism;
LIHC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.14	0.61	4.78e-36	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.96	0.35	1.73e-11	Diabetic kidney disease;
LIHC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.82	-8.91	-0.43	3.12e-17	Vitiligo;
LIHC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.68	13.61	0.59	5.27e-34	Reticulocyte fraction of red cells;
LIHC	cis	rs2108622	0.727	rs2158511	chr19:15986647	C/T	cg13772218	chr19:15982569	NA	0.36	7.5	0.38	5.71e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.41	-8.39	-0.41	1.33e-15	Obesity-related traits;
LIHC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.36	5.97	0.31	5.79e-9	Monobrow;
LIHC	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg00042356	chr1:8021962	PARK7	0.88	9.23	0.45	2.97e-18	Inflammatory bowel disease;
LIHC	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.07	0.36	8.67e-12	Exhaled nitric oxide output;
LIHC	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.52	7.68	0.38	1.68e-13	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.41	8.21	0.41	4.71e-15	Renal cell carcinoma;
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06420487	chr17:61919686	SMARCD2	0.45	6.02	0.31	4.5e-9	Height;
LIHC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg18357526	chr6:26021779	HIST1H4A	0.6	8.47	0.42	7.14e-16	Blood metabolite levels;
LIHC	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.62	11.95	0.54	9.32e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7872515	0.536	rs10820938	chr9:94841980	C/T	cg01248375	chr9:94877805	SPTLC1	0.56	6.63	0.34	1.33e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13332130	chr19:41284234	RAB4B	-0.49	-6.4	-0.33	5.1e-10	Systolic blood pressure;
LIHC	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.47	-0.37	6.61e-13	Response to antipsychotic treatment;
LIHC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg14092571	chr14:90743983	NA	0.39	6.22	0.32	1.45e-9	Mortality in heart failure;
LIHC	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.86	-17.65	-0.69	5.23e-50	Testicular germ cell tumor;
LIHC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.27	-0.32	1.11e-9	IgG glycosylation;
LIHC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg20195005	chr22:42527684	CYP2D6	0.31	5.88	0.3	9.93e-9	Birth weight;
LIHC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.35	-6.22	-0.32	1.47e-9	Platelet distribution width;
LIHC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.51	-8.56	-0.42	3.8e-16	Bipolar disorder;
LIHC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	8.12e-10	Red blood cell count;
LIHC	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg06935464	chr4:38784597	TLR10	0.44	6.61	0.34	1.49e-10	Breast cancer;
LIHC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.69	10.45	0.49	2.36e-22	Neutrophil percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14257814	chr17:30470253	RHOT1	0.47	6.04	0.31	3.94e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	7.95	0.4	2.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg27438040	chr6:136611664	BCLAF1	-0.44	-6.41	-0.33	4.88e-10	Eotaxin levels;
LIHC	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.56	7.59	0.38	3.08e-13	Eotaxin levels;
LIHC	cis	rs9309473	1.000	rs6546835	chr2:73664715	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-7.05	-0.36	9.96e-12	Metabolite levels;
LIHC	cis	rs2710642	0.564	rs7583570	chr2:62852926	C/T	cg17519650	chr2:63277830	OTX1	0.43	6.89	0.35	2.65e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2033908	0.558	rs6486064	chr11:12869509	T/C	cg25843174	chr11:12811716	TEAD1	-0.31	-7.11	-0.36	6.71e-12	Sitting height ratio;
LIHC	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.27	-0.41	3.09e-15	Putamen volume;
LIHC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.77	-11.23	-0.52	3.94e-25	Coronary artery disease;
LIHC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg23205692	chr1:25664452	TMEM50A	0.36	5.8	0.3	1.5e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs9921222	0.597	rs3848369	chr16:415078	C/T	cg08923669	chr16:420230	MRPL28	-0.43	-6.17	-0.32	1.94e-9	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.88	-16.9	-0.67	5.32e-47	Height;
LIHC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24973585	chr14:103851607	MARK3	-0.43	-6.13	-0.31	2.48e-9	Pancreatic cancer;
LIHC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.49e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.99	16.98	0.68	2.52e-47	Cognitive ability;
LIHC	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.67	0.34	1.06e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.78	-11.2	-0.52	5.15e-25	Glomerular filtration rate (creatinine);
LIHC	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.46	-7.08	-0.36	8.29e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	cis	rs11229555	0.645	rs11229457	chr11:58207203	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.32	-6.99	-0.35	1.45e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.92	6.89	0.35	2.76e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.35	0.37	1.48e-12	Monocyte percentage of white cells;
LIHC	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.42	-6.28	-0.32	1.03e-9	Diastolic blood pressure;
LIHC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.58	8.51	0.42	5.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.609	rs567851	chr11:71592419	G/C	cg26138937	chr11:71823887	C11orf51	1.04	8.4	0.41	1.17e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs9649465	0.934	rs718781	chr7:123313573	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.08	-0.4	1.09e-14	Migraine;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.7.38331565R	chr7:38365040	NA	-0.5	-6.5	-0.33	2.79e-10	Hepatitis;
LIHC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.05	14.07	0.61	8.82e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg01858014	chr14:56050164	KTN1	-0.64	-7.01	-0.35	1.29e-11	Putamen volume;
LIHC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.36	9.43	0.45	6.41e-19	Asthma (sex interaction);
LIHC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.46	1.47e-19	Bladder cancer;
LIHC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.57	-0.59	7.14e-34	Ulcerative colitis;
LIHC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.34e-17	Gut microbiome composition (summer);
LIHC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.22	-19.21	-0.72	2.69e-56	Type 1 diabetes nephropathy;
LIHC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg05501817	chr11:14380813	RRAS2	-0.43	-5.87	-0.3	1.03e-8	Sense of smell;
LIHC	cis	rs3812111	0.586	rs7763110	chr6:116456335	G/A	cg08036074	chr6:116424633	NT5DC1	-0.5	-8.57	-0.42	3.7e-16	Age-related macular degeneration;
LIHC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.86	-0.35	3.23e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg17764715	chr19:33622953	WDR88	0.4	5.72	0.3	2.29e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.18	-0.32	1.87e-9	Mean corpuscular volume;
LIHC	cis	rs8062405	0.625	rs8060365	chr16:28911309	C/A	cg00204512	chr16:28754710	NA	-0.38	-6.51	-0.33	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.44	-7.52	-0.38	4.91e-13	Dementia with Lewy bodies;
LIHC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.83	-0.47	3.04e-20	Tonsillectomy;
LIHC	cis	rs6504950	0.800	rs9916547	chr17:53006890	G/A	cg10237252	chr17:52977213	TOM1L1	-0.34	-5.99	-0.31	5.22e-9	Breast cancer;
LIHC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.33	-6.57	-0.33	1.9e-10	DNA methylation (variation);
LIHC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.64	10.53	0.49	1.19e-22	Platelet count;
LIHC	cis	rs10792665	0.844	rs7125791	chr11:82680505	G/A	cg24227371	chr11:82718527	RAB30	-0.31	-7.51	-0.38	5.14e-13	Obesity-related traits;
LIHC	cis	rs8067354	0.540	rs1051424	chr17:58024324	A/G	cg13753209	chr17:57696993	CLTC	0.72	10.55	0.5	1.02e-22	Hemoglobin concentration;
LIHC	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.53	8.57	0.42	3.54e-16	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.35	-7.2	-0.36	3.82e-12	Renal cell carcinoma;
LIHC	cis	rs2412488	0.962	rs1531748	chr4:54265333	A/G	cg22241045	chr4:54363911	LNX1	-0.47	-7.52	-0.38	4.91e-13	DNA methylation (variation);
LIHC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg19682013	chr15:45996608	NA	0.4	7.12	0.36	6.25e-12	Waist circumference;Weight;
LIHC	cis	rs11098699	0.948	rs4833888	chr4:124208497	G/T	cg09941581	chr4:124220074	SPATA5	-0.32	-5.77	-0.3	1.75e-8	Mosquito bite size;
LIHC	cis	rs2108622	1.000	rs55744319	chr19:15981821	G/A	cg13772218	chr19:15982569	NA	0.42	8.58	0.42	3.34e-16	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-13.89	-0.6	4.2e-35	Prudent dietary pattern;
LIHC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs77633900	0.772	rs78181637	chr15:76672569	A/C	cg21673338	chr15:77095150	SCAPER	-0.52	-5.96	-0.31	6.26e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.87e-10	Aortic root size;
LIHC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.49	8.43	0.41	9.57e-16	Mean corpuscular volume;
LIHC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-7.63	-0.38	2.42e-13	Fibrinogen levels;
LIHC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.69	-11.88	-0.54	1.68e-27	Refractive error;
LIHC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.6	8.81	0.43	6.54e-17	Response to diuretic therapy;
LIHC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.56	-8.28	-0.41	2.89e-15	Ulcerative colitis;
LIHC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.56	9.25	0.45	2.4e-18	Childhood ear infection;
LIHC	cis	rs4650994	0.593	rs12074085	chr1:178504163	G/A	cg05350800	chr1:178550844	NA	-0.3	-6.42	-0.33	4.65e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.88	13.16	0.58	2.8099999999999997e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.68	10.01	0.48	7.67e-21	Bronchopulmonary dysplasia;
LIHC	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.41	0.33	4.71e-10	Mean corpuscular volume;
LIHC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg14930904	chr10:32216787	ARHGAP12	0.34	5.98	0.31	5.74e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.62	12.47	0.56	1.11e-29	Plateletcrit;Platelet count;
LIHC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.85	0.39	5.27e-14	Lymphocyte counts;
LIHC	cis	rs6545883	0.894	rs2694649	chr2:61573826	G/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.46	-0.37	7.39e-13	Tuberculosis;
LIHC	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg20991723	chr1:152506922	NA	0.59	10.49	0.49	1.6400000000000001e-22	Hair morphology;
LIHC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.5	8.5	0.42	5.78e-16	Response to temozolomide;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21153962	chr11:57102758	SSRP1	0.45	6.53	0.33	2.44e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.44e-11	Response to antipsychotic treatment;
LIHC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.07	-0.31	3.41e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg08824895	chr13:115047677	UPF3A	-0.48	-6.92	-0.35	2.28e-11	Schizophrenia;
LIHC	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19671926	chr4:122722719	EXOSC9	0.5	7.37	0.37	1.26e-12	Type 2 diabetes;
LIHC	cis	rs7818688	0.697	rs60003497	chr8:95983423	A/T	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.8	-14.4	-0.61	4.4e-37	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs7192750	0.586	rs62053803	chr16:71989413	G/A	cg06353428	chr16:71660113	MARVELD3	0.78	9.09	0.44	8.46e-18	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg12698662	chr3:15914712	MIR563	-0.37	-6.72	-0.34	7.42e-11	Mean platelet volume;
LIHC	cis	rs244293	0.965	rs244368	chr17:53186537	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.47	-0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.3	5.85	0.3	1.14e-8	Platelet count;
LIHC	cis	rs72843506	0.656	rs80250684	chr17:19958296	C/T	cg12065943	chr17:19881925	AKAP10	-0.33	-6.01	-0.31	4.71e-9	Schizophrenia;
LIHC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg19513890	chr22:42538836	CYP2D7P1	0.41	8.09	0.4	1.02e-14	Cognitive function;
LIHC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.33	-5.73	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9918079	0.560	rs7662032	chr4:15635414	C/G	cg21123203	chr4:15471301	CC2D2A	-0.45	-7.3	-0.37	2.04e-12	Obesity-related traits;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11057824	chr14:50471938	C14orf182	0.42	6.82	0.35	4.2e-11	Cognitive function;
LIHC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08822215	chr16:89438651	ANKRD11	-0.5	-7.96	-0.4	2.57e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.33	5.83	0.3	1.28e-8	Menarche (age at onset);
LIHC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg21466736	chr12:48725269	NA	-0.71	-10.78	-0.5	1.62e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17554472	chr22:41940697	POLR3H	-0.53	-5.89	-0.3	9.25e-9	Vitiligo;
LIHC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.47	0.49	1.98e-22	Vitiligo;
LIHC	cis	rs8084351	0.577	rs4444405	chr18:50621027	C/A	cg24270629	chr18:50823537	DCC	0.44	6.66	0.34	1.07e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.35	5.8	0.3	1.53e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	6.48	0.33	3.11e-10	Schizophrenia;
LIHC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.77	-0.3	1.79e-8	Pulse pressure;
LIHC	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg10587741	chr22:38071170	LGALS1	0.43	7.56	0.38	3.77e-13	Fat distribution (HIV);
LIHC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.55	8.89	0.43	3.56e-17	Body mass index;
LIHC	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.38	6.63	0.34	1.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg14146966	chr2:61757674	XPO1	0.47	8.21	0.41	4.61e-15	Tuberculosis;
LIHC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg17771515	chr6:154831774	CNKSR3	0.56	5.91	0.3	8.35e-9	Lipoprotein (a) levels;
LIHC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.96	0.54	8.55e-28	Post bronchodilator FEV1;
LIHC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg23387056	chr11:14280742	SPON1	0.43	5.99	0.31	5.25e-9	Mitochondrial DNA levels;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-6.61	-0.34	1.46e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21545522	chr1:205238299	TMCC2	0.31	6.37	0.33	6.11e-10	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.44	-7.32	-0.37	1.78e-12	Body mass index;
LIHC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-11.75	-0.54	5.38e-27	Menarche (age at onset);
LIHC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.52	-0.56	7.52e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg08345082	chr10:99160200	RRP12	-0.39	-6.62	-0.34	1.38e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9549328	0.527	rs9549622	chr13:113640064	A/C	cg14765414	chr13:113652335	MCF2L	-0.39	-6.47	-0.33	3.3e-10	Systolic blood pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07798295	chr16:89715839	CHMP1A	-0.44	-6.34	-0.32	7.48e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.46	0.49	2.04e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.88	12.41	0.56	1.83e-29	Psoriasis;
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.54	-0.38	4.18e-13	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00699235	chr12:49962218	MCRS1	0.45	6.3	0.32	9.36e-10	Pancreatic cancer;
LIHC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.46	-7.39	-0.37	1.17e-12	Blood protein levels;
LIHC	trans	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg23598604	chr1:99732472	LPPR4	-0.29	-6.06	-0.31	3.63e-9	Multiple myeloma;
LIHC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.62	-11.66	-0.53	1.13e-26	Mean corpuscular volume;
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.57	9.16	0.44	4.89e-18	Obesity-related traits;
LIHC	trans	rs10761482	0.566	rs10159663	chr10:62208417	A/G	cg17314160	chr12:110399253	GIT2	0.41	6.27	0.32	1.11e-9	Schizophrenia;
LIHC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.6	10.94	0.51	4.3e-24	Fat distribution (HIV);
LIHC	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg00601450	chr5:74908170	NA	-0.45	-6.55	-0.33	2.16e-10	Age-related disease endophenotypes;
LIHC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.31	-6.32	-0.32	8.08e-10	Renal cell carcinoma;
LIHC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.41	-6.48	-0.33	3.27e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.93e-9	Breast cancer;
LIHC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg02376097	chr19:46275166	DMPK	-0.46	-7.19	-0.36	4.21e-12	Coronary artery disease;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20756454	chr17:28951397	LRRC37B2	0.39	6.4	0.33	5.06e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.46	-6.61	-0.34	1.45e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.52	8.27	0.41	2.96e-15	Total body bone mineral density;
LIHC	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg19508488	chr2:152266495	RIF1	0.51	7.0	0.35	1.39e-11	Squamous cell lung carcinoma;
LIHC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	6.0	0.31	5.05e-9	Schizophrenia;
LIHC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg15105060	chr4:7024189	TBC1D14	-0.75	-6.63	-0.34	1.3100000000000001e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg16970926	chr12:29381810	FAR2	0.33	6.93	0.35	2.1e-11	QT interval;
LIHC	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg00204748	chr12:29376779	FAR2	0.38	7.0	0.35	1.36e-11	QT interval;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.76e-9	Menopause (age at onset);
LIHC	cis	rs7546668	1.000	rs4233533	chr1:15829187	G/A	cg11706911	chr1:15910989	AGMAT	0.44	6.67	0.34	1.04e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-1.18	-10.26	-0.49	1.01e-21	Breast cancer;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	cis	rs8081395	0.836	rs2150879	chr17:57859210	G/A	cg13753209	chr17:57696993	CLTC	-0.46	-7.15	-0.36	5.43e-12	White blood cell count;
LIHC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.42	7.79	0.39	8.17e-14	Schizophrenia;
LIHC	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-6.7	-0.34	8.7e-11	Endometrial cancer;
LIHC	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.5	7.82	0.39	6.79e-14	Alzheimer's disease (survival time);
LIHC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.99	0.35	1.48e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03670153	chr3:184079754	CLCN2;POLR2H	0.46	6.61	0.34	1.51e-10	Pancreatic cancer;
LIHC	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.22	0.32	1.42e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg16434002	chr17:42200994	HDAC5	-0.53	-7.71	-0.38	1.4e-13	Total body bone mineral density;
LIHC	cis	rs10207060	0.500	rs2118399	chr2:240683795	T/C	cg07506560	chr2:240697449	NA	0.39	5.76	0.3	1.84e-8	Obesity-related traits;
LIHC	cis	rs2637266	0.967	rs2579760	chr10:78321768	A/C	cg18941641	chr10:78392320	NA	0.28	5.97	0.31	5.87e-9	Pulmonary function;
LIHC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.91	-0.54	1.33e-27	Urate levels in overweight individuals;
LIHC	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.74	-0.3	2.07e-8	Diastolic blood pressure;
LIHC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.63	11.08	0.51	1.43e-24	Mean corpuscular volume;
LIHC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.06	-0.36	9.32e-12	IgG glycosylation;
LIHC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23978390	chr7:1156363	C7orf50	0.51	7.61	0.38	2.77e-13	Longevity;Endometriosis;
LIHC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.79	10.03	0.48	6.26e-21	Gut microbiome composition (summer);
LIHC	cis	rs17433710	0.516	rs4411113	chr1:162668008	G/T	cg01063088	chr1:162760584	HSD17B7	0.44	6.32	0.32	8.32e-10	Dupuytren's disease;
LIHC	cis	rs425535	0.588	rs13136948	chr4:74806194	A/T	cg02530824	chr4:74847766	PF4	-0.39	-5.98	-0.31	5.65e-9	Blood protein levels;
LIHC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.9	16.66	0.67	4.63e-46	Menopause (age at onset);
LIHC	cis	rs16828019	0.777	rs11209363	chr1:41485077	T/C	cg03962019	chr1:41807865	NA	0.5	7.09	0.36	7.76e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.77	12.55	0.56	5.52e-30	Corneal astigmatism;
LIHC	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg08539965	chr1:21396338	EIF4G3	0.34	5.86	0.3	1.09e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.49	8.67	0.42	1.72e-16	IgG glycosylation;
LIHC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.95	-0.31	6.51e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs34779708	0.733	rs7070778	chr10:35541688	T/C	cg03585969	chr10:35415529	CREM	0.76	10.83	0.51	1.05e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.58	9.33	0.45	1.41e-18	Multiple sclerosis;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03366896	chr10:135186866	ECHS1	0.42	6.25	0.32	1.24e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.99	0.31	5.2e-9	Tonsillectomy;
LIHC	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.16	-0.36	5.13e-12	Metabolite levels;
LIHC	cis	rs243505	0.660	rs3807451	chr7:148538622	T/C	cg09806900	chr7:148480153	CUL1	0.44	6.22	0.32	1.44e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.38e-11	Aortic root size;
LIHC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.29	-0.32	9.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.12	10.26	0.49	1.06e-21	Diabetic retinopathy;
LIHC	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg03229431	chr7:123269106	ASB15	-0.37	-8.04	-0.4	1.53e-14	Migraine;
LIHC	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.62	-0.34	1.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.95	-0.31	6.67e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.97	-0.31	5.93e-9	Personality dimensions;
LIHC	cis	rs2540917	0.631	rs11884411	chr2:60669494	C/T	cg00543073	chr2:60773386	BCL11A	0.3	5.88	0.3	9.88e-9	Mean corpuscular volume;
LIHC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.49	7.67	0.38	1.79e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg04013166	chr16:89971882	TCF25	0.61	8.01	0.4	1.87e-14	Skin colour saturation;
LIHC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg03959625	chr15:84868606	LOC388152	0.46	5.75	0.3	1.99e-8	Schizophrenia;
LIHC	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg25902810	chr10:99078978	FRAT1	0.7	10.37	0.49	4.26e-22	Monocyte count;
LIHC	trans	rs10411161	0.702	rs11878586	chr19:52388576	A/G	cg22319618	chr22:45562946	NUP50	-0.62	-8.49	-0.42	6.32e-16	Breast cancer;
LIHC	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg12903224	chr12:29470962	FAR2	-0.41	-6.56	-0.33	1.99e-10	QT interval;
LIHC	cis	rs600806	0.778	rs9661614	chr1:110021837	T/C	cg08911820	chr1:110026001	ATXN7L2	0.53	6.61	0.34	1.5e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs61542988	0.570	rs62448268	chr7:22829464	G/A	cg11367502	chr7:22862612	TOMM7	0.56	9.07	0.44	9.4e-18	Fibrinogen levels;
LIHC	cis	rs861318	0.702	rs2814771	chr1:159012238	A/G	cg11003133	chr1:159046391	AIM2	0.32	6.63	0.34	1.3100000000000001e-10	Obesity-related traits;
LIHC	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.78	-14.04	-0.6	1.09e-35	Longevity;
LIHC	trans	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg26939375	chr7:64535504	NA	-0.44	-7.45	-0.37	7.9e-13	Aortic root size;
LIHC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg10756647	chr7:56101905	PSPH	-1.07	-13.17	-0.58	2.44e-32	Diabetic kidney disease;
LIHC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03065641	chr8:145133200	EXOSC4	0.4	6.29	0.32	9.72e-10	Cognitive function;
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.7	-10.23	-0.48	1.32e-21	Eosinophil percentage of white cells;
LIHC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	trans	rs1347297	0.526	rs919177	chr2:179258923	C/T	cg14011486	chr1:26737247	LIN28	0.52	7.87	0.39	4.8e-14	Alzheimer disease and age of onset;
LIHC	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg04719120	chr6:96025338	MANEA	-0.56	-5.88	-0.3	9.69e-9	Behavioural disinhibition (generation interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00021237	chr8:67525849	MYBL1	-0.32	-6.33	-0.32	7.89e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.12	0.36	6.4e-12	Breast cancer;
LIHC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.55	7.17	0.36	4.74e-12	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26376749	chr17:30677620	ZNF207	0.48	6.65	0.34	1.13e-10	Pancreatic cancer;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.85	-0.3	1.16e-8	Total body bone mineral density;
LIHC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.44	-6.41	-0.33	4.71e-10	Menarche (age at onset);
LIHC	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg21171335	chr12:122356390	WDR66	-0.42	-6.81	-0.35	4.37e-11	Mean corpuscular volume;
LIHC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.43	7.57	0.38	3.61e-13	Aortic root size;
LIHC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.54	5.75	0.3	2.01e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg13271783	chr10:134563150	INPP5A	-0.6	-7.18	-0.36	4.32e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	0.92	6.82	0.35	4.21e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg20335179	chr10:1068567	C10orf110;IDI2	-0.61	-6.92	-0.35	2.23e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.63	-9.01	-0.44	1.44e-17	Blood metabolite levels;
LIHC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg24296786	chr1:45957014	TESK2	-0.41	-5.94	-0.31	6.87e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg12454167	chr3:186435060	KNG1	0.4	9.11	0.44	7.3e-18	Blood protein levels;
LIHC	cis	rs1030877	1.000	rs2254301	chr2:105880734	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.68	11.83	0.54	2.67e-27	Obesity-related traits;
LIHC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-9.78	-0.47	4.43e-20	Mean corpuscular volume;
LIHC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg04865290	chr3:52927548	TMEM110	-0.55	-6.17	-0.32	1.89e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg00529422	chr1:16285251	ZBTB17	0.33	6.3	0.32	9.39e-10	Systolic blood pressure;
LIHC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.74	14.42	0.61	3.67e-37	Mortality in heart failure;
LIHC	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.67	8.4	0.41	1.21e-15	Corneal astigmatism;
LIHC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21582582	chr3:182698605	DCUN1D1	0.54	6.92	0.35	2.31e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.66	-9.37	-0.45	1.01e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.61	-8.9	-0.43	3.41e-17	White matter hyperintensity burden;
LIHC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-6.89	-0.35	2.72e-11	Body mass index;
LIHC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-9.21	-0.45	3.3e-18	Morning vs. evening chronotype;
LIHC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	10.8	0.5	1.4e-23	Post bronchodilator FEV1;
LIHC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg05697976	chr12:29376483	FAR2	0.3	6.17	0.32	1.9e-9	QT interval;
LIHC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.46	7.89	0.39	4.26e-14	Mean corpuscular volume;
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.53	7.76	0.39	9.78e-14	Menarche (age at onset);
LIHC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.39	0.33	5.45e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.34	-8.44	-0.42	9.11e-16	Hip circumference;Waist circumference;
LIHC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.51	8.18	0.4	5.67e-15	Breast cancer;
LIHC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.34	-7.53	-0.38	4.63e-13	Ulcerative colitis;
LIHC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.9	-13.6	-0.59	5.5e-34	Sudden cardiac arrest;
LIHC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.44	-0.42	8.96e-16	Type 2 diabetes;
LIHC	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.34	-6.29	-0.32	9.79e-10	Ankylosing spondylitis;
LIHC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.87	8.72	0.43	1.19e-16	Body mass index;
LIHC	cis	rs903552	0.935	rs4965871	chr15:102003810	A/T	cg19295451	chr15:102010161	PCSK6	-0.45	-6.44	-0.33	4.11e-10	Diabetic kidney disease;
LIHC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg20283391	chr11:68216788	NA	0.36	5.73	0.3	2.21e-8	Total body bone mineral density;
LIHC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.3	-0.55	4.71e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12980942	0.748	rs35501756	chr19:41823497	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.81	0.35	4.29e-11	Coronary artery disease;
LIHC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.48	-7.24	-0.36	3.02e-12	Cognitive function;
LIHC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.44	6.23	0.32	1.39e-9	Iron status biomarkers;
LIHC	cis	rs10411936	1.000	rs10411936	chr19:16548375	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	-0.43	-5.85	-0.3	1.12e-8	White blood cell count;Multiple sclerosis;
LIHC	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg20569855	chr1:109824440	PSRC1	-0.53	-6.8	-0.34	4.79e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.74e-11	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg11764359	chr7:65958608	NA	0.58	6.02	0.31	4.44e-9	Diabetic kidney disease;
LIHC	cis	rs2282032	0.527	rs8009799	chr14:90766365	A/G	cg04374321	chr14:90722782	PSMC1	0.49	7.07	0.36	8.56e-12	Longevity;
LIHC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.48	7.42	0.37	9.61e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg02269571	chr22:50332266	NA	-0.66	-9.1	-0.44	7.88e-18	Schizophrenia;
LIHC	cis	rs1198430	0.639	rs16860685	chr1:23766644	A/G	cg19827787	chr1:23763612	ASAP3	0.27	5.9	0.3	8.71e-9	Total cholesterol levels;
LIHC	cis	rs11166927	1.000	rs13256625	chr8:140805003	G/T	cg16909799	chr8:140841666	TRAPPC9	0.51	8.14	0.4	7.6e-15	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.65	-0.38	2e-13	Electroencephalogram traits;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.95	-0.31	6.51e-9	Total body bone mineral density;
LIHC	cis	rs8016982	0.662	rs1957546	chr14:81639984	C/T	cg01989461	chr14:81687754	GTF2A1	0.53	8.99	0.44	1.7e-17	Schizophrenia;
LIHC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.4	-0.37	1.07e-12	Bipolar disorder;
LIHC	cis	rs7106204	0.609	rs12276488	chr11:24250211	G/A	ch.11.24196551F	chr11:24239977	NA	0.59	6.35	0.32	6.8e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.71	-10.84	-0.51	1.02e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.25	0.45	2.54e-18	Cognitive ability;
LIHC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	6.1	0.31	2.82e-9	Uric acid clearance;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20150972	chr6:13574573	SIRT5	0.41	6.29	0.32	9.92e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.61	-8.26	-0.41	3.25e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-0.67	-11.74	-0.54	5.62e-27	Pediatric autoimmune diseases;
LIHC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.05	0.4	1.36e-14	Response to antipsychotic treatment;
LIHC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg08213375	chr14:104286397	PPP1R13B	0.51	9.7	0.46	7.9e-20	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.71e-33	Diabetic kidney disease;
LIHC	cis	rs11031096	0.568	rs10767891	chr11:4234524	A/G	cg18678763	chr11:4115507	RRM1	-0.4	-5.97	-0.31	5.83e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.91	0.43	3.16e-17	Exhaled nitric oxide output;
LIHC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.06	-0.31	3.5e-9	Type 2 diabetes;
LIHC	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.45	7.26	0.37	2.66e-12	Corneal astigmatism;
LIHC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.09	0.4	1.05e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg22212156	chr20:32031449	SNTA1	-0.42	-6.05	-0.31	3.72e-9	Neuroblastoma;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07424592	chr7:64974309	NA	-0.44	-6.69	-0.34	8.93e-11	Calcium levels;
LIHC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.58	8.42	0.41	1.01e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg07964097	chr12:131708081	NA	-0.23	-6.06	-0.31	3.66e-9	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.22	-0.32	1.44e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	0.85	11.09	0.51	1.32e-24	Skin colour saturation;
LIHC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	trans	rs9859557	0.904	rs6443732	chr3:180733341	G/A	cg26202529	chr2:23865356	KLHL29	-0.43	-6.36	-0.33	6.62e-10	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.37	6.51	0.33	2.76e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.52	9.59	0.46	1.94e-19	Total body bone mineral density;
LIHC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.12	-0.36	6.36e-12	Bipolar disorder;
LIHC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg24130564	chr14:104152367	KLC1	-0.57	-9.38	-0.45	9.31e-19	Reticulocyte count;
LIHC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg16822855	chr3:40428330	ENTPD3	0.35	6.38	0.33	5.91e-10	Renal cell carcinoma;
LIHC	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-0.52	-6.98	-0.35	1.49e-11	Pulse pressure;
LIHC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20135002	chr11:47629003	NA	-0.58	-10.01	-0.48	7.32e-21	Subjective well-being;
LIHC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.76	0.47	5.37e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg21724239	chr8:58056113	NA	0.48	5.78	0.3	1.66e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-15.09	-0.63	8.71e-40	Intelligence (multi-trait analysis);
LIHC	trans	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	9.54	0.46	2.89e-19	Eotaxin levels;
LIHC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-9.3	-0.45	1.67e-18	Schizophrenia;
LIHC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.59	-8.17	-0.4	6.22e-15	Response to antineoplastic agents;
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg00204748	chr12:29376779	FAR2	0.44	8.32	0.41	2.08e-15	QT interval;
LIHC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	7.12	0.36	6.29e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg06640241	chr16:89574553	SPG7	0.79	14.57	0.62	9.46e-38	Multiple myeloma (IgH translocation);
LIHC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-9.36	-0.45	1.09e-18	Parkinson's disease;
LIHC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.49	6.21	0.32	1.52e-9	Gut microbiome composition (summer);
LIHC	cis	rs10508774	0.733	rs12254344	chr10:32857229	G/A	cg01819863	chr10:32635814	EPC1	0.61	5.83	0.3	1.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	0.6	8.75	0.43	9.91e-17	Prudent dietary pattern;
LIHC	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	5.09e-12	Corneal astigmatism;
LIHC	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg06854084	chr10:101292507	NKX2-3	0.33	6.0	0.31	4.91e-9	Dental caries;
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27189623	chr16:705930	WDR90	0.42	6.91	0.35	2.43e-11	Height;
LIHC	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg05865280	chr17:75406074	SEPT9	0.62	12.15	0.55	1.72e-28	Airflow obstruction;
LIHC	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.44	-7.14	-0.36	5.69e-12	Corneal astigmatism;
LIHC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.5	-6.36	-0.32	6.65e-10	Menarche (age at onset);
LIHC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.99	21.0	0.75	1.71e-63	Bone mineral density;
LIHC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.85	0.3	1.17e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.45	6.3	0.32	8.95e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.39	-13.36	-0.59	4.78e-33	Psoriasis vulgaris;
LIHC	cis	rs6061231	0.958	rs2379126	chr20:60953005	C/A	cg06026331	chr20:60912101	LAMA5	0.44	6.13	0.31	2.43e-9	Colorectal cancer;
LIHC	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.72	12.51	0.56	8.06e-30	Eosinophil percentage of white cells;
LIHC	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.86	17.89	0.7	5.61e-51	Testicular germ cell tumor;
LIHC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.59	-7.55	-0.38	4.02e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.32	1.29e-9	Calcium levels;
LIHC	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg22705602	chr4:152727874	NA	-0.3	-6.33	-0.32	7.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.48	0.62	2.2e-37	Prudent dietary pattern;
LIHC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.44	7.18	0.36	4.36e-12	Red blood cell count;
LIHC	cis	rs3106136	0.649	rs7672613	chr4:95299150	G/A	cg11021082	chr4:95130006	SMARCAD1	0.36	6.13	0.31	2.4e-9	Capecitabine sensitivity;
LIHC	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.56	-0.42	3.86e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs74544699	1.000	rs78267059	chr4:74798010	G/A	cg16072462	chr4:74847758	PF4	0.6	6.14	0.32	2.27e-9	Growth-regulated protein alpha levels;
LIHC	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg17830980	chr10:43048298	ZNF37B	0.42	7.94	0.39	3.02e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	10.47	0.49	1.94e-22	Lung cancer in ever smokers;
LIHC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	12.45	0.56	1.29e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.52e-9	Schizophrenia;
LIHC	cis	rs2380220	0.808	rs2386669	chr6:95902121	C/T	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.53	8.14	0.4	7.34e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.91	-16.39	-0.66	5.74e-45	Colorectal cancer;
LIHC	cis	rs4268898	0.636	rs72803210	chr2:24615710	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-9.43	-0.45	6.25e-19	Asthma;
LIHC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg14222432	chr12:29376421	FAR2	0.36	7.05	0.36	9.82e-12	QT interval;
LIHC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.19	-0.36	4.16e-12	Alcohol dependence;
LIHC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	9.82	0.47	3.2e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg14222432	chr12:29376421	FAR2	0.37	7.11	0.36	6.68e-12	QT interval;
LIHC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.26	6.19	0.32	1.74e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	trans	rs2209875	1.000	rs2209875	chr9:91813461	G/A	cg26057616	chr1:222234397	NA	0.37	6.15	0.32	2.21e-9	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02775353	chr7:101814109	CUX1	0.45	6.14	0.32	2.27e-9	Hepatitis;
LIHC	cis	rs11673344	0.864	rs8104919	chr19:37503783	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.2	-0.32	1.66e-9	Obesity-related traits;
LIHC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.9e-9	Body mass index;
LIHC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg22027985	chr11:4115532	RRM1	-0.43	-5.73	-0.3	2.18e-8	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.7	0.73	2.92e-58	Smoking behavior;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02949340	chr10:102820489	KAZALD1	-0.42	-6.45	-0.33	3.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.43e-8	Hepatitis;
LIHC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.68	10.96	0.51	3.67e-24	Multiple myeloma (IgH translocation);
LIHC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.41	6.94	0.35	2.03e-11	Schizophrenia;
LIHC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg25838818	chr2:108905173	SULT1C2	0.41	7.2	0.36	3.88e-12	Blood pressure;
LIHC	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.1400000000000002e-19	Corneal astigmatism;
LIHC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.37	-6.61	-0.34	1.49e-10	Psoriasis;
LIHC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg05527609	chr1:210001259	C1orf107	0.42	6.2	0.32	1.62e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.44	8.0	0.4	1.92e-14	Neurofibrillary tangles;
LIHC	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.23	-0.32	1.37e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.41	5.91	0.3	8.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg04025307	chr7:1156635	C7orf50	0.48	7.95	0.4	2.7e-14	Longevity;Endometriosis;
LIHC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	7.0	0.35	1.37e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.34	-5.9	-0.3	8.75e-9	IgG glycosylation;
LIHC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	trans	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg07393940	chr7:158741817	NA	-0.56	-6.7	-0.34	8.72e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs72653721	0.689	rs61669862	chr6:11068598	T/C	cg13562911	chr6:11044106	ELOVL2	0.51	7.54	0.38	4.23e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg16558253	chr16:72132732	DHX38	-0.36	-5.78	-0.3	1.66e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.19e-9	Bipolar disorder;
LIHC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-7.33	-0.37	1.63e-12	Obesity (extreme);
LIHC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.4	-0.45	7.84e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs7116495	1.000	rs7116495	chr11:71762085	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg20295408	chr7:1910781	MAD1L1	0.49	7.04	0.36	1.04e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.68	0.46	9.64e-20	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27109971	chr18:267637	THOC1	0.45	6.44	0.33	4.05e-10	Pancreatic cancer;
LIHC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.48	-5.83	-0.3	1.25e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs11871801	0.517	rs684214	chr17:40696915	C/T	cg14558262	chr17:40713999	COASY	0.5	6.91	0.35	2.44e-11	Crohn's disease;
LIHC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.6	-10.38	-0.49	3.96e-22	Menopause (age at onset);
LIHC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.75	14.39	0.61	4.87e-37	Crohn's disease;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.92	13.13	0.58	3.67e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.22e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.95	-12.12	-0.55	2.25e-28	Body mass index;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg07133347	chr1:107600762	PRMT6	0.45	6.76	0.34	5.9e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4908768	0.911	rs6693127	chr1:8774973	G/A	cg20416874	chr1:8611966	RERE	0.53	7.93	0.39	3.25e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25334215	chr11:33163286	CSTF3	0.27	6.04	0.31	3.95e-9	Cognitive function;
LIHC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg14092571	chr14:90743983	NA	-0.41	-6.53	-0.33	2.34e-10	Mortality in heart failure;
LIHC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.54	-7.13	-0.36	6.06e-12	Initial pursuit acceleration;
LIHC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-6.03	-0.31	4.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.71e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs783540	1.000	rs783540	chr15:83254708	C/T	cg18393722	chr15:85113863	UBE2QP1	0.38	6.61	0.34	1.48e-10	Schizophrenia;
LIHC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.39	-6.23	-0.32	1.4e-9	Blood pressure (smoking interaction);
LIHC	cis	rs4908768	0.859	rs55802878	chr1:8666411	T/C	cg20416874	chr1:8611966	RERE	0.52	7.41	0.37	9.9e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.56	-6.8	-0.35	4.55e-11	Breast cancer;
LIHC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.56	7.76	0.39	1.01e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.49	7.24	0.36	3e-12	Personality dimensions;
LIHC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.86	0.57	3.86e-31	Alzheimer's disease;
LIHC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.75	-11.27	-0.52	2.98e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs116248771	0.739	rs73156488	chr3:158413942	C/G	cg16708174	chr3:158430962	RARRES1	0.49	6.48	0.33	3.25e-10	diarrhoeal disease at age 2;
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg03721293	chr16:90014378	DEF8	0.42	6.92	0.35	2.28e-11	Skin colour saturation;
LIHC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	7.99	0.4	2.07e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-6.63	-0.34	1.34e-10	Vitiligo;
LIHC	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.53	-8.87	-0.43	4.05e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.33	-0.49	5.77e-22	Hemoglobin concentration;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg27432699	chr2:27873401	GPN1	-0.56	-8.19	-0.41	5.17e-15	Total body bone mineral density;
LIHC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg00343986	chr7:65444356	GUSB	0.4	6.05	0.31	3.88e-9	Aortic root size;
LIHC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.98	10.01	0.48	7.2e-21	Plasma clusterin levels;
LIHC	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg18898632	chr2:242989856	NA	-0.7	-8.69	-0.43	1.58e-16	Obesity-related traits;
LIHC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.75	-0.3	1.98e-8	Arsenic metabolism;
LIHC	trans	rs8030605	0.704	rs72740574	chr15:56637007	T/A	cg01710580	chr16:598674	SOLH	-0.66	-6.09	-0.31	3.08e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg12863693	chr15:85201151	NMB	-0.4	-5.8	-0.3	1.47e-8	Schizophrenia;
LIHC	trans	rs1902066	0.647	rs2503749	chr6:81349756	G/T	cg07248951	chr1:36397042	EIF2C3	0.4	6.08	0.31	3.18e-9	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19850565	chr19:35168394	ZNF302	0.43	6.06	0.31	3.55e-9	Pancreatic cancer;
LIHC	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.55	8.21	0.41	4.51e-15	Body mass index;
LIHC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.99	15.45	0.64	3.09e-41	Breast cancer;
LIHC	trans	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg09872104	chr7:134855509	C7orf49	-0.79	-6.33	-0.32	7.48e-10	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg24101359	chr6:42928495	GNMT	0.44	5.88	0.3	9.53e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg20636351	chr8:55087400	NA	-0.38	-7.73	-0.39	1.2e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.0	-0.4	1.92e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02886208	chr11:14281011	SPON1	-0.57	-8.48	-0.42	6.68e-16	Mitochondrial DNA levels;
LIHC	cis	rs12986413	0.624	rs2238599	chr19:2140009	C/T	cg09261902	chr19:2140048	AP3D1	0.4	6.83	0.35	3.92e-11	Height;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg11062466	chr8:58055876	NA	0.52	7.51	0.38	5.12e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7945071	0.507	rs1596295	chr11:110253214	G/A	cg04157658	chr11:110243994	NA	0.33	6.08	0.31	3.15e-9	Cognitive function;
LIHC	cis	rs4716602	0.573	rs34810003	chr7:156160883	T/C	cg16983916	chr7:156159713	NA	-0.32	-5.71	-0.3	2.43e-8	Anti-saccade response;
LIHC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06050784	chr16:88016603	BANP	0.36	6.56	0.33	2.02e-10	Menopause (age at onset);
LIHC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.57	0.59	7.69e-34	Lung cancer in ever smokers;
LIHC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	9.55	0.46	2.66e-19	Platelet count;
LIHC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02290350	chr8:58132656	NA	0.46	8.88	0.43	3.78e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.55	-9.17	-0.44	4.62e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg10792982	chr14:105748885	BRF1	0.45	6.25	0.32	1.19e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.42	-0.37	9.26e-13	Psoriasis;
LIHC	cis	rs8067354	0.574	rs2531898	chr17:58012351	G/C	cg02344993	chr17:57696989	CLTC	0.65	10.29	0.49	8.48e-22	Hemoglobin concentration;
LIHC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.5	9.22	0.45	3.22e-18	Hemoglobin concentration;
LIHC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.5	-0.46	3.7e-19	Blood metabolite levels;
LIHC	trans	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg16088116	chr21:44841560	SIK1	-0.41	-6.27	-0.32	1.11e-9	Coronary artery disease;
LIHC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.41	-0.56	1.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.81	0.39	7.07e-14	Lymphocyte counts;
LIHC	cis	rs9420	0.528	rs7117896	chr11:57388551	G/A	cg19752551	chr11:57585705	CTNND1	-0.48	-6.21	-0.32	1.53e-9	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14934978	chr8:28352084	FZD3	-0.53	-6.27	-0.32	1.12e-9	Systolic blood pressure;
LIHC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg23229984	chr5:148520753	ABLIM3	0.49	5.72	0.3	2.39e-8	Breast cancer;
LIHC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.56	0.38	3.69e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.91	0.35	2.45e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg00343986	chr7:65444356	GUSB	-0.41	-6.08	-0.31	3.23e-9	Aortic root size;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg00800038	chr16:89945340	TCF25	0.63	10.06	0.48	5.2e-21	Skin colour saturation;
LIHC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.51	6.32	0.32	8.16e-10	Serum sulfate level;
LIHC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.59	0.38	3.04e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.55	9.06	0.44	1.02e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.34	0.49	5.68e-22	Colorectal cancer;
LIHC	cis	rs6596100	0.538	rs1393244	chr5:132186007	T/G	cg02081065	chr5:132209139	LEAP2	0.27	6.1	0.31	2.89e-9	Breast cancer;
LIHC	trans	rs9914544	0.545	rs9903574	chr17:18768582	C/T	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.79	-0.34	5.11e-11	Educational attainment (years of education);
LIHC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.56	11.06	0.51	1.61e-24	Coronary artery disease;
LIHC	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg07424592	chr7:64974309	NA	0.77	8.94	0.44	2.49e-17	Gout;
LIHC	cis	rs2412488	0.853	rs35089837	chr4:54354341	C/T	cg22241045	chr4:54363911	LNX1	0.41	6.69	0.34	8.88e-11	DNA methylation (variation);
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.25	0.32	1.23e-9	Prudent dietary pattern;
LIHC	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg11204139	chr17:3907470	NA	0.6	6.98	0.35	1.49e-11	Type 2 diabetes;
LIHC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Parkinson's disease;
LIHC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg06640241	chr16:89574553	SPG7	0.63	9.92	0.47	1.45e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg17750252	chr2:136567154	LCT	-0.33	-5.97	-0.31	6.06e-9	Mosquito bite size;
LIHC	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.01	-21.76	-0.76	1.58e-66	Platelet distribution width;
LIHC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.53	8.26	0.41	3.25e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.4	6.85	0.35	3.5e-11	Alcohol dependence;
LIHC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg03037974	chr15:76606532	NA	-0.61	-10.3	-0.49	7.81e-22	Blood metabolite levels;
LIHC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	7.32	0.37	1.82e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.85	13.54	0.59	1.01e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.39	0.33	5.33e-10	Renal cell carcinoma;
LIHC	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.78	-0.3	1.69e-8	Resting heart rate;
LIHC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg18867708	chr6:26865862	GUSBL1	0.52	8.03	0.4	1.64e-14	Schizophrenia;
LIHC	cis	rs9993613	1.000	rs6446849	chr4:73459446	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.38	-6.14	-0.32	2.29e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-5.94	-0.31	7.08e-9	Systolic blood pressure;
LIHC	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg17623882	chr6:41773611	USP49	-0.44	-5.91	-0.3	8.28e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs4684776	0.935	rs11714039	chr3:11365448	G/A	cg00170343	chr3:11313890	ATG7	-0.51	-6.91	-0.35	2.31e-11	Small vessel stroke;
LIHC	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.45	-8.8	-0.43	7.1e-17	LDL cholesterol levels;
LIHC	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.3	-5.73	-0.3	2.15e-8	Red blood cell count;
LIHC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.67	-10.15	-0.48	2.47e-21	Total body bone mineral density;
LIHC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.67	10.16	0.48	2.36e-21	Breast cancer;
LIHC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	11.27	0.52	2.96e-25	LDL cholesterol;
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.63	-9.6	-0.46	1.82e-19	Renal cell carcinoma;
LIHC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.46	7.29	0.37	2.11e-12	HDL cholesterol levels;
LIHC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.98	-12.8	-0.57	6.5e-31	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08392591	chr16:89556376	ANKRD11	0.4	5.95	0.31	6.5e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.86	-11.24	-0.52	3.86e-25	Schizophrenia;
LIHC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.32	-6.87	-0.35	2.96e-11	Longevity;
LIHC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg00277334	chr10:82204260	NA	-0.54	-6.42	-0.33	4.65e-10	Post bronchodilator FEV1;
LIHC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.72	-12.53	-0.56	6.55e-30	Refractive error;
LIHC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.9	0.6	4.07e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2422052	0.530	rs11683225	chr2:118644135	C/A	cg22545206	chr2:118617499	NA	0.37	6.17	0.32	1.88e-9	Mosquito bite size;
LIHC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-6.1	-0.31	2.84e-9	Total body bone mineral density;
LIHC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.32	0.37	1.83e-12	Bipolar disorder;
LIHC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.34	12.73	0.57	1.22e-30	Uric acid levels;
LIHC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg14067834	chr17:29058358	SUZ12P	0.69	6.65	0.34	1.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg17724175	chr1:150552817	MCL1	-0.37	-7.4	-0.37	1.09e-12	Tonsillectomy;
LIHC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.89	12.41	0.56	1.96e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-7.78	-0.39	8.41e-14	Lung cancer;
LIHC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.81	0.3	1.4e-8	Schizophrenia;
LIHC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.41	6.46	0.33	3.56e-10	Resting heart rate;
LIHC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.37	-5.98	-0.31	5.53e-9	Bipolar disorder;
LIHC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.42e-20	Height;
LIHC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.69	0.69	3.49e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.49	7.85	0.39	5.26e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.7	7.37	0.37	1.33e-12	Diabetic kidney disease;
LIHC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.48	7.61	0.38	2.7e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-6.93	-0.35	2.15e-11	Body mass index;
LIHC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.4	7.09	0.36	7.58e-12	Obesity;
LIHC	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.63	-7.6	-0.38	2.83e-13	Mosquito bite size;
LIHC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.37	0.33	5.95e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.82	-12.21	-0.55	1.02e-28	Obesity-related traits;
LIHC	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.32	-5.86	-0.3	1.07e-8	Asthma;
LIHC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.44	0.59	2.44e-33	Airflow obstruction;
LIHC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.09	0.36	7.92e-12	Self-reported allergy;
LIHC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-11.0	-0.51	2.68e-24	Morning vs. evening chronotype;
LIHC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.76	8.48	0.42	6.74e-16	Vitiligo;
LIHC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06636551	chr8:101224915	SPAG1	0.49	9.27	0.45	2.12e-18	Atrioventricular conduction;
LIHC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-7.02	-0.36	1.18e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.95	-0.47	1.22e-20	Chronic sinus infection;
LIHC	cis	rs6516091	0.850	rs62199232	chr20:6050137	T/G	cg25325723	chr20:6104886	FERMT1	-0.71	-5.88	-0.3	9.8e-9	Abdominal aortic aneurysm;
LIHC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.88	-12.95	-0.57	1.76e-31	Chronic sinus infection;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg18050295	chr3:12949921	IQSEC1	0.43	7.1	0.36	7.34e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-7.76	-0.39	9.69e-14	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg16586182	chr3:47516702	SCAP	-0.51	-9.16	-0.44	4.8e-18	Colorectal cancer;
LIHC	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-0.87	-9.46	-0.46	5.11e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg11235426	chr6:292522	DUSP22	-0.46	-6.27	-0.32	1.06e-9	Menopause (age at onset);
LIHC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.35	-5.85	-0.3	1.18e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg11279151	chr3:101281821	RG9MTD1	0.39	5.89	0.3	9.32e-9	Colorectal cancer;
LIHC	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg18898632	chr2:242989856	NA	-0.68	-8.55	-0.42	4.28e-16	Obesity-related traits;
LIHC	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.37	0.33	5.93e-10	Ileal carcinoids;
LIHC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.29e-19	Bipolar disorder;
LIHC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.48	7.45	0.37	7.74e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-0.97	-13.09	-0.58	5.02e-32	Post bronchodilator FEV1;
LIHC	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.33	0.37	1.7e-12	IgG glycosylation;
LIHC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.83	0.3	1.3e-8	HDL cholesterol levels;
LIHC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	1.04	10.72	0.5	2.69e-23	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01482980	chr7:92861284	CCDC132	0.46	6.82	0.35	4.18e-11	Cognitive function;
LIHC	trans	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.12e-10	Aortic root size;
LIHC	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.52	6.07	0.31	3.41e-9	Mammographic density (dense area);
LIHC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg10241871	chr14:102965420	TECPR2	-0.49	-7.42	-0.37	9.1e-13	Plateletcrit;
LIHC	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18125265	chr1:6546646	PLEKHG5	0.47	7.09	0.36	7.65e-12	Pancreatic cancer;
LIHC	cis	rs2479724	0.870	rs7766960	chr6:41918190	T/G	cg17623882	chr6:41773611	USP49	-0.5	-7.4	-0.37	1.09e-12	Menarche (age at onset);
LIHC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.52	7.76	0.39	9.7e-14	Height;
LIHC	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.45	0.33	3.84e-10	Resting heart rate;
LIHC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg19752551	chr11:57585705	CTNND1	-0.52	-7.35	-0.37	1.52e-12	Schizophrenia;
LIHC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg19302996	chr17:73780495	UNK	0.48	6.28	0.32	1.01e-9	Psoriasis;
LIHC	cis	rs17776563	0.887	rs8024142	chr15:89132693	G/A	cg05013243	chr15:89149849	MIR1179	0.41	6.77	0.34	5.49e-11	Thyroid hormone levels;
LIHC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.71	-8.99	-0.44	1.74e-17	Mean platelet volume;
LIHC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.43	-7.48	-0.37	6.49e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.87	0.57	3.48e-31	Prudent dietary pattern;
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.43	6.2	0.32	1.62e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.53	7.95	0.39	2.77e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.24	-19.5	-0.73	1.76e-57	Type 1 diabetes nephropathy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15813570	chr14:64854563	MTHFD1	0.44	6.4	0.33	5.26e-10	Pancreatic cancer;
LIHC	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.69	0.34	8.9e-11	Lung cancer in ever smokers;
LIHC	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.42	6.65	0.34	1.14e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.67	0.53	1.01e-26	Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.33	-0.32	7.64e-10	Gut microbiome composition (summer);
LIHC	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.57	9.24	0.45	2.71e-18	Lymphocyte counts;
LIHC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg20487152	chr13:99095054	FARP1	-0.39	-6.53	-0.33	2.41e-10	Longevity;
LIHC	cis	rs12744310	0.887	rs35932978	chr1:41785445	A/C	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.92e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.43	6.76	0.34	6.05e-11	Breast cancer;
LIHC	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.45	-7.06	-0.36	9.56e-12	Multiple sclerosis;
LIHC	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.87	0.3	1.05e-8	Lung cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25782445	chr7:99006594	BUD31;PDAP1	0.46	6.37	0.33	6.08e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.46	6.1	0.31	2.83e-9	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	trans	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg20587970	chr11:113659929	NA	-0.57	-7.14	-0.36	5.56e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7091068	0.616	rs7084701	chr10:95482249	A/G	cg20715218	chr10:95462985	C10orf4	0.54	5.82	0.3	1.32e-8	Urinary tract infection frequency;
LIHC	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg18912006	chr12:123335444	HIP1R	0.72	7.39	0.37	1.11e-12	Adiponectin levels;
LIHC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg14061069	chr19:46274453	DMPK	-0.4	-6.33	-0.32	7.86e-10	Coronary artery disease;
LIHC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.38	5.75	0.3	1.97e-8	Reticulocyte count;
LIHC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.47	8.28	0.41	2.78e-15	N-glycan levels;
LIHC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.56	5.73	0.3	2.2e-8	Smoking initiation;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.84	0.63	8.42e-39	Prudent dietary pattern;
LIHC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.42	7.43	0.37	8.84e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	2.04e-15	Motion sickness;
LIHC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.36	5.9	0.3	8.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg12863693	chr15:85201151	NMB	0.49	7.06	0.36	9.47e-12	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg01206211	chr2:36825736	FEZ2	0.45	7.35	0.37	1.48e-12	Height;
LIHC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.11	0.36	6.7e-12	Axial length;
LIHC	cis	rs6442522	0.606	rs3773458	chr3:15495654	A/G	cg16303742	chr3:15540471	COLQ	0.39	6.3	0.32	9.08e-10	Uric acid levels;
LIHC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.07	19.22	0.72	2.49e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.53	-8.35	-0.41	1.75e-15	High light scatter reticulocyte count;
LIHC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.48	7.52	0.38	4.99e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.99	0.31	5.2e-9	Tonsillectomy;
LIHC	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-0.9	-10.64	-0.5	5.17e-23	Mitochondrial DNA levels;
LIHC	trans	rs2352908	0.786	rs6572526	chr14:49429557	G/A	cg16568472	chr20:3190600	ITPA	-0.45	-6.04	-0.31	3.92e-9	Social communication problems;
LIHC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg01320579	chr17:75405842	SEPT9	0.52	7.44	0.37	8.37e-13	Airflow obstruction;
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.6	8.37	0.41	1.45e-15	Eotaxin levels;
LIHC	trans	rs10411161	0.748	rs56705839	chr19:52377236	A/G	cg22319618	chr22:45562946	NUP50	-0.54	-6.81	-0.35	4.33e-11	Breast cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04371528	chr3:20081516	KAT2B	0.42	6.1	0.31	2.94e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg25894440	chr7:65020034	NA	-0.41	-6.61	-0.34	1.48e-10	Calcium levels;
LIHC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.6	-0.5	6.66e-23	Chronic sinus infection;
LIHC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg18887096	chr2:219472410	PLCD4	0.37	6.53	0.33	2.44e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7188697	0.922	rs37056	chr16:58560877	G/A	cg02549819	chr16:58548995	SETD6	-0.46	-7.21	-0.36	3.65e-12	QT interval;
LIHC	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.78	14.14	0.61	4.63e-36	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.52	9.24	0.45	2.77e-18	Coronary artery disease;
LIHC	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.04	-0.31	4.12e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs673253	0.686	rs2819333	chr1:44014573	A/T	cg06090383	chr4:174292579	SAP30	-0.42	-6.15	-0.32	2.19e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.52	6.46	0.33	3.56e-10	Metabolite levels;
LIHC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.79	-12.22	-0.55	9.41e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.7	0.34	8.52e-11	Systolic blood pressure;
LIHC	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	cg10932868	chr11:921992	NA	0.33	5.99	0.31	5.32e-9	Alzheimer's disease (late onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18850112	chr2:70329648	NA	0.44	6.54	0.33	2.2e-10	Hepatitis;
LIHC	cis	rs13161895	1.000	rs12656814	chr5:179471556	G/A	cg06664874	chr5:179499304	RNF130	0.61	7.56	0.38	3.66e-13	LDL cholesterol;
LIHC	cis	rs12744310	0.887	rs12032040	chr1:41818307	C/T	cg03962019	chr1:41807865	NA	0.4	6.38	0.33	5.74e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.94	16.17	0.66	4.53e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9322817	0.902	rs7764251	chr6:105197091	G/T	cg02098413	chr6:105308735	HACE1	-0.38	-6.13	-0.31	2.38e-9	Thyroid stimulating hormone;
LIHC	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.03e-26	Chronic sinus infection;
LIHC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg03929089	chr4:120376271	NA	0.5	7.35	0.37	1.46e-12	Body mass index;
LIHC	cis	rs9649465	0.967	rs7809453	chr7:123301940	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.59e-14	Migraine;
LIHC	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg16914508	chr2:239161102	PER2	0.83	5.97	0.31	5.94e-9	Irritable bowel syndrome;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.1	-0.51	1.16e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs3106136	0.647	rs6532483	chr4:95293558	A/T	cg11021082	chr4:95130006	SMARCAD1	0.35	5.98	0.31	5.48e-9	Capecitabine sensitivity;
LIHC	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.28	6.04	0.31	4.12e-9	Pulmonary function;
LIHC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg25356066	chr3:128598488	ACAD9	0.52	7.21	0.36	3.68e-12	IgG glycosylation;
LIHC	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.22	0.32	1.47e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.92	-0.31	7.68e-9	Life satisfaction;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26398333	chr1:153895721	GATAD2B	0.49	6.99	0.35	1.41e-11	Pancreatic cancer;
LIHC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.92	11.62	0.53	1.58e-26	Coronary artery disease;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.52	-6.63	-0.34	1.34e-10	Coronary artery calcification;
LIHC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg16989086	chr20:62203971	PRIC285	0.52	7.4	0.37	1.09e-12	Glioblastoma;
LIHC	cis	rs10128251	0.962	rs10752281	chr10:5711220	C/T	cg24097872	chr10:5724021	NA	-0.77	-11.11	-0.52	1.05e-24	Childhood ear infection;
LIHC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	-0.5	-7.22	-0.36	3.32e-12	Glycated hemoglobin levels;
LIHC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg09137382	chr11:130731461	NA	0.41	6.16	0.32	2.07e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.22	0.32	1.42e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg00825309	chr19:58991885	ZNF446	-0.53	-8.17	-0.4	6.22e-15	Uric acid clearance;
LIHC	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.74	-11.1	-0.51	1.22e-24	Obesity-related traits;
LIHC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs986417	0.901	rs7160405	chr14:60970004	G/C	cg27398547	chr14:60952738	C14orf39	0.85	9.85	0.47	2.61e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.62	9.68	0.46	9.32e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg15691649	chr6:25882328	NA	0.77	10.33	0.49	5.74e-22	Blood metabolite levels;
LIHC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.35	-6.37	-0.33	6.12e-10	Aortic root size;
LIHC	cis	rs7546668	1.000	rs7546668	chr1:15855123	G/C	cg11706911	chr1:15910989	AGMAT	0.45	6.97	0.35	1.67e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.61e-12	Bipolar disorder;
LIHC	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.61	0.38	2.64e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.46	6.98	0.35	1.55e-11	Diastolic blood pressure;
LIHC	cis	rs7212590	0.618	rs59767604	chr17:58041339	C/G	cg10252138	chr17:58120427	NA	-0.6	-6.07	-0.31	3.35e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs72653721	0.689	rs4713160	chr6:11057513	T/A	cg13562911	chr6:11044106	ELOVL2	0.51	7.53	0.38	4.55e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg09417038	chr21:47716443	C21orf57	-0.54	-8.11	-0.4	9.2e-15	Testicular germ cell tumor;
LIHC	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.89	-0.35	2.64e-11	Blood protein levels;
LIHC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.22e-26	Motion sickness;
LIHC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.99	0.51	2.87e-24	Platelet count;
LIHC	trans	rs78049276	0.688	rs75697049	chr4:148375242	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.6	-0.38	2.94e-13	Pulse pressure;
LIHC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.59	-10.77	-0.5	1.71e-23	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6600671	1.000	rs1591882	chr1:121183313	G/A	cg09829573	chr1:144692074	NBPF9	-0.42	-7.62	-0.38	2.45e-13	Hip geometry;
LIHC	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg10756647	chr7:56101905	PSPH	1.0	11.73	0.54	5.99e-27	Gout;
LIHC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.49	6.1	0.31	2.89e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.45	7.25	0.36	2.81e-12	Red blood cell count;
LIHC	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-7.04	-0.36	1.08e-11	Neuroticism;
LIHC	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.6	-0.34	1.57e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9513627	1.000	rs4294655	chr13:100216696	A/G	cg25919922	chr13:100150906	NA	0.78	7.03	0.36	1.13e-11	Obesity-related traits;
LIHC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.53	0.64	1.5e-41	Chronic sinus infection;
LIHC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.53	0.33	2.35e-10	Lung cancer;
LIHC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg12365402	chr11:9010492	NRIP3	-0.25	-6.32	-0.32	8.25e-10	Hemoglobin concentration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23891596	chr19:50169132	IRF3;BCL2L12	0.48	7.03	0.36	1.13e-11	Lung function (FEV1/FVC);
LIHC	trans	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg10756647	chr7:56101905	PSPH	1.11	13.27	0.58	1.06e-32	Diabetic kidney disease;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-0.52	-7.54	-0.38	4.13e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.26	7.01	0.35	1.26e-11	Type 2 diabetes;
LIHC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.0	0.31	5.09e-9	Educational attainment;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-6.24	-0.32	1.3e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-7.99	-0.4	2.05e-14	Obesity-related traits;
LIHC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-10.43	-0.49	2.72e-22	Breast cancer;
LIHC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.32	-0.32	7.98e-10	Longevity;Endometriosis;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs10838687	0.867	rs2957873	chr11:47249294	G/A	cg25783544	chr11:47291846	MADD	-0.5	-6.53	-0.33	2.36e-10	Proinsulin levels;
LIHC	cis	rs25645	0.502	rs1563103	chr17:38111740	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-7.29	-0.37	2.19e-12	Myeloid white cell count;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.1	0.4	9.76e-15	Height;
LIHC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-12.06	-0.55	3.7e-28	Alzheimer's disease (late onset);
LIHC	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.39	6.31	0.32	8.74e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.44	-7.11	-0.36	6.88e-12	Menarche (age at onset);
LIHC	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Systemic lupus erythematosus;
LIHC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.44	7.18	0.36	4.36e-12	Red blood cell count;
LIHC	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.86	0.6	5.82e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	5.89	0.3	9.12e-9	Protein C levels;
LIHC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.55	-9.23	-0.45	2.94e-18	Blood metabolite levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07466437	chr6:8086756	EEF1E1;SCARNA27	-0.37	-6.11	-0.31	2.72e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.8	12.68	0.57	1.83e-30	Cognitive test performance;
LIHC	cis	rs67981189	0.593	rs3784067	chr14:71480178	G/C	cg15816911	chr14:71606274	NA	0.39	6.18	0.32	1.81e-9	Schizophrenia;
LIHC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.67	-9.57	-0.46	2.15e-19	Obesity-related traits;
LIHC	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg07689907	chr11:61582574	FADS1	0.41	5.96	0.31	6.39e-9	Trans fatty acid levels;
LIHC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.5	-12.47	-0.56	1.14e-29	Alzheimer's disease (late onset);
LIHC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.33	-6.57	-0.33	1.9e-10	Body mass index;
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.67	12.8	0.57	6.41e-31	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1355223	0.902	rs1588353	chr11:34730814	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.39	-0.33	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19280121	chr17:21117780	TMEM11	0.43	6.14	0.32	2.24e-9	Pancreatic cancer;
LIHC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.48	-5.8	-0.3	1.48e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.14	0.32	2.3e-9	Cognitive ability;
LIHC	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.7e-11	Ileal carcinoids;
LIHC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg11764359	chr7:65958608	NA	0.55	5.83	0.3	1.29e-8	Diabetic kidney disease;
LIHC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg02079420	chr8:82753780	SNX16	0.37	6.8	0.34	4.77e-11	Diastolic blood pressure;
LIHC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7219021	1.000	rs7219021	chr17:46840541	A/C	cg14968300	chr8:23585186	NA	-0.33	-6.22	-0.32	1.43e-9	Schizophrenia or bipolar disorder;
LIHC	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.27	7.33	0.37	1.69e-12	Type 2 diabetes;
LIHC	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.79	-14.06	-0.61	9.24e-36	Height;
LIHC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.69	0.53	8.72e-27	Motion sickness;
LIHC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg11812906	chr14:75593930	NEK9	0.39	6.1	0.31	2.94e-9	IgG glycosylation;
LIHC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.68	10.63	0.5	5.23e-23	Platelet count;
LIHC	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.78	-8.51	-0.42	5.6e-16	Exhaled nitric oxide output;
LIHC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.57	9.3	0.45	1.69e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg22563815	chr15:78856949	CHRNA5	-0.32	-5.73	-0.3	2.2e-8	Sudden cardiac arrest;
LIHC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.34	14.36	0.61	6.27e-37	Eosinophil percentage of granulocytes;
LIHC	trans	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg26939375	chr7:64535504	NA	-0.38	-6.07	-0.31	3.32e-9	Aortic root size;
LIHC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.84	13.35	0.59	4.99e-33	Breast cancer;
LIHC	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg08824895	chr13:115047677	UPF3A	0.49	6.98	0.35	1.51e-11	Schizophrenia;
LIHC	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg14092571	chr14:90743983	NA	0.43	6.88	0.35	2.89e-11	Mortality in heart failure;
LIHC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.51	-7.26	-0.37	2.65e-12	High light scatter reticulocyte count;
LIHC	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.23	-0.48	1.3e-21	Eye color traits;
LIHC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg02640540	chr1:67518911	SLC35D1	0.43	6.8	0.35	4.68e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.57	-13.96	-0.6	2.36e-35	White blood cell count (basophil);
LIHC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.74	12.78	0.57	7.66e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.38	7.07	0.36	8.66e-12	Corneal structure;
LIHC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.67	5.85	0.3	1.13e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg22961513	chr11:14280813	SPON1	-0.43	-6.45	-0.33	3.82e-10	Mitochondrial DNA levels;
LIHC	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg20991723	chr1:152506922	NA	0.39	5.91	0.3	8.08e-9	Hair morphology;
LIHC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.6	8.95	0.44	2.35e-17	Recombination rate (females);
LIHC	cis	rs7703744	0.747	rs7707470	chr5:118680273	G/A	cg04195774	chr5:118677172	TNFAIP8	-0.41	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.7	-10.23	-0.48	1.32e-21	Eosinophil percentage of white cells;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08493338	chr16:354269	AXIN1	0.42	6.32	0.32	8.16e-10	Bilirubin levels;
LIHC	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.9	-0.39	3.77e-14	Capecitabine sensitivity;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.4	-5.77	-0.3	1.78e-8	Longevity;
LIHC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.86	13.05	0.58	7.33e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4878497	0.582	rs7874563	chr9:32443974	T/C	cg14296220	chr9:32431791	ACO1	0.57	9.82	0.47	3.27e-20	Inflammatory skin disease;
LIHC	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg23229016	chr1:26872525	RPS6KA1	0.23	6.02	0.31	4.41e-9	Glucose homeostasis traits;
LIHC	cis	rs7116495	1.000	rs531326	chr11:71570656	A/G	cg26138937	chr11:71823887	C11orf51	0.69	6.63	0.34	1.32e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg14709524	chr16:89940631	TCF25	0.54	7.0	0.35	1.33e-11	Skin colour saturation;
LIHC	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.16	0.48	2.34e-21	Post bronchodilator FEV1;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.18	-0.36	4.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs1030268	0.651	rs12707118	chr7:133474900	C/T	cg10665199	chr7:133106180	EXOC4	-0.43	-6.08	-0.31	3.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8084351	0.524	rs10853628	chr18:50770638	T/C	cg24270629	chr18:50823537	DCC	-0.46	-6.84	-0.35	3.56e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.18	-0.48	2e-21	Extrinsic epigenetic age acceleration;
LIHC	trans	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg16088116	chr21:44841560	SIK1	-0.41	-6.39	-0.33	5.52e-10	Coronary artery disease;
LIHC	cis	rs8084351	0.577	rs4453578	chr18:50620752	A/G	cg24270629	chr18:50823537	DCC	0.44	6.7	0.34	8.42e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.91	9.65	0.46	1.23e-19	Alzheimer's disease (late onset);
LIHC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.64	12.57	0.56	4.76e-30	Schizophrenia;
LIHC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg03859395	chr2:55845619	SMEK2	0.83	14.77	0.62	1.52e-38	Metabolic syndrome;
LIHC	cis	rs3762637	0.941	rs9863712	chr3:122099906	C/T	cg24169773	chr3:122142474	KPNA1	-0.48	-9.29	-0.45	1.82e-18	LDL cholesterol levels;
LIHC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.35	-8.63	-0.42	2.42e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	7.99	0.4	2.07e-14	Schizophrenia;
LIHC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.39	6.07	0.31	3.38e-9	Multiple sclerosis;
LIHC	cis	rs992157	0.764	rs2891076	chr2:219184398	C/T	cg00012203	chr2:219082015	ARPC2	0.75	10.52	0.49	1.33e-22	Colorectal cancer;
LIHC	cis	rs903552	1.000	rs12915569	chr15:102001883	G/A	cg19295451	chr15:102010161	PCSK6	-0.43	-5.87	-0.3	1e-8	Diabetic kidney disease;
LIHC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.1	-0.31	2.89e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.39	7.28	0.37	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9475752	0.744	rs9464407	chr6:56779570	A/G	cg25726699	chr6:135826776	C6orf217	0.4	6.09	0.31	2.99e-9	Menarche (age at onset);
LIHC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.94	17.86	0.69	7.08e-51	Menopause (age at onset);
LIHC	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	0.51	9.29	0.45	1.81e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-9.1	-0.44	7.52e-18	Platelet distribution width;
LIHC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.16e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs354225	0.608	rs168505	chr2:54920968	C/T	cg26097391	chr2:54893211	SPTBN1	0.44	6.26	0.32	1.18e-9	Schizophrenia;
LIHC	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.18	0.61	3.24e-36	Bipolar disorder;
LIHC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg14067834	chr17:29058358	SUZ12P	0.71	7.01	0.35	1.26e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.56	7.38	0.37	1.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg07541023	chr7:19748670	TWISTNB	0.4	6.02	0.31	4.46e-9	Thyroid stimulating hormone;
LIHC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg17980119	chr2:219472607	PLCD4	0.35	6.02	0.31	4.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg17764715	chr19:33622953	WDR88	0.41	5.74	0.3	2.09e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	0.73	12.47	0.56	1.11e-29	Testicular germ cell tumor;
LIHC	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.36	-6.3	-0.32	8.93e-10	Menopause (age at onset);
LIHC	trans	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg01596870	chr19:55963115	NA	-0.62	-7.22	-0.36	3.4e-12	Obesity-related traits;
LIHC	cis	rs9473924	0.542	rs9296645	chr6:50831194	A/G	cg14470998	chr6:50812995	TFAP2B	0.89	10.14	0.48	2.75e-21	Body mass index;
LIHC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs17094222	0.812	rs1891914	chr10:102434048	T/A	cg26540559	chr10:102447443	NA	0.33	6.28	0.32	1.02e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.47	-0.42	7.37e-16	Colorectal cancer;
LIHC	cis	rs2607426	0.681	rs2254338	chr19:41255603	G/A	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.56	-6.64	-0.34	1.21e-10	Blood protein levels;
LIHC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.71	-0.34	8.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.54	0.53	2.98e-26	Tonsillectomy;
LIHC	cis	rs9513627	0.915	rs73556174	chr13:100121797	T/C	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.66	-10.93	-0.51	4.67e-24	Bipolar disorder;
LIHC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.76	-17.73	-0.69	2.51e-50	Brugada syndrome;
LIHC	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.55	7.34	0.37	1.53e-12	Vitiligo;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.52	-0.33	2.46e-10	Total body bone mineral density;
LIHC	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-0.78	-8.49	-0.42	6.5e-16	Exhaled nitric oxide output;
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21747090	chr2:27597821	SNX17	-0.41	-6.12	-0.31	2.64e-9	Total body bone mineral density;
LIHC	cis	rs10056811	0.538	rs2035191	chr5:74413713	T/C	cg19683494	chr5:74908142	NA	0.58	7.15	0.36	5.23e-12	Coronary artery disease;
LIHC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.95	0.31	6.78e-9	HDL cholesterol levels;
LIHC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.53	8.12	0.4	8.59e-15	Resting heart rate;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg14601621	chr9:97848457	C9orf3	0.36	6.1	0.31	2.84e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.43	6.21	0.32	1.51e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20203792	chr4:20701925	PACRGL	0.42	6.76	0.34	5.8e-11	Cognitive function;
LIHC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg20302533	chr7:39170763	POU6F2	0.38	7.02	0.35	1.22e-11	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg25894440	chr7:65020034	NA	0.54	6.22	0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg07451762	chr16:28383216	NA	0.39	7.05	0.36	9.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.4	7.33	0.37	1.69e-12	Schizophrenia;
LIHC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg25801113	chr15:45476975	SHF	0.38	6.51	0.33	2.69e-10	Uric acid levels;
LIHC	cis	rs5769707	0.777	rs8141219	chr22:50044546	A/G	cg07959070	chr22:50026188	C22orf34	-0.35	-8.83	-0.43	5.38e-17	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.47	-7.75	-0.39	1.03e-13	Endometrial cancer;
LIHC	trans	rs6058796	1.000	rs6058796	chr20:31255829	C/T	cg02600331	chr11:130417168	NA	0.36	7.84	0.39	5.92e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	trans	rs10411161	0.702	rs10423838	chr19:52387283	C/T	cg22319618	chr22:45562946	NUP50	-0.61	-8.37	-0.41	1.47e-15	Breast cancer;
LIHC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07305463	chr2:136567211	LCT	-0.4	-7.6	-0.38	2.8e-13	Mosquito bite size;
LIHC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	0.81	14.08	0.61	7.7e-36	Eosinophil percentage of white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06380923	chr16:2273553	E4F1	0.44	6.1	0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.26	-0.32	1.16e-9	Prevalent atrial fibrillation;
LIHC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.82	-0.39	6.62e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.3	6.3	0.32	9.02e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.22	14.7	0.62	3.05e-38	Psoriasis vulgaris;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs12980942	0.810	rs8105901	chr19:41792092	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.83	0.35	3.95e-11	Coronary artery disease;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg19318889	chr4:1322082	MAEA	0.39	6.35	0.32	6.73e-10	Obesity-related traits;
LIHC	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg22951263	chr5:87985283	NA	-0.39	-6.72	-0.34	7.43e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4699052	1.000	rs7661702	chr4:104140129	C/G	cg16532752	chr4:104119610	CENPE	-0.43	-6.94	-0.35	1.98e-11	Testicular germ cell tumor;
LIHC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg14440974	chr22:39074834	NA	-0.43	-6.84	-0.35	3.77e-11	Menopause (age at onset);
LIHC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.8e-13	Alzheimer's disease (late onset);
LIHC	cis	rs16958440	0.867	rs10083937	chr18:44695602	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.71	-9.2	-0.45	3.59e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.62	8.62	0.42	2.45e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.57	-0.46	2.3e-19	Initial pursuit acceleration;
LIHC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.93	-0.31	7.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.15	-0.74	4.44e-60	Height;
LIHC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	6.11e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1865721	0.682	rs3745082	chr18:73142734	G/T	cg26385618	chr18:73139727	C18orf62	-0.28	-7.66	-0.38	1.87e-13	Intelligence;
LIHC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.48	-7.14	-0.36	5.52e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.41	-8.63	-0.42	2.28e-16	Obesity-related traits;
LIHC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.28	0.52	2.58e-25	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01593421	chr7:65303149	NA	0.48	6.51	0.33	2.74e-10	Hepatitis;
LIHC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.61	6.87	0.35	3e-11	Menarche (age at onset);
LIHC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.42	-0.37	9.42e-13	IgG glycosylation;
LIHC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-7.59	-0.38	3.02e-13	Chronic sinus infection;
LIHC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-6.24	-0.32	1.29e-9	Subjective well-being;
LIHC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.42	9.56	0.46	2.46e-19	Erythrocyte sedimentation rate;
LIHC	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.98	9.0	0.44	1.56e-17	White matter integrity;
LIHC	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.36	-8.56	-0.42	3.75e-16	Cutaneous nevi;
LIHC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.61	9.44	0.45	6.02e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg02187348	chr16:89574699	SPG7	0.45	6.55	0.33	2.16e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.86	0.3	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.3	-0.41	2.41e-15	Chronic sinus infection;
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08677398	chr8:58056175	NA	0.41	6.27	0.32	1.07e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg08847533	chr14:75593920	NEK9	-0.57	-9.32	-0.45	1.45e-18	IgG glycosylation;
LIHC	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.62	7.25	0.37	2.76e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg09455208	chr3:40491958	NA	-0.32	-6.25	-0.32	1.25e-9	Renal cell carcinoma;
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.76	-12.93	-0.57	2.03e-31	Bipolar disorder and schizophrenia;
LIHC	cis	rs12931792	0.682	rs12373078	chr16:30187676	T/G	cg17640201	chr16:30407289	ZNF48	0.39	6.45	0.33	3.84e-10	Tonsillectomy;
LIHC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04476341	chr5:669733	TPPP	0.39	8.78	0.43	7.81e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg24514230	chr11:3688722	CHRNA10	0.42	7.07	0.36	8.57e-12	Bipolar disorder;
LIHC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.63	-0.34	1.29e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.62	12.71	0.57	1.37e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.46	8.55	0.42	4.2e-16	Testicular germ cell tumor;
LIHC	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.3	6.41	0.33	4.79e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg19735590	chr5:154026979	NA	0.48	6.07	0.31	3.34e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg15123519	chr2:136567270	LCT	-0.36	-5.85	-0.3	1.14e-8	Corneal structure;
LIHC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.53	5.77	0.3	1.73e-8	Alzheimer's disease;
LIHC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.96	-18.76	-0.71	1.72e-54	Intelligence (multi-trait analysis);
LIHC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.42	6.8	0.35	4.66e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.43	9.17	0.44	4.56e-18	Migraine;
LIHC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.77	-0.57	8.31e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg18225595	chr11:63971243	STIP1	0.65	8.14	0.4	7.43e-15	Mean platelet volume;
LIHC	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	11.06	0.51	1.62e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.86	13.05	0.58	7.33e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.47	-7.68	-0.38	1.64e-13	Cognitive function;
LIHC	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-5.82	-0.3	1.35e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.46	6.8	0.35	4.67e-11	Aortic root size;
LIHC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.56	0.42	3.77e-16	Motion sickness;
LIHC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.36	-5.72	-0.3	2.3e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04530015	chr2:215796436	ABCA12	-0.38	-6.23	-0.32	1.38e-9	Neuroblastoma;
LIHC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.61	-8.65	-0.42	2.08e-16	Blood metabolite levels;
LIHC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg26939375	chr7:64535504	NA	0.47	7.13	0.36	5.83e-12	Aortic root size;
LIHC	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.79	15.25	0.64	2.04e-40	Testicular germ cell tumor;
LIHC	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg23248424	chr5:179741104	GFPT2	-0.43	-6.32	-0.32	8.05e-10	Height;
LIHC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	0.74	8.02	0.4	1.71e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.74	-0.3	2.12e-8	Axial length;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13446235	chr16:90039146	AFG3L1;CENPBD1	0.5	6.92	0.35	2.19e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs903552	0.932	rs1587108	chr15:102006825	G/A	cg25677261	chr15:102009856	PCSK6	-0.45	-6.0	-0.31	5.05e-9	Diabetic kidney disease;
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.52	0.77	1.68e-69	Height;
LIHC	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.87	13.61	0.59	5.27e-34	Gastritis;
LIHC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.94	0.39	2.89e-14	Motion sickness;
LIHC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-0.83	-6.87	-0.35	3.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg03037974	chr15:76606532	NA	-0.79	-16.53	-0.67	1.6e-45	Blood metabolite levels;
LIHC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.81	9.58	0.46	2.01e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.99	-0.4	2.12e-14	Total cholesterol levels;
LIHC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.87	12.03	0.55	5.07e-28	Post bronchodilator FEV1;
LIHC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.37	6.44	0.33	3.95e-10	Methadone dose in opioid dependence;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.67	8.37	0.41	1.5e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.86	-0.3	1.06e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.67	-0.34	1.01e-10	Obesity-related traits;
LIHC	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	18.04	0.7	1.42e-51	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12463550	chr7:65579703	CRCP	0.7	7.18	0.36	4.49e-12	Diabetic kidney disease;
LIHC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg23485639	chr6:28045615	ZNF165	0.38	5.95	0.31	6.46e-9	Cardiac Troponin-T levels;
LIHC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.26	0.37	2.61e-12	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.46	-6.1	-0.31	2.91e-9	Glioblastoma;Glioma;
LIHC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.91	8.56	0.42	3.82e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg23254163	chr1:152506842	NA	0.23	5.96	0.31	6.15e-9	Hair morphology;
LIHC	cis	rs3770081	1.000	rs12328085	chr2:86262009	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-9.3	-0.45	1.76e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.71	11.17	0.52	6.58e-25	Corneal astigmatism;
LIHC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.68	0.34	9.78e-11	Sudden cardiac arrest;
LIHC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.74	0.34	6.66e-11	Rheumatoid arthritis;
LIHC	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg09060608	chr5:178986726	RUFY1	0.38	5.79	0.3	1.59e-8	Lung cancer;
LIHC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.56	8.94	0.44	2.52e-17	Birth weight;
LIHC	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.4	-0.37	1.03e-12	Brugada syndrome;
LIHC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02985541	chr2:219472218	PLCD4	0.45	8.47	0.42	7.32e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg05425664	chr17:57184151	TRIM37	0.41	5.76	0.3	1.88e-8	Testicular germ cell tumor;
LIHC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.69	11.51	0.53	4.06e-26	Menopause (age at onset);
LIHC	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.44	11.32	0.52	1.95e-25	Cutaneous nevi;
LIHC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.89	16.12	0.66	7.14e-44	Menopause (age at onset);
LIHC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg12798992	chr6:167411361	FGFR1OP	0.6	10.15	0.48	2.49e-21	Crohn's disease;
LIHC	trans	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg19894588	chr14:64061835	NA	-0.68	-10.12	-0.48	3.18e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg00204512	chr16:28754710	NA	0.39	6.93	0.35	2.12e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.41	6.41	0.33	4.8e-10	Mean corpuscular volume;
LIHC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg06289844	chr6:126071538	HEY2	0.34	5.88	0.3	9.94e-9	Brugada syndrome;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.74	-9.03	-0.44	1.25e-17	Morning vs. evening chronotype;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08722104	chr11:47448306	PSMC3	0.45	7.11	0.36	6.98e-12	Cognitive function;
LIHC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	0.58	9.68	0.46	9.37e-20	Intracerebral hemorrhage;White matter hyperintensity burden;
LIHC	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.26	6.15	0.32	2.14e-9	Heart rate;
LIHC	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.46	7.43	0.37	8.61e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	1.1	13.84	0.6	6.94e-35	Blood protein levels;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21747090	chr2:27597821	SNX17	-0.39	-5.77	-0.3	1.79e-8	Total body bone mineral density;
LIHC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.48	-8.02	-0.4	1.74e-14	Platelet distribution width;
LIHC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg12310025	chr6:25882481	NA	-0.45	-6.95	-0.35	1.82e-11	Height;
LIHC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-15.95	-0.65	3.35e-43	Electrocardiographic conduction measures;
LIHC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.86	0.43	4.49e-17	Cognitive ability;
LIHC	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.3	7.05	0.36	1.01e-11	Blood protein levels;
LIHC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.45	-7.42	-0.37	9.54e-13	Menarche (age at onset);
LIHC	cis	rs7707921	1.000	rs79616997	chr5:81504600	G/T	cg15871215	chr5:81402204	ATG10	-0.6	-5.95	-0.31	6.57e-9	Breast cancer;
LIHC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg07451762	chr16:28383216	NA	0.33	6.13	0.31	2.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.32e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg04727924	chr7:799746	HEATR2	-0.59	-8.52	-0.42	5.21e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs3106136	0.649	rs11097426	chr4:95309450	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.85	0.3	1.13e-8	Capecitabine sensitivity;
LIHC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.99	-0.31	5.18e-9	Colorectal cancer;
LIHC	trans	rs875971	0.571	rs160641	chr7:65577346	G/A	cg26939375	chr7:64535504	NA	-0.41	-6.4	-0.33	5.04e-10	Aortic root size;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.09	-0.31	3.02e-9	Total body bone mineral density;
LIHC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.48	-6.39	-0.33	5.3e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.45	6.82	0.35	4.01e-11	Survival in rectal cancer;
LIHC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.67	6.28	0.32	1.01e-9	Menopause (age at onset);
LIHC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-6.19	-0.32	1.76e-9	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.59	0.34	1.7e-10	Mean corpuscular volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26817334	chr2:119613580	NA	0.46	6.04	0.31	4.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	5.94	0.31	6.94e-9	Lymphocyte counts;
LIHC	cis	rs7116495	0.618	rs7943227	chr11:71670721	G/A	cg26138937	chr11:71823887	C11orf51	-0.7	-7.08	-0.36	8.39e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.55	12.13	0.55	2.03e-28	Fat distribution (HIV);
LIHC	cis	rs6088813	0.961	rs1886691	chr20:33986271	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-5.88	-0.3	9.69e-9	Height;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg13271783	chr10:134563150	INPP5A	-0.56	-7.09	-0.36	7.62e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-5.97	-0.31	5.95e-9	Red cell distribution width;
LIHC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.74	-13.29	-0.58	8.62e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.57	8.71	0.43	1.28e-16	Type 2 diabetes;
LIHC	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg16322792	chr1:120165303	ZNF697	0.46	8.45	0.42	8.77e-16	Systemic lupus erythematosus;
LIHC	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg11642891	chr2:3452563	TTC15	-0.42	-6.69	-0.34	9.12e-11	Obesity-related traits;
LIHC	cis	rs635808	0.561	rs491700	chr6:167171838	A/G	cg05573767	chr6:167171394	RPS6KA2	-0.34	-7.26	-0.37	2.55e-12	Dental caries;
LIHC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.89	0.43	3.56e-17	Lung cancer;
LIHC	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	1.12	8.77	0.43	8.35e-17	Arsenic metabolism;
LIHC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.56	-8.85	-0.43	4.92e-17	Platelet distribution width;
LIHC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg11057378	chr10:81107060	PPIF	0.37	6.0	0.31	5.15e-9	Height;
LIHC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.89	-0.3	9.39e-9	Pulse pressure;
LIHC	cis	rs244293	0.931	rs2170942	chr17:53209515	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.44	-0.37	8.44e-13	Menarche (age at onset);
LIHC	cis	rs12594515	0.591	rs35554150	chr15:45990298	G/A	cg01629716	chr15:45996671	NA	0.55	6.35	0.32	6.98e-10	Waist circumference;Weight;
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.3e-9	Total body bone mineral density;
LIHC	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.67	13.37	0.59	4.49e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.38	-6.25	-0.32	1.22e-9	Corneal astigmatism;
LIHC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg21548813	chr6:291882	DUSP22	-0.46	-6.28	-0.32	1.02e-9	Menopause (age at onset);
LIHC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg22903471	chr2:27725779	GCKR	-0.43	-6.32	-0.32	7.98e-10	Blood metabolite levels;
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg14393609	chr7:65229607	NA	0.44	6.47	0.33	3.34e-10	Aortic root size;
LIHC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg19678392	chr7:94953810	PON1	0.47	5.81	0.3	1.44e-8	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08677398	chr8:58056175	NA	0.41	5.99	0.31	5.21e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.64	11.61	0.53	1.68e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.51	7.68	0.38	1.69e-13	Inflammatory bowel disease;
LIHC	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg02702477	chr5:179499311	RNF130	-0.75	-10.33	-0.49	5.85e-22	LDL cholesterol;
LIHC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg03060546	chr3:49711283	APEH	0.4	5.99	0.31	5.39e-9	Menarche (age at onset);
LIHC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.4	-7.28	-0.37	2.29e-12	IgG glycosylation;
LIHC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.58	0.34	1.74e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg16088116	chr21:44841560	SIK1	-0.42	-6.52	-0.33	2.59e-10	Coronary artery disease;
LIHC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.41	-8.32	-0.41	2.07e-15	Immature fraction of reticulocytes;
LIHC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.61e-14	Motion sickness;
LIHC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.87	-0.35	2.97e-11	Mean corpuscular volume;
LIHC	cis	rs507080	0.697	rs656287	chr11:118571790	A/G	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs400736	0.602	rs7553544	chr1:8165719	C/T	cg25007680	chr1:8021821	PARK7	-0.49	-6.55	-0.33	2.13e-10	Response to antidepressants and depression;
LIHC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-6.76	-0.34	6.15e-11	Personality dimensions;
LIHC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	6.83	0.35	3.84e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.67	14.0	0.6	1.66e-35	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26795923	chr22:19165960	SLC25A1	0.51	6.15	0.32	2.22e-9	Hepatitis;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.45e-10	Prudent dietary pattern;
LIHC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg07234388	chr1:156261841	TMEM79	0.47	8.19	0.41	5.11e-15	Tonsillectomy;
LIHC	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.74	9.6	0.46	1.81e-19	Psoriasis vulgaris;
LIHC	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.8	-17.78	-0.69	1.5e-50	Urate levels in lean individuals;
LIHC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.57	9.19	0.45	3.87e-18	Multiple sclerosis;
LIHC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg17724175	chr1:150552817	MCL1	0.45	9.26	0.45	2.34e-18	Melanoma;
LIHC	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.6	9.92	0.47	1.54e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.54	8.02	0.4	1.73e-14	Multiple sclerosis;
LIHC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.71e-12	Waist circumference;Weight;
LIHC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	18.79	0.71	1.3e-54	Smoking behavior;
LIHC	trans	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg17675199	chr6:35436792	RPL10A	-0.4	-8.31	-0.41	2.35e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.06	0.36	9.15e-12	Diastolic blood pressure;
LIHC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg18944383	chr4:111397179	ENPEP	0.31	7.43	0.37	8.81e-13	Coronary artery disease;
LIHC	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.41	-7.15	-0.36	5.38e-12	Lung cancer;
LIHC	trans	rs1814175	0.645	rs599890	chr11:49711718	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	1.96e-11	Height;
LIHC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.79	10.32	0.49	6.46e-22	Body mass index;
LIHC	cis	rs75908454	1.000	rs79744616	chr6:169827524	T/G	cg19338460	chr6:170058176	WDR27	-0.87	-7.81	-0.39	7.2e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1494950	0.744	rs4367169	chr4:15029803	C/T	cg12377275	chr4:15005593	CPEB2	0.85	7.46	0.37	7.2e-13	Political ideology;
LIHC	trans	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg11693508	chr17:37793320	STARD3	0.66	6.35	0.32	6.81e-10	Bipolar disorder;
LIHC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.7	12.54	0.56	6.03e-30	Colorectal cancer;
LIHC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	7.22	0.36	3.35e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06636551	chr8:101224915	SPAG1	-0.47	-8.33	-0.41	2e-15	Atrioventricular conduction;
LIHC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.69	6.74	0.34	6.73e-11	Breast cancer;
LIHC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.83	9.1	0.44	7.39e-18	Vitiligo;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13409248	chr3:40428643	ENTPD3	0.48	8.18	0.4	5.67e-15	Renal cell carcinoma;
LIHC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg04498913	chr7:1135747	C7orf50	0.37	5.73	0.3	2.19e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg10932868	chr11:921992	NA	0.38	7.14	0.36	5.52e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04961397	chr16:30990708	SETD1A	-0.43	-6.27	-0.32	1.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16958440	0.867	rs57744138	chr18:44700482	A/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03122602	chr16:89799836	ZNF276	-0.44	-6.89	-0.35	2.75e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.95	0.57	1.78e-31	Prudent dietary pattern;
LIHC	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.59	-9.28	-0.45	2.02e-18	Dental caries;
LIHC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.69	8.9	0.43	3.25e-17	Fat distribution (HIV);
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg22528358	chr1:107598549	PRMT6	0.68	11.4	0.52	9.54e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.54	-0.46	2.88e-19	Ulcerative colitis;
LIHC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.83	0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.53	-8.04	-0.4	1.52e-14	White matter hyperintensity burden;
LIHC	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-8.31	-0.41	2.31e-15	Morning vs. evening chronotype;
LIHC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12516959	chr21:47718080	NA	-0.39	-6.22	-0.32	1.47e-9	Testicular germ cell tumor;
LIHC	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.53	9.43	0.45	6.42e-19	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.78	0.34	5.25e-11	Diabetic kidney disease;
LIHC	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg12454167	chr3:186435060	KNG1	0.32	7.68	0.38	1.73e-13	Blood protein levels;
LIHC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	10.17	0.48	2.1e-21	Monocyte percentage of white cells;
LIHC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.86	15.12	0.63	6.29e-40	Oral cavity cancer;
LIHC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.18	0.44	4.05e-18	Lung cancer in ever smokers;
LIHC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.37	6.72	0.34	7.42e-11	IgG glycosylation;
LIHC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-12.54	-0.56	6.12e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.13	0.55	2.1e-28	Mean platelet volume;
LIHC	cis	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg13443165	chr9:33130375	B4GALT1	-0.34	-5.94	-0.31	7.03e-9	IgG glycosylation;
LIHC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.05	14.07	0.61	8.82e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.93	-0.51	4.89e-24	Hemoglobin concentration;
LIHC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	8.6	0.42	2.89e-16	Obesity-related traits;
LIHC	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.75	-0.71	1.96e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.01	-0.31	4.69e-9	Longevity;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg18954051	chr12:66554863	TMBIM4	0.54	6.17	0.32	1.92e-9	Mean platelet volume;
LIHC	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg14146966	chr2:61757674	XPO1	0.49	8.61	0.42	2.74e-16	Tuberculosis;
LIHC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.59	0.62	8.17e-38	Prudent dietary pattern;
LIHC	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.53	7.75	0.39	1.08e-13	Corneal astigmatism;
LIHC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg16736954	chr20:23401023	NAPB	0.71	8.5	0.42	5.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-8.13	-0.4	7.92e-15	Extraversion;
LIHC	cis	rs937213	0.676	rs8042456	chr15:40290476	G/T	cg20255370	chr15:40268687	EIF2AK4	-0.44	-6.79	-0.34	5.07e-11	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.41	-6.04	-0.31	3.95e-9	Coronary artery disease;
LIHC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.63	9.57	0.46	2.29e-19	Height;
LIHC	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	cg04338863	chr8:33670619	NA	0.31	5.8	0.3	1.49e-8	Body mass index;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.79	0.62	1.31e-38	Prudent dietary pattern;
LIHC	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.51	6.14	0.32	2.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg27170947	chr2:26402098	FAM59B	0.65	7.73	0.39	1.23e-13	Gut microbiome composition (summer);
LIHC	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg19513890	chr22:42538836	CYP2D7P1	-0.4	-7.69	-0.38	1.59e-13	Cognitive function;
LIHC	cis	rs1823913	0.599	rs1378156	chr2:192137192	A/T	cg12404831	chr2:192114017	MYO1B	-0.28	-5.72	-0.3	2.31e-8	Obesity-related traits;
LIHC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.6	8.68	0.42	1.61e-16	Menarche (age at onset);
LIHC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-6.34	-0.32	7.39e-10	Blood pressure (smoking interaction);
LIHC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.57	11.03	0.51	2.07e-24	Coronary artery disease;
LIHC	cis	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg19680485	chr15:31195859	MTMR15	-0.55	-5.9	-0.3	8.62e-9	Hypertriglyceridemia;
LIHC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.75	0.39	1.06e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-8.97	-0.44	1.97e-17	Gut microbiome composition (summer);
LIHC	trans	rs783540	0.967	rs2870966	chr15:83295244	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.34	-0.32	7.22e-10	Schizophrenia;
LIHC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.51	0.33	2.69e-10	Obesity-related traits;
LIHC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.32e-37	Blood metabolite levels;
LIHC	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.86	-0.35	3.14e-11	Blood metabolite levels;
LIHC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.59	9.9	0.47	1.71e-20	Height;
LIHC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg14440974	chr22:39074834	NA	-0.42	-6.72	-0.34	7.42e-11	Menopause (age at onset);
LIHC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.57	0.38	3.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.4	7.6	0.38	2.86e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.57	-0.67	1.08e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.54	-9.15	-0.44	5.06e-18	Smoking initiation;
LIHC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-10.9	-0.51	6.28e-24	Type 2 diabetes;
LIHC	cis	rs7106204	1.000	rs7110656	chr11:24216034	G/T	ch.11.24196551F	chr11:24239977	NA	0.68	6.83	0.35	3.89e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs12931792	0.782	rs6565176	chr16:30174926	T/C	cg17640201	chr16:30407289	ZNF48	0.47	7.26	0.37	2.66e-12	Tonsillectomy;
LIHC	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.43	-8.64	-0.42	2.2e-16	Obesity-related traits;
LIHC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.64	0.53	1.34e-26	Platelet count;
LIHC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.72	0.3	2.27e-8	Self-reported allergy;
LIHC	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.8	-0.39	7.78e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.53	5.77	0.3	1.73e-8	Alzheimer's disease;
LIHC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg16339924	chr4:17578868	LAP3	0.43	5.74	0.3	2.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08280861	chr8:58055591	NA	0.52	6.04	0.31	3.92e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.64	-9.72	-0.47	6.96e-20	Renal cell carcinoma;
LIHC	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg16691251	chr5:66510806	NA	0.48	6.82	0.35	4.24e-11	Breast cancer;
LIHC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.06	9.36	0.45	1.06e-18	Diabetic retinopathy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10705386	chr10:69644512	SIRT1	-0.54	-6.22	-0.32	1.43e-9	Systolic blood pressure;
LIHC	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.92	-0.3	7.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.57	9.05	0.44	1.11e-17	Menarche (age at onset);
LIHC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.58	6.44	0.33	4.09e-10	Neutrophil percentage of white cells;
LIHC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.79	-7.96	-0.4	2.57e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg02297831	chr4:17616191	MED28	-0.41	-5.9	-0.3	8.98e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.57	5.99	0.31	5.3300000000000004e-09	Hip geometry;
LIHC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-12.28	-0.55	5.55e-29	Electrocardiographic conduction measures;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.86	-0.3	1.08e-8	Total body bone mineral density;
LIHC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.57	8.51	0.42	5.71e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.65	-0.42	1.99e-16	Total cholesterol levels;
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg16070018	chr6:26224392	HIST1H3E	0.59	7.45	0.37	7.55e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg17749961	chr2:30669863	LCLAT1	0.47	6.01	0.31	4.68e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.54	0.33	2.22e-10	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.74	13.21	0.58	1.74e-32	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19723775	chr5:179050963	HNRNPH1	0.45	6.97	0.35	1.65e-11	Lung cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02056921	chr1:901892	PLEKHN1	0.39	6.42	0.33	4.52e-10	Cognitive function;
LIHC	cis	rs7078219	0.523	rs10883366	chr10:101287785	G/A	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.89	-0.3	9.19e-9	Dental caries;
LIHC	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg05714579	chr10:131428358	MGMT	-0.46	-7.7	-0.38	1.46e-13	Response to temozolomide;
LIHC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20135002	chr11:47629003	NA	-0.57	-9.61	-0.46	1.68e-19	Subjective well-being;
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg00280220	chr17:61926910	NA	0.42	6.83	0.35	3.82e-11	Prudent dietary pattern;
LIHC	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg16724585	chr3:197361211	NA	-0.46	-6.4	-0.33	5.25e-10	Pancreatic cancer;
LIHC	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.7	9.86	0.47	2.48e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.55	9.15	0.44	5.17e-18	Longevity;Endometriosis;
LIHC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.48	8.99	0.44	1.69e-17	Hemoglobin concentration;
LIHC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg17845761	chr1:175162550	KIAA0040	-0.31	-5.81	-0.3	1.45e-8	Diastolic blood pressure;
LIHC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.09	-0.4	1.03e-14	Body mass index;
LIHC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.32	6.99	0.35	1.44e-11	Ulcerative colitis;
LIHC	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.79	-0.69	1.42e-50	Schizophrenia;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11509341	chr2:75787820	FAM176A	-0.37	-6.13	-0.31	2.46e-9	Triglycerides;
LIHC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.05	-0.48	5.62e-21	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs539514	0.690	rs1924214	chr13:76317632	A/G	cg04757411	chr13:76259545	LMO7	-0.46	-8.21	-0.41	4.48e-15	Type 1 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24541279	chr10:71993373	PPA1	0.46	6.24	0.32	1.27e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	1.03	20.75	0.75	1.71e-62	Breast cancer;
LIHC	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.96	0.4	2.5e-14	Corneal astigmatism;
LIHC	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.84	-0.3	1.23e-8	Resting heart rate;
LIHC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.68	10.95	0.51	4.04e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	12.5	0.56	8.95e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.97	15.12	0.63	6.35e-40	Vitamin D levels;
LIHC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.22	-16.58	-0.67	9.99e-46	Ulcerative colitis;
LIHC	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg06640241	chr16:89574553	SPG7	0.51	7.62	0.38	2.5e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.37	-7.89	-0.39	4.16e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.07e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3106136	0.678	rs7675615	chr4:95295352	T/G	cg11021082	chr4:95130006	SMARCAD1	0.35	6.0	0.31	5.07e-9	Capecitabine sensitivity;
LIHC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.4	-5.95	-0.31	6.68e-9	Iron status biomarkers;
LIHC	cis	rs2274273	0.805	rs28612464	chr14:55816411	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.59	-0.34	1.66e-10	Protein biomarker;
LIHC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.52	-7.32	-0.37	1.73e-12	Body mass index;
LIHC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.59	8.52	0.42	5.05e-16	Coronary artery disease;
LIHC	trans	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg08566640	chr11:64091735	NA	-0.61	-10.1	-0.48	3.57e-21	Height;
LIHC	cis	rs611744	0.967	rs660065	chr8:109191932	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.61	-0.34	1.44e-10	Longevity;
LIHC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02985541	chr2:219472218	PLCD4	-0.41	-6.64	-0.34	1.24e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7923837	0.663	rs7903302	chr10:94429511	T/C	cg25506282	chr10:94462361	NA	0.45	7.77	0.39	9.38e-14	Body mass index;Multiple sclerosis;
LIHC	cis	rs2108622	0.559	rs7252638	chr19:15981025	G/C	cg13772218	chr19:15982569	NA	0.37	7.83	0.39	6.2e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02593601	chr10:17707418	STAM	0.36	6.24	0.32	1.27e-9	Hepatitis;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.56	-0.33	1.97e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.12	0.4	8.28e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.36	-0.41	1.64e-15	HDL cholesterol;
LIHC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.43	6.02	0.31	4.51e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.62	11.25	0.52	3.39e-25	Gestational age at birth (maternal effect);
LIHC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.89	-18.17	-0.7	4.07e-52	Height;
LIHC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.84	10.57	0.5	8.49e-23	Cognitive function;
LIHC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.57	9.28	0.45	1.95e-18	Longevity;Endometriosis;
LIHC	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg20991723	chr1:152506922	NA	0.39	5.92	0.3	7.98e-9	Hair morphology;
LIHC	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg09695851	chr17:3907499	NA	0.63	7.27	0.37	2.41e-12	Type 2 diabetes;
LIHC	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	6.12	0.31	2.62e-9	Response to antipsychotic treatment;
LIHC	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.37	-6.15	-0.32	2.13e-9	Total cholesterol levels;
LIHC	cis	rs1983891	0.706	rs745548	chr6:41557117	G/T	cg20194872	chr6:41519635	FOXP4	-0.4	-6.16	-0.32	2.05e-9	Prostate cancer;
LIHC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.24	-0.36	2.95e-12	Ulcerative colitis;
LIHC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.4	6.65	0.34	1.15e-10	Red blood cell count;
LIHC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.75	9.23	0.45	2.79e-18	Morning vs. evening chronotype;
LIHC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17094222	0.812	rs7900417	chr10:102434576	T/C	cg26540559	chr10:102447443	NA	0.33	6.23	0.32	1.36e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.88	14.38	0.61	5.1e-37	Multiple sclerosis;
LIHC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.68	12.48	0.56	1.02e-29	Mortality in heart failure;
LIHC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg03013999	chr17:37608204	MED1	-0.36	-5.96	-0.31	6.11e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs4919087	0.715	rs2484881	chr10:98998266	C/T	cg25902810	chr10:99078978	FRAT1	-0.51	-5.91	-0.3	8.29e-9	Monocyte count;
LIHC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.05	0.36	1e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.39	-0.37	1.14e-12	Metabolite levels;
LIHC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-9.39	-0.45	8.98e-19	Crohn's disease;
LIHC	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.68	-12.29	-0.55	5.3e-29	Mean platelet volume;
LIHC	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.06e-17	Severe influenza A (H1N1) infection;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg00424677	chr19:32836465	ZNF507	-0.51	-6.24	-0.32	1.27e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.67	-11.44	-0.53	6.78e-26	Pediatric autoimmune diseases;
LIHC	cis	rs2540917	0.669	rs12105503	chr2:60650742	A/G	cg00543073	chr2:60773386	BCL11A	-0.33	-6.54	-0.33	2.28e-10	Mean corpuscular volume;
LIHC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.12	0.66	7.17e-44	Breast cancer;
LIHC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.75	5.91	0.3	8.09e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg16970926	chr12:29381810	FAR2	0.33	7.2	0.36	3.77e-12	QT interval;
LIHC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs10216189	1.000	rs4724699	chr7:5526712	G/A	cg05318486	chr7:5553423	FBXL18	-0.57	-8.46	-0.42	8.15e-16	Relative hand skill in reading disability;
LIHC	cis	rs7602441	0.521	rs12052706	chr2:14765777	A/G	cg06545361	chr2:14773388	FAM84A	0.52	5.97	0.31	5.9e-9	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg14092571	chr14:90743983	NA	-0.41	-6.53	-0.33	2.34e-10	Mortality in heart failure;
LIHC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg24879335	chr3:133465180	TF	0.28	6.45	0.33	3.83e-10	Iron status biomarkers;
LIHC	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.38	6.84	0.35	3.69e-11	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10149326	chr7:6630190	C7orf26	-0.45	-6.5	-0.33	2.85e-10	Pancreatic cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01295842	chr19:16683254	SLC35E1	-0.49	-6.39	-0.33	5.36e-10	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg11764359	chr7:65958608	NA	0.59	6.14	0.32	2.32e-9	Diabetic kidney disease;
LIHC	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg06360820	chr2:242988706	NA	-0.79	-11.58	-0.53	2.18e-26	Obesity-related traits;
LIHC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.28e-9	Menopause (age at onset);
LIHC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.28	0.49	9.02e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.3	16.95	0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02290350	chr8:58132656	NA	0.49	10.03	0.48	6.34e-21	Developmental language disorder (linguistic errors);
LIHC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.58	8.91	0.43	3.08e-17	Multiple sclerosis;
LIHC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.8	-9.83	-0.47	2.95e-20	Mean platelet volume;
LIHC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07305463	chr2:136567211	LCT	-0.39	-5.98	-0.31	5.48e-9	Corneal structure;
LIHC	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.32	-7.25	-0.36	2.84e-12	Cutaneous nevi;
LIHC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.91	16.91	0.67	4.8e-47	Menopause (age at onset);
LIHC	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-12.84	-0.57	4.67e-31	Pediatric autoimmune diseases;
LIHC	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.98	-0.35	1.54e-11	Bipolar disorder;
LIHC	cis	rs903552	0.800	rs6598478	chr15:102001696	A/T	cg19295451	chr15:102010161	PCSK6	-0.45	-6.05	-0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.98	0.31	5.48e-9	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs2274273	0.837	rs59871474	chr14:55779363	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.56	-0.33	1.95e-10	Protein biomarker;
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg19016816	chr7:1267987	NA	0.26	5.8	0.3	1.49e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg20195005	chr22:42527684	CYP2D6	0.31	5.96	0.31	6.14e-9	Birth weight;
LIHC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.72	11.6	0.53	1.79e-26	Body mass index;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg00121389	chr8:17555302	MTUS1	0.53	6.95	0.35	1.87e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.49	-16.54	-0.67	1.41e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs7192750	0.583	rs2550043	chr16:72067491	T/C	cg14768367	chr16:72042858	DHODH	0.63	6.18	0.32	1.77e-9	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.05	0.48	5.37e-21	Colorectal cancer;
LIHC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.36	0.56	2.93e-29	Colorectal cancer;
LIHC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg00800038	chr16:89945340	TCF25	-0.63	-9.48	-0.46	4.32e-19	Skin colour saturation;
LIHC	cis	rs963731	0.649	rs1454223	chr2:39224351	G/T	cg04010122	chr2:39346883	SOS1	-0.7	-5.97	-0.31	5.98e-9	Corticobasal degeneration;
LIHC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.54	-7.68	-0.38	1.64e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.66	-6.3	-0.32	9.05e-10	Breast cancer;
LIHC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	1.0	11.25	0.52	3.51e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg21361702	chr7:150065534	REPIN1	0.47	6.54	0.33	2.25e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23526204	chr20:43992176	SYS1;SYS1-DBNDD2	0.46	6.89	0.35	2.77e-11	Lung function (FEV1/FVC);
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg05064044	chr6:292385	DUSP22	-0.51	-6.72	-0.34	7.68e-11	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg00280220	chr17:61926910	NA	0.41	6.74	0.34	6.76e-11	Prudent dietary pattern;
LIHC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.65	8.37	0.41	1.55e-15	Morning vs. evening chronotype;
LIHC	cis	rs8081395	0.627	rs180536	chr17:57996806	G/A	cg02344993	chr17:57696989	CLTC	0.45	7.55	0.38	3.92e-13	White blood cell count;
LIHC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg15691649	chr6:25882328	NA	-0.51	-7.33	-0.37	1.65e-12	Blood metabolite levels;
LIHC	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg22834771	chr12:69754056	YEATS4	-0.4	-6.01	-0.31	4.75e-9	Response to diuretic therapy;
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.5	8.9	0.43	3.35e-17	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.75	0.39	1.03e-13	Obesity-related traits;
LIHC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.75	13.69	0.6	2.53e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.63	-0.46	1.45e-19	Response to antipsychotic treatment;
LIHC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.85	-0.35	3.49e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.44	-7.88	-0.39	4.51e-14	Inhibitory control;
LIHC	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Corneal astigmatism;
LIHC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00166722	chr3:10149974	C3orf24	0.51	5.92	0.3	7.85e-9	Alzheimer's disease;
LIHC	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg07134254	chr20:33865797	NA	0.51	5.83	0.3	1.25e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.76	11.64	0.53	1.32e-26	Corneal astigmatism;
LIHC	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.39	8.63	0.42	2.35e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg12046867	chr14:103022105	NA	-0.49	-6.59	-0.34	1.65e-10	Platelet count;
LIHC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg24130564	chr14:104152367	KLC1	-0.54	-8.94	-0.44	2.54e-17	Reticulocyte count;
LIHC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg16434002	chr17:42200994	HDAC5	0.42	6.29	0.32	9.8e-10	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg25894440	chr7:65020034	NA	-0.53	-5.87	-0.3	1.03e-8	Diabetic kidney disease;
LIHC	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg27433088	chr4:174089019	GALNT7	0.41	6.95	0.35	1.86e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg03264133	chr6:25882463	NA	-0.41	-6.24	-0.32	1.33e-9	Height;
LIHC	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg24069376	chr3:38537580	EXOG	0.44	7.99	0.4	2.12e-14	Electrocardiographic conduction measures;
LIHC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg04013166	chr16:89971882	TCF25	0.49	5.84	0.3	1.22e-8	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg18306943	chr3:40428807	ENTPD3	0.36	6.33	0.32	7.52e-10	Renal cell carcinoma;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg05185784	chr16:90016020	DEF8	-0.44	-6.0	-0.31	4.97e-9	Skin colour saturation;
LIHC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.45	-0.45	5.64e-19	Hemoglobin concentration;
LIHC	cis	rs11630290	0.592	rs12594446	chr15:64156674	G/T	cg12036633	chr15:63758958	NA	0.64	6.86	0.35	3.28e-11	Iris characteristics;
LIHC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02475777	chr4:1388615	CRIPAK	0.43	6.43	0.33	4.3e-10	Longevity;
LIHC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.42	6.69	0.34	9.31e-11	Menopause (age at onset);
LIHC	cis	rs744487	0.960	rs11581688	chr1:234726532	C/G	cg09691134	chr1:234734475	NA	0.36	5.75	0.3	1.98e-8	LDL cholesterol;
LIHC	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg16405210	chr4:1374714	KIAA1530	0.41	6.07	0.31	3.46e-9	Obesity-related traits;
LIHC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg05044414	chr3:183734942	ABCC5	0.34	5.91	0.3	8.16e-9	Anterior chamber depth;
LIHC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.47	6.6	0.34	1.57e-10	Tonsillectomy;
LIHC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02985541	chr2:219472218	PLCD4	0.44	8.13	0.4	7.89e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.47	7.94	0.39	2.91e-14	Mean corpuscular volume;
LIHC	cis	rs11718455	0.563	rs6809096	chr3:43902494	G/C	cg08738300	chr3:44038990	NA	0.36	6.08	0.31	3.16e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.73	8.06	0.4	1.25e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.8	10.78	0.5	1.55e-23	Response to hepatitis C treatment;
LIHC	cis	rs7503168	1.000	rs1037590	chr17:33902635	G/T	cg20932281	chr17:33905541	PEX12	0.57	7.32	0.37	1.83e-12	Plateletcrit;
LIHC	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.56	9.62	0.46	1.54e-19	Schizophrenia;
LIHC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.03	-0.31	4.29e-9	Longevity;
LIHC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.87	-15.11	-0.63	6.87e-40	Colorectal cancer;
LIHC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-8.21	-0.41	4.47e-15	Longevity;Endometriosis;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.69	-10.11	-0.48	3.37e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.33	0.45	1.39e-18	Hemoglobin concentration;
LIHC	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.75	12.46	0.56	1.27e-29	Menarche (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06329143	chr18:48556512	SMAD4	-0.44	-6.26	-0.32	1.15e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4700695	0.841	rs448454	chr5:65293462	G/A	cg21114390	chr5:65439923	SFRS12	0.49	6.58	0.34	1.77e-10	Facial morphology (factor 19);
LIHC	cis	rs3853824	0.965	rs6503766	chr17:54899945	G/A	cg13675837	chr17:54910204	DGKE	0.42	5.93	0.31	7.59e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67981189	0.574	rs221916	chr14:71592078	C/T	cg15816911	chr14:71606274	NA	-0.44	-7.03	-0.36	1.12e-11	Schizophrenia;
LIHC	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg10820045	chr2:198174542	NA	0.51	7.87	0.39	4.87e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.62	9.8	0.47	3.93e-20	Corneal astigmatism;
LIHC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.76	-11.32	-0.52	1.94e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.09	0.31	2.99e-9	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-8.29	-0.41	2.67e-15	Gut microbiome composition (summer);
LIHC	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.52	-6.68	-0.34	9.48e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.1	0.44	7.64e-18	Menarche (age at onset);
LIHC	cis	rs61990749	0.571	rs2364841	chr14:78284036	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.48	-6.01	-0.31	4.79e-9	Fibroblast growth factor basic levels;
LIHC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.38	5.76	0.3	1.83e-8	Prostate cancer;
LIHC	cis	rs655641	1.000	rs2458500	chr11:85779310	A/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.01	-0.31	4.83e-9	Platelet count;
LIHC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg09137382	chr11:130731461	NA	0.44	6.83	0.35	3.88e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg26149184	chr10:133730230	NA	0.47	7.44	0.37	7.99e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg14092571	chr14:90743983	NA	-0.39	-6.15	-0.32	2.13e-9	Mortality in heart failure;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.64	0.38	2.16e-13	Height;
LIHC	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg20636351	chr8:55087400	NA	-0.39	-8.16	-0.4	6.68e-15	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs3736485	0.903	rs11630842	chr15:51750652	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.35	-0.32	6.98e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	0.68	12.99	0.57	1.26e-31	Systemic lupus erythematosus;
LIHC	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg20129853	chr10:51489980	NA	0.42	8.98	0.44	1.84e-17	Prostate-specific antigen levels;
LIHC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.0	0.4	1.96e-14	Response to antipsychotic treatment;
LIHC	cis	rs6726292	0.539	rs34928331	chr2:55227383	G/T	cg09592903	chr2:55203963	RTN4	-0.47	-7.2	-0.36	3.92e-12	Obesity (extreme);
LIHC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.52	7.58	0.38	3.23e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.72	11.04	0.51	1.9e-24	Aortic root size;
LIHC	cis	rs3780378	0.682	rs7861755	chr9:5273180	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.12	-0.4	8.45e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.54	-0.69	1.42e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.39	6.01	0.31	4.72e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg01364799	chr7:75623366	TMEM120A	-0.4	-6.02	-0.31	4.6e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.52	7.26	0.37	2.62e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg03037974	chr15:76606532	NA	0.73	14.53	0.62	1.41e-37	Blood metabolite levels;
LIHC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	7.78	0.39	8.77e-14	Protein C levels;
LIHC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.19	-5.75	-0.3	1.96e-8	Cutaneous nevi;
LIHC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs57590327	0.503	rs2372905	chr3:81504592	C/G	cg07356753	chr3:81810745	GBE1	0.46	6.91	0.35	2.38e-11	Extraversion;
LIHC	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg01864069	chr14:103024347	NA	-0.34	-5.78	-0.3	1.71e-8	Platelet count;
LIHC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg11784071	chr10:104629166	AS3MT	-0.35	-5.79	-0.3	1.64e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.32	-5.9	-0.3	8.92e-9	Red blood cell count;
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.71	10.37	0.49	4.26e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg04229842	chr17:55038233	COIL	-0.38	-6.12	-0.31	2.52e-9	Oropharynx cancer;
LIHC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.46	-7.58	-0.38	3.2e-13	Smoking behavior;
LIHC	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.31	0.55	4.46e-29	Coffee consumption (cups per day);
LIHC	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs7534824	0.625	rs61780331	chr1:101480610	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.76	0.34	5.97e-11	Refractive astigmatism;
LIHC	cis	rs72653721	0.730	rs17764682	chr6:11058815	A/C	cg13562911	chr6:11044106	ELOVL2	0.52	7.56	0.38	3.74e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs12022452	0.544	rs11208423	chr1:41029614	T/C	cg25568243	chr1:40974465	DEM1	0.44	5.81	0.3	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg16822855	chr3:40428330	ENTPD3	0.33	6.06	0.31	3.59e-9	Renal cell carcinoma;
LIHC	cis	rs11229555	0.598	rs7930623	chr11:58197641	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg08135965	chr6:41755394	TOMM6	0.44	5.91	0.3	8.34e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.38	-0.41	1.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg03859395	chr2:55845619	SMEK2	0.86	14.22	0.61	2.18e-36	Metabolic syndrome;
LIHC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.71	6.85	0.35	3.46e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg14092571	chr14:90743983	NA	0.39	6.07	0.31	3.38e-9	Mortality in heart failure;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg27493151	chr19:38701994	DPF1	0.44	6.36	0.33	6.52e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.41	-0.49	3.05e-22	Alcohol dependence;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg00280220	chr17:61926910	NA	0.43	6.83	0.35	3.79e-11	Prudent dietary pattern;
LIHC	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg10790698	chr19:18539756	SSBP4	-0.37	-7.45	-0.37	7.91e-13	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09747232	chr8:103827049	NA	0.45	6.33	0.32	7.65e-10	Pancreatic cancer;
LIHC	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.45	6.72	0.34	7.71e-11	Nonalcoholic fatty liver disease;
LIHC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.4	0.45	7.82e-19	Total body bone mineral density;
LIHC	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.24	-0.52	3.81e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.35	6.59	0.34	1.63e-10	Tonsillectomy;
LIHC	trans	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg26939375	chr7:64535504	NA	0.41	6.46	0.33	3.51e-10	Aortic root size;
LIHC	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.69	-0.5	3.32e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9918079	0.542	rs6414765	chr4:15626493	G/A	cg21329975	chr4:15471214	CC2D2A	-0.38	-5.75	-0.3	2.03e-8	Obesity-related traits;
LIHC	cis	rs5753037	0.615	rs131279	chr22:30155251	G/C	cg01021169	chr22:30184971	ASCC2	-0.31	-5.76	-0.3	1.89e-8	Type 1 diabetes;
LIHC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.41	8.26	0.41	3.16e-15	Cardiovascular disease risk factors;
LIHC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.45	5.99	0.31	5.29e-9	Obesity-related traits;
LIHC	cis	rs2257205	0.600	rs8071081	chr17:56709055	T/G	cg12560992	chr17:57184187	TRIM37	0.68	7.43	0.37	8.67e-13	Pancreatic cancer;
LIHC	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.94	-0.39	2.98e-14	Coronary artery disease;
LIHC	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg00792783	chr2:198669748	PLCL1	0.41	5.97	0.31	5.97e-9	Dermatomyositis;
LIHC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.55	6.79	0.34	4.98e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19723775	chr5:179050963	HNRNPH1	0.41	6.39	0.33	5.57e-10	Lung cancer;
LIHC	cis	rs2286503	0.752	rs2286504	chr7:22854847	G/T	cg11367502	chr7:22862612	TOMM7	0.47	8.14	0.4	7.59e-15	Fibrinogen;
LIHC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.58	7.36	0.37	1.39e-12	Height;
LIHC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.55	-9.24	-0.45	2.66e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg04691961	chr3:161091175	C3orf57	-0.33	-5.75	-0.3	1.93e-8	Morning vs. evening chronotype;
LIHC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.47	-6.88	-0.35	2.94e-11	Corneal structure;
LIHC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.64e-16	Motion sickness;
LIHC	cis	rs12644436	0.711	rs4693188	chr4:88787174	A/G	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	cis	rs72772090	0.908	rs76539796	chr5:96038675	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-6.47	-0.33	3.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.57	-9.78	-0.47	4.48e-20	Platelet distribution width;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.77	-11.92	-0.54	1.27e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.57	8.23	0.41	3.85e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.63	6.84	0.35	3.71e-11	Homocysteine levels;
LIHC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.63	10.87	0.51	7.53e-24	Lymphocyte counts;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.21e-12	Renal cell carcinoma;
LIHC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.87	6.27	0.32	1.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.66	9.36	0.45	1.09e-18	Schizophrenia;
LIHC	cis	rs7638909	0.512	rs6804918	chr3:38598956	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.41	-6.04	-0.31	3.96e-9	Electrocardiographic conduction measures;
LIHC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.85	0.35	3.51e-11	Schizophrenia;
LIHC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.68	-9.31	-0.45	1.61e-18	Corneal structure;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.46	8.26	0.41	3.27e-15	Prudent dietary pattern;
LIHC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.53	-8.36	-0.41	1.64e-15	Uric acid clearance;
LIHC	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg23682824	chr7:23144976	KLHL7	0.43	6.47	0.33	3.41e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22442454	chr1:209979470	IRF6	0.4	6.11	0.31	2.77e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.21	-0.58	1.78e-32	Glomerular filtration rate (creatinine);
LIHC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.57	0.38	3.41e-13	Morning vs. evening chronotype;
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.72	-13.89	-0.6	4.19e-35	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.8	0.35	4.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.47	7.61	0.38	2.62e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.6	-0.34	1.62e-10	Body mass index;
LIHC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.78	-0.3	1.71e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.01	0.44	1.49e-17	Schizophrenia;
LIHC	cis	rs6060717	0.610	rs1891151	chr20:34612726	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.47	-0.37	6.82e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.54	7.87	0.39	4.77e-14	Diastolic blood pressure;
LIHC	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg26536354	chr8:144654954	C8orf73	0.53	5.77	0.3	1.75e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg01652190	chr22:50026171	C22orf34	-0.31	-7.09	-0.36	7.83e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.05	0.31	3.87e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6752107	0.901	rs11679791	chr2:234156536	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	7.09	0.36	7.59e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg05714579	chr10:131428358	MGMT	0.41	6.56	0.33	2e-10	Response to temozolomide;
LIHC	cis	rs4407350	0.748	rs131170	chr22:44901601	C/A	cg04154583	chr22:44889756	LDOC1L	0.29	5.75	0.3	1.99e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.11	-0.36	7.03e-12	Monocyte percentage of white cells;
LIHC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	10.19	0.48	1.85e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.36	-0.49	4.78e-22	Rheumatoid arthritis;
LIHC	trans	rs6489882	0.867	rs7298184	chr12:113368249	C/A	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05127153	chr1:6452942	ACOT7	0.44	6.12	0.31	2.5e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.18	-0.4	5.48e-15	Lymphocyte counts;
LIHC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.58	8.78	0.43	7.69e-17	Response to diuretic therapy;
LIHC	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg03999872	chr20:62272968	STMN3	0.38	5.73	0.3	2.2e-8	Prostate cancer;
LIHC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.61	7.31	0.37	1.85e-12	Cognitive function;
LIHC	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.68	13.17	0.58	2.6e-32	Leprosy;
LIHC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.06	-0.31	3.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.21	-0.32	1.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs732505	1.000	rs10417622	chr19:5592547	T/C	cg26242866	chr19:5711310	LONP1	0.89	6.52	0.33	2.59e-10	vWF and FVIII levels;
LIHC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.15	26.69	0.82	1.33e-85	Cognitive ability;
LIHC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.46	6.7	0.34	8.64e-11	Asthma;
LIHC	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.58	-6.48	-0.33	3.13e-10	Metabolite levels;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.37	6.03	0.31	4.16e-9	Cystic fibrosis severity;
LIHC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4407350	0.756	rs131158	chr22:44891873	A/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.39	-0.33	5.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.49	-8.23	-0.41	3.91e-15	Schizophrenia;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	23.03	0.78	1.56e-71	Prudent dietary pattern;
LIHC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.52	7.72	0.39	1.31e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	9.38	0.45	9.36e-19	Eosinophilic esophagitis;
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg22663859	chr13:21900854	NA	0.46	7.32	0.37	1.79e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-0.72	-7.4	-0.37	1.04e-12	Putamen volume;
LIHC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg13409248	chr3:40428643	ENTPD3	-0.44	-7.45	-0.37	7.75e-13	Renal cell carcinoma;
LIHC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.22	-0.45	3.08e-18	Electroencephalogram traits;
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg20295408	chr7:1910781	MAD1L1	-0.48	-7.07	-0.36	8.96e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.59	7.68	0.38	1.71e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.76	0.34	6.13e-11	Lung cancer in ever smokers;
LIHC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg16576597	chr16:28551801	NUPR1	0.36	5.75	0.3	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.15	-10.76	-0.5	1.93e-23	Breast cancer;
LIHC	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg18887096	chr2:219472410	PLCD4	0.39	6.76	0.34	6.11e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.33	-8.01	-0.4	1.87e-14	Immature fraction of reticulocytes;
LIHC	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.34	5.87	0.3	1.04e-8	Metabolite levels;
LIHC	cis	rs7119038	0.818	rs7942535	chr11:118681464	C/T	cg19308663	chr11:118741387	NA	-0.4	-6.18	-0.32	1.85e-9	Sjögren's syndrome;
LIHC	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.73	7.55	0.38	4.04e-13	Bipolar disorder;
LIHC	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg02811702	chr13:24901961	NA	0.24	5.86	0.3	1.06e-8	Obesity-related traits;
LIHC	cis	rs11696739	0.866	rs1535882	chr20:1600524	T/C	cg15722679	chr20:1638393	SIRPG	0.41	7.91	0.39	3.5e-14	Mean platelet volume;
LIHC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-6.83	-0.35	3.79e-11	Vitiligo;
LIHC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg17294928	chr15:75287854	SCAMP5	-0.45	-5.73	-0.3	2.23e-8	Lung cancer;
LIHC	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg19680672	chr10:131412579	MGMT	-0.45	-7.03	-0.36	1.14e-11	Response to temozolomide;
LIHC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.44	6.96	0.35	1.73e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-6.49	-0.33	3.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08219700	chr8:58056026	NA	0.46	5.8	0.3	1.48e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	0.69	7.39	0.37	1.16e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06002616	chr8:101225028	SPAG1	-0.34	-5.76	-0.3	1.9e-8	Atrioventricular conduction;
LIHC	cis	rs7119038	0.818	rs11826521	chr11:118610549	G/T	cg19308663	chr11:118741387	NA	0.43	5.74	0.3	2.14e-8	Sjögren's syndrome;
LIHC	cis	rs10065203	0.527	rs181927	chr5:14351946	G/T	cg26595256	chr5:14380529	TRIO	-0.42	-6.55	-0.33	2.08e-10	Paclitaxel-induced neuropathy;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.76	-12.99	-0.57	1.24e-31	Bipolar disorder and schizophrenia;
LIHC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg24130564	chr14:104152367	KLC1	-0.55	-9.15	-0.44	5.13e-18	Reticulocyte count;
LIHC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.56	-10.02	-0.48	7.03e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg08847533	chr14:75593920	NEK9	0.53	7.98	0.4	2.3e-14	IgG glycosylation;
LIHC	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg15605315	chr1:45957053	TESK2	0.45	5.86	0.3	1.07e-8	High light scatter reticulocyte count;
LIHC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.14	-0.32	2.25e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.25	-7.77	-0.39	9.36e-14	Mean corpuscular volume;
LIHC	cis	rs16912285	0.688	rs11827298	chr11:24324000	G/A	ch.11.24196551F	chr11:24239977	NA	0.76	10.02	0.48	6.8e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25047243	chr2:32502969	YIPF4	-0.46	-6.12	-0.31	2.63e-9	Systolic blood pressure;
LIHC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.48	6.8	0.35	4.58e-11	Lung cancer;
LIHC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.31e-20	Menopause (age at onset);
LIHC	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.23	-0.32	1.38e-9	Coronary artery disease;
LIHC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.43	-6.52	-0.33	2.51e-10	Asthma (sex interaction);
LIHC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.61	-0.38	2.66e-13	Schizophrenia;
LIHC	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.56e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06002616	chr8:101225028	SPAG1	0.34	5.84	0.3	1.2e-8	Atrioventricular conduction;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg24955955	chr5:415729	AHRR	0.32	6.63	0.34	1.28e-10	Cystic fibrosis severity;
LIHC	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.76	-9.67	-0.46	1.03e-19	Body mass index;
LIHC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.44e-19	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.47	7.14	0.36	5.53e-12	Cognitive function;
LIHC	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	14.03	0.6	1.22e-35	Coffee consumption (cups per day);
LIHC	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.73	-0.3	2.21e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg25894440	chr7:65020034	NA	-0.56	-6.39	-0.33	5.3e-10	Diabetic kidney disease;
LIHC	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.0	-0.35	1.32e-11	Prevalent atrial fibrillation;
LIHC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.72	-10.09	-0.48	3.9e-21	Multiple sclerosis;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs7238033	0.624	rs7229967	chr18:43312368	C/T	cg20610511	chr18:43302872	SLC14A1	0.37	6.18	0.32	1.83e-9	Bladder cancer;
LIHC	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.55	-8.36	-0.41	1.61e-15	Schizophrenia;
LIHC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.64e-11	Aortic root size;
LIHC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	8.87	0.43	4.29e-17	Body mass index (adult);
LIHC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs546131	0.642	rs568529	chr11:34842506	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.37	0.45	1e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.34	-7.21	-0.36	3.7e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.47	-6.25	-0.32	1.22e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.22	0.45	3.2e-18	Platelet count;
LIHC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.68	-0.34	9.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.56	8.98	0.44	1.88e-17	Corneal astigmatism;
LIHC	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.75	12.14	0.55	1.85e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.59	0.46	1.84e-19	Corneal astigmatism;
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg12903224	chr12:29470962	FAR2	-0.42	-6.81	-0.35	4.43e-11	QT interval;
LIHC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg10755058	chr3:40428713	ENTPD3	0.39	6.6	0.34	1.61e-10	Renal cell carcinoma;
LIHC	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.56	-7.58	-0.38	3.34e-13	HIV-1 control;
LIHC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.6	-9.26	-0.45	2.32e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg12798992	chr6:167411361	FGFR1OP	0.45	6.69	0.34	9.06e-11	Crohn's disease;
LIHC	cis	rs7091068	0.706	rs4919398	chr10:95429162	C/T	cg20715218	chr10:95462985	C10orf4	0.57	6.17	0.32	1.91e-9	Urinary tract infection frequency;
LIHC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.47	-7.34	-0.37	1.61e-12	Neurofibrillary tangles;
LIHC	trans	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg17675199	chr6:35436792	RPL10A	0.32	6.37	0.33	6.25e-10	Coronary artery disease;
LIHC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.86	15.21	0.64	2.93e-40	Headache;
LIHC	cis	rs2412488	0.893	rs12642403	chr4:54361640	A/G	cg22241045	chr4:54363911	LNX1	-0.45	-7.62	-0.38	2.57e-13	DNA methylation (variation);
LIHC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.46	0.62	2.59e-37	Prudent dietary pattern;
LIHC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.9	0.3	8.79e-9	Self-reported allergy;
LIHC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg11812906	chr14:75593930	NEK9	-0.4	-5.97	-0.31	5.95e-9	IgG glycosylation;
LIHC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.64	7.57	0.38	3.57e-13	Heart rate;
LIHC	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.33	7.05	0.36	9.97e-12	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.51	7.86	0.39	5.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7818688	0.697	rs11778553	chr8:95978260	C/T	cg16049864	chr8:95962084	TP53INP1	0.56	6.08	0.31	3.21e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.85	-0.51	9.04e-24	Chronic sinus infection;
LIHC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.36	6.15	0.32	2.14e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.75	11.64	0.53	1.31e-26	Eye color traits;
LIHC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.64	8.74	0.43	1.08e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.92	22.14	0.77	5.17e-68	Colorectal cancer;
LIHC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.21e-26	Motion sickness;
LIHC	cis	rs3736485	0.932	rs2278990	chr15:51914662	G/A	cg08986416	chr15:51914746	DMXL2	-0.47	-7.01	-0.35	1.28e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.53	-8.59	-0.42	3.12e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.37	0.41	1.55e-15	Platelet count;
LIHC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.05	0.63	1.26e-39	Chronic sinus infection;
LIHC	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.75	-13.22	-0.58	1.69e-32	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs10949834	0.824	rs3801461	chr7:73536368	C/G	cg07137043	chr7:73588983	EIF4H	-0.61	-6.04	-0.31	3.98e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.4	-0.41	1.19e-15	Gut microbiome composition (summer);
LIHC	cis	rs6596100	0.538	rs34592321	chr5:132181675	G/C	cg02081065	chr5:132209139	LEAP2	0.29	6.28	0.32	1.05e-9	Breast cancer;
LIHC	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07151155	chr5:1473589	LPCAT1	-0.4	-6.15	-0.32	2.18e-9	Breast cancer;
LIHC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	13.01	0.58	1.03e-31	Psoriasis;
LIHC	cis	rs12702595	0.936	rs6960832	chr7:7267787	G/T	cg04827551	chr7:7268805	C1GALT1	0.39	7.07	0.36	8.94e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.17	0.58	2.51e-32	Psoriasis;
LIHC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.46	6.43	0.33	4.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1144333	1.000	rs12082448	chr1:76353225	C/T	cg03433033	chr1:76189801	ACADM	0.57	8.59	0.42	3.18e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.06	-0.36	9.32e-12	Facial morphology (factor 17, height of vermillion upper lip);
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.07	0.4	1.23e-14	Height;
LIHC	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.79	0.34	4.93e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.21	-0.32	1.56e-9	Diastolic blood pressure;
LIHC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-1.0	-11.73	-0.54	6.22e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.29	-6.58	-0.34	1.73e-10	Migraine;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg26338869	chr17:61819248	STRADA	0.61	8.84	0.43	5.21e-17	Prudent dietary pattern;
LIHC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs10411936	0.924	rs8110761	chr19:16501005	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.43	5.89	0.3	9.26e-9	White blood cell count;Multiple sclerosis;
LIHC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg07424592	chr7:64974309	NA	0.68	8.19	0.4	5.43e-15	Diabetic kidney disease;
LIHC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.53	8.36	0.41	1.63e-15	Tumor biomarkers;
LIHC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.5	-6.04	-0.31	4.03e-9	Migraine;Coronary artery disease;
LIHC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.84	12.14	0.55	1.84e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg01231543	chr16:68741748	NA	0.37	5.76	0.3	1.86e-8	Colorectal cancer;
LIHC	cis	rs7072216	0.621	rs3750605	chr10:100175654	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.74	-0.3	2.1e-8	Metabolite levels;
LIHC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg06611532	chr13:114900021	NA	0.38	6.91	0.35	2.42e-11	Schizophrenia;
LIHC	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.65	9.5	0.46	3.67e-19	Bipolar disorder;
LIHC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-6.65	-0.34	1.19e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg18375707	chr11:64034959	PLCB3	-0.44	-5.83	-0.3	1.29e-8	Body mass index;
LIHC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg07134254	chr20:33865797	NA	0.53	6.23	0.32	1.36e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02985541	chr2:219472218	PLCD4	-0.43	-8.04	-0.4	1.53e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02290350	chr8:58132656	NA	0.44	8.59	0.42	3.22e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4671458	0.724	rs56219461	chr2:63669666	G/A	cg17519650	chr2:63277830	OTX1	-0.57	-6.57	-0.33	1.87e-10	Subjective well-being;
LIHC	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.7	-6.34	-0.32	7.2e-10	Obesity;Body mass index;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21448741	chr8:58168803	NA	0.37	5.95	0.31	6.81e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.62	8.31	0.41	2.32e-15	Motion sickness;
LIHC	cis	rs10197940	0.753	rs2290368	chr2:152266473	T/C	cg19508488	chr2:152266495	RIF1	0.74	12.56	0.56	4.98e-30	Lung cancer;
LIHC	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg27523141	chr10:43048294	ZNF37B	-0.37	-6.3	-0.32	8.92e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.37	2.22e-12	Migraine;Coronary artery disease;
LIHC	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg23254163	chr1:152506842	NA	0.22	5.79	0.3	1.64e-8	Hair morphology;
LIHC	cis	rs5770917	1.000	rs3213445	chr22:51015838	T/C	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.42	-6.06	-0.31	3.57e-9	Narcolepsy;
LIHC	cis	rs4970966	0.855	rs11204701	chr1:150662179	A/T	cg17724175	chr1:150552817	MCL1	-0.37	-5.97	-0.31	6.03e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.04	-0.36	1.08e-11	Reticulocyte count;
LIHC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.5	8.47	0.42	7.54e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg11204139	chr17:3907470	NA	0.59	6.67	0.34	1.01e-10	Type 2 diabetes;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.54	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.93	0.31	7.51e-9	Electroencephalogram traits;
LIHC	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg18898632	chr2:242989856	NA	-0.69	-8.75	-0.43	9.88e-17	Obesity-related traits;
LIHC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.7	-6.78	-0.34	5.31e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1789	0.903	rs4616746	chr4:15673098	A/G	cg21123203	chr4:15471301	CC2D2A	-0.43	-6.78	-0.34	5.25e-11	Blood protein levels;
LIHC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.98	13.29	0.58	8.46e-33	Heart rate;
LIHC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.83	-0.3	1.29e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.35	14.76	0.62	1.75e-38	Eosinophil percentage of granulocytes;
LIHC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg15902774	chr15:75289873	SCAMP5	-0.41	-6.36	-0.33	6.61e-10	Lung cancer;
LIHC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg18357645	chr12:58087776	OS9	-0.47	-7.66	-0.38	1.88e-13	Multiple sclerosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06625838	chr5:162865006	CCNG1	0.45	6.93	0.35	2.08e-11	Cognitive function;
LIHC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.36	-5.95	-0.31	6.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg02811702	chr13:24901961	NA	0.25	6.33	0.32	7.79e-10	Obesity-related traits;
LIHC	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg21366198	chr4:185655624	MLF1IP	0.53	8.44	0.42	9.3e-16	Kawasaki disease;
LIHC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.5	6.31	0.32	8.66e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.61	-8.9	-0.43	3.41e-17	White matter hyperintensity burden;
LIHC	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.94	-14.41	-0.61	3.92e-37	Uric acid levels;
LIHC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.76	9.06	0.44	1.02e-17	Menarche (age at onset);
LIHC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	7.43	0.37	9.02e-13	Platelet count;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.62	9.93	0.47	1.42e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18176703	chr3:115503520	NA	-0.42	-6.07	-0.31	3.36e-9	Longevity;
LIHC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.73	-0.43	1.13e-16	Crohn's disease;
LIHC	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-8.7	-0.43	1.47e-16	Blood pressure (smoking interaction);
LIHC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.82	-12.74	-0.57	1.1e-30	Total body bone mineral density;
LIHC	cis	rs6088813	1.000	rs6142376	chr20:33992761	T/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.88	-0.3	9.69e-9	Height;
LIHC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg00142150	chr22:38071001	LGALS1	0.7	11.36	0.52	1.42e-25	Fat distribution (HIV);
LIHC	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg23730037	chr7:158596552	ESYT2	-0.43	-6.63	-0.34	1.3e-10	Height;
LIHC	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.83	10.73	0.5	2.48e-23	Blood protein levels;
LIHC	cis	rs943466	1.000	rs6933607	chr6:33743997	G/A	cg25922239	chr6:33757077	LEMD2	-0.47	-5.77	-0.3	1.75e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.87	-0.63	6.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16262614	chr3:133464971	TF	0.28	6.28	0.32	1.01e-9	Iron status biomarkers;
LIHC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.59	8.51	0.42	5.51e-16	Obesity-related traits;
LIHC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.57	7.74	0.39	1.11e-13	Bone mineral density (spine);
LIHC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	6.01	0.31	4.84e-9	Schizophrenia;
LIHC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-5.71	-0.3	2.44e-8	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01153342	chr14:74254319	C14orf43	0.47	7.6	0.38	2.88e-13	Cognitive function;
LIHC	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.5	9.49	0.46	4.03e-19	Testicular germ cell tumor;
LIHC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg06742321	chr12:123595122	PITPNM2	0.31	5.9	0.3	8.99e-9	Platelet count;
LIHC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-9.93	-0.47	1.42e-20	Mean corpuscular volume;
LIHC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.44	0.42	8.99e-16	Birth weight;
LIHC	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.61	-6.2	-0.32	1.62e-9	Pancreatic cancer;
LIHC	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.85	-0.39	5.45e-14	Mean corpuscular hemoglobin;
LIHC	trans	rs983392	0.709	rs1426250	chr11:60001325	A/G	cg17275991	chr19:58003312	ZNF419	0.43	6.13	0.31	2.45e-9	Alzheimer's disease (late onset);
LIHC	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.62	0.34	1.37e-10	Corneal astigmatism;
LIHC	cis	rs4919087	0.683	rs7091162	chr10:99071242	G/T	cg25902810	chr10:99078978	FRAT1	-0.6	-7.23	-0.36	3.16e-12	Monocyte count;
LIHC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.24e-10	Major depressive disorder;
LIHC	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.52	6.41	0.33	4.8e-10	Breast cancer;
LIHC	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.42e-20	Height;
LIHC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-8.97	-0.44	1.99e-17	Type 2 diabetes;
LIHC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.47	7.24	0.36	2.98e-12	Asthma (sex interaction);
LIHC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.75	0.34	6.4e-11	Rheumatoid arthritis;
LIHC	cis	rs13272623	0.502	rs268601	chr8:71518548	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.76	-0.3	1.89e-8	IgG glycosylation;
LIHC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-7.05	-0.36	1.03e-11	Breast cancer;
LIHC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.56	8.14	0.4	7.48e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.545	rs35536987	chr14:56024021	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-6.11	-0.31	2.74e-9	Putamen volume;
LIHC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.6	-8.47	-0.42	7.25e-16	Blood metabolite levels;
LIHC	cis	rs12095069	1	rs12095069	chr1:76463072	T/C	cg10523679	chr1:76189770	ACADM	0.42	5.96	0.31	6.4e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8192917	1.000	rs6573911	chr14:25100933	A/G	cg03875678	chr14:25103546	GZMB	-0.4	-7.15	-0.36	5.2e-12	Vitiligo;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.02	0.31	4.59e-9	Morning vs. evening chronotype;
LIHC	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-0.66	-6.65	-0.34	1.15e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6952808	0.743	rs10266703	chr7:1918941	C/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.4	-0.41	1.21e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.39	-6.51	-0.33	2.65e-10	Menopause (age at onset);
LIHC	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg01864836	chr14:55583639	NA	-0.4	-7.48	-0.38	6.21e-13	Protein biomarker;
LIHC	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.53	8.28	0.41	2.83e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg08499158	chr17:42289980	UBTF	-0.48	-7.81	-0.39	7.16e-14	Total body bone mineral density;
LIHC	cis	rs965469	0.779	rs6515810	chr20:3370861	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-6.34	-0.32	7.07e-10	IFN-related cytopenia;
LIHC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.85	0.54	2.18e-27	High light scatter reticulocyte count;
LIHC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.4	7.15	0.36	5.3e-12	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.6	7.84	0.39	5.8e-14	Post bronchodilator FEV1;
LIHC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg25894440	chr7:65020034	NA	-0.54	-6.27	-0.32	1.08e-9	Diabetic kidney disease;
LIHC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.34	5.94	0.31	6.86e-9	Psoriasis;
LIHC	cis	rs11966931	0.711	rs9320236	chr6:108089688	G/T	cg04749840	chr6:108095067	SCML4	-0.37	-6.65	-0.34	1.17e-10	Neutrophil percentage of white cells;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-7.32	-0.37	1.75e-12	Testicular germ cell tumor;
LIHC	trans	rs2744203	1.000	rs72610888	chr6:104655184	C/T	cg27088726	chr16:83171155	CDH13	-0.45	-6.07	-0.31	3.35e-9	IgG glycosylation;
LIHC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.63	-9.58	-0.46	2.14e-19	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg00280220	chr17:61926910	NA	0.44	7.15	0.36	5.34e-12	Prudent dietary pattern;
LIHC	cis	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg14515779	chr1:101123966	NA	-0.69	-13.84	-0.6	6.8000000000000005e-35	Monocyte count;
LIHC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.68	-0.42	1.69e-16	Primary biliary cholangitis;
LIHC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.76	11.62	0.53	1.52e-26	Corneal astigmatism;
LIHC	cis	rs1113500	0.787	rs4571989	chr1:108631344	G/A	cg06207961	chr1:108661230	NA	0.31	5.93	0.31	7.41e-9	Growth-regulated protein alpha levels;
LIHC	trans	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg07393940	chr7:158741817	NA	0.56	6.66	0.34	1.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg16836995	chr17:43662488	NA	-0.76	-7.78	-0.39	8.38e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.52	8.61	0.42	2.75e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7572733	0.555	rs11889006	chr2:198928647	A/G	cg00792783	chr2:198669748	PLCL1	0.4	5.76	0.3	1.86e-8	Dermatomyositis;
LIHC	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg14146966	chr2:61757674	XPO1	0.47	8.25	0.41	3.46e-15	Tuberculosis;
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.8	12.59	0.56	4.04e-30	Longevity;
LIHC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.33	-5.83	-0.3	1.32e-8	Headache;
LIHC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.86	0.43	4.31e-17	Lung cancer;
LIHC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-8.21	-0.41	4.73e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.41	6.92	0.35	2.3e-11	Blood metabolite levels;
LIHC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.33	0.32	7.63e-10	Renal cell carcinoma;
LIHC	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg01864069	chr14:103024347	NA	-0.34	-5.76	-0.3	1.83e-8	Platelet count;
LIHC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.73e-12	Personality dimensions;
LIHC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.46	-7.37	-0.37	1.32e-12	Menarche (age at onset);
LIHC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.61	-8.56	-0.42	3.9e-16	Blood metabolite levels;
LIHC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.43	7.02	0.35	1.21e-11	Height;
LIHC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg19635926	chr16:89946313	TCF25	0.5	6.48	0.33	3.24e-10	Skin colour saturation;
LIHC	cis	rs79149102	0.737	rs16973172	chr15:75156944	G/A	cg16226627	chr15:75307476	SCAMP5	0.44	6.13	0.31	2.45e-9	Lung cancer;
LIHC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.85	0.3	1.18e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg03037974	chr15:76606532	NA	0.76	14.76	0.62	1.78e-38	Blood metabolite levels;
LIHC	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg14146966	chr2:61757674	XPO1	0.47	8.16	0.4	6.3e-15	Tuberculosis;
LIHC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.23	-0.41	4.01e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg10932868	chr11:921992	NA	0.39	7.29	0.37	2.22e-12	Alzheimer's disease (late onset);
LIHC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.84	0.43	5.15e-17	Motion sickness;
LIHC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs2273156	1.000	rs12880809	chr14:35475656	A/G	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs7119038	0.818	rs56758835	chr11:118615340	G/A	cg19308663	chr11:118741387	NA	0.43	5.79	0.3	1.56e-8	Sjögren's syndrome;
LIHC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	15.23	0.64	2.5e-40	Menopause (age at onset);
LIHC	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.8	14.1	0.61	6.78e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.59	9.74	0.47	5.94e-20	Resting heart rate;
LIHC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03352830	chr11:487213	PTDSS2	0.8	6.45	0.33	3.76e-10	Body mass index;
LIHC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.52e-14	Platelet count;
LIHC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.38	-0.56	2.36e-29	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18710692	chr13:20437712	ZMYM5	-0.48	-6.6	-0.34	1.55e-10	Longevity;
LIHC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.62	0.42	2.46e-16	Menarche (age at onset);
LIHC	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.54	-0.38	4.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.9	-0.3	8.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.21	-0.36	3.53e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.56	8.23	0.41	3.98e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs67981189	0.593	rs2526883	chr14:71369575	T/G	cg15816911	chr14:71606274	NA	-0.4	-6.47	-0.33	3.4e-10	Schizophrenia;
LIHC	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	9.84	0.47	2.86e-20	Hypertriglyceridemia;
LIHC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	5.86	0.3	1.11e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.37	5.95	0.31	6.5e-9	Menopause (age at onset);
LIHC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	1.01	20.22	0.74	2.4e-60	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25340675	chr3:121468720	GOLGB1	-0.49	-6.43	-0.33	4.2e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg21167532	chr1:33231272	KIAA1522	0.37	6.38	0.33	5.86e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.35	-0.45	1.16e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs7551222	0.789	rs4951408	chr1:204558984	C/G	cg20240347	chr1:204465584	NA	-0.33	-6.72	-0.34	7.72e-11	Schizophrenia;
LIHC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.06	-0.36	9.1e-12	Personality dimensions;
LIHC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.42	0.69	4.42e-49	Smoking behavior;
LIHC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg20607798	chr8:58055168	NA	0.49	6.23	0.32	1.34e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.41	6.44	0.33	4.1e-10	Obesity-related traits;
LIHC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg05535760	chr7:792225	HEATR2	-0.48	-6.56	-0.33	2.01e-10	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.07	0.68	1.05e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.91	0.47	1.64e-20	Crohn's disease;
LIHC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.71	-0.46	7.8500000000000006e-20	Colorectal cancer;
LIHC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg25344623	chr2:136566232	LCT	-0.37	-5.93	-0.31	7.26e-9	Corneal structure;
LIHC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.48	-7.27	-0.37	2.45e-12	Cognitive function;
LIHC	cis	rs4742903	0.875	rs10991141	chr9:106938280	T/C	cg14250997	chr9:106856677	SMC2	0.35	5.94	0.31	7.03e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1419980	0.730	rs11531089	chr12:7749855	G/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.3	-0.49	7.3e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg09182678	chr22:50328711	NA	-0.43	-6.12	-0.31	2.57e-9	Schizophrenia;
LIHC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg20991723	chr1:152506922	NA	0.57	10.01	0.48	7.37e-21	Hair morphology;
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.38	-0.33	5.85e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg04310649	chr10:35416472	CREM	-0.42	-5.75	-0.3	1.96e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg11170685	chr14:101005511	BEGAIN	0.38	6.08	0.31	3.21e-9	Bipolar disorder;
LIHC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg03037974	chr15:76606532	NA	0.73	14.44	0.62	3.04e-37	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01218756	chr4:48695242	FRYL	0.31	6.86	0.35	3.16e-11	Cognitive function;
LIHC	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg20194872	chr6:41519635	FOXP4	0.4	6.31	0.32	8.5e-10	Prostate cancer;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.67	11.07	0.51	1.53e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.6	8.93	0.43	2.64e-17	Recombination rate (females);
LIHC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.66	-9.6	-0.46	1.82e-19	Parkinson's disease;
LIHC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20135002	chr11:47629003	NA	0.5	8.4	0.41	1.17e-15	Subjective well-being;
LIHC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.53	8.06	0.4	1.3e-14	Diastolic blood pressure;
LIHC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.52	0.59	1.18e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.28	0.32	1.03e-9	Schizophrenia;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.05	-0.31	3.87e-9	Total body bone mineral density;
LIHC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.39	5.76	0.3	1.87e-8	Menarche (age at onset);
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg15382696	chr6:118971807	C6orf204	0.63	6.37	0.33	6.05e-10	Diastolic blood pressure;
LIHC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg23262073	chr20:60523788	NA	-0.29	-6.02	-0.31	4.47e-9	Body mass index;
LIHC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.74	-16.71	-0.67	2.94e-46	Brugada syndrome;
LIHC	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.36	-8.86	-0.43	4.31e-17	Blood metabolite ratios;
LIHC	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.72	7.31	0.37	1.95e-12	Alzheimer's disease;
LIHC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.08	-0.4	1.11e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs832187	0.813	rs704369	chr3:63868271	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.47	6.8	0.35	4.75e-11	Schizophrenia;
LIHC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.48	-7.85	-0.39	5.32e-14	Menarche (age at onset);
LIHC	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg08992911	chr2:238395768	MLPH	0.54	5.98	0.31	5.71e-9	Prostate cancer;
LIHC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.62	-8.46	-0.42	7.72e-16	Body mass index;
LIHC	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.51	7.94	0.39	2.9e-14	Alzheimer's disease (survival time);
LIHC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13047869	chr3:10149882	C3orf24	0.42	5.87	0.3	1.03e-8	Alzheimer's disease;
LIHC	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.78	12.99	0.57	1.28e-31	Phospholipid levels (plasma);
LIHC	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg23682824	chr7:23144976	KLHL7	0.42	6.29	0.32	9.83e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	1.03	20.74	0.75	1.9e-62	Breast cancer;
LIHC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.09	-8.17	-0.4	5.96e-15	Body mass index;
LIHC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	10.35	0.49	4.94e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14620208	chr9:140652685	EHMT1	0.42	6.24	0.32	1.29e-9	Longevity;
LIHC	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg27206522	chr1:152595629	LCE3A	-0.24	-5.78	-0.3	1.7e-8	Psoriasis;
LIHC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.5	8.55	0.42	4.06e-16	Response to temozolomide;
LIHC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.52	8.21	0.41	4.53e-15	Total body bone mineral density;
LIHC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.66	11.37	0.52	1.21e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs8108269	1.000	rs8108269	chr19:46158513	G/T	cg13320842	chr19:46175254	GIPR	-0.41	-7.79	-0.39	7.91e-14	Type 2 diabetes;
LIHC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	11.77	0.54	4.57e-27	Post bronchodilator FEV1;
LIHC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg20933634	chr6:27740509	NA	0.48	6.26	0.32	1.15e-9	Parkinson's disease;
LIHC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	cis	rs7116495	1.000	rs548961	chr11:71793887	G/A	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	cg04338863	chr8:33670619	NA	0.31	5.8	0.3	1.49e-8	Body mass index;
LIHC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.75	12.49	0.56	9.64e-30	Oral cavity cancer;
LIHC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs10845606	0.505	rs2160972	chr12:12838608	C/T	cg04607235	chr12:12878440	APOLD1	0.46	6.7	0.34	8.41e-11	Systemic lupus erythematosus;
LIHC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg12560992	chr17:57184187	TRIM37	0.73	10.71	0.5	2.93e-23	Cognitive test performance;
LIHC	cis	rs7487075	0.619	rs67249026	chr12:46835768	T/C	cg23829395	chr12:46796953	NA	0.35	6.19	0.32	1.76e-9	Itch intensity from mosquito bite;
LIHC	cis	rs8067354	0.574	rs1295923	chr17:57960436	A/G	cg02344993	chr17:57696989	CLTC	0.66	10.3	0.49	7.37e-22	Hemoglobin concentration;
LIHC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg14067834	chr17:29058358	SUZ12P	0.67	6.54	0.33	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-6.45	-0.33	3.78e-10	Initial pursuit acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06713199	chr3:28390809	AZI2	0.36	6.13	0.31	2.41e-9	Cognitive function;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05262634	chr1:38157968	CDCA8	-0.54	-6.12	-0.31	2.6e-9	Systolic blood pressure;
LIHC	cis	rs4908760	0.899	rs61783642	chr1:8591397	T/C	cg20416874	chr1:8611966	RERE	-0.67	-14.25	-0.61	1.67e-36	Vitiligo;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.55	0.56	5.59e-30	Prudent dietary pattern;
LIHC	cis	rs9628987	0.569	rs2289732	chr1:8423877	G/C	cg20416874	chr1:8611966	RERE	0.53	6.36	0.33	6.49e-10	Breast cancer;
LIHC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.4	8.04	0.4	1.48e-14	Cardiovascular disease risk factors;
LIHC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.55	0.42	4.23e-16	Birth weight;
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.12	0.31	2.57e-9	Renal cell carcinoma;
LIHC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00475322	chr7:917719	C7orf20	0.39	6.42	0.33	4.68e-10	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.59	-9.91	-0.47	1.66e-20	HDL cholesterol;
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-8.31	-0.41	2.3e-15	Bipolar disorder;
LIHC	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.67	6.82	0.35	4.03e-11	Schizophrenia;
LIHC	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	7.8	0.39	7.47e-14	LDL cholesterol;
LIHC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.78	-0.82	6.04e-86	Myeloid white cell count;
LIHC	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.62	-9.62	-0.46	1.52e-19	Lung cancer;
LIHC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.47	7.67	0.38	1.79e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.49	5.82	0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.57	-7.86	-0.39	5.04e-14	Response to antineoplastic agents;
LIHC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.43	-6.89	-0.35	2.68e-11	Lung function (FEV1);
LIHC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg03983715	chr16:68378420	PRMT7	-0.52	-6.2	-0.32	1.67e-9	Schizophrenia;
LIHC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.63	12.47	0.56	1.12e-29	Gestational age at birth (maternal effect);
LIHC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.69	-0.76	3.18e-66	Height;
LIHC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.54	-9.61	-0.46	1.62e-19	Alzheimer's disease (late onset);
LIHC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.87	-17.89	-0.7	5.5e-51	Height;
LIHC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.27e-12	Bipolar disorder;
LIHC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.91	-0.51	5.71e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	18.23	0.7	2.43e-52	Smoking behavior;
LIHC	cis	rs12477438	0.539	rs62156558	chr2:99553104	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.08	-0.48	4.3e-21	Chronic sinus infection;
LIHC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.66	-9.21	-0.45	3.36e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg02272795	chr19:15279244	NOTCH3	-0.31	-5.75	-0.3	2.02e-8	Pulse pressure;
LIHC	cis	rs9649465	0.967	rs10224062	chr7:123304609	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.56e-14	Migraine;
LIHC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-0.74	-10.31	-0.49	6.85e-22	Initial pursuit acceleration;
LIHC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.51	10.6	0.5	6.69e-23	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.84	0.43	5.07e-17	Corneal astigmatism;
LIHC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	6.86	0.35	3.25e-11	Waist circumference;Hip circumference;
LIHC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.53	5.82	0.3	1.36e-8	Inflammatory bowel disease;
LIHC	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg08800856	chr11:64428347	NRXN2	0.39	6.04	0.31	4.13e-9	Body mass index;Urate levels;
LIHC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-0.66	-10.97	-0.51	3.34e-24	Pediatric autoimmune diseases;
LIHC	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.58	-8.78	-0.43	8.02e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs679087	0.833	rs302343	chr12:29940206	T/G	cg14258853	chr12:29935411	TMTC1	-0.45	-6.84	-0.35	3.58e-11	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg01629716	chr15:45996671	NA	0.51	9.16	0.44	4.72e-18	Waist circumference;Weight;
LIHC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.52	8.29	0.41	2.66e-15	Total body bone mineral density;
LIHC	cis	rs1866706	0.896	rs4757062	chr11:12876491	C/T	cg25843174	chr11:12811716	TEAD1	-0.28	-6.01	-0.31	4.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.13	0.48	2.79e-21	Schizophrenia;
LIHC	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg14092571	chr14:90743983	NA	0.42	6.52	0.33	2.57e-10	Mortality in heart failure;
LIHC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.34	8.84	0.43	5.03e-17	Schizophrenia;
LIHC	cis	rs716804	0.740	rs7107290	chr11:10294772	G/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.89	-0.3	9.09e-9	Neuroticism;
LIHC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg17750252	chr2:136567154	LCT	0.35	6.32	0.32	8.34e-10	Mosquito bite size;
LIHC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg21361702	chr7:150065534	REPIN1	0.47	6.57	0.33	1.9e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04013166	chr16:89971882	TCF25	0.48	6.11	0.31	2.75e-9	Skin colour saturation;
LIHC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.52	8.46	0.42	7.64e-16	Schizophrenia;
LIHC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.32	8.34	0.41	1.89e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.97e-10	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.59	0.34	1.64e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.4	0.52	9.54e-26	Colorectal cancer;
LIHC	cis	rs16958440	0.708	rs1434528	chr18:44632323	G/A	cg17192377	chr18:44677553	HDHD2	0.52	6.53	0.33	2.38e-10	Sitting height ratio;
LIHC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.58	-0.53	2.23e-26	Platelet distribution width;
LIHC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00958927	chr1:175162553	KIAA0040	0.39	6.67	0.34	1.01e-10	Alcohol dependence;
LIHC	cis	rs864643	0.891	rs1068953	chr3:39556561	A/G	cg05136238	chr3:39556330	MOBP	0.32	5.81	0.3	1.47e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs611744	0.836	rs684412	chr8:109210905	T/A	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	7.54	0.38	4.22e-13	Lymphocyte counts;
LIHC	trans	rs6489882	0.867	rs6489875	chr12:113368030	G/A	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	15.08	0.63	9.62e-40	Menopause (age at onset);
LIHC	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg24069376	chr3:38537580	EXOG	-0.38	-6.84	-0.35	3.64e-11	Electrocardiographic conduction measures;
LIHC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.19	0.32	1.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	8.18	0.4	5.67e-15	Platelet count;
LIHC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.86	0.3	1.08e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17106184	1.000	rs12063943	chr1:51223263	T/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.86	-0.35	3.32e-11	Type 2 diabetes;
LIHC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.6	5.76	0.3	1.84e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs8067354	0.574	rs1292035	chr17:57989557	G/A	cg13753209	chr17:57696993	CLTC	0.71	10.57	0.5	8.45e-23	Hemoglobin concentration;
LIHC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-7.48	-0.37	6.53e-13	Electroencephalogram traits;
LIHC	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg18887096	chr2:219472410	PLCD4	0.36	6.18	0.32	1.87e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.46	5.74	0.3	2.14e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22442454	chr1:209979470	IRF6	0.4	6.07	0.31	3.43e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.47	-8.31	-0.41	2.33e-15	Tuberculosis;
LIHC	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.57	0.38	3.53e-13	Refractive astigmatism;
LIHC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.85	-14.2	-0.61	2.64e-36	Post bronchodilator FEV1;
LIHC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-5.96	-0.31	6.25e-9	Height;
LIHC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.39	-5.99	-0.31	5.24e-9	Blood pressure (smoking interaction);
LIHC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-6.72	-0.34	7.5e-11	Colorectal cancer;
LIHC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-9.0	-0.44	1.61e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg18954051	chr12:66554863	TMBIM4	0.39	6.2	0.32	1.65e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.52	-7.93	-0.39	3.13e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.06	0.44	1.06e-17	Height;
LIHC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.66	8.26	0.41	3.31e-15	Mean platelet volume;
LIHC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-6.49	-0.33	3.08e-10	Pancreatic cancer;
LIHC	cis	rs9473924	0.542	rs9473939	chr6:50877477	T/G	cg14470998	chr6:50812995	TFAP2B	0.91	10.53	0.49	1.22e-22	Body mass index;
LIHC	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	20.56	0.74	1.01e-61	Colorectal cancer;
LIHC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.84	10.13	0.48	2.89e-21	Mean platelet volume;
LIHC	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.65	10.18	0.48	1.94e-21	Type 2 diabetes;
LIHC	cis	rs11053548	0.678	rs11053550	chr12:10172353	T/C	cg04314261	chr12:10163030	CLEC12B	0.42	6.3	0.32	9.31e-10	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs288342	0.832	rs288240	chr2:183644191	T/C	cg02625481	chr2:183667124	NA	-0.29	-5.93	-0.31	7.36e-9	Recurrent major depressive disorder;
LIHC	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.78	-0.3	1.71e-8	Response to amphetamines;
LIHC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg15208524	chr1:10270712	KIF1B	0.38	5.72	0.3	2.29e-8	Hepatocellular carcinoma;
LIHC	cis	rs11627756	0.957	rs11846451	chr14:103131723	T/C	cg12046867	chr14:103022105	NA	0.39	5.93	0.31	7.27e-9	Mean platelet volume;
LIHC	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.31	-5.81	-0.3	1.47e-8	Red blood cell count;
LIHC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg26441486	chr22:50317300	CRELD2	0.36	6.38	0.33	5.73e-10	Schizophrenia;
LIHC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.35	7.74	0.39	1.17e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.44	7.46	0.37	7.29e-13	Mean corpuscular volume;
LIHC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.77e-22	Hemoglobin concentration;
LIHC	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg20607798	chr8:58055168	NA	0.59	6.85	0.35	3.44e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19717773	chr7:2847554	GNA12	-0.4	-7.04	-0.36	1.06e-11	Height;
LIHC	cis	rs6442522	0.640	rs3773447	chr3:15520019	G/T	cg16303742	chr3:15540471	COLQ	0.39	6.36	0.33	6.44e-10	Uric acid levels;
LIHC	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.33	6.92	0.35	2.24e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4773330	0.925	rs1891962	chr13:111809528	C/T	cg26911804	chr13:111806221	ARHGEF7	0.62	6.09	0.31	3.04e-9	Bilirubin levels;
LIHC	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.83	-14.54	-0.62	1.3e-37	Schizophrenia;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.38	-5.83	-0.3	1.31e-8	Testicular germ cell tumor;
LIHC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.54	-8.18	-0.4	5.8e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1997066	0.920	rs7088485	chr10:106725993	T/C	cg21239439	chr6:170038665	WDR27	0.67	6.08	0.31	3.23e-9	Diabetic kidney disease;
LIHC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg03929089	chr4:120376271	NA	-0.4	-6.09	-0.31	3.02e-9	HDL cholesterol;
LIHC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.83	0.3	1.29e-8	Schizophrenia;
LIHC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.96	-0.31	6.39e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg04511125	chr2:88470314	THNSL2	-0.4	-5.72	-0.3	2.35e-8	Response to metformin (IC50);
LIHC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg18357645	chr12:58087776	OS9	-0.44	-7.03	-0.36	1.12e-11	Multiple sclerosis;
LIHC	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.37	-0.33	6.16e-10	Bipolar disorder;
LIHC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.72	10.73	0.5	2.34e-23	Mosquito bite size;
LIHC	cis	rs10416265	0.528	rs17884930	chr19:33595390	A/G	cg17764715	chr19:33622953	WDR88	0.48	6.37	0.33	6.05e-10	Bone properties (heel);
LIHC	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.77	-7.17	-0.36	4.76e-12	Triglycerides;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07638904	chr22:19166425	SLC25A1	-0.47	-6.17	-0.32	1.95e-9	Systolic blood pressure;
LIHC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.6	10.08	0.48	4.24e-21	Height;
LIHC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.68	-13.09	-0.58	5.25e-32	Body mass index;
LIHC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21467203	chr3:49911342	NA	0.43	7.61	0.38	2.66e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.3	-0.32	9.23e-10	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.72	0.57	1.29e-30	Prudent dietary pattern;
LIHC	cis	rs3814244	0.528	rs61923060	chr12:68391121	T/C	cg15249341	chr12:68405565	NA	-0.32	-6.28	-0.32	1.03e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14559409	chr10:65930703	NA	0.36	6.35	0.32	6.69e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.56	0.53	2.57e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.46	-6.96	-0.35	1.78e-11	Schizophrenia;
LIHC	cis	rs11673344	0.704	rs826262	chr19:37419442	G/A	cg27390819	chr19:37464633	NA	-0.48	-5.83	-0.3	1.3e-8	Obesity-related traits;
LIHC	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.58	0.42	3.3e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg18944383	chr4:111397179	ENPEP	-0.31	-6.77	-0.34	5.74e-11	Coronary artery disease;
LIHC	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.55	-7.98	-0.4	2.18e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.76	-0.3	1.88e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.74	-0.5	2.14e-23	Longevity;Endometriosis;
LIHC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.45	-6.98	-0.35	1.5e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.69	-8.53	-0.42	4.71e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs17776563	0.887	rs28790085	chr15:89128287	T/C	cg05013243	chr15:89149849	MIR1179	0.4	6.69	0.34	9.16e-11	Thyroid hormone levels;
LIHC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.68	-9.16	-0.44	4.92e-18	Sudden cardiac arrest;
LIHC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg15704280	chr7:45808275	SEPT13	-0.51	-7.76	-0.39	9.91e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.59	0.42	3.1e-16	Birth weight;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06044117	chr11:95523445	FAM76B;CEP57	0.5	6.6	0.34	1.55e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2479724	0.625	rs9394835	chr6:41818200	A/T	cg17623882	chr6:41773611	USP49	-0.39	-5.79	-0.3	1.57e-8	Menarche (age at onset);
LIHC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.58	-11.08	-0.51	1.36e-24	Mean corpuscular volume;
LIHC	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.97	7.08	0.36	8.01e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.46	-0.33	3.61e-10	Personality dimensions;
LIHC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-15.2	-0.63	3.13e-40	Migraine;
LIHC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.76	12.68	0.57	1.9e-30	Psoriasis;
LIHC	cis	rs12079745	0.793	rs114133365	chr1:169270540	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	1.96e-11	QT interval;
LIHC	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.46	8.06	0.4	1.33e-14	Type 2 diabetes;
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.92	-0.3	7.75e-9	Menopause (age at onset);
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.51	8.7	0.43	1.42e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.45	7.19	0.36	4e-12	Cognitive function;
LIHC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg07148914	chr20:33460835	GGT7	-0.57	-8.53	-0.42	4.82e-16	Height;
LIHC	trans	rs72960926	0.744	rs55962148	chr6:74962021	G/T	cg07247405	chr1:2484626	LOC115110	0.53	6.38	0.33	5.78e-10	Metabolite levels (MHPG);
LIHC	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.49	-7.69	-0.38	1.59e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs12125971	1.000	rs12026381	chr1:107459241	C/T	cg08941669	chr1:7778234	CAMTA1	0.57	6.09	0.31	3e-9	Intelligence;
LIHC	cis	rs17125944	0.615	rs11629431	chr14:53320528	C/G	cg00686598	chr14:53173677	PSMC6	-0.76	-8.71	-0.43	1.36e-16	Alzheimer's disease (late onset);
LIHC	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.32	7.26	0.37	2.64e-12	Blood metabolite ratios;
LIHC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.7	-0.34	8.5e-11	Morning vs. evening chronotype;
LIHC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-6.38	-0.33	5.82e-10	Urate levels in lean individuals;
LIHC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.75	12.36	0.56	2.92e-29	Anterior chamber depth;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg04998419	chr1:40626967	RLF	-0.42	-6.14	-0.32	2.24e-9	Eotaxin levels;
LIHC	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg03146154	chr1:46216737	IPP	-0.4	-6.54	-0.33	2.24e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.9	8.67	0.42	1.7e-16	Plasma clusterin levels;
LIHC	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.68	0.38	1.68e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.56	8.49	0.42	6.22e-16	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.46	6.81	0.35	4.38e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.73	11.88	0.54	1.69e-27	Chronic lymphocytic leukemia;
LIHC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.7	-10.22	-0.48	1.44e-21	Coronary artery disease;
LIHC	trans	rs12807809	0.588	rs61910607	chr11:124609369	T/G	cg14028684	chr12:48723360	H1FNT	0.42	6.43	0.33	4.4e-10	Schizophrenia;
LIHC	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg11783602	chr8:55087084	NA	-0.31	-6.2	-0.32	1.66e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.96	0.31	6.36e-9	Renal cell carcinoma;
LIHC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.52	7.47	0.37	6.66e-13	Initial pursuit acceleration;
LIHC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	11.07	0.51	1.54e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	0.86	13.43	0.59	2.5e-33	Skin colour saturation;
LIHC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.49	9.19	0.44	3.94e-18	Hemoglobin concentration;
LIHC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg16070018	chr6:26224392	HIST1H3E	0.61	7.33	0.37	1.67e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg17385448	chr1:15911702	AGMAT	0.38	6.48	0.33	3.23e-10	Systolic blood pressure;
LIHC	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg10820045	chr2:198174542	NA	-0.56	-9.22	-0.45	3.01e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.25	0.32	1.24e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg27205649	chr11:78285834	NARS2	0.41	6.31	0.32	8.48e-10	Alzheimer's disease (survival time);
LIHC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg14440974	chr22:39074834	NA	-0.36	-5.97	-0.31	5.9e-9	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.63	9.7	0.46	8.18e-20	Renal cell carcinoma;
LIHC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.49	-8.03	-0.4	1.56e-14	Height;
LIHC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.32	-0.32	8.05e-10	Axial length;
LIHC	cis	rs926392	0.932	rs6124105	chr20:37686081	G/A	cg16355469	chr20:37678765	NA	0.38	5.98	0.31	5.76e-9	Dialysis-related mortality;
LIHC	cis	rs17106184	1.000	rs59390962	chr1:51314531	C/T	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11885407	chr3:193310886	OPA1	-0.5	-6.93	-0.35	2.06e-11	Pancreatic cancer;
LIHC	cis	rs6750047	0.628	rs2855655	chr2:38304488	T/C	cg07380506	chr2:38303506	CYP1B1	0.58	6.8	0.35	4.55e-11	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04498913	chr7:1135747	C7orf50	0.44	6.94	0.35	1.98e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.35	7.47	0.37	6.54e-13	Obesity (extreme);
LIHC	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.47	7.16	0.36	5.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg11212589	chr17:38028394	ZPBP2	0.37	7.74	0.39	1.16e-13	Self-reported allergy;
LIHC	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.66	-11.16	-0.52	7.05e-25	Pediatric autoimmune diseases;
LIHC	cis	rs2637266	0.628	rs846632	chr10:78535759	C/A	cg18941641	chr10:78392320	NA	0.28	5.96	0.31	6.12e-9	Pulmonary function;
LIHC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.42	-9.99	-0.48	8.51e-21	Type 2 diabetes;
LIHC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg17135325	chr3:160939158	NMD3	0.42	6.1	0.31	2.84e-9	Morning vs. evening chronotype;
LIHC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	8.18	0.4	5.52e-15	HIV-1 control;
LIHC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg15848620	chr12:58087721	OS9	0.57	7.84	0.39	5.67e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg20607798	chr8:58055168	NA	0.49	6.94	0.35	2.02e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg04013166	chr16:89971882	TCF25	0.49	6.07	0.31	3.31e-9	Skin colour saturation;
LIHC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.65	8.39	0.41	1.32e-15	Blood metabolite levels;
LIHC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	1.0	9.9	0.47	1.8e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2710642	0.611	rs2204656	chr2:62883868	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.21	-0.32	1.53e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.42	-5.85	-0.3	1.13e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg19635926	chr16:89946313	TCF25	0.52	7.02	0.36	1.17e-11	Skin colour saturation;
LIHC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.33	-0.37	1.73e-12	Type 2 diabetes;
LIHC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-6.0	-0.31	5.06e-9	Morning vs. evening chronotype;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.69	0.38	1.6e-13	Prudent dietary pattern;
LIHC	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.48	-7.28	-0.37	2.34e-12	Blood protein levels;
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg02290350	chr8:58132656	NA	0.3	6.85	0.35	3.41e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.0	0.31	4.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg11342453	chr6:26196699	NA	0.53	5.92	0.3	7.83e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.37e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.63	7.99	0.4	2.15e-14	Morning vs. evening chronotype;
LIHC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.91	16.8	0.67	1.33e-46	Menopause (age at onset);
LIHC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-26.39	-0.82	1.66e-84	Myeloid white cell count;
LIHC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-7.07	-0.36	8.59e-12	Schizophrenia;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg03735888	chr19:58951602	ZNF132	0.4	7.11	0.36	6.68e-12	Uric acid clearance;
LIHC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.51	-8.41	-0.41	1.13e-15	Menarche (age at onset);
LIHC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.43	5.8	0.3	1.54e-8	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg18944383	chr4:111397179	ENPEP	-0.35	-8.19	-0.4	5.43e-15	Coronary artery disease;
LIHC	cis	rs2997447	0.723	rs2802337	chr1:26474398	G/C	cg19633962	chr1:26362018	EXTL1	-0.54	-6.33	-0.32	7.49e-10	QRS complex (12-leadsum);
LIHC	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.41	-8.57	-0.42	3.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg03517284	chr6:25882590	NA	-0.39	-5.9	-0.3	8.72e-9	Height;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08219700	chr8:58056026	NA	0.52	7.14	0.36	5.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg09835421	chr16:68378352	PRMT7	-0.5	-5.94	-0.31	7.02e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	0.87	16.49	0.67	2.27e-45	Schizophrenia;
LIHC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	1.04	15.73	0.65	2.54e-42	Breast cancer;
LIHC	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.61	-6.71	-0.34	8.22e-11	Hair shape;
LIHC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.03	-0.44	1.3e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.45	-6.49	-0.33	2.94e-10	Breast cancer;
LIHC	cis	rs425535	0.619	rs3906613	chr4:74828447	G/A	cg02530824	chr4:74847766	PF4	-0.37	-5.95	-0.31	6.57e-9	Blood protein levels;
LIHC	trans	rs1864585	0.505	rs73208792	chr8:10680471	C/T	cg26278703	chr11:58910052	FAM111A	0.74	6.69	0.34	9.38e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg18964960	chr10:1102726	WDR37	0.67	6.31	0.32	8.41e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.57	-7.6	-0.38	2.89e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.0	19.63	0.73	5.46e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs4919087	0.545	rs793531	chr10:99041167	G/T	cg25902810	chr10:99078978	FRAT1	-0.6	-6.68	-0.34	9.74e-11	Monocyte count;
LIHC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-7.94	-0.39	2.85e-14	Crohn's disease;
LIHC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg06453172	chr10:134556979	INPP5A	0.57	8.04	0.4	1.47e-14	Migraine;
LIHC	cis	rs6545883	0.894	rs2694634	chr2:61551435	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.3	-0.37	2.04e-12	Tuberculosis;
LIHC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.53	-6.3	-0.32	8.92e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.58	11.25	0.52	3.32e-25	Coronary artery disease;
LIHC	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.81	-0.39	6.99e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg11783602	chr8:55087084	NA	-0.31	-6.09	-0.31	3.02e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg06096015	chr1:231504339	EGLN1	0.49	9.29	0.45	1.9e-18	Hemoglobin concentration;
LIHC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg09163369	chr1:210001066	C1orf107	0.48	5.71	0.3	2.44e-8	Orofacial clefts;
LIHC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.69	7.99	0.4	2.07e-14	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.83	10.86	0.51	8.58e-24	Cognitive function;
LIHC	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.6	7.38	0.37	1.24e-12	Coronary artery disease;
LIHC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs965469	0.779	rs6037548	chr20:3299299	G/A	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs6586163	0.843	rs7069061	chr10:90754909	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-8.36	-0.41	1.64e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.59	10.79	0.5	1.47e-23	Coronary artery disease;
LIHC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.33	6.05	0.31	3.87e-9	Aortic root size;
LIHC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg12365402	chr11:9010492	NRIP3	0.31	7.97	0.4	2.37e-14	Hemoglobin concentration;
LIHC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.46	7.67	0.38	1.82e-13	Mean corpuscular volume;
LIHC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.71	7.97	0.4	2.41e-14	Lymphocyte counts;
LIHC	cis	rs797680	0.856	rs7547244	chr1:93781768	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.04	-0.31	3.95e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22496380	chr5:211416	CCDC127	-1.05	-10.66	-0.5	4.14e-23	Breast cancer;
LIHC	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.62	6.13	0.31	2.44e-9	Carotid intima media thickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24376286	chr2:198245629	NA	0.34	6.36	0.33	6.28e-10	Pancreatic cancer;
LIHC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.19	0.32	1.7e-9	Menopause (age at onset);
LIHC	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	0.94	12.07	0.55	3.4e-28	Economic and political preferences (immigration/crime);
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.72	-0.39	1.34e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg00280220	chr17:61926910	NA	0.43	6.89	0.35	2.71e-11	Prudent dietary pattern;
LIHC	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.34	-0.45	1.31e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg25214090	chr10:38739885	LOC399744	0.44	6.91	0.35	2.32e-11	Diastolic blood pressure;
LIHC	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-7.65	-0.38	2.05e-13	Exhaled nitric oxide output;
LIHC	cis	rs7534824	0.625	rs3087816	chr1:101441775	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.93	0.35	2.07e-11	Refractive astigmatism;
LIHC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg09182678	chr22:50328711	NA	-0.43	-6.16	-0.32	2.04e-9	Schizophrenia;
LIHC	cis	rs7520050	0.902	rs1355642	chr1:46598903	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.23	0.32	1.34e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.46	6.21	0.32	1.54e-9	Resting heart rate;
LIHC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.94	15.25	0.64	2e-40	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg22771759	chr13:24902376	NA	0.32	6.7	0.34	8.43e-11	Obesity-related traits;
LIHC	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	1.22	9.95	0.47	1.15e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg10820045	chr2:198174542	NA	0.41	6.04	0.31	4.05e-9	Dermatomyositis;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg02640540	chr1:67518911	SLC35D1	0.41	6.38	0.33	5.76e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20135002	chr11:47629003	NA	-0.56	-9.44	-0.45	6.07e-19	Subjective well-being;
LIHC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-8.98	-0.44	1.88e-17	IgG glycosylation;
LIHC	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg07148914	chr20:33460835	GGT7	-0.5	-7.14	-0.36	5.67e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	12.66	0.56	2.21e-30	Cognitive test performance;
LIHC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.93	14.4	0.61	4.4e-37	Vitamin D levels;
LIHC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.33	5.8	0.3	1.48e-8	Body mass index;
LIHC	cis	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg05636881	chr10:105038444	INA	0.42	6.48	0.33	3.25e-10	Migraine;
LIHC	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.54	-8.16	-0.4	6.28e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.12	0.31	2.56e-9	Renal cell carcinoma;
LIHC	trans	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg14791747	chr16:20752902	THUMPD1	0.49	6.84	0.35	3.76e-11	Dental caries;
LIHC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.65	-10.42	-0.49	2.9e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.96	-0.44	2.1e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs7537052	0.669	rs4652903	chr1:36642858	C/T	cg24686825	chr1:36642396	MAP7D1	-0.46	-8.52	-0.42	5.01e-16	Schizophrenia;
LIHC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg06026331	chr20:60912101	LAMA5	0.52	7.17	0.36	4.71e-12	Colorectal cancer;
LIHC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.5	8.83	0.43	5.53e-17	Colorectal cancer;
LIHC	cis	rs2274273	0.840	rs10142448	chr14:55838108	G/T	cg01864836	chr14:55583639	NA	0.35	6.57	0.33	1.87e-10	Protein biomarker;
LIHC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg27478167	chr7:817139	HEATR2	-0.42	-6.01	-0.31	4.77e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.16	-0.32	2.1e-9	Alzheimer's disease (late onset);
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.66	10.44	0.49	2.55e-22	Longevity;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.98	0.47	9.22e-21	Lymphocyte counts;
LIHC	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.84	-13.19	-0.58	2.14e-32	Obesity-related traits;
LIHC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	0.93	12.07	0.55	3.51e-28	Post bronchodilator FEV1;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07024458	chr16:56390600	GNAO1	0.45	6.65	0.34	1.16e-10	Pancreatic cancer;
LIHC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.44	0.33	4.02e-10	Renal cell carcinoma;
LIHC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.72	9.07	0.44	9.36e-18	Body mass index;
LIHC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-7.45	-0.37	7.94e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg08975724	chr8:8085496	FLJ10661	0.41	5.96	0.31	6.3e-9	Mood instability;
LIHC	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.14	9.55	0.46	2.67e-19	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg07393940	chr7:158741817	NA	0.55	6.37	0.33	6.26e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.72	-0.34	7.58e-11	Bladder cancer;
LIHC	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.41	-6.43	-0.33	4.32e-10	Coronary artery disease;
LIHC	cis	rs6815814	0.678	rs9715841	chr4:38774503	T/C	cg06935464	chr4:38784597	TLR10	0.38	5.94	0.31	7.12e-9	Breast cancer;
LIHC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.48	0.49	1.76e-22	Obesity-related traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11952604	chr15:69113456	ANP32A	-0.53	-6.14	-0.32	2.3e-9	Systolic blood pressure;
LIHC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg00656387	chr3:40428638	ENTPD3	-0.45	-7.64	-0.38	2.26e-13	Renal cell carcinoma;
LIHC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.86	0.3	1.08e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2334880	0.638	rs17343777	chr16:71439172	T/A	cg06353428	chr16:71660113	MARVELD3	-0.88	-7.72	-0.39	1.3e-13	Malaria;
LIHC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.79	-12.2	-0.55	1.17e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.77	-0.34	5.79e-11	Lymphocyte counts;
LIHC	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.81	-9.62	-0.46	1.56e-19	Mean platelet volume;
LIHC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-9.72	-0.47	7.09e-20	Mean corpuscular volume;
LIHC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg17980119	chr2:219472607	PLCD4	0.36	6.21	0.32	1.55e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.45	7.25	0.37	2.78e-12	Red blood cell count;
LIHC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg02269571	chr22:50332266	NA	-0.61	-8.7	-0.43	1.44e-16	Schizophrenia;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg06598544	chr20:61472147	COL9A3	-0.9	-8.58	-0.42	3.3e-16	Obesity-related traits;
LIHC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.58	-0.46	2e-19	Mean platelet volume;
LIHC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.95	-0.47	1.22e-20	Chronic sinus infection;
LIHC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.73	-8.63	-0.42	2.35e-16	Hip circumference adjusted for BMI;
LIHC	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.41	6.95	0.35	1.85e-11	Electroencephalogram traits;
LIHC	cis	rs3781684	1.000	rs2233551	chr11:76814471	A/G	cg19164997	chr11:76818702	CAPN5	-0.42	-5.92	-0.3	7.92e-9	Cognitive performance;
LIHC	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.86	0.3	1.09e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.79	-0.73	1.21e-58	Height;
LIHC	cis	rs1982963	1.000	rs1982963	chr14:52509101	C/T	cg10843707	chr14:52510701	NID2	-0.47	-8.37	-0.41	1.5e-15	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs77637988	0.604	rs7566239	chr2:48598882	G/A	cg00032884	chr2:48540671	FOXN2	0.4	6.33	0.32	7.64e-10	Joint mobility (Beighton score);
LIHC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-5.81	-0.3	1.45e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9322817	0.691	rs2400071	chr6:105344075	C/T	cg02098413	chr6:105308735	HACE1	0.42	7.96	0.4	2.52e-14	Thyroid stimulating hormone;
LIHC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.91	0.3	8.38e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.56	0.46	2.44e-19	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.83	-0.3	1.28e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-21.62	-0.76	6.02e-66	Height;
LIHC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.72	9.18	0.44	4.2e-18	Mean corpuscular hemoglobin;
LIHC	cis	rs61041384	0.661	rs4148864	chr12:123580657	C/T	cg25930673	chr12:123319894	HIP1R	0.65	6.08	0.31	3.2e-9	Schizophrenia;
LIHC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-7.79	-0.39	7.86e-14	Gut microbiome composition (summer);
LIHC	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.72	-16.2	-0.66	3.33e-44	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	8.24	0.41	3.65e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.7	10.21	0.48	1.59e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.9	-0.51	6.28e-24	Lung cancer;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg10862848	chr6:42927986	GNMT	-0.3	-6.69	-0.34	9.2e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9513627	1.000	rs2390279	chr13:100208705	A/G	cg25919922	chr13:100150906	NA	-0.73	-6.97	-0.35	1.62e-11	Obesity-related traits;
LIHC	cis	rs12079745	0.793	rs114369903	chr1:169251394	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-6.79	-0.34	5.08e-11	QT interval;
LIHC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.82	-0.35	4.13e-11	Personality dimensions;
LIHC	cis	rs4728302	0.869	rs6467510	chr7:133607968	A/G	cg10665199	chr7:133106180	EXOC4	0.38	6.72	0.34	7.63e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.11	0.4	9.35e-15	Response to antipsychotic treatment;
LIHC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.84	10.9	0.51	6e-24	Cognitive function;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg22272508	chr17:34961264	MRM1	0.57	6.08	0.31	3.2e-9	Mean platelet volume;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01087294	chr15:90456194	C15orf38	-0.39	-6.13	-0.31	2.36e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.38	6.32	0.32	8.35e-10	Height;
LIHC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.57	-8.42	-0.41	1.02e-15	Cerebrospinal P-tau181p levels;
LIHC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.91e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3812111	0.774	rs564253	chr6:116424714	C/T	cg08036074	chr6:116424633	NT5DC1	-0.67	-12.11	-0.55	2.5e-28	Age-related macular degeneration;
LIHC	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.92	-13.68	-0.59	2.89e-34	Corneal structure;
LIHC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.78	11.25	0.52	3.39e-25	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.44	-7.42	-0.37	9.51e-13	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.36	-0.33	6.47e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.52	8.17	0.4	5.95e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.69	0.5	3.44e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs61712019	0.679	rs11126613	chr2:77722435	C/T	cg11252801	chr2:77748917	LRRTM4	0.56	7.73	0.39	1.2e-13	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.46	8.48	0.42	6.72e-16	Prudent dietary pattern;
LIHC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.03	-0.4	1.57e-14	Monocyte percentage of white cells;
LIHC	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg25952890	chr19:58913133	NA	0.68	7.37	0.37	1.26e-12	Mean platelet volume;
LIHC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg07689907	chr11:61582574	FADS1	0.39	5.77	0.3	1.78e-8	Trans fatty acid levels;
LIHC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.51	8.38	0.41	1.37e-15	Schizophrenia;
LIHC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg06096015	chr1:231504339	EGLN1	0.48	9.09	0.44	8.04e-18	Hemoglobin concentration;
LIHC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.45	-7.28	-0.37	2.25e-12	Red blood cell count;
LIHC	cis	rs611744	0.905	rs408506	chr8:109154233	A/C	cg18478394	chr8:109455254	TTC35	-0.35	-6.05	-0.31	3.82e-9	Dupuytren's disease;
LIHC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.51	7.44	0.37	8.19e-13	Type 2 diabetes;
LIHC	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.58	7.71	0.38	1.36e-13	Body mass index (adult);
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.56	10.27	0.49	9.91e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.47	-7.03	-0.36	1.12e-11	P wave terminal force;
LIHC	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	0.69	8.77	0.43	8.56e-17	Corneal structure;
LIHC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.55	-0.42	4.1e-16	Type 2 diabetes;
LIHC	trans	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg01596870	chr19:55963115	NA	-0.65	-9.28	-0.45	1.99e-18	Obesity-related traits;
LIHC	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.3	-6.15	-0.32	2.2e-9	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.76e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.49	7.25	0.37	2.78e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg07541023	chr7:19748670	TWISTNB	0.39	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LIHC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs4716602	0.596	rs10270517	chr7:156160010	A/G	cg16983916	chr7:156159713	NA	-0.32	-5.71	-0.3	2.43e-8	Anti-saccade response;
LIHC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.37	-5.82	-0.3	1.33e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg19318889	chr4:1322082	MAEA	0.46	6.49	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs12458462	0.851	rs60298379	chr18:77488422	C/T	cg11879182	chr18:77439856	CTDP1	0.83	13.38	0.59	4.01e-33	Monocyte count;
LIHC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.78	12.76	0.57	8.79e-31	Fat distribution (HIV);
LIHC	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.87	9.54	0.46	2.85e-19	Alzheimer's disease (late onset);
LIHC	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg10820045	chr2:198174542	NA	-0.57	-9.34	-0.45	1.24e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-8.25	-0.41	3.45e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg13385521	chr17:29058706	SUZ12P	-0.58	-5.86	-0.3	1.08e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs9940464	0.871	rs12597099	chr16:83366896	C/G	cg13016115	chr14:23388406	RBM23	0.38	6.16	0.32	2.09e-9	Malaria;
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.91	-0.3	8.35e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg02447239	chr2:235936137	SH3BP4	0.36	6.36	0.33	6.58e-10	Dialysis-related mortality;
LIHC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.06	16.62	0.67	6.67e-46	Breast cancer;
LIHC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	12.62	0.56	3.12e-30	Prudent dietary pattern;
LIHC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.97	0.35	1.68e-11	Breast cancer;
LIHC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.46	-7.25	-0.36	2.82e-12	Neurofibrillary tangles;
LIHC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	8.44	0.42	8.94e-16	Blood metabolite levels;
LIHC	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.69	10.74	0.5	2.24e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg00149659	chr3:10157352	C3orf10	0.66	6.49	0.33	2.94e-10	Alzheimer's disease;
LIHC	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.32	6.75	0.34	6.52e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.97	12.69	0.57	1.64e-30	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.58	7.84	0.39	5.93e-14	Bone mineral density (spine);
LIHC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg08694578	chr2:241835147	C2orf54	-0.51	-7.18	-0.36	4.38e-12	Urinary metabolites;
LIHC	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.47e-9	Cognitive performance;
LIHC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.59	-7.63	-0.38	2.3e-13	Post bronchodilator FEV1;
LIHC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.68	9.93	0.47	1.42e-20	Menarche (age at onset);
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg10774155	chr7:65338427	VKORC1L1	0.45	6.82	0.35	4.12e-11	Calcium levels;
LIHC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	7.79	0.39	8.28e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg05484376	chr2:27715224	FNDC4	0.39	6.61	0.34	1.46e-10	Total body bone mineral density;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.71	-0.34	8.05e-11	Total body bone mineral density;
LIHC	cis	rs2071426	0.959	rs1934955	chr10:96788561	A/G	cg09036531	chr10:96991505	NA	-0.5	-5.91	-0.3	8.38e-9	Blood metabolite levels;
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.88	-0.3	9.71e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	0.93	10.88	0.51	7.18e-24	Breast cancer;
LIHC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.19	0.32	1.68e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.62	-10.18	-0.48	1.88e-21	Malaria;
LIHC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.75	11.3	0.52	2.26e-25	Obesity-related traits;
LIHC	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.49	7.07	0.36	8.55e-12	Dialysis-related mortality;
LIHC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.42	-0.37	9.42e-13	IgG glycosylation;
LIHC	cis	rs249954	0.512	rs249867	chr16:23668568	G/A	cg05131483	chr16:23706242	ERN2	0.38	6.3	0.32	8.91e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.98	15.32	0.64	1.03e-40	Metabolic syndrome;
LIHC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.33	7.05	0.36	9.84e-12	Bone mineral density;
LIHC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.46	0.53	5.85e-26	Colorectal cancer;
LIHC	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-1.0	-14.71	-0.62	2.7e-38	Corneal structure;
LIHC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.64	-0.53	1.27e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.53	9.36	0.45	1.11e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg11764359	chr7:65958608	NA	0.57	5.99	0.31	5.39e-9	Diabetic kidney disease;
LIHC	trans	rs1864585	0.520	rs73208791	chr8:10680338	T/C	cg26278703	chr11:58910052	FAM111A	0.74	6.83	0.35	3.95e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.5	7.48	0.38	6.2800000000000005e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.54	9.84	0.47	2.83e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.24	-5.91	-0.3	8.23e-9	Primary biliary cholangitis;
LIHC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.66	6.27	0.32	1.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.38	5.75	0.3	1.94e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.75	12.04	0.55	4.32e-28	Eosinophil percentage of white cells;
LIHC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.02	0.31	4.48e-9	Eosinophil percentage of white cells;
LIHC	cis	rs10508774	1.000	rs58783140	chr10:32909603	C/T	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-16.0	-0.65	2.15e-43	Gut microbiome composition (summer);
LIHC	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg03934865	chr2:198174659	NA	0.46	6.53	0.33	2.36e-10	Intracranial aneurysm;
LIHC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.6	-10.59	-0.5	7.25e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg00280220	chr17:61926910	NA	0.44	7.07	0.36	8.7e-12	Prudent dietary pattern;
LIHC	cis	rs11779988	0.543	rs410445	chr8:17882304	C/T	cg01800426	chr8:17659068	MTUS1	-0.43	-6.32	-0.32	7.98e-10	Breast cancer;
LIHC	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg17845761	chr1:175162550	KIAA0040	-0.36	-5.85	-0.3	1.15e-8	Alcohol dependence;
LIHC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.46	7.54	0.38	4.31e-13	Aortic root size;
LIHC	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.71	-11.11	-0.51	1.1e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.68	10.71	0.5	2.84e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-6.03	-0.31	4.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.56e-8	Bladder cancer;
LIHC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18000306	chr6:288505	NA	0.36	6.78	0.34	5.32e-11	Menopause (age at onset);
LIHC	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.71	11.53	0.53	3.24e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.52	-0.49	1.36e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.28e-34	Aortic root size;
LIHC	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.47	0.53	5.44e-26	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.56	0.33	2.03e-10	Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.53	-0.62	1.41e-37	Alzheimer's disease (late onset);
LIHC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.47	-12.03	-0.55	5.04e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg01652190	chr22:50026171	C22orf34	-0.28	-6.1	-0.31	2.89e-9	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6088813	0.925	rs4353719	chr20:33977349	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.76	0.5	1.86e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.47	7.36	0.37	1.35e-12	HDL cholesterol levels;
LIHC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.18	0.32	1.78e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.09	0.31	3.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.83	-8.11	-0.4	9.15e-15	Body mass index;
LIHC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.55	-10.16	-0.48	2.28e-21	Coronary artery disease;
LIHC	cis	rs74181299	0.648	rs1050676	chr2:65310831	A/T	cg05010058	chr2:65284262	CEP68	-0.4	-6.66	-0.34	1.13e-10	Pulse pressure;
LIHC	cis	rs4924590	0.531	rs2114477	chr15:42227441	C/T	cg20935245	chr15:42234343	EHD4	-0.4	-7.22	-0.36	3.4e-12	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LIHC	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg20240347	chr1:204465584	NA	0.29	6.19	0.32	1.77e-9	Schizophrenia;
LIHC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.95	0.31	6.61e-9	Height;
LIHC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.89	10.17	0.48	2.12e-21	Primary sclerosing cholangitis;
LIHC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.82	-0.63	1.03e-38	Chronic sinus infection;
LIHC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg03146154	chr1:46216737	IPP	0.5	8.54	0.42	4.4e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7106204	0.514	rs1596280	chr11:24250853	T/C	ch.11.24196551F	chr11:24239977	NA	0.83	11.91	0.54	1.39e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.4	0.33	5.27e-10	Breast cancer;
LIHC	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.51	-7.24	-0.36	3.03e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.36	-7.64	-0.38	2.15e-13	Longevity;
LIHC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	trans	rs6934970	1.000	rs6933881	chr6:113123860	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-6.09	-0.31	3.1e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-10.41	-0.49	3.06e-22	Body mass index;
LIHC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.04	0.36	1.06e-11	Neutrophil percentage of white cells;
LIHC	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg19920283	chr7:105172520	RINT1	0.47	5.98	0.31	5.72e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.68	10.21	0.48	1.49e-21	Height;
LIHC	cis	rs10454142	0.845	rs56391806	chr2:48631977	C/T	cg15846641	chr2:48541264	FOXN2	0.5	6.53	0.33	2.41e-10	Sex hormone-binding globulin levels;
LIHC	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.5	-7.41	-0.37	9.89e-13	Body mass index;
LIHC	cis	rs7119038	0.774	rs73005426	chr11:118681083	A/G	cg19308663	chr11:118741387	NA	0.39	6.04	0.31	4.11e-9	Sjögren's syndrome;
LIHC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.6	0.34	1.54e-10	Morning vs. evening chronotype;
LIHC	cis	rs4919087	0.561	rs7101333	chr10:99083669	A/G	cg25902810	chr10:99078978	FRAT1	-0.59	-6.88	-0.35	2.82e-11	Monocyte count;
LIHC	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.58	-7.96	-0.4	2.62e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.49	9.17	0.44	4.42e-18	Hemoglobin concentration;
LIHC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-8.69	-0.43	1.58e-16	Vitiligo;
LIHC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.58	9.23	0.45	2.81e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.36	1.17e-11	Diabetic kidney disease;
LIHC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg07090678	chr1:91966139	CDC7	0.5	6.78	0.34	5.44e-11	Breast cancer;
LIHC	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.34	7.04	0.36	1.07e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-8.39	-0.41	1.28e-15	Total body bone mineral density;
LIHC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg14222432	chr12:29376421	FAR2	0.36	6.84	0.35	3.63e-11	QT interval;
LIHC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg03037974	chr15:76606532	NA	-0.65	-11.6	-0.53	1.8e-26	Blood metabolite levels;
LIHC	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.23	-0.32	1.37e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg14146966	chr2:61757674	XPO1	0.41	6.83	0.35	3.8e-11	Tuberculosis;
LIHC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.81	-0.35	4.44e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2637030	0.559	rs256110	chr5:52879803	A/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.59	0.34	1.7e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs10733682	0.659	rs867560	chr9:129465233	C/G	cg00232160	chr9:129468157	NA	-0.34	-5.93	-0.31	7.28e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-8.17	-0.4	6.11e-15	Hepatocellular carcinoma;
LIHC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.72	-0.47	6.94e-20	Blood metabolite levels;
LIHC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.33	5.72	0.3	2.33e-8	Schizophrenia;
LIHC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	18.21	0.7	2.91e-52	Smoking behavior;
LIHC	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	0.81	8.27	0.41	3.05e-15	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.84	-0.3	1.23e-8	Resting heart rate;
LIHC	cis	rs151997	0.962	rs27268	chr5:50184778	T/C	cg06027927	chr5:50259733	NA	0.56	7.61	0.38	2.71e-13	Callous-unemotional behaviour;
LIHC	cis	rs798766	0.909	rs11724531	chr4:1753424	A/G	cg21231739	chr4:1642635	FAM53A	-0.37	-5.93	-0.31	7.49e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.64	-0.34	1.22e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.86	0.47	2.37e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7212590	0.655	rs8067568	chr17:57999215	A/G	cg10252138	chr17:58120427	NA	-0.6	-6.15	-0.32	2.15e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07963361	chr7:87505792	SLC25A40;DBF4	0.47	6.41	0.33	4.78e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8084351	0.599	rs12967441	chr18:50675912	G/A	cg24270629	chr18:50823537	DCC	-0.45	-6.66	-0.34	1.1e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.51	7.97	0.4	2.36e-14	Lymphocyte counts;
LIHC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.71	13.22	0.58	1.59e-32	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22446331	chr18:19750865	GATA6	0.46	6.82	0.35	4.05e-11	Pancreatic cancer;
LIHC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.61	8.4	0.41	1.17e-15	Platelet count;
LIHC	trans	rs2270927	0.510	rs6891108	chr5:75579152	C/A	cg13563193	chr19:33072644	PDCD5	0.99	9.64	0.46	1.26e-19	Mean corpuscular volume;
LIHC	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.32	-6.54	-0.33	2.29e-10	Bone mineral density;
LIHC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.15	-0.44	5.35e-18	Subjective well-being;
LIHC	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	0.81	6.75	0.34	6.35e-11	Cannabis dependence symptom count;
LIHC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg11766577	chr21:47581405	C21orf56	-0.39	-5.9	-0.3	8.59e-9	Testicular germ cell tumor;
LIHC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.63	-6.01	-0.31	4.82e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	8.61	0.42	2.74e-16	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.46	0.46	5.21e-19	Height;
LIHC	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.45	7.32	0.37	1.84e-12	Corneal astigmatism;
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg19318889	chr4:1322082	MAEA	0.52	8.69	0.43	1.57e-16	Obesity-related traits;
LIHC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.28	-7.37	-0.37	1.27e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.71	0.34	8.07e-11	Bipolar disorder;
LIHC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.89	16.15	0.66	5.35e-44	Aortic root size;
LIHC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg20651018	chr11:3035856	CARS	-0.35	-5.76	-0.3	1.88e-8	Longevity;
LIHC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg27433088	chr4:174089019	GALNT7	0.38	6.93	0.35	2.07e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg24693881	chr1:107596107	NA	0.52	9.23	0.45	2.85e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs55702914	0.809	rs6738721	chr2:198182334	A/G	cg10820045	chr2:198174542	NA	-0.41	-6.05	-0.31	3.79e-9	Major depression and alcohol dependence;
LIHC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.67	-9.18	-0.44	4.08e-18	Longevity;
LIHC	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg25179470	chr10:102756915	LZTS2	0.43	6.07	0.31	3.36e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs713477	1.000	rs28604440	chr14:55911324	C/T	cg13175173	chr14:55914753	NA	-0.33	-7.52	-0.38	4.76e-13	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.22	0.52	4.23e-25	Motion sickness;
LIHC	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg02702477	chr5:179499311	RNF130	1.01	13.24	0.58	1.43e-32	LDL cholesterol;
LIHC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.35	-0.32	6.93e-10	Colorectal cancer;
LIHC	cis	rs11958404	0.546	rs6556332	chr5:157433684	A/G	cg05962755	chr5:157440814	NA	0.61	7.9	0.39	3.75e-14	IgG glycosylation;
LIHC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.61	0.38	2.7e-13	Prudent dietary pattern;
LIHC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.01	-0.44	1.43e-17	Bipolar disorder;
LIHC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.74	-0.34	6.91e-11	Bladder cancer;
LIHC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.53	-8.67	-0.42	1.76e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	1.06	15.96	0.65	2.91e-43	Breast cancer;
LIHC	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.71	14.64	0.62	5.01e-38	Schizophrenia;
LIHC	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.59	-6.6	-0.34	1.6e-10	Hippocampal volume;
LIHC	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	5.76e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12220238	0.841	rs7919010	chr10:76111137	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.27	0.32	1.07e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg20607764	chr19:44506953	ZNF230	0.44	7.09	0.36	7.7e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.67	9.74	0.47	6.14e-20	Monocyte percentage of white cells;
LIHC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02450064	chr17:40260053	DHX58	-0.29	-6.07	-0.31	3.49e-9	Fibrinogen levels;
LIHC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.83	-0.35	3.85e-11	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.96	-0.44	2.11e-17	Blood metabolite levels;
LIHC	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	0.85	10.95	0.51	3.98e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.7	0.57	1.5e-30	Total body bone mineral density;
LIHC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.39	-6.7	-0.34	8.6e-11	Mean corpuscular volume;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.1	-0.31	2.94e-9	Total body bone mineral density;
LIHC	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg00409905	chr10:38381863	ZNF37A	0.47	7.56	0.38	3.71e-13	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.63	8.59	0.42	3.11e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.5	8.08	0.4	1.12e-14	Corneal astigmatism;
LIHC	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg05771511	chr15:63340396	TPM1	-0.44	-5.94	-0.31	7.01e-9	Orofacial clefts;
LIHC	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.51	8.44	0.42	9.03e-16	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.68	0.65	4.03e-42	Electrocardiographic conduction measures;
LIHC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.5	7.47	0.37	6.91e-13	Diastolic blood pressure;
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.72	-0.39	1.26e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.54	0.53	2.97e-26	Prudent dietary pattern;
LIHC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.71	-8.44	-0.42	9.36e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.63	7.34	0.37	1.59e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06387028	chr7:72395397	POM121	0.47	6.18	0.32	1.78e-9	Hepatitis;
LIHC	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs67981189	0.593	rs4147077	chr14:71454870	A/G	cg15816911	chr14:71606274	NA	0.42	6.7	0.34	8.37e-11	Schizophrenia;
LIHC	trans	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg26939375	chr7:64535504	NA	-0.39	-6.25	-0.32	1.22e-9	Aortic root size;
LIHC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg15691649	chr6:25882328	NA	-0.51	-7.33	-0.37	1.65e-12	Blood metabolite levels;
LIHC	cis	rs7572733	0.536	rs6732517	chr2:198912902	G/C	cg00792783	chr2:198669748	PLCL1	0.4	5.85	0.3	1.13e-8	Dermatomyositis;
LIHC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg15123519	chr2:136567270	LCT	-0.37	-6.08	-0.31	3.25e-9	Corneal structure;
LIHC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.98	-18.35	-0.7	7.7e-53	Breast cancer;
LIHC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg02640540	chr1:67518911	SLC35D1	0.43	6.81	0.35	4.37e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.64	8.93	0.43	2.76e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	16.92	0.67	4.41e-47	Lung cancer in ever smokers;
LIHC	cis	rs16828019	0.929	rs35883594	chr1:41744093	A/G	cg03387723	chr1:41708464	SCMH1	-0.43	-6.82	-0.35	4.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.69	-9.33	-0.45	1.33e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07677032	chr17:61819896	STRADA	0.42	6.09	0.31	2.96e-9	Prudent dietary pattern;
LIHC	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.41	8.12	0.4	8.56e-15	Testicular germ cell tumor;
LIHC	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.01	-0.31	4.66e-9	Tuberculosis;
LIHC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.38	0.59	3.92e-33	Chronic sinus infection;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25116269	chr2:55509523	PRDXDD1P	0.57	7.3	0.37	2.05e-12	Lung function (FEV1/FVC);
LIHC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.64	11.67	0.53	1.07e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg00280220	chr17:61926910	NA	0.43	6.83	0.35	3.87e-11	Prudent dietary pattern;
LIHC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-14.43	-0.62	3.3e-37	Systemic lupus erythematosus;
LIHC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.43e-20	Menopause (age at onset);
LIHC	cis	rs3015497	0.711	rs4343181	chr14:51162848	C/T	cg09863266	chr14:51125203	SAV1	-0.38	-5.93	-0.31	7.29e-9	Mean platelet volume;
LIHC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.48	-5.92	-0.3	7.89e-9	Narcolepsy;
LIHC	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg18964960	chr10:1102726	WDR37	0.66	5.9	0.3	8.54e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-9.49	-0.46	3.97e-19	Platelet count;
LIHC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg25039879	chr17:56429692	SUPT4H1	0.42	5.93	0.31	7.56e-9	Cognitive test performance;
LIHC	cis	rs1712517	0.771	rs10883858	chr10:105127708	G/A	cg05636881	chr10:105038444	INA	0.48	7.54	0.38	4.29e-13	Migraine;
LIHC	cis	rs12980942	1.000	rs8109167	chr19:41823167	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.47	5.91	0.3	8.07e-9	Coronary artery disease;
LIHC	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.12	-0.31	2.52e-9	Blood pressure;
LIHC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-11.05	-0.51	1.77e-24	Colorectal cancer;
LIHC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg10621924	chr7:39171070	POU6F2	0.42	6.66	0.34	1.1e-10	IgG glycosylation;
LIHC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg26441486	chr22:50317300	CRELD2	0.35	5.93	0.31	7.4e-9	Schizophrenia;
LIHC	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.68	13.04	0.58	8.05e-32	Systemic lupus erythematosus;
LIHC	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.51	7.94	0.39	2.93e-14	Recalcitrant atopic dermatitis;
LIHC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.32	-12.51	-0.56	8.09e-30	Plateletcrit;
LIHC	cis	rs7224685	0.569	rs10521129	chr17:4008820	C/T	cg11204139	chr17:3907470	NA	0.6	7.38	0.37	1.21e-12	Type 2 diabetes;
LIHC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.59	-8.43	-0.41	9.93e-16	Blood metabolite levels;
LIHC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.31	-5.91	-0.3	8.44e-9	Body mass index;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg09417038	chr21:47716443	C21orf57	0.52	7.94	0.39	2.93e-14	Testicular germ cell tumor;
LIHC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.8	7.86	0.39	5.22e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg06917634	chr15:78832804	PSMA4	-0.44	-5.91	-0.3	8.24e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16532752	chr4:104119610	CENPE	0.4	6.34	0.32	7.33e-10	Type 2 diabetes;
LIHC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.66	-13.1	-0.58	4.7e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs7818688	0.697	rs112076731	chr8:95978121	C/G	cg16049864	chr8:95962084	TP53INP1	0.62	6.77	0.34	5.7e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.52	8.31	0.41	2.26e-15	Fuchs's corneal dystrophy;
LIHC	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg18964960	chr10:1102726	WDR37	0.7	6.6	0.34	1.52e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.43	0.37	8.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg15208524	chr1:10270712	KIF1B	0.41	6.24	0.32	1.32e-9	Hepatocellular carcinoma;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.59	10.9	0.51	5.86e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9303280	0.618	rs4065986	chr17:38102641	G/A	cg17467752	chr17:38218738	THRA	0.39	6.36	0.33	6.28e-10	Self-reported allergy;
LIHC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.92	16.56	0.67	1.24e-45	Parkinson's disease;
LIHC	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.38	5.97	0.31	5.92e-9	Menopause (age at onset);
LIHC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg24203234	chr3:128598194	ACAD9	0.44	6.18	0.32	1.78e-9	IgG glycosylation;
LIHC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.65	0.38	2e-13	Electroencephalogram traits;
LIHC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.53	8.39	0.41	1.31e-15	Total body bone mineral density;
LIHC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg18270830	chr10:32634957	EPC1	0.53	6.6	0.34	1.61e-10	Sexual dysfunction (female);
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.64	9.35	0.45	1.16e-18	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.57	5.92	0.3	8.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	1.000	rs3742566	chr14:55595839	T/A	cg01864836	chr14:55583639	NA	-0.36	-6.13	-0.31	2.43e-9	Protein biomarker;
LIHC	cis	rs1664789	0.904	rs1694063	chr5:53279558	G/A	ch.5.1024479R	chr5:53302184	ARL15	0.54	8.39	0.41	1.31e-15	Waist circumference adjusted for body mass index;
LIHC	cis	rs6750047	0.756	rs336038	chr2:38260750	C/G	cg07380506	chr2:38303506	CYP1B1	0.5	6.1	0.31	2.9e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.09	-10.22	-0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.43	-7.78	-0.39	8.65e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs77633900	0.772	rs77582696	chr15:76669153	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-5.78	-0.3	1.73e-8	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.42	7.29	0.37	2.17e-12	Aortic root size;
LIHC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.4	-7.11	-0.36	6.7e-12	Diastolic blood pressure;
LIHC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08392591	chr16:89556376	ANKRD11	-0.39	-6.02	-0.31	4.41e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.59e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg07382826	chr16:28625726	SULT1A1	0.49	7.5	0.38	5.61e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.89	-0.3	9.23e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.88	9.85	0.47	2.52e-20	Triglycerides;
LIHC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg11764359	chr7:65958608	NA	0.61	6.37	0.33	6.21e-10	Diabetic kidney disease;
LIHC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.74	14.71	0.62	2.82e-38	Menopause (age at onset);
LIHC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.47	7.47	0.37	6.85e-13	Height;
LIHC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg05555928	chr11:63887634	MACROD1	0.56	7.54	0.38	4.22e-13	Mean platelet volume;
LIHC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.4	-0.41	1.22e-15	Chronic sinus infection;
LIHC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs2637266	1.000	rs10824429	chr10:78346196	G/T	cg18941641	chr10:78392320	NA	0.3	6.36	0.33	6.4e-10	Pulmonary function;
LIHC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg14440974	chr22:39074834	NA	-0.36	-6.03	-0.31	4.15e-9	Menopause (age at onset);
LIHC	cis	rs249954	0.512	rs34514	chr16:23670597	G/A	cg05131483	chr16:23706242	ERN2	0.38	6.3	0.32	8.91e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.47	-7.83	-0.39	6.05e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	0.94	9.28	0.45	1.95e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.69	-10.88	-0.51	7.35e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.93	-0.51	4.89e-24	Hemoglobin concentration;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.69	0.34	8.89e-11	Renal cell carcinoma;
LIHC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg10932868	chr11:921992	NA	0.34	6.32	0.32	8.22e-10	Alzheimer's disease (late onset);
LIHC	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.39	-6.31	-0.32	8.65e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.85	11.5	0.53	4.15e-26	Menopause (age at onset);
LIHC	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.27	6.35	0.32	6.73e-10	Heart rate;
LIHC	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.31	-0.32	8.51e-10	Prevalent atrial fibrillation;
LIHC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-7.79	-0.39	8.3e-14	Gut microbiome composition (summer);
LIHC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg26692224	chr17:62915920	LRRC37A3	-0.68	-6.76	-0.34	5.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.06	-0.36	9.26e-12	Bipolar disorder;
LIHC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.35	-6.35	-0.32	6.94e-10	Aortic root size;
LIHC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.56	9.28	0.45	1.96e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.71	-0.34	7.94e-11	Lymphocyte counts;
LIHC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	1.05	12.56	0.56	5.19e-30	Eosinophil percentage of granulocytes;
LIHC	trans	rs3783890	0.832	rs34243429	chr14:93804125	C/T	cg02802420	chr16:69363236	PDF;COG8	0.34	6.47	0.33	3.44e-10	Body mass index;
LIHC	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg15412446	chr2:106886593	NA	0.39	5.73	0.3	2.17e-8	Facial morphology (factor 23);
LIHC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg12798992	chr6:167411361	FGFR1OP	-0.41	-6.38	-0.33	5.82e-10	Primary biliary cholangitis;
LIHC	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg16589663	chr20:23618590	CST3	0.72	7.24	0.36	2.95e-12	Chronic kidney disease;
LIHC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.48	-7.89	-0.39	4.16e-14	Menarche (age at onset);
LIHC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.79	-0.3	1.58e-8	Ulcerative colitis;
LIHC	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-0.84	-9.11	-0.44	7.04e-18	Exhaled nitric oxide output;
LIHC	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg07661805	chr8:143867942	LY6D	-0.31	-6.68	-0.34	9.41e-11	Urinary tract infection frequency;
LIHC	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg20283391	chr11:68216788	NA	-0.52	-6.15	-0.32	2.16e-9	Total body bone mineral density (age 45-60);
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg00187635	chr16:83986795	OSGIN1	0.41	6.04	0.31	4.02e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02290350	chr8:58132656	NA	0.39	8.87	0.43	4.18e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.934	rs1668178	chr8:109191700	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.34	0.32	7.37e-10	Renal cell carcinoma;
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.6	-9.74	-0.47	6.02e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.5	6.57	0.33	1.9e-10	Subjective well-being;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.36	-0.37	1.35e-12	Bipolar disorder;
LIHC	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.64	6.4	0.33	5.15e-10	Lymphocyte counts;
LIHC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.81	12.87	0.57	3.42e-31	Diastolic blood pressure;
LIHC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg07382826	chr16:28625726	SULT1A1	0.5	7.74	0.39	1.13e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14671364	chr1:107599128	PRMT6	-0.54	-7.9	-0.39	3.92e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.2	-0.32	1.58e-9	Fear of minor pain;
LIHC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-10.37	-0.49	4.44e-22	Platelet count;
LIHC	cis	rs1385374	0.920	rs11059911	chr12:129271936	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.7	0.38	1.52e-13	Systemic lupus erythematosus;
LIHC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.68	11.91	0.54	1.4e-27	Menopause (age at onset);
LIHC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg04013166	chr16:89971882	TCF25	0.47	6.02	0.31	4.48e-9	Skin colour saturation;
LIHC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.92	17.21	0.68	3.1e-48	Aortic root size;
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg21522988	chr12:29376872	FAR2	0.29	6.58	0.34	1.77e-10	QT interval;
LIHC	cis	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg00509281	chr10:62554092	CDC2;CDK1	-0.33	-5.85	-0.3	1.17e-8	Schizophrenia;
LIHC	cis	rs7707921	0.914	rs4081859	chr5:81466669	G/A	cg15871215	chr5:81402204	ATG10	0.59	5.85	0.3	1.15e-8	Breast cancer;
LIHC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14304014	chr19:1625356	TCF3	0.43	6.79	0.34	5e-11	Bilirubin levels;
LIHC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg23029597	chr12:123009494	RSRC2	0.45	6.41	0.33	4.96e-10	Body mass index;
LIHC	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.35	6.08	0.31	3.24e-9	Schizophrenia;
LIHC	cis	rs986417	0.786	rs7156379	chr14:61110634	G/C	cg27398547	chr14:60952738	C14orf39	0.65	6.47	0.33	3.43e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-11.52	-0.53	3.63e-26	Platelet distribution width;
LIHC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.25	-0.32	1.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.75	0.39	1.04e-13	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.51	6.6	0.34	1.53e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg15744005	chr10:104629667	AS3MT	-0.39	-8.64	-0.42	2.15e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.47	-0.46	4.7e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-6.82	-0.35	4.13e-11	Chronic sinus infection;
LIHC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17554472	chr22:41940697	POLR3H	0.56	6.23	0.32	1.34e-9	Vitiligo;
LIHC	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.57	-9.19	-0.44	4.02e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg07424592	chr7:64974309	NA	0.81	9.05	0.44	1.13e-17	Diabetic kidney disease;
LIHC	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg01364799	chr7:75623366	TMEM120A	0.47	7.13	0.36	6.19e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.68	11.96	0.54	8.99e-28	Obesity-related traits;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.93	0.39	3.23e-14	Lymphocyte counts;
LIHC	cis	rs1823913	0.927	rs56209234	chr2:192126474	T/C	cg12404831	chr2:192114017	MYO1B	0.33	6.69	0.34	9.35e-11	Obesity-related traits;
LIHC	cis	rs11233413	1.000	rs11233405	chr11:82709630	A/G	cg24227371	chr11:82718527	RAB30	0.33	7.09	0.36	7.54e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs3755132	0.929	rs976016	chr2:15772865	A/G	cg12888861	chr2:15731646	DDX1	0.39	5.98	0.31	5.65e-9	Wilms tumor;
LIHC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.48	-18.2	-0.7	3.22e-52	Breast cancer;
LIHC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.47	-6.82	-0.35	4.17e-11	Corneal structure;
LIHC	cis	rs74233809	1.000	rs11191472	chr10:104707016	A/T	cg03493300	chr10:104813866	CNNM2	0.46	5.89	0.3	9.22e-9	Birth weight;
LIHC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.83	-0.3	1.26e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg16423285	chr20:60520624	NA	0.52	8.67	0.42	1.71e-16	Obesity-related traits;
LIHC	trans	rs8113308	0.810	rs55810059	chr19:52450728	G/A	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20979786	chr7:74072997	GTF2I	0.37	6.06	0.31	3.56e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.41	7.9	0.39	3.83e-14	Testicular germ cell tumor;
LIHC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg00204512	chr16:28754710	NA	0.41	7.29	0.37	2.19e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg02297831	chr4:17616191	MED28	0.42	6.63	0.34	1.28e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02985541	chr2:219472218	PLCD4	0.44	7.99	0.4	2.04e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.51	7.46	0.37	7.36e-13	HDL cholesterol;
LIHC	cis	rs72627123	0.867	rs75773875	chr14:74498053	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	9.1	0.44	7.55e-18	Morning vs. evening chronotype;
LIHC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg04756594	chr16:24857601	SLC5A11	0.48	7.42	0.37	9.33e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	0.73	10.2	0.48	1.68e-21	Initial pursuit acceleration;
LIHC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12516959	chr21:47718080	NA	0.35	5.84	0.3	1.21e-8	Testicular germ cell tumor;
LIHC	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.62	7.56	0.38	3.78e-13	Breast cancer;
LIHC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.57	7.86	0.39	4.91e-14	Morning vs. evening chronotype;
LIHC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	12.97	0.57	1.48e-31	Cognitive test performance;
LIHC	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.28	-6.28	-0.32	1.06e-9	DNA methylation (variation);
LIHC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.56	-8.44	-0.42	9.22e-16	Platelet distribution width;
LIHC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg10360323	chr17:41437877	NA	0.39	5.71	0.3	2.44e-8	Menopause (age at onset);
LIHC	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.32	5.85	0.3	1.13e-8	Protein biomarker;
LIHC	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg10820045	chr2:198174542	NA	0.46	6.8	0.35	4.58e-11	Intracranial aneurysm;
LIHC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.11	0.52	1.04e-24	Platelet count;
LIHC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-7.99	-0.4	2.14e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.55	8.06	0.4	1.3e-14	Diastolic blood pressure;
LIHC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.92	17.02	0.68	1.74e-47	Menopause (age at onset);
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg15145357	chr6:170893815	PDCD2	-0.53	-6.3	-0.32	9.05e-10	Response to hepatitis C treatment;
LIHC	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-5.83	-0.3	1.31e-8	Blood metabolite levels;
LIHC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg05555928	chr11:63887634	MACROD1	0.56	7.56	0.38	3.66e-13	Mean platelet volume;
LIHC	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19671926	chr4:122722719	EXOSC9	0.49	7.16	0.36	4.87e-12	Type 2 diabetes;
LIHC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.58	0.59	6.99e-34	Cognitive test performance;
LIHC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.48	-18.04	-0.7	1.35e-51	Breast cancer;
LIHC	trans	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg26939375	chr7:64535504	NA	0.42	6.71	0.34	8.32e-11	Aortic root size;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.49	0.56	9.37e-30	Prudent dietary pattern;
LIHC	cis	rs17106184	1.000	rs72904726	chr1:51339332	T/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.5	-0.33	2.91e-10	Type 2 diabetes;
LIHC	cis	rs11630290	0.736	rs4777370	chr15:64160104	G/A	cg12036633	chr15:63758958	NA	0.61	5.84	0.3	1.21e-8	Iris characteristics;
LIHC	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.39	5.98	0.31	5.7e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.34	-6.29	-0.32	9.45e-10	Aortic root size;
LIHC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.54	6.86	0.35	3.28e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg05207973	chr5:176823642	SLC34A1	0.34	6.1	0.31	2.89e-9	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg05527609	chr1:210001259	C1orf107	-0.66	-8.52	-0.42	5.08e-16	Red blood cell count;
LIHC	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.07	-0.36	8.77e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs61677309	1.000	rs55940627	chr11:118163920	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.58	0.34	1.82e-10	Lung cancer in ever smokers;
LIHC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	12.32	0.55	3.97e-29	Response to antipsychotic treatment;
LIHC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.85	-14.65	-0.62	4.59e-38	Dental caries;
LIHC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.56	-8.68	-0.42	1.66e-16	Diastolic blood pressure;
LIHC	cis	rs1712517	0.771	rs61871160	chr10:105144288	C/T	cg05636881	chr10:105038444	INA	0.5	7.71	0.38	1.36e-13	Migraine;
LIHC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.77	12.6	0.56	3.53e-30	Psoriasis;
LIHC	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg03056468	chr15:68155977	NA	-0.43	-6.15	-0.32	2.13e-9	Alopecia areata;
LIHC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.74	-14.17	-0.61	3.62e-36	Height;
LIHC	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-0.76	-8.81	-0.43	6.55e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg12698662	chr3:15914712	MIR563	-0.37	-7.02	-0.35	1.22e-11	Mean platelet volume;
LIHC	cis	rs35160687	0.644	rs1863056	chr2:86491245	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.35	5.75	0.3	2.01e-8	Night sleep phenotypes;
LIHC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.37	6.84	0.35	3.77e-11	Aortic root size;
LIHC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11645453	chr3:52864694	ITIH4	0.21	5.84	0.3	1.23e-8	Bipolar disorder;
LIHC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-9.53	-0.46	3.04e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.6	-7.42	-0.37	9.66e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	0.82	9.42	0.45	6.85e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs3849570	0.555	rs9968070	chr3:82010368	G/A	cg07356753	chr3:81810745	GBE1	-0.42	-6.34	-0.32	7.14e-10	Waist circumference;Body mass index;
LIHC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.55	0.33	2.07e-10	Obesity-related traits;
LIHC	trans	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg05926928	chr17:57297772	GDPD1	-0.52	-7.53	-0.38	4.62e-13	Schizophrenia;
LIHC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.3	6.44	0.33	4.12e-10	Platelet distribution width;
LIHC	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg05110241	chr16:68378359	PRMT7	-0.54	-6.53	-0.33	2.36e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.52	8.36	0.41	1.56e-15	Blood protein levels;
LIHC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08219700	chr8:58056026	NA	0.54	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg09182678	chr22:50328711	NA	-0.44	-6.23	-0.32	1.37e-9	Schizophrenia;
LIHC	cis	rs7619427	0.643	rs67261579	chr3:44084328	C/T	cg24966902	chr3:44043705	NA	0.51	6.59	0.34	1.68e-10	Schizophrenia;
LIHC	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg00292662	chr22:38071168	LGALS1	0.39	6.65	0.34	1.19e-10	Fat distribution (HIV);
LIHC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.45	-7.39	-0.37	1.14e-12	Blood metabolite levels;
LIHC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.39	0.37	1.11e-12	Menarche (age at onset);
LIHC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	trans	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg10756647	chr7:56101905	PSPH	0.64	8.81	0.43	6.36e-17	Corneal structure;
LIHC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-13.48	-0.59	1.59e-33	Total body bone mineral density;
LIHC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.63	0.38	2.36e-13	Tonsillectomy;
LIHC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg25039879	chr17:56429692	SUPT4H1	0.84	9.58	0.46	1.99e-19	Cognitive test performance;
LIHC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-6.0	-0.31	5.1e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7192380	0.651	rs6499239	chr16:69686748	G/A	cg15192750	chr16:69999425	NA	0.36	5.72	0.3	2.28e-8	Sjögren's syndrome;
LIHC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.44	0.37	8.37e-13	Airflow obstruction;
LIHC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.65	-8.24	-0.41	3.72e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs12644436	0.711	rs4693190	chr4:88787765	G/A	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg16070018	chr6:26224392	HIST1H3E	0.78	7.45	0.37	7.6e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.83	9.81	0.47	3.64e-20	Iron status biomarkers;
LIHC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg10621924	chr7:39171070	POU6F2	0.42	6.51	0.33	2.67e-10	IgG glycosylation;
LIHC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-9.29	-0.45	1.9e-18	Platelet count;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11112892	chr5:131563589	P4HA2	0.49	6.2	0.32	1.59e-9	Hepatitis;
LIHC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.57	0.33	1.83e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.71	9.53	0.46	2.99e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.67	11.71	0.53	7.53e-27	Menopause (age at onset);
LIHC	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.39	5.97	0.31	5.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.22	0.45	3.17e-18	Bipolar disorder;
LIHC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.49	6.41	0.33	4.74e-10	Orofacial clefts;
LIHC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg03013999	chr17:37608204	MED1	-0.34	-5.77	-0.3	1.76e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.26	7.07	0.36	8.79e-12	Cardiovascular disease risk factors;
LIHC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.8	13.98	0.6	1.96e-35	Coronary artery disease;
LIHC	trans	rs17433710	0.516	rs6689396	chr1:162676698	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.27	-0.32	1.09e-9	Dupuytren's disease;
LIHC	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs4908768	0.539	rs1318218	chr1:8658712	T/C	cg20416874	chr1:8611966	RERE	-0.63	-11.71	-0.53	7.32e-27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7129220	0.512	rs1867136	chr11:10228843	C/T	cg01453529	chr11:10209919	SBF2	-0.43	-7.88	-0.39	4.41e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.64	10.94	0.51	4.39e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2573652	0.722	rs11852383	chr15:100542765	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.68	-11.64	-0.53	1.36e-26	Height;
LIHC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.52	8.2	0.41	4.9e-15	Height;
LIHC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.85	12.53	0.56	6.5e-30	Psoriasis;
LIHC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg05941027	chr17:61774174	LIMD2	0.35	7.44	0.37	8.1e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.28	-0.32	1.05e-9	Coronary artery disease;
LIHC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.96	-0.31	6.44e-9	Obesity-related traits;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.71	10.31	0.49	7.13e-22	Menarche (age at onset);
LIHC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.48	-8.16	-0.4	6.29e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg17771515	chr6:154831774	CNKSR3	0.56	6.02	0.31	4.6e-9	Lipoprotein (a) levels;
LIHC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg07424592	chr7:64974309	NA	0.8	9.21	0.45	3.38e-18	Diabetic kidney disease;
LIHC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg27432699	chr2:27873401	GPN1	0.52	7.76	0.39	1.02e-13	Total body bone mineral density;
LIHC	cis	rs2029362	0.611	rs10767665	chr11:27733858	C/T	cg18117895	chr11:27722066	BDNF	-0.38	-5.76	-0.3	1.86e-8	Total body bone mineral density;
LIHC	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.37	6.38	0.33	5.81e-10	Response to Dalcetrapib treatment in acute coronary syndrome;
LIHC	cis	rs1062177	0.694	rs2915816	chr5:151115857	G/A	cg00977110	chr5:151150581	G3BP1	-0.5	-6.57	-0.33	1.93e-10	Preschool internalizing problems;
LIHC	cis	rs10508774	1.000	rs55773420	chr10:32824910	T/C	cg01819863	chr10:32635814	EPC1	0.65	6.03	0.31	4.19e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg24110177	chr3:50126178	RBM5	-0.51	-7.95	-0.39	2.79e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg14779329	chr11:130786720	SNX19	0.43	6.53	0.33	2.39e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.75	-0.3	2e-8	Red blood cell count;
LIHC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	10.39	0.49	3.61e-22	Multiple sclerosis;
LIHC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.01	-24.63	-0.8	9.28e-78	Prudent dietary pattern;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.48	7.19	0.36	4.03e-12	Cystic fibrosis severity;
LIHC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.68	0.34	9.54e-11	Alzheimer's disease;
LIHC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.23	-0.32	1.39e-9	Mean corpuscular volume;
LIHC	cis	rs12702595	0.590	rs13244913	chr7:7264089	T/C	cg04827551	chr7:7268805	C1GALT1	0.38	6.8	0.35	4.7e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.57	6.07	0.31	3.48e-9	Hip geometry;
LIHC	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-8.53	-0.42	4.87e-16	Body mass index;
LIHC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg13047869	chr3:10149882	C3orf24	0.48	5.89	0.3	9.41e-9	Alzheimer's disease;
LIHC	cis	rs12086130	0.892	rs59595057	chr1:51493428	A/G	cg07174182	chr1:51127561	FAF1	-0.82	-9.27	-0.45	2.14e-18	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.52	7.58	0.38	3.3e-13	Obesity-related traits;
LIHC	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg10756647	chr7:56101905	PSPH	0.95	11.81	0.54	3.04e-27	Gout;
LIHC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.25	-10.81	-0.5	1.22e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	9.75	0.47	5.39e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.47	-0.49	1.92e-22	Rheumatoid arthritis;
LIHC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.94	0.44	2.39e-17	Platelet count;
LIHC	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg07706471	chr12:123319906	HIP1R	0.72	8.12	0.4	8.26e-15	Adiponectin levels;
LIHC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg18121669	chr1:26560928	CCDC21	0.52	8.2	0.41	5.05e-15	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.79	-0.39	8.02e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.31	-0.37	1.84e-12	Response to antipsychotic treatment;
LIHC	trans	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg17675199	chr6:35436792	RPL10A	0.33	6.4	0.33	5.15e-10	Coronary artery disease;
LIHC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.79	15.01	0.63	1.83e-39	Blood protein levels;
LIHC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.68	0.53	9.51e-27	Alzheimer's disease;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19687152	chr14:102968497	TECPR2	0.54	6.68	0.34	9.55e-11	Lung function (FEV1);
LIHC	trans	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg26939375	chr7:64535504	NA	0.43	6.96	0.35	1.72e-11	Aortic root size;
LIHC	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.33	7.52	0.38	4.74e-13	Blood metabolite ratios;
LIHC	cis	rs1419980	0.730	rs7132588	chr12:7754616	T/A	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	trans	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg10756647	chr7:56101905	PSPH	1.03	12.46	0.56	1.23e-29	Diabetic kidney disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18311516	chr14:102514894	DYNC1H1	0.43	6.17	0.32	1.95e-9	Longevity;
LIHC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs11955398	0.716	rs1379115	chr5:59997886	A/C	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.41	-7.0	-0.35	1.39e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs2637030	0.515	rs256103	chr5:53012475	A/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.73	0.34	6.99e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.34	-0.32	7.4e-10	Obesity-related traits;
LIHC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.31	-0.45	1.6e-18	Electroencephalogram traits;
LIHC	cis	rs623264	0.920	rs668692	chr19:5469832	A/G	cg03088458	chr19:5478473	NA	-0.36	-5.81	-0.3	1.41e-8	Interleukin-2 receptor antagonist levels;
LIHC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.45	-6.21	-0.32	1.55e-9	Initial pursuit acceleration;
LIHC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg26531700	chr6:26746687	NA	0.39	6.4	0.33	5.18e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2270927	0.510	rs4352583	chr5:75576716	A/G	cg13563193	chr19:33072644	PDCD5	0.99	8.99	0.44	1.66e-17	Mean corpuscular volume;
LIHC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg10932868	chr11:921992	NA	0.34	6.37	0.33	5.94e-10	Alzheimer's disease (late onset);
LIHC	cis	rs17106184	1.000	rs72898946	chr1:50959262	A/C	cg07174182	chr1:51127561	FAF1	-0.61	-6.81	-0.35	4.38e-11	Type 2 diabetes;
LIHC	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg18700516	chr19:44507157	ZNF230	0.35	5.79	0.3	1.56e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4586057	0.514	rs10881844	chr10:92648024	A/G	cg14313238	chr10:92632228	RPP30	0.35	5.91	0.3	8.17e-9	Economic and political preferences (time);
LIHC	trans	rs879568	0.708	rs644056	chr18:34270525	C/G	cg16486109	chr11:613632	IRF7	0.39	6.05	0.31	3.82e-9	QRS duration;
LIHC	cis	rs16958440	0.867	rs16949157	chr18:44691324	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs2531992	0.925	rs2531993	chr16:4014245	A/G	cg05927578	chr16:4029543	ADCY9	0.57	6.31	0.32	8.61e-10	Waist circumference;
LIHC	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg01969543	chr11:61895209	INCENP	-0.43	-6.04	-0.31	4.04e-9	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00810945	chr16:21964237	UQCRC2	0.4	6.25	0.32	1.23e-9	Cognitive function;
LIHC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.66	10.65	0.5	4.59e-23	Response to diuretic therapy;
LIHC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.92	-0.47	1.48e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg00280220	chr17:61926910	NA	0.43	6.79	0.34	4.99e-11	Prudent dietary pattern;
LIHC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg16049864	chr8:95962084	TP53INP1	0.45	6.9	0.35	2.56e-11	Type 2 diabetes;
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg10360139	chr7:1886902	MAD1L1	-0.42	-6.51	-0.33	2.63e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02475777	chr4:1388615	CRIPAK	-0.47	-6.89	-0.35	2.74e-11	Obesity-related traits;
LIHC	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg17074339	chr11:11642133	GALNTL4	0.44	6.9	0.35	2.6e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.6	-7.01	-0.35	1.25e-11	Menarche (age at onset);
LIHC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg07952391	chr2:88470173	THNSL2	0.67	6.04	0.31	4.05e-9	Plasma clusterin levels;
LIHC	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.83	-0.39	5.99e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg00142150	chr22:38071001	LGALS1	0.71	11.51	0.53	3.83e-26	Fat distribution (HIV);
LIHC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.34	-0.32	7.46e-10	Renal cell carcinoma;
LIHC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.47	7.69	0.38	1.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11955398	0.625	rs12655515	chr5:59974098	G/C	cg02684056	chr5:59996105	DEPDC1B	0.42	5.9	0.3	8.62e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.43	0.37	8.93e-13	Renal cell carcinoma;
LIHC	cis	rs8017423	0.845	rs114583024	chr14:90727628	T/C	cg14092571	chr14:90743983	NA	-0.38	-6.02	-0.31	4.54e-9	Mortality in heart failure;
LIHC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	10.99	0.51	2.83e-24	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.4	-0.41	1.23e-15	Renal cell carcinoma;
LIHC	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg20016023	chr10:99160130	RRP12	-0.35	-5.84	-0.3	1.19e-8	Monocyte percentage of white cells;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.65	-8.41	-0.41	1.15e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg23533926	chr12:111358616	MYL2	-0.33	-6.18	-0.32	1.81e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg18887096	chr2:219472410	PLCD4	0.37	6.65	0.34	1.13e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.49	6.24	0.32	1.31e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.63	-12.08	-0.55	3.3e-28	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg14440974	chr22:39074834	NA	-0.37	-6.18	-0.32	1.87e-9	Menopause (age at onset);
LIHC	trans	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg19894588	chr14:64061835	NA	0.68	10.38	0.49	4.1e-22	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg14829360	chr17:73884958	NA	0.44	6.97	0.35	1.67e-11	Psoriasis;
LIHC	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg04725166	chr1:7887271	PER3	-0.44	-7.66	-0.38	1.94e-13	Crohn's disease;
LIHC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	8.1	0.4	1e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg07061783	chr6:25882402	NA	-0.83	-9.96	-0.47	1.11e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02303361	chr19:47354240	AP2S1	0.37	6.06	0.31	3.5e-9	Metabolic traits;
LIHC	cis	rs9503598	0.502	rs6939748	chr6:3430584	C/T	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.86	-0.3	1.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.72	-0.3	2.27e-8	Red blood cell count;
LIHC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.89	-18.21	-0.7	2.9e-52	Height;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.21	0.48	1.49e-21	Colorectal cancer;
LIHC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.36	0.33	6.53e-10	Glycated hemoglobin levels;
LIHC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg14779329	chr11:130786720	SNX19	0.4	6.15	0.32	2.14e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.87	-12.29	-0.55	5.42e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.48	-6.33	-0.32	7.74e-10	Pursuit maintenance gain;
LIHC	trans	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg04373760	chr16:53404718	NA	0.6	7.66	0.38	1.89e-13	Hypertriglyceridemia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21024969	chr6:163994355	QKI	0.33	6.28	0.32	1.03e-9	Pancreatic cancer;
LIHC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.6	-0.38	2.88e-13	Morning vs. evening chronotype;
LIHC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.73	-11.97	-0.54	7.94e-28	Body mass index;
LIHC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.85	0.35	3.51e-11	Schizophrenia;
LIHC	cis	rs4878497	0.532	rs10813817	chr9:32448745	T/C	cg14296220	chr9:32431791	ACO1	0.55	9.13	0.44	5.91e-18	Inflammatory skin disease;
LIHC	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.63	-6.1	-0.31	2.92e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	7.87	0.39	4.84e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.85	0.35	3.39e-11	Height;
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.86	0.3	1.12e-8	Aortic root size;
LIHC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.3e-9	Aortic root size;
LIHC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-9.75	-0.47	5.67e-20	Vitiligo;
LIHC	cis	rs4759375	1.000	rs10082867	chr12:123796997	A/G	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs1395	0.744	rs72817536	chr2:27497548	A/G	cg22903471	chr2:27725779	GCKR	-0.45	-6.07	-0.31	3.33e-9	Blood metabolite levels;
LIHC	trans	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg10756647	chr7:56101905	PSPH	0.47	6.95	0.35	1.81e-11	Aortic root size;
LIHC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.51	-6.3	-0.32	9.22e-10	Menarche (age at onset);
LIHC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.29	6.7	0.34	8.43e-11	Crohn's disease;
LIHC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg21960279	chr19:17905606	B3GNT3	0.51	7.85	0.39	5.56e-14	Tumor biomarkers;
LIHC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.39	0.45	8.39e-19	IgG glycosylation;
LIHC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.66	-14.1	-0.61	6.37e-36	Brugada syndrome;
LIHC	cis	rs860295	0.967	rs6665227	chr1:155710460	T/C	cg02153340	chr1:155202674	NA	-0.31	-5.72	-0.3	2.38e-8	Body mass index;
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg18090489	chr13:45992445	SLC25A30	0.48	6.52	0.33	2.48e-10	Leprosy;
LIHC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.66	0.42	1.95e-16	Bladder cancer;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.09	0.55	2.94e-28	Prudent dietary pattern;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26762173	chr8:28351567	FZD3	-0.58	-6.56	-0.33	2e-10	Systolic blood pressure;
LIHC	cis	rs11867934	0.577	rs9893676	chr17:17054951	C/G	cg26176665	chr17:16994978	MPRIP	0.43	6.09	0.31	2.98e-9	Diabetic retinopathy;
LIHC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.9	19.13	0.72	5.41e-56	Blood protein levels;
LIHC	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.46	-0.42	7.81e-16	Extraversion;
LIHC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18357526	chr6:26021779	HIST1H4A	0.46	6.78	0.34	5.44e-11	Height;
LIHC	cis	rs8067354	0.574	rs1292035	chr17:57989557	G/A	cg02344993	chr17:57696989	CLTC	0.67	10.55	0.5	1.06e-22	Hemoglobin concentration;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.21	-0.32	1.56e-9	Diastolic blood pressure;
LIHC	cis	rs116248771	0.739	rs73156425	chr3:158345677	G/A	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.75e-10	diarrhoeal disease at age 2;
LIHC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	11.97	0.54	8.45e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3106136	0.678	rs12646487	chr4:95279907	T/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.92	0.3	7.93e-9	Capecitabine sensitivity;
LIHC	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg14709524	chr16:89940631	TCF25	0.5	6.53	0.33	2.36e-10	Skin colour saturation;
LIHC	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.36	7.55	0.38	3.97e-13	Plateletcrit;Platelet count;
LIHC	cis	rs6537837	0.701	rs12021920	chr1:110147287	C/T	cg05049280	chr1:110155535	GNAT2	0.48	5.72	0.3	2.39e-8	Major depressive disorder;
LIHC	cis	rs6988636	0.818	rs1713733	chr8:124199458	A/G	cg15893493	chr8:124194847	FAM83A	-0.67	-6.9	-0.35	2.61e-11	Urinary uromodulin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04987883	chr5:153826560	SAP30L	0.46	6.06	0.31	3.51e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.54	-8.3	-0.41	2.49e-15	P wave terminal force;
LIHC	cis	rs3731896	0.571	rs77251296	chr2:220193172	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.56	6.52	0.33	2.58e-10	Educational attainment;
LIHC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.42	-7.38	-0.37	1.24e-12	Coronary artery disease;
LIHC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.35	-7.34	-0.37	1.55e-12	Longevity;
LIHC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.45	-8.28	-0.41	2.77e-15	Schizophrenia;
LIHC	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	7.69	0.38	1.53e-13	Response to antipsychotic treatment;
LIHC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg16989086	chr20:62203971	PRIC285	0.57	8.2	0.41	5.08e-15	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	trans	rs910316	0.737	rs175045	chr14:75475275	A/C	cg07213720	chr6:35227408	ZNF76	-0.45	-6.35	-0.32	6.82e-10	Height;
LIHC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.57	-9.38	-0.45	9.69e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.63	7.99	0.4	2.09e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.52	-6.81	-0.35	4.47e-11	Vitiligo;
LIHC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.07e-18	Schizophrenia;
LIHC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23903597	chr17:61704154	MAP3K3	-0.44	-6.04	-0.31	4.04e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	10.71	0.5	2.92e-23	Platelet count;
LIHC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg16583315	chr14:65563665	MAX	-0.39	-7.96	-0.4	2.56e-14	Obesity-related traits;
LIHC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg03037974	chr15:76606532	NA	-0.51	-8.06	-0.4	1.32e-14	Blood metabolite levels;
LIHC	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	6.46	0.33	3.68e-10	Type 2 diabetes;
LIHC	cis	rs2273156	0.706	rs7153550	chr14:35501800	A/G	cg16230307	chr14:35515116	FAM177A1	-0.43	-6.16	-0.32	2.01e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg12463550	chr7:65579703	CRCP	0.69	7.15	0.36	5.29e-12	Diabetic kidney disease;
LIHC	cis	rs11931598	0.511	rs35772786	chr4:7021211	T/G	cg02503808	chr4:7069936	GRPEL1	0.49	7.68	0.38	1.73e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17996757	chr7:131013207	MKLN1	0.44	6.36	0.33	6.4e-10	Cognitive function;
LIHC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs918629	0.530	rs2042340	chr5:95235193	T/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.74	-0.34	6.85e-11	IgG glycosylation;
LIHC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.51	8.2	0.41	4.78e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg03934865	chr2:198174659	NA	0.46	6.79	0.34	5.08e-11	Dermatomyositis;
LIHC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.44	7.23	0.36	3.16e-12	Red blood cell count;
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs17106184	0.901	rs72904745	chr1:51363273	C/G	cg07174182	chr1:51127561	FAF1	-0.76	-7.66	-0.38	1.97e-13	Type 2 diabetes;
LIHC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.57	9.99	0.48	8.76e-21	Mean corpuscular volume;
LIHC	cis	rs10416265	0.528	rs10420258	chr19:33602757	C/T	cg17764715	chr19:33622953	WDR88	0.49	6.48	0.33	3.28e-10	Bone properties (heel);
LIHC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.64	10.33	0.49	5.92e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg00085434	chr11:14927489	NA	0.41	5.89	0.3	9.43e-9	Vitamin D levels;
LIHC	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.94	-16.87	-0.67	6.63e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs8067354	0.681	rs76856339	chr17:57800966	G/A	cg02344993	chr17:57696989	CLTC	0.72	12.04	0.55	4.49e-28	Hemoglobin concentration;
LIHC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg14393609	chr7:65229607	NA	-0.37	-5.83	-0.3	1.27e-8	Aortic root size;
LIHC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-9.9	-0.47	1.82e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-9.09	-0.44	8.45e-18	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.49	-9.49	-0.46	4.1e-19	Coronary artery disease;
LIHC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.63	0.46	1.41e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.36	-8.65	-0.42	2.07e-16	Cutaneous nevi;
LIHC	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.5	-5.73	-0.3	2.24e-8	Ulcerative colitis;
LIHC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg07424592	chr7:64974309	NA	0.76	8.83	0.43	5.38e-17	Diabetic kidney disease;
LIHC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.94	0.31	6.86e-9	Menopause (age at onset);
LIHC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-8.52	-0.42	5.33e-16	Chronic sinus infection;
LIHC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.69	-9.52	-0.46	3.37e-19	Corneal structure;
LIHC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.36	-7.02	-0.35	1.24e-11	Body mass index;
LIHC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg05555928	chr11:63887634	MACROD1	0.53	7.28	0.37	2.27e-12	Mean platelet volume;
LIHC	cis	rs812925	0.519	rs1186706	chr2:61673394	G/T	cg14146966	chr2:61757674	XPO1	0.39	6.44	0.33	4.04e-10	Immature fraction of reticulocytes;
LIHC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.66	10.09	0.48	3.92e-21	Longevity;
LIHC	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.9	0.35	2.6e-11	Bipolar disorder;
LIHC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.69	0.5	3.35e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	6.3	0.32	8.93e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg24826892	chr11:71159390	DHCR7	0.47	6.21	0.32	1.51e-9	Vitamin D levels;
LIHC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.53	-7.52	-0.38	4.76e-13	Body mass index;
LIHC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-7.52	-0.38	4.85e-13	Chronic sinus infection;
LIHC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	7.0	0.35	1.34e-11	Personality dimensions;
LIHC	cis	rs12403795	1.000	rs12403795	chr1:150278389	A/G	cg15654264	chr1:150340011	RPRD2	0.46	6.21	0.32	1.51e-9	Illicit drug use;
LIHC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.43	5.87	0.3	1.02e-8	Nonalcoholic fatty liver disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05680085	chr2:227700568	RHBDD1	-0.43	-6.28	-0.32	1.05e-9	Cognitive function;
LIHC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.78e-10	Menarche (age at onset);
LIHC	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg02023728	chr11:77925099	USP35	0.34	6.14	0.32	2.28e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.49	-8.84	-0.43	4.99e-17	Body mass index;
LIHC	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.26	-0.41	3.27e-15	Response to antipsychotic treatment;
LIHC	cis	rs11761441	0.669	rs13241486	chr7:79536	G/C	cg22368281	chr7:82270	NA	0.27	5.84	0.3	1.19e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs57908212	1	rs57908212	chr19:2161321	T/C	cg09261902	chr19:2140048	AP3D1	0.38	6.38	0.33	5.78e-10	Red blood cell count;Hemoglobin concentration;Hematocrit;
LIHC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.81	10.32	0.49	6.41e-22	Cognitive function;
LIHC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	11.16	0.52	7.02e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs12752401	0.867	rs67349818	chr1:103030560	T/C	cg03332897	chr19:740442	PALM	0.46	6.13	0.31	2.4e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.48	-9.34	-0.45	1.28e-18	Mean corpuscular volume;
LIHC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.21	-0.32	1.57e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.51	-9.65	-0.46	1.21e-19	Mean corpuscular volume;
LIHC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	6.11e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.45	8.13	0.4	7.75e-15	Prudent dietary pattern;
LIHC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg05207973	chr5:176823642	SLC34A1	0.33	5.98	0.31	5.51e-9	Urinary electrolytes (magnesium/calcium ratio);
LIHC	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.6	9.72	0.47	7.19e-20	Corneal astigmatism;
LIHC	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.85	0.35	3.4e-11	Renal cell carcinoma;
LIHC	trans	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg10756647	chr7:56101905	PSPH	1.09	13.38	0.59	4.07e-33	Diabetic kidney disease;
LIHC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.47	8.57	0.42	3.7e-16	Colorectal cancer;
LIHC	cis	rs6545883	0.759	rs777585	chr2:61412559	A/G	cg14146966	chr2:61757674	XPO1	-0.38	-6.43	-0.33	4.38e-10	Tuberculosis;
LIHC	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.47	7.29	0.37	2.1e-12	Blood protein levels;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg21548813	chr6:291882	DUSP22	-0.56	-7.59	-0.38	3.12e-13	Menopause (age at onset);
LIHC	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.32	8.06	0.4	1.26e-14	Gut microbiome composition (winter);
LIHC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg09795085	chr6:101329169	ASCC3	0.53	7.48	0.37	6.49e-13	Neuroticism;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.65	11.36	0.52	1.36e-25	Longevity;Endometriosis;
LIHC	cis	rs988712	0.672	rs35038967	chr11:27703480	T/A	cg18117895	chr11:27722066	BDNF	0.54	7.46	0.37	7.35e-13	Obesity;
LIHC	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg16586182	chr3:47516702	SCAP	-0.54	-9.77	-0.47	4.62e-20	Colorectal cancer;
LIHC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.68	-0.42	1.69e-16	Primary biliary cholangitis;
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.63	9.66	0.46	1.09e-19	Renal cell carcinoma;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.36	-6.17	-0.32	1.88e-9	Headache;
LIHC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.48	-8.96	-0.44	2.06e-17	Body mass index;
LIHC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.08	0.44	8.84e-18	Platelet count;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.6	-8.17	-0.4	5.85e-15	Menopause (age at onset);
LIHC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.53	-6.44	-0.33	4.07e-10	Menarche (age at onset);
LIHC	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.61	-10.06	-0.48	4.99e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs611744	0.967	rs2600615	chr8:109201170	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.69	-12.17	-0.55	1.47e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.59	9.76	0.47	5.07e-20	HDL cholesterol;
LIHC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.68	9.99	0.48	8.82e-21	Testicular germ cell tumor;
LIHC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.43	6.78	0.34	5.28e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.37	7.33	0.37	1.66e-12	Alcohol dependence;
LIHC	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.59	-8.98	-0.44	1.88e-17	White matter hyperintensity burden;
LIHC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	0.96	10.08	0.48	4.42e-21	Vitiligo;
LIHC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.63	0.38	2.29e-13	Mean platelet volume;
LIHC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7.1e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.9	16.38	0.66	6.1e-45	Coronary artery disease;
LIHC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.44e-11	IgG glycosylation;
LIHC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.59	-11.21	-0.52	4.82e-25	Coronary artery disease;
LIHC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg05590025	chr7:65112418	INTS4L2	-0.67	-7.36	-0.37	1.34e-12	Diabetic kidney disease;
LIHC	cis	rs10847980	0.590	rs58182048	chr12:123287708	C/T	cg22842854	chr12:123319900	HIP1R	0.91	9.9	0.47	1.79e-20	Adiponectin levels;
LIHC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.69	-8.31	-0.41	2.35e-15	Morning vs. evening chronotype;
LIHC	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.38	6.96	0.35	1.7e-11	Response to antipsychotic treatment;
LIHC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg24879335	chr3:133465180	TF	0.28	6.45	0.33	3.83e-10	Iron status biomarkers;
LIHC	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg20194872	chr6:41519635	FOXP4	0.4	6.51	0.33	2.76e-10	Prostate cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03778895	chr13:50699716	DLEU2	-0.41	-6.65	-0.34	1.16e-10	Calcium levels;
LIHC	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.03	0.6	1.24e-35	Bipolar disorder;
LIHC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-26.83	-0.82	3.79e-86	Myeloid white cell count;
LIHC	cis	rs11031096	0.678	rs12222136	chr11:4180148	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.5e-9	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21023284	chr11:6624872	ILK;RRP8	0.52	6.73	0.34	7.28e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	10.27	0.49	9.91e-22	Bipolar disorder and schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11120115	chr7:98649861	SMURF1	0.46	7.02	0.35	1.2e-11	Longevity;
LIHC	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.08	0.48	4.36e-21	Fuchs's corneal dystrophy;
LIHC	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg15192750	chr16:69999425	NA	0.44	6.74	0.34	6.73e-11	IgE levels;
LIHC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs963731	0.649	rs297159	chr2:39328827	C/T	cg04010122	chr2:39346883	SOS1	-0.75	-6.21	-0.32	1.55e-9	Corticobasal degeneration;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg16327326	chr16:1662895	IFT140	-0.42	-6.21	-0.32	1.56e-9	Bipolar disorder;
LIHC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.52	-9.17	-0.44	4.43e-18	N-glycan levels;
LIHC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg24585782	chr17:78113791	EIF4A3	-0.45	-5.99	-0.31	5.19e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.79	-10.67	-0.5	3.86e-23	Post bronchodilator FEV1;
LIHC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.61	-9.01	-0.44	1.44e-17	Height;
LIHC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	7.18	0.36	4.3e-12	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg14473756	chr11:122847823	NA	-0.37	-6.67	-0.34	1.02e-10	Menarche (age at onset);
LIHC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-9.18	-0.44	4.21e-18	Parkinson's disease;
LIHC	trans	rs3176789	0.647	rs7309767	chr12:9920899	G/T	cg18988856	chr7:99425577	CYP3A43	0.19	6.15	0.32	2.14e-9	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LIHC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.67	9.49	0.46	4.02e-19	Coronary artery disease;
LIHC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.97	-0.44	2.02e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.33	-6.16	-0.32	2.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.9	0.3	8.84e-9	Menopause (age at onset);
LIHC	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.56	-8.11	-0.4	9.32e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg26395211	chr5:140044315	WDR55	-0.41	-6.04	-0.31	3.93e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.49	6.79	0.34	5.01e-11	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.45	5.93	0.31	7.5e-9	Obesity-related traits;
LIHC	cis	rs3734219	0.506	rs13197104	chr6:3355944	T/C	cg18842474	chr6:3356384	SLC22A23	0.41	6.68	0.34	9.47e-11	Red cell distribution width;
LIHC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-1.0	-17.68	-0.69	3.86e-50	Tonsillectomy;
LIHC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	6.48	0.33	3.28e-10	Menarche (age at onset);
LIHC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.86	0.43	4.29e-17	Corneal astigmatism;
LIHC	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.15	-0.32	2.13e-9	Diastolic blood pressure;
LIHC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.63	-8.64	-0.42	2.13e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg15352829	chr14:105391018	PLD4	0.43	8.77	0.43	8.68e-17	Rheumatoid arthritis;
LIHC	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg27205649	chr11:78285834	NARS2	-0.38	-5.72	-0.3	2.29e-8	Alzheimer's disease (survival time);
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.83	-0.35	3.81e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-22.14	-0.77	5.15e-68	Coronary artery disease;
LIHC	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg05110241	chr16:68378359	PRMT7	-0.52	-6.35	-0.32	6.81e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	8.94e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.48	-8.09	-0.4	1.05e-14	Uric acid levels;
LIHC	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.58	6.14	0.31	2.32e-9	Hip geometry;
LIHC	cis	rs9473924	1.000	rs6922746	chr6:50889828	A/T	cg14470998	chr6:50812995	TFAP2B	0.49	7.35	0.37	1.52e-12	Body mass index;
LIHC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-9.01	-0.44	1.5e-17	Parkinson's disease;
LIHC	cis	rs16854884	0.710	rs1867607	chr3:143809274	T/C	cg06585982	chr3:143692056	C3orf58	0.42	5.94	0.31	7.14e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.79	0.3	1.58e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.29	-0.45	1.82e-18	Diabetic kidney disease;
LIHC	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.53	6.02	0.31	4.48e-9	Alzheimer's disease;
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.93	-15.61	-0.64	7.81e-42	Longevity;
LIHC	trans	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.39	-0.33	5.47e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.8	0.5	1.31e-23	Colorectal cancer;
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg19318889	chr4:1322082	MAEA	0.39	6.28	0.32	1.02e-9	Obesity-related traits;
LIHC	cis	rs3736485	0.934	rs11635592	chr15:51859786	A/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.56	-6.76	-0.34	5.92e-11	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27649522	chr12:12877729	APOLD1	0.42	6.35	0.32	6.93e-10	Pancreatic cancer;
LIHC	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg23533926	chr12:111358616	MYL2	-0.36	-6.86	-0.35	3.18e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.83	10.61	0.5	6.37e-23	Cognitive function;
LIHC	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg01320579	chr17:75405842	SEPT9	0.53	7.4	0.37	1.06e-12	Airflow obstruction;
LIHC	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.25	6.8	0.35	4.62e-11	Type 2 diabetes;
LIHC	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-20.66	-0.75	4.04e-62	Exhaled nitric oxide output;
LIHC	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.77	-13.02	-0.58	9.29e-32	Coronary artery disease;
LIHC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.96	-17.35	-0.68	7.99e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.35	-5.93	-0.31	7.32e-9	Menopause (age at onset);
LIHC	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg14675211	chr2:100938903	LONRF2	0.55	8.11	0.4	9.12e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs17106184	0.892	rs76589723	chr1:51208574	G/A	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs365132	0.875	rs353496	chr5:176429898	T/C	cg16309518	chr5:176445507	NA	-0.53	-9.85	-0.47	2.53e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.58	7.53	0.38	4.56e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg18912006	chr12:123335444	HIP1R	-0.63	-7.51	-0.38	5.33e-13	Schizophrenia;
LIHC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.49	5.81	0.3	1.44e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.71	-6.3	-0.32	9.09e-10	Obesity;Body mass index;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg20607798	chr8:58055168	NA	0.64	8.21	0.41	4.61e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.44	-0.37	8.36e-13	Post bronchodilator FEV1;
LIHC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg02269571	chr22:50332266	NA	0.6	8.45	0.42	8.41e-16	Schizophrenia;
LIHC	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg17135325	chr3:160939158	NMD3	0.45	6.86	0.35	3.25e-11	Morning vs. evening chronotype;
LIHC	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	1.17	11.34	0.52	1.61e-25	Uric acid levels;
LIHC	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14154082	chr13:112174009	NA	0.3	6.39	0.33	5.52e-10	Menarche (age at onset);
LIHC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.0	15.51	0.64	1.82e-41	Breast cancer;
LIHC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.29	6.86	0.35	3.3e-11	Primary biliary cholangitis;
LIHC	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.54	-5.98	-0.31	5.78e-9	Blood protein levels;
LIHC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.45	6.32	0.32	8.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.21	0.61	2.47e-36	Chronic sinus infection;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.27	0.32	1.06e-9	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg00656387	chr3:40428638	ENTPD3	0.44	7.45	0.37	7.71e-13	Renal cell carcinoma;
LIHC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-10.45	-0.49	2.28e-22	Mean corpuscular volume;
LIHC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.38	6.07	0.31	3.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	IgM levels;
LIHC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.01	-7.81	-0.39	7.07e-14	Body mass index;
LIHC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg14515779	chr1:101123966	NA	0.49	6.76	0.34	6e-11	Monocyte count;
LIHC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-8.43	-0.41	1e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg25894440	chr7:65020034	NA	0.55	6.21	0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs2292096	0.866	rs35796457	chr1:200696601	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-6.03	-0.31	4.24e-9	Epilepsy;
LIHC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.48	7.34	0.37	1.59e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.72	0.3	2.3e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.77	-0.39	9.19e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.75	-11.51	-0.53	3.86e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	0.61	8.02	0.4	1.66e-14	Lung cancer;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.4	5.97	0.31	6.08e-9	Educational attainment;
LIHC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.36	0.41	1.61e-15	Lung cancer in ever smokers;
LIHC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg12386194	chr3:101231763	SENP7	0.41	6.26	0.32	1.17e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.59	-7.42	-0.37	9.22e-13	Platelet count;
LIHC	cis	rs1144333	0.655	rs114383686	chr1:76325327	C/T	cg03433033	chr1:76189801	ACADM	0.58	8.65	0.42	1.97e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	3.09e-9	Mortality in heart failure;
LIHC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.8	9.09	0.44	8.24e-18	Vitiligo;
LIHC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.56	-7.74	-0.39	1.15e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.26	-0.45	2.23e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs7395581	0.797	rs10838681	chr11:47275064	C/T	cg25783544	chr11:47291846	MADD	0.44	6.31	0.32	8.58e-10	HDL cholesterol;
LIHC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.17	19.76	0.73	1.67e-58	IgG glycosylation;
LIHC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.62	6.52	0.33	2.57e-10	Gut microbiome composition (summer);
LIHC	cis	rs507080	0.733	rs517445	chr11:118573535	A/G	cg04173919	chr11:118528438	PHLDB1	0.32	6.02	0.31	4.44e-9	Serum metabolite levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13629201	chr9:5111420	JAK2	0.4	6.15	0.32	2.11e-9	Longevity;
LIHC	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.72	0.5	2.69e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-8.22	-0.41	4.25e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.7	-12.34	-0.56	3.35e-29	Height;
LIHC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.13	10.46	0.49	2.1e-22	Diabetic retinopathy;
LIHC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	7.14	0.36	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.67	0.59	3.13e-34	Lung cancer in ever smokers;
LIHC	cis	rs11718455	0.585	rs1491708	chr3:43911578	C/T	cg08738300	chr3:44038990	NA	0.37	6.26	0.32	1.17e-9	Coronary artery disease;
LIHC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.06	-0.48	5.08e-21	Response to antipsychotic treatment;
LIHC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.38	6.3	0.32	9.32e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.75	-11.33	-0.52	1.8e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	trans	rs17288586	1.000	rs17288586	chr6:45819770	C/T	cg03694391	chr13:111100098	COL4A2	0.31	6.15	0.32	2.22e-9	Response to paliperidone in schizophrenia (CGI-S score);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01365452	chr4:7043077	CCDC96	0.47	6.92	0.35	2.3e-11	Pancreatic cancer;
LIHC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.33	0.32	7.81e-10	Height;
LIHC	cis	rs1029738	0.500	rs13227539	chr7:22884156	C/G	cg11367502	chr7:22862612	TOMM7	-0.36	-6.07	-0.31	3.41e-9	Fibrinogen levels;
LIHC	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	9.7e-13	Putamen volume;
LIHC	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.64	9.52	0.46	3.37e-19	Schizophrenia (inflammation and infection response interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20824237	chr3:99979579	TBC1D23	0.43	6.05	0.31	3.76e-9	Pancreatic cancer;
LIHC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21016266	chr12:122356598	WDR66	0.52	7.6	0.38	2.94e-13	Mean corpuscular volume;
LIHC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.65	7.84	0.39	5.61e-14	Schizophrenia;
LIHC	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.45	0.42	8.29e-16	Response to antipsychotic treatment;
LIHC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.77	-11.42	-0.53	8.6e-26	Personality dimensions;
LIHC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg03859395	chr2:55845619	SMEK2	0.92	16.06	0.66	1.2e-43	Metabolic syndrome;
LIHC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.4	-0.33	5.09e-10	Response to antipsychotic treatment;
LIHC	trans	rs9940464	0.901	rs4782770	chr16:83362689	C/G	cg02755603	chr20:18548475	LOC388789	0.35	6.17	0.32	1.95e-9	Malaria;
LIHC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.11	15.85	0.65	8.47e-43	Primary sclerosing cholangitis;
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg00091569	chr3:40428383	ENTPD3	0.41	6.97	0.35	1.67e-11	Renal cell carcinoma;
LIHC	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.27	0.32	1.08e-9	Educational attainment;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05262316	chr6:64345491	NA	0.38	6.22	0.32	1.47e-9	Pancreatic cancer;
LIHC	cis	rs9980664	1.000	rs9980664	chr21:34734510	G/T	cg04842828	chr21:34696676	IFNAR1	0.46	6.06	0.31	3.57e-9	Cognitive decline (age-related);
LIHC	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-7.65	-0.38	2.05e-13	Exhaled nitric oxide output;
LIHC	cis	rs1144333	0.655	rs58722308	chr1:76423525	A/G	cg22875332	chr1:76189707	ACADM	0.4	6.06	0.31	3.51e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05464172	chr8:97247954	UQCRB	0.44	7.13	0.36	6.06e-12	Cognitive function;
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.21e-14	Prudent dietary pattern;
LIHC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.6	9.29	0.45	1.91e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.56	10.03	0.48	6.55e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.34	7.96	0.4	2.59e-14	Blood metabolite ratios;
LIHC	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	19.23	0.72	2.29e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.48	6.78	0.34	5.2e-11	Diastolic blood pressure;
LIHC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg22633049	chr21:46681294	NA	-0.36	-6.18	-0.32	1.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20080320	chr15:28363860	HERC2	-0.42	-6.73	-0.34	6.97e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.35	7.9	0.39	3.85e-14	Type 2 diabetes;
LIHC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-6.01	-0.31	4.67e-9	Breast cancer;
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.83	13.13	0.58	3.52e-32	Height;
LIHC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.65	0.53	1.26e-26	Alzheimer's disease;
LIHC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.54	8.08	0.4	1.14e-14	Height;
LIHC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-6.81	-0.35	4.4e-11	Bipolar disorder;
LIHC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.39	7.24	0.36	3.03e-12	Schizophrenia;
LIHC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.38	6.06	0.31	3.69e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs75908454	1.000	rs80114444	chr6:169939774	G/A	cg19338460	chr6:170058176	WDR27	-0.8	-7.47	-0.37	6.58e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs35955747	0.902	rs131202	chr22:31709309	A/C	cg22777020	chr22:31556080	RNF185	0.5	5.89	0.3	9.22e-9	Neutrophil count;Sum basophil neutrophil counts;
LIHC	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg19735590	chr5:154026979	NA	-0.51	-5.99	-0.31	5.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg14515779	chr1:101123966	NA	-0.47	-6.53	-0.33	2.41e-10	Monocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24783322	chr8:49834643	SNAI2	0.44	6.14	0.32	2.25e-9	Pancreatic cancer;
LIHC	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	12.02	0.54	5.41e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg18279126	chr7:2041391	MAD1L1	0.39	6.56	0.33	2.04e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.39	-7.19	-0.36	4.18e-12	Height;
LIHC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.2	-0.36	3.88e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg16586182	chr3:47516702	SCAP	-0.5	-9.14	-0.44	5.5e-18	Colorectal cancer;
LIHC	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.86	0.47	2.39e-20	Colorectal cancer;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg23411876	chr7:140396886	LOC100134713;NDUFB2	0.47	6.84	0.35	3.6e-11	Alopecia areata;
LIHC	trans	rs6600671	0.934	rs7528274	chr1:121286901	A/T	cg09829573	chr1:144692074	NBPF9	-0.41	-7.33	-0.37	1.69e-12	Hip geometry;
LIHC	cis	rs2412488	0.893	rs4864767	chr4:54367136	G/A	cg22241045	chr4:54363911	LNX1	0.44	7.38	0.37	1.24e-12	DNA methylation (variation);
LIHC	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.65	-0.34	1.15e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg11062466	chr8:58055876	NA	0.49	7.11	0.36	6.72e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg00204512	chr16:28754710	NA	0.4	7.01	0.35	1.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.77	-13.25	-0.58	1.25e-32	Aortic root size;
LIHC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7251275	0.744	rs17655646	chr19:44134936	G/A	cg17121205	chr19:44009353	PHLDB3	0.4	5.94	0.31	7.16e-9	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.44	-0.33	4.11e-10	Capecitabine sensitivity;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg12863693	chr15:85201151	NMB	0.49	6.93	0.35	2.12e-11	Schizophrenia;
LIHC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	10.57	0.5	8.64e-23	Total body bone mineral density;
LIHC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs7119038	0.779	rs73005502	chr11:118697906	A/G	cg19308663	chr11:118741387	NA	0.44	5.75	0.3	2.02e-8	Sjögren's syndrome;
LIHC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.35	-6.5	-0.33	2.89e-10	IgG glycosylation;
LIHC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.52	6.58	0.34	1.72e-10	Menarche (age at onset);
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg06882758	chr19:58662330	ZNF329	0.93	6.97	0.35	1.6e-11	Cholesterol, total;
LIHC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.54	0.59	9.65e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.17	0.32	1.89e-9	Cognitive ability;
LIHC	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg01657329	chr11:68192670	LRP5	0.53	6.01	0.31	4.85e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg08135965	chr6:41755394	TOMM6	0.46	6.13	0.31	2.41e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19717773	chr7:2847554	GNA12	-0.42	-6.32	-0.32	8.1e-10	Height;
LIHC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.7	11.19	0.52	5.5e-25	Neuroticism;
LIHC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02985541	chr2:219472218	PLCD4	0.44	8.29	0.41	2.53e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg25344623	chr2:136566232	LCT	-0.36	-7.34	-0.37	1.6e-12	Mosquito bite size;
LIHC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.73	-11.93	-0.54	1.12e-27	Body mass index;
LIHC	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.7	8.94	0.44	2.49e-17	Exhaled nitric oxide output;
LIHC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.14	0.31	2.35e-9	Blood metabolite levels;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.57	-6.63	-0.34	1.32e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.42e-14	Morning vs. evening chronotype;
LIHC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.98	-9.72	-0.47	6.81e-20	Platelet count;
LIHC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.47	7.4	0.37	1.07e-12	Cocaine dependence;
LIHC	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg16346588	chr10:242978	ZMYND11	-0.5	-5.88	-0.3	9.83e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.49	6.35	0.32	7.03e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6442522	0.560	rs7631005	chr3:15515061	C/T	cg16303742	chr3:15540471	COLQ	0.36	5.9	0.3	8.58e-9	Uric acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03065641	chr8:145133200	EXOSC4	0.51	7.42	0.37	9.38e-13	Pancreatic cancer;
LIHC	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg00792783	chr2:198669748	PLCL1	-0.41	-5.94	-0.31	7.02e-9	Intracranial aneurysm;
LIHC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.25	-0.32	1.24e-9	Total body bone mineral density;
LIHC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.56	10.05	0.48	5.41e-21	Alcohol dependence;
LIHC	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.47	-0.33	3.42e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	9.02	0.44	1.37e-17	Cognitive ability;
LIHC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.96	0.4	2.55e-14	Lung cancer in ever smokers;
LIHC	cis	rs9918079	0.506	rs7696127	chr4:15642953	T/A	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.12	-0.36	6.56e-12	Obesity-related traits;
LIHC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.66	10.35	0.49	5.03e-22	Breast cancer;
LIHC	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.73	-11.39	-0.52	1.11e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg08888203	chr3:10149979	C3orf24	0.53	6.36	0.33	6.62e-10	Alzheimer's disease;
LIHC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.81	0.39	6.86e-14	Alzheimer's disease;
LIHC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.88	-0.3	9.63e-9	Menopause (age at onset);
LIHC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.4	6.65	0.34	1.15e-10	Red blood cell count;
LIHC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg03859395	chr2:55845619	SMEK2	-0.48	-7.62	-0.38	2.46e-13	Metabolic syndrome;
LIHC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.46e-8	Menopause (age at onset);
LIHC	cis	rs10792665	0.698	rs948184	chr11:82722659	G/A	cg24227371	chr11:82718527	RAB30	-0.38	-9.3	-0.45	1.69e-18	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09983252	chr4:119555556	NA	0.38	6.24	0.32	1.28e-9	Pancreatic cancer;
LIHC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.7	7.03	0.36	1.16e-11	Vitiligo;
LIHC	cis	rs4700695	0.925	rs12653007	chr5:65396965	G/A	cg21114390	chr5:65439923	SFRS12	-0.5	-6.92	-0.35	2.24e-11	Facial morphology (factor 19);
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.73	0.57	1.2e-30	Alzheimer's disease;
LIHC	cis	rs6539247	0.527	rs10778456	chr12:106448302	C/T	cg20883310	chr12:106464547	NUAK1	0.42	6.72	0.34	7.75e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.52	-8.14	-0.4	7.6e-15	Blood trace element (Zn levels);
LIHC	cis	rs7546668	1.000	rs3795758	chr1:15853551	C/T	cg11706911	chr1:15910989	AGMAT	0.44	6.83	0.35	3.91e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-6.98	-0.35	1.51e-11	Morning vs. evening chronotype;
LIHC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	8.78	0.43	8.08e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.47	0.49	1.88e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.45	-8.29	-0.41	2.65e-15	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02290350	chr8:58132656	NA	0.51	11.03	0.51	2.11e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.22	0.52	4.41e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg18887096	chr2:219472410	PLCD4	0.37	6.43	0.33	4.28e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg26211634	chr5:139558579	C5orf32	0.39	6.14	0.31	2.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4700695	1.000	rs12518359	chr5:65397909	T/C	cg21114390	chr5:65439923	SFRS12	-0.5	-6.92	-0.35	2.3e-11	Facial morphology (factor 19);
LIHC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.67	9.23	0.45	2.8e-18	Mean platelet volume;
LIHC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22168489	chr12:122356033	WDR66	0.38	6.16	0.32	2.07e-9	Mean corpuscular volume;
LIHC	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	0.59	6.19	0.32	1.71e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.42	6.19	0.32	1.76e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	1.0	11.19	0.52	5.68e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs263063	0.920	rs4807681	chr19:5037764	T/C	cg18473234	chr19:5097819	KDM4B	-0.55	-6.86	-0.35	3.19e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.79	12.82	0.57	5.31e-31	Night sleep phenotypes;
LIHC	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.56	-8.33	-0.41	2.05e-15	White matter hyperintensity burden;
LIHC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.36	-0.33	6.48e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.23	0.36	3.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg16034541	chr3:195490309	MUC4	0.63	9.95	0.47	1.14e-20	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18357526	chr6:26021779	HIST1H4A	0.7	8.97	0.44	1.92e-17	Urate levels;
LIHC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.16	-0.55	1.65e-28	Colorectal cancer;
LIHC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04221910	chr5:616842	CEP72	0.41	7.33	0.37	1.63e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25632853	chr15:73088954	NA	0.37	6.14	0.32	2.31e-9	Triglyceride levels;
LIHC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.52	7.35	0.37	1.49e-12	Morning vs. evening chronotype;
LIHC	cis	rs2737618	0.674	rs2737683	chr1:200092448	G/A	cg21825944	chr1:200113062	NR5A2	-0.48	-8.07	-0.4	1.22e-14	Uric acid levels;
LIHC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.45	-7.58	-0.38	3.19e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.23	-0.41	4.01e-15	Total cholesterol levels;
LIHC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.36	7.2	0.36	3.94e-12	Renal cell carcinoma;
LIHC	cis	rs477692	0.648	rs10829603	chr10:131327351	T/G	cg19680672	chr10:131412579	MGMT	-0.39	-5.96	-0.31	6.43e-9	Response to temozolomide;
LIHC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg23352942	chr3:46931381	PTH1R	-0.28	-7.21	-0.36	3.61e-12	Birth weight;
LIHC	cis	rs847649	0.842	rs1608651	chr7:102624192	C/T	cg18108683	chr7:102477205	FBXL13	0.48	7.13	0.36	6.11e-12	Morning vs. evening chronotype;
LIHC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.89	7.37	0.37	1.33e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.56	0.5	9.87e-23	Vitiligo;
LIHC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Corneal astigmatism;
LIHC	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg03989125	chr22:38214979	NA	-0.43	-5.97	-0.31	5.97e-9	Glioblastoma;Glioma;
LIHC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-6.9	-0.35	2.48e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.2	0.52	4.97e-25	Body mass index;
LIHC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.14	0.58	3.31e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs611744	0.967	rs597992	chr8:109193808	A/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.76	11.05	0.51	1.81e-24	Response to antineoplastic agents;
LIHC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.82	-11.55	-0.53	2.74e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.81	9.2	0.45	3.64e-18	Primary sclerosing cholangitis;
LIHC	cis	rs7872515	0.838	rs7860518	chr9:94826465	C/T	cg01248375	chr9:94877805	SPTLC1	0.53	7.55	0.38	4.1e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg20607798	chr8:58055168	NA	0.49	6.13	0.31	2.37e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736485	0.934	rs28648597	chr15:51856066	T/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.45	8.24	0.41	3.71e-15	Multiple myeloma;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19550733	chr1:25869992	LDLRAP1	-0.47	-6.1	-0.31	2.86e-9	Thyroid stimulating hormone;
LIHC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.4	-5.74	-0.3	2.15e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg08528486	chr13:113648767	MCF2L	-0.4	-6.31	-0.32	8.41e-10	Systolic blood pressure;
LIHC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-0.74	-8.61	-0.42	2.67e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.38	7.12	0.36	6.6e-12	Metabolite levels;
LIHC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.69	0.5	3.46e-23	Cannabis dependence symptom count;
LIHC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.61	-8.38	-0.41	1.4e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.5	-9.36	-0.45	1.12e-18	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs3770081	1.000	rs57398459	chr2:86291326	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.49	-0.42	6.21e-16	Facial emotion recognition (sad faces);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10909163	chr13:41635251	WBP4	0.41	6.16	0.32	2.02e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.57	9.68	0.46	9.89e-20	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg08888203	chr3:10149979	C3orf24	0.61	6.65	0.34	1.17e-10	Alzheimer's disease;
LIHC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.34	7.72	0.39	1.3e-13	Crohn's disease;
LIHC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.44e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.31	0.45	1.53e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg00656387	chr3:40428638	ENTPD3	0.42	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	trans	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg26043149	chr18:55253948	FECH	0.38	6.04	0.31	3.96e-9	Bone mineral density;
LIHC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.84	0.43	5.31e-17	Menarche (age at onset);
LIHC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	7.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.26	-0.37	2.62e-12	Personality dimensions;
LIHC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.94	0.54	1.07e-27	Motion sickness;
LIHC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-11.1	-0.51	1.19e-24	Coronary artery disease;
LIHC	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.56	8.8	0.43	6.83e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4728302	0.869	rs6955240	chr7:133581873	G/A	cg10665199	chr7:133106180	EXOC4	0.35	6.2	0.32	1.63e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.47	6.97	0.35	1.65e-11	Thyroid stimulating hormone;
LIHC	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.84	-13.67	-0.59	2.94e-34	Morning vs. evening chronotype;
LIHC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.86	0.3	1.11e-8	Bladder cancer;
LIHC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.69	-7.12	-0.36	6.45e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.25	-5.87	-0.3	1.06e-8	Longevity;Endometriosis;
LIHC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.96	-0.47	1.11e-20	Schizophrenia;
LIHC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.71	-7.09	-0.36	7.81e-12	Vitiligo;
LIHC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.59	10.12	0.48	3.12e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02359409	chr6:42947317	PEX6	-0.44	-6.22	-0.32	1.45e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.52	8.48	0.42	7.03e-16	Obesity-related traits;
LIHC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.88	-0.3	9.88e-9	Mean corpuscular volume;
LIHC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.12	0.4	8.29e-15	Morning vs. evening chronotype;
LIHC	cis	rs7677751	0.943	rs9991165	chr4:55124591	A/G	cg17187183	chr4:55093834	PDGFRA	0.69	8.07	0.4	1.22e-14	Corneal astigmatism;
LIHC	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	11.06	0.51	1.62e-24	Post bronchodilator FEV1;
LIHC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg04511125	chr2:88470314	THNSL2	-0.42	-6.39	-0.33	5.38e-10	Response to metformin (IC50);
LIHC	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.09	0.31	3.01e-9	Mean corpuscular volume;
LIHC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.81	7.78	0.39	8.84e-14	Diabetic retinopathy;
LIHC	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-8.14	-0.4	7.29e-15	Neuroticism;
LIHC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg03859395	chr2:55845619	SMEK2	0.8	14.18	0.61	3.31e-36	Metabolic syndrome;
LIHC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.06	-0.31	3.61e-9	Heart rate;
LIHC	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg06766960	chr11:133703094	NA	0.45	6.8	0.35	4.57e-11	Childhood ear infection;
LIHC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.36	5.76	0.3	1.89e-8	Menopause (age at onset);
LIHC	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg08345082	chr10:99160200	RRP12	-0.39	-6.72	-0.34	7.76e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.5	7.66	0.38	1.91e-13	Height;
LIHC	cis	rs12702595	0.509	rs11767985	chr7:7264352	A/C	cg04827551	chr7:7268805	C1GALT1	0.33	6.16	0.32	2.06e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg09990169	chr2:241835740	C2orf54	-0.66	-9.56	-0.46	2.43e-19	Urinary metabolites;
LIHC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.3	-0.32	9.13e-10	Headache;
LIHC	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.77	8.81	0.43	6.28e-17	Exhaled nitric oxide levels;
LIHC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.55	6.54	0.33	2.27e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg24130564	chr14:104152367	KLC1	0.45	7.51	0.38	5.13e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.45	6.22	0.32	1.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.8	-12.68	-0.57	1.78e-30	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.98	-11.29	-0.52	2.41e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4908760	0.965	rs10864354	chr1:8549741	C/T	cg20416874	chr1:8611966	RERE	-0.66	-13.45	-0.59	2.22e-33	Vitiligo;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08219700	chr8:58056026	NA	0.46	6.87	0.35	2.98e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.84	-0.39	5.96e-14	Total body bone mineral density;
LIHC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.51	0.42	5.46e-16	Initial pursuit acceleration;
LIHC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.6	-12.22	-0.55	9.85e-29	Plateletcrit;Platelet count;
LIHC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.79	-0.34	4.89e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.55	-9.21	-0.45	3.46e-18	Cognitive function;
LIHC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.22	-0.52	4.51e-25	Coronary artery disease;
LIHC	cis	rs7614311	0.681	rs6801346	chr3:63947128	A/G	cg22134162	chr3:63841271	THOC7	0.49	5.77	0.3	1.77e-8	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg16479474	chr6:28041457	NA	0.39	6.52	0.33	2.57e-10	Cardiac Troponin-T levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.46	6.62	0.34	1.36e-10	Pancreatic cancer;
LIHC	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.7	7.36	0.37	1.36e-12	Blood protein levels;
LIHC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-9.76	-0.47	5.12e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1559088	0.501	rs8100568	chr19:33567565	T/C	cg27124370	chr19:33622961	WDR88	0.46	6.27	0.32	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.85	-0.6	6.1e-35	Coffee consumption (cups per day);
LIHC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.97	15.17	0.63	3.99e-40	Metabolic syndrome;
LIHC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-13.39	-0.59	3.64e-33	Vitiligo;
LIHC	cis	rs4684776	0.935	rs12636305	chr3:11418924	T/G	cg00170343	chr3:11313890	ATG7	-0.43	-5.89	-0.3	9.39e-9	Small vessel stroke;
LIHC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.59	-11.32	-0.52	1.84e-25	Body mass index;
LIHC	trans	rs12019136	1	rs12019136	chr19:5835677	G/A	cg16574191	chr19:14063234	PODNL1;DCAF15	-0.79	-6.22	-0.32	1.44e-9	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
LIHC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.78	8.69	0.43	1.55e-16	Vitiligo;
LIHC	cis	rs3790645	1.000	rs444482	chr1:26890648	C/G	cg23229016	chr1:26872525	RPS6KA1	0.23	5.77	0.3	1.78e-8	Glucose homeostasis traits;
LIHC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg05564831	chr3:52568323	NT5DC2	0.4	6.63	0.34	1.28e-10	Bipolar disorder;
LIHC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.79	-8.97	-0.44	1.94e-17	Vitiligo;
LIHC	cis	rs507080	0.922	rs518028	chr11:118564982	T/C	cg04173919	chr11:118528438	PHLDB1	0.36	6.6	0.34	1.53e-10	Serum metabolite levels;
LIHC	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg26536354	chr8:144654954	C8orf73	0.55	6.19	0.32	1.76e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs6695567	1.000	rs6695567	chr1:53629585	G/A	cg20326410	chr1:53600821	SLC1A7	0.3	6.35	0.32	6.87e-10	Systemic lupus erythematosus;
LIHC	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-0.71	-7.3	-0.37	1.98e-12	Putamen volume;
LIHC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.37	5.71	0.3	2.45e-8	Resting heart rate;
LIHC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.35	0.37	1.46e-12	IgG glycosylation;
LIHC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02969873	chr4:1330999	MAEA	-0.41	-6.31	-0.32	8.59e-10	Longevity;
LIHC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.71	-0.34	7.87e-11	Response to antipsychotic treatment;
LIHC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.55	0.53	2.76e-26	Platelet count;
LIHC	cis	rs2033908	0.589	rs4757060	chr11:12842990	G/A	cg25843174	chr11:12811716	TEAD1	-0.26	-6.2	-0.32	1.63e-9	Sitting height ratio;
LIHC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg16346588	chr10:242978	ZMYND11	-0.48	-5.89	-0.3	9.23e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg17980119	chr2:219472607	PLCD4	0.35	6.05	0.31	3.84e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.92	-0.6	3.33e-35	Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.87	12.05	0.55	3.97e-28	Post bronchodilator FEV1;
LIHC	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.6	7.0	0.35	1.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg10820045	chr2:198174542	NA	0.46	6.99	0.35	1.42e-11	Dermatomyositis;
LIHC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.4	-6.19	-0.32	1.75e-9	Menarche (age at onset);
LIHC	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.78	0.5	1.63e-23	Colorectal cancer;
LIHC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg04498913	chr7:1135747	C7orf50	0.37	5.71	0.3	2.4e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.61	-8.56	-0.42	3.9e-16	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15042806	chr16:23652268	DCTN5;PALB2	0.46	6.11	0.31	2.7e-9	Pancreatic cancer;
LIHC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-8.7	-0.43	1.43e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25275331	chr1:40723935	ZMPSTE24	-0.41	-6.1	-0.31	2.94e-9	Pancreatic cancer;
LIHC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.84	-0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.91	0.35	2.42e-11	Breast cancer;
LIHC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.74	0.34	6.9e-11	Bipolar disorder;
LIHC	cis	rs12702595	0.818	rs7791957	chr7:7270034	T/C	cg04827551	chr7:7268805	C1GALT1	0.37	6.7	0.34	8.49e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	0.4	6.34	0.32	7.43e-10	Cognitive function;
LIHC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.12	-0.31	2.55e-9	Schizophrenia;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27297192	chr10:134578999	INPP5A	0.53	7.43	0.37	8.83e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs11696739	0.536	rs3761268	chr20:1601167	C/T	cg15722679	chr20:1638393	SIRPG	0.55	9.88	0.47	2.12e-20	Mean platelet volume;
LIHC	cis	rs57244997	0.544	rs77182940	chr6:162443721	T/C	cg17173639	chr6:162384350	PARK2	-0.6	-7.46	-0.37	7e-13	Mosquito bite size;
LIHC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg05697976	chr12:29376483	FAR2	0.31	6.17	0.32	1.9e-9	QT interval;
LIHC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-8.01	-0.4	1.76e-14	Schizophrenia;
LIHC	cis	rs11630290	0.592	rs1039818	chr15:64155296	A/G	cg12036633	chr15:63758958	NA	0.63	6.75	0.34	6.36e-11	Iris characteristics;
LIHC	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.25	5.86	0.3	1.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.5	6.27	0.32	1.06e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.63	0.53	1.38e-26	Monocyte percentage of white cells;
LIHC	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-7.79	-0.39	7.89e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.48	0.46	4.54e-19	Electroencephalogram traits;
LIHC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.49	-0.49	1.65e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.63	11.25	0.52	3.44e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs6442522	0.610	rs6808644	chr3:15527047	G/A	cg16303742	chr3:15540471	COLQ	0.4	6.39	0.33	5.45e-10	Uric acid levels;
LIHC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg10932868	chr11:921992	NA	0.4	7.56	0.38	3.84e-13	Alzheimer's disease (late onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04104609	chr2:219523980	ZNF142;BCS1L	0.38	6.1	0.31	2.91e-9	Lung function (FEV1/FVC);
LIHC	cis	rs77861329	1.000	rs114209632	chr3:52188361	C/T	cg08692210	chr3:52188851	WDR51A	0.81	7.23	0.36	3.12e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.82	-0.39	6.67e-14	Coronary artery disease;
LIHC	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.9	0.35	2.6e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg23758822	chr17:41437982	NA	0.96	18.2	0.7	2.94e-52	Menopause (age at onset);
LIHC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs13113518	0.812	rs56055342	chr4:56407095	T/C	cg15358633	chr12:38710606	ALG10B	0.43	6.11	0.31	2.65e-9	Height;
LIHC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.23	-0.41	3.99e-15	Schizophrenia;
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.47	7.01	0.35	1.25e-11	Cystic fibrosis severity;
LIHC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.59	8.92	0.43	2.8e-17	Platelet count;
LIHC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.67	-13.29	-0.58	8.44e-33	Body mass index;
LIHC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.53	-0.38	4.46e-13	Tonsillectomy;
LIHC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.49	8.02	0.4	1.73e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.52	-8.84	-0.43	5.33e-17	Height;
LIHC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20135002	chr11:47629003	NA	0.56	9.53	0.46	3.03e-19	Subjective well-being;
LIHC	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.48	9.14	0.44	5.68e-18	Testicular germ cell tumor;
LIHC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.49	7.59	0.38	3.13e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.75	-9.95	-0.47	1.14e-20	Schizophrenia;
LIHC	cis	rs8017423	0.967	rs11849641	chr14:90727647	T/C	cg14092571	chr14:90743983	NA	-0.38	-6.02	-0.31	4.54e-9	Mortality in heart failure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16993936	chr10:13146903	OPTN	-0.44	-6.86	-0.35	3.34e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg17135325	chr3:160939158	NMD3	0.6	8.69	0.43	1.48e-16	Parkinson's disease;
LIHC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg11812906	chr14:75593930	NEK9	-0.43	-6.99	-0.35	1.47e-11	IgG glycosylation;
LIHC	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.78	0.43	8.06e-17	Exhaled nitric oxide levels;
LIHC	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	7.79	0.39	8.15e-14	Blood protein levels;
LIHC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.61	0.34	1.44e-10	Bipolar disorder;
LIHC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.88	-0.39	4.48e-14	Chronic sinus infection;
LIHC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.67	-9.5	-0.46	3.64e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.54e-11	Type 2 diabetes;
LIHC	cis	rs10838687	0.800	rs4752983	chr11:47352138	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.83	-0.3	1.27e-8	Proinsulin levels;
LIHC	cis	rs7534824	0.625	rs6692186	chr1:101470217	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.76	0.34	5.97e-11	Refractive astigmatism;
LIHC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.87	0.3	1.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.4e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26076054	chr5:421317	AHRR	0.27	5.97	0.31	5.91e-9	Cystic fibrosis severity;
LIHC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.57	8.45	0.42	8.54e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.51	0.42	5.54e-16	Initial pursuit acceleration;
LIHC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06634786	chr22:41940651	POLR3H	0.56	6.07	0.31	3.46e-9	Vitiligo;
LIHC	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg06096015	chr1:231504339	EGLN1	0.43	7.26	0.37	2.64e-12	Red blood cell count;
LIHC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.26	-0.37	2.55e-12	Bipolar disorder;
LIHC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs965469	1.000	rs6051716	chr20:3267736	C/T	cg25506879	chr20:3388711	C20orf194	-0.59	-6.67	-0.34	1e-10	IFN-related cytopenia;
LIHC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.64	6.52	0.33	2.59e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg05084668	chr3:125655381	ALG1L	-0.41	-6.39	-0.33	5.28e-10	Blood pressure (smoking interaction);
LIHC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	13.93	0.6	3.03e-35	Chronic sinus infection;
LIHC	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg03934865	chr2:198174659	NA	0.51	7.68	0.38	1.66e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg27490568	chr2:178487706	NA	0.7	9.33	0.45	1.37e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.48	7.11	0.36	6.64e-12	Glioblastoma;
LIHC	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.55	-0.42	4.13e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.37	5.73	0.3	2.22e-8	Coronary artery disease;
LIHC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19500275	chr17:80737654	TBCD	0.41	5.73	0.3	2.2e-8	Glycated hemoglobin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02837703	chr11:67236413	TMEM134	0.45	6.38	0.33	5.77e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.74	-13.04	-0.58	8.03e-32	Birth weight;
LIHC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.6	-0.42	2.83e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.41	0.61	3.94e-37	Prudent dietary pattern;
LIHC	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.46	-5.83	-0.3	1.27e-8	Panic disorder;
LIHC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.4	12.55	0.56	5.75e-30	Uric acid levels;
LIHC	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg23229016	chr1:26872525	RPS6KA1	-0.24	-6.23	-0.32	1.36e-9	Glucose homeostasis traits;
LIHC	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg00601450	chr5:74908170	NA	0.59	7.17	0.36	4.61e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8084351	0.577	rs4371227	chr18:50657284	C/T	cg24270629	chr18:50823537	DCC	-0.43	-6.36	-0.33	6.41e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs10733682	0.524	rs10987418	chr9:129462563	A/G	cg00232160	chr9:129468157	NA	0.39	6.95	0.35	1.84e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg20607798	chr8:58055168	NA	0.49	6.11	0.31	2.75e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.64	-11.26	-0.52	3.18e-25	Breast cancer;
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg16970926	chr12:29381810	FAR2	0.3	6.24	0.32	1.3e-9	QT interval;
LIHC	cis	rs7911264	0.628	rs7921040	chr10:94418425	G/A	cg25506282	chr10:94462361	NA	0.38	6.46	0.33	3.56e-10	Inflammatory bowel disease;
LIHC	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.38	7.11	0.36	6.95e-12	Metabolite levels;
LIHC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.34	0.32	7.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs240764	0.687	rs239209	chr6:101140977	T/C	cg12253828	chr6:101329408	ASCC3	0.43	6.48	0.33	3.14e-10	Neuroticism;
LIHC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.67	8.91	0.43	3e-17	Schizophrenia;
LIHC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.69	0.53	8.52e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04902049	chr1:36622448	MAP7D1	0.42	6.18	0.32	1.81e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-8.59	-0.42	3.25e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.39	-6.22	-0.32	1.44e-9	Testicular germ cell tumor;
LIHC	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.8	13.96	0.6	2.22e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.93	15.25	0.64	2.01e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs16828019	0.777	rs35496942	chr1:41488904	G/A	cg03962019	chr1:41807865	NA	0.5	7.0	0.35	1.38e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.9e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.54	-6.81	-0.35	4.45e-11	Lung cancer in ever smokers;
LIHC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.33	7.08	0.36	8.47e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg16309518	chr5:176445507	NA	-0.58	-11.52	-0.53	3.76e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.45	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg09990169	chr2:241835740	C2orf54	-0.66	-9.51	-0.46	3.52e-19	Urinary metabolites;
LIHC	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-8.98	-0.44	1.81e-17	Capecitabine sensitivity;
LIHC	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg24060327	chr5:131705240	SLC22A5	0.55	7.44	0.37	8.01e-13	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.05	0.6	1.02e-35	Chronic sinus infection;
LIHC	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.61	-9.54	-0.46	2.87e-19	Blood trace element (Zn levels);
LIHC	cis	rs9783347	1.000	rs4150610	chr11:18364140	A/G	cg15585147	chr11:18324498	HPS5	0.43	6.77	0.34	5.74e-11	Pancreatic cancer;
LIHC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.08	-0.36	8.26e-12	Personality dimensions;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg14817848	chr12:12715558	DUSP16	-0.51	-7.7	-0.38	1.46e-13	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg05697976	chr12:29376483	FAR2	0.33	6.76	0.34	6.05e-11	QT interval;
LIHC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-7.45	-0.37	7.91e-13	Platelet distribution width;
LIHC	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.36	-7.14	-0.36	5.69e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg21466736	chr12:48725269	NA	-0.63	-9.13	-0.44	6.16e-18	Glycated hemoglobin levels;
LIHC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg25039879	chr17:56429692	SUPT4H1	0.76	8.87	0.43	4.17e-17	Cognitive test performance;
LIHC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.14	0.31	2.35e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08822215	chr16:89438651	ANKRD11	-0.4	-6.29	-0.32	9.94e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs6066825	0.590	rs6063307	chr20:47304045	A/G	cg18078177	chr20:47281410	PREX1	0.47	8.11	0.4	9.16e-15	Colorectal cancer;
LIHC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs72772090	1.000	rs56116814	chr5:96048714	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.48	-5.86	-0.3	1.07e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.58	8.45	0.42	8.28e-16	Bipolar disorder;
LIHC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.5	7.92	0.39	3.42e-14	Diastolic blood pressure;
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.32	1.31e-9	Calcium levels;
LIHC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-10.14	-0.48	2.67e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg02640540	chr1:67518911	SLC35D1	0.44	6.08	0.31	3.29e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.41	6.31	0.32	8.87e-10	Night sleep phenotypes;
LIHC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.27	-0.41	3.08e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.54	9.08	0.44	8.92e-18	Colorectal cancer;
LIHC	trans	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.26	-0.32	1.16e-9	Endometrial cancer;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.73	-12.98	-0.57	1.32e-31	Prudent dietary pattern;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg01766191	chr11:57103423	SSRP1	-0.45	-6.05	-0.31	3.83e-9	Alopecia areata;
LIHC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.75	-11.42	-0.53	8.56e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg07636037	chr3:49044803	WDR6	-0.55	-6.19	-0.32	1.77e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.5	7.82	0.39	6.55e-14	Alzheimer's disease (survival time);
LIHC	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	7.65	0.38	2.03e-13	Height;
LIHC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.32	0.68	1.09e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.87	0.3	1.04e-8	Personality dimensions;
LIHC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg12373951	chr3:133503437	NA	0.55	9.43	0.45	6.44e-19	Iron status biomarkers;
LIHC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.91	9.25	0.45	2.53e-18	Mean corpuscular hemoglobin;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.46	-7.92	-0.39	3.38e-14	Total body bone mineral density;
LIHC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.59	8.15	0.4	7.03e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.41	0.45	7.76e-19	Resting heart rate;
LIHC	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.73	11.92	0.54	1.27e-27	White matter hyperintensity burden;
LIHC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.77	0.34	5.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06240896	chr7:100136768	AGFG2	0.42	6.05	0.31	3.76e-9	Migraine with aura;
LIHC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg16836995	chr17:43662488	NA	-0.73	-7.2	-0.36	3.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.71	11.37	0.52	1.27e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.58	-11.46	-0.53	5.97e-26	Coronary artery disease;
LIHC	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg17749961	chr2:30669863	LCLAT1	-0.48	-6.23	-0.32	1.4e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.23e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.22e-11	Aortic root size;
LIHC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg07645718	chr20:61493192	TCFL5	-0.7	-6.16	-0.32	2.07e-9	Obesity-related traits;
LIHC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.72	12.12	0.55	2.26e-28	Total body bone mineral density;
LIHC	cis	rs738722	1.000	rs1807609	chr22:29131129	T/C	cg15103426	chr22:29168792	CCDC117	0.43	5.87	0.3	1.03e-8	Optic cup area;Esophageal cancer and gastric cancer;
LIHC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg05896524	chr21:47604654	C21orf56	0.44	6.64	0.34	1.25e-10	Testicular germ cell tumor;
LIHC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.47	7.06	0.36	9.22e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg15848620	chr12:58087721	OS9	-0.55	-7.43	-0.37	8.57e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.52	9.0	0.44	1.55e-17	Coronary artery disease;
LIHC	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.73	14.04	0.6	1.15e-35	Mortality in heart failure;
LIHC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.81	9.14	0.44	5.55e-18	Vitiligo;
LIHC	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.74	0.39	1.11e-13	Platelet count;
LIHC	cis	rs2997447	0.706	rs61776622	chr1:26469035	A/G	cg19633962	chr1:26362018	EXTL1	-0.7	-6.33	-0.32	7.75e-10	QRS complex (12-leadsum);
LIHC	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.44	7.28	0.37	2.26e-12	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04051962	chr16:1570409	IFT140	0.38	6.08	0.31	3.19e-9	Longevity;
LIHC	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg12140854	chr5:148520817	ABLIM3	-0.44	-5.95	-0.31	6.73e-9	Breast cancer;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.39	0.33	5.57e-10	Hematocrit;
LIHC	trans	rs7022054	0.502	rs5010022	chr9:7216586	G/A	cg26740341	chr6:22874184	NA	0.27	6.24	0.32	1.28e-9	Schizophrenia;
LIHC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg00225070	chr15:80189496	MTHFS	-0.6	-9.8	-0.47	3.7e-20	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.51	8.09	0.4	1.06e-14	Total body bone mineral density;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.43	-6.4	-0.33	5.11e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.68	-11.08	-0.51	1.44e-24	Breast cancer;
LIHC	cis	rs2336384	1.000	rs6672267	chr1:12054911	A/G	cg13216073	chr1:12042593	MFN2	0.43	6.38	0.33	5.61e-10	Platelet count;
LIHC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg20651018	chr11:3035856	CARS	-0.35	-5.83	-0.3	1.29e-8	Longevity;
LIHC	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-7.26	-0.37	2.71e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.79	13.09	0.58	5.05e-32	Breast cancer;
LIHC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-0.82	-9.43	-0.45	6.2800000000000005e-19	Schizophrenia;
LIHC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.52	0.46	3.1400000000000002e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2016586	0.802	rs8142446	chr22:36115128	A/G	cg26342177	chr22:36113512	APOL5	-0.38	-6.49	-0.33	3.01e-10	Body mass index;
LIHC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg14906510	chr12:7781169	NA	0.47	7.32	0.37	1.82e-12	HDL cholesterol levels;
LIHC	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg20991723	chr1:152506922	NA	0.55	9.08	0.44	8.68e-18	Hair morphology;
LIHC	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.22	-0.32	1.43e-9	Tuberculosis;
LIHC	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.24	-0.36	2.94e-12	Tuberculosis;
LIHC	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.52	-6.68	-0.34	9.91e-11	Type 2 diabetes;
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg06951627	chr6:26196580	NA	0.53	6.27	0.32	1.07e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.44	0.33	3.94e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	7.1	0.36	7.39e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17428076	0.801	rs62182392	chr2:172721762	G/A	cg13550731	chr2:172543902	DYNC1I2	0.36	5.89	0.3	9.09e-9	Myopia;
LIHC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	0.8	5.98	0.31	5.57e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.47	-5.8	-0.3	1.54e-8	Exhaled nitric oxide output;
LIHC	cis	rs2257205	0.667	rs8070007	chr17:56709169	A/G	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs963731	0.649	rs297129	chr2:39299271	C/T	cg04010122	chr2:39346883	SOS1	0.64	5.8	0.3	1.54e-8	Corticobasal degeneration;
LIHC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.78	-11.27	-0.52	2.8e-25	Motion sickness;
LIHC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.75	8.85	0.43	4.68e-17	Morning vs. evening chronotype;
LIHC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.03	-0.4	1.58e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1499280	0.920	rs10471365	chr5:52108572	T/C	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.44	0.49	2.57e-22	Obesity-related traits;
LIHC	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg14146966	chr2:61757674	XPO1	0.47	8.24	0.41	3.77e-15	Tuberculosis;
LIHC	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.16e-11	Ileal carcinoids;
LIHC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.55	8.63	0.42	2.36e-16	Tumor biomarkers;
LIHC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.47	8.57	0.42	3.7e-16	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.66	0.56	2.18e-30	Prudent dietary pattern;
LIHC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.61	8.42	0.41	1.04e-15	Menarche (age at onset);
LIHC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg03037974	chr15:76606532	NA	0.75	14.56	0.62	1.04e-37	Blood metabolite levels;
LIHC	cis	rs6421571	0.565	rs10892263	chr11:118587319	T/C	cg19308663	chr11:118741387	NA	0.42	5.73	0.3	2.24e-8	Primary biliary cholangitis;
LIHC	cis	rs11871801	0.918	rs4633765	chr17:40682341	T/A	cg14558262	chr17:40713999	COASY	-0.5	-6.83	-0.35	3.91e-11	Crohn's disease;
LIHC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.86	-0.35	3.26e-11	Aortic root size;
LIHC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs425535	0.619	rs12498174	chr4:74825768	T/C	cg02530824	chr4:74847766	PF4	-0.37	-5.95	-0.31	6.57e-9	Blood protein levels;
LIHC	cis	rs2274273	0.868	rs1572611	chr14:55833874	T/A	cg01864836	chr14:55583639	NA	-0.38	-6.65	-0.34	1.19e-10	Protein biomarker;
LIHC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.58	10.05	0.48	5.41e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg12501888	chr15:85177176	SCAND2	-0.5	-7.84	-0.39	5.74e-14	P wave terminal force;
LIHC	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.16	-0.32	2.04e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.42	-5.93	-0.31	7.51e-9	Aortic root size;
LIHC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.62	10.39	0.49	3.83e-22	Obesity-related traits;
LIHC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.5	5.85	0.3	1.16e-8	Bladder cancer;
LIHC	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg11161837	chr1:110010384	SYPL2	0.47	6.15	0.32	2.17e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.8	-0.39	7.42e-14	Obesity-related traits;
LIHC	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	0.81	10.19	0.48	1.88e-21	Economic and political preferences (immigration/crime);
LIHC	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.45	-0.37	7.79e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs72627509	0.587	rs17087401	chr4:57901155	G/T	cg26694713	chr4:57773883	REST	0.59	7.46	0.37	7.3e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg27234864	chr13:21295941	IL17D	0.42	6.09	0.31	3.07e-9	Dental caries;
LIHC	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.64	7.38	0.37	1.25e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs9921222	0.521	rs9935268	chr16:381562	G/C	cg12437481	chr16:420112	MRPL28	-0.61	-8.52	-0.42	5.04e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg09165964	chr15:75287851	SCAMP5	-0.59	-7.76	-0.39	1.01e-13	Lung cancer;
LIHC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.64e-30	Menopause (age at onset);
LIHC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg12140854	chr5:148520817	ABLIM3	-0.52	-5.81	-0.3	1.4e-8	Breast cancer;
LIHC	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.54	-7.26	-0.37	2.56e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg14222432	chr12:29376421	FAR2	0.36	7.05	0.36	9.82e-12	QT interval;
LIHC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	trans	rs10847980	0.623	rs28681105	chr12:123875525	T/C	cg07919128	chr17:18022025	MYO15A	-0.75	-7.5	-0.38	5.62e-13	Adiponectin levels;
LIHC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg23533926	chr12:111358616	MYL2	-0.32	-6.23	-0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.87	-0.51	7.74e-24	Chronic sinus infection;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27613455	chr17:38020644	IKZF3	0.39	6.64	0.34	1.22e-10	Cognitive function;
LIHC	cis	rs7619427	0.544	rs9877020	chr3:43992455	A/G	cg24966902	chr3:44043705	NA	-0.43	-6.62	-0.34	1.43e-10	Schizophrenia;
LIHC	cis	rs7587476	0.765	rs2121284	chr2:215656260	T/C	cg04004882	chr2:215674386	BARD1	-0.55	-7.77	-0.39	9.06e-14	Neuroblastoma;
LIHC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.59	-9.32	-0.45	1.42e-18	Platelet count;
LIHC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.69	-9.67	-0.46	1.04e-19	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07157506	chr18:12883603	PTPN2	0.45	6.94	0.35	1.96e-11	Pancreatic cancer;
LIHC	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.94	17.07	0.68	1.12e-47	Parkinson's disease;
LIHC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg20933634	chr6:27740509	NA	0.48	6.35	0.32	6.8e-10	Parkinson's disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21983178	chr1:45120676	TMEM53	0.41	6.18	0.32	1.84e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.84	-0.43	5.25e-17	Atrioventricular conduction;
LIHC	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.49	9.25	0.45	2.46e-18	Testicular germ cell tumor;
LIHC	trans	rs2744203	1.000	rs72610886	chr6:104647207	C/G	cg27088726	chr16:83171155	CDH13	-0.46	-6.08	-0.31	3.14e-9	IgG glycosylation;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02676523	chr16:4027674	ADCY9	-0.43	-6.5	-0.33	2.78e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.83	10.48	0.49	1.76e-22	Cognitive function;
LIHC	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg03934865	chr2:198174659	NA	0.45	6.53	0.33	2.35e-10	Dermatomyositis;
LIHC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.63	-10.01	-0.48	7.61e-21	Dental caries;
LIHC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.69	-9.18	-0.44	4.15e-18	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20623868	chr19:15666885	NA	-0.39	-6.05	-0.31	3.77e-9	Triglycerides;
LIHC	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg09065629	chr16:1709722	CRAMP1L	0.35	6.03	0.31	4.34e-9	Coronary artery disease;
LIHC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-11.21	-0.52	4.56e-25	Platelet count;
LIHC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.85	-0.3	1.16e-8	Longevity;
LIHC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.34	-7.53	-0.38	4.64e-13	Ulcerative colitis;
LIHC	trans	rs9914544	0.545	rs2305064	chr17:18770733	G/A	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.73	-0.34	7.38e-11	Educational attainment (years of education);
LIHC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.15	0.36	5.45e-12	Bipolar disorder;
LIHC	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg21724239	chr8:58056113	NA	0.5	6.51	0.33	2.61e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08280861	chr8:58055591	NA	0.55	6.26	0.32	1.13e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21016266	chr12:122356598	WDR66	0.43	6.95	0.35	1.9e-11	Mean corpuscular volume;
LIHC	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.52	6.42	0.33	4.67e-10	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.49	-7.28	-0.37	2.37e-12	Longevity;Endometriosis;
LIHC	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg07856975	chr6:36356162	ETV7	-0.35	-5.77	-0.3	1.8e-8	Platelet distribution width;
LIHC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.82	9.35	0.45	1.15e-18	Vitiligo;
LIHC	cis	rs1113500	0.805	rs11185244	chr1:108601147	C/T	cg06207961	chr1:108661230	NA	0.31	5.71	0.3	2.44e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.41	-5.74	-0.3	2.08e-8	Total body bone mineral density;
LIHC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.5	-8.22	-0.41	4.26e-15	Longevity;Endometriosis;
LIHC	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.87	14.85	0.63	7.65e-39	Gastritis;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.39	0.33	5.4e-10	Glycated hemoglobin levels;
LIHC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.49	-0.33	2.96e-10	Menarche (age at onset);
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg27432699	chr2:27873401	GPN1	-0.53	-7.64	-0.38	2.26e-13	Total body bone mineral density;
LIHC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.42	-6.52	-0.33	2.5e-10	Height;
LIHC	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.78	-0.6	1.17e-34	Bipolar disorder and schizophrenia;
LIHC	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	23.48	0.79	2.8e-73	Colorectal cancer;
LIHC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.78	-0.3	1.72e-8	Mean corpuscular volume;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg27094323	chr7:1216898	NA	-0.4	-5.88	-0.3	9.8e-9	Longevity;Endometriosis;
LIHC	trans	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg17675199	chr6:35436792	RPL10A	0.32	6.36	0.33	6.34e-10	Coronary artery disease;
LIHC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg27205649	chr11:78285834	NARS2	0.39	5.93	0.31	7.41e-9	Alzheimer's disease (survival time);
LIHC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg14440974	chr22:39074834	NA	-0.44	-7.14	-0.36	5.81e-12	Menopause (age at onset);
LIHC	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.69	7.9	0.39	3.79e-14	Schizophrenia;
LIHC	cis	rs9443189	0.950	rs1280039	chr6:76514940	C/T	cg01950844	chr6:76311363	SENP6	0.48	5.74	0.3	2.1e-8	Prostate cancer;
LIHC	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.5	9.7	0.46	7.91e-20	Testicular germ cell tumor;
LIHC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.1	-0.51	1.13e-24	Response to antipsychotic treatment;
LIHC	trans	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg01596870	chr19:55963115	NA	-0.64	-8.65	-0.42	2.07e-16	Obesity-related traits;
LIHC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.56	10.35	0.49	4.97e-22	Methadone dose in opioid dependence;
LIHC	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.48	7.16	0.36	5.12e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.15	-27.54	-0.83	8.62e-89	Myeloid white cell count;
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.53	7.8	0.39	7.61e-14	Lymphocyte counts;
LIHC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.99	16.75	0.67	2.06e-46	Platelet count;
LIHC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.78	12.9	0.57	2.66e-31	Oral cavity cancer;
LIHC	cis	rs7818688	0.654	rs896848	chr8:95981810	G/A	cg16049864	chr8:95962084	TP53INP1	0.56	6.31	0.32	8.77e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.96	18.62	0.71	6.55e-54	Intelligence (multi-trait analysis);
LIHC	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	0.84	14.49	0.62	1.92e-37	Eosinophil percentage of white cells;
LIHC	trans	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg10756647	chr7:56101905	PSPH	1.0	11.41	0.53	8.84e-26	Diabetic kidney disease;
LIHC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.51	-7.81	-0.39	6.95e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.5	-8.1	-0.4	9.85e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs3736485	0.966	rs8040538	chr15:51904584	G/A	cg08986416	chr15:51914746	DMXL2	-0.44	-6.3	-0.32	9.07e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1419980	0.730	rs11054871	chr12:7770878	C/G	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-13.24	-0.58	1.31e-32	Morning vs. evening chronotype;
LIHC	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.13	-0.31	2.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.73	10.38	0.49	4.11e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.52	6.2	0.32	1.64e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.73	-0.54	6.15e-27	Coffee consumption (cups per day);
LIHC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.38	8.75	0.43	9.76e-17	Blood protein levels;
LIHC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.57	7.39	0.37	1.11e-12	Parkinson's disease;
LIHC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	8.71	0.43	1.35e-16	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-7.19	-0.36	4.14e-12	Body mass index;
LIHC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg20026190	chr17:76395443	PGS1	0.39	5.82	0.3	1.39e-8	HDL cholesterol levels;
LIHC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.07	0.31	3.4e-9	HDL cholesterol;
LIHC	cis	rs8081395	0.801	rs2665405	chr17:57875292	G/A	cg13753209	chr17:57696993	CLTC	-0.45	-6.96	-0.35	1.78e-11	White blood cell count;
LIHC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg06766960	chr11:133703094	NA	-0.44	-6.78	-0.34	5.18e-11	Childhood ear infection;
LIHC	cis	rs546131	0.642	rs7946980	chr11:34820438	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.43	0.33	4.38e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.62	6.92	0.35	2.26e-11	Schizophrenia;
LIHC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg14779329	chr11:130786720	SNX19	0.38	5.88	0.3	9.95e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg03013999	chr17:37608204	MED1	-0.36	-5.95	-0.31	6.7e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.08	-0.31	3.16e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.46	6.81	0.35	4.35e-11	Aortic root size;
LIHC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg15848620	chr12:58087721	OS9	0.51	6.41	0.33	4.86e-10	Multiple sclerosis;
LIHC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg08847533	chr14:75593920	NEK9	-0.57	-9.16	-0.44	4.75e-18	IgG glycosylation;
LIHC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs8010715	0.785	rs2877611	chr14:24595430	C/T	cg23112188	chr14:24563095	PCK2	-0.28	-5.77	-0.3	1.76e-8	IgG glycosylation;
LIHC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.75	-7.71	-0.38	1.35e-13	Vitiligo;
LIHC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.55	9.33	0.45	1.34e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.72	0.39	1.3e-13	Prudent dietary pattern;
LIHC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.49	6.36	0.33	6.5e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20818191	chr4:866154	GAK	0.48	6.97	0.35	1.59e-11	Longevity;
LIHC	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	1.05	12.48	0.56	9.97e-30	Red blood cell traits;
LIHC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	6.1	0.31	2.79e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.28	-0.45	1.93e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.26	-0.37	2.68e-12	Body mass index;
LIHC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	9.4	0.45	8.17e-19	Mean platelet volume;
LIHC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	8.71	0.43	1.33e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.83	0.63	9.29e-39	Prudent dietary pattern;
LIHC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.83	16.39	0.66	5.97e-45	Response to diuretic therapy;
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.33	2.99e-10	Alzheimer's disease;
LIHC	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.6	7.4	0.37	1.09e-12	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.65	0.42	1.97e-16	Motion sickness;
LIHC	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.61	-8.06	-0.4	1.33e-14	Motion sickness;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.34	-0.37	1.59e-12	Schizophrenia;
LIHC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg18357526	chr6:26021779	HIST1H4A	0.43	6.45	0.33	3.82e-10	Height;
LIHC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.7	10.98	0.51	3.2e-24	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs2637266	0.783	rs12268496	chr10:78487192	G/A	cg18941641	chr10:78392320	NA	0.27	5.75	0.3	2.02e-8	Pulmonary function;
LIHC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.44	6.37	0.33	5.95e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.49	-0.46	3.95e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.37	6.71	0.34	7.95e-11	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs34375054	0.672	rs2291248	chr12:125619308	C/T	cg25124228	chr12:125621409	AACS	-0.42	-7.0	-0.35	1.39e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-7.75	-0.39	1.04e-13	Coronary artery disease;
LIHC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.49	7.46	0.37	7.04e-13	Resting heart rate;
LIHC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg05590025	chr7:65112418	INTS4L2	0.64	7.14	0.36	5.49e-12	Diabetic kidney disease;
LIHC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.04	19.37	0.72	6.21e-57	IgG glycosylation;
LIHC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.12	-0.31	2.6e-9	Mean corpuscular volume;
LIHC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18357526	chr6:26021779	HIST1H4A	0.49	7.23	0.36	3.24e-12	Height;
LIHC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.13	0.36	6.18e-12	Axial length;
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.95	0.57	1.78e-31	Prudent dietary pattern;
LIHC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.76	0.65	1.93e-42	Tonsillectomy;
LIHC	cis	rs9372498	0.536	rs1761624	chr6:118642722	C/T	cg01339444	chr6:118972232	C6orf204	0.76	6.35	0.32	6.89e-10	Diastolic blood pressure;
LIHC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.52	-10.17	-0.48	2.08e-21	Mean corpuscular volume;
LIHC	cis	rs10849689	1	rs10849689	chr12:110493222	A/G	cg12870014	chr12:110450643	ANKRD13A	0.8	10.45	0.49	2.34e-22	Schizophrenia;
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg09417038	chr21:47716443	C21orf57	-0.47	-7.1	-0.36	7.2e-12	Testicular germ cell tumor;
LIHC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.45	7.49	0.38	5.94e-13	Height;
LIHC	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg03959625	chr15:84868606	LOC388152	0.46	6.51	0.33	2.67e-10	Schizophrenia;
LIHC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-7.46	-0.37	7.12e-13	Platelet count;
LIHC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00152838	chr16:24741724	TNRC6A	0.5	6.28	0.32	1.03e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.9	-0.43	3.26e-17	Bipolar disorder;
LIHC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg11861562	chr11:117069780	TAGLN	0.49	8.15	0.4	6.89e-15	Blood protein levels;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.56	-0.56	4.98e-30	Bipolar disorder and schizophrenia;
LIHC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.46	-9.4	-0.45	8.13e-19	Birth weight;
LIHC	trans	rs10411161	0.702	rs8110073	chr19:52383123	C/A	cg22319618	chr22:45562946	NUP50	-0.59	-8.05	-0.4	1.41e-14	Breast cancer;
LIHC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg13844804	chr7:814759	HEATR2	0.43	5.73	0.3	2.25e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.88	-0.39	4.39e-14	Response to antipsychotic treatment;
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.61	-8.75	-0.43	9.63e-17	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04213235	chr1:145826932	GPR89A	0.47	6.74	0.34	6.65e-11	Pancreatic cancer;
LIHC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.35e-16	Motion sickness;
LIHC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.78	12.45	0.56	1.29e-29	Corneal astigmatism;
LIHC	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	7.04	0.36	1.06e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.95	-0.4	2.66e-14	Response to antipsychotic treatment;
LIHC	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.39	-5.81	-0.3	1.45e-8	Ulcerative colitis;
LIHC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.12	-12.95	-0.57	1.75e-31	Vitiligo;
LIHC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-17.57	-0.69	1.09e-49	Height;
LIHC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.49	0.33	3.07e-10	Menarche (age at onset);
LIHC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg18306943	chr3:40428807	ENTPD3	0.36	6.02	0.31	4.48e-9	Renal cell carcinoma;
LIHC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.77	0.43	8.58e-17	Height;
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.43	7.97	0.4	2.46e-14	Prudent dietary pattern;
LIHC	cis	rs74181299	0.571	rs2302647	chr2:65283174	G/A	cg05010058	chr2:65284262	CEP68	0.37	5.96	0.31	6.35e-9	Pulse pressure;
LIHC	cis	rs3106136	0.678	rs7685514	chr4:95292089	T/C	cg11021082	chr4:95130006	SMARCAD1	0.35	6.1	0.31	2.9e-9	Capecitabine sensitivity;
LIHC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg18016565	chr1:150552671	MCL1	0.52	9.88	0.47	2.09e-20	Melanoma;
LIHC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	1.09	7.82	0.39	6.53e-14	Arsenic metabolism;
LIHC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg14558262	chr17:40713999	COASY	0.63	9.76	0.47	5.2e-20	Crohn's disease;
LIHC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02985541	chr2:219472218	PLCD4	-0.43	-6.95	-0.35	1.86e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	0.84	7.15	0.36	5.14e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.39	6.98	0.35	1.53e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.42	6.92	0.35	2.24e-11	Red blood cell count;
LIHC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg11764359	chr7:65958608	NA	0.61	6.44	0.33	4.09e-10	Diabetic kidney disease;
LIHC	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.68	-12.22	-0.55	9.28e-29	Pediatric autoimmune diseases;
LIHC	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.67	8.97	0.44	2.01e-17	Coronary artery disease;
LIHC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.87	-18.87	-0.71	6.06e-55	Height;
LIHC	cis	rs9392556	0.626	rs626080	chr6:4101567	A/G	cg10424681	chr6:4079350	C6orf201;C6orf146	-0.24	-6.1	-0.31	2.86e-9	Blood metabolite levels;
LIHC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.19	-0.32	1.71e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9682041	0.561	rs7643214	chr3:170144281	C/T	cg11886554	chr3:170076028	SKIL	0.78	5.94	0.31	6.94e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg03237606	chr10:63212265	TMEM26	0.34	7.67	0.38	1.8e-13	Night sleep phenotypes;
LIHC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.56	9.45	0.46	5.53e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3814244	0.528	rs12582272	chr12:68400078	T/A	cg15249341	chr12:68405565	NA	-0.31	-6.09	-0.31	3e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs8192917	0.832	rs9671454	chr14:25102056	G/C	cg08766149	chr14:25103301	GZMB	0.33	7.24	0.36	2.92e-12	Vitiligo;
LIHC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg00677901	chr16:88017247	BANP	0.53	8.25	0.41	3.35e-15	Menopause (age at onset);
LIHC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.68	-13.18	-0.58	2.31e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.98	-13.62	-0.59	4.82e-34	Corneal structure;
LIHC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg00204512	chr16:28754710	NA	0.41	7.13	0.36	6e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.73	-13.64	-0.59	4.06e-34	Height;
LIHC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg06766960	chr11:133703094	NA	-0.4	-6.1	-0.31	2.8e-9	Childhood ear infection;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13508402	chr7:127670570	SND1;LRRC4	0.38	6.06	0.31	3.65e-9	Bilirubin levels;
LIHC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	9.13	0.44	6.1e-18	Bipolar disorder;
LIHC	cis	rs611744	0.967	rs677288	chr8:109177539	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg07549590	chr16:15018862	NA	-0.33	-6.2	-0.32	1.66e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.48	-7.49	-0.38	5.84e-13	Blood protein levels;
LIHC	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.62	11.62	0.53	1.6e-26	Schizophrenia;
LIHC	cis	rs7818688	0.697	rs28399553	chr8:95906794	A/G	cg16049864	chr8:95962084	TP53INP1	0.58	6.64	0.34	1.25e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg02569458	chr12:86230093	RASSF9	0.46	6.09	0.31	3.1e-9	Major depressive disorder;
LIHC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg08132940	chr7:1081526	C7orf50	-0.7	-6.11	-0.31	2.68e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6545883	0.794	rs778152	chr2:61608540	C/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.42	-0.37	9.46e-13	Tuberculosis;
LIHC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	6.79	0.34	5.1e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.73	11.5	0.53	4.27e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.76	7.42	0.37	9.11e-13	Diabetic retinopathy;
LIHC	cis	rs6788895	1.000	rs79709238	chr3:150488477	A/C	cg07663535	chr3:150480033	SIAH2	0.56	7.02	0.35	1.23e-11	Breast cancer;
LIHC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg07061783	chr6:25882402	NA	-0.83	-9.92	-0.47	1.48e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg01021169	chr22:30184971	ASCC2	-0.36	-6.95	-0.35	1.86e-11	Type 1 diabetes;
LIHC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.82	0.3	1.33e-8	Electroencephalogram traits;
LIHC	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	7.81	0.39	7.16e-14	Electrocardiographic conduction measures;
LIHC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.92	-15.73	-0.65	2.52e-42	Tonsillectomy;
LIHC	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg01364799	chr7:75623366	TMEM120A	0.51	7.75	0.39	1.05e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-6.21	-0.32	1.51e-9	IFN-related cytopenia;
LIHC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.36	6.01	0.31	4.75e-9	Electroencephalogram traits;
LIHC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.36	-0.41	1.6e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg22771759	chr13:24902376	NA	0.31	6.24	0.32	1.3e-9	Obesity-related traits;
LIHC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.71	10.67	0.5	3.78e-23	Aortic root size;
LIHC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.97	0.47	9.99e-21	Menopause (age at onset);
LIHC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.14	0.32	2.28e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72781680	0.752	rs12616649	chr2:23890913	G/A	cg08917208	chr2:24149416	ATAD2B	1.03	8.34	0.41	1.84e-15	Lymphocyte counts;
LIHC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.44	6.8	0.35	4.58e-11	Methadone dose in opioid dependence;
LIHC	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.42	6.87	0.35	3.01e-11	Menopause (age at onset);
LIHC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg24296786	chr1:45957014	TESK2	-0.5	-7.5	-0.38	5.41e-13	Platelet count;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-7.85	-0.39	5.58e-14	Obesity-related traits;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14671364	chr1:107599128	PRMT6	0.48	7.18	0.36	4.37e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	1.17	13.75	0.6	1.47e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.53	6.25	0.32	1.25e-9	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs3096299	0.754	rs3096296	chr16:89411010	C/A	cg06640241	chr16:89574553	SPG7	0.5	7.55	0.38	3.91e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs16958440	0.867	rs79285649	chr18:44699019	A/T	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.58	-8.45	-0.42	8.35e-16	Glaucoma (primary open-angle);
LIHC	cis	rs1983891	1.000	rs913074	chr6:41538545	T/C	cg20194872	chr6:41519635	FOXP4	0.41	6.36	0.33	6.31e-10	Prostate cancer;
LIHC	cis	rs4728302	0.869	rs6962865	chr7:133599433	T/A	cg10665199	chr7:133106180	EXOC4	0.38	6.63	0.34	1.28e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg16275483	chr1:110013120	SYPL2	-0.48	-5.95	-0.31	6.81e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.04	-0.51	1.98e-24	Crohn's disease;
LIHC	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.45	6.88	0.35	2.86e-11	Height;
LIHC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06002616	chr8:101225028	SPAG1	0.35	5.94	0.31	6.88e-9	Atrioventricular conduction;
LIHC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.82	-13.04	-0.58	7.86e-32	Colorectal cancer;
LIHC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	1.04	20.61	0.74	6.26e-62	Breast cancer;
LIHC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.26	0.37	2.71e-12	Lung cancer in ever smokers;
LIHC	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.45	-6.45	-0.33	3.8e-10	Blood protein levels;
LIHC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.45	5.95	0.31	6.61e-9	High light scatter reticulocyte count;
LIHC	cis	rs12611088	0.571	rs2305375	chr19:44013260	C/T	cg13740135	chr19:44006432	PHLDB3	-0.41	-6.27	-0.32	1.11e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.34	-6.29	-0.32	9.45e-10	Aortic root size;
LIHC	cis	rs616147	0.627	rs816510	chr3:39472295	G/T	cg17944282	chr3:39448217	RPSA	-0.42	-5.79	-0.3	1.58e-8	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.82	0.35	4.15e-11	Educational attainment;
LIHC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.19	0.52	5.5e-25	Colorectal cancer;
LIHC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.87	10.81	0.5	1.21e-23	Bladder cancer;
LIHC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.59	8.59	0.42	3.15e-16	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg10932868	chr11:921992	NA	0.35	6.42	0.33	4.59e-10	Alzheimer's disease (late onset);
LIHC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.81	0.54	3.03e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-30.73	-0.86	2.05e-100	Myeloid white cell count;
LIHC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	10.58	0.5	8.1e-23	Total cholesterol levels;
LIHC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.78	-0.3	1.68e-8	Personality dimensions;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs3762637	0.941	rs28679619	chr3:122100349	C/A	cg24169773	chr3:122142474	KPNA1	-0.48	-9.29	-0.45	1.82e-18	LDL cholesterol levels;
LIHC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00152838	chr16:24741724	TNRC6A	-0.49	-6.47	-0.33	3.47e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1789	0.903	rs4616746	chr4:15673098	A/G	cg21329975	chr4:15471214	CC2D2A	-0.4	-5.99	-0.31	5.2e-9	Blood protein levels;
LIHC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.61	8.62	0.42	2.48e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg26536354	chr8:144654954	C8orf73	0.56	6.23	0.32	1.35e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.22e-24	Breast cancer;
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.95	15.38	0.64	6.02e-41	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.65	-8.07	-0.4	1.22e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg15691649	chr6:25882328	NA	-0.39	-6.18	-0.32	1.79e-9	Height;
LIHC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.83	0.35	3.86e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.07	-0.36	8.68e-12	Personality dimensions;
LIHC	cis	rs6500637	0.570	rs1049205	chr16:4942099	C/T	cg08329684	chr16:4932620	PPL	-0.42	-7.28	-0.37	2.37e-12	Cancer;
LIHC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg04727924	chr7:799746	HEATR2	-0.59	-8.06	-0.4	1.3e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.77	-0.47	4.66e-20	Response to antipsychotic treatment;
LIHC	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.28	5.91	0.3	8.17e-9	Pulmonary function;
LIHC	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8081395	0.741	rs180519	chr17:58016271	G/A	cg13753209	chr17:57696993	CLTC	0.39	5.96	0.31	6.22e-9	White blood cell count;
LIHC	trans	rs783540	0.967	rs34186444	chr15:83287500	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.71	-0.34	7.92e-11	Schizophrenia;
LIHC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.5	9.17	0.44	4.39e-18	Alcohol dependence;
LIHC	cis	rs1986734	0.619	rs13106227	chr4:77418681	G/A	cg24201034	chr4:77507246	SHROOM3	-0.38	-6.12	-0.31	2.62e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg23262073	chr20:60523788	NA	-0.3	-5.98	-0.31	5.6e-9	Body mass index;
LIHC	trans	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg10208301	chr11:6592745	DNHD1	-0.48	-6.4	-0.33	5.06e-10	Coronary artery calcification;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08722720	chr15:34331557	AVEN;CHRM5	0.5	7.07	0.36	8.88e-12	Pancreatic cancer;
LIHC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.58	-0.5	8.01e-23	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20930802	chr3:44519333	ZNF445	0.44	6.17	0.32	1.89e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16828019	0.852	rs71648535	chr1:41613750	G/A	cg20697417	chr1:41786797	NA	0.35	6.64	0.34	1.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7534824	0.625	rs58234233	chr1:101510440	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.42	0.37	9.55e-13	Refractive astigmatism;
LIHC	trans	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.1	-0.36	7.05e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.6	-0.34	1.62e-10	Body mass index;
LIHC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.64	-12.3	-0.55	4.93e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.58	9.98	0.47	9.3e-21	Colorectal cancer;
LIHC	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.1	0.44	7.77e-18	Coffee consumption (cups per day);
LIHC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.8	13.32	0.58	6.62e-33	Breast cancer;
LIHC	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.5	7.68	0.38	1.7e-13	Diastolic blood pressure;
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg12903224	chr12:29470962	FAR2	-0.37	-5.95	-0.31	6.8e-9	QT interval;
LIHC	cis	rs9921222	0.597	rs3848369	chr16:415078	C/T	cg00101154	chr16:420108	MRPL28	-0.63	-9.89	-0.47	1.94e-20	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs4834770	1.000	rs4834771	chr4:120242772	C/A	cg09307838	chr4:120376055	NA	0.43	6.5	0.33	2.87e-10	Blood protein levels;
LIHC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.42e-23	Mean corpuscular volume;
LIHC	cis	rs8141529	0.515	rs13056243	chr22:29349306	A/G	cg15103426	chr22:29168792	CCDC117	-0.43	-6.14	-0.32	2.24e-9	Lymphocyte counts;
LIHC	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-5.94	-0.31	7.08e-9	Systolic blood pressure;
LIHC	trans	rs7142002	1.000	rs7142002	chr14:102360745	T/C	cg18984499	chr17:8286166	RPL26	0.65	6.19	0.32	1.77e-9	Autism;
LIHC	cis	rs11630290	0.736	rs28621516	chr15:64156314	G/A	cg12036633	chr15:63758958	NA	-0.64	-6.05	-0.31	3.8e-9	Iris characteristics;
LIHC	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg07423050	chr13:99094983	FARP1	-0.36	-6.17	-0.32	1.96e-9	Educational attainment (years of education);
LIHC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-7.75	-0.39	1.07e-13	Electroencephalogram traits;
LIHC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.62	-7.87	-0.39	4.85e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg13047869	chr3:10149882	C3orf24	0.48	5.89	0.3	9.41e-9	Alzheimer's disease;
LIHC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22168489	chr12:122356033	WDR66	0.37	5.87	0.3	1.04e-8	Mean corpuscular volume;
LIHC	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.51	-6.58	-0.34	1.81e-10	Coronary artery disease;
LIHC	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.41	6.44	0.33	4.13e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.14	0.48	2.62e-21	Hypertriglyceridemia;
LIHC	cis	rs7249142	0.563	rs11669860	chr19:19277296	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-6.32	-0.32	8.34e-10	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.6	8.73	0.43	1.17e-16	Response to diuretic therapy;
LIHC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07305463	chr2:136567211	LCT	0.34	6.61	0.34	1.48e-10	Mosquito bite size;
LIHC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-11.28	-0.52	2.62e-25	Body mass index;
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.4	-5.72	-0.3	2.28e-8	Blood metabolite levels;
LIHC	cis	rs11098699	0.821	rs13109534	chr4:124211262	T/C	cg09941581	chr4:124220074	SPATA5	0.32	6.4	0.33	5.2e-10	Mosquito bite size;
LIHC	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.56	-7.78	-0.39	8.94e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.33	0.58	6.18e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.39	-0.49	3.81e-22	Coronary artery disease;
LIHC	trans	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg17675199	chr6:35436792	RPL10A	0.34	6.63	0.34	1.32e-10	Coronary artery disease;
LIHC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg23485639	chr6:28045615	ZNF165	0.37	5.89	0.3	9.34e-9	Cardiac Troponin-T levels;
LIHC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.4	0.45	8.31e-19	Bipolar disorder;
LIHC	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg08992911	chr2:238395768	MLPH	0.49	5.96	0.31	6.24e-9	Prostate cancer;
LIHC	cis	rs6782228	0.606	rs6439135	chr3:128358633	G/A	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.38	6.39	0.33	5.49e-10	Body mass index;
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27297192	chr10:134578999	INPP5A	0.56	8.46	0.42	8.05e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.94	-11.92	-0.54	1.22e-27	Body mass index;
LIHC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.63	10.38	0.49	4.13e-22	Lung cancer;
LIHC	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg27426351	chr10:43362370	NA	0.48	5.81	0.3	1.46e-8	Blood protein levels;
LIHC	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	7.46	0.37	7.42e-13	Blood protein levels;
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.68	9.31	0.45	1.58e-18	Calcium levels;
LIHC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.29	-7.68	-0.38	1.69e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	9.13	0.44	6.06e-18	Initial pursuit acceleration;
LIHC	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.14	0.36	5.5e-12	Lung cancer;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg00800038	chr16:89945340	TCF25	-0.6	-9.53	-0.46	3.02e-19	Skin colour saturation;
LIHC	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.4	0.45	8.36e-19	Corneal astigmatism;
LIHC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.45	5.89	0.3	9.42e-9	High light scatter reticulocyte count;
LIHC	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg02269571	chr22:50332266	NA	0.73	8.09	0.4	1.07e-14	Schizophrenia;
LIHC	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	6.91	0.35	2.32e-11	Eotaxin levels;
LIHC	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.73	-0.34	7.17e-11	Schizophrenia;
LIHC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.89	-0.35	2.72e-11	IgG glycosylation;
LIHC	cis	rs3106136	0.681	rs28458965	chr4:95302476	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.34	6.82	0.35	4.06e-11	Renal cell carcinoma;
LIHC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg05590025	chr7:65112418	INTS4L2	0.56	6.31	0.32	8.58e-10	Diabetic kidney disease;
LIHC	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.19e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.94	20.36	0.74	6.6e-61	Blood protein levels;
LIHC	cis	rs1034435	0.547	rs743846	chr22:48900819	C/T	cg05992904	chr22:48892994	FAM19A5	-0.45	-8.0	-0.4	2e-14	Late-onset Alzheimer's disease;
LIHC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.89	9.87	0.47	2.27e-20	Triglycerides;
LIHC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg19318889	chr4:1322082	MAEA	-0.38	-6.16	-0.32	2.01e-9	Obesity-related traits;
LIHC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.63	-9.64	-0.46	1.3e-19	Colorectal cancer;
LIHC	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg05527609	chr1:210001259	C1orf107	-0.54	-7.75	-0.39	1.03e-13	Red blood cell count;
LIHC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg18357526	chr6:26021779	HIST1H4A	0.5	6.95	0.35	1.86e-11	Blood metabolite levels;
LIHC	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg09795085	chr6:101329169	ASCC3	0.45	6.52	0.33	2.55e-10	Neuroticism;
LIHC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.8	0.34	4.81e-11	Crohn's disease;
LIHC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	0.87	6.27	0.32	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.48	11.13	0.52	9.45e-25	Iron status biomarkers (transferrin levels);
LIHC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.49	8.1	0.4	9.75e-15	Corneal astigmatism;
LIHC	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.41	-6.07	-0.31	3.45e-9	Height;
LIHC	cis	rs2274273	0.934	rs10144418	chr14:55817708	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.55	-0.33	2.18e-10	Protein biomarker;
LIHC	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.49	7.17	0.36	4.79e-12	Dialysis-related mortality;
LIHC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.31	0.41	2.29e-15	Multiple sclerosis;
LIHC	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	1.02	9.18	0.44	4.24e-18	Gut microbiota (bacterial taxa);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26561342	chr1:45241260	SNORD55;RPS8;SNORD46	-0.36	-6.05	-0.31	3.83e-9	Pancreatic cancer;
LIHC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.6	0.53	1.9e-26	Tonsillectomy;
LIHC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.54	0.56	6.16e-30	Electrocardiographic conduction measures;
LIHC	cis	rs7534824	0.543	rs61780295	chr1:101400264	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	7.07	0.36	8.96e-12	Refractive astigmatism;
LIHC	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.39	6.18	0.32	1.85e-9	Schizophrenia;
LIHC	cis	rs546131	0.642	rs2956073	chr11:34842883	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.65	9.31	0.45	1.64e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.64	-0.38	2.21e-13	Electroencephalogram traits;
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg05697976	chr12:29376483	FAR2	0.31	6.38	0.33	5.76e-10	QT interval;
LIHC	cis	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs1144333	0.655	rs4949681	chr1:76409828	C/T	cg03433033	chr1:76189801	ACADM	0.54	7.64	0.38	2.14e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.93	14.8	0.62	1.14e-38	Breast cancer;
LIHC	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg14345882	chr6:26364793	BTN3A2	0.34	5.74	0.3	2.04e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.59	7.94	0.39	2.92e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.44	-0.33	4.09e-10	Type 2 diabetes;
LIHC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.45	5.88	0.3	9.86e-9	Ulcerative colitis;
LIHC	cis	rs17106184	0.786	rs56985406	chr1:50999695	G/A	cg07174182	chr1:51127561	FAF1	-0.7	-7.11	-0.36	6.97e-12	Type 2 diabetes;
LIHC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.92	0.31	7.65e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.49	0.53	4.77e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-11.98	-0.54	7.21e-28	Total cholesterol levels;
LIHC	trans	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg26939375	chr7:64535504	NA	0.4	6.25	0.32	1.24e-9	Aortic root size;
LIHC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.98	-18.24	-0.7	2.17e-52	Breast cancer;
LIHC	trans	rs6934970	1.000	rs6934919	chr6:113124141	G/A	cg02462569	chr6:150064036	NUP43	-0.46	-6.09	-0.31	3.1e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.63	8.57	0.42	3.58e-16	Neuroticism;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg15383120	chr6:291909	DUSP22	-0.48	-6.29	-0.32	9.8e-10	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08804807	chr5:173315313	CPEB4	0.48	6.38	0.33	5.66e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7712401	0.791	rs6872932	chr5:122145636	A/G	cg18764291	chr5:122110994	SNX2	0.35	5.99	0.31	5.26e-9	Mean platelet volume;
LIHC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.63	8.01	0.4	1.76e-14	Morning vs. evening chronotype;
LIHC	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-11.0	-0.51	2.62e-24	Coffee consumption (cups per day);
LIHC	cis	rs7568498	1.000	rs10164593	chr2:161981972	C/T	cg22496339	chr2:162101262	NA	-0.53	-6.04	-0.31	4.02e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	trans	rs9914544	0.678	rs28374894	chr17:18761659	C/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Educational attainment (years of education);
LIHC	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.61	0.56	3.24e-30	Electrocardiographic conduction measures;
LIHC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.65	12.69	0.57	1.71e-30	High light scatter reticulocyte count;
LIHC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.87	10.96	0.51	3.84e-24	Mean platelet volume;
LIHC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.44	6.04	0.31	4.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.36	-6.48	-0.33	3.3e-10	Coronary artery disease;
LIHC	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.78	-7.47	-0.37	6.69e-13	Diabetic retinopathy;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02034447	chr16:89574710	SPG7	0.48	7.44	0.37	8.18e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18252515	chr7:66147081	NA	0.44	5.87	0.3	1.05e-8	Aortic root size;
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.61	9.46	0.46	4.98e-19	Longevity;Endometriosis;
LIHC	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.31	0.32	8.86e-10	Morning vs. evening chronotype;
LIHC	cis	rs2191566	0.664	rs4482396	chr19:44562000	C/T	cg20607764	chr19:44506953	ZNF230	-0.37	-6.15	-0.32	2.19e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.73	-12.14	-0.55	1.84e-28	Body mass index;
LIHC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.26	0.37	2.61e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.35	-6.1	-0.31	2.9e-9	Schizophrenia;
LIHC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.36	-6.53	-0.33	2.39e-10	Aortic root size;
LIHC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	1.09	11.36	0.52	1.33e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21545522	chr1:205238299	TMCC2	0.31	5.93	0.31	7.3e-9	Red blood cell count;
LIHC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg15691649	chr6:25882328	NA	-0.43	-6.27	-0.32	1.06e-9	Blood metabolite levels;
LIHC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.68	13.41	0.59	2.94e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.8	0.35	4.65e-11	Systolic blood pressure;
LIHC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.4	-0.37	1.06e-12	Platelet distribution width;
LIHC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.95	13.09	0.58	5.31e-32	Heart rate;
LIHC	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.34	-7.31	-0.37	1.86e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07305463	chr2:136567211	LCT	-0.38	-5.9	-0.3	8.86e-9	Corneal structure;
LIHC	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-0.94	-15.9	-0.65	5.45e-43	Longevity;
LIHC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.56	8.13	0.4	8.07e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.29	0.49	8.41e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.34	6.66	0.34	1.12e-10	Multiple system atrophy;
LIHC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.71	-9.8	-0.47	3.75e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.02	15.66	0.65	4.93e-42	Breast cancer;
LIHC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.62	8.97	0.44	1.95e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.35	5.83	0.3	1.26e-8	Monocyte count;
LIHC	cis	rs2645424	0.635	rs6980952	chr8:11716473	C/G	cg21281001	chr8:11725306	CTSB	-0.47	-7.48	-0.38	6.26e-13	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
LIHC	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.58	-8.56	-0.42	3.86e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.93	-9.34	-0.45	1.29e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.72	-7.59	-0.38	3.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.58	-10.29	-0.49	8.43e-22	Platelet distribution width;
LIHC	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-7.99	-0.4	2.03e-14	Colorectal cancer;
LIHC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-7.25	-0.36	2.89e-12	Schizophrenia;
LIHC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.68	0.34	9.42e-11	Height;
LIHC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.31	-0.45	1.65e-18	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06514377	chr2:3320918	TSSC1	0.41	6.05	0.31	3.76e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.9	0.54	1.53e-27	High light scatter reticulocyte count;
LIHC	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.51	-0.33	2.67e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg20607798	chr8:58055168	NA	0.48	6.01	0.31	4.7e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16958440	0.867	rs59217333	chr18:44694844	A/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.69	8.8	0.43	6.79e-17	Initial pursuit acceleration;
LIHC	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.68	-10.14	-0.48	2.71e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs11955398	0.647	rs57521726	chr5:59984897	A/T	cg02684056	chr5:59996105	DEPDC1B	0.44	6.25	0.32	1.23e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.3	0.49	7.65e-22	Colorectal cancer;
LIHC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs78049276	0.736	rs72957606	chr4:148400011	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-7.79	-0.39	8.15e-14	Pulse pressure;
LIHC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.57	0.38	3.47e-13	IgG glycosylation;
LIHC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.13	0.44	6.13e-18	IgG glycosylation;
LIHC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.29	6.71	0.34	8.2e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.52	0.53	3.69e-26	Prudent dietary pattern;
LIHC	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	trans	rs17513961	1.000	rs17513961	chr7:46392567	G/T	cg26298814	chr3:33259889	SUSD5	0.66	6.12	0.31	2.59e-9	Treatment response for severe sepsis;
LIHC	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.27	5.71	0.3	2.42e-8	Pulmonary function;
LIHC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg01518246	chr11:63870912	FLRT1;MACROD1	0.42	5.89	0.3	9.46e-9	Mean platelet volume;
LIHC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg05110241	chr16:68378359	PRMT7	-0.61	-6.77	-0.34	5.71e-11	Schizophrenia;
LIHC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.69	12.86	0.57	3.85e-31	Mortality in heart failure;
LIHC	cis	rs4407350	0.967	rs4522715	chr22:44922347	G/A	cg26276947	chr22:44892394	LDOC1L	0.35	6.35	0.32	6.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.74	7.74	0.39	1.13e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.52	-6.51	-0.33	2.6e-10	Major depressive disorder;
LIHC	cis	rs4742903	0.935	rs17237053	chr9:106946359	C/T	cg14250997	chr9:106856677	SMC2	-0.37	-6.44	-0.33	4.12e-10	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.42	0.37	9.56e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06943149	chr12:77157476	ZDHHC17	0.39	6.56	0.33	2.02e-10	Cognitive function;
LIHC	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg27205649	chr11:78285834	NARS2	0.39	5.94	0.31	7.15e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.44	0.37	8.29e-13	Bone mineral density;
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.63	9.71	0.46	7.86e-20	Renal cell carcinoma;
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.45e-10	Prudent dietary pattern;
LIHC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.37	0.45	1e-18	Total body bone mineral density;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.27	0.41	3.07e-15	Height;
LIHC	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.35	-0.32	6.87e-10	HDL cholesterol;
LIHC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg18279126	chr7:2041391	MAD1L1	0.37	5.74	0.3	2.12e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs11229555	0.645	rs12283414	chr11:58176920	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	5.82e-9	Menopause (age at onset);
LIHC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.65	10.29	0.49	7.96e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08280861	chr8:58055591	NA	0.5	6.1	0.31	2.89e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-12.05	-0.55	4.29e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2019216	0.967	rs1877500	chr17:21886233	T/C	cg22648282	chr17:21454238	C17orf51	-0.34	-5.83	-0.3	1.31e-8	Pelvic organ prolapse;
LIHC	cis	rs10949834	0.793	rs810534	chr7:73505045	A/G	cg07137043	chr7:73588983	EIF4H	0.56	6.15	0.32	2.11e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.27	0.61	1.37e-36	Myeloid white cell count;
LIHC	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg25344623	chr2:136566232	LCT	-0.33	-5.71	-0.3	2.4e-8	Corneal structure;
LIHC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.37	-5.82	-0.3	1.36e-8	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg03647239	chr10:116582469	FAM160B1	0.42	6.18	0.32	1.87e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg23283495	chr1:209979779	IRF6	0.36	6.09	0.31	3.01e-9	Monobrow;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs943466	1.000	rs943466	chr6:33731787	A/G	cg25922239	chr6:33757077	LEMD2	0.43	6.02	0.31	4.52e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-28.58	-0.84	1.21e-92	Myeloid white cell count;
LIHC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg22834771	chr12:69754056	YEATS4	-0.47	-8.2	-0.41	5.05e-15	Blood protein levels;
LIHC	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.35	-6.34	-0.32	7.18e-10	Blood pressure (smoking interaction);
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg00800038	chr16:89945340	TCF25	-0.6	-9.78	-0.47	4.42e-20	Skin colour saturation;
LIHC	cis	rs526821	0.595	rs608964	chr11:55339266	G/A	cg04317927	chr11:55418816	OR4S2	0.47	8.99	0.44	1.66e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg26031613	chr14:104095156	KLC1	0.92	9.22	0.45	3.22e-18	Body mass index;
LIHC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	2.97e-23	Bladder cancer;
LIHC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg11764359	chr7:65958608	NA	0.58	5.98	0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.37	-5.74	-0.3	2.12e-8	Alzheimer's disease (survival time);
LIHC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.78	-12.84	-0.57	4.6e-31	Breast cancer;
LIHC	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Corneal astigmatism;
LIHC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg20283391	chr11:68216788	NA	-0.38	-5.95	-0.31	6.45e-9	Bone mineral density (spine);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03802069	chr3:137482593	SOX14	0.44	6.07	0.31	3.45e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.98	-0.4	2.2e-14	Response to antipsychotic treatment;
LIHC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg19682013	chr15:45996608	NA	0.42	7.31	0.37	1.95e-12	Waist circumference;Weight;
LIHC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.64	8.51	0.42	5.41e-16	Gut microbiome composition (summer);
LIHC	cis	rs2257205	0.667	rs75982345	chr17:56708836	T/C	cg12560992	chr17:57184187	TRIM37	0.63	6.1	0.31	2.94e-9	Pancreatic cancer;
LIHC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.81	12.51	0.56	7.67e-30	Breast cancer;
LIHC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.45	-7.13	-0.36	6.15e-12	Morning vs. evening chronotype;
LIHC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.21	11.49	0.53	4.56e-26	Uric acid levels;
LIHC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg06742321	chr12:123595122	PITPNM2	0.32	6.02	0.31	4.43e-9	Platelet count;
LIHC	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.53	5.73	0.3	2.21e-8	IgG glycosylation;
LIHC	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg15192750	chr16:69999425	NA	0.44	6.73	0.34	7.17e-11	IgE levels;
LIHC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	6.61	0.34	1.49e-10	Axial length;
LIHC	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-7.84	-0.39	5.92e-14	Electrocardiographic conduction measures;
LIHC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg15832292	chr6:96025679	MANEA	0.7	8.71	0.43	1.32e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4716602	0.596	rs12698432	chr7:156158719	C/G	cg16983916	chr7:156159713	NA	0.32	5.87	0.3	1.02e-8	Anti-saccade response;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02711724	chr8:130877076	FAM49B	-0.42	-6.05	-0.31	3.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16958440	0.867	rs58061761	chr18:44686165	T/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.37	-5.83	-0.3	1.27e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg00792783	chr2:198669748	PLCL1	0.42	6.11	0.31	2.67e-9	Dermatomyositis;
LIHC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.67	8.56	0.42	4e-16	Initial pursuit acceleration;
LIHC	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.37	9.92	0.47	1.47e-20	Weight;
LIHC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg15848620	chr12:58087721	OS9	-0.52	-7.08	-0.36	8.2e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg19635926	chr16:89946313	TCF25	0.56	7.48	0.37	6.53e-13	Skin colour saturation;
LIHC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.59	8.45	0.42	8.27e-16	Lung cancer;
LIHC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.36	7.4	0.37	1.09e-12	Renal cell carcinoma;
LIHC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg15123519	chr2:136567270	LCT	0.44	8.69	0.43	1.48e-16	Mosquito bite size;
LIHC	cis	rs72627509	0.680	rs3733309	chr4:57857188	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.63	-9.05	-0.44	1.11e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg19155557	chr3:41240643	CTNNB1	0.53	7.04	0.36	1.07e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg09795085	chr6:101329169	ASCC3	-0.47	-6.22	-0.32	1.43e-9	Neuroticism;
LIHC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.76	0.34	6.09e-11	Gut microbiome composition (summer);
LIHC	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-8.6	-0.42	2.94e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-6.53	-0.33	2.4e-10	Height;
LIHC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.84	-0.35	3.7e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.11e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.63	-0.34	1.29e-10	IgG glycosylation;
LIHC	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.66	-0.34	1.07e-10	Diastolic blood pressure;
LIHC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.39	-0.33	5.54e-10	Tonsillectomy;
LIHC	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02985541	chr2:219472218	PLCD4	0.43	7.91	0.39	3.66e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg02290350	chr8:58132656	NA	0.33	7.04	0.36	1.06e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg10360323	chr17:41437877	NA	0.4	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-9.21	-0.45	3.25e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs16837677	1.000	rs78365002	chr1:156716689	G/A	cg19377421	chr1:156697041	ISG20L2;C1orf66	0.63	6.23	0.32	1.37e-9	Sjögren's syndrome;
LIHC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.54	-18.33	-0.7	9.37e-53	Breast cancer;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.6	-8.85	-0.43	4.8e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.41	6.56	0.33	1.94e-10	Menarche (age at onset);
LIHC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.84e-9	Aortic root size;
LIHC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.05	0.31	3.78e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.51	-8.4	-0.41	1.18e-15	Mean corpuscular volume;
LIHC	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg22771759	chr13:24902376	NA	0.33	6.66	0.34	1.1e-10	Obesity-related traits;
LIHC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.36	0.33	6.47e-10	Major depressive disorder;
LIHC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg03962019	chr1:41807865	NA	0.5	7.34	0.37	1.53e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.66	0.34	1.12e-10	Response to antipsychotic treatment;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.24	0.58	1.32e-32	Prudent dietary pattern;
LIHC	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.72	-0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.4	-10.47	-0.49	1.96e-22	Asthma (sex interaction);
LIHC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.61	6.99	0.35	1.48e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6442522	0.640	rs2655258	chr3:15525894	A/G	cg16303742	chr3:15540471	COLQ	0.4	6.4	0.33	5.05e-10	Uric acid levels;
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.78	0.34	5.19e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	cis	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg27432699	chr2:27873401	GPN1	0.46	6.84	0.35	3.7e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.39	-6.89	-0.35	2.61e-11	Crohn's disease;
LIHC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-7.68	-0.38	1.64e-13	Personality dimensions;
LIHC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs2257205	0.667	rs7342841	chr17:56916156	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-6.67	-0.34	1.05e-10	Pancreatic cancer;
LIHC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.22	0.52	4.19e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	0.91	16.75	0.67	2.13e-46	Bone mineral density;
LIHC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-9.23	-0.45	2.91e-18	Mean corpuscular volume;
LIHC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.59	8.76	0.43	9.33e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs867371	1.000	rs8042464	chr15:82465536	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.05	-0.36	1e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7116495	1.000	rs517837	chr11:71802359	A/G	cg26138937	chr11:71823887	C11orf51	-0.77	-7.42	-0.37	9.42e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	1.23	11.09	0.51	1.24e-24	Obesity-related traits;
LIHC	cis	rs10751667	0.557	rs4077531	chr11:1013167	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	10.79	0.5	1.45e-23	Alzheimer's disease (late onset);
LIHC	cis	rs10242455	0.571	rs41279866	chr7:99315276	C/T	cg18809830	chr7:99032528	PTCD1	-0.86	-6.72	-0.34	7.74e-11	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.23	0.55	9.21e-29	Motion sickness;
LIHC	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.83	16.09	0.66	9.46e-44	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg19318889	chr4:1322082	MAEA	0.46	6.48	0.33	3.24e-10	Obesity-related traits;
LIHC	cis	rs8081395	0.603	rs1292047	chr17:57955166	C/T	cg02344993	chr17:57696989	CLTC	0.45	7.54	0.38	4.26e-13	White blood cell count;
LIHC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-11.09	-0.51	1.23e-24	Chronic sinus infection;
LIHC	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.58	9.58	0.46	2.02e-19	Corneal astigmatism;
LIHC	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg25364880	chr3:44379878	C3orf23	0.52	7.06	0.36	9.51e-12	Depressive symptoms;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg27411370	chr8:25316735	KCTD9;CDCA2	-0.5	-6.14	-0.32	2.33e-9	Preeclampsia;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	23.89	0.79	6.71e-75	Prudent dietary pattern;
LIHC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.53	8.67	0.42	1.73e-16	Total body bone mineral density;
LIHC	cis	rs507080	0.961	rs660489	chr11:118549964	C/A	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.07e-22	Hypertriglyceridemia;
LIHC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.11	0.51	1.11e-24	Motion sickness;
LIHC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.09e-10	Bipolar disorder;
LIHC	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.61	-0.42	2.76e-16	Waist circumference;Body mass index;
LIHC	trans	rs6489882	0.902	rs1981557	chr12:113372866	G/C	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.42	7.22	0.36	3.35e-12	Aortic root size;
LIHC	trans	rs4596713	0.507	rs9314865	chr9:71801495	A/G	cg16512924	chr15:28394682	HERC2	0.38	6.17	0.32	1.94e-9	Headache;
LIHC	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25216538	chr4:6925470	TBC1D14	0.44	6.82	0.35	4.07e-11	Bilirubin levels;
LIHC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12463550	chr7:65579703	CRCP	0.69	7.12	0.36	6.23e-12	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08280861	chr8:58055591	NA	0.49	6.17	0.32	1.9e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.65	-7.0	-0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.57	-0.42	3.57e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.08e-8	Coronary artery disease;
LIHC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.89	-0.3	9.2e-9	Body mass index;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg00864860	chr1:7907996	UTS2	0.61	5.89	0.3	9.21e-9	Inflammatory bowel disease;
LIHC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.41	6.58	0.34	1.81e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.96	-0.44	2.11e-17	Blood metabolite levels;
LIHC	cis	rs4700695	0.925	rs4700693	chr5:65399078	A/G	cg21114390	chr5:65439923	SFRS12	-0.46	-6.06	-0.31	3.66e-9	Facial morphology (factor 19);
LIHC	trans	rs67539049	1.000	rs73546312	chr8:11302709	G/A	cg21071117	chr11:124747075	ROBO3	-0.38	-6.14	-0.32	2.33e-9	Itch intensity from mosquito bite;
LIHC	cis	rs3814113	0.586	rs10962662	chr9:16889937	C/A	cg13173848	chr9:16870893	BNC2	-0.71	-8.69	-0.43	1.48e-16	Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;
LIHC	cis	rs1853665	0.623	rs56363137	chr6:150287154	G/C	cg16301758	chr6:150275521	NA	-0.46	-6.31	-0.32	8.66e-10	Radiation response;
LIHC	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg23682824	chr7:23144976	KLHL7	0.39	5.83	0.3	1.26e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.13	-0.66	6.34e-44	Diabetic kidney disease;
LIHC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.55	8.5	0.42	5.96e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg22834771	chr12:69754056	YEATS4	-0.45	-7.29	-0.37	2.19e-12	Response to diuretic therapy;
LIHC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.88	-0.43	3.78e-17	Skin colour saturation;
LIHC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg06466757	chr4:1255808	NA	0.35	5.88	0.3	1e-8	Obesity-related traits;
LIHC	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs10916814	0.610	rs4655223	chr1:20901688	C/G	cg24502330	chr1:20914028	CDA	-0.32	-6.85	-0.35	3.52e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24583131	chr6:18265189	DEK	0.43	6.71	0.34	8.2e-11	Cognitive function;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.6	8.85	0.43	4.74e-17	Prudent dietary pattern;
LIHC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg13409248	chr3:40428643	ENTPD3	0.41	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.36	5.91	0.3	8.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.99e-10	Personality dimensions;
LIHC	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-7.13	-0.36	5.88e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg20240347	chr1:204465584	NA	-0.34	-7.23	-0.36	3.15e-12	Schizophrenia;
LIHC	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.48	7.96	0.4	2.51e-14	Schizophrenia;
LIHC	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.57	-13.99	-0.6	1.79e-35	White blood cell count (basophil);
LIHC	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.56	10.3	0.49	7.81e-22	Lewy body disease;
LIHC	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.04	-20.11	-0.74	6.25e-60	Exhaled nitric oxide output;
LIHC	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg03037974	chr15:76606532	NA	0.63	10.8	0.5	1.39e-23	Blood metabolite levels;
LIHC	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.12	0.4	8.51e-15	IgG glycosylation;
LIHC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.83	10.86	0.51	8.58e-24	Cognitive function;
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg05697976	chr12:29376483	FAR2	0.31	6.3	0.32	9.14e-10	QT interval;
LIHC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.61	7.14	0.36	5.75e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.44	8.34	0.41	1.82e-15	Schizophrenia;
LIHC	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg19752551	chr11:57585705	CTNND1	-0.47	-6.49	-0.33	2.97e-10	Schizophrenia;
LIHC	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg25627403	chr19:41769009	HNRNPUL1	-0.55	-6.8	-0.35	4.66e-11	Coronary artery disease;
LIHC	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-0.9	-9.03	-0.44	1.28e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg04013166	chr16:89971882	TCF25	0.52	6.46	0.33	3.55e-10	Skin colour saturation;
LIHC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.9	14.17	0.61	3.42e-36	Metabolic syndrome;
LIHC	cis	rs61677309	0.964	rs60652614	chr11:118168543	G/T	cg06090739	chr11:118230722	UBE4A	0.34	6.29	0.32	9.96e-10	Lung cancer in ever smokers;
LIHC	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02985541	chr2:219472218	PLCD4	-0.39	-6.52	-0.33	2.58e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4650994	0.593	rs28445692	chr1:178511892	G/C	cg05350800	chr1:178550844	NA	-0.33	-7.11	-0.36	6.87e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.89	-0.3	9.44e-9	Body mass index;
LIHC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.78	-13.53	-0.59	1.05e-33	Coronary artery disease;
LIHC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg13840445	chr6:53530628	KLHL31	-0.86	-5.74	-0.3	2.11e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.36	-6.58	-0.34	1.74e-10	Aortic root size;
LIHC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.89	-0.3	9.22e-9	Life satisfaction;
LIHC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg13175981	chr1:150552382	MCL1	-0.44	-6.16	-0.32	2.07e-9	Tonsillectomy;
LIHC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg27478167	chr7:817139	HEATR2	-0.51	-6.82	-0.35	4.1e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	7.51	0.38	5.26e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs16828019	0.852	rs3904243	chr1:41574852	T/G	cg03962019	chr1:41807865	NA	0.5	7.22	0.36	3.33e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg25344623	chr2:136566232	LCT	-0.43	-8.85	-0.43	4.86e-17	Mosquito bite size;
LIHC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.87	-9.75	-0.47	5.67e-20	Vitiligo;
LIHC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.45	5.75	0.3	2.02e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg16724585	chr3:197361211	NA	0.44	6.25	0.32	1.2e-9	Pancreatic cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07085156	chr10:64959524	JMJD1C	-0.28	-6.37	-0.33	6.12e-10	Calcium levels;
LIHC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08280861	chr8:58055591	NA	0.52	5.87	0.3	1.01e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg26939375	chr7:64535504	NA	0.41	6.47	0.33	3.36e-10	Aortic root size;
LIHC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.54	6.49	0.33	3.01e-10	Bipolar disorder;
LIHC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg20569855	chr1:109824440	PSRC1	0.49	6.55	0.33	2.12e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.66	0.34	1.1e-10	Dupuytren's disease;
LIHC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.39	-0.49	3.83e-22	Platelet count;
LIHC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	0.87	11.96	0.54	8.55e-28	Post bronchodilator FEV1;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg09521871	chr19:3752665	APBA3	-0.38	-6.12	-0.31	2.53e-9	Calcium levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17979863	chr2:231852034	NA	0.41	6.49	0.33	3.06e-10	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14022721	chr22:25507536	KIAA1671	0.46	6.93	0.35	2.1e-11	Pancreatic cancer;
LIHC	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.65	6.53	0.33	2.35e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	7.91	0.39	3.63e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg25214090	chr10:38739885	LOC399744	0.44	6.99	0.35	1.42e-11	Diastolic blood pressure;
LIHC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.53	-0.49	1.24e-22	Chronic sinus infection;
LIHC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs2412488	0.893	rs7686876	chr4:54281075	C/T	cg22241045	chr4:54363911	LNX1	-0.41	-6.71	-0.34	8.15e-11	DNA methylation (variation);
LIHC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg06565975	chr8:143823917	SLURP1	0.33	6.19	0.32	1.69e-9	Urinary tract infection frequency;
LIHC	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.7	14.78	0.62	1.42e-38	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.42	-7.14	-0.36	5.79e-12	Monocyte count;
LIHC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-9.11	-0.44	6.82e-18	Blood metabolite levels;
LIHC	cis	rs12365397	0.569	rs1353465	chr11:43242587	A/G	cg16667275	chr11:43333495	API5	-0.38	-5.76	-0.3	1.87e-8	Migraine;
LIHC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.27	-6.69	-0.34	9.31e-11	Mean corpuscular volume;
LIHC	trans	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg09045935	chr12:6379348	NA	0.84	6.92	0.35	2.28e-11	Blood metabolite levels;
LIHC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg26980034	chr6:53530624	KLHL31	-0.86	-5.78	-0.3	1.66e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.24	-6.53	-0.33	2.41e-10	Type 2 diabetes;
LIHC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.34	-7.2	-0.36	3.84e-12	Bone mineral density;
LIHC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.52	-8.29	-0.41	2.66e-15	Uric acid clearance;
LIHC	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.37	-6.48	-0.33	3.29e-10	Asthma;
LIHC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.13e-14	Neuroticism;
LIHC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.4	7.6	0.38	2.91e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg25182066	chr10:30743637	MAP3K8	0.58	9.06	0.44	1.02e-17	Inflammatory bowel disease;
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27297192	chr10:134578999	INPP5A	0.52	7.02	0.35	1.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04460041	chr16:2293178	DCI	0.43	6.17	0.32	1.89e-9	Longevity;
LIHC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.57	-8.68	-0.42	1.61e-16	High light scatter reticulocyte count;
LIHC	cis	rs7502590	0.920	rs56084168	chr17:79084574	C/T	cg02064366	chr17:79045526	BAIAP2	0.54	6.49	0.33	3.1e-10	Neuroticism;
LIHC	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg26138144	chr22:38071188	LGALS1	0.42	7.76	0.39	9.63e-14	Fat distribution (HIV);
LIHC	cis	rs8016982	0.632	rs7142641	chr14:81677454	A/G	cg01989461	chr14:81687754	GTF2A1	0.53	9.24	0.45	2.77e-18	Schizophrenia;
LIHC	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.74	-0.34	6.59e-11	Neuroticism;
LIHC	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.11	-0.31	2.7e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.5	0.38	5.5e-13	Aortic root size;
LIHC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-1.0	-17.38	-0.68	6.17e-49	Monocyte percentage of white cells;
LIHC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.62	-9.36	-0.45	1.1e-18	Colorectal cancer;
LIHC	cis	rs7095607	0.606	rs6480313	chr10:69957928	C/T	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.64e-9	Lung function (FVC);
LIHC	cis	rs3015497	0.616	rs6572678	chr14:51090115	T/G	cg09863266	chr14:51125203	SAV1	-0.39	-6.18	-0.32	1.85e-9	Mean platelet volume;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18769103	chr1:236445447	ERO1LB	-0.5	-6.59	-0.34	1.66e-10	Systolic blood pressure;
LIHC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4684776	0.935	rs4684067	chr3:11408873	G/C	cg00170343	chr3:11313890	ATG7	-0.45	-6.2	-0.32	1.64e-9	Small vessel stroke;
LIHC	trans	rs800082	0.768	rs2222702	chr3:144258814	T/A	cg24215973	chr2:240111563	HDAC4	0.44	6.26	0.32	1.15e-9	Smoking behavior;
LIHC	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.18	0.44	4.06e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.91	-0.3	8.23e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg27253887	chr6:149867208	PPIL4	-0.54	-6.08	-0.31	3.29e-9	Response to hepatitis C treatment;
LIHC	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.62	11.49	0.53	4.61e-26	Airflow obstruction;
LIHC	cis	rs16858210	0.607	rs953419	chr3:183585883	C/T	cg25686905	chr3:183603175	PARL	0.45	8.11	0.4	9.4e-15	Menopause (age at onset);
LIHC	trans	rs7916441	1.000	rs1815314	chr10:80928793	C/T	cg19914578	chr14:75530481	ACYP1	-0.48	-6.25	-0.32	1.19e-9	Height;Sitting height ratio;
LIHC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.24	-0.36	3.03e-12	Body mass index;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.31	2.73e-9	Mean corpuscular volume;
LIHC	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.58	-8.34	-0.41	1.79e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.72	-11.73	-0.54	6.04e-27	Oral cavity cancer;
LIHC	cis	rs10106298	1.000	rs4734654	chr8:103669991	A/G	cg10187029	chr8:103597600	NA	0.53	6.93	0.35	2.13e-11	Schizophrenia;
LIHC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.57	7.97	0.4	2.43e-14	Bladder cancer;
LIHC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.2	-0.52	5.02e-25	Hemoglobin concentration;
LIHC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.97e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.35	-8.2	-0.41	4.96e-15	Educational attainment (years of education);
LIHC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg24296786	chr1:45957014	TESK2	-0.39	-5.88	-0.3	9.53e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-1.01	-10.79	-0.5	1.49e-23	Breast cancer;
LIHC	cis	rs17739167	0.550	rs2665213	chr15:42234265	T/G	cg20935245	chr15:42234343	EHD4	-0.42	-7.82	-0.39	6.41e-14	Monocyte count;
LIHC	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg16070123	chr10:51489643	NA	-0.38	-5.94	-0.31	7.02e-9	Prostate-specific antigen levels;
LIHC	cis	rs6695567	0.869	rs1679941	chr1:53614976	A/G	cg20326410	chr1:53600821	SLC1A7	0.27	5.86	0.3	1.1e-8	Systemic lupus erythematosus;
LIHC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.53	8.7	0.43	1.41e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	0.98	10.55	0.5	1e-22	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs3106136	0.678	rs11944992	chr4:95298176	G/A	cg11021082	chr4:95130006	SMARCAD1	0.36	6.13	0.31	2.4e-9	Capecitabine sensitivity;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01145284	chr2:10580628	ODC1	0.4	6.26	0.32	1.16e-9	Longevity;
LIHC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg10790698	chr19:18539756	SSBP4	-0.37	-7.68	-0.38	1.66e-13	Breast cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24196351	chr3:149182962	NA	0.42	6.05	0.31	3.74e-9	Bilirubin levels;
LIHC	cis	rs7223966	0.655	rs9906924	chr17:61634538	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	5.9	0.3	8.81e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.72	-0.34	7.44e-11	Protein biomarker;
LIHC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg17385448	chr1:15911702	AGMAT	-0.33	-5.83	-0.3	1.25e-8	Systolic blood pressure;
LIHC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	9.55	0.46	2.64e-19	Response to bleomycin (chromatid breaks);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03373091	chr22:38902403	DDX17	-0.44	-6.78	-0.34	5.33e-11	Pancreatic cancer;
LIHC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.45	-9.07	-0.44	9.18e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.97	18.14	0.7	5.46e-52	Breast cancer;
LIHC	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.13	-0.44	6.31e-18	Bipolar disorder;
LIHC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.12	0.52	1.03e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	7.15	0.36	5.41e-12	Protein C levels;
LIHC	trans	rs9641123	0.609	rs982457	chr7:93209963	C/T	cg09745688	chr16:2908918	PRSS22	-0.36	-6.21	-0.32	1.57e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.82	-0.3	1.32e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg03037974	chr15:76606532	NA	0.78	15.75	0.65	2.13e-42	Blood metabolite levels;
LIHC	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.7	-0.34	8.45e-11	Migraine;Coronary artery disease;
LIHC	cis	rs1256061	0.669	rs1256065	chr14:64698932	G/T	cg23250157	chr14:64679961	SYNE2	0.4	5.83	0.3	1.29e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg02993280	chr1:107599747	PRMT6	-0.71	-11.61	-0.53	1.65e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.58	-8.77	-0.43	8.49e-17	Prostate cancer;
LIHC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.38e-27	Lymphocyte counts;
LIHC	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.11	-0.31	2.68e-9	Tuberculosis;
LIHC	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.79	-9.11	-0.44	6.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16684958	chr7:75615977	POR	-0.51	-8.5	-0.42	6.02e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.84e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.52	-8.17	-0.4	6.09e-15	Height;
LIHC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.49	7.54	0.38	4.29e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8084351	0.599	rs2000696	chr18:50706382	G/A	cg24270629	chr18:50823537	DCC	-0.43	-6.24	-0.32	1.26e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-0.82	-14.76	-0.62	1.74e-38	Exhaled nitric oxide output;
LIHC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.97	-0.51	3.48e-24	Primary sclerosing cholangitis;
LIHC	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.22	-5.99	-0.31	5.23e-9	Type 2 diabetes;
LIHC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg17724175	chr1:150552817	MCL1	-0.33	-6.15	-0.32	2.15e-9	Tonsillectomy;
LIHC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.4	7.03	0.36	1.15e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.56	9.49	0.46	4.04e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.68	11.24	0.52	3.84e-25	Mean platelet volume;
LIHC	cis	rs2070433	0.799	rs7279002	chr21:47910523	C/T	cg12379764	chr21:47803548	PCNT	-0.6	-8.9	-0.43	3.29e-17	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.26	-0.45	2.3e-18	Diabetic kidney disease;
LIHC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg05425664	chr17:57184151	TRIM37	-0.4	-5.79	-0.3	1.59e-8	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21448741	chr8:58168803	NA	0.33	6.0	0.31	4.9e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.87	15.84	0.65	8.87e-43	Dental caries;
LIHC	cis	rs3761218	0.668	rs6052079	chr20:3774209	G/T	cg25011176	chr20:3776985	CDC25B	-0.44	-6.22	-0.32	1.42e-9	Bipolar disorder;
LIHC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.12	0.55	2.35e-28	Cognitive test performance;
LIHC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.55	7.69	0.38	1.55e-13	Post bronchodilator FEV1;
LIHC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	21.25	0.75	1.75e-64	Chronic sinus infection;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.73	-10.92	-0.51	5.09e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.7	9.0	0.44	1.62e-17	Body mass index;
LIHC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.27	0.52	3e-25	Hemoglobin concentration;
LIHC	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	12.14	0.55	1.89e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-9.25	-0.45	2.45e-18	Schizophrenia;
LIHC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19524238	chr7:2802976	GNA12	-0.4	-5.89	-0.3	9.15e-9	Height;
LIHC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	8.09	0.4	1.05e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20197516	chr17:80373348	C17orf101	0.37	6.32	0.32	8.31e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.82	-11.88	-0.54	1.71e-27	Diastolic blood pressure;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg02018802	chr2:220362948	GMPPA	0.46	6.53	0.33	2.42e-10	Alopecia areata;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.76	10.84	0.51	9.55e-24	Menarche (age at onset);
LIHC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	10.67	0.5	3.98e-23	Menopause (age at onset);
LIHC	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.49	-8.91	-0.43	3e-17	Atrioventricular conduction;
LIHC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.42	-6.93	-0.35	2.11e-11	Blood pressure (smoking interaction);
LIHC	cis	rs1023500	1.000	rs6002552	chr22:42338351	G/A	cg04733989	chr22:42467013	NAGA	-0.5	-5.93	-0.31	7.53e-9	Schizophrenia;
LIHC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.56	7.22	0.36	3.44e-12	Parkinson's disease;
LIHC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11878675	chr2:74211845	NA	-0.44	-6.48	-0.33	3.12e-10	Cognitive function;
LIHC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.49	-9.3	-0.45	1.75e-18	Body mass index;
LIHC	cis	rs3770081	1.000	rs3770081	chr2:86280925	G/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.46	6.34	0.32	7.3e-10	Facial emotion recognition (sad faces);
LIHC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.61	0.56	3.36e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg03037974	chr15:76606532	NA	0.8	16.63	0.67	6.35e-46	Blood metabolite levels;
LIHC	cis	rs611744	0.905	rs640950	chr8:109157819	T/A	cg18478394	chr8:109455254	TTC35	0.35	5.87	0.3	1.05e-8	Dupuytren's disease;
LIHC	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	8.9	0.43	3.3e-17	Initial pursuit acceleration;
LIHC	cis	rs4450131	1.000	rs4450131	chr10:126383363	C/T	cg20435097	chr10:126320824	FAM53B	0.49	8.97	0.44	2.05e-17	White blood cell count (basophil);
LIHC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.53	-6.3	-0.32	8.92e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg04610667	chr7:75704037	NA	0.35	6.25	0.32	1.23e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg00071026	chr13:113650936	MCF2L	-0.37	-5.73	-0.3	2.2e-8	Systolic blood pressure;
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.3	-5.87	-0.3	1.04e-8	Tonsillectomy;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04324509	chr3:101295624	PCNP	0.4	6.35	0.32	6.77e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14205524	chr15:42787946	SNAP23	-0.46	-7.31	-0.37	1.88e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg02297831	chr4:17616191	MED28	0.44	6.24	0.32	1.26e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	7.0	0.35	1.34e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-0.85	-10.68	-0.5	3.62e-23	Blood pressure (smoking interaction);
LIHC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg07061783	chr6:25882402	NA	-0.42	-6.06	-0.31	3.62e-9	Blood metabolite levels;
LIHC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg17279839	chr7:150038598	RARRES2	-0.58	-11.8	-0.54	3.54e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2412488	0.853	rs6838260	chr4:54355824	C/T	cg22241045	chr4:54363911	LNX1	-0.4	-6.54	-0.33	2.22e-10	DNA methylation (variation);
LIHC	cis	rs4742903	0.967	rs10820600	chr9:106856692	T/C	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.35	-0.61	6.85e-37	Systemic lupus erythematosus;
LIHC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.23	-7.16	-0.36	4.92e-12	Motion sickness;
LIHC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg13271783	chr10:134563150	INPP5A	-0.59	-7.13	-0.36	5.92e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg26338869	chr17:61819248	STRADA	0.53	7.21	0.36	3.73e-12	Height;
LIHC	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg16673477	chr19:18812017	CRTC1	0.43	7.19	0.36	3.99e-12	Menarche (age at onset);
LIHC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16262614	chr3:133464971	TF	0.28	6.29	0.32	9.91e-10	Iron status biomarkers;
LIHC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-6.58	-0.34	1.81e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.48	-8.3	-0.41	2.51e-15	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.44	-7.75	-0.39	1.04e-13	Aortic root size;
LIHC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.57	8.48	0.42	7.1e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg15192750	chr16:69999425	NA	0.47	7.05	0.36	9.97e-12	IgE levels;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.51	-5.84	-0.3	1.23e-8	Ulcerative colitis;
LIHC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg03146154	chr1:46216737	IPP	-0.39	-6.37	-0.33	6.12e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.71	8.28	0.41	2.8e-15	Dental caries;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03044510	chr21:27107978	ATP5J;GABPA	-0.44	-6.63	-0.34	1.28e-10	Pancreatic cancer;
LIHC	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg18941641	chr10:78392320	NA	0.26	5.76	0.3	1.83e-8	Pulmonary function;
LIHC	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg10621924	chr7:39171070	POU6F2	0.4	6.32	0.32	8.26e-10	IgG glycosylation;
LIHC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg24977027	chr2:88469347	THNSL2	-0.34	-5.9	-0.3	8.69e-9	Response to metformin (IC50);
LIHC	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.6	-0.34	1.53e-10	Metabolite levels;
LIHC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.59	7.87	0.39	4.73e-14	Blood metabolite levels;
LIHC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.55	-9.04	-0.44	1.18e-17	Blood metabolite levels;
LIHC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.81	0.67	1.23e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7106204	0.513	rs2165784	chr11:24249360	C/A	ch.11.24196551F	chr11:24239977	NA	0.83	12.0	0.54	6.57e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.17	0.81	7.78e-80	Chronic sinus infection;
LIHC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.96	9.22	0.45	3.12e-18	Eosinophil percentage of granulocytes;
LIHC	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	6.03	0.31	4.14e-9	Schizophrenia;
LIHC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	10.16	0.48	2.3e-21	Personality dimensions;
LIHC	cis	rs62458065	1.000	rs79538247	chr7:32467792	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.64	-7.07	-0.36	8.98e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg00280220	chr17:61926910	NA	0.42	6.87	0.35	2.99e-11	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06128509	chr10:91461539	KIF20B	0.44	6.71	0.34	8.26e-11	Cognitive function;
LIHC	cis	rs882732	0.947	rs3762123	chr14:95029163	A/G	cg14866387	chr14:95027382	SERPINA4	-0.44	-6.45	-0.33	3.86e-10	Blood protein levels;
LIHC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.89	-0.3	9.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg01652190	chr22:50026171	C22orf34	-0.31	-6.98	-0.35	1.51e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.2	0.32	1.62e-9	Ulcerative colitis;
LIHC	trans	rs61931739	0.711	rs7968821	chr12:34318351	G/A	cg26384229	chr12:38710491	ALG10B	0.45	6.13	0.31	2.42e-9	Morning vs. evening chronotype;
LIHC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.89	0.3	9.33e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.11	-0.4	8.86e-15	Morning vs. evening chronotype;
LIHC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-9.88	-0.47	2.04e-20	Tonsillectomy;
LIHC	cis	rs1144333	0.655	rs1146649	chr1:76268803	A/G	cg22875332	chr1:76189707	ACADM	-0.44	-6.76	-0.34	5.87e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.93	8.86	0.43	4.36e-17	Eosinophil percentage of granulocytes;
LIHC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.61	0.53	1.69e-26	Monocyte percentage of white cells;
LIHC	cis	rs882732	1.000	rs3762122	chr14:95029351	A/T	cg14866387	chr14:95027382	SERPINA4	-0.44	-6.46	-0.33	3.59e-10	Blood protein levels;
LIHC	cis	rs1865721	0.728	rs67357037	chr18:73219024	G/T	cg26385618	chr18:73139727	C18orf62	-0.27	-6.98	-0.35	1.54e-11	Intelligence;
LIHC	cis	rs9918079	0.542	rs1789	chr4:15664535	G/A	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.21	-0.32	1.54e-9	Obesity-related traits;
LIHC	cis	rs12611088	0.932	rs1799778	chr19:44059141	G/T	cg13740135	chr19:44006432	PHLDB3	0.4	5.72	0.3	2.3e-8	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.47	7.55	0.38	4.09e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.03	-0.31	4.33e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04221910	chr5:616842	CEP72	0.41	7.28	0.37	2.28e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.86	0.35	3.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg00204748	chr12:29376779	FAR2	0.38	7.03	0.36	1.16e-11	QT interval;
LIHC	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg02023728	chr11:77925099	USP35	0.33	6.0	0.31	4.91e-9	Alzheimer's disease (survival time);
LIHC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.31	-0.37	1.95e-12	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	trans	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg10756647	chr7:56101905	PSPH	0.63	8.62	0.42	2.51e-16	Corneal structure;
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.54	8.23	0.41	4e-15	Longevity;
LIHC	cis	rs867186	0.614	rs77221305	chr20:33452040	T/C	cg08999081	chr20:33150536	PIGU	0.64	5.8	0.3	1.49e-8	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.84	-0.54	2.51e-27	Alzheimer's disease;
LIHC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.58	-7.59	-0.38	3.09e-13	Initial pursuit acceleration;
LIHC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg10935138	chr17:73851978	WBP2	0.49	7.26	0.37	2.57e-12	White matter hyperintensity burden;
LIHC	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg20503657	chr10:835505	NA	0.64	5.75	0.3	1.93e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg04998671	chr14:104000505	TRMT61A	-0.43	-5.73	-0.3	2.19e-8	Coronary artery disease;
LIHC	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.71	-15.75	-0.65	2.12e-42	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.5	9.62	0.46	1.5e-19	Prostate cancer;
LIHC	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.89	0.54	1.6e-27	Colorectal cancer;
LIHC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.52	-0.38	4.8e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8010715	0.816	rs7153156	chr14:24598846	A/G	cg23112188	chr14:24563095	PCK2	-0.29	-6.08	-0.31	3.25e-9	IgG glycosylation;
LIHC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	0.78	5.94	0.31	6.97e-9	IgG glycosylation;
LIHC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.52e-9	Vitamin D levels;
LIHC	cis	rs7116495	1.000	rs7101701	chr11:71762155	A/G	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs4728302	0.869	rs10231102	chr7:133573310	G/A	cg10665199	chr7:133106180	EXOC4	0.35	6.11	0.31	2.77e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.56	-0.38	3.62e-13	QT interval;
LIHC	cis	rs3736485	0.934	rs4143721	chr15:51866781	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.3e-9	Aortic root size;
LIHC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.8	9.56	0.46	2.48e-19	Bladder cancer;
LIHC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.24	0.52	3.7e-25	Personality dimensions;
LIHC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.65	-9.23	-0.45	2.99e-18	Vitamin D levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13530817	chr7:72951610	BCL7B	-0.41	-6.18	-0.32	1.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs895636	0.848	rs2840037	chr2:45189872	G/A	cg16198908	chr2:45192207	NA	0.39	5.94	0.31	6.97e-9	Metabolite levels;Fasting plasma glucose;
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.73	13.2	0.58	1.95e-32	Prudent dietary pattern;
LIHC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg08213375	chr14:104286397	PPP1R13B	0.52	9.89	0.47	1.85e-20	Schizophrenia;
LIHC	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.7	-10.21	-0.48	1.51e-21	Eosinophil percentage of white cells;
LIHC	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.26	5.94	0.31	6.95e-9	Heart rate;
LIHC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.49	0.59	1.47e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.64	10.75	0.5	2.12e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.45	0.33	3.89e-10	Facial emotion recognition (sad faces);
LIHC	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.56	-6.19	-0.32	1.69e-9	Educational attainment;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05908079	chr5:64065005	SDCCAG10;SFRS12IP1	-0.5	-6.53	-0.33	2.44e-10	Systolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02010524	chr4:57333365	SRP72	0.46	6.04	0.31	3.95e-9	Pancreatic cancer;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.62	8.97	0.44	2e-17	Menarche (age at onset);
LIHC	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg16589663	chr20:23618590	CST3	0.75	7.64	0.38	2.28e-13	Chronic kidney disease;
LIHC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.7	11.2	0.52	4.96e-25	Oral cavity cancer;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7188697	0.922	rs11862156	chr16:58596753	C/T	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs3814231	0.531	rs12771689	chr10:115467068	A/G	cg24846397	chr10:115438155	CASP7	-0.43	-7.18	-0.36	4.34e-12	Vitiligo;
LIHC	cis	rs7872515	0.887	rs10820937	chr9:94840206	T/C	cg01248375	chr9:94877805	SPTLC1	0.56	8.23	0.41	4.04e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.59	-10.13	-0.48	2.93e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg00750074	chr16:89608354	SPG7	-0.4	-6.03	-0.31	4.15e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13409248	chr3:40428643	ENTPD3	0.51	8.39	0.41	1.28e-15	Renal cell carcinoma;
LIHC	trans	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg10756647	chr7:56101905	PSPH	1.05	12.6	0.56	3.63e-30	Diabetic kidney disease;
LIHC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.41	4.57e-15	Morning vs. evening chronotype;
LIHC	cis	rs12744310	1.000	rs57529969	chr1:41771683	G/A	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9420	0.528	rs10896632	chr11:57390302	G/A	cg19752551	chr11:57585705	CTNND1	-0.47	-6.12	-0.31	2.59e-9	Schizophrenia;
LIHC	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg06565975	chr8:143823917	SLURP1	-0.31	-5.89	-0.3	9.24e-9	Urinary tract infection frequency;
LIHC	trans	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg01134436	chr17:81009848	B3GNTL1	0.82	6.92	0.35	2.19e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs6466055	0.777	rs10953470	chr7:104871892	G/T	cg04380332	chr7:105027541	SRPK2	0.36	6.84	0.35	3.56e-11	Schizophrenia;
LIHC	cis	rs6942756	0.774	rs6946288	chr7:129004277	A/G	cg02491457	chr7:128862824	NA	-0.54	-8.21	-0.41	4.45e-15	White matter hyperintensity burden;
LIHC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg07599136	chr5:415885	AHRR	0.74	11.89	0.54	1.65e-27	Fat distribution (HIV);
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27297192	chr10:134578999	INPP5A	0.54	7.52	0.38	5e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.54	7.67	0.38	1.75e-13	Platelet count;
LIHC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00598335	chr8:11627530	NEIL2	-0.4	-5.88	-0.3	9.85e-9	Triglycerides;
LIHC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.34	-0.49	5.46e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.45	6.32	0.32	8.06e-10	Obesity-related traits;
LIHC	cis	rs546131	0.642	rs568529	chr11:34842506	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.55	7.16	0.36	5.1e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.04	-0.48	5.98e-21	Response to antipsychotic treatment;
LIHC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-10.24	-0.48	1.17e-21	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.86	8.94	0.44	2.49e-17	Inflammatory bowel disease;
LIHC	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg26138144	chr22:38071188	LGALS1	0.72	10.53	0.49	1.17e-22	Fat distribution (HIV);
LIHC	cis	rs600806	0.714	rs2781552	chr1:110025881	A/G	cg08911820	chr1:110026001	ATXN7L2	0.55	6.8	0.35	4.67e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.02e-16	Height;
LIHC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg19680672	chr10:131412579	MGMT	-0.44	-6.89	-0.35	2.76e-11	Response to temozolomide;
LIHC	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.56	10.94	0.51	4.4e-24	Coronary artery disease;
LIHC	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.32	-6.21	-0.32	1.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.53	7.53	0.38	4.59e-13	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.33	14.33	0.61	8.06e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs2108622	0.727	rs12611308	chr19:15978586	C/T	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.87e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.88	-0.3	9.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg11062466	chr8:58055876	NA	-0.49	-7.4	-0.37	1.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.47	0.42	7.58e-16	Motion sickness;
LIHC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.51	-10.55	-0.5	1.05e-22	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	9.04e-33	Prudent dietary pattern;
LIHC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.45	7.27	0.37	2.4e-12	Platelet count;
LIHC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.8	9.02	0.44	1.43e-17	Vitiligo;
LIHC	cis	rs1475718	0.526	rs10785876	chr9:137122767	C/G	cg21243944	chr9:137118148	NA	-0.45	-6.28	-0.32	1e-9	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-8.8	-0.43	7e-17	Chronic sinus infection;
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg00204748	chr12:29376779	FAR2	0.42	7.83	0.39	6.32e-14	QT interval;
LIHC	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.62	-12.31	-0.55	4.33e-29	Migraine;
LIHC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.65	13.0	0.58	1.15e-31	Schizophrenia;
LIHC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.59	-9.3	-0.45	1.74e-18	Dental caries;
LIHC	cis	rs72772090	0.708	rs17082200	chr5:96048604	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.47	-5.78	-0.3	1.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12611088	0.965	rs3810378	chr19:44081601	C/G	cg13740135	chr19:44006432	PHLDB3	-0.39	-5.73	-0.3	2.26e-8	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs778371	0.671	rs13008436	chr2:233719948	C/T	cg08000102	chr2:233561755	GIGYF2	-0.8	-9.37	-0.45	9.9e-19	Schizophrenia;
LIHC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.13e-14	Neuroticism;
LIHC	trans	rs675026	0.926	rs604844	chr6:154454973	C/T	cg11601662	chr7:30066256	FKBP14	-0.49	-6.11	-0.31	2.73e-9	Hypertension;
LIHC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.7	0.34	8.59e-11	Bipolar disorder;
LIHC	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.45	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	11.85	0.54	2.26e-27	Cognitive test performance;
LIHC	cis	rs7160336	0.515	rs7152352	chr14:74611271	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	-0.4	-5.76	-0.3	1.86e-8	Blood protein levels;
LIHC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.21	-0.36	3.61e-12	Personality dimensions;
LIHC	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg05926928	chr17:57297772	GDPD1	0.56	7.27	0.37	2.46e-12	Opioid sensitivity;
LIHC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.66	10.7	0.5	3.11e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg02990361	chr1:107599529	PRMT6	-0.66	-10.94	-0.51	4.5e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs116248771	0.739	rs4680456	chr3:158397842	C/T	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.32e-10	diarrhoeal disease at age 2;
LIHC	cis	rs61712019	0.679	rs1997526	chr2:77713329	G/C	cg11252801	chr2:77748917	LRRTM4	0.55	7.57	0.38	3.46e-13	Schizophrenia;
LIHC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	ch.11.42038R	chr11:967971	AP2A2	-0.53	-9.76	-0.47	5.2e-20	Alzheimer's disease (late onset);
LIHC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.9	-0.3	8.55e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.77	-13.25	-0.58	1.25e-32	Aortic root size;
LIHC	cis	rs4742903	0.904	rs2417487	chr9:106887581	A/G	cg14250997	chr9:106856677	SMC2	0.41	7.28	0.37	2.31e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg09222892	chr1:25734099	RHCE	-0.47	-8.69	-0.43	1.58e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.46	-7.08	-0.36	8.32e-12	Height;
LIHC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg05973401	chr12:123451056	ABCB9	0.45	6.21	0.32	1.56e-9	Neutrophil percentage of white cells;
LIHC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.67	7.01	0.35	1.31e-11	Schizophrenia;
LIHC	cis	rs9814567	0.752	rs4955468	chr3:134340850	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-8.87	-0.43	4.03e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.44	6.09	0.31	3.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.66	11.73	0.54	6.38e-27	High light scatter reticulocyte count;
LIHC	cis	rs6782228	0.565	rs11719239	chr3:128419054	A/G	cg16766828	chr3:128327626	NA	-0.38	-5.98	-0.31	5.54e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-6.06	-0.31	3.65e-9	Eosinophil percentage of white cells;
LIHC	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.4	5.73	0.3	2.15e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg14222432	chr12:29376421	FAR2	-0.34	-6.74	-0.34	6.84e-11	QT interval;
LIHC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.71	-13.88	-0.6	4.88e-35	Body mass index;
LIHC	cis	rs243505	0.660	rs10274535	chr7:148543525	A/G	cg09806900	chr7:148480153	CUL1	0.43	6.07	0.31	3.49e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.64e-11	Aortic root size;
LIHC	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.75	0.39	1.04e-13	Lung cancer;
LIHC	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.37	6.14	0.32	2.24e-9	Lewy body disease;
LIHC	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.48	8.89	0.43	3.67e-17	Testicular germ cell tumor;
LIHC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.74	12.06	0.55	3.84e-28	Body mass index;
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.49	7.58	0.38	3.24e-13	Testicular germ cell tumor;
LIHC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.67	-9.19	-0.44	3.94e-18	Longevity;
LIHC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-11.15	-0.52	7.97e-25	Mean corpuscular volume;
LIHC	cis	rs7793919	0.726	rs4720401	chr7:4780943	G/A	cg09789173	chr7:4769017	FOXK1	0.73	10.54	0.5	1.13e-22	Mosquito bite size;
LIHC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.86	-0.3	1.09e-8	Total body bone mineral density;
LIHC	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg21466736	chr12:48725269	NA	-0.55	-7.35	-0.37	1.43e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs3736485	0.966	rs11070856	chr15:51853817	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.5	6.72	0.34	7.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg27432699	chr2:27873401	GPN1	-0.49	-7.07	-0.36	8.55e-12	Total body bone mineral density;
LIHC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg00339695	chr16:24857497	SLC5A11	0.32	5.87	0.3	1.03e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-10.38	-0.49	4.08e-22	Asthma;
LIHC	trans	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg04373760	chr16:53404718	NA	0.59	7.59	0.38	3.1e-13	Hypertriglyceridemia;
LIHC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	trans	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.6e-9	Coronary artery disease;
LIHC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.8	13.11	0.58	4.45e-32	Parkinson's disease;
LIHC	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg15893493	chr8:124194847	FAM83A	0.89	8.31	0.41	2.26e-15	Urinary uromodulin levels;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.4	0.81	1.02e-80	Prudent dietary pattern;
LIHC	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.78	10.4	0.49	3.41e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg03934865	chr2:198174659	NA	0.54	8.73	0.43	1.14e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.6	8.14	0.4	7.2e-15	Bone mineral density (spine);
LIHC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.62	9.36	0.45	1.12e-18	Subjective well-being;
LIHC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs600806	0.745	rs12136063	chr1:110014170	A/G	cg23091122	chr1:110024289	SYPL2	0.4	5.72	0.3	2.36e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg16586182	chr3:47516702	SCAP	-0.58	-10.97	-0.51	3.34e-24	Colorectal cancer;
LIHC	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.23	-0.32	1.35e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.57	7.4	0.37	1.07e-12	Bone mineral density (spine);
LIHC	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.53	-8.22	-0.41	4.16e-15	Waist circumference;Body mass index;
LIHC	cis	rs3820500	0.543	rs6676578	chr1:117968957	G/A	cg20383390	chr1:117909022	MAN1A2	0.46	5.92	0.3	7.76e-9	Pneumonia;
LIHC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.15	-0.44	5.19e-18	Ulcerative colitis;
LIHC	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.67	-0.42	1.82e-16	Colorectal cancer;
LIHC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.64	7.89	0.39	4.03e-14	Heart rate;
LIHC	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	0.37	5.79	0.3	1.55e-8	Coronary artery disease;
LIHC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.8	13.41	0.59	3.01e-33	Psoriasis;
LIHC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg23533926	chr12:111358616	MYL2	-0.32	-6.12	-0.31	2.61e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-0.84	-10.48	-0.49	1.75e-22	Blood pressure (smoking interaction);
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.51	7.21	0.36	3.59e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg00529422	chr1:16285251	ZBTB17	-0.34	-6.66	-0.34	1.09e-10	Systolic blood pressure;
LIHC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.64	6.34	0.32	7.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	8.91	0.43	3.19e-17	Menarche (age at onset);
LIHC	cis	rs507080	0.733	rs552079	chr11:118573022	T/C	cg04173919	chr11:118528438	PHLDB1	0.32	6.02	0.31	4.44e-9	Serum metabolite levels;
LIHC	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	0.93	11.38	0.52	1.13e-25	Post bronchodilator FEV1;
LIHC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.18	-0.36	4.29e-12	Body mass index;
LIHC	cis	rs7619427	0.915	rs7625849	chr3:44079200	G/A	cg24966902	chr3:44043705	NA	0.51	7.19	0.36	4.09e-12	Schizophrenia;
LIHC	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg21123203	chr4:15471301	CC2D2A	-0.47	-7.83	-0.39	6.07e-14	Obesity-related traits;
LIHC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg00864860	chr1:7907996	UTS2	0.58	5.85	0.3	1.17e-8	Inflammatory bowel disease;
LIHC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg03983715	chr16:68378420	PRMT7	-0.53	-6.18	-0.32	1.79e-9	Schizophrenia;
LIHC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.54	-7.05	-0.36	1.02e-11	Pancreatic cancer;
LIHC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.51	9.05	0.44	1.11e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.19e-12	HDL cholesterol levels;
LIHC	cis	rs2108622	1.000	rs62107762	chr19:15982538	C/G	cg13772218	chr19:15982569	NA	0.41	8.53	0.42	4.66e-16	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg01864836	chr14:55583639	NA	-0.43	-8.14	-0.4	7.49e-15	Protein biomarker;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17791867	chr7:112579927	C7orf60	0.45	6.81	0.35	4.35e-11	Cognitive function;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22704915	chr10:73079101	SLC29A3	-0.45	-6.09	-0.31	3.01e-9	Longevity;
LIHC	trans	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg16011800	chr17:1958478	HIC1	-0.53	-7.47	-0.37	6.95e-13	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.96	-0.31	6.44e-9	Total body bone mineral density;
LIHC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.53	-7.19	-0.36	4.2e-12	Pancreatic cancer;
LIHC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg07713946	chr22:31675144	LIMK2	-0.43	-7.72	-0.39	1.28e-13	Colorectal cancer;
LIHC	cis	rs7129220	0.512	rs7936409	chr11:10086260	A/C	cg01453529	chr11:10209919	SBF2	-0.4	-7.0	-0.35	1.32e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs17106184	1.000	rs72904771	chr1:51393412	A/G	cg07174182	chr1:51127561	FAF1	-0.75	-7.9	-0.39	3.96e-14	Type 2 diabetes;
LIHC	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.79	-0.34	4.9e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.43	6.49	0.33	2.97e-10	Height;
LIHC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.34	0.52	1.64e-25	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.66	-10.88	-0.51	7.36e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.43	6.17	0.32	1.97e-9	Blood protein levels;
LIHC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.61	-8.59	-0.42	3.14e-16	Blood metabolite levels;
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.44	-7.28	-0.37	2.37e-12	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.39	0.37	1.15e-12	Obesity-related traits;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.66	12.3	0.55	4.94e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2637266	0.655	rs846595	chr10:78531300	C/T	cg18941641	chr10:78392320	NA	0.28	6.12	0.31	2.52e-9	Pulmonary function;
LIHC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.16	-0.32	2.1e-9	Colorectal cancer;
LIHC	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.4	7.6	0.38	2.91e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-0.96	-22.67	-0.77	4.29e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.42	6.26	0.32	1.14e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.6	8.43	0.41	9.62e-16	Morning vs. evening chronotype;
LIHC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	10.28	0.49	8.94e-22	Resting heart rate;
LIHC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	7.12	0.36	6.32e-12	Body mass index;
LIHC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.12	11.56	0.53	2.54e-26	Opioid sensitivity;
LIHC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	9.47	0.46	4.71e-19	Alzheimer's disease (late onset);
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.84e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25521047	chr19:37341219	ZNF345	0.42	6.37	0.33	5.98e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.97	-0.35	1.65e-11	IgG glycosylation;
LIHC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.84	-9.3	-0.45	1.71e-18	Vitiligo;
LIHC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.42	6.96	0.35	1.76e-11	Red blood cell count;
LIHC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.45	7.74	0.39	1.14e-13	Mean corpuscular volume;
LIHC	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-0.86	-5.78	-0.3	1.71e-8	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.23	-15.85	-0.65	8.1e-43	Diabetic kidney disease;
LIHC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.5	0.69	2.02e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.45	6.61	0.34	1.5e-10	Dermatomyositis;
LIHC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.53	8.38	0.41	1.38e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-9.97	-0.47	1.01e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg22532475	chr10:104410764	TRIM8	-0.34	-6.34	-0.32	7.41e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.79	-12.23	-0.55	8.49e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg16346588	chr10:242978	ZMYND11	-0.47	-5.84	-0.3	1.2e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg18225595	chr11:63971243	STIP1	0.59	5.76	0.3	1.85e-8	Mean platelet volume;
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg16482183	chr6:26056742	HIST1H1C	0.36	5.73	0.3	2.24e-8	Height;
LIHC	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.09	-0.4	1.04e-14	Colorectal cancer;
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.5	-6.83	-0.35	3.78e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.73	0.62	2.3e-38	Prudent dietary pattern;
LIHC	cis	rs546131	0.642	rs7131074	chr11:34839105	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	1.08	10.66	0.5	4.13e-23	Eosinophil percentage of granulocytes;
LIHC	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22546437	chr19:47987707	KPTN	0.45	6.26	0.32	1.16e-9	Pancreatic cancer;
LIHC	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-6.65	-0.34	1.15e-10	Mosquito bite size;
LIHC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.43	6.83	0.35	3.92e-11	Red blood cell count;
LIHC	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.73	0.3	2.26e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.99	-0.35	1.43e-11	Longevity;Endometriosis;
LIHC	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.32	-6.71	-0.34	8.11e-11	Platelet distribution width;
LIHC	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.39	6.39	0.33	5.56e-10	Bone mineral density;
LIHC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.37	0.59	4.28e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.62	-0.38	2.51e-13	Metabolite levels;
LIHC	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	9.77	0.47	4.63e-20	Response to antipsychotic treatment;
LIHC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg13753209	chr17:57696993	CLTC	0.72	11.22	0.52	4.32e-25	Hemoglobin concentration;
LIHC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg06565975	chr8:143823917	SLURP1	-0.43	-7.4	-0.37	1.07e-12	Urinary tract infection frequency;
LIHC	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.43	6.89	0.35	2.65e-11	Response to antidepressants and depression;
LIHC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.6	10.93	0.51	4.83e-24	Mean corpuscular volume;
LIHC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.15	-0.4	6.88e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.59	-8.56	-0.42	3.92e-16	Testicular germ cell tumor;
LIHC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.87	-0.3	1.01e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.54	7.58	0.38	3.18e-13	Lymphocyte counts;
LIHC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg03854865	chr6:26224070	HIST1H3E	0.64	7.15	0.36	5.46e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.65	0.34	1.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg14593290	chr7:50529359	DDC	-0.45	-7.43	-0.37	8.79e-13	Malaria;
LIHC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.53	-6.78	-0.34	5.19e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.48	7.0	0.35	1.37e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.45	-0.33	3.93e-10	Diabetic kidney disease;
LIHC	cis	rs16828019	0.929	rs12037037	chr1:41698256	C/T	cg20697417	chr1:41786797	NA	0.34	6.51	0.33	2.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.76	9.01	0.44	1.49e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs7577696	0.597	rs56322034	chr2:32353013	T/C	cg02381751	chr2:32503542	YIPF4	-0.45	-6.2	-0.32	1.62e-9	Inflammatory biomarkers;
LIHC	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg19683494	chr5:74908142	NA	0.49	6.58	0.34	1.76e-10	Age-related disease endophenotypes;
LIHC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg23352942	chr3:46931381	PTH1R	0.24	6.06	0.31	3.66e-9	Birth weight;
LIHC	cis	rs12144044	0.701	rs2999159	chr1:113230758	A/G	cg22162597	chr1:113214053	CAPZA1	-0.7	-8.35	-0.41	1.73e-15	Glomerular filtration rate (creatinine);
LIHC	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.58	-9.56	-0.46	2.37e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3015497	0.789	rs10133849	chr14:51121700	A/G	cg09863266	chr14:51125203	SAV1	-0.42	-6.73	-0.34	7.35e-11	Mean platelet volume;
LIHC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.45	6.51	0.33	2.64e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg05425664	chr17:57184151	TRIM37	-0.46	-5.76	-0.3	1.83e-8	Vitamin D levels;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-14.43	-0.62	3.29e-37	Prudent dietary pattern;
LIHC	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.31	6.16	0.32	2.02e-9	Cancer;
LIHC	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg22771759	chr13:24902376	NA	0.33	6.93	0.35	2.07e-11	Obesity-related traits;
LIHC	cis	rs797680	0.856	rs9432681	chr1:93761896	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	0.34	6.06	0.31	3.5e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.99	0.6	1.73e-35	Coffee consumption (cups per day);
LIHC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg20933634	chr6:27740509	NA	0.48	6.26	0.32	1.15e-9	Parkinson's disease;
LIHC	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	6.95	0.35	1.83e-11	Blood protein levels;
LIHC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.47	-0.33	3.46e-10	Renal cell carcinoma;
LIHC	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	11.15	0.52	7.94e-25	Colorectal cancer;
LIHC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.41	6.18	0.32	1.8e-9	Eosinophil percentage of white cells;
LIHC	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.53	-7.35	-0.37	1.49e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LIHC	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.31	0.49	7.15e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-9.67	-0.46	1e-19	Electroencephalogram traits;
LIHC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.46	-7.8	-0.39	7.5e-14	Lung cancer;
LIHC	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg26831259	chr4:1366826	KIAA1530	0.35	5.79	0.3	1.63e-8	Obesity-related traits;
LIHC	cis	rs8084351	0.599	rs12454147	chr18:50707053	G/T	cg24270629	chr18:50823537	DCC	-0.43	-6.32	-0.32	8.15e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.94	-0.35	2e-11	IgG glycosylation;
LIHC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg12698662	chr3:15914712	MIR563	-0.37	-6.89	-0.35	2.64e-11	Mean platelet volume;
LIHC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg11861562	chr11:117069780	TAGLN	0.47	7.7	0.38	1.48e-13	Blood protein levels;
LIHC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.55	0.38	4.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.4	0.41	1.21e-15	Eosinophil percentage of white cells;
LIHC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg24209194	chr3:40518798	ZNF619	0.48	7.12	0.36	6.53e-12	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06096824	chr1:51443952	NA	-0.45	-6.1	-0.31	2.86e-9	Pancreatic cancer;
LIHC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg27386326	chr11:61587980	NA	0.7	14.83	0.63	9.05e-39	LDL cholesterol;
LIHC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.14	0.36	5.79e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg00209037	chr22:46443395	NA	0.65	8.14	0.4	7.37e-15	Dupuytren's disease;
LIHC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.58	5.72	0.3	2.3e-8	Neutrophil percentage of white cells;
LIHC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	15.13	0.63	5.95e-40	Menarche (age at onset);
LIHC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.44	5.78	0.3	1.68e-8	Subjective well-being;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20278634	chr1:36274212	EIF2C4	-0.53	-6.48	-0.33	3.11e-10	Systolic blood pressure;
LIHC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs17106184	0.892	rs72900928	chr1:51103180	T/G	cg07174182	chr1:51127561	FAF1	-0.65	-7.04	-0.36	1.03e-11	Type 2 diabetes;
LIHC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.68	-0.42	1.69e-16	Skin colour saturation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14347670	chr6:41908995	CCND3	0.41	6.68	0.34	9.48e-11	Cognitive function;
LIHC	trans	rs6489882	0.607	rs4767033	chr12:113364382	T/A	cg10175203	chr3:128143634	NA	0.39	6.39	0.33	5.57e-10	Chronic lymphocytic leukemia;
LIHC	trans	rs7504990	0.722	rs12958987	chr18:50359002	G/T	cg08535148	chr4:26321143	RBPJ	0.52	6.64	0.34	1.21e-10	Gallbladder cancer;
LIHC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.56	-7.82	-0.39	6.52e-14	Menopause (age at onset);
LIHC	cis	rs8020095	0.528	rs1044745	chr14:67800815	G/A	cg03487553	chr14:67822707	ATP6V1D	-0.35	-6.02	-0.31	4.55e-9	Depression (quantitative trait);
LIHC	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg22951263	chr5:87985283	NA	-0.41	-7.09	-0.36	7.72e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	5.9	0.3	8.78e-9	Platelet count;
LIHC	cis	rs539514	0.612	rs9573648	chr13:76309279	A/G	cg04757411	chr13:76259545	LMO7	-0.45	-8.06	-0.4	1.3e-14	Type 1 diabetes;
LIHC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.41	0.33	4.89e-10	Schizophrenia;
LIHC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.51	8.45	0.42	8.61e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20135002	chr11:47629003	NA	-0.53	-8.97	-0.44	1.94e-17	Subjective well-being;
LIHC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.63	10.23	0.48	1.35e-21	Resting heart rate;
LIHC	cis	rs240764	0.619	rs10872623	chr6:101165047	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-6.03	-0.31	4.27e-9	Neuroticism;
LIHC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	12.05	0.55	3.99e-28	High light scatter reticulocyte count;
LIHC	cis	rs55665837	0.540	rs12290926	chr11:14695046	A/G	cg25251204	chr11:14927456	NA	0.42	5.95	0.31	6.48e-9	Vitamin D levels;
LIHC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.76	9.89	0.47	1.91e-20	Selective IgA deficiency;
LIHC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.6	-8.61	-0.42	2.76e-16	Blood pressure (smoking interaction);
LIHC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.65	-7.06	-0.36	9.41e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.17	-0.36	4.54e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.57	-9.76	-0.47	5.37e-20	Blood metabolite levels;
LIHC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.61	9.13	0.44	6.16e-18	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg26338869	chr17:61819248	STRADA	-0.52	-7.12	-0.36	6.46e-12	Height;
LIHC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.58	8.19	0.41	5.15e-15	Bladder cancer;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.68	0.57	1.91e-30	Alzheimer's disease;
LIHC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.5	6.41	0.33	4.95e-10	Initial pursuit acceleration;
LIHC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.21e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg15123519	chr2:136567270	LCT	-0.37	-7.39	-0.37	1.14e-12	Mosquito bite size;
LIHC	cis	rs1866706	0.896	rs7945921	chr11:12875794	C/A	cg25843174	chr11:12811716	TEAD1	-0.29	-6.08	-0.31	3.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg10932868	chr11:921992	NA	0.39	7.31	0.37	1.89e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-8.47	-0.42	7.4e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.94	12.06	0.55	3.84e-28	HIV-1 control;
LIHC	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.57	0.38	3.6e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-7.7	-0.38	1.5e-13	Uric acid levels;
LIHC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.61	8.48	0.42	6.79e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-7.0	-0.35	1.35e-11	Hepatocellular carcinoma;
LIHC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.11	13.94	0.6	2.76e-35	Body mass index;
LIHC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.37	6.53	0.33	2.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.51	-6.66	-0.34	1.12e-10	Gut microbiome composition (summer);
LIHC	cis	rs965469	1.000	rs2092990	chr20:3346338	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.51	-0.33	2.73e-10	IFN-related cytopenia;
LIHC	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.44	-0.33	4.15e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.6	-10.04	-0.48	5.91e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.68	11.07	0.51	1.53e-24	Multiple myeloma (IgH translocation);
LIHC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.68e-14	Mean platelet volume;
LIHC	cis	rs903552	0.800	rs6598479	chr15:102005913	A/C	cg19295451	chr15:102010161	PCSK6	-0.5	-6.79	-0.34	5.09e-11	Diabetic kidney disease;
LIHC	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	10.62	0.5	6.05e-23	Lung cancer in ever smokers;
LIHC	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg04998671	chr14:104000505	TRMT61A	0.46	6.47	0.33	3.33e-10	Coronary artery disease;
LIHC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.69	12.16	0.55	1.55e-28	Colorectal cancer;
LIHC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.8	0.54	3.31e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs11212260	0.512	rs79797517	chr11:107173777	T/C	cg25435332	chr11:107328525	CWF19L2	0.73	6.69	0.34	9.13e-11	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	9.04e-33	Prudent dietary pattern;
LIHC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.07	0.31	3.39e-9	Tonsillectomy;
LIHC	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg00935119	chr6:36647544	CDKN1A	0.46	6.5	0.33	2.92e-10	QRS duration;
LIHC	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg12798992	chr6:167411361	FGFR1OP	0.44	6.8	0.34	4.81e-11	Primary biliary cholangitis;
LIHC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	7.99	0.4	2.09e-14	Menarche (age at onset);
LIHC	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.47	-9.13	-0.44	6.09e-18	LDL cholesterol levels;
LIHC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-8.29	-0.41	2.6e-15	Parkinson's disease;
LIHC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg23149560	chr2:74406255	MOBKL1B	0.41	5.74	0.3	2.05e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg10932868	chr11:921992	NA	0.39	7.31	0.37	1.89e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.94	-0.31	7.03e-9	Total body bone mineral density;
LIHC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg22834771	chr12:69754056	YEATS4	-0.4	-6.01	-0.31	4.64e-9	Response to diuretic therapy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24865495	chr11:63912769	MACROD1	-0.4	-6.21	-0.32	1.5e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2901460	0.509	rs12465313	chr2:62078301	G/A	cg02183531	chr2:62113199	CCT4	-0.42	-6.09	-0.31	3.09e-9	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12463550	chr7:65579703	CRCP	0.71	7.42	0.37	9.62e-13	Diabetic kidney disease;
LIHC	cis	rs9810089	0.708	rs619605	chr3:136087012	G/C	cg21827317	chr3:136751795	NA	0.43	5.84	0.3	1.22e-8	Gestational age at birth (child effect);
LIHC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg18944383	chr4:111397179	ENPEP	0.32	7.4	0.37	1.03e-12	Height;
LIHC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.33	0.32	7.76e-10	Major depressive disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19455953	chr2:207630073	FASTKD2;MDH1B	0.36	6.34	0.32	7.39e-10	Cognitive function;
LIHC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg14067834	chr17:29058358	SUZ12P	-0.62	-6.33	-0.32	7.89e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.3	0.37	2e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17183009	chr3:120277827	NA	0.52	6.08	0.31	3.18e-9	Corneal astigmatism;
LIHC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.58	-7.96	-0.4	2.62e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.52	6.64	0.34	1.23e-10	Initial pursuit acceleration;
LIHC	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.07	-0.31	3.47e-9	Educational attainment (college completion);
LIHC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg02079420	chr8:82753780	SNX16	-0.36	-6.64	-0.34	1.21e-10	Diastolic blood pressure;
LIHC	cis	rs1355223	0.902	rs34751755	chr11:34694243	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.07	-0.31	3.3e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg16434002	chr17:42200994	HDAC5	-0.53	-7.67	-0.38	1.78e-13	Total body bone mineral density;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.68	12.06	0.55	3.63e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.75	-0.47	5.45e-20	Chronic sinus infection;
LIHC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg17135325	chr3:160939158	NMD3	0.55	7.85	0.39	5.36e-14	Parkinson's disease;
LIHC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-5.72	-0.3	2.27e-8	Fibrinogen levels;
LIHC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.55	-0.46	2.64e-19	Obesity-related traits;
LIHC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg04511125	chr2:88470314	THNSL2	-0.42	-6.38	-0.33	5.63e-10	Response to metformin (IC50);
LIHC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.77	12.8	0.57	6.22e-31	Psoriasis;
LIHC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg08499158	chr17:42289980	UBTF	-0.48	-7.72	-0.39	1.33e-13	Total body bone mineral density;
LIHC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.57	7.83	0.39	6.11e-14	Bladder cancer;
LIHC	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-8.23	-0.41	4.08e-15	Parkinson's disease;
LIHC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.15	0.52	7.7e-25	Coronary artery disease;
LIHC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg03665457	chr10:38645376	HSD17B7P2	0.4	5.93	0.31	7.25e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg11812906	chr14:75593930	NEK9	0.38	5.88	0.3	9.97e-9	IgG glycosylation;
LIHC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.98	15.36	0.64	7.67e-41	Breast cancer;
LIHC	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.54	-10.41	-0.49	3.25e-22	Schizophrenia;
LIHC	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg19773385	chr1:10388646	KIF1B	-0.46	-7.54	-0.38	4.14e-13	Hepatocellular carcinoma;
LIHC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.7	9.03	0.44	1.26e-17	Body mass index;
LIHC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.54	7.8	0.39	7.46e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.53	7.49	0.38	6.06e-13	Pulse pressure;
LIHC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.04	-0.31	4.07e-9	Height;
LIHC	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.83	-9.57	-0.46	2.19e-19	Prostate cancer;
LIHC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-10.28	-0.49	8.58e-22	Type 2 diabetes;
LIHC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg10130564	chr11:117069849	TAGLN	0.35	6.0	0.31	4.89e-9	Blood protein levels;
LIHC	cis	rs238295	0.805	rs6085211	chr20:5552847	G/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.53	-7.19	-0.36	4.16e-12	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.86e-11	Dermatomyositis;
LIHC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	9.15	0.44	5.34e-18	Lung cancer;
LIHC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.26	0.68	1.94e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	8.87	0.43	4.28e-17	IgG glycosylation;
LIHC	cis	rs6669384	0.774	rs7551724	chr1:208030856	C/T	cg22525895	chr1:207977042	MIR29B2	-0.52	-6.05	-0.31	3.88e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg20476274	chr7:133979776	SLC35B4	0.71	11.76	0.54	4.65e-27	Mean platelet volume;
LIHC	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg23280166	chr11:118938394	VPS11	-0.44	-5.79	-0.3	1.62e-8	Coronary artery disease;
LIHC	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.89	16.31	0.66	1.16e-44	Menopause (age at onset);
LIHC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.64	6.72	0.34	7.68e-11	Gut microbiome composition (summer);
LIHC	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	0.85	10.0	0.48	7.79e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg04610667	chr7:75704037	NA	0.35	6.12	0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2191566	0.960	rs56171514	chr19:44506110	G/C	cg20607764	chr19:44506953	ZNF230	-0.38	-5.93	-0.31	7.43e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.32	5.82	0.3	1.36e-8	Diastolic blood pressure;
LIHC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.81	-13.49	-0.59	1.55e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4788570	0.584	rs11075898	chr16:71705215	T/C	cg06353428	chr16:71660113	MARVELD3	1.39	14.48	0.62	2.14e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.28	0.52	2.74e-25	Motion sickness;
LIHC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21467203	chr3:49911342	NA	0.37	6.44	0.33	4.06e-10	Menarche (age at onset);
LIHC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.34	-6.78	-0.34	5.26e-11	Homoarginine levels;
LIHC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.49	7.79	0.39	7.98e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.76	-0.3	1.92e-8	Menopause (age at onset);
LIHC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02244288	chr16:89573955	SPG7	-0.3	-5.76	-0.3	1.85e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.95	-0.47	1.15e-20	Response to antipsychotic treatment;
LIHC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.74	11.99	0.54	7.03e-28	Coronary artery disease;
LIHC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.41	-0.33	4.78e-10	Total body bone mineral density;
LIHC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	7.75	0.39	1.07e-13	Platelet count;
LIHC	cis	rs74233809	1.000	rs11191502	chr10:104765494	T/G	cg03493300	chr10:104813866	CNNM2	0.45	6.06	0.31	3.69e-9	Birth weight;
LIHC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.8	14.91	0.63	4.23e-39	Blood protein levels;
LIHC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg14906510	chr12:7781169	NA	0.48	7.38	0.37	1.25e-12	HDL cholesterol levels;
LIHC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.54	7.14	0.36	5.59e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.7	10.01	0.48	7.71e-21	Lymphocyte counts;
LIHC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.52	-9.23	-0.45	2.82e-18	Blood protein levels;
LIHC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg13856295	chr9:139396418	NOTCH1	-0.34	-5.74	-0.3	2.14e-8	Monocyte percentage of white cells;
LIHC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.5e-9	Aortic root size;
LIHC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-6.28	-0.32	1.01e-9	Body mass index;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08677398	chr8:58056175	NA	0.4	6.02	0.31	4.61e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3823572	0.504	rs2971977	chr7:133648347	C/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.85	-0.3	1.18e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.76	0.43	9.46e-17	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.11	-0.48	3.34e-21	Longevity;Endometriosis;
LIHC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-9.11	-0.44	7.24e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	12.0	0.54	6.38e-28	Response to antipsychotic treatment;
LIHC	cis	rs3820500	0.543	rs1289820	chr1:117921039	T/G	cg20383390	chr1:117909022	MAN1A2	0.44	5.75	0.3	1.93e-8	Pneumonia;
LIHC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg12160578	chr15:63334699	TPM1	0.6	8.58	0.42	3.46e-16	Platelet count;
LIHC	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.79	-17.59	-0.69	8.57e-50	Urate levels in lean individuals;
LIHC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg11764359	chr7:65958608	NA	-0.59	-6.13	-0.31	2.49e-9	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg00091569	chr3:40428383	ENTPD3	0.4	6.79	0.34	4.86e-11	Renal cell carcinoma;
LIHC	cis	rs965469	1.000	rs6051705	chr20:3253143	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.99	-0.35	1.44e-11	IFN-related cytopenia;
LIHC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.53	-6.48	-0.33	3.2e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.9e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.5	-6.71	-0.34	8.04e-11	Height;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.49	0.62	2.02e-37	Prudent dietary pattern;
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07424592	chr7:64974309	NA	0.44	6.75	0.34	6.28e-11	Calcium levels;
LIHC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.64	12.12	0.55	2.29e-28	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23228418	chr1:151119228	SEMA6C	0.58	7.76	0.39	9.67e-14	Hepatitis;
LIHC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.26	0.41	3.22e-15	Motion sickness;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg00091569	chr3:40428383	ENTPD3	0.35	6.05	0.31	3.74e-9	Renal cell carcinoma;
LIHC	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.59	8.88	0.43	3.95e-17	Recombination rate (females);
LIHC	cis	rs11098699	0.821	rs4833887	chr4:124208033	T/C	cg09941581	chr4:124220074	SPATA5	0.33	6.52	0.33	2.57e-10	Mosquito bite size;
LIHC	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	6.37	0.33	6.01e-10	Platelet distribution width;
LIHC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.42	-7.12	-0.36	6.42e-12	Educational attainment;
LIHC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	7.96	0.4	2.52e-14	Multiple sclerosis;
LIHC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg03264133	chr6:25882463	NA	-0.42	-6.26	-0.32	1.17e-9	Height;
LIHC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.79	-0.34	4.91e-11	Height;
LIHC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.5	-0.38	5.55e-13	Uric acid levels;
LIHC	cis	rs797680	0.856	rs11164876	chr1:93630510	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.35	-6.13	-0.31	2.46e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.52	-7.28	-0.37	2.31e-12	Menopause (age at onset);
LIHC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.3	6.3	0.32	9.1e-10	Bone mineral density;
LIHC	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	1.0	18.52	0.71	1.54e-53	Coronary artery disease;
LIHC	cis	rs244293	0.637	rs6504945	chr17:52999956	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-6.94	-0.35	2.02e-11	Menarche (age at onset);
LIHC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.19	-18.27	-0.7	1.61e-52	Type 1 diabetes nephropathy;
LIHC	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.63	-0.34	1.34e-10	Metabolite levels;
LIHC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.95	0.31	6.79e-9	Electroencephalogram traits;
LIHC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.53	-9.49	-0.46	4.23e-19	Lung cancer in ever smokers;
LIHC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.72	7.52	0.38	4.86e-13	Vitiligo;
LIHC	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg00012203	chr2:219082015	ARPC2	-0.44	-5.88	-0.3	9.98e-9	Ulcerative colitis;
LIHC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.71	0.43	1.36e-16	Cognitive test performance;
LIHC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.22	-0.36	3.41e-12	Monocyte percentage of white cells;
LIHC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.26	-6.2	-0.32	1.58e-9	Subjective well-being;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24051152	chr8:145133159	EXOSC4	0.4	6.06	0.31	3.59e-9	Cognitive function;
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.68	-8.07	-0.4	1.19e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.51	8.23	0.41	4.08e-15	Schizophrenia;
LIHC	cis	rs611744	0.967	rs594405	chr8:109193607	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg18944383	chr4:111397179	ENPEP	0.27	6.95	0.35	1.82e-11	Height;
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg04013166	chr16:89971882	TCF25	0.6	7.85	0.39	5.58e-14	Skin colour saturation;
LIHC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.54	10.31	0.49	6.89e-22	Sense of smell;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg02993280	chr1:107599747	PRMT6	-0.7	-11.29	-0.52	2.49e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.87	-0.39	4.63e-14	Psoriasis;
LIHC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.38e-27	Lymphocyte counts;
LIHC	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg22705602	chr4:152727874	NA	-0.31	-6.53	-0.33	2.38e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.52	6.87	0.35	3.02e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma (childhood onset);
LIHC	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.75	-0.47	5.67e-20	Colorectal cancer;
LIHC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg15017067	chr4:17643749	FAM184B	0.33	5.74	0.3	2.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	cis	rs920590	0.679	rs4577973	chr8:19658017	A/G	cg01411142	chr8:19674711	INTS10	0.43	6.5	0.33	2.76e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.6	10.53	0.49	1.17e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-8.65	-0.42	2.01e-16	Gut microbiome composition (summer);
LIHC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-8.71	-0.43	1.28e-16	Vitamin D levels;
LIHC	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	1.14	9.17	0.44	4.47e-18	Gut microbiota (bacterial taxa);
LIHC	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.27	-13.85	-0.6	6.39e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.64	7.3	0.37	2.1e-12	Influenza A (H1N1) severity;
LIHC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg05425664	chr17:57184151	TRIM37	0.42	6.04	0.31	4.13e-9	Testicular germ cell tumor;
LIHC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-7.77	-0.39	9.08e-14	Bipolar disorder;
LIHC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.72	0.39	1.29e-13	Electroencephalogram traits;
LIHC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.01	15.28	0.64	1.49e-40	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08535374	chr1:110679730	NA	0.51	7.06	0.36	9.17e-12	Pancreatic cancer;
LIHC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	10.28	0.49	8.93e-22	Platelet count;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg04024499	chr13:25860865	MTMR6	0.46	7.58	0.38	3.37e-13	Calcium levels;
LIHC	cis	rs6466055	0.720	rs4730072	chr7:104832260	A/T	cg04380332	chr7:105027541	SRPK2	-0.35	-6.64	-0.34	1.24e-10	Schizophrenia;
LIHC	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg01657329	chr11:68192670	LRP5	-0.59	-6.66	-0.34	1.1e-10	Total body bone mineral density (age 45-60);
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.52	-7.06	-0.36	9.29e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.93	-0.39	3.05e-14	Total cholesterol levels;
LIHC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21724239	chr8:58056113	NA	0.57	6.31	0.32	8.56e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03517284	chr6:25882590	NA	-0.46	-7.16	-0.36	5.12e-12	Height;
LIHC	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.62	-0.34	1.36e-10	Hip circumference;Waist circumference;
LIHC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.71	14.23	0.61	2.12e-36	Systemic lupus erythematosus;
LIHC	cis	rs7961581	0.763	rs7306184	chr12:71618203	C/T	cg05756094	chr12:71608604	NA	0.36	5.82	0.3	1.33e-8	Type 2 diabetes;
LIHC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.46	-7.73	-0.39	1.2e-13	Electroencephalogram traits;
LIHC	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.99	-0.35	1.43e-11	Metabolite levels;
LIHC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg11212589	chr17:38028394	ZPBP2	0.36	7.32	0.37	1.73e-12	Self-reported allergy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00297767	chr21:40721426	HMGN1	0.46	6.47	0.33	3.4e-10	Lung function (FEV1/FVC);
LIHC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg08499158	chr17:42289980	UBTF	0.51	8.67	0.42	1.81e-16	Total body bone mineral density;
LIHC	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg07862535	chr7:139043722	LUC7L2	0.58	10.01	0.48	7.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-7.3	-0.37	2.1e-12	Post bronchodilator FEV1;
LIHC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.97	15.12	0.63	6.35e-40	Vitamin D levels;
LIHC	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.87	0.3	1.05e-8	Rheumatoid arthritis;
LIHC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg02836325	chr17:76403955	PGS1	0.34	6.67	0.34	1.04e-10	HDL cholesterol levels;
LIHC	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.67	11.83	0.54	2.59e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.54	8.06	0.4	1.27e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.89	0.39	4.02e-14	Multiple sclerosis;
LIHC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.34	0.49	5.4e-22	Bladder cancer;
LIHC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg02269571	chr22:50332266	NA	-0.63	-8.95	-0.44	2.24e-17	Schizophrenia;
LIHC	cis	rs3903072	0.652	rs501630	chr11:65637273	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-7.22	-0.36	3.5e-12	Breast cancer;
LIHC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg22676075	chr6:135203613	NA	0.41	6.59	0.34	1.66e-10	Red blood cell count;
LIHC	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-8.23	-0.41	3.93e-15	Putamen volume;
LIHC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.36	-6.38	-0.33	5.77e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	5.98e-9	Menopause (age at onset);
LIHC	cis	rs7212590	0.581	rs28539312	chr17:57834602	A/C	cg10252138	chr17:58120427	NA	-0.59	-5.91	-0.3	8.3e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.38	6.06	0.31	3.55e-9	Menopause (age at onset);
LIHC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-8.88	-0.43	3.84e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg20302533	chr7:39170763	POU6F2	0.38	7.02	0.35	1.22e-11	IgG glycosylation;
LIHC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.46	-7.87	-0.39	4.75e-14	Multiple sclerosis;
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg18279126	chr7:2041391	MAD1L1	0.4	6.74	0.34	6.58e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03468541	chr14:89029199	ZC3H14	0.59	7.81	0.39	6.98e-14	Lung function (FEV1/FVC);
LIHC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg25801113	chr15:45476975	SHF	0.39	6.62	0.34	1.41e-10	Uric acid levels;
LIHC	cis	rs7546668	1.000	rs6686966	chr1:15835472	C/T	cg11706911	chr1:15910989	AGMAT	0.45	6.91	0.35	2.41e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.33	-7.82	-0.39	6.53e-14	Corneal astigmatism;
LIHC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.38	0.52	1.2e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.53	-9.14	-0.44	5.78e-18	Pelvic organ prolapse;
LIHC	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02668984	chr17:48172022	PDK2	0.39	6.51	0.33	2.76e-10	Cognitive function;
LIHC	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.54	8.13	0.4	8.11e-15	HDL cholesterol;
LIHC	cis	rs4684776	0.935	rs35166981	chr3:11385356	G/T	cg00170343	chr3:11313890	ATG7	-0.49	-6.57	-0.33	1.85e-10	Small vessel stroke;
LIHC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.39	6.96	0.35	1.71e-11	Aortic root size;
LIHC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.03e-20	Schizophrenia;
LIHC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00152838	chr16:24741724	TNRC6A	-0.52	-6.02	-0.31	4.48e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg20240347	chr1:204465584	NA	-0.36	-7.42	-0.37	9.17e-13	Schizophrenia;
LIHC	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.0	-0.31	5.12e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.95	-0.35	1.81e-11	Neutrophil percentage of white cells;
LIHC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs5770917	1.000	rs3213445	chr22:51015838	T/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.52	-6.95	-0.35	1.84e-11	Narcolepsy;
LIHC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.82	-9.1	-0.44	7.86e-18	Vitiligo;
LIHC	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg04865290	chr3:52927548	TMEM110	-0.46	-6.2	-0.32	1.66e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg24545908	chr18:68097886	NA	0.41	7.21	0.36	3.68e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.52	7.2	0.36	3.78e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.6	9.31	0.45	1.55e-18	Height;
LIHC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.39	-0.49	3.73e-22	Rheumatoid arthritis;
LIHC	cis	rs12744310	1.000	rs12035012	chr1:41750648	C/A	cg03962019	chr1:41807865	NA	0.38	6.19	0.32	1.73e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.4	6.25	0.32	1.21e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.71	0.5	2.81e-23	Alzheimer's disease;
LIHC	cis	rs2412488	0.853	rs6818788	chr4:54356173	C/T	cg22241045	chr4:54363911	LNX1	0.42	6.72	0.34	7.65e-11	DNA methylation (variation);
LIHC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg20560298	chr2:73613845	ALMS1	-0.36	-5.79	-0.3	1.55e-8	Schizophrenia;
LIHC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.42	-6.96	-0.35	1.72e-11	IgG glycosylation;
LIHC	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg03934865	chr2:198174659	NA	0.48	7.02	0.35	1.23e-11	Dermatomyositis;
LIHC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.45	6.59	0.34	1.62e-10	Aortic root size;
LIHC	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs9917256	0.748	rs1955337	chr2:169129145	G/T	cg07857142	chr2:169103971	STK39	0.52	5.78	0.3	1.7e-8	Parkinson's disease;
LIHC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.34e-11	Aortic root size;
LIHC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.17e-11	Alzheimer's disease;
LIHC	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.03	-0.36	1.13e-11	Neuranatomic and neurocognitive phenotypes;
LIHC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.5	-0.33	2.81e-10	Height;
LIHC	trans	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg24637308	chr11:6592297	DNHD1	0.43	6.1	0.31	2.94e-9	Coronary artery calcification;
LIHC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.43	7.37	0.37	1.26e-12	Aortic root size;
LIHC	cis	rs11671005	0.571	rs56243535	chr19:59006150	C/T	cg25952890	chr19:58913133	NA	0.66	6.68	0.34	9.8e-11	Mean platelet volume;
LIHC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.12	-0.55	2.19e-28	Colorectal cancer;
LIHC	cis	rs2292864	0.764	rs3785872	chr17:45372075	G/A	cg18085866	chr17:45331354	ITGB3	-0.67	-7.02	-0.35	1.22e-11	Left atrial antero-posterior diameter;
LIHC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26072250	chr5:443457	EXOC3;C5orf55	-0.47	-7.03	-0.36	1.16e-11	Cystic fibrosis severity;
LIHC	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg05425664	chr17:57184151	TRIM37	-0.46	-5.79	-0.3	1.58e-8	Vitamin D levels;
LIHC	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.7	-10.65	-0.5	4.59e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.47	0.37	6.95e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.72	-11.37	-0.52	1.31e-25	White matter hyperintensity burden;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg14913676	chr19:46234055	FBXO46	-0.48	-6.16	-0.32	2.02e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-6.65	-0.34	1.19e-10	Ileal carcinoids;
LIHC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.44	7.01	0.35	1.26e-11	Total body bone mineral density;
LIHC	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.23	-0.32	1.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.5	7.66	0.38	1.95e-13	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07677032	chr17:61819896	STRADA	0.41	6.09	0.31	3.04e-9	Prudent dietary pattern;
LIHC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg14558262	chr17:40713999	COASY	0.62	9.41	0.45	7.34e-19	Crohn's disease;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.15	0.4	7.16e-15	Height;
LIHC	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg26395211	chr5:140044315	WDR55	0.41	6.13	0.31	2.42e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.81	13.56	0.59	7.91e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.29	-6.39	-0.33	5.28e-10	Pulmonary function;
LIHC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg03859395	chr2:55845619	SMEK2	0.82	14.0	0.6	1.62e-35	Metabolic syndrome;
LIHC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg01864069	chr14:103024347	NA	-0.46	-7.35	-0.37	1.5e-12	Platelet count;
LIHC	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.32	-8.64	-0.42	2.13e-16	Intelligence;
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg13482628	chr17:19912719	NA	0.39	6.37	0.33	6.02e-10	Schizophrenia;
LIHC	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.58	10.78	0.5	1.54e-23	Leprosy;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21930229	chr1:32758033	HDAC1	0.42	6.45	0.33	3.84e-10	Metabolic traits;
LIHC	cis	rs937213	0.573	rs2412464	chr15:40303842	G/A	cg01081584	chr15:40268610	EIF2AK4	-0.37	-6.28	-0.32	1.03e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg21877656	chr19:58662188	ZNF329	1.08	8.49	0.42	6.2e-16	Cholesterol, total;
LIHC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.8	11.84	0.54	2.41e-27	Height;
LIHC	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.26	-0.32	1.15e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.51	8.24	0.41	3.74e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12062639	chr20:23401060	NAPB	0.85	10.27	0.49	9.25e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg07150772	chr14:90864620	CALM1	-0.42	-6.02	-0.31	4.5e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg03477792	chr4:77819574	ANKRD56	0.59	8.68	0.42	1.64e-16	Emphysema distribution in smoking;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06656553	chr16:89960601	TCF25	-0.46	-5.86	-0.3	1.12e-8	Skin colour saturation;
LIHC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.38	6.05	0.31	3.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	0.92	15.85	0.65	8.21e-43	Testicular germ cell tumor;
LIHC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.64	-10.79	-0.5	1.48e-23	Total body bone mineral density;
LIHC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.53	6.96	0.35	1.7e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg15902774	chr15:75289873	SCAMP5	0.33	5.95	0.31	6.79e-9	Systemic lupus erythematosus;
LIHC	cis	rs11098699	0.784	rs7684146	chr4:124207309	C/A	cg09941581	chr4:124220074	SPATA5	0.32	6.38	0.33	5.62e-10	Mosquito bite size;
LIHC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18357526	chr6:26021779	HIST1H4A	0.67	8.52	0.42	5.34e-16	Uric acid levels;
LIHC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.41	-0.56	1.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-0.68	-12.23	-0.55	8.93e-29	Pediatric autoimmune diseases;
LIHC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.61	5.89	0.3	9.18e-9	Urate levels in lean individuals;
LIHC	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.53	-6.06	-0.31	3.62e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.59	0.38	3.07e-13	Bipolar disorder;
LIHC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04787407	chr4:99916511	METAP1	0.42	6.82	0.35	4.06e-11	Cognitive function;
LIHC	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg10127483	chr1:110009974	SYPL2	0.49	5.99	0.31	5.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.87	-0.35	3.06e-11	Hepatocellular carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05570707	chr2:24270316	C2orf44	0.48	6.7	0.34	8.61e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-7.04	-0.36	1.04e-11	Monocyte percentage of white cells;
LIHC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.69	0.34	9.1e-11	Platelet count;
LIHC	trans	rs6489882	0.867	rs4766664	chr12:113362997	T/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6.08e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg01864836	chr14:55583639	NA	-0.35	-6.02	-0.31	4.62e-9	Protein biomarker;
LIHC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg09835421	chr16:68378352	PRMT7	-0.5	-5.92	-0.3	7.91e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-6.64	-0.34	1.26e-10	IgG glycosylation;
LIHC	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg20194872	chr6:41519635	FOXP4	0.4	6.43	0.33	4.26e-10	Prostate cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01086369	chr19:50885373	NR1H2	0.45	6.77	0.34	5.53e-11	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21565415	chr11:618993	MUPCDH	-0.44	-6.42	-0.33	4.62e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.68	13.35	0.59	5.14e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-8.12	-0.4	8.51e-15	Vitamin D levels;
LIHC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.42	-6.56	-0.33	2.01e-10	Educational attainment;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.94	0.44	2.39e-17	Platelet count;
LIHC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.97	17.45	0.69	3.29e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs77861329	1.000	rs17051977	chr3:52182944	A/G	cg08692210	chr3:52188851	WDR51A	0.83	8.12	0.4	8.62e-15	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-9.24	-0.45	2.64e-18	Ulcerative colitis;
LIHC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.88	0.39	4.52e-14	Tonsillectomy;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.79	-12.81	-0.57	5.78e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg18121669	chr1:26560928	CCDC21	0.5	8.0	0.4	1.91e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.63	-8.86	-0.43	4.45e-17	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.59	-0.34	1.62e-10	Renal cell carcinoma;
LIHC	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.47	6.29	0.32	9.64e-10	Cognitive test performance;
LIHC	cis	rs9473924	0.542	rs9473946	chr6:50892950	G/A	cg14470998	chr6:50812995	TFAP2B	0.91	10.53	0.49	1.22e-22	Body mass index;
LIHC	trans	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.74	0.34	6.68e-11	Mean corpuscular volume;
LIHC	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg14092571	chr14:90743983	NA	0.44	6.76	0.34	5.93e-11	Mortality in heart failure;
LIHC	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg14593290	chr7:50529359	DDC	0.62	9.75	0.47	5.55e-20	Malaria;
LIHC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg25640893	chr7:99214727	ZNF498	-0.85	-6.05	-0.31	3.87e-9	Blood metabolite levels;
LIHC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.56	8.83	0.43	5.37e-17	Menarche (age at onset);
LIHC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg14558114	chr2:88469736	THNSL2	0.6	5.72	0.3	2.35e-8	Plasma clusterin levels;
LIHC	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-7.09	-0.36	7.68e-12	Hepatocellular carcinoma;
LIHC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.52	-9.47	-0.46	4.91e-19	Colorectal cancer;
LIHC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.35	-0.32	6.77e-10	Total body bone mineral density;
LIHC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.5	7.53	0.38	4.44e-13	Resting heart rate;
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg27094323	chr7:1216898	NA	-0.4	-5.71	-0.3	2.41e-8	Longevity;Endometriosis;
LIHC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.35	5.86	0.3	1.09e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg24637308	chr11:6592297	DNHD1	0.44	6.17	0.32	1.98e-9	Coronary artery calcification;
LIHC	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.77	12.66	0.56	2.16e-30	Gastritis;
LIHC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg01557791	chr16:72042693	DHODH	-0.45	-7.52	-0.38	4.95e-13	Fibrinogen levels;
LIHC	cis	rs72653721	0.627	rs12662634	chr6:11074191	G/A	cg13562911	chr6:11044106	ELOVL2	0.51	7.25	0.37	2.75e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg18898632	chr2:242989856	NA	-0.47	-6.5	-0.33	2.86e-10	Obesity-related traits;
LIHC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.89	-0.3	9.08e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs3789045	0.774	rs12039365	chr1:204488687	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-6.6	-0.34	1.61e-10	Educational attainment (college completion);
LIHC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.61	-9.1	-0.44	7.44e-18	Parkinson's disease;
LIHC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.5	8.46	0.42	7.92e-16	Methadone dose in opioid dependence;
LIHC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.43	7.88	0.39	4.46e-14	Testicular germ cell tumor;
LIHC	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21659725	chr3:3221576	CRBN	0.72	11.66	0.53	1.14e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.96	-0.31	6.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00938859	chr5:1591904	SDHAP3	0.58	7.07	0.36	8.53e-12	Breast cancer;
LIHC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.45	7.93	0.39	3.17e-14	Tuberculosis;
LIHC	cis	rs11628318	0.515	rs11850580	chr14:103156586	C/T	cg12046867	chr14:103022105	NA	0.4	6.12	0.31	2.62e-9	Platelet count;
LIHC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.96	18.26	0.7	1.78e-52	Breast cancer;
LIHC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.76	11.49	0.53	4.66e-26	Corneal astigmatism;
LIHC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.92e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.41	-6.2	-0.32	1.59e-9	Dementia with Lewy bodies;
LIHC	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.63	10.22	0.48	1.38e-21	Schizophrenia;
LIHC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.28	0.32	1.04e-9	Heart rate;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22624212	chr21:44298959	WDR4	0.42	6.57	0.33	1.82e-10	Cognitive function;
LIHC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.6	10.98	0.51	3.05e-24	Total body bone mineral density;
LIHC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg19682013	chr15:45996608	NA	0.41	7.16	0.36	4.83e-12	Waist circumference;Weight;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19824334	chr17:73851399	WBP2	0.44	6.38	0.33	5.71e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg18964960	chr10:1102726	WDR37	0.67	6.21	0.32	1.53e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.39	6.01	0.31	4.89e-9	Glycated hemoglobin levels;
LIHC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg01670876	chr14:74891361	TMEM90A	-0.58	-6.78	-0.34	5.31e-11	Mild influenza (H1N1) infection;
LIHC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.46	6.74	0.34	6.88e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs988712	0.672	rs925947	chr11:27667367	G/T	cg18117895	chr11:27722066	BDNF	0.49	6.85	0.35	3.45e-11	Obesity;
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg21522988	chr12:29376872	FAR2	0.29	6.39	0.33	5.52e-10	QT interval;
LIHC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg14440974	chr22:39074834	NA	-0.45	-7.3	-0.37	2.09e-12	Menopause (age at onset);
LIHC	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.3	-0.37	2.09e-12	Tuberculosis;
LIHC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.77	9.67	0.46	9.97e-20	Cognitive function;
LIHC	cis	rs28595532	0.545	rs13101451	chr4:119253427	A/G	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg20568497	chr10:133558893	NA	0.41	6.11	0.31	2.7e-9	Survival in rectal cancer;
LIHC	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.57	9.56	0.46	2.41e-19	Dupuytren's disease;
LIHC	cis	rs2191566	0.959	rs7256345	chr19:44510905	T/G	cg20607764	chr19:44506953	ZNF230	-0.45	-7.51	-0.38	5.32e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7729447	0.776	rs17442964	chr5:32693916	G/A	cg16267343	chr5:32710456	NPR3	0.48	5.86	0.3	1.09e-8	Blood pressure;
LIHC	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg17074339	chr11:11642133	GALNTL4	0.45	7.01	0.35	1.3e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.63	-7.77	-0.39	9.29e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.0	-0.35	1.37e-11	Blood pressure;
LIHC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.18	-0.32	1.85e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.11	0.58	4.33e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.88	8.29	0.41	2.69e-15	Lymphocyte counts;
LIHC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.47	7.19	0.36	4.12e-12	Cognitive test performance;
LIHC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26897989	chr16:1907736	C16orf73	-0.47	-5.92	-0.3	7.79e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.61	-0.42	2.68e-16	Total cholesterol levels;
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.52	6.31	0.32	8.85e-10	Alzheimer's disease;
LIHC	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.48e-9	Cognitive performance;
LIHC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.11	0.4	9.35e-15	Response to antipsychotic treatment;
LIHC	trans	rs11157436	0.918	rs1983522	chr14:22618541	G/A	cg13567813	chr19:50879636	NR1H2	0.43	6.28	0.32	1.02e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-7.02	-0.35	1.23e-11	Hepatocellular carcinoma;
LIHC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.4	-5.73	-0.3	2.17e-8	Blood metabolite levels;
LIHC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.1	0.55	2.67e-28	Body mass index;
LIHC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.62	10.35	0.49	5.15e-22	Platelet count;
LIHC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.5	-7.22	-0.36	3.4e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.32	-8.38	-0.41	1.38e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12464559	0.649	rs4510224	chr2:152593795	C/T	cg01189475	chr2:152685088	ARL5A	0.64	7.22	0.36	3.4e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.44	7.44	0.37	8.11e-13	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs9649465	0.806	rs6971297	chr7:123293342	A/T	cg03229431	chr7:123269106	ASB15	-0.39	-8.3	-0.41	2.38e-15	Migraine;
LIHC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg04756594	chr16:24857601	SLC5A11	0.47	7.25	0.37	2.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.59	9.36	0.45	1.11e-18	High light scatter reticulocyte count;
LIHC	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-6.63	-0.34	1.34e-10	Schizophrenia;
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.76	11.25	0.52	3.28e-25	Menarche (age at onset);
LIHC	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg00071026	chr13:113650936	MCF2L	-0.37	-5.88	-0.3	9.52e-9	Systolic blood pressure;
LIHC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.71	-0.38	1.4e-13	Type 2 diabetes;
LIHC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg17724175	chr1:150552817	MCL1	0.39	7.79	0.39	8.31e-14	Melanoma;
LIHC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg25356066	chr3:128598488	ACAD9	0.53	7.47	0.37	6.95e-13	IgG glycosylation;
LIHC	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.84	9.12	0.44	6.47e-18	Alzheimer's disease (late onset);
LIHC	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.46e-15	Facial morphology (factor 19);
LIHC	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	13.02	0.58	9.68e-32	Cognitive test performance;
LIHC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.41	-5.79	-0.3	1.55e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs812925	0.502	rs6545868	chr2:61655365	T/C	cg14146966	chr2:61757674	XPO1	-0.36	-5.96	-0.31	6.23e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs7165170	0.549	rs10852134	chr15:91099216	G/T	cg26821196	chr15:91095069	CRTC3	0.4	7.21	0.36	3.72e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg02869306	chr7:64672164	INTS4L1	0.28	6.19	0.32	1.73e-9	Calcium levels;
LIHC	cis	rs240764	0.717	rs183566	chr6:101142605	A/T	cg12253828	chr6:101329408	ASCC3	0.42	6.36	0.33	6.6e-10	Neuroticism;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.25	0.41	3.48e-15	Renal cell carcinoma;
LIHC	cis	rs10792665	0.724	rs7131003	chr11:82699180	G/A	cg24227371	chr11:82718527	RAB30	-0.38	-9.38	-0.45	9.74e-19	Obesity-related traits;
LIHC	trans	rs1414896	0.692	rs11165355	chr1:95726660	C/T	cg24483554	chr1:179544584	NPHS2	0.25	6.11	0.31	2.65e-9	Non-alcoholic fatty liver disease histology (AST);
LIHC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs7776786	0.934	rs13243526	chr7:18812917	C/T	cg13420273	chr7:18810212	HDAC9	-0.28	-6.09	-0.31	3.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23992171	chr20:33460724	GGT7	-0.54	-7.4	-0.37	1.05e-12	Systolic blood pressure;
LIHC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	-0.62	-7.97	-0.4	2.35e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.28	-0.37	2.32e-12	Response to antipsychotic treatment;
LIHC	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.56	9.57	0.46	2.23e-19	Schizophrenia;
LIHC	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02985541	chr2:219472218	PLCD4	-0.39	-6.52	-0.33	2.58e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg21466736	chr12:48725269	NA	-0.7	-10.76	-0.5	1.83e-23	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs2176862	1.000	rs73073732	chr3:46620238	G/A	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.6	-6.32	-0.32	8.15e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg06343869	chr13:115079967	ZNF828	-0.41	-6.18	-0.32	1.78e-9	Morning vs. evening chronotype;
LIHC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-7.78	-0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.73	13.13	0.58	3.7e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.36	0.45	1.08e-18	Hemoglobin concentration;
LIHC	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg27255678	chr10:102756921	LZTS2	0.52	7.25	0.36	2.89e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg20607798	chr8:58055168	NA	0.49	6.13	0.31	2.37e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.51e-16	Platelet count;
LIHC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.47	-17.98	-0.7	2.32e-51	Breast cancer;
LIHC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg13152130	chr6:118910203	C6orf204	-0.64	-6.95	-0.35	1.83e-11	Diastolic blood pressure;
LIHC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.87	-0.3	1.03e-8	Body mass index;
LIHC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg03854865	chr6:26224070	HIST1H3E	0.66	7.18	0.36	4.4e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.27	0.32	1.09e-9	Ileal carcinoids;
LIHC	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.87	-0.39	4.6e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.95	22.45	0.77	3.15e-69	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.54	8.61	0.42	2.63e-16	Corneal astigmatism;
LIHC	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg01864836	chr14:55583639	NA	-0.36	-6.65	-0.34	1.16e-10	Protein biomarker;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.63	9.39	0.45	8.96e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	12.22	0.55	9.68e-29	Platelet count;
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	11.13	0.52	9e-25	Height;
LIHC	cis	rs9596863	1.000	rs1379831	chr13:54418506	C/G	ch.13.53330881F	chr13:54432880	NA	0.42	5.85	0.3	1.15e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.19	-0.58	2.08e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.45	-5.84	-0.3	1.2e-8	Resting heart rate;
LIHC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.62	8.15	0.4	6.8e-15	Motion sickness;
LIHC	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.26	-0.32	1.14e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-8.53	-0.42	4.75e-16	Morning vs. evening chronotype;
LIHC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg17279839	chr7:150038598	RARRES2	0.6	12.1	0.55	2.77e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg05185784	chr16:90016020	DEF8	-0.47	-6.11	-0.31	2.68e-9	Skin colour saturation;
LIHC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	6.04	0.31	4.01e-9	Electroencephalogram traits;
LIHC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.41	6.18	0.32	1.8e-9	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg03119618	chr19:38572401	SIPA1L3	0.4	6.46	0.33	3.69e-10	Oropharynx cancer;
LIHC	trans	rs10213084	0.920	rs1104532	chr4:147519769	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.46	6.64	0.34	1.23e-10	Heart rate;
LIHC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	11.3	0.52	2.24e-25	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs16912285	0.688	rs1899541	chr11:24339624	T/C	ch.11.24196551F	chr11:24239977	NA	0.75	9.67	0.46	1.07e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.41	6.59	0.34	1.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg18473234	chr19:5097819	KDM4B	-0.58	-6.96	-0.35	1.78e-11	Monocyte percentage of white cells;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02254876	chr3:42922351	NA	-0.39	-6.05	-0.31	3.7e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-5.78	-0.3	1.66e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	8.73	0.43	1.16e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6977660	1.000	rs13233821	chr7:19813637	A/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.92	0.31	7.63e-9	Thyroid stimulating hormone;
LIHC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.9e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg12863693	chr15:85201151	NMB	0.48	6.44	0.33	3.97e-10	Schizophrenia;
LIHC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	10.09	0.48	3.89e-21	Menarche (age at onset);
LIHC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.73e-12	Personality dimensions;
LIHC	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg16586182	chr3:47516702	SCAP	0.51	9.01	0.44	1.45e-17	Colorectal cancer;
LIHC	cis	rs922107	0.738	rs10922667	chr1:90039527	T/A	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.56	-0.38	3.64e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.58	8.22	0.41	4.19e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg26031613	chr14:104095156	KLC1	0.4	5.82	0.3	1.38e-8	Coronary artery disease;
LIHC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.49	6.36	0.33	6.41e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-7.9	-0.39	3.73e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.52	7.21	0.36	3.62e-12	Morning vs. evening chronotype;
LIHC	cis	rs1355223	0.902	rs860712	chr11:34743494	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg20016023	chr10:99160130	RRP12	-0.41	-6.62	-0.34	1.4e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.55	7.77	0.39	9.17e-14	Height;
LIHC	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.34	-0.32	7.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg22961513	chr11:14280813	SPON1	0.5	7.67	0.38	1.78e-13	Mitochondrial DNA levels;
LIHC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg22676075	chr6:135203613	NA	0.4	6.41	0.33	4.74e-10	Red blood cell count;
LIHC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Body mass index;
LIHC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.5	0.38	5.43e-13	Bipolar disorder;
LIHC	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg20283391	chr11:68216788	NA	-0.39	-6.04	-0.31	4.1e-9	Total body bone mineral density;
LIHC	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.61	-6.82	-0.35	4.06e-11	Opioid sensitivity;
LIHC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.42	-7.0	-0.35	1.39e-11	Blood pressure (smoking interaction);
LIHC	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg22842854	chr12:123319900	HIP1R	-0.8	-8.98	-0.44	1.82e-17	Adiponectin levels;
LIHC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.56	7.32	0.37	1.82e-12	Initial pursuit acceleration;
LIHC	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03149093	chr19:12035973	ZNF700	0.48	6.54	0.33	2.26e-10	Lung function (FEV1/FVC);
LIHC	cis	rs988712	0.672	rs16917237	chr11:27702383	A/C	cg18117895	chr11:27722066	BDNF	-0.52	-7.18	-0.36	4.36e-12	Obesity;
LIHC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.96	12.69	0.57	1.68e-30	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.48	6.42	0.33	4.63e-10	Blood metabolite levels;
LIHC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.58	10.25	0.48	1.11e-21	Alcohol dependence;
LIHC	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.31	-0.37	1.89e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs45544231	0.544	rs9931232	chr16:52572832	A/G	cg09051775	chr16:52580266	TOX3	0.31	5.73	0.3	2.25e-8	Restless legs syndrome;
LIHC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	10.5	0.49	1.56e-22	Body mass index (adult);
LIHC	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.98	0.4	2.29e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	-0.51	-7.89	-0.39	4.06e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18635645	chr1:85667791	SYDE2	0.47	6.87	0.35	3e-11	Pancreatic cancer;
LIHC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.87	-13.34	-0.59	5.45e-33	Lymphocyte percentage of white cells;
LIHC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg22633049	chr21:46681294	NA	-0.38	-6.48	-0.33	3.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg16506815	chr2:162101123	NA	0.5	8.2	0.41	4.99e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.62	-6.14	-0.31	2.33e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg25074458	chr19:9946388	PIN1	0.43	6.54	0.33	2.27e-10	Alopecia areata;
LIHC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-21.37	-0.76	5.99e-65	Height;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17327406	chr4:6303265	WFS1	0.42	6.23	0.32	1.35e-9	Longevity;
LIHC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.44	7.19	0.36	4.05e-12	Red blood cell count;
LIHC	cis	rs10128251	0.743	rs2386636	chr10:5712087	G/T	cg24097872	chr10:5724021	NA	0.72	11.12	0.52	9.72e-25	Childhood ear infection;
LIHC	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.14	0.61	4.57e-36	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04024839	chr7:99613205	ZKSCAN1	-0.47	-6.6	-0.34	1.54e-10	Pancreatic cancer;
LIHC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.46	6.45	0.33	3.85e-10	Diastolic blood pressure;
LIHC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.82	-12.54	-0.56	6.04e-30	Total body bone mineral density;
LIHC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.79	12.75	0.57	1.01e-30	Resting heart rate;
LIHC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.61	11.36	0.52	1.36e-25	Coronary artery disease;
LIHC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-9.92	-0.47	1.51e-20	Mosquito bite size;
LIHC	trans	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg17675199	chr6:35436792	RPL10A	0.31	6.1	0.31	2.85e-9	Coronary artery disease;
LIHC	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.58	-6.56	-0.33	1.96e-10	Left atrial antero-posterior diameter;
LIHC	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.74	-9.24	-0.45	2.64e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.89	0.3	9.05e-9	Birth weight;
LIHC	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg17509989	chr5:176798049	RGS14	0.75	8.76	0.43	8.9e-17	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	1.01	11.52	0.53	3.47e-26	Primary sclerosing cholangitis;
LIHC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg18121669	chr1:26560928	CCDC21	0.5	8.0	0.4	1.91e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg07061783	chr6:25882402	NA	-0.48	-6.69	-0.34	9.05e-11	Blood metabolite levels;
LIHC	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-0.8	-6.4	-0.33	5.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg25894440	chr7:65020034	NA	-0.53	-6.17	-0.32	1.93e-9	Diabetic kidney disease;
LIHC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	ch.11.42038R	chr11:967971	AP2A2	0.54	9.81	0.47	3.52e-20	Alzheimer's disease (late onset);
LIHC	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.72	0.34	7.54e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.49	-0.38	5.81e-13	Schizophrenia;
LIHC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg02376097	chr19:46275166	DMPK	0.54	9.44	0.45	5.96e-19	Coronary artery disease;
LIHC	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.54	-8.2	-0.41	4.99e-15	Response to antidepressants and depression;
LIHC	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg09829573	chr1:144692074	NBPF9	0.41	7.46	0.37	7.18e-13	Hip geometry;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg07133347	chr1:107600762	PRMT6	-0.45	-6.89	-0.35	2.62e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.54	0.53	3.03e-26	Motion sickness;
LIHC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.6e-11	Aortic root size;
LIHC	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.93	0.39	3.23e-14	Refractive astigmatism;
LIHC	cis	rs847649	0.694	rs11770319	chr7:102770170	C/G	cg18108683	chr7:102477205	FBXL13	0.43	6.47	0.33	3.3e-10	Morning vs. evening chronotype;
LIHC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.41	5.92	0.3	8.02e-9	Longevity;
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg20090690	chr10:134436459	INPP5A	0.44	5.71	0.3	2.44e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg25952890	chr19:58913133	NA	-0.69	-7.49	-0.38	6.04e-13	Mean platelet volume;
LIHC	cis	rs16912285	0.591	rs7929025	chr11:24363324	A/C	ch.11.24196551F	chr11:24239977	NA	0.72	8.84	0.43	5.05e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	6.32	0.32	7.95e-10	Lung cancer in ever smokers;
LIHC	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg22771759	chr13:24902376	NA	0.32	6.76	0.34	5.94e-11	Obesity-related traits;
LIHC	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.83	-0.3	1.29e-8	Coronary artery disease;
LIHC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.35	6.5	0.33	2.81e-10	Aortic root size;
LIHC	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.45	8.16	0.4	6.3e-15	Platelet distribution width;
LIHC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	0.92	14.88	0.63	6.05e-39	Testicular germ cell tumor;
LIHC	trans	rs11689435	0.925	rs1478594	chr2:218346172	C/T	cg13544946	chr9:35729779	TLN1	-0.44	-6.31	-0.32	8.88e-10	Metabolite levels (MHPG);
LIHC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.25	0.64	1.91e-40	Menopause (age at onset);
LIHC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	0.87	11.88	0.54	1.69e-27	Skin colour saturation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05744073	chr17:1953268	MIR132	0.42	6.92	0.35	2.21e-11	Cognitive function;
LIHC	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.32	21.27	0.75	1.45e-64	Corneal structure;
LIHC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.84	15.9	0.65	5.03e-43	Multiple myeloma (IgH translocation);
LIHC	trans	rs668210	0.793	rs507672	chr11:65767153	C/T	cg17712092	chr4:129076599	LARP1B	-0.58	-6.3	-0.32	9.01e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg02297831	chr4:17616191	MED28	0.42	6.66	0.34	1.11e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.68	-7.32	-0.37	1.75e-12	Post bronchodilator FEV1;
LIHC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.27	0.41	2.94e-15	Schizophrenia;
LIHC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.48	-6.45	-0.33	3.88e-10	Tuberculosis;
LIHC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.68	11.36	0.52	1.41e-25	Menopause (age at onset);
LIHC	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.91	9.87	0.47	2.19e-20	Alzheimer's disease (late onset);
LIHC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.62	10.78	0.5	1.57e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.55	0.33	2.15e-10	Schizophrenia;
LIHC	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.42	6.82	0.35	4.26e-11	Lewy body disease;
LIHC	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.54	-7.67	-0.38	1.82e-13	Blood pressure (smoking interaction);
LIHC	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.28	19.72	0.73	2.38e-58	Corneal structure;
LIHC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.41	6.32	0.32	8.18e-10	Resting heart rate;
LIHC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.64	10.67	0.5	4.01e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.79	10.3	0.49	7.7e-22	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.71	12.82	0.57	5.47e-31	Platelet count;
LIHC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.65	12.0	0.54	6.25e-28	Gestational age at birth (maternal effect);
LIHC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.91	16.89	0.67	5.59e-47	Aortic root size;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.49	6.38	0.33	5.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.48	-7.95	-0.39	2.79e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg14440974	chr22:39074834	NA	-0.43	-7.0	-0.35	1.37e-11	Menopause (age at onset);
LIHC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg00101154	chr16:420108	MRPL28	-0.6	-8.96	-0.44	2.14e-17	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2540917	0.678	rs11900608	chr2:60657362	A/G	cg00543073	chr2:60773386	BCL11A	-0.31	-6.33	-0.32	7.8e-10	Mean corpuscular volume;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15942720	chr14:51706980	TMX1	-0.54	-6.62	-0.34	1.4e-10	Systolic blood pressure;
LIHC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11270836	1	rs11270836	chr4:38625915	T/TACATTATGTCATTTCACA	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	8.35	0.41	1.7e-15	Mumps;
LIHC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	17.38	0.68	6.24e-49	Lung cancer in ever smokers;
LIHC	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg20435097	chr10:126320824	FAM53B	0.34	5.79	0.3	1.58e-8	Asthma;
LIHC	cis	rs832187	0.813	rs704368	chr3:63868337	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.47	6.8	0.35	4.75e-11	Schizophrenia;
LIHC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.33	8.09	0.4	1.07e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10857712	0.950	rs11101744	chr10:135226041	G/C	cg19623624	chr10:135278901	LOC619207	-0.4	-6.38	-0.33	5.81e-10	Systemic lupus erythematosus;
LIHC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.9	-13.5	-0.59	1.35e-33	Breast cancer;
LIHC	cis	rs10861342	0.892	rs10459207	chr12:105531072	C/T	cg23923672	chr12:105501055	KIAA1033	0.7	8.54	0.42	4.64e-16	IgG glycosylation;
LIHC	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.63	-11.94	-0.54	1.09e-27	Endometriosis;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21448741	chr8:58168803	NA	0.33	5.88	0.3	1e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.31	-6.67	-0.34	1.03e-10	Platelet distribution width;
LIHC	trans	rs6934970	1.000	rs10457250	chr6:113049142	C/A	cg09308777	chr6:169852575	NA	0.61	6.22	0.32	1.44e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg14784868	chr12:69753453	YEATS4	0.52	7.34	0.37	1.59e-12	Response to diuretic therapy;
LIHC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-14.14	-0.61	4.59e-36	Prudent dietary pattern;
LIHC	cis	rs55665837	0.701	rs11023278	chr11:14641184	G/T	cg00085434	chr11:14927489	NA	0.43	5.99	0.31	5.36e-9	Vitamin D levels;
LIHC	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg11005552	chr10:105648138	OBFC1	0.39	6.21	0.32	1.51e-9	Coronary artery disease;
LIHC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.34	-0.45	1.28e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02985541	chr2:219472218	PLCD4	-0.42	-6.74	-0.34	6.74e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	7.67	0.38	1.86e-13	Obesity-related traits;
LIHC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg05941027	chr17:61774174	LIMD2	0.31	6.19	0.32	1.69e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.15	-0.48	2.55e-21	Platelet count;
LIHC	cis	rs2273156	0.929	rs7144646	chr14:35454701	C/G	cg16230307	chr14:35515116	FAM177A1	-0.41	-5.97	-0.31	6.06e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg17724175	chr1:150552817	MCL1	0.38	7.59	0.38	3.03e-13	Melanoma;
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.47	0.33	3.38e-10	Bipolar disorder;
LIHC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.47	-6.56	-0.33	1.94e-10	Breast cancer;
LIHC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.45	-0.33	3.93e-10	Schizophrenia;
LIHC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3770081	1.000	rs61477982	chr2:86160532	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.69	-6.23	-0.32	1.33e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.53	8.62	0.42	2.59e-16	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LIHC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.1	0.36	7.18e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.55	8.23	0.41	4e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08137080	chr1:16482430	EPHA2	0.4	6.24	0.32	1.28e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7654585	1.000	rs7654585	chr4:25942751	A/G	cg10409131	chr4:25915609	C4orf52	0.48	7.39	0.37	1.17e-12	Obesity-related traits;
LIHC	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.29	0.32	9.59e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-8.51	-0.42	5.62e-16	Body mass index;
LIHC	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg17834443	chr8:19674713	INTS10	-0.41	-6.41	-0.33	4.71e-10	Breast cancer;
LIHC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.56	8.11	0.4	9.11e-15	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs4728302	0.869	rs958404	chr7:133597186	G/T	cg10665199	chr7:133106180	EXOC4	-0.36	-6.13	-0.31	2.41e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg09222892	chr1:25734099	RHCE	-0.48	-8.9	-0.43	3.32e-17	Erythrocyte sedimentation rate;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg10164272	chr16:89456328	ANKRD11	0.46	6.57	0.33	1.9e-10	Alopecia areata;
LIHC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.83	-12.1	-0.55	2.72e-28	Coronary artery disease;
LIHC	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.6	9.71	0.46	7.43e-20	Eosinophilic esophagitis;
LIHC	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg12379764	chr21:47803548	PCNT	0.63	8.78	0.43	7.84e-17	Lymphocyte counts;
LIHC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.74	-11.25	-0.52	3.48e-25	Coronary artery disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00166836	chr6:149721425	MAP3K7IP2;SUMO4	-0.44	-6.66	-0.34	1.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7937890	0.559	rs2575825	chr11:14472096	T/C	cg02886208	chr11:14281011	SPON1	-0.46	-6.58	-0.34	1.75e-10	Mitochondrial DNA levels;
LIHC	cis	rs2758596	0.826	rs2251615	chr1:156202300	C/T	cg25208724	chr1:156163844	SLC25A44	0.75	7.76	0.39	9.6e-14	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.48	6.38	0.33	5.82e-10	Major depressive disorder;
LIHC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.44	-5.93	-0.31	7.54e-9	Coronary artery calcification;
LIHC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg22842854	chr12:123319900	HIP1R	-0.74	-9.83	-0.47	2.99e-20	Schizophrenia;
LIHC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.54	8.47	0.42	7.32e-16	Serum sulfate level;
LIHC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg08896387	chr1:24191740	FUCA1	0.37	5.95	0.31	6.74e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.92	11.7	0.53	7.75e-27	Coronary artery disease;
LIHC	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg15123519	chr2:136567270	LCT	-0.38	-6.08	-0.31	3.3e-9	Corneal structure;
LIHC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.24	0.41	3.73e-15	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.28	-0.32	1.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.72	6.37	0.33	6.12e-10	Cognitive function;
LIHC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.39e-8	Menopause (age at onset);
LIHC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.67	11.04	0.51	1.99e-24	Type 2 diabetes;
LIHC	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg26536354	chr8:144654954	C8orf73	0.56	6.4	0.33	5.22e-10	Attention deficit hyperactivity disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03944305	chr16:28222588	XPO6	0.42	6.19	0.32	1.71e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.4	-6.48	-0.33	3.19e-10	Menarche (age at onset);
LIHC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg13628971	chr7:2884303	GNA12	0.38	6.17	0.32	1.88e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.42	6.34	0.32	7.47e-10	Total body bone mineral density;
LIHC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.45e-18	Bipolar disorder;
LIHC	cis	rs7395581	0.959	rs7120118	chr11:47286290	T/C	cg25783544	chr11:47291846	MADD	0.43	6.28	0.32	1.01e-9	HDL cholesterol;
LIHC	cis	rs7106204	0.562	rs7109606	chr11:24251314	G/T	ch.11.24196551F	chr11:24239977	NA	0.83	11.82	0.54	2.81e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg01864836	chr14:55583639	NA	-0.4	-7.5	-0.38	5.55e-13	Protein biomarker;
LIHC	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.53	-7.58	-0.38	3.19e-13	Obesity-related traits;
LIHC	cis	rs11603020	0.851	rs10896631	chr11:57381263	T/C	cg19752551	chr11:57585705	CTNND1	-0.46	-5.98	-0.31	5.62e-9	Blood protein levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00313642	chr3:196014711	PCYT1A	0.43	6.2	0.32	1.58e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.75	-0.3	1.99e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg22676075	chr6:135203613	NA	0.39	6.46	0.33	3.51e-10	Red blood cell count;
LIHC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg00292662	chr22:38071168	LGALS1	0.38	6.45	0.33	3.82e-10	Fat distribution (HIV);
LIHC	trans	rs4290604	0.679	rs73083545	chr2:237983894	C/G	cg15676719	chr1:167598521	RCSD1	0.4	6.26	0.32	1.16e-9	Asthma;
LIHC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.53	8.71	0.43	1.31e-16	Lung cancer;
LIHC	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.51	0.53	4.03e-26	Coffee consumption (cups per day);
LIHC	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05063087	chr10:102133314	C10orf75	0.48	6.51	0.33	2.75e-10	Lung function (FEV1/FVC);
LIHC	trans	rs6489882	0.807	rs61266553	chr12:113371977	A/G	cg10175203	chr3:128143634	NA	0.38	6.13	0.31	2.41e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.48	6.22	0.32	1.44e-9	Gut microbiome composition (summer);
LIHC	cis	rs4332037	0.664	rs56259105	chr7:1978002	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.97	-0.31	5.95e-9	Bipolar disorder;
LIHC	cis	rs1144333	0.655	rs79322031	chr1:76391978	C/T	cg22875332	chr1:76189707	ACADM	0.42	6.3	0.32	9.03e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.67	0.57	1.98e-30	Total body bone mineral density;
LIHC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg15017067	chr4:17643749	FAM184B	0.34	5.9	0.3	8.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.76	-10.58	-0.5	8.35e-23	Ear protrusion;
LIHC	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg04374321	chr14:90722782	PSMC1	0.74	14.13	0.61	4.86e-36	Mortality in heart failure;
LIHC	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.75	-0.3	1.96e-8	Response to antipsychotic treatment;
LIHC	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.44	5.85	0.3	1.14e-8	Interleukin-18 levels;
LIHC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg16070018	chr6:26224392	HIST1H3E	0.57	7.01	0.35	1.25e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.6	8.42	0.41	1.01e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.47	7.83	0.39	6.19e-14	Multiple sclerosis;
LIHC	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.42	-8.18	-0.4	5.54e-15	Type 1 diabetes;
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg05564831	chr3:52568323	NT5DC2	0.38	6.05	0.31	3.88e-9	Bipolar disorder;
LIHC	cis	rs1256061	0.624	rs944047	chr14:64700292	C/T	cg23250157	chr14:64679961	SYNE2	0.4	5.9	0.3	8.74e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7712401	0.818	rs13166350	chr5:122153569	C/T	cg18764291	chr5:122110994	SNX2	0.36	6.09	0.31	3.08e-9	Mean platelet volume;
LIHC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.85	-0.67	8.58e-47	Systemic lupus erythematosus;
LIHC	trans	rs11724903	0.935	rs7340820	chr4:183220197	C/T	cg16239906	chr20:35724590	RBL1	-0.64	-6.32	-0.32	8.18e-10	Smoking initiation;
LIHC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-7.96	-0.4	2.64e-14	Cognitive function;
LIHC	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg03342759	chr3:160939853	NMD3	0.55	6.5	0.33	2.9e-10	Morning vs. evening chronotype;
LIHC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg09417038	chr21:47716443	C21orf57	-0.5	-7.29	-0.37	2.12e-12	Testicular germ cell tumor;
LIHC	cis	rs6973256	0.637	rs12539993	chr7:133418799	C/T	cg10665199	chr7:133106180	EXOC4	0.34	5.92	0.3	7.79e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.94	-0.31	6.83e-9	Tonsillectomy;
LIHC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.08	-0.48	4.34e-21	Tonsillectomy;
LIHC	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg27366882	chr3:133540807	NA	-0.38	-7.43	-0.37	8.49e-13	Iron status biomarkers;
LIHC	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.9	-14.88	-0.63	5.71e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.11e-27	IgG glycosylation;
LIHC	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.7	10.01	0.48	7.7e-21	Lymphocyte counts;
LIHC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.77	0.3	1.76e-8	Self-reported allergy;
LIHC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.83	0.54	2.58e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.61	0.53	1.76e-26	Coffee consumption (cups per day);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27161463	chr11:118123074	MPZL3	0.41	6.17	0.32	1.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg10546459	chr2:36825355	FEZ2	0.49	6.03	0.31	4.31e-9	Height;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg18306943	chr3:40428807	ENTPD3	-0.44	-7.81	-0.39	6.94e-14	Renal cell carcinoma;
LIHC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.46	-8.14	-0.4	7.23e-15	IgG glycosylation;
LIHC	cis	rs57590327	0.528	rs4856346	chr3:81502655	T/G	cg07356753	chr3:81810745	GBE1	0.46	6.8	0.35	4.6e-11	Extraversion;
LIHC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	8.12	0.4	8.8e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.57	7.11	0.36	6.9e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	7.66	0.38	1.94e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.55	10.94	0.51	4.42e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.87	13.09	0.58	4.92e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg04381043	chr16:89341467	ANKRD11	0.39	6.3	0.32	9.33e-10	Bipolar disorder;
LIHC	cis	rs74181299	0.784	rs2723085	chr2:65297359	C/G	cg05010058	chr2:65284262	CEP68	0.39	6.54	0.33	2.22e-10	Pulse pressure;
LIHC	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.47	-6.25	-0.32	1.22e-9	Blood metabolite levels;
LIHC	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.52	7.61	0.38	2.63e-13	Body mass index;
LIHC	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg04155231	chr12:9217510	LOC144571	0.31	5.8	0.3	1.5e-8	Sjögren's syndrome;
LIHC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg02269571	chr22:50332266	NA	-0.56	-7.83	-0.39	6.08e-14	Schizophrenia;
LIHC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.28e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.25	-0.32	1.21e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2e-12	Exhaled nitric oxide output;
LIHC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.77	8.62	0.42	2.6e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg07424592	chr7:64974309	NA	-0.8	-9.28	-0.45	1.99e-18	Diabetic kidney disease;
LIHC	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.72e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.85	0.3	1.13e-8	Eosinophil percentage of white cells;
LIHC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.16	0.48	2.26e-21	Platelet count;
LIHC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.76	12.8	0.57	6.44e-31	Anterior chamber depth;
LIHC	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.11	0.31	2.65e-9	Asthma;
LIHC	cis	rs7554547	0.871	rs11588551	chr1:11941936	A/G	cg07603449	chr1:11986842	KIAA2013	0.34	5.77	0.3	1.81e-8	Nonsyndromic cleft lip with cleft palate;
LIHC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	trans	rs4714291	1.000	rs847769	chr6:40050171	T/C	cg02267698	chr19:7991119	CTXN1	0.38	6.15	0.32	2.15e-9	Strep throat;
LIHC	trans	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg24036039	chr1:3397125	ARHGEF16	0.37	6.09	0.31	3.05e-9	Schizophrenia;
LIHC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.92	-10.12	-0.48	3.02e-21	Red cell distribution width;
LIHC	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.86	0.35	3.19e-11	Dermatomyositis;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.31	-0.37	1.89e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg10935138	chr17:73851978	WBP2	0.45	6.96	0.35	1.75e-11	White matter hyperintensity burden;
LIHC	cis	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg01364799	chr7:75623366	TMEM120A	-0.47	-6.52	-0.33	2.45e-10	Eotaxin levels;
LIHC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg00656387	chr3:40428638	ENTPD3	0.42	6.74	0.34	6.71e-11	Renal cell carcinoma;
LIHC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16558253	chr16:72132732	DHX38	0.37	5.99	0.31	5.46e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.53	9.22	0.45	3.12e-18	Mean corpuscular volume;
LIHC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	1.02	10.41	0.49	3.06e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	8.29	0.41	2.61e-15	Lymphocyte counts;
LIHC	cis	rs6750047	0.585	rs4670234	chr2:38272477	C/T	cg07380506	chr2:38303506	CYP1B1	0.61	7.89	0.39	4.19e-14	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.71	-0.34	8.26e-11	Height;
LIHC	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.84	0.39	5.72e-14	Refractive astigmatism;
LIHC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.46	7.11	0.36	6.98e-12	Blood protein levels;
LIHC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.83	-12.75	-0.57	9.91e-31	Total body bone mineral density;
LIHC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.35	5.73	0.3	2.23e-8	Lung cancer;
LIHC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg07952391	chr2:88470173	THNSL2	0.66	5.86	0.3	1.1e-8	Plasma clusterin levels;
LIHC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.64	8.13	0.4	8.12e-15	Morning vs. evening chronotype;
LIHC	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg22903471	chr2:27725779	GCKR	-0.32	-5.94	-0.31	6.92e-9	Total body bone mineral density;
LIHC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg05361325	chr10:32636312	EPC1	0.49	5.99	0.31	5.44e-9	Sexual dysfunction (female);
LIHC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06108461	chr20:60628389	TAF4	-0.53	-6.93	-0.35	2.08e-11	Body mass index;
LIHC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.3	-0.32	9.4e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg03689076	chr20:33865952	NA	-0.55	-6.58	-0.34	1.78e-10	Attention deficit hyperactivity disorder;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg04657419	chr5:60454782	C5orf43	-0.27	-6.04	-0.31	3.91e-9	Calcium levels;
LIHC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg18887096	chr2:219472410	PLCD4	-0.38	-5.73	-0.3	2.17e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.75	10.9	0.51	5.9e-24	Corneal astigmatism;
LIHC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.41	-0.49	3.17e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.96	19.34	0.72	8.24e-57	Height;
LIHC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.43	6.97	0.35	1.61e-11	Alcohol dependence;
LIHC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.76	6.11	0.31	2.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15358052	chr14:69865456	SLC39A9;ERH	0.34	6.53	0.33	2.37e-10	Calcium levels;
LIHC	cis	rs3736485	0.966	rs2414109	chr15:51901015	C/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.12	-0.31	2.53e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.06	0.36	9.23e-12	Hemoglobin concentration;
LIHC	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.53	9.23	0.45	2.83e-18	Obesity-related traits;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10590909	chr10:70286987	SLC25A16	-0.45	-6.23	-0.32	1.38e-9	Lung cancer in ever smokers;
LIHC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.27	-0.37	2.41e-12	Response to antipsychotic treatment;
LIHC	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.53	9.14	0.44	5.57e-18	Coronary artery disease;
LIHC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.86	0.39	5.05e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.43	5.85	0.3	1.14e-8	Life satisfaction;
LIHC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg04727924	chr7:799746	HEATR2	-0.61	-8.98	-0.44	1.9e-17	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7668874	0.779	rs4604123	chr4:116750790	T/C	cg08917878	chr5:172668965	NA	-0.3	-6.05	-0.31	3.89e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg05044414	chr3:183734942	ABCC5	0.35	6.22	0.32	1.49e-9	Anterior chamber depth;
LIHC	cis	rs8084351	0.577	rs4939723	chr18:50673089	G/A	cg24270629	chr18:50823537	DCC	-0.44	-6.54	-0.33	2.18e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.56	-7.27	-0.37	2.51e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-15.08	-0.63	9.66e-40	Chronic sinus infection;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07573366	chr7:32802765	NA	0.28	6.6	0.34	1.54e-10	Longevity;
LIHC	cis	rs11233413	1.000	rs7106216	chr11:82712618	A/G	cg24227371	chr11:82718527	RAB30	-0.33	-7.16	-0.36	4.96e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs2421770	0.530	rs4756217	chr11:35366733	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.6	-0.38	2.95e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.67	12.0	0.54	6.22e-28	Colorectal cancer;
LIHC	cis	rs3770081	0.536	rs7562837	chr2:86306251	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.96	-12.72	-0.57	1.29e-30	Facial emotion recognition (sad faces);
LIHC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.51	-8.98	-0.44	1.82e-17	Lymphocyte percentage of white cells;
LIHC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg14067834	chr17:29058358	SUZ12P	0.71	7.09	0.36	7.5e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.9	-14.86	-0.63	6.84e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.55	8.13	0.4	8.15e-15	Longevity;
LIHC	cis	rs6788895	1.000	rs7636866	chr3:150461568	A/T	cg07663535	chr3:150480033	SIAH2	0.52	6.37	0.33	6.08e-10	Breast cancer;
LIHC	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.44	7.37	0.37	1.32e-12	Crohn's disease;
LIHC	cis	rs4853525	0.522	rs6744420	chr2:191589082	A/G	cg05765582	chr2:191677683	NA	-0.3	-5.89	-0.3	9.07e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.68e-18	Waist circumference;Weight;
LIHC	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.57	-14.08	-0.61	7.81e-36	White blood cell count (basophil);
LIHC	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg00601450	chr5:74908170	NA	-0.48	-6.84	-0.35	3.62e-11	Age-related disease endophenotypes;
LIHC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg12310025	chr6:25882481	NA	-0.42	-6.32	-0.32	8.09e-10	Height;
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg12792011	chr19:58661915	ZNF329	0.95	7.77	0.39	9.44e-14	Cholesterol, total;
LIHC	trans	rs2363709	1.000	rs7620108	chr3:67423817	A/G	cg15775005	chr18:9136598	ANKRD12	-0.81	-6.07	-0.31	3.33e-9	IgE levels;
LIHC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	6.86	0.35	3.21e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.3	-16.62	-0.67	6.84e-46	Diabetic kidney disease;
LIHC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs10213084	1.000	rs7671823	chr4:147497707	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.66	-9.44	-0.45	5.77e-19	Bronchopulmonary dysplasia;
LIHC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.82	0.51	1.15e-23	Colorectal cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26155979	chr10:105110866	PCGF6	-0.47	-6.27	-0.32	1.07e-9	Hepatitis;
LIHC	cis	rs2273156	1.000	rs8017191	chr14:35469991	G/A	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.26	-0.52	3.07e-25	Diastolic blood pressure;
LIHC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.1e-51	Menopause (age at onset);
LIHC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.55	-0.33	2.08e-10	Response to antipsychotic treatment;
LIHC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.49	-6.85	-0.35	3.49e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26856583	chr16:87425887	MAP1LC3B;FBXO31	0.43	6.19	0.32	1.76e-9	Pancreatic cancer;
LIHC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.6	0.38	2.88e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-6.61	-0.34	1.47e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07627390	chr16:23652638	PALB2;DCTN5	-0.47	-6.97	-0.35	1.61e-11	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19916637	chr8:95961757	TP53INP1	-0.47	-7.11	-0.36	6.8e-12	Pancreatic cancer;
LIHC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.33	-7.27	-0.37	2.5e-12	Ulcerative colitis;
LIHC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.53	8.06	0.4	1.3e-14	Diastolic blood pressure;
LIHC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.72	-10.89	-0.51	6.35e-24	Response to antineoplastic agents;
LIHC	cis	rs7712401	0.623	rs922140	chr5:122088890	A/G	cg18764291	chr5:122110994	SNX2	0.39	6.52	0.33	2.47e-10	Mean platelet volume;
LIHC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.85	11.0	0.51	2.59e-24	Heart rate;
LIHC	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.35	6.51	0.33	2.67e-10	Coronary artery disease;
LIHC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.78e-15	Body mass index;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg10217327	chr6:118973057	C6orf204	-0.67	-6.63	-0.34	1.29e-10	Diastolic blood pressure;
LIHC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.38	6.34	0.32	7.33e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.0	12.77	0.57	8.55e-31	HIV-1 control;
LIHC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.28	-0.32	1.02e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-5.88	-0.3	9.83e-9	Bladder cancer;
LIHC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg19920283	chr7:105172520	RINT1	0.64	5.8	0.3	1.55e-8	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3789045	0.729	rs61817460	chr1:204543579	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.44	-6.78	-0.34	5.31e-11	Educational attainment (college completion);
LIHC	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg24069376	chr3:38537580	EXOG	-0.41	-7.75	-0.39	1.03e-13	Electrocardiographic conduction measures;
LIHC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.43	6.19	0.32	1.76e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.47	-7.55	-0.38	3.9e-13	Neurofibrillary tangles;
LIHC	cis	rs2758596	1.000	rs2758596	chr1:156189286	C/T	cg24450063	chr1:156163899	SLC25A44	1.0	10.5	0.49	1.49e-22	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.6	-10.61	-0.5	6.15e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.45e-10	Prudent dietary pattern;
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.54	7.89	0.39	4e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.71	11.2	0.52	5.31e-25	Educational attainment;
LIHC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg24849736	chr1:201084428	NA	-0.33	-5.93	-0.31	7.59e-9	Permanent tooth development;
LIHC	cis	rs6504950	0.679	rs9908752	chr17:52983216	C/T	cg10237252	chr17:52977213	TOM1L1	-0.36	-6.31	-0.32	8.86e-10	Breast cancer;
LIHC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.0	-8.14	-0.4	7.3e-15	Body mass index;
LIHC	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.32	-0.32	7.93e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.68	-11.2	-0.52	5.01e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.42	-8.49	-0.42	6.34e-16	Obesity-related traits;
LIHC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.58	-9.41	-0.45	7.53e-19	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg21573476	chr21:45109991	RRP1B	-0.6	-11.29	-0.52	2.54e-25	Mean corpuscular volume;
LIHC	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg08135965	chr6:41755394	TOMM6	0.45	6.03	0.31	4.14e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.37	6.2	0.32	1.66e-9	Alzheimer's disease (late onset);
LIHC	trans	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg18335740	chr13:41363409	SLC25A15	0.38	6.64	0.34	1.21e-10	Lewy body disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13938963	chr4:68411314	CENPC1	0.47	6.74	0.34	6.63e-11	Lung function (FEV1/FVC);
LIHC	cis	rs59698941	0.943	rs59634464	chr5:132178735	A/G	cg02081065	chr5:132209139	LEAP2	0.3	6.38	0.33	5.75e-10	Apolipoprotein A-IV levels;
LIHC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	cis	rs4919087	0.748	rs701810	chr10:98974849	C/T	cg25902810	chr10:99078978	FRAT1	-0.54	-6.25	-0.32	1.22e-9	Monocyte count;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	1.000	rs12134896	chr1:8656227	G/A	cg20416874	chr1:8611966	RERE	0.55	7.17	0.36	4.69e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.51	-6.06	-0.31	3.58e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	12.12	0.55	2.33e-28	Eye color traits;
LIHC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.96	-0.44	2.11e-17	Blood metabolite levels;
LIHC	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.75	10.99	0.51	2.96e-24	Response to antineoplastic agents;
LIHC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17507749	chr15:85114479	UBE2QP1	0.7	8.04	0.4	1.44e-14	Schizophrenia;
LIHC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.47	-0.33	3.34e-10	Blood metabolite levels;
LIHC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.42	0.62	3.58e-37	Prudent dietary pattern;
LIHC	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.26	6.09	0.31	3.08e-9	Heart rate;
LIHC	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg20387954	chr3:183756860	HTR3D	0.29	6.17	0.32	1.95e-9	Anterior chamber depth;
LIHC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.26	-0.41	3.31e-15	Chronic sinus infection;
LIHC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg18912006	chr12:123335444	HIP1R	-0.63	-7.64	-0.38	2.14e-13	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg25894440	chr7:65020034	NA	0.51	5.9	0.3	8.83e-9	Diabetic kidney disease;
LIHC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.75e-8	Parkinson's disease;
LIHC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.58	9.25	0.45	2.4e-18	Multiple sclerosis;
LIHC	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.51e-11	Type 2 diabetes;
LIHC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.45	7.79	0.39	8.32e-14	Mean corpuscular volume;
LIHC	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg08126542	chr6:37504118	NA	0.41	6.65	0.34	1.18e-10	Cognitive performance;
LIHC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg16479474	chr6:28041457	NA	0.47	7.15	0.36	5.22e-12	Parkinson's disease;
LIHC	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16684958	chr7:75615977	POR	0.52	8.59	0.42	3.22e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.71	-12.27	-0.55	6.53e-29	Height;
LIHC	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg00012203	chr2:219082015	ARPC2	0.76	10.74	0.5	2.16e-23	Colorectal cancer;
LIHC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.36	5.89	0.3	9.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.53	0.64	1.5e-41	Chronic sinus infection;
LIHC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.72	-12.41	-0.56	1.96e-29	Refractive error;
LIHC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.82	16.24	0.66	2.33e-44	Testicular germ cell tumor;
LIHC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-10.69	-0.5	3.39e-23	Platelet count;
LIHC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg21017887	chr14:105400489	NA	0.67	12.32	0.55	4.03e-29	Rheumatoid arthritis;
LIHC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	13.23	0.58	1.43e-32	Chronic sinus infection;
LIHC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.53	-6.53	-0.33	2.37e-10	Schizophrenia;
LIHC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.39	-6.01	-0.31	4.66e-9	Blood pressure (smoking interaction);
LIHC	cis	rs4908760	0.864	rs6701331	chr1:8670206	A/C	cg20416874	chr1:8611966	RERE	-0.64	-12.41	-0.56	1.83e-29	Vitiligo;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.73	-11.04	-0.51	1.88e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.49	-6.03	-0.31	4.35e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg08822215	chr16:89438651	ANKRD11	-0.46	-7.23	-0.36	3.15e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.53	-6.46	-0.33	3.52e-10	Menarche (age at onset);
LIHC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	8.57	0.42	3.68e-16	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.92	0.35	2.23e-11	Diabetic kidney disease;
LIHC	trans	rs1075232	1.000	rs72722861	chr15:31704288	G/A	cg17859187	chr1:168147929	TIPRL	0.75	6.04	0.31	3.96e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	trans	rs6489882	0.867	rs10850098	chr12:113362058	C/G	cg10175203	chr3:128143634	NA	0.39	6.39	0.33	5.5e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.78	-0.39	8.39e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg19682013	chr15:45996608	NA	-0.4	-7.11	-0.36	6.73e-12	Waist circumference;Weight;
LIHC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-0.83	-6.87	-0.35	3.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.33	-8.42	-0.41	1.01e-15	Hip circumference;Waist circumference;
LIHC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.81	-0.3	1.41e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.52	-8.15	-0.4	6.8e-15	Extraversion;
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.73	10.79	0.5	1.43e-23	Subjective well-being;
LIHC	cis	rs28489187	0.706	rs66811655	chr1:85831544	T/G	cg16011679	chr1:85725395	C1orf52	0.45	5.71	0.3	2.44e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg16970926	chr12:29381810	FAR2	0.29	6.1	0.31	2.81e-9	QT interval;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08134106	chr19:57999036	ZNF419	-0.54	-6.18	-0.32	1.79e-9	Systolic blood pressure;
LIHC	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-0.65	-7.93	-0.39	3.15e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.3	6.5	0.33	2.92e-10	Pulmonary function;
LIHC	cis	rs909002	0.759	rs10914454	chr1:32078940	G/A	cg13919466	chr1:32135498	COL16A1	-0.35	-6.58	-0.34	1.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.41	6.09	0.31	2.98e-9	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg06271696	chr7:157225062	NA	-0.37	-6.52	-0.33	2.54e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.61	9.51	0.46	3.62e-19	Tonsillectomy;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg19635926	chr16:89946313	TCF25	0.57	7.56	0.38	3.82e-13	Skin colour saturation;
LIHC	cis	rs194045	0.511	rs1611991	chr16:29151593	C/T	cg16691023	chr16:29205632	NA	-0.49	-6.55	-0.33	2.13e-10	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-6.78	-0.34	5.31e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg18944383	chr4:111397179	ENPEP	0.26	6.38	0.33	5.72e-10	Coronary artery disease;
LIHC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg11764359	chr7:65958608	NA	-0.58	-5.98	-0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs16828019	0.789	rs36084778	chr1:41479538	A/G	cg03387723	chr1:41708464	SCMH1	-0.42	-6.7	-0.34	8.55e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.25	0.41	3.56e-15	IgG glycosylation;
LIHC	cis	rs72627123	0.867	rs58102735	chr14:74467531	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.63	0.42	2.42e-16	Morning vs. evening chronotype;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22535921	chr3:58419709	PDHB	0.6	7.47	0.37	6.55e-13	Hepatitis;
LIHC	cis	rs748404	0.601	rs489964	chr15:43517554	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.36	-5.99	-0.31	5.25e-9	Lung cancer;
LIHC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.45	-6.11	-0.31	2.74e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6466055	0.720	rs1204077	chr7:104984019	T/C	cg04380332	chr7:105027541	SRPK2	0.37	6.91	0.35	2.32e-11	Schizophrenia;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg00280220	chr17:61926910	NA	0.44	7.12	0.36	6.29e-12	Prudent dietary pattern;
LIHC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.05	0.51	1.78e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg25894440	chr7:65020034	NA	-0.45	-5.79	-0.3	1.6e-8	Diabetic kidney disease;
LIHC	cis	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg20368463	chr18:77673604	PQLC1	-0.34	-5.79	-0.3	1.6e-8	Schizophrenia;
LIHC	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	0.85	10.88	0.51	7.23e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.84	-0.3	1.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs910316	0.737	rs175045	chr14:75475275	A/C	cg00929392	chr1:19283191	IFFO2	-0.45	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg05041596	chr11:89867385	NAALAD2	0.43	7.54	0.38	4.23e-13	White blood cell types;
LIHC	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.32	7.5	0.38	5.5e-13	Weight;
LIHC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.42	7.87	0.39	4.71e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7937890	0.559	rs2575830	chr11:14485602	C/A	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.71	-9.21	-0.45	3.42e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.73	-11.49	-0.53	4.78e-26	White matter hyperintensity burden;
LIHC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.64	-12.8	-0.57	6.41e-31	Sense of smell;
LIHC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg26149184	chr10:133730230	NA	0.48	7.51	0.38	5.25e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg11648662	chr10:69524272	NA	0.33	6.08	0.31	3.2e-9	Calcium levels;
LIHC	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.78	12.95	0.57	1.68e-31	Phospholipid levels (plasma);
LIHC	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.92	-0.3	7.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs77861329	1.000	rs352150	chr3:52209995	A/G	cg08692210	chr3:52188851	WDR51A	0.84	8.06	0.4	1.32e-14	Macrophage inflammatory protein 1b levels;
LIHC	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-8.22	-0.41	4.3e-15	Exhaled nitric oxide output;
LIHC	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.35	6.12	0.31	2.57e-9	Metabolite levels;
LIHC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.44	6.19	0.32	1.71e-9	Height;
LIHC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11958404	0.615	rs7717217	chr5:157447749	C/T	cg05962755	chr5:157440814	NA	0.59	7.83	0.39	6.15e-14	IgG glycosylation;
LIHC	cis	rs7945718	0.840	rs10741601	chr11:12735873	T/C	cg25843174	chr11:12811716	TEAD1	0.3	6.86	0.35	3.34e-11	Educational attainment (years of education);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19970425	chr15:55581976	RAB27A	0.4	6.24	0.32	1.28e-9	Calcium levels;
LIHC	cis	rs17106184	0.901	rs59600829	chr1:51405667	C/T	cg07174182	chr1:51127561	FAF1	-0.75	-7.9	-0.39	3.96e-14	Type 2 diabetes;
LIHC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.56	-8.01	-0.4	1.84e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12500138	1.000	rs72995997	chr4:166215850	G/A	cg25064052	chr4:166216151	KLHL2	-0.61	-5.77	-0.3	1.8e-8	Cognitive function;
LIHC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.41	5.83	0.3	1.3e-8	Cognitive ability;
LIHC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.39	8.03	0.4	1.54e-14	Type 2 diabetes;
LIHC	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.49	8.75	0.43	9.76e-17	Urate levels in overweight individuals;
LIHC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.86	9.05	0.44	1.12e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21702128	chr5:142784721	NR3C1	0.44	6.31	0.32	8.47e-10	Pancreatic cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21487267	chr8:41386754	GINS4	-0.52	-6.5	-0.33	2.83e-10	Systolic blood pressure;
LIHC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.08	12.77	0.57	8.03e-31	Vitiligo;
LIHC	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg05110241	chr16:68378359	PRMT7	-0.51	-6.07	-0.31	3.45e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-8.03	-0.4	1.59e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	0.91	17.11	0.68	7.42e-48	Bone mineral density;
LIHC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.94	17.56	0.69	1.21e-49	Menopause (age at onset);
LIHC	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.54	10.25	0.48	1.12e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.63	-8.76	-0.43	9.31e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg10755058	chr3:40428713	ENTPD3	0.42	7.14	0.36	5.46e-12	Renal cell carcinoma;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05590233	chr17:109545	RPH3AL	0.42	6.05	0.31	3.91e-9	Longevity;
LIHC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.76	-11.98	-0.54	7.57e-28	Colorectal cancer;
LIHC	cis	rs11644362	1.000	rs4781349	chr16:12987249	T/C	cg06890432	chr16:12997467	SHISA9	-0.4	-6.77	-0.34	5.57e-11	Positive affect;Subjective well-being;
LIHC	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.56	-13.79	-0.6	1.05e-34	White blood cell count (basophil);
LIHC	cis	rs7116495	1.000	rs2186637	chr11:71570115	C/T	cg26138937	chr11:71823887	C11orf51	0.68	6.63	0.34	1.3100000000000001e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.25	-0.41	3.35e-15	Putamen volume;
LIHC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg13844804	chr7:814759	HEATR2	0.44	5.94	0.31	6.96e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.15	-0.36	5.32e-12	Mean platelet volume;
LIHC	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.33	-0.41	1.92e-15	Extraversion;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.64	0.42	2.24e-16	Lymphocyte counts;
LIHC	cis	rs2108622	0.727	rs8102532	chr19:15980060	G/A	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.72	-0.47	7.19e-20	Ulcerative colitis;
LIHC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg09222892	chr1:25734099	RHCE	-0.47	-8.85	-0.43	4.7e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.44	8.1	0.4	9.71e-15	Prudent dietary pattern;
LIHC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.33	0.45	1.38e-18	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.58	0.59	6.97e-34	Prudent dietary pattern;
LIHC	cis	rs12464559	0.649	rs4393745	chr2:152594206	G/T	cg01189475	chr2:152685088	ARL5A	0.7	7.91	0.39	3.58e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.77	5.74	0.3	2.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.6	7.73	0.39	1.2e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.96	10.83	0.51	1.06e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs1144333	0.655	rs1146602	chr1:76239309	A/G	cg22875332	chr1:76189707	ACADM	-0.44	-6.46	-0.33	3.56e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg18357645	chr12:58087776	OS9	-0.41	-5.93	-0.31	7.46e-9	Multiple sclerosis;
LIHC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.72	-10.85	-0.51	8.84e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg24209194	chr3:40518798	ZNF619	0.49	7.23	0.36	3.17e-12	Renal cell carcinoma;
LIHC	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg02733842	chr7:1102375	C7orf50	-0.69	-7.68	-0.38	1.75e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.66	13.84	0.6	6.58e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.35	0.59	5.28e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.74	13.35	0.59	5.24e-33	Prudent dietary pattern;
LIHC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.37	6.51	0.33	2.76e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.94	13.39	0.59	3.54e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg22199361	chr20:5081567	C20orf30	-0.44	-7.13	-0.36	6.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.28	0.32	1.05e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg03959625	chr15:84868606	LOC388152	0.45	6.29	0.32	9.46e-10	Schizophrenia;
LIHC	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.3	-6.21	-0.32	1.54e-9	Lupus nephritis in systemic lupus erythematosus;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24123311	chr19:48675164	NA	0.41	6.19	0.32	1.69e-9	Bilirubin levels;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.63	-0.59	4.33e-34	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	0.85	10.0	0.48	7.79e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.63	0.5	5.27e-23	Fuchs's corneal dystrophy;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg05969148	chr19:51307846	C19orf48	-0.41	-6.55	-0.33	2.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg25281562	chr12:121454272	C12orf43	0.38	6.49	0.33	2.98e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-9.94	-0.47	1.28e-20	Initial pursuit acceleration;
LIHC	cis	rs10744422	1.000	rs2343108	chr12:123331301	C/T	cg25930673	chr12:123319894	HIP1R	-0.93	-12.2	-0.55	1.12e-28	Schizophrenia;
LIHC	cis	rs713477	1.000	rs10782426	chr14:55890702	G/A	cg13175173	chr14:55914753	NA	-0.31	-7.0	-0.35	1.33e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.82	0.6	8.14e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs7945718	0.870	rs10765988	chr11:12731218	C/T	cg25843174	chr11:12811716	TEAD1	0.29	6.55	0.33	2.12e-10	Educational attainment (years of education);
LIHC	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.7	-0.34	8.57e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.68	0.46	9.72e-20	Alzheimer's disease;
LIHC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-11.52	-0.53	3.63e-26	Platelet distribution width;
LIHC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.12	0.55	2.32e-28	Menopause (age at onset);
LIHC	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	cg10932868	chr11:921992	NA	0.35	6.53	0.33	2.41e-10	Alzheimer's disease (late onset);
LIHC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.75	-11.5	-0.53	4.42e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.86	17.86	0.69	6.99e-51	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	6.49	0.33	3.05e-10	Blood protein levels;
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.6	7.47	0.37	6.87e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.35	0.56	3.04e-29	Cognitive test performance;
LIHC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	7.65	0.38	2.05e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.5	-7.3	-0.37	2.06e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.29	7.33	0.37	1.63e-12	Resting heart rate;
LIHC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.56	7.57	0.38	3.61e-13	Blood metabolite levels;
LIHC	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg26677194	chr12:130822605	PIWIL1	0.53	7.23	0.36	3.17e-12	Menopause (age at onset);
LIHC	trans	rs2211698	1.000	rs2070364	chr21:35827222	G/A	cg18044562	chr7:50468399	IKZF1	0.5	7.22	0.36	3.44e-12	Cancer;
LIHC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.11	15.74	0.65	2.26e-42	Gut microbiome composition (summer);
LIHC	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg04592579	chr7:75616294	TMEM120A	-0.35	-6.08	-0.31	3.15e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.42	5.98	0.31	5.52e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.88	-0.54	1.8e-27	Coffee consumption (cups per day);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06367102	chr7:1192688	ZFAND2A	0.56	6.91	0.35	2.38e-11	Lung function (FEV1);
LIHC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg23262073	chr20:60523788	NA	-0.29	-5.9	-0.3	8.92e-9	Body mass index;
LIHC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs2625529	0.938	rs9120	chr15:72115763	G/A	cg16672083	chr15:72433130	SENP8	-0.33	-6.14	-0.32	2.26e-9	Red blood cell count;
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.52	7.07	0.36	9e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.16	-0.48	2.32e-21	Response to antipsychotic treatment;
LIHC	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.2	28.8	0.84	1.89e-93	Schizophrenia;
LIHC	cis	rs12744310	1.000	rs12030372	chr1:41762029	A/G	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.88	0.39	4.52e-14	Tonsillectomy;
LIHC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.77	12.34	0.56	3.42e-29	Corneal astigmatism;
LIHC	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.86	-0.3	1.09e-8	Calcium levels;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22752049	chr19:45805741	MARK4	0.5	6.06	0.31	3.64e-9	Lung function (FEV1);
LIHC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.87	12.43	0.56	1.59e-29	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26979339	chr12:107168153	RIC8B	-0.46	-6.71	-0.34	7.96e-11	Cognitive function;
LIHC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13409248	chr3:40428643	ENTPD3	0.4	6.6	0.34	1.52e-10	Renal cell carcinoma;
LIHC	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.88	-0.35	2.88e-11	Schizophrenia;
LIHC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-8.97	-0.44	1.94e-17	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.85	-0.39	5.38e-14	Coronary artery disease;
LIHC	cis	rs16922576	0.623	rs2104166	chr9:5230447	T/C	cg02405213	chr9:5042618	JAK2	-0.64	-9.88	-0.47	1.98e-20	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.6	-0.38	2.92e-13	Breast cancer;
LIHC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.06	-0.51	1.7e-24	Chronic sinus infection;
LIHC	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	0.8	9.18	0.44	4.14e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs4934494	0.636	rs34408087	chr10:91543551	G/A	cg19698084	chr10:91461284	KIF20B	-0.44	-5.88	-0.3	9.5e-9	Red blood cell count;
LIHC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.44	-9.39	-0.45	8.77e-19	Rheumatoid arthritis;
LIHC	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.33	6.98	0.35	1.5e-11	Sitting height ratio;
LIHC	trans	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg10756647	chr7:56101905	PSPH	1.07	13.05	0.58	6.97e-32	Diabetic kidney disease;
LIHC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.1	-10.33	-0.49	5.84e-22	Breast cancer;
LIHC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-8.15	-0.4	7.15e-15	Inflammatory bowel disease;
LIHC	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.59	-9.85	-0.47	2.5e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	11.19	0.52	5.58e-25	Motion sickness;
LIHC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.13	0.31	2.44e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs9467160	0.501	rs1772257	chr6:24441214	C/T	cg20631270	chr6:24437470	GPLD1	-0.41	-6.09	-0.31	3.07e-9	Liver enzyme levels;
LIHC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	1.0	11.97	0.54	8.13e-28	Red blood cell traits;
LIHC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.48	7.75	0.39	1.07e-13	Cognitive function;
LIHC	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-9.57	-0.46	2.22e-19	Schizophrenia;
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg21486233	chr12:29375141	FAR2	0.3	5.82	0.3	1.36e-8	QT interval;
LIHC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg15848620	chr12:58087721	OS9	-0.55	-7.43	-0.37	8.96e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg26752888	chr8:11627280	NEIL2	0.56	7.37	0.37	1.28e-12	Myopia (pathological);
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03067192	chr7:72300134	SBDSP;TYW1B	0.46	6.12	0.31	2.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.7	-0.34	8.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs16944613	0.588	rs8024734	chr15:91107067	T/C	cg26821196	chr15:91095069	CRTC3	0.45	7.58	0.38	3.22e-13	Colorectal cancer;
LIHC	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg20697417	chr1:41786797	NA	0.31	5.91	0.3	8.3e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.54	0.56	6.37e-30	Alzheimer's disease;
LIHC	cis	rs7546668	1.000	rs10803392	chr1:15876758	C/T	cg11706911	chr1:15910989	AGMAT	0.45	6.74	0.34	6.81e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.71	-0.34	8.05e-11	Total body bone mineral density;
LIHC	cis	rs2710642	0.576	rs974344	chr2:62883176	C/G	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.44	8.17	0.4	6.08e-15	Prudent dietary pattern;
LIHC	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg20703997	chr1:4087676	NA	0.51	6.47	0.33	3.38e-10	Interleukin-17 levels;
LIHC	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.73	11.97	0.54	8.28e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.29	-6.56	-0.33	2.03e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.48e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.22	0.32	1.42e-9	Mean corpuscular volume;
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.74	0.3	2.04e-8	Longevity;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18679782	chr19:10216839	SNORD105;PPAN-P2RY11;PPAN	0.45	6.25	0.32	1.21e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg10932868	chr11:921992	NA	0.35	6.48	0.33	3.25e-10	Alzheimer's disease (late onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06766273	chr11:62521983	ZBTB3	0.54	7.91	0.39	3.7e-14	Pancreatic cancer;
LIHC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.74	9.65	0.46	1.24e-19	Body mass index;
LIHC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.91	-0.43	3.13e-17	Colorectal cancer;
LIHC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.69	0.6	2.47e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.69	0.38	1.62e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs6545883	0.894	rs778158	chr2:61555421	A/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.35	-0.37	1.48e-12	Tuberculosis;
LIHC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg20335179	chr10:1068567	C10orf110;IDI2	0.55	5.77	0.3	1.78e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.95	-0.4	2.69e-14	Migraine;Coronary artery disease;
LIHC	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.71e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg15192750	chr16:69999425	NA	0.47	6.97	0.35	1.64e-11	IgE levels;
LIHC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.99	0.31	5.44e-9	Aortic root size;
LIHC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	11.16	0.52	7.29e-25	Lung cancer in ever smokers;
LIHC	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.33	-0.32	7.73e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.66	-9.86	-0.47	2.31e-20	Coronary artery disease;
LIHC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg09835421	chr16:68378352	PRMT7	-0.49	-6.0	-0.31	4.94e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LIHC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	4.03e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12644436	0.577	rs4635785	chr4:88784220	A/G	cg06891869	chr4:88767617	MEPE	0.44	7.76	0.39	9.6e-14	HIV-1 viral setpoint;
LIHC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg03959625	chr15:84868606	LOC388152	0.45	6.52	0.33	2.48e-10	Schizophrenia;
LIHC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.06	-0.31	3.59e-9	Schizophrenia;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.31	-0.37	1.9e-12	Longevity;Endometriosis;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.06	0.55	3.63e-28	Prudent dietary pattern;
LIHC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.49	-0.53	4.55e-26	Type 2 diabetes;
LIHC	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg27205649	chr11:78285834	NARS2	-0.38	-5.88	-0.3	9.86e-9	Alzheimer's disease (survival time);
LIHC	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.56	7.65	0.38	2.08e-13	Dialysis-related mortality;
LIHC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.1	9.96	0.47	1.1e-20	Diabetic retinopathy;
LIHC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.88	0.35	2.92e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.83	0.39	6.05e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs507080	0.883	rs558593	chr11:118562520	C/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.73e-10	Serum metabolite levels;
LIHC	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.55	-9.91	-0.47	1.62e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg15871215	chr5:81402204	ATG10	0.68	8.24	0.41	3.82e-15	Breast cancer;
LIHC	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg25894440	chr7:65020034	NA	-0.55	-6.3	-0.32	9.1e-10	Diabetic kidney disease;
LIHC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.6	-8.51	-0.42	5.36e-16	Blood metabolite levels;
LIHC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg03146154	chr1:46216737	IPP	0.48	8.08	0.4	1.12e-14	Red blood cell count;Reticulocyte count;
LIHC	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.71	10.25	0.48	1.14e-21	Prostate cancer;
LIHC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-8.02	-0.4	1.75e-14	Schizophrenia;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.5	6.74	0.34	6.82e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg23485639	chr6:28045615	ZNF165	0.36	5.75	0.3	2e-8	Cardiac Troponin-T levels;
LIHC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.88	8.42	0.41	1.04e-15	Inflammatory bowel disease;
LIHC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.65	-11.6	-0.53	1.8e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.42	-7.74	-0.39	1.1e-13	Schizophrenia;
LIHC	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	10.87	0.51	7.54e-24	Alzheimer's disease (late onset);
LIHC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.8	13.2	0.58	1.86e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.79	-0.3	1.57e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.95	0.51	3.9e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.57	-7.35	-0.37	1.45e-12	Blood trace element (Cu levels);
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.69	9.4	0.45	8.19e-19	Aortic root size;
LIHC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	8.23	0.41	4.04e-15	Multiple sclerosis;
LIHC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.39	-7.1	-0.36	7.43e-12	Electrocardiographic conduction measures;
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04498913	chr7:1135747	C7orf50	0.44	6.97	0.35	1.68e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.39e-18	Subjective well-being;
LIHC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg05555928	chr11:63887634	MACROD1	0.48	6.12	0.31	2.56e-9	Mean platelet volume;
LIHC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.5	16.55	0.67	1.29e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	20.67	0.75	3.66e-62	Prudent dietary pattern;
LIHC	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.81	14.11	0.61	5.84e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.32	-0.64	1.07e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	0.8	7.37	0.37	1.26e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9918079	0.560	rs10008376	chr4:15623955	A/G	cg16509355	chr4:15471240	CC2D2A	0.44	6.83	0.35	3.91e-11	Obesity-related traits;
LIHC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.42	5.96	0.31	6.39e-9	Coronary artery disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00345621	chr19:1277218	C19orf24	-0.39	-6.4	-0.33	5.2400000000000005e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11212260	0.655	rs11212212	chr11:107286118	T/C	cg25435332	chr11:107328525	CWF19L2	0.8	8.47	0.42	7.45e-16	IgG glycosylation;
LIHC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17507749	chr15:85114479	UBE2QP1	0.75	8.58	0.42	3.44e-16	Schizophrenia;
LIHC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-9.26	-0.45	2.38e-18	Schizophrenia;
LIHC	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.88e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.12e-15	Prudent dietary pattern;
LIHC	cis	rs965469	1.000	rs3310	chr20:3237232	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.78	-0.34	5.35e-11	IFN-related cytopenia;
LIHC	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.53	-7.48	-0.38	6.19e-13	Cognitive function;
LIHC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.67	-9.28	-0.45	1.98e-18	Aortic root size;
LIHC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.57	9.28	0.45	2.01e-18	Multiple sclerosis;
LIHC	cis	rs1144333	0.850	rs1251273	chr1:76288617	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.77	-0.34	5.58e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.04	21.76	0.76	1.69e-66	Schizophrenia;
LIHC	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg17385448	chr1:15911702	AGMAT	0.4	6.81	0.35	4.41e-11	Systolic blood pressure;
LIHC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.03e-19	Height;
LIHC	cis	rs747782	0.646	rs75129833	chr11:47846202	T/C	cg20307385	chr11:47447363	PSMC3	-0.56	-6.05	-0.31	3.89e-9	Intraocular pressure;
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.59	8.69	0.43	1.5e-16	Prudent dietary pattern;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg27141850	chr2:20869434	GDF7	-0.34	-6.29	-0.32	9.66e-10	Abdominal aortic aneurysm;
LIHC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg01300405	chr19:19626978	NDUFA13;TSSK6	-0.49	-6.07	-0.31	3.37e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.36	6.55	0.33	2.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	10.18	0.48	1.89e-21	Platelet count;
LIHC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.51	9.61	0.46	1.66e-19	Atrioventricular conduction;
LIHC	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.57	-9.81	-0.47	3.57e-20	Recombination rate (males);
LIHC	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.99	-0.35	1.42e-11	Metabolite levels;
LIHC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.38	6.07	0.31	3.36e-9	Menopause (age at onset);
LIHC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.11	-0.31	2.75e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10197940	0.967	rs4664423	chr2:152266311	T/C	cg06191203	chr2:152266755	RIF1	-0.52	-9.97	-0.47	1.04e-20	Lung cancer;
LIHC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.46	7.01	0.35	1.31e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.75	13.68	0.59	2.85e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg12365402	chr11:9010492	NRIP3	0.29	7.59	0.38	3.01e-13	Hemoglobin concentration;
LIHC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	1.1	12.95	0.57	1.73e-31	Eosinophil percentage of granulocytes;
LIHC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.68	-9.41	-0.45	7.46e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.6	9.09	0.44	8.14e-18	Menopause (age at onset);
LIHC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.48	8.07	0.4	1.22e-14	Obesity-related traits;
LIHC	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	cg04338863	chr8:33670619	NA	0.31	5.8	0.3	1.53e-8	Body mass index;
LIHC	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.42	-0.33	4.6e-10	Total cholesterol levels;
LIHC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.06	-12.43	-0.56	1.56e-29	Vitiligo;
LIHC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.75	11.05	0.51	1.83e-24	Corneal astigmatism;
LIHC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.86	0.51	8.25e-24	Monocyte percentage of white cells;
LIHC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.68	8.51	0.42	5.44e-16	Mean platelet volume;
LIHC	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.51	-0.49	1.42e-22	Eye color traits;
LIHC	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg19920283	chr7:105172520	RINT1	0.48	5.93	0.31	7.6e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg04719120	chr6:96025338	MANEA	0.55	6.49	0.33	3.03e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.72	-0.3	2.3e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg25039879	chr17:56429692	SUPT4H1	0.79	8.95	0.44	2.32e-17	Cognitive test performance;
LIHC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.06e-25	Tonsillectomy;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.77	-0.43	8.6e-17	Total body bone mineral density;
LIHC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg16576597	chr16:28551801	NUPR1	0.37	5.86	0.3	1.09e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.92	-0.35	2.2e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg07959070	chr22:50026188	C22orf34	-0.3	-7.22	-0.36	3.33e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.36	5.89	0.3	9.4e-9	Platelet distribution width;
LIHC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.38e-26	Corneal astigmatism;
LIHC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.34	8.33	0.41	1.99e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.69	0.43	1.55e-16	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg10755058	chr3:40428713	ENTPD3	0.41	7.06	0.36	9.58e-12	Renal cell carcinoma;
LIHC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.45	6.23	0.32	1.36e-9	Height;
LIHC	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.73	7.87	0.39	4.75e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg12560992	chr17:57184187	TRIM37	-0.81	-11.82	-0.54	2.93e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.42	-6.49	-0.33	3.1e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LIHC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.01	-0.44	1.43e-17	Bipolar disorder;
LIHC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.41	-6.47	-0.33	3.33e-10	Lymphocyte percentage of white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19613905	chr15:56757180	MNS1	0.4	6.76	0.34	6.05e-11	Cognitive function;
LIHC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	7.54	0.38	4.16e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.85	12.86	0.57	3.79e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04252558	chr8:74884436	TCEB1	-0.51	-6.26	-0.32	1.18e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.59	5.76	0.3	1.91e-8	Plasma clusterin levels;
LIHC	cis	rs17094222	0.812	rs11190644	chr10:102433046	C/T	cg26540559	chr10:102447443	NA	0.33	6.41	0.33	4.83e-10	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg05262829	chr1:226921576	ITPKB	0.43	8.44	0.42	8.83e-16	Parkinson's disease;
LIHC	cis	rs1639906	0.895	rs78469080	chr7:2200729	G/A	cg22963979	chr7:1858916	MAD1L1	0.41	5.76	0.3	1.85e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg22528358	chr1:107598549	PRMT6	-0.73	-12.36	-0.56	2.95e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs67981189	0.593	rs7152845	chr14:71527223	A/G	cg15816911	chr14:71606274	NA	0.42	6.81	0.35	4.46e-11	Schizophrenia;
LIHC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	6.81	0.35	4.49e-11	Menopause (age at onset);
LIHC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.77	-10.77	-0.5	1.67e-23	Systemic lupus erythematosus;
LIHC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.64	9.72	0.47	6.93e-20	Height;
LIHC	cis	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Extraversion;
LIHC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.63	11.25	0.52	3.44e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs4908768	0.539	rs7537982	chr1:8644007	C/T	cg20416874	chr1:8611966	RERE	-0.63	-12.64	-0.56	2.64e-30	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.45	6.18	0.32	1.85e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.15	0.4	7.04e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17152411	0.895	rs61872120	chr10:126583588	T/G	cg07906193	chr10:126599966	NA	0.43	6.94	0.35	1.93e-11	Height;
LIHC	trans	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.2	-0.41	4.87e-15	Obesity-related traits;
LIHC	cis	rs1494950	1.000	rs7661252	chr4:14981989	C/T	cg12377275	chr4:15005593	CPEB2	-0.82	-7.1	-0.36	7.45e-12	Political ideology;
LIHC	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.65	13.14	0.58	3.18e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.61	0.53	1.76e-26	Coffee consumption (cups per day);
LIHC	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.64	-9.24	-0.45	2.77e-18	White matter hyperintensity burden;
LIHC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.74	12.55	0.56	5.73e-30	Aortic root size;
LIHC	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.75	0.39	1.08e-13	Corneal astigmatism;
LIHC	cis	rs6596100	0.538	rs66481372	chr5:132179592	T/A	cg02081065	chr5:132209139	LEAP2	0.3	6.38	0.33	5.75e-10	Breast cancer;
LIHC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg16970926	chr12:29381810	FAR2	0.31	6.35	0.32	7.06e-10	QT interval;
LIHC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.5	-7.62	-0.38	2.53e-13	Extraversion;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05965430	chr12:49962171	MCRS1	0.41	6.52	0.33	2.59e-10	Calcium levels;
LIHC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.56	-8.42	-0.41	1.05e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg05527609	chr1:210001259	C1orf107	0.59	8.04	0.4	1.44e-14	Red blood cell count;
LIHC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	trans	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg14791747	chr16:20752902	THUMPD1	-0.48	-6.6	-0.34	1.58e-10	Dental caries;
LIHC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.5	6.24	0.32	1.31e-9	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.33	-6.16	-0.32	2.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4908768	0.501	rs12046643	chr1:8547866	A/C	cg20416874	chr1:8611966	RERE	-0.69	-14.73	-0.62	2.25e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-12.46	-0.56	1.21e-29	Vitiligo;
LIHC	cis	rs1385374	0.920	rs61946174	chr12:129272971	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.66	0.38	1.97e-13	Systemic lupus erythematosus;
LIHC	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.53	8.89	0.43	3.62e-17	Schizophrenia;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg05867307	chr4:144106066	USP38	0.43	6.04	0.31	3.96e-9	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.47	-7.67	-0.38	1.83e-13	Longevity;Endometriosis;
LIHC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg13175981	chr1:150552382	MCL1	-0.44	-6.01	-0.31	4.84e-9	Tonsillectomy;
LIHC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.53	6.89	0.35	2.62e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg12253828	chr6:101329408	ASCC3	-0.4	-6.08	-0.31	3.12e-9	Neuroticism;
LIHC	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.53	6.8	0.35	4.57e-11	Mosquito bite size;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02119764	chr16:53469525	RBL2	-0.41	-6.22	-0.32	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.58	9.21	0.45	3.39e-18	Obesity-related traits;
LIHC	trans	rs9914544	0.545	rs4290526	chr17:18772967	T/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.52	-0.33	2.51e-10	Educational attainment (years of education);
LIHC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08736216	chr1:53307985	ZYG11A	-0.32	-6.13	-0.31	2.37e-9	Monocyte count;
LIHC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.82	12.26	0.55	6.73e-29	Motion sickness;
LIHC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.97	17.45	0.69	3.2e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.35e-9	Total body bone mineral density;
LIHC	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	6.56	0.33	2.01e-10	Schizophrenia;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-9.02	-0.44	1.39e-17	Lymphocyte counts;
LIHC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1029738	0.500	rs10264536	chr7:22884898	G/A	cg11367502	chr7:22862612	TOMM7	-0.37	-6.09	-0.31	2.96e-9	Fibrinogen levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25671374	chr19:10230567	EIF3G	0.44	6.09	0.31	3.02e-9	Lung function (FEV1/FVC);
LIHC	trans	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg10756647	chr7:56101905	PSPH	0.47	6.95	0.35	1.86e-11	Aortic root size;
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-9.32	-0.45	1.52e-18	Longevity;Endometriosis;
LIHC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg16070123	chr10:51489643	NA	0.38	6.03	0.31	4.15e-9	Prostate-specific antigen levels;
LIHC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg16836995	chr17:43662488	NA	-0.76	-7.81	-0.39	7.02e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.44	6.01	0.31	4.75e-9	Iron status biomarkers;
LIHC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-11.45	-0.53	6.49e-26	Electrocardiographic conduction measures;
LIHC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.41	-6.38	-0.33	5.89e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.19	-0.63	3.57e-40	Coronary artery disease;
LIHC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.56	8.88	0.43	3.89e-17	Heart rate;
LIHC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.4	-6.07	-0.31	3.31e-9	Multiple myeloma;
LIHC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg16736954	chr20:23401023	NAPB	0.72	8.44	0.42	9.01e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17102423	0.806	rs4902362	chr14:65582755	G/A	cg16583315	chr14:65563665	MAX	0.4	8.02	0.4	1.68e-14	Obesity-related traits;
LIHC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg12863693	chr15:85201151	NMB	0.43	5.91	0.3	8.36e-9	Schizophrenia;
LIHC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg14092571	chr14:90743983	NA	-0.38	-5.98	-0.31	5.75e-9	Mortality in heart failure;
LIHC	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.66	7.96	0.4	2.59e-14	Itch intensity from mosquito bite;
LIHC	trans	rs4714291	0.832	rs761798	chr6:40087514	C/T	cg02267698	chr19:7991119	CTXN1	0.39	6.59	0.34	1.67e-10	Strep throat;
LIHC	cis	rs6060717	0.653	rs2590962	chr20:34615363	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.99	-0.4	2.14e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs847649	1.000	rs13233521	chr7:102593794	C/T	cg18108683	chr7:102477205	FBXL13	0.47	7.31	0.37	1.96e-12	Morning vs. evening chronotype;
LIHC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	6.04	0.31	4e-9	Obesity-related traits;
LIHC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.71	12.42	0.56	1.69e-29	Platelet distribution width;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04525508	chr3:124774877	HEG1	-0.47	-6.53	-0.33	2.36e-10	Bilirubin levels;
LIHC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.62	0.42	2.5e-16	Motion sickness;
LIHC	cis	rs3736485	0.932	rs4775946	chr15:51775930	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.15	-0.32	2.11e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.34	0.45	1.31e-18	Bipolar disorder;
LIHC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-12.15	-0.55	1.7e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.27	-0.7	1.6e-52	Height;
LIHC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.7	0.46	8.04e-20	Electroencephalogram traits;
LIHC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.62	-9.96	-0.47	1.12e-20	Metabolic syndrome;
LIHC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg05343316	chr1:45956843	TESK2	-0.44	-6.11	-0.31	2.69e-9	High light scatter reticulocyte count;
LIHC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.13	-0.44	6.13e-18	Bipolar disorder;
LIHC	cis	rs4908768	0.906	rs12401496	chr1:8600401	C/T	cg20416874	chr1:8611966	RERE	0.57	8.73	0.43	1.16e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.29	-6.78	-0.34	5.17e-11	Longevity;Endometriosis;
LIHC	cis	rs420259	0.727	rs249869	chr16:23666557	G/T	cg05131483	chr16:23706242	ERN2	0.34	5.8	0.3	1.55e-8	Bipolar disorder;
LIHC	cis	rs7923837	0.651	rs10882092	chr10:94379223	G/A	cg25506282	chr10:94462361	NA	0.34	5.75	0.3	2.02e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.33	-6.54	-0.33	2.19e-10	DNA methylation (variation);
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.47	-7.57	-0.38	3.56e-13	Testicular germ cell tumor;
LIHC	trans	rs9641123	0.670	rs2677089	chr7:93260091	A/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.47	-0.33	3.33e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.41	-5.91	-0.3	8.08e-9	Asthma;
LIHC	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.51	-0.62	1.72e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.78	12.51	0.56	8.17e-30	Corneal astigmatism;
LIHC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.04	-0.4	1.46e-14	Crohn's disease;
LIHC	cis	rs2412488	0.893	rs10007903	chr4:54341313	G/A	cg22241045	chr4:54363911	LNX1	-0.41	-6.57	-0.33	1.86e-10	DNA methylation (variation);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25907053	chr2:70369816	NA	-0.45	-6.3	-0.32	9.37e-10	Immature fraction of reticulocytes;
LIHC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.69	-8.53	-0.42	4.68e-16	Gut microbiome composition (summer);
LIHC	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.1	-0.31	2.95e-9	Ulcerative colitis;
LIHC	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.36	-6.27	-0.32	1.09e-9	Menopause (age at onset);
LIHC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.66	10.85	0.51	9.37e-24	Pulse pressure;
LIHC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.58	0.53	2.23e-26	Coronary artery disease;
LIHC	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.39	-6.61	-0.34	1.47e-10	Menopause (age at onset);
LIHC	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg10820045	chr2:198174542	NA	0.45	6.81	0.35	4.4e-11	Intracranial aneurysm;
LIHC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.48	-7.86	-0.39	4.92e-14	Blood metabolite levels;
LIHC	cis	rs11229555	0.609	rs34782543	chr11:58187398	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6782228	0.675	rs56141228	chr3:128386042	C/T	cg16766828	chr3:128327626	NA	-0.43	-6.77	-0.34	5.68e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-7.21	-0.36	3.52e-12	Uric acid levels;
LIHC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	8.47	0.42	7.24e-16	Eotaxin levels;
LIHC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.49	8.27	0.41	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.11	0.31	2.69e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.47	6.62	0.34	1.37e-10	Schizophrenia;
LIHC	cis	rs9596863	0.898	rs9596847	chr13:54322250	A/G	ch.13.53330881F	chr13:54432880	NA	0.42	5.73	0.3	2.19e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10967178	chr1:6454278	ACOT7	0.42	6.2	0.32	1.61e-9	Pancreatic cancer;
LIHC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.72	-10.85	-0.51	8.84e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg00204748	chr12:29376779	FAR2	0.42	7.7	0.38	1.44e-13	QT interval;
LIHC	cis	rs7395581	1.000	rs7395581	chr11:47246397	G/A	cg25783544	chr11:47291846	MADD	-0.48	-7.01	-0.35	1.3e-11	HDL cholesterol;
LIHC	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	8.75	0.43	9.65e-17	Eotaxin levels;
LIHC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.18	-0.36	4.33e-12	Response to antipsychotic treatment;
LIHC	cis	rs2625529	0.668	rs12914070	chr15:72334279	T/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.92	-0.3	8.01e-9	Red blood cell count;
LIHC	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg10820045	chr2:198174542	NA	0.47	7.11	0.36	7.02e-12	Dermatomyositis;
LIHC	cis	rs11955398	0.501	rs10067618	chr5:60010995	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.41	-5.8	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg07952391	chr2:88470173	THNSL2	0.64	5.71	0.3	2.45e-8	Plasma clusterin levels;
LIHC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21467203	chr3:49911342	NA	0.53	9.63	0.46	1.36e-19	Body mass index;
LIHC	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.23	-0.32	1.38e-9	Pancreatic cancer;
LIHC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.74e-11	IgG glycosylation;
LIHC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.15	-0.36	5.25e-12	Monocyte percentage of white cells;
LIHC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg18964960	chr10:1102726	WDR37	0.62	6.17	0.32	1.95e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg19680672	chr10:131412579	MGMT	0.46	7.09	0.36	7.94e-12	Response to temozolomide;
LIHC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.59	8.81	0.43	6.59e-17	Platelet count;
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13126279	chr21:47581558	C21orf56	-0.39	-5.98	-0.31	5.77e-9	Testicular germ cell tumor;
LIHC	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.5	-6.32	-0.32	8.24e-10	Heschl's gyrus morphology;
LIHC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg00277334	chr10:82204260	NA	-0.46	-6.65	-0.34	1.18e-10	Post bronchodilator FEV1;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.92	0.3	7.8e-9	Personality dimensions;
LIHC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.5	-8.05	-0.4	1.35e-14	Diastolic blood pressure;
LIHC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.75	-0.34	6.21e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.37	-0.33	5.98e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.74	10.86	0.51	8.51e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.52	7.08	0.36	8.02e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11586658	chr5:131563581	P4HA2	-0.58	-6.67	-0.34	1.03e-10	Systolic blood pressure;
LIHC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.37	7.39	0.37	1.1e-12	Immature fraction of reticulocytes;
LIHC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.56	11.68	0.53	9.35e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg09165964	chr15:75287851	SCAMP5	-0.61	-8.24	-0.41	3.8e-15	Lung cancer;
LIHC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.32	0.32	8e-10	Multiple sclerosis;
LIHC	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg03146154	chr1:46216737	IPP	-0.4	-6.54	-0.33	2.27e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.26	-18.9	-0.71	4.78e-55	Ulcerative colitis;
LIHC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg18769074	chr3:133464867	TF	0.27	5.89	0.3	9.42e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.69	7.93	0.39	3.15e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.93	-0.35	2.07e-11	Menarche (age at onset);
LIHC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs6442522	0.809	rs6805196	chr3:15451978	T/C	cg16303742	chr3:15540471	COLQ	0.37	5.96	0.31	6.26e-9	Uric acid levels;
LIHC	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg27211696	chr2:191398769	TMEM194B	-0.46	-6.04	-0.31	4.13e-9	Diastolic blood pressure;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.68	0.5	3.67e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-6.18	-0.32	1.85e-9	Bladder cancer;
LIHC	cis	rs3018712	0.532	rs2513280	chr11:68416907	C/G	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.12e-8	Total body bone mineral density;
LIHC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.17	30.78	0.86	1.34e-100	IgG glycosylation;
LIHC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.77	0.3	1.77e-8	Menopause (age at onset);
LIHC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.62	-8.23	-0.41	3.89e-15	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg04374321	chr14:90722782	PSMC1	0.74	14.2	0.61	2.61e-36	Mortality in heart failure;
LIHC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.54	0.46	2.76e-19	Bipolar disorder;
LIHC	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	11.84	0.54	2.36e-27	Electrocardiographic conduction measures;
LIHC	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg25344623	chr2:136566232	LCT	-0.37	-5.99	-0.31	5.2e-9	Corneal structure;
LIHC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.65	0.42	2.04e-16	Schizophrenia;
LIHC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.23	-7.27	-0.37	2.53e-12	Mean corpuscular volume;
LIHC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.8	0.5	1.39e-23	Platelet count;
LIHC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	6.59	0.34	1.67e-10	Renal cell carcinoma;
LIHC	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.52	-7.49	-0.38	5.81e-13	Response to antidepressants and depression;
LIHC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.49	6.54	0.33	2.19e-10	Coronary artery disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18513200	chr4:13629548	BOD1L	-0.6	-7.16	-0.36	4.83e-12	Systolic blood pressure;
LIHC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg21734168	chr11:67353974	GSTP1	-0.28	-6.79	-0.34	4.99e-11	Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg00656387	chr3:40428638	ENTPD3	0.47	7.78	0.39	8.83e-14	Renal cell carcinoma;
LIHC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	1.05	15.87	0.65	7.12e-43	Breast cancer;
LIHC	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.5	7.51	0.38	5.13e-13	Corneal astigmatism;
LIHC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	2.97e-11	Renal cell carcinoma;
LIHC	cis	rs9309711	0.922	rs7561600	chr2:3486093	G/C	cg10845886	chr2:3471009	TTC15	-0.53	-9.77	-0.47	4.77e-20	Neurofibrillary tangles;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11418967	chr3:143689972	C3orf58	0.46	6.2	0.32	1.59e-9	Lung function (FEV1/FVC);
LIHC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg19645103	chr12:69753606	YEATS4	-0.47	-6.4	-0.33	5.12e-10	Response to diuretic therapy;
LIHC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.58	-9.46	-0.46	5.22e-19	Lymphocyte counts;
LIHC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.53	6.1	0.31	2.86e-9	Pancreatic cancer;
LIHC	cis	rs6450176	0.556	rs111423662	chr5:53288661	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.02	-17.85	-0.69	8.03e-51	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.82	0.5	1.18e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3018712	0.532	rs4930589	chr11:68415257	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.12e-8	Total body bone mineral density;
LIHC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.52	-7.7	-0.38	1.43e-13	Total body bone mineral density;
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg02782426	chr3:40428986	ENTPD3	0.35	6.52	0.33	2.46e-10	Renal cell carcinoma;
LIHC	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg01843034	chr6:37503916	NA	-0.42	-6.75	-0.34	6.51e-11	Cognitive performance;
LIHC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.33	-0.49	5.77e-22	Pancreatic cancer;
LIHC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg17724175	chr1:150552817	MCL1	0.38	7.59	0.38	3.03e-13	Melanoma;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg03721293	chr16:90014378	DEF8	0.39	6.53	0.33	2.32e-10	Skin colour saturation;
LIHC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	8.77	0.43	8.65e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg19645103	chr12:69753606	YEATS4	-0.39	-5.8	-0.3	1.54e-8	Blood protein levels;
LIHC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.4	7.82	0.39	6.73e-14	Coronary artery disease or large artery stroke;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.26	-0.37	2.61e-12	Renal cell carcinoma;
LIHC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.76	13.74	0.6	1.6e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02034447	chr16:89574710	SPG7	0.49	7.38	0.37	1.25e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs7911264	0.628	rs7921040	chr10:94418425	G/A	cg00519463	chr10:94352821	KIF11	-0.47	-6.43	-0.33	4.27e-10	Inflammatory bowel disease;
LIHC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.5	-0.46	3.75e-19	Obesity-related traits;
LIHC	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg02951883	chr7:2050386	MAD1L1	0.56	7.47	0.37	6.56e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.52	0.33	2.51e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg16970926	chr12:29381810	FAR2	0.32	6.8	0.34	4.75e-11	QT interval;
LIHC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-1.08	-13.54	-0.59	9.58e-34	Dilated cardiomyopathy;
LIHC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.21	-0.45	3.39e-18	Alzheimer's disease;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg22996534	chr8:17658847	MTUS1	-0.59	-6.09	-0.31	3.04e-9	Obesity-related traits;
LIHC	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg23250157	chr14:64679961	SYNE2	0.41	6.07	0.31	3.45e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.43	-6.81	-0.35	4.53e-11	Menarche (age at onset);
LIHC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.81	0.35	4.53e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.63	11.31	0.52	2e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg00977110	chr5:151150581	G3BP1	0.54	6.9	0.35	2.47e-11	Preschool internalizing problems;
LIHC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.49	-0.46	4.06e-19	Bipolar disorder;
LIHC	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.43	0.37	8.72e-13	Type 2 diabetes;
LIHC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.49	6.34	0.32	7.17e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.06e-9	Primary biliary cholangitis;
LIHC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.0	-0.44	1.55e-17	Obesity-related traits;
LIHC	cis	rs965469	1.000	rs6037532	chr20:3267911	T/C	cg25506879	chr20:3388711	C20orf194	-0.58	-7.06	-0.36	9.15e-12	IFN-related cytopenia;
LIHC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs332507	0.869	rs3772784	chr3:124394657	A/G	cg05980111	chr3:124395277	KALRN	0.36	6.13	0.31	2.47e-9	Plateletcrit;
LIHC	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg03929089	chr4:120376271	NA	-0.45	-6.84	-0.35	3.59e-11	Pediatric bone mineral density (spine);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19332409	chr7:156467866	RNF32	-0.45	-6.67	-0.34	1.02e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.79	11.76	0.54	4.87e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-1.05	-11.69	-0.53	8.49e-27	Dilated cardiomyopathy;
LIHC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg07713946	chr22:31675144	LIMK2	0.41	7.29	0.37	2.2e-12	Colorectal cancer;
LIHC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	15.79	0.65	1.42e-42	Lung cancer in ever smokers;
LIHC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.47	-0.49	1.97e-22	Hemoglobin concentration;
LIHC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.38	5.78	0.3	1.65e-8	Resting heart rate;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16574807	chr4:6945745	TBC1D14	0.39	6.3	0.32	9.17e-10	Bilirubin levels;
LIHC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg23533926	chr12:111358616	MYL2	-0.34	-6.64	-0.34	1.21e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.43	9.17	0.44	4.56e-18	Migraine;
LIHC	cis	rs10861342	0.892	rs2044307	chr12:105531171	G/T	cg23923672	chr12:105501055	KIAA1033	0.65	7.59	0.38	3.01e-13	IgG glycosylation;
LIHC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.96	-0.31	6.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg13263691	chr18:77568018	NA	0.23	6.17	0.32	1.93e-9	Schizophrenia;
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.62	6.93	0.35	2.15e-11	Alzheimer's disease;
LIHC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg16102536	chr7:156981717	UBE3C	0.36	6.03	0.31	4.18e-9	Body mass index;
LIHC	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg22663859	chr13:21900854	NA	0.48	7.9	0.39	3.76e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.47	-7.67	-0.38	1.86e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	12.12	0.55	2.24e-28	Schizophrenia;
LIHC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.33	-6.62	-0.34	1.4e-10	Body mass index;
LIHC	trans	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-6.62	-0.34	1.42e-10	Endometrial cancer;
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.62	10.03	0.48	6.5e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.46	-6.86	-0.35	3.32e-11	Diastolic blood pressure;
LIHC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16346588	chr10:242978	ZMYND11	-0.39	-6.01	-0.31	4.88e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.62	6.96	0.35	1.76e-11	Menarche (age at onset);
LIHC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.83	-0.35	3.91e-11	Diabetic kidney disease;
LIHC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs6596100	0.538	rs34626261	chr5:132174880	A/C	cg02081065	chr5:132209139	LEAP2	0.29	6.16	0.32	2.05e-9	Breast cancer;
LIHC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.67	-0.34	1.04e-10	Total cholesterol levels;
LIHC	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.28	-6.31	-0.32	8.87e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.21	0.41	4.57e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.57	10.55	0.5	1.05e-22	Leprosy;
LIHC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.44e-19	Bipolar disorder;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg20985075	chr1:35325271	C1orf212	-0.4	-6.05	-0.31	3.73e-9	Eotaxin levels;
LIHC	cis	rs9918079	0.542	rs6414765	chr4:15626493	G/A	cg21123203	chr4:15471301	CC2D2A	-0.44	-6.97	-0.35	1.69e-11	Obesity-related traits;
LIHC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.34	6.25	0.32	1.24e-9	Total body bone mineral density;
LIHC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.99	10.98	0.51	3.27e-24	Triglycerides;
LIHC	cis	rs11958404	0.860	rs72818116	chr5:157440616	G/T	cg05962755	chr5:157440814	NA	0.99	11.5	0.53	4.32e-26	IgG glycosylation;
LIHC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.58	8.12	0.4	8.47e-15	Bladder cancer;
LIHC	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-8.44	-0.42	9.05e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg17724175	chr1:150552817	MCL1	0.39	7.79	0.39	8.31e-14	Melanoma;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg19469297	chr7:45151440	TBRG4	-0.45	-6.79	-0.34	5.07e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.54	0.33	2.26e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.06	-0.51	1.58e-24	Hemoglobin concentration;
LIHC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-10.11	-0.48	3.43e-21	Lung cancer;
LIHC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.27	-0.58	1.02e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	10.78	0.5	1.65e-23	Platelet distribution width;
LIHC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.14	0.32	2.24e-9	Renal cell carcinoma;
LIHC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.63	10.31	0.49	7.02e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.63	9.92	0.47	1.52e-20	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.62	-6.91	-0.35	2.38e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.18	0.55	1.36e-28	Prudent dietary pattern;
LIHC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07305463	chr2:136567211	LCT	-0.34	-6.42	-0.33	4.52e-10	Mosquito bite size;
LIHC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.42	0.41	1.07e-15	Osteoporosis;
LIHC	cis	rs712039	0.652	rs853196	chr17:35848659	A/T	cg16670864	chr17:35848621	DUSP14	0.34	5.75	0.3	1.97e-8	Tuberculosis;
LIHC	cis	rs77633900	0.772	rs387321	chr15:76743565	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-5.95	-0.31	6.51e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg14067834	chr17:29058358	SUZ12P	0.71	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg18306943	chr3:40428807	ENTPD3	0.35	6.09	0.31	3.1e-9	Renal cell carcinoma;
LIHC	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.37	5.91	0.3	8.11e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09799432	chr1:87170127	SH3GLB1	-0.45	-6.12	-0.31	2.58e-9	Pancreatic cancer;
LIHC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.69	10.05	0.48	5.25e-21	Total body bone mineral density;
LIHC	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg05187965	chr10:45406764	TMEM72	-0.24	-5.72	-0.3	2.38e-8	Mean corpuscular volume;
LIHC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.39	-6.32	-0.32	8.02e-10	Red blood cell count;
LIHC	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg10978503	chr1:24200527	CNR2	0.37	8.7	0.43	1.38e-16	Immature fraction of reticulocytes;
LIHC	trans	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg24133106	chr7:129690864	ZC3HC1	-0.49	-6.13	-0.31	2.38e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LIHC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.23	-6.24	-0.32	1.32e-9	Type 2 diabetes;
LIHC	cis	rs926392	0.589	rs6093115	chr20:37693817	T/C	cg16355469	chr20:37678765	NA	0.48	6.97	0.35	1.63e-11	Dialysis-related mortality;
LIHC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.54	-8.76	-0.43	9.2e-17	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.57	6.76	0.34	5.85e-11	Alzheimer's disease;
LIHC	cis	rs6450176	0.564	rs374050	chr5:53331646	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.5	-0.59	1.4e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.29	-0.41	2.58e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.48	0.46	4.45e-19	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11212172	chr10:53459438	PRKG1;CSTF2T	0.49	6.91	0.35	2.37e-11	Pancreatic cancer;
LIHC	cis	rs2574704	0.810	rs11708985	chr3:11651896	G/C	cg15876825	chr3:11651881	VGLL4	-0.52	-8.5	-0.42	6.14e-16	Body mass index;
LIHC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.43	-0.33	4.24e-10	Type 2 diabetes;
LIHC	cis	rs7551222	0.749	rs11240764	chr1:204569376	A/G	cg20240347	chr1:204465584	NA	-0.31	-6.36	-0.33	6.39e-10	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06420487	chr17:61919686	SMARCD2	0.44	6.01	0.31	4.68e-9	Height;
LIHC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.48	5.71	0.3	2.42e-8	Bladder cancer;
LIHC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.4	-6.03	-0.31	4.16e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.66	11.37	0.52	1.29e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs6897795	0.680	rs9329137	chr5:177616370	C/T	cg19598605	chr2:70056955	GMCL1	-0.53	-7.16	-0.36	4.9e-12	Plateletcrit;
LIHC	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16684958	chr7:75615977	POR	0.51	8.48	0.42	7.08e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.34	0.37	1.6e-12	Diabetic kidney disease;
LIHC	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg20129853	chr10:51489980	NA	-0.41	-9.02	-0.44	1.34e-17	Prostate-specific antigen levels;
LIHC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.59	0.56	3.89e-30	Colorectal cancer;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08280861	chr8:58055591	NA	0.49	6.05	0.31	3.9e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.68	-0.46	9.68e-20	Crohn's disease;
LIHC	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg07671805	chr5:74907694	NA	0.45	5.84	0.3	1.24e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.59	-7.88	-0.39	4.35e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.52	9.04	0.44	1.2e-17	Coronary artery disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24162759	chr1:224622126	WDR26	0.43	6.16	0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.38	-6.07	-0.31	3.35e-9	Homoarginine levels;
LIHC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.52e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.57	9.77	0.47	4.67e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.61	-0.38	2.7e-13	Homocysteine levels;
LIHC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	0.85	11.06	0.51	1.62e-24	Skin colour saturation;
LIHC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.9e-9	Menopause (age at onset);
LIHC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.33	-0.32	7.6e-10	Personality dimensions;
LIHC	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.6	0.38	2.88e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02290350	chr8:58132656	NA	0.48	9.01	0.44	1.51e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg12501888	chr15:85177176	SCAND2	-0.48	-7.33	-0.37	1.69e-12	P wave terminal force;
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg00106254	chr7:1943704	MAD1L1	0.41	6.64	0.34	1.24e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.22	0.55	9.97e-29	Eye color traits;
LIHC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.7	-0.5	3.06e-23	Alzheimer's disease (late onset);
LIHC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.11	0.44	7.34e-18	Menarche (age at onset);
LIHC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.54	-9.56	-0.46	2.33e-19	Total body bone mineral density;
LIHC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.33	-5.72	-0.3	2.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7212590	0.618	rs7219051	chr17:58032710	G/A	cg10252138	chr17:58120427	NA	-0.58	-5.87	-0.3	1.01e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.93	17.45	0.69	3.28e-49	Menopause (age at onset);
LIHC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.63	8.39	0.41	1.34e-15	Coronary artery disease;
LIHC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.84	0.3	1.24e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.96	20.52	0.74	1.45e-61	IgG glycosylation;
LIHC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.76	-11.66	-0.53	1.11e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg12798992	chr6:167411361	FGFR1OP	0.43	6.73	0.34	7.25e-11	Primary biliary cholangitis;
LIHC	cis	rs797680	0.821	rs2391254	chr1:93795166	A/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.9	-0.3	8.86e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.67	0.42	1.73e-16	Platelet count;
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-6.0	-0.31	5.09e-9	Longevity;Endometriosis;
LIHC	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.68	-0.34	9.73e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.61	-10.12	-0.48	3.16e-21	Obesity-related traits;
LIHC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.7	0.69	3.05e-50	Gut microbiome composition (summer);
LIHC	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.35	8.04	0.4	1.52e-14	Educational attainment (years of education);
LIHC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.29	7.29	0.37	2.12e-12	Crohn's disease;
LIHC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.44	0.37	8.24e-13	Bone mineral density;
LIHC	cis	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg01364799	chr7:75623366	TMEM120A	-0.47	-6.47	-0.33	3.45e-10	Eotaxin levels;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg17100207	chr8:21776848	XPO7	-0.5	-6.14	-0.32	2.26e-9	Monocyte count;
LIHC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.79	8.66	0.42	1.89e-16	Vitiligo;
LIHC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	7.43	0.37	8.8e-13	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.98	17.57	0.69	1.09e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.92	15.34	0.64	8.99e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs17106184	0.892	rs72902708	chr1:51213677	C/T	cg07174182	chr1:51127561	FAF1	-0.64	-7.3	-0.37	2.04e-12	Type 2 diabetes;
LIHC	trans	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg16088116	chr21:44841560	SIK1	-0.4	-6.11	-0.31	2.7e-9	Coronary artery disease;
LIHC	cis	rs785830	0.717	rs600951	chr9:224742	A/G	cg14500300	chr9:211689	NA	0.27	6.18	0.32	1.81e-9	Platelet distribution width;
LIHC	cis	rs714515	0.511	rs9425301	chr1:172363815	A/C	cg01573306	chr1:172330400	DNM3	0.38	5.73	0.3	2.16e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13409248	chr3:40428643	ENTPD3	0.43	6.92	0.35	2.2e-11	Renal cell carcinoma;
LIHC	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.47	-6.22	-0.32	1.47e-9	Vitiligo;
LIHC	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg12698662	chr3:15914712	MIR563	-0.37	-6.8	-0.35	4.64e-11	Mean platelet volume;
LIHC	cis	rs864643	0.945	rs614453	chr3:39582567	C/T	cg05136238	chr3:39556330	MOBP	0.34	5.78	0.3	1.66e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.53	-0.38	4.6e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15731816	chr14:75230414	YLPM1	0.39	7.04	0.36	1.04e-11	Cognitive function;
LIHC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.9	-0.3	8.91e-9	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.24	-15.85	-0.65	7.92e-43	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06826115	chr15:67835137	MAP2K5	-0.46	-6.12	-0.31	2.5e-9	Pancreatic cancer;
LIHC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.81	12.21	0.55	1.07e-28	Chronic sinus infection;
LIHC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.39	0.41	1.26e-15	Alzheimer's disease;
LIHC	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.89	-14.66	-0.62	4.07e-38	Gut microbiota (bacterial taxa);
LIHC	cis	rs797680	0.891	rs9432453	chr1:93771629	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.97	-0.31	5.84e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs17286411	0.750	rs4788568	chr16:71913025	C/T	cg06353428	chr16:71660113	MARVELD3	0.56	7.06	0.36	9.2e-12	Blood protein levels;
LIHC	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.23	-6.62	-0.34	1.37e-10	Monocyte percentage of white cells;Monocyte count;
LIHC	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	9.52	0.46	3.34e-19	Multiple sclerosis;
LIHC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.71	-0.54	7.14e-27	Type 2 diabetes;
LIHC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.53	6.8	0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg03934865	chr2:198174659	NA	-0.47	-6.84	-0.35	3.6e-11	Dermatomyositis;
LIHC	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.17	-10.09	-0.48	3.91e-21	Schizophrenia;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.2	0.32	1.62e-9	Prudent dietary pattern;
LIHC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg02070205	chr10:30722105	MAP3K8	-0.43	-5.75	-0.3	1.97e-8	Inflammatory bowel disease;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.27	0.55	6.03e-29	Prudent dietary pattern;
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg20090690	chr10:134436459	INPP5A	0.45	6.27	0.32	1.1e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12079745	0.623	rs12091133	chr1:169387826	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.82	-7.17	-0.36	4.62e-12	QT interval;
LIHC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.99	-13.1	-0.58	4.68e-32	HIV-1 control;
LIHC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.53	6.48	0.33	3.12e-10	Morning vs. evening chronotype;
LIHC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.47	16.77	0.67	1.78e-46	Eosinophil percentage of granulocytes;
LIHC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.2	-0.45	3.66e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.14	0.55	1.97e-28	Prudent dietary pattern;
LIHC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.39	0.45	8.48e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg01411142	chr8:19674711	INTS10	-0.5	-7.83	-0.39	6.38e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	6.77	0.34	5.51e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.98	10.89	0.51	6.78e-24	IgG glycosylation;
LIHC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg18225595	chr11:63971243	STIP1	0.59	5.75	0.3	1.96e-8	Mean platelet volume;
LIHC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.49	7.25	0.37	2.73e-12	Obesity-related traits;
LIHC	cis	rs9322817	0.535	rs6922070	chr6:105165743	G/A	cg02098413	chr6:105308735	HACE1	-0.38	-5.91	-0.3	8.07e-9	Thyroid stimulating hormone;
LIHC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.51	7.08	0.36	8.1e-12	Aortic root size;
LIHC	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg21584241	chr15:63341463	TPM1	0.44	6.38	0.33	5.9e-10	Orofacial clefts;
LIHC	trans	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg17675199	chr6:35436792	RPL10A	-0.41	-8.31	-0.41	2.2e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.93	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	trans	rs887797	0.704	rs759118	chr17:64547530	C/T	cg10016972	chr12:133370462	GOLGA3	-0.42	-6.13	-0.31	2.48e-9	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg25801113	chr15:45476975	SHF	0.38	6.55	0.33	2.1e-10	Uric acid levels;
LIHC	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg05340658	chr4:99064831	C4orf37	0.71	10.77	0.5	1.74e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg16434002	chr17:42200994	HDAC5	-0.53	-7.75	-0.39	1.04e-13	Total body bone mineral density;
LIHC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg10755058	chr3:40428713	ENTPD3	0.41	6.99	0.35	1.47e-11	Renal cell carcinoma;
LIHC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.6	8.61	0.42	2.67e-16	Coronary artery disease;
LIHC	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.48	8.69	0.43	1.5e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.32	6.71	0.34	7.99e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.54	9.07	0.44	9.71e-18	Cognitive function;
LIHC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.59	7.96	0.4	2.5e-14	Blood metabolite levels;
LIHC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.79	0.3	1.6e-8	Height;
LIHC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg14440974	chr22:39074834	NA	0.45	7.28	0.37	2.3e-12	Menopause (age at onset);
LIHC	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.33	0.49	5.83e-22	Hypertriglyceridemia;
LIHC	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	8.34	0.41	1.84e-15	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.47	-7.68	-0.38	1.66e-13	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.18	0.32	1.79e-9	Bladder cancer;
LIHC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg03934865	chr2:198174659	NA	0.52	8.04	0.4	1.51e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.51	-0.53	3.98e-26	Coronary artery disease;
LIHC	cis	rs2637266	0.783	rs846597	chr10:78529114	A/G	cg18941641	chr10:78392320	NA	0.28	6.06	0.31	3.66e-9	Pulmonary function;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.97	-0.31	6.04e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.43	0.33	4.24e-10	Prudent dietary pattern;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05514743	chr19:14629124	DNAJB1	-0.53	-6.08	-0.31	3.26e-9	Systolic blood pressure;
LIHC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-11.15	-0.52	7.8e-25	Platelet count;
LIHC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg19635926	chr16:89946313	TCF25	0.48	6.17	0.32	1.97e-9	Skin colour saturation;
LIHC	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg03037974	chr15:76606532	NA	-0.51	-8.09	-0.4	1.07e-14	Blood metabolite levels;
LIHC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg15691649	chr6:25882328	NA	-0.46	-6.07	-0.31	3.47e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-8.94	-0.44	2.51e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.61	9.51	0.46	3.62e-19	Tonsillectomy;
LIHC	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg20240347	chr1:204465584	NA	-0.31	-6.35	-0.32	7.01e-10	Schizophrenia;
LIHC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.37	6.16	0.32	2.06e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.7e-9	Blood metabolite levels;
LIHC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.18	-0.32	1.87e-9	Alzheimer's disease (late onset);
LIHC	cis	rs3770081	1.000	rs3770081	chr2:86280925	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.74	-0.43	1.08e-16	Facial emotion recognition (sad faces);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23361579	chr13:114087964	ADPRHL1	0.4	6.22	0.32	1.42e-9	Longevity;
LIHC	cis	rs7818688	0.697	rs76631135	chr8:95980988	G/T	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs10845606	0.505	rs2417221	chr12:12829914	C/T	cg09462578	chr12:12878428	APOLD1	0.44	6.76	0.34	5.8200000000000003e-11	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.5	-0.33	2.81e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.99	15.84	0.65	8.78e-43	Metabolic syndrome;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01585758	chr2:203102753	SUMO1	0.39	6.17	0.32	1.96e-9	Cognitive function;
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.94	0.31	6.93e-9	Aortic root size;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg09417038	chr21:47716443	C21orf57	-0.54	-8.07	-0.4	1.19e-14	Testicular germ cell tumor;
LIHC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.98	17.79	0.69	1.4e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7188697	0.922	rs4471670	chr16:58601365	G/A	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg14345882	chr6:26364793	BTN3A2	0.4	6.07	0.31	3.43e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	1.11	12.06	0.55	3.7e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.36	0.49	4.64e-22	Obesity-related traits;
LIHC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg27247782	chr7:158767135	NA	0.37	7.02	0.35	1.23e-11	Facial morphology (factor 20);
LIHC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg16479474	chr6:28041457	NA	0.48	7.19	0.36	4.12e-12	Parkinson's disease;
LIHC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.43	-6.89	-0.35	2.7e-11	Menarche (age at onset);
LIHC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg14004847	chr7:1930337	MAD1L1	0.53	7.83	0.39	6.24e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.24	-0.32	1.29e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg22676075	chr6:135203613	NA	-0.42	-6.56	-0.33	2.05e-10	Red blood cell count;
LIHC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.79	-0.5	1.51e-23	Mean corpuscular volume;
LIHC	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.56	0.33	1.99e-10	Response to antipsychotic treatment;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27310827	chr1:1163671	SDF4	-0.42	-6.59	-0.34	1.64e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg11060661	chr22:24314208	DDT;DDTL	0.61	10.44	0.49	2.53e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.46	-7.05	-0.36	1.01e-11	Height;
LIHC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.41	-6.49	-0.33	2.95e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg20283391	chr11:68216788	NA	0.38	6.11	0.31	2.72e-9	Total body bone mineral density;
LIHC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.63	-0.46	1.43e-19	Response to antipsychotic treatment;
LIHC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.06e-9	Tonsillectomy;
LIHC	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg13047869	chr3:10149882	C3orf24	0.48	6.44	0.33	4.02e-10	Alzheimer's disease;
LIHC	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg09165964	chr15:75287851	SCAMP5	0.5	7.0	0.35	1.32e-11	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg12863693	chr15:85201151	NMB	0.43	6.01	0.31	4.71e-9	Schizophrenia;
LIHC	cis	rs10733682	0.659	rs1887970	chr9:129464827	C/T	cg00232160	chr9:129468157	NA	0.35	6.06	0.31	3.68e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-8.18	-0.4	5.74e-15	Body mass index;
LIHC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.77	11.99	0.54	7.12e-28	Corneal astigmatism;
LIHC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.28e-34	Aortic root size;
LIHC	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.49	0.46	4.13e-19	Coffee consumption (cups per day);
LIHC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.66	-9.97	-0.47	1.01e-20	Subjective well-being;
LIHC	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	9.55	0.46	2.66e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg05185784	chr16:90016020	DEF8	-0.52	-6.58	-0.34	1.79e-10	Skin colour saturation;
LIHC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.87	-0.3	1.02e-8	Red blood cell count;
LIHC	cis	rs420259	0.549	rs40076	chr16:23692405	A/G	cg05131483	chr16:23706242	ERN2	0.37	6.01	0.31	4.88e-9	Bipolar disorder;
LIHC	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg09454613	chr16:77233327	SYCE1L;MON1B	-0.4	-6.16	-0.32	2.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg19635926	chr16:89946313	TCF25	0.54	7.03	0.36	1.11e-11	Skin colour saturation;
LIHC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.57	9.12	0.44	6.41e-18	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg25894440	chr7:65020034	NA	0.53	6.14	0.31	2.32e-9	Diabetic kidney disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27313007	chr17:78617750	RPTOR	0.43	6.52	0.33	2.5e-10	Longevity;
LIHC	cis	rs2108622	0.727	rs7256877	chr19:15980683	T/C	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.94	-0.31	7.16e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.02	-0.31	4.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.72	6.69	0.34	9.13e-11	Cognitive function;
LIHC	cis	rs2607426	1.000	rs2607421	chr19:41277077	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.49	-5.88	-0.3	9.77e-9	Blood protein levels;
LIHC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.8	12.39	0.56	2.21e-29	Resting heart rate;
LIHC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.59	6.75	0.34	6.23e-11	Axial length;
LIHC	trans	rs8117834	0.574	rs6086329	chr20:8082061	T/C	cg00593689	chr4:53575888	NA	0.38	6.5	0.33	2.77e-10	Chronic kidney disease;
LIHC	cis	rs6449957	0.639	rs251398	chr5:67509801	C/T	cg23036683	chr5:67512108	NA	-0.52	-7.68	-0.38	1.74e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.66	-9.91	-0.47	1.63e-20	Monocyte count;
LIHC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.2	0.41	4.76e-15	Corneal astigmatism;
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg24884572	chr19:58661833	ZNF329	0.98	7.71	0.38	1.36e-13	Cholesterol, total;
LIHC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	0.87	11.66	0.53	1.1e-26	Skin colour saturation;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07383130	chr1:16161673	FLJ37453	0.48	6.67	0.34	1.01e-10	Hepatitis;
LIHC	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.68	-0.42	1.63e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.34	5.83	0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg16102536	chr7:156981717	UBE3C	0.35	5.85	0.3	1.17e-8	Body mass index;
LIHC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.3	0.32	8.96e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-8.57	-0.42	3.58e-16	Body mass index (adult);
LIHC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.75	0.39	1.04e-13	Mean platelet volume;
LIHC	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	7.0	0.35	1.32e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.8	-0.3	1.48e-8	Longevity;
LIHC	cis	rs7091068	0.671	rs604489	chr10:95405408	T/C	cg20715218	chr10:95462985	C10orf4	-0.6	-6.87	-0.35	3.04e-11	Urinary tract infection frequency;
LIHC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.89	0.3	9.03e-9	Birth weight;
LIHC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.19	0.32	1.68e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg04865290	chr3:52927548	TMEM110	-0.42	-6.34	-0.32	7.28e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.62	-6.86	-0.35	3.28e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-0.66	-10.94	-0.51	4.39e-24	Total body bone mineral density;
LIHC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.06	0.4	1.29e-14	Tonsillectomy;
LIHC	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-6.36	-0.33	6.45e-10	Diastolic blood pressure;
LIHC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.37	-6.65	-0.34	1.19e-10	Aortic root size;
LIHC	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.76	5.95	0.31	6.71e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.7	-0.38	1.45e-13	Electroencephalogram traits;
LIHC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.44	7.86	0.39	5.13e-14	Platelet distribution width;
LIHC	trans	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.46	-5.74	-0.3	2.11e-8	Blood protein levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16803707	chr20:1099736	PSMF1	0.47	6.35	0.32	6.94e-10	Pancreatic cancer;
LIHC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.96	17.56	0.69	1.12e-49	Breast cancer;
LIHC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg20387954	chr3:183756860	HTR3D	0.29	6.17	0.32	1.9e-9	Anterior chamber depth;
LIHC	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg05765582	chr2:191677683	NA	0.3	5.72	0.3	2.3e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs3790645	1.000	rs3127013	chr1:26891360	T/G	cg17456097	chr1:26900765	RPS6KA1	0.41	5.9	0.3	8.96e-9	Glucose homeostasis traits;
LIHC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg27141850	chr2:20869434	GDF7	0.33	6.73	0.34	7.15e-11	Abdominal aortic aneurysm;
LIHC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.52	7.68	0.38	1.71e-13	Height;
LIHC	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.75	0.3	2.03e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22857025	chr5:266934	NA	1.08	7.25	0.37	2.79e-12	Breast cancer;
LIHC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg12751644	chr20:60527061	NA	-0.36	-6.06	-0.31	3.61e-9	Body mass index;
LIHC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.71	-0.38	1.37e-13	Gut microbiome composition (summer);
LIHC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.39	8.28	0.41	2.83e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.96	-17.16	-0.68	4.62e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs3823572	0.564	rs2953621	chr7:133662403	C/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.71	-0.3	2.46e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.25	0.32	1.23e-9	Prudent dietary pattern;
LIHC	cis	rs3770081	1.000	rs75038217	chr2:86348025	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-7.75	-0.39	1.08e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.53	7.83	0.39	6.05e-14	Height;
LIHC	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg08135965	chr6:41755394	TOMM6	0.44	5.72	0.3	2.34e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg04571941	chr7:5463284	TNRC18	-0.43	-6.05	-0.31	3.81e-9	Alopecia areata;
LIHC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.27	-0.32	1.11e-9	Tonsillectomy;
LIHC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.96	17.51	0.69	1.9e-49	Breast cancer;
LIHC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.77	0.34	5.69e-11	Height;
LIHC	cis	rs7818688	0.697	rs80217195	chr8:95986853	T/C	cg16049864	chr8:95962084	TP53INP1	0.59	6.42	0.33	4.5e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg06096015	chr1:231504339	EGLN1	-0.51	-9.36	-0.45	1.06e-18	Hemoglobin concentration;
LIHC	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	0.74	8.04	0.4	1.46e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.22	0.55	9.92e-29	Prudent dietary pattern;
LIHC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.04	0.36	1.06e-11	Neutrophil percentage of white cells;
LIHC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg07424592	chr7:64974309	NA	0.8	9.41	0.45	7.59e-19	Diabetic kidney disease;
LIHC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg02711726	chr17:80685570	FN3KRP	0.32	5.81	0.3	1.41e-8	Breast cancer;
LIHC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-6.84	-0.35	3.73e-11	Bladder cancer;
LIHC	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.1	-0.31	2.87e-9	Ulcerative colitis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03212183	chr16:81565917	CMIP	0.43	6.53	0.33	2.44e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.43	-0.37	8.54e-13	Renal cell carcinoma;
LIHC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.21	0.36	3.61e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.65	12.48	0.56	1.02e-29	High light scatter reticulocyte count;
LIHC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.07	-0.31	3.44e-9	Mean corpuscular volume;
LIHC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg04013166	chr16:89971882	TCF25	0.52	6.46	0.33	3.55e-10	Skin colour saturation;
LIHC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.1	0.36	7.33e-12	Heart rate;
LIHC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg22633049	chr21:46681294	NA	-0.38	-6.5	-0.33	2.91e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12602486	1.000	rs76926880	chr17:42247377	C/G	cg13607699	chr17:42295918	UBTF	-0.75	-6.42	-0.33	4.46e-10	Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.76	0.39	1e-13	Prudent dietary pattern;
LIHC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.53	-0.38	4.48e-13	Total body bone mineral density;
LIHC	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.62	11.48	0.53	4.92e-26	Airflow obstruction;
LIHC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.58e-15	Gut microbiome composition (summer);
LIHC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-9.21	-0.45	3.3e-18	Electroencephalogram traits;
LIHC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.55	8.05	0.4	1.41e-14	Longevity;Endometriosis;
LIHC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.55	-8.24	-0.41	3.6e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.68	6.88	0.35	2.81e-11	Bipolar disorder;
LIHC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.56	-8.41	-0.41	1.09e-15	Ulcerative colitis;
LIHC	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	0.97	13.95	0.6	2.52e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.35	6.48	0.33	3.24e-10	Blood metabolite levels;
LIHC	trans	rs8020941	0.585	rs77608728	chr14:97519423	G/A	cg18504190	chr11:1649947	HCCA2;KRTAP5-5	0.46	6.04	0.31	3.92e-9	Diabetic kidney disease;
LIHC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.08	0.48	4.28e-21	Alzheimer's disease (late onset);
LIHC	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.19	0.32	1.76e-9	Mean corpuscular volume;
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.82	10.25	0.48	1.14e-21	Bladder cancer;
LIHC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.37	-5.98	-0.31	5.49e-9	Dementia with Lewy bodies;
LIHC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.54	0.46	2.9e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.47	-7.71	-0.38	1.35e-13	Testicular germ cell tumor;
LIHC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.11	0.44	7.21e-18	Lung cancer in ever smokers;
LIHC	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg17771515	chr6:154831774	CNKSR3	0.59	6.15	0.32	2.17e-9	Lipoprotein (a) levels;
LIHC	cis	rs35150201	1.000	rs35150201	chr7:135346262	T/G	cg23117316	chr7:135346802	PL-5283	-0.3	-6.46	-0.33	3.65e-10	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LIHC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.78	-0.3	1.65e-8	Subjective well-being;
LIHC	cis	rs10419226	0.809	rs8102046	chr19:18795578	T/G	cg16673477	chr19:18812017	CRTC1	-0.36	-5.94	-0.31	6.86e-9	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg17135325	chr3:160939158	NMD3	-0.5	-6.95	-0.35	1.82e-11	Parkinson's disease;
LIHC	cis	rs7116495	1.000	rs564170	chr11:71569979	T/C	cg26138937	chr11:71823887	C11orf51	0.68	6.63	0.34	1.3100000000000001e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.18	-0.32	1.79e-9	Mean corpuscular volume;
LIHC	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg00142150	chr22:38071001	LGALS1	0.45	7.55	0.38	4.08e-13	Fat distribution (HIV);
LIHC	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.78	-0.34	5.34e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-7.81	-0.39	7.14e-14	Uric acid levels;
LIHC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg03517284	chr6:25882590	NA	-0.41	-6.2	-0.32	1.63e-9	Height;
LIHC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.44	-5.93	-0.31	7.26e-9	Schizophrenia;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.88	-0.3	9.68e-9	Total body bone mineral density;
LIHC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.41	-6.98	-0.35	1.51e-11	Monocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17396978	chr15:57210912	TCF12;LOC145783	0.46	6.27	0.32	1.1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4934494	0.768	rs7078321	chr10:91438098	C/T	cg19698084	chr10:91461284	KIF20B	-0.49	-6.49	-0.33	2.93e-10	Red blood cell count;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg00958676	chr8:9911641	MSRA	-0.61	-6.67	-0.34	1.01e-10	Preeclampsia;
LIHC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg23461800	chr14:103021989	NA	0.44	5.95	0.31	6.67e-9	Platelet count;
LIHC	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.3	-0.32	9.05e-10	Post bronchodilator FEV1;
LIHC	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg10820045	chr2:198174542	NA	0.45	6.82	0.35	4.18e-11	Dermatomyositis;
LIHC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.65	-9.37	-0.45	1.02e-18	Initial pursuit acceleration;
LIHC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg20140201	chr2:241835670	C2orf54	0.46	6.11	0.31	2.73e-9	Urinary metabolites;
LIHC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.38	-5.95	-0.31	6.82e-9	Heart rate;
LIHC	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.39	8.32	0.41	2.19e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.45	7.69	0.38	1.58e-13	Mean corpuscular volume;
LIHC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	11.09	0.51	1.23e-24	Lymphocyte percentage of white cells;
LIHC	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-7.02	-0.36	1.18e-11	Metabolite levels;
LIHC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.35	-0.41	1.68e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.57	7.5	0.38	5.51e-13	Initial pursuit acceleration;
LIHC	trans	rs7121800	0.962	rs11031119	chr11:30525773	A/G	cg03935116	chr12:31476565	FAM60A;FLJ13224	0.28	6.06	0.31	3.57e-9	Pit-and-Fissure caries;
LIHC	cis	rs8067354	0.540	rs7221472	chr17:58036737	C/T	cg13753209	chr17:57696993	CLTC	0.71	10.58	0.5	8.01e-23	Hemoglobin concentration;
LIHC	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg21584241	chr15:63341463	TPM1	0.44	6.38	0.33	5.9e-10	Orofacial clefts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05470809	chr4:175205489	KIAA1712;FBXO8	0.52	7.25	0.36	2.73e-12	Pancreatic cancer;
LIHC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17990871	chr1:1677678	SLC35E2	-0.36	-5.74	-0.3	2.11e-8	Body mass index;
LIHC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs17106184	1.000	rs80326064	chr1:51240851	C/T	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.18e-10	Type 2 diabetes;
LIHC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.41	6.6	0.34	1.53e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.51	-7.55	-0.38	3.93e-13	Total body bone mineral density;
LIHC	trans	rs792448	0.743	rs351386	chr1:212421771	C/T	cg20223728	chr6:6006398	NRN1	0.35	6.17	0.32	1.95e-9	White blood cell count (basophil);
LIHC	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg24220031	chr2:73402428	NA	-0.28	-6.06	-0.31	3.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04004882	chr2:215674386	BARD1	0.51	6.27	0.32	1.11e-9	Neuroblastoma;
LIHC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.31	5.75	0.3	1.99e-8	Diastolic blood pressure;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00098280	chr18:29523426	KIAA1012	-0.53	-6.66	-0.34	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg26138937	chr11:71823887	C11orf51	1.3	10.45	0.49	2.25e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs11951515	0.508	rs6860493	chr5:43602713	T/C	cg01983248	chr5:43482804	C5orf28	-0.4	-6.49	-0.33	2.93e-10	Metabolite levels  (X-11787);
LIHC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg22676075	chr6:135203613	NA	0.38	6.17	0.32	1.93e-9	Red blood cell count;
LIHC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-7.11	-0.36	6.77e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.21	0.41	4.72e-15	Lung cancer;
LIHC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.4	5.97	0.31	5.87e-9	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.53	6.46	0.33	3.66e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.86	0.3	1.11e-8	Platelet count;
LIHC	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.86	12.6	0.56	3.61e-30	Menarche (age at onset);
LIHC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.38	-0.49	4.15e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.22	-5.86	-0.3	1.08e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.53	8.44	0.42	8.82e-16	Total body bone mineral density;
LIHC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.47	-7.62	-0.38	2.49e-13	Mean corpuscular volume;
LIHC	cis	rs7005606	0.532	rs1579033	chr8:32298180	C/G	cg16623836	chr8:32453385	NRG1	-0.35	-5.81	-0.3	1.4e-8	Hirschsprung disease;
LIHC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.4	-7.19	-0.36	4.23e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2617583	0.935	rs1354139	chr5:1451782	T/C	cg07151155	chr5:1473589	LPCAT1	-0.41	-6.21	-0.32	1.51e-9	Breast cancer;
LIHC	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg06359132	chr10:99160096	RRP12	-0.38	-5.83	-0.3	1.31e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs963731	0.522	rs297148	chr2:39323166	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-6.03	-0.31	4.15e-9	Corticobasal degeneration;
LIHC	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.11	-0.48	3.33e-21	Response to antipsychotic treatment;
LIHC	trans	rs10411161	0.752	rs10402107	chr19:52384600	A/G	cg22319618	chr22:45562946	NUP50	-0.59	-8.12	-0.4	8.66e-15	Breast cancer;
LIHC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.44	6.1	0.31	2.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8014671	0.532	rs1953800	chr14:70958696	T/C	cg25576086	chr14:70833871	SYNJ2BP	0.45	6.94	0.35	2.03e-11	Prostate cancer;
LIHC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg08345082	chr10:99160200	RRP12	-0.39	-6.53	-0.33	2.38e-10	Monocyte percentage of white cells;
LIHC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.72	-0.43	1.19e-16	Body mass index (adult);
LIHC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.96	-0.35	1.78e-11	Diabetic kidney disease;
LIHC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.35	5.71	0.3	2.42e-8	Crohn's disease;
LIHC	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21659725	chr3:3221576	CRBN	0.56	8.18	0.4	5.53e-15	Body mass index;
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg14222432	chr12:29376421	FAR2	0.38	7.24	0.36	2.93e-12	QT interval;
LIHC	trans	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg16088116	chr21:44841560	SIK1	-0.42	-6.52	-0.33	2.59e-10	Coronary artery disease;
LIHC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.41	6.15	0.32	2.16e-9	Tuberculosis;
LIHC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg17135325	chr3:160939158	NMD3	0.56	8.21	0.41	4.71e-15	Parkinson's disease;
LIHC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06544989	chr22:39130855	UNC84B	0.4	6.55	0.33	2.12e-10	Menopause (age at onset);
LIHC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.62	9.96	0.47	1.06e-20	Platelet distribution width;
LIHC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg07706471	chr12:123319906	HIP1R	-0.58	-7.69	-0.38	1.62e-13	Schizophrenia;
LIHC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.44	6.08	0.31	3.19e-9	Height;
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg03854865	chr6:26224070	HIST1H3E	0.62	7.11	0.36	6.65e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.21	5.98	0.31	5.7e-9	Childhood ear infection;
LIHC	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-7.44	-0.37	8.29e-13	Hepatocellular carcinoma;
LIHC	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg07706471	chr12:123319906	HIP1R	-0.59	-7.78	-0.39	8.57e-14	Schizophrenia;
LIHC	trans	rs3749855	0.679	rs13201114	chr6:17265647	G/A	cg00118684	chr18:13726609	RNMT;C18orf19	-0.61	-6.08	-0.31	3.12e-9	Glucose homeostasis traits;
LIHC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg15832292	chr6:96025679	MANEA	0.62	7.17	0.36	4.71e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	8.64	0.42	2.15e-16	Coronary artery disease;
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.59	-8.46	-0.42	7.73e-16	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg19318889	chr4:1322082	MAEA	0.48	6.57	0.33	1.85e-10	Obesity-related traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18350524	chr12:93835624	UBE2N	-0.41	-6.1	-0.31	2.84e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg03013999	chr17:37608204	MED1	-0.36	-5.91	-0.3	8.4e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg18867708	chr6:26865862	GUSBL1	0.52	7.87	0.39	4.72e-14	Schizophrenia;
LIHC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.58	8.81	0.43	6.49e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-8.97	-0.44	1.97e-17	Chronic sinus infection;
LIHC	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg10820045	chr2:198174542	NA	0.48	7.47	0.37	6.93e-13	Dermatomyositis;
LIHC	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.83	-0.3	1.28e-8	Resting heart rate;
LIHC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg14784868	chr12:69753453	YEATS4	0.56	7.93	0.39	3.09e-14	Response to diuretic therapy;
LIHC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg11317459	chr13:21872234	NA	-1.09	-12.65	-0.56	2.35e-30	White matter hyperintensity burden;
LIHC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.75	-13.92	-0.6	3.4000000000000003e-35	Height;
LIHC	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.7	-10.23	-0.48	1.32e-21	Eosinophil percentage of white cells;
LIHC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg16070018	chr6:26224392	HIST1H3E	0.55	6.52	0.33	2.6e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.61	-9.96	-0.47	1.08e-20	Temperament;
LIHC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.64	11.59	0.53	2.03e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg02023728	chr11:77925099	USP35	-0.34	-6.0	-0.31	5.01e-9	Alzheimer's disease (survival time);
LIHC	cis	rs797680	0.856	rs797672	chr1:93702119	A/T	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.41	-6.16	-0.32	2.07e-9	Menarche (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15034757	chr3:186617939	NA	0.47	6.05	0.31	3.83e-9	Hepatitis;
LIHC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.61	8.66	0.42	1.94e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6976053	0.518	rs144173	chr7:100416250	A/G	cg01903971	chr7:100434983	NA	-0.39	-6.18	-0.32	1.79e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	trans	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg09872104	chr7:134855509	C7orf49	-0.77	-6.24	-0.32	1.33e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.69	10.53	0.49	1.18e-22	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.26	6.22	0.32	1.45e-9	Childhood ear infection;
LIHC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.15	0.36	5.42e-12	Lung cancer;
LIHC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.41	0.53	9.2e-26	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.88	-8.51	-0.42	5.51e-16	Platelet count;
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.95	13.47	0.59	1.73e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.81	-0.3	1.42e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg06359132	chr10:99160096	RRP12	0.38	5.87	0.3	1.05e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg11204139	chr17:3907470	NA	0.59	7.95	0.39	2.83e-14	Type 2 diabetes;
LIHC	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg13699009	chr12:122356056	WDR66	-0.4	-6.75	-0.34	6.42e-11	Mean corpuscular volume;
LIHC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.81	0.3	1.43e-8	Life satisfaction;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11166741	chr7:42951557	C7orf25	-0.43	-6.16	-0.32	2.03e-9	Bilirubin levels;
LIHC	cis	rs17106184	0.583	rs57793888	chr1:51201424	A/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.86	-0.35	3.32e-11	Type 2 diabetes;
LIHC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14331148	chr19:47551893	TMEM160	0.52	6.74	0.34	6.76e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-10.19	-0.48	1.76e-21	Asthma;
LIHC	cis	rs7116495	1.000	rs10751189	chr11:71670578	C/G	cg26138937	chr11:71823887	C11orf51	0.7	7.22	0.36	3.42e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.59	0.53	1.97e-26	Motion sickness;
LIHC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs17152411	1.000	rs7082846	chr10:126593310	C/A	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.28	-17.05	-0.68	1.28e-47	Diabetic kidney disease;
LIHC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.35	-7.56	-0.38	3.66e-13	Longevity;
LIHC	cis	rs10216189	0.785	rs4352753	chr7:5527223	A/C	cg05318486	chr7:5553423	FBXL18	-0.44	-6.17	-0.32	1.93e-9	Relative hand skill in reading disability;
LIHC	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06634786	chr22:41940651	POLR3H	0.57	6.26	0.32	1.12e-9	Vitiligo;
LIHC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-6.09	-0.31	3.07e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs17152411	0.895	rs11245418	chr10:126586319	T/C	cg07906193	chr10:126599966	NA	0.44	6.89	0.35	2.74e-11	Height;
LIHC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.99	-0.31	5.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.76	11.66	0.53	1.1e-26	Corneal astigmatism;
LIHC	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.67	-12.75	-0.57	9.86e-31	Body mass index;
LIHC	cis	rs7707921	1.000	rs7707921	chr5:81538046	T/A	cg15871215	chr5:81402204	ATG10	0.61	5.79	0.3	1.56e-8	Breast cancer;
LIHC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.81	0.35	4.49e-11	Menopause (age at onset);
LIHC	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-10.67	-0.5	3.88e-23	Pediatric autoimmune diseases;
LIHC	cis	rs965469	1.000	rs6051810	chr20:3355384	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-6.6	-0.34	1.57e-10	IFN-related cytopenia;
LIHC	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.81	-0.39	7.29e-14	Response to antipsychotic treatment;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.45	8.41	0.41	1.09e-15	Prudent dietary pattern;
LIHC	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.0	0.35	1.39e-11	Type 2 diabetes;
LIHC	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.49	-7.95	-0.4	2.68e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg21919602	chr1:242011447	EXO1	-0.36	-5.74	-0.3	2.09e-8	Menopause (age at onset);
LIHC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.6	8.78	0.43	8.09e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.63	8.78	0.43	8.13e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs72627509	0.638	rs12648928	chr4:57902506	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-7.31	-0.37	1.88e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.9	-0.39	3.77e-14	Capecitabine sensitivity;
LIHC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.37	-0.33	6.13e-10	Height;
LIHC	cis	rs3823572	0.542	rs2346269	chr7:133643066	C/T	cg03336402	chr7:133662267	EXOC4	-0.47	-5.81	-0.3	1.4e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs783540	0.934	rs783532	chr15:83249367	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.79	-0.34	4.83e-11	Schizophrenia;
LIHC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.48	-8.79	-0.43	7.41e-17	Mean corpuscular volume;
LIHC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.67	10.34	0.49	5.4e-22	Cognitive function;
LIHC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.54	10.34	0.49	5.67e-22	Asthma;
LIHC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg21724239	chr8:58056113	NA	0.45	6.0	0.31	5.15e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-0.95	-20.93	-0.75	3.29e-63	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.14	0.68	5.42e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.53	-6.44	-0.33	4.07e-10	Menarche (age at onset);
LIHC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.85	0.3	1.15e-8	Longevity;
LIHC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.09	0.44	8.32e-18	Schizophrenia;
LIHC	cis	rs7487075	0.558	rs12580460	chr12:46648983	G/A	cg15584813	chr12:47219626	SLC38A4	0.32	5.93	0.31	7.37e-9	Itch intensity from mosquito bite;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13663170	chr4:1976361	WHSC1;SCARNA22	0.49	6.19	0.32	1.71e-9	Systolic blood pressure;
LIHC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.5	8.98	0.44	1.86e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.57	-0.38	3.54e-13	Schizophrenia;
LIHC	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg08668510	chr10:1095578	IDI1	0.63	6.11	0.31	2.79e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs72843506	0.656	rs28622601	chr17:19958654	G/C	cg12065943	chr17:19881925	AKAP10	-0.33	-6.01	-0.31	4.71e-9	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs67981189	0.593	rs10132984	chr14:71477227	A/T	cg15816911	chr14:71606274	NA	0.4	6.38	0.33	5.79e-10	Schizophrenia;
LIHC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg03854865	chr6:26224070	HIST1H3E	0.63	7.07	0.36	8.82e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.92	0.51	5.31e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs74233809	1.000	rs12219027	chr10:104811203	T/C	cg03493300	chr10:104813866	CNNM2	0.48	6.36	0.33	6.41e-10	Birth weight;
LIHC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.8e-12	Waist circumference;Weight;
LIHC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	8.75	0.43	9.57e-17	Schizophrenia;
LIHC	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.71	-10.15	-0.48	2.5e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.41	0.56	1.91e-29	Cognitive test performance;
LIHC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-13.02	-0.58	9.31e-32	Homoarginine levels;
LIHC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.65	9.57	0.46	2.17e-19	Corneal astigmatism;
LIHC	cis	rs16828019	0.777	rs115916606	chr1:41642700	C/G	cg03387723	chr1:41708464	SCMH1	-0.44	-7.13	-0.36	6.14e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.24	0.41	3.81e-15	Eotaxin levels;
LIHC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.74	11.18	0.52	5.92e-25	Corneal astigmatism;
LIHC	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg08126542	chr6:37504118	NA	-0.41	-6.6	-0.34	1.53e-10	Cognitive performance;
LIHC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.23	-0.45	2.97e-18	Alzheimer's disease;
LIHC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-7.36	-0.37	1.34e-12	Crohn's disease;
LIHC	cis	rs986417	1.000	rs10136642	chr14:60946098	G/C	cg27398547	chr14:60952738	C14orf39	0.81	9.39	0.45	8.69e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20135002	chr11:47629003	NA	-0.58	-10.13	-0.48	2.9e-21	Subjective well-being;
LIHC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg15208524	chr1:10270712	KIF1B	0.38	5.74	0.3	2.1e-8	Hepatocellular carcinoma;
LIHC	cis	rs8084351	0.599	rs4614799	chr18:50694304	A/G	cg24270629	chr18:50823537	DCC	0.45	6.74	0.34	6.67e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.57	7.88	0.39	4.28e-14	Height;
LIHC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	10.0	0.48	8.11e-21	Platelet count;
LIHC	cis	rs11734570	0.581	rs73811714	chr4:38588327	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.52	6.84	0.35	3.76e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.48	-0.33	3.26e-10	Height;
LIHC	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.34	7.65	0.38	2.03e-13	Blood metabolite ratios;
LIHC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-0.89	-9.64	-0.46	1.26e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg21724239	chr8:58056113	NA	0.49	5.86	0.3	1.09e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02290350	chr8:58132656	NA	0.45	8.65	0.42	2.09e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.17	-0.44	4.52e-18	Bipolar disorder;
LIHC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	10.43	0.49	2.59e-22	Lung cancer in ever smokers;
LIHC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.2	0.45	3.71e-18	Schizophrenia;
LIHC	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.43	-6.69	-0.34	8.95e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.41	8.73	0.43	1.16e-16	Coronary artery disease;
LIHC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.34	0.55	3.55e-29	Cognitive test performance;
LIHC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.85	8.46	0.42	7.87e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19858173	chr2:128099688	MAP3K2	-0.27	-6.38	-0.33	5.81e-10	Calcium levels;
LIHC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.07	0.51	1.47e-24	Colorectal cancer;
LIHC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg07148914	chr20:33460835	GGT7	0.51	5.75	0.3	1.94e-8	Protein C levels;
LIHC	cis	rs10838687	0.736	rs1449626	chr11:47290759	A/C	cg26139080	chr11:47293733	MADD	-0.42	-5.84	-0.3	1.23e-8	Proinsulin levels;
LIHC	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.44	0.37	8.16e-13	Endometrial cancer;
LIHC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.45	-6.01	-0.31	4.71e-9	Total body bone mineral density;
LIHC	cis	rs4917833	0.789	rs3179357	chr10:100218732	C/T	cg19043522	chr10:100227446	HPSE2	-0.41	-5.87	-0.3	1.01e-8	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.62	-0.5	5.69e-23	Hemoglobin concentration;
LIHC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg14092571	chr14:90743983	NA	-0.38	-6.12	-0.31	2.58e-9	Mortality in heart failure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25163015	chr11:64052221	BAD;GPR137	0.45	6.22	0.32	1.44e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg03874509	chr1:107600012	PRMT6	0.74	11.64	0.53	1.36e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg21919602	chr1:242011447	EXO1	-0.37	-5.76	-0.3	1.86e-8	Menopause (age at onset);
LIHC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.02	0.35	1.21e-11	Aortic root size;
LIHC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.69	-9.34	-0.45	1.3e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.45	-8.11	-0.4	8.87e-15	N-glycan levels;
LIHC	trans	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg17675199	chr6:35436792	RPL10A	-0.4	-8.18	-0.4	5.57e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs55702914	0.742	rs6744206	chr2:198148522	A/G	cg03934865	chr2:198174659	NA	-0.4	-5.8	-0.3	1.52e-8	Major depression and alcohol dependence;
LIHC	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	0.67	8.55	0.42	4.1e-16	Corneal structure;
LIHC	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.55	10.04	0.48	5.92e-21	Lewy body disease;
LIHC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg09417038	chr21:47716443	C21orf57	-0.51	-7.4	-0.37	1.05e-12	Testicular germ cell tumor;
LIHC	cis	rs4453791	1.000	rs35674337	chr3:38878881	G/A	cg02254461	chr3:39195904	CSRNP1	0.64	5.76	0.3	1.86e-8	Social communication problems;
LIHC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.41	6.04	0.31	4.01e-9	Methadone dose in opioid dependence;
LIHC	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg14067834	chr17:29058358	SUZ12P	0.7	7.0	0.35	1.32e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.45	8.0	0.4	1.9e-14	IgG glycosylation;
LIHC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.79	13.3	0.58	8.3e-33	Psoriasis;
LIHC	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs243505	0.691	rs243483	chr7:148449163	A/G	cg09806900	chr7:148480153	CUL1	-0.42	-5.98	-0.31	5.57e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.59	8.17	0.4	6.2e-15	Eotaxin levels;
LIHC	cis	rs249954	0.512	rs7588	chr16:23681165	G/A	cg09867953	chr16:23706666	ERN2	0.36	6.09	0.31	3.07e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.48	0.37	6.49e-13	Height;
LIHC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg10587741	chr22:38071170	LGALS1	0.73	12.69	0.57	1.7e-30	Fat distribution (HIV);
LIHC	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.41	6.32	0.32	7.95e-10	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-8.96	-0.44	2.11e-17	Parkinson's disease;
LIHC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.73	-10.28	-0.49	9.12e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg13957321	chr17:43675089	NA	0.5	8.0	0.4	2.01e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg08992911	chr2:238395768	MLPH	0.64	6.47	0.33	3.36e-10	Prostate cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05464172	chr8:97247954	UQCRB	0.45	6.55	0.33	2.07e-10	Pancreatic cancer;
LIHC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.3	7.79e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs72843506	0.586	rs79246843	chr17:19842062	G/A	cg12065943	chr17:19881925	AKAP10	-0.39	-6.57	-0.33	1.93e-10	Schizophrenia;
LIHC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.13	25.87	0.81	1.63e-82	Cognitive ability;
LIHC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.34	7.31	0.37	1.89e-12	Bone mineral density;
LIHC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.33	-0.41	2.03e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.16	-28.66	-0.84	6.08e-93	Myeloid white cell count;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.56	5.74	0.3	2.05e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11817910	chr12:31944836	H3F3C	0.47	6.43	0.33	4.35e-10	Hepatitis;
LIHC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.55	-8.38	-0.41	1.39e-15	Extraversion;
LIHC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg23690444	chr14:81902736	NA	-0.5	-6.89	-0.35	2.76e-11	Night sleep phenotypes;
LIHC	cis	rs12101261	1.000	rs2160215	chr14:81461472	T/C	cg06600135	chr14:81408086	NA	0.37	6.33	0.32	7.5e-10	Graves' disease;
LIHC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.86	12.65	0.56	2.29e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs922107	0.764	rs4658279	chr1:90022799	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.73	-0.39	1.21e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.5	-7.82	-0.39	6.65e-14	Schizophrenia;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.77	-0.3	1.82e-8	Bipolar disorder and schizophrenia;
LIHC	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.76	-11.98	-0.54	7.22e-28	Eosinophil percentage of white cells;
LIHC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.41	6.5	0.33	2.85e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.62	11.05	0.51	1.76e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs1000083	0.748	rs1830368	chr5:96634367	T/C	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24110177	chr3:50126178	RBM5	0.42	6.46	0.33	3.55e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.26	-6.3	-0.32	9.18e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg00277334	chr10:82204260	NA	-0.54	-6.68	-0.34	9.51e-11	Post bronchodilator FEV1;
LIHC	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg07424592	chr7:64974309	NA	0.78	8.94	0.44	2.44e-17	Diabetic kidney disease;
LIHC	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03352830	chr11:487213	PTDSS2	0.79	6.38	0.33	5.73e-10	Body mass index;
LIHC	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.15	-9.46	-0.46	4.94e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7872515	0.775	rs1970121	chr9:94870152	A/C	cg01248375	chr9:94877805	SPTLC1	-0.53	-8.04	-0.4	1.51e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.36	6.08	0.31	3.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.03e-8	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.09	0.44	8.2e-18	Bipolar disorder;
LIHC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.59	-8.93	-0.43	2.73e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.94	15.54	0.64	1.36e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.55	5.83	0.3	1.3e-8	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.43	-6.49	-0.33	3.1e-10	Asthma;
LIHC	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	0.74	6.31	0.32	8.57e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.55	-9.93	-0.47	1.39e-20	Alzheimer's disease (late onset);
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.54	-9.22	-0.45	3.15e-18	Paraoxonase activity;
LIHC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.49	-7.59	-0.38	3.01e-13	Crohn's disease;
LIHC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.23	0.45	2.89e-18	Mean platelet volume;
LIHC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg10935138	chr17:73851978	WBP2	0.81	7.31	0.37	1.88e-12	Psoriasis;
LIHC	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.42	-5.76	-0.3	1.84e-8	Pulse pressure;
LIHC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	5.84	0.3	1.21e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg00612595	chr21:47717864	NA	-0.35	-5.76	-0.3	1.85e-8	Testicular germ cell tumor;
LIHC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg22633049	chr21:46681294	NA	-0.36	-6.24	-0.32	1.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-13.1	-0.58	4.62e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.4	5.78	0.3	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.59	10.31	0.49	6.75e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.84	0.54	2.44e-27	Cognitive test performance;
LIHC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.6	9.83	0.47	3.03e-20	Resting heart rate;
LIHC	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	8.16	0.4	6.41e-15	Type 2 diabetes;
LIHC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	0.92	8.97	0.44	1.95e-17	Alzheimer's disease;
LIHC	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.75	0.3	1.98e-8	Superior frontal gyrus grey matter volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03530756	chr16:3285262	ZNF200	0.46	6.42	0.33	4.68e-10	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.24	0.55	7.84e-29	Prudent dietary pattern;
LIHC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.36	-6.28	-0.32	1.02e-9	Headache;
LIHC	cis	rs9394841	0.692	rs3806113	chr6:41876335	C/T	cg17623882	chr6:41773611	USP49	-0.45	-6.85	-0.35	3.35e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg16558253	chr16:72132732	DHX38	-0.38	-6.43	-0.33	4.3e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs2997447	0.739	rs3008223	chr1:26389633	T/C	cg19633962	chr1:26362018	EXTL1	-0.53	-5.99	-0.31	5.23e-9	QRS complex (12-leadsum);
LIHC	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.65	-9.98	-0.47	9.4499999999999992e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	7.01	0.35	1.31e-11	Blood protein levels;
LIHC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg25356066	chr3:128598488	ACAD9	0.55	7.67	0.38	1.85e-13	IgG glycosylation;
LIHC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.73	7.45	0.37	7.71e-13	Inflammatory bowel disease;
LIHC	trans	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg26338869	chr17:61819248	STRADA	0.52	6.91	0.35	2.33e-11	Height;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.11	-0.31	2.78e-9	Total body bone mineral density;
LIHC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.1	9.68	0.46	9.54e-20	Diabetic retinopathy;
LIHC	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-6.61	-0.34	1.51e-10	Eye color traits;
LIHC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-13.02	-0.58	9.16e-32	Refractive error;
LIHC	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.81	0.47	3.5e-20	Corneal astigmatism;
LIHC	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.57	6.17	0.32	1.94e-9	Mammographic density (dense area);
LIHC	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.59	-10.07	-0.48	4.73e-21	Diisocyanate-induced asthma;
LIHC	trans	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg11693508	chr17:37793320	STARD3	0.61	6.14	0.32	2.24e-9	Bipolar disorder;
LIHC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.45	7.55	0.38	4.11e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.51	5.72	0.3	2.33e-8	Type 1 diabetes nephropathy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24685795	chr17:34851276	ZNHIT3	0.53	6.99	0.35	1.41e-11	Systolic blood pressure;
LIHC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.69	13.74	0.6	1.68e-34	Coronary artery disease;
LIHC	trans	rs6489882	0.867	rs7132404	chr12:113368605	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg22079354	chr11:130786696	SNX19	0.42	6.02	0.31	4.43e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.72	0.57	1.29e-30	Prudent dietary pattern;
LIHC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.57	11.5	0.53	4.28e-26	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg14593290	chr7:50529359	DDC	0.42	6.89	0.35	2.67e-11	Malaria;
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.88	-0.3	9.68e-9	Total body bone mineral density;
LIHC	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.65	-0.38	2.11e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-6.2	-0.32	1.67e-9	Subjective well-being;
LIHC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.01	-0.31	4.78e-9	Obesity-related traits;
LIHC	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg26531700	chr6:26746687	NA	0.39	6.4	0.33	5.18e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.44	7.02	0.36	1.17e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg09572067	chr16:29127029	RRN3P2	0.56	8.51	0.42	5.35e-16	Menopause (age at onset);
LIHC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.96	9.09	0.44	7.98e-18	Psoriasis;
LIHC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.13	-17.49	-0.69	2.27e-49	Gut microbiome composition (summer);
LIHC	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.6	0.5	6.89e-23	Alzheimer's disease;
LIHC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg24879335	chr3:133465180	TF	0.37	8.37	0.41	1.49e-15	Iron status biomarkers;
LIHC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.6	10.51	0.49	1.45e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.39	6.43	0.33	4.39e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.59	0.38	3.09e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.38	8.17	0.4	5.93e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-0.83	-10.33	-0.49	5.79e-22	Blood pressure (smoking interaction);
LIHC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.78	0.3	1.71e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.68	11.27	0.52	2.96e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.48	6.61	0.34	1.48e-10	Breast cancer;
LIHC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.3	6.35	0.32	6.86e-10	Bone mineral density;
LIHC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.35	6.37	0.33	6.16e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	0.85	6.15	0.32	2.22e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LIHC	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.82	-0.57	5.55e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.24	0.32	1.31e-9	Tonsillectomy;
LIHC	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	10.44	0.49	2.51e-22	Diisocyanate-induced asthma;
LIHC	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.56	7.37	0.37	1.31e-12	Interleukin-17 levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05170863	chr8:109261119	EIF3E	0.43	6.35	0.32	6.74e-10	Cognitive function;
LIHC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg09990169	chr2:241835740	C2orf54	-0.66	-9.32	-0.45	1.47e-18	Urinary metabolites;
LIHC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	8.06	0.4	1.3e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg12458913	chr13:53173898	NA	0.48	7.9	0.39	3.83e-14	Lewy body disease;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	trans	rs783540	0.934	rs4779053	chr15:83371598	T/C	cg18393722	chr15:85113863	UBE2QP1	0.38	6.67	0.34	1.03e-10	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg07862535	chr7:139043722	LUC7L2	-0.6	-10.31	-0.49	6.76e-22	Diisocyanate-induced asthma;
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.61	-8.07	-0.4	1.19e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.54	9.21	0.45	3.44e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.44	-8.22	-0.41	4.38e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg14393609	chr7:65229607	NA	-0.39	-5.79	-0.3	1.61e-8	Aortic root size;
LIHC	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.73	0.34	7.17e-11	Type 2 diabetes;
LIHC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.54	8.35	0.41	1.67e-15	Multiple sclerosis;
LIHC	cis	rs12477438	0.539	rs13394175	chr2:99590713	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-7.0	-0.35	1.37e-11	Chronic sinus infection;
LIHC	cis	rs876084	0.505	rs12546625	chr8:121155225	C/T	cg06265175	chr8:121136014	COL14A1	0.39	6.09	0.31	3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.57	0.71	1.01e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7818688	0.697	rs11783985	chr8:95979886	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs990171	0.560	rs4851548	chr2:102767532	A/G	cg22835712	chr2:102737379	NA	0.61	6.06	0.31	3.54e-9	Lymphocyte counts;
LIHC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02985541	chr2:219472218	PLCD4	0.43	7.91	0.39	3.66e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7116495	0.867	rs604671	chr11:71555904	A/G	cg26138937	chr11:71823887	C11orf51	0.64	5.95	0.31	6.58e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.69	11.67	0.53	1.01e-26	Hemoglobin concentration;
LIHC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg14758556	chr20:62440591	NA	0.42	6.75	0.34	6.51e-11	Atopic dermatitis;
LIHC	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.84	11.11	0.52	1.07e-24	Post bronchodilator FEV1;
LIHC	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.7	-8.08	-0.4	1.12e-14	Putamen volume;
LIHC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	6.75	0.34	6.17e-11	Schizophrenia;
LIHC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg19635926	chr16:89946313	TCF25	0.5	6.48	0.33	3.24e-10	Skin colour saturation;
LIHC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg16736954	chr20:23401023	NAPB	0.71	8.5	0.42	5.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.56	0.67	1.24e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs11233413	0.508	rs7947780	chr11:82643760	A/C	cg24227371	chr11:82718527	RAB30	0.31	6.85	0.35	3.44e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	0.87	11.95	0.54	9.72e-28	Skin colour saturation;
LIHC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.78	-0.3	1.64e-8	Life satisfaction;
LIHC	cis	rs6750795	0.777	rs10210351	chr2:232348665	A/G	cg19187155	chr2:232395269	NMUR1	0.54	7.78	0.39	8.39e-14	Height;
LIHC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.42	-7.23	-0.36	3.27e-12	Height;
LIHC	cis	rs2635047	0.631	rs2668778	chr18:44745185	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.97	0.31	5.98e-9	Educational attainment;
LIHC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.67	-6.54	-0.33	2.3e-10	Breast cancer;
LIHC	cis	rs17286411	0.750	rs11075910	chr16:71936733	A/G	cg06353428	chr16:71660113	MARVELD3	0.57	7.14	0.36	5.62e-12	Blood protein levels;
LIHC	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.58	6.28	0.32	1.05e-9	Blood protein levels;
LIHC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.61	-8.14	-0.4	7.23e-15	Colorectal cancer;
LIHC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg07636037	chr3:49044803	WDR6	-0.79	-8.23	-0.41	4.01e-15	Cognitive function;
LIHC	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	0.71	8.87	0.43	4.17e-17	Corneal structure;
LIHC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.61	10.94	0.51	4.51e-24	Mean corpuscular volume;
LIHC	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4407350	0.806	rs5765706	chr22:44909045	A/G	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.06	-0.31	3.69e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg16511985	chr3:153974050	SGEF	0.42	9.11	0.44	7.14e-18	Coronary artery disease;
LIHC	cis	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg07356753	chr3:81810745	GBE1	-0.52	-7.95	-0.4	2.68e-14	Extraversion;
LIHC	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg04610667	chr7:75704037	NA	0.33	5.94	0.31	6.98e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.12	0.48	3.02e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.62	0.53	1.56e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg24220031	chr2:73402428	NA	-0.27	-5.9	-0.3	8.62e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.59	10.32	0.49	6.42e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.49	7.65	0.38	2.11e-13	Total body bone mineral density;
LIHC	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg02272795	chr19:15279244	NOTCH3	-0.31	-6.2	-0.32	1.61e-9	Pulse pressure;
LIHC	trans	rs6692729	0.931	rs1296171	chr1:227059606	C/G	cg24931520	chr6:99291587	NA	0.36	6.07	0.31	3.44e-9	Electrodermal activity;
LIHC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.32	7.41	0.37	9.76e-13	Immature fraction of reticulocytes;
LIHC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.9	-0.3	8.56e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1823913	1.000	rs4853461	chr2:192119298	C/T	cg12404831	chr2:192114017	MYO1B	-0.33	-6.58	-0.34	1.75e-10	Obesity-related traits;
LIHC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-8.39	-0.41	1.29e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.18	-0.32	1.87e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.58	7.6	0.38	2.94e-13	Age-related disease endophenotypes;
LIHC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg00409905	chr10:38381863	ZNF37A	0.44	6.88	0.35	2.86e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.46	-10.53	-0.49	1.2e-22	Arsenic metabolism;
LIHC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-8.66	-0.42	1.86e-16	Morning vs. evening chronotype;
LIHC	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.98	-0.4	2.19e-14	Type 2 diabetes;
LIHC	cis	rs4700695	0.841	rs36301	chr5:65348940	A/G	cg21114390	chr5:65439923	SFRS12	0.45	5.87	0.3	1.01e-8	Facial morphology (factor 19);
LIHC	trans	rs13325613	0.915	rs1542755	chr3:46272440	A/C	cg26337592	chr1:153642686	ILF2	-0.69	-6.48	-0.33	3.22e-10	Monocyte count;
LIHC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.53	7.92	0.39	3.29e-14	Height;
LIHC	cis	rs4934494	0.727	rs12572012	chr10:91487649	A/T	cg19698084	chr10:91461284	KIF20B	-0.48	-6.4	-0.33	5.06e-10	Red blood cell count;
LIHC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	8.79	0.43	7.61e-17	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08219700	chr8:58056026	NA	0.53	7.22	0.36	3.36e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	9.9	0.47	1.76e-20	Chronic sinus infection;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17302176	chr4:139936680	CCRN4L	0.42	6.16	0.32	2e-9	Migraine with aura;
LIHC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	15.14	0.63	5.55e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.66	-0.42	1.93e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.94	-0.31	7.2e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09115837	chr10:79541592	NA	0.41	6.03	0.31	4.15e-9	Pancreatic cancer;
LIHC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.56	7.68	0.38	1.65e-13	Blood metabolite levels;
LIHC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.58	0.38	3.34e-13	Bipolar disorder;
LIHC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.98	18.32	0.7	9.86e-53	Monocyte percentage of white cells;
LIHC	cis	rs1122900	1.000	rs1122900	chr5:36689181	A/C	cg24186104	chr5:36689192	NA	-0.29	-5.88	-0.3	9.5e-9	Aggressive periodontitis;
LIHC	cis	rs903552	0.935	rs4965871	chr15:102003810	A/T	cg25677261	chr15:102009856	PCSK6	-0.45	-6.36	-0.33	6.57e-10	Diabetic kidney disease;
LIHC	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.78	-10.19	-0.48	1.77e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06656553	chr16:89960601	TCF25	-0.49	-6.21	-0.32	1.55e-9	Skin colour saturation;
LIHC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.51	8.26	0.41	3.19e-15	Schizophrenia;
LIHC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.25	-0.45	2.55e-18	Bipolar disorder;
LIHC	cis	rs507080	0.922	rs638805	chr11:118558889	G/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.62	9.2	0.45	3.52e-18	Schizophrenia;
LIHC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.44	-7.43	-0.37	8.87e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs11212260	0.512	rs78057192	chr11:107132514	G/A	cg25435332	chr11:107328525	CWF19L2	0.75	7.21	0.36	3.66e-12	IgG glycosylation;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg14671364	chr1:107599128	PRMT6	0.48	6.99	0.35	1.45e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.66	-11.06	-0.51	1.61e-24	Bipolar disorder;
LIHC	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.8	-8.97	-0.44	1.95e-17	Exhaled nitric oxide output;
LIHC	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.7	-11.85	-0.54	2.28e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.84	10.07	0.48	4.51e-21	Cognitive function;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09578308	chr8:124780849	FAM91A1	-0.58	-7.55	-0.38	3.94e-13	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.4	-6.41	-0.33	4.95e-10	Height;
LIHC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.93	0.43	2.71e-17	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.42	0.33	4.46e-10	Rheumatoid arthritis;
LIHC	trans	rs334353	1.000	rs334366	chr9:101929237	A/T	cg06788856	chr17:1821969	NA	-0.35	-6.24	-0.32	1.29e-9	Age-related macular degeneration;
LIHC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg07061783	chr6:25882402	NA	-0.43	-6.07	-0.31	3.41e-9	Blood metabolite levels;
LIHC	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.36	0.33	6.32e-10	Heart rate;
LIHC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.59	6.98	0.35	1.54e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02985541	chr2:219472218	PLCD4	0.42	6.89	0.35	2.68e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.95	-9.84	-0.47	2.88e-20	Breast cancer;
LIHC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg27433088	chr4:174089019	GALNT7	0.4	7.34	0.37	1.55e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.56	0.46	2.49e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.4	6.25	0.32	1.26e-9	Resting heart rate;
LIHC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.87	-0.35	3.09e-11	Hemoglobin concentration;
LIHC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.52	8.05	0.4	1.34e-14	Cognitive function;
LIHC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.56	9.82	0.47	3.3e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.26	0.52	3.16e-25	Personality dimensions;
LIHC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-9.68	-0.46	9.32e-20	Asthma;
LIHC	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	0.71	7.76	0.39	1.02e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.9	0.39	3.83e-14	Triglyceride levels;
LIHC	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.31	-6.56	-0.33	2.03e-10	Platelet distribution width;
LIHC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.43	5.91	0.3	8.32e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.88	0.39	4.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.57	11.5	0.53	4.35e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg12193833	chr17:30244370	NA	-0.51	-5.79	-0.3	1.56e-8	Hip circumference adjusted for BMI;
LIHC	trans	rs11165623	0.602	rs12120893	chr1:97007132	C/T	cg10631902	chr5:14652156	NA	-0.25	-6.09	-0.31	3.12e-9	Hip circumference;Waist circumference;
LIHC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg15208524	chr1:10270712	KIF1B	0.41	6.09	0.31	3.05e-9	Hepatocellular carcinoma;
LIHC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.49	9.07	0.44	9.82e-18	Hemoglobin concentration;
LIHC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.77	11.95	0.54	9.51e-28	Corneal astigmatism;
LIHC	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg25344623	chr2:136566232	LCT	0.42	8.59	0.42	3.22e-16	Mosquito bite size;
LIHC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.78	15.68	0.65	4.06e-42	White blood cell count (neutrophil);
LIHC	cis	rs10792665	0.724	rs10898071	chr11:82727891	C/T	cg24227371	chr11:82718527	RAB30	-0.39	-9.65	-0.46	1.17e-19	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.43	6.01	0.31	4.72e-9	Uric acid clearance;
LIHC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.1	0.4	9.96e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.86	-0.3	1.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg22676075	chr6:135203613	NA	0.41	6.74	0.34	6.73e-11	Red blood cell count;
LIHC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	7.99	0.4	2.02e-14	Mood instability;
LIHC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.74	-10.61	-0.5	6.46e-23	Pancreatic cancer;
LIHC	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.23	-6.24	-0.32	1.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	trans	rs10411161	0.702	rs8113584	chr19:52383874	A/G	cg22319618	chr22:45562946	NUP50	-0.6	-8.17	-0.4	6.12e-15	Breast cancer;
LIHC	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg00901687	chr17:48585270	MYCBPAP	0.44	6.62	0.34	1.37e-10	Visceral fat;
LIHC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.74	-0.34	6.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.84	0.54	2.45e-27	Prudent dietary pattern;
LIHC	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.64	-0.34	1.27e-10	Schizophrenia;
LIHC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02985541	chr2:219472218	PLCD4	0.39	7.07	0.36	8.62e-12	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.31	-6.85	-0.35	3.41e-11	Ulcerative colitis;
LIHC	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg07599136	chr5:415885	AHRR	0.62	10.13	0.48	2.81e-21	Fat distribution (HIV);
LIHC	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg14146966	chr2:61757674	XPO1	-0.44	-7.37	-0.37	1.28e-12	Tuberculosis;
LIHC	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.64	10.75	0.5	2.12e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.15	0.4	6.93e-15	Total body bone mineral density;
LIHC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.7	-11.08	-0.51	1.43e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.45	6.23	0.32	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg21361702	chr7:150065534	REPIN1	0.46	6.24	0.32	1.3e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.39	6.22	0.32	1.49e-9	Menopause (age at onset);
LIHC	cis	rs2629540	0.544	rs2629529	chr10:126534415	A/C	cg08799069	chr10:126477246	METTL10	0.44	6.26	0.32	1.13e-9	Cocaine dependence;
LIHC	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg12046867	chr14:103022105	NA	-0.42	-6.65	-0.34	1.18e-10	Platelet count;
LIHC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-7.76	-0.39	9.79e-14	Crohn's disease;
LIHC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg11764359	chr7:65958608	NA	0.57	6.0	0.31	4.9e-9	Diabetic kidney disease;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	1.18	10.86	0.51	8.1e-24	Obesity-related traits;
LIHC	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	trans	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg01134436	chr17:81009848	B3GNTL1	0.8	6.64	0.34	1.27e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.78	0.34	5.43e-11	Aortic root size;
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg00656387	chr3:40428638	ENTPD3	0.5	8.52	0.42	5.28e-16	Renal cell carcinoma;
LIHC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-11.13	-0.52	9.01e-25	Personality dimensions;
LIHC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.47	6.32	0.32	7.93e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.28	-0.32	1e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.34	-6.94	-0.35	1.99e-11	Colorectal cancer;
LIHC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.96	0.6	2.22e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs412658	0.812	rs17554725	chr19:22317759	A/G	cg05197062	chr11:11642011	GALNTL4	-0.46	-6.44	-0.33	4.05e-10	Telomere length;
LIHC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-1.11	-12.36	-0.56	2.88e-29	White matter hyperintensity burden;
LIHC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.78	14.4	0.61	4.49e-37	Obesity-related traits;
LIHC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.1	0.36	7.06e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.33	0.49	6.19e-22	Schizophrenia;
LIHC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.75	-0.39	1.05e-13	Total body bone mineral density;
LIHC	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg20356878	chr3:121714668	ILDR1	-0.36	-5.72	-0.3	2.29e-8	Multiple sclerosis;
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-8.82	-0.43	6.09e-17	Prudent dietary pattern;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-7.21	-0.36	3.6e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg00225070	chr15:80189496	MTHFS	0.44	7.24	0.36	3.01e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18252515	chr7:66147081	NA	0.42	6.04	0.31	4.13e-9	Aortic root size;
LIHC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	11.9	0.54	1.46e-27	Lung cancer in ever smokers;
LIHC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.64e-23	Alzheimer's disease;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.74	-13.38	-0.59	3.85e-33	Prudent dietary pattern;
LIHC	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.74	-0.34	6.73e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.52	6.26	0.32	1.14e-9	Alzheimer's disease;
LIHC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	6.04e-40	Intelligence (multi-trait analysis);
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.48	-6.49	-0.33	2.95e-10	Menopause (age at onset);
LIHC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.01	0.35	1.31e-11	Mean platelet volume;
LIHC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg20295408	chr7:1910781	MAD1L1	-0.53	-7.51	-0.38	5.08e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.47	0.56	1.09e-29	Prudent dietary pattern;
LIHC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg03959625	chr15:84868606	LOC388152	0.44	6.07	0.31	3.31e-9	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07562458	chr1:224622430	WDR26	-0.49	-6.48	-0.33	3.16e-10	Pancreatic cancer;
LIHC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.57	0.33	1.83e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg00343986	chr7:65444356	GUSB	-0.38	-5.72	-0.3	2.27e-8	Aortic root size;
LIHC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg06565975	chr8:143823917	SLURP1	-0.42	-7.76	-0.39	1e-13	Urinary tract infection frequency;
LIHC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-0.98	-10.34	-0.49	5.67e-22	Vitiligo;
LIHC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.7	0.34	8.58e-11	Lung cancer in ever smokers;
LIHC	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.37	-0.33	6.19e-10	Hepatocellular carcinoma;
LIHC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.1	0.44	7.71e-18	IgG glycosylation;
LIHC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.78	-0.39	8.52e-14	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.69	7.07	0.36	8.52e-12	Alzheimer's disease;
LIHC	cis	rs867186	0.614	rs34526995	chr20:33518834	G/T	cg08999081	chr20:33150536	PIGU	0.66	5.93	0.31	7.22e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.45	-5.98	-0.31	5.57e-9	Obesity-related traits;
LIHC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg25024717	chr12:54324583	NA	-0.31	-6.16	-0.32	2.03e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-8.95	-0.44	2.25e-17	Gut microbiome composition (summer);
LIHC	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	0.73	12.59	0.56	3.9e-30	Testicular germ cell tumor;
LIHC	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	6.77	0.34	5.56e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	6.65	0.34	1.14e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg14580859	chr9:123691850	NA	0.4	6.96	0.35	1.79e-11	Rheumatoid arthritis;
LIHC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.63	11.05	0.51	1.77e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.04e-10	Menopause (age at onset);
LIHC	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.6	8.92	0.43	2.8e-17	Recombination rate (females);
LIHC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg16102536	chr7:156981717	UBE3C	0.36	6.06	0.31	3.66e-9	Body mass index;
LIHC	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.42	6.39	0.33	5.44e-10	Alzheimer's disease (survival time);
LIHC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg18306943	chr3:40428807	ENTPD3	0.33	5.81	0.3	1.45e-8	Renal cell carcinoma;
LIHC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.5	7.38	0.37	1.24e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.85	14.74	0.62	2.1e-38	Headache;
LIHC	trans	rs1450439	0.898	rs7697872	chr4:139495443	G/A	cg27294979	chr16:69786225	NOB1	0.44	6.41	0.33	4.72e-10	Lung function (forced expiratory volume in 1 second);
LIHC	cis	rs7818688	0.674	rs74632106	chr8:95978032	A/G	cg16049864	chr8:95962084	TP53INP1	0.62	6.77	0.34	5.73e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg20283391	chr11:68216788	NA	-0.48	-7.07	-0.36	8.55e-12	Total body bone mineral density;
LIHC	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg26694713	chr4:57773883	REST	0.67	9.29	0.45	1.91e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.58	-0.34	1.82e-10	Body mass index;
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg09417038	chr21:47716443	C21orf57	-0.47	-7.05	-0.36	1e-11	Testicular germ cell tumor;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10633746	chr17:18164442	SMCR7	0.38	6.34	0.32	7.19e-10	Cognitive function;
LIHC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	12.62	0.56	2.98e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg16822855	chr3:40428330	ENTPD3	0.32	5.91	0.3	8.44e-9	Renal cell carcinoma;
LIHC	trans	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.21	-0.36	3.6e-12	Total body bone mineral density;
LIHC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs4865169	0.560	rs1277312	chr4:57902945	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	9.49	0.46	4.07e-19	Breast cancer;
LIHC	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg02023728	chr11:77925099	USP35	-0.37	-6.49	-0.33	2.99e-10	Alzheimer's disease (survival time);
LIHC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.83e-10	Aortic root size;
LIHC	cis	rs4742903	0.935	rs4743694	chr9:106933163	C/G	cg14250997	chr9:106856677	SMC2	0.35	5.91	0.3	8.24e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.4	-0.33	5.1e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);
LIHC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	17.99	0.7	2.19e-51	Smoking behavior;
LIHC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.85	13.94	0.6	2.63e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.44	-5.79	-0.3	1.63e-8	Vitiligo;
LIHC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	10.47	0.49	1.91e-22	Multiple sclerosis;
LIHC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.02	-0.35	1.23e-11	Breast cancer;
LIHC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.39	0.45	8.39e-19	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.53	6.91	0.35	2.4e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.72	-10.89	-0.51	6.78e-24	Aortic root size;
LIHC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	0.92	13.5	0.59	1.32e-33	Post bronchodilator FEV1;
LIHC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.49	-0.49	1.62e-22	Hemoglobin concentration;
LIHC	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.55	7.43	0.37	9.02e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.2	0.45	3.58e-18	Eosinophil percentage of white cells;
LIHC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.72	-11.03	-0.51	2.11e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-8.35	-0.41	1.74e-15	Putamen volume;
LIHC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.27	0.41	3.06e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.13	0.31	2.44e-9	Schizophrenia;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.9	-0.35	2.49e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.63	0.38	2.37e-13	Prudent dietary pattern;
LIHC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.83	15.35	0.64	8.04e-41	Multiple myeloma (IgH translocation);
LIHC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg06212747	chr3:49208901	KLHDC8B	0.5	6.43	0.33	4.32e-10	Parkinson's disease;
LIHC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.56	6.23	0.32	1.4e-9	Axial length;
LIHC	cis	rs600806	0.683	rs10857789	chr1:110012293	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.24	-0.32	1.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-8.13	-0.4	8.08e-15	Tonsillectomy;
LIHC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg22633049	chr21:46681294	NA	-0.36	-6.29	-0.32	9.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg24450063	chr1:156163899	SLC25A44	1.08	18.16	0.7	4.42e-52	Testicular germ cell tumor;
LIHC	cis	rs807029	0.533	rs67692077	chr10:102740271	T/C	cg25179470	chr10:102756915	LZTS2	0.45	6.36	0.32	6.65e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.69	-0.34	9.08e-11	Bladder cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10185667	chr17:66507857	PRKAR1A	0.45	6.14	0.32	2.24e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.03	0.31	4.36e-9	Rheumatoid arthritis;
LIHC	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.49	-8.24	-0.41	3.61e-15	Cocaine dependence;
LIHC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18252515	chr7:66147081	NA	0.42	6.1	0.31	2.89e-9	Aortic root size;
LIHC	trans	rs1814175	0.588	rs4076322	chr11:49745094	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.59	-0.74	7.56e-62	Height;
LIHC	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg12560992	chr17:57184187	TRIM37	0.64	8.13	0.4	8.05e-15	Vitamin D levels;
LIHC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.8	12.06	0.55	3.81e-28	Vitamin D levels;
LIHC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.19	0.4	5.35e-15	Motion sickness;
LIHC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.7	-6.36	-0.33	6.59e-10	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07305049	chr22:21354332	THAP7	0.48	6.96	0.35	1.76e-11	Hepatitis;
LIHC	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.84	0.3	1.19e-8	Tuberculosis;
LIHC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg25894440	chr7:65020034	NA	0.54	6.18	0.32	1.78e-9	Diabetic kidney disease;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	0.59	8.7	0.43	1.42e-16	Prudent dietary pattern;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.85	7.44	0.37	7.99e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.64	0.42	2.26e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.99	0.51	2.87e-24	Platelet count;
LIHC	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.7	-10.55	-0.5	1e-22	Subjective well-being;
LIHC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.43	-6.71	-0.34	8.24e-11	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21784052	chr20:47835958	DDX27	-0.45	-6.27	-0.32	1.11e-9	Pancreatic cancer;
LIHC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.37	6.06	0.31	3.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg19539972	chr4:7069911	GRPEL1	0.48	7.92	0.39	3.47e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs3770081	0.590	rs11891333	chr2:86178394	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.75	-8.67	-0.42	1.72e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs273218	0.694	rs274369	chr5:53379987	G/C	ch.5.1024479R	chr5:53302184	ARL15	0.55	8.97	0.44	1.97e-17	Migraine;
LIHC	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg20435097	chr10:126320824	FAM53B	-0.43	-6.23	-0.32	1.39e-9	Cocaine dependence;
LIHC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg12863693	chr15:85201151	NMB	0.47	6.76	0.34	5.88e-11	Schizophrenia;
LIHC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.0	14.18	0.61	3.28e-36	Cognitive function;
LIHC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	9.52	0.46	3.23e-19	Alzheimer's disease;
LIHC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.3	-5.89	-0.3	9.21e-9	Colorectal cancer;
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.64	9.31	0.45	1.56e-18	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg09904177	chr6:26538194	HMGN4	-0.53	-5.76	-0.3	1.83e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.57	7.5	0.38	5.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.26	-0.32	1.16e-9	Neuroticism;
LIHC	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.75	-0.3	1.94e-8	Blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20617956	chr10:82168530	C10orf58	0.46	6.43	0.33	4.22e-10	Pancreatic cancer;
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg00612595	chr21:47717864	NA	0.35	5.88	0.3	9.55e-9	Testicular germ cell tumor;
LIHC	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.57	7.71	0.38	1.41e-13	Opioid sensitivity;
LIHC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.45	-6.16	-0.32	2.04e-9	Initial pursuit acceleration;
LIHC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	7.81	0.39	7.1e-14	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.44	0.49	2.46e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.5	8.47	0.42	7.51e-16	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.26	0.49	1e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.57	-8.38	-0.41	1.37e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.68	11.92	0.54	1.25e-27	Colorectal cancer;
LIHC	cis	rs13394619	0.620	rs11674184	chr2:11721535	T/G	cg07314298	chr2:11723111	GREB1	-0.6	-11.47	-0.53	5.26e-26	Endometriosis;
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.5	8.13	0.4	7.78e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	5.8	0.3	1.55e-8	Birth weight;
LIHC	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.43	7.85	0.39	5.33e-14	Electrocardiographic conduction measures;
LIHC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg18898632	chr2:242989856	NA	-0.59	-8.01	-0.4	1.81e-14	Obesity-related traits;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04282497	chr4:82350883	RASGEF1B	0.4	6.04	0.31	4.12e-9	Longevity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00271154	chr2:113033418	ZC3H6	0.42	6.87	0.35	3.09e-11	Pancreatic cancer;
LIHC	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.66	0.46	1.12e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.38	-6.44	-0.33	4.1e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs3015497	0.616	rs10131107	chr14:51062455	G/A	cg09863266	chr14:51125203	SAV1	-0.38	-5.99	-0.31	5.36e-9	Mean platelet volume;
LIHC	cis	rs713477	0.935	rs4901567	chr14:55912698	C/T	cg13175173	chr14:55914753	NA	-0.33	-7.61	-0.38	2.68e-13	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.31	0.52	2.03e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.26	-0.32	1.17e-9	Vitiligo;
LIHC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.58	6.9	0.35	2.58e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	trans	rs8030605	0.778	rs72740578	chr15:56638096	G/A	cg01710580	chr16:598674	SOLH	-0.66	-6.09	-0.31	3.08e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.4	6.09	0.31	2.99e-9	Reticulocyte fraction of red cells;
LIHC	cis	rs2710642	0.586	rs6545961	chr2:62814166	A/T	cg17519650	chr2:63277830	OTX1	0.45	7.1	0.36	7.43e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.42	0.62	3.58e-37	Prudent dietary pattern;
LIHC	cis	rs7546668	1.000	rs4233535	chr1:15845197	G/C	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7095607	0.704	rs34869044	chr10:69953763	C/T	cg18986048	chr10:69913749	MYPN	0.43	6.53	0.33	2.36e-10	Lung function (FVC);
LIHC	trans	rs7922314	1.000	rs10995340	chr10:64632908	G/A	cg06816054	chr8:27695695	PBK	0.56	6.22	0.32	1.48e-9	Cutaneous psoriasis;
LIHC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.49	-0.42	6.46e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.65	9.01	0.44	1.46e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	8.59	0.42	3.17e-16	Multiple sclerosis;
LIHC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.81	14.79	0.62	1.31e-38	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.92	16.62	0.67	7e-46	Menopause (age at onset);
LIHC	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg14345882	chr6:26364793	BTN3A2	0.39	5.95	0.31	6.64e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20011983	chr2:74347215	NA	-0.4	-5.89	-0.3	9.15e-9	Gestational age at birth (maternal effect);
LIHC	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.59	14.69	0.62	3.26e-38	White blood cell count (basophil);
LIHC	cis	rs74544699	1.000	rs77149208	chr4:74768731	C/A	cg02530824	chr4:74847766	PF4	0.66	6.88	0.35	2.83e-11	Growth-regulated protein alpha levels;
LIHC	trans	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg26939375	chr7:64535504	NA	0.4	6.42	0.33	4.54e-10	Aortic root size;
LIHC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.56	10.03	0.48	6.55e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.95	-0.31	6.54e-9	Menopause (age at onset);
LIHC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	10.15	0.48	2.52e-21	Personality dimensions;
LIHC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.66	10.42	0.49	2.95e-22	Lymphocyte counts;
LIHC	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.46	6.28	0.32	1.02e-9	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg15832292	chr6:96025679	MANEA	-0.58	-7.72	-0.39	1.27e-13	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	11.8	0.54	3.38e-27	Schizophrenia;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg24452005	chr18:9913478	VAPA	-0.43	-6.11	-0.31	2.67e-9	Bipolar disorder;
LIHC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg27432699	chr2:27873401	GPN1	-0.6	-8.52	-0.42	5.34e-16	Total body bone mineral density;
LIHC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.57	6.32	0.32	7.99e-10	Axial length;
LIHC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg05941027	chr17:61774174	LIMD2	0.37	7.78	0.39	8.77e-14	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.33	-7.58	-0.38	3.23e-13	Breast cancer;
LIHC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.6	12.67	0.57	2.03e-30	Fat distribution (HIV);
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07562135	chr19:39340654	HNRNPL	0.5	6.51	0.33	2.61e-10	Hepatitis;
LIHC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs992157	0.730	rs2382828	chr2:219184492	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.21	0.48	1.49e-21	Colorectal cancer;
LIHC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg12798992	chr6:167411361	FGFR1OP	0.48	7.18	0.36	4.3e-12	Crohn's disease;
LIHC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.22	-0.36	3.4e-12	Schizophrenia;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg10799249	chr10:422187	DIP2C	0.4	6.29	0.32	9.48e-10	Electroencephalogram traits;
LIHC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg14784868	chr12:69753453	YEATS4	0.52	7.34	0.37	1.59e-12	Response to diuretic therapy;
LIHC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.66	-9.43	-0.45	6.3e-19	Initial pursuit acceleration;
LIHC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg18944383	chr4:111397179	ENPEP	-0.36	-8.17	-0.4	6.22e-15	Coronary artery disease;
LIHC	trans	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg10208301	chr11:6592745	DNHD1	0.45	6.4	0.33	5.12e-10	Coronary artery calcification;
LIHC	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24914313	chr13:41636195	WBP4	0.44	6.33	0.32	7.86e-10	Pancreatic cancer;
LIHC	cis	rs238295	0.805	rs6053525	chr20:5577000	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.95	-0.35	1.83e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-10.15	-0.48	2.52e-21	Body mass index;
LIHC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg09835421	chr16:68378352	PRMT7	-0.81	-9.77	-0.47	4.67e-20	Schizophrenia;
LIHC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg22834771	chr12:69754056	YEATS4	-0.47	-7.99	-0.4	2.03e-14	Response to diuretic therapy;
LIHC	cis	rs1823913	0.599	rs13027086	chr2:192158784	A/G	cg12404831	chr2:192114017	MYO1B	0.28	5.76	0.3	1.85e-8	Obesity-related traits;
LIHC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.43	5.98	0.31	5.51e-9	Coronary artery disease;
LIHC	cis	rs11931598	0.782	rs4689581	chr4:7048134	C/T	cg26116260	chr4:7069785	GRPEL1	-0.43	-6.92	-0.35	2.2e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.43	-8.5	-0.42	5.76e-16	Testicular germ cell tumor;
LIHC	trans	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.98	-0.35	1.57e-11	Aortic root size;
LIHC	cis	rs600806	0.888	rs638542	chr1:109845252	G/A	cg16275483	chr1:110013120	SYPL2	-0.51	-6.19	-0.32	1.7e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.48e-8	Axial length;
LIHC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-13.51	-0.59	1.28e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs539514	0.690	rs2328953	chr13:76317459	T/G	cg04757411	chr13:76259545	LMO7	-0.45	-8.03	-0.4	1.61e-14	Type 1 diabetes;
LIHC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.58	-8.59	-0.42	3.2e-16	Parkinson's disease;
LIHC	cis	rs365132	0.875	rs353494	chr5:176431759	C/G	cg16309518	chr5:176445507	NA	-0.53	-9.96	-0.47	1.06e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	trans	rs72960926	0.744	rs72952257	chr6:74924073	A/G	cg07247405	chr1:2484626	LOC115110	0.56	6.62	0.34	1.36e-10	Metabolite levels (MHPG);
LIHC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.86	0.35	3.15e-11	Gut microbiome composition (summer);
LIHC	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.2	0.48	1.72e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs963731	0.649	rs10183915	chr2:39218887	A/T	cg04010122	chr2:39346883	SOS1	-0.79	-6.04	-0.31	3.97e-9	Corticobasal degeneration;
LIHC	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.27	6.21	0.32	1.57e-9	Heart rate;
LIHC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	8.87	0.43	4.24e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.86	11.06	0.51	1.63e-24	Heart rate;
LIHC	cis	rs3736485	0.868	rs8023455	chr15:51936510	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-5.95	-0.31	6.66e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.73	10.67	0.5	3.84e-23	Chronic sinus infection;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06873352	chr17:61820015	STRADA	0.54	8.04	0.4	1.49e-14	Height;
LIHC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.58	9.19	0.44	3.92e-18	Lymphocyte counts;
LIHC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.04	0.55	4.36e-28	Alzheimer's disease;
LIHC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	21.11	0.75	6.65e-64	Smoking behavior;
LIHC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.85	15.31	0.64	1.2e-40	Aortic root size;
LIHC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.22	0.52	4.42e-25	Coronary artery disease;
LIHC	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.34	-7.24	-0.36	2.94e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.13	-0.44	6.13e-18	Bipolar disorder;
LIHC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.81	13.37	0.59	4.38e-33	Breast cancer;
LIHC	trans	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg26939375	chr7:64535504	NA	0.43	6.94	0.35	2.02e-11	Aortic root size;
LIHC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.4	-6.78	-0.34	5.24e-11	Monocyte count;
LIHC	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.39	5.79	0.3	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.97	-0.31	5.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.06	-0.4	1.25e-14	Migraine;
LIHC	cis	rs9596863	1.000	rs4471558	chr13:54413349	A/T	ch.13.53330881F	chr13:54432880	NA	0.43	6.09	0.31	3.06e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg12798992	chr6:167411361	FGFR1OP	0.53	8.74	0.43	1.04e-16	Crohn's disease;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.63	0.53	1.42e-26	Height;
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.45	8.32	0.41	2.12e-15	Prudent dietary pattern;
LIHC	cis	rs7238033	0.641	rs11877028	chr18:43317866	C/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.47	0.33	3.3e-10	Bladder cancer;
LIHC	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-0.66	-6.75	-0.34	6.43e-11	Putamen volume;
LIHC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-12.17	-0.55	1.42e-28	Alzheimer's disease (late onset);
LIHC	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg03934865	chr2:198174659	NA	0.51	7.72	0.39	1.3e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs700651	0.789	rs1147169	chr2:198901395	C/T	cg03934865	chr2:198174659	NA	-0.46	-6.4	-0.33	5.19e-10	Intracranial aneurysm;
LIHC	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg09445902	chr10:555545	DIP2C	-0.4	-6.49	-0.33	3.1e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.45	6.21	0.32	1.53e-9	Initial pursuit acceleration;
LIHC	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.63	-0.42	2.4e-16	Response to antipsychotic treatment;
LIHC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg21724239	chr8:58056113	NA	0.49	6.41	0.33	4.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg22563815	chr15:78856949	CHRNA5	0.35	6.4	0.33	5.07e-10	Sudden cardiac arrest;
LIHC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.74	13.15	0.58	3.05e-32	Platelet count;
LIHC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg03037974	chr15:76606532	NA	0.74	14.45	0.62	2.79e-37	Blood metabolite levels;
LIHC	trans	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg19862616	chr7:65841803	NCRNA00174	0.61	9.05	0.44	1.11e-17	Eotaxin levels;
LIHC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.46	-11.99	-0.54	6.92e-28	Hip circumference adjusted for BMI;
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg08119480	chr6:150067491	NUP43	-0.47	-6.03	-0.31	4.17e-9	Response to hepatitis C treatment;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.02e-13	Prudent dietary pattern;
LIHC	cis	rs11245387	0.564	rs7915429	chr10:126510089	T/C	cg08799069	chr10:126477246	METTL10	-0.44	-6.75	-0.34	6.49e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16684958	chr7:75615977	POR	0.49	8.57	0.42	3.56e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-5.99	-0.31	5.42e-9	Aortic root size;
LIHC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.72	-8.87	-0.43	4.15e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-0.82	-11.53	-0.53	3.19e-26	Left atrial antero-posterior diameter;
LIHC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.26	-18.71	-0.71	2.75e-54	Ulcerative colitis;
LIHC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.14	0.4	7.31e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	8.7	0.43	1.39e-16	Mean corpuscular hemoglobin;
LIHC	cis	rs10861342	0.579	rs77585712	chr12:105482251	T/C	cg23923672	chr12:105501055	KIAA1033	0.65	7.48	0.38	6.2800000000000005e-13	IgG glycosylation;
LIHC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02034447	chr16:89574710	SPG7	-0.48	-7.53	-0.38	4.71e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.38	-0.33	5.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.35	-8.12	-0.4	8.76e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.47	7.66	0.38	1.88e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12016809	chr21:47604291	C21orf56	0.47	7.25	0.36	2.83e-12	Testicular germ cell tumor;
LIHC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.9	-0.35	2.48e-11	Acylcarnitine levels;
LIHC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg15848620	chr12:58087721	OS9	-0.54	-7.42	-0.37	9.2e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.54	-8.28	-0.41	2.76e-15	Crohn's disease;
LIHC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.85	-15.03	-0.63	1.49e-39	Aortic root size;
LIHC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.61	9.3	0.45	1.74e-18	Height;
LIHC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.3	7.14	0.36	5.63e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.52e-14	Platelet count;
LIHC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.44	-6.14	-0.32	2.24e-9	Diastolic blood pressure;
LIHC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-6.05	-0.31	3.72e-9	Colorectal cancer;
LIHC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg05973401	chr12:123451056	ABCB9	0.43	6.39	0.33	5.58e-10	Platelet count;
LIHC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20456258	chr4:962124	DGKQ	0.36	6.96	0.35	1.77e-11	Sjögren's syndrome;
LIHC	cis	rs17106184	1.000	rs59097691	chr1:51394098	C/T	cg07174182	chr1:51127561	FAF1	-0.74	-8.35	-0.41	1.69e-15	Type 2 diabetes;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.99	-0.35	1.41e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.68	11.96	0.54	8.87e-28	High light scatter reticulocyte count;
LIHC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg02290350	chr8:58132656	NA	0.38	7.94	0.39	2.87e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-10.59	-0.5	7.75e-23	Platelet count;
LIHC	cis	rs17106184	0.892	rs58029717	chr1:51162128	A/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.74	-0.34	6.82e-11	Type 2 diabetes;
LIHC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-7.97	-0.4	2.32e-14	Urinary metabolites;
LIHC	cis	rs1113500	0.636	rs3853493	chr1:108637193	G/A	cg06207961	chr1:108661230	NA	0.31	5.99	0.31	5.21e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs1144333	0.655	rs7418941	chr1:76436020	A/G	cg22875332	chr1:76189707	ACADM	0.41	6.19	0.32	1.69e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.71	0.43	1.36e-16	Exhaled nitric oxide levels;
LIHC	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg02290350	chr8:58132656	NA	0.47	9.11	0.44	7.19e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.82	0.65	1.09e-42	Chronic sinus infection;
LIHC	cis	rs2274273	1.000	rs2274273	chr14:55614636	A/G	cg01864836	chr14:55583639	NA	0.36	6.24	0.32	1.32e-9	Protein biomarker;
LIHC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.58	-11.52	-0.53	3.53e-26	Tonsillectomy;
LIHC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.7	0.34	8.58e-11	Lung cancer in ever smokers;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.24	0.58	1.32e-32	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03694515	chr18:32870085	ZNF271;ZNF397OS	0.46	7.3	0.37	2.02e-12	Pancreatic cancer;
LIHC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.57	10.41	0.49	3.26e-22	Alzheimer's disease (late onset);
LIHC	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.51	9.28	0.45	2.05e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs12079745	0.793	rs10800443	chr1:169355529	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-6.83	-0.35	3.83e-11	QT interval;
LIHC	cis	rs10411936	0.692	rs3810196	chr19:16601154	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	6.5	0.33	2.92e-10	White blood cell count;Multiple sclerosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13006718	chr18:33078008	INO80C	0.48	6.86	0.35	3.2e-11	Pancreatic cancer;
LIHC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg25344623	chr2:136566232	LCT	0.44	8.88	0.43	3.96e-17	Mosquito bite size;
LIHC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg26149184	chr10:133730230	NA	0.47	7.47	0.37	6.93e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg09222892	chr1:25734099	RHCE	-0.43	-7.91	-0.39	3.61e-14	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	6.87	0.35	3.04e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.83	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-6.0	-0.31	5.01e-9	Life satisfaction;
LIHC	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.63	-9.78	-0.47	4.28e-20	Retinal vascular caliber;
LIHC	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.5	8.29	0.41	2.7e-15	Plateletcrit;Platelet count;
LIHC	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.39	6.11	0.31	2.64e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.61	-9.25	-0.45	2.52e-18	Smoking behavior;
LIHC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.97	9.87	0.47	2.22e-20	Plasma clusterin levels;
LIHC	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.6	8.95	0.44	2.33e-17	Recombination rate (females);
LIHC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg08807892	chr2:162101083	NA	0.45	7.64	0.38	2.14e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.76	9.32	0.45	1.49e-18	Morning vs. evening chronotype;
LIHC	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.75	11.53	0.53	3.35e-26	Metabolite levels;
LIHC	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.33	6.13	0.31	2.37e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg15017067	chr4:17643749	FAM184B	0.34	5.86	0.3	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	7.71	0.38	1.4e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg17385448	chr1:15911702	AGMAT	0.4	6.55	0.33	2.1e-10	Systolic blood pressure;
LIHC	cis	rs7116495	0.500	rs7123992	chr11:71746447	C/T	cg26138937	chr11:71823887	C11orf51	-0.69	-6.98	-0.35	1.5e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs1144333	0.655	rs76416835	chr1:76341511	G/T	cg10523679	chr1:76189770	ACADM	0.45	5.96	0.31	6.18e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21467203	chr3:49911342	NA	0.39	6.63	0.34	1.28e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg17623882	chr6:41773611	USP49	-0.44	-5.87	-0.3	1.04e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg14829360	chr17:73884958	NA	0.39	6.59	0.34	1.67e-10	White matter hyperintensity burden;
LIHC	cis	rs12464559	0.522	rs4664498	chr2:152575417	A/G	cg01189475	chr2:152685088	ARL5A	0.7	8.87	0.43	4.05e-17	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	2.09e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2637266	0.714	rs7895605	chr10:78454207	G/A	cg18941641	chr10:78392320	NA	0.27	5.87	0.3	1.02e-8	Pulmonary function;
LIHC	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-7.76	-0.39	1.02e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg16989086	chr20:62203971	PRIC285	0.57	8.2	0.41	5.04e-15	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	cis	rs7091068	0.671	rs514120	chr10:95404400	G/A	cg20715218	chr10:95462985	C10orf4	-0.63	-6.91	-0.35	2.37e-11	Urinary tract infection frequency;
LIHC	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.61	-0.42	2.81e-16	Colorectal cancer;
LIHC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg00101154	chr16:420108	MRPL28	-0.6	-8.26	-0.41	3.18e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.52	6.86	0.35	3.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs7116495	0.867	rs601865	chr11:71581938	G/A	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.3e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.79	12.86	0.57	3.74e-31	Fat distribution (HIV);
LIHC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg21395723	chr22:39101663	GTPBP1	-0.38	-6.56	-0.33	1.99e-10	Menopause (age at onset);
LIHC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.6	-0.38	2.86e-13	Total body bone mineral density;
LIHC	trans	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg17675199	chr6:35436792	RPL10A	-0.4	-8.33	-0.41	1.98e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.36	0.33	6.32e-10	Renal cell carcinoma;
LIHC	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.35	6.77	0.34	5.68e-11	Stem cell growth factor beta levels;
LIHC	cis	rs1868673	0.503	rs73169812	chr3:150242749	A/T	cg10752315	chr3:150238463	NA	0.3	5.92	0.3	7.73e-9	Waist circumference;
LIHC	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.68	-6.33	-0.32	7.79e-10	Bipolar disorder;
LIHC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.33	1.94e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4908768	0.906	rs12410336	chr1:8623664	A/G	cg25722041	chr1:8623473	RERE	0.43	6.13	0.31	2.45e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.6	7.61	0.38	2.62e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.19	-0.32	1.73e-9	Total body bone mineral density;
LIHC	trans	rs13267838	1.000	rs13267838	chr8:25196710	G/T	cg24998791	chr8:10454100	NA	0.48	6.11	0.31	2.74e-9	Glucose homeostasis traits;
LIHC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg14067834	chr17:29058358	SUZ12P	0.71	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.61	7.03	0.36	1.09e-11	Menarche (age at onset);
LIHC	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.63	0.34	1.3e-10	Mean corpuscular volume;
LIHC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.03	0.36	1.13e-11	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23628684	chr21:30446052	CCT8	0.52	7.54	0.38	4.28e-13	Pancreatic cancer;
LIHC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg00809820	chr17:80708513	TBCD;FN3K	-0.34	-6.0	-0.31	4.95e-9	Glycated hemoglobin levels;
LIHC	cis	rs6586163	1.000	rs6586164	chr10:90752031	T/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-8.24	-0.41	3.65e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	11.06	0.51	1.62e-24	Post bronchodilator FEV1;
LIHC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.6	-9.84	-0.47	2.81e-20	Post bronchodilator FEV1;
LIHC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	9.92	0.47	1.45e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg18192155	chr21:44258298	NA	-0.39	-5.9	-0.3	8.61e-9	Information processing speed;
LIHC	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16684958	chr7:75615977	POR	0.39	6.39	0.33	5.41e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06676920	chr19:13873854	CCDC130;MRI1	0.42	6.57	0.33	1.86e-10	Pancreatic cancer;
LIHC	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-6.43	-0.33	4.4e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	6.82	0.35	4.1e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.92	12.98	0.57	1.38e-31	Primary sclerosing cholangitis;
LIHC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.95	-0.31	6.7e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.52	-0.49	1.32e-22	Rheumatoid arthritis;
LIHC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.63	-6.33	-0.32	7.77e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17106184	1.000	rs12058681	chr1:51346663	A/T	cg07174182	chr1:51127561	FAF1	-0.62	-6.51	-0.33	2.6200000000000003e-10	Type 2 diabetes;
LIHC	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg16589663	chr20:23618590	CST3	0.78	8.01	0.4	1.84e-14	Chronic kidney disease;
LIHC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.54	-9.74	-0.47	6.24e-20	Lung cancer;
LIHC	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.24	-0.32	1.27e-9	Response to antipsychotic treatment;
LIHC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg02269571	chr22:50332266	NA	0.61	8.64	0.42	2.24e-16	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.67	8.4	0.41	1.18e-15	Gut microbiome composition (summer);
LIHC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.41	-6.43	-0.33	4.34e-10	Schizophrenia;
LIHC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	7.63	0.38	2.35e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.49	-8.07	-0.4	1.21e-14	Electroencephalogram traits;
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.7	-6.23	-0.32	1.36e-9	Body mass index;
LIHC	cis	rs4820539	0.802	rs5759587	chr22:23441515	C/G	cg14186256	chr22:23484241	RTDR1	0.84	15.3	0.64	1.32e-40	Bone mineral density;
LIHC	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.4	6.16	0.32	2.06e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg25019722	chr6:37503610	NA	-0.32	-5.73	-0.3	2.19e-8	Cognitive performance;
LIHC	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg11161837	chr1:110010384	SYPL2	0.45	6.04	0.31	4.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6466055	0.777	rs10487150	chr7:104797450	A/C	cg04380332	chr7:105027541	SRPK2	-0.35	-6.51	-0.33	2.6200000000000003e-10	Schizophrenia;
LIHC	cis	rs12464559	0.522	rs13016166	chr2:152624144	G/A	cg01189475	chr2:152685088	ARL5A	0.72	9.16	0.44	4.95e-18	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.57	7.78	0.39	8.78e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.87	13.1	0.58	4.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg04082016	chr2:20871401	NA	-0.42	-7.46	-0.37	7.29e-13	Abdominal aortic aneurysm;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.71	-0.34	7.93e-11	Lymphocyte counts;
LIHC	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg12165864	chr7:66369176	NA	-0.48	-6.85	-0.35	3.45e-11	Corneal structure;
LIHC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg23031969	chr7:5014415	RNF216L	-0.43	-6.04	-0.31	4.09e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07012231	chr7:47384322	TNS3	-0.38	-6.05	-0.31	3.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.54	6.27	0.32	1.11e-9	Mammographic density (dense area);
LIHC	cis	rs4773330	1.000	rs831169	chr13:111797920	G/A	cg26911804	chr13:111806221	ARHGEF7	-0.62	-6.08	-0.31	3.3e-9	Bilirubin levels;
LIHC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.38	-6.82	-0.35	4.06e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg21573476	chr21:45109991	RRP1B	0.51	9.22	0.45	3.23e-18	Mean corpuscular volume;
LIHC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.29	-0.37	2.1e-12	Breast cancer;
LIHC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.52	-0.33	2.49e-10	Obesity-related traits;
LIHC	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.64	-10.66	-0.5	4.28e-23	Waist circumference;Body mass index;
LIHC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg07451762	chr16:28383216	NA	0.39	6.88	0.35	2.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-7.39	-0.37	1.14e-12	Cognitive function;
LIHC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.29	-0.32	9.98e-10	Fear of minor pain;
LIHC	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-0.83	-9.15	-0.44	5.25e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.77	0.34	5.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.68	-12.39	-0.56	2.28e-29	Breast cancer;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg07133347	chr1:107600762	PRMT6	0.46	6.8	0.35	4.71e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs783540	0.935	rs2278355	chr15:83331155	C/T	cg18393722	chr15:85113863	UBE2QP1	0.38	6.44	0.33	4.04e-10	Schizophrenia;
LIHC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg20607798	chr8:58055168	NA	0.7	8.27	0.41	3.06e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.33	6.87	0.35	3.09e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.39	-6.0	-0.31	4.96e-9	Total body bone mineral density;
LIHC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.56	6.97	0.35	1.64e-11	Parkinson's disease;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg01696603	chr6:125623444	HDDC2	0.44	6.65	0.34	1.19e-10	Electroencephalogram traits;
LIHC	cis	rs12602486	1.000	rs12601855	chr17:42224023	A/G	cg08193365	chr17:42277699	NA	1.08	7.74	0.39	1.12e-13	Glycated hemoglobin levels;
LIHC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.81	11.72	0.54	6.48e-27	Coronary artery disease;
LIHC	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.49e-22	Fuchs's corneal dystrophy;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05315670	chr11:64037304	BAD	-0.39	-6.28	-0.32	1.04e-9	Immature fraction of reticulocytes;
LIHC	cis	rs6594499	0.872	rs6594498	chr5:110458351	G/A	cg04022379	chr5:110408740	TSLP	0.49	8.11	0.4	9.18e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6466055	0.932	rs6466056	chr7:104929267	T/C	cg04380332	chr7:105027541	SRPK2	0.34	6.4	0.33	5.02e-10	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg02297831	chr4:17616191	MED28	-0.49	-7.52	-0.38	4.88e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.85	0.3	1.12e-8	Menopause (age at onset);
LIHC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.28e-27	Motion sickness;
LIHC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.56	5.85	0.3	1.12e-8	Smoking initiation;
LIHC	trans	rs6489882	0.867	rs4767031	chr12:113362751	C/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6.08e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs1593	0.734	rs6815076	chr4:187224558	G/C	cg14349977	chr4:187219430	NA	0.5	7.63	0.38	2.36e-13	Activated partial thromboplastin time;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19941170	chr5:172067912	NEURL1B	0.41	6.11	0.31	2.7e-9	Migraine with aura;
LIHC	cis	rs7914558	0.646	rs12768205	chr10:104647849	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.34	-0.37	1.54e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg22356347	chr1:167427500	CD247	-0.33	-5.74	-0.3	2.12e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.2e-11	Aortic root size;
LIHC	cis	rs4407350	0.870	rs2213373	chr22:44911669	C/T	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.06	-0.31	3.69e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs55702914	1.000	rs56234206	chr2:198215995	T/A	cg10820045	chr2:198174542	NA	0.38	5.8	0.3	1.51e-8	Major depression and alcohol dependence;
LIHC	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.59	-9.67	-0.46	1.07e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg17724175	chr1:150552817	MCL1	0.46	8.92	0.43	2.8e-17	Melanoma;
LIHC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs10605167	1	rs10605167	chr11:94828467	TCTC/T	cg22167515	chr1:91192466	NA	0.39	6.37	0.33	5.94e-10	Mean platelet volume;
LIHC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs4700695	0.841	rs706679	chr5:65317181	A/G	cg21114390	chr5:65439923	SFRS12	-0.44	-5.75	-0.3	1.96e-8	Facial morphology (factor 19);
LIHC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.68	0.38	1.72e-13	Bipolar disorder;
LIHC	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs3814231	0.531	rs11196446	chr10:115471016	A/C	cg24846397	chr10:115438155	CASP7	-0.42	-7.18	-0.36	4.42e-12	Vitiligo;
LIHC	cis	rs1144333	0.579	rs35591768	chr1:76308257	C/T	cg03433033	chr1:76189801	ACADM	0.46	7.18	0.36	4.43e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.55	-0.38	3.9e-13	Body mass index;
LIHC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg05941027	chr17:61774174	LIMD2	0.3	5.97	0.31	5.91e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.76	-11.57	-0.53	2.32e-26	Obesity-related traits;
LIHC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-26.25	-0.82	5.98e-84	Myeloid white cell count;
LIHC	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	1.06	7.65	0.38	2.03e-13	Arsenic metabolism;
LIHC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg07451762	chr16:28383216	NA	0.39	6.84	0.35	3.64e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg26338869	chr17:61819248	STRADA	0.52	6.89	0.35	2.77e-11	Height;
LIHC	cis	rs79387448	0.745	rs6749440	chr2:103101846	C/T	cg09003973	chr2:102972529	NA	0.81	7.11	0.36	6.95e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs9367716	0.912	rs9382695	chr6:57110054	G/T	cg03371099	chr6:57305889	PRIM2	-0.35	-5.72	-0.3	2.37e-8	Coronary artery disease;
LIHC	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg02023728	chr11:77925099	USP35	0.41	7.7	0.38	1.45e-13	Testicular germ cell tumor;
LIHC	cis	rs12079745	0.590	rs80215043	chr1:169193763	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.18	-0.32	1.81e-9	QT interval;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14473243	chr5:137514312	BRD8;KIF20A	0.49	6.41	0.33	4.88e-10	Lung function (FEV1/FVC);
LIHC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.82	0.3	1.38e-8	Putamen volume;
LIHC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.37	5.86	0.3	1.07e-8	Menopause (age at onset);
LIHC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.11e-18	Bipolar disorder;
LIHC	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	12.01	0.54	5.59e-28	Post bronchodilator FEV1;
LIHC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.29	16.89	0.67	5.55e-47	Diabetic kidney disease;
LIHC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg25828445	chr12:7781288	NA	0.4	6.23	0.32	1.38e-9	HDL cholesterol levels;
LIHC	cis	rs7945718	0.563	rs4525215	chr11:12664830	T/C	cg25843174	chr11:12811716	TEAD1	0.31	6.96	0.35	1.76e-11	Educational attainment (years of education);
LIHC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.34	-6.27	-0.32	1.12e-9	Monocyte count;
LIHC	cis	rs655641	1.000	rs2509609	chr11:85779162	C/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.01	-0.31	4.83e-9	Platelet count;
LIHC	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.91e-23	Hypertriglyceridemia;
LIHC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg12560992	chr17:57184187	TRIM37	0.56	7.72	0.39	1.3e-13	Cognitive test performance;
LIHC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.51	8.56	0.42	4e-16	Obesity-related traits;
LIHC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.42	7.76	0.39	9.78e-14	Electrocardiographic conduction measures;
LIHC	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg07382826	chr16:28625726	SULT1A1	0.52	7.88	0.39	4.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.7	-0.5	3e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	7.51	0.38	5.16e-13	Obesity-related traits;
LIHC	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.38	6.19	0.32	1.74e-9	Adiposity;
LIHC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.77	-15.37	-0.64	6.82e-41	Height;
LIHC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.51	-0.38	5.35e-13	Chronic sinus infection;
LIHC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.46	7.37	0.37	1.27e-12	Lung cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23151374	chr4:164415611	C4orf43	0.45	6.88	0.35	2.9100000000000002e-11	Pancreatic cancer;
LIHC	cis	rs10792665	0.686	rs1904428	chr11:82718252	A/C	cg24227371	chr11:82718527	RAB30	0.39	9.53	0.46	2.98e-19	Obesity-related traits;
LIHC	trans	rs1864585	0.520	rs73208793	chr8:10680785	T/C	cg20373634	chr10:103911536	NOLC1	-0.47	-6.19	-0.32	1.76e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.61	-5.97	-0.31	5.9e-9	Urate levels in lean individuals;
LIHC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg17675199	chr6:35436792	RPL10A	0.35	6.86	0.35	3.26e-11	Coronary artery disease;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.69	-10.27	-0.49	9.86e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.28	-0.37	2.29e-12	IgG glycosylation;
LIHC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.79	12.07	0.55	3.43e-28	Total body bone mineral density;
LIHC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.64	7.89	0.39	4.15e-14	Gut microbiome composition (summer);
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07677032	chr17:61819896	STRADA	0.43	6.07	0.31	3.49e-9	Prudent dietary pattern;
LIHC	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.72	10.16	0.48	2.22e-21	Metabolite levels;
LIHC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg26149184	chr10:133730230	NA	0.46	7.49	0.38	5.99e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.57	7.59	0.38	3.02e-13	Bone mineral density (spine);
LIHC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.97	-0.51	3.47e-24	Bipolar disorder and schizophrenia;
LIHC	trans	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg00938859	chr5:1591904	SDHAP3	0.56	6.81	0.35	4.43e-11	Breast cancer;
LIHC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.78	-0.43	8.15e-17	Monocyte count;
LIHC	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.34	-7.05	-0.36	9.96e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.86	13.02	0.58	9.5e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02290350	chr8:58132656	NA	0.5	10.64	0.5	5.15e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.37	-6.11	-0.31	2.68e-9	Blood metabolite levels;
LIHC	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.6	7.67	0.38	1.83e-13	Morning vs. evening chronotype;
LIHC	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.54	8.25	0.41	3.54e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.52	7.79	0.39	8.16e-14	Colorectal cancer;
LIHC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.56	-8.57	-0.42	3.55e-16	Height;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.68	-9.97	-0.47	1.03e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg03934865	chr2:198174659	NA	0.55	8.81	0.43	6.23e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.9	0.3	8.72e-9	Resting heart rate;
LIHC	cis	rs3770081	0.590	rs34522092	chr2:86208305	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-8.2	-0.41	4.82e-15	Facial emotion recognition (sad faces);
LIHC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.55	8.81	0.43	6.22e-17	Birth weight;
LIHC	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg07959070	chr22:50026188	C22orf34	-0.3	-7.22	-0.36	3.33e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.65	-9.5	-0.46	3.83e-19	Total body bone mineral density;
LIHC	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg10820045	chr2:198174542	NA	-0.5	-7.63	-0.38	2.36e-13	Dermatomyositis;
LIHC	cis	rs1499280	0.736	rs7719930	chr5:52105307	T/C	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.73	11.96	0.54	8.84e-28	Anterior chamber depth;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11453347	chr10:127512288	UROS;BCCIP	0.46	6.72	0.34	7.45e-11	Cognitive function;
LIHC	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.97	-0.35	1.65e-11	Metabolite levels;
LIHC	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg04850286	chr10:81895943	PLAC9	0.32	5.92	0.3	7.74e-9	Sarcoidosis;
LIHC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg00677901	chr16:88017247	BANP	-0.57	-8.78	-0.43	7.93e-17	Menopause (age at onset);
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.46	-0.33	3.52e-10	Renal cell carcinoma;
LIHC	trans	rs9500256	0.903	rs726783	chr6:58332861	A/C	cg03371099	chr6:57305889	PRIM2	-0.36	-6.38	-0.33	5.9e-10	Eosinophilic esophagitis (pediatric);
LIHC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.07	15.36	0.64	7.19e-41	Cognitive function;
LIHC	cis	rs28530618	0.603	rs11697988	chr20:31248176	C/G	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.85	-0.3	1.17e-8	Birth weight;
LIHC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg10935138	chr17:73851978	WBP2	0.44	6.98	0.35	1.56e-11	White matter hyperintensity burden;
LIHC	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.83	12.42	0.56	1.79e-29	Body mass index;
LIHC	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.1	0.36	7.17e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg19318889	chr4:1322082	MAEA	0.43	6.21	0.32	1.57e-9	Obesity-related traits;
LIHC	trans	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg13698153	chr12:118541722	VSIG10	0.61	6.34	0.32	7.37e-10	Vitiligo;
LIHC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.38	6.96	0.35	1.8e-11	IgG glycosylation;
LIHC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.45	7.72	0.39	1.29e-13	Mean corpuscular volume;
LIHC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.98	-0.54	7.28e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.81	-0.39	7.11e-14	Total cholesterol levels;
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.39	6.04	0.31	4.12e-9	Testicular germ cell tumor;
LIHC	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19437070	chr15:78442260	IDH3A	-0.57	-7.4	-0.37	1.08e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.53	-8.96	-0.44	2.15e-17	Paraoxonase activity;
LIHC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.41	-6.98	-0.35	1.51e-11	Monocyte count;
LIHC	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.9	9.72	0.47	7.27e-20	Alzheimer's disease (late onset);
LIHC	cis	rs818427	0.964	rs459102	chr5:112228765	C/A	cg07820702	chr5:112228657	REEP5	-0.37	-5.83	-0.3	1.28e-8	Total body bone mineral density;
LIHC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.56	9.78	0.47	4.35e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg16797656	chr11:68205561	LRP5	0.42	6.15	0.32	2.21e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs7312774	0.618	rs4964518	chr12:107466217	C/T	cg16260113	chr12:107380972	MTERFD3	1.04	13.38	0.59	3.83e-33	Severe influenza A (H1N1) infection;
LIHC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.93	0.31	7.59e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.6	11.26	0.52	3.12e-25	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.75	11.3	0.52	2.24e-25	Corneal astigmatism;
LIHC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.66	0.53	1.15e-26	Alzheimer's disease;
LIHC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg06808227	chr14:105710500	BRF1	-0.48	-5.9	-0.3	8.64e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.57	-7.6	-0.38	2.89e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.03	20.69	0.75	3.07e-62	Schizophrenia;
LIHC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-0.97	-10.49	-0.49	1.69e-22	Vitiligo;
LIHC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.35	0.41	1.71e-15	Platelet count;
LIHC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.57	-7.05	-0.36	1e-11	Blood metabolite levels;
LIHC	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg27147174	chr7:100797783	AP1S1	-0.46	-6.29	-0.32	9.54e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.45	-7.25	-0.36	2.81e-12	Morning vs. evening chronotype;
LIHC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.49	-7.54	-0.38	4.38e-13	Corneal astigmatism;
LIHC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	13.82	0.6	8.23e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg04082016	chr2:20871401	NA	0.38	7.28	0.37	2.25e-12	Abdominal aortic aneurysm;
LIHC	cis	rs1494950	1.000	rs9998291	chr4:15022277	A/G	cg12377275	chr4:15005593	CPEB2	-0.85	-7.42	-0.37	9.57e-13	Political ideology;
LIHC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.0	0.31	5.07e-9	Blood metabolite levels;
LIHC	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg09238746	chr17:78121135	EIF4A3	-0.87	-14.13	-0.61	4.98e-36	Yeast infection;
LIHC	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.5	9.55	0.46	2.56e-19	Testicular germ cell tumor;
LIHC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg04013166	chr16:89971882	TCF25	0.53	6.64	0.34	1.23e-10	Skin colour saturation;
LIHC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg03037974	chr15:76606532	NA	-0.6	-10.03	-0.48	6.11e-21	Blood metabolite levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05620814	chr16:74640948	GLG1	0.49	6.14	0.32	2.26e-9	Hepatitis;
LIHC	cis	rs365132	0.875	rs353479	chr5:176372593	C/T	cg16309518	chr5:176445507	NA	-0.52	-9.87	-0.47	2.21e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.58	9.87	0.47	2.13e-20	Colorectal cancer;
LIHC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.64	10.17	0.48	2.13e-21	Dental caries;
LIHC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.81	-0.35	4.46e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03053427	chr7:75649626	STYXL1	0.45	6.73	0.34	7.05e-11	Cognitive function;
LIHC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-8.4	-0.41	1.24e-15	Gut microbiome composition (summer);
LIHC	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.74	-0.3	2.07e-8	Diastolic blood pressure;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.41	0.37	9.74e-13	Height;
LIHC	cis	rs3015497	0.789	rs3015496	chr14:51114051	T/C	cg09863266	chr14:51125203	SAV1	-0.42	-6.83	-0.35	3.79e-11	Mean platelet volume;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg03874509	chr1:107600012	PRMT6	-0.77	-12.17	-0.55	1.47e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.41	-6.94	-0.35	1.95e-11	Monocyte count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15203618	chr11:85646125	NA	-0.4	-6.22	-0.32	1.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00365505	chr7:150066001	REPIN1	-0.48	-6.53	-0.33	2.34e-10	Pancreatic cancer;
LIHC	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg04469686	chr1:162760199	HSD17B7	-0.41	-6.53	-0.33	2.38e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg11812906	chr14:75593930	NEK9	0.73	13.53	0.59	1.05e-33	Height;
LIHC	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.88	11.95	0.54	9.25e-28	Post bronchodilator FEV1;
LIHC	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.9	14.88	0.63	5.84e-39	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg08132940	chr7:1081526	C7orf50	-0.74	-6.36	-0.33	6.5e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg22532475	chr10:104410764	TRIM8	0.37	6.39	0.33	5.3e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6964587	1.000	rs7781597	chr7:91588194	T/C	cg17063962	chr7:91808500	NA	1.02	19.09	0.72	8.15e-56	Breast cancer;
LIHC	trans	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg26939375	chr7:64535504	NA	0.39	6.15	0.32	2.12e-9	Aortic root size;
LIHC	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg10820045	chr2:198174542	NA	-0.54	-8.82	-0.43	6.04e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-8.46	-0.42	7.96e-16	Primary biliary cholangitis;
LIHC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.7	6.9	0.35	2.56e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.97	0.4	2.38e-14	Tonsillectomy;
LIHC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.93	0.39	3.07e-14	Tonsillectomy;
LIHC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.55	8.57	0.42	3.72e-16	Dental caries;
LIHC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21448741	chr8:58168803	NA	0.36	5.91	0.3	8.43e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.36	6.06	0.31	3.7e-9	Monobrow;
LIHC	cis	rs370915	0.963	rs59452206	chr4:187816484	G/T	cg12892747	chr4:187813459	NA	-0.42	-6.54	-0.33	2.3e-10	Gout;
LIHC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.77	11.99	0.54	7.12e-28	Corneal astigmatism;
LIHC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.34	-0.41	1.83e-15	Gut microbiome composition (summer);
LIHC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.82	-12.95	-0.57	1.74e-31	Total body bone mineral density;
LIHC	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.42	6.86	0.35	3.16e-11	Adiposity;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.93	-0.31	7.3e-9	Total body bone mineral density;
LIHC	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg04552319	chr11:89519481	NA	-0.33	-5.72	-0.3	2.32e-8	White blood cell types;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg03874509	chr1:107600012	PRMT6	0.7	11.31	0.52	2.12e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg16486109	chr11:613632	IRF7	0.59	6.29	0.32	9.88e-10	Systemic lupus erythematosus;
LIHC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.45	7.13	0.36	5.99e-12	Breast cancer;
LIHC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.51	8.32	0.41	2.06e-15	Schizophrenia;
LIHC	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.36	-7.73	-0.39	1.23e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	9.17	0.44	4.45e-18	Menarche (age at onset);
LIHC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.76	-0.43	9.08e-17	Total cholesterol levels;
LIHC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg20735989	chr4:730612	PCGF3	-0.67	-8.84	-0.43	5.17e-17	White blood cell count;
LIHC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.68	-13.35	-0.59	5.14e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20887711	chr4:1340912	KIAA1530	0.8	12.08	0.55	3.18e-28	Longevity;
LIHC	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.35	7.5	0.38	5.41e-13	Metabolite levels (MHPG);
LIHC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.2	0.32	1.63e-9	Initial pursuit acceleration;
LIHC	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16684958	chr7:75615977	POR	0.51	8.54	0.42	4.54e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.39	6.98	0.35	1.54e-11	Psoriasis;
LIHC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.82	-0.35	4.18e-11	Fear of minor pain;
LIHC	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-9.11	-0.44	7.22e-18	Total cholesterol levels;
LIHC	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.26	-6.93	-0.35	2.09e-11	Type 2 diabetes;
LIHC	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.53	-8.6	-0.42	2.94e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.6	7.05	0.36	1e-11	Cognitive function;
LIHC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.83	16.41	0.66	5e-45	Response to diuretic therapy;
LIHC	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.16	-0.32	2.08e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7635838	0.892	rs7372723	chr3:11466511	G/A	cg00170343	chr3:11313890	ATG7	0.43	6.77	0.34	5.46e-11	HDL cholesterol;
LIHC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.45	6.41	0.33	4.71e-10	Coronary artery disease;
LIHC	trans	rs6578985	0.828	rs12290802	chr11:2121754	G/A	cg20230732	chr3:128721448	CCDC48	0.38	6.2	0.32	1.67e-9	Femoral neck bone geometry and menarche (age at onset);
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	21.96	0.76	2.7e-67	Height;
LIHC	cis	rs2836974	0.583	rs8132993	chr21:40716410	T/C	cg11890956	chr21:40555474	PSMG1	0.55	8.16	0.4	6.58e-15	Cognitive function;
LIHC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg00409905	chr10:38381863	ZNF37A	-0.43	-6.74	-0.34	6.8e-11	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs7238033	0.663	rs11082467	chr18:43318644	A/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.5	0.33	2.87e-10	Bladder cancer;
LIHC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg05697976	chr12:29376483	FAR2	0.31	6.13	0.31	2.44e-9	QT interval;
LIHC	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg02023728	chr11:77925099	USP35	-0.33	-5.84	-0.3	1.2e-8	Alzheimer's disease (survival time);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13327734	chr17:4634568	MED11	0.48	6.59	0.34	1.71e-10	Pancreatic cancer;
LIHC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.45	8.37	0.41	1.45e-15	Schizophrenia;
LIHC	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.6	-9.1	-0.44	7.88e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg26931527	chr16:83979911	NA	0.48	6.15	0.32	2.19e-9	Pursuit maintenance gain;
LIHC	cis	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg11879182	chr18:77439856	CTDP1	0.83	13.38	0.59	4.01e-33	Monocyte count;
LIHC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.79	12.43	0.56	1.53e-29	Breast cancer;
LIHC	trans	rs10411161	0.810	rs11667971	chr19:52407694	G/A	cg22319618	chr22:45562946	NUP50	-0.61	-7.0	-0.35	1.35e-11	Breast cancer;
LIHC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	0.83	7.02	0.36	1.18e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.48	6.51	0.33	2.69e-10	Inflammatory skin disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17520314	chr17:79604207	NPLOC4	0.51	6.54	0.33	2.31e-10	Lung function (FEV1/FVC);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06269035	chr16:1663677	CRAMP1L	-0.47	-6.7	-0.34	8.71e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs243505	0.660	rs1880358	chr7:148572504	C/T	cg09806900	chr7:148480153	CUL1	0.43	6.26	0.32	1.15e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg08822215	chr16:89438651	ANKRD11	-0.45	-7.08	-0.36	8.05e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs57590327	0.679	rs7639135	chr3:81608976	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-6.54	-0.33	2.25e-10	Extraversion;
LIHC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	5.79	0.3	1.6e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08555112	chr17:48942811	TOB1	0.49	7.72	0.39	1.33e-13	Cognitive function;
LIHC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.51	-0.33	2.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.69	-9.92	-0.47	1.47e-20	Initial pursuit acceleration;
LIHC	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-10.07	-0.48	4.8e-21	Morning vs. evening chronotype;
LIHC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.32	-6.14	-0.32	2.28e-9	Body mass index;
LIHC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.05	-0.58	7.55e-32	Bipolar disorder and schizophrenia;
LIHC	cis	rs1943345	0.830	rs571055	chr11:82898829	G/C	cg07047830	chr11:82868014	PCF11	0.44	6.93	0.35	2.13e-11	Obesity-related traits;
LIHC	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.65	-6.86	-0.35	3.2e-11	Exhaled nitric oxide output;
LIHC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.45	-7.2	-0.36	3.81e-12	Cognitive function;
LIHC	trans	rs2579103	0.767	rs1347844	chr12:90663216	G/A	cg00091569	chr3:40428383	ENTPD3	0.37	6.05	0.31	3.8e-9	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01130162	chr16:838502	CHTF18;RPUSD1	-0.41	-6.13	-0.31	2.38e-9	Cognitive function;
LIHC	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg02023728	chr11:77925099	USP35	0.32	5.85	0.3	1.14e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.9	-11.95	-0.54	1e-27	Cognitive test performance;
LIHC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-8.63	-0.42	2.37e-16	Chronic sinus infection;
LIHC	cis	rs1419980	0.730	rs11054870	chr12:7770803	A/C	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.53	6.5	0.33	2.78e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg00106254	chr7:1943704	MAD1L1	0.4	6.36	0.33	6.59e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg19302996	chr17:73780495	UNK	-0.55	-6.8	-0.35	4.72e-11	Psoriasis;
LIHC	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.58	-8.63	-0.42	2.29e-16	Blood protein levels;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg13152130	chr6:118910203	C6orf204	-0.65	-7.34	-0.37	1.61e-12	Diastolic blood pressure;
LIHC	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-11.48	-0.53	5.09e-26	Urinary metabolites;
LIHC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	8.04e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27297192	chr10:134578999	INPP5A	0.53	7.55	0.38	4e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg12903224	chr12:29470962	FAR2	-0.42	-6.74	-0.34	6.88e-11	QT interval;
LIHC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.6	-8.48	-0.42	6.68e-16	Coronary artery disease;
LIHC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	1.04	13.43	0.59	2.56e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6867032	1.000	rs4074914	chr5:2020274	C/T	cg26168224	chr5:2018326	NA	0.31	7.66	0.38	1.91e-13	Gut microbiome composition (winter);
LIHC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.48	7.56	0.38	3.62e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	0.78	10.26	0.49	1.03e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11062956	chr16:2723328	NA	-0.42	-6.25	-0.32	1.24e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg11070056	chr1:107600091	PRMT6	0.63	10.48	0.49	1.73e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.39	-0.71	5.32e-53	Height;
LIHC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg06207120	chr15:45996521	NA	-0.32	-6.3	-0.32	9.36e-10	Waist circumference;Weight;
LIHC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg05590025	chr7:65112418	INTS4L2	0.6	6.43	0.33	4.2e-10	Diabetic kidney disease;
LIHC	cis	rs918629	0.716	rs7700895	chr5:95273410	T/A	cg10483112	chr5:95245456	ELL2	-0.36	-6.28	-0.32	1.04e-9	IgG glycosylation;
LIHC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.73	-0.3	2.17e-8	Uric acid levels;
LIHC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.47	9.4	0.45	8.21e-19	Schizophrenia;
LIHC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.93	-17.48	-0.69	2.41e-49	Lung cancer in ever smokers;
LIHC	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08109568	chr15:31115862	NA	-0.42	-5.88	-0.3	9.59e-9	Huntington's disease progression;
LIHC	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg25124228	chr12:125621409	AACS	-0.43	-6.68	-0.34	9.67e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg18225595	chr11:63971243	STIP1	0.64	6.55	0.33	2.15e-10	Mean platelet volume;
LIHC	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.4	5.88	0.3	9.88e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.45e-9	Coronary artery calcification;
LIHC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	8.04	0.4	1.5e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs77633900	0.772	rs284907	chr15:76741569	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-5.83	-0.3	1.31e-8	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg24385632	chr11:16838615	PLEKHA7	0.45	6.67	0.34	1.04e-10	Alopecia areata;
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.46	-0.33	3.52e-10	Renal cell carcinoma;
LIHC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.4	6.01	0.31	4.77e-9	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.62	10.14	0.48	2.63e-21	Schizophrenia;
LIHC	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.6	-8.7	-0.43	1.46e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.31	-0.32	8.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.54	8.24	0.41	3.59e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg21531657	chr3:10005747	TMEM111	-0.39	-5.93	-0.31	7.5e-9	Alzheimer's disease;
LIHC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.88	15.8	0.65	1.25e-42	Aortic root size;
LIHC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.61	-0.5	6.24e-23	Breast cancer;
LIHC	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.2	-0.32	1.6e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.51	9.1	0.44	7.55e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.7	-8.28	-0.41	2.76e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.87	10.79	0.5	1.54e-23	Bladder cancer;
LIHC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.53	8.58	0.42	3.45e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Coronary artery disease;
LIHC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.42	5.95	0.31	6.61e-9	Height;
LIHC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg18867708	chr6:26865862	GUSBL1	-0.5	-7.62	-0.38	2.58e-13	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg24209194	chr3:40518798	ZNF619	0.56	8.1	0.4	9.68e-15	Renal cell carcinoma;
LIHC	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.13	0.31	2.44e-9	HDL cholesterol;
LIHC	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.49	-7.49	-0.38	5.97e-13	Ulcerative colitis;
LIHC	cis	rs2257205	0.667	rs9904996	chr17:56711707	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.38	-6.34	-0.32	7.24e-10	Dementia with Lewy bodies;
LIHC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.79	-13.7	-0.6	2.34e-34	Body mass index;
LIHC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.35	5.75	0.3	2.01e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.38	-5.85	-0.3	1.12e-8	Cognitive function;
LIHC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.38	-0.33	5.85e-10	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.83	0.39	6.3e-14	Motion sickness;
LIHC	cis	rs1953600	0.521	rs7067644	chr10:81924245	A/G	cg27417294	chr10:81904244	PLAC9	0.36	5.93	0.31	7.52e-9	Sarcoidosis;
LIHC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.44	6.3	0.32	9.33e-10	Coronary artery disease;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg25329415	chr6:28076851	NA	0.27	5.71	0.3	2.44e-8	Cardiac Troponin-T levels;
LIHC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.07	0.4	1.19e-14	Lymphocyte counts;
LIHC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.22e-34	Aortic root size;
LIHC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.32	6.11	0.31	2.78e-9	Body mass index;
LIHC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.8	9.16	0.44	4.96e-18	Primary sclerosing cholangitis;
LIHC	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.64	11.3	0.52	2.21e-25	Schizophrenia;
LIHC	cis	rs7116495	1.000	rs550230	chr11:71602222	A/G	cg26138937	chr11:71823887	C11orf51	0.69	6.9	0.35	2.48e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.65	9.56	0.46	2.42e-19	Monocyte count;
LIHC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg24209194	chr3:40518798	ZNF619	0.45	6.6	0.34	1.56e-10	Renal cell carcinoma;
LIHC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg07424592	chr7:64974309	NA	0.8	9.08	0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.5	-8.3	-0.41	2.45e-15	Urate levels in overweight individuals;
LIHC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16684958	chr7:75615977	POR	-0.5	-8.48	-0.42	6.66e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1983891	0.954	rs4714481	chr6:41521110	T/C	cg20194872	chr6:41519635	FOXP4	0.42	6.61	0.34	1.48e-10	Prostate cancer;
LIHC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.34	6.78	0.34	5.27e-11	Renal cell carcinoma;
LIHC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.41	-0.33	4.72e-10	Menarche (age at onset);
LIHC	cis	rs16912285	0.688	rs12284649	chr11:24316260	T/A	ch.11.24196551F	chr11:24239977	NA	0.75	9.83	0.47	2.93e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.68	-0.34	9.73e-11	Diastolic blood pressure;
LIHC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	trans	rs10213084	1.000	rs13115724	chr4:147510680	A/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.47	6.04	0.31	3.94e-9	Heart rate;
LIHC	cis	rs7095607	0.606	rs7084233	chr10:69958343	T/C	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.66e-9	Lung function (FVC);
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	7.05	0.36	9.73e-12	Renal cell carcinoma;
LIHC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.35	0.41	1.67e-15	Lung cancer in ever smokers;
LIHC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.35	-6.39	-0.33	5.29e-10	Aortic root size;
LIHC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-8.77	-0.43	8.3e-17	IgG glycosylation;
LIHC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.66	12.76	0.57	9.24e-31	Rheumatoid arthritis;
LIHC	trans	rs711244	0.541	rs12478822	chr2:37048951	C/G	cg21937867	chr17:74536062	PRCD	-0.33	-6.29	-0.32	9.93e-10	Mean platelet volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06738889	chr1:150208936	ANP32E	0.49	7.72	0.39	1.25e-13	Pancreatic cancer;
LIHC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg02640540	chr1:67518911	SLC35D1	-0.43	-5.94	-0.31	6.85e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.49	7.08	0.36	8.15e-12	Educational attainment;
LIHC	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.57	0.38	3.49e-13	Refractive astigmatism;
LIHC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.77	15.36	0.64	7.26e-41	Mortality in heart failure;
LIHC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19717773	chr7:2847554	GNA12	-0.32	-5.88	-0.3	9.54e-9	Height;
LIHC	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg17623882	chr6:41773611	USP49	-0.43	-5.85	-0.3	1.13e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.13	19.41	0.72	4.04e-57	Nonalcoholic fatty liver disease;
LIHC	cis	rs12744310	1.000	rs34190295	chr1:41765879	T/C	cg03962019	chr1:41807865	NA	0.38	6.22	0.32	1.46e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	0.98	10.99	0.51	2.84e-24	White matter hyperintensity burden;
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.76	11.91	0.54	1.33e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.58	-10.29	-0.49	8e-22	Platelet distribution width;
LIHC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.47	7.78	0.39	8.57e-14	Multiple sclerosis;
LIHC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.67	5.78	0.3	1.65e-8	Inflammatory bowel disease;
LIHC	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.27	-0.49	9.26e-22	Response to antipsychotic treatment;
LIHC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.11	-0.4	8.86e-15	Morning vs. evening chronotype;
LIHC	trans	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg09045935	chr12:6379348	NA	0.93	8.01	0.4	1.85e-14	Blood metabolite levels;
LIHC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.29	-19.21	-0.72	2.54e-56	Type 1 diabetes nephropathy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07017693	chr10:71912317	SAR1A	-0.42	-6.3	-0.32	9.31e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg03934865	chr2:198174659	NA	0.46	6.88	0.35	2.82e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.37	-5.8	-0.3	1.49e-8	Glioblastoma;
LIHC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.53	-9.96	-0.47	1.13e-20	Mean corpuscular volume;
LIHC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.79	12.59	0.56	4.04e-30	Breast cancer;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.36	0.61	6.46e-37	Prudent dietary pattern;
LIHC	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.45	7.27	0.37	2.49e-12	Corneal astigmatism;
LIHC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.94	17.78	0.69	1.48e-50	Menopause (age at onset);
LIHC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.96	17.37	0.68	6.51e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	0.655	rs17097695	chr1:76387258	A/C	cg10523679	chr1:76189770	ACADM	0.46	6.2	0.32	1.67e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg27205649	chr11:78285834	NARS2	-0.41	-6.03	-0.31	4.27e-9	Alzheimer's disease (survival time);
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.82	0.43	5.97e-17	Prudent dietary pattern;
LIHC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.55	-9.37	-0.45	1.04e-18	Mean corpuscular volume;
LIHC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.53	-6.19	-0.32	1.73e-9	Ulcerative colitis;
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.49	7.76	0.39	9.79e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.58	9.59	0.46	1.86e-19	Body mass index;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-9.47	-0.46	4.59e-19	Tonsillectomy;
LIHC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.52	8.59	0.42	3.04e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	0.75	9.37	0.45	1.01e-18	Corneal structure;
LIHC	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg11395062	chr17:14139857	CDRT15	0.53	9.52	0.46	3.17e-19	Temperament;
LIHC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.65	6.43	0.33	4.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg16743903	chr16:89593216	SPG7	-0.3	-5.78	-0.3	1.72e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.71	-8.44	-0.42	8.82e-16	Vitiligo;
LIHC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	8.12	0.4	8.31e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.45	7.35	0.37	1.43e-12	Response to temozolomide;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08206623	chr11:2907334	CDKN1C	0.62	8.46	0.42	7.7e-16	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15044954	chr7:89874365	C7orf63	0.52	7.24	0.36	2.97e-12	Pancreatic cancer;
LIHC	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8064024	0.513	rs1049207	chr16:4934564	C/G	cg08329684	chr16:4932620	PPL	-0.42	-7.46	-0.37	7.4e-13	Cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05663655	chr7:107532014	DLD	0.45	6.14	0.32	2.31e-9	Pancreatic cancer;
LIHC	cis	rs9473924	0.542	rs55648125	chr6:50816718	A/G	cg14470998	chr6:50812995	TFAP2B	1.03	8.21	0.41	4.52e-15	Body mass index;
LIHC	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.15	-0.52	7.67e-25	Eye color traits;
LIHC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.42	7.76	0.39	9.78e-14	Electrocardiographic conduction measures;
LIHC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.85	0.54	2.3e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.19	0.55	1.22e-28	Cognitive test performance;
LIHC	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.48	6.8	0.35	4.58e-11	Lung cancer;
LIHC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.69	11.97	0.54	8.25e-28	Menopause (age at onset);
LIHC	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.36	-0.41	1.65e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26600917	chr1:110162534	AMPD2	0.46	6.68	0.34	9.77e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg02993280	chr1:107599747	PRMT6	0.67	10.62	0.5	5.97e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs507080	0.922	rs12796373	chr11:118554939	G/A	cg04173919	chr11:118528438	PHLDB1	0.33	6.24	0.32	1.33e-9	Serum metabolite levels;
LIHC	cis	rs17152411	0.895	rs11245420	chr10:126586469	T/C	cg07906193	chr10:126599966	NA	0.44	6.89	0.35	2.74e-11	Height;
LIHC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.48	6.96	0.35	1.76e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.19	-0.32	1.71e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg27205649	chr11:78285834	NARS2	-0.39	-5.74	-0.3	2.1e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.55	8.01	0.4	1.88e-14	Mean corpuscular volume;
LIHC	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg03934865	chr2:198174659	NA	0.47	6.77	0.34	5.59e-11	Dermatomyositis;
LIHC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.84	0.3	1.25e-8	Bipolar disorder;
LIHC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.94	13.69	0.6	2.5e-34	Psoriasis;
LIHC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.93	0.31	7.42e-9	Schizophrenia;
LIHC	cis	rs7534824	0.625	rs61782078	chr1:101498212	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	7.36	0.37	1.42e-12	Refractive astigmatism;
LIHC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.04	0.4	1.53e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.92	-16.04	-0.66	1.46e-43	Oral cavity cancer;
LIHC	trans	rs3743102	0.591	rs17841171	chr15:83358388	C/T	cg01542190	chr22:50604728	NA	0.56	7.7	0.38	1.53e-13	Colorectal adenoma (advanced);
LIHC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.48	-10.31	-0.49	7.25e-22	Birth weight;
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.56	-8.38	-0.41	1.42e-15	Testicular germ cell tumor;
LIHC	trans	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.96	-0.44	2.18e-17	Type 2 diabetes;
LIHC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.89	-17.61	-0.69	7.36e-50	Height;
LIHC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg05082376	chr22:42548792	NA	-0.41	-5.84	-0.3	1.25e-8	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.63	-8.85	-0.43	4.9e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2637030	0.559	rs256117	chr5:52916684	G/A	cg06476337	chr5:52856530	NDUFS4	0.43	6.82	0.35	4.25e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.1e-34	Gastritis;
LIHC	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg12903224	chr12:29470962	FAR2	-0.4	-6.55	-0.33	2.1e-10	QT interval;
LIHC	trans	rs859980	0.514	rs9386402	chr6:104519786	C/T	cg26891649	chr19:36239208	LIN37	0.42	6.21	0.32	1.53e-9	Tourette's syndrome or obsessive-compulsive disorder;
LIHC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.73	14.01	0.6	1.47e-35	Mortality in heart failure;
LIHC	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.46	5.91	0.3	8.47e-9	Panic disorder;
LIHC	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg00012203	chr2:219082015	ARPC2	-0.49	-6.29	-0.32	9.75e-10	Ulcerative colitis;
LIHC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.09	0.31	3.01e-9	Rheumatoid arthritis;
LIHC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.14	-0.32	2.23e-9	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.45	7.26	0.37	2.6e-12	Corneal astigmatism;
LIHC	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.7	-14.39	-0.61	4.79e-37	Schizophrenia;
LIHC	cis	rs1775715	1.000	rs1251363	chr10:32328526	G/C	cg14930904	chr10:32216787	ARHGAP12	-0.41	-7.23	-0.36	3.09e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg11062466	chr8:58055876	NA	0.4	5.97	0.31	6.07e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.57	7.57	0.38	3.55e-13	Pulse pressure;
LIHC	cis	rs965469	0.779	rs6051693	chr20:3244449	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-6.33	-0.32	7.92e-10	IFN-related cytopenia;
LIHC	cis	rs8032158	1.000	rs67505007	chr15:56196253	C/T	cg24530489	chr15:56299380	NA	0.43	6.01	0.31	4.81e-9	Keloid;
LIHC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg11839771	chr15:80205821	ST20	-0.32	-6.89	-0.35	2.67e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg27170947	chr2:26402098	FAM59B	0.65	8.31	0.41	2.31e-15	Gut microbiome composition (summer);
LIHC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg20302533	chr7:39170763	POU6F2	0.37	6.69	0.34	9.14e-11	IgG glycosylation;
LIHC	cis	rs12220238	0.841	rs10824163	chr10:76136589	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.2	0.32	1.66e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.23	-0.36	3.08e-12	Migraine;Coronary artery disease;
LIHC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.4	6.1	0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.66	-10.98	-0.51	3.27e-24	Childhood ear infection;
LIHC	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.42	-0.37	9.12e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.72	9.4	0.45	7.97e-19	Eosinophilic esophagitis;
LIHC	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.61	9.13	0.44	6.25e-18	Menopause (age at onset);
LIHC	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg20636351	chr8:55087400	NA	-0.35	-7.16	-0.36	5.02e-12	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08606075	chr2:677472	TMEM18	-0.49	-6.11	-0.31	2.66e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.47	6.35	0.32	6.74e-10	High light scatter reticulocyte count;
LIHC	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.16	0.4	6.69e-15	Corneal astigmatism;
LIHC	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-7.79	-0.39	8.3e-14	Exhaled nitric oxide output;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25201980	chr8:146127417	ZNF250	0.4	6.17	0.32	1.98e-9	Pancreatic cancer;
LIHC	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg08345082	chr10:99160200	RRP12	-0.39	-6.64	-0.34	1.23e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.89	10.73	0.5	2.34e-23	Primary sclerosing cholangitis;
LIHC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.77	0.47	4.76e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.59	-8.01	-0.4	1.77e-14	Sudden cardiac arrest;
LIHC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.69	13.73	0.6	1.86e-34	Coronary artery disease;
LIHC	cis	rs7119038	0.818	rs3889239	chr11:118619960	C/T	cg19308663	chr11:118741387	NA	0.43	5.76	0.3	1.86e-8	Sjögren's syndrome;
LIHC	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	1.14	8.85	0.43	4.77e-17	Arsenic metabolism;
LIHC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-7.71	-0.38	1.37e-13	Gut microbiome composition (summer);
LIHC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.21	-0.36	3.63e-12	Response to antipsychotic treatment;
LIHC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg06808227	chr14:105710500	BRF1	-0.5	-6.11	-0.31	2.74e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg06664874	chr5:179499304	RNF130	0.58	7.09	0.36	7.61e-12	LDL cholesterol;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg13099829	chr1:2237991	SKI	0.44	6.45	0.33	3.71e-10	Neuroblastoma;
LIHC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.48	7.57	0.38	3.54e-13	Height;
LIHC	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.29	5.77	0.3	1.82e-8	Cancer;
LIHC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.43	-5.75	-0.3	2.03e-8	Childhood ear infection;
LIHC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.8	-0.35	4.64e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17507749	chr15:85114479	UBE2QP1	0.78	8.96	0.44	2.18e-17	Schizophrenia;
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7668874	0.779	rs7688185	chr4:116779145	T/G	cg08917878	chr5:172668965	NA	-0.3	-6.1	-0.31	2.8e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-7.7	-0.38	1.5e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.64	9.66	0.46	1.14e-19	Menarche (age at onset);
LIHC	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg14250997	chr9:106856677	SMC2	0.41	7.33	0.37	1.71e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg06766960	chr11:133703094	NA	-0.6	-9.4	-0.45	8.11e-19	Childhood ear infection;
LIHC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-9.32	-0.45	1.46e-18	Schizophrenia;
LIHC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.3	-0.45	1.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.44	-8.65	-0.42	2.07e-16	Testicular germ cell tumor;
LIHC	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.96	-0.35	1.75e-11	Endometrial cancer;
LIHC	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	0.85	8.74	0.43	1.03e-16	Blood pressure (smoking interaction);
LIHC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.04	-0.31	3.95e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	13.52	0.59	1.16e-33	Cognitive test performance;
LIHC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg03013999	chr17:37608204	MED1	-0.36	-6.0	-0.31	5e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.67	10.1	0.48	3.71e-21	Breast cancer;
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.67	-0.42	1.77e-16	Renal cell carcinoma;
LIHC	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.44	6.8	0.34	4.76e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	9.21	0.45	3.29e-18	Lymphocyte counts;
LIHC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.44	0.49	2.57e-22	Obesity-related traits;
LIHC	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg25364880	chr3:44379878	C3orf23	0.6	8.46	0.42	8.16e-16	Depressive symptoms;
LIHC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.75	5.9	0.3	8.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.3	6.44	0.33	3.94e-10	Pulmonary function;
LIHC	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.32	6.76	0.34	6.12e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs77861329	1.000	rs123681	chr3:52209320	A/G	cg08692210	chr3:52188851	WDR51A	0.83	7.96	0.4	2.61e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02985541	chr2:219472218	PLCD4	0.42	6.94	0.35	1.94e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg08888203	chr3:10149979	C3orf24	0.44	5.79	0.3	1.57e-8	Alzheimer's disease;
LIHC	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg23202291	chr11:1979235	NA	0.43	6.21	0.32	1.56e-9	DNA methylation (variation);
LIHC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg26939375	chr7:64535504	NA	-0.46	-7.58	-0.38	3.25e-13	Calcium levels;
LIHC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.14	-14.84	-0.63	8.28e-39	Ulcerative colitis;
LIHC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg21734168	chr11:67353974	GSTP1	-0.28	-6.8	-0.35	4.59e-11	Mean corpuscular volume;
LIHC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.23	-0.75	2.17e-64	Height;
LIHC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.95	-9.26	-0.45	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg25011176	chr20:3776985	CDC25B	-0.41	-5.87	-0.3	1.06e-8	Bipolar disorder;
LIHC	cis	rs826838	0.874	rs844115	chr12:39117384	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.82	-0.39	6.83e-14	Heart rate;
LIHC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.74	0.43	1.08e-16	Motion sickness;
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg06115535	chr2:131100015	IMP4;CCDC115	-0.43	-6.71	-0.34	8.06e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.68	0.38	1.68e-13	Post bronchodilator FEV1;
LIHC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.94	10.94	0.51	4.31e-24	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg08668510	chr10:1095578	IDI1	0.7	7.0	0.35	1.36e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Educational attainment;
LIHC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.71	12.68	0.57	1.87e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.41	-6.53	-0.33	2.44e-10	Testicular germ cell tumor;
LIHC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.74	-11.57	-0.53	2.33e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.95	0.31	6.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	cis	rs988712	0.705	rs11030099	chr11:27677583	C/A	cg18117895	chr11:27722066	BDNF	0.5	6.81	0.35	4.4e-11	Obesity;
LIHC	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg14092571	chr14:90743983	NA	0.43	6.87	0.35	2.97e-11	Mortality in heart failure;
LIHC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.58	-10.11	-0.48	3.34e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.94	-16.55	-0.67	1.27e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg02993280	chr1:107599747	PRMT6	0.69	11.3	0.52	2.19e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg07424592	chr7:64974309	NA	0.82	9.64	0.46	1.27e-19	Diabetic kidney disease;
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg19318889	chr4:1322082	MAEA	0.53	8.85	0.43	4.76e-17	Obesity-related traits;
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.21	-0.32	1.57e-9	Longevity;
LIHC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.02e-11	Red blood cell count;
LIHC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.75	-16.75	-0.67	2.14e-46	Brugada syndrome;
LIHC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.59	-10.41	-0.49	3.06e-22	Age at first birth;
LIHC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-6.23	-0.32	1.38e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.33	-0.37	1.68e-12	Diabetic kidney disease;
LIHC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.51	6.92	0.35	2.25e-11	Monobrow;
LIHC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.54	-6.9	-0.35	2.57e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-10.47	-0.49	1.93e-22	Morning vs. evening chronotype;
LIHC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.73	-0.3	2.19e-8	Fear of minor pain;
LIHC	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.42	8.46	0.42	7.64e-16	Renal cell carcinoma;
LIHC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.64	8.61	0.42	2.74e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.56	-7.49	-0.38	5.82e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-14.67	-0.62	3.78e-38	Chronic sinus infection;
LIHC	cis	rs75920871	0.528	rs983567	chr11:116783600	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-5.9	-0.3	8.52e-9	Subjective well-being;
LIHC	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.61	-0.38	2.72e-13	QT interval;
LIHC	cis	rs4908768	0.579	rs75634300	chr1:8872455	C/T	cg20416874	chr1:8611966	RERE	0.41	6.01	0.31	4.7e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24883642	chr15:40226588	EIF2AK4	0.41	6.17	0.32	1.93e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21467203	chr3:49911342	NA	-0.49	-8.53	-0.42	4.89e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-15.33	-0.64	9.77e-41	Headache;
LIHC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20135002	chr11:47629003	NA	-0.54	-9.26	-0.45	2.36e-18	Subjective well-being;
LIHC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.45	-0.33	3.93e-10	Diabetic kidney disease;
LIHC	cis	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.78	-0.34	5.24e-11	Atopic dermatitis;
LIHC	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-7.91	-0.39	3.51e-14	Homocysteine levels;
LIHC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs4908768	0.501	rs11121186	chr1:8540341	G/A	cg20416874	chr1:8611966	RERE	-0.67	-14.02	-0.6	1.3e-35	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.45e-29	Menopause (age at onset);
LIHC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.5	-6.89	-0.35	2.69e-11	Cognitive ability;
LIHC	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.72	12.8	0.57	6.57e-31	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.93	-12.33	-0.55	3.7e-29	Schizophrenia;
LIHC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.77	-14.71	-0.62	2.61e-38	Mortality in heart failure;
LIHC	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg05765582	chr2:191677683	NA	0.29	5.72	0.3	2.39e-8	Mean platelet volume;
LIHC	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.8	11.97	0.54	8.44e-28	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.32	-0.49	6.64e-22	Waist circumference;Body mass index;
LIHC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.67	11.93	0.54	1.11e-27	High light scatter reticulocyte count;
LIHC	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg07451762	chr16:28383216	NA	0.42	7.53	0.38	4.61e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.46	6.78	0.34	5.38e-11	Cognitive test performance;
LIHC	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.64	-0.34	1.22e-10	Metabolite levels;
LIHC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.17	28.71	0.84	3.97e-93	IgG glycosylation;
LIHC	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg16684958	chr7:75615977	POR	-0.5	-8.47	-0.42	7.2e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.46	7.86	0.39	5.1e-14	Mean corpuscular volume;
LIHC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg14393609	chr7:65229607	NA	0.37	5.72	0.3	2.3e-8	Aortic root size;
LIHC	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg21573476	chr21:45109991	RRP1B	0.43	8.11	0.4	8.89e-15	Mean corpuscular volume;
LIHC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.67	8.88	0.43	3.94e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.75	12.68	0.57	1.77e-30	Aortic root size;
LIHC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg21724239	chr8:58056113	NA	0.45	5.98	0.31	5.49e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.91	-15.52	-0.64	1.65e-41	Tonsillectomy;
LIHC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg05973401	chr12:123451056	ABCB9	0.43	5.94	0.31	7.13e-9	Neutrophil percentage of white cells;
LIHC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.71	-6.72	-0.34	7.44e-11	Breast cancer;
LIHC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.68	-9.42	-0.45	7e-19	Type 2 diabetes;
LIHC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.8	10.01	0.48	7.23e-21	Body mass index;
LIHC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.64	-0.59	4.13e-34	Aortic root size;
LIHC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.69	-11.37	-0.52	1.3e-25	Refractive error;
LIHC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.88	11.1	0.51	1.14e-24	Mean platelet volume;
LIHC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.55	8.78	0.43	8.16e-17	Height;
LIHC	cis	rs4908760	0.539	rs6698830	chr1:8854545	C/T	cg20416874	chr1:8611966	RERE	-0.57	-10.28	-0.49	8.98e-22	Vitiligo;
LIHC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.81	-0.3	1.41e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	8.78	0.43	7.81e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.81	14.18	0.61	3.16e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.21	0.45	3.26e-18	Bipolar disorder;
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.6	9.53	0.46	3.07e-19	Obesity-related traits;
LIHC	cis	rs12313068	0.709	rs10849698	chr12:110504798	C/G	cg12870014	chr12:110450643	ANKRD13A	0.83	11.04	0.51	1.85e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	0.76	8.3	0.41	2.44e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.74	-0.3	2.12e-8	Tonsillectomy;
LIHC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.83	-0.3	1.26e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg24542714	chr1:46669345	POMGNT1;C1orf190	-0.43	-7.2	-0.36	3.92e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6596100	0.538	rs17594964	chr5:132188712	A/G	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	6.75	0.34	6.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.95	-0.31	6.49e-9	Systemic lupus erythematosus;
LIHC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg10130564	chr11:117069849	TAGLN	-0.36	-6.3	-0.32	8.97e-10	Blood protein levels;
LIHC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.86	13.0	0.58	1.15e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs903552	0.935	rs8041582	chr15:102005851	G/A	cg25677261	chr15:102009856	PCSK6	-0.46	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06844545	chr6:163836348	QKI	-0.44	-6.37	-0.33	5.98e-10	Triglycerides;
LIHC	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21467203	chr3:49911342	NA	-0.59	-10.62	-0.5	5.81e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg26139080	chr11:47293733	MADD	-0.5	-8.36	-0.41	1.56e-15	HDL cholesterol;
LIHC	cis	rs6504950	0.720	rs9913784	chr17:52989071	A/T	cg10237252	chr17:52977213	TOM1L1	-0.41	-7.17	-0.36	4.59e-12	Breast cancer;
LIHC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs4132509	0.948	rs12032342	chr1:243834360	G/A	cg21452805	chr1:244014465	NA	0.44	5.8	0.3	1.55e-8	RR interval (heart rate);
LIHC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.4	6.54	0.33	2.27e-10	Red blood cell count;
LIHC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	4.04e-13	Bipolar disorder;
LIHC	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.33e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg05255149	chr17:80675120	FN3KRP	0.43	6.14	0.32	2.28e-9	Glycated hemoglobin levels;
LIHC	trans	rs2359714	0.935	rs7339896	chr1:118798414	A/G	cg19861078	chr7:7936962	NA	0.32	6.11	0.31	2.65e-9	Breast size;
LIHC	cis	rs16828019	0.852	rs35992757	chr1:41652862	C/T	cg03962019	chr1:41807865	NA	0.53	7.53	0.38	4.66e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.59	-9.85	-0.47	2.5e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.57	9.89	0.47	1.94e-20	Longevity;Endometriosis;
LIHC	cis	rs1144333	1.000	rs17097863	chr1:76468787	T/G	cg10523679	chr1:76189770	ACADM	0.42	5.94	0.31	6.96e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09109880	chr4:184365620	CDKN2AIP	0.51	6.44	0.33	4.14e-10	Hepatitis;
LIHC	cis	rs9596863	0.898	rs9568915	chr13:54341214	T/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.1	0.31	2.79e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.56	7.5	0.38	5.44e-13	Vitiligo;
LIHC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.57	7.21	0.36	3.51e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg27255678	chr10:102756921	LZTS2	0.52	7.27	0.37	2.51e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4908760	0.566	rs7532459	chr1:8677773	C/G	cg20416874	chr1:8611966	RERE	-0.63	-11.99	-0.54	6.59e-28	Vitiligo;
LIHC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.39	-5.81	-0.3	1.39e-8	Lung cancer;
LIHC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.0	0.48	8.15e-21	Crohn's disease;
LIHC	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	1.02	19.55	0.73	1.15e-57	Breast cancer;
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg00035636	chr13:21900591	NA	0.37	6.05	0.31	3.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06123940	chr18:29597493	RNF125	0.47	7.7	0.38	1.53e-13	Longevity;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg04013166	chr16:89971882	TCF25	0.61	7.99	0.4	2.07e-14	Skin colour saturation;
LIHC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg17750252	chr2:136567154	LCT	0.35	6.15	0.32	2.2e-9	Mosquito bite size;
LIHC	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.5	8.0	0.4	1.88e-14	Corneal astigmatism;
LIHC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.25e-11	Ileal carcinoids;
LIHC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-6.81	-0.35	4.41e-11	Prostate cancer;
LIHC	cis	rs2777491	0.874	rs11633799	chr15:41576538	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.53	-0.38	4.56e-13	Ulcerative colitis;
LIHC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.42	-5.91	-0.3	8.1e-9	Longevity;
LIHC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.57	-8.57	-0.42	3.52e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.48	-8.01	-0.4	1.83e-14	Mean corpuscular volume;
LIHC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg15123519	chr2:136567270	LCT	-0.36	-5.77	-0.3	1.76e-8	Corneal structure;
LIHC	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.38	-6.79	-0.34	5.04e-11	Obesity;
LIHC	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.86	-0.3	1.07e-8	Response to antipsychotic treatment;
LIHC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.6	-8.5	-0.42	6.02e-16	Blood pressure (smoking interaction);
LIHC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.46	-6.07	-0.31	3.37e-9	Height;
LIHC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.44	7.15	0.36	5.35e-12	Methadone dose in opioid dependence;
LIHC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.74	-11.27	-0.52	2.8e-25	Coronary artery disease;
LIHC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.26	-0.37	2.62e-12	Migraine;Coronary artery disease;
LIHC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	trans	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-6.51	-0.33	2.65e-10	Mosquito bite size;
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05665937	chr4:1216051	CTBP1	0.39	6.2	0.32	1.59e-9	Obesity-related traits;
LIHC	cis	rs600806	0.714	rs2781552	chr1:110025881	A/G	cg23091122	chr1:110024289	SYPL2	0.45	6.07	0.31	3.37e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg14440974	chr22:39074834	NA	-0.45	-7.3	-0.37	2.09e-12	Menopause (age at onset);
LIHC	cis	rs7712401	0.755	rs3756362	chr5:122108890	C/G	cg18764291	chr5:122110994	SNX2	0.33	5.82	0.3	1.36e-8	Mean platelet volume;
LIHC	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.5	9.21	0.45	3.26e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.89	0.35	2.71e-11	Lung cancer in ever smokers;
LIHC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg07117364	chr1:16154769	NA	0.38	5.72	0.3	2.38e-8	Dilated cardiomyopathy;
LIHC	cis	rs11603020	0.950	rs11229067	chr11:57374946	A/C	cg19752551	chr11:57585705	CTNND1	0.46	6.1	0.31	2.89e-9	Blood protein levels;
LIHC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.89	-13.81	-0.6	9.11e-35	Body mass index;
LIHC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.59	-11.17	-0.52	6.66e-25	Lymphocyte percentage of white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11317019	chr17:42219250	C17orf53	0.38	6.17	0.32	1.9e-9	Cognitive function;
LIHC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.44	7.22	0.36	3.46e-12	Testicular germ cell tumor;
LIHC	cis	rs600806	0.665	rs1368988	chr1:110012123	A/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.15	-0.32	2.17e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg25356066	chr3:128598488	ACAD9	0.53	7.47	0.37	6.95e-13	IgG glycosylation;
LIHC	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.7	-7.93	-0.39	3.19e-14	White matter integrity;Neutrophil percentage of white cells;
LIHC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.57	0.38	3.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.01	-0.31	4.88e-9	Electroencephalogram traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08330117	chr8:90770456	RIPK2	0.44	6.18	0.32	1.78e-9	Pancreatic cancer;
LIHC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06803689	chr22:29949796	THOC5	-0.46	-6.57	-0.33	1.9e-10	Pancreatic cancer;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.6	-8.62	-0.42	2.59e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.59	-8.21	-0.41	4.63e-15	Menopause (age at onset);
LIHC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg03327327	chr1:214779620	CENPF	0.47	6.08	0.31	3.17e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg10820045	chr2:198174542	NA	-0.58	-9.75	-0.47	5.68e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.56	9.35	0.45	1.21e-18	Colorectal cancer;
LIHC	cis	rs9392556	0.509	rs588158	chr6:4079592	G/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.34	-6.64	-0.34	1.25e-10	Blood metabolite levels;
LIHC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.37	-0.33	5.99e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.54	9.23	0.45	2.97e-18	Schizophrenia;
LIHC	cis	rs963731	0.649	rs7568552	chr2:39257667	T/C	cg04010122	chr2:39346883	SOS1	-0.75	-6.37	-0.33	6.19e-10	Corticobasal degeneration;
LIHC	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg20129853	chr10:51489980	NA	-0.41	-8.74	-0.43	1.04e-16	Prostate-specific antigen levels;
LIHC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg01652190	chr22:50026171	C22orf34	-0.29	-6.61	-0.34	1.52e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.85	-13.55	-0.59	8.73e-34	Schizophrenia;
LIHC	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.9	11.29	0.52	2.51e-25	Coronary artery disease;
LIHC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg16586182	chr3:47516702	SCAP	0.44	7.47	0.37	6.57e-13	Colorectal cancer;
LIHC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.25	-0.37	2.74e-12	Body mass index;
LIHC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-6.5	-0.33	2.81e-10	Blood metabolite levels;
LIHC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg22532475	chr10:104410764	TRIM8	-0.38	-6.69	-0.34	9.11e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.2	-0.32	1.58e-9	Bipolar disorder;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17284865	chr1:155197511	GBAP1	0.38	6.26	0.32	1.16e-9	Bilirubin levels;
LIHC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-7.12	-0.36	6.2e-12	Vitiligo;
LIHC	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg23250157	chr14:64679961	SYNE2	0.41	6.12	0.31	2.5e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.22	-0.45	3.11e-18	Electroencephalogram traits;
LIHC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.27	-17.12	-0.68	6.98e-48	Diabetic kidney disease;
LIHC	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.73	-11.84	-0.54	2.43e-27	Systemic lupus erythematosus;
LIHC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.65	10.55	0.5	1.03e-22	Schizophrenia;
LIHC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.9	-0.35	2.48e-11	IgG glycosylation;
LIHC	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.4	6.41	0.33	4.74e-10	Red blood cell count;
LIHC	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.51	-7.73	-0.39	1.2e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs57244997	0.725	rs67597312	chr6:162411023	A/G	cg17173639	chr6:162384350	PARK2	-0.53	-6.96	-0.35	1.78e-11	Mosquito bite size;
LIHC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	11.28	0.52	2.64e-25	Cognitive test performance;
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.47	7.72	0.39	1.32e-13	Testicular germ cell tumor;
LIHC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.79	0.39	8.12e-14	Multiple sclerosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21939482	chr7:6388130	C7orf70	0.41	6.58	0.34	1.73e-10	Cognitive function;
LIHC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	9.47	0.46	4.84e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg23605328	chr1:201951606	RNPEP	0.38	6.07	0.31	3.35e-9	Monocyte percentage of white cells;
LIHC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Parkinson's disease;
LIHC	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.48	6.86	0.35	3.23e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.68	-0.34	9.99e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg16423285	chr20:60520624	NA	-0.49	-8.1	-0.4	1.01e-14	Obesity-related traits;
LIHC	cis	rs2274273	0.840	rs3742569	chr14:55818706	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.58	-0.34	1.79e-10	Protein biomarker;
LIHC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-13.42	-0.59	2.69e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg16797656	chr11:68205561	LRP5	0.5	7.73	0.39	1.25e-13	Total body bone mineral density;
LIHC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.83	0.54	2.59e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.66	7.24	0.36	3.02e-12	Exhaled nitric oxide output;
LIHC	cis	rs55665837	0.701	rs11023272	chr11:14630370	T/C	cg16394018	chr11:14927549	NA	0.41	5.81	0.3	1.45e-8	Vitamin D levels;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.61	-11.83	-0.54	2.74e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	10.0	0.48	8.11e-21	Platelet count;
LIHC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-19.19	-0.72	3.27e-56	Coronary artery disease;
LIHC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.73	0.3	2.15e-8	Coronary artery disease;
LIHC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.8	12.34	0.56	3.46e-29	Dental caries;
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg06497051	chr1:156261200	TMEM79	0.37	6.0	0.31	5.1e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.86	14.84	0.63	8.69e-39	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-7.64	-0.38	2.24e-13	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.39	-5.91	-0.3	8.32e-9	Total body bone mineral density;
LIHC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.28	0.37	2.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.63	0.46	1.44e-19	Height;
LIHC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.64	-6.88	-0.35	2.84e-11	Gut microbiome composition (summer);
LIHC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	12.32	0.55	4e-29	Response to bleomycin (chromatid breaks);
LIHC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-7.79	-0.39	8.3e-14	Gut microbiome composition (summer);
LIHC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.34	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.83	13.83	0.6	7.49e-35	Aortic root size;
LIHC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.39	7.04	0.36	1.04e-11	Psoriasis;
LIHC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.47	-7.46	-0.37	7.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-9.06	-0.44	1.03e-17	Body mass index;
LIHC	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.43	7.02	0.35	1.16e-11	Menopause (age at onset);
LIHC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg15123519	chr2:136567270	LCT	-0.46	-9.47	-0.46	4.86e-19	Mosquito bite size;
LIHC	cis	rs61041384	0.661	rs4759407	chr12:123689674	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-6.14	-0.32	2.28e-9	Schizophrenia;
LIHC	cis	rs7703744	0.747	rs6896559	chr5:118678718	G/C	cg10911160	chr5:118691794	TNFAIP8	-0.49	-5.79	-0.3	1.56e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.59	-9.28	-0.45	2.02e-18	Dental caries;
LIHC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg17724175	chr1:150552817	MCL1	0.46	9.16	0.44	4.94e-18	Melanoma;
LIHC	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg19875535	chr5:140030758	IK	-0.34	-5.73	-0.3	2.17e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.53	8.01	0.4	1.79e-14	Morning vs. evening chronotype;
LIHC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11645453	chr3:52864694	ITIH4	0.22	5.82	0.3	1.38e-8	Bipolar disorder;
LIHC	cis	rs748404	0.511	rs12442190	chr15:43445305	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.36	-5.81	-0.3	1.41e-8	Lung cancer;
LIHC	trans	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg10208301	chr11:6592745	DNHD1	-0.44	-6.35	-0.32	6.91e-10	Coronary artery calcification;
LIHC	cis	rs8053891	0.673	rs10492825	chr16:72018417	T/C	cg01557791	chr16:72042693	DHODH	-0.5	-7.34	-0.37	1.53e-12	Coronary artery disease;
LIHC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg26149184	chr10:133730230	NA	0.47	7.49	0.38	5.75e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.4	0.33	5.2e-10	Lung cancer in ever smokers;
LIHC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.63	9.88	0.47	2.06e-20	Corneal astigmatism;
LIHC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg14779329	chr11:130786720	SNX19	0.38	5.8	0.3	1.54e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.81	6.79	0.34	4.99e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.75e-22	Hemoglobin concentration;
LIHC	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg22875332	chr1:76189707	ACADM	0.4	6.25	0.32	1.22e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	6.92	0.35	2.21e-11	Bipolar disorder;
LIHC	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.38	0.33	5.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.25	-0.41	3.47e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.01	-0.44	1.43e-17	Bipolar disorder;
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg20016023	chr10:99160130	RRP12	-0.41	-6.35	-0.32	7.01e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	13.44	0.59	2.41e-33	Lung cancer in ever smokers;
LIHC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.62	6.75	0.34	6.3e-11	Gut microbiome composition (summer);
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.67	10.06	0.48	4.98e-21	Menarche (age at onset);
LIHC	cis	rs2607426	1.000	rs13108	chr19:41271104	T/C	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.47	-5.83	-0.3	1.3e-8	Blood protein levels;
LIHC	cis	rs78062588	1.000	rs73001418	chr1:154585594	T/A	cg24304309	chr1:154577895	ADAR	-0.5	-5.86	-0.3	1.11e-8	Lung cancer;
LIHC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.54	0.33	2.29e-10	Heart rate;
LIHC	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.56	9.2	0.45	3.7e-18	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.56	-8.89	-0.43	3.46e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1198430	1.000	rs1198434	chr1:23758134	A/G	cg19827787	chr1:23763612	ASAP3	0.36	6.11	0.31	2.69e-9	Total cholesterol levels;
LIHC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.38	6.15	0.32	2.21e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.67	0.42	1.82e-16	Motion sickness;
LIHC	trans	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg24637308	chr11:6592297	DNHD1	0.43	6.04	0.31	4.13e-9	Coronary artery calcification;
LIHC	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.57e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.63	7.94	0.39	2.86e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.94	-0.39	2.96e-14	Response to antipsychotic treatment;
LIHC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.76	0.54	4.69e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	17.4	0.69	5.02e-49	Lung cancer in ever smokers;
LIHC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	7.13	0.36	6.19e-12	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00319567	chr13:60971258	TDRD3	0.5	7.06	0.36	9.6e-12	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.61e-14	Prudent dietary pattern;
LIHC	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.44	-6.09	-0.31	3e-9	Obesity-related traits;
LIHC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg15848620	chr12:58087721	OS9	-0.55	-7.35	-0.37	1.46e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.95	0.47	1.22e-20	Alzheimer's disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14819942	chr15:35414228	NA	0.48	6.6	0.34	1.6e-10	Hepatitis;
LIHC	cis	rs12744310	1.000	rs12749636	chr1:41758446	A/G	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs1075232	0.655	rs28451043	chr15:31587562	A/T	cg04373760	chr16:53404718	NA	0.65	6.23	0.32	1.38e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.88	-8.49	-0.42	6.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg07424592	chr7:64974309	NA	0.81	9.47	0.46	4.62e-19	Diabetic kidney disease;
LIHC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.74	-10.82	-0.51	1.14e-23	White blood cell count;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.24	0.81	4.1e-80	Prudent dietary pattern;
LIHC	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.73	0.34	7.31e-11	Dupuytren's disease;
LIHC	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.67	11.5	0.53	4.27e-26	Diisocyanate-induced asthma;
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.4	-6.18	-0.32	1.8e-9	Psoriasis;
LIHC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg16283753	chr6:170068014	WDR27	0.45	5.99	0.31	5.46e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.0	-0.35	1.37e-11	Blood pressure;
LIHC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.53	-6.49	-0.33	2.94e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg27366882	chr3:133540807	NA	-0.43	-7.29	-0.37	2.18e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs72781680	0.566	rs72794293	chr2:23898149	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	6.14	0.31	2.33e-9	Lymphocyte counts;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11814935	chr1:202858358	RABIF	-0.5	-7.31	-0.37	1.91e-12	Cognitive function;
LIHC	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.7	-12.74	-0.57	1.12e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.07	0.48	4.62e-21	Alzheimer's disease (late onset);
LIHC	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg18590015	chr6:138745469	NHSL1	0.4	6.21	0.32	1.56e-9	Electroencephalogram traits;
LIHC	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg10381502	chr11:71823885	C11orf51	1.06	9.3	0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg27129171	chr3:47204927	SETD2	0.5	7.49	0.38	6.12e-13	Birth weight;
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg24101359	chr6:42928495	GNMT	0.43	5.87	0.3	1.04e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.64	9.65	0.46	1.19e-19	Monocyte percentage of white cells;
LIHC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg03037974	chr15:76606532	NA	0.74	14.46	0.62	2.53e-37	Blood metabolite levels;
LIHC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.43	7.4	0.37	1.06e-12	Aortic root size;
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg20822365	chr15:83621694	HOMER2	0.41	6.05	0.31	3.8e-9	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-6.96	-0.35	1.71e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03147627	chr4:83956202	COPS4	0.44	6.2	0.32	1.59e-9	Pancreatic cancer;
LIHC	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.45	-7.15	-0.36	5.2e-12	Multiple sclerosis;
LIHC	cis	rs7212590	0.655	rs56198517	chr17:57976582	G/T	cg10252138	chr17:58120427	NA	-0.62	-6.64	-0.34	1.23e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.07	-0.4	1.19e-14	Morning vs. evening chronotype;
LIHC	trans	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg09872104	chr7:134855509	C7orf49	-0.74	-6.08	-0.31	3.19e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs7095607	0.606	rs10998011	chr10:69958623	A/G	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.66e-9	Lung function (FVC);
LIHC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.55	-13.16	-0.58	2.77e-32	White blood cell count (basophil);
LIHC	cis	rs9948	1.000	rs2276654	chr2:97492479	G/A	cg01990225	chr2:97406019	LMAN2L	-0.66	-6.24	-0.32	1.32e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.6	11.92	0.54	1.25e-27	Plateletcrit;Platelet count;
LIHC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg16497277	chr3:49208875	KLHDC8B	0.47	5.98	0.31	5.67e-9	Menarche (age at onset);
LIHC	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg21522988	chr12:29376872	FAR2	-0.26	-5.9	-0.3	8.71e-9	QT interval;
LIHC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.93	0.39	3.07e-14	Tonsillectomy;
LIHC	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg09795085	chr6:101329169	ASCC3	0.48	6.65	0.34	1.18e-10	Neuroticism;
LIHC	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.8	0.39	7.44e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs11800820	0.557	rs55881259	chr1:246665951	C/T	cg16700716	chr1:246684329	NA	0.48	8.1	0.4	9.84e-15	Obesity-related traits;
LIHC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg05941027	chr17:61774174	LIMD2	0.34	6.92	0.35	2.2e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7238033	0.620	rs11082469	chr18:43321269	A/G	cg20610511	chr18:43302872	SLC14A1	0.37	6.15	0.32	2.17e-9	Bladder cancer;
LIHC	cis	rs10508774	1.000	rs72795572	chr10:32909986	G/T	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.71	10.26	0.49	1.01e-21	Monocyte count;
LIHC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.74	-13.63	-0.59	4.25e-34	Height;
LIHC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.1	-0.7	7.56e-52	Tonsillectomy;
LIHC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	10.25	0.48	1.12e-21	Multiple sclerosis;
LIHC	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg01864069	chr14:103024347	NA	-0.35	-5.9	-0.3	8.57e-9	Platelet count;
LIHC	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg02344993	chr17:57696989	CLTC	0.58	9.4	0.45	7.78e-19	Hemoglobin concentration;
LIHC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.42	0.33	4.67e-10	Lung cancer in ever smokers;
LIHC	cis	rs1075232	1.000	rs12439239	chr15:31651718	G/A	cg01030201	chr15:31746330	NA	-0.78	-6.11	-0.31	2.66e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.68	9.64	0.46	1.26e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.8	-13.6	-0.59	5.71e-34	Platelet distribution width;
LIHC	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.85	17.39	0.68	5.72e-49	Longevity;
LIHC	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.73	8.5	0.42	6.14e-16	Dental caries;
LIHC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.2	11.07	0.51	1.45e-24	Uric acid levels;
LIHC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04221910	chr5:616842	CEP72	-0.42	-7.45	-0.37	7.47e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.51	8.24	0.41	3.83e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.72	-11.42	-0.53	8.13e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs61677309	0.964	rs112753655	chr11:118154795	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.11	0.52	1.07e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	6.94	0.35	1.98e-11	Menopause (age at onset);
LIHC	cis	rs240764	0.697	rs370757	chr6:101134156	T/C	cg09795085	chr6:101329169	ASCC3	0.45	6.16	0.32	2.01e-9	Neuroticism;
LIHC	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	0.9	12.36	0.56	2.98e-29	Post bronchodilator FEV1;
LIHC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.68	-0.38	1.65e-13	Chronic sinus infection;
LIHC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.45	7.77	0.39	9.2e-14	Schizophrenia;
LIHC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.56	7.44	0.37	8.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg25665528	chr16:2260870	C16orf79	-0.47	-9.63	-0.46	1.42e-19	Height;
LIHC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.47	-0.33	3.3e-10	Type 2 diabetes;
LIHC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.57	10.29	0.49	7.98e-22	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.93	-18.22	-0.7	2.47e-52	Height;
LIHC	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.48	7.39	0.37	1.11e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs17152411	0.895	rs7906592	chr10:126627861	C/G	cg07906193	chr10:126599966	NA	0.47	7.31	0.37	1.93e-12	Height;
LIHC	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg01858014	chr14:56050164	KTN1	-0.72	-7.0	-0.35	1.36e-11	Putamen volume;
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg00656387	chr3:40428638	ENTPD3	0.51	8.67	0.42	1.82e-16	Renal cell carcinoma;
LIHC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.5e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2380220	0.872	rs67846436	chr6:95951521	G/T	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.54e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4908768	0.520	rs6681362	chr1:8658527	T/G	cg20416874	chr1:8611966	RERE	-0.63	-11.71	-0.53	7.32e-27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.43	6.51	0.33	2.6200000000000003e-10	Type 2 diabetes;
LIHC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.79	13.33	0.58	6.25e-33	Colorectal cancer;
LIHC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.36	6.48	0.33	3.18e-10	Ewing sarcoma;
LIHC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.56	7.58	0.38	3.27e-13	Blood metabolite levels;
LIHC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.57	8.34	0.41	1.84e-15	Mean corpuscular volume;
LIHC	cis	rs7106204	1.000	rs6484025	chr11:24214514	C/G	ch.11.24196551F	chr11:24239977	NA	0.67	6.69	0.34	9.15e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.21	0.32	1.54e-9	Educational attainment;
LIHC	cis	rs903552	0.866	rs11247296	chr15:102007919	T/C	cg06707286	chr15:102010195	PCSK6	-0.51	-7.47	-0.37	6.81e-13	Diabetic kidney disease;
LIHC	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg06265175	chr8:121136014	COL14A1	0.48	7.72	0.39	1.34e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.25	0.41	3.42e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg03128534	chr1:43423976	SLC2A1	-0.48	-6.04	-0.31	4.12e-9	Red cell distribution width;
LIHC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.89	-0.3	9.39e-9	Pulse pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08400120	chr3:169940839	PRKCI	0.45	6.3	0.32	9.07e-10	Pancreatic cancer;
LIHC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.66	0.34	1.12e-10	Response to antipsychotic treatment;
LIHC	trans	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.19	0.32	1.7e-9	Coronary artery calcification;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.75	0.43	9.61e-17	Prudent dietary pattern;
LIHC	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.54	5.88	0.3	9.83e-9	Systemic lupus erythematosus;
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	0.81	11.77	0.54	4.57e-27	Menarche (age at onset);
LIHC	cis	rs4450131	0.897	rs10901796	chr10:126335586	T/C	cg20435097	chr10:126320824	FAM53B	-0.51	-9.37	-0.45	9.77e-19	White blood cell count (basophil);
LIHC	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.6	8.41	0.41	1.13e-15	Eotaxin levels;
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg20090690	chr10:134436459	INPP5A	0.44	5.74	0.3	2.12e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.78	-8.55	-0.42	4.1e-16	Vitiligo;
LIHC	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.41	-6.77	-0.34	5.62e-11	Schizophrenia;
LIHC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.02	-0.36	1.17e-11	Schizophrenia;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.38	-0.37	1.22e-12	Total body bone mineral density;
LIHC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.65	10.01	0.48	7.65e-21	Breast cancer;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg09224379	chr16:11052486	CLEC16A	0.37	6.38	0.33	5.62e-10	Alopecia areata;
LIHC	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.96e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs16958440	0.867	rs61689863	chr18:44669157	A/T	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.49	-8.21	-0.41	4.68e-15	Menarche (age at onset);
LIHC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.19	0.61	3.03e-36	Chronic sinus infection;
LIHC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.78	-11.72	-0.54	6.62e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3823572	0.542	rs10271889	chr7:133635846	A/G	cg03336402	chr7:133662267	EXOC4	0.47	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg16486109	chr11:613632	IRF7	0.57	5.75	0.3	1.93e-8	Systemic lupus erythematosus;
LIHC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.67	0.42	1.71e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.96	0.31	6.36e-9	Renal cell carcinoma;
LIHC	cis	rs1892700	1.000	rs4816463	chr21:34999978	C/T	cg14850771	chr21:34775459	IFNGR2	-0.45	-6.03	-0.31	4.2e-9	Educational attainment;
LIHC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.8	-11.74	-0.54	5.8e-27	Response to antineoplastic agents;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20414838	chr1:53704138	MAGOH	-0.48	-6.11	-0.31	2.78e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	16.79	0.67	1.46e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.29	6.4	0.33	5.23e-10	Pulmonary function;
LIHC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.69	-7.62	-0.38	2.55e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.45	-0.33	3.8e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23404012	chr14:71066865	MED6	0.36	6.71	0.34	8.31e-11	Calcium levels;
LIHC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.52	-0.38	4.76e-13	Personality dimensions;
LIHC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg05941027	chr17:61774174	LIMD2	0.34	6.92	0.35	2.2e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.43	6.72	0.34	7.84e-11	Height;
LIHC	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.79	-0.34	4.93e-11	Blood pressure;
LIHC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.56	-10.07	-0.48	4.52e-21	Alzheimer's disease (late onset);
LIHC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.62	7.15	0.36	5.45e-12	Bipolar disorder;
LIHC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg20129853	chr10:51489980	NA	-0.4	-8.62	-0.42	2.59e-16	Prostate-specific antigen levels;
LIHC	cis	rs1419980	0.730	rs11054897	chr12:7774251	A/G	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	7.74e-24	Hip circumference adjusted for BMI;
LIHC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.97	18.83	0.71	9.25e-55	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.22	-0.36	3.34e-12	Bipolar disorder;
LIHC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.64e-11	Aortic root size;
LIHC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.37	5.73	0.3	2.25e-8	Lung cancer;
LIHC	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg27205649	chr11:78285834	NARS2	0.39	5.92	0.3	7.82e-9	Alzheimer's disease (survival time);
LIHC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.4	0.33	4.98e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.48	-7.72	-0.39	1.29e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg03013999	chr17:37608204	MED1	0.35	5.78	0.3	1.71e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg08210727	chr20:33865349	NA	-0.51	-5.91	-0.3	8.36e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.66	8.61	0.42	2.8e-16	Gut microbiome composition (summer);
LIHC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.31	0.52	2.1e-25	Menarche (age at onset);
LIHC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.42	-0.33	4.56e-10	Menarche (age at onset);
LIHC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.8e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.02	-0.35	1.22e-11	Breast cancer;
LIHC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.89	11.05	0.51	1.79e-24	Coronary artery disease;
LIHC	cis	rs57590327	0.503	rs6800295	chr3:81593011	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-8.18	-0.4	5.73e-15	Extraversion;
LIHC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.77	0.5	1.73e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-6.43	-0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg20991723	chr1:152506922	NA	0.51	8.71	0.43	1.29e-16	Hair morphology;
LIHC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.82	-0.3	1.36e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.64	10.66	0.5	4.14e-23	Lymphocyte counts;
LIHC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.26	-0.37	2.56e-12	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06444125	chr16:30103218	TBX6	-0.4	-6.06	-0.31	3.55e-9	Pancreatic cancer;
LIHC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	12.59	0.56	4.13e-30	Response to antipsychotic treatment;
LIHC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.37	-5.75	-0.3	1.95e-8	Platelet count;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.95	0.63	3.03e-39	Prudent dietary pattern;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20197516	chr17:80373348	C17orf101	0.41	6.22	0.32	1.47e-9	Longevity;
LIHC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.02	14.54	0.62	1.3e-37	Cognitive function;
LIHC	cis	rs7095607	0.693	rs7896727	chr10:69952376	C/T	cg18986048	chr10:69913749	MYPN	0.43	6.53	0.33	2.36e-10	Lung function (FVC);
LIHC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.72	-0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg18478394	chr8:109455254	TTC35	0.38	6.54	0.33	2.25e-10	Dupuytren's disease;
LIHC	cis	rs3018712	0.532	rs2513294	chr11:68421194	C/T	cg16797656	chr11:68205561	LRP5	-0.44	-5.81	-0.3	1.44e-8	Total body bone mineral density;
LIHC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.35	8.74	0.43	1.09e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg19752551	chr11:57585705	CTNND1	-0.51	-7.25	-0.37	2.72e-12	Schizophrenia;
LIHC	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.12	-0.44	6.34e-18	Schizophrenia;
LIHC	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg12698662	chr3:15914712	MIR563	-0.39	-7.21	-0.36	3.62e-12	Mean platelet volume;
LIHC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.47	7.73	0.39	1.22e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	5.91	0.3	8.25e-9	Bipolar disorder;
LIHC	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg20991723	chr1:152506922	NA	0.38	5.81	0.3	1.42e-8	Hair morphology;
LIHC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.4	6.22	0.32	1.45e-9	Mean platelet volume;
LIHC	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.74	13.06	0.58	6.53e-32	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.38	-0.45	9.67e-19	Bipolar disorder;
LIHC	cis	rs3106136	0.843	rs6532479	chr4:95259235	C/A	cg11021082	chr4:95130006	SMARCAD1	0.41	7.33	0.37	1.66e-12	Capecitabine sensitivity;
LIHC	cis	rs1000083	0.915	rs1820160	chr5:96609774	T/C	ch.5.96698337R	chr5:96672581	NA	0.95	7.69	0.38	1.55e-13	Cisplatin-induced ototoxicity;
LIHC	cis	rs3780378	0.875	rs2031906	chr9:5087495	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-8.54	-0.42	4.54e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg07150772	chr14:90864620	CALM1	-0.42	-5.88	-0.3	9.62e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.38	0.33	5.66e-10	Lung cancer in ever smokers;
LIHC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.22	0.32	1.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg10127483	chr1:110009974	SYPL2	0.49	6.34	0.32	7.25e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.14	-0.4	7.54e-15	Exhaled nitric oxide output;
LIHC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.16	17.97	0.7	2.69e-51	Gut microbiome composition (summer);
LIHC	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-0.81	-9.21	-0.45	3.34e-18	Exhaled nitric oxide output;
LIHC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.99	-18.44	-0.71	3.31e-53	Breast cancer;
LIHC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg16226627	chr15:75307476	SCAMP5	0.51	8.81	0.43	6.34e-17	Lung cancer;
LIHC	trans	rs4819388	0.915	rs7278940	chr21:45648992	C/T	cg17383793	chr5:52405638	MOCS2	-0.4	-6.31	-0.32	8.81e-10	Celiac disease;
LIHC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg02079420	chr8:82753780	SNX16	-0.36	-6.64	-0.34	1.21e-10	Diastolic blood pressure;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg10854029	chr8:22926554	TNFRSF10B	-0.63	-7.23	-0.36	3.21e-12	Preeclampsia;
LIHC	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg14515779	chr1:101123966	NA	-0.48	-6.95	-0.35	1.83e-11	Monocyte count;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.59	8.75	0.43	9.61e-17	Prudent dietary pattern;
LIHC	cis	rs4845459	0.967	rs6701307	chr1:152590444	G/A	cg20634798	chr1:152595351	LCE3A	-0.31	-6.13	-0.31	2.46e-9	Psoriasis;
LIHC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.75	0.43	1.01e-16	Motion sickness;
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.11	-0.55	2.53e-28	Alzheimer's disease;
LIHC	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.48	6.99	0.35	1.43e-11	Dialysis-related mortality;
LIHC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg05697976	chr12:29376483	FAR2	-0.3	-6.11	-0.31	2.75e-9	QT interval;
LIHC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21467203	chr3:49911342	NA	-0.55	-10.33	-0.49	6.04e-22	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00371891	chr19:4723959	DPP9	0.43	6.34	0.32	7.38e-10	Pancreatic cancer;
LIHC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.8	12.48	0.56	1.04e-29	Breast cancer;
LIHC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-11.72	-0.54	6.49e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.53	7.77	0.39	9.51e-14	Type 2 diabetes;
LIHC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.56	-15.01	-0.63	1.72e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg02297831	chr4:17616191	MED28	0.44	6.81	0.35	4.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg01557791	chr16:72042693	DHODH	-0.42	-6.97	-0.35	1.63e-11	Fibrinogen levels;
LIHC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg11861562	chr11:117069780	TAGLN	0.37	5.83	0.3	1.27e-8	Blood protein levels;
LIHC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.68	0.38	1.72e-13	Bipolar disorder;
LIHC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.19	-0.36	4.16e-12	Bipolar disorder;
LIHC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.53	8.57	0.42	3.56e-16	Anterior chamber depth;
LIHC	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.41	-0.41	1.15e-15	Schizophrenia;
LIHC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.91	10.34	0.49	5.39e-22	Triglycerides;
LIHC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg05020625	chr6:43252858	TTBK1	0.23	6.27	0.32	1.08e-9	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg24209194	chr3:40518798	ZNF619	0.64	9.71	0.46	7.46e-20	Renal cell carcinoma;
LIHC	trans	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg20327061	chr1:6640478	ZBTB48	-0.52	-6.19	-0.32	1.73e-9	Vitiligo;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg24924221	chr8:22856702	RHOBTB2	0.62	6.13	0.31	2.43e-9	Musician's dystonia;
LIHC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg09238746	chr17:78121135	EIF4A3	-0.48	-7.2	-0.36	3.86e-12	Yeast infection;
LIHC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.78	11.76	0.54	4.71e-27	Coronary artery disease;
LIHC	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.49	9.04	0.44	1.18e-17	Testicular germ cell tumor;
LIHC	trans	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg14393609	chr7:65229607	NA	0.38	5.71	0.3	2.41e-8	Aortic root size;
LIHC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.77	-0.34	5.69e-11	Diabetic kidney disease;
LIHC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg26441486	chr22:50317300	CRELD2	-0.35	-6.32	-0.32	7.96e-10	Schizophrenia;
LIHC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.33	2.47e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	0.97	10.19	0.48	1.76e-21	Vitiligo;
LIHC	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg10932868	chr11:921992	NA	0.34	6.3	0.32	9.29e-10	Alzheimer's disease (late onset);
LIHC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.63	12.87	0.57	3.55e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	7.25	0.36	2.88e-12	Menopause (age at onset);
LIHC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.13	0.48	2.85e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg12751644	chr20:60527061	NA	-0.37	-6.27	-0.32	1.09e-9	Body mass index;
LIHC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.35	5.86	0.3	1.11e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.42	7.32	0.37	1.79e-12	Aortic root size;
LIHC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg17294928	chr15:75287854	SCAMP5	-0.48	-6.26	-0.32	1.15e-9	Lung cancer;
LIHC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.77	12.6	0.56	3.56e-30	Anterior chamber depth;
LIHC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.02e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.78	0.43	7.87e-17	Bipolar disorder;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg03874509	chr1:107600012	PRMT6	-0.78	-12.53	-0.56	6.65e-30	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.42	-5.74	-0.3	2.05e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.49	-6.24	-0.32	1.31e-9	Panic disorder;
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.52	-0.46	3.24e-19	Calcium levels;
LIHC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg15902774	chr15:75289873	SCAMP5	0.43	6.44	0.33	4.07e-10	Lung cancer;
LIHC	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.51e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1892700	0.821	rs16990760	chr21:34924243	T/C	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.74	-0.3	2.09e-8	Educational attainment;
LIHC	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg25566285	chr7:158114605	PTPRN2	0.23	6.22	0.32	1.43e-9	Calcium levels;
LIHC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.99	-0.51	2.91e-24	Hemoglobin concentration;
LIHC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.45	7.76	0.39	1.02e-13	Mean corpuscular volume;
LIHC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-6.14	-0.31	2.33e-9	Testicular germ cell tumor;
LIHC	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs17309827	0.965	rs13206693	chr6:3433347	T/C	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.81	-0.3	1.45e-8	Crohn's disease;
LIHC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.41	6.04	0.31	4.07e-9	Monobrow;
LIHC	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.48	6.63	0.34	1.28e-10	Bipolar disorder;
LIHC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg12365402	chr11:9010492	NRIP3	0.29	7.58	0.38	3.27e-13	Hemoglobin concentration;
LIHC	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.38	-0.37	1.19e-12	Urate levels in overweight individuals;
LIHC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.14e-14	Mean platelet volume;
LIHC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	10.67	0.5	3.76e-23	Body mass index (adult);
LIHC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.65	10.79	0.5	1.51e-23	Response to diuretic therapy;
LIHC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.96	18.61	0.71	6.65e-54	Ewing sarcoma;
LIHC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	8.87	0.43	4.19e-17	Platelet count;
LIHC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-0.79	-9.02	-0.44	1.36e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.56e-8	Bladder cancer;
LIHC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.92	11.62	0.53	1.58e-26	Coronary artery disease;
LIHC	cis	rs1559088	0.847	rs7255968	chr19:33601902	A/T	cg17764715	chr19:33622953	WDR88	0.48	6.93	0.35	2.07e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.49	7.63	0.38	2.36e-13	Birth weight;
LIHC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.51	6.22	0.32	1.46e-9	Renal function-related traits (BUN);
LIHC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg02272795	chr19:15279244	NOTCH3	-0.31	-5.75	-0.3	2.02e-8	Pulse pressure;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.51	8.97	0.44	1.95e-17	Total body bone mineral density;
LIHC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.1	10.01	0.48	7.28e-21	Diabetic retinopathy;
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.07	23.76	0.79	2.28e-74	Schizophrenia;
LIHC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	16.08	0.66	9.9e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.66	9.01	0.44	1.5e-17	Schizophrenia;
LIHC	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg00204748	chr12:29376779	FAR2	0.45	8.66	0.42	1.83e-16	QT interval;
LIHC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.78	13.14	0.58	3.32e-32	Coronary artery disease;
LIHC	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs2637266	0.600	rs2395430	chr10:78465471	G/A	cg18941641	chr10:78392320	NA	0.28	6.06	0.31	3.58e-9	Pulmonary function;
LIHC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs11673344	0.633	rs519606	chr19:37433229	C/T	cg27390819	chr19:37464633	NA	-0.49	-5.84	-0.3	1.23e-8	Obesity-related traits;
LIHC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.67	8.81	0.43	6.31e-17	Schizophrenia;
LIHC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.52	9.54	0.46	2.83e-19	Hemoglobin concentration;
LIHC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.76	14.62	0.62	6.3e-38	Crohn's disease;
LIHC	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.36	6.58	0.34	1.81e-10	Testicular germ cell tumor;
LIHC	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg03859395	chr2:55845619	SMEK2	0.86	14.22	0.61	2.18e-36	Metabolic syndrome;
LIHC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.48	6.12	0.31	2.58e-9	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.38	0.56	2.46e-29	Menopause (age at onset);
LIHC	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg21174375	chr14:64681225	SYNE2	0.4	6.38	0.33	5.7e-10	Atrial fibrillation;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.59	-9.24	-0.45	2.67e-18	Height;
LIHC	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg25019722	chr6:37503610	NA	-0.32	-5.74	-0.3	2.08e-8	Cognitive performance;
LIHC	cis	rs9918079	0.560	rs13147590	chr4:15621188	A/G	cg21123203	chr4:15471301	CC2D2A	0.43	6.78	0.34	5.4e-11	Obesity-related traits;
LIHC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.35	-6.69	-0.34	9.26e-11	Body mass index;
LIHC	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.81	0.3	1.45e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg10208301	chr11:6592745	DNHD1	0.45	6.48	0.33	3.22e-10	Coronary artery calcification;
LIHC	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.29	-0.32	9.83e-10	Prevalent atrial fibrillation;
LIHC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg07706471	chr12:123319906	HIP1R	-0.62	-8.2	-0.41	4.94e-15	Schizophrenia;
LIHC	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.86	0.39	5.19e-14	Corneal astigmatism;
LIHC	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.46	-6.96	-0.35	1.7e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.41	-0.53	8.75e-26	Chronic sinus infection;
LIHC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg03735888	chr19:58951602	ZNF132	0.39	6.92	0.35	2.31e-11	Uric acid clearance;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12960782	chr5:59996455	DEPDC1B	0.46	7.17	0.36	4.73e-12	Cognitive function;
LIHC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.47	-7.8	-0.39	7.41e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.64	0.34	1.25e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06350524	chr2:169747178	SPC25	-0.48	-6.5	-0.33	2.88e-10	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.69	7.42	0.37	9.12e-13	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05468429	chr6:7248862	RREB1	0.45	6.65	0.34	1.17e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.67	9.5	0.46	3.84e-19	Multiple sclerosis;
LIHC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	1.06	16.14	0.66	5.7e-44	Breast cancer;
LIHC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.79	10.1	0.48	3.61e-21	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05513509	chr18:20513742	RBBP8	-0.43	-6.05	-0.31	3.76e-9	Pancreatic cancer;
LIHC	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.32	-0.45	1.49e-18	Type 2 diabetes;
LIHC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	5.87	0.3	1.04e-8	Schizophrenia;
LIHC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.34	-0.59	5.65e-33	Vitiligo;
LIHC	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg07382826	chr16:28625726	SULT1A1	-0.45	-6.49	-0.33	3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.46	5.99	0.31	5.3300000000000004e-09	Major depressive disorder;
LIHC	trans	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg10756647	chr7:56101905	PSPH	1.11	13.47	0.59	1.75e-33	Diabetic kidney disease;
LIHC	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.54	6.73	0.34	7.19e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.58	0.42	3.46e-16	Lymphocyte counts;
LIHC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.75	-14.05	-0.6	1.01e-35	Height;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.76	0.43	9.1e-17	Bone mineral density (hip);Bone mineral density;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00166836	chr6:149721425	MAP3K7IP2;SUMO4	0.44	6.05	0.31	3.8e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.51	-0.46	3.63e-19	Mean platelet volume;
LIHC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.02	-0.31	4.55e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.25	-13.18	-0.58	2.36e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs17106184	0.786	rs12091670	chr1:51200136	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.94	-0.35	1.98e-11	Type 2 diabetes;
LIHC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.86	-11.17	-0.52	6.42e-25	Coronary artery disease;
LIHC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg00277334	chr10:82204260	NA	-0.54	-6.72	-0.34	7.7e-11	Post bronchodilator FEV1;
LIHC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg16346588	chr10:242978	ZMYND11	0.47	5.85	0.3	1.15e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-8.19	-0.41	5.15e-15	Schizophrenia;
LIHC	cis	rs926392	0.965	rs6129166	chr20:37688825	T/C	cg16355469	chr20:37678765	NA	0.37	5.89	0.3	9.19e-9	Dialysis-related mortality;
LIHC	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.97	-0.31	5.79e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.1	-0.4	9.8e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	7.33	0.37	1.63e-12	Tonsillectomy;
LIHC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg18016565	chr1:150552671	MCL1	0.56	10.29	0.49	8.1e-22	Melanoma;
LIHC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-9.95	-0.47	1.22e-20	Asthma;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.86	0.3	1.12e-8	Calcium levels;
LIHC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21467203	chr3:49911342	NA	-0.54	-9.69	-0.46	8.77e-20	Body mass index;
LIHC	cis	rs72653721	0.938	rs12529809	chr6:10980639	C/T	cg13562911	chr6:11044106	ELOVL2	0.5	6.92	0.35	2.19e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	8.89e-15	Prudent dietary pattern;
LIHC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.59	-8.02	-0.4	1.71e-14	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.45	5.9	0.3	8.93e-9	High light scatter reticulocyte count;
LIHC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.61e-12	Bipolar disorder;
LIHC	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.4	7.74	0.39	1.15e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.39	0.33	5.52e-10	Ileal carcinoids;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.44	8.08	0.4	1.11e-14	Prudent dietary pattern;
LIHC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.79	-7.74	-0.39	1.13e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.53	0.49	1.23e-22	Vitiligo;
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.63	0.42	2.38e-16	Lymphocyte counts;
LIHC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.44	6.1	0.31	2.9e-9	Initial pursuit acceleration;
LIHC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.75	-9.27	-0.45	2.14e-18	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08252533	chr2:238875575	UBE2F	-0.41	-6.29	-0.32	9.84e-10	Pancreatic cancer;
LIHC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs2625529	0.775	rs35673773	chr15:72399886	C/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.86	-0.3	1.06e-8	Red blood cell count;
LIHC	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.62	9.44	0.45	6.16e-19	Eotaxin levels;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07677032	chr17:61819896	STRADA	0.42	6.14	0.31	2.34e-9	Prudent dietary pattern;
LIHC	cis	rs7523273	0.565	rs2796251	chr1:207903688	C/G	cg22525895	chr1:207977042	MIR29B2	-0.55	-8.32	-0.41	2.11e-15	Schizophrenia;
LIHC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg09835421	chr16:68378352	PRMT7	-0.49	-6.0	-0.31	5.16e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs965469	0.779	rs6139071	chr20:3299054	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-6.6	-0.34	1.53e-10	IFN-related cytopenia;
LIHC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.34	5.85	0.3	1.12e-8	Parkinson's disease;
LIHC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg00612595	chr21:47717864	NA	-0.36	-5.91	-0.3	8.14e-9	Testicular germ cell tumor;
LIHC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg23205692	chr1:25664452	TMEM50A	0.37	5.86	0.3	1.06e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs61542988	0.535	rs10807813	chr7:22829961	C/T	cg11367502	chr7:22862612	TOMM7	0.56	9.08	0.44	9.14e-18	Fibrinogen levels;
LIHC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.76	0.54	4.68e-27	Motion sickness;
LIHC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.66e-9	Bipolar disorder;
LIHC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11645453	chr3:52864694	ITIH4	-0.22	-6.08	-0.31	3.17e-9	Bipolar disorder;
LIHC	cis	rs72627123	0.867	rs113768127	chr14:74467839	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.63	0.42	2.42e-16	Morning vs. evening chronotype;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.64	-0.34	1.21e-10	Blood metabolite levels;
LIHC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.35	-5.73	-0.3	2.16e-8	Height;
LIHC	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg10820045	chr2:198174542	NA	0.5	7.84	0.39	5.61e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg01788221	chr16:89496183	ANKRD11	-0.37	-5.8	-0.3	1.5e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	7.46	0.37	7.01e-13	Height;
LIHC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.81	16.55	0.67	1.33e-45	Gestational age at birth (maternal effect);
LIHC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg18912006	chr12:123335444	HIP1R	-0.63	-7.58	-0.38	3.35e-13	Schizophrenia;
LIHC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11645453	chr3:52864694	ITIH4	0.22	5.96	0.31	6.38e-9	Bipolar disorder;
LIHC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.55	7.82	0.39	6.61e-14	HIV-1 control;
LIHC	cis	rs4908768	0.501	rs11121212	chr1:8725993	C/T	cg20416874	chr1:8611966	RERE	-0.64	-12.76	-0.57	8.8e-31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.46	-17.68	-0.69	3.78e-50	Breast cancer;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	0.6	8.78	0.43	8.04e-17	Prudent dietary pattern;
LIHC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg08916839	chr5:415575	AHRR	0.29	6.21	0.32	1.58e-9	Cystic fibrosis severity;
LIHC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.41	6.32	0.32	8.02e-10	Post bronchodilator FEV1;
LIHC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.46	-12.03	-0.55	4.97e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.38	6.86	0.35	3.18e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg22907277	chr7:1156413	C7orf50	0.61	5.85	0.3	1.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.38	-6.38	-0.33	5.91e-10	Educational attainment;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.85	0.43	4.74e-17	Prudent dietary pattern;
LIHC	cis	rs11577318	0.579	rs10794532	chr1:26694260	T/C	cg18121669	chr1:26560928	CCDC21	-0.49	-7.24	-0.36	3.02e-12	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-11.13	-0.52	8.81e-25	Brugada syndrome;
LIHC	trans	rs4714291	0.802	rs1474870	chr6:39980359	C/T	cg02267698	chr19:7991119	CTXN1	0.39	6.51	0.33	2.61e-10	Strep throat;
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.59	7.56	0.38	3.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg07599136	chr5:415885	AHRR	0.39	6.71	0.34	8.01e-11	Cystic fibrosis severity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14996935	chr7:91875850	KRIT1;ANKIB1	0.41	6.18	0.32	1.85e-9	Cognitive function;
LIHC	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg23091122	chr1:110024289	SYPL2	-0.51	-6.89	-0.35	2.77e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.45	-7.39	-0.37	1.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9341808	0.556	rs10455370	chr6:81040867	A/G	cg08355045	chr6:80787529	NA	-0.31	-6.2	-0.32	1.67e-9	Sitting height ratio;
LIHC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg23625390	chr15:77176239	SCAPER	0.35	6.04	0.31	4.01e-9	Blood metabolite levels;
LIHC	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg03959625	chr15:84868606	LOC388152	0.42	5.76	0.3	1.87e-8	Schizophrenia;
LIHC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg02297831	chr4:17616191	MED28	0.47	6.89	0.35	2.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.51	7.57	0.38	3.53e-13	Corneal astigmatism;
LIHC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-6.92	-0.35	2.3e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13409248	chr3:40428643	ENTPD3	0.42	6.77	0.34	5.75e-11	Renal cell carcinoma;
LIHC	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg09795085	chr6:101329169	ASCC3	-0.4	-5.78	-0.3	1.7e-8	Neuroticism;
LIHC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.08	0.44	9.16e-18	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04197313	chr15:67547198	IQCH;AAGAB	-0.44	-6.62	-0.34	1.42e-10	Cognitive function;
LIHC	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg01864836	chr14:55583639	NA	-0.41	-7.64	-0.38	2.15e-13	Protein biomarker;
LIHC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.46	7.04	0.36	1.04e-11	Height;
LIHC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02244288	chr16:89573955	SPG7	-0.31	-6.0	-0.31	4.99e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg10820045	chr2:198174542	NA	-0.58	-9.72	-0.47	6.93e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.6	0.34	1.59e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.37	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg23250157	chr14:64679961	SYNE2	0.42	6.17	0.32	1.9e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.61	-0.34	1.5e-10	Eosinophil percentage of white cells;
LIHC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.24	0.52	3.67e-25	Platelet count;
LIHC	trans	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.51	-0.38	5.36e-13	Schizophrenia;
LIHC	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.71	-8.43	-0.41	9.67e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.65	10.19	0.48	1.74e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.69	8.46	0.42	7.65e-16	Mean platelet volume;
LIHC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.39	5.84	0.3	1.23e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.5e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.64	-10.37	-0.49	4.38e-22	Inflammatory bowel disease;
LIHC	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.49	6.16	0.32	2e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.72	11.23	0.52	4.1e-25	Phospholipid levels (plasma);
LIHC	cis	rs11229555	0.574	rs12292024	chr11:58186716	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13393964	chr16:20753279	THUMPD1	0.44	6.05	0.31	3.9e-9	Pancreatic cancer;
LIHC	cis	rs16828019	0.852	rs34286980	chr1:41608389	A/G	cg20697417	chr1:41786797	NA	0.35	6.64	0.34	1.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	6.83	0.35	3.81e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.76e-11	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.48	7.01	0.35	1.25e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09825030	chr2:85568866	NA	0.45	6.09	0.31	3.06e-9	Hepatitis;
LIHC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.55	9.14	0.44	5.79e-18	Colorectal cancer;
LIHC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.5	-0.53	4.41e-26	Coronary artery disease;
LIHC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs244293	0.931	rs2787484	chr17:53210120	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.45	-0.37	7.67e-13	Menarche (age at onset);
LIHC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.46	-5.93	-0.31	7.62e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.7	-15.3	-0.64	1.32e-40	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.74	8.96	0.44	2.1e-17	Cognitive function;
LIHC	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-5.92	-0.3	7.99e-9	Resting heart rate;
LIHC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.93	-0.31	7.49e-9	Personality dimensions;
LIHC	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.35	7.15	0.36	5.23e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.69	-10.61	-0.5	6.52e-23	Eosinophil percentage of white cells;
LIHC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.09	-0.31	3.08e-9	Bipolar disorder;
LIHC	cis	rs716804	0.740	rs10840385	chr11:10307636	T/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.78	-0.3	1.64e-8	Neuroticism;
LIHC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6977660	0.943	rs6959678	chr7:19821759	C/A	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg10281770	chr17:80606947	WDR45L	0.71	12.24	0.55	8.34e-29	Breast cancer;
LIHC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg16479474	chr6:28041457	NA	0.38	6.44	0.33	4.05e-10	Parkinson's disease;
LIHC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.84	13.68	0.59	2.79e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg23791538	chr6:167370224	RNASET2	-0.44	-7.23	-0.36	3.21e-12	Crohn's disease;
LIHC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.25	-0.41	3.37e-15	Chronic sinus infection;
LIHC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00152838	chr16:24741724	TNRC6A	0.49	6.15	0.32	2.19e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3780378	0.875	rs10115312	chr9:5003973	G/T	cg02405213	chr9:5042618	JAK2	-0.47	-7.91	-0.39	3.6e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.39	6.63	0.34	1.34e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg05527609	chr1:210001259	C1orf107	0.43	6.34	0.32	7.27e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg04306507	chr14:55594613	LGALS3	0.32	6.12	0.31	2.51e-9	Protein biomarker;
LIHC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.43	5.88	0.3	9.81e-9	Initial pursuit acceleration;
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.27	-0.37	2.51e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg11861562	chr11:117069780	TAGLN	-0.48	-7.88	-0.39	4.56e-14	Blood protein levels;
LIHC	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.25	-0.36	2.81e-12	IgG glycosylation;
LIHC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13104704	chr22:24192004	NA	0.48	7.16	0.36	4.93e-12	Cognitive function;
LIHC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.75	12.55	0.56	5.49e-30	Mean platelet volume;
LIHC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-12.32	-0.55	3.93e-29	Alzheimer's disease (late onset);
LIHC	cis	rs16828019	0.852	rs12048187	chr1:41616183	A/G	cg03962019	chr1:41807865	NA	0.53	7.51	0.38	5.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg22705602	chr4:152727874	NA	-0.31	-6.44	-0.33	4.04e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.25	-0.32	1.23e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.69	7.06	0.36	9.61e-12	Alzheimer's disease;
LIHC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	9.9	0.47	1.76e-20	Chronic sinus infection;
LIHC	trans	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg00571809	chr1:3397113	ARHGEF16	0.38	6.17	0.32	1.91e-9	Schizophrenia;
LIHC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.62	6.46	0.33	3.53e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.5	8.89	0.43	3.7e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg19680672	chr10:131412579	MGMT	-0.42	-6.58	-0.34	1.75e-10	Response to temozolomide;
LIHC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.9	-12.49	-0.56	9.66e-30	Diastolic blood pressure;
LIHC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.97	0.35	1.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg07322936	chr10:88137208	NA	0.45	5.87	0.3	1.03e-8	Schizophrenia;
LIHC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7095607	0.704	rs6480309	chr10:69953066	G/A	cg18986048	chr10:69913749	MYPN	0.43	6.53	0.33	2.36e-10	Lung function (FVC);
LIHC	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.62	-11.78	-0.54	4.19e-27	Neurofibrillary tangles;
LIHC	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.95	-12.38	-0.56	2.37e-29	Obesity-related traits;
LIHC	cis	rs2257205	0.667	rs9916423	chr17:56773834	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-6.56	-0.33	2e-10	Pancreatic cancer;
LIHC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	15.8	0.65	1.29e-42	Nonalcoholic fatty liver disease;
LIHC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.89e-30	Menopause (age at onset);
LIHC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.86	-0.39	4.89e-14	Morning vs. evening chronotype;
LIHC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	0.6	10.97	0.51	3.36e-24	Fat distribution (HIV);
LIHC	cis	rs2933343	1.000	rs1683776	chr3:128622760	G/T	cg25356066	chr3:128598488	ACAD9	0.52	6.77	0.34	5.59e-11	IgG glycosylation;
LIHC	cis	rs2016586	0.802	rs2009168	chr22:36117854	A/G	cg26342177	chr22:36113512	APOL5	0.4	6.81	0.35	4.37e-11	Body mass index;
LIHC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg26566898	chr11:117069891	TAGLN	0.47	7.36	0.37	1.39e-12	Blood protein levels;
LIHC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	6.03	0.31	4.24e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.46	-7.51	-0.38	5.36e-13	Cognitive function;
LIHC	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-9.97	-0.47	1.01e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24229701	chr12:130821962	PIWIL1	0.45	6.82	0.35	4.24e-11	Menopause (age at onset);
LIHC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.75	-14.74	-0.62	2.01e-38	Height;
LIHC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.73	6.52	0.33	2.58e-10	Mean corpuscular hemoglobin;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27555392	chr1:16679092	FBXO42	0.47	6.8	0.35	4.68e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.56	7.29	0.37	2.1e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg15892785	chr1:6309343	GPR153	-0.49	-5.82	-0.3	1.39e-8	QT interval;
LIHC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg00277334	chr10:82204260	NA	-0.51	-6.4	-0.33	5.12e-10	Post bronchodilator FEV1;
LIHC	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg12661370	chr5:149340060	SLC26A2	-0.55	-6.65	-0.34	1.16e-10	HIV-1 control;
LIHC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg17135325	chr3:160939158	NMD3	0.58	8.15	0.4	6.81e-15	Parkinson's disease;
LIHC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-0.8	-6.73	-0.34	7.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	trans	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg26939375	chr7:64535504	NA	-0.44	-7.05	-0.36	1.01e-11	Aortic root size;
LIHC	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.41	6.73	0.34	6.99e-11	Lewy body disease;
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08677398	chr8:58056175	NA	0.41	6.32	0.32	8.32e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.78	6.12	0.31	2.63e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.51	8.14	0.4	7.61e-15	Schizophrenia;
LIHC	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg21016266	chr12:122356598	WDR66	-0.38	-5.98	-0.31	5.52e-9	Mean corpuscular volume;
LIHC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs7227401	1.000	rs7227401	chr18:21938658	G/T	cg27130769	chr7:5417105	TNRC18	0.69	6.18	0.32	1.83e-9	Osteoporosis-related phenotypes;
LIHC	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.84	7.2	0.36	3.88e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.48	7.71	0.38	1.37e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.78	12.04	0.55	4.41e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.64	6.86	0.35	3.25e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	7.11	0.36	6.65e-12	Menarche (age at onset);
LIHC	cis	rs847649	0.699	rs10241865	chr7:102527517	G/A	cg18108683	chr7:102477205	FBXL13	-0.48	-7.41	-0.37	1.03e-12	Morning vs. evening chronotype;
LIHC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.33	-6.46	-0.33	3.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.37	0.56	2.56e-29	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs611744	0.967	rs645241	chr8:109190963	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.51	-0.46	3.55e-19	Gut microbiome composition (summer);
LIHC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.36	-0.33	6.6e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg12698662	chr3:15914712	MIR563	0.35	6.54	0.33	2.23e-10	Mean platelet volume;
LIHC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.74	-0.3	2.1e-8	Body mass index;
LIHC	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.33	-0.32	7.6e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs55665837	0.701	rs10160597	chr11:14603992	G/A	cg25251204	chr11:14927456	NA	0.43	6.0	0.31	4.94e-9	Vitamin D levels;
LIHC	cis	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg00576331	chr11:65640516	EFEMP2	-0.41	-5.86	-0.3	1.07e-8	DNA methylation (variation);
LIHC	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08893839	chr5:154027129	NA	0.49	6.69	0.34	8.95e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs600806	0.778	rs1525916	chr1:110010949	A/G	cg10127483	chr1:110009974	SYPL2	0.45	5.75	0.3	1.95e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg20487152	chr13:99095054	FARP1	-0.37	-6.18	-0.32	1.82e-9	Longevity;
LIHC	trans	rs1432089	0.773	rs72700812	chr4:171785370	C/A	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.89	-10.94	-0.51	4.26e-24	Primary sclerosing cholangitis;
LIHC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.51	7.26	0.37	2.58e-12	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.3	6.49	0.33	3.01e-10	Pulmonary function;
LIHC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.45	-5.88	-0.3	1e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs546131	0.642	rs1949046	chr11:34836989	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.28	-0.32	1.01e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.68	-10.98	-0.51	3.04e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.76	9.07	0.44	9.49e-18	Menarche (age at onset);
LIHC	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg27386326	chr11:61587980	NA	0.7	14.97	0.63	2.57e-39	Trans fatty acid levels;
LIHC	cis	rs11958404	0.615	rs10061079	chr5:157449968	G/C	cg05962755	chr5:157440814	NA	0.59	7.83	0.39	6.15e-14	IgG glycosylation;
LIHC	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.37	-6.72	-0.34	7.52e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17554472	chr22:41940697	POLR3H	0.51	5.81	0.3	1.45e-8	Vitiligo;
LIHC	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg11642891	chr2:3452563	TTC15	-0.45	-7.19	-0.36	4.2e-12	Obesity-related traits;
LIHC	cis	rs7810240	0.967	rs2373695	chr7:150083090	C/T	cg10018233	chr7:150070692	REPIN1	-0.41	-6.52	-0.33	2.45e-10	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LIHC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.96	-0.31	6.31e-9	Calcium levels;
LIHC	cis	rs332507	0.571	rs2291988	chr3:124369650	T/C	cg05980111	chr3:124395277	KALRN	0.31	6.03	0.31	4.23e-9	Plateletcrit;
LIHC	trans	rs7448080	0.702	rs76712096	chr5:123344307	A/G	cg23779626	chr6:33864747	NA	-0.59	-6.06	-0.31	3.62e-9	Alcohol dependence (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09920427	chr19:12777674	MORG1;MAN2B1	0.43	7.12	0.36	6.28e-12	Cognitive function;
LIHC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02251663	chr11:14281053	SPON1	-0.42	-5.81	-0.3	1.41e-8	Mitochondrial DNA levels;
LIHC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.48	-7.11	-0.36	6.69e-12	Height;
LIHC	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.55	-7.8	-0.39	7.8e-14	Response to antineoplastic agents;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25404025	chr5:52777789	FST	-0.39	-6.3	-0.32	9.42e-10	Migraine with aura;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25846302	chr15:102501640	WASH3P	0.5	6.65	0.34	1.17e-10	Hepatitis;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.74	-0.47	5.88e-20	Initial pursuit acceleration;
LIHC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.18	-0.36	4.45e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Hypertriglyceridemia;
LIHC	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.84	-0.3	1.24e-8	Biliary atresia;
LIHC	cis	rs9596863	0.898	rs9563174	chr13:54335298	G/A	ch.13.53330881F	chr13:54432880	NA	0.45	6.18	0.32	1.78e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs507080	0.769	rs570836	chr11:118512162	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	5.83	0.3	1.29e-8	Serum metabolite levels;
LIHC	trans	rs10411161	0.748	rs58120918	chr19:52368346	C/T	cg22319618	chr22:45562946	NUP50	-0.53	-6.52	-0.33	2.49e-10	Breast cancer;
LIHC	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg11502198	chr6:26597334	ABT1	0.41	5.76	0.3	1.86e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg12463550	chr7:65579703	CRCP	-0.72	-7.57	-0.38	3.61e-13	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01812826	chr8:123793836	ZHX2	0.42	6.03	0.31	4.14e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.58	0.46	1.99e-19	Bipolar disorder;
LIHC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-8.43	-0.41	9.5e-16	Bipolar disorder;
LIHC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg02297831	chr4:17616191	MED28	0.42	6.66	0.34	1.13e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg05941027	chr17:61774174	LIMD2	0.3	5.99	0.31	5.18e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3857067	1.000	rs7685048	chr4:95027784	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.35	-0.37	1.43e-12	QT interval;
LIHC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.46	6.43	0.33	4.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.24	-16.01	-0.65	1.96e-43	Diabetic kidney disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16910340	chr3:28390302	AZI2	0.46	6.62	0.34	1.39e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12271800	chr19:59028764	ZBTB45	0.39	6.16	0.32	2.07e-9	Immature fraction of reticulocytes;
LIHC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.47	-8.52	-0.42	5.13e-16	Colorectal cancer;
LIHC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	6.03	0.31	4.29e-9	Cognitive test performance;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs2979489	0.891	rs16877096	chr8:30364388	T/C	cg26383811	chr8:30366931	RBPMS	-0.77	-12.63	-0.56	2.88e-30	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.42	-0.37	9.63e-13	Psoriasis;
LIHC	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.53	-6.02	-0.31	4.53e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	1.01	10.14	0.48	2.67e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.81	12.73	0.57	1.24e-30	Glomerular filtration rate (creatinine);
LIHC	trans	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg03814316	chr16:29997655	TAOK2	0.41	6.35	0.32	6.99e-10	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg02527881	chr3:46936655	PTH1R	-0.54	-11.92	-0.54	1.2e-27	Birth weight;
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.46	5.82	0.3	1.34e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.63	10.19	0.48	1.86e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.36	0.33	6.48e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.52	-10.55	-0.5	1.01e-22	Late-onset Alzheimer's disease;
LIHC	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg19774624	chr17:42201019	HDAC5	0.66	9.92	0.47	1.47e-20	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.47	-7.51	-0.38	5.1e-13	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06649899	chr16:67261154	TMEM208;LRRC29	0.45	6.62	0.34	1.39e-10	Pancreatic cancer;
LIHC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg13699009	chr12:122356056	WDR66	-0.46	-7.71	-0.38	1.35e-13	Mean corpuscular volume;
LIHC	cis	rs4908768	0.501	rs12061328	chr1:8531963	C/T	cg20416874	chr1:8611966	RERE	-0.68	-14.66	-0.62	4.19e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg17328964	chr8:145687451	CYHR1	0.46	7.53	0.38	4.68e-13	Age at first birth;
LIHC	cis	rs6001982	0.541	rs7284768	chr22:41047764	C/T	cg14879645	chr22:41048474	NA	-0.4	-5.81	-0.3	1.46e-8	Breast cancer;
LIHC	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.87	0.57	3.54e-31	Monocyte count;
LIHC	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.27	0.49	9.73e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg16377998	chr18:6284498	L3MBTL4	0.37	6.34	0.32	7.34e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03258011	chr17:54857409	NA	0.42	6.3	0.32	9.01e-10	Cognitive function;
LIHC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	12.32	0.55	3.94e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs919433	0.756	rs7575389	chr2:198198489	A/G	cg03934865	chr2:198174659	NA	-0.54	-8.38	-0.41	1.42e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.15	-0.32	2.22e-9	Total body bone mineral density;
LIHC	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.9	0.3	8.61e-9	Lung cancer;
LIHC	cis	rs2710642	0.721	rs6757128	chr2:62891752	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-7.16	-0.36	4.81e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg15841412	chr13:111365552	ING1	-0.47	-5.9	-0.3	8.7e-9	Coronary artery disease;
LIHC	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.15	-0.32	2.2e-9	Mean corpuscular volume;
LIHC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.26	-0.58	1.16e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs7945718	0.811	rs7104832	chr11:12786489	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.76	0.39	9.99e-14	Educational attainment (years of education);
LIHC	cis	rs3770081	1.000	rs2278087	chr2:86281946	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.69	-0.43	1.57e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.42	-6.85	-0.35	3.35e-11	Response to temozolomide;
LIHC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-8.97	-0.44	1.97e-17	Bipolar disorder;
LIHC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.6	8.03	0.4	1.57e-14	Neutrophil percentage of white cells;
LIHC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.6	9.09	0.44	8.26e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.61	7.28	0.37	2.36e-12	Cognitive function;
LIHC	trans	rs9356009	0.764	rs9347727	chr6:158293573	T/C	cg16165903	chr3:32023351	ZNF860;OSBPL10	0.65	6.29	0.32	9.64e-10	Lipoprotein (a) - cholesterol levels;
LIHC	cis	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg19752551	chr11:57585705	CTNND1	-0.46	-5.98	-0.31	5.62e-9	Blood protein levels;
LIHC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.2	-0.32	1.63e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.48e-14	Aortic root size;
LIHC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.72	-0.34	7.74e-11	Psoriasis;
LIHC	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg18404041	chr3:52824283	ITIH1	-0.59	-9.64	-0.46	1.31e-19	Bipolar disorder;
LIHC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg00935119	chr6:36647544	CDKN1A	0.46	6.51	0.33	2.6200000000000003e-10	QRS duration;
LIHC	cis	rs6001982	0.541	rs6002000	chr22:41051109	G/A	cg14879645	chr22:41048474	NA	0.4	5.8	0.3	1.53e-8	Breast cancer;
LIHC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.34	5.79	0.3	1.61e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	6.37	0.33	6.06e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	9.12	0.44	6.36e-18	Lymphocyte counts;
LIHC	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.68	-0.34	9.67e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg05941027	chr17:61774174	LIMD2	0.31	6.19	0.32	1.69e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.77	10.1	0.48	3.62e-21	Body mass index;
LIHC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.52	-0.38	5.01e-13	Aortic root size;
LIHC	cis	rs4788570	0.615	rs11075894	chr16:71690030	C/T	cg06353428	chr16:71660113	MARVELD3	1.44	15.51	0.64	1.81e-41	Intelligence (multi-trait analysis);
LIHC	cis	rs2380220	0.808	rs2716072	chr6:95909773	A/G	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.47	-6.61	-0.34	1.5e-10	Electroencephalogram traits;
LIHC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.25	-0.32	1.19e-9	Mean corpuscular volume;
LIHC	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg22138327	chr13:27999177	GTF3A	0.76	6.15	0.32	2.16e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02963556	chr12:132588637	EP400NL	0.42	6.11	0.31	2.76e-9	Immature fraction of reticulocytes;
LIHC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.42	-0.37	9.47e-13	Obesity-related traits;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.63	9.27	0.45	2.11e-18	Menarche (age at onset);
LIHC	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs3106136	0.843	rs724260	chr4:95260685	A/G	cg11021082	chr4:95130006	SMARCAD1	0.41	7.31	0.37	1.85e-12	Capecitabine sensitivity;
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.35	5.82	0.3	1.34e-8	Height;
LIHC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.81	9.67	0.46	1.06e-19	Cognitive function;
LIHC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.88	-12.82	-0.57	5.58e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.54	-0.33	2.2e-10	Metabolite levels;
LIHC	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-8.11	-0.4	9.04e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg03037974	chr15:76606532	NA	-0.6	-10.09	-0.48	4.04e-21	Blood metabolite levels;
LIHC	cis	rs10845606	0.781	rs7972866	chr12:12828320	C/T	cg09462578	chr12:12878428	APOLD1	-0.46	-6.87	-0.35	2.99e-11	Systemic lupus erythematosus;
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03526160	chr20:43586170	TOMM34	-0.42	-6.25	-0.32	1.19e-9	Gut microbiome composition (summer);
LIHC	cis	rs6750047	0.549	rs151096	chr2:38316571	A/C	cg07380506	chr2:38303506	CYP1B1	-0.45	-5.96	-0.31	6.12e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg06363034	chr20:62225388	GMEB2	-0.43	-7.29	-0.37	2.13e-12	Glioblastoma;
LIHC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg07689907	chr11:61582574	FADS1	0.39	5.79	0.3	1.58e-8	Trans fatty acid levels;
LIHC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.32	-6.72	-0.34	7.49e-11	Platelet distribution width;
LIHC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.6	-7.39	-0.37	1.13e-12	Lung cancer in ever smokers;
LIHC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.61	-7.32	-0.37	1.77e-12	Mean platelet volume;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg22528358	chr1:107598549	PRMT6	-0.67	-11.45	-0.53	6.46e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.38	-6.95	-0.35	1.81e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.41	6.5	0.33	2.93e-10	Blood protein levels;
LIHC	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.01	-0.31	4.7e-9	Coronary artery disease;
LIHC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg03146154	chr1:46216737	IPP	0.48	8.08	0.4	1.12e-14	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1432089	0.773	rs2877574	chr4:171783865	T/C	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.9	-16.35	-0.66	8.55e-45	Height;
LIHC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00152838	chr16:24741724	TNRC6A	-0.49	-6.04	-0.31	4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	9.12	0.44	6.8e-18	Lung cancer;
LIHC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.43	6.72	0.34	7.79e-11	Methadone dose in opioid dependence;
LIHC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.35	1.25e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.82e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.01	-0.35	1.24e-11	Bipolar disorder;
LIHC	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg27203090	chr3:33138513	GLB1;TMPPE	-0.55	-6.91	-0.35	2.4e-11	Major depressive disorder;
LIHC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg18867708	chr6:26865862	GUSBL1	0.52	7.85	0.39	5.3e-14	Schizophrenia;
LIHC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.45	-8.7	-0.43	1.45e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.15	-0.48	2.55e-21	Platelet count;
LIHC	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	6.57	0.33	1.89e-10	Response to antipsychotic treatment;
LIHC	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg00204512	chr16:28754710	NA	-0.37	-6.44	-0.33	4.15e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.93e-11	Ileal carcinoids;
LIHC	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.5	7.44	0.37	8.06e-13	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs11971779	0.650	rs4732380	chr7:139126859	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	9.92	0.47	1.46e-20	Diisocyanate-induced asthma;
LIHC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.49	6.93	0.35	2.1e-11	Orofacial clefts;
LIHC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg02297831	chr4:17616191	MED28	0.41	6.64	0.34	1.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6722750	0.783	rs11125991	chr2:64387765	A/G	cg22352474	chr2:64371530	PELI1	0.46	6.6	0.34	1.59e-10	Neuroticism;
LIHC	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-9.89	-0.47	1.96e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.6	-10.74	-0.5	2.18e-23	Breast cancer;
LIHC	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.14	-0.4	7.54e-15	Exhaled nitric oxide output;
LIHC	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg09238746	chr17:78121135	EIF4A3	-0.87	-13.78	-0.6	1.11e-34	Yeast infection;
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-9.88	-0.47	2.12e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	6.81	0.35	4.42e-11	Renal cell carcinoma;
LIHC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.28	6.7	0.34	8.68e-11	Primary biliary cholangitis;
LIHC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg05590025	chr7:65112418	INTS4L2	-0.7	-7.31	-0.37	1.88e-12	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23894291	chr15:57025234	ZNF280D	0.49	6.8	0.35	4.66e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-9.8	-0.47	3.72e-20	Asthma;
LIHC	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg14593290	chr7:50529359	DDC	-0.64	-10.27	-0.49	9.62e-22	Malaria;
LIHC	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.58	7.78	0.39	8.74e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16346588	chr10:242978	ZMYND11	0.37	5.73	0.3	2.18e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.35	7.14	0.36	5.67e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg12516959	chr21:47718080	NA	0.4	6.69	0.34	9.26e-11	Testicular germ cell tumor;
LIHC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.45	6.98	0.35	1.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg13271783	chr10:134563150	INPP5A	-0.52	-6.54	-0.33	2.18e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs918629	0.530	rs1057963	chr5:95235748	G/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.77	-0.34	5.52e-11	IgG glycosylation;
LIHC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg05714579	chr10:131428358	MGMT	0.41	6.71	0.34	7.86e-11	Response to temozolomide;
LIHC	cis	rs7116495	1.000	rs10751193	chr11:71785356	A/C	cg26138937	chr11:71823887	C11orf51	-0.78	-7.7	-0.38	1.45e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.31	-0.32	8.81e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11696739	0.513	rs2209313	chr20:1599142	A/G	cg15722679	chr20:1638393	SIRPG	-0.53	-9.56	-0.46	2.35e-19	Mean platelet volume;
LIHC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg14132834	chr19:41945861	ATP5SL	0.45	6.61	0.34	1.5e-10	Height;
LIHC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.66	-0.38	1.93e-13	Psoriasis;
LIHC	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg14593290	chr7:50529359	DDC	-0.61	-9.94	-0.47	1.31e-20	Malaria;
LIHC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.51	6.49	0.33	2.95e-10	Initial pursuit acceleration;
LIHC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-8.5	-0.42	6.08e-16	Blood metabolite levels;
LIHC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.45	6.33	0.32	7.72e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.5	7.26	0.37	2.61e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs913351	0.826	rs633858	chr9:129725493	A/G	cg14563165	chr9:130214037	LRSAM1;RPL12	0.87	6.22	0.32	1.48e-9	Lewy body disease;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13409248	chr3:40428643	ENTPD3	0.47	7.75	0.39	1.04e-13	Renal cell carcinoma;
LIHC	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.37	0.41	1.54e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.38	7.07	0.36	9.01e-12	Total body bone mineral density;
LIHC	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.38	-5.97	-0.31	5.79e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	13.29	0.58	8.87e-33	Mean platelet volume;
LIHC	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg26138937	chr11:71823887	C11orf51	-0.82	-8.15	-0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-12.82	-0.57	5.32e-31	Morning vs. evening chronotype;
LIHC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.3	0.52	2.33e-25	Colorectal cancer;
LIHC	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg06585982	chr3:143692056	C3orf58	0.58	7.58	0.38	3.23e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.55	9.42	0.45	7.17e-19	Aortic root size;
LIHC	cis	rs10771511	1	rs10771511	chr12:29437217	T/C	cg14222432	chr12:29376421	FAR2	0.31	6.42	0.33	4.67e-10	Platelet distribution width;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17258537	chr5:179401804	RNF130	0.43	6.28	0.32	1.01e-9	Bilirubin levels;
LIHC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.61	8.35	0.41	1.77e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg26138937	chr11:71823887	C11orf51	0.83	8.2	0.41	4.93e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-7.7	-0.38	1.5e-13	Uric acid levels;
LIHC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg25894440	chr7:65020034	NA	-0.53	-5.96	-0.31	6.29e-9	Diabetic kidney disease;
LIHC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.66	-9.4	-0.45	7.86e-19	Initial pursuit acceleration;
LIHC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg25039879	chr17:56429692	SUPT4H1	0.79	8.89	0.43	3.47e-17	Cognitive test performance;
LIHC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg12798992	chr6:167411361	FGFR1OP	0.46	6.72	0.34	7.71e-11	Crohn's disease;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00802000	chr16:706648	WDR90	-0.38	-6.22	-0.32	1.49e-9	Height;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg16586182	chr3:47516702	SCAP	-0.4	-6.73	-0.34	7e-11	Birth weight;
LIHC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.93	0.31	7.21e-9	Birth weight;
LIHC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.41	6.76	0.34	6.12e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.34	-8.03	-0.4	1.57e-14	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-7.13	-0.36	5.98e-12	Vitamin D levels;
LIHC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.76	-0.3	1.9e-8	Coronary artery disease;
LIHC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.7	-11.23	-0.52	4.1e-25	Lung cancer;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.78	0.43	8.04e-17	Prudent dietary pattern;
LIHC	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	7.88	0.39	4.55e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.58	8.81	0.43	6.21e-17	Tumor biomarkers;
LIHC	cis	rs6442522	0.671	rs2305616	chr3:15515695	C/T	cg16303742	chr3:15540471	COLQ	0.39	6.53	0.33	2.33e-10	Uric acid levels;
LIHC	cis	rs9322817	0.513	rs2499661	chr6:105300074	C/G	cg02098413	chr6:105308735	HACE1	0.43	7.92	0.39	3.38e-14	Thyroid stimulating hormone;
LIHC	trans	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg26939375	chr7:64535504	NA	0.41	6.48	0.33	3.12e-10	Aortic root size;
LIHC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg03934865	chr2:198174659	NA	-0.62	-10.27	-0.49	9.44e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9309473	1.000	rs6546837	chr2:73677898	G/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.83	-0.35	3.84e-11	Metabolite levels;
LIHC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg12863693	chr15:85201151	NMB	0.49	7.11	0.36	6.72e-12	Schizophrenia;
LIHC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.94	0.31	6.97e-9	Eosinophil percentage of white cells;
LIHC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.46	10.39	0.49	3.84e-22	Iron status biomarkers (transferrin levels);
LIHC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.47	6.55	0.33	2.1e-10	Morning vs. evening chronotype;
LIHC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg22079354	chr11:130786696	SNX19	0.41	5.92	0.3	7.84e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.58	10.69	0.5	3.33e-23	Leprosy;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.49	-7.82	-0.39	6.58e-14	Testicular germ cell tumor;
LIHC	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.56	6.55	0.33	2.06e-10	Mammographic density (dense area);
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg11342453	chr6:26196699	NA	0.53	5.92	0.3	7.83e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.3	0.55	4.96e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs631288	0.793	rs6681716	chr1:146707824	A/C	cg25205988	chr1:146714368	CHD1L	0.7	7.94	0.39	2.98e-14	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.47	6.63	0.34	1.3e-10	Schizophrenia;
LIHC	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.69	-10.69	-0.5	3.32e-23	Monocyte count;
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.68	-9.62	-0.46	1.52e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg18490616	chr2:88469792	THNSL2	0.65	6.6	0.34	1.54e-10	Plasma clusterin levels;
LIHC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.36	0.33	6.62e-10	Renal cell carcinoma;
LIHC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.01	15.55	0.64	1.32e-41	Orofacial clefts;
LIHC	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg20636351	chr8:55087400	NA	-0.36	-7.31	-0.37	1.87e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs77861329	1.000	rs9843299	chr3:52137469	G/T	cg08692210	chr3:52188851	WDR51A	0.83	7.55	0.38	4.05e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.52	7.48	0.37	6.35e-13	Schizophrenia;
LIHC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg16586182	chr3:47516702	SCAP	-0.5	-8.93	-0.43	2.66e-17	Colorectal cancer;
LIHC	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.52	-7.99	-0.4	2.15e-14	Waist circumference;Body mass index;
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12516959	chr21:47718080	NA	0.37	6.14	0.32	2.3e-9	Testicular germ cell tumor;
LIHC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	15.12	0.63	6.51e-40	IgG glycosylation;
LIHC	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg21252483	chr19:49399788	TULP2	-0.6	-9.52	-0.46	3.25e-19	Red cell distribution width;
LIHC	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.34	-0.45	1.31e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs4919087	0.590	rs7915926	chr10:99054052	C/T	cg25902810	chr10:99078978	FRAT1	-0.64	-7.08	-0.36	8.39e-12	Monocyte count;
LIHC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.46	-7.53	-0.38	4.48e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.84	0.35	3.69e-11	Dermatomyositis;
LIHC	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.47	-7.11	-0.36	6.91e-12	Adiposity;
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg20607798	chr8:58055168	NA	0.66	8.39	0.41	1.26e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-0.82	-10.24	-0.48	1.2e-21	Blood pressure (smoking interaction);
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg02993280	chr1:107599747	PRMT6	-0.61	-9.76	-0.47	5.01e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-9.57	-0.46	2.24e-19	Ulcerative colitis;
LIHC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg05896524	chr21:47604654	C21orf56	0.46	7.01	0.35	1.32e-11	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.61	9.44	0.45	6.16e-19	Height;
LIHC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-15.01	-0.63	1.81e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.36	5.76	0.3	1.89e-8	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg01339444	chr6:118972232	C6orf204	0.59	5.82	0.3	1.32e-8	Diastolic blood pressure;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08326511	chr2:120124503	C2orf76;DBI	-0.45	-6.04	-0.31	4.11e-9	Hepatitis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21250466	chr4:854474	GAK	-0.41	-6.09	-0.31	2.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.57	-0.5	8.62e-23	Platelet count;
LIHC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21467203	chr3:49911342	NA	0.52	9.35	0.45	1.18e-18	Body mass index;
LIHC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.86	-14.42	-0.62	3.58e-37	Body mass index;
LIHC	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.23	-0.32	1.39e-9	Educational attainment (college completion);
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg17723122	chr1:205641542	SLC45A3	0.38	5.75	0.3	1.99e-8	Menarche (age at onset);
LIHC	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg12046867	chr14:103022105	NA	0.43	6.71	0.34	8e-11	Platelet count;
LIHC	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.32	-7.07	-0.36	8.52e-12	Congenital heart disease (maternal effect);
LIHC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg10932868	chr11:921992	NA	0.34	6.35	0.32	6.92e-10	Alzheimer's disease (late onset);
LIHC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.72	-13.44	-0.59	2.39e-33	Height;
LIHC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.25	-5.87	-0.3	1.05e-8	Subjective well-being;
LIHC	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.22	-0.41	4.13e-15	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg21734168	chr11:67353974	GSTP1	-0.28	-6.75	-0.34	6.38e-11	Mean corpuscular volume;
LIHC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.48	5.72	0.3	2.37e-8	Testicular germ cell tumor;
LIHC	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.42	7.97	0.4	2.39e-14	Height;
LIHC	cis	rs11871801	0.541	rs4793090	chr17:40686342	G/A	cg14558262	chr17:40713999	COASY	-0.57	-8.83	-0.43	5.54e-17	Crohn's disease;
LIHC	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.33	7.72	0.39	1.32e-13	Educational attainment (years of education);
LIHC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.47	-0.33	3.48e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.64	8.32	0.41	2.18e-15	Motion sickness;
LIHC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.83	0.39	6.3e-14	Schizophrenia;
LIHC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.45	6.59	0.34	1.62e-10	Aortic root size;
LIHC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg16070123	chr10:51489643	NA	0.38	6.03	0.31	4.15e-9	Prostate-specific antigen levels;
LIHC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.8	11.02	0.51	2.29e-24	Blood metabolite levels;
LIHC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-7.79	-0.39	8.22e-14	Neuroticism;
LIHC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.56	-9.29	-0.45	1.79e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg12365402	chr11:9010492	NRIP3	0.34	8.64	0.42	2.23e-16	Hemoglobin concentration;
LIHC	cis	rs11671005	0.651	rs35117909	chr19:58912906	G/A	cg25952890	chr19:58913133	NA	0.7	7.2	0.36	3.96e-12	Mean platelet volume;
LIHC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.36	8.32	0.41	2.16e-15	Crohn's disease;
LIHC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg02640540	chr1:67518911	SLC35D1	0.43	5.93	0.31	7.24e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg10932868	chr11:921992	NA	-0.39	-7.37	-0.37	1.28e-12	Alzheimer's disease (late onset);
LIHC	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.33	-6.28	-0.32	1.03e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.78	-8.51	-0.42	5.6e-16	Exhaled nitric oxide output;
LIHC	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.84	14.74	0.62	2.06e-38	Body mass index;
LIHC	trans	rs2537594	0.936	rs1404418	chr7:17814085	A/T	cg21197435	chr1:23671362	HNRNPR	0.42	6.04	0.31	3.92e-9	Mean corpuscular hemoglobin;
LIHC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.71	0.54	7.1e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.43	5.94	0.31	6.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.7	-10.46	-0.49	2.05e-22	Platelet count;
LIHC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.38	-6.59	-0.34	1.66e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.48	7.0	0.35	1.39e-11	Smoking behavior;
LIHC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.46	5.95	0.31	6.52e-9	Mean platelet volume;
LIHC	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.19	-0.32	1.72e-9	Blood metabolite levels;
LIHC	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.37	-5.85	-0.3	1.15e-8	Hypospadias;
LIHC	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-8.03	-0.4	1.61e-14	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg25894440	chr7:65020034	NA	-0.56	-6.48	-0.33	3.21e-10	Diabetic kidney disease;
LIHC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.28	0.41	2.8e-15	Lung cancer;
LIHC	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.77	-0.34	5.57e-11	Schizophrenia;
LIHC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.66	10.72	0.5	2.52e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.81	0.54	3.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg02269571	chr22:50332266	NA	0.63	8.4	0.41	1.18e-15	Schizophrenia;
LIHC	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.5	-0.33	2.86e-10	Metabolite levels;
LIHC	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.5	8.06	0.4	1.3e-14	Corneal astigmatism;
LIHC	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg17218026	chr1:154582156	ADAR	0.33	6.35	0.32	6.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-6.42	-0.33	4.43e-10	Height;
LIHC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg03859395	chr2:55845619	SMEK2	0.85	15.1	0.63	7.58e-40	Metabolic syndrome;
LIHC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.99	0.51	2.93e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.45	-12.12	-0.55	2.26e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.69	12.85	0.57	4.29e-31	Schizophrenia;
LIHC	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.62	9.27	0.45	2.11e-18	Type 2 diabetes;
LIHC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.3	-6.01	-0.31	4.72e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.53	8.01	0.4	1.8e-14	Uric acid clearance;
LIHC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.52	-15.89	-0.65	5.89e-43	Breast cancer;
LIHC	cis	rs903552	1.000	rs12908310	chr15:102003635	A/G	cg06707286	chr15:102010195	PCSK6	-0.44	-6.33	-0.32	7.48e-10	Diabetic kidney disease;
LIHC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg05425664	chr17:57184151	TRIM37	-0.44	-6.11	-0.31	2.64e-9	Testicular germ cell tumor;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02119073	chr17:77984409	TBC1D16	0.41	6.52	0.33	2.55e-10	Immature fraction of reticulocytes;
LIHC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg19774624	chr17:42201019	HDAC5	-0.42	-5.93	-0.31	7.55e-9	Total body bone mineral density;
LIHC	cis	rs74233809	0.901	rs12416331	chr10:104928914	T/A	cg03493300	chr10:104813866	CNNM2	0.45	5.85	0.3	1.14e-8	Birth weight;
LIHC	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.63	8.77	0.43	8.59e-17	Neuroticism;
LIHC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-10.62	-0.5	5.66e-23	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24508996	chr1:16057163	PLEKHM2	-0.38	-6.05	-0.31	3.7e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.27	-0.32	1.11e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg01557791	chr16:72042693	DHODH	-0.43	-7.11	-0.36	6.79e-12	Fibrinogen levels;
LIHC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.72	-10.35	-0.49	5.27e-22	Lung cancer in ever smokers;
LIHC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02985541	chr2:219472218	PLCD4	0.45	8.68	0.42	1.62e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22168489	chr12:122356033	WDR66	0.46	6.52	0.33	2.53e-10	Mean corpuscular volume;
LIHC	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg07541023	chr7:19748670	TWISTNB	0.4	5.85	0.3	1.13e-8	Thyroid stimulating hormone;
LIHC	cis	rs4788570	0.615	rs7193549	chr16:71649416	T/C	cg06353428	chr16:71660113	MARVELD3	1.45	15.74	0.65	2.22e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.93	11.77	0.54	4.3e-27	Coronary artery disease;
LIHC	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg03934865	chr2:198174659	NA	-0.46	-6.69	-0.34	9.33e-11	Dermatomyositis;
LIHC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.69	-0.34	8.96e-11	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg07424592	chr7:64974309	NA	0.81	9.2	0.45	3.52e-18	Diabetic kidney disease;
LIHC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.35	-6.11	-0.31	2.75e-9	IgG glycosylation;
LIHC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.4	8.77	0.43	8.77e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.37	6.21	0.32	1.5e-9	Monobrow;
LIHC	cis	rs8064024	0.599	rs882235	chr16:4931651	C/T	cg08329684	chr16:4932620	PPL	0.35	5.9	0.3	8.87e-9	Cancer;
LIHC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg18306943	chr3:40428807	ENTPD3	0.34	6.06	0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.94	-0.35	1.98e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg06766960	chr11:133703094	NA	-0.65	-10.94	-0.51	4.36e-24	Childhood ear infection;
LIHC	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-1.06	-12.26	-0.55	6.67e-29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4908768	0.906	rs114812780	chr1:8528854	G/T	cg25722041	chr1:8623473	RERE	0.41	5.86	0.3	1.11e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	7.48	0.37	6.53e-13	Parkinson's disease;
LIHC	cis	rs13161895	0.702	rs73810942	chr5:179499267	C/A	cg06664874	chr5:179499304	RNF130	0.68	7.29	0.37	2.15e-12	LDL cholesterol;
LIHC	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.8	11.03	0.51	2.11e-24	Body mass index;
LIHC	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.48	6.37	0.33	6.24e-10	IFN-related cytopenia;
LIHC	cis	rs9378688	0.654	rs2505658	chr6:2329626	C/T	cg12303981	chr6:2244766	GMDS	-0.45	-6.08	-0.31	3.2e-9	Caudate nucleus volume;
LIHC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.59	-0.5	7.37e-23	Alzheimer's disease;
LIHC	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.49	-9.29	-0.45	1.82e-18	Endometriosis;
LIHC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg13409248	chr3:40428643	ENTPD3	0.39	6.31	0.32	8.42e-10	Renal cell carcinoma;
LIHC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.06	0.31	3.55e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.28	0.55	5.86e-29	Cognitive test performance;
LIHC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte percentage of white cells;
LIHC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg03959625	chr15:84868606	LOC388152	0.48	6.75	0.34	6.18e-11	Schizophrenia;
LIHC	cis	rs2834188	1.000	rs4408796	chr21:34698741	C/G	cg14352951	chr21:34696688	IFNAR1	-0.48	-6.65	-0.34	1.16e-10	Narcolepsy;
LIHC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.6	8.33	0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg02297831	chr4:17616191	MED28	0.42	6.69	0.34	9.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.08	-0.36	8.34e-12	Heart rate;
LIHC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg27433088	chr4:174089019	GALNT7	0.38	6.93	0.35	2.07e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg11764359	chr7:65958608	NA	-0.56	-5.87	-0.3	1.03e-8	Diabetic kidney disease;
LIHC	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.92e-12	Growth-regulated protein alpha levels;
LIHC	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-20.23	-0.74	2.18e-60	Exhaled nitric oxide output;
LIHC	cis	rs9828933	0.577	rs832193	chr3:63854445	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.85	11.3	0.52	2.24e-25	Type 2 diabetes;
LIHC	cis	rs11031096	0.655	rs12275634	chr11:4211754	T/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.92	-0.3	7.73e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.56	-8.16	-0.4	6.58e-15	Cognitive ability;
LIHC	cis	rs10420951	0.617	rs74497531	chr19:18578178	G/A	cg10790698	chr19:18539756	SSBP4	-0.42	-5.83	-0.3	1.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.68	-13.47	-0.59	1.73e-33	Body mass index;
LIHC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg03037974	chr15:76606532	NA	0.73	14.3	0.61	1.08e-36	Blood metabolite levels;
LIHC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.5	-12.47	-0.56	1.14e-29	Alzheimer's disease (late onset);
LIHC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	10.25	0.48	1.15e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.84	-0.35	3.75e-11	Prevalent atrial fibrillation;
LIHC	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.89	17.95	0.7	3.24e-51	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg00677901	chr16:88017247	BANP	0.53	8.01	0.4	1.88e-14	Menopause (age at onset);
LIHC	cis	rs9918079	0.542	rs1789	chr4:15664535	G/A	cg21329975	chr4:15471214	CC2D2A	-0.41	-6.13	-0.31	2.37e-9	Obesity-related traits;
LIHC	trans	rs10497394	1.000	rs1435767	chr2:174299698	C/T	cg03284310	chr10:124894415	HMX3	0.51	6.23	0.32	1.37e-9	Otitis media (chronic/recurrent);
LIHC	cis	rs9322817	0.691	rs2486138	chr6:105290223	G/A	cg02098413	chr6:105308735	HACE1	0.45	8.41	0.41	1.15e-15	Thyroid stimulating hormone;
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.12	0.55	2.24e-28	Height;
LIHC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-6.04	-0.31	3.95e-9	Total body bone mineral density;
LIHC	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.81	-0.43	6.52e-17	Response to antipsychotic treatment;
LIHC	cis	rs2599510	0.811	rs2710615	chr2:32791222	A/T	cg02381751	chr2:32503542	YIPF4	0.49	6.63	0.34	1.32e-10	Interleukin-18 levels;
LIHC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.5e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.81	6.79	0.34	4.99e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs7714584	1.000	rs10065172	chr5:150227998	C/T	cg20675040	chr8:143813288	C8orf55	0.34	6.06	0.31	3.59e-9	Crohn's disease;
LIHC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.63	10.41	0.49	3.16e-22	Resting heart rate;
LIHC	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg15282417	chr9:129245246	FAM125B	0.38	6.2	0.32	1.66e-9	Intraocular pressure;
LIHC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.48	0.56	9.96e-30	Menopause (age at onset);
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.66	-0.42	1.9e-16	Obesity-related traits;
LIHC	cis	rs7116495	1.000	rs610041	chr11:71797968	A/G	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	trans	rs6600671	0.934	rs12131379	chr1:121293437	T/C	cg09829573	chr1:144692074	NBPF9	-0.41	-7.38	-0.37	1.23e-12	Hip geometry;
LIHC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.45	-7.28	-0.37	2.24e-12	Crohn's disease;
LIHC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.63	10.05	0.48	5.47e-21	Oral cavity cancer;
LIHC	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1355223	0.816	rs2136506	chr11:34748260	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.46	-0.33	3.61e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg25356066	chr3:128598488	ACAD9	0.52	6.98	0.35	1.5e-11	IgG glycosylation;
LIHC	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.57	-9.29	-0.45	1.85e-18	Menarche (age at onset);
LIHC	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg27386326	chr11:61587980	NA	0.68	14.61	0.62	6.93e-38	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.38	8.44	0.42	9.06e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.37	-6.34	-0.32	7.33e-10	Mean arterial pressure;
LIHC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg03037974	chr15:76606532	NA	0.74	14.52	0.62	1.55e-37	Blood metabolite levels;
LIHC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.53	-7.46	-0.37	7.05e-13	Body mass index;
LIHC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.13	14.81	0.63	1.06e-38	Body mass index;
LIHC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-14.54	-0.62	1.22e-37	Electrocardiographic conduction measures;
LIHC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg02269571	chr22:50332266	NA	-0.56	-7.71	-0.38	1.4e-13	Schizophrenia;
LIHC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg03735888	chr19:58951602	ZNF132	0.4	6.97	0.35	1.67e-11	Uric acid clearance;
LIHC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22168489	chr12:122356033	WDR66	-0.36	-5.89	-0.3	9.4e-9	Mean corpuscular volume;
LIHC	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.87	0.3	1.04e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg20991723	chr1:152506922	NA	0.59	10.51	0.49	1.45e-22	Hair morphology;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13409248	chr3:40428643	ENTPD3	0.49	8.22	0.41	4.34e-15	Renal cell carcinoma;
LIHC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-0.96	-22.24	-0.77	2.12e-68	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13148511	chr17:4710380	PLD2	-0.46	-6.32	-0.32	8.1e-10	Systolic blood pressure;
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.19	0.32	1.76e-9	Renal cell carcinoma;
LIHC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.26	0.49	1e-21	Fibroblast growth factor basic levels;
LIHC	trans	rs743793	0.875	rs137379	chr22:33578150	T/C	cg20274824	chr1:36638199	MAP7D1	0.46	6.42	0.33	4.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.39	7.79	0.39	8.31e-14	Renal cell carcinoma;
LIHC	trans	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg18335740	chr13:41363409	SLC25A15	0.38	6.31	0.32	8.73e-10	Lewy body disease;
LIHC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs5762813	0.566	rs28360615	chr22:29338656	G/C	cg15103426	chr22:29168792	CCDC117	0.43	6.04	0.31	3.93e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	trans	rs78049276	0.736	rs6841473	chr4:148407652	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.58	-7.06	-0.36	9.43e-12	Pulse pressure;
LIHC	cis	rs838721	1.000	rs838717	chr2:234296444	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.4	-5.82	-0.3	1.33e-8	Total body bone mineral density;
LIHC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	12.74	0.57	1.08e-30	Schizophrenia;
LIHC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.38	5.77	0.3	1.77e-8	Mean corpuscular volume;
LIHC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.61	-10.66	-0.5	4.1000000000000003e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-7.26	-0.37	2.59e-12	Asthma;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.23	-0.32	1.36e-9	Total body bone mineral density;
LIHC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg22079354	chr11:130786696	SNX19	0.41	5.82	0.3	1.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs8177876	0.915	rs6420418	chr16:81128014	G/T	cg19254163	chr11:60623782	GPR44	-0.46	-6.04	-0.31	3.96e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06656553	chr16:89960601	TCF25	-0.49	-6.18	-0.32	1.86e-9	Skin colour saturation;
LIHC	cis	rs965469	1.000	rs6051718	chr20:3270370	C/T	cg25506879	chr20:3388711	C20orf194	-0.6	-6.91	-0.35	2.43e-11	IFN-related cytopenia;
LIHC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17708016	chr12:54321992	NA	0.42	7.17	0.36	4.8e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg16970926	chr12:29381810	FAR2	0.29	6.01	0.31	4.78e-9	QT interval;
LIHC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.03	0.31	4.26e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.37	6.42	0.33	4.5e-10	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.59	0.53	1.98e-26	Prudent dietary pattern;
LIHC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.26	-0.45	2.39e-18	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.29	6.98	0.35	1.52e-11	Primary biliary cholangitis;
LIHC	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.43	6.34	0.32	7.21e-10	Neuroticism;
LIHC	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.6	0.34	1.59e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-7.04	-0.36	1.06e-11	Diabetic kidney disease;
LIHC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.87	0.35	3.14e-11	Gut microbiome composition (summer);
LIHC	cis	rs10508774	0.810	rs11008937	chr10:32728750	A/T	cg01819863	chr10:32635814	EPC1	0.61	5.87	0.3	1.03e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.59	-8.4	-0.41	1.22e-15	Blood metabolite levels;
LIHC	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.7	8.86	0.43	4.55e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-9.17	-0.44	4.37e-18	Response to antipsychotic treatment;
LIHC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.44	-0.42	9.17e-16	Total body bone mineral density;
LIHC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00958927	chr1:175162553	KIAA0040	-0.39	-6.34	-0.32	7.27e-10	Alcohol dependence;
LIHC	cis	rs6752107	0.967	rs2880080	chr2:234154139	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	7.97	0.4	2.47e-14	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg09137382	chr11:130731461	NA	0.42	6.26	0.32	1.18e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs3849570	0.555	rs4452351	chr3:82007977	C/T	cg07356753	chr3:81810745	GBE1	-0.43	-6.51	-0.33	2.64e-10	Waist circumference;Body mass index;
LIHC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.63	7.0	0.35	1.36e-11	Alzheimer's disease;
LIHC	cis	rs4919087	0.590	rs1088187	chr10:99027581	T/C	cg25902810	chr10:99078978	FRAT1	-0.57	-6.32	-0.32	7.96e-10	Monocyte count;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.33	-0.32	7.8e-10	Metabolite levels;
LIHC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.7	10.58	0.5	8.1e-23	Height;
LIHC	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg23533926	chr12:111358616	MYL2	0.33	6.37	0.33	6.13e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	16.18	0.66	4.04e-44	Lung cancer in ever smokers;
LIHC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.81	6.87	0.35	3.02e-11	Body mass index;
LIHC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-9.04	-0.44	1.23e-17	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20979128	chr1:16271176	ZBTB17	0.45	6.74	0.34	6.77e-11	Longevity;
LIHC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.76	-12.73	-0.57	1.14e-30	Aortic root size;
LIHC	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.74	-12.11	-0.55	2.39e-28	Obesity-related traits;
LIHC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.7	10.22	0.48	1.4e-21	Coronary artery disease;
LIHC	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg05926928	chr17:57297772	GDPD1	-0.7	-7.87	-0.39	4.73e-14	Opioid sensitivity;
LIHC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.75	-0.3	2e-8	Body mass index;
LIHC	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.63	-0.42	2.43e-16	Schizophrenia;
LIHC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.39	6.46	0.33	3.58e-10	Red blood cell count;
LIHC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs4948275	0.530	rs2139778	chr10:63134943	A/T	cg03237606	chr10:63212265	TMEM26	0.29	6.35	0.32	6.95e-10	Night sleep phenotypes;
LIHC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg26149184	chr10:133730230	NA	0.5	7.95	0.39	2.74e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.87	0.3	1.05e-8	Birth weight;
LIHC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg06359132	chr10:99160096	RRP12	-0.37	-5.93	-0.31	7.28e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21448741	chr8:58168803	NA	0.36	6.72	0.34	7.69e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg04315214	chr1:2043799	PRKCZ	0.46	7.24	0.36	3.03e-12	Height;
LIHC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.6	-0.34	1.55e-10	Menarche (age at onset);
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.36	6.05	0.31	3.82e-9	Height;
LIHC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg07671805	chr5:74907694	NA	-0.52	-6.32	-0.32	7.97e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.59	6.58	0.34	1.8e-10	Axial length;
LIHC	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.38	-6.68	-0.34	9.6e-11	Obesity;
LIHC	trans	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.15e-10	Aortic root size;
LIHC	cis	rs7078219	0.505	rs10883373	chr10:101292484	G/A	cg06854084	chr10:101292507	NKX2-3	-0.34	-6.22	-0.32	1.44e-9	Dental caries;
LIHC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.52	6.08	0.31	3.27e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.35	5.77	0.3	1.81e-8	Type 2 diabetes;
LIHC	trans	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg17675199	chr6:35436792	RPL10A	0.33	6.69	0.34	9.16e-11	Coronary artery disease;
LIHC	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.92e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg20607798	chr8:58055168	NA	0.49	6.13	0.31	2.41e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg16586182	chr3:47516702	SCAP	-0.39	-6.68	-0.34	9.89e-11	Birth weight;
LIHC	cis	rs9649465	0.967	rs1506642	chr7:123390058	A/G	cg03229431	chr7:123269106	ASB15	-0.38	-8.14	-0.4	7.19e-15	Migraine;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18000306	chr6:288505	NA	-0.33	-6.09	-0.31	3.1e-9	Menopause (age at onset);
LIHC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.78	-11.37	-0.52	1.27e-25	Dental caries;
LIHC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.32	-6.93	-0.35	2.08e-11	Longevity;
LIHC	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-0.57	-6.87	-0.35	2.97e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26734620	chr12:56694298	CS	1.23	10.54	0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-12.37	-0.56	2.67e-29	Prudent dietary pattern;
LIHC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13878775	chr2:242041740	MTERFD2	-0.52	-6.17	-0.32	1.92e-9	Systolic blood pressure;
LIHC	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09406631	chr2:209119940	IDH1	0.41	6.29	0.32	9.7e-10	Metabolic traits;
LIHC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs679087	0.932	rs721617	chr12:29934586	C/T	cg14258853	chr12:29935411	TMTC1	0.47	7.41	0.37	9.98e-13	Schizophrenia;
LIHC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.43	-7.04	-0.36	1.05e-11	Menarche (age at onset);
LIHC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.71	8.55	0.42	4.28e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.9	0.3	8.51e-9	Body mass index;
LIHC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.68	13.04	0.58	8.03e-32	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg00225070	chr15:80189496	MTHFS	0.59	9.64	0.46	1.28e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.68e-17	Prudent dietary pattern;
LIHC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-8.83	-0.43	5.44e-17	Morning vs. evening chronotype;
LIHC	trans	rs6489882	0.867	rs7306205	chr12:113366899	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.97	-0.31	5.82e-9	Life satisfaction;
LIHC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	1.13	9.95	0.47	1.16e-20	Alzheimer's disease;
LIHC	cis	rs1144333	0.850	rs1144341	chr1:76282659	T/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.74	-0.34	6.7e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg18357645	chr12:58087776	OS9	-0.41	-6.41	-0.33	4.82e-10	Multiple sclerosis;
LIHC	trans	rs9914544	0.545	rs7222748	chr17:18787976	T/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.57	-0.33	1.82e-10	Educational attainment (years of education);
LIHC	cis	rs9328573	1.000	rs10468183	chr15:100512047	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.5	-7.67	-0.38	1.77e-13	Urate levels in lean individuals;
LIHC	cis	rs4700695	1.000	rs111338	chr5:65420393	G/A	cg21114390	chr5:65439923	SFRS12	-0.52	-7.03	-0.36	1.14e-11	Facial morphology (factor 19);
LIHC	cis	rs7075426	0.646	rs4934210	chr10:88203667	G/A	cg07322936	chr10:88137208	NA	0.48	6.31	0.32	8.53e-10	Migraine without aura;
LIHC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg25894440	chr7:65020034	NA	0.54	6.22	0.32	1.43e-9	Diabetic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24995352	chr10:13203403	MCM10	0.43	6.26	0.32	1.18e-9	Cognitive function;
LIHC	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg16797656	chr11:68205561	LRP5	0.59	7.98	0.4	2.22e-14	Monobrow;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg03075683	chr16:11038168	CLEC16A	-0.53	-6.44	-0.33	4.13e-10	Facial morphology (factor 20);
LIHC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg14440974	chr22:39074834	NA	0.46	7.37	0.37	1.29e-12	Menopause (age at onset);
LIHC	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.31	-0.32	8.77e-10	Hepatocellular carcinoma;
LIHC	cis	rs2279817	0.780	rs35588575	chr1:18007045	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.73	-0.39	1.2e-13	Neuroticism;
LIHC	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.37	7.35	0.37	1.46e-12	Growth-regulated protein alpha levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12270129	chr12:121734046	CAMKK2	-0.42	-6.45	-0.33	3.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.46	-0.46	5.1e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.73	-13.37	-0.59	4.31e-33	Pediatric autoimmune diseases;
LIHC	cis	rs922107	0.713	rs359942	chr1:89975959	C/T	cg15422784	chr1:90023713	LRRC8B	0.49	7.84	0.39	5.89e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs12980942	1.000	rs7257742	chr19:41827352	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.95	0.31	6.73e-9	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1419980	0.730	rs57772215	chr12:7746385	A/G	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.72	-12.76	-0.57	9.29e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.77	-0.34	5.53e-11	Response to antipsychotic treatment;
LIHC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	9.35	0.45	1.19e-18	Mean platelet volume;
LIHC	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.32	-8.5	-0.42	6.16e-16	Intelligence;
LIHC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.05	0.31	3.88e-9	Aortic root size;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg26304593	chr6:42947056	PEX6	-0.47	-6.05	-0.31	3.9e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg06096015	chr1:231504339	EGLN1	-0.5	-9.35	-0.45	1.22e-18	Hemoglobin concentration;
LIHC	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg26441486	chr22:50317300	CRELD2	0.35	5.97	0.31	5.85e-9	Schizophrenia;
LIHC	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.29	-6.35	-0.32	6.72e-10	DNA methylation (variation);
LIHC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg03037974	chr15:76606532	NA	-0.61	-10.28	-0.49	8.59e-22	Blood metabolite levels;
LIHC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.48	-8.2	-0.41	4.91e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.92	-0.3	8.02e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-6.54	-0.33	2.28e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	0.72	6.23	0.32	1.38e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.44	6.91	0.35	2.37e-11	Mortality in heart failure;
LIHC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.98	14.97	0.63	2.48e-39	IgG glycosylation;
LIHC	cis	rs36051895	0.623	rs7847811	chr9:5237081	T/C	cg02405213	chr9:5042618	JAK2	-0.66	-10.64	-0.5	5.12e-23	Pediatric autoimmune diseases;
LIHC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-9.32	-0.45	1.52e-18	Mean corpuscular volume;
LIHC	cis	rs9513627	1.000	rs7317126	chr13:100119739	T/A	cg25919922	chr13:100150906	NA	-0.78	-7.02	-0.35	1.19e-11	Obesity-related traits;
LIHC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.2e-13	Heart rate;
LIHC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-8.12	-0.4	8.47e-15	Longevity;Endometriosis;
LIHC	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg18306943	chr3:40428807	ENTPD3	-0.34	-5.93	-0.31	7.57e-9	Renal cell carcinoma;
LIHC	cis	rs7116495	1.000	rs10751190	chr11:71680757	C/T	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.9	13.71	0.6	2.13e-34	Vitamin D levels;
LIHC	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg14550611	chr19:41354682	CYP2A6	0.46	7.39	0.37	1.11e-12	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LIHC	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.39	6.38	0.33	5.87e-10	Lewy body disease;
LIHC	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg20240347	chr1:204465584	NA	-0.36	-7.62	-0.38	2.58e-13	Schizophrenia;
LIHC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg18016565	chr1:150552671	MCL1	-0.55	-11.08	-0.51	1.37e-24	Tonsillectomy;
LIHC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.8	-0.34	4.77e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.61	8.86	0.43	4.31e-17	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.55	-9.46	-0.46	5.27e-19	Reticulocyte count;
LIHC	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.1	-0.55	2.74e-28	Coffee consumption (cups per day);
LIHC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg18270830	chr10:32634957	EPC1	0.57	7.13	0.36	6.03e-12	Sexual dysfunction (female);
LIHC	cis	rs61677309	1.000	rs56318049	chr11:118166608	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.58	0.34	1.82e-10	Lung cancer in ever smokers;
LIHC	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25632853	chr15:73088954	NA	-0.39	-6.48	-0.33	3.15e-10	Triglyceride levels;
LIHC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg07451762	chr16:28383216	NA	0.4	7.18	0.36	4.29e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20285559	chr1:6688542	THAP3	-0.42	-6.28	-0.32	1.02e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7944735	0.564	rs60929305	chr11:47523589	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-6.15	-0.32	2.18e-9	Intraocular pressure;
LIHC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.07	0.55	3.42e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg18306943	chr3:40428807	ENTPD3	0.34	5.8	0.3	1.5e-8	Renal cell carcinoma;
LIHC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.26	6.54	0.33	2.23e-10	Breast cancer;Mosquito bite size;
LIHC	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25632853	chr15:73088954	NA	0.38	6.35	0.32	7.05e-10	Triglyceride levels;
LIHC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg09990169	chr2:241835740	C2orf54	-0.65	-10.48	-0.49	1.83e-22	Urinary metabolites;
LIHC	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg13753209	chr17:57696993	CLTC	0.76	12.15	0.55	1.75e-28	Hemoglobin concentration;
LIHC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.97	0.4	2.39e-14	Schizophrenia;
LIHC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.57	-5.86	-0.3	1.11e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	8.19	0.41	5.15e-15	Schizophrenia;
LIHC	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.56	-6.42	-0.33	4.54e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	0.89	7.55	0.38	4.12e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg23625390	chr15:77176239	SCAPER	-0.46	-7.55	-0.38	4.01e-13	Blood metabolite levels;
LIHC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.04	-0.44	1.2e-17	Alzheimer's disease;
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04025307	chr7:1156635	C7orf50	0.54	7.07	0.36	8.81e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-7.74	-0.39	1.17e-13	Crohn's disease;
LIHC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.72	9.41	0.45	7.3e-19	Body mass index;
LIHC	cis	rs7707921	0.881	rs73134722	chr5:81326622	G/A	cg15871215	chr5:81402204	ATG10	-0.6	-5.77	-0.3	1.82e-8	Breast cancer;
LIHC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg03859395	chr2:55845619	SMEK2	0.81	14.32	0.61	9.15e-37	Metabolic syndrome;
LIHC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.11	0.36	6.88e-12	Bipolar disorder;
LIHC	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.31	6.66	0.34	1.1e-10	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	10.77	0.5	1.81e-23	Myopia (pathological);
LIHC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.46	-7.43	-0.37	8.52e-13	Menarche (age at onset);
LIHC	cis	rs8056893	0.714	rs3760002	chr16:68408836	A/G	cg02226672	chr16:68398533	SMPD3	0.42	5.92	0.3	7.96e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13099106	chr12:120525172	CCDC64	0.41	6.39	0.33	5.42e-10	Cognitive function;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	8.72	0.43	1.25e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs116248771	0.739	rs2291595	chr3:158378847	A/G	cg16708174	chr3:158430962	RARRES1	0.48	6.38	0.33	5.61e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.5	-7.51	-0.38	5.32e-13	Total body bone mineral density;
LIHC	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.85	10.21	0.48	1.51e-21	Mean platelet volume;
LIHC	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	0.38	6.09	0.31	3.03e-9	Coronary artery disease;
LIHC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.58	9.91	0.47	1.65e-20	Colorectal cancer;
LIHC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.8	0.35	4.71e-11	Lung cancer;
LIHC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg11952622	chr19:58962976	ZNF324B	0.49	7.31	0.37	1.85e-12	Uric acid clearance;
LIHC	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg08345082	chr10:99160200	RRP12	-0.4	-6.6	-0.34	1.6e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg02886208	chr11:14281011	SPON1	-0.52	-7.33	-0.37	1.7e-12	Mitochondrial DNA levels;
LIHC	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.42	6.8	0.35	4.59e-11	Menopause (age at onset);
LIHC	cis	rs611744	0.967	rs637626	chr8:109235785	G/T	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.45	7.47	0.37	6.81e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08280861	chr8:58055591	NA	-0.49	-6.09	-0.31	3.04e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.38	-6.07	-0.31	3.39e-9	Neurofibrillary tangles;
LIHC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg05697976	chr12:29376483	FAR2	0.31	6.13	0.31	2.44e-9	QT interval;
LIHC	cis	rs7523273	0.568	rs11118668	chr1:208017915	A/G	cg22525895	chr1:207977042	MIR29B2	0.6	6.9	0.35	2.47e-11	Schizophrenia;
LIHC	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.5	-7.17	-0.36	4.74e-12	Menarche (age at onset);
LIHC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.5	-7.62	-0.38	2.57e-13	Cognitive function;
LIHC	cis	rs34375054	0.752	rs12582867	chr12:125659798	A/C	cg25124228	chr12:125621409	AACS	-0.42	-7.07	-0.36	8.89e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg18844144	chr14:23528430	ACIN1	0.39	6.75	0.34	6.26e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg08126542	chr6:37504118	NA	-0.37	-6.25	-0.32	1.23e-9	Cognitive performance;
LIHC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.76	-0.3	1.84e-8	Ulcerative colitis;
LIHC	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.59	8.12	0.4	8.73e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.48	6.62	0.34	1.36e-10	Height;
LIHC	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.75	-0.39	1.02e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.43	5.9	0.3	8.52e-9	Life satisfaction;
LIHC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.79	13.15	0.58	3.06e-32	Breast cancer;
LIHC	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.81	0.35	4.4e-11	Height;
LIHC	cis	rs6695567	1.000	rs6672178	chr1:53629849	C/T	cg20326410	chr1:53600821	SLC1A7	0.3	6.34	0.32	7.26e-10	Systemic lupus erythematosus;
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-9.83	-0.47	3e-20	Longevity;Endometriosis;
LIHC	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg09572067	chr16:29127029	RRN3P2	0.54	8.69	0.43	1.53e-16	Menopause (age at onset);
LIHC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.49	7.08	0.36	8.48e-12	Asthma;
LIHC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.33	-6.06	-0.31	3.62e-9	Aortic root size;
LIHC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.86	15.64	0.65	5.86e-42	Coronary artery disease;
LIHC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	1.02e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.39	-5.82	-0.3	1.34e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg10687131	chr2:20871002	GDF7	-0.36	-6.86	-0.35	3.16e-11	Abdominal aortic aneurysm;
LIHC	cis	rs7129556	0.520	rs6592737	chr11:77322619	A/T	cg03570279	chr11:77446074	RSF1	-0.36	-6.71	-0.34	8.27e-11	Weight loss (gastric bypass surgery);
LIHC	cis	rs3780378	0.875	rs4372063	chr9:5003338	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-7.25	-0.37	2.73e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg24044564	chr13:99115944	STK24	0.49	7.03	0.36	1.15e-11	Obesity-related traits;
LIHC	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	7.33	0.37	1.66e-12	Morning vs. evening chronotype;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.68	0.8	5.83e-78	Prudent dietary pattern;
LIHC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-7.79	-0.39	7.9e-14	Crohn's disease;
LIHC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20135002	chr11:47629003	NA	-0.54	-9.11	-0.44	7.33e-18	Subjective well-being;
LIHC	cis	rs2108622	0.683	rs111388185	chr19:15977414	T/C	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg21298408	chr8:18027853	NAT1	-0.26	-6.18	-0.32	1.81e-9	Monocyte count;
LIHC	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02359409	chr6:42947317	PEX6	-0.41	-5.91	-0.3	8.38e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.39	-6.0	-0.31	5.11e-9	Blood pressure (smoking interaction);
LIHC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.72	-11.45	-0.53	6.44e-26	Inflammatory bowel disease;
LIHC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg02290350	chr8:58132656	NA	0.41	7.7	0.38	1.43e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs78049276	0.688	rs17612693	chr4:148365339	T/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.69	-0.38	1.6e-13	Pulse pressure;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.44	8.14	0.4	7.19e-15	Prudent dietary pattern;
LIHC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.55	11.28	0.52	2.75e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.91	0.3	8.3e-9	Bipolar disorder;
LIHC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.15	-28.19	-0.84	3.3e-91	Myeloid white cell count;
LIHC	cis	rs2540917	0.728	rs888082	chr2:60629609	C/T	cg00543073	chr2:60773386	BCL11A	-0.34	-6.67	-0.34	1.04e-10	Mean corpuscular volume;
LIHC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.05	9.76	0.47	5.19e-20	Diabetic retinopathy;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg05484376	chr2:27715224	FNDC4	0.37	6.34	0.32	7.32e-10	Total body bone mineral density;
LIHC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-6.59	-0.34	1.67e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg05481257	chr2:20870211	GDF7	-0.43	-8.25	-0.41	3.42e-15	Abdominal aortic aneurysm;
LIHC	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.51	-0.38	5.36e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.06e-8	Blood metabolite levels;
LIHC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.54	7.69	0.38	1.55e-13	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23283076	chr1:27114325	PIGV	-0.52	-6.14	-0.32	2.34e-9	Systolic blood pressure;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06420487	chr17:61919686	SMARCD2	0.42	5.78	0.3	1.69e-8	Height;
LIHC	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.6	10.25	0.48	1.16e-21	HDL cholesterol;
LIHC	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg14515779	chr1:101123966	NA	0.46	6.6	0.34	1.61e-10	Monocyte count;
LIHC	cis	rs876084	0.505	rs12680859	chr8:121118968	A/G	cg06265175	chr8:121136014	COL14A1	0.42	6.91	0.35	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg03934865	chr2:198174659	NA	-0.59	-9.44	-0.45	5.84e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg25039879	chr17:56429692	SUPT4H1	0.79	8.97	0.44	1.98e-17	Cognitive test performance;
LIHC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg18306943	chr3:40428807	ENTPD3	0.35	6.09	0.31	3.1e-9	Renal cell carcinoma;
LIHC	cis	rs6787391	0.933	rs12330193	chr3:4748862	C/T	cg11584376	chr3:4789075	ITPR1	-0.38	-5.84	-0.3	1.2e-8	Breast cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23131702	chr10:5726677	C10orf18	0.44	6.22	0.32	1.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4728302	0.838	rs10225115	chr7:133591435	C/T	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.88	-0.3	9.71e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.39	6.29	0.32	9.64e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs7551222	0.646	rs4951384	chr1:204452514	A/T	cg20240347	chr1:204465584	NA	-0.31	-6.55	-0.33	2.09e-10	Schizophrenia;
LIHC	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg25019722	chr6:37503610	NA	-0.37	-6.38	-0.33	5.8e-10	Cognitive performance;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.61	8.77	0.43	8.39e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	9.76	0.47	5.23e-20	Personality dimensions;
LIHC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.51	-7.35	-0.37	1.48e-12	Lung cancer;
LIHC	cis	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg24110177	chr3:50126178	RBM5	-0.5	-7.78	-0.39	8.56e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs787274	0.867	rs787269	chr9:115548676	T/C	cg13803584	chr9:115635662	SNX30	-0.58	-6.32	-0.32	8.19e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	11.69	0.53	8.43e-27	Colorectal cancer;
LIHC	cis	rs12079745	0.793	rs78483993	chr1:169410428	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.72	-6.62	-0.34	1.37e-10	QT interval;
LIHC	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.46	6.06	0.31	3.54e-9	Menopause (age at onset);
LIHC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg17385448	chr1:15911702	AGMAT	0.34	5.88	0.3	9.56e-9	Systolic blood pressure;
LIHC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.72	10.28	0.49	8.94e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs17106184	1.000	rs72904719	chr1:51324546	G/T	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.48	7.71	0.38	1.42e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-10.44	-0.49	2.52e-22	Platelet count;
LIHC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg12463550	chr7:65579703	CRCP	0.7	6.74	0.34	6.84e-11	Diabetic kidney disease;
LIHC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.84	14.35	0.61	7.23e-37	Monocyte count;
LIHC	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.66	-9.79	-0.47	4.12e-20	Coronary artery disease;
LIHC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-0.93	-14.71	-0.62	2.61e-38	Type 1 diabetes nephropathy;
LIHC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.79	6.64	0.34	1.22e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg12179176	chr11:130786555	SNX19	0.61	8.84	0.43	5.17e-17	Schizophrenia;
LIHC	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00938859	chr5:1591904	SDHAP3	0.57	7.0	0.35	1.36e-11	Breast cancer;
LIHC	cis	rs812925	0.537	rs778139	chr2:61684564	A/G	cg14146966	chr2:61757674	XPO1	-0.39	-6.55	-0.33	2.1e-10	Immature fraction of reticulocytes;
LIHC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg14829360	chr17:73884958	NA	-0.49	-7.25	-0.36	2.84e-12	Psoriasis;
LIHC	trans	rs4714291	0.802	rs2983140	chr6:40017224	A/G	cg02267698	chr19:7991119	CTXN1	-0.42	-7.02	-0.35	1.18e-11	Strep throat;
LIHC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.27	-6.76	-0.34	5.97e-11	Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.75	-11.73	-0.54	6.36e-27	Motion sickness;
LIHC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.4	-0.37	1.04e-12	Blood protein levels;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07308232	chr7:1071921	C7orf50	-0.38	-6.12	-0.31	2.61e-9	Longevity;Endometriosis;
LIHC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.5	-8.88	-0.43	3.86e-17	Total body bone mineral density;
LIHC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.39	5.71	0.3	2.41e-8	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs6058796	0.892	rs34894833	chr20:31247154	G/A	cg02600331	chr11:130417168	NA	0.32	6.92	0.35	2.17e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.61	-9.06	-0.44	1.02e-17	Bone mineral density (hip);Bone mineral density;
LIHC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.81	14.19	0.61	2.86e-36	Coronary artery disease;
LIHC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-12.07	-0.55	3.48e-28	Headache;
LIHC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.5	7.83	0.39	6.02e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.16	-0.36	5.12e-12	Reticulocyte count;
LIHC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.25e-16	Schizophrenia;
LIHC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.53	-0.76	1.31e-65	Height;
LIHC	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.5	-6.2	-0.32	1.58e-9	Resting heart rate;
LIHC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.73	0.3	2.22e-8	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg24209194	chr3:40518798	ZNF619	0.55	8.02	0.4	1.69e-14	Renal cell carcinoma;
LIHC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg22842854	chr12:123319900	HIP1R	-0.65	-8.57	-0.42	3.5e-16	Schizophrenia;
LIHC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg26395211	chr5:140044315	WDR55	-0.41	-5.89	-0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	Androgen levels;
LIHC	trans	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg14791747	chr16:20752902	THUMPD1	0.46	6.24	0.32	1.28e-9	Dental caries;
LIHC	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.33	0.52	1.78e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.22	-5.97	-0.31	6.07e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.15	-0.48	2.53e-21	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs9836270	1.000	rs9836270	chr3:131916996	G/T	cg13445339	chr1:11721249	FBXO44	-0.36	-6.18	-0.32	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg16486109	chr11:613632	IRF7	0.58	6.22	0.32	1.48e-9	Systemic lupus erythematosus;
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.34	-6.74	-0.34	6.79e-11	Renal cell carcinoma;
LIHC	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg05010058	chr2:65284262	CEP68	-0.4	-6.78	-0.34	5.35e-11	Pulse pressure;
LIHC	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.42	-6.13	-0.31	2.44e-9	IgG glycosylation;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg09453983	chr4:146080425	OTUD4	-0.24	-6.15	-0.32	2.11e-9	Calcium levels;
LIHC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg17385448	chr1:15911702	AGMAT	0.37	6.44	0.33	4.09e-10	Systolic blood pressure;
LIHC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg12798992	chr6:167411361	FGFR1OP	0.51	8.33	0.41	1.97e-15	Primary biliary cholangitis;
LIHC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.36	8.19	0.4	5.25e-15	Ulcerative colitis;
LIHC	trans	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg21659725	chr3:3221576	CRBN	0.62	6.76	0.34	5.97e-11	Schizophrenia;
LIHC	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.56	8.27	0.41	2.93e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg17750252	chr2:136567154	LCT	-0.35	-6.33	-0.32	7.54e-10	Mosquito bite size;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg00612595	chr21:47717864	NA	-0.35	-5.71	-0.3	2.45e-8	Testicular germ cell tumor;
LIHC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.41	-6.64	-0.34	1.21e-10	Menarche (age at onset);
LIHC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.63	12.68	0.57	1.89e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.66	8.28	0.41	2.87e-15	Mean platelet volume;
LIHC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21467203	chr3:49911342	NA	-0.43	-7.71	-0.38	1.38e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.65	-7.96	-0.4	2.53e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.35	-6.32	-0.32	8e-10	Psoriasis;
LIHC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.07	14.15	0.61	4.34e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.48	5.78	0.3	1.64e-8	Total body bone mineral density;
LIHC	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.12	25.1	0.81	1.47e-79	Cognitive ability;
LIHC	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.4	5.71	0.3	2.45e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg22601191	chr20:60968625	CABLES2	0.45	5.81	0.3	1.4e-8	Colorectal cancer;
LIHC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.13	-0.31	2.37e-9	Ulcerative colitis;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.67e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.32	7.36	0.37	1.42e-12	Crohn's disease;
LIHC	cis	rs4908768	0.906	rs12410336	chr1:8623664	A/G	cg20416874	chr1:8611966	RERE	0.57	8.75	0.43	1.02e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.72	-11.91	-0.54	1.32e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg10790698	chr19:18539756	SSBP4	-0.36	-7.26	-0.37	2.63e-12	Breast cancer;
LIHC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.58	-8.74	-0.43	1.08e-16	Height;
LIHC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.77	-15.12	-0.63	6.75e-40	Height;
LIHC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.54	0.46	2.8e-19	Morning vs. evening chronotype;
LIHC	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.05	-0.31	3.89e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.61	8.35	0.41	1.75e-15	Coronary artery disease;
LIHC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.55	7.46	0.37	6.99e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18210722	chr7:74379144	GATSL1	-0.49	-6.07	-0.31	3.4e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.4	6.58	0.34	1.79e-10	Red blood cell count;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13231117	chr2:96193797	NA	0.5	7.04	0.36	1.07e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.43	6.83	0.35	3.86e-11	Melanoma;
LIHC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.34	-6.32	-0.32	7.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7614311	0.731	rs3733121	chr3:63850660	C/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.38	-0.33	5.68e-10	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.44	6.08	0.31	3.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13745513	chr9:131018379	GOLGA2	0.45	6.2	0.32	1.6e-9	Hepatitis;
LIHC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-6.91	-0.35	2.35e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18252515	chr7:66147081	NA	0.42	5.88	0.3	9.6e-9	Aortic root size;
LIHC	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.89	-0.3	9.33e-9	Type 2 diabetes;
LIHC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.28	0.45	1.98e-18	Eosinophil percentage of white cells;
LIHC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg26692224	chr17:62915920	LRRC37A3	-0.73	-7.05	-0.36	1.01e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-8.43	-0.41	9.64e-16	Gut microbiome composition (summer);
LIHC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	trans	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg18335740	chr13:41363409	SLC25A15	0.35	6.15	0.32	2.19e-9	Lewy body disease;
LIHC	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.41	-6.11	-0.31	2.66e-9	Diastolic blood pressure;
LIHC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.33	-5.77	-0.3	1.76e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg25356066	chr3:128598488	ACAD9	-0.48	-6.79	-0.34	5.05e-11	IgG glycosylation;
LIHC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	0.87	11.95	0.54	9.72e-28	Skin colour saturation;
LIHC	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	0.67	8.59	0.42	3.21e-16	Corneal structure;
LIHC	cis	rs2292864	0.764	rs72825627	chr17:45386289	C/G	cg18085866	chr17:45331354	ITGB3	-0.6	-6.26	-0.32	1.12e-9	Left atrial antero-posterior diameter;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06873352	chr17:61820015	STRADA	0.5	7.44	0.37	8.28e-13	Height;
LIHC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.55	9.11	0.44	6.99e-18	Longevity;Endometriosis;
LIHC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-10.74	-0.5	2.25e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg16558253	chr16:72132732	DHX38	-0.41	-6.82	-0.35	4.06e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.41	6.93	0.35	2.07e-11	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06154860	chr7:14029085	ETV1	0.46	7.07	0.36	8.71e-12	Cognitive function;
LIHC	trans	rs6489882	0.867	rs4766673	chr12:113365161	C/T	cg10175203	chr3:128143634	NA	-0.39	-6.4	-0.33	5.11e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg05084668	chr3:125655381	ALG1L	-0.34	-6.1	-0.31	2.87e-9	Blood pressure (smoking interaction);
LIHC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg13628971	chr7:2884303	GNA12	0.37	5.75	0.3	2.01e-8	Height;
LIHC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.34	-6.13	-0.31	2.39e-9	Platelet distribution width;
LIHC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.42	6.75	0.34	6.41e-11	Cognitive function;
LIHC	cis	rs7258465	1.000	rs8111708	chr19:18558876	A/G	cg10790698	chr19:18539756	SSBP4	-0.37	-7.7	-0.38	1.52e-13	Breast cancer;
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.41	-8.44	-0.42	9e-16	Renal cell carcinoma;
LIHC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	0.49	7.27	0.37	2.44e-12	Methadone dose in opioid dependence;
LIHC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.45	6.67	0.34	1.01e-10	Survival in rectal cancer;
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08677398	chr8:58056175	NA	0.41	6.35	0.32	6.79e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg14758556	chr20:62440591	NA	0.42	6.63	0.34	1.33e-10	Glioblastoma;
LIHC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.26	0.58	1.15e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.25	-0.32	1.24e-9	Response to antipsychotic treatment;
LIHC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.15	0.4	6.99e-15	Coronary artery disease;
LIHC	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg20578329	chr17:80767326	TBCD	-0.69	-6.93	-0.35	2.06e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	trans	rs4604234	0.803	rs79048064	chr6:80977098	G/T	cg08069338	chr6:160207898	SNORA29;TCP1	0.63	6.16	0.32	2.07e-9	Cancer;
LIHC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.59	10.3	0.49	7.86e-22	Dupuytren's disease;
LIHC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg13409248	chr3:40428643	ENTPD3	-0.39	-6.25	-0.32	1.22e-9	Renal cell carcinoma;
LIHC	cis	rs2288912	0.620	rs875255	chr19:45493635	C/G	cg13119609	chr19:45449297	APOC2	-0.21	-6.08	-0.31	3.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03043160	chr13:76056444	TBC1D4	-0.49	-6.52	-0.33	2.6e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.32	-8.36	-0.41	1.55e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21467203	chr3:49911342	NA	-0.41	-7.03	-0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg14515779	chr1:101123966	NA	0.52	7.42	0.37	9.23e-13	Monocyte count;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg03013999	chr17:37608204	MED1	-0.36	-6.06	-0.31	3.53e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg21252483	chr19:49399788	TULP2	-0.88	-9.9	-0.47	1.78e-20	Red cell distribution width;
LIHC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.7	-13.06	-0.58	6.64e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.5	6.63	0.34	1.32e-10	Emphysema distribution in smoking;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.99	-0.4	2.14e-14	Lymphocyte counts;
LIHC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg14829360	chr17:73884958	NA	-0.52	-7.79	-0.39	8.23e-14	Psoriasis;
LIHC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.39	6.15	0.32	2.16e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-21.57	-0.76	9e-66	Height;
LIHC	cis	rs17106184	1.000	rs113910111	chr1:51328773	T/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.59	-0.34	1.68e-10	Type 2 diabetes;
LIHC	cis	rs2191566	0.960	rs11083732	chr19:44520743	T/C	cg18700516	chr19:44507157	ZNF230	-0.35	-5.86	-0.3	1.11e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6750047	0.647	rs11124632	chr2:38276412	G/C	cg07380506	chr2:38303506	CYP1B1	0.59	7.56	0.38	3.66e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs1494950	1.000	rs1494950	chr4:14967169	A/G	cg12377275	chr4:15005593	CPEB2	-0.79	-6.7	-0.34	8.77e-11	Political ideology;
LIHC	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	0.92	12.6	0.56	3.81e-30	Mitochondrial DNA levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg02674305	chr20:34359915	PHF20	0.42	6.05	0.31	3.73e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.55	-0.46	2.64e-19	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19504496	chr19:36119917	RBM42	0.47	6.57	0.33	1.85e-10	Pancreatic cancer;
LIHC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-7.37	-0.37	1.33e-12	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.06	-0.31	3.55e-9	Renal cell carcinoma;
LIHC	trans	rs2579103	0.767	rs1595601	chr12:90661368	T/C	cg00091569	chr3:40428383	ENTPD3	0.37	6.12	0.31	2.5e-9	Body mass index;
LIHC	trans	rs2270927	0.510	rs1995381	chr5:75570658	C/T	cg13563193	chr19:33072644	PDCD5	-0.88	-9.19	-0.45	3.91e-18	Mean corpuscular volume;
LIHC	cis	rs12079745	0.793	rs12071224	chr1:169191945	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-7.15	-0.36	5.34e-12	QT interval;
LIHC	trans	rs13325613	0.915	rs71327041	chr3:46267582	C/T	cg26337592	chr1:153642686	ILF2	0.68	6.18	0.32	1.81e-9	Monocyte count;
LIHC	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.28	5.77	0.3	1.82e-8	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.67	6.76	0.34	5.87e-11	Vitiligo;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.7	-10.13	-0.48	2.89e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.26	-0.52	3.2e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs17106184	1.000	rs80297338	chr1:51255677	C/A	cg07174182	chr1:51127561	FAF1	-0.64	-6.89	-0.35	2.74e-11	Type 2 diabetes;
LIHC	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg25364880	chr3:44379878	C3orf23	0.56	7.62	0.38	2.53e-13	Depressive symptoms;
LIHC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.08	0.31	3.28e-9	Electroencephalogram traits;
LIHC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.12	0.55	2.21e-28	Menopause (age at onset);
LIHC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg02290350	chr8:58132656	NA	0.32	7.17	0.36	4.73e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg04014059	chr22:45813624	RIBC2	-0.46	-6.02	-0.31	4.37e-9	Tonsillectomy;
LIHC	cis	rs2380220	0.808	rs2613547	chr6:95910311	C/T	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.43	-6.98	-0.35	1.53e-11	Migraine;
LIHC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.35	6.65	0.34	1.14e-10	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.51	0.38	5.31e-13	Renal cell carcinoma;
LIHC	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg11395062	chr17:14139857	CDRT15	0.52	9.27	0.45	2.11e-18	Temperament;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	9.26	0.45	2.38e-18	Height;
LIHC	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.12	23.57	0.79	1.24e-73	Schizophrenia;
LIHC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg26939375	chr7:64535504	NA	0.47	7.05	0.36	9.74e-12	Aortic root size;
LIHC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.03	-0.4	1.61e-14	Type 2 diabetes;
LIHC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg18016565	chr1:150552671	MCL1	-0.49	-9.6	-0.46	1.74e-19	Tonsillectomy;
LIHC	cis	rs9328573	1.000	rs9328573	chr15:100511004	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.49	-7.42	-0.37	9.54e-13	Urate levels in lean individuals;
LIHC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.57	0.38	3.52e-13	Mean platelet volume;
LIHC	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.4	-6.67	-0.34	1.03e-10	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.77	-0.54	4.39e-27	Type 2 diabetes;
LIHC	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg01557791	chr16:72042693	DHODH	-0.67	-9.17	-0.44	4.68e-18	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LIHC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.42	6.74	0.34	6.75e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03878208	chr11:72483293	STARD10	0.63	5.76	0.3	1.83e-8	Type 2 diabetes;
LIHC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.39e-18	Subjective well-being;
LIHC	cis	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-10.32	-0.49	6.67e-22	Breast cancer;
LIHC	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg00012203	chr2:219082015	ARPC2	0.76	10.73	0.5	2.34e-23	Colorectal cancer;
LIHC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-8.77	-0.43	8.79e-17	Platelet distribution width;
LIHC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.65	-9.76	-0.47	5.33e-20	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs6815814	0.731	rs11735251	chr4:38773057	T/A	cg06935464	chr4:38784597	TLR10	0.38	5.96	0.31	6.18e-9	Breast cancer;
LIHC	cis	rs2467099	0.679	rs59867239	chr17:73931787	G/A	cg08125733	chr17:73851984	WBP2	0.46	5.85	0.3	1.12e-8	Systolic blood pressure;
LIHC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg15691649	chr6:25882328	NA	-0.55	-7.07	-0.36	8.53e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.47	-7.2	-0.36	3.8e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.21	-0.32	1.5e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.0	-0.31	4.92e-9	Ulcerative colitis;
LIHC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.57	10.03	0.48	6.57e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.81	10.3	0.49	7.59e-22	Cognitive function;
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg04078321	chr6:155635785	TFB1M	-0.55	-6.38	-0.33	5.82e-10	Response to hepatitis C treatment;
LIHC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17507749	chr15:85114479	UBE2QP1	0.62	6.83	0.35	3.88e-11	Schizophrenia;
LIHC	cis	rs4908768	0.822	rs12122737	chr1:8616404	C/A	cg20416874	chr1:8611966	RERE	0.59	9.5	0.46	3.81e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-9.77	-0.47	4.96e-20	Blood metabolite levels;
LIHC	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.73	0.39	1.21e-13	Lymphocyte counts;
LIHC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.44	5.84	0.3	1.19e-8	High light scatter reticulocyte count;
LIHC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.39	-0.71	5.32e-53	Height;
LIHC	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.54	-10.63	-0.5	5.5e-23	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16684958	chr7:75615977	POR	0.5	8.51	0.42	5.35e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.27	-0.32	1.08e-9	Obesity-related traits;
LIHC	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.84	9.0	0.44	1.54e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.61	0.8	1.08e-77	Prudent dietary pattern;
LIHC	trans	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg01134436	chr17:81009848	B3GNTL1	0.84	6.81	0.35	4.34e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.81	-0.73	1e-58	Height;
LIHC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-15.49	-0.64	2.29e-41	Gut microbiome composition (summer);
LIHC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.53	8.07	0.4	1.19e-14	Longevity;
LIHC	cis	rs7188861	1.000	rs731774	chr16:11456266	C/T	cg01510278	chr16:11456238	NA	-0.49	-6.08	-0.31	3.23e-9	HDL cholesterol;
LIHC	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg05315195	chr6:109294784	ARMC2	-0.53	-5.75	-0.3	1.99e-8	Prostate cancer;
LIHC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg07424592	chr7:64974309	NA	-0.79	-9.28	-0.45	1.95e-18	Diabetic kidney disease;
LIHC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.22	0.52	4.5e-25	Hip circumference adjusted for BMI;
LIHC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.43	-5.94	-0.31	7.08e-9	Systolic blood pressure;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.51	6.46	0.33	3.53e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.91	0.54	1.3e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.83	-0.3	1.28e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.58	0.59	6.97e-34	Prudent dietary pattern;
LIHC	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.57	-0.42	3.57e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.86	12.52	0.56	7.02e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.67	10.53	0.49	1.18e-22	Schizophrenia;
LIHC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.4	8.39	0.41	1.26e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.45	-7.56	-0.38	3.76e-13	Dementia with Lewy bodies;
LIHC	cis	rs1274963	0.601	rs784503	chr3:39197731	A/G	cg02254461	chr3:39195904	CSRNP1	-0.52	-6.5	-0.33	2.92e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg16736954	chr20:23401023	NAPB	0.7	8.08	0.4	1.15e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	0.72	8.27	0.41	3.05e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-8.95	-0.44	2.36e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.37	6.64	0.34	1.22e-10	Aortic root size;
LIHC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.72	-0.5	2.52e-23	Total cholesterol levels;
LIHC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.89	-0.3	8.99e-9	Mean corpuscular volume;
LIHC	cis	rs67981189	0.593	rs221917	chr14:71590003	C/T	cg15816911	chr14:71606274	NA	-0.42	-7.0	-0.35	1.4e-11	Schizophrenia;
LIHC	cis	rs965469	0.895	rs6051729	chr20:3290615	A/G	cg25506879	chr20:3388711	C20orf194	-0.56	-6.84	-0.35	3.73e-11	IFN-related cytopenia;
LIHC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-0.69	-8.43	-0.41	9.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg00280220	chr17:61926910	NA	0.42	6.84	0.35	3.66e-11	Prudent dietary pattern;
LIHC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.52	9.2	0.45	3.72e-18	Tuberculosis;
LIHC	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg23791764	chr18:32556832	MAPRE2	0.53	7.57	0.38	3.46e-13	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs116248771	0.691	rs2363658	chr3:158395866	G/C	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.32e-10	diarrhoeal disease at age 2;
LIHC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.51	6.55	0.33	2.07e-10	Initial pursuit acceleration;
LIHC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.19	0.36	4.2e-12	Aortic root size;
LIHC	cis	rs243505	0.660	rs3779038	chr7:148542822	C/T	cg09806900	chr7:148480153	CUL1	0.43	6.07	0.31	3.42e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg03854865	chr6:26224070	HIST1H3E	0.59	6.49	0.33	3.04e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.37e-37	Blood metabolite levels;
LIHC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg13393036	chr8:95962371	TP53INP1	0.37	7.64	0.38	2.26e-13	Type 2 diabetes;
LIHC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.94	17.71	0.69	2.79e-50	Menopause (age at onset);
LIHC	cis	rs911119	0.913	rs6048924	chr20:23578996	G/A	cg16589663	chr20:23618590	CST3	0.66	6.89	0.35	2.7e-11	Chronic kidney disease;
LIHC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.38	-0.41	1.36e-15	Schizophrenia;
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.88	-0.47	2.06e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg06969265	chr17:73775802	H3F3B	0.78	6.86	0.35	3.31e-11	Psoriasis;
LIHC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.52	-0.38	4.91e-13	Psoriasis;
LIHC	trans	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg09045935	chr12:6379348	NA	-0.68	-6.69	-0.34	9.35e-11	Blood metabolite levels;
LIHC	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.42	7.97	0.4	2.39e-14	Height;
LIHC	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.64	-0.46	1.31e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs10761482	0.601	rs10733764	chr10:62210345	C/G	cg17314160	chr12:110399253	GIT2	-0.4	-6.16	-0.32	2.07e-9	Schizophrenia;
LIHC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.32	5.76	0.3	1.85e-8	Pancreatic cancer;
LIHC	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.07e-22	Colorectal cancer;
LIHC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.45	-0.62	2.88e-37	Alzheimer's disease (late onset);
LIHC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.65	0.53	1.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg25783544	chr11:47291846	MADD	0.42	6.02	0.31	4.51e-9	HDL cholesterol;
LIHC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.6	-7.68	-0.38	1.66e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg14515779	chr1:101123966	NA	0.63	11.7	0.53	7.93e-27	Monocyte count;
LIHC	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.6	8.34	0.41	1.79e-15	Obesity-related traits;
LIHC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.85	-0.3	1.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.36	6.6	0.34	1.54e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.46	-5.8	-0.3	1.52e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2933343	1.000	rs6785869	chr3:128643144	G/A	cg25356066	chr3:128598488	ACAD9	0.53	6.97	0.35	1.64e-11	IgG glycosylation;
LIHC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.98	-16.5	-0.67	2.13e-45	Cognitive ability;
LIHC	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg14345882	chr6:26364793	BTN3A2	0.39	5.76	0.3	1.88e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg16926213	chr1:1841314	NA	0.33	5.97	0.31	5.86e-9	Body mass index;
LIHC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg16506815	chr2:162101123	NA	0.5	8.26	0.41	3.13e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg03037974	chr15:76606532	NA	0.68	12.74	0.57	1.1e-30	Blood metabolite levels;
LIHC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg00204512	chr16:28754710	NA	0.33	6.15	0.32	2.13e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.67	-8.91	-0.43	3.19e-17	Aortic root size;
LIHC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.63	7.52	0.38	4.88e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs244293	0.931	rs244370	chr17:53185267	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00152838	chr16:24741724	TNRC6A	-0.47	-6.28	-0.32	1.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.42	6.99	0.35	1.41e-11	Lewy body disease;
LIHC	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.5	-6.32	-0.32	8.24e-10	Heschl's gyrus morphology;
LIHC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	6.05	0.31	3.81e-9	Tonsillectomy;
LIHC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg19645103	chr12:69753606	YEATS4	-0.39	-5.87	-0.3	1.02e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4834770	1.000	rs878375	chr4:120237574	T/C	cg09307838	chr4:120376055	NA	0.42	6.24	0.32	1.26e-9	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.33	-18.21	-0.7	2.75e-52	Diabetic kidney disease;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.62	10.8	0.5	1.4e-23	Colorectal cancer;
LIHC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.36	-0.37	1.38e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.76	-0.3	1.88e-8	Mortality in heart failure;
LIHC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg23625390	chr15:77176239	SCAPER	-0.43	-6.57	-0.33	1.9e-10	Blood metabolite levels;
LIHC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.52	0.42	5.27e-16	Lung cancer in ever smokers;
LIHC	trans	rs10242455	0.571	rs73713594	chr7:99326498	A/G	cg09045935	chr12:6379348	NA	0.73	6.07	0.31	3.48e-9	Blood metabolite levels;
LIHC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.45	0.42	8.23e-16	Lung cancer in ever smokers;
LIHC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg24879335	chr3:133465180	TF	0.28	6.36	0.33	6.64e-10	Iron status biomarkers;
LIHC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.56	7.28	0.37	2.31e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.84	-13.66	-0.59	3.47e-34	Longevity;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg03934865	chr2:198174659	NA	0.46	6.73	0.34	7.14e-11	Dermatomyositis;
LIHC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.83	13.4	0.59	3.42e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg12903224	chr12:29470962	FAR2	-0.42	-6.66	-0.34	1.12e-10	QT interval;
LIHC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.34	0.56	3.31e-29	Cognitive test performance;
LIHC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.46	-5.94	-0.31	7.17e-9	Subjective well-being;
LIHC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.37	6.09	0.31	3.11e-9	Menopause (age at onset);
LIHC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8084351	0.569	rs1078459	chr18:50776291	T/G	cg24270629	chr18:50823537	DCC	-0.47	-7.1	-0.36	7.36e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12414872	chr3:52030010	RPL29	0.46	6.35	0.32	6.91e-10	Lung function (FEV1/FVC);
LIHC	cis	rs72627509	0.629	rs1718824	chr4:57903747	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	7.36	0.37	1.36e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.35	-7.04	-0.36	1.08e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs12744310	0.887	rs12022655	chr1:41816319	G/T	cg03962019	chr1:41807865	NA	0.38	6.12	0.31	2.54e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.47	7.47	0.37	6.79e-13	Multiple sclerosis;
LIHC	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.8	9.75	0.47	5.79e-20	Psoriasis vulgaris;
LIHC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.53	9.76	0.47	5.11e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4908768	0.906	rs74324642	chr1:8620172	A/C	cg25722041	chr1:8623473	RERE	0.43	6.05	0.31	3.71e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.53	-0.38	4.43e-13	Alzheimer's disease;
LIHC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg17834443	chr8:19674713	INTS10	0.49	7.27	0.37	2.53e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	12.35	0.56	3.17e-29	Alzheimer's disease;
LIHC	trans	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs539514	0.690	rs4885345	chr13:76318453	C/T	cg04757411	chr13:76259545	LMO7	0.48	8.43	0.41	1e-15	Type 1 diabetes;
LIHC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.52	0.33	2.45e-10	Bipolar disorder;
LIHC	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.57	8.7	0.43	1.47e-16	Coronary artery disease;
LIHC	cis	rs7961581	0.748	rs6421232	chr12:71622905	C/T	cg05756094	chr12:71608604	NA	0.41	6.69	0.34	9e-11	Type 2 diabetes;
LIHC	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.68	7.32	0.37	1.8e-12	Exhaled nitric oxide output;
LIHC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg19016816	chr7:1267987	NA	0.28	6.21	0.32	1.54e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-8.79	-0.43	7.5e-17	Type 2 diabetes;
LIHC	cis	rs4788570	0.511	rs4788830	chr16:71732267	A/G	cg06353428	chr16:71660113	MARVELD3	1.35	13.8	0.6	1e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg03146154	chr1:46216737	IPP	-0.39	-6.38	-0.33	5.75e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.63e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-7.19	-0.36	4.06e-12	Schizophrenia;
LIHC	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg00677901	chr16:88017247	BANP	0.54	8.24	0.41	3.82e-15	Menopause (age at onset);
LIHC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg07061783	chr6:25882402	NA	-0.54	-6.72	-0.34	7.6e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg11632617	chr15:75315747	PPCDC	-0.45	-6.37	-0.33	6.25e-10	Blood trace element (Zn levels);
LIHC	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.99	-9.56	-0.46	2.4e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.98	0.44	1.88e-17	Cognitive ability;
LIHC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg15744005	chr10:104629667	AS3MT	0.39	8.55	0.42	4.15e-16	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.36	5.83	0.3	1.28e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.54	7.06	0.36	9.48e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg06565975	chr8:143823917	SLURP1	0.32	6.02	0.31	4.59e-9	Urinary tract infection frequency;
LIHC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23572578	chr14:102975895	ANKRD9	-0.54	-6.29	-0.32	9.67e-10	Systolic blood pressure;
LIHC	trans	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04207741	chr12:57482553	NAB2	-0.45	-6.15	-0.32	2.11e-9	Pancreatic cancer;
LIHC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-7.02	-0.35	1.22e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs2302190	0.882	rs3809709	chr17:56590559	C/T	cg12560992	chr17:57184187	TRIM37	0.71	9.03	0.44	1.25e-17	Vitamin D levels;
LIHC	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1866706	0.865	rs4757956	chr11:12876666	G/A	cg25843174	chr11:12811716	TEAD1	-0.31	-6.53	-0.33	2.32e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.48	-8.19	-0.4	5.31e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.6	-8.56	-0.42	3.9e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg05361325	chr10:32636312	EPC1	-0.52	-6.47	-0.33	3.39e-10	Sexual dysfunction (female);
LIHC	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.44	-8.48	-0.42	6.86e-16	Testicular germ cell tumor;
LIHC	cis	rs1892700	0.764	rs13047862	chr21:34873559	A/G	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.45	-0.53	6.66e-26	Total cholesterol levels;
LIHC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.03	-0.36	1.14e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg14067834	chr17:29058358	SUZ12P	0.69	6.88	0.35	2.8e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.92	11.74	0.54	5.85e-27	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.85	-13.92	-0.6	3.35e-35	Breast cancer;
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.38	5.78	0.3	1.73e-8	Testicular germ cell tumor;
LIHC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.76	12.78	0.57	7.43e-31	Aortic root size;
LIHC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.66	-10.98	-0.51	3.27e-24	Childhood ear infection;
LIHC	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg11946769	chr3:48343235	NME6	-0.49	-6.23	-0.32	1.37e-9	Educational attainment (years of education);
LIHC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.78	-11.76	-0.54	4.72e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.82	-13.6	-0.59	5.83e-34	Aortic root size;
LIHC	trans	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg10756647	chr7:56101905	PSPH	1.07	13.4	0.59	3.25e-33	Diabetic kidney disease;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg02990361	chr1:107599529	PRMT6	-0.68	-11.28	-0.52	2.68e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg13919466	chr1:32135498	COL16A1	-0.37	-6.73	-0.34	6.96e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg27490568	chr2:178487706	NA	0.7	9.33	0.45	1.37e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-10.56	-0.5	9.4e-23	Skin colour saturation;
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.71	-12.79	-0.57	7.27e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.61	12.79	0.57	6.97e-31	Fat distribution (HIV);
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.93	12.6	0.56	3.66e-30	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-10.28	-0.49	9.14e-22	Alzheimer's disease;
LIHC	trans	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg01596870	chr19:55963115	NA	-0.65	-9.24	-0.45	2.67e-18	Obesity-related traits;
LIHC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.46	7.36	0.37	1.39e-12	Multiple sclerosis;
LIHC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg15534755	chr11:117069859	TAGLN	0.36	6.17	0.32	1.99e-9	Blood protein levels;
LIHC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.85	8.27	0.41	3.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	cis	rs35160687	0.644	rs2113615	chr2:86517602	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.02	0.31	4.55e-9	Night sleep phenotypes;
LIHC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.46	6.75	0.34	6.33e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.4	6.71	0.34	7.96e-11	Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.25	-0.32	1.21e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.97	-17.64	-0.69	5.52e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-19.93	-0.73	3.23e-59	Height;
LIHC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.75	-0.3	1.96e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg13264159	chr8:625131	ERICH1	-0.62	-6.31	-0.32	8.6e-10	IgG glycosylation;
LIHC	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.51	-0.33	2.73e-10	Hepatocellular carcinoma;
LIHC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.83	10.53	0.49	1.21e-22	Cognitive function;
LIHC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.64	11.68	0.53	9.31e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.74	12.49	0.56	9.24e-30	Menopause (age at onset);
LIHC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.67	-6.58	-0.34	1.81e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg26395211	chr5:140044315	WDR55	-0.41	-6.01	-0.31	4.69e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.81	0.47	3.42e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.99	0.35	1.44e-11	Heart rate;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.57	-10.47	-0.49	1.97e-22	Alzheimer's disease (late onset);
LIHC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg00149659	chr3:10157352	C3orf10	0.66	6.49	0.33	2.94e-10	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12484590	chr1:156475177	NA	0.48	7.33	0.37	1.66e-12	Cognitive function;
LIHC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg18016565	chr1:150552671	MCL1	0.59	11.48	0.53	4.85e-26	Melanoma;
LIHC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg15534755	chr11:117069859	TAGLN	0.37	6.28	0.32	1.04e-9	Blood protein levels;
LIHC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.39	-0.52	1.1e-25	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.41	5.86	0.3	1.11e-8	Iron status biomarkers;
LIHC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1144333	1.000	rs1340684	chr1:76471146	T/C	cg03433033	chr1:76189801	ACADM	0.52	7.58	0.38	3.19e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs611744	0.967	rs673854	chr8:109191838	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.7	0.43	1.37e-16	Dupuytren's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24923219	chr11:94964236	SESN3	0.43	6.11	0.31	2.74e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27297192	chr10:134578999	INPP5A	0.53	7.34	0.37	1.58e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-21.04	-0.75	1.16e-63	Height;
LIHC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg22633049	chr21:46681294	NA	-0.36	-6.16	-0.32	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.79	12.43	0.56	1.53e-29	Blood metabolite levels;
LIHC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.69	0.73	3.11e-58	Smoking behavior;
LIHC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.76	11.67	0.53	1.03e-26	Corneal astigmatism;
LIHC	cis	rs17106184	1.000	rs115072809	chr1:51023860	C/T	cg07174182	chr1:51127561	FAF1	-0.66	-7.07	-0.36	8.68e-12	Type 2 diabetes;
LIHC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.13	-0.31	2.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs1144333	1.000	rs78223982	chr1:76465203	T/C	cg03433033	chr1:76189801	ACADM	0.51	7.5	0.38	5.47e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.78	-14.61	-0.62	6.38e-38	Mortality in heart failure;
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.58	-0.34	1.78e-10	Longevity;Endometriosis;
LIHC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg22834771	chr12:69754056	YEATS4	-0.49	-8.48	-0.42	6.84e-16	Blood protein levels;
LIHC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.81	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs882732	1.000	rs8019677	chr14:95040431	C/T	cg14866387	chr14:95027382	SERPINA4	-0.44	-6.1	-0.31	2.94e-9	Blood protein levels;
LIHC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.58	-9.41	-0.45	7.29e-19	Colorectal cancer;
LIHC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.44	5.97	0.31	5.87e-9	Iron status biomarkers;
LIHC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.47	6.91	0.35	2.45e-11	Aortic root size;
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.44e-19	Bipolar disorder;
LIHC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.36	-0.37	1.41e-12	Obesity-related traits;
LIHC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.48	-0.46	4.57e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9980664	1.000	rs9978280	chr21:34736946	C/A	cg04842828	chr21:34696676	IFNAR1	0.46	6.15	0.32	2.21e-9	Cognitive decline (age-related);
LIHC	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.49	0.33	2.93e-10	Diastolic blood pressure;
LIHC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg03037974	chr15:76606532	NA	0.87	22.42	0.77	4.06e-69	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg11062466	chr8:58055876	NA	0.4	5.83	0.3	1.29e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.52	-0.46	3.16e-19	Schizophrenia;
LIHC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-0.97	-23.17	-0.78	4.65e-72	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7106204	0.514	rs2099889	chr11:24255971	A/G	ch.11.24196551F	chr11:24239977	NA	0.84	12.17	0.55	1.5e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.26	-6.22	-0.32	1.46e-9	Cutaneous nevi;
LIHC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.99	-0.31	5.31e-9	Longevity;
LIHC	cis	rs2882877	0.610	rs1123109	chr2:190444392	C/T	cg10752008	chr2:190445175	SLC40A1	-0.61	-7.42	-0.37	9.13e-13	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg23780635	chr8:1880114	ARHGEF10	0.29	6.05	0.31	3.83e-9	Myopia (pathological);
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg00280220	chr17:61926910	NA	0.42	6.55	0.33	2.06e-10	Prudent dietary pattern;
LIHC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.71	-11.02	-0.51	2.34e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1775715	0.870	rs1755085	chr10:32250931	T/C	cg14930904	chr10:32216787	ARHGAP12	0.4	7.08	0.36	8.33e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs16957091	0.909	rs3742988	chr15:43016475	A/G	cg24196017	chr15:43021976	CDAN1	-0.42	-6.01	-0.31	4.81e-9	MGMT methylation in smokers;
LIHC	cis	rs15676	0.783	rs2977996	chr9:131582625	C/T	cg00228799	chr9:131580591	ENDOG	0.47	6.96	0.35	1.73e-11	Blood metabolite levels;
LIHC	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-10.73	-0.5	2.37e-23	Rheumatoid arthritis;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.63	9.71	0.46	7.86e-20	Renal cell carcinoma;
LIHC	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-9.62	-0.46	1.5700000000000001e-19	Coffee consumption (cups per day);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01089589	chr2:10920095	ATP6V1C2	0.42	6.04	0.31	4.09e-9	Bilirubin levels;
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg21522988	chr12:29376872	FAR2	0.3	6.93	0.35	2.1e-11	QT interval;
LIHC	cis	rs539514	0.627	rs9544034	chr13:76293764	G/A	cg04757411	chr13:76259545	LMO7	-0.47	-8.22	-0.41	4.35e-15	Type 1 diabetes;
LIHC	cis	rs17106184	0.892	rs113730976	chr1:51217085	T/C	cg07174182	chr1:51127561	FAF1	-0.64	-7.3	-0.37	2.04e-12	Type 2 diabetes;
LIHC	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg03037974	chr15:76606532	NA	0.8	16.39	0.66	5.59e-45	Blood metabolite levels;
LIHC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg03959625	chr15:84868606	LOC388152	0.47	6.72	0.34	7.43e-11	Schizophrenia;
LIHC	cis	rs4788570	0.615	rs1423983	chr16:71701248	G/A	cg06353428	chr16:71660113	MARVELD3	1.4	14.67	0.62	4.04e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.4e-11	Diabetic kidney disease;
LIHC	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.63	-9.01	-0.44	1.51e-17	White matter hyperintensity burden;
LIHC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg20607798	chr8:58055168	NA	0.48	6.61	0.34	1.5e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg06972381	chr11:32851378	PRRG4	0.4	6.5	0.33	2.81e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.6	8.07	0.4	1.17e-14	Blood metabolite levels;
LIHC	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg23091122	chr1:110024289	SYPL2	-0.52	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.61	-7.44	-0.37	8e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.21	-0.32	1.52e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.73	-0.43	1.17e-16	Type 2 diabetes;
LIHC	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg05163923	chr11:71159392	DHCR7	-0.6	-7.37	-0.37	1.3e-12	Vitamin D levels;
LIHC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-0.62	-6.26	-0.32	1.18e-9	Obesity-related traits;
LIHC	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.32	0.49	6.7e-22	Diisocyanate-induced asthma;
LIHC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.76	15.09	0.63	8.84e-40	Mortality in heart failure;
LIHC	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	9.43	0.45	6.22e-19	Response to antipsychotic treatment;
LIHC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.59	8.28	0.41	2.72e-15	Blood metabolite levels;
LIHC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.46	8.09	0.4	1.05e-14	IgG glycosylation;
LIHC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	1.01	19.45	0.72	2.77e-57	Breast cancer;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02290350	chr8:58132656	NA	0.49	10.28	0.49	8.55e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.42	-5.76	-0.3	1.83e-8	Total body bone mineral density;
LIHC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.38	7.38	0.37	1.23e-12	Alcohol dependence;
LIHC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.5	6.19	0.32	1.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-0.89	-9.83	-0.47	3.11e-20	Magnesium levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11662638	chr2:45878864	PRKCE	-0.44	-6.36	-0.33	6.35e-10	Systolic blood pressure;
LIHC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg08499158	chr17:42289980	UBTF	-0.52	-9.04	-0.44	1.16e-17	Total body bone mineral density;
LIHC	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.82	0.6	7.75e-35	Coffee consumption (cups per day);
LIHC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg23283495	chr1:209979779	IRF6	0.42	6.87	0.35	3.08e-11	Cleft lip with or without cleft palate;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20286844	chr1:204485360	MDM4	0.41	6.21	0.32	1.5e-9	Cognitive function;
LIHC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg10820045	chr2:198174542	NA	0.57	9.51	0.46	3.43e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.68	-10.7	-0.5	3.12e-23	Skin colour saturation;
LIHC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.11	9.63	0.46	1.35e-19	Diabetic retinopathy;
LIHC	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg10319629	chr12:132285459	NA	-0.43	-7.45	-0.37	7.9e-13	Migraine;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.46	8.32	0.41	2.19e-15	Prudent dietary pattern;
LIHC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg24130564	chr14:104152367	KLC1	-0.54	-8.8	-0.43	6.79e-17	Reticulocyte count;
LIHC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.81	-6.59	-0.34	1.63e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.89	0.35	2.77e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.44	-7.37	-0.37	1.29e-12	Height;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-7.18	-0.36	4.4e-12	Lymphocyte counts;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg02592271	chr2:27665507	KRTCAP3	0.44	6.09	0.31	2.99e-9	Total body bone mineral density;
LIHC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.96	17.55	0.69	1.24e-49	Breast cancer;
LIHC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.81e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg00800038	chr16:89945340	TCF25	-0.63	-9.48	-0.46	4.32e-19	Skin colour saturation;
LIHC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.54	7.33	0.37	1.64e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.53	8.35	0.41	1.71e-15	Anterior chamber depth;
LIHC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16346588	chr10:242978	ZMYND11	0.39	6.0	0.31	5.01e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs986417	1.000	rs2224410	chr14:60970531	T/C	cg27398547	chr14:60952738	C14orf39	0.84	9.62	0.46	1.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.66	-5.94	-0.31	6.85e-9	Menopause (age at onset);
LIHC	cis	rs55665837	0.701	rs10766188	chr11:14660826	T/C	cg00085434	chr11:14927489	NA	0.42	5.89	0.3	9.38e-9	Vitamin D levels;
LIHC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.22	0.61	2.3e-36	Multiple sclerosis;
LIHC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.75	8.57	0.42	3.54e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs17106184	1.000	rs114210346	chr1:51398101	G/C	cg07174182	chr1:51127561	FAF1	-0.74	-8.35	-0.41	1.69e-15	Type 2 diabetes;
LIHC	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.34	7.75	0.39	1.03e-13	Blood metabolite ratios;
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg00091569	chr3:40428383	ENTPD3	0.39	6.6	0.34	1.59e-10	Renal cell carcinoma;
LIHC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.63	-5.84	-0.3	1.24e-8	Red cell distribution width;
LIHC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg02290350	chr8:58132656	NA	0.32	7.07	0.36	8.87e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs8113308	0.810	rs8105910	chr19:52447068	A/G	cg14959425	chr7:20447707	ITGB8	-0.47	-6.1	-0.31	2.88e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.43	-6.87	-0.35	3e-11	Height;
LIHC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.48	6.51	0.33	2.74e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.95	22.44	0.77	3.39e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.67	8.47	0.42	7.25e-16	Mean platelet volume;
LIHC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.47	6.78	0.34	5.15e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	11.11	0.52	1.07e-24	Post bronchodilator FEV1;
LIHC	cis	rs17106184	1.000	rs72902765	chr1:51256698	T/G	cg07174182	chr1:51127561	FAF1	-0.64	-6.89	-0.35	2.74e-11	Type 2 diabetes;
LIHC	cis	rs9596863	0.861	rs4088520	chr13:54441906	C/T	ch.13.53330881F	chr13:54432880	NA	-0.43	-6.08	-0.31	3.27e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.82	9.48	0.46	4.4e-19	Cognitive function;
LIHC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	9.97	0.47	1.01e-20	Alzheimer's disease (late onset);
LIHC	trans	rs16875255	0.505	rs7656616	chr4:24187951	A/G	cg24654547	chr16:68057165	DUS2L;DDX28	-0.49	-6.12	-0.31	2.51e-9	Parental longevity (combined parental age at death);
LIHC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.57	9.63	0.46	1.4e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.6	-0.38	2.92e-13	Initial pursuit acceleration;
LIHC	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg08992911	chr2:238395768	MLPH	-0.5	-5.92	-0.31	7.62e-9	Prostate cancer;
LIHC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.8	0.3	1.51e-8	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	24.16	0.79	6.12e-76	Prudent dietary pattern;
LIHC	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.76	-7.06	-0.36	9.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.46	7.6	0.38	2.88e-13	Alcohol dependence;
LIHC	cis	rs7546668	1.000	rs10803390	chr1:15865418	G/A	cg11706911	chr1:15910989	AGMAT	0.44	6.66	0.34	1.1e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.85	-0.3	1.13e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg14393609	chr7:65229607	NA	0.37	5.88	0.3	9.55e-9	Aortic root size;
LIHC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.42	5.72	0.3	2.38e-8	Height;
LIHC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.49	8.86	0.43	4.51e-17	HDL cholesterol levels;
LIHC	cis	rs7188697	0.845	rs1981960	chr16:58597289	C/G	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.86	11.13	0.52	9.49e-25	Cognitive function;
LIHC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.68	-0.5	3.48e-23	Alzheimer's disease;
LIHC	cis	rs7432375	0.901	rs1729951	chr3:136500733	T/G	cg21827317	chr3:136751795	NA	-0.46	-5.99	-0.31	5.29e-9	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.31	5.94	0.31	7.09e-9	Type 2 diabetes;
LIHC	trans	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.54	-0.33	2.26e-10	Educational attainment (years of education);
LIHC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.47	-0.37	6.65e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs3770081	1.000	rs60479377	chr2:86283948	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.96	-11.43	-0.53	7.58e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.37	5.8	0.3	1.5e-8	Menopause (age at onset);
LIHC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs11644362	1.000	rs72782620	chr16:12987416	T/A	cg06890432	chr16:12997467	SHISA9	-0.4	-6.77	-0.34	5.57e-11	Positive affect;Subjective well-being;
LIHC	cis	rs8084351	0.599	rs11082969	chr18:50680524	C/G	cg24270629	chr18:50823537	DCC	-0.47	-7.08	-0.36	8.42e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs11229555	0.645	rs10466659	chr11:58190112	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.67	9.95	0.47	1.22e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11053548	0.678	rs12228507	chr12:10174173	G/A	cg04314261	chr12:10163030	CLEC12B	0.41	6.24	0.32	1.27e-9	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-5.84	-0.3	1.2e-8	Aortic root size;
LIHC	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.49	8.29	0.41	2.7e-15	Schizophrenia;
LIHC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	1.02	11.32	0.52	1.91e-25	Triglycerides;
LIHC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20135002	chr11:47629003	NA	-0.53	-9.08	-0.44	8.63e-18	Subjective well-being;
LIHC	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.29	-6.81	-0.35	4.31e-11	Hip circumference;Waist circumference;
LIHC	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.59	-8.14	-0.4	7.28e-15	Vitamin D levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04860157	chr6:36842651	PPIL1	0.46	6.37	0.33	6.02e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.5	0.42	5.96e-16	Motion sickness;
LIHC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.22	-0.48	1.45e-21	Pancreatic cancer;
LIHC	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs6693295	0.711	rs4417032	chr1:246226428	G/A	cg22732515	chr19:44031385	ETHE1	0.45	6.28	0.32	1.01e-9	Migraine - clinic-based;Migraine with aura;
LIHC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.63	11.04	0.51	1.88e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.15e-11	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.77	-0.67	1.7e-46	Diabetic kidney disease;
LIHC	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg15192750	chr16:69999425	NA	0.43	6.37	0.33	5.95e-10	IgE levels;
LIHC	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.88	-6.95	-0.35	1.9e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.68	-0.42	1.68e-16	Cognitive function;
LIHC	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg07424592	chr7:64974309	NA	0.78	8.94	0.44	2.44e-17	Diabetic kidney disease;
LIHC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg00343986	chr7:65444356	GUSB	0.4	5.91	0.3	8.49e-9	Aortic root size;
LIHC	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.59	-11.6	-0.53	1.89e-26	Plateletcrit;Platelet count;
LIHC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.54	8.29	0.41	2.66e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.09	0.4	1.06e-14	Lymphocyte counts;
LIHC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg16434002	chr17:42200994	HDAC5	-0.51	-7.31	-0.37	1.88e-12	Total body bone mineral density;
LIHC	cis	rs2257205	0.667	rs77326197	chr17:56905618	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-6.46	-0.33	3.5e-10	Pancreatic cancer;
LIHC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.91	15.05	0.63	1.28e-39	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.69	11.35	0.52	1.45e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.87	12.87	0.57	3.59e-31	Menarche (age at onset);
LIHC	trans	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg16011800	chr17:1958478	HIC1	-0.46	-6.54	-0.33	2.29e-10	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.46	7.2	0.36	3.78e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-7.66	-0.38	1.97e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.37	5.93	0.31	7.28e-9	Lewy body disease;
LIHC	cis	rs1865721	1.000	rs8096298	chr18:73187608	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.57	-0.38	3.61e-13	Intelligence;
LIHC	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.53	-0.38	4.6e-13	Tuberculosis;
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02475777	chr4:1388615	CRIPAK	0.39	6.0	0.31	5.13e-9	Obesity-related traits;
LIHC	cis	rs11229555	0.645	rs7117080	chr11:58178677	C/G	cg15696309	chr11:58395628	NA	-0.64	-7.68	-0.38	1.67e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg24069376	chr3:38537580	EXOG	-0.43	-7.94	-0.39	2.98e-14	Electrocardiographic conduction measures;
LIHC	cis	rs7091068	0.616	rs1409336	chr10:95479674	T/G	cg20715218	chr10:95462985	C10orf4	0.54	5.82	0.3	1.32e-8	Urinary tract infection frequency;
LIHC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.66	9.76	0.47	5.32e-20	Breast cancer;
LIHC	cis	rs4908768	0.680	rs11121225	chr1:8816438	G/A	cg20416874	chr1:8611966	RERE	0.49	6.48	0.33	3.18e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-7.88	-0.39	4.34e-14	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.39	6.07	0.31	3.41e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.46	-7.56	-0.38	3.78e-13	Height;
LIHC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg17135325	chr3:160939158	NMD3	-0.5	-7.39	-0.37	1.15e-12	Morning vs. evening chronotype;
LIHC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05665937	chr4:1216051	CTBP1	0.45	5.82	0.3	1.32e-8	Obesity-related traits;
LIHC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.54e-9	Aortic root size;
LIHC	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg14146966	chr2:61757674	XPO1	0.48	8.31	0.41	2.23e-15	Tuberculosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27499259	chr13:28400924	NA	0.44	6.08	0.31	3.2e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.15	0.55	1.79e-28	Prudent dietary pattern;
LIHC	cis	rs10792665	0.640	rs7947363	chr11:82620671	C/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.13	-0.31	2.46e-9	Obesity-related traits;
LIHC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.43	-0.41	9.58e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.65	12.12	0.55	2.24e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs80282103	0.618	rs74117850	chr10:1165777	T/C	cg08668510	chr10:1095578	IDI1	0.63	6.06	0.31	3.51e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1355223	0.902	rs7130325	chr11:34750959	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.46	-0.33	3.61e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.85	0.3	1.17e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.92	-0.35	2.21e-11	Gout;
LIHC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.37	-7.96	-0.4	2.53e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	trans	rs72960926	0.744	rs114317207	chr6:74955867	C/T	cg07247405	chr1:2484626	LOC115110	0.53	6.37	0.33	6.01e-10	Metabolite levels (MHPG);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08269949	chr6:26538502	HMGN4	0.48	7.41	0.37	9.97e-13	Cognitive function;
LIHC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg12365402	chr11:9010492	NRIP3	0.31	7.91	0.39	3.7e-14	Hemoglobin concentration;
LIHC	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-17.06	-0.68	1.14e-47	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19614157	chr2:24150126	ATAD2B	0.51	6.37	0.33	6.23e-10	Hepatitis;
LIHC	trans	rs3783890	1.000	rs59713276	chr14:93738204	T/C	cg02802420	chr16:69363236	PDF;COG8	0.33	6.42	0.33	4.63e-10	Body mass index;
LIHC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.94	17.97	0.7	2.51e-51	Menopause (age at onset);
LIHC	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.87	10.9	0.51	6.08e-24	Prostate cancer;
LIHC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.77	-0.3	1.82e-8	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.43	6.16	0.32	2.08e-9	Aortic root size;
LIHC	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg21486233	chr12:29375141	FAR2	0.3	5.82	0.3	1.36e-8	QT interval;
LIHC	cis	rs79149102	0.737	rs113915655	chr15:75219722	T/C	cg16226627	chr15:75307476	SCAMP5	0.44	6.22	0.32	1.41e-9	Lung cancer;
LIHC	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.6	9.64	0.46	1.31e-19	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.61e-14	Prudent dietary pattern;
LIHC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.41	6.73	0.34	7.38e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02809263	chr1:70671218	LRRC40;SFRS11	0.44	6.24	0.32	1.3e-9	Pancreatic cancer;
LIHC	cis	rs3018712	0.532	rs2510397	chr11:68419559	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-5.79	-0.3	1.56e-8	Total body bone mineral density;
LIHC	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.34	0.41	1.88e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	0.96	18.06	0.7	1.09e-51	Monocyte percentage of white cells;
LIHC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.58	10.09	0.48	4.04e-21	Mean corpuscular volume;
LIHC	trans	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg26939375	chr7:64535504	NA	0.41	6.49	0.33	2.98e-10	Aortic root size;
LIHC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg02297831	chr4:17616191	MED28	0.47	6.93	0.35	2.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.38	-6.62	-0.34	1.36e-10	Permanent tooth development;
LIHC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-7.9	-0.39	3.88e-14	Platelet count;
LIHC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg05973401	chr12:123451056	ABCB9	0.47	6.12	0.31	2.6e-9	Neutrophil percentage of white cells;
LIHC	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.36	7.2	0.36	3.78e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.55	-7.92	-0.39	3.28e-14	Alzheimer's disease;
LIHC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.54	-0.59	9.42e-34	Vitiligo;
LIHC	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3823572	0.511	rs2971982	chr7:133657698	C/T	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.63	0.53	1.49e-26	Platelet count;
LIHC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg21756720	chr8:11724777	CTSB	0.5	5.92	0.3	7.86e-9	Neuroticism;
LIHC	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-9.32	-0.45	1.51e-18	Platelet distribution width;
LIHC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg06565975	chr8:143823917	SLURP1	0.34	6.35	0.32	6.98e-10	Urinary tract infection frequency;
LIHC	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.67	-9.38	-0.45	9.54e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.54	7.57	0.38	3.41e-13	Pulse pressure;
LIHC	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21545522	chr1:205238299	TMCC2	0.35	6.74	0.34	6.72e-11	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-6.15	-0.32	2.15e-9	Height;
LIHC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.22	0.45	3.17e-18	Bipolar disorder;
LIHC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-7.11	-0.36	6.92e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.55	-8.81	-0.43	6.23e-17	Menarche (age at onset);
LIHC	cis	rs2257205	0.667	rs6503881	chr17:56911251	C/T	cg12560992	chr17:57184187	TRIM37	0.66	7.24	0.36	3.03e-12	Pancreatic cancer;
LIHC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-8.67	-0.42	1.78e-16	Vitiligo;
LIHC	trans	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17183009	chr3:120277827	NA	0.52	6.23	0.32	1.38e-9	Corneal astigmatism;
LIHC	cis	rs4934494	0.911	rs6586213	chr10:91416084	G/A	cg19698084	chr10:91461284	KIF20B	-0.45	-6.18	-0.32	1.85e-9	Red blood cell count;
LIHC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.96	0.54	8.58e-28	Response to antipsychotic treatment;
LIHC	cis	rs4764487	0.687	rs3181300	chr12:6345199	C/T	cg08284733	chr12:6341482	CD9	0.33	5.74	0.3	2.07e-8	Mean platelet volume;
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.62	9.54	0.46	2.84e-19	Renal cell carcinoma;
LIHC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.47	7.85	0.39	5.34e-14	Mean corpuscular volume;
LIHC	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.43	6.54	0.33	2.21e-10	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg19431293	chr4:1319136	MAEA	-0.44	-7.01	-0.35	1.3e-11	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.21e-12	Renal cell carcinoma;
LIHC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.33	-7.23	-0.36	3.22e-12	Ulcerative colitis;
LIHC	trans	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg23283495	chr1:209979779	IRF6	-0.37	-6.32	-0.32	8.3e-10	Monobrow;
LIHC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.95	-16.46	-0.66	2.89e-45	Tonsillectomy;
LIHC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.91	11.07	0.51	1.51e-24	Primary sclerosing cholangitis;
LIHC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.85	-0.35	3.53e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.03	-0.48	6.26e-21	Neuroticism;
LIHC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg03959625	chr15:84868606	LOC388152	0.42	5.84	0.3	1.24e-8	Schizophrenia;
LIHC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg22532475	chr10:104410764	TRIM8	-0.3	-5.94	-0.31	7.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-9.69	-0.46	9.19e-20	Skin colour saturation;
LIHC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.48	0.46	4.53e-19	Bipolar disorder;
LIHC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.88	-8.8	-0.43	6.97e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.22	11.52	0.53	3.75e-26	Uric acid levels;
LIHC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.97	-0.44	2.02e-17	Blood metabolite levels;
LIHC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.36	-0.37	1.35e-12	Obesity-related traits;
LIHC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg13409248	chr3:40428643	ENTPD3	0.38	5.84	0.3	1.23e-8	Renal cell carcinoma;
LIHC	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.68	0.38	1.73e-13	Systemic lupus erythematosus;
LIHC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.39	6.25	0.32	1.22e-9	Tonsillectomy;
LIHC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg18898632	chr2:242989856	NA	-0.7	-8.65	-0.42	2.05e-16	Obesity-related traits;
LIHC	cis	rs763512	0.504	rs11652399	chr17:35869781	G/T	cg16670864	chr17:35848621	DUSP14	0.34	5.72	0.3	2.35e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg22777020	chr22:31556080	RNF185	-0.55	-6.26	-0.32	1.15e-9	Colorectal cancer;
LIHC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.45	6.01	0.31	4.73e-9	High light scatter reticulocyte count;
LIHC	cis	rs7707921	0.881	rs324914	chr5:81389950	C/T	cg15871215	chr5:81402204	ATG10	0.59	5.83	0.3	1.27e-8	Breast cancer;
LIHC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.39	-5.96	-0.31	6.34e-9	Systemic sclerosis;
LIHC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.41	0.52	9.38e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.0	0.31	4.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.41	-11.08	-0.51	1.41e-24	Longevity;Endometriosis;
LIHC	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.54	6.33	0.32	7.84e-10	Mammographic density (dense area);
LIHC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-7.83	-0.39	6.27e-14	Initial pursuit acceleration;
LIHC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.44	5.9	0.3	8.82e-9	Subjective well-being;
LIHC	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg19500275	chr17:80737654	TBCD	0.5	7.34	0.37	1.6e-12	Glycated hemoglobin levels;
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.39	-6.16	-0.32	2.06e-9	Testicular germ cell tumor;
LIHC	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.58	6.41	0.33	4.92e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	9.22	0.45	3.01e-18	Parkinson's disease;
LIHC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.55	-0.38	3.87e-13	Chronic sinus infection;
LIHC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04025307	chr7:1156635	C7orf50	0.55	7.33	0.37	1.68e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04013166	chr16:89971882	TCF25	0.6	7.9	0.39	3.72e-14	Skin colour saturation;
LIHC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.53	-0.79	1.77e-73	Height;
LIHC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.58	-9.79	-0.47	4.03e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg00091569	chr3:40428383	ENTPD3	0.35	5.73	0.3	2.18e-8	Renal cell carcinoma;
LIHC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.39	-6.74	-0.34	6.71e-11	Headache;
LIHC	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	0.79	9.18	0.44	4.09e-18	Exhaled nitric oxide output;
LIHC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.35	-6.39	-0.33	5.29e-10	Aortic root size;
LIHC	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg24642439	chr20:33292090	TP53INP2	0.78	10.13	0.48	2.79e-21	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg20651018	chr11:3035856	CARS	-0.35	-5.79	-0.3	1.63e-8	Longevity;
LIHC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg07148914	chr20:33460835	GGT7	-0.55	-8.29	-0.41	2.63e-15	Height;
LIHC	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg00277334	chr10:82204260	NA	-0.49	-6.02	-0.31	4.4e-9	Post bronchodilator FEV1;
LIHC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg02290350	chr8:58132656	NA	0.32	6.97	0.35	1.63e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg18809830	chr7:99032528	PTCD1	-0.83	-6.45	-0.33	3.76e-10	Blood metabolite levels;
LIHC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	8.01	0.4	1.76e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.17	0.32	1.88e-9	Cognitive ability;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg19635926	chr16:89946313	TCF25	0.57	7.56	0.38	3.82e-13	Skin colour saturation;
LIHC	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg04865290	chr3:52927548	TMEM110	-0.48	-7.04	-0.36	1.03e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs360798	0.532	rs12713468	chr2:62983213	G/A	cg17519650	chr2:63277830	OTX1	-0.54	-8.38	-0.41	1.44e-15	Coronary artery disease;
LIHC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg03037974	chr15:76606532	NA	-0.66	-11.75	-0.54	5.35e-27	Blood metabolite levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20750930	chr12:133159939	FBRSL1	0.43	6.35	0.32	6.75e-10	Longevity;
LIHC	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23598886	chr18:12777645	NA	-0.46	-6.16	-0.32	2.03e-9	Inflammatory skin disease;
LIHC	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.88	-0.47	2.04e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.84	-0.3	1.2e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.67	10.27	0.49	9.62e-22	Longevity;
LIHC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.39	0.37	1.15e-12	Lung cancer;
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	0.72	12.48	0.56	1.02e-29	Testicular germ cell tumor;
LIHC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.89	0.65	5.71e-43	White blood cell count;
LIHC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-11.32	-0.52	1.97e-25	Chronic sinus infection;
LIHC	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.52	8.97	0.44	1.98e-17	Coronary artery disease;
LIHC	cis	rs1144333	1.000	rs5745392	chr1:76306809	C/T	cg22875332	chr1:76189707	ACADM	0.44	7.07	0.36	8.86e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg24069376	chr3:38537580	EXOG	0.43	7.9	0.39	3.93e-14	Electrocardiographic conduction measures;
LIHC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	8.18	0.4	5.65e-15	Response to antipsychotic treatment;
LIHC	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg22771759	chr13:24902376	NA	0.33	6.75	0.34	6.21e-11	Obesity-related traits;
LIHC	cis	rs9513627	0.588	rs9585073	chr13:100128516	A/G	cg25919922	chr13:100150906	NA	-0.77	-6.89	-0.35	2.74e-11	Obesity-related traits;
LIHC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-8.89	-0.43	3.59e-17	Gut microbiome composition (summer);
LIHC	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-8.47	-0.42	7.3e-16	Morning vs. evening chronotype;
LIHC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg19645103	chr12:69753606	YEATS4	0.44	5.98	0.31	5.6e-9	Response to diuretic therapy;
LIHC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.44	5.83	0.3	1.3e-8	Initial pursuit acceleration;
LIHC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.16	30.42	0.85	2.6e-99	IgG glycosylation;
LIHC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.06e-25	Tonsillectomy;
LIHC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.41	-6.2	-0.32	1.58e-9	Platelet count;
LIHC	cis	rs2108225	0.714	rs929394	chr7:107437252	C/T	cg18560240	chr7:107437656	SLC26A3	-0.54	-8.74	-0.43	1.03e-16	Ulcerative colitis;
LIHC	cis	rs16912059	0.661	rs16912302	chr11:24267144	A/G	ch.11.24196551F	chr11:24239977	NA	0.73	6.09	0.31	3.04e-9	Thrombin-antithrombin complex levels in ischemic stroke;
LIHC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	6.05	0.31	3.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.43	5.81	0.3	1.43e-8	Alzheimer's disease;
LIHC	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.83e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg12437481	chr16:420112	MRPL28	-0.63	-9.05	-0.44	1.11e-17	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.91	14.48	0.62	2.15e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-14.64	-0.62	4.92e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.78	-13.92	-0.6	3.4000000000000003e-35	Coronary artery disease;
LIHC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.26	-0.37	2.61e-12	Pancreatic cancer;
LIHC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.32e-9	Lung cancer in ever smokers;
LIHC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.61	-9.61	-0.46	1.63e-19	Monocyte percentage of white cells;
LIHC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.38	5.94	0.31	6.96e-9	Resting heart rate;
LIHC	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg16070018	chr6:26224392	HIST1H3E	0.57	6.63	0.34	1.28e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.49	-7.64	-0.38	2.21e-13	P wave terminal force;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02664216	chr12:19592651	AEBP2	0.45	6.23	0.32	1.34e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.36	0.61	6.46e-37	Prudent dietary pattern;
LIHC	cis	rs7395581	0.959	rs7129661	chr11:47268550	T/G	cg26139080	chr11:47293733	MADD	-0.49	-8.28	-0.41	2.71e-15	HDL cholesterol;
LIHC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.51	7.99	0.4	2.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg14580859	chr9:123691850	NA	0.39	6.79	0.34	4.96e-11	Rheumatoid arthritis;
LIHC	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.53	-8.72	-0.43	1.27e-16	Cocaine dependence;
LIHC	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	0.86	7.22	0.36	3.31e-12	Uric acid levels;
LIHC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.58	-0.53	2.12e-26	Chronic sinus infection;
LIHC	cis	rs4917833	0.700	rs7067691	chr10:100221081	T/C	cg19043522	chr10:100227446	HPSE2	0.4	5.77	0.3	1.8e-8	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.51	-8.9	-0.43	3.28e-17	Total body bone mineral density;
LIHC	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.42	6.8	0.35	4.59e-11	Menopause (age at onset);
LIHC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.81	10.09	0.48	4.05e-21	Cognitive function;
LIHC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.8	-0.3	1.51e-8	Menopause (age at onset);
LIHC	cis	rs4660306	0.614	rs12032658	chr1:45923851	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	6.8	0.35	4.57e-11	Homocysteine levels;
LIHC	trans	rs7504990	0.722	rs34899419	chr18:50359614	G/C	cg08535148	chr4:26321143	RBPJ	0.54	6.73	0.34	7.03e-11	Gallbladder cancer;
LIHC	cis	rs7078219	0.505	rs1548964	chr10:101289653	C/G	cg06854084	chr10:101292507	NKX2-3	0.32	5.75	0.3	1.97e-8	Dental caries;
LIHC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.24e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.88	-17.76	-0.69	1.76e-50	Height;
LIHC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.67	10.1	0.48	3.78e-21	Response to diuretic therapy;
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg14646974	chr10:38645378	HSD17B7P2	-0.42	-5.92	-0.31	7.67e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.25	-13.43	-0.59	2.45e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18441082	chr5:16466057	ZNF622	0.46	6.65	0.34	1.16e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg10820045	chr2:198174542	NA	0.46	6.82	0.35	4.02e-11	Dermatomyositis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17947461	chr1:87797169	LMO4	0.45	6.52	0.33	2.49e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg02344993	chr17:57696989	CLTC	-0.57	-9.29	-0.45	1.78e-18	Hemoglobin concentration;
LIHC	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.78	12.96	0.57	1.57e-31	Phospholipid levels (plasma);
LIHC	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg06026331	chr20:60912101	LAMA5	0.48	6.44	0.33	4.05e-10	Colorectal cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06552368	chr11:118972898	DPAGT1	-0.52	-6.45	-0.33	3.88e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.73	0.34	7.2e-11	Bipolar disorder;
LIHC	trans	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg10756647	chr7:56101905	PSPH	1.1	13.4	0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg24826892	chr11:71159390	DHCR7	0.49	6.27	0.32	1.08e-9	Vitamin D levels;
LIHC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg18867708	chr6:26865862	GUSBL1	0.54	8.24	0.41	3.74e-15	Schizophrenia;
LIHC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	9.58	0.46	2.02e-19	Lung cancer in ever smokers;
LIHC	cis	rs16958440	0.609	rs75911383	chr18:44716011	C/T	cg17192377	chr18:44677553	HDHD2	0.91	8.68	0.42	1.64e-16	Sitting height ratio;
LIHC	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.43	7.81	0.39	6.88e-14	Schizophrenia;
LIHC	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.36	-8.56	-0.42	3.75e-16	Cutaneous nevi;
LIHC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.54	7.72	0.39	1.25e-13	Prostate cancer;
LIHC	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.51	8.25	0.41	3.48e-15	Corneal astigmatism;
LIHC	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg20283391	chr11:68216788	NA	0.38	6.12	0.31	2.51e-9	Total body bone mineral density;
LIHC	cis	rs981946	0.965	rs9503565	chr6:3369031	A/G	cg18842474	chr6:3356384	SLC22A23	0.38	5.92	0.31	7.7e-9	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
LIHC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.64	9.7	0.46	8.08e-20	Corneal astigmatism;
LIHC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.77	0.39	9.22e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.77	0.34	5.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs12493885	0.725	rs73158427	chr3:153721493	T/A	cg10247383	chr3:153839028	SGEF	0.65	6.12	0.31	2.58e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs986417	0.901	rs1010052	chr14:61003071	G/A	cg27398547	chr14:60952738	C14orf39	0.83	9.47	0.46	4.66e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.4	8.12	0.4	8.47e-15	Cardiovascular disease risk factors;
LIHC	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.25	6.23	0.32	1.35e-9	Obesity-related traits;
LIHC	cis	rs9513627	1.000	rs7338761	chr13:100119731	A/G	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.91	-0.75	3.87e-63	Height;
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg12064134	chr16:90016061	DEF8	-0.46	-6.11	-0.31	2.78e-9	Skin colour saturation;
LIHC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg19318889	chr4:1322082	MAEA	0.46	6.48	0.33	3.24e-10	Obesity-related traits;
LIHC	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.45	7.18	0.36	4.39e-12	Corneal astigmatism;
LIHC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.56	5.77	0.3	1.81e-8	Smoking initiation;
LIHC	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg13512537	chr8:22265999	SLC39A14	-0.35	-5.94	-0.31	6.86e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.12	16.62	0.67	6.91e-46	Sexual dysfunction (female);
LIHC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	trans	rs12780046	0.656	rs1970536	chr10:100823868	T/C	cg05980083	chr9:112191166	PTPN3	-0.47	-6.27	-0.32	1.09e-9	Non-glioblastoma glioma;
LIHC	cis	rs2607426	0.681	rs17726258	chr19:41287605	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.5	-6.5	-0.33	2.77e-10	Blood protein levels;
LIHC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg22496339	chr2:162101262	NA	-0.52	-7.07	-0.36	8.57e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs4407350	1.000	rs4373014	chr22:44922424	C/T	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.05	-0.31	3.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11630290	0.592	rs11071769	chr15:64156842	G/C	cg12036633	chr15:63758958	NA	0.62	6.62	0.34	1.43e-10	Iris characteristics;
LIHC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.07	-0.63	1e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.66	-9.21	-0.45	3.36e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-15.23	-0.64	2.43e-40	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.36	0.49	4.72e-22	Colorectal cancer;
LIHC	cis	rs422249	0.593	rs174613	chr11:61628492	G/A	cg27386326	chr11:61587980	NA	0.33	5.82	0.3	1.36e-8	Trans fatty acid levels;
LIHC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg15691649	chr6:25882328	NA	-0.51	-7.39	-0.37	1.14e-12	Blood metabolite levels;
LIHC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-14.25	-0.61	1.64e-36	Height;
LIHC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.6	-7.62	-0.38	2.54e-13	Diastolic blood pressure;
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.45	7.66	0.38	1.91e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-9.54	-0.46	2.69e-19	Mean corpuscular volume;
LIHC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg14092571	chr14:90743983	NA	-0.38	-6.05	-0.31	3.86e-9	Mortality in heart failure;
LIHC	cis	rs75908454	1.000	rs74908176	chr6:169936353	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.75	-0.39	1.04e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.53	8.85	0.43	4.92e-17	Type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg00091569	chr3:40428383	ENTPD3	0.4	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.85	10.68	0.5	3.59e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.53	8.8	0.43	7.06e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs1385374	0.920	rs61946175	chr12:129273021	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.66	0.38	1.97e-13	Systemic lupus erythematosus;
LIHC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs918629	0.567	rs10069748	chr5:95241222	C/T	cg10483112	chr5:95245456	ELL2	0.38	7.03	0.36	1.16e-11	IgG glycosylation;
LIHC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-12.5	-0.56	8.97e-30	Vitiligo;
LIHC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.72	-10.28	-0.49	9.19e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.59	7.59	0.38	3e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.57	9.86	0.47	2.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.4	-6.47	-0.33	3.43e-10	Anterior chamber depth;
LIHC	cis	rs2274273	1.000	rs3825613	chr14:55593172	A/C	cg01864836	chr14:55583639	NA	-0.36	-6.15	-0.32	2.14e-9	Protein biomarker;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg01737828	chr15:75230659	COX5A	-0.48	-6.18	-0.32	1.82e-9	Facial morphology (factor 20);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17040068	chr7:102715209	ARMC10;FBXL13	0.45	6.59	0.34	1.62e-10	Pancreatic cancer;
LIHC	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.5	-7.81	-0.39	7.2e-14	Cocaine dependence;
LIHC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.45	7.84	0.39	5.68e-14	Mean corpuscular volume;
LIHC	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg03037974	chr15:76606532	NA	0.74	14.43	0.62	3.4e-37	Blood metabolite levels;
LIHC	cis	rs1982963	0.950	rs2645749	chr14:52502795	C/A	cg10843707	chr14:52510701	NID2	-0.43	-7.18	-0.36	4.27e-12	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.41	7.13	0.36	6.12e-12	Alzheimer's disease (late onset);
LIHC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.64	-9.09	-0.44	8.02e-18	Blood metabolite levels;
LIHC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.65	8.36	0.41	1.57e-15	Gut microbiome composition (summer);
LIHC	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg26138937	chr11:71823887	C11orf51	-1.32	-10.9	-0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.34	6.21	0.32	1.57e-9	Mean corpuscular volume;
LIHC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg03037974	chr15:76606532	NA	0.74	14.44	0.62	3.1e-37	Blood metabolite levels;
LIHC	cis	rs2235649	0.592	rs7197113	chr16:1969483	G/A	cg00564555	chr16:1970112	NA	-0.28	-5.93	-0.31	7.45e-9	Blood metabolite levels;
LIHC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.52	8.27	0.41	2.91e-15	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.96e-16	Prudent dietary pattern;
LIHC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.41	-8.63	-0.42	2.28e-16	Obesity-related traits;
LIHC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.33	-0.41	1.97e-15	Gut microbiome composition (summer);
LIHC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.38	7.83	0.39	6.01e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs4699052	1.000	rs4699055	chr4:104154500	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-6.63	-0.34	1.3100000000000001e-10	Testicular germ cell tumor;
LIHC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.44	-7.16	-0.36	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	10.74	0.5	2.16e-23	Lung cancer in ever smokers;
LIHC	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.45	6.04	0.31	3.94e-9	Bladder cancer;
LIHC	cis	rs2467099	0.786	rs1463486	chr17:73943942	G/A	cg08125733	chr17:73851984	WBP2	0.46	5.78	0.3	1.69e-8	Systolic blood pressure;
LIHC	cis	rs17428076	0.793	rs7584258	chr2:172659836	A/G	cg13550731	chr2:172543902	DYNC1I2	0.39	6.23	0.32	1.4e-9	Myopia;
LIHC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Educational attainment;
LIHC	cis	rs6782228	0.606	rs2712405	chr3:128332082	T/C	cg16766828	chr3:128327626	NA	-0.41	-6.42	-0.33	4.62e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.25	-7.77	-0.39	9.52e-14	Motion sickness;
LIHC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.68	-0.34	9.86e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.65	0.56	2.36e-30	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.44	8.07	0.4	1.17e-14	Prudent dietary pattern;
LIHC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg03037974	chr15:76606532	NA	0.66	11.99	0.54	7.01e-28	Blood metabolite levels;
LIHC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.43	6.75	0.34	6.44e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg08847533	chr14:75593920	NEK9	-0.58	-9.46	-0.46	5.32e-19	IgG glycosylation;
LIHC	cis	rs2412488	0.893	rs11947256	chr4:54289362	G/A	cg22241045	chr4:54363911	LNX1	-0.43	-6.97	-0.35	1.68e-11	DNA methylation (variation);
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.67	10.06	0.48	4.98e-21	Menarche (age at onset);
LIHC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.45	6.19	0.32	1.74e-9	Tonsillectomy;
LIHC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	1.0	23.05	0.78	1.35e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.86	-8.68	-0.42	1.67e-16	Blood protein levels;
LIHC	cis	rs600806	0.854	rs367586	chr1:109850122	C/A	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.03	-0.31	4.24e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.39	-0.37	1.14e-12	Body mass index;
LIHC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.45	6.56	0.33	1.97e-10	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08188400	chr19:7969347	MAP2K7	0.46	6.98	0.35	1.55e-11	Pancreatic cancer;
LIHC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.59	0.5	7.61e-23	Colorectal cancer;
LIHC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.54	8.05	0.4	1.35e-14	Colorectal cancer;
LIHC	cis	rs3791406	0.500	rs3791414	chr2:240032214	T/C	cg14550559	chr2:240039617	HDAC4	-0.67	-8.38	-0.41	1.36e-15	Skin aging (microtopography measurement);
LIHC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.61	-10.92	-0.51	4.95e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	11.44	0.53	7.25e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.57	0.53	2.29e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg11632617	chr15:75315747	PPCDC	0.47	6.66	0.34	1.1e-10	Blood trace element (Zn levels);
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7116495	1.000	rs55972015	chr11:71642576	C/G	cg26138937	chr11:71823887	C11orf51	-0.76	-7.75	-0.39	1.09e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.39	6.23	0.32	1.37e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.33	-6.36	-0.33	6.39e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02477380	chr7:156931759	UBE3C	-0.4	-6.31	-0.32	8.85e-10	Calcium levels;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.03	-0.44	1.24e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.76	18.08	0.7	9.06e-52	Brugada syndrome;
LIHC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.33	7.3	0.37	2.01e-12	Ulcerative colitis;
LIHC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.71	10.55	0.5	1.02e-22	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.25	0.32	1.23e-9	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	0.39	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	6.29	0.32	9.6e-10	Schizophrenia;
LIHC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.73	0.65	2.57e-42	Lymphocyte percentage of white cells;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg04857149	chr18:24237060	NA	-0.46	-6.05	-0.31	3.74e-9	Electroencephalogram traits;
LIHC	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg13753209	chr17:57696993	CLTC	0.77	12.28	0.55	6.02e-29	Hemoglobin concentration;
LIHC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.7	-12.84	-0.57	4.5e-31	Dental caries;
LIHC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg21466736	chr12:48725269	NA	0.69	10.86	0.51	8.09e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-7.43	-0.37	8.69e-13	Schizophrenia;
LIHC	cis	rs7756236	0.521	rs9462209	chr6:36628042	T/G	cg08179530	chr6:36648295	CDKN1A	0.41	6.07	0.31	3.41e-9	QRS duration;
LIHC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg05044414	chr3:183734942	ABCC5	0.34	5.97	0.31	6.01e-9	Anterior chamber depth;
LIHC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg21724239	chr8:58056113	NA	0.46	6.23	0.32	1.36e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.15	0.32	2.13e-9	Diastolic blood pressure;
LIHC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.8	-12.45	-0.56	1.35e-29	Total body bone mineral density;
LIHC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-21.62	-0.76	6.02e-66	Height;
LIHC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-7.86	-0.39	5.08e-14	Red cell distribution width;Reticulocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22627950	chr7:44622302	TMED4	0.47	6.58	0.34	1.79e-10	Pancreatic cancer;
LIHC	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.43	8.41	0.41	1.12e-15	Testicular germ cell tumor;
LIHC	trans	rs7714584	0.590	rs4352593	chr5:150269332	T/C	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg03934865	chr2:198174659	NA	0.57	8.76	0.43	9.31e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.45	-0.33	3.8e-10	Mean corpuscular volume;
LIHC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.64	0.34	1.24e-10	Rheumatoid arthritis;
LIHC	trans	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.78e-9	Ulcerative colitis;
LIHC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg23978390	chr7:1156363	C7orf50	-0.52	-8.07	-0.4	1.22e-14	Longevity;Endometriosis;
LIHC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg01788221	chr16:89496183	ANKRD11	-0.4	-6.23	-0.32	1.36e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.41	-7.17	-0.36	4.8e-12	Lung cancer;
LIHC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.95	0.31	6.6e-9	Height;
LIHC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.55e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.44	-8.05	-0.4	1.41e-14	Electrocardiographic conduction measures;
LIHC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-7.05	-0.36	9.98e-12	Monocyte percentage of white cells;
LIHC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.5	7.45	0.37	7.51e-13	Coronary artery disease;
LIHC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.42	6.47	0.33	3.36e-10	Height;
LIHC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.15	0.36	5.29e-12	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.24	0.41	3.82e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098699	0.821	rs2047582	chr4:124232496	C/A	cg09941581	chr4:124220074	SPATA5	0.31	6.16	0.32	2e-9	Mosquito bite size;
LIHC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.42	7.01	0.35	1.26e-11	Crohn's disease;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg04013166	chr16:89971882	TCF25	0.55	7.23	0.36	3.16e-12	Skin colour saturation;
LIHC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.54	-0.38	4.32e-13	Chronic sinus infection;
LIHC	cis	rs12744310	0.887	rs28566545	chr1:41783233	G/A	cg03962019	chr1:41807865	NA	0.39	6.23	0.32	1.38e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.21	-0.32	1.52e-9	Tonsillectomy;
LIHC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.58	7.6	0.38	2.9e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.94	-0.35	1.96e-11	Acylcarnitine levels;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg26218726	chr12:122018391	KDM2B	-0.43	-6.17	-0.32	1.9e-9	Neuroblastoma;
LIHC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06634786	chr22:41940651	POLR3H	0.55	6.04	0.31	4e-9	Vitiligo;
LIHC	cis	rs3736485	0.966	rs4775958	chr15:51891562	G/C	cg08986416	chr15:51914746	DMXL2	-0.41	-6.02	-0.31	4.61e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.37	7.39	0.37	1.1e-12	Immature fraction of reticulocytes;
LIHC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.71	-0.3	2.43e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg21573476	chr21:45109991	RRP1B	-0.52	-9.8	-0.47	3.81e-20	Mean corpuscular volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12508214	chr8:124553600	FBXO32	0.39	6.22	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.65	6.97	0.35	1.63e-11	Alzheimer's disease;
LIHC	trans	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.42	6.28	0.32	1.01e-9	Endometrial cancer;
LIHC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.12	0.4	8.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.74	0.39	1.12e-13	Mean platelet volume;
LIHC	cis	rs1914816	0.941	rs2957037	chr15:76485536	A/G	cg03037974	chr15:76606532	NA	-0.59	-6.2	-0.32	1.67e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.38	5.83	0.3	1.26e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	12.14	0.55	1.86e-28	Schizophrenia;
LIHC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs2163237	0.965	rs6748103	chr2:55986042	C/T	cg18811423	chr2:55921094	PNPT1	0.5	7.02	0.35	1.18e-11	IgG glycosylation;
LIHC	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.44	-8.88	-0.43	3.88e-17	Type 1 diabetes;
LIHC	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.43	8.3	0.41	2.46e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg05044414	chr3:183734942	ABCC5	0.35	6.16	0.32	2.07e-9	Anterior chamber depth;
LIHC	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.86	0.47	2.39e-20	Colorectal cancer;
LIHC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.96	-17.19	-0.68	3.41e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.34	7.32	0.37	1.79e-12	Metabolite levels (MHPG);
LIHC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.55	8.75	0.43	1.01e-16	Birth weight;
LIHC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	0.74	8.02	0.4	1.71e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	10.22	0.48	1.39e-21	Multiple sclerosis;
LIHC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg23791538	chr6:167370224	RNASET2	0.45	6.8	0.35	4.62e-11	Primary biliary cholangitis;
LIHC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.95	0.31	6.79e-9	Electroencephalogram traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24995352	chr10:13203403	MCM10	0.46	6.07	0.31	3.31e-9	Pancreatic cancer;
LIHC	cis	rs903552	0.935	rs12907726	chr15:102003626	C/G	cg25677261	chr15:102009856	PCSK6	-0.43	-5.92	-0.3	7.76e-9	Diabetic kidney disease;
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.44	6.13	0.31	2.49e-9	Aortic root size;
LIHC	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.52	9.79	0.47	3.98e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.88	-0.43	3.8e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.74	-0.54	5.79e-27	Coffee consumption (cups per day);
LIHC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.5	5.92	0.3	7.8e-9	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs238295	0.805	rs6053486	chr20:5530767	T/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.86	-0.35	3.22e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.49	7.47	0.37	6.83e-13	Obesity-related traits;
LIHC	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.5	7.26	0.37	2.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.66	6.74	0.34	6.83e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.76e-11	Coronary artery disease;
LIHC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.7	-9.23	-0.45	2.83e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.34	-5.74	-0.3	2.09e-8	IgG glycosylation;
LIHC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-9.37	-0.45	9.88e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg26566898	chr11:117069891	TAGLN	0.48	7.41	0.37	1.01e-12	Blood protein levels;
LIHC	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg16309518	chr5:176445507	NA	0.49	8.88	0.43	3.92e-17	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.45	-7.26	-0.37	2.55e-12	Fibrinogen levels;
LIHC	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.34	12.54	0.56	6.12e-30	Uric acid levels;
LIHC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.66e-9	Bipolar disorder;
LIHC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.66	9.79	0.47	4.16e-20	Menopause (age at onset);
LIHC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.12	-0.52	9.86e-25	Coronary artery disease;
LIHC	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.89	0.35	2.69e-11	Educational attainment;
LIHC	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.88	-14.96	-0.63	2.73e-39	Gastritis;
LIHC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.26	6.17	0.32	1.95e-9	Crohn's disease;
LIHC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.66	6.97	0.35	1.65e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10505247	chr1:207226475	PFKFB2	0.44	6.06	0.31	3.57e-9	Lung function (FEV1/FVC);
LIHC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.89	-17.99	-0.7	2.08e-51	Coronary artery disease;
LIHC	cis	rs716804	0.703	rs4491213	chr11:10306882	G/C	cg01453529	chr11:10209919	SBF2	-0.29	-5.87	-0.3	1.01e-8	Neuroticism;
LIHC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.39	6.27	0.32	1.09e-9	Menopause (age at onset);
LIHC	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.44	6.89	0.35	2.63e-11	Ulcerative colitis;
LIHC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.71	10.56	0.5	9.29e-23	Aortic root size;
LIHC	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.42	6.33	0.32	7.77e-10	Neutrophil percentage of white cells;
LIHC	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.48	7.2	0.36	3.87e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Corneal astigmatism;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.76	13.95	0.6	2.59e-35	Blood protein levels;
LIHC	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg01990225	chr2:97406019	LMAN2L	-0.7	-6.44	-0.33	4.12e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs4908768	0.539	rs2100888	chr1:8659282	T/A	cg20416874	chr1:8611966	RERE	-0.61	-11.1	-0.51	1.17e-24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.54	-8.71	-0.43	1.34e-16	Total body bone mineral density;
LIHC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.43	-0.56	1.59e-29	Alzheimer's disease;
LIHC	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg10587741	chr22:38071170	LGALS1	0.44	7.97	0.4	2.42e-14	Fat distribution (HIV);
LIHC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.66	8.68	0.43	1.61e-16	Response to antineoplastic agents;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.21e-12	Renal cell carcinoma;
LIHC	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.42	5.89	0.3	9.06e-9	Breast cancer;
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.46	-0.37	7.36e-13	Renal cell carcinoma;
LIHC	cis	rs4794202	0.700	rs11079797	chr17:45912302	C/T	cg10638573	chr17:45915098	SCRN2	0.51	5.99	0.31	5.41e-9	Alzheimer's disease (cognitive decline);
LIHC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg05484376	chr2:27715224	FNDC4	0.34	5.75	0.3	2.03e-8	Total body bone mineral density;
LIHC	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.02e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg00277334	chr10:82204260	NA	-0.47	-6.81	-0.35	4.34e-11	Post bronchodilator FEV1;
LIHC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.54	0.56	6.32e-30	Gut microbiome composition (summer);
LIHC	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-10.05	-0.48	5.39e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-6.54	-0.33	2.29e-10	Metabolite levels;
LIHC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-7.5	-0.38	5.58e-13	Crohn's disease;
LIHC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.96	-0.31	6.13e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05590025	chr7:65112418	INTS4L2	-0.46	-6.93	-0.35	2.1e-11	Calcium levels;
LIHC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.58	-11.27	-0.52	2.83e-25	Body mass index;
LIHC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs713477	0.654	rs6573030	chr14:55913720	T/G	cg13175173	chr14:55914753	NA	-0.32	-7.2	-0.36	3.78e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.22	5.78	0.3	1.66e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.45	-0.46	5.33e-19	Colorectal cancer;
LIHC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.46	7.09	0.36	7.93e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4920343	0.698	rs578988	chr1:19077291	T/C	cg19637330	chr1:19110922	NA	0.31	5.75	0.3	1.97e-8	Knee osteoarthritis;
LIHC	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.25	-6.48	-0.33	3.28e-10	Menarche (age at onset);
LIHC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.26	-0.45	2.26e-18	Hemoglobin concentration;
LIHC	trans	rs10511404	1.000	rs10511404	chr3:120518357	G/A	cg09889680	chr22:21922804	UBE2L3	-0.51	-6.51	-0.33	2.65e-10	Tumor necrosis factor alpha levels;
LIHC	trans	rs1347297	0.614	rs4894017	chr2:179281062	C/T	cg14011486	chr1:26737247	LIN28	0.63	10.08	0.48	4.18e-21	Alzheimer disease and age of onset;
LIHC	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.38	12.4	0.56	2.02e-29	Uric acid levels;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg07061783	chr6:25882402	NA	0.43	5.76	0.3	1.85e-8	Blood metabolite levels;
LIHC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.45	-7.55	-0.38	4.01e-13	Testicular germ cell tumor;
LIHC	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.69	0.43	1.51e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg15123519	chr2:136567270	LCT	-0.37	-5.92	-0.3	7.82e-9	Corneal structure;
LIHC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.51	-18.77	-0.71	1.57e-54	Breast cancer;
LIHC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.31	0.32	8.71e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.25	0.52	3.29e-25	Coronary artery disease;
LIHC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.35	7.35	0.37	1.45e-12	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.5	0.38	5.37e-13	Electroencephalogram traits;
LIHC	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.55	-8.85	-0.43	4.87e-17	Eosinophilic esophagitis;
LIHC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.95	-0.31	6.63e-9	Menopause (age at onset);
LIHC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.72	-10.9	-0.51	6e-24	Aortic root size;
LIHC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.82e-31	Breast cancer;
LIHC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.88	15.2	0.63	3.17e-40	Colorectal cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21897413	chr5:176944084	DDX41	-0.42	-6.17	-0.32	1.91e-9	Immature fraction of reticulocytes;
LIHC	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6466055	0.777	rs6466053	chr7:104923929	C/T	cg04380332	chr7:105027541	SRPK2	0.37	6.86	0.35	3.2e-11	Schizophrenia;
LIHC	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.52	7.42	0.37	9.45e-13	Asthma;
LIHC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.41	0.41	1.16e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.44	-6.39	-0.33	5.52e-10	Diastolic blood pressure;
LIHC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.29	-6.64	-0.34	1.26e-10	Crohn's disease;
LIHC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg05564831	chr3:52568323	NT5DC2	0.38	6.16	0.32	2.07e-9	Bipolar disorder;
LIHC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.91	-0.54	1.32e-27	Type 2 diabetes;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.15	-0.44	5.12e-18	Corneal structure;
LIHC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.17	0.32	1.94e-9	Blood metabolite levels;
LIHC	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-7.89	-0.39	4.15e-14	Initial pursuit acceleration;
LIHC	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.7	11.46	0.53	5.82e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02985541	chr2:219472218	PLCD4	-0.44	-7.99	-0.4	2.04e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02034447	chr16:89574710	SPG7	0.45	6.76	0.34	5.97e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg03959625	chr15:84868606	LOC388152	0.46	5.75	0.3	1.98e-8	Bipolar disorder lithium response (categorical) or schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10162261	chr22:38598048	MAFF	-0.42	-6.12	-0.31	2.5e-9	Pancreatic cancer;
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg05697976	chr12:29376483	FAR2	0.34	7.0	0.35	1.35e-11	QT interval;
LIHC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.74	9.72	0.47	6.84e-20	Coronary artery disease;
LIHC	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.66	10.06	0.48	5.04e-21	Height;
LIHC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg18357645	chr12:58087776	OS9	-0.44	-7.02	-0.35	1.19e-11	Multiple sclerosis;
LIHC	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.65	7.76	0.39	1.01e-13	Homocysteine levels;
LIHC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.87	11.3	0.52	2.32e-25	Coronary artery disease;
LIHC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.6	7.05	0.36	1e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg21174375	chr14:64681225	SYNE2	0.39	6.05	0.31	3.75e-9	Atrial fibrillation;
LIHC	cis	rs807029	0.577	rs750866	chr10:102761458	A/G	cg17130504	chr10:102756923	LZTS2	0.53	7.13	0.36	5.98e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg21724239	chr8:58056113	NA	0.49	6.42	0.33	4.65e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg08888203	chr3:10149979	C3orf24	0.57	6.55	0.33	2.08e-10	Alzheimer's disease;
LIHC	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.27	-6.78	-0.34	5.29e-11	Mean corpuscular volume;
LIHC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.71	0.57	1.43e-30	Menopause (age at onset);
LIHC	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg23109721	chr2:106886537	NA	0.58	5.77	0.3	1.77e-8	Facial morphology (factor 23);
LIHC	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.21	16.37	0.66	6.78e-45	Blood protein levels;
LIHC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.32	-8.28	-0.41	2.87e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-5.75	-0.3	2.01e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg12257692	chr3:49977190	RBM6	-0.36	-5.76	-0.3	1.89e-8	Menarche (age at onset);
LIHC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg02811702	chr13:24901961	NA	0.26	6.61	0.34	1.5e-10	Obesity-related traits;
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	5.85	0.3	1.13e-8	Height;
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02359409	chr6:42947317	PEX6	-0.49	-6.87	-0.35	3.06e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7212590	0.581	rs8064505	chr17:57838831	G/A	cg10252138	chr17:58120427	NA	-0.59	-5.88	-0.3	9.59e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.77	0.5	1.73e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08392591	chr16:89556376	ANKRD11	0.42	6.28	0.32	1.01e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.71	10.83	0.51	1.03e-23	Phospholipid levels (plasma);
LIHC	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg10790698	chr19:18539756	SSBP4	-0.37	-7.49	-0.38	5.79e-13	Breast cancer;
LIHC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg08345082	chr10:99160200	RRP12	-0.37	-6.13	-0.31	2.37e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs1668357	1.000	rs1668357	chr7:38004406	G/T	cg04044224	chr2:238499793	RAB17	-0.32	-6.12	-0.31	2.63e-9	Myopia (pathological);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06984945	chr6:26660160	ZNF322A	0.42	6.15	0.32	2.16e-9	Pancreatic cancer;
LIHC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg19338460	chr6:170058176	WDR27	-0.38	-5.9	-0.3	8.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.36	5.96	0.31	6.35e-9	Blood metabolite levels;
LIHC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04317338	chr11:64019027	PLCB3	-0.5	-6.91	-0.35	2.42e-11	Platelet count;
LIHC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg10621924	chr7:39171070	POU6F2	0.42	6.51	0.33	2.67e-10	IgG glycosylation;
LIHC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.5	7.81	0.39	6.97e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.42	-5.74	-0.3	2.06e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.64	11.51	0.53	3.76e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.61	-10.63	-0.5	5.22e-23	Crohn's disease;
LIHC	cis	rs1198430	1.000	rs946268	chr1:23747766	A/G	cg13183780	chr1:23809682	ASAP3	-0.52	-7.56	-0.38	3.72e-13	Total cholesterol levels;
LIHC	cis	rs4407350	1.000	rs5765725	chr22:44921706	A/C	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.0	-0.31	4.91e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.39	6.28	0.32	1.02e-9	Intraocular pressure;
LIHC	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.45	-6.69	-0.34	9.34e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs7523273	0.925	rs2745977	chr1:208017360	C/A	cg22525895	chr1:207977042	MIR29B2	-0.67	-9.96	-0.47	1.08e-20	Schizophrenia;
LIHC	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg13919466	chr1:32135498	COL16A1	-0.32	-6.12	-0.31	2.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.84	-11.79	-0.54	3.68e-27	Obesity-related traits;
LIHC	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.84	-0.3	1.2e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs12286929	0.577	rs7101437	chr11:115063641	A/G	cg04055981	chr11:115044050	NA	-0.54	-8.45	-0.42	8.62e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	trans	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg10756647	chr7:56101905	PSPH	-1.02	-12.5	-0.56	8.8e-30	Diabetic kidney disease;
LIHC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.69	0.34	9.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.43	7.15	0.36	5.39e-12	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg00280220	chr17:61926910	NA	0.44	7.18	0.36	4.43e-12	Prudent dietary pattern;
LIHC	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg02269571	chr22:50332266	NA	-0.61	-8.43	-0.41	1e-15	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.38	0.33	5.69e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg17135325	chr3:160939158	NMD3	0.53	7.5	0.38	5.58e-13	Parkinson's disease;
LIHC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg12437481	chr16:420112	MRPL28	-0.55	-7.65	-0.38	2.08e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.33	-0.32	7.75e-10	Mean corpuscular volume;
LIHC	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg18081818	chr7:23246105	NA	-0.4	-6.01	-0.31	4.83e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	11.44	0.53	7.07e-26	Lung cancer in ever smokers;
LIHC	cis	rs10847980	0.590	rs78462864	chr12:123365867	C/T	cg07706471	chr12:123319906	HIP1R	0.73	7.48	0.38	6.14e-13	Adiponectin levels;
LIHC	cis	rs2273156	1.000	rs12050402	chr14:35461816	C/T	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-7.08	-0.36	8.37e-12	Hemoglobin concentration;
LIHC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.9	0.39	3.77e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.59	-9.73	-0.47	6.76e-20	Colorectal cancer;
LIHC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg06096015	chr1:231504339	EGLN1	0.49	9.04	0.44	1.16e-17	Hemoglobin concentration;
LIHC	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg05765582	chr2:191677683	NA	0.29	5.72	0.3	2.39e-8	Mean platelet volume;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.19	-0.32	1.72e-9	Total body bone mineral density;
LIHC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.23	-0.41	3.9e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.71	0.3	2.42e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.27	-0.32	1.11e-9	Tonsillectomy;
LIHC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.1	-0.4	9.51e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg23262073	chr20:60523788	NA	-0.29	-6.03	-0.31	4.28e-9	Body mass index;
LIHC	cis	rs7116495	0.881	rs7924516	chr11:71667989	T/C	cg26138937	chr11:71823887	C11orf51	-0.81	-7.95	-0.39	2.76e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg23625390	chr15:77176239	SCAPER	0.36	5.79	0.3	1.59e-8	Blood metabolite levels;
LIHC	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.88	11.02	0.51	2.2e-24	Prostate cancer;
LIHC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.81	-0.35	4.41e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.5	-9.19	-0.44	3.97e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.61	7.64	0.38	2.15e-13	Airflow obstruction;
LIHC	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg22771759	chr13:24902376	NA	0.32	6.7	0.34	8.55e-11	Obesity-related traits;
LIHC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg07414643	chr4:187882934	NA	0.23	5.93	0.31	7.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11624085	chr17:8464688	MYH10	0.37	6.18	0.32	1.86e-9	Bilirubin levels;
LIHC	trans	rs800082	0.516	rs1178893	chr3:144239246	A/C	cg24215973	chr2:240111563	HDAC4	0.5	6.75	0.34	6.27e-11	Smoking behavior;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02065141	chr10:135101714	TUBGCP2	0.47	6.07	0.31	3.38e-9	Hip circumference;
LIHC	cis	rs8053891	0.756	rs35800852	chr16:72002105	G/T	cg01557791	chr16:72042693	DHODH	-0.49	-7.0	-0.35	1.35e-11	Coronary artery disease;
LIHC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.29	-0.41	2.56e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg00339695	chr16:24857497	SLC5A11	-0.39	-6.47	-0.33	3.49e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.95	-0.39	2.84e-14	Body mass index;
LIHC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.62	8.4	0.41	1.18e-15	Initial pursuit acceleration;
LIHC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.99	0.54	6.68e-28	Motion sickness;
LIHC	cis	rs12594515	0.600	rs12903858	chr15:45972166	A/G	cg01629716	chr15:45996671	NA	0.38	6.77	0.34	5.67e-11	Waist circumference;Weight;
LIHC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.58	6.45	0.33	3.81e-10	Axial length;
LIHC	cis	rs35883536	0.708	rs34689792	chr1:101097753	A/G	cg14515779	chr1:101123966	NA	-0.67	-13.18	-0.58	2.42e-32	Monocyte count;
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	0.906	rs12402539	chr1:8538303	C/A	cg20416874	chr1:8611966	RERE	0.57	9.07	0.44	9.19e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg06026331	chr20:60912101	LAMA5	0.4	5.79	0.3	1.56e-8	Colorectal cancer;
LIHC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg24642439	chr20:33292090	TP53INP2	0.68	7.81	0.39	7.1e-14	Protein C levels;
LIHC	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg04025307	chr7:1156635	C7orf50	0.38	6.01	0.31	4.63e-9	Longevity;Endometriosis;
LIHC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-8.15	-0.4	7.18e-15	Ulcerative colitis;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.85	-15.27	-0.64	1.69e-40	Bipolar disorder and schizophrenia;
LIHC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.57	0.53	2.44e-26	Tonsillectomy;
LIHC	cis	rs77669868	0.929	rs3782007	chr11:114066438	A/G	cg01914181	chr11:114070210	ZBTB16	-0.61	-8.61	-0.42	2.74e-16	Monocyte percentage of white cells;
LIHC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.47	-7.01	-0.35	1.29e-11	HDL cholesterol;
LIHC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.59	10.06	0.48	5.19e-21	Dupuytren's disease;
LIHC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08819884	chr3:3168225	TRNT1	-0.49	-6.36	-0.33	6.6e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.59	-8.36	-0.41	1.65e-15	Blood metabolite levels;
LIHC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.46	7.4	0.37	1.05e-12	Monocyte count;
LIHC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.51	-8.28	-0.41	2.76e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.57	0.5	8.82e-23	Bladder cancer;
LIHC	cis	rs74181299	0.533	rs7585500	chr2:65372337	A/C	cg05010058	chr2:65284262	CEP68	-0.35	-5.71	-0.3	2.39e-8	Pulse pressure;
LIHC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg14440974	chr22:39074834	NA	-0.39	-6.28	-0.32	1.05e-9	Menopause (age at onset);
LIHC	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs7487075	0.504	rs7312682	chr12:46647998	C/T	cg15584813	chr12:47219626	SLC38A4	0.32	5.93	0.31	7.37e-9	Itch intensity from mosquito bite;
LIHC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg11812906	chr14:75593930	NEK9	-0.45	-6.83	-0.35	3.8e-11	IgG glycosylation;
LIHC	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.37	8.67	0.42	1.8e-16	Educational attainment (years of education);
LIHC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-6.87	-0.35	3.06e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg27433088	chr4:174089019	GALNT7	0.29	5.72	0.3	2.31e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	trans	rs11153056	0.500	rs72939809	chr6:107537039	G/C	cg12119218	chr10:70287206	SLC25A16	-0.45	-6.11	-0.31	2.67e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.5	10.01	0.48	7.57e-21	Tonsillectomy;
LIHC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.03	15.95	0.65	3.18e-43	Breast cancer;
LIHC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.41	-8.13	-0.4	7.83e-15	Urinary metabolites;
LIHC	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	1.06	11.94	0.54	1.02e-27	IgG glycosylation;
LIHC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	0.92	15.83	0.65	9.93e-43	Testicular germ cell tumor;
LIHC	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.65	-7.0	-0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	9.99	0.48	8.52e-21	Body mass index;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg15848620	chr12:58087721	OS9	-0.55	-7.41	-0.37	1.03e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.6	8.79	0.43	7.43e-17	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.25	-16.5	-0.67	2.19e-45	Diabetic kidney disease;
LIHC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.08	0.44	9.04e-18	Bipolar disorder;
LIHC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs903552	0.736	rs11858491	chr15:102007456	C/T	cg06707286	chr15:102010195	PCSK6	0.5	7.36	0.37	1.41e-12	Diabetic kidney disease;
LIHC	cis	rs3820500	0.585	rs2256057	chr1:117942591	T/C	cg20383390	chr1:117909022	MAN1A2	0.46	5.87	0.3	1.03e-8	Pneumonia;
LIHC	cis	rs3768716	0.500	rs777329	chr2:215742595	A/G	cg04004882	chr2:215674386	BARD1	-0.51	-6.98	-0.35	1.57e-11	Neuroblastoma;
LIHC	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.48	7.05	0.36	9.83e-12	Asthma;
LIHC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	7.64	0.38	2.2e-13	Platelet count;
LIHC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.49	5.86	0.3	1.11e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg27490568	chr2:178487706	NA	0.36	5.76	0.3	1.87e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.65	-9.48	-0.46	4.25e-19	White matter hyperintensity burden;
LIHC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21467203	chr3:49911342	NA	0.52	9.35	0.45	1.18e-18	Body mass index;
LIHC	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg12863693	chr15:85201151	NMB	0.43	6.01	0.31	4.71e-9	Schizophrenia;
LIHC	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.5	-10.75	-0.5	2.08e-23	White blood cell count (basophil);
LIHC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.38	-6.99	-0.35	1.42e-11	Electrocardiographic conduction measures;
LIHC	cis	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg19680485	chr15:31195859	MTMR15	-0.52	-5.73	-0.3	2.18e-8	Hypertriglyceridemia;
LIHC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.43	-0.49	2.62e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg17980119	chr2:219472607	PLCD4	0.36	6.21	0.32	1.55e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.18	-0.4	5.48e-15	Lymphocyte counts;
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.13e-9	Total body bone mineral density;
LIHC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg18357526	chr6:26021779	HIST1H4A	0.41	6.26	0.32	1.15e-9	Height;
LIHC	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.67	11.01	0.51	2.37e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.13	0.58	3.68e-32	Cognitive test performance;
LIHC	cis	rs4700695	0.614	rs251285	chr5:65211137	A/T	cg21114390	chr5:65439923	SFRS12	0.46	5.83	0.3	1.3e-8	Facial morphology (factor 19);
LIHC	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.85	-10.42	-0.49	3.01e-22	Prostate cancer;
LIHC	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-11.11	-0.51	1.1e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs918629	0.716	rs6897997	chr5:95270241	C/T	cg10483112	chr5:95245456	ELL2	-0.37	-6.31	-0.32	8.49e-10	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.99	0.54	6.68e-28	Motion sickness;
LIHC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.51	6.63	0.34	1.3100000000000001e-10	Alzheimer's disease;
LIHC	cis	rs28475163	1.000	rs28475163	chr11:327143	G/A	cg03071500	chr11:325964	NA	-0.46	-7.29	-0.37	2.13e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.76	11.38	0.52	1.15e-25	Menarche (age at onset);
LIHC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.58	0.56	4.35e-30	Cognitive test performance;
LIHC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.92	0.35	2.21e-11	Gout;
LIHC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.38e-9	Aortic root size;
LIHC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.01	0.4	1.79e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg10127483	chr1:110009974	SYPL2	0.47	5.81	0.3	1.46e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg25730555	chr22:47059586	GRAMD4	0.36	5.76	0.3	1.87e-8	Urate levels in obese individuals;
LIHC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.52	7.12	0.36	6.34e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.5	-8.01	-0.4	1.77e-14	Colorectal cancer;
LIHC	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg05714579	chr10:131428358	MGMT	0.39	6.24	0.32	1.31e-9	Response to temozolomide;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.75	0.62	1.8e-38	Prudent dietary pattern;
LIHC	trans	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	6.35	0.32	7.01e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg01518246	chr11:63870912	FLRT1;MACROD1	0.49	7.2	0.36	3.88e-12	Mean platelet volume;
LIHC	cis	rs2559856	1.000	rs2559854	chr12:102090246	C/T	cg12924262	chr12:102091054	CHPT1	0.48	7.61	0.38	2.61e-13	Blood protein levels;
LIHC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.45	-10.59	-0.5	7.39e-23	Arsenic metabolism;
LIHC	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.72	-12.62	-0.56	2.99e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	7.43	0.37	8.79e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.84	-7.93	-0.39	3.23e-14	Hippocampal volume;
LIHC	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.67	10.64	0.5	4.79e-23	Colorectal adenoma (advanced);
LIHC	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.36	7.2	0.36	3.78e-12	Blood protein levels;
LIHC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	9.78	0.47	4.54e-20	Lung cancer in ever smokers;
LIHC	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.47	0.49	1.94e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.89	-0.35	2.62e-11	Neutrophil percentage of white cells;
LIHC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.73	10.7	0.5	3.12e-23	Breast cancer;
LIHC	cis	rs3744061	0.776	rs9916811	chr17:74749273	C/T	cg13533061	chr17:74712429	JMJD6	0.39	5.96	0.31	6.17e-9	Retinal arteriolar caliber;
LIHC	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.59	5.76	0.3	1.84e-8	Breast cancer;
LIHC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg02711726	chr17:80685570	FN3KRP	0.37	6.92	0.35	2.17e-11	Breast cancer;
LIHC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.76	-10.01	-0.48	7.66e-21	Schizophrenia;
LIHC	trans	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg15676719	chr1:167598521	RCSD1	-0.39	-6.91	-0.35	2.35e-11	Systemic lupus erythematosus;
LIHC	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.84	-0.39	5.62e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10717766	chr19:5134118	KDM4B	-0.4	-6.09	-0.31	3.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-10.99	-0.51	2.84e-24	Personality dimensions;
LIHC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg00656387	chr3:40428638	ENTPD3	-0.43	-6.77	-0.34	5.48e-11	Renal cell carcinoma;
LIHC	cis	rs911119	0.955	rs61035931	chr20:23595714	A/G	cg16589663	chr20:23618590	CST3	0.72	7.6	0.38	2.88e-13	Chronic kidney disease;
LIHC	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.47	5.94	0.31	6.94e-9	Panic disorder;
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg09417038	chr21:47716443	C21orf57	0.47	6.87	0.35	2.97e-11	Testicular germ cell tumor;
LIHC	cis	rs9473924	0.542	rs6901576	chr6:50926064	G/T	cg14470998	chr6:50812995	TFAP2B	-0.79	-7.48	-0.38	6.18e-13	Body mass index;
LIHC	cis	rs8081395	0.801	rs2665404	chr17:57875396	A/G	cg02344993	chr17:57696989	CLTC	0.45	7.4	0.37	1.04e-12	White blood cell count;
LIHC	cis	rs72772090	1.000	rs72772092	chr5:96046912	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.63	-0.34	1.33e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg03874509	chr1:107600012	PRMT6	0.75	11.96	0.54	8.65e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.92	19.27	0.72	1.53e-56	Bone mineral density;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.3	0.61	1.09e-36	Prudent dietary pattern;
LIHC	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg26031613	chr14:104095156	KLC1	1.15	14.94	0.63	3.25e-39	Body mass index;
LIHC	cis	rs903552	0.736	rs11858491	chr15:102007456	C/T	cg04789225	chr15:102009795	PCSK6	0.43	5.9	0.3	8.85e-9	Diabetic kidney disease;
LIHC	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.07	-0.31	3.45e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7529073	0.545	rs1431985	chr1:214148246	C/T	cg24083324	chr1:214162604	PROX1	-0.46	-6.79	-0.34	4.95e-11	Schizophrenia;
LIHC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-8.44	-0.42	9.19e-16	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.85	13.94	0.6	2.63e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.27	0.52	2.81e-25	Prudent dietary pattern;
LIHC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.6	8.28	0.41	2.74e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg07541023	chr7:19748670	TWISTNB	0.41	6.33	0.32	7.57e-10	Thyroid stimulating hormone;
LIHC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20135002	chr11:47629003	NA	-0.53	-8.91	-0.43	3e-17	Subjective well-being;
LIHC	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.88	0.35	2.8e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs716804	0.566	rs7927874	chr11:10324191	T/C	cg01453529	chr11:10209919	SBF2	-0.3	-5.74	-0.3	2.08e-8	Neuroticism;
LIHC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.44	-8.02	-0.4	1.67e-14	Body mass index;
LIHC	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg01652190	chr22:50026171	C22orf34	-0.33	-7.47	-0.37	6.55e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg20848291	chr7:100343083	ZAN	-0.49	-7.1	-0.36	7.27e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.52	6.08	0.31	3.14e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.62	6.15	0.32	2.14e-9	Carotid intima media thickness;
LIHC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.85	-16.43	-0.66	3.86e-45	Coronary artery disease;
LIHC	cis	rs3812111	0.646	rs9481609	chr6:116489854	T/C	cg08036074	chr6:116424633	NT5DC1	-0.52	-8.69	-0.43	1.49e-16	Age-related macular degeneration;
LIHC	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.27	6.29	0.32	9.52e-10	Heart rate;
LIHC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.38	-5.8	-0.3	1.54e-8	Menarche (age at onset);
LIHC	cis	rs12295403	0.964	rs34364314	chr11:18691674	G/A	cg09887367	chr11:18690185	NA	-0.39	-6.45	-0.33	3.86e-10	Ovarian reserve;
LIHC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-8.09	-0.4	1.02e-14	Vitiligo;
LIHC	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg05760424	chr2:242988095	NA	-0.48	-6.87	-0.35	3.08e-11	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14671666	chr5:41904456	C5orf51	-0.48	-6.49	-0.33	3.1e-10	Pancreatic cancer;
LIHC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.48	-7.88	-0.39	4.28e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.31	-17.56	-0.69	1.13e-49	Diabetic kidney disease;
LIHC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs2882877	0.610	rs13008848	chr2:190445284	C/G	cg10752008	chr2:190445175	SLC40A1	0.61	7.58	0.38	3.29e-13	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg12931157	chr6:41040265	C6orf130;NFYA	-0.45	-6.63	-0.34	1.3e-10	Alopecia areata;
LIHC	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg08992911	chr2:238395768	MLPH	0.51	5.96	0.31	6.22e-9	Prostate cancer;
LIHC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.39	0.45	8.49e-19	Hemoglobin concentration;
LIHC	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.26	19.13	0.72	5.57e-56	Corneal structure;
LIHC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.72	-0.3	2.33e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.39	0.33	5.53e-10	Lung cancer in ever smokers;
LIHC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.96	-0.4	2.58e-14	Monocyte percentage of white cells;
LIHC	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg14222432	chr12:29376421	FAR2	0.35	6.89	0.35	2.67e-11	QT interval;
LIHC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.01	0.31	4.66e-9	Resting heart rate;
LIHC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.66e-9	Bipolar disorder;
LIHC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-17.84	-0.69	8.39e-51	Height;
LIHC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.36	6.75	0.34	6.5e-11	Schizophrenia;
LIHC	cis	rs986417	0.551	rs1956553	chr14:60952298	T/A	cg27398547	chr14:60952738	C14orf39	0.83	9.68	0.46	9.59e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg14709524	chr16:89940631	TCF25	-0.5	-6.82	-0.35	4.09e-11	Skin colour saturation;
LIHC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.47	6.65	0.34	1.19e-10	Schizophrenia;
LIHC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.37	-0.37	1.31e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg24203234	chr3:128598194	ACAD9	0.44	5.95	0.31	6.6e-9	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.61	-7.89	-0.39	4.08e-14	Motion sickness;
LIHC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg18651192	chr3:125677574	NA	0.41	5.75	0.3	1.94e-8	Metabolite levels (HVA/5-HIAA ratio);
LIHC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03701779	chr10:74927978	FAM149B1;ECD	0.45	6.57	0.33	1.9e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg19920283	chr7:105172520	RINT1	0.47	5.74	0.3	2.09e-8	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4908768	0.594	rs11121228	chr1:8830642	T/C	cg20416874	chr1:8611966	RERE	0.45	6.47	0.33	3.37e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg09165964	chr15:75287851	SCAMP5	-0.41	-5.77	-0.3	1.82e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.02	-0.35	1.2e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs943466	0.911	rs111352628	chr6:33742490	A/G	cg25922239	chr6:33757077	LEMD2	-0.48	-6.04	-0.31	3.96e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.66	0.5	4.09e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.33	-5.94	-0.31	6.93e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg00656387	chr3:40428638	ENTPD3	0.42	6.95	0.35	1.81e-11	Renal cell carcinoma;
LIHC	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.58	6.74	0.34	6.76e-11	Height;
LIHC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg09182678	chr22:50328711	NA	-0.69	-7.92	-0.39	3.46e-14	Mean platelet volume;
LIHC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.69	-0.38	1.63e-13	Calcium levels;
LIHC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.31	-5.78	-0.3	1.7e-8	Huntington's disease progression;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21668880	chr6:34759629	UHRF1BP1	-0.43	-6.3	-0.32	8.92e-10	Triglycerides;
LIHC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg24296786	chr1:45957014	TESK2	-0.47	-6.48	-0.33	3.24e-10	Platelet count;
LIHC	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-8.51	-0.42	5.58e-16	Morning vs. evening chronotype;
LIHC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.42	0.41	1.07e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.53	8.37	0.41	1.45e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3812111	0.809	rs11965969	chr6:116452203	T/G	cg08036074	chr6:116424633	NT5DC1	-0.52	-8.84	-0.43	5.2e-17	Age-related macular degeneration;
LIHC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg25039879	chr17:56429692	SUPT4H1	0.75	8.46	0.42	7.96e-16	Cognitive test performance;
LIHC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-9.97	-0.47	9.82e-21	Breast cancer;
LIHC	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.17	-0.36	4.54e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25889035	chr2:236826311	AGAP1	0.4	6.2	0.32	1.59e-9	Longevity;
LIHC	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.48	7.06	0.36	9.48e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10847980	0.590	rs75217947	chr12:123346177	G/C	cg25930673	chr12:123319894	HIP1R	1.15	12.96	0.57	1.56e-31	Adiponectin levels;
LIHC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.37	-0.33	6.16e-10	Mean corpuscular volume;
LIHC	cis	rs3812111	0.677	rs1204838	chr6:116515224	C/A	cg08036074	chr6:116424633	NT5DC1	-0.41	-6.51	-0.33	2.63e-10	Age-related macular degeneration;
LIHC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.61	6.11	0.31	2.73e-9	Neutrophil percentage of white cells;
LIHC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-8.11	-0.4	9.18e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs7165170	0.678	rs13379889	chr15:91195039	A/G	cg26821196	chr15:91095069	CRTC3	-0.37	-6.88	-0.35	2.8e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.63	7.14	0.36	5.55e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02802775	chr11:31391443	DNAJC24;DCDC1	-0.41	-6.49	-0.33	3e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.57	-0.33	1.84e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg12903224	chr12:29470962	FAR2	-0.42	-6.8	-0.35	4.72e-11	QT interval;
LIHC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.65	9.2	0.45	3.71e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg09795085	chr6:101329169	ASCC3	0.53	7.45	0.37	7.93e-13	Neuroticism;
LIHC	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg09238746	chr17:78121135	EIF4A3	-0.63	-10.5	-0.49	1.6e-22	Yeast infection;
LIHC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	8.5	0.42	5.94e-16	Lung cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16823064	chr1:19206559	ALDH4A1	0.42	6.27	0.32	1.06e-9	Hepatitis;
LIHC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.71	10.56	0.5	9.29e-23	Aortic root size;
LIHC	cis	rs7937890	0.695	rs17557844	chr11:14262559	A/G	cg22961513	chr11:14280813	SPON1	0.42	5.99	0.31	5.46e-9	Mitochondrial DNA levels;
LIHC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.85	11.0	0.51	2.59e-24	Heart rate;
LIHC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.68	13.52	0.59	1.12e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11955398	0.678	rs12522801	chr5:59978406	A/G	cg02684056	chr5:59996105	DEPDC1B	0.41	6.09	0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg19680672	chr10:131412579	MGMT	0.41	6.25	0.32	1.22e-9	Response to temozolomide;
LIHC	cis	rs3106136	1.000	rs3106134	chr4:95128091	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.56	-0.42	3.78e-16	Capecitabine sensitivity;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg16132339	chr22:24313637	DDTL;DDT	-0.64	-10.28	-0.49	9.11e-22	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	trans	rs7217932	0.571	rs763368	chr17:69877392	C/T	cg08017189	chr16:85680248	KIAA0182	-0.38	-6.29	-0.32	9.99e-10	Bone mineral density;
LIHC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.74	0.34	6.72e-11	Diabetic kidney disease;
LIHC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.51	-7.8	-0.39	7.67e-14	Crohn's disease;
LIHC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.13	0.52	9.15e-25	Coronary artery disease;
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.43	-6.95	-0.35	1.89e-11	Blood pressure (smoking interaction);
LIHC	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.48	7.35	0.37	1.48e-12	Adiposity;
LIHC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.59	0.5	7.75e-23	Bladder cancer;
LIHC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.7	-9.36	-0.45	1.08e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg12140854	chr5:148520817	ABLIM3	-0.42	-6.06	-0.31	3.5e-9	Breast cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03122602	chr16:89799836	ZNF276	0.4	6.21	0.32	1.52e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.58	-10.48	-0.49	1.78e-22	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.36	6.46	0.33	3.56e-10	Ewing sarcoma;
LIHC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.6	9.01	0.44	1.51e-17	Gout;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg15684274	chr1:892857	NOC2L	0.44	6.31	0.32	8.47e-10	Longevity;
LIHC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.25	-5.87	-0.3	1.04e-8	Age at first birth;
LIHC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.33	0.32	7.66e-10	Multiple sclerosis;
LIHC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	0.91	7.14	0.36	5.67e-12	IgG glycosylation;
LIHC	cis	rs4845459	0.967	rs4845454	chr1:152592184	C/T	cg20634798	chr1:152595351	LCE3A	-0.3	-5.85	-0.3	1.12e-8	Psoriasis;
LIHC	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.81	-0.3	1.4e-8	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.71	-0.34	8.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.96	-16.94	-0.68	3.59e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.77	11.96	0.54	8.88e-28	Corneal astigmatism;
LIHC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.81	-0.73	1.07e-58	Height;
LIHC	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.76	-8.39	-0.41	1.34e-15	Exhaled nitric oxide output;
LIHC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.82e-10	Fibrinogen levels;
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.45	7.14	0.36	5.48e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg15192750	chr16:69999425	NA	0.44	6.7	0.34	8.36e-11	IgE levels;
LIHC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.65	8.3	0.41	2.52e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.49	7.44	0.37	7.99e-13	Adiposity;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15803506	chr10:135125704	ZNF511	-0.39	-6.15	-0.32	2.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg18225595	chr11:63971243	STIP1	0.68	8.49	0.42	6.35e-16	Mean platelet volume;
LIHC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.59	0.34	1.62e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.8	12.57	0.56	4.87e-30	Multiple system atrophy;
LIHC	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg07706471	chr12:123319906	HIP1R	-0.71	-8.07	-0.4	1.19e-14	Adiponectin levels;
LIHC	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.6	-8.51	-0.42	5.7e-16	Blood pressure (smoking interaction);
LIHC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.79	-0.34	5.05e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.32	1.29e-9	Aortic root size;
LIHC	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs10838687	0.932	rs4752973	chr11:47269159	T/C	cg25783544	chr11:47291846	MADD	0.47	6.22	0.32	1.46e-9	Proinsulin levels;
LIHC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.62	6.48	0.33	3.24e-10	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.91	-18.87	-0.71	6.43e-55	Height;
LIHC	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg16070018	chr6:26224392	HIST1H3E	0.69	7.41	0.37	1e-12	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.87	0.3	1.04e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14557232	chr4:1368966	KIAA1530	0.4	6.24	0.32	1.27e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.55	8.11	0.4	9.47e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.54e-79	Prudent dietary pattern;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.95	-0.31	6.51e-9	Total body bone mineral density;
LIHC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	0.96	17.71	0.69	2.87e-50	Menopause (age at onset);
LIHC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.53	8.04	0.4	1.45e-14	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.13	0.36	5.82e-12	Selective IgA deficiency;
LIHC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.61	-8.92	-0.43	2.98e-17	Blood metabolite levels;
LIHC	cis	rs9682041	0.561	rs9856511	chr3:170140165	C/G	cg11886554	chr3:170076028	SKIL	0.76	5.85	0.3	1.15e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.58	8.67	0.42	1.82e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg18898632	chr2:242989856	NA	-0.67	-7.87	-0.39	4.69e-14	Obesity-related traits;
LIHC	cis	rs4788570	0.566	rs10468265	chr16:71476943	T/C	cg06353428	chr16:71660113	MARVELD3	-1.13	-10.16	-0.48	2.27e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.42e-20	Height;
LIHC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg00677901	chr16:88017247	BANP	0.51	7.96	0.4	2.5e-14	Menopause (age at onset);
LIHC	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg01652190	chr22:50026171	C22orf34	-0.35	-7.82	-0.39	6.61e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.74	12.13	0.55	2.1e-28	Mean platelet volume;
LIHC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.2	-0.41	4.92e-15	Chronic sinus infection;
LIHC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.65	11.78	0.54	3.99e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8053891	0.673	rs12444854	chr16:72024490	G/A	cg01557791	chr16:72042693	DHODH	-0.45	-6.69	-0.34	8.9e-11	Coronary artery disease;
LIHC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.53	7.78	0.39	8.66e-14	Longevity;Endometriosis;
LIHC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.46	5.83	0.3	1.26e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.24	0.41	3.6e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	11.54	0.53	3.08e-26	Menarche (age at onset);
LIHC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.65	8.84	0.43	5.07e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.97	13.44	0.59	2.33e-33	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.19	-0.32	1.69e-9	Colorectal cancer;
LIHC	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.92	-0.43	2.97e-17	Total cholesterol levels;
LIHC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.53	0.33	2.43e-10	Cognitive ability;
LIHC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.58	10.82	0.5	1.17e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.75	-0.3	1.96e-8	Subjective well-being;
LIHC	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.75	-0.3	1.94e-8	Blood pressure;
LIHC	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg03441853	chr15:73075003	ADPGK	0.28	5.93	0.31	7.45e-9	Triglyceride levels;
LIHC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.6	-9.25	-0.45	2.51e-18	Platelet count;
LIHC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.59	8.94	0.44	2.42e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg15654264	chr1:150340011	RPRD2	0.49	8.13	0.4	7.9e-15	Migraine;
LIHC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.72	13.24	0.58	1.37e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	12.06	0.55	3.86e-28	Cognitive ability;
LIHC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.84	-0.43	5.04e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.51	-0.38	5.28e-13	Initial pursuit acceleration;
LIHC	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.4	-7.27	-0.37	2.46e-12	Hepatocellular carcinoma;
LIHC	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg12034943	chr19:18811790	CRTC1	0.36	5.91	0.3	8.33e-9	Menarche (age at onset);
LIHC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg23280166	chr11:118938394	VPS11	-0.45	-6.16	-0.32	2.02e-9	Coronary artery disease;
LIHC	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.44	0.33	4.09e-10	Lymphocyte counts;
LIHC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.5	8.59	0.42	3.17e-16	Height;
LIHC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	7.31	0.37	1.84e-12	Total body bone mineral density;
LIHC	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.49	-7.26	-0.37	2.56e-12	Mortality in heart failure;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg05565475	chr9:136223383	SURF2;SURF1	-0.37	-6.24	-0.32	1.33e-9	Eotaxin levels;
LIHC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.82	0.3	1.38e-8	Eosinophil percentage of white cells;
LIHC	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.63	8.63	0.42	2.28e-16	Coronary artery disease;
LIHC	cis	rs7542375	0.507	rs2484697	chr1:221094718	A/G	cg16008148	chr1:221062819	NA	0.3	6.53	0.33	2.36e-10	Obesity-related traits;
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg21486233	chr12:29375141	FAR2	0.31	6.25	0.32	1.22e-9	QT interval;
LIHC	trans	rs16962242	1.000	rs10220272	chr13:104049710	G/T	cg12071008	chr17:76457640	DNAH17	0.46	6.09	0.31	3.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.57	0.5	9e-23	Bladder cancer;
LIHC	cis	rs5753037	0.543	rs131267	chr22:30147861	A/G	cg01021169	chr22:30184971	ASCC2	-0.31	-5.87	-0.3	1.02e-8	Type 1 diabetes;
LIHC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.93	0.31	7.59e-9	Electroencephalogram traits;
LIHC	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg19875535	chr5:140030758	IK	-0.38	-6.7	-0.34	8.8e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.52	-6.8	-0.35	4.57e-11	Initial pursuit acceleration;
LIHC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.49	-8.41	-0.41	1.16e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.74	9.63	0.46	1.45e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27227643	chr15:59949760	GTF2A2	-0.43	-6.06	-0.31	3.69e-9	Pancreatic cancer;
LIHC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.36	0.45	1.1e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.89	10.61	0.5	6.2e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.55	-7.69	-0.38	1.6e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg03037974	chr15:76606532	NA	-0.5	-8.07	-0.4	1.22e-14	Blood metabolite levels;
LIHC	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg26395211	chr5:140044315	WDR55	0.43	6.35	0.32	6.94e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.52	9.26	0.45	2.24e-18	Total body bone mineral density;
LIHC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.92	-0.43	2.81e-17	Blood metabolite levels;
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.65	-9.95	-0.47	1.21e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.12e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs713477	0.654	rs998871	chr14:55918302	G/A	cg13175173	chr14:55914753	NA	-0.31	-6.79	-0.34	4.91e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.26	0.32	1.14e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.01	15.7	0.65	3.23e-42	Skin colour saturation;
LIHC	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.53	-0.33	2.39e-10	Body mass index;
LIHC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg15192750	chr16:69999425	NA	-0.45	-6.85	-0.35	3.48e-11	IgE levels;
LIHC	cis	rs9918079	0.560	rs4698402	chr4:15629803	G/A	cg24225360	chr4:15471699	CC2D2A	-0.38	-6.01	-0.31	4.81e-9	Obesity-related traits;
LIHC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.77	0.39	8.99e-14	Bipolar disorder;
LIHC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.75	0.54	5.11e-27	Cognitive test performance;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.88	0.57	3.25e-31	Prudent dietary pattern;
LIHC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.71	9.3	0.45	1.76e-18	Gut microbiome composition (summer);
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02359409	chr6:42947317	PEX6	-0.45	-6.0	-0.31	5.07e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.74	0.43	1.08e-16	Motion sickness;
LIHC	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg23942311	chr14:51606299	NA	0.35	7.29	0.37	2.17e-12	Cancer;
LIHC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.38	0.61	5.11e-37	Chronic sinus infection;
LIHC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.1	-12.99	-0.57	1.23e-31	Vitiligo;
LIHC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.67	13.28	0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs600806	0.850	rs4970846	chr1:109946095	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.57	-6.93	-0.35	2.14e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7432375	0.901	rs9836231	chr3:136414321	C/T	cg21827317	chr3:136751795	NA	-0.44	-5.8	-0.3	1.49e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg17385448	chr1:15911702	AGMAT	-0.4	-6.39	-0.33	5.31e-10	Systolic blood pressure;
LIHC	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.47	7.29	0.37	2.22e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg05484376	chr2:27715224	FNDC4	0.39	6.61	0.34	1.46e-10	Total body bone mineral density;
LIHC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.34e-11	Aortic root size;
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.66	-0.34	1.12e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21747090	chr2:27597821	SNX17	-0.43	-6.52	-0.33	2.49e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.37	7.58	0.38	3.32e-13	Optic cup area;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.02	0.51	2.22e-24	Height;
LIHC	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.1	-16.35	-0.66	8.27e-45	Corneal structure;
LIHC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-8.78	-0.43	7.96e-17	Morning vs. evening chronotype;
LIHC	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.52	-7.64	-0.38	2.16e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg04610667	chr7:75704037	NA	0.33	5.95	0.31	6.71e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg18016565	chr1:150552671	MCL1	-0.5	-9.63	-0.46	1.39e-19	Melanoma;
LIHC	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.29	-0.32	9.91e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg05590025	chr7:65112418	INTS4L2	-0.54	-5.83	-0.3	1.26e-8	Gout;
LIHC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.63	11.41	0.53	9.06e-26	Gestational age at birth (maternal effect);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15620385	chr12:26986279	ITPR2	0.42	6.04	0.31	3.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.34	8.25	0.41	3.46e-15	Immature fraction of reticulocytes;
LIHC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.73	-7.27	-0.37	2.49e-12	Vitiligo;
LIHC	cis	rs72627509	0.638	rs12642622	chr4:57902276	G/A	cg26694713	chr4:57773883	REST	0.6	7.46	0.37	7.4e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.54	-7.78	-0.39	8.58e-14	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs1144333	0.655	rs5745465	chr1:76346832	A/G	cg10523679	chr1:76189770	ACADM	0.45	5.94	0.31	7.15e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.3.541014R	chr3:25654052	TOP2B	-0.43	-6.08	-0.31	3.15e-9	Hepatitis;
LIHC	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	0.88	14.57	0.62	1e-37	Left atrial antero-posterior diameter;
LIHC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg21573476	chr21:45109991	RRP1B	-0.56	-10.49	-0.49	1.62e-22	Mean corpuscular volume;
LIHC	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.5	6.15	0.32	2.19e-9	Plateletcrit;
LIHC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.46	-7.44	-0.37	8.15e-13	Menarche (age at onset);
LIHC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.53	-8.81	-0.43	6.55e-17	Blood metabolite levels;
LIHC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg24203234	chr3:128598194	ACAD9	0.44	6.2	0.32	1.61e-9	IgG glycosylation;
LIHC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.38	7.15	0.36	5.33e-12	Schizophrenia;
LIHC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.69	0.34	9.11e-11	Morning vs. evening chronotype;
LIHC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-9.01	-0.44	1.47e-17	Menarche (age at onset);
LIHC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg25382214	chr1:3105252	PRDM16	-0.28	-6.14	-0.32	2.28e-9	Migraine;
LIHC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg27205649	chr11:78285834	NARS2	0.38	5.79	0.3	1.57e-8	Alzheimer's disease (survival time);
LIHC	cis	rs4700695	0.841	rs957526	chr5:65345830	A/G	cg21114390	chr5:65439923	SFRS12	0.5	6.71	0.34	8.23e-11	Facial morphology (factor 19);
LIHC	cis	rs332507	0.601	rs3772777	chr3:124372449	G/A	cg05980111	chr3:124395277	KALRN	0.31	6.04	0.31	4.13e-9	Plateletcrit;
LIHC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.88	0.57	3.27e-31	Mean platelet volume;
LIHC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs11671005	0.568	rs73068329	chr19:59080325	C/T	cg25952890	chr19:58913133	NA	0.68	6.92	0.35	2.18e-11	Mean platelet volume;
LIHC	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	25.99	0.81	5.69e-83	Schizophrenia;
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-7.65	-0.38	2.06e-13	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.95	0.57	1.78e-31	Prudent dietary pattern;
LIHC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg09222892	chr1:25734099	RHCE	0.48	8.89	0.43	3.54e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.36	-6.18	-0.32	1.84e-9	Immature fraction of reticulocytes;
LIHC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.79	9.02	0.44	1.41e-17	Cannabis dependence symptom count;
LIHC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24820996	chr19:17791300	UNC13A	-0.31	-6.13	-0.31	2.48e-9	Schizophrenia;
LIHC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.36	-5.72	-0.3	2.34e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.22e-10	Aortic root size;
LIHC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-8.34	-0.41	1.86e-15	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.21	0.61	2.47e-36	Chronic sinus infection;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg12143784	chr7:64541923	NA	-0.35	-6.08	-0.31	3.2e-9	Calcium levels;
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.78	12.04	0.55	4.43e-28	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg16070018	chr6:26224392	HIST1H3E	0.59	7.45	0.37	7.55e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-9.35	-0.45	1.15e-18	Platelet count;
LIHC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.55	-8.83	-0.43	5.38e-17	Cognitive function;
LIHC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-6.88	-0.35	2.9100000000000002e-11	Chronic sinus infection;
LIHC	cis	rs4908768	0.906	rs55830087	chr1:8681550	C/T	cg20416874	chr1:8611966	RERE	0.54	7.66	0.38	1.91e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg03229431	chr7:123269106	ASB15	-0.37	-8.04	-0.4	1.53e-14	Migraine;
LIHC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.6	8.93	0.43	2.6e-17	Recombination rate (females);
LIHC	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg24579218	chr15:68104479	NA	-0.34	-5.88	-0.3	9.59e-9	Restless legs syndrome;
LIHC	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.51	8.37	0.41	1.48e-15	Resting heart rate;
LIHC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.68	-10.53	-0.49	1.2e-22	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.44	17.23	0.68	2.52e-48	Breast cancer;
LIHC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg26072250	chr5:443457	EXOC3;C5orf55	-0.47	-6.14	-0.32	2.25e-9	Fat distribution (HIV);
LIHC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg03859395	chr2:55845619	SMEK2	-0.48	-7.75	-0.39	1.05e-13	Metabolic syndrome;
LIHC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.68	13.73	0.6	1.72e-34	Coronary artery disease;
LIHC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.52	6.83	0.35	3.86e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	0.96	14.8	0.62	1.23e-38	Corneal structure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08167039	chr1:762232	NCRNA00115;LOC643837	0.49	7.09	0.36	7.74e-12	Pancreatic cancer;
LIHC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	0.78	6.33	0.32	7.91e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.23	0.32	1.35e-9	Schizophrenia;
LIHC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-26.66	-0.82	1.61e-85	Myeloid white cell count;
LIHC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.38	-0.66	6.14e-45	Gut microbiome composition (summer);
LIHC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.45	6.89	0.35	2.65e-11	Coronary artery disease;
LIHC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.5	5.94	0.31	7.18e-9	Menarche (age at onset);
LIHC	cis	rs2191566	0.960	rs7255315	chr19:44510933	A/T	cg18700516	chr19:44507157	ZNF230	-0.35	-5.79	-0.3	1.62e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.67	9.84	0.47	2.79e-20	Menarche (age at onset);
LIHC	cis	rs2257205	0.667	rs8068677	chr17:56869386	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.77	-0.34	5.48e-11	Pancreatic cancer;
LIHC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.51	-0.33	2.74e-10	Cognitive test performance;
LIHC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.75e-8	Parkinson's disease;
LIHC	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.51	8.67	0.42	1.71e-16	Coronary artery disease;
LIHC	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.27	6.34	0.32	7.38e-10	Heart rate;
LIHC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.65	0.38	2e-13	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg00656387	chr3:40428638	ENTPD3	0.42	7.03	0.36	1.13e-11	Renal cell carcinoma;
LIHC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-15.02	-0.63	1.64e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.22	-0.48	1.48e-21	Blood metabolite levels;
LIHC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	21.66	0.76	4.25e-66	Chronic sinus infection;
LIHC	trans	rs6759518	0.557	rs1275529	chr2:27431413	T/C	cg01061843	chr6:74171491	MTO1	0.94	6.09	0.31	3.04e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.54	-9.55	-0.46	2.62e-19	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.35	-5.88	-0.3	1e-8	Breast size;
LIHC	cis	rs12744310	0.887	rs12028244	chr1:41809162	C/T	cg03962019	chr1:41807865	NA	0.39	6.2	0.32	1.65e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs970821	0.667	rs2385507	chr8:124744639	T/C	cg00283535	chr8:124749564	ANXA13	0.42	7.7	0.38	1.46e-13	Breast cancer;
LIHC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.26	6.63	0.34	1.3e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg14222432	chr12:29376421	FAR2	0.36	6.91	0.35	2.42e-11	QT interval;
LIHC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.43	8.0	0.4	1.98e-14	Electrocardiographic conduction measures;
LIHC	cis	rs15676	0.947	rs2759009	chr9:131599008	C/T	cg00228799	chr9:131580591	ENDOG	0.44	6.74	0.34	6.67e-11	Blood metabolite levels;
LIHC	trans	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.19	0.32	1.76e-9	Mean corpuscular volume;
LIHC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg02980000	chr4:1222292	CTBP1	-0.54	-7.56	-0.38	3.83e-13	Obesity-related traits;
LIHC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.26	0.55	6.9e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.73	-0.3	2.16e-8	Arsenic metabolism;
LIHC	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.97	-8.6	-0.42	3e-16	White matter integrity;
LIHC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg04155231	chr12:9217510	LOC144571	0.32	6.18	0.32	1.78e-9	Sjögren's syndrome;
LIHC	cis	rs7395581	0.918	rs326214	chr11:47298360	G/A	cg26139080	chr11:47293733	MADD	0.48	7.99	0.4	2.1e-14	HDL cholesterol;
LIHC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg03983715	chr16:68378420	PRMT7	0.46	5.95	0.31	6.69e-9	Schizophrenia;
LIHC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.61	9.71	0.46	7.77e-20	Age at first birth;
LIHC	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.06	18.6	0.71	7.9e-54	Triglycerides;
LIHC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.55	5.8	0.3	1.48e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.96	-11.22	-0.52	4.25e-25	Vitiligo;
LIHC	cis	rs7635838	0.892	rs4684775	chr3:11436413	A/G	cg00170343	chr3:11313890	ATG7	0.45	7.04	0.36	1.08e-11	HDL cholesterol;
LIHC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg06050784	chr16:88016603	BANP	0.34	6.24	0.32	1.27e-9	Menopause (age at onset);
LIHC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.19	0.45	3.84e-18	Platelet count;
LIHC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.6	9.42	0.45	6.86e-19	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs3736485	0.966	rs2414114	chr15:51905781	T/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.11	-0.31	2.75e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.61	8.92	0.43	2.9e-17	Prudent dietary pattern;
LIHC	cis	rs787274	1.000	rs4979153	chr9:115554984	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-6.68	-0.34	9.69e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.76	10.78	0.5	1.59e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg12798992	chr6:167411361	FGFR1OP	0.46	7.4	0.37	1.04e-12	Crohn's disease;
LIHC	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	0.92	10.62	0.5	5.97e-23	Breast cancer;
LIHC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.46	7.34	0.37	1.57e-12	Platelet count;
LIHC	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg02248941	chr16:2239361	CASKIN1	0.35	6.74	0.34	6.95e-11	Height;
LIHC	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg14473756	chr11:122847823	NA	0.33	5.96	0.31	6.22e-9	Menarche (age at onset);
LIHC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.72	10.8	0.5	1.37e-23	Corneal astigmatism;
LIHC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.33	6.25	0.32	1.22e-9	Multiple system atrophy;
LIHC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.5	7.87	0.39	4.83e-14	Total body bone mineral density;
LIHC	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.59	10.69	0.5	3.32e-23	Total body bone mineral density;
LIHC	cis	rs11098699	0.821	rs6811630	chr4:124222254	G/A	cg09941581	chr4:124220074	SPATA5	0.34	6.79	0.34	4.84e-11	Mosquito bite size;
LIHC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.91	16.05	0.66	1.27e-43	Colorectal cancer;
LIHC	cis	rs9473924	0.542	rs13195969	chr6:50814627	C/A	cg14470998	chr6:50812995	TFAP2B	0.98	11.12	0.52	9.6e-25	Body mass index;
LIHC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.4	-5.85	-0.3	1.14e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs75908454	1.000	rs16888050	chr6:169874072	C/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.79	-0.39	8.32e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.89	-0.51	6.8e-24	Mean corpuscular volume;
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.19	0.55	1.29e-28	Height;
LIHC	trans	rs1923243	0.546	rs11210226	chr1:73854284	A/G	cg25308542	chr13:92000113	MIR17HG	0.42	6.28	0.32	1.02e-9	Migraine;
LIHC	cis	rs477692	0.648	rs10829603	chr10:131327351	T/G	cg05714579	chr10:131428358	MGMT	0.38	6.06	0.31	3.67e-9	Response to temozolomide;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.59	0.56	3.89e-30	Prudent dietary pattern;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20248075	chr14:71865085	SNORD56B	0.33	6.1	0.31	2.8e-9	Hepatitis;
LIHC	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.41	6.52	0.33	2.49e-10	Alzheimer's disease (survival time);
LIHC	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg10820045	chr2:198174542	NA	-0.57	-9.61	-0.46	1.67e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs10159528	0.533	rs2175200	chr10:87368788	C/T	cg11737403	chr19:57791287	ZNF460	-0.41	-6.08	-0.31	3.21e-9	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.64	8.73	0.43	1.11e-16	Coronary artery disease;
LIHC	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg25828445	chr12:7781288	NA	0.45	6.82	0.35	4.02e-11	HDL cholesterol levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27613455	chr17:38020644	IKZF3	0.4	6.09	0.31	3.11e-9	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.47	0.33	3.44e-10	Renal cell carcinoma;
LIHC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.4	6.55	0.33	2.15e-10	Red blood cell count;
LIHC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.86	11.08	0.51	1.43e-24	Coronary artery disease;
LIHC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.41	-6.01	-0.31	4.85e-9	Cognitive function;
LIHC	cis	rs2084898	0.943	rs477337	chr11:120000885	T/C	cg13907859	chr11:120009124	TRIM29	-0.53	-6.57	-0.33	1.86e-10	Stroke (pediatric);
LIHC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg23485639	chr6:28045615	ZNF165	0.38	5.87	0.3	1.03e-8	Parkinson's disease;
LIHC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.4	5.71	0.3	2.41e-8	Blood protein levels;
LIHC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.4	-0.45	7.89e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.21e-11	Cognitive function;
LIHC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.7	12.03	0.55	4.76e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.51	-6.1	-0.31	2.89e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs1823913	1.000	rs6704784	chr2:192109558	T/G	cg12404831	chr2:192114017	MYO1B	-0.34	-6.85	-0.35	3.41e-11	Obesity-related traits;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.18	0.55	1.41e-28	Height;
LIHC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	6.56	0.33	1.97e-10	Systolic blood pressure;
LIHC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg05973401	chr12:123451056	ABCB9	-0.45	-6.17	-0.32	1.96e-9	Neutrophil percentage of white cells;
LIHC	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg27205649	chr11:78285834	NARS2	0.38	5.81	0.3	1.43e-8	Alzheimer's disease (survival time);
LIHC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.69	13.29	0.58	8.71e-33	Systemic lupus erythematosus;
LIHC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.89	-0.3	9.33e-9	Type 2 diabetes;
LIHC	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.42	-6.73	-0.34	7.06e-11	Obesity-related traits;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.56	-8.18	-0.4	5.51e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.46	0.71	2.76e-53	Tonsillectomy;
LIHC	cis	rs3736485	0.966	rs8042289	chr15:51899884	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.29	-0.32	9.87e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12980942	0.872	rs7258749	chr19:41806647	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.18	0.32	1.8e-9	Coronary artery disease;
LIHC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	6.73	0.34	7.14e-11	Renal cell carcinoma;
LIHC	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-0.85	-9.78	-0.47	4.54e-20	Alzheimer's disease (late onset);
LIHC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg00225070	chr15:80189496	MTHFS	0.59	9.65	0.46	1.16e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg00656387	chr3:40428638	ENTPD3	0.5	8.47	0.42	7.31e-16	Renal cell carcinoma;
LIHC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs1494373	0.543	rs12564479	chr1:220862692	C/A	cg06786860	chr1:220876396	NA	-0.44	-6.53	-0.33	2.35e-10	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.58e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg13446199	chr8:143762866	PSCA	-0.2	-5.81	-0.3	1.43e-8	Urinary tract infection frequency;
LIHC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21467203	chr3:49911342	NA	0.43	7.54	0.38	4.31e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.88	14.23	0.61	2.01e-36	Colorectal cancer;
LIHC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.61	11.3	0.52	2.28e-25	Alzheimer's disease (late onset);
LIHC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.42	6.29	0.32	9.63e-10	Schizophrenia;
LIHC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	5.96	0.31	6.36e-9	Schizophrenia;
LIHC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.74	11.55	0.53	2.87e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.73	-9.71	-0.46	7.77e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.56	7.02	0.35	1.21e-11	Homocysteine levels;
LIHC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.41	-7.19	-0.36	4.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.57	-8.26	-0.41	3.13e-15	Blood metabolite levels;
LIHC	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.13	-9.96	-0.47	1.12e-20	Schizophrenia;
LIHC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.43	-5.77	-0.3	1.81e-8	Blood metabolite levels;
LIHC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-10.48	-0.49	1.84e-22	Schizophrenia;
LIHC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.18	-9.22	-0.45	3.12e-18	Body mass index;
LIHC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg19318889	chr4:1322082	MAEA	0.43	6.51	0.33	2.76e-10	Obesity-related traits;
LIHC	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.45	-7.16	-0.36	5.01e-12	Blood metabolite levels;
LIHC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.32	-6.12	-0.31	2.56e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs911119	0.913	rs6048926	chr20:23580987	C/A	cg16589663	chr20:23618590	CST3	0.66	6.9	0.35	2.51e-11	Chronic kidney disease;
LIHC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg00792783	chr2:198669748	PLCL1	0.43	6.09	0.31	3e-9	Dermatomyositis;
LIHC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.4	-6.78	-0.34	5.24e-11	Monocyte count;
LIHC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.72	11.82	0.54	2.88e-27	Anterior chamber depth;
LIHC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.79	0.39	8.3e-14	Coronary artery disease;
LIHC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg15123519	chr2:136567270	LCT	-0.36	-7.2	-0.36	3.89e-12	Mosquito bite size;
LIHC	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.45	-0.53	6.37e-26	Bipolar disorder and schizophrenia;
LIHC	trans	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg17314160	chr12:110399253	GIT2	-0.43	-6.59	-0.34	1.68e-10	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.21	-0.32	1.52e-9	Response to antipsychotic treatment;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg18173454	chr10:15209775	NMT2	-0.49	-6.16	-0.32	2.03e-9	Facial morphology (factor 20);
LIHC	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.29	-0.32	9.78e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-9.56	-0.46	2.44e-19	Blood protein levels;
LIHC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.73e-12	Personality dimensions;
LIHC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg07424592	chr7:64974309	NA	-0.8	-9.23	-0.45	2.94e-18	Diabetic kidney disease;
LIHC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg22777020	chr22:31556080	RNF185	-0.56	-6.33	-0.32	7.64e-10	Colorectal cancer;
LIHC	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg24631222	chr15:78858424	CHRNA5	0.41	6.06	0.31	3.53e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg15192750	chr16:69999425	NA	0.43	6.85	0.35	3.53e-11	IgE levels;
LIHC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.25	-16.5	-0.67	2.19e-45	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02896705	chr19:18112042	ARRDC2	-0.43	-6.77	-0.34	5.77e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg03934865	chr2:198174659	NA	0.45	6.44	0.33	4e-10	Dermatomyositis;
LIHC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.59	0.56	4.07e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-1.04	-10.67	-0.5	3.8e-23	Breast cancer;
LIHC	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg16355469	chr20:37678765	NA	0.39	6.39	0.33	5.57e-10	Dialysis-related mortality;
LIHC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.7	0.53	7.84e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-5.81	-0.3	1.43e-8	Neuroticism;
LIHC	cis	rs2073300	1.000	rs6048833	chr20:23462185	G/A	cg12062639	chr20:23401060	NAPB	0.78	9.81	0.47	3.62e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg01629716	chr15:45996671	NA	0.52	9.47	0.46	4.7e-19	Waist circumference;Weight;
LIHC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.75	-9.95	-0.47	1.19e-20	Schizophrenia;
LIHC	trans	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg10208301	chr11:6592745	DNHD1	0.45	6.06	0.31	3.58e-9	Coronary artery calcification;
LIHC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.12	-0.44	6.34e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.29	0.45	1.9e-18	Corneal astigmatism;
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg26939375	chr7:64535504	NA	0.44	7.56	0.38	3.63e-13	Calcium levels;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg19000871	chr14:103996768	TRMT61A	0.37	6.32	0.32	8.16e-10	Reticulocyte count;
LIHC	cis	rs4908760	0.613	rs12403640	chr1:8817863	C/T	cg20416874	chr1:8611966	RERE	-0.58	-10.45	-0.49	2.22e-22	Vitiligo;
LIHC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.47	-17.87	-0.69	6.8e-51	Breast cancer;
LIHC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.28	5.95	0.31	6.61e-9	Type 2 diabetes;
LIHC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.45	6.58	0.34	1.8e-10	Tonsillectomy;
LIHC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.3	6.93	0.35	2.14e-11	Crohn's disease;
LIHC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.52	-0.38	4.86e-13	Platelet count;
LIHC	trans	rs4566648	0.593	rs10012008	chr4:84183228	A/G	cg06219686	chr17:29421884	NF1	-0.53	-6.16	-0.32	2.08e-9	Monocyte count;
LIHC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.96	-0.35	1.72e-11	Monocyte percentage of white cells;
LIHC	cis	rs2574704	1.000	rs2043576	chr3:11649609	T/C	cg15876825	chr3:11651881	VGLL4	-0.48	-8.02	-0.4	1.73e-14	Body mass index;
LIHC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.51	8.3	0.41	2.43e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.2	-0.45	3.55e-18	Aortic root size;
LIHC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-0.78	-8.59	-0.42	3.14e-16	Exhaled nitric oxide output;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg08733086	chr1:154947035	CKS1B;SHC1	-0.47	-7.09	-0.36	7.91e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.73	13.28	0.58	9.71e-33	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19138499	chr6:139248115	REPS1	0.27	6.04	0.31	4.12e-9	Cognitive function;
LIHC	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg23091122	chr1:110024289	SYPL2	-0.46	-6.09	-0.31	2.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.72	-9.12	-0.44	6.62e-18	Gut microbiome composition (summer);
LIHC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs4362	0.934	rs4335	chr17:61565025	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.37	5.73	0.3	2.2e-8	Blood metabolite levels;
LIHC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg18375707	chr11:64034959	PLCB3	-0.52	-7.89	-0.39	4.08e-14	Body mass index;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.51	7.3	0.37	2.02e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg23625390	chr15:77176239	SCAPER	-0.35	-5.8	-0.3	1.55e-8	Blood metabolite levels;
LIHC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.74	-7.1	-0.36	7.45e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.44	-7.37	-0.37	1.31e-12	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.06	-0.78	1.24e-71	Height;
LIHC	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg25364880	chr3:44379878	C3orf23	0.53	7.1	0.36	7.12e-12	Depressive symptoms;
LIHC	trans	rs7226229	0.950	rs2291037	chr17:20924523	C/T	cg05051152	chr8:124408913	ATAD2	-0.45	-6.21	-0.32	1.55e-9	Blood trace element (Se levels);
LIHC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-5.81	-0.3	1.42e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.64	-8.43	-0.41	9.9e-16	Red blood cell count;
LIHC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.89	-0.39	4.04e-14	Chronic sinus infection;
LIHC	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg10560079	chr2:191398806	TMEM194B	-0.72	-10.43	-0.49	2.68e-22	Diastolic blood pressure;
LIHC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.22	-16.04	-0.66	1.42e-43	Diabetic kidney disease;
LIHC	cis	rs7116495	1.000	rs2363736	chr11:71656967	T/A	cg26138937	chr11:71823887	C11orf51	-0.71	-7.0	-0.35	1.32e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.37	-7.84	-0.39	5.88e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.49	9.06	0.44	1.01e-17	Hemoglobin concentration;
LIHC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.55	-6.51	-0.33	2.67e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7116495	1.000	rs4338555	chr11:71755696	T/C	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.76	12.53	0.56	6.59e-30	Anterior chamber depth;
LIHC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26076054	chr5:421317	AHRR	0.27	6.02	0.31	4.54e-9	Cystic fibrosis severity;
LIHC	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.56	-13.79	-0.6	1.05e-34	White blood cell count (basophil);
LIHC	cis	rs7238033	0.624	rs9304321	chr18:43308188	C/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.49	17.34	0.68	8.86e-49	Eosinophil percentage of granulocytes;
LIHC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg12270520	chr8:146023939	ZNF517	-0.37	-5.94	-0.31	7.07e-9	Age at first birth;
LIHC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.63	10.63	0.5	5.27e-23	Menopause (age at onset);
LIHC	cis	rs903552	1.000	rs12908406	chr15:102004046	C/T	cg06707286	chr15:102010195	PCSK6	-0.46	-6.57	-0.33	1.91e-10	Diabetic kidney disease;
LIHC	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg17802220	chr15:77601643	NA	-0.4	-6.0	-0.31	4.9e-9	Risky sexual behaviors (alcohol dependence interaction);
LIHC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	13.33	0.58	6.33e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.43	0.33	4.18e-10	Bipolar disorder;
LIHC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.43	7.12	0.36	6.24e-12	Platelet distribution width;
LIHC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg11062466	chr8:58055876	NA	0.39	5.72	0.3	2.34e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.52	5.78	0.3	1.72e-8	Coronary artery disease;
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.61	-12.89	-0.57	2.94e-31	Plateletcrit;Platelet count;
LIHC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs9513627	1.000	rs7321381	chr13:100126156	G/A	cg25919922	chr13:100150906	NA	-0.77	-6.95	-0.35	1.82e-11	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.19	0.36	4.21e-12	Renal cell carcinoma;
LIHC	trans	rs673253	0.686	rs2819333	chr1:44014573	A/T	cg22385623	chr1:145397480	NA	-0.39	-6.13	-0.31	2.46e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12702595	0.643	rs6463663	chr7:7259577	A/G	cg04827551	chr7:7268805	C1GALT1	0.33	6.13	0.31	2.48e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.73	-11.98	-0.54	7.23e-28	White matter hyperintensity burden;
LIHC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.32	-6.27	-0.32	1.11e-9	Alcohol dependence;
LIHC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.88	0.43	3.79e-17	Alzheimer's disease;
LIHC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg07645718	chr20:61493192	TCFL5	0.79	6.45	0.33	3.85e-10	Obesity-related traits;
LIHC	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg19680672	chr10:131412579	MGMT	-0.44	-6.73	-0.34	7.38e-11	Response to temozolomide;
LIHC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	11.49	0.53	4.76e-26	Monocyte percentage of white cells;
LIHC	cis	rs77861329	1.000	rs55664415	chr3:52124885	G/A	cg08692210	chr3:52188851	WDR51A	0.82	7.39	0.37	1.17e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.58	0.53	2.23e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-7.99	-0.4	2.14e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg05973401	chr12:123451056	ABCB9	0.41	6.28	0.32	1.02e-9	Platelet count;
LIHC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.95	0.31	6.5e-9	Bipolar disorder;
LIHC	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.79	0.39	8.09e-14	Educational attainment (years of education);
LIHC	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.75	12.95	0.57	1.81e-31	Breast cancer;
LIHC	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg16583315	chr14:65563665	MAX	-0.4	-8.12	-0.4	8.41e-15	Obesity-related traits;
LIHC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.94	-22.79	-0.78	1.45e-70	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06557630	chr16:49889701	NA	0.39	6.18	0.32	1.79e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg00091569	chr3:40428383	ENTPD3	0.4	6.79	0.34	4.99e-11	Renal cell carcinoma;
LIHC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.24	0.55	7.91e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg17385448	chr1:15911702	AGMAT	0.35	6.11	0.31	2.64e-9	Systolic blood pressure;
LIHC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg02297831	chr4:17616191	MED28	0.39	6.24	0.32	1.33e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.45	6.83	0.35	3.98e-11	Schizophrenia;
LIHC	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	1.12	10.52	0.49	1.33e-22	Gut microbiota (bacterial taxa);
LIHC	cis	rs5753037	0.803	rs131262	chr22:30133044	G/T	cg01021169	chr22:30184971	ASCC2	-0.32	-5.96	-0.31	6.37e-9	Type 1 diabetes;
LIHC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.68	0.38	1.72e-13	Bipolar disorder;
LIHC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.42	0.37	9.27e-13	Bipolar disorder;
LIHC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.97	18.03	0.7	1.51e-51	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07898084	chr13:53029385	CKAP2	0.48	6.78	0.34	5.24e-11	Pancreatic cancer;
LIHC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00152838	chr16:24741724	TNRC6A	-0.53	-6.57	-0.33	1.91e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.54	-0.38	4.21e-13	Monocyte percentage of white cells;
LIHC	cis	rs80282103	0.618	rs59377495	chr10:1157019	C/T	cg08668510	chr10:1095578	IDI1	0.62	6.02	0.31	4.48e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.4	8.25	0.41	3.44e-15	Renal cell carcinoma;
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.26	-0.32	1.18e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.65	-0.38	2e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.6	-9.0	-0.44	1.61e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.77	11.76	0.54	4.8400000000000004e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-10.36	-0.49	4.59e-22	Inflammatory bowel disease;
LIHC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.57	9.5	0.46	3.7e-19	Corneal astigmatism;
LIHC	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.58	-0.34	1.79e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.56	0.53	2.64e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15888741	chr10:15139207	RPP38;C10orf111	-0.51	-6.82	-0.35	4.03e-11	Systolic blood pressure;
LIHC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.86	0.57	3.86e-31	Alzheimer's disease;
LIHC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.24	0.36	3.02e-12	Protein C levels;
LIHC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.69	10.42	0.49	2.88e-22	Height;
LIHC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-6.93	-0.35	2.15e-11	Psoriasis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03379200	chr15:91537914	PRC1	0.47	6.27	0.32	1.11e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg15744005	chr10:104629667	AS3MT	-0.36	-7.87	-0.39	4.67e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-8.49	-0.42	6.2e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.84	0.43	4.99e-17	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.57	6.37	0.33	6.13e-10	Axial length;
LIHC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.5	6.65	0.34	1.16e-10	Menopause (age at onset);
LIHC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.96	-0.35	1.79e-11	Sudden cardiac arrest;
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	13.95	0.6	2.42e-35	Cognitive test performance;
LIHC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.51	7.27	0.37	2.39e-12	Body mass index;
LIHC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg25344623	chr2:136566232	LCT	-0.39	-7.83	-0.39	6.24e-14	Mosquito bite size;
LIHC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg07424592	chr7:64974309	NA	0.81	9.05	0.44	1.13e-17	Diabetic kidney disease;
LIHC	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.59	9.33	0.45	1.34e-18	Response to antidepressants and depression;
LIHC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.58	-0.46	2.09e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs72653721	0.838	rs10498676	chr6:11026999	C/T	cg13562911	chr6:11044106	ELOVL2	0.48	7.15	0.36	5.22e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs9513627	1.000	rs73556165	chr13:100120317	C/T	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.58	0.38	3.3e-13	IgG glycosylation;
LIHC	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.99	-13.97	-0.6	2.17e-35	Corneal structure;
LIHC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	0.85	7.15	0.36	5.17e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.64	10.26	0.49	1.03e-21	Total body bone mineral density;
LIHC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.8	0.54	3.57e-27	Motion sickness;
LIHC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	0.97	19.98	0.73	2.22e-59	IgG glycosylation;
LIHC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.68	-12.17	-0.55	1.52e-28	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12040534	chr17:17942854	ATPAF2;C17orf39	0.5	6.94	0.35	1.98e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.56	-9.5	-0.46	3.64e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.75	11.27	0.52	2.82e-25	Subjective well-being;
LIHC	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-6.32	-0.32	8.07e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.86	0.43	4.31e-17	Lung cancer;
LIHC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Vitiligo;
LIHC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg04511125	chr2:88470314	THNSL2	-0.42	-6.37	-0.33	6.22e-10	Response to metformin (IC50);
LIHC	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.69	10.45	0.49	2.36e-22	Neutrophil percentage of white cells;
LIHC	cis	rs17428076	0.836	rs12622895	chr2:172686304	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.38	-6.32	-0.32	8.22e-10	Myopia;
LIHC	cis	rs11644362	0.932	rs34290494	chr16:12987705	A/C	cg06890432	chr16:12997467	SHISA9	-0.4	-6.77	-0.34	5.6e-11	Positive affect;Subjective well-being;
LIHC	cis	rs7212590	0.748	rs8074843	chr17:57935935	C/G	cg10252138	chr17:58120427	NA	-0.64	-6.78	-0.34	5.15e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6876835	0.553	rs7734641	chr5:6598782	C/T	cg04204831	chr5:6583394	LOC255167	0.42	6.44	0.33	3.97e-10	Visceral fat;
LIHC	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.68	-10.11	-0.48	3.29e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.72	11.3	0.52	2.18e-25	Lung disease severity in cystic fibrosis;
LIHC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.09	20.85	0.75	6.7e-63	Multiple system atrophy;
LIHC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.68	12.62	0.56	3.16e-30	Coronary artery disease;
LIHC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-8.47	-0.42	7.37e-16	Parkinson's disease;
LIHC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16024904	chr19:17905718	B3GNT3	0.43	6.16	0.32	2.05e-9	Tumor biomarkers;
LIHC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.34	5.91	0.3	8.06e-9	Body mass index;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08434171	chr17:16284988	UBB	-0.45	-6.68	-0.34	9.52e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.46	0.33	3.5e-10	Height;
LIHC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.63	9.99	0.48	9e-21	Corneal astigmatism;
LIHC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg19645103	chr12:69753606	YEATS4	-0.46	-6.3	-0.32	9.14e-10	Response to diuretic therapy;
LIHC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.48	-0.33	3.16e-10	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs7616330	0.887	rs1947150	chr3:71113096	A/G	cg01511742	chr3:71112437	FOXP1	-0.53	-7.02	-0.36	1.18e-11	QT interval;
LIHC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.76	11.26	0.52	3.15e-25	Subjective well-being;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg19635926	chr16:89946313	TCF25	0.57	7.64	0.38	2.25e-13	Skin colour saturation;
LIHC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg00647820	chr17:40259828	DHX58	0.28	5.91	0.3	8.44e-9	Fibrinogen levels;
LIHC	cis	rs4759375	1.000	rs28592032	chr12:123879445	C/T	cg00376283	chr12:123451042	ABCB9	0.49	6.29	0.32	9.47e-10	HDL cholesterol;
LIHC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.82	-15.43	-0.64	3.95e-41	Multiple myeloma (IgH translocation);
LIHC	cis	rs7116495	1.000	rs642573	chr11:71780854	G/C	cg26138937	chr11:71823887	C11orf51	-0.74	-7.3	-0.37	2e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs9649465	0.967	rs12531955	chr7:123377066	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.16	-0.4	6.39e-15	Migraine;
LIHC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.65	-9.4	-0.45	8.29e-19	Schizophrenia;
LIHC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-9.97	-0.47	9.83e-21	Obesity-related traits;
LIHC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.24	6.14	0.32	2.3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02196734	chr15:75018032	CYP1A1	0.52	6.87	0.35	3.02e-11	Hepatitis;
LIHC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.85	0.3	1.14e-8	Renal cell carcinoma;
LIHC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.03	0.36	1.15e-11	Diabetic kidney disease;
LIHC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg04719120	chr6:96025338	MANEA	0.62	6.8	0.35	4.59e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.53	-7.41	-0.37	9.92e-13	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.71	-12.02	-0.54	5.42e-28	Prudent dietary pattern;
LIHC	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.41	-6.81	-0.35	4.37e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.58	8.51	0.42	5.7e-16	Menarche (age at onset);
LIHC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.02	14.54	0.62	1.3e-37	Cognitive function;
LIHC	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.64	0.46	1.26e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.66	-11.29	-0.52	2.43e-25	Menopause (age at onset);
LIHC	cis	rs2191566	0.639	rs7260075	chr19:44566766	T/C	cg20607764	chr19:44506953	ZNF230	-0.37	-6.15	-0.32	2.16e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.51	-0.49	1.47e-22	Breast cancer;
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-7.55	-0.38	3.93e-13	Lymphocyte counts;
LIHC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.74	13.32	0.58	6.84e-33	Prostate cancer;
LIHC	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.61	11.25	0.52	3.45e-25	Mean platelet volume;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg11070056	chr1:107600091	PRMT6	-0.65	-11.08	-0.51	1.34e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7940866	0.874	rs10894290	chr11:130811049	T/G	cg12179176	chr11:130786555	SNX19	0.55	7.93	0.39	3.19e-14	Schizophrenia;
LIHC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	1.07	16.08	0.66	9.77e-44	Breast cancer;
LIHC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg11764359	chr7:65958608	NA	0.58	6.12	0.31	2.54e-9	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	10.55	0.5	1.04e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.5	-0.38	5.49e-13	Chronic sinus infection;
LIHC	trans	rs4376189	0.614	rs12643220	chr4:186635633	G/C	cg03610073	chr4:154604770	TLR2	-0.44	-6.1	-0.31	2.91e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.66	11.89	0.54	1.56e-27	Menarche (age at onset);
LIHC	cis	rs214034	0.505	rs6712768	chr2:17932873	G/A	cg08383160	chr2:17981519	NA	-0.31	-5.75	-0.3	1.95e-8	Response to amphetamines;
LIHC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg06207120	chr15:45996521	NA	0.31	5.83	0.3	1.27e-8	Waist circumference;Weight;
LIHC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.72	-0.5	2.67e-23	Schizophrenia;
LIHC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.47	7.17	0.36	4.62e-12	QT interval;
LIHC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg15660573	chr17:549704	VPS53	0.51	8.31	0.41	2.23e-15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg11861562	chr11:117069780	TAGLN	0.48	7.96	0.4	2.5e-14	Blood protein levels;
LIHC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.77	11.64	0.53	1.34e-26	Coronary artery disease;
LIHC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg26149184	chr10:133730230	NA	0.46	7.2	0.36	3.97e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.9e-9	Menopause (age at onset);
LIHC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg15123519	chr2:136567270	LCT	0.45	8.91	0.43	3.02e-17	Mosquito bite size;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.82	-0.3	1.39e-8	Total body bone mineral density;
LIHC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.35	-5.89	-0.3	9.4e-9	IgG glycosylation;
LIHC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.18	0.44	4.13e-18	Bipolar disorder;
LIHC	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg27205649	chr11:78285834	NARS2	0.38	5.86	0.3	1.09e-8	Alzheimer's disease (survival time);
LIHC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.45	-0.37	7.54e-13	IgG glycosylation;
LIHC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg06565975	chr8:143823917	SLURP1	-0.42	-7.76	-0.39	1e-13	Urinary tract infection frequency;
LIHC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	7.57	0.38	3.46e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14396892	chr9:96623032	NA	-0.33	-6.3	-0.32	9.26e-10	DNA methylation (variation);
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.58	9.41	0.45	7.25e-19	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.65	-10.52	-0.49	1.28e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg10411590	chr13:21900810	NA	0.42	6.83	0.35	3.88e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.75	-0.34	6.31e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg24296786	chr1:45957014	TESK2	-0.39	-5.88	-0.3	9.77e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.43	5.99	0.31	5.37e-9	Pediatric autoimmune diseases;
LIHC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.06e-10	Renal cell carcinoma;
LIHC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.47	7.52	0.38	5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.4	5.81	0.3	1.45e-8	Blood metabolite levels;
LIHC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.41	6.05	0.31	3.72e-9	Neuroticism;
LIHC	cis	rs74233809	1.000	rs11191587	chr10:104929716	T/C	cg03493300	chr10:104813866	CNNM2	0.46	6.14	0.32	2.29e-9	Birth weight;
LIHC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.94	-9.27	-0.45	2.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.83	0.35	3.89e-11	Morning vs. evening chronotype;
LIHC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.74	10.41	0.49	3.04e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.49	-0.49	1.65e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs72843506	0.586	rs75048432	chr17:19960884	G/A	cg12065943	chr17:19881925	AKAP10	-0.33	-6.01	-0.31	4.71e-9	Schizophrenia;
LIHC	cis	rs9513627	1.000	rs7985908	chr13:100186218	T/C	cg25919922	chr13:100150906	NA	0.78	7.12	0.36	6.36e-12	Obesity-related traits;
LIHC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.99	-0.54	6.78e-28	Response to antipsychotic treatment;
LIHC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.35	6.38	0.33	5.81e-10	Aortic root size;
LIHC	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.48	9.07	0.44	9.75e-18	Testicular germ cell tumor;
LIHC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	0.89	6.49	0.33	3.1e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.24	0.41	3.82e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6976053	0.518	rs144173	chr7:100416250	A/G	cg08302003	chr7:100435192	NA	-0.39	-6.21	-0.32	1.56e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.43	-6.49	-0.33	3.07e-10	HDL cholesterol;
LIHC	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.8	-14.24	-0.61	1.95e-36	Monocyte count;
LIHC	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.0	9.53	0.46	2.98e-19	Type 2 diabetes nephropathy;
LIHC	trans	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.67e-11	Aortic root size;
LIHC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	1.02	16.76	0.67	1.93e-46	Diastolic blood pressure;Systolic blood pressure;
LIHC	trans	rs13113518	0.812	rs2048564	chr4:56274132	G/A	cg15358633	chr12:38710606	ALG10B	0.44	6.38	0.33	5.68e-10	Height;
LIHC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.26	-6.95	-0.35	1.85e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.4	-5.72	-0.3	2.28e-8	Longevity;
LIHC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.32	14.14	0.61	4.7e-36	Eosinophil percentage of granulocytes;
LIHC	cis	rs16858210	0.874	rs34113436	chr3:183573836	G/A	cg25686905	chr3:183603175	PARL	-0.51	-9.59	-0.46	1.88e-19	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04260516	chr14:24630327	IRF9	0.42	6.31	0.32	8.45e-10	Pancreatic cancer;
LIHC	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.74	0.3	2.13e-8	Iron status biomarkers;
LIHC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg09222892	chr1:25734099	RHCE	-0.47	-8.56	-0.42	3.77e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg03146154	chr1:46216737	IPP	0.39	6.44	0.33	4.04e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-7.89	-0.39	4.22e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.47	7.39	0.37	1.11e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21448741	chr8:58168803	NA	0.36	6.72	0.34	7.69e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs1789	0.903	rs4470622	chr4:15674175	T/G	cg24225360	chr4:15471699	CC2D2A	-0.37	-5.82	-0.3	1.36e-8	Blood protein levels;
LIHC	cis	rs1075232	0.579	rs58156651	chr15:31749067	C/A	cg01030201	chr15:31746330	NA	-0.84	-6.85	-0.35	3.41e-11	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg09003973	chr2:102972529	NA	0.82	7.15	0.36	5.19e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.68	11.8	0.54	3.52e-27	Iron status biomarkers;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.54	8.39	0.41	1.26e-15	Longevity;Endometriosis;
LIHC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.76	0.69	1.81e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg09572067	chr16:29127029	RRN3P2	-0.61	-9.39	-0.45	8.5e-19	Menopause (age at onset);
LIHC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.78	11.86	0.54	2.04e-27	Dental caries;
LIHC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg23485639	chr6:28045615	ZNF165	0.39	6.05	0.31	3.78e-9	Cardiac Troponin-T levels;
LIHC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.09	-0.36	7.75e-12	Personality dimensions;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-7.06	-0.36	9.21e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.51	-7.38	-0.37	1.18e-12	Height;
LIHC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.9	0.3	8.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07305463	chr2:136567211	LCT	0.4	7.5	0.38	5.5e-13	Mosquito bite size;
LIHC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg13395646	chr4:1353034	KIAA1530	0.39	6.17	0.32	1.97e-9	Obesity-related traits;
LIHC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.65	10.46	0.49	2.08e-22	Lymphocyte counts;
LIHC	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.69	-12.02	-0.55	5.21e-28	Height;
LIHC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.4	6.36	0.33	6.35e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.66	11.51	0.53	3.81e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.77	10.12	0.48	3.12e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.4	7.24	0.36	3.06e-12	Schizophrenia;
LIHC	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.55	-7.04	-0.36	1.03e-11	Major depressive disorder;
LIHC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.53	8.7	0.43	1.41e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs8108269	0.911	rs10404527	chr19:46160703	G/A	cg13320842	chr19:46175254	GIPR	0.43	8.05	0.4	1.37e-14	Type 2 diabetes;
LIHC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.65	10.22	0.48	1.44e-21	Resting heart rate;
LIHC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.8	11.97	0.54	8.05e-28	Coronary artery disease;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.68	0.62	3.45e-38	Prudent dietary pattern;
LIHC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.4	-8.48	-0.42	6.68e-16	Obesity-related traits;
LIHC	cis	rs8084351	0.560	rs28718037	chr18:50572697	A/G	cg24270629	chr18:50823537	DCC	0.38	5.77	0.3	1.76e-8	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.66	9.66	0.46	1.12e-19	Corneal astigmatism;
LIHC	cis	rs1198430	0.568	rs1119439	chr1:23828904	A/T	cg19827787	chr1:23763612	ASAP3	0.36	5.79	0.3	1.62e-8	Total cholesterol levels;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.49	-0.33	2.94e-10	Total body bone mineral density;
LIHC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-8.44	-0.42	9.35e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.58	8.16	0.4	6.57e-15	Aortic root size;
LIHC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.53	6.35	0.32	6.86e-10	Morning vs. evening chronotype;
LIHC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg00292662	chr22:38071168	LGALS1	0.64	10.15	0.48	2.48e-21	Fat distribution (HIV);
LIHC	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.55e-18	Atrioventricular conduction;
LIHC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg13175981	chr1:150552382	MCL1	-0.43	-5.96	-0.31	6.39e-9	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs1865721	0.804	rs62089468	chr18:73158850	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.28	-0.37	2.28e-12	Intelligence;
LIHC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.5	0.67	2.13e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.53	5.74	0.3	2.12e-8	Menopause (age at onset);
LIHC	trans	rs875971	0.545	rs316328	chr7:65608838	A/G	cg26939375	chr7:64535504	NA	-0.38	-6.22	-0.32	1.43e-9	Aortic root size;
LIHC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg14067834	chr17:29058358	SUZ12P	-0.64	-6.76	-0.34	6.04e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19671926	chr4:122722719	EXOSC9	0.46	6.69	0.34	9.2e-11	Type 2 diabetes;
LIHC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	10.47	0.49	2.03e-22	Response to antipsychotic treatment;
LIHC	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.25	-0.32	1.21e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.9	12.01	0.54	5.56e-28	Post bronchodilator FEV1;
LIHC	trans	rs1814175	0.588	rs34449937	chr11:49756013	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.81	0.35	4.37e-11	Height;
LIHC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	7.86	0.39	5.12e-14	Lymphocyte counts;
LIHC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.71	10.59	0.5	7.45e-23	Height;
LIHC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.59	9.19	0.44	3.96e-18	Urinary tract infection frequency;
LIHC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg11057378	chr10:81107060	PPIF	0.37	6.0	0.31	5.15e-9	Height;
LIHC	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg00091569	chr3:40428383	ENTPD3	-0.36	-6.12	-0.31	2.62e-9	Renal cell carcinoma;
LIHC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.95	-12.28	-0.55	5.99e-29	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.79	-0.34	4.9e-11	Diabetic kidney disease;
LIHC	trans	rs75804782	0.521	rs56176151	chr2:239440220	T/C	cg01134436	chr17:81009848	B3GNTL1	0.71	6.11	0.31	2.75e-9	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	1.07	15.69	0.65	3.58e-42	Breast cancer;
LIHC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.93	0.31	7.61e-9	Height;
LIHC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.72	12.63	0.56	2.89e-30	Lewy body disease;
LIHC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.59	8.44	0.42	9.07e-16	Blood metabolite levels;
LIHC	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg00977110	chr5:151150581	G3BP1	0.54	6.96	0.35	1.79e-11	Preschool internalizing problems;
LIHC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.42	5.87	0.3	1.04e-8	Blood protein levels;
LIHC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.79	0.39	8.33e-14	Mean platelet volume;
LIHC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg02297831	chr4:17616191	MED28	0.49	7.6	0.38	2.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.51e-16	Platelet count;
LIHC	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.47	-6.15	-0.32	2.11e-9	Menopause (age at onset);
LIHC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.85	-0.43	4.96e-17	Ulcerative colitis;
LIHC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg09182678	chr22:50328711	NA	-0.4	-5.98	-0.31	5.63e-9	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg18709589	chr6:96969512	KIAA0776	-0.48	-5.95	-0.31	6.65e-9	Migraine;Coronary artery disease;
LIHC	cis	rs7635838	0.892	rs9836167	chr3:11493392	C/T	cg00170343	chr3:11313890	ATG7	0.4	6.33	0.32	7.55e-10	HDL cholesterol;
LIHC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg14067834	chr17:29058358	SUZ12P	0.61	6.36	0.32	6.65e-10	Body mass index;
LIHC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.33	5.76	0.3	1.9e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.88	10.98	0.51	3.09e-24	Prostate cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg19687152	chr14:102968497	TECPR2	0.4	6.05	0.31	3.82e-9	Longevity;
LIHC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.31	-6.98	-0.35	1.49e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.76	12.67	0.57	2.02e-30	Parkinson's disease;
LIHC	cis	rs858239	0.863	rs274054	chr7:23390467	G/C	cg00469287	chr7:23338798	C7orf30	0.49	6.71	0.34	8.02e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.44	6.49	0.33	2.95e-10	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.41	6.32	0.32	8.18e-10	Resting heart rate;
LIHC	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.37	-0.45	1.05e-18	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07325041	chr3:17783979	TBC1D5	0.43	6.26	0.32	1.17e-9	Cognitive function;
LIHC	cis	rs8020095	0.571	rs8022328	chr14:67253035	A/G	cg03487553	chr14:67822707	ATP6V1D	0.35	6.07	0.31	3.33e-9	Depression (quantitative trait);
LIHC	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg10820045	chr2:198174542	NA	0.55	8.78	0.43	8.21e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.42	0.45	7.19e-19	Bipolar disorder;
LIHC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.57	7.8	0.39	7.33e-14	Neuroblastoma;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.45	-0.53	6.37e-26	Bipolar disorder and schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09623986	chr2:74753896	AUP1;DQX1	0.42	6.19	0.32	1.68e-9	Longevity;
LIHC	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.96e-9	Pulmonary function;
LIHC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.49	6.55	0.33	2.09e-10	Emphysema distribution in smoking;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14862791	chr5:34839623	TTC23L	0.44	6.36	0.33	6.5e-10	Pancreatic cancer;
LIHC	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.61	5.88	0.3	9.8e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg27386326	chr11:61587980	NA	-0.65	-13.1	-0.58	4.78e-32	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-14.73	-0.62	2.25e-38	Refractive error;
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg08469215	chr1:156261351	TMEM79	0.41	6.57	0.33	1.9e-10	Tonsillectomy;
LIHC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.67	11.29	0.52	2.52e-25	Lymphocyte counts;
LIHC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.56	10.17	0.48	2.16e-21	Methadone dose in opioid dependence;
LIHC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg08847533	chr14:75593920	NEK9	-0.55	-8.87	-0.43	4.2e-17	IgG glycosylation;
LIHC	cis	rs2412488	0.853	rs9996883	chr4:54357177	C/T	cg22241045	chr4:54363911	LNX1	0.41	6.55	0.33	2.05e-10	DNA methylation (variation);
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.68	-9.8	-0.47	3.73e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-18.42	-0.71	4.09e-53	Height;
LIHC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.52	9.15	0.44	5.08e-18	N-glycan levels;
LIHC	cis	rs16828019	0.929	rs111309254	chr1:41736000	A/G	cg20697417	chr1:41786797	NA	0.34	6.53	0.33	2.32e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4951018	0.526	rs6693913	chr1:205654061	G/C	cg17723122	chr1:205641542	SLC45A3	0.43	6.45	0.33	3.89e-10	Prostate-specific antigen levels;
LIHC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	11.39	0.52	1.04e-25	Lung cancer in ever smokers;
LIHC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.95	-9.36	-0.45	1.09e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2271001	0.869	rs2042688	chr11:19186294	G/T	cg12999362	chr7:75947528	NA	-0.36	-6.09	-0.31	3.01e-9	Gut microbiome composition (winter);
LIHC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4759375	1.000	rs61953394	chr12:123753372	T/C	cg00376283	chr12:123451042	ABCB9	-0.5	-6.24	-0.32	1.27e-9	HDL cholesterol;
LIHC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.8	-0.39	7.44e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg19680672	chr10:131412579	MGMT	-0.43	-6.65	-0.34	1.14e-10	Response to temozolomide;
LIHC	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16684958	chr7:75615977	POR	0.51	8.59	0.42	3.18e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4700695	0.697	rs251319	chr5:65239468	A/G	cg21114390	chr5:65439923	SFRS12	0.49	6.67	0.34	1.05e-10	Facial morphology (factor 19);
LIHC	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.4	6.39	0.33	5.57e-10	Intraocular pressure;
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.59	0.59	6.1e-34	Prudent dietary pattern;
LIHC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-6.3	-0.32	9.28e-10	Eosinophil percentage of white cells;
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.74	-0.3	2.04e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.5	-7.64	-0.38	2.17e-13	Corneal astigmatism;
LIHC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.93	-0.39	3.22e-14	Type 2 diabetes;
LIHC	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.72	-12.03	-0.55	4.82e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05472934	chr7:22766657	IL6	0.53	8.44	0.42	8.9e-16	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LIHC	cis	rs3743266	0.507	rs10162677	chr15:60748568	C/T	cg22293140	chr15:60689852	ANXA2	-0.64	-6.11	-0.31	2.64e-9	Menarche (age at onset);
LIHC	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.77	9.86	0.47	2.4e-20	Body mass index;
LIHC	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.52	7.57	0.38	3.53e-13	Dialysis-related mortality;
LIHC	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.62	-7.86	-0.39	5.01e-14	Macular telangiectasia type 2;
LIHC	cis	rs1419980	0.730	rs11534793	chr12:7752966	G/A	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05665937	chr4:1216051	CTBP1	0.45	6.08	0.31	3.23e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.47	6.34	0.32	7.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs77669868	0.929	rs76761091	chr11:114067058	A/G	cg01914181	chr11:114070210	ZBTB16	0.65	8.78	0.43	8.24e-17	Monocyte percentage of white cells;
LIHC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg14132834	chr19:41945861	ATP5SL	0.45	6.57	0.33	1.88e-10	Height;
LIHC	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.57	6.8	0.35	4.67e-11	Mammographic density (dense area);
LIHC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.67	12.08	0.55	3.21e-28	Reticulocyte fraction of red cells;
LIHC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg17135325	chr3:160939158	NMD3	0.53	7.55	0.38	4.1e-13	Morning vs. evening chronotype;
LIHC	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.59	-0.38	3e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg23806715	chr17:73775811	H3F3B	0.76	7.08	0.36	8.35e-12	Psoriasis;
LIHC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-9.19	-0.45	3.86e-18	Parkinson's disease;
LIHC	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg13482628	chr17:19912719	NA	0.4	6.63	0.34	1.35e-10	Schizophrenia;
LIHC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.47	-7.41	-0.37	1.03e-12	Blood metabolite levels;
LIHC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-5.99	-0.31	5.42e-9	Aortic root size;
LIHC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.47	7.79	0.39	7.98e-14	Vitiligo;
LIHC	cis	rs3018712	0.532	rs2513282	chr11:68418311	A/C	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.12e-8	Total body bone mineral density;
LIHC	trans	rs1864585	0.520	rs7817252	chr8:10685932	C/A	cg26278703	chr11:58910052	FAM111A	0.68	6.05	0.31	3.77e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.64	-8.17	-0.4	5.85e-15	Gut microbiome composition (summer);
LIHC	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.38	-0.33	5.68e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg00280220	chr17:61926910	NA	0.42	6.9	0.35	2.56e-11	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.19	-0.52	5.65e-25	Chronic sinus infection;
LIHC	cis	rs11671005	0.779	rs731259	chr19:58989424	C/T	cg25952890	chr19:58913133	NA	0.73	7.45	0.37	7.73e-13	Mean platelet volume;
LIHC	cis	rs4764487	0.687	rs10744702	chr12:6349127	G/A	cg08284733	chr12:6341482	CD9	0.38	6.46	0.33	3.61e-10	Mean platelet volume;
LIHC	cis	rs34540877	1.000	rs34552729	chr19:33153320	C/T	cg22980127	chr19:33182716	NUDT19	0.86	5.97	0.31	5.84e-9	Red cell distribution width;
LIHC	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.9	-0.35	2.5e-11	Total cholesterol levels;
LIHC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.39	-11.19	-0.52	5.46e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.76	-9.44	-0.45	6.06e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg24225360	chr4:15471699	CC2D2A	0.4	6.44	0.33	4e-10	Obesity-related traits;
LIHC	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-9.25	-0.45	2.45e-18	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.52	5.99	0.31	5.37e-9	Alzheimer's disease;
LIHC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg25039879	chr17:56429692	SUPT4H1	0.77	8.97	0.44	2e-17	Cognitive test performance;
LIHC	cis	rs6001982	0.541	rs733999	chr22:41050335	C/G	cg14879645	chr22:41048474	NA	0.4	5.91	0.3	8.13e-9	Breast cancer;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg00061764	chr3:67564432	SUCLG2	0.43	6.2	0.32	1.66e-9	Electroencephalogram traits;
LIHC	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.66	0.34	1.1e-10	Dupuytren's disease;
LIHC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.72	-0.43	1.24e-16	Obesity-related traits;
LIHC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg10820045	chr2:198174542	NA	0.56	8.88	0.43	3.78e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.61	-0.34	1.5e-10	Eosinophil percentage of white cells;
LIHC	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.49	-7.77	-0.39	9.17e-14	Testicular germ cell tumor;
LIHC	cis	rs4589502	0.557	rs11071923	chr15:67157715	C/G	cg12317470	chr15:67143691	NA	0.53	6.1	0.31	2.8e-9	Lung cancer (smoking interaction);
LIHC	trans	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg01596870	chr19:55963115	NA	-0.61	-7.22	-0.36	3.5e-12	Obesity-related traits;
LIHC	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg04607235	chr12:12878440	APOLD1	0.51	7.84	0.39	5.88e-14	Pulse pressure;
LIHC	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17554472	chr22:41940697	POLR3H	-0.54	-5.76	-0.3	1.84e-8	Vitiligo;
LIHC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.38	-6.04	-0.31	4.04e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.46	-7.47	-0.37	6.96e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.8	-0.75	1.1e-62	Height;
LIHC	cis	rs8020095	0.571	rs8003929	chr14:67533273	C/G	cg03487553	chr14:67822707	ATP6V1D	-0.38	-6.55	-0.33	2.12e-10	Depression (quantitative trait);
LIHC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2384207	0.818	rs1458366	chr12:113672577	A/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.47	5.74	0.3	2.04e-8	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	7.42	0.37	9.34e-13	Platelet count;
LIHC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg21665744	chr7:39171113	POU6F2	0.32	5.98	0.31	5.52e-9	IgG glycosylation;
LIHC	trans	rs3783890	0.887	rs2295704	chr14:93814212	T/A	cg02802420	chr16:69363236	PDF;COG8	0.33	6.29	0.32	9.92e-10	Body mass index;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09952564	chr10:5979174	FBXO18	0.51	6.7	0.34	8.34e-11	Hip circumference;
LIHC	trans	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg07393940	chr7:158741817	NA	0.56	6.79	0.34	5.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20476274	chr7:133979776	SLC35B4	0.38	6.09	0.31	3.1e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.69	6.37	0.33	6.16e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs72627123	0.531	rs3742806	chr14:74532523	A/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	8.7	0.43	1.38e-16	Morning vs. evening chronotype;
LIHC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.46	7.08	0.36	8.37e-12	Obesity-related traits;
LIHC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg03859395	chr2:55845619	SMEK2	0.84	14.81	0.63	1.07e-38	Metabolic syndrome;
LIHC	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.59	-0.42	3.21e-16	QRS duration;
LIHC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.74	-9.69	-0.46	8.93e-20	Morning vs. evening chronotype;
LIHC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.28	0.32	1.02e-9	Major depressive disorder;
LIHC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.8	13.49	0.59	1.47e-33	Psoriasis;
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-6.77	-0.34	5.58e-11	Total body bone mineral density;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.35	-6.87	-0.35	3.01e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23687960	chr8:63951868	GGH	0.42	6.06	0.31	3.65e-9	Cognitive function;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg19487717	chr11:70263216	CTTN	0.43	6.48	0.33	3.12e-10	Immature fraction of reticulocytes;
LIHC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg05555928	chr11:63887634	MACROD1	0.56	7.53	0.38	4.48e-13	Mean platelet volume;
LIHC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-7.35	-0.37	1.48e-12	Crohn's disease;
LIHC	cis	rs7707921	1.000	rs1019806	chr5:81551659	G/A	cg15871215	chr5:81402204	ATG10	0.6	5.89	0.3	9.45e-9	Breast cancer;
LIHC	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	trans	rs35668226	0.891	rs10886850	chr10:122859864	A/C	cg08474467	chr16:593365	SOLH	0.38	6.6	0.34	1.6e-10	Type 2 diabetes;
LIHC	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16684958	chr7:75615977	POR	-0.51	-8.61	-0.42	2.78e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.06	9.65	0.46	1.25e-19	Diabetic retinopathy;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg24594292	chr6:111179867	NA	0.61	6.53	0.33	2.32e-10	Mean platelet volume;
LIHC	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.36	8.12	0.4	8.38e-15	Educational attainment (years of education);
LIHC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.87	0.3	1.04e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs11724903	0.935	rs11732243	chr4:183214784	T/C	cg16239906	chr20:35724590	RBL1	-0.64	-6.1	-0.31	2.83e-9	Smoking initiation;
LIHC	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg22771759	chr13:24902376	NA	0.3	6.04	0.31	4.1e-9	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13409248	chr3:40428643	ENTPD3	0.5	8.35	0.41	1.7e-15	Renal cell carcinoma;
LIHC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.66	13.29	0.58	8.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	11.08	0.51	1.33e-24	Monocyte percentage of white cells;
LIHC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.66	12.84	0.57	4.6e-31	Rheumatoid arthritis;
LIHC	trans	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg17675199	chr6:35436792	RPL10A	0.31	6.08	0.31	3.13e-9	Coronary artery disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03320005	chr20:62886973	PCMTD2	-0.4	-6.09	-0.31	3.08e-9	Calcium levels;
LIHC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.52	7.57	0.38	3.51e-13	Prostate cancer;
LIHC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs546131	0.642	rs11603751	chr11:34820809	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.36	-0.33	6.29e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.55	8.64	0.42	2.14e-16	Corneal astigmatism;
LIHC	cis	rs7091068	0.522	rs11187621	chr10:95483074	T/C	cg20715218	chr10:95462985	C10orf4	0.52	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LIHC	cis	rs7944584	0.588	rs11988	chr11:47261260	G/A	cg20307385	chr11:47447363	PSMC3	0.6	6.67	0.34	1.02e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.32	-0.49	6.6e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs9649465	0.934	rs34030532	chr7:123274992	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-9.04	-0.44	1.15e-17	Migraine;
LIHC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.47	6.55	0.33	2.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.56	-0.38	3.74e-13	Waist circumference;Body mass index;
LIHC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg20607798	chr8:58055168	NA	0.46	6.3	0.32	9.07e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.54	-8.21	-0.41	4.64e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.95	-0.31	6.8e-9	Type 2 diabetes;
LIHC	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.54	5.8	0.3	1.48e-8	Multiple sclerosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20232060	chr3:141457873	RNF7	0.44	6.98	0.35	1.55e-11	Cognitive function;
LIHC	cis	rs7395581	0.797	rs10838681	chr11:47275064	C/T	cg26139080	chr11:47293733	MADD	-0.48	-7.96	-0.4	2.57e-14	HDL cholesterol;
LIHC	cis	rs3743266	0.507	rs34092508	chr15:60722979	C/T	cg22293140	chr15:60689852	ANXA2	-0.64	-6.31	-0.32	8.54e-10	Menarche (age at onset);
LIHC	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg01320579	chr17:75405842	SEPT9	0.53	6.9	0.35	2.56e-11	Airflow obstruction;
LIHC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	trans	rs800082	1.000	rs1961653	chr3:144286098	C/T	cg24215973	chr2:240111563	HDAC4	-0.5	-7.31	-0.37	1.93e-12	Smoking behavior;
LIHC	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.21	0.45	3.35e-18	Response to antipsychotic treatment;
LIHC	cis	rs6088813	1.000	rs6088816	chr20:33982435	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.88	-0.3	9.69e-9	Height;
LIHC	cis	rs7187994	0.848	rs16974532	chr16:84783310	G/A	cg07647771	chr16:84786436	USP10	-0.33	-6.5	-0.33	2.92e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.51	-7.38	-0.37	1.19e-12	Response to diuretic therapy;
LIHC	cis	rs5753037	0.745	rs9306465	chr22:30221826	T/A	cg01021169	chr22:30184971	ASCC2	-0.35	-6.51	-0.33	2.7e-10	Type 1 diabetes;
LIHC	cis	rs9596863	0.898	rs7984502	chr13:54344640	T/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.1	0.31	2.94e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2071426	0.959	rs35427080	chr10:96803649	A/G	cg09036531	chr10:96991505	NA	-0.51	-6.21	-0.32	1.53e-9	Blood metabolite levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12282830	chr22:29784441	AP1B1	-0.4	-6.17	-0.32	1.96e-9	Longevity;
LIHC	cis	rs7129220	0.588	rs7939064	chr11:10102846	A/C	cg01453529	chr11:10209919	SBF2	-0.41	-7.3	-0.37	2.1e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	-0.59	-8.6	-0.42	2.89e-16	Prudent dietary pattern;
LIHC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.7	10.45	0.49	2.37e-22	Mosquito bite size;
LIHC	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.57	-13.96	-0.6	2.36e-35	White blood cell count (basophil);
LIHC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg15832292	chr6:96025679	MANEA	0.62	7.15	0.36	5.19e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02985541	chr2:219472218	PLCD4	0.47	8.89	0.43	3.53e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg16070018	chr6:26224392	HIST1H3E	0.58	6.93	0.35	2.09e-11	Gout;Renal underexcretion gout;
LIHC	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.86	0.43	4.37e-17	Exhaled nitric oxide levels;
LIHC	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.54	-8.41	-0.41	1.11e-15	Menopause (age at onset);
LIHC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.31	6.45	0.33	3.92e-10	QRS complex (12-leadsum);
LIHC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg04756594	chr16:24857601	SLC5A11	0.61	8.45	0.42	8.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9649465	1.000	rs11770041	chr7:123365788	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.15e-15	Migraine;
LIHC	trans	rs6695572	0.697	rs57371116	chr1:77971960	G/T	cg04606550	chr5:14226569	TRIO	0.39	6.08	0.31	3.24e-9	Body mass index;
LIHC	cis	rs11212260	0.655	rs78002743	chr11:107324329	C/G	cg25435332	chr11:107328525	CWF19L2	0.82	8.43	0.41	9.83e-16	IgG glycosylation;
LIHC	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg23091122	chr1:110024289	SYPL2	-0.49	-6.46	-0.33	3.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg12863693	chr15:85201151	NMB	0.47	6.73	0.34	7.03e-11	Schizophrenia;
LIHC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18252515	chr7:66147081	NA	-0.43	-6.04	-0.31	4.06e-9	Aortic root size;
LIHC	trans	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	6.2	0.32	1.65e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7116495	0.609	rs3016291	chr11:71583482	A/C	cg26138937	chr11:71823887	C11orf51	0.69	6.69	0.34	9.16e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.96	14.9	0.63	4.73e-39	Breast cancer;
LIHC	cis	rs425535	0.619	rs7671525	chr4:74792031	C/A	cg02530824	chr4:74847766	PF4	-0.38	-5.77	-0.3	1.74e-8	Blood protein levels;
LIHC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	1.05	12.42	0.56	1.73e-29	Vitiligo;
LIHC	cis	rs77633900	0.772	rs157788	chr15:76806011	T/C	cg21673338	chr15:77095150	SCAPER	-0.53	-6.09	-0.31	3.11e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.13	-16.71	-0.67	3.15e-46	Gut microbiome composition (summer);
LIHC	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.56	-0.38	3.79e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg10792982	chr14:105748885	BRF1	0.46	5.94	0.31	7.16e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7116495	0.786	rs10736785	chr11:71718912	C/A	cg26138937	chr11:71823887	C11orf51	-0.81	-8.16	-0.4	6.65e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg14773178	chr5:1868261	NA	0.26	6.62	0.34	1.37e-10	Cardiovascular disease risk factors;
LIHC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.75	13.03	0.58	8.69e-32	Height;
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4742903	0.967	rs3739737	chr9:106858192	A/G	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.58	8.7	0.43	1.44e-16	Height;
LIHC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-10.28	-0.49	8.89e-22	Dental caries;
LIHC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.48	7.96	0.4	2.56e-14	Mean corpuscular volume;
LIHC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12379764	chr21:47803548	PCNT	-0.6	-8.72	-0.43	1.21e-16	Testicular germ cell tumor;
LIHC	cis	rs11671005	0.735	rs11084544	chr19:58940127	C/G	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.22e-13	Mean platelet volume;
LIHC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg20607798	chr8:58055168	NA	0.48	5.97	0.31	5.95e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.67	11.14	0.52	8.12e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg09238746	chr17:78121135	EIF4A3	-0.4	-6.13	-0.31	2.45e-9	Yeast infection;
LIHC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.75	11.88	0.54	1.71e-27	Corneal astigmatism;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19892525	chr11:108157498	ATM	-0.43	-6.52	-0.33	2.49e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.39	0.52	1.03e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.57	8.26	0.41	3.32e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.23	0.55	8.88e-29	Alzheimer's disease;
LIHC	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg18898632	chr2:242989856	NA	-0.45	-6.19	-0.32	1.72e-9	Obesity-related traits;
LIHC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.79	0.39	7.91e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.51	-7.26	-0.37	2.58e-12	High light scatter reticulocyte count;
LIHC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.25	-0.32	1.21e-9	Lung cancer;
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg00914777	chr14:93651123	MOAP1;C14orf109	0.39	6.59	0.34	1.69e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs8016947	0.583	rs12879818	chr14:35830938	G/A	cg03549618	chr14:35838977	NA	0.44	6.98	0.35	1.54e-11	Psoriasis;
LIHC	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg05110241	chr16:68378359	PRMT7	-0.54	-6.53	-0.33	2.36e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.44	7.66	0.38	1.99e-13	Schizophrenia;
LIHC	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.56	-8.06	-0.4	1.34e-14	Neuroticism;
LIHC	cis	rs882732	1.000	rs10134935	chr14:95037079	T/C	cg14866387	chr14:95027382	SERPINA4	-0.42	-6.01	-0.31	4.7e-9	Blood protein levels;
LIHC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.83	0.54	2.59e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.56	-9.52	-0.46	3.24e-19	Calcium levels;
LIHC	trans	rs10411161	0.580	rs12151288	chr19:52381552	A/G	cg22319618	chr22:45562946	NUP50	-0.49	-7.27	-0.37	2.47e-12	Breast cancer;
LIHC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.75	-0.39	1.08e-13	Morning vs. evening chronotype;
LIHC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.49	6.32	0.32	7.93e-10	Emphysema distribution in smoking;
LIHC	cis	rs12744310	1.000	rs12032756	chr1:41761429	G/A	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs9914544	0.545	rs8068683	chr17:18761827	T/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Educational attainment (years of education);
LIHC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.4	6.58	0.34	1.78e-10	Red blood cell count;
LIHC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.71	7.33	0.37	1.65e-12	Vitiligo;
LIHC	cis	rs116248771	0.739	rs12629635	chr3:158322069	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.08	0.31	3.12e-9	diarrhoeal disease at age 2;
LIHC	cis	rs244293	0.700	rs12939352	chr17:53007655	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-7.31	-0.37	1.9e-12	Menarche (age at onset);
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.58	-0.34	1.74e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs922107	0.713	rs2061478	chr1:90044453	G/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.73	-0.39	1.19e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.47	7.76	0.39	9.85e-14	Multiple sclerosis;
LIHC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.82	0.47	3.16e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9378688	0.654	rs2505659	chr6:2326637	G/A	cg12303981	chr6:2244766	GMDS	-0.45	-6.06	-0.31	3.59e-9	Caudate nucleus volume;
LIHC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.78	-0.34	5.36e-11	Height;
LIHC	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.38	-6.64	-0.34	1.21e-10	Schizophrenia;
LIHC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.71	12.89	0.57	2.92e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg02023728	chr11:77925099	USP35	-0.36	-6.22	-0.32	1.43e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.7	9.46	0.46	5.05e-19	Corneal structure;
LIHC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.66	-9.81	-0.47	3.55e-20	Menarche (age at onset);
LIHC	trans	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04565464	chr8:145669602	NFKBIL2	0.4	6.69	0.34	9.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs4908768	0.906	rs11121223	chr1:8772845	T/A	cg20416874	chr1:8611966	RERE	0.55	7.86	0.39	4.97e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.27	-0.37	2.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs7116495	1.000	rs3018301	chr11:71792071	A/G	cg26138937	chr11:71823887	C11orf51	-0.64	-6.55	-0.33	2.09e-10	Severe influenza A (H1N1) infection;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01287788	chr2:86362935	SNORD94;PTCD3	-0.69	-10.76	-0.5	1.94e-23	Lung function (FEV1/FVC);
LIHC	cis	rs151997	0.671	rs27845	chr5:50197420	A/C	cg06027927	chr5:50259733	NA	0.44	6.53	0.33	2.38e-10	Callous-unemotional behaviour;
LIHC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.49	-0.38	5.99e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.17	-0.36	4.67e-12	Personality dimensions;
LIHC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.79	9.9	0.47	1.7e-20	Cognitive function;
LIHC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.25	0.55	7.29e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.39	-0.56	2.33e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg20240347	chr1:204465584	NA	-0.36	-7.6	-0.38	2.88e-13	Schizophrenia;
LIHC	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.75	13.15	0.58	2.93e-32	Eosinophil percentage of white cells;
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.64	9.29	0.45	1.79e-18	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3917254	0.570	rs2310187	chr2:102750428	G/T	cg22835712	chr2:102737379	NA	-0.52	-6.51	-0.33	2.69e-10	Blood protein levels;
LIHC	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg25665528	chr16:2260870	C16orf79	-0.36	-6.32	-0.32	8.36e-10	Height;
LIHC	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.4	-5.98	-0.31	5.7e-9	Red blood cell traits;
LIHC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg18478394	chr8:109455254	TTC35	0.43	7.48	0.37	6.5e-13	Dupuytren's disease;
LIHC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.28	-5.82	-0.3	1.33e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.49	5.91	0.3	8.45e-9	Serum sulfate level;
LIHC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.85	0.35	3.46e-11	Personality dimensions;
LIHC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06544989	chr22:39130855	UNC84B	0.38	5.95	0.31	6.62e-9	Menopause (age at onset);
LIHC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.57	9.82	0.47	3.27e-20	Colorectal cancer;
LIHC	cis	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg19680485	chr15:31195859	MTMR15	-0.53	-5.85	-0.3	1.12e-8	Hypertriglyceridemia;
LIHC	trans	rs11689435	0.925	rs2373065	chr2:218351628	C/T	cg13544946	chr9:35729779	TLN1	-0.41	-6.1	-0.31	2.82e-9	Metabolite levels (MHPG);
LIHC	cis	rs1292059	1	rs1292059	chr17:57957888	T/A	cg13753209	chr17:57696993	CLTC	0.69	10.29	0.49	8.02e-22	Eosinophil percentage of granulocytes;
LIHC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	6.98	0.35	1.52e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.02e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.42	-6.86	-0.35	3.21e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11077998	0.723	rs3829566	chr17:80528996	C/T	cg11779900	chr17:80519722	FOXK2	-0.39	-5.79	-0.3	1.56e-8	Reticulocyte fraction of red cells;
LIHC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.7	0.73	2.92e-58	Smoking behavior;
LIHC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-10.78	-0.5	1.56e-23	Schizophrenia;
LIHC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.32	-0.32	8.36e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.59	-11.47	-0.53	5.62e-26	Body mass index;
LIHC	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.9	18.39	0.71	5.07e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.46	-9.0	-0.44	1.54e-17	LDL cholesterol levels;
LIHC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.63	0.38	2.32e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-0.98	-23.24	-0.78	2.31e-72	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.39	-5.99	-0.31	5.24e-9	Blood pressure (smoking interaction);
LIHC	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.37	-6.9	-0.35	2.58e-11	Height;
LIHC	trans	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.37	-6.28	-0.32	1.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.08	0.31	3.18e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.42	6.27	0.32	1.1e-9	Obesity-related traits;
LIHC	trans	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.22	-0.32	1.42e-9	Coronary artery disease;
LIHC	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.89	0.39	4.23e-14	Motion sickness;
LIHC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.5	8.9	0.43	3.27e-17	HDL cholesterol levels;
LIHC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	1.0	18.58	0.71	8.76e-54	Breast cancer;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22929808	chr12:58027113	B4GALNT1	0.45	6.22	0.32	1.42e-9	Pancreatic cancer;
LIHC	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.61	-11.76	-0.54	5.01e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg16576597	chr16:28551801	NUPR1	0.37	5.95	0.31	6.7e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.36	5.81	0.3	1.4e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.91	0.3	8.47e-9	Height;
LIHC	cis	rs2637266	0.716	rs2579734	chr10:78441306	A/G	cg18941641	chr10:78392320	NA	0.27	5.85	0.3	1.13e-8	Pulmonary function;
LIHC	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg25182066	chr10:30743637	MAP3K8	-0.48	-7.93	-0.39	3.23e-14	Inflammatory bowel disease;
LIHC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg12046867	chr14:103022105	NA	0.51	7.11	0.36	6.88e-12	Platelet count;
LIHC	cis	rs7523273	0.565	rs2025374	chr1:207887536	A/G	cg22525895	chr1:207977042	MIR29B2	-0.5	-7.79	-0.39	8.07e-14	Schizophrenia;
LIHC	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-10.79	-0.5	1.45e-23	Myopia (pathological);
LIHC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	13.29	0.58	8.97e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7619427	0.908	rs62253229	chr3:44080221	G/A	cg24966902	chr3:44043705	NA	0.43	6.19	0.32	1.69e-9	Schizophrenia;
LIHC	cis	rs11098699	1.000	rs7663175	chr4:124175909	G/T	cg09941581	chr4:124220074	SPATA5	0.34	6.35	0.32	6.66e-10	Mosquito bite size;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03729566	chr7:1059678	C7orf50	0.39	6.07	0.31	3.43e-9	Longevity;
LIHC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.78	13.52	0.59	1.17e-33	Aortic root size;
LIHC	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg02251663	chr11:14281053	SPON1	-0.43	-5.99	-0.31	5.36e-9	Mitochondrial DNA levels;
LIHC	cis	rs4716602	0.596	rs12386632	chr7:156158221	G/A	cg16983916	chr7:156159713	NA	-0.32	-5.84	-0.3	1.22e-8	Anti-saccade response;
LIHC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.2	-0.32	1.6e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.15e-9	Mortality in heart failure;
LIHC	cis	rs611744	0.846	rs405534	chr8:109154408	T/A	cg18478394	chr8:109455254	TTC35	0.34	5.81	0.3	1.44e-8	Dupuytren's disease;
LIHC	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	5.97	0.31	6.04e-9	Schizophrenia;
LIHC	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-9.07	-0.44	9.69e-18	Colorectal cancer;
LIHC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.48	6.89	0.35	2.75e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg06935464	chr4:38784597	TLR10	0.4	6.31	0.32	8.86e-10	Breast cancer;
LIHC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.89	0.3	9.29e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg16736954	chr20:23401023	NAPB	0.52	5.89	0.3	9.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs11724903	1.000	rs17072957	chr4:183201342	A/G	cg16239906	chr20:35724590	RBL1	0.61	6.22	0.32	1.48e-9	Smoking initiation;
LIHC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg17372223	chr3:52568218	NT5DC2	0.36	5.97	0.31	5.98e-9	Bipolar disorder;
LIHC	cis	rs4407350	0.721	rs131156	chr22:44891370	T/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.36	-0.33	6.35e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20601684	chr10:27792608	RAB18	0.55	6.89	0.35	2.63e-11	Systolic blood pressure;
LIHC	cis	rs4728302	0.869	rs6963032	chr7:133599527	T/C	cg10665199	chr7:133106180	EXOC4	0.38	6.69	0.34	9.03e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs797680	0.786	rs9432465	chr1:93780591	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.04	-0.31	3.95e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.74	14.52	0.62	1.51e-37	Mortality in heart failure;
LIHC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	13.48	0.59	1.64e-33	Primary sclerosing cholangitis;
LIHC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.25	-0.37	2.72e-12	IgG glycosylation;
LIHC	cis	rs2224391	1.000	rs2773320	chr6:5261681	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.41	-6.13	-0.31	2.46e-9	Height;
LIHC	cis	rs2834188	1.000	rs2252931	chr21:34704320	A/G	cg14352951	chr21:34696688	IFNAR1	0.44	5.77	0.3	1.77e-8	Narcolepsy;
LIHC	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg17135325	chr3:160939158	NMD3	0.42	5.73	0.3	2.21e-8	Parkinson's disease;
LIHC	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.68	10.72	0.5	2.59e-23	Colorectal adenoma (advanced);
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-9.78	-0.47	4.49e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg17724175	chr1:150552817	MCL1	0.49	9.58	0.46	2.01e-19	Melanoma;
LIHC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg20651018	chr11:3035856	CARS	-0.37	-6.21	-0.32	1.52e-9	Longevity;
LIHC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.35	-0.32	6.82e-10	Mood instability;
LIHC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs7267979	0.565	rs4815432	chr20:25556403	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.27	-0.32	1.12e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.38	6.27	0.32	1.07e-9	Height;
LIHC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.54	-7.44	-0.37	7.95e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs17106184	1.000	rs72902767	chr1:51260999	A/G	cg07174182	chr1:51127561	FAF1	-0.64	-6.93	-0.35	2.12e-11	Type 2 diabetes;
LIHC	cis	rs3806933	0.522	rs13157863	chr5:110470505	G/A	cg04022379	chr5:110408740	TSLP	0.55	8.49	0.42	6.41e-16	Eosinophilic esophagitis;
LIHC	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.49	-7.05	-0.36	9.72e-12	Parkinson's disease;
LIHC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg06766960	chr11:133703094	NA	-0.49	-7.63	-0.38	2.3e-13	Childhood ear infection;
LIHC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.9	0.39	3.83e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.99	-0.31	5.28e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.37	0.33	6.08e-10	Cognitive test performance;
LIHC	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg06533319	chr4:3265114	C4orf44	0.35	6.52	0.33	2.51e-10	Parental longevity (mother's age at death);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22874560	chr6:37225361	TMEM217;TBC1D22B	-0.53	-6.05	-0.31	3.78e-9	Lung function (FEV1);
LIHC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.57	8.73	0.43	1.11e-16	Type 2 diabetes;
LIHC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.81	-8.68	-0.42	1.62e-16	Vitiligo;
LIHC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg03146154	chr1:46216737	IPP	-0.38	-6.26	-0.32	1.17e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs17125944	0.615	rs2357945	chr14:53318434	A/G	cg00686598	chr14:53173677	PSMC6	-0.78	-9.33	-0.45	1.36e-18	Alzheimer's disease (late onset);
LIHC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.61	7.02	0.35	1.19e-11	Menarche (age at onset);
LIHC	cis	rs12079745	0.590	rs12095526	chr1:169401827	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.73	-6.71	-0.34	8.31e-11	QT interval;
LIHC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.55	6.8	0.35	4.71e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg14515779	chr1:101123966	NA	-0.67	-13.11	-0.58	4.4e-32	Monocyte count;
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	0.99	14.86	0.63	7.07e-39	Skin colour saturation;
LIHC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg06026331	chr20:60912101	LAMA5	0.48	6.44	0.33	4.05e-10	Colorectal cancer;
LIHC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.34	-0.32	7.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.84	-0.51	1.02e-23	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03185820	chr7:149158252	ZNF777	0.47	7.36	0.37	1.38e-12	Cognitive function;
LIHC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.56	2.95e-29	Glomerular filtration rate (creatinine);
LIHC	trans	rs2270927	0.510	rs35764719	chr5:75573550	G/T	cg13563193	chr19:33072644	PDCD5	0.95	9.22	0.45	3.07e-18	Mean corpuscular volume;
LIHC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07305463	chr2:136567211	LCT	-0.37	-7.17	-0.36	4.76e-12	Mosquito bite size;
LIHC	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-6.95	-0.35	1.87e-11	Vitamin D levels;
LIHC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.66	0.65	4.89e-42	Chronic sinus infection;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg01012308	chr16:3767753	TRAP1	-0.39	-6.18	-0.32	1.79e-9	Eotaxin levels;
LIHC	cis	rs1198430	0.683	rs1198440	chr1:23780861	C/A	cg13183780	chr1:23809682	ASAP3	-0.37	-6.46	-0.33	3.6e-10	Total cholesterol levels;
LIHC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.49	-0.33	3.02e-10	Response to antipsychotic treatment;
LIHC	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.7	-7.62	-0.38	2.52e-13	Exhaled nitric oxide output;
LIHC	cis	rs17152411	1.000	rs2241541	chr10:126671673	T/C	cg07906193	chr10:126599966	NA	0.5	7.84	0.39	5.77e-14	Height;
LIHC	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.49	7.48	0.38	6.27e-13	Adiposity;
LIHC	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg14473756	chr11:122847823	NA	-0.37	-6.67	-0.34	1.02e-10	Menarche (age at onset);
LIHC	cis	rs922107	0.738	rs12118443	chr1:90038588	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.03	21.19	0.75	2.92e-64	Schizophrenia;
LIHC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.5	8.24	0.41	3.6e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	6.91	0.35	2.44e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg03037974	chr15:76606532	NA	-0.58	-9.79	-0.47	4.01e-20	Blood metabolite levels;
LIHC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	trans	rs743793	0.875	rs137386	chr22:33580920	C/T	cg20274824	chr1:36638199	MAP7D1	0.46	6.42	0.33	4.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg01652190	chr22:50026171	C22orf34	-0.29	-6.34	-0.32	7.24e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.4	7.59	0.38	3.02e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.63	10.23	0.48	1.35e-21	Resting heart rate;
LIHC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.58	10.22	0.48	1.42e-21	Dupuytren's disease;
LIHC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.66	6.97	0.35	1.65e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01459673	chr8:95907442	CCNE2	-0.42	-6.33	-0.32	7.51e-10	Longevity;
LIHC	cis	rs10861342	0.786	rs11112393	chr12:105548053	C/T	cg23923672	chr12:105501055	KIAA1033	0.69	8.54	0.42	4.33e-16	IgG glycosylation;
LIHC	cis	rs507080	0.885	rs4938530	chr11:118560570	G/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.61	0.34	1.44e-10	Serum metabolite levels;
LIHC	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.66	9.65	0.46	1.17e-19	Monocyte count;
LIHC	cis	rs9473924	0.542	rs67538952	chr6:50894400	T/C	cg14470998	chr6:50812995	TFAP2B	0.94	10.94	0.51	4.27e-24	Body mass index;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02447287	chr2:238707023	RBM44	0.41	6.31	0.32	8.46e-10	Bilirubin levels;
LIHC	cis	rs4586057	0.514	rs7083729	chr10:92624670	T/C	cg14313238	chr10:92632228	RPP30	0.37	6.15	0.32	2.2e-9	Economic and political preferences (time);
LIHC	trans	rs1974653	0.781	rs175162	chr22:20113253	A/C	cg20152630	chr19:46405944	MYPOP	0.47	6.07	0.31	3.48e-9	Schizophrenia;
LIHC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg03264133	chr6:25882463	NA	-0.41	-6.22	-0.32	1.48e-9	Height;
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.55	6.53	0.33	2.39e-10	Alzheimer's disease;
LIHC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.78	-12.11	-0.55	2.45e-28	Total body bone mineral density;
LIHC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.49	-8.15	-0.4	7.18e-15	Longevity;Endometriosis;
LIHC	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-8.45	-0.42	8.7e-16	Gut microbiome composition (summer);
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26618056	chr16:25043323	NA	-0.42	-6.1	-0.31	2.86e-9	Obesity-related traits;
LIHC	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg25457927	chr22:38595422	NA	-0.3	-6.84	-0.35	3.62e-11	Breast cancer;
LIHC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg18016565	chr1:150552671	MCL1	0.49	9.32	0.45	1.49e-18	Melanoma;
LIHC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.4	6.15	0.32	2.12e-9	Coronary artery disease;
LIHC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.79	16.64	0.67	5.93e-46	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg00280220	chr17:61926910	NA	0.42	6.87	0.35	3.08e-11	Prudent dietary pattern;
LIHC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.76	12.66	0.56	2.2e-30	Menarche (age at onset);
LIHC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.51	6.39	0.33	5.45e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.55	8.12	0.4	8.48e-15	Lymphocyte counts;
LIHC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.47	7.57	0.38	3.62e-13	Type 2 diabetes;
LIHC	cis	rs7129220	0.623	rs35815123	chr11:10119764	G/A	cg01453529	chr11:10209919	SBF2	-0.39	-6.93	-0.35	2.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg00204748	chr12:29376779	FAR2	0.44	8.27	0.41	2.93e-15	QT interval;
LIHC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.42	-6.2	-0.32	1.67e-9	Iron status biomarkers;
LIHC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg18016565	chr1:150552671	MCL1	-0.48	-9.29	-0.45	1.78e-18	Melanoma;
LIHC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	12.64	0.56	2.5e-30	Schizophrenia;
LIHC	trans	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg26939375	chr7:64535504	NA	0.42	6.71	0.34	8.22e-11	Aortic root size;
LIHC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	11.77	0.54	4.58e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.72	11.12	0.52	1.01e-24	Corneal astigmatism;
LIHC	cis	rs57590327	0.503	rs4856350	chr3:81503374	G/A	cg07356753	chr3:81810745	GBE1	0.46	6.8	0.35	4.6e-11	Extraversion;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.54	-7.15	-0.36	5.27e-12	Menopause (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27493151	chr19:38701994	DPF1	0.39	6.04	0.31	4.13e-9	Longevity;
LIHC	cis	rs12079745	0.793	rs10919104	chr1:169209118	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-6.9	-0.35	2.59e-11	QT interval;
LIHC	trans	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.37	-0.33	6.01e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.23e-9	Menopause (age at onset);
LIHC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.52	7.81	0.39	6.99e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.65	6.12	0.31	2.58e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.38	6.2	0.32	1.67e-9	Menopause (age at onset);
LIHC	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg17294928	chr15:75287854	SCAMP5	0.44	6.15	0.32	2.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.48	-6.06	-0.31	3.67e-9	Diisocyanate-induced asthma;
LIHC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.22	-0.58	1.56e-32	Primary sclerosing cholangitis;
LIHC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.04e-8	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.56	8.11	0.4	9.02e-15	Renal cell carcinoma;
LIHC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg10217327	chr6:118973057	C6orf204	0.69	7.04	0.36	1.03e-11	Diastolic blood pressure;
LIHC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.61	9.76	0.47	5.35e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.64	6.7	0.34	8.47e-11	Schizophrenia;
LIHC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg17724175	chr1:150552817	MCL1	0.43	8.34	0.41	1.82e-15	Melanoma;
LIHC	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.73	11.24	0.52	3.58e-25	Metabolite levels;
LIHC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.66	-8.93	-0.43	2.69e-17	Aortic root size;
LIHC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.65	-12.41	-0.56	1.82e-29	Schizophrenia;
LIHC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.7	-11.01	-0.51	2.49e-24	Coronary artery disease;
LIHC	cis	rs507080	0.845	rs509641	chr11:118558952	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.26	0.32	1.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.45	-0.33	3.79e-10	Monocyte percentage of white cells;
LIHC	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.54	-12.56	-0.56	5.03e-30	White blood cell count (basophil);
LIHC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg03013999	chr17:37608204	MED1	-0.36	-6.07	-0.31	3.33e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20399842	chr2:21346738	NA	0.41	6.74	0.34	6.88e-11	Longevity;
LIHC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.31	-6.65	-0.34	1.17e-10	Platelet distribution width;
LIHC	cis	rs9948	1.000	rs72811623	chr2:97496473	C/T	cg01990225	chr2:97406019	LMAN2L	-0.65	-6.05	-0.31	3.75e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.95	0.63	3.11e-39	Myeloid white cell count;
LIHC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-6.95	-0.35	1.82e-11	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-9.8	-0.47	3.72e-20	Asthma;
LIHC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.63	-8.94	-0.44	2.56e-17	Blood metabolite levels;
LIHC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.83	11.93	0.54	1.14e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg25173405	chr17:45401733	C17orf57	-0.5	-7.03	-0.36	1.1e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs36051895	0.623	rs7859361	chr9:5237479	C/T	cg02405213	chr9:5042618	JAK2	-0.66	-10.64	-0.5	5.12e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.76	-0.34	5.9e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	7.92	0.39	3.27e-14	Schizophrenia;
LIHC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.06	-0.4	1.33e-14	Morning vs. evening chronotype;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.51	6.61	0.34	1.51e-10	Menopause (age at onset);
LIHC	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.54	0.42	4.57e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-11.45	-0.53	6.29e-26	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.26	0.41	3.14e-15	Motion sickness;
LIHC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.32	7.06	0.36	9.6e-12	Ulcerative colitis;
LIHC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.65	-6.71	-0.34	8.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.59	-10.14	-0.48	2.72e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg09445902	chr10:555545	DIP2C	-0.4	-6.46	-0.33	3.7e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.44	-6.74	-0.34	6.9e-11	Schizophrenia;
LIHC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.11	0.36	6.66e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg06265175	chr8:121136014	COL14A1	0.49	7.84	0.39	5.83e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7684253	0.587	rs4339274	chr4:57747634	A/G	cg26694713	chr4:57773883	REST	0.43	6.13	0.31	2.37e-9	Migraine;
LIHC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg18944383	chr4:111397179	ENPEP	-0.28	-6.46	-0.33	3.62e-10	Coronary artery disease;
LIHC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.9	0.43	3.4e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.86	12.49	0.56	9.45e-30	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.37	6.11	0.31	2.72e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg24580635	chr7:76178542	LOC100133091	-0.45	-6.52	-0.33	2.47e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.31	0.41	2.3e-15	Motion sickness;
LIHC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg07117364	chr1:16154769	NA	0.37	5.72	0.3	2.29e-8	Dilated cardiomyopathy;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.72	-11.99	-0.54	6.97e-28	Height;
LIHC	cis	rs4845459	0.967	rs6677595	chr1:152590187	C/T	cg20634798	chr1:152595351	LCE3A	-0.31	-6.13	-0.31	2.46e-9	Psoriasis;
LIHC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.36	-7.3	-0.37	2e-12	Colorectal cancer;
LIHC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg10381502	chr11:71823885	C11orf51	-1.06	-9.3	-0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg24296786	chr1:45957014	TESK2	-0.5	-7.57	-0.38	3.54e-13	Platelet count;
LIHC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg05425664	chr17:57184151	TRIM37	0.43	5.96	0.31	6.44e-9	Testicular germ cell tumor;
LIHC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.69	12.23	0.55	9.12e-29	Iron status biomarkers;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17875760	chr17:1802361	RPA1	0.48	7.04	0.36	1.06e-11	Hepatitis;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15611993	chr17:14110542	COX10	0.41	6.12	0.31	2.5e-9	Calcium levels;
LIHC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.65	10.73	0.5	2.43e-23	Smoking initiation;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg10217327	chr6:118973057	C6orf204	0.69	7.04	0.36	1.03e-11	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.51	0.56	8.03e-30	Prudent dietary pattern;
LIHC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.13	-0.31	2.46e-9	Ulcerative colitis;
LIHC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.84	-0.43	5.27e-17	Type 2 diabetes;
LIHC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg07636037	chr3:49044803	WDR6	-0.8	-8.16	-0.4	6.27e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	1.08	14.69	0.62	3.18e-38	Heart rate;
LIHC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg05555928	chr11:63887634	MACROD1	0.44	5.74	0.3	2.09e-8	Mean platelet volume;
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg24955955	chr5:415729	AHRR	0.32	6.63	0.34	1.28e-10	Cystic fibrosis severity;
LIHC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.54	-8.4	-0.41	1.24e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.66	11.63	0.53	1.47e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg03945807	chr20:60948434	NA	0.39	6.39	0.33	5.51e-10	Colorectal cancer;
LIHC	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.55	-6.76	-0.34	6.03e-11	QRS duration;
LIHC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.61	-0.56	3.48e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg21466736	chr12:48725269	NA	-0.56	-7.58	-0.38	3.22e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.28	-0.32	1.02e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.67	0.46	1.07e-19	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.72	11.02	0.51	2.35e-24	Metabolite levels;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.34	-5.71	-0.3	2.39e-8	Height;
LIHC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg16127683	chr15:40268777	EIF2AK4	-0.63	-8.06	-0.4	1.33e-14	Response to haloperidol in psychosis;
LIHC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg12560992	chr17:57184187	TRIM37	0.52	7.16	0.36	4.9e-12	Cognitive test performance;
LIHC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg22079354	chr11:130786696	SNX19	0.42	6.09	0.31	2.98e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs72653721	0.938	rs72653722	chr6:10976212	A/C	cg13562911	chr6:11044106	ELOVL2	0.52	7.22	0.36	3.43e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg18016565	chr1:150552671	MCL1	0.5	9.51	0.46	3.62e-19	Melanoma;
LIHC	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg00601450	chr5:74908170	NA	0.58	7.03	0.36	1.15e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.85	12.82	0.57	5.41e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.88	0.3	9.84e-9	Tonsillectomy;
LIHC	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25632853	chr15:73088954	NA	0.36	6.07	0.31	3.46e-9	Triglyceride levels;
LIHC	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.33	6.25	0.32	1.24e-9	Protein biomarker;
LIHC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.62	0.42	2.56e-16	Menarche (age at onset);
LIHC	cis	rs471756	0.523	rs605001	chr9:223843	T/A	cg14500300	chr9:211689	NA	0.27	6.23	0.32	1.36e-9	Mean platelet volume;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15664069	chr6:2989243	DKFZP686I15217	0.54	7.32	0.37	1.82e-12	Lung function (FEV1/FVC);
LIHC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	1.03	20.74	0.75	1.89e-62	Breast cancer;
LIHC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.73	-10.42	-0.49	2.92e-22	White blood cell count;
LIHC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.43	-6.52	-0.33	2.51e-10	Asthma (sex interaction);
LIHC	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs57244997	0.725	rs7746052	chr6:162436267	G/A	cg17173639	chr6:162384350	PARK2	-0.49	-6.42	-0.33	4.48e-10	Mosquito bite size;
LIHC	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.68	6.74	0.34	6.66e-11	Neuroticism;
LIHC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.46	-5.86	-0.3	1.08e-8	Pancreatic cancer;
LIHC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.1	-0.4	9.86e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.86	13.68	0.59	2.84e-34	Metabolic syndrome;
LIHC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs1494950	1.000	rs2643079	chr4:14992496	A/G	cg12377275	chr4:15005593	CPEB2	-0.79	-6.68	-0.34	9.6e-11	Political ideology;
LIHC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg14092571	chr14:90743983	NA	-0.38	-5.95	-0.31	6.46e-9	Mortality in heart failure;
LIHC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg14222432	chr12:29376421	FAR2	0.36	6.93	0.35	2.16e-11	QT interval;
LIHC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg26939375	chr7:64535504	NA	-0.45	-7.94	-0.39	2.89e-14	Calcium levels;
LIHC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.38e-11	Aortic root size;
LIHC	cis	rs9378688	1.000	rs9405550	chr6:2230064	A/C	cg12303981	chr6:2244766	GMDS	0.49	6.18	0.32	1.78e-9	Caudate nucleus volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12600695	chr5:137513806	BRD8;KIF20A	0.47	6.42	0.33	4.52e-10	Pancreatic cancer;
LIHC	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.54	-6.72	-0.34	7.54e-11	Mean platelet volume;
LIHC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.53	-0.42	4.65e-16	Asthma;
LIHC	cis	rs2637266	0.597	rs846615	chr10:78548489	A/G	cg18941641	chr10:78392320	NA	-0.28	-5.93	-0.31	7.48e-9	Pulmonary function;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06468809	chr16:4378402	NA	0.5	7.12	0.36	6.28e-12	Lung function (FEV1/FVC);
LIHC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.81	10.32	0.49	6.41e-22	Cognitive function;
LIHC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.87	11.29	0.52	2.49e-25	Coronary artery disease;
LIHC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.35	5.92	0.3	7.96e-9	IgG glycosylation;
LIHC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs9649465	0.935	rs3807636	chr7:123368488	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.15e-15	Migraine;
LIHC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.47	-0.33	3.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.6	8.93	0.43	2.6e-17	Recombination rate (females);
LIHC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-17.23	-0.68	2.46e-48	Chronic sinus infection;
LIHC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.42	-7.46	-0.37	7.43e-13	Height;
LIHC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.37	7.23	0.36	3.2e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.58	-9.96	-0.47	1.07e-20	Colorectal cancer;
LIHC	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.48	-7.36	-0.37	1.4e-12	Longevity;Endometriosis;
LIHC	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.43	5.73	0.3	2.25e-8	Menopause (age at onset);
LIHC	cis	rs8192282	0.739	rs61811362	chr1:154512495	G/A	cg16683920	chr1:154474344	TDRD10;SHE	0.53	6.46	0.33	3.6e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LIHC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg10241871	chr14:102965420	TECPR2	0.39	6.27	0.32	1.06e-9	Plateletcrit;
LIHC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.65	-8.95	-0.44	2.37e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.33	-5.85	-0.3	1.15e-8	Migraine;Coronary artery disease;
LIHC	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.79	-11.08	-0.51	1.37e-24	Ear protrusion;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19517509	chr12:120933726	DYNLL1	0.42	6.48	0.33	3.16e-10	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03480535	chr4:87856849	AFF1	0.6	9.02	0.44	1.43e-17	Pancreatic cancer;
LIHC	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.56	9.51	0.46	3.4e-19	Colorectal cancer;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg09417038	chr21:47716443	C21orf57	-0.48	-7.23	-0.36	3.1e-12	Testicular germ cell tumor;
LIHC	cis	rs4716602	0.548	rs34245976	chr7:156160897	T/G	cg16983916	chr7:156159713	NA	-0.32	-5.75	-0.3	2.01e-8	Anti-saccade response;
LIHC	cis	rs61712019	0.679	rs17648803	chr2:77725425	A/T	cg11252801	chr2:77748917	LRRTM4	0.55	7.71	0.38	1.36e-13	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-11.75	-0.54	5.35e-27	Prudent dietary pattern;
LIHC	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.82	7.64	0.38	2.28e-13	LDL cholesterol;
LIHC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg26692224	chr17:62915920	LRRC37A3	-0.72	-6.93	-0.35	2.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.45	6.01	0.31	4.84e-9	Initial pursuit acceleration;
LIHC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.67	11.98	0.54	7.42e-28	High light scatter reticulocyte count;
LIHC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg09835421	chr16:68378352	PRMT7	-0.83	-9.47	-0.46	4.92e-19	Magnesium levels;
LIHC	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg27124370	chr19:33622961	WDR88	0.54	7.73	0.39	1.18e-13	Bone properties (heel);
LIHC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.44	7.7	0.38	1.44e-13	Aortic root size;
LIHC	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.58	-0.34	1.82e-10	Body mass index;
LIHC	cis	rs17152411	0.901	rs7098050	chr10:126657015	G/T	cg07906193	chr10:126599966	NA	0.5	7.73	0.39	1.2e-13	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01525244	chr22:39548611	CBX7	0.5	6.29	0.32	9.84e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6960043	0.875	rs6976381	chr7:15048814	T/C	cg19272540	chr7:15055459	NA	-0.22	-6.13	-0.31	2.42e-9	Type 2 diabetes;
LIHC	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-7.93	-0.39	3.05e-14	Longevity;
LIHC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.34	-6.71	-0.34	7.98e-11	Body mass index;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg19635926	chr16:89946313	TCF25	-0.48	-6.74	-0.34	6.69e-11	Skin colour saturation;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.96	-0.31	6.12e-9	Total body bone mineral density;
LIHC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.31	6.44	0.33	4.13e-10	Bone mineral density;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.25	0.55	7.25e-29	Prudent dietary pattern;
LIHC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-7.18	-0.36	4.38e-12	Schizophrenia;
LIHC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-0.96	-21.06	-0.75	1.01e-63	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-11.35	-0.52	1.45e-25	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg23533926	chr12:111358616	MYL2	-0.32	-6.34	-0.32	7.37e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.6	0.59	5.67e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.28	0.32	1.04e-9	Heart rate;
LIHC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.9	0.3	8.85e-9	Aortic root size;
LIHC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.49	5.79	0.3	1.58e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.44	0.37	8.23e-13	Renal cell carcinoma;
LIHC	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.34	-5.82	-0.3	1.36e-8	Menopause (age at onset);
LIHC	cis	rs1494950	1.000	rs17309950	chr4:15073913	G/A	cg12377275	chr4:15005593	CPEB2	-0.87	-7.42	-0.37	9.28e-13	Political ideology;
LIHC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	1.02	13.17	0.58	2.63e-32	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	7.89	0.39	4.01e-14	Blood protein levels;
LIHC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.57	9.14	0.44	5.57e-18	Lymphocyte counts;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17096262	chr10:29759227	SVIL	0.36	6.18	0.32	1.86e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.04	0.44	1.19e-17	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.7	7.1	0.36	7.09e-12	Alzheimer's disease;
LIHC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.0	-0.31	4.96e-9	Total body bone mineral density;
LIHC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08219700	chr8:58056026	NA	0.52	6.22	0.32	1.43e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.37	0.33	6.08e-10	Cognitive test performance;
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.12	0.58	3.97e-32	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15312298	chr8:127570908	FAM84B	0.46	7.24	0.36	2.95e-12	Pancreatic cancer;
LIHC	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.75	0.47	5.75e-20	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg15711740	chr2:61764176	XPO1	0.43	5.87	0.3	1.01e-8	Tuberculosis;
LIHC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.54	8.66	0.42	1.93e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg21573476	chr21:45109991	RRP1B	0.43	7.65	0.38	2.1e-13	Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00711773	chr3:40351057	EIF1B	-0.43	-6.28	-0.32	1.03e-9	Pancreatic cancer;
LIHC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02475777	chr4:1388615	CRIPAK	0.42	6.33	0.32	7.8e-10	Longevity;
LIHC	cis	rs1570989	0.841	rs9369032	chr6:12025822	C/T	cg17804551	chr6:12015979	HIVEP1	-0.4	-5.96	-0.31	6.27e-9	Alcohol and nicotine co-dependence;
LIHC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg16586182	chr3:47516702	SCAP	0.49	8.95	0.44	2.39e-17	Colorectal cancer;
LIHC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg04083430	chr16:4736063	MGRN1	-0.43	-5.81	-0.3	1.44e-8	Schizophrenia;
LIHC	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.1	0.31	2.92e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.35	-7.16	-0.36	5.02e-12	Colorectal cancer;
LIHC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg04359351	chr2:3481828	TTC15	0.28	5.94	0.31	7.04e-9	Neurofibrillary tangles;
LIHC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18867708	chr6:26865862	GUSBL1	0.55	8.31	0.41	2.23e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg12798992	chr6:167411361	FGFR1OP	0.53	8.71	0.43	1.29e-16	Crohn's disease;
LIHC	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.62	-8.39	-0.41	1.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17152411	0.843	rs7896051	chr10:126583119	T/C	cg07906193	chr10:126599966	NA	0.43	6.84	0.35	3.73e-11	Height;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg20090690	chr10:134436459	INPP5A	0.44	5.71	0.3	2.44e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.49	6.21	0.32	1.57e-9	Pancreatic cancer;
LIHC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.92	17.23	0.68	2.4e-48	Coronary artery disease;
LIHC	cis	rs1198430	0.602	rs12401753	chr1:23762679	A/G	cg13183780	chr1:23809682	ASAP3	-0.35	-6.28	-0.32	1.05e-9	Total cholesterol levels;
LIHC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.04	0.4	1.49e-14	Tonsillectomy;
LIHC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	0.72	12.43	0.56	1.57e-29	Testicular germ cell tumor;
LIHC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.52	-7.84	-0.39	5.84e-14	Platelet count;
LIHC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg19680672	chr10:131412579	MGMT	-0.42	-6.58	-0.34	1.75e-10	Response to temozolomide;
LIHC	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.71	10.92	0.51	5.26e-24	Monocyte count;
LIHC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.19	-0.32	1.72e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16922576	0.656	rs2093448	chr9:5230444	T/G	cg02405213	chr9:5042618	JAK2	-0.64	-9.87	-0.47	2.26e-20	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs12702595	0.553	rs6463661	chr7:7259370	G/A	cg04827551	chr7:7268805	C1GALT1	0.33	6.15	0.32	2.16e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg16479474	chr6:28041457	NA	0.45	6.78	0.34	5.41e-11	Parkinson's disease;
LIHC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg04511125	chr2:88470314	THNSL2	-0.43	-6.49	-0.33	2.98e-10	Response to metformin (IC50);
LIHC	trans	rs12204683	0.963	rs2629470	chr6:80176289	A/G	cg03122264	chr6:127797208	C6orf174	-0.48	-6.29	-0.32	9.65e-10	Presence of antiphospholipid antibodies;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg08853494	chr4:76439657	RCHY1;THAP6	-0.43	-6.2	-0.32	1.64e-9	Alopecia areata;
LIHC	cis	rs12644436	0.628	rs4693890	chr4:88783734	G/C	cg06891869	chr4:88767617	MEPE	0.43	7.62	0.38	2.59e-13	HIV-1 viral setpoint;
LIHC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.86	-0.43	4.6e-17	Colorectal cancer;
LIHC	cis	rs243505	0.762	rs10241408	chr7:148481488	G/A	cg09806900	chr7:148480153	CUL1	0.45	6.7	0.34	8.62e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7546668	1.000	rs2295626	chr1:15874961	T/A	cg11706911	chr1:15910989	AGMAT	0.44	6.71	0.34	8.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4653663	0.533	rs4653660	chr1:225915468	G/C	cg20799095	chr1:225924665	NA	0.37	5.71	0.3	2.43e-8	Neuroticism;
LIHC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.84	10.05	0.48	5.24e-21	Cognitive function;
LIHC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg12863693	chr15:85201151	NMB	0.44	6.16	0.32	2.06e-9	Schizophrenia;
LIHC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg00142150	chr22:38071001	LGALS1	0.63	8.24	0.41	3.69e-15	Fat distribution (HIV);
LIHC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.78	12.88	0.57	3.2e-31	Anterior chamber depth;
LIHC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.67	-11.99	-0.54	6.78e-28	Diastolic blood pressure;
LIHC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.53	7.81	0.39	7.09e-14	Height;
LIHC	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.54	-7.49	-0.38	5.92e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.05	-0.44	1.13e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.37	6.13	0.31	2.44e-9	Blood metabolite levels;
LIHC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.41	-0.45	7.59e-19	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.47	-0.37	6.81e-13	Response to antipsychotic treatment;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg08867150	chr8:28259493	NA	-0.6	-6.06	-0.31	3.69e-9	Obesity-related traits;
LIHC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.93	0.43	2.74e-17	Lung cancer in ever smokers;
LIHC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	14.24	0.61	1.84e-36	Primary sclerosing cholangitis;
LIHC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	10.35	0.49	4.98e-22	Menarche (age at onset);
LIHC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg18944383	chr4:111397179	ENPEP	-0.28	-6.47	-0.33	3.38e-10	Coronary artery disease;
LIHC	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.35	7.25	0.36	2.87e-12	Sitting height ratio;
LIHC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.21	-0.32	1.55e-9	Body mass index;
LIHC	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.94	-12.39	-0.56	2.28e-29	Obesity-related traits;
LIHC	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.73	7.51	0.38	5.05e-13	Schizophrenia;
LIHC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.48	-7.48	-0.38	6.17e-13	Breast size;
LIHC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.47	0.42	7.63e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	6.15	0.32	2.15e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.45	-0.42	8.19e-16	Heart rate;
LIHC	trans	rs950169	0.614	rs765524	chr15:84681782	G/T	cg24036039	chr1:3397125	ARHGEF16	0.37	6.36	0.33	6.6e-10	Schizophrenia;
LIHC	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg20129853	chr10:51489980	NA	-0.41	-9.04	-0.44	1.15e-17	Prostate-specific antigen levels;
LIHC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg12253828	chr6:101329408	ASCC3	0.45	7.16	0.36	5.08e-12	Neuroticism;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07305463	chr2:136567211	LCT	0.38	7.19	0.36	4.04e-12	Mosquito bite size;
LIHC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.82	-11.62	-0.53	1.58e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.55	-0.38	4.04e-13	Prevalent atrial fibrillation;
LIHC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg03037974	chr15:76606532	NA	-0.63	-11.13	-0.52	9.43e-25	Blood metabolite levels;
LIHC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	1.0	17.2	0.68	3.31e-48	Breast cancer;
LIHC	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg22054328	chr4:184930219	STOX2	-0.37	-6.42	-0.33	4.68e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.57	-8.62	-0.42	2.51e-16	Recombination rate (females);
LIHC	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.64	-10.98	-0.51	3.11e-24	Pediatric autoimmune diseases;
LIHC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs6775745	0.541	rs16838395	chr3:131755693	A/G	cg12213930	chr3:131751605	CPNE4	-0.4	-5.87	-0.3	1.05e-8	Neutrophil count;
LIHC	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.72	10.68	0.5	3.75e-23	Subjective well-being;
LIHC	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg13919466	chr1:32135498	COL16A1	0.32	6.2	0.32	1.66e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6466055	0.777	rs66599006	chr7:104934271	A/G	cg04380332	chr7:105027541	SRPK2	0.37	6.86	0.35	3.2e-11	Schizophrenia;
LIHC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05665937	chr4:1216051	CTBP1	0.45	6.08	0.31	3.19e-9	Obesity-related traits;
LIHC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.65	0.56	2.36e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	21.15	0.75	4.38e-64	Smoking behavior;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.5	-0.42	5.9e-16	Renal cell carcinoma;
LIHC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.62	0.42	2.48e-16	Menarche (age at onset);
LIHC	cis	rs9658691	0.607	rs12411452	chr10:90780607	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.93	-6.71	-0.34	8.01e-11	Mosquito bite size;
LIHC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.01	15.13	0.63	5.71e-40	Breast cancer;
LIHC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.08	-0.31	3.25e-9	Total body bone mineral density;
LIHC	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.61	-9.01	-0.44	1.48e-17	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.79	13.15	0.58	3.06e-32	Breast cancer;
LIHC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.5	-8.04	-0.4	1.49e-14	Cognitive function;
LIHC	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.84	-10.02	-0.48	7.1e-21	Facial emotion recognition (sad faces);
LIHC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.33	-6.08	-0.31	3.18e-9	Adiponectin levels;
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.48	0.56	1.07e-29	Alzheimer's disease;
LIHC	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.23e-24	Breast cancer;
LIHC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.91	-15.09	-0.63	8.71e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.29	6.01	0.31	4.76e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg10820045	chr2:198174542	NA	0.54	8.98	0.44	1.89e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg09069446	chr16:4462122	CORO7	-0.35	-5.72	-0.3	2.3e-8	Schizophrenia;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg02407032	chr11:47600271	KBTBD4;NDUFS3	-0.45	-6.1	-0.31	2.82e-9	Alopecia areata;
LIHC	cis	rs861318	0.702	rs2852695	chr1:159015933	G/A	cg11003133	chr1:159046391	AIM2	0.32	6.27	0.32	1.08e-9	Obesity-related traits;
LIHC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06634786	chr22:41940651	POLR3H	0.52	5.77	0.3	1.79e-8	Vitiligo;
LIHC	cis	rs7602441	0.521	rs78567942	chr2:14767845	C/A	cg06545361	chr2:14773388	FAM84A	0.5	5.89	0.3	9.41e-9	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.43	-6.76	-0.34	5.87e-11	Dental caries;
LIHC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.43	10.11	0.48	3.42e-21	Diastolic blood pressure;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02726883	chr17:29421732	NF1	-0.43	-6.1	-0.31	2.79e-9	Triglycerides;
LIHC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.37	-0.41	1.51e-15	Chronic sinus infection;
LIHC	cis	rs7116495	1.000	rs10898814	chr11:71736505	T/C	cg26138937	chr11:71823887	C11orf51	-0.81	-8.04	-0.4	1.43e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg20607798	chr8:58055168	NA	0.64	8.27	0.41	3.01e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6442522	0.809	rs972685	chr3:15484269	G/A	cg16303742	chr3:15540471	COLQ	0.39	6.17	0.32	1.88e-9	Uric acid levels;
LIHC	cis	rs13177918	0.603	rs2748241	chr5:149827494	C/T	cg14059543	chr5:149831962	NA	-0.48	-7.48	-0.37	6.51e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg13607699	chr17:42295918	UBTF	-0.36	-5.76	-0.3	1.91e-8	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs11673344	0.832	rs2011475	chr19:37545614	C/T	cg27390819	chr19:37464633	NA	-0.5	-6.02	-0.31	4.58e-9	Obesity-related traits;
LIHC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.31	7.2	0.36	3.95e-12	Crohn's disease;
LIHC	cis	rs2029362	0.611	rs2883187	chr11:27741092	G/A	cg18117895	chr11:27722066	BDNF	-0.41	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.59	7.03	0.36	1.16e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs2637266	0.783	rs7898786	chr10:78481338	T/C	cg18941641	chr10:78392320	NA	0.27	5.93	0.31	7.54e-9	Pulmonary function;
LIHC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.36	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg27205649	chr11:78285834	NARS2	0.42	6.39	0.33	5.55e-10	Alzheimer's disease (survival time);
LIHC	cis	rs12980942	0.872	rs16958994	chr19:41824981	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.47	5.91	0.3	8.07e-9	Coronary artery disease;
LIHC	cis	rs238295	0.846	rs6053528	chr20:5582598	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.91	-0.35	2.44e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.5	7.81	0.39	6.96e-14	Glomerular filtration rate (creatinine);
LIHC	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.97	12.67	0.57	1.94e-30	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07254608	chr8:41997973	NA	0.43	6.15	0.32	2.12e-9	Pancreatic cancer;
LIHC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg13468214	chr4:1046988	NA	0.36	6.7	0.34	8.47e-11	Recombination rate (males);
LIHC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	6.06	0.31	3.67e-9	Mean platelet volume;
LIHC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.92	16.63	0.67	6.55e-46	Colorectal cancer;
LIHC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.24	5.97	0.31	5.99e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.56	8.78	0.43	7.88e-17	Red cell distribution width;
LIHC	cis	rs11053548	0.646	rs11053549	chr12:10172178	C/T	cg04314261	chr12:10163030	CLEC12B	0.42	6.3	0.32	9.31e-10	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs12644436	0.896	rs7655253	chr4:88777396	A/C	cg06891869	chr4:88767617	MEPE	-0.32	-5.95	-0.31	6.79e-9	HIV-1 viral setpoint;
LIHC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.37	0.33	6.21e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7187994	0.848	rs34457873	chr16:84782871	T/G	cg07647771	chr16:84786436	USP10	-0.33	-6.47	-0.33	3.47e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.58	-0.34	1.75e-10	Gut microbiome composition (summer);
LIHC	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.24	12.75	0.57	1.02e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.58	9.63	0.46	1.4e-19	Resting heart rate;
LIHC	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg03037974	chr15:76606532	NA	0.72	13.99	0.6	1.75e-35	Blood metabolite levels;
LIHC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.69	-9.54	-0.46	2.72e-19	Lung cancer in ever smokers;
LIHC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.82	-12.49	-0.56	9.47e-30	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.48	-0.56	9.93e-30	Colorectal cancer;
LIHC	cis	rs16958440	0.867	rs77599321	chr18:44689642	T/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.54	8.84	0.43	5.09e-17	Aortic root size;
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg10096929	chr1:156261403	TMEM79	0.4	6.61	0.34	1.43e-10	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.55	-8.35	-0.41	1.7e-15	Platelet count;
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-6.96	-0.35	1.75e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.48	-8.69	-0.43	1.57e-16	Colorectal cancer;
LIHC	cis	rs6446731	0.734	rs7675084	chr4:3273908	C/T	cg06533319	chr4:3265114	C4orf44	-0.33	-6.28	-0.32	1.02e-9	Mean platelet volume;
LIHC	cis	rs9918079	0.560	rs7685083	chr4:15610771	G/A	cg16509355	chr4:15471240	CC2D2A	0.46	7.09	0.36	7.8e-12	Obesity-related traits;
LIHC	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.46	8.59	0.42	3.15e-16	Testicular germ cell tumor;
LIHC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.97	9.87	0.47	2.22e-20	Plasma clusterin levels;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15559938	chr1:206837731	NA	0.42	6.59	0.34	1.67e-10	Metabolic traits;
LIHC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-6.6	-0.34	1.6e-10	Type 2 diabetes;
LIHC	cis	rs1843834	0.634	rs923901	chr2:225477276	A/T	cg22455342	chr2:225449267	CUL3	0.45	6.07	0.31	3.48e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.43	-6.02	-0.31	4.44e-9	Height;
LIHC	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg08992911	chr2:238395768	MLPH	0.55	6.05	0.31	3.84e-9	Prostate cancer;
LIHC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.36	-5.76	-0.3	1.9e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg27386326	chr11:61587980	NA	0.71	15.2	0.64	3.08e-40	Trans fatty acid levels;
LIHC	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.51	-0.38	5.12e-13	Mood instability;
LIHC	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.5	7.86	0.39	5.04e-14	Alzheimer's disease (survival time);
LIHC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.78	-12.82	-0.57	5.52e-31	Breast cancer;
LIHC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.53	9.18	0.44	4.13e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02985541	chr2:219472218	PLCD4	0.4	7.29	0.37	2.12e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	9.19	0.45	3.88e-18	IgG glycosylation;
LIHC	trans	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.46	-0.49	2.03e-22	Schizophrenia;
LIHC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-8.55	-0.42	4.26e-16	Fibrinogen levels;
LIHC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.39	-6.31	-0.32	8.75e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.82	-0.39	6.57e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.35	5.95	0.31	6.52e-9	Educational attainment;
LIHC	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.63	11.65	0.53	1.24e-26	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.39	6.29	0.32	9.86e-10	Menopause (age at onset);
LIHC	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	0.8	6.78	0.34	5.13e-11	Cannabis dependence symptom count;
LIHC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.83	15.23	0.64	2.39e-40	IgG glycosylation;
LIHC	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.53	8.42	0.41	1.05e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.69	-0.62	3.11e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg05343316	chr1:45956843	TESK2	-0.53	-7.76	-0.39	1.01e-13	Platelet count;
LIHC	trans	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.09e-10	Aortic root size;
LIHC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	9.99	0.48	8.39e-21	Schizophrenia;
LIHC	cis	rs4684776	0.867	rs7640175	chr3:11353039	G/A	cg00170343	chr3:11313890	ATG7	-0.53	-7.28	-0.37	2.31e-12	Small vessel stroke;
LIHC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.4	5.95	0.31	6.52e-9	Neurofibrillary tangles;
LIHC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg12463550	chr7:65579703	CRCP	0.7	7.15	0.36	5.32e-12	Diabetic kidney disease;
LIHC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg00225070	chr15:80189496	MTHFS	0.45	7.42	0.37	9.33e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.33	0.49	6e-22	Melanoma;
LIHC	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.12e-9	Coronary artery disease;
LIHC	cis	rs4763879	0.739	rs2895988	chr12:9828427	T/G	cg26689682	chr12:9723402	NA	-0.36	-5.92	-0.3	8.03e-9	Type 1 diabetes;
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.96	-0.31	6.26e-9	Menopause (age at onset);
LIHC	cis	rs2292096	1.000	rs12756996	chr1:200780333	T/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-5.92	-0.3	7.95e-9	Epilepsy;
LIHC	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.33	-6.54	-0.33	2.19e-10	DNA methylation (variation);
LIHC	cis	rs17152411	0.600	rs4962711	chr10:126644482	T/C	cg07906193	chr10:126599966	NA	-0.31	-6.22	-0.32	1.48e-9	Height;
LIHC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg12798992	chr6:167411361	FGFR1OP	0.6	10.0	0.48	8.15e-21	Crohn's disease;
LIHC	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.73	-0.54	6.15e-27	Coffee consumption (cups per day);
LIHC	cis	rs1892700	0.840	rs111479052	chr21:34866825	A/G	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.53	8.15	0.4	7.07e-15	Lymphocyte counts;
LIHC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.81	-13.57	-0.59	7.51e-34	Platelet distribution width;
LIHC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg14092571	chr14:90743983	NA	0.4	6.2	0.32	1.65e-9	Mortality in heart failure;
LIHC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.76	0.5	1.86e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.55	-0.38	3.94e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg19875535	chr5:140030758	IK	0.37	6.08	0.31	3.2e-9	Schizophrenia;
LIHC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg16586182	chr3:47516702	SCAP	0.49	8.67	0.42	1.81e-16	Colorectal cancer;
LIHC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	10.1	0.48	3.53e-21	Resting heart rate;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.61	-8.83	-0.43	5.34e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7116495	1.000	rs3814721	chr11:71709272	C/T	cg26138937	chr11:71823887	C11orf51	-0.74	-7.47	-0.37	6.83e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg09795085	chr6:101329169	ASCC3	0.55	7.41	0.37	9.69e-13	Neuroticism;
LIHC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.43	-5.73	-0.3	2.26e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg05697976	chr12:29376483	FAR2	0.34	7.01	0.35	1.26e-11	QT interval;
LIHC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.58	8.24	0.41	3.7e-15	Blood metabolite levels;
LIHC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg00990874	chr7:1149470	C7orf50	-0.63	-8.83	-0.43	5.36e-17	Bronchopulmonary dysplasia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02514519	chr11:61348922	SYT7	0.49	7.11	0.36	6.87e-12	Lung function (FEV1/FVC);
LIHC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	11.41	0.53	9.02e-26	Mean platelet volume;
LIHC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.53	0.42	4.64e-16	Schizophrenia;
LIHC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18252515	chr7:66147081	NA	0.43	6.08	0.31	3.2e-9	Aortic root size;
LIHC	cis	rs4407350	1.000	rs1475991	chr22:44923160	T/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.03	-0.31	4.31e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11255230	chr18:60987808	BCL2	0.45	6.66	0.34	1.09e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12594515	0.694	rs2068294	chr15:45985548	G/T	cg01629716	chr15:45996671	NA	0.51	9.3	0.45	1.65e-18	Waist circumference;Weight;
LIHC	cis	rs6466055	0.720	rs35757884	chr7:105020534	G/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.02	-0.35	1.2e-11	Schizophrenia;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01836096	chr8:145578603	C8ORFK29	0.41	6.21	0.32	1.56e-9	Immature fraction of reticulocytes;
LIHC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg03854865	chr6:26224070	HIST1H3E	0.56	6.37	0.33	6.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg26939375	chr7:64535504	NA	0.46	6.79	0.34	5.08e-11	Aortic root size;
LIHC	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-8.27	-0.41	2.95e-15	Hepatocellular carcinoma;
LIHC	trans	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg00426498	chr17:27507667	MYO18A	-0.34	-6.19	-0.32	1.69e-9	Orofacial clefts;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15155463	chr2:71693793	DYSF	0.53	7.04	0.36	1.04e-11	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.58	7.56	0.38	3.72e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22168489	chr12:122356033	WDR66	-0.36	-5.94	-0.31	7.04e-9	Mean corpuscular volume;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg02990361	chr1:107599529	PRMT6	0.63	10.37	0.49	4.27e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.5	7.91	0.39	3.58e-14	Alzheimer's disease (survival time);
LIHC	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.43	6.65	0.34	1.14e-10	Fibroblast growth factor basic levels;
LIHC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.62	6.17	0.32	1.96e-9	Type 2 diabetes nephropathy;
LIHC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.98	-0.35	1.52e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.42	5.98	0.31	5.71e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.67	-0.34	1.02e-10	Homocysteine levels;
LIHC	cis	rs6066825	0.644	rs2092492	chr20:47338650	A/G	cg18078177	chr20:47281410	PREX1	0.4	6.49	0.33	2.98e-10	Colorectal cancer;
LIHC	cis	rs2236267	0.693	rs8008120	chr14:88622367	A/C	cg02175263	chr14:88627849	NA	0.31	5.94	0.31	6.85e-9	Food antigen IgG levels;
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg12568669	chr8:11666485	FDFT1	-0.3	-6.04	-0.31	3.96e-9	Monocyte count;
LIHC	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	1.04	13.07	0.58	5.89e-32	Economic and political preferences (immigration/crime);
LIHC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.58	0.34	1.73e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.82	8.6	0.42	3e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	0.79	10.99	0.51	3e-24	Left atrial antero-posterior diameter;
LIHC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.58	9.45	0.45	5.66e-19	Lymphocyte counts;
LIHC	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg06026331	chr20:60912101	LAMA5	0.48	6.44	0.33	4.05e-10	Colorectal cancer;
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.61	10.28	0.49	8.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.53	8.19	0.4	5.43e-15	Resting heart rate;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.13	0.55	2.03e-28	Height;
LIHC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs12744310	0.887	rs35410722	chr1:41796264	C/T	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.77e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.56	7.12	0.36	6.36e-12	Preschool internalizing problems;
LIHC	cis	rs2708977	1.000	rs2708977	chr2:97230074	G/A	cg01950434	chr2:97203154	ARID5A	-0.52	-7.91	-0.39	3.62e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs1902066	0.604	rs2444820	chr6:81379924	C/G	cg07248951	chr1:36397042	EIF2C3	0.4	6.05	0.31	3.81e-9	Breast cancer;
LIHC	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.59	7.92	0.39	3.42e-14	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg06611532	chr13:114900021	NA	0.41	7.55	0.38	4.03e-13	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04619800	chr15:83654972	FAM103A1	0.48	6.96	0.35	1.75e-11	Lung function (FEV1/FVC);
LIHC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg14092571	chr14:90743983	NA	-0.37	-5.81	-0.3	1.47e-8	Mortality in heart failure;
LIHC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.44	-6.67	-0.34	1.03e-10	Height;
LIHC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-15.03	-0.63	1.46e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17507749	chr15:85114479	UBE2QP1	0.78	8.96	0.44	2.18e-17	Schizophrenia;
LIHC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.11	-0.4	8.86e-15	Morning vs. evening chronotype;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.47	-6.42	-0.33	4.59e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20600053	chr18:56806937	SEC11C	0.53	7.25	0.36	2.81e-12	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.4e-23	Mean corpuscular volume;
LIHC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-6.27	-0.32	1.09e-9	Initial pursuit acceleration;
LIHC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.27	0.32	1.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs36051895	0.623	rs11506668	chr9:5252789	C/T	cg02405213	chr9:5042618	JAK2	-0.62	-9.88	-0.47	2.05e-20	Pediatric autoimmune diseases;
LIHC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg12751644	chr20:60527061	NA	-0.35	-5.81	-0.3	1.44e-8	Body mass index;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.93	0.63	3.62e-39	Prudent dietary pattern;
LIHC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.49	-6.63	-0.34	1.3100000000000001e-10	Body mass index;
LIHC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.5	0.53	4.43e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.62	-8.77	-0.43	8.61e-17	Blood metabolite levels;
LIHC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.5	-0.38	5.5e-13	Aortic root size;
LIHC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.59	-9.87	-0.47	2.2e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.77	11.14	0.52	8.36e-25	Obesity-related traits;
LIHC	cis	rs4700695	0.534	rs153373	chr5:65426159	G/A	cg21114390	chr5:65439923	SFRS12	-0.52	-5.89	-0.3	9.12e-9	Facial morphology (factor 19);
LIHC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg22676075	chr6:135203613	NA	0.41	6.59	0.34	1.66e-10	Red blood cell count;
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.68	9.79	0.47	4.15e-20	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-11.75	-0.54	5.31e-27	Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25561913	chr10:77161129	ZNF503;C10orf41	0.49	6.73	0.34	7.28e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.18	-0.48	1.91e-21	Alzheimer's disease;
LIHC	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.65	-7.0	-0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.76	-11.71	-0.53	7.35e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs77669868	0.703	rs61904685	chr11:114072659	G/A	cg01914181	chr11:114070210	ZBTB16	0.52	6.26	0.32	1.15e-9	Monocyte percentage of white cells;
LIHC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg17689763	chr4:710664	PCGF3	-0.72	-10.11	-0.48	3.44e-21	White blood cell count;
LIHC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.4	-6.4	-0.33	5.27e-10	Menopause (age at onset);
LIHC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.22	-0.55	9.39e-29	Colorectal cancer;
LIHC	cis	rs244293	0.965	rs2529507	chr17:53181272	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.53	0.33	2.32e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg07451762	chr16:28383216	NA	0.39	7.05	0.36	9.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05935374	chr11:82782929	RAB30	0.45	6.93	0.35	2.04e-11	Cognitive function;
LIHC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.65	-8.3	-0.41	2.44e-15	Body mass index;
LIHC	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.57	8.16	0.4	6.63e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17022488	chr1:29462399	NA	-0.46	-6.6	-0.34	1.59e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.46	7.28	0.37	2.37e-12	Height;
LIHC	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg04306507	chr14:55594613	LGALS3	0.33	6.41	0.33	4.92e-10	Protein biomarker;
LIHC	cis	rs74181299	0.571	rs6728523	chr2:65282708	G/C	cg05010058	chr2:65284262	CEP68	0.37	5.96	0.31	6.35e-9	Pulse pressure;
LIHC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.95	-0.31	6.69e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.47	6.22	0.32	1.43e-9	Morning vs. evening chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23642001	chr8:67025419	NA	0.46	6.08	0.31	3.2e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.31	6.1	0.31	2.93e-9	Colorectal cancer;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.89	12.6	0.56	3.52e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05277466	chr16:88082055	BANP	0.38	6.05	0.31	3.7e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs61440199	0.786	rs73818813	chr3:20148085	C/T	cg00235661	chr3:20228976	SGOL1	-0.41	-5.82	-0.3	1.35e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8108269	0.956	rs8107527	chr19:46158417	G/A	cg13320842	chr19:46175254	GIPR	0.41	7.74	0.39	1.16e-13	Type 2 diabetes;
LIHC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.67	-8.3	-0.41	2.49e-15	Gut microbiome composition (summer);
LIHC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.72	-11.53	-0.53	3.33e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16684958	chr7:75615977	POR	0.52	8.59	0.42	3.22e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.24	0.36	2.94e-12	Renal cell carcinoma;
LIHC	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-5.93	-0.31	7.35e-9	Metabolite levels;
LIHC	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.65	12.56	0.56	5.03e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg17675199	chr6:35436792	RPL10A	0.37	7.39	0.37	1.11e-12	Monocyte count;
LIHC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.47	-9.62	-0.46	1.55e-19	Immature fraction of reticulocytes;
LIHC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.4	6.94	0.35	1.93e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.48	8.13	0.4	8.02e-15	Aortic root size;
LIHC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.78	0.43	7.81e-17	Electroencephalogram traits;
LIHC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.5	-0.56	8.37e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16684958	chr7:75615977	POR	0.52	8.69	0.43	1.48e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.86	-0.39	4.96e-14	Intelligence;
LIHC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.51	8.98	0.44	1.86e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.65	0.38	2e-13	Bipolar disorder;
LIHC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg06238570	chr21:40685208	BRWD1	-0.56	-6.74	-0.34	6.88e-11	Cognitive function;
LIHC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.6	-6.97	-0.35	1.63e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08219700	chr8:58056026	NA	0.43	6.11	0.31	2.73e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.05	-0.31	3.78e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg22951263	chr5:87985283	NA	-0.36	-6.53	-0.33	2.33e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	-0.41	-5.8	-0.3	1.47e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg10381502	chr11:71823885	C11orf51	1.02	8.51	0.42	5.38e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.32	16.14	0.66	5.8e-44	Alzheimer's disease (late onset);
LIHC	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.46	-0.33	3.5e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.81	-0.3	1.43e-8	Biliary atresia;
LIHC	trans	rs2270927	0.510	rs2937749	chr5:75571564	T/G	cg13563193	chr19:33072644	PDCD5	0.89	8.27	0.41	3.09e-15	Mean corpuscular volume;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg20365580	chr8:22414115	SORBS3	-0.33	-6.61	-0.34	1.49e-10	Monocyte count;
LIHC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.6	6.94	0.35	1.98e-11	Menarche (age at onset);
LIHC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.5	0.42	6e-16	Motion sickness;
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.41	0.33	4.69e-10	Renal cell carcinoma;
LIHC	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.68	11.01	0.51	2.36e-24	Type 2 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19482537	chr5:156692823	CYFIP2	0.48	6.48	0.33	3.19e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg05590025	chr7:65112418	INTS4L2	0.58	6.63	0.34	1.34e-10	Diabetic kidney disease;
LIHC	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.29	-6.61	-0.34	1.45e-10	DNA methylation (variation);
LIHC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.46	0.53	5.8e-26	Colorectal cancer;
LIHC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.6	-9.03	-0.44	1.3e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs74181299	0.571	rs7559813	chr2:65278023	A/G	cg05010058	chr2:65284262	CEP68	-0.37	-6.06	-0.31	3.61e-9	Pulse pressure;
LIHC	cis	rs9328573	1.000	rs12440915	chr15:100509915	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.47	-7.09	-0.36	7.78e-12	Urate levels in lean individuals;
LIHC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-0.91	-12.37	-0.56	2.63e-29	Mitochondrial DNA levels;
LIHC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.57	9.62	0.46	1.5700000000000001e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg08847533	chr14:75593920	NEK9	-0.55	-8.87	-0.43	4.2e-17	IgG glycosylation;
LIHC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.3e-11	Height;
LIHC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.43	6.16	0.32	2.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.46	8.09	0.4	1.04e-14	IgG glycosylation;
LIHC	cis	rs1144333	0.655	rs79322031	chr1:76391978	C/T	cg10523679	chr1:76189770	ACADM	0.46	6.33	0.32	7.79e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06438815	chr21:46292710	PTTG1IP	0.41	6.24	0.32	1.27e-9	Pancreatic cancer;
LIHC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.46	8.17	0.4	6.03e-15	IgG glycosylation;
LIHC	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.93	-0.51	4.75e-24	Eye color traits;
LIHC	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-11.81	-0.54	3.05e-27	Pediatric autoimmune diseases;
LIHC	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg05353290	chr17:79219831	SLC38A10	0.39	5.96	0.31	6.42e-9	Frontotemporal dementia;
LIHC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg07424592	chr7:64974309	NA	0.74	8.56	0.42	3.98e-16	Diabetic kidney disease;
LIHC	cis	rs11023332	0.617	rs1451678	chr11:14781621	A/G	cg19336497	chr11:14380999	RRAS2	-0.35	-6.18	-0.32	1.77e-9	Adiponectin levels;Vitamin D levels;
LIHC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg27490568	chr2:178487706	NA	0.38	6.03	0.31	4.34e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs360929	0.505	rs10010138	chr4:152926202	T/C	cg22325059	chr7:6648166	C7orf26	0.58	6.05	0.31	3.71e-9	Volumetric brain MRI;
LIHC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.67	-11.15	-0.52	7.7e-25	Childhood ear infection;
LIHC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.67	-0.38	1.76e-13	Vitiligo;
LIHC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg04317338	chr11:64019027	PLCB3	0.59	8.09	0.4	1.02e-14	Platelet count;
LIHC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.08	0.31	3.22e-9	Rheumatoid arthritis;
LIHC	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.19	6.12	0.31	2.63e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.51	-10.26	-0.49	1.01e-21	Abdominal aortic aneurysm;
LIHC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.91	10.2	0.48	1.73e-21	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.27	-6.72	-0.34	7.83e-11	Cutaneous nevi;
LIHC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.61	7.28	0.37	2.36e-12	Cognitive function;
LIHC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.79	-0.34	4.96e-11	Aortic root size;
LIHC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.1	12.88	0.57	3.09e-31	Vitiligo;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.97	-0.35	1.6e-11	Diastolic blood pressure;
LIHC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.37	6.17	0.32	1.94e-9	Blood metabolite levels;
LIHC	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.79	11.28	0.52	2.77e-25	Pediatric areal bone mineral density (radius);
LIHC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.78	8.83	0.43	5.47e-17	Vitiligo;
LIHC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.61	-10.23	-0.48	1.29e-21	Colorectal cancer;
LIHC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.6	8.43	0.41	1.01e-15	Aortic root size;
LIHC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.39	0.33	5.51e-10	Parkinson's disease;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.61	8.92	0.43	2.92e-17	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.77e-9	Prudent dietary pattern;
LIHC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.78	6.6	0.34	1.57e-10	Body mass index;
LIHC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.46	-8.58	-0.42	3.3e-16	Body mass index;
LIHC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg07560587	chr16:88016574	BANP	0.35	5.72	0.3	2.27e-8	Menopause (age at onset);
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.58	8.88	0.43	3.91e-17	Longevity;Endometriosis;
LIHC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.43	-6.6	-0.34	1.61e-10	Height;
LIHC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.67	8.59	0.42	3.12e-16	Initial pursuit acceleration;
LIHC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-14.26	-0.61	1.58e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.79	10.34	0.49	5.46e-22	Body mass index;
LIHC	cis	rs7551222	0.752	rs35270244	chr1:204548416	A/C	cg20240347	chr1:204465584	NA	-0.32	-6.42	-0.33	4.6e-10	Schizophrenia;
LIHC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.64	0.46	1.31e-19	Bipolar disorder;
LIHC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.86	-13.15	-0.58	3e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.39	6.98	0.35	1.53e-11	Schizophrenia;
LIHC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg14393609	chr7:65229607	NA	-0.37	-5.83	-0.3	1.27e-8	Aortic root size;
LIHC	cis	rs9783347	1.000	rs12286683	chr11:18348662	G/T	cg15585147	chr11:18324498	HPS5	0.43	6.73	0.34	6.95e-11	Pancreatic cancer;
LIHC	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg09824255	chr5:140014002	CD14	0.29	6.22	0.32	1.46e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg06640241	chr16:89574553	SPG7	-0.51	-8.04	-0.4	1.47e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05025164	chr4:1340916	KIAA1530	0.53	8.15	0.4	7.17e-15	Obesity-related traits;
LIHC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-8.26	-0.41	3.15e-15	Dental caries;
LIHC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	6.06	0.31	3.61e-9	Schizophrenia;
LIHC	cis	rs4586057	0.514	rs7909232	chr10:92651479	G/A	cg14313238	chr10:92632228	RPP30	0.36	6.04	0.31	4.12e-9	Economic and political preferences (time);
LIHC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.53	-9.35	-0.45	1.18e-18	Blood protein levels;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg26668828	chr6:292823	DUSP22	-0.6	-8.06	-0.4	1.26e-14	Menopause (age at onset);
LIHC	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.96	-8.6	-0.42	2.98e-16	White matter integrity;
LIHC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.36	0.33	6.36e-10	Schizophrenia;
LIHC	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg10241871	chr14:102965420	TECPR2	-0.47	-7.16	-0.36	5.08e-12	Blood protein levels;
LIHC	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.51	8.86	0.43	4.47e-17	Coronary artery disease;
LIHC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.58	8.51	0.42	5.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.43	5.84	0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.94	-0.31	6.82e-9	Resting heart rate;
LIHC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.79	-15.83	-0.65	1.03e-42	Refractive error;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13340481	chr17:27275985	PHF12	0.43	6.12	0.31	2.6e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg20607798	chr8:58055168	NA	0.59	6.8	0.35	4.58e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.51	0.53	3.97e-26	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00810945	chr16:21964237	UQCRC2	0.45	6.35	0.32	6.76e-10	Pancreatic cancer;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg00280220	chr17:61926910	NA	0.42	6.51	0.33	2.66e-10	Prudent dietary pattern;
LIHC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg14393609	chr7:65229607	NA	0.44	6.49	0.33	2.98e-10	Calcium levels;
LIHC	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.58	8.25	0.41	3.45e-15	Facial morphology (factor 19);
LIHC	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-6.65	-0.34	1.19e-10	Total body bone mineral density (age 45-60);
LIHC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	1.12	7.93	0.39	3.21e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg07952391	chr2:88470173	THNSL2	0.77	7.15	0.36	5.27e-12	Plasma clusterin levels;
LIHC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.86	10.36	0.49	4.56e-22	Cognitive function;
LIHC	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.41	-8.28	-0.41	2.77e-15	White blood cell count (basophil);
LIHC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.56	-8.1	-0.4	1e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.58	8.31	0.41	2.23e-15	Urinary tract infection frequency;
LIHC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg11057378	chr10:81107060	PPIF	0.36	5.92	0.3	7.77e-9	Height;
LIHC	cis	rs963731	0.737	rs79756054	chr2:39338998	A/G	cg04010122	chr2:39346883	SOS1	0.6	5.92	0.3	7.81e-9	Corticobasal degeneration;
LIHC	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg17294928	chr15:75287854	SCAMP5	0.45	6.42	0.33	4.54e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.8	15.71	0.65	3.04e-42	Smoking behavior;
LIHC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.75	7.71	0.38	1.41e-13	Mean platelet volume;
LIHC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	15.84	0.65	9.42e-43	Nonalcoholic fatty liver disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22779765	chr14:103369786	TRAF3	0.48	6.86	0.35	3.14e-11	Longevity;
LIHC	cis	rs10503871	0.816	rs3779639	chr8:30407991	A/G	cg26383811	chr8:30366931	RBPMS	-0.39	-6.58	-0.34	1.73e-10	Metabolite levels  (X-11787);
LIHC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-6.85	-0.35	3.49e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg02269571	chr22:50332266	NA	-0.66	-8.97	-0.44	2.03e-17	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.93	-0.31	7.23e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12602486	1.000	rs78673779	chr17:42217936	G/A	cg08193365	chr17:42277699	NA	1.08	7.74	0.39	1.12e-13	Glycated hemoglobin levels;
LIHC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.52	0.53	3.51e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg17135325	chr3:160939158	NMD3	0.54	7.63	0.38	2.42e-13	Parkinson's disease;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg11070056	chr1:107600091	PRMT6	0.68	11.61	0.53	1.68e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.96e-11	Rheumatoid arthritis;
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg05697976	chr12:29376483	FAR2	0.32	6.65	0.34	1.14e-10	QT interval;
LIHC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.61	0.67	7.88e-46	Smoking behavior;
LIHC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.73	12.53	0.56	6.85e-30	Mean platelet volume;
LIHC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-7.96	-0.4	2.51e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.34	6.66	0.34	1.07e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25616684	chr1:38478508	UTP11L	0.43	6.09	0.31	3e-9	Lung function (FEV1/FVC);
LIHC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.39	0.33	5.38e-10	Schizophrenia;
LIHC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.45	6.58	0.34	1.81e-10	Tonsillectomy;
LIHC	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.42	-6.46	-0.33	3.65e-10	Cognitive test performance;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.43	-5.79	-0.3	1.6e-8	Total body bone mineral density;
LIHC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg03037974	chr15:76606532	NA	0.8	16.71	0.67	3.06e-46	Blood metabolite levels;
LIHC	cis	rs3790645	1.000	rs396997	chr1:26893067	T/C	cg23229016	chr1:26872525	RPS6KA1	0.23	5.75	0.3	1.95e-8	Glucose homeostasis traits;
LIHC	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.45	6.79	0.34	5.06e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.49	-7.54	-0.38	4.38e-13	Corneal astigmatism;
LIHC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18876405	chr7:65276391	NA	0.32	5.74	0.3	2.06e-8	Aortic root size;
LIHC	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.54	6.71	0.34	8.3e-11	QRS duration;
LIHC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.87	10.02	0.48	6.8e-21	Eosinophil percentage of granulocytes;
LIHC	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg07706471	chr12:123319906	HIP1R	0.72	8.13	0.4	7.75e-15	Adiponectin levels;
LIHC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.83	12.12	0.55	2.32e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.75	0.3	1.97e-8	Morning vs. evening chronotype;
LIHC	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.55	-8.25	-0.41	3.39e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6442522	0.560	rs2255897	chr3:15520677	A/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.01	-0.31	4.71e-9	Uric acid levels;
LIHC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.67	8.6	0.42	2.99e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.54	-0.86	3e-103	Myeloid white cell count;
LIHC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.41	6.93	0.35	2.06e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LIHC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.54	8.61	0.42	2.62e-16	Colorectal cancer;
LIHC	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs244293	1.000	rs244289	chr17:53231788	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.16	-0.36	4.99e-12	Menarche (age at onset);
LIHC	trans	rs6489882	0.867	rs4767032	chr12:113363077	T/G	cg10175203	chr3:128143634	NA	0.39	6.38	0.33	5.72e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.08e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.5	9.08	0.44	8.57e-18	Height;
LIHC	trans	rs1864585	0.520	rs17720365	chr8:10679499	C/G	cg20373634	chr10:103911536	NOLC1	0.42	6.06	0.31	3.58e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs3112357	1.000	rs3112339	chr7:135381500	G/C	cg20392616	chr7:135392013	SLC13A4	0.41	6.81	0.35	4.52e-11	Plantar warts;
LIHC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.46	7.1	0.36	7.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.59	-8.24	-0.41	3.65e-15	Obesity-related traits;
LIHC	cis	rs10503871	0.967	rs2294085	chr8:30436779	C/T	cg26383811	chr8:30366931	RBPMS	0.46	8.17	0.4	6.22e-15	Metabolite levels  (X-11787);
LIHC	cis	rs62229266	0.572	rs4816518	chr21:37453307	C/T	cg12218747	chr21:37451666	NA	-0.44	-7.13	-0.36	6e-12	Mitral valve prolapse;
LIHC	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg03543861	chr21:44258195	NA	0.53	7.77	0.39	9.24e-14	Information processing speed;
LIHC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg24163568	chr5:669837	TPPP	-0.4	-8.49	-0.42	6.5e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7619427	0.643	rs6794506	chr3:44015668	A/G	cg24966902	chr3:44043705	NA	-0.57	-6.35	-0.32	6.71e-10	Schizophrenia;
LIHC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs9649465	1.000	rs6963231	chr7:123374766	A/G	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.25e-15	Migraine;
LIHC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.68	0.43	1.6e-16	Lung cancer in ever smokers;
LIHC	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.66	-6.32	-0.32	7.94e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg07424592	chr7:64974309	NA	-0.82	-9.61	-0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.32	-5.71	-0.3	2.43e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19400876	chr1:54411017	LRRC42;HSPB11	-0.41	-6.48	-0.33	3.13e-10	Calcium levels;
LIHC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg20991723	chr1:152506922	NA	0.59	10.28	0.49	8.92e-22	Hair morphology;
LIHC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.53	6.87	0.35	3.01e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.97	9.88	0.47	1.97e-20	Plasma clusterin levels;
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg08687515	chr19:58661962	ZNF329	0.99	7.82	0.39	6.56e-14	Cholesterol, total;
LIHC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg06012730	chr15:75315579	PPCDC	-0.35	-6.35	-0.32	6.82e-10	Blood trace element (Zn levels);
LIHC	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.41	-7.3	-0.37	2e-12	Height;
LIHC	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.45	8.51	0.42	5.45e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg21466736	chr12:48725269	NA	0.58	7.78	0.39	8.42e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.42	-5.76	-0.3	1.85e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05288857	chr19:2226551	DOT1L	-0.41	-6.34	-0.32	7.06e-10	Calcium levels;
LIHC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.39	-0.33	5.29e-10	Type 2 diabetes;
LIHC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg03037974	chr15:76606532	NA	-0.59	-9.92	-0.47	1.48e-20	Blood metabolite levels;
LIHC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-0.97	-23.17	-0.78	4.65e-72	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.73	10.29	0.49	8.17e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.63	8.11	0.4	9.29e-15	Blood metabolite levels;
LIHC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.42	0.41	1.07e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.68e-16	Motion sickness;
LIHC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.6	-8.83	-0.43	5.45e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.48	7.64	0.38	2.19e-13	Blood protein levels;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	trans	rs9914544	0.545	rs9912713	chr17:18771145	G/A	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.75	-0.34	6.53e-11	Educational attainment (years of education);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18649979	chr19:21688263	ZNF429	-0.42	-6.62	-0.34	1.43e-10	Bilirubin levels;
LIHC	cis	rs4650994	0.593	rs12096732	chr1:178523164	C/T	cg05350800	chr1:178550844	NA	-0.34	-7.39	-0.37	1.13e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.39	6.26	0.32	1.18e-9	Mean corpuscular volume;
LIHC	cis	rs7116495	1.000	rs11235440	chr11:71826644	A/G	cg10381502	chr11:71823885	C11orf51	0.55	5.91	0.3	8.06e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs965469	1.000	rs6037535	chr20:3270621	C/T	cg25506879	chr20:3388711	C20orf194	-0.6	-6.88	-0.35	2.84e-11	IFN-related cytopenia;
LIHC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.65	-10.32	-0.49	6.5600000000000005e-22	Monocyte percentage of white cells;
LIHC	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg00977110	chr5:151150581	G3BP1	-0.56	-7.17	-0.36	4.52e-12	Preschool internalizing problems;
LIHC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.59	0.38	3.09e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs858239	0.712	rs199650	chr7:23367189	C/T	cg00469287	chr7:23338798	C7orf30	-0.47	-6.29	-0.32	9.52e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2257205	0.667	rs9912325	chr17:56873934	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.61	-0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg07061783	chr6:25882402	NA	0.66	8.45	0.42	8.25e-16	Blood metabolite levels;
LIHC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg00800038	chr16:89945340	TCF25	-0.63	-9.49	-0.46	4.05e-19	Skin colour saturation;
LIHC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.44	5.81	0.3	1.44e-8	Obesity-related traits;
LIHC	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.46e-15	Facial morphology (factor 19);
LIHC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-13.72	-0.6	1.94e-34	Chronic sinus infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12841375	chr6:52929709	FBXO9	0.41	6.4	0.33	5.21e-10	Cognitive function;
LIHC	cis	rs12086130	0.892	rs72906845	chr1:51491469	G/T	cg07174182	chr1:51127561	FAF1	-0.88	-9.84	-0.47	2.7e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.91	-10.19	-0.48	1.8e-21	Red cell distribution width;
LIHC	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.54	0.33	2.25e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.34	7.4	0.37	1.09e-12	Ulcerative colitis;
LIHC	cis	rs6977660	1.000	rs6973890	chr7:19820497	T/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-11.95	-0.54	9.7e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.74	-0.47	5.88e-20	Initial pursuit acceleration;
LIHC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.45	10.22	0.48	1.46e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.48	7.6	0.38	2.91e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-6.24	-0.32	1.27e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.07	-0.36	8.67e-12	Vitiligo;
LIHC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.55	0.64	1.25e-41	Chronic sinus infection;
LIHC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.97	11.03	0.51	2.11e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	ch.11.42038R	chr11:967971	AP2A2	0.54	9.86	0.47	2.46e-20	Alzheimer's disease (late onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02006803	chr2:128990870	NA	-0.42	-6.96	-0.35	1.79e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.63	9.1	0.44	7.36e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1664789	1.000	rs1694066	chr5:53282535	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.47	0.42	7.55e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs6967414	0.786	rs6463578	chr7:6753050	C/A	cg00387323	chr7:6746715	ZNF12	0.64	7.01	0.35	1.29e-11	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.39	6.07	0.31	3.45e-9	Coronary artery disease;
LIHC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	11.1	0.51	1.16e-24	Lung cancer in ever smokers;
LIHC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.74	13.45	0.59	2.14e-33	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs11630290	0.592	rs1017531	chr15:64158650	G/A	cg12036633	chr15:63758958	NA	0.63	6.81	0.35	4.47e-11	Iris characteristics;
LIHC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg14092571	chr14:90743983	NA	-0.38	-5.94	-0.31	7.01e-9	Mortality in heart failure;
LIHC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg18912006	chr12:123335444	HIP1R	-0.64	-7.69	-0.38	1.55e-13	Schizophrenia;
LIHC	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.46	6.77	0.34	5.64e-11	Height;
LIHC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.5	-7.35	-0.37	1.44e-12	Obesity-related traits;
LIHC	cis	rs6782228	0.675	rs6806687	chr3:128391789	C/T	cg16766828	chr3:128327626	NA	0.42	6.68	0.34	9.83e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.59	-0.5	7.31e-23	Total cholesterol levels;
LIHC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.47	7.06	0.36	9.58e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.45	0.82	1.07e-84	Cognitive ability;
LIHC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06636551	chr8:101224915	SPAG1	0.48	9.13	0.44	6.29e-18	Atrioventricular conduction;
LIHC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.48	7.78	0.39	8.46e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg03146154	chr1:46216737	IPP	-0.39	-6.51	-0.33	2.74e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg14146966	chr2:61757674	XPO1	0.45	7.77	0.39	9.17e-14	Tuberculosis;
LIHC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.38	6.92	0.35	2.18e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg12046867	chr14:103022105	NA	-0.48	-6.94	-0.35	1.94e-11	Platelet count;
LIHC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg10664184	chr19:17420304	DDA1	0.45	5.73	0.3	2.25e-8	Systemic lupus erythematosus;
LIHC	cis	rs916888	0.821	rs199499	chr17:44865498	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	5.82	0.3	1.35e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11645453	chr3:52864694	ITIH4	0.21	5.84	0.3	1.23e-8	Bipolar disorder;
LIHC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.5	7.64	0.38	2.17e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.84	0.6	6.88e-35	Bipolar disorder;
LIHC	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.51	7.26	0.37	2.59e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.8	-12.61	-0.56	3.44e-30	Tonsillectomy;
LIHC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-0.68	-7.43	-0.37	8.96e-13	Coronary artery disease;
LIHC	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-8.48	-0.42	6.83e-16	Vitamin D levels;
LIHC	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.88	15.02	0.63	1.6e-39	Schizophrenia;
LIHC	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.27	-0.32	1.12e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs62244186	0.773	rs6809116	chr3:44712097	A/C	cg25364880	chr3:44379878	C3orf23	0.59	8.11	0.4	9.37e-15	Depressive symptoms;
LIHC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.25	0.55	7.29e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25048357	chr11:118955763	HMBS	0.48	6.77	0.34	5.77e-11	Lung function (FEV1/FVC);
LIHC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.29	-0.32	9.77e-10	Menopause (age at onset);
LIHC	cis	rs7534824	0.625	rs12563134	chr1:101468558	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.67	-7.66	-0.38	1.95e-13	Refractive astigmatism;
LIHC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.41	-5.75	-0.3	2.03e-8	Longevity;
LIHC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg25039879	chr17:56429692	SUPT4H1	0.78	8.84	0.43	5.15e-17	Cognitive test performance;
LIHC	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.56	-8.24	-0.41	3.6e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg24247472	chr17:46908838	CALCOCO2	-0.41	-6.24	-0.32	1.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg27433088	chr4:174089019	GALNT7	0.39	7.18	0.36	4.26e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.77	-14.11	-0.61	5.89e-36	Longevity;
LIHC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24549020	chr5:56110836	MAP3K1	0.51	6.37	0.33	5.98e-10	Type 2 diabetes;
LIHC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.67	13.2	0.58	2.02e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.54	8.75	0.43	9.56e-17	Body mass index;
LIHC	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	0.88	5.94	0.31	7.13e-9	Mitochondrial DNA levels;
LIHC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.34	-8.53	-0.42	4.81e-16	Hip circumference;Waist circumference;
LIHC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.9e-19	Alzheimer's disease;
LIHC	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.29	-0.32	9.9e-10	Breast cancer;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.4	-0.33	5e-10	Total body bone mineral density;
LIHC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	11.81	0.54	3.21e-27	Platelet count;
LIHC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22618164	chr12:122356400	WDR66	0.5	7.75	0.39	1.03e-13	Mean corpuscular volume;
LIHC	cis	rs963731	0.579	rs1454220	chr2:39277108	G/A	cg04010122	chr2:39346883	SOS1	-0.69	-6.25	-0.32	1.22e-9	Corticobasal degeneration;
LIHC	cis	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg19680485	chr15:31195859	MTMR15	-0.54	-6.05	-0.31	3.73e-9	Hypertriglyceridemia;
LIHC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6565180	0.888	rs12921440	chr16:30408765	C/T	cg17640201	chr16:30407289	ZNF48	0.8	13.76	0.6	1.39e-34	Tonsillectomy;
LIHC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.59	7.45	0.37	7.91e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg01864836	chr14:55583639	NA	0.44	8.71	0.43	1.37e-16	Protein biomarker;
LIHC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.81	-0.3	1.41e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05323904	chr16:691677	FAM195A	0.47	6.91	0.35	2.45e-11	Pancreatic cancer;
LIHC	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg22771759	chr13:24902376	NA	0.31	6.45	0.33	3.75e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg00656387	chr3:40428638	ENTPD3	0.51	8.48	0.42	6.9e-16	Renal cell carcinoma;
LIHC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.55	8.25	0.41	3.42e-15	Gout;
LIHC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.72	0.3	2.33e-8	Renal function-related traits (BUN);
LIHC	cis	rs12744310	0.943	rs35493284	chr1:41755189	T/A	cg03962019	chr1:41807865	NA	0.38	6.19	0.32	1.73e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7712401	0.686	rs154509	chr5:122198340	T/A	cg18764291	chr5:122110994	SNX2	0.33	5.84	0.3	1.25e-8	Mean platelet volume;
LIHC	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.58	9.28	0.45	1.95e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.16	0.36	5.05e-12	Schizophrenia;
LIHC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg06640241	chr16:89574553	SPG7	0.66	10.71	0.5	2.79e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.5	8.19	0.41	5.12e-15	Schizophrenia;
LIHC	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.44	6.77	0.34	5.56e-11	Alzheimer's disease (survival time);
LIHC	cis	rs9918079	0.560	rs10008975	chr4:15624571	C/T	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.19	-0.32	1.71e-9	Obesity-related traits;
LIHC	cis	rs17125944	0.556	rs1952088	chr14:53319832	A/C	cg00686598	chr14:53173677	PSMC6	-0.81	-9.47	-0.46	4.7e-19	Alzheimer's disease (late onset);
LIHC	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	0.92	17.64	0.69	5.57e-50	Schizophrenia;
LIHC	cis	rs3762637	0.943	rs10222564	chr3:122266336	T/C	cg24169773	chr3:122142474	KPNA1	-0.44	-8.73	-0.43	1.11e-16	LDL cholesterol levels;
LIHC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	12.75	0.57	1.01e-30	Electrocardiographic conduction measures;
LIHC	cis	rs655641	1.000	rs588076	chr11:85691662	C/G	cg09030501	chr11:85779252	PICALM	0.54	6.36	0.33	6.51e-10	Platelet count;
LIHC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.77	-0.3	1.79e-8	Heart rate;
LIHC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg02187348	chr16:89574699	SPG7	0.47	6.17	0.32	1.88e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg00129232	chr17:37814104	STARD3	-0.4	-6.45	-0.33	3.86e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-8.53	-0.42	4.81e-16	Obesity-related traits;
LIHC	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-7.59	-0.38	3.03e-13	Brugada syndrome;
LIHC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	10.83	0.51	1.04e-23	Platelet count;
LIHC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.5	-7.26	-0.37	2.56e-12	Uric acid levels;
LIHC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.72	-9.35	-0.45	1.21e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.89	-15.52	-0.64	1.66e-41	Aortic root size;
LIHC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.41	7.53	0.38	4.67e-13	Electrocardiographic conduction measures;
LIHC	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.0	0.35	1.39e-11	Type 2 diabetes;
LIHC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.61e-12	Bipolar disorder;
LIHC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg02079420	chr8:82753780	SNX16	0.34	6.19	0.32	1.77e-9	Diastolic blood pressure;
LIHC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg23791538	chr6:167370224	RNASET2	0.5	8.17	0.4	6e-15	Crohn's disease;
LIHC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.69	10.14	0.48	2.7e-21	Prostate cancer;
LIHC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.24	-7.42	-0.37	9.47e-13	Motion sickness;
LIHC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.43	-7.06	-0.36	9.29e-12	IgG glycosylation;
LIHC	cis	rs7872515	0.838	rs6479403	chr9:94829156	A/G	cg01248375	chr9:94877805	SPTLC1	0.53	7.89	0.39	4.11e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.84	0.35	3.73e-11	Bipolar disorder;
LIHC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.93	0.54	1.12e-27	Alzheimer's disease;
LIHC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.2	0.45	3.71e-18	Schizophrenia;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.48	7.33	0.37	1.63e-12	Testicular germ cell tumor;
LIHC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.46	-7.03	-0.36	1.15e-11	Glycated hemoglobin levels;
LIHC	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.39	-6.29	-0.32	9.47e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs10050311	0.790	rs72667716	chr4:87833928	G/A	cg04118154	chr1:45140072	C1orf228;TMEM53	-0.48	-6.18	-0.32	1.81e-9	Insulin-related traits;
LIHC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.81	-0.3	1.46e-8	Blood protein levels;
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.67	9.98	0.47	9.49e-21	Menarche (age at onset);
LIHC	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.79	13.79	0.6	1e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg16724585	chr3:197361211	NA	-0.46	-6.4	-0.33	5.25e-10	Pancreatic cancer;
LIHC	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.94	17.64	0.69	5.76e-50	Menopause (age at onset);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26079571	chr12:3186499	TSPAN9	-0.45	-6.13	-0.31	2.48e-9	Bilirubin levels;
LIHC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-6.11	-0.31	2.71e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg17652424	chr22:38574118	PLA2G6	-0.2	-6.03	-0.31	4.22e-9	Cutaneous nevi;
LIHC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.88	-0.54	1.78e-27	Type 2 diabetes;
LIHC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs7944735	0.508	rs2138767	chr11:47629793	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-5.99	-0.31	5.38e-9	Intraocular pressure;
LIHC	cis	rs3027234	0.734	rs11650309	chr17:8129538	C/G	cg06726167	chr17:8076949	TMEM107	-0.54	-6.08	-0.31	3.28e-9	Telomere length;
LIHC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.16	0.36	5.04e-12	Self-reported allergy;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09901100	chr7:134867116	NA	0.41	6.07	0.31	3.34e-9	Longevity;
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.62	7.76	0.39	9.81e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.66	0.53	1.11e-26	Alzheimer's disease;
LIHC	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg03929089	chr4:120376271	NA	0.62	6.35	0.32	6.82e-10	Body mass index;
LIHC	cis	rs4759375	0.790	rs28820735	chr12:123878507	C/T	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.6e-10	HDL cholesterol;
LIHC	cis	rs7091068	0.518	rs4919436	chr10:95461475	C/T	cg20715218	chr10:95462985	C10orf4	0.59	8.52	0.42	5.08e-16	Urinary tract infection frequency;
LIHC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg01652190	chr22:50026171	C22orf34	-0.3	-6.78	-0.34	5.31e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.43	-5.86	-0.3	1.1e-8	Longevity;
LIHC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.71	-0.43	1.32e-16	Blood metabolite levels;
LIHC	cis	rs7607659	1	rs7607659	chr2:105267490	C/T	cg12236088	chr2:105275812	NA	-0.53	-6.32	-0.32	8.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.6	8.03	0.4	1.61e-14	Breast cancer;
LIHC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.51	-18.32	-0.7	1.05e-52	Breast cancer;
LIHC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs7534824	0.543	rs60978318	chr1:101400413	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.74	0.39	1.15e-13	Refractive astigmatism;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.2	-0.32	1.66e-9	Alzheimer's disease (late onset);
LIHC	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.46	-6.72	-0.34	7.84e-11	Atrial fibrillation;
LIHC	cis	rs67981189	0.679	rs221901	chr14:71602226	C/T	cg15816911	chr14:71606274	NA	-0.4	-6.41	-0.33	4.72e-10	Schizophrenia;
LIHC	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.73	-0.3	2.21e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	1.03	14.16	0.61	3.84e-36	Corneal structure;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-6.93	-0.35	2.11e-11	Renal cell carcinoma;
LIHC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.48	6.82	0.35	4.16e-11	Tonsillectomy;
LIHC	cis	rs10838687	0.800	rs7124958	chr11:47347260	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.82	-0.3	1.39e-8	Proinsulin levels;
LIHC	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.41	6.58	0.34	1.75e-10	Intraocular pressure;
LIHC	cis	rs7116495	1.000	rs28504107	chr11:71832519	G/A	cg26138937	chr11:71823887	C11orf51	0.73	7.41	0.37	9.67e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.43	6.58	0.34	1.74e-10	Longevity;
LIHC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.99	0.31	5.45e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4650994	0.571	rs35758545	chr1:178511924	C/T	cg05350800	chr1:178550844	NA	-0.33	-7.11	-0.36	6.87e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10792665	0.844	rs7930200	chr11:82649880	T/C	cg24227371	chr11:82718527	RAB30	-0.31	-7.47	-0.37	6.66e-13	Obesity-related traits;
LIHC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.77	9.24	0.45	2.7e-18	Cognitive function;
LIHC	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-7.85	-0.39	5.31e-14	Obesity-related traits;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg24693881	chr1:107596107	NA	-0.55	-9.66	-0.46	1.13e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.44	-6.47	-0.33	3.47e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.34	7.4	0.37	1.09e-12	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.13	-0.31	2.46e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg23254163	chr1:152506842	NA	0.23	5.91	0.3	8.5e-9	Hair morphology;
LIHC	cis	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg20368463	chr18:77673604	PQLC1	0.5	5.76	0.3	1.89e-8	Opioid sensitivity;
LIHC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg22633049	chr21:46681294	NA	-0.34	-5.99	-0.31	5.42e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.52	-0.38	4.86e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.69	-10.5	-0.49	1.54e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg07424592	chr7:64974309	NA	0.73	8.54	0.42	4.46e-16	Diabetic kidney disease;
LIHC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.55	9.3	0.45	1.68e-18	Prostate cancer;
LIHC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.66	-0.34	1.13e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs4689642	0.709	rs4689090	chr4:7226751	G/T	cg21353189	chr4:7228343	SORCS2	0.36	6.1	0.31	2.9e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.07e-10	Bipolar disorder;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736485	0.934	rs2414106	chr15:51868741	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.05e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.47	-7.95	-0.4	2.69e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.89	13.38	0.59	3.89e-33	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	11.04	0.51	1.89e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg10845886	chr2:3471009	TTC15	-0.45	-8.12	-0.4	8.53e-15	Neurofibrillary tangles;
LIHC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.41	-0.53	8.75e-26	Chronic sinus infection;
LIHC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.72	9.19	0.45	3.85e-18	Gut microbiome composition (summer);
LIHC	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.36	0.33	6.41e-10	Platelet distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09002469	chr12:123459295	OGFOD2;ABCB9	0.45	6.36	0.33	6.58e-10	Pancreatic cancer;
LIHC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.85	-15.13	-0.63	5.9e-40	Dental caries;
LIHC	cis	rs1712517	0.771	rs2292807	chr10:105155645	T/C	cg05636881	chr10:105038444	INA	0.48	7.4	0.37	1.07e-12	Migraine;
LIHC	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.44	-7.3	-0.37	2.05e-12	Schizophrenia;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.48	-6.79	-0.34	5.01e-11	Lymphocyte counts;
LIHC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.92	0.3	7.9e-9	Nonalcoholic fatty liver disease;
LIHC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.57	-0.38	3.46e-13	Morning vs. evening chronotype;
LIHC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.71	13.22	0.58	1.7e-32	Height;
LIHC	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	trans	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg26939375	chr7:64535504	NA	-0.39	-6.14	-0.32	2.25e-9	Aortic root size;
LIHC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg04592579	chr7:75616294	TMEM120A	-0.39	-6.68	-0.34	9.71e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.64	7.4	0.37	1.07e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-10.96	-0.51	3.59e-24	Colorectal cancer;
LIHC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg06238570	chr21:40685208	BRWD1	0.58	6.99	0.35	1.48e-11	Cognitive function;
LIHC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg23690444	chr14:81902736	NA	-0.49	-6.8	-0.35	4.74e-11	Night sleep phenotypes;
LIHC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.59	-8.15	-0.4	6.93e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg27205649	chr11:78285834	NARS2	0.39	5.91	0.3	8.1e-9	Alzheimer's disease (survival time);
LIHC	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg06265175	chr8:121136014	COL14A1	0.48	7.83	0.39	6.23e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.08	0.31	3.27e-9	Ulcerative colitis;
LIHC	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.73	0.39	1.18e-13	Alzheimer's disease;
LIHC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	1.03	18.23	0.7	2.34e-52	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	1.09	11.36	0.52	1.33e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-6.48	-0.33	3.19e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-6.92	-0.35	2.29e-11	Blood protein levels;
LIHC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.28	0.32	1.01e-9	Melanoma;
LIHC	cis	rs7633770	0.643	rs59048074	chr3:46689155	C/T	cg11219411	chr3:46661640	NA	-0.36	-5.95	-0.31	6.55e-9	Coronary artery disease;
LIHC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.68	0.46	9.74e-20	Morning vs. evening chronotype;
LIHC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg03476357	chr21:30257390	N6AMT1	0.53	7.74	0.39	1.15e-13	Cognitive test performance;
LIHC	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg04610667	chr7:75704037	NA	-0.35	-6.25	-0.32	1.23e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.67	13.33	0.58	6.18e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16684958	chr7:75615977	POR	0.5	8.56	0.42	3.99e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.37	0.33	5.96e-10	Rheumatoid arthritis;
LIHC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.8	-13.23	-0.58	1.52e-32	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg13409248	chr3:40428643	ENTPD3	-0.37	-6.06	-0.31	3.65e-9	Renal cell carcinoma;
LIHC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.53	-7.08	-0.36	8.26e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs714027	0.511	rs131274	chr22:30153864	G/A	cg01021169	chr22:30184971	ASCC2	-0.31	-5.72	-0.3	2.34e-8	Lymphocyte counts;
LIHC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.45	-7.94	-0.39	2.94e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs244293	0.965	rs244346	chr17:53196383	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.74	-13.62	-0.59	4.7e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.71	-7.08	-0.36	8.3e-12	Vitiligo;
LIHC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6516091	0.850	rs75701968	chr20:6049985	C/T	cg25325723	chr20:6104886	FERMT1	-0.71	-5.88	-0.3	9.8e-9	Abdominal aortic aneurysm;
LIHC	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg12140854	chr5:148520817	ABLIM3	0.45	6.22	0.32	1.47e-9	Breast cancer;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.49	7.65	0.38	2.01e-13	Testicular germ cell tumor;
LIHC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg04727924	chr7:799746	HEATR2	-0.59	-8.06	-0.4	1.3e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg02573091	chr5:74908125	NA	0.5	6.27	0.32	1.07e-9	Coronary artery disease;
LIHC	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-7.22	-0.36	3.46e-12	Obesity-related traits;
LIHC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.66	-8.9	-0.43	3.31e-17	Sudden cardiac arrest;
LIHC	trans	rs1347297	0.789	rs7589565	chr2:179282337	A/G	cg14011486	chr1:26737247	LIN28	0.45	7.09	0.36	7.87e-12	Alzheimer disease and age of onset;
LIHC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg04719120	chr6:96025338	MANEA	0.64	6.8	0.35	4.64e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.47e-18	Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23097686	chr12:98910128	TMPO;LOC100128191	-0.42	-6.05	-0.31	3.76e-9	Cognitive function;
LIHC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-9.45	-0.46	5.47e-19	Body mass index;
LIHC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg03732007	chr1:2071316	PRKCZ	0.35	6.09	0.31	3.09e-9	Height;
LIHC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg07636037	chr3:49044803	WDR6	-0.66	-6.17	-0.32	1.95e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg16906346	chr6:24646782	KIAA0319	-0.55	-7.65	-0.38	2.06e-13	Colorectal or endometrial cancer;
LIHC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.88	0.43	3.84e-17	Lung cancer;
LIHC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	0.69	7.55	0.38	4.08e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.01e-30	Alzheimer's disease;
LIHC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.52e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs4908760	0.669	rs4908506	chr1:8728978	A/C	cg20416874	chr1:8611966	RERE	-0.62	-11.78	-0.54	4.18e-27	Vitiligo;
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg00091569	chr3:40428383	ENTPD3	0.39	6.54	0.33	2.25e-10	Renal cell carcinoma;
LIHC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.42	-7.18	-0.36	4.3e-12	Educational attainment;
LIHC	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg07322936	chr10:88137208	NA	-0.46	-5.92	-0.31	7.63e-9	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-7.36	-0.37	1.37e-12	Height;
LIHC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg05110241	chr16:68378359	PRMT7	-0.52	-5.76	-0.3	1.87e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.64	9.05	0.44	1.11e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg12193833	chr17:30244370	NA	-0.51	-5.75	-0.3	1.94e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs332507	0.601	rs7653534	chr3:124358041	T/C	cg05980111	chr3:124395277	KALRN	0.31	6.04	0.31	4.04e-9	Plateletcrit;
LIHC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-0.96	-22.31	-0.77	1.07e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.84	0.35	3.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg14515779	chr1:101123966	NA	-0.59	-11.25	-0.52	3.52e-25	Monocyte count;
LIHC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.45	5.97	0.31	5.81e-9	High light scatter reticulocyte count;
LIHC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.41	-0.37	9.78e-13	Response to antipsychotic treatment;
LIHC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.46	7.72	0.39	1.26e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.8	-10.87	-0.51	8.03e-24	Blood pressure (smoking interaction);
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.39	-5.72	-0.3	2.38e-8	Longevity;
LIHC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.98	-17.84	-0.69	8.33e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs1400745	0.812	rs72678789	chr14:35348201	T/G	cg16230307	chr14:35515116	FAM177A1	-0.38	-6.02	-0.31	4.38e-9	Monocyte count;
LIHC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg24296786	chr1:45957014	TESK2	-0.48	-6.23	-0.32	1.35e-9	Platelet count;
LIHC	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.04	-0.31	4.01e-9	Corneal structure;
LIHC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-1.0	-17.34	-0.68	9.29e-49	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.48	-7.06	-0.36	9.3e-12	Obesity-related traits;
LIHC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.89	-0.43	3.45e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1419980	0.730	rs11054939	chr12:7782439	C/G	cg10578777	chr12:7781093	NA	-0.4	-5.86	-0.3	1.1e-8	HDL cholesterol levels;
LIHC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.76e-11	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg23682824	chr7:23144976	KLHL7	0.43	6.51	0.33	2.64e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.12	0.4	8.3e-15	Height;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.61	0.42	2.67e-16	Lymphocyte counts;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03424826	chr18:59561551	RNF152	0.47	6.51	0.33	2.67e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.11	-0.78	7.6e-72	Height;
LIHC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.48	7.4	0.37	1.06e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2412488	0.893	rs7682199	chr4:54343363	A/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.78	-0.34	5.19e-11	DNA methylation (variation);
LIHC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.28	-17.19	-0.68	3.6e-48	Diabetic kidney disease;
LIHC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.41	-5.75	-0.3	1.93e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg12798992	chr6:167411361	FGFR1OP	-0.47	-7.37	-0.37	1.26e-12	Graves' disease;
LIHC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.37	-6.23	-0.32	1.34e-9	Educational attainment;
LIHC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg17420585	chr12:42539391	GXYLT1	-0.38	-6.15	-0.32	2.22e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19671926	chr4:122722719	EXOSC9	0.53	8.02	0.4	1.64e-14	Type 2 diabetes;
LIHC	cis	rs61677309	1.000	rs67774926	chr11:118157623	C/G	cg06090739	chr11:118230722	UBE4A	0.35	6.6	0.34	1.53e-10	Lung cancer in ever smokers;
LIHC	trans	rs10411161	0.702	rs8110546	chr19:52383556	C/A	cg22319618	chr22:45562946	NUP50	-0.6	-8.08	-0.4	1.13e-14	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01435196	chr19:46009946	VASP	0.5	6.79	0.34	4.94e-11	Lung function (FEV1/FVC);
LIHC	cis	rs74544699	1.000	rs116254820	chr4:74804444	G/A	cg02530824	chr4:74847766	PF4	0.62	6.4	0.33	5.22e-10	Growth-regulated protein alpha levels;
LIHC	trans	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg10756647	chr7:56101905	PSPH	1.11	13.62	0.59	4.91e-34	Diabetic kidney disease;
LIHC	cis	rs507080	0.733	rs544452	chr11:118571357	G/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg04450456	chr4:17643702	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.62	-7.39	-0.37	1.11e-12	QRS complex (12-leadsum);
LIHC	trans	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-8.53	-0.42	4.81e-16	Obesity-related traits;
LIHC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.22e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg01629716	chr15:45996671	NA	0.52	9.56	0.46	2.41e-19	Waist circumference;Weight;
LIHC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.43	9.16	0.44	4.77e-18	Migraine;
LIHC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.39	7.45	0.37	7.9e-13	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.56	9.12	0.44	6.64e-18	Body mass index;
LIHC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.5	9.28	0.45	2.01e-18	Hemoglobin concentration;
LIHC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	1.08	12.3	0.55	4.95e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.53	-8.62	-0.42	2.59e-16	Body mass index;
LIHC	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.66	0.34	1.1e-10	Dupuytren's disease;
LIHC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.51	7.19	0.36	4.09e-12	Menopause (age at onset);
LIHC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.88	-0.39	4.49e-14	Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg14440974	chr22:39074834	NA	0.44	7.07	0.36	8.66e-12	Menopause (age at onset);
LIHC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.48	6.04	0.31	3.93e-9	Mean platelet volume;
LIHC	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08677755	chr19:7604888	PNPLA6	-0.42	-6.6	-0.34	1.58e-10	Calcium levels;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg07002622	chr6:118822466	C6orf204;BRD7P3	0.56	5.92	0.3	7.98e-9	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09910967	chr6:139456200	HECA	-0.44	-6.3	-0.32	9.27e-10	Pancreatic cancer;
LIHC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.57	0.5	9e-23	Personality dimensions;
LIHC	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs116248771	0.739	rs73156495	chr3:158420547	C/T	cg16708174	chr3:158430962	RARRES1	0.46	6.31	0.32	8.56e-10	diarrhoeal disease at age 2;
LIHC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	1.01	19.24	0.72	2.01e-56	Breast cancer;
LIHC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.34	6.09	0.31	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.03e-20	Schizophrenia;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12379764	chr21:47803548	PCNT	-0.54	-7.99	-0.4	2.08e-14	Testicular germ cell tumor;
LIHC	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.2	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs5015933	0.815	rs13294021	chr9:128068388	G/A	cg14078157	chr9:128172775	NA	-0.37	-6.0	-0.31	4.99e-9	Body mass index;
LIHC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.76	-7.89	-0.39	4.16e-14	Vitiligo;
LIHC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.33	-0.45	1.33e-18	Heart rate;
LIHC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.45	-7.87	-0.39	4.77e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.53	7.44	0.37	8.1e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.4	-0.37	1.04e-12	Vitiligo;
LIHC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg19635926	chr16:89946313	TCF25	0.5	6.45	0.33	3.88e-10	Skin colour saturation;
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27297192	chr10:134578999	INPP5A	-0.48	-6.77	-0.34	5.53e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.66	-9.94	-0.47	1.27e-20	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.42	-0.33	4.6e-10	Obesity-related traits;
LIHC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12602486	0.744	rs12603404	chr17:42223914	G/A	cg13607699	chr17:42295918	UBTF	-0.72	-6.27	-0.32	1.12e-9	Glycated hemoglobin levels;
LIHC	cis	rs867186	0.541	rs117391907	chr20:33338811	G/A	cg08999081	chr20:33150536	PIGU	0.6	5.75	0.3	1.98e-8	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg19920283	chr7:105172520	RINT1	-0.48	-6.17	-0.32	1.97e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs992157	0.764	rs1870123	chr2:219187698	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.1	0.48	3.8e-21	Colorectal cancer;
LIHC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg15902774	chr15:75289873	SCAMP5	0.33	5.83	0.3	1.31e-8	Systemic lupus erythematosus;
LIHC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg25894440	chr7:65020034	NA	-0.54	-6.27	-0.32	1.06e-9	Diabetic kidney disease;
LIHC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.39	-8.15	-0.4	6.78e-15	Obesity-related traits;
LIHC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg09911534	chr15:67153556	NA	-0.43	-5.75	-0.3	1.97e-8	Lung cancer (smoking interaction);
LIHC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.62	9.97	0.47	1.05e-20	Monocyte count;
LIHC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.5	-6.07	-0.31	3.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26734620	chr12:56694298	CS	-1.3	-11.32	-0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15506890	chr2:3487001	NA	-0.49	-7.5	-0.38	5.38e-13	Neurofibrillary tangles;
LIHC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.55	0.71	1.22e-53	Tonsillectomy;
LIHC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.49	9.07	0.44	9.82e-18	Hemoglobin concentration;
LIHC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.51	6.09	0.31	3.03e-9	Pancreatic cancer;
LIHC	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.56	-8.64	-0.42	2.16e-16	Blood protein levels;
LIHC	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg04756594	chr16:24857601	SLC5A11	0.38	6.43	0.33	4.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	15.59	0.64	9.01e-42	Tonsillectomy;
LIHC	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg26241852	chr15:40650142	DISP2	-0.48	-6.1	-0.31	2.79e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.92	0.43	2.89e-17	Height;
LIHC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg24130564	chr14:104152367	KLC1	-0.38	-6.05	-0.31	3.83e-9	Schizophrenia;
LIHC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.46	7.77	0.39	9.13e-14	Tuberculosis;
LIHC	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg01285391	chr19:53465759	ZNF816A	-0.33	-5.85	-0.3	1.14e-8	Psoriasis;
LIHC	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.15	16.19	0.66	3.6e-44	Corneal structure;
LIHC	trans	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg17675199	chr6:35436792	RPL10A	0.33	6.52	0.33	2.57e-10	Coronary artery disease;
LIHC	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.35	6.04	0.31	3.96e-9	Schizophrenia;
LIHC	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.25	0.36	2.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.68	0.78	3.75e-70	Chronic sinus infection;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.56	-9.58	-0.46	1.99e-19	Aortic root size;
LIHC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.78	0.3	1.69e-8	Bladder cancer;
LIHC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.62	-8.6	-0.42	2.89e-16	Body mass index;
LIHC	cis	rs2029362	0.513	rs10767667	chr11:27746549	C/T	cg18117895	chr11:27722066	BDNF	-0.39	-5.76	-0.3	1.87e-8	Total body bone mineral density;
LIHC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.34	6.4	0.33	5.16e-10	Renal cell carcinoma;
LIHC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.26	-6.83	-0.35	3.79e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.78	0.54	3.93e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg23043544	chr7:2124092	MAD1L1	-0.4	-5.99	-0.31	5.41e-9	Bipolar disorder;
LIHC	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg00935119	chr6:36647544	CDKN1A	0.49	7.03	0.36	1.16e-11	QRS duration;
LIHC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.93	15.41	0.64	4.56e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-8.96	-0.44	2.12e-17	Blood metabolite levels;
LIHC	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	6.19	0.32	1.75e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	10.73	0.5	2.39e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.97	0.44	1.95e-17	Platelet count;
LIHC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg08302003	chr7:100435192	NA	-0.39	-6.32	-0.32	8.02e-10	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.92	0.65	4.3e-43	Electrocardiographic conduction measures;
LIHC	cis	rs611744	0.967	rs688746	chr8:109225725	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	22.41	0.77	4.49e-69	Body mass index (adult);
LIHC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	7.83	0.39	6.24e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.64	0.38	2.16e-13	Prudent dietary pattern;
LIHC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-12.94	-0.57	1.9e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9348721	0.562	rs9393716	chr6:26376868	A/G	cg09904177	chr6:26538194	HMGN4	-0.5	-5.89	-0.3	9.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8084351	0.560	rs7506428	chr18:50557938	A/C	cg24270629	chr18:50823537	DCC	0.39	5.85	0.3	1.12e-8	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs16877106	1.000	rs73252579	chr4:25316691	G/A	cg04796973	chr4:25314218	ZCCHC4	0.61	5.77	0.3	1.75e-8	Weight;
LIHC	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.06	-0.36	9.17e-12	Blood protein levels;
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg03854865	chr6:26224070	HIST1H3E	0.63	7.23	0.36	3.28e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs16958440	0.867	rs3809965	chr18:44676872	G/A	cg17192377	chr18:44677553	HDHD2	0.93	8.68	0.42	1.66e-16	Sitting height ratio;
LIHC	trans	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg10756647	chr7:56101905	PSPH	-0.47	-7.05	-0.36	1.01e-11	Aortic root size;
LIHC	cis	rs72627123	0.656	rs76479281	chr14:74564609	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	8.36	0.41	1.65e-15	Morning vs. evening chronotype;
LIHC	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.35	7.47	0.37	6.59e-13	Obesity (extreme);
LIHC	cis	rs9443189	0.901	rs2038624	chr6:76560707	T/C	cg01950844	chr6:76311363	SENP6	-0.52	-6.76	-0.34	5.8200000000000003e-11	Prostate cancer;
LIHC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21467203	chr3:49911342	NA	-0.55	-10.06	-0.48	4.97e-21	Body mass index;
LIHC	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.48	7.37	0.37	1.29e-12	Systemic lupus erythematosus;
LIHC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	13.85	0.6	6.18e-35	Primary sclerosing cholangitis;
LIHC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.16	0.32	2.01e-9	Tonsillectomy;
LIHC	cis	rs9322817	1.000	rs6942231	chr6:105191814	C/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.39	-0.33	5.59e-10	Thyroid stimulating hormone;
LIHC	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.58	10.75	0.5	2.06e-23	Leprosy;
LIHC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.6	8.15	0.4	7.09e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21101222	chr5:151138161	ATOX1	-0.46	-7.14	-0.36	5.8e-12	Pancreatic cancer;
LIHC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.61	-11.0	-0.51	2.6e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08677398	chr8:58056175	NA	0.4	6.27	0.32	1.11e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13647721	chr17:30228624	UTP6	0.69	7.18	0.36	4.43e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.64	-9.95	-0.47	1.22e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-6.03	-0.31	4.15e-9	Colorectal cancer;
LIHC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-8.1	-0.4	9.94e-15	Menarche (age at onset);
LIHC	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg08462924	chr1:41848221	NA	0.35	5.94	0.31	6.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2292096	1.000	rs2275193	chr1:200824108	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-6.07	-0.31	3.48e-9	Epilepsy;
LIHC	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.94	-0.35	1.93e-11	Schizophrenia;
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.44	-7.09	-0.36	7.74e-12	Testicular germ cell tumor;
LIHC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.35	0.45	1.19e-18	Eosinophil percentage of white cells;
LIHC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	11.29	0.52	2.51e-25	Type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01813165	chr2:202646406	ALS2	0.4	6.33	0.32	7.71e-10	Cognitive function;
LIHC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg04865290	chr3:52927548	TMEM110	-0.51	-5.87	-0.3	1.02e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.53	7.64	0.38	2.25e-13	Type 2 diabetes;
LIHC	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.38	-6.48	-0.33	3.11e-10	Hypertension (SNP x SNP interaction);
LIHC	cis	rs61542988	0.570	rs7781074	chr7:22826360	A/G	cg11367502	chr7:22862612	TOMM7	-0.54	-8.85	-0.43	4.71e-17	Fibrinogen levels;
LIHC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.67	11.26	0.52	3.06e-25	Superior crus of antihelix expression;
LIHC	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.7	7.36	0.37	1.36e-12	Blood protein levels;
LIHC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-6.37	-0.33	5.95e-10	Electroencephalogram traits;
LIHC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.37	6.48	0.33	3.12e-10	Facial morphology (factor 20);
LIHC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07092213	chr7:1199455	ZFAND2A	0.41	6.1	0.31	2.8e-9	Longevity;Endometriosis;
LIHC	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.1	-0.4	9.8e-15	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.57	8.6	0.42	2.94e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.56	-6.39	-0.33	5.45e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	0.7	8.81	0.43	6.38e-17	Corneal structure;
LIHC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.44	-7.39	-0.37	1.17e-12	Platelet distribution width;
LIHC	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.07e-17	Severe influenza A (H1N1) infection;
LIHC	trans	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	6.29e-33	Diabetic kidney disease;
LIHC	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.49	0.49	1.7e-22	Hypertriglyceridemia;
LIHC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs922107	0.738	rs12125224	chr1:90053563	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.69	-0.38	1.58e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.36	-5.77	-0.3	1.75e-8	Red blood cell count;
LIHC	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg06565975	chr8:143823917	SLURP1	0.32	6.25	0.32	1.2e-9	Urinary tract infection frequency;
LIHC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.68	-9.28	-0.45	1.97e-18	Corneal structure;
LIHC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.76	-14.45	-0.62	2.88e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01947301	chr1:205718900	NUCKS1	-0.48	-7.03	-0.36	1.14e-11	Cognitive function;
LIHC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.74	12.24	0.55	8.17e-29	Mean platelet volume;
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.19	0.55	1.27e-28	Height;
LIHC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg25894440	chr7:65020034	NA	0.58	6.75	0.34	6.47e-11	Diabetic kidney disease;
LIHC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg00091569	chr3:40428383	ENTPD3	0.38	6.46	0.33	3.66e-10	Renal cell carcinoma;
LIHC	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-6.17	-0.32	1.9e-9	Resting heart rate;
LIHC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.46	-0.42	8.02e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19717773	chr7:2847554	GNA12	-0.41	-6.65	-0.34	1.16e-10	Height;
LIHC	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg04944784	chr2:26401820	FAM59B	0.7	7.54	0.38	4.23e-13	Gut microbiome composition (summer);
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg14222432	chr12:29376421	FAR2	0.37	7.11	0.36	6.68e-12	QT interval;
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg00280220	chr17:61926910	NA	0.42	6.84	0.35	3.58e-11	Prudent dietary pattern;
LIHC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.61	10.6	0.5	6.81e-23	Colorectal cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03327327	chr1:214779620	CENPF	-0.45	-6.68	-0.34	9.47e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.44	-6.01	-0.31	4.89e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.25	-6.84	-0.35	3.7e-11	Type 2 diabetes;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.28	-6.07	-0.31	3.46e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg10845886	chr2:3471009	TTC15	-0.43	-7.68	-0.38	1.67e-13	Neurofibrillary tangles;
LIHC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.53	-8.21	-0.41	4.64e-15	Total body bone mineral density;
LIHC	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.11	-0.4	8.96e-15	Response to antipsychotic treatment;
LIHC	cis	rs6546537	0.955	rs35947226	chr2:69845829	C/G	cg10773587	chr2:69614142	GFPT1	-0.43	-5.95	-0.31	6.75e-9	Serum thyroid-stimulating hormone levels;
LIHC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg18478394	chr8:109455254	TTC35	0.42	7.24	0.36	3.07e-12	Dupuytren's disease;
LIHC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.77	9.67	0.46	9.97e-20	Cognitive function;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.4	0.81	1.03e-80	Prudent dietary pattern;
LIHC	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-6.19	-0.32	1.73e-9	Tuberculosis;
LIHC	cis	rs12744310	0.836	rs12048808	chr1:41814308	G/C	cg03962019	chr1:41807865	NA	0.4	5.92	0.31	7.69e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	6.33	0.32	7.48e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.99	-0.44	1.66e-17	Obesity-related traits;
LIHC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	8.56	0.42	3.99e-16	Blood metabolite levels;
LIHC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	6.32	0.32	8.11e-10	Coronary artery disease;
LIHC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.56	-0.5	9.46e-23	Chronic sinus infection;
LIHC	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.67	13.07	0.58	6.1e-32	Leprosy;
LIHC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-6.05	-0.31	3.71e-9	Total body bone mineral density;
LIHC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs3736485	0.934	rs7170330	chr15:51859313	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.12	-0.55	2.19e-28	Colorectal cancer;
LIHC	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.73	-0.34	7.35e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	10.33	0.49	5.86e-22	Monocyte percentage of white cells;
LIHC	cis	rs7944735	0.508	rs75334064	chr11:47759590	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.76	-0.3	1.88e-8	Intraocular pressure;
LIHC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.59	7.55	0.38	4e-13	Parkinson's disease;
LIHC	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-19.73	-0.73	2.19e-58	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14196353	chr11:111750159	C11orf1;FDXACB1	0.48	6.38	0.33	5.6e-10	Pancreatic cancer;
LIHC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg26395211	chr5:140044315	WDR55	0.41	5.98	0.31	5.53e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.94	17.53	0.69	1.51e-49	IgG glycosylation;
LIHC	cis	rs3736485	0.966	rs4775960	chr15:51891698	C/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.34	-0.32	7.32e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.6	10.32	0.49	6.32e-22	Diisocyanate-induced asthma;
LIHC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-7.03	-0.36	1.14e-11	Vitiligo;
LIHC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.72	8.48	0.42	6.69e-16	Menarche (age at onset);
LIHC	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.52	-8.67	-0.42	1.75e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	0.82	9.23	0.45	2.89e-18	Opioid sensitivity;
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.22	0.55	9.92e-29	Prudent dietary pattern;
LIHC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg00990874	chr7:1149470	C7orf50	-0.62	-8.99	-0.44	1.71e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs17106184	0.892	rs12086130	chr1:51173603	C/T	cg07174182	chr1:51127561	FAF1	-0.62	-6.85	-0.35	3.53e-11	Type 2 diabetes;
LIHC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.26e-27	Motion sickness;
LIHC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.55	-6.9	-0.35	2.48e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9309473	1.000	rs6546839	chr2:73680508	G/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.83	-0.35	3.84e-11	Metabolite levels;
LIHC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17554472	chr22:41940697	POLR3H	0.54	5.93	0.31	7.34e-9	Vitiligo;
LIHC	trans	rs11088226	0.538	rs4816436	chr21:33880251	A/G	cg09050820	chr6:167586206	TCP10L2	0.49	7.59	0.38	3.08e-13	Gastritis;
LIHC	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg26220594	chr1:19110978	NA	-0.36	-6.13	-0.31	2.49e-9	Drug-induced liver injury (nitrofurantoin);
LIHC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.82	-0.63	1.04e-38	Alzheimer's disease (late onset);
LIHC	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.63	8.14	0.4	7.46e-15	Neuroticism;
LIHC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-11.55	-0.53	2.86e-26	Platelet distribution width;
LIHC	trans	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.2	-0.36	3.85e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	7.57	0.38	3.51e-13	Obesity-related traits;
LIHC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.97	0.47	1.05e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.54	-8.97	-0.44	2.02e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.01	15.07	0.63	1.01e-39	Breast cancer;
LIHC	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.41	0.45	7.5e-19	Coffee consumption (cups per day);
LIHC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.87	11.49	0.53	4.51e-26	Heart rate;
LIHC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.53	5.78	0.3	1.68e-8	Menopause (age at onset);
LIHC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg14393609	chr7:65229607	NA	-0.37	-5.85	-0.3	1.18e-8	Aortic root size;
LIHC	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.82	11.06	0.51	1.64e-24	Menopause (age at onset);
LIHC	trans	rs4714291	0.832	rs1404002	chr6:40064600	C/T	cg02267698	chr19:7991119	CTXN1	-0.39	-6.59	-0.34	1.71e-10	Strep throat;
LIHC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.5	9.57	0.46	2.14e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg18898632	chr2:242989856	NA	-0.55	-7.5	-0.38	5.71e-13	Obesity-related traits;
LIHC	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg25251204	chr11:14927456	NA	-0.41	-5.81	-0.3	1.4e-8	Adiponectin levels;Vitamin D levels;
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12016809	chr21:47604291	C21orf56	0.49	7.55	0.38	4.03e-13	Testicular germ cell tumor;
LIHC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-6.99	-0.35	1.46e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.65	11.65	0.53	1.25e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.84	-8.2	-0.41	4.76e-15	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg06565975	chr8:143823917	SLURP1	-0.44	-8.04	-0.4	1.46e-14	Urinary tract infection frequency;
LIHC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.92	0.54	1.23e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg03342759	chr3:160939853	NMD3	0.55	6.5	0.33	2.9e-10	Morning vs. evening chronotype;
LIHC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg00142150	chr22:38071001	LGALS1	0.7	11.49	0.53	4.61e-26	Fat distribution (HIV);
LIHC	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.69	-14.38	-0.61	5.3e-37	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg07234388	chr1:156261841	TMEM79	0.49	9.03	0.44	1.32e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7116495	1.000	rs560777	chr11:71770602	C/T	cg26138937	chr11:71823887	C11orf51	0.8	7.69	0.38	1.53e-13	Severe influenza A (H1N1) infection;
LIHC	trans	rs6058796	1.000	rs13042452	chr20:31240068	T/C	cg02600331	chr11:130417168	NA	0.34	6.93	0.35	2.07e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.74	-0.34	6.91e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-11.08	-0.51	1.41e-24	Coronary artery disease;
LIHC	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg14515779	chr1:101123966	NA	0.46	6.6	0.34	1.61e-10	Monocyte count;
LIHC	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.57	-0.38	3.52e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.34	-7.38	-0.37	1.19e-12	Ulcerative colitis;
LIHC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.33	7.38	0.37	1.23e-12	Ulcerative colitis;
LIHC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	8.86	0.43	4.34e-17	Menarche (age at onset);
LIHC	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.6	9.01	0.44	1.46e-17	Recombination rate (females);
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.62	-9.17	-0.44	4.57e-18	Menarche (age at onset);
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.62	-9.05	-0.44	1.09e-17	Testicular germ cell tumor;
LIHC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.57	-6.46	-0.33	3.59e-10	Alzheimer's disease;
LIHC	trans	rs783540	0.843	rs9652567	chr15:83368514	T/G	cg18393722	chr15:85113863	UBE2QP1	0.37	6.45	0.33	3.72e-10	Schizophrenia;
LIHC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.73	11.41	0.53	9.01e-26	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg11764359	chr7:65958608	NA	0.58	5.87	0.3	1.01e-8	Diabetic kidney disease;
LIHC	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg12698662	chr3:15914712	MIR563	0.4	7.35	0.37	1.48e-12	Mean platelet volume;
LIHC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg07134254	chr20:33865797	NA	-0.53	-6.26	-0.32	1.15e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg14393609	chr7:65229607	NA	-0.38	-6.04	-0.31	4.01e-9	Aortic root size;
LIHC	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.73	-12.34	-0.56	3.42e-29	Longevity;
LIHC	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.91	-6.55	-0.33	2.07e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs965469	0.779	rs6051772	chr20:3328654	C/G	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs11112613	0.609	rs7350593	chr12:106038119	C/T	cg03607813	chr12:105948248	NA	0.44	6.9	0.35	2.51e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.82	11.65	0.53	1.17e-26	Body mass index;
LIHC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08219700	chr8:58056026	NA	0.53	6.46	0.33	3.64e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.89e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.55	6.31	0.32	8.76e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.61	10.29	0.49	7.89e-22	Alcohol dependence;
LIHC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.79	-9.6	-0.46	1.81e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs16944613	0.510	rs8030781	chr15:91143072	T/C	cg26821196	chr15:91095069	CRTC3	0.33	6.22	0.32	1.43e-9	Colorectal cancer;
LIHC	cis	rs11229555	0.645	rs7931394	chr11:58212617	T/A	cg15696309	chr11:58395628	NA	-0.65	-7.63	-0.38	2.37e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02985541	chr2:219472218	PLCD4	-0.38	-6.57	-0.33	1.83e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg03721293	chr16:90014378	DEF8	0.41	6.89	0.35	2.62e-11	Skin colour saturation;
LIHC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg01864069	chr14:103024347	NA	-0.47	-7.45	-0.37	7.91e-13	Platelet count;
LIHC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.12	-0.31	2.59e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.68	-0.34	9.41e-11	Fear of minor pain;
LIHC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.51	0.42	5.56e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.81	7.69	0.38	1.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.68	-10.92	-0.51	5.23e-24	Lung cancer;
LIHC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.71	9.13	0.44	5.97e-18	Body mass index;
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.3	0.49	7.49e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.8	-0.47	3.82e-20	Mean platelet volume;
LIHC	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg12253828	chr6:101329408	ASCC3	-0.39	-5.97	-0.31	6.04e-9	Neuroticism;
LIHC	trans	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.09	0.31	3.12e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	8.6	0.42	2.91e-16	Multiple sclerosis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01699524	chr5:7869638	MTRR;FASTKD3	-0.5	-6.03	-0.31	4.16e-9	Systolic blood pressure;
LIHC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg21724239	chr8:58056113	NA	0.46	6.08	0.31	3.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.35	-0.37	1.45e-12	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.93	-0.35	2.17e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.64	-16.58	-0.67	1.01e-45	Breast cancer;
LIHC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.31	6.73	0.34	7.28e-11	Ulcerative colitis;
LIHC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg27205649	chr11:78285834	NARS2	-0.39	-5.93	-0.31	7.3e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.51	-0.38	5.11e-13	Mean platelet volume;
LIHC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg06046430	chr4:77819534	ANKRD56	0.51	6.26	0.32	1.12e-9	Emphysema distribution in smoking;
LIHC	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.68	7.16	0.36	5.09e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.86	14.92	0.63	4.06e-39	Headache;
LIHC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-18.79	-0.71	1.34e-54	Height;
LIHC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.34	6.18	0.32	1.8e-9	Aortic root size;
LIHC	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.4	8.71	0.43	1.34e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.43	6.64	0.34	1.24e-10	Methadone dose in opioid dependence;
LIHC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.89	16.18	0.66	4.13e-44	Coronary artery disease;
LIHC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.29	-0.32	9.94e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.32	-0.55	4.18e-29	Colorectal cancer;
LIHC	cis	rs12095069	1	rs12095069	chr1:76463072	T/C	cg03433033	chr1:76189801	ACADM	0.51	7.48	0.38	6.2800000000000005e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.36	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.42	6.86	0.35	3.16e-11	Red blood cell count;
LIHC	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.85	0.39	5.53e-14	LDL cholesterol;
LIHC	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.49	7.15	0.36	5.38e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.64	-10.9	-0.51	6.13e-24	Crohn's disease;
LIHC	trans	rs975809	0.966	rs11004607	chr10:56622686	G/T	cg06521597	chr19:2783551	SGTA	0.42	6.21	0.32	1.56e-9	Carotid intima media thickness;
LIHC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg02640540	chr1:67518911	SLC35D1	0.44	5.96	0.31	6.15e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs1419980	0.730	rs7978534	chr12:7773878	C/T	cg10578777	chr12:7781093	NA	-0.39	-5.79	-0.3	1.55e-8	HDL cholesterol levels;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.66	-9.67	-0.46	1.05e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	6.43	0.33	4.19e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs16828019	0.640	rs1140227	chr1:41493811	C/T	cg03387723	chr1:41708464	SCMH1	-0.41	-6.62	-0.34	1.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg10127483	chr1:110009974	SYPL2	0.5	6.4	0.33	5.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.62	10.3	0.49	7.4e-22	Mean platelet volume;
LIHC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.7	-11.61	-0.53	1.73e-26	Age at first birth;
LIHC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.39	6.99	0.35	1.48e-11	Aortic root size;
LIHC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03517284	chr6:25882590	NA	-0.48	-7.32	-0.37	1.73e-12	Height;
LIHC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg18289306	chr13:113640169	MCF2L	0.37	6.15	0.32	2.14e-9	Systolic blood pressure;
LIHC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.37	6.74	0.34	6.67e-11	Ewing sarcoma;
LIHC	trans	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg19894588	chr14:64061835	NA	-0.65	-9.13	-0.44	6.03e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-0.8	-8.86	-0.43	4.35e-17	Alzheimer's disease (late onset);
LIHC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.67	10.64	0.5	5.13e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24838063	chr12:130822603	PIWIL1	0.65	9.2	0.45	3.5e-18	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09400194	chr10:81107848	PPIF	0.44	6.41	0.33	4.97e-10	Pancreatic cancer;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.49e-11	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23633679	chr1:173793655	CENPL;DARS2	0.49	7.41	0.37	9.91e-13	Cognitive function;
LIHC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.86	11.46	0.53	5.78e-26	Coronary artery disease;
LIHC	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.26	-6.11	-0.31	2.71e-9	Longevity;Endometriosis;
LIHC	cis	rs9522267	0.737	rs9515455	chr13:112239671	A/G	cg10483660	chr13:112241077	NA	0.24	6.07	0.31	3.36e-9	Hepatitis;
LIHC	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.69	7.21	0.36	3.66e-12	Blood protein levels;
LIHC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg02269571	chr22:50332266	NA	0.61	8.64	0.42	2.24e-16	Schizophrenia;
LIHC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.55	8.24	0.41	3.7e-15	HIV-1 control;
LIHC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.38	6.13	0.31	2.46e-9	Melanoma;
LIHC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.34	5.83	0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.19e-18	Hemoglobin concentration;
LIHC	cis	rs11229555	0.645	rs7930547	chr11:58197616	A/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.58	7.51	0.38	5.11e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.49e-9	Neuroticism;
LIHC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.62	-9.98	-0.47	9.33e-21	Obesity-related traits;
LIHC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.4	6.45	0.33	3.71e-10	Fibrinogen levels;
LIHC	cis	rs4950322	0.512	rs2883318	chr1:146849143	A/C	cg25205988	chr1:146714368	CHD1L	-0.42	-5.95	-0.31	6.66e-9	Protein quantitative trait loci;
LIHC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	1.09	12.06	0.55	3.66e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	0.81	9.25	0.45	2.56e-18	Exhaled nitric oxide output;
LIHC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.54	8.23	0.41	4e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.62	0.59	4.81e-34	Prudent dietary pattern;
LIHC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.26	15.31	0.64	1.14e-40	Psoriasis vulgaris;
LIHC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg22834771	chr12:69754056	YEATS4	-0.39	-5.84	-0.3	1.24e-8	Response to diuretic therapy;
LIHC	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg09795085	chr6:101329169	ASCC3	0.52	7.4	0.37	1.06e-12	Neuroticism;
LIHC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.54	9.33	0.45	1.39e-18	Mean corpuscular volume;
LIHC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-5.81	-0.3	1.44e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.82	13.2	0.58	1.95e-32	Colorectal cancer;
LIHC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg08992911	chr2:238395768	MLPH	0.55	6.44	0.33	4.12e-10	Prostate cancer;
LIHC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg16479474	chr6:28041457	NA	0.46	6.58	0.34	1.78e-10	Depression;
LIHC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.31	6.26	0.32	1.15e-9	Body mass index;
LIHC	cis	rs12286929	0.609	rs12417740	chr11:115098436	A/G	cg04055981	chr11:115044050	NA	-0.43	-6.29	-0.32	9.59e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.86	0.39	4.96e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04025307	chr7:1156635	C7orf50	0.54	7.3	0.37	2.02e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.56	-9.1	-0.44	7.76e-18	Longevity;Endometriosis;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09328466	chr7:64023458	ZNF680	-0.38	-6.1	-0.31	2.85e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.47	-5.94	-0.31	6.94e-9	Menarche (age at onset);
LIHC	trans	rs875971	1.000	rs778722	chr7:65844828	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.29	-5.88	-0.3	9.92e-9	Longevity;
LIHC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.32	-5.72	-0.3	2.29e-8	Headache;
LIHC	cis	rs74233809	1.000	rs11191555	chr10:104857523	A/C	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs238295	0.805	rs6038214	chr20:5569822	C/G	cg24001556	chr20:5591874	RP5-1022P6.2	0.51	7.01	0.35	1.31e-11	Occipital cortical area (total cortical area interaction);
LIHC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.35	-0.7	7.75e-53	Height;
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11987759	chr7:65425863	GUSB	0.38	5.97	0.31	5.84e-9	Aortic root size;
LIHC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg18279126	chr7:2041391	MAD1L1	0.35	5.88	0.3	9.92e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs7714584	1.000	rs11746108	chr5:150264622	C/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08081407	chr3:57583693	ARF4	0.53	7.5	0.38	5.71e-13	Lung function (FEV1/FVC);
LIHC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.73	0.57	1.22e-30	Mean platelet volume;
LIHC	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.46	-6.98	-0.35	1.55e-11	Schizophrenia;
LIHC	cis	rs2997447	0.802	rs61776621	chr1:26459058	C/G	cg19633962	chr1:26362018	EXTL1	-0.65	-5.76	-0.3	1.87e-8	QRS complex (12-leadsum);
LIHC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-1.19	-10.49	-0.49	1.66e-22	Breast cancer;
LIHC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13047869	chr3:10149882	C3orf24	0.52	6.18	0.32	1.81e-9	Alzheimer's disease;
LIHC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg10932868	chr11:921992	NA	0.39	7.25	0.37	2.71e-12	Alzheimer's disease (late onset);
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04025307	chr7:1156635	C7orf50	0.54	7.09	0.36	7.73e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg10360323	chr17:41437877	NA	0.4	5.98	0.31	5.76e-9	Menopause (age at onset);
LIHC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg17980119	chr2:219472607	PLCD4	0.36	6.19	0.32	1.72e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.49	-7.22	-0.36	3.35e-12	Obesity (extreme);
LIHC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg03013999	chr17:37608204	MED1	0.35	5.8	0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.63	-8.95	-0.44	2.28e-17	Blood metabolite levels;
LIHC	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.49	-0.33	2.93e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.6	-7.97	-0.4	2.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	6.45	0.33	3.81e-10	Ileal carcinoids;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10659575	chr11:102188233	BIRC3	0.46	7.49	0.38	6.03e-13	Cognitive function;
LIHC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03264133	chr6:25882463	NA	0.53	6.64	0.34	1.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10420951	0.579	rs79341622	chr19:18598213	T/C	cg10790698	chr19:18539756	SSBP4	-0.42	-5.99	-0.31	5.44e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg16797656	chr11:68205561	LRP5	0.59	8.18	0.4	5.52e-15	Total body bone mineral density (age 45-60);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19748516	chr19:18684528	UBA52	-0.45	-7.0	-0.35	1.34e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11673344	0.670	rs505717	chr19:37430316	A/G	cg27390819	chr19:37464633	NA	-0.5	-6.01	-0.31	4.88e-9	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg26695010	chr11:65641043	EFEMP2	0.45	6.25	0.32	1.22e-9	Eosinophil percentage of white cells;
LIHC	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.8	-0.35	4.56e-11	IgG glycosylation;
LIHC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-7.12	-0.36	6.34e-12	Vitiligo;
LIHC	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg01236616	chr12:121019343	POP5	-1.32	-17.01	-0.68	1.81e-47	Type 1 diabetes nephropathy;
LIHC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.82	12.33	0.55	3.65e-29	Motion sickness;
LIHC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.17	0.36	4.66e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.54	8.06	0.4	1.34e-14	HIV-1 control;
LIHC	cis	rs9918079	0.506	rs7696127	chr4:15642953	T/A	cg21329975	chr4:15471214	CC2D2A	-0.41	-6.19	-0.32	1.69e-9	Obesity-related traits;
LIHC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.59	5.81	0.3	1.42e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.31	6.52	0.33	2.51e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs74544699	1.000	rs938094	chr4:74805942	C/G	cg02530824	chr4:74847766	PF4	0.6	6.3	0.32	9.31e-10	Growth-regulated protein alpha levels;
LIHC	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg26138937	chr11:71823887	C11orf51	1.35	11.5	0.53	4.41e-26	Severe influenza A (H1N1) infection;
LIHC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg18912006	chr12:123335444	HIP1R	-0.63	-7.64	-0.38	2.14e-13	Schizophrenia;
LIHC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.59	7.58	0.38	3.25e-13	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.89	-18.28	-0.7	1.41e-52	Height;
LIHC	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg10756647	chr7:56101905	PSPH	1.01	11.86	0.54	2.03e-27	Gout;
LIHC	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.4	-7.01	-0.35	1.29e-11	Coronary artery disease or large artery stroke;
LIHC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.35e-16	Motion sickness;
LIHC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg25405998	chr7:65216604	CCT6P1	0.44	6.52	0.33	2.47e-10	Calcium levels;
LIHC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.19	-0.4	5.24e-15	Alzheimer's disease;
LIHC	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.91	13.79	0.6	1.02e-34	Obesity-related traits;
LIHC	cis	rs611744	0.967	rs653633	chr8:109196151	T/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	trans	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg10756647	chr7:56101905	PSPH	1.08	13.39	0.59	3.64e-33	Diabetic kidney disease;
LIHC	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.68	11.08	0.51	1.41e-24	Diisocyanate-induced asthma;
LIHC	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.41	-11.54	-0.53	2.99e-26	Hip circumference adjusted for BMI;
LIHC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg05590025	chr7:65112418	INTS4L2	0.67	7.36	0.37	1.34e-12	Diabetic kidney disease;
LIHC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	0.84	10.77	0.5	1.74e-23	Cognitive function;
LIHC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg25894440	chr7:65020034	NA	-0.55	-6.36	-0.33	6.33e-10	Diabetic kidney disease;
LIHC	cis	rs7914558	0.646	rs7909591	chr10:104659018	G/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.2	-0.36	3.87e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	7.25	0.37	2.78e-12	Systemic lupus erythematosus;
LIHC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	9.13	0.44	6.13e-18	Mean platelet volume;
LIHC	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	0.77	10.41	0.49	3.03e-22	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg14393609	chr7:65229607	NA	0.43	6.16	0.32	2.05e-9	Aortic root size;
LIHC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	trans	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg26939375	chr7:64535504	NA	0.42	6.75	0.34	6.45e-11	Aortic root size;
LIHC	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.47	-8.63	-0.42	2.41e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg19801120	chr6:53530570	KLHL31	-0.9	-6.21	-0.32	1.57e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.89	18.43	0.71	3.71e-53	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15543284	chr2:54785307	SPTBN1	0.48	7.07	0.36	8.52e-12	Lung function (FEV1/FVC);
LIHC	trans	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg12575136	chr18:32820987	ZNF397	0.48	7.2	0.36	3.8e-12	White blood cell count;
LIHC	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.33	6.4	0.33	5.01e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg19947233	chr4:90032727	TIGD2	-0.44	-6.17	-0.32	1.92e-9	Alopecia areata;
LIHC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.77	12.14	0.55	1.93e-28	Corneal astigmatism;
LIHC	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg15208524	chr1:10270712	KIF1B	0.45	6.69	0.34	8.9e-11	Hepatocellular carcinoma;
LIHC	cis	rs6442522	0.966	rs6792128	chr3:15458857	A/G	cg16303742	chr3:15540471	COLQ	0.41	6.94	0.35	1.92e-11	Uric acid levels;
LIHC	cis	rs1419980	0.730	rs11054866	chr12:7770533	T/C	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg14515779	chr1:101123966	NA	-0.57	-10.7	-0.5	3.14e-23	Monocyte count;
LIHC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg15832292	chr6:96025679	MANEA	0.54	7.08	0.36	8.22e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.42	6.42	0.33	4.49e-10	Longevity;
LIHC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.76	13.98	0.6	1.96e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg14829360	chr17:73884958	NA	-0.56	-8.24	-0.41	3.64e-15	Psoriasis;
LIHC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	14.91	0.63	4.59e-39	Menarche (age at onset);
LIHC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.47	-11.82	-0.54	2.81e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg10820045	chr2:198174542	NA	0.4	5.92	0.3	7.95e-9	Dermatomyositis;
LIHC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	11.33	0.52	1.76e-25	Monocyte percentage of white cells;
LIHC	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg16479474	chr6:28041457	NA	0.38	6.32	0.32	8.32e-10	Parkinson's disease;
LIHC	trans	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg01596870	chr19:55963115	NA	-0.6	-7.67	-0.38	1.83e-13	Obesity-related traits;
LIHC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	0.75	7.02	0.35	1.22e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.81	-0.39	6.87e-14	Capecitabine sensitivity;
LIHC	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.42	-6.48	-0.33	3.23e-10	Neutrophil percentage of white cells;
LIHC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.42	-0.37	9.58e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.04e-8	Coronary artery disease;
LIHC	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.48	7.0	0.35	1.38e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg03037974	chr15:76606532	NA	0.76	14.77	0.62	1.62e-38	Blood metabolite levels;
LIHC	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg14593290	chr7:50529359	DDC	0.64	9.98	0.47	9.69e-21	Malaria;
LIHC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06463759	chr7:128502823	ATP6V1F	0.55	7.9	0.39	3.9e-14	Lung function (FEV1/FVC);
LIHC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.2	-0.36	3.86e-12	Monocyte percentage of white cells;
LIHC	cis	rs5769765	0.624	rs138843	chr22:50183162	C/T	cg02269571	chr22:50332266	NA	-0.57	-7.6	-0.38	2.85e-13	Schizophrenia;
LIHC	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg10560079	chr2:191398806	TMEM194B	-0.69	-9.84	-0.47	2.74e-20	Diastolic blood pressure;
LIHC	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.84	10.22	0.48	1.43e-21	Mean platelet volume;
LIHC	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.32	-6.44	-0.33	4.09e-10	DNA methylation (variation);
LIHC	cis	rs10411936	0.785	rs2363120	chr19:16519871	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	-0.43	-5.92	-0.31	7.69e-9	White blood cell count;Multiple sclerosis;
LIHC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.64	-8.79	-0.43	7.59e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg07117364	chr1:16154769	NA	-0.39	-6.98	-0.35	1.52e-11	Dilated cardiomyopathy;
LIHC	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	7.26	0.37	2.7e-12	Blood protein levels;
LIHC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	0.93	17.08	0.68	1.03e-47	Menopause (age at onset);
LIHC	trans	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg19894588	chr14:64061835	NA	0.67	9.94	0.47	1.31e-20	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs4671400	0.543	rs62152274	chr2:61499588	C/A	cg14146966	chr2:61757674	XPO1	-0.37	-5.86	-0.3	1.1e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.57	-7.63	-0.38	2.28e-13	Coronary artery disease;
LIHC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg12661370	chr5:149340060	SLC26A2	0.5	5.89	0.3	9.34e-9	HIV-1 control;
LIHC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.85	12.38	0.56	2.46e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.53e-8	Breast cancer;
LIHC	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.63	0.42	2.28e-16	Lymphocyte counts;
LIHC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.77	15.18	0.63	3.75e-40	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	9.11	0.44	6.86e-18	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10352719	chr14:24769404	DHRS1;C14orf21	0.43	6.68	0.34	9.52e-11	Cognitive function;
LIHC	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.67	6.77	0.34	5.65e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.75	11.24	0.52	3.62e-25	Subjective well-being;
LIHC	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg14515779	chr1:101123966	NA	-0.68	-13.21	-0.58	1.81e-32	Monocyte count;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6442522	0.678	rs13085575	chr3:15499330	C/T	cg16303742	chr3:15540471	COLQ	0.44	7.54	0.38	4.14e-13	Uric acid levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04837231	chr1:7885239	PER3	-0.43	-6.83	-0.35	3.9e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06679563	chr19:33622563	WDR88	-0.42	-6.85	-0.35	3.5e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.76	12.92	0.57	2.3e-31	Obesity-related traits;
LIHC	cis	rs9513627	1.000	rs7321269	chr13:100126271	C/T	cg25919922	chr13:100150906	NA	-0.77	-6.94	-0.35	2.01e-11	Obesity-related traits;
LIHC	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-8.71	-0.43	1.28e-16	Blood metabolite levels;
LIHC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.59	-10.18	-0.48	1.95e-21	Alcohol dependence;
LIHC	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.61	-0.38	2.77e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.58	7.81	0.39	6.88e-14	Blood metabolite levels;
LIHC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	0.87	7.44	0.37	8e-13	Body mass index;
LIHC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.93	17.12	0.68	6.92e-48	Parkinson's disease;
LIHC	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.52	-0.33	2.5e-10	Total cholesterol levels;
LIHC	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.57	-8.76	-0.43	8.89e-17	Smoking behavior;
LIHC	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.58	7.74	0.39	1.12e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-7.72	-0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs16912285	0.688	rs1899540	chr11:24339992	A/G	ch.11.24196551F	chr11:24239977	NA	0.71	8.42	0.41	1.04e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.69	0.34	8.94e-11	Obesity-related traits;
LIHC	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.54	-8.65	-0.42	2.07e-16	Colorectal cancer;
LIHC	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.42	-0.45	6.9e-19	Schizophrenia;
LIHC	cis	rs903552	1.000	rs12908310	chr15:102003635	A/G	cg19295451	chr15:102010161	PCSK6	-0.44	-6.17	-0.32	1.97e-9	Diabetic kidney disease;
LIHC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16693872	chr5:176882643	PRR7	-0.4	-6.44	-0.33	4.02e-10	Pancreatic cancer;
LIHC	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg15123519	chr2:136567270	LCT	-0.32	-5.72	-0.3	2.29e-8	Corneal structure;
LIHC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.1	0.55	2.7e-28	Motion sickness;
LIHC	cis	rs2286503	0.809	rs4719716	chr7:22861369	G/A	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	trans	rs7927370	0.510	rs11559578	chr11:54994975	C/A	cg15704280	chr7:45808275	SEPT13	0.58	7.15	0.36	5.28e-12	Systemic lupus erythematosus;
LIHC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.98	-0.31	5.7e-9	Colorectal cancer;
LIHC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	8.25	0.41	3.5e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs246600	0.543	rs246607	chr5:142513686	C/T	cg04118306	chr8:24772350	NEFM	0.36	6.05	0.31	3.82e-9	Coronary artery disease;
LIHC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.54	-10.14	-0.48	2.68e-21	Vitamin D levels;
LIHC	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg24391279	chr8:1708526	NA	-0.35	-5.85	-0.3	1.14e-8	Systolic blood pressure;
LIHC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.48	5.78	0.3	1.64e-8	Total body bone mineral density;
LIHC	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-7.67	-0.38	1.8e-13	Longevity;
LIHC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.47	0.46	4.69e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.68	11.53	0.53	3.23e-26	Menopause (age at onset);
LIHC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg09222892	chr1:25734099	RHCE	-0.45	-8.22	-0.41	4.25e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.78	-12.74	-0.57	1.11e-30	Breast cancer;
LIHC	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg07817648	chr10:79422355	NA	-0.3	-6.16	-0.32	2.09e-9	Mortality in heart failure;
LIHC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.48	7.33	0.37	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.94	-12.61	-0.56	3.44e-30	Cognitive test performance;
LIHC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.64	0.65	5.62e-42	Breast cancer;
LIHC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.09	-0.36	7.75e-12	Personality dimensions;
LIHC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.38	-6.04	-0.31	4.13e-9	Bipolar disorder;
LIHC	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.75	0.39	1.09e-13	Systemic lupus erythematosus;
LIHC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.82	0.3	1.33e-8	Asthma;
LIHC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.3	-0.49	7.81e-22	Blood metabolite levels;
LIHC	cis	rs8064299	0.536	rs2290038	chr17:72786611	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.71	-12.16	-0.55	1.62e-28	Monocyte count;
LIHC	cis	rs2412488	0.927	rs6554105	chr4:54290677	A/C	cg22241045	chr4:54363911	LNX1	-0.43	-6.96	-0.35	1.7e-11	DNA methylation (variation);
LIHC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	6.68	0.34	9.85e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg07424592	chr7:64974309	NA	0.74	8.6	0.42	2.91e-16	Diabetic kidney disease;
LIHC	trans	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-8.26	-0.41	3.2e-15	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg05185784	chr16:90016020	DEF8	-0.44	-5.71	-0.3	2.4e-8	Skin colour saturation;
LIHC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.38	6.0	0.31	5.01e-9	Menopause (age at onset);
LIHC	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.32	-0.32	8.31e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.19	-0.32	1.7e-9	Total body bone mineral density;
LIHC	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.91	0.57	2.58e-31	Monocyte count;
LIHC	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.79	0.47	3.98e-20	Corneal astigmatism;
LIHC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	8.09	0.4	1.04e-14	Mean platelet volume;
LIHC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.84	14.53	0.62	1.36e-37	Headache;
LIHC	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg08135965	chr6:41755394	TOMM6	0.45	5.94	0.31	6.83e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs11673344	0.504	rs1667377	chr19:37491868	G/A	cg27390819	chr19:37464633	NA	-0.47	-6.15	-0.32	2.22e-9	Obesity-related traits;
LIHC	cis	rs7395581	0.879	rs3758673	chr11:47278917	C/T	cg25783544	chr11:47291846	MADD	0.45	6.66	0.34	1.06e-10	HDL cholesterol;
LIHC	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.38	5.94	0.31	6.89e-9	Lewy body disease;
LIHC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-8.03	-0.4	1.64e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.78	11.66	0.53	1.08e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg27432699	chr2:27873401	GPN1	-0.49	-7.07	-0.36	8.55e-12	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23821755	chr1:173684675	KLHL20	0.45	6.24	0.32	1.27e-9	Pancreatic cancer;
LIHC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.51	-0.38	5.04e-13	Chronic sinus infection;
LIHC	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	0.65	6.37	0.33	6.28e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.43	-0.37	8.87e-13	Psoriasis;
LIHC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.4	-5.88	-0.3	9.73e-9	Rheumatoid arthritis;
LIHC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.52	0.33	2.48e-10	Schizophrenia;
LIHC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.69	11.78	0.54	4.16e-27	Crohn's disease;
LIHC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	0.89	7.01	0.35	1.24e-11	IgG glycosylation;
LIHC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.52	8.01	0.4	1.77e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.69	-0.34	8.95e-11	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.94	0.35	2.02e-11	Renal cell carcinoma;
LIHC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.22e-11	Body mass index;
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg05423712	chr8:605100	NA	-0.47	-6.28	-0.32	1.02e-9	Neuroticism;
LIHC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.63	9.89	0.47	1.86e-20	Corneal astigmatism;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15916349	chr3:171758196	FNDC3B	0.44	6.15	0.32	2.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11396746	chr16:1877632	FAHD1;HAGH	-0.46	-6.3	-0.32	9.21e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	5.75	0.3	1.97e-8	Resting heart rate;
LIHC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-14.92	-0.63	3.92e-39	Mortality in heart failure;
LIHC	trans	rs7336933	0.866	rs4941411	chr13:42471498	T/C	cg13659026	chr2:85788631	GGCX	-0.76	-6.2	-0.32	1.63e-9	Calcium levels;
LIHC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.41	0.33	4.83e-10	Renal cell carcinoma;
LIHC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-10.33	-0.49	6.16e-22	Vitiligo;
LIHC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.74	0.34	6.72e-11	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05052194	chr1:2160249	SKI	0.53	7.37	0.37	1.28e-12	Lung function (FEV1/FVC);
LIHC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.64	-11.25	-0.52	3.33e-25	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.58	0.42	3.31e-16	Prudent dietary pattern;
LIHC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.67	8.31	0.41	2.32e-15	Gut microbiome composition (summer);
LIHC	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg27432699	chr2:27873401	GPN1	-0.54	-7.94	-0.39	2.93e-14	Total body bone mineral density;
LIHC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.89	-20.26	-0.74	1.6e-60	Height;
LIHC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.26	-0.32	1.15e-9	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.8	-0.35	4.57e-11	Aortic root size;
LIHC	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.67	-0.38	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.45	7.14	0.36	5.56e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.26	-0.37	2.61e-12	Metabolite levels (Pyroglutamine);
LIHC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.15	-0.48	2.43e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.54e-9	Alzheimer's disease;
LIHC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03169527	chr3:11888582	C3orf31	0.49	7.26	0.37	2.7e-12	Cognitive function;
LIHC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.83	0.3	1.27e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs17095355	1.000	rs13377046	chr10:111729228	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.93	-0.31	7.5e-9	Biliary atresia;
LIHC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg04315214	chr1:2043799	PRKCZ	0.43	6.61	0.34	1.47e-10	Height;
LIHC	cis	rs907683	0.559	rs4674394	chr2:220289870	C/T	cg15015639	chr2:220282977	DES	-0.36	-8.65	-0.42	2.09e-16	Resting heart rate;
LIHC	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	9.86	0.47	2.39e-20	Colorectal cancer;
LIHC	cis	rs2273156	1.000	rs12880928	chr14:35475678	A/G	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs11671005	0.735	rs11084543	chr19:58932701	T/C	cg25952890	chr19:58913133	NA	0.67	7.2	0.36	3.89e-12	Mean platelet volume;
LIHC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.15	26.68	0.82	1.39e-85	Cognitive ability;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08023809	chr12:53645616	MFSD5	0.49	6.93	0.35	2.1e-11	Lung function (FEV1/FVC);
LIHC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.51	8.27	0.41	3.05e-15	Chronic sinus infection;
LIHC	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg23254163	chr1:152506842	NA	0.23	6.08	0.31	3.14e-9	Hair morphology;
LIHC	cis	rs28530618	0.515	rs6579027	chr20:31239025	G/T	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.89	-0.3	9.06e-9	Birth weight;
LIHC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.48	-7.1	-0.36	7.38e-12	Aortic root size;
LIHC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.75	-0.3	1.94e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.89	-0.35	2.69e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02034447	chr16:89574710	SPG7	0.47	7.12	0.36	6.54e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.73	-11.46	-0.53	6.2e-26	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.89	-0.35	2.76e-11	Aortic root size;
LIHC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	1.04	15.17	0.63	4.22e-40	Breast cancer;
LIHC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	10.93	0.51	4.9e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg18809830	chr7:99032528	PTCD1	-0.81	-6.46	-0.33	3.52e-10	Blood metabolite levels;
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.25	-6.11	-0.31	2.65e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.52	8.27	0.41	3.01e-15	Age at first birth;
LIHC	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Intracranial aneurysm;
LIHC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.47	-7.22	-0.36	3.39e-12	Schizophrenia;
LIHC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.79	-0.3	1.56e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.07	0.55	3.41e-28	Motion sickness;
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.33	-0.41	1.94e-15	Obesity-related traits;
LIHC	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.59	7.25	0.37	2.76e-12	Interstitial lung disease;
LIHC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.58	7.45	0.37	7.89e-13	Morning vs. evening chronotype;
LIHC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.81	0.57	6.14e-31	Mean platelet volume;
LIHC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.92	-0.31	7.7e-9	Personality dimensions;
LIHC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11987759	chr7:65425863	GUSB	-0.38	-6.03	-0.31	4.21e-9	Aortic root size;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.5	-7.59	-0.38	3.01e-13	Menopause (age at onset);
LIHC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg09222892	chr1:25734099	RHCE	-0.45	-7.96	-0.4	2.6e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs16944613	0.510	rs7165429	chr15:91151881	C/T	cg26821196	chr15:91095069	CRTC3	0.34	6.27	0.32	1.08e-9	Colorectal cancer;
LIHC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.82	0.65	1.09e-42	Chronic sinus infection;
LIHC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg12798992	chr6:167411361	FGFR1OP	0.42	6.57	0.33	1.87e-10	Primary biliary cholangitis;
LIHC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-6.93	-0.35	2.13e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	0.8	10.63	0.5	5.36e-23	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.34	6.69	0.34	9.17e-11	Cancer;
LIHC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.66	9.39	0.45	8.81e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg06651054	chr15:83680015	C15orf40	-0.42	-6.34	-0.32	7.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.25	-5.9	-0.3	8.85e-9	Subjective well-being;
LIHC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.82	12.59	0.56	4.04e-30	Metabolic syndrome;
LIHC	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg02491457	chr7:128862824	NA	0.58	9.59	0.46	1.9e-19	White matter hyperintensity burden;
LIHC	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg12858261	chr2:113808755	IL1F8	0.34	5.86	0.3	1.1e-8	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.33	6.19	0.32	1.7e-9	Height;
LIHC	cis	rs2816062	0.813	rs2745314	chr1:18902851	T/A	cg18795169	chr1:18902165	NA	-0.79	-17.2	-0.68	3.35e-48	Urate levels in lean individuals;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.68e-17	Prudent dietary pattern;
LIHC	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg00469287	chr7:23338798	C7orf30	0.41	5.75	0.3	1.97e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17554472	chr22:41940697	POLR3H	0.55	6.33	0.32	7.79e-10	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg05865280	chr17:75406074	SEPT9	0.58	15.36	0.64	7.48e-41	Airflow obstruction;
LIHC	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.37	5.85	0.3	1.13e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.46	-0.37	7.01e-13	Lymphocyte counts;
LIHC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg09182678	chr22:50328711	NA	0.7	8.3	0.41	2.39e-15	Schizophrenia;
LIHC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.67	6.05	0.31	3.71e-9	Body mass index;
LIHC	cis	rs2632516	1.000	rs2526378	chr17:56404349	A/G	cg12560992	chr17:57184187	TRIM37	0.43	5.83	0.3	1.3e-8	Alzheimer's disease;Alzheimer's disease in APOE e4- carriers;Monocyte count;
LIHC	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.52	-6.0	-0.31	4.96e-9	Ulcerative colitis;
LIHC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.47	6.92	0.35	2.3e-11	HDL cholesterol;
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-5.71	-0.3	2.44e-8	Longevity;
LIHC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.11	-0.36	6.77e-12	Schizophrenia;
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg09417038	chr21:47716443	C21orf57	0.46	7.14	0.36	5.48e-12	Testicular germ cell tumor;
LIHC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.78	-14.15	-0.61	4.04e-36	Platelet count;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg09126038	chr10:8056860	NA	0.38	6.51	0.33	2.74e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-0.85	-9.58	-0.46	2.07e-19	Magnesium levels;
LIHC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17467752	chr17:38218738	THRA	-0.42	-6.94	-0.35	1.98e-11	Asthma and hay fever;
LIHC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.88	14.01	0.6	1.47e-35	Metabolic syndrome;
LIHC	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.55	-0.33	2.12e-10	Body mass index;
LIHC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg10621924	chr7:39171070	POU6F2	-0.41	-6.35	-0.32	6.84e-10	IgG glycosylation;
LIHC	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	7.08	0.36	8.08e-12	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.52	0.33	2.59e-10	Renal cell carcinoma;
LIHC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	6.58	0.34	1.79e-10	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08496016	chr9:99181722	ZNF367	0.41	6.26	0.32	1.17e-9	Pancreatic cancer;
LIHC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.52	7.58	0.38	3.19e-13	Longevity;Endometriosis;
LIHC	cis	rs76533333	0.564	rs7331609	chr13:113420339	C/T	cg08557188	chr13:113420371	ATP11A	-0.77	-5.83	-0.3	1.32e-8	Red cell distribution width;
LIHC	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.78	-14.99	-0.63	2.15e-39	Longevity;
LIHC	cis	rs838721	0.574	rs11676156	chr2:234259001	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	5.88	0.3	9.84e-9	Total body bone mineral density;
LIHC	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.42	6.13	0.31	2.37e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.38	9.51	0.46	3.45e-19	Cutaneous nevi;
LIHC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.21	-0.41	4.67e-15	Gut microbiome composition (summer);
LIHC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg05343316	chr1:45956843	TESK2	0.45	6.66	0.34	1.13e-10	High light scatter reticulocyte count;
LIHC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.53	-8.42	-0.41	1.06e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.75	-9.95	-0.47	1.14e-20	Schizophrenia;
LIHC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg20283391	chr11:68216788	NA	-0.37	-5.94	-0.31	7.17e-9	Total body bone mineral density;
LIHC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20135002	chr11:47629003	NA	-0.52	-8.73	-0.43	1.15e-16	Subjective well-being;
LIHC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.47	-5.73	-0.3	2.2e-8	Parkinson's disease;
LIHC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg25894440	chr7:65020034	NA	-0.54	-6.13	-0.31	2.46e-9	Diabetic kidney disease;
LIHC	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	6.13	0.31	2.36e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.74	-8.06	-0.4	1.31e-14	Vitiligo;
LIHC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.81	-0.3	1.4e-8	Colorectal cancer;
LIHC	cis	rs1355223	0.902	rs11605785	chr11:34751387	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.55	-0.33	2.09e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs151997	0.630	rs26064	chr5:50217806	T/C	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.43	-6.77	-0.34	5.62e-11	Iron status biomarkers;
LIHC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.94e-9	Body mass index;
LIHC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	9.37	0.45	1e-18	Platelet count;
LIHC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.42	7.23	0.36	3.23e-12	Platelet distribution width;
LIHC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.52	-6.97	-0.35	1.61e-11	Blood metabolite levels;
LIHC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.91	16.91	0.67	4.67e-47	Aortic root size;
LIHC	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.47	8.66	0.42	1.89e-16	Sense of smell;
LIHC	cis	rs10916814	0.546	rs1890006	chr1:20898841	G/T	cg24502330	chr1:20914028	CDA	-0.3	-6.7	-0.34	8.63e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg00656387	chr3:40428638	ENTPD3	0.4	6.56	0.33	2.01e-10	Renal cell carcinoma;
LIHC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.35	8.88	0.43	3.78e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg01843034	chr6:37503916	NA	0.4	6.56	0.33	2e-10	Cognitive performance;
LIHC	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.69	9.29	0.45	1.81e-18	Body mass index;
LIHC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg12310025	chr6:25882481	NA	-0.42	-6.34	-0.32	7.32e-10	Height;
LIHC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.4	-6.23	-0.32	1.37e-9	Educational attainment;
LIHC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-13.93	-0.6	2.98e-35	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.93	0.35	2.16e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.51	6.29	0.32	9.56e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.89	0.3	9.45e-9	Body mass index;
LIHC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.5	7.38	0.37	1.23e-12	Total body bone mineral density;
LIHC	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.58	0.5	8.3300000000000006e-23	Colorectal cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03904586	chr7:559740	PDGFA	0.42	6.08	0.31	3.19e-9	Lung function (FEV1/FVC);
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.52	7.64	0.38	2.23e-13	Longevity;
LIHC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.72	0.39	1.33e-13	Obesity-related traits;
LIHC	cis	rs2033908	0.588	rs1899068	chr11:12872156	A/T	cg25843174	chr11:12811716	TEAD1	0.32	7.52	0.38	5e-13	Sitting height ratio;
LIHC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg05590025	chr7:65112418	INTS4L2	-0.58	-5.89	-0.3	9.23e-9	Diabetic kidney disease;
LIHC	trans	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg10208301	chr11:6592745	DNHD1	0.45	6.45	0.33	3.73e-10	Coronary artery calcification;
LIHC	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.59	9.63	0.46	1.44e-19	Corneal astigmatism;
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.69	-12.76	-0.57	9.53e-31	Breast cancer;
LIHC	cis	rs10838687	0.736	rs16938581	chr11:47271039	G/A	cg25783544	chr11:47291846	MADD	0.46	5.84	0.3	1.2e-8	Proinsulin levels;
LIHC	cis	rs6449957	0.832	rs11742365	chr5:67470244	C/G	cg23036683	chr5:67512108	NA	0.47	6.6	0.34	1.53e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.28	0.58	9.81e-33	Cognitive test performance;
LIHC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs10411936	0.962	rs2607278	chr19:16568197	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	-0.43	-5.8	-0.3	1.5e-8	White blood cell count;Multiple sclerosis;
LIHC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.45	6.37	0.33	6.18e-10	Aortic root size;
LIHC	cis	rs3018712	0.532	rs28551086	chr11:68400739	G/A	cg16797656	chr11:68205561	LRP5	0.48	6.03	0.31	4.31e-9	Total body bone mineral density;
LIHC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.49	-6.01	-0.31	4.67e-9	Alzheimer's disease;
LIHC	cis	rs67981189	0.593	rs2877714	chr14:71568215	G/T	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg11057378	chr10:81107060	PPIF	0.37	6.01	0.31	4.75e-9	Height;
LIHC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.24	-0.52	3.79e-25	Response to antipsychotic treatment;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-7.5	-0.38	5.62e-13	Lymphocyte counts;
LIHC	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.37	7.04	0.36	1.04e-11	Testicular germ cell tumor;
LIHC	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg15664640	chr17:80829946	TBCD	0.46	7.54	0.38	4.31e-13	Breast cancer;
LIHC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	1.2	14.83	0.63	8.74e-39	Eosinophil percentage of granulocytes;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg09948192	chr4:7069943	GRPEL1	0.43	6.04	0.31	4e-9	Alopecia areata;
LIHC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.67	6.57	0.33	1.88e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.43	-8.53	-0.42	4.8e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.5	-5.74	-0.3	2.13e-8	Corneal curvature;
LIHC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg22834771	chr12:69754056	YEATS4	-0.39	-5.91	-0.3	8.46e-9	Response to diuretic therapy;
LIHC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.54e-9	Aortic root size;
LIHC	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg01320579	chr17:75405842	SEPT9	0.55	7.33	0.37	1.71e-12	Airflow obstruction;
LIHC	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.07	-0.31	3.42e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.06	-0.36	9.24e-12	Inflammatory bowel disease;
LIHC	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.61	5.72	0.3	2.36e-8	Migraine;Coronary artery disease;
LIHC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.71	-11.96	-0.54	8.52e-28	Body mass index;
LIHC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg07959070	chr22:50026188	C22orf34	-0.32	-8.44	-0.42	8.89e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg22951263	chr5:87985283	NA	-0.41	-7.09	-0.36	7.72e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.91	0.35	2.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs12086130	0.881	rs77603669	chr1:51423779	G/T	cg07174182	chr1:51127561	FAF1	-0.72	-7.52	-0.38	4.76e-13	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.92	18.77	0.71	1.58e-54	Bone mineral density;
LIHC	cis	rs11673344	0.864	rs703535	chr19:37505740	A/G	cg27390819	chr19:37464633	NA	-0.52	-6.38	-0.33	5.73e-10	Obesity-related traits;
LIHC	cis	rs9309473	0.950	rs6705977	chr2:73849170	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.56	-0.33	1.95e-10	Metabolite levels;
LIHC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.11	28.78	0.84	2.24e-93	IgG glycosylation;
LIHC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.81	17.77	0.69	1.64e-50	Gestational age at birth (maternal effect);
LIHC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-9.33	-0.45	1.35e-18	Mean corpuscular volume;
LIHC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg24296786	chr1:45957014	TESK2	-0.49	-7.17	-0.36	4.75e-12	Platelet count;
LIHC	cis	rs988712	0.672	rs12419948	chr11:27666984	T/A	cg18117895	chr11:27722066	BDNF	0.49	6.85	0.35	3.45e-11	Obesity;
LIHC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.69e-11	IgG glycosylation;
LIHC	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma (childhood onset);
LIHC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.3	-6.94	-0.35	1.97e-11	Menarche (age at onset);
LIHC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-8.18	-0.4	5.72e-15	Sudden cardiac arrest;
LIHC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg14580859	chr9:123691850	NA	0.39	6.85	0.35	3.45e-11	Rheumatoid arthritis;
LIHC	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.6	-9.74	-0.47	6.21e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg05760424	chr2:242988095	NA	-0.5	-6.67	-0.34	1.03e-10	Obesity-related traits;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg07341007	chr3:195489909	MUC4	-0.45	-7.83	-0.39	6.12e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.58	6.44	0.33	4.09e-10	Neutrophil percentage of white cells;
LIHC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.26	0.68	1.78e-48	Smoking behavior;
LIHC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg18944383	chr4:111397179	ENPEP	0.25	6.22	0.32	1.43e-9	Height;
LIHC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg09222892	chr1:25734099	RHCE	-0.48	-8.9	-0.43	3.41e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.69	10.19	0.48	1.74e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg10299061	chr3:53078990	SFMBT1	-0.4	-6.04	-0.31	3.93e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.43	0.33	4.28e-10	Aortic root size;
LIHC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg06634786	chr22:41940651	POLR3H	-0.53	-6.26	-0.32	1.17e-9	Neuroticism;
LIHC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.46	7.08	0.36	8.47e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.56	7.89	0.39	4.17e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21313137	chr20:44462302	SNX21	0.66	8.93	0.43	2.66e-17	Lung function (FEV1/FVC);
LIHC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg03859395	chr2:55845619	SMEK2	-0.82	-14.54	-0.62	1.23e-37	Metabolic syndrome;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.76	0.54	4.68e-27	Height;
LIHC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg25344623	chr2:136566232	LCT	0.38	7.29	0.37	2.21e-12	Mosquito bite size;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.48	0.56	1.05e-29	Prudent dietary pattern;
LIHC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.54	7.13	0.36	5.97e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.6	-0.34	1.58e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg25039879	chr17:56429692	SUPT4H1	0.76	8.75	0.43	1.02e-16	Cognitive test performance;
LIHC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.66	6.03	0.31	4.31e-9	Inflammatory bowel disease;
LIHC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1144333	0.850	rs1251274	chr1:76288587	T/C	cg03433033	chr1:76189801	ACADM	-0.56	-8.49	-0.42	6.24e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.49	9.36	0.45	1.11e-18	Atrioventricular conduction;
LIHC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.91	-0.51	5.6e-24	Hemoglobin concentration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02998992	chr17:19265610	B9D1	0.44	6.28	0.32	1.03e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.97	-16.61	-0.67	7.62e-46	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg27494647	chr7:150038898	RARRES2	0.32	5.83	0.3	1.26e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.59	-9.69	-0.46	8.69e-20	Inflammatory bowel disease;
LIHC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02398342	chr17:80708632	TBCD;FN3K	-0.41	-6.31	-0.32	8.63e-10	Glycated hemoglobin levels;
LIHC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.48	8.48	0.42	6.69e-16	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17024643	chr1:214725274	PTPN14	0.42	6.36	0.33	6.36e-10	Lung function (FEV1/FVC);
LIHC	cis	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg20368463	chr18:77673604	PQLC1	-0.37	-6.44	-0.33	4.15e-10	Schizophrenia;
LIHC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.35	-8.81	-0.43	6.62e-17	Asthma (sex interaction);
LIHC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg01557791	chr16:72042693	DHODH	-0.45	-7.52	-0.38	4.95e-13	Fibrinogen levels;
LIHC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.22	0.36	3.31e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-11.55	-0.53	2.75e-26	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07089834	chr17:79239572	SLC38A10	0.42	6.22	0.32	1.41e-9	Longevity;
LIHC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.92	13.04	0.58	7.93e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	7.99	0.4	2.04e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg13385521	chr17:29058706	SUZ12P	-0.8	-8.34	-0.41	1.83e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.95	0.39	2.81e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.86	-14.65	-0.62	4.49e-38	Oral cavity cancer;
LIHC	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.64	11.19	0.52	5.6e-25	Response to bleomycin (chromatid breaks);
LIHC	cis	rs2257205	0.667	rs7207254	chr17:56912572	C/T	cg12560992	chr17:57184187	TRIM37	0.6	5.88	0.3	9.65e-9	Pancreatic cancer;
LIHC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.37	5.9	0.3	8.53e-9	Resting heart rate;
LIHC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.98	-18.67	-0.71	3.85e-54	Breast cancer;
LIHC	cis	rs2108622	0.701	rs118144071	chr19:15979194	A/G	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.17	-0.32	1.91e-9	Schizophrenia;
LIHC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg25344623	chr2:136566232	LCT	0.32	6.13	0.31	2.39e-9	Mosquito bite size;
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.38	-7.47	-0.37	6.77e-13	Renal cell carcinoma;
LIHC	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-8.25	-0.41	3.5e-15	Hepatocellular carcinoma;
LIHC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg15534755	chr11:117069859	TAGLN	0.4	6.75	0.34	6.43e-11	Blood protein levels;
LIHC	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.66	8.15	0.4	7.18e-15	Crohn's disease;
LIHC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg03013999	chr17:37608204	MED1	0.36	6.03	0.31	4.18e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.73	-0.39	1.24e-13	Total body bone mineral density;
LIHC	trans	rs800082	1.000	rs9849975	chr3:144294530	A/G	cg24215973	chr2:240111563	HDAC4	-0.42	-6.12	-0.31	2.56e-9	Smoking behavior;
LIHC	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg20991723	chr1:152506922	NA	0.54	9.49	0.46	4.07e-19	Hair morphology;
LIHC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-0.96	-21.95	-0.76	2.89e-67	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg13535736	chr9:111863775	C9orf5	-0.4	-6.0	-0.31	4.89e-9	Menarche (age at onset);
LIHC	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.43	-0.37	9.04e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.77	11.72	0.54	6.72e-27	Breast cancer;
LIHC	cis	rs7639513	0.520	rs4684111	chr3:12729485	T/G	cg23032965	chr3:12705835	RAF1	0.56	6.08	0.31	3.3e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.38	6.07	0.31	3.39e-9	Melanoma;
LIHC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.52	8.59	0.42	3.05e-16	Colorectal cancer;
LIHC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg19302996	chr17:73780495	UNK	-0.54	-6.72	-0.34	7.78e-11	Psoriasis;
LIHC	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg13919466	chr1:32135498	COL16A1	-0.31	-6.0	-0.31	4.92e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs965469	0.779	rs2236114	chr20:3296040	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	trans	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.55	0.59	9.11e-34	Diabetic kidney disease;
LIHC	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg10587741	chr22:38071170	LGALS1	0.68	9.51	0.46	3.59e-19	Fat distribution (HIV);
LIHC	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.5	7.46	0.37	7.1e-13	Blood protein levels;
LIHC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	1.03	15.42	0.64	4.12e-41	Breast cancer;
LIHC	cis	rs477895	0.941	rs12808002	chr11:64110932	C/T	cg04317338	chr11:64019027	PLCB3	0.84	7.6	0.38	2.82e-13	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.78	-12.06	-0.55	3.85e-28	Motion sickness;
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08280861	chr8:58055591	NA	0.54	6.1	0.31	2.9e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs2274273	0.905	rs8007614	chr14:55586575	A/G	cg01864836	chr14:55583639	NA	-0.39	-7.45	-0.37	7.89e-13	Protein biomarker;
LIHC	trans	rs12753920	0.683	rs4658128	chr1:92574745	G/A	cg15668468	chr10:118892869	VAX1	0.44	6.18	0.32	1.79e-9	Systemic lupus erythematosus;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01110552	chr10:103578627	MGEA5	0.4	6.68	0.34	9.48e-11	Cognitive function;
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06656553	chr16:89960601	TCF25	-0.46	-5.86	-0.3	1.08e-8	Skin colour saturation;
LIHC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg25344623	chr2:136566232	LCT	-0.4	-8.05	-0.4	1.34e-14	Mosquito bite size;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.67	11.66	0.53	1.1e-26	Longevity;Endometriosis;
LIHC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-12.96	-0.57	1.63e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg27478167	chr7:817139	HEATR2	-0.42	-5.96	-0.31	6.25e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.57	10.4	0.49	3.53e-22	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs8064024	0.557	rs7193783	chr16:4949608	A/C	cg08329684	chr16:4932620	PPL	-0.38	-6.59	-0.34	1.69e-10	Cancer;
LIHC	cis	rs7937890	0.535	rs2575857	chr11:14501296	C/T	cg02886208	chr11:14281011	SPON1	-0.44	-6.15	-0.32	2.17e-9	Mitochondrial DNA levels;
LIHC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.82	10.14	0.48	2.72e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg03264133	chr6:25882463	NA	-0.42	-6.26	-0.32	1.18e-9	Height;
LIHC	cis	rs4671458	0.762	rs12464471	chr2:63686428	A/G	cg17519650	chr2:63277830	OTX1	-0.55	-6.33	-0.32	7.76e-10	Subjective well-being;
LIHC	trans	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg10756647	chr7:56101905	PSPH	1.1	13.34	0.59	5.59e-33	Diabetic kidney disease;
LIHC	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.48	-7.87	-0.39	4.69e-14	Menopause (age at onset);
LIHC	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02985541	chr2:219472218	PLCD4	-0.36	-6.36	-0.33	6.34e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.8	-0.35	4.57e-11	Aortic root size;
LIHC	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg12374095	chr12:54320830	NA	0.44	6.36	0.33	6.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	trans	rs3176789	0.647	rs9971740	chr12:9921527	C/T	cg18988856	chr7:99425577	CYP3A43	0.19	6.16	0.32	2.05e-9	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LIHC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22442454	chr1:209979470	IRF6	0.39	5.92	0.3	7.76e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.65	6.88	0.35	2.89e-11	Type 2 diabetes;
LIHC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.1	20.95	0.75	2.8e-63	Multiple system atrophy;
LIHC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-0.71	-7.56	-0.38	3.63e-13	Putamen volume;
LIHC	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.72	-13.46	-0.59	1.89e-33	Mortality in heart failure;
LIHC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg03264133	chr6:25882463	NA	-0.38	-5.72	-0.3	2.36e-8	Height;
LIHC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.4	-6.38	-0.33	5.61e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg18944383	chr4:111397179	ENPEP	-0.25	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs963731	0.649	rs6544191	chr2:39266384	C/T	cg04010122	chr2:39346883	SOS1	-0.75	-6.29	-0.32	9.91e-10	Corticobasal degeneration;
LIHC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.91	16.91	0.67	4.58e-47	Aortic root size;
LIHC	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01174859	chr7:128379317	CALU	-0.44	-6.39	-0.33	5.47e-10	Pancreatic cancer;
LIHC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg26116260	chr4:7069785	GRPEL1	0.43	6.9	0.35	2.52e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg13446199	chr8:143762866	PSCA	-0.2	-5.78	-0.3	1.71e-8	Urinary tract infection frequency;
LIHC	cis	rs10503871	0.594	rs10954994	chr8:30306419	C/A	cg26383811	chr8:30366931	RBPMS	0.4	6.9	0.35	2.61e-11	Metabolite levels  (X-11787);
LIHC	cis	rs35883536	1.000	rs2065784	chr1:101096056	A/G	cg14515779	chr1:101123966	NA	0.64	12.16	0.55	1.65e-28	Monocyte count;
LIHC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg16584290	chr5:462447	EXOC3	0.36	5.71	0.3	2.45e-8	Cystic fibrosis severity;
LIHC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	10.93	0.51	4.65e-24	Platelet count;
LIHC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.8	-12.69	-0.57	1.65e-30	Coronary artery disease;
LIHC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-8.98	-0.44	1.87e-17	Body mass index;
LIHC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.35	6.45	0.33	3.86e-10	Aortic root size;
LIHC	cis	rs7703744	0.639	rs1396609	chr5:118685885	A/G	cg04195774	chr5:118677172	TNFAIP8	-0.41	-5.97	-0.31	5.79e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.99	0.31	5.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17152411	1.000	rs733401	chr10:126594158	A/T	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.33e-12	Height;
LIHC	cis	rs9473924	0.542	rs9473954	chr6:50928547	G/A	cg14470998	chr6:50812995	TFAP2B	0.86	7.83	0.39	6.39e-14	Body mass index;
LIHC	trans	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg17712092	chr4:129076599	LARP1B	0.57	6.17	0.32	1.9e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	7.29	0.37	2.15e-12	Osteoporosis;
LIHC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.52	-9.23	-0.45	2.82e-18	Blood protein levels;
LIHC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg01652190	chr22:50026171	C22orf34	-0.29	-6.32	-0.32	8.06e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.69	-0.34	9.25e-11	Schizophrenia;
LIHC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24229701	chr12:130821962	PIWIL1	0.43	6.14	0.32	2.26e-9	Menopause (age at onset);
LIHC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.76	10.02	0.48	6.72e-21	Selective IgA deficiency;
LIHC	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg26138937	chr11:71823887	C11orf51	-1.32	-10.43	-0.49	2.71e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.83e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs249954	0.512	rs249867	chr16:23668568	G/A	cg01460202	chr16:23706506	ERN2	0.36	5.97	0.31	5.9e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12016809	chr21:47604291	C21orf56	0.41	6.09	0.31	3e-9	Testicular germ cell tumor;
LIHC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.87	11.42	0.53	8.52e-26	Dilated cardiomyopathy;
LIHC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.78	-14.05	-0.6	1.03e-35	Refractive error;
LIHC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.56	-9.97	-0.47	1.04e-20	Schizophrenia;
LIHC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.85	15.07	0.63	1.06e-39	Dental caries;
LIHC	cis	rs864643	1.000	rs1768267	chr3:39560436	T/A	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.23	0.45	2.97e-18	IgG glycosylation;
LIHC	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.49	7.19	0.36	3.98e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.25	5.96	0.31	6.39e-9	Crohn's disease;
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.58	0.38	3.25e-13	Height;
LIHC	cis	rs4908760	0.731	rs12075458	chr1:8758794	C/A	cg20416874	chr1:8611966	RERE	-0.63	-11.97	-0.54	8.48e-28	Vitiligo;
LIHC	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.46	-7.11	-0.36	6.73e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9596863	0.898	rs9568919	chr13:54352229	T/G	ch.13.53330881F	chr13:54432880	NA	0.45	6.04	0.31	3.93e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.55	8.78	0.43	7.98e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs57502260	0.915	rs75202638	chr11:68210421	C/T	cg20283391	chr11:68216788	NA	-0.47	-5.8	-0.3	1.55e-8	Total body bone mineral density (age 45-60);
LIHC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg17135325	chr3:160939158	NMD3	0.54	7.76	0.39	1.01e-13	Parkinson's disease;
LIHC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs9940464	0.933	rs13333697	chr16:83367411	C/T	cg13016115	chr14:23388406	RBM23	0.38	6.15	0.32	2.21e-9	Malaria;
LIHC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-6.57	-0.33	1.91e-10	Menarche (age at onset);
LIHC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.8	-12.0	-0.54	6.26e-28	Coronary artery disease;
LIHC	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg25783544	chr11:47291846	MADD	0.44	6.33	0.32	7.7e-10	HDL cholesterol;
LIHC	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.59	9.51	0.46	3.56e-19	Neutrophil percentage of white cells;
LIHC	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.64	10.44	0.49	2.5e-22	Inflammatory bowel disease;
LIHC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17507749	chr15:85114479	UBE2QP1	0.63	7.3	0.37	2e-12	Schizophrenia;
LIHC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.97	-0.35	1.65e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg24130564	chr14:104152367	KLC1	-0.54	-9.03	-0.44	1.29e-17	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.94	16.78	0.67	1.6e-46	Breast cancer;
LIHC	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg27523141	chr10:43048294	ZNF37B	0.37	6.36	0.33	6.61e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7091068	0.507	rs913046	chr10:95408484	A/C	cg20715218	chr10:95462985	C10orf4	0.55	8.9	0.43	3.26e-17	Urinary tract infection frequency;
LIHC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.49	-7.61	-0.38	2.71e-13	Diastolic blood pressure;
LIHC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.19	-0.36	4.17e-12	Bipolar disorder;
LIHC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg16479474	chr6:28041457	NA	0.38	6.24	0.32	1.29e-9	Parkinson's disease;
LIHC	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg24130564	chr14:104152367	KLC1	-0.56	-9.02	-0.44	1.42e-17	Reticulocyte count;
LIHC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg26149184	chr10:133730230	NA	0.47	7.49	0.38	5.75e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	6.93	0.35	2.06e-11	Exhaled nitric oxide output;
LIHC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.04	-0.36	1.09e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01714823	chr3:195269708	PPP1R2	0.53	6.2	0.32	1.62e-9	Hepatitis;
LIHC	trans	rs13113518	0.812	rs4864996	chr4:56319088	A/C	cg15358633	chr12:38710606	ALG10B	0.44	6.34	0.32	7.47e-10	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07560662	chr1:117113232	CD58	0.47	6.48	0.33	3.14e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19671926	chr4:122722719	EXOSC9	-0.45	-6.66	-0.34	1.07e-10	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg03013999	chr17:37608204	MED1	-0.36	-5.95	-0.31	6.7e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg00280220	chr17:61926910	NA	0.42	6.74	0.34	6.67e-11	Prudent dietary pattern;
LIHC	cis	rs6793245	0.810	rs9843500	chr3:38588095	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.51	-7.48	-0.37	6.46e-13	QT interval;
LIHC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.67	-11.62	-0.53	1.57e-26	Platelet distribution width;
LIHC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.58e-9	Childhood ear infection;
LIHC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.61	-0.34	1.52e-10	Diabetic kidney disease;
LIHC	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.79	15.12	0.63	6.73e-40	Testicular germ cell tumor;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22786486	chr22:20073528	MIR1306;DGCR8	0.42	6.08	0.31	3.3e-9	Lung function (FEV1);
LIHC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.92	-12.17	-0.55	1.51e-28	Schizophrenia;
LIHC	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.59	9.1	0.44	7.4e-18	White matter hyperintensity burden;
LIHC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.74	13.69	0.59	2.63e-34	Height;
LIHC	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg18367735	chr17:79674897	NA	0.72	6.82	0.35	4.2e-11	Dental caries;
LIHC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	11.87	0.54	1.92e-27	Lung cancer in ever smokers;
LIHC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg25828445	chr12:7781288	NA	-0.42	-6.53	-0.33	2.4e-10	HDL cholesterol levels;
LIHC	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.26	-6.24	-0.32	1.26e-9	Heart rate;
LIHC	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.89	13.34	0.59	5.48e-33	Obesity-related traits;
LIHC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg03037974	chr15:76606532	NA	0.74	14.58	0.62	8.64e-38	Blood metabolite levels;
LIHC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.88	0.39	4.27e-14	Lung disease severity in cystic fibrosis;
LIHC	trans	rs7120489	0.655	rs7940867	chr11:12445264	T/C	cg08537300	chr5:179058959	NA	0.58	6.31	0.32	8.59e-10	Mortality in heart failure;
LIHC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg14228332	chr4:119757509	SEC24D	0.67	6.45	0.33	3.8e-10	Cannabis dependence symptom count;
LIHC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.88	-16.75	-0.67	2e-46	Coronary artery disease;
LIHC	cis	rs11671005	0.735	rs12981649	chr19:58930043	G/C	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs1355223	0.902	rs4465347	chr11:34727333	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.43	-0.33	4.36e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg00656387	chr3:40428638	ENTPD3	0.39	6.03	0.31	4.26e-9	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21565415	chr11:618993	MUPCDH	0.39	6.36	0.33	6.34e-10	Cognitive function;
LIHC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg00101154	chr16:420108	MRPL28	-0.42	-6.4	-0.33	5.18e-10	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10932289	chr17:55038442	COIL	-0.48	-6.83	-0.35	3.94e-11	Pancreatic cancer;
LIHC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.55	5.71	0.3	2.44e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg22974920	chr21:40686053	BRWD1	-0.4	-5.85	-0.3	1.13e-8	Cognitive function;
LIHC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.61	0.46	1.6e-19	Platelet count;
LIHC	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.82	-0.3	1.35e-8	Total body bone mineral density (age 45-60);
LIHC	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.24	13.36	0.59	4.6e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.0	0.31	5.09e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-8.1	-0.4	9.94e-15	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07907917	chr19:40949191	SERTAD3	0.41	6.19	0.32	1.71e-9	Pancreatic cancer;
LIHC	cis	rs7688540	0.723	rs17521834	chr4:225449	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.26	-5.82	-0.3	1.38e-8	Facial morphology (factor 6, height of vermillion lower lip);
LIHC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.05	-0.31	3.7e-9	Tonsillectomy;
LIHC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.3	-5.89	-0.3	9.21e-9	Colorectal cancer;
LIHC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.78	-0.3	1.73e-8	Body mass index;
LIHC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02985541	chr2:219472218	PLCD4	0.42	6.91	0.35	2.38e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs62458065	1.000	rs10250808	chr7:32466153	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.65	-7.37	-0.37	1.3e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg21252483	chr19:49399788	TULP2	-0.78	-9.73	-0.47	6.48e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.39	0.33	5.46e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.47	7.85	0.39	5.27e-14	Menopause (age at onset);
LIHC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	5.77	0.3	1.82e-8	Coronary artery disease;
LIHC	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.69	9.42	0.45	6.73e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg05973401	chr12:123451056	ABCB9	0.51	8.11	0.4	9.26e-15	Platelet count;
LIHC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.23	0.41	4.04e-15	Motion sickness;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.8	0.57	6.46e-31	Prudent dietary pattern;
LIHC	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.53	-6.24	-0.32	1.32e-9	Ulcerative colitis;
LIHC	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg03037974	chr15:76606532	NA	0.54	8.81	0.43	6.58e-17	Blood metabolite levels;
LIHC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg16479474	chr6:28041457	NA	0.47	7.15	0.36	5.3e-12	Parkinson's disease;
LIHC	cis	rs11958404	0.615	rs7703242	chr5:157447920	T/C	cg05962755	chr5:157440814	NA	0.59	7.83	0.39	6.15e-14	IgG glycosylation;
LIHC	cis	rs11031096	0.678	rs1442727	chr11:4188188	G/T	cg18678763	chr11:4115507	RRM1	0.39	5.79	0.3	1.56e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.47	-7.1	-0.36	7.19e-12	Adiposity;
LIHC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg23262073	chr20:60523788	NA	-0.29	-5.93	-0.31	7.44e-9	Body mass index;
LIHC	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.67	6.64	0.34	1.26e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.4	0.37	1.07e-12	Diastolic blood pressure;
LIHC	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.34	-7.08	-0.36	8.14e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LIHC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.07	-0.44	9.45e-18	Bipolar disorder;
LIHC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-9.8	-0.47	3.86e-20	Alzheimer's disease;
LIHC	cis	rs4788570	0.566	rs16972808	chr16:71478717	A/G	cg06353428	chr16:71660113	MARVELD3	-0.99	-9.14	-0.44	5.79e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.45	6.91	0.35	2.36e-11	Metabolite levels (Pyroglutamine);
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg03524611	chr8:27631853	ESCO2	-0.58	-6.12	-0.31	2.56e-9	Obesity-related traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03031660	chr17:73257791	MRPS7;GGA3	-0.46	-6.08	-0.31	3.21e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.74	13.3	0.58	8.41e-33	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.55	-9.11	-0.44	7.01e-18	Cognitive function;
LIHC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.42	5.89	0.3	9.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.46	-8.73	-0.43	1.14e-16	Testicular germ cell tumor;
LIHC	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	0.98	15.49	0.64	2.24e-41	Corneal structure;
LIHC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg25039879	chr17:56429692	SUPT4H1	0.75	8.46	0.42	7.96e-16	Cognitive test performance;
LIHC	cis	rs11673344	0.704	rs1667384	chr19:37416754	C/T	cg27390819	chr19:37464633	NA	-0.5	-6.01	-0.31	4.69e-9	Obesity-related traits;
LIHC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.46	-5.79	-0.3	1.56e-8	Renal function-related traits (BUN);
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18000306	chr6:288505	NA	0.34	6.37	0.33	6.22e-10	Menopause (age at onset);
LIHC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.75	7.44	0.37	8.47e-13	Diabetic retinopathy;
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.05	-0.31	3.78e-9	Total body bone mineral density;
LIHC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.69	8.07	0.4	1.19e-14	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg01596870	chr19:55963115	NA	-0.61	-7.07	-0.36	8.6e-12	Obesity-related traits;
LIHC	cis	rs11671005	0.735	rs11668789	chr19:58928309	C/T	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs623264	0.920	rs676382	chr19:5469107	C/T	cg03088458	chr19:5478473	NA	-0.36	-6.23	-0.32	1.34e-9	Interleukin-2 receptor antagonist levels;
LIHC	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg14146966	chr2:61757674	XPO1	0.48	8.52	0.42	5.13e-16	Tuberculosis;
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg00204748	chr12:29376779	FAR2	0.43	8.01	0.4	1.83e-14	QT interval;
LIHC	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.42	7.8	0.39	7.64e-14	Height;
LIHC	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-0.79	-8.65	-0.42	1.96e-16	Exhaled nitric oxide output;
LIHC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg20684491	chr1:25596433	NA	0.29	5.89	0.3	9.04e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.31	-0.52	2.11e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.58	9.91	0.47	1.63e-20	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03060925	chr19:41256330	C19orf54;SNRPA	0.45	6.09	0.31	2.96e-9	Pancreatic cancer;
LIHC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.44	6.49	0.33	3.06e-10	Methadone dose in opioid dependence;
LIHC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-8.97	-0.44	1.96e-17	Morning vs. evening chronotype;
LIHC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	7.19	0.36	4.18e-12	Multiple sclerosis;
LIHC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg14132834	chr19:41945861	ATP5SL	0.44	6.49	0.33	3.04e-10	Height;
LIHC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.88	-0.65	6.03e-43	Chronic sinus infection;
LIHC	cis	rs4728302	0.838	rs10264922	chr7:133598975	A/G	cg10665199	chr7:133106180	EXOC4	0.38	6.63	0.34	1.28e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg20016023	chr10:99160130	RRP12	-0.37	-5.94	-0.31	6.94e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs6693295	0.793	rs2787962	chr1:246240267	A/G	cg22732515	chr19:44031385	ETHE1	0.42	6.05	0.31	3.86e-9	Migraine - clinic-based;Migraine with aura;
LIHC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.5	7.99	0.4	2.03e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.35	-0.32	6.85e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg05527609	chr1:210001259	C1orf107	0.43	6.36	0.33	6.51e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.74	11.48	0.53	5.2e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4789452	0.595	rs7359497	chr17:75352173	C/T	cg05865280	chr17:75406074	SEPT9	0.34	6.97	0.35	1.63e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.6	-8.95	-0.44	2.33e-17	QRS duration;
LIHC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.13	-0.31	2.41e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.22	0.32	1.42e-9	Mean corpuscular volume;
LIHC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.63	-6.38	-0.33	5.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.39	0.37	1.13e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg27129171	chr3:47204927	SETD2	0.48	7.67	0.38	1.79e-13	Birth weight;
LIHC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg17980119	chr2:219472607	PLCD4	0.34	5.87	0.3	1.06e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-0.69	-10.39	-0.49	3.57e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.45	7.11	0.36	6.72e-12	HDL cholesterol levels;
LIHC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.54	-0.5	1.12e-22	Total cholesterol levels;
LIHC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3744061	0.520	rs4322697	chr17:74648642	C/T	cg13533061	chr17:74712429	JMJD6	-0.29	-5.76	-0.3	1.89e-8	Retinal arteriolar caliber;
LIHC	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.38	-6.26	-0.32	1.12e-9	Corneal astigmatism;
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg14393609	chr7:65229607	NA	0.44	6.56	0.33	2.04e-10	Calcium levels;
LIHC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg23461800	chr14:103021989	NA	-0.5	-7.11	-0.36	6.66e-12	Platelet count;
LIHC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.86	11.01	0.51	2.45e-24	Cognitive function;
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg07599136	chr5:415885	AHRR	0.39	6.75	0.34	6.32e-11	Cystic fibrosis severity;
LIHC	cis	rs7487075	0.578	rs10880967	chr12:46812023	T/C	cg23829395	chr12:46796953	NA	0.35	6.26	0.32	1.16e-9	Itch intensity from mosquito bite;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17412405	chr5:114880687	FEM1C	-0.56	-6.24	-0.32	1.33e-9	Systolic blood pressure;
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.41	-0.41	1.15e-15	Renal cell carcinoma;
LIHC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.48	7.38	0.37	1.24e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg10756647	chr7:56101905	PSPH	1.09	13.52	0.59	1.17e-33	Diabetic kidney disease;
LIHC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg19318889	chr4:1322082	MAEA	-0.47	-6.56	-0.33	1.96e-10	Obesity-related traits;
LIHC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.76	10.89	0.51	6.38e-24	Response to antineoplastic agents;
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02475777	chr4:1388615	CRIPAK	0.4	6.15	0.32	2.15e-9	Obesity-related traits;
LIHC	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg00280220	chr17:61926910	NA	-0.39	-6.26	-0.32	1.13e-9	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.65	0.46	1.16e-19	Coffee consumption (cups per day);
LIHC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg17135325	chr3:160939158	NMD3	0.56	8.25	0.41	3.54e-15	Parkinson's disease;
LIHC	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg23422044	chr7:1970798	MAD1L1	-0.51	-5.93	-0.31	7.59e-9	Bipolar disorder;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.57	-8.45	-0.42	8.77e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	trans	rs6489882	0.902	rs3815178	chr12:113376320	C/T	cg10175203	chr3:128143634	NA	0.38	6.17	0.32	1.96e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg20368463	chr18:77673604	PQLC1	0.54	6.64	0.34	1.26e-10	Opioid sensitivity;
LIHC	cis	rs1892700	0.764	rs78478169	chr21:34906428	T/C	cg14850771	chr21:34775459	IFNGR2	-0.45	-5.91	-0.3	8.47e-9	Educational attainment;
LIHC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg05564831	chr3:52568323	NT5DC2	0.38	6.16	0.32	2.07e-9	Bipolar disorder;
LIHC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.39	6.85	0.35	3.53e-11	Monocyte percentage of white cells;
LIHC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs4759375	0.748	rs73230017	chr12:123418231	G/A	cg25930673	chr12:123319894	HIP1R	0.6	5.92	0.31	7.72e-9	HDL cholesterol;
LIHC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	17.36	0.68	7.38e-49	Lung cancer in ever smokers;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	7.99	0.4	2.16e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.68e-13	Airflow obstruction;
LIHC	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.37	-6.45	-0.33	3.73e-10	Menopause (age at onset);
LIHC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.88	10.83	0.51	1.1e-23	Bladder cancer;
LIHC	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	0.57	9.46	0.46	5.2e-19	Testicular germ cell tumor;
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg26939375	chr7:64535504	NA	0.47	7.14	0.36	5.64e-12	Aortic root size;
LIHC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg12501888	chr15:85177176	SCAND2	-0.5	-7.79	-0.39	8.05e-14	P wave terminal force;
LIHC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.0	-0.35	1.32e-11	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.45	6.36	0.33	6.33e-10	Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.75	13.7	0.6	2.43e-34	Prudent dietary pattern;
LIHC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.07	0.31	3.45e-9	Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07284286	chr16:58662935	CNOT1	0.48	7.06	0.36	9.47e-12	Lung function (FEV1/FVC);
LIHC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg16262614	chr3:133464971	TF	-0.34	-6.93	-0.35	2.1e-11	Iron status biomarkers (transferrin levels);
LIHC	cis	rs918629	0.567	rs7716691	chr5:95237040	C/T	cg10483112	chr5:95245456	ELL2	-0.37	-6.83	-0.35	3.84e-11	IgG glycosylation;
LIHC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.92	-15.35	-0.64	8.04e-41	Intelligence (multi-trait analysis);
LIHC	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.55	8.19	0.41	5.15e-15	Platelet count;
LIHC	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.38	-0.33	5.77e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs611744	0.967	rs602384	chr8:109188185	G/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg22481606	chr17:56429567	SUPT4H1	-0.4	-6.44	-0.33	4.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.85	12.57	0.56	4.66e-30	Menarche (age at onset);
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.4	6.12	0.31	2.56e-9	Testicular germ cell tumor;
LIHC	trans	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg09872104	chr7:134855509	C7orf49	-0.76	-6.09	-0.31	2.99e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.46	5.95	0.31	6.73e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.22e-26	Motion sickness;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09426994	chr11:118478258	PHLDB1	-0.44	-6.04	-0.31	4.04e-9	Longevity;
LIHC	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.1	0.44	7.66e-18	Platelet count;
LIHC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	1.02	20.23	0.74	2.11e-60	Breast cancer;
LIHC	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19613905	chr15:56757180	MNS1	0.49	7.53	0.38	4.46e-13	Pancreatic cancer;
LIHC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.1	-0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17001868	0.527	rs9611324	chr22:40781162	T/C	cg07138101	chr22:40742427	ADSL	0.53	6.46	0.33	3.67e-10	Mammographic density (dense area);
LIHC	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.2	16.23	0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.52	-0.33	2.46e-10	Response to antipsychotic treatment;
LIHC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.66	9.75	0.47	5.4e-20	Breast cancer;
LIHC	cis	rs62179067	0.708	rs11885400	chr2:179936237	G/T	cg07532576	chr2:179544947	TTN	0.61	5.8	0.3	1.49e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg21573476	chr21:45109991	RRP1B	-0.51	-9.68	-0.46	9.91e-20	Mean corpuscular volume;
LIHC	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	1.03	9.14	0.44	5.57e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg15691649	chr6:25882328	NA	-0.37	-5.86	-0.3	1.07e-8	Height;
LIHC	cis	rs7129556	0.520	rs7943742	chr11:77268856	C/T	cg03570279	chr11:77446074	RSF1	-0.36	-6.68	-0.34	9.43e-11	Weight loss (gastric bypass surgery);
LIHC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.68	-8.51	-0.42	5.57e-16	Mean platelet volume;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.52	7.39	0.37	1.17e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	1.17	10.46	0.49	2.17e-22	Type 2 diabetes;
LIHC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.7	0.69	3.05e-50	Gut microbiome composition (summer);
LIHC	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.29	-0.32	9.47e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg00204748	chr12:29376779	FAR2	0.34	6.48	0.33	3.22e-10	QT interval;
LIHC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.8	8.66	0.42	1.84e-16	Vitiligo;
LIHC	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	7.84	0.39	5.79e-14	LDL cholesterol;
LIHC	cis	rs7546668	1.000	rs1467513	chr1:15894959	T/C	cg11706911	chr1:15910989	AGMAT	0.45	6.75	0.34	6.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg03809021	chr16:89831123	FANCA	0.55	6.28	0.32	9.99e-10	Skin aging (microtopography measurement);
LIHC	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.85	11.34	0.52	1.6e-25	Menopause (age at onset);
LIHC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	6.13	0.31	2.45e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.82	-0.35	4.09e-11	Response to antipsychotic treatment;
LIHC	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.5	7.08	0.36	8.02e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-6.54	-0.33	2.24e-10	Hepatocellular carcinoma;
LIHC	trans	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg19676328	chr12:49525230	TUBA1B	-0.44	-6.36	-0.33	6.31e-10	Total cholesterol levels;
LIHC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.33	0.52	1.74e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.46	6.75	0.34	6.33e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7116495	1.000	rs4944258	chr11:71743393	T/A	cg26138937	chr11:71823887	C11orf51	-0.82	-8.15	-0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-5.79	-0.3	1.57e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.45	7.48	0.37	6.21e-13	Corneal astigmatism;
LIHC	cis	rs72627123	0.619	rs79575309	chr14:74590230	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.87	8.47	0.42	7.59e-16	Morning vs. evening chronotype;
LIHC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.7	-9.51	-0.46	3.59e-19	Blood metabolite levels;
LIHC	cis	rs4908760	0.613	rs12024032	chr1:8808185	A/G	cg20416874	chr1:8611966	RERE	0.53	8.98	0.44	1.83e-17	Vitiligo;
LIHC	cis	rs74181299	0.684	rs11126028	chr2:65338150	C/G	cg05010058	chr2:65284262	CEP68	-0.36	-6.01	-0.31	4.82e-9	Pulse pressure;
LIHC	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.34e-9	Lewy body disease;
LIHC	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.77	0.39	9e-14	Systemic lupus erythematosus;
LIHC	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09048334	chr6:37012640	NA	0.46	6.25	0.32	1.21e-9	Hepatitis;
LIHC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.47	-7.26	-0.37	2.59e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.43	6.91	0.35	2.36e-11	Melanoma;
LIHC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.5	-6.15	-0.32	2.18e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.37	-6.21	-0.32	1.56e-9	IgG glycosylation;
LIHC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.81	0.35	4.5e-11	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs72627123	0.867	rs112965033	chr14:74461117	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.85	8.17	0.4	6.07e-15	Morning vs. evening chronotype;
LIHC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg16479474	chr6:28041457	NA	0.43	6.65	0.34	1.15e-10	Parkinson's disease;
LIHC	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.4	-0.37	1.04e-12	Coronary artery disease;
LIHC	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.89	0.43	3.56e-17	Lung cancer;
LIHC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.72	-0.34	7.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg10360323	chr17:41437877	NA	0.41	6.09	0.31	3.1e-9	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13670615	chr19:49140625	SEC1;DBP	0.45	6.69	0.34	9.27e-11	Lung function (FEV1/FVC);
LIHC	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.2	-0.32	1.59e-9	Diastolic blood pressure;
LIHC	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg12379764	chr21:47803548	PCNT	0.64	9.0	0.44	1.55e-17	Lymphocyte counts;
LIHC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.4	-5.85	-0.3	1.14e-8	Menarche (age at onset);
LIHC	cis	rs507080	0.885	rs7926959	chr11:118559866	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.59	0.34	1.62e-10	Serum metabolite levels;
LIHC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg01788221	chr16:89496183	ANKRD11	-0.4	-6.26	-0.32	1.17e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07305463	chr2:136567211	LCT	-0.38	-5.87	-0.3	1.02e-8	Corneal structure;
LIHC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.44	-7.58	-0.38	3.27e-13	Lung cancer;
LIHC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-7.41	-0.37	9.68e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9596863	0.898	rs9563177	chr13:54368853	A/G	ch.13.53330881F	chr13:54432880	NA	0.43	5.8	0.3	1.53e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg10932868	chr11:921992	NA	0.38	7.34	0.37	1.59e-12	Alzheimer's disease (late onset);
LIHC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.75	10.63	0.5	5.19e-23	Dental caries;
LIHC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	0.96	16.32	0.66	1.1e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7635838	0.819	rs12714866	chr3:11539058	C/T	cg00170343	chr3:11313890	ATG7	0.4	6.21	0.32	1.54e-9	HDL cholesterol;
LIHC	trans	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg26939375	chr7:64535504	NA	0.42	6.82	0.35	4.26e-11	Aortic root size;
LIHC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-8.75	-0.43	1e-16	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07087156	chr2:228190257	NA	0.43	6.51	0.33	2.6200000000000003e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	8.84	0.43	5.04e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.56	8.16	0.4	6.48e-15	Cognitive ability;
LIHC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg19635926	chr16:89946313	TCF25	0.49	6.21	0.32	1.56e-9	Skin colour saturation;
LIHC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.5	-7.99	-0.4	2.13e-14	Cognitive function;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08005411	chr12:69753742	YEATS4	0.45	6.28	0.32	1.02e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg02353165	chr6:42928485	GNMT	0.52	7.64	0.38	2.24e-13	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.22	0.41	4.4e-15	Corneal astigmatism;
LIHC	cis	rs4407350	0.870	rs5765714	chr22:44915203	T/C	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.2	-0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs783540	0.967	rs7494860	chr15:83334419	A/G	cg18393722	chr15:85113863	UBE2QP1	0.36	6.29	0.32	9.73e-10	Schizophrenia;
LIHC	cis	rs10847980	0.623	rs28613486	chr12:123867268	T/C	cg00376283	chr12:123451042	ABCB9	0.62	6.57	0.33	1.92e-10	Adiponectin levels;
LIHC	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.48	7.23	0.36	3.21e-12	Diastolic blood pressure;
LIHC	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg03934865	chr2:198174659	NA	-0.48	-7.04	-0.36	1.04e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.87	13.3	0.58	8.03e-33	Lymphocyte percentage of white cells;
LIHC	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.91	11.43	0.53	7.43e-26	Prostate cancer;
LIHC	cis	rs4908768	0.906	rs12145445	chr1:8604370	C/G	cg20416874	chr1:8611966	RERE	0.57	8.73	0.43	1.16e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs611744	0.905	rs677031	chr8:109152068	G/A	cg18478394	chr8:109455254	TTC35	0.34	5.75	0.3	1.95e-8	Dupuytren's disease;
LIHC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg15848620	chr12:58087721	OS9	0.5	6.26	0.32	1.18e-9	Multiple sclerosis;
LIHC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.96	0.35	1.77e-11	Gout;
LIHC	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.7	-12.3	-0.55	5.02e-29	Pediatric autoimmune diseases;
LIHC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.74	11.17	0.52	6.82e-25	Menarche (age at onset);
LIHC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.38	5.95	0.31	6.53e-9	Menopause (age at onset);
LIHC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.82	-0.35	4.26e-11	Diabetic kidney disease;
LIHC	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.39	-6.61	-0.34	1.47e-10	Menopause (age at onset);
LIHC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.93	14.23	0.61	2.05e-36	Sudden cardiac arrest;
LIHC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.95	10.81	0.5	1.29e-23	Neuroticism;
LIHC	trans	rs4704846	0.660	rs246882	chr5:156559014	G/A	cg02632742	chr2:60187357	NA	-0.6	-6.04	-0.31	3.99e-9	Blood protein levels;
LIHC	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.63	-11.83	-0.54	2.57e-27	Neurofibrillary tangles;
LIHC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.94	-0.31	6.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.57	10.01	0.48	7.51e-21	Alcohol dependence;
LIHC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	6.05	0.31	3.77e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.97	-12.37	-0.56	2.71e-29	HIV-1 control;
LIHC	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.5	-7.36	-0.37	1.34e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.99	18.43	0.71	3.79e-53	Breast cancer;
LIHC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.43	0.41	9.62e-16	Morning vs. evening chronotype;
LIHC	trans	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.34	8.83	0.43	5.49e-17	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19050596	chr2:191879164	STAT1	0.43	6.15	0.32	2.1e-9	Pancreatic cancer;
LIHC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.98	0.54	7.35e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.47	9.72	0.47	7.12e-20	Immature fraction of reticulocytes;
LIHC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg05754148	chr16:3507555	NAT15	0.38	6.28	0.32	1e-9	Tuberculosis;
LIHC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg15534755	chr11:117069859	TAGLN	0.39	6.59	0.34	1.63e-10	Blood protein levels;
LIHC	cis	rs903552	0.800	rs1587107	chr15:102006485	T/C	cg00659931	chr15:102010125	PCSK6	-0.49	-6.51	-0.33	2.63e-10	Diabetic kidney disease;
LIHC	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.63	8.97	0.44	1.92e-17	Monocyte count;
LIHC	cis	rs9322817	0.902	rs9404576	chr6:105184640	T/G	cg02098413	chr6:105308735	HACE1	-0.39	-6.54	-0.33	2.23e-10	Thyroid stimulating hormone;
LIHC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg18887096	chr2:219472410	PLCD4	0.4	6.96	0.35	1.79e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	4.12e-15	Schizophrenia;
LIHC	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.43	0.62	3.28e-37	Prudent dietary pattern;
LIHC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.51	0.46	3.49e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg02702477	chr5:179499311	RNF130	0.75	10.44	0.49	2.46e-22	LDL cholesterol;
LIHC	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.46	7.47	0.37	6.72e-13	Schizophrenia;
LIHC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.14e-25	Corneal astigmatism;
LIHC	cis	rs67981189	0.593	rs10140917	chr14:71491820	T/C	cg15816911	chr14:71606274	NA	0.41	6.52	0.33	2.54e-10	Schizophrenia;
LIHC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg14343924	chr8:8086146	FLJ10661	0.47	6.46	0.33	3.6e-10	Systolic blood pressure;
LIHC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.35	-0.59	4.98e-33	Ulcerative colitis;
LIHC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.45	6.41	0.33	4.71e-10	Morning vs. evening chronotype;
LIHC	cis	rs72843506	0.656	rs10459970	chr17:19937341	G/A	cg12065943	chr17:19881925	AKAP10	-0.41	-6.93	-0.35	2.14e-11	Schizophrenia;
LIHC	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg08126542	chr6:37504118	NA	-0.35	-5.95	-0.31	6.82e-9	Cognitive performance;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg19373090	chr19:797215	PTBP1	-0.6	-6.77	-0.34	5.5e-11	Systolic blood pressure;
LIHC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.74	-0.43	1.04e-16	Cognitive function;
LIHC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.47	6.37	0.33	6.06e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg24209194	chr3:40518798	ZNF619	0.44	6.3	0.32	9.19e-10	Renal cell carcinoma;
LIHC	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	0.95	10.75	0.5	2.04e-23	Breast cancer;
LIHC	cis	rs924607	0.510	rs1709542	chr5:662543	A/G	cg07001201	chr5:642380	CEP72	-0.37	-6.66	-0.34	1.09e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.26	-6.1	-0.31	2.88e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7116495	0.867	rs481300	chr11:71578383	G/A	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.27e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg04013166	chr16:89971882	TCF25	0.53	6.69	0.34	8.94e-11	Skin colour saturation;
LIHC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.87	0.43	4.21e-17	Menarche (age at onset);
LIHC	cis	rs17125944	0.615	rs7145392	chr14:53321016	G/A	cg00686598	chr14:53173677	PSMC6	-0.78	-9.03	-0.44	1.3e-17	Alzheimer's disease (late onset);
LIHC	cis	rs922107	0.701	rs2125723	chr1:90031845	C/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.65	-0.38	2.04e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg18809830	chr7:99032528	PTCD1	-0.82	-6.37	-0.33	5.95e-10	Blood metabolite levels;
LIHC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg20607798	chr8:58055168	NA	0.51	6.45	0.33	3.82e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.36	-0.45	1.06e-18	Gut microbiome composition (summer);
LIHC	cis	rs4764124	1.000	rs4764124	chr12:14966604	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.43	7.17	0.36	4.8e-12	Pubertal anthropometrics;
LIHC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.48	7.1	0.36	7.11e-12	Personality dimensions;
LIHC	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg24331049	chr13:111365604	ING1	0.64	10.61	0.5	6.41e-23	Coronary artery disease;
LIHC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.8	-14.11	-0.61	5.8e-36	Coronary artery disease;
LIHC	trans	rs4578769	0.918	rs6507457	chr18:20626436	C/T	cg04130657	chr1:161102858	DEDD	0.39	6.35	0.32	6.89e-10	Eosinophil percentage of white cells;
LIHC	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg15841412	chr13:111365552	ING1	-0.47	-5.93	-0.31	7.47e-9	Coronary artery disease;
LIHC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg23625390	chr15:77176239	SCAPER	0.34	5.92	0.3	7.87e-9	Blood metabolite levels;
LIHC	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.41	-6.24	-0.32	1.29e-9	Systemic sclerosis;
LIHC	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg03060546	chr3:49711283	APEH	-0.67	-8.97	-0.44	2e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.59	-9.62	-0.46	1.55e-19	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs3736485	0.966	rs11070862	chr15:51902227	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.21	-0.32	1.54e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.49	-0.33	3e-10	Height;
LIHC	cis	rs11098699	0.821	rs931705	chr4:124205194	C/T	cg09941581	chr4:124220074	SPATA5	0.32	6.38	0.33	5.62e-10	Mosquito bite size;
LIHC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.52	-0.38	4.83e-13	Response to antipsychotic treatment;
LIHC	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg03934865	chr2:198174659	NA	0.45	6.64	0.34	1.26e-10	Dermatomyositis;
LIHC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg17724175	chr1:150552817	MCL1	0.41	8.17	0.4	6.08e-15	Melanoma;
LIHC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg16586182	chr3:47516702	SCAP	0.61	11.96	0.54	9.17e-28	Colorectal cancer;
LIHC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg23084528	chr10:38645450	HSD17B7P2	0.43	6.02	0.31	4.4e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7937890	0.598	rs10734225	chr11:14442994	C/G	cg02886208	chr11:14281011	SPON1	-0.53	-7.27	-0.37	2.43e-12	Mitochondrial DNA levels;
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg07234388	chr1:156261841	TMEM79	-0.5	-8.95	-0.44	2.37e-17	Tonsillectomy;
LIHC	cis	rs8062405	0.625	rs8060365	chr16:28911309	C/A	cg07451762	chr16:28383216	NA	-0.37	-6.43	-0.33	4.31e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.61	6.08	0.31	3.16e-9	Hip geometry;
LIHC	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-6.86	-0.35	3.26e-11	Neuroticism;
LIHC	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.55	-0.33	2.14e-10	Response to antipsychotic treatment;
LIHC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19524238	chr7:2802976	GNA12	-0.4	-5.79	-0.3	1.61e-8	Height;
LIHC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.23	0.41	3.98e-15	Platelet count;
LIHC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.6	8.43	0.41	1.01e-15	Aortic root size;
LIHC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.34	5.79	0.3	1.61e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06253862	chr6:160201362	SNORA20;TCP1	0.51	6.5	0.33	2.77e-10	Systolic blood pressure;
LIHC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.71	-12.36	-0.56	2.98e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg14092571	chr14:90743983	NA	-0.4	-6.25	-0.32	1.2e-9	Mortality in heart failure;
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21448741	chr8:58168803	NA	0.35	5.75	0.3	1.99e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.34	-7.2	-0.36	3.75e-12	Longevity;
LIHC	cis	rs4965272	0.830	rs11637820	chr15:100560239	C/T	cg09918751	chr15:100517450	ADAMTS17	0.45	6.25	0.32	1.19e-9	Gastroesophageal reflux disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27074985	chr4:111118232	ELOVL6	0.42	6.65	0.34	1.16e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.67	-0.38	1.86e-13	Ulcerative colitis;
LIHC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-1.06	-13.52	-0.59	1.14e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.79	9.9	0.47	1.7e-20	Cognitive function;
LIHC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.35	0.41	1.77e-15	Motion sickness;
LIHC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.43	8.13	0.4	8.01e-15	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs3736485	0.966	rs10851500	chr15:51783820	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-6.05	-0.31	3.78e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.44	5.73	0.3	2.22e-8	Subjective well-being;
LIHC	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.93	0.51	4.89e-24	Lung cancer in ever smokers;
LIHC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg03146154	chr1:46216737	IPP	-0.38	-6.26	-0.32	1.17e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.4	-6.05	-0.31	3.88e-9	Blood pressure (smoking interaction);
LIHC	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.45	6.79	0.34	5.04e-11	Night sleep phenotypes;
LIHC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.3	-6.91	-0.35	2.42e-11	Menarche (age at onset);
LIHC	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.34	7.65	0.38	2.03e-13	Blood metabolite ratios;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.28	0.41	2.88e-15	Height;
LIHC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.97	21.07	0.75	9.06e-64	Bone mineral density;
LIHC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg20607798	chr8:58055168	NA	0.46	6.62	0.34	1.42e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.45	6.13	0.31	2.43e-9	Life satisfaction;
LIHC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.7	-8.34	-0.41	1.83e-15	Morning vs. evening chronotype;
LIHC	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.4	7.42	0.37	9.4e-13	Testicular germ cell tumor;
LIHC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	0.85	11.09	0.51	1.32e-24	Skin colour saturation;
LIHC	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.27	-0.37	2.41e-12	Migraine;Coronary artery disease;
LIHC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.27	-5.9	-0.3	8.82e-9	Type 2 diabetes;
LIHC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.38	-5.9	-0.3	8.81e-9	Glioblastoma;
LIHC	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.36	-6.18	-0.32	1.78e-9	Hypertension (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg25894440	chr7:65020034	NA	-0.53	-6.11	-0.31	2.72e-9	Diabetic kidney disease;
LIHC	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.45	7.25	0.36	2.86e-12	Corneal astigmatism;
LIHC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.43	0.41	9.62e-16	Morning vs. evening chronotype;
LIHC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg13647721	chr17:30228624	UTP6	-0.69	-6.16	-0.32	2e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.61	-8.99	-0.44	1.73e-17	Recombination rate (females);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03130149	chr11:3819041	PGAP2;NUP98	0.38	6.12	0.31	2.58e-9	Cognitive function;
LIHC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.13	9.99	0.48	8.57e-21	Alzheimer's disease;
LIHC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.6	9.77	0.47	4.93e-20	Resting heart rate;
LIHC	trans	rs6563898	0.915	rs6563892	chr16:83348255	A/G	cg13016115	chr14:23388406	RBM23	-0.42	-6.13	-0.31	2.49e-9	IgE levels in asthmatics (D.f. specific);
LIHC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.27	-7.05	-0.36	1e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01301323	chr12:77252588	CSRP2	-0.4	-6.64	-0.34	1.22e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg01788221	chr16:89496183	ANKRD11	-0.37	-5.75	-0.3	1.99e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.69	0.57	1.7e-30	Mean platelet volume;
LIHC	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.79	-0.39	8.1e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.51	-0.33	2.65e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.51	0.38	5.21e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.58	10.23	0.48	1.32e-21	Dupuytren's disease;
LIHC	cis	rs12500138	1.000	rs114597618	chr4:166169289	A/G	cg25064052	chr4:166216151	KLHL2	-0.67	-6.15	-0.32	2.14e-9	Cognitive function;
LIHC	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.88	0.57	3.23e-31	Colorectal cancer;
LIHC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17554472	chr22:41940697	POLR3H	0.54	5.9	0.3	8.82e-9	Vitiligo;
LIHC	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	5.71	0.3	2.43e-8	Platelet count;
LIHC	cis	rs2257205	0.667	rs4340382	chr17:56738919	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.47	-0.33	3.49e-10	Pancreatic cancer;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15667495	chr17:40719620	MLX	-0.41	-6.37	-0.33	6.25e-10	Triglycerides;
LIHC	cis	rs2191566	0.664	rs55958002	chr19:44543788	A/T	cg20607764	chr19:44506953	ZNF230	-0.37	-6.22	-0.32	1.45e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.72	10.25	0.48	1.16e-21	Menarche (age at onset);
LIHC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg22834771	chr12:69754056	YEATS4	-0.47	-8.06	-0.4	1.32e-14	Blood protein levels;
LIHC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.8	11.59	0.53	1.95e-26	Coronary artery disease;
LIHC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.37	5.75	0.3	1.95e-8	Erythrocyte sedimentation rate;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26926833	chr16:30194886	CORO1A	0.43	6.32	0.32	8.38e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	7.14	0.36	5.52e-12	Exhaled nitric oxide output;
LIHC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.57	7.82	0.39	6.76e-14	Eosinophil percentage of white cells;
LIHC	cis	rs11628318	0.563	rs1190344	chr14:103097912	A/G	cg23461800	chr14:103021989	NA	-0.4	-5.99	-0.31	5.24e-9	Platelet count;
LIHC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.55	-8.57	-0.42	3.73e-16	Coronary artery disease;
LIHC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.36	-5.79	-0.3	1.63e-8	Height;
LIHC	cis	rs28830936	0.966	rs28451764	chr15:42126583	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.8	-0.3	1.51e-8	Diastolic blood pressure;
LIHC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.47	-0.56	1.12e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs55665837	0.701	rs12787709	chr11:14639257	G/A	cg19336497	chr11:14380999	RRAS2	-0.36	-5.76	-0.3	1.92e-8	Vitamin D levels;
LIHC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg03959625	chr15:84868606	LOC388152	0.44	6.03	0.31	4.19e-9	Schizophrenia;
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12016809	chr21:47604291	C21orf56	0.46	6.91	0.35	2.34e-11	Testicular germ cell tumor;
LIHC	cis	rs3857067	1.000	rs6532463	chr4:95027048	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.35	-0.37	1.43e-12	QT interval;
LIHC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-6.63	-0.34	1.3100000000000001e-10	Breast cancer;
LIHC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg12798992	chr6:167411361	FGFR1OP	0.62	10.03	0.48	6.57e-21	Crohn's disease;
LIHC	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.5	9.55	0.46	2.69e-19	Testicular germ cell tumor;
LIHC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.23	6.12	0.31	2.5e-9	Calcium levels;
LIHC	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.72	-9.72	-0.47	7e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-0.96	-18.11	-0.7	7.31e-52	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.5	6.55	0.33	2.09e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg22153463	chr1:85462885	MCOLN2	0.52	6.23	0.32	1.34e-9	Serum sulfate level;
LIHC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.92	0.3	7.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.75	0.34	6.38e-11	Alzheimer's disease;
LIHC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.48	6.41	0.33	4.93e-10	Mean platelet volume;
LIHC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	1.0	11.25	0.52	3.51e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.95	0.31	6.79e-9	IgG glycosylation;
LIHC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	15.1	0.63	7.64e-40	Chronic sinus infection;
LIHC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.75	14.45	0.62	2.74e-37	Mortality in heart failure;
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg03959625	chr15:84868606	LOC388152	0.47	6.43	0.33	4.31e-10	Schizophrenia;
LIHC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	1.02	19.65	0.73	4.62e-58	Breast cancer;
LIHC	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.63	-0.42	2.43e-16	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00838250	chr3:186287958	TBCCD1;DNAJB11	0.48	7.18	0.36	4.29e-12	Cognitive function;
LIHC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	2.97e-9	Mortality in heart failure;
LIHC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.43	7.34	0.37	1.58e-12	Aortic root size;
LIHC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.37	6.15	0.32	2.18e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16242708	chr19:40596726	ZNF780A	0.48	6.24	0.32	1.27e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.74	-0.5	2.21e-23	Bipolar disorder and schizophrenia;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg19422253	chr3:149212391	TM4SF4	0.56	6.16	0.32	2.07e-9	Mean platelet volume;
LIHC	cis	rs3823572	0.564	rs4728305	chr7:133666949	C/T	cg03336402	chr7:133662267	EXOC4	-0.47	-5.72	-0.3	2.29e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06656553	chr16:89960601	TCF25	-0.5	-6.47	-0.33	3.34e-10	Skin colour saturation;
LIHC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.46	-7.36	-0.37	1.38e-12	Birth weight;
LIHC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.31	0.32	8.85e-10	Rheumatoid arthritis;
LIHC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.56	11.38	0.52	1.13e-25	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1144333	0.510	rs1250882	chr1:76287314	C/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.91	-0.3	8.23e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg09795085	chr6:101329169	ASCC3	-0.54	-7.51	-0.38	5.06e-13	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11682216	chr4:68411177	CENPC1	-0.48	-6.76	-0.34	6.14e-11	Pancreatic cancer;
LIHC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.96	18.62	0.71	6.55e-54	Intelligence (multi-trait analysis);
LIHC	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.38	-0.33	5.65e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.37	-7.95	-0.39	2.81e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs11031096	0.678	rs12292724	chr11:4176671	T/A	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.33e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg07451762	chr16:28383216	NA	0.38	6.87	0.35	3.09e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11229555	0.598	rs11229426	chr11:58180063	T/C	cg15696309	chr11:58395628	NA	-0.66	-7.76	-0.39	1.02e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-7.3	-0.37	2.04e-12	Hepatocellular carcinoma;
LIHC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.54	-10.98	-0.51	3.14e-24	Tonsillectomy;
LIHC	cis	rs9378688	1.000	rs3800187	chr6:2222253	C/T	cg12303981	chr6:2244766	GMDS	-0.49	-6.22	-0.32	1.48e-9	Caudate nucleus volume;
LIHC	cis	rs611744	0.934	rs624311	chr8:109204437	A/G	cg21045802	chr8:109455806	TTC35	0.52	8.88	0.43	3.94e-17	Dupuytren's disease;
LIHC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.72	-12.35	-0.56	3.11e-29	Refractive error;
LIHC	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.57	-8.63	-0.42	2.43e-16	Menopause (age at onset);
LIHC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.56	0.33	2.04e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.26	0.41	3.22e-15	Motion sickness;
LIHC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	8.57	0.42	3.56e-16	Platelet count;
LIHC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.29	-0.61	1.14e-36	Longevity;
LIHC	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.46	-6.08	-0.31	3.19e-9	Testicular germ cell tumor;Testicular germ cell cancer;
LIHC	trans	rs10411161	1.000	rs3848562	chr19:52379835	C/T	cg22319618	chr22:45562946	NUP50	0.56	7.8	0.39	7.66e-14	Breast cancer;
LIHC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.63	8.71	0.43	1.3e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15235185	chr1:193028809	TROVE2;UCHL5	0.4	6.06	0.31	3.51e-9	Pancreatic cancer;
LIHC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg02951883	chr7:2050386	MAD1L1	0.38	5.74	0.3	2.13e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.38	-0.41	1.44e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12016809	chr21:47604291	C21orf56	-0.4	-5.86	-0.3	1.09e-8	Testicular germ cell tumor;
LIHC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.25	0.45	2.57e-18	Gut microbiome composition (summer);
LIHC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	0.98	10.28	0.49	8.96e-22	Cannabis dependence symptom count;
LIHC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	1.02	19.57	0.73	9.58e-58	Migraine;
LIHC	trans	rs6489882	0.867	rs4766672	chr12:113365148	A/G	cg10175203	chr3:128143634	NA	0.39	6.36	0.33	6.4e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.4	7.14	0.36	5.82e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-8.75	-0.43	9.93e-17	Schizophrenia;
LIHC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.82	0.47	3.25e-20	Alzheimer's disease;
LIHC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg16586182	chr3:47516702	SCAP	0.48	8.54	0.42	4.56e-16	Colorectal cancer;
LIHC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.71	11.02	0.51	2.19e-24	Corneal astigmatism;
LIHC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.03	-0.58	8.44e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.1	-0.44	7.75e-18	Alzheimer's disease;
LIHC	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg11204139	chr17:3907470	NA	0.62	8.63	0.42	2.38e-16	Type 2 diabetes;
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg07599136	chr5:415885	AHRR	0.39	6.65	0.34	1.14e-10	Cystic fibrosis severity;
LIHC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg18306943	chr3:40428807	ENTPD3	0.35	5.82	0.3	1.39e-8	Renal cell carcinoma;
LIHC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.59	10.28	0.49	9.1e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.32	16.34	0.66	8.98e-45	Alzheimer's disease (late onset);
LIHC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg19338460	chr6:170058176	WDR27	-0.38	-5.9	-0.3	8.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.83	-0.43	5.45e-17	Type 2 diabetes;
LIHC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.42	-6.46	-0.33	3.6e-10	Colorectal cancer;
LIHC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg17135325	chr3:160939158	NMD3	0.41	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Blood protein levels;
LIHC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg00529422	chr1:16285251	ZBTB17	0.34	6.57	0.33	1.92e-10	Systolic blood pressure;
LIHC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	trans	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.41	0.33	4.71e-10	Ulcerative colitis;
LIHC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.31	6.44	0.33	4.04e-10	QRS complex (12-leadsum);
LIHC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	ch.11.42038R	chr11:967971	AP2A2	0.55	9.92	0.47	1.51e-20	Alzheimer's disease (late onset);
LIHC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.68	-0.34	9.49e-11	Personality dimensions;
LIHC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.56	8.56	0.42	4e-16	Longevity;Endometriosis;
LIHC	cis	rs2836950	0.501	rs1474490	chr21:40716136	C/A	cg06238570	chr21:40685208	BRWD1	-0.38	-6.06	-0.31	3.55e-9	Menarche (age at onset);
LIHC	cis	rs7134594	0.539	rs7294688	chr12:110054765	C/G	cg05360138	chr12:110035743	NA	-0.42	-6.06	-0.31	3.54e-9	HDL cholesterol;
LIHC	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.74	7.79	0.39	8.11e-14	Blood pressure (smoking interaction);
LIHC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.61	-0.46	1.65e-19	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.46	-0.37	7.36e-13	Renal cell carcinoma;
LIHC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg00832105	chr8:11331707	NA	0.3	5.78	0.3	1.66e-8	Myopia (pathological);
LIHC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	trans	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg06755612	chr14:45603778	FKBP3;FANCM	-0.49	-6.12	-0.31	2.59e-9	Vitiligo;
LIHC	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.87	16.43	0.66	4.18e-45	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.5	-7.82	-0.39	6.5e-14	Crohn's disease;
LIHC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.4	-6.24	-0.32	1.28e-9	Educational attainment;
LIHC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.45	-7.4	-0.37	1.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg24163568	chr5:669837	TPPP	-0.37	-8.03	-0.4	1.62e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg10360323	chr17:41437877	NA	0.39	5.73	0.3	2.23e-8	Menopause (age at onset);
LIHC	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	1.04	13.48	0.59	1.63e-33	Red blood cell traits;
LIHC	cis	rs16958440	0.867	rs75808931	chr18:44693042	C/T	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg16736954	chr20:23401023	NAPB	0.54	6.02	0.31	4.6e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.78	-11.94	-0.54	1.05e-27	Subjective well-being;
LIHC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.77	0.5	1.73e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg25894440	chr7:65020034	NA	-0.53	-6.04	-0.31	4.05e-9	Diabetic kidney disease;
LIHC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.51	7.93	0.39	3.24e-14	Pulse pressure;
LIHC	trans	rs352889	1.000	rs352892	chr2:143757925	G/T	cg11565512	chr5:126627355	MEGF10	0.22	6.07	0.31	3.39e-9	Toenail selenium levels;
LIHC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.89	16.23	0.66	2.63e-44	Coronary artery disease;
LIHC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	6.0	0.31	4.96e-9	Renal cell carcinoma;
LIHC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.08	19.27	0.72	1.45e-56	Nonalcoholic fatty liver disease;
LIHC	trans	rs8117834	0.605	rs12480533	chr20:8082896	A/G	cg00593689	chr4:53575888	NA	0.38	6.5	0.33	2.77e-10	Chronic kidney disease;
LIHC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.3	-5.72	-0.3	2.31e-8	Mean corpuscular volume;
LIHC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg27494647	chr7:150038898	RARRES2	-0.32	-5.8	-0.3	1.53e-8	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg23556447	chr6:90529595	MDN1	-0.39	-6.05	-0.31	3.76e-9	Body mass index;
LIHC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16434002	chr17:42200994	HDAC5	0.51	7.41	0.37	9.76e-13	Total body bone mineral density;
LIHC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.67	6.71	0.34	7.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.68	-0.38	1.7e-13	Chronic sinus infection;
LIHC	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg07636037	chr3:49044803	WDR6	-0.53	-6.15	-0.32	2.16e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21515243	chr18:21033072	RIOK3	0.49	7.42	0.37	9.16e-13	Pancreatic cancer;
LIHC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg08807892	chr2:162101083	NA	0.37	5.89	0.3	9.25e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs546131	0.642	rs11602870	chr11:34841902	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.35	-7.04	-0.36	1.08e-11	Bronchopulmonary dysplasia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07569756	chr17:48474564	LRRC59	0.43	6.23	0.32	1.39e-9	Pancreatic cancer;
LIHC	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.86	-0.39	5.04e-14	Coronary artery disease;
LIHC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg21395723	chr22:39101663	GTPBP1	0.37	5.78	0.3	1.67e-8	Menopause (age at onset);
LIHC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.57	-0.33	1.86e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs10508774	0.850	rs2152161	chr10:32932785	T/A	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg01652190	chr22:50026171	C22orf34	-0.33	-7.39	-0.37	1.14e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg06719391	chr11:2554330	KCNQ1	-0.55	-6.28	-0.32	1.06e-9	Bronchial neuroendocrine tumor;
LIHC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.63	9.88	0.47	2.07e-20	Educational attainment;
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg14393609	chr7:65229607	NA	0.41	6.91	0.35	2.39e-11	Calcium levels;
LIHC	trans	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.36	5.94	0.31	7.06e-9	Cystic fibrosis severity;
LIHC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-10.79	-0.5	1.5e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.71	-9.54	-0.46	2.73e-19	Asthma;
LIHC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg03013999	chr17:37608204	MED1	-0.36	-6.06	-0.31	3.53e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.79	11.22	0.52	4.36e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.99	-18.63	-0.71	5.83e-54	Breast cancer;
LIHC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg22223119	chr13:99095684	FARP1	-0.39	-5.84	-0.3	1.23e-8	Neuroticism;
LIHC	cis	rs16958440	0.867	rs9304342	chr18:44720199	T/G	cg17192377	chr18:44677553	HDHD2	0.91	8.68	0.42	1.64e-16	Sitting height ratio;
LIHC	cis	rs3736485	0.899	rs6493505	chr15:51845172	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.29	-0.32	9.83e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.62	-0.38	2.57e-13	Aortic root size;
LIHC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.61	9.19	0.45	3.76e-18	Longevity;
LIHC	cis	rs965469	0.545	rs6051845	chr20:3402792	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-6.28	-0.32	1.02e-9	IFN-related cytopenia;
LIHC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.93	17.8	0.69	1.27e-50	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.37	5.95	0.31	6.5e-9	Menopause (age at onset);
LIHC	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.83	11.06	0.51	1.62e-24	Post bronchodilator FEV1;
LIHC	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.39	-5.81	-0.3	1.39e-8	Lung cancer;
LIHC	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg16473166	chr22:50639996	SELO	0.6	8.82	0.43	5.88e-17	Obesity-related traits;
LIHC	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.83	16.02	0.65	1.79e-43	Testicular germ cell tumor;
LIHC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.63	-6.73	-0.34	7.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.52	8.2	0.41	4.9e-15	Height;
LIHC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg25344623	chr2:136566232	LCT	-0.35	-6.84	-0.35	3.65e-11	Mosquito bite size;
LIHC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.93	0.7	3.71e-51	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.72	0.69	2.59e-50	Tonsillectomy;
LIHC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.15	-0.36	5.28e-12	Response to antipsychotic treatment;
LIHC	trans	rs11724903	0.935	rs10520526	chr4:183217796	C/T	cg16239906	chr20:35724590	RBL1	-0.63	-6.07	-0.31	3.3e-9	Smoking initiation;
LIHC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.46e-27	Lymphocyte counts;
LIHC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.93	0.51	4.9e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.31	-0.45	1.62e-18	Blood metabolite levels;
LIHC	cis	rs11673344	0.764	rs565721	chr19:37455831	G/A	cg27390819	chr19:37464633	NA	-0.53	-6.29	-0.32	9.74e-10	Obesity-related traits;
LIHC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.39	0.52	1.05e-25	Menopause (age at onset);
LIHC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg03665457	chr10:38645376	HSD17B7P2	0.44	6.09	0.31	3.12e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg02811702	chr13:24901961	NA	0.25	6.24	0.32	1.3e-9	Obesity-related traits;
LIHC	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.68	-10.02	-0.48	7.02e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.73	-13.75	-0.6	1.54e-34	Height;
LIHC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-6.35	-0.32	6.66e-10	Blood pressure (smoking interaction);
LIHC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-8.33	-0.41	2e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg10932868	chr11:921992	NA	0.39	7.49	0.38	5.97e-13	Alzheimer's disease (late onset);
LIHC	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	6.91	0.35	2.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.73	-0.57	1.23e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9921222	0.565	rs1805105	chr16:396264	A/G	cg26913058	chr16:419975	MRPL28	-0.49	-7.33	-0.37	1.64e-12	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.81	0.35	4.49e-11	Menopause (age at onset);
LIHC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.92	16.52	0.67	1.74e-45	Parkinson's disease;
LIHC	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.44	8.62	0.42	2.45e-16	Testicular germ cell tumor;
LIHC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.6e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg10792982	chr14:105748885	BRF1	0.46	5.94	0.31	7.16e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.46	6.19	0.32	1.76e-9	Height;
LIHC	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.59	8.23	0.41	3.98e-15	Psoriasis vulgaris;
LIHC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.42	8.56	0.42	3.86e-16	Immature fraction of reticulocytes;
LIHC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.87	15.64	0.65	5.61e-42	Dental caries;
LIHC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	18.23	0.7	2.43e-52	Smoking behavior;
LIHC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	9.83	0.47	3.1e-20	Colorectal cancer;
LIHC	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.63	-9.31	-0.45	1.54e-18	White matter hyperintensity burden;
LIHC	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.82	0.39	6.81e-14	Lung cancer in ever smokers;
LIHC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg03013999	chr17:37608204	MED1	0.35	5.8	0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.58e-15	Gut microbiome composition (summer);
LIHC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.85	13.96	0.6	2.33e-35	Multiple sclerosis;
LIHC	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	trans	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.12e-10	Aortic root size;
LIHC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg03037974	chr15:76606532	NA	0.71	13.6	0.59	5.9e-34	Blood metabolite levels;
LIHC	cis	rs10847980	0.590	rs75217947	chr12:123346177	G/C	cg18912006	chr12:123335444	HIP1R	0.76	7.68	0.38	1.67e-13	Adiponectin levels;
LIHC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05564831	chr3:52568323	NT5DC2	0.34	5.81	0.3	1.47e-8	Bipolar disorder;
LIHC	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg07148914	chr20:33460835	GGT7	0.43	6.04	0.31	4.06e-9	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20087917	chr14:77924039	C14orf133;AHSA1	0.44	6.77	0.34	5.56e-11	Pancreatic cancer;
LIHC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.62	0.34	1.39e-10	Educational attainment;
LIHC	cis	rs9896052	0.614	rs9892171	chr17:73452529	C/T	cg25649188	chr17:73499917	CASKIN2	0.46	6.91	0.35	2.34e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.58	-7.15	-0.36	5.23e-12	Vitamin D levels;
LIHC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.38	6.08	0.31	3.16e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs2851682	0.908	rs2727265	chr11:61609004	C/A	cg27386326	chr11:61587980	NA	0.57	8.21	0.41	4.67e-15	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs4908768	0.539	rs6670508	chr1:8647917	G/C	cg20416874	chr1:8611966	RERE	-0.65	-12.06	-0.55	3.77e-28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06667416	chr3:186501294	EIF4A2;SNORD2	0.43	6.22	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg14146966	chr2:61757674	XPO1	0.48	8.39	0.41	1.32e-15	Tuberculosis;
LIHC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.69	-0.67	3.8e-46	Systemic lupus erythematosus;
LIHC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg01629716	chr15:45996671	NA	-0.54	-9.78	-0.47	4.31e-20	Waist circumference;Weight;
LIHC	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.45	-6.98	-0.35	1.56e-11	Multiple sclerosis;
LIHC	cis	rs7716219	0.638	rs1559213	chr5:54870190	A/C	cg14753740	chr5:54468940	CDC20B;MIR449C	0.54	7.38	0.37	1.24e-12	Height;
LIHC	cis	rs7923452	0.641	rs928055	chr10:30731146	G/A	cg25182066	chr10:30743637	MAP3K8	0.38	5.8	0.3	1.55e-8	Itch intensity from mosquito bite;
LIHC	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.34	-6.38	-0.33	5.59e-10	Ankylosing spondylitis;
LIHC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.66	-11.34	-0.52	1.59e-25	Menopause (age at onset);
LIHC	cis	rs1029738	0.500	rs6972589	chr7:22883467	A/G	cg11367502	chr7:22862612	TOMM7	-0.35	-5.82	-0.3	1.34e-8	Fibrinogen levels;
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.55	6.53	0.33	2.43e-10	Alzheimer's disease;
LIHC	cis	rs7129220	0.512	rs2119991	chr11:10226268	A/G	cg01453529	chr11:10209919	SBF2	-0.43	-7.88	-0.39	4.45e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16024904	chr19:17905718	B3GNT3	0.44	6.3	0.32	9.21e-10	Tumor biomarkers;
LIHC	trans	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg10756647	chr7:56101905	PSPH	-0.44	-6.37	-0.33	6.05e-10	Aortic root size;
LIHC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.78	14.43	0.62	3.44e-37	Graves' disease;
LIHC	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.39	6.61	0.34	1.49e-10	Endometrial cancer;
LIHC	cis	rs12431939	1.000	rs7148508	chr14:51635137	G/A	cg23942311	chr14:51606299	NA	-0.35	-5.78	-0.3	1.71e-8	Cancer;
LIHC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg14061069	chr19:46274453	DMPK	-0.56	-8.79	-0.43	7.65e-17	Coronary artery disease;
LIHC	cis	rs6060717	0.654	rs8122716	chr20:34607001	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-7.57	-0.38	3.41e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.48	7.1	0.36	7.4e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.65	-8.74	-0.43	1.09e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.82	-0.35	4.17e-11	Type 2 diabetes;
LIHC	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.97e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03651904	chr19:2807229	THOP1	0.43	6.12	0.31	2.57e-9	Longevity;
LIHC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.41	6.01	0.31	4.67e-9	Gout;
LIHC	cis	rs4788570	0.697	rs4788443	chr16:71805160	G/A	cg06353428	chr16:71660113	MARVELD3	1.33	13.58	0.59	6.87e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.5	-0.38	5.71e-13	Mean platelet volume;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg18887096	chr2:219472410	PLCD4	0.37	6.41	0.33	4.9e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.42	6.35	0.32	6.66e-10	Heart rate;
LIHC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.39	-6.33	-0.32	7.5e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.55	9.09	0.44	8.22e-18	Total body bone mineral density;
LIHC	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.38	12.35	0.56	3.16e-29	Uric acid levels;
LIHC	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.65	-0.34	1.15e-10	Prevalent atrial fibrillation;
LIHC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.57	7.72	0.39	1.32e-13	Coronary artery disease;
LIHC	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.43	-5.81	-0.3	1.4e-8	Interleukin-18 levels;
LIHC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.47	8.73	0.43	1.17e-16	Body mass index;
LIHC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs1664789	1.000	rs1664785	chr5:53281502	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.68	0.42	1.61e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg09835421	chr16:68378352	PRMT7	-0.47	-5.76	-0.3	1.86e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.63	-9.52	-0.46	3.25e-19	Aortic root size;
LIHC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.79	0.3	1.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.73	-0.47	6.76e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.77	14.01	0.6	1.46e-35	Iron status biomarkers;
LIHC	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.71	-0.3	2.41e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.44	6.47	0.33	3.46e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.85	-0.43	4.73e-17	Bipolar disorder;
LIHC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.52	0.56	7.27e-30	Menopause (age at onset);
LIHC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.4	0.41	1.19e-15	Platelet count;
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13126279	chr21:47581558	C21orf56	0.41	6.5	0.33	2.84e-10	Testicular germ cell tumor;
LIHC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.48	-7.31	-0.37	1.93e-12	Height;
LIHC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.58e-32	Colorectal cancer;
LIHC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.41	6.84	0.35	3.69e-11	Endometrial cancer;
LIHC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2455826	0.544	rs2470517	chr3:15759360	T/A	cg12698662	chr3:15914712	MIR563	-0.41	-5.72	-0.3	2.38e-8	Inflammatory skin disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03834947	chr15:65321822	MTFMT	-0.44	-6.31	-0.32	8.52e-10	Pancreatic cancer;
LIHC	cis	rs67981189	0.574	rs4467005	chr14:71498656	C/T	cg15816911	chr14:71606274	NA	0.43	6.9	0.35	2.57e-11	Schizophrenia;
LIHC	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.74	-0.3	2.14e-8	Mortality in heart failure;
LIHC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.56e-16	Primary biliary cholangitis;
LIHC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	7.07	0.36	8.93e-12	Protein C levels;
LIHC	trans	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.38	0.59	4.07e-33	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24511898	chr2:242576823	ATG4B;THAP4	0.44	6.89	0.35	2.7e-11	Pancreatic cancer;
LIHC	cis	rs11212260	0.655	rs11212231	chr11:107306200	C/G	cg25435332	chr11:107328525	CWF19L2	0.84	8.08	0.4	1.15e-14	IgG glycosylation;
LIHC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg14393609	chr7:65229607	NA	0.45	6.67	0.34	1.02e-10	Aortic root size;
LIHC	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.47	-7.47	-0.37	6.6e-13	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.51	8.02	0.4	1.72e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.03	-21.18	-0.75	3.36e-64	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.62	-11.18	-0.52	6.12e-25	Breast cancer;
LIHC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03925425	chr13:111768023	ARHGEF7	-0.41	-6.12	-0.31	2.6e-9	Obesity-related traits;
LIHC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17507749	chr15:85114479	UBE2QP1	0.66	7.57	0.38	3.48e-13	Schizophrenia;
LIHC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg10932868	chr11:921992	NA	0.4	7.54	0.38	4.38e-13	Alzheimer's disease (late onset);
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg01818776	chr8:25202910	DOCK5	0.37	6.36	0.33	6.43e-10	Monocyte count;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09875780	chr16:89357086	ANKRD11	0.44	6.14	0.32	2.34e-9	Lung function (FEV1);
LIHC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.48	6.13	0.31	2.42e-9	Mean platelet volume;
LIHC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.11	-0.36	6.62e-12	Coronary artery disease;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg05315874	chr8:20054693	ATP6V1B2	-0.6	-6.16	-0.32	2.03e-9	Obesity-related traits;
LIHC	cis	rs990171	0.506	rs9284725	chr2:102744854	C/A	cg22835712	chr2:102737379	NA	0.57	8.79	0.43	7.18e-17	Lymphocyte counts;
LIHC	trans	rs1814175	0.530	rs11040482	chr11:49727068	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.78	0.34	5.32e-11	Height;
LIHC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.73	-0.5	2.48e-23	Mean corpuscular volume;
LIHC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.47	5.82	0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.95	0.65	3.35e-43	Electrocardiographic conduction measures;
LIHC	trans	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg10756647	chr7:56101905	PSPH	1.0	11.41	0.53	8.84e-26	Diabetic kidney disease;
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.36	6.1	0.31	2.95e-9	Height;
LIHC	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.62	10.72	0.5	2.7e-23	Breast cancer;
LIHC	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.74	7.38	0.37	1.19e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg10756647	chr7:56101905	PSPH	1.01	11.98	0.54	7.24e-28	Diabetic kidney disease;
LIHC	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.32	7.21	0.36	3.6e-12	Blood metabolite ratios;
LIHC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.51	8.18	0.4	5.61e-15	Schizophrenia;
LIHC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.44	-6.59	-0.34	1.64e-10	Tuberculosis;
LIHC	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.53	-7.1	-0.36	7.24e-12	IFN-related cytopenia;
LIHC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.03	0.36	1.14e-11	Osteoporosis;
LIHC	cis	rs11229555	0.645	rs12794534	chr11:58179568	C/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04317338	chr11:64019027	PLCB3	0.5	7.01	0.35	1.31e-11	Platelet count;
LIHC	trans	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg05848834	chr11:43543746	NA	-0.3	-6.26	-0.32	1.13e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg10774155	chr7:65338427	VKORC1L1	-0.43	-6.41	-0.33	4.94e-10	Calcium levels;
LIHC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg04315214	chr1:2043799	PRKCZ	0.46	7.24	0.36	3.03e-12	Height;
LIHC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.55	-6.44	-0.33	3.94e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2176862	1.000	rs114992459	chr3:46611799	C/A	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.34	-0.32	7.42e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs11971779	0.715	rs6467854	chr7:139127083	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	9.92	0.47	1.46e-20	Diisocyanate-induced asthma;
LIHC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.53	6.35	0.32	6.99e-10	Morning vs. evening chronotype;
LIHC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg15412446	chr2:106886593	NA	-0.69	-6.87	-0.35	3.07e-11	Facial morphology (factor 23);
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.08	0.36	8.38e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.08	9.8	0.47	3.72e-20	Diabetic retinopathy;
LIHC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.41	6.58	0.34	1.78e-10	Intraocular pressure;
LIHC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Educational attainment (college completion);
LIHC	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg20891283	chr12:69753455	YEATS4	0.47	6.52	0.33	2.49e-10	Response to diuretic therapy;
LIHC	cis	rs11673344	0.711	rs112857724	chr19:37521078	G/T	cg27390819	chr19:37464633	NA	-0.49	-5.97	-0.31	6.08e-9	Obesity-related traits;
LIHC	cis	rs332507	0.830	rs3772786	chr3:124395250	A/C	cg05980111	chr3:124395277	KALRN	0.46	7.02	0.35	1.22e-11	Plateletcrit;
LIHC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.29	-0.32	9.43e-10	Tonsillectomy;
LIHC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26031613	chr14:104095156	KLC1	1.06	14.08	0.61	7.86e-36	Body mass index;
LIHC	cis	rs77637988	0.604	rs78597273	chr2:48607804	G/A	cg15846641	chr2:48541264	FOXN2	0.57	7.51	0.38	5.34e-13	Joint mobility (Beighton score);
LIHC	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg14515779	chr1:101123966	NA	0.49	6.76	0.34	6e-11	Monocyte count;
LIHC	cis	rs9326778	0.520	rs4348263	chr5:108845690	C/T	cg17395555	chr5:108820864	NA	-0.37	-6.26	-0.32	1.12e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-7.04	-0.36	1.08e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	0.85	11.13	0.52	9.19e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.11	-10.29	-0.49	8.37e-22	Alzheimer's disease;
LIHC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg19635926	chr16:89946313	TCF25	0.46	5.89	0.3	9.29e-9	Interleukin-17 levels;
LIHC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.3	-0.45	1.77e-18	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	13.75	0.6	1.51e-34	Alzheimer's disease;
LIHC	trans	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg04882175	chr6:131122610	NA	-0.48	-6.05	-0.31	3.7e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs2019960	0.759	rs2608025	chr8:129173122	A/G	cg15331705	chr8:129180010	NA	-0.36	-6.61	-0.34	1.52e-10	Hodgkin's lymphoma;Multiple sclerosis;
LIHC	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-7.57	-0.38	3.57e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.67	8.52	0.42	5.23e-16	Mean platelet volume;
LIHC	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.62	10.4	0.49	3.36e-22	Recombination rate (males);
LIHC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.37	-5.89	-0.3	9.12e-9	Alzheimer's disease (late onset);
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg24955955	chr5:415729	AHRR	0.32	6.47	0.33	3.33e-10	Cystic fibrosis severity;
LIHC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26059219	chr3:4508837	SUMF1	0.42	6.15	0.32	2.13e-9	Pancreatic cancer;
LIHC	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-8.13	-0.4	8.15e-15	Body mass index;
LIHC	cis	rs7116495	1.000	rs2250866	chr11:71804513	A/G	cg26138937	chr11:71823887	C11orf51	-0.76	-7.68	-0.38	1.7e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.78	-12.44	-0.56	1.52e-29	Dental caries;
LIHC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg16070018	chr6:26224392	HIST1H3E	0.65	7.79	0.39	7.91e-14	Gout;Renal underexcretion gout;
LIHC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.53	-8.98	-0.44	1.89e-17	Colorectal cancer;
LIHC	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.48	7.33	0.37	1.66e-12	HDL cholesterol;
LIHC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.69	7.28	0.37	2.3e-12	Alzheimer's disease;
LIHC	cis	rs10736390	0.538	rs12410550	chr1:55107306	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.69	-12.06	-0.55	3.93e-28	Survival in pancreatic cancer;
LIHC	cis	rs2816062	0.786	rs2816059	chr1:18902977	G/A	cg18795169	chr1:18902165	NA	-0.79	-17.25	-0.68	1.97e-48	Urate levels in lean individuals;
LIHC	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.61	0.34	1.46e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.76	11.83	0.54	2.59e-27	Eye color traits;
LIHC	cis	rs12413816	0.824	rs1571008	chr10:13760776	T/C	cg16485048	chr10:13749193	FRMD4A	0.58	8.67	0.42	1.8e-16	Red cell distribution width;
LIHC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg25894440	chr7:65020034	NA	-0.54	-6.27	-0.32	1.08e-9	Diabetic kidney disease;
LIHC	cis	rs8020095	0.528	rs6573760	chr14:67677375	G/T	cg03487553	chr14:67822707	ATP6V1D	-0.34	-5.75	-0.3	1.93e-8	Depression (quantitative trait);
LIHC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.34	6.73	0.34	7.29e-11	Multiple sclerosis;
LIHC	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.57	-8.61	-0.42	2.76e-16	Blood protein levels;
LIHC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.22	-0.36	3.35e-12	Schizophrenia;
LIHC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	0.91	16.72	0.67	2.75e-46	Bone mineral density;
LIHC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-17.37	-0.68	7.01e-49	Height;
LIHC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.51	-7.77	-0.39	9.16e-14	P wave terminal force;
LIHC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.57	-7.44	-0.37	7.96e-13	Vitiligo;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00154443	chr16:71917454	ATXN1L;ZNF821	0.45	6.08	0.31	3.29e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg23978390	chr7:1156363	C7orf50	0.43	6.19	0.32	1.74e-9	Longevity;Endometriosis;
LIHC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.57	-8.17	-0.4	6.13e-15	High light scatter reticulocyte percentage of red cells;
LIHC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.52	6.77	0.34	5.48e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-6.32	-0.32	8.28e-10	Morning vs. evening chronotype;
LIHC	cis	rs4789452	0.716	rs1105410	chr17:75383942	C/T	cg06761530	chr17:75373219	SEPT9	-0.46	-5.99	-0.31	5.31e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg10756647	chr7:56101905	PSPH	1.07	13.46	0.59	1.91e-33	Diabetic kidney disease;
LIHC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.48	7.45	0.37	7.7e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2681424	1.000	rs2681424	chr3:121769522	T/C	cg03946530	chr15:65596423	NA	0.49	6.2	0.32	1.65e-9	Multiple sclerosis;
LIHC	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg08125733	chr17:73851984	WBP2	0.5	8.12	0.4	8.52e-15	White matter hyperintensity burden;
LIHC	cis	rs8064024	0.604	rs1049212	chr16:4932929	A/G	cg08329684	chr16:4932620	PPL	-0.44	-7.79	-0.39	7.92e-14	Cancer;
LIHC	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg06336613	chr15:77223807	RCN2	0.41	5.92	0.31	7.71e-9	Blood metabolite levels;
LIHC	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.68	11.78	0.54	4.19e-27	Colorectal cancer;
LIHC	cis	rs1144333	0.850	rs1146651	chr1:76273594	C/A	cg03433033	chr1:76189801	ACADM	-0.56	-8.58	-0.42	3.33e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg25783544	chr11:47291846	MADD	0.39	5.75	0.3	1.96e-8	HDL cholesterol;
LIHC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.69	-0.5	3.38e-23	Hemoglobin concentration;
LIHC	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.78	-6.63	-0.34	1.28e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26367235	chr2:239997305	HDAC4	-0.4	-6.3	-0.32	9.2e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.7	-13.74	-0.6	1.67e-34	Body mass index;
LIHC	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.6	-0.34	1.57e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7091068	0.616	rs1890657	chr10:95506087	G/A	cg20715218	chr10:95462985	C10orf4	0.58	6.05	0.31	3.9e-9	Urinary tract infection frequency;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15827486	chr2:98262568	COX5B	-0.39	-6.12	-0.31	2.62e-9	Cognitive function;
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.58	7.51	0.38	5.35e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	0.906	rs12122851	chr1:8634290	A/G	cg25722041	chr1:8623473	RERE	-0.41	-6.09	-0.31	3.09e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.94	17.84	0.69	8.48e-51	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg26338869	chr17:61819248	STRADA	0.53	7.14	0.36	5.49e-12	Height;
LIHC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.98	11.98	0.54	7.58e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs11053548	0.614	rs11053555	chr12:10175993	G/A	cg04314261	chr12:10163030	CLEC12B	0.38	5.91	0.3	8.29e-9	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.79	-0.39	8.05e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.54	8.56	0.42	3.99e-16	Inflammatory bowel disease;
LIHC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.76	-0.43	8.95e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11761441	0.669	rs13241486	chr7:79536	G/C	cg13828236	chr7:80970	NA	0.34	8.33	0.41	2.01e-15	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.19	0.58	2.12e-32	Psoriasis;
LIHC	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg02023728	chr11:77925099	USP35	-0.33	-5.92	-0.3	8.01e-9	Alzheimer's disease (survival time);
LIHC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.65	0.42	2e-16	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.63	-8.49	-0.42	6.43e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.5	6.54	0.33	2.18e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg19336497	chr11:14380999	RRAS2	0.34	5.75	0.3	1.95e-8	Mitochondrial DNA levels;
LIHC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.55	-7.91	-0.39	3.5e-14	Uric acid levels;
LIHC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg04025307	chr7:1156635	C7orf50	0.44	5.98	0.31	5.71e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.87	11.48	0.53	5.01e-26	Blood metabolite levels;
LIHC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.74	0.43	1.08e-16	Motion sickness;
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.6	0.77	7.76e-70	Height;
LIHC	cis	rs11955398	0.583	rs7719726	chr5:59949537	T/C	cg02684056	chr5:59996105	DEPDC1B	0.43	5.98	0.31	5.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.47	6.02	0.31	4.39e-9	Alzheimer's disease;
LIHC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	5.72	0.3	2.35e-8	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.54	9.08	0.44	8.7e-18	Blood metabolite levels;
LIHC	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.45	-5.94	-0.31	7.07e-9	Obesity (extreme);
LIHC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg11161837	chr1:110010384	SYPL2	0.44	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg15105060	chr4:7024189	TBC1D14	-0.72	-6.36	-0.33	6.34e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.85	14.78	0.62	1.39e-38	Monocyte count;
LIHC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg22676075	chr6:135203613	NA	0.39	6.25	0.32	1.24e-9	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.72	9.25	0.45	2.55e-18	Eosinophilic esophagitis;
LIHC	cis	rs17106184	1.000	rs72902777	chr1:51272278	T/C	cg07174182	chr1:51127561	FAF1	-0.65	-6.99	-0.35	1.46e-11	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.66	0.38	1.89e-13	Prudent dietary pattern;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs2282802	0.685	rs2436391	chr5:139557385	C/T	cg26211634	chr5:139558579	C5orf32	-0.39	-6.05	-0.31	3.82e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-7.46	-0.37	7.22e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.41	-0.33	4.77e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg18016565	chr1:150552671	MCL1	0.57	11.59	0.53	1.95e-26	Tonsillectomy;
LIHC	cis	rs61041384	0.661	rs77193970	chr12:123516317	G/A	cg25930673	chr12:123319894	HIP1R	0.65	6.14	0.31	2.33e-9	Schizophrenia;
LIHC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.42	-0.33	4.67e-10	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7707921	1.000	rs6884232	chr5:81550043	G/A	cg15871215	chr5:81402204	ATG10	0.59	5.86	0.3	1.12e-8	Breast cancer;
LIHC	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.34	-5.77	-0.3	1.78e-8	Schizophrenia;
LIHC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.74e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.88	-0.57	3.09e-31	Acylcarnitine levels;
LIHC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg00091569	chr3:40428383	ENTPD3	-0.36	-6.12	-0.31	2.52e-9	Renal cell carcinoma;
LIHC	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.53	-0.69	1.51e-49	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08677398	chr8:58056175	NA	0.4	5.82	0.3	1.39e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.7	0.34	8.58e-11	Lung cancer in ever smokers;
LIHC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.52e-12	Personality dimensions;
LIHC	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg16589663	chr20:23618590	CST3	0.76	7.87	0.39	4.59e-14	Chronic kidney disease;
LIHC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.54	0.42	4.33e-16	Platelet count;
LIHC	cis	rs903552	1.000	rs4965873	chr15:102004023	A/G	cg25677261	chr15:102009856	PCSK6	0.46	6.23	0.32	1.37e-9	Diabetic kidney disease;
LIHC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.33	-6.3	-0.32	8.96e-10	Body mass index;
LIHC	cis	rs2971970	0.519	rs2346272	chr7:133654830	T/C	cg03336402	chr7:133662267	EXOC4	-0.48	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.55	5.78	0.3	1.65e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.47	7.53	0.38	4.6e-13	HDL cholesterol levels;
LIHC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-15.27	-0.64	1.71e-40	Ulcerative colitis;
LIHC	cis	rs3106136	0.814	rs10020236	chr4:95277993	A/G	cg11021082	chr4:95130006	SMARCAD1	0.38	6.56	0.33	2.02e-10	Capecitabine sensitivity;
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg00656387	chr3:40428638	ENTPD3	0.5	8.57	0.42	3.52e-16	Renal cell carcinoma;
LIHC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.62	9.83	0.47	3e-20	Corneal astigmatism;
LIHC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.52	-0.33	2.54e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg10935138	chr17:73851978	WBP2	0.45	6.94	0.35	1.98e-11	White matter hyperintensity burden;
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.64	-8.19	-0.4	5.32e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs507080	0.663	rs7926970	chr11:118559881	T/G	cg04173919	chr11:118528438	PHLDB1	0.35	6.62	0.34	1.42e-10	Serum metabolite levels;
LIHC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.16	0.52	6.89e-25	Monocyte percentage of white cells;
LIHC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.66	-0.42	1.92e-16	Heart rate;
LIHC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.49	9.9	0.47	1.7e-20	Tonsillectomy;
LIHC	cis	rs11212260	0.655	rs11212216	chr11:107291251	T/A	cg25435332	chr11:107328525	CWF19L2	0.8	8.13	0.4	7.75e-15	IgG glycosylation;
LIHC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.92	16.53	0.67	1.54e-45	Colorectal cancer;
LIHC	cis	rs2574704	0.816	rs2443722	chr3:11663732	A/G	cg15876825	chr3:11651881	VGLL4	-0.49	-7.38	-0.37	1.21e-12	Body mass index;
LIHC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg07713946	chr22:31675144	LIMK2	0.41	7.46	0.37	7.26e-13	Colorectal cancer;
LIHC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.49	0.33	3.09e-10	Initial pursuit acceleration;
LIHC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.31	0.58	7.5e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.25	5.79	0.3	1.63e-8	Childhood ear infection;
LIHC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.93	17.25	0.68	2.02e-48	Menopause (age at onset);
LIHC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg16586182	chr3:47516702	SCAP	-0.5	-9.13	-0.44	6.21e-18	Colorectal cancer;
LIHC	trans	rs11014306	1.000	rs6482455	chr10:25200457	C/G	cg17214381	chr4:188916668	ZFP42	-0.56	-6.13	-0.31	2.42e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs12744310	1.000	rs12036555	chr1:41777990	T/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.94	-0.31	7.07e-9	Colorectal cancer;
LIHC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25508545	chr19:49467065	FTL	0.43	6.3	0.32	8.9e-10	Pancreatic cancer;
LIHC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.39	5.9	0.3	8.83e-9	Educational attainment;
LIHC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.1	0.31	2.92e-9	Electroencephalogram traits;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.45	-6.25	-0.32	1.2e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	8.27	0.41	2.93e-15	Platelet count;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24450312	chr1:206681158	RASSF5	-0.42	-6.51	-0.33	2.69e-10	Bilirubin levels;
LIHC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.46	0.37	7.27e-13	Glycated hemoglobin levels;
LIHC	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg17130504	chr10:102756923	LZTS2	0.56	7.78	0.39	8.74e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12286929	0.617	rs11607801	chr11:115077367	A/C	cg04055981	chr11:115044050	NA	0.5	7.97	0.4	2.38e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.9	-0.3	8.64e-9	Diisocyanate-induced asthma;
LIHC	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	0.98	15.35	0.64	8.11e-41	Corneal structure;
LIHC	cis	rs11702148	0.505	rs28422170	chr21:34980443	G/C	cg14850771	chr21:34775459	IFNGR2	0.45	7.12	0.36	6.58e-12	Mean corpuscular hemoglobin;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.16	-0.32	2e-9	Longevity;Endometriosis;
LIHC	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg22705602	chr4:152727874	NA	-0.4	-7.13	-0.36	5.92e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.61	9.71	0.47	7.37e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs1865721	1.000	rs62089508	chr18:73193344	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.82	0.47	3.22e-20	Coffee consumption (cups per day);
LIHC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.55	-0.38	4e-13	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-5.86	-0.3	1.07e-8	Body mass index;
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.77	11.46	0.53	6.06e-26	Menarche (age at onset);
LIHC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.98	0.4	2.2e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21467203	chr3:49911342	NA	-0.5	-9.2	-0.45	3.73e-18	Body mass index;
LIHC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.01	-0.51	2.51e-24	Extrinsic epigenetic age acceleration;
LIHC	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.4	5.72	0.3	2.36e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.39	6.1	0.31	2.82e-9	Coronary artery disease;
LIHC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	7.46	0.37	6.98e-13	Schizophrenia;
LIHC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.61	-0.34	1.45e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6066825	0.644	rs2869669	chr20:47321449	T/C	cg18078177	chr20:47281410	PREX1	0.43	7.0	0.35	1.35e-11	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04421424	chr19:57791681	ZNF460	0.46	7.08	0.36	8.39e-12	Cognitive function;
LIHC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.42	-7.85	-0.39	5.27e-14	Neurofibrillary tangles;
LIHC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.47	-6.86	-0.35	3.26e-11	Aortic root size;
LIHC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.4	6.44	0.33	4e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.27	0.45	2.13e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg26138144	chr22:38071188	LGALS1	0.75	14.01	0.6	1.51e-35	Fat distribution (HIV);
LIHC	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg25783544	chr11:47291846	MADD	-0.42	-6.09	-0.31	3.1e-9	HDL cholesterol;
LIHC	cis	rs2737618	0.674	rs2737684	chr1:200092951	C/T	cg21825944	chr1:200113062	NR5A2	-0.46	-7.84	-0.39	5.87e-14	Uric acid levels;
LIHC	cis	rs4742903	1.000	rs4742905	chr9:106856972	G/C	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.17	0.36	4.76e-12	Parkinson's disease;
LIHC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.91	0.54	1.39e-27	Colorectal cancer;
LIHC	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.97	0.6	2.11e-35	Coffee consumption (cups per day);
LIHC	cis	rs2279817	0.735	rs71644064	chr1:18000044	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-8.05	-0.4	1.36e-14	Neuroticism;
LIHC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.87	-0.54	1.88e-27	Type 2 diabetes;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg25405998	chr7:65216604	CCT6P1	0.44	6.53	0.33	2.41e-10	Calcium levels;
LIHC	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg07689907	chr11:61582574	FADS1	0.39	5.79	0.3	1.58e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.38	-6.45	-0.33	3.89e-10	Menopause (age at onset);
LIHC	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.4	7.43	0.37	8.74e-13	Testicular germ cell tumor;
LIHC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs1494950	0.661	rs4698307	chr4:14978435	G/A	cg12377275	chr4:15005593	CPEB2	-0.79	-6.71	-0.34	8.25e-11	Political ideology;
LIHC	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg23533926	chr12:111358616	MYL2	-0.32	-6.12	-0.31	2.61e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07772128	chr15:75095447	CSK	0.35	6.2	0.32	1.65e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.86	-0.3	1.11e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.38	-6.62	-0.34	1.4e-10	Mitochondrial DNA levels;
LIHC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.32	5.9	0.3	8.91e-9	Mean corpuscular volume;
LIHC	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.29	6.22	0.32	1.43e-9	Pulmonary function;
LIHC	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	7.37	0.37	1.27e-12	Systemic lupus erythematosus;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06350176	chr11:67375936	NDUFV1	0.4	6.13	0.31	2.43e-9	Longevity;
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.52	6.92	0.35	2.19e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07305506	chr3:152058521	MBNL1;TMEM14E	0.33	6.24	0.32	1.27e-9	Hepatitis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23084309	chr19:6280164	MLLT1	-0.51	-6.21	-0.32	1.57e-9	Hepatitis;
LIHC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22961513	chr11:14280813	SPON1	0.48	7.41	0.37	1e-12	Mitochondrial DNA levels;
LIHC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.72	12.77	0.57	8.53e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.95	0.65	3.35e-43	Electrocardiographic conduction measures;
LIHC	cis	rs7258465	0.965	rs748609	chr19:18560282	T/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.31	-0.37	1.92e-12	Breast cancer;
LIHC	trans	rs8117834	0.574	rs73076229	chr20:8081430	G/A	cg00593689	chr4:53575888	NA	0.38	6.36	0.33	6.66e-10	Chronic kidney disease;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11636631	chr22:20428109	NA	-0.42	-6.14	-0.32	2.23e-9	Migraine with aura;
LIHC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.13	-0.31	2.4e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-1.19	-10.49	-0.49	1.66e-22	Breast cancer;
LIHC	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.99	15.72	0.65	2.66e-42	Obesity;Body mass index;
LIHC	cis	rs28735056	0.565	rs2012687	chr18:77711127	G/T	cg20368463	chr18:77673604	PQLC1	-0.36	-6.11	-0.31	2.73e-9	Schizophrenia;
LIHC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.51	0.53	3.98e-26	High light scatter reticulocyte count;
LIHC	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.68	-12.26	-0.55	7.03e-29	Pediatric autoimmune diseases;
LIHC	cis	rs1555399	0.868	rs7160944	chr14:67983485	G/A	cg16224230	chr14:67978224	TMEM229B	-0.25	-6.04	-0.31	4.02e-9	Parkinson's disease;
LIHC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.34	-6.38	-0.33	5.67e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.32	0.32	8.12e-10	Prudent dietary pattern;
LIHC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.06	0.55	3.67e-28	Alzheimer's disease;
LIHC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-8.23	-0.41	3.86e-15	Lung cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02546883	chr6:157721111	C6orf35	0.5	6.98	0.35	1.55e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg05110241	chr16:68378359	PRMT7	-0.7	-7.36	-0.37	1.38e-12	Schizophrenia;
LIHC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.75	-12.45	-0.56	1.34e-29	Aortic root size;
LIHC	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.48	6.51	0.33	2.69e-10	Inflammatory skin disease;
LIHC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02290350	chr8:58132656	NA	0.38	7.93	0.39	3.13e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.48	-8.02	-0.4	1.73e-14	Blood metabolite levels;
LIHC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	14.8	0.62	1.24e-38	Chronic sinus infection;
LIHC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.47	-6.86	-0.35	3.21e-11	Corneal structure;
LIHC	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.28	-0.32	1.02e-9	Schizophrenia;
LIHC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.57	7.18	0.36	4.25e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.43	7.91	0.39	3.71e-14	Schizophrenia;
LIHC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.52	-7.73	-0.39	1.24e-13	Total body bone mineral density;
LIHC	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.39	6.21	0.32	1.51e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	0.89	8.58	0.42	3.41e-16	Alzheimer's disease;
LIHC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.27e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.56	0.8	1.79e-77	Prudent dietary pattern;
LIHC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.39	-0.33	5.45e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg08888203	chr3:10149979	C3orf24	0.45	5.88	0.3	9.54e-9	Alzheimer's disease;
LIHC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg09835421	chr16:68378352	PRMT7	-0.51	-6.08	-0.31	3.26e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.67	-8.01	-0.4	1.79e-14	Morning vs. evening chronotype;
LIHC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.67	9.77	0.47	4.76e-20	IgG glycosylation;
LIHC	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.53	6.31	0.32	8.67e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.84	11.81	0.54	3.05e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.71	10.56	0.5	9.29e-23	Aortic root size;
LIHC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.28	-6.9	-0.35	2.48e-11	Mean corpuscular volume;
LIHC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.25	0.32	1.24e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.47	-0.42	7.57e-16	Chronic sinus infection;
LIHC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg21724239	chr8:58056113	NA	0.43	5.85	0.3	1.18e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3790645	1.000	rs369385	chr1:26893229	C/T	cg17456097	chr1:26900765	RPS6KA1	0.4	5.82	0.3	1.33e-8	Glucose homeostasis traits;
LIHC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.95	-0.57	1.71e-31	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-11.96	-0.54	8.84e-28	Colorectal cancer;
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	9.26	0.45	2.38e-18	Height;
LIHC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.27	-0.32	1.1e-9	Coronary artery disease;
LIHC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.57	-6.44	-0.33	4.08e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs74181299	0.520	rs11684110	chr2:65368290	A/G	cg05010058	chr2:65284262	CEP68	-0.35	-5.81	-0.3	1.45e-8	Pulse pressure;
LIHC	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.47	9.75	0.47	5.69e-20	Immature fraction of reticulocytes;
LIHC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.01	-0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.36	-0.33	6.49e-10	Bipolar disorder;
LIHC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.51	0.33	2.68e-10	Mean corpuscular volume;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.67	10.1	0.48	3.76e-21	Menarche (age at onset);
LIHC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.31	6.04	0.31	3.99e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.45	-6.82	-0.35	4.08e-11	Asthma (sex interaction);
LIHC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	8.87	0.43	4.26e-17	Schizophrenia;
LIHC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.72	-0.34	7.41e-11	Mood instability;
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27297192	chr10:134578999	INPP5A	0.53	7.39	0.37	1.15e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg19920283	chr7:105172520	RINT1	0.66	6.02	0.31	4.39e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg13446199	chr8:143762866	PSCA	-0.2	-5.76	-0.3	1.85e-8	Urinary tract infection frequency;
LIHC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.22	-0.36	3.41e-12	Bipolar disorder;
LIHC	cis	rs55665837	0.665	rs11023273	chr11:14630819	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-6.21	-0.32	1.57e-9	Vitamin D levels;
LIHC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs600806	0.778	rs518697	chr1:110014778	G/A	cg23091122	chr1:110024289	SYPL2	-0.44	-6.09	-0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg27490568	chr2:178487706	NA	0.81	7.56	0.38	3.8e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg26542501	chr3:124449238	UMPS	-0.46	-6.2	-0.32	1.61e-9	DNA methylation (variation);
LIHC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.72	11.73	0.54	6.15e-27	Breast cancer;
LIHC	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.34	6.69	0.34	9.17e-11	Cancer;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-8.31	-0.41	2.22e-15	Lymphocyte counts;
LIHC	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-9.38	-0.45	9.05e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.87	-13.79	-0.6	1.06e-34	Metabolic syndrome;
LIHC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.47	-6.11	-0.31	2.67e-9	Parkinson's disease;
LIHC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.11	0.36	6.76e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg08847533	chr14:75593920	NEK9	-0.38	-6.46	-0.33	3.59e-10	Caffeine consumption;
LIHC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg00792783	chr2:198669748	PLCL1	0.41	5.93	0.31	7.58e-9	Intracranial aneurysm;
LIHC	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.54	8.54	0.42	4.39e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg12365402	chr11:9010492	NRIP3	0.31	7.91	0.39	3.7e-14	Hemoglobin concentration;
LIHC	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.36	7.12	0.36	6.52e-12	Multiple sclerosis;
LIHC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-6.52	-0.33	2.58e-10	Vitiligo;
LIHC	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg01528321	chr10:82214614	TSPAN14	-0.67	-7.23	-0.36	3.27e-12	Post bronchodilator FEV1;
LIHC	cis	rs3736485	0.903	rs11630743	chr15:51750609	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.24	-0.32	1.26e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg11764359	chr7:65958608	NA	0.58	5.9	0.3	8.51e-9	Diabetic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24634408	chr4:177250214	SPCS3	0.27	6.22	0.32	1.48e-9	Cognitive function;
LIHC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg22346081	chr1:109937191	SORT1	-0.51	-6.02	-0.31	4.51e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs3780378	0.875	rs7869668	chr9:5069837	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-9.2	-0.45	3.68e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.57	-10.8	-0.5	1.38e-23	Alzheimer's disease (late onset);
LIHC	cis	rs4699052	0.662	rs1996346	chr4:104250324	C/T	cg16532752	chr4:104119610	CENPE	-0.37	-5.75	-0.3	2e-8	Testicular germ cell tumor;
LIHC	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	0.79	9.08	0.44	8.8e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.63	-9.31	-0.45	1.55e-18	Total body bone mineral density;
LIHC	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg14515779	chr1:101123966	NA	0.47	6.73	0.34	7.27e-11	Monocyte count;
LIHC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.58	7.58	0.38	3.23e-13	Parkinson's disease;
LIHC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.57	10.94	0.51	4.38e-24	Coronary artery disease;
LIHC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg12463550	chr7:65579703	CRCP	0.78	6.81	0.35	4.52e-11	Gout;
LIHC	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.32	-0.7	1.01e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.95	15.72	0.65	2.84e-42	Metabolic syndrome;
LIHC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.64	9.32	0.45	1.51e-18	Corneal astigmatism;
LIHC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg16586182	chr3:47516702	SCAP	-0.5	-8.93	-0.43	2.66e-17	Colorectal cancer;
LIHC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.42	6.0	0.31	5.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.43	6.12	0.31	2.51e-9	Longevity;Endometriosis;
LIHC	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.53	-7.58	-0.38	3.19e-13	Obesity-related traits;
LIHC	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.47	0.33	3.39e-10	Ileal carcinoids;
LIHC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg22777020	chr22:31556080	RNF185	-0.56	-6.47	-0.33	3.38e-10	Colorectal cancer;
LIHC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.5	7.06	0.36	9.17e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.56	9.99	0.48	8.35e-21	Age at first birth;
LIHC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.71	-13.31	-0.58	7.39e-33	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.39	6.95	0.35	1.88e-11	Obesity;
LIHC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.79	-0.3	1.61e-8	Pulse pressure;
LIHC	trans	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg17712092	chr4:129076599	LARP1B	-0.69	-10.6	-0.5	6.74e-23	Eosinophil percentage of white cells;
LIHC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-1.0	-19.13	-0.72	5.67e-56	Breast cancer;
LIHC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.48	8.61	0.42	2.62e-16	Alcohol dependence;
LIHC	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.84	0.65	9.2e-43	Electrocardiographic conduction measures;
LIHC	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg26139080	chr11:47293733	MADD	-0.5	-8.36	-0.41	1.64e-15	HDL cholesterol;
LIHC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.48	7.09	0.36	7.95e-12	Response to diuretic therapy;
LIHC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.66	10.07	0.48	4.8e-21	Body mass index;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23939932	chr2:242664240	ING5	-0.4	-6.08	-0.31	3.14e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg18016565	chr1:150552671	MCL1	0.56	10.68	0.5	3.68e-23	Melanoma;
LIHC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	7.86	0.39	5.17e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs11605275	1.000	rs76735151	chr11:20026419	G/A	cg14835545	chr11:20032148	NAV2	-0.71	-6.63	-0.34	1.32e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.86	-0.3	1.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4759375	0.598	rs11060762	chr12:123403710	C/A	cg25930673	chr12:123319894	HIP1R	0.62	6.43	0.33	4.2e-10	HDL cholesterol;
LIHC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06026331	chr20:60912101	LAMA5	0.39	5.79	0.3	1.59e-8	Colorectal cancer;
LIHC	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs611744	0.967	rs584555	chr8:109218612	C/G	cg18478394	chr8:109455254	TTC35	0.42	7.18	0.36	4.37e-12	Dupuytren's disease;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.01e-19	Renal cell carcinoma;
LIHC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.77	-11.73	-0.54	6.02e-27	Total body bone mineral density;
LIHC	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	8.49	0.42	6.42e-16	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.39	-8.91	-0.43	3.09e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.86	0.3	1.07e-8	Educational attainment;
LIHC	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.5	7.96	0.4	2.49e-14	Cocaine dependence;
LIHC	cis	rs7258015	1.000	rs7257871	chr19:10449252	T/C	cg13981319	chr19:10446556	ICAM3	0.46	7.21	0.36	3.68e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs4908768	0.657	rs1353130	chr1:8822364	T/C	cg20416874	chr1:8611966	RERE	0.46	6.59	0.34	1.64e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3760776	0.522	rs78060698	chr19:5832773	G/A	cg25387410	chr19:5844109	FUT3	-0.63	-7.27	-0.37	2.43e-12	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
LIHC	cis	rs882732	1.000	rs910342	chr14:95038047	G/T	cg14866387	chr14:95027382	SERPINA4	-0.46	-6.19	-0.32	1.74e-9	Blood protein levels;
LIHC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.47	8.18	0.4	5.76e-15	Colorectal cancer;
LIHC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.53	-9.05	-0.44	1.1e-17	Total body bone mineral density;
LIHC	cis	rs9527	0.518	rs11191530	chr10:104800044	C/T	cg15744005	chr10:104629667	AS3MT	0.46	6.37	0.33	6.22e-10	Arsenic metabolism;
LIHC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.91	-0.3	8.14e-9	Life satisfaction;
LIHC	trans	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.18	-0.4	5.47e-15	Obesity-related traits;
LIHC	cis	rs1403694	1.000	rs1648716	chr3:186439529	C/T	cg12454167	chr3:186435060	KNG1	0.29	7.17	0.36	4.62e-12	Blood protein levels;
LIHC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-8.09	-0.4	1.03e-14	Total body bone mineral density;
LIHC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.59	7.58	0.38	3.25e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.31	-0.32	8.41e-10	Total body bone mineral density;
LIHC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg12365402	chr11:9010492	NRIP3	-0.27	-6.64	-0.34	1.27e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.43	-6.98	-0.35	1.5e-11	Monobrow;
LIHC	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.58	-0.38	3.29e-13	QT interval;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg13152130	chr6:118910203	C6orf204	-0.65	-7.47	-0.37	6.87e-13	Diastolic blood pressure;
LIHC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.41	6.1	0.31	2.84e-9	Age at first birth;
LIHC	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg02450064	chr17:40260053	DHX58	-0.3	-6.07	-0.31	3.47e-9	Fibrinogen levels;
LIHC	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.56	-9.8	-0.47	3.86e-20	Gout;
LIHC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg18944383	chr4:111397179	ENPEP	0.25	6.14	0.32	2.3e-9	Height;
LIHC	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.32	-5.94	-0.31	6.94e-9	Systemic lupus erythematosus;
LIHC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg06265175	chr8:121136014	COL14A1	0.48	7.83	0.39	6.23e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.57	-6.01	-0.31	4.63e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs7619427	1.000	rs6788179	chr3:44062007	G/A	cg24966902	chr3:44043705	NA	0.53	7.37	0.37	1.31e-12	Schizophrenia;
LIHC	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.37	-0.33	6.18e-10	Putamen volume;
LIHC	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.39	9.57	0.46	2.29e-19	Blood metabolite ratios;
LIHC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg15269541	chr15:43626905	ADAL	-0.3	-5.88	-0.3	9.9e-9	Lung cancer in ever smokers;
LIHC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.4	8.66	0.42	1.88e-16	Prostate-specific antigen levels;
LIHC	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-5.88	-0.3	9.69e-9	Diastolic blood pressure;
LIHC	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.81	-0.3	1.47e-8	Red blood cell count;
LIHC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18357526	chr6:26021779	HIST1H4A	0.54	7.21	0.36	3.61e-12	Blood metabolite levels;
LIHC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg18887096	chr2:219472410	PLCD4	0.35	6.06	0.31	3.63e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7911264	1.000	rs10786052	chr10:94446635	T/C	cg25506282	chr10:94462361	NA	0.43	7.46	0.37	7.3e-13	Inflammatory bowel disease;
LIHC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.41	-9.73	-0.47	6.34e-20	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg08345082	chr10:99160200	RRP12	-0.38	-6.25	-0.32	1.23e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.94	22.36	0.77	6.84e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.79	12.1	0.55	2.79e-28	Breast cancer;
LIHC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.59	-0.59	6.14e-34	Coffee consumption (cups per day);
LIHC	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg02081065	chr5:132209139	LEAP2	0.26	5.73	0.3	2.23e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs965469	1.000	rs6051806	chr20:3350319	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.43	-0.33	4.33e-10	IFN-related cytopenia;
LIHC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.64	11.35	0.52	1.45e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.03	-0.31	4.16e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.83	-13.78	-0.6	1.2e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs72627123	0.749	rs58199545	chr14:74452495	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.46	0.42	8.11e-16	Morning vs. evening chronotype;
LIHC	cis	rs5769765	0.773	rs7410304	chr22:50316835	T/C	cg02269571	chr22:50332266	NA	-0.63	-8.59	-0.42	3.16e-16	Schizophrenia;
LIHC	trans	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.41	0.33	4.71e-10	Ulcerative colitis;
LIHC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.33	-0.45	1.33e-18	Hemoglobin concentration;
LIHC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	6.39	0.33	5.34e-10	Parkinson's disease;
LIHC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg13047869	chr3:10149882	C3orf24	0.5	6.16	0.32	2.08e-9	Alzheimer's disease;
LIHC	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.74	12.06	0.55	3.84e-28	Body mass index;
LIHC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.59	8.72	0.43	1.27e-16	Body mass index;
LIHC	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.58	0.42	3.36e-16	Corneal astigmatism;
LIHC	cis	rs10861342	1.000	rs11112390	chr12:105542200	A/C	cg23923672	chr12:105501055	KIAA1033	0.68	8.46	0.42	7.85e-16	IgG glycosylation;
LIHC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg06951627	chr6:26196580	NA	0.46	5.8	0.3	1.5e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.42	-6.08	-0.31	3.22e-9	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	6.6	0.34	1.54e-10	Iron status biomarkers;
LIHC	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg17724175	chr1:150552817	MCL1	-0.33	-6.31	-0.32	8.86e-10	Tonsillectomy;
LIHC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-8.77	-0.43	8.3e-17	IgG glycosylation;
LIHC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	9.43	0.45	6.32e-19	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13921570	chr2:74730534	LOC151534;LBX2	0.39	6.23	0.32	1.38e-9	Cognitive function;
LIHC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.38	-0.64	6.28e-41	Headache;
LIHC	cis	rs76533333	0.564	rs114940891	chr13:113419784	A/T	cg08557188	chr13:113420371	ATP11A	-0.8	-6.03	-0.31	4.29e-9	Red cell distribution width;
LIHC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.49	7.55	0.38	3.94e-13	Methadone dose in opioid dependence;
LIHC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-11.89	-0.54	1.6e-27	Primary sclerosing cholangitis;
LIHC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-9.31	-0.45	1.56e-18	Mean corpuscular volume;
LIHC	trans	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.45	-6.44	-0.33	4.11e-10	Type 2 diabetes;
LIHC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	trans	rs6512645	1.000	rs6512645	chr20:49087012	A/G	cg12401738	chr4:39460100	LIAS;RPL9	0.42	6.13	0.31	2.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-11.15	-0.52	7.67e-25	Platelet count;
LIHC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.74	13.71	0.6	2.19e-34	Blood protein levels;
LIHC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg06466757	chr4:1255808	NA	0.35	5.93	0.31	7.24e-9	Obesity-related traits;
LIHC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-7.41	-0.37	1.02e-12	Longevity;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.74	-0.34	6.85e-11	Total body bone mineral density;
LIHC	trans	rs10761482	0.532	rs1938533	chr10:62234109	G/C	cg17314160	chr12:110399253	GIT2	-0.41	-6.11	-0.31	2.73e-9	Schizophrenia;
LIHC	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg17385448	chr1:15911702	AGMAT	0.4	6.73	0.34	7.25e-11	Systolic blood pressure;
LIHC	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.26	-0.32	1.12e-9	Corneal astigmatism;
LIHC	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg16070018	chr6:26224392	HIST1H3E	0.44	6.16	0.32	2.09e-9	Gout;Renal underexcretion gout;
LIHC	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.5	-0.46	3.77e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12220238	0.915	rs10824164	chr10:76137032	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2257205	0.667	rs8075108	chr17:56657248	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-6.69	-0.34	8.94e-11	Pancreatic cancer;
LIHC	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg12863693	chr15:85201151	NMB	0.44	6.06	0.31	3.66e-9	Schizophrenia;
LIHC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-8.47	-0.42	7.53e-16	Body mass index;
LIHC	cis	rs400736	0.550	rs426561	chr1:8057254	T/C	cg25007680	chr1:8021821	PARK7	0.53	7.16	0.36	5.06e-12	Response to antidepressants and depression;
LIHC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.64	-11.81	-0.54	3.25e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2997447	0.761	rs56299762	chr1:26441638	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.98	-0.31	5.59e-9	QRS complex (12-leadsum);
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg14651457	chr8:12611650	LONRF1	-0.54	-6.78	-0.34	5.37e-11	Monocyte count;
LIHC	cis	rs9473924	0.505	rs7768747	chr6:50931762	G/A	cg14470998	chr6:50812995	TFAP2B	0.86	7.83	0.39	6.39e-14	Body mass index;
LIHC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg16576597	chr16:28551801	NUPR1	0.37	5.85	0.3	1.13e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.37	0.33	6.04e-10	Height;
LIHC	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.59	8.04	0.4	1.49e-14	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.34	5.89	0.3	9.43e-9	Electroencephalogram traits;
LIHC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs4950322	0.512	rs12409455	chr1:146850284	A/G	cg25205988	chr1:146714368	CHD1L	-0.41	-5.95	-0.31	6.75e-9	Protein quantitative trait loci;
LIHC	cis	rs7106204	0.609	rs11824883	chr11:24284952	G/A	ch.11.24196551F	chr11:24239977	NA	0.69	6.41	0.33	4.84e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs2363709	1.000	rs2363709	chr3:67417105	G/A	cg22969669	chr19:19613165	GATAD2A	0.66	6.13	0.31	2.48e-9	IgE levels;
LIHC	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.46	-6.69	-0.34	9.07e-11	Neuroticism;
LIHC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.64e-30	Menopause (age at onset);
LIHC	trans	rs12960119	0.536	rs12957996	chr18:23723250	C/T	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.37	-5.92	-0.3	7.73e-9	Mortality in heart failure;
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16781439	chr22:29469035	KREMEN1	0.4	6.14	0.32	2.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.32	-6.72	-0.34	7.69e-11	Longevity;
LIHC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.65	11.43	0.53	7.39e-26	Longevity;Endometriosis;
LIHC	cis	rs4742903	0.935	rs9942894	chr9:106914905	A/G	cg14250997	chr9:106856677	SMC2	0.37	6.35	0.32	6.73e-10	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.8e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg09990169	chr2:241835740	C2orf54	-0.66	-9.26	-0.45	2.24e-18	Urinary metabolites;
LIHC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.35	6.07	0.31	3.34e-9	Body mass index;
LIHC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02985541	chr2:219472218	PLCD4	0.42	6.89	0.35	2.72e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	20.66	0.75	4e-62	Height;
LIHC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.55	7.29	0.37	2.14e-12	Emphysema distribution in smoking;
LIHC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.67	-9.93	-0.47	1.42e-20	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.94	17.61	0.69	7.29e-50	Menopause (age at onset);
LIHC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg21531657	chr3:10005747	TMEM111	0.39	5.83	0.3	1.28e-8	Alzheimer's disease;
LIHC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.49	7.55	0.38	3.94e-13	Methadone dose in opioid dependence;
LIHC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg00809820	chr17:80708513	TBCD;FN3K	0.35	6.0	0.31	5.03e-9	Glycated hemoglobin levels;
LIHC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.52	8.07	0.4	1.17e-14	Tonsillectomy;
LIHC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	7.97	0.4	2.34e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg23533926	chr12:111358616	MYL2	-0.31	-6.18	-0.32	1.85e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25216613	chr1:3541447	TPRG1L	-0.6	-6.98	-0.35	1.58e-11	Systolic blood pressure;
LIHC	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.96	0.6	2.31e-35	Coffee consumption (cups per day);
LIHC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.96	-0.31	6.11e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.97	0.54	8.37e-28	Coffee consumption (cups per day);
LIHC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.23	-10.59	-0.5	7.19e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs10878977	0.586	rs2006838	chr12:69816232	A/C	cg17330252	chr12:69809627	NA	0.37	5.88	0.3	9.79e-9	Colorectal cancer;
LIHC	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-12.43	-0.56	1.57e-29	Pediatric autoimmune diseases;
LIHC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg12042659	chr19:58951599	ZNF132	0.38	6.38	0.33	5.89e-10	Uric acid clearance;
LIHC	trans	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg09872104	chr7:134855509	C7orf49	-0.76	-6.09	-0.31	2.99e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.76	-0.43	9.08e-17	Total cholesterol levels;
LIHC	cis	rs7106204	0.513	rs7131112	chr11:24249402	A/G	ch.11.24196551F	chr11:24239977	NA	0.79	10.77	0.5	1.71e-23	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg05425664	chr17:57184151	TRIM37	-0.41	-5.87	-0.3	1e-8	Testicular germ cell tumor;
LIHC	cis	rs611744	0.935	rs679077	chr8:109244742	G/T	cg18478394	chr8:109455254	TTC35	0.38	6.55	0.33	2.09e-10	Dupuytren's disease;
LIHC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.81	12.74	0.57	1.12e-30	Height;
LIHC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.71	13.42	0.59	2.79e-33	Mortality in heart failure;
LIHC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21467203	chr3:49911342	NA	-0.41	-7.17	-0.36	4.75e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.59	0.46	1.93e-19	Mean platelet volume;
LIHC	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.97	10.75	0.5	2.07e-23	Neuroticism;
LIHC	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.44	-0.33	3.95e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs55665837	0.701	rs11023278	chr11:14641184	G/T	cg16394018	chr11:14927549	NA	0.41	5.71	0.3	2.45e-8	Vitamin D levels;
LIHC	cis	rs10792665	1.000	rs10792665	chr11:82649768	G/T	cg24227371	chr11:82718527	RAB30	-0.29	-6.56	-0.33	1.99e-10	Obesity-related traits;
LIHC	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.42	7.5	0.38	5.37e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg17074339	chr11:11642133	GALNTL4	0.45	7.11	0.36	6.86e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.43	6.01	0.31	4.72e-9	Uric acid clearance;
LIHC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.49	5.77	0.3	1.79e-8	Morning vs. evening chronotype;
LIHC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.02e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.33	-8.4	-0.41	1.24e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg15676719	chr1:167598521	RCSD1	0.38	6.64	0.34	1.2e-10	Systemic lupus erythematosus;
LIHC	cis	rs25645	0.502	rs1007654	chr17:38111354	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-7.29	-0.37	2.19e-12	Myeloid white cell count;
LIHC	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.8	-0.47	3.81e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.52	-8.5	-0.42	5.84e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.64	10.3	0.49	7.46e-22	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24835014	chr4:76911891	SDAD1	-0.45	-6.19	-0.32	1.7e-9	Pancreatic cancer;
LIHC	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg14222432	chr12:29376421	FAR2	0.35	6.68	0.34	9.96e-11	QT interval;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22352273	chr2:238969464	SCLY	0.57	7.42	0.37	9.08e-13	Lung function (FEV1/FVC);
LIHC	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.13	-0.31	2.35e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.46	7.2	0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12379764	chr21:47803548	PCNT	-0.55	-8.15	-0.4	6.76e-15	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.45	0.56	1.28e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.55	9.91	0.47	1.65e-20	Mean corpuscular volume;
LIHC	cis	rs9649465	0.902	rs10253850	chr7:123273095	T/C	cg03229431	chr7:123269106	ASB15	-0.42	-9.27	-0.45	2.12e-18	Migraine;
LIHC	cis	rs17152411	0.600	rs10901841	chr10:126632386	C/A	cg07906193	chr10:126599966	NA	-0.29	-5.72	-0.3	2.35e-8	Height;
LIHC	trans	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg09357268	chr20:43379437	KCNK15	-0.29	-6.07	-0.31	3.31e-9	Triglycerides;
LIHC	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.2	0.32	1.62e-9	Renal cell carcinoma;
LIHC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.57	0.46	2.2e-19	Attention deficit hyperactivity disorder;
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.95	0.35	1.89e-11	Renal cell carcinoma;
LIHC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg16586182	chr3:47516702	SCAP	-0.54	-9.83	-0.47	2.93e-20	Colorectal cancer;
LIHC	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg23587288	chr2:27483067	SLC30A3	-0.31	-5.91	-0.3	8.1e-9	Blood metabolite levels;
LIHC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.2	-0.32	1.65e-9	Total body bone mineral density;
LIHC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.45	7.97	0.4	2.42e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs17776563	0.959	rs1348003	chr15:89113441	G/C	cg05013243	chr15:89149849	MIR1179	0.45	7.51	0.38	5.07e-13	Thyroid hormone levels;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.04	0.55	4.65e-28	Prudent dietary pattern;
LIHC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20135002	chr11:47629003	NA	0.51	8.67	0.42	1.77e-16	Subjective well-being;
LIHC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg19680672	chr10:131412579	MGMT	-0.46	-7.03	-0.36	1.16e-11	Response to temozolomide;
LIHC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.3	-7.03	-0.36	1.15e-11	Menarche (age at onset);
LIHC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.78	12.89	0.57	2.83e-31	Anterior chamber depth;
LIHC	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.41	6.58	0.34	1.75e-10	Intraocular pressure;
LIHC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.99e-10	Personality dimensions;
LIHC	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.85	-0.3	1.14e-8	Urinary tract infection frequency;
LIHC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.49	7.76	0.39	1.02e-13	Platelet count;
LIHC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.79	11.74	0.54	5.69e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-5.73	-0.3	2.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs507080	0.733	rs4393358	chr11:118569097	C/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.09	0.31	3.01e-9	Serum metabolite levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg27402845	chr11:1000533	AP2A2	0.44	6.52	0.33	2.57e-10	Bilirubin levels;
LIHC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.37	6.28	0.32	1.02e-9	IgG glycosylation;
LIHC	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.9	-0.39	3.79e-14	Vitamin D levels;
LIHC	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.51e-18	Coffee consumption (cups per day);
LIHC	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg18225595	chr11:63971243	STIP1	-0.64	-9.72	-0.47	7.28e-20	Platelet count;
LIHC	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg20129853	chr10:51489980	NA	-0.43	-9.44	-0.45	6.14e-19	Prostate-specific antigen levels;
LIHC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg15691649	chr6:25882328	NA	-0.61	-8.21	-0.41	4.46e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.48	5.71	0.3	2.42e-8	Bladder cancer;
LIHC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.77	14.88	0.63	5.65e-39	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.23	-0.52	3.98e-25	Coronary artery disease;
LIHC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs263063	0.764	rs2291149	chr19:5077336	G/A	cg18473234	chr19:5097819	KDM4B	0.56	6.99	0.35	1.47e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.81	13.22	0.58	1.59e-32	Breast cancer;
LIHC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.74	0.34	6.71e-11	Tonsillectomy;
LIHC	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg06634786	chr22:41940651	POLR3H	0.56	6.16	0.32	2e-9	Vitiligo;
LIHC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.83	0.54	2.58e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs61550741	1.000	rs2833286	chr21:32499577	A/G	cg23515853	chr17:79372528	BAHCC1	-0.66	-6.21	-0.32	1.55e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.5	-7.67	-0.38	1.86e-13	Cognitive function;
LIHC	trans	rs35668226	1.000	rs36040970	chr10:122848990	G/C	cg08474467	chr16:593365	SOLH	0.41	6.04	0.31	4e-9	Type 2 diabetes;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.58	-5.9	-0.3	8.72e-9	Diastolic blood pressure;
LIHC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.88	-13.66	-0.59	3.36e-34	Body mass index;
LIHC	cis	rs5769765	0.624	rs138843	chr22:50183162	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.53	-6.34	-0.32	7.11e-10	Schizophrenia;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04362095	chr11:63592001	C11orf84	-0.46	-6.92	-0.35	2.18e-11	Pulse pressure;
LIHC	cis	rs6504622	0.537	rs197919	chr17:45003675	C/T	cg16759221	chr17:45003025	GOSR2	-0.33	-5.82	-0.3	1.38e-8	Orofacial clefts;
LIHC	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.2	-0.32	1.6e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg03517284	chr6:25882590	NA	-0.44	-6.65	-0.34	1.17e-10	Height;
LIHC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.93	0.31	7.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg09904177	chr6:26538194	HMGN4	0.44	6.32	0.32	8.32e-10	Small cell lung carcinoma;
LIHC	cis	rs911119	0.954	rs116786204	chr20:23599918	T/G	cg16589663	chr20:23618590	CST3	0.72	7.6	0.38	2.88e-13	Chronic kidney disease;
LIHC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.81	-0.35	4.41e-11	Psoriasis;
LIHC	cis	rs903552	0.935	rs4965387	chr15:102003209	G/A	cg19295451	chr15:102010161	PCSK6	-0.45	-6.36	-0.32	6.65e-10	Diabetic kidney disease;
LIHC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.89	-0.35	2.63e-11	Hepatocellular carcinoma;
LIHC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg24977027	chr2:88469347	THNSL2	-0.34	-5.96	-0.31	6.14e-9	Response to metformin (IC50);
LIHC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-7.69	-0.38	1.59e-13	Systemic lupus erythematosus;
LIHC	cis	rs7238033	0.624	rs8096571	chr18:43314473	T/A	cg20610511	chr18:43302872	SLC14A1	0.37	6.24	0.32	1.31e-9	Bladder cancer;
LIHC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg00204748	chr12:29376779	FAR2	0.4	7.49	0.38	5.92e-13	QT interval;
LIHC	trans	rs1814175	0.646	rs10839335	chr11:49715265	G/T	cg03929089	chr4:120376271	NA	-0.86	-16.65	-0.67	5.35e-46	Height;
LIHC	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.76	12.7	0.57	1.59e-30	Menarche (age at onset);
LIHC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.6	-9.2	-0.45	3.53e-18	Uric acid clearance;
LIHC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-9.0	-0.44	1.56e-17	Bipolar disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01272058	chr19:40926777	NA	0.49	6.58	0.34	1.78e-10	Lung function (FEV1/FVC);
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg18306943	chr3:40428807	ENTPD3	0.4	7.01	0.35	1.29e-11	Renal cell carcinoma;
LIHC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-7.78	-0.39	8.7e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.22	5.95	0.31	6.58e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-0.85	-9.21	-0.45	3.37e-18	Exhaled nitric oxide output;
LIHC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.7	10.64	0.5	4.85e-23	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.57	-9.05	-0.44	1.12e-17	Coronary artery disease;
LIHC	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg02951883	chr7:2050386	MAD1L1	-0.48	-7.45	-0.37	7.63e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg17130504	chr10:102756923	LZTS2	0.56	7.78	0.39	8.74e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.77	-0.3	1.8e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.77	11.49	0.53	4.61e-26	Subjective well-being;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.26	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.3	-5.81	-0.3	1.41e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.47	8.45	0.42	8.36e-16	IgG glycosylation;
LIHC	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.33	-0.37	1.71e-12	Response to antipsychotic treatment;
LIHC	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.84	9.03	0.44	1.26e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.42	-0.33	4.49e-10	Height;
LIHC	cis	rs6442522	0.678	rs3773451	chr3:15510133	T/G	cg16303742	chr3:15540471	COLQ	0.45	7.68	0.38	1.7e-13	Uric acid levels;
LIHC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.46	6.11	0.31	2.66e-9	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.82	-0.57	5.53e-31	Alzheimer's disease;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.13	-0.31	2.49e-9	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg18279126	chr7:2041391	MAD1L1	0.38	6.41	0.33	4.89e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.59	-0.38	3.04e-13	Calcium levels;
LIHC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.95	9.7	0.46	8.02e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs9513627	1.000	rs73556181	chr13:100122092	G/A	cg25919922	chr13:100150906	NA	-0.8	-7.07	-0.36	8.77e-12	Obesity-related traits;
LIHC	cis	rs11605275	0.892	rs16937352	chr11:20032010	G/C	cg14835545	chr11:20032148	NAV2	-0.8	-7.38	-0.37	1.18e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.82	0.47	3.16e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.88	0.3	9.7e-9	Tonsillectomy;
LIHC	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.37e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.12e-9	Menopause (age at onset);
LIHC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.53	7.69	0.38	1.58e-13	Type 2 diabetes;
LIHC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	1.01	19.45	0.72	2.9e-57	Breast cancer;
LIHC	cis	rs6976053	0.518	rs144173	chr7:100416250	A/G	cg03098644	chr7:100410630	EPHB4	-0.42	-6.78	-0.34	5.38e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg09222892	chr1:25734099	RHCE	-0.46	-8.47	-0.42	7.22e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.32	-0.32	8.21e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.85e-13	Lymphocyte counts;
LIHC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.41	6.84	0.35	3.76e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg14515779	chr1:101123966	NA	0.45	6.37	0.33	6.13e-10	Monocyte count;
LIHC	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.66	0.46	1.1e-19	Corneal astigmatism;
LIHC	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.49	7.79	0.39	7.92e-14	Blood protein levels;
LIHC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg07636037	chr3:49044803	WDR6	-0.79	-8.19	-0.4	5.34e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.07	-0.48	4.52e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	cis	rs1866706	0.865	rs17488051	chr11:12861994	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-6.92	-0.35	2.28e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7897654	0.571	rs12767543	chr10:104631663	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.54	-0.38	4.23e-13	Schizophrenia;
LIHC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.95	22.44	0.77	3.39e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.62	8.96	0.44	2.07e-17	Left atrial antero-posterior diameter;
LIHC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs61712019	0.724	rs11126614	chr2:77722736	G/A	cg11252801	chr2:77748917	LRRTM4	0.56	7.73	0.39	1.2e-13	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22365063	chr1:231473646	C1orf124;EXOC8	-0.48	-7.04	-0.36	1.05e-11	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.32	6.26	0.32	1.13e-9	Sitting height ratio;
LIHC	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.49	8.86	0.43	4.29e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs61712019	1.000	rs2861076	chr2:77703418	A/G	cg11252801	chr2:77748917	LRRTM4	0.51	7.81	0.39	6.95e-14	Schizophrenia;
LIHC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.76	0.54	4.95e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-13.49	-0.59	1.52e-33	Systemic lupus erythematosus;
LIHC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12463550	chr7:65579703	CRCP	0.59	5.92	0.3	7.93e-9	Diabetic kidney disease;
LIHC	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-0.81	-10.59	-0.5	7.31e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.44	6.56	0.33	1.97e-10	Survival in rectal cancer;
LIHC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.61	9.96	0.47	1.1e-20	Multiple myeloma (IgH translocation);
LIHC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.53	6.13	0.31	2.36e-9	Axial length;
LIHC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg02297831	chr4:17616191	MED28	-0.43	-6.94	-0.35	1.95e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg20129853	chr10:51489980	NA	-0.41	-9.01	-0.44	1.51e-17	Prostate-specific antigen levels;
LIHC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.44	5.9	0.3	8.89e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2257205	0.667	rs8068677	chr17:56869386	G/A	cg12560992	chr17:57184187	TRIM37	0.67	7.2	0.36	3.87e-12	Pancreatic cancer;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-7.12	-0.36	6.24e-12	Total body bone mineral density;
LIHC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.37	-0.59	4.35e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00833344	chr2:150426294	MMADHC	0.42	6.45	0.33	3.86e-10	Pancreatic cancer;
LIHC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.3	5.79	0.3	1.56e-8	Cognitive function;
LIHC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.29	6.95	0.35	1.83e-11	Mean corpuscular volume;
LIHC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg14067834	chr17:29058358	SUZ12P	0.67	6.62	0.34	1.36e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.65	9.15	0.44	5.13e-18	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08464520	chr19:56104287	FIZ1	0.43	6.26	0.32	1.15e-9	Longevity;
LIHC	cis	rs918629	0.530	rs6889029	chr5:95251238	A/G	cg10483112	chr5:95245456	ELL2	0.37	6.6	0.34	1.58e-10	IgG glycosylation;
LIHC	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg27490568	chr2:178487706	NA	1.04	11.88	0.54	1.72e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02290350	chr8:58132656	NA	0.44	9.28	0.45	2.02e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.89	-0.43	3.7e-17	Blood metabolite levels;
LIHC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg10096929	chr1:156261403	TMEM79	0.35	6.15	0.32	2.17e-9	Tonsillectomy;
LIHC	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.45	6.38	0.33	5.65e-10	Posterior cortical atrophy and Alzheimer's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12465518	chr17:58308936	SCARNA20;USP32	0.44	6.07	0.31	3.44e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.38	-6.62	-0.34	1.43e-10	Monocyte percentage of white cells;
LIHC	cis	rs4407350	1.000	rs5765748	chr22:44925328	A/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.02	-0.31	4.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.89	9.02	0.44	1.38e-17	Type 2 diabetes nephropathy;
LIHC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-7.0	-0.35	1.36e-11	Putamen volume;
LIHC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.44	6.27	0.32	1.1e-9	Breast cancer;
LIHC	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg03806693	chr22:41940476	POLR3H	-0.49	-6.29	-0.32	9.67e-10	Vitiligo;
LIHC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.38	-5.75	-0.3	1.95e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg14906510	chr12:7781169	NA	0.45	7.11	0.36	6.88e-12	HDL cholesterol levels;
LIHC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.53	8.57	0.42	3.63e-16	Mean corpuscular volume;
LIHC	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.77	-0.3	1.81e-8	Mortality in heart failure;
LIHC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg10546459	chr2:36825355	FEZ2	-0.5	-6.11	-0.31	2.72e-9	Height;
LIHC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg00601450	chr5:74908170	NA	-0.68	-8.92	-0.43	2.92e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg06882758	chr19:58662330	ZNF329	0.92	6.85	0.35	3.54e-11	Cholesterol, total;
LIHC	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg03934865	chr2:198174659	NA	0.46	6.76	0.34	5.8e-11	Dermatomyositis;
LIHC	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.68	8.52	0.42	5.06e-16	Corneal astigmatism;
LIHC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.06	-0.48	4.98e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg26695010	chr11:65641043	EFEMP2	0.43	5.98	0.31	5.66e-9	Eosinophil percentage of white cells;
LIHC	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-9.02	-0.44	1.34e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-8.17	-0.4	6.11e-15	Pulse pressure;
LIHC	cis	rs832187	0.704	rs3774720	chr3:63951765	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.48	-6.73	-0.34	7.05e-11	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg25894440	chr7:65020034	NA	0.55	6.21	0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.11e-31	Sense of smell;
LIHC	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	11.08	0.51	1.44e-24	Post bronchodilator FEV1;
LIHC	cis	rs4899554	0.640	rs1569328	chr14:75741751	A/G	cg18117039	chr14:75741733	NA	-0.64	-9.77	-0.47	4.74e-20	Inflammatory bowel disease;
LIHC	cis	rs2073300	1.000	rs6137975	chr20:23461778	A/G	cg12062639	chr20:23401060	NAPB	-0.75	-9.17	-0.44	4.53e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.45	8.32	0.41	2.17e-15	Platelet distribution width;
LIHC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.05	15.11	0.63	7.4e-40	Cognitive function;
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.18	-13.11	-0.58	4.12e-32	White matter hyperintensity burden;
LIHC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.42	5.75	0.3	2.01e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21448741	chr8:58168803	NA	0.33	6.0	0.31	4.95e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.86	10.75	0.5	2.1e-23	Bladder cancer;
LIHC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs7258950	1.000	rs7258950	chr19:11250139	C/T	cg07962303	chr19:11253944	NA	0.59	6.95	0.35	1.85e-11	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.64	-0.5	5.15e-23	Eye color traits;
LIHC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	9.02	0.44	1.37e-17	Motion sickness;
LIHC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.6	9.81	0.47	3.63e-20	Resting heart rate;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17930852	chr1:45957182	TESK2	-0.38	-6.03	-0.31	4.16e-9	Calcium levels;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-11.26	-0.52	3.19e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.18	-0.32	1.78e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11718455	0.585	rs11719257	chr3:43914854	A/T	cg08738300	chr3:44038990	NA	0.37	6.31	0.32	8.55e-10	Coronary artery disease;
LIHC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs72960926	0.744	rs72952275	chr6:74926492	A/G	cg07247405	chr1:2484626	LOC115110	0.56	6.62	0.34	1.36e-10	Metabolite levels (MHPG);
LIHC	cis	rs11958404	0.789	rs78112793	chr5:157428226	A/G	cg05962755	chr5:157440814	NA	0.96	10.59	0.5	7.36e-23	IgG glycosylation;
LIHC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17554472	chr22:41940697	POLR3H	-0.52	-5.9	-0.3	8.58e-9	Vitiligo;
LIHC	trans	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg10756647	chr7:56101905	PSPH	-1.1	-13.35	-0.59	4.97e-33	Diabetic kidney disease;
LIHC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	1.02	14.29	0.61	1.2e-36	Breast cancer;
LIHC	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-7.94	-0.39	2.86e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	9.51	0.46	3.59e-19	Total body bone mineral density;
LIHC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.64	0.56	2.67e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg18944383	chr4:111397179	ENPEP	0.32	7.17	0.36	4.67e-12	Coronary artery disease;
LIHC	cis	rs2637266	0.783	rs10824437	chr10:78469493	C/T	cg18941641	chr10:78392320	NA	0.27	5.86	0.3	1.09e-8	Pulmonary function;
LIHC	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.57	6.23	0.32	1.37e-9	Bipolar disorder;
LIHC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.5	0.77	1.86e-69	Chronic sinus infection;
LIHC	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.16e-11	Ileal carcinoids;
LIHC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	ch.11.42038R	chr11:967971	AP2A2	0.55	9.83	0.47	3.01e-20	Alzheimer's disease (late onset);
LIHC	trans	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg04373760	chr16:53404718	NA	0.59	7.57	0.38	3.57e-13	Hypertriglyceridemia;
LIHC	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg19683494	chr5:74908142	NA	-0.58	-7.57	-0.38	3.52e-13	Age-related disease endophenotypes;
LIHC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg16989086	chr20:62203971	PRIC285	0.57	8.25	0.41	3.51e-15	Glioblastoma;
LIHC	cis	rs8192917	1.000	rs6573910	chr14:25100882	A/G	cg08766149	chr14:25103301	GZMB	-0.33	-7.61	-0.38	2.76e-13	Vitiligo;
LIHC	cis	rs4407350	1.000	rs4823330	chr22:44923080	G/A	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.03	-0.31	4.3e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	6.8	0.34	4.77e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01999652	chr6:28220110	ZKSCAN4	0.46	6.99	0.35	1.47e-11	Cognitive function;
LIHC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg05347473	chr6:146136440	FBXO30	0.37	5.99	0.31	5.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.63	11.33	0.52	1.72e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg15691649	chr6:25882328	NA	0.75	10.29	0.49	8.23e-22	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08677398	chr8:58056175	NA	0.4	6.27	0.32	1.08e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg02951883	chr7:2050386	MAD1L1	-0.46	-6.35	-0.32	6.77e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg02023728	chr11:77925099	USP35	0.37	6.63	0.34	1.28e-10	Testicular germ cell tumor;
LIHC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.78	9.56	0.46	2.39e-19	Morning vs. evening chronotype;
LIHC	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.66	0.5	4.1000000000000003e-23	Colorectal cancer;
LIHC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg07117364	chr1:16154769	NA	-0.39	-6.96	-0.35	1.77e-11	Dilated cardiomyopathy;
LIHC	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.62	-8.93	-0.44	2.58e-17	Aortic root size;
LIHC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	9.06	0.44	1.04e-17	Initial pursuit acceleration;
LIHC	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg14593290	chr7:50529359	DDC	0.42	6.94	0.35	2.03e-11	Malaria;
LIHC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.33	2.47e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.35	8.1	0.4	9.89e-15	Crohn's disease;
LIHC	trans	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.18	0.32	1.85e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg24884572	chr19:58661833	ZNF329	0.97	7.48	0.38	6.13e-13	Cholesterol, total;
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg00656387	chr3:40428638	ENTPD3	0.49	8.34	0.41	1.81e-15	Renal cell carcinoma;
LIHC	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg03585969	chr10:35415529	CREM	0.76	11.02	0.51	2.18e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.49	-6.86	-0.35	3.21e-11	Urate levels in overweight individuals;
LIHC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg15472170	chr1:12012720	PLOD1	0.38	6.79	0.34	5.01e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.62	-10.85	-0.51	9.07e-24	Inflammatory bowel disease;
LIHC	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.96	-0.35	1.75e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.74	0.34	6.94e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg22633049	chr21:46681294	NA	-0.38	-6.32	-0.32	8.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg21724239	chr8:58056113	NA	0.47	6.17	0.32	1.96e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.77	11.96	0.54	8.81e-28	Corneal astigmatism;
LIHC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.7	0.5	3.19e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.67	8.47	0.42	7.35e-16	Corneal astigmatism;
LIHC	trans	rs6600671	0.899	rs11249432	chr1:121283476	T/A	cg09829573	chr1:144692074	NBPF9	-0.4	-7.25	-0.36	2.86e-12	Hip geometry;
LIHC	cis	rs6815814	0.731	rs10776483	chr4:38775040	A/G	cg06935464	chr4:38784597	TLR10	0.38	5.94	0.31	7.12e-9	Breast cancer;
LIHC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.09	-0.44	8.01e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4650994	0.593	rs2811302	chr1:178552875	C/T	cg05350800	chr1:178550844	NA	-0.34	-7.76	-0.39	9.71e-14	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24923311	chr20:30697516	TM9SF4	0.43	6.23	0.32	1.41e-9	Cognitive function;
LIHC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.35	5.72	0.3	2.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.79	0.39	8.02e-14	Renal cell carcinoma;
LIHC	cis	rs3106136	0.837	rs2289186	chr4:95255637	T/G	cg11021082	chr4:95130006	SMARCAD1	0.4	7.15	0.36	5.27e-12	Capecitabine sensitivity;
LIHC	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.9	-0.35	2.49e-11	Schizophrenia;
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-8.64	-0.42	2.16e-16	Lymphocyte counts;
LIHC	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg12858261	chr2:113808755	IL1F8	0.38	6.59	0.34	1.65e-10	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs425535	0.619	rs10938105	chr4:74826087	C/A	cg02530824	chr4:74847766	PF4	-0.37	-5.95	-0.31	6.57e-9	Blood protein levels;
LIHC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.27e-19	Initial pursuit acceleration;
LIHC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	9.49	0.46	3.94e-19	Response to antipsychotic treatment;
LIHC	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.42	-5.83	-0.3	1.3e-8	Large artery stroke;
LIHC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.72	0.39	1.3e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.96	20.4	0.74	4.35e-61	Bone mineral density;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg11618577	chr2:27665543	KRTCAP3	0.43	5.9	0.3	8.71e-9	Total body bone mineral density;
LIHC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.76	0.5	1.87e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.26	-0.32	1.12e-9	Coronary artery disease;
LIHC	cis	rs7523273	0.546	rs2796261	chr1:207888760	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-7.99	-0.4	2.14e-14	Schizophrenia;
LIHC	cis	rs655641	0.859	rs654194	chr11:85700000	C/A	cg09030501	chr11:85779252	PICALM	-0.54	-6.32	-0.32	8.19e-10	Platelet count;
LIHC	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.71	-10.62	-0.5	5.64e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.54	6.06	0.31	3.62e-9	Alzheimer's disease;
LIHC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.37	-6.66	-0.34	1.07e-10	Height;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-6.49	-0.33	3e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.27	0.45	2.08e-18	Platelet count;
LIHC	cis	rs2204008	0.682	rs10880321	chr12:38370110	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.42	-0.37	9.16e-13	Bladder cancer;
LIHC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.48	-0.53	5.07e-26	Type 2 diabetes;
LIHC	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18011946	chr5:65440816	SFRS12	0.44	6.1	0.31	2.83e-9	Pancreatic cancer;
LIHC	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.42	7.97	0.4	2.39e-14	Height;
LIHC	cis	rs7520050	0.933	rs6661163	chr1:46255004	A/G	cg03146154	chr1:46216737	IPP	-0.37	-5.92	-0.3	7.8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg05484376	chr2:27715224	FNDC4	0.38	6.46	0.33	3.57e-10	Total body bone mineral density;
LIHC	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg10587741	chr22:38071170	LGALS1	0.68	9.43	0.45	6.42e-19	Fat distribution (HIV);
LIHC	cis	rs12602486	1.000	rs2285952	chr17:42268595	G/A	cg13607699	chr17:42295918	UBTF	-0.76	-6.42	-0.33	4.65e-10	Glycated hemoglobin levels;
LIHC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg24209194	chr3:40518798	ZNF619	0.49	7.37	0.37	1.32e-12	Renal cell carcinoma;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.73	-9.76	-0.47	5.17e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.77	9.67	0.46	9.97e-20	Cognitive function;
LIHC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.66	10.12	0.48	3.16e-21	Height;
LIHC	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.65	10.31	0.49	7.15e-22	Resting heart rate;
LIHC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg03476357	chr21:30257390	N6AMT1	0.54	7.92	0.39	3.27e-14	Cognitive test performance;
LIHC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.32	0.52	1.99e-25	Motion sickness;
LIHC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.37	6.67	0.34	1.03e-10	Aortic root size;
LIHC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.47	7.47	0.37	6.79e-13	Multiple sclerosis;
LIHC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Life satisfaction;
LIHC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04476341	chr5:669733	TPPP	0.39	8.79	0.43	7.64e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.58	-8.7	-0.43	1.44e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2963155	1.000	rs2963155	chr5:142756004	C/T	cg17617527	chr5:142782415	NR3C1	-0.51	-7.07	-0.36	8.69e-12	Breast cancer;
LIHC	cis	rs1256061	0.624	rs1152577	chr14:64697485	T/G	cg23250157	chr14:64679961	SYNE2	0.42	6.1	0.31	2.93e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg10756647	chr7:56101905	PSPH	-1.03	-12.6	-0.56	3.71e-30	Diabetic kidney disease;
LIHC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs75908454	1.000	rs77114281	chr6:169846419	G/A	cg19338460	chr6:170058176	WDR27	-0.84	-7.39	-0.37	1.15e-12	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg03934865	chr2:198174659	NA	0.55	8.38	0.41	1.42e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.56	-7.93	-0.39	3.1e-14	Coronary artery disease;
LIHC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg19302996	chr17:73780495	UNK	-0.55	-6.82	-0.35	4.18e-11	Psoriasis;
LIHC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.87	11.41	0.52	9.38e-26	Coronary artery disease;
LIHC	cis	rs55665837	0.701	rs12787709	chr11:14639257	G/A	cg00085434	chr11:14927489	NA	0.43	5.88	0.3	9.55e-9	Vitamin D levels;
LIHC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.71	10.72	0.5	2.67e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.09e-8	Electroencephalogram traits;
LIHC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.67	13.3	0.58	7.93e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs72653721	0.689	rs17697089	chr6:11065856	C/T	cg13562911	chr6:11044106	ELOVL2	0.51	7.49	0.38	6.05e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.06	0.44	1.05e-17	Schizophrenia;
LIHC	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg00277334	chr10:82204260	NA	-0.61	-7.08	-0.36	8e-12	Post bronchodilator FEV1;
LIHC	cis	rs7095944	0.584	rs4962691	chr10:126424137	C/T	cg20435097	chr10:126320824	FAM53B	0.38	6.27	0.32	1.09e-9	Asthma;
LIHC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.13	-0.44	5.88e-18	Bipolar disorder;
LIHC	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.51	-8.01	-0.4	1.79e-14	Urate levels in overweight individuals;
LIHC	cis	rs10792665	0.724	rs948183	chr11:82722300	C/T	cg24227371	chr11:82718527	RAB30	-0.38	-9.3	-0.45	1.69e-18	Obesity-related traits;
LIHC	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg17135325	chr3:160939158	NMD3	0.42	5.73	0.3	2.21e-8	Parkinson's disease;
LIHC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.65	-13.9	-0.6	3.83e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs10838687	0.736	rs2242261	chr11:47266808	T/G	cg25783544	chr11:47291846	MADD	0.46	5.89	0.3	9.29e-9	Proinsulin levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13434278	chr19:1941928	CSNK1G2	-0.55	-6.12	-0.31	2.57e-9	Systolic blood pressure;
LIHC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg16586182	chr3:47516702	SCAP	0.61	11.96	0.54	8.96e-28	Colorectal cancer;
LIHC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.48	-0.53	4.92e-26	Glomerular filtration rate (creatinine);
LIHC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.68	0.38	1.64e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs3790844	0.955	rs3790848	chr1:200006111	C/A	cg13229857	chr1:200006247	NR5A2	0.37	6.06	0.31	3.6e-9	Pancreatic cancer;
LIHC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg12798992	chr6:167411361	FGFR1OP	0.61	10.26	0.49	1.02e-21	Crohn's disease;
LIHC	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg15123519	chr2:136567270	LCT	0.42	8.2	0.41	5.02e-15	Mosquito bite size;
LIHC	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg25364880	chr3:44379878	C3orf23	0.52	7.1	0.36	7.13e-12	Depressive symptoms;
LIHC	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	0.92	9.86	0.47	2.4e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.89	-0.3	9.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.39	-9.35	-0.45	1.17e-18	Breast cancer;
LIHC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-0.9	-16.76	-0.67	1.84e-46	Bone mineral density;
LIHC	cis	rs4671458	0.802	rs72821624	chr2:63691920	A/G	cg17519650	chr2:63277830	OTX1	-0.52	-5.95	-0.31	6.81e-9	Subjective well-being;
LIHC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21467203	chr3:49911342	NA	-0.43	-7.74	-0.39	1.17e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs864643	0.945	rs1355733	chr3:39562656	G/A	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg24977027	chr2:88469347	THNSL2	-0.34	-5.88	-0.3	9.53e-9	Response to metformin (IC50);
LIHC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.49	-5.89	-0.3	9.39e-9	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.7	-7.58	-0.38	3.24e-13	Exhaled nitric oxide output;
LIHC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.88	-17.39	-0.69	5.48e-49	Height;
LIHC	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.85	-0.39	5.32e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	1.04	21.26	0.75	1.55e-64	Platelet distribution width;
LIHC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17554472	chr22:41940697	POLR3H	0.56	6.01	0.31	4.84e-9	Vitiligo;
LIHC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03122164	chr19:39421160	MRPS12;SARS2	-0.41	-6.05	-0.31	3.84e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg03037974	chr15:76606532	NA	0.89	23.01	0.78	1.97e-71	Blood metabolite levels;
LIHC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.19	-0.48	1.84e-21	Longevity;Endometriosis;
LIHC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg24130564	chr14:104152367	KLC1	-0.55	-8.91	-0.43	3.16e-17	Reticulocyte count;
LIHC	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-7.07	-0.36	8.61e-12	Morning vs. evening chronotype;
LIHC	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-10.16	-0.48	2.23e-21	Coffee consumption (cups per day);
LIHC	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.63	-10.45	-0.49	2.37e-22	Waist circumference;Body mass index;
LIHC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7923837	0.651	rs10882095	chr10:94394402	T/G	cg25506282	chr10:94462361	NA	0.34	5.74	0.3	2.06e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs12744310	1.000	rs34759578	chr1:41774350	G/A	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20440901	chr2:228582758	SLC19A3	-0.56	-7.0	-0.35	1.4e-11	Systolic blood pressure;
LIHC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	8.96	0.44	2.09e-17	Eosinophil percentage of white cells;
LIHC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21467203	chr3:49911342	NA	0.44	7.76	0.39	1.01e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.41	-0.33	4.78e-10	Total body bone mineral density;
LIHC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.56	-9.52	-0.46	3.31e-19	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs7106204	0.925	rs3924745	chr11:24223001	G/A	ch.11.24196551F	chr11:24239977	NA	0.8	11.25	0.52	3.54e-25	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.37	-6.38	-0.33	5.74e-10	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg10755058	chr3:40428713	ENTPD3	0.4	6.94	0.35	1.95e-11	Renal cell carcinoma;
LIHC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.56	-8.82	-0.43	5.78e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs4714291	0.698	rs2983144	chr6:40046724	G/A	cg02267698	chr19:7991119	CTXN1	-0.4	-6.74	-0.34	6.89e-11	Strep throat;
LIHC	cis	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg01864836	chr14:55583639	NA	-0.37	-6.35	-0.32	6.94e-10	Protein biomarker;
LIHC	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.97	-0.31	5.92e-9	Colorectal cancer;
LIHC	trans	rs1814175	0.646	rs10839335	chr11:49715265	G/T	cg18944383	chr4:111397179	ENPEP	0.27	6.78	0.34	5.32e-11	Height;
LIHC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg14092571	chr14:90743983	NA	-0.39	-6.16	-0.32	2.02e-9	Mortality in heart failure;
LIHC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.55	-9.1	-0.44	7.49e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.23	-0.52	4.09e-25	Eye color traits;
LIHC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg01652190	chr22:50026171	C22orf34	-0.33	-7.21	-0.36	3.52e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.51	0.53	4.07e-26	Lung cancer in ever smokers;
LIHC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg16822855	chr3:40428330	ENTPD3	0.34	6.18	0.32	1.85e-9	Renal cell carcinoma;
LIHC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9513627	1.000	rs7317330	chr13:100119876	T/G	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.19	-0.4	5.17e-15	Morning vs. evening chronotype;
LIHC	cis	rs17106184	1.000	rs72898971	chr1:50971408	A/G	cg07174182	chr1:51127561	FAF1	-0.64	-6.76	-0.34	6.13e-11	Type 2 diabetes;
LIHC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.53	8.66	0.42	1.89e-16	Dialysis-related mortality;
LIHC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.15	0.32	2.13e-9	Rheumatoid arthritis;
LIHC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.66	11.43	0.53	7.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg12863693	chr15:85201151	NMB	0.41	5.83	0.3	1.31e-8	Schizophrenia;
LIHC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.68	-0.34	9.46e-11	Mean corpuscular volume;
LIHC	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg12140854	chr5:148520817	ABLIM3	0.44	6.13	0.31	2.37e-9	Breast cancer;
LIHC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.49	8.31	0.41	2.22e-15	Response to temozolomide;
LIHC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg07308232	chr7:1071921	C7orf50	-0.39	-6.12	-0.31	2.56e-9	Longevity;Endometriosis;
LIHC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.5	7.61	0.38	2.72e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.57	8.96	0.44	2.06e-17	Lung cancer in ever smokers;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg06021753	chr8:22102407	POLR3D	-0.62	-6.18	-0.32	1.82e-9	Obesity-related traits;
LIHC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg17385448	chr1:15911702	AGMAT	0.34	5.87	0.3	1.01e-8	Systolic blood pressure;
LIHC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.71	-12.4	-0.56	2.03e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.49	7.76	0.39	9.79e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.57	-0.33	1.83e-10	Fear of minor pain;
LIHC	cis	rs11822910	0.953	rs11827928	chr11:57197890	A/G	cg00522883	chr11:57194120	SLC43A3	0.7	8.4	0.41	1.2e-15	Platelet distribution width;
LIHC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.26	0.37	2.59e-12	Gout;Renal underexcretion gout;
LIHC	trans	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg17675199	chr6:35436792	RPL10A	-0.38	-7.38	-0.37	1.22e-12	Monocyte count;
LIHC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg20129853	chr10:51489980	NA	-0.4	-8.66	-0.42	1.92e-16	Prostate-specific antigen levels;
LIHC	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-8.8	-0.43	6.88e-17	Extraversion;
LIHC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.7e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg16226627	chr15:75307476	SCAMP5	0.54	9.74	0.47	5.98e-20	Lung cancer;
LIHC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.73	-0.65	2.38e-42	Headache;
LIHC	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg00277334	chr10:82204260	NA	-0.56	-7.04	-0.36	1.06e-11	Post bronchodilator FEV1;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg24151027	chr5:77656318	SCAMP1	0.4	6.07	0.31	3.35e-9	Urinary tract infection frequency;
LIHC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg18306943	chr3:40428807	ENTPD3	0.35	5.84	0.3	1.18e-8	Renal cell carcinoma;
LIHC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-8.51	-0.42	5.43e-16	Vitiligo;
LIHC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.63	-10.1	-0.48	3.57e-21	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02580404	chr16:19729857	C16orf88;IQCK	0.39	6.19	0.32	1.76e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	ch.11.42038R	chr11:967971	AP2A2	0.53	9.58	0.46	2.01e-19	Alzheimer's disease (late onset);
LIHC	cis	rs2637030	0.559	rs423014	chr5:52894598	A/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.2	-0.36	3.96e-12	Coronary artery disease;
LIHC	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	1.06	8.55	0.42	4.25e-16	Cannabis dependence symptom count;
LIHC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-8.07	-0.4	1.23e-14	Ulcerative colitis;
LIHC	cis	rs7116495	0.881	rs1892921	chr11:71702138	G/A	cg26138937	chr11:71823887	C11orf51	-0.82	-8.35	-0.41	1.75e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-7.77	-0.39	9.22e-14	Crohn's disease;
LIHC	cis	rs7577696	0.554	rs34835885	chr2:32325414	G/A	cg02381751	chr2:32503542	YIPF4	-0.45	-6.06	-0.31	3.63e-9	Inflammatory biomarkers;
LIHC	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.44	-8.55	-0.42	4.15e-16	Testicular germ cell tumor;
LIHC	trans	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	5.93e-33	Diabetic kidney disease;
LIHC	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.44	7.02	0.36	1.18e-11	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.7	-10.26	-0.49	1e-21	Coronary artery disease;
LIHC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg13047869	chr3:10149882	C3orf24	0.5	6.08	0.31	3.23e-9	Alzheimer's disease;
LIHC	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg10381502	chr11:71823885	C11orf51	1.06	9.3	0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.08	0.48	4.14e-21	Alzheimer's disease (late onset);
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.64	10.38	0.49	3.94e-22	Longevity;
LIHC	cis	rs12464559	0.522	rs12472627	chr2:152633114	C/T	cg01189475	chr2:152685088	ARL5A	0.66	8.39	0.41	1.29e-15	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.7	6.81	0.35	4.44e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.6	6.83	0.35	3.82e-11	Menarche (age at onset);
LIHC	trans	rs7395555	1.000	rs4945404	chr11:80077022	G/T	cg06295071	chr21:33766731	URB1	-0.42	-6.24	-0.32	1.3e-9	Response to antipsychotic treatment;
LIHC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	9.22	0.45	3.06e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	0.55	10.36	0.49	4.85e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg05425664	chr17:57184151	TRIM37	-0.53	-7.46	-0.37	7.11e-13	Cognitive test performance;
LIHC	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.45	0.42	8.29e-16	Response to antipsychotic treatment;
LIHC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-8.34	-0.41	1.89e-15	Parkinson's disease;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg19635926	chr16:89946313	TCF25	0.48	6.46	0.33	3.67e-10	Skin colour saturation;
LIHC	trans	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg16011800	chr17:1958478	HIC1	-0.51	-7.19	-0.36	4.14e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.7	-12.95	-0.57	1.75e-31	Mean platelet volume;
LIHC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.56	-9.22	-0.45	3.21e-18	Coronary artery disease;
LIHC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-12.46	-0.56	1.21e-29	Vitiligo;
LIHC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.6	9.77	0.47	4.93e-20	Resting heart rate;
LIHC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.47	7.77	0.39	9.33e-14	Multiple sclerosis;
LIHC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17467752	chr17:38218738	THRA	0.42	6.82	0.35	4.15e-11	Asthma;
LIHC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.38	-6.69	-0.34	8.95e-11	Facial morphology (factor 20);
LIHC	cis	rs3736485	0.934	rs1902593	chr15:51882080	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg07706471	chr12:123319906	HIP1R	-0.55	-6.87	-0.35	3.01e-11	Schizophrenia;
LIHC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-22.74	-0.78	2.2e-70	Height;
LIHC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.46	7.6	0.38	2.88e-13	Alcohol dependence;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg14354430	chr9:136911493	BRD3	0.42	6.24	0.32	1.32e-9	Alopecia areata;
LIHC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg05044414	chr3:183734942	ABCC5	0.33	5.94	0.31	6.88e-9	Anterior chamber depth;
LIHC	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.78	0.3	1.65e-8	Bladder cancer;
LIHC	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-5.73	-0.3	2.26e-8	Ulcerative colitis;
LIHC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.73	-12.07	-0.55	3.51e-28	Systemic lupus erythematosus;
LIHC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.62	-9.71	-0.46	7.82e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1144333	0.655	rs931506	chr1:76401349	T/C	cg22875332	chr1:76189707	ACADM	0.41	6.22	0.32	1.42e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.35	8.82	0.43	6.11e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.93	-12.35	-0.56	3.04e-29	Schizophrenia;
LIHC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04877780	chr17:80710066	TBCD	-0.53	-6.45	-0.33	3.82e-10	Systolic blood pressure;
LIHC	cis	rs4728302	0.869	rs13221033	chr7:133617487	T/A	cg10665199	chr7:133106180	EXOC4	0.37	6.33	0.32	7.72e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	1.13	8.8	0.43	6.86e-17	Arsenic metabolism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00552226	chr2:70475288	TIA1	0.54	7.36	0.37	1.35e-12	Pancreatic cancer;
LIHC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg12437481	chr16:420112	MRPL28	-0.65	-8.73	-0.43	1.13e-16	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09302904	chr17:62340561	TEX2	-0.48	-6.2	-0.32	1.64e-9	Lung cancer in ever smokers;
LIHC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.17	0.4	5.94e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	13.49	0.59	1.49e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.14	0.36	5.5e-12	Lung cancer;
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.31	0.32	8.87e-10	Renal cell carcinoma;
LIHC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.95	0.31	6.6e-9	Tonsillectomy;
LIHC	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25632853	chr15:73088954	NA	-0.36	-5.92	-0.3	7.76e-9	Triglyceride levels;
LIHC	cis	rs3770081	1.000	rs60981340	chr2:86177046	G/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.83	0.3	1.27e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.68	0.69	3.9e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg09990169	chr2:241835740	C2orf54	-0.67	-10.61	-0.5	6.47e-23	Urinary metabolites;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13093793	chr14:35099518	SNX6	0.47	6.62	0.34	1.41e-10	Lung function (FEV1/FVC);
LIHC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.37	2.53e-12	Blood pressure;
LIHC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg23533926	chr12:111358616	MYL2	-0.32	-6.12	-0.31	2.61e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg04013166	chr16:89971882	TCF25	0.53	6.67	0.34	1.04e-10	Skin colour saturation;
LIHC	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg10820045	chr2:198174542	NA	0.51	7.99	0.4	2.03e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.65	10.4	0.49	3.53e-22	Age at first birth;
LIHC	cis	rs11673344	0.764	rs569371	chr19:37453997	A/G	cg27390819	chr19:37464633	NA	-0.51	-6.23	-0.32	1.37e-9	Obesity-related traits;
LIHC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.56	0.42	3.89e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg22907277	chr7:1156413	C7orf50	0.58	8.82	0.43	5.97e-17	Longevity;Endometriosis;
LIHC	cis	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg20932281	chr17:33905541	PEX12	-0.57	-6.54	-0.33	2.21e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	9.15	0.44	5.21e-18	Menarche (age at onset);
LIHC	cis	rs7523273	0.568	rs55935450	chr1:208018779	T/A	cg22525895	chr1:207977042	MIR29B2	-0.57	-6.41	-0.33	4.74e-10	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01002560	chr7:16460779	ISPD	0.55	7.01	0.35	1.26e-11	Hepatitis;
LIHC	cis	rs7617773	0.963	rs6771787	chr3:48194242	C/T	cg11946769	chr3:48343235	NME6	-0.66	-8.46	-0.42	7.79e-16	Coronary artery disease;
LIHC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.67	-8.26	-0.41	3.13e-15	Gut microbiome composition (summer);
LIHC	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.87	15.85	0.65	8.35e-43	Body mass index;
LIHC	cis	rs7534824	0.625	rs6699653	chr1:101499162	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.23	0.36	3.2e-12	Refractive astigmatism;
LIHC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.81	0.3	1.43e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-6.07	-0.31	3.35e-9	IgG glycosylation;
LIHC	cis	rs11673344	0.864	rs11670216	chr19:37503428	G/C	cg27390819	chr19:37464633	NA	-0.51	-6.21	-0.32	1.57e-9	Obesity-related traits;
LIHC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg06627628	chr2:24431161	ITSN2	-0.44	-5.89	-0.3	9.14e-9	Quantitative traits;
LIHC	cis	rs1419980	0.730	rs11054916	chr12:7777083	T/C	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	6.88	0.35	2.8e-11	Menopause (age at onset);
LIHC	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.04	-0.31	3.92e-9	Blood pressure;
LIHC	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.71	12.58	0.56	4.47e-30	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.78e-23	Hemoglobin concentration;
LIHC	cis	rs16828019	0.777	rs35044078	chr1:41474400	C/G	cg03962019	chr1:41807865	NA	0.49	6.93	0.35	2.09e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07305463	chr2:136567211	LCT	0.39	7.54	0.38	4.37e-13	Mosquito bite size;
LIHC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.52	-8.03	-0.4	1.63e-14	Lymphocyte counts;
LIHC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.95	-11.15	-0.52	7.82e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg26149184	chr10:133730230	NA	0.46	7.26	0.37	2.56e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs675828	0.620	rs4772498	chr13:103350564	T/C	cg16283183	chr3:45718805	LIMD1	-0.39	-6.05	-0.31	3.77e-9	Borderline personality disorder;
LIHC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.36	6.67	0.34	1.05e-10	Total body bone mineral density;
LIHC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.54	-9.25	-0.45	2.49e-18	Myeloid white cell count;
LIHC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.07	0.61	8.69e-36	Chronic sinus infection;
LIHC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.65	-12.41	-0.56	1.87e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs4776059	0.724	rs11633933	chr15:52948357	T/C	cg22715398	chr15:52968154	KIAA1370	-0.41	-6.47	-0.33	3.48e-10	Schizophrenia;
LIHC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg07959070	chr22:50026188	C22orf34	-0.3	-7.17	-0.36	4.65e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.46	-0.49	2.04e-22	Total cholesterol levels;
LIHC	cis	rs2412488	0.853	rs7688853	chr4:54353215	C/T	cg22241045	chr4:54363911	LNX1	0.41	6.83	0.35	3.89e-11	DNA methylation (variation);
LIHC	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg05197062	chr11:11642011	GALNTL4	0.42	6.06	0.31	3.68e-9	Telomere length;
LIHC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.79	12.59	0.56	4.04e-30	Breast cancer;
LIHC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.32	0.58	6.47e-33	Cognitive test performance;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03276813	chr2:182757157	SSFA2	0.42	6.04	0.31	4.09e-9	Cognitive function;
LIHC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	1.02	19.6	0.73	7.06e-58	Breast cancer;
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.46	6.52	0.33	2.49e-10	Longevity;Endometriosis;
LIHC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg16822855	chr3:40428330	ENTPD3	0.35	6.38	0.33	5.91e-10	Renal cell carcinoma;
LIHC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.68	11.31	0.52	2.14e-25	Mean platelet volume;
LIHC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.62	0.42	2.48e-16	Initial pursuit acceleration;
LIHC	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.92	-0.3	7.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.52	-7.69	-0.38	1.53e-13	Total body bone mineral density;
LIHC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.4	6.35	0.32	6.97e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.24	6.09	0.31	3.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs56146971	0.714	rs17804071	chr14:91852876	C/T	cg16433844	chr14:91963127	SMEK1	-0.49	-5.86	-0.3	1.08e-8	Alzheimer disease and age of onset;
LIHC	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg18289306	chr13:113640169	MCF2L	0.43	6.88	0.35	2.89e-11	Systolic blood pressure;
LIHC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg05973401	chr12:123451056	ABCB9	0.41	6.02	0.31	4.4e-9	Platelet count;
LIHC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	10.23	0.48	1.31e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg15848620	chr12:58087721	OS9	-0.55	-7.42	-0.37	9.54e-13	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg07332563	chr6:291687	DUSP22	-0.51	-7.03	-0.36	1.15e-11	Menopause (age at onset);
LIHC	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.22	12.75	0.57	9.9e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.37e-9	Aortic root size;
LIHC	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.57	0.42	3.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.1	10.01	0.48	7.28e-21	Diabetic retinopathy;
LIHC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.52	9.54	0.46	2.71e-19	Endometrial cancer;
LIHC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.43	7.29	0.37	2.2e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg23533926	chr12:111358616	MYL2	-0.33	-6.18	-0.32	1.82e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.59	8.75	0.43	1e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs6108011	0.659	rs62202266	chr20:7580935	C/T	cg13422339	chr21:47602486	C21orf56	0.52	6.07	0.31	3.41e-9	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs12602486	1.000	rs2285952	chr17:42268595	G/A	cg08193365	chr17:42277699	NA	1.04	7.22	0.36	3.49e-12	Glycated hemoglobin levels;
LIHC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.45	5.73	0.3	2.19e-8	Blood protein levels;
LIHC	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.55	-13.2	-0.58	1.87e-32	White blood cell count (basophil);
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg12903224	chr12:29470962	FAR2	-0.38	-5.99	-0.31	5.41e-9	QT interval;
LIHC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.57	-6.41	-0.33	4.91e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.75	10.97	0.51	3.53e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-10.81	-0.5	1.31e-23	Total body bone mineral density;
LIHC	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.63	-8.7	-0.43	1.46e-16	Menopause (age at onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05191825	chr12:108956318	ISCU;SART3	-0.46	-6.16	-0.32	2.05e-9	Systolic blood pressure;
LIHC	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.59	6.92	0.35	2.29e-11	Putamen volume;
LIHC	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.46	-6.11	-0.31	2.65e-9	Sjögren's syndrome;
LIHC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.92e-12	Menopause (age at onset);
LIHC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.5	6.49	0.33	3.09e-10	Initial pursuit acceleration;
LIHC	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.56	9.13	0.44	5.91e-18	Eosinophilic esophagitis;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07677032	chr17:61819896	STRADA	0.42	6.26	0.32	1.14e-9	Prudent dietary pattern;
LIHC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.65	8.36	0.41	1.64e-15	Gut microbiome composition (summer);
LIHC	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg05110241	chr16:68378359	PRMT7	-0.55	-6.59	-0.34	1.7e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs760762	0.660	rs6513714	chr20:39916401	A/T	cg06424997	chr20:39929561	ZHX3	0.35	5.73	0.3	2.2e-8	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LIHC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	1.0	17.55	0.69	1.25e-49	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.99	16.2	0.66	3.27e-44	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs61041384	0.661	rs79304919	chr12:123427951	C/T	cg25930673	chr12:123319894	HIP1R	0.66	5.73	0.3	2.26e-8	Schizophrenia;
LIHC	cis	rs2108622	0.711	rs113059233	chr19:15977368	G/A	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.08	0.4	1.14e-14	Alzheimer's disease;
LIHC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.83	15.51	0.64	1.8e-41	Multiple myeloma (IgH translocation);
LIHC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.5	0.53	4.16e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs965469	1.000	rs6037551	chr20:3306690	T/C	cg25506879	chr20:3388711	C20orf194	-0.6	-6.91	-0.35	2.43e-11	IFN-related cytopenia;
LIHC	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg09835421	chr16:68378352	PRMT7	-0.48	-5.91	-0.3	8.43e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg15534755	chr11:117069859	TAGLN	0.39	6.62	0.34	1.37e-10	Blood protein levels;
LIHC	trans	rs2077654	0.818	rs4148636	chr11:17427363	A/G	cg02039634	chr12:132603558	EP400NL	0.61	6.22	0.32	1.45e-9	Gout;
LIHC	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.35e-11	Protein C levels;
LIHC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.28	-0.45	2.03e-18	Gut microbiome composition (summer);
LIHC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.47	-6.81	-0.35	4.31e-11	Corneal structure;
LIHC	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.59	-0.34	1.66e-10	Neuroticism;
LIHC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-7.39	-0.37	1.14e-12	Neuroticism;
LIHC	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-7.03	-0.36	1.1e-11	Opioid sensitivity;
LIHC	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg06533319	chr4:3265114	C4orf44	0.33	5.79	0.3	1.58e-8	Parental longevity (mother's age at death);
LIHC	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg21573476	chr21:45109991	RRP1B	0.54	9.63	0.46	1.44e-19	Mean corpuscular volume;
LIHC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-9.48	-0.46	4.54e-19	Mean corpuscular volume;
LIHC	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.42	7.94	0.39	2.85e-14	Height;
LIHC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07305463	chr2:136567211	LCT	-0.38	-5.84	-0.3	1.2e-8	Corneal structure;
LIHC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg18478394	chr8:109455254	TTC35	0.42	7.24	0.36	2.98e-12	Dupuytren's disease;
LIHC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.7	0.34	8.58e-11	Lung cancer in ever smokers;
LIHC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.78	-14.06	-0.61	9.68e-36	Refractive error;
LIHC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.03	-7.25	-0.36	2.89e-12	Body mass index;
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg10096929	chr1:156261403	TMEM79	-0.38	-6.32	-0.32	8.11e-10	Tonsillectomy;
LIHC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.49	-7.0	-0.35	1.39e-11	High light scatter reticulocyte count;
LIHC	cis	rs17106184	1.000	rs72898923	chr1:50931683	C/T	cg07174182	chr1:51127561	FAF1	-0.6	-6.79	-0.34	5.04e-11	Type 2 diabetes;
LIHC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.54	6.21	0.32	1.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs832187	0.679	rs9879045	chr3:64001925	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.51	-6.83	-0.35	3.78e-11	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg25894440	chr7:65020034	NA	0.53	6.15	0.32	2.19e-9	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22136351	chr5:94982375	RFESD	0.5	7.24	0.36	2.99e-12	Lung function (FEV1/FVC);
LIHC	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.32	0.32	8.38e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg14440974	chr22:39074834	NA	-0.36	-5.97	-0.31	5.9e-9	Menopause (age at onset);
LIHC	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg00977110	chr5:151150581	G3BP1	0.55	7.06	0.36	9.23e-12	Preschool internalizing problems;
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21448741	chr8:58168803	NA	0.37	6.61	0.34	1.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg20607798	chr8:58055168	NA	0.64	7.99	0.4	2.15e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.44	6.83	0.35	4.01e-11	Schizophrenia;
LIHC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.53	-7.34	-0.37	1.56e-12	Pulse pressure;
LIHC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg16586182	chr3:47516702	SCAP	0.59	10.65	0.5	4.46e-23	Colorectal cancer;
LIHC	cis	rs12464559	0.579	rs6740508	chr2:152613212	T/A	cg01189475	chr2:152685088	ARL5A	0.63	7.48	0.38	6.14e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-7.57	-0.38	3.62e-13	Glomerular filtration rate in non diabetics (creatinine);
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	7.18	0.36	4.36e-12	Renal cell carcinoma;
LIHC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg19920283	chr7:105172520	RINT1	0.65	5.96	0.31	6.19e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4834770	0.792	rs6823331	chr4:120180790	T/C	cg09307838	chr4:120376055	NA	0.41	5.87	0.3	1.05e-8	Blood protein levels;
LIHC	cis	rs7188697	0.922	rs28479997	chr16:58614877	G/A	cg02549819	chr16:58548995	SETD6	0.49	7.64	0.38	2.27e-13	QT interval;
LIHC	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg20019720	chr6:154832845	CNKSR3	0.47	7.11	0.36	6.88e-12	Lipoprotein (a) levels;
LIHC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.88	15.91	0.65	4.93e-43	Aortic root size;
LIHC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01200585	chr1:228362443	C1orf69	0.47	7.11	0.36	6.64e-12	Diastolic blood pressure;
LIHC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.43	6.1	0.31	2.83e-9	Blood protein levels;
LIHC	cis	rs611744	0.967	rs682007	chr8:109210326	G/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs11229555	0.574	rs72919749	chr11:58323467	T/C	cg15696309	chr11:58395628	NA	-0.63	-5.96	-0.31	6.41e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg23091122	chr1:110024289	SYPL2	-0.45	-5.94	-0.31	7.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.33	6.08	0.31	3.28e-9	Facial morphology (factor 20);
LIHC	cis	rs1144333	1.000	rs1340684	chr1:76471146	T/C	cg10523679	chr1:76189770	ACADM	0.44	6.1	0.31	2.86e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.91	16.89	0.67	5.59e-47	Aortic root size;
LIHC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.08	-0.51	1.35e-24	Alzheimer's disease;
LIHC	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.77	-6.44	-0.33	4.06e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.11	-0.52	1.06e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.46	-0.42	7.82e-16	Colorectal cancer;
LIHC	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	19.24	0.72	2.06e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.25	-0.52	3.46e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-10.97	-0.51	3.43e-24	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13115616	chr1:17338059	ATP13A2	0.39	6.12	0.31	2.61e-9	Pancreatic cancer;
LIHC	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.44	7.14	0.36	5.6e-12	Corneal astigmatism;
LIHC	cis	rs12922040	1.000	rs12922040	chr16:15869466	C/T	cg08214245	chr16:15829296	MYH11	-0.29	-5.86	-0.3	1.08e-8	Serum uric acid levels in response to allopurinol in gout;
LIHC	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.76	14.39	0.61	4.79e-37	Mortality in heart failure;
LIHC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-6.34	-0.32	7.21e-10	Type 2 diabetes;
LIHC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.45	0.33	3.75e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7534824	0.625	rs61782085	chr1:101518270	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	6.95	0.35	1.89e-11	Refractive astigmatism;
LIHC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.7	7.38	0.37	1.23e-12	Alzheimer's disease;
LIHC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.48	-7.37	-0.37	1.29e-12	Fibrinogen levels;
LIHC	cis	rs17433710	0.543	rs4657227	chr1:162653333	A/T	cg01063088	chr1:162760584	HSD17B7	0.44	6.09	0.31	3.07e-9	Dupuytren's disease;
LIHC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-6.53	-0.33	2.34e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg12658694	chr1:38397304	INPP5B	-0.57	-8.64	-0.42	2.19e-16	Coronary artery disease;
LIHC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.93	13.34	0.58	5.81e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.85	-0.3	1.18e-8	Biliary atresia;
LIHC	cis	rs11958404	0.932	rs72816598	chr5:157436017	G/A	cg05962755	chr5:157440814	NA	1.0	11.6	0.53	1.82e-26	IgG glycosylation;
LIHC	trans	rs3743102	0.591	rs8040152	chr15:83356728	C/T	cg01542190	chr22:50604728	NA	-0.55	-7.44	-0.37	7.96e-13	Colorectal adenoma (advanced);
LIHC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.07	-0.36	8.6e-12	Vitiligo;
LIHC	cis	rs507080	0.771	rs687664	chr11:118574185	C/A	cg04173919	chr11:118528438	PHLDB1	0.32	6.02	0.31	4.44e-9	Serum metabolite levels;
LIHC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.06	15.28	0.64	1.54e-40	Cognitive function;
LIHC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.72	0.3	2.33e-8	Bipolar disorder;
LIHC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.68	-12.72	-0.57	1.24e-30	Refractive error;
LIHC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.06	-14.43	-0.62	3.39e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.98	-0.31	5.67e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.79	12.54	0.56	5.98e-30	Corneal astigmatism;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.01	15.54	0.64	1.41e-41	Skin colour saturation;
LIHC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg14067834	chr17:29058358	SUZ12P	0.71	6.92	0.35	2.24e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.76	-8.31	-0.41	2.22e-15	Exhaled nitric oxide output;
LIHC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.61	6.74	0.34	6.88e-11	Vitiligo;
LIHC	cis	rs918629	0.798	rs3777168	chr5:95285771	G/A	cg10483112	chr5:95245456	ELL2	-0.37	-6.22	-0.32	1.42e-9	IgG glycosylation;
LIHC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.47e-18	Bipolar disorder;
LIHC	cis	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg20368463	chr18:77673604	PQLC1	-0.39	-6.91	-0.35	2.31e-11	Schizophrenia;
LIHC	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.27	-6.42	-0.33	4.68e-10	Heart rate;
LIHC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.14	-21.79	-0.76	1.28e-66	Triglycerides;
LIHC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg06565975	chr8:143823917	SLURP1	0.33	6.17	0.32	1.93e-9	Urinary tract infection frequency;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.11	0.4	9.21e-15	Height;
LIHC	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.21e-9	Mean corpuscular volume;
LIHC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.54	8.91	0.43	3.17e-17	Aortic root size;
LIHC	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-7.24	-0.36	2.91e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.76	14.6	0.62	7.44e-38	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.97	19.09	0.72	8.38e-56	Intelligence (multi-trait analysis);
LIHC	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7520050	0.902	rs1355642	chr1:46598903	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.42	6.16	0.32	1.99e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg03934865	chr2:198174659	NA	0.45	6.49	0.33	2.96e-10	Dermatomyositis;
LIHC	trans	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg06175025	chr14:78082992	SPTLC2	0.45	6.62	0.34	1.38e-10	Skin aging (microtopography measurement);
LIHC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.39	-0.45	8.59e-19	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.66	11.01	0.51	2.37e-24	Platelet distribution width;
LIHC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg12863693	chr15:85201151	NMB	0.48	7.01	0.35	1.27e-11	Schizophrenia;
LIHC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.29	-0.45	1.85e-18	Ulcerative colitis;
LIHC	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.46	6.56	0.33	1.96e-10	Height;
LIHC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.48	6.33	0.32	7.79e-10	Schizophrenia;
LIHC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.95e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.83	-0.3	1.31e-8	Red blood cell count;
LIHC	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.47	7.5	0.38	5.67e-13	Height;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06438056	chr1:33502433	AK2	-0.49	-6.18	-0.32	1.84e-9	Systolic blood pressure;
LIHC	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg07862535	chr7:139043722	LUC7L2	-0.61	-10.69	-0.5	3.36e-23	Diisocyanate-induced asthma;
LIHC	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	6.44	0.33	4.11e-10	Bipolar disorder;
LIHC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.82	0.35	4.07e-11	Gut microbiome composition (summer);
LIHC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.74	-12.45	-0.56	1.32e-29	Menarche (age at onset);
LIHC	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.36	3.49e-12	Protein C levels;
LIHC	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.63	-5.99	-0.31	5.42e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.51	7.15	0.36	5.2e-12	Monobrow;
LIHC	cis	rs4450131	0.522	rs35645049	chr10:126368119	C/G	cg20435097	chr10:126320824	FAM53B	0.67	12.23	0.55	8.49e-29	White blood cell count (basophil);
LIHC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20135002	chr11:47629003	NA	-0.54	-8.99	-0.44	1.71e-17	Subjective well-being;
LIHC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.54	7.53	0.38	4.56e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.59	-0.38	3.03e-13	Ulcerative colitis;
LIHC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.53	7.79	0.39	7.8500000000000006e-14	Initial pursuit acceleration;
LIHC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.96	0.51	3.7e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg07061783	chr6:25882402	NA	-0.46	-6.48	-0.33	3.17e-10	Blood metabolite levels;
LIHC	cis	rs17428076	0.793	rs3765166	chr2:172693780	G/A	cg13550731	chr2:172543902	DYNC1I2	0.37	6.14	0.32	2.32e-9	Myopia;
LIHC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg03264133	chr6:25882463	NA	-0.38	-5.72	-0.3	2.36e-8	Height;
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg15382696	chr6:118971807	C6orf204	0.63	6.16	0.32	1.99e-9	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21448741	chr8:58168803	NA	0.36	6.75	0.34	6.49e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.29	0.41	2.57e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.32	-0.52	1.87e-25	Alzheimer's disease;
LIHC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg13395646	chr4:1353034	KIAA1530	0.42	6.54	0.33	2.24e-10	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14295958	chr14:24025576	THTPA	0.53	6.83	0.35	3.81e-11	Lung function (FEV1/FVC);
LIHC	cis	rs28489187	0.706	rs2300637	chr1:85822772	T/C	cg16011679	chr1:85725395	C1orf52	0.47	5.86	0.3	1.11e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.68	-10.94	-0.51	4.49e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs7534824	0.625	rs7521668	chr1:101491108	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.61	-6.78	-0.34	5.29e-11	Refractive astigmatism;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg19437070	chr15:78442260	IDH3A	-0.44	-6.82	-0.35	4.24e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.55	7.06	0.36	9.1e-12	Schizophrenia;
LIHC	cis	rs7395581	0.959	rs2013867	chr11:47260272	A/G	cg25783544	chr11:47291846	MADD	0.43	6.39	0.33	5.28e-10	HDL cholesterol;
LIHC	cis	rs611744	0.967	rs627019	chr8:109222544	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.81	-14.19	-0.61	3e-36	Coronary artery disease;
LIHC	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.88	10.95	0.51	3.9e-24	Coronary artery disease;
LIHC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.82	-14.5	-0.62	1.77e-37	Aortic root size;
LIHC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.4	7.23	0.36	3.28e-12	Psoriasis;
LIHC	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.58	6.42	0.33	4.54e-10	Axial length;
LIHC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	9.86	0.47	2.3e-20	Total body bone mineral density;
LIHC	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg22890737	chr4:3514540	LRPAP1	0.45	6.35	0.32	7.05e-10	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14676711	chr18:48405181	ME2	-0.48	-6.04	-0.31	3.94e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg08539965	chr1:21396338	EIF4G3	0.32	5.74	0.3	2.11e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.72	-0.3	2.3e-8	Response to amphetamines;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-6.23	-0.32	1.37e-9	Longevity;
LIHC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.61	9.75	0.47	5.6e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs1113500	0.787	rs473704	chr1:108637310	T/C	cg06207961	chr1:108661230	NA	-0.31	-5.86	-0.3	1.12e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs9649465	1.000	rs4588795	chr7:123349924	A/G	cg03229431	chr7:123269106	ASB15	0.35	7.6	0.38	2.9e-13	Migraine;
LIHC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.55	7.92	0.39	3.27e-14	Mean corpuscular volume;
LIHC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-8.9	-0.43	3.44e-17	Dental caries;
LIHC	cis	rs7106204	1.000	rs7925633	chr11:24214815	A/G	ch.11.24196551F	chr11:24239977	NA	0.67	6.75	0.34	6.4e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.66	-0.38	1.97e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.84	6.21	0.32	1.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.68	0.57	1.84e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.2e-10	Renal cell carcinoma;
LIHC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg27124370	chr19:33622961	WDR88	0.55	7.91	0.39	3.68e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.62	11.4	0.52	9.78e-26	Total body bone mineral density;
LIHC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	9.15	0.44	5.43e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.43	5.75	0.3	1.99e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.45	0.37	7.71e-13	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.29	-17.09	-0.68	9.12e-48	Diabetic kidney disease;
LIHC	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.34	-6.01	-0.31	4.65e-9	Breast cancer;
LIHC	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.88	0.39	4.47e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.54	8.54	0.42	4.39e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.42	-7.03	-0.36	1.1e-11	Breast cancer;
LIHC	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.81	-0.35	4.31e-11	Hip circumference;Waist circumference;
LIHC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.35	7.64	0.38	2.2e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.52	0.38	4.75e-13	Prudent dietary pattern;
LIHC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.62	-0.38	2.51e-13	Chronic sinus infection;
LIHC	cis	rs5753037	0.809	rs2074706	chr22:30200893	G/C	cg01021169	chr22:30184971	ASCC2	-0.36	-6.79	-0.34	4.94e-11	Type 1 diabetes;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-0.73	-8.17	-0.4	6.1e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16684958	chr7:75615977	POR	0.52	8.53	0.42	4.68e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg00792783	chr2:198669748	PLCL1	0.46	6.86	0.35	3.19e-11	Dermatomyositis;
LIHC	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.58	-8.56	-0.42	3.86e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs151997	0.853	rs3846498	chr5:50253625	A/C	cg06027927	chr5:50259733	NA	-0.62	-8.81	-0.43	6.3e-17	Callous-unemotional behaviour;
LIHC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.95	-16.46	-0.66	2.89e-45	Tonsillectomy;
LIHC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.69	10.0	0.48	7.86e-21	Prostate cancer;
LIHC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg03934865	chr2:198174659	NA	-0.61	-9.82	-0.47	3.31e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.33	-5.95	-0.31	6.79e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg09835421	chr16:68378352	PRMT7	-0.82	-9.6	-0.46	1.8e-19	Magnesium levels;
LIHC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.18	0.44	4.33e-18	Electroencephalogram traits;
LIHC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg17724175	chr1:150552817	MCL1	0.46	8.94	0.44	2.47e-17	Melanoma;
LIHC	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.81	-0.5	1.28e-23	Alzheimer's disease (late onset);
LIHC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	trans	rs11689435	0.843	rs16857695	chr2:218344486	G/A	cg13544946	chr9:35729779	TLN1	-0.44	-6.35	-0.32	6.82e-10	Metabolite levels (MHPG);
LIHC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05665937	chr4:1216051	CTBP1	0.44	5.8	0.3	1.47e-8	Obesity-related traits;
LIHC	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4728302	0.869	rs889826	chr7:133595871	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.54	0.33	2.24e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.49	-8.66	-0.42	1.87e-16	Endometrial cancer;
LIHC	cis	rs77669868	0.810	rs686494	chr11:114070160	A/G	cg01914181	chr11:114070210	ZBTB16	-0.57	-7.68	-0.38	1.68e-13	Monocyte percentage of white cells;
LIHC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg19318889	chr4:1322082	MAEA	0.46	7.73	0.39	1.24e-13	Obesity-related traits;
LIHC	cis	rs9649465	0.967	rs12538876	chr7:123296320	C/A	cg03229431	chr7:123269106	ASB15	-0.39	-8.22	-0.41	4.29e-15	Migraine;
LIHC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.7	-0.43	1.45e-16	Subjective well-being;
LIHC	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg08992911	chr2:238395768	MLPH	0.49	5.96	0.31	6.24e-9	Prostate cancer;
LIHC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17554472	chr22:41940697	POLR3H	0.53	5.88	0.3	9.54e-9	Vitiligo;
LIHC	trans	rs7952251	0.549	rs17114089	chr11:112451038	A/G	cg03183631	chr4:26819811	NA	-0.3	-6.14	-0.32	2.23e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg02891314	chr5:179741120	GFPT2	-0.5	-7.0	-0.35	1.36e-11	Height;
LIHC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.52	7.19	0.36	4.19e-12	Height;
LIHC	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.41	-0.37	9.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.53	8.1	0.4	9.65e-15	Diastolic blood pressure;
LIHC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	7.46	0.37	7.01e-13	Height;
LIHC	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.89	-0.35	2.69e-11	Self-reported allergy;
LIHC	trans	rs1427593	1.000	rs1991411	chr2:137534796	T/C	cg04243827	chr5:3103718	NA	0.41	6.07	0.31	3.32e-9	Pancreatic cancer;
LIHC	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	9.86	0.47	2.35e-20	LDL cholesterol;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.6	9.31	0.45	1.59e-18	Height;
LIHC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05360265	chr6:147525477	STXBP5	-0.46	-6.22	-0.32	1.44e-9	Pancreatic cancer;
LIHC	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.73	-11.36	-0.52	1.41e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.79	0.47	3.95e-20	Alzheimer's disease;
LIHC	cis	rs2380220	0.872	rs2613529	chr6:95945036	C/T	cg15832292	chr6:96025679	MANEA	-0.6	-6.73	-0.34	7.25e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.05	0.31	3.77e-9	Rheumatoid arthritis;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.43	-6.01	-0.31	4.79e-9	Total body bone mineral density;
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg07725925	chr16:89976287	TCF25	0.45	6.17	0.32	1.93e-9	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg13409248	chr3:40428643	ENTPD3	0.38	6.19	0.32	1.71e-9	Renal cell carcinoma;
LIHC	trans	rs1814175	0.616	rs10839349	chr11:49753748	C/A	cg03929089	chr4:120376271	NA	-0.86	-16.6	-0.67	8.18e-46	Height;
LIHC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.05	-0.31	3.78e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg17410650	chr12:54324560	NA	-0.42	-8.2	-0.41	4.86e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg08528486	chr13:113648767	MCF2L	-0.39	-6.35	-0.32	6.69e-10	Systolic blood pressure;
LIHC	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.75	-0.71	1.86e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	7.0	0.35	1.35e-11	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.34	-6.29	-0.32	9.45e-10	Aortic root size;
LIHC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs11673344	0.618	rs4420645	chr19:37544988	C/T	cg27390819	chr19:37464633	NA	-0.51	-6.13	-0.31	2.38e-9	Obesity-related traits;
LIHC	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg18192155	chr21:44258298	NA	0.45	6.49	0.33	3.01e-10	Information processing speed;
LIHC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg07134254	chr20:33865797	NA	-0.53	-6.2	-0.32	1.59e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	0.52	9.66	0.46	1.11e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.9	-0.35	2.6e-11	Gut microbiome composition (summer);
LIHC	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg24579218	chr15:68104479	NA	-0.34	-5.89	-0.3	9.29e-9	Restless legs syndrome;
LIHC	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-7.06	-0.36	9.4e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs9596863	0.898	rs4573825	chr13:54324876	A/G	ch.13.53330881F	chr13:54432880	NA	0.42	5.73	0.3	2.19e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.34	-0.37	1.54e-12	Total cholesterol levels;
LIHC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg04450456	chr4:17643702	FAM184B	0.36	6.1	0.31	2.83e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00938859	chr5:1591904	SDHAP3	0.57	7.09	0.36	7.91e-12	Breast cancer;
LIHC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.45	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.64	11.01	0.51	2.46e-24	Colorectal cancer;
LIHC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.5	0.33	2.86e-10	Bipolar disorder;
LIHC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-8.96	-0.44	2.07e-17	Heart rate;
LIHC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.43	8.47	0.42	7.48e-16	Height;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18278596	chr14:105915860	MTA1	0.42	6.45	0.33	3.87e-10	Immature fraction of reticulocytes;
LIHC	trans	rs1432089	0.773	rs72700809	chr4:171784801	C/T	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	1.05	13.94	0.6	2.69e-35	Body mass index;
LIHC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08957018	chr22:42487540	NDUFA6	0.47	6.83	0.35	3.85e-11	Pancreatic cancer;
LIHC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.5	8.45	0.42	8.27e-16	Rheumatoid arthritis;
LIHC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	7.06	0.36	9.13e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg14930904	chr10:32216787	ARHGAP12	0.36	6.25	0.32	1.21e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.77	-10.74	-0.5	2.31e-23	Ear protrusion;
LIHC	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg27279351	chr12:120934652	DYNLL1	0.51	7.81	0.39	7.28e-14	High light scatter reticulocyte count;
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.44	8.14	0.4	7.19e-15	Prudent dietary pattern;
LIHC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.82	0.43	5.89e-17	Initial pursuit acceleration;
LIHC	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.63e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4903214	0.848	rs11627178	chr14:74718280	G/C	cg11132536	chr14:74711944	VSX2	-0.24	-5.91	-0.3	8.47e-9	Inflammatory bowel disease;
LIHC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.99	19.71	0.73	2.65e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs1075232	1.000	rs16956838	chr15:31819695	C/G	cg01030201	chr15:31746330	NA	-0.75	-6.33	-0.32	7.87e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg21174375	chr14:64681225	SYNE2	-0.36	-5.87	-0.3	1.02e-8	Atrial fibrillation;
LIHC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.5	6.2	0.32	1.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.74	-11.3	-0.52	2.27e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	9.87e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.5	7.9	0.39	3.77e-14	Total body bone mineral density;
LIHC	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg02811702	chr13:24901961	NA	0.23	5.76	0.3	1.89e-8	Obesity-related traits;
LIHC	cis	rs35362007	0.530	rs79171925	chr14:96003075	T/C	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.8	6.57	0.33	1.93e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.62	-9.44	-0.45	6.06e-19	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.23	-0.36	3.08e-12	Migraine;Coronary artery disease;
LIHC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.46	-6.48	-0.33	3.17e-10	Tonsillectomy;
LIHC	cis	rs1664789	1.000	rs1664789	chr5:53282649	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.51	-8.2	-0.41	5.03e-15	Waist circumference adjusted for body mass index;
LIHC	trans	rs13113518	0.812	rs11945371	chr4:56275230	G/T	cg15358633	chr12:38710606	ALG10B	0.42	6.04	0.31	3.98e-9	Height;
LIHC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg22633049	chr21:46681294	NA	-0.38	-6.51	-0.33	2.64e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21467203	chr3:49911342	NA	0.4	6.77	0.34	5.51e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.5	-0.38	5.49e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.52	8.84	0.43	5.2e-17	Coronary artery disease;
LIHC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	1.0	19.01	0.72	1.74e-55	Breast cancer;
LIHC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg09238746	chr17:78121135	EIF4A3	-0.67	-10.36	-0.49	4.55e-22	Yeast infection;
LIHC	cis	rs6977660	0.943	rs10240816	chr7:19819620	A/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.29	21.97	0.77	2.37e-67	Corneal structure;
LIHC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.95	-0.31	6.69e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	5.83	0.3	1.28e-8	Obesity-related traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05291385	chr2:73461228	CCT7;C2orf7	-0.56	-6.55	-0.33	2.13e-10	Systolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05889321	chr10:97416837	ALDH18A1	0.52	8.58	0.42	3.42e-16	Cognitive function;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09331995	chr7:27309021	NA	0.42	6.84	0.35	3.55e-11	Bilirubin levels;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.42	-5.75	-0.3	2.02e-8	Life satisfaction;
LIHC	trans	rs875971	0.545	rs801212	chr7:66015630	C/G	cg26939375	chr7:64535504	NA	-0.4	-6.31	-0.32	8.63e-10	Aortic root size;
LIHC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.46	9.5e-20	Bipolar disorder;
LIHC	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.27	5.72	0.3	2.35e-8	Pulmonary function;
LIHC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	0.79	11.67	0.53	9.87e-27	Monocyte percentage of white cells;
LIHC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.45	-7.29	-0.37	2.2e-12	Crohn's disease;
LIHC	cis	rs831571	0.653	rs73120967	chr3:64070372	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-5.93	-0.31	7.48e-9	Type 2 diabetes;
LIHC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg14440974	chr22:39074834	NA	-0.44	-6.94	-0.35	1.95e-11	Menopause (age at onset);
LIHC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.33	8.03	0.4	1.61e-14	Primary biliary cholangitis;
LIHC	cis	rs7534824	0.625	rs61780328	chr1:101458754	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.49	0.38	5.92e-13	Refractive astigmatism;
LIHC	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg26139080	chr11:47293733	MADD	-0.51	-8.64	-0.42	2.24e-16	HDL cholesterol;
LIHC	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.4	-6.29	-0.32	9.87e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.86	-14.98	-0.63	2.28e-39	Height;
LIHC	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.31	-8.46	-0.42	7.65e-16	Intelligence;
LIHC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.48	7.78	0.39	8.47e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.81	7.72	0.39	1.29e-13	Diabetic retinopathy;
LIHC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.63	8.01	0.4	1.76e-14	Morning vs. evening chronotype;
LIHC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg27309282	chr4:1016081	FGFRL1	0.37	6.15	0.32	2.16e-9	Oropharynx cancer;
LIHC	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg17074339	chr11:11642133	GALNTL4	0.4	6.09	0.31	3.09e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	trans	rs7714584	1.000	rs6579803	chr5:150255559	C/T	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	6.77	0.34	5.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg12863693	chr15:85201151	NMB	0.49	7.15	0.36	5.22e-12	Schizophrenia;
LIHC	cis	rs4407350	0.868	rs5765719	chr22:44917849	A/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.23	-0.32	1.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.32	5.92	0.3	7.9e-9	Height;
LIHC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.07	-12.44	-0.56	1.42e-29	Vitiligo;
LIHC	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.27	-6.28	-0.32	1e-9	Educational attainment (years of education);
LIHC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.74	-0.43	1.09e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.43	6.84	0.35	3.62e-11	Prostate-specific antigen levels;
LIHC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.41	6.01	0.31	4.67e-9	Gout;
LIHC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg17294928	chr15:75287854	SCAMP5	-0.47	-6.12	-0.31	2.57e-9	Lung cancer;
LIHC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg18912006	chr12:123335444	HIP1R	-0.58	-7.11	-0.36	6.8e-12	Schizophrenia;
LIHC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.7	12.05	0.55	4.21e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.45	-7.56	-0.38	3.85e-13	Educational attainment;
LIHC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg02573091	chr5:74908125	NA	-0.51	-6.13	-0.31	2.46e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.66	-7.94	-0.39	2.98e-14	Morning vs. evening chronotype;
LIHC	cis	rs74181299	0.964	rs2723065	chr2:65279414	A/G	cg05010058	chr2:65284262	CEP68	0.4	6.78	0.34	5.3e-11	Pulse pressure;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.94	14.52	0.62	1.56e-37	Skin colour saturation;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.73	-11.99	-0.54	7e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21843114	chr4:26334859	RBPJ	0.45	6.1	0.31	2.83e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.66	-9.86	-0.47	2.31e-20	Coronary artery disease;
LIHC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg25828445	chr12:7781288	NA	0.44	6.76	0.34	6.04e-11	HDL cholesterol levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24557133	chr1:234509059	C1orf31	-0.56	-6.52	-0.33	2.53e-10	Systolic blood pressure;
LIHC	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.5	-0.38	5.48e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg20607798	chr8:58055168	NA	0.45	6.44	0.33	3.94e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.71	-10.58	-0.5	8.16e-23	Aortic root size;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg24157651	chr18:47018588	SNORD58A;SNORD58B;RPL17	-0.5	-6.23	-0.32	1.4e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs714515	0.502	rs4916254	chr1:172364012	G/A	cg01573306	chr1:172330400	DNM3	0.39	5.73	0.3	2.26e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.5e-21	Bladder cancer;
LIHC	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	8.34	0.41	1.89e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.65	0.34	1.15e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.36	0.33	6.47e-10	Red cell distribution width;
LIHC	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-7.43	-0.37	8.94e-13	Vitiligo;
LIHC	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.77	0.34	5.63e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs820218	0.847	rs820190	chr17:73625286	G/A	cg14452952	chr6:108548360	SNX3	0.38	6.03	0.31	4.16e-9	Rotator cuff tears;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11625262	chr3:156393772	TIPARP;LOC100287227	-0.44	-6.23	-0.32	1.4e-9	Longevity;
LIHC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27297192	chr10:134578999	INPP5A	-0.51	-7.9	-0.39	3.8e-14	Migraine;
LIHC	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	1.05	12.58	0.56	4.2000000000000004e-30	Red blood cell traits;
LIHC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-11.71	-0.54	7.28e-27	Dental caries;
LIHC	cis	rs7116495	0.609	rs2276396	chr11:71823905	G/C	cg10381502	chr11:71823885	C11orf51	1.05	8.87	0.43	4.11e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	6.72	0.34	7.53e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.8	-8.83	-0.43	5.64e-17	Schizophrenia;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.95	0.31	6.58e-9	Aortic root size;
LIHC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg27478167	chr7:817139	HEATR2	-0.41	-5.82	-0.3	1.38e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.18e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.54	6.45	0.33	3.89e-10	Alzheimer's disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20658100	chr13:74707145	KLF12	0.36	6.28	0.32	1.03e-9	Calcium levels;
LIHC	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.76	-12.29	-0.55	5.43e-29	Morning vs. evening chronotype;
LIHC	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.91	18.75	0.71	1.96e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.28	17.42	0.69	4.2e-49	Diabetic kidney disease;
LIHC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.61	10.5	0.49	1.6e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2336384	1.000	rs1810563	chr1:12054030	A/G	cg13216073	chr1:12042593	MFN2	-0.45	-6.52	-0.33	2.49e-10	Platelet count;
LIHC	trans	rs1814175	0.588	rs34449937	chr11:49756013	G/A	cg03929089	chr4:120376271	NA	-0.85	-16.54	-0.67	1.44e-45	Height;
LIHC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	7.36	0.37	1.42e-12	Obesity-related traits;
LIHC	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg13639189	chr17:80606880	WDR45L	0.67	11.21	0.52	4.76e-25	Breast cancer;
LIHC	trans	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg10756647	chr7:56101905	PSPH	-1.07	-13.17	-0.58	2.44e-32	Diabetic kidney disease;
LIHC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.0	-0.35	1.32e-11	Height;
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.54	7.9	0.39	3.9e-14	Height;
LIHC	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.16	-0.4	6.39e-15	Response to antipsychotic treatment;
LIHC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.04	-17.41	-0.69	4.75e-49	Dilated cardiomyopathy;
LIHC	cis	rs918629	0.798	rs10052503	chr5:95283658	A/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.3	-0.32	9.17e-10	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg12863693	chr15:85201151	NMB	0.44	6.33	0.32	7.52e-10	Schizophrenia;
LIHC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.5	7.23	0.36	3.12e-12	Height;
LIHC	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.08	0.48	4.39e-21	Diisocyanate-induced asthma;
LIHC	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-8.39	-0.41	1.27e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1450439	0.948	rs7698039	chr4:139495535	G/T	cg27294979	chr16:69786225	NOB1	0.44	6.41	0.33	4.72e-10	Lung function (forced expiratory volume in 1 second);
LIHC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-6.12	-0.31	2.57e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs832187	0.704	rs832195	chr3:63864612	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.5	7.08	0.36	8.1e-12	Schizophrenia;
LIHC	cis	rs12286929	0.933	rs11215381	chr11:115022233	T/C	cg04055981	chr11:115044050	NA	0.42	6.84	0.35	3.57e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-8.83	-0.43	5.66e-17	Schizophrenia;
LIHC	cis	rs5753037	0.809	rs140150	chr22:30185719	C/G	cg01021169	chr22:30184971	ASCC2	-0.36	-6.84	-0.35	3.71e-11	Type 1 diabetes;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07677032	chr17:61819896	STRADA	-0.4	-5.8	-0.3	1.52e-8	Prudent dietary pattern;
LIHC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	7.83	0.39	6.35e-14	Body mass index;
LIHC	cis	rs2292864	1.000	rs2292864	chr17:45367681	C/T	cg18085866	chr17:45331354	ITGB3	-0.52	-5.88	-0.3	9.96e-9	Left atrial antero-posterior diameter;
LIHC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-12.69	-0.57	1.66e-30	Response to antipsychotic treatment;
LIHC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.39	-10.52	-0.49	1.26e-22	Asthma (sex interaction);
LIHC	cis	rs10508774	1.000	rs72795557	chr10:32870507	C/G	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.51	7.95	0.39	2.8e-14	Lymphocyte counts;
LIHC	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.57	9.12	0.44	6.65e-18	Corneal astigmatism;
LIHC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17467752	chr17:38218738	THRA	0.64	11.78	0.54	4.19e-27	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.3	-0.32	9.3e-10	Renal cell carcinoma;
LIHC	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.63	10.35	0.49	5.25e-22	Phospholipid levels (plasma);
LIHC	cis	rs3736485	0.934	rs4143724	chr15:51870413	T/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.05e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.16	-0.48	2.35e-21	Response to antipsychotic treatment;
LIHC	cis	rs71017072	1	rs71017072	chr7:19794295	G/GA	cg07541023	chr7:19748670	TWISTNB	0.39	5.97	0.31	5.81e-9	Rubella;
LIHC	cis	rs17094222	0.797	rs1541264	chr10:102433682	C/T	cg26540559	chr10:102447443	NA	0.31	6.08	0.31	3.16e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.51	-0.79	2.04e-73	Height;
LIHC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg12046867	chr14:103022105	NA	-0.47	-6.79	-0.34	4.94e-11	Platelet count;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg10780191	chr14:69261284	ZFP36L1	-0.77	-6.48	-0.33	3.21e-10	Mild influenza (H1N1) infection;
LIHC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	7.88	0.39	4.32e-14	Height;
LIHC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg20684491	chr1:25596433	NA	-0.29	-6.04	-0.31	3.97e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.5	5.88	0.3	9.95e-9	Schizophrenia;
LIHC	cis	rs74181299	0.712	rs2241161	chr2:65290842	A/C	cg05010058	chr2:65284262	CEP68	-0.36	-6.31	-0.32	8.66e-10	Pulse pressure;
LIHC	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg14146966	chr2:61757674	XPO1	0.32	5.72	0.3	2.34e-8	Tuberculosis;
LIHC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.42	-6.53	-0.33	2.34e-10	Morning vs. evening chronotype;
LIHC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-7.12	-0.36	6.48e-12	Longevity;
LIHC	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.44	7.82	0.39	6.76e-14	Breast cancer;
LIHC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.5	-6.34	-0.32	7.07e-10	Menarche (age at onset);
LIHC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg19635926	chr16:89946313	TCF25	0.51	6.41	0.33	4.89e-10	Skin colour saturation;
LIHC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg07382826	chr16:28625726	SULT1A1	0.51	7.92	0.39	3.41e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.24	6.03	0.31	4.25e-9	Migraine;
LIHC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.44	0.37	8.39e-13	Bone mineral density;
LIHC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.85	-0.65	8.31e-43	Chronic sinus infection;
LIHC	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg02344993	chr17:57696989	CLTC	0.7	11.66	0.53	1.16e-26	Hemoglobin concentration;
LIHC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.2	0.61	2.65e-36	Chronic sinus infection;
LIHC	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.34	-7.15	-0.36	5.15e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.98	21.51	0.76	1.58e-65	Bone mineral density;
LIHC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.57	-0.38	3.54e-13	Ulcerative colitis;
LIHC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.92	0.3	7.91e-9	Body mass index;
LIHC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.59	-9.32	-0.45	1.44e-18	Bipolar disorder;
LIHC	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.52	-8.04	-0.4	1.47e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.62	-11.1	-0.51	1.2e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1986734	0.555	rs12512288	chr4:77416817	C/G	cg24201034	chr4:77507246	SHROOM3	-0.37	-5.93	-0.31	7.46e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.27	0.37	2.43e-12	Vitiligo;
LIHC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.97	0.31	5.81e-9	Schizophrenia;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.86	-0.39	5.22e-14	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg01788221	chr16:89496183	ANKRD11	-0.38	-6.0	-0.31	5.1e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.38	0.37	1.23e-12	Vitiligo;
LIHC	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg14550611	chr19:41354682	CYP2A6	0.36	5.78	0.3	1.64e-8	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LIHC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg12046867	chr14:103022105	NA	-0.48	-6.94	-0.35	1.94e-11	Platelet count;
LIHC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg14558114	chr2:88469736	THNSL2	0.6	5.72	0.3	2.35e-8	Plasma clusterin levels;
LIHC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.2	0.41	4.78e-15	Lymphocyte counts;
LIHC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.8	13.8	0.6	9.38e-35	Parkinson's disease;
LIHC	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.76	-12.32	-0.55	4.07e-29	Adiposity;
LIHC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.51	7.25	0.36	2.88e-12	Menopause (age at onset);
LIHC	trans	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg21659725	chr3:3221576	CRBN	0.6	6.47	0.33	3.42e-10	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.89	0.35	2.69e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7326068	0.524	rs2497488	chr13:21201476	A/T	cg12081946	chr13:21296465	IL17D	0.37	5.98	0.31	5.58e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.89	13.62	0.59	4.7e-34	Vitamin D levels;
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.64	-9.72	-0.47	6.96e-20	Renal cell carcinoma;
LIHC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.99	21.59	0.76	7.69e-66	Bone mineral density;
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg11062466	chr8:58055876	NA	0.51	7.6	0.38	2.84e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00612595	chr21:47717864	NA	-0.42	-6.62	-0.34	1.36e-10	Testicular germ cell tumor;
LIHC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.03	-0.31	4.29e-9	Schizophrenia;
LIHC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.77	9.4	0.45	8.09e-19	Mean platelet volume;
LIHC	cis	rs2279817	0.818	rs34421778	chr1:17984859	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.14	-0.36	5.63e-12	Neuroticism;
LIHC	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.5	8.13	0.4	7.9e-15	Corneal astigmatism;
LIHC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg16103275	chr6:290800	DUSP22	0.53	7.13	0.36	6.01e-12	Menopause (age at onset);
LIHC	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg11441379	chr12:63026424	NA	-0.61	-6.22	-0.32	1.45e-9	IgG glycosylation;
LIHC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-7.88	-0.39	4.34e-14	Longevity;Endometriosis;
LIHC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.29	-6.25	-0.32	1.19e-9	Longevity;
LIHC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.96	0.4	2.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs11229555	0.645	rs12290089	chr11:58176849	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.52	-9.23	-0.45	2.82e-18	Blood protein levels;
LIHC	cis	rs3106136	0.534	rs13109764	chr4:95304506	T/C	cg11021082	chr4:95130006	SMARCAD1	0.34	5.85	0.3	1.14e-8	Capecitabine sensitivity;
LIHC	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.36	5.86	0.3	1.08e-8	Platelet distribution width;
LIHC	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.3	-0.37	2.01e-12	Mean platelet volume;
LIHC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg24826892	chr11:71159390	DHCR7	0.52	6.69	0.34	9.2e-11	Vitamin D levels;
LIHC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.26	-6.36	-0.33	6.6e-10	Cutaneous nevi;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15984612	chr8:145514624	BOP1;HSF1	0.46	6.87	0.35	3.07e-11	Cognitive function;
LIHC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.39	-0.71	5.32e-53	Height;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04577441	chr4:100870687	LOC256880;H2AFZ	0.31	6.13	0.31	2.47e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11645453	chr3:52864694	ITIH4	0.21	5.83	0.3	1.26e-8	Bipolar disorder;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02951021	chr12:120934296	DYNLL1	-0.43	-6.38	-0.33	5.65e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.38	-6.31	-0.32	8.67e-10	Blood metabolite levels;
LIHC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.51	0.33	2.64e-10	Renal cell carcinoma;
LIHC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.45	5.8	0.3	1.54e-8	Colorectal cancer;
LIHC	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.0	0.44	1.56e-17	Schizophrenia;
LIHC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg17279839	chr7:150038598	RARRES2	0.5	10.72	0.5	2.57e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.45	-0.37	7.79e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	0.97	12.07	0.55	3.61e-28	Economic and political preferences (immigration/crime);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26716323	chr7:22862328	TOMM7	0.5	6.89	0.35	2.7e-11	Pancreatic cancer;
LIHC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg25039879	chr17:56429692	SUPT4H1	0.81	8.45	0.42	8.63e-16	Cognitive test performance;
LIHC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.58	5.72	0.3	2.33e-8	Neutrophil percentage of white cells;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg18016565	chr1:150552671	MCL1	-0.5	-9.37	-0.45	1.04e-18	Tonsillectomy;
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.09	-0.4	1.02e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg13318129	chr22:45737514	FAM118A	-0.5	-7.59	-0.38	3.04e-13	Tonsillectomy;
LIHC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-7.36	-0.37	1.34e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg10820045	chr2:198174542	NA	0.46	6.97	0.35	1.68e-11	Dermatomyositis;
LIHC	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg05697976	chr12:29376483	FAR2	-0.29	-5.98	-0.31	5.69e-9	QT interval;
LIHC	cis	rs12602486	1.000	rs12601855	chr17:42224023	A/G	cg13607699	chr17:42295918	UBTF	-0.72	-6.27	-0.32	1.12e-9	Glycated hemoglobin levels;
LIHC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.79	12.84	0.57	4.55e-31	Colorectal cancer;
LIHC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.79	6.78	0.34	5.18e-11	Type 2 diabetes;
LIHC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg23625390	chr15:77176239	SCAPER	-0.38	-6.62	-0.34	1.43e-10	Blood metabolite levels;
LIHC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.21	6.82	0.35	4.23e-11	Motion sickness;
LIHC	cis	rs10861342	1.000	rs115224406	chr12:105578060	C/T	cg23923672	chr12:105501055	KIAA1033	0.68	7.98	0.4	2.26e-14	IgG glycosylation;
LIHC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.92	0.43	2.77e-17	Cognitive test performance;
LIHC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	10.28	0.49	8.86e-22	Alzheimer's disease;
LIHC	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.54e-11	Type 2 diabetes;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	0.81	11.77	0.54	4.57e-27	Menarche (age at onset);
LIHC	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.42	5.83	0.3	1.32e-8	Diastolic blood pressure;
LIHC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.94	0.35	1.95e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg11764359	chr7:65958608	NA	0.56	5.87	0.3	1.05e-8	Diabetic kidney disease;
LIHC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.45	-7.07	-0.36	9.03e-12	Cognitive function;
LIHC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.31	6.39	0.33	5.45e-10	Immature fraction of reticulocytes;
LIHC	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	11.71	0.54	7.17e-27	Coronary artery disease;
LIHC	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.64	-10.13	-0.48	2.98e-21	Rheumatoid arthritis;
LIHC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.76	-10.79	-0.5	1.46e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.46	0.53	5.78e-26	Coronary artery disease;
LIHC	trans	rs4799915	1.000	rs3865391	chr18:34929280	C/T	cg11874882	chr17:31910113	ACCN1	-0.28	-6.53	-0.33	2.38e-10	Response to iloperidone treatment (QT prolongation);
LIHC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.76	0.54	4.78e-27	Motion sickness;
LIHC	cis	rs1198430	0.639	rs685059	chr1:23783185	C/G	cg13183780	chr1:23809682	ASAP3	-0.38	-6.54	-0.33	2.21e-10	Total cholesterol levels;
LIHC	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg17294928	chr15:75287854	SCAMP5	0.46	6.19	0.32	1.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg04691961	chr3:161091175	C3orf57	-0.34	-6.01	-0.31	4.81e-9	Morning vs. evening chronotype;
LIHC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.28	0.49	8.95e-22	Colorectal cancer;
LIHC	cis	rs17152411	0.895	rs7900929	chr10:126584999	A/C	cg07906193	chr10:126599966	NA	0.38	6.26	0.32	1.18e-9	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23151374	chr4:164415611	C4orf43	0.38	6.39	0.33	5.55e-10	Cognitive function;
LIHC	cis	rs797680	0.789	rs531514	chr1:93700212	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.56	9.09	0.44	8.02e-18	Corneal astigmatism;
LIHC	cis	rs17854409	0.764	rs3761301	chr20:61494021	C/T	cg06598544	chr20:61472147	COL9A3	-0.87	-7.36	-0.37	1.39e-12	Obesity-related traits;
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg14222432	chr12:29376421	FAR2	0.38	7.32	0.37	1.75e-12	QT interval;
LIHC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.4	0.37	1.09e-12	Lung cancer in ever smokers;
LIHC	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-8.11	-0.4	9.19e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.36	7.4	0.37	1.09e-12	Renal cell carcinoma;
LIHC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	11.06	0.51	1.69e-24	Chronic sinus infection;
LIHC	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.6	-10.06	-0.48	4.92e-21	Coronary artery disease;
LIHC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.52	8.05	0.4	1.34e-14	Lymphocyte counts;
LIHC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.66	-9.97	-0.47	1.01e-20	Subjective well-being;
LIHC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg24209194	chr3:40518798	ZNF619	0.49	7.37	0.37	1.32e-12	Renal cell carcinoma;
LIHC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.15	0.36	5.42e-12	Lung cancer;
LIHC	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.94	-7.0	-0.35	1.32e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.57	-8.87	-0.43	4.04e-17	Dental caries;
LIHC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.06	0.31	3.63e-9	Electroencephalogram traits;
LIHC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.14	0.31	2.35e-9	Melanoma;
LIHC	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg03585969	chr10:35415529	CREM	0.76	11.0	0.51	2.6e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20225246	chr19:2200020	DOT1L	0.47	6.95	0.35	1.86e-11	Bilirubin levels;
LIHC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.29e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-10.81	-0.5	1.23e-23	Morning vs. evening chronotype;
LIHC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs2997447	0.846	rs12067677	chr1:26411971	C/T	cg19633962	chr1:26362018	EXTL1	-0.59	-6.93	-0.35	2.09e-11	QRS complex (12-leadsum);
LIHC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.27	5.73	0.3	2.18e-8	Ulcerative colitis;
LIHC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg01652190	chr22:50026171	C22orf34	-0.3	-6.9	-0.35	2.57e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-7.57	-0.38	3.4e-13	Gut microbiome composition (summer);
LIHC	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.31	-0.37	1.91e-12	Tuberculosis;
LIHC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.53	0.33	2.31e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.5	6.47	0.33	3.31e-10	Subjective well-being;
LIHC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg17750252	chr2:136567154	LCT	0.33	6.16	0.32	2.01e-9	Mosquito bite size;
LIHC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-8.65	-0.42	1.97e-16	Schizophrenia;
LIHC	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.27	-0.49	9.9e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	trans	rs10411161	0.702	rs7251571	chr19:52389057	A/G	cg22319618	chr22:45562946	NUP50	-0.61	-8.56	-0.42	3.75e-16	Breast cancer;
LIHC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.29	-0.37	2.1e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.27	-0.45	2.15e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.75	8.97	0.44	1.99e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.42e-14	Morning vs. evening chronotype;
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg23990641	chr6:118823964	C6orf204;BRD7P3	0.44	5.97	0.31	5.95e-9	Diastolic blood pressure;
LIHC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg23517279	chr6:96025343	MANEA	-0.61	-6.25	-0.32	1.23e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.56	8.13	0.4	8.02e-15	Bone properties (heel);
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.36	5.98	0.31	5.77e-9	Height;
LIHC	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.4	-6.49	-0.33	3.07e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg01557791	chr16:72042693	DHODH	-0.42	-6.17	-0.32	1.91e-9	Coronary artery disease;
LIHC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg27523141	chr10:43048294	ZNF37B	0.37	6.27	0.32	1.11e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs738321	0.756	rs12169611	chr22:38513735	T/C	cg25457927	chr22:38595422	NA	-0.29	-6.46	-0.33	3.53e-10	Breast cancer;
LIHC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg20487152	chr13:99095054	FARP1	-0.37	-6.22	-0.32	1.42e-9	Longevity;
LIHC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.64	0.53	1.33e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.6	-9.05	-0.44	1.08e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg06050784	chr16:88016603	BANP	0.36	6.57	0.33	1.93e-10	Menopause (age at onset);
LIHC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.53	-7.29	-0.37	2.18e-12	IgG glycosylation;
LIHC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.63	5.82	0.3	1.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg01903971	chr7:100434983	NA	-0.39	-6.35	-0.32	6.79e-10	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg16103275	chr6:290800	DUSP22	0.5	6.44	0.33	4.08e-10	Menopause (age at onset);
LIHC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.51	9.01	0.44	1.48e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4684776	1.000	rs7645555	chr3:11416009	T/G	cg00170343	chr3:11313890	ATG7	-0.43	-5.81	-0.3	1.45e-8	Small vessel stroke;
LIHC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg18944383	chr4:111397179	ENPEP	-0.34	-8.2	-0.41	4.77e-15	Coronary artery disease;
LIHC	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-8.96	-0.44	2.07e-17	Extraversion;
LIHC	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.23	6.34	0.32	7.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.65	0.34	1.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.81	13.05	0.58	7.15e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs983392	0.709	rs1349667	chr11:59993346	T/A	cg17275991	chr19:58003312	ZNF419	0.43	6.06	0.31	3.64e-9	Alzheimer's disease (late onset);
LIHC	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.5	-8.07	-0.4	1.18e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.88	-16.9	-0.67	5.32e-47	Height;
LIHC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.4	-5.82	-0.3	1.38e-8	Narcolepsy;
LIHC	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg22951263	chr5:87985283	NA	-0.41	-7.17	-0.36	4.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg22842854	chr12:123319900	HIP1R	-0.67	-8.8	-0.43	7.1e-17	Schizophrenia;
LIHC	cis	rs17286411	0.750	rs4788575	chr16:71931126	T/G	cg03805757	chr16:71968109	PKD1L3	0.42	5.89	0.3	9.23e-9	Blood protein levels;
LIHC	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	9.04	0.44	1.17e-17	Post bronchodilator FEV1;
LIHC	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.78	13.14	0.58	3.32e-32	Coronary artery disease;
LIHC	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	0.57	8.62	0.42	2.61e-16	Atopic dermatitis;
LIHC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22748539	chr11:68830527	TPCN2	0.4	6.26	0.32	1.16e-9	Pancreatic cancer;
LIHC	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.53	-0.38	4.64e-13	Prevalent atrial fibrillation;
LIHC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.49	-7.54	-0.38	4.38e-13	Corneal astigmatism;
LIHC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.53	-6.34	-0.32	7.32e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-16.98	-0.68	2.56e-47	Systemic lupus erythematosus;
LIHC	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg05110241	chr16:68378359	PRMT7	-0.5	-5.95	-0.31	6.56e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg10756647	chr7:56101905	PSPH	0.95	9.96	0.47	1.08e-20	Gout;
LIHC	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.56	13.83	0.6	7.33e-35	White blood cell count (basophil);
LIHC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg10763598	chr19:19431466	KIAA0892;SF4	0.5	5.78	0.3	1.72e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.45	7.4	0.37	1.05e-12	Multiple sclerosis;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.39	-6.01	-0.31	4.71e-9	Prudent dietary pattern;
LIHC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.47	6.26	0.32	1.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	6.73	0.34	7.23e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.17	-0.4	5.85e-15	Morning vs. evening chronotype;
LIHC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.12	0.4	8.61e-15	Birth weight;
LIHC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg26149184	chr10:133730230	NA	0.47	7.48	0.37	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.7.2226368R	chr7:103835598	ORC5L	-0.36	-6.15	-0.32	2.12e-9	Cognitive function;
LIHC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.54	-0.5	1.08e-22	Total cholesterol levels;
LIHC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.37	-7.3	-0.37	2.09e-12	Urinary metabolites;
LIHC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.95	20.54	0.74	1.24e-61	Blood protein levels;
LIHC	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.48e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg10820045	chr2:198174542	NA	0.45	6.73	0.34	7.37e-11	Intracranial aneurysm;
LIHC	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.44	-7.91	-0.39	3.68e-14	Coronary artery disease;
LIHC	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-9.47	-0.46	4.9e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09328466	chr7:64023458	ZNF680	-0.43	-6.46	-0.33	3.6e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.46	6.69	0.34	8.94e-11	Asthma;
LIHC	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.59	6.02	0.31	4.42e-9	Hip geometry;
LIHC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.43	7.87	0.39	4.77e-14	Schizophrenia;
LIHC	cis	rs10454142	1.000	rs10454142	chr2:48646399	T/C	cg15846641	chr2:48541264	FOXN2	0.46	6.03	0.31	4.31e-9	Sex hormone-binding globulin levels;
LIHC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.89	9.87	0.47	2.27e-20	Triglycerides;
LIHC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.79	-0.34	5.03e-11	Gut microbiome composition (summer);
LIHC	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.6	-6.87	-0.35	3.04e-11	Urinary tract infection frequency;
LIHC	cis	rs6442522	0.550	rs4036833	chr3:15406428	G/C	cg16303742	chr3:15540471	COLQ	0.4	6.84	0.35	3.64e-11	Uric acid levels;
LIHC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.44	-6.5	-0.33	2.83e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg19318889	chr4:1322082	MAEA	-0.48	-7.92	-0.39	3.27e-14	Obesity-related traits;
LIHC	cis	rs35955747	0.902	rs12167361	chr22:31696278	G/C	cg22777020	chr22:31556080	RNF185	-0.49	-5.76	-0.3	1.91e-8	Neutrophil count;Sum basophil neutrophil counts;
LIHC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.55	-8.8	-0.43	7.02e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.12	-8.41	-0.41	1.13e-15	Body mass index;
LIHC	cis	rs12101261	1.000	rs8003061	chr14:81451956	G/A	cg06600135	chr14:81408086	NA	0.37	6.3	0.32	8.99e-10	Graves' disease;
LIHC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.6	8.88	0.43	3.79e-17	Recombination rate (females);
LIHC	trans	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg09779027	chr19:7224513	INSR	0.29	6.75	0.34	6.17e-11	Hypothyroidism;
LIHC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.38	6.12	0.31	2.54e-9	Prostate-specific antigen levels;
LIHC	cis	rs3736485	0.966	rs8031903	chr15:51838161	C/T	cg08986416	chr15:51914746	DMXL2	-0.41	-6.07	-0.31	3.49e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11249189	chr17:42148592	G6PC3	0.41	6.12	0.31	2.5e-9	Cognitive function;
LIHC	cis	rs2292096	1.000	rs12747799	chr1:200717686	A/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.12	-0.31	2.57e-9	Epilepsy;
LIHC	cis	rs10845606	0.581	rs10772591	chr12:12834802	A/G	cg09462578	chr12:12878428	APOLD1	-0.49	-7.41	-0.37	1.02e-12	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg17830980	chr10:43048298	ZNF37B	0.38	6.87	0.35	2.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-6.57	-0.33	1.93e-10	Schizophrenia;
LIHC	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.53	-0.33	2.32e-10	Metabolite levels;
LIHC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	7.17	0.36	4.52e-12	Menopause (age at onset);
LIHC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.63	11.05	0.51	1.77e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.79	11.29	0.52	2.5e-25	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg20607798	chr8:58055168	NA	0.57	6.65	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.22	-6.27	-0.32	1.07e-9	Calcium levels;
LIHC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.23	18.11	0.7	7.3e-52	Type 1 diabetes nephropathy;
LIHC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.59	-9.12	-0.44	6.34e-18	Height;
LIHC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg08896387	chr1:24191740	FUCA1	0.38	6.05	0.31	3.89e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.12	12.79	0.57	7.08e-31	Vitiligo;
LIHC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg03859395	chr2:55845619	SMEK2	-0.51	-8.71	-0.43	1.29e-16	Metabolic syndrome;
LIHC	cis	rs11662586	1.000	rs12605316	chr18:77693600	C/T	cg20368463	chr18:77673604	PQLC1	0.43	6.7	0.34	8.66e-11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.48	8.65	0.42	1.98e-16	Colorectal cancer;
LIHC	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg01864836	chr14:55583639	NA	-0.4	-7.52	-0.38	4.98e-13	Protein biomarker;
LIHC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.28	6.89	0.35	2.69e-11	Primary biliary cholangitis;
LIHC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.46	0.53	5.85e-26	Colorectal cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10998122	chr11:64008466	FKBP2	0.43	6.1	0.31	2.88e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12744310	0.887	rs12047161	chr1:41807528	G/T	cg03962019	chr1:41807865	NA	0.39	6.28	0.32	1.05e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg07541023	chr7:19748670	TWISTNB	0.41	6.34	0.32	7.43e-10	Thyroid stimulating hormone;
LIHC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.57	-0.5	8.92e-23	Chronic sinus infection;
LIHC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.5	7.33	0.37	1.71e-12	Obesity-related traits;
LIHC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.78	-11.79	-0.54	3.59e-27	Response to antineoplastic agents;
LIHC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.48	8.2	0.41	4.97e-15	Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.68	7.1	0.36	7.41e-12	Alzheimer's disease;
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.37	6.67	0.34	1.02e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg12463550	chr7:65579703	CRCP	0.73	7.14	0.36	5.8e-12	Diabetic kidney disease;
LIHC	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.75	-12.91	-0.57	2.39e-31	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.4	0.33	5e-10	Renal cell carcinoma;
LIHC	cis	rs10503871	0.625	rs13256027	chr8:30305180	G/A	cg26383811	chr8:30366931	RBPMS	0.4	6.86	0.35	3.28e-11	Metabolite levels  (X-11787);
LIHC	cis	rs4908768	0.906	rs10492966	chr1:8598005	C/T	cg25722041	chr1:8623473	RERE	0.41	5.93	0.31	7.22e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.41	-7.36	-0.37	1.4e-12	Prudent dietary pattern;
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg03721293	chr16:90014378	DEF8	0.41	6.81	0.35	4.5e-11	Skin colour saturation;
LIHC	cis	rs11690935	0.959	rs6738445	chr2:172599615	T/C	cg13550731	chr2:172543902	DYNC1I2	0.89	17.2	0.68	3.37e-48	Schizophrenia;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg15871215	chr5:81402204	ATG10	0.68	8.17	0.4	6.13e-15	Breast cancer;
LIHC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.56	5.77	0.3	1.81e-8	Smoking initiation;
LIHC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg10932868	chr11:921992	NA	0.36	6.72	0.34	7.46e-11	Alzheimer's disease (late onset);
LIHC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.71	-0.38	1.37e-13	Gut microbiome composition (summer);
LIHC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.6	-0.34	1.61e-10	Height;
LIHC	cis	rs7739232	0.920	rs77374381	chr6:53530662	A/G	cg15658676	chr6:53530538	KLHL31	-1.03	-7.33	-0.37	1.7e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs9649465	0.967	rs12706546	chr7:123353414	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-7.95	-0.39	2.77e-14	Migraine;
LIHC	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-7.16	-0.36	4.84e-12	Hepatocellular carcinoma;
LIHC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.4	6.74	0.34	6.68e-11	Blood metabolite levels;
LIHC	cis	rs2274273	0.529	rs7149965	chr14:55508191	G/A	cg01864836	chr14:55583639	NA	-0.36	-5.87	-0.3	1.02e-8	Protein biomarker;
LIHC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.13	15.25	0.64	2.08e-40	Diabetic kidney disease;
LIHC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.08	-0.31	3.21e-9	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.64e-30	Menopause (age at onset);
LIHC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg25204440	chr1:209979598	IRF6	0.5	7.8	0.39	7.47e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	trans	rs11689435	0.925	rs7420802	chr2:218351314	T/C	cg13544946	chr9:35729779	TLN1	-0.43	-6.27	-0.32	1.12e-9	Metabolite levels (MHPG);
LIHC	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-0.8	-8.66	-0.42	1.95e-16	Exhaled nitric oxide output;
LIHC	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg07636037	chr3:49044803	WDR6	-0.52	-6.44	-0.33	4.09e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11008690	chr8:54934459	TCEA1	0.42	6.13	0.31	2.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs911119	0.955	rs6036474	chr20:23604414	G/A	cg16589663	chr20:23618590	CST3	0.78	8.08	0.4	1.09e-14	Chronic kidney disease;
LIHC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00958927	chr1:175162553	KIAA0040	-0.38	-6.16	-0.32	2.08e-9	Alcohol dependence;
LIHC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-6.23	-0.32	1.4e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.85	0.35	3.42e-11	Diabetic kidney disease;
LIHC	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.39	6.34	0.32	7.24e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.78	-0.34	5.16e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.44	-8.38	-0.41	1.4e-15	Schizophrenia;
LIHC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.6	0.5	6.67e-23	Bladder cancer;
LIHC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.63	0.56	2.91e-30	Total body bone mineral density;
LIHC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.96	-0.4	2.57e-14	Coronary artery disease;
LIHC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg10932868	chr11:921992	NA	0.38	7.05	0.36	1.01e-11	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-21.67	-0.76	3.64e-66	Prudent dietary pattern;
LIHC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-7.62	-0.38	2.44e-13	Cognitive function;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.5	0.33	2.88e-10	Prudent dietary pattern;
LIHC	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02985541	chr2:219472218	PLCD4	-0.42	-6.82	-0.35	4.02e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.66	10.87	0.51	7.44e-24	Platelet distribution width;
LIHC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.37e-11	Red blood cell count;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08530205	chr7:101849354	CUX1	0.41	6.12	0.31	2.61e-9	Longevity;
LIHC	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.62	10.71	0.5	2.9e-23	Breast cancer;
LIHC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05535760	chr7:792225	HEATR2	0.93	12.55	0.56	5.75e-30	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7937890	0.559	rs2575852	chr11:14533368	G/A	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.4	8.8	0.43	7.12e-17	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg01320579	chr17:75405842	SEPT9	0.5	7.15	0.36	5.46e-12	Airflow obstruction;
LIHC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.79	14.94	0.63	3.5e-39	Coronary artery disease;
LIHC	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.97e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2412488	0.893	rs12511253	chr4:54363801	G/A	cg22241045	chr4:54363911	LNX1	0.46	7.61	0.38	2.7e-13	DNA methylation (variation);
LIHC	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg01236616	chr12:121019343	POP5	-1.32	-17.01	-0.68	1.81e-47	Type 1 diabetes nephropathy;
LIHC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.17	-0.32	1.9e-9	Total body bone mineral density;
LIHC	cis	rs80282103	0.618	rs1079389	chr10:1161980	A/G	cg08668510	chr10:1095578	IDI1	0.64	6.17	0.32	1.9e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs611744	0.967	rs677842	chr8:109212468	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.52	8.02	0.4	1.74e-14	Cognitive function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27072603	chr15:40660990	DISP2	-0.37	-6.18	-0.32	1.79e-9	Calcium levels;
LIHC	trans	rs9323205	0.531	rs55681440	chr14:51542179	T/C	cg02322135	chr4:113969312	ANK2	0.42	6.16	0.32	1.99e-9	Cancer;
LIHC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.64	11.84	0.54	2.37e-27	Lymphocyte percentage of white cells;
LIHC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.89	-0.47	1.88e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.94	0.63	3.29e-39	Prudent dietary pattern;
LIHC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs655641	0.954	rs601185	chr11:85686151	A/T	cg09030501	chr11:85779252	PICALM	-0.51	-6.14	-0.32	2.23e-9	Platelet count;
LIHC	cis	rs9328573	0.935	rs12900347	chr15:100509459	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.47	-7.1	-0.36	7.44e-12	Urate levels in lean individuals;
LIHC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.78	9.11	0.44	7.25e-18	Cognitive function;
LIHC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.88	12.43	0.56	1.59e-29	Blood metabolite levels;
LIHC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.42	-6.67	-0.34	1.02e-10	Menarche (age at onset);
LIHC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.26	0.41	3.34e-15	Schizophrenia;
LIHC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.42	-0.33	4.43e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.35	-8.16	-0.4	6.31e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.44	-5.72	-0.3	2.27e-8	Schizophrenia;
LIHC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.44e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs9940464	0.835	rs4782773	chr16:83369284	C/A	cg02755603	chr20:18548475	LOC388789	0.34	6.06	0.31	3.62e-9	Malaria;
LIHC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.51	-7.8	-0.39	7.62e-14	Menarche (age at onset);
LIHC	cis	rs1419980	0.730	rs11533526	chr12:7750484	C/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.38	5.83	0.3	1.26e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs526821	0.553	rs295597	chr11:55470003	T/C	cg03929089	chr4:120376271	NA	-0.45	-6.71	-0.34	7.87e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs2625529	0.816	rs4777467	chr15:72138478	T/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.82	-0.3	1.32e-8	Red blood cell count;
LIHC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.22	-0.45	3.13e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.93	13.32	0.58	6.93e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9434723	0.844	rs9434729	chr1:9303940	G/C	cg04199779	chr1:9294473	H6PD	0.53	5.94	0.31	6.87e-9	Height;
LIHC	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg06102954	chr21:42741788	MX2	0.39	6.56	0.33	2e-10	Melanoma;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.63	0.53	1.47e-26	Prudent dietary pattern;
LIHC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.17	0.36	4.76e-12	Parkinson's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11239145	chr4:26320844	RBPJ	0.46	6.29	0.32	9.98e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.64	-8.06	-0.4	1.29e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.41	0.37	9.8e-13	Morning vs. evening chronotype;
LIHC	cis	rs9918079	0.560	rs12651550	chr4:15641018	G/C	cg21329975	chr4:15471214	CC2D2A	-0.41	-6.19	-0.32	1.69e-9	Obesity-related traits;
LIHC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.49	-0.53	4.52e-26	Type 2 diabetes;
LIHC	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.34	-7.05	-0.36	9.96e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.43	-6.43	-0.33	4.34e-10	Cognitive function;
LIHC	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.37	-7.8	-0.39	7.46e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18000306	chr6:288505	NA	0.35	6.48	0.33	3.21e-10	Menopause (age at onset);
LIHC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.12	0.4	8.29e-15	Morning vs. evening chronotype;
LIHC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.65	-12.21	-0.55	1.08e-28	Paraoxonase activity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25632300	chr5:174905618	SFXN1	-0.46	-6.66	-0.34	1.13e-10	Cognitive function;
LIHC	cis	rs1322512	0.917	rs2623956	chr6:152971617	G/A	cg03415253	chr6:152958462	SYNE1	-0.33	-5.96	-0.31	6.42e-9	Tonometry;
LIHC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.47	-11.82	-0.54	2.81e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg04306507	chr14:55594613	LGALS3	0.33	6.37	0.33	6.21e-10	Protein biomarker;
LIHC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.61e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10861342	1.000	rs34705618	chr12:105518611	C/G	cg23923672	chr12:105501055	KIAA1033	0.66	7.75	0.39	1.08e-13	IgG glycosylation;
LIHC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.79	12.72	0.57	1.25e-30	Corneal astigmatism;
LIHC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg21665744	chr7:39171113	POU6F2	0.33	5.99	0.31	5.21e-9	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.41	7.61	0.38	2.74e-13	Prudent dietary pattern;
LIHC	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.74	10.66	0.5	4.27e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg01788221	chr16:89496183	ANKRD11	-0.42	-6.53	-0.33	2.4e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs9367716	0.741	rs9396266	chr6:57107322	C/T	cg03371099	chr6:57305889	PRIM2	0.35	5.74	0.3	2.14e-8	Coronary artery disease;
LIHC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg23517279	chr6:96025343	MANEA	0.58	6.64	0.34	1.21e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg13628971	chr7:2884303	GNA12	0.44	6.96	0.35	1.71e-11	Height;
LIHC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.41	-0.49	3.04e-22	Platelet count;
LIHC	cis	rs6448317	0.556	rs4697496	chr4:24907809	C/T	cg21108841	chr4:24914750	CCDC149	0.53	6.57	0.33	1.92e-10	Heschl's gyrus morphology;
LIHC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.58	0.42	3.44e-16	Initial pursuit acceleration;
LIHC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	5.98	0.31	5.55e-9	Coronary artery disease;
LIHC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.35	0.64	7.98e-41	Chronic sinus infection;
LIHC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg06289844	chr6:126071538	HEY2	0.34	5.96	0.31	6.33e-9	Brugada syndrome;
LIHC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	7.24	0.36	3.03e-12	Monocyte percentage of white cells;
LIHC	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23598886	chr18:12777645	NA	-0.42	-5.74	-0.3	2.11e-8	Inflammatory skin disease;
LIHC	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.68	-7.36	-0.37	1.39e-12	Exhaled nitric oxide output;
LIHC	cis	rs7487075	0.823	rs34472481	chr12:46836348	C/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.13	0.31	2.38e-9	Itch intensity from mosquito bite;
LIHC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.78	14.69	0.62	3.25e-38	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.41	0.53	9e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg00974761	chr17:33866073	SLFN12L	-0.38	-7.61	-0.38	2.69e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.37	6.39	0.33	5.51e-10	HIV-1 susceptibility;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.86	-15.69	-0.65	3.44e-42	Height;
LIHC	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.53	-0.42	4.75e-16	Atrioventricular conduction;
LIHC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.8	0.6	9.84e-35	Primary sclerosing cholangitis;
LIHC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.72	10.26	0.48	1.07e-21	Selective IgA deficiency;
LIHC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	11.44	0.53	7.03e-26	Colorectal cancer;
LIHC	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.55	-7.8	-0.39	7.82e-14	Colorectal cancer;
LIHC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg09182678	chr22:50328711	NA	-0.39	-5.82	-0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.63	10.68	0.5	3.63e-23	Colorectal cancer;
LIHC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.85	10.35	0.49	5.14e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-13.04	-0.58	7.68e-32	Height;
LIHC	cis	rs28595532	0.545	rs17594782	chr4:119250877	G/T	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07063032	chr18:3450262	TGIF1	0.49	6.66	0.34	1.08e-10	Lung function (FEV1/FVC);
LIHC	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg05714579	chr10:131428358	MGMT	0.41	6.72	0.34	7.77e-11	Response to temozolomide;
LIHC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.71	7.38	0.37	1.23e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.55	-7.81	-0.39	7.23e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg23205692	chr1:25664452	TMEM50A	0.37	5.92	0.31	7.71e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.77	11.46	0.53	6.06e-26	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg10755058	chr3:40428713	ENTPD3	0.4	6.87	0.35	3.05e-11	Renal cell carcinoma;
LIHC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.69	-9.04	-0.44	1.19e-17	Motion sickness;
LIHC	cis	rs4908768	0.657	rs11121229	chr1:8831283	C/T	cg20416874	chr1:8611966	RERE	-0.49	-6.68	-0.34	9.8e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13713052	chr3:122102218	FAM162A;CCDC58	0.52	8.04	0.4	1.48e-14	Cognitive function;
LIHC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.49	7.32	0.37	1.79e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg23091122	chr1:110024289	SYPL2	-0.52	-6.86	-0.35	3.22e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs249954	0.512	rs7588	chr16:23681165	G/A	cg05131483	chr16:23706242	ERN2	0.38	6.16	0.32	2.03e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.57	-10.13	-0.48	2.83e-21	Age at first birth;
LIHC	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	6.75	0.34	6.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.35	5.82	0.3	1.32e-8	Electroencephalogram traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24991452	chr6:35996059	MAPK14	0.48	6.78	0.34	5.34e-11	Pancreatic cancer;
LIHC	trans	rs3783890	1.000	rs12590553	chr14:93737668	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.21	0.32	1.56e-9	Body mass index;
LIHC	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.34	7.76	0.39	9.97e-14	Blood metabolite ratios;
LIHC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg07636037	chr3:49044803	WDR6	-0.84	-8.52	-0.42	5.33e-16	Cognitive function;
LIHC	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg22771759	chr13:24902376	NA	0.31	6.47	0.33	3.49e-10	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.45e-11	Height;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg25204440	chr1:209979598	IRF6	0.51	8.04	0.4	1.48e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg17724175	chr1:150552817	MCL1	0.39	7.59	0.38	3.05e-13	Melanoma;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.57	7.62	0.38	2.58e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11869233	chr2:48009809	MSH6	0.39	6.13	0.31	2.4e-9	Pancreatic cancer;
LIHC	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.58	-0.38	3.2e-13	Homocysteine levels;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.13	0.31	2.49e-9	Aortic root size;
LIHC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg19680672	chr10:131412579	MGMT	-0.4	-6.12	-0.31	2.56e-9	Response to temozolomide;
LIHC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.51	0.33	2.68e-10	Mean corpuscular volume;
LIHC	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg25182066	chr10:30743637	MAP3K8	-0.48	-7.93	-0.39	3.23e-14	Inflammatory bowel disease;
LIHC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.73	11.0	0.51	2.65e-24	Corneal astigmatism;
LIHC	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.43	7.59	0.38	3.07e-13	Endometrial cancer;
LIHC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.93	0.47	1.43e-20	Alzheimer's disease;
LIHC	cis	rs11888559	0.655	rs4673244	chr2:204043066	A/T	cg24605529	chr2:203879461	NBEAL1	0.76	5.81	0.3	1.44e-8	Height;
LIHC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.1	20.8	0.75	1.13e-62	Multiple system atrophy;
LIHC	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.45	5.93	0.31	7.26e-9	Alzheimer's disease;
LIHC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.77	-0.47	4.65e-20	Schizophrenia;
LIHC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.62	-6.69	-0.34	8.97e-11	Alzheimer's disease;
LIHC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.64	-10.02	-0.48	6.67e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-8.3	-0.41	2.44e-15	Extraversion;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12484756	chr19:10764617	ILF3;LOC147727	0.52	6.69	0.34	9.4e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg05590025	chr7:65112418	INTS4L2	-0.59	-6.58	-0.34	1.81e-10	Diabetic kidney disease;
LIHC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.66	0.38	1.95e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.42	-0.37	9.39e-13	Morning vs. evening chronotype;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20463403	chr6:36168142	BRPF3	0.44	6.42	0.33	4.53e-10	Longevity;
LIHC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.96	-22.46	-0.77	2.73e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.0	0.31	4.91e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6973256	0.661	rs2550989	chr7:133500313	A/T	cg03336402	chr7:133662267	EXOC4	-0.49	-6.68	-0.34	9.43e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12602486	1.000	rs76913347	chr17:42267048	C/T	cg08193365	chr17:42277699	NA	1.04	7.22	0.36	3.49e-12	Glycated hemoglobin levels;
LIHC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.09	20.67	0.75	3.54e-62	Multiple system atrophy;
LIHC	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.58	10.49	0.49	1.7e-22	Lewy body disease;
LIHC	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.43	7.66	0.38	1.95e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.25	6.5	0.33	2.81e-10	Type 2 diabetes;
LIHC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.52	-6.11	-0.31	2.67e-9	Corneal curvature;
LIHC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.79	12.54	0.56	5.98e-30	Corneal astigmatism;
LIHC	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg07451762	chr16:28383216	NA	0.33	6.84	0.35	3.74e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.51	-6.87	-0.35	2.99e-11	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01717254	chr2:85843265	USP39	0.47	6.4	0.33	5.08e-10	Pancreatic cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21119375	chr2:44393385	NA	-0.4	-6.17	-0.32	1.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.54	-8.13	-0.4	7.9e-15	Platelet count;
LIHC	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-0.86	-9.39	-0.45	8.54e-19	Exhaled nitric oxide output;
LIHC	cis	rs1165668	0.816	rs1866069	chr12:104310545	G/T	cg21863207	chr12:104234989	NT5DC3	-0.45	-7.68	-0.38	1.67e-13	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg19623624	chr10:135278901	LOC619207	-0.42	-6.52	-0.33	2.55e-10	Systemic lupus erythematosus;
LIHC	trans	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg10208301	chr11:6592745	DNHD1	0.45	6.04	0.31	4.06e-9	Coronary artery calcification;
LIHC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.36	5.85	0.3	1.16e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1914816	0.941	rs2938691	chr15:76507206	G/A	cg03037974	chr15:76606532	NA	-0.6	-6.23	-0.32	1.4e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.26	-0.37	2.68e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg03934865	chr2:198174659	NA	0.44	6.63	0.34	1.3e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg25894440	chr7:65020034	NA	-0.52	-6.0	-0.31	5.05e-9	Diabetic kidney disease;
LIHC	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg03934865	chr2:198174659	NA	0.44	6.27	0.32	1.07e-9	Dermatomyositis;
LIHC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-7.75	-0.39	1.03e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.94	17.96	0.7	2.83e-51	Menopause (age at onset);
LIHC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.46	6.24	0.32	1.32e-9	Cognitive function;
LIHC	cis	rs9322817	0.691	rs9486015	chr6:105254000	C/T	cg02098413	chr6:105308735	HACE1	-0.42	-7.76	-0.39	9.72e-14	Thyroid stimulating hormone;
LIHC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.53	7.9	0.39	3.83e-14	Longevity;Endometriosis;
LIHC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg02836325	chr17:76403955	PGS1	0.33	6.53	0.33	2.42e-10	HDL cholesterol levels;
LIHC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.91	-0.3	8.14e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.53	9.33	0.45	1.41e-18	Breast cancer;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.72	14.22	0.61	2.23e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg06951627	chr6:26196580	NA	0.54	5.92	0.3	7.89e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Cleft plate (environmental tobacco smoke interaction);
LIHC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.57	-10.55	-0.5	1.04e-22	Total body bone mineral density;
LIHC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.66	7.04	0.36	1.08e-11	Gut microbiome composition (summer);
LIHC	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.37	7.34	0.37	1.55e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.33	-6.01	-0.31	4.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg05128992	chr18:3450160	TGIF1	-0.36	-6.5	-0.33	2.78e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.84	0.3	1.18e-8	Tuberculosis;
LIHC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg10664184	chr19:17420304	DDA1	0.46	5.86	0.3	1.07e-8	Systemic lupus erythematosus;
LIHC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00152838	chr16:24741724	TNRC6A	0.45	5.93	0.31	7.58e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.37	7.37	0.37	1.26e-12	Renal cell carcinoma;
LIHC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.62	7.58	0.38	3.3e-13	Cognitive function;
LIHC	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.58	8.92	0.43	2.86e-17	Corneal astigmatism;
LIHC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.29	0.49	7.98e-22	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg02886208	chr11:14281011	SPON1	-0.55	-7.78	-0.39	8.91e-14	Mitochondrial DNA levels;
LIHC	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.61	7.49	0.38	6.11e-13	Exhaled nitric oxide output;
LIHC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-7.11	-0.36	6.92e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.58	9.54	0.46	2.7e-19	Resting heart rate;
LIHC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.79	12.43	0.56	1.56e-29	Longevity;
LIHC	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.28	0.32	1.02e-9	Mean corpuscular volume;
LIHC	cis	rs17711722	0.690	rs116823227	chr7:65331001	A/G	cg18876405	chr7:65276391	NA	0.52	7.82	0.39	6.62e-14	Calcium levels;
LIHC	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.47	6.98	0.35	1.56e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg16724585	chr3:197361211	NA	-0.47	-6.25	-0.32	1.21e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01516881	chr6:292596	DUSP22	-0.51	-6.55	-0.33	2.13e-10	Menopause (age at onset);
LIHC	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.45	6.19	0.32	1.73e-9	Resting heart rate;
LIHC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.39	5.93	0.31	7.59e-9	Height;
LIHC	trans	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg10756647	chr7:56101905	PSPH	-0.44	-6.35	-0.32	6.68e-10	Aortic root size;
LIHC	cis	rs8038465	0.638	rs7495543	chr15:73955133	G/C	cg15420318	chr15:73925796	NPTN	0.44	6.75	0.34	6.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.67	0.42	1.71e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3812111	0.774	rs563962	chr6:116431372	G/A	cg08036074	chr6:116424633	NT5DC1	0.67	12.01	0.54	5.76e-28	Age-related macular degeneration;
LIHC	trans	rs214034	0.825	rs2710655	chr2:17853822	T/C	cg09061216	chr1:1558936	MIB2	0.53	6.24	0.32	1.29e-9	Response to amphetamines;
LIHC	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.34	-6.49	-0.33	3.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4700695	0.698	rs416369	chr5:65231058	C/T	cg21114390	chr5:65439923	SFRS12	0.49	6.55	0.33	2.15e-10	Facial morphology (factor 19);
LIHC	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg03934865	chr2:198174659	NA	0.46	6.61	0.34	1.44e-10	Intracranial aneurysm;
LIHC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07305463	chr2:136567211	LCT	-0.37	-5.97	-0.31	6.07e-9	Corneal structure;
LIHC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg24826892	chr11:71159390	DHCR7	0.52	6.69	0.34	9.16e-11	Vitamin D levels;
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg21522988	chr12:29376872	FAR2	0.3	6.99	0.35	1.48e-11	QT interval;
LIHC	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg01864836	chr14:55583639	NA	0.38	6.94	0.35	1.94e-11	Protein biomarker;
LIHC	cis	rs3789045	0.774	rs12041243	chr1:204490470	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-6.55	-0.33	2.15e-10	Educational attainment (college completion);
LIHC	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.46	7.5	0.38	5.65e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg14779329	chr11:130786720	SNX19	0.4	6.04	0.31	4.02e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs2096176	0.632	rs1339814	chr10:26312824	C/T	cg01396774	chr2:218299024	DIRC3	-0.31	-6.16	-0.32	2.06e-9	Obesity-related traits;
LIHC	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.92	-0.54	1.19e-27	Alzheimer's disease;
LIHC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.94	0.68	3.74e-47	Parkinson's disease;
LIHC	cis	rs1400745	0.756	rs10136352	chr14:35334555	C/T	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.94	-0.39	2.96e-14	Monocyte count;
LIHC	cis	rs629922	0.671	rs513039	chr11:114037158	G/A	cg01914181	chr11:114070210	ZBTB16	0.43	6.06	0.31	3.53e-9	Paneth cell defects in Crohn's disease;
LIHC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.58e-32	Colorectal cancer;
LIHC	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.37	-6.27	-0.32	1.09e-9	Menopause (age at onset);
LIHC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg25600027	chr14:23388339	RBM23	-0.41	-5.95	-0.31	6.63e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs507080	0.736	rs658676	chr11:118571123	C/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.31e-10	Aortic root size;
LIHC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg21466736	chr12:48725269	NA	-0.62	-9.16	-0.44	4.73e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs72843506	0.586	rs59890010	chr17:19863673	C/T	cg12065943	chr17:19881925	AKAP10	-0.38	-6.4	-0.33	5.06e-10	Schizophrenia;
LIHC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-6.87	-0.35	3.09e-11	Chronic sinus infection;
LIHC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	0.85	11.15	0.52	7.77e-25	Iron status biomarkers;
LIHC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg06808227	chr14:105710500	BRF1	-0.54	-6.8	-0.35	4.54e-11	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.26	0.68	1.78e-48	Smoking behavior;
LIHC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.41	-6.5	-0.33	2.9e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.77	0.8	2.76e-78	Prudent dietary pattern;
LIHC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg09222892	chr1:25734099	RHCE	-0.46	-8.36	-0.41	1.57e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.49	8.16	0.4	6.57e-15	Blood metabolite levels;
LIHC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.4	-6.58	-0.34	1.78e-10	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg00938859	chr5:1591904	SDHAP3	0.59	7.19	0.36	4.19e-12	Breast cancer;
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.92	-0.54	1.19e-27	Alzheimer's disease;
LIHC	cis	rs611744	0.967	rs662591	chr8:109211358	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	0.87	14.21	0.61	2.47e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	7.6	0.38	2.8e-13	Alzheimer's disease;
LIHC	cis	rs965469	0.948	rs6051769	chr20:3326438	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.6	-0.34	1.6e-10	IFN-related cytopenia;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.5	5.96	0.31	6.25e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg19676328	chr12:49525230	TUBA1B	-0.38	-6.13	-0.31	2.4e-9	Total cholesterol levels;
LIHC	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.62	-8.38	-0.41	1.38e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs9641123	0.639	rs2190333	chr7:93245171	A/G	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs7487075	0.780	rs2279559	chr12:46767175	A/C	cg11331445	chr12:47219877	SLC38A4	0.29	5.93	0.31	7.49e-9	Itch intensity from mosquito bite;
LIHC	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.65	-0.38	2.13e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	trans	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.15e-10	Aortic root size;
LIHC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.44	-7.16	-0.36	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.25	-0.32	1.23e-9	Metabolite levels;
LIHC	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-0.83	-9.47	-0.46	4.76e-19	Mitochondrial DNA levels;
LIHC	cis	rs8010715	0.816	rs11574503	chr14:24601318	C/G	cg23112188	chr14:24563095	PCK2	0.29	6.09	0.31	3.07e-9	IgG glycosylation;
LIHC	cis	rs428668	0.681	rs430961	chr5:150700559	C/G	cg11125805	chr5:150678162	SLC36A3	0.4	8.1	0.4	9.92e-15	Skin aging (microtopography measurement);
LIHC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.57	8.54	0.42	4.39e-16	Cognitive function;
LIHC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.88	15.9	0.65	5.13e-43	Aortic root size;
LIHC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11645453	chr3:52864694	ITIH4	0.22	5.77	0.3	1.75e-8	Bipolar disorder;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02169333	chr16:57023494	NLRC5	0.43	6.17	0.32	1.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.72	12.05	0.55	4.09e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.31	-0.37	1.93e-12	Tuberculosis;
LIHC	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-6.04	-0.31	4.09e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg09836344	chr4:1243392	C4orf42;CTBP1	0.51	6.46	0.33	3.53e-10	Mosquito bite size;
LIHC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg07150772	chr14:90864620	CALM1	0.4	5.72	0.3	2.36e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.2	-0.32	1.67e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.53	6.9	0.35	2.49e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.66	13.19	0.58	2.06e-32	High light scatter reticulocyte count;
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.68	9.31	0.45	1.58e-18	Aortic root size;
LIHC	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.47	-0.42	7.47e-16	Exhaled nitric oxide output;
LIHC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06426011	chr16:12798592	CPPED1	0.57	6.93	0.35	2.05e-11	Systolic blood pressure;
LIHC	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.32	-5.76	-0.3	1.87e-8	Lewy body disease;
LIHC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07305463	chr2:136567211	LCT	-0.39	-5.98	-0.31	5.48e-9	Corneal structure;
LIHC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-1.04	-10.71	-0.5	2.87e-23	Breast cancer;
LIHC	cis	rs6973256	0.543	rs13243553	chr7:133506955	A/G	cg10665199	chr7:133106180	EXOC4	-0.34	-5.86	-0.3	1.11e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.79	15.9	0.65	5.24e-43	Colorectal cancer;
LIHC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-7.24	-0.36	2.94e-12	Hemoglobin concentration;
LIHC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.26	-6.1	-0.31	2.87e-9	Subjective well-being;
LIHC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg26373071	chr5:1325741	CLPTM1L	0.36	5.8	0.3	1.49e-8	Lung cancer;
LIHC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18252515	chr7:66147081	NA	0.43	5.98	0.31	5.68e-9	Aortic root size;
LIHC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg12463550	chr7:65579703	CRCP	0.68	7.05	0.36	9.9e-12	Diabetic kidney disease;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8028182	0.583	rs4886722	chr15:75921636	C/A	cg20655648	chr15:75932815	IMP3	0.46	6.52	0.33	2.53e-10	Sudden cardiac arrest;
LIHC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.29	-0.49	8.14e-22	Response to antipsychotic treatment;
LIHC	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg03934865	chr2:198174659	NA	-0.54	-8.16	-0.4	6.53e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.75	13.57	0.59	7.33e-34	Platelet count;
LIHC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg10402321	chr1:26617780	UBXN11	-0.38	-5.8	-0.3	1.48e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.96	-0.35	1.73e-11	Total body bone mineral density;
LIHC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg03037974	chr15:76606532	NA	-0.64	-11.12	-0.52	9.9e-25	Blood metabolite levels;
LIHC	cis	rs17152411	1.000	rs11245432	chr10:126616861	G/A	cg07906193	chr10:126599966	NA	0.47	7.32	0.37	1.76e-12	Height;
LIHC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.71	-0.34	8.27e-11	Coronary artery disease;
LIHC	trans	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg18335740	chr13:41363409	SLC25A15	0.35	6.29	0.32	9.44e-10	Lewy body disease;
LIHC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.15e-16	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20682991	chr2:74981952	NA	0.34	6.17	0.32	1.98e-9	Pancreatic cancer;
LIHC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.15	0.36	5.37e-12	Axial length;
LIHC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-17.04	-0.68	1.4e-47	Height;
LIHC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg04176888	chr19:41596066	CYP2A13	0.36	6.07	0.31	3.31e-9	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05596267	chr15:34331198	CHRM5;AVEN	-0.43	-6.28	-0.32	1.06e-9	Systolic blood pressure;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08168689	chr14:76455272	C14orf179	0.47	6.14	0.32	2.31e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2152924	0.539	rs1765756	chr1:110007652	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-6.68	-0.34	9.9e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs2272990	0.558	rs6907943	chr6:3078266	A/C	cg22816218	chr6:3091462	RIPK1	-0.56	-6.48	-0.33	3.24e-10	Preschool internalizing problems;
LIHC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg01557791	chr16:72042693	DHODH	-0.4	-6.59	-0.34	1.69e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.42	-6.62	-0.34	1.4e-10	Educational attainment;
LIHC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.68	0.34	9.75e-11	Height;
LIHC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.51	7.06	0.36	9.43e-12	Aortic root size;
LIHC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg20568497	chr10:133558893	NA	0.43	6.63	0.34	1.29e-10	Survival in rectal cancer;
LIHC	cis	rs8083850	0.748	rs11661696	chr18:50755536	C/T	cg24270629	chr18:50823537	DCC	-0.48	-6.93	-0.35	2.06e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.75	-12.45	-0.56	1.34e-29	Aortic root size;
LIHC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.76	12.92	0.57	2.22e-31	Mean platelet volume;
LIHC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.49	7.09	0.36	7.69e-12	Body mass index;
LIHC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03576123	chr11:487126	PTDSS2	-1.25	-8.51	-0.42	5.45e-16	Body mass index;
LIHC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.06	12.41	0.56	1.86e-29	Psoriasis vulgaris;
LIHC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.91	16.89	0.67	5.59e-47	Aortic root size;
LIHC	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.21	-0.32	1.52e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs45544231	0.569	rs1362546	chr16:52549935	C/T	cg09051775	chr16:52580266	TOX3	-0.31	-5.73	-0.3	2.19e-8	Restless legs syndrome;
LIHC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg10578777	chr12:7781093	NA	-0.46	-8.26	-0.41	3.21e-15	HDL cholesterol levels;
LIHC	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.69	-0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg26395211	chr5:140044315	WDR55	0.41	6.08	0.31	3.16e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.27	-0.37	2.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg20016023	chr10:99160130	RRP12	-0.4	-6.11	-0.31	2.68e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.27	0.52	2.9e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg19635926	chr16:89946313	TCF25	0.5	6.48	0.33	3.24e-10	Skin colour saturation;
LIHC	cis	rs3849570	0.555	rs4481177	chr3:81996817	A/T	cg07356753	chr3:81810745	GBE1	0.43	6.85	0.35	3.42e-11	Waist circumference;Body mass index;
LIHC	trans	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg05791018	chr13:19965014	NA	-0.28	-6.29	-0.32	9.62e-10	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.83	13.53	0.59	1.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg27523141	chr10:43048294	ZNF37B	0.37	6.51	0.33	2.74e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.87	-12.34	-0.55	3.58e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg14004847	chr7:1930337	MAD1L1	-0.39	-5.86	-0.3	1.09e-8	Schizophrenia;
LIHC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.81	-14.44	-0.62	3.14e-37	Body mass index;
LIHC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.46	6.04	0.31	4.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs244293	0.665	rs6504947	chr17:53004144	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.56	-0.33	2.03e-10	Menarche (age at onset);
LIHC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-8.27	-0.41	2.98e-15	Blood metabolite levels;
LIHC	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.33	7.64	0.38	2.18e-13	Blood metabolite ratios;
LIHC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.62	8.98	0.44	1.89e-17	Blood metabolite levels;
LIHC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.77	0.47	4.63e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.97	16.32	0.66	1.07e-44	Breast cancer;
LIHC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-7.03	-0.36	1.14e-11	Depression;
LIHC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	6.98	0.35	1.56e-11	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16262614	chr3:133464971	TF	0.28	6.21	0.32	1.51e-9	Iron status biomarkers;
LIHC	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-1.06	-11.77	-0.54	4.58e-27	Dilated cardiomyopathy;
LIHC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.05	0.63	1.26e-39	Chronic sinus infection;
LIHC	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.54	8.25	0.41	3.54e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02132458	chr4:57333267	SRP72	0.5	7.29	0.37	2.18e-12	Cognitive function;
LIHC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg00656387	chr3:40428638	ENTPD3	-0.45	-7.6	-0.38	2.92e-13	Renal cell carcinoma;
LIHC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-10.93	-0.51	4.69e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.71	9.85	0.47	2.63e-20	Menarche (age at onset);
LIHC	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.51	8.17	0.4	6.15e-15	Corneal astigmatism;
LIHC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.08	13.05	0.58	7.11e-32	Vitiligo;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00648153	chr6:74364149	SLC17A5	0.47	7.21	0.36	3.59e-12	Cognitive function;
LIHC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.59	-11.48	-0.53	4.87e-26	Tonsillectomy;
LIHC	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.49	-6.82	-0.35	4.24e-11	Obesity-related traits;
LIHC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-6.86	-0.35	3.32e-11	Waist circumference;Hip circumference;
LIHC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg12661370	chr5:149340060	SLC26A2	-0.56	-6.77	-0.34	5.6e-11	HIV-1 control;
LIHC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.92	-10.22	-0.48	1.4e-21	Red cell distribution width;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06420487	chr17:61919686	SMARCD2	0.42	5.78	0.3	1.69e-8	Height;
LIHC	cis	rs4407350	0.756	rs3827401	chr22:44890618	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.43	0.33	4.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.32	-6.26	-0.32	1.16e-9	DNA methylation (variation);
LIHC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg24296786	chr1:45957014	TESK2	-0.46	-6.2	-0.32	1.59e-9	Platelet count;
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	25.06	0.8	2.11e-79	Prudent dietary pattern;
LIHC	trans	rs1347297	0.756	rs10173183	chr2:179276427	C/T	cg14011486	chr1:26737247	LIN28	0.45	6.92	0.35	2.22e-11	Alzheimer disease and age of onset;
LIHC	cis	rs3812111	0.677	rs1204787	chr6:116535380	C/G	cg08036074	chr6:116424633	NT5DC1	-0.38	-6.26	-0.32	1.18e-9	Age-related macular degeneration;
LIHC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.28	-0.45	1.99e-18	Schizophrenia;
LIHC	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs17106184	1.000	rs12076849	chr1:51362441	C/T	cg07174182	chr1:51127561	FAF1	-0.75	-8.1	-0.4	1.01e-14	Type 2 diabetes;
LIHC	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.9	-18.35	-0.7	7.53e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12444684	chr1:65431340	JAK1	0.42	6.09	0.31	3e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.55	-8.43	-0.41	9.93e-16	Height;
LIHC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg17294928	chr15:75287854	SCAMP5	-0.51	-6.44	-0.33	3.97e-10	Lung cancer;
LIHC	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.45	0.42	8.29e-16	Response to antipsychotic treatment;
LIHC	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.34	5.79	0.3	1.6e-8	Platelet distribution width;
LIHC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.16	-0.36	5.11e-12	Diabetic kidney disease;
LIHC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.59	0.42	3.08e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.34	6.27	0.32	1.06e-9	Aortic root size;
LIHC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.24e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg12046867	chr14:103022105	NA	0.43	6.67	0.34	1.02e-10	Platelet count;
LIHC	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.24	0.48	1.25e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.46	9.29	0.45	1.81e-18	Immature fraction of reticulocytes;
LIHC	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	1.05	11.06	0.51	1.64e-24	IgG glycosylation;
LIHC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	5.77	0.3	1.81e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg15691649	chr6:25882328	NA	-0.44	-6.98	-0.35	1.58e-11	Height;
LIHC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.56	8.7	0.43	1.46e-16	White matter hyperintensity burden;
LIHC	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.2	16.23	0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.75	-10.18	-0.48	1.98e-21	Psoriasis vulgaris;
LIHC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg03060546	chr3:49711283	APEH	0.38	5.73	0.3	2.16e-8	Menarche (age at onset);
LIHC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.48	8.54	0.42	4.44e-16	Mean corpuscular volume;
LIHC	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg09572067	chr16:29127029	RRN3P2	0.5	8.0	0.4	1.94e-14	Menopause (age at onset);
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg14393609	chr7:65229607	NA	-0.43	-6.4	-0.33	5.1e-10	Calcium levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13319049	chr4:39699555	UBE2K	-0.5	-6.06	-0.31	3.57e-9	Systolic blood pressure;
LIHC	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg00792783	chr2:198669748	PLCL1	0.42	6.03	0.31	4.36e-9	Intracranial aneurysm;
LIHC	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg16652328	chr3:33138982	GLB1;TMPPE	-0.6	-8.24	-0.41	3.73e-15	Major depressive disorder;
LIHC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	6.51	0.33	2.72e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.83	-9.66	-0.46	1.15e-19	Cognitive function;
LIHC	trans	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg20587970	chr11:113659929	NA	-0.56	-7.15	-0.36	5.39e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.55	0.64	1.25e-41	Chronic sinus infection;
LIHC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.87	-8.76	-0.43	8.93e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3812111	0.676	rs9488853	chr6:116477518	C/T	cg08036074	chr6:116424633	NT5DC1	-0.49	-8.22	-0.41	4.26e-15	Age-related macular degeneration;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg00656387	chr3:40428638	ENTPD3	0.46	7.41	0.37	9.89e-13	Renal cell carcinoma;
LIHC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg07148914	chr20:33460835	GGT7	0.48	6.97	0.35	1.62e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.59	9.47	0.46	4.88e-19	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.48	5.76	0.3	1.84e-8	Morning vs. evening chronotype;
LIHC	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-0.96	-17.56	-0.69	1.19e-49	Exhaled nitric oxide levels;
LIHC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.54	-7.07	-0.36	9.05e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.23	15.76	0.65	1.95e-42	Alzheimer's disease (late onset);
LIHC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.43	6.51	0.33	2.67e-10	Post bronchodilator FEV1;
LIHC	cis	rs74233809	1.000	rs3781285	chr10:104825665	C/G	cg03493300	chr10:104813866	CNNM2	0.47	6.15	0.32	2.18e-9	Birth weight;
LIHC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.31e-22	Colorectal cancer;
LIHC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.67	-7.93	-0.39	3.05e-14	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg03037974	chr15:76606532	NA	-0.6	-9.92	-0.47	1.49e-20	Blood metabolite levels;
LIHC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.64	0.34	1.2e-10	Rheumatoid arthritis;
LIHC	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.53	-8.25	-0.41	3.57e-15	Triglyceride levels;
LIHC	cis	rs6973256	0.605	rs7808879	chr7:133345471	A/T	cg10665199	chr7:133106180	EXOC4	0.34	5.85	0.3	1.16e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.78	-0.76	1.34e-66	Height;
LIHC	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.17	-0.44	4.52e-18	Bipolar disorder;
LIHC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.63	9.84	0.47	2.82e-20	Corneal astigmatism;
LIHC	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2439831	0.614	rs2467733	chr15:43693328	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	15.73	0.65	2.44e-42	Lung cancer in ever smokers;
LIHC	cis	rs11671005	0.695	rs11673069	chr19:58934918	C/G	cg25952890	chr19:58913133	NA	0.68	7.26	0.37	2.62e-12	Mean platelet volume;
LIHC	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-6.66	-0.34	1.11e-10	Homocysteine levels;
LIHC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-5.92	-0.3	7.98e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11779988	0.545	rs422746	chr8:17784486	C/A	cg01800426	chr8:17659068	MTUS1	-0.42	-5.9	-0.3	8.53e-9	Breast cancer;
LIHC	cis	rs7192750	0.586	rs8054175	chr16:71990424	G/A	cg06353428	chr16:71660113	MARVELD3	0.8	9.06	0.44	1.02e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.4	6.76	0.34	5.84e-11	Electroencephalogram traits;
LIHC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.66	-11.52	-0.53	3.63e-26	Platelet distribution width;
LIHC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs10276381	0.685	rs56398224	chr7:28205748	A/AT	cg23620719	chr7:28220237	JAZF1	0.63	6.96	0.35	1.72e-11	Crohn's disease;
LIHC	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.81	8.46	0.42	7.83e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.49	-0.62	1.9e-37	Longevity;
LIHC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.8	-0.3	1.51e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.81	-0.39	7.24e-14	Blood metabolite levels;
LIHC	cis	rs7116495	1.000	rs10128658	chr11:71733519	C/T	cg10381502	chr11:71823885	C11orf51	-0.54	-5.78	-0.3	1.73e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.71	-9.95	-0.47	1.18e-20	Menarche (age at onset);
LIHC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.71	11.02	0.51	2.19e-24	Corneal astigmatism;
LIHC	cis	rs3823572	0.564	rs2953619	chr7:133669649	C/G	cg03336402	chr7:133662267	EXOC4	-0.49	-5.87	-0.3	1e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	13.94	0.6	2.67e-35	Nonalcoholic fatty liver disease;
LIHC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg18357526	chr6:26021779	HIST1H4A	0.54	7.49	0.38	6.1e-13	Blood metabolite levels;
LIHC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.48	-0.33	3.14e-10	Bipolar disorder;
LIHC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.59	6.93	0.35	2.13e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.85	8.27	0.41	3.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	ch.8.2353618R	chr8:119282796	SAMD12	-0.46	-6.14	-0.32	2.35e-9	Thyroid stimulating hormone;
LIHC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.55	6.84	0.35	3.77e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.76	0.47	5.24e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.63	9.87	0.47	2.14e-20	Tonsillectomy;
LIHC	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.46	-7.65	-0.38	2.1e-13	Schizophrenia;
LIHC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.41	-6.0	-0.31	4.9e-9	Calcium levels;
LIHC	cis	rs17106184	1.000	rs2095865	chr1:51299687	C/T	cg07174182	chr1:51127561	FAF1	-0.63	-6.74	-0.34	6.65e-11	Type 2 diabetes;
LIHC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.45	-7.4	-0.37	1.07e-12	Alzheimer's disease (late onset);
LIHC	trans	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.59	7.49	0.38	6.04e-13	Corneal astigmatism;
LIHC	cis	rs11955398	0.647	rs6449483	chr5:59995393	C/T	cg02684056	chr5:59996105	DEPDC1B	0.43	6.14	0.32	2.24e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-10.72	-0.5	2.64e-23	Obesity-related traits;
LIHC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-7.07	-0.36	8.56e-12	Hepatocellular carcinoma;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.33	0.32	7.68e-10	Prudent dietary pattern;
LIHC	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.47	8.93	0.43	2.6e-17	Testicular germ cell tumor;
LIHC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.87	0.51	7.98e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs1347297	0.526	rs6757186	chr2:179259719	G/C	cg14011486	chr1:26737247	LIN28	0.51	7.84	0.39	5.61e-14	Alzheimer disease and age of onset;
LIHC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.66	10.59	0.5	7.44e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.54	-8.77	-0.43	8.3e-17	IgG glycosylation;
LIHC	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.51	7.02	0.35	1.18e-11	Morning vs. evening chronotype;
LIHC	cis	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg07460842	chr6:66804631	NA	0.49	5.8	0.3	1.47e-8	Metabolite levels;
LIHC	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg25182066	chr10:30743637	MAP3K8	-0.45	-7.29	-0.37	2.17e-12	Inflammatory bowel disease;
LIHC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.74	0.47	5.88e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.71	6.63	0.34	1.34e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.24	-15.85	-0.65	7.92e-43	Diabetic kidney disease;
LIHC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.77	-0.3	1.76e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	8.17	0.4	6.14e-15	Eotaxin levels;
LIHC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	13.42	0.59	2.81e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.4	0.49	3.53e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-14.94	-0.63	3.24e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1144333	1.000	rs5745392	chr1:76306809	C/T	cg03433033	chr1:76189801	ACADM	0.58	8.77	0.43	8.65e-17	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-6.64	-0.34	1.25e-10	Morning vs. evening chronotype;
LIHC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg03647239	chr10:116582469	FAM160B1	-0.42	-5.75	-0.3	2.03e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.21	0.55	1.04e-28	Prudent dietary pattern;
LIHC	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg03645007	chr3:50255295	SLC38A3	0.49	5.91	0.3	8.29e-9	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.51	7.5	0.38	5.48e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.01	0.4	1.79e-14	Body mass index;
LIHC	cis	rs7238033	0.560	rs2170974	chr18:43308810	A/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.33	-6.14	-0.31	2.35e-9	Body mass index;
LIHC	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	9.1	0.44	7.53e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.37	8.52	0.42	5.28e-16	Educational attainment (years of education);
LIHC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	10.53	0.49	1.2e-22	Lung cancer;
LIHC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.97	0.44	1.97e-17	Motion sickness;
LIHC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.93	-15.44	-0.64	3.63e-41	Lymphocyte percentage of white cells;
LIHC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.91	0.43	3.16e-17	Exhaled nitric oxide output;
LIHC	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.37	-6.3	-0.32	9.4e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.49	5.86	0.3	1.11e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.35	3.39e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.51	-9.02	-0.44	1.34e-17	Total body bone mineral density;
LIHC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.77	-14.4	-0.61	4.35e-37	Obesity-related traits;
LIHC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.72e-46	Parkinson's disease;
LIHC	cis	rs12922317	0.964	rs16958789	chr16:12075648	G/A	cg09319797	chr16:12061715	TNFRSF17	0.42	7.28	0.37	2.33e-12	Schizophrenia;
LIHC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-23.71	-0.79	3.38e-74	Height;
LIHC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.89	0.51	6.65e-24	Colorectal cancer;
LIHC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07305463	chr2:136567211	LCT	-0.38	-5.81	-0.3	1.42e-8	Corneal structure;
LIHC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg00204512	chr16:28754710	NA	0.34	6.37	0.33	6.01e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.07	-15.09	-0.63	8.6e-40	Cognitive function;
LIHC	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.77	-0.34	5.56e-11	Metabolite levels;
LIHC	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg07451762	chr16:28383216	NA	-0.36	-6.38	-0.33	5.76e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg11707391	chr8:10001627	MSRA	-0.47	-6.12	-0.31	2.63e-9	Monocyte count;
LIHC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg09182678	chr22:50328711	NA	-0.7	-8.06	-0.4	1.28e-14	Schizophrenia;
LIHC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.33	0.45	1.36e-18	Platelet count;
LIHC	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg00277334	chr10:82204260	NA	-0.57	-7.44	-0.37	8.36e-13	Post bronchodilator FEV1;
LIHC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-10.31	-0.49	6.75e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.95	0.44	2.31e-17	Bipolar disorder;
LIHC	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.54	10.53	0.49	1.24e-22	Testicular germ cell tumor;
LIHC	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	7.88	0.39	4.55e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6788895	1.000	rs41372346	chr3:150489116	C/G	cg09723797	chr3:150481914	SIAH2	0.81	10.89	0.51	6.69e-24	Breast cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25195416	chr21:46696626	POFUT2	0.4	6.11	0.31	2.78e-9	Bilirubin levels;
LIHC	cis	rs3780378	0.682	rs7861763	chr9:5273194	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-8.22	-0.41	4.21e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.42	7.7	0.38	1.51e-13	Schizophrenia;
LIHC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg10360323	chr17:41437877	NA	0.39	5.71	0.3	2.44e-8	Menopause (age at onset);
LIHC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.12e-20	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.57	9.96	0.47	1.08e-20	Chronic sinus infection;
LIHC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs4722404	0.502	rs7804033	chr7:3110005	G/A	cg19214707	chr7:3157722	NA	-0.33	-5.78	-0.3	1.72e-8	Atopic dermatitis;
LIHC	cis	rs12586317	0.690	rs56797330	chr14:35833078	G/A	cg03549618	chr14:35838977	NA	-0.38	-6.06	-0.31	3.65e-9	Psoriasis;
LIHC	cis	rs9503598	0.502	rs6923831	chr6:3430889	T/A	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.85	-0.3	1.18e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03004097	chr2:239197782	PER2	0.49	6.17	0.32	1.9e-9	Lung function (FEV1/FVC);
LIHC	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.27	-0.45	2.08e-18	Capecitabine sensitivity;
LIHC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.58	12.11	0.55	2.54e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.35	-0.68	7.89e-49	Schizophrenia;
LIHC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.12	-0.4	8.3e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.51	6.69	0.34	9.2e-11	Subjective well-being;
LIHC	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg02269571	chr22:50332266	NA	0.6	8.42	0.41	1.06e-15	Schizophrenia;
LIHC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-0.97	-23.17	-0.78	4.65e-72	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18252515	chr7:66147081	NA	-0.48	-7.01	-0.35	1.27e-11	Aortic root size;
LIHC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.7	11.99	0.54	6.64e-28	Blood protein levels;
LIHC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	11.46	0.53	6.13e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24520871	chr10:73074265	NA	0.46	6.63	0.34	1.33e-10	Pancreatic cancer;
LIHC	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-8.8	-0.43	6.91e-17	Bipolar disorder;
LIHC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.85	15.43	0.64	3.77e-41	Aortic root size;
LIHC	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.91	11.87	0.54	1.84e-27	Coronary artery disease;
LIHC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-12.06	-0.55	3.65e-28	Alzheimer's disease (late onset);
LIHC	cis	rs2016586	0.929	rs5999961	chr22:36105275	A/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.22	-0.32	1.41e-9	Body mass index;
LIHC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.58	0.56	4.44e-30	Cognitive test performance;
LIHC	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.49	8.2	0.41	4.99e-15	Schizophrenia;
LIHC	cis	rs2607426	0.681	rs2303723	chr19:41230995	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.52	-6.2	-0.32	1.67e-9	Blood protein levels;
LIHC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.69	-11.88	-0.54	1.69e-27	Blood protein levels;
LIHC	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.59	8.15	0.4	6.91e-15	Eotaxin levels;
LIHC	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg22705602	chr4:152727874	NA	0.29	6.09	0.31	3.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.06	-0.31	3.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.83	14.32	0.61	9.09e-37	Body mass index (adult);
LIHC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	0.8	12.01	0.54	5.61e-28	Monocyte percentage of white cells;
LIHC	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.67	0.5	3.84e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-0.89	-13.02	-0.58	9.67e-32	Post bronchodilator FEV1;
LIHC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg03037974	chr15:76606532	NA	0.74	14.45	0.62	2.85e-37	Blood metabolite levels;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.77	11.29	0.52	2.47e-25	Menarche (age at onset);
LIHC	trans	rs4596713	0.508	rs7862404	chr9:71779903	G/A	cg16512924	chr15:28394682	HERC2	0.39	6.25	0.32	1.21e-9	Headache;
LIHC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.68	0.34	9.43e-11	Bipolar disorder;
LIHC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.59	0.38	3e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.39	6.42	0.33	4.68e-10	Prevalent atrial fibrillation;
LIHC	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.4	6.61	0.34	1.46e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	8.08	0.4	1.13e-14	LDL cholesterol;
LIHC	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg04725166	chr1:7887271	PER3	-0.41	-7.51	-0.38	5.08e-13	Crohn's disease;
LIHC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-7.67	-0.38	1.85e-13	Body mass index (adult);
LIHC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.82	0.39	6.69e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.89	-0.35	2.62e-11	IgG glycosylation;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17461271	chr1:172717683	NA	0.34	6.29	0.32	9.84e-10	Immature fraction of reticulocytes;
LIHC	trans	rs1434538	0.837	rs7694131	chr4:96064089	A/G	cg16708938	chr21:44832350	NA	-0.32	-6.07	-0.31	3.47e-9	Coronary artery disease;
LIHC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg16479474	chr6:28041457	NA	0.5	5.88	0.3	9.81e-9	Depression;
LIHC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.85	15.3	0.64	1.23e-40	Aortic root size;
LIHC	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.45	6.72	0.34	7.71e-11	Night sleep phenotypes;
LIHC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.43	6.15	0.32	2.22e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.47	-7.67	-0.38	1.83e-13	Cognitive function;
LIHC	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg03645007	chr3:50255295	SLC38A3	0.51	6.05	0.31	3.89e-9	Schizophrenia;
LIHC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg26441486	chr22:50317300	CRELD2	-0.33	-5.91	-0.3	8.35e-9	Schizophrenia;
LIHC	cis	rs1865721	0.761	rs11660256	chr18:73219532	C/T	cg26385618	chr18:73139727	C18orf62	-0.27	-6.83	-0.35	3.94e-11	Intelligence;
LIHC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.08	14.3	0.61	1.05e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-9.66	-0.46	1.1e-19	Body mass index;
LIHC	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg05197062	chr11:11642011	GALNTL4	0.43	6.34	0.32	7.14e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg17519650	chr2:63277830	OTX1	-0.53	-8.14	-0.4	7.53e-15	Coronary artery disease;
LIHC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.72	0.3	2.33e-8	Electroencephalogram traits;
LIHC	cis	rs7103411	0.637	rs7116850	chr11:27645530	C/T	cg18117895	chr11:27722066	BDNF	-0.46	-6.51	-0.33	2.61e-10	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.83	0.3	1.3e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg10756647	chr7:56101905	PSPH	0.45	6.64	0.34	1.2e-10	Aortic root size;
LIHC	cis	rs2274273	0.870	rs17741831	chr14:55816715	T/A	cg01864836	chr14:55583639	NA	-0.37	-6.59	-0.34	1.66e-10	Protein biomarker;
LIHC	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg18964960	chr10:1102726	WDR37	0.67	6.24	0.32	1.29e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.53	5.77	0.3	1.82e-8	Menopause (age at onset);
LIHC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg24826892	chr11:71159390	DHCR7	0.54	7.09	0.36	7.79e-12	Vitamin D levels;
LIHC	cis	rs74233809	1.000	rs12219304	chr10:104931584	G/C	cg03493300	chr10:104813866	CNNM2	0.47	6.02	0.31	4.57e-9	Birth weight;
LIHC	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg07424592	chr7:64974309	NA	0.77	8.87	0.43	4.13e-17	Diabetic kidney disease;
LIHC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-0.81	-7.01	-0.35	1.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.75	-11.12	-0.52	1.03e-24	Corneal astigmatism;
LIHC	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg06064525	chr11:970664	AP2A2	-0.5	-12.26	-0.55	7.1e-29	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.55	5.78	0.3	1.71e-8	IgG glycosylation;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.63	9.26	0.45	2.34e-18	Menarche (age at onset);
LIHC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.0	-0.31	4.92e-9	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00437311	chr19:37178174	NA	0.51	8.3	0.41	2.52e-15	Calcium levels;
LIHC	cis	rs7944735	0.508	rs7115371	chr11:47564587	G/A	cg20307385	chr11:47447363	PSMC3	-0.52	-5.86	-0.3	1.07e-8	Intraocular pressure;
LIHC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.61e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs577948	0.770	rs488062	chr11:122050913	A/G	cg10262710	chr11:122074011	LOC399959	0.36	6.2	0.32	1.62e-9	Myopia (pathological);
LIHC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.05	-0.31	3.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.7	-9.81	-0.47	3.51e-20	Initial pursuit acceleration;
LIHC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.53	9.21	0.45	3.26e-18	Mean corpuscular volume;
LIHC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.31	-0.37	1.88e-12	Lymphocyte counts;
LIHC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.16	0.77	4.33e-68	Chronic sinus infection;
LIHC	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.78	9.03	0.44	1.31e-17	Exhaled nitric oxide output;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00367488	chr2:120020686	STEAP3	0.38	6.06	0.31	3.6e-9	Bilirubin levels;
LIHC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.93	-0.81	1e-82	Myeloid white cell count;
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.74	0.34	6.75e-11	Renal cell carcinoma;
LIHC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.52	-10.11	-0.48	3.52e-21	Mean corpuscular volume;
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg24955955	chr5:415729	AHRR	0.32	6.64	0.34	1.26e-10	Cystic fibrosis severity;
LIHC	trans	rs8073060	0.827	rs66878360	chr17:33866337	C/A	cg19694781	chr19:47549865	TMEM160	0.63	6.7	0.34	8.77e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	1.15	19.06	0.72	1.07e-55	Red blood cell traits;
LIHC	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.5	-6.84	-0.35	3.62e-11	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg10587741	chr22:38071170	LGALS1	0.44	7.76	0.39	9.85e-14	Fat distribution (HIV);
LIHC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.61	7.53	0.38	4.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.43	-6.84	-0.35	3.56e-11	Multiple sclerosis;
LIHC	cis	rs7818688	0.653	rs11783522	chr8:95886624	G/A	cg16049864	chr8:95962084	TP53INP1	0.58	6.37	0.33	6.09e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	10.88	0.51	7.15e-24	Myopia (pathological);
LIHC	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.64	-11.44	-0.53	7.15e-26	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.52	-6.97	-0.35	1.62e-11	Blood metabolite levels;
LIHC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.72	9.33	0.45	1.36e-18	Gut microbiome composition (summer);
LIHC	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.27	-14.15	-0.61	4.12e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg14393609	chr7:65229607	NA	-0.39	-6.59	-0.34	1.7e-10	Calcium levels;
LIHC	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.56	-8.56	-0.42	3.84e-16	White matter hyperintensity burden;
LIHC	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.7	-6.37	-0.33	6.05e-10	Obesity;Body mass index;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.96e-16	Prudent dietary pattern;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.01	0.51	2.38e-24	Height;
LIHC	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-0.76	-8.81	-0.43	6.55e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.73	-0.3	2.15e-8	Uric acid levels;
LIHC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.3	-6.88	-0.35	2.87e-11	Menarche (age at onset);
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.79	0.39	8.02e-14	Renal cell carcinoma;
LIHC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.69	-13.22	-0.58	1.61e-32	Height;
LIHC	cis	rs45535039	0.506	rs4936467	chr11:119086629	A/T	cg16724696	chr11:118992527	HINFP	-0.51	-6.99	-0.35	1.48e-11	Plateletcrit;
LIHC	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg19773385	chr1:10388646	KIF1B	-0.33	-6.09	-0.31	3.03e-9	Hepatocellular carcinoma;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg24846343	chr22:24311635	DDTL	0.74	15.15	0.63	4.77e-40	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.02	-0.31	4.56e-9	Obesity-related traits;
LIHC	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.94	-17.68	-0.69	3.78e-50	Schizophrenia;
LIHC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.27	-7.17	-0.36	4.67e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-6.53	-0.33	2.35e-10	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.3	0.58	7.93e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.44	0.37	8.24e-13	Bone mineral density;
LIHC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.87	0.39	4.71e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.77	-11.49	-0.53	4.46e-26	Personality dimensions;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.41	5.97	0.31	5.86e-9	Menopause (age at onset);
LIHC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.85	10.99	0.51	2.87e-24	Heart rate;
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.73	-9.43	-0.45	6.56e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.5	8.39	0.41	1.27e-15	Obesity-related traits;
LIHC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.43	-6.37	-0.33	6.14e-10	Alzheimer's disease;
LIHC	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.36	-6.09	-0.31	3.01e-9	Inflammatory skin disease;
LIHC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.35	8.81	0.43	6.52e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11172286	chr11:47600544	KBTBD4;NDUFS3	0.45	6.17	0.32	1.98e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.67	6.19	0.32	1.73e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg02931644	chr1:25747376	RHCE	0.38	8.35	0.41	1.78e-15	Erythrocyte sedimentation rate;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03387256	chr10:90750898	FAS;ACTA2	0.4	6.24	0.32	1.31e-9	Cognitive function;
LIHC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.5	-8.94	-0.44	2.5e-17	Longevity;
LIHC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.61	-10.75	-0.5	2.11e-23	Itch intensity from mosquito bite;
LIHC	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg26138937	chr11:71823887	C11orf51	-1.22	-9.87	-0.47	2.26e-20	Severe influenza A (H1N1) infection;
LIHC	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.49	-7.61	-0.38	2.74e-13	Blood pressure (smoking interaction);
LIHC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.27	-0.37	2.46e-12	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13626624	chr20:656518	SCRT2	0.49	6.45	0.33	3.88e-10	Lung function (FEV1/FVC);
LIHC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.62	-10.68	-0.5	3.6e-23	Height;
LIHC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.37	5.92	0.3	7.78e-9	Perceived unattractiveness to mosquitoes;
LIHC	trans	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg21659725	chr3:3221576	CRBN	0.6	6.07	0.31	3.36e-9	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15330255	chr10:103454985	FBXW4	0.47	6.42	0.33	4.59e-10	Hepatitis;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg24101359	chr6:42928495	GNMT	0.46	6.23	0.32	1.4e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6691722	0.503	rs2274168	chr1:24707211	G/T	cg18323236	chr1:24743029	NIPAL3	0.41	7.44	0.37	8.21e-13	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.78	-0.3	1.67e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.85	0.3	1.14e-8	Bladder cancer;
LIHC	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.63	-10.14	-0.48	2.6e-21	Proinsulin levels;
LIHC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.69	-9.82	-0.47	3.15e-20	Red blood cell count;
LIHC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.51	7.08	0.36	8.1e-12	Aortic root size;
LIHC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg16102536	chr7:156981717	UBE3C	-0.35	-5.81	-0.3	1.41e-8	Body mass index;
LIHC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	0.89	8.75	0.43	9.84e-17	Alzheimer's disease;
LIHC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.37	-6.72	-0.34	7.69e-11	IgG glycosylation;
LIHC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.35	0.32	6.71e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg03859395	chr2:55845619	SMEK2	0.86	15.51	0.64	1.78e-41	Metabolic syndrome;
LIHC	cis	rs4788570	0.615	rs7195059	chr16:71718366	C/T	cg06353428	chr16:71660113	MARVELD3	1.4	14.37	0.61	5.77e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.13	0.55	2.11e-28	Prudent dietary pattern;
LIHC	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.79	11.18	0.52	6.27e-25	Body mass index;
LIHC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.27	-0.37	2.54e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.63	-11.24	-0.52	3.79e-25	Dental caries;
LIHC	cis	rs4684776	0.935	rs6781986	chr3:11374899	T/A	cg00170343	chr3:11313890	ATG7	-0.51	-6.84	-0.35	3.66e-11	Small vessel stroke;
LIHC	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.98	0.54	7.79e-28	Coffee consumption (cups per day);
LIHC	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.43	0.33	4.32e-10	Educational attainment;
LIHC	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.88	15.14	0.63	5.21e-40	Parkinson's disease;
LIHC	cis	rs12980942	1.000	rs2241719	chr19:41829581	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.81	0.35	4.29e-11	Coronary artery disease;
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12016809	chr21:47604291	C21orf56	-0.4	-5.94	-0.31	6.91e-9	Testicular germ cell tumor;
LIHC	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.85	-10.43	-0.49	2.73e-22	Type 2 diabetes;
LIHC	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg16691251	chr5:66510806	NA	-0.46	-6.2	-0.32	1.63e-9	Breast cancer;
LIHC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg17135325	chr3:160939158	NMD3	0.48	7.2	0.36	3.87e-12	Morning vs. evening chronotype;
LIHC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.5	-6.36	-0.33	6.62e-10	Coronary artery calcification;
LIHC	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg03146154	chr1:46216737	IPP	-0.37	-6.02	-0.31	4.45e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13639582	chr19:49402099	TULP2	0.42	6.1	0.31	2.81e-9	Immature fraction of reticulocytes;
LIHC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.87	15.76	0.65	1.94e-42	Multiple myeloma (IgH translocation);
LIHC	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg10381502	chr11:71823885	C11orf51	-0.91	-8.83	-0.43	5.64e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.42	-0.33	4.48e-10	Menarche (age at onset);
LIHC	cis	rs7503168	0.558	rs11870472	chr17:33872649	G/A	cg05299278	chr17:33885742	SLFN14	-0.29	-6.0	-0.31	5.09e-9	Plateletcrit;
LIHC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg22961513	chr11:14280813	SPON1	0.47	7.2	0.36	3.8e-12	Mitochondrial DNA levels;
LIHC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg22809023	chr3:195622598	TNK2	0.42	5.74	0.3	2.14e-8	Pancreatic cancer;
LIHC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg10820045	chr2:198174542	NA	-0.62	-10.85	-0.51	8.91e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-12.18	-0.55	1.42e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.51	6.19	0.32	1.7e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.66	5.74	0.3	2.11e-8	Body mass index;
LIHC	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.6	-5.95	-0.31	6.69e-9	Urate levels in lean individuals;
LIHC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.65	0.46	1.17e-19	Mean platelet volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17422427	chr2:241507521	RNPEPL1	0.4	6.9	0.35	2.56e-11	Cognitive function;
LIHC	cis	rs5756931	0.503	rs2012725	chr22:38536861	C/G	cg25457927	chr22:38595422	NA	-0.26	-6.43	-0.33	4.23e-10	Triglycerides;
LIHC	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg15704280	chr7:45808275	SEPT13	0.62	6.29	0.32	9.87e-10	Axial length;
LIHC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg03037974	chr15:76606532	NA	-0.61	-10.28	-0.49	8.59e-22	Blood metabolite levels;
LIHC	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg24229701	chr12:130821962	PIWIL1	0.45	6.74	0.34	6.91e-11	Menopause (age at onset);
LIHC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.88	-16.9	-0.67	5.15e-47	Homoarginine levels;
LIHC	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg22356347	chr1:167427500	CD247	-0.34	-5.81	-0.3	1.45e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs10792665	0.934	rs4114984	chr11:82672616	C/A	cg24227371	chr11:82718527	RAB30	-0.32	-7.57	-0.38	3.53e-13	Obesity-related traits;
LIHC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.36e-11	Red blood cell count;
LIHC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.5	-0.38	5.59e-13	Capecitabine sensitivity;
LIHC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg18016565	chr1:150552671	MCL1	0.49	9.43	0.45	6.57e-19	Melanoma;
LIHC	cis	rs4650994	0.593	rs10798618	chr1:178519124	A/C	cg05350800	chr1:178550844	NA	-0.35	-7.59	-0.38	2.98e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.51	7.32	0.37	1.81e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg26338869	chr17:61819248	STRADA	0.53	7.14	0.36	5.6e-12	Height;
LIHC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.57	-6.41	-0.33	4.84e-10	Ulcerative colitis;
LIHC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.41	5.74	0.3	2.09e-8	Tonsillectomy;
LIHC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.5	9.51	0.46	3.41e-19	Testicular germ cell tumor;
LIHC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.83	-8.84	-0.43	5.26e-17	Facial morphology (factor 23);
LIHC	cis	rs77633900	0.772	rs2956873	chr15:76695305	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-5.88	-0.3	9.53e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.87	0.3	1.04e-8	Electroencephalogram traits;
LIHC	trans	rs12752401	0.867	rs34777937	chr1:103036317	C/A	cg03332897	chr19:740442	PALM	0.46	6.11	0.31	2.68e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.47	-8.28	-0.41	2.86e-15	Lung cancer;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.69	6.91	0.35	2.44e-11	Vitiligo;
LIHC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg19338460	chr6:170058176	WDR27	-0.37	-5.72	-0.3	2.28e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg23555395	chr2:238036564	NA	-0.31	-5.84	-0.3	1.22e-8	Systemic lupus erythematosus;
LIHC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.46	7.4	0.37	1.09e-12	Monocyte count;
LIHC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	12.06	0.55	3.77e-28	High light scatter reticulocyte count;
LIHC	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg04374321	chr14:90722782	PSMC1	-0.71	-12.78	-0.57	7.49e-31	Mortality in heart failure;
LIHC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.61	-7.73	-0.39	1.17e-13	Diastolic blood pressure;
LIHC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-6.53	-0.33	2.38e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.69	-0.34	9.08e-11	Dental caries;
LIHC	trans	rs2579103	0.729	rs1344964	chr12:90670653	C/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.17	0.32	1.94e-9	Body mass index;
LIHC	cis	rs6448317	0.556	rs4481227	chr4:24906858	C/T	cg21108841	chr4:24914750	CCDC149	0.53	6.57	0.33	1.92e-10	Heschl's gyrus morphology;
LIHC	cis	rs7903847	0.620	rs10882907	chr10:99125788	C/G	cg20016023	chr10:99160130	RRP12	0.37	5.81	0.3	1.44e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.12	13.03	0.58	8.92e-32	Vitiligo;
LIHC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.5	-0.42	6.02e-16	Total cholesterol levels;
LIHC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg16479474	chr6:28041457	NA	-0.46	-6.42	-0.33	4.46e-10	Depression;
LIHC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.66	-8.76	-0.43	8.91e-17	White blood cell count;
LIHC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.29	21.31	0.76	1.03e-64	Corneal structure;
LIHC	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.46	-0.33	3.53e-10	Bipolar disorder;
LIHC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.92	-14.62	-0.62	6.11e-38	Vitamin D levels;
LIHC	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.56	10.72	0.5	2.51e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	6.73	0.34	6.96e-11	Homocysteine levels;
LIHC	cis	rs847851	0.617	rs9380478	chr6:34960811	A/T	cg13137465	chr6:34857473	ANKS1A	0.67	7.53	0.38	4.57e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.33	0.32	7.68e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12661088	chr5:43120934	ZNF131	0.44	6.65	0.34	1.13e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.36	5.79	0.3	1.57e-8	Dupuytren's disease;
LIHC	cis	rs6669384	0.774	rs7550821	chr1:208029947	C/T	cg22525895	chr1:207977042	MIR29B2	-0.49	-6.13	-0.31	2.4e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.88	0.43	3.98e-17	Multiple sclerosis;
LIHC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2710642	0.721	rs58305080	chr2:62895132	C/T	cg17519650	chr2:63277830	OTX1	0.53	7.82	0.39	6.46e-14	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.8	14.53	0.62	1.4e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.06e-25	Tonsillectomy;
LIHC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.57	6.41	0.33	4.77e-10	Axial length;
LIHC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.68	13.18	0.58	2.41e-32	High light scatter reticulocyte count;
LIHC	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.41	-6.69	-0.34	9.33e-11	Schizophrenia;
LIHC	cis	rs611744	0.967	rs475865	chr8:109235858	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg04374321	chr14:90722782	PSMC1	0.48	6.53	0.33	2.34e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.43	8.15	0.4	7.01e-15	Mean corpuscular volume;Mean platelet volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24809768	chr5:167914047	RARS	0.48	7.26	0.37	2.58e-12	Cognitive function;
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.95	20.05	0.74	1.12e-59	Height;
LIHC	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg24130564	chr14:104152367	KLC1	-0.44	-7.34	-0.37	1.62e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg13271783	chr10:134563150	INPP5A	-0.57	-6.61	-0.34	1.44e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.0	-0.31	4.94e-9	Cognitive function;
LIHC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.75	0.3	2e-8	Self-reported allergy;
LIHC	cis	rs59901009	0.954	rs55893317	chr11:10180991	A/G	cg01453529	chr11:10209919	SBF2	-0.31	-6.04	-0.31	4.1e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.68	11.27	0.52	2.96e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.64	0.42	2.27e-16	Corneal astigmatism;
LIHC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg18912006	chr12:123335444	HIP1R	-0.63	-7.64	-0.38	2.14e-13	Schizophrenia;
LIHC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.9	-19.96	-0.73	2.68e-59	Height;
LIHC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.69	-12.28	-0.55	5.55e-29	Iron status biomarkers;
LIHC	cis	rs273218	0.573	rs10513033	chr5:53333477	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-15.33	-0.64	9.9e-41	Migraine;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07991241	chr10:33269695	NA	0.51	7.91	0.39	3.54e-14	Pancreatic cancer;
LIHC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.63	-0.38	2.31e-13	Prevalent atrial fibrillation;
LIHC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg12437481	chr16:420112	MRPL28	-0.65	-8.73	-0.43	1.15e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.51	-8.88	-0.43	3.81e-17	Mean corpuscular volume;
LIHC	cis	rs4934494	0.768	rs17125834	chr10:91433162	G/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.49	-0.33	2.93e-10	Red blood cell count;
LIHC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg20933634	chr6:27740509	NA	0.49	6.4	0.33	5.26e-10	Parkinson's disease;
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg03874509	chr1:107600012	PRMT6	0.76	12.17	0.55	1.44e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20135002	chr11:47629003	NA	-0.58	-10.04	-0.48	5.83e-21	Subjective well-being;
LIHC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.36	-0.37	1.35e-12	Bipolar disorder;
LIHC	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg07862535	chr7:139043722	LUC7L2	0.58	9.92	0.47	1.53e-20	Diisocyanate-induced asthma;
LIHC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	8.07	0.4	1.23e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	8.52	0.42	5.19e-16	Eotaxin levels;
LIHC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.45	5.77	0.3	1.82e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00166836	chr6:149721425	MAP3K7IP2;SUMO4	0.42	6.06	0.31	3.67e-9	Pancreatic cancer;
LIHC	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg04610667	chr7:75704037	NA	-0.35	-6.18	-0.32	1.86e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg12903224	chr12:29470962	FAR2	-0.39	-6.28	-0.32	1.02e-9	QT interval;
LIHC	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.82	0.35	4.1e-11	Dermatomyositis;
LIHC	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg24579218	chr15:68104479	NA	-0.33	-5.73	-0.3	2.18e-8	Restless legs syndrome;
LIHC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.57	9.96	0.47	1.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.75	-0.6	1.56e-34	Coffee consumption (cups per day);
LIHC	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.6	6.01	0.31	4.64e-9	Carotid intima media thickness;
LIHC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.26	-0.32	1.12e-9	Alzheimer's disease (late onset);
LIHC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.36	-5.84	-0.3	1.23e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg05197062	chr11:11642011	GALNTL4	0.46	6.72	0.34	7.6e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.88	0.54	1.69e-27	Prudent dietary pattern;
LIHC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg13535736	chr9:111863775	C9orf5	-0.39	-5.94	-0.31	7.12e-9	Menarche (age at onset);
LIHC	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.43	6.53	0.33	2.34e-10	Metabolite levels (Pyroglutamine);
LIHC	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-8.45	-0.42	8.33e-16	Blood trace element (Cu levels);
LIHC	cis	rs4699052	0.507	rs10005997	chr4:104301711	C/G	cg16532752	chr4:104119610	CENPE	-0.46	-6.5	-0.33	2.81e-10	Testicular germ cell tumor;
LIHC	cis	rs2010672	0.500	rs9888660	chr15:91160768	C/T	cg26821196	chr15:91095069	CRTC3	0.35	6.28	0.32	1.01e-9	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LIHC	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	5.82	0.3	1.35e-8	Morning vs. evening chronotype;
LIHC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.51	-7.62	-0.38	2.55e-13	Metabolic syndrome;
LIHC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.22	0.41	4.3e-15	Lymphocyte counts;
LIHC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	0.95	9.86	0.47	2.37e-20	Vitiligo;
LIHC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.39	0.49	3.59e-22	Morning vs. evening chronotype;
LIHC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.29	7.09	0.36	7.62e-12	Schizophrenia;
LIHC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.54	6.27	0.32	1.06e-9	Alzheimer's disease;
LIHC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-11.45	-0.53	6.64e-26	Glomerular filtration rate (creatinine);
LIHC	cis	rs77669868	0.640	rs2073848	chr11:114051904	A/G	cg01914181	chr11:114070210	ZBTB16	0.54	7.06	0.36	9.31e-12	Monocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.4	0.33	5e-10	Renal cell carcinoma;
LIHC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.96	-0.63	2.86e-39	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.25	0.64	1.91e-40	Chronic sinus infection;
LIHC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.52	8.57	0.42	3.68e-16	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09514589	chr15:76603992	ETFA	0.45	6.18	0.32	1.8e-9	Pancreatic cancer;
LIHC	cis	rs249954	0.512	rs171617	chr16:23694774	A/T	cg09867953	chr16:23706666	ERN2	0.35	5.96	0.31	6.16e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg23625390	chr15:77176239	SCAPER	-0.38	-6.03	-0.31	4.18e-9	Blood metabolite levels;
LIHC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg25281562	chr12:121454272	C12orf43	-0.33	-5.76	-0.3	1.91e-8	N-glycan levels;
LIHC	trans	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18070394	chr4:2470786	RNF4	0.39	6.06	0.31	3.51e-9	Height;
LIHC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.19e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.79	0.3	1.62e-8	Body mass index;
LIHC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.0	-0.31	4.98e-9	Diastolic blood pressure;
LIHC	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.37	5.96	0.31	6.29e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs11229555	0.645	rs34054511	chr11:58204943	A/C	cg15696309	chr11:58395628	NA	-0.65	-7.71	-0.38	1.41e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.41	-6.24	-0.32	1.27e-9	Resting heart rate;
LIHC	cis	rs6545883	0.894	rs2694649	chr2:61573826	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.74	0.3	2.12e-8	Tuberculosis;
LIHC	cis	rs644148	0.748	rs542150	chr19:44967453	T/C	cg15540054	chr19:45004280	ZNF180	0.78	10.72	0.5	2.66e-23	Personality dimensions;
LIHC	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.84	-8.67	-0.42	1.76e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.25	-18.36	-0.7	6.9e-53	Ulcerative colitis;
LIHC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg17750252	chr2:136567154	LCT	-0.35	-6.31	-0.32	8.48e-10	Mosquito bite size;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12379764	chr21:47803548	PCNT	0.56	8.42	0.41	1.05e-15	Testicular germ cell tumor;
LIHC	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg25566285	chr7:158114605	PTPRN2	0.22	5.94	0.31	7.2e-9	Calcium levels;
LIHC	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg03934865	chr2:198174659	NA	0.48	6.91	0.35	2.38e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.6	9.53	0.46	3.11e-19	Platelet distribution width;
LIHC	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.48	-9.45	-0.46	5.33e-19	LDL cholesterol levels;
LIHC	cis	rs8084351	0.524	rs11082974	chr18:50770171	C/A	cg24270629	chr18:50823537	DCC	-0.47	-6.89	-0.35	2.65e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.59	9.89	0.47	1.91e-20	Electroencephalogram traits;
LIHC	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.66	8.25	0.41	3.4e-15	Corneal astigmatism;
LIHC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.66	-10.83	-0.51	1.04e-23	Childhood ear infection;
LIHC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.3	-16.86	-0.67	7.26e-47	Diabetic kidney disease;
LIHC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.28	-0.37	2.3e-12	Body mass index;
LIHC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg14067834	chr17:29058358	SUZ12P	0.68	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	12.49	0.56	9.07e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.53	-7.34	-0.37	1.6e-12	Obesity-related traits;
LIHC	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.7	10.9	0.51	6.1e-24	Monocyte count;
LIHC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.83	14.84	0.63	8.54e-39	Height;
LIHC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.38	-6.26	-0.32	1.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.51	9.01	0.44	1.48e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.81	16.46	0.66	3e-45	Gestational age at birth (maternal effect);
LIHC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.13e-14	Neuroticism;
LIHC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.55	-0.33	2.12e-10	Neuroticism;
LIHC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.2	0.41	4.76e-15	Corneal astigmatism;
LIHC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg16479474	chr6:28041457	NA	-0.46	-6.58	-0.34	1.77e-10	Depression;
LIHC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.6	10.38	0.49	4.01e-22	Height;
LIHC	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.56	-6.34	-0.32	7.15e-10	Ulcerative colitis;
LIHC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg11212589	chr17:38028394	ZPBP2	0.32	6.44	0.33	4.06e-10	Self-reported allergy;
LIHC	cis	rs16958440	0.581	rs11875768	chr18:44689360	T/G	cg17192377	chr18:44677553	HDHD2	0.71	7.79	0.39	8.32e-14	Sitting height ratio;
LIHC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	10.3	0.49	7.28e-22	Blood protein levels;
LIHC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg14779329	chr11:130786720	SNX19	-0.41	-6.26	-0.32	1.17e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	1.04	13.41	0.59	2.97e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.67	-14.14	-0.61	4.54e-36	Sense of smell;
LIHC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.63	0.38	2.39e-13	Bipolar disorder;
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg04352962	chr1:209979756	IRF6	0.4	6.2	0.32	1.63e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.02e-17	Arsenic metabolism;
LIHC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg20195005	chr22:42527684	CYP2D6	0.31	5.88	0.3	9.59e-9	Birth weight;
LIHC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg10319629	chr12:132285459	NA	0.46	8.04	0.4	1.47e-14	Migraine;
LIHC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg20946044	chr11:1010712	AP2A2	0.34	5.98	0.31	5.67e-9	Alzheimer's disease (late onset);
LIHC	cis	rs3770081	1.000	rs3731819	chr2:86368641	C/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.06	0.31	3.59e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.6	0.56	3.52e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.71	0.43	1.35e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18842717	chr11:3400387	ZNF195	0.48	6.86	0.35	3.32e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.34	-6.41	-0.33	4.91e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs600806	0.888	rs680434	chr1:109842271	C/T	cg16275483	chr1:110013120	SYPL2	-0.5	-6.09	-0.31	3.09e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6604026	0.555	rs56044027	chr1:93082694	C/T	cg13858687	chr1:93297071	RPL5	0.6	5.71	0.3	2.41e-8	Multiple sclerosis;
LIHC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12463550	chr7:65579703	CRCP	0.6	6.63	0.34	1.29e-10	Diabetic kidney disease;
LIHC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.65	0.53	1.16e-26	Monocyte percentage of white cells;
LIHC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.34	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23043544	chr7:2124092	MAD1L1	-0.41	-6.61	-0.34	1.49e-10	Neuroticism;
LIHC	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.56	-7.22	-0.36	3.39e-12	Type 2 diabetes;
LIHC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.37	6.01	0.31	4.67e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.47	0.46	4.62e-19	Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Parkinson's disease;
LIHC	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.62	-0.38	2.56e-13	Prevalent atrial fibrillation;
LIHC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.05	-0.51	1.78e-24	Hemoglobin concentration;
LIHC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	8.03	0.4	1.63e-14	Platelet count;
LIHC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg06634786	chr22:41940651	POLR3H	-0.52	-5.73	-0.3	2.26e-8	Neuroticism;
LIHC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs963731	0.737	rs10194374	chr2:39244914	G/A	cg04010122	chr2:39346883	SOS1	-0.68	-5.86	-0.3	1.1e-8	Corticobasal degeneration;
LIHC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg07971674	chr14:23388846	RBM23	-0.4	-5.76	-0.3	1.92e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.33	-0.32	7.52e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.89	-0.47	1.91e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.39	-0.37	1.14e-12	Response to antipsychotic treatment;
LIHC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg25329415	chr6:28076851	NA	0.27	5.81	0.3	1.46e-8	Cardiac Troponin-T levels;
LIHC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.39	-0.45	8.63e-19	Gut microbiome composition (summer);
LIHC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.88	-0.39	4.53e-14	Neuroticism;
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.37	-6.08	-0.31	3.18e-9	Blood metabolite levels;
LIHC	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.73	12.67	0.57	1.94e-30	Menopause (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20753294	chr5:142782791	NR3C1	-0.47	-6.49	-0.33	3.03e-10	Longevity;
LIHC	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg14250997	chr9:106856677	SMC2	0.43	7.36	0.37	1.36e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.66	11.47	0.53	5.36e-26	Superior crus of antihelix expression;
LIHC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.46	-11.62	-0.53	1.61e-26	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.74	-12.35	-0.56	3.04e-29	Aortic root size;
LIHC	cis	rs1775715	0.870	rs1251407	chr10:32238325	A/G	cg14930904	chr10:32216787	ARHGAP12	0.39	6.96	0.35	1.76e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg16011800	chr17:1958478	HIC1	0.47	6.9	0.35	2.56e-11	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.68	10.72	0.5	2.61e-23	Colorectal adenoma (advanced);
LIHC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.71	-0.71	2.82e-54	Height;
LIHC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.47	6.76	0.34	5.98e-11	Schizophrenia;
LIHC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.36	7.33	0.37	1.7e-12	Renal cell carcinoma;
LIHC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.01	0.48	7.51e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3823572	0.564	rs2953620	chr7:133666388	T/C	cg03336402	chr7:133662267	EXOC4	-0.48	-5.75	-0.3	1.96e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22654626	chr19:18699620	C19orf60	-0.46	-6.34	-0.32	7.16e-10	Triglycerides;
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.62	6.93	0.35	2.15e-11	Alzheimer's disease;
LIHC	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg07541023	chr7:19748670	TWISTNB	0.41	6.29	0.32	9.52e-10	Thyroid stimulating hormone;
LIHC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg09662798	chr17:73498302	CASKIN2	0.5	6.21	0.32	1.53e-9	Mean platelet volume;
LIHC	cis	rs4755351	0.553	rs10836024	chr11:33147564	C/T	cg05567920	chr11:33183001	CSTF3	0.42	6.21	0.32	1.56e-9	Lung cancer in ever smokers;
LIHC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.62	0.38	2.45e-13	Lymphocyte counts;
LIHC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg00318621	chr2:106887213	NA	-0.51	-8.73	-0.43	1.17e-16	Facial morphology (factor 23);
LIHC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.67	-0.34	1.01e-10	Mean corpuscular volume;
LIHC	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.56	8.69	0.43	1.5e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22926252	chr12:14956350	WBP11;C12orf60	0.42	6.81	0.35	4.29e-11	Calcium levels;
LIHC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg11861562	chr11:117069780	TAGLN	0.47	7.81	0.39	7.29e-14	Blood protein levels;
LIHC	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg02702477	chr5:179499311	RNF130	0.81	11.28	0.52	2.69e-25	LDL cholesterol;
LIHC	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.49	6.9	0.35	2.55e-11	Morning vs. evening chronotype;
LIHC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-7.46	-0.37	7.11e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	0.94	15.98	0.65	2.44e-43	Testicular germ cell tumor;
LIHC	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.56	-6.42	-0.33	4.64e-10	Primary sclerosing cholangitis;
LIHC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.45	7.31	0.37	1.87e-12	Bipolar disorder;
LIHC	cis	rs3853824	0.965	rs7217601	chr17:54904121	A/G	cg13675837	chr17:54910204	DGKE	0.41	5.9	0.3	8.85e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.61	6.06	0.31	3.51e-9	Carotid intima media thickness;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21504918	chr5:150400001	GPX3	0.4	6.94	0.35	1.92e-11	Cognitive function;
LIHC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.32	6.32	0.32	8.07e-10	Monocyte count;
LIHC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.79	-0.39	7.89e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.61	0.38	2.64e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.87	-0.63	6.47e-39	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.8	0.39	7.36e-14	Prudent dietary pattern;
LIHC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.0	0.31	4.95e-9	Cognitive ability;
LIHC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.88	14.99	0.63	2.11e-39	Parkinson's disease;
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg18279126	chr7:2041391	MAD1L1	0.36	5.89	0.3	9.29e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-7.6	-0.38	2.84e-13	Lymphocyte counts;
LIHC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06002616	chr8:101225028	SPAG1	-0.35	-5.76	-0.3	1.85e-8	Atrioventricular conduction;
LIHC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	trans	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg26939375	chr7:64535504	NA	0.41	6.43	0.33	4.31e-10	Aortic root size;
LIHC	cis	rs981946	0.570	rs6917778	chr6:3358935	G/T	cg18842474	chr6:3356384	SLC22A23	0.39	6.29	0.32	9.68e-10	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.71	-12.42	-0.56	1.78e-29	Prudent dietary pattern;
LIHC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-8.71	-0.43	1.35e-16	Chronic sinus infection;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03149313	chr1:226595334	PARP1	-0.42	-6.29	-0.32	9.72e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.84	-0.57	4.43e-31	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08280861	chr8:58055591	NA	0.49	6.13	0.31	2.38e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.5	6.23	0.32	1.36e-9	Menarche (age at onset);
LIHC	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg12193833	chr17:30244370	NA	-0.56	-6.01	-0.31	4.65e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.88	0.3	9.85e-9	Lung cancer;
LIHC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg08992911	chr2:238395768	MLPH	0.55	6.21	0.32	1.52e-9	Prostate cancer;
LIHC	trans	rs75804782	0.572	rs72982580	chr2:239447783	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	6.27	0.32	1.11e-9	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg18016565	chr1:150552671	MCL1	0.52	9.57	0.46	2.2e-19	Melanoma;
LIHC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg12463550	chr7:65579703	CRCP	-0.59	-5.96	-0.31	6.21e-9	Diabetic kidney disease;
LIHC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.17	12.88	0.57	3.32e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.85	12.94	0.57	1.93e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19346786	chr7:2764209	NA	-0.36	-5.78	-0.3	1.65e-8	Height;
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.82	0.39	6.83e-14	Height;
LIHC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.49	7.66	0.38	1.99e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.31	0.41	2.25e-15	Schizophrenia;
LIHC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.45	-6.07	-0.31	3.34e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12344004	chr15:89877906	POLG	-0.49	-6.1	-0.31	2.92e-9	Systolic blood pressure;
LIHC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06212747	chr3:49208901	KLHDC8B	0.65	8.87	0.43	4.27e-17	Menarche (age at onset);
LIHC	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.82	-0.39	6.77e-14	Body mass index;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.64	-9.72	-0.47	6.96e-20	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06366937	chr1:74663927	TNNI3K;FPGT;LRRIQ3	-0.44	-6.06	-0.31	3.6e-9	Pancreatic cancer;
LIHC	trans	rs60752752	0.852	rs3014807	chr1:153368020	A/C	cg14901121	chr8:98817630	LAPTM4B	0.4	6.67	0.34	1.02e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17928095	chr1:156252714	TMEM79;SMG5	0.46	6.68	0.34	9.55e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.45	-7.13	-0.36	5.98e-12	Type 2 diabetes;
LIHC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.17	-0.44	4.37e-18	Alzheimer's disease;
LIHC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	10.92	0.51	4.94e-24	Motion sickness;
LIHC	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.52	8.45	0.42	8.71e-16	Corneal astigmatism;
LIHC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.26	-0.37	2.62e-12	Bipolar disorder;
LIHC	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.59	8.81	0.43	6.56e-17	Recombination rate (females);
LIHC	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-0.78	-8.67	-0.42	1.81e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.49	-0.46	4.06e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05902531	chr12:58239324	CTDSP2	-0.47	-6.93	-0.35	2.14e-11	Systolic blood pressure;
LIHC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs12079745	0.793	rs78566263	chr1:169316011	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-7.08	-0.36	8.09e-12	QT interval;
LIHC	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.76	0.3	1.85e-8	Tuberculosis;
LIHC	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg03146154	chr1:46216737	IPP	-0.37	-6.2	-0.32	1.62e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs17301259	0.729	rs2519922	chr7:88379849	T/C	cg07470830	chr6:76000847	NA	0.36	6.05	0.31	3.75e-9	Heschl's gyrus morphology;
LIHC	cis	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg18809830	chr7:99032528	PTCD1	-0.82	-6.63	-0.34	1.34e-10	Blood metabolite levels;
LIHC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19671926	chr4:122722719	EXOSC9	0.55	8.56	0.42	3.92e-16	Type 2 diabetes;
LIHC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.54e-20	Crohn's disease;
LIHC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.85	0.3	1.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.73	0.39	1.19e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.48	7.74	0.39	1.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs35160687	0.644	rs4832264	chr2:86486834	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.35	5.75	0.3	2.01e-8	Night sleep phenotypes;
LIHC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg14067834	chr17:29058358	SUZ12P	0.62	6.38	0.33	5.64e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.4	-7.35	-0.37	1.46e-12	Hepatocellular carcinoma;
LIHC	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg25952890	chr19:58913133	NA	0.7	7.64	0.38	2.23e-13	Mean platelet volume;
LIHC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.26	0.58	1.15e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs6546886	0.536	rs828870	chr2:74322244	A/G	cg19729930	chr2:74357872	NA	-0.32	-5.94	-0.31	7.13e-9	Dialysis-related mortality;
LIHC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-7.84	-0.39	5.63e-14	Total body bone mineral density;
LIHC	trans	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.45	-6.44	-0.33	3.95e-10	Type 2 diabetes;
LIHC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08392591	chr16:89556376	ANKRD11	0.41	6.11	0.31	2.7e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7546668	1.000	rs3795759	chr1:15853628	C/T	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.88	-0.35	2.88e-11	IgG glycosylation;
LIHC	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	trans	rs76485637	0.651	rs12921905	chr16:7989960	A/G	cg15006175	chr8:145698660	KIFC2	-0.33	-6.04	-0.31	4.05e-9	Pediatric bone mineral density (spine);
LIHC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.63	-11.47	-0.53	5.66e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.16	30.42	0.85	2.6e-99	IgG glycosylation;
LIHC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.58	10.08	0.48	4.26e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	1.07	17.72	0.69	2.53e-50	Metabolic syndrome;
LIHC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00149659	chr3:10157352	C3orf10	0.51	5.99	0.31	5.36e-9	Alzheimer's disease;
LIHC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	7.97	0.4	2.35e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg24642844	chr7:1081250	C7orf50	-0.83	-6.68	-0.34	9.72e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.26	6.96	0.35	1.71e-11	Type 2 diabetes;
LIHC	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs3770081	1.000	rs111295372	chr2:86283357	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.58	9.34	0.45	1.32e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg18016565	chr1:150552671	MCL1	0.5	9.52	0.46	3.37e-19	Melanoma;
LIHC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg20651018	chr11:3035856	CARS	-0.34	-5.9	-0.3	8.67e-9	Longevity;
LIHC	trans	rs11165623	0.602	rs7521690	chr1:97015761	A/C	cg10631902	chr5:14652156	NA	-0.25	-6.18	-0.32	1.83e-9	Hip circumference;Waist circumference;
LIHC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.32	6.37	0.33	6.04e-10	Platelet distribution width;
LIHC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.0	24.04	0.79	1.73e-75	IgG glycosylation;
LIHC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.81	-8.21	-0.41	4.61e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs55702914	0.746	rs4850425	chr2:198152786	T/C	cg10820045	chr2:198174542	NA	-0.41	-6.21	-0.32	1.54e-9	Major depression and alcohol dependence;
LIHC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.26	0.52	3.05e-25	Platelet count;
LIHC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.53	-5.77	-0.3	1.81e-8	Menarche (age at onset);
LIHC	cis	rs8038465	0.561	rs59104311	chr15:73845185	G/A	cg15420318	chr15:73925796	NPTN	0.5	7.2	0.36	3.87e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg10664184	chr19:17420304	DDA1	0.46	5.86	0.3	1.07e-8	Systemic lupus erythematosus;
LIHC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.79	-12.55	-0.56	5.8e-30	Coronary artery disease;
LIHC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg02319142	chr5:149339858	SLC26A2	0.38	6.16	0.32	2.08e-9	HIV-1 control;
LIHC	cis	rs943466	1.000	rs6933174	chr6:33751003	G/A	cg25922239	chr6:33757077	LEMD2	-0.47	-5.77	-0.3	1.75e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.12	-0.44	6.77e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.15	-0.32	2.21e-9	Ulcerative colitis;
LIHC	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg03805757	chr16:71968109	PKD1L3	-0.67	-7.71	-0.38	1.41e-13	Post bronchodilator FEV1;
LIHC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1165668	0.816	rs1866072	chr12:104310706	C/G	cg21863207	chr12:104234989	NT5DC3	0.45	7.81	0.39	6.9e-14	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg12798992	chr6:167411361	FGFR1OP	0.48	7.35	0.37	1.51e-12	Crohn's disease;
LIHC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg07150772	chr14:90864620	CALM1	-0.42	-5.88	-0.3	9.75e-9	Gut microbiota (bacterial taxa);
LIHC	trans	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg10756647	chr7:56101905	PSPH	1.11	13.23	0.58	1.43e-32	Diabetic kidney disease;
LIHC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.94	-19.05	-0.72	1.13e-55	Schizophrenia;
LIHC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.33	-5.99	-0.31	5.37e-9	Facial morphology (factor 20);
LIHC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-9.14	-0.44	5.49e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.63	10.84	0.51	9.98e-24	Colorectal cancer;
LIHC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.48	7.8	0.39	7.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.66	0.42	1.92e-16	Birth weight;
LIHC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.54	-6.63	-0.34	1.33e-10	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26217633	chr17:33469413	NLE1	0.41	6.07	0.31	3.36e-9	Pancreatic cancer;
LIHC	cis	rs9322817	0.691	rs2499666	chr6:105318576	A/G	cg02098413	chr6:105308735	HACE1	0.42	7.71	0.38	1.35e-13	Thyroid stimulating hormone;
LIHC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.68	6.93	0.35	2.09e-11	Bipolar disorder;
LIHC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.85	10.6	0.5	6.8e-23	Mean platelet volume;
LIHC	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.34e-24	Subjective well-being;
LIHC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.53	0.56	6.44e-30	Mean platelet volume;
LIHC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.57	6.76	0.34	6.15e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs76051363	0.500	rs73070422	chr4:1016645	C/G	cg06222114	chr4:1004783	FGFRL1	-0.55	-5.87	-0.3	1.05e-8	Total body bone mineral density;
LIHC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.07e-18	Schizophrenia;
LIHC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.76	0.34	5.8200000000000003e-11	Renal cell carcinoma;
LIHC	cis	rs3853824	0.932	rs3986358	chr17:54898301	T/C	cg13675837	chr17:54910204	DGKE	0.4	6.0	0.31	5.16e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.37	-6.04	-0.31	4.11e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg07424592	chr7:64974309	NA	0.79	8.97	0.44	1.98e-17	Diabetic kidney disease;
LIHC	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.53	8.02	0.4	1.68e-14	Corneal astigmatism;
LIHC	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg07636037	chr3:49044803	WDR6	-0.55	-6.39	-0.33	5.38e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg23091122	chr1:110024289	SYPL2	-0.46	-6.06	-0.31	3.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.65	0.5	4.45e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.68	-10.43	-0.49	2.69e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg16822855	chr3:40428330	ENTPD3	0.33	5.96	0.31	6.43e-9	Renal cell carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07781848	chr12:123868310	SETD8	0.48	6.47	0.33	3.46e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg16434002	chr17:42200994	HDAC5	-0.48	-7.17	-0.36	4.64e-12	Total body bone mineral density;
LIHC	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg15103426	chr22:29168792	CCDC117	0.44	6.07	0.31	3.39e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.93	0.31	7.28e-9	Educational attainment;
LIHC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.95	0.31	6.65e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7945705	0.967	rs10840147	chr11:8920704	A/G	cg12365402	chr11:9010492	NRIP3	0.31	7.89	0.39	4.04e-14	Hemoglobin concentration;
LIHC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.03	18.24	0.7	2.12e-52	Subjective well-being;
LIHC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg16102536	chr7:156981717	UBE3C	0.34	5.77	0.3	1.75e-8	Body mass index;
LIHC	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.6	6.63	0.34	1.33e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.67	0.5	3.94e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-7.56	-0.38	3.67e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.45	-6.39	-0.33	5.54e-10	Blood protein levels;
LIHC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.49	9.85	0.47	2.67e-20	Tonsillectomy;
LIHC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.09	0.4	1.04e-14	Lung cancer;
LIHC	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg04725166	chr1:7887271	PER3	0.4	7.1	0.36	7.27e-12	Crohn's disease;
LIHC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.58	8.02	0.4	1.72e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.81	-0.35	4.39e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg20607798	chr8:58055168	NA	0.46	6.62	0.34	1.42e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.35	5.86	0.3	1.06e-8	Type 2 diabetes;
LIHC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg07061783	chr6:25882402	NA	0.43	5.93	0.31	7.31e-9	Blood metabolite levels;
LIHC	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.79	-14.39	-0.61	4.98e-37	Longevity;
LIHC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.61	9.48	0.46	4.56e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.69	7.27	0.37	2.52e-12	Exhaled nitric oxide output;
LIHC	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.89	18.15	0.7	4.86e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08280861	chr8:58055591	NA	0.49	6.11	0.31	2.69e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.56	8.46	0.42	7.75e-16	Resting heart rate;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27309920	chr12:6798957	ZNF384	0.48	7.02	0.35	1.2e-11	Pancreatic cancer;
LIHC	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-9.27	-0.45	2.16e-18	Colorectal cancer;
LIHC	cis	rs28530618	0.580	rs4607010	chr20:31255271	G/C	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.87	-0.3	1.04e-8	Birth weight;
LIHC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.47	7.76	0.39	9.73e-14	Response to temozolomide;
LIHC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.47	-6.93	-0.35	2.15e-11	Psoriasis;
LIHC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg06238570	chr21:40685208	BRWD1	0.57	6.8	0.34	4.78e-11	Cognitive function;
LIHC	cis	rs11673344	0.800	rs8108214	chr19:37516086	C/T	cg27390819	chr19:37464633	NA	0.49	6.09	0.31	3.1e-9	Obesity-related traits;
LIHC	cis	rs4728302	0.869	rs6954712	chr7:133618853	G/A	cg10665199	chr7:133106180	EXOC4	0.36	6.15	0.32	2.22e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01587390	chr19:10221818	PPAN-P2RY11;P2RY11;PPAN	0.44	6.78	0.34	5.25e-11	Longevity;
LIHC	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.24	-0.48	1.21e-21	Eye color traits;
LIHC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg10932868	chr11:921992	NA	0.34	6.32	0.32	8.22e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg00409905	chr10:38381863	ZNF37A	0.43	6.42	0.33	4.47e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6586163	1.000	rs3824729	chr10:90752616	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.56	-8.3	-0.41	2.41e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.78	10.99	0.51	2.95e-24	Blood metabolite levels;
LIHC	cis	rs7534824	0.625	rs3087816	chr1:101441775	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	7.02	0.35	1.22e-11	Refractive astigmatism;
LIHC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2016586	0.929	rs5755924	chr22:36114621	A/G	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.28	-0.52	2.73e-25	Total cholesterol levels;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.51	7.09	0.36	7.72e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg08992911	chr2:238395768	MLPH	0.5	6.06	0.31	3.63e-9	Prostate cancer;
LIHC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.13	0.68	6.02e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06544989	chr22:39130855	UNC84B	0.39	5.87	0.3	1.06e-8	Menopause (age at onset);
LIHC	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg11235426	chr6:292522	DUSP22	-0.52	-6.88	-0.35	2.84e-11	Menopause (age at onset);
LIHC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg25894440	chr7:65020034	NA	0.55	6.21	0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.78	-14.31	-0.61	1e-36	Longevity;
LIHC	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg02344993	chr17:57696989	CLTC	0.71	11.8	0.54	3.5e-27	Hemoglobin concentration;
LIHC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17467752	chr17:38218738	THRA	0.42	6.94	0.35	2.01e-11	Asthma;
LIHC	cis	rs1419980	0.730	rs7958896	chr12:7774118	A/G	cg10578777	chr12:7781093	NA	-0.39	-5.79	-0.3	1.55e-8	HDL cholesterol levels;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	25.06	0.8	2.11e-79	Prudent dietary pattern;
LIHC	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg24112000	chr20:60950667	NA	-0.61	-9.79	-0.47	3.98e-20	Colorectal cancer;
LIHC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.3	-6.79	-0.34	4.98e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	cis	rs4853036	0.904	rs7578366	chr2:70135695	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.75	-0.34	6.19e-11	Colorectal or endometrial cancer;
LIHC	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg27490568	chr2:178487706	NA	0.82	9.74	0.47	6.06e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.31	-6.16	-0.32	2.02e-9	Homoarginine levels;
LIHC	cis	rs7534824	0.625	rs61782085	chr1:101518270	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	7.2	0.36	3.92e-12	Refractive astigmatism;
LIHC	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23598886	chr18:12777645	NA	0.48	6.48	0.33	3.13e-10	Inflammatory skin disease;
LIHC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg20090690	chr10:134436459	INPP5A	0.44	5.8	0.3	1.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.35	-7.02	-0.36	1.16e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	7.7	0.38	1.47e-13	Response to antipsychotic treatment;
LIHC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.4	-7.49	-0.38	5.97e-13	Electrocardiographic conduction measures;
LIHC	cis	rs17106184	1.000	rs72902744	chr1:51243642	A/G	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.18e-10	Type 2 diabetes;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	0.61	8.76	0.43	8.92e-17	Prudent dietary pattern;
LIHC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.41	-6.92	-0.35	2.23e-11	Monocyte count;
LIHC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.49	7.19	0.36	3.98e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.71	11.39	0.52	1.11e-25	Oral cavity cancer;
LIHC	cis	rs7267979	0.527	rs6083891	chr20:25574272	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.44	-6.02	-0.31	4.47e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2070433	0.534	rs2839269	chr21:47891491	A/G	cg12379764	chr21:47803548	PCNT	0.55	8.06	0.4	1.33e-14	Lymphocyte counts;
LIHC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.42	-8.48	-0.42	7.01e-16	Obesity-related traits;
LIHC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.74	11.52	0.53	3.52e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.67	8.57	0.42	3.69e-16	Corneal structure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06818786	chr11:71639753	RNF121;LOC100133315	0.42	6.08	0.31	3.22e-9	Cognitive function;
LIHC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.62	-10.39	-0.49	3.62e-22	Alcohol dependence;
LIHC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.43	6.12	0.31	2.51e-9	Longevity;Endometriosis;
LIHC	cis	rs4716602	0.596	rs10275400	chr7:156161550	A/G	cg16983916	chr7:156159713	NA	-0.33	-5.87	-0.3	1.01e-8	Anti-saccade response;
LIHC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.4	6.3	0.32	9.28e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.51	7.84	0.39	5.83e-14	Coronary artery disease;
LIHC	trans	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-6.59	-0.34	1.64e-10	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.06	0.51	1.66e-24	Menarche (age at onset);
LIHC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-6.67	-0.34	1.06e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.59	-6.96	-0.35	1.8e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.75	13.6	0.59	5.64e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.71	-9.11	-0.44	7.04e-18	Response to metformin (IC50);
LIHC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.65	6.6	0.34	1.54e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.09	0.44	8.39e-18	Menarche (age at onset);
LIHC	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.85	-13.66	-0.59	3.28e-34	Breast cancer;
LIHC	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.48	-0.42	6.87e-16	Putamen volume;
LIHC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.05	-0.4	1.37e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.64	-10.14	-0.48	2.68e-21	Colorectal cancer;
LIHC	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.5	9.35	0.45	1.19e-18	Testicular germ cell tumor;
LIHC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.33	-7.09	-0.36	7.53e-12	Longevity;
LIHC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.2	0.52	5.25e-25	Hip circumference adjusted for BMI;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25396690	chr2:7006004	CMPK2	-0.61	-6.93	-0.35	2.05e-11	Systolic blood pressure;
LIHC	trans	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.49	-7.2	-0.36	3.78e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2292096	0.850	rs12747569	chr1:200745215	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.03	-0.31	4.17e-9	Epilepsy;
LIHC	cis	rs6815814	0.731	rs4513579	chr4:38773816	T/C	cg06935464	chr4:38784597	TLR10	0.38	5.96	0.31	6.18e-9	Breast cancer;
LIHC	cis	rs4908768	0.534	rs11586056	chr1:8845199	G/T	cg20416874	chr1:8611966	RERE	0.45	6.44	0.33	4.04e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs6747952	0.899	rs1374387	chr2:239085687	A/C	cg17459225	chr2:239074497	NA	0.36	5.81	0.3	1.4e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	8.49	0.42	6.46e-16	HIV-1 control;
LIHC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.0	0.31	5.11e-9	Tonsillectomy;
LIHC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.63	0.42	2.42e-16	Birth weight;
LIHC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.88	12.24	0.55	7.93e-29	Blood metabolite levels;
LIHC	cis	rs16828019	0.929	rs35286837	chr1:41682998	T/G	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.84e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20135002	chr11:47629003	NA	0.58	10.16	0.48	2.36e-21	Subjective well-being;
LIHC	cis	rs8081395	0.801	rs2645479	chr17:57920532	A/G	cg13753209	chr17:57696993	CLTC	0.46	7.1	0.36	7.07e-12	White blood cell count;
LIHC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.97	-18.25	-0.7	1.88e-52	Breast cancer;
LIHC	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.07e-22	Colorectal cancer;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06656553	chr16:89960601	TCF25	-0.49	-6.26	-0.32	1.13e-9	Skin colour saturation;
LIHC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg23485639	chr6:28045615	ZNF165	0.4	6.3	0.32	9.03e-10	Cardiac Troponin-T levels;
LIHC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.66	-9.03	-0.44	1.26e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.47	7.36	0.37	1.36e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg24579218	chr15:68104479	NA	-0.34	-5.79	-0.3	1.58e-8	Restless legs syndrome;
LIHC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.33	-0.37	1.71e-12	Bipolar disorder;
LIHC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	1.05	10.88	0.51	7.21e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-5.81	-0.3	1.44e-8	Menarche (age at onset);
LIHC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg00204512	chr16:28754710	NA	0.41	7.16	0.36	4.9e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.97	16.94	0.68	3.57e-47	Lymphocyte percentage of white cells;
LIHC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg26692224	chr17:62915920	LRRC37A3	-0.73	-7.05	-0.36	9.77e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs1419980	0.730	rs11054944	chr12:7783201	A/C	cg10578777	chr12:7781093	NA	-0.4	-5.74	-0.3	2.15e-8	HDL cholesterol levels;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10687131	chr2:20871002	GDF7	-0.38	-7.31	-0.37	1.88e-12	Abdominal aortic aneurysm;
LIHC	cis	rs919433	0.756	rs7575389	chr2:198198489	A/G	cg10820045	chr2:198174542	NA	-0.55	-8.95	-0.44	2.34e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.47	6.88	0.35	2.82e-11	Personality dimensions;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25053907	chr4:492859	ZNF721;PIGG	0.44	6.12	0.31	2.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.82	16.12	0.66	6.98e-44	Testicular germ cell tumor;
LIHC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg00129232	chr17:37814104	STARD3	-0.35	-5.74	-0.3	2.07e-8	Self-reported allergy;
LIHC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.76	9.02	0.44	1.36e-17	Schizophrenia;
LIHC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.63	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.75	14.91	0.63	4.48e-39	Mortality in heart failure;
LIHC	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.68	-11.57	-0.53	2.48e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	1.05	22.28	0.77	1.42e-68	Breast cancer;
LIHC	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.39	-6.82	-0.35	4.08e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.51	7.98	0.4	2.25e-14	Lymphocyte counts;
LIHC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02290350	chr8:58132656	NA	0.4	8.21	0.41	4.42e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.92	-0.3	7.72e-9	Urinary tract infection frequency;
LIHC	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.63	0.38	2.29e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs507080	0.961	rs4938522	chr11:118548671	A/T	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07949612	chr2:69664562	NFU1	0.48	6.92	0.35	2.19e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	8.16	0.4	6.33e-15	Personality dimensions;
LIHC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-8.78	-0.43	7.96e-17	Morning vs. evening chronotype;
LIHC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg20607798	chr8:58055168	NA	0.58	6.77	0.34	5.5e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.2	-0.45	3.56e-18	Bipolar disorder;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg12046867	chr14:103022105	NA	0.48	6.83	0.35	3.89e-11	Platelet count;
LIHC	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.45	7.27	0.37	2.49e-12	Corneal astigmatism;
LIHC	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg02795151	chr17:7402630	POLR2A	0.51	5.81	0.3	1.44e-8	Androgen levels;
LIHC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	0.83	10.92	0.51	5.22e-24	Skin colour saturation;
LIHC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.25	-0.74	1.79e-60	Height;
LIHC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.15	-0.36	5.43e-12	Menopause (age at onset);
LIHC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.45	0.82	1.05e-84	Cognitive ability;
LIHC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.53	-9.55	-0.46	2.65e-19	Type 2 diabetes;
LIHC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.87	7.82	0.39	6.72e-14	Platelet count;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26308477	chr20:44065479	NA	-0.48	-6.1	-0.31	2.84e-9	Systolic blood pressure;
LIHC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.29	0.37	2.15e-12	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19315081	chr11:10326100	ADM	0.5	7.23	0.36	3.24e-12	Pancreatic cancer;
LIHC	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.76	12.47	0.56	1.17e-29	Phospholipid levels (plasma);
LIHC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg03037974	chr15:76606532	NA	0.74	14.46	0.62	2.52e-37	Blood metabolite levels;
LIHC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.38	-6.63	-0.34	1.33e-10	Monocyte percentage of white cells;
LIHC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-8.62	-0.42	2.54e-16	Neuroticism;
LIHC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.91	0.35	2.32e-11	Axial length;
LIHC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg14906510	chr12:7781169	NA	0.48	7.4	0.37	1.07e-12	HDL cholesterol levels;
LIHC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.72	11.44	0.53	7.22e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg00656387	chr3:40428638	ENTPD3	0.47	7.79	0.39	8.3e-14	Renal cell carcinoma;
LIHC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.91	15.08	0.63	9.78e-40	Colorectal cancer;
LIHC	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg06664874	chr5:179499304	RNF130	0.64	7.33	0.37	1.71e-12	LDL cholesterol;
LIHC	trans	rs1432089	0.773	rs6844102	chr4:171784000	G/A	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.94	17.91	0.7	4.57e-51	Menopause (age at onset);
LIHC	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.75	0.39	1.06e-13	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	1.0	17.19	0.68	3.43e-48	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.41	-8.68	-0.42	1.62e-16	Breast size;
LIHC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.03	14.58	0.62	8.66e-38	Cognitive function;
LIHC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.97	0.31	5.92e-9	Life satisfaction;
LIHC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg13607699	chr17:42295918	UBTF	0.77	15.73	0.65	2.48e-42	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19763699	chr10:17756784	STAM	-0.31	-6.62	-0.34	1.4e-10	Calcium levels;
LIHC	trans	rs10230207	0.893	rs4337996	chr7:19616566	A/T	cg04830814	chr5:32174484	GOLPH3	-0.41	-6.11	-0.31	2.77e-9	Intracranial aneurysm;
LIHC	cis	rs9367716	0.868	rs9396267	chr6:57110411	C/G	cg03371099	chr6:57305889	PRIM2	0.35	5.71	0.3	2.4e-8	Coronary artery disease;
LIHC	cis	rs9896052	0.580	rs6416846	chr17:73462573	A/G	cg25649188	chr17:73499917	CASKIN2	0.5	7.43	0.37	8.87e-13	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-5.87	-0.3	1.05e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-9.73	-0.47	6.56e-20	Mosquito bite size;
LIHC	cis	rs7487075	0.780	rs2279559	chr12:46767175	A/C	cg21428710	chr12:47219797	SLC38A4	0.28	5.92	0.31	7.71e-9	Itch intensity from mosquito bite;
LIHC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.43	6.29	0.32	9.97e-10	Lipoprotein (a) levels;
LIHC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.55	10.38	0.49	4.13e-22	Atrioventricular conduction;
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg00091569	chr3:40428383	ENTPD3	0.37	6.31	0.32	8.47e-10	Renal cell carcinoma;
LIHC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.08	-0.4	1.1e-14	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg01374398	chr3:47516975	SCAP	0.47	6.63	0.34	1.35e-10	Migraine with aura;
LIHC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	0.95	13.51	0.59	1.26e-33	Cognitive function;
LIHC	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22509189	chr2:225307070	NA	-0.54	-7.06	-0.36	9.44e-12	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-9.16	-0.44	4.8e-18	Colorectal cancer;
LIHC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.47e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg18898632	chr2:242989856	NA	-0.7	-8.87	-0.43	4.22e-17	Obesity-related traits;
LIHC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.88	0.35	2.78e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs526821	0.553	rs295597	chr11:55470003	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-7.7	-0.38	1.52e-13	Pediatric bone mineral density (spine);
LIHC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg26441486	chr22:50317300	CRELD2	0.35	6.33	0.32	7.65e-10	Schizophrenia;
LIHC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.92	0.54	1.25e-27	Colorectal cancer;
LIHC	cis	rs7091068	0.615	rs11187609	chr10:95467031	A/C	cg20715218	chr10:95462985	C10orf4	0.6	6.93	0.35	2.16e-11	Urinary tract infection frequency;
LIHC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	1.0	19.05	0.72	1.18e-55	Breast cancer;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg14611757	chr11:1012211	AP2A2	0.61	6.2	0.32	1.58e-9	Mean platelet volume;
LIHC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.24	-0.32	1.27e-9	Mean corpuscular volume;
LIHC	cis	rs240764	0.725	rs239193	chr6:101131848	T/C	cg09795085	chr6:101329169	ASCC3	0.44	6.05	0.31	3.88e-9	Neuroticism;
LIHC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.67	0.59	3.13e-34	Lung cancer in ever smokers;
LIHC	trans	rs12960119	0.536	rs11083162	chr18:23720997	T/A	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs3753275	0.690	rs4908762	chr1:8563663	C/T	cg20416874	chr1:8611966	RERE	-0.47	-5.9	-0.3	8.95e-9	Educational attainment;
LIHC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-6.33	-0.32	7.71e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg05262829	chr1:226921576	ITPKB	0.44	8.25	0.41	3.4e-15	Parkinson's disease;
LIHC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg18944383	chr4:111397179	ENPEP	-0.35	-8.02	-0.4	1.71e-14	Height;
LIHC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.5	6.22	0.32	1.45e-9	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07248407	chr19:10829176	MIR638;DNM2	-0.44	-6.31	-0.32	8.75e-10	Pancreatic cancer;
LIHC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg17279839	chr7:150038598	RARRES2	0.38	7.58	0.38	3.38e-13	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00054692	chr7:23338750	C7orf30	0.47	6.61	0.34	1.47e-10	Pancreatic cancer;
LIHC	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.53	8.54	0.42	4.44e-16	QT interval;
LIHC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-11.26	-0.52	3.02e-25	Vitiligo;
LIHC	cis	rs11168351	0.889	rs12817104	chr12:48382573	G/C	cg21466736	chr12:48725269	NA	-0.44	-6.1	-0.31	2.85e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.71	0.38	1.35e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.76	13.09	0.58	5.08e-32	Mean platelet volume;
LIHC	cis	rs1075232	0.655	rs72711420	chr15:32170148	T/A	cg01030201	chr15:31746330	NA	-0.76	-5.73	-0.3	2.2e-8	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.72	-0.5	2.64e-23	Total cholesterol levels;
LIHC	cis	rs911119	1.000	rs13039536	chr20:23612305	A/G	cg16589663	chr20:23618590	CST3	0.75	7.77	0.39	9.23e-14	Chronic kidney disease;
LIHC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg07424592	chr7:64974309	NA	0.82	9.64	0.46	1.27e-19	Diabetic kidney disease;
LIHC	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.46	-7.02	-0.36	1.18e-11	Diastolic blood pressure;
LIHC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.32	-8.08	-0.4	1.16e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02244288	chr16:89573955	SPG7	-0.32	-6.17	-0.32	1.91e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.6	6.44	0.33	4.1e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg00564555	chr16:1970112	NA	0.27	6.23	0.32	1.39e-9	Insulin-like growth factors;
LIHC	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-8.05	-0.4	1.4e-14	Morning vs. evening chronotype;
LIHC	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg27239842	chr4:2403781	ZFYVE28	0.54	6.35	0.32	6.72e-10	Influenza A (H1N1) severity;
LIHC	cis	rs8067354	0.574	rs2250526	chr17:57951973	G/A	cg02344993	chr17:57696989	CLTC	0.64	10.01	0.48	7.25e-21	Hemoglobin concentration;
LIHC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	8.93	0.43	2.62e-17	Platelet count;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg02207200	chr8:17353980	SLC7A2	-0.47	-6.09	-0.31	2.97e-9	Monocyte count;
LIHC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.98	10.7	0.5	3.12e-23	Triglycerides;
LIHC	cis	rs600626	0.529	rs57188913	chr11:75473294	T/C	cg24262691	chr11:75473276	NA	0.44	6.56	0.33	2e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	12.55	0.56	5.65e-30	Schizophrenia;
LIHC	cis	rs11671005	0.779	rs3794970	chr19:58986260	C/T	cg25952890	chr19:58913133	NA	-0.59	-6.09	-0.31	3.04e-9	Mean platelet volume;
LIHC	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	10.45	0.49	2.34e-22	Post bronchodilator FEV1;
LIHC	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg00292662	chr22:38071168	LGALS1	0.65	8.48	0.42	6.78e-16	Fat distribution (HIV);
LIHC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.63	-0.34	1.28e-10	Height;
LIHC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	14.28	0.61	1.29e-36	Cognitive test performance;
LIHC	trans	rs61332075	0.501	rs56387323	chr2:239387399	T/C	cg01134436	chr17:81009848	B3GNTL1	0.86	7.2	0.36	3.82e-12	Lung function (FEV1/FVC);
LIHC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.47	7.65	0.38	2.07e-13	Migraine;
LIHC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.01	0.31	4.75e-9	Schizophrenia;
LIHC	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.37	8.52	0.42	5.35e-16	Congenital heart disease (maternal effect);
LIHC	cis	rs1823913	1.000	rs4853564	chr2:192123665	C/T	cg12404831	chr2:192114017	MYO1B	-0.32	-6.54	-0.33	2.21e-10	Obesity-related traits;
LIHC	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.65	9.53	0.46	2.93e-19	Monocyte count;
LIHC	cis	rs17152411	1.000	rs17152381	chr10:126592903	T/G	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	8.83	0.43	5.46e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.32	-5.91	-0.3	8.38e-9	Lewy body disease;
LIHC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg19636519	chr7:99541626	NA	0.3	5.74	0.3	2.07e-8	Coronary artery disease;
LIHC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.04	0.4	1.47e-14	Alzheimer's disease;
LIHC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg15123519	chr2:136567270	LCT	0.43	8.96	0.44	2.08e-17	Mosquito bite size;
LIHC	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg23682824	chr7:23144976	KLHL7	0.43	6.52	0.33	2.56e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.89	-0.51	6.7e-24	Platelet count;
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13409248	chr3:40428643	ENTPD3	0.49	8.22	0.41	4.34e-15	Renal cell carcinoma;
LIHC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06636551	chr8:101224915	SPAG1	-0.46	-8.7	-0.43	1.42e-16	Atrioventricular conduction;
LIHC	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.45	6.68	0.34	9.63e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.54	-0.46	2.86e-19	Blood metabolite levels;
LIHC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.38	6.83	0.35	3.83e-11	Aortic root size;
LIHC	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.43	-0.33	4.2e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.5	8.14	0.4	7.53e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.72	12.8	0.57	6.26e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.02e-17	Arsenic metabolism;
LIHC	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.46	-7.04	-0.36	1.09e-11	Adiposity;
LIHC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-13.57	-0.59	7.41e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.73	6.26	0.32	1.13e-9	Body mass index;
LIHC	cis	rs2599510	0.811	rs2710625	chr2:32822957	G/A	cg02381751	chr2:32503542	YIPF4	0.46	5.97	0.31	6.03e-9	Interleukin-18 levels;
LIHC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.96	18.39	0.71	5.32e-53	Menopause (age at onset);
LIHC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg25329415	chr6:28076851	NA	0.27	5.81	0.3	1.46e-8	Cardiac Troponin-T levels;
LIHC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.39	-0.33	5.54e-10	Tonsillectomy;
LIHC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg20684491	chr1:25596433	NA	-0.29	-6.04	-0.31	3.97e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.63	-8.58	-0.42	3.37e-16	Sudden cardiac arrest;
LIHC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21448741	chr8:58168803	NA	0.32	6.03	0.31	4.14e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9325144	0.768	rs11168750	chr12:38992710	C/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.83	-0.3	1.26e-8	Morning vs. evening chronotype;
LIHC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.52	-8.76	-0.43	8.89e-17	Obesity-related traits;
LIHC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.54	11.85	0.54	2.27e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9534288	0.751	rs2806920	chr13:46514506	T/C	cg15192986	chr13:46630673	CPB2	0.54	7.62	0.38	2.47e-13	Blood protein levels;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg22528358	chr1:107598549	PRMT6	-0.63	-9.58	-0.46	2.13e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg01864836	chr14:55583639	NA	-0.4	-7.48	-0.38	6.21e-13	Protein biomarker;
LIHC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg10360323	chr17:41437877	NA	0.41	6.04	0.31	4.09e-9	Menopause (age at onset);
LIHC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.59	-0.46	1.92e-19	Schizophrenia;
LIHC	trans	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.18e-10	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13867718	chr16:29973267	TMEM219	0.43	6.17	0.32	1.94e-9	Pancreatic cancer;
LIHC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.84	0.3	1.24e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg09033563	chr22:24373618	LOC391322	-0.46	-6.44	-0.33	3.96e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.52	-7.53	-0.38	4.53e-13	Recombination rate (females);
LIHC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.98	-18.28	-0.7	1.42e-52	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02047359	chr10:75174015	ANXA7	0.41	6.67	0.34	1.05e-10	Cognitive function;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.91	0.43	3.16e-17	Prudent dietary pattern;
LIHC	trans	rs2744203	1.000	rs72610884	chr6:104643279	T/C	cg27088726	chr16:83171155	CDH13	-0.46	-6.08	-0.31	3.14e-9	IgG glycosylation;
LIHC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg15472797	chr10:135243109	NA	-0.39	-5.93	-0.31	7.49e-9	Systemic lupus erythematosus;
LIHC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg18944383	chr4:111397179	ENPEP	0.24	6.15	0.32	2.17e-9	Coronary artery disease;
LIHC	cis	rs57502260	0.704	rs12286536	chr11:68290234	C/G	cg20283391	chr11:68216788	NA	-0.5	-6.06	-0.31	3.57e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs7635838	0.892	rs3942925	chr3:11442921	T/C	cg00170343	chr3:11313890	ATG7	0.42	6.49	0.33	3.09e-10	HDL cholesterol;
LIHC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.4	7.33	0.37	1.67e-12	Psoriasis;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg12064134	chr16:90016061	DEF8	-0.46	-6.11	-0.31	2.78e-9	Skin colour saturation;
LIHC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.64	-0.38	2.15e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg08135965	chr6:41755394	TOMM6	0.45	5.97	0.31	6.1e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg15585264	chr19:41770827	HNRNPUL1	-0.54	-6.53	-0.33	2.38e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.57	-8.49	-0.42	6.39e-16	Blood protein levels;
LIHC	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.67	13.33	0.58	6.19e-33	Leprosy;
LIHC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg08539965	chr1:21396338	EIF4G3	-0.32	-5.77	-0.3	1.77e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	cis	rs963731	0.649	rs78905728	chr2:39339241	G/T	cg04010122	chr2:39346883	SOS1	0.68	6.06	0.31	3.6e-9	Corticobasal degeneration;
LIHC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.4e-30	Menopause (age at onset);
LIHC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.5	-8.05	-0.4	1.39e-14	Coronary artery disease;
LIHC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg22676075	chr6:135203613	NA	0.38	6.24	0.32	1.29e-9	Red blood cell count;
LIHC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.53	8.06	0.4	1.31e-14	Gout;
LIHC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.75	0.3	2.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.75	14.46	0.62	2.57e-37	Mortality in heart failure;
LIHC	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	5.78	0.3	1.68e-8	Height;
LIHC	cis	rs4908760	0.965	rs10864356	chr1:8569871	A/T	cg20416874	chr1:8611966	RERE	-0.68	-14.62	-0.62	6.36e-38	Vitiligo;
LIHC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg07424592	chr7:64974309	NA	0.75	8.79	0.43	7.66e-17	Diabetic kidney disease;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg00280220	chr17:61926910	NA	0.43	6.87	0.35	3.04e-11	Prudent dietary pattern;
LIHC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.42	-7.17	-0.36	4.71e-12	Platelet distribution width;
LIHC	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.41	7.49	0.38	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.52	-6.47	-0.33	3.3e-10	Schizophrenia;
LIHC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.0	-10.13	-0.48	2.84e-21	Vitiligo;
LIHC	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.03	0.36	1.11e-11	Exhaled nitric oxide output;
LIHC	cis	rs903552	0.736	rs9806369	chr15:102008430	A/C	cg04789225	chr15:102009795	PCSK6	-0.47	-6.22	-0.32	1.45e-9	Diabetic kidney disease;
LIHC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.5	7.89	0.39	4.16e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11958404	0.615	rs7724696	chr5:157450852	A/C	cg05962755	chr5:157440814	NA	0.59	7.83	0.39	6.15e-14	IgG glycosylation;
LIHC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-11.15	-0.52	7.8e-25	Platelet count;
LIHC	cis	rs3112357	0.951	rs3112348	chr7:135387953	A/G	cg20392616	chr7:135392013	SLC13A4	0.41	6.81	0.35	4.32e-11	Plantar warts;
LIHC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.03	0.4	1.55e-14	Body mass index;
LIHC	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.49	-6.86	-0.35	3.31e-11	Life satisfaction;
LIHC	trans	rs35668226	1.000	rs35668226	chr10:122849667	A/G	cg08474467	chr16:593365	SOLH	0.41	6.04	0.31	4e-9	Type 2 diabetes;
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg21294424	chr19:58662284	ZNF329	0.93	7.26	0.37	2.55e-12	Cholesterol, total;
LIHC	cis	rs2257205	0.667	rs7213035	chr17:56857281	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.61	-0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg08911820	chr1:110026001	ATXN7L2	-0.66	-8.07	-0.4	1.19e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg15155738	chr12:121454335	C12orf43	0.54	7.76	0.39	9.67e-14	N-glycan levels;
LIHC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.28	0.55	5.77e-29	Electrocardiographic conduction measures;
LIHC	cis	rs7617773	0.638	rs7644414	chr3:48299079	A/T	cg11946769	chr3:48343235	NME6	0.77	9.48	0.46	4.33e-19	Coronary artery disease;
LIHC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3770081	1.000	rs3770082	chr2:86280922	T/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-8.88	-0.43	3.77e-17	Facial emotion recognition (sad faces);
LIHC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg18944383	chr4:111397179	ENPEP	0.28	6.46	0.33	3.54e-10	Coronary artery disease;
LIHC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg11070056	chr1:107600091	PRMT6	-0.63	-10.52	-0.49	1.34e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg16558253	chr16:72132732	DHX38	-0.38	-6.43	-0.33	4.3e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg03665457	chr10:38645376	HSD17B7P2	0.4	5.91	0.3	8.16e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	1.01	13.1	0.58	4.75e-32	Red blood cell traits;
LIHC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.5	-0.56	8.37e-30	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10490227	chr1:40348903	TRIT1	0.45	6.66	0.34	1.1e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg26138937	chr11:71823887	C11orf51	-1.25	-10.59	-0.5	7.2e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg01864836	chr14:55583639	NA	-0.44	-8.63	-0.42	2.36e-16	Protein biomarker;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07792822	chr1:157961914	KIRREL	0.42	7.16	0.36	5.06e-12	Pancreatic cancer;
LIHC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg25344623	chr2:136566232	LCT	-0.4	-8.36	-0.41	1.61e-15	Mosquito bite size;
LIHC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	1.05	15.38	0.64	6.23e-41	Breast cancer;
LIHC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	1.11	13.81	0.6	9.05e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.68	-0.5	3.47e-23	Breast cancer;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12016809	chr21:47604291	C21orf56	0.46	6.99	0.35	1.49e-11	Testicular germ cell tumor;
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.57	10.05	0.48	5.41e-21	Longevity;Endometriosis;
LIHC	trans	rs875971	0.660	rs801193	chr7:66030612	A/C	cg26939375	chr7:64535504	NA	-0.41	-6.74	-0.34	6.73e-11	Aortic root size;
LIHC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.56	0.42	3.8e-16	Motion sickness;
LIHC	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.45	-0.46	5.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.45	6.64	0.34	1.21e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.41	-7.33	-0.37	1.66e-12	Aortic root size;
LIHC	trans	rs35333254	1.000	rs35333254	chr4:14438810	A/G	cg20299935	chr17:21795943	NA	-0.54	-6.56	-0.33	2.02e-10	Age-related hearing impairment;
LIHC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.59	7.58	0.38	3.25e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.52	-5.83	-0.3	1.32e-8	Ulcerative colitis;
LIHC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg14930904	chr10:32216787	ARHGAP12	0.38	6.83	0.35	3.99e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg02993280	chr1:107599747	PRMT6	-0.58	-9.04	-0.44	1.17e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	0.89	6.49	0.33	3.1e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg07713946	chr22:31675144	LIMK2	0.31	6.05	0.31	3.76e-9	Colorectal cancer;
LIHC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20135002	chr11:47629003	NA	-0.53	-9.01	-0.44	1.47e-17	Subjective well-being;
LIHC	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1639906	0.729	rs17186614	chr7:2231002	G/A	cg02951883	chr7:2050386	MAD1L1	0.58	7.56	0.38	3.81e-13	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs78049276	0.688	rs80157433	chr4:148370548	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.66	-0.38	1.97e-13	Pulse pressure;
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17608500	chr1:154955711	FLAD1	0.42	6.5	0.33	2.9e-10	Obesity-related traits;
LIHC	cis	rs1144333	0.510	rs1250882	chr1:76287314	C/A	cg03433033	chr1:76189801	ACADM	-0.53	-7.42	-0.37	9.61e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	11.61	0.53	1.63e-26	Height;
LIHC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg11764359	chr7:65958608	NA	0.56	5.99	0.31	5.28e-9	Diabetic kidney disease;
LIHC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.48	7.38	0.37	1.18e-12	Height;
LIHC	cis	rs17711722	0.690	rs116823227	chr7:65331001	A/G	cg14393609	chr7:65229607	NA	0.42	5.73	0.3	2.19e-8	Calcium levels;
LIHC	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-16.25	-0.66	2.14e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg18887096	chr2:219472410	PLCD4	0.36	6.36	0.33	6.49e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.8	7.18	0.36	4.34e-12	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs986417	1.000	rs958504	chr14:60949740	G/A	cg27398547	chr14:60952738	C14orf39	0.83	9.57	0.46	2.19e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.16	-0.44	4.95e-18	Bipolar disorder;
LIHC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-15.04	-0.63	1.4e-39	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17630771	chr11:101981004	YAP1	0.49	6.88	0.35	2.82e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg06935464	chr4:38784597	TLR10	0.46	7.19	0.36	4.1e-12	Breast cancer;
LIHC	trans	rs1432089	0.773	rs62344304	chr4:171786925	C/A	cg02328223	chr3:127541927	MGLL	-0.42	-6.09	-0.31	3.09e-9	Endometriosis;
LIHC	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.1	-0.4	9.58e-15	Colorectal cancer;
LIHC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.48	0.56	1.04e-29	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg14092571	chr14:90743983	NA	-0.37	-5.79	-0.3	1.59e-8	Mortality in heart failure;
LIHC	cis	rs10878977	0.565	rs6581891	chr12:69813215	T/C	cg17330252	chr12:69809627	NA	0.38	5.99	0.31	5.44e-9	Colorectal cancer;
LIHC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.77	-12.01	-0.54	5.95e-28	Anterior chamber depth;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg26939375	chr7:64535504	NA	0.47	7.12	0.36	6.39e-12	Aortic root size;
LIHC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg17845761	chr1:175162550	KIAA0040	-0.36	-5.89	-0.3	9.17e-9	Alcohol dependence;
LIHC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.41e-37	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25072359	chr17:41440525	NA	0.39	6.12	0.31	2.58e-9	Menopause (age at onset);
LIHC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.39	-5.96	-0.31	6.24e-9	Menarche (age at onset);
LIHC	cis	rs2073300	1.000	rs6114135	chr20:23456746	C/A	cg12062639	chr20:23401060	NAPB	0.75	9.04	0.44	1.2e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.25	-0.36	2.89e-12	Hepatocellular carcinoma;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.01	-0.4	1.84e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg14170313	chr9:77112896	RORB	-0.5	-6.42	-0.33	4.55e-10	Vitiligo;
LIHC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.81	-0.3	1.46e-8	Blood protein levels;
LIHC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg10018233	chr7:150070692	REPIN1	0.5	8.43	0.41	9.5e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.56	-10.61	-0.5	6.25e-23	Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03925809	chr19:6393419	GTF2F1	0.46	6.8	0.35	4.72e-11	Pancreatic cancer;
LIHC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.68	-9.92	-0.47	1.53e-20	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.51	-8.09	-0.4	1.04e-14	Colorectal cancer;
LIHC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg20607798	chr8:58055168	NA	0.65	7.65	0.38	2.05e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.62	9.83	0.47	3e-20	Corneal astigmatism;
LIHC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.88	16.67	0.67	4.28e-46	Multiple myeloma (IgH translocation);
LIHC	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.49	-9.44	-0.45	5.8e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs918629	0.530	rs3815768	chr5:95236459	C/T	cg10483112	chr5:95245456	ELL2	-0.37	-6.76	-0.34	5.99e-11	IgG glycosylation;
LIHC	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.56	8.27	0.41	3.07e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.61	8.78	0.43	8.21e-17	Menarche (age at onset);
LIHC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02985541	chr2:219472218	PLCD4	0.42	6.84	0.35	3.73e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.5	0.38	5.65e-13	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.66	8.28	0.41	2.74e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg20651018	chr11:3035856	CARS	-0.35	-5.88	-0.3	1e-8	Longevity;
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23260799	chr11:451101	PTDSS2	0.4	6.11	0.31	2.74e-9	Obesity-related traits;
LIHC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.11	16.42	0.66	4.34e-45	Sexual dysfunction (female);
LIHC	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.5	9.4	0.45	8.12e-19	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06811360	chr17:8089327	NA	0.44	6.09	0.31	3e-9	Pancreatic cancer;
LIHC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.44	6.44	0.33	4.13e-10	Methadone dose in opioid dependence;
LIHC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22906224	chr7:99728672	NA	0.45	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.26	-0.32	1.16e-9	Total body bone mineral density;
LIHC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06002616	chr8:101225028	SPAG1	0.34	5.83	0.3	1.29e-8	Atrioventricular conduction;
LIHC	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg11839771	chr15:80205821	ST20	-0.32	-6.99	-0.35	1.45e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs7587476	1.000	rs1542173	chr2:215657560	C/T	cg04004882	chr2:215674386	BARD1	-0.52	-6.93	-0.35	2.12e-11	Neuroblastoma;
LIHC	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.31	2.7e-9	Mean corpuscular volume;
LIHC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.37	6.24	0.32	1.27e-9	Monobrow;
LIHC	cis	rs6442522	0.966	rs3856828	chr3:15488997	T/C	cg16303742	chr3:15540471	COLQ	0.46	7.61	0.38	2.61e-13	Uric acid levels;
LIHC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg09835421	chr16:68378352	PRMT7	-0.8	-9.47	-0.46	4.73e-19	Schizophrenia;
LIHC	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.3	-5.87	-0.3	1.03e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14497545	chr4:140754475	MAML3	-0.62	-9.01	-0.44	1.48e-17	Lung function (FEV1/FVC);
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.44	7.22	0.36	3.46e-12	Testicular germ cell tumor;
LIHC	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.71	-6.58	-0.34	1.76e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.69	-9.18	-0.44	4.15e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.9	0.35	2.47e-11	Height;
LIHC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	21.27	0.75	1.51e-64	Chronic sinus infection;
LIHC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.54	6.3	0.32	9.21e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.61	10.2	0.48	1.69e-21	Platelet count;
LIHC	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.99	19.41	0.72	4.04e-57	Platelet distribution width;
LIHC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.65	-6.99	-0.35	1.44e-11	Exhaled nitric oxide output;
LIHC	cis	rs7534824	0.543	rs61780300	chr1:101403601	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	7.66	0.38	1.97e-13	Refractive astigmatism;
LIHC	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg04118878	chr10:71993077	PPA1	0.59	6.59	0.34	1.71e-10	Blood protein levels;
LIHC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.87	-0.35	3.09e-11	Hemoglobin concentration;
LIHC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.9	15.31	0.64	1.17e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.5	-6.15	-0.32	2.2e-9	Menarche (age at onset);
LIHC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.85	-0.3	1.13e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.5	-0.38	5.67e-13	Height;
LIHC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.28	-6.98	-0.35	1.56e-11	Mean corpuscular volume;
LIHC	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-6.22	-0.32	1.48e-9	Coronary artery disease;
LIHC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.52	6.12	0.31	2.61e-9	Post bronchodilator FEV1;
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21747090	chr2:27597821	SNX17	-0.43	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LIHC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.12	-0.31	2.62e-9	Colorectal cancer;
LIHC	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	0.65	7.22	0.36	3.45e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs17152411	0.652	rs3740535	chr10:126676686	T/C	cg07906193	chr10:126599966	NA	-0.29	-5.81	-0.3	1.47e-8	Height;
LIHC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.53	-7.6	-0.38	2.95e-13	Blood metabolite levels;
LIHC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.46	5.92	0.3	7.9e-9	Obesity (extreme);
LIHC	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.69	-0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.04e-14	Height;
LIHC	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.47	5.8	0.3	1.49e-8	Economic and political preferences (feminism/equality);
LIHC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.4	0.45	8.18e-19	Platelet count;
LIHC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.59	0.34	1.66e-10	Bipolar disorder;
LIHC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.79	12.43	0.56	1.53e-29	Breast cancer;
LIHC	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.48	9.35	0.45	1.17e-18	Testicular germ cell tumor;
LIHC	cis	rs6466055	0.932	rs2057883	chr7:104929837	C/G	cg04380332	chr7:105027541	SRPK2	0.34	6.4	0.33	5.02e-10	Schizophrenia;
LIHC	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg02023728	chr11:77925099	USP35	0.32	5.82	0.3	1.34e-8	Alzheimer's disease (survival time);
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-6.55	-0.33	2.15e-10	Total body bone mineral density;
LIHC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.69	-7.11	-0.36	6.92e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.63	8.59	0.42	3.14e-16	Menarche (age at onset);
LIHC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.48	-7.55	-0.38	3.88e-13	Age at first birth;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.59	0.53	1.98e-26	Prudent dietary pattern;
LIHC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.16	-0.55	1.68e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg02187348	chr16:89574699	SPG7	0.4	5.72	0.3	2.34e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.95	-0.31	6.74e-9	Body mass index;
LIHC	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.57	-6.32	-0.32	8.08e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs965469	1.000	rs6037567	chr20:3332160	C/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.59e-11	IFN-related cytopenia;
LIHC	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13973472	chr14:55032305	NA	0.4	6.43	0.33	4.39e-10	Parkinson's disease;
LIHC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg09222892	chr1:25734099	RHCE	0.48	8.98	0.44	1.82e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg14709524	chr16:89940631	TCF25	0.59	7.74	0.39	1.14e-13	Skin colour saturation;
LIHC	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg07322936	chr10:88137208	NA	-0.47	-6.12	-0.31	2.51e-9	Schizophrenia;
LIHC	cis	rs903552	1.000	rs8043205	chr15:102005749	A/G	cg00659931	chr15:102010125	PCSK6	-0.46	-6.19	-0.32	1.7e-9	Diabetic kidney disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14561318	chr22:18507401	MICAL3	0.49	6.96	0.35	1.79e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.39	5.71	0.3	2.44e-8	Life satisfaction;
LIHC	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.62	7.19	0.36	4.21e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg09990169	chr2:241835740	C2orf54	-0.44	-6.47	-0.33	3.38e-10	Urinary metabolites;
LIHC	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.45	5.78	0.3	1.66e-8	RR interval (heart rate);
LIHC	cis	rs3812111	0.774	rs563176	chr6:116431426	C/A	cg08036074	chr6:116424633	NT5DC1	0.66	11.74	0.54	5.72e-27	Age-related macular degeneration;
LIHC	cis	rs4407350	0.870	rs5764873	chr22:44908153	G/A	cg11695653	chr22:44894386	LDOC1L	-0.35	-6.02	-0.31	4.45e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.95	9.7	0.46	8.02e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.44	5.78	0.3	1.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.79	-9.6	-0.46	1.81e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.33	-6.14	-0.31	2.35e-9	Red blood cell count;
LIHC	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg11204139	chr17:3907470	NA	0.53	7.05	0.36	9.93e-12	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs7523273	0.853	rs7537216	chr1:208006429	A/T	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.59	-0.5	7.74e-23	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07956936	chr16:72127419	TXNL4B;DHX38	0.48	7.26	0.37	2.67e-12	Cognitive function;
LIHC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs16958440	0.581	rs11872531	chr18:44689234	C/A	cg17192377	chr18:44677553	HDHD2	0.71	7.79	0.39	8.32e-14	Sitting height ratio;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21747090	chr2:27597821	SNX17	-0.43	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LIHC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg15691649	chr6:25882328	NA	-0.54	-7.82	-0.39	6.76e-14	Blood metabolite levels;
LIHC	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	0.76	8.36	0.41	1.61e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg14440974	chr22:39074834	NA	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.53	8.5	0.42	5.98e-16	Blood protein levels;
LIHC	trans	rs3858145	0.588	rs2305083	chr10:70044937	C/A	cg04882175	chr6:131122610	NA	-0.51	-6.08	-0.31	3.24e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.45	-8.7	-0.43	1.45e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.15	0.55	1.69e-28	Height;
LIHC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg00901687	chr17:48585270	MYCBPAP	0.45	6.39	0.33	5.4e-10	Visceral fat;
LIHC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg05941027	chr17:61774174	LIMD2	0.35	7.35	0.37	1.44e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.64	-8.24	-0.41	3.67e-15	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.56	-8.22	-0.41	4.17e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.34	5.82	0.3	1.38e-8	Psoriasis;
LIHC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.54	6.27	0.32	1.06e-9	Alzheimer's disease;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-11.15	-0.52	7.49e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.68	-8.56	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs783540	1.000	rs7496954	chr15:83345536	T/G	cg18393722	chr15:85113863	UBE2QP1	0.4	6.93	0.35	2.11e-11	Schizophrenia;
LIHC	cis	rs1555322	0.530	rs2425049	chr20:33874720	C/T	cg07134254	chr20:33865797	NA	0.5	5.99	0.31	5.29e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg19636519	chr7:99541626	NA	-0.31	-6.17	-0.32	1.93e-9	Coronary artery disease;
LIHC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.02	0.68	1.67e-47	Tonsillectomy;
LIHC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.22	0.32	1.43e-9	Hepatocellular carcinoma;
LIHC	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.43	6.86	0.35	3.16e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.79	-0.3	1.61e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.79	11.34	0.52	1.64e-25	Coronary artery disease;
LIHC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.55	8.39	0.41	1.3e-15	Gout;
LIHC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.16	0.44	4.73e-18	Menarche (age at onset);
LIHC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	7.89	0.39	4.08e-14	Schizophrenia;
LIHC	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.54	-0.38	4.37e-13	Prevalent atrial fibrillation;
LIHC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.03e-26	Chronic sinus infection;
LIHC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg14393609	chr7:65229607	NA	-0.37	-5.81	-0.3	1.4e-8	Aortic root size;
LIHC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.39	-6.25	-0.32	1.25e-9	Menarche (age at onset);
LIHC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.63	9.53	0.46	2.97e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27297192	chr10:134578999	INPP5A	0.53	7.42	0.37	9.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7119038	0.818	rs6589686	chr11:118612565	G/A	cg19308663	chr11:118741387	NA	0.41	6.26	0.32	1.15e-9	Sjögren's syndrome;
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.7	7.1	0.36	7.09e-12	Alzheimer's disease;
LIHC	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.38	7.38	0.37	1.18e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.88	13.69	0.59	2.55e-34	Vitamin D levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00780250	chr4:39979372	PDS5A	-0.49	-6.67	-0.34	1.01e-10	Bilirubin levels;
LIHC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.53	9.42	0.45	6.92e-19	Total body bone mineral density;
LIHC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg08676812	chr11:65308423	LTBP3	1.05	7.32	0.37	1.84e-12	Height;
LIHC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.99	-0.57	1.23e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.43	-6.76	-0.34	5.81e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.62	-10.06	-0.48	5.05e-21	Malaria;
LIHC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg16970926	chr12:29381810	FAR2	0.3	6.24	0.32	1.27e-9	QT interval;
LIHC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg24296786	chr1:45957014	TESK2	-0.49	-6.65	-0.34	1.15e-10	Platelet count;
LIHC	cis	rs9649465	0.967	rs7791183	chr7:123343719	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-7.99	-0.4	2.04e-14	Migraine;
LIHC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.44	0.37	8.24e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.55	-0.42	4.23e-16	Blood pressure (smoking interaction);
LIHC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12463550	chr7:65579703	CRCP	0.68	7.3	0.37	2.02e-12	Diabetic kidney disease;
LIHC	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.33	-7.49	-0.38	5.8e-13	Blood metabolite ratios;
LIHC	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.23	-13.15	-0.58	2.89e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	0.91	13.03	0.58	8.76e-32	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.57	8.68	0.42	1.69e-16	Longevity;Endometriosis;
LIHC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.62	0.53	1.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.51	8.47	0.42	7.21e-16	Electroencephalogram traits;
LIHC	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.47	-6.57	-0.33	1.93e-10	Schizophrenia;
LIHC	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.37	6.21	0.32	1.54e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LIHC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.75	-0.3	1.96e-8	Type 2 diabetes;
LIHC	cis	rs600806	0.683	rs10857789	chr1:110012293	C/T	cg11161837	chr1:110010384	SYPL2	0.46	6.32	0.32	8.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	6.11	0.31	2.7e-9	Electroencephalogram traits;
LIHC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.59	9.77	0.47	4.76e-20	Type 2 diabetes;
LIHC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.32	6.22	0.32	1.43e-9	Type 2 diabetes;
LIHC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.25	-7.95	-0.39	2.73e-14	Mean corpuscular volume;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.38	-5.83	-0.3	1.31e-8	Testicular germ cell tumor;
LIHC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg19645103	chr12:69753606	YEATS4	-0.52	-7.54	-0.38	4.4e-13	Response to diuretic therapy;
LIHC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.78	15.26	0.64	1.75e-40	Mortality in heart failure;
LIHC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.6	-12.08	-0.55	3.12e-28	Coronary artery disease;
LIHC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	9.65	0.46	1.24e-19	Resting heart rate;
LIHC	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.22	-6.08	-0.31	3.17e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.46	-5.94	-0.31	6.99e-9	Pancreatic cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15509053	chr7:123558137	NA	0.43	6.2	0.32	1.67e-9	Hepatitis;
LIHC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.04	0.31	4.13e-9	Tonsillectomy;
LIHC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.02	-0.51	2.28e-24	Chronic sinus infection;
LIHC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.0	0.31	5.11e-9	Tonsillectomy;
LIHC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.75	9.16	0.44	4.76e-18	Morning vs. evening chronotype;
LIHC	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.4	-6.56	-0.33	2.03e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.35	0.32	7.04e-10	Ulcerative colitis;
LIHC	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.36	6.19	0.32	1.77e-9	Cognitive performance;
LIHC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.64	-10.34	-0.49	5.72e-22	Inflammatory bowel disease;
LIHC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	22.02	0.77	1.47e-67	Cognitive ability;
LIHC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.66	6.51	0.33	2.69e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.44	-6.48	-0.33	3.29e-10	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.52	6.22	0.32	1.42e-9	Serum sulfate level;
LIHC	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1789	0.868	rs4631041	chr4:15673395	A/T	cg21123203	chr4:15471301	CC2D2A	-0.43	-6.78	-0.34	5.25e-11	Blood protein levels;
LIHC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23485639	chr6:28045615	ZNF165	0.43	5.73	0.3	2.21e-8	Depression;
LIHC	cis	rs1023500	1.000	rs1047997	chr22:42334953	C/G	cg04733989	chr22:42467013	NAGA	-0.52	-6.1	-0.31	2.91e-9	Schizophrenia;
LIHC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg06565975	chr8:143823917	SLURP1	0.33	6.28	0.32	1.01e-9	Urinary tract infection frequency;
LIHC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	1.23	10.89	0.51	6.79e-24	Obesity-related traits;
LIHC	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-15.67	-0.65	4.28e-42	Electrocardiographic conduction measures;
LIHC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.83	13.74	0.6	1.7e-34	Breast cancer;
LIHC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.57	-8.5	-0.42	5.94e-16	Parkinson's disease;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.45	8.41	0.41	1.09e-15	Prudent dietary pattern;
LIHC	cis	rs2176862	1.000	rs56398705	chr3:46619615	C/G	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.3	-0.32	9.3e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.64	10.54	0.5	1.13e-22	Platelet count;
LIHC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.57	10.43	0.49	2.77e-22	Diastolic blood pressure;
LIHC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg18357645	chr12:58087776	OS9	-0.45	-6.91	-0.35	2.43e-11	Multiple sclerosis;
LIHC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	18.21	0.7	2.91e-52	Tonsillectomy;
LIHC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.26e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.53	0.38	4.5e-13	Electroencephalogram traits;
LIHC	cis	rs13088318	0.504	rs2553419	chr3:101068620	C/T	cg19452782	chr3:101232218	SENP7	-0.42	-6.24	-0.32	1.32e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg18335740	chr13:41363409	SLC25A15	0.35	6.06	0.31	3.51e-9	Lewy body disease;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.57	0.56	4.62e-30	Prudent dietary pattern;
LIHC	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2516739	1.000	rs2516739	chr16:2097158	A/G	cg13974317	chr22:21056282	TMEM191A	-0.52	-6.16	-0.32	1.99e-9	Longevity;
LIHC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.18	0.44	4.13e-18	Bipolar disorder;
LIHC	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg16914508	chr2:239161102	PER2	0.83	5.97	0.31	5.94e-9	Irritable bowel syndrome;
LIHC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.13	0.36	6.01e-12	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.43	7.38	0.37	1.18e-12	Cognitive function;
LIHC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.02	-0.31	4.51e-9	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs4818225	0.536	rs2838000	chr21:42646518	A/G	cg00046021	chr7:100858451	PLOD3	-0.54	-6.45	-0.33	3.92e-10	Educational attainment;
LIHC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.48	6.36	0.33	6.52e-10	Major depressive disorder;
LIHC	cis	rs74181299	0.684	rs1420183	chr2:65309988	A/G	cg05010058	chr2:65284262	CEP68	-0.39	-6.3	-0.32	9.17e-10	Pulse pressure;
LIHC	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg13385521	chr17:29058706	SUZ12P	-0.68	-6.26	-0.32	1.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.46	-0.33	3.61e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg04306507	chr14:55594613	LGALS3	0.31	5.92	0.3	7.94e-9	Protein biomarker;
LIHC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg07061783	chr6:25882402	NA	-0.47	-6.66	-0.34	1.13e-10	Blood metabolite levels;
LIHC	cis	rs1355223	0.902	rs7102625	chr11:34739717	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	6.04	0.31	4.04e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.56	-8.52	-0.42	5.21e-16	White matter hyperintensity burden;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg06565975	chr8:143823917	SLURP1	-0.4	-6.63	-0.34	1.32e-10	Urinary tract infection frequency;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.71	7.33	0.37	1.65e-12	Vitiligo;
LIHC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg23533926	chr12:111358616	MYL2	-0.32	-6.36	-0.33	6.62e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1986734	0.555	rs12500824	chr4:77416627	A/G	cg24201034	chr4:77507246	SHROOM3	-0.37	-5.77	-0.3	1.76e-8	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	0.71	7.93	0.39	3.1e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.51	9.34	0.45	1.28e-18	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6586163	1.000	rs1926196	chr10:90753748	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.57	8.4	0.41	1.23e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.98	14.99	0.63	2.05e-39	Breast cancer;
LIHC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.62	11.24	0.52	3.65e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.43	-8.86	-0.43	4.4e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs17106184	1.000	rs60048959	chr1:51403897	C/T	cg07174182	chr1:51127561	FAF1	-0.75	-7.9	-0.39	3.96e-14	Type 2 diabetes;
LIHC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-13.94	-0.6	2.75e-35	Headache;
LIHC	cis	rs8084351	0.577	rs4315409	chr18:50660629	C/T	cg24270629	chr18:50823537	DCC	-0.44	-6.47	-0.33	3.3e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-12.76	-0.57	9.38e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.88	-0.35	2.89e-11	Response to antipsychotic treatment;
LIHC	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.64	13.16	0.58	2.71e-32	Gestational age at birth (maternal effect);
LIHC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.74	9.58	0.46	2.08e-19	Fat distribution (HIV);
LIHC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.27	-0.32	1.09e-9	Lung cancer;
LIHC	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg27255678	chr10:102756921	LZTS2	0.51	7.17	0.36	4.72e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17848531	chr2:182756352	SSFA2	0.46	6.25	0.32	1.24e-9	Pancreatic cancer;
LIHC	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.44	6.57	0.33	1.84e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.67	10.14	0.48	2.65e-21	Response to diuretic therapy;
LIHC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-11.0	-0.51	2.64e-24	Lung cancer;
LIHC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg24296786	chr1:45957014	TESK2	-0.51	-7.42	-0.37	9.41e-13	Platelet count;
LIHC	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.79	6.39	0.33	5.48e-10	Body mass index;
LIHC	trans	rs72960926	0.744	rs56365866	chr6:74910810	T/C	cg07247405	chr1:2484626	LOC115110	0.53	6.1	0.31	2.91e-9	Metabolite levels (MHPG);
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.72	-10.78	-0.5	1.55e-23	Lymphocyte counts;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.68	0.8	5.83e-78	Prudent dietary pattern;
LIHC	cis	rs10508774	1.000	rs1829545	chr10:32906377	G/A	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04530015	chr2:215796436	ABCA12	0.45	7.55	0.38	4.06e-13	Neuroblastoma;
LIHC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.34	6.32	0.32	8.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.42	6.39	0.33	5.37e-10	Neutrophil percentage of white cells;
LIHC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg19318889	chr4:1322082	MAEA	0.47	6.51	0.33	2.69e-10	Obesity-related traits;
LIHC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs11645898	0.504	rs79169855	chr16:71950201	A/G	cg03805757	chr16:71968109	PKD1L3	-0.84	-7.96	-0.4	2.51e-14	Blood protein levels;
LIHC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.1	-0.36	7.24e-12	Vitiligo;
LIHC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg26677194	chr12:130822605	PIWIL1	0.5	6.69	0.34	9.05e-11	Menopause (age at onset);
LIHC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.75	-0.5	1.99e-23	Hemoglobin concentration;
LIHC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.68	-10.42	-0.49	2.93e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.44	6.64	0.34	1.26e-10	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg23533926	chr12:111358616	MYL2	-0.33	-6.26	-0.32	1.12e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	1.08	14.26	0.61	1.61e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6429082	0.967	rs704709	chr1:235620964	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	6.43	0.33	4.18e-10	Adiposity;
LIHC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.9	-12.69	-0.57	1.72e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg07082267	chr16:85429035	NA	0.37	6.02	0.31	4.62e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs7937890	0.559	rs6486197	chr11:14529874	C/G	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs882732	1.000	rs882732	chr14:95027722	G/A	cg14866387	chr14:95027382	SERPINA4	-0.42	-6.06	-0.31	3.56e-9	Blood protein levels;
LIHC	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.38	6.47	0.33	3.43e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.27	-0.41	3.05e-15	Gut microbiome composition (summer);
LIHC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.56	-11.21	-0.52	4.82e-25	Blood protein levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13881405	chr9:92220388	GADD45G	0.41	6.34	0.32	7.33e-10	Pancreatic cancer;
LIHC	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.94	-12.35	-0.56	3.3e-29	Obesity-related traits;
LIHC	cis	rs6459788	0.934	rs10807646	chr7:157260294	C/T	cg06271696	chr7:157225062	NA	-0.37	-6.4	-0.33	5.11e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	11.11	0.52	1.05e-24	Monocyte percentage of white cells;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg11877270	chr2:65658583	SPRED2	-0.4	-6.14	-0.32	2.28e-9	Body mass index;
LIHC	trans	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg10208301	chr11:6592745	DNHD1	0.47	6.35	0.32	6.86e-10	Coronary artery calcification;
LIHC	cis	rs7075426	0.669	rs10887608	chr10:88191938	A/G	cg07322936	chr10:88137208	NA	-0.47	-6.09	-0.31	3.1e-9	Migraine without aura;
LIHC	trans	rs3783890	0.887	rs71429791	chr14:93798425	G/A	cg02802420	chr16:69363236	PDF;COG8	0.33	6.44	0.33	4e-10	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12828867	chr5:61708427	IPO11	0.46	6.21	0.32	1.57e-9	Pancreatic cancer;
LIHC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.1	0.31	2.93e-9	Tonsillectomy;
LIHC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.84	-0.43	5.06e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.5	7.82	0.39	6.79e-14	Alzheimer's disease (survival time);
LIHC	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg12698662	chr3:15914712	MIR563	-0.37	-6.75	-0.34	6.25e-11	Mean platelet volume;
LIHC	cis	rs17094222	0.812	rs4919479	chr10:102434147	A/G	cg26540559	chr10:102447443	NA	0.33	6.28	0.32	1.02e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1113500	0.805	rs11185248	chr1:108611001	A/G	cg06207961	chr1:108661230	NA	-0.31	-5.77	-0.3	1.82e-8	Growth-regulated protein alpha levels;
LIHC	trans	rs10411161	0.702	rs10402630	chr19:52384570	G/A	cg22319618	chr22:45562946	NUP50	-0.59	-8.12	-0.4	8.66e-15	Breast cancer;
LIHC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.41	6.17	0.32	1.98e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs7119038	0.818	rs76704408	chr11:118683327	G/T	cg19308663	chr11:118741387	NA	0.39	6.04	0.31	4.11e-9	Sjögren's syndrome;
LIHC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.68	-12.37	-0.56	2.57e-29	Blood protein levels;
LIHC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.46	7.08	0.36	8.47e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	0.91	15.28	0.64	1.49e-40	Testicular germ cell tumor;
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg09417038	chr21:47716443	C21orf57	0.48	7.23	0.36	3.21e-12	Testicular germ cell tumor;
LIHC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg00204512	chr16:28754710	NA	0.4	6.92	0.35	2.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.57	8.71	0.43	1.35e-16	Height;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg02249930	chr10:70166207	RUFY2	-0.58	-6.44	-0.33	4.15e-10	Bronchial neuroendocrine tumor;
LIHC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg27523141	chr10:43048294	ZNF37B	-0.39	-7.0	-0.35	1.35e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs74233809	0.748	rs10786736	chr10:104849116	G/C	cg03493300	chr10:104813866	CNNM2	0.45	5.99	0.31	5.2e-9	Birth weight;
LIHC	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.5	9.09	0.44	7.92e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-7.21	-0.36	3.6e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	0.74	13.0	0.58	1.08e-31	Testicular germ cell tumor;
LIHC	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-7.23	-0.36	3.27e-12	Vitamin D levels;
LIHC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.74	8.13	0.4	7.98e-15	Gut microbiome composition (summer);
LIHC	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg24112000	chr20:60950667	NA	0.45	7.05	0.36	9.99e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.81	13.54	0.59	9.55e-34	Aortic root size;
LIHC	cis	rs34540877	1.000	rs34767952	chr19:33122517	G/A	cg22980127	chr19:33182716	NUDT19	1.03	6.83	0.35	3.95e-11	Red cell distribution width;
LIHC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.54	7.93	0.39	3.14e-14	Longevity;Endometriosis;
LIHC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg14558114	chr2:88469736	THNSL2	-0.37	-5.8	-0.3	1.49e-8	Response to metformin (IC50);
LIHC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	0.93	6.55	0.33	2.08e-10	Height;
LIHC	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.39	0.41	1.3e-15	Eotaxin levels;
LIHC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Blood protein levels;
LIHC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.38	6.13	0.31	2.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.8	-14.12	-0.61	5.69e-36	Body mass index;
LIHC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.83	10.69	0.5	3.38e-23	Cognitive function;
LIHC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg14067834	chr17:29058358	SUZ12P	0.64	6.53	0.33	2.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg13319975	chr6:146136371	FBXO30	0.37	6.01	0.31	4.88e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg26874164	chr19:58962979	ZNF324B	0.44	6.05	0.31	3.86e-9	Uric acid clearance;
LIHC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.63	0.56	2.89e-30	Alzheimer's disease;
LIHC	trans	rs9914544	0.564	rs11548434	chr17:18761508	G/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.69e-10	Educational attainment (years of education);
LIHC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.06	-0.31	3.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.77	12.14	0.55	1.93e-28	Corneal astigmatism;
LIHC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.72	0.34	7.68e-11	Renal cell carcinoma;
LIHC	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg04592579	chr7:75616294	TMEM120A	0.36	6.17	0.32	1.89e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg27432699	chr2:27873401	GPN1	-0.6	-8.67	-0.42	1.72e-16	Total body bone mineral density;
LIHC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-6.68	-0.34	9.94e-11	Blood metabolite levels;
LIHC	trans	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.82e-10	Fibrinogen levels;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.42	-5.82	-0.3	1.34e-8	Total body bone mineral density;
LIHC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg18357526	chr6:26021779	HIST1H4A	0.62	8.69	0.43	1.58e-16	Blood metabolite levels;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg13226919	chr1:222919977	FAM177B	0.26	6.29	0.32	9.98e-10	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg15902774	chr15:75289873	SCAMP5	0.46	6.48	0.33	3.27e-10	Blood trace element (Zn levels);
LIHC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.41	-8.12	-0.4	8.53e-15	Urinary metabolites;
LIHC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.46	6.22	0.32	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.0	0.35	1.34e-11	Aortic root size;
LIHC	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-12.25	-0.55	7.7e-29	Coronary artery disease;
LIHC	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.77	-11.79	-0.54	3.68e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.77	12.57	0.56	4.66e-30	Fat distribution (HIV);
LIHC	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.41	-5.8	-0.3	1.5e-8	Tuberculosis;
LIHC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.36	-6.86	-0.35	3.25e-11	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00359868	chr21:40752339	WRB	0.47	6.36	0.33	6.38e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg18252515	chr7:66147081	NA	-0.64	-8.46	-0.42	7.89e-16	Corneal structure;
LIHC	cis	rs74664507	0.527	rs4961501	chr9:16851678	T/G	cg13173848	chr9:16870893	BNC2	0.6	6.55	0.33	2.15e-10	Squamous cell carcinoma;
LIHC	cis	rs797680	0.822	rs7541304	chr1:93757838	T/A	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.87	0.3	1.02e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs11958404	0.932	rs72816540	chr5:157414500	T/C	cg05962755	chr5:157440814	NA	0.86	10.11	0.48	3.51e-21	IgG glycosylation;
LIHC	cis	rs10242455	0.571	rs45527841	chr7:99310965	C/T	cg18809830	chr7:99032528	PTCD1	-0.85	-6.79	-0.34	4.88e-11	Blood metabolite levels;
LIHC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.67	10.0	0.48	8.13e-21	Coronary artery disease;
LIHC	cis	rs735860	0.700	rs209524	chr6:53213226	G/C	cg10236188	chr6:53219634	NA	0.42	7.67	0.38	1.81e-13	Glaucoma;
LIHC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.01e-16	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25080152	chr8:128748155	MYC	0.45	6.25	0.32	1.23e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.12	-0.4	8.27e-15	Alzheimer's disease;
LIHC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.46	6.83	0.35	3.89e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.65	13.83	0.6	7.52e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.48	7.06	0.36	9.58e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.78	15.26	0.64	1.75e-40	Mortality in heart failure;
LIHC	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg18898632	chr2:242989856	NA	-0.57	-7.72	-0.39	1.32e-13	Obesity-related traits;
LIHC	trans	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg21659725	chr3:3221576	CRBN	0.78	12.16	0.55	1.61e-28	Resting heart rate;
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg00656387	chr3:40428638	ENTPD3	0.49	8.35	0.41	1.73e-15	Renal cell carcinoma;
LIHC	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg00012203	chr2:219082015	ARPC2	-0.45	-6.06	-0.31	3.55e-9	Ulcerative colitis;
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg07234388	chr1:156261841	TMEM79	0.52	9.39	0.45	8.5e-19	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05835761	chr10:73648991	NA	0.52	7.8	0.39	7.53e-14	Pancreatic cancer;
LIHC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.61	0.67	7.88e-46	Smoking behavior;
LIHC	cis	rs2070433	0.904	rs11701571	chr21:47963149	A/G	cg12379764	chr21:47803548	PCNT	0.6	8.4	0.41	1.23e-15	Lymphocyte counts;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.6	10.91	0.51	5.64e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	8.72	0.43	1.21e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.67	11.84	0.54	2.54e-27	Colorectal cancer;
LIHC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg18912006	chr12:123335444	HIP1R	-0.64	-7.69	-0.38	1.55e-13	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg10756647	chr7:56101905	PSPH	1.11	13.6	0.59	5.63e-34	Diabetic kidney disease;
LIHC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.5	7.62	0.38	2.58e-13	Diastolic blood pressure;
LIHC	cis	rs6977660	1.000	rs10275322	chr7:19821220	C/T	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.1	-0.75	6.87e-64	Height;
LIHC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.58e-15	Gut microbiome composition (summer);
LIHC	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-6.45	-0.33	3.72e-10	Neuroticism;
LIHC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.92	-16.02	-0.65	1.72e-43	Tonsillectomy;
LIHC	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.78	12.59	0.56	4.07e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	1.11	10.24	0.48	1.26e-21	Gut microbiota (bacterial taxa);
LIHC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11166927	0.703	rs2126128	chr8:140788299	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.36	-5.94	-0.31	7.11e-9	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.62	-10.39	-0.49	3.69e-22	Alcohol dependence;
LIHC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.37	0.41	1.55e-15	Platelet count;
LIHC	trans	rs17464492	0.592	rs2121631	chr8:128386556	A/G	cg09205595	chr7:150782539	AGAP3	-0.38	-6.31	-0.32	8.53e-10	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs2997447	0.706	rs17184898	chr1:26447870	A/T	cg19633962	chr1:26362018	EXTL1	-0.64	-5.88	-0.3	9.64e-9	QRS complex (12-leadsum);
LIHC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg18944383	chr4:111397179	ENPEP	0.34	7.75	0.39	1.03e-13	Height;
LIHC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.36	-0.56	3.02e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg20735989	chr4:730612	PCGF3	-0.67	-8.67	-0.42	1.74e-16	White blood cell count;
LIHC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.32	-7.14	-0.36	5.66e-12	Ulcerative colitis;
LIHC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs11229555	0.645	rs12274866	chr11:58177129	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2834188	1.000	rs1018741	chr21:34686345	G/A	cg14352951	chr21:34696688	IFNAR1	0.47	6.43	0.33	4.24e-10	Narcolepsy;
LIHC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg03037974	chr15:76606532	NA	0.72	13.82	0.6	8.32e-35	Blood metabolite levels;
LIHC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18252515	chr7:66147081	NA	0.42	5.83	0.3	1.31e-8	Aortic root size;
LIHC	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2e-12	Exhaled nitric oxide output;
LIHC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-8.91	-0.43	2.98e-17	IgG glycosylation;
LIHC	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.48	9.69	0.46	8.91e-20	Plateletcrit;Platelet count;
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.11	0.36	6.94e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma (childhood onset);
LIHC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.13	-0.55	2.01e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.45e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs17854409	0.764	rs8114722	chr20:61478492	G/A	cg07645718	chr20:61493192	TCFL5	0.8	6.18	0.32	1.83e-9	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03909902	chr12:108154529	PRDM4	0.52	6.53	0.33	2.43e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.47	-7.08	-0.36	8.16e-12	P wave terminal force;
LIHC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.98	21.26	0.75	1.65e-64	Bone mineral density;
LIHC	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.56	-7.08	-0.36	8.39e-12	Post bronchodilator FEV1;
LIHC	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.42	-6.17	-0.32	1.91e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg17750252	chr2:136567154	LCT	0.35	6.09	0.31	3.09e-9	Mosquito bite size;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01177235	chr9:33265011	SUGT1P1;CHMP5;BAG1	-0.49	-6.51	-0.33	2.72e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.88	18.17	0.7	4.21e-52	Height;
LIHC	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg04359351	chr2:3481828	TTC15	0.3	5.76	0.3	1.88e-8	Neurofibrillary tangles;
LIHC	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg06026331	chr20:60912101	LAMA5	0.66	9.3	0.45	1.77e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.23	-0.52	4.09e-25	Eye color traits;
LIHC	cis	rs17094222	0.812	rs1891915	chr10:102433860	T/C	cg26540559	chr10:102447443	NA	0.33	6.37	0.33	6.18e-10	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16262614	chr3:133464971	TF	-0.28	-6.2	-0.32	1.6e-9	Iron status biomarkers;
LIHC	trans	rs17433710	0.516	rs6689396	chr1:162676698	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-6.31	-0.32	8.52e-10	Dupuytren's disease;
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg03721293	chr16:90014378	DEF8	0.43	7.2	0.36	3.97e-12	Skin colour saturation;
LIHC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg10628098	chr11:65292300	SCYL1	-0.38	-5.94	-0.31	6.94e-9	Bone mineral density;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.71	-10.91	-0.51	5.44e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11628318	0.515	rs1951630	chr14:103076807	A/T	cg12046867	chr14:103022105	NA	-0.38	-5.73	-0.3	2.16e-8	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01947862	chr2:86116624	ST3GAL5	0.49	6.66	0.34	1.12e-10	Pancreatic cancer;
LIHC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.98	0.35	1.52e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	7.24	0.36	2.98e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.62	-9.98	-0.47	9.33e-21	Obesity-related traits;
LIHC	cis	rs655641	0.954	rs497711	chr11:85764875	T/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.16	-0.32	2.03e-9	Platelet count;
LIHC	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08893839	chr5:154027129	NA	-0.51	-6.92	-0.35	2.19e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	6.68	0.34	9.52e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg16486109	chr11:613632	IRF7	0.59	6.24	0.32	1.29e-9	Systemic lupus erythematosus;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.49	-0.38	5.88e-13	Lymphocyte counts;
LIHC	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg26138937	chr11:71823887	C11orf51	1.34	10.79	0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs4742903	0.967	rs10991120	chr9:106909051	C/T	cg14250997	chr9:106856677	SMC2	0.38	6.75	0.34	6.24e-11	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs11014306	1.000	rs4504964	chr10:25208507	G/A	cg19056833	chr13:114749079	RASA3	0.65	6.19	0.32	1.69e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.4	-6.46	-0.33	3.71e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.54	-9.51	-0.46	3.57e-19	Systemic lupus erythematosus;
LIHC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-6.79	-0.34	4.94e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg17372223	chr3:52568218	NT5DC2	0.36	5.84	0.3	1.2e-8	Cognitive function;
LIHC	cis	rs7780883	0.821	rs1978181	chr7:77061342	A/G	cg12876866	chr7:77025528	PION	-0.48	-5.83	-0.3	1.29e-8	Cervical cancer;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07677032	chr17:61819896	STRADA	0.41	5.84	0.3	1.19e-8	Prudent dietary pattern;
LIHC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.66	10.04	0.48	6.06e-21	Body mass index;
LIHC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.81	0.39	7.22e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.49	-8.31	-0.41	2.32e-15	Schizophrenia;
LIHC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.31	5.71	0.3	2.44e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.66	-12.77	-0.57	8.28e-31	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7716219	0.572	rs62359607	chr5:54877085	T/C	cg14753740	chr5:54468940	CDC20B;MIR449C	0.43	6.11	0.31	2.73e-9	Height;
LIHC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg03476357	chr21:30257390	N6AMT1	-0.53	-7.8	-0.39	7.35e-14	Cognitive test performance;
LIHC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg16586182	chr3:47516702	SCAP	-0.58	-11.36	-0.52	1.41e-25	Colorectal cancer;
LIHC	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.17	9.23	0.45	2.83e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8053891	0.507	rs34150651	chr16:72028112	G/A	cg01557791	chr16:72042693	DHODH	-0.39	-6.17	-0.32	1.91e-9	Coronary artery disease;
LIHC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.49	8.8	0.43	7.1e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.48	7.76	0.39	9.76e-14	Lung cancer;
LIHC	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs847851	0.617	rs9368844	chr6:34978030	T/C	cg13137465	chr6:34857473	ANKS1A	0.67	7.59	0.38	2.97e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2479724	0.776	rs12523672	chr6:41749692	T/G	cg17623882	chr6:41773611	USP49	0.56	8.72	0.43	1.23e-16	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.49	-0.42	6.42e-16	Renal cell carcinoma;
LIHC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	12.32	0.55	3.98e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.49	7.6	0.38	2.92e-13	Diastolic blood pressure;
LIHC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-19.97	-0.73	2.33e-59	Coronary artery disease;
LIHC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.38	6.28	0.32	1.05e-9	Height;
LIHC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.47	-6.03	-0.31	4.32e-9	Pancreatic cancer;
LIHC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.12	0.31	2.57e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg22676075	chr6:135203613	NA	0.39	6.18	0.32	1.78e-9	Red blood cell count;
LIHC	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg01028140	chr2:1542097	TPO	-0.45	-7.16	-0.36	4.98e-12	IgG glycosylation;
LIHC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.93	14.87	0.63	6.14e-39	Metabolic syndrome;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09060823	chr12:56862504	SPRYD4	0.45	6.7	0.34	8.8e-11	Cognitive function;
LIHC	cis	rs11786130	1.000	rs10956401	chr8:129002419	G/A	cg01765152	chr8:129005526	PVT1	-0.32	-7.02	-0.35	1.19e-11	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19717773	chr7:2847554	GNA12	0.39	7.57	0.38	3.49e-13	Loneliness (linear analysis);
LIHC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.81	11.61	0.53	1.75e-26	Coronary artery disease;
LIHC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.44	5.77	0.3	1.82e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.65	0.38	2e-13	Bipolar disorder;
LIHC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.3	-6.77	-0.34	5.75e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs79387448	0.745	rs72993760	chr2:103151704	G/A	cg09003973	chr2:102972529	NA	0.85	7.47	0.37	6.82e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs10847980	0.590	rs58182048	chr12:123287708	C/T	cg25930673	chr12:123319894	HIP1R	1.09	11.71	0.53	7.59e-27	Adiponectin levels;
LIHC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.93	-12.35	-0.56	3.04e-29	Schizophrenia;
LIHC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg00012203	chr2:219082015	ARPC2	-0.75	-10.45	-0.49	2.23e-22	Colorectal cancer;
LIHC	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg15123519	chr2:136567270	LCT	-0.37	-5.92	-0.3	7.82e-9	Corneal structure;
LIHC	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.46	6.33	0.32	7.73e-10	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02250992	chr12:125348168	SCARB1	-0.55	-6.16	-0.32	2.1e-9	Systolic blood pressure;
LIHC	cis	rs2016586	0.929	rs5750161	chr22:36113236	T/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.3	-0.32	9.32e-10	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09766628	chr17:4634728	MED11	0.46	6.54	0.33	2.2e-10	Lung function (FEV1/FVC);
LIHC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg04315214	chr1:2043799	PRKCZ	0.46	7.19	0.36	4.04e-12	Height;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12016809	chr21:47604291	C21orf56	-0.47	-7.23	-0.36	3.19e-12	Testicular germ cell tumor;
LIHC	cis	rs2901460	0.509	rs12463815	chr2:62087165	C/T	cg02183531	chr2:62113199	CCT4	-0.4	-5.88	-0.3	1e-8	Mean corpuscular volume;
LIHC	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.05	23.55	0.79	1.5e-73	Platelet distribution width;
LIHC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.46e-8	Menopause (age at onset);
LIHC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.26	-17.06	-0.68	1.18e-47	Diabetic kidney disease;
LIHC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	5.97	0.31	6.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.71	10.72	0.5	2.51e-23	Aortic root size;
LIHC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.27	-0.32	1.11e-9	Longevity;
LIHC	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.37	12.26	0.55	6.87e-29	Uric acid levels;
LIHC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg22633049	chr21:46681294	NA	-0.36	-6.35	-0.32	7.05e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2279817	0.863	rs35871295	chr1:17984468	A/T	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.14	-0.36	5.63e-12	Neuroticism;
LIHC	cis	rs36051895	0.559	rs7874495	chr9:5209804	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-10.38	-0.49	3.95e-22	Pediatric autoimmune diseases;
LIHC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.51	7.28	0.37	2.3e-12	Body mass index;
LIHC	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg03999872	chr20:62272968	STMN3	0.41	6.08	0.31	3.29e-9	Prostate cancer;
LIHC	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg13753209	chr17:57696993	CLTC	0.76	12.01	0.54	5.85e-28	Hemoglobin concentration;
LIHC	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.61	-0.42	2.75e-16	Exhaled nitric oxide output;
LIHC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.39e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.64	10.12	0.48	3.23e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.39	-6.5	-0.33	2.85e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs6977660	1.000	rs13237667	chr7:19820288	G/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.77	11.41	0.53	8.73e-26	Menarche (age at onset);
LIHC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg12365402	chr11:9010492	NRIP3	-0.3	-8.05	-0.4	1.35e-14	Hemoglobin concentration;
LIHC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.07	0.55	3.41e-28	Motion sickness;
LIHC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.35	0.37	1.47e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	11.88	0.54	1.7e-27	Height;
LIHC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.58	0.53	2.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.77	0.34	5.77e-11	Tonsillectomy;
LIHC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.41	7.01	0.35	1.26e-11	Alcohol dependence;
LIHC	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg14593290	chr7:50529359	DDC	0.62	9.78	0.47	4.43e-20	Malaria;
LIHC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	0.83	7.02	0.36	1.18e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25212763	chr13:113532716	ATP11A	-0.38	-6.07	-0.31	3.36e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26714650	chr12:56694279	CS	-1.21	-14.74	-0.62	1.97e-38	Psoriasis vulgaris;
LIHC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.77	-0.34	5.45e-11	Bipolar disorder;
LIHC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2834188	1.000	rs1018742	chr21:34686381	A/G	cg14352951	chr21:34696688	IFNAR1	0.47	6.43	0.33	4.24e-10	Narcolepsy;
LIHC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-19.18	-0.72	3.53e-56	Coronary artery disease;
LIHC	cis	rs16858210	0.647	rs12107414	chr3:183574548	G/C	cg25686905	chr3:183603175	PARL	-0.52	-9.26	-0.45	2.28e-18	Menopause (age at onset);
LIHC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.74	6.37	0.33	6.03e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.91	-10.69	-0.5	3.46e-23	Vitiligo;
LIHC	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00938859	chr5:1591904	SDHAP3	0.55	6.64	0.34	1.22e-10	Breast cancer;
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	10.02	0.48	6.9e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.7	0.38	1.46e-13	Systemic lupus erythematosus;
LIHC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.28	-0.32	1.02e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.53	9.01	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.61	-0.59	5.27e-34	Coffee consumption (cups per day);
LIHC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.64	6.54	0.33	2.31e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg06565975	chr8:143823917	SLURP1	0.34	6.69	0.34	8.92e-11	Urinary tract infection frequency;
LIHC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg02353165	chr6:42928485	GNMT	0.6	8.96	0.44	2.21e-17	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01889020	chr15:66545863	MEGF11	0.5	6.36	0.33	6.43e-10	Hepatitis;
LIHC	cis	rs11098699	0.821	rs904712	chr4:124225337	T/C	cg09941581	chr4:124220074	SPATA5	0.33	6.57	0.33	1.86e-10	Mosquito bite size;
LIHC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21545522	chr1:205238299	TMCC2	0.37	7.1	0.36	7.18e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.78	-0.34	5.4e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.82	10.25	0.48	1.14e-21	Bladder cancer;
LIHC	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.85	-0.54	2.3e-27	Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08219700	chr8:58056026	NA	0.46	5.78	0.3	1.71e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.94	17.57	0.69	1.1e-49	Menopause (age at onset);
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.97	-0.35	1.59e-11	Total body bone mineral density;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg11563264	chr4:190862026	FRG1	-0.45	-6.14	-0.32	2.33e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.5	7.9	0.39	3.97e-14	Adiposity;
LIHC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-5.87	-0.3	1.05e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.73	10.37	0.49	4.46e-22	Menarche (age at onset);
LIHC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.6	9.11	0.44	7.04e-18	Menopause (age at onset);
LIHC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.37	-5.99	-0.31	5.18e-9	Menarche (age at onset);
LIHC	cis	rs36051895	0.623	rs11506293	chr9:5257430	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-9.79	-0.47	3.96e-20	Pediatric autoimmune diseases;
LIHC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.7	-9.81	-0.47	3.58e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.73	-9.55	-0.46	2.53e-19	Body mass index;
LIHC	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.91	0.3	8.09e-9	Educational attainment;
LIHC	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg12560992	chr17:57184187	TRIM37	0.65	8.51	0.42	5.46e-16	Vitamin D levels;
LIHC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	10.53	0.49	1.22e-22	Total cholesterol levels;
LIHC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.37	5.77	0.3	1.81e-8	Coronary artery disease;
LIHC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.29	0.32	9.49e-10	Menarche (age at onset);
LIHC	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg18367735	chr17:79674897	NA	0.69	7.75	0.39	1.09e-13	Dental caries;
LIHC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.53	8.19	0.4	5.29e-15	Bronchopulmonary dysplasia;
LIHC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.62	-8.23	-0.41	3.95e-15	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.72	-9.81	-0.47	3.52e-20	Asthma;
LIHC	cis	rs11671005	0.532	rs35983901	chr19:59016790	G/A	cg25952890	chr19:58913133	NA	0.64	6.47	0.33	3.4e-10	Mean platelet volume;
LIHC	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg18898632	chr2:242989856	NA	-0.47	-6.44	-0.33	4e-10	Obesity-related traits;
LIHC	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.37	6.02	0.31	4.57e-9	Prostate cancer;
LIHC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg16586182	chr3:47516702	SCAP	-0.5	-8.93	-0.43	2.66e-17	Colorectal cancer;
LIHC	cis	rs16828019	0.929	rs35883594	chr1:41744093	A/G	cg03962019	chr1:41807865	NA	0.52	7.28	0.37	2.27e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg25182066	chr10:30743637	MAP3K8	-0.62	-10.02	-0.48	7.09e-21	Inflammatory bowel disease;
LIHC	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.58	7.79	0.39	8.18e-14	Economic and political preferences (feminism/equality);
LIHC	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg15051332	chr6:41514432	FOXP4	0.41	5.72	0.3	2.32e-8	Prostate cancer;
LIHC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.32	5.9	0.3	8.85e-9	Height;
LIHC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg18016565	chr1:150552671	MCL1	-0.5	-10.31	-0.49	6.9e-22	Tonsillectomy;
LIHC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20135002	chr11:47629003	NA	0.55	9.32	0.45	1.45e-18	Subjective well-being;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10994681	chr11:31672091	ELP4	0.3	6.39	0.33	5.52e-10	Cognitive function;
LIHC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.77	12.14	0.55	1.93e-28	Corneal astigmatism;
LIHC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.99	-16.89	-0.67	5.71e-47	Tonsillectomy;
LIHC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.69	12.11	0.55	2.57e-28	Colorectal cancer;
LIHC	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.71	0.43	1.36e-16	Exhaled nitric oxide levels;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.83	0.43	5.67e-17	Prudent dietary pattern;
LIHC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.41	-7.2	-0.36	3.76e-12	Diastolic blood pressure;
LIHC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.59	0.42	3.03e-16	Motion sickness;
LIHC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.48	7.61	0.38	2.76e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-7.23	-0.36	3.25e-12	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.6	9.92	0.47	1.5e-20	Eosinophilic esophagitis;
LIHC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9596863	0.898	rs8000553	chr13:54344501	C/T	ch.13.53330881F	chr13:54432880	NA	0.45	6.1	0.31	2.94e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg25364880	chr3:44379878	C3orf23	0.57	7.89	0.39	4.26e-14	Depressive symptoms;
LIHC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.43	5.92	0.3	7.89e-9	Height;
LIHC	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.81	-0.39	6.91e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.47	6.4	0.33	5.13e-10	High light scatter reticulocyte count;
LIHC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg13395646	chr4:1353034	KIAA1530	0.41	6.49	0.33	2.97e-10	Obesity-related traits;
LIHC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.24	-0.32	1.29e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs3784262	0.839	rs1579744	chr15:58229523	G/A	cg12031962	chr15:58353849	ALDH1A2	0.31	6.04	0.31	4.1e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg09182678	chr22:50328711	NA	-0.43	-6.09	-0.31	2.99e-9	Schizophrenia;
LIHC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.51	6.51	0.33	2.63e-10	Menarche (age at onset);
LIHC	trans	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.34	6.94	0.35	1.97e-11	Renal cell carcinoma;
LIHC	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg07150772	chr14:90864620	CALM1	-0.42	-5.89	-0.3	9.19e-9	Gut microbiota (bacterial taxa);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13546538	chr9:111754815	CTNNAL1	0.46	6.07	0.31	3.47e-9	Hepatitis;
LIHC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.46	4.67e-19	Bipolar disorder;
LIHC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.34	7.41	0.37	1.02e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.08e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.56	0.33	2.03e-10	Hemoglobin concentration;
LIHC	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.62	10.47	0.49	1.93e-22	Recombination rate (males);
LIHC	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.4	5.81	0.3	1.42e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.27	0.37	2.49e-12	Diabetic kidney disease;
LIHC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.46	7.68	0.38	1.7e-13	Response to temozolomide;
LIHC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg18478394	chr8:109455254	TTC35	0.44	7.57	0.38	3.6e-13	Dupuytren's disease;
LIHC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.6	7.67	0.38	1.83e-13	Morning vs. evening chronotype;
LIHC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	9.57	0.46	2.3e-19	Tonsillectomy;
LIHC	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg16724585	chr3:197361211	NA	-0.46	-6.44	-0.33	4.17e-10	Pancreatic cancer;
LIHC	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.46	-6.79	-0.34	5.11e-11	Dermatomyositis;
LIHC	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.64	10.7	0.5	3.05e-23	Coronary artery disease;
LIHC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.59	8.37	0.41	1.45e-15	Blood metabolite levels;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.92	0.57	2.17e-31	Prudent dietary pattern;
LIHC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.75	-0.3	1.95e-8	IgG glycosylation;
LIHC	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.26	-0.32	1.17e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.34	-0.59	5.58e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.48	7.75	0.39	1.08e-13	Schizophrenia;
LIHC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg27523141	chr10:43048294	ZNF37B	-0.36	-6.27	-0.32	1.11e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12079745	0.590	rs9628661	chr1:169310283	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-7.08	-0.36	8.09e-12	QT interval;
LIHC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.75	14.5	0.62	1.82e-37	Mortality in heart failure;
LIHC	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	7.21	0.36	3.66e-12	Blood protein levels;
LIHC	trans	rs3858145	0.588	rs7081284	chr10:70044792	C/G	cg04882175	chr6:131122610	NA	-0.51	-6.09	-0.31	3.06e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.53	-8.98	-0.44	1.91e-17	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-10.89	-0.51	6.6e-24	Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-8.3	-0.41	2.49e-15	Gut microbiome composition (summer);
LIHC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.66	0.56	2.23e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.01	0.44	1.52e-17	IgG glycosylation;
LIHC	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	8.28	0.41	2.85e-15	Testicular germ cell tumor;
LIHC	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	0.92	6.78	0.34	5.32e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.44	6.02	0.31	4.43e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.72	13.23	0.58	1.55e-32	Prudent dietary pattern;
LIHC	cis	rs17776563	0.922	rs12148331	chr15:89110081	C/T	cg05013243	chr15:89149849	MIR1179	0.47	7.74	0.39	1.09e-13	Thyroid hormone levels;
LIHC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg21395723	chr22:39101663	GTPBP1	0.37	5.83	0.3	1.27e-8	Menopause (age at onset);
LIHC	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.64	-0.42	2.13e-16	Brugada syndrome;
LIHC	cis	rs17253792	0.545	rs34136598	chr14:56013238	C/T	cg01858014	chr14:56050164	KTN1	-0.63	-5.87	-0.3	1.03e-8	Putamen volume;
LIHC	cis	rs6539247	0.583	rs880297	chr12:106443266	C/T	cg20883310	chr12:106464547	NUAK1	0.45	7.43	0.37	8.62e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.46	8.51	0.42	5.64e-16	Testicular germ cell tumor;
LIHC	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.57	0.33	1.84e-10	Body mass index;
LIHC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.66e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.41	-7.99	-0.4	2.08e-14	Type 1 diabetes;
LIHC	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.46	8.19	0.41	5.13e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs9900497	0.504	rs2228100	chr17:19642952	C/G	cg22552966	chr17:19620595	SLC47A2	0.48	10.29	0.49	8.23e-22	Response to paliperidone in schizophrenia (CGI-S score);
LIHC	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.55	5.73	0.3	2.22e-8	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.81	-12.53	-0.56	6.69e-30	Total body bone mineral density;
LIHC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg19680672	chr10:131412579	MGMT	-0.46	-7.01	-0.35	1.29e-11	Response to temozolomide;
LIHC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.54	-7.81	-0.39	7.12e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.12	0.55	2.3e-28	Prudent dietary pattern;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21792150	chr3:101567884	NFKBIZ	-0.58	-6.65	-0.34	1.19e-10	Systolic blood pressure;
LIHC	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.41	-7.39	-0.37	1.16e-12	Hepatocellular carcinoma;
LIHC	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.36	5.78	0.3	1.69e-8	Body mass index;
LIHC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.55	-0.33	2.08e-10	Response to antipsychotic treatment;
LIHC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.67	-11.9	-0.54	1.46e-27	Menopause (age at onset);
LIHC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.33	-5.73	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.68	-8.54	-0.42	4.61e-16	Asthma;
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.47	5.86	0.3	1.12e-8	Alzheimer's disease;
LIHC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.59	10.13	0.48	2.84e-21	Height;
LIHC	cis	rs8072100	0.905	rs8078686	chr17:45735706	T/C	cg08085267	chr17:45401833	C17orf57	0.57	8.28	0.41	2.76e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.58	-9.1	-0.44	7.58e-18	Height;
LIHC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.81	13.14	0.58	3.16e-32	Colorectal cancer;
LIHC	trans	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg10756647	chr7:56101905	PSPH	1.08	13.46	0.59	2e-33	Diabetic kidney disease;
LIHC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg22633049	chr21:46681294	NA	0.37	6.41	0.33	4.78e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.47	7.68	0.38	1.69e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3770081	1.000	rs6750765	chr2:86300308	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.86	-8.52	-0.42	5.12e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg19680672	chr10:131412579	MGMT	-0.39	-5.98	-0.31	5.5e-9	Response to temozolomide;
LIHC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-14.86	-0.63	6.92e-39	Gut microbiome composition (summer);
LIHC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.52	6.83	0.35	3.85e-11	Osteoporosis;
LIHC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg07424592	chr7:64974309	NA	0.84	9.67	0.46	1.07e-19	Diabetic kidney disease;
LIHC	cis	rs77637988	0.631	rs7573316	chr2:48600692	C/T	cg00032884	chr2:48540671	FOXN2	0.41	6.43	0.33	4.38e-10	Joint mobility (Beighton score);
LIHC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg03146154	chr1:46216737	IPP	-0.37	-5.9	-0.3	8.66e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.49	7.28	0.37	2.36e-12	Thyroid stimulating hormone;
LIHC	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.57	-8.21	-0.41	4.51e-15	Body mass index;
LIHC	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00949670	chr12:120967105	COQ5	0.49	6.72	0.34	7.53e-11	Pancreatic cancer;
LIHC	cis	rs2274273	1.000	rs10149435	chr14:55627489	C/T	cg01864836	chr14:55583639	NA	-0.35	-6.01	-0.31	4.68e-9	Protein biomarker;
LIHC	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.45	8.74	0.43	1.07e-16	Testicular germ cell tumor;
LIHC	cis	rs6604026	0.555	rs3790450	chr1:93091065	A/G	cg13858687	chr1:93297071	RPL5	0.6	5.71	0.3	2.41e-8	Multiple sclerosis;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.93	13.32	0.58	6.93e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10838708	1.000	rs10838708	chr11:47441513	G/A	cg20135002	chr11:47629003	NA	-0.44	-7.06	-0.36	9.38e-12	Height;
LIHC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26734620	chr12:56694298	CS	-0.89	-9.01	-0.44	1.45e-17	Psoriasis vulgaris;
LIHC	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.53	10.14	0.48	2.59e-21	Prostate cancer;
LIHC	trans	rs6489882	0.763	rs1859329	chr12:113376452	C/T	cg10175203	chr3:128143634	NA	0.38	6.17	0.32	1.96e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-11.86	-0.54	2.03e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	0.79	11.36	0.52	1.43e-25	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.34	0.52	1.64e-25	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.47	0.33	3.39e-10	Mean platelet volume;
LIHC	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.56	6.49	0.33	2.99e-10	Primary sclerosing cholangitis;
LIHC	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.45	8.08	0.4	1.1e-14	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.94	17.91	0.7	4.65e-51	Menopause (age at onset);
LIHC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.94	0.44	2.53e-17	Motion sickness;
LIHC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	9.5	0.46	3.84e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.42	-0.33	4.61e-10	Total body bone mineral density;
LIHC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.52	0.53	3.51e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs77861329	1.000	rs13314125	chr3:52115398	C/T	cg08692210	chr3:52188851	WDR51A	0.82	7.39	0.37	1.17e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.96	0.44	2.19e-17	Lung cancer;
LIHC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.6	-6.96	-0.35	1.73e-11	Bipolar disorder;
LIHC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg20607798	chr8:58055168	NA	0.45	6.35	0.32	6.93e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.46	-6.45	-0.33	3.88e-10	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.59	7.44	0.37	8.3e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.15	0.32	2.16e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.63	-9.0	-0.44	1.58e-17	White matter hyperintensity burden;
LIHC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.49	-7.54	-0.38	4.38e-13	Corneal astigmatism;
LIHC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.52	6.02	0.31	4.48e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.4	8.1	0.4	9.51e-15	Renal cell carcinoma;
LIHC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	11.37	0.52	1.21e-25	Monocyte percentage of white cells;
LIHC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg25742201	chr17:35306863	AATF	-0.54	-6.11	-0.31	2.67e-9	Bronchial neuroendocrine tumor;
LIHC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.57	0.38	3.5e-13	Morning vs. evening chronotype;
LIHC	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.76	0.34	5.81e-11	Bipolar disorder;
LIHC	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg19000871	chr14:103996768	TRMT61A	-0.38	-6.16	-0.32	2.08e-9	Coronary artery disease;
LIHC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.94	0.39	2.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs6968419	0.802	rs6978849	chr7:115809732	A/C	cg00405060	chr16:4016306	ADCY9	-0.43	-6.53	-0.33	2.38e-10	Intraocular pressure;
LIHC	trans	rs4714291	0.674	rs3008837	chr6:40046725	C/T	cg02267698	chr19:7991119	CTXN1	-0.4	-6.74	-0.34	6.89e-11	Strep throat;
LIHC	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.7	-12.48	-0.56	9.96e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.38	-0.37	1.23e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.83	0.43	5.71e-17	Exhaled nitric oxide levels;
LIHC	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg16558253	chr16:72132732	DHX38	-0.38	-6.49	-0.33	2.98e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.35	14.76	0.62	1.75e-38	Eosinophil percentage of granulocytes;
LIHC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.17	-0.78	4.65e-72	Height;
LIHC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.26	-7.16	-0.36	4.97e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-13.51	-0.59	1.28e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.31	6.16	0.32	2.01e-9	Cancer;
LIHC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	8.18	0.4	5.51e-15	Coronary artery disease;
LIHC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.76	-13.02	-0.58	9.81e-32	Platelet distribution width;
LIHC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7508	0.511	rs208025	chr8:17878170	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-6.02	-0.31	4.45e-9	Atrial fibrillation;
LIHC	cis	rs4500972	1	rs4500972	chr2:73767897	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.86	-0.35	3.31e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.77	11.39	0.52	1.06e-25	Response to antineoplastic agents;
LIHC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-6.8	-0.34	4.76e-11	Electroencephalogram traits;
LIHC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.39	-0.33	5.44e-10	Menarche (age at onset);
LIHC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.36	-7.23	-0.36	3.18e-12	Renal cell carcinoma;
LIHC	cis	rs904251	0.523	rs9349039	chr6:37480392	A/G	cg08126542	chr6:37504118	NA	-0.37	-6.33	-0.32	7.78e-10	Cognitive performance;
LIHC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.44	7.1	0.36	7.26e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.31	-5.73	-0.3	2.24e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14405528	chr22:47372700	TBC1D22A	-0.43	-6.08	-0.31	3.3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.6	10.25	0.48	1.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08905662	chr7:102789948	NAPEPLD	0.46	6.86	0.35	3.25e-11	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08413153	chr17:46185283	SNX11	0.42	6.26	0.32	1.14e-9	Pancreatic cancer;
LIHC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.58	-10.29	-0.49	8.43e-22	Platelet distribution width;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15877295	chr7:138915876	UBN2	0.4	6.33	0.32	7.84e-10	Cognitive function;
LIHC	cis	rs6545883	0.859	rs7561672	chr2:61519094	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.25	-0.37	2.76e-12	Tuberculosis;
LIHC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg15123519	chr2:136567270	LCT	0.39	7.22	0.36	3.36e-12	Mosquito bite size;
LIHC	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.88	-0.35	2.94e-11	Total cholesterol levels;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.63	9.7	0.46	8.21e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.48	-8.6	-0.42	2.96e-16	Asthma;
LIHC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.75e-12	IgG glycosylation;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.45	0.33	3.9e-10	Renal cell carcinoma;
LIHC	cis	rs17152411	0.895	rs7079153	chr10:126587146	C/G	cg07906193	chr10:126599966	NA	0.42	6.62	0.34	1.35e-10	Height;
LIHC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg00277334	chr10:82204260	NA	-0.52	-6.32	-0.32	8.01e-10	Post bronchodilator FEV1;
LIHC	trans	rs259842	0.800	rs6725456	chr2:180718419	C/T	cg03498402	chr16:67219437	EXOC3L	0.43	6.1	0.31	2.9e-9	Blood protein levels;
LIHC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.46	-7.54	-0.38	4.22e-13	Alzheimer's disease (late onset);
LIHC	cis	rs7487075	0.558	rs4768692	chr12:46639635	T/C	cg15584813	chr12:47219626	SLC38A4	0.32	5.94	0.31	7.04e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.75	12.43	0.56	1.57e-29	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.39e-8	Menopause (age at onset);
LIHC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-6.97	-0.35	1.66e-11	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	8.33	0.41	1.94e-15	HIV-1 control;
LIHC	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.45	-0.37	7.93e-13	Tuberculosis;
LIHC	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.76	6.49	0.33	3.05e-10	Blood protein levels;
LIHC	cis	rs249954	0.512	rs35633	chr16:23704005	C/T	cg05131483	chr16:23706242	ERN2	0.36	5.88	0.3	9.92e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.57	9.39	0.45	9.01e-19	Corneal astigmatism;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17024643	chr1:214725274	PTPN14	-0.41	-6.6	-0.34	1.55e-10	Triglycerides;
LIHC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.46	6.43	0.33	4.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg25214090	chr10:38739885	LOC399744	-0.4	-6.39	-0.33	5.31e-10	Diastolic blood pressure;
LIHC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	8.29	0.41	2.69e-15	Lymphocyte counts;
LIHC	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.53	9.91	0.47	1.63e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.46	8.09	0.4	1.04e-14	IgG glycosylation;
LIHC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg13607699	chr17:42295918	UBTF	-0.44	-6.9	-0.35	2.6e-11	Total body bone mineral density;
LIHC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.87	0.35	3.05e-11	Heart rate;
LIHC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-8.53	-0.42	4.93e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.36	-5.86	-0.3	1.08e-8	Platelet distribution width;
LIHC	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.79	14.15	0.61	4.33e-36	Response to bleomycin (chromatid breaks);
LIHC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	10.4	0.49	3.38e-22	Lung cancer;
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.36	0.33	6.49e-10	Obesity-related traits;
LIHC	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg12253828	chr6:101329408	ASCC3	-0.41	-6.43	-0.33	4.31e-10	Neuroticism;
LIHC	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.76	13.09	0.58	5.09e-32	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Blood protein levels;
LIHC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4742903	0.935	rs1413341	chr9:106973013	C/T	cg14250997	chr9:106856677	SMC2	0.34	5.73	0.3	2.19e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12516959	chr21:47718080	NA	-0.4	-6.43	-0.33	4.34e-10	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg00280220	chr17:61926910	NA	0.43	6.77	0.34	5.78e-11	Prudent dietary pattern;
LIHC	cis	rs903552	1.000	rs11634912	chr15:102005510	A/G	cg25677261	chr15:102009856	PCSK6	-0.46	-6.22	-0.32	1.44e-9	Diabetic kidney disease;
LIHC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.55	7.12	0.36	6.57e-12	Parkinson's disease;
LIHC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg15848620	chr12:58087721	OS9	-0.54	-7.35	-0.37	1.46e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7534824	0.625	rs61780285	chr1:101357627	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	7.07	0.36	8.81e-12	Refractive astigmatism;
LIHC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg04719120	chr6:96025338	MANEA	0.51	6.51	0.33	2.66e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	1.04	17.54	0.69	1.36e-49	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.47	7.96	0.4	2.63e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg09990169	chr2:241835740	C2orf54	-0.65	-10.47	-0.49	1.97e-22	Urinary metabolites;
LIHC	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs7503807	0.837	rs9915667	chr17:78754340	A/G	cg09596252	chr17:78655493	RPTOR	-0.42	-7.46	-0.37	7.43e-13	Obesity;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg00091569	chr3:40428383	ENTPD3	-0.33	-5.81	-0.3	1.41e-8	Renal cell carcinoma;
LIHC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg15123519	chr2:136567270	LCT	0.36	7.19	0.36	3.99e-12	Mosquito bite size;
LIHC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg24296786	chr1:45957014	TESK2	-0.49	-7.14	-0.36	5.74e-12	Platelet count;
LIHC	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.78	-0.5	1.56e-23	Inflammatory bowel disease;
LIHC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.72	-11.71	-0.53	7.35e-27	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.41	6.92	0.35	2.26e-11	Blood metabolite levels;
LIHC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-0.6	-6.89	-0.35	2.76e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.48	6.48	0.33	3.12e-10	Monobrow;
LIHC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.61	-5.9	-0.3	8.79e-9	Vitiligo;
LIHC	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.1.1079286F	chr1:33292969	S100PBP	-0.45	-7.38	-0.37	1.23e-12	Hepatitis;
LIHC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg24879335	chr3:133465180	TF	0.28	6.31	0.32	8.88e-10	Iron status biomarkers;
LIHC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.28	0.52	2.74e-25	Motion sickness;
LIHC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	6.89	0.35	2.61e-11	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21581312	chr15:35529473	LOC723972	0.4	6.09	0.31	2.99e-9	Bilirubin levels;
LIHC	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-7.43	-0.37	8.53e-13	Post bronchodilator FEV1;
LIHC	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg25356066	chr3:128598488	ACAD9	0.54	7.21	0.36	3.62e-12	IgG glycosylation;
LIHC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.35	-6.39	-0.33	5.29e-10	Aortic root size;
LIHC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.84e-10	Diabetic kidney disease;
LIHC	cis	rs10838687	0.736	rs2633083	chr11:47249420	T/C	cg25783544	chr11:47291846	MADD	-0.47	-5.9	-0.3	8.83e-9	Proinsulin levels;
LIHC	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.39	-6.41	-0.33	4.74e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg03859395	chr2:55845619	SMEK2	0.72	11.75	0.54	5.37e-27	Metabolic syndrome;
LIHC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.67	-11.63	-0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs1982963	0.585	rs61971558	chr14:52496024	G/A	cg10843707	chr14:52510701	NID2	0.42	6.15	0.32	2.13e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10959786	chr13:74708124	KLF12	0.4	6.36	0.33	6.37e-10	Cognitive function;
LIHC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg08847533	chr14:75593920	NEK9	-0.37	-6.24	-0.32	1.3e-9	Caffeine consumption;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg20295408	chr7:1910781	MAD1L1	-0.53	-7.58	-0.38	3.37e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.53	9.99	0.48	8.91e-21	Testicular germ cell tumor;
LIHC	cis	rs735860	0.726	rs209518	chr6:53208016	C/A	cg10236188	chr6:53219634	NA	0.42	7.83	0.39	6.26e-14	Glaucoma;
LIHC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.43	6.77	0.34	5.57e-11	Height;
LIHC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	10.16	0.48	2.37e-21	Coronary artery disease;
LIHC	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs797680	0.789	rs797671	chr1:93700363	C/A	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg07884673	chr3:53033167	SFMBT1	0.91	6.6	0.34	1.58e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg11764359	chr7:65958608	NA	0.59	6.26	0.32	1.18e-9	Diabetic kidney disease;
LIHC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.41	7.01	0.35	1.24e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.5	-0.33	2.91e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs9921222	0.597	rs3848369	chr16:415078	C/T	cg12437481	chr16:420112	MRPL28	-0.75	-11.92	-0.54	1.24e-27	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	0.46	6.11	0.31	2.76e-9	Pulmonary function decline;
LIHC	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-9.62	-0.46	1.5e-19	Colorectal cancer;
LIHC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.44	-0.49	2.4e-22	Chronic sinus infection;
LIHC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg02297831	chr4:17616191	MED28	0.46	7.18	0.36	4.31e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg16684958	chr7:75615977	POR	0.39	6.1	0.31	2.8e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.84	0.35	3.59e-11	Bipolar disorder;
LIHC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	0.9	16.17	0.66	4.42e-44	Bone mineral density;
LIHC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.68	0.57	1.87e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.78	12.83	0.57	5.04e-31	Oral cavity cancer;
LIHC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg15208524	chr1:10270712	KIF1B	0.41	6.16	0.32	2.03e-9	Hepatocellular carcinoma;
LIHC	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	0.65	6.47	0.33	3.43e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.82	16.98	0.68	2.5e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.5	-0.33	2.8e-10	Longevity;Endometriosis;
LIHC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.46	-6.25	-0.32	1.24e-9	Iron status biomarkers;
LIHC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	12.11	0.55	2.53e-28	High light scatter reticulocyte count;
LIHC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.88	0.39	4.37e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.48	7.68	0.38	1.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07390141	chr15:93427738	NA	-0.36	-6.96	-0.35	1.73e-11	Cognitive function;
LIHC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	1.06	14.25	0.61	1.67e-36	Body mass index;
LIHC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.4	-17.27	-0.68	1.77e-48	Breast cancer;
LIHC	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.92e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg24203234	chr3:128598194	ACAD9	0.45	6.27	0.32	1.07e-9	IgG glycosylation;
LIHC	trans	rs11644362	0.576	rs35738878	chr16:12981880	T/C	cg14384093	chr9:111878565	C9orf5	-0.29	-6.21	-0.32	1.5e-9	Positive affect;Subjective well-being;
LIHC	trans	rs12960119	0.536	rs12956263	chr18:23726864	C/A	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.35	7.01	0.35	1.25e-11	Renal cell carcinoma;
LIHC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.62e-15	Motion sickness;
LIHC	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.97	10.53	0.49	1.19e-22	IgG glycosylation;
LIHC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.25	0.55	7.29e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.54	9.49	0.46	4.03e-19	Systemic lupus erythematosus;
LIHC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.8	-0.3	1.51e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	ch.11.42038R	chr11:967971	AP2A2	0.53	9.58	0.46	2.01e-19	Alzheimer's disease (late onset);
LIHC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01200585	chr1:228362443	C1orf69	0.41	6.26	0.32	1.14e-9	Diastolic blood pressure;
LIHC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.26e-27	Motion sickness;
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg14440974	chr22:39074834	NA	-0.36	-6.06	-0.31	3.56e-9	Menopause (age at onset);
LIHC	trans	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg25214090	chr10:38739885	LOC399744	-0.39	-6.37	-0.33	6.04e-10	Diastolic blood pressure;
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.8	-9.85	-0.47	2.56e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.52	-7.95	-0.39	2.75e-14	Systemic lupus erythematosus;
LIHC	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21640587	chr11:117668038	DSCAML1	0.55	6.9	0.35	2.58e-11	Myopia;
LIHC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.06	-0.4	1.29e-14	Body mass index;
LIHC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.13	-0.31	2.37e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.63	8.6	0.42	2.86e-16	Coronary artery disease;
LIHC	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.36	-6.6	-0.34	1.6e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg12798992	chr6:167411361	FGFR1OP	0.53	8.66	0.42	1.87e-16	Crohn's disease;
LIHC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.35	0.56	3.25e-29	Schizophrenia;
LIHC	trans	rs9914544	0.564	rs4334348	chr17:18787004	G/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.57	-0.33	1.82e-10	Educational attainment (years of education);
LIHC	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg17708016	chr12:54321992	NA	0.41	7.26	0.37	2.68e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg09904177	chr6:26538194	HMGN4	0.46	7.9	0.39	3.78e-14	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg13628971	chr7:2884303	GNA12	0.48	6.88	0.35	2.94e-11	Height;
LIHC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.57e-15	Bladder cancer;
LIHC	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.49	7.64	0.38	2.23e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-7.39	-0.37	1.12e-12	Mortality in heart failure;
LIHC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg18016565	chr1:150552671	MCL1	0.5	9.62	0.46	1.5700000000000001e-19	Tonsillectomy;
LIHC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	1.03	18.02	0.7	1.6e-51	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.58	7.5	0.38	5.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.95	11.14	0.52	8.8e-25	Triglycerides;
LIHC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.06	0.58	6.4e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.34	-0.37	1.61e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.96e-16	Prudent dietary pattern;
LIHC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	7.99	0.4	2.09e-14	Menarche (age at onset);
LIHC	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.37	-0.33	5.95e-10	Fear of minor pain;
LIHC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg02297831	chr4:17616191	MED28	-0.49	-7.76	-0.39	9.88e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.83	-0.3	1.25e-8	Blood metabolite levels;
LIHC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.42	7.9	0.39	3.73e-14	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.31	2.9e-9	Arsenic metabolism;
LIHC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	8.52	0.42	5.2e-16	Platelet count;
LIHC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.04	0.36	1.04e-11	Self-reported allergy;
LIHC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	0.88	5.96	0.31	6.31e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.29	6.4	0.33	5.23e-10	Pulmonary function;
LIHC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.85	0.65	8.24e-43	Electrocardiographic conduction measures;
LIHC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.6	8.77	0.43	8.32e-17	Emphysema distribution in smoking;
LIHC	cis	rs600626	0.578	rs11821808	chr11:75451187	C/T	cg24262691	chr11:75473276	NA	0.43	6.5	0.33	2.9e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.56	7.5	0.38	5.66e-13	Eotaxin levels;
LIHC	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg02070205	chr10:30722105	MAP3K8	-0.43	-5.79	-0.3	1.63e-8	Inflammatory bowel disease;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.68	6.93	0.35	2.11e-11	Alzheimer's disease;
LIHC	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg20129853	chr10:51489980	NA	-0.39	-8.56	-0.42	3.77e-16	Prostate-specific antigen levels;
LIHC	cis	rs10481151	1.000	rs10481151	chr8:124831834	A/G	cg02993010	chr8:124780839	FAM91A1	-0.5	-5.73	-0.3	2.23e-8	Cognitive performance;
LIHC	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.6	10.0	0.48	7.8e-21	HDL cholesterol;
LIHC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg03959625	chr15:84868606	LOC388152	0.47	6.6	0.34	1.52e-10	Schizophrenia;
LIHC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.63	9.44	0.45	5.85e-19	Testicular germ cell tumor;
LIHC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg12751644	chr20:60527061	NA	-0.36	-5.94	-0.31	7.17e-9	Body mass index;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23788167	chr9:74979561	ZFAND5	0.43	6.13	0.31	2.46e-9	Hepatitis;
LIHC	cis	rs8049040	1.000	rs7197127	chr16:71473836	G/A	cg06353428	chr16:71660113	MARVELD3	-0.61	-6.28	-0.32	1.02e-9	Blood protein levels;
LIHC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16262614	chr3:133464971	TF	0.28	6.39	0.33	5.36e-10	Iron status biomarkers;
LIHC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-13.99	-0.6	1.73e-35	Headache;
LIHC	trans	rs12960119	0.536	rs34503500	chr18:23728195	G/A	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.49	-8.19	-0.4	5.31e-15	Cocaine dependence;
LIHC	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.76	-11.46	-0.53	5.97e-26	Personality dimensions;
LIHC	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.83	8.9	0.43	3.24e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.69	9.95	0.47	1.14e-20	Lymphocyte counts;
LIHC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	5.85	0.3	1.18e-8	Bipolar disorder;
LIHC	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.01e-22	Hypertriglyceridemia;
LIHC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.55	-7.25	-0.37	2.79e-12	Gut microbiome composition (summer);
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg14709524	chr16:89940631	TCF25	0.58	7.44	0.37	8.46e-13	Skin colour saturation;
LIHC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-8.44	-0.42	9.09e-16	Morning vs. evening chronotype;
LIHC	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.19	-5.99	-0.31	5.28e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	0.75	8.5	0.42	5.86e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.54	-8.54	-0.42	4.4e-16	Morning vs. evening chronotype;
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.55	-0.33	2.06e-10	Schizophrenia;
LIHC	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11693508	chr17:37793320	STARD3	-0.67	-7.26	-0.37	2.66e-12	Bipolar disorder;
LIHC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.18e-41	Mortality in heart failure;
LIHC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.38	-6.15	-0.32	2.17e-9	Response to temozolomide;
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.8	-9.7	-0.46	8.04e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg07382826	chr16:28625726	SULT1A1	0.5	7.73	0.39	1.19e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08585897	chr16:75680535	KARS;TERF2IP	0.5	6.35	0.32	6.93e-10	Systolic blood pressure;
LIHC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.91	-7.79	-0.39	7.8500000000000006e-14	IgG glycosylation;
LIHC	cis	rs10838687	0.669	rs830084	chr11:47251652	T/C	cg25783544	chr11:47291846	MADD	-0.47	-5.92	-0.3	7.95e-9	Proinsulin levels;
LIHC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.47	6.74	0.34	6.6e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg02290350	chr8:58132656	NA	0.48	9.33	0.45	1.38e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.53	7.99	0.4	2.04e-14	Gout;
LIHC	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg05714579	chr10:131428358	MGMT	0.39	6.25	0.32	1.19e-9	Response to temozolomide;
LIHC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.17	0.52	6.87e-25	Platelet count;
LIHC	trans	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg19894588	chr14:64061835	NA	-0.46	-7.4	-0.37	1.08e-12	Fat distribution (HIV);
LIHC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.28	-0.32	1.02e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23374814	chr5:72292757	FCHO2	-0.43	-6.25	-0.32	1.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4908768	0.501	rs2016084	chr1:8613418	C/A	cg20416874	chr1:8611966	RERE	-0.68	-14.82	-0.63	1.02e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	4.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	1.11	12.08	0.55	3.25e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.35	-0.45	1.18e-18	Schizophrenia;
LIHC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.61	0.46	1.59e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.37e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.23	0.36	3.26e-12	Parkinson's disease;
LIHC	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.56	6.27	0.32	1.06e-9	Hip geometry;
LIHC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.59	6.84	0.35	3.71e-11	Iron status biomarkers;
LIHC	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg20991723	chr1:152506922	NA	0.53	8.76	0.43	9.49e-17	Hair morphology;
LIHC	cis	rs12464559	0.522	rs6749823	chr2:152565055	C/T	cg01189475	chr2:152685088	ARL5A	0.68	8.08	0.4	1.15e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.68	10.39	0.49	3.8e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg12863693	chr15:85201151	NMB	-0.48	-7.04	-0.36	1.03e-11	Schizophrenia;
LIHC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs72843506	0.722	rs78041331	chr17:20208846	G/T	cg12065943	chr17:19881925	AKAP10	-0.38	-6.26	-0.32	1.15e-9	Schizophrenia;
LIHC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.66	12.02	0.54	5.37e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg26441486	chr22:50317300	CRELD2	0.38	6.22	0.32	1.45e-9	Schizophrenia;
LIHC	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.37	-9.03	-0.44	1.29e-17	Resting heart rate;
LIHC	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg16088116	chr21:44841560	SIK1	-0.39	-6.09	-0.31	2.98e-9	Pulmonary function;
LIHC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09717979	chr4:103790325	UBE2D3;CISD2	0.46	6.13	0.31	2.38e-9	Lung function (FEV1/FVC);
LIHC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.79	0.34	4.99e-11	Rheumatoid arthritis;
LIHC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.03e-20	Schizophrenia;
LIHC	trans	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg05791018	chr13:19965014	NA	-0.28	-6.16	-0.32	2e-9	Schizophrenia;
LIHC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg08392591	chr16:89556376	ANKRD11	0.41	6.14	0.32	2.31e-9	Multiple myeloma (IgH translocation);
LIHC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.35	-0.78	8.99e-73	Height;
LIHC	cis	rs2637266	0.703	rs2583062	chr10:78558472	T/C	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.96e-9	Pulmonary function;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.25	0.32	1.24e-9	Prudent dietary pattern;
LIHC	trans	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.46	0.33	3.67e-10	Aortic root size;
LIHC	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg10820045	chr2:198174542	NA	-0.58	-9.64	-0.46	1.29e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs922107	0.738	rs1031684	chr1:90051225	G/A	cg15422784	chr1:90023713	LRRC8B	-0.49	-7.77	-0.39	9.02e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.54	0.38	4.18e-13	Neuroticism;
LIHC	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.5	-7.32	-0.37	1.83e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.73	-11.96	-0.54	8.79e-28	Body mass index;
LIHC	cis	rs12986413	0.874	rs4806832	chr19:2184652	C/T	cg09261902	chr19:2140048	AP3D1	0.41	6.95	0.35	1.89e-11	Height;
LIHC	trans	rs783540	0.967	rs783526	chr15:83285795	C/A	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.7	-0.34	8.41e-11	Schizophrenia;
LIHC	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.37	10.08	0.48	4.43e-21	Weight;
LIHC	cis	rs12928939	0.520	rs8051760	chr16:71811098	C/A	cg00732059	chr16:71740210	PHLPP2	-0.33	-5.8	-0.3	1.51e-8	Post bronchodilator FEV1;
LIHC	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.49	8.7	0.43	1.43e-16	Male sexual orientation;
LIHC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs1190552	0.846	rs11160683	chr14:102933347	A/G	cg10241871	chr14:102965420	TECPR2	-0.5	-7.88	-0.39	4.31e-14	Blood protein levels;
LIHC	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.78	14.4	0.61	4.42e-37	Longevity;
LIHC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg12046867	chr14:103022105	NA	-0.59	-8.58	-0.42	3.25e-16	Platelet count;
LIHC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg03983715	chr16:68378420	PRMT7	-0.51	-5.95	-0.31	6.56e-9	Schizophrenia;
LIHC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.39	0.41	1.28e-15	Lung cancer;
LIHC	cis	rs7897654	0.571	rs12764049	chr10:104634956	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-7.62	-0.38	2.53e-13	Schizophrenia;
LIHC	cis	rs7116495	1.000	rs493065	chr11:71796929	T/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg17706124	chr4:3521738	LRPAP1	0.41	6.22	0.32	1.43e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg18129178	chr5:148520854	ABLIM3	-0.42	-6.85	-0.35	3.39e-11	Breast cancer;
LIHC	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.56	-6.4	-0.33	5.19e-10	Ulcerative colitis;
LIHC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	7.72	0.39	1.27e-13	Lung cancer in ever smokers;
LIHC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.48	7.67	0.38	1.82e-13	Birth weight;
LIHC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg07424592	chr7:64974309	NA	0.79	9.2	0.45	3.71e-18	Diabetic kidney disease;
LIHC	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.87	0.3	1.04e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.85	7.8	0.39	7.47e-14	LDL cholesterol;
LIHC	cis	rs151997	1.000	rs42415	chr5:50207442	T/A	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25916527	chr5:72292534	FCHO2	0.42	6.33	0.32	7.67e-10	Longevity;
LIHC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg18887096	chr2:219472410	PLCD4	0.38	6.54	0.33	2.21e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20922377	chr15:48623205	DUT	-0.56	-6.54	-0.33	2.25e-10	Systolic blood pressure;
LIHC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.04	0.44	1.15e-17	Eosinophil percentage of white cells;
LIHC	cis	rs6449957	0.639	rs251397	chr5:67508511	A/G	cg23036683	chr5:67512108	NA	0.52	7.62	0.38	2.54e-13	Cleft lip with or without cleft palate;
LIHC	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	8.22	0.41	4.16e-15	Eotaxin levels;
LIHC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.69	-9.7	-0.46	7.94e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.67	9.54	0.46	2.87e-19	Coronary artery disease;
LIHC	trans	rs6108011	0.659	rs6108023	chr20:7590607	C/T	cg13422339	chr21:47602486	C21orf56	0.52	6.08	0.31	3.29e-9	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	18.13	0.7	5.95e-52	Tonsillectomy;
LIHC	cis	rs11031096	0.678	rs11031184	chr11:4186192	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-5.88	-0.3	1e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs4714291	0.802	rs911818	chr6:39988816	C/A	cg02267698	chr19:7991119	CTXN1	-0.39	-6.49	-0.33	3.07e-10	Strep throat;
LIHC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.59	-10.14	-0.48	2.77e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-0.6	-8.68	-0.43	1.59e-16	Obesity-related traits;
LIHC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.6	-9.2	-0.45	3.53e-18	Uric acid clearance;
LIHC	cis	rs2073499	0.935	rs2236939	chr3:50243510	G/T	cg03645007	chr3:50255295	SLC38A3	0.5	6.89	0.35	2.66e-11	Schizophrenia;
LIHC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg19635926	chr16:89946313	TCF25	0.48	6.17	0.32	1.97e-9	Skin colour saturation;
LIHC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.43	0.53	7.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.8	13.25	0.58	1.3e-32	Oral cavity cancer;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	7.2	0.36	3.94e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.36	-0.33	6.6e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.53	-9.39	-0.45	8.92e-19	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-12.66	-0.56	2.1000000000000002e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.52	6.2	0.32	1.65e-9	Retinal vascular caliber;
LIHC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.48	7.74	0.39	1.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17784606	chr1:1190558	UBE2J2	0.42	6.07	0.31	3.35e-9	Longevity;
LIHC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.64	10.05	0.48	5.31e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.71	-10.93	-0.51	4.6e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26933736	chr6:83902998	RWDD2A;PGM3	0.41	6.12	0.31	2.54e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg13152130	chr6:118910203	C6orf204	-0.61	-6.58	-0.34	1.81e-10	Renal cell carcinoma;
LIHC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-7.04	-0.36	1.04e-11	Neutrophil percentage of white cells;
LIHC	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.49	8.84	0.43	5.32e-17	Reticulocyte count;
LIHC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-0.87	-11.05	-0.51	1.83e-24	Blood pressure (smoking interaction);
LIHC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-6.19	-0.32	1.73e-9	Testicular germ cell tumor;
LIHC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.88	-0.3	9.96e-9	Personality dimensions;
LIHC	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg24069376	chr3:38537580	EXOG	0.43	7.98	0.4	2.27e-14	Electrocardiographic conduction measures;
LIHC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg21466736	chr12:48725269	NA	0.63	9.14	0.44	5.64e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.82	-0.3	1.39e-8	Personality dimensions;
LIHC	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.39	0.33	5.43e-10	Hepatocellular carcinoma;
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg07424592	chr7:64974309	NA	0.44	6.73	0.34	7.36e-11	Calcium levels;
LIHC	cis	rs11671005	0.610	rs8103813	chr19:59072684	C/T	cg25952890	chr19:58913133	NA	0.68	6.92	0.35	2.18e-11	Mean platelet volume;
LIHC	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.34	7.26	0.37	2.67e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	0.39	6.26	0.32	1.12e-9	Coronary artery disease;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.61	-8.66	-0.42	1.84e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	8.23	0.41	3.87e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.71	-12.6	-0.56	3.73e-30	Refractive error;
LIHC	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	0.8	11.43	0.53	7.64e-26	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4689642	0.709	rs4689656	chr4:7225745	A/G	cg21353189	chr4:7228343	SORCS2	0.37	6.39	0.33	5.58e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.43	7.33	0.37	1.64e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2637030	0.559	rs372006	chr5:52875859	T/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.37	0.33	5.95e-10	Platelet count;
LIHC	trans	rs7714584	1.000	rs11950957	chr5:150253914	G/A	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg23435118	chr5:141488016	NDFIP1	-0.44	-6.12	-0.31	2.61e-9	Crohn's disease;
LIHC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.01e-12	HDL cholesterol levels;
LIHC	cis	rs11971779	0.680	rs7785903	chr7:139122643	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	9.73	0.47	6.52e-20	Diisocyanate-induced asthma;
LIHC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.57	9.28	0.45	1.92e-18	Lymphocyte counts;
LIHC	cis	rs17106184	1.000	rs59128535	chr1:51340401	T/A	cg07174182	chr1:51127561	FAF1	-0.62	-6.95	-0.35	1.89e-11	Type 2 diabetes;
LIHC	cis	rs6604026	0.555	rs1415296	chr1:93090476	C/G	cg13858687	chr1:93297071	RPL5	-0.61	-5.95	-0.31	6.7e-9	Multiple sclerosis;
LIHC	cis	rs35160687	0.623	rs7569654	chr2:86478022	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	6.31	0.32	8.7e-10	Night sleep phenotypes;
LIHC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08392591	chr16:89556376	ANKRD11	0.42	6.2	0.32	1.6e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg15691649	chr6:25882328	NA	-0.53	-7.65	-0.38	2.07e-13	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04277470	chr13:41707106	KBTBD6	0.41	6.19	0.32	1.69e-9	Cognitive function;
LIHC	cis	rs3106136	0.743	rs6847767	chr4:95276951	C/G	cg11021082	chr4:95130006	SMARCAD1	0.39	6.62	0.34	1.41e-10	Capecitabine sensitivity;
LIHC	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.43	6.46	0.33	3.7e-10	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg05917732	chr6:152623304	SYNE1	0.54	6.59	0.34	1.64e-10	Glycated hemoglobin levels;
LIHC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.87	-0.35	2.98e-11	Coronary artery disease;
LIHC	cis	rs28830936	0.934	rs4923915	chr15:42119606	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.08	-0.31	3.26e-9	Diastolic blood pressure;
LIHC	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.71	-8.07	-0.4	1.17e-14	Vitiligo;
LIHC	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.79	0.47	3.95e-20	Alzheimer's disease;
LIHC	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg14146966	chr2:61757674	XPO1	0.48	8.27	0.41	3.07e-15	Tuberculosis;
LIHC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.96	18.31	0.7	1.11e-52	Ewing sarcoma;
LIHC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.32	-0.45	1.53e-18	Schizophrenia;
LIHC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-8.33	-0.41	1.99e-15	Blood protein levels;
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg00800038	chr16:89945340	TCF25	-0.67	-10.78	-0.5	1.64e-23	Skin colour saturation;
LIHC	trans	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg15993354	chr19:12912590	PRDX2	0.51	6.15	0.32	2.11e-9	Inflammatory bowel disease;
LIHC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02187348	chr16:89574699	SPG7	0.5	7.41	0.37	1.01e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs12446632	0.941	rs11640942	chr16:19919946	C/T	cg24307341	chr1:21904484	ALPL	0.54	6.08	0.31	3.13e-9	BMI in smokers;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index (joint analysis main effects and smoking interaction);Waist circumference;Obesity;Body mass index in physically active individuals;Childhood body mass index;Menarche (age at onset);Body mass index;Hip circumference;
LIHC	cis	rs2108622	0.683	rs6512067	chr19:15982951	G/T	cg13772218	chr19:15982569	NA	0.34	7.17	0.36	4.74e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.45	9.93e-19	Bipolar disorder;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg26709693	chr4:1305780	MAEA	0.41	6.19	0.32	1.72e-9	Longevity;
LIHC	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.47	-7.65	-0.38	2.01e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.42	5.91	0.3	8.15e-9	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00280220	chr17:61926910	NA	0.42	6.83	0.35	3.97e-11	Prudent dietary pattern;
LIHC	cis	rs8078723	0.705	rs8065443	chr17:38208940	A/G	cg17467752	chr17:38218738	THRA	-0.84	-16.47	-0.67	2.7e-45	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg07424592	chr7:64974309	NA	0.84	9.64	0.46	1.3e-19	Diabetic kidney disease;
LIHC	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.5	6.03	0.31	4.19e-9	Serum sulfate level;
LIHC	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg12940439	chr1:67600707	NA	-0.35	-6.17	-0.32	1.94e-9	Psoriasis;
LIHC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.32	-6.97	-0.35	1.66e-11	Longevity;
LIHC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.49	9.89	0.47	1.92e-20	Tonsillectomy;
LIHC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.37	-0.33	5.99e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.39	-6.07	-0.31	3.43e-9	Lung cancer;
LIHC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.49	0.59	1.48e-33	Cognitive test performance;
LIHC	cis	rs12611088	0.602	rs2599455	chr19:44025235	T/A	cg13740135	chr19:44006432	PHLDB3	-0.41	-6.03	-0.31	4.21e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.51e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2304069	0.909	rs8073	chr5:149362400	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.92	-11.65	-0.53	1.17e-26	HIV-1 control;
LIHC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.56	-12.18	-0.55	1.37e-28	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.38	6.15	0.32	2.21e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg10820045	chr2:198174542	NA	0.47	7.1	0.36	7.21e-12	Dermatomyositis;
LIHC	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.49	6.03	0.31	4.23e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs3853824	0.965	rs4793834	chr17:54903662	C/T	cg13675837	chr17:54910204	DGKE	0.41	5.9	0.3	8.85e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg26338869	chr17:61819248	STRADA	0.53	7.15	0.36	5.36e-12	Height;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.27	0.32	1.08e-9	Renal cell carcinoma;
LIHC	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg05110241	chr16:68378359	PRMT7	-0.62	-7.07	-0.36	9e-12	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04413644	chr1:9242184	NA	0.41	6.14	0.32	2.27e-9	Migraine with aura;
LIHC	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg07423050	chr13:99094983	FARP1	-0.36	-5.96	-0.31	6.24e-9	Longevity;
LIHC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21467203	chr3:49911342	NA	0.42	7.39	0.37	1.14e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.43	6.57	0.33	1.93e-10	Body mass index;Social communication problems;
LIHC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.6	0.34	1.61e-10	Hemoglobin concentration;
LIHC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.63	-8.86	-0.43	4.45e-17	Blood metabolite levels;
LIHC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.51	7.09	0.36	7.53e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg03146154	chr1:46216737	IPP	-0.45	-7.12	-0.36	6.42e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs146671954	1	rs146671954	chr9:136934203	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.49	-0.33	3.06e-10	Red cell distribution width;
LIHC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.47	-7.31	-0.37	1.86e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs831571	0.774	rs254858	chr3:64056255	G/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.46	5.84	0.3	1.2e-8	Type 2 diabetes;
LIHC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-0.87	-9.68	-0.46	9.74e-20	Vitiligo;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.91	0.57	2.57e-31	Prudent dietary pattern;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg01032570	chr8:22224534	SLC39A14	-0.5	-6.06	-0.31	3.52e-9	Preeclampsia;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.65	0.5	4.77e-23	Lymphocyte counts;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg00800038	chr16:89945340	TCF25	-0.66	-10.35	-0.49	5.25e-22	Skin colour saturation;
LIHC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	10.89	0.51	6.48e-24	Cognitive test performance;
LIHC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.8	-7.7	-0.38	1.47e-13	Diabetic retinopathy;
LIHC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.12	0.4	8.61e-15	Lymphocyte counts;
LIHC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.33	0.41	2.02e-15	Lung cancer in ever smokers;
LIHC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-15.05	-0.63	1.24e-39	Refractive error;
LIHC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	trans	rs8113308	0.810	rs8100541	chr19:52449695	A/G	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs3823572	0.542	rs11764961	chr7:133631142	C/A	cg03336402	chr7:133662267	EXOC4	0.47	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.59	-6.21	-0.32	1.53e-9	Systemic lupus erythematosus;
LIHC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.9	0.35	2.49e-11	Diabetic kidney disease;
LIHC	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-5.72	-0.3	2.38e-8	Coronary artery disease;
LIHC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-6.9	-0.35	2.47e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17216904	chr3:57262489	APPL1	0.49	7.14	0.36	5.55e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.58	9.28	0.45	1.95e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.77	9.9	0.47	1.72e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.69	0.43	1.55e-16	Schizophrenia;
LIHC	cis	rs12022452	0.591	rs61781641	chr1:40983084	G/T	cg25568243	chr1:40974465	DEM1	0.46	6.17	0.32	1.91e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg03854865	chr6:26224070	HIST1H3E	0.65	7.31	0.37	1.96e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.5	0.56	8.64e-30	Alzheimer's disease;
LIHC	cis	rs986417	1.000	rs1018531	chr14:60970844	C/T	cg27398547	chr14:60952738	C14orf39	0.85	9.85	0.47	2.61e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg00204748	chr12:29376779	FAR2	0.42	7.83	0.39	6.32e-14	QT interval;
LIHC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06634786	chr22:41940651	POLR3H	0.55	5.99	0.31	5.39e-9	Vitiligo;
LIHC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.57	11.14	0.52	8.29e-25	Mean corpuscular volume;
LIHC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.69	10.84	0.51	9.52e-24	Total body bone mineral density;
LIHC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.32	0.52	1.84e-25	Platelet count;
LIHC	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg04267008	chr7:1944627	MAD1L1	0.5	6.73	0.34	7.34e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.54	8.72	0.43	1.2e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.63	9.81	0.47	3.55e-20	Longevity;Endometriosis;
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.63	-7.22	-0.36	3.43e-12	Alzheimer's disease;
LIHC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02290350	chr8:58132656	NA	0.4	8.44	0.42	9.38e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-6.4	-0.33	4.98e-10	IFN-related cytopenia;
LIHC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21467203	chr3:49911342	NA	-0.41	-7.07	-0.36	9e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.89	0.39	4.21e-14	Tonsillectomy;
LIHC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	8.95	0.44	2.24e-17	Monocyte count;
LIHC	cis	rs8084351	0.577	rs4078161	chr18:50609919	G/T	cg24270629	chr18:50823537	DCC	0.44	6.73	0.34	7.36e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg00091569	chr3:40428383	ENTPD3	0.4	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.39	-0.33	5.32e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-9.92	-0.47	1.55e-20	Morning vs. evening chronotype;
LIHC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.24	-0.36	3.02e-12	Response to antipsychotic treatment;
LIHC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.42	5.79	0.3	1.63e-8	Schizophrenia;
LIHC	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.77	9.41	0.45	7.41e-19	Schizophrenia;
LIHC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.63	-0.46	1.43e-19	Response to antipsychotic treatment;
LIHC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg04310649	chr10:35416472	CREM	-0.45	-6.08	-0.31	3.17e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.72	-0.3	2.3e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.6e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.49	-7.59	-0.38	3.01e-13	Menarche (age at onset);
LIHC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.72	-9.53	-0.46	2.97e-19	Body mass index;
LIHC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg25024717	chr12:54324583	NA	-0.38	-8.15	-0.4	6.74e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.48	10.1	0.48	3.8e-21	White blood cell count (basophil);
LIHC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.6	8.43	0.41	1.01e-15	Aortic root size;
LIHC	cis	rs529866	0.500	rs918739	chr16:11439733	G/T	cg00044050	chr16:11439710	C16orf75	-0.44	-6.1	-0.31	2.95e-9	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.49	7.71	0.38	1.42e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.69	-6.83	-0.35	3.82e-11	Vitiligo;
LIHC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg03013999	chr17:37608204	MED1	-0.34	-5.91	-0.3	8.27e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.49	7.79	0.39	8.07e-14	Blood protein levels;
LIHC	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg14515779	chr1:101123966	NA	-0.66	-12.58	-0.56	4.52e-30	Monocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06747863	chr12:118810789	TAOK3	0.4	6.21	0.32	1.51e-9	Pancreatic cancer;
LIHC	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.31	7.71	0.38	1.36e-13	Gut microbiome composition (winter);
LIHC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg09835421	chr16:68378352	PRMT7	-0.86	-10.1	-0.48	3.72e-21	Schizophrenia;
LIHC	cis	rs10426930	0.752	rs10401934	chr19:5038715	C/T	cg18473234	chr19:5097819	KDM4B	0.56	6.38	0.33	5.87e-10	Monocyte percentage of white cells;
LIHC	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg03934865	chr2:198174659	NA	0.47	6.62	0.34	1.42e-10	Intracranial aneurysm;
LIHC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-8.96	-0.44	2.14e-17	Dental caries;
LIHC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs918629	0.724	rs3734131	chr5:95278679	G/A	cg10483112	chr5:95245456	ELL2	-0.36	-6.1	-0.31	2.87e-9	IgG glycosylation;
LIHC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17554472	chr22:41940697	POLR3H	-0.53	-5.82	-0.3	1.35e-8	Vitiligo;
LIHC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.38	-0.52	1.17e-25	Coronary artery disease;
LIHC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg06096015	chr1:231504339	EGLN1	0.49	9.37	0.45	9.83e-19	Hemoglobin concentration;
LIHC	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.04e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	5.83	0.3	1.28e-8	Coronary artery disease;
LIHC	cis	rs12644436	0.628	rs1381961	chr4:88802458	C/G	cg06891869	chr4:88767617	MEPE	0.42	7.38	0.37	1.22e-12	HIV-1 viral setpoint;
LIHC	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.58e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.53	-8.11	-0.4	8.95e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.37	5.8	0.3	1.55e-8	Testicular germ cell tumor;
LIHC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.41	0.33	4.79e-10	Renal cell carcinoma;
LIHC	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg12034943	chr19:18811790	CRTC1	-0.37	-5.85	-0.3	1.14e-8	Menarche (age at onset);
LIHC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.65	-9.2	-0.45	3.65e-18	Body mass index;
LIHC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.47	6.41	0.33	4.89e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs963731	0.677	rs297122	chr2:39309141	T/C	cg04010122	chr2:39346883	SOS1	-0.71	-5.76	-0.3	1.86e-8	Corticobasal degeneration;
LIHC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.52	0.49	1.29e-22	Total body bone mineral density;
LIHC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.68	10.3	0.49	7.56e-22	Height;
LIHC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.41	6.44	0.33	4.1e-10	Obesity-related traits;
LIHC	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	0.89	10.3	0.49	7.5e-22	Mitochondrial DNA levels;
LIHC	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.35	7.1	0.36	7.41e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LIHC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.49	-9.12	-0.44	6.66e-18	Asthma;
LIHC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.37	7.51	0.38	5.24e-13	Alcohol dependence;
LIHC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	10.33	0.49	6.03e-22	Lung cancer;
LIHC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.58	9.63	0.46	1.45e-19	Body mass index;
LIHC	cis	rs4788570	0.584	rs9934301	chr16:71756845	C/G	cg06353428	chr16:71660113	MARVELD3	1.35	13.66	0.59	3.43e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.81	-0.3	1.42e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.55	-8.99	-0.44	1.76e-17	Longevity;Endometriosis;
LIHC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg05590025	chr7:65112418	INTS4L2	-0.68	-7.63	-0.38	2.29e-13	Diabetic kidney disease;
LIHC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.56	-9.09	-0.44	8.38e-18	Obesity-related traits;
LIHC	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-6.43	-0.33	4.2e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.64	9.08	0.44	8.77e-18	Motion sickness;
LIHC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg00204512	chr16:28754710	NA	0.34	6.26	0.32	1.15e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-8.5	-0.42	6.15e-16	Chronic sinus infection;
LIHC	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.8	0.3	1.49e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.54	-7.87	-0.39	4.7e-14	Menopause (age at onset);
LIHC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.67	9.91	0.47	1.64e-20	Testicular germ cell tumor;
LIHC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg10820045	chr2:198174542	NA	0.53	8.62	0.42	2.58e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.5	-8.01	-0.4	1.77e-14	Colorectal cancer;
LIHC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.66	9.36	0.45	1.09e-18	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11095277	chr14:50151270	POLE2	0.46	6.44	0.33	4.02e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.53	-7.96	-0.4	2.54e-14	Resting heart rate;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg05896524	chr21:47604654	C21orf56	0.46	6.85	0.35	3.4e-11	Testicular germ cell tumor;
LIHC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.44	6.08	0.31	3.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.7	-9.73	-0.47	6.44e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.44	6.75	0.34	6.53e-11	Neutrophil percentage of white cells;
LIHC	cis	rs12986413	0.967	rs4807211	chr19:2174643	G/A	cg09261902	chr19:2140048	AP3D1	0.37	6.38	0.33	5.85e-10	Height;
LIHC	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg22705602	chr4:152727874	NA	0.32	6.86	0.35	3.16e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.87	-0.3	1.01e-8	Axial length;
LIHC	cis	rs6788895	1.000	rs73010967	chr3:150498056	T/C	cg07663535	chr3:150480033	SIAH2	0.55	6.97	0.35	1.69e-11	Breast cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19149222	chr2:74682139	INO80B	0.39	6.66	0.34	1.06e-10	Calcium levels;
LIHC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg11764359	chr7:65958608	NA	0.55	6.53	0.33	2.35e-10	Diabetic kidney disease;
LIHC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.68	7.33	0.37	1.69e-12	Gut microbiome composition (summer);
LIHC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.53	8.09	0.4	1.08e-14	Mean corpuscular volume;
LIHC	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.48	7.05	0.36	9.83e-12	Asthma;
LIHC	cis	rs7116495	0.867	rs506395	chr11:71577953	A/G	cg26138937	chr11:71823887	C11orf51	0.69	6.83	0.35	3.91e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs400736	0.576	rs10864328	chr1:8164456	G/C	cg25007680	chr1:8021821	PARK7	-0.48	-7.22	-0.36	3.31e-12	Response to antidepressants and depression;
LIHC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.27	0.41	3.07e-15	Platelet count;
LIHC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.12	0.4	8.83e-15	Motion sickness;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs1144333	0.655	rs12402347	chr1:76447986	C/T	cg22875332	chr1:76189707	ACADM	0.41	6.01	0.31	4.79e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs11039100	0.850	rs11039168	chr11:5844723	C/A	cg11650987	chr12:10280440	CLEC7A	0.42	6.19	0.32	1.77e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg10932868	chr11:921992	NA	0.36	6.77	0.34	5.46e-11	Alzheimer's disease (late onset);
LIHC	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg26138937	chr11:71823887	C11orf51	-1.32	-10.9	-0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs11673344	0.832	rs77772684	chr19:37546740	C/G	cg27390819	chr19:37464633	NA	-0.51	-6.13	-0.31	2.38e-9	Obesity-related traits;
LIHC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.06	-22.02	-0.77	1.48e-67	Cognitive ability;
LIHC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.17	-0.36	4.59e-12	Reticulocyte count;
LIHC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.46	-6.48	-0.33	3.24e-10	Initial pursuit acceleration;
LIHC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.16	-0.32	1.99e-9	Mean corpuscular volume;
LIHC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.95	-0.47	1.22e-20	Chronic sinus infection;
LIHC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	6.03	0.31	4.36e-9	Putamen volume;
LIHC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.47	6.74	0.34	6.8e-11	Diastolic blood pressure;
LIHC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-0.48	-6.19	-0.32	1.71e-9	Lung cancer;
LIHC	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.7	10.62	0.5	5.74e-23	Metabolite levels;
LIHC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg00142150	chr22:38071001	LGALS1	0.7	11.36	0.52	1.36e-25	Fat distribution (HIV);
LIHC	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.86e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.34	-5.83	-0.3	1.28e-8	Mean platelet volume;
LIHC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.38	5.98	0.31	5.47e-9	Schizophrenia;
LIHC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.44	7.64	0.38	2.17e-13	Monocyte percentage of white cells;
LIHC	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.33	0.52	1.78e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg00101154	chr16:420108	MRPL28	-0.59	-8.9	-0.43	3.38e-17	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.2	-0.75	2.88e-64	Height;
LIHC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg18912006	chr12:123335444	HIP1R	-0.68	-8.05	-0.4	1.37e-14	Schizophrenia;
LIHC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.87	0.54	1.88e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19935506	chr2:242626874	DTYMK	0.38	6.26	0.32	1.15e-9	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04640194	chr12:56754023	STAT2	0.48	7.0	0.35	1.38e-11	Pancreatic cancer;
LIHC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.83	0.35	3.89e-11	Morning vs. evening chronotype;
LIHC	cis	rs11673344	0.800	rs826323	chr19:37504953	G/A	cg27390819	chr19:37464633	NA	-0.5	-6.2	-0.32	1.66e-9	Obesity-related traits;
LIHC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.61e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.9	19.55	0.73	1.18e-57	Blood protein levels;
LIHC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.5	-0.42	6.02e-16	Total cholesterol levels;
LIHC	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.8	14.01	0.6	1.44e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs10916814	0.546	rs10799644	chr1:20903195	G/T	cg24502330	chr1:20914028	CDA	-0.3	-6.6	-0.34	1.55e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	cis	rs2380220	0.808	rs2263180	chr6:95902309	G/A	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.25	-0.36	2.8e-12	Renal cell carcinoma;
LIHC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.77	0.3	1.82e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg26229092	chr10:31816809	ZEB1	-0.3	-7.28	-0.37	2.35e-12	Calcium levels;
LIHC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.54	8.96	0.44	2.14e-17	Blood metabolite levels;
LIHC	cis	rs2274273	0.805	rs8012156	chr14:55552500	G/T	cg01864836	chr14:55583639	NA	-0.36	-6.2	-0.32	1.65e-9	Protein biomarker;
LIHC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.67	-11.63	-0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.02	-19.22	-0.72	2.33e-56	Exhaled nitric oxide output;
LIHC	cis	rs6691722	0.503	rs2274167	chr1:24707296	C/T	cg18323236	chr1:24743029	NIPAL3	0.41	7.44	0.37	8.21e-13	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs4934494	0.727	rs3824607	chr10:91471015	A/G	cg19698084	chr10:91461284	KIF20B	-0.47	-6.35	-0.32	6.84e-10	Red blood cell count;
LIHC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.53	8.41	0.41	1.16e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.51	8.81	0.43	6.64e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.47	-7.56	-0.38	3.74e-13	Diastolic blood pressure;
LIHC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.33	5.87	0.3	1.01e-8	Migraine;Coronary artery disease;
LIHC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs903552	0.866	rs11247296	chr15:102007919	T/C	cg19295451	chr15:102010161	PCSK6	-0.53	-7.51	-0.38	5.04e-13	Diabetic kidney disease;
LIHC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.44	-10.74	-0.5	2.14e-23	Plateletcrit;
LIHC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg03013999	chr17:37608204	MED1	-0.36	-6.01	-0.31	4.76e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08280861	chr8:58055591	NA	0.56	6.2	0.32	1.61e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.65e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.6	8.55	0.42	4.08e-16	Blood metabolite levels;
LIHC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.4	6.69	0.34	9.14e-11	Mean corpuscular volume;
LIHC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.7	-11.06	-0.51	1.61e-24	Inflammatory bowel disease;
LIHC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.75	-10.96	-0.51	3.76e-24	Corneal astigmatism;
LIHC	trans	rs11153056	0.538	rs9386626	chr6:107543195	G/A	cg12119218	chr10:70287206	SLC25A16	-0.44	-6.17	-0.32	1.88e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.44	6.83	0.35	3.94e-11	Methadone dose in opioid dependence;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg04352962	chr1:209979756	IRF6	0.38	5.9	0.3	8.81e-9	Cleft lip with or without cleft palate;
LIHC	trans	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg01596870	chr19:55963115	NA	-0.65	-8.58	-0.42	3.29e-16	Obesity-related traits;
LIHC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	9.08	0.44	8.81e-18	Initial pursuit acceleration;
LIHC	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.55	7.75	0.39	1.06e-13	Neuroticism;
LIHC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.06e-10	Bipolar disorder;
LIHC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.4	-0.59	3.27e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.95	-0.51	4e-24	Hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.33	-18.21	-0.7	2.75e-52	Diabetic kidney disease;
LIHC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	0.85	11.71	0.53	7.62e-27	Skin colour saturation;
LIHC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-9.42	-0.45	7.12e-19	Alzheimer's disease;
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.07	-0.31	3.36e-9	Total body bone mineral density;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12879381	chr18:12326166	TUBB6	0.41	6.06	0.31	3.65e-9	Immature fraction of reticulocytes;
LIHC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.2	0.45	3.58e-18	Eosinophil percentage of white cells;
LIHC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	5.91	0.3	8.46e-9	Bipolar disorder;
LIHC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.34e-11	Aortic root size;
LIHC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.2	0.55	1.13e-28	Cognitive test performance;
LIHC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg14440974	chr22:39074834	NA	-0.38	-6.26	-0.32	1.18e-9	Menopause (age at onset);
LIHC	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg03934865	chr2:198174659	NA	0.48	6.95	0.35	1.88e-11	Dermatomyositis;
LIHC	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.98	-0.35	1.54e-11	Blood pressure;
LIHC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.89	13.63	0.59	4.49e-34	Vitamin D levels;
LIHC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.55	-9.67	-0.46	1.04e-19	Type 2 diabetes;
LIHC	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.34	-6.81	-0.35	4.5e-11	DNA methylation (variation);
LIHC	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg14146966	chr2:61757674	XPO1	0.42	6.92	0.35	2.22e-11	Tuberculosis;
LIHC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg01256987	chr12:42539512	GXYLT1	0.36	5.95	0.31	6.57e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4788570	0.697	rs4788559	chr16:71848959	T/C	cg06353428	chr16:71660113	MARVELD3	1.29	13.29	0.58	8.47e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg02023728	chr11:77925099	USP35	-0.36	-6.36	-0.33	6.49e-10	Alzheimer's disease (survival time);
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.4	-6.93	-0.35	2.06e-11	Renal cell carcinoma;
LIHC	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14154082	chr13:112174009	NA	0.3	6.31	0.32	8.82e-10	Menarche (age at onset);
LIHC	cis	rs243505	0.528	rs6977453	chr7:148474746	A/G	cg09806900	chr7:148480153	CUL1	0.43	6.48	0.33	3.26e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.62	8.98	0.44	1.83e-17	Schizophrenia;
LIHC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.61	6.16	0.32	2.01e-9	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	7.59	0.38	3.15e-13	Menarche (age at onset);
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.54	-0.42	4.55e-16	Total body bone mineral density;
LIHC	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.94	-0.31	6.82e-9	Resting heart rate;
LIHC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.86	0.3	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg14132834	chr19:41945861	ATP5SL	0.41	6.03	0.31	4.15e-9	Height;
LIHC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.42	5.88	0.3	9.66e-9	Aortic root size;
LIHC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.55	-0.5	1.05e-22	Aortic root size;
LIHC	cis	rs10508774	1.000	rs12268559	chr10:32856746	A/C	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.44	7.13	0.36	6.14e-12	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09864156	chr10:70939728	SUPV3L1	0.42	6.68	0.34	9.55e-11	Pancreatic cancer;
LIHC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.48	-7.07	-0.36	8.55e-12	Body mass index;
LIHC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg18912006	chr12:123335444	HIP1R	-0.6	-7.27	-0.37	2.47e-12	Schizophrenia;
LIHC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.99	18.86	0.71	6.53e-55	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11932961	chr4:129733571	PHF17	0.49	6.12	0.31	2.55e-9	Lung function (FEV1/FVC);
LIHC	cis	rs35661897	0.920	rs12476220	chr2:227312391	A/C	cg03426602	chr2:227312417	NA	0.55	5.78	0.3	1.69e-8	Urinary tract infection frequency;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.63	11.96	0.54	8.57e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	0.95	16.21	0.66	2.97e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.44	7.12	0.36	6.38e-12	Total body bone mineral density;
LIHC	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.45	6.67	0.34	1.05e-10	Survival in rectal cancer;
LIHC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.7e-10	Uric acid levels;
LIHC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.71	11.02	0.51	2.19e-24	Corneal astigmatism;
LIHC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.94	17.81	0.69	1.1e-50	Menopause (age at onset);
LIHC	cis	rs3213545	0.676	rs1179998	chr12:121483653	G/A	cg02403541	chr12:121454288	C12orf43	0.45	7.6	0.38	2.87e-13	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.4	6.36	0.33	6.44e-10	Menopause (age at onset);
LIHC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.3	-6.98	-0.35	1.58e-11	Menarche (age at onset);
LIHC	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg23254163	chr1:152506842	NA	0.23	5.91	0.3	8.5e-9	Hair morphology;
LIHC	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.85	-0.39	5.38e-14	Coronary artery disease;
LIHC	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.69	9.28	0.45	1.94e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.53	0.49	1.23e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	6.14	0.32	2.27e-9	IgG glycosylation;
LIHC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.73	-0.3	2.15e-8	Axial length;
LIHC	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.78	-10.28	-0.49	8.57e-22	Body mass index;
LIHC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.58	-9.38	-0.45	9.54e-19	Blood trace element (Zn levels);
LIHC	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.41	7.21	0.36	3.67e-12	Prevalent atrial fibrillation;
LIHC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg18769074	chr3:133464867	TF	0.26	5.78	0.3	1.64e-8	Iron status biomarkers (transferrin levels);
LIHC	cis	rs3736485	0.673	rs8033234	chr15:51956117	T/C	cg08986416	chr15:51914746	DMXL2	-0.43	-5.95	-0.31	6.65e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	17.31	0.68	1.2e-48	Lung cancer in ever smokers;
LIHC	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.51	-0.42	5.57e-16	Blood pressure (smoking interaction);
LIHC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	0.9	6.59	0.34	1.65e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02290350	chr8:58132656	NA	0.36	7.69	0.38	1.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.13	-0.36	6.07e-12	Ulcerative colitis;
LIHC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.06	-0.31	3.56e-9	Ulcerative colitis;
LIHC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Amyotrophic lateral sclerosis (age of onset);
LIHC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg18016565	chr1:150552671	MCL1	0.51	9.67	0.46	1.03e-19	Melanoma;
LIHC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.72	-0.5	2.54e-23	Chronic sinus infection;
LIHC	cis	rs7937890	0.559	rs2597200	chr11:14485600	A/G	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs11760633	0.615	rs62435650	chr7:1823265	A/G	cg23422044	chr7:1970798	MAD1L1	-0.37	-5.79	-0.3	1.59e-8	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.94	0.39	2.95e-14	Motion sickness;
LIHC	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.4	9.54	0.46	2.73e-19	Blood metabolite ratios;
LIHC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg03859395	chr2:55845619	SMEK2	0.86	15.36	0.64	7.32e-41	Metabolic syndrome;
LIHC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.66	7.02	0.35	1.22e-11	Type 2 diabetes;
LIHC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg07706471	chr12:123319906	HIP1R	-0.59	-7.83	-0.39	6.07e-14	Schizophrenia;
LIHC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.58	9.81	0.47	3.55e-20	Childhood ear infection;
LIHC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.81	-0.47	3.57e-20	Response to antipsychotic treatment;
LIHC	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg00277334	chr10:82204260	NA	-0.54	-6.66	-0.34	1.11e-10	Post bronchodilator FEV1;
LIHC	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.31	-7.08	-0.36	8.09e-12	Hip circumference;Waist circumference;
LIHC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.34	5.91	0.3	8.36e-9	Parkinson's disease;
LIHC	cis	rs11971779	0.838	rs4728468	chr7:139122978	G/A	cg07862535	chr7:139043722	LUC7L2	0.6	9.89	0.47	1.85e-20	Diisocyanate-induced asthma;
LIHC	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg14292368	chr19:18793705	CRTC1	-0.42	-5.83	-0.3	1.28e-8	Menarche (age at onset);
LIHC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.65	12.59	0.56	3.92e-30	High light scatter reticulocyte count;
LIHC	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg24112000	chr20:60950667	NA	-0.62	-8.2	-0.41	5.05e-15	Colorectal cancer;
LIHC	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-7.06	-0.36	9.45e-12	Response to bleomycin (chromatid breaks);
LIHC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.75	-11.66	-0.53	1.16e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.26	-6.23	-0.32	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg03517284	chr6:25882590	NA	0.39	5.8	0.3	1.54e-8	Height;
LIHC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.59	9.4	0.45	7.89e-19	Multiple myeloma (IgH translocation);
LIHC	cis	rs385076	0.562	rs1119292	chr2:32045773	C/T	cg02381751	chr2:32503542	YIPF4	-0.41	-5.73	-0.3	2.16e-8	Interleukin-18 levels;
LIHC	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-6.88	-0.35	2.85e-11	Endometrial cancer;
LIHC	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.35	-0.45	1.16e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.07	-0.31	3.42e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.11	-0.31	2.78e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg25039879	chr17:56429692	SUPT4H1	0.75	8.44	0.42	8.81e-16	Cognitive test performance;
LIHC	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg12463550	chr7:65579703	CRCP	0.69	6.62	0.34	1.42e-10	Gout;
LIHC	cis	rs922107	0.738	rs12410381	chr1:90036694	T/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-9.52	-0.46	3.37e-19	Response to antipsychotic treatment;
LIHC	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg12458913	chr13:53173898	NA	0.48	7.89	0.39	4.16e-14	Lewy body disease;
LIHC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10820045	chr2:198174542	NA	-0.6	-10.24	-0.48	1.25e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs965469	0.724	rs6051818	chr20:3362033	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-6.37	-0.33	6.27e-10	IFN-related cytopenia;
LIHC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg14906510	chr12:7781169	NA	0.48	7.36	0.37	1.4e-12	HDL cholesterol levels;
LIHC	cis	rs240764	0.697	rs239194	chr6:101131959	G/A	cg09795085	chr6:101329169	ASCC3	0.45	6.12	0.31	2.5e-9	Neuroticism;
LIHC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	5.97	0.31	5.87e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg13647721	chr17:30228624	UTP6	0.76	8.52	0.42	5.17e-16	Hip circumference adjusted for BMI;
LIHC	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.85	-0.39	5.25e-14	Response to antipsychotic treatment;
LIHC	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.32	6.95	0.35	1.84e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg05185784	chr16:90016020	DEF8	-0.43	-5.87	-0.3	1.04e-8	Skin colour saturation;
LIHC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.87	-0.3	1e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg08345082	chr10:99160200	RRP12	-0.37	-6.13	-0.31	2.37e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs922107	0.738	rs35176344	chr1:90045973	T/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.79	-0.39	8.16e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03517284	chr6:25882590	NA	-0.48	-7.32	-0.37	1.73e-12	Height;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.44	7.89	0.39	4.06e-14	Prudent dietary pattern;
LIHC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.83	14.36	0.61	6.26e-37	Aortic root size;
LIHC	cis	rs2334880	0.836	rs9939458	chr16:71667131	T/G	cg06353428	chr16:71660113	MARVELD3	1.46	15.76	0.65	1.89e-42	Malaria;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17697381	chr3:148709363	GYG1	0.45	6.58	0.34	1.77e-10	Lung function (FEV1/FVC);
LIHC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg24209194	chr3:40518798	ZNF619	0.49	7.37	0.37	1.32e-12	Renal cell carcinoma;
LIHC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.33	-6.7	-0.34	8.75e-11	Platelet distribution width;
LIHC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.5	-7.19	-0.36	4.09e-12	High light scatter reticulocyte count;
LIHC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg14067834	chr17:29058358	SUZ12P	0.65	6.66	0.34	1.08e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg20090690	chr10:134436459	INPP5A	0.44	5.78	0.3	1.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06873352	chr17:61820015	STRADA	0.52	7.56	0.38	3.63e-13	Height;
LIHC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg26566898	chr11:117069891	TAGLN	0.39	6.0	0.31	5.02e-9	Blood protein levels;
LIHC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.33	5.9	0.3	8.66e-9	Schizophrenia;
LIHC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.21	0.32	1.51e-9	Schizophrenia;
LIHC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.62	-8.73	-0.43	1.12e-16	Blood metabolite levels;
LIHC	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg19623624	chr10:135278901	LOC619207	0.42	6.52	0.33	2.55e-10	Systemic lupus erythematosus;
LIHC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.05	0.36	9.76e-12	Morning vs. evening chronotype;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-7.5	-0.38	5.53e-13	Lymphocyte counts;
LIHC	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.49	-6.0	-0.31	5.05e-9	Type 2 diabetes;
LIHC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg09182678	chr22:50328711	NA	-0.41	-6.05	-0.31	3.72e-9	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-10.5	-0.49	1.5e-22	Platelet count;
LIHC	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.27	5.73	0.3	2.18e-8	Pulmonary function;
LIHC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg12064134	chr16:90016061	DEF8	0.36	5.96	0.31	6.14e-9	Squamous cell carcinoma;
LIHC	cis	rs12644436	0.587	rs6853109	chr4:88783555	A/G	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.46	-17.61	-0.69	7.47e-50	Breast cancer;
LIHC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.52	7.37	0.37	1.34e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg25344623	chr2:136566232	LCT	-0.38	-6.48	-0.33	3.11e-10	Corneal structure;
LIHC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.54	-7.7	-0.38	1.5e-13	Body mass index;
LIHC	cis	rs9543976	0.858	rs9530447	chr13:76166802	G/A	cg01531495	chr13:76123901	UCHL3	0.48	5.75	0.3	1.98e-8	Diabetic retinopathy;
LIHC	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg08126542	chr6:37504118	NA	-0.37	-6.27	-0.32	1.09e-9	Cognitive performance;
LIHC	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg01858014	chr14:56050164	KTN1	-0.72	-6.6	-0.34	1.61e-10	Putamen volume;
LIHC	cis	rs7534824	0.582	rs17448827	chr1:101421407	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.23	0.36	3.17e-12	Refractive astigmatism;
LIHC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.93	16.99	0.68	2.33e-47	Parkinson's disease;
LIHC	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.53	8.35	0.41	1.71e-15	Anterior chamber depth;
LIHC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.46	5.85	0.3	1.18e-8	Alzheimer's disease;
LIHC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	16.39	0.66	5.75e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.75	8.56	0.42	3.87e-16	Cognitive function;
LIHC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg21531657	chr3:10005747	TMEM111	0.4	6.14	0.31	2.34e-9	Alzheimer's disease;
LIHC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-9.16	-0.44	4.98e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	6.4	0.33	5.16e-10	Renal cell carcinoma;
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.4	-5.83	-0.3	1.31e-8	Longevity;
LIHC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg19500275	chr17:80737654	TBCD	0.44	6.07	0.31	3.46e-9	Glycated hemoglobin levels;
LIHC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.12	0.4	8.81e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg05163923	chr11:71159392	DHCR7	-0.56	-6.93	-0.35	2.13e-11	Vitamin D levels;
LIHC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.68	-9.33	-0.45	1.41e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.0	0.4	1.99e-14	Tonsillectomy;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18368637	chr6:144179905	LTV1	0.48	6.3	0.32	9.15e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.41	-6.01	-0.31	4.87e-9	Height;
LIHC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs7116495	0.881	rs1573500	chr11:71732790	C/G	cg26138937	chr11:71823887	C11orf51	-0.69	-6.97	-0.35	1.69e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.75	-15.39	-0.64	5.8e-41	Body mass index;
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg04013166	chr16:89971882	TCF25	0.55	7.16	0.36	4.96e-12	Skin colour saturation;
LIHC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.37	-6.13	-0.31	2.37e-9	Educational attainment;
LIHC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.66	-13.27	-0.58	1.05e-32	Glomerular filtration rate (creatinine);
LIHC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.63	9.05	0.44	1.07e-17	Corneal astigmatism;
LIHC	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25632853	chr15:73088954	NA	0.38	6.32	0.32	7.95e-10	Triglyceride levels;
LIHC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.67	11.37	0.52	1.29e-25	Lymphocyte counts;
LIHC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.59	-11.39	-0.52	1.08e-25	Type 2 diabetes;
LIHC	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	7.9	0.39	3.88e-14	Response to antipsychotic treatment;
LIHC	trans	rs7874142	0.616	rs10858280	chr9:137687875	A/G	cg18109838	chr5:88185987	MEF2C	-0.39	-7.74	-0.39	1.15e-13	Longevity;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.58	9.04	0.44	1.19e-17	Uric acid clearance;
LIHC	cis	rs12980942	1.000	rs34945449	chr19:41819824	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.88	0.3	9.67e-9	Coronary artery disease;
LIHC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.37	7.44	0.37	8.21e-13	Ewing sarcoma;
LIHC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.37	5.97	0.31	5.87e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.13	-0.31	2.49e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg14580859	chr9:123691850	NA	0.39	6.78	0.34	5.43e-11	Rheumatoid arthritis;
LIHC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.2	0.64	3.05e-40	Chronic sinus infection;
LIHC	cis	rs240764	0.711	rs240112	chr6:101059253	C/A	cg09795085	chr6:101329169	ASCC3	0.5	6.89	0.35	2.64e-11	Neuroticism;
LIHC	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.36	6.93	0.35	2.05e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.1	0.4	1.01e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.66	8.24	0.41	3.72e-15	Gut microbiome composition (summer);
LIHC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.69	0.43	1.58e-16	Lung cancer in ever smokers;
LIHC	cis	rs12101261	0.580	rs3783950	chr14:81448282	C/G	cg06600135	chr14:81408086	NA	-0.41	-7.53	-0.38	4.63e-13	Graves' disease;
LIHC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.38	6.95	0.35	1.91e-11	Aortic root size;
LIHC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.49	-7.67	-0.38	1.78e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.67	6.36	0.33	6.45e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.46	6.09	0.31	2.97e-9	Menopause (age at onset);
LIHC	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.49	-6.8	-0.35	4.62e-11	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.7	-0.34	8.76e-11	Diabetic kidney disease;
LIHC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.51	7.83	0.39	6.19e-14	Recalcitrant atopic dermatitis;
LIHC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.6	-8.51	-0.42	5.64e-16	Blood metabolite levels;
LIHC	cis	rs3736485	0.966	rs11070860	chr15:51892654	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.29	-0.32	9.87e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg09003973	chr2:102972529	NA	1.12	10.33	0.49	5.96e-22	Gut microbiota (bacterial taxa);
LIHC	cis	rs12644436	0.711	rs13107383	chr4:88787535	C/A	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.05e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.15	0.36	5.37e-12	Axial length;
LIHC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg17980119	chr2:219472607	PLCD4	0.35	5.91	0.3	8.24e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.53	-8.96	-0.44	2.16e-17	Total body bone mineral density;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg23179321	chr10:15138793	C10orf111;RPP38	-0.54	-6.12	-0.31	2.61e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.58	-8.85	-0.43	4.93e-17	Smoking behavior;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.58	7.75	0.39	1.05e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-8.69	-0.43	1.55e-16	Vitiligo;
LIHC	cis	rs2997447	0.653	rs2802329	chr1:26466189	T/C	cg19633962	chr1:26362018	EXTL1	-0.54	-6.2	-0.32	1.66e-9	QRS complex (12-leadsum);
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.43	8.07	0.4	1.21e-14	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg00280220	chr17:61926910	NA	0.43	6.89	0.35	2.76e-11	Prudent dietary pattern;
LIHC	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.45	-5.77	-0.3	1.82e-8	Diisocyanate-induced asthma;
LIHC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-14.75	-0.62	1.81e-38	Gut microbiome composition (summer);
LIHC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.66	10.66	0.5	4.41e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.07	-0.51	1.45e-24	Morning vs. evening chronotype;
LIHC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.35	6.1	0.31	2.94e-9	Metabolite levels;
LIHC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.83	9.14	0.44	5.75e-18	Initial pursuit acceleration;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg01301323	chr12:77252588	CSRP2	0.44	6.26	0.32	1.13e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.16	-0.32	1.99e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.69	-13.57	-0.59	7.32e-34	Body mass index;
LIHC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.58	8.45	0.42	8.34e-16	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.45	-7.5	-0.38	5.7e-13	Response to temozolomide;
LIHC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.47	0.42	7.58e-16	Motion sickness;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.76	0.54	4.64e-27	Alzheimer's disease;
LIHC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.82	0.47	3.13e-20	Menopause (age at onset);
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.0	0.58	1.11e-31	Prudent dietary pattern;
LIHC	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	0.55	10.45	0.49	2.28e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs943466	0.955	rs2281819	chr6:33771673	T/A	cg25922239	chr6:33757077	LEMD2	-0.53	-7.11	-0.36	6.99e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-11.83	-0.54	2.67e-27	Pediatric autoimmune diseases;
LIHC	cis	rs1419980	0.730	rs11054699	chr12:7744539	G/A	cg10578777	chr12:7781093	NA	-0.39	-5.74	-0.3	2.04e-8	HDL cholesterol levels;
LIHC	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.55	-6.42	-0.33	4.57e-10	Urinary tract infection frequency;
LIHC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.75	8.57	0.42	3.69e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg23091122	chr1:110024289	SYPL2	-0.46	-6.06	-0.31	3.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.32	-0.32	8.18e-10	Metabolite levels;
LIHC	cis	rs7534824	0.625	rs17409422	chr1:101502386	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.77	7.1	0.36	7.05e-12	Refractive astigmatism;
LIHC	cis	rs2257205	0.667	rs9909763	chr17:56629640	C/T	cg12560992	chr17:57184187	TRIM37	0.68	7.68	0.38	1.64e-13	Pancreatic cancer;
LIHC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	12.42	0.56	1.74e-29	Schizophrenia;
LIHC	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-5.75	-0.3	1.93e-8	Blood metabolite levels;
LIHC	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.43	7.98	0.4	2.3e-14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LIHC	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.58	-7.46	-0.37	7.16e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	6.02	0.31	4.41e-9	Schizophrenia;
LIHC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg09455208	chr3:40491958	NA	-0.33	-6.58	-0.34	1.77e-10	Renal cell carcinoma;
LIHC	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg27205649	chr11:78285834	NARS2	0.44	6.64	0.34	1.22e-10	Alzheimer's disease (survival time);
LIHC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg05185784	chr16:90016020	DEF8	0.38	6.35	0.32	6.81e-10	Squamous cell carcinoma;
LIHC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.64	11.61	0.53	1.65e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.15	-12.04	-0.55	4.49e-28	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg15208524	chr1:10270712	KIF1B	0.44	6.38	0.33	5.61e-10	Hepatocellular carcinoma;
LIHC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.57	-7.93	-0.39	3.13e-14	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14431619	chr19:11266544	SPC24	0.44	6.41	0.33	4.88e-10	Pancreatic cancer;
LIHC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.47	-0.37	6.56e-13	Schizophrenia;
LIHC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.66	0.38	1.9e-13	Tonsillectomy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10238396	chr2:64067940	UGP2	-0.51	-6.32	-0.32	8.3e-10	Systolic blood pressure;
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg02635209	chr6:118822505	C6orf204;BRD7P3	0.49	5.74	0.3	2.1e-8	Diastolic blood pressure;
LIHC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg03013999	chr17:37608204	MED1	-0.36	-6.07	-0.31	3.33e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.69	-0.38	1.61e-13	Height;
LIHC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg18769074	chr3:133464867	TF	0.26	6.11	0.31	2.64e-9	Iron status biomarkers;
LIHC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.61	0.46	1.58e-19	Height;
LIHC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.63e-13	Bone mineral density;
LIHC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.06	0.44	9.98e-18	Lung cancer in ever smokers;
LIHC	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-0.75	-7.77	-0.39	9.43e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.75	-5.8	-0.3	1.54e-8	Systolic blood pressure;
LIHC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.02	-0.31	4.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.73	-0.39	1.2e-13	Bipolar disorder;
LIHC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.32	-0.58	6.54e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.75	0.3	2.03e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg10755058	chr3:40428713	ENTPD3	0.38	6.37	0.33	6.25e-10	Renal cell carcinoma;
LIHC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.14	-0.52	8.66e-25	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.7	13.15	0.58	3.03e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs546131	0.642	rs11605381	chr11:34847193	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.5	9.61	0.46	1.62e-19	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	-0.44	-6.89	-0.35	2.72e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13198984	chr17:80129470	CCDC57	-0.33	-5.8	-0.3	1.54e-8	Life satisfaction;
LIHC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs7651039	0.641	rs2455810	chr3:15657082	A/T	cg16303742	chr3:15540471	COLQ	0.55	9.63	0.46	1.43e-19	Coronary heart disease;
LIHC	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg18192155	chr21:44258298	NA	0.45	7.12	0.36	6.21e-12	Information processing speed;
LIHC	trans	rs2847476	0.690	rs7929497	chr11:114192132	C/G	cg04426326	chr15:59499030	LDHAL6B;MYO1E	-0.36	-6.05	-0.31	3.81e-9	Volumetric brain MRI;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23347958	chr17:41561300	DHX8	-0.55	-6.41	-0.33	4.76e-10	Systolic blood pressure;
LIHC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.6	9.12	0.44	6.67e-18	Gout;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.02	-0.51	2.34e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg25344623	chr2:136566232	LCT	0.42	8.59	0.42	3.11e-16	Mosquito bite size;
LIHC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg00750074	chr16:89608354	SPG7	-0.38	-5.89	-0.3	9.38e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg05564831	chr3:52568323	NT5DC2	0.38	6.13	0.31	2.4e-9	Bipolar disorder;
LIHC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.4	-7.27	-0.37	2.52e-12	Prudent dietary pattern;
LIHC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.19	0.4	5.3e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.36	5.96	0.31	6.31e-9	Height;
LIHC	cis	rs7091068	0.518	rs726817	chr10:95459817	C/T	cg20715218	chr10:95462985	C10orf4	0.59	8.43	0.41	1.01e-15	Urinary tract infection frequency;
LIHC	cis	rs4759375	0.598	rs4759359	chr12:123398454	C/G	cg25930673	chr12:123319894	HIP1R	-0.66	-8.05	-0.4	1.38e-14	HDL cholesterol;
LIHC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.13	0.31	2.43e-9	Coronary artery disease;
LIHC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.54	-0.46	2.86e-19	Blood metabolite levels;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.39	6.9	0.35	2.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg14061069	chr19:46274453	DMPK	0.72	13.38	0.59	3.82e-33	Coronary artery disease;
LIHC	cis	rs9378688	0.654	rs35224259	chr6:2363505	G/A	cg12303981	chr6:2244766	GMDS	0.47	6.28	0.32	1.04e-9	Caudate nucleus volume;
LIHC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-6.53	-0.33	2.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg05590025	chr7:65112418	INTS4L2	-0.57	-6.2	-0.32	1.67e-9	Diabetic kidney disease;
LIHC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.41	-0.45	7.59e-19	Schizophrenia;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg20684973	chr10:105127632	TAF5	-0.56	-6.16	-0.32	1.99e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.77	0.34	5.65e-11	Renal cell carcinoma;
LIHC	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.56	6.06	0.31	3.53e-9	Primary sclerosing cholangitis;
LIHC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.44	6.95	0.35	1.81e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.75	-12.45	-0.56	1.34e-29	Aortic root size;
LIHC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg25364880	chr3:44379878	C3orf23	-0.53	-7.33	-0.37	1.72e-12	Depressive symptoms;
LIHC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.4	-6.43	-0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.08	-0.44	8.81e-18	Aortic root size;
LIHC	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.09	0.36	7.85e-12	Exhaled nitric oxide output;
LIHC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg02187348	chr16:89574699	SPG7	0.44	6.41	0.33	4.8e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg10621924	chr7:39171070	POU6F2	0.41	6.45	0.33	3.86e-10	IgG glycosylation;
LIHC	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.78	-0.5	1.58e-23	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08677398	chr8:58056175	NA	0.42	5.73	0.3	2.2e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.51	7.09	0.36	7.78e-12	Morning vs. evening chronotype;
LIHC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.79	0.39	8.28e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.06	-0.36	9.4e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg26138144	chr22:38071188	LGALS1	0.71	10.35	0.49	5.19e-22	Fat distribution (HIV);
LIHC	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.65	-9.56	-0.46	2.36e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.16	0.32	2.04e-9	Diastolic blood pressure;
LIHC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.53	0.53	3.36e-26	Lung cancer in ever smokers;
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.51	7.94	0.39	2.96e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.22	0.52	4.23e-25	Motion sickness;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.47	5.84	0.3	1.22e-8	Bronchopulmonary dysplasia;
LIHC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	trans	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg24133106	chr7:129690864	ZC3HC1	-0.49	-6.11	-0.31	2.68e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.77	11.8	0.54	3.47e-27	Menarche (age at onset);
LIHC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg16989086	chr20:62203971	PRIC285	0.57	8.13	0.4	7.82e-15	Glioblastoma;
LIHC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.45	6.39	0.33	5.32e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg18478394	chr8:109455254	TTC35	0.41	6.73	0.34	7.31e-11	Dupuytren's disease;
LIHC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.33	-5.77	-0.3	1.79e-8	Headache;
LIHC	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-0.89	-10.59	-0.5	7.24e-23	Mitochondrial DNA levels;
LIHC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.59	11.13	0.52	9.02e-25	Systemic lupus erythematosus;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.52	7.54	0.38	4.33e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	10.0	0.48	7.88e-21	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg00656387	chr3:40428638	ENTPD3	0.49	8.06	0.4	1.29e-14	Renal cell carcinoma;
LIHC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-8.71	-0.43	1.29e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08386886	chr17:41277274	BRCA1;NBR2	0.49	6.35	0.32	6.87e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14067834	chr17:29058358	SUZ12P	-0.65	-6.88	-0.35	2.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.59	-8.27	-0.41	3.07e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.41	0.33	4.77e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17818399	0.788	rs13013245	chr2:46806086	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.47	7.15	0.36	5.3e-12	Height;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03344030	chr19:48673649	LIG1	-0.47	-6.61	-0.34	1.46e-10	Systolic blood pressure;
LIHC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.8	11.92	0.54	1.26e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg08382946	chr5:1082689	SLC12A7	0.42	6.34	0.32	7.06e-10	QT interval;
LIHC	cis	rs655641	1.000	rs627818	chr11:85698207	A/T	cg09030501	chr11:85779252	PICALM	-0.49	-6.0	-0.31	4.89e-9	Platelet count;
LIHC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.45	7.53	0.38	4.54e-13	Mean corpuscular volume;
LIHC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Body mass index;
LIHC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.78	-0.34	5.35e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7116495	0.609	rs7924834	chr11:71644333	C/T	cg10381502	chr11:71823885	C11orf51	0.82	7.73	0.39	1.19e-13	Severe influenza A (H1N1) infection;
LIHC	trans	rs800082	0.702	rs1726522	chr3:144253391	A/G	cg24215973	chr2:240111563	HDAC4	-0.44	-6.51	-0.33	2.66e-10	Smoking behavior;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11234017	chr17:42767172	CCDC43	0.41	6.8	0.35	4.69e-11	Cognitive function;
LIHC	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg08126542	chr6:37504118	NA	-0.36	-6.14	-0.31	2.35e-9	Cognitive performance;
LIHC	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg04492858	chr10:133558786	NA	0.44	6.42	0.33	4.59e-10	Survival in rectal cancer;
LIHC	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.65	0.53	1.17e-26	Body mass index;
LIHC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.96	-0.35	1.71e-11	Personality dimensions;
LIHC	cis	rs6782228	0.606	rs2811497	chr3:128363332	C/T	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg20569855	chr1:109824440	PSRC1	-0.46	-6.21	-0.32	1.56e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	trans	rs6934970	1.000	rs17759304	chr6:113099084	C/T	cg09308777	chr6:169852575	NA	-0.65	-6.9	-0.35	2.46e-11	Bipolar disorder (body mass index interaction);
LIHC	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.32	-5.72	-0.3	2.32e-8	Lewy body disease;
LIHC	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-8.09	-0.4	1.07e-14	Exhaled nitric oxide output;
LIHC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg06096015	chr1:231504339	EGLN1	0.47	8.74	0.43	1.06e-16	Hemoglobin concentration;
LIHC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.51	7.83	0.39	6.08e-14	Total body bone mineral density;
LIHC	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-6.52	-0.33	2.6e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.29	-0.32	9.49e-10	Response to antipsychotic treatment;
LIHC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg10932868	chr11:921992	NA	0.35	6.47	0.33	3.47e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15643885	chr8:17434749	PDGFRL	0.47	6.25	0.32	1.19e-9	Lung function (FEV1/FVC);
LIHC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.42	0.41	1.02e-15	Schizophrenia;
LIHC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.77	0.3	1.81e-8	Bladder cancer;
LIHC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.57	7.98	0.4	2.26e-14	Lung cancer;
LIHC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg18129178	chr5:148520854	ABLIM3	0.48	7.48	0.37	6.4e-13	Breast cancer;
LIHC	cis	rs1144333	0.655	rs11162053	chr1:76470267	A/C	cg03433033	chr1:76189801	ACADM	0.52	7.62	0.38	2.52e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.6	7.32	0.37	1.79e-12	Interstitial lung disease;
LIHC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg09911534	chr15:67153556	NA	0.44	6.87	0.35	2.98e-11	Lung cancer (smoking interaction);
LIHC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.65	-10.73	-0.5	2.45e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg25427524	chr10:38739819	LOC399744	0.46	7.8	0.39	7.36e-14	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg02344993	chr17:57696989	CLTC	0.73	12.38	0.56	2.54e-29	Hemoglobin concentration;
LIHC	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.75	11.14	0.52	8.26e-25	Subjective well-being;
LIHC	trans	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg08566640	chr11:64091735	NA	-0.67	-6.1	-0.31	2.84e-9	IgM levels;
LIHC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.7	-6.71	-0.34	8.24e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg00292662	chr22:38071168	LGALS1	0.59	9.32	0.45	1.53e-18	Fat distribution (HIV);
LIHC	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.7	0.34	8.35e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg04896959	chr15:78267971	NA	-0.33	-5.93	-0.31	7.24e-9	Coronary artery disease or large artery stroke;
LIHC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.57	-8.73	-0.43	1.17e-16	Corneal astigmatism;
LIHC	trans	rs11010290	0.639	rs752431	chr10:36038275	A/G	cg08927738	chr20:52687394	BCAS1	-0.47	-6.28	-0.32	1e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
LIHC	trans	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg25214090	chr10:38739885	LOC399744	0.41	6.9	0.35	2.51e-11	Diastolic blood pressure;
LIHC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.05	0.48	5.25e-21	Melanoma;
LIHC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.43	7.38	0.37	1.24e-12	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13501090	chr1:115212659	DENND2C	0.5	7.18	0.36	4.35e-12	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs11627756	0.958	rs2146431	chr14:103071861	A/G	cg12046867	chr14:103022105	NA	0.42	6.48	0.33	3.12e-10	Mean platelet volume;
LIHC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.04	-0.48	5.96e-21	Platelet count;
LIHC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.12	-0.44	6.53e-18	Hemoglobin concentration;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.85	-0.3	1.16e-8	Total body bone mineral density;
LIHC	cis	rs965469	1.000	rs2236089	chr20:3257194	C/A	cg25506879	chr20:3388711	C20orf194	-0.62	-7.11	-0.36	7.02e-12	IFN-related cytopenia;
LIHC	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg07451762	chr16:28383216	NA	0.32	6.05	0.31	3.83e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.6	-8.22	-0.41	4.17e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg04610667	chr7:75704037	NA	-0.35	-6.21	-0.32	1.54e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.64	0.38	2.23e-13	Diastolic blood pressure;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg11342453	chr6:26196699	NA	0.53	5.92	0.3	7.83e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-1.02	-19.52	-0.73	1.47e-57	Breast cancer;
LIHC	cis	rs1555322	0.530	rs2425044	chr20:33869735	C/T	cg03689076	chr20:33865952	NA	0.58	6.66	0.34	1.06e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.82	0.3	1.32e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.49	-7.19	-0.36	4.17e-12	Aortic root size;
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06656553	chr16:89960601	TCF25	-0.48	-6.09	-0.31	3.09e-9	Skin colour saturation;
LIHC	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg01557791	chr16:72042693	DHODH	-0.73	-11.51	-0.53	3.99e-26	Fibrinogen levels;
LIHC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	1.02	12.94	0.57	1.96e-31	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.9	-14.98	-0.63	2.27e-39	Tonsillectomy;
LIHC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.69	0.73	3.11e-58	Smoking behavior;
LIHC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.27	-0.49	9.61e-22	Response to antipsychotic treatment;
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12379764	chr21:47803548	PCNT	-0.57	-8.36	-0.41	1.65e-15	Testicular germ cell tumor;
LIHC	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.21	-0.32	1.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.82	-0.3	1.34e-8	Melanoma;
LIHC	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03352830	chr11:487213	PTDSS2	0.8	6.45	0.33	3.76e-10	Body mass index;
LIHC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg18016565	chr1:150552671	MCL1	0.49	9.26	0.45	2.3e-18	Melanoma;
LIHC	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg00291366	chr1:12616550	NA	0.43	8.92	0.43	2.79e-17	Optic cup area;
LIHC	trans	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.36	0.33	6.63e-10	Ulcerative colitis;
LIHC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg00677901	chr16:88017247	BANP	0.55	8.53	0.42	4.67e-16	Menopause (age at onset);
LIHC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.73	-0.43	1.12e-16	Obesity-related traits;
LIHC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18252515	chr7:66147081	NA	0.45	6.36	0.33	6.61e-10	Aortic root size;
LIHC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.57	8.17	0.4	6.01e-15	Mean corpuscular volume;
LIHC	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-0.9	-10.74	-0.5	2.29e-23	Mitochondrial DNA levels;
LIHC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-9.62	-0.46	1.5700000000000001e-19	Total cholesterol levels;
LIHC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.6	7.87	0.39	4.57e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.37	-0.33	6.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs965469	1.000	rs6051703	chr20:3252347	A/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.99	-0.35	1.44e-11	IFN-related cytopenia;
LIHC	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.21	0.58	1.74e-32	Prudent dietary pattern;
LIHC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg17980119	chr2:219472607	PLCD4	0.34	5.79	0.3	1.62e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs903552	1.000	rs34937195	chr15:102003631	C/A	cg06707286	chr15:102010195	PCSK6	-0.44	-6.33	-0.32	7.48e-10	Diabetic kidney disease;
LIHC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	7.93e-10	Red blood cell count;
LIHC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.06e-10	Renal cell carcinoma;
LIHC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs2274273	0.840	rs1045002	chr14:55818517	T/A	cg01864836	chr14:55583639	NA	-0.38	-6.66	-0.34	1.08e-10	Protein biomarker;
LIHC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg09182678	chr22:50328711	NA	-0.41	-6.05	-0.31	3.72e-9	Schizophrenia;
LIHC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs1113500	0.787	rs10881501	chr1:108641745	C/T	cg06207961	chr1:108661230	NA	0.31	6.07	0.31	3.43e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.72	9.38	0.45	9.41e-19	Dilated cardiomyopathy;
LIHC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.84	-13.89	-0.6	4.23e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.84	0.43	5.15e-17	Motion sickness;
LIHC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.55	-9.18	-0.44	4.21e-18	Cognitive function;
LIHC	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.6	8.2	0.41	4.99e-15	Bladder cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08030934	chr13:21678628	NA	0.45	6.81	0.35	4.3e-11	Bilirubin levels;
LIHC	cis	rs1400745	0.756	rs799682	chr14:35349984	G/C	cg16230307	chr14:35515116	FAM177A1	0.39	6.21	0.32	1.5e-9	Monocyte count;
LIHC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.76	9.09	0.44	8.16e-18	Menarche (age at onset);
LIHC	trans	rs4596713	0.508	rs13289984	chr9:71775047	A/C	cg16512924	chr15:28394682	HERC2	0.39	6.25	0.32	1.21e-9	Headache;
LIHC	cis	rs611744	0.868	rs612722	chr8:109194850	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs611744	0.934	rs672408	chr8:109224390	A/G	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.37	0.45	1e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12101261	0.925	rs2300519	chr14:81458762	T/A	cg06600135	chr14:81408086	NA	0.37	6.3	0.32	9.16e-10	Graves' disease;
LIHC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.86	-12.53	-0.56	6.86e-30	Diastolic blood pressure;
LIHC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.65	5.82	0.3	1.35e-8	Body mass index;
LIHC	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg07959070	chr22:50026188	C22orf34	-0.3	-7.22	-0.36	3.33e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	0.94	17.64	0.69	5.29e-50	Breast cancer;
LIHC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.33	-6.12	-0.31	2.51e-9	Migraine;
LIHC	cis	rs9322817	0.691	rs6907016	chr6:105211360	G/A	cg02098413	chr6:105308735	HACE1	-0.42	-7.53	-0.38	4.46e-13	Thyroid stimulating hormone;
LIHC	cis	rs9472202	1.000	rs9472202	chr6:44021286	C/T	cg12481212	chr6:44020245	NA	0.39	6.57	0.33	1.9e-10	Behavioral disturbance or psychiatric symptoms in prion disease;
LIHC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Body mass index;
LIHC	trans	rs7618501	0.570	rs7613875	chr3:49971514	C/A	cg21659725	chr3:3221576	CRBN	0.7	11.14	0.52	8.59e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.62	6.95	0.35	1.81e-11	Alzheimer's disease;
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-9.03	-0.44	1.29e-17	Total body bone mineral density;
LIHC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.18	-0.32	1.86e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg26441486	chr22:50317300	CRELD2	0.35	6.15	0.32	2.21e-9	Schizophrenia;
LIHC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.75	15.0	0.63	1.87e-39	Height;
LIHC	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.09	0.36	7.85e-12	Exhaled nitric oxide output;
LIHC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-7.59	-0.38	3.15e-13	LDL cholesterol;
LIHC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.32	-7.21	-0.36	3.56e-12	Menarche (age at onset);
LIHC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-6.85	-0.35	3.54e-11	Chronic sinus infection;
LIHC	trans	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg26939375	chr7:64535504	NA	0.4	6.31	0.32	8.63e-10	Aortic root size;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.95	-14.63	-0.62	5.6e-38	Skin colour saturation;
LIHC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg20129853	chr10:51489980	NA	0.42	9.02	0.44	1.38e-17	Prostate-specific antigen levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03283842	chr2:179343803	FKBP7;PLEKHA3;MIR548N	0.43	6.16	0.32	2.04e-9	Pancreatic cancer;
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.51	7.26	0.37	2.56e-12	Lymphocyte counts;
LIHC	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.64	-7.47	-0.37	6.56e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.79	-15.3	-0.64	1.25e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.57	-8.32	-0.41	2.14e-15	Blood pressure (smoking interaction);
LIHC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.55	-0.38	3.95e-13	Height;
LIHC	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.31	-0.45	1.56e-18	Colorectal cancer;
LIHC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-12.17	-0.55	1.5e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.32	7.39	0.37	1.13e-12	Crohn's disease;
LIHC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.8	-11.77	-0.54	4.58e-27	Blood metabolite levels;
LIHC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.92	-11.79	-0.54	3.72e-27	HIV-1 control;
LIHC	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg02562419	chr6:159049626	TMEM181	0.45	6.17	0.32	1.92e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.44	8.19	0.4	5.4e-15	Prudent dietary pattern;
LIHC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.97	0.6	2.02e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.64	10.63	0.5	5.26e-23	Menopause (age at onset);
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.8	12.76	0.57	9.12e-31	Longevity;
LIHC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.61	8.72	0.43	1.19e-16	HIV-1 control;
LIHC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.45	-7.52	-0.38	4.8e-13	Fibrinogen levels;
LIHC	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.73	-0.39	1.18e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.57	-9.53	-0.46	3.09e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17106184	1.000	rs12074982	chr1:51387415	T/C	cg07174182	chr1:51127561	FAF1	-0.75	-7.63	-0.38	2.42e-13	Type 2 diabetes;
LIHC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.35	6.66	0.34	1.08e-10	HDL cholesterol levels;
LIHC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg23485639	chr6:28045615	ZNF165	0.38	5.87	0.3	1.03e-8	Parkinson's disease;
LIHC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.52	7.37	0.37	1.31e-12	Height;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.86	0.39	5.2e-14	Prudent dietary pattern;
LIHC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.56	10.02	0.48	7.09e-21	Platelet distribution width;
LIHC	cis	rs2030401	0.603	rs1727301	chr12:123664514	G/A	cg00376283	chr12:123451042	ABCB9	0.53	8.4	0.41	1.25e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7606173	0.534	rs10445937	chr2:60637656	A/G	cg08245425	chr17:34957834	MRM1	0.47	6.04	0.31	4.04e-9	F-cell distribution;Red cell distribution width;
LIHC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.35	0.52	1.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.42e-17	Lung cancer in ever smokers;
LIHC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00958927	chr1:175162553	KIAA0040	0.39	6.55	0.33	2.11e-10	Alcohol dependence;
LIHC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02985541	chr2:219472218	PLCD4	-0.42	-6.83	-0.35	3.99e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg06096015	chr1:231504339	EGLN1	0.49	9.19	0.45	3.77e-18	Hemoglobin concentration;
LIHC	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.77	11.12	0.52	9.58e-25	Personality dimensions;
LIHC	cis	rs422249	0.634	rs174615	chr11:61628964	T/A	cg27386326	chr11:61587980	NA	0.33	5.78	0.3	1.67e-8	Trans fatty acid levels;
LIHC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.82	-0.3	1.34e-8	Type 2 diabetes;
LIHC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	11.13	0.52	9.02e-25	Type 2 diabetes;
LIHC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.59	7.89	0.39	4.14e-14	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.5	-0.33	2.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-6.48	-0.33	3.22e-10	Eosinophil percentage of white cells;
LIHC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.95	-0.31	6.73e-9	Monocyte percentage of white cells;
LIHC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.56	7.68	0.38	1.65e-13	Blood metabolite levels;
LIHC	cis	rs9378688	0.654	rs11963138	chr6:2264559	A/C	cg12303981	chr6:2244766	GMDS	-0.43	-6.09	-0.31	3.04e-9	Caudate nucleus volume;
LIHC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-8.02	-0.4	1.68e-14	Menarche (age at onset);
LIHC	cis	rs3770081	1.000	rs77309268	chr2:86293294	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.49	-0.42	6.21e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.57	9.46	0.46	5.26e-19	Body mass index;
LIHC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.52	9.37	0.45	9.85e-19	Total body bone mineral density;
LIHC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.53	7.48	0.37	6.33e-13	Prostate cancer;
LIHC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.75	-14.21	-0.61	2.43e-36	Mortality in heart failure;
LIHC	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.97	10.75	0.5	2.07e-23	Neuroticism;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.45	-0.37	7.93e-13	Tuberculosis;
LIHC	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.37	0.33	5.99e-10	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.18	-0.48	2e-21	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.0	-0.31	5.09e-9	Total body bone mineral density;
LIHC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.13	0.55	2.04e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.52	18.78	0.71	1.37e-54	Breast cancer;
LIHC	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.54	0.33	2.25e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.12	-0.44	6.77e-18	Bipolar disorder;
LIHC	trans	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg17675199	chr6:35436792	RPL10A	0.31	6.22	0.32	1.49e-9	Coronary artery disease;
LIHC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg15448220	chr1:150897856	SETDB1	0.39	6.14	0.32	2.31e-9	Tonsillectomy;
LIHC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.4	5.84	0.3	1.24e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg17074339	chr11:11642133	GALNTL4	0.47	7.32	0.37	1.78e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67981189	0.593	rs8008111	chr14:71531246	G/C	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.63e-11	Schizophrenia;
LIHC	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg27203090	chr3:33138513	GLB1;TMPPE	-0.54	-6.17	-0.32	1.93e-9	Major depressive disorder;
LIHC	trans	rs6489882	0.867	rs4766663	chr12:113362974	C/T	cg10175203	chr3:128143634	NA	-0.37	-6.11	-0.31	2.72e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs11689435	0.925	rs4555323	chr2:218352602	C/A	cg13544946	chr9:35729779	TLN1	-0.45	-6.36	-0.33	6.42e-10	Metabolite levels (MHPG);
LIHC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.65	8.2	0.41	4.79e-15	Morning vs. evening chronotype;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00050938	chr3:50296100	GNAI2	-0.41	-7.07	-0.36	8.78e-12	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.52	-7.85	-0.39	5.46e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.47	-6.62	-0.34	1.38e-10	Coronary artery disease;
LIHC	cis	rs970821	0.667	rs11774647	chr8:124743895	T/C	cg00283535	chr8:124749564	ANXA13	0.42	7.52	0.38	4.93e-13	Breast cancer;
LIHC	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs36051895	0.589	rs1322222	chr9:5190444	A/G	cg02405213	chr9:5042618	JAK2	-0.69	-11.65	-0.53	1.23e-26	Pediatric autoimmune diseases;
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.18	-0.4	5.48e-15	Lymphocyte counts;
LIHC	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg03934865	chr2:198174659	NA	0.49	7.5	0.38	5.42e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.8	11.88	0.54	1.7e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9473924	0.580	rs68118663	chr6:50815367	C/T	cg14470998	chr6:50812995	TFAP2B	0.93	10.62	0.5	6.08e-23	Body mass index;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.78	10.23	0.48	1.3e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.45	0.33	3.75e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7577696	0.568	rs7562653	chr2:32478629	T/C	cg02381751	chr2:32503542	YIPF4	0.48	6.65	0.34	1.17e-10	Inflammatory biomarkers;
LIHC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.44	-7.38	-0.37	1.19e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs11229555	0.645	rs12785578	chr11:58206432	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg10932868	chr11:921992	NA	0.39	7.38	0.37	1.22e-12	Alzheimer's disease (late onset);
LIHC	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.43	7.91	0.39	3.6e-14	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg06238570	chr21:40685208	BRWD1	0.58	6.79	0.34	5.07e-11	Cognitive function;
LIHC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.8	-7.7	-0.38	1.47e-13	Diabetic retinopathy;
LIHC	trans	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg17675199	chr6:35436792	RPL10A	0.34	6.63	0.34	1.32e-10	Coronary artery disease;
LIHC	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.33	5.89	0.3	9.24e-9	Body mass index;
LIHC	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg10820045	chr2:198174542	NA	0.51	8.2	0.41	4.84e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7945718	0.621	rs10831888	chr11:12665604	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.67	0.38	1.75e-13	Educational attainment (years of education);
LIHC	cis	rs7578199	0.962	rs11680329	chr2:242186837	C/T	cg19372975	chr2:242212901	HDLBP	-0.6	-5.78	-0.3	1.72e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.64	-10.73	-0.5	2.42e-23	Childhood ear infection;
LIHC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg18944383	chr4:111397179	ENPEP	0.25	6.15	0.32	2.21e-9	Coronary artery disease;
LIHC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg23283495	chr1:209979779	IRF6	0.35	5.99	0.31	5.17e-9	Monobrow;
LIHC	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg15103426	chr22:29168792	CCDC117	0.43	5.81	0.3	1.45e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02136628	chr17:41476456	ARL4D	-0.52	-6.18	-0.32	1.79e-9	Systolic blood pressure;
LIHC	cis	rs3736594	0.513	rs78170284	chr2:27835082	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.76	0.34	5.84e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs4689642	0.666	rs4689659	chr4:7228214	C/T	cg21353189	chr4:7228343	SORCS2	0.36	6.22	0.32	1.49e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg04709771	chr16:646395	RAB40C	0.47	8.3	0.41	2.44e-15	Height;
LIHC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs74181299	0.684	rs17040050	chr2:65327042	G/A	cg05010058	chr2:65284262	CEP68	-0.4	-6.71	-0.34	8.22e-11	Pulse pressure;
LIHC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.91	0.47	1.6e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	6.9	0.35	2.6e-11	Renal cell carcinoma;
LIHC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg14092571	chr14:90743983	NA	-0.42	-6.72	-0.34	7.72e-11	Mortality in heart failure;
LIHC	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.34	0.37	1.61e-12	Lung cancer;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.52	7.6	0.38	2.88e-13	Height;
LIHC	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg10862848	chr6:42927986	GNMT	-0.24	-5.86	-0.3	1.1e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg15832292	chr6:96025679	MANEA	0.7	8.72	0.43	1.21e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.61	10.33	0.49	6.17e-22	Retinal vascular caliber;
LIHC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.36	-0.33	6.55e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.11e-18	Bipolar disorder;
LIHC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg25894440	chr7:65020034	NA	0.54	6.22	0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg21361702	chr7:150065534	REPIN1	-0.45	-6.08	-0.31	3.26e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg21573476	chr21:45109991	RRP1B	-0.49	-9.12	-0.44	6.71e-18	Mean corpuscular volume;
LIHC	trans	rs2270927	0.790	rs4613682	chr5:75576455	G/C	cg13563193	chr19:33072644	PDCD5	0.87	9.63	0.46	1.44e-19	Mean corpuscular volume;
LIHC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	0.85	11.16	0.52	7.43e-25	Severe influenza A (H1N1) infection;
LIHC	trans	rs1997066	0.920	rs58578339	chr10:106726669	A/C	cg21239439	chr6:170038665	WDR27	0.67	6.08	0.31	3.23e-9	Diabetic kidney disease;
LIHC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.67	11.5	0.53	4.19e-26	Menopause (age at onset);
LIHC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.5	-7.79	-0.39	8.06e-14	Diastolic blood pressure;
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg14222432	chr12:29376421	FAR2	0.37	7.13	0.36	5.83e-12	QT interval;
LIHC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg12292205	chr6:26970375	C6orf41	0.34	5.83	0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.42	7.29	0.37	2.17e-12	Aortic root size;
LIHC	trans	rs13381277	1.000	rs937898	chr18:74330672	C/G	cg17352830	chr21:37617589	DOPEY2	0.56	6.63	0.34	1.33e-10	Dental caries;
LIHC	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg21017887	chr14:105400489	NA	0.67	12.39	0.56	2.21e-29	Systemic lupus erythematosus;
LIHC	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg27147174	chr7:100797783	AP1S1	-0.46	-6.32	-0.32	8.1e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-12.15	-0.55	1.77e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.27	-0.37	2.47e-12	Blood metabolite levels;
LIHC	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg06598544	chr20:61472147	COL9A3	-0.9	-8.42	-0.41	1.07e-15	Obesity-related traits;
LIHC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	16.14	0.66	5.71e-44	Lung cancer in ever smokers;
LIHC	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg23587288	chr2:27483067	SLC30A3	0.31	6.05	0.31	3.75e-9	Blood metabolite levels;
LIHC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.54	0.46	2.71e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.68	-10.39	-0.49	3.83e-22	Pediatric autoimmune diseases;
LIHC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.38	-0.37	1.25e-12	Bipolar disorder;
LIHC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	7.15	0.36	5.15e-12	Schizophrenia;
LIHC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.39	0.52	1.05e-25	Cognitive test performance;
LIHC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.35	0.59	5.07e-33	Chronic sinus infection;
LIHC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.53	-6.44	-0.33	4.07e-10	Menarche (age at onset);
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.64	-8.03	-0.4	1.58e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg25344623	chr2:136566232	LCT	-0.41	-8.45	-0.42	8.52e-16	Mosquito bite size;
LIHC	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg08824895	chr13:115047677	UPF3A	0.48	6.89	0.35	2.7e-11	Schizophrenia;
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.44	6.22	0.32	1.43e-9	Calcium levels;
LIHC	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.18e-9	Blood pressure;
LIHC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.37	5.73	0.3	2.23e-8	Coronary artery disease;
LIHC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.8	7.86	0.39	5.07e-14	Platelet count;
LIHC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.68	13.42	0.59	2.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21448741	chr8:58168803	NA	0.34	6.14	0.32	2.31e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.45	-6.98	-0.35	1.55e-11	Type 2 diabetes;
LIHC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-8.19	-0.4	5.3e-15	Urinary metabolites;
LIHC	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.49	7.19	0.36	3.98e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs509477	0.718	rs273363	chr18:32594703	A/G	cg23791764	chr18:32556832	MAPRE2	0.47	6.32	0.32	8.16e-10	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-7.49	-0.38	5.9e-13	Personality dimensions;
LIHC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.88	-0.3	9.51e-9	Longevity;
LIHC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg10431340	chr1:161279108	MPZ	0.66	5.88	0.3	9.54e-9	Rheumatoid arthritis;
LIHC	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-6.91	-0.35	2.43e-11	Insulin-like growth factors;
LIHC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-7.54	-0.38	4.32e-13	Neuroticism;
LIHC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.16	-15.86	-0.65	7.8e-43	Diabetic kidney disease;
LIHC	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.44	-6.84	-0.35	3.57e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	6.07	0.31	3.45e-9	Mean platelet volume;
LIHC	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg14146966	chr2:61757674	XPO1	0.47	8.12	0.4	8.6e-15	Tuberculosis;
LIHC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	16.97	0.68	2.72e-47	Lung cancer in ever smokers;
LIHC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.56	-8.16	-0.4	6.59e-15	Coronary artery disease;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18110333	chr6:292329	DUSP22	-0.54	-7.16	-0.36	5.04e-12	Menopause (age at onset);
LIHC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.1	-13.13	-0.58	3.72e-32	Vitiligo;
LIHC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs4407350	0.729	rs6007167	chr22:44888124	A/G	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.48	-0.33	3.13e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.35	-7.1	-0.36	7.06e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg15105060	chr4:7024189	TBC1D14	-0.81	-6.47	-0.33	3.48e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg13319975	chr6:146136371	FBXO30	-0.35	-5.83	-0.3	1.28e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	0.84	13.55	0.59	8.5e-34	Left atrial antero-posterior diameter;
LIHC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21653586	chr11:10530636	NA	0.47	6.04	0.31	3.92e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.73	-13.51	-0.59	1.28e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.69	10.52	0.49	1.36e-22	Height;Educational attainment;Head circumference (infant);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21638374	chr5:147763491	FBXO38	0.47	6.58	0.34	1.74e-10	Lung function (FEV1/FVC);
LIHC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.66	9.98	0.48	9.17e-21	Response to diuretic therapy;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.29	-0.32	9.64e-10	Total body bone mineral density;
LIHC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	6.66	0.34	1.12e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17106184	1.000	rs12068606	chr1:51351281	C/T	cg07174182	chr1:51127561	FAF1	-0.58	-6.53	-0.33	2.34e-10	Type 2 diabetes;
LIHC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.7	0.34	8.77e-11	Mean corpuscular volume;
LIHC	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg27255678	chr10:102756921	LZTS2	0.43	5.88	0.3	9.66e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7729447	0.813	rs1031648	chr5:32692105	T/A	cg16267343	chr5:32710456	NPR3	0.47	5.76	0.3	1.88e-8	Blood pressure;
LIHC	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg09904177	chr6:26538194	HMGN4	-0.37	-5.79	-0.3	1.57e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.06	-0.36	9.13e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg15902774	chr15:75289873	SCAMP5	0.39	5.82	0.3	1.33e-8	Lung cancer;
LIHC	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.33	-7.1	-0.36	7.05e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.53	6.83	0.35	3.94e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.31	6.69	0.34	9.31e-11	Facial morphology (factor 15, philtrum width);
LIHC	trans	rs9914544	0.545	rs9915343	chr17:18766494	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Educational attainment (years of education);
LIHC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.34	-18.25	-0.7	1.9e-52	Diabetic kidney disease;
LIHC	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.59	-8.11	-0.4	8.91e-15	Psoriasis vulgaris;
LIHC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.81	-0.3	1.42e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.6	9.02	0.44	1.39e-17	Longevity;
LIHC	cis	rs7238033	0.609	rs28898869	chr18:43315591	A/C	cg20610511	chr18:43302872	SLC14A1	0.38	6.27	0.32	1.1e-9	Bladder cancer;
LIHC	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.51	-5.97	-0.31	6e-9	Ulcerative colitis;
LIHC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.99	19.75	0.73	1.74e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg01843034	chr6:37503916	NA	-0.46	-7.99	-0.4	2.03e-14	Cognitive performance;
LIHC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.01e-8	Tonsillectomy;
LIHC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.55	8.31	0.41	2.28e-15	Platelet count;
LIHC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-8.89	-0.43	3.62e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg10587741	chr22:38071170	LGALS1	-0.73	-12.93	-0.57	2.03e-31	Fat distribution (HIV);
LIHC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.28e-34	Aortic root size;
LIHC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.53	-6.44	-0.33	4e-10	Colorectal cancer;
LIHC	cis	rs4903214	1.000	rs2024244	chr14:74710864	C/A	cg11132536	chr14:74711944	VSX2	-0.27	-6.52	-0.33	2.56e-10	Inflammatory bowel disease;
LIHC	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.66	13.23	0.58	1.43e-32	Leprosy;
LIHC	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.43	5.79	0.3	1.56e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.78	9.02	0.44	1.35e-17	Exhaled nitric oxide output;
LIHC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.6	11.92	0.54	1.25e-27	Plateletcrit;Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02441305	chr17:42767179	CCDC43	-0.46	-6.31	-0.32	8.7e-10	Pancreatic cancer;
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	6.22	0.32	1.43e-9	Height;
LIHC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.22	0.48	1.39e-21	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg05555928	chr11:63887634	MACROD1	0.54	7.49	0.38	5.8e-13	Mean platelet volume;
LIHC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.75	-7.29	-0.37	2.22e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg02196655	chr2:10830764	NOL10	0.37	5.75	0.3	2.01e-8	Prostate cancer;
LIHC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.43	-6.96	-0.35	1.76e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs943466	0.955	rs3763253	chr6:33772761	C/T	cg25922239	chr6:33757077	LEMD2	0.46	6.27	0.32	1.08e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs6545883	0.894	rs6545845	chr2:61437044	G/C	cg15711740	chr2:61764176	XPO1	0.43	5.91	0.3	8.1e-9	Tuberculosis;
LIHC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.84	0.69	8.98e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.83	0.54	2.7e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.53	7.4	0.37	1.09e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	0.9	16.36	0.66	7.78e-45	Menopause (age at onset);
LIHC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.44	-7.45	-0.37	7.53e-13	Headache;
LIHC	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.44	6.77	0.34	5.69e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.44	6.64	0.34	1.2e-10	Dementia with Lewy bodies;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04132851	chr1:85155548	SSX2IP	0.49	6.71	0.34	8.2e-11	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.6e-18	Bipolar disorder;
LIHC	cis	rs3770081	0.590	rs79771503	chr2:86466739	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.74	-7.32	-0.37	1.79e-12	Facial emotion recognition (sad faces);
LIHC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.0	-0.54	6.29e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.56	-6.49	-0.33	2.93e-10	Ulcerative colitis;
LIHC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.56	-6.05	-0.31	3.89e-9	Menarche (age at onset);
LIHC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.72	-0.3	2.33e-8	Height;
LIHC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.6	10.23	0.48	1.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.39	-0.37	1.14e-12	Total body bone mineral density;
LIHC	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.57	9.86	0.47	2.31e-20	Dupuytren's disease;
LIHC	trans	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.21	0.32	1.53e-9	Ulcerative colitis;
LIHC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.62	-8.77	-0.43	8.61e-17	Blood metabolite levels;
LIHC	cis	rs2637266	0.783	rs12258504	chr10:78477055	C/T	cg18941641	chr10:78392320	NA	0.27	5.82	0.3	1.33e-8	Pulmonary function;
LIHC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.23	0.55	8.75e-29	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.57	9.62	0.46	1.53e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg16583315	chr14:65563665	MAX	0.42	8.67	0.42	1.73e-16	Obesity-related traits;
LIHC	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg24692254	chr21:30365293	RNF160	0.46	7.27	0.37	2.43e-12	Dental caries;
LIHC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	7.11	0.36	6.93e-12	Schizophrenia;
LIHC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.66	9.82	0.47	3.18e-20	Total body bone mineral density;
LIHC	cis	rs1355223	0.902	rs1258470	chr11:34729265	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.43	6.03	0.31	4.34e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg09445902	chr10:555545	DIP2C	0.38	6.09	0.31	3.05e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.86	-0.39	5.17e-14	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	8.11	0.4	9.02e-15	LDL cholesterol;
LIHC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.58	5.79	0.3	1.58e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-10.41	-0.49	3.14e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg11057378	chr10:81107060	PPIF	0.37	5.92	0.3	7.8e-9	Height;
LIHC	cis	rs11212260	0.655	rs11212225	chr11:107296099	G/T	cg25435332	chr11:107328525	CWF19L2	0.75	7.84	0.39	5.64e-14	IgG glycosylation;
LIHC	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	19.23	0.72	2.29e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.0	-0.4	1.93e-14	Alzheimer's disease;
LIHC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-8.44	-0.42	8.82e-16	Neuroticism;
LIHC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg11899201	chr4:82391576	RASGEF1B	-0.34	-6.6	-0.34	1.59e-10	Oropharynx cancer;
LIHC	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.7	7.92	0.39	3.33e-14	Lymphocyte counts;
LIHC	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.65	6.97	0.35	1.67e-11	Homocysteine levels;
LIHC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs16877106	1.000	rs73254140	chr4:25318393	G/C	cg04796973	chr4:25314218	ZCCHC4	0.62	5.85	0.3	1.18e-8	Weight;
LIHC	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.31	-0.32	8.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.16	0.4	6.56e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.35	-0.41	1.7e-15	Response to antipsychotic treatment;
LIHC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	trans	rs2694917	0.669	rs813497	chr12:56924116	A/G	cg15380473	chr2:11864427	NA	-0.51	-6.26	-0.32	1.13e-9	Blood metabolite ratios;
LIHC	cis	rs17125944	0.686	rs7145440	chr14:53333717	A/G	cg00686598	chr14:53173677	PSMC6	-0.74	-8.63	-0.42	2.4e-16	Alzheimer's disease (late onset);
LIHC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg14092571	chr14:90743983	NA	0.4	6.27	0.32	1.06e-9	Mortality in heart failure;
LIHC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.52	-0.38	4.86e-13	Platelet count;
LIHC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.65	9.18	0.44	4.29e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.68	-8.82	-0.43	6.12e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11822910	0.724	rs7106223	chr11:57190448	A/G	cg00522883	chr11:57194120	SLC43A3	-0.71	-8.5	-0.42	6.09e-16	Platelet distribution width;
LIHC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg06115741	chr20:33292138	TP53INP2	0.58	7.83	0.39	6e-14	Coronary artery disease;
LIHC	cis	rs116248771	0.739	rs4334688	chr3:158358666	C/G	cg16708174	chr3:158430962	RARRES1	0.48	6.42	0.33	4.44e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.34	0.52	1.63e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg02990361	chr1:107599529	PRMT6	0.63	10.59	0.5	7.44e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24110177	chr3:50126178	RBM5	0.42	6.49	0.33	3.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg05372495	chr19:1063624	ABCA7	-0.42	-6.66	-0.34	1.1e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg16797656	chr11:68205561	LRP5	0.51	8.11	0.4	9.12e-15	Total body bone mineral density;
LIHC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.64	0.53	1.34e-26	Platelet count;
LIHC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.72	-12.89	-0.57	2.96e-31	Colorectal cancer;
LIHC	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.42	-6.35	-0.32	6.88e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.57	0.33	1.85e-10	Mean corpuscular volume;
LIHC	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg20240347	chr1:204465584	NA	-0.35	-7.18	-0.36	4.42e-12	Schizophrenia;
LIHC	cis	rs1639906	1.000	rs1637759	chr7:2220053	C/T	cg18044113	chr7:2236405	MAD1L1	-0.36	-5.76	-0.3	1.88e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.2e-8	Vitiligo;
LIHC	cis	rs4908768	0.906	rs28422051	chr1:8618337	T/C	cg20416874	chr1:8611966	RERE	0.57	8.88	0.43	3.81e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg02931644	chr1:25747376	RHCE	0.35	7.63	0.38	2.28e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg16970926	chr12:29381810	FAR2	0.28	5.94	0.31	6.84e-9	QT interval;
LIHC	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.5	-0.38	5.39e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.62	-12.91	-0.57	2.4e-31	Urate levels;
LIHC	cis	rs9810089	0.843	rs834304	chr3:136111658	G/T	cg21827317	chr3:136751795	NA	0.43	5.72	0.3	2.32e-8	Gestational age at birth (child effect);
LIHC	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.52	7.16	0.36	4.96e-12	Morning vs. evening chronotype;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00166327	chr13:73356072	PIBF1;DIS3	-0.47	-6.11	-0.31	2.68e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.63	-12.45	-0.56	1.37e-29	Urate levels in overweight individuals;
LIHC	cis	rs6088813	0.925	rs1540928	chr20:33961845	C/A	cg14752227	chr20:34000481	UQCC	-0.4	-5.8	-0.3	1.53e-8	Height;
LIHC	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.66	10.41	0.49	3.24e-22	Type 2 diabetes;
LIHC	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.46	-6.83	-0.35	3.92e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.32	0.37	1.8e-12	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.45	6.41	0.33	4.74e-10	Pancreatic cancer;
LIHC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04025307	chr7:1156635	C7orf50	0.55	7.31	0.37	1.9e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.26	-0.41	3.22e-15	Response to antipsychotic treatment;
LIHC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs926392	0.965	rs6124106	chr20:37693042	G/A	cg16355469	chr20:37678765	NA	0.36	5.77	0.3	1.77e-8	Dialysis-related mortality;
LIHC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.73	-11.62	-0.53	1.6e-26	Fibrinogen levels;
LIHC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg05110241	chr16:68378359	PRMT7	-0.51	-5.82	-0.3	1.38e-8	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00954536	chr5:110427846	WDR36	0.41	6.28	0.32	1e-9	Calcium levels;
LIHC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	7.73	0.39	1.24e-13	Mean platelet volume;
LIHC	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg27433088	chr4:174089019	GALNT7	0.4	7.28	0.37	2.3e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.52	9.96	0.47	1.13e-20	Testicular germ cell tumor;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.92	12.64	0.56	2.52e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.25	0.32	1.22e-9	Height;
LIHC	cis	rs11630290	0.604	rs17775820	chr15:64168582	G/A	cg12036633	chr15:63758958	NA	-0.64	-5.78	-0.3	1.73e-8	Iris characteristics;
LIHC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.45e-16	Motion sickness;
LIHC	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.92	-0.35	2.19e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	7.65	0.38	2.03e-13	Aortic root size;
LIHC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.42	0.33	4.56e-10	Glycated hemoglobin levels;
LIHC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg21361702	chr7:150065534	REPIN1	0.46	6.24	0.32	1.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.37	-9.43	-0.45	6.63e-19	Longevity;Endometriosis;
LIHC	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	6.64	0.34	1.26e-10	Menarche (age at onset);
LIHC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.36	5.75	0.3	1.98e-8	Schizophrenia;
LIHC	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.44	6.02	0.31	4.48e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.62	0.46	1.47e-19	Bipolar disorder;
LIHC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.28	-5.72	-0.3	2.3e-8	Aortic root size;
LIHC	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg09572067	chr16:29127029	RRN3P2	0.51	8.06	0.4	1.3e-14	Menopause (age at onset);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22542420	chr17:43183176	NMT1	0.45	6.66	0.34	1.07e-10	Bilirubin levels;
LIHC	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	7.4	0.37	1.1e-12	Height;
LIHC	trans	rs783540	0.835	rs783522	chr15:83280613	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.14	-0.32	2.27e-9	Schizophrenia;
LIHC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.57	-10.16	-0.48	2.26e-21	Schizophrenia;
LIHC	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-0.67	-11.75	-0.54	5.12e-27	Pediatric autoimmune diseases;
LIHC	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.69	0.34	9.11e-11	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.41	-5.72	-0.3	2.37e-8	Life satisfaction;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25940730	chr4:16228647	TAPT1;FLJ39653	-0.42	-6.3	-0.32	9.03e-10	Pancreatic cancer;
LIHC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.98	14.29	0.61	1.24e-36	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	4.98e-12	Corneal astigmatism;
LIHC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02034447	chr16:89574710	SPG7	0.47	7.19	0.36	3.99e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.22	-0.36	3.49e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.39	-9.33	-0.45	1.36e-18	Breast cancer;
LIHC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg07148914	chr20:33460835	GGT7	-0.55	-8.29	-0.41	2.63e-15	Height;
LIHC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.81	8.62	0.42	2.59e-16	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.4	-7.33	-0.37	1.69e-12	Aortic root size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07699235	chr13:39260309	FREM2	0.39	6.14	0.32	2.29e-9	Cognitive function;
LIHC	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.22	0.41	4.31e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17554472	chr22:41940697	POLR3H	-0.51	-5.72	-0.3	2.37e-8	Vitiligo;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17675882	chr20:35374068	NDRG3	0.42	6.71	0.34	7.97e-11	Cognitive function;
LIHC	cis	rs11031096	0.655	rs12293706	chr11:4211581	C/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.92	-0.3	7.73e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg06792154	chr17:29157990	ATAD5	0.4	6.34	0.32	7.11e-10	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.71	-0.65	3.04e-42	Chronic sinus infection;
LIHC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg05343316	chr1:45956843	TESK2	0.45	6.59	0.34	1.62e-10	High light scatter reticulocyte count;
LIHC	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.52	-8.67	-0.42	1.75e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.54	9.17	0.44	4.44e-18	Mean corpuscular volume;
LIHC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20307385	chr11:47447363	PSMC3	-0.44	-5.82	-0.3	1.36e-8	Subjective well-being;
LIHC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.78	12.34	0.56	3.35e-29	Corneal astigmatism;
LIHC	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.36	6.94	0.35	2.03e-11	Growth-regulated protein alpha levels;
LIHC	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.58	-0.34	1.82e-10	Body mass index;
LIHC	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.67	10.52	0.49	1.33e-22	Obesity-related traits;
LIHC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg03854865	chr6:26224070	HIST1H3E	0.7	7.73	0.39	1.17e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07305463	chr2:136567211	LCT	0.39	7.32	0.37	1.79e-12	Mosquito bite size;
LIHC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg24826892	chr11:71159390	DHCR7	0.45	5.78	0.3	1.72e-8	Vitamin D levels;
LIHC	cis	rs986417	0.892	rs55695351	chr14:60796565	G/T	cg27398547	chr14:60952738	C14orf39	-0.72	-7.37	-0.37	1.29e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs2737618	0.651	rs2816974	chr1:200082686	C/G	cg21825944	chr1:200113062	NR5A2	0.46	7.86	0.39	5.05e-14	Uric acid levels;
LIHC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg17724175	chr1:150552817	MCL1	-0.38	-7.84	-0.39	5.72e-14	Tonsillectomy;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-5.75	-0.3	1.94e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.71	-11.02	-0.51	2.18e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.43	7.2	0.36	3.9e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs611744	0.967	rs627604	chr8:109189819	C/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.15	0.4	6.82e-15	Lung cancer;
LIHC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.75	-10.73	-0.5	2.44e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.12	-11.47	-0.53	5.57e-26	Type 1 diabetes nephropathy;
LIHC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21467203	chr3:49911342	NA	-0.45	-8.11	-0.4	9.18e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3106136	0.681	rs1609423	chr4:95301949	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.43	0.33	4.22e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg22903471	chr2:27725779	GCKR	-0.31	-5.91	-0.3	8.38e-9	Total body bone mineral density;
LIHC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.47	7.36	0.37	1.38e-12	Red blood cell count;Reticulocyte count;
LIHC	trans	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg26939375	chr7:64535504	NA	-0.43	-6.82	-0.35	4.17e-11	Aortic root size;
LIHC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.29	-6.86	-0.35	3.15e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.44	6.34	0.32	7.48e-10	Aortic root size;
LIHC	cis	rs1144333	0.655	rs1144337	chr1:76278877	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-8.54	-0.42	4.34e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.68	10.02	0.48	7.06e-21	Monocyte percentage of white cells;
LIHC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.85	-15.0	-0.63	2e-39	Aortic root size;
LIHC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00152838	chr16:24741724	TNRC6A	-0.54	-6.56	-0.33	1.96e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.7	-10.26	-0.49	1.04e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.74	11.1	0.51	1.15e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	1.000	rs60144605	chr1:76359699	A/C	cg22875332	chr1:76189707	ACADM	0.4	6.33	0.32	7.88e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.59	8.97	0.44	1.94e-17	Longevity;Endometriosis;
LIHC	cis	rs16912285	0.535	rs6484040	chr11:24309809	C/A	ch.11.24196551F	chr11:24239977	NA	0.8	10.91	0.51	5.6e-24	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.25	0.45	2.46e-18	Eosinophil percentage of white cells;
LIHC	cis	rs922107	0.846	rs359925	chr1:89996336	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.42	-0.37	9.38e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.43	-7.39	-0.37	1.14e-12	Educational attainment;
LIHC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.85	12.94	0.57	1.93e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg16797656	chr11:68205561	LRP5	0.49	8.44	0.42	9.06e-16	Total body bone mineral density;
LIHC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg16070123	chr10:51489643	NA	0.38	6.03	0.31	4.15e-9	Prostate-specific antigen levels;
LIHC	cis	rs17152411	0.947	rs7079199	chr10:126590820	A/C	cg07906193	chr10:126599966	NA	0.48	7.31	0.37	1.9e-12	Height;
LIHC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.76	-11.66	-0.53	1.11e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg00204512	chr16:28754710	NA	0.29	5.71	0.3	2.39e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.11	0.31	2.72e-9	Myopia (pathological);
LIHC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.16	0.55	1.55e-28	Platelet count;
LIHC	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.54	-8.58	-0.42	3.46e-16	Waist circumference;Body mass index;
LIHC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.41	0.33	4.72e-10	Total body bone mineral density;
LIHC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.93	12.7	0.57	1.59e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	10.53	0.49	1.2e-22	Lung cancer;
LIHC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.79	8.5	0.42	5.76e-16	Plateletcrit;
LIHC	cis	rs12079745	0.793	rs11806445	chr1:169219029	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.75	-6.98	-0.35	1.53e-11	QT interval;
LIHC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg07706471	chr12:123319906	HIP1R	-0.62	-8.14	-0.4	7.53e-15	Schizophrenia;
LIHC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.64	11.65	0.53	1.25e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.73	0.34	7.17e-11	Type 2 diabetes;
LIHC	cis	rs4934494	0.768	rs12570813	chr10:91390731	C/T	cg19698084	chr10:91461284	KIF20B	-0.46	-6.29	-0.32	9.75e-10	Red blood cell count;
LIHC	cis	rs12594515	0.548	rs12912226	chr15:45985708	T/G	cg01629716	chr15:45996671	NA	0.54	6.17	0.32	1.98e-9	Waist circumference;Weight;
LIHC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg08499158	chr17:42289980	UBTF	-0.49	-8.39	-0.41	1.31e-15	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.43	-8.33	-0.41	1.94e-15	Obesity-related traits;
LIHC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg18867708	chr6:26865862	GUSBL1	0.52	8.03	0.4	1.64e-14	Schizophrenia;
LIHC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.06	0.31	3.52e-9	Cognitive ability;
LIHC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.71	9.51	0.46	3.52e-19	Mean platelet volume;
LIHC	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.39	-5.93	-0.31	7.26e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs5753037	0.809	rs740041	chr22:30200099	A/G	cg01021169	chr22:30184971	ASCC2	-0.35	-6.66	-0.34	1.08e-10	Type 1 diabetes;
LIHC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20011983	chr2:74347215	NA	-0.39	-5.77	-0.3	1.81e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs507080	0.922	rs644498	chr11:118567486	T/C	cg04173919	chr11:118528438	PHLDB1	0.36	6.68	0.34	9.53e-11	Serum metabolite levels;
LIHC	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	0.55	10.39	0.49	3.56e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg17845761	chr1:175162550	KIAA0040	-0.37	-6.14	-0.31	2.35e-9	Alcohol dependence;
LIHC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.6	-7.15	-0.36	5.35e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.43	7.29	0.37	2.12e-12	Obesity (extreme);
LIHC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.73	-0.5	2.35e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11760633	0.747	rs11765289	chr7:1833097	C/G	cg23422044	chr7:1970798	MAD1L1	-0.42	-6.24	-0.32	1.32e-9	Coronary artery disease;
LIHC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg05555928	chr11:63887634	MACROD1	0.55	7.54	0.38	4.38e-13	Attention deficit hyperactivity disorder;
LIHC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg22633049	chr21:46681294	NA	0.36	6.09	0.31	3e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.11	-0.48	3.39e-21	Response to antipsychotic treatment;
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	8.03	0.4	1.55e-14	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.59	-8.72	-0.43	1.21e-16	Prudent dietary pattern;
LIHC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	11.99	0.54	6.66e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.57	9.19	0.45	3.88e-18	HDL cholesterol;
LIHC	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.23	0.32	1.36e-9	Mean corpuscular volume;
LIHC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.82	0.39	6.4e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6586163	0.872	rs7910825	chr10:90743341	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.53	-7.76	-0.39	9.9e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.41	-7.38	-0.37	1.18e-12	Aortic root size;
LIHC	trans	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg10756647	chr7:56101905	PSPH	1.11	13.6	0.59	5.63e-34	Diabetic kidney disease;
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05025164	chr4:1340916	KIAA1530	0.76	11.62	0.53	1.56e-26	Longevity;
LIHC	cis	rs59698941	0.882	rs6871970	chr5:132189594	G/A	cg02081065	chr5:132209139	LEAP2	0.27	6.11	0.31	2.69e-9	Apolipoprotein A-IV levels;
LIHC	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.62	6.25	0.32	1.25e-9	Lymphocyte counts;
LIHC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.99	0.35	1.47e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.42	6.82	0.35	4.2e-11	QT interval;
LIHC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.29	-0.32	9.7e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.38	6.63	0.34	1.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27256523	chr13:48877460	RB1	0.45	6.05	0.31	3.76e-9	Lung function (FEV1/FVC);
LIHC	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg26441486	chr22:50317300	CRELD2	-0.35	-6.12	-0.31	2.5e-9	Schizophrenia;
LIHC	cis	rs17125944	0.686	rs7158555	chr14:53362006	G/A	cg00686598	chr14:53173677	PSMC6	-0.79	-8.89	-0.43	3.49e-17	Alzheimer's disease (late onset);
LIHC	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg18887096	chr2:219472410	PLCD4	0.36	6.32	0.32	8.27e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.72	-0.5	2.69e-23	Coronary artery disease;
LIHC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.23	0.64	2.5e-40	Menopause (age at onset);
LIHC	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg04306507	chr14:55594613	LGALS3	0.33	6.36	0.33	6.32e-10	Protein biomarker;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg14393609	chr7:65229607	NA	-0.44	-6.49	-0.33	3.1e-10	Corneal structure;
LIHC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.83	0.3	1.29e-8	Self-reported allergy;
LIHC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.85	9.65	0.46	1.23e-19	Initial pursuit acceleration;
LIHC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.69	12.4	0.56	2.04e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg26138144	chr22:38071188	LGALS1	0.75	14.21	0.61	2.53e-36	Fat distribution (HIV);
LIHC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg03037974	chr15:76606532	NA	-0.59	-10.09	-0.48	4.02e-21	Blood metabolite levels;
LIHC	trans	rs9914544	0.524	rs8071147	chr17:18790678	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.57	-0.33	1.82e-10	Educational attainment (years of education);
LIHC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg12374095	chr12:54320830	NA	0.45	6.98	0.35	1.57e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.59	-0.38	3.04e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs61712019	0.679	rs2861054	chr2:77716564	A/C	cg11252801	chr2:77748917	LRRTM4	0.56	7.73	0.39	1.2e-13	Schizophrenia;
LIHC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg21747090	chr2:27597821	SNX17	-0.43	-6.28	-0.32	1.01e-9	Total body bone mineral density;
LIHC	cis	rs16944613	0.636	rs6416552	chr15:91132111	T/C	cg26821196	chr15:91095069	CRTC3	0.44	7.53	0.38	4.6e-13	Colorectal cancer;
LIHC	trans	rs7226229	0.950	rs2291037	chr17:20924523	C/T	cg20684973	chr10:105127632	TAF5	-0.45	-6.16	-0.32	2.08e-9	Blood trace element (Se levels);
LIHC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.85	0.35	3.42e-11	Gut microbiome composition (summer);
LIHC	cis	rs4908760	0.539	rs2185205	chr1:8882664	T/A	cg20416874	chr1:8611966	RERE	-0.51	-8.88	-0.43	3.94e-17	Vitiligo;
LIHC	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07305463	chr2:136567211	LCT	0.39	7.07	0.36	8.54e-12	Mosquito bite size;
LIHC	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.36	9.74	0.47	5.88e-20	Weight;
LIHC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	5.82	0.3	1.35e-8	Schizophrenia;
LIHC	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.56	-8.09	-0.4	1.09e-14	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06268701	chr1:110091083	GNAI3	-0.45	-6.08	-0.31	3.23e-9	Pancreatic cancer;
LIHC	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	ch.11.42038R	chr11:967971	AP2A2	0.58	10.71	0.5	2.85e-23	Alzheimer's disease (late onset);
LIHC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.44	-8.14	-0.4	7.23e-15	Platelet distribution width;
LIHC	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg26031613	chr14:104095156	KLC1	1.14	14.82	0.63	1.04e-38	Body mass index;
LIHC	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.45	6.85	0.35	3.51e-11	Height;
LIHC	trans	rs6934970	1.000	rs12196496	chr6:113021779	T/A	cg09308777	chr6:169852575	NA	0.58	6.2	0.32	1.6e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6060717	0.610	rs6060755	chr20:34606915	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.13	-0.36	5.92e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.29	6.36	0.32	6.66e-10	Pulmonary function;
LIHC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21467203	chr3:49911342	NA	0.44	7.74	0.39	1.1e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4908768	0.501	rs4908761	chr1:8552219	G/A	cg20416874	chr1:8611966	RERE	-0.65	-13.51	-0.59	1.31e-33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg03060546	chr3:49711283	APEH	0.39	5.87	0.3	1.01e-8	Menarche (age at onset);
LIHC	cis	rs8017423	0.845	rs80167706	chr14:90727629	G/C	cg14092571	chr14:90743983	NA	-0.38	-6.02	-0.31	4.54e-9	Mortality in heart failure;
LIHC	cis	rs2412488	0.927	rs1481819	chr4:54254146	G/A	cg22241045	chr4:54363911	LNX1	-0.46	-7.29	-0.37	2.2e-12	DNA methylation (variation);
LIHC	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.29	6.36	0.33	6.44e-10	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.94	11.06	0.51	1.58e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg07706471	chr12:123319906	HIP1R	0.57	7.62	0.38	2.57e-13	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.47	7.63	0.38	2.31e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.35	5.96	0.31	6.29e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.97	17.94	0.7	3.35e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs546131	0.642	rs1594425	chr11:34833322	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.67	-0.34	1.04e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg14784868	chr12:69753453	YEATS4	0.53	7.53	0.38	4.48e-13	Response to diuretic therapy;
LIHC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	5.81	0.3	1.47e-8	Lung cancer in ever smokers;
LIHC	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.37	-6.01	-0.31	4.68e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg16684958	chr7:75615977	POR	-0.51	-8.54	-0.42	4.47e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23152667	chr5:77072348	TBCA	-0.46	-6.5	-0.33	2.76e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2016586	0.802	rs5999972	chr22:36115542	A/C	cg26342177	chr22:36113512	APOL5	-0.39	-6.55	-0.33	2.13e-10	Body mass index;
LIHC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.5	-8.04	-0.4	1.53e-14	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.7	0.38	1.5e-13	Prudent dietary pattern;
LIHC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.01e-8	Tonsillectomy;
LIHC	cis	rs10847980	0.590	rs78462864	chr12:123365867	C/T	cg22842854	chr12:123319900	HIP1R	0.88	8.94	0.44	2.48e-17	Adiponectin levels;
LIHC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.56	9.84	0.47	2.69e-20	Alcohol dependence;
LIHC	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	7.88	0.39	4.34e-14	IgG glycosylation;
LIHC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.37	7.17	0.36	4.73e-12	Body mass index;
LIHC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.75	0.39	1.08e-13	Cognitive function;
LIHC	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg18898632	chr2:242989856	NA	-0.58	-7.77	-0.39	9.21e-14	Obesity-related traits;
LIHC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg05185784	chr16:90016020	DEF8	-0.48	-5.92	-0.3	7.94e-9	Skin colour saturation;
LIHC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs57244997	0.725	rs7742640	chr6:162413624	T/C	cg17173639	chr6:162384350	PARK2	-0.52	-6.8	-0.35	4.65e-11	Mosquito bite size;
LIHC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.47	7.76	0.39	9.96e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11234065	chr5:89825590	LYSMD3	0.41	6.33	0.32	7.48e-10	Pancreatic cancer;
LIHC	cis	rs1198430	0.852	rs909537	chr1:23810063	C/G	cg19827787	chr1:23763612	ASAP3	0.38	6.68	0.34	9.55e-11	Total cholesterol levels;
LIHC	cis	rs72772090	0.710	rs112178674	chr5:96060355	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.2	-0.36	3.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.44	-7.53	-0.38	4.55e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg25894440	chr7:65020034	NA	-0.54	-6.22	-0.32	1.43e-9	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.48	7.17	0.36	4.54e-12	Pancreatic cancer;
LIHC	cis	rs17106184	1.000	rs60483827	chr1:51301657	G/A	cg07174182	chr1:51127561	FAF1	-0.63	-6.72	-0.34	7.77e-11	Type 2 diabetes;
LIHC	cis	rs6586163	1.000	rs1324551	chr10:90751516	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-8.76	-0.43	9.2e-17	Chronic lymphocytic leukemia;
LIHC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg26874164	chr19:58962979	ZNF324B	0.59	9.16	0.44	4.85e-18	Uric acid clearance;
LIHC	cis	rs1075232	1.000	rs4450360	chr15:31682030	G/A	cg01030201	chr15:31746330	NA	-0.81	-6.25	-0.32	1.21e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.66	-8.92	-0.43	2.86e-17	White blood cell count;
LIHC	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg14515779	chr1:101123966	NA	0.48	6.95	0.35	1.83e-11	Monocyte count;
LIHC	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.09e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs9596863	0.898	rs35646102	chr13:54364897	G/T	ch.13.53330881F	chr13:54432880	NA	0.43	5.8	0.3	1.53e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.67	-9.14	-0.44	5.87e-18	Platelet count;
LIHC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.57	9.05	0.44	1.13e-17	Corneal astigmatism;
LIHC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.27	0.58	1.07e-32	Cognitive test performance;
LIHC	cis	rs635808	0.520	rs656938	chr6:167172048	C/T	cg05573767	chr6:167171394	RPS6KA2	0.34	7.49	0.38	5.99e-13	Dental caries;
LIHC	cis	rs12220238	0.915	rs11000987	chr10:76073265	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04317338	chr11:64019027	PLCB3	0.49	6.81	0.35	4.48e-11	Platelet count;
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.92	-0.54	1.19e-27	Alzheimer's disease;
LIHC	trans	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg19894588	chr14:64061835	NA	-0.63	-8.81	-0.43	6.48e-17	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-6.9	-0.35	2.47e-11	Menopause (age at onset);
LIHC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17554472	chr22:41940697	POLR3H	0.54	5.8	0.3	1.48e-8	Vitiligo;
LIHC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.34	0.32	7.2e-10	Glycated hemoglobin levels;
LIHC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg20195005	chr22:42527684	CYP2D6	0.32	6.15	0.32	2.19e-9	Birth weight;
LIHC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	8.19	0.4	5.35e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg21003380	chr1:156261207	TMEM79	0.38	6.07	0.31	3.49e-9	Tonsillectomy;
LIHC	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.98	16.95	0.68	3.29e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.75	8.71	0.43	1.33e-16	Exhaled nitric oxide output;
LIHC	trans	rs6866721	0.791	rs7704477	chr5:116217035	A/G	cg07571379	chr11:134631427	NA	-0.28	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.51	-8.56	-0.42	3.76e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.84	13.46	0.59	1.96e-33	Schizophrenia;
LIHC	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg15192750	chr16:69999425	NA	0.47	7.03	0.36	1.11e-11	IgE levels;
LIHC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-7.99	-0.4	2.1e-14	Tonsillectomy;
LIHC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-9.99	-0.48	8.96e-21	Alzheimer's disease;
LIHC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.25	-0.41	3.44e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.67e-9	Schizophrenia;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg14709524	chr16:89940631	TCF25	0.54	7.0	0.35	1.33e-11	Skin colour saturation;
LIHC	cis	rs8027181	0.682	rs11637168	chr15:73100694	C/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.43	6.73	0.34	7.07e-11	Triglyceride levels;
LIHC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02034447	chr16:89574710	SPG7	0.5	7.67	0.38	1.82e-13	Multiple myeloma (IgH translocation);
LIHC	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.5	7.18	0.36	4.25e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.74	-13.25	-0.58	1.28e-32	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs10411161	0.702	rs10423835	chr19:52387322	A/G	cg22319618	chr22:45562946	NUP50	-0.61	-8.42	-0.41	1.06e-15	Breast cancer;
LIHC	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.69	-12.54	-0.56	5.98e-30	Mean platelet volume;
LIHC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.57	10.11	0.48	3.39e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.36	5.77	0.3	1.77e-8	Schizophrenia;
LIHC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.71	-8.06	-0.4	1.3e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.74	0.34	6.75e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg20651018	chr11:3035856	CARS	0.36	6.13	0.31	2.36e-9	Longevity;
LIHC	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-8.59	-0.42	3.22e-16	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24656492	chr10:70940659	SUPV3L1	0.46	6.73	0.34	7.09e-11	Cognitive function;
LIHC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	1.06	14.27	0.61	1.46e-36	Heart rate;
LIHC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.89	0.3	9.32e-9	Menopause (age at onset);
LIHC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	1.03	20.93	0.75	3.47e-63	Breast cancer;
LIHC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.64	11.58	0.53	2.1e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg25039879	chr17:56429692	SUPT4H1	0.79	8.95	0.44	2.37e-17	Cognitive test performance;
LIHC	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg15871215	chr5:81402204	ATG10	-0.67	-8.01	-0.4	1.87e-14	Breast cancer;
LIHC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.26	-18.85	-0.71	7.11e-55	Ulcerative colitis;
LIHC	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.8	14.16	0.61	3.74e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.58	9.51	0.46	3.44e-19	Corneal astigmatism;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.71	-10.95	-0.51	4.09e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.69	-0.34	9.35e-11	Eosinophil percentage of white cells;
LIHC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg21395723	chr22:39101663	GTPBP1	0.36	6.22	0.32	1.46e-9	Menopause (age at onset);
LIHC	cis	rs77861329	1.000	rs59890038	chr3:52147850	A/G	cg08692210	chr3:52188851	WDR51A	0.85	8.07	0.4	1.24e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.77	-0.69	1.66e-50	Schizophrenia;
LIHC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg03929089	chr4:120376271	NA	-0.4	-6.09	-0.31	3.02e-9	HDL cholesterol;
LIHC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.85	12.22	0.55	9.54e-29	Glomerular filtration rate (creatinine);
LIHC	trans	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg14898824	chr12:64851143	TBK1	-0.33	-6.28	-0.32	1.02e-9	Schizophrenia;
LIHC	cis	rs918629	0.530	rs3777193	chr5:95246760	G/A	cg10483112	chr5:95245456	ELL2	-0.38	-7.12	-0.36	6.43e-12	IgG glycosylation;
LIHC	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.73	0.3	2.18e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02034447	chr16:89574710	SPG7	0.49	7.33	0.37	1.73e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.78e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.44	-7.23	-0.36	3.14e-12	Platelet distribution width;
LIHC	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.76	11.03	0.51	2.02e-24	Obesity-related traits;
LIHC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.59	6.71	0.34	8.15e-11	Neutrophil percentage of white cells;
LIHC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.74	7.63	0.38	2.35e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.53e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13265914	chr8:21999630	REEP4	0.48	7.19	0.36	4.22e-12	Pancreatic cancer;
LIHC	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.55	-0.33	2.1e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01297674	chr2:122406765	CLASP1	0.43	6.55	0.33	2.15e-10	Cognitive function;
LIHC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.8	8.9	0.43	3.22e-17	Vitiligo;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13409248	chr3:40428643	ENTPD3	0.49	8.22	0.41	4.34e-15	Renal cell carcinoma;
LIHC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.75	6.8	0.35	4.7e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LIHC	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.25	0.36	2.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.63	-9.95	-0.47	1.16e-20	Rheumatoid arthritis;
LIHC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg14092571	chr14:90743983	NA	0.4	6.25	0.32	1.19e-9	Mortality in heart failure;
LIHC	cis	rs17152411	0.652	rs4246208	chr10:126654898	C/T	cg07906193	chr10:126599966	NA	-0.31	-6.16	-0.32	2.02e-9	Height;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.07	-0.31	3.38e-9	Total body bone mineral density;
LIHC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.7	-9.73	-0.47	6.44e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.36	6.11	0.31	2.76e-9	Schizophrenia;
LIHC	cis	rs526821	0.595	rs499446	chr11:55355722	A/G	cg04317927	chr11:55418816	OR4S2	0.47	8.82	0.43	6.11e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-8.05	-0.4	1.35e-14	Morning vs. evening chronotype;
LIHC	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.33	6.96	0.35	1.74e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.71	13.76	0.6	1.4e-34	Menopause (age at onset);
LIHC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.74	-0.43	1.1e-16	Blood metabolite levels;
LIHC	cis	rs2997447	0.846	rs61775431	chr1:26411275	T/G	cg19633962	chr1:26362018	EXTL1	-0.7	-6.4	-0.33	5.06e-10	QRS complex (12-leadsum);
LIHC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.88	13.19	0.58	2.08e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg22552966	chr17:19620595	SLC47A2	-0.47	-9.58	-0.46	2.09e-19	Response to paliperidone in schizophrenia (CGI-S score);
LIHC	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.49	5.75	0.3	2.01e-8	Menarche (age at onset);
LIHC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.86	-14.23	-0.61	2.11e-36	Post bronchodilator FEV1;
LIHC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.76	6.04	0.31	4.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.48	-0.33	3.25e-10	Endometrial cancer;
LIHC	cis	rs240764	0.717	rs239215	chr6:101147426	A/G	cg12253828	chr6:101329408	ASCC3	0.42	6.45	0.33	3.74e-10	Neuroticism;
LIHC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg06207120	chr15:45996521	NA	-0.33	-6.23	-0.32	1.41e-9	Waist circumference;Weight;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.25	-0.36	2.8e-12	Renal cell carcinoma;
LIHC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.38	-9.64	-0.46	1.26e-19	Asthma (sex interaction);
LIHC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.54	0.77	1.37e-69	Chronic sinus infection;
LIHC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg22528358	chr1:107598549	PRMT6	0.72	11.91	0.54	1.35e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg12463550	chr7:65579703	CRCP	0.7	7.15	0.36	5.32e-12	Diabetic kidney disease;
LIHC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.15e-16	Motion sickness;
LIHC	cis	rs12980942	0.935	rs1865052	chr19:41824467	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.93	0.31	7.26e-9	Coronary artery disease;
LIHC	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.49	-9.28	-0.45	1.99e-18	Endometriosis;
LIHC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.86	0.51	8.31e-24	Lung cancer in ever smokers;
LIHC	cis	rs1144333	1.000	rs2202019	chr1:76299181	G/A	cg10523679	chr1:76189770	ACADM	0.47	6.79	0.34	5e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6466055	1.000	rs6466055	chr7:104929064	A/C	cg04380332	chr7:105027541	SRPK2	0.34	6.4	0.33	5.02e-10	Schizophrenia;
LIHC	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.93	-16.39	-0.66	5.96e-45	Oral cavity cancer;
LIHC	cis	rs4908768	0.579	rs12142911	chr1:8857245	C/G	cg20416874	chr1:8611966	RERE	0.4	5.77	0.3	1.75e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.67	-6.74	-0.34	6.71e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	7.86	0.39	5.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.36	0.37	1.38e-12	Morning vs. evening chronotype;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.76	11.18	0.52	6.04e-25	Menarche (age at onset);
LIHC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-29.44	-0.85	8.75e-96	Myeloid white cell count;
LIHC	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-7.39	-0.37	1.12e-12	Mortality in heart failure;
LIHC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.58	-7.6	-0.38	2.92e-13	Initial pursuit acceleration;
LIHC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	trans	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg05197062	chr11:11642011	GALNTL4	-0.42	-6.11	-0.31	2.73e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11060661	chr22:24314208	DDT;DDTL	0.66	11.57	0.53	2.32e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.66	-8.04	-0.4	1.5e-14	Homocysteine levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13173722	chr20:60553138	TAF4	0.48	6.49	0.33	3.03e-10	Hepatitis;
LIHC	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.67	10.26	0.49	1.02e-21	Colorectal adenoma (advanced);
LIHC	trans	rs10761482	0.500	rs7098650	chr10:62277679	C/T	cg17314160	chr12:110399253	GIT2	-0.43	-6.28	-0.32	1.01e-9	Schizophrenia;
LIHC	cis	rs9649465	0.967	rs9641717	chr7:123350060	C/T	cg03229431	chr7:123269106	ASB15	-0.37	-7.8	-0.39	7.33e-14	Migraine;
LIHC	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	0.59	6.35	0.32	6.8e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-7.19	-0.36	4.11e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.23	-0.55	8.74e-29	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg16822855	chr3:40428330	ENTPD3	-0.32	-5.74	-0.3	2.11e-8	Renal cell carcinoma;
LIHC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.25	-5.97	-0.31	5.96e-9	Cutaneous nevi;
LIHC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.55	-9.06	-0.44	1.05e-17	Cognitive function;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06577708	chr3:64008893	PSMD6	0.42	6.1	0.31	2.79e-9	Migraine with aura;
LIHC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg14222432	chr12:29376421	FAR2	0.36	6.97	0.35	1.68e-11	QT interval;
LIHC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.57	9.26	0.45	2.32e-18	Lymphocyte counts;
LIHC	cis	rs17106184	1.000	rs58795848	chr1:51283510	A/G	cg07174182	chr1:51127561	FAF1	-0.64	-7.22	-0.36	3.47e-12	Type 2 diabetes;
LIHC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.77	11.65	0.53	1.23e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.42	7.26	0.37	2.7e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.77	0.3	1.82e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.06	0.31	3.67e-9	Schizophrenia;
LIHC	cis	rs12403795	0.505	rs11811787	chr1:150200487	C/T	cg15654264	chr1:150340011	RPRD2	-0.4	-5.84	-0.3	1.21e-8	Illicit drug use;
LIHC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg10360323	chr17:41437877	NA	0.39	5.75	0.3	1.98e-8	Menopause (age at onset);
LIHC	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.59	-7.24	-0.36	2.96e-12	Vitamin D levels;
LIHC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.32	6.82	0.35	4.13e-11	Schizophrenia;
LIHC	cis	rs864643	1.000	rs1513213	chr3:39550897	G/A	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.31	-0.32	8.81e-10	Total body bone mineral density;
LIHC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg10932868	chr11:921992	NA	0.37	7.0	0.35	1.33e-11	Alzheimer's disease (late onset);
LIHC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.84	-0.35	3.62e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.56	8.85	0.43	4.65e-17	Corneal astigmatism;
LIHC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.53	-0.46	3.04e-19	Blood metabolite levels;
LIHC	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.21	10.85	0.51	9.25e-24	Uric acid levels;
LIHC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg04359351	chr2:3481828	TTC15	0.28	5.94	0.31	7.04e-9	Neurofibrillary tangles;
LIHC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg12373951	chr3:133503437	NA	-0.43	-6.67	-0.34	1.01e-10	Iron status biomarkers;
LIHC	trans	rs3743102	0.527	rs117959961	chr15:83339895	C/T	cg01542190	chr22:50604728	NA	-0.54	-7.18	-0.36	4.29e-12	Colorectal adenoma (advanced);
LIHC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	7.6	0.38	2.88e-13	Schizophrenia;
LIHC	cis	rs8083850	0.635	rs9954344	chr18:50861056	C/G	cg24270629	chr18:50823537	DCC	0.56	8.41	0.41	1.16e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg00091569	chr3:40428383	ENTPD3	0.38	6.27	0.32	1.09e-9	Renal cell carcinoma;
LIHC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-7.34	-0.37	1.54e-12	Morning vs. evening chronotype;
LIHC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.46	6.74	0.34	6.88e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg00792783	chr2:198669748	PLCL1	0.45	6.69	0.34	9.26e-11	Intracranial aneurysm;
LIHC	trans	rs3858145	0.588	rs4142049	chr10:70044452	C/A	cg04882175	chr6:131122610	NA	-0.51	-6.09	-0.31	3.06e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg17724175	chr1:150552817	MCL1	0.43	8.59	0.42	3.2e-16	Melanoma;
LIHC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.86	12.83	0.57	5.16e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-6.12	-0.31	2.56e-9	Morning vs. evening chronotype;
LIHC	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg09594475	chr20:60884601	LAMA5	0.58	6.56	0.33	1.94e-10	Colorectal cancer;
LIHC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.5	-0.33	2.85e-10	Colorectal cancer;
LIHC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.51	0.46	3.51e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.39	5.9	0.3	8.89e-9	Tuberculosis;
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.43	7.87	0.39	4.56e-14	Prudent dietary pattern;
LIHC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.37	0.41	1.53e-15	Motion sickness;
LIHC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.54	-6.65	-0.34	1.18e-10	Menarche (age at onset);
LIHC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg02297831	chr4:17616191	MED28	0.49	7.61	0.38	2.63e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.37	-5.78	-0.3	1.7e-8	Diastolic blood pressure;
LIHC	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs903552	1.000	rs4965873	chr15:102004023	A/G	cg19295451	chr15:102010161	PCSK6	0.47	6.52	0.33	2.52e-10	Diabetic kidney disease;
LIHC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09863094	chr10:134546253	INPP5A	0.4	6.12	0.31	2.55e-9	Immature fraction of reticulocytes;
LIHC	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.5	7.9	0.39	3.92e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03226425	chr6:170151538	C6orf70;TCTE3	0.53	7.89	0.39	4.25e-14	Cognitive function;
LIHC	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-5.9	-0.3	8.63e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.69	7.93	0.39	3.15e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.41	6.32	0.32	8.33e-10	Lung cancer;
LIHC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.43	6.43	0.33	4.37e-10	Methadone dose in opioid dependence;
LIHC	cis	rs17106184	1.000	rs72904737	chr1:51351846	G/A	cg07174182	chr1:51127561	FAF1	-0.59	-6.12	-0.31	2.52e-9	Type 2 diabetes;
LIHC	cis	rs4934494	0.727	rs36019294	chr10:91537579	G/A	cg19698084	chr10:91461284	KIF20B	-0.44	-5.88	-0.3	9.5e-9	Red blood cell count;
LIHC	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.7	6.51	0.33	2.72e-10	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.31	6.39	0.33	5.42e-10	Bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03900353	chr1:212732456	NA	0.39	6.33	0.32	7.87e-10	Cognitive function;
LIHC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.95	0.31	6.81e-9	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.38	0.33	5.76e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg01864836	chr14:55583639	NA	-0.42	-8.19	-0.4	5.27e-15	Protein biomarker;
LIHC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.51	-0.49	1.38e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6973256	0.568	rs7800126	chr7:133521356	A/C	cg10665199	chr7:133106180	EXOC4	0.35	5.85	0.3	1.14e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg03013999	chr17:37608204	MED1	-0.36	-6.07	-0.31	3.33e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.51	-0.33	2.7e-10	Ulcerative colitis;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.52	-8.16	-0.4	6.64e-15	Body mass index;
LIHC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.65	11.25	0.52	3.49e-25	Menopause (age at onset);
LIHC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.81	-0.3	1.42e-8	Uric acid levels;
LIHC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.44	7.22	0.36	3.5e-12	Red blood cell count;
LIHC	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg09238746	chr17:78121135	EIF4A3	0.41	6.3	0.32	9.38e-10	Yeast infection;
LIHC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	1.07	14.34	0.61	7.59e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg22890737	chr4:3514540	LRPAP1	0.44	7.21	0.36	3.55e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03517284	chr6:25882590	NA	0.53	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09695851	chr17:3907499	NA	0.69	8.62	0.42	2.6e-16	Type 2 diabetes;
LIHC	cis	rs4728302	0.869	rs6955279	chr7:133612113	C/T	cg10665199	chr7:133106180	EXOC4	0.4	6.92	0.35	2.3e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg05896524	chr21:47604654	C21orf56	-0.46	-7.1	-0.36	7.48e-12	Testicular germ cell tumor;
LIHC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.59	6.94	0.35	1.92e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-9.22	-0.45	3.14e-18	Schizophrenia;
LIHC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg02290350	chr8:58132656	NA	0.41	8.7	0.43	1.43e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07305463	chr2:136567211	LCT	0.37	6.44	0.33	4.01e-10	Mosquito bite size;
LIHC	cis	rs1434579	0.615	rs1560915	chr19:44937379	C/T	cg15540054	chr19:45004280	ZNF180	0.65	9.81	0.47	3.44e-20	Tuberculosis;
LIHC	cis	rs6663390	0.510	rs2267897	chr1:208075378	C/T	cg03990033	chr1:208084030	CD34	0.48	5.8	0.3	1.53e-8	Facial morphology (factor 18);
LIHC	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.77	0.34	5.63e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg12365402	chr11:9010492	NRIP3	-0.28	-7.21	-0.36	3.58e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.67	11.86	0.54	2.12e-27	Longevity;Endometriosis;
LIHC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-7.31	-0.37	1.9e-12	Osteoporosis;
LIHC	cis	rs1144333	0.655	rs1144337	chr1:76278877	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.66	-0.34	1.07e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.65	-9.6	-0.46	1.77e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.64	-10.53	-0.49	1.21e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg20933634	chr6:27740509	NA	-0.43	-5.78	-0.3	1.71e-8	Parkinson's disease;
LIHC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg05425664	chr17:57184151	TRIM37	-0.43	-6.0	-0.31	5.13e-9	Testicular germ cell tumor;
LIHC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg18016565	chr1:150552671	MCL1	-0.5	-10.32	-0.49	6.68e-22	Tonsillectomy;
LIHC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.27	-6.61	-0.34	1.51e-10	Cutaneous nevi;
LIHC	cis	rs7129220	0.512	rs16907504	chr11:10169531	C/G	cg01453529	chr11:10209919	SBF2	-0.37	-6.71	-0.34	7.98e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.4	-5.93	-0.31	7.52e-9	Schizophrenia;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.64	-10.39	-0.49	3.66e-22	Prudent dietary pattern;
LIHC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.26	-18.71	-0.71	2.75e-54	Ulcerative colitis;
LIHC	cis	rs8067354	0.574	rs2250526	chr17:57951973	G/A	cg13753209	chr17:57696993	CLTC	0.69	10.21	0.48	1.52e-21	Hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.56	8.91	0.43	3.14e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg18306943	chr3:40428807	ENTPD3	0.35	5.87	0.3	1.01e-8	Renal cell carcinoma;
LIHC	cis	rs864643	1.000	rs866537	chr3:39571616	T/C	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.42	-6.73	-0.34	7e-11	Inhibitory control;
LIHC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg14779329	chr11:130786720	SNX19	0.42	6.34	0.32	7.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs3736228	0.604	rs3018716	chr11:68404222	T/C	cg16797656	chr11:68205561	LRP5	0.49	6.24	0.32	1.3e-9	Bone mineral density;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11032208	chr5:95997736	CAST	-0.54	-6.73	-0.34	7.03e-11	Systolic blood pressure;
LIHC	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg07541023	chr7:19748670	TWISTNB	0.39	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LIHC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.56e-16	Primary biliary cholangitis;
LIHC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-1.01	-10.4	-0.49	3.45e-22	Breast cancer;
LIHC	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-9.18	-0.44	4.23e-18	Schizophrenia;
LIHC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-9.09	-0.44	8.36e-18	Mean corpuscular hemoglobin;
LIHC	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.61	-7.38	-0.37	1.2e-12	Blood metabolite levels;
LIHC	cis	rs611744	0.901	rs673981	chr8:109191917	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.44	7.78	0.39	8.74e-14	Aortic root size;
LIHC	trans	rs10411161	1.000	rs8106929	chr19:52368467	A/G	cg22319618	chr22:45562946	NUP50	-0.52	-7.07	-0.36	8.85e-12	Breast cancer;
LIHC	trans	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.52	-0.33	2.59e-10	Aortic root size;
LIHC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.51	7.95	0.39	2.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.27	-0.58	1.06e-32	Primary sclerosing cholangitis;
LIHC	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.83	16.02	0.65	1.79e-43	Testicular germ cell tumor;
LIHC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	8.07	0.4	1.21e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.78	-0.34	5.41e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg27205649	chr11:78285834	NARS2	-0.39	-5.89	-0.3	8.99e-9	Alzheimer's disease (survival time);
LIHC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-6.76	-0.34	6.13e-11	Renal function-related traits (BUN);
LIHC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.52	-0.33	2.52e-10	Mean corpuscular volume;
LIHC	cis	rs1494950	1.000	rs73797775	chr4:14976930	T/C	cg12377275	chr4:15005593	CPEB2	-0.79	-6.71	-0.34	8.25e-11	Political ideology;
LIHC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.27	-6.04	-0.31	4.06e-9	Gut microbiome composition (winter);
LIHC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.66	-0.34	1.09e-10	Bipolar disorder;
LIHC	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.26	-0.49	1.06e-21	Response to antipsychotic treatment;
LIHC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.9	0.3	8.52e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg13175981	chr1:150552382	MCL1	0.49	7.06	0.36	9.41e-12	Urate levels;
LIHC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs600806	0.683	rs10857789	chr1:110012293	C/T	cg16275483	chr1:110013120	SYPL2	-0.49	-6.22	-0.32	1.42e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg23091122	chr1:110024289	SYPL2	-0.49	-6.49	-0.33	2.97e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.95	0.39	2.83e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.45	6.54	0.33	2.27e-10	Longevity;
LIHC	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.73	0.39	1.18e-13	Alzheimer's disease;
LIHC	cis	rs7534824	0.625	rs7414132	chr1:101526413	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.74	7.14	0.36	5.75e-12	Refractive astigmatism;
LIHC	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.52	-8.36	-0.41	1.6e-15	Endometriosis;
LIHC	cis	rs8083850	0.666	rs965943	chr18:50857430	A/G	cg24270629	chr18:50823537	DCC	-0.58	-8.93	-0.43	2.7e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.93	-14.97	-0.63	2.44e-39	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.46	7.09	0.36	7.91e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs655641	1.000	rs544458	chr11:85778924	C/T	cg09030501	chr11:85779252	PICALM	-0.48	-5.72	-0.3	2.3e-8	Platelet count;
LIHC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	8.28	0.41	2.86e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.74	14.14	0.61	4.76e-36	Mortality in heart failure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg27303430	chr2:227663593	IRS1	-0.52	-6.07	-0.31	3.34e-9	Systolic blood pressure;
LIHC	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.46	8.33	0.41	1.96e-15	Multiple myeloma;
LIHC	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg06096015	chr1:231504339	EGLN1	-0.45	-7.43	-0.37	8.77e-13	Red blood cell count;
LIHC	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.43	6.71	0.34	7.91e-11	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.56	10.26	0.49	1.02e-21	Methadone dose in opioid dependence;
LIHC	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.42	-8.37	-0.41	1.48e-15	Testicular germ cell tumor;
LIHC	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-7.23	-0.36	3.16e-12	Serum thyroid-stimulating hormone levels;
LIHC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-7.55	-0.38	4.07e-13	Homoarginine levels;
LIHC	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.52	8.15	0.4	6.78e-15	HDL cholesterol;
LIHC	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.78	7.46	0.37	7.42e-13	Blood protein levels;
LIHC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-8.99	-0.44	1.66e-17	Longevity;Endometriosis;
LIHC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.42	7.29	0.37	2.22e-12	Aortic root size;
LIHC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.64	11.89	0.54	1.54e-27	Rheumatoid arthritis;
LIHC	cis	rs3812111	0.665	rs517352	chr6:116429623	T/A	cg08036074	chr6:116424633	NT5DC1	0.67	12.09	0.55	2.93e-28	Age-related macular degeneration;
LIHC	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.31	-0.37	1.89e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.96	11.79	0.54	3.72e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.22	0.52	4.31e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.7	-6.42	-0.33	4.61e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.68	9.8	0.47	3.72e-20	Testicular germ cell tumor;
LIHC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.87	-0.3	1.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.61	-8.53	-0.42	4.88e-16	Blood metabolite levels;
LIHC	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.61	0.53	1.76e-26	Coffee consumption (cups per day);
LIHC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.42	-0.33	4.64e-10	Longevity;Endometriosis;
LIHC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	7.07	0.36	8.98e-12	Parkinson's disease;
LIHC	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg06360820	chr2:242988706	NA	-0.84	-11.72	-0.54	6.95e-27	Obesity-related traits;
LIHC	cis	rs509477	0.718	rs273344	chr18:32603927	C/T	cg23791764	chr18:32556832	MAPRE2	0.45	6.16	0.32	2.08e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.61	7.33	0.37	1.64e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs12752401	0.867	rs12751548	chr1:103067463	A/G	cg17681729	chr19:740608	PALM	-0.43	-6.22	-0.32	1.43e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	trans	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.48	-0.37	6.16e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-23.71	-0.79	3.38e-74	Height;
LIHC	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg10820045	chr2:198174542	NA	0.53	8.44	0.42	9.26e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.56	-6.11	-0.31	2.74e-9	Menarche (age at onset);
LIHC	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg25110126	chr1:46999211	NA	0.41	6.09	0.31	2.96e-9	Monobrow;
LIHC	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.53	6.71	0.34	7.87e-11	Tourette syndrome;
LIHC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg02290350	chr8:58132656	NA	-0.37	-7.62	-0.38	2.56e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.56	-8.94	-0.44	2.57e-17	Menarche (age at onset);
LIHC	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	8.59	0.42	3.24e-16	Birth weight;
LIHC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.48	7.91	0.39	3.67e-14	Multiple sclerosis;
LIHC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	13.59	0.59	6.2e-34	Chronic sinus infection;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg00280220	chr17:61926910	NA	0.43	6.89	0.35	2.64e-11	Prudent dietary pattern;
LIHC	cis	rs738321	0.756	rs12167576	chr22:38512562	G/A	cg25457927	chr22:38595422	NA	-0.29	-6.47	-0.33	3.49e-10	Breast cancer;
LIHC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg12641515	chr19:46296257	DMWD	0.46	6.94	0.35	1.97e-11	Coronary artery disease;
LIHC	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.81	9.5	0.46	3.89e-19	Bladder cancer;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg14393609	chr7:65229607	NA	0.45	6.59	0.34	1.63e-10	Calcium levels;
LIHC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12463550	chr7:65579703	CRCP	0.68	6.97	0.35	1.62e-11	Gout;
LIHC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21467203	chr3:49911342	NA	-0.44	-7.79	-0.39	7.94e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg20636351	chr8:55087400	NA	-0.39	-8.04	-0.4	1.43e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.38	0.33	5.67e-10	Lung cancer in ever smokers;
LIHC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	8.74	0.43	1.05e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	9.07e-10	Aortic root size;
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg00204748	chr12:29376779	FAR2	0.42	7.89	0.39	4.23e-14	QT interval;
LIHC	cis	rs7534824	0.583	rs6577225	chr1:101506126	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	7.2	0.36	3.9e-12	Refractive astigmatism;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13469346	chr3:53195186	PRKCD	0.42	6.25	0.32	1.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00495681	chr13:53174319	NA	-0.39	-6.29	-0.32	9.92e-10	Lewy body disease;
LIHC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.63	10.41	0.49	3.21e-22	Platelet count;
LIHC	cis	rs16828019	0.929	rs12029321	chr1:41682530	G/C	cg03387723	chr1:41708464	SCMH1	-0.44	-7.23	-0.36	3.16e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.37	6.04	0.31	4.13e-9	Prostate cancer;
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.31	-0.41	2.31e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.57	-0.33	1.91e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1419980	0.730	rs73260714	chr12:7781057	C/G	cg10578777	chr12:7781093	NA	-0.4	-5.83	-0.3	1.26e-8	HDL cholesterol levels;
LIHC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.57	9.52	0.46	3.26e-19	Cognitive function;
LIHC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg14393609	chr7:65229607	NA	-0.38	-6.03	-0.31	4.25e-9	Aortic root size;
LIHC	cis	rs3018712	0.547	rs4930237	chr11:68414038	C/G	cg16797656	chr11:68205561	LRP5	-0.45	-5.88	-0.3	9.91e-9	Total body bone mineral density;
LIHC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-10.79	-0.5	1.5e-23	Asthma;
LIHC	cis	rs240764	0.645	rs240111	chr6:101059499	C/A	cg09795085	chr6:101329169	ASCC3	0.46	6.57	0.33	1.85e-10	Neuroticism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04498032	chr1:155242826	CLK2	0.38	6.39	0.33	5.38e-10	Cognitive function;
LIHC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.37	0.66	6.68e-45	Smoking behavior;
LIHC	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.54	-8.77	-0.43	8.27e-17	Post bronchodilator FEV1;
LIHC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-9.03	-0.44	1.24e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.76	-0.43	9.08e-17	Total cholesterol levels;
LIHC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg14440974	chr22:39074834	NA	0.35	5.79	0.3	1.59e-8	Menopause (age at onset);
LIHC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.47	0.33	3.38e-10	Bipolar disorder;
LIHC	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.8	7.69	0.38	1.56e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs17711722	0.690	rs116823227	chr7:65331001	A/G	cg26939375	chr7:64535504	NA	0.44	6.09	0.31	3.11e-9	Calcium levels;
LIHC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.59	-9.97	-0.47	9.88e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.33	0.37	1.62e-12	Glycated hemoglobin levels;
LIHC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.35	7.33	0.37	1.7e-12	Cancer;
LIHC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.74	12.17	0.55	1.48e-28	Menarche (age at onset);
LIHC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.27e-19	Initial pursuit acceleration;
LIHC	cis	rs67981189	0.593	rs4132848	chr14:71459359	A/T	cg15816911	chr14:71606274	NA	0.42	6.7	0.34	8.37e-11	Schizophrenia;
LIHC	trans	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg17675199	chr6:35436792	RPL10A	0.43	8.89	0.43	3.45e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.53	-0.76	1.31e-65	Height;
LIHC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg21573476	chr21:45109991	RRP1B	-0.45	-8.78	-0.43	7.83e-17	Mean corpuscular volume;
LIHC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.01	-0.4	1.81e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-11.03	-0.51	2.02e-24	Type 2 diabetes;
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.73	10.31	0.49	7.04e-22	Menarche (age at onset);
LIHC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.47	0.37	6.62e-13	Tonsillectomy;
LIHC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736594	0.513	rs2384627	chr2:27774449	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.82	0.35	4.26e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.57	-9.5	-0.46	3.85e-19	Cognitive function;
LIHC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.55	7.29	0.37	2.14e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4742903	1.000	rs1026181	chr9:106893334	A/G	cg14250997	chr9:106856677	SMC2	0.41	7.42	0.37	9.4e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.94	-12.58	-0.56	4.46e-30	HIV-1 control;
LIHC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.6	-7.28	-0.37	2.35e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg25730555	chr22:47059586	GRAMD4	0.36	6.02	0.31	4.6e-9	Urate levels in obese individuals;
LIHC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.97	11.78	0.54	4.14e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs12464559	0.649	rs3768658	chr2:152677674	T/C	cg01189475	chr2:152685088	ARL5A	0.64	7.48	0.38	6.16e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.64	-10.78	-0.5	1.64e-23	Colorectal cancer;
LIHC	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.92	0.3	7.73e-9	Mean corpuscular volume;
LIHC	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.81	-0.39	7.2e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.47	-0.37	6.66e-13	Post bronchodilator FEV1;
LIHC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg19302996	chr17:73780495	UNK	0.6	9.74	0.47	6.25e-20	White matter hyperintensity burden;
LIHC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-9.82	-0.47	3.24e-20	Venous thromboembolism (SNP x SNP interaction);
LIHC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.86	0.35	3.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.63	12.47	0.56	1.14e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.16	-0.32	2.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs6489882	0.867	rs6489866	chr12:113363408	A/G	cg10175203	chr3:128143634	NA	0.39	6.38	0.33	5.72e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg02290350	chr8:58132656	NA	0.33	7.41	0.37	1.01e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.2	-0.32	1.65e-9	Lung cancer;
LIHC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	6.11e-31	Breast cancer;
LIHC	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.77	-0.3	1.75e-8	Coronary artery disease;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg23131131	chr22:24373011	LOC391322	0.51	6.52	0.33	2.47e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.25	-0.32	1.21e-9	Metabolite levels;
LIHC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.64	11.09	0.51	1.28e-24	Coronary artery disease;
LIHC	cis	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg19680485	chr15:31195859	MTMR15	-0.54	-6.0	-0.31	5.11e-9	Hypertriglyceridemia;
LIHC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.95	0.35	1.82e-11	Height;
LIHC	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg17724175	chr1:150552817	MCL1	0.51	10.16	0.48	2.22e-21	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.3	-5.71	-0.3	2.44e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.1	-0.31	2.91e-9	Tuberculosis;
LIHC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg18306943	chr3:40428807	ENTPD3	0.34	6.06	0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg17724175	chr1:150552817	MCL1	0.42	8.03	0.4	1.61e-14	Melanoma;
LIHC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.44	-0.56	1.42e-29	Colorectal cancer;
LIHC	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.32	-6.47	-0.33	3.3e-10	Sitting height ratio;
LIHC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.47	6.89	0.35	2.72e-11	Tonsillectomy;
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.85	-0.35	3.44e-11	Total body bone mineral density;
LIHC	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg09003973	chr2:102972529	NA	0.53	6.04	0.31	4.09e-9	Blood protein levels;
LIHC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.49	7.75	0.39	1.08e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.52	0.56	7.07e-30	Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg00280220	chr17:61926910	NA	0.44	7.07	0.36	8.7e-12	Prudent dietary pattern;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.19	-0.41	5.17e-15	Total body bone mineral density;
LIHC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg07424592	chr7:64974309	NA	0.83	9.5	0.46	3.78e-19	Diabetic kidney disease;
LIHC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.07	-0.48	4.6e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.93	-18.8	-0.71	1.15e-54	Schizophrenia;
LIHC	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.59	-8.61	-0.42	2.72e-16	Facial morphology (factor 19);
LIHC	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg02269571	chr22:50332266	NA	0.61	8.65	0.42	2.06e-16	Schizophrenia;
LIHC	cis	rs7707921	0.767	rs226202	chr5:81571669	C/T	cg15871215	chr5:81402204	ATG10	0.7	8.44	0.42	8.92e-16	Breast cancer;
LIHC	cis	rs12980942	0.872	rs11879562	chr19:41804976	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.28	0.32	1.02e-9	Coronary artery disease;
LIHC	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.44	-5.93	-0.31	7.56e-9	Neuroticism;
LIHC	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg20697417	chr1:41786797	NA	0.33	6.24	0.32	1.32e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.68	10.65	0.5	4.44e-23	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.85	-0.3	1.13e-8	Red blood cell count;
LIHC	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg13798912	chr7:905769	UNC84A	-0.55	-6.72	-0.34	7.39e-11	Cerebrospinal P-tau181p levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11034861	chr16:67194079	TRADD;FBXL8	0.55	6.9	0.35	2.49e-11	Hepatitis;
LIHC	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.4	7.92	0.39	3.35e-14	Cardiovascular disease risk factors;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.31	0.52	2.06e-25	Prudent dietary pattern;
LIHC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.87	-0.47	2.26e-20	Tonsillectomy;
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg12792011	chr19:58661915	ZNF329	0.96	7.98	0.4	2.18e-14	Cholesterol, total;
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.1	-0.31	2.91e-9	Calcium levels;
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.47	-7.33	-0.37	1.71e-12	Testicular germ cell tumor;
LIHC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg04719120	chr6:96025338	MANEA	0.55	6.49	0.33	3.03e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg00280220	chr17:61926910	NA	0.43	6.79	0.34	4.99e-11	Prudent dietary pattern;
LIHC	cis	rs240764	0.594	rs7356804	chr6:101078438	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.91	0.3	8.43e-9	Neuroticism;
LIHC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.74	-8.25	-0.41	3.55e-15	Putamen volume;
LIHC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.83	0.51	1.03e-23	Colorectal cancer;
LIHC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.46	6.46	0.33	3.53e-10	Schizophrenia;
LIHC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.77	10.43	0.49	2.66e-22	Coronary artery disease;
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg00280220	chr17:61926910	NA	-0.39	-6.13	-0.31	2.46e-9	Prudent dietary pattern;
LIHC	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.48	7.57	0.38	3.6e-13	Alzheimer's disease (survival time);
LIHC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-10.74	-0.5	2.25e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg10820045	chr2:198174542	NA	-0.53	-8.33	-0.41	1.96e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.01	-0.35	1.28e-11	Inflammatory bowel disease;
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.95	-0.35	1.8e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs2758596	0.826	rs2251615	chr1:156202300	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	10.6	0.5	7.13e-23	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	0.91	6.58	0.34	1.8e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.58	7.95	0.39	2.73e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.76	0.65	1.9e-42	Lymphocyte percentage of white cells;
LIHC	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg04218760	chr10:45406644	TMEM72	-0.19	-5.76	-0.3	1.88e-8	Mean corpuscular volume;
LIHC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg17764715	chr19:33622953	WDR88	0.45	6.59	0.34	1.68e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg27205649	chr11:78285834	NARS2	0.42	6.25	0.32	1.24e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.56	8.23	0.41	4e-15	Blood metabolite levels;
LIHC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.49	0.49	1.62e-22	Bladder cancer;
LIHC	cis	rs4706831	0.663	rs1984242	chr6:81051245	A/G	cg08355045	chr6:80787529	NA	0.34	7.02	0.35	1.19e-11	Joint mobility (Beighton score);
LIHC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.48	-0.53	5.03e-26	Platelet distribution width;
LIHC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.6	8.97	0.44	1.94e-17	Recombination rate (females);
LIHC	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.65	-9.53	-0.46	2.91e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.48	-5.77	-0.3	1.75e-8	Menarche (age at onset);
LIHC	trans	rs875971	0.964	rs778723	chr7:65829497	T/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg09222892	chr1:25734099	RHCE	0.48	9.06	0.44	1.02e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.38	7.45	0.37	7.46e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.5	-6.5	-0.33	2.81e-10	Pancreatic cancer;
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02034447	chr16:89574710	SPG7	0.46	7.07	0.36	8.75e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.36	-0.33	6.34e-10	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.79	0.34	4.86e-11	Renal cell carcinoma;
LIHC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg11161837	chr1:110010384	SYPL2	0.45	6.25	0.32	1.21e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg21747090	chr2:27597821	SNX17	-0.41	-5.98	-0.31	5.55e-9	Total body bone mineral density;
LIHC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.43	-6.97	-0.35	1.64e-11	Menarche (age at onset);
LIHC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.71	11.02	0.51	2.19e-24	Corneal astigmatism;
LIHC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.97	0.31	5.81e-9	Renal cell carcinoma;
LIHC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg04498913	chr7:1135747	C7orf50	0.39	5.85	0.3	1.14e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs2380220	0.872	rs66723559	chr6:95956338	T/C	cg15832292	chr6:96025679	MANEA	-0.6	-6.65	-0.34	1.16e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.91	-0.35	2.37e-11	Axial length;
LIHC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.46	1.47e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg03806693	chr22:41940476	POLR3H	-0.92	-10.86	-0.51	8.58e-24	Vitiligo;
LIHC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-7.17	-0.36	4.57e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.66	-0.34	1.13e-10	Schizophrenia;
LIHC	cis	rs655641	1.000	rs669556	chr11:85781322	A/G	cg09030501	chr11:85779252	PICALM	0.49	5.74	0.3	2.04e-8	Platelet count;
LIHC	cis	rs28530618	0.603	rs750401	chr20:31246638	G/C	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.85	-0.3	1.17e-8	Birth weight;
LIHC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg11764359	chr7:65958608	NA	0.6	6.38	0.33	5.71e-10	Diabetic kidney disease;
LIHC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.79	0.3	1.58e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.6	11.13	0.52	8.91e-25	Menopause (age at onset);
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.68	10.09	0.48	3.86e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.54	8.54	0.42	4.44e-16	Total body bone mineral density;
LIHC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.49	5.8	0.3	1.48e-8	Schizophrenia;
LIHC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-8.97	-0.44	1.95e-17	Bipolar disorder;
LIHC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.83	0.3	1.3e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs4742903	0.875	rs7037174	chr9:106924871	C/T	cg14250997	chr9:106856677	SMC2	0.35	5.98	0.31	5.54e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.92	-0.35	2.21e-11	Gout;
LIHC	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.71	-10.37	-0.49	4.43e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.33	6.51	0.33	2.63e-10	Renal cell carcinoma;
LIHC	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.67	0.34	1.01e-10	Ileal carcinoids;
LIHC	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg14515779	chr1:101123966	NA	-0.58	-10.74	-0.5	2.15e-23	Monocyte count;
LIHC	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.62	-6.69	-0.34	9.05e-11	Type 2 diabetes;
LIHC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg09455208	chr3:40491958	NA	0.37	7.11	0.36	6.66e-12	Renal cell carcinoma;
LIHC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.72	-12.98	-0.57	1.37e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.41	-7.78	-0.39	8.82e-14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LIHC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.54	-7.67	-0.38	1.86e-13	Bipolar disorder;
LIHC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.61	-9.97	-0.47	1.02e-20	Alcohol dependence;
LIHC	cis	rs1664789	0.587	rs697112	chr5:53260679	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.43	6.76	0.34	6.04e-11	Waist circumference adjusted for body mass index;
LIHC	cis	rs10411936	0.712	rs8100755	chr19:16593415	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	6.81	0.35	4.36e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.73	11.34	0.52	1.62e-25	Height;
LIHC	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg23587288	chr2:27483067	SLC30A3	-0.34	-6.32	-0.32	8e-10	Blood metabolite levels;
LIHC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg00204512	chr16:28754710	NA	0.4	7.03	0.36	1.11e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23260799	chr11:451101	PTDSS2	0.5	7.64	0.38	2.24e-13	Pancreatic cancer;
LIHC	cis	rs2274273	0.712	rs9806049	chr14:55525589	C/A	cg01864836	chr14:55583639	NA	-0.38	-6.52	-0.33	2.53e-10	Protein biomarker;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01584634	chr11:72525302	ATG16L2	0.5	6.18	0.32	1.85e-9	Hepatitis;
LIHC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.5	8.45	0.42	8.59e-16	Response to temozolomide;
LIHC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg06466757	chr4:1255808	NA	-0.35	-5.89	-0.3	9.43e-9	Obesity-related traits;
LIHC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.15	-0.36	5.18e-12	Bipolar disorder;
LIHC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.34	8.83	0.43	5.49e-17	Schizophrenia;
LIHC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg00012203	chr2:219082015	ARPC2	0.51	6.7	0.34	8.4e-11	Ulcerative colitis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18618936	chr12:122255346	SETD1B	0.45	6.45	0.33	3.79e-10	Longevity;
LIHC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	7.84	0.39	5.89e-14	Mean platelet volume;
LIHC	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.5	7.64	0.38	2.2e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.46	6.1	0.31	2.93e-9	Cognitive test performance;
LIHC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.2	0.48	1.73e-21	Alzheimer's disease (late onset);
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.12	0.4	8.4e-15	Height;
LIHC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.36	-7.88	-0.39	4.27e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-7.06	-0.36	9.62e-12	Mean corpuscular hemoglobin;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg16822855	chr3:40428330	ENTPD3	0.33	5.96	0.31	6.36e-9	Renal cell carcinoma;
LIHC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.5	-7.63	-0.38	2.31e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.1	0.36	7.18e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs7508	0.511	rs2237853	chr8:17877880	G/A	cg01800426	chr8:17659068	MTUS1	-0.43	-6.19	-0.32	1.67e-9	Atrial fibrillation;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20451802	chr7:132937811	EXOC4	-0.42	-6.1	-0.31	2.9e-9	Calcium levels;
LIHC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.49	6.31	0.32	8.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg25251204	chr11:14927456	NA	0.41	5.87	0.3	1.03e-8	Vitamin D levels;
LIHC	cis	rs17539620	0.628	rs62432730	chr6:154830717	G/A	cg17771515	chr6:154831774	CNKSR3	0.59	6.25	0.32	1.24e-9	Lipoprotein (a) levels;
LIHC	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.63	9.33	0.45	1.35e-18	Vitamin D levels;
LIHC	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.31	7.54	0.38	4.32e-13	Gut microbiome composition (winter);
LIHC	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.97	-0.31	5.93e-9	Lewy body disease;
LIHC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	17.04	0.68	1.44e-47	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg09417038	chr21:47716443	C21orf57	-0.5	-7.34	-0.37	1.55e-12	Testicular germ cell tumor;
LIHC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.64	-0.5	5.01e-23	Lung cancer;
LIHC	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.74	-11.34	-0.52	1.58e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.53	7.91	0.39	3.69e-14	Longevity;Endometriosis;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12516959	chr21:47718080	NA	0.36	5.96	0.31	6.42e-9	Testicular germ cell tumor;
LIHC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.4	8.79	0.43	7.63e-17	Erythrocyte sedimentation rate;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12635664	chr10:71930586	SAR1A	-0.39	-6.09	-0.31	2.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg12373951	chr3:133503437	NA	0.42	6.88	0.35	2.94e-11	Iron status biomarkers;
LIHC	cis	rs7116495	1.000	rs661242	chr11:71579229	T/C	cg26138937	chr11:71823887	C11orf51	0.69	6.83	0.35	3.91e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.86	-0.39	4.9e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.63	-10.19	-0.48	1.78e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg06627628	chr2:24431161	ITSN2	-0.44	-5.89	-0.3	9.14e-9	Quantitative traits;
LIHC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.25	-0.41	3.44e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.18	-0.55	1.4e-28	Colorectal cancer;
LIHC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.02	-0.44	1.42e-17	Bipolar disorder;
LIHC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg18289306	chr13:113640169	MCF2L	0.4	6.57	0.33	1.85e-10	Systolic blood pressure;
LIHC	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.87e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs2758596	1.000	rs2736608	chr1:156180349	T/A	cg25208724	chr1:156163844	SLC25A44	0.73	7.35	0.37	1.49e-12	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.29	0.37	2.1e-12	Height;
LIHC	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.38	-8.35	-0.41	1.71e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs6594499	0.872	rs10055177	chr5:110450584	T/G	cg04022379	chr5:110408740	TSLP	0.5	8.29	0.41	2.69e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg03805757	chr16:71968109	PKD1L3	-0.64	-7.11	-0.36	6.73e-12	Post bronchodilator FEV1;
LIHC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-5.83	-0.3	1.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-10.28	-0.49	8.89e-22	Dental caries;
LIHC	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.76	-13.15	-0.58	3.05e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.44	5.92	0.3	7.76e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.54	-0.38	4.22e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg00576331	chr11:65640516	EFEMP2	-0.4	-5.72	-0.3	2.39e-8	Breast cancer;
LIHC	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.5	9.49	0.46	4.13e-19	Testicular germ cell tumor;
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.8	12.89	0.57	2.89e-31	Longevity;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08460793	chr16:11836374	TXNDC11	0.39	6.48	0.33	3.13e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72653721	0.838	rs72653724	chr6:11028293	C/T	cg13562911	chr6:11044106	ELOVL2	0.51	7.38	0.37	1.24e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.49	6.51	0.33	2.66e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.3	0.61	1.07e-36	Multiple sclerosis;
LIHC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.38	6.84	0.35	3.67e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10660249	chr9:5833007	ERMP1	0.44	6.62	0.34	1.36e-10	Pancreatic cancer;
LIHC	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.61	-6.54	-0.33	2.29e-10	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.5	-9.17	-0.44	4.64e-18	Reticulocyte fraction of red cells;
LIHC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg10820045	chr2:198174542	NA	-0.58	-9.8	-0.47	3.76e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs35883536	0.967	rs9433740	chr1:101133985	G/A	cg14515779	chr1:101123966	NA	0.67	13.04	0.58	8.23e-32	Monocyte count;
LIHC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.79	16.55	0.67	1.35e-45	Gestational age at birth (maternal effect);
LIHC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg06064525	chr11:970664	AP2A2	-0.44	-10.82	-0.5	1.2e-23	Alzheimer's disease (late onset);
LIHC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg14092571	chr14:90743983	NA	-0.41	-6.53	-0.33	2.34e-10	Mortality in heart failure;
LIHC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21467203	chr3:49911342	NA	-0.44	-7.91	-0.39	3.57e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.61	5.94	0.31	7.06e-9	Alzheimer's disease;
LIHC	cis	rs507080	0.769	rs570952	chr11:118500193	T/C	cg04173919	chr11:118528438	PHLDB1	0.32	5.79	0.3	1.59e-8	Serum metabolite levels;
LIHC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.14	-12.16	-0.55	1.66e-28	Platelet count;
LIHC	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.79	-6.79	-0.34	5.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3770081	1.000	rs58365138	chr2:86213105	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.79	-8.14	-0.4	7.46e-15	Facial emotion recognition (sad faces);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01779903	chr5:148205646	ADRB2	0.35	6.24	0.32	1.31e-9	Calcium levels;
LIHC	cis	rs11760633	0.672	rs10950377	chr7:1835894	C/G	cg23422044	chr7:1970798	MAD1L1	0.38	5.92	0.3	7.87e-9	Coronary artery disease;
LIHC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.04	-0.4	1.52e-14	Obesity-related traits;
LIHC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.45	6.29	0.32	9.72e-10	Obesity-related traits;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.66	-10.01	-0.48	7.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.64	-7.36	-0.37	1.38e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.68	12.3	0.55	5.01e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.18	-0.52	6.29e-25	Response to antipsychotic treatment;
LIHC	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.61	8.98	0.44	1.91e-17	Recombination rate (females);
LIHC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.44	-11.88	-0.54	1.79e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	1.04	12.27	0.55	6.08e-29	Red blood cell traits;
LIHC	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg23461800	chr14:103021989	NA	-0.38	-5.78	-0.3	1.69e-8	Platelet count;
LIHC	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg14250997	chr9:106856677	SMC2	-0.43	-7.59	-0.38	2.97e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.47e-18	Bipolar disorder;
LIHC	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.34	-0.32	7.24e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg05343316	chr1:45956843	TESK2	-0.42	-6.19	-0.32	1.69e-9	High light scatter reticulocyte count;
LIHC	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.39	-7.1	-0.36	7.28e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.7	-0.38	1.51e-13	Psoriasis;
LIHC	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg06611532	chr13:114900021	NA	0.38	6.93	0.35	2.06e-11	Schizophrenia;
LIHC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.52	-9.15	-0.44	5.28e-18	Longevity;
LIHC	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.17	26.54	0.82	4.52e-85	Schizophrenia;
LIHC	cis	rs4650994	0.593	rs12040058	chr1:178503557	C/G	cg05350800	chr1:178550844	NA	-0.3	-6.42	-0.33	4.65e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.68	9.96	0.47	1.12e-20	Cisplatin-induced ototoxicity;
LIHC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg03934865	chr2:198174659	NA	0.52	7.88	0.39	4.35e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg12042659	chr19:58951599	ZNF132	0.37	6.31	0.32	8.45e-10	Uric acid clearance;
LIHC	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.26	-0.41	3.28e-15	Colorectal cancer;
LIHC	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.91	11.37	0.52	1.3e-25	Coronary artery disease;
LIHC	cis	rs16912285	0.688	rs59246618	chr11:24315201	G/T	ch.11.24196551F	chr11:24239977	NA	0.79	10.81	0.5	1.31e-23	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.28	0.52	2.71e-25	Menarche (age at onset);
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg20090690	chr10:134436459	INPP5A	0.44	5.76	0.3	1.84e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10878977	0.565	rs7964397	chr12:69811876	C/A	cg17330252	chr12:69809627	NA	0.38	5.97	0.31	6.01e-9	Colorectal cancer;
LIHC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-14.34	-0.61	7.29e-37	Height;
LIHC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.45	-0.49	2.25e-22	Breast cancer;
LIHC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-7.21	-0.36	3.56e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05704155	chr1:10459140	PGD	-0.42	-6.83	-0.35	3.87e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg26763362	chr17:18266135	SHMT1	-0.27	-6.01	-0.31	4.65e-9	Multiple sclerosis;
LIHC	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg24450063	chr1:156163899	SLC25A44	1.06	18.31	0.7	1.08e-52	Testicular germ cell tumor;
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg04013166	chr16:89971882	TCF25	0.6	7.92	0.39	3.27e-14	Skin colour saturation;
LIHC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.63	0.67	6.53e-46	Smoking behavior;
LIHC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01458420	chr20:48532416	SPATA2	-0.39	-6.04	-0.31	4.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.96	20.39	0.74	4.7e-61	IgG glycosylation;
LIHC	cis	rs3820500	0.543	rs2767318	chr1:118068558	G/A	cg20383390	chr1:117909022	MAN1A2	-0.45	-5.96	-0.31	6.27e-9	Pneumonia;
LIHC	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg14515779	chr1:101123966	NA	-0.49	-7.03	-0.36	1.16e-11	Monocyte count;
LIHC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	8.75	0.43	9.66e-17	Total body bone mineral density;
LIHC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.64	8.12	0.4	8.72e-15	Attention deficit hyperactivity disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23861078	chr2:27435638	SLC5A6;C2orf28	0.42	6.47	0.33	3.35e-10	Cognitive function;
LIHC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20135002	chr11:47629003	NA	-0.45	-7.83	-0.39	6.01e-14	Neuroticism;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07385723	chr6:170065891	WDR27	0.37	6.13	0.31	2.44e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.74	-8.06	-0.4	1.27e-14	Uric acid levels;
LIHC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg16558253	chr16:72132732	DHX38	-0.51	-8.1	-0.4	9.86e-15	Fibrinogen levels;
LIHC	cis	rs539514	0.690	rs528783	chr13:76319460	T/C	cg04757411	chr13:76259545	LMO7	-0.47	-8.13	-0.4	7.86e-15	Type 1 diabetes;
LIHC	cis	rs7703051	0.707	rs7730344	chr5:74587940	C/A	cg19683494	chr5:74908142	NA	0.49	7.21	0.36	3.55e-12	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.45	6.72	0.34	7.41e-11	Blood protein levels;
LIHC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	6.1	0.31	2.81e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs8103278	0.740	rs72626215	chr19:46294136	G/A	cg11657440	chr19:46296263	DMWD	-0.51	-7.55	-0.38	4.07e-13	Coronary artery disease;
LIHC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.58	8.71	0.43	1.36e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.46	-6.52	-0.33	2.5e-10	Schizophrenia;
LIHC	cis	rs15676	0.783	rs4837316	chr9:131577450	A/G	cg00228799	chr9:131580591	ENDOG	0.48	6.91	0.35	2.42e-11	Blood metabolite levels;
LIHC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.68	-10.93	-0.51	4.57e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	10.81	0.5	1.26e-23	Colorectal cancer;
LIHC	cis	rs7116495	1.000	rs659513	chr11:71812411	C/T	cg10381502	chr11:71823885	C11orf51	0.56	5.73	0.3	2.22e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06636551	chr8:101224915	SPAG1	-0.47	-8.71	-0.43	1.34e-16	Atrioventricular conduction;
LIHC	cis	rs4908768	1.000	rs12122666	chr1:8741438	A/C	cg25722041	chr1:8623473	RERE	-0.45	-6.3	-0.32	9.41e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg19635926	chr16:89946313	TCF25	0.51	6.44	0.33	4.05e-10	Skin colour saturation;
LIHC	cis	rs11229555	0.645	rs10896778	chr11:58193925	T/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6061231	0.958	rs2427305	chr20:60953749	G/C	cg06026331	chr20:60912101	LAMA5	0.44	6.13	0.31	2.43e-9	Colorectal cancer;
LIHC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.56	-8.18	-0.4	5.53e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.65	8.96	0.44	2.11e-17	Menopause (age at onset);
LIHC	trans	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg10756647	chr7:56101905	PSPH	0.46	6.93	0.35	2.1e-11	Aortic root size;
LIHC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.38	6.41	0.33	4.79e-10	Schizophrenia;
LIHC	cis	rs9543976	1.000	rs3818355	chr13:76196867	C/T	cg01531495	chr13:76123901	UCHL3	0.49	5.8	0.3	1.48e-8	Diabetic retinopathy;
LIHC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.52	-6.68	-0.34	9.65e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg16479474	chr6:28041457	NA	0.46	6.59	0.34	1.71e-10	Depression;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18016822	chr2:45838545	SRBD1	0.44	6.55	0.33	2.14e-10	Calcium levels;
LIHC	cis	rs1865721	0.771	rs72975988	chr18:73128289	T/G	cg26385618	chr18:73139727	C18orf62	-0.32	-8.5	-0.42	6.16e-16	Intelligence;
LIHC	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.44	-8.12	-0.4	8.51e-15	Vitamin D levels;
LIHC	cis	rs10847980	0.590	rs75217947	chr12:123346177	G/C	cg07706471	chr12:123319906	HIP1R	0.78	8.73	0.43	1.15e-16	Adiponectin levels;
LIHC	cis	rs4908768	0.657	rs4908778	chr1:8804888	C/G	cg20416874	chr1:8611966	RERE	0.43	6.43	0.33	4.37e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.83	10.69	0.5	3.38e-23	Cognitive function;
LIHC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg20651018	chr11:3035856	CARS	-0.37	-6.12	-0.31	2.63e-9	Longevity;
LIHC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.4	-7.39	-0.37	1.16e-12	Neurofibrillary tangles;
LIHC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg12751644	chr20:60527061	NA	-0.35	-5.87	-0.3	1.03e-8	Body mass index;
LIHC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg09137382	chr11:130731461	NA	0.41	6.09	0.31	2.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.38	6.29	0.32	9.8e-10	Lung cancer;
LIHC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg12046867	chr14:103022105	NA	-0.57	-8.36	-0.41	1.6e-15	Platelet count;
LIHC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.81	0.57	5.88e-31	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05509352	chr5:142092851	NA	0.41	6.28	0.32	1e-9	Calcium levels;
LIHC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-17.32	-0.68	1.11e-48	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22958951	chr11:119252637	USP2	0.44	6.59	0.34	1.67e-10	Cognitive function;
LIHC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.78	12.19	0.55	1.27e-28	Corneal astigmatism;
LIHC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg04719120	chr6:96025338	MANEA	0.5	6.19	0.32	1.74e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.49	-6.96	-0.35	1.75e-11	Body mass index;
LIHC	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.1	-0.31	2.91e-9	Tuberculosis;
LIHC	trans	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.61	-0.42	2.66e-16	Gut microbiome composition (summer);
LIHC	cis	rs12464559	0.522	rs6759419	chr2:152549703	G/A	cg01189475	chr2:152685088	ARL5A	0.66	7.87	0.39	4.8e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs903552	1.000	rs12907048	chr15:102003873	G/T	cg00659931	chr15:102010125	PCSK6	-0.44	-5.97	-0.31	5.86e-9	Diabetic kidney disease;
LIHC	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.72	-7.92	-0.39	3.3e-14	Exhaled nitric oxide output;
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg09033563	chr22:24373618	LOC391322	-0.44	-6.02	-0.31	4.42e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02902865	chr1:12679132	DHRS3	0.42	6.71	0.34	7.99e-11	Cognitive function;
LIHC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg12798992	chr6:167411361	FGFR1OP	0.52	8.53	0.42	4.81e-16	Crohn's disease;
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg11766577	chr21:47581405	C21orf56	0.38	6.04	0.31	4.04e-9	Testicular germ cell tumor;
LIHC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.59	-7.64	-0.38	2.21e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.18	0.32	1.85e-9	Morning vs. evening chronotype;
LIHC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-6.4	-0.33	5.2e-10	Educational attainment;
LIHC	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.13	-0.44	5.97e-18	Exhaled nitric oxide output;
LIHC	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-8.19	-0.4	5.21e-15	Exhaled nitric oxide output;
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-7.94	-0.39	2.98e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.64	-9.49	-0.46	4e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.66	9.66	0.46	1.13e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.86	-0.35	3.18e-11	Diabetic kidney disease;
LIHC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.98	-0.44	1.87e-17	Heart rate;
LIHC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	0.86	11.64	0.53	1.33e-26	Post bronchodilator FEV1;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.68	0.57	1.91e-30	Alzheimer's disease;
LIHC	trans	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.6e-9	Coronary artery disease;
LIHC	cis	rs4759375	1.000	rs73231952	chr12:123785538	C/A	cg00376283	chr12:123451042	ABCB9	-0.49	-6.31	-0.32	8.53e-10	HDL cholesterol;
LIHC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.92	-10.12	-0.48	3.02e-21	Red cell distribution width;
LIHC	trans	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg19894588	chr14:64061835	NA	-0.63	-8.76	-0.43	9.08e-17	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08219700	chr8:58056026	NA	0.5	6.39	0.33	5.5e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.44	6.4	0.33	5.1e-10	Longevity;Endometriosis;
LIHC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.79	9.51	0.46	3.56e-19	Cognitive function;
LIHC	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	ch.11.42038R	chr11:967971	AP2A2	0.57	10.75	0.5	2.01e-23	Alzheimer's disease (late onset);
LIHC	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.36	-0.45	1.07e-18	Schizophrenia;
LIHC	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-11.07	-0.51	1.45e-24	Morning vs. evening chronotype;
LIHC	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg24069376	chr3:38537580	EXOG	0.42	7.6	0.38	2.91e-13	Electrocardiographic conduction measures;
LIHC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg26138144	chr22:38071188	LGALS1	0.75	14.21	0.61	2.53e-36	Fat distribution (HIV);
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.82	12.15	0.55	1.81e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg13264159	chr8:625131	ERICH1	-0.62	-6.28	-0.32	1.06e-9	IgG glycosylation;
LIHC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.01	-0.48	7.62e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg13409248	chr3:40428643	ENTPD3	0.38	6.03	0.31	4.32e-9	Renal cell carcinoma;
LIHC	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg26138937	chr11:71823887	C11orf51	-1.28	-10.45	-0.49	2.31e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.65	8.12	0.4	8.56e-15	Corneal astigmatism;
LIHC	cis	rs1075232	1.000	rs12440544	chr15:32096504	C/T	cg01030201	chr15:31746330	NA	-0.82	-6.4	-0.33	4.98e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.3	6.36	0.33	6.42e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg06664874	chr5:179499304	RNF130	0.58	7.16	0.36	5.09e-12	LDL cholesterol;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.47	7.76	0.39	1.01e-13	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.81	-0.35	4.45e-11	Diabetic kidney disease;
LIHC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.66	10.0	0.48	8.28e-21	Lung cancer;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00705661	chr14:93706609	BTBD7	0.5	6.31	0.32	8.57e-10	Hip circumference;
LIHC	cis	rs75908454	1.000	rs76451345	chr6:169806527	T/C	cg19338460	chr6:170058176	WDR27	-0.83	-7.47	-0.37	6.59e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs17152411	1.000	rs7089014	chr10:126590342	G/A	cg07906193	chr10:126599966	NA	0.46	7.11	0.36	6.9e-12	Height;
LIHC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.07	15.36	0.64	7.19e-41	Cognitive function;
LIHC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg16479474	chr6:28041457	NA	0.41	5.84	0.3	1.22e-8	Parkinson's disease;
LIHC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg06064525	chr11:970664	AP2A2	-0.44	-10.75	-0.5	2.12e-23	Alzheimer's disease (late onset);
LIHC	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05731713	chr7:157510257	PTPRN2	0.24	6.52	0.33	2.47e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs55702914	0.746	rs4850425	chr2:198152786	T/C	cg03934865	chr2:198174659	NA	-0.4	-5.76	-0.3	1.88e-8	Major depression and alcohol dependence;
LIHC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.95	0.31	6.48e-9	Electroencephalogram traits;
LIHC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg14473756	chr11:122847823	NA	-0.35	-6.21	-0.32	1.56e-9	Menarche (age at onset);
LIHC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.5	8.86	0.43	4.58e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	10.54	0.5	1.13e-22	Platelet count;
LIHC	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg17830980	chr10:43048298	ZNF37B	0.41	7.7	0.38	1.47e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.48	-18.17	-0.7	4.09e-52	Breast cancer;
LIHC	cis	rs2574704	0.851	rs2574718	chr3:11660689	A/T	cg15876825	chr3:11651881	VGLL4	0.49	7.91	0.39	3.62e-14	Body mass index;
LIHC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.44	-7.22	-0.36	3.29e-12	Blood pressure (smoking interaction);
LIHC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg16576597	chr16:28551801	NUPR1	0.37	6.03	0.31	4.25e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.51	6.22	0.32	1.42e-9	Heart rate;
LIHC	cis	rs611744	0.967	rs630492	chr8:109215368	C/T	cg18478394	chr8:109455254	TTC35	-0.39	-6.93	-0.35	2.08e-11	Dupuytren's disease;
LIHC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.18	0.36	4.45e-12	Bipolar disorder;
LIHC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg24203234	chr3:128598194	ACAD9	0.44	6.13	0.31	2.42e-9	IgG glycosylation;
LIHC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-7.31	-0.37	1.95e-12	Lung cancer;
LIHC	trans	rs2395128	0.834	rs7092435	chr10:76670311	C/G	cg24341800	chr11:107992076	ACAT1	0.5	6.28	0.32	1.05e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs6450176	0.633	rs10054623	chr5:53343821	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.2	-0.58	1.94e-32	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg03934865	chr2:198174659	NA	-0.48	-7.02	-0.35	1.22e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	0.55	8.56	0.42	3.82e-16	Atopic dermatitis;
LIHC	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.63	7.26	0.37	2.65e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.54	7.62	0.38	2.5e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.64	12.26	0.55	6.92e-29	High light scatter reticulocyte count;
LIHC	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.46	8.81	0.43	6.43e-17	Testicular germ cell tumor;
LIHC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.76	11.21	0.52	4.67e-25	Resting heart rate;
LIHC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.45	6.24	0.32	1.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-7.52	-0.38	4.84e-13	Lymphocyte counts;
LIHC	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-10.67	-0.5	3.79e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.61	10.22	0.48	1.4e-21	Crohn's disease;
LIHC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg23461800	chr14:103021989	NA	-0.43	-6.05	-0.31	3.77e-9	Platelet count;
LIHC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.67	9.78	0.47	4.46e-20	Corneal astigmatism;
LIHC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.86	-0.35	3.29e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs16912285	0.688	rs12276587	chr11:24280656	C/G	ch.11.24196551F	chr11:24239977	NA	-0.77	-10.85	-0.51	8.96e-24	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs1144333	0.655	rs12405994	chr1:76435420	A/T	cg10523679	chr1:76189770	ACADM	0.45	6.13	0.31	2.48e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.31	6.34	0.32	7.39e-10	Platelet distribution width;
LIHC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg22842854	chr12:123319900	HIP1R	-0.75	-9.92	-0.47	1.46e-20	Schizophrenia;
LIHC	cis	rs35160687	0.644	rs11127024	chr2:86505453	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.36	5.88	0.3	9.52e-9	Night sleep phenotypes;
LIHC	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.48	-7.03	-0.36	1.14e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2629540	0.580	rs2930796	chr10:126485684	A/G	cg08799069	chr10:126477246	METTL10	0.44	6.28	0.32	1.05e-9	Cocaine dependence;
LIHC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.44	-0.53	7.3e-26	Coronary artery disease;
LIHC	cis	rs546131	0.642	rs12808574	chr11:34852120	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.51	6.42	0.33	4.47e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg00647820	chr17:40259828	DHX58	-0.28	-5.91	-0.3	8.35e-9	Fibrinogen levels;
LIHC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	0.69	11.34	0.52	1.68e-25	Menopause (age at onset);
LIHC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.42	6.96	0.35	1.7e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-7.36	-0.37	1.34e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg18306943	chr3:40428807	ENTPD3	0.35	6.09	0.31	3.1e-9	Renal cell carcinoma;
LIHC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-8.3	-0.41	2.46e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.33	0.52	1.82e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs13063635	0.915	rs41289616	chr3:45997263	T/C	cg21656520	chr2:210867290	RPE	0.85	6.08	0.31	3.19e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.37e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Schizophrenia;
LIHC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg17279839	chr7:150038598	RARRES2	0.51	10.71	0.5	2.84e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.44	7.99	0.4	2.07e-14	Prudent dietary pattern;
LIHC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.86	6.31	0.32	8.54e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.47	-6.93	-0.35	2.15e-11	Psoriasis;
LIHC	cis	rs12295403	1.000	rs12295403	chr11:18689653	G/T	cg09887367	chr11:18690185	NA	-0.41	-7.02	-0.35	1.21e-11	Ovarian reserve;
LIHC	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg10820045	chr2:198174542	NA	-0.47	-7.19	-0.36	4.07e-12	Dermatomyositis;
LIHC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	12.57	0.56	4.66e-30	Electrocardiographic conduction measures;
LIHC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.19	0.32	1.75e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.28	6.05	0.31	3.89e-9	Ulcerative colitis;
LIHC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.66	0.38	1.96e-13	Electroencephalogram traits;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.85	0.3	1.17e-8	Alzheimer's disease;
LIHC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.56	-0.5	9.69e-23	Mean corpuscular volume;
LIHC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg21996761	chr11:64428434	NRXN2	0.35	5.81	0.3	1.39e-8	Body mass index;Urate levels;
LIHC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.69	10.99	0.51	2.91e-24	Platelet count;
LIHC	cis	rs8081395	0.932	rs2777885	chr17:57830473	C/A	cg02344993	chr17:57696989	CLTC	-0.45	-7.28	-0.37	2.28e-12	White blood cell count;
LIHC	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.32	-6.02	-0.31	4.49e-9	Coronary artery disease or large artery stroke;
LIHC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.48	7.84	0.39	5.97e-14	Multiple sclerosis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22951283	chr11:67797908	NDUFS8	0.45	6.47	0.33	3.33e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg17410650	chr12:54324560	NA	-0.4	-7.3	-0.37	1.98e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg06359132	chr10:99160096	RRP12	-0.4	-6.04	-0.31	4.02e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16780568	chr10:89578019	ATAD1;CFLP1	-0.44	-6.39	-0.33	5.35e-10	Pancreatic cancer;
LIHC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.82	0.3	1.38e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.26	-6.92	-0.35	2.22e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.9	0.54	1.49e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.33	-0.32	7.6e-10	Bipolar disorder;
LIHC	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.41	-7.15	-0.36	5.38e-12	Lung cancer;
LIHC	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.56	6.23	0.32	1.36e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26734620	chr12:56694298	CS	-1.25	-11.04	-0.51	1.96e-24	Psoriasis vulgaris;
LIHC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.33	-7.25	-0.36	2.83e-12	Ulcerative colitis;
LIHC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg27523141	chr10:43048294	ZNF37B	0.38	6.42	0.33	4.69e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg15123519	chr2:136567270	LCT	-0.37	-5.87	-0.3	1.01e-8	Corneal structure;
LIHC	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.51	-6.52	-0.33	2.59e-10	Pursuit maintenance gain;
LIHC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.32	6.76	0.34	5.95e-11	Bone mineral density;
LIHC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.27	7.31	0.37	1.95e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg10755058	chr3:40428713	ENTPD3	0.4	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.36	7.97	0.4	2.31e-14	Blood metabolite ratios;
LIHC	trans	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg18393722	chr15:85113863	UBE2QP1	0.4	6.89	0.35	2.72e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-12.05	-0.55	4.02e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.55	0.38	4.03e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.17	0.4	5.99e-15	Lymphocyte counts;
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.31	-0.37	1.89e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.54	-8.45	-0.42	8.72e-16	Breast size;
LIHC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg22633049	chr21:46681294	NA	-0.38	-6.47	-0.33	3.38e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs143111788	1	rs143111788	chr6:41919175	CCAGCTACT/C	cg17623882	chr6:41773611	USP49	-0.5	-7.4	-0.37	1.09e-12	Red cell distribution width;
LIHC	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg25686905	chr3:183603175	PARL	-0.49	-9.29	-0.45	1.78e-18	Menopause (age at onset);
LIHC	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg03934865	chr2:198174659	NA	0.51	7.82	0.39	6.8e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.41	6.95	0.35	1.86e-11	Blood metabolite levels;
LIHC	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg07959070	chr22:50026188	C22orf34	-0.3	-7.22	-0.36	3.33e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.68	-10.2	-0.48	1.66e-21	Mosquito bite size;
LIHC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.66	10.03	0.48	6.25e-21	Breast cancer;
LIHC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.24	0.36	3.03e-12	Aortic root size;
LIHC	cis	rs9596863	1.000	rs9568948	chr13:54437693	A/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.91	0.3	8.34e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg27490568	chr2:178487706	NA	-0.76	-9.64	-0.46	1.27e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs12753920	0.724	rs7541482	chr1:92566853	G/C	cg15668468	chr10:118892869	VAX1	0.43	6.11	0.31	2.75e-9	Systemic lupus erythematosus;
LIHC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.0	0.6	1.63e-35	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs45544231	0.544	rs8052175	chr16:52577142	C/T	cg09051775	chr16:52580266	TOX3	-0.32	-5.89	-0.3	9.47e-9	Restless legs syndrome;
LIHC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.54	0.46	2.76e-19	Bipolar disorder;
LIHC	cis	rs1892700	0.764	rs62227660	chr21:34891096	G/A	cg14850771	chr21:34775459	IFNGR2	-0.45	-5.93	-0.31	7.59e-9	Educational attainment;
LIHC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.53	-7.68	-0.38	1.64e-13	Prostate cancer;
LIHC	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.4	7.68	0.38	1.65e-13	Coronary artery disease;
LIHC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.67	8.97	0.44	1.99e-17	Blood metabolite levels;
LIHC	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg14146966	chr2:61757674	XPO1	0.45	7.69	0.38	1.61e-13	Tuberculosis;
LIHC	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.99e-50	Schizophrenia;
LIHC	cis	rs9506514	0.509	rs9509294	chr13:21174645	T/A	cg27234864	chr13:21295941	IL17D	-0.33	-5.89	-0.3	9.45e-9	Coronary artery calcification;
LIHC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.49	-7.63	-0.38	2.37e-13	Schizophrenia;
LIHC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.42	-0.37	9.42e-13	IgG glycosylation;
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg11342453	chr6:26196699	NA	0.52	5.8	0.3	1.55e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.5	7.95	0.4	2.7e-14	Blood protein levels;
LIHC	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	6.49	0.33	3.05e-10	Blood protein levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07837717	chr19:2841006	ZNF555	-0.42	-6.32	-0.32	8.27e-10	Cognitive function;
LIHC	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.73	11.69	0.53	8.59e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.4	-6.84	-0.35	3.65e-11	Type 2 diabetes;
LIHC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.39	-5.77	-0.3	1.81e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg14580859	chr9:123691850	NA	0.38	6.69	0.34	9.15e-11	Rheumatoid arthritis;
LIHC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.58	-0.38	3.38e-13	Monocyte percentage of white cells;
LIHC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg05941027	chr17:61774174	LIMD2	0.29	5.82	0.3	1.39e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs600806	0.888	rs680434	chr1:109842271	C/T	cg23091122	chr1:110024289	SYPL2	-0.46	-5.82	-0.3	1.37e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.5	-7.27	-0.37	2.47e-12	Obesity-related traits;
LIHC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.63	12.52	0.56	7.21e-30	Gestational age at birth (maternal effect);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21113846	chr7:837536	NA	-0.46	-6.51	-0.33	2.69e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.61	-7.32	-0.37	1.77e-12	Mean platelet volume;
LIHC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg07560587	chr16:88016574	BANP	0.36	5.8	0.3	1.48e-8	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.39	6.19	0.32	1.77e-9	Menopause (age at onset);
LIHC	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.7	8.2	0.41	4.81e-15	Dental caries;
LIHC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.9	-12.77	-0.57	8.49e-31	Chronic sinus infection;
LIHC	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.68	11.14	0.52	8.17e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.37	-6.05	-0.31	3.9e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7911264	0.628	rs6583833	chr10:94409800	C/T	cg25506282	chr10:94462361	NA	0.37	6.25	0.32	1.19e-9	Inflammatory bowel disease;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg05697976	chr12:29376483	FAR2	0.34	7.08	0.36	8.25e-12	QT interval;
LIHC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg07424592	chr7:64974309	NA	0.81	9.05	0.44	1.13e-17	Diabetic kidney disease;
LIHC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.48	0.42	6.83e-16	Schizophrenia;
LIHC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.76	7.82	0.39	6.6e-14	Arsenic metabolism;
LIHC	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg02702477	chr5:179499311	RNF130	0.9	11.93	0.54	1.11e-27	LDL cholesterol;
LIHC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.2	18.27	0.7	1.57e-52	Ulcerative colitis;
LIHC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg18016565	chr1:150552671	MCL1	-0.5	-10.34	-0.49	5.31e-22	Tonsillectomy;
LIHC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	0.99	10.53	0.49	1.22e-22	White matter hyperintensity burden;
LIHC	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg14146966	chr2:61757674	XPO1	-0.48	-8.45	-0.42	8.2e-16	Tuberculosis;
LIHC	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	7.15	0.36	5.37e-12	Neutrophil percentage of white cells;
LIHC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.76	0.34	5.88e-11	Personality dimensions;
LIHC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg25952890	chr19:58913133	NA	0.69	7.43	0.37	8.91e-13	Mean platelet volume;
LIHC	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg26138937	chr11:71823887	C11orf51	-1.31	-10.43	-0.49	2.7e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg16511985	chr3:153974050	SGEF	-0.41	-8.79	-0.43	7.42e-17	Coronary artery disease;
LIHC	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg12140854	chr5:148520817	ABLIM3	0.44	5.98	0.31	5.64e-9	Breast cancer;
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.65	9.45	0.46	5.5e-19	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.11	0.4	9.47e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.36	2.88e-12	Educational attainment;
LIHC	cis	rs7894407	0.504	rs7089271	chr10:105176914	A/G	cg05636881	chr10:105038444	INA	0.42	6.68	0.34	9.85e-11	White matter hyperintensity burden;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.81	0.76	1.06e-66	Height;
LIHC	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.42	6.3	0.32	9.12e-10	Neuroticism;
LIHC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.51	0.56	7.88e-30	Menopause (age at onset);
LIHC	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg07884673	chr3:53033167	SFMBT1	0.91	6.6	0.34	1.58e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.31	-0.37	1.86e-12	Height;
LIHC	cis	rs74233809	1.000	rs11191531	chr10:104806898	G/C	cg03493300	chr10:104813866	CNNM2	0.47	6.26	0.32	1.16e-9	Birth weight;
LIHC	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.68	7.85	0.39	5.41e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2257205	0.667	rs8070407	chr17:56709172	G/A	cg12560992	chr17:57184187	TRIM37	0.69	7.62	0.38	2.44e-13	Pancreatic cancer;
LIHC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.76	10.07	0.48	4.72e-21	Coronary artery disease;
LIHC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.06	-0.51	1.7e-24	Chronic sinus infection;
LIHC	trans	rs4714291	0.832	rs1923462	chr6:39976100	T/C	cg02267698	chr19:7991119	CTXN1	-0.39	-6.43	-0.33	4.42e-10	Strep throat;
LIHC	cis	rs2279817	0.780	rs3766312	chr1:17978644	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-7.2	-0.36	3.8e-12	Neuroticism;
LIHC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.63	-5.96	-0.31	6.27e-9	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19140410	chr17:78518857	RPTOR	0.49	6.73	0.34	7.22e-11	Lung function (FEV1/FVC);
LIHC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.75	-0.3	2.03e-8	Uric acid levels;
LIHC	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.45	6.79	0.34	5.04e-11	Night sleep phenotypes;
LIHC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-6.35	-0.32	7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.56	8.47	0.42	7.31e-16	Menarche (age at onset);
LIHC	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	9.59	0.46	1.95e-19	Type 2 diabetes;
LIHC	trans	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	Height;
LIHC	cis	rs11166927	0.548	rs28366721	chr8:140827797	C/G	cg16909799	chr8:140841666	TRAPPC9	-0.44	-7.04	-0.36	1.04e-11	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.39	-5.79	-0.3	1.63e-8	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17756712	0.607	rs1747599	chr6:633557	C/A	cg14374089	chr6:596013	EXOC2	0.4	5.71	0.3	2.42e-8	Vertical cup-disc ratio;
LIHC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	9.0	0.44	1.63e-17	Body mass index (adult);
LIHC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.8	7.86	0.39	5.07e-14	Platelet count;
LIHC	cis	rs9378688	1.000	rs9378687	chr6:2218835	A/G	cg12303981	chr6:2244766	GMDS	-0.5	-6.34	-0.32	7.23e-10	Caudate nucleus volume;
LIHC	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.27	-18.69	-0.71	3.23e-54	Ulcerative colitis;
LIHC	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.41	6.34	0.32	7.22e-10	Red blood cell traits;
LIHC	cis	rs28595532	0.545	rs13144171	chr4:119257458	G/A	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg06565975	chr8:143823917	SLURP1	0.33	6.33	0.32	7.51e-10	Urinary tract infection frequency;
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.6	8.75	0.43	9.75e-17	Menarche (age at onset);
LIHC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.64	-11.26	-0.52	3.18e-25	Breast cancer;
LIHC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg24296786	chr1:45957014	TESK2	0.5	7.01	0.35	1.25e-11	Platelet count;
LIHC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg13844804	chr7:814759	HEATR2	0.43	5.87	0.3	1.04e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.58	-8.61	-0.42	2.66e-16	Blood protein levels;
LIHC	trans	rs783540	0.500	rs7178459	chr15:83398384	T/C	cg18393722	chr15:85113863	UBE2QP1	0.46	6.53	0.33	2.39e-10	Schizophrenia;
LIHC	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.46	6.94	0.35	1.92e-11	Height;
LIHC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg14132834	chr19:41945861	ATP5SL	-0.4	-5.96	-0.31	6.44e-9	Height;
LIHC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.13	0.52	9.37e-25	Coronary artery disease;
LIHC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2607426	0.579	rs1869710	chr19:41256375	C/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.53	-5.85	-0.3	1.12e-8	Blood protein levels;
LIHC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.41	0.49	3.05e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg20195005	chr22:42527684	CYP2D6	0.3	5.76	0.3	1.85e-8	Birth weight;
LIHC	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg07234388	chr1:156261841	TMEM79	0.51	8.85	0.43	4.8e-17	Tonsillectomy;
LIHC	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg06664874	chr5:179499304	RNF130	0.67	7.7	0.38	1.51e-13	LDL cholesterol;
LIHC	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg25783544	chr11:47291846	MADD	0.41	5.95	0.31	6.76e-9	HDL cholesterol;
LIHC	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg06533319	chr4:3265114	C4orf44	0.31	5.75	0.3	1.99e-8	Mean platelet volume;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg16927353	chr2:10442868	HPCAL1	-0.43	-6.17	-0.32	1.92e-9	Neuroblastoma;
LIHC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.8	-0.3	1.5e-8	Monocyte percentage of white cells;
LIHC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.14	0.4	7.28e-15	Schizophrenia;
LIHC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.76	6.04	0.31	4.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg14440974	chr22:39074834	NA	0.35	5.91	0.3	8.08e-9	Menopause (age at onset);
LIHC	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.68	-0.34	9.52e-11	Exhaled nitric oxide output;
LIHC	cis	rs3790844	0.613	rs12030331	chr1:200001547	G/A	cg07208853	chr1:200005219	NR5A2	0.38	8.29	0.41	2.59e-15	Pancreatic cancer;
LIHC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.63	10.31	0.49	7.02e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1144333	0.655	rs12401729	chr1:76336586	T/G	cg03433033	chr1:76189801	ACADM	0.54	7.44	0.37	8.34e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.77	5.74	0.3	2.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg25665528	chr16:2260870	C16orf79	-0.37	-6.61	-0.34	1.48e-10	Height;
LIHC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg09695851	chr17:3907499	NA	-0.57	-7.01	-0.35	1.31e-11	Type 2 diabetes;
LIHC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.72	-9.65	-0.46	1.25e-19	Sudden cardiac arrest;
LIHC	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.56	8.8	0.43	6.83e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.76	12.5	0.56	8.46e-30	Gastritis;
LIHC	cis	rs11233413	1.000	rs11233413	chr11:82723072	T/C	cg24227371	chr11:82718527	RAB30	-0.32	-7.07	-0.36	8.87e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.31	0.32	8.7e-10	HDL cholesterol;
LIHC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.94	0.54	1.07e-27	Platelet count;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.54	6.55	0.33	2.09e-10	Alzheimer's disease;
LIHC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg10932868	chr11:921992	NA	0.37	7.01	0.35	1.26e-11	Alzheimer's disease (late onset);
LIHC	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.39	-6.56	-0.33	1.99e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.53	-6.75	-0.34	6.37e-11	Type 2 diabetes;
LIHC	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.56	6.67	0.34	1.03e-10	Primary sclerosing cholangitis;
LIHC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.23	-0.64	2.38e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	10.0	0.48	8.05e-21	Mean platelet volume;
LIHC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10792665	0.573	rs7104980	chr11:82575195	C/G	cg24227371	chr11:82718527	RAB30	-0.28	-6.61	-0.34	1.45e-10	Obesity-related traits;
LIHC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.47	7.9	0.39	3.86e-14	Tuberculosis;
LIHC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12016809	chr21:47604291	C21orf56	0.41	5.97	0.31	6.06e-9	Testicular germ cell tumor;
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-8.47	-0.42	7.57e-16	Lymphocyte counts;
LIHC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.97	-9.8	-0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg09594475	chr20:60884601	LAMA5	0.58	6.21	0.32	1.51e-9	Colorectal cancer;
LIHC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg14092571	chr14:90743983	NA	-0.38	-6.13	-0.31	2.46e-9	Mortality in heart failure;
LIHC	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.57e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	0.82	6.42	0.33	4.69e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.68	-11.34	-0.52	1.59e-25	Menopause (age at onset);
LIHC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-6.47	-0.33	3.47e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg01320579	chr17:75405842	SEPT9	-0.5	-7.28	-0.37	2.33e-12	Airflow obstruction;
LIHC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.64	0.53	1.34e-26	Lung cancer in ever smokers;
LIHC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.69	-11.68	-0.53	9.73e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.49	8.22	0.41	4.28e-15	Schizophrenia;
LIHC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg13628971	chr7:2884303	GNA12	0.4	6.32	0.32	8.35e-10	Height;
LIHC	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg20016023	chr10:99160130	RRP12	0.43	7.06	0.36	9.41e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.75	-9.63	-0.46	1.45e-19	Body mass index;
LIHC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.3	-0.32	9.15e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg22561889	chr6:118971681	C6orf204	-0.55	-6.53	-0.33	2.39e-10	Diastolic blood pressure;
LIHC	cis	rs6442522	0.615	rs13060973	chr3:15500933	A/G	cg16303742	chr3:15540471	COLQ	-0.44	-7.43	-0.37	9.01e-13	Uric acid levels;
LIHC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs16986825	0.607	rs5762852	chr22:29242473	T/C	cg15103426	chr22:29168792	CCDC117	0.44	5.87	0.3	1e-8	Pancreatic cancer;
LIHC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.71	-0.5	2.86e-23	Mean corpuscular volume;
LIHC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.44	-0.64	3.61e-41	Chronic sinus infection;
LIHC	cis	rs9649465	0.967	rs12534834	chr7:123307079	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.58e-14	Migraine;
LIHC	cis	rs62179067	0.708	rs10497532	chr2:179935156	C/T	cg20701897	chr2:179586761	TTN	-0.48	-5.77	-0.3	1.82e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs62179067	0.708	rs11887988	chr2:179943041	G/A	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg20487152	chr13:99095054	FARP1	-0.37	-6.21	-0.32	1.56e-9	Longevity;
LIHC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg17294928	chr15:75287854	SCAMP5	-0.53	-6.71	-0.34	8.12e-11	Lung cancer;
LIHC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg14393609	chr7:65229607	NA	0.43	6.14	0.31	2.34e-9	Calcium levels;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.4	-0.33	5e-10	Total body bone mineral density;
LIHC	cis	rs36051895	0.623	rs10118267	chr9:5243736	T/C	cg02405213	chr9:5042618	JAK2	-0.65	-10.34	-0.49	5.29e-22	Pediatric autoimmune diseases;
LIHC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg18222961	chr2:48009935	MSH6	-0.49	-6.3	-0.32	9.23e-10	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg00343986	chr7:65444356	GUSB	0.4	5.99	0.31	5.42e-9	Aortic root size;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg14348182	chr9:138823525	NA	0.37	6.24	0.32	1.26e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs72843506	0.656	rs7210439	chr17:19986041	T/C	cg12065943	chr17:19881925	AKAP10	-0.33	-5.76	-0.3	1.9e-8	Schizophrenia;
LIHC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg03929089	chr4:120376271	NA	-0.44	-6.66	-0.34	1.12e-10	HDL cholesterol;
LIHC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.85	-15.31	-0.64	1.2e-40	Aortic root size;
LIHC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.43	-6.86	-0.35	3.18e-11	Menarche (age at onset);
LIHC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.71	6.8	0.35	4.68e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.44	5.86	0.3	1.07e-8	Obesity (extreme);
LIHC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.85	12.93	0.57	2.16e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04400940	chr3:150329548	SELT	0.42	6.23	0.32	1.36e-9	Immature fraction of reticulocytes;
LIHC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.93	16.86	0.67	7.27e-47	Parkinson's disease;
LIHC	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg17130504	chr10:102756923	LZTS2	0.55	7.56	0.38	3.84e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.81e-10	Obesity-related traits;
LIHC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg09222892	chr1:25734099	RHCE	0.45	8.27	0.41	3e-15	Erythrocyte sedimentation rate;
LIHC	trans	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg26939375	chr7:64535504	NA	0.39	6.21	0.32	1.52e-9	Aortic root size;
LIHC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.85	0.3	1.17e-8	Menopause (age at onset);
LIHC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.65	6.59	0.34	1.69e-10	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02891801	chr12:6472782	SCNN1A	0.44	6.28	0.32	1.06e-9	Pancreatic cancer;
LIHC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.15	0.66	5.24e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs918629	0.530	rs11738768	chr5:95237780	C/A	cg10483112	chr5:95245456	ELL2	-0.36	-6.55	-0.33	2.08e-10	IgG glycosylation;
LIHC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05347473	chr6:146136440	FBXO30	0.35	5.85	0.3	1.13e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	8.53	0.42	4.9e-16	Mean corpuscular hemoglobin;
LIHC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg16736954	chr20:23401023	NAPB	0.73	8.68	0.43	1.6e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.58	0.42	3.35e-16	Corneal astigmatism;
LIHC	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	7.26	0.37	2.55e-12	Mean corpuscular hemoglobin;
LIHC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg18887096	chr2:219472410	PLCD4	-0.37	-6.36	-0.33	6.53e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs67981189	0.537	rs1978164	chr14:71361367	C/G	cg15816911	chr14:71606274	NA	-0.41	-6.62	-0.34	1.37e-10	Schizophrenia;
LIHC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	7.4	0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.85	-18.17	-0.7	4.19e-52	Longevity;
LIHC	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.0	10.47	0.49	1.95e-22	Platelet distribution width;
LIHC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.74	-0.34	6.74e-11	Bladder cancer;
LIHC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.91	0.35	2.33e-11	Height;
LIHC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.95	22.44	0.77	3.39e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.28	-0.37	2.25e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg06565975	chr8:143823917	SLURP1	-0.37	-6.72	-0.34	7.67e-11	Urinary tract infection frequency;
LIHC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-12.28	-0.55	5.65e-29	Vitiligo;
LIHC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg12365402	chr11:9010492	NRIP3	0.33	8.53	0.42	4.87e-16	Hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26347064	chr19:45211248	CEACAM16	0.39	6.36	0.33	6.29e-10	Pancreatic cancer;
LIHC	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.81	-0.3	1.42e-8	Response to antipsychotic treatment;
LIHC	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.26	20.28	0.74	1.38e-60	Corneal structure;
LIHC	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.9	11.12	0.52	9.62e-25	Coronary artery disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00435469	chr11:1495117	HCCA2	0.41	6.17	0.32	1.91e-9	Longevity;
LIHC	cis	rs8113308	0.689	rs8112515	chr19:52491250	A/G	cg25782003	chr19:52490127	ZNF350	0.62	5.97	0.31	5.98e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.36	6.06	0.31	3.69e-9	Height;
LIHC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.53	8.38	0.41	1.38e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.15	0.36	5.37e-12	Axial length;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg02990361	chr1:107599529	PRMT6	-0.57	-9.18	-0.44	4.31e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.62	10.27	0.49	9.42e-22	Neutrophil percentage of white cells;
LIHC	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.44	6.26	0.32	1.17e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg02290350	chr8:58132656	NA	0.47	9.32	0.45	1.45e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.4	-6.59	-0.34	1.69e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	19.18	0.72	3.65e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.95	-9.26	-0.45	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2073499	0.935	rs2624837	chr3:50205962	A/G	cg21659725	chr3:3221576	CRBN	-0.61	-6.52	-0.33	2.56e-10	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.61	7.24	0.36	2.95e-12	Cognitive function;
LIHC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00152838	chr16:24741724	TNRC6A	-0.48	-6.37	-0.33	6.16e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11671664	0.732	rs67775326	chr19:46160969	A/G	cg13320842	chr19:46175254	GIPR	0.7	11.87	0.54	1.94e-27	Type 2 diabetes;Body mass index;Body mass index (SNP x SNP interaction);
LIHC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg14067834	chr17:29058358	SUZ12P	0.68	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.57	0.33	1.91e-10	Lung cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07880337	chr3:194304578	NA	0.51	6.62	0.34	1.41e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	7.97	0.4	2.34e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.8	-0.47	3.88e-20	Rheumatoid arthritis;
LIHC	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.46	-6.86	-0.35	3.32e-11	Diastolic blood pressure;
LIHC	trans	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	2.02e-33	Diabetic kidney disease;
LIHC	cis	rs7116495	1.000	rs4121395	chr11:71669242	C/T	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg09182678	chr22:50328711	NA	-0.44	-6.2	-0.32	1.67e-9	Schizophrenia;
LIHC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-0.93	-18.02	-0.7	1.62e-51	Homoarginine levels;
LIHC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.3	-6.94	-0.35	1.96e-11	Menarche (age at onset);
LIHC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.91	-0.3	8.25e-9	Breast cancer;
LIHC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs6445975	0.667	rs34532954	chr3:58243594	C/A	cg23715586	chr3:58305044	RPP14	-0.34	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LIHC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg07148914	chr20:33460835	GGT7	0.51	5.75	0.3	1.94e-8	Protein C levels;
LIHC	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.22	10.2	0.48	1.66e-21	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.29	-7.8	-0.39	7.47e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	ch.11.42038R	chr11:967971	AP2A2	0.53	9.69	0.46	8.55e-20	Alzheimer's disease (late onset);
LIHC	cis	rs17106184	1.000	rs12062764	chr1:51296907	G/A	cg07174182	chr1:51127561	FAF1	-0.61	-6.85	-0.35	3.54e-11	Type 2 diabetes;
LIHC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.38	5.74	0.3	2.05e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.57	8.04	0.4	1.44e-14	Neuroticism;
LIHC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.52	7.24	0.36	3.05e-12	Height;
LIHC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.38	6.21	0.32	1.5e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.39	-7.16	-0.36	4.84e-12	Hepatocellular carcinoma;
LIHC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.49	8.6	0.42	2.9e-16	Height;
LIHC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.21	0.36	3.64e-12	Hemoglobin concentration;
LIHC	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	9.73	0.47	6.69e-20	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg18081818	chr7:23246105	NA	-0.4	-5.76	-0.3	1.83e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3106136	0.807	rs6851128	chr4:95259455	A/G	cg11021082	chr4:95130006	SMARCAD1	0.41	7.3	0.37	2.07e-12	Capecitabine sensitivity;
LIHC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.75	15.06	0.63	1.09e-39	Menopause (age at onset);
LIHC	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	10.08	0.48	4.42e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.48	-7.7	-0.38	1.52e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg03037974	chr15:76606532	NA	0.74	14.5	0.62	1.73e-37	Blood metabolite levels;
LIHC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.5	-8.59	-0.42	3.19e-16	Blood protein levels;
LIHC	trans	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg16724585	chr3:197361211	NA	-0.42	-6.15	-0.32	2.11e-9	Pancreatic cancer;
LIHC	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.28	6.24	0.32	1.32e-9	Pulmonary function;
LIHC	trans	rs933688	0.527	rs1511344	chr5:90582914	G/C	cg19365810	chr7:152064079	MLL3	0.42	6.27	0.32	1.1e-9	Smoking behavior;
LIHC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.46	7.79	0.39	8.2e-14	Height;
LIHC	trans	rs10213084	1.000	rs28617320	chr4:147480098	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.51	6.1	0.31	2.81e-9	Heart rate;
LIHC	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.38	6.04	0.31	3.94e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.38	-5.89	-0.3	9.21e-9	Cognitive function;
LIHC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg16102536	chr7:156981717	UBE3C	-0.36	-6.14	-0.32	2.25e-9	Body mass index;
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.28	0.32	1.02e-9	Renal cell carcinoma;
LIHC	cis	rs11958404	0.932	rs11950881	chr5:157410550	C/T	cg05962755	chr5:157440814	NA	0.93	10.14	0.48	2.62e-21	IgG glycosylation;
LIHC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-6.81	-0.35	4.48e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.19	0.36	4.06e-12	Parkinson's disease;
LIHC	trans	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.93	-0.35	2.16e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs72829446	0.530	rs2228132	chr17:7411770	C/T	cg02795151	chr17:7402630	POLR2A	0.54	6.24	0.32	1.29e-9	Androgen levels;
LIHC	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg14515779	chr1:101123966	NA	-0.48	-6.8	-0.35	4.71e-11	Monocyte count;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg06207460	chr9:4741011	AK3	-0.47	-6.12	-0.31	2.6e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.95	-0.31	6.49e-9	Systemic lupus erythematosus;
LIHC	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg27426351	chr10:43362370	NA	0.47	5.75	0.3	1.95e-8	Blood protein levels;
LIHC	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.44	7.99	0.4	2.1e-14	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.47	9.68	0.46	9.79e-20	Immature fraction of reticulocytes;
LIHC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.34	-0.32	7.08e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg18081818	chr7:23246105	NA	-0.4	-6.03	-0.31	4.26e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.91	6.85	0.35	3.55e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg00990874	chr7:1149470	C7orf50	-0.55	-8.16	-0.4	6.37e-15	Bronchopulmonary dysplasia;
LIHC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.41	6.17	0.32	1.88e-9	Height;
LIHC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg05973401	chr12:123451056	ABCB9	0.45	5.82	0.3	1.36e-8	Neutrophil percentage of white cells;
LIHC	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26190225	chr4:71570509	RUFY3	-0.63	-6.22	-0.32	1.48e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg25039879	chr17:56429692	SUPT4H1	0.83	9.38	0.45	9.11e-19	Cognitive test performance;
LIHC	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg06026331	chr20:60912101	LAMA5	-0.53	-8.72	-0.43	1.21e-16	Colorectal cancer;
LIHC	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.32	8.06	0.4	1.26e-14	Schizophrenia;
LIHC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.2	-0.36	3.84e-12	Bipolar disorder;
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.42	-5.84	-0.3	1.22e-8	Total body bone mineral density;
LIHC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.31	-0.37	1.84e-12	Response to antipsychotic treatment;
LIHC	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.77	-0.3	1.8e-8	Crohn's disease;
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.69	9.44	0.45	5.86e-19	Calcium levels;
LIHC	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg12560992	chr17:57184187	TRIM37	0.68	8.8	0.43	7e-17	Vitamin D levels;
LIHC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-9.19	-0.45	3.81e-18	Tonsillectomy;
LIHC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.63	6.42	0.33	4.57e-10	Migraine;Coronary artery disease;
LIHC	cis	rs79387448	0.745	rs7587856	chr2:103144305	C/A	cg09003973	chr2:102972529	NA	0.85	7.47	0.37	6.82e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs6450176	0.680	rs255756	chr5:53309364	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.0	-17.95	-0.7	3.13e-51	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.91	0.35	2.36e-11	Bipolar disorder;
LIHC	cis	rs903552	1.000	rs8041563	chr15:102005824	G/C	cg00659931	chr15:102010125	PCSK6	-0.46	-6.2	-0.32	1.63e-9	Diabetic kidney disease;
LIHC	trans	rs1814175	0.618	rs7483546	chr11:49714784	C/A	cg03929089	chr4:120376271	NA	-0.85	-16.55	-0.67	1.36e-45	Height;
LIHC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.52	6.92	0.35	2.27e-11	Height;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.07	-0.4	1.22e-14	Response to antipsychotic treatment;
LIHC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.44	0.45	6.1e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.26	6.09	0.31	3.08e-9	Heart rate;
LIHC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.54	-0.42	4.32e-16	Type 2 diabetes;
LIHC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.98	0.44	1.9e-17	Cognitive ability;
LIHC	cis	rs509477	0.718	rs273353	chr18:32599361	G/A	cg23791764	chr18:32556832	MAPRE2	0.45	6.1	0.31	2.81e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.52	9.15	0.44	5.38e-18	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06866400	chr6:143771904	ADAT2;PEX3	-0.42	-6.17	-0.32	1.89e-9	Pancreatic cancer;
LIHC	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	1.21	9.74	0.47	6.08e-20	Gut microbiota (bacterial taxa);
LIHC	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.25	-13.17	-0.58	2.47e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.36	0.41	1.66e-15	Height;
LIHC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.45	7.12	0.36	6.52e-12	HDL cholesterol levels;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.47	0.62	2.34e-37	Prudent dietary pattern;
LIHC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.7	0.34	8.36e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.37	6.43	0.33	4.28e-10	Monocyte percentage of white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04844971	chr15:50979486	TRPM7	0.45	6.41	0.33	4.79e-10	Pancreatic cancer;
LIHC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.5	-0.33	2.9e-10	Bipolar disorder;
LIHC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.59	-0.38	3.07e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.53	0.49	1.21e-22	Hypertriglyceridemia;
LIHC	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.53	-7.58	-0.38	3.19e-13	Obesity-related traits;
LIHC	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg03934865	chr2:198174659	NA	0.52	7.86	0.39	4.89e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg05697976	chr12:29376483	FAR2	0.29	5.96	0.31	6.37e-9	QT interval;
LIHC	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	trans	rs8113308	0.810	rs8100521	chr19:52449643	A/G	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.63	0.46	1.42e-19	Morning vs. evening chronotype;
LIHC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-12.99	-0.57	1.25e-31	Primary sclerosing cholangitis;
LIHC	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.15	-0.36	5.19e-12	Migraine;Coronary artery disease;
LIHC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg05025164	chr4:1340916	KIAA1530	-0.49	-6.83	-0.35	3.99e-11	Systolic blood pressure;
LIHC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-5.99	-0.31	5.37e-9	Menarche (age at onset);
LIHC	cis	rs25645	0.502	rs17609240	chr17:38110689	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.5	-7.43	-0.37	8.75e-13	Myeloid white cell count;
LIHC	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.4	0.56	1.98e-29	Monocyte count;
LIHC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.42	-6.78	-0.34	5.28e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.81	-0.3	1.45e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-11.52	-0.53	3.52e-26	Platelet count;
LIHC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.42	6.65	0.34	1.17e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg11070056	chr1:107600091	PRMT6	0.68	11.42	0.53	8.6e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg10820045	chr2:198174542	NA	0.48	7.31	0.37	1.88e-12	Dermatomyositis;
LIHC	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg02290350	chr8:58132656	NA	0.47	9.16	0.44	4.93e-18	Developmental language disorder (linguistic errors);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00124920	chr1:178515751	C1orf220	0.4	6.14	0.32	2.24e-9	Longevity;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2274273	0.901	rs68046603	chr14:55762803	T/A	cg01864836	chr14:55583639	NA	-0.37	-6.46	-0.33	3.52e-10	Protein biomarker;
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.73	10.56	0.5	9.52e-23	Menarche (age at onset);
LIHC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.3	7.46	0.37	7.32e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.42	-5.91	-0.3	8.4e-9	Colorectal cancer;
LIHC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-9.13	-0.44	6.13e-18	Gut microbiome composition (summer);
LIHC	cis	rs716804	0.740	rs7116147	chr11:10287310	A/G	cg01453529	chr11:10209919	SBF2	-0.29	-5.87	-0.3	1.01e-8	Neuroticism;
LIHC	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg27205649	chr11:78285834	NARS2	-0.39	-6.0	-0.31	5.01e-9	Alzheimer's disease (survival time);
LIHC	cis	rs17152411	0.652	rs2114834	chr10:126650186	A/G	cg07906193	chr10:126599966	NA	-0.35	-7.01	-0.35	1.31e-11	Height;
LIHC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.62	-0.46	1.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	7.55	0.38	3.96e-13	Parkinson's disease;
LIHC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.3	8.53e-9	Obesity (extreme);
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.9	0.39	3.89e-14	Prudent dietary pattern;
LIHC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4919087	0.683	rs1687372	chr10:98978185	A/T	cg25902810	chr10:99078978	FRAT1	-0.55	-6.28	-0.32	1.01e-9	Monocyte count;
LIHC	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.89	12.47	0.56	1.12e-29	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.8	-8.37	-0.41	1.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.39	6.38	0.33	5.72e-10	Response to antipsychotic treatment;
LIHC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-10.29	-0.49	8.32e-22	Vitiligo;
LIHC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.44	8.22	0.41	4.19e-15	Schizophrenia;
LIHC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg03146154	chr1:46216737	IPP	-0.38	-5.85	-0.3	1.13e-8	High light scatter reticulocyte count;
LIHC	cis	rs8084351	0.577	rs12454410	chr18:50655969	T/C	cg24270629	chr18:50823537	DCC	-0.43	-6.36	-0.33	6.41e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.34	-0.32	7.4e-10	Obesity-related traits;
LIHC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-1.09	-17.39	-0.69	5.58e-49	Urate levels;
LIHC	trans	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg14791747	chr16:20752902	THUMPD1	-0.49	-6.86	-0.35	3.2e-11	Dental caries;
LIHC	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.72	0.5	2.59e-23	Colorectal cancer;
LIHC	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.85	11.56	0.53	2.51e-26	Menopause (age at onset);
LIHC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.17	-0.4	6.05e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-6.91	-0.35	2.39e-11	Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13409248	chr3:40428643	ENTPD3	0.5	8.4	0.41	1.24e-15	Renal cell carcinoma;
LIHC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	7.11	0.36	6.83e-12	Protein C levels;
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21448741	chr8:58168803	NA	0.37	6.63	0.34	1.29e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.44e-11	IgG glycosylation;
LIHC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.51	-7.79	-0.39	7.91e-14	Total body bone mineral density;
LIHC	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg14515779	chr1:101123966	NA	0.51	8.14	0.4	7.5e-15	Monocyte count;
LIHC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs2637266	0.905	rs34173296	chr10:78343389	C/T	cg18941641	chr10:78392320	NA	0.29	5.96	0.31	6.27e-9	Pulmonary function;
LIHC	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.83	0.3	1.31e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	trans	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg10756647	chr7:56101905	PSPH	1.11	13.47	0.59	1.75e-33	Diabetic kidney disease;
LIHC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.8	-18.23	-0.7	2.41e-52	Urate levels in lean individuals;
LIHC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.53	7.65	0.38	2.05e-13	Urinary tract infection frequency;
LIHC	cis	rs7616330	0.790	rs2140131	chr3:71044545	A/G	cg01511742	chr3:71112437	FOXP1	-0.45	-6.11	-0.31	2.69e-9	QT interval;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.1e-31	Prudent dietary pattern;
LIHC	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.84	16.76	0.67	1.92e-46	Longevity;
LIHC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.93	18.77	0.71	1.55e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.4	7.24	0.36	2.96e-12	Psoriasis;
LIHC	cis	rs6141600	0.760	rs2746097	chr20:34672923	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-5.73	-0.3	2.19e-8	Height;Hip circumference;
LIHC	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg20636351	chr8:55087400	NA	0.34	7.18	0.36	4.46e-12	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.67	-0.42	1.83e-16	Colorectal cancer;
LIHC	trans	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.75	-7.82	-0.39	6.8e-14	Vitiligo;
LIHC	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.32	7.23	0.36	3.19e-12	Blood metabolite ratios;
LIHC	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg23555395	chr2:238036564	NA	-0.31	-5.8	-0.3	1.47e-8	Systemic lupus erythematosus;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.73	-11.18	-0.52	6.3e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg17135325	chr3:160939158	NMD3	0.52	7.34	0.37	1.61e-12	Morning vs. evening chronotype;
LIHC	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16684958	chr7:75615977	POR	0.4	6.57	0.33	1.87e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.66	8.01	0.4	1.81e-14	Itch intensity from mosquito bite;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17074969	chr3:14220346	LSM3;XPC	-0.48	-6.34	-0.32	7.13e-10	Pancreatic cancer;
LIHC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg01629716	chr15:45996671	NA	0.51	9.16	0.44	4.72e-18	Waist circumference;Weight;
LIHC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.55e-9	Vitamin D levels;
LIHC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.37	6.56	0.33	2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	6.03	0.31	4.15e-9	Mean platelet volume;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01083598	chr16:54155993	NA	0.49	6.88	0.35	2.88e-11	Hepatitis;
LIHC	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.4	-5.9	-0.3	8.88e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.65	-0.5	4.5e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg17750252	chr2:136567154	LCT	-0.35	-6.41	-0.33	4.7e-10	Mosquito bite size;
LIHC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.46	8.26	0.41	3.15e-15	Platelet distribution width;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.73	14.3	0.61	1.14e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.46	0.56	1.25e-29	Cognitive test performance;
LIHC	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	7.34	0.37	1.56e-12	Adiposity;
LIHC	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.09	23.82	0.79	1.3e-74	Schizophrenia;
LIHC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	11.85	0.54	2.34e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	7.57	0.38	3.42e-13	Mood instability;
LIHC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	11.07	0.51	1.46e-24	Lung cancer in ever smokers;
LIHC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12463550	chr7:65579703	CRCP	0.7	7.4	0.37	1.04e-12	Diabetic kidney disease;
LIHC	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.45	7.66	0.38	1.95e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-15.52	-0.64	1.65e-41	Tonsillectomy;
LIHC	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg20991723	chr1:152506922	NA	0.53	8.76	0.43	9.49e-17	Hair morphology;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.13	0.55	2e-28	Prudent dietary pattern;
LIHC	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-10.8	-0.5	1.39e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.86	0.39	5.2e-14	Prudent dietary pattern;
LIHC	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.56	8.7	0.43	1.44e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6691722	0.583	rs35671964	chr1:24695749	C/G	cg18323236	chr1:24743029	NIPAL3	0.35	6.39	0.33	5.44e-10	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg03970086	chr16:88974840	CBFA2T3	0.34	6.52	0.33	2.56e-10	Social autistic-like traits;
LIHC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.55	-8.9	-0.43	3.36e-17	Cognitive function;
LIHC	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	0.91	6.76	0.34	5.85e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.56	5.79	0.3	1.61e-8	Smoking initiation;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	0.6	8.57	0.42	3.65e-16	Prudent dietary pattern;
LIHC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.9	10.77	0.5	1.76e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.74	0.3	2.08e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.29	-0.41	2.65e-15	Response to antipsychotic treatment;
LIHC	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.62	11.29	0.52	2.46e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.02	0.31	4.57e-9	Electroencephalogram traits;
LIHC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.63	-8.66	-0.42	1.88e-16	Testicular germ cell tumor;
LIHC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Parkinson's disease;
LIHC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05025164	chr4:1340916	KIAA1530	0.41	6.37	0.33	6.05e-10	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg23587288	chr2:27483067	SLC30A3	-0.32	-6.03	-0.31	4.19e-9	Blood metabolite levels;
LIHC	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg14078157	chr9:128172775	NA	0.44	7.91	0.39	3.62e-14	Mean arterial pressure;
LIHC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	6.92	0.35	2.3e-11	HDL cholesterol;
LIHC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.76e-46	Parkinson's disease;
LIHC	cis	rs16828019	0.640	rs1140227	chr1:41493811	C/T	cg03962019	chr1:41807865	NA	0.5	7.06	0.36	9.29e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	10.7	0.5	2.97e-23	Cognitive test performance;
LIHC	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.47	6.85	0.35	3.41e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10792665	0.640	rs114349340	chr11:82629151	T/C	cg24227371	chr11:82718527	RAB30	-0.27	-6.13	-0.31	2.41e-9	Obesity-related traits;
LIHC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.52	-7.3	-0.37	2.03e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg02418909	chr7:4811322	NA	-0.44	-6.09	-0.31	3.1e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16993936	chr10:13146903	OPTN	0.46	7.03	0.36	1.1e-11	Longevity;
LIHC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-19.79	-0.73	1.21e-58	Height;
LIHC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.73	13.97	0.6	2.03e-35	Ewing sarcoma;
LIHC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg12373951	chr3:133503437	NA	-0.5	-7.11	-0.36	6.64e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs6782228	0.606	rs7613073	chr3:128388503	T/G	cg16766828	chr3:128327626	NA	-0.42	-6.59	-0.34	1.64e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg00656387	chr3:40428638	ENTPD3	0.49	8.3	0.41	2.38e-15	Renal cell carcinoma;
LIHC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.4	6.32	0.32	7.97e-10	Menopause (age at onset);
LIHC	cis	rs332507	0.830	rs12639478	chr3:124404958	T/A	cg05980111	chr3:124395277	KALRN	0.45	6.91	0.35	2.34e-11	Plateletcrit;
LIHC	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs35160687	0.644	rs11680025	chr2:86545338	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.35	5.74	0.3	2.08e-8	Night sleep phenotypes;
LIHC	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg26677194	chr12:130822605	PIWIL1	0.53	7.23	0.36	3.17e-12	Menopause (age at onset);
LIHC	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg04267008	chr7:1944627	MAD1L1	0.46	6.1	0.31	2.86e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.25	-5.83	-0.3	1.28e-8	Blood metabolite ratios;
LIHC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.6	8.31	0.41	2.35e-15	Coronary artery disease;
LIHC	cis	rs4908768	0.906	rs2144463	chr1:8583293	C/A	cg20416874	chr1:8611966	RERE	0.57	8.7	0.43	1.42e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg19680672	chr10:131412579	MGMT	0.42	6.4	0.33	5.01e-10	Response to temozolomide;
LIHC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.5	6.99	0.35	1.48e-11	Aortic root size;
LIHC	cis	rs10838687	1.000	rs10838687	chr11:47312892	T/G	cg26139080	chr11:47293733	MADD	-0.43	-6.29	-0.32	9.45e-10	Proinsulin levels;
LIHC	cis	rs963731	0.579	rs1454226	chr2:39246862	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-5.84	-0.3	1.19e-8	Corticobasal degeneration;
LIHC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.14	0.31	2.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.21	0.32	1.53e-9	Response to antipsychotic treatment;
LIHC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg04450456	chr4:17643702	FAM184B	0.34	5.73	0.3	2.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.41	6.43	0.33	4.21e-10	Ulcerative colitis;
LIHC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.66	11.5	0.53	4.24e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2279817	0.818	rs11582250	chr1:17994234	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.41	-5.8	-0.3	1.49e-8	Neuroticism;
LIHC	cis	rs12286929	0.702	rs11215419	chr11:115081810	A/T	cg04055981	chr11:115044050	NA	0.48	7.48	0.37	6.37e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.64	7.76	0.39	9.75e-14	Heart rate;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.65	0.38	2.03e-13	Height;
LIHC	trans	rs875971	0.545	rs316324	chr7:65610614	A/G	cg26939375	chr7:64535504	NA	-0.41	-6.47	-0.33	3.32e-10	Aortic root size;
LIHC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.73	-0.43	1.13e-16	Crohn's disease;
LIHC	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg03854865	chr6:26224070	HIST1H3E	0.47	5.96	0.31	6.11e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg25039879	chr17:56429692	SUPT4H1	0.84	9.58	0.46	1.99e-19	Cognitive test performance;
LIHC	cis	rs243505	0.624	rs6975291	chr7:148548393	C/G	cg09806900	chr7:148480153	CUL1	0.43	6.09	0.31	3.02e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2191566	0.664	rs3810406	chr19:44556381	G/T	cg20607764	chr19:44506953	ZNF230	-0.37	-6.19	-0.32	1.7e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.27	0.32	1.07e-9	Menopause (age at onset);
LIHC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	1.01	16.22	0.66	2.71e-44	Metabolic syndrome;
LIHC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.64	-0.67	5.54e-46	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.78	12.21	0.55	1.08e-28	Corneal astigmatism;
LIHC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg22633049	chr21:46681294	NA	-0.37	-6.48	-0.33	3.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.46	6.01	0.31	4.8e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.6	8.83	0.43	5.59e-17	Recombination rate (females);
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.85	-0.35	3.53e-11	Longevity;Endometriosis;
LIHC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.63	-10.88	-0.51	7.07e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.33	0.32	7.65e-10	Height;
LIHC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.87	13.0	0.58	1.08e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-13.18	-0.58	2.37e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg11642891	chr2:3452563	TTC15	-0.43	-6.83	-0.35	3.97e-11	Obesity-related traits;
LIHC	trans	rs10213084	1.000	rs56221117	chr4:147498316	T/G	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	trans	rs1974653	0.781	rs9605062	chr22:20089880	T/C	cg20152630	chr19:46405944	MYPOP	0.47	6.05	0.31	3.86e-9	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg19682013	chr15:45996608	NA	-0.4	-6.88	-0.35	2.94e-11	Waist circumference;Weight;
LIHC	cis	rs17776563	0.919	rs1348005	chr15:89113482	A/G	cg05013243	chr15:89149849	MIR1179	0.45	7.61	0.38	2.61e-13	Thyroid hormone levels;
LIHC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.06	0.36	9.34e-12	Height;
LIHC	cis	rs7818688	0.578	rs11786451	chr8:95897031	T/G	cg16049864	chr8:95962084	TP53INP1	0.54	6.12	0.31	2.57e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06558623	chr16:89946397	TCF25	0.87	13.6	0.59	5.77e-34	Interleukin-17 levels;
LIHC	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg25182066	chr10:30743637	MAP3K8	0.44	7.26	0.37	2.61e-12	Inflammatory bowel disease;
LIHC	cis	rs11871801	0.918	rs34460267	chr17:40615865	T/C	cg14558262	chr17:40713999	COASY	0.5	6.83	0.35	3.98e-11	Crohn's disease;
LIHC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.22	0.41	4.32e-15	Motion sickness;
LIHC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg20335179	chr10:1068567	C10orf110;IDI2	-0.57	-6.02	-0.31	4.52e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.39	14.51	0.62	1.68e-37	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4407350	0.837	rs4823328	chr22:44908999	C/T	cg04154583	chr22:44889756	LDOC1L	0.3	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.56	-8.86	-0.43	4.61e-17	Longevity;Endometriosis;
LIHC	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg14146966	chr2:61757674	XPO1	0.47	8.19	0.4	5.25e-15	Tuberculosis;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.36	0.33	6.44e-10	Prudent dietary pattern;
LIHC	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg07959070	chr22:50026188	C22orf34	-0.32	-7.87	-0.39	4.63e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.72	9.47	0.46	4.85e-19	Body mass index;
LIHC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.35	-6.45	-0.33	3.84e-10	Aortic root size;
LIHC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg23485639	chr6:28045615	ZNF165	0.38	5.97	0.31	6.04e-9	Cardiac Troponin-T levels;
LIHC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.74	0.34	6.71e-11	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08219700	chr8:58056026	NA	0.52	7.12	0.36	6.34e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs55665837	0.701	rs11023272	chr11:14630370	T/C	cg19336497	chr11:14380999	RRAS2	-0.37	-6.21	-0.32	1.54e-9	Vitamin D levels;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.62	0.5	5.79e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-7.08	-0.36	8.29e-12	Heart rate;
LIHC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.45	6.37	0.33	6.18e-10	Aortic root size;
LIHC	cis	rs9322817	0.625	rs2499655	chr6:105307435	G/A	cg02098413	chr6:105308735	HACE1	0.44	8.32	0.41	2.16e-15	Thyroid stimulating hormone;
LIHC	cis	rs11671005	0.652	rs11545185	chr19:59028585	G/A	cg25952890	chr19:58913133	NA	0.64	6.24	0.32	1.3e-9	Mean platelet volume;
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.85	-15.27	-0.64	1.69e-40	Bipolar disorder and schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01301323	chr12:77252588	CSRP2	0.43	7.14	0.36	5.57e-12	Longevity;
LIHC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.16e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg06565975	chr8:143823917	SLURP1	0.33	6.14	0.32	2.24e-9	Urinary tract infection frequency;
LIHC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.68	10.06	0.48	4.89e-21	Coronary artery disease;
LIHC	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg24542714	chr1:46669345	POMGNT1;C1orf190	0.44	7.28	0.37	2.33e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.57	10.01	0.48	7.47e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.32	-0.32	8.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.88	0.39	4.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-7.73	-0.39	1.18e-13	Longevity;
LIHC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg15704280	chr7:45808275	SEPT13	-0.47	-7.03	-0.36	1.14e-11	HDL cholesterol;
LIHC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg08528486	chr13:113648767	MCF2L	-0.41	-6.59	-0.34	1.68e-10	Systolic blood pressure;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.45	8.1	0.4	9.53e-15	Prudent dietary pattern;
LIHC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.6	8.88	0.43	3.98e-17	Height;
LIHC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg09137382	chr11:130731461	NA	0.42	6.35	0.32	6.9e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7979473	1	rs7979473	chr12:121420260	A/G	cg02403541	chr12:121454288	C12orf43	-0.36	-6.05	-0.31	3.71e-9	C-reactive protein;
LIHC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.3	0.37	2.01e-12	Lung cancer;
LIHC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	7.52	0.38	4.75e-13	Educational attainment;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg16989107	chr1:46598393	PIK3R3	0.44	6.36	0.33	6.36e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.76	0.3	1.87e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7635838	0.859	rs9875414	chr3:11453559	A/G	cg00170343	chr3:11313890	ATG7	0.42	6.55	0.33	2.17e-10	HDL cholesterol;
LIHC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-7.16	-0.36	4.98e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	12.71	0.57	1.38e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg14553853	chr4:85888001	WDFY3;C4orf12	-0.36	-5.84	-0.3	1.18e-8	Oropharynx cancer;
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.0	-0.31	5.02e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.44	-6.96	-0.35	1.79e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.45	7.29	0.37	2.11e-12	Crohn's disease;
LIHC	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.66	11.1	0.51	1.19e-24	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.91	0.3	8.33e-9	Birth weight;
LIHC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.48	7.86	0.39	5.08e-14	Multiple sclerosis;
LIHC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.98	-18.41	-0.71	4.45e-53	Breast cancer;
LIHC	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.08	0.31	3.13e-9	Ileal carcinoids;
LIHC	cis	rs7911264	0.628	rs7078243	chr10:94414263	A/C	cg25506282	chr10:94462361	NA	0.38	6.37	0.33	6.01e-10	Inflammatory bowel disease;
LIHC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.56	12.28	0.55	5.81e-29	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg16589663	chr20:23618590	CST3	0.72	7.32	0.37	1.76e-12	Chronic kidney disease;
LIHC	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg21016266	chr12:122356598	WDR66	-0.38	-5.95	-0.31	6.81e-9	Mean corpuscular volume;
LIHC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.51	-5.71	-0.3	2.39e-8	Gut microbiome composition (summer);
LIHC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.47	7.96	0.4	2.6e-14	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-6.15	-0.32	2.16e-9	Schizophrenia;
LIHC	trans	rs7714584	1.000	rs10463240	chr5:150256853	A/C	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.87	0.3	1.04e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.37	9.53	0.46	3.06e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg14146966	chr2:61757674	XPO1	-0.46	-7.91	-0.39	3.7e-14	Tuberculosis;
LIHC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.82	-0.35	4.09e-11	Coronary artery disease;
LIHC	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.44	6.83	0.35	4.01e-11	Schizophrenia;
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.53	7.97	0.4	2.41e-14	Height;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.63	9.73	0.47	6.48e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.48	0.49	1.87e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	8.43	0.41	9.56e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg12046867	chr14:103022105	NA	-0.5	-7.08	-0.36	8.37e-12	Platelet count;
LIHC	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg10756647	chr7:56101905	PSPH	1.02	12.11	0.55	2.53e-28	Diabetic kidney disease;
LIHC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.86	-0.3	1.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.44	6.67	0.34	1.05e-10	Post bronchodilator FEV1;
LIHC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06634786	chr22:41940651	POLR3H	-0.6	-6.51	-0.33	2.63e-10	Vitiligo;
LIHC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.73	-0.3	2.19e-8	Total body bone mineral density;
LIHC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00152838	chr16:24741724	TNRC6A	0.5	6.16	0.32	2.05e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg07424592	chr7:64974309	NA	0.84	9.64	0.46	1.3e-19	Diabetic kidney disease;
LIHC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.52	8.53	0.42	4.91e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg03037974	chr15:76606532	NA	0.74	14.63	0.62	5.72e-38	Blood metabolite levels;
LIHC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.41	-6.0	-0.31	5.08e-9	Height;
LIHC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.31	-0.32	8.65e-10	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.48	-6.27	-0.32	1.09e-9	Corneal structure;
LIHC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg14222432	chr12:29376421	FAR2	0.36	7.01	0.35	1.27e-11	QT interval;
LIHC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.91	0.3	8.47e-9	Height;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg27189623	chr16:705930	WDR90	0.36	6.11	0.31	2.74e-9	Height;
LIHC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.71	-12.73	-0.57	1.17e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	10.6	0.5	7e-23	Platelet distribution width;
LIHC	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg09307838	chr4:120376055	NA	0.51	7.5	0.38	5.51e-13	Corneal astigmatism;
LIHC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.73	11.94	0.54	1.05e-27	Body mass index;
LIHC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	0.54	7.09	0.36	7.55e-12	Pulse pressure;
LIHC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg12140854	chr5:148520817	ABLIM3	-0.53	-5.9	-0.3	8.73e-9	Breast cancer;
LIHC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.78	10.39	0.49	3.62e-22	Systemic lupus erythematosus;
LIHC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.67e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg07636037	chr3:49044803	WDR6	-0.82	-8.32	-0.41	2.09e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	7.67	0.38	1.83e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.59	-11.97	-0.54	8.22e-28	Plateletcrit;Platelet count;
LIHC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.54	-6.42	-0.33	4.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.47	-0.37	6.59e-13	Tuberculosis;
LIHC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg24826892	chr11:71159390	DHCR7	0.52	6.85	0.35	3.52e-11	Vitamin D levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08276543	chr12:124856791	NCOR2	0.46	6.86	0.35	3.14e-11	Longevity;
LIHC	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg20129853	chr10:51489980	NA	-0.4	-8.57	-0.42	3.62e-16	Prostate-specific antigen levels;
LIHC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.68	12.19	0.55	1.24e-28	Breast cancer;
LIHC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.25	-0.32	1.25e-9	Mean corpuscular volume;
LIHC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-0.61	-8.18	-0.4	5.65e-15	Lung cancer;
LIHC	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	9.62	0.46	1.49e-19	Platelet count;
LIHC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.15	11.65	0.53	1.23e-26	Primary sclerosing cholangitis;
LIHC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.39	9.53	0.46	2.97e-19	Blood metabolite ratios;
LIHC	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	10.62	0.5	5.94e-23	Menarche (age at onset);
LIHC	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.31	7.39	0.37	1.13e-12	Corneal astigmatism;
LIHC	trans	rs561341	0.700	rs886223	chr17:30229877	G/T	cg20587970	chr11:113659929	NA	-0.5	-6.34	-0.32	7.45e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs2191566	0.664	rs6509138	chr19:44570393	C/A	cg20607764	chr19:44506953	ZNF230	-0.37	-6.23	-0.32	1.36e-9	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.67	13.37	0.59	4.2e-33	Leprosy;
LIHC	cis	rs6448317	1.000	rs11934149	chr4:24938953	T/C	cg21108841	chr4:24914750	CCDC149	-0.47	-6.0	-0.31	5e-9	Heschl's gyrus morphology;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17635903	chr4:4871426	NA	0.44	6.29	0.32	9.83e-10	Lung function (FEV1/FVC);
LIHC	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg16797656	chr11:68205561	LRP5	-0.57	-7.64	-0.38	2.19e-13	Total body bone mineral density (age 45-60);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.43	6.21	0.32	1.55e-9	Pancreatic cancer;
LIHC	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.76	0.39	1.01e-13	Alzheimer's disease;
LIHC	cis	rs7095607	0.606	rs7100561	chr10:69958472	G/A	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.66e-9	Lung function (FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13704629	chr14:73396469	DCAF4	0.39	6.06	0.31	3.58e-9	Pancreatic cancer;
LIHC	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15572692	chr19:14016919	C19orf57;CC2D1A	-0.45	-6.09	-0.31	2.96e-9	Systolic blood pressure;
LIHC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.33	-0.37	1.64e-12	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05313302	chr10:75006908	DNAJC9	-0.4	-6.31	-0.32	8.71e-10	Pancreatic cancer;
LIHC	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg03934865	chr2:198174659	NA	0.46	6.58	0.34	1.74e-10	Intracranial aneurysm;
LIHC	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	8.87	0.43	4.17e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg22887498	chr19:39401301	NA	0.42	6.22	0.32	1.46e-9	Immature fraction of reticulocytes;
LIHC	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.46	6.71	0.34	8.19e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.28	-6.72	-0.34	7.85e-11	Alcohol dependence;
LIHC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg21395723	chr22:39101663	GTPBP1	0.41	6.88	0.35	2.8e-11	Menopause (age at onset);
LIHC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20135002	chr11:47629003	NA	-0.58	-9.79	-0.47	4.23e-20	Subjective well-being;
LIHC	cis	rs2274273	0.719	rs17740551	chr14:55751325	C/T	cg01864836	chr14:55583639	NA	-0.36	-5.9	-0.3	8.84e-9	Protein biomarker;
LIHC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.9	-0.3	8.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.72	-12.45	-0.56	1.37e-29	Intelligence (multi-trait analysis);
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01516881	chr6:292596	DUSP22	-0.52	-6.65	-0.34	1.15e-10	Menopause (age at onset);
LIHC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg06050784	chr16:88016603	BANP	0.34	6.18	0.32	1.78e-9	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.75	0.3	2.01e-8	Alzheimer's disease;
LIHC	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.4	-0.37	1.07e-12	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20831041	chr11:464554	PTDSS2	0.45	6.84	0.35	3.77e-11	Longevity;
LIHC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.86	-0.3	1.11e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg23605328	chr1:201951606	RNPEP	0.39	6.18	0.32	1.86e-9	Monocyte percentage of white cells;
LIHC	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.37	-6.04	-0.31	4.1e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs74544699	1.000	rs57274239	chr4:74789027	A/G	cg16072462	chr4:74847758	PF4	0.59	6.03	0.31	4.32e-9	Growth-regulated protein alpha levels;
LIHC	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.96	9.93	0.47	1.44e-20	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.16	0.55	1.68e-28	Prudent dietary pattern;
LIHC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg07234388	chr1:156261841	TMEM79	0.5	8.8	0.43	6.86e-17	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.28	0.55	5.92e-29	Prudent dietary pattern;
LIHC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.36	-9.31	-0.45	1.59e-18	Asthma (sex interaction);
LIHC	cis	rs1190552	0.706	rs10135045	chr14:102872469	T/G	cg10241871	chr14:102965420	TECPR2	0.39	5.94	0.31	6.98e-9	Blood protein levels;
LIHC	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.86	-6.54	-0.33	2.21e-10	Systolic blood pressure;
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.37	-6.11	-0.31	2.76e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs911119	0.913	rs2405392	chr20:23569186	C/T	cg16589663	chr20:23618590	CST3	0.65	6.74	0.34	6.57e-11	Chronic kidney disease;
LIHC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.56	8.66	0.42	1.87e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs1030268	0.859	rs10954428	chr7:133388056	C/T	cg03336402	chr7:133662267	EXOC4	-0.48	-6.76	-0.34	5.97e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.59	0.59	6.08e-34	Diabetic kidney disease;
LIHC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.5	-6.59	-0.34	1.69e-10	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12096988	chr19:57702809	ZNF264	-0.59	-6.83	-0.35	3.98e-11	Systolic blood pressure;
LIHC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	18.14	0.7	5.53e-52	Tonsillectomy;
LIHC	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg12698662	chr3:15914712	MIR563	-0.37	-6.82	-0.35	4.07e-11	Mean platelet volume;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs593982	0.858	rs480989	chr11:65493992	A/G	cg08755490	chr11:65554678	OVOL1	0.5	6.6	0.34	1.53e-10	Atopic dermatitis;
LIHC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg03013999	chr17:37608204	MED1	-0.34	-5.79	-0.3	1.58e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.34	-5.88	-0.3	9.83e-9	IgG glycosylation;
LIHC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.72	7.49	0.38	5.76e-13	Vitiligo;
LIHC	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	22.27	0.77	1.53e-68	Colorectal cancer;
LIHC	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.32	6.82	0.35	4.09e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.65	9.97	0.47	1.02e-20	Renal cell carcinoma;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.01	-0.48	7.15e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg15192750	chr16:69999425	NA	0.46	6.06	0.31	3.63e-9	IgE levels;
LIHC	cis	rs965469	0.843	rs6037580	chr20:3351374	A/G	cg25506879	chr20:3388711	C20orf194	-0.54	-6.52	-0.33	2.58e-10	IFN-related cytopenia;
LIHC	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.4	5.74	0.3	2.12e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.44	-7.26	-0.37	2.63e-12	IgG glycosylation;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.43	-8.92	-0.43	2.97e-17	Abdominal aortic aneurysm;
LIHC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.46	-7.46	-0.37	7.37e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19671926	chr4:122722719	EXOSC9	0.56	8.66	0.42	1.93e-16	Type 2 diabetes;
LIHC	cis	rs2019216	1.000	rs2019216	chr17:21909650	C/T	cg22648282	chr17:21454238	C17orf51	-0.35	-6.09	-0.31	3.01e-9	Pelvic organ prolapse;
LIHC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.33	-0.32	7.54e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs11098699	0.821	rs931708	chr4:124202363	G/A	cg09941581	chr4:124220074	SPATA5	0.32	6.29	0.32	9.59e-10	Mosquito bite size;
LIHC	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.22	-5.99	-0.31	5.4e-9	Hepatitis;
LIHC	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.61	-10.83	-0.51	1.06e-23	Diisocyanate-induced asthma;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg02782426	chr3:40428986	ENTPD3	-0.32	-6.1	-0.31	2.81e-9	Renal cell carcinoma;
LIHC	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg15549821	chr19:49342101	PLEKHA4	-0.99	-9.4	-0.45	8.24e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	9.16	0.44	4.85e-18	Schizophrenia;
LIHC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.36	6.06	0.31	3.58e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.46	7.09	0.36	7.91e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs10916814	0.632	rs4655224	chr1:20902195	A/C	cg24502330	chr1:20914028	CDA	-0.31	-6.79	-0.34	4.83e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.66	-9.78	-0.47	4.43e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs11229555	0.645	rs12269745	chr11:58176875	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.4	6.36	0.33	6.58e-10	Red blood cell count;
LIHC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.42	-0.33	4.46e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.47	7.59	0.38	2.97e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg11243680	chr12:31881778	AMN1	-0.58	-6.83	-0.35	3.92e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04313349	chr17:76778764	CYTH1	0.45	6.19	0.32	1.69e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.9	-18.4	-0.71	4.84e-53	Height;
LIHC	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg08135965	chr6:41755394	TOMM6	0.44	5.72	0.3	2.34e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg09835421	chr16:68378352	PRMT7	-0.82	-9.6	-0.46	1.8e-19	Schizophrenia;
LIHC	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.31	7.1	0.36	7.42e-12	Blood metabolite ratios;
LIHC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.58	10.18	0.48	1.89e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs61440199	1.000	rs73818811	chr3:20144715	G/A	cg00235661	chr3:20228976	SGOL1	-0.41	-5.84	-0.3	1.23e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25613101	chr22:38577875	PLA2G6	0.51	6.75	0.34	6.31e-11	Lung function (FEV1/FVC);
LIHC	cis	rs965469	0.779	rs6515791	chr20:3310443	C/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.14	-0.32	2.28e-9	IFN-related cytopenia;
LIHC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.35	5.72	0.3	2.29e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.56	7.69	0.38	1.6e-13	IFN-related cytopenia;
LIHC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.18	-0.52	6.27e-25	Response to antipsychotic treatment;
LIHC	cis	rs11212260	0.655	rs11212221	chr11:107293365	T/C	cg25435332	chr11:107328525	CWF19L2	0.79	8.09	0.4	1.08e-14	IgG glycosylation;
LIHC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.6	-0.42	2.82e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg03934865	chr2:198174659	NA	0.54	8.25	0.41	3.45e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8016982	0.662	rs7144005	chr14:81656437	C/T	cg01989461	chr14:81687754	GTF2A1	0.53	9.25	0.45	2.59e-18	Schizophrenia;
LIHC	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.36	-0.41	1.59e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02187348	chr16:89574699	SPG7	0.52	7.7	0.38	1.43e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.41	0.45	7.7e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.75	-0.34	6.27e-11	Morning vs. evening chronotype;
LIHC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02187348	chr16:89574699	SPG7	0.47	6.42	0.33	4.45e-10	Multiple myeloma (IgH translocation);
LIHC	trans	rs10213084	1.000	rs10212914	chr4:147499085	T/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.65	9.77	0.47	4.95e-20	Height;
LIHC	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg02466173	chr16:30829666	NA	-0.43	-6.66	-0.34	1.11e-10	Multiple myeloma;
LIHC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.21	-0.48	1.55e-21	Blood metabolite levels;
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.63	7.04	0.36	1.03e-11	Alzheimer's disease;
LIHC	cis	rs35883536	1.000	rs4243810	chr1:101139914	T/C	cg14515779	chr1:101123966	NA	-0.67	-13.3	-0.58	8.12e-33	Monocyte count;
LIHC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg18887096	chr2:219472410	PLCD4	0.35	6.22	0.32	1.49e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg03721293	chr16:90014378	DEF8	0.42	7.06	0.36	9.13e-12	Skin colour saturation;
LIHC	cis	rs986417	0.636	rs8020587	chr14:60952612	A/G	cg27398547	chr14:60952738	C14orf39	0.83	9.68	0.46	9.59e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.49	6.12	0.31	2.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg03037974	chr15:76606532	NA	0.74	14.67	0.62	3.89e-38	Blood metabolite levels;
LIHC	cis	rs34172651	0.545	rs8056132	chr16:24716348	A/G	cg00339695	chr16:24857497	SLC5A11	0.37	6.12	0.31	2.62e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2257205	0.667	rs9893027	chr17:56653448	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.89	0.43	3.61e-17	Menarche (age at onset);
LIHC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg26692224	chr17:62915920	LRRC37A3	-0.68	-6.29	-0.32	9.66e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.96	20.09	0.74	7.44e-60	IgG glycosylation;
LIHC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-10.98	-0.51	3.14e-24	Mean corpuscular volume;
LIHC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.5	-9.96	-0.47	1.1e-20	Tonsillectomy;
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.69	9.72	0.47	7.18e-20	Menarche (age at onset);
LIHC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.55	8.18	0.4	5.76e-15	Longevity;Endometriosis;
LIHC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.52	7.74	0.39	1.13e-13	Colorectal cancer;
LIHC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.66	-13.16	-0.58	2.78e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg08896387	chr1:24191740	FUCA1	0.39	6.15	0.32	2.18e-9	Immature fraction of reticulocytes;
LIHC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.48	0.56	1.05e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs600806	0.888	rs652651	chr1:109844532	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.57	-6.67	-0.34	1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.86	8.61	0.42	2.73e-16	Mean platelet volume;
LIHC	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.71	-0.34	7.92e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17414733	chr19:21688647	ZNF429	-0.43	-6.63	-0.34	1.28e-10	Bilirubin levels;
LIHC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg20283391	chr11:68216788	NA	-0.51	-6.14	-0.32	2.3e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.89	12.47	0.56	1.12e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg11783602	chr8:55087084	NA	-0.31	-6.09	-0.31	3.02e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs11673344	0.864	rs1879497	chr19:37632877	G/T	cg27390819	chr19:37464633	NA	-0.51	-6.16	-0.32	2.05e-9	Obesity-related traits;
LIHC	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.59	9.16	0.44	4.84e-18	Uric acid clearance;
LIHC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.3	-6.22	-0.32	1.44e-9	Blood metabolite levels;
LIHC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.7	12.49	0.56	9.26e-30	Iron status biomarkers;
LIHC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	8.41	0.41	1.1e-15	Schizophrenia;
LIHC	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.8	10.09	0.48	4.11e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg10935138	chr17:73851978	WBP2	0.48	7.21	0.36	3.72e-12	White matter hyperintensity burden;
LIHC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.68	-11.09	-0.51	1.25e-24	Itch intensity from mosquito bite;
LIHC	cis	rs7188697	0.922	rs37057	chr16:58561954	T/C	cg02549819	chr16:58548995	SETD6	-0.45	-7.2	-0.36	3.85e-12	QT interval;
LIHC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.6	7.77	0.39	9.45e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.56	-7.95	-0.39	2.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2851682	0.611	rs2072114	chr11:61605215	A/G	cg27386326	chr11:61587980	NA	0.57	9.2	0.45	3.72e-18	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg14292368	chr19:18793705	CRTC1	0.41	5.74	0.3	2.14e-8	Menarche (age at onset);
LIHC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.69	6.02	0.31	4.6e-9	Body mass index;
LIHC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg03013999	chr17:37608204	MED1	0.34	5.73	0.3	2.21e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.37	-6.45	-0.33	3.89e-10	Type 2 diabetes;
LIHC	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.68	-11.68	-0.53	9.05e-27	Pediatric autoimmune diseases;
LIHC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg05590025	chr7:65112418	INTS4L2	-0.57	-6.35	-0.32	7.03e-10	Diabetic kidney disease;
LIHC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	1.06	15.77	0.65	1.75e-42	Breast cancer;
LIHC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg20607798	chr8:58055168	NA	0.46	5.81	0.3	1.44e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.63	10.21	0.48	1.54e-21	Longevity;
LIHC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.18	31.11	0.86	9.11e-102	IgG glycosylation;
LIHC	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.41	6.39	0.33	5.4e-10	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg20636351	chr8:55087400	NA	-0.38	-7.73	-0.39	1.2e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg22705602	chr4:152727874	NA	-0.29	-6.31	-0.32	8.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.51	8.05	0.4	1.37e-14	Platelet count;
LIHC	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.76	9.51	0.46	3.47e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.93	0.43	2.71e-17	Multiple sclerosis;
LIHC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.63	0.38	2.29e-13	Mean platelet volume;
LIHC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.17	0.36	4.71e-12	Morning vs. evening chronotype;
LIHC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.36	-5.74	-0.3	2.12e-8	Red blood cell count;
LIHC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.47	5.72	0.3	2.31e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg09695851	chr17:3907499	NA	0.62	7.19	0.36	3.98e-12	Type 2 diabetes;
LIHC	cis	rs61041384	0.661	rs74240771	chr12:123696963	G/A	cg00376283	chr12:123451042	ABCB9	-0.54	-5.89	-0.3	9.12e-9	Schizophrenia;
LIHC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19500275	chr17:80737654	TBCD	0.41	5.76	0.3	1.86e-8	Glycated hemoglobin levels;
LIHC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	7.73	0.39	1.18e-13	Aortic root size;
LIHC	trans	rs1484948	0.567	rs1567941	chr11:41947842	G/A	cg09339301	chr6:163836245	QKI	0.56	6.18	0.32	1.79e-9	RR interval (heart rate);
LIHC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.26	0.41	3.22e-15	Motion sickness;
LIHC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.66	10.76	0.5	1.94e-23	Psoriasis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18465072	chr17:30327605	SUZ12	0.3	6.08	0.31	3.21e-9	Cognitive function;
LIHC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.66	9.39	0.45	8.81e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	9.08	0.44	9.09e-18	LDL cholesterol;
LIHC	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg08126542	chr6:37504118	NA	-0.37	-6.27	-0.32	1.09e-9	Cognitive performance;
LIHC	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.63	-8.49	-0.42	6.43e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.6	-8.59	-0.42	3.21e-16	Blood metabolite levels;
LIHC	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	trans	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.36	6.64	0.34	1.27e-10	Blood metabolite levels;
LIHC	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.29	-6.56	-0.33	2.03e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs55665837	0.701	rs11023272	chr11:14630370	T/C	cg25251204	chr11:14927456	NA	0.43	5.98	0.31	5.71e-9	Vitamin D levels;
LIHC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg13753209	chr17:57696993	CLTC	0.72	11.42	0.53	8.26e-26	Hemoglobin concentration;
LIHC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg18306943	chr3:40428807	ENTPD3	0.33	5.74	0.3	2.14e-8	Renal cell carcinoma;
LIHC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.68	8.5	0.42	5.96e-16	Mean platelet volume;
LIHC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.6	7.86	0.39	4.91e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10197940	0.901	rs2290367	chr2:152266731	T/A	cg06191203	chr2:152266755	RIF1	-0.52	-10.11	-0.48	3.35e-21	Lung cancer;
LIHC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-6.14	-0.32	2.32e-9	Type 2 diabetes;
LIHC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.5	8.67	0.42	1.72e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.72	7.88	0.39	4.32e-14	Dental caries;
LIHC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg00601450	chr5:74908170	NA	-0.68	-9.22	-0.45	3.22e-18	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.0	-0.54	6.29e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.55	5.86	0.3	1.08e-8	IgG glycosylation;
LIHC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.67	-8.4	-0.41	1.18e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg03989125	chr22:38214979	NA	-0.44	-6.14	-0.32	2.26e-9	Glioblastoma;Glioma;
LIHC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.45	-9.06	-0.44	1.05e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.65	0.53	1.21e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg16394018	chr11:14927549	NA	0.39	5.74	0.3	2.04e-8	Vitamin D levels;
LIHC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	1.03	20.84	0.75	7.83e-63	Breast cancer;
LIHC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.0	-0.51	2.57e-24	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.66	8.01	0.4	1.84e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.04	-0.36	1.03e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-6.72	-0.34	7.55e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs61677309	1.000	rs59399105	chr11:118168568	C/A	cg06090739	chr11:118230722	UBE4A	0.34	6.29	0.32	9.96e-10	Lung cancer in ever smokers;
LIHC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.38	-5.78	-0.3	1.64e-8	P wave terminal force;
LIHC	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.02	-19.88	-0.73	5.23e-59	Exhaled nitric oxide output;
LIHC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg03929089	chr4:120376271	NA	-0.43	-6.58	-0.34	1.75e-10	HDL cholesterol;
LIHC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	12.33	0.55	3.82e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg15534755	chr11:117069859	TAGLN	0.39	6.64	0.34	1.25e-10	Blood protein levels;
LIHC	cis	rs7937890	0.598	rs10734225	chr11:14442994	C/G	cg22961513	chr11:14280813	SPON1	-0.43	-6.14	-0.32	2.25e-9	Mitochondrial DNA levels;
LIHC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-8.11	-0.4	9.18e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.35	0.45	1.17e-18	Electroencephalogram traits;
LIHC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.41	0.33	4.79e-10	Renal cell carcinoma;
LIHC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.58	0.53	2.28e-26	High light scatter reticulocyte count;
LIHC	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	0.75	7.56	0.38	3.76e-13	Arsenic metabolism;
LIHC	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg06353428	chr16:71660113	MARVELD3	-0.69	-7.34	-0.37	1.54e-12	Blood protein levels;
LIHC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-21.99	-0.77	1.96e-67	Coronary artery disease;
LIHC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.1	-0.31	2.85e-9	Systolic blood pressure;
LIHC	cis	rs2380220	0.808	rs2716070	chr6:95912375	T/C	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg10932868	chr11:921992	NA	0.4	7.48	0.38	6.23e-13	Alzheimer's disease (late onset);
LIHC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	9.41	0.45	7.73e-19	IgG glycosylation;
LIHC	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg10820045	chr2:198174542	NA	0.48	7.31	0.37	1.95e-12	Intracranial aneurysm;
LIHC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg19318889	chr4:1322082	MAEA	0.43	5.87	0.3	1.04e-8	Obesity-related traits;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18502306	chr4:8376764	ACOX3	0.45	7.0	0.35	1.4e-11	Longevity;
LIHC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.73	-12.28	-0.55	5.79e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.62	-7.71	-0.38	1.37e-13	Gut microbiome composition (summer);
LIHC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.46	10.4	0.49	3.2800000000000002e-22	Iron status biomarkers (transferrin levels);
LIHC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14154082	chr13:112174009	NA	0.3	6.24	0.32	1.3e-9	Menarche (age at onset);
LIHC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.68	-14.2	-0.61	2.76e-36	Sense of smell;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg26338869	chr17:61819248	STRADA	0.53	7.21	0.36	3.73e-12	Height;
LIHC	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.68	11.72	0.54	6.59e-27	Pediatric autoimmune diseases;
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.65	9.22	0.45	3.05e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg06937548	chr11:34938143	PDHX;APIP	-0.58	-7.52	-0.38	4.95e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.89	-0.3	9.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.46	6.58	0.34	1.8e-10	Sudden cardiac arrest;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25005279	chr10:135113451	TUBGCP2	0.43	6.36	0.33	6.35e-10	Longevity;
LIHC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.85	-10.49	-0.49	1.6400000000000001e-22	Mean platelet volume;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg03395511	chr6:291903	DUSP22	-0.48	-6.39	-0.33	5.36e-10	Menopause (age at onset);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20700762	chr2:192108893	MYO1B	-0.32	-7.4	-0.37	1.05e-12	Calcium levels;
LIHC	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.7	8.93	0.43	2.7e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.55	0.46	2.51e-19	Coffee consumption (cups per day);
LIHC	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg14146966	chr2:61757674	XPO1	0.45	7.69	0.38	1.61e-13	Tuberculosis;
LIHC	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2.05e-9	Ulcerative colitis;
LIHC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.33	6.94	0.35	2.02e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.28	-0.32	1.04e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg11764359	chr7:65958608	NA	0.58	6.06	0.31	3.57e-9	Diabetic kidney disease;
LIHC	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.21	0.48	1.49e-21	Colorectal cancer;
LIHC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg20140201	chr2:241835670	C2orf54	-0.46	-6.13	-0.31	2.37e-9	Urinary metabolites;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg03574000	chr4:103746999	UBE2D3	-0.3	-6.05	-0.31	3.72e-9	Oropharynx cancer;
LIHC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.62	-10.11	-0.48	3.32e-21	Bipolar disorder;
LIHC	cis	rs151997	0.962	rs32482	chr5:50207118	T/C	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs9513627	0.915	rs9585070	chr13:100118843	G/C	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs4450131	0.522	rs2272005	chr10:126402100	C/T	cg20435097	chr10:126320824	FAM53B	0.65	11.88	0.54	1.77e-27	White blood cell count (basophil);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23335946	chr1:185125966	C1orf25;C1orf26	0.48	6.55	0.33	2.08e-10	Pancreatic cancer;
LIHC	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.83	7.74	0.39	1.1e-13	LDL cholesterol;
LIHC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg03689076	chr20:33865952	NA	0.58	6.68	0.34	9.81e-11	Attention deficit hyperactivity disorder;
LIHC	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg17749961	chr2:30669863	LCLAT1	0.47	6.01	0.31	4.74e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-7.24	-0.36	2.89e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.48	-6.7	-0.34	8.53e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.43	7.06	0.36	9.48e-12	Red blood cell count;
LIHC	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-6.52	-0.33	2.6e-10	Hepatocellular carcinoma;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23643835	chr7:45809304	SEPT13	0.4	6.41	0.33	4.93e-10	Longevity;
LIHC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.46	4.67e-19	Bipolar disorder;
LIHC	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg09537434	chr19:41945824	ATP5SL	1.02	21.05	0.75	1.07e-63	Height;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg13957321	chr17:43675089	NA	0.5	7.97	0.4	2.42e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.44	8.07	0.4	1.21e-14	Prudent dietary pattern;
LIHC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.7	13.52	0.59	1.19e-33	N-glycan levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22140136	chr19:10491633	TYK2	0.47	6.82	0.35	4.05e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2421770	0.530	rs3847621	chr11:35364435	G/A	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.59	-0.38	3.02e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg24296786	chr1:45957014	TESK2	-0.4	-5.88	-0.3	9.62e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.59	-0.42	3.19e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.93	-0.35	2.12e-11	Total body bone mineral density;
LIHC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1144333	1.000	rs5745542	chr1:76365073	C/G	cg03433033	chr1:76189801	ACADM	0.54	7.97	0.4	2.39e-14	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.78	0.3	1.72e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12086130	0.892	rs72906804	chr1:51450144	A/G	cg07174182	chr1:51127561	FAF1	-0.92	-9.87	-0.47	2.14e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs2997447	0.668	rs59978831	chr1:26446351	T/A	cg19633962	chr1:26362018	EXTL1	-0.64	-5.88	-0.3	9.64e-9	QRS complex (12-leadsum);
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08219700	chr8:58056026	NA	-0.5	-6.92	-0.35	2.21e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6060717	0.702	rs6060756	chr20:34608479	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.49	8.56	0.42	3.9e-16	Hip circumference adjusted for BMI;
LIHC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.46	6.11	0.31	2.66e-9	Menopause (age at onset);
LIHC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-9.49	-0.46	4.2e-19	Colorectal cancer;
LIHC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.91	0.3	8.47e-9	Height;
LIHC	cis	rs16958440	0.867	rs16949275	chr18:44700703	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.42	7.36	0.37	1.4e-12	Mean corpuscular volume;
LIHC	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.38	-7.82	-0.39	6.6e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg22532475	chr10:104410764	TRIM8	0.36	6.45	0.33	3.71e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.6	-10.39	-0.49	3.67e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg07451762	chr16:28383216	NA	0.33	6.03	0.31	4.23e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg20607798	chr8:58055168	NA	0.45	6.05	0.31	3.76e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12463199	chr20:49126897	PTPN1	0.37	6.31	0.32	8.52e-10	Cognitive function;
LIHC	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg11070056	chr1:107600091	PRMT6	-0.72	-12.31	-0.55	4.65e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.32	5.96	0.31	6.15e-9	Body mass index;
LIHC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.49	5.78	0.3	1.68e-8	Bladder cancer;
LIHC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.44	6.34	0.32	7.48e-10	Aortic root size;
LIHC	cis	rs7534824	0.543	rs6577221	chr1:101420406	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	7.53	0.38	4.57e-13	Refractive astigmatism;
LIHC	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4663866	0.901	rs3739066	chr2:239184124	G/T	cg16914508	chr2:239161102	PER2	0.8	5.84	0.3	1.23e-8	Irritable bowel syndrome;
LIHC	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.51	7.08	0.36	8.1e-12	Aortic root size;
LIHC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.52	-9.17	-0.44	4.63e-18	Blood protein levels;
LIHC	cis	rs6722750	0.840	rs6712700	chr2:64374041	A/G	cg22352474	chr2:64371530	PELI1	0.64	9.71	0.46	7.5599999999999994e-20	Neuroticism;
LIHC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.6	9.95	0.47	1.21e-20	Height;
LIHC	cis	rs12744310	1.000	rs12029950	chr1:41753165	G/A	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.82e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg26939375	chr7:64535504	NA	0.41	6.47	0.33	3.36e-10	Aortic root size;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg20399509	chr21:47717575	C21orf57	0.37	5.83	0.3	1.28e-8	Testicular germ cell tumor;
LIHC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.74	0.3	2.07e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.24	-0.41	3.62e-15	Chronic sinus infection;
LIHC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.49	8.31	0.41	2.27e-15	Response to temozolomide;
LIHC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.69	12.31	0.55	4.59e-29	Iron status biomarkers;
LIHC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.23e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21016266	chr12:122356598	WDR66	-0.44	-6.99	-0.35	1.41e-11	Mean corpuscular volume;
LIHC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg04025307	chr7:1156635	C7orf50	0.48	7.95	0.39	2.78e-14	Longevity;Endometriosis;
LIHC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.89	14.17	0.61	3.55e-36	Metabolic syndrome;
LIHC	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg25182066	chr10:30743637	MAP3K8	-0.63	-10.11	-0.48	3.45e-21	Inflammatory bowel disease;
LIHC	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg18898632	chr2:242989856	NA	-0.57	-7.59	-0.38	3.11e-13	Obesity-related traits;
LIHC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg18944383	chr4:111397179	ENPEP	-0.35	-8.15	-0.4	7.15e-15	Coronary artery disease;
LIHC	cis	rs7116495	1.000	rs1783961	chr11:71576095	A/C	cg26138937	chr11:71823887	C11orf51	0.71	6.93	0.35	2.15e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-8.45	-0.42	8.65e-16	Vitiligo;
LIHC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	7.32	0.37	1.8e-12	Total body bone mineral density;
LIHC	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.09	0.44	8.02e-18	Coffee consumption (cups per day);
LIHC	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg19539972	chr4:7069911	GRPEL1	0.7	10.11	0.48	3.36e-21	Monocyte percentage of white cells;
LIHC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	6.17	0.32	1.97e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6442522	0.671	rs2305615	chr3:15517025	G/A	cg16303742	chr3:15540471	COLQ	0.39	6.48	0.33	3.18e-10	Uric acid levels;
LIHC	cis	rs4788570	0.615	rs4788822	chr16:71681515	A/G	cg06353428	chr16:71660113	MARVELD3	1.45	15.73	0.65	2.59e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg25783544	chr11:47291846	MADD	0.4	5.74	0.3	2.04e-8	HDL cholesterol;
LIHC	trans	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg01596870	chr19:55963115	NA	-0.67	-9.66	-0.46	1.09e-19	Obesity-related traits;
LIHC	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01719123	chr8:28244050	ZNF395	0.5	7.0	0.35	1.33e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.46	0.46	5.05e-19	Coffee consumption (cups per day);
LIHC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.48	-7.39	-0.37	1.17e-12	Diastolic blood pressure;
LIHC	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.45	-6.95	-0.35	1.87e-11	Multiple sclerosis;
LIHC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.26	-0.48	1.08e-21	Alzheimer's disease;
LIHC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.43	5.76	0.3	1.86e-8	Lymphocyte counts;
LIHC	cis	rs35160687	0.623	rs35408390	chr2:86471782	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	6.38	0.33	5.64e-10	Night sleep phenotypes;
LIHC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.64	-10.67	-0.5	3.99e-23	Bipolar disorder;
LIHC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-10.5	-0.49	1.58e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs6445975	0.715	rs3773007	chr3:58269566	G/T	cg23715586	chr3:58305044	RPP14	-0.38	-6.42	-0.33	4.58e-10	Systemic lupus erythematosus;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.6	8.46	0.42	8.19e-16	Testicular germ cell tumor;
LIHC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.41	-7.86	-0.39	5.03e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs2257205	0.667	rs74961279	chr17:56904991	C/T	cg12560992	chr17:57184187	TRIM37	0.67	7.23	0.36	3.24e-12	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.26	0.45	2.37e-18	Bipolar disorder;
LIHC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	trans	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg10756647	chr7:56101905	PSPH	-0.63	-8.52	-0.42	5.08e-16	Corneal structure;
LIHC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12463550	chr7:65579703	CRCP	0.68	7.09	0.36	7.93e-12	Diabetic kidney disease;
LIHC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	7.08	0.36	8e-12	Schizophrenia;
LIHC	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.51	7.95	0.4	2.66e-14	Diastolic blood pressure;
LIHC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.65	-6.64	-0.34	1.23e-10	Vitiligo;
LIHC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs11229030	0.893	rs2581925	chr11:57207414	G/A	cg00522883	chr11:57194120	SLC43A3	-0.41	-5.88	-0.3	9.96e-9	Crohn's disease;
LIHC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.05	0.58	7.07e-32	Colorectal cancer;
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.45	-9.69	-0.46	8.99e-20	Abdominal aortic aneurysm;
LIHC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.36	-6.5	-0.33	2.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.72	-0.39	1.26e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg13628971	chr7:2884303	GNA12	0.4	6.36	0.33	6.41e-10	Height;
LIHC	cis	rs9473924	0.542	rs9473925	chr6:50834565	T/C	cg14470998	chr6:50812995	TFAP2B	0.93	10.64	0.5	5.15e-23	Body mass index;
LIHC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg16576597	chr16:28551801	NUPR1	0.38	6.23	0.32	1.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.14	0.32	2.28e-9	Total body bone mineral density;
LIHC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg07061783	chr6:25882402	NA	-0.48	-6.69	-0.34	9.05e-11	Blood metabolite levels;
LIHC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08392591	chr16:89556376	ANKRD11	0.39	5.91	0.3	8.31e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-0.97	-10.49	-0.49	1.69e-22	Vitiligo;
LIHC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	9.02	0.44	1.37e-17	Motion sickness;
LIHC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.26	-0.32	1.12e-9	Coronary artery disease;
LIHC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	11.51	0.53	4e-26	Lung cancer in ever smokers;
LIHC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.38	5.92	0.3	7.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg05527609	chr1:210001259	C1orf107	-0.58	-7.83	-0.39	6.22e-14	Red blood cell count;
LIHC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.57	9.75	0.47	5.63e-20	Dental caries;
LIHC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg13628971	chr7:2884303	GNA12	0.41	6.53	0.33	2.37e-10	Height;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.58	-8.55	-0.42	4.11e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.39	6.2	0.32	1.59e-9	Menopause (age at onset);
LIHC	cis	rs34540877	1.000	rs35760204	chr19:33130534	C/G	cg22980127	chr19:33182716	NUDT19	1.03	6.81	0.35	4.36e-11	Red cell distribution width;
LIHC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.49	8.02	0.4	1.73e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.5	-6.27	-0.32	1.06e-9	Menarche (age at onset);
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.73	-0.3	2.21e-8	Longevity;Endometriosis;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.6	6.5	0.33	2.8e-10	Alzheimer's disease;
LIHC	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.5	6.34	0.32	7.34e-10	Blood metabolite levels;
LIHC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.77	11.7	0.53	8.12e-27	Coronary artery disease;
LIHC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.46	-6.27	-0.32	1.08e-9	Initial pursuit acceleration;
LIHC	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg15282417	chr9:129245246	FAM125B	-0.39	-6.28	-0.32	1.04e-9	Intraocular pressure;
LIHC	cis	rs1256061	0.624	rs1760988	chr14:64696813	A/G	cg23250157	chr14:64679961	SYNE2	0.43	6.19	0.32	1.76e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg13957321	chr17:43675089	NA	-0.44	-7.28	-0.37	2.27e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-7.03	-0.36	1.1e-11	Opioid sensitivity;
LIHC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.45	6.68	0.34	9.63e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.78	7.32	0.37	1.83e-12	Plasma clusterin levels;
LIHC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.48	-7.44	-0.37	8.11e-13	Blood trace element (Zn levels);
LIHC	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.25	6.27	0.32	1.08e-9	Menarche (age at onset);
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	6.57	0.33	1.87e-10	Lymphocyte counts;
LIHC	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.4	7.2	0.36	3.74e-12	Monocyte percentage of white cells;
LIHC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.72	-0.5	2.62e-23	Chronic sinus infection;
LIHC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.44	6.79	0.34	4.95e-11	Melanoma;
LIHC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg09137382	chr11:130731461	NA	0.4	5.93	0.31	7.39e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.61	-9.78	-0.47	4.52e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg02290350	chr8:58132656	NA	0.31	6.89	0.35	2.77e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg02804564	chr10:112679224	NCRNA00081;SHOC2	0.41	6.54	0.33	2.19e-10	Morning vs. evening chronotype;
LIHC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.91	0.39	3.59e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.47	0.33	3.4e-10	Aortic root size;
LIHC	cis	rs12286929	0.898	rs11215384	chr11:115023851	C/G	cg04055981	chr11:115044050	NA	0.42	6.66	0.34	1.08e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.66	9.58	0.46	2.12e-19	Menarche (age at onset);
LIHC	trans	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg10208301	chr11:6592745	DNHD1	0.45	6.39	0.33	5.4e-10	Coronary artery calcification;
LIHC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.59	5.72	0.3	2.3e-8	Plasma clusterin levels;
LIHC	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	11.16	0.52	7.09e-25	Prudent dietary pattern;
LIHC	cis	rs6442522	0.611	rs1983085	chr3:15529543	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.32	-0.32	8.25e-10	Uric acid levels;
LIHC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg05484376	chr2:27715224	FNDC4	0.4	6.74	0.34	6.89e-11	Total body bone mineral density;
LIHC	cis	rs3741798	1.000	rs3741798	chr12:12496086	C/T	cg08615371	chr12:12503544	MANSC1	0.9	7.32	0.37	1.74e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.71	-9.26	-0.45	2.25e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.05	-17.45	-0.69	3.27e-49	Dilated cardiomyopathy;
LIHC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg03037974	chr15:76606532	NA	0.8	16.43	0.66	3.98e-45	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20314438	chr6:126661369	C6orf173	0.49	6.63	0.34	1.35e-10	Pancreatic cancer;
LIHC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.21	0.61	2.47e-36	Chronic sinus infection;
LIHC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.45	5.81	0.3	1.4e-8	Colorectal cancer;
LIHC	cis	rs11229555	0.645	rs35279927	chr11:58212129	G/T	cg15696309	chr11:58395628	NA	-0.65	-7.63	-0.38	2.37e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12220238	0.841	rs10824146	chr10:76076779	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.27	0.32	1.07e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.65	10.37	0.49	4.5e-22	Blood trace element (Zn levels);
LIHC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	12.08	0.55	3.21e-28	High light scatter reticulocyte count;
LIHC	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg01843034	chr6:37503916	NA	-0.38	-6.38	-0.33	5.74e-10	Cognitive performance;
LIHC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9590974	0.663	rs837	chr13:47224772	G/A	cg04092803	chr13:47240378	LRCH1	0.26	5.73	0.3	2.17e-8	PR segment;
LIHC	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.47	7.12	0.36	6.26e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.03	15.95	0.65	3.18e-43	Breast cancer;
LIHC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.04	-0.48	5.87e-21	Response to antipsychotic treatment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01457413	chr19:9879603	ZNF846	0.44	6.2	0.32	1.62e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.45	6.79	0.34	5.04e-11	Night sleep phenotypes;
LIHC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.81	7.14	0.36	5.64e-12	Arsenic metabolism;
LIHC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.13	0.58	3.64e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.35	5.81	0.3	1.43e-8	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.7	12.73	0.57	1.15e-30	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg14515779	chr1:101123966	NA	0.46	6.6	0.34	1.61e-10	Monocyte count;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg26075905	chr14:102391388	PPP2R5C	0.52	6.3	0.32	9.26e-10	Lung function (FEV1);
LIHC	cis	rs10838687	0.736	rs2242262	chr11:47266540	G/T	cg25783544	chr11:47291846	MADD	0.46	5.89	0.3	9.29e-9	Proinsulin levels;
LIHC	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.57	-8.19	-0.41	5.13e-15	Neuroticism;
LIHC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.92	17.07	0.68	1.09e-47	Menopause (age at onset);
LIHC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	12.64	0.56	2.5e-30	Schizophrenia;
LIHC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg08213375	chr14:104286397	PPP1R13B	0.51	9.28	0.45	1.98e-18	Schizophrenia;
LIHC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.84	-0.43	5.07e-17	Blood metabolite levels;
LIHC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.78	0.39	8.87e-14	Lung cancer;
LIHC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.45	6.31	0.32	8.56e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-0.82	-8.98	-0.44	1.81e-17	Alzheimer's disease (late onset);
LIHC	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg03146154	chr1:46216737	IPP	-0.39	-6.5	-0.33	2.88e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.6	-11.38	-0.52	1.19e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.49	-6.7	-0.34	8.38e-11	Heschl's gyrus morphology;
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11987759	chr7:65425863	GUSB	-0.38	-6.02	-0.31	4.52e-9	Calcium levels;
LIHC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-0.85	-11.3	-0.52	2.33e-25	Skin colour saturation;
LIHC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.8	0.3	1.54e-8	Menopause (age at onset);
LIHC	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg09918751	chr15:100517450	ADAMTS17	0.71	12.72	0.57	1.33e-30	Height;
LIHC	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg02290350	chr8:58132656	NA	0.47	9.18	0.44	4.31e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg20283391	chr11:68216788	NA	-0.46	-5.71	-0.3	2.43e-8	Total body bone mineral density (age 45-60);
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.49	6.65	0.34	1.14e-10	Menopause (age at onset);
LIHC	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.49	9.89	0.47	1.92e-20	LDL cholesterol levels;
LIHC	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg04610667	chr7:75704037	NA	0.35	6.2	0.32	1.61e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.71	-10.68	-0.5	3.68e-23	Subjective well-being;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.66	8.05	0.4	1.35e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.46	7.09	0.36	7.93e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-6.18	-0.32	1.87e-9	Tuberculosis;
LIHC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.64	8.73	0.43	1.11e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-6.25	-0.32	1.22e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg15123519	chr2:136567270	LCT	0.35	6.64	0.34	1.26e-10	Mosquito bite size;
LIHC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.92	13.04	0.58	7.93e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs1814175	0.616	rs10839342	chr11:49742687	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.59	-0.74	7.56e-62	Height;
LIHC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-22.09	-0.77	8.21e-68	Coronary artery disease;
LIHC	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg12046867	chr14:103022105	NA	0.47	7.33	0.37	1.72e-12	Platelet count;
LIHC	cis	rs5753037	0.702	rs249398	chr22:30214704	G/C	cg01021169	chr22:30184971	ASCC2	-0.35	-6.69	-0.34	9.37e-11	Type 1 diabetes;
LIHC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.95	20.5	0.74	1.68e-61	Blood protein levels;
LIHC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06134974	chr12:51477539	CSRNP2	0.43	6.23	0.32	1.37e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	7.06	0.36	9.28e-12	Bipolar disorder;
LIHC	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg14250997	chr9:106856677	SMC2	0.42	7.3	0.37	2.03e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.48	-7.04	-0.36	1.03e-11	Obesity-related traits;
LIHC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.31	0.68	1.13e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.84	7.51	0.38	5.07e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs712039	0.652	rs60112577	chr17:35833209	G/A	cg16670864	chr17:35848621	DUSP14	0.34	5.73	0.3	2.19e-8	Tuberculosis;
LIHC	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.91	-13.06	-0.58	6.52e-32	Post bronchodilator FEV1;
LIHC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.08	-0.4	1.09e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.94	-0.31	6.91e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg17385448	chr1:15911702	AGMAT	0.34	5.96	0.31	6.15e-9	Systolic blood pressure;
LIHC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.36	1.17e-11	Diabetic kidney disease;
LIHC	cis	rs2834188	1.000	rs2409488	chr21:34688914	A/C	cg04842828	chr21:34696676	IFNAR1	0.45	6.09	0.31	3.1e-9	Narcolepsy;
LIHC	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.43	9.16	0.44	4.81e-18	Migraine;
LIHC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.7	8.57	0.42	3.61e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1712517	1.000	rs1712517	chr10:105033015	C/T	cg05636881	chr10:105038444	INA	0.4	6.3	0.32	8.99e-10	Migraine;
LIHC	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.32	-6.39	-0.33	5.55e-10	Renal cell carcinoma;
LIHC	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.49	7.49	0.38	5.99e-13	Height;
LIHC	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg06565975	chr8:143823917	SLURP1	-0.31	-5.79	-0.3	1.56e-8	Urinary tract infection frequency;
LIHC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg01864069	chr14:103024347	NA	0.45	7.01	0.35	1.3e-11	Platelet count;
LIHC	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.73	-0.3	2.19e-8	Neuroticism;
LIHC	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.86	-0.39	4.95e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.2	-0.32	1.58e-9	Fear of minor pain;
LIHC	cis	rs2607426	1.000	rs2604877	chr19:41275048	T/C	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.49	-5.88	-0.3	9.77e-9	Blood protein levels;
LIHC	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg22705602	chr4:152727874	NA	-0.3	-6.44	-0.33	4.04e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.43	-9.22	-0.45	3.04e-18	Rheumatoid arthritis;
LIHC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.84	0.43	4.99e-17	Multiple sclerosis;
LIHC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg00277334	chr10:82204260	NA	0.55	6.74	0.34	6.86e-11	Post bronchodilator FEV1;
LIHC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.14	-0.32	2.29e-9	Type 2 diabetes;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg00911488	chr4:106068604	TET2	-0.4	-6.16	-0.32	2e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.35	7.18	0.36	4.5e-12	Cancer;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.21	0.55	1.02e-28	Prudent dietary pattern;
LIHC	cis	rs35362007	0.530	rs79171925	chr14:96003075	T/C	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.87	7.09	0.36	7.84e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.72	-0.43	1.24e-16	Renal cell carcinoma;
LIHC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.83	-0.3	1.29e-8	Personality dimensions;
LIHC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13296214	chr12:9436248	LOC642846	0.48	9.04	0.44	1.15e-17	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.49	8.54	0.42	4.42e-16	Dental caries;
LIHC	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg01864836	chr14:55583639	NA	-0.35	-6.35	-0.32	6.86e-10	Protein biomarker;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.91	0.43	3.08e-17	Prudent dietary pattern;
LIHC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-10.88	-0.51	6.98e-24	Brugada syndrome;
LIHC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.96	-18.12	-0.7	6.26e-52	QT interval;
LIHC	cis	rs35883536	1.000	rs1610387	chr1:101123943	T/G	cg14515779	chr1:101123966	NA	-0.69	-13.94	-0.6	2.76e-35	Monocyte count;
LIHC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.25	-6.3	-0.32	9.22e-10	Hepatitis;
LIHC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.49	-7.91	-0.39	3.59e-14	Diastolic blood pressure;
LIHC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg02297831	chr4:17616191	MED28	0.42	6.73	0.34	7.12e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.55	-8.83	-0.43	5.44e-17	Menarche (age at onset);
LIHC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.76	-10.98	-0.51	3.1e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.36	-6.27	-0.32	1.09e-9	Menopause (age at onset);
LIHC	cis	rs6782228	0.565	rs2811496	chr3:128359958	A/T	cg16766828	chr3:128327626	NA	-0.4	-6.34	-0.32	7.21e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.32	-5.92	-0.31	7.69e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-8.91	-0.43	3.12e-17	Vitiligo;
LIHC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.44	0.66	3.67e-45	Smoking behavior;
LIHC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.55	9.58	0.46	2.04e-19	Mean corpuscular volume;
LIHC	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.17	-0.36	4.64e-12	Metabolite levels;
LIHC	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	6.4	0.33	5.14e-10	Coronary artery disease;
LIHC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.35	0.52	1.49e-25	Coronary artery disease;
LIHC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	0.53	7.11	0.36	6.93e-12	Pulse pressure;
LIHC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.5	6.14	0.31	2.35e-9	Menarche (age at onset);
LIHC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.13	-0.31	2.41e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs494453	0.583	rs564807	chr1:112212301	A/G	cg13908074	chr2:149259371	MBD5	0.4	6.44	0.33	3.96e-10	Osteoporosis-related phenotypes;
LIHC	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.45	-7.06	-0.36	9.61e-12	Multiple sclerosis;
LIHC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.81	16.6	0.67	8.41e-46	White blood cell count;
LIHC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.56	8.62	0.42	2.52e-16	Multiple sclerosis;
LIHC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg04310649	chr10:35416472	CREM	0.42	5.81	0.3	1.41e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.79	-0.3	1.63e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg21466736	chr12:48725269	NA	0.62	8.99	0.44	1.67e-17	Glycated hemoglobin levels;
LIHC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.93	-0.31	7.3e-9	Colorectal cancer;
LIHC	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-6.92	-0.35	2.28e-11	Hepatocellular carcinoma;
LIHC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.4	7.19	0.36	4.14e-12	Hepatocellular carcinoma;
LIHC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.51	7.07	0.36	8.59e-12	Morning vs. evening chronotype;
LIHC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.12	0.44	6.46e-18	Platelet count;
LIHC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01765077	chr12:122356316	WDR66	0.56	7.68	0.38	1.7e-13	Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21219744	chr4:44680344	GUF1	0.4	6.18	0.32	1.83e-9	Cognitive function;
LIHC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.55	9.24	0.45	2.6e-18	Obesity-related traits;
LIHC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.49	-0.33	3.04e-10	Height;
LIHC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-8.42	-0.41	1.03e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs16828019	0.777	rs12739052	chr1:41464455	C/A	cg03387723	chr1:41708464	SCMH1	-0.45	-6.66	-0.34	1.07e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.37	6.83	0.35	4.01e-11	Ewing sarcoma;
LIHC	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.43	6.08	0.31	3.29e-9	Tuberculosis;
LIHC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-6.6	-0.34	1.56e-10	Schizophrenia;
LIHC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-8.36	-0.41	1.6e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.92	15.43	0.64	3.78e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10744422	0.748	rs1671688	chr12:123255733	A/T	cg25930673	chr12:123319894	HIP1R	-0.81	-10.13	-0.48	2.8e-21	Schizophrenia;
LIHC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.37	-6.07	-0.31	3.43e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg03037974	chr15:76606532	NA	0.8	16.45	0.66	3.41e-45	Blood metabolite levels;
LIHC	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.85	7.21	0.36	3.56e-12	Uric acid levels;
LIHC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.07	0.44	9.86e-18	Melanoma;
LIHC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.36	-6.02	-0.31	4.61e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3106136	0.681	rs11097422	chr4:95302982	C/G	cg11021082	chr4:95130006	SMARCAD1	0.34	5.85	0.3	1.14e-8	Capecitabine sensitivity;
LIHC	cis	rs526821	0.595	rs485555	chr11:55323570	A/G	cg04317927	chr11:55418816	OR4S2	-0.47	-9.01	-0.44	1.43e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.54	-8.3	-0.41	2.44e-15	Coronary artery disease;
LIHC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.9e-9	Body mass index;
LIHC	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.78	8.89	0.43	3.7e-17	Exhaled nitric oxide levels;
LIHC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.52	-8.8	-0.43	7.1e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.59	-9.32	-0.45	1.48e-18	Post bronchodilator FEV1;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg04296903	chr1:1203256	UBE2J2	0.39	6.52	0.33	2.54e-10	Oropharynx cancer;
LIHC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg26441486	chr22:50317300	CRELD2	0.35	6.22	0.32	1.45e-9	Schizophrenia;
LIHC	cis	rs11621710	0.557	rs799474	chr14:35516099	C/G	cg16230307	chr14:35515116	FAM177A1	0.48	8.55	0.42	4.2e-16	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.47	7.81	0.39	7.12e-14	Menopause (age at onset);
LIHC	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.72	8.36	0.41	1.62e-15	Red blood cell traits;
LIHC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg03854865	chr6:26224070	HIST1H3E	0.59	6.43	0.33	4.33e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.16	-8.65	-0.42	2.07e-16	Body mass index;
LIHC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.52	-7.3	-0.37	2.03e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.74	-11.35	-0.52	1.43e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg18225595	chr11:63971243	STIP1	0.64	6.43	0.33	4.37e-10	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.31	0.55	4.43e-29	Motion sickness;
LIHC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02985541	chr2:219472218	PLCD4	-0.42	-6.86	-0.35	3.26e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.89	0.3	9.07e-9	Electroencephalogram traits;
LIHC	cis	rs8056893	0.714	rs6499173	chr16:68388115	G/A	cg02226672	chr16:68398533	SMPD3	0.44	6.31	0.32	8.55e-10	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-17.11	-0.68	7.32e-48	Body mass index;
LIHC	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.58	-7.01	-0.35	1.24e-11	Vitamin D levels;
LIHC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.41	5.87	0.3	1.01e-8	Coronary artery disease;
LIHC	trans	rs7849581	1	rs7849581	chr9:9924724	A/G	cg15290081	chr7:76254647	POMZP3;LOC100133091	0.57	6.67	0.34	1.02e-10	Myopia (pathological);
LIHC	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg18912006	chr12:123335444	HIP1R	0.72	7.44	0.37	8.06e-13	Adiponectin levels;
LIHC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.52	-8.53	-0.42	4.8e-16	Fibrinogen levels;
LIHC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12830829	chr14:51707081	TMX1	-0.53	-8.02	-0.4	1.7e-14	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg10820045	chr2:198174542	NA	0.5	7.55	0.38	3.91e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.41	-7.27	-0.37	2.47e-12	Coronary artery disease;
LIHC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.39	-6.08	-0.31	3.27e-9	Height;
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg26939375	chr7:64535504	NA	0.47	7.15	0.36	5.18e-12	Aortic root size;
LIHC	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.15	-0.32	2.22e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg02290350	chr8:58132656	NA	0.33	7.25	0.36	2.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.53	8.97	0.44	2.01e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.93	10.72	0.5	2.51e-23	Triglycerides;
LIHC	cis	rs4690686	0.964	rs1840270	chr4:177246288	G/C	cg17059388	chr4:177262070	NA	0.38	6.93	0.35	2.1e-11	Essential tremor;
LIHC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-7.56	-0.38	3.76e-13	Electroencephalogram traits;
LIHC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.48	-7.66	-0.38	1.92e-13	Neurofibrillary tangles;
LIHC	trans	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg21051086	chr3:73046214	PPP4R2	-0.39	-6.22	-0.32	1.44e-9	Pancreatic cancer;
LIHC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg03517284	chr6:25882590	NA	-0.39	-5.81	-0.3	1.44e-8	Height;
LIHC	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	0.86	8.75	0.43	1e-16	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LIHC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg08847533	chr14:75593920	NEK9	-0.51	-7.81	-0.39	7.14e-14	IgG glycosylation;
LIHC	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg09795085	chr6:101329169	ASCC3	0.52	7.13	0.36	6.12e-12	Neuroticism;
LIHC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg26149184	chr10:133730230	NA	0.47	7.5	0.38	5.69e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.54	8.14	0.4	7.27e-15	Longevity;
LIHC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	1.14	9.55	0.46	2.6e-19	Schizophrenia;
LIHC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg00204512	chr16:28754710	NA	0.37	6.63	0.34	1.33e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.85	0.39	5.58e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-0.83	-9.22	-0.45	3.15e-18	Vitiligo;
LIHC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.8	12.66	0.56	2.11e-30	Breast cancer;
LIHC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg04374321	chr14:90722782	PSMC1	0.47	6.5	0.33	2.85e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg15208524	chr1:10270712	KIF1B	0.38	5.87	0.3	1.04e-8	Hepatocellular carcinoma;
LIHC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg12373951	chr3:133503437	NA	0.46	7.65	0.38	2.03e-13	Iron status biomarkers;
LIHC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.67	10.34	0.49	5.7e-22	Corneal astigmatism;
LIHC	cis	rs4407350	0.756	rs131168	chr22:44896225	T/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.46	-0.33	3.68e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.47	-6.51	-0.33	2.64e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs911119	0.866	rs2405393	chr20:23569392	G/C	cg16589663	chr20:23618590	CST3	0.65	6.74	0.34	6.57e-11	Chronic kidney disease;
LIHC	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg26211634	chr5:139558579	C5orf32	-0.38	-5.85	-0.3	1.15e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.77	0.34	5.65e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg01364799	chr7:75623366	TMEM120A	0.48	7.36	0.37	1.36e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs6489882	0.867	rs1859335	chr12:113367325	C/T	cg10175203	chr3:128143634	NA	0.38	6.12	0.31	2.6e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.47	-0.53	5.57e-26	Platelet distribution width;
LIHC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.61	-7.92	-0.39	3.4e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.95	14.93	0.63	3.78e-39	Metabolic syndrome;
LIHC	cis	rs4788570	0.697	rs2173702	chr16:71812671	G/A	cg06353428	chr16:71660113	MARVELD3	1.34	13.32	0.58	6.95e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs11124272	0.761	rs4952244	chr2:32036625	G/A	cg02381751	chr2:32503542	YIPF4	-0.42	-5.78	-0.3	1.71e-8	Interleukin-18 levels;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.28	0.55	6e-29	Prudent dietary pattern;
LIHC	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.53	-7.76	-0.39	9.99e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Alcohol dependence;
LIHC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg00935119	chr6:36647544	CDKN1A	0.41	5.94	0.31	6.85e-9	QRS duration;
LIHC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.64	0.34	1.2e-10	Rheumatoid arthritis;
LIHC	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18252515	chr7:66147081	NA	-0.52	-6.38	-0.33	5.61e-10	Corneal structure;
LIHC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.33	7.12	0.36	6.46e-12	Multiple sclerosis;
LIHC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg22676075	chr6:135203613	NA	0.39	6.44	0.33	4.09e-10	Red blood cell count;
LIHC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.58	0.59	6.99e-34	Cognitive test performance;
LIHC	cis	rs17286411	0.671	rs2036338	chr16:71788830	C/G	cg06353428	chr16:71660113	MARVELD3	-0.44	-6.52	-0.33	2.49e-10	Blood protein levels;
LIHC	cis	rs2108622	0.647	rs111427692	chr19:15977479	A/T	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.81e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.98	0.54	7.28e-28	Motion sickness;
LIHC	cis	rs17106184	1.000	rs72898951	chr1:50963518	G/C	cg07174182	chr1:51127561	FAF1	-0.59	-6.66	-0.34	1.07e-10	Type 2 diabetes;
LIHC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.56	-8.44	-0.42	9.31e-16	Height;
LIHC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.62	0.5	5.92e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.35	5.79	0.3	1.58e-8	Height;
LIHC	trans	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04565464	chr8:145669602	NFKBIL2	0.37	6.19	0.32	1.76e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs12464559	0.522	rs7424335	chr2:152593741	C/T	cg01189475	chr2:152685088	ARL5A	0.74	9.21	0.45	3.25e-18	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.43	-0.41	1e-15	Response to antipsychotic treatment;
LIHC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.88	0.67	6.27e-47	Lung cancer in ever smokers;
LIHC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17507749	chr15:85114479	UBE2QP1	0.66	7.3	0.37	1.97e-12	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07071157	chr11:72525331	ATG16L2	-0.45	-6.06	-0.31	3.55e-9	Pancreatic cancer;
LIHC	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	9.25	0.45	2.5e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.56	8.17	0.4	5.88e-15	Recombination rate (females);
LIHC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.56	0.5	9.48e-23	Bladder cancer;
LIHC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.53e-9	Menopause (age at onset);
LIHC	cis	rs10503871	0.625	rs13250304	chr8:30346587	G/A	cg26383811	chr8:30366931	RBPMS	0.43	7.48	0.37	6.46e-13	Metabolite levels  (X-11787);
LIHC	cis	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg22857025	chr5:266934	NA	-1.45	-16.93	-0.68	4.11e-47	Breast cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16249105	chr10:120938029	PRDX3	-0.39	-6.07	-0.31	3.38e-9	Bilirubin levels;
LIHC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.5	-12.47	-0.56	1.14e-29	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.39	7.91	0.39	3.5e-14	Renal cell carcinoma;
LIHC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.04	-17.29	-0.68	1.35e-48	Dilated cardiomyopathy;
LIHC	cis	rs116248771	0.690	rs16829314	chr3:158416409	C/T	cg16708174	chr3:158430962	RARRES1	0.46	6.13	0.31	2.45e-9	diarrhoeal disease at age 2;
LIHC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.37	-5.9	-0.3	8.74e-9	Menopause (age at onset);
LIHC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.79	11.65	0.53	1.22e-26	Metabolic syndrome;
LIHC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.65	8.69	0.43	1.56e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.76	-0.34	6.1e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.8	-0.3	1.53e-8	Systemic lupus erythematosus;
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg02990361	chr1:107599529	PRMT6	0.64	10.78	0.5	1.64e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.81	0.54	3.03e-27	Cognitive test performance;
LIHC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.83	0.35	3.8e-11	Gut microbiome composition (summer);
LIHC	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg01652190	chr22:50026171	C22orf34	-0.29	-6.34	-0.32	7.24e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-11.35	-0.52	1.43e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	11.29	0.52	2.49e-25	Prudent dietary pattern;
LIHC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.71	-0.65	3.04e-42	Chronic sinus infection;
LIHC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.86	12.49	0.56	9.45e-30	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.08	13.8	0.6	9.47e-35	Economic and political preferences (immigration/crime);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23671189	chr11:68830561	TPCN2	0.4	6.15	0.32	2.15e-9	Bilirubin levels;
LIHC	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg12798992	chr6:167411361	FGFR1OP	0.47	6.94	0.35	2.04e-11	Crohn's disease;
LIHC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.14e-11	Alzheimer's disease;
LIHC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg18478394	chr8:109455254	TTC35	0.42	7.34	0.37	1.54e-12	Dupuytren's disease;
LIHC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg12374095	chr12:54320830	NA	0.45	6.95	0.35	1.81e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg01843034	chr6:37503916	NA	-0.41	-6.75	-0.34	6.5e-11	Cognitive performance;
LIHC	cis	rs7619427	0.908	rs7653170	chr3:44076195	T/A	cg24966902	chr3:44043705	NA	0.5	7.05	0.36	9.76e-12	Schizophrenia;
LIHC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.45	7.71	0.38	1.35e-13	Lung cancer;
LIHC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.44	-0.33	3.97e-10	Type 2 diabetes;
LIHC	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.31	-8.64	-0.42	2.13e-16	Intelligence;
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg00800038	chr16:89945340	TCF25	-0.6	-9.53	-0.46	3.02e-19	Skin colour saturation;
LIHC	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-0.67	-6.96	-0.35	1.79e-11	Coronary artery disease;
LIHC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.27	0.32	1.11e-9	Renal cell carcinoma;
LIHC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.6	10.15	0.48	2.46e-21	Height;
LIHC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.3	0.37	1.99e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.9e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.33	-8.22	-0.41	4.27e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs903552	1.000	rs34937195	chr15:102003631	C/A	cg19295451	chr15:102010161	PCSK6	-0.44	-6.17	-0.32	1.97e-9	Diabetic kidney disease;
LIHC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg07560587	chr16:88016574	BANP	0.38	5.98	0.31	5.55e-9	Menopause (age at onset);
LIHC	cis	rs12220238	0.915	rs7073139	chr10:76071189	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.58	7.69	0.38	1.63e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.3	-6.42	-0.33	4.43e-10	Weight;
LIHC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg05044414	chr3:183734942	ABCC5	0.33	5.91	0.3	8.1e-9	Anterior chamber depth;
LIHC	cis	rs11628318	0.564	rs8006489	chr14:103121232	G/A	cg12046867	chr14:103022105	NA	0.39	5.92	0.3	7.76e-9	Platelet count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26875902	chr16:2223324	TRAF7	-0.39	-6.4	-0.33	5.01e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.62	-8.73	-0.43	1.12e-16	Blood metabolite levels;
LIHC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.51	-5.78	-0.3	1.69e-8	Gut microbiome composition (summer);
LIHC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	1.05	13.69	0.6	2.46e-34	Red blood cell traits;
LIHC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	1.04	15.25	0.64	2.08e-40	Breast cancer;
LIHC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.45	-5.91	-0.3	8.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-0.84	-10.43	-0.49	2.67e-22	Blood pressure (smoking interaction);
LIHC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.48	7.05	0.36	9.79e-12	Aortic root size;
LIHC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.58	-9.48	-0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg08824895	chr13:115047677	UPF3A	0.5	7.26	0.37	2.59e-12	Schizophrenia;
LIHC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.74e-11	IgG glycosylation;
LIHC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.58	6.25	0.32	1.21e-9	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg17764715	chr19:33622953	WDR88	-0.51	-6.77	-0.34	5.76e-11	Bone properties (heel);
LIHC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.71	7.17	0.36	4.8e-12	Vitiligo;
LIHC	trans	rs6489882	0.867	rs6489877	chr12:113368079	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.06	-0.31	3.56e-9	Metabolite levels;
LIHC	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.16	0.32	2.07e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.36	-6.11	-0.31	2.71e-9	Schizophrenia;
LIHC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02985541	chr2:219472218	PLCD4	0.43	6.95	0.35	1.84e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.26	6.23	0.32	1.35e-9	Primary biliary cholangitis;
LIHC	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.1	-0.31	2.9e-9	Bipolar disorder;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15136424	chr2:173989197	ZAK	-0.29	-6.26	-0.32	1.12e-9	Calcium levels;
LIHC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.67	9.89	0.47	1.88e-20	Schizophrenia;
LIHC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg15534755	chr11:117069859	TAGLN	0.37	6.26	0.32	1.12e-9	Blood protein levels;
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	7.47	0.37	6.71e-13	Obesity-related traits;
LIHC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.4	-5.86	-0.3	1.08e-8	Narcolepsy;
LIHC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.32	5.94	0.31	7.04e-9	Renal cell carcinoma;
LIHC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.45	-0.42	8.73e-16	Osteoporosis;
LIHC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.77	-15.73	-0.65	2.5e-42	Height;
LIHC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.57	8.55	0.42	4.32e-16	Platelet count;
LIHC	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14396892	chr9:96623032	NA	-0.32	-6.21	-0.32	1.5e-9	DNA methylation (variation);
LIHC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg16684958	chr7:75615977	POR	-0.51	-8.58	-0.42	3.48e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.69	8.76	0.43	9.54e-17	Blood metabolite levels;
LIHC	trans	rs3858145	0.506	rs10762224	chr10:70086313	A/G	cg08973675	chr10:101380289	SLC25A28	0.52	6.36	0.33	6.54e-10	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg23375431	chr12:122242145	LOC338799;SETD1B	-0.37	-6.2	-0.32	1.6e-9	Neuroblastoma;
LIHC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18252515	chr7:66147081	NA	0.42	5.89	0.3	9.22e-9	Aortic root size;
LIHC	trans	rs6058796	0.681	rs28529295	chr20:31274668	C/G	cg02600331	chr11:130417168	NA	0.37	7.71	0.38	1.37e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02985541	chr2:219472218	PLCD4	0.45	8.71	0.43	1.33e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	1.01	16.48	0.67	2.61e-45	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.2	-0.32	1.63e-9	Colorectal cancer;
LIHC	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg06664874	chr5:179499304	RNF130	0.66	7.56	0.38	3.69e-13	LDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22207900	chr11:64072031	ESRRA;C11orf20	0.44	6.31	0.32	8.77e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7106204	0.514	rs7118022	chr11:24253352	C/T	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11579281	chr15:62352619	VPS13C	-0.43	-6.13	-0.31	2.38e-9	Pancreatic cancer;
LIHC	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.4	6.74	0.34	6.7e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.55	8.09	0.4	1.05e-14	High light scatter reticulocyte count;
LIHC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.55	9.43	0.45	6.61e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.71	10.94	0.51	4.4e-24	Cognitive test performance;
LIHC	cis	rs7961581	0.719	rs1620771	chr12:71592703	T/G	cg05756094	chr12:71608604	NA	0.4	6.48	0.33	3.16e-10	Type 2 diabetes;
LIHC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	14.23	0.61	2.11e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.44	6.64	0.34	1.24e-10	Educational attainment;
LIHC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.5	7.99	0.4	2.11e-14	Diastolic blood pressure;
LIHC	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.43	6.11	0.31	2.71e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.87	-7.6	-0.38	2.92e-13	White matter integrity;
LIHC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-18.37	-0.7	6.1e-53	Ulcerative colitis;
LIHC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.37	7.26	0.37	2.65e-12	Multiple system atrophy;
LIHC	trans	rs10213084	1.000	rs10002085	chr4:147491160	G/A	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs35883536	1.000	rs3861733	chr1:101111807	G/A	cg14515779	chr1:101123966	NA	-0.66	-13.17	-0.58	2.6e-32	Monocyte count;
LIHC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs28829049	0.536	rs2073106	chr1:19549343	G/C	cg13387374	chr1:19411106	UBR4	0.41	6.0	0.31	5.01e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.5	-0.33	2.86e-10	Metabolite levels;
LIHC	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.17	15.19	0.63	3.36e-40	Blood protein levels;
LIHC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.91	16.91	0.67	4.8e-47	Menopause (age at onset);
LIHC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.49	0.33	2.93e-10	Heart rate;
LIHC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg24879335	chr3:133465180	TF	0.28	6.35	0.32	6.74e-10	Iron status biomarkers;
LIHC	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.2	0.36	3.83e-12	Corneal astigmatism;
LIHC	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.76	10.84	0.51	1.02e-23	Pediatric areal bone mineral density (radius);
LIHC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.35	-0.32	6.86e-10	Schizophrenia;
LIHC	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.54	-13.09	-0.58	5.17e-32	White blood cell count (basophil);
LIHC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.51	8.15	0.4	6.91e-15	Height;
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13409248	chr3:40428643	ENTPD3	-0.49	-8.38	-0.41	1.39e-15	Renal cell carcinoma;
LIHC	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.69	-6.73	-0.34	7.01e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.79	6.06	0.31	3.65e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.58	7.72	0.39	1.27e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.82	-0.35	4.18e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	8.03	0.4	1.58e-14	Response to antipsychotic treatment;
LIHC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.62	-0.5	5.71e-23	Hemoglobin concentration;
LIHC	cis	rs16944613	0.510	rs8026218	chr15:91145265	C/T	cg26821196	chr15:91095069	CRTC3	0.3	5.78	0.3	1.66e-8	Colorectal cancer;
LIHC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.66	8.66	0.42	1.91e-16	Initial pursuit acceleration;
LIHC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg08392591	chr16:89556376	ANKRD11	0.41	6.18	0.32	1.86e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.25	0.55	7.54e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.58	-9.91	-0.47	1.57e-20	Diisocyanate-induced asthma;
LIHC	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.25e-19	Corneal astigmatism;
LIHC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-9.13	-0.44	6.11e-18	Parkinson's disease;
LIHC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	10.21	0.48	1.51e-21	Resting heart rate;
LIHC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.63	0.56	2.8e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg05896524	chr21:47604654	C21orf56	0.49	7.57	0.38	3.56e-13	Testicular germ cell tumor;
LIHC	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02985541	chr2:219472218	PLCD4	-0.36	-6.05	-0.31	3.83e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6442522	0.606	rs2345105	chr3:15495764	G/A	cg16303742	chr3:15540471	COLQ	0.39	6.39	0.33	5.38e-10	Uric acid levels;
LIHC	cis	rs7395581	0.959	rs35879051	chr11:47275882	C/G	cg26139080	chr11:47293733	MADD	-0.5	-8.53	-0.42	4.94e-16	HDL cholesterol;
LIHC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.52	9.18	0.44	4.24e-18	N-glycan levels;
LIHC	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.33	-7.54	-0.38	4.2e-13	Breast cancer;
LIHC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.31	-6.68	-0.34	9.75e-11	Bone mineral density;
LIHC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg05044414	chr3:183734942	ABCC5	-0.33	-6.26	-0.32	1.12e-9	Anterior chamber depth;
LIHC	cis	rs7654585	0.962	rs2309289	chr4:25947094	T/A	cg10409131	chr4:25915609	C4orf52	0.47	7.3	0.37	2.02e-12	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05896465	chr22:45560692	NUP50	0.48	6.88	0.35	2.87e-11	Pancreatic cancer;
LIHC	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.6	-10.65	-0.5	4.59e-23	Colorectal cancer;
LIHC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	9.38	0.45	9.34e-19	Eosinophilic esophagitis;
LIHC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.82	-0.35	4.15e-11	Schizophrenia;
LIHC	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg26031613	chr14:104095156	KLC1	-0.4	-5.72	-0.3	2.31e-8	Coronary artery disease;
LIHC	cis	rs9649465	1.000	rs3807634	chr7:123382290	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.19	-0.41	5.09e-15	Migraine;
LIHC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.35	-0.61	6.8e-37	Electrocardiographic conduction measures;
LIHC	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06108461	chr20:60628389	TAF4	-0.52	-6.83	-0.35	3.84e-11	Body mass index;
LIHC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.32	0.37	1.74e-12	Morning vs. evening chronotype;
LIHC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	12.96	0.57	1.6e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.77	-0.47	4.66e-20	Response to antipsychotic treatment;
LIHC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg27494647	chr7:150038898	RARRES2	0.31	5.76	0.3	1.91e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg24296786	chr1:45957014	TESK2	-0.49	-7.33	-0.37	1.71e-12	Platelet count;
LIHC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.38	-6.33	-0.32	7.79e-10	IgG glycosylation;
LIHC	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.42	-0.37	9.23e-13	Adiposity;
LIHC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-7.67	-0.38	1.82e-13	Tonsillectomy;
LIHC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	7.97	0.4	2.47e-14	Diastolic blood pressure;
LIHC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.46	-7.41	-0.37	9.73e-13	Menarche (age at onset);
LIHC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-17.58	-0.69	9.47e-50	Body mass index;
LIHC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.08	15.65	0.65	4.97e-42	Cognitive function;
LIHC	cis	rs360798	0.532	rs11125942	chr2:62966758	T/C	cg17519650	chr2:63277830	OTX1	-0.42	-6.63	-0.34	1.3100000000000001e-10	Coronary artery disease;
LIHC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.53	8.55	0.42	4.03e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg12903224	chr12:29470962	FAR2	-0.42	-6.73	-0.34	7.04e-11	QT interval;
LIHC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.18	-0.55	1.37e-28	Alzheimer's disease;
LIHC	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.77	-0.69	1.66e-50	Schizophrenia;
LIHC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.39	5.74	0.3	2.12e-8	Lymphocyte counts;
LIHC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg22777020	chr22:31556080	RNF185	-0.56	-6.33	-0.32	7.64e-10	Colorectal cancer;
LIHC	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	9.39e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.4	8.66	0.42	1.88e-16	Prostate-specific antigen levels;
LIHC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.63	11.35	0.52	1.44e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs249954	0.512	rs35634	chr16:23697679	C/T	cg05131483	chr16:23706242	ERN2	0.37	6.05	0.31	3.82e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.66	-9.16	-0.44	5.01e-18	Vitamin D levels;
LIHC	cis	rs7487075	0.619	rs2408498	chr12:46796900	G/A	cg23829395	chr12:46796953	NA	0.36	6.34	0.32	7.12e-10	Itch intensity from mosquito bite;
LIHC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-1.0	-19.24	-0.72	2.07e-56	Breast cancer;
LIHC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.76	14.6	0.62	7.58e-38	Crohn's disease;
LIHC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.58	8.61	0.42	2.68e-16	Platelet count;
LIHC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-11.44	-0.53	7.1e-26	Lymphocyte percentage of white cells;
LIHC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg05501817	chr11:14380813	RRAS2	-0.45	-6.36	-0.33	6.39e-10	Sense of smell;
LIHC	cis	rs903552	1.000	rs12904206	chr15:102006294	C/T	cg06707286	chr15:102010195	PCSK6	-0.44	-6.26	-0.32	1.13e-9	Diabetic kidney disease;
LIHC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	0.53	7.11	0.36	6.93e-12	Pulse pressure;
LIHC	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Colorectal cancer;
LIHC	trans	rs3783890	1.000	rs3783890	chr14:93790276	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.32	0.32	8.12e-10	Body mass index;
LIHC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg18944383	chr4:111397179	ENPEP	0.25	6.31	0.32	8.46e-10	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10996143	chr20:1373995	FKBP1A	0.44	6.89	0.35	2.75e-11	Pancreatic cancer;
LIHC	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.9	-0.39	3.77e-14	Capecitabine sensitivity;
LIHC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.6	-8.03	-0.4	1.63e-14	Diastolic blood pressure;
LIHC	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg23682824	chr7:23144976	KLHL7	0.4	6.08	0.31	3.27e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.67	0.34	1.03e-10	Renal cell carcinoma;
LIHC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	15.3	0.64	1.21e-40	Menopause (age at onset);
LIHC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.6	-6.97	-0.35	1.69e-11	Menarche (age at onset);
LIHC	cis	rs959260	1.000	rs4789185	chr17:73383368	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.8	-0.3	1.51e-8	Systemic lupus erythematosus;
LIHC	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.4	6.25	0.32	1.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg17710535	chr19:10819994	QTRT1	0.4	6.11	0.31	2.68e-9	Inflammatory skin disease;
LIHC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	6.11e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.68	9.14	0.44	5.58e-18	Aortic root size;
LIHC	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.44	-7.21	-0.36	3.55e-12	Schizophrenia;
LIHC	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.56	7.87	0.39	4.6e-14	Schizophrenia;
LIHC	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.42	-6.39	-0.33	5.38e-10	Multiple sclerosis;
LIHC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.3	-0.32	8.98e-10	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08413565	chr3:129035733	H1FX;C3orf47	0.44	6.53	0.33	2.42e-10	Cognitive function;
LIHC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.54	-0.73	1.25e-57	Coronary artery disease;
LIHC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-17.89	-0.7	5.68e-51	Height;
LIHC	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	8.36	0.41	1.62e-15	Height;
LIHC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.98	11.38	0.52	1.18e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.34	7.34	0.37	1.59e-12	Bone mineral density;
LIHC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.38	0.45	9.63e-19	Platelet count;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06289967	chr15:41523422	CHP;EXD1	-0.55	-6.39	-0.33	5.54e-10	Systolic blood pressure;
LIHC	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.31	0.55	4.54e-29	Eye color traits;
LIHC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.7	-0.38	1.43e-13	Total body bone mineral density;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-7.0	-0.35	1.37e-11	Total body bone mineral density;
LIHC	trans	rs17023017	1.000	rs17023017	chr4:96025094	A/C	cg02979839	chr5:176957063	FAM193B	0.37	6.05	0.31	3.86e-9	Hen's egg allergy;
LIHC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.59	10.94	0.51	4.32e-24	Alcohol dependence;
LIHC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.42	8.99	0.44	1.71e-17	Coronary artery disease;
LIHC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg22946670	chr1:154909930	PMVK	0.42	6.04	0.31	4.13e-9	Thyroid cancer;
LIHC	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-8.55	-0.42	4.05e-16	Waist circumference;Body mass index;
LIHC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.64	0.56	2.67e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1075232	0.826	rs16956738	chr15:31736231	C/T	cg01030201	chr15:31746330	NA	0.69	5.83	0.3	1.29e-8	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.83	8.89	0.43	3.5e-17	Vitiligo;
LIHC	cis	rs7937890	0.706	rs7115393	chr11:14268378	T/A	cg22961513	chr11:14280813	SPON1	0.42	5.75	0.3	1.99e-8	Mitochondrial DNA levels;
LIHC	cis	rs12986413	0.559	rs1859951	chr19:2142633	C/G	cg09261902	chr19:2140048	AP3D1	0.39	6.67	0.34	1.01e-10	Height;
LIHC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs9322817	0.691	rs1455935	chr6:105230312	C/G	cg02098413	chr6:105308735	HACE1	-0.43	-7.84	-0.39	5.92e-14	Thyroid stimulating hormone;
LIHC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg03627880	chr6:151815985	C6orf97	0.42	6.14	0.32	2.26e-9	Menarche (age at onset);
LIHC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	1.06	22.62	0.77	6.65e-70	Breast cancer;
LIHC	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.61	-6.82	-0.35	4.06e-11	Opioid sensitivity;
LIHC	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.62	-0.34	1.43e-10	IgG glycosylation;
LIHC	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.7	10.9	0.51	6.1e-24	Monocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09098825	chr3:47866946	DHX30	0.44	6.12	0.31	2.54e-9	Lung function (FEV1/FVC);
LIHC	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg09795085	chr6:101329169	ASCC3	-0.42	-5.79	-0.3	1.58e-8	Neuroticism;
LIHC	cis	rs6750047	0.638	rs336031	chr2:38265130	C/A	cg07380506	chr2:38303506	CYP1B1	-0.51	-5.98	-0.31	5.69e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.31	-7.14	-0.36	5.6e-12	Menarche (age at onset);
LIHC	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.25	-0.32	1.21e-9	Schizophrenia;
LIHC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.54	10.54	0.5	1.09e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs3018712	0.532	rs11228312	chr11:68415517	G/T	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.12e-8	Total body bone mineral density;
LIHC	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.92	11.74	0.54	5.67e-27	Coronary artery disease;
LIHC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.5	0.38	5.46e-13	Schizophrenia;
LIHC	cis	rs2292096	1.000	rs16847180	chr1:200731556	A/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-5.97	-0.31	5.97e-9	Epilepsy;
LIHC	cis	rs3770081	1.000	rs2241437	chr2:86360573	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-9.09	-0.44	8.29e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.52	-8.03	-0.4	1.56e-14	Cognitive function;
LIHC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.65	-7.82	-0.39	6.42e-14	Mean platelet volume;
LIHC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg04310649	chr10:35416472	CREM	-0.44	-5.9	-0.3	8.73e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1664789	1.000	rs1664783	chr5:53279515	T/A	ch.5.1024479R	chr5:53302184	ARL15	0.51	8.33	0.41	2.03e-15	Waist circumference adjusted for body mass index;
LIHC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.23	0.32	1.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	11.52	0.53	3.64e-26	Coronary artery disease;
LIHC	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.81	0.35	4.49e-11	Dermatomyositis;
LIHC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.7	-10.56	-0.5	9.63e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12744310	0.887	rs35436312	chr1:41793358	G/A	cg03962019	chr1:41807865	NA	0.39	6.38	0.33	5.89e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs1864585	0.520	rs73208790	chr8:10680025	T/A	cg26278703	chr11:58910052	FAM111A	0.74	6.83	0.35	3.95e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs743757	1.000	rs2236988	chr3:50504896	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.4	5.71	0.3	2.45e-8	Diastolic blood pressure;
LIHC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.77	-0.3	1.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.84	-0.3	1.22e-8	Bipolar disorder;
LIHC	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.54	-6.58	-0.34	1.74e-10	Homocysteine levels;
LIHC	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.05	-0.4	1.37e-14	Capecitabine sensitivity;
LIHC	cis	rs57590327	0.503	rs1461611	chr3:81512061	C/A	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Extraversion;
LIHC	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.48	-8.26	-0.41	3.13e-15	Brugada syndrome;
LIHC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.45	6.24	0.32	1.33e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs1144333	0.737	rs1144339	chr1:76280543	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-8.58	-0.42	3.33e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg27478167	chr7:817139	HEATR2	-0.41	-5.92	-0.3	7.9e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.63	-0.38	2.36e-13	Total body bone mineral density;
LIHC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg06565975	chr8:143823917	SLURP1	0.34	6.68	0.34	9.62e-11	Urinary tract infection frequency;
LIHC	cis	rs965469	0.947	rs6037578	chr20:3345911	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.52	-0.33	2.58e-10	IFN-related cytopenia;
LIHC	trans	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.42	-0.33	4.68e-10	Endometrial cancer;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	1.98e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg08668510	chr10:1095578	IDI1	0.67	6.78	0.34	5.16e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.65	-0.34	1.13e-10	Mean corpuscular volume;
LIHC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16262614	chr3:133464971	TF	0.29	6.47	0.33	3.44e-10	Iron status biomarkers;
LIHC	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.7	-11.14	-0.52	8.29e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.67	10.83	0.51	1.03e-23	Platelet count;
LIHC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.42	8.38	0.41	1.4e-15	Obesity-related traits;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	11.9	0.54	1.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs16828019	0.852	rs11209576	chr1:41586029	T/C	cg20697417	chr1:41786797	NA	0.32	6.12	0.31	2.52e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-6.09	-0.31	3.12e-9	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.94	-16.15	-0.66	5.05e-44	Electrocardiographic conduction measures;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23181591	chr8:123793873	ZHX2	0.42	6.05	0.31	3.75e-9	Pancreatic cancer;
LIHC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg15704280	chr7:45808275	SEPT13	-0.46	-6.9	-0.35	2.56e-11	HDL cholesterol;
LIHC	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg05707623	chr12:122985044	ZCCHC8	0.48	6.36	0.33	6.59e-10	Body mass index;
LIHC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.45	-6.56	-0.33	1.99e-10	Narcolepsy;
LIHC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg12297030	chr17:43662878	NA	-0.63	-6.08	-0.31	3.25e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.69	-11.0	-0.51	2.64e-24	Lung cancer;
LIHC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-7.05	-0.36	1.03e-11	Breast cancer;
LIHC	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.53	-7.6	-0.38	2.92e-13	Obesity-related traits;
LIHC	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs6714710	0.812	rs6543040	chr2:98343254	C/T	cg26665480	chr2:98280029	ACTR1B	0.41	5.91	0.3	8.12e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg06359132	chr10:99160096	RRP12	-0.4	-6.33	-0.32	7.89e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.44	-0.33	4.17e-10	Crohn's disease;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06656553	chr16:89960601	TCF25	-0.46	-5.91	-0.3	8.17e-9	Skin colour saturation;
LIHC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.35e-16	Motion sickness;
LIHC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-0.96	-10.22	-0.48	1.46e-21	Magnesium levels;
LIHC	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.51	8.29	0.41	2.61e-15	Corneal astigmatism;
LIHC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.35	-0.7	7.66e-53	Ulcerative colitis;
LIHC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-6.14	-0.32	2.26e-9	Menarche (age at onset);
LIHC	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.13	0.48	2.92e-21	Diisocyanate-induced asthma;
LIHC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.54	-8.77	-0.43	8.66e-17	Prudent dietary pattern;
LIHC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.39	6.91	0.35	2.44e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.68	9.86	0.47	2.3e-20	Schizophrenia;
LIHC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.26	-0.37	2.64e-12	Psoriasis;
LIHC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.1	-0.4	9.71e-15	Chronic sinus infection;
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.51	6.03	0.31	4.36e-9	Alzheimer's disease;
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg13126279	chr21:47581558	C21orf56	0.37	5.73	0.3	2.2e-8	Testicular germ cell tumor;
LIHC	cis	rs12922040	0.651	rs35288467	chr16:15866954	C/A	cg08214245	chr16:15829296	MYH11	-0.29	-5.93	-0.31	7.28e-9	Serum uric acid levels in response to allopurinol in gout;
LIHC	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.89	18.6	0.71	7.32e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg05771511	chr15:63340396	TPM1	-0.44	-5.94	-0.31	7.01e-9	Orofacial clefts;
LIHC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.74	-13.92	-0.6	3.33e-35	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19553056	chr4:142142166	ZNF330	0.41	6.51	0.33	2.61e-10	Cognitive function;
LIHC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.45	6.39	0.33	5.32e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.73	-10.26	-0.49	1.02e-21	Dilated cardiomyopathy;
LIHC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.52	8.12	0.4	8.61e-15	Type 2 diabetes;
LIHC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.55	-9.04	-0.44	1.18e-17	Blood metabolite levels;
LIHC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.92	-0.43	2.9e-17	Type 2 diabetes;
LIHC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.95	-16.99	-0.68	2.33e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	0.69	8.29	0.41	2.64e-15	Corneal curvature;
LIHC	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg25344623	chr2:136566232	LCT	-0.33	-5.85	-0.3	1.18e-8	Corneal structure;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.36	5.9	0.3	8.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.59	-11.45	-0.53	6.32e-26	Coronary artery disease;
LIHC	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.34	0.45	1.27e-18	Melanoma;
LIHC	cis	rs4908768	0.906	rs11121207	chr1:8681848	C/A	cg25722041	chr1:8623473	RERE	0.43	5.75	0.3	2.01e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.66	10.77	0.5	1.77e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg14473756	chr11:122847823	NA	-0.36	-6.6	-0.34	1.54e-10	Menarche (age at onset);
LIHC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-9.88	-0.47	2.06e-20	Mean corpuscular volume;
LIHC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	18.59	0.71	8.47e-54	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg13535736	chr9:111863775	C9orf5	-0.4	-5.99	-0.31	5.37e-9	Menarche (age at onset);
LIHC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.76	0.3	1.83e-8	Menopause (age at onset);
LIHC	cis	rs28830936	0.966	rs28680296	chr15:42121538	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.14	-0.31	2.34e-9	Diastolic blood pressure;
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg05697976	chr12:29376483	FAR2	0.32	6.37	0.33	5.95e-10	QT interval;
LIHC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.81	8.01	0.4	1.77e-14	Body mass index;
LIHC	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.61	10.09	0.48	4.11e-21	Recombination rate (males);
LIHC	cis	rs7091068	0.671	rs588912	chr10:95402929	T/C	cg20715218	chr10:95462985	C10orf4	-0.61	-6.95	-0.35	1.83e-11	Urinary tract infection frequency;
LIHC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.8	-12.48	-0.56	1.06e-29	Total body bone mineral density;
LIHC	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.11e-27	IgG glycosylation;
LIHC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.5	-7.64	-0.38	2.15e-13	Pulse pressure;
LIHC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.48	0.46	4.3e-19	Tonsillectomy;
LIHC	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg00938859	chr5:1591904	SDHAP3	0.59	7.19	0.36	4.19e-12	Breast cancer;
LIHC	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.28	6.51	0.33	2.67e-10	Educational attainment (years of education);
LIHC	cis	rs7116495	0.881	rs598835	chr11:71797727	C/T	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.43	5.87	0.3	1.04e-8	Life satisfaction;
LIHC	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.43	0.33	4.4e-10	Mean corpuscular volume;
LIHC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.3	-0.37	2.09e-12	Platelet count;
LIHC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg05044414	chr3:183734942	ABCC5	0.35	6.11	0.31	2.76e-9	Anterior chamber depth;
LIHC	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg01181863	chr3:195395398	SDHAP2	-0.63	-8.0	-0.4	1.98e-14	Pancreatic cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07327396	chr4:128886243	C4orf29;MFSD8	0.44	6.66	0.34	1.08e-10	Cognitive function;
LIHC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg08213375	chr14:104286397	PPP1R13B	0.36	5.86	0.3	1.11e-8	Reticulocyte count;
LIHC	cis	rs3736485	0.966	rs6493513	chr15:51910174	G/A	cg08986416	chr15:51914746	DMXL2	-0.47	-6.97	-0.35	1.65e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.5	7.89	0.39	4.19e-14	Alzheimer's disease (survival time);
LIHC	cis	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg20932281	chr17:33905541	PEX12	0.42	5.74	0.3	2.12e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg05197062	chr11:11642011	GALNTL4	0.44	6.45	0.33	3.88e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20307385	chr11:47447363	PSMC3	-0.46	-5.98	-0.31	5.68e-9	Subjective well-being;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16123319	chr15:49913299	DTWD1;C15orf33	-0.58	-6.6	-0.34	1.6e-10	Systolic blood pressure;
LIHC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg16102536	chr7:156981717	UBE3C	0.35	5.92	0.3	7.91e-9	Body mass index;
LIHC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.58	-11.39	-0.52	1.1e-25	Coronary artery disease;
LIHC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.43	-0.59	2.6e-33	Vitiligo;
LIHC	cis	rs7116495	1.000	rs10736786	chr11:71763274	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs4908768	0.906	rs114812780	chr1:8528854	G/T	cg20416874	chr1:8611966	RERE	0.58	9.08	0.44	9.16e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.44	-0.33	4.08e-10	HDL cholesterol;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02951695	chr10:134400351	INPP5A	0.41	6.05	0.31	3.86e-9	Immature fraction of reticulocytes;
LIHC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.77	12.14	0.55	1.95e-28	Corneal astigmatism;
LIHC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.13	-0.36	5.98e-12	Body mass index;
LIHC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg03735888	chr19:58951602	ZNF132	0.4	7.03	0.36	1.13e-11	Uric acid clearance;
LIHC	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.36	-6.07	-0.31	3.34e-9	Educational attainment;
LIHC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.6	7.56	0.38	3.76e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg00631329	chr6:26305371	NA	-0.34	-5.74	-0.3	2.05e-8	Educational attainment;
LIHC	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.73	8.23	0.41	4.06e-15	Height;
LIHC	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg23495837	chr4:3480318	DOK7	-0.39	-6.22	-0.32	1.41e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg18289306	chr13:113640169	MCF2L	0.42	6.18	0.32	1.78e-9	Systolic blood pressure;
LIHC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg07689907	chr11:61582574	FADS1	0.39	5.77	0.3	1.78e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.44	-0.33	4.04e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11779988	0.545	rs4124900	chr8:17785266	A/G	cg01800426	chr8:17659068	MTUS1	-0.42	-5.92	-0.3	7.96e-9	Breast cancer;
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.42	-5.82	-0.3	1.34e-8	Total body bone mineral density;
LIHC	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.4	0.37	1.07e-12	Fuchs's corneal dystrophy;
LIHC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.84e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12922040	0.651	rs35288467	chr16:15866954	C/A	cg27174420	chr16:15820903	MYH11	-0.33	-5.76	-0.3	1.89e-8	Serum uric acid levels in response to allopurinol in gout;
LIHC	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-6.2	-0.32	1.66e-9	Homocysteine levels;
LIHC	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.54	8.36	0.41	1.61e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.44	6.79	0.34	4.88e-11	Methadone dose in opioid dependence;
LIHC	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg19920283	chr7:105172520	RINT1	0.47	5.74	0.3	2.09e-8	Bipolar disorder (body mass index interaction);
LIHC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-12.25	-0.55	7.5e-29	Refractive error;
LIHC	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg20129853	chr10:51489980	NA	0.42	9.0	0.44	1.54e-17	Prostate-specific antigen levels;
LIHC	cis	rs1570989	0.571	rs6916066	chr6:12016009	G/C	cg17804551	chr6:12015979	HIVEP1	0.41	7.18	0.36	4.44e-12	Alcohol and nicotine co-dependence;
LIHC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.88	17.03	0.68	1.5e-47	Blood protein levels;
LIHC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-6.19	-0.32	1.68e-9	Neuroticism;
LIHC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.67	12.96	0.57	1.57e-31	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.44	8.61	0.42	2.69e-16	Schizophrenia;
LIHC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.61	0.59	5.31e-34	Colorectal cancer;
LIHC	trans	rs60752752	0.852	rs6680386	chr1:153371085	A/G	cg14901121	chr8:98817630	LAPTM4B	0.44	7.09	0.36	7.77e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2412488	0.893	rs17082923	chr4:54363481	C/T	cg22241045	chr4:54363911	LNX1	0.46	7.65	0.38	2.07e-13	DNA methylation (variation);
LIHC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.6	8.65	0.42	2.09e-16	Platelet count;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.06	0.31	3.53e-9	Prudent dietary pattern;
LIHC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.43	-6.45	-0.33	3.89e-10	Cognitive function;
LIHC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg11764359	chr7:65958608	NA	-0.58	-5.98	-0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs11098699	0.784	rs6534393	chr4:124238947	C/T	cg09941581	chr4:124220074	SPATA5	-0.32	-6.29	-0.32	9.56e-10	Mosquito bite size;
LIHC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg08847533	chr14:75593920	NEK9	-0.38	-6.46	-0.33	3.54e-10	Caffeine consumption;
LIHC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	cis	rs17152411	0.711	rs7096822	chr10:126664166	T/C	cg07906193	chr10:126599966	NA	0.34	6.06	0.31	3.52e-9	Height;
LIHC	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg17830980	chr10:43048298	ZNF37B	-0.45	-8.71	-0.43	1.34e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.68	9.84	0.47	2.83e-20	Height;
LIHC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.36	-0.37	1.35e-12	Obesity-related traits;
LIHC	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg18898632	chr2:242989856	NA	-0.57	-7.72	-0.39	1.32e-13	Obesity-related traits;
LIHC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg01864069	chr14:103024347	NA	0.52	8.51	0.42	5.64e-16	Platelet count;
LIHC	cis	rs1144333	0.655	rs931506	chr1:76401349	T/C	cg10523679	chr1:76189770	ACADM	0.47	6.41	0.33	4.78e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08392591	chr16:89556376	ANKRD11	-0.48	-7.54	-0.38	4.25e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg15848620	chr12:58087721	OS9	-0.55	-7.43	-0.37	8.96e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	6.75	0.34	6.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01200585	chr1:228362443	C1orf69	0.5	6.29	0.32	9.77e-10	Diastolic blood pressure;
LIHC	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-0.9	-9.03	-0.44	1.28e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs3736485	0.899	rs7183479	chr15:51942207	C/G	cg08986416	chr15:51914746	DMXL2	-0.43	-6.18	-0.32	1.81e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.42	-6.37	-0.33	6.25e-10	Cognitive function;
LIHC	cis	rs738321	0.756	rs11570745	chr22:38513493	C/T	cg25457927	chr22:38595422	NA	-0.29	-6.46	-0.33	3.53e-10	Breast cancer;
LIHC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg16479474	chr6:28041457	NA	0.39	6.38	0.33	5.78e-10	Parkinson's disease;
LIHC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.46	6.8	0.35	4.72e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02290350	chr8:58132656	NA	0.47	9.29	0.45	1.8e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg14829360	chr17:73884958	NA	-0.38	-6.44	-0.33	4.01e-10	White matter hyperintensity burden;
LIHC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-6.7	-0.34	8.72e-11	Bipolar disorder;
LIHC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg10587741	chr22:38071170	LGALS1	0.73	12.66	0.56	2.14e-30	Fat distribution (HIV);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08058610	chr19:52674483	ZNF836	0.41	6.15	0.32	2.2e-9	Cognitive function;
LIHC	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.5	7.39	0.37	1.13e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg06742321	chr12:123595122	PITPNM2	0.3	5.78	0.3	1.65e-8	Platelet count;
LIHC	cis	rs8044995	0.636	rs12596500	chr16:68299771	G/A	cg05110241	chr16:68378359	PRMT7	-0.63	-6.33	-0.32	7.65e-10	Schizophrenia;
LIHC	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.4	-0.33	5.09e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg04317338	chr11:64019027	PLCB3	0.84	7.87	0.39	4.58e-14	Mean platelet volume;
LIHC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.36	5.83	0.3	1.29e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg01652190	chr22:50026171	C22orf34	-0.28	-5.99	-0.31	5.3e-9	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.69	-6.36	-0.33	6.36e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.36	-5.85	-0.3	1.15e-8	Height;
LIHC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs907683	0.559	rs11685408	chr2:220291474	T/C	cg15015639	chr2:220282977	DES	0.35	8.37	0.41	1.53e-15	Resting heart rate;
LIHC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.65	-0.34	1.13e-10	Mean corpuscular volume;
LIHC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.95	0.31	6.79e-9	Electroencephalogram traits;
LIHC	cis	rs74181299	0.684	rs9797989	chr2:65336529	T/C	cg05010058	chr2:65284262	CEP68	-0.41	-6.78	-0.34	5.31e-11	Pulse pressure;
LIHC	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-8.81	-0.43	6.19e-17	Parkinson's disease;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.73	-11.22	-0.52	4.32e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.51	-7.42	-0.37	9.4e-13	Height;
LIHC	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.39	6.14	0.32	2.29e-9	Alzheimer's disease (survival time);
LIHC	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg13919466	chr1:32135498	COL16A1	-0.33	-6.38	-0.33	5.64e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.35	-0.41	1.68e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg15472797	chr10:135243109	NA	-0.4	-6.79	-0.34	4.89e-11	Systemic lupus erythematosus;
LIHC	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg09795085	chr6:101329169	ASCC3	-0.47	-6.86	-0.35	3.28e-11	Neuroticism;
LIHC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	3e-9	Mortality in heart failure;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.46	0.42	7.75e-16	Lymphocyte counts;
LIHC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.57	7.02	0.35	1.22e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24549020	chr5:56110836	MAP3K1	0.51	6.4	0.33	5.12e-10	Initial pursuit acceleration;
LIHC	cis	rs986417	0.901	rs2350901	chr14:60948128	A/G	cg27398547	chr14:60952738	C14orf39	0.8	8.98	0.44	1.86e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.12	0.36	6.59e-12	Renal cell carcinoma;
LIHC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.43	7.07	0.36	8.77e-12	Response to temozolomide;
LIHC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	6.08	0.31	3.29e-9	Educational attainment;
LIHC	cis	rs62458065	0.925	rs10243243	chr7:32460709	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.66	-7.29	-0.37	2.22e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs12980942	0.630	rs7256856	chr19:41788352	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.29	0.32	9.54e-10	Coronary artery disease;
LIHC	cis	rs12644436	0.602	rs4082043	chr4:88780140	C/T	cg06891869	chr4:88767617	MEPE	0.43	7.59	0.38	3.12e-13	HIV-1 viral setpoint;
LIHC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg22563815	chr15:78856949	CHRNA5	0.36	6.53	0.33	2.44e-10	Sudden cardiac arrest;
LIHC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg05941027	chr17:61774174	LIMD2	0.35	7.35	0.37	1.48e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2257205	0.667	rs9893027	chr17:56653448	G/C	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05665937	chr4:1216051	CTBP1	0.44	5.71	0.3	2.42e-8	Obesity-related traits;
LIHC	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg06935464	chr4:38784597	TLR10	0.49	7.53	0.38	4.47e-13	Breast cancer;
LIHC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.41	6.58	0.34	1.79e-10	Cognitive function;
LIHC	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.82	9.06	0.44	1.02e-17	Vitiligo;
LIHC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	0.84	6.37	0.33	6.05e-10	Plateletcrit;
LIHC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.49	7.68	0.38	1.71e-13	Blood protein levels;
LIHC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-9.65	-0.46	1.23e-19	Asthma;
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.19	-0.32	1.74e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.58	-8.81	-0.43	6.35e-17	White matter hyperintensity burden;
LIHC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-8.56	-0.42	3.77e-16	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs2016586	0.965	rs5995162	chr22:36118936	T/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.18	-0.32	1.78e-9	Body mass index;
LIHC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02985541	chr2:219472218	PLCD4	0.44	8.5	0.42	5.86e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg08888203	chr3:10149979	C3orf24	0.5	6.37	0.33	6.27e-10	Alzheimer's disease;
LIHC	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.37e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.47	-6.97	-0.35	1.66e-11	Menarche (age at onset);
LIHC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.36	5.88	0.3	9.91e-9	Height;
LIHC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.19	-0.32	1.69e-9	Type 2 diabetes;
LIHC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.67	12.05	0.55	3.99e-28	High light scatter reticulocyte count;
LIHC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.49	7.09	0.36	7.83e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.72	11.19	0.52	5.63e-25	Corneal astigmatism;
LIHC	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.87e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.76	-0.34	6e-11	Gut microbiome composition (summer);
LIHC	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg26811252	chr16:29126840	RRN3P2	0.41	6.67	0.34	1.02e-10	Menopause (age at onset);
LIHC	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.35	-5.72	-0.3	2.28e-8	Platelet count;
LIHC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.56	0.53	2.57e-26	Tonsillectomy;
LIHC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg05697976	chr12:29376483	FAR2	0.33	6.73	0.34	7.09e-11	QT interval;
LIHC	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg03962019	chr1:41807865	NA	-0.33	-5.76	-0.3	1.87e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg03934865	chr2:198174659	NA	0.45	6.52	0.33	2.5e-10	Dermatomyositis;
LIHC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.72	13.62	0.59	4.85e-34	Height;
LIHC	trans	rs71435601	0.943	rs71435593	chr2:21302020	T/C	cg01780092	chr15:83380063	AP3B2	0.61	6.14	0.32	2.25e-9	Cholesterol, total;
LIHC	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.82	-14.85	-0.63	7.7e-39	Height;
LIHC	cis	rs17152411	0.895	rs7079416	chr10:126587312	C/G	cg07906193	chr10:126599966	NA	0.42	6.61	0.34	1.48e-10	Height;
LIHC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.43	8.0	0.4	1.98e-14	Electrocardiographic conduction measures;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23849483	chr19:15224544	SYDE1	0.44	6.42	0.33	4.69e-10	Longevity;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	0.62	8.97	0.44	2.01e-17	Prudent dietary pattern;
LIHC	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.41	6.33	0.32	7.85e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.54	0.5	1.14e-22	Lymphocyte counts;
LIHC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.79	9.9	0.47	1.7e-20	Cognitive function;
LIHC	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-14.13	-0.61	5.04e-36	Mortality in heart failure;
LIHC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.69	10.71	0.5	2.95e-23	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs365132	0.846	rs353470	chr5:176444861	C/T	cg16309518	chr5:176445507	NA	-0.53	-9.9	-0.47	1.79e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.89	0.3	9.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.7	12.88	0.57	3.32e-31	Dental caries;
LIHC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg05484376	chr2:27715224	FNDC4	0.36	6.18	0.32	1.8e-9	Total body bone mineral density;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.75	-0.34	6.23e-11	Total body bone mineral density;
LIHC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.87	13.13	0.58	3.75e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6088813	1.000	rs6579234	chr20:33983485	A/G	cg14752227	chr20:34000481	UQCC	-0.4	-5.75	-0.3	1.99e-8	Height;
LIHC	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	trans	rs11689435	0.925	rs1478593	chr2:218346137	G/A	cg13544946	chr9:35729779	TLN1	-0.44	-6.35	-0.32	6.82e-10	Metabolite levels (MHPG);
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21747090	chr2:27597821	SNX17	-0.42	-6.16	-0.32	2.02e-9	Total body bone mineral density;
LIHC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.58	6.23	0.32	1.36e-9	Systemic lupus erythematosus;
LIHC	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.6	7.36	0.37	1.37e-12	Coronary artery disease;
LIHC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.57	11.02	0.51	2.22e-24	Coronary artery disease;
LIHC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-8.17	-0.4	5.84e-15	Lung cancer;
LIHC	trans	rs6934970	0.860	rs12194046	chr6:112989209	A/G	cg09308777	chr6:169852575	NA	-0.68	-6.29	-0.32	9.73e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs10849605	1.000	rs10849605	chr12:1064438	C/T	cg22937753	chr12:1022477	RAD52	0.38	7.36	0.37	1.35e-12	Lung cancer;
LIHC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.4	-6.21	-0.32	1.56e-9	Testicular germ cell tumor;
LIHC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.69	0.34	8.9e-11	Lung cancer in ever smokers;
LIHC	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-7.04	-0.36	1.04e-11	Opioid sensitivity;
LIHC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.67	8.38	0.41	1.38e-15	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.02	-0.51	2.36e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.96	-0.31	6.3e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.65	-16.58	-0.67	9.67e-46	Breast cancer;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.85e-9	Menopause (age at onset);
LIHC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg25039879	chr17:56429692	SUPT4H1	-0.73	-9.39	-0.45	8.74e-19	Cognitive test performance;
LIHC	cis	rs11644362	0.966	rs976011	chr16:12992910	C/T	cg06890432	chr16:12997467	SHISA9	-0.39	-6.59	-0.34	1.64e-10	Positive affect;Subjective well-being;
LIHC	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg08847533	chr14:75593920	NEK9	-0.44	-7.11	-0.36	7.01e-12	Caffeine consumption;
LIHC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.51	6.57	0.33	1.91e-10	Initial pursuit acceleration;
LIHC	cis	rs546131	0.614	rs35264793	chr11:34834844	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.34	1.66e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.25	5.78	0.3	1.73e-8	Migraine;
LIHC	cis	rs600626	0.588	rs11236526	chr11:75467605	G/A	cg24262691	chr11:75473276	NA	0.44	6.56	0.33	2.02e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.1	11.28	0.52	2.73e-25	Opioid sensitivity;
LIHC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.7	-0.5	3.15e-23	Breast cancer;
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.49	7.93	0.39	3.04e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg18357645	chr12:58087776	OS9	0.48	8.08	0.4	1.12e-14	Multiple sclerosis;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.75	0.57	1.04e-30	Prudent dietary pattern;
LIHC	trans	rs6489882	0.703	rs11066452	chr12:113361574	G/T	cg10175203	chr3:128143634	NA	0.4	6.41	0.33	4.85e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.54	9.14	0.44	5.75e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs739401	0.619	rs10766481	chr11:2961512	G/C	cg25174290	chr11:3078921	CARS	0.56	8.47	0.42	7.29e-16	Longevity;
LIHC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.46	-0.37	7.22e-13	Initial pursuit acceleration;
LIHC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg18306943	chr3:40428807	ENTPD3	0.33	5.88	0.3	9.6e-9	Renal cell carcinoma;
LIHC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg14671364	chr1:107599128	PRMT6	0.5	7.3	0.37	2.03e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg00656387	chr3:40428638	ENTPD3	0.43	7.37	0.37	1.29e-12	Renal cell carcinoma;
LIHC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	3.96e-13	Electroencephalogram traits;
LIHC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.45	6.2	0.32	1.59e-9	Height;
LIHC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.59	-9.1	-0.44	7.62e-18	Dental caries;
LIHC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.94	0.31	6.91e-9	Renal cell carcinoma;
LIHC	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg25566285	chr7:158114605	PTPRN2	-0.22	-5.93	-0.31	7.54e-9	Calcium levels;
LIHC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	6.95	0.35	1.87e-11	Breast cancer;
LIHC	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.37	-0.37	1.28e-12	Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg24209194	chr3:40518798	ZNF619	0.43	6.22	0.32	1.44e-9	Renal cell carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26348180	chr3:193852754	HES1	0.51	6.8	0.35	4.77e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.86	11.79	0.54	3.63e-27	Blood metabolite levels;
LIHC	cis	rs4788570	0.584	rs7204608	chr16:71678679	C/G	cg06353428	chr16:71660113	MARVELD3	-1.08	-12.53	-0.56	6.79e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.33	-6.04	-0.31	3.96e-9	Coronary artery disease or large artery stroke;
LIHC	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.19	-0.36	4.2e-12	Inflammatory bowel disease;
LIHC	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg26116260	chr4:7069785	GRPEL1	-1.01	-12.32	-0.55	4.12e-29	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.83	0.67	9.95e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1190552	0.761	rs4900536	chr14:102862994	A/G	cg10241871	chr14:102965420	TECPR2	0.38	5.99	0.31	5.46e-9	Blood protein levels;
LIHC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.69	0.34	9.15e-11	Lung cancer in ever smokers;
LIHC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.03	0.51	2.04e-24	Colorectal cancer;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg01646665	chr1:156251436	TMEM79;SMG5	0.3	5.84	0.3	1.22e-8	Tonsillectomy;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg04519895	chr17:42785931	DBF4B	-0.4	-6.12	-0.31	2.59e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.71	6.42	0.33	4.56e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg19743168	chr1:23544995	NA	0.34	5.72	0.3	2.33e-8	Height;
LIHC	cis	rs2637266	0.685	rs2395427	chr10:78462535	G/A	cg18941641	chr10:78392320	NA	0.27	5.79	0.3	1.61e-8	Pulmonary function;
LIHC	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.53	10.01	0.48	7.51e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg24879335	chr3:133465180	TF	0.29	6.47	0.33	3.49e-10	Iron status biomarkers;
LIHC	trans	rs10411161	0.640	rs7252303	chr19:52389357	G/A	cg22319618	chr22:45562946	NUP50	-0.62	-8.57	-0.42	3.59e-16	Breast cancer;
LIHC	cis	rs4908768	0.871	rs11121221	chr1:8767529	A/G	cg20416874	chr1:8611966	RERE	0.53	8.36	0.41	1.56e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.04	-0.36	1.05e-11	Major depressive disorder;
LIHC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.49	7.44	0.37	8.3e-13	Height;
LIHC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg16434002	chr17:42200994	HDAC5	0.54	7.77	0.39	9.14e-14	Total body bone mineral density;
LIHC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.42	6.62	0.34	1.42e-10	Melanoma;
LIHC	cis	rs17750015	0.733	rs12454365	chr18:54396215	G/A	cg18434998	chr18:54306185	TXNL1	-0.48	-6.64	-0.34	1.2e-10	Depression and alcohol dependence;
LIHC	trans	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg07424592	chr7:64974309	NA	0.78	8.31	0.41	2.26e-15	Diabetic kidney disease;
LIHC	cis	rs1494950	1.000	rs10013449	chr4:15069589	G/A	cg12377275	chr4:15005593	CPEB2	-0.88	-7.56	-0.38	3.77e-13	Political ideology;
LIHC	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.31	6.11	0.31	2.77e-9	Metabolite levels (MHPG);
LIHC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.09	13.07	0.58	6.34e-32	Vitiligo;
LIHC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08392591	chr16:89556376	ANKRD11	0.39	5.89	0.3	9.4e-9	Multiple myeloma (IgH translocation);
LIHC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.43	6.08	0.31	3.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg13753209	chr17:57696993	CLTC	0.73	11.6	0.53	1.87e-26	Hemoglobin concentration;
LIHC	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg23587288	chr2:27483067	SLC30A3	-0.32	-6.11	-0.31	2.74e-9	Blood metabolite levels;
LIHC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.71	10.58	0.5	8.11e-23	Aortic root size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14929913	chr10:1147979	WDR37	-0.42	-6.33	-0.32	7.74e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.4	-0.37	1.07e-12	Bipolar disorder;
LIHC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06002616	chr8:101225028	SPAG1	0.35	6.03	0.31	4.34e-9	Atrioventricular conduction;
LIHC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.3	-0.61	1.06e-36	Alzheimer's disease;
LIHC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg02640540	chr1:67518911	SLC35D1	0.41	6.46	0.33	3.55e-10	Lymphocyte percentage of white cells;
LIHC	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.45	7.28	0.37	2.35e-12	Corneal astigmatism;
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.6	-0.42	2.86e-16	Renal cell carcinoma;
LIHC	cis	rs7106204	0.609	rs11825384	chr11:24285137	G/T	ch.11.24196551F	chr11:24239977	NA	0.68	6.21	0.32	1.55e-9	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.03	-0.36	1.13e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.53	-8.42	-0.41	1.04e-15	Anterior chamber depth;
LIHC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.95	12.87	0.57	3.44e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.57	8.57	0.42	3.71e-16	Height;
LIHC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.82	0.39	6.47e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs2274273	0.554	rs3742564	chr14:55530120	C/T	cg01864836	chr14:55583639	NA	0.38	6.3	0.32	9.25e-10	Protein biomarker;
LIHC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg13628971	chr7:2884303	GNA12	0.39	5.89	0.3	9.27e-9	Height;
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg05185784	chr16:90016020	DEF8	-0.48	-6.39	-0.33	5.56e-10	Skin colour saturation;
LIHC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.98	0.31	5.74e-9	Menopause (age at onset);
LIHC	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg02023728	chr11:77925099	USP35	0.32	5.84	0.3	1.18e-8	Alzheimer's disease (survival time);
LIHC	cis	rs151997	0.924	rs32480	chr5:50208099	G/A	cg06027927	chr5:50259733	NA	0.57	7.72	0.39	1.31e-13	Callous-unemotional behaviour;
LIHC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.68	7.84	0.39	5.88e-14	Dental caries;
LIHC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg16586182	chr3:47516702	SCAP	-0.47	-8.5	-0.42	6.1e-16	Colorectal cancer;
LIHC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs2380220	0.808	rs2716072	chr6:95909773	A/G	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg18016565	chr1:150552671	MCL1	0.54	10.05	0.48	5.25e-21	Melanoma;
LIHC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.62	9.47	0.46	4.77e-19	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25937148	chr3:43147320	C3orf39	0.6	8.01	0.4	1.78e-14	Lung function (FEV1/FVC);
LIHC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	0.77	5.9	0.3	8.85e-9	IgG glycosylation;
LIHC	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg05535760	chr7:792225	HEATR2	-0.64	-7.49	-0.38	6.02e-13	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6598955	0.670	rs6598942	chr1:26531034	C/T	cg04990556	chr1:26633338	UBXN11	-0.57	-9.11	-0.44	7.15e-18	Obesity-related traits;
LIHC	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.74	13.11	0.58	4.34e-32	Eosinophil percentage of white cells;
LIHC	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg17074339	chr11:11642133	GALNTL4	0.45	7.11	0.36	6.86e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.6	9.61	0.46	1.59e-19	Response to antidepressants and depression;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12863373	chr8:27695096	PBK	0.45	6.17	0.32	1.98e-9	Pancreatic cancer;
LIHC	cis	rs7542375	0.524	rs2807869	chr1:221094068	A/G	cg16008148	chr1:221062819	NA	0.3	6.53	0.33	2.36e-10	Obesity-related traits;
LIHC	cis	rs9309473	0.950	rs10207264	chr2:73714097	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.66	-0.34	1.12e-10	Metabolite levels;
LIHC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg16070018	chr6:26224392	HIST1H3E	0.57	6.81	0.35	4.47e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg16797656	chr11:68205561	LRP5	0.5	7.82	0.39	6.67e-14	Total body bone mineral density;
LIHC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	5.64e-22	Corneal astigmatism;
LIHC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.38	-6.69	-0.34	9.03e-11	Aortic root size;
LIHC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg22319618	chr22:45562946	NUP50	0.59	8.03	0.4	1.58e-14	Breast cancer;
LIHC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.71	12.91	0.57	2.57e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.91	-0.47	1.62e-20	Total cholesterol levels;
LIHC	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	11.02	0.51	2.23e-24	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.75	13.59	0.59	6.12e-34	Platelet count;
LIHC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.35	-5.89	-0.3	9.4e-9	IgG glycosylation;
LIHC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.6	8.58	0.42	3.42e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.77	-15.14	-0.63	5.41e-40	Height;
LIHC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.66	5.89	0.3	9.33e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg03342759	chr3:160939853	NMD3	0.57	7.58	0.38	3.33e-13	Morning vs. evening chronotype;
LIHC	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.63	12.47	0.56	1.14e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.3	-0.37	2.05e-12	Longevity;
LIHC	cis	rs1023500	1.000	rs1023499	chr22:42340582	T/C	cg04733989	chr22:42467013	NAGA	-0.51	-6.05	-0.31	3.75e-9	Schizophrenia;
LIHC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.75	12.25	0.55	7.33e-29	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs77861329	1.000	rs1237830	chr3:52202820	T/C	cg08692210	chr3:52188851	WDR51A	0.83	7.86	0.39	5.11e-14	Macrophage inflammatory protein 1b levels;
LIHC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.76	10.04	0.48	6.09e-21	Fat distribution (HIV);
LIHC	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.11e-13	Lung cancer;
LIHC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg14393609	chr7:65229607	NA	0.38	5.87	0.3	1.02e-8	Aortic root size;
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.64	9.38	0.45	9.33e-19	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg03013999	chr17:37608204	MED1	0.36	6.01	0.31	4.67e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg27386326	chr11:61587980	NA	0.72	15.17	0.63	4.31e-40	Bipolar disorder;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-7.0	-0.35	1.37e-11	Total body bone mineral density;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00480142	chr12:96046743	NA	0.4	6.5	0.33	2.8e-10	Longevity;
LIHC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.65	-10.5	-0.49	1.58e-22	Monocyte percentage of white cells;
LIHC	cis	rs6450176	0.638	rs11746856	chr5:53291295	A/C	ch.5.1024479R	chr5:53302184	ARL15	-1.02	-19.14	-0.72	5.26e-56	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.94	0.54	1.01e-27	Eye color traits;
LIHC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.97	14.95	0.63	3.06e-39	Metabolic syndrome;
LIHC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.83	15.32	0.64	1.09e-40	IgG glycosylation;
LIHC	trans	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.51	-6.33	-0.32	7.89e-10	Ulcerative colitis;
LIHC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs12752401	0.867	rs12751548	chr1:103067463	A/G	cg03332897	chr19:740442	PALM	-0.46	-6.19	-0.32	1.68e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.33	0.41	1.93e-15	Height;
LIHC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.65	0.34	1.16e-10	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.61e-9	Alzheimer's disease;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.57	-7.9	-0.39	3.76e-14	Menopause (age at onset);
LIHC	cis	rs12611088	0.571	rs8110232	chr19:44027390	T/C	cg13740135	chr19:44006432	PHLDB3	-0.41	-6.09	-0.31	3.07e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.68	10.34	0.49	5.33e-22	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg25894440	chr7:65020034	NA	-0.52	-5.98	-0.31	5.56e-9	Diabetic kidney disease;
LIHC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg27478167	chr7:817139	HEATR2	-0.51	-6.75	-0.34	6.36e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.64	0.34	1.2e-10	Lung cancer;
LIHC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.38	-0.68	6.12e-49	Gut microbiome composition (summer);
LIHC	cis	rs507080	0.961	rs642497	chr11:118550784	C/A	cg04173919	chr11:118528438	PHLDB1	0.32	5.99	0.31	5.42e-9	Serum metabolite levels;
LIHC	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.33	0.32	7.63e-10	Renal cell carcinoma;
LIHC	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.15	-0.36	5.19e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.39	6.68	0.34	9.64e-11	Mitochondrial DNA levels;
LIHC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg18887096	chr2:219472410	PLCD4	0.37	6.42	0.33	4.6e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.56	-0.38	3.81e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg27366882	chr3:133540807	NA	-0.41	-6.86	-0.35	3.16e-11	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02034447	chr16:89574710	SPG7	0.46	7.06	0.36	9.18e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs3820500	0.543	rs1316011	chr1:117941924	C/T	cg20383390	chr1:117909022	MAN1A2	0.45	5.82	0.3	1.39e-8	Pneumonia;
LIHC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.93	17.27	0.68	1.69e-48	Breast cancer;
LIHC	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.43	8.34	0.41	1.8e-15	Testicular germ cell tumor;
LIHC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg10130564	chr11:117069849	TAGLN	-0.37	-6.18	-0.32	1.81e-9	Blood protein levels;
LIHC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg06784218	chr1:46089804	CCDC17	0.41	6.34	0.32	7.23e-10	Platelet count;
LIHC	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.78	-8.48	-0.42	7.05e-16	Exhaled nitric oxide output;
LIHC	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.49	7.1	0.36	7.22e-12	Blood metabolite levels;
LIHC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.56	-7.28	-0.37	2.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.46	8.33	0.41	1.99e-15	Prudent dietary pattern;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg26383753	chr2:85199382	KCMF1	-0.5	-6.34	-0.32	7.11e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.41	-7.44	-0.37	8.34e-13	Hepatocellular carcinoma;
LIHC	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg02811702	chr13:24901961	NA	0.24	6.3	0.32	9e-10	Obesity-related traits;
LIHC	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.01	-0.31	4.71e-9	Response to antipsychotic treatment;
LIHC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg03859395	chr2:55845619	SMEK2	0.78	13.38	0.59	3.98e-33	Metabolic syndrome;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.72	-11.0	-0.51	2.7e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04004882	chr2:215674386	BARD1	-0.52	-6.94	-0.35	1.98e-11	Neuroblastoma;
LIHC	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs6061231	0.916	rs58488796	chr20:60949050	G/C	cg06026331	chr20:60912101	LAMA5	0.44	6.14	0.32	2.29e-9	Colorectal cancer;
LIHC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.43	7.37	0.37	1.26e-12	Aortic root size;
LIHC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	5.98	0.31	5.71e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-11.42	-0.53	8.44e-26	Colorectal cancer;
LIHC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg17830980	chr10:43048298	ZNF37B	0.42	7.94	0.39	3.02e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.51	8.57	0.42	3.72e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02985541	chr2:219472218	PLCD4	-0.36	-6.34	-0.32	7.29e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.49	6.83	0.35	3.97e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.23	6.27	0.32	1.11e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.3	-0.41	2.51e-15	Response to antipsychotic treatment;
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13409248	chr3:40428643	ENTPD3	0.48	8.18	0.4	5.67e-15	Renal cell carcinoma;
LIHC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.47	-7.97	-0.4	2.35e-14	Male sexual orientation;
LIHC	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.9	18.26	0.7	1.79e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.78	-0.3	1.73e-8	Response to antipsychotic treatment;
LIHC	cis	rs2257205	0.588	rs7209327	chr17:56741834	A/G	cg12560992	chr17:57184187	TRIM37	0.71	7.79	0.39	8.05e-14	Pancreatic cancer;
LIHC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.69	-12.96	-0.57	1.66e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.94	17.69	0.69	3.46e-50	Menopause (age at onset);
LIHC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg00934597	chr7:893267	UNC84A	0.48	5.87	0.3	1.02e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.26	6.11	0.31	2.74e-9	Crohn's disease;
LIHC	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.6	-9.02	-0.44	1.38e-17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LIHC	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.38	-8.14	-0.4	7.31e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.55	-8.24	-0.41	3.6e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.52	-7.15	-0.36	5.3e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.09	20.44	0.74	3.03e-61	Mitochondrial DNA levels;
LIHC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg21531657	chr3:10005747	TMEM111	0.39	5.88	0.3	9.77e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.59	7.56	0.38	3.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.65	-0.34	1.14e-10	Height;
LIHC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.22	0.41	4.32e-15	Motion sickness;
LIHC	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	0.71	8.29	0.41	2.67e-15	Gut microbiota (bacterial taxa);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23797200	chr17:40174494	NKIRAS2	-0.64	-9.01	-0.44	1.52e-17	Lung function (FEV1/FVC);
LIHC	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg12365402	chr11:9010492	NRIP3	0.24	5.84	0.3	1.19e-8	Reticulocyte fraction of red cells;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg07725925	chr16:89976287	TCF25	0.44	6.03	0.31	4.15e-9	Skin colour saturation;
LIHC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	12.36	0.56	2.9e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg00977110	chr5:151150581	G3BP1	0.52	6.54	0.33	2.3e-10	Preschool internalizing problems;
LIHC	cis	rs7238033	0.624	rs9967412	chr18:43308889	C/G	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.94	9.25	0.45	2.52e-18	Eosinophil percentage of granulocytes;
LIHC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.2	0.32	1.64e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.28e-9	Menopause (age at onset);
LIHC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.24	0.36	3e-12	Self-reported allergy;
LIHC	cis	rs10847980	0.623	rs28681105	chr12:123875525	T/C	cg00376283	chr12:123451042	ABCB9	0.63	6.61	0.34	1.5e-10	Adiponectin levels;
LIHC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.93	0.31	7.23e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.18	-0.44	4.35e-18	Bipolar disorder;
LIHC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg02297831	chr4:17616191	MED28	0.47	6.93	0.35	2.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1419980	0.730	rs11054915	chr12:7777003	G/T	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	trans	rs2710642	0.564	rs60144282	chr2:62843163	G/T	cg23713900	chr18:615496	CLUL1	-0.24	-6.23	-0.32	1.4e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.46	-8.58	-0.42	3.26e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs28595532	0.545	rs17516512	chr4:119258491	T/C	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	cis	rs3213545	0.645	rs2859398	chr12:121479655	T/C	cg02403541	chr12:121454288	C12orf43	0.48	8.0	0.4	1.9e-14	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs9918079	0.560	rs13147590	chr4:15621188	A/G	cg24225360	chr4:15471699	CC2D2A	0.36	5.78	0.3	1.69e-8	Obesity-related traits;
LIHC	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.47	-7.04	-0.36	1.06e-11	Adiposity;
LIHC	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg09795085	chr6:101329169	ASCC3	0.51	7.12	0.36	6.46e-12	Neuroticism;
LIHC	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.49	-9.03	-0.44	1.27e-17	Atrioventricular conduction;
LIHC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.66	12.17	0.55	1.44e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg10932868	chr11:921992	NA	0.38	7.31	0.37	1.87e-12	Alzheimer's disease (late onset);
LIHC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg25344623	chr2:136566232	LCT	-0.37	-5.99	-0.31	5.43e-9	Corneal structure;
LIHC	cis	rs1789	0.839	rs9997068	chr4:15650990	T/C	cg21329975	chr4:15471214	CC2D2A	-0.42	-6.33	-0.32	7.71e-10	Blood protein levels;
LIHC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.3	-0.45	1.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.76	10.35	0.49	5.09e-22	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg11764359	chr7:65958608	NA	0.57	5.99	0.31	5.32e-9	Diabetic kidney disease;
LIHC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.52	-9.14	-0.44	5.5e-18	Total body bone mineral density;
LIHC	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.54	-6.29	-0.32	9.48e-10	IFN-related cytopenia;
LIHC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs2033908	0.620	rs7113256	chr11:12845849	T/C	cg25843174	chr11:12811716	TEAD1	-0.34	-7.55	-0.38	4.02e-13	Sitting height ratio;
LIHC	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.68	-11.25	-0.52	3.46e-25	Eosinophil percentage of white cells;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg23681251	chr19:48202226	GLTSCR1	0.39	6.39	0.33	5.53e-10	Bipolar disorder;
LIHC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.58e-9	Childhood ear infection;
LIHC	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	trans	rs7504990	0.802	rs752870	chr18:50386335	C/T	cg08535148	chr4:26321143	RBPJ	0.52	6.2	0.32	1.61e-9	Gallbladder cancer;
LIHC	cis	rs2737618	0.722	rs2737680	chr1:200088559	C/A	cg21825944	chr1:200113062	NR5A2	-0.49	-8.33	-0.41	2.02e-15	Uric acid levels;
LIHC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.0	15.19	0.63	3.59e-40	Orofacial clefts;
LIHC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.47	6.41	0.33	4.89e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg10792982	chr14:105748885	BRF1	0.44	6.0	0.31	5.16e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.05	0.31	3.74e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg18541006	chr1:21754153	NA	-0.29	-6.7	-0.34	8.55e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.35	0.32	7e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg14067834	chr17:29058358	SUZ12P	0.68	6.7	0.34	8.55e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.38	6.05	0.31	3.88e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.84	-15.72	-0.65	2.73e-42	Height;
LIHC	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.29	-6.77	-0.34	5.62e-11	Hip circumference;Waist circumference;
LIHC	cis	rs903552	0.932	rs2172851	chr15:102012626	C/T	cg25677261	chr15:102009856	PCSK6	-0.48	-6.43	-0.33	4.28e-10	Diabetic kidney disease;
LIHC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg09222892	chr1:25734099	RHCE	-0.46	-8.24	-0.41	3.62e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.7	0.57	1.51e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.39	5.83	0.3	1.27e-8	Height;
LIHC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	8.62	0.42	2.51e-16	Initial pursuit acceleration;
LIHC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.04	21.39	0.76	4.82e-65	IgG glycosylation;
LIHC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.46	-6.49	-0.33	3.1e-10	Kawasaki disease;
LIHC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg02187348	chr16:89574699	SPG7	0.52	7.57	0.38	3.53e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.88	-0.3	9.55e-9	Morning vs. evening chronotype;
LIHC	cis	rs4853036	1.000	rs34587942	chr2:70081501	G/A	cg02498382	chr2:70120550	SNRNP27	-0.37	-5.94	-0.31	6.99e-9	Colorectal or endometrial cancer;
LIHC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.6	0.67	8.6e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.48	7.85	0.39	5.54e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg22153745	chr1:153894579	GATAD2B	-0.41	-6.33	-0.32	7.79e-10	Total cholesterol levels;
LIHC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.4	6.46	0.33	3.7e-10	Response to temozolomide;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11688874	chr10:28822482	WAC	0.44	7.04	0.36	1.04e-11	Cognitive function;
LIHC	cis	rs2637030	0.559	rs256107	chr5:52873776	C/T	cg06476337	chr5:52856530	NDUFS4	0.43	6.79	0.34	5e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	trans	rs6991952	0.702	rs12541705	chr8:25709710	A/C	cg03796024	chr10:3151764	PFKP	0.35	6.21	0.32	1.5e-9	Inguinal hernia;
LIHC	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	7.05	0.36	9.97e-12	Bipolar disorder;
LIHC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg06466757	chr4:1255808	NA	0.34	5.79	0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	1.17	9.75	0.47	5.68e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Colorectal cancer;
LIHC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.78	0.34	5.4e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.29	-17.47	-0.69	2.78e-49	Diabetic kidney disease;
LIHC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	7.23	0.36	3.1e-12	Schizophrenia;
LIHC	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.3	-5.86	-0.3	1.08e-8	Cognitive function;
LIHC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg15448220	chr1:150897856	SETDB1	0.43	6.75	0.34	6.28e-11	Melanoma;
LIHC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.24	0.32	1.3e-9	Schizophrenia;
LIHC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.58	-11.24	-0.52	3.64e-25	Body mass index;
LIHC	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg01864836	chr14:55583639	NA	-0.42	-8.04	-0.4	1.49e-14	Protein biomarker;
LIHC	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.73	-0.3	2.24e-8	Coronary artery disease;
LIHC	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17467752	chr17:38218738	THRA	-0.83	-16.23	-0.66	2.56e-44	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.16	0.55	1.58e-28	Prudent dietary pattern;
LIHC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.73	0.43	1.17e-16	Motion sickness;
LIHC	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-6.51	-0.33	2.63e-10	Schizophrenia;
LIHC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg05527609	chr1:210001259	C1orf107	-0.55	-7.68	-0.38	1.72e-13	Red blood cell count;
LIHC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.64	-0.42	2.27e-16	Heart rate;
LIHC	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-7.13	-0.36	5.88e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	7.75	0.39	1.08e-13	Obesity-related traits;
LIHC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.76	10.76	0.5	1.89e-23	Breast cancer;
LIHC	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-0.79	-11.53	-0.53	3.29e-26	Obesity-related traits;
LIHC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-1.05	-13.0	-0.57	1.17e-31	Dilated cardiomyopathy;
LIHC	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-7.42	-0.37	9.3e-13	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	1.99e-16	Corneal astigmatism;
LIHC	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg07636037	chr3:49044803	WDR6	-0.55	-5.97	-0.31	5.88e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18867708	chr6:26865862	GUSBL1	-0.51	-7.86	-0.39	4.96e-14	Schizophrenia;
LIHC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.41	5.79	0.3	1.57e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01200585	chr1:228362443	C1orf69	-0.39	-5.85	-0.3	1.15e-8	Diastolic blood pressure;
LIHC	cis	rs365132	0.846	rs184784	chr5:176440229	G/T	cg16309518	chr5:176445507	NA	-0.53	-9.89	-0.47	1.88e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs11212260	0.655	rs11212229	chr11:107301248	C/T	cg25435332	chr11:107328525	CWF19L2	0.82	8.3	0.41	2.4e-15	IgG glycosylation;
LIHC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02886208	chr11:14281011	SPON1	0.61	9.02	0.44	1.38e-17	Mitochondrial DNA levels;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06656553	chr16:89960601	TCF25	-0.49	-6.21	-0.32	1.55e-9	Skin colour saturation;
LIHC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.94	-0.31	6.93e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.73	-0.3	2.21e-8	Blood pressure;
LIHC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.43	6.27	0.32	1.08e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.79	9.59	0.46	1.84e-19	Bone mineral density;
LIHC	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg00825309	chr19:58991885	ZNF446	-0.69	-10.71	-0.5	2.72e-23	Uric acid clearance;
LIHC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg07713946	chr22:31675144	LIMK2	0.43	7.8	0.39	7.68e-14	Colorectal cancer;
LIHC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-8.12	-0.4	8.55e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.48	7.06	0.36	9.42e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.31	-6.5	-0.33	2.84e-10	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg25894440	chr7:65020034	NA	-0.53	-6.2	-0.32	1.64e-9	Diabetic kidney disease;
LIHC	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg20435097	chr10:126320824	FAM53B	0.38	6.42	0.33	4.64e-10	Asthma;
LIHC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg25364880	chr3:44379878	C3orf23	0.55	7.58	0.38	3.32e-13	Depressive symptoms;
LIHC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg14440974	chr22:39074834	NA	-0.37	-6.32	-0.32	8.16e-10	Menopause (age at onset);
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs151997	1.000	rs42736	chr5:50244838	G/C	cg06027927	chr5:50259733	NA	0.6	7.94	0.39	2.93e-14	Callous-unemotional behaviour;
LIHC	cis	rs1892700	1.000	rs1892700	chr21:35016137	G/A	cg14850771	chr21:34775459	IFNGR2	-0.44	-5.86	-0.3	1.11e-8	Educational attainment;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg11766577	chr21:47581405	C21orf56	-0.4	-6.25	-0.32	1.2e-9	Testicular germ cell tumor;
LIHC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.42	6.55	0.33	2.17e-10	Lung cancer;
LIHC	trans	rs78049276	0.736	rs77028772	chr4:148364920	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.61	-7.54	-0.38	4.36e-13	Pulse pressure;
LIHC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.5	-0.33	2.76e-10	Resting heart rate;
LIHC	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.47	-6.04	-0.31	3.99e-9	Cutaneous psoriasis;
LIHC	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.69	10.65	0.5	4.73e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.49	-7.24	-0.36	3.06e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.05	0.44	1.13e-17	Platelet count;
LIHC	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg27203090	chr3:33138513	GLB1;TMPPE	-0.56	-6.94	-0.35	2.01e-11	Major depressive disorder;
LIHC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg10932868	chr11:921992	NA	0.35	6.46	0.33	3.55e-10	Alzheimer's disease (late onset);
LIHC	cis	rs9309473	0.950	rs6726694	chr2:73847230	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.47	-0.33	3.46e-10	Metabolite levels;
LIHC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.14	0.68	5.42e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.58	-9.28	-0.45	1.94e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.59	0.56	4.16e-30	Total body bone mineral density;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08493051	chr2:3487164	NA	0.52	6.26	0.32	1.15e-9	Systolic blood pressure;
LIHC	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.81e-10	Obesity-related traits;
LIHC	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg01557791	chr16:72042693	DHODH	-0.53	-7.34	-0.37	1.57e-12	Coronary artery disease;
LIHC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.74	-0.34	6.95e-11	Schizophrenia;
LIHC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08392591	chr16:89556376	ANKRD11	0.52	8.31	0.41	2.27e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.34	22.96	0.78	3.03e-71	Corneal structure;
LIHC	cis	rs7523273	0.505	rs34277355	chr1:207881491	C/A	cg22525895	chr1:207977042	MIR29B2	0.49	7.68	0.38	1.75e-13	Schizophrenia;
LIHC	trans	rs5756813	0.646	rs3788528	chr22:38146433	T/C	cg19894588	chr14:64061835	NA	0.43	6.31	0.32	8.55e-10	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.3	0.32	9.2e-10	Prudent dietary pattern;
LIHC	trans	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.1	-0.36	7.18e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.46	-7.19	-0.36	4.14e-12	Morning vs. evening chronotype;
LIHC	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg12698662	chr3:15914712	MIR563	-0.36	-6.58	-0.34	1.72e-10	Mean platelet volume;
LIHC	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-9.12	-0.44	6.43e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg25801113	chr15:45476975	SHF	0.37	6.24	0.32	1.28e-9	Uric acid levels;
LIHC	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.41	7.27	0.37	2.51e-12	Capecitabine sensitivity;
LIHC	cis	rs1494950	0.661	rs2643084	chr4:14998608	T/C	cg12377275	chr4:15005593	CPEB2	-0.79	-6.68	-0.34	9.6e-11	Political ideology;
LIHC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.08	-0.4	1.11e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.68	10.11	0.48	3.43e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.66	0.34	1.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.01	-0.35	1.27e-11	Height;
LIHC	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.63	-10.04	-0.48	5.66e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7487075	0.619	rs7311504	chr12:46830776	G/A	cg23829395	chr12:46796953	NA	0.34	6.02	0.31	4.6e-9	Itch intensity from mosquito bite;
LIHC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.56	15.15	0.63	5.17e-40	Alzheimer's disease (late onset);
LIHC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.6	8.35	0.41	1.76e-15	Behavioural disinhibition (generation interaction);
LIHC	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.76	11.54	0.53	3.13e-26	Metabolite levels;
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.04	-0.31	4.03e-9	Aortic root size;
LIHC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	8.19	0.4	5.35e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.8	-0.39	7.78e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7635838	0.785	rs2574698	chr3:11557126	G/A	cg00170343	chr3:11313890	ATG7	0.37	5.73	0.3	2.26e-8	HDL cholesterol;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06420487	chr17:61919686	SMARCD2	0.42	5.76	0.3	1.88e-8	Height;
LIHC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.03e-20	Schizophrenia;
LIHC	trans	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg09045935	chr12:6379348	NA	0.93	7.65	0.38	2.07e-13	Blood metabolite levels;
LIHC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.58	6.2	0.32	1.65e-9	Neutrophil percentage of white cells;
LIHC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.53	-6.44	-0.33	4.07e-10	Menarche (age at onset);
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.0	-0.31	5.01e-9	Diastolic blood pressure;
LIHC	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-8.24	-0.41	3.73e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7546668	1.000	rs6695562	chr1:15842842	C/T	cg11706911	chr1:15910989	AGMAT	0.45	6.96	0.35	1.7e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs56146971	0.703	rs76533089	chr14:91863973	G/T	cg16433844	chr14:91963127	SMEK1	-0.51	-5.84	-0.3	1.19e-8	Alzheimer disease and age of onset;
LIHC	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.51	6.29	0.32	9.43e-10	Menarche (age at onset);
LIHC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.72	-9.14	-0.44	5.77e-18	Gut microbiome composition (summer);
LIHC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.75	12.01	0.54	5.98e-28	Night sleep phenotypes;
LIHC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.52	-8.77	-0.43	8.8e-17	Lung cancer;
LIHC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-0.85	-9.45	-0.45	5.58e-19	Schizophrenia;
LIHC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.86	-0.39	4.92e-14	Response to antipsychotic treatment;
LIHC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.58	11.15	0.52	7.7e-25	Coronary artery disease;
LIHC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.53	-0.42	4.97e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.34	5.87	0.3	1.05e-8	IgG glycosylation;
LIHC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.69	-9.29	-0.45	1.84e-18	Calcium levels;
LIHC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.25	-0.48	1.1e-21	Hemoglobin concentration;
LIHC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.46	-7.19	-0.36	4.15e-12	Alcohol dependence;
LIHC	cis	rs16828019	0.704	rs34486565	chr1:41522510	C/T	cg03962019	chr1:41807865	NA	0.49	7.06	0.36	9.32e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.66	0.46	1.12e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs15676	0.679	rs6478853	chr9:131588813	C/G	cg00228799	chr9:131580591	ENDOG	-0.47	-6.91	-0.35	2.39e-11	Blood metabolite levels;
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg19635926	chr16:89946313	TCF25	0.54	7.2	0.36	3.9e-12	Skin colour saturation;
LIHC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-9.5	-0.46	3.87e-19	Schizophrenia;
LIHC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg12863693	chr15:85201151	NMB	0.47	6.84	0.35	3.73e-11	Schizophrenia;
LIHC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.56	-8.61	-0.42	2.68e-16	Blood trace element (Zn levels);
LIHC	cis	rs11673344	0.583	rs7254411	chr19:37525871	G/A	cg27390819	chr19:37464633	NA	-0.44	-5.82	-0.3	1.33e-8	Obesity-related traits;
LIHC	cis	rs9596863	0.898	rs6561746	chr13:54358368	T/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.82	0.3	1.38e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg14709524	chr16:89940631	TCF25	0.59	7.7	0.38	1.47e-13	Skin colour saturation;
LIHC	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg12698662	chr3:15914712	MIR563	-0.36	-6.57	-0.33	1.93e-10	Mean platelet volume;
LIHC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.91	16.9	0.67	5.17e-47	Aortic root size;
LIHC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-8.03	-0.4	1.61e-14	Putamen volume;
LIHC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs10186029	0.676	rs4673720	chr2:213941581	G/A	cg08319019	chr2:214017104	IKZF2	0.41	5.8	0.3	1.49e-8	Systemic sclerosis;
LIHC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.71	0.38	1.41e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.3	0.32	9.39e-10	Tonsillectomy;
LIHC	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.62	-10.32	-0.49	6.68e-22	Breast cancer;
LIHC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.54	7.24	0.36	3.06e-12	Pancreatic cancer;
LIHC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg16070018	chr6:26224392	HIST1H3E	0.55	6.77	0.34	5.69e-11	Gout;Renal underexcretion gout;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01334186	chr1:151372572	PSMB4	0.43	6.68	0.34	9.83e-11	Pancreatic cancer;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg05863534	chr17:34948351	DHRS11	-0.42	-6.4	-0.33	5.07e-10	Alopecia areata;
LIHC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.36	0.45	1.13e-18	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg18306943	chr3:40428807	ENTPD3	0.33	5.72	0.3	2.35e-8	Renal cell carcinoma;
LIHC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg19682013	chr15:45996608	NA	0.39	6.63	0.34	1.29e-10	Waist circumference;Weight;
LIHC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg01320579	chr17:75405842	SEPT9	0.5	7.16	0.36	5e-12	Airflow obstruction;
LIHC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg12798992	chr6:167411361	FGFR1OP	-0.47	-7.37	-0.37	1.28e-12	Crohn's disease;
LIHC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg15832292	chr6:96025679	MANEA	0.61	7.72	0.39	1.27e-13	Behavioural disinhibition (generation interaction);
LIHC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.36	-6.13	-0.31	2.48e-9	IgG glycosylation;
LIHC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	10.5	0.49	1.53e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg05926928	chr17:57297772	GDPD1	-0.48	-6.44	-0.33	3.95e-10	Opioid sensitivity;
LIHC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-7.78	-0.39	8.89e-14	Psoriasis;
LIHC	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	6.79	0.34	4.83e-11	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.43	6.49	0.33	2.93e-10	Heart rate;
LIHC	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.21	-0.52	4.62e-25	Response to antipsychotic treatment;
LIHC	cis	rs1355223	0.902	rs286858	chr11:34717357	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.45	6.29	0.32	9.77e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.89	-14.58	-0.62	8.39e-38	Longevity;
LIHC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01200585	chr1:228362443	C1orf69	-0.39	-5.83	-0.3	1.3e-8	Diastolic blood pressure;
LIHC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.46	-0.37	7.05e-13	Initial pursuit acceleration;
LIHC	cis	rs36051895	0.732	rs7046736	chr9:5015732	C/A	cg02405213	chr9:5042618	JAK2	-0.64	-11.12	-0.52	9.66e-25	Pediatric autoimmune diseases;
LIHC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02228675	chr17:40259724	DHX58	0.24	5.71	0.3	2.4e-8	Fibrinogen levels;
LIHC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.29	-0.45	1.8e-18	Type 2 diabetes;
LIHC	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.51	-8.49	-0.42	6.52e-16	Pubertal anthropometrics;
LIHC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.66	9.15	0.44	5.17e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05347473	chr6:146136440	FBXO30	-0.35	-5.88	-0.3	9.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	cis	rs74233809	1.000	rs10883808	chr10:104721126	A/T	cg03493300	chr10:104813866	CNNM2	0.45	5.95	0.31	6.73e-9	Birth weight;
LIHC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.4	5.73	0.3	2.24e-8	Menarche (age at onset);
LIHC	cis	rs15676	0.947	rs7854319	chr9:131567995	G/A	cg00228799	chr9:131580591	ENDOG	-0.45	-6.78	-0.34	5.33e-11	Blood metabolite levels;
LIHC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.65	-0.38	2.08e-13	Chronic sinus infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11339840	chr1:203596058	ATP2B4	0.39	6.29	0.32	9.69e-10	Cognitive function;
LIHC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg21734168	chr11:67353974	GSTP1	-0.28	-6.79	-0.34	4.99e-11	Mean corpuscular volume;
LIHC	cis	rs75908454	1.000	rs2865094	chr6:169919616	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.45	-0.37	7.84e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.7	10.21	0.48	1.57e-21	Coronary artery disease;
LIHC	cis	rs75908454	1.000	rs78797236	chr6:169820344	G/A	cg19338460	chr6:170058176	WDR27	-0.86	-7.47	-0.37	6.6e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.77	-0.47	4.92e-20	Total cholesterol levels;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg14257396	chr1:107603778	NA	-0.38	-6.34	-0.32	7.32e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs876084	0.505	rs4407921	chr8:121156585	C/T	cg06265175	chr8:121136014	COL14A1	0.43	6.88	0.35	2.9e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.53	-5.93	-0.31	7.57e-9	Ulcerative colitis;
LIHC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.82	-8.76	-0.43	9.32e-17	Vitiligo;
LIHC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.54	-6.49	-0.33	2.97e-10	Blood metabolite levels;
LIHC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.95	0.35	1.82e-11	Height;
LIHC	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg01843034	chr6:37503916	NA	-0.48	-8.24	-0.41	3.59e-15	Cognitive performance;
LIHC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs332507	0.830	rs13097438	chr3:124429848	T/C	cg05980111	chr3:124395277	KALRN	0.41	6.19	0.32	1.71e-9	Plateletcrit;
LIHC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-5.98	-0.31	5.75e-9	Aortic root size;
LIHC	trans	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg03941975	chr13:19919758	LOC100101938	-0.24	-6.08	-0.31	3.3e-9	Urinary tract infection frequency;
LIHC	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.27	6.35	0.32	6.99e-10	Heart rate;
LIHC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.82	9.64	0.46	1.29e-19	Iron status biomarkers;
LIHC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg22842854	chr12:123319900	HIP1R	0.65	8.57	0.42	3.5e-16	Schizophrenia;
LIHC	cis	rs1008375	0.897	rs4334752	chr4:17615430	C/T	cg02297831	chr4:17616191	MED28	0.49	7.4	0.37	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg19645103	chr12:69753606	YEATS4	-0.44	-5.96	-0.31	6.44e-9	Response to diuretic therapy;
LIHC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.28	-0.32	1.01e-9	Schizophrenia;
LIHC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.65	10.92	0.51	5.18e-24	Psoriasis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01836096	chr8:145578603	C8ORFK29	0.42	6.15	0.32	2.11e-9	Longevity;
LIHC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg00792783	chr2:198669748	PLCL1	0.45	6.5	0.33	2.9e-10	Intracranial aneurysm;
LIHC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg15605315	chr1:45957053	TESK2	-0.44	-5.76	-0.3	1.84e-8	Platelet count;
LIHC	trans	rs6489882	0.902	rs7966314	chr12:113372539	C/T	cg10175203	chr3:128143634	NA	-0.38	-6.19	-0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.46	6.22	0.32	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-7.52	-0.38	4.84e-13	Lymphocyte counts;
LIHC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-9.66	-0.46	1.07e-19	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.77	-11.48	-0.53	4.99e-26	Height;
LIHC	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26734620	chr12:56694298	CS	1.28	10.93	0.51	4.77e-24	Psoriasis vulgaris;
LIHC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.63	8.63	0.42	2.38e-16	Vitamin D levels;
LIHC	cis	rs243505	0.660	rs243487	chr7:148448211	G/A	cg09806900	chr7:148480153	CUL1	-0.43	-6.01	-0.31	4.89e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	8.3	0.41	2.45e-15	Eotaxin levels;
LIHC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.89	-0.3	9.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.85	-12.92	-0.57	2.19e-31	Obesity-related traits;
LIHC	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.45	-9.04	-0.44	1.21e-17	Plateletcrit;Platelet count;
LIHC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	8.17	0.4	6.09e-15	Type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12887701	chr11:96123196	JRKL;CCDC82	0.45	6.33	0.32	7.66e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.44	6.96	0.35	1.79e-11	Cognitive function;
LIHC	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg10820045	chr2:198174542	NA	-0.46	-7.25	-0.36	2.85e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg01843034	chr6:37503916	NA	-0.37	-6.07	-0.31	3.49e-9	Cognitive performance;
LIHC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.17	0.32	1.96e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg04310649	chr10:35416472	CREM	-0.42	-5.71	-0.3	2.45e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg00091569	chr3:40428383	ENTPD3	0.38	6.51	0.33	2.63e-10	Renal cell carcinoma;
LIHC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.07	18.56	0.71	1.07e-53	Testicular germ cell tumor;
LIHC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.7	0.34	8.75e-11	Hemoglobin concentration;
LIHC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.89e-30	Menopause (age at onset);
LIHC	cis	rs4788570	0.584	rs4788548	chr16:71655361	A/G	cg06353428	chr16:71660113	MARVELD3	1.01	10.93	0.51	4.65e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg01843034	chr6:37503916	NA	-0.47	-7.94	-0.39	2.86e-14	Cognitive performance;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07120806	chr4:1873451	WHSC1	0.45	6.17	0.32	1.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.76	0.43	9.26e-17	Cognitive ability;
LIHC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.72	0.47	7.13e-20	Tonsillectomy;
LIHC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.55	7.44	0.37	8.16e-13	Ulcerative colitis;
LIHC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.69	11.33	0.52	1.78e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9888615	0.646	rs3825593	chr14:53386237	C/G	cg00686598	chr14:53173677	PSMC6	-0.46	-6.12	-0.31	2.51e-9	Systolic blood pressure;
LIHC	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.84	-0.3	1.21e-8	Biliary atresia;
LIHC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg22676075	chr6:135203613	NA	0.4	6.51	0.33	2.73e-10	Red blood cell count;
LIHC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.82	0.51	1.15e-23	Colorectal cancer;
LIHC	cis	rs965469	0.857	rs6037523	chr20:3249463	A/T	cg25506879	chr20:3388711	C20orf194	-0.56	-6.86	-0.35	3.2e-11	IFN-related cytopenia;
LIHC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	trans	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg10756647	chr7:56101905	PSPH	-0.47	-7.03	-0.36	1.14e-11	Aortic root size;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.46	-6.42	-0.33	4.65e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.72	-0.39	1.32e-13	Platelet count;
LIHC	cis	rs62380364	0.626	rs11749912	chr5:88065628	A/G	cg22951263	chr5:87985283	NA	-0.42	-7.05	-0.36	9.96e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18128437	chr3:167453397	PDCD10;SERPINI1	0.47	6.38	0.33	5.84e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.45	6.7	0.34	8.53e-11	Blood protein levels;
LIHC	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.02	20.1	0.74	7.18e-60	Platelet distribution width;
LIHC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg13271783	chr10:134563150	INPP5A	-0.61	-7.26	-0.37	2.56e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.38	-0.56	2.36e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1865721	1.000	rs62089511	chr18:73197629	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.16e-13	Intelligence;
LIHC	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.6	-6.19	-0.32	1.77e-9	Multiple sclerosis;
LIHC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.71	0.38	1.43e-13	Bipolar disorder;
LIHC	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-10.56	-0.5	9.69e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg08135965	chr6:41755394	TOMM6	0.44	5.72	0.3	2.34e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.77	9.2	0.45	3.66e-18	Morning vs. evening chronotype;
LIHC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg06634786	chr22:41940651	POLR3H	-0.53	-6.26	-0.32	1.17e-9	Vitiligo;
LIHC	cis	rs9918079	0.560	rs10008975	chr4:15624571	C/T	cg21123203	chr4:15471301	CC2D2A	-0.45	-7.23	-0.36	3.12e-12	Obesity-related traits;
LIHC	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.46e-25	Eye color traits;
LIHC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05771511	chr15:63340396	TPM1	-0.47	-6.96	-0.35	1.73e-11	Platelet count;
LIHC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg07382826	chr16:28625726	SULT1A1	0.52	7.84	0.39	5.68e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.29	21.48	0.76	2.15e-65	Corneal structure;
LIHC	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.3	7.05	0.36	1.01e-11	Blood protein levels;
LIHC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.59	6.99	0.35	1.44e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.36	0.45	1.1e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.66	11.86	0.54	2.12e-27	Breast cancer;
LIHC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.36	5.95	0.31	6.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.01	-0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.41	-6.26	-0.32	1.16e-9	Lung cancer;
LIHC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.56	-11.21	-0.52	4.69e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg23461800	chr14:103021989	NA	-0.45	-6.12	-0.31	2.63e-9	Platelet count;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.3	-0.32	9.26e-10	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03562264	chr6:36646551	CDKN1A	0.54	6.76	0.34	5.89e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6466055	0.637	rs1144	chr7:104756355	T/C	cg04380332	chr7:105027541	SRPK2	-0.33	-6.29	-0.32	9.69e-10	Schizophrenia;
LIHC	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-8.0	-0.4	1.94e-14	Morning vs. evening chronotype;
LIHC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg10790698	chr19:18539756	SSBP4	0.32	6.8	0.34	4.78e-11	Breast cancer;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.44	7.91	0.39	3.7e-14	Prudent dietary pattern;
LIHC	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg08847533	chr14:75593920	NEK9	0.48	7.42	0.37	9.52e-13	IgG glycosylation;
LIHC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.25	-5.89	-0.3	9.48e-9	Subjective well-being;
LIHC	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg07636037	chr3:49044803	WDR6	-0.53	-5.87	-0.3	1.03e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4561483	0.798	rs456325	chr16:12012562	C/G	cg08843971	chr16:11963173	GSPT1	-0.35	-7.08	-0.36	8.15e-12	Testicular germ cell tumor;
LIHC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.52	7.63	0.38	2.37e-13	Initial pursuit acceleration;
LIHC	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.5	9.63	0.46	1.4e-19	Testicular germ cell tumor;
LIHC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.55	9.49	0.46	3.99e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.73	-0.34	7.2e-11	Arsenic metabolism;
LIHC	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.49	-0.59	1.51e-33	Coffee consumption (cups per day);
LIHC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.17	-0.32	1.9e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7945718	0.650	rs10831889	chr11:12665834	A/T	cg25843174	chr11:12811716	TEAD1	0.34	7.69	0.38	1.55e-13	Educational attainment (years of education);
LIHC	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.25	0.52	3.45e-25	Coronary artery disease;
LIHC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.51	8.81	0.43	6.36e-17	Alcohol dependence;
LIHC	cis	rs6594499	0.872	rs6880351	chr5:110451664	C/G	cg04022379	chr5:110408740	TSLP	0.49	8.2	0.41	4.92e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-7.94	-0.39	2.88e-14	Educational attainment (years of education);
LIHC	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.48	-7.95	-0.4	2.67e-14	Cognitive function;
LIHC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	8.77	0.43	8.72e-17	IgG glycosylation;
LIHC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.33	-6.11	-0.31	2.75e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs16828019	0.852	rs71648535	chr1:41613750	G/A	cg03387723	chr1:41708464	SCMH1	-0.45	-7.22	-0.36	3.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-7.48	-0.38	6.14e-13	Migraine;Coronary artery disease;
LIHC	trans	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.37	0.33	5.97e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.23	-6.13	-0.31	2.41e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.42	5.87	0.3	1.04e-8	Blood protein levels;
LIHC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-8.1	-0.4	9.94e-15	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.58	-8.94	-0.44	2.42e-17	Renal cell carcinoma;
LIHC	cis	rs7897654	0.571	rs12765002	chr10:104635348	C/T	cg15744005	chr10:104629667	AS3MT	-0.37	-7.53	-0.38	4.5e-13	Schizophrenia;
LIHC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13409248	chr3:40428643	ENTPD3	0.49	8.3	0.41	2.48e-15	Renal cell carcinoma;
LIHC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg04756594	chr16:24857601	SLC5A11	0.47	7.32	0.37	1.8e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg06060754	chr5:176797920	RGS14	0.61	7.74	0.39	1.16e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.35	5.89	0.3	9.24e-9	Systemic lupus erythematosus;
LIHC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.94	0.44	2.5e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.52	8.5	0.42	5.78e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25671651	chr2:203776787	ALS2CR8;WDR12	0.43	6.64	0.34	1.22e-10	Cognitive function;
LIHC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.07	20.73	0.75	2.12e-62	IgG glycosylation;
LIHC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg01864069	chr14:103024347	NA	-0.46	-7.26	-0.37	2.66e-12	Platelet count;
LIHC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.08	0.66	9.77e-44	Breast cancer;
LIHC	cis	rs11630290	0.592	rs1039817	chr15:64155367	T/A	cg12036633	chr15:63758958	NA	0.63	6.75	0.34	6.36e-11	Iris characteristics;
LIHC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg16684958	chr7:75615977	POR	-0.5	-8.27	-0.41	2.91e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.63	11.08	0.51	1.34e-24	Platelet distribution width;
LIHC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.56	-8.58	-0.42	3.32e-16	Platelet distribution width;
LIHC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.82e-31	Blood metabolite levels;
LIHC	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg22951263	chr5:87985283	NA	0.4	7.09	0.36	7.67e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.53	-8.3	-0.41	2.51e-15	Blood pressure (smoking interaction);
LIHC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.89	0.35	2.64e-11	Axial length;
LIHC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.69	-6.72	-0.34	7.78e-11	Multiple sclerosis;
LIHC	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.6	9.04	0.44	1.22e-17	Menopause (age at onset);
LIHC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.92	11.62	0.53	1.58e-26	Coronary artery disease;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.72	-11.13	-0.52	8.93e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4478037	0.822	rs3924695	chr3:33122085	C/T	cg16652328	chr3:33138982	GLB1;TMPPE	-0.52	-6.79	-0.34	4.93e-11	Major depressive disorder;
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11060661	chr22:24314208	DDT;DDTL	0.61	10.43	0.49	2.79e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.22	15.86	0.65	7.79e-43	Alzheimer's disease (late onset);
LIHC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.61	0.5	6.33e-23	Colorectal cancer;
LIHC	cis	rs10792665	0.606	rs7131210	chr11:82609340	A/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.39	-0.33	5.53e-10	Obesity-related traits;
LIHC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg14440974	chr22:39074834	NA	0.44	7.04	0.36	1.07e-11	Menopause (age at onset);
LIHC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg15848620	chr12:58087721	OS9	-0.55	-7.43	-0.37	8.96e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	9.0	0.44	1.63e-17	Body mass index (adult);
LIHC	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.62	11.56	0.53	2.66e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.84	0.43	5.15e-17	Motion sickness;
LIHC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.48	6.52	0.33	2.49e-10	Arsenic metabolism;
LIHC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.73	0.43	1.12e-16	Lung cancer in ever smokers;
LIHC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.05	0.51	1.82e-24	Coronary artery disease;
LIHC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.51	-9.46	-0.46	5.27e-19	Colorectal cancer;
LIHC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg01444801	chr10:135216882	MTG1	-0.65	-9.78	-0.47	4.59e-20	Systemic lupus erythematosus;
LIHC	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.46	-6.42	-0.33	4.46e-10	Schizophrenia;
LIHC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.34	6.6	0.34	1.56e-10	Multiple system atrophy;
LIHC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.67	8.4	0.41	1.19e-15	Gut microbiome composition (summer);
LIHC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.72	-0.3	2.34e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.71	-0.34	7.98e-11	Psoriasis;
LIHC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.77	12.85	0.57	4.21e-31	Oral cavity cancer;
LIHC	cis	rs7945718	0.621	rs10831890	chr11:12671211	A/G	cg25843174	chr11:12811716	TEAD1	0.33	7.64	0.38	2.21e-13	Educational attainment (years of education);
LIHC	cis	rs75908454	1.000	rs75490272	chr6:169900464	C/T	cg19338460	chr6:170058176	WDR27	-0.75	-6.8	-0.35	4.69e-11	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.88	12.74	0.57	1.06e-30	Diastolic blood pressure;
LIHC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.71	-8.73	-0.43	1.13e-16	Gut microbiome composition (summer);
LIHC	cis	rs2845885	0.744	rs2701540	chr11:63869107	T/A	cg05555928	chr11:63887634	MACROD1	0.48	6.26	0.32	1.17e-9	Body mass index;
LIHC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.33	6.05	0.31	3.83e-9	Aortic root size;
LIHC	cis	rs74233809	1.000	rs10883832	chr10:104871279	T/G	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg12698662	chr3:15914712	MIR563	-0.35	-6.53	-0.33	2.33e-10	Mean platelet volume;
LIHC	trans	rs259842	0.800	rs6725456	chr2:180718419	C/T	cg00945735	chr7:41982767	NA	0.39	6.05	0.31	3.89e-9	Blood protein levels;
LIHC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg26692224	chr17:62915920	LRRC37A3	0.68	6.44	0.33	4.06e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	13.94	0.6	2.65e-35	Primary sclerosing cholangitis;
LIHC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.78	0.5	1.65e-23	Personality dimensions;
LIHC	cis	rs7523273	0.565	rs11118453	chr1:207887996	A/C	cg22525895	chr1:207977042	MIR29B2	0.53	7.91	0.39	3.54e-14	Schizophrenia;
LIHC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.44	6.27	0.32	1.06e-9	Asthma;
LIHC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg16586182	chr3:47516702	SCAP	-0.46	-8.05	-0.4	1.39e-14	Colorectal cancer;
LIHC	trans	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	6.39	0.33	5.39e-10	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.86	-0.65	7.39e-43	Height;
LIHC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-6.65	-0.34	1.17e-10	Schizophrenia;
LIHC	cis	rs1030268	1.000	rs1030268	chr7:133606631	C/T	cg03336402	chr7:133662267	EXOC4	0.5	6.85	0.35	3.44e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.41	-6.23	-0.32	1.37e-9	Multiple myeloma;
LIHC	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.64	-0.59	4.14e-34	Coffee consumption (cups per day);
LIHC	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.87	-0.51	7.86e-24	Eye color traits;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg02209998	chr8:649235	ERICH1	0.62	6.28	0.32	1e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.25	5.84	0.3	1.24e-8	Crohn's disease;
LIHC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.62	9.47	0.46	4.67e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.45	7.17	0.36	4.62e-12	Lipoprotein (a) levels;
LIHC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg18944383	chr4:111397179	ENPEP	0.25	6.08	0.31	3.24e-9	Coronary artery disease;
LIHC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg14092571	chr14:90743983	NA	-0.38	-5.96	-0.31	6.43e-9	Mortality in heart failure;
LIHC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.57	6.48	0.33	3.26e-10	Body mass index;
LIHC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.97	17.95	0.7	3.2e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.71	-12.24	-0.55	8.01e-29	Refractive error;
LIHC	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.76	-0.34	5.93e-11	Endometrial cancer;
LIHC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.42	6.05	0.31	3.82e-9	Breast cancer;
LIHC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00829944	chr11:64052608	BAD;GPR137	-0.46	-6.44	-0.33	4.1e-10	Parental extreme longevity (95 years and older);
LIHC	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg08126542	chr6:37504118	NA	-0.36	-5.92	-0.3	7.8e-9	Cognitive performance;
LIHC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.35	0.32	6.89e-10	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.69e-19	Waist circumference;Weight;
LIHC	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.47	-0.49	1.92e-22	Rheumatoid arthritis;
LIHC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg03934865	chr2:198174659	NA	0.54	8.56	0.42	3.8e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02985541	chr2:219472218	PLCD4	0.45	8.65	0.42	2.09e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.99	21.57	0.76	9.43e-66	Bone mineral density;
LIHC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.09	-0.36	7.72e-12	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.61	0.53	1.66e-26	Motion sickness;
LIHC	cis	rs10847980	0.590	rs12319654	chr12:123327160	C/T	cg07706471	chr12:123319906	HIP1R	0.77	8.68	0.42	1.66e-16	Adiponectin levels;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.98	0.35	1.54e-11	Renal cell carcinoma;
LIHC	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.6	8.49	0.42	6.23e-16	Neuroticism;
LIHC	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg19680672	chr10:131412579	MGMT	-0.39	-5.91	-0.3	8.15e-9	Response to temozolomide;
LIHC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.85	-0.3	1.14e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.8	-0.39	7.43e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.46	6.88	0.35	2.83e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg01364799	chr7:75623366	TMEM120A	0.52	7.83	0.39	6.35e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7116495	0.737	rs7102192	chr11:71648169	G/A	cg26138937	chr11:71823887	C11orf51	-0.74	-7.36	-0.37	1.42e-12	Severe influenza A (H1N1) infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05677249	chr15:77158041	SCAPER	0.33	6.05	0.31	3.9e-9	Pancreatic cancer;
LIHC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg04998671	chr14:104000505	TRMT61A	-0.44	-6.12	-0.31	2.55e-9	Coronary artery disease;
LIHC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.28e-34	Aortic root size;
LIHC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	10.52	0.49	1.32e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05234169	chr12:82752252	CCDC59;C12orf26	0.49	6.6	0.34	1.53e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.6	10.73	0.5	2.44e-23	Breast cancer;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-7.17	-0.36	4.76e-12	Chronic sinus infection;
LIHC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg21466736	chr12:48725269	NA	-0.71	-10.89	-0.51	6.64e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg06466757	chr4:1255808	NA	-0.34	-5.78	-0.3	1.7e-8	Obesity-related traits;
LIHC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.85	-16.46	-0.66	3.16e-45	Coronary artery disease;
LIHC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	0.98	13.8	0.6	9.83e-35	Cognitive function;
LIHC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.67	8.4	0.41	1.19e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.15	0.48	2.49e-21	Crohn's disease;
LIHC	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.43	7.76	0.39	9.65e-14	Monocyte percentage of white cells;
LIHC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.64	-10.54	-0.5	1.15e-22	Total body bone mineral density;
LIHC	cis	rs1914816	1.000	rs1914816	chr15:76546933	G/A	cg03037974	chr15:76606532	NA	-0.58	-5.91	-0.3	8.35e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs847649	1.000	rs847648	chr7:102553850	C/T	cg18108683	chr7:102477205	FBXL13	-0.49	-7.36	-0.37	1.38e-12	Morning vs. evening chronotype;
LIHC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg15123519	chr2:136567270	LCT	0.39	7.42	0.37	9.66e-13	Mosquito bite size;
LIHC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.75e-12	Waist circumference;Weight;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08219700	chr8:58056026	NA	0.53	7.27	0.37	2.4e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.46	8.84	0.43	5.1e-17	Testicular germ cell tumor;
LIHC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.6	0.53	1.92e-26	Platelet count;
LIHC	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg21877656	chr19:58662188	ZNF329	1.07	8.51	0.42	5.37e-16	Cholesterol, total;
LIHC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.77	11.88	0.54	1.76e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8084351	0.512	rs7229129	chr18:50804372	C/T	cg24270629	chr18:50823537	DCC	-0.49	-7.38	-0.37	1.24e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.32	7.32	0.37	1.75e-12	Blood metabolite ratios;
LIHC	cis	rs8016982	0.662	rs9806020	chr14:81668555	A/C	cg01989461	chr14:81687754	GTF2A1	0.51	8.85	0.43	4.71e-17	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.38	6.13	0.31	2.43e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.67	-0.34	1.05e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.75	-11.22	-0.52	4.47e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-14.49	-0.62	2.01e-37	Alzheimer's disease (late onset);
LIHC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	1.03	11.15	0.52	7.78e-25	Triglycerides;
LIHC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.86	-0.3	1.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06634786	chr22:41940651	POLR3H	0.56	6.08	0.31	3.22e-9	Vitiligo;
LIHC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.99	-0.31	5.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg17385448	chr1:15911702	AGMAT	0.4	6.63	0.34	1.34e-10	Systolic blood pressure;
LIHC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.6	6.94	0.35	1.98e-11	Menarche (age at onset);
LIHC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.17	0.32	1.88e-9	Menopause (age at onset);
LIHC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.33	0.32	7.65e-10	Height;
LIHC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.6	-0.56	3.74e-30	Alzheimer's disease;
LIHC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.57	8.5	0.42	5.79e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6450176	0.587	rs10471884	chr5:53344135	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.2	-0.58	1.94e-32	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.31	-6.77	-0.34	5.61e-11	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06793798	chr10:62538126	CDK1;CDC2	0.46	6.22	0.32	1.47e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	0.84	13.52	0.59	1.11e-33	Left atrial antero-posterior diameter;
LIHC	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg18898632	chr2:242989856	NA	-0.48	-6.83	-0.35	3.89e-11	Obesity-related traits;
LIHC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21467203	chr3:49911342	NA	-0.44	-7.85	-0.39	5.53e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22122414	chr8:53627067	RB1CC1	0.42	6.25	0.32	1.24e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.09	-0.36	7.61e-12	Response to bleomycin (chromatid breaks);
LIHC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.12	-0.36	6.23e-12	Blood metabolite levels;
LIHC	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg00601450	chr5:74908170	NA	0.59	7.12	0.36	6.53e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.37	0.45	1e-18	Bipolar disorder;
LIHC	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg15123519	chr2:136567270	LCT	-0.33	-5.73	-0.3	2.25e-8	Corneal structure;
LIHC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.02	0.51	2.22e-24	Coronary artery disease;
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.7	10.23	0.48	1.34e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.53	9.08	0.44	9.01e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.44	7.6	0.38	2.95e-13	Schizophrenia;
LIHC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.6	-10.68	-0.5	3.73e-23	Colorectal cancer;
LIHC	cis	rs17106184	1.000	rs72898910	chr1:50908098	C/G	cg07174182	chr1:51127561	FAF1	-0.54	-6.13	-0.31	2.46e-9	Type 2 diabetes;
LIHC	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.68	13.26	0.58	1.13e-32	High light scatter reticulocyte count;
LIHC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.04	0.31	4.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-0.75	-6.16	-0.32	2.05e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.6	-7.97	-0.4	2.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.48	6.93	0.35	2.1e-11	Dermatomyositis;
LIHC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.57	-9.52	-0.46	3.13e-19	Cognitive function;
LIHC	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.48	8.04	0.4	1.5e-14	Schizophrenia;
LIHC	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.95	-0.35	1.83e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.4	8.66	0.42	1.96e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.75	11.33	0.52	1.75e-25	Subjective well-being;
LIHC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.53	-11.18	-0.52	6.31e-25	Urate levels;
LIHC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-6.1	-0.31	2.85e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.78	-0.54	4.01e-27	Coffee consumption (cups per day);
LIHC	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg23091122	chr1:110024289	SYPL2	-0.48	-6.42	-0.33	4.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.41	-6.93	-0.35	2.07e-11	Monocyte count;
LIHC	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg02811702	chr13:24901961	NA	0.25	6.31	0.32	8.75e-10	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10459717	chr5:6633577	NSUN2;SRD5A1	0.46	6.27	0.32	1.07e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.4	-0.45	8.3e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.24	0.45	2.71e-18	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg07424592	chr7:64974309	NA	0.8	9.21	0.45	3.38e-18	Diabetic kidney disease;
LIHC	cis	rs17286411	0.777	rs4788569	chr16:71914785	A/G	cg03805757	chr16:71968109	PKD1L3	0.41	5.85	0.3	1.13e-8	Blood protein levels;
LIHC	trans	rs2579103	0.767	rs1371084	chr12:90667767	A/G	cg00091569	chr3:40428383	ENTPD3	0.39	6.17	0.32	1.88e-9	Body mass index;
LIHC	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.91	0.43	3.16e-17	Exhaled nitric oxide output;
LIHC	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg22705602	chr4:152727874	NA	0.32	6.65	0.34	1.18e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.6	8.66	0.42	1.9e-16	Platelet distribution width;
LIHC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.57	11.03	0.51	2.04e-24	Coronary artery disease;
LIHC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg21466736	chr12:48725269	NA	0.57	8.99	0.44	1.7e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg03959625	chr15:84868606	LOC388152	0.43	5.9	0.3	8.58e-9	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.73	12.71	0.57	1.42e-30	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.41	6.6	0.34	1.6e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.52	9.17	0.44	4.63e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.77	-11.72	-0.54	6.88e-27	Cognitive ability;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.18	-0.58	2.36e-32	Bipolar disorder and schizophrenia;
LIHC	cis	rs4919087	0.590	rs61569149	chr10:99073879	A/G	cg25902810	chr10:99078978	FRAT1	-0.6	-7.23	-0.36	3.16e-12	Monocyte count;
LIHC	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.61	8.57	0.42	3.66e-16	Response to bleomycin (chromatid breaks);
LIHC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.16	-0.36	5.12e-12	Reticulocyte count;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg03571225	chr17:54991993	TRIM25	-0.42	-6.05	-0.31	3.81e-9	Electroencephalogram traits;
LIHC	cis	rs9628987	0.500	rs11580417	chr1:8430224	G/A	cg20416874	chr1:8611966	RERE	0.51	5.91	0.3	8.29e-9	Breast cancer;
LIHC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg01256987	chr12:42539512	GXYLT1	-0.43	-7.17	-0.36	4.53e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.68	10.37	0.49	4.43e-22	Longevity;
LIHC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.85	10.18	0.48	1.99e-21	Cognitive function;
LIHC	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg20636351	chr8:55087400	NA	-0.41	-8.26	-0.41	3.14e-15	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg25344623	chr2:136566232	LCT	-0.34	-5.99	-0.31	5.25e-9	Corneal structure;
LIHC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.53	7.64	0.38	2.19e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs4878497	0.646	rs2068116	chr9:32435978	C/T	cg14296220	chr9:32431791	ACO1	0.58	10.05	0.48	5.58e-21	Inflammatory skin disease;
LIHC	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg17724175	chr1:150552817	MCL1	0.42	8.19	0.41	5.08e-15	Melanoma;
LIHC	cis	rs9816226	0.938	rs73052046	chr3:185832414	C/T	cg00760338	chr3:185826511	ETV5	-0.7	-6.18	-0.32	1.81e-9	Obesity;Body mass index;
LIHC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.31	8.06	0.4	1.26e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.6	-10.04	-0.48	5.85e-21	Schizophrenia;
LIHC	cis	rs965469	0.947	rs1854834	chr20:3376619	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.81	-0.35	4.48e-11	IFN-related cytopenia;
LIHC	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.31	-6.07	-0.31	3.48e-9	Testicular germ cell tumor;
LIHC	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg07706471	chr12:123319906	HIP1R	-0.6	-7.43	-0.37	8.64e-13	Schizophrenia;
LIHC	trans	rs72960926	0.744	rs11754787	chr6:74915037	A/T	cg07247405	chr1:2484626	LOC115110	0.52	6.04	0.31	4.09e-9	Metabolite levels (MHPG);
LIHC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.74	-13.99	-0.6	1.75e-35	Mortality in heart failure;
LIHC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg05110241	chr16:68378359	PRMT7	-0.87	-10.12	-0.48	3.17e-21	Schizophrenia;
LIHC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.31	-7.22	-0.36	3.39e-12	Menarche (age at onset);
LIHC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs3736485	0.934	rs17609666	chr15:51858038	G/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.58	-11.44	-0.53	6.94e-26	Coronary artery disease;
LIHC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.8	-8.98	-0.44	1.8e-17	Schizophrenia;
LIHC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs4716602	0.596	rs34977094	chr7:156160864	C/T	cg16983916	chr7:156159713	NA	-0.32	-5.71	-0.3	2.43e-8	Anti-saccade response;
LIHC	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg10104451	chr8:143696006	ARC	-0.49	-6.34	-0.32	7.1e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.31	6.2	0.32	1.6e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.88	-0.3	9.64e-9	Schizophrenia;
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.67	-0.34	1.04e-10	Total body bone mineral density;
LIHC	cis	rs2084898	0.891	rs504236	chr11:120000263	T/C	cg13907859	chr11:120009124	TRIM29	-0.52	-6.42	-0.33	4.67e-10	Stroke (pediatric);
LIHC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.59	-0.5	7.59e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.55	9.5	0.46	3.79e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg16394018	chr11:14927549	NA	0.4	5.72	0.3	2.29e-8	Vitamin D levels;
LIHC	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-0.79	-9.02	-0.44	1.36e-17	Gut microbiota (bacterial taxa);
LIHC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg18944383	chr4:111397179	ENPEP	0.25	6.33	0.32	7.77e-10	Coronary artery disease;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.74	-0.3	2.1e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs712039	0.652	rs712038	chr17:35762557	G/A	cg16670864	chr17:35848621	DUSP14	0.35	5.85	0.3	1.15e-8	Tuberculosis;
LIHC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.6	9.85	0.47	2.61e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.66	-0.34	1.11e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7919006	1.000	rs7901229	chr10:76804824	A/G	cg01390419	chr10:76803856	DUPD1	0.48	7.65	0.38	2.09e-13	Weight;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg12143784	chr7:64541923	NA	0.37	6.42	0.33	4.55e-10	Calcium levels;
LIHC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg17279839	chr7:150038598	RARRES2	0.51	10.79	0.5	1.48e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-6.87	-0.35	3.08e-11	Homocysteine levels;
LIHC	cis	rs74181299	0.819	rs2723086	chr2:65297686	C/T	cg05010058	chr2:65284262	CEP68	0.39	6.63	0.34	1.32e-10	Pulse pressure;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg13628971	chr7:2884303	GNA12	0.39	5.82	0.3	1.36e-8	Height;
LIHC	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.38	-8.09	-0.4	1.06e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.98	0.31	5.53e-9	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-7.15	-0.36	5.46e-12	Menarche (age at onset);
LIHC	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.28	0.32	1.05e-9	Lymphocyte counts;
LIHC	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-0.74	-6.49	-0.33	3.08e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.56	0.62	1.09e-37	Prudent dietary pattern;
LIHC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.5	8.84	0.43	5.06e-17	Height;
LIHC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.81	-0.3	1.4e-8	Blood metabolite levels;
LIHC	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.62	-0.34	1.36e-10	Hip circumference;Waist circumference;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.52	0.56	7.34e-30	Prudent dietary pattern;
LIHC	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.7	-10.95	-0.51	3.89e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.43	6.54	0.33	2.22e-10	Schizophrenia;
LIHC	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg16691251	chr5:66510806	NA	0.45	5.86	0.3	1.09e-8	Breast cancer;
LIHC	cis	rs67981189	0.572	rs2810077	chr14:71363814	A/G	cg15816911	chr14:71606274	NA	-0.37	-5.98	-0.31	5.54e-9	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.71	0.38	1.35e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.79	0.5	1.49e-23	Platelet count;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.36	5.82	0.3	1.32e-8	Obesity-related traits;
LIHC	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.9	11.22	0.52	4.37e-25	Prostate cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg26144629	chr1:207926000	CD46	-0.47	-6.49	-0.33	3.02e-10	Longevity;
LIHC	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg06664874	chr5:179499304	RNF130	0.58	7.13	0.36	5.93e-12	LDL cholesterol;
LIHC	cis	rs8083850	0.635	rs12968567	chr18:50873468	T/C	cg24270629	chr18:50823537	DCC	0.53	8.03	0.4	1.53e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg19894588	chr14:64061835	NA	-0.47	-7.4	-0.37	1.05e-12	Fat distribution (HIV);
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg15382696	chr6:118971807	C6orf204	-0.69	-6.85	-0.35	3.35e-11	Diastolic blood pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04249525	chr7:152373324	XRCC2	0.42	6.14	0.32	2.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11689435	0.925	rs71401198	chr2:218344355	G/T	cg13544946	chr9:35729779	TLN1	-0.46	-6.52	-0.33	2.57e-10	Metabolite levels (MHPG);
LIHC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.03	14.59	0.62	7.75e-38	Cognitive function;
LIHC	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg21573476	chr21:45109991	RRP1B	0.47	7.93	0.39	3.15e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.7	-9.33	-0.45	1.35e-18	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs11157436	1.000	rs2293731	chr14:22616834	C/G	cg13567813	chr19:50879636	NR1H2	0.43	6.19	0.32	1.68e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg16479474	chr6:28041457	NA	-0.45	-6.41	-0.33	4.74e-10	Depression;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.61	10.64	0.5	4.85e-23	Height;
LIHC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.43	7.64	0.38	2.24e-13	IgG glycosylation;
LIHC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.26	-6.06	-0.31	3.5e-9	Subjective well-being;
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.31	-0.32	8.81e-10	Total body bone mineral density;
LIHC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg04013166	chr16:89971882	TCF25	0.48	5.81	0.3	1.46e-8	Skin colour saturation;
LIHC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg01411142	chr8:19674711	INTS10	0.53	8.06	0.4	1.28e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.75	0.3	1.96e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs611744	0.967	rs635219	chr8:109229243	C/T	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.48	7.24	0.36	2.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.58	0.34	1.74e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.68	0.38	1.66e-13	Height;
LIHC	cis	rs9871864	0.868	rs13094888	chr3:20350308	G/C	cg00235661	chr3:20228976	SGOL1	-0.31	-5.9	-0.3	8.9e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.12	-0.36	6.52e-12	Inflammatory bowel disease;
LIHC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.19e-12	HDL cholesterol levels;
LIHC	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	0.86	14.19	0.61	2.98e-36	Testicular germ cell tumor;
LIHC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.18	-0.36	4.37e-12	Breast cancer;
LIHC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.93	15.18	0.63	3.68e-40	Metabolic syndrome;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20341384	chr10:131568735	NA	0.43	6.61	0.34	1.44e-10	Immature fraction of reticulocytes;
LIHC	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg20140201	chr2:241835670	C2orf54	-0.54	-8.33	-0.41	2.05e-15	Urinary metabolites;
LIHC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.59	5.79	0.3	1.61e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.4	8.76	0.43	9.1e-17	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg12365402	chr11:9010492	NRIP3	0.26	6.71	0.34	7.92e-11	Hemoglobin concentration;
LIHC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.87	0.35	2.96e-11	Colorectal cancer;
LIHC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg13753209	chr17:57696993	CLTC	0.73	11.68	0.53	9.69e-27	Hemoglobin concentration;
LIHC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.12	0.55	2.21e-28	Menopause (age at onset);
LIHC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.53	7.38	0.37	1.19e-12	Schizophrenia;
LIHC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.59	8.05	0.4	1.34e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.74	-10.55	-0.5	1.02e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg12046867	chr14:103022105	NA	-0.43	-6.8	-0.35	4.54e-11	Platelet count;
LIHC	cis	rs4908768	0.725	rs11121214	chr1:8728665	C/T	cg20416874	chr1:8611966	RERE	0.5	7.08	0.36	8.18e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg12311636	chr6:118886798	C6orf204	-0.56	-6.41	-0.33	4.89e-10	Diastolic blood pressure;
LIHC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.53	7.01	0.35	1.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.59	7.38	0.37	1.21e-12	Initial pursuit acceleration;
LIHC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-8.53	-0.42	4.75e-16	Morning vs. evening chronotype;
LIHC	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.86	0.43	4.37e-17	Exhaled nitric oxide levels;
LIHC	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg16586182	chr3:47516702	SCAP	0.51	9.01	0.44	1.45e-17	Colorectal cancer;
LIHC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-9.33	-0.45	1.32e-18	Prudent dietary pattern;
LIHC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.33	7.22	0.36	3.33e-12	Ulcerative colitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13048808	chr17:11924852	MAP2K4	0.46	6.17	0.32	1.96e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	6.01	0.31	4.78e-9	Response to antipsychotic treatment;
LIHC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.4	5.78	0.3	1.71e-8	Aortic root size;
LIHC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg26072250	chr5:443457	EXOC3;C5orf55	0.44	6.38	0.33	5.76e-10	Cystic fibrosis severity;
LIHC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg19735590	chr5:154026979	NA	-0.48	-5.97	-0.31	6.07e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.18	-0.32	1.81e-9	Colorectal cancer;
LIHC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.25	5.89	0.3	9.42e-9	Childhood ear infection;
LIHC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-6.87	-0.35	3.09e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.72	14.4	0.61	4.38e-37	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.77e-9	Prudent dietary pattern;
LIHC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.59	-9.47	-0.46	4.78e-19	Urate levels in obese individuals;
LIHC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.19	-0.45	3.81e-18	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.4	8.07	0.4	1.21e-14	Renal cell carcinoma;
LIHC	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-10.52	-0.49	1.29e-22	Bipolar disorder;
LIHC	cis	rs4908768	0.501	rs12756257	chr1:8616933	C/A	cg20416874	chr1:8611966	RERE	-0.68	-14.82	-0.63	1.02e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.53	7.36	0.37	1.39e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.49	6.43	0.33	4.3e-10	Morning vs. evening chronotype;
LIHC	cis	rs80282103	0.618	rs1079390	chr10:1161653	C/A	cg08668510	chr10:1095578	IDI1	0.63	6.08	0.31	3.13e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	18.35	0.7	7.4e-53	Tonsillectomy;
LIHC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.68	9.19	0.44	3.98e-18	Mean platelet volume;
LIHC	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg18887096	chr2:219472410	PLCD4	0.39	6.76	0.34	6.11e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg11783602	chr8:55087084	NA	-0.33	-6.5	-0.33	2.82e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg07148914	chr20:33460835	GGT7	-0.55	-7.74	-0.39	1.13e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.42	5.8	0.3	1.48e-8	Uric acid clearance;
LIHC	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.98	0.31	5.65e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.5	-6.81	-0.35	4.45e-11	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.01	15.53	0.64	1.55e-41	Skin colour saturation;
LIHC	cis	rs4407350	1.000	rs4823331	chr22:44923082	T/C	cg26276947	chr22:44892394	LDOC1L	0.33	6.01	0.31	4.83e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg20452738	chr1:226828650	ITPKB	-0.21	-6.09	-0.31	3.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.67	-11.31	-0.52	2.06e-25	Childhood ear infection;
LIHC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.77	-0.3	1.8e-8	Pulse pressure;
LIHC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs716804	0.740	rs2044143	chr11:10286758	A/G	cg01453529	chr11:10209919	SBF2	-0.29	-5.87	-0.3	1.01e-8	Neuroticism;
LIHC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19723775	chr5:179050963	HNRNPH1	0.41	6.44	0.33	4.1e-10	Lung cancer;
LIHC	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.71	0.57	1.36e-30	Airflow obstruction;
LIHC	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	6.93	0.35	2.05e-11	Endometrial cancer;
LIHC	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-9.54	-0.46	2.78e-19	Colorectal cancer;
LIHC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	1.01	19.44	0.72	3.27e-57	Breast cancer;
LIHC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.51	-9.36	-0.45	1.07e-18	Asthma;
LIHC	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg16850897	chr7:100343110	ZAN	-0.44	-6.41	-0.33	4.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg15123519	chr2:136567270	LCT	-0.35	-5.86	-0.3	1.08e-8	Corneal structure;
LIHC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.83	0.3	1.3e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-7.01	-0.35	1.29e-11	HDL cholesterol;
LIHC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.8	0.3	1.51e-8	Melanoma;
LIHC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg00204512	chr16:28754710	NA	0.36	6.46	0.33	3.53e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg15848620	chr12:58087721	OS9	-0.6	-8.11	-0.4	8.91e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg20435097	chr10:126320824	FAM53B	0.36	5.98	0.31	5.7e-9	Asthma;
LIHC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg23352942	chr3:46931381	PTH1R	-0.27	-6.99	-0.35	1.44e-11	Birth weight;
LIHC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.79	-6.61	-0.34	1.47e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs11098699	0.821	rs4833886	chr4:124206263	A/C	cg09941581	chr4:124220074	SPATA5	0.32	6.39	0.33	5.31e-10	Mosquito bite size;
LIHC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.41	-0.33	4.97e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.98	-0.31	5.56e-9	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08219700	chr8:58056026	NA	0.49	6.61	0.34	1.47e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.84	15.39	0.64	5.83e-41	Menopause (age at onset);
LIHC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg20684491	chr1:25596433	NA	0.29	5.9	0.3	8.58e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.42	7.12	0.36	6.56e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg15105060	chr4:7024189	TBC1D14	-0.74	-6.3	-0.32	9.22e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg13175981	chr1:150552382	MCL1	-0.44	-6.16	-0.32	2.07e-9	Tonsillectomy;
LIHC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg12458913	chr13:53173898	NA	0.44	7.03	0.36	1.1e-11	Lewy body disease;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.42	-0.41	1.02e-15	Lymphocyte counts;
LIHC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.35	1.23e-11	Diabetic kidney disease;
LIHC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-8.64	-0.42	2.18e-16	Primary biliary cholangitis;
LIHC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.79	9.9	0.47	1.7e-20	Cognitive function;
LIHC	cis	rs6669384	0.774	rs4844624	chr1:208035446	A/G	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.84	-0.3	1.21e-8	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg22528358	chr1:107598549	PRMT6	-0.71	-11.85	-0.54	2.22e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.85	0.57	4.29e-31	Colorectal cancer;
LIHC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.82	-12.37	-0.56	2.72e-29	Motion sickness;
LIHC	cis	rs10916814	0.632	rs1890003	chr1:20899101	T/C	cg24502330	chr1:20914028	CDA	-0.3	-6.7	-0.34	8.63e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg24296786	chr1:45957014	TESK2	0.5	7.59	0.38	3.05e-13	Platelet count;
LIHC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.93	-12.35	-0.56	3.04e-29	Schizophrenia;
LIHC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg23730037	chr7:158596552	ESYT2	-0.41	-6.31	-0.32	8.88e-10	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01250699	chr8:22225185	SLC39A14	0.4	6.06	0.31	3.67e-9	Pancreatic cancer;
LIHC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.48	7.84	0.39	5.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07305463	chr2:136567211	LCT	0.37	6.55	0.33	2.1e-10	Mosquito bite size;
LIHC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg12751644	chr20:60527061	NA	-0.36	-5.88	-0.3	9.74e-9	Body mass index;
LIHC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.82	14.43	0.62	3.29e-37	Aortic root size;
LIHC	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg20240347	chr1:204465584	NA	-0.35	-7.48	-0.37	6.51e-13	Schizophrenia;
LIHC	cis	rs61712019	0.679	rs13029065	chr2:77721076	G/A	cg11252801	chr2:77748917	LRRTM4	0.56	7.73	0.39	1.2e-13	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.56	6.74	0.34	6.9e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg16070018	chr6:26224392	HIST1H3E	0.6	7.53	0.38	4.45e-13	Gout;Renal underexcretion gout;
LIHC	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg22903471	chr2:27725779	GCKR	0.31	6.05	0.31	3.86e-9	Total body bone mineral density;
LIHC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.52	8.21	0.41	4.63e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs72627123	0.867	rs80083802	chr14:74456996	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.46	0.42	8.11e-16	Morning vs. evening chronotype;
LIHC	cis	rs2274273	0.837	rs56949365	chr14:55790078	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.57	-0.33	1.9e-10	Protein biomarker;
LIHC	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg20476274	chr7:133979776	SLC35B4	0.72	10.0	0.48	8.14e-21	Mean platelet volume;
LIHC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11958404	1.000	rs72816523	chr5:157403168	G/C	cg05962755	chr5:157440814	NA	1.07	11.91	0.54	1.38e-27	IgG glycosylation;
LIHC	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg00085434	chr11:14927489	NA	0.41	5.81	0.3	1.41e-8	Vitamin D levels;
LIHC	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.58	8.87	0.43	4.22e-17	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.79	9.13	0.44	5.94e-18	Hip circumference adjusted for BMI;
LIHC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.95	0.31	6.6e-9	Tonsillectomy;
LIHC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	2.01e-11	Height;
LIHC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.16	-0.36	5.03e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.36	-0.41	1.63e-15	Response to antipsychotic treatment;
LIHC	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg13962466	chr20:25176127	ENTPD6	0.42	5.89	0.3	9.41e-9	Colorectal or endometrial cancer;
LIHC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.95	17.38	0.68	6.34e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg03689076	chr20:33865952	NA	0.58	6.68	0.34	9.81e-11	Attention deficit hyperactivity disorder;
LIHC	cis	rs4650994	0.571	rs11588907	chr1:178509462	C/T	cg05350800	chr1:178550844	NA	-0.3	-6.41	-0.33	4.84e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.9	-0.47	1.73e-20	Hemoglobin concentration;
LIHC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.68	11.16	0.52	7.19e-25	Menopause (age at onset);
LIHC	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21045802	chr8:109455806	TTC35	0.44	7.52	0.38	4.9e-13	Dupuytren's disease;
LIHC	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg00166722	chr3:10149974	C3orf24	0.47	5.76	0.3	1.86e-8	Alzheimer's disease;
LIHC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.37	0.66	6.68e-45	Smoking behavior;
LIHC	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.71	10.58	0.5	7.85e-23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.26	-0.37	2.56e-12	IgG glycosylation;
LIHC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg26692224	chr17:62915920	LRRC37A3	-0.71	-6.81	-0.35	4.44e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.46	-7.47	-0.37	6.88e-13	Menarche (age at onset);
LIHC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-7.19	-0.36	4.13e-12	Height;
LIHC	cis	rs17106184	1.000	rs3789588	chr1:51266523	G/A	cg07174182	chr1:51127561	FAF1	-0.65	-6.99	-0.35	1.46e-11	Type 2 diabetes;
LIHC	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.39	-7.61	-0.38	2.67e-13	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.62	-0.42	2.61e-16	Crohn's disease;
LIHC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg25801113	chr15:45476975	SHF	-0.38	-6.34	-0.32	7.2e-10	Uric acid levels;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.54	0.38	4.18e-13	Height;
LIHC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg13446199	chr8:143762866	PSCA	-0.2	-5.76	-0.3	1.85e-8	Urinary tract infection frequency;
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.92	0.3	7.84e-9	Alzheimer's disease;
LIHC	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.57	0.33	1.92e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg02836325	chr17:76403955	PGS1	0.31	6.08	0.31	3.3e-9	HDL cholesterol levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg02028489	chr16:31505237	C16orf58	0.41	6.42	0.33	4.59e-10	Longevity;
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19500275	chr17:80737654	TBCD	-0.51	-7.61	-0.38	2.63e-13	Glycated hemoglobin levels;
LIHC	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg20634798	chr1:152595351	LCE3A	-0.31	-6.03	-0.31	4.26e-9	Psoriasis;
LIHC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.9	-18.46	-0.71	2.88e-53	Height;
LIHC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	trans	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg01596870	chr19:55963115	NA	0.66	10.03	0.48	6.53e-21	Obesity-related traits;
LIHC	cis	rs2115630	0.577	rs7164817	chr15:85379544	T/C	cg12501888	chr15:85177176	SCAND2	-0.42	-6.09	-0.31	3.1e-9	P wave terminal force;
LIHC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.63	10.82	0.5	1.18e-23	Birth weight;
LIHC	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.39	-5.76	-0.3	1.91e-8	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.6	8.71	0.43	1.32e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs959260	1.000	rs959260	chr17:73369422	C/T	cg20590849	chr17:73267439	MIF4GD	-0.53	-5.75	-0.3	1.96e-8	Systemic lupus erythematosus;
LIHC	cis	rs12602486	1.000	rs12602486	chr17:42241929	T/G	cg13607699	chr17:42295918	UBTF	-0.75	-6.42	-0.33	4.46e-10	Glycated hemoglobin levels;
LIHC	cis	rs7212590	0.655	rs34687426	chr17:57997857	A/G	cg10252138	chr17:58120427	NA	-0.65	-6.92	-0.35	2.25e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.97	-0.44	1.96e-17	Skin colour saturation;
LIHC	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg08345082	chr10:99160200	RRP12	0.37	6.18	0.32	1.82e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.42e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.11	0.4	8.86e-15	Morning vs. evening chronotype;
LIHC	cis	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg16589663	chr20:23618590	CST3	0.61	5.93	0.31	7.52e-9	Chronic kidney disease;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg10150615	chr22:24372951	LOC391322	-0.56	-8.09	-0.4	1.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.25	6.02	0.31	4.61e-9	Primary biliary cholangitis;
LIHC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg12940439	chr1:67600707	NA	0.39	7.16	0.36	5.04e-12	Psoriasis;
LIHC	trans	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg01596870	chr19:55963115	NA	-0.67	-9.61	-0.46	1.58e-19	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-10.27	-0.49	9.91e-22	Dental caries;
LIHC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	9.79	0.47	4.03e-20	Multiple sclerosis;
LIHC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.65	10.87	0.51	7.9e-24	Type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.75	0.39	1.09e-13	Renal cell carcinoma;
LIHC	trans	rs7395555	0.848	rs4944251	chr11:80076944	G/A	cg06295071	chr21:33766731	URB1	-0.42	-6.08	-0.31	3.19e-9	Response to antipsychotic treatment;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.45	0.46	5.34e-19	Corneal astigmatism;
LIHC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.65	-12.63	-0.56	2.85e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs922107	0.846	rs359922	chr1:89994577	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.42	-0.37	9.38e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg13259811	chr8:22550831	EGR3	-0.57	-6.47	-0.33	3.33e-10	Preeclampsia;
LIHC	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.47	6.19	0.32	1.74e-9	Glioblastoma;Glioma;
LIHC	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg10167463	chr7:75959203	YWHAG	-0.44	-6.78	-0.34	5.27e-11	Multiple sclerosis;
LIHC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.64	-9.08	-0.44	8.7e-18	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg00656387	chr3:40428638	ENTPD3	0.5	8.33	0.41	1.91e-15	Renal cell carcinoma;
LIHC	cis	rs1499280	1.000	rs6879147	chr5:52087852	T/G	cg21153758	chr5:52083992	ITGA1;PELO	-0.71	-6.56	-0.33	1.99e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.61	-7.41	-0.37	1.02e-12	Macular telangiectasia type 2;
LIHC	cis	rs9513627	0.748	rs61525545	chr13:100118261	T/C	cg25919922	chr13:100150906	NA	-0.78	-7.02	-0.35	1.19e-11	Obesity-related traits;
LIHC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.84	-0.35	3.65e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-8.43	-0.41	9.99e-16	Height;
LIHC	cis	rs4908760	0.965	rs7542312	chr1:8573471	G/C	cg20416874	chr1:8611966	RERE	-0.67	-14.21	-0.61	2.4e-36	Vitiligo;
LIHC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.32	0.41	2.05e-15	Lung cancer;
LIHC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.38	-5.75	-0.3	2.03e-8	Longevity;Endometriosis;
LIHC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg17279839	chr7:150038598	RARRES2	-0.37	-7.36	-0.37	1.36e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6750047	0.515	rs13417487	chr2:38289162	G/T	cg07380506	chr2:38303506	CYP1B1	0.65	7.99	0.4	2.15e-14	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg22676075	chr6:135203613	NA	0.38	6.25	0.32	1.26e-9	Red blood cell count;
LIHC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg05110241	chr16:68378359	PRMT7	-0.63	-7.06	-0.36	9.6e-12	Schizophrenia;
LIHC	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.79	-9.66	-0.46	1.12e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.56	-0.38	3.81e-13	Body mass index;
LIHC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.98	-0.44	1.81e-17	Blood metabolite levels;
LIHC	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	0.97	14.03	0.6	1.24e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.63	-0.34	1.28e-10	Height;
LIHC	cis	rs924607	0.510	rs1709542	chr5:662543	A/G	cg04476341	chr5:669733	TPPP	0.28	6.13	0.31	2.36e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.45	-6.12	-0.31	2.51e-9	Major depressive disorder;
LIHC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.41	-7.15	-0.36	5.42e-12	Aortic root size;
LIHC	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.32	0.55	4.05e-29	Coffee consumption (cups per day);
LIHC	cis	rs6065325	0.514	rs55715261	chr20:40109855	C/T	cg06610464	chr20:40243608	CHD6	0.38	6.14	0.32	2.28e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg18887096	chr2:219472410	PLCD4	0.37	6.41	0.33	4.77e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.33	-6.36	-0.33	6.45e-10	Body mass index;
LIHC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.86	13.01	0.58	9.87e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.5	0.77	1.88e-69	Height;
LIHC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	13.05	0.58	7.15e-32	Prudent dietary pattern;
LIHC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.62	0.56	3.04e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg19680672	chr10:131412579	MGMT	0.41	6.31	0.32	8.74e-10	Response to temozolomide;
LIHC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.08	0.48	4.35e-21	Colorectal cancer;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02359409	chr6:42947317	PEX6	-0.49	-6.44	-0.33	4.03e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg15691649	chr6:25882328	NA	-0.54	-7.82	-0.39	6.76e-14	Blood metabolite levels;
LIHC	trans	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg10756647	chr7:56101905	PSPH	1.04	12.56	0.56	5.14e-30	Diabetic kidney disease;
LIHC	cis	rs249954	0.559	rs35586	chr16:23677006	A/G	cg05131483	chr16:23706242	ERN2	0.39	6.3	0.32	9.01e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	9.25	0.45	2.43e-18	Mean platelet volume;
LIHC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.74	11.5	0.53	4.22e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.6	-0.42	2.91e-16	Cognitive function;
LIHC	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.32	-6.09	-0.31	3.02e-9	Systemic lupus erythematosus;
LIHC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg12863693	chr15:85201151	NMB	0.45	6.23	0.32	1.36e-9	Schizophrenia;
LIHC	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.45	6.78	0.34	5.25e-11	Schizophrenia;
LIHC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg08469215	chr1:156261351	TMEM79	0.36	6.15	0.32	2.19e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-1.03	-15.87	-0.65	6.99e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-8.52	-0.42	5.08e-16	Gut microbiome composition (summer);
LIHC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.48	7.94	0.39	3.03e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.01e-19	Renal cell carcinoma;
LIHC	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.62	8.92	0.43	2.9e-17	Schizophrenia;
LIHC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.0	0.31	5.11e-9	Electroencephalogram traits;
LIHC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg26138937	chr11:71823887	C11orf51	-1.01	-8.93	-0.43	2.69e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.78	11.71	0.54	7.24e-27	Dental caries;
LIHC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg12798992	chr6:167411361	FGFR1OP	0.53	8.75	0.43	9.73e-17	Crohn's disease;
LIHC	cis	rs77633900	0.772	rs284884	chr15:76828289	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-5.92	-0.3	7.98e-9	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.67	13.3	0.58	8.19e-33	Leprosy;
LIHC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.77	0.34	5.75e-11	Subjective well-being;
LIHC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.85	-0.35	3.51e-11	Monocyte percentage of white cells;
LIHC	cis	rs7487075	0.619	rs7959731	chr12:46839657	A/C	cg23829395	chr12:46796953	NA	-0.34	-6.05	-0.31	3.78e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.07	16.04	0.66	1.47e-43	Cognitive function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg04639062	chr2:21265939	APOB	0.44	7.25	0.36	2.88e-12	Calcium levels;
LIHC	cis	rs922107	0.934	rs6700967	chr1:90017273	C/G	cg15422784	chr1:90023713	LRRC8B	-0.49	-7.9	-0.39	3.96e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.5	7.93	0.39	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2257205	0.667	rs6503876	chr17:56814988	G/C	cg12560992	chr17:57184187	TRIM37	0.71	7.81	0.39	7.13e-14	Pancreatic cancer;
LIHC	trans	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg02174006	chr10:86088279	FAM190B	0.45	6.04	0.31	3.95e-9	Cannabis use (initiation);
LIHC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	7.68	0.38	1.7e-13	Body mass index;
LIHC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.23	6.18	0.32	1.85e-9	Calcium levels;
LIHC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.45	7.75	0.39	1.05e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.47	8.6	0.42	2.87e-16	Mean corpuscular volume;
LIHC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	1.01	10.04	0.48	5.84e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg05110241	chr16:68378359	PRMT7	-0.86	-9.84	-0.47	2.8e-20	Magnesium levels;
LIHC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.58	-10.37	-0.49	4.26e-22	Platelet distribution width;
LIHC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.47	7.23	0.36	3.18e-12	Asthma (sex interaction);
LIHC	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.16	0.48	2.21e-21	Colorectal cancer;
LIHC	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.74	12.92	0.57	2.19e-31	Eosinophil percentage of white cells;
LIHC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	17.04	0.68	1.44e-47	Lung cancer in ever smokers;
LIHC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.33	-18.17	-0.7	3.94e-52	Diabetic kidney disease;
LIHC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.13	-0.36	5.99e-12	Personality dimensions;
LIHC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.35	5.82	0.3	1.35e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.77	0.34	5.49e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.46	0.46	5.03e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg19635926	chr16:89946313	TCF25	0.51	7.13	0.36	5.91e-12	Skin colour saturation;
LIHC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12463550	chr7:65579703	CRCP	0.69	7.2	0.36	3.93e-12	Diabetic kidney disease;
LIHC	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.09	0.58	5.2e-32	Colorectal cancer;
LIHC	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.25	6.87	0.35	3.08e-11	Type 2 diabetes;
LIHC	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.44	-6.22	-0.32	1.47e-9	Schizophrenia;
LIHC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.95	-0.31	6.62e-9	Body mass index;
LIHC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.66	0.38	1.9e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2257205	0.667	rs7217890	chr17:56731265	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg07689907	chr11:61582574	FADS1	-0.41	-6.06	-0.31	3.57e-9	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14634319	chr12:57030450	BAZ2A	0.45	6.07	0.31	3.41e-9	Pancreatic cancer;
LIHC	cis	rs11822910	0.737	rs2581924	chr11:57208468	C/T	cg00522883	chr11:57194120	SLC43A3	0.56	6.96	0.35	1.7e-11	Platelet distribution width;
LIHC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.16	-0.32	2.07e-9	Pancreatic cancer;
LIHC	cis	rs3736485	0.934	rs4775953	chr15:51873173	G/T	cg08986416	chr15:51914746	DMXL2	-0.43	-6.4	-0.33	5.14e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.69	10.52	0.49	1.27e-22	Height;
LIHC	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	0.91	10.58	0.5	8.3e-23	Breast cancer;
LIHC	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.03	-0.44	1.31e-17	Capecitabine sensitivity;
LIHC	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.39	-6.31	-0.32	8.75e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.92	0.43	2.9e-17	Mean corpuscular hemoglobin;
LIHC	trans	rs216345	1.000	rs216345	chr9:33799370	C/T	cg14607208	chr9:38546089	NA	0.4	6.2	0.32	1.58e-9	Bipolar disorder;
LIHC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg00934597	chr7:893267	UNC84A	0.48	5.79	0.3	1.57e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.4	-7.38	-0.37	1.2e-12	Schizophrenia;
LIHC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.97	9.88	0.47	1.97e-20	Plasma clusterin levels;
LIHC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg22633049	chr21:46681294	NA	-0.38	-6.41	-0.33	4.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.41	5.98	0.31	5.52e-9	Plateletcrit;
LIHC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.83	0.39	6.05e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	9.09	0.44	8.28e-18	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-23.92	-0.79	5.08e-75	Height;
LIHC	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg10241871	chr14:102965420	TECPR2	-0.48	-7.57	-0.38	3.47e-13	Blood protein levels;
LIHC	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.58	-0.42	3.44e-16	Colorectal cancer;
LIHC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.38	7.01	0.35	1.27e-11	IgG glycosylation;
LIHC	trans	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg17675199	chr6:35436792	RPL10A	0.34	6.65	0.34	1.17e-10	Coronary artery disease;
LIHC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	6.14	0.32	2.25e-9	Cognitive test performance;
LIHC	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg14146966	chr2:61757674	XPO1	0.44	7.31	0.37	1.96e-12	Tuberculosis;
LIHC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.91	13.57	0.59	7.7e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14154082	chr13:112174009	NA	0.28	5.98	0.31	5.48e-9	Menarche (age at onset);
LIHC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.38	-5.92	-0.3	7.91e-9	Blood pressure (smoking interaction);
LIHC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21467203	chr3:49911342	NA	0.44	7.81	0.39	7.1e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.44	0.37	8.24e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.71	7.18	0.36	4.38e-12	Alzheimer's disease;
LIHC	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.56	-8.07	-0.4	1.18e-14	Blood pressure (smoking interaction);
LIHC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.74	6.99	0.35	1.49e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17152411	0.625	rs10736892	chr10:126594892	G/A	cg07906193	chr10:126599966	NA	-0.3	-5.82	-0.3	1.32e-8	Height;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg03383472	chr7:2314947	SNX8	0.49	6.67	0.34	1.01e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg02269571	chr22:50332266	NA	-0.62	-8.78	-0.43	7.76e-17	Schizophrenia;
LIHC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.87	13.14	0.58	3.25e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.73	0.5	2.39e-23	Bladder cancer;
LIHC	cis	rs9473924	0.505	rs7745565	chr6:50860083	A/G	cg14470998	chr6:50812995	TFAP2B	0.93	10.83	0.51	1.08e-23	Body mass index;
LIHC	cis	rs2933343	1.000	rs876755	chr3:128627933	C/T	cg25356066	chr3:128598488	ACAD9	0.53	7.0	0.35	1.39e-11	IgG glycosylation;
LIHC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-7.69	-0.38	1.6e-13	Migraine;Coronary artery disease;
LIHC	cis	rs4742903	0.875	rs10820609	chr9:106907332	G/A	cg14250997	chr9:106856677	SMC2	0.37	6.61	0.34	1.48e-10	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.98	-0.31	5.7e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04207741	chr12:57482553	NAB2	0.46	6.09	0.31	3.03e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.82e-31	Breast cancer;
LIHC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg05564831	chr3:52568323	NT5DC2	0.35	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-7.77	-0.39	9.19e-14	Alzheimer's disease;
LIHC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg09222892	chr1:25734099	RHCE	-0.47	-8.55	-0.42	4.28e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg05044414	chr3:183734942	ABCC5	-0.35	-5.91	-0.3	8.48e-9	Anterior chamber depth;
LIHC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.24	-0.32	1.26e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs12464559	0.649	rs4453694	chr2:152539550	T/C	cg01189475	chr2:152685088	ARL5A	0.66	7.82	0.39	6.42e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.41	-6.37	-0.33	6.26e-10	Alzheimer's disease (survival time);
LIHC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg09990169	chr2:241835740	C2orf54	-0.64	-9.07	-0.44	9.5e-18	Urinary metabolites;
LIHC	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.93	7.04	0.36	1.04e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.82	-11.43	-0.53	7.73e-26	Obesity-related traits;
LIHC	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.48	7.85	0.39	5.43e-14	Dialysis-related mortality;
LIHC	cis	rs11786130	1.000	rs4733812	chr8:128999640	C/T	cg01765152	chr8:129005526	PVT1	-0.31	-6.97	-0.35	1.6e-11	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg12661370	chr5:149340060	SLC26A2	0.48	5.8	0.3	1.49e-8	HIV-1 control;
LIHC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg14580859	chr9:123691850	NA	0.4	7.0	0.35	1.39e-11	Rheumatoid arthritis;
LIHC	cis	rs1144333	0.655	rs76735776	chr1:76455211	A/G	cg22875332	chr1:76189707	ACADM	0.4	5.93	0.31	7.24e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.6	8.79	0.43	7.43e-17	Menarche (age at onset);
LIHC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.49	6.29	0.32	9.61e-10	Initial pursuit acceleration;
LIHC	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg20129853	chr10:51489980	NA	-0.44	-8.78	-0.43	7.79e-17	Prostate-specific antigen levels;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	0.58	8.33	0.41	1.98e-15	Prudent dietary pattern;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07677032	chr17:61819896	STRADA	0.42	6.11	0.31	2.72e-9	Prudent dietary pattern;
LIHC	cis	rs6445967	0.689	rs11714574	chr3:58380465	A/T	cg23715586	chr3:58305044	RPP14	0.38	6.31	0.32	8.85e-10	Platelet count;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	6.86	0.35	3.23e-11	Height;
LIHC	cis	rs16858210	0.607	rs35205152	chr3:183563329	C/A	cg25686905	chr3:183603175	PARL	-0.51	-8.76	-0.43	8.95e-17	Menopause (age at onset);
LIHC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.26	0.52	3.09e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.51	0.56	7.86e-30	Prudent dietary pattern;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.51	5.86	0.3	1.08e-8	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg13409248	chr3:40428643	ENTPD3	0.46	7.43	0.37	8.67e-13	Renal cell carcinoma;
LIHC	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg17085576	chr10:5658249	NA	-0.32	-6.15	-0.32	2.2e-9	Breast cancer;
LIHC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg25039879	chr17:56429692	SUPT4H1	0.76	8.75	0.43	1.02e-16	Cognitive test performance;
LIHC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21545522	chr1:205238299	TMCC2	0.3	5.74	0.3	2.08e-8	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs8081395	0.866	rs2777899	chr17:57832391	T/G	cg13753209	chr17:57696993	CLTC	-0.48	-7.3	-0.37	2.08e-12	White blood cell count;
LIHC	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg07706471	chr12:123319906	HIP1R	-0.56	-7.36	-0.37	1.37e-12	Schizophrenia;
LIHC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.49	-7.66	-0.38	1.95e-13	Fibrinogen levels;
LIHC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg18225595	chr11:63971243	STIP1	0.67	8.32	0.41	2.14e-15	Mean platelet volume;
LIHC	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.97	-17.82	-0.69	1.03e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg12310025	chr6:25882481	NA	-0.42	-6.34	-0.32	7.27e-10	Height;
LIHC	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg00792783	chr2:198669748	PLCL1	0.42	6.16	0.32	2.09e-9	Intracranial aneurysm;
LIHC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.71	-11.02	-0.51	2.22e-24	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04358685	chr3:12598421	MKRN2	0.52	6.72	0.34	7.84e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg08992911	chr2:238395768	MLPH	0.52	6.34	0.32	7.29e-10	Prostate cancer;
LIHC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg22842854	chr12:123319900	HIP1R	-0.6	-7.29	-0.37	2.2e-12	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06498398	chr8:11627480	NEIL2	0.49	6.91	0.35	2.36e-11	Pancreatic cancer;
LIHC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.82	-14.14	-0.61	4.66e-36	Psoriasis;
LIHC	cis	rs8084351	0.577	rs4456578	chr18:50621094	A/G	cg24270629	chr18:50823537	DCC	0.44	6.71	0.34	8.04e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.48	-6.8	-0.35	4.56e-11	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg07713946	chr22:31675144	LIMK2	-0.42	-7.43	-0.37	8.83e-13	Colorectal cancer;
LIHC	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.63	10.72	0.5	2.51e-23	Coronary artery disease;
LIHC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-6.89	-0.35	2.77e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.61	11.64	0.53	1.3e-26	Schizophrenia;
LIHC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.58	8.47	0.42	7.55e-16	Blood metabolite levels;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg08804258	chr3:8543341	LMCD1	-0.42	-6.04	-0.31	4.03e-9	Alopecia areata;
LIHC	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.47	5.79	0.3	1.57e-8	Economic and political preferences (feminism/equality);
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.57	-0.38	3.41e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.76	-11.32	-0.52	1.86e-25	IgG glycosylation;
LIHC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.39	0.52	1.05e-25	Menopause (age at onset);
LIHC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.39	-5.71	-0.3	2.44e-8	Cognitive function;
LIHC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.51	-8.36	-0.41	1.62e-15	Blood metabolite levels;
LIHC	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg03037974	chr15:76606532	NA	0.74	14.45	0.62	2.85e-37	Blood metabolite levels;
LIHC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.89	0.47	1.87e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.13	0.48	2.88e-21	Alzheimer's disease (late onset);
LIHC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg07148914	chr20:33460835	GGT7	0.54	6.11	0.31	2.66e-9	Protein C levels;
LIHC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2834188	1.000	rs2834187	chr21:34687410	A/G	cg14352951	chr21:34696688	IFNAR1	0.47	6.48	0.33	3.12e-10	Narcolepsy;
LIHC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.85	-12.11	-0.55	2.54e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs77633900	0.772	rs172244	chr15:76722769	A/T	cg21673338	chr15:77095150	SCAPER	-0.53	-5.92	-0.3	7.98e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg09238746	chr17:78121135	EIF4A3	-0.79	-12.15	-0.55	1.76e-28	Yeast infection;
LIHC	cis	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg05084668	chr3:125655381	ALG1L	-0.34	-6.13	-0.31	2.39e-9	Blood pressure (smoking interaction);
LIHC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg14828511	chr1:107599125	PRMT6	-0.43	-6.16	-0.32	1.99e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06212747	chr3:49208901	KLHDC8B	0.59	7.92	0.39	3.35e-14	Parkinson's disease;
LIHC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.55	5.82	0.3	1.33e-8	Vitiligo;
LIHC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg07451762	chr16:28383216	NA	0.4	7.03	0.36	1.13e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	0.52	9.65	0.46	1.17e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs11627756	0.846	rs12887440	chr14:103083899	G/A	cg12046867	chr14:103022105	NA	-0.38	-5.84	-0.3	1.21e-8	Mean platelet volume;
LIHC	cis	rs116248771	0.739	rs78151625	chr3:158316726	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.02	0.31	4.41e-9	diarrhoeal disease at age 2;
LIHC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20307385	chr11:47447363	PSMC3	-0.46	-6.01	-0.31	4.67e-9	Subjective well-being;
LIHC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.48	6.32	0.32	8.38e-10	Initial pursuit acceleration;
LIHC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.78	-0.34	5.17e-11	Aortic root size;
LIHC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.65	10.7	0.5	3.02e-23	Platelet distribution width;
LIHC	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.51	8.96	0.44	2.18e-17	Coronary artery disease;
LIHC	cis	rs17106184	1.000	rs114736728	chr1:51374608	T/G	cg07174182	chr1:51127561	FAF1	-0.75	-7.65	-0.38	2.01e-13	Type 2 diabetes;
LIHC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.76	-0.3	1.86e-8	Uric acid levels;
LIHC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.46	6.08	0.31	3.28e-9	Schizophrenia;
LIHC	cis	rs12464559	0.579	rs6433590	chr2:152588120	A/C	cg01189475	chr2:152685088	ARL5A	0.67	7.78	0.39	8.52e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg05185784	chr16:90016020	DEF8	-0.5	-6.39	-0.33	5.56e-10	Skin colour saturation;
LIHC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.54	7.29	0.37	2.16e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.99	-19.64	-0.73	4.88e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg06640241	chr16:89574553	SPG7	0.8	14.65	0.62	4.68e-38	Multiple myeloma (IgH translocation);
LIHC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.68	-11.14	-0.52	8.32e-25	Bipolar disorder;
LIHC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg05110241	chr16:68378359	PRMT7	-0.6	-7.05	-0.36	9.98e-12	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-7.8	-0.39	7.55e-14	Vitamin D levels;
LIHC	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.72	-12.17	-0.55	1.53e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.12	0.44	6.48e-18	Response to antipsychotic treatment;
LIHC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.4e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.8	-11.97	-0.54	8.41e-28	Height;
LIHC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg15848620	chr12:58087721	OS9	-0.53	-7.14	-0.36	5.69e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.32	-0.41	2.05e-15	Blood protein levels;
LIHC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.42e-30	Alzheimer's disease;
LIHC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.61	7.5	0.38	5.64e-13	Heart rate;
LIHC	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.58	0.46	2e-19	Corneal astigmatism;
LIHC	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg19752551	chr11:57585705	CTNND1	-0.48	-6.67	-0.34	1.06e-10	Schizophrenia;
LIHC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-11.68	-0.53	9.81e-27	Headache;
LIHC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg12661370	chr5:149340060	SLC26A2	0.5	5.99	0.31	5.42e-9	HIV-1 control;
LIHC	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.53	0.49	1.23e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.45	5.99	0.31	5.26e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-9.54	-0.46	2.73e-19	Ulcerative colitis;
LIHC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.69	7.55	0.38	4.03e-13	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg21522988	chr12:29376872	FAR2	0.28	6.42	0.33	4.61e-10	QT interval;
LIHC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.81	0.43	6.38e-17	Schizophrenia;
LIHC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg22777020	chr22:31556080	RNF185	-0.55	-6.26	-0.32	1.15e-9	Colorectal cancer;
LIHC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs12744310	1.000	rs60552457	chr1:41759499	C/A	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.4	6.06	0.31	3.63e-9	Lipoprotein (a) levels;
LIHC	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-13.08	-0.58	5.37e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.35	6.21	0.32	1.51e-9	Platelet distribution width;
LIHC	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.61	7.78	0.39	8.39e-14	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.71	-13.64	-0.59	4.1e-34	Body mass index;
LIHC	cis	rs1863824	0.625	rs10887599	chr10:88168780	G/A	cg07322936	chr10:88137208	NA	-0.47	-5.99	-0.31	5.43e-9	Schizophrenia;
LIHC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.01	-0.31	4.86e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.48	6.3	0.32	9.36e-10	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21718627	chr11:87035156	TMEM135	-0.26	-6.26	-0.32	1.14e-9	Calcium levels;
LIHC	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.05	0.44	1.07e-17	Coffee consumption (cups per day);
LIHC	trans	rs11638815	0.626	rs11633829	chr15:83326938	C/T	cg18393722	chr15:85113863	UBE2QP1	0.37	6.08	0.31	3.13e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LIHC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.33	-0.37	1.67e-12	Bipolar disorder;
LIHC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg05555928	chr11:63887634	MACROD1	0.44	5.73	0.3	2.15e-8	Mean platelet volume;
LIHC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.58e-15	Gut microbiome composition (summer);
LIHC	cis	rs2191566	0.664	rs7250774	chr19:44551867	A/T	cg20607764	chr19:44506953	ZNF230	-0.37	-6.25	-0.32	1.21e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.4	5.97	0.31	6.01e-9	Gout;
LIHC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.34	0.55	3.56e-29	Menopause (age at onset);
LIHC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.07	0.36	8.98e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg00809820	chr17:80708513	TBCD;FN3K	0.34	5.87	0.3	1.01e-8	Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	13.35	0.59	5.37e-33	Psoriasis;
LIHC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg11372090	chr7:37488660	ELMO1	-0.38	-6.22	-0.32	1.45e-9	Oropharynx cancer;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.48	0.62	2.23e-37	Prudent dietary pattern;
LIHC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.45	-7.21	-0.36	3.63e-12	Menarche (age at onset);
LIHC	cis	rs713477	0.712	rs72717779	chr14:55893440	A/G	cg13175173	chr14:55914753	NA	-0.31	-7.15	-0.36	5.45e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.85	-0.3	1.14e-8	Total body bone mineral density;
LIHC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-6.63	-0.34	1.27e-10	Migraine;Coronary artery disease;
LIHC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.12	10.23	0.48	1.36e-21	Uric acid levels;
LIHC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg18016565	chr1:150552671	MCL1	0.52	9.64	0.46	1.29e-19	Melanoma;
LIHC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg20090690	chr10:134436459	INPP5A	0.44	5.76	0.3	1.86e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs72960926	0.744	rs1931272	chr6:74950681	C/T	cg07247405	chr1:2484626	LOC115110	0.53	6.38	0.33	5.78e-10	Metabolite levels (MHPG);
LIHC	cis	rs716804	0.740	rs12290748	chr11:10262206	G/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.78	-0.3	1.67e-8	Neuroticism;
LIHC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.44	-6.97	-0.35	1.64e-11	Menarche (age at onset);
LIHC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.48	-8.15	-0.4	6.75e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.36	0.49	4.72e-22	Colorectal cancer;
LIHC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.46	9.63	0.46	1.39e-19	Birth weight;
LIHC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs8084351	0.539	rs8085965	chr18:50561632	G/T	cg24270629	chr18:50823537	DCC	0.4	5.91	0.3	8.17e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg09723797	chr3:150481914	SIAH2	-0.81	-11.88	-0.54	1.75e-27	Breast cancer;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg01629716	chr15:45996671	NA	0.52	9.65	0.46	1.25e-19	Waist circumference;Weight;
LIHC	cis	rs9309473	1.000	rs6546838	chr2:73679280	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.83	-0.35	3.84e-11	Metabolite levels;
LIHC	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.99	0.44	1.65e-17	Exhaled nitric oxide levels;
LIHC	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	0.79	10.78	0.5	1.56e-23	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.43	-6.52	-0.33	2.51e-10	Asthma (sex interaction);
LIHC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.73	-13.75	-0.6	1.54e-34	Height;
LIHC	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.52	8.94	0.44	2.46e-17	Coronary artery disease;
LIHC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.32	7.77	0.39	9.19e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.76	-10.68	-0.5	3.57e-23	Colorectal cancer;
LIHC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.8	6.9	0.35	2.59e-11	Arsenic metabolism;
LIHC	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg27129171	chr3:47204927	SETD2	-0.53	-8.35	-0.41	1.72e-15	Colorectal cancer;
LIHC	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.78	13.26	0.58	1.1e-32	Coronary artery disease;
LIHC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg21573476	chr21:45109991	RRP1B	-0.61	-11.46	-0.53	6.02e-26	Mean corpuscular volume;
LIHC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.42	-6.62	-0.34	1.37e-10	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg18016565	chr1:150552671	MCL1	0.55	10.21	0.48	1.55e-21	Melanoma;
LIHC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.48	-0.33	3.23e-10	Mean corpuscular volume;
LIHC	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg14146966	chr2:61757674	XPO1	0.47	8.15	0.4	6.85e-15	Tuberculosis;
LIHC	cis	rs151997	0.962	rs27936	chr5:50181418	T/A	cg06027927	chr5:50259733	NA	0.57	7.61	0.38	2.61e-13	Callous-unemotional behaviour;
LIHC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-9.35	-0.45	1.18e-18	Primary sclerosing cholangitis;
LIHC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg08694578	chr2:241835147	C2orf54	-0.47	-6.46	-0.33	3.51e-10	Urinary metabolites;
LIHC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.74	9.22	0.45	3.15e-18	Gut microbiome composition (summer);
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.48	-7.41	-0.37	1e-12	Longevity;Endometriosis;
LIHC	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.6e-27	Coronary artery disease;
LIHC	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg02344993	chr17:57696989	CLTC	0.71	11.85	0.54	2.25e-27	Hemoglobin concentration;
LIHC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.44	7.22	0.36	3.3e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.84	14.14	0.61	4.52e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.92e-12	Menopause (age at onset);
LIHC	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.4	6.04	0.31	4.12e-9	Reticulocyte fraction of red cells;
LIHC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.29	0.55	5.1e-29	Cognitive test performance;
LIHC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.01	-0.4	1.77e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg25251204	chr11:14927456	NA	0.41	5.87	0.3	1.03e-8	Vitamin D levels;
LIHC	trans	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg16088116	chr21:44841560	SIK1	-0.42	-6.49	-0.33	2.93e-10	Coronary artery disease;
LIHC	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg08539965	chr1:21396338	EIF4G3	-0.32	-5.74	-0.3	2.08e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg15848620	chr12:58087721	OS9	-0.54	-7.42	-0.37	9.55e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.5	-0.49	1.5e-22	Chronic sinus infection;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04816434	chr15:22945077	CYFIP1	-0.44	-6.63	-0.34	1.32e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.56	10.13	0.48	2.81e-21	Methadone dose in opioid dependence;
LIHC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	0.98	10.53	0.49	1.23e-22	Vitiligo;
LIHC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.98	0.47	9.29e-21	Platelet count;
LIHC	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg27386326	chr11:61587980	NA	0.69	14.03	0.6	1.29e-35	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.19	-0.32	1.73e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.81	8.62	0.42	2.59e-16	Vitiligo;
LIHC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13126279	chr21:47581558	C21orf56	-0.39	-5.96	-0.31	6.17e-9	Testicular germ cell tumor;
LIHC	trans	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.54	-0.33	2.26e-10	Educational attainment (years of education);
LIHC	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.19	0.32	1.7e-9	Heart rate;
LIHC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.56	-6.77	-0.34	5.65e-11	Alzheimer's disease;
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07308232	chr7:1071921	C7orf50	-0.36	-5.81	-0.3	1.43e-8	Longevity;Endometriosis;
LIHC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-9.98	-0.47	9.32e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg01652190	chr22:50026171	C22orf34	-0.31	-7.08	-0.36	8.46e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.65	0.38	2.09e-13	Electroencephalogram traits;
LIHC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg13535736	chr9:111863775	C9orf5	-0.38	-5.78	-0.3	1.71e-8	Menarche (age at onset);
LIHC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.8	9.02	0.44	1.43e-17	Vitiligo;
LIHC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.38	-0.33	5.85e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg18630855	chr2:37459194	CEBPZ;C2orf56	-0.42	-6.71	-0.34	7.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.7	0.38	1.48e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg00280220	chr17:61926910	NA	0.42	6.87	0.35	2.99e-11	Prudent dietary pattern;
LIHC	cis	rs151997	1.000	rs151997	chr5:50233199	A/G	cg06027927	chr5:50259733	NA	-0.58	-7.91	-0.39	3.53e-14	Callous-unemotional behaviour;
LIHC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.58e-15	Motion sickness;
LIHC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.95	16.87	0.67	6.67e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.98	13.3	0.58	7.84e-33	Heart rate;
LIHC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.6	10.65	0.5	4.53e-23	Schizophrenia;
LIHC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.4	-0.33	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.09	0.4	1.06e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.7	10.77	0.5	1.68e-23	Monocyte count;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.69	10.09	0.48	3.89e-21	Lymphocyte counts;
LIHC	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.57	0.42	3.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.54	7.05	0.36	1.02e-11	Type 2 diabetes;
LIHC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.68	12.94	0.57	1.89e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg03037974	chr15:76606532	NA	-0.6	-9.92	-0.47	1.49e-20	Blood metabolite levels;
LIHC	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg07689907	chr11:61582574	FADS1	0.41	5.94	0.31	6.98e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02985541	chr2:219472218	PLCD4	-0.35	-6.13	-0.31	2.4e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.56	-9.53	-0.46	3.04e-19	Blood metabolite levels;
LIHC	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.26	-0.32	1.18e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.53	8.02	0.4	1.74e-14	Height;
LIHC	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs2073499	0.935	rs2236939	chr3:50243510	G/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	5.83	0.3	1.27e-8	Schizophrenia;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.6	-0.34	1.56e-10	Hepatocellular carcinoma;
LIHC	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.72	-8.54	-0.42	4.39e-16	Blood pressure (smoking interaction);
LIHC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.22e-26	Motion sickness;
LIHC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.46	7.1	0.36	7.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.48	-9.28	-0.45	2e-18	Testicular germ cell tumor;
LIHC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.35	-6.24	-0.32	1.3e-9	Height;
LIHC	cis	rs1198430	1.000	rs1198432	chr1:23756155	C/T	cg19827787	chr1:23763612	ASAP3	-0.36	-6.32	-0.32	8.19e-10	Total cholesterol levels;
LIHC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.33	0.32	7.54e-10	Hepatocellular carcinoma;
LIHC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg02980000	chr4:1222292	CTBP1	-0.53	-7.33	-0.37	1.63e-12	Obesity-related traits;
LIHC	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg22138327	chr13:27999177	GTF3A	0.76	6.26	0.32	1.17e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.96	-11.14	-0.52	8.25e-25	Vitiligo;
LIHC	cis	rs1190552	1.000	rs1190552	chr14:102911907	A/G	cg10241871	chr14:102965420	TECPR2	0.46	7.13	0.36	6.16e-12	Blood protein levels;
LIHC	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.17	26.38	0.82	1.97e-84	Schizophrenia;
LIHC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.53	-8.28	-0.41	2.8e-15	Uric acid clearance;
LIHC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.88	-0.54	1.78e-27	Type 2 diabetes;
LIHC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.43	-8.53	-0.42	4.8e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-10.23	-0.48	1.32e-21	Neutrophil percentage of white cells;
LIHC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3853824	1.000	rs2197258	chr17:54878582	A/T	cg13675837	chr17:54910204	DGKE	0.39	5.88	0.3	9.79e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7116495	0.609	rs1541304	chr11:71714078	T/C	cg26138937	chr11:71823887	C11orf51	-1.32	-10.9	-0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.43	6.04	0.31	3.98e-9	Tonsillectomy;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21953508	chr4:38690502	KLF3	0.48	6.4	0.33	5.2e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg21361702	chr7:150065534	REPIN1	0.45	6.15	0.32	2.17e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg14222432	chr12:29376421	FAR2	0.36	6.91	0.35	2.42e-11	QT interval;
LIHC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.7	-0.5	3.15e-23	Breast cancer;
LIHC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.64	-0.38	2.14e-13	Calcium levels;
LIHC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.48	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.21	0.41	4.74e-15	Bladder cancer;
LIHC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.59	10.44	0.49	2.54e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.68	-0.38	1.64e-13	Schizophrenia;
LIHC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.2	15.24	0.64	2.21e-40	Alzheimer's disease (late onset);
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg14709524	chr16:89940631	TCF25	0.55	7.23	0.36	3.12e-12	Skin colour saturation;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.64	10.22	0.48	1.4e-21	Longevity;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07050032	chr17:78009173	CCDC40;TBC1D16	-0.53	-6.15	-0.32	2.17e-9	Systolic blood pressure;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24316073	chr7:150773456	SLC4A2	0.36	6.16	0.32	1.99e-9	Longevity;
LIHC	cis	rs10411936	0.712	rs8103521	chr19:16589750	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	6.9	0.35	2.57e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs9513627	1.000	rs6491512	chr13:100199741	C/T	cg25919922	chr13:100150906	NA	0.77	6.89	0.35	2.62e-11	Obesity-related traits;
LIHC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.48	7.21	0.36	3.64e-12	Prostate cancer;
LIHC	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg22771759	chr13:24902376	NA	0.31	6.44	0.33	4.02e-10	Obesity-related traits;
LIHC	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.4	-6.42	-0.33	4.6e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg02990361	chr1:107599529	PRMT6	0.59	9.78	0.47	4.29e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17213078	0.602	rs4851926	chr2:106742660	A/G	cg16099169	chr2:106886729	NA	0.43	6.53	0.33	2.36e-10	Facial morphology (factor 23);
LIHC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	1.18	12.71	0.57	1.35e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.65	9.09	0.44	8.3e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg21252483	chr19:49399788	TULP2	-0.98	-10.98	-0.51	3.08e-24	Red cell distribution width;
LIHC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02711726	chr17:80685570	FN3KRP	-0.4	-7.16	-0.36	4.91e-12	Glycated hemoglobin levels;
LIHC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.19	-0.32	1.71e-9	Schizophrenia;
LIHC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg12365402	chr11:9010492	NRIP3	0.27	6.2	0.32	1.63e-9	Hematocrit;
LIHC	cis	rs10508774	1.000	rs72793580	chr10:32725421	C/T	cg01819863	chr10:32635814	EPC1	0.67	6.23	0.32	1.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10423674	0.526	rs11085241	chr19:18828546	G/A	cg14292368	chr19:18793705	CRTC1	-0.42	-5.82	-0.3	1.34e-8	Menarche (age at onset);
LIHC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15483964	chr1:16482439	EPHA2	-0.51	-6.14	-0.32	2.25e-9	Systolic blood pressure;
LIHC	cis	rs6586163	0.872	rs7082101	chr10:90741615	C/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.53	-7.78	-0.39	8.86e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	16.65	0.67	5.29e-46	Nonalcoholic fatty liver disease;
LIHC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.58	0.46	2.06e-19	Bipolar disorder;
LIHC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.94	17.79	0.69	1.4e-50	Menopause (age at onset);
LIHC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.76	-9.33	-0.45	1.32e-18	Morning vs. evening chronotype;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.48	8.02	0.4	1.69e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs4908768	0.501	rs7527389	chr1:8556545	A/G	cg20416874	chr1:8611966	RERE	-0.67	-14.23	-0.61	2.07e-36	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg25894440	chr7:65020034	NA	0.53	6.07	0.31	3.34e-9	Diabetic kidney disease;
LIHC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.32	0.32	7.96e-10	Longevity;
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.54	-0.33	2.19e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.53	9.33	0.45	1.41e-18	Breast cancer;
LIHC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	13.48	0.59	1.64e-33	Primary sclerosing cholangitis;
LIHC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-12.88	-0.57	3.19e-31	Total body bone mineral density;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg12424548	chr11:2591932	KCNQ1	0.36	6.04	0.31	4.1e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.43	-6.0	-0.31	5.04e-9	Longevity;
LIHC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2710642	0.564	rs60144282	chr2:62843163	G/T	cg17519650	chr2:63277830	OTX1	0.46	7.29	0.37	2.19e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18404039	chr20:3184938	DDRGK1	0.47	6.44	0.33	4.01e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg07150772	chr14:90864620	CALM1	-0.41	-5.83	-0.3	1.29e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20135002	chr11:47629003	NA	0.52	8.72	0.43	1.26e-16	Subjective well-being;
LIHC	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-0.67	-7.54	-0.38	4.33e-13	Gut microbiota (bacterial taxa);
LIHC	trans	rs875971	0.660	rs801211	chr7:66015689	T/G	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.47	-9.61	-0.46	1.6e-19	Immature fraction of reticulocytes;
LIHC	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.47	-6.55	-0.33	2.17e-10	Life satisfaction;
LIHC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.72	7.26	0.37	2.61e-12	Vitiligo;
LIHC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-9.49	-0.46	3.97e-19	Platelet count;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08219700	chr8:58056026	NA	0.53	6.96	0.35	1.71e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04779191	chr16:69166964	CHTF8;CIRH1A	0.4	6.51	0.33	2.6200000000000003e-10	Metabolic traits;
LIHC	cis	rs7091068	0.616	rs7093903	chr10:95484010	C/T	cg20715218	chr10:95462985	C10orf4	-0.52	-5.97	-0.31	5.87e-9	Urinary tract infection frequency;
LIHC	cis	rs4699052	0.662	rs1400363	chr4:104250722	A/C	cg16532752	chr4:104119610	CENPE	-0.37	-5.72	-0.3	2.32e-8	Testicular germ cell tumor;
LIHC	trans	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg09872104	chr7:134855509	C7orf49	-0.78	-6.31	-0.32	8.48e-10	Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg03929089	chr4:120376271	NA	-0.43	-6.58	-0.34	1.78e-10	Coronary artery disease;
LIHC	cis	rs151349	1.000	rs151345	chr20:57586849	G/C	cg23907860	chr20:57583709	CTSZ	-0.44	-7.18	-0.36	4.35e-12	Platelet distribution width;
LIHC	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.33	-12.81	-0.57	5.98e-31	Psoriasis vulgaris;
LIHC	cis	rs7523273	0.526	rs1204708	chr1:208024062	G/C	cg22525895	chr1:207977042	MIR29B2	-0.59	-9.2	-0.45	3.5e-18	Schizophrenia;
LIHC	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.66	10.35	0.49	5.05e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.28	0.41	2.77e-15	Morning vs. evening chronotype;
LIHC	cis	rs7674212	0.541	rs11727498	chr4:104100987	C/T	cg16532752	chr4:104119610	CENPE	-0.42	-6.66	-0.34	1.06e-10	Type 2 diabetes;
LIHC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.35	6.38	0.33	5.59e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.0	0.31	5.11e-9	Electroencephalogram traits;
LIHC	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg08992911	chr2:238395768	MLPH	0.55	6.05	0.31	3.84e-9	Prostate cancer;
LIHC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.23e-15	Bladder cancer;
LIHC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-22.08	-0.77	9.16e-68	Coronary artery disease;
LIHC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.72	-0.34	7.6e-11	Psoriasis;
LIHC	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.97	10.89	0.51	6.51e-24	IgG glycosylation;
LIHC	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.56	7.62	0.38	2.51e-13	Hemoglobin concentration;Hematocrit;
LIHC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.14	0.52	8.37e-25	Menarche (age at onset);
LIHC	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.72	-11.21	-0.52	4.73e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	9.43	0.45	6.58e-19	Lymphocyte counts;
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.51	7.42	0.37	9.34e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.78	-0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-0.83	-6.87	-0.35	3.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	8.38	0.41	1.43e-15	Testicular germ cell tumor;
LIHC	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg03805757	chr16:71968109	PKD1L3	-0.47	-5.81	-0.3	1.43e-8	Post bronchodilator FEV1;
LIHC	cis	rs238295	0.805	rs1056244	chr20:5551034	G/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.53	-7.19	-0.36	4.16e-12	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg20991723	chr1:152506922	NA	0.4	6.15	0.32	2.19e-9	Hair morphology;
LIHC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.53	6.91	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs15676	0.947	rs2293968	chr9:131587240	G/A	cg00228799	chr9:131580591	ENDOG	0.46	7.1	0.36	7.08e-12	Blood metabolite levels;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.83	0.35	3.94e-11	Schizophrenia;
LIHC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg03013999	chr17:37608204	MED1	0.35	5.74	0.3	2.11e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-8.43	-0.41	9.85e-16	Gut microbiome composition (summer);
LIHC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.6	-8.09	-0.4	1.05e-14	Diastolic blood pressure;
LIHC	cis	rs600806	0.676	rs2781553	chr1:110026989	G/T	cg02415029	chr1:110025642	ATXN7L2	0.46	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.72	0.39	1.3e-13	Morning vs. evening chronotype;
LIHC	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.49	6.5	0.33	2.88e-10	Mean corpuscular volume;
LIHC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.46	6.39	0.33	5.38e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.93	15.26	0.64	1.83e-40	Cognitive ability;
LIHC	cis	rs600806	0.665	rs1368988	chr1:110012123	A/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.58	-0.38	3.35e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.66	0.42	1.89e-16	Motion sickness;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16821904	chr2:87169999	RGPD1;RGPD2	0.36	6.92	0.35	2.17e-11	Bilirubin levels;
LIHC	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.63	-10.59	-0.5	7.33e-23	Waist circumference;Body mass index;
LIHC	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.39	-6.46	-0.33	3.6e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	7.89	0.39	4.21e-14	Coronary artery disease;
LIHC	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.54	-0.33	2.27e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.53	9.0	0.44	1.59e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25631650	chr19:633157	POLRMT	0.38	6.12	0.31	2.62e-9	Metabolic traits;
LIHC	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg01557791	chr16:72042693	DHODH	-0.42	-6.25	-0.32	1.24e-9	Coronary artery disease;
LIHC	cis	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg01364799	chr7:75623366	TMEM120A	0.46	6.66	0.34	1.08e-10	Eotaxin levels;
LIHC	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.35	-6.06	-0.31	3.69e-9	Menopause (age at onset);
LIHC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	1.02	10.59	0.5	7.69e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.91	13.07	0.58	5.94e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.67	0.34	1.04e-10	Renal cell carcinoma;
LIHC	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg15902774	chr15:75289873	SCAMP5	0.34	5.96	0.31	6.21e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11673344	0.864	rs8108727	chr19:37581524	T/C	cg27390819	chr19:37464633	NA	-0.51	-6.19	-0.32	1.73e-9	Obesity-related traits;
LIHC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.97e-24	Aortic root size;
LIHC	cis	rs6782228	0.651	rs9852825	chr3:128387357	C/G	cg16766828	chr3:128327626	NA	-0.43	-6.77	-0.34	5.68e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.43	5.9	0.3	8.52e-9	Life satisfaction;
LIHC	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg07959070	chr22:50026188	C22orf34	-0.35	-8.95	-0.44	2.35e-17	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.33	0.41	2.02e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.85	12.77	0.57	8.07e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.63	11.43	0.53	7.57e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	8.56	0.42	3.93e-16	Platelet count;
LIHC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.22	-0.52	4.43e-25	Primary sclerosing cholangitis;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.85	-0.47	2.55e-20	Height;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg27572074	chr19:42419406	NA	-0.5	-6.76	-0.34	5.92e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Corneal astigmatism;
LIHC	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	0.79	8.86	0.43	4.51e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.32	-5.71	-0.3	2.44e-8	Lewy body disease;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.55	8.89	0.43	3.56e-17	Total body bone mineral density;
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.38	6.12	0.31	2.63e-9	Prudent dietary pattern;
LIHC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.29	21.48	0.76	2.15e-65	Corneal structure;
LIHC	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.32	-7.25	-0.36	2.84e-12	Cutaneous nevi;
LIHC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg03037974	chr15:76606532	NA	0.75	14.59	0.62	8.08e-38	Blood metabolite levels;
LIHC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.5	7.83	0.39	6.08e-14	Total body bone mineral density;
LIHC	cis	rs16828019	0.852	rs71648534	chr1:41613747	G/T	cg03387723	chr1:41708464	SCMH1	-0.45	-7.22	-0.36	3.37e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg23533926	chr12:111358616	MYL2	0.33	6.47	0.33	3.34e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg03989125	chr22:38214979	NA	-0.42	-5.83	-0.3	1.26e-8	Glioblastoma;Glioma;
LIHC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg22633049	chr21:46681294	NA	-0.36	-6.29	-0.32	9.51e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.61	7.55	0.38	3.87e-13	Corneal astigmatism;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.4	-0.33	5.21e-10	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg18279126	chr7:2041391	MAD1L1	0.36	5.95	0.31	6.6e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg10483660	chr13:112241077	NA	-0.23	-6.09	-0.31	3.03e-9	Hepatitis;
LIHC	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg16275483	chr1:110013120	SYPL2	-0.5	-6.35	-0.32	6.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4700695	0.841	rs251305	chr5:65249859	C/T	cg21114390	chr5:65439923	SFRS12	0.49	6.63	0.34	1.3e-10	Facial morphology (factor 19);
LIHC	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.67	11.13	0.52	8.9e-25	White matter hyperintensity burden;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.82	0.43	5.84e-17	Height;
LIHC	cis	rs2191566	0.960	rs11083733	chr19:44520919	G/C	cg18700516	chr19:44507157	ZNF230	-0.35	-5.86	-0.3	1.11e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9503598	0.543	rs4959832	chr6:3435112	A/C	cg00476032	chr6:3446245	SLC22A23	-0.33	-5.99	-0.31	5.28e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg16736954	chr20:23401023	NAPB	0.72	8.46	0.42	7.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.86	0.39	5.19e-14	Coronary artery disease;
LIHC	cis	rs3823572	0.586	rs2953625	chr7:133657789	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.59	-0.81	1.83e-81	Myeloid white cell count;
LIHC	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg00601450	chr5:74908170	NA	-0.56	-6.74	-0.34	6.81e-11	Coronary artery disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05651185	chr6:125421530	NA	-0.34	-6.07	-0.31	3.41e-9	Calcium levels;
LIHC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.63	7.97	0.4	2.46e-14	Initial pursuit acceleration;
LIHC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.51	-7.11	-0.36	6.66e-12	Menarche (age at onset);
LIHC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.68	10.64	0.5	4.84e-23	Response to diuretic therapy;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08677398	chr8:58056175	NA	0.41	6.32	0.32	8.32e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27221266	chr10:96122679	NOC3L	0.57	8.17	0.4	6.13e-15	Pancreatic cancer;
LIHC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.22	-0.32	1.43e-9	Alzheimer's disease (late onset);
LIHC	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.31	6.87	0.35	2.98e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LIHC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-7.96	-0.4	2.58e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg17130504	chr10:102756923	LZTS2	0.54	7.53	0.38	4.48e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12611088	0.510	rs1133929	chr19:43983740	T/C	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.2	-0.32	1.58e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02971882	chr4:71554083	UTP3	-0.43	-6.59	-0.34	1.71e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.37	0.56	2.77e-29	Menopause (age at onset);
LIHC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.45	-6.49	-0.33	2.98e-10	P wave terminal force;
LIHC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg25894440	chr7:65020034	NA	-0.54	-6.31	-0.32	8.47e-10	Diabetic kidney disease;
LIHC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg05343316	chr1:45956843	TESK2	0.45	6.63	0.34	1.33e-10	High light scatter reticulocyte count;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.52	-7.12	-0.36	6.43e-12	Menopause (age at onset);
LIHC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg15691649	chr6:25882328	NA	-0.54	-7.82	-0.39	6.76e-14	Blood metabolite levels;
LIHC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.3	0.41	2.45e-15	IgG glycosylation;
LIHC	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg21605333	chr4:119757512	SEC24D	0.8	6.87	0.35	3.14e-11	Cannabis dependence symptom count;
LIHC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-10.84	-0.51	9.9899999999999993e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-0.98	-22.85	-0.78	8.02e-71	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11031096	0.655	rs10835736	chr11:4212013	G/A	cg18678763	chr11:4115507	RRM1	-0.39	-5.73	-0.3	2.17e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.81	13.05	0.58	7.15e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.47	-7.44	-0.37	8.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.47	6.43	0.33	4.25e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	0.79	10.13	0.48	2.96e-21	Blood pressure (smoking interaction);
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.67	9.84	0.47	2.78e-20	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.42	6.77	0.34	5.56e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.72	-9.57	-0.46	2.2e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	10.7	0.5	3.14e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg17980119	chr2:219472607	PLCD4	0.34	5.88	0.3	9.92e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.95	-0.31	6.78e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.84	15.05	0.63	1.27e-39	Aortic root size;
LIHC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.44	-7.27	-0.37	2.5e-12	Mean corpuscular volume;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.68	10.97	0.51	3.31e-24	Multiple myeloma (IgH translocation);
LIHC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.55	15.16	0.63	4.37e-40	Alzheimer's disease (late onset);
LIHC	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.34	5.86	0.3	1.11e-8	Mean arterial pressure;
LIHC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-9.0	-0.44	1.55e-17	Schizophrenia;
LIHC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.48	7.68	0.38	1.72e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08237663	chr3:130745839	NEK11;ASTE1	0.41	6.18	0.32	1.83e-9	Cognitive function;
LIHC	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.91	14.98	0.63	2.4e-39	Colorectal cancer;
LIHC	cis	rs2108622	0.649	rs113055956	chr19:15977312	T/A	cg13772218	chr19:15982569	NA	0.37	7.87	0.39	4.72e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07744623	chr20:44462345	SNX21	0.5	6.71	0.34	7.86e-11	Lung function (FEV1/FVC);
LIHC	cis	rs797680	0.856	rs10874762	chr1:93639101	T/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.67e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg03721293	chr16:90014378	DEF8	0.36	6.31	0.32	8.62e-10	Skin colour saturation;
LIHC	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.65	-6.99	-0.35	1.44e-11	Exhaled nitric oxide output;
LIHC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02290350	chr8:58132656	NA	0.4	8.41	0.41	1.13e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	11.0	0.51	2.72e-24	Lung cancer in ever smokers;
LIHC	cis	rs9322817	0.691	rs6571207	chr6:105242161	A/C	cg02098413	chr6:105308735	HACE1	-0.41	-7.62	-0.38	2.5e-13	Thyroid stimulating hormone;
LIHC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Blood protein levels;
LIHC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.16	-0.44	5.01e-18	Bipolar disorder;
LIHC	cis	rs9513627	1.000	rs4584676	chr13:100160560	A/G	cg25919922	chr13:100150906	NA	0.77	7.05	0.36	1.01e-11	Obesity-related traits;
LIHC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.28	0.37	2.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs4730268	0.950	rs2158837	chr7:107440451	C/T	cg18560240	chr7:107437656	SLC26A3	-0.51	-6.29	-0.32	9.84e-10	IgG glycosylation;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.01	0.44	1.44e-17	Height;
LIHC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.85	-0.43	4.66e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.61	-0.38	2.77e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25525087	chr17:17743565	NA	-0.4	-6.09	-0.31	3e-9	Cognitive function;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg18697163	chr20:60738480	SS18L1	0.47	6.72	0.34	7.66e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs965469	1.000	rs6037579	chr20:3347980	G/A	cg25506879	chr20:3388711	C20orf194	-0.56	-6.62	-0.34	1.41e-10	IFN-related cytopenia;
LIHC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.48	7.56	0.38	3.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.91	-10.15	-0.48	2.5e-21	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg16275483	chr1:110013120	SYPL2	-0.47	-5.83	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17554472	chr22:41940697	POLR3H	0.55	6.23	0.32	1.38e-9	Cannabis dependence symptom count;
LIHC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg07560587	chr16:88016574	BANP	0.43	6.86	0.35	3.31e-11	Menopause (age at onset);
LIHC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs2629540	0.508	rs12217633	chr10:126533872	A/G	cg08799069	chr10:126477246	METTL10	-0.44	-6.77	-0.34	5.65e-11	Cocaine dependence;
LIHC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.76	12.92	0.57	2.27e-31	Anterior chamber depth;
LIHC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.46	-0.62	2.58e-37	Systemic lupus erythematosus;
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg00684032	chr4:1343700	KIAA1530	0.4	6.82	0.35	4.22e-11	Obesity-related traits;
LIHC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.83	0.43	5.58e-17	Menarche (age at onset);
LIHC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	1.0	19.05	0.72	1.18e-55	Breast cancer;
LIHC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg09835421	chr16:68378352	PRMT7	-0.88	-10.26	-0.48	1.07e-21	Schizophrenia;
LIHC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.8	12.89	0.57	3.02e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.9	19.46	0.72	2.57e-57	Blood protein levels;
LIHC	cis	rs6504950	0.800	rs8065361	chr17:53008853	A/T	cg10237252	chr17:52977213	TOM1L1	-0.34	-5.99	-0.31	5.22e-9	Breast cancer;
LIHC	trans	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg04373760	chr16:53404718	NA	0.61	7.96	0.4	2.63e-14	Hypertriglyceridemia;
LIHC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.68	-12.01	-0.54	5.72e-28	Bone mineral density;
LIHC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.73	6.63	0.34	1.35e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.45	6.34	0.32	7.19e-10	Aortic root size;
LIHC	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12026394	chr9:100745975	ANP32B	0.5	6.56	0.33	1.96e-10	Hepatitis;
LIHC	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.67	8.91	0.43	3.13e-17	Corneal astigmatism;
LIHC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg23533926	chr12:111358616	MYL2	-0.35	-6.7	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.43	-6.03	-0.31	4.24e-9	Blood metabolite levels;
LIHC	cis	rs12101261	1.000	rs17111346	chr14:81452172	G/A	cg06600135	chr14:81408086	NA	0.36	6.25	0.32	1.21e-9	Graves' disease;
LIHC	cis	rs611744	0.967	rs686265	chr8:109199763	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-7.4	-0.37	1.04e-12	Electroencephalogram traits;
LIHC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.92	-0.39	3.42e-14	Morning vs. evening chronotype;
LIHC	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.99	-0.51	2.91e-24	Eye color traits;
LIHC	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	0.61	8.76	0.43	8.97e-17	Post bronchodilator FEV1;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg18576335	chr17:8110165	AURKB	0.41	6.18	0.32	1.78e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg03387723	chr1:41708464	SCMH1	-0.41	-6.76	-0.34	5.83e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs5753618	0.539	rs695438	chr22:31811876	G/C	cg02404636	chr22:31891804	SFI1	0.33	5.73	0.3	2.18e-8	Colorectal cancer;
LIHC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	1.03	13.13	0.58	3.46e-32	Primary sclerosing cholangitis;
LIHC	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14154082	chr13:112174009	NA	0.29	6.15	0.32	2.2e-9	Menarche (age at onset);
LIHC	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.36	0.33	6.32e-10	Heart rate;
LIHC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.47	6.72	0.34	7.41e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg17135325	chr3:160939158	NMD3	0.55	7.71	0.38	1.36e-13	Parkinson's disease;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg04632378	chr13:21900426	NA	0.39	6.49	0.33	3.09e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg27386326	chr11:61587980	NA	0.68	14.61	0.62	6.93e-38	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.65	-0.34	1.17e-10	Psoriasis;
LIHC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.75	11.41	0.52	9.41e-26	Corneal astigmatism;
LIHC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	1.06	22.62	0.77	6.65e-70	Breast cancer;
LIHC	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.58	-8.8	-0.43	6.68e-17	Red cell distribution width;
LIHC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	12.36	0.56	2.95e-29	Gut microbiome composition (summer);
LIHC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.72	-0.34	7.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.11	0.52	1.04e-24	Platelet count;
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.59	10.25	0.48	1.11e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	6.14	0.31	2.32e-9	Educational attainment;
LIHC	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.62	9.22	0.45	3.13e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs7777677	0.925	rs6956269	chr7:142369136	T/G	cg21680980	chr1:221069572	NA	-0.48	-6.08	-0.31	3.27e-9	Alcoholic chronic pancreatitis;
LIHC	cis	rs903552	0.800	rs28470883	chr15:102000824	G/A	cg19295451	chr15:102010161	PCSK6	-0.46	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.85	13.42	0.59	2.73e-33	Gastritis;
LIHC	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.91	-0.3	8.46e-9	Systolic blood pressure;
LIHC	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.27	-0.37	2.41e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg07895657	chr22:50616420	PANX2	-0.37	-6.5	-0.33	2.89e-10	Obesity-related traits;
LIHC	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg01652190	chr22:50026171	C22orf34	-0.29	-6.3	-0.32	9.2e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs847851	0.569	rs3800439	chr6:34961406	T/C	cg13137465	chr6:34857473	ANKS1A	0.67	7.53	0.38	4.57e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.94	17.96	0.7	2.83e-51	Menopause (age at onset);
LIHC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.48	-10.17	-0.48	2.18e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.39	5.71	0.3	2.41e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.96	17.76	0.69	1.79e-50	Monocyte percentage of white cells;
LIHC	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg14146966	chr2:61757674	XPO1	0.45	7.58	0.38	3.27e-13	Tuberculosis;
LIHC	trans	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.31	0.32	8.4e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg01646665	chr1:156251436	TMEM79;SMG5	-0.3	-5.76	-0.3	1.84e-8	Tonsillectomy;
LIHC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.86	-13.02	-0.58	9.33e-32	Obesity-related traits;
LIHC	cis	rs7487075	0.619	rs6582645	chr12:46805144	C/T	cg23829395	chr12:46796953	NA	0.36	6.29	0.32	9.45e-10	Itch intensity from mosquito bite;
LIHC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.65	6.94	0.35	2.01e-11	Blood protein levels;
LIHC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.42	7.17	0.36	4.75e-12	Mean corpuscular volume;
LIHC	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg20636351	chr8:55087400	NA	-0.32	-6.54	-0.33	2.22e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg19500098	chr13:21900506	NA	0.4	6.49	0.33	3.06e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11628318	0.515	rs9324049	chr14:103096352	T/C	cg12046867	chr14:103022105	NA	-0.37	-5.72	-0.3	2.28e-8	Platelet count;
LIHC	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg12698662	chr3:15914712	MIR563	-0.39	-7.27	-0.37	2.46e-12	Mean platelet volume;
LIHC	trans	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	6.97	0.35	1.59e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.56	-8.45	-0.42	8.7e-16	Height;
LIHC	cis	rs7095607	0.538	rs2634708	chr10:69920013	C/A	cg18986048	chr10:69913749	MYPN	0.49	7.33	0.37	1.65e-12	Lung function (FVC);
LIHC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg19680672	chr10:131412579	MGMT	-0.39	-5.92	-0.3	8.01e-9	Response to temozolomide;
LIHC	cis	rs2108622	0.727	rs7253873	chr19:15980900	A/G	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.08	0.31	3.3e-9	Personality dimensions;
LIHC	cis	rs2191566	0.747	rs4803667	chr19:44533604	T/C	cg18700516	chr19:44507157	ZNF230	-0.37	-6.18	-0.32	1.83e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-1.08	-13.82	-0.6	8.26e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg22842854	chr12:123319900	HIP1R	-0.68	-8.81	-0.43	6.29e-17	Schizophrenia;
LIHC	cis	rs4699052	0.928	rs4456958	chr4:104215332	A/G	cg16532752	chr4:104119610	CENPE	-0.4	-6.37	-0.33	6.09e-10	Testicular germ cell tumor;
LIHC	cis	rs4699052	0.928	rs2169511	chr4:104192580	G/A	cg16532752	chr4:104119610	CENPE	-0.4	-6.35	-0.32	6.81e-10	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.6	0.42	2.91e-16	Menarche (age at onset);
LIHC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.83	13.45	0.59	2.22e-33	Colorectal cancer;
LIHC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg20933634	chr6:27740509	NA	0.47	6.04	0.31	3.91e-9	Parkinson's disease;
LIHC	cis	rs6782228	0.675	rs4857918	chr3:128383960	T/C	cg16766828	chr3:128327626	NA	-0.43	-6.8	-0.35	4.66e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.79	6.39	0.33	5.48e-10	Body mass index;
LIHC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.81	-0.3	1.45e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg16586182	chr3:47516702	SCAP	-0.48	-8.48	-0.42	6.9e-16	QT interval;
LIHC	cis	rs2625529	0.667	rs16956381	chr15:72193237	A/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.77	-0.3	1.73e-8	Red blood cell count;
LIHC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg07061783	chr6:25882402	NA	-0.5	-6.39	-0.33	5.49e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg03037974	chr15:76606532	NA	-0.69	-11.33	-0.52	1.74e-25	Blood metabolite levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg25025968	chr11:4116056	RRM1	-0.41	-7.04	-0.36	1.09e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.89	-0.43	3.56e-17	Skin colour saturation;
LIHC	cis	rs7712401	0.525	rs193541	chr5:122253304	C/T	cg18764291	chr5:122110994	SNX2	0.41	6.86	0.35	3.22e-11	Mean platelet volume;
LIHC	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.49	9.42	0.45	6.86e-19	Testicular germ cell tumor;
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.57	9.91	0.47	1.67e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.42	-6.17	-0.32	1.98e-9	Systemic lupus erythematosus;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02359409	chr6:42947317	PEX6	-0.47	-6.58	-0.34	1.76e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.6	7.67	0.38	1.83e-13	Morning vs. evening chronotype;
LIHC	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.53	-0.38	4.68e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4908768	0.657	rs6693466	chr1:8817938	C/T	cg20416874	chr1:8611966	RERE	0.46	6.59	0.34	1.64e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.42	7.39	0.37	1.16e-12	Aortic root size;
LIHC	cis	rs72829446	0.530	rs9906913	chr17:7411360	G/A	cg02795151	chr17:7402630	POLR2A	0.54	6.4	0.33	5.07e-10	Androgen levels;
LIHC	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.05	-0.31	3.75e-9	Mean corpuscular volume;
LIHC	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg04118878	chr10:71993077	PPA1	0.58	6.06	0.31	3.56e-9	Blood protein levels;
LIHC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.67	12.44	0.56	1.45e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs57590327	0.679	rs13082609	chr3:81642131	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-6.79	-0.34	4.92e-11	Extraversion;
LIHC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.6	0.59	5.67e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs6141600	0.540	rs761312	chr20:34687809	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.63	-0.34	1.33e-10	Height;Hip circumference;
LIHC	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.15	0.32	2.13e-9	Mean corpuscular volume;
LIHC	cis	rs4700695	0.841	rs152994	chr5:65262989	A/G	cg21114390	chr5:65439923	SFRS12	0.44	5.72	0.3	2.31e-8	Facial morphology (factor 19);
LIHC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.73	9.92	0.47	1.53e-20	Body mass index;
LIHC	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg05697976	chr12:29376483	FAR2	0.3	5.79	0.3	1.57e-8	QT interval;
LIHC	cis	rs882732	1.000	rs10149354	chr14:95038368	C/T	cg14866387	chr14:95027382	SERPINA4	-0.46	-6.25	-0.32	1.2e-9	Blood protein levels;
LIHC	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.64	-9.93	-0.47	1.4e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1494950	0.661	rs2702521	chr4:15017141	C/T	cg12377275	chr4:15005593	CPEB2	-0.79	-7.13	-0.36	5.96e-12	Political ideology;
LIHC	cis	rs8081395	0.932	rs2777885	chr17:57830473	C/A	cg13753209	chr17:57696993	CLTC	-0.48	-7.28	-0.37	2.35e-12	White blood cell count;
LIHC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.48	6.51	0.33	2.63e-10	Emphysema distribution in smoking;
LIHC	cis	rs1165668	0.785	rs2070908	chr12:104324182	C/G	cg21863207	chr12:104234989	NT5DC3	-0.44	-7.47	-0.37	6.76e-13	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs2292096	0.929	rs12729842	chr1:200761806	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-6.13	-0.31	2.38e-9	Epilepsy;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.4	5.88	0.3	9.88e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.4	-0.37	1.04e-12	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg16822855	chr3:40428330	ENTPD3	0.33	5.9	0.3	8.89e-9	Renal cell carcinoma;
LIHC	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg03146154	chr1:46216737	IPP	-0.39	-5.93	-0.31	7.45e-9	High light scatter reticulocyte count;
LIHC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg02376097	chr19:46275166	DMPK	0.54	9.5	0.46	3.73e-19	Coronary artery disease;
LIHC	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	0.84	15.0	0.63	2.02e-39	Exhaled nitric oxide output;
LIHC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg18270830	chr10:32634957	EPC1	0.53	6.48	0.33	3.19e-10	Sexual dysfunction (female);
LIHC	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg24220031	chr2:73402428	NA	-0.27	-5.9	-0.3	8.62e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11488864	chr4:8379238	ACOX3	0.45	6.31	0.32	8.8e-10	Bilirubin levels;
LIHC	trans	rs78049276	0.736	rs73855814	chr4:148397751	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.44	-0.37	8.18e-13	Pulse pressure;
LIHC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.75	-0.3	1.98e-8	Bipolar disorder;
LIHC	cis	rs3770081	0.793	rs74743393	chr2:86227421	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.42	-0.41	1.03e-15	Facial emotion recognition (sad faces);
LIHC	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.53	-6.48	-0.33	3.12e-10	Schizophrenia;
LIHC	cis	rs507080	0.733	rs488141	chr11:118571168	A/G	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs7258015	0.865	rs1058154	chr19:10446897	C/A	cg13981319	chr19:10446556	ICAM3	0.45	6.57	0.33	1.9e-10	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.38	-0.37	1.25e-12	Tuberculosis;
LIHC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.62	-9.26	-0.45	2.31e-18	Parkinson's disease;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.24	0.55	7.84e-29	Prudent dietary pattern;
LIHC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.6	8.19	0.4	5.36e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.46	-11.99	-0.54	6.92e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs9596863	0.950	rs6561749	chr13:54435195	G/C	ch.13.53330881F	chr13:54432880	NA	-0.45	-6.46	-0.33	3.68e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.56	-10.16	-0.48	2.37e-21	Alzheimer's disease (late onset);
LIHC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.36	7.02	0.35	1.22e-11	Multiple system atrophy;
LIHC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.67	-10.15	-0.48	2.47e-21	Total body bone mineral density;
LIHC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.65	-5.78	-0.3	1.68e-8	Vitiligo;
LIHC	cis	rs600806	0.888	rs461200	chr1:109855404	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.87	-0.3	1.05e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.36	-6.32	-0.32	8.01e-10	Smoking behavior;
LIHC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.31	5.73	0.3	2.21e-8	Mean corpuscular volume;
LIHC	cis	rs6586163	0.872	rs7069841	chr10:90741955	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.53	-7.78	-0.39	8.86e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.75	-0.34	6.3e-11	Total body bone mineral density;
LIHC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.48	7.59	0.38	3.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg18446336	chr7:2847575	GNA12	-0.33	-6.46	-0.33	3.56e-10	Height;
LIHC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.8	0.54	3.57e-27	Motion sickness;
LIHC	cis	rs3743266	0.507	rs11637887	chr15:60765216	C/T	cg22293140	chr15:60689852	ANXA2	-0.62	-5.86	-0.3	1.08e-8	Menarche (age at onset);
LIHC	cis	rs2540917	0.594	rs56180823	chr2:60662004	A/G	cg00543073	chr2:60773386	BCL11A	-0.32	-6.4	-0.33	5.12e-10	Mean corpuscular volume;
LIHC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.49	-8.15	-0.4	6.76e-15	Menarche (age at onset);
LIHC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-10.78	-0.5	1.56e-23	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.94	18.02	0.7	1.57e-51	Menopause (age at onset);
LIHC	cis	rs2758596	0.826	rs2758602	chr1:156198232	T/G	cg24450063	chr1:156163899	SLC25A44	0.99	10.48	0.49	1.76e-22	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg26139080	chr11:47293733	MADD	-0.5	-8.45	-0.42	8.46e-16	HDL cholesterol;
LIHC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	8.75	0.43	9.66e-17	Total body bone mineral density;
LIHC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.76	11.91	0.54	1.36e-27	Breast cancer;
LIHC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.53	-6.7	-0.34	8.49e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.8	6.58	0.34	1.76e-10	Body mass index;
LIHC	trans	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg10756647	chr7:56101905	PSPH	-0.46	-6.8	-0.35	4.82e-11	Calcium levels;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.7	11.41	0.53	8.88e-26	Pulse pressure;
LIHC	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	0.69	7.42	0.37	9.54e-13	Coronary artery disease;
LIHC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg09417038	chr21:47716443	C21orf57	-0.53	-7.89	-0.39	4.05e-14	Testicular germ cell tumor;
LIHC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg04013166	chr16:89971882	TCF25	0.49	6.08	0.31	3.24e-9	Skin colour saturation;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg21584241	chr15:63341463	TPM1	0.44	6.38	0.33	5.9e-10	Orofacial clefts;
LIHC	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	0.71	7.93	0.39	3.1e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.19	-0.36	4.24e-12	Schizophrenia;
LIHC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.43e-23	Personality dimensions;
LIHC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.47	7.56	0.38	3.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg14004847	chr7:1930337	MAD1L1	0.55	7.97	0.4	2.39e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.87	-0.43	4.13e-17	Gut microbiome composition (summer);
LIHC	cis	rs2637266	0.663	rs846581	chr10:78497984	C/T	cg18941641	chr10:78392320	NA	0.27	5.83	0.3	1.3e-8	Pulmonary function;
LIHC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.84	16.35	0.66	8.71e-45	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg18081818	chr7:23246105	NA	-0.46	-7.08	-0.36	8.14e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.41	6.3	0.32	8.98e-10	Diastolic blood pressure;
LIHC	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.52	9.83	0.47	2.9e-20	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.75	0.43	1.01e-16	Menarche (age at onset);
LIHC	cis	rs9322817	0.691	rs2499663	chr6:105300570	A/G	cg02098413	chr6:105308735	HACE1	-0.43	-7.92	-0.39	3.37e-14	Thyroid stimulating hormone;
LIHC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg27478167	chr7:817139	HEATR2	-0.4	-5.77	-0.3	1.82e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16684958	chr7:75615977	POR	0.4	6.57	0.33	1.87e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07781247	chr5:93954443	ANKRD32;C5orf36	0.39	6.26	0.32	1.17e-9	Migraine with aura;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg02132458	chr4:57333267	SRP72	-0.57	-6.2	-0.32	1.64e-9	Bronchial neuroendocrine tumor;
LIHC	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg26031613	chr14:104095156	KLC1	1.03	12.96	0.57	1.56e-31	Body mass index;
LIHC	cis	rs2073499	0.873	rs6446202	chr3:50219991	C/G	cg03645007	chr3:50255295	SLC38A3	0.42	5.82	0.3	1.35e-8	Schizophrenia;
LIHC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.76	0.34	5.89e-11	Body mass index;
LIHC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.36	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.66	10.12	0.48	3.16e-21	Height;
LIHC	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.26	6.03	0.31	4.27e-9	Heart rate;
LIHC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.43	-6.79	-0.34	4.95e-11	Multiple myeloma;
LIHC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.22	0.32	1.42e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.15	-0.32	2.2e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs11711311	0.712	rs6764048	chr3:113332859	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.38	6.59	0.34	1.69e-10	IgG glycosylation;
LIHC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.42	-0.37	9.41e-13	Platelet count;
LIHC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-8.93	-0.43	2.61e-17	Total body bone mineral density;
LIHC	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.63	-9.42	-0.45	6.94e-19	Smoking behavior;
LIHC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.06	0.4	1.31e-14	Morning vs. evening chronotype;
LIHC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.98	0.31	5.55e-9	Schizophrenia;
LIHC	cis	rs16828019	0.777	rs10489521	chr1:41508490	C/T	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.56	-9.75	-0.47	5.66e-20	Vitiligo;
LIHC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg13160058	chr8:26243215	BNIP3L	-0.33	-6.43	-0.33	4.18e-10	Red cell distribution width;
LIHC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.56	-0.46	2.47e-19	Blood metabolite levels;
LIHC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.54	-0.46	2.71e-19	Colorectal cancer;
LIHC	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-10.71	-0.5	2.82e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.82	-12.51	-0.56	8.16e-30	Vitamin D levels;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	-0.6	-8.78	-0.43	7.97e-17	Prudent dietary pattern;
LIHC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20307385	chr11:47447363	PSMC3	-0.48	-6.32	-0.32	8.05e-10	Subjective well-being;
LIHC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg03721293	chr16:90014378	DEF8	0.36	5.72	0.3	2.33e-8	Skin colour saturation;
LIHC	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg00977110	chr5:151150581	G3BP1	0.56	7.0	0.35	1.37e-11	Preschool internalizing problems;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.45e-13	Prudent dietary pattern;
LIHC	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-5.71	-0.3	2.43e-8	Tuberculosis;
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.36	-5.89	-0.3	9.19e-9	Height;
LIHC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	trans	rs11153056	0.500	rs17068076	chr6:107537007	T/C	cg12119218	chr10:70287206	SLC25A16	-0.45	-6.13	-0.31	2.39e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.92	0.47	1.48e-20	Coffee consumption (cups per day);
LIHC	trans	rs57549656	0.799	rs56348918	chr19:2710486	C/T	cg08586426	chr11:33915315	LMO2	-0.28	-6.1	-0.31	2.93e-9	Schizophrenia;
LIHC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.59	9.9	0.47	1.71e-20	Height;
LIHC	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg04592579	chr7:75616294	TMEM120A	0.41	7.1	0.36	7.46e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs5769765	0.773	rs9616751	chr22:50222236	T/G	cg02269571	chr22:50332266	NA	-0.84	-10.16	-0.48	2.32e-21	Schizophrenia;
LIHC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20135002	chr11:47629003	NA	0.55	9.19	0.45	3.91e-18	Subjective well-being;
LIHC	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.22e-24	Breast cancer;
LIHC	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.74	-9.6	-0.46	1.75e-19	Coronary artery disease;
LIHC	cis	rs8062405	0.728	rs8056890	chr16:28897452	G/A	cg07451762	chr16:28383216	NA	0.33	6.03	0.31	4.23e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27297192	chr10:134578999	INPP5A	0.51	7.62	0.38	2.58e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg02269571	chr22:50332266	NA	0.59	8.37	0.41	1.46e-15	Schizophrenia;
LIHC	cis	rs1494950	1.000	rs12512141	chr4:15013361	A/C	cg12377275	chr4:15005593	CPEB2	-0.84	-7.53	-0.38	4.59e-13	Political ideology;
LIHC	cis	rs11628318	0.515	rs4906248	chr14:103126570	A/T	cg12046867	chr14:103022105	NA	0.39	5.92	0.3	7.82e-9	Platelet count;
LIHC	cis	rs7296418	0.961	rs61955196	chr12:123451018	G/C	cg00376283	chr12:123451042	ABCB9	0.75	12.87	0.57	3.51e-31	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17829318	chr4:37688612	RELL1	0.4	6.5	0.33	2.78e-10	Cognitive function;
LIHC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.34	-9.95	-0.47	1.19e-20	Plateletcrit;
LIHC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.38	8.15	0.4	6.96e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11858249	chr21:45079790	HSF2BP;RRP1B	0.39	6.13	0.31	2.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg07636037	chr3:49044803	WDR6	-0.55	-6.2	-0.32	1.67e-9	Educational attainment (years of education);
LIHC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.38	0.33	5.62e-10	Schizophrenia;
LIHC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.97	-0.31	5.91e-9	Calcium levels;
LIHC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.54	9.06	0.44	1.02e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.69	8.46	0.42	8.07e-16	Mean platelet volume;
LIHC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.11	0.31	2.79e-9	Menopause (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24592846	chr11:129873229	NCRNA00167;PRDM10	0.43	6.1	0.31	2.88e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.56	-5.92	-0.3	7.82e-9	Vitiligo;
LIHC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-7.42	-0.37	9.28e-13	Initial pursuit acceleration;
LIHC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.51	6.68	0.34	9.84e-11	Morning vs. evening chronotype;
LIHC	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-0.79	-8.41	-0.41	1.15e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1712517	0.744	rs11191641	chr10:105052940	C/T	cg05636881	chr10:105038444	INA	0.46	7.01	0.35	1.31e-11	Migraine;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.33	0.32	7.63e-10	Prudent dietary pattern;
LIHC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.47	6.23	0.32	1.37e-9	Obesity (extreme);
LIHC	trans	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg10208301	chr11:6592745	DNHD1	0.43	6.04	0.31	4.05e-9	Coronary artery calcification;
LIHC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg24209194	chr3:40518798	ZNF619	0.45	6.47	0.33	3.34e-10	Renal cell carcinoma;
LIHC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.14	16.33	0.66	1e-44	Gut microbiome composition (summer);
LIHC	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.33	-0.52	1.76e-25	Coronary artery disease;
LIHC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.87	13.11	0.58	4.23e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.68	0.34	9.43e-11	Bipolar disorder;
LIHC	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.36	5.82	0.3	1.36e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg17456097	chr1:26900765	RPS6KA1	0.42	5.94	0.31	6.95e-9	Glucose homeostasis traits;
LIHC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.98	-0.57	1.31e-31	Type 2 diabetes;
LIHC	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg12140854	chr5:148520817	ABLIM3	0.42	5.72	0.3	2.35e-8	Breast cancer;
LIHC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.88	-18.22	-0.7	2.48e-52	Height;
LIHC	cis	rs16828019	0.852	rs71648534	chr1:41613747	G/T	cg03962019	chr1:41807865	NA	0.53	7.51	0.38	5.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.45	6.92	0.35	2.28e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.47	-6.1	-0.31	2.9e-9	Mean corpuscular volume;
LIHC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-7.3	-0.37	2e-12	Mean corpuscular volume;
LIHC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs6586163	0.872	rs7910660	chr10:90743197	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.53	-7.76	-0.39	9.9e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.72	10.61	0.5	6.32e-23	Subjective well-being;
LIHC	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	trans	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.43	-6.1	-0.31	2.8e-9	Type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.55	6.49	0.33	3.01e-10	Alzheimer's disease;
LIHC	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	7.3	0.37	2.03e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.53	6.2	0.32	1.67e-9	Alzheimer's disease;
LIHC	cis	rs2637266	0.626	rs846616	chr10:78547311	A/G	cg18941641	chr10:78392320	NA	0.28	6.09	0.31	3.04e-9	Pulmonary function;
LIHC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-9.37	-0.45	9.88e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1712517	0.773	rs1063461	chr10:105049105	C/G	cg05636881	chr10:105038444	INA	0.45	6.9	0.35	2.53e-11	Migraine;
LIHC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.47	-7.12	-0.36	6.56e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.53e-15	Facial morphology (factor 19);
LIHC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.64	-9.14	-0.44	5.69e-18	Blood metabolite levels;
LIHC	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.82	-0.47	3.29e-20	Ulcerative colitis;
LIHC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.73	0.34	7.11e-11	Lung cancer in ever smokers;
LIHC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.94	0.31	7.17e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12927205	0.510	rs7185601	chr16:72035082	A/G	cg14768367	chr16:72042858	DHODH	0.55	5.87	0.3	1.05e-8	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.49	5.74	0.3	2.12e-8	Alzheimer's disease;
LIHC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.4	-6.69	-0.34	9.35e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.56	8.23	0.41	3.98e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-9.05	-0.44	1.08e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.59	-10.31	-0.49	6.75e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg01864069	chr14:103024347	NA	-0.46	-7.35	-0.37	1.5e-12	Platelet count;
LIHC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.34	-6.11	-0.31	2.72e-9	Height;
LIHC	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.49	-8.2	-0.41	4.98e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.36	5.84	0.3	1.24e-8	Height;
LIHC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg01843034	chr6:37503916	NA	-0.47	-7.28	-0.37	2.35e-12	Cognitive performance;
LIHC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg15208524	chr1:10270712	KIF1B	0.41	6.16	0.32	2.08e-9	Hepatocellular carcinoma;
LIHC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06874399	chr5:79704109	ZFYVE16	0.43	6.17	0.32	1.88e-9	Migraine with aura;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06712627	chr1:91966606	CDC7	-0.44	-6.13	-0.31	2.46e-9	Longevity;
LIHC	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.22	0.48	1.37e-21	Colorectal cancer;
LIHC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.85	12.91	0.57	2.45e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.28	-6.08	-0.31	3.15e-9	Pulmonary function;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05321960	chr1:155904084	KIAA0907	0.41	6.05	0.31	3.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3736485	0.934	rs2899475	chr15:51883051	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.53	8.02	0.4	1.67e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg06485521	chr6:53530600	KLHL31	-0.88	-5.87	-0.3	1.02e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs244293	0.831	rs8072090	chr17:53174434	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.47	-7.2	-0.36	3.94e-12	Menarche (age at onset);
LIHC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.21	0.55	1.05e-28	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs539514	0.516	rs9318377	chr13:76410018	G/A	cg04757411	chr13:76259545	LMO7	0.37	5.74	0.3	2.07e-8	Type 1 diabetes;
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22442454	chr1:209979470	IRF6	-0.39	-5.92	-0.3	7.91e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.98	0.31	5.5e-9	Obesity-related traits;
LIHC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.44	-8.35	-0.41	1.67e-15	Neurofibrillary tangles;
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.13e-10	Alzheimer's disease;
LIHC	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg14146966	chr2:61757674	XPO1	0.48	8.31	0.41	2.31e-15	Tuberculosis;
LIHC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg24296786	chr1:45957014	TESK2	-0.49	-7.33	-0.37	1.71e-12	Platelet count;
LIHC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.76	8.42	0.41	1.06e-15	Initial pursuit acceleration;
LIHC	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg23280166	chr11:118938394	VPS11	-0.45	-6.03	-0.31	4.37e-9	Coronary artery disease;
LIHC	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.61	0.5	6.15e-23	Colorectal cancer;
LIHC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg07952391	chr2:88470173	THNSL2	0.76	6.94	0.35	1.95e-11	Plasma clusterin levels;
LIHC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.42	-6.72	-0.34	7.56e-11	Multiple myeloma;
LIHC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.91	16.89	0.67	5.59e-47	Aortic root size;
LIHC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-7.75	-0.39	1.03e-13	Longevity;Endometriosis;
LIHC	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.47	-0.37	6.92e-13	Adiposity;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13409248	chr3:40428643	ENTPD3	0.47	7.79	0.39	8.02e-14	Renal cell carcinoma;
LIHC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.3	-6.23	-0.32	1.34e-9	Blood metabolite levels;
LIHC	trans	rs13098911	0.540	rs4388012	chr3:45996501	A/G	cg21656520	chr2:210867290	RPE	0.85	6.08	0.31	3.19e-9	Celiac disease;
LIHC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.41	-6.34	-0.32	7.24e-10	Platelet count;
LIHC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs986417	0.748	rs10136486	chr14:60946111	C/T	cg27398547	chr14:60952738	C14orf39	0.81	9.4	0.45	8.33e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.65	6.89	0.35	2.64e-11	Type 2 diabetes;
LIHC	trans	rs56347314	0.587	rs17765644	chr17:69179492	C/T	cg11497526	chr17:35902366	SYNRG	0.3	6.08	0.31	3.29e-9	Chin dimples;
LIHC	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.91	11.33	0.52	1.81e-25	Coronary artery disease;
LIHC	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.38	-6.84	-0.35	3.72e-11	Height;
LIHC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.64	11.0	0.51	2.7e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.32	7.17	0.36	4.54e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.44	-6.85	-0.35	3.37e-11	Neurofibrillary tangles;
LIHC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.8	-0.54	3.51e-27	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.27	-7.07	-0.36	8.94e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg02290350	chr8:58132656	NA	0.47	8.61	0.42	2.81e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	8.03	0.4	1.54e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs75064307	0.834	rs9288870	chr3:108113469	G/C	cg03329597	chr3:108125523	MYH15	0.5	6.7	0.34	8.42e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.9	-0.3	8.7e-9	Coronary artery disease;
LIHC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.87	-0.51	7.62e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.63	-10.44	-0.49	2.4e-22	Obesity-related traits;
LIHC	cis	rs249954	0.512	rs703767	chr16:23661639	G/C	cg05131483	chr16:23706242	ERN2	0.38	6.17	0.32	1.9e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.36	-5.81	-0.3	1.44e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.08	-0.4	1.12e-14	Exhaled nitric oxide output;
LIHC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg03146154	chr1:46216737	IPP	-0.37	-6.08	-0.31	3.28e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.59	10.02	0.48	6.76e-21	HDL cholesterol;
LIHC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	5.99	0.31	5.32e-9	Schizophrenia;
LIHC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg19680672	chr10:131412579	MGMT	-0.39	-5.92	-0.31	7.71e-9	Response to temozolomide;
LIHC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07305463	chr2:136567211	LCT	0.4	7.5	0.38	5.66e-13	Mosquito bite size;
LIHC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.55	10.23	0.48	1.31e-21	Methadone dose in opioid dependence;
LIHC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg12798992	chr6:167411361	FGFR1OP	0.47	6.97	0.35	1.63e-11	Crohn's disease;
LIHC	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg09795085	chr6:101329169	ASCC3	-0.55	-7.64	-0.38	2.27e-13	Neuroticism;
LIHC	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.66	0.42	1.95e-16	Corneal astigmatism;
LIHC	cis	rs1823913	0.599	rs17412635	chr2:192159560	A/G	cg12404831	chr2:192114017	MYO1B	-0.28	-5.74	-0.3	2.11e-8	Obesity-related traits;
LIHC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.43	-0.37	8.87e-13	Psoriasis;
LIHC	cis	rs6893300	0.560	rs1019443	chr5:179207547	A/G	cg14593053	chr5:179126677	CANX	-0.4	-7.12	-0.36	6.34e-12	Resting heart rate;
LIHC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.24e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.32	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg19645103	chr12:69753606	YEATS4	-0.44	-5.87	-0.3	1.02e-8	Response to diuretic therapy;
LIHC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	7.82	0.39	6.55e-14	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.68	9.29	0.45	1.81e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.57	0.53	2.46e-26	Motion sickness;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg22705602	chr4:152727874	NA	0.31	5.89	0.3	9.18e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg05484376	chr2:27715224	FNDC4	0.37	6.35	0.32	6.78e-10	Total body bone mineral density;
LIHC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26502414	chr17:2414945	METT10D	-0.36	-5.74	-0.3	2.09e-8	Myopia (pathological);
LIHC	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg08992911	chr2:238395768	MLPH	0.62	6.2	0.32	1.62e-9	Prostate cancer;
LIHC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.99	10.76	0.5	1.9e-23	Triglycerides;
LIHC	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.27	0.32	1.12e-9	Body mass index;
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.34	6.22	0.32	1.47e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.48	7.96	0.4	2.51e-14	Schizophrenia;
LIHC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg05941027	chr17:61774174	LIMD2	0.3	6.02	0.31	4.53e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.85	13.77	0.6	1.22e-34	Colorectal cancer;
LIHC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-8.82	-0.43	6.16e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs16958440	0.867	rs77149690	chr18:44697143	T/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.8	0.47	3.71e-20	Mean platelet volume;
LIHC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	9.87	0.47	2.21e-20	Alzheimer's disease;
LIHC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.46	-6.41	-0.33	4.97e-10	Schizophrenia;
LIHC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.94	-0.31	6.85e-9	Menopause (age at onset);
LIHC	cis	rs7249142	0.563	rs11669860	chr19:19277296	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-5.81	-0.3	1.42e-8	IgG glycosylation;
LIHC	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg04317338	chr11:64019027	PLCB3	0.86	8.31	0.41	2.26e-15	Mean platelet volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02718464	chr13:41384019	SUGT1L1;SLC25A15;MIR621	-0.44	-6.36	-0.33	6.47e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1434579	0.865	rs12983504	chr19:44942959	G/A	cg15540054	chr19:45004280	ZNF180	0.57	7.97	0.4	2.39e-14	Tuberculosis;
LIHC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.6	8.66	0.42	1.87e-16	Emphysema distribution in smoking;
LIHC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg25039879	chr17:56429692	SUPT4H1	0.76	8.71	0.43	1.34e-16	Cognitive test performance;
LIHC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.45	7.36	0.37	1.41e-12	Red blood cell count;
LIHC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.38	6.54	0.33	2.31e-10	Schizophrenia;
LIHC	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg24579218	chr15:68104479	NA	-0.34	-5.83	-0.3	1.27e-8	Restless legs syndrome;
LIHC	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg17130504	chr10:102756923	LZTS2	0.55	7.49	0.38	6.03e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-0.78	-8.54	-0.42	4.49e-16	Exhaled nitric oxide output;
LIHC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.71	-0.34	8.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.68	-12.41	-0.56	1.82e-29	Iron status biomarkers;
LIHC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.4	5.85	0.3	1.15e-8	Lipoprotein (a) levels;
LIHC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.41	5.84	0.3	1.22e-8	Blood protein levels;
LIHC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.66	-12.95	-0.57	1.67e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-10.46	-0.49	2.1e-22	Platelet count;
LIHC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	1.0	12.33	0.55	3.76e-29	Primary sclerosing cholangitis;
LIHC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.75e-22	Hemoglobin concentration;
LIHC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.87	8.53	0.42	4.82e-16	Mean platelet volume;
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg26338869	chr17:61819248	STRADA	0.52	7.13	0.36	5.88e-12	Height;
LIHC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.34	-7.32	-0.37	1.8e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.41	-5.72	-0.3	2.28e-8	Aortic root size;
LIHC	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg24848339	chr3:12840334	CAND2	0.32	6.58	0.34	1.76e-10	QRS complex (12-leadsum);
LIHC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.41	6.75	0.34	6.44e-11	Red blood cell count;
LIHC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.44	6.79	0.34	4.98e-11	Methadone dose in opioid dependence;
LIHC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg24296786	chr1:45957014	TESK2	-0.51	-7.52	-0.38	4.86e-13	Platelet count;
LIHC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.92	-0.31	7.68e-9	Life satisfaction;
LIHC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg10820045	chr2:198174542	NA	0.54	8.56	0.42	3.82e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17106184	1.000	rs72904730	chr1:51342035	G/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.5	-0.33	2.91e-10	Type 2 diabetes;
LIHC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27189623	chr16:705930	WDR90	0.42	7.04	0.36	1.06e-11	Height;
LIHC	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg17182837	chr8:41585554	ANK1	-0.23	-5.76	-0.3	1.92e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.07	0.36	8.51e-12	Bipolar disorder;
LIHC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.17	0.66	4.23e-44	Electrocardiographic conduction measures;
LIHC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-8.16	-0.4	6.28e-15	Body mass index;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24510909	chr7:44122661	POLM	-0.54	-6.12	-0.31	2.54e-9	Systolic blood pressure;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.42	-7.77	-0.39	9.5e-14	Abdominal aortic aneurysm;
LIHC	cis	rs1144333	1.000	rs5745343	chr1:76273805	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-8.14	-0.4	7.56e-15	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.93	-11.69	-0.53	8.71e-27	Schizophrenia;
LIHC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.97	0.57	1.49e-31	Colorectal cancer;
LIHC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-6.3	-0.32	9.39e-10	Chronic sinus infection;
LIHC	trans	rs10213084	1.000	rs10213084	chr4:147499338	G/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.41	7.45	0.37	7.66e-13	Response to antipsychotic treatment;
LIHC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-8.32	-0.41	2.09e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.47	0.46	4.64e-19	Corneal astigmatism;
LIHC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.77	0.34	5.55e-11	Menopause (age at onset);
LIHC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.76	0.67	1.87e-46	Lung cancer in ever smokers;
LIHC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg24881330	chr22:46731750	TRMU	-0.63	-6.58	-0.34	1.76e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.81	-0.3	1.45e-8	Personality dimensions;
LIHC	cis	rs6584283	0.875	rs1548962	chr10:101289735	C/G	cg06854084	chr10:101292507	NKX2-3	0.32	5.84	0.3	1.23e-8	Ulcerative colitis;
LIHC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.69	13.29	0.58	8.71e-33	Systemic lupus erythematosus;
LIHC	cis	rs3736485	0.966	rs7174435	chr15:51895065	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.25	-0.32	1.21e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.46	7.2	0.36	3.93e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.62	-9.71	-0.46	7.66e-20	Schizophrenia;
LIHC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.61	8.5	0.42	5.93e-16	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.15	0.32	2.14e-9	Mean corpuscular volume;
LIHC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.4	5.84	0.3	1.25e-8	Schizophrenia;
LIHC	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	9.36	0.45	1.07e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.31	-0.32	8.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1075232	1.000	rs12438318	chr15:31680445	G/A	cg01030201	chr15:31746330	NA	-0.79	-6.11	-0.31	2.7e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	1.02	10.23	0.48	1.29e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg10820045	chr2:198174542	NA	0.47	7.18	0.36	4.28e-12	Dermatomyositis;
LIHC	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.2	15.85	0.65	8.12e-43	Blood protein levels;
LIHC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.92	15.94	0.65	3.78e-43	Tonsillectomy;
LIHC	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	0.98	10.23	0.48	1.3e-21	Mean corpuscular volume;
LIHC	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.54	-8.48	-0.42	6.69e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.54	-8.32	-0.41	2.15e-15	QRS duration;
LIHC	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.41e-9	Prostate cancer;
LIHC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.54	0.33	2.19e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02290350	chr8:58132656	NA	0.38	7.98	0.4	2.2e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg05185784	chr16:90016020	DEF8	-0.46	-6.17	-0.32	1.91e-9	Skin colour saturation;
LIHC	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.75	11.53	0.53	3.22e-26	Eye color traits;
LIHC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg11062466	chr8:58055876	NA	0.39	5.9	0.3	8.84e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.03	-0.44	1.25e-17	Ulcerative colitis;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg02993280	chr1:107599747	PRMT6	0.69	11.3	0.52	2.19e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.13	-0.31	2.47e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg15105060	chr4:7024189	TBC1D14	-0.75	-6.22	-0.32	1.45e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg21486233	chr12:29375141	FAR2	0.32	6.36	0.33	6.44e-10	QT interval;
LIHC	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg00938859	chr5:1591904	SDHAP3	0.59	7.19	0.36	4.19e-12	Breast cancer;
LIHC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.89	0.3	9.21e-9	Bipolar disorder;
LIHC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.12	-0.44	6.77e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.52	-6.51	-0.33	2.6e-10	Major depressive disorder;
LIHC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg11839771	chr15:80205821	ST20	-0.32	-6.69	-0.34	9.34e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.38	0.49	3.89e-22	Post bronchodilator FEV1;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26297968	chr2:211035960	C2orf67	-0.42	-6.95	-0.35	1.85e-11	Cognitive function;
LIHC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-7.57	-0.38	3.55e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg09232555	chr8:11619866	NA	0.33	5.85	0.3	1.13e-8	Myopia (pathological);
LIHC	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg09904177	chr6:26538194	HMGN4	0.35	6.24	0.32	1.31e-9	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26461676	chr17:19140887	EPN2	0.5	7.01	0.35	1.29e-11	Lung function (FEV1/FVC);
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg05484376	chr2:27715224	FNDC4	0.39	6.53	0.33	2.36e-10	Total body bone mineral density;
LIHC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg03959625	chr15:84868606	LOC388152	0.48	6.73	0.34	7.07e-11	Schizophrenia;
LIHC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.53	-7.78	-0.39	8.79e-14	Coronary artery disease;
LIHC	cis	rs12086130	0.892	rs113588455	chr1:51494003	G/A	cg07174182	chr1:51127561	FAF1	-0.88	-9.84	-0.47	2.7e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs9378688	1.000	rs3823287	chr6:2244721	A/C	cg12303981	chr6:2244766	GMDS	-0.48	-6.32	-0.32	8.22e-10	Caudate nucleus volume;
LIHC	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.45	6.14	0.32	2.3e-9	High light scatter reticulocyte count;
LIHC	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.77	14.32	0.61	9.33e-37	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.45	7.4	0.37	1.09e-12	Response to temozolomide;
LIHC	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg03689076	chr20:33865952	NA	0.57	6.56	0.33	1.97e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg16822855	chr3:40428330	ENTPD3	-0.35	-6.54	-0.33	2.28e-10	Renal cell carcinoma;
LIHC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.1	9.99	0.48	8.88e-21	Diabetic retinopathy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14173624	chr17:72199366	RPL38	0.42	6.19	0.32	1.69e-9	Cognitive function;
LIHC	cis	rs74544699	1.000	rs629315	chr4:74776218	C/T	cg02530824	chr4:74847766	PF4	0.58	6.24	0.32	1.31e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.52	8.22	0.41	4.29e-15	Lymphocyte counts;
LIHC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.5	5.77	0.3	1.76e-8	Alzheimer's disease;
LIHC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.58	8.49	0.42	6.53e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.5	9.44	0.45	5.76e-19	Testicular germ cell tumor;
LIHC	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg06804625	chr1:109812012	CELSR2	0.41	5.83	0.3	1.26e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.57	8.02	0.4	1.66e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.15	-0.32	2.22e-9	Calcium levels;
LIHC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.56	7.83	0.39	6.39e-14	Neuroblastoma;
LIHC	cis	rs7651039	0.641	rs2455916	chr3:15667383	C/T	cg16303742	chr3:15540471	COLQ	0.55	9.72	0.47	6.93e-20	Coronary heart disease;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg01007350	chr1:165551424	LOC400794	0.47	6.25	0.32	1.19e-9	Hip circumference;
LIHC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.49	-7.28	-0.37	2.38e-12	Blood trace element (Zn levels);
LIHC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	0.39	6.15	0.32	2.2e-9	Coronary artery disease;
LIHC	cis	rs11951515	0.508	rs10059993	chr5:43598352	A/G	cg01983248	chr5:43482804	C5orf28	-0.35	-5.87	-0.3	1.04e-8	Metabolite levels  (X-11787);
LIHC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg14092571	chr14:90743983	NA	-0.4	-6.27	-0.32	1.12e-9	Mortality in heart failure;
LIHC	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.76	-10.52	-0.49	1.34e-22	Personality dimensions;
LIHC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.7	0.34	8.58e-11	Lung cancer in ever smokers;
LIHC	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg22809023	chr3:195622598	TNK2	0.47	6.97	0.35	1.64e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.13	0.44	6.32e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg12858261	chr2:113808755	IL1F8	-0.33	-5.75	-0.3	2e-8	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12296079	chr11:61849674	NA	-0.39	-6.14	-0.32	2.23e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	11.02	0.51	2.24e-24	Lung cancer in ever smokers;
LIHC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.68	-0.38	1.67e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.83	-0.43	5.7e-17	Body mass index;
LIHC	cis	rs10097731	0.908	rs77317991	chr8:82032468	C/T	cg25230327	chr8:82042993	NA	-0.56	-6.68	-0.34	9.73e-11	Serum total protein level;
LIHC	trans	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-6.41	-0.33	4.95e-10	Dental caries;
LIHC	cis	rs970821	0.667	rs6470183	chr8:124752408	C/T	cg00283535	chr8:124749564	ANXA13	-0.44	-8.03	-0.4	1.61e-14	Breast cancer;
LIHC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.92	16.47	0.67	2.85e-45	Colorectal cancer;
LIHC	cis	rs80282103	0.618	rs11819230	chr10:1128812	A/G	cg18964960	chr10:1102726	WDR37	0.66	5.9	0.3	8.54e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.95	16.39	0.66	5.75e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.44	6.6	0.34	1.6e-10	Rheumatoid arthritis;
LIHC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.89	0.6	4.46e-35	Primary sclerosing cholangitis;
LIHC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg15902774	chr15:75289873	SCAMP5	0.4	5.83	0.3	1.29e-8	Lung cancer;
LIHC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg00656387	chr3:40428638	ENTPD3	-0.4	-6.65	-0.34	1.16e-10	Renal cell carcinoma;
LIHC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg18016565	chr1:150552671	MCL1	0.56	10.38	0.49	3.86e-22	Melanoma;
LIHC	cis	rs4934494	0.681	rs12572928	chr10:91553549	C/T	cg19698084	chr10:91461284	KIF20B	-0.44	-5.72	-0.3	2.37e-8	Red blood cell count;
LIHC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.63	10.9	0.51	6.24e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.36	-0.41	1.61e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.37	-6.06	-0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.36	11.96	0.54	8.66e-28	Uric acid levels;
LIHC	trans	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg10756647	chr7:56101905	PSPH	-1.09	-13.39	-0.59	3.61e-33	Diabetic kidney disease;
LIHC	cis	rs15676	0.947	rs2997913	chr9:131589033	C/T	cg00228799	chr9:131580591	ENDOG	0.45	6.77	0.34	5.47e-11	Blood metabolite levels;
LIHC	cis	rs16828019	0.929	rs2363805	chr1:41719434	G/T	cg20697417	chr1:41786797	NA	0.34	6.55	0.33	2.11e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs61041384	1.000	rs4759367	chr12:123656544	G/A	cg00376283	chr12:123451042	ABCB9	-0.57	-6.34	-0.32	7.45e-10	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3770081	0.590	rs12622715	chr2:86453563	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.72	-7.66	-0.38	1.98e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.62	-10.17	-0.48	2.09e-21	Schizophrenia;
LIHC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.38	6.36	0.33	6.31e-10	Blood metabolite levels;
LIHC	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.66	-10.4	-0.49	3.42e-22	White matter hyperintensity burden;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27333693	chr10:23002092	PIP4K2A	0.45	7.1	0.36	7.2e-12	Cognitive function;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21448741	chr8:58168803	NA	0.36	6.66	0.34	1.09e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.71	-10.08	-0.48	4.42e-21	Bronchopulmonary dysplasia;
LIHC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.92	16.75	0.67	2.14e-46	Colorectal cancer;
LIHC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.55	7.03	0.36	1.16e-11	Initial pursuit acceleration;
LIHC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.21	0.52	4.87e-25	Coronary artery disease;
LIHC	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.21	-0.32	1.53e-9	Coronary artery disease;
LIHC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2380220	0.810	rs66524640	chr6:95956566	T/C	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.52e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg05044414	chr3:183734942	ABCC5	0.33	5.94	0.31	6.88e-9	Anterior chamber depth;
LIHC	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg13628971	chr7:2884303	GNA12	0.44	7.53	0.38	4.44e-13	Height;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.24	0.81	4.27e-80	Prudent dietary pattern;
LIHC	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.35	-7.52	-0.38	4.74e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.91	-15.18	-0.63	3.74e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg18404041	chr3:52824283	ITIH1	0.42	5.83	0.3	1.28e-8	Schizophrenia;
LIHC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.63	10.23	0.48	1.35e-21	Resting heart rate;
LIHC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg18944383	chr4:111397179	ENPEP	0.25	6.22	0.32	1.44e-9	Coronary artery disease;
LIHC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.07	-0.31	3.32e-9	Alzheimer's disease (late onset);
LIHC	trans	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17243582	chr15:59969081	BNIP2	0.47	6.55	0.33	2.14e-10	Hepatitis;
LIHC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.32	6.11	0.31	2.78e-9	Body mass index;
LIHC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg12661370	chr5:149340060	SLC26A2	0.64	10.24	0.48	1.2e-21	HIV-1 control;
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21448741	chr8:58168803	NA	0.36	6.28	0.32	1.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.67	11.53	0.53	3.21e-26	Diisocyanate-induced asthma;
LIHC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.12	0.4	8.57e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.48	10.89	0.51	6.77e-24	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.96	14.39	0.61	5.01e-37	Primary sclerosing cholangitis;
LIHC	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg03689076	chr20:33865952	NA	0.54	6.02	0.31	4.48e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.49	7.2	0.36	3.95e-12	Longevity;
LIHC	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.5	7.48	0.38	6.17e-13	Thyroid stimulating hormone;
LIHC	cis	rs10861342	1.000	rs1076	chr12:105562788	C/T	cg23923672	chr12:105501055	KIAA1033	-0.65	-7.74	-0.39	1.12e-13	IgG glycosylation;
LIHC	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg27005118	chr17:13972210	COX10	-0.35	-6.49	-0.33	3.02e-10	Temperament;
LIHC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.48	-7.68	-0.38	1.7e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7712401	0.791	rs1870559	chr5:122116706	G/C	cg18764291	chr5:122110994	SNX2	0.35	5.94	0.31	7.13e-9	Mean platelet volume;
LIHC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg14067834	chr17:29058358	SUZ12P	0.65	6.78	0.34	5.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.79	-0.3	1.56e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.23	0.32	1.34e-9	Schizophrenia;
LIHC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.87	-0.3	1.05e-8	Aortic root size;
LIHC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg14440974	chr22:39074834	NA	-0.35	-5.89	-0.3	9.27e-9	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.48	7.0	0.35	1.36e-11	Aortic root size;
LIHC	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.44	7.84	0.39	5.96e-14	Corneal structure;
LIHC	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.75	13.27	0.58	1.08e-32	Eosinophil percentage of white cells;
LIHC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	7.1	0.36	7.1e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg18446336	chr7:2847575	GNA12	-0.31	-6.02	-0.31	4.43e-9	Height;
LIHC	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.53	-0.42	4.87e-16	Body mass index;
LIHC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg22633049	chr21:46681294	NA	-0.35	-6.02	-0.31	4.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12744310	0.945	rs72665692	chr1:41775379	A/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs16958440	1.000	rs62096471	chr18:44643814	T/C	cg17192377	chr18:44677553	HDHD2	0.6	6.76	0.34	5.88e-11	Sitting height ratio;
LIHC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg15691649	chr6:25882328	NA	0.48	6.78	0.34	5.34e-11	Blood metabolite levels;
LIHC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.6	10.67	0.5	3.87e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-12.41	-0.56	1.81e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.62	-9.14	-0.44	5.77e-18	Parkinson's disease;
LIHC	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg15282417	chr9:129245246	FAM125B	0.38	6.11	0.31	2.67e-9	Intraocular pressure;
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.19	-0.36	4.14e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.52	7.26	0.37	2.62e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.44	8.35	0.41	1.74e-15	Tuberculosis;
LIHC	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-0.74	-8.61	-0.42	2.74e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.42	-8.52	-0.42	5.13e-16	Obesity-related traits;
LIHC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg18654377	chr3:49208889	KLHDC8B	0.48	5.74	0.3	2.09e-8	Menarche (age at onset);
LIHC	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg06359132	chr10:99160096	RRP12	-0.43	-6.7	-0.34	8.71e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-0.83	-13.11	-0.58	4.27e-32	Obesity-related traits;
LIHC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.17	0.55	1.43e-28	Cognitive test performance;
LIHC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.6	0.42	2.93e-16	Motion sickness;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17146150	chr15:56657437	TEX9	0.42	6.17	0.32	1.92e-9	Cognitive function;
LIHC	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.7	11.6	0.53	1.81e-26	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.45	6.48	0.33	3.22e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.09	0.51	1.32e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.19	-0.4	5.37e-15	Schizophrenia;
LIHC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-7.44	-0.37	8.4e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs8084351	0.534	rs13381767	chr18:50574947	G/A	cg24270629	chr18:50823537	DCC	0.4	5.99	0.31	5.31e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-6.15	-0.32	2.16e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26329349	chr8:67974458	COPS5	0.44	6.82	0.35	4.25e-11	Cognitive function;
LIHC	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.45	8.18	0.4	5.6e-15	Monocyte percentage of white cells;
LIHC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.38	-6.11	-0.31	2.75e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.82	0.3	1.38e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02732134	chr10:101732382	DNMBP	0.4	6.23	0.32	1.41e-9	Pancreatic cancer;
LIHC	cis	rs4908768	0.520	rs6695867	chr1:8730779	G/A	cg20416874	chr1:8611966	RERE	-0.62	-12.34	-0.56	3.41e-29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.46	8.48	0.42	6.9e-16	Glycated hemoglobin levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg10545927	chr1:33117362	RBBP4;ZBTB8OS	-0.42	-6.59	-0.34	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg25204440	chr1:209979598	IRF6	0.54	8.14	0.4	7.41e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.5	-0.33	2.85e-10	Colorectal cancer;
LIHC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.59	9.35	0.45	1.15e-18	Uric acid clearance;
LIHC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.48	6.23	0.32	1.35e-9	Coronary artery calcification;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.25	-0.32	1.21e-9	Longevity;
LIHC	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg18478394	chr8:109455254	TTC35	0.37	6.44	0.33	4.05e-10	Dupuytren's disease;
LIHC	cis	rs700651	0.789	rs892514	chr2:198905270	T/C	cg03934865	chr2:198174659	NA	0.47	6.56	0.33	1.95e-10	Intracranial aneurysm;
LIHC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7937890	0.559	rs2575823	chr11:14521354	C/A	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg26031613	chr14:104095156	KLC1	1.15	15.1	0.63	7.52e-40	Body mass index;
LIHC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.44	8.59	0.42	3.21e-16	Testicular germ cell tumor;
LIHC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.56	-0.33	2.04e-10	Mean corpuscular volume;
LIHC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	1.07	11.21	0.52	4.87e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06636551	chr8:101224915	SPAG1	-0.47	-8.81	-0.43	6.44e-17	Atrioventricular conduction;
LIHC	cis	rs1494950	1.000	rs2643077	chr4:14990765	T/C	cg12377275	chr4:15005593	CPEB2	-0.79	-6.62	-0.34	1.35e-10	Political ideology;
LIHC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.45	7.67	0.38	1.77e-13	Mean corpuscular volume;
LIHC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.49	-7.58	-0.38	3.25e-13	P wave terminal force;
LIHC	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg25364880	chr3:44379878	C3orf23	0.59	8.13	0.4	8.16e-15	Depressive symptoms;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	ch.7.1415213R	chr7:66262805	RABGEF1	0.4	6.63	0.34	1.35e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.05	0.4	1.35e-14	Platelet count;
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.36	-0.33	6.33e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.51	9.51	0.46	3.42e-19	Hemoglobin concentration;
LIHC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.65	13.8	0.6	9.51e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.64	-10.31	-0.49	7.02e-22	Monocyte percentage of white cells;
LIHC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg21466736	chr12:48725269	NA	0.63	9.14	0.44	5.64e-18	Glycated hemoglobin levels;
LIHC	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.36	6.18	0.32	1.82e-9	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.76	11.7	0.53	7.91e-27	Eye color traits;
LIHC	cis	rs12286929	0.639	rs10891802	chr11:115043888	C/A	cg04055981	chr11:115044050	NA	0.39	6.5	0.33	2.82e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg16587974	chr5:76383162	LOC728723;ZBED3	-0.48	-6.3	-0.32	9.41e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.47	7.72	0.39	1.28e-13	Alcohol dependence;
LIHC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.79	9.17	0.44	4.59e-18	Cognitive test performance;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05277466	chr16:88082055	BANP	0.44	6.46	0.33	3.7e-10	Immature fraction of reticulocytes;
LIHC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.79	-0.5	1.5e-23	Mean corpuscular volume;
LIHC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.72	-9.53	-0.46	2.93e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg20240347	chr1:204465584	NA	-0.36	-7.68	-0.38	1.64e-13	Schizophrenia;
LIHC	cis	rs13343954	0.825	rs7259371	chr19:33534641	G/A	cg27124370	chr19:33622961	WDR88	0.42	5.8	0.3	1.52e-8	Colorectal cancer;
LIHC	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.56	0.46	2.44e-19	Morning vs. evening chronotype;
LIHC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.43	-0.49	2.72e-22	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.4	-6.26	-0.32	1.14e-9	Educational attainment;
LIHC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.52	-9.29	-0.45	1.79e-18	Blood protein levels;
LIHC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.24	19.11	0.72	6.71e-56	Type 1 diabetes nephropathy;
LIHC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.45	6.07	0.31	3.47e-9	Initial pursuit acceleration;
LIHC	cis	rs11098699	0.784	rs6838926	chr4:124219260	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.29	0.32	9.63e-10	Mosquito bite size;
LIHC	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.06	-0.31	3.67e-9	Tuberculosis;
LIHC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg21734168	chr11:67353974	GSTP1	-0.26	-6.26	-0.32	1.12e-9	Mean corpuscular volume;
LIHC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.59	8.13	0.4	7.9e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg11642891	chr2:3452563	TTC15	-0.45	-7.21	-0.36	3.52e-12	Obesity-related traits;
LIHC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.39	-7.09	-0.36	7.92e-12	Electrocardiographic conduction measures;
LIHC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.4	-6.76	-0.34	5.83e-11	Facial morphology (factor 20);
LIHC	cis	rs2191566	0.845	rs7258517	chr19:44535999	G/T	cg18700516	chr19:44507157	ZNF230	-0.37	-6.18	-0.32	1.83e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.14	-0.36	5.49e-12	Longevity;Endometriosis;
LIHC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.02	0.51	2.34e-24	Menarche (age at onset);
LIHC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.12	-26.32	-0.82	3.17e-84	Cognitive ability;
LIHC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg17980119	chr2:219472607	PLCD4	0.36	6.25	0.32	1.19e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg19680485	chr15:31195859	MTMR15	0.55	6.39	0.33	5.35e-10	Hypertriglyceridemia;
LIHC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	12.77	0.57	8.31e-31	Electrocardiographic conduction measures;
LIHC	cis	rs611744	0.967	rs686630	chr8:109233239	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.02	-0.35	1.19e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627123	0.656	rs75646425	chr14:74529433	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	8.7	0.43	1.38e-16	Morning vs. evening chronotype;
LIHC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-8.84	-0.43	5.04e-17	Parkinson's disease;
LIHC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.14	0.58	3.2e-32	Cognitive test performance;
LIHC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.24	-5.73	-0.3	2.21e-8	Childhood ear infection;
LIHC	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.76	11.53	0.53	3.26e-26	Subjective well-being;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19266034	chr7:108210536	THAP5;DNAJB9	0.54	7.08	0.36	8.31e-12	Lung function (FEV1/FVC);
LIHC	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.2	0.32	1.62e-9	Ulcerative colitis;
LIHC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.7	-10.26	-0.49	1e-21	Coronary artery disease;
LIHC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.45	0.33	3.79e-10	Body mass index;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg07725925	chr16:89976287	TCF25	-0.42	-5.83	-0.3	1.31e-8	Skin colour saturation;
LIHC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs80282103	0.618	rs56004802	chr10:1159187	C/T	cg08668510	chr10:1095578	IDI1	0.63	6.14	0.31	2.35e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.45	7.4	0.37	1.09e-12	Response to temozolomide;
LIHC	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.14	15.97	0.65	2.7e-43	Corneal structure;
LIHC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.75e-12	IgG glycosylation;
LIHC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.87	13.2	0.58	1.92e-32	Vitamin D levels;
LIHC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.19	-0.52	5.73e-25	Response to antipsychotic treatment;
LIHC	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.49	-9.32	-0.45	1.45e-18	Endometriosis;
LIHC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	8.15	0.4	6.94e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3106136	0.678	rs17021531	chr4:95280514	A/C	cg11021082	chr4:95130006	SMARCAD1	0.34	5.87	0.3	1.04e-8	Capecitabine sensitivity;
LIHC	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-8.38	-0.41	1.35e-15	Parkinson's disease;
LIHC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-23.35	-0.78	8.99e-73	Height;
LIHC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.1	-0.44	7.62e-18	Bipolar disorder;
LIHC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg24130564	chr14:104152367	KLC1	0.44	7.2	0.36	3.75e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.44	-6.28	-0.32	1.04e-9	Height;
LIHC	cis	rs12079745	1.000	rs12081562	chr1:169176266	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-6.58	-0.34	1.81e-10	QT interval;
LIHC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	8.12	0.4	8.48e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.84	17.59	0.69	9.04e-50	Longevity;
LIHC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.59	8.07	0.4	1.22e-14	Aortic root size;
LIHC	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.58	7.78	0.39	8.74e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-12.85	-0.57	4.01e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.55	6.31	0.32	8.76e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.02e-17	Arsenic metabolism;
LIHC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.48e-11	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16924120	chr12:118814149	SUDS3	0.46	6.51	0.33	2.68e-10	Pancreatic cancer;
LIHC	trans	rs10411161	1.000	rs8109345	chr19:52364933	T/C	cg22319618	chr22:45562946	NUP50	-0.52	-7.03	-0.36	1.1e-11	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13789711	chr9:139743225	PHPT1	0.37	6.19	0.32	1.72e-9	Cognitive function;
LIHC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.59	0.62	8.17e-38	Prudent dietary pattern;
LIHC	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg02503808	chr4:7069936	GRPEL1	-0.81	-8.79	-0.43	7.37e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.54	5.93	0.31	7.36e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-0.8	-7.52	-0.38	4.89e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg03934865	chr2:198174659	NA	-0.49	-7.2	-0.36	3.98e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.0	0.58	1.15e-31	Schizophrenia;
LIHC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg15412446	chr2:106886593	NA	-0.69	-6.88	-0.35	2.79e-11	Facial morphology (factor 23);
LIHC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.46	6.43	0.33	4.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.73	-0.3	2.2e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.64	-9.17	-0.44	4.47e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.01	-0.35	1.29e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.79	-0.43	7.56e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.61	9.11	0.44	6.97e-18	Menarche (age at onset);
LIHC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.87	-12.64	-0.56	2.5e-30	Diastolic blood pressure;Systolic blood pressure;
LIHC	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.57	7.04	0.36	1.03e-11	Breast cancer;
LIHC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg03013999	chr17:37608204	MED1	0.36	6.07	0.31	3.35e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.01	-0.35	1.28e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.0	-0.31	5.15e-9	Schizophrenia;
LIHC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.32	-8.24	-0.41	3.65e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg12365402	chr11:9010492	NRIP3	-0.33	-8.46	-0.42	7.72e-16	Hemoglobin concentration;
LIHC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.56	7.35	0.37	1.47e-12	Body mass index;
LIHC	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.59	7.78	0.39	8.9e-14	Economic and political preferences (feminism/equality);
LIHC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg15848620	chr12:58087721	OS9	-0.58	-8.02	-0.4	1.65e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.7	-7.55	-0.38	3.91e-13	Neuroticism;
LIHC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.87	15.07	0.63	9.92e-40	Parkinson's disease;
LIHC	cis	rs10792665	0.573	rs7130900	chr11:82574135	C/T	cg24227371	chr11:82718527	RAB30	-0.28	-6.49	-0.33	2.93e-10	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00648153	chr6:74364149	SLC17A5	0.45	6.22	0.32	1.48e-9	Pancreatic cancer;
LIHC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg13446199	chr8:143762866	PSCA	-0.2	-5.79	-0.3	1.59e-8	Urinary tract infection frequency;
LIHC	cis	rs732505	0.764	rs73920020	chr19:5583514	T/C	cg26242866	chr19:5711310	LONP1	0.83	6.11	0.31	2.65e-9	vWF and FVIII levels;
LIHC	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-5.72	-0.3	2.38e-8	Neuroticism;
LIHC	cis	rs7945705	0.967	rs10840147	chr11:8920704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.06	0.36	9.39e-12	Hemoglobin concentration;
LIHC	cis	rs10426930	0.714	rs858422	chr19:5049483	T/C	cg18473234	chr19:5097819	KDM4B	-0.55	-6.18	-0.32	1.86e-9	Monocyte percentage of white cells;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21774865	chr7:157009442	UBE3C	0.42	6.81	0.35	4.49e-11	Immature fraction of reticulocytes;
LIHC	cis	rs12286929	1.000	rs12286929	chr11:115022404	A/G	cg04055981	chr11:115044050	NA	0.4	6.59	0.34	1.66e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg22676075	chr6:135203613	NA	-0.42	-6.69	-0.34	9.1e-11	Red blood cell count;
LIHC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.74	14.2	0.61	2.61e-36	Mortality in heart failure;
LIHC	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg10820045	chr2:198174542	NA	0.47	7.44	0.37	7.99e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg02376097	chr19:46275166	DMPK	0.54	9.36	0.45	1.07e-18	Coronary artery disease;
LIHC	cis	rs903552	0.932	rs11858490	chr15:102007443	G/T	cg00659931	chr15:102010125	PCSK6	0.47	6.49	0.33	2.95e-10	Diabetic kidney disease;
LIHC	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-6.44	-0.33	3.95e-10	Ulcerative colitis;
LIHC	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg23254163	chr1:152506842	NA	0.23	5.98	0.31	5.64e-9	Hair morphology;
LIHC	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.4	5.95	0.31	6.72e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.73	11.67	0.53	1.05e-26	Morning vs. evening chronotype;
LIHC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg23262073	chr20:60523788	NA	-0.29	-6.23	-0.32	1.38e-9	Body mass index;
LIHC	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.2	-17.56	-0.69	1.16e-49	Ulcerative colitis;
LIHC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg14779329	chr11:130786720	SNX19	0.4	6.03	0.31	4.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00280220	chr17:61926910	NA	0.42	6.68	0.34	9.73e-11	Prudent dietary pattern;
LIHC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg16226627	chr15:75307476	SCAMP5	0.53	9.45	0.45	5.7e-19	Lung cancer;
LIHC	cis	rs9309473	0.950	rs10206899	chr2:73900900	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.48	-0.33	3.23e-10	Metabolite levels;
LIHC	cis	rs17152411	0.947	rs61873270	chr10:126595923	C/A	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.56	-7.79	-0.39	7.99e-14	Total body bone mineral density;
LIHC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg13753209	chr17:57696993	CLTC	-0.73	-11.64	-0.53	1.35e-26	Obesity-related traits;
LIHC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg07959070	chr22:50026188	C22orf34	-0.3	-7.7	-0.38	1.44e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.38	8.94	0.44	2.41e-17	Height;
LIHC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.41	6.21	0.32	1.54e-9	Lymphocyte counts;
LIHC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.4	6.45	0.33	3.75e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.56e-16	Primary biliary cholangitis;
LIHC	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.68	-9.49	-0.46	4.13e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.76	12.04	0.55	4.42e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.43	-7.07	-0.36	8.9e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.05	9.76	0.47	5.19e-20	Diabetic retinopathy;
LIHC	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.32	-0.32	8.34e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.57	-8.73	-0.43	1.16e-16	Blood trace element (Zn levels);
LIHC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg16586182	chr3:47516702	SCAP	0.6	11.71	0.54	7.09e-27	Colorectal cancer;
LIHC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg03037974	chr15:76606532	NA	0.6	10.27	0.49	9.71e-22	Blood metabolite levels;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.68	11.66	0.53	1.15e-26	Prudent dietary pattern;
LIHC	cis	rs9378688	0.654	rs2479011	chr6:2355749	C/T	cg12303981	chr6:2244766	GMDS	0.41	5.82	0.3	1.35e-8	Caudate nucleus volume;
LIHC	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.7	-9.76	-0.47	5.1e-20	Morning vs. evening chronotype;
LIHC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.47	7.97	0.4	2.37e-14	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25947998	chr8:42948467	SGK196	0.42	6.1	0.31	2.82e-9	Pancreatic cancer;
LIHC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	8.21	0.41	4.56e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.42	-6.89	-0.35	2.72e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.43	-6.58	-0.34	1.75e-10	Cognitive function;
LIHC	cis	rs7534824	0.625	rs61782081	chr1:101507074	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.24	0.36	2.99e-12	Refractive astigmatism;
LIHC	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.51	-8.05	-0.4	1.38e-14	HDL cholesterol;
LIHC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.73	-0.34	7.04e-11	Gut microbiome composition (summer);
LIHC	cis	rs4742903	1.000	rs2274724	chr9:106860568	C/T	cg14250997	chr9:106856677	SMC2	0.42	7.42	0.37	9.36e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2191566	0.960	rs11083732	chr19:44520743	T/C	cg20607764	chr19:44506953	ZNF230	-0.41	-6.7	-0.34	8.79e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg00280220	chr17:61926910	NA	-0.43	-6.83	-0.35	3.84e-11	Prudent dietary pattern;
LIHC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-10.28	-0.49	8.65e-22	Mood instability;
LIHC	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.85	-0.39	5.25e-14	Metabolite levels;
LIHC	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.54	-0.33	2.31e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.33	0.41	1.97e-15	Menarche (age at onset);
LIHC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.4	-5.94	-0.31	7.11e-9	Calcium levels;
LIHC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.88	13.57	0.59	7.71e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.49e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg02272795	chr19:15279244	NOTCH3	-0.31	-6.24	-0.32	1.29e-9	Pulse pressure;
LIHC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg23262073	chr20:60523788	NA	-0.28	-6.04	-0.31	4.03e-9	Body mass index;
LIHC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.54	8.03	0.4	1.61e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.72	-0.3	2.35e-8	Breast cancer;
LIHC	cis	rs74233809	1.000	rs12413046	chr10:104871204	A/G	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.67	9.86	0.47	2.45e-20	Schizophrenia;
LIHC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-7.18	-0.36	4.41e-12	Personality dimensions;
LIHC	cis	rs10949834	0.730	rs2237503	chr7:73509326	G/C	cg07137043	chr7:73588983	EIF4H	-0.56	-6.19	-0.32	1.71e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg00656387	chr3:40428638	ENTPD3	0.44	7.45	0.37	7.71e-13	Renal cell carcinoma;
LIHC	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-6.07	-0.31	3.33e-9	Ulcerative colitis;
LIHC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	1.01	19.44	0.72	3.13e-57	Breast cancer;
LIHC	cis	rs11958404	0.615	rs6556333	chr5:157445659	T/C	cg05962755	chr5:157440814	NA	0.63	8.24	0.41	3.77e-15	IgG glycosylation;
LIHC	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg10820045	chr2:198174542	NA	0.45	7.21	0.36	3.68e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02873525	chr19:48675305	NA	0.4	6.06	0.31	3.52e-9	Migraine with aura;
LIHC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.46	6.22	0.32	1.43e-9	Major depressive disorder;
LIHC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg16736954	chr20:23401023	NAPB	0.72	8.6	0.42	3.02e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.48	-6.34	-0.32	7.41e-10	Panic disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07473001	chr8:73920952	TERF1	0.44	6.05	0.31	3.87e-9	Lung function (FEV1/FVC);
LIHC	trans	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.67	-6.5	-0.33	2.83e-10	Migraine;Coronary artery disease;
LIHC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.34	5.88	0.3	1e-8	Monobrow;
LIHC	cis	rs7129220	0.588	rs72860548	chr11:10128679	C/G	cg01453529	chr11:10209919	SBF2	-0.39	-6.8	-0.35	4.7e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs16854884	0.660	rs990320	chr3:143796305	T/C	cg06585982	chr3:143692056	C3orf58	0.42	5.85	0.3	1.13e-8	Economic and political preferences (feminism/equality);
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg27166718	chr6:118880109	PLN;C6orf204	0.53	6.16	0.32	2.08e-9	Diastolic blood pressure;
LIHC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.87	-0.35	3.02e-11	Neuroticism;
LIHC	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.96	-10.46	-0.49	2.05e-22	Platelet distribution width;
LIHC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.49e-10	Alzheimer's disease;
LIHC	cis	rs61712019	0.785	rs66637022	chr2:77741882	C/T	cg11252801	chr2:77748917	LRRTM4	0.53	8.36	0.41	1.61e-15	Schizophrenia;
LIHC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.11	-0.55	2.54e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22496380	chr5:211416	CCDC127	-0.94	-8.83	-0.43	5.36e-17	Breast cancer;
LIHC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg12863693	chr15:85201151	NMB	0.45	6.03	0.31	4.27e-9	Schizophrenia;
LIHC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg13957321	chr17:43675089	NA	0.5	7.97	0.4	2.46e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.42	6.72	0.34	7.62e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	8.87e-33	Prudent dietary pattern;
LIHC	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.52	7.68	0.38	1.7e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2257205	0.667	rs6503884	chr17:56940026	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-6.69	-0.34	9.14e-11	Pancreatic cancer;
LIHC	cis	rs1866706	0.963	rs7106148	chr11:12878142	C/T	cg25843174	chr11:12811716	TEAD1	0.3	6.28	0.32	1.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg27255678	chr10:102756921	LZTS2	0.5	7.16	0.36	5.05e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.6	-6.67	-0.34	1.03e-10	Body mass index;
LIHC	cis	rs3112357	1.000	rs3110796	chr7:135377929	A/G	cg20392616	chr7:135392013	SLC13A4	0.4	6.62	0.34	1.36e-10	Plantar warts;
LIHC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.36	0.33	6.41e-10	Platelet distribution width;
LIHC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.38e-12	Bipolar disorder;
LIHC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.39	6.04	0.31	3.95e-9	Multiple sclerosis;
LIHC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.25	-0.32	1.24e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.3	-0.37	2.09e-12	Tuberculosis;
LIHC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg14146966	chr2:61757674	XPO1	0.47	8.19	0.41	5.2e-15	Tuberculosis;
LIHC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg06050784	chr16:88016603	BANP	0.37	6.73	0.34	7.16e-11	Menopause (age at onset);
LIHC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.58	-9.09	-0.44	8.35e-18	Menarche (age at onset);
LIHC	cis	rs965469	0.779	rs6037541	chr20:3287704	G/C	cg25506879	chr20:3388711	C20orf194	-0.5	-6.17	-0.32	1.92e-9	IFN-related cytopenia;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-16.23	-0.66	2.5e-44	Height;
LIHC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.82	9.9	0.47	1.76e-20	Cognitive function;
LIHC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.56	-9.03	-0.44	1.3e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.85	0.43	4.91e-17	Menarche (age at onset);
LIHC	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg12160578	chr15:63334699	TPM1	-0.62	-8.3	-0.41	2.45e-15	Orofacial clefts;
LIHC	cis	rs3799378	0.582	rs1796518	chr6:26388672	C/T	cg09904177	chr6:26538194	HMGN4	-0.43	-6.64	-0.34	1.27e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21545522	chr1:205238299	TMCC2	0.3	5.74	0.3	2.08e-8	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs3731827	0.511	rs72843872	chr2:85820027	A/G	cg16865965	chr2:85811662	VAMP5	0.42	5.85	0.3	1.14e-8	Prostate cancer;
LIHC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.29	7.59	0.38	3.11e-13	Bipolar disorder;
LIHC	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.07	-0.4	1.22e-14	Response to antipsychotic treatment;
LIHC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg18357645	chr12:58087776	OS9	0.44	6.74	0.34	6.57e-11	Multiple sclerosis;
LIHC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	7.12	0.36	6.41e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg24209194	chr3:40518798	ZNF619	0.56	8.11	0.4	9.34e-15	Renal cell carcinoma;
LIHC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	5.71	0.3	2.43e-8	Platelet count;
LIHC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07640336	chr12:132677496	NA	0.36	7.46	0.37	7.25e-13	Anti-saccade response;
LIHC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	8.29	0.41	2.69e-15	Lymphocyte counts;
LIHC	cis	rs3106136	0.814	rs6825005	chr4:95277009	T/C	cg11021082	chr4:95130006	SMARCAD1	0.39	6.62	0.34	1.41e-10	Capecitabine sensitivity;
LIHC	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg06714761	chr1:201096289	NA	0.35	5.87	0.3	1.04e-8	Permanent tooth development;
LIHC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.43	7.43	0.37	8.98e-13	Schizophrenia;
LIHC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.68	5.87	0.3	1.04e-8	Body mass index;
LIHC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.48	-7.95	-0.4	2.69e-14	Cognitive function;
LIHC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.66	-10.5	-0.49	1.52e-22	Prostate cancer;
LIHC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	11.28	0.52	2.63e-25	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	4.04e-13	Bipolar disorder;
LIHC	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.73	12.81	0.57	5.69e-31	Eosinophil percentage of white cells;
LIHC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.3	-6.26	-0.32	1.18e-9	Blood metabolite levels;
LIHC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.46	7.32	0.37	1.83e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg10935138	chr17:73851978	WBP2	0.49	7.22	0.36	3.33e-12	White matter hyperintensity burden;
LIHC	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.51e-11	Type 2 diabetes;
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.82	-0.35	4.24e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.76	0.34	5.86e-11	Tonsillectomy;
LIHC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.95	-0.35	1.81e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg05941027	chr17:61774174	LIMD2	0.3	5.99	0.31	5.18e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs77637988	0.604	rs6722246	chr2:48597045	T/G	cg00032884	chr2:48540671	FOXN2	0.38	5.94	0.31	6.95e-9	Joint mobility (Beighton score);
LIHC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.72	-7.91	-0.39	3.69e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.36	-0.33	6.49e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg03874509	chr1:107600012	PRMT6	0.76	12.16	0.55	1.6e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12644436	0.628	rs721782	chr4:88781437	T/G	cg06891869	chr4:88767617	MEPE	0.44	7.66	0.38	1.88e-13	HIV-1 viral setpoint;
LIHC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.43	0.56	1.65e-29	Menopause (age at onset);
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg14709524	chr16:89940631	TCF25	0.59	7.53	0.38	4.51e-13	Skin colour saturation;
LIHC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.74	10.69	0.5	3.27e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.15	0.32	2.13e-9	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.58	7.63	0.38	2.4e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4725617	0.686	rs4283960	chr7:143103380	C/T	cg03150622	chr7:143105826	EPHA1	0.7	9.73	0.47	6.73e-20	Blood protein levels;
LIHC	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg20240347	chr1:204465584	NA	-0.36	-7.61	-0.38	2.63e-13	Schizophrenia;
LIHC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.7	-7.67	-0.38	1.82e-13	Neuroticism;
LIHC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.4	-6.36	-0.33	6.47e-10	Menopause (age at onset);
LIHC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.68	-0.42	1.69e-16	Primary biliary cholangitis;
LIHC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.94	-0.31	6.83e-9	Tonsillectomy;
LIHC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg25039879	chr17:56429692	SUPT4H1	0.76	8.2	0.41	4.97e-15	Cognitive test performance;
LIHC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.45	-0.37	7.62e-13	Height;
LIHC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.18	-0.32	1.78e-9	Schizophrenia;
LIHC	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.5	9.5	0.46	3.65e-19	Testicular germ cell tumor;
LIHC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.18	0.32	1.81e-9	Schizophrenia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12928759	chr2:74756470	HTRA2;AUP1	-0.42	-6.47	-0.33	3.36e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.48	5.94	0.31	6.94e-9	Interleukin-17 levels;
LIHC	trans	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg10756647	chr7:56101905	PSPH	-1.08	-13.26	-0.58	1.18e-32	Diabetic kidney disease;
LIHC	trans	rs3783890	0.778	rs11622997	chr14:93819246	G/A	cg02802420	chr16:69363236	PDF;COG8	0.32	6.05	0.31	3.72e-9	Body mass index;
LIHC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.57	-8.42	-0.41	1.04e-15	Parkinson's disease;
LIHC	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	9.51	0.46	3.54e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.96	0.35	1.7e-11	Diabetic kidney disease;
LIHC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.37	6.12	0.31	2.54e-9	Blood metabolite levels;
LIHC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg17135325	chr3:160939158	NMD3	0.42	6.09	0.31	3.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg27129171	chr3:47204927	SETD2	0.48	7.61	0.38	2.76e-13	Birth weight;
LIHC	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.58	6.42	0.33	4.6e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.26	-0.58	1.12e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.52	7.67	0.38	1.76e-13	Corneal astigmatism;
LIHC	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.44	6.83	0.35	3.9e-11	Neutrophil percentage of white cells;
LIHC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.52	-8.07	-0.4	1.2e-14	Diastolic blood pressure;
LIHC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg14393609	chr7:65229607	NA	0.41	6.84	0.35	3.69e-11	Calcium levels;
LIHC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	0.81	6.8	0.35	4.74e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23651146	chr3:57261829	APPL1	-0.55	-6.12	-0.31	2.62e-9	Systolic blood pressure;
LIHC	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg12373951	chr3:133503437	NA	-0.48	-6.66	-0.34	1.13e-10	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.36	5.91	0.3	8.35e-9	Height;
LIHC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.67	-9.54	-0.46	2.84e-19	Bronchopulmonary dysplasia;
LIHC	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg04374321	chr14:90722782	PSMC1	0.71	13.4	0.59	3.35e-33	Mortality in heart failure;
LIHC	trans	rs2000813	0.857	rs12326641	chr18:47102997	C/A	cg01564661	chr14:105942636	CRIP2	0.34	6.25	0.32	1.2e-9	Coronary artery disease;
LIHC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs9888615	1.000	rs7161281	chr14:53350479	A/G	cg00686598	chr14:53173677	PSMC6	-0.5	-6.25	-0.32	1.22e-9	Systolic blood pressure;
LIHC	cis	rs1400745	0.756	rs799682	chr14:35349984	G/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.67	-0.38	1.83e-13	Monocyte count;
LIHC	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-12.25	-0.55	7.35e-29	Response to antipsychotic treatment;
LIHC	cis	rs10411936	0.712	rs9305079	chr19:16591464	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.98	0.35	1.51e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.77	0.39	9.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2257205	0.667	rs11651859	chr17:56731926	G/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg14593290	chr7:50529359	DDC	0.49	7.86	0.39	5.03e-14	Malaria;
LIHC	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.55	-10.3	-0.49	7.72e-22	Neurofibrillary tangles;
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.55	6.49	0.33	2.97e-10	Alzheimer's disease;
LIHC	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.43	7.04	0.36	1.09e-11	Menopause (age at onset);
LIHC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.48	7.59	0.38	3.02e-13	Systemic lupus erythematosus;
LIHC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-9.57	-0.46	2.27e-19	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.23	-0.36	3.11e-12	Renal cell carcinoma;
LIHC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.36	7.4	0.37	1.09e-12	Renal cell carcinoma;
LIHC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.43	6.96	0.35	1.79e-11	Height;
LIHC	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.93	18.93	0.72	3.5e-55	Bone mineral density;
LIHC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.84	-0.3	1.22e-8	Inflammatory bowel disease;
LIHC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.55e-9	Vitamin D levels;
LIHC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.49	-7.74	-0.39	1.1e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg06012730	chr15:75315579	PPCDC	-0.35	-6.32	-0.32	7.99e-10	Blood trace element (Zn levels);
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-8.67	-0.42	1.78e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg26441486	chr22:50317300	CRELD2	0.35	6.17	0.32	1.88e-9	Schizophrenia;
LIHC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.54	-8.4	-0.41	1.24e-15	High light scatter reticulocyte count;
LIHC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.29	-7.36	-0.37	1.36e-12	Mean corpuscular volume;
LIHC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.47e-27	Lymphocyte counts;
LIHC	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	8.37	0.41	1.54e-15	Eotaxin levels;
LIHC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.44	8.41	0.41	1.14e-15	Tuberculosis;
LIHC	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.58	7.38	0.37	1.18e-12	Corneal astigmatism;
LIHC	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.57	7.53	0.38	4.42e-13	Opioid sensitivity;
LIHC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg12798992	chr6:167411361	FGFR1OP	0.61	10.15	0.48	2.53e-21	Crohn's disease;
LIHC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.54	-6.44	-0.33	4.01e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	0.87	9.63	0.46	1.37e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg14146966	chr2:61757674	XPO1	0.49	8.64	0.42	2.2e-16	Tuberculosis;
LIHC	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.76	-12.93	-0.57	1.99e-31	Anterior chamber depth;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg00057700	chr10:124768526	ACADSB;IKZF5	-0.4	-6.1	-0.31	2.87e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.5	0.33	2.79e-10	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.29	7.06	0.36	9.48e-12	Primary biliary cholangitis;
LIHC	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.74	0.3	2.12e-8	Menopause (age at onset);
LIHC	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	0.71	8.81	0.43	6.18e-17	Corneal structure;
LIHC	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02985541	chr2:219472218	PLCD4	0.36	5.77	0.3	1.77e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg20129853	chr10:51489980	NA	0.4	8.78	0.43	7.92e-17	Prostate-specific antigen levels;
LIHC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.04	14.68	0.62	3.42e-38	Cognitive function;
LIHC	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg14651457	chr8:12611650	LONRF1	0.53	6.75	0.34	6.4e-11	Myopia (pathological);
LIHC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg02297831	chr4:17616191	MED28	0.41	6.64	0.34	1.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg24203234	chr3:128598194	ACAD9	0.45	6.32	0.32	8.11e-10	IgG glycosylation;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.01	-0.4	1.77e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12016809	chr21:47604291	C21orf56	0.46	6.86	0.35	3.17e-11	Testicular germ cell tumor;
LIHC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.93	-16.26	-0.66	1.86e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg13319975	chr6:146136371	FBXO30	0.37	6.01	0.31	4.88e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.77	-0.39	9.47e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg07393940	chr7:158741817	NA	0.55	6.56	0.33	1.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.35	-0.45	1.16e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05771511	chr15:63340396	TPM1	-0.46	-6.95	-0.35	1.88e-11	Platelet count;
LIHC	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.92	-8.18	-0.4	5.59e-15	White matter integrity;
LIHC	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.43	-0.41	9.86e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.69	0.73	3.11e-58	Smoking behavior;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23628684	chr21:30446052	CCT8	0.44	6.94	0.35	2.03e-11	Cognitive function;
LIHC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.43	7.1	0.36	7.38e-12	Mood instability;
LIHC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.78e-19	Waist circumference;Weight;
LIHC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.96	-0.54	8.86e-28	Chronic sinus infection;
LIHC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-5.74	-0.3	2.06e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg15123519	chr2:136567270	LCT	0.35	5.77	0.3	1.78e-8	Corneal structure;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.54	-8.69	-0.43	1.51e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg23131131	chr22:24373011	LOC391322	-0.59	-7.95	-0.4	2.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.75	-11.55	-0.53	2.73e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.44	7.12	0.36	6.28e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.93	-0.31	7.36e-9	Total body bone mineral density;
LIHC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-6.39	-0.33	5.49e-10	Colorectal cancer;
LIHC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg04013166	chr16:89971882	TCF25	0.51	6.45	0.33	3.9e-10	Skin colour saturation;
LIHC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.03	0.31	4.18e-9	Menopause (age at onset);
LIHC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg10845886	chr2:3471009	TTC15	-0.44	-7.81	-0.39	6.99e-14	Neurofibrillary tangles;
LIHC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.9	19.5	0.73	1.8e-57	Blood protein levels;
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg19635926	chr16:89946313	TCF25	0.56	7.51	0.38	5.34e-13	Skin colour saturation;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.9	-0.35	2.49e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs471756	0.523	rs604470	chr9:223979	A/G	cg14500300	chr9:211689	NA	0.28	6.26	0.32	1.12e-9	Mean platelet volume;
LIHC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.68	-11.48	-0.53	4.99e-26	Colorectal cancer;
LIHC	trans	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg04565464	chr8:145669602	NFKBIL2	0.38	6.28	0.32	1.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.51	-6.22	-0.32	1.48e-9	Alzheimer's disease;
LIHC	trans	rs2363709	1.000	rs6770280	chr3:67416712	T/C	cg25028035	chr6:42016671	CCND3	-0.83	-6.16	-0.32	2.04e-9	IgE levels;
LIHC	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs903552	0.736	rs9806369	chr15:102008430	A/C	cg16179521	chr15:102009894	PCSK6	-0.43	-5.75	-0.3	1.95e-8	Diabetic kidney disease;
LIHC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-12.24	-0.55	8.2e-29	Body mass index;
LIHC	cis	rs8192917	1.000	rs10909625	chr14:25101629	A/G	cg08766149	chr14:25103301	GZMB	0.34	7.76	0.39	9.94e-14	Vitiligo;
LIHC	cis	rs11212260	0.655	rs79269916	chr11:107337478	G/A	cg25435332	chr11:107328525	CWF19L2	0.84	8.24	0.41	3.8e-15	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.52	-6.07	-0.31	3.33e-9	Ulcerative colitis;
LIHC	cis	rs757081	0.667	rs644419	chr11:17212375	C/T	cg15432903	chr11:17409602	KCNJ11	0.44	6.03	0.31	4.37e-9	Systolic blood pressure;
LIHC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.53	0.53	3.21e-26	Motion sickness;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.83	-0.35	3.96e-11	Total body bone mineral density;
LIHC	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.35	-6.05	-0.31	3.73e-9	Asthma;
LIHC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.71	11.05	0.51	1.77e-24	Corneal astigmatism;
LIHC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.9	0.6	4.02e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18000306	chr6:288505	NA	0.36	6.96	0.35	1.71e-11	Menopause (age at onset);
LIHC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.1	10.04	0.48	5.77e-21	Diabetic retinopathy;
LIHC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20859470	chr1:153963593	RPS27	0.43	6.38	0.33	5.68e-10	Cognitive function;
LIHC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.71	11.58	0.53	2.16e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs244293	0.899	rs244344	chr17:53196998	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.56	10.36	0.49	4.79e-22	Methadone dose in opioid dependence;
LIHC	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg00792783	chr2:198669748	PLCL1	-0.42	-6.09	-0.31	3.08e-9	Intracranial aneurysm;
LIHC	cis	rs9309473	1.000	rs6756987	chr2:73687077	G/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.8	-0.34	4.77e-11	Metabolite levels;
LIHC	trans	rs12753920	0.642	rs2893200	chr1:92608029	C/T	cg15668468	chr10:118892869	VAX1	0.44	6.33	0.32	7.7e-10	Systemic lupus erythematosus;
LIHC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.53	7.29	0.37	2.14e-12	Morning vs. evening chronotype;
LIHC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.74	6.37	0.33	6.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg02993280	chr1:107599747	PRMT6	-0.68	-10.98	-0.51	3.09e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.5e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.41	6.75	0.34	6.3e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs3764618	1.000	rs2287754	chr19:49496494	C/T	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.72	-6.06	-0.31	3.55e-9	Follicule stimulating hormone;
LIHC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.99	-0.31	5.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg14593290	chr7:50529359	DDC	-0.4	-6.6	-0.34	1.59e-10	Malaria;
LIHC	trans	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg10381502	chr11:71823885	C11orf51	-1.03	-9.31	-0.45	1.59e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg24130564	chr14:104152367	KLC1	-0.54	-8.8	-0.43	6.79e-17	Reticulocyte count;
LIHC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.85	-12.38	-0.56	2.42e-29	Tonsillectomy;
LIHC	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.49	7.56	0.38	3.81e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-7.22	-0.36	3.46e-12	Obesity-related traits;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13126279	chr21:47581558	C21orf56	-0.39	-5.96	-0.31	6.17e-9	Testicular germ cell tumor;
LIHC	trans	rs947612	0.576	rs9359011	chr6:73706941	C/T	cg13494037	chr12:24737079	C12orf67	0.39	6.42	0.33	4.58e-10	HIV-1 viral setpoint;Body mass index;
LIHC	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.57	-8.99	-0.44	1.69e-17	Red cell distribution width;
LIHC	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.69	10.86	0.51	8.06e-24	Colorectal adenoma (advanced);
LIHC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	7.22	0.36	3.44e-12	Coronary artery disease;
LIHC	cis	rs12986413	0.967	rs1074047	chr19:2158748	A/G	cg09261902	chr19:2140048	AP3D1	0.38	6.38	0.33	5.62e-10	Height;
LIHC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26031613	chr14:104095156	KLC1	1.12	14.59	0.62	7.81e-38	Body mass index;
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	0.53	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg06585982	chr3:143692056	C3orf58	0.5	7.09	0.36	7.64e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs6504622	0.537	rs189899	chr17:45000529	G/C	cg16759221	chr17:45003025	GOSR2	-0.32	-5.75	-0.3	2e-8	Orofacial clefts;
LIHC	cis	rs7654585	0.782	rs2309288	chr4:25947097	C/A	cg10409131	chr4:25915609	C4orf52	0.47	7.3	0.37	1.99e-12	Obesity-related traits;
LIHC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg15123519	chr2:136567270	LCT	-0.45	-9.26	-0.45	2.36e-18	Mosquito bite size;
LIHC	cis	rs709400	0.633	rs8019578	chr14:103977724	A/G	cg26031613	chr14:104095156	KLC1	0.75	9.38	0.45	9.49e-19	Body mass index;
LIHC	trans	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg01134436	chr17:81009848	B3GNTL1	0.81	6.6	0.34	1.61e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.97	14.95	0.63	3.06e-39	Metabolic syndrome;
LIHC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.59	-6.05	-0.31	3.87e-9	Alcohol dependence;
LIHC	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	cis	rs3106136	0.843	rs11727030	chr4:95262665	A/G	cg11021082	chr4:95130006	SMARCAD1	0.4	7.22	0.36	3.49e-12	Capecitabine sensitivity;
LIHC	cis	rs6691722	0.503	rs1064842	chr1:24706269	A/G	cg18323236	chr1:24743029	NIPAL3	0.39	7.24	0.36	2.95e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.81	-0.39	7.01e-14	Type 2 diabetes;
LIHC	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.84	0.35	3.59e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.72	-11.36	-0.52	1.36e-25	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-10.24	-0.48	1.17e-21	Mean corpuscular volume;
LIHC	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.61	0.5	6.15e-23	Colorectal cancer;
LIHC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.22	-10.55	-0.5	1.07e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	0.99	14.44	0.62	3.15e-37	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg23533926	chr12:111358616	MYL2	0.31	6.05	0.31	3.88e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.47	7.17	0.36	4.57e-12	Triglyceride levels;
LIHC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.42	-6.14	-0.32	2.25e-9	Heart rate;
LIHC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.66	10.36	0.49	4.77e-22	Lymphocyte counts;
LIHC	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.54	-7.67	-0.38	1.78e-13	Serum thyroid-stimulating hormone levels;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.27	0.58	1.02e-32	Prudent dietary pattern;
LIHC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18579396	chr17:41623924	ETV4	0.51	7.01	0.35	1.26e-11	Lung function (FEV1/FVC);
LIHC	cis	rs36051895	0.623	rs10975024	chr9:5246403	A/T	cg02405213	chr9:5042618	JAK2	-0.58	-9.4	-0.45	8.19e-19	Pediatric autoimmune diseases;
LIHC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.84	0.3	1.22e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.4	0.41	1.23e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.69	10.48	0.49	1.74e-22	Response to antineoplastic agents;
LIHC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg14829360	chr17:73884958	NA	-0.52	-7.83	-0.39	5.99e-14	Psoriasis;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20990694	chr7:150417431	GIMAP1	0.35	6.08	0.31	3.24e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10744422	0.800	rs6489240	chr12:123275030	T/C	cg07706471	chr12:123319906	HIP1R	-0.57	-7.33	-0.37	1.71e-12	Schizophrenia;
LIHC	cis	rs10744422	0.748	rs1671688	chr12:123255733	A/T	cg07706471	chr12:123319906	HIP1R	-0.57	-7.36	-0.37	1.36e-12	Schizophrenia;
LIHC	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg20291162	chr17:40259547	DHX58	-0.41	-6.47	-0.33	3.34e-10	Fibrinogen levels;
LIHC	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.46	-8.81	-0.43	6.34e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	trans	rs2211698	0.881	rs2070360	chr21:35826828	T/A	cg18044562	chr7:50468399	IKZF1	0.44	6.77	0.34	5.59e-11	Cancer;
LIHC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.54	8.64	0.42	2.18e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs4407350	0.837	rs5765707	chr22:44909507	A/T	cg04154583	chr22:44889756	LDOC1L	0.3	5.86	0.3	1.09e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.51	8.7	0.43	1.42e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg07959070	chr22:50026188	C22orf34	-0.34	-8.76	-0.43	9.09e-17	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg20129853	chr10:51489980	NA	-0.39	-8.51	-0.42	5.5e-16	Prostate-specific antigen levels;
LIHC	cis	rs8141529	0.600	rs16986838	chr22:29312578	C/T	cg15103426	chr22:29168792	CCDC117	0.43	6.05	0.31	3.85e-9	Lymphocyte counts;
LIHC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-6.6	-0.34	1.61e-10	Fibrinogen levels;
LIHC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.15	-0.48	2.43e-21	Platelet count;
LIHC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.55	8.69	0.43	1.49e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.48	-6.88	-0.35	2.83e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.32	14.2	0.61	2.75e-36	Eosinophil percentage of granulocytes;
LIHC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.51	-7.25	-0.37	2.74e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-8.08	-0.4	1.1e-14	Putamen volume;
LIHC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.85	-0.35	3.47e-11	Mean corpuscular volume;
LIHC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.45	6.3	0.32	9.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.61	-6.27	-0.32	1.07e-9	Lymphocyte counts;
LIHC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-7.43	-0.37	8.77e-13	Height;
LIHC	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg11812906	chr14:75593930	NEK9	0.43	6.58	0.34	1.81e-10	IgG glycosylation;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg00800038	chr16:89945340	TCF25	0.59	9.69	0.46	9.12e-20	Skin colour saturation;
LIHC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.44	6.18	0.32	1.78e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.97	15.08	0.63	9.28e-40	Metabolic syndrome;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-5.92	-0.3	8e-9	Corneal structure;
LIHC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg11204139	chr17:3907470	NA	0.56	6.69	0.34	9.15e-11	Type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.51	7.65	0.38	2.11e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.59	9.57	0.46	2.2e-19	Multiple sclerosis;
LIHC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.96	0.35	1.74e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19671926	chr4:122722719	EXOSC9	0.54	8.36	0.41	1.6e-15	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.8	0.8	1.96e-78	Prudent dietary pattern;
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg20295408	chr7:1910781	MAD1L1	0.43	6.03	0.31	4.22e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11779988	0.516	rs426498	chr8:17897158	T/C	cg04898035	chr8:17640624	MTUS1	-0.33	-5.76	-0.3	1.85e-8	Breast cancer;
LIHC	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg06697600	chr4:7070879	GRPEL1	0.76	9.26	0.45	2.39e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.02	-0.65	1.68e-43	Electrocardiographic conduction measures;
LIHC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.52	8.36	0.41	1.55e-15	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.37	6.35	0.32	6.98e-10	Cognitive function;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.5	0.33	2.88e-10	Prudent dietary pattern;
LIHC	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	trans	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.72	10.69	0.5	3.3e-23	Corneal astigmatism;
LIHC	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.39	-5.92	-0.3	7.75e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10276381	0.579	rs73072539	chr7:28146255	C/G	cg23620719	chr7:28220237	JAZF1	0.63	7.04	0.36	1.05e-11	Crohn's disease;
LIHC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg13385521	chr17:29058706	SUZ12P	0.59	5.86	0.3	1.09e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg06026331	chr20:60912101	LAMA5	-0.51	-8.61	-0.42	2.8e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg17469321	chr7:55412551	NA	-0.46	-6.75	-0.34	6.23e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.15	-0.32	2.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	9.15	0.44	5.41e-18	Lung cancer in ever smokers;
LIHC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.37	-0.56	2.66e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.7	-8.68	-0.43	1.59e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg17427986	chr1:154402922	IL6R	0.49	6.93	0.35	2.17e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.64	6.95	0.35	1.88e-11	Alzheimer's disease;
LIHC	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7534824	0.625	rs17409499	chr1:101504936	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.21	0.36	3.58e-12	Refractive astigmatism;
LIHC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg15123519	chr2:136567270	LCT	-0.37	-5.87	-0.3	1.05e-8	Corneal structure;
LIHC	cis	rs7503168	0.730	rs11655803	chr17:33952696	T/C	cg20932281	chr17:33905541	PEX12	0.54	7.01	0.35	1.25e-11	Plateletcrit;
LIHC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg16586182	chr3:47516702	SCAP	0.61	12.05	0.55	3.96e-28	Colorectal cancer;
LIHC	cis	rs75908454	1.000	rs117712749	chr6:169836055	C/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.77	-0.39	9.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	1.01	13.1	0.58	4.73e-32	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg02503808	chr4:7069936	GRPEL1	0.39	5.92	0.3	8.03e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg18867708	chr6:26865862	GUSBL1	0.52	8.1	0.4	9.8e-15	Schizophrenia;
LIHC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	9.2	0.45	3.49e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg25388301	chr11:62439134	C11orf83;C11orf48	-0.52	-6.24	-0.32	1.27e-9	Lung function (FEV1);
LIHC	cis	rs6448317	0.556	rs4697495	chr4:24907501	A/G	cg21108841	chr4:24914750	CCDC149	0.53	6.57	0.33	1.92e-10	Heschl's gyrus morphology;
LIHC	cis	rs1029738	0.615	rs3757447	chr7:22894735	A/T	cg22407942	chr7:22894828	SNORD93	-0.34	-6.48	-0.33	3.12e-10	Fibrinogen levels;
LIHC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.49	-0.38	5.98e-13	Total body bone mineral density;
LIHC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg18016565	chr1:150552671	MCL1	0.6	11.8	0.54	3.46e-27	Tonsillectomy;
LIHC	cis	rs4934494	0.681	rs1129777	chr10:91468925	C/G	cg19698084	chr10:91461284	KIF20B	-0.47	-6.35	-0.32	6.84e-10	Red blood cell count;
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.7	-11.39	-0.52	1.04e-25	Prudent dietary pattern;
LIHC	cis	rs16870629	0.567	rs35661060	chr5:1060379	G/A	cg00278107	chr5:1061253	SLC12A7	0.96	17.59	0.69	8.46e-50	QT interval;
LIHC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.39	6.24	0.32	1.26e-9	Response to temozolomide;
LIHC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.48	7.57	0.38	3.46e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg16970926	chr12:29381810	FAR2	0.28	5.97	0.31	6.02e-9	QT interval;
LIHC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg10360323	chr17:41437877	NA	0.4	5.99	0.31	5.19e-9	Menopause (age at onset);
LIHC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.71	10.49	0.49	1.63e-22	Corneal astigmatism;
LIHC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.08	-0.44	8.66e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg26441486	chr22:50317300	CRELD2	0.36	6.38	0.33	5.73e-10	Schizophrenia;
LIHC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.4	0.52	9.54e-26	Colorectal cancer;
LIHC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.47	7.66	0.38	1.95e-13	Type 2 diabetes;
LIHC	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg11812906	chr14:75593930	NEK9	0.42	6.47	0.33	3.47e-10	IgG glycosylation;
LIHC	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.45	6.79	0.34	5e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.08	0.31	3.14e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg01652190	chr22:50026171	C22orf34	-0.34	-7.53	-0.38	4.66e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.45	7.37	0.37	1.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg05110241	chr16:68378359	PRMT7	-0.68	-7.49	-0.38	5.88e-13	Magnesium levels;
LIHC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	0.39	6.26	0.32	1.12e-9	Coronary artery disease;
LIHC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.33	-17.89	-0.7	5.71e-51	Gout;
LIHC	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.5	7.38	0.37	1.18e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs600806	0.888	rs652651	chr1:109844532	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.73	-0.3	2.21e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9596863	0.898	rs35732706	chr13:54343886	T/G	ch.13.53330881F	chr13:54432880	NA	0.45	6.16	0.32	2.06e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	8.51	0.42	5.55e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.86	0.63	6.95e-39	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.48	8.76	0.43	9.48e-17	Hemoglobin concentration;
LIHC	cis	rs6141769	0.542	rs7360824	chr20:31315158	A/G	cg13636640	chr20:31349939	DNMT3B	-0.32	-5.74	-0.3	2.08e-8	Subjective well-being;
LIHC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.43	8.1	0.4	9.52e-15	Schizophrenia;
LIHC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg03945807	chr20:60948434	NA	0.4	6.5	0.33	2.86e-10	Colorectal cancer;
LIHC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.34	18.69	0.71	3.43e-54	Gout;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16958440	1.000	rs2289130	chr18:44626630	T/G	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.42	6.77	0.34	5.73e-11	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.21	0.55	1.06e-28	Prudent dietary pattern;
LIHC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02450064	chr17:40260053	DHX58	0.28	5.99	0.31	5.19e-9	Fibrinogen levels;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-6.31	-0.32	8.58e-10	Tuberculosis;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.71	-10.97	-0.51	3.4e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.57e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg10756647	chr7:56101905	PSPH	1.1	13.21	0.58	1.86e-32	Diabetic kidney disease;
LIHC	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.97	7.09	0.36	7.81e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	trans	rs11157436	0.918	rs11157427	chr14:22622247	T/G	cg13567813	chr19:50879636	NR1H2	0.41	6.11	0.31	2.77e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.09	0.31	3.1e-9	Bipolar disorder;
LIHC	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg08992911	chr2:238395768	MLPH	0.52	6.0	0.31	5e-9	Prostate cancer;
LIHC	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.81	-0.39	7.3e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg18016565	chr1:150552671	MCL1	0.56	10.67	0.5	3.76e-23	Urate levels;
LIHC	cis	rs4407350	1.000	rs5765745	chr22:44924894	A/G	cg11695653	chr22:44894386	LDOC1L	-0.35	-5.73	-0.3	2.21e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	1.000	rs72718804	chr14:55630610	G/A	cg01864836	chr14:55583639	NA	-0.36	-6.09	-0.31	3.02e-9	Protein biomarker;
LIHC	cis	rs7116495	1.000	rs2511075	chr11:71780257	T/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2834215	0.753	rs9976794	chr21:34868143	T/A	cg14850771	chr21:34775459	IFNGR2	0.42	6.07	0.31	3.39e-9	Crohn's disease;
LIHC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.7	-9.6	-0.46	1.75e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3110496	0.750	rs497993	chr17:27895528	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.45	5.82	0.3	1.37e-8	Height;
LIHC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.31	-5.92	-0.3	7.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4663866	1.000	rs34897410	chr2:239182123	T/C	cg16914508	chr2:239161102	PER2	0.8	5.9	0.3	8.86e-9	Irritable bowel syndrome;
LIHC	cis	rs77633900	0.772	rs157778	chr15:76759444	G/C	cg21673338	chr15:77095150	SCAPER	-0.52	-6.11	-0.31	2.78e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06656553	chr16:89960601	TCF25	-0.5	-6.47	-0.33	3.34e-10	Skin colour saturation;
LIHC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12463550	chr7:65579703	CRCP	0.68	7.14	0.36	5.69e-12	Diabetic kidney disease;
LIHC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.38e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.53	8.85	0.43	4.92e-17	Type 2 diabetes;
LIHC	cis	rs3770081	1.000	rs77621359	chr2:86330353	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.11	0.31	2.74e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.46	-9.0	-0.44	1.54e-17	LDL cholesterol levels;
LIHC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.79	11.98	0.54	7.34e-28	Dental caries;
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02290350	chr8:58132656	NA	0.48	9.92	0.47	1.54e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg17135325	chr3:160939158	NMD3	0.55	7.83	0.39	6.04e-14	Parkinson's disease;
LIHC	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg01843034	chr6:37503916	NA	-0.45	-7.79	-0.39	8.01e-14	Cognitive performance;
LIHC	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.47	5.91	0.3	8.23e-9	Resting heart rate;
LIHC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.64	-11.4	-0.52	9.9e-26	Dental caries;
LIHC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-7.15	-0.36	5.15e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.59	7.4	0.37	1.08e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03744954	chr7:23637556	CCDC126	-0.42	-6.37	-0.33	6.08e-10	Cognitive function;
LIHC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.27	-6.61	-0.34	1.51e-10	Cutaneous nevi;
LIHC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.47	-8.72	-0.43	1.24e-16	Body mass index;
LIHC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.57	-8.23	-0.41	4.06e-15	Initial pursuit acceleration;
LIHC	cis	rs367615	0.591	rs4530812	chr5:108858587	A/C	cg17395555	chr5:108820864	NA	-0.28	-5.98	-0.31	5.62e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7095607	0.606	rs10998014	chr10:69959567	C/A	cg18986048	chr10:69913749	MYPN	0.39	5.95	0.31	6.77e-9	Lung function (FVC);
LIHC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.47	0.53	5.31e-26	Coronary artery disease;
LIHC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg27211696	chr2:191398769	TMEM194B	-0.49	-6.45	-0.33	3.85e-10	Diastolic blood pressure;
LIHC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.53	0.56	6.83e-30	Electrocardiographic conduction measures;
LIHC	trans	rs9834975	0.544	rs12485294	chr3:122285005	G/A	cg18228109	chr6:162684441	PARK2	0.34	6.06	0.31	3.56e-9	Diastolic blood pressure;
LIHC	cis	rs74233809	1.000	rs11191575	chr10:104898337	C/T	cg03493300	chr10:104813866	CNNM2	0.47	6.3	0.32	9.19e-10	Birth weight;
LIHC	cis	rs2997447	0.846	rs3008234	chr1:26405458	A/G	cg19633962	chr1:26362018	EXTL1	-0.63	-5.85	-0.3	1.17e-8	QRS complex (12-leadsum);
LIHC	cis	rs6001982	0.541	rs55775429	chr22:41049460	A/G	cg14879645	chr22:41048474	NA	0.4	5.82	0.3	1.35e-8	Breast cancer;
LIHC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.64	-10.0	-0.48	8.22e-21	Dental caries;
LIHC	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg18225595	chr11:63971243	STIP1	0.45	6.96	0.35	1.69e-11	Platelet count;
LIHC	cis	rs2599510	0.693	rs2754514	chr2:32788836	T/A	cg02381751	chr2:32503542	YIPF4	0.48	6.47	0.33	3.41e-10	Interleukin-18 levels;
LIHC	cis	rs11229555	0.645	rs10466679	chr11:58188257	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.36	-0.37	1.39e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-9.38	-0.45	9.24e-19	Skin colour saturation;
LIHC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.41	-6.98	-0.35	1.51e-11	Type 2 diabetes;
LIHC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.32	14.2	0.61	2.75e-36	Eosinophil percentage of granulocytes;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-7.66	-0.38	1.98e-13	Glycated hemoglobin levels;
LIHC	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.35	-8.03	-0.4	1.58e-14	Congenital heart disease (maternal effect);
LIHC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	11.37	0.52	1.22e-25	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	0.7	8.03	0.4	1.56e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.73	-10.26	-0.49	1.02e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.73	-0.34	7.33e-11	Mood instability;
LIHC	trans	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg07393940	chr7:158741817	NA	-0.57	-6.8	-0.35	4.81e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.56	9.53	0.46	3.1e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.82	-13.02	-0.58	9.36e-32	Colorectal cancer;
LIHC	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.75	14.54	0.62	1.23e-37	Mortality in heart failure;
LIHC	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg15867164	chr4:3464754	DOK7	-0.42	-7.26	-0.37	2.59e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs55665837	0.540	rs10832299	chr11:14769392	G/A	cg25251204	chr11:14927456	NA	0.41	5.79	0.3	1.56e-8	Vitamin D levels;
LIHC	cis	rs918629	0.679	rs58921760	chr5:95270865	A/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.34	-0.32	7.39e-10	IgG glycosylation;
LIHC	cis	rs963731	0.649	rs297149	chr2:39324469	G/C	cg04010122	chr2:39346883	SOS1	-0.7	-6.27	-0.32	1.08e-9	Corticobasal degeneration;
LIHC	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	10.32	0.49	6.7e-22	Fibroblast growth factor basic levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04817870	chr17:79963651	ASPSCR1	0.4	6.05	0.31	3.79e-9	Longevity;
LIHC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-6.71	-0.34	8.13e-11	IgG glycosylation;
LIHC	cis	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg19680485	chr15:31195859	MTMR15	-0.55	-5.98	-0.31	5.64e-9	Hypertriglyceridemia;
LIHC	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.29	-0.45	1.89e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.79	-0.57	7.03e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.95	-0.31	6.6e-9	Diabetic kidney disease;
LIHC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02985541	chr2:219472218	PLCD4	-0.39	-5.94	-0.31	7.1e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg19308663	chr11:118741387	NA	0.46	6.01	0.31	4.8e-9	Sjögren's syndrome;
LIHC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg14067834	chr17:29058358	SUZ12P	0.63	6.38	0.33	5.64e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg15691649	chr6:25882328	NA	0.41	6.06	0.31	3.51e-9	Blood metabolite levels;
LIHC	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg19671926	chr4:122722719	EXOSC9	0.46	6.68	0.34	9.6e-11	Type 2 diabetes;
LIHC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-16.98	-0.68	2.53e-47	Gut microbiome composition (summer);
LIHC	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.39	8.56	0.42	3.9e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.38	6.1	0.31	2.94e-9	Response to temozolomide;
LIHC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.35	6.38	0.33	5.9e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.43	7.11	0.36	6.62e-12	Red blood cell count;
LIHC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.57	-0.46	2.15e-19	Initial pursuit acceleration;
LIHC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21545522	chr1:205238299	TMCC2	0.29	5.93	0.31	7.36e-9	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2629751	0.512	rs2723868	chr12:104422317	C/T	cg14987745	chr12:104360022	TDG	-0.69	-6.84	-0.35	3.6e-11	Hepatitis C induced liver fibrosis;
LIHC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-10.18	-0.48	1.91e-21	Mean corpuscular volume;
LIHC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.37	5.81	0.3	1.47e-8	Lewy body disease;
LIHC	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.49	6.59	0.34	1.69e-10	Glioblastoma;Glioma;
LIHC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.35	0.45	1.16e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.31	6.66	0.34	1.12e-10	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.98	-18.56	-0.71	1.1e-53	Breast cancer;
LIHC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.86	-0.3	1.07e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.43	5.98	0.31	5.54e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	1.08	14.49	0.62	1.89e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg01864069	chr14:103024347	NA	0.45	7.15	0.36	5.15e-12	Platelet count;
LIHC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg15902774	chr15:75289873	SCAMP5	0.44	6.46	0.33	3.65e-10	Lung cancer;
LIHC	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg01652190	chr22:50026171	C22orf34	-0.35	-7.98	-0.4	2.28e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg03013999	chr17:37608204	MED1	-0.35	-5.82	-0.3	1.38e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.59	-8.0	-0.4	1.98e-14	Waist circumference;Body mass index;
LIHC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.08	-0.31	3.27e-9	Alzheimer's disease (late onset);
LIHC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	8.54	0.42	4.53e-16	IgG glycosylation;
LIHC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg11212589	chr17:38028394	ZPBP2	0.37	7.51	0.38	5.25e-13	Self-reported allergy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27266822	chr1:16073415	TMEM82	0.41	6.49	0.33	2.94e-10	Cognitive function;
LIHC	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.3	7.38	0.37	1.19e-12	Gut microbiome composition (winter);
LIHC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg05896524	chr21:47604654	C21orf56	0.45	6.8	0.35	4.58e-11	Testicular germ cell tumor;
LIHC	cis	rs238295	0.766	rs6053517	chr20:5564774	T/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.93	-0.35	2.05e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.57	8.07	0.4	1.17e-14	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.53	-6.34	-0.32	7.32e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.77	-0.67	1.76e-46	Ulcerative colitis;
LIHC	cis	rs2257205	0.667	rs28363312	chr17:56788293	C/A	cg12560992	chr17:57184187	TRIM37	0.72	7.97	0.4	2.33e-14	Pancreatic cancer;
LIHC	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	8.73	0.43	1.11e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.56	8.97	0.44	1.92e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs3736485	0.966	rs2124878	chr15:51906337	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.57e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg25902810	chr10:99078978	FRAT1	0.62	8.75	0.43	1e-16	Monocyte count;
LIHC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.97	20.63	0.74	5.12e-62	Bone mineral density;
LIHC	cis	rs7487075	0.578	rs12319162	chr12:46837914	T/C	cg23829395	chr12:46796953	NA	0.34	6.05	0.31	3.81e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.84	11.44	0.53	7.07e-26	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18986451	chr3:100428869	TFG	0.45	7.25	0.36	2.81e-12	Pancreatic cancer;
LIHC	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.39	5.77	0.3	1.79e-8	Menopause (age at onset);
LIHC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg20487152	chr13:99095054	FARP1	-0.38	-6.29	-0.32	9.88e-10	Longevity;
LIHC	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg23485639	chr6:28045615	ZNF165	0.38	5.9	0.3	8.99e-9	Parkinson's disease;
LIHC	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.49	7.77	0.39	9.18e-14	Height;
LIHC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg19318889	chr4:1322082	MAEA	0.47	6.43	0.33	4.23e-10	Obesity-related traits;
LIHC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.75	9.84	0.47	2.86e-20	Selective IgA deficiency;
LIHC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.31	0.37	1.94e-12	Morning vs. evening chronotype;
LIHC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.54	0.33	2.2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.8	11.24	0.52	3.72e-25	Body mass index;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg03509753	chr7:148922340	ZNF282	-0.37	-6.37	-0.33	6.13e-10	Pain;
LIHC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.68	13.67	0.59	3.1e-34	Glomerular filtration rate (creatinine);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08663953	chr5:72804550	NA	0.48	6.31	0.32	8.52e-10	Hepatitis;
LIHC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg04498913	chr7:1135747	C7orf50	0.37	5.71	0.3	2.44e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs7534824	0.625	rs7514731	chr1:101449675	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	7.82	0.39	6.78e-14	Refractive astigmatism;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25300318	chr2:200527297	NA	0.43	6.52	0.33	2.6e-10	Bilirubin levels;
LIHC	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.73	-0.34	6.95e-11	Metabolite levels;
LIHC	cis	rs2710642	0.721	rs1038572	chr2:62902019	G/T	cg17519650	chr2:63277830	OTX1	0.51	7.19	0.36	4.12e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.58	-8.08	-0.4	1.09e-14	Response to antineoplastic agents;
LIHC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.2	-0.36	3.77e-12	Type 2 diabetes;
LIHC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.4	-8.48	-0.42	6.68e-16	Obesity-related traits;
LIHC	cis	rs77637988	0.578	rs11683099	chr2:48611519	A/T	cg15846641	chr2:48541264	FOXN2	0.55	7.33	0.37	1.66e-12	Joint mobility (Beighton score);
LIHC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26897989	chr16:1907736	C16orf73	-0.49	-5.96	-0.31	6.16e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25009504	chr18:21269793	LAMA3	0.42	6.1	0.31	2.82e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-9.6	-0.46	1.81e-19	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.32	0.58	6.74e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg03037974	chr15:76606532	NA	0.8	16.45	0.66	3.41e-45	Blood metabolite levels;
LIHC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19524238	chr7:2802976	GNA12	-0.39	-5.8	-0.3	1.53e-8	Height;
LIHC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.88	-0.3	9.85e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	9.12	0.44	6.58e-18	Lymphocyte counts;
LIHC	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.34	0.49	5.68e-22	Colorectal cancer;
LIHC	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-21.03	-0.75	1.3e-63	Colorectal cancer;
LIHC	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.56	-0.33	1.94e-10	Metabolite levels;
LIHC	cis	rs6442522	0.560	rs924812	chr3:15516481	T/C	cg16303742	chr3:15540471	COLQ	0.36	5.91	0.3	8.12e-9	Uric acid levels;
LIHC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.43	6.16	0.32	2.08e-9	Aortic root size;
LIHC	cis	rs240764	0.711	rs240148	chr6:101076767	C/T	cg09795085	chr6:101329169	ASCC3	0.51	7.16	0.36	4.85e-12	Neuroticism;
LIHC	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.32	7.72	0.39	1.27e-13	Corneal astigmatism;
LIHC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg11406765	chr11:980039	AP2A2	-0.35	-5.78	-0.3	1.69e-8	Alzheimer's disease (late onset);
LIHC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg13446199	chr8:143762866	PSCA	-0.2	-5.85	-0.3	1.12e-8	Urinary tract infection frequency;
LIHC	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.77	-6.44	-0.33	4.06e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09090048	chr11:134093731	VPS26B;NCAPD3	0.43	6.35	0.32	6.77e-10	Lung function (FEV1/FVC);
LIHC	cis	rs600626	0.541	rs11236528	chr11:75469476	T/C	cg24262691	chr11:75473276	NA	0.43	6.37	0.33	6e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.34	-6.69	-0.34	9.39e-11	Platelet distribution width;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24229963	chr8:82633648	ZFAND1	0.4	6.17	0.32	1.91e-9	Cognitive function;
LIHC	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.49	-7.59	-0.38	3.02e-13	Blood pressure (smoking interaction);
LIHC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-6.11	-0.31	2.66e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.17	0.44	4.36e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.2	-0.41	4.94e-15	Body mass index;
LIHC	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg20016023	chr10:99160130	RRP12	0.41	6.54	0.33	2.19e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.57	9.62	0.46	1.46e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.25	0.48	1.14e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.52	-5.85	-0.3	1.18e-8	Breast cancer;
LIHC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.75	10.9	0.51	6e-24	Corneal astigmatism;
LIHC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.25e-16	Schizophrenia;
LIHC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg05044414	chr3:183734942	ABCC5	0.32	6.06	0.31	3.7e-9	Anterior chamber depth;
LIHC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg12463550	chr7:65579703	CRCP	0.78	7.59	0.38	3.04e-13	Diabetic kidney disease;
LIHC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.66	13.89	0.6	4.28e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.6	6.28	0.32	1.01e-9	Blood pressure;
LIHC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.31	2.9e-9	Arsenic metabolism;
LIHC	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	0.77	9.25	0.45	2.58e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg02023728	chr11:77925099	USP35	0.48	9.06	0.44	1.02e-17	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.24	-15.85	-0.65	7.92e-43	Diabetic kidney disease;
LIHC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.95	0.31	6.47e-9	Schizophrenia;
LIHC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-7.73	-0.39	1.25e-13	Coronary artery disease;
LIHC	cis	rs611744	0.934	rs682954	chr8:109210559	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-11.25	-0.52	3.3e-25	Prudent dietary pattern;
LIHC	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg18121669	chr1:26560928	CCDC21	-0.5	-7.56	-0.38	3.72e-13	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg02811702	chr13:24901961	NA	0.25	6.33	0.32	7.79e-10	Obesity-related traits;
LIHC	cis	rs7502590	1.000	rs72854146	chr17:79078610	A/G	cg02064366	chr17:79045526	BAIAP2	0.53	6.28	0.32	1.02e-9	Neuroticism;
LIHC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	9.56	0.46	2.32e-19	Schizophrenia;
LIHC	cis	rs3770081	1.000	rs59947468	chr2:86289436	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.96	-11.41	-0.53	9.09e-26	Facial emotion recognition (sad faces);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08857478	chr17:74722826	JMJD6;C17orf95	0.43	6.55	0.33	2.14e-10	Cognitive function;
LIHC	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.47	8.89	0.43	3.68e-17	Endometriosis;
LIHC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.38	-0.56	2.41e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg13318129	chr22:45737514	FAM118A	0.47	7.43	0.37	8.82e-13	Tonsillectomy;
LIHC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.91	-0.39	3.48e-14	Monocyte percentage of white cells;
LIHC	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg17385448	chr1:15911702	AGMAT	-0.41	-7.13	-0.36	5.88e-12	Systolic blood pressure;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.12e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.29	-0.37	2.12e-12	Monocyte percentage of white cells;
LIHC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.82	0.35	4.04e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg26545112	chr7:97833388	LMTK2	0.36	6.05	0.31	3.71e-9	Longevity;
LIHC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.4	-6.62	-0.34	1.4e-10	Bipolar disorder;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.68	-10.42	-0.49	2.9e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.16	0.32	2.02e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg03859395	chr2:55845619	SMEK2	0.91	15.73	0.65	2.49e-42	Metabolic syndrome;
LIHC	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg16558253	chr16:72132732	DHX38	-0.4	-6.84	-0.35	3.75e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.32	-0.32	8.05e-10	Axial length;
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.83	0.3	1.26e-8	Calcium levels;
LIHC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.34	10.17	0.48	2.17e-21	Obesity-related traits;
LIHC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.45	-7.27	-0.37	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.4	6.81	0.35	4.42e-11	Obesity-related traits;
LIHC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg24296786	chr1:45957014	TESK2	0.51	7.57	0.38	3.52e-13	Platelet count;
LIHC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.38	5.83	0.3	1.26e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg19318889	chr4:1322082	MAEA	0.43	5.9	0.3	8.7e-9	Obesity-related traits;
LIHC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.59e-14	Motion sickness;
LIHC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg03517284	chr6:25882590	NA	-0.44	-6.65	-0.34	1.17e-10	Height;
LIHC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.7	-10.27	-0.49	9.92e-22	Platelet count;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02963556	chr12:132588637	EP400NL	0.52	6.12	0.31	2.51e-9	Lung function (FEV1);
LIHC	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg11204139	chr17:3907470	NA	-0.53	-6.19	-0.32	1.73e-9	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.26e-27	Motion sickness;
LIHC	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	10.19	0.48	1.86e-21	Colorectal cancer;
LIHC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.13	-0.44	6.13e-18	Bipolar disorder;
LIHC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg17182837	chr8:41585554	ANK1	-0.23	-5.77	-0.3	1.77e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg03037974	chr15:76606532	NA	-0.61	-10.28	-0.49	8.54e-22	Blood metabolite levels;
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.01	-0.35	1.26e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs3736757	0.603	rs9425340	chr1:184650963	T/C	cg07817967	chr1:184721222	EDEM3	0.36	5.78	0.3	1.65e-8	Obesity-related traits;
LIHC	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.43	6.23	0.32	1.33e-9	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-7.15	-0.36	5.36e-12	Breast cancer;
LIHC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.51	-6.85	-0.35	3.42e-11	Narcolepsy;
LIHC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.35	-8.25	-0.41	3.57e-15	Immature fraction of reticulocytes;
LIHC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg14440974	chr22:39074834	NA	-0.36	-6.12	-0.31	2.63e-9	Menopause (age at onset);
LIHC	cis	rs116248771	0.739	rs73156423	chr3:158345628	C/A	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.77e-10	diarrhoeal disease at age 2;
LIHC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg05501817	chr11:14380813	RRAS2	-0.45	-6.28	-0.32	1.01e-9	Sense of smell;
LIHC	cis	rs546131	0.642	rs35833762	chr11:34845858	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.79e-31	Breast cancer;
LIHC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.02	0.31	4.41e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.32	6.71	0.34	8.06e-11	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.73	-9.76	-0.47	5.02e-20	Asthma;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg10774155	chr7:65338427	VKORC1L1	0.45	6.56	0.33	2.02e-10	Calcium levels;
LIHC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.55	-8.6	-0.42	2.92e-16	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	8.48	0.42	7.04e-16	Total body bone mineral density;
LIHC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.66	0.53	1.12e-26	Colorectal cancer;
LIHC	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.87	0.43	4.04e-17	Coffee consumption (cups per day);
LIHC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.47	6.23	0.32	1.34e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs17433710	0.543	rs4657222	chr1:162644317	C/G	cg01063088	chr1:162760584	HSD17B7	-0.4	-5.75	-0.3	2.01e-8	Dupuytren's disease;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.44	6.85	0.35	3.4e-11	Testicular germ cell tumor;
LIHC	cis	rs9503598	0.644	rs7774747	chr6:3430996	A/G	cg00476032	chr6:3446245	SLC22A23	-0.32	-6.1	-0.31	2.79e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	trans	rs800082	0.839	rs62275528	chr3:144293687	T/C	cg24215973	chr2:240111563	HDAC4	-0.49	-6.83	-0.35	3.97e-11	Smoking behavior;
LIHC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-8.57	-0.42	3.54e-16	Chronic sinus infection;
LIHC	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.63	-6.8	-0.35	4.67e-11	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.83	10.51	0.49	1.38e-22	Cognitive function;
LIHC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	9.09	0.44	7.98e-18	Motion sickness;
LIHC	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg03934865	chr2:198174659	NA	0.47	6.84	0.35	3.75e-11	Intracranial aneurysm;
LIHC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg02902477	chr6:26197071	HIST1H3D	0.53	5.73	0.3	2.15e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.53	-7.4	-0.37	1.04e-12	Body mass index;
LIHC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	9.76	0.47	5.27e-20	Colorectal cancer;
LIHC	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.49	-6.14	-0.32	2.23e-9	Diisocyanate-induced asthma;
LIHC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.48	-0.37	6.34e-13	Chronic sinus infection;
LIHC	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.58	9.18	0.44	4.3e-18	Breast cancer;
LIHC	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg20991723	chr1:152506922	NA	0.51	8.75	0.43	1.01e-16	Hair morphology;
LIHC	cis	rs9628987	0.569	rs11121174	chr1:8431105	C/G	cg20416874	chr1:8611966	RERE	0.49	5.99	0.31	5.3300000000000004e-09	Breast cancer;
LIHC	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg09572067	chr16:29127029	RRN3P2	0.51	8.11	0.4	9.47e-15	Menopause (age at onset);
LIHC	cis	rs249954	0.512	rs249870	chr16:23666178	C/A	cg01460202	chr16:23706506	ERN2	0.36	5.97	0.31	5.9e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4788570	0.615	rs2334880	chr16:71653637	A/G	cg06353428	chr16:71660113	MARVELD3	1.33	14.1	0.61	6.87e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.69	-0.5	3.41e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.1	-0.31	2.95e-9	Ulcerative colitis;
LIHC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.34e-11	Aortic root size;
LIHC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	9.12	0.44	6.71e-18	Platelet count;
LIHC	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.46	7.1	0.36	7.09e-12	Diastolic blood pressure;
LIHC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.46	-0.33	3.56e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.58	9.85	0.47	2.55e-20	HDL cholesterol;
LIHC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg16586182	chr3:47516702	SCAP	0.61	12.12	0.55	2.35e-28	Colorectal cancer;
LIHC	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.47	7.0	0.35	1.38e-11	Diastolic blood pressure;
LIHC	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg04998671	chr14:104000505	TRMT61A	-0.43	-5.8	-0.3	1.55e-8	Coronary artery disease;
LIHC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.46	0.33	3.52e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.44	-7.05	-0.36	9.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg06640241	chr16:89574553	SPG7	0.81	14.87	0.63	6.34e-39	Multiple myeloma (IgH translocation);
LIHC	cis	rs6722750	0.905	rs10170666	chr2:64379672	G/A	cg22352474	chr2:64371530	PELI1	0.54	7.59	0.38	3.13e-13	Neuroticism;
LIHC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg05484376	chr2:27715224	FNDC4	-0.38	-6.41	-0.33	4.71e-10	Total body bone mineral density;
LIHC	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.5	6.03	0.31	4.19e-9	Serum sulfate level;
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.39	7.72	0.39	1.25e-13	Pursuit maintenance gain;
LIHC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.83	-13.21	-0.58	1.76e-32	Colorectal cancer;
LIHC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.45	7.35	0.37	1.45e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg18944383	chr4:111397179	ENPEP	-0.28	-7.17	-0.36	4.55e-12	Height;
LIHC	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.72	10.24	0.48	1.23e-21	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.6	-8.97	-0.44	1.95e-17	Height;
LIHC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg03959625	chr15:84868606	LOC388152	0.47	6.68	0.34	9.94e-11	Schizophrenia;
LIHC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.4	8.79	0.43	7.25e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.63	9.56	0.46	2.45e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.22e-11	Aortic root size;
LIHC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	12.97	0.57	1.48e-31	Cognitive test performance;
LIHC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.56	-8.8	-0.43	6.74e-17	Red cell distribution width;
LIHC	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg00792783	chr2:198669748	PLCL1	-0.42	-6.02	-0.31	4.44e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.57	-10.34	-0.49	5.44e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.46	8.27	0.41	2.96e-15	Total body bone mineral density;
LIHC	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.07	-14.42	-0.61	3.67e-37	Economic and political preferences (immigration/crime);
LIHC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.45	7.14	0.36	5.7e-12	Height;
LIHC	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-6.73	-0.34	7.36e-11	Schizophrenia;
LIHC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.9	14.23	0.61	2.08e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.63	0.46	1.45e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10508774	1.000	rs117289882	chr10:32837927	T/C	cg01819863	chr10:32635814	EPC1	0.65	5.97	0.31	5.96e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.34	-0.7	8.56e-53	Height;
LIHC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.08	16.15	0.66	5.45e-44	Sexual dysfunction (female);
LIHC	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.17	-0.36	4.54e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.61	10.58	0.5	7.87e-23	Diisocyanate-induced asthma;
LIHC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.89	0.43	3.64e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg15541040	chr2:3486749	NA	-0.39	-5.72	-0.3	2.37e-8	Neurofibrillary tangles;
LIHC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.95	-0.51	3.91e-24	Platelet count;
LIHC	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.83	7.67	0.38	1.78e-13	Uric acid levels;
LIHC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.45	5.73	0.3	2.22e-8	Mean platelet volume;
LIHC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg12501888	chr15:85177176	SCAND2	-0.52	-8.1	-0.4	9.48e-15	P wave terminal force;
LIHC	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.68	-10.13	-0.48	2.97e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.89	-0.3	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7919006	0.590	rs72642258	chr10:76803416	A/G	cg01390419	chr10:76803856	DUPD1	0.5	7.82	0.39	6.68e-14	Weight;
LIHC	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.64	0.42	2.14e-16	Corneal astigmatism;
LIHC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-8.39	-0.41	1.25e-15	Morning vs. evening chronotype;
LIHC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.43	5.95	0.31	6.76e-9	Life satisfaction;
LIHC	cis	rs6001982	0.510	rs55844816	chr22:40803112	C/T	cg07138101	chr22:40742427	ADSL	0.59	6.36	0.33	6.56e-10	Breast cancer;
LIHC	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.19	-0.32	1.73e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-9.15	-0.44	5.45e-18	Blood metabolite levels;
LIHC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.62	9.79	0.47	4.12e-20	Longevity;
LIHC	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	7.03	0.36	1.11e-11	Protein C levels;
LIHC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.46	-0.37	7.34e-13	Response to antipsychotic treatment;
LIHC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.28	-0.55	5.59e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg23743573	chr11:89867420	NAALAD2	0.39	5.85	0.3	1.15e-8	White blood cell types;
LIHC	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg20129853	chr10:51489980	NA	0.39	8.49	0.42	6.42e-16	Prostate-specific antigen levels;
LIHC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.62	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	7.93	0.39	3.05e-14	Parkinson's disease;
LIHC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.61	-0.81	1.64e-81	Myeloid white cell count;
LIHC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.34	6.01	0.31	4.66e-9	Schizophrenia;
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	9.12	0.44	6.58e-18	Morning vs. evening chronotype;
LIHC	cis	rs9543976	0.920	rs9543992	chr13:76175074	G/A	cg01531495	chr13:76123901	UCHL3	0.49	5.84	0.3	1.23e-8	Diabetic retinopathy;
LIHC	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	9.26	0.45	2.28e-18	Schizophrenia;
LIHC	cis	rs1789	0.868	rs4631041	chr4:15673395	A/T	cg21329975	chr4:15471214	CC2D2A	-0.4	-5.99	-0.31	5.2e-9	Blood protein levels;
LIHC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg16405210	chr4:1374714	KIAA1530	0.45	6.1	0.31	2.8e-9	Systolic blood pressure;
LIHC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.49	-8.06	-0.4	1.33e-14	Aortic root size;
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.45	-6.85	-0.35	3.38e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.74	-0.34	6.84e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1185460	0.547	rs34150933	chr11:118911039	C/T	cg23280166	chr11:118938394	VPS11	-0.45	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg20335179	chr10:1068567	C10orf110;IDI2	-0.61	-6.73	-0.34	7.32e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7602441	0.521	rs6704919	chr2:14768496	G/A	cg06545361	chr2:14773388	FAM84A	0.49	5.72	0.3	2.32e-8	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg13628971	chr7:2884303	GNA12	0.34	5.74	0.3	2.12e-8	Height;
LIHC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.29	7.64	0.38	2.28e-13	Bipolar disorder;
LIHC	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.44	7.33	0.37	1.66e-12	Crohn's disease;
LIHC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21545522	chr1:205238299	TMCC2	0.37	7.15	0.36	5.22e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-0.79	-9.02	-0.44	1.36e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.88	18.04	0.7	1.32e-51	Height;
LIHC	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.82	-10.76	-0.5	1.89e-23	Blood pressure (smoking interaction);
LIHC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.79	-10.09	-0.48	4e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.51	0.46	3.43e-19	Lymphocyte counts;
LIHC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg04310649	chr10:35416472	CREM	-0.42	-5.74	-0.3	2.06e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1920116	0.778	rs2421830	chr3:169554129	G/A	cg00669760	chr2:44735195	C2orf34	0.38	6.12	0.31	2.51e-9	Glioma (high-grade);
LIHC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.32	0.52	1.95e-25	Menarche (age at onset);
LIHC	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.6	-7.53	-0.38	4.49e-13	Post bronchodilator FEV1;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-7.32	-0.37	1.75e-12	Testicular germ cell tumor;
LIHC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.36	-0.37	1.4e-12	Cognitive test performance;
LIHC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.78	-0.39	8.65e-14	Ulcerative colitis;
LIHC	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.41	7.48	0.37	6.44e-13	Testicular germ cell tumor;
LIHC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.32	-6.26	-0.32	1.19e-9	Body mass index;
LIHC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs4920343	0.671	rs1010113	chr1:19071752	T/C	cg19637330	chr1:19110922	NA	0.31	5.82	0.3	1.38e-8	Knee osteoarthritis;
LIHC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-6.57	-0.33	1.93e-10	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg16836995	chr17:43662488	NA	-0.75	-7.69	-0.38	1.55e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17152411	0.895	rs7094116	chr10:126587644	T/G	cg07906193	chr10:126599966	NA	0.42	6.64	0.34	1.22e-10	Height;
LIHC	trans	rs1581253	1.000	rs1581253	chr2:180335135	A/G	cg23035555	chr19:3500370	DOHH	-0.48	-6.28	-0.32	1.05e-9	Gestational age at birth in labor-initiated deliveries (child effect);
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.65e-10	Body mass index;
LIHC	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.32	7.58	0.38	3.28e-13	Corneal astigmatism;
LIHC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17467752	chr17:38218738	THRA	0.4	6.05	0.31	3.79e-9	Myeloid white cell count;
LIHC	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg03387723	chr1:41708464	SCMH1	-0.4	-6.53	-0.33	2.36e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	0.91	6.6	0.34	1.58e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.06e-19	Renal cell carcinoma;
LIHC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.48e-8	Axial length;
LIHC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.26	-6.09	-0.31	3.09e-9	Primary biliary cholangitis;
LIHC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.71	-0.38	1.41e-13	Schizophrenia;
LIHC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.39	-6.15	-0.32	2.19e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg22961513	chr11:14280813	SPON1	-0.5	-7.69	-0.38	1.62e-13	Mitochondrial DNA levels;
LIHC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg13535736	chr9:111863775	C9orf5	-0.4	-6.11	-0.31	2.67e-9	Menarche (age at onset);
LIHC	cis	rs965469	0.724	rs2007022	chr20:3237674	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-6.24	-0.32	1.3e-9	IFN-related cytopenia;
LIHC	cis	rs7119038	0.818	rs17122453	chr11:118683564	G/A	cg19308663	chr11:118741387	NA	0.39	6.03	0.31	4.2e-9	Sjögren's syndrome;
LIHC	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg11070056	chr1:107600091	PRMT6	0.7	12.12	0.55	2.31e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.68	12.95	0.57	1.69e-31	Systemic lupus erythematosus;
LIHC	cis	rs6782228	0.651	rs9289332	chr3:128387884	C/G	cg16766828	chr3:128327626	NA	-0.43	-6.77	-0.34	5.68e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs3736485	0.966	rs10467923	chr15:51767265	A/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.75	-0.3	2.01e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	0.77	8.38	0.41	1.38e-15	Testicular germ cell tumor;
LIHC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.13	0.44	6.02e-18	Hemoglobin concentration;
LIHC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.98	17.39	0.69	5.65e-49	Intelligence (multi-trait analysis);
LIHC	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.69	-9.89	-0.47	1.83e-20	Eosinophil percentage of white cells;
LIHC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.46	7.88	0.39	4.32e-14	Mean corpuscular volume;
LIHC	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7674212	0.541	rs2720460	chr4:104054686	C/T	cg16532752	chr4:104119610	CENPE	0.44	6.92	0.35	2.18e-11	Type 2 diabetes;
LIHC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.86	-0.3	1.09e-8	Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.15	0.55	1.81e-28	Prudent dietary pattern;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.44	6.22	0.32	1.43e-9	Calcium levels;
LIHC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.52	7.68	0.38	1.69e-13	Height;
LIHC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.34	-5.81	-0.3	1.43e-8	Schizophrenia;
LIHC	cis	rs4700695	0.841	rs706680	chr5:65317338	T/C	cg21114390	chr5:65439923	SFRS12	0.45	5.87	0.3	1.05e-8	Facial morphology (factor 19);
LIHC	trans	rs3743102	0.591	rs78104714	chr15:83381199	C/G	cg01542190	chr22:50604728	NA	-0.55	-7.39	-0.37	1.14e-12	Colorectal adenoma (advanced);
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.48	0.37	6.49e-13	Height;
LIHC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg15691649	chr6:25882328	NA	-0.55	-7.11	-0.36	6.75e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.44	6.46	0.33	3.53e-10	Blood protein levels;
LIHC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg13844804	chr7:814759	HEATR2	0.44	5.88	0.3	9.97e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg14593290	chr7:50529359	DDC	0.55	8.74	0.43	1.05e-16	Malaria;
LIHC	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.51	-8.61	-0.42	2.64e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.57	10.48	0.49	1.74e-22	Alzheimer's disease (late onset);
LIHC	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.63	9.18	0.44	4.19e-18	Schizophrenia;
LIHC	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.81	0.47	3.5e-20	Corneal astigmatism;
LIHC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.47	-0.37	6.71e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg08499158	chr17:42289980	UBTF	0.5	8.11	0.4	9.22e-15	Total body bone mineral density;
LIHC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.48	7.96	0.4	2.56e-14	Mean corpuscular volume;
LIHC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	0.84	11.03	0.51	2.02e-24	Skin colour saturation;
LIHC	cis	rs1865721	0.761	rs36002108	chr18:73220472	C/T	cg26385618	chr18:73139727	C18orf62	-0.27	-6.83	-0.35	3.94e-11	Intelligence;
LIHC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.68	-9.36	-0.45	1.11e-18	Aortic root size;
LIHC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21467203	chr3:49911342	NA	-0.62	-11.31	-0.52	2.03e-25	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.46	0.46	5.19e-19	Corneal astigmatism;
LIHC	cis	rs17152411	1.000	rs7086447	chr10:126593553	C/A	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg16970926	chr12:29381810	FAR2	0.35	7.5	0.38	5.52e-13	QT interval;
LIHC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.39	7.57	0.38	3.45e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.31e-22	Colorectal cancer;
LIHC	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.38	7.82	0.39	6.44e-14	Optic cup area;
LIHC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg15848620	chr12:58087721	OS9	-0.59	-8.2	-0.41	4.96e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12516959	chr21:47718080	NA	0.36	5.85	0.3	1.17e-8	Testicular germ cell tumor;
LIHC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	11.54	0.53	3.02e-26	Personality dimensions;
LIHC	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.73	-7.82	-0.39	6.58e-14	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.36	-6.35	-0.32	6.66e-10	Lewy body disease;
LIHC	trans	rs877282	0.583	rs11253429	chr10:823234	A/C	cg22713356	chr15:30763199	NA	0.79	6.78	0.34	5.39e-11	Uric acid levels;
LIHC	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg12193833	chr17:30244370	NA	-0.51	-5.94	-0.31	6.92e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.83	0.3	1.29e-8	Menopause (age at onset);
LIHC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.36	7.98	0.4	2.21e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg12903224	chr12:29470962	FAR2	-0.41	-6.54	-0.33	2.3e-10	QT interval;
LIHC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.6	0.67	8e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.39	6.16	0.32	2e-9	Menopause (age at onset);
LIHC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg25344623	chr2:136566232	LCT	-0.37	-5.93	-0.31	7.26e-9	Corneal structure;
LIHC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg18016565	chr1:150552671	MCL1	0.56	10.71	0.5	2.81e-23	Melanoma;
LIHC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.82	0.39	6.84e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1712517	0.740	rs4917387	chr10:105108455	T/C	cg05636881	chr10:105038444	INA	0.49	7.58	0.38	3.25e-13	Migraine;
LIHC	cis	rs4759375	1.000	rs28532037	chr12:123883406	G/A	cg00376283	chr12:123451042	ABCB9	0.5	6.13	0.31	2.45e-9	HDL cholesterol;
LIHC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs713477	1.000	rs8010013	chr14:55884828	A/C	cg13175173	chr14:55914753	NA	-0.31	-7.1	-0.36	7.2e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.51	-0.76	1.55e-65	Height;
LIHC	cis	rs7572733	0.536	rs6732517	chr2:198912902	G/C	cg10820045	chr2:198174542	NA	0.41	6.11	0.31	2.68e-9	Dermatomyositis;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.09	-0.4	1.07e-14	Lymphocyte counts;
LIHC	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.53	-5.99	-0.31	5.26e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg22676075	chr6:135203613	NA	0.37	6.14	0.32	2.3e-9	Red blood cell count;
LIHC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08822215	chr16:89438651	ANKRD11	0.38	6.1	0.31	2.83e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.64	-0.38	2.21e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.66	0.59	3.34e-34	Lung cancer in ever smokers;
LIHC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	1.01	19.29	0.72	1.3e-56	Breast cancer;
LIHC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.58	0.42	3.35e-16	Birth weight;
LIHC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg18944383	chr4:111397179	ENPEP	0.25	6.16	0.32	1.99e-9	Coronary artery disease;
LIHC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.63	10.86	0.51	8.15e-24	Platelet distribution width;
LIHC	cis	rs10242455	0.571	rs45593341	chr7:99304911	C/A	cg18809830	chr7:99032528	PTCD1	-0.83	-6.63	-0.34	1.3100000000000001e-10	Blood metabolite levels;
LIHC	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.85	8.79	0.43	7.29e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.05	24.76	0.8	2.84e-78	IgG glycosylation;
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.68	-0.34	9.94e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11645453	chr3:52864694	ITIH4	0.21	5.75	0.3	2.01e-8	Bipolar disorder;
LIHC	cis	rs2834188	0.737	rs2834179	chr21:34679731	A/G	cg14352951	chr21:34696688	IFNAR1	0.47	6.51	0.33	2.61e-10	Narcolepsy;
LIHC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.48	7.33	0.37	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.67	-6.94	-0.35	1.95e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.07	-20.84	-0.75	7.84e-63	Multiple system atrophy;
LIHC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06640241	chr16:89574553	SPG7	0.65	10.39	0.49	3.56e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.24e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg14779329	chr11:130786720	SNX19	0.43	6.53	0.33	2.39e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg06634786	chr22:41940651	POLR3H	0.56	6.16	0.32	2e-9	Vitiligo;
LIHC	cis	rs116248771	0.739	rs4680448	chr3:158349978	C/A	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.77e-10	diarrhoeal disease at age 2;
LIHC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.49	-7.83	-0.39	6.39e-14	Schizophrenia;
LIHC	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg06611532	chr13:114900021	NA	0.41	7.54	0.38	4.25e-13	Schizophrenia;
LIHC	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	7.87	0.39	4.58e-14	Blood protein levels;
LIHC	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg08539965	chr1:21396338	EIF4G3	-0.34	-6.26	-0.32	1.15e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7520258	1	rs7520258	chr1:236313127	A/G	cg17269430	chr1:236305619	GPR137B	0.85	7.95	0.39	2.78e-14	Response to antipsychotic treatment in schizophrenia (working memory);
LIHC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	9.11	0.44	7.02e-18	Mean platelet volume;
LIHC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.38	6.01	0.31	4.72e-9	Menopause (age at onset);
LIHC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.5	0.33	2.86e-10	Bipolar disorder;
LIHC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg03517284	chr6:25882590	NA	-0.37	-5.72	-0.3	2.34e-8	Height;
LIHC	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.94e-10	Metabolite levels;
LIHC	trans	rs7714584	1.000	rs2880791	chr5:150267376	C/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.05	0.36	9.83e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg02640540	chr1:67518911	SLC35D1	0.43	5.93	0.31	7.24e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.93	-0.47	1.36e-20	Obesity-related traits;
LIHC	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg20607764	chr19:44506953	ZNF230	-0.42	-6.85	-0.35	3.51e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-10.54	-0.49	1.16e-22	Platelet count;
LIHC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.64	8.06	0.4	1.31e-14	Morning vs. evening chronotype;
LIHC	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.42	5.91	0.3	8.35e-9	Tuberculosis;
LIHC	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.64	6.8	0.34	4.81e-11	Neutrophil percentage of white cells;
LIHC	trans	rs11088226	1.000	rs2833890	chr21:33927886	A/G	cg09050820	chr6:167586206	TCP10L2	-0.76	-11.66	-0.53	1.1e-26	Gastritis;
LIHC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.66	10.47	0.49	1.96e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.51	-6.39	-0.33	5.41e-10	Pancreatic cancer;
LIHC	cis	rs62481355	1.000	rs62481355	chr7:127201664	C/T	cg25922125	chr7:127225783	GCC1	-0.44	-5.77	-0.3	1.73e-8	Type 2 diabetes;
LIHC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.03e-40	Aortic root size;
LIHC	trans	rs9531686	0.967	rs9546997	chr13:85547901	G/T	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.3	0.32	9.32e-10	Anorexia nervosa;
LIHC	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs2016586	0.894	rs5995155	chr22:36102700	A/G	cg26342177	chr22:36113512	APOL5	-0.37	-6.2	-0.32	1.6e-9	Body mass index;
LIHC	cis	rs3770081	1.000	rs2278087	chr2:86281946	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.03	0.31	4.36e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.98	21.52	0.76	1.48e-65	Bone mineral density;
LIHC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.63	8.98	0.44	1.8e-17	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2334880	0.678	rs34400718	chr16:71455852	G/A	cg06353428	chr16:71660113	MARVELD3	-0.86	-8.49	-0.42	6.59e-16	Malaria;
LIHC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	0.96	10.29	0.49	7.91e-22	Vitiligo;
LIHC	cis	rs16912285	0.688	rs12805482	chr11:24346955	C/A	ch.11.24196551F	chr11:24239977	NA	0.72	8.3	0.41	2.5e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.55	7.87	0.39	4.78e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.42	0.56	1.8e-29	Prudent dietary pattern;
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.47	-7.07	-0.36	8.88e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-8.24	-0.41	3.73e-15	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.1	0.55	2.58e-28	Prudent dietary pattern;
LIHC	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.61	8.3	0.41	2.45e-15	Eotaxin levels;
LIHC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg26338869	chr17:61819248	STRADA	0.61	8.82	0.43	6.02e-17	Prudent dietary pattern;
LIHC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.79	-0.3	1.58e-8	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.29	-5.71	-0.3	2.39e-8	Renal cell carcinoma;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.87	-0.35	3.14e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13789711	chr9:139743225	PHPT1	0.43	6.56	0.33	1.94e-10	Pancreatic cancer;
LIHC	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg03037974	chr15:76606532	NA	-0.63	-10.88	-0.51	7.1e-24	Blood metabolite levels;
LIHC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.06	0.63	1.09e-39	Menopause (age at onset);
LIHC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg07661805	chr8:143867942	LY6D	-0.32	-6.87	-0.35	3.11e-11	Urinary tract infection frequency;
LIHC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.68	-9.51	-0.46	3.48e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.93	0.47	1.36e-20	Crohn's disease;
LIHC	cis	rs61677309	1.000	rs12577045	chr11:118151446	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.6	0.34	1.53e-10	Lung cancer in ever smokers;
LIHC	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg00977110	chr5:151150581	G3BP1	-0.51	-6.32	-0.32	8.22e-10	Preschool internalizing problems;
LIHC	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.54	8.58	0.42	3.3e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.82	-0.3	1.38e-8	Red blood cell count;
LIHC	cis	rs422249	0.896	rs174449	chr11:61640379	A/G	cg27386326	chr11:61587980	NA	0.35	6.24	0.32	1.27e-9	Trans fatty acid levels;
LIHC	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.7	8.94	0.44	2.49e-17	Exhaled nitric oxide output;
LIHC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.76	7.09	0.36	7.83e-12	Plasma clusterin levels;
LIHC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg09137382	chr11:130731461	NA	0.41	6.09	0.31	2.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.37	-6.91	-0.35	2.42e-11	Type 2 diabetes;
LIHC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.85	0.69	8.27e-51	Gut microbiome composition (summer);
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.47	5.73	0.3	2.21e-8	Alzheimer's disease;
LIHC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg13647721	chr17:30228624	UTP6	0.8	7.65	0.38	2.07e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg00343986	chr7:65444356	GUSB	0.39	5.77	0.3	1.76e-8	Aortic root size;
LIHC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.2	-0.32	1.65e-9	Obesity-related traits;
LIHC	cis	rs10508774	1.000	rs72780316	chr10:32924848	C/G	cg01819863	chr10:32635814	EPC1	0.64	5.83	0.3	1.28e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.49	5.85	0.3	1.18e-8	Schizophrenia;
LIHC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.51	8.15	0.4	6.83e-15	Platelet count;
LIHC	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.66	-9.91	-0.47	1.63e-20	Monocyte count;
LIHC	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg16583315	chr14:65563665	MAX	-0.39	-7.88	-0.39	4.33e-14	Obesity-related traits;
LIHC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.63	7.33	0.37	1.72e-12	Menarche (age at onset);
LIHC	cis	rs61677309	0.558	rs7940047	chr11:118142619	C/T	cg06090739	chr11:118230722	UBE4A	0.31	6.02	0.31	4.56e-9	Lung cancer in ever smokers;
LIHC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.72	0.3	2.27e-8	Self-reported allergy;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg11062466	chr8:58055876	NA	-0.51	-7.42	-0.37	9.43e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.64	0.34	1.25e-10	Bipolar disorder;
LIHC	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-0.83	-8.24	-0.41	3.84e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.57	-8.56	-0.42	3.98e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6061231	0.958	rs2427304	chr20:60953584	G/A	cg24112000	chr20:60950667	NA	-0.6	-8.34	-0.41	1.78e-15	Colorectal cancer;
LIHC	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.44	-0.42	9.43e-16	Exhaled nitric oxide output;
LIHC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.15e-11	Height;
LIHC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg16479474	chr6:28041457	NA	0.47	6.96	0.35	1.73e-11	Parkinson's disease;
LIHC	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.46	-0.37	7.02e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-7.04	-0.36	1.07e-11	Electroencephalogram traits;
LIHC	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.48	-7.1	-0.36	7.39e-12	Multiple sclerosis;
LIHC	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.61	5.95	0.31	6.66e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.47	-8.16	-0.4	6.39e-15	Brugada syndrome;
LIHC	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg26441486	chr22:50317300	CRELD2	0.37	6.3	0.32	9.03e-10	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11234017	chr17:42767172	CCDC43	0.47	7.16	0.36	4.9e-12	Pancreatic cancer;
LIHC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.37	-6.26	-0.32	1.16e-9	Blood metabolite levels;
LIHC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.75	-0.5	1.99e-23	Total cholesterol levels;
LIHC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.3	-7.85	-0.39	5.24e-14	Birth weight;
LIHC	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.42	-7.05	-0.36	9.77e-12	Schizophrenia;
LIHC	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-7.5	-0.38	5.56e-13	Homocysteine levels;
LIHC	cis	rs3736594	0.513	rs62138965	chr2:27816593	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.35	3.5e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	trans	rs11689435	0.925	rs13013662	chr2:218345080	C/G	cg13544946	chr9:35729779	TLN1	-0.44	-6.35	-0.32	6.82e-10	Metabolite levels (MHPG);
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06420487	chr17:61919686	SMARCD2	0.42	5.8	0.3	1.51e-8	Height;
LIHC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg25329415	chr6:28076851	NA	0.27	5.71	0.3	2.44e-8	Cardiac Troponin-T levels;
LIHC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg06784218	chr1:46089804	CCDC17	0.37	5.82	0.3	1.39e-8	Platelet count;
LIHC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.5	-8.88	-0.43	3.88e-17	Coronary artery disease;
LIHC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	1.0	14.66	0.62	4.2e-38	Intelligence (multi-trait analysis);
LIHC	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	9.09	0.44	8.46e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg19683494	chr5:74908142	NA	0.48	6.39	0.33	5.32e-10	Age-related disease endophenotypes;
LIHC	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg08508337	chr8:144660607	NAPRT1	-0.61	-5.8	-0.3	1.49e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs12986413	0.934	rs6510645	chr19:2158398	T/C	cg09261902	chr19:2140048	AP3D1	0.39	6.55	0.33	2.09e-10	Height;
LIHC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	0.88	12.17	0.55	1.43e-28	Skin colour saturation;
LIHC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.95	0.31	6.6e-9	Height;
LIHC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.48	-18.03	-0.7	1.51e-51	Breast cancer;
LIHC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg09182678	chr22:50328711	NA	-0.4	-5.91	-0.3	8.41e-9	Schizophrenia;
LIHC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	0.5	7.48	0.37	6.37e-13	Methadone dose in opioid dependence;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21512275	chr2:157198069	NA	0.58	8.19	0.4	5.16e-15	Pancreatic cancer;
LIHC	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg02023728	chr11:77925099	USP35	-0.32	-5.72	-0.3	2.3e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.94	-0.31	6.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9649465	0.967	rs1008539	chr7:123305518	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.56e-14	Migraine;
LIHC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.46	-7.65	-0.38	2.02e-13	Breast cancer;
LIHC	cis	rs2404602	0.587	rs17380507	chr15:77235361	C/T	cg03037974	chr15:76606532	NA	0.73	14.01	0.6	1.43e-35	Blood metabolite levels;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.59	-8.56	-0.42	3.92e-16	Testicular germ cell tumor;
LIHC	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.47	-0.76	2.26e-65	Height;
LIHC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	trans	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.44	7.7	0.38	1.44e-13	Aortic root size;
LIHC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg06102954	chr21:42741788	MX2	-0.38	-6.49	-0.33	2.94e-10	Melanoma;
LIHC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg25344623	chr2:136566232	LCT	-0.38	-6.1	-0.31	2.88e-9	Corneal structure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05098230	chr7:92076734	GATAD1	-0.57	-6.56	-0.33	2.02e-10	Systolic blood pressure;
LIHC	cis	rs8049603	0.524	rs10492790	chr16:23076410	C/T	cg16484020	chr16:23217411	SCNN1G	-0.23	-5.88	-0.3	9.67e-9	Multiple sclerosis;
LIHC	cis	rs8067354	0.958	rs2777889	chr17:57848006	A/G	cg02344993	chr17:57696989	CLTC	0.52	8.25	0.41	3.51e-15	Hemoglobin concentration;
LIHC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg26531700	chr6:26746687	NA	0.38	6.19	0.32	1.7e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13053135	chr2:234359932	DGKD	0.42	6.42	0.33	4.56e-10	Longevity;
LIHC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.61	-5.9	-0.3	8.67e-9	Urate levels in lean individuals;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg26939375	chr7:64535504	NA	0.48	7.24	0.36	3.07e-12	Calcium levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06790019	chr1:44435457	DPH2	0.42	6.15	0.32	2.14e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.33	-0.76	8.44e-65	Height;
LIHC	trans	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg26939375	chr7:64535504	NA	0.4	6.31	0.32	8.63e-10	Aortic root size;
LIHC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.39	0.52	1.09e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.69	-0.34	9.29e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	7.86	0.39	5.11e-14	HDL cholesterol;
LIHC	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg18289306	chr13:113640169	MCF2L	0.43	6.98	0.35	1.5e-11	Systolic blood pressure;
LIHC	cis	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg00086871	chr4:6988644	TBC1D14	0.85	6.11	0.31	2.71e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.66	0.34	1.08e-10	Ileal carcinoids;
LIHC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg01652190	chr22:50026171	C22orf34	-0.3	-7.01	-0.35	1.28e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs10411161	0.702	rs6509591	chr19:52391940	A/T	cg22319618	chr22:45562946	NUP50	-0.61	-8.27	-0.41	3.02e-15	Breast cancer;
LIHC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.41	-6.64	-0.34	1.24e-10	Lung cancer;
LIHC	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg05926928	chr17:57297772	GDPD1	0.61	6.72	0.34	7.44e-11	Opioid sensitivity;
LIHC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg01652190	chr22:50026171	C22orf34	-0.32	-7.39	-0.37	1.12e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg26441486	chr22:50317300	CRELD2	-0.35	-6.32	-0.32	7.96e-10	Schizophrenia;
LIHC	cis	rs67981189	0.593	rs2877708	chr14:71484126	C/G	cg15816911	chr14:71606274	NA	0.4	6.35	0.32	6.99e-10	Schizophrenia;
LIHC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg18944383	chr4:111397179	ENPEP	0.34	8.18	0.4	5.47e-15	Height;
LIHC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.07	-25.45	-0.81	6.64e-81	IgG glycosylation;
LIHC	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg17385448	chr1:15911702	AGMAT	0.39	6.51	0.33	2.75e-10	Systolic blood pressure;
LIHC	cis	rs16854884	0.710	rs9829796	chr3:143801416	C/T	cg06585982	chr3:143692056	C3orf58	0.42	5.95	0.31	6.79e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.67	8.47	0.42	7.28e-16	Gut microbiome composition (summer);
LIHC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.46	-0.37	7.25e-13	Mean platelet volume;
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-7.6	-0.38	2.92e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.77	11.67	0.53	1.02e-26	Coronary artery disease;
LIHC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2637266	0.875	rs115333453	chr10:78369011	G/A	cg18941641	chr10:78392320	NA	0.27	5.73	0.3	2.2e-8	Pulmonary function;
LIHC	cis	rs3815308	0.530	rs12983546	chr19:2195065	G/T	cg09261902	chr19:2140048	AP3D1	0.37	6.11	0.31	2.79e-9	Breast cancer;
LIHC	cis	rs77861329	1.000	rs9847092	chr3:52199453	T/C	cg08692210	chr3:52188851	WDR51A	0.81	7.77	0.39	9.13e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.54	-0.5	1.15e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.41	-0.41	1.11e-15	Schizophrenia;
LIHC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg12798992	chr6:167411361	FGFR1OP	0.47	6.93	0.35	2.07e-11	Rheumatoid arthritis;
LIHC	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	8.91	0.43	3.18e-17	Exhaled nitric oxide levels;
LIHC	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.29	6.22	0.32	1.43e-9	Pulmonary function;
LIHC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg21466736	chr12:48725269	NA	0.33	5.95	0.31	6.81e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.35	5.73	0.3	2.25e-8	Lung cancer;
LIHC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg14779329	chr11:130786720	SNX19	0.38	5.82	0.3	1.34e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	7.02	0.36	1.17e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.34e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.68	-0.42	1.69e-16	Skin colour saturation;
LIHC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.93	-0.39	3.04e-14	Type 2 diabetes;
LIHC	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	11.97	0.54	8.24e-28	Schizophrenia;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06577708	chr3:64008893	PSMD6	-0.44	-6.36	-0.33	6.59e-10	Triglycerides;
LIHC	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17467752	chr17:38218738	THRA	-0.54	-9.18	-0.44	4.33e-18	Myeloid white cell count;
LIHC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.77	-0.43	8.74e-17	Monocyte count;
LIHC	cis	rs763121	0.657	rs5995603	chr22:39040733	G/A	cg14440974	chr22:39074834	NA	-0.41	-6.31	-0.32	8.88e-10	Menopause (age at onset);
LIHC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.42	-7.77	-0.39	9.38e-14	Mean corpuscular volume;
LIHC	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.85	14.23	0.61	2e-36	Body mass index;
LIHC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.6	-10.25	-0.48	1.14e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.63	5.84	0.3	1.23e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	trans	rs4566648	0.593	rs10002954	chr4:84177179	G/A	cg06219686	chr17:29421884	NF1	-0.52	-6.12	-0.31	2.53e-9	Monocyte count;
LIHC	cis	rs611744	0.967	rs596245	chr8:109240822	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.54	0.33	2.29e-10	Dupuytren's disease;
LIHC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg00204748	chr12:29376779	FAR2	-0.41	-7.32	-0.37	1.84e-12	QT interval;
LIHC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22618164	chr12:122356400	WDR66	0.54	9.11	0.44	7.22e-18	Mean corpuscular volume;
LIHC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.5	-8.6	-0.42	2.95e-16	Mean corpuscular volume;
LIHC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.03	-0.44	1.28e-17	Bipolar disorder;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19819135	chr1:70710422	SFRS11	0.42	6.21	0.32	1.53e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-6.59	-0.34	1.67e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.4	-8.39	-0.41	1.29e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.67	10.88	0.51	7.31e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	7.63	0.38	2.29e-13	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.42	7.49	0.38	6.03e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19884546	chr22:38082237	NOL12	0.43	6.58	0.34	1.75e-10	Cognitive function;
LIHC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg20487152	chr13:99095054	FARP1	-0.38	-6.2	-0.32	1.64e-9	Neuroticism;
LIHC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.88	-15.33	-0.64	9.23e-41	Colorectal cancer;
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.56	9.46	0.46	5.21e-19	Aortic root size;
LIHC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-12.17	-0.55	1.5e-28	Alzheimer's disease (late onset);
LIHC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-0.61	-8.18	-0.4	5.65e-15	Lung cancer;
LIHC	trans	rs11689435	0.925	rs34042566	chr2:218352970	G/A	cg13544946	chr9:35729779	TLN1	-0.45	-6.36	-0.33	6.42e-10	Metabolite levels (MHPG);
LIHC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.37	6.12	0.31	2.62e-9	Lung cancer;
LIHC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.53	6.89	0.35	2.76e-11	Initial pursuit acceleration;
LIHC	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg00601450	chr5:74908170	NA	-0.59	-7.12	-0.36	6.53e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-6.92	-0.35	2.19e-11	Metabolite levels;
LIHC	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.46	-6.86	-0.35	3.15e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg13647721	chr17:30228624	UTP6	0.75	8.24	0.41	3.59e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.6	9.12	0.44	6.67e-18	Gout;
LIHC	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.44	7.85	0.39	5.29e-14	Inhibitory control;
LIHC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.58	9.92	0.47	1.49e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2901460	0.509	rs66481227	chr2:62117600	C/T	cg02183531	chr2:62113199	CCT4	-0.43	-6.26	-0.32	1.16e-9	Mean corpuscular volume;
LIHC	cis	rs4650994	0.593	rs12735140	chr1:178544218	C/A	cg05350800	chr1:178550844	NA	-0.35	-7.64	-0.38	2.26e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs797680	0.856	rs11164902	chr1:93778794	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.67e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.69	8.59	0.42	3.21e-16	IgG glycosylation;
LIHC	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.63	0.34	1.34e-10	Diastolic blood pressure;
LIHC	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.67	-8.66	-0.42	1.89e-16	Corneal structure;
LIHC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.26	0.37	2.61e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.52	8.44	0.41	9.43e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.87	13.29	0.58	8.66e-33	Lymphocyte percentage of white cells;
LIHC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg17310611	chr1:113615709	LRIG2	-0.54	-6.14	-0.32	2.29e-9	Bronchial neuroendocrine tumor;
LIHC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.33	0.64	9.41e-41	Chronic sinus infection;
LIHC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.6	10.26	0.49	1.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2412488	0.854	rs12511088	chr4:54363262	G/A	cg22241045	chr4:54363911	LNX1	0.46	7.64	0.38	2.25e-13	DNA methylation (variation);
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.93	13.32	0.58	6.93e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20135002	chr11:47629003	NA	-0.58	-10.13	-0.48	2.9e-21	Subjective well-being;
LIHC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg18306943	chr3:40428807	ENTPD3	0.35	5.72	0.3	2.3e-8	Renal cell carcinoma;
LIHC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	6.19	0.32	1.69e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs7577696	0.597	rs13006495	chr2:32355490	C/T	cg02381751	chr2:32503542	YIPF4	-0.44	-6.14	-0.31	2.34e-9	Inflammatory biomarkers;
LIHC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg07424592	chr7:64974309	NA	0.75	8.59	0.42	3.09e-16	Diabetic kidney disease;
LIHC	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.77	10.8	0.5	1.34e-23	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.41	7.68	0.38	1.71e-13	Schizophrenia;
LIHC	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.73	12.77	0.57	8.21e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs926392	0.666	rs912179	chr20:37710775	G/A	cg16355469	chr20:37678765	NA	0.51	7.39	0.37	1.16e-12	Dialysis-related mortality;
LIHC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg09990169	chr2:241835740	C2orf54	-0.67	-9.56	-0.46	2.34e-19	Urinary metabolites;
LIHC	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg05621596	chr22:47072043	GRAMD4	-0.68	-10.32	-0.49	6.49e-22	Urate levels in obese individuals;
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.59	7.63	0.38	2.42e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.53	6.86	0.35	3.17e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.94	0.31	6.9e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.92	-9.51	-0.46	3.53e-19	Ulcerative colitis;
LIHC	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.28	5.91	0.3	8.28e-9	Pulmonary function;
LIHC	cis	rs61863818	0.557	rs7919862	chr10:99149964	C/T	cg06359132	chr10:99160096	RRP12	0.35	5.78	0.3	1.67e-8	Monocyte percentage of white cells;
LIHC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg25039879	chr17:56429692	SUPT4H1	0.53	7.32	0.37	1.76e-12	Cognitive test performance;
LIHC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.49	-7.7	-0.38	1.48e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs7487075	0.558	rs3847985	chr12:46655287	G/A	cg15584813	chr12:47219626	SLC38A4	0.32	5.79	0.3	1.63e-8	Itch intensity from mosquito bite;
LIHC	trans	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg17675199	chr6:35436792	RPL10A	0.37	7.36	0.37	1.4e-12	Monocyte count;
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.55	-6.44	-0.33	4.07e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.61	7.78	0.39	8.51e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	24.9	0.8	8.31e-79	Schizophrenia;
LIHC	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-11.2	-0.52	5.29e-25	Morning vs. evening chronotype;
LIHC	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.14	-0.36	5.58e-12	Metabolite levels (Pyroglutamine);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15238519	chr22:50683529	TUBGCP6	-0.44	-6.16	-0.32	2.04e-9	Systolic blood pressure;
LIHC	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	1.13	8.8	0.43	6.86e-17	Arsenic metabolism;
LIHC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.75	0.39	1.06e-13	Protein C levels;
LIHC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.53	-8.57	-0.42	3.67e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.38	0.41	1.38e-15	Lymphocyte counts;
LIHC	cis	rs2637030	0.559	rs256105	chr5:53013889	T/C	cg06476337	chr5:52856530	NDUFS4	0.42	6.73	0.34	6.99e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg25356066	chr3:128598488	ACAD9	0.55	7.7	0.38	1.51e-13	IgG glycosylation;
LIHC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.53	8.8	0.43	7.1e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg17927777	chr20:33865990	NA	-0.55	-6.41	-0.33	4.88e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs2834188	0.889	rs1467849	chr21:34682069	G/T	cg14352951	chr21:34696688	IFNAR1	0.48	6.73	0.34	7.25e-11	Narcolepsy;
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg26939375	chr7:64535504	NA	0.48	7.22	0.36	3.46e-12	Aortic root size;
LIHC	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.43	6.62	0.34	1.36e-10	Neuroticism;
LIHC	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.21	-0.48	1.57e-21	Eye color traits;
LIHC	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.55	9.6	0.46	1.74e-19	Total cholesterol levels;
LIHC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.24	-7.38	-0.37	1.23e-12	Mean corpuscular volume;
LIHC	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.65	7.72	0.39	1.28e-13	Heart rate;
LIHC	cis	rs2710642	0.564	rs6545963	chr2:62822891	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-7.07	-0.36	8.99e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.53	0.49	1.21e-22	Hypertriglyceridemia;
LIHC	trans	rs1864585	0.552	rs73208794	chr8:10681248	C/G	cg26278703	chr11:58910052	FAM111A	0.72	6.57	0.33	1.84e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs6967414	0.792	rs6954012	chr7:6755724	A/C	cg00387323	chr7:6746715	ZNF12	0.65	7.19	0.36	3.99e-12	Hematocrit;Hemoglobin concentration;
LIHC	trans	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg05791018	chr13:19965014	NA	-0.27	-6.2	-0.32	1.62e-9	Schizophrenia;
LIHC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.46	-0.46	5.03e-19	Heart rate;
LIHC	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.62	-7.15	-0.36	5.27e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12744310	0.943	rs12027685	chr1:41756298	G/A	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.82e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-6.13	-0.31	2.48e-9	Initial pursuit acceleration;
LIHC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.48	-7.66	-0.38	1.89e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	1.23	10.89	0.51	6.79e-24	Obesity-related traits;
LIHC	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.2	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg18887096	chr2:219472410	PLCD4	0.35	6.26	0.32	1.13e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg10756647	chr7:56101905	PSPH	1.07	13.36	0.59	4.62e-33	Diabetic kidney disease;
LIHC	cis	rs1775715	1.000	rs1251355	chr10:32290146	C/G	cg14930904	chr10:32216787	ARHGAP12	0.4	7.2	0.36	3.85e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.57	10.49	0.49	1.7e-22	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.28	16.98	0.68	2.52e-47	Diabetic kidney disease;
LIHC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg24130564	chr14:104152367	KLC1	-0.54	-8.8	-0.43	6.79e-17	Reticulocyte count;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.44	8.17	0.4	6.08e-15	Prudent dietary pattern;
LIHC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.73	-7.22	-0.36	3.35e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2242420	0.920	rs6679565	chr1:21962551	A/G	cg18150885	chr1:21978612	RAP1GAP	0.46	5.88	0.3	9.92e-9	Hematological and biochemical traits;
LIHC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.73	-13.52	-0.59	1.16e-33	Height;
LIHC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.72	10.18	0.48	1.95e-21	Selective IgA deficiency;
LIHC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg10932868	chr11:921992	NA	0.39	7.47	0.37	6.59e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.85	0.35	3.4e-11	Bipolar disorder;
LIHC	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg09695851	chr17:3907499	NA	0.63	8.26	0.41	3.18e-15	Type 2 diabetes;
LIHC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.61	8.46	0.42	8.08e-16	Coronary artery disease;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg10360323	chr17:41437877	NA	0.41	5.9	0.3	8.74e-9	Menopause (age at onset);
LIHC	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg11783602	chr8:55087084	NA	-0.34	-6.57	-0.33	1.92e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs797680	0.856	rs1335679	chr1:93645182	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.87	-0.3	1.03e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg06951627	chr6:26196580	NA	0.53	6.27	0.32	1.07e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.81	13.62	0.59	4.64e-34	Parkinson's disease;
LIHC	cis	rs911119	0.955	rs6114201	chr20:23607231	T/A	cg16589663	chr20:23618590	CST3	0.71	7.51	0.38	5.15e-13	Chronic kidney disease;
LIHC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.84	-0.3	1.21e-8	Biliary atresia;
LIHC	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.37e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.55	6.09	0.31	3.12e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.85	-14.17	-0.61	3.43e-36	Post bronchodilator FEV1;
LIHC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.92	0.54	1.29e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs700651	0.789	rs2196176	chr2:198904914	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.55	0.33	2.06e-10	Intracranial aneurysm;
LIHC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.12	0.61	5.45e-36	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.57	-0.38	3.55e-13	Body mass index;
LIHC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-5.9	-0.3	8.58e-9	Vitiligo;
LIHC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.88e-10	Fibrinogen levels;
LIHC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg15051332	chr6:41514432	FOXP4	0.41	5.74	0.3	2.05e-8	Prostate cancer;
LIHC	cis	rs6977660	1.000	rs10240227	chr7:19823188	T/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	trans	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04565464	chr8:145669602	NFKBIL2	0.4	6.69	0.34	9.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-6.66	-0.34	1.08e-10	Schizophrenia;
LIHC	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg05185784	chr16:90016020	DEF8	-0.49	-6.28	-0.32	1.01e-9	Skin colour saturation;
LIHC	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.38	6.15	0.32	2.21e-9	Height;
LIHC	cis	rs2737618	0.674	rs2821334	chr1:200093887	G/T	cg21825944	chr1:200113062	NR5A2	-0.46	-7.74	-0.39	1.15e-13	Uric acid levels;
LIHC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.03e-11	Ileal carcinoids;
LIHC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg10978503	chr1:24200527	CNR2	-0.38	-9.1	-0.44	7.34e-18	Immature fraction of reticulocytes;
LIHC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.46	-6.64	-0.34	1.21e-10	Longevity;
LIHC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.43	-0.59	2.6e-33	Vitiligo;
LIHC	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.66	10.52	0.49	1.36e-22	Schizophrenia;
LIHC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg12365402	chr11:9010492	NRIP3	0.31	7.91	0.39	3.7e-14	Hemoglobin concentration;
LIHC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg21017887	chr14:105400489	NA	0.66	12.3	0.55	4.76e-29	Rheumatoid arthritis;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06420487	chr17:61919686	SMARCD2	0.44	5.95	0.31	6.77e-9	Height;
LIHC	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.64	0.46	1.33e-19	Corneal astigmatism;
LIHC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.78	11.14	0.52	8.22e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs75908454	0.661	rs79884685	chr6:169800884	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.52	-0.38	4.91e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg09904177	chr6:26538194	HMGN4	-0.53	-5.72	-0.3	2.37e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.13	25.37	0.81	1.29e-80	Cognitive ability;
LIHC	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	7.67	0.38	1.81e-13	Blood protein levels;
LIHC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.16	0.36	4.92e-12	Height;
LIHC	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.67	10.9	0.51	6.18e-24	White matter hyperintensity burden;
LIHC	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg12698662	chr3:15914712	MIR563	0.37	6.73	0.34	7.01e-11	Mean platelet volume;
LIHC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.81	12.96	0.57	1.6e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs6499255	0.953	rs3811349	chr16:69791266	T/G	cg15192750	chr16:69999425	NA	0.45	6.85	0.35	3.49e-11	IgE levels;
LIHC	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.41	7.65	0.38	2.04e-13	Testicular germ cell tumor;
LIHC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg19683494	chr5:74908142	NA	0.57	7.62	0.38	2.47e-13	Age-related disease endophenotypes;
LIHC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg07424592	chr7:64974309	NA	-0.76	-8.58	-0.42	3.38e-16	Diabetic kidney disease;
LIHC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.97	0.47	1.01e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.21	0.48	1.49e-21	Colorectal cancer;
LIHC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg18016565	chr1:150552671	MCL1	0.5	9.74	0.47	5.99e-20	Melanoma;
LIHC	cis	rs2526882	0.542	rs714421	chr14:71359585	A/G	cg15816911	chr14:71606274	NA	-0.36	-5.81	-0.3	1.46e-8	Schizophrenia;
LIHC	cis	rs1165668	0.958	rs1165674	chr12:104320597	T/C	cg21863207	chr12:104234989	NT5DC3	-0.4	-6.36	-0.33	6.43e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg04998671	chr14:104000505	TRMT61A	-0.44	-5.93	-0.31	7.61e-9	Coronary artery disease;
LIHC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.52	7.89	0.39	4.09e-14	Resting heart rate;
LIHC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09065629	chr16:1709722	CRAMP1L	0.33	5.93	0.31	7.41e-9	Coronary artery disease;
LIHC	cis	rs9783347	0.961	rs2061163	chr11:18322924	A/C	cg15585147	chr11:18324498	HPS5	0.45	7.02	0.35	1.22e-11	Pancreatic cancer;
LIHC	trans	rs875971	1.000	rs811880	chr7:65818646	T/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg01081584	chr15:40268610	EIF2AK4	0.53	6.15	0.32	2.19e-9	Corneal curvature;
LIHC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg07645718	chr20:61493192	TCFL5	0.68	5.87	0.3	1.04e-8	Obesity-related traits;
LIHC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.57	9.96	0.47	1.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg20140201	chr2:241835670	C2orf54	-0.46	-6.15	-0.32	2.2e-9	Urinary metabolites;
LIHC	trans	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg17675199	chr6:35436792	RPL10A	0.43	8.89	0.43	3.45e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2637266	0.783	rs1660908	chr10:78494856	T/C	cg18941641	chr10:78392320	NA	0.27	5.86	0.3	1.1e-8	Pulmonary function;
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.88	-0.35	2.83e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.62	9.84	0.47	2.74e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.542	rs9926968	chr16:381561	A/C	cg12437481	chr16:420112	MRPL28	-0.61	-8.52	-0.42	5.04e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.34	8.25	0.41	3.46e-15	Immature fraction of reticulocytes;
LIHC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.73	7.56	0.38	3.68e-13	Cannabis dependence symptom count;
LIHC	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.49	-6.38	-0.33	5.88e-10	Height;
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02290350	chr8:58132656	NA	0.49	10.56	0.5	9.22e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.82	0.43	5.8e-17	Motion sickness;
LIHC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg16586182	chr3:47516702	SCAP	-0.46	-8.3	-0.41	2.38e-15	Colorectal cancer;
LIHC	trans	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg10756647	chr7:56101905	PSPH	1.11	13.6	0.59	5.63e-34	Diabetic kidney disease;
LIHC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg10932868	chr11:921992	NA	0.39	7.49	0.38	5.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-6.96	-0.35	1.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.46	6.69	0.34	8.94e-11	Asthma;
LIHC	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.37	-6.18	-0.32	1.81e-9	Endometrial cancer;
LIHC	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.56	0.38	3.73e-13	Exhaled nitric oxide output;
LIHC	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.52	-7.34	-0.37	1.6e-12	Obesity-related traits;
LIHC	cis	rs17095355	0.786	rs61624875	chr10:111722489	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.85	-0.3	1.15e-8	Biliary atresia;
LIHC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg20607798	chr8:58055168	NA	0.5	5.91	0.3	8.11e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg13119609	chr19:45449297	APOC2	-0.23	-6.64	-0.34	1.25e-10	Blood protein levels;
LIHC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.37	1.38e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.48	7.13	0.36	5.83e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs258892	0.895	rs13170247	chr5:72069684	A/G	cg21869765	chr5:72125136	TNPO1	-0.39	-5.83	-0.3	1.3e-8	Small cell lung carcinoma;
LIHC	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg20129853	chr10:51489980	NA	-0.42	-9.23	-0.45	2.82e-18	Prostate-specific antigen levels;
LIHC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.34	6.18	0.32	1.8e-9	Aortic root size;
LIHC	cis	rs9596863	1.000	rs9596862	chr13:54432908	A/G	ch.13.53330881F	chr13:54432880	NA	0.46	6.3	0.32	8.9e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.83	0.57	5.17e-31	Prudent dietary pattern;
LIHC	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.47	0.49	1.99e-22	Hypertriglyceridemia;
LIHC	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.75	-0.3	1.94e-8	Blood pressure;
LIHC	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.54	-0.33	2.29e-10	Metabolite levels;
LIHC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03756088	chr1:230203084	GALNT2	-0.45	-6.66	-0.34	1.11e-10	Pancreatic cancer;
LIHC	cis	rs2737618	0.722	rs2821330	chr1:200082464	C/T	cg21825944	chr1:200113062	NR5A2	0.34	5.81	0.3	1.42e-8	Uric acid levels;
LIHC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.58	0.53	2.13e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.5	8.53	0.42	4.88e-16	Methadone dose in opioid dependence;
LIHC	cis	rs918629	0.530	rs3777200	chr5:95234791	A/G	cg10483112	chr5:95245456	ELL2	0.36	6.53	0.33	2.38e-10	IgG glycosylation;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.66	-9.69	-0.46	8.97e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.88	14.59	0.62	7.91e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.22	-0.36	3.35e-12	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04770364	chr12:120127985	CIT	0.42	6.18	0.32	1.87e-9	Pancreatic cancer;
LIHC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.29	0.55	5.28e-29	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.29	6.78	0.34	5.35e-11	Primary biliary cholangitis;
LIHC	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg03805757	chr16:71968109	PKD1L3	-0.74	-8.81	-0.43	6.44e-17	Post bronchodilator FEV1;
LIHC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.37	-5.97	-0.31	6.01e-9	Response to antipsychotic treatment;
LIHC	cis	rs425535	0.619	rs4694658	chr4:74822174	A/G	cg02530824	chr4:74847766	PF4	-0.39	-6.26	-0.32	1.13e-9	Blood protein levels;
LIHC	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	0.86	6.18	0.32	1.8e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.26	6.99	0.35	1.48e-11	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg25894440	chr7:65020034	NA	-0.52	-5.78	-0.3	1.68e-8	Diabetic kidney disease;
LIHC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.39	6.68	0.34	9.64e-11	Mitochondrial DNA levels;
LIHC	trans	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg15676719	chr1:167598521	RCSD1	-0.37	-6.65	-0.34	1.18e-10	Systemic lupus erythematosus;
LIHC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.47	6.33	0.32	7.76e-10	Major depressive disorder;
LIHC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg15902774	chr15:75289873	SCAMP5	0.45	6.8	0.35	4.58e-11	Lung cancer;
LIHC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.45	-5.98	-0.31	5.75e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-1.06	-8.0	-0.4	1.89e-14	Body mass index;
LIHC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg08528486	chr13:113648767	MCF2L	-0.42	-6.63	-0.34	1.33e-10	Systolic blood pressure;
LIHC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg16479474	chr6:28041457	NA	0.47	6.96	0.35	1.73e-11	Parkinson's disease;
LIHC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.64	-8.5	-0.42	5.86e-16	Motion sickness;
LIHC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.51	-7.27	-0.37	2.45e-12	Uric acid levels;
LIHC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	16.69	0.67	3.75e-46	Platelet count;
LIHC	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.74	9.01	0.44	1.43e-17	Primary sclerosing cholangitis;
LIHC	trans	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	6.66	0.34	1.11e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-9.47	-0.46	4.86e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg08345082	chr10:99160200	RRP12	-0.39	-6.76	-0.34	5.96e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.69	9.33	0.45	1.37e-18	Aortic root size;
LIHC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg09835421	chr16:68378352	PRMT7	-0.81	-9.4	-0.45	8.11e-19	Schizophrenia;
LIHC	cis	rs3812111	0.692	rs7739896	chr6:116488906	A/G	cg08036074	chr6:116424633	NT5DC1	-0.46	-7.73	-0.39	1.17e-13	Age-related macular degeneration;
LIHC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.48	0.42	6.79e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.43	-0.41	1e-15	Chronic sinus infection;
LIHC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.69	-10.17	-0.48	2.16e-21	Height;
LIHC	cis	rs1865721	0.804	rs1319789	chr18:73161157	C/A	cg26385618	chr18:73139727	C18orf62	-0.29	-7.14	-0.36	5.77e-12	Intelligence;
LIHC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.54	6.16	0.32	1.99e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-6.02	-0.31	4.39e-9	Educational attainment;
LIHC	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.35	0.45	1.13e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg09222892	chr1:25734099	RHCE	-0.45	-8.1	-0.4	1.01e-14	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg05484376	chr2:27715224	FNDC4	0.4	6.83	0.35	3.85e-11	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26097504	chr15:40857435	C15orf57	0.51	7.14	0.36	5.73e-12	Pancreatic cancer;
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04347379	chr7:794485	HEATR2	-0.4	-5.71	-0.3	2.4e-8	Cerebrospinal P-tau181p levels;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg24915371	chr2:232646458	PDE6D	-0.38	-6.04	-0.31	4.08e-9	Body mass index;
LIHC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg17691542	chr6:26056736	HIST1H1C	0.42	6.17	0.32	1.98e-9	Height;
LIHC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00958927	chr1:175162553	KIAA0040	-0.4	-6.55	-0.33	2.08e-10	Alcohol dependence;
LIHC	cis	rs6977660	1.000	rs714239	chr7:19803944	C/T	cg07541023	chr7:19748670	TWISTNB	0.39	6.07	0.31	3.31e-9	Thyroid stimulating hormone;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24415082	chr16:74700811	RFWD3	0.49	7.03	0.36	1.14e-11	Pancreatic cancer;
LIHC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.36	7.08	0.36	8.12e-12	Alcohol dependence;
LIHC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.67	13.31	0.58	7.08e-33	Menopause (age at onset);
LIHC	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.89	15.24	0.64	2.19e-40	Gastritis;
LIHC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-12.01	-0.54	5.64e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.89	18.09	0.7	8.88e-52	Height;
LIHC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg16970926	chr12:29381810	FAR2	0.28	5.94	0.31	7.19e-9	QT interval;
LIHC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg15123519	chr2:136567270	LCT	0.44	8.77	0.43	8.82e-17	Corneal structure;
LIHC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.26	0.32	1.18e-9	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20506460	chr20:43150682	SERINC3	0.42	6.2	0.32	1.63e-9	Pancreatic cancer;
LIHC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.48	7.07	0.36	9.02e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg00990874	chr7:1149470	C7orf50	-0.62	-9.08	-0.44	8.97e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.83	0.35	3.91e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.43	-6.99	-0.35	1.41e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg25039879	chr17:56429692	SUPT4H1	0.43	6.03	0.31	4.37e-9	Cognitive test performance;
LIHC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.16	-0.36	5.11e-12	Diabetic kidney disease;
LIHC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.49	-7.23	-0.36	3.18e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg17135325	chr3:160939158	NMD3	0.55	7.8	0.39	7.67e-14	Parkinson's disease;
LIHC	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg02269571	chr22:50332266	NA	-0.56	-7.74	-0.39	1.12e-13	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.38	6.75	0.34	6.53e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg07424592	chr7:64974309	NA	0.77	8.9	0.43	3.31e-17	Diabetic kidney disease;
LIHC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.71	0.3	2.46e-8	Electroencephalogram traits;
LIHC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.5e-12	Obesity-related traits;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg16358155	chr3:195490169	MUC4	-0.45	-6.8	-0.35	4.6e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg10792982	chr14:105748885	BRF1	0.46	6.29	0.32	9.86e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.55	-7.84	-0.39	5.95e-14	Lymphocyte counts;
LIHC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg20651018	chr11:3035856	CARS	-0.37	-6.12	-0.31	2.5e-9	Longevity;
LIHC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg14391382	chr7:866102	UNC84A	0.38	5.71	0.3	2.44e-8	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.19	-0.52	5.65e-25	Chronic sinus infection;
LIHC	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.36	0.45	1.08e-18	Hemoglobin concentration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23645831	chr1:15944060	DDI2	-0.43	-6.09	-0.31	3e-9	Longevity;
LIHC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg03945807	chr20:60948434	NA	-0.36	-6.44	-0.33	3.97e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs16944613	0.588	rs12438183	chr15:91139244	T/C	cg26821196	chr15:91095069	CRTC3	0.43	7.2	0.36	3.91e-12	Colorectal cancer;
LIHC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.58	-9.68	-0.46	9.68e-20	Height;
LIHC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg06238570	chr21:40685208	BRWD1	0.39	6.38	0.33	5.67e-10	Menarche (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18890249	chr10:51361773	LOC728407;PARG	-0.39	-6.57	-0.33	1.83e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.04	-0.31	4.11e-9	Tuberculosis;
LIHC	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.81e-10	Obesity-related traits;
LIHC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-11.98	-0.54	7.41e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.43e-16	Motion sickness;
LIHC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg12863693	chr15:85201151	NMB	0.49	6.78	0.34	5.41e-11	Schizophrenia;
LIHC	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.54	-13.08	-0.58	5.56e-32	White blood cell count (basophil);
LIHC	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.64	11.7	0.53	7.69e-27	Mean platelet volume;
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8067354	0.574	rs1292050	chr17:57965169	T/C	cg13753209	chr17:57696993	CLTC	0.7	10.33	0.49	5.98e-22	Hemoglobin concentration;
LIHC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.25e-11	Ileal carcinoids;
LIHC	trans	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg18335740	chr13:41363409	SLC25A15	0.34	6.08	0.31	3.19e-9	Lewy body disease;
LIHC	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg02023728	chr11:77925099	USP35	-0.35	-6.18	-0.32	1.83e-9	Alzheimer's disease (survival time);
LIHC	trans	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	8.64	0.42	2.19e-16	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg07706471	chr12:123319906	HIP1R	-0.62	-7.89	-0.39	4.16e-14	Schizophrenia;
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg12798992	chr6:167411361	FGFR1OP	0.42	6.61	0.34	1.48e-10	Primary biliary cholangitis;
LIHC	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.14	-10.24	-0.48	1.26e-21	Schizophrenia;
LIHC	cis	rs7523273	0.597	rs2724384	chr1:207930203	G/A	cg22525895	chr1:207977042	MIR29B2	0.64	7.4	0.37	1.03e-12	Schizophrenia;
LIHC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.59	-9.28	-0.45	2.02e-18	Dental caries;
LIHC	cis	rs2737618	0.698	rs2737678	chr1:200088041	C/T	cg21825944	chr1:200113062	NR5A2	-0.41	-6.66	-0.34	1.11e-10	Uric acid levels;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.99	-23.08	-0.78	1.05e-71	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	3.04e-30	Menopause (age at onset);
LIHC	cis	rs10508774	0.733	rs3758380	chr10:33188453	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.82	0.3	1.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg17623882	chr6:41773611	USP49	-0.44	-5.85	-0.3	1.15e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.46	-7.37	-0.37	1.32e-12	Menarche (age at onset);
LIHC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.5	7.22	0.36	3.4e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg08694578	chr2:241835147	C2orf54	-0.63	-10.06	-0.48	4.99e-21	Urinary metabolites;
LIHC	cis	rs12702595	0.643	rs2108787	chr7:7259034	G/A	cg04827551	chr7:7268805	C1GALT1	0.31	5.72	0.3	2.27e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg14440974	chr22:39074834	NA	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3770081	0.793	rs60719866	chr2:86284378	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.57	8.8	0.43	7.13e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.53	-0.53	3.21e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.81	0.54	3.25e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.74	6.33	0.32	7.53e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.23e-16	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.53	5.77	0.3	1.73e-8	Alzheimer's disease;
LIHC	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08893839	chr5:154027129	NA	-0.5	-6.83	-0.35	3.95e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg19743168	chr1:23544995	NA	-0.36	-6.64	-0.34	1.26e-10	Height;
LIHC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.13	0.4	8.17e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.81	-15.26	-0.64	1.89e-40	Blood protein levels;
LIHC	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg07862535	chr7:139043722	LUC7L2	-0.6	-10.34	-0.49	5.72e-22	Diisocyanate-induced asthma;
LIHC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.13	-0.31	2.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	0.82	11.56	0.53	2.5e-26	Left atrial antero-posterior diameter;
LIHC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.29	7.82	0.39	6.55e-14	Skin aging (microtopography measurement);
LIHC	cis	rs3812111	0.838	rs476330	chr6:116433265	C/T	cg08036074	chr6:116424633	NT5DC1	0.65	11.2	0.52	5.37e-25	Age-related macular degeneration;
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.95	0.31	6.77e-9	Renal cell carcinoma;
LIHC	cis	rs2412488	0.893	rs11734681	chr4:54353092	G/A	cg22241045	chr4:54363911	LNX1	-0.43	-7.06	-0.36	9.37e-12	DNA methylation (variation);
LIHC	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.21	-0.32	1.52e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.06	-0.31	3.67e-9	Tuberculosis;
LIHC	cis	rs1144333	1.000	rs5745354	chr1:76275178	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.47	-0.33	3.31e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.52	8.12	0.4	8.73e-15	Lymphocyte counts;
LIHC	trans	rs9641123	0.639	rs2528537	chr7:93247388	A/T	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.58	-0.34	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg16586182	chr3:47516702	SCAP	0.44	7.49	0.38	5.98e-13	Colorectal cancer;
LIHC	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-8.09	-0.4	1.06e-14	Putamen volume;
LIHC	cis	rs1865721	1.000	rs17284077	chr18:73204128	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.56	-0.38	3.8e-13	Intelligence;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg07424592	chr7:64974309	NA	0.8	9.21	0.45	3.38e-18	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg24209194	chr3:40518798	ZNF619	0.54	7.82	0.39	6.75e-14	Renal cell carcinoma;
LIHC	trans	rs7504990	0.691	rs76571698	chr18:50366942	C/T	cg08535148	chr4:26321143	RBPJ	0.54	6.66	0.34	1.06e-10	Gallbladder cancer;
LIHC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.12	-0.44	6.77e-18	Bipolar disorder;
LIHC	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.78	-0.39	8.73e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.53	6.36	0.33	6.35e-10	Pancreatic cancer;
LIHC	cis	rs2191566	0.922	rs7245749	chr19:44513932	G/A	cg20607764	chr19:44506953	ZNF230	-0.41	-6.69	-0.34	9.11e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.74	10.94	0.51	4.24e-24	Corneal astigmatism;
LIHC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.66	0.65	4.89e-42	Chronic sinus infection;
LIHC	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.49	7.24	0.36	2.96e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.54	9.7	0.46	8.28e-20	Coronary artery disease;
LIHC	cis	rs244293	0.795	rs11079151	chr17:53095366	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.51	0.38	5.12e-13	Menarche (age at onset);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg01296682	chr20:5891730	CHGB	0.4	6.37	0.33	6.26e-10	Morning vs. evening chronotype;
LIHC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.8	16.2	0.66	3.29e-44	White blood cell count;
LIHC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	1.14	13.45	0.59	2.16e-33	Eosinophil percentage of granulocytes;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg00204748	chr12:29376779	FAR2	0.43	8.05	0.4	1.36e-14	QT interval;
LIHC	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg19773385	chr1:10388646	KIF1B	-0.47	-8.19	-0.41	5.14e-15	Hepatocellular carcinoma;
LIHC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.89	-13.53	-0.59	1.02e-33	Sudden cardiac arrest;
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08677398	chr8:58056175	NA	-0.42	-5.74	-0.3	2.09e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.64	-13.05	-0.58	7.41e-32	Itch intensity from mosquito bite;
LIHC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.16	-0.36	4.9e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg12458913	chr13:53173898	NA	0.5	8.04	0.4	1.5e-14	Lewy body disease;
LIHC	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg14345882	chr6:26364793	BTN3A2	0.34	5.74	0.3	2.04e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21530174	chr5:151031796	NA	0.5	6.91	0.35	2.38e-11	Lung function (FEV1/FVC);
LIHC	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg14092571	chr14:90743983	NA	0.42	5.8	0.3	1.54e-8	Mortality in heart failure;
LIHC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06636551	chr8:101224915	SPAG1	-0.49	-8.9	-0.43	3.27e-17	Atrioventricular conduction;
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02290350	chr8:58132656	NA	0.5	9.61	0.46	1.6e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.56	9.93	0.47	1.34e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4742903	0.935	rs10991166	chr9:106974096	T/C	cg14250997	chr9:106856677	SMC2	0.36	6.1	0.31	2.85e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg22223119	chr13:99095684	FARP1	-0.59	-8.5	-0.42	6e-16	Obesity-related traits;
LIHC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.57	-0.33	1.86e-10	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.6	9.81	0.47	3.5e-20	Corneal astigmatism;
LIHC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.3	0.32	9.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08219700	chr8:58056026	NA	0.53	6.36	0.33	6.29e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.4	7.49	0.38	6.05e-13	Schizophrenia;
LIHC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.1	-0.36	7.08e-12	Monocyte percentage of white cells;
LIHC	trans	rs4710654	0.516	rs34124069	chr6:68508308	T/C	cg00011122	chr16:11439027	C16orf75	-0.4	-6.09	-0.31	3.01e-9	Response to amphetamines;
LIHC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg22842854	chr12:123319900	HIP1R	-0.74	-9.71	-0.46	7.68e-20	Schizophrenia;
LIHC	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg14558114	chr2:88469736	THNSL2	0.64	5.85	0.3	1.12e-8	Plasma clusterin levels;
LIHC	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.0	0.48	8.3e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg04592579	chr7:75616294	TMEM120A	-0.39	-6.68	-0.34	9.71e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.31	0.49	7.15e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.42	-7.77	-0.39	9.38e-14	Mean corpuscular volume;
LIHC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.7	9.4	0.45	7.79e-19	Aortic root size;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.69	-10.81	-0.5	1.21e-23	Lung cancer;
LIHC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.55	-0.38	3.92e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.64	0.53	1.34e-26	Platelet count;
LIHC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.65	-10.93	-0.51	4.88e-24	Childhood ear infection;
LIHC	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.52	9.62	0.46	1.49e-19	Testicular germ cell tumor;
LIHC	cis	rs67981189	0.593	rs2810101	chr14:71429827	G/C	cg15816911	chr14:71606274	NA	-0.4	-6.45	-0.33	3.85e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17875356	chr3:114807036	ZBTB20	0.26	6.38	0.33	5.84e-10	Cognitive function;
LIHC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.22	-5.95	-0.31	6.65e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9896052	0.614	rs34042490	chr17:73452956	T/C	cg25649188	chr17:73499917	CASKIN2	0.43	6.7	0.34	8.81e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.85	-0.35	3.44e-11	Total cholesterol levels;
LIHC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.64	-8.18	-0.4	5.66e-15	Gut microbiome composition (summer);
LIHC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.46	-7.61	-0.38	2.61e-13	Response to temozolomide;
LIHC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.99	-15.67	-0.65	4.36e-42	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs2029362	0.611	rs2030324	chr11:27726915	A/G	cg18117895	chr11:27722066	BDNF	-0.39	-5.89	-0.3	9.49e-9	Total body bone mineral density;
LIHC	cis	rs847649	0.732	rs6465876	chr7:102497569	G/T	cg18108683	chr7:102477205	FBXL13	-0.5	-7.8	-0.39	7.37e-14	Morning vs. evening chronotype;
LIHC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	7.1	0.36	7.09e-12	Response to antipsychotic treatment;
LIHC	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	6.89	0.35	2.69e-11	Lung cancer in ever smokers;
LIHC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.32	-8.23	-0.41	3.86e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.46	0.37	7.3e-13	Obesity-related traits;
LIHC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06656553	chr16:89960601	TCF25	-0.49	-6.01	-0.31	4.66e-9	Skin colour saturation;
LIHC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.84	-0.3	1.19e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs17106184	1.000	rs72898980	chr1:50986747	A/G	cg07174182	chr1:51127561	FAF1	-0.7	-7.11	-0.36	6.97e-12	Type 2 diabetes;
LIHC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs7872515	0.887	rs7856177	chr9:94839342	A/G	cg01248375	chr9:94877805	SPTLC1	0.56	8.23	0.41	4.04e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.85	-0.51	8.78e-24	Response to antipsychotic treatment;
LIHC	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.56	-8.06	-0.4	1.34e-14	Neuroticism;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07677032	chr17:61819896	STRADA	0.42	5.98	0.31	5.66e-9	Prudent dietary pattern;
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg26338869	chr17:61819248	STRADA	0.5	6.5	0.33	2.87e-10	Height;
LIHC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-13.45	-0.59	2.16e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.87	-0.3	1.02e-8	Personality dimensions;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg05673432	chr3:15919505	NA	0.43	6.09	0.31	3.1e-9	Alopecia areata;
LIHC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.32e-9	Lung cancer in ever smokers;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg05484376	chr2:27715224	FNDC4	0.38	6.4	0.33	5.02e-10	Total body bone mineral density;
LIHC	trans	rs983392	0.709	rs11826180	chr11:59991333	T/C	cg17275991	chr19:58003312	ZNF419	0.42	6.06	0.31	3.61e-9	Alzheimer's disease (late onset);
LIHC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg18944383	chr4:111397179	ENPEP	0.28	7.18	0.36	4.32e-12	Height;
LIHC	cis	rs9649465	0.967	rs1005567	chr7:123305836	A/T	cg03229431	chr7:123269106	ASB15	0.37	8.05	0.4	1.37e-14	Migraine;
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs34375054	0.573	rs34579346	chr12:125658174	T/C	cg25124228	chr12:125621409	AACS	-0.43	-6.63	-0.34	1.29e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs62229266	0.587	rs62229264	chr21:37452213	G/A	cg12218747	chr21:37451666	NA	-0.44	-7.14	-0.36	5.77e-12	Mitral valve prolapse;
LIHC	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg03934865	chr2:198174659	NA	-0.54	-8.31	-0.41	2.25e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.44	8.39	0.41	1.27e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.14	0.4	7.27e-15	Lung cancer;
LIHC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg09835421	chr16:68378352	PRMT7	-0.53	-6.0	-0.31	5.12e-9	HDL cholesterol;
LIHC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg11764359	chr7:65958608	NA	0.59	6.08	0.31	3.26e-9	Diabetic kidney disease;
LIHC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.48	-0.37	6.39e-13	Initial pursuit acceleration;
LIHC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg03859395	chr2:55845619	SMEK2	0.81	13.83	0.6	7.61e-35	Metabolic syndrome;
LIHC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.85	13.68	0.59	2.7200000000000002e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.73e-10	Bipolar disorder;
LIHC	cis	rs1144333	0.850	rs1144341	chr1:76282659	T/G	cg03433033	chr1:76189801	ACADM	-0.56	-8.51	-0.42	5.6e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs13190036	0.892	rs71601339	chr5:176544496	A/G	cg06532880	chr5:176731545	PRELID1;RAB24	0.45	5.85	0.3	1.16e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.72	-10.7	-0.5	2.98e-23	Vitamin D levels;
LIHC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.56	0.46	2.44e-19	Morning vs. evening chronotype;
LIHC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-5.73	-0.3	2.23e-8	Colorectal cancer;
LIHC	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg00977110	chr5:151150581	G3BP1	0.56	7.04	0.36	1.08e-11	Preschool internalizing problems;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg00035636	chr13:21900591	NA	0.39	6.47	0.33	3.47e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs243505	0.595	rs10233740	chr7:148567263	C/T	cg09806900	chr7:148480153	CUL1	0.44	6.29	0.32	9.47e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.67	9.28	0.45	2.01e-18	Menopause (age at onset);
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg04013166	chr16:89971882	TCF25	0.6	7.92	0.39	3.27e-14	Skin colour saturation;
LIHC	cis	rs16858210	0.837	rs11716104	chr3:183581999	G/C	cg25686905	chr3:183603175	PARL	-0.5	-9.57	-0.46	2.17e-19	Menopause (age at onset);
LIHC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	6.47	0.33	3.34e-10	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.47	-6.16	-0.32	2.09e-9	Parkinson's disease;
LIHC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.91	16.53	0.67	1.58e-45	Bone mineral density;
LIHC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.56	-9.26	-0.45	2.26e-18	Colorectal cancer;
LIHC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg16926213	chr1:1841314	NA	0.31	5.72	0.3	2.3e-8	Body mass index;
LIHC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg20283391	chr11:68216788	NA	-0.51	-6.37	-0.33	6.18e-10	Total body bone mineral density (age 45-60);
LIHC	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.64	9.24	0.45	2.64e-18	Lymphocyte counts;
LIHC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.49	-7.3	-0.37	2.08e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	7.28	0.37	2.29e-12	Cognitive test performance;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.41	0.33	4.82e-10	Alzheimer's disease;
LIHC	cis	rs2274273	1.000	rs15870	chr14:55619311	A/G	cg01864836	chr14:55583639	NA	-0.36	-6.12	-0.31	2.62e-9	Protein biomarker;
LIHC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	6.83	0.35	3.81e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.64	-11.26	-0.52	3.18e-25	Breast cancer;
LIHC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg07424592	chr7:64974309	NA	0.73	8.54	0.42	4.46e-16	Diabetic kidney disease;
LIHC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg01864069	chr14:103024347	NA	0.46	7.16	0.36	5.09e-12	Platelet count;
LIHC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	1.13	13.51	0.59	1.31e-33	Eosinophil percentage of granulocytes;
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.88	0.3	9.7e-9	Tonsillectomy;
LIHC	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.53	-8.52	-0.42	5.34e-16	Cocaine dependence;
LIHC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.54	-8.18	-0.4	5.69e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.95	20.47	0.74	2.21e-61	Blood protein levels;
LIHC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.5	-8.2	-0.41	4.88e-15	Cognitive function;
LIHC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.74	-0.34	6.69e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.16	-0.36	5.03e-12	Mean platelet volume;
LIHC	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-10.7	-0.5	3.07e-23	Mitochondrial DNA levels;
LIHC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.34	-0.49	5.34e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.53	7.16	0.36	4.87e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.51	-6.61	-0.34	1.49e-10	Monobrow;
LIHC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	11.47	0.53	5.4e-26	Multiple sclerosis;
LIHC	cis	rs59901009	0.911	rs61192802	chr11:10200742	A/G	cg01453529	chr11:10209919	SBF2	-0.33	-6.52	-0.33	2.59e-10	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs16828019	0.777	rs12748235	chr1:41466221	G/A	cg03962019	chr1:41807865	NA	0.53	7.01	0.35	1.26e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.49	8.48	0.42	6.84e-16	Methadone dose in opioid dependence;
LIHC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.89	0.51	6.71e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.77	0.3	1.77e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg09035930	chr12:129282057	SLC15A4	0.7	13.25	0.58	1.26e-32	Systemic lupus erythematosus;
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg09417038	chr21:47716443	C21orf57	-0.5	-7.34	-0.37	1.56e-12	Testicular germ cell tumor;
LIHC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.61	10.4	0.49	3.35e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.94	0.51	4.23e-24	Monocyte percentage of white cells;
LIHC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	10.83	0.51	1.06e-23	Platelet count;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg16103275	chr6:290800	DUSP22	0.52	7.06	0.36	9.28e-12	Menopause (age at onset);
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg14393609	chr7:65229607	NA	0.41	7.03	0.36	1.16e-11	Calcium levels;
LIHC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.32	0.37	1.74e-12	Monocyte percentage of white cells;
LIHC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.86	-0.3	1.08e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs61677309	0.964	rs59138930	chr11:118173783	C/T	cg06090739	chr11:118230722	UBE4A	0.35	6.44	0.33	4.11e-10	Lung cancer in ever smokers;
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg06882758	chr19:58662330	ZNF329	0.92	6.85	0.35	3.54e-11	Cholesterol, total;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.04	-0.4	1.46e-14	Type 2 diabetes;
LIHC	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.23	0.32	1.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27367952	chr2:219221586	C2orf62	0.56	8.12	0.4	8.5e-15	Pancreatic cancer;
LIHC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.86	0.35	3.17e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02290350	chr8:58132656	NA	0.43	8.86	0.43	4.56e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg02219949	chr17:45927392	SP6	0.43	5.73	0.3	2.26e-8	Ease of getting up in the morning;
LIHC	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg08222618	chr4:941054	TMEM175	0.54	6.63	0.34	1.28e-10	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs13190036	0.748	rs28395268	chr5:176710547	C/G	cg06532880	chr5:176731545	PRELID1;RAB24	-0.44	-6.3	-0.32	9.16e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08206623	chr11:2907334	CDKN1C	-0.46	-6.99	-0.35	1.4e-11	Cognitive function;
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13409248	chr3:40428643	ENTPD3	0.49	8.22	0.41	4.34e-15	Renal cell carcinoma;
LIHC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.44	6.22	0.32	1.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3764618	1.000	rs7409311	chr19:49492822	G/A	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.78	-6.14	-0.32	2.3e-9	Follicule stimulating hormone;
LIHC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.55	-0.33	2.06e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.84	-0.3	1.2e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs546131	0.642	rs12291580	chr11:34846732	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.53	-0.33	2.4e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2257205	0.667	rs28380401	chr17:56755613	T/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.68	-0.34	9.69e-11	Pancreatic cancer;
LIHC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.42	0.45	7.03e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.45	5.87	0.3	1.02e-8	Subjective well-being;
LIHC	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.05	0.44	1.12e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.75	-12.45	-0.56	1.34e-29	Aortic root size;
LIHC	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.44	-5.86	-0.3	1.07e-8	Obesity (extreme);
LIHC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-6.7	-0.34	8.61e-11	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg14146966	chr2:61757674	XPO1	0.49	8.39	0.41	1.32e-15	Tuberculosis;
LIHC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.52	7.78	0.39	8.45e-14	Height;
LIHC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg00656387	chr3:40428638	ENTPD3	0.38	5.96	0.31	6.26e-9	Renal cell carcinoma;
LIHC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	1.07	14.92	0.63	3.91e-39	Heart rate;
LIHC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.77	-14.79	-0.62	1.3e-38	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs75804782	0.521	rs56387296	chr2:239426298	A/G	cg01134436	chr17:81009848	B3GNTL1	0.75	6.44	0.33	3.99e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs11229030	0.893	rs2264054	chr11:57209488	G/A	cg00522883	chr11:57194120	SLC43A3	-0.42	-5.97	-0.31	6.08e-9	Crohn's disease;
LIHC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	9.2	0.45	3.65e-18	Eosinophilic esophagitis;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg00280220	chr17:61926910	NA	0.43	6.87	0.35	3.04e-11	Prudent dietary pattern;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.28	-6.28	-0.32	1.05e-9	Gut microbiome composition (winter);
LIHC	cis	rs7577696	0.539	rs13010405	chr2:32338204	A/T	cg02381751	chr2:32503542	YIPF4	-0.43	-6.0	-0.31	4.89e-9	Inflammatory biomarkers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12774921	chr16:89608299	SPG7	0.48	7.27	0.37	2.52e-12	Pancreatic cancer;
LIHC	cis	rs9649465	0.967	rs13244694	chr7:123329879	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.02e-15	Migraine;
LIHC	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.13	10.92	0.51	4.98e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg26138144	chr22:38071188	LGALS1	-0.76	-14.37	-0.61	5.81e-37	Fat distribution (HIV);
LIHC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	11.75	0.54	5.15e-27	Platelet count;
LIHC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg03037974	chr15:76606532	NA	0.8	16.65	0.67	5.49e-46	Blood metabolite levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19226866	chr11:63993875	NUDT22;TRPT1	0.51	6.57	0.33	1.84e-10	Hepatitis;
LIHC	cis	rs6586163	0.967	rs10887877	chr10:90753038	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.56	-8.3	-0.41	2.48e-15	Chronic lymphocytic leukemia;
LIHC	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.29	0.55	5.1e-29	Cognitive test performance;
LIHC	cis	rs9513627	1.000	rs7338335	chr13:100125296	G/C	cg25919922	chr13:100150906	NA	-0.76	-6.66	-0.34	1.07e-10	Obesity-related traits;
LIHC	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.6	-8.32	-0.41	2.17e-15	Major depressive disorder;
LIHC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-6.02	-0.31	4.53e-9	Calcium levels;
LIHC	cis	rs4934494	0.723	rs17127001	chr10:91522689	G/A	cg19698084	chr10:91461284	KIF20B	-0.44	-5.88	-0.3	9.5e-9	Red blood cell count;
LIHC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg07424592	chr7:64974309	NA	0.81	9.12	0.44	6.81e-18	Diabetic kidney disease;
LIHC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.68	0.34	9.67e-11	Bipolar disorder;
LIHC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.53	-0.42	4.83e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg00085434	chr11:14927489	NA	0.41	5.81	0.3	1.41e-8	Vitamin D levels;
LIHC	cis	rs11690935	0.879	rs13017585	chr2:172721808	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-17.1	-0.68	8.44e-48	Schizophrenia;
LIHC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.36	5.77	0.3	1.77e-8	Schizophrenia;
LIHC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.69	0.34	9.13e-11	Morning vs. evening chronotype;
LIHC	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.46	-6.53	-0.33	2.43e-10	Life satisfaction;
LIHC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg17385448	chr1:15911702	AGMAT	-0.35	-6.09	-0.31	3.12e-9	Systolic blood pressure;
LIHC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.58	10.7	0.5	3.04e-23	Menopause (age at onset);
LIHC	cis	rs7523273	0.565	rs2796280	chr1:207889345	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-7.99	-0.4	2.14e-14	Schizophrenia;
LIHC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.52	-8.41	-0.41	1.12e-15	Multiple sclerosis;
LIHC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.45	7.49	0.38	5.81e-13	Multiple sclerosis;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.87	0.3	1.01e-8	Self-reported allergy;
LIHC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg16822855	chr3:40428330	ENTPD3	0.33	5.97	0.31	5.81e-9	Renal cell carcinoma;
LIHC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg05714579	chr10:131428358	MGMT	0.41	6.71	0.34	7.86e-11	Response to temozolomide;
LIHC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg16070123	chr10:51489643	NA	0.38	6.03	0.31	4.15e-9	Prostate-specific antigen levels;
LIHC	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.36	0.49	4.72e-22	Colorectal cancer;
LIHC	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.44	0.33	4.13e-10	Axial length;
LIHC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.57	0.38	3.61e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg18306943	chr3:40428807	ENTPD3	0.35	5.84	0.3	1.18e-8	Renal cell carcinoma;
LIHC	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.56	7.74	0.39	1.11e-13	Eotaxin levels;
LIHC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg08210727	chr20:33865349	NA	0.5	5.77	0.3	1.81e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.6e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1555322	0.530	rs2425044	chr20:33869735	C/T	cg07134254	chr20:33865797	NA	0.53	6.27	0.32	1.11e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.44	7.6	0.38	2.95e-13	Schizophrenia;
LIHC	cis	rs7075426	0.905	rs11202038	chr10:88204877	C/T	cg07322936	chr10:88137208	NA	0.5	7.06	0.36	9.3e-12	Migraine without aura;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg16970926	chr12:29381810	FAR2	0.3	6.4	0.33	5.26e-10	QT interval;
LIHC	cis	rs7116495	0.867	rs60461859	chr11:71576918	G/A	cg26138937	chr11:71823887	C11orf51	0.76	6.65	0.34	1.17e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs17152411	1.000	rs11245451	chr10:126661428	C/T	cg07906193	chr10:126599966	NA	0.51	7.94	0.39	2.88e-14	Height;
LIHC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.76	-7.6	-0.38	2.89e-13	Platelet count;
LIHC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.1	0.31	2.84e-9	Renal cell carcinoma;
LIHC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg13175981	chr1:150552382	MCL1	0.52	7.08	0.36	8.05e-12	Urate levels;
LIHC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	18.46	0.71	2.79e-53	Tonsillectomy;
LIHC	cis	rs1401454	1.000	rs1401454	chr11:16250183	C/T	cg02656851	chr11:16430247	SOX6	-0.33	-6.23	-0.32	1.35e-9	Blood pressure;
LIHC	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.3	-0.41	2.45e-15	Schizophrenia;
LIHC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.48	7.81	0.39	6.9e-14	Tuberculosis;
LIHC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.73	-0.34	7.04e-11	Gut microbiome composition (summer);
LIHC	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-7.19	-0.36	4.03e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg00280220	chr17:61926910	NA	0.43	6.74	0.34	6.62e-11	Prudent dietary pattern;
LIHC	cis	rs1982963	0.901	rs1566131	chr14:52514684	G/A	cg10843707	chr14:52510701	NID2	-0.5	-8.81	-0.43	6.53e-17	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.45	7.17	0.36	4.6e-12	Total body bone mineral density;
LIHC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.76	0.47	5.37e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05329982	chr11:62359210	TUT1	0.45	6.98	0.35	1.54e-11	Cognitive function;
LIHC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg06742321	chr12:123595122	PITPNM2	0.33	6.16	0.32	2.1e-9	Platelet count;
LIHC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.44	7.39	0.37	1.13e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.66	-12.55	-0.56	5.79e-30	Height;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg21914477	chr6:5067092	NA	0.42	6.45	0.33	3.91e-10	Longevity;
LIHC	cis	rs2074193	1.000	rs2074193	chr12:47771429	T/G	cg02516419	chr12:47771422	NA	0.51	7.73	0.39	1.22e-13	Migraine with aura;
LIHC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg07061783	chr6:25882402	NA	-0.48	-6.73	-0.34	7.17e-11	Blood metabolite levels;
LIHC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.79	-0.34	4.84e-11	Bladder cancer;
LIHC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-16.68	-0.67	3.84e-46	Primary sclerosing cholangitis;
LIHC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.73	-0.3	2.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.54	8.72	0.43	1.22e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	10.69	0.5	3.41e-23	Coronary artery disease;
LIHC	cis	rs4908768	0.539	rs7526171	chr1:8650185	T/C	cg20416874	chr1:8611966	RERE	-0.65	-12.11	-0.55	2.4e-28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg22771759	chr13:24902376	NA	0.33	6.66	0.34	1.1e-10	Obesity-related traits;
LIHC	cis	rs16958440	0.737	rs16950096	chr18:44745546	T/C	cg17192377	chr18:44677553	HDHD2	0.73	5.76	0.3	1.87e-8	Sitting height ratio;
LIHC	cis	rs17106184	1.000	rs12073283	chr1:51219188	C/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.86	-0.35	3.32e-11	Type 2 diabetes;
LIHC	cis	rs7119038	0.774	rs2004781	chr11:118619253	C/T	cg19308663	chr11:118741387	NA	0.43	5.76	0.3	1.86e-8	Sjögren's syndrome;
LIHC	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.88	-6.61	-0.34	1.46e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	10.72	0.5	2.54e-23	Personality dimensions;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27115996	chr7:102741563	NAPEPLD	0.34	6.07	0.31	3.34e-9	Hepatitis;
LIHC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-19.7	-0.73	2.72e-58	Height;
LIHC	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg07647771	chr16:84786436	USP10	-0.35	-7.01	-0.35	1.32e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.43	-6.7	-0.34	8.55e-11	Adiposity;
LIHC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.66	11.69	0.53	8.98e-27	Total body bone mineral density;
LIHC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.52	8.05	0.4	1.39e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06420487	chr17:61919686	SMARCD2	0.45	6.11	0.31	2.68e-9	Height;
LIHC	cis	rs74181299	0.684	rs10185243	chr2:65355744	G/T	cg05010058	chr2:65284262	CEP68	-0.39	-6.56	-0.33	1.94e-10	Pulse pressure;
LIHC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.2	-0.32	1.58e-9	Bipolar disorder;
LIHC	cis	rs6831256	0.550	rs9993109	chr4:3473659	A/G	cg23495837	chr4:3480318	DOK7	-0.35	-5.88	-0.3	9.83e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.49	-8.11	-0.4	9.23e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.93	0.51	4.56e-24	Colorectal cancer;
LIHC	cis	rs9322817	0.691	rs2290515	chr6:105232204	C/T	cg02098413	chr6:105308735	HACE1	-0.43	-7.85	-0.39	5.55e-14	Thyroid stimulating hormone;
LIHC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg02503808	chr4:7069936	GRPEL1	0.45	7.04	0.36	1.07e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.92	0.3	7.85e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.37	8.39	0.41	1.26e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	11.06	0.51	1.58e-24	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01934856	chr1:10720466	CASZ1	-0.44	-6.96	-0.35	1.76e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.9	8.61	0.42	2.72e-16	Mean corpuscular hemoglobin;
LIHC	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg23422044	chr7:1970798	MAD1L1	-0.6	-6.79	-0.34	4.92e-11	Bipolar disorder;
LIHC	cis	rs77633900	0.772	rs16968196	chr15:76682238	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-5.93	-0.31	7.22e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-7.88	-0.39	4.34e-14	Crohn's disease;
LIHC	trans	rs6489882	0.902	rs3759375	chr12:113373588	A/G	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.55	8.58	0.42	3.25e-16	Longevity;Endometriosis;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg19056506	chr17:79633562	CCDC137;C17orf90	0.46	6.27	0.32	1.08e-9	Glycated hemoglobin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04362369	chr14:21905501	CHD8	0.49	6.18	0.32	1.77e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.47	-7.82	-0.39	6.79e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.12	-0.4	8.49e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs4407350	0.682	rs135624	chr22:44890685	C/G	cg26276947	chr22:44892394	LDOC1L	-0.33	-6.37	-0.33	6.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.1	0.31	2.82e-9	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.3	-0.32	8.92e-10	Diabetic kidney disease;
LIHC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	12.98	0.57	1.33e-31	Cognitive test performance;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.72	-10.64	-0.5	4.82e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17776563	0.887	rs72763817	chr15:89141238	C/G	cg05013243	chr15:89149849	MIR1179	0.42	6.92	0.35	2.18e-11	Thyroid hormone levels;
LIHC	cis	rs15676	1.000	rs15676	chr9:131572027	A/G	cg00228799	chr9:131580591	ENDOG	-0.45	-7.05	-0.36	1.02e-11	Blood metabolite levels;
LIHC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.6	-11.61	-0.53	1.76e-26	Asthma;
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg05185784	chr16:90016020	DEF8	-0.47	-6.08	-0.31	3.18e-9	Skin colour saturation;
LIHC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.31	0.41	2.33e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.25	0.48	1.08e-21	Hypertriglyceridemia;
LIHC	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.49	6.12	0.31	2.56e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.77	-11.88	-0.54	1.7e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.47	-6.18	-0.32	1.86e-9	Pursuit maintenance gain;
LIHC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.39	-6.33	-0.32	7.5e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs1419980	0.730	rs7962586	chr12:7772315	G/A	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.53	7.5	0.38	5.39e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.69	11.74	0.54	5.61e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.31	7.33	0.37	1.71e-12	Crohn's disease;
LIHC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg19743168	chr1:23544995	NA	0.34	5.72	0.3	2.33e-8	Height;
LIHC	cis	rs10744422	0.748	rs1671688	chr12:123255733	A/T	cg22842854	chr12:123319900	HIP1R	-0.64	-8.07	-0.4	1.24e-14	Schizophrenia;
LIHC	cis	rs17106184	1.000	rs3789576	chr1:50945526	G/T	cg07174182	chr1:51127561	FAF1	-0.61	-6.85	-0.35	3.54e-11	Type 2 diabetes;
LIHC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.4e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7945718	0.621	rs7931351	chr11:12692162	A/T	cg25843174	chr11:12811716	TEAD1	0.35	7.98	0.4	2.22e-14	Educational attainment (years of education);
LIHC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-0.96	-16.32	-0.66	1.1e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs8016982	0.531	rs2241622	chr14:81737290	A/G	cg01989461	chr14:81687754	GTF2A1	0.51	8.37	0.41	1.49e-15	Schizophrenia;
LIHC	cis	rs546131	0.642	rs1897203	chr11:34821988	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.41	-0.33	4.91e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.45	-7.26	-0.37	2.55e-12	Fibrinogen levels;
LIHC	cis	rs6442522	0.809	rs13081119	chr3:15451021	A/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.15	-0.32	2.12e-9	Uric acid levels;
LIHC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg16102536	chr7:156981717	UBE3C	0.35	5.92	0.3	7.91e-9	Body mass index;
LIHC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.37	-0.33	5.99e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	0.87	11.66	0.53	1.1e-26	Skin colour saturation;
LIHC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20135002	chr11:47629003	NA	-0.57	-9.63	-0.46	1.43e-19	Subjective well-being;
LIHC	cis	rs17106184	1.000	rs58446086	chr1:50971801	A/G	cg07174182	chr1:51127561	FAF1	-0.64	-6.76	-0.34	6.13e-11	Type 2 diabetes;
LIHC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.5	-7.12	-0.36	6.31e-12	Body mass index;
LIHC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg03859395	chr2:55845619	SMEK2	0.86	15.43	0.64	4.04e-41	Metabolic syndrome;
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.93	13.39	0.59	3.79e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.57	0.46	2.29e-19	Height;
LIHC	cis	rs4759375	1.000	rs11057223	chr12:123755055	T/C	cg00376283	chr12:123451042	ABCB9	-0.5	-6.25	-0.32	1.24e-9	HDL cholesterol;
LIHC	cis	rs9394841	0.692	rs9357371	chr6:41885319	A/C	cg17623882	chr6:41773611	USP49	-0.45	-6.05	-0.31	3.72e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg08799069	chr10:126477246	METTL10	0.35	6.03	0.31	4.17e-9	Asthma;
LIHC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.93	15.11	0.63	7.03e-40	Tonsillectomy;
LIHC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.19	-0.32	1.74e-9	Arsenic metabolism;
LIHC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.31	-0.32	8.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg20636351	chr8:55087400	NA	-0.4	-8.06	-0.4	1.31e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.46	6.75	0.34	6.3e-11	Gout;
LIHC	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.52	-0.38	4.89e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg06466757	chr4:1255808	NA	-0.34	-5.78	-0.3	1.7e-8	Obesity-related traits;
LIHC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.46	7.07	0.36	8.97e-12	Blood protein levels;
LIHC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg20607798	chr8:58055168	NA	0.49	6.23	0.32	1.34e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg01364799	chr7:75623366	TMEM120A	-0.43	-6.36	-0.33	6.51e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.16	0.32	2.03e-9	Rheumatoid arthritis;
LIHC	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14426781	chr11:129149366	NA	0.42	6.06	0.31	3.68e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	7.32	0.37	1.79e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.57	-0.5	8.95e-23	Hemoglobin concentration;
LIHC	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.54	7.07	0.36	8.83e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.79	-0.34	5.05e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg21123203	chr4:15471301	CC2D2A	0.47	7.51	0.38	5.29e-13	Obesity-related traits;
LIHC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.95	13.02	0.58	9.71e-32	Heart rate;
LIHC	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.49	7.19	0.36	3.98e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.15	-0.32	2.12e-9	Tuberculosis;
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21448741	chr8:58168803	NA	-0.35	-6.55	-0.33	2.17e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.07	-9.79	-0.47	4.12e-20	Diabetic retinopathy;
LIHC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.57	-10.94	-0.51	4.3e-24	Systemic lupus erythematosus;
LIHC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.73	-0.3	2.23e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.58	8.32	0.41	2.13e-15	Lung cancer;
LIHC	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	6.94	0.35	1.94e-11	Eotaxin levels;
LIHC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg19743168	chr1:23544995	NA	-0.35	-5.85	-0.3	1.13e-8	Height;
LIHC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.97	12.66	0.56	2.12e-30	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	22.89	0.78	5.84e-71	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13409248	chr3:40428643	ENTPD3	0.46	7.68	0.38	1.64e-13	Renal cell carcinoma;
LIHC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.77	-7.94	-0.39	2.97e-14	Alzheimer's disease;
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.71	10.21	0.48	1.49e-21	Menarche (age at onset);
LIHC	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22509189	chr2:225307070	NA	-0.55	-6.81	-0.35	4.28e-11	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs3812111	0.676	rs1114228	chr6:116502011	T/A	cg08036074	chr6:116424633	NT5DC1	-0.52	-8.71	-0.43	1.33e-16	Age-related macular degeneration;
LIHC	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.57	7.18	0.36	4.3e-12	Systemic lupus erythematosus;
LIHC	cis	rs10508774	1.000	rs12247495	chr10:32802829	G/C	cg01819863	chr10:32635814	EPC1	0.65	6.08	0.31	3.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.33	-6.64	-0.34	1.21e-10	Renal cell carcinoma;
LIHC	cis	rs911119	0.866	rs6048925	chr20:23579056	C/A	cg16589663	chr20:23618590	CST3	0.66	6.9	0.35	2.51e-11	Chronic kidney disease;
LIHC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.11	-0.36	6.68e-12	Alcohol dependence;
LIHC	cis	rs244293	0.965	rs244341	chr17:53198922	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06119275	chr12:133384736	GOLGA3	0.43	6.27	0.32	1.11e-9	Hepatitis;
LIHC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.34	13.9	0.6	3.84e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.56	-7.23	-0.36	3.11e-12	Prostate cancer;
LIHC	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.57	-13.94	-0.6	2.64e-35	White blood cell count (basophil);
LIHC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.87	-0.35	3.08e-11	IgG glycosylation;
LIHC	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.61	-12.27	-0.55	6.39e-29	Plateletcrit;Platelet count;
LIHC	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-6.31	-0.32	8.81e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.69	-0.34	9.07e-11	Neuroticism;
LIHC	cis	rs846178	1	rs846178	chr4:2485615	A/C	cg16474684	chr4:2470049	RNF4	-0.53	-7.46	-0.37	7.12e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	0.95	18.11	0.7	7.3e-52	Ewing sarcoma;
LIHC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.38	-6.39	-0.33	5.41e-10	Educational attainment;
LIHC	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.03	-0.36	1.14e-11	Breast cancer;
LIHC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.4	-5.72	-0.3	2.36e-8	Iron status biomarkers;
LIHC	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.72	0.34	7.5e-11	Mean corpuscular volume;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg00280220	chr17:61926910	NA	0.43	7.02	0.35	1.19e-11	Prudent dietary pattern;
LIHC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-21.83	-0.76	8.53e-67	Height;
LIHC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.06	0.4	1.27e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.54	5.72	0.3	2.28e-8	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03909902	chr12:108154529	PRDM4	-0.48	-6.85	-0.35	3.43e-11	Cognitive function;
LIHC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.49	6.24	0.32	1.32e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs13113518	0.812	rs13140173	chr4:56393331	C/T	cg15358633	chr12:38710606	ALG10B	0.44	6.29	0.32	9.82e-10	Height;
LIHC	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.52	-0.38	4.89e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs10420951	0.617	rs74389203	chr19:18606656	G/A	cg10790698	chr19:18539756	SSBP4	-0.42	-5.86	-0.3	1.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs539514	0.563	rs7991448	chr13:76334061	G/A	cg04757411	chr13:76259545	LMO7	-0.4	-6.67	-0.34	1.03e-10	Type 1 diabetes;
LIHC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.44	6.24	0.32	1.31e-9	Schizophrenia;
LIHC	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.49	7.06	0.36	9.46e-12	Schizophrenia;
LIHC	cis	rs526231	0.819	rs411648	chr5:102602902	A/T	cg05225461	chr5:102596755	C5orf30	0.38	5.89	0.3	9.25e-9	Primary biliary cholangitis;
LIHC	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.42	-6.88	-0.35	2.92e-11	Height;
LIHC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.78	-8.7	-0.43	1.41e-16	Vitiligo;
LIHC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	14.29	0.61	1.24e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg16088116	chr21:44841560	SIK1	-0.39	-6.04	-0.31	4.12e-9	Coronary artery disease;
LIHC	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-6.21	-0.32	1.51e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg12863693	chr15:85201151	NMB	0.43	6.13	0.31	2.4e-9	Schizophrenia;
LIHC	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	1.16	13.06	0.58	6.69e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.1	0.31	2.93e-9	Tonsillectomy;
LIHC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	1.19	10.9	0.51	5.99e-24	Obesity-related traits;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03685817	chr19:32876832	ZNF507	-0.27	-6.47	-0.33	3.31e-10	Calcium levels;
LIHC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg21573476	chr21:45109991	RRP1B	-0.53	-10.07	-0.48	4.64e-21	Mean corpuscular volume;
LIHC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.83	-0.35	3.94e-11	Response to antipsychotic treatment;
LIHC	cis	rs16944613	0.510	rs7163773	chr15:91144486	G/C	cg26821196	chr15:91095069	CRTC3	0.32	5.99	0.31	5.4e-9	Colorectal cancer;
LIHC	cis	rs1198430	0.759	rs1198438	chr1:23749557	C/G	cg19827787	chr1:23763612	ASAP3	0.27	5.97	0.31	5.85e-9	Total cholesterol levels;
LIHC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.53	0.56	6.44e-30	Mean platelet volume;
LIHC	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.3	-5.94	-0.31	6.9e-9	Platelet distribution width;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06656553	chr16:89960601	TCF25	-0.5	-6.45	-0.33	3.81e-10	Skin colour saturation;
LIHC	cis	rs13062095	0.505	rs2553425	chr3:101103623	C/G	cg19452782	chr3:101232218	SENP7	-0.41	-6.12	-0.31	2.57e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	6.84	0.35	3.73e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.56	-6.57	-0.33	1.92e-10	Ulcerative colitis;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.6	8.97	0.44	2e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13161895	0.887	rs1103811	chr5:179413168	G/A	cg02702477	chr5:179499311	RNF130	0.64	9.15	0.44	5.18e-18	LDL cholesterol;
LIHC	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.49	-7.34	-0.37	1.55e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.6	8.88	0.43	3.91e-17	Recombination rate (females);
LIHC	trans	rs2211698	1.000	rs78238889	chr21:35839837	C/T	cg18044562	chr7:50468399	IKZF1	0.5	7.13	0.36	6.12e-12	Cancer;
LIHC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.87	-6.69	-0.34	9.4e-11	Systolic blood pressure;
LIHC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.33	0.37	1.64e-12	Airflow obstruction;
LIHC	cis	rs861020	0.560	rs649275	chr1:209950681	T/C	cg05527609	chr1:210001259	C1orf107	0.55	8.71	0.43	1.37e-16	Orofacial clefts;
LIHC	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.47	-0.62	2.32e-37	Electrocardiographic conduction measures;
LIHC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.39	6.04	0.31	4.07e-9	Menopause (age at onset);
LIHC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg15902774	chr15:75289873	SCAMP5	0.42	6.05	0.31	3.88e-9	Lung cancer;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.49e-10	Prudent dietary pattern;
LIHC	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.79	8.49	0.42	6.4e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.74	14.15	0.61	4.29e-36	Mortality in heart failure;
LIHC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-9.25	-0.45	2.5e-18	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg11764359	chr7:65958608	NA	0.56	5.96	0.31	6.14e-9	Diabetic kidney disease;
LIHC	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg08847533	chr14:75593920	NEK9	-0.54	-8.32	-0.41	2.08e-15	IgG glycosylation;
LIHC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.58	9.27	0.45	2.11e-18	Lymphocyte counts;
LIHC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.38	-6.01	-0.31	4.82e-9	Mortality in heart failure;
LIHC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.67	-8.08	-0.4	1.14e-14	Mean platelet volume;
LIHC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg00815214	chr21:47717953	NA	0.35	5.86	0.3	1.08e-8	Testicular germ cell tumor;
LIHC	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.46	8.32	0.41	2.07e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs4907240	0.922	rs4907246	chr2:97326286	T/C	cg26665480	chr2:98280029	ACTR1B	-0.41	-6.07	-0.31	3.47e-9	Event-related brain oscillations;
LIHC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00152838	chr16:24741724	TNRC6A	-0.5	-5.84	-0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9473924	0.580	rs66462826	chr6:50814877	C/A	cg14470998	chr6:50812995	TFAP2B	0.93	10.62	0.5	6.08e-23	Body mass index;
LIHC	cis	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg03342759	chr3:160939853	NMD3	0.56	7.4	0.37	1.04e-12	Morning vs. evening chronotype;
LIHC	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	18.26	0.7	1.79e-52	Colorectal cancer;
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg14222432	chr12:29376421	FAR2	0.38	7.4	0.37	1.1e-12	QT interval;
LIHC	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.85	10.58	0.5	8.2000000000000006e-23	Prostate cancer;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13409248	chr3:40428643	ENTPD3	0.47	7.68	0.38	1.72e-13	Renal cell carcinoma;
LIHC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.16	-0.36	5.11e-12	Alcohol dependence;
LIHC	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.81	-0.43	6.51e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.44	-0.45	5.94e-19	Schizophrenia;
LIHC	cis	rs1789	0.786	rs6449161	chr4:15692954	A/G	cg21123203	chr4:15471301	CC2D2A	-0.44	-6.84	-0.35	3.69e-11	Blood protein levels;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg26338869	chr17:61819248	STRADA	0.52	6.97	0.35	1.61e-11	Height;
LIHC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.48	-8.13	-0.4	7.87e-15	Dementia with Lewy bodies;
LIHC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.74	11.34	0.52	1.62e-25	Corneal astigmatism;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.53	6.78	0.34	5.4e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2257205	0.667	rs9889494	chr17:56629764	T/C	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.94	17.64	0.69	5.76e-50	Menopause (age at onset);
LIHC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.2e-22	Cognitive function;
LIHC	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.71	0.43	1.36e-16	Exhaled nitric oxide levels;
LIHC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	0.68	8.62	0.42	2.47e-16	Corneal structure;
LIHC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.11	0.36	6.63e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.28	0.41	2.8e-15	Lung cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17752083	chr10:135101849	TUBGCP2	0.38	6.17	0.32	1.93e-9	Pancreatic cancer;
LIHC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.58	9.91	0.47	1.65e-20	Colorectal cancer;
LIHC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg12751644	chr20:60527061	NA	-0.36	-5.96	-0.31	6.13e-9	Body mass index;
LIHC	cis	rs7078219	0.897	rs10883360	chr10:101281158	C/G	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.72	-0.3	2.29e-8	Dental caries;
LIHC	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.73	11.2	0.52	5.32e-25	Metabolite levels;
LIHC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.24	6.07	0.31	3.34e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.65	7.0	0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs972578	1.000	rs1071961	chr22:43349699	C/A	cg01576275	chr22:43409880	NA	-0.32	-5.71	-0.3	2.45e-8	Mean platelet volume;
LIHC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18867708	chr6:26865862	GUSBL1	0.54	8.18	0.4	5.77e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs55702914	0.742	rs6744206	chr2:198148522	A/G	cg10820045	chr2:198174542	NA	-0.39	-5.98	-0.31	5.55e-9	Major depression and alcohol dependence;
LIHC	cis	rs3849570	0.555	rs6790351	chr3:82008988	C/T	cg07356753	chr3:81810745	GBE1	-0.42	-6.45	-0.33	3.89e-10	Waist circumference;Body mass index;
LIHC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.56	-8.31	-0.41	2.2e-15	Height;
LIHC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.17	0.36	4.54e-12	Aortic root size;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13665852	chr10:13146898	OPTN	0.42	6.29	0.32	9.73e-10	Longevity;
LIHC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.57	8.04	0.4	1.46e-14	Aortic root size;
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.18	-0.55	1.33e-28	Alzheimer's disease;
LIHC	trans	rs11157436	0.958	rs17255510	chr14:22662856	C/T	cg13567813	chr19:50879636	NR1H2	-0.42	-6.09	-0.31	3.02e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.15	0.32	2.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.69	-8.98	-0.44	1.9e-17	Asthma;
LIHC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.41	-6.16	-0.32	2.01e-9	Calcium levels;
LIHC	cis	rs72653721	0.617	rs60043068	chr6:11035426	A/C	cg13562911	chr6:11044106	ELOVL2	0.39	5.79	0.3	1.56e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.56	6.79	0.34	4.99e-11	Cognitive function;
LIHC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.64	-9.66	-0.46	1.15e-19	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17507749	chr15:85114479	UBE2QP1	0.7	7.87	0.39	4.7e-14	Schizophrenia;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26168469	chr14:96505617	C14orf132	0.44	6.05	0.31	3.75e-9	Myopia (pathological);
LIHC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.0	-22.47	-0.77	2.54e-69	Height;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09669930	chr6:11233125	NEDD9	-0.43	-6.3	-0.32	9.14e-10	Hepatitis;
LIHC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	trans	rs11039100	1.000	rs11039101	chr11:5827080	A/G	cg11650987	chr12:10280440	CLEC7A	-0.4	-6.04	-0.31	4.1e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.53	7.84	0.39	5.65e-14	Lymphocyte counts;
LIHC	cis	rs16828019	0.704	rs4996176	chr1:41488168	G/T	cg03962019	chr1:41807865	NA	0.5	7.0	0.35	1.38e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1823913	1.000	rs4853562	chr2:192118422	A/G	cg12404831	chr2:192114017	MYO1B	-0.33	-6.58	-0.34	1.75e-10	Obesity-related traits;
LIHC	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg09795085	chr6:101329169	ASCC3	0.52	7.13	0.36	6.12e-12	Neuroticism;
LIHC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-7.26	-0.37	2.64e-12	Ulcerative colitis;
LIHC	cis	rs11229555	0.645	rs4506677	chr11:58213852	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.63	-0.38	2.37e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.47	-7.29	-0.37	2.21e-12	Vitiligo;
LIHC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.78	-11.98	-0.54	7.44e-28	Dental caries;
LIHC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.31	6.6	0.34	1.57e-10	Platelet distribution width;
LIHC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.66	-9.85	-0.47	2.49e-20	Testicular germ cell tumor;
LIHC	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.5	9.32	0.45	1.48e-18	Type 2 diabetes;
LIHC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.35	-6.48	-0.33	3.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.47	-0.49	1.95e-22	Chronic sinus infection;
LIHC	cis	rs6977660	0.941	rs4721825	chr7:19823427	A/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.83	0.3	1.27e-8	Thyroid stimulating hormone;
LIHC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	0.87	11.97	0.54	7.87e-28	Skin colour saturation;
LIHC	trans	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg17675199	chr6:35436792	RPL10A	0.32	6.41	0.33	4.87e-10	Coronary artery disease;
LIHC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.16	0.48	2.21e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.43	6.74	0.34	6.82e-11	Height;
LIHC	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.46	8.88	0.43	3.83e-17	Testicular germ cell tumor;
LIHC	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.6	-9.36	-0.45	1.1e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	trans	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg00789545	chr14:102770909	RAGE	0.35	6.05	0.31	3.87e-9	Total body bone mineral density;
LIHC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.53	0.46	2.97e-19	Morning vs. evening chronotype;
LIHC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg00277334	chr10:82204260	NA	-0.53	-6.47	-0.33	3.37e-10	Post bronchodilator FEV1;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17967728	chr15:52263786	LEO1	-0.42	-6.06	-0.31	3.52e-9	Alopecia areata;
LIHC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.44	-0.42	9.17e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg00977110	chr5:151150581	G3BP1	0.56	7.12	0.36	6.6e-12	Preschool internalizing problems;
LIHC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.24	6.19	0.32	1.7e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.41	6.63	0.34	1.35e-10	Ulcerative colitis;
LIHC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.04	9.46	0.46	5.21e-19	Diabetic retinopathy;
LIHC	cis	rs2997447	0.601	rs61776580	chr1:26432719	C/T	cg19633962	chr1:26362018	EXTL1	-0.63	-5.75	-0.3	1.96e-8	QRS complex (12-leadsum);
LIHC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.92	-10.22	-0.48	1.4e-21	Red cell distribution width;
LIHC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.37	6.07	0.31	3.43e-9	Monobrow;
LIHC	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-8.28	-0.41	2.77e-15	Neuroticism;
LIHC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00260888	chr20:30865478	KIF3B	0.5	6.82	0.35	4.11e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.6	10.28	0.49	8.76e-22	HDL cholesterol;
LIHC	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.23	-0.32	1.34e-9	Bipolar disorder;
LIHC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.51	5.71	0.3	2.41e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.21	-0.36	3.52e-12	Personality dimensions;
LIHC	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.03	-0.36	1.14e-11	Breast cancer;
LIHC	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.71	0.43	1.36e-16	Exhaled nitric oxide levels;
LIHC	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg01028140	chr2:1542097	TPO	-0.45	-7.08	-0.36	8.24e-12	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	0.83	11.51	0.53	3.9e-26	Interleukin-17 levels;
LIHC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.61	0.67	7.88e-46	Smoking behavior;
LIHC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg06363034	chr20:62225388	GMEB2	-0.43	-7.33	-0.37	1.73e-12	Glioblastoma;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg00715988	chr14:96968640	PAPOLA	-0.38	-6.4	-0.33	5.11e-10	Electroencephalogram traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00261252	chr4:79860706	PAQR3	-0.48	-6.8	-0.35	4.65e-11	Pancreatic cancer;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg23640757	chr6:7889014	TXNDC5	-0.38	-6.37	-0.33	6.1e-10	Pain;
LIHC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg09222892	chr1:25734099	RHCE	-0.45	-8.27	-0.41	3e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs77637988	0.603	rs72820445	chr2:48607856	T/C	cg00032884	chr2:48540671	FOXN2	0.4	6.19	0.32	1.68e-9	Joint mobility (Beighton score);
LIHC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.69	-0.34	8.96e-11	Alzheimer's disease (late onset);
LIHC	cis	rs7188697	0.769	rs9932944	chr16:58616165	C/T	cg02549819	chr16:58548995	SETD6	0.49	7.65	0.38	2e-13	QT interval;
LIHC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.62	10.19	0.48	1.84e-21	Lung cancer;
LIHC	cis	rs17102423	0.573	rs7144259	chr14:65537559	T/A	cg11161011	chr14:65562177	MAX	-0.42	-5.78	-0.3	1.69e-8	Obesity-related traits;
LIHC	trans	rs4129059	1.000	rs61443257	chr1:214673211	G/A	cg08187585	chr14:105393182	PLD4	-0.35	-6.77	-0.34	5.62e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.3	0.32	8.96e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.87e-10	Asthma;
LIHC	cis	rs8014671	0.546	rs12433355	chr14:70819717	T/C	cg25576086	chr14:70833871	SYNJ2BP	-0.54	-10.2	-0.48	1.6e-21	Prostate cancer;
LIHC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.26e-51	Menopause (age at onset);
LIHC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-8.44	-0.42	8.91e-16	Morning vs. evening chronotype;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06467587	chr16:15808736	MYH11;NDE1	0.42	6.12	0.31	2.56e-9	Longevity;
LIHC	cis	rs62458065	1.000	rs10246687	chr7:32465183	T/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.64	-7.32	-0.37	1.77e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.77	8.68	0.42	1.69e-16	Exhaled nitric oxide output;
LIHC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg06640241	chr16:89574553	SPG7	0.85	15.92	0.65	4.43e-43	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	1.06	12.64	0.56	2.63e-30	Vitiligo;
LIHC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.44	5.87	0.3	1.05e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9473924	0.505	rs9473938	chr6:50874050	C/T	cg14470998	chr6:50812995	TFAP2B	0.95	10.98	0.51	3.11e-24	Body mass index;
LIHC	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg03962019	chr1:41807865	NA	0.51	7.42	0.37	9.28e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.85	0.54	2.26e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.44	6.82	0.35	4.03e-11	Neutrophil percentage of white cells;
LIHC	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.49	5.99	0.31	5.26e-9	Alzheimer's disease;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.75	-0.3	1.94e-8	Total body bone mineral density;
LIHC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.82	12.91	0.57	2.45e-31	Height;
LIHC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg25588787	chr5:154027256	NA	-0.4	-5.91	-0.3	8.33e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs34245846	0.704	rs11264278	chr1:154845534	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.88	12.76	0.57	8.76e-31	Atrial fibrillation;
LIHC	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.53	-7.93	-0.39	3.22e-14	Body mass index;
LIHC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.3	0.49	7.38e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	trans	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg10756647	chr7:56101905	PSPH	1.06	12.78	0.57	7.55e-31	Diabetic kidney disease;
LIHC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg11057378	chr10:81107060	PPIF	0.38	6.23	0.32	1.38e-9	Height;
LIHC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.44	-7.62	-0.38	2.58e-13	Alzheimer's disease (late onset);
LIHC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg12560992	chr17:57184187	TRIM37	0.5	6.2	0.32	1.58e-9	Primary tooth development (time to first tooth eruption);
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg12629250	chr15:20149347	NA	0.38	6.05	0.31	3.77e-9	Electroencephalogram traits;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg07133347	chr1:107600762	PRMT6	-0.45	-6.88	-0.35	2.82e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.84	0.78	8.76e-71	Height;
LIHC	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.46	-0.33	3.67e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01200585	chr1:228362443	C1orf69	0.4	6.09	0.31	3.07e-9	Diastolic blood pressure;
LIHC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.66	-9.07	-0.44	9.22e-18	Schizophrenia;
LIHC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.03	-21.44	-0.76	3.08e-65	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	trans	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.05	24.84	0.8	1.41e-78	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg07424592	chr7:64974309	NA	0.81	9.45	0.45	5.58e-19	Diabetic kidney disease;
LIHC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	10.84	0.51	9.62e-24	Lung cancer in ever smokers;
LIHC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.61	6.7	0.34	8.75e-11	Alzheimer's disease;
LIHC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.52	7.96	0.4	2.62e-14	Resting heart rate;
LIHC	cis	rs7116495	1.000	rs17161966	chr11:71815308	T/C	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs11779988	0.545	rs431961	chr8:17786204	T/G	cg01800426	chr8:17659068	MTUS1	-0.4	-5.85	-0.3	1.16e-8	Breast cancer;
LIHC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.57	0.33	1.83e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg17764715	chr19:33622953	WDR88	0.41	5.75	0.3	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.75e-12	IgG glycosylation;
LIHC	cis	rs8081395	0.737	rs4968401	chr17:58040730	T/C	cg13753209	chr17:57696993	CLTC	-0.39	-5.92	-0.3	7.98e-9	White blood cell count;
LIHC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.45	-6.77	-0.34	5.46e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.93	-16.39	-0.66	5.96e-45	Oral cavity cancer;
LIHC	cis	rs10792665	0.512	rs6592087	chr11:82595975	A/T	cg24227371	chr11:82718527	RAB30	-0.28	-6.82	-0.35	4.17e-11	Obesity-related traits;
LIHC	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.37	-8.88	-0.43	3.92e-17	Cutaneous nevi;
LIHC	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg07483650	chr1:248525007	OR2T4	0.44	7.84	0.39	5.94e-14	Common traits (Other);
LIHC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.38	7.62	0.38	2.47e-13	Immature fraction of reticulocytes;
LIHC	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02290350	chr8:58132656	NA	0.51	10.45	0.49	2.28e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.67	0.38	1.79e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.66	8.43	0.41	9.65e-16	Exhaled nitric oxide output;
LIHC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.42	6.13	0.31	2.44e-9	Platelet count;
LIHC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.53	8.53	0.42	4.71e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-10.06	-0.48	5.05e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg14345882	chr6:26364793	BTN3A2	0.39	5.76	0.3	1.88e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.93	-0.35	2.08e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7520050	0.966	rs7515491	chr1:46355079	A/G	cg03146154	chr1:46216737	IPP	-0.37	-5.91	-0.3	8.14e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.53	6.42	0.33	4.45e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs509477	1.000	rs7240845	chr18:32574960	G/C	cg23791764	chr18:32556832	MAPRE2	-0.49	-6.7	-0.34	8.58e-11	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.75	12.3	0.55	4.82e-29	Colorectal cancer;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.46	7.71	0.38	1.36e-13	Testicular germ cell tumor;
LIHC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.08e-11	Alzheimer's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01739569	chr14:31091426	SCFD1	-0.47	-6.04	-0.31	3.97e-9	Systolic blood pressure;
LIHC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.35	6.2	0.32	1.63e-9	Psoriasis;
LIHC	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-18.0	-0.7	2e-51	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg06207120	chr15:45996521	NA	0.31	5.83	0.3	1.27e-8	Waist circumference;Weight;
LIHC	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.76	-0.3	1.91e-8	Bipolar disorder;
LIHC	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	1.07	8.66	0.42	1.91e-16	Cannabis dependence symptom count;
LIHC	cis	rs7258015	1.000	rs3176768	chr19:10449665	A/G	cg13981319	chr19:10446556	ICAM3	-0.44	-6.91	-0.35	2.33e-11	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.82	11.11	0.51	1.09e-24	Coronary artery disease;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg03721293	chr16:90014378	DEF8	0.42	7.0	0.35	1.34e-11	Skin colour saturation;
LIHC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.55	-0.38	3.95e-13	Height;
LIHC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.13	-0.31	2.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13633754	chr9:95858523	C9orf89	-0.41	-6.32	-0.32	7.96e-10	Pancreatic cancer;
LIHC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg19645103	chr12:69753606	YEATS4	0.4	6.04	0.31	3.98e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2834188	0.961	rs8130807	chr21:34690013	A/G	cg14352951	chr21:34696688	IFNAR1	0.47	6.53	0.33	2.35e-10	Narcolepsy;
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.51	6.7	0.34	8.62e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.24e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.39	-5.8	-0.3	1.54e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.93	16.94	0.68	3.74e-47	Parkinson's disease;
LIHC	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.74	-9.01	-0.44	1.44e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.88	15.54	0.64	1.41e-41	Aortic root size;
LIHC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg10932868	chr11:921992	NA	0.34	6.32	0.32	8.33e-10	Alzheimer's disease (late onset);
LIHC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.26	0.32	1.17e-9	Mean corpuscular volume;
LIHC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.68	0.78	3.75e-70	Chronic sinus infection;
LIHC	trans	rs10038113	0.530	rs7445227	chr5:26024457	T/G	cg05807885	chr1:204183355	GOLT1A	0.32	6.36	0.33	6.51e-10	Autism;
LIHC	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.44	0.42	9.3e-16	Birth weight;
LIHC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.12	0.31	2.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg10411590	chr13:21900810	NA	0.42	6.83	0.35	3.88e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	14.87	0.63	6.62e-39	Menopause (age at onset);
LIHC	trans	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg10756647	chr7:56101905	PSPH	0.63	8.62	0.42	2.51e-16	Corneal structure;
LIHC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.74	12.47	0.56	1.14e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1400745	0.718	rs1200414	chr14:35330893	G/A	cg05294307	chr14:35346193	BAZ1A	-0.45	-7.54	-0.38	4.33e-13	Monocyte count;
LIHC	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.69	-11.98	-0.54	7.7e-28	Height;
LIHC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-6.47	-0.33	3.43e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.56	9.7	0.46	7.96e-20	Alcohol dependence;
LIHC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg11212589	chr17:38028394	ZPBP2	0.35	7.09	0.36	7.92e-12	Self-reported allergy;
LIHC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.68	8.9	0.43	3.33e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.4	-8.48	-0.42	6.71e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.31	21.37	0.76	6.13e-65	Corneal structure;
LIHC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.49	6.36	0.33	6.31e-10	Gut microbiome composition (summer);
LIHC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg27490568	chr2:178487706	NA	0.37	5.82	0.3	1.34e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg02297831	chr4:17616191	MED28	0.41	6.47	0.33	3.44e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-0.48	-6.2	-0.32	1.61e-9	Lung cancer;
LIHC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.25e-12	Bipolar disorder;
LIHC	trans	rs6489882	0.867	rs2384072	chr12:113367422	T/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.62	-9.44	-0.45	6.11e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.72	9.65	0.46	1.21e-19	Body mass index;
LIHC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Bone mineral density;
LIHC	cis	rs17433710	0.543	rs4233392	chr1:162645571	T/C	cg01063088	chr1:162760584	HSD17B7	0.44	6.09	0.31	3.11e-9	Dupuytren's disease;
LIHC	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.3	7.27	0.37	2.44e-12	Alcohol dependence;
LIHC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg22842854	chr12:123319900	HIP1R	0.64	8.45	0.42	8.3e-16	Schizophrenia;
LIHC	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-12.01	-0.54	5.58e-28	Eye color traits;
LIHC	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1914816	1.000	rs2255408	chr15:76503295	G/T	cg03037974	chr15:76606532	NA	0.6	6.14	0.31	2.32e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.53	9.48	0.46	4.43e-19	Total body bone mineral density;
LIHC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg17859187	chr1:168147929	TIPRL	0.41	5.72	0.3	2.27e-8	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.87	-0.65	6.88e-43	Height;
LIHC	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	6.2	0.32	1.66e-9	Body mass index;
LIHC	cis	rs2010672	0.500	rs11631439	chr15:91143805	C/A	cg26821196	chr15:91095069	CRTC3	0.32	5.99	0.31	5.4e-9	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LIHC	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.42	-7.23	-0.36	3.22e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg25182066	chr10:30743637	MAP3K8	-0.46	-7.36	-0.37	1.4e-12	Inflammatory bowel disease;
LIHC	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-7.96	-0.4	2.49e-14	Morning vs. evening chronotype;
LIHC	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.63	5.84	0.3	1.21e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.61	-0.38	2.69e-13	Prevalent atrial fibrillation;
LIHC	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.42	12.22	0.55	9.43e-29	Uric acid levels;
LIHC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs8084351	0.517	rs7505888	chr18:50565946	T/C	cg24270629	chr18:50823537	DCC	0.41	6.22	0.32	1.44e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-6.85	-0.35	3.44e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7534824	0.543	rs6693339	chr1:101424431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.67	-7.64	-0.38	2.13e-13	Refractive astigmatism;
LIHC	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.84	0.43	4.98e-17	Coffee consumption (cups per day);
LIHC	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.29	6.68	0.34	9.63e-11	Educational attainment (years of education);
LIHC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.67	-11.66	-0.53	1.13e-26	Lymphocyte counts;
LIHC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.33	-0.41	1.97e-15	Gut microbiome composition (summer);
LIHC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.72	-0.39	1.33e-13	Monocyte percentage of white cells;
LIHC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.51	8.22	0.41	4.35e-15	Gout;
LIHC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	6.28	0.32	1.01e-9	Coronary artery disease;
LIHC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.88	0.35	2.86e-11	Cognitive ability;
LIHC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.41	-0.41	1.12e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.53	8.56	0.42	3.89e-16	Blood protein levels;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg15181151	chr6:150070149	PCMT1	0.4	6.59	0.34	1.71e-10	Lung cancer;
LIHC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.45	-6.02	-0.31	4.48e-9	Coronary artery calcification;
LIHC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs7100689	0.615	rs10788639	chr10:82233225	C/G	cg00277334	chr10:82204260	NA	-0.44	-6.01	-0.31	4.77e-9	Post bronchodilator FEV1;
LIHC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.5	-8.63	-0.42	2.42e-16	Dental caries;
LIHC	trans	rs4924935	0.509	rs28540773	chr17:18761754	T/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Pancreatic cancer;
LIHC	cis	rs4919087	0.748	rs701817	chr10:98977329	G/C	cg25902810	chr10:99078978	FRAT1	-0.56	-6.44	-0.33	4.08e-10	Monocyte count;
LIHC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.36	9.4	0.45	7.99e-19	Schizophrenia;
LIHC	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg17294928	chr15:75287854	SCAMP5	0.43	6.19	0.32	1.69e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.19	0.4	5.25e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	15.69	0.65	3.53e-42	Lung cancer in ever smokers;
LIHC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.52	7.2	0.36	3.74e-12	Morning vs. evening chronotype;
LIHC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.21	15.73	0.65	2.39e-42	Diabetic kidney disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17765461	chr19:1408416	DAZAP1	-0.45	-6.58	-0.34	1.75e-10	Calcium levels;
LIHC	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.52	6.6	0.34	1.57e-10	Prostate cancer;
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.73	-10.66	-0.5	4.25e-23	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.93	15.81	0.65	1.21e-42	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.46	7.47	0.37	6.82e-13	Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg20607798	chr8:58055168	NA	0.62	7.91	0.39	3.52e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg17372223	chr3:52568218	NT5DC2	0.37	5.74	0.3	2.04e-8	Bipolar disorder;
LIHC	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg12253828	chr6:101329408	ASCC3	-0.39	-5.95	-0.31	6.78e-9	Neuroticism;
LIHC	cis	rs61677309	1.000	rs55899310	chr11:118158702	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg12365402	chr11:9010492	NRIP3	0.32	7.84	0.39	5.97e-14	Hemoglobin concentration;
LIHC	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17467752	chr17:38218738	THRA	-0.56	-9.58	-0.46	2.08e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6445975	0.619	rs112015230	chr3:58262204	T/C	cg23715586	chr3:58305044	RPP14	-0.37	-6.2	-0.32	1.65e-9	Systemic lupus erythematosus;
LIHC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.73	11.89	0.54	1.57e-27	Body mass index;
LIHC	cis	rs4908768	0.906	rs12403339	chr1:8558292	G/A	cg25722041	chr1:8623473	RERE	0.41	5.85	0.3	1.18e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.43	7.08	0.36	8.36e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.08	21.35	0.76	7.34e-65	Myeloid white cell count;
LIHC	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.33	-6.49	-0.33	2.93e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg18655438	chr5:1077845	SLC12A7	-0.35	-5.74	-0.3	2.14e-8	QT interval;
LIHC	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.49	0.49	1.7e-22	Hypertriglyceridemia;
LIHC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.48	-7.97	-0.4	2.43e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.35	7.7	0.38	1.44e-13	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.35	5.81	0.3	1.43e-8	Blood metabolite levels;
LIHC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.86	10.59	0.5	7.21e-23	Mean platelet volume;
LIHC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.9	19.55	0.73	1.18e-57	Blood protein levels;
LIHC	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.12	0.31	2.54e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.71	13.11	0.58	4.35e-32	Mean platelet volume;
LIHC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.12e-8	Bipolar disorder;
LIHC	trans	rs35213789	0.887	rs210603	chr7:69236235	C/T	cg11912179	chr11:134026542	NCAPD3	-0.39	-7.01	-0.35	1.27e-11	Childhood ear infection;
LIHC	cis	rs11673344	0.764	rs826303	chr19:37442451	C/A	cg27390819	chr19:37464633	NA	-0.53	-6.42	-0.33	4.52e-10	Obesity-related traits;
LIHC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.77	12.14	0.55	1.93e-28	Corneal astigmatism;
LIHC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.33	5.72	0.3	2.37e-8	Mood instability;
LIHC	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09695851	chr17:3907499	NA	-0.57	-8.18	-0.4	5.65e-15	Type 2 diabetes;
LIHC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.7	-0.38	1.44e-13	Aortic root size;
LIHC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.38	-6.39	-0.33	5.53e-10	Educational attainment;
LIHC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg14393609	chr7:65229607	NA	-0.38	-5.87	-0.3	1.02e-8	Aortic root size;
LIHC	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22509189	chr2:225307070	NA	-0.63	-7.57	-0.38	3.54e-13	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.94	10.62	0.5	5.85e-23	Breast cancer;
LIHC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.85	10.23	0.48	1.34e-21	Mean platelet volume;
LIHC	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg15871215	chr5:81402204	ATG10	-0.68	-8.24	-0.41	3.82e-15	Breast cancer;
LIHC	cis	rs4917833	0.752	rs4598598	chr10:100216817	C/T	cg19043522	chr10:100227446	HPSE2	0.41	5.85	0.3	1.14e-8	Pediatric bone mineral density (femoral neck);
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.58	-8.12	-0.4	8.67e-15	Menopause (age at onset);
LIHC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.6	7.65	0.38	2.05e-13	Parkinson's disease;
LIHC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.66	-7.5	-0.38	5.58e-13	Migraine;Coronary artery disease;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg24859375	chr12:7121914	LPCAT3	0.41	6.18	0.32	1.85e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.49	6.12	0.31	2.53e-9	Alzheimer's disease;
LIHC	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg12374095	chr12:54320830	NA	0.44	6.43	0.33	4.26e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.09	-0.44	8.23e-18	Bipolar disorder;
LIHC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-1.15	-10.21	-0.48	1.54e-21	Breast cancer;
LIHC	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg03962019	chr1:41807865	NA	0.49	7.08	0.36	8.11e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10848704	0.525	rs4073984	chr12:2885780	G/A	cg19995117	chr12:2880862	NA	0.33	6.07	0.31	3.47e-9	Quantitative traits;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg04013166	chr16:89971882	TCF25	0.61	8.56	0.42	3.94e-16	Skin colour saturation;
LIHC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg15691649	chr6:25882328	NA	-0.51	-7.33	-0.37	1.65e-12	Blood metabolite levels;
LIHC	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.05	9.72	0.47	7.24e-20	Diabetic retinopathy;
LIHC	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Colorectal cancer;
LIHC	cis	rs16828019	0.852	rs12742803	chr1:41648131	G/A	cg20697417	chr1:41786797	NA	0.35	6.65	0.34	1.15e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg18944383	chr4:111397179	ENPEP	0.27	7.16	0.36	5.01e-12	Height;
LIHC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.27	-0.32	1.07e-9	Longevity;Endometriosis;
LIHC	cis	rs11229555	0.645	rs12272911	chr11:58183839	G/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06536200	chr11:44117561	EXT2	0.43	6.19	0.32	1.74e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9918079	0.506	rs7696127	chr4:15642953	T/A	cg21123203	chr4:15471301	CC2D2A	-0.45	-7.26	-0.37	2.6e-12	Obesity-related traits;
LIHC	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.98	0.54	7.79e-28	Coffee consumption (cups per day);
LIHC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	7.51	0.38	5.33e-13	Schizophrenia;
LIHC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.59	7.36	0.37	1.38e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.46	7.62	0.38	2.48e-13	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs903552	0.800	rs6598478	chr15:102001696	A/T	cg06707286	chr15:102010195	PCSK6	-0.44	-5.97	-0.31	5.84e-9	Diabetic kidney disease;
LIHC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.36	5.71	0.3	2.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4908768	0.906	rs2144463	chr1:8583293	C/A	cg25722041	chr1:8623473	RERE	0.41	5.81	0.3	1.45e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.79	-11.8	-0.54	3.34e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.47	8.05	0.4	1.42e-14	Mean corpuscular volume;
LIHC	cis	rs7212590	0.748	rs8073489	chr17:57861794	A/C	cg10252138	chr17:58120427	NA	-0.61	-6.21	-0.32	1.5e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.74	12.61	0.56	3.38e-30	Menopause (age at onset);
LIHC	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.14	-0.4	7.63e-15	Capecitabine sensitivity;
LIHC	cis	rs174601	0.684	rs174528	chr11:61543499	T/C	cg27386326	chr11:61587980	NA	0.63	12.92	0.57	2.17e-31	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg09829573	chr1:144692074	NBPF9	-0.45	-8.09	-0.4	1.05e-14	Hip geometry;
LIHC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.47	-7.32	-0.37	1.76e-12	Blood protein levels;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.53	0.53	3.28e-26	Prudent dietary pattern;
LIHC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg17279839	chr7:150038598	RARRES2	0.5	10.64	0.5	4.85e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	11.05	0.51	1.79e-24	Alzheimer's disease (late onset);
LIHC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.58	-9.95	-0.47	1.17e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.31	-6.22	-0.32	1.46e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02290350	chr8:58132656	NA	0.48	9.92	0.47	1.54e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.49	8.1	0.4	9.6e-15	Electroencephalogram traits;
LIHC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.56	9.41	0.45	7.27e-19	Aortic root size;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.93	0.31	7.39e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.54	0.33	2.3e-10	Axial length;
LIHC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6977660	1.000	rs6974669	chr7:19793296	T/A	cg07541023	chr7:19748670	TWISTNB	0.41	6.26	0.32	1.15e-9	Thyroid stimulating hormone;
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg05527609	chr1:210001259	C1orf107	0.43	6.34	0.32	7.38e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg17279839	chr7:150038598	RARRES2	0.38	7.77	0.39	9.54e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg25114630	chr15:101792522	CHSY1	0.55	6.88	0.35	2.78e-11	Corneal structure;
LIHC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-14.48	-0.62	2.26e-37	Electrocardiographic conduction measures;
LIHC	cis	rs2274273	0.624	rs10143136	chr14:55743528	G/A	cg01864836	chr14:55583639	NA	-0.36	-5.85	-0.3	1.15e-8	Protein biomarker;
LIHC	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	26.43	0.82	1.25e-84	Schizophrenia;
LIHC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs35123781	0.696	rs4912755	chr5:139070651	A/G	cg10513866	chr5:139070639	NA	0.45	5.86	0.3	1.11e-8	Schizophrenia;
LIHC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.69	11.77	0.54	4.42e-27	Crohn's disease;
LIHC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.43	6.73	0.34	7.07e-11	Melanoma;
LIHC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.01	13.49	0.59	1.47e-33	Cognitive function;
LIHC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.64	8.32	0.41	2.11e-15	Skin colour saturation;
LIHC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.7	-13.37	-0.59	4.49e-33	Body mass index;
LIHC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.44	5.78	0.3	1.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2257205	0.667	rs9899893	chr17:56754597	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-6.47	-0.33	3.49e-10	Pancreatic cancer;
LIHC	cis	rs11761441	0.669	rs13241486	chr7:79536	G/C	cg12845006	chr7:82380	NA	0.38	7.26	0.37	2.61e-12	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.56	10.87	0.51	7.82e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg05564831	chr3:52568323	NT5DC2	0.37	5.91	0.3	8.46e-9	Bipolar disorder;
LIHC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-7.85	-0.39	5.26e-14	Total body bone mineral density;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14257396	chr1:107603778	NA	-0.35	-5.92	-0.3	8.04e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg10130564	chr11:117069849	TAGLN	0.37	6.3	0.32	9.03e-10	Blood protein levels;
LIHC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.34	-0.37	1.54e-12	Body mass index;
LIHC	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.74	11.34	0.52	1.56e-25	Eye color traits;
LIHC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.5	10.59	0.5	7.42e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	trans	rs12428820	0.615	rs9537077	chr13:55913054	A/C	cg18058532	chr11:31832710	PAX6	-0.53	-6.11	-0.31	2.64e-9	Pediatric bone mineral content (hip);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15623503	chr8:12990913	DLC1	-0.59	-6.6	-0.34	1.57e-10	Systolic blood pressure;
LIHC	cis	rs72653721	0.793	rs57864468	chr6:10966671	G/C	cg13562911	chr6:11044106	ELOVL2	0.48	6.83	0.35	3.96e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg17218026	chr1:154582156	ADAR	-0.34	-6.5	-0.33	2.83e-10	Blood protein levels;
LIHC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.47	8.08	0.4	1.09e-14	Mean corpuscular volume;
LIHC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.91	-0.39	3.5e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.37	-6.64	-0.34	1.2e-10	Aortic root size;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.5	7.42	0.37	9.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.25	-0.32	1.22e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-8.71	-0.43	1.28e-16	Blood metabolite levels;
LIHC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	1.03	18.9	0.71	4.73e-55	Multiple system atrophy;
LIHC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.59	8.59	0.42	3.03e-16	Response to diuretic therapy;
LIHC	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg00204748	chr12:29376779	FAR2	0.34	6.47	0.33	3.46e-10	QT interval;
LIHC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg16102536	chr7:156981717	UBE3C	0.35	5.85	0.3	1.17e-8	Body mass index;
LIHC	cis	rs509477	0.718	rs273348	chr18:32601632	A/C	cg23791764	chr18:32556832	MAPRE2	0.48	6.64	0.34	1.22e-10	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.85	0.39	5.31e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.36	-6.55	-0.33	2.06e-10	Type 2 diabetes;
LIHC	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg07382826	chr16:28625726	SULT1A1	0.51	7.92	0.39	3.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.4	-8.45	-0.42	8.25e-16	Obesity-related traits;
LIHC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.42	6.7	0.34	8.59e-11	Schizophrenia;
LIHC	cis	rs9649465	0.935	rs1605285	chr7:123374412	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-7.92	-0.39	3.46e-14	Migraine;
LIHC	cis	rs3764618	0.892	rs3764616	chr19:49497022	A/C	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.71	-5.81	-0.3	1.41e-8	Follicule stimulating hormone;
LIHC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg10820045	chr2:198174542	NA	-0.56	-9.18	-0.44	4.13e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg02487422	chr3:49467188	NICN1	-0.44	-5.79	-0.3	1.63e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	1.23	10.89	0.51	6.79e-24	Obesity-related traits;
LIHC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.39	-6.85	-0.35	3.53e-11	Aortic root size;
LIHC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.75	0.39	1.08e-13	Birth weight;
LIHC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	1.01	19.29	0.72	1.3e-56	Breast cancer;
LIHC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.45	7.34	0.37	1.56e-12	Response to temozolomide;
LIHC	cis	rs3736485	0.934	rs1077361	chr15:51880919	T/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.36	5.82	0.3	1.36e-8	Monocyte count;
LIHC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.43	6.75	0.34	6.51e-11	Red blood cell count;
LIHC	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg07382826	chr16:28625726	SULT1A1	0.52	7.89	0.39	4.02e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.22	5.84	0.3	1.21e-8	Hepatitis;
LIHC	cis	rs7937890	0.559	rs2597219	chr11:14530866	C/G	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.44	6.05	0.31	3.88e-9	Inflammatory skin disease;
LIHC	cis	rs10431058	1.000	rs10431058	chr11:107481518	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	-0.42	-6.79	-0.34	4.96e-11	Common traits (Other);
LIHC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.76	10.04	0.48	6.09e-21	Fat distribution (HIV);
LIHC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.81	9.13	0.44	6.14e-18	Vitiligo;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23894205	chr12:14967370	C12orf69;C12orf60	-0.29	-7.13	-0.36	6.14e-12	Calcium levels;
LIHC	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg02023728	chr11:77925099	USP35	-0.33	-5.92	-0.3	7.73e-9	Alzheimer's disease (survival time);
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.52	-9.09	-0.44	8.14e-18	Total body bone mineral density;
LIHC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.5	10.44	0.49	2.49e-22	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg11657440	chr19:46296263	DMWD	-0.53	-8.35	-0.41	1.76e-15	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.47	6.43	0.33	4.25e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-7.74	-0.39	1.15e-13	Bipolar disorder;
LIHC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg15848620	chr12:58087721	OS9	0.5	6.53	0.33	2.37e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.69	-10.39	-0.49	3.73e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7937890	0.532	rs2575833	chr11:14492505	A/C	cg02886208	chr11:14281011	SPON1	-0.46	-6.47	-0.33	3.47e-10	Mitochondrial DNA levels;
LIHC	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg20129853	chr10:51489980	NA	-0.42	-9.19	-0.45	3.82e-18	Prostate-specific antigen levels;
LIHC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg09182678	chr22:50328711	NA	-0.7	-8.0	-0.4	1.94e-14	Schizophrenia;
LIHC	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	0.85	12.36	0.56	2.85e-29	Left atrial antero-posterior diameter;
LIHC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	16.94	0.68	3.66e-47	Lung cancer in ever smokers;
LIHC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg20818283	chr2:191399100	TMEM194B	0.45	6.17	0.32	1.96e-9	Pulse pressure;
LIHC	cis	rs2257205	0.667	rs79155614	chr17:56722496	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.62	10.4	0.49	3.54e-22	Alcohol dependence;
LIHC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.44	0.53	7.17e-26	Alzheimer's disease;
LIHC	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.35	5.83	0.3	1.27e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg06533319	chr4:3265114	C4orf44	-0.3	-5.73	-0.3	2.21e-8	Mean platelet volume;
LIHC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.65	9.23	0.45	2.93e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg25902810	chr10:99078978	FRAT1	0.69	10.46	0.49	2.2e-22	Monocyte count;
LIHC	cis	rs9378688	0.654	rs2450299	chr6:2318710	C/T	cg12303981	chr6:2244766	GMDS	-0.42	-5.9	-0.3	8.89e-9	Caudate nucleus volume;
LIHC	trans	rs16863064	1.000	rs16863064	chr3:187887577	G/C	cg02569115	chr17:76922138	TIMP2	-0.36	-6.22	-0.32	1.41e-9	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg03013999	chr17:37608204	MED1	-0.34	-5.76	-0.3	1.91e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs17002069	0.836	rs55916800	chr22:41049315	T/C	cg14879645	chr22:41048474	NA	0.4	5.91	0.3	8.13e-9	Schizophrenia;
LIHC	cis	rs2412488	0.893	rs6839922	chr4:54359468	C/G	cg22241045	chr4:54363911	LNX1	0.46	7.66	0.38	1.93e-13	DNA methylation (variation);
LIHC	cis	rs7212938	0.570	rs8071050	chr17:38106599	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.39	-5.82	-0.3	1.35e-8	Asthma and hay fever;
LIHC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.65	8.9	0.43	3.28e-17	Initial pursuit acceleration;
LIHC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.19	0.32	1.71e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs507080	0.883	rs692750	chr11:118538308	G/T	cg04173919	chr11:118528438	PHLDB1	0.32	6.03	0.31	4.21e-9	Serum metabolite levels;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.85	-0.3	1.14e-8	Total body bone mineral density;
LIHC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.44	-0.37	8.44e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13036575	chr4:39184472	WDR19	-0.41	-6.03	-0.31	4.14e-9	Cognitive function;
LIHC	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.82	7.67	0.38	1.85e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-7.36	-0.37	1.41e-12	Vitiligo;
LIHC	trans	rs3112255	0.935	rs1467130	chr2:101306319	T/C	cg06958034	chr1:23346203	KDM1A	-0.46	-6.06	-0.31	3.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.95e-9	Menopause (age at onset);
LIHC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.45	6.27	0.32	1.09e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg03037974	chr15:76606532	NA	-0.61	-10.22	-0.48	1.38e-21	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.28e-27	Motion sickness;
LIHC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg01629716	chr15:45996671	NA	0.51	9.16	0.44	4.72e-18	Waist circumference;Weight;
LIHC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg22705602	chr4:152727874	NA	0.34	7.24	0.36	3.05e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg22676075	chr6:135203613	NA	0.42	6.79	0.34	5.01e-11	Red blood cell count;
LIHC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.52	-7.42	-0.37	9.26e-13	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.41	8.31	0.41	2.34e-15	Renal cell carcinoma;
LIHC	cis	rs10792665	0.724	rs1904427	chr11:82714248	A/G	cg24227371	chr11:82718527	RAB30	-0.38	-9.44	-0.45	6.14e-19	Obesity-related traits;
LIHC	trans	rs11157436	0.918	rs1983520	chr14:22618343	A/C	cg13567813	chr19:50879636	NR1H2	0.43	6.28	0.32	1.02e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.57	15.22	0.64	2.55e-40	Alzheimer's disease (late onset);
LIHC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.76	-8.55	-0.42	4.17e-16	Exhaled nitric oxide output;
LIHC	cis	rs8084351	0.599	rs7506904	chr18:50625779	G/A	cg24270629	chr18:50823537	DCC	0.39	5.89	0.3	9.18e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg20240347	chr1:204465584	NA	-0.31	-6.14	-0.32	2.32e-9	Schizophrenia;
LIHC	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.49	7.72	0.39	1.33e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.63	-9.0	-0.44	1.58e-17	White matter hyperintensity burden;
LIHC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg02269571	chr22:50332266	NA	0.61	8.64	0.42	2.24e-16	Schizophrenia;
LIHC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg12798992	chr6:167411361	FGFR1OP	0.47	6.97	0.35	1.63e-11	Crohn's disease;
LIHC	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.86	-15.43	-0.64	3.83e-41	Body mass index;
LIHC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.46	-6.0	-0.31	5.07e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.59	-7.05	-0.36	9.82e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.71	9.07	0.44	9.29e-18	Gut microbiome composition (summer);
LIHC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.52	7.44	0.37	8.45e-13	Initial pursuit acceleration;
LIHC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.6	9.12	0.44	6.65e-18	Platelet count;
LIHC	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg11161837	chr1:110010384	SYPL2	0.45	6.06	0.31	3.51e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.99	0.48	9e-21	Lung cancer;
LIHC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.41	7.6	0.38	2.79e-13	Schizophrenia;
LIHC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.71	0.67	3.15e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs611744	0.967	rs702805	chr8:109235929	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.63	9.21	0.45	3.37e-18	Menarche (age at onset);
LIHC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	1.07	11.81	0.54	3.07e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10792665	0.512	rs7118894	chr11:82606385	G/A	cg24227371	chr11:82718527	RAB30	-0.28	-6.57	-0.33	1.86e-10	Obesity-related traits;
LIHC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-5.98	-0.31	5.47e-9	Obesity-related traits;
LIHC	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg05262829	chr1:226921576	ITPKB	0.43	8.18	0.4	5.56e-15	Parkinson's disease;
LIHC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg16822855	chr3:40428330	ENTPD3	0.34	6.26	0.32	1.15e-9	Renal cell carcinoma;
LIHC	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg18867708	chr6:26865862	GUSBL1	0.5	7.39	0.37	1.15e-12	Schizophrenia;
LIHC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg15691649	chr6:25882328	NA	-0.38	-5.86	-0.3	1.09e-8	Height;
LIHC	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.7	-15.47	-0.64	2.8e-41	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg22705602	chr4:152727874	NA	-0.29	-6.2	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.48	-8.95	-0.44	2.36e-17	Body mass index;
LIHC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.77	11.85	0.54	2.25e-27	Corneal astigmatism;
LIHC	cis	rs10864907	0.553	rs7580877	chr2:113718310	C/A	cg12858261	chr2:113808755	IL1F8	0.35	6.0	0.31	5.13e-9	Pulmonary function;
LIHC	trans	rs10213084	1.000	rs10212913	chr4:147499058	T/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs2625529	0.818	rs2246225	chr15:72115230	C/T	cg16672083	chr15:72433130	SENP8	0.34	6.33	0.32	7.91e-10	Red blood cell count;
LIHC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.92	16.6	0.67	8.07e-46	Colorectal cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13795838	chr10:134539818	INPP5A	0.47	6.72	0.34	7.53e-11	Longevity;
LIHC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.74	14.15	0.61	4.13e-36	Mortality in heart failure;
LIHC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.5	5.88	0.3	9.65e-9	Bladder cancer;
LIHC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.54	-8.87	-0.43	4.23e-17	Colorectal cancer;
LIHC	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg00277334	chr10:82204260	NA	-0.58	-7.53	-0.38	4.6e-13	Post bronchodilator FEV1;
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.0	-0.44	1.6e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.71	-0.3	2.43e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.4	0.81	1.03e-80	Prudent dietary pattern;
LIHC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.66	-0.34	1.12e-10	HDL cholesterol;
LIHC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.81	-0.35	4.34e-11	Personality dimensions;
LIHC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg11812906	chr14:75593930	NEK9	0.41	6.34	0.32	7.2e-10	IgG glycosylation;
LIHC	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg22463517	chr17:26988906	SDF2;SUPT6H	0.44	6.04	0.31	4e-9	Plasma amyloid beta peptide concentrations (ABx-40);
LIHC	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg19978540	chr12:3409405	NA	0.34	6.04	0.31	4.09e-9	Hippocampal sclerosis of aging;
LIHC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.53	0.49	1.23e-22	Platelet count;
LIHC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	6.75	0.34	6.29e-11	Lung cancer in ever smokers;
LIHC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.62	-0.34	1.42e-10	Bipolar disorder;
LIHC	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.73	-7.25	-0.37	2.79e-12	Alzheimer's disease;
LIHC	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.31	6.51	0.33	2.71e-10	Ulcerative colitis;
LIHC	cis	rs3814244	0.528	rs11177002	chr12:68397157	C/T	cg15249341	chr12:68405565	NA	-0.33	-6.37	-0.33	6.11e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.54	7.47	0.37	6.75e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg07725925	chr16:89976287	TCF25	0.45	6.16	0.32	2e-9	Skin colour saturation;
LIHC	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg23422044	chr7:1970798	MAD1L1	-0.69	-10.6	-0.5	6.81e-23	Bipolar disorder;
LIHC	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg01652190	chr22:50026171	C22orf34	-0.34	-7.48	-0.37	6.49e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg03037974	chr15:76606532	NA	-0.59	-9.91	-0.47	1.6e-20	Blood metabolite levels;
LIHC	cis	rs4934494	0.768	rs34379399	chr10:91443283	C/T	cg19698084	chr10:91461284	KIF20B	-0.49	-6.49	-0.33	2.93e-10	Red blood cell count;
LIHC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg00204512	chr16:28754710	NA	0.4	6.95	0.35	1.83e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	11.06	0.51	1.62e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs4934494	0.727	rs3758388	chr10:91488979	A/T	cg19698084	chr10:91461284	KIF20B	-0.48	-6.4	-0.33	5.06e-10	Red blood cell count;
LIHC	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg03146154	chr1:46216737	IPP	-0.37	-6.18	-0.32	1.8e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg26939375	chr7:64535504	NA	-0.38	-6.08	-0.31	3.14e-9	Aortic root size;
LIHC	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	0.86	7.71	0.38	1.35e-13	Breast cancer;
LIHC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-5.89	-0.3	9.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.55	7.76	0.39	9.78e-14	Lung cancer;
LIHC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.03	-7.25	-0.36	2.89e-12	Body mass index;
LIHC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg00612595	chr21:47717864	NA	0.36	5.96	0.31	6.27e-9	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.51	5.87	0.3	1.02e-8	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13409248	chr3:40428643	ENTPD3	0.49	8.21	0.41	4.7e-15	Renal cell carcinoma;
LIHC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.51	6.22	0.32	1.42e-9	Heart rate;
LIHC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.36	5.9	0.3	8.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.65	6.4	0.33	5.15e-10	Alzheimer's disease;
LIHC	cis	rs10106298	1.000	rs17773903	chr8:103685172	A/G	cg10187029	chr8:103597600	NA	0.52	6.96	0.35	1.75e-11	Schizophrenia;
LIHC	cis	rs15676	0.783	rs2280845	chr9:131583170	T/C	cg00228799	chr9:131580591	ENDOG	0.49	7.13	0.36	6.06e-12	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg20607798	chr8:58055168	NA	0.46	5.85	0.3	1.14e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.03	11.32	0.52	1.87e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg27478167	chr7:817139	HEATR2	-0.41	-5.83	-0.3	1.32e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.41	0.45	7.38e-19	Hemoglobin concentration;
LIHC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.56	6.02	0.31	4.47e-9	Gut microbiome composition (summer);
LIHC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.53	-8.57	-0.42	3.67e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	7.47	0.37	6.93e-13	Lung cancer in ever smokers;
LIHC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.5	8.11	0.4	9.45e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.67	-0.34	1.02e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.77	13.39	0.59	3.53e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.42	6.68	0.34	9.96e-11	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.51	0.62	1.6e-37	Prudent dietary pattern;
LIHC	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg19683494	chr5:74908142	NA	-0.67	-9.29	-0.45	1.85e-18	Age-related disease endophenotypes;
LIHC	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.43	-8.26	-0.41	3.28e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg09990169	chr2:241835740	C2orf54	-0.67	-9.56	-0.46	2.34e-19	Urinary metabolites;
LIHC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg17980119	chr2:219472607	PLCD4	0.35	6.05	0.31	3.84e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.6	9.15	0.44	5.11e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2070488	0.813	rs3749387	chr3:38496193	G/C	cg24069376	chr3:38537580	EXOG	0.42	7.64	0.38	2.26e-13	Electrocardiographic conduction measures;
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg05697976	chr12:29376483	FAR2	0.33	6.76	0.34	6.05e-11	QT interval;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00767560	chr19:19887256	LOC284440	0.51	7.25	0.36	2.72e-12	Pancreatic cancer;
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg26939375	chr7:64535504	NA	0.47	7.19	0.36	4.13e-12	Calcium levels;
LIHC	cis	rs62458065	1.000	rs979355	chr7:32463933	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.65	7.41	0.37	1.01e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.57	-9.85	-0.47	2.64e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	8.03	0.4	1.63e-14	Multiple sclerosis;
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.39	0.33	5.45e-10	Renal cell carcinoma;
LIHC	cis	rs3820500	0.543	rs9727433	chr1:117967602	T/A	cg20383390	chr1:117909022	MAN1A2	0.44	5.72	0.3	2.34e-8	Pneumonia;
LIHC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-7.21	-0.36	3.6e-12	Longevity;
LIHC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.87	0.35	3.04e-11	Lung cancer in ever smokers;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg16900814	chr1:173990879	NA	0.51	6.17	0.32	1.92e-9	Glycated hemoglobin levels;
LIHC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.4	7.59	0.38	3.02e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9378688	0.929	rs9392373	chr6:2210006	T/A	cg12303981	chr6:2244766	GMDS	-0.51	-6.53	-0.33	2.45e-10	Caudate nucleus volume;
LIHC	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.53	-0.33	2.41e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg14393609	chr7:65229607	NA	-0.37	-5.76	-0.3	1.83e-8	Aortic root size;
LIHC	cis	rs11888559	0.655	rs4675314	chr2:204005532	A/G	cg24605529	chr2:203879461	NBEAL1	0.8	6.1	0.31	2.8e-9	Height;
LIHC	cis	rs4663866	0.901	rs3739067	chr2:239184203	G/A	cg16914508	chr2:239161102	PER2	0.81	5.74	0.3	2.13e-8	Irritable bowel syndrome;
LIHC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.92	16.22	0.66	2.79e-44	Breast cancer;
LIHC	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.72	9.04	0.44	1.2e-17	Eosinophilic esophagitis;
LIHC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg14779329	chr11:130786720	SNX19	0.42	6.34	0.32	7.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-7.81	-0.39	7.18e-14	Parkinson's disease;
LIHC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg17750252	chr2:136567154	LCT	0.36	6.32	0.32	7.97e-10	Mosquito bite size;
LIHC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.74	11.96	0.54	8.97e-28	Body mass index;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg09922871	chr2:71559595	ZNF638	-0.41	-6.45	-0.33	3.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16804848	chr11:64052165	GPR137;BAD	0.5	6.85	0.35	3.52e-11	Lung function (FEV1/FVC);
LIHC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.36	-0.56	3e-29	Type 2 diabetes;
LIHC	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg17074339	chr11:11642133	GALNTL4	0.4	6.09	0.31	3.09e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.52	8.76	0.43	9.25e-17	Schizophrenia;
LIHC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.97	-0.44	1.96e-17	Skin colour saturation;
LIHC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.39	6.37	0.33	6.06e-10	Alzheimer's disease (late onset);
LIHC	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.7	10.77	0.5	1.68e-23	Monocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05310920	chr2:150186634	LYPD6	0.44	6.24	0.32	1.32e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	10.68	0.5	3.6e-23	Response to antipsychotic treatment;
LIHC	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg27205649	chr11:78285834	NARS2	-0.38	-5.71	-0.3	2.43e-8	Alzheimer's disease (survival time);
LIHC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.53	-0.38	4.6e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-7.09	-0.36	7.59e-12	Hepatocellular carcinoma;
LIHC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.2	-0.32	1.58e-9	Fear of minor pain;
LIHC	cis	rs1198430	1.000	rs1198439	chr1:23749593	A/T	cg19827787	chr1:23763612	ASAP3	0.34	6.39	0.33	5.38e-10	Total cholesterol levels;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.39	6.02	0.31	4.55e-9	Obesity-related traits;
LIHC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-9.03	-0.44	1.31e-17	Bipolar disorder;
LIHC	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg08528486	chr13:113648767	MCF2L	-0.39	-6.31	-0.32	8.5e-10	Systolic blood pressure;
LIHC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.11e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.41	0.49	3.05e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.71	11.53	0.53	3.24e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26080798	chr6:20402092	E2F3	0.54	6.88	0.35	2.94e-11	Lung function (FEV1/FVC);
LIHC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.5	7.53	0.38	4.44e-13	Resting heart rate;
LIHC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.66	10.13	0.48	2.85e-21	Height;
LIHC	cis	rs4742903	0.846	rs7022158	chr9:106924872	A/G	cg14250997	chr9:106856677	SMC2	0.36	6.06	0.31	3.61e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08677398	chr8:58056175	NA	0.41	6.16	0.32	2.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-5.96	-0.31	6.17e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24372485	chr19:2078331	MOBKL2A	0.44	6.52	0.33	2.51e-10	Bilirubin levels;
LIHC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.87	-0.3	1.01e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02985541	chr2:219472218	PLCD4	0.44	8.46	0.42	7.9e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg06710121	chr8:12235606	FAM66A	-0.37	-5.88	-0.3	9.65e-9	Monocyte count;
LIHC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.93	0.31	7.53e-9	Electroencephalogram traits;
LIHC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.74	5.88	0.3	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs8117834	0.574	rs6118058	chr20:8086554	T/C	cg00593689	chr4:53575888	NA	0.38	6.44	0.33	3.98e-10	Chronic kidney disease;
LIHC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.96	10.53	0.49	1.19e-22	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.12	-0.31	2.53e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.39	-6.29	-0.32	9.75e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg04310649	chr10:35416472	CREM	-0.43	-5.81	-0.3	1.42e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.46	-6.76	-0.34	5.84e-11	Menopause (age at onset);
LIHC	cis	rs2904967	0.500	rs3896078	chr11:64874262	C/G	cg19545356	chr11:64851426	ZFPL1;CDCA5	-1.01	-6.5	-0.33	2.83e-10	Mean corpuscular volume;
LIHC	cis	rs16958440	0.867	rs62095427	chr18:44594221	G/A	cg17192377	chr18:44677553	HDHD2	0.66	6.78	0.34	5.38e-11	Sitting height ratio;
LIHC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	1.08	14.69	0.62	3.18e-38	Heart rate;
LIHC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.79	-11.89	-0.54	1.62e-27	Coronary artery disease;
LIHC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.44	-0.42	8.96e-16	Body mass index (adult);
LIHC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.99	-10.2	-0.48	1.71e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.29	-0.32	9.81e-10	Total body bone mineral density;
LIHC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg09417038	chr21:47716443	C21orf57	-0.52	-7.38	-0.37	1.19e-12	Testicular germ cell tumor;
LIHC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.01	-0.35	1.28e-11	Reticulocyte count;
LIHC	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg18357526	chr6:26021779	HIST1H4A	0.63	8.91	0.43	3.08e-17	Blood metabolite levels;
LIHC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.29	0.66	1.49e-44	Smoking behavior;
LIHC	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.76	-11.48	-0.53	5.19e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg12798992	chr6:167411361	FGFR1OP	0.53	8.71	0.43	1.29e-16	Crohn's disease;
LIHC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.6	-0.38	2.93e-13	Calcium levels;
LIHC	cis	rs35160687	0.509	rs13024436	chr2:86534521	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.07	0.31	3.31e-9	Night sleep phenotypes;
LIHC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.21	15.32	0.64	1.04e-40	Alzheimer's disease (late onset);
LIHC	cis	rs3770081	1.000	rs6705122	chr2:86176258	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.83	0.3	1.27e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg16070123	chr10:51489643	NA	-0.38	-6.08	-0.31	3.26e-9	Prostate-specific antigen levels;
LIHC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.12	0.52	9.62e-25	Platelet count;
LIHC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.73	-11.01	-0.51	2.42e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.69	-7.66	-0.38	1.92e-13	Neuroticism;
LIHC	cis	rs4780355	0.619	rs918737	chr16:11439639	T/C	cg00044050	chr16:11439710	C16orf75	-0.45	-6.18	-0.32	1.86e-9	Crohn's disease and psoriasis;
LIHC	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.32	6.7	0.34	8.61e-11	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg25237894	chr2:233734115	C2orf82	0.37	6.99	0.35	1.43e-11	Schizophrenia;
LIHC	cis	rs7703051	0.707	rs7730344	chr5:74587940	C/A	cg00601450	chr5:74908170	NA	0.39	5.94	0.31	7.04e-9	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.38	6.27	0.32	1.07e-9	Height;
LIHC	cis	rs611744	0.934	rs2848619	chr8:109198185	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.8e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs151997	0.925	rs27270	chr5:50183712	A/G	cg06027927	chr5:50259733	NA	-0.56	-7.7	-0.38	1.45e-13	Callous-unemotional behaviour;
LIHC	cis	rs747782	0.639	rs4752872	chr11:47853795	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.89	-0.3	9.2e-9	Intraocular pressure;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	0.61	8.65	0.42	2.06e-16	Prudent dietary pattern;
LIHC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg21361702	chr7:150065534	REPIN1	0.45	6.17	0.32	1.94e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.46	-8.78	-0.43	7.98e-17	Neurofibrillary tangles;
LIHC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.64	-9.08	-0.44	9e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.74	-0.47	6.22e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	trans	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.14	-0.32	2.29e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.09	0.44	8.32e-18	Schizophrenia;
LIHC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.41	-5.79	-0.3	1.55e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.88	8.33	0.41	1.97e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.5	7.83	0.39	6.23e-14	Total body bone mineral density;
LIHC	cis	rs7961581	0.748	rs1588493	chr12:71598228	A/G	cg05756094	chr12:71608604	NA	0.4	6.49	0.33	3e-10	Type 2 diabetes;
LIHC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.63	9.86	0.47	2.47e-20	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.54	-6.87	-0.35	2.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.75	9.43	0.45	6.22e-19	Urate levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04250904	chr19:12623422	ZNF709	0.4	6.42	0.33	4.46e-10	Bilirubin levels;
LIHC	cis	rs12744310	1.000	rs12037560	chr1:41763891	C/A	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.84	12.76	0.57	9.4e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12464559	0.649	rs10171724	chr2:152672482	T/A	cg01189475	chr2:152685088	ARL5A	0.63	7.38	0.37	1.2e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	8.06	0.4	1.33e-14	Triglyceride levels;
LIHC	cis	rs600806	0.778	rs10494040	chr1:110015732	C/T	cg23091122	chr1:110024289	SYPL2	-0.44	-6.09	-0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.3	-7.86	-0.39	4.96e-14	Intelligence;
LIHC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg06784218	chr1:46089804	CCDC17	0.37	5.82	0.3	1.39e-8	Platelet count;
LIHC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.45	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-11.12	-0.52	9.64e-25	Primary sclerosing cholangitis;
LIHC	trans	rs983392	0.709	rs7928895	chr11:59975165	G/A	cg17275991	chr19:58003312	ZNF419	0.44	6.14	0.32	2.24e-9	Alzheimer's disease (late onset);
LIHC	cis	rs238295	0.805	rs6053500	chr20:5542683	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-7.0	-0.35	1.4e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg21724239	chr8:58056113	NA	0.48	6.38	0.33	5.84e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.44	6.67	0.34	1.04e-10	Neutrophil percentage of white cells;
LIHC	cis	rs11671005	0.656	rs55928441	chr19:59009674	T/C	cg25952890	chr19:58913133	NA	0.67	6.4	0.33	4.99e-10	Mean platelet volume;
LIHC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-9.51	-0.46	3.39e-19	Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg10755058	chr3:40428713	ENTPD3	0.38	6.53	0.33	2.38e-10	Renal cell carcinoma;
LIHC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.73	7.39	0.37	1.15e-12	Vitiligo;
LIHC	cis	rs918629	0.530	rs56156268	chr5:95240659	G/A	cg10483112	chr5:95245456	ELL2	-0.38	-6.91	-0.35	2.41e-11	IgG glycosylation;
LIHC	cis	rs507080	0.807	rs7926944	chr11:118559828	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.8e-10	Serum metabolite levels;
LIHC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.45	-7.08	-0.36	8.2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.84	0.3	1.19e-8	Personality dimensions;
LIHC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.58	6.48	0.33	3.23e-10	Axial length;
LIHC	cis	rs4450131	0.500	rs2362515	chr10:126336158	C/T	cg20435097	chr10:126320824	FAM53B	0.69	12.37	0.56	2.56e-29	White blood cell count (basophil);
LIHC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.74	0.3	2.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2997447	0.706	rs2783713	chr1:26429351	C/A	cg19633962	chr1:26362018	EXTL1	-0.56	-6.24	-0.32	1.29e-9	QRS complex (12-leadsum);
LIHC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.33	0.32	7.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.34	8.19	0.4	5.21e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.95	-0.35	1.82e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg08469215	chr1:156261351	TMEM79	-0.38	-6.25	-0.32	1.21e-9	Tonsillectomy;
LIHC	cis	rs57244997	0.685	rs1954916	chr6:162447612	A/G	cg17173639	chr6:162384350	PARK2	-0.62	-7.4	-0.37	1.09e-12	Mosquito bite size;
LIHC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.98	11.98	0.54	7.58e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs2108622	0.683	rs112571591	chr19:15977445	G/A	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.81e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.42	-7.16	-0.36	5.07e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs611744	0.967	rs591792	chr8:109200446	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.75	14.25	0.61	1.74e-36	Myeloid white cell count;
LIHC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-12.06	-0.55	3.91e-28	Blood metabolite levels;
LIHC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs807029	0.533	rs67813203	chr10:102738551	A/G	cg25179470	chr10:102756915	LZTS2	0.45	6.38	0.33	5.65e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg19318889	chr4:1322082	MAEA	0.4	6.62	0.34	1.37e-10	Obesity-related traits;
LIHC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.44	0.45	6.14e-19	Melanoma;
LIHC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.53	8.17	0.4	5.88e-15	Lymphocyte counts;
LIHC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.52	8.53	0.42	4.91e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.87	-0.3	1.04e-8	Body mass index;
LIHC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.47	7.88	0.39	4.39e-14	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.38	-5.9	-0.3	8.94e-9	Platelet count;
LIHC	trans	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg26951091	chr14:76844913	ESRRB	0.58	6.14	0.32	2.34e-9	Putamen volume;
LIHC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg18887096	chr2:219472410	PLCD4	0.4	6.96	0.35	1.79e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-8.09	-0.4	1.04e-14	Lung cancer;
LIHC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.67	8.36	0.41	1.59e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	8.22	0.41	4.21e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	11.68	0.53	9.78e-27	Lung cancer in ever smokers;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08280861	chr8:58055591	NA	0.49	6.13	0.31	2.38e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg08125733	chr17:73851984	WBP2	0.5	8.24	0.41	3.71e-15	White matter hyperintensity burden;
LIHC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.63	-0.46	1.36e-19	Gut microbiome composition (summer);
LIHC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.85	10.33	0.49	5.75e-22	Cognitive function;
LIHC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	13.59	0.59	5.98e-34	Psoriasis;
LIHC	cis	rs5753037	0.504	rs140114	chr22:30133881	C/T	cg01021169	chr22:30184971	ASCC2	-0.32	-6.05	-0.31	3.8e-9	Type 1 diabetes;
LIHC	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.48	6.93	0.35	2.07e-11	Smoking behavior;
LIHC	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg15664640	chr17:80829946	TBCD	-0.57	-5.97	-0.31	5.98e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.62	9.03	0.44	1.28e-17	Schizophrenia;
LIHC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg17980119	chr2:219472607	PLCD4	0.34	5.71	0.3	2.4e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.38	-5.92	-0.31	7.71e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	1.01	15.71	0.65	3.05e-42	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	8.18	0.4	5.67e-15	Platelet count;
LIHC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.79	8.97	0.44	1.95e-17	Vitiligo;
LIHC	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.46	6.56	0.33	2.01e-10	Breast cancer;
LIHC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.18	-0.36	4.33e-12	Response to antipsychotic treatment;
LIHC	cis	rs9783347	1.000	rs10741741	chr11:18342081	C/T	cg15585147	chr11:18324498	HPS5	-0.37	-6.15	-0.32	2.18e-9	Pancreatic cancer;
LIHC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.76	7.05	0.36	9.82e-12	Plasma clusterin levels;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg14393609	chr7:65229607	NA	0.42	7.11	0.36	6.92e-12	Calcium levels;
LIHC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.64	-0.34	1.21e-10	Neuroticism;
LIHC	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.61	-9.05	-0.44	1.11e-17	Monocyte count;
LIHC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01200585	chr1:228362443	C1orf69	-0.39	-5.78	-0.3	1.7e-8	Diastolic blood pressure;
LIHC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.58	0.34	1.79e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.68	-11.94	-0.54	1.08e-27	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02396668	chr19:50528878	VRK3;ZNF473	0.42	6.5	0.33	2.86e-10	Cognitive function;
LIHC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg24977027	chr2:88469347	THNSL2	-0.46	-6.61	-0.34	1.44e-10	Response to metformin (IC50);
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg19901994	chr8:27288146	PTK2B	0.56	6.07	0.31	3.35e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.57	10.1	0.48	3.58e-21	Dupuytren's disease;
LIHC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg19539972	chr4:7069911	GRPEL1	-0.64	-9.05	-0.44	1.12e-17	Monocyte percentage of white cells;
LIHC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.04	0.55	4.52e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.75e-9	Prudent dietary pattern;
LIHC	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg27205649	chr11:78285834	NARS2	-0.39	-5.81	-0.3	1.46e-8	Alzheimer's disease (survival time);
LIHC	cis	rs1983891	0.909	rs4714482	chr6:41528199	G/A	cg20194872	chr6:41519635	FOXP4	0.43	6.84	0.35	3.74e-11	Prostate cancer;
LIHC	cis	rs2380220	0.808	rs2716069	chr6:95912976	C/G	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01089589	chr2:10920095	ATP6V1C2	0.46	6.63	0.34	1.29e-10	Longevity;
LIHC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.32	0.45	1.45e-18	Electroencephalogram traits;
LIHC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.65	-11.04	-0.51	1.97e-24	Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04238871	chr10:126431886	FAM53B	0.43	6.44	0.33	4.06e-10	Pancreatic cancer;
LIHC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.83	0.3	1.3e-8	Self-reported allergy;
LIHC	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.59	9.9	0.47	1.7e-20	Dupuytren's disease;
LIHC	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.51	7.26	0.37	2.63e-12	Obesity-related traits;
LIHC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.33	14.33	0.61	8.06e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	1.08	9.29	0.45	1.79e-18	Alzheimer's disease;
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.46	5.77	0.3	1.82e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23903597	chr17:61704154	MAP3K3	0.44	6.02	0.31	4.42e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg07959070	chr22:50026188	C22orf34	-0.34	-8.68	-0.42	1.61e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	7.54	0.38	4.22e-13	Lymphocyte counts;
LIHC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.09	19.43	0.72	3.36e-57	Nonalcoholic fatty liver disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19252891	chr7:75132457	SPDYE5	0.5	6.88	0.35	2.88e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg14222432	chr12:29376421	FAR2	0.35	6.64	0.34	1.27e-10	QT interval;
LIHC	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18156793	chr20:32031936	SNTA1	0.44	6.74	0.34	6.72e-11	Pancreatic cancer;
LIHC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.39	5.88	0.3	9.8e-9	Height;
LIHC	cis	rs7945718	0.621	rs7943920	chr11:12695614	A/G	cg25843174	chr11:12811716	TEAD1	0.33	7.68	0.38	1.7e-13	Educational attainment (years of education);
LIHC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22379573	chr1:197704774	DENND1B	-0.37	-6.11	-0.31	2.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.59	5.94	0.31	7.19e-9	Carotid intima media thickness;
LIHC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-8.49	-0.42	6.57e-16	Lung cancer in ever smokers;
LIHC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg05207973	chr5:176823642	SLC34A1	0.34	5.93	0.31	7.41e-9	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs11581903	0.568	rs11205977	chr1:53068093	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.8	5.99	0.31	5.34e-9	Joint mobility (Beighton score);
LIHC	trans	rs11724903	0.935	rs7437074	chr4:183219488	G/A	cg16239906	chr20:35724590	RBL1	-0.62	-6.08	-0.31	3.24e-9	Smoking initiation;
LIHC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.49	9.71	0.46	7.58e-20	Breast cancer;
LIHC	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.89	10.61	0.5	6.2e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.89	-12.9	-0.57	2.65e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-5.77	-0.3	1.8e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.75	8.63	0.42	2.33e-16	Schizophrenia;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25001845	chr14:75201709	FCF1	0.39	6.14	0.32	2.33e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.78	6.17	0.32	1.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.52	-6.85	-0.35	3.35e-11	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	1.0	8.35	0.41	1.7e-15	Lymphocyte counts;
LIHC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs7039377	0.554	rs12351753	chr9:38673105	C/G	cg14625731	chr9:38672608	NA	-0.47	-7.57	-0.38	3.4e-13	Obesity-related traits;
LIHC	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.6	-8.83	-0.43	5.43e-17	Blood pressure (smoking interaction);
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.13	0.4	7.79e-15	Height;
LIHC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg15123519	chr2:136567270	LCT	0.45	8.83	0.43	5.46e-17	Mosquito bite size;
LIHC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.44	-6.48	-0.33	3.15e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg12903224	chr12:29470962	FAR2	-0.42	-6.73	-0.34	7.04e-11	QT interval;
LIHC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.43	8.02	0.4	1.74e-14	Electrocardiographic conduction measures;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04849995	chr17:66016719	NA	0.42	6.1	0.31	2.92e-9	Pancreatic cancer;
LIHC	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.7	14.52	0.62	1.54e-37	Schizophrenia;
LIHC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.89	14.04	0.6	1.15e-35	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.49	8.25	0.41	3.52e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1494950	0.661	rs1908446	chr4:15002784	C/T	cg12377275	chr4:15005593	CPEB2	-0.83	-7.36	-0.37	1.35e-12	Political ideology;
LIHC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.48	6.32	0.32	8.08e-10	Initial pursuit acceleration;
LIHC	trans	rs983392	0.709	rs11230194	chr11:59980315	C/G	cg17275991	chr19:58003312	ZNF419	0.44	6.26	0.32	1.12e-9	Alzheimer's disease (late onset);
LIHC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	6.04e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.89	10.8	0.5	1.32e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs12602486	1.000	rs76971031	chr17:42242724	T/G	cg08193365	chr17:42277699	NA	1.05	7.39	0.37	1.16e-12	Glycated hemoglobin levels;
LIHC	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	0.3	7.27	0.37	2.46e-12	Gut microbiome composition (winter);
LIHC	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.44	8.33	0.41	1.99e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-8.63	-0.42	2.41e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.59	-8.84	-0.43	5.05e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-1.08	-16.93	-0.68	3.93e-47	Urate levels;
LIHC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.46	0.33	3.68e-10	Schizophrenia;
LIHC	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg18081818	chr7:23246105	NA	-0.4	-5.9	-0.3	8.69e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs990171	0.506	rs2041748	chr2:102756295	A/G	cg22835712	chr2:102737379	NA	0.57	8.89	0.43	3.55e-17	Lymphocyte counts;
LIHC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.41	-5.72	-0.3	2.27e-8	Initial pursuit acceleration;
LIHC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.28	0.52	2.74e-25	Menopause (age at onset);
LIHC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.49	-7.88	-0.39	4.37e-14	Vitiligo;
LIHC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.62	-9.49	-0.46	4.2e-19	Aortic root size;
LIHC	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-18.95	-0.72	2.93e-55	Height;
LIHC	cis	rs2257205	0.667	rs7209498	chr17:56680642	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.86	0.39	5.22e-14	Pancreatic cancer;
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-0.63	-9.21	-0.45	3.46e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.49	9.09	0.44	8.42e-18	Hemoglobin concentration;
LIHC	cis	rs12431939	1.000	rs12432466	chr14:51638873	T/C	cg23942311	chr14:51606299	NA	-0.36	-6.06	-0.31	3.58e-9	Cancer;
LIHC	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-5.83	-0.3	1.32e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	11.02	0.51	2.24e-24	Lung cancer in ever smokers;
LIHC	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg05010058	chr2:65284262	CEP68	0.39	6.61	0.34	1.5e-10	Pulse pressure;
LIHC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.78	9.78	0.47	4.48e-20	Body mass index;
LIHC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.48	-6.5	-0.33	2.88e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.48	-0.33	3.22e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.44	5.99	0.31	5.34e-9	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00402069	chr5:89770788	POLR3G;MBLAC2	0.4	6.09	0.31	2.96e-9	Lung function (FEV1/FVC);
LIHC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.45	6.37	0.33	6.18e-10	Aortic root size;
LIHC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg23625390	chr15:77176239	SCAPER	0.34	5.91	0.3	8.37e-9	Blood metabolite levels;
LIHC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.36	-0.37	1.35e-12	Obesity-related traits;
LIHC	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.1	0.31	2.94e-9	Rheumatoid arthritis;
LIHC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.26	0.52	3.09e-25	Colorectal cancer;
LIHC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.8	-0.39	7.74e-14	Total body bone mineral density;
LIHC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.52	8.59	0.42	3.13e-16	Blood metabolite levels;
LIHC	cis	rs11688816	0.904	rs2539984	chr2:63133584	G/C	cg17519650	chr2:63277830	OTX1	0.38	5.87	0.3	1.02e-8	Body mass index;
LIHC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.46	5.9	0.3	8.84e-9	Height;
LIHC	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	7.63	0.38	2.3e-13	Body mass index;
LIHC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.48	7.33	0.37	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12463550	chr7:65579703	CRCP	0.67	6.9	0.35	2.49e-11	Diabetic kidney disease;
LIHC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg03146154	chr1:46216737	IPP	-0.41	-6.25	-0.32	1.2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7116495	1.000	rs495567	chr11:71795488	C/T	cg26138937	chr11:71823887	C11orf51	-0.68	-6.84	-0.35	3.56e-11	Severe influenza A (H1N1) infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13794888	chr15:75917792	SNUPN	0.47	7.48	0.37	6.48e-13	Pancreatic cancer;
LIHC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05909891	chr12:19565983	NA	0.44	6.53	0.33	2.45e-10	Hepatitis;
LIHC	cis	rs1400745	0.718	rs799681	chr14:35350579	A/G	cg16230307	chr14:35515116	FAM177A1	0.39	6.25	0.32	1.24e-9	Monocyte count;
LIHC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-6.51	-0.33	2.76e-10	Personality dimensions;
LIHC	cis	rs17776563	0.887	rs72761998	chr15:89125207	G/T	cg05013243	chr15:89149849	MIR1179	0.4	6.55	0.33	2.05e-10	Thyroid hormone levels;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06420487	chr17:61919686	SMARCD2	0.42	5.78	0.3	1.69e-8	Height;
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27297192	chr10:134578999	INPP5A	0.53	7.06	0.36	9.16e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.58	-11.39	-0.52	1.1e-25	Coronary artery disease;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.44	-12.29	-0.55	5.18e-29	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.05	-0.31	3.86e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.44	0.33	4.1e-10	Lymphocyte counts;
LIHC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.4	0.33	5.2e-10	Lung cancer in ever smokers;
LIHC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.13	0.31	2.48e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.5	7.35	0.37	1.43e-12	Type 2 diabetes;
LIHC	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.63	10.84	0.51	1.01e-23	Breast cancer;
LIHC	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg05110241	chr16:68378359	PRMT7	-0.49	-5.97	-0.31	5.84e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg10360323	chr17:41437877	NA	0.41	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.38	7.38	0.37	1.2e-12	Growth-regulated protein alpha levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23099349	chr6:26032281	HIST1H3B	0.4	6.76	0.34	5.93e-11	Cognitive function;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg18954051	chr12:66554863	TMBIM4	0.34	6.04	0.31	4.06e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.53	-8.56	-0.42	3.78e-16	Cocaine dependence;
LIHC	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg07706471	chr12:123319906	HIP1R	-0.58	-7.47	-0.37	6.97e-13	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00473112	chr11:507177	RNH1	0.39	6.36	0.33	6.44e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.62	10.13	0.48	2.86e-21	Coronary artery disease;
LIHC	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.74	12.71	0.57	1.4e-30	Menopause (age at onset);
LIHC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.39	7.24	0.36	3e-12	Rheumatoid arthritis;
LIHC	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.32	-5.92	-0.3	7.79e-9	Type 1 diabetes;
LIHC	cis	rs9378688	0.654	rs11242758	chr6:2362266	A/G	cg12303981	chr6:2244766	GMDS	0.44	6.02	0.31	4.46e-9	Caudate nucleus volume;
LIHC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	11.46	0.53	5.76e-26	Platelet count;
LIHC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.57	0.5	9e-23	Bladder cancer;
LIHC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.85	-0.54	2.23e-27	Type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg18306943	chr3:40428807	ENTPD3	0.35	6.01	0.31	4.63e-9	Renal cell carcinoma;
LIHC	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.83	-8.78	-0.43	7.86e-17	Blood pressure (smoking interaction);
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.29	0.41	2.71e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06656553	chr16:89960601	TCF25	-0.46	-5.81	-0.3	1.47e-8	Skin colour saturation;
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.19	0.55	1.2e-28	Height;
LIHC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-7.19	-0.36	4.09e-12	Schizophrenia;
LIHC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg12365402	chr11:9010492	NRIP3	-0.25	-5.97	-0.31	5.92e-9	Hematocrit;
LIHC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.23	6.25	0.32	1.19e-9	Calcium levels;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg02990361	chr1:107599529	PRMT6	-0.66	-11.05	-0.51	1.78e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg14779329	chr11:130786720	SNX19	0.38	5.99	0.31	5.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.53	-0.69	1.51e-49	Schizophrenia;
LIHC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.61	8.86	0.43	4.39e-17	Emphysema distribution in smoking;
LIHC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.08	26.07	0.82	2.79e-83	IgG glycosylation;
LIHC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.54	-10.81	-0.5	1.28e-23	Airflow obstruction;
LIHC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg21573476	chr21:45109991	RRP1B	0.45	8.33	0.41	1.93e-15	Mean corpuscular volume;
LIHC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8084351	0.582	rs7505556	chr18:50571419	A/G	cg24270629	chr18:50823537	DCC	0.39	6.04	0.31	4.06e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg12903224	chr12:29470962	FAR2	-0.41	-6.45	-0.33	3.89e-10	QT interval;
LIHC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs7945718	0.621	rs4370915	chr11:12664998	C/T	cg25843174	chr11:12811716	TEAD1	0.32	7.26	0.37	2.65e-12	Educational attainment (years of education);
LIHC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.06	0.31	3.68e-9	Menopause (age at onset);
LIHC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.39	-6.33	-0.32	7.5e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.49	9.45	0.46	5.4e-19	Testicular germ cell tumor;
LIHC	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.19	0.41	5.17e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.61e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.57	9.46	0.46	5.2e-19	Colorectal cancer;
LIHC	cis	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg03493300	chr10:104813866	CNNM2	0.42	5.81	0.3	1.43e-8	Birth weight;
LIHC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.65	12.73	0.57	1.23e-30	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01519350	chr3:137906342	ARMC8	0.42	6.78	0.34	5.4e-11	Cognitive function;
LIHC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg05484376	chr2:27715224	FNDC4	-0.33	-5.74	-0.3	2.13e-8	Total body bone mineral density;
LIHC	cis	rs9596863	0.898	rs9568917	chr13:54351040	G/A	ch.13.53330881F	chr13:54432880	NA	0.45	6.06	0.31	3.57e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.83	9.53	0.46	3.06e-19	Mitochondrial DNA levels;
LIHC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.27	0.45	2.08e-18	Platelet count;
LIHC	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg23091122	chr1:110024289	SYPL2	-0.46	-6.09	-0.31	2.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs943466	1.000	rs943461	chr6:33769409	C/G	cg25922239	chr6:33757077	LEMD2	-0.5	-6.41	-0.33	4.91e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg03037974	chr15:76606532	NA	0.74	14.5	0.62	1.73e-37	Blood metabolite levels;
LIHC	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg25649188	chr17:73499917	CASKIN2	-0.43	-6.95	-0.35	1.87e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-6.92	-0.35	2.26e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg06359132	chr10:99160096	RRP12	-0.42	-6.37	-0.33	5.93e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg12798992	chr6:167411361	FGFR1OP	0.48	7.18	0.36	4.46e-12	Crohn's disease;
LIHC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.45	-6.7	-0.34	8.64e-11	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg17724175	chr1:150552817	MCL1	0.47	9.35	0.45	1.19e-18	Melanoma;
LIHC	cis	rs922107	0.713	rs6680212	chr1:90045922	C/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.73	-0.39	1.19e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg10820045	chr2:198174542	NA	-0.48	-7.22	-0.36	3.31e-12	Dermatomyositis;
LIHC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	17.31	0.68	1.13e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.36	8.21	0.41	4.7e-15	Educational attainment (years of education);
LIHC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.67	12.31	0.55	4.37e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg08345082	chr10:99160200	RRP12	-0.4	-6.66	-0.34	1.12e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.46	7.18	0.36	4.42e-12	Cocaine dependence;
LIHC	cis	rs797680	0.856	rs2765545	chr1:93677269	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.65e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.85	-0.35	3.49e-11	Obesity (extreme);
LIHC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg11812906	chr14:75593930	NEK9	-0.48	-7.73	-0.39	1.2e-13	IgG glycosylation;
LIHC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.66	-8.3	-0.41	2.37e-15	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.71	-11.86	-0.54	2.06e-27	Aortic root size;
LIHC	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg07424592	chr7:64974309	NA	0.78	8.92	0.43	2.85e-17	Gout;
LIHC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.74	0.39	1.16e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.71	10.63	0.5	5.5e-23	Aortic root size;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.28	0.55	5.92e-29	Prudent dietary pattern;
LIHC	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.02	-0.31	4.52e-9	Blood pressure;
LIHC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.75	7.02	0.35	1.2e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.6	10.34	0.49	5.69e-22	Colorectal cancer;
LIHC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg21361702	chr7:150065534	REPIN1	0.44	5.99	0.31	5.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.85	13.77	0.6	1.22e-34	Colorectal cancer;
LIHC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg08210727	chr20:33865349	NA	0.5	5.77	0.3	1.76e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.81	-0.3	1.47e-8	Bipolar disorder;
LIHC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.77	-0.54	4.37e-27	Coronary artery disease;
LIHC	cis	rs11997175	0.569	rs36034014	chr8:33814219	G/A	ch.8.33884649F	chr8:33765107	NA	-0.4	-6.54	-0.33	2.28e-10	Body mass index;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.94	-0.31	7.08e-9	Fibrinogen levels;
LIHC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg16479474	chr6:28041457	NA	0.39	6.68	0.34	9.59e-11	Cardiac Troponin-T levels;
LIHC	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.63	12.47	0.56	1.14e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.45	7.1	0.36	7.45e-12	HDL cholesterol levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22554796	chr10:32345272	KIF5B	0.46	6.42	0.33	4.62e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg11764359	chr7:65958608	NA	0.6	6.38	0.33	5.71e-10	Diabetic kidney disease;
LIHC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.43	7.14	0.36	5.56e-12	Fibrinogen levels;
LIHC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-22.78	-0.78	1.48e-70	Myeloid white cell count;
LIHC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.3	0.45	1.65e-18	Melanoma;
LIHC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg02297831	chr4:17616191	MED28	0.42	5.91	0.3	8.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.66	10.18	0.48	1.95e-21	Type 2 diabetes;
LIHC	cis	rs2274273	0.870	rs4366639	chr14:55790516	T/G	cg01864836	chr14:55583639	NA	-0.37	-6.57	-0.33	1.9e-10	Protein biomarker;
LIHC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.6	-0.34	1.57e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.83	0.3	1.31e-8	Menopause (age at onset);
LIHC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Blood protein levels;
LIHC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.56	-8.54	-0.42	4.63e-16	Platelet distribution width;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg09260627	chr8:8243751	NA	0.67	6.11	0.31	2.71e-9	Musician's dystonia;
LIHC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.47	8.47	0.42	7.22e-16	Colorectal cancer;
LIHC	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg27386326	chr11:61587980	NA	0.69	14.74	0.62	2.09e-38	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.27	-13.8	-0.6	9.37e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg27433088	chr4:174089019	GALNT7	0.4	7.32	0.37	1.81e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.49	7.36	0.37	1.35e-12	Lymphocyte percentage of white cells;
LIHC	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.69	12.34	0.56	3.46e-29	Breast cancer;
LIHC	cis	rs1882538	0.504	rs6951416	chr7:133092278	A/G	cg10665199	chr7:133106180	EXOC4	0.5	8.19	0.41	5.08e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.56	-0.5	9.46e-23	Hemoglobin concentration;
LIHC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.39	6.98	0.35	1.5e-11	Red cell distribution width;
LIHC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.86	10.31	0.49	7.18e-22	Cognitive function;
LIHC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.77	0.3	1.76e-8	Self-reported allergy;
LIHC	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.3	0.37	1.99e-12	Blood protein levels;
LIHC	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.88	-10.46	-0.49	2.14e-22	Red blood cell traits;
LIHC	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg12903224	chr12:29470962	FAR2	-0.4	-6.59	-0.34	1.63e-10	QT interval;
LIHC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-6.86	-0.35	3.3e-11	Chronic sinus infection;
LIHC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-7.0	-0.35	1.37e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg03517284	chr6:25882590	NA	-0.38	-5.74	-0.3	2.06e-8	Height;
LIHC	trans	rs2073499	0.873	rs6446202	chr3:50219991	C/G	cg21659725	chr3:3221576	CRBN	0.68	8.03	0.4	1.63e-14	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26670552	chr16:69600032	NFAT5;MIR1538	0.44	6.26	0.32	1.16e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg17135325	chr3:160939158	NMD3	0.6	8.9	0.43	3.23e-17	Parkinson's disease;
LIHC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.47	-8.03	-0.4	1.6e-14	Neuroticism;
LIHC	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	1.14	8.88	0.43	3.89e-17	Arsenic metabolism;
LIHC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	12.17	0.55	1.53e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg04166393	chr7:2884313	GNA12	0.49	6.43	0.33	4.29e-10	Height;
LIHC	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.24	-0.36	2.99e-12	Tuberculosis;
LIHC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg02640540	chr1:67518911	SLC35D1	0.44	6.06	0.31	3.5e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.59	7.28	0.37	2.27e-12	Coronary artery disease;
LIHC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg03854865	chr6:26224070	HIST1H3E	0.51	6.36	0.33	6.42e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.5	-6.36	-0.33	6.62e-10	Coronary artery calcification;
LIHC	trans	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg10756647	chr7:56101905	PSPH	-1.08	-13.26	-0.58	1.18e-32	Diabetic kidney disease;
LIHC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-10.48	-0.49	1.75e-22	Blood pressure (smoking interaction);
LIHC	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.58	-9.12	-0.44	6.77e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.7	7.1	0.36	7.09e-12	Alzheimer's disease;
LIHC	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.23	-0.32	1.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09544279	chr5:179921349	CNOT6	-0.44	-6.92	-0.35	2.22e-11	Pancreatic cancer;
LIHC	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.41	6.31	0.32	8.89e-10	Neuroticism;
LIHC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg05896524	chr21:47604654	C21orf56	0.44	6.61	0.34	1.49e-10	Testicular germ cell tumor;
LIHC	cis	rs1163251	0.729	rs686362	chr1:120221011	T/C	cg19096424	chr1:120255104	PHGDH	0.49	6.09	0.31	3.06e-9	Blood metabolite levels;
LIHC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.07	-0.36	8.54e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg26441486	chr22:50317300	CRELD2	0.36	6.14	0.32	2.24e-9	Schizophrenia;
LIHC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.44	8.99	0.44	1.75e-17	Tonsillectomy;
LIHC	cis	rs10916814	0.632	rs10916819	chr1:20901000	A/G	cg24502330	chr1:20914028	CDA	-0.31	-6.8	-0.35	4.68e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg00035636	chr13:21900591	NA	0.4	6.8	0.35	4.65e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.36	5.99	0.31	5.44e-9	Height;
LIHC	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg08992911	chr2:238395768	MLPH	0.5	6.01	0.31	4.86e-9	Prostate cancer;
LIHC	cis	rs12220238	0.908	rs10824133	chr10:76020585	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.3	0.32	9e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs11958404	0.932	rs60504573	chr5:157436786	T/A	cg05962755	chr5:157440814	NA	0.99	11.5	0.53	4.32e-26	IgG glycosylation;
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.31	-0.32	8.57e-10	Longevity;Endometriosis;
LIHC	trans	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg17675199	chr6:35436792	RPL10A	0.3	6.13	0.31	2.45e-9	Coronary artery disease;
LIHC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg13844804	chr7:814759	HEATR2	0.42	5.73	0.3	2.25e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-1.03	-13.39	-0.59	3.59e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.53	7.77	0.39	9.51e-14	Type 2 diabetes;
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.35	-5.92	-0.3	7.95e-9	Height;
LIHC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg25344623	chr2:136566232	LCT	0.44	8.85	0.43	4.92e-17	Mosquito bite size;
LIHC	cis	rs6967414	1.000	rs6967414	chr7:6749758	G/A	cg00387323	chr7:6746715	ZNF12	0.62	7.07	0.36	8.81e-12	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.39	-0.33	5.54e-10	Tonsillectomy;
LIHC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.48	0.53	4.87e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.68	-10.04	-0.48	5.7e-21	Obesity-related traits;
LIHC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg00318621	chr2:106887213	NA	0.62	6.33	0.32	7.86e-10	Facial morphology (factor 23);
LIHC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.5	7.08	0.36	8.44e-12	Tonsillectomy;
LIHC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.23	-0.36	3.09e-12	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3736485	0.966	rs6493510	chr15:51900651	T/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.01e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.08	-0.48	4.4e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.67	-11.63	-0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.26	-6.21	-0.32	1.57e-9	Heart rate;
LIHC	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.85	-13.68	-0.59	2.8e-34	Schizophrenia;
LIHC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02985541	chr2:219472218	PLCD4	-0.38	-6.72	-0.34	7.62e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.57	9.89	0.47	1.96e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg19773385	chr1:10388646	KIF1B	-0.48	-8.19	-0.41	5.17e-15	Hepatocellular carcinoma;
LIHC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.71	-0.34	8.08e-11	Response to antipsychotic treatment;
LIHC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.35	-5.81	-0.3	1.44e-8	IgG glycosylation;
LIHC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	1.03	13.28	0.58	9.93e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg17135325	chr3:160939158	NMD3	0.57	8.16	0.4	6.34e-15	Parkinson's disease;
LIHC	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg20991723	chr1:152506922	NA	0.49	8.25	0.41	3.57e-15	Hair morphology;
LIHC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg00074818	chr8:8560427	CLDN23	-0.39	-6.32	-0.32	8.12e-10	Obesity-related traits;
LIHC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.38	-6.45	-0.33	3.77e-10	Educational attainment;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.28	0.55	6e-29	Prudent dietary pattern;
LIHC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.75	13.03	0.58	8.69e-32	Coronary artery disease;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg18279126	chr7:2041391	MAD1L1	0.39	6.58	0.33	1.82e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.34	-12.2	-0.55	1.1e-28	Psoriasis vulgaris;
LIHC	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg24069376	chr3:38537580	EXOG	0.43	8.04	0.4	1.48e-14	Electrocardiographic conduction measures;
LIHC	cis	rs7534824	0.625	rs6686202	chr1:101493078	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.76	7.05	0.36	1.01e-11	Refractive astigmatism;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.39	-0.37	1.17e-12	Lymphocyte counts;
LIHC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.5	8.31	0.41	2.23e-15	Longevity;Endometriosis;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg09367891	chr1:107599246	PRMT6	0.7	11.72	0.54	6.82e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.38	-6.37	-0.33	5.95e-10	Menopause (age at onset);
LIHC	cis	rs8081395	0.836	rs1295926	chr17:57909373	A/G	cg02344993	chr17:57696989	CLTC	-0.45	-7.38	-0.37	1.25e-12	White blood cell count;
LIHC	cis	rs4906332	0.782	rs12880224	chr14:104006414	C/G	cg04998671	chr14:104000505	TRMT61A	-0.56	-7.15	-0.36	5.42e-12	Coronary artery disease;
LIHC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.76	11.45	0.53	6.36e-26	Coronary artery disease;
LIHC	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.88	-0.3	9.7e-9	Systolic blood pressure;
LIHC	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.58	-7.55	-0.38	4.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg07636037	chr3:49044803	WDR6	-0.62	-6.61	-0.34	1.46e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.91	-15.16	-0.63	4.42e-40	Schizophrenia;
LIHC	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	0.69	7.92	0.39	3.46e-14	Dental caries;
LIHC	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.42	6.27	0.32	1.06e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.72	-11.01	-0.51	2.54e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg18357645	chr12:58087776	OS9	-0.42	-6.25	-0.32	1.25e-9	Multiple sclerosis;
LIHC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.22	-0.36	3.3e-12	Aortic root size;
LIHC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.51	6.24	0.32	1.3e-9	Total body bone mineral density;
LIHC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.88	10.66	0.5	4.25e-23	Prostate cancer;
LIHC	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.29	-6.61	-0.34	1.45e-10	DNA methylation (variation);
LIHC	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg11783602	chr8:55087084	NA	-0.31	-6.2	-0.32	1.66e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.53	8.16	0.4	6.33e-15	Longevity;
LIHC	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.59	8.12	0.4	8.73e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.93	-12.67	-0.57	2.02e-30	Post bronchodilator FEV1;
LIHC	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg12798992	chr6:167411361	FGFR1OP	0.42	6.57	0.33	1.87e-10	Primary biliary cholangitis;
LIHC	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.34	-0.32	7.37e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg00977110	chr5:151150581	G3BP1	0.51	6.34	0.32	7.1e-10	Preschool internalizing problems;
LIHC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.45	-8.06	-0.4	1.29e-14	Prudent dietary pattern;
LIHC	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.82	-11.74	-0.54	5.64e-27	Response to antineoplastic agents;
LIHC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.44	-7.39	-0.37	1.17e-12	Platelet distribution width;
LIHC	cis	rs10838687	0.736	rs16938581	chr11:47271039	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.89	-0.3	9.47e-9	Proinsulin levels;
LIHC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	0.92	6.37	0.33	5.99e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.73	12.13	0.55	2.16e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.32	8.09	0.4	1.04e-14	Schizophrenia;
LIHC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg04155231	chr12:9217510	LOC144571	0.32	6.2	0.32	1.62e-9	Sjögren's syndrome;
LIHC	cis	rs11671005	0.693	rs11668757	chr19:58928299	A/T	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.65e-16	Motion sickness;
LIHC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.99	0.35	1.42e-11	Gut microbiome composition (summer);
LIHC	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg11783602	chr8:55087084	NA	-0.34	-6.57	-0.33	1.92e-10	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.1e-34	Gastritis;
LIHC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.68	10.69	0.5	3.27e-23	Response to diuretic therapy;
LIHC	trans	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg19894588	chr14:64061835	NA	-0.57	-8.11	-0.4	9.21e-15	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.7	-10.37	-0.49	4.24e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2901460	0.509	rs11125898	chr2:62079895	T/C	cg02183531	chr2:62113199	CCT4	-0.4	-5.89	-0.3	9.36e-9	Mean corpuscular volume;
LIHC	trans	rs9834975	0.544	rs9811581	chr3:122280746	A/G	cg18228109	chr6:162684441	PARK2	-0.32	-6.04	-0.31	4.04e-9	Diastolic blood pressure;
LIHC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.78	11.84	0.54	2.36e-27	Dental caries;
LIHC	trans	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg01596870	chr19:55963115	NA	-0.6	-7.15	-0.36	5.16e-12	Obesity-related traits;
LIHC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.4	-6.66	-0.34	1.1e-10	Facial morphology (factor 20);
LIHC	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.56	-6.77	-0.34	5.74e-11	Mosquito bite size;
LIHC	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.32	-6.2	-0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg21573476	chr21:45109991	RRP1B	-0.51	-9.33	-0.45	1.41e-18	Mean corpuscular volume;
LIHC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg03517284	chr6:25882590	NA	-0.38	-5.8	-0.3	1.5e-8	Height;
LIHC	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.59	-8.31	-0.41	2.27e-15	Facial morphology (factor 19);
LIHC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg05555928	chr11:63887634	MACROD1	0.51	6.6	0.34	1.59e-10	Mean platelet volume;
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg24209194	chr3:40518798	ZNF619	0.44	6.35	0.32	6.74e-10	Renal cell carcinoma;
LIHC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.46	0.33	3.67e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-7.46	-0.37	6.99e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.6	-0.34	1.56e-10	Putamen volume;
LIHC	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.38	12.19	0.55	1.26e-28	Uric acid levels;
LIHC	cis	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg18809830	chr7:99032528	PTCD1	-0.86	-6.7	-0.34	8.38e-11	Blood metabolite levels;
LIHC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.0	-0.31	4.97e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.27	7.2	0.36	3.94e-12	Cardiovascular disease risk factors;
LIHC	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg00800038	chr16:89945340	TCF25	-0.57	-8.64	-0.42	2.12e-16	Skin colour saturation;
LIHC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.79	14.76	0.62	1.72e-38	Crohn's disease;
LIHC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.14	0.4	7.27e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.74	0.3	2.14e-8	Alzheimer's disease;
LIHC	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.77	15.04	0.63	1.35e-39	Testicular germ cell tumor;
LIHC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	8.36	0.41	1.58e-15	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs72960926	0.744	rs72950579	chr6:74915560	G/A	cg07247405	chr1:2484626	LOC115110	0.54	6.32	0.32	8.29e-10	Metabolite levels (MHPG);
LIHC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.49	-8.76	-0.43	9.04e-17	Asthma;
LIHC	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.69	-11.84	-0.54	2.54e-27	Pediatric autoimmune diseases;
LIHC	cis	rs4689642	0.709	rs13133665	chr4:7226157	G/A	cg21353189	chr4:7228343	SORCS2	0.37	6.24	0.32	1.29e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.54	-14.63	-0.62	5.45e-38	Alzheimer's disease (late onset);
LIHC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	9.66	0.46	1.13e-19	Hemoglobin concentration;
LIHC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg15691649	chr6:25882328	NA	0.45	6.38	0.33	5.73e-10	Blood metabolite levels;
LIHC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.38	5.97	0.31	5.99e-9	Lewy body disease;
LIHC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.04	-0.31	4.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.74	10.67	0.5	3.8e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg17764715	chr19:33622953	WDR88	0.41	5.83	0.3	1.28e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg02187348	chr16:89574699	SPG7	0.51	7.6	0.38	2.8e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs74233809	1.000	rs17115213	chr10:104681143	A/G	cg03493300	chr10:104813866	CNNM2	0.47	6.07	0.31	3.31e-9	Birth weight;
LIHC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg07451762	chr16:28383216	NA	0.33	6.75	0.34	6.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.41	7.04	0.36	1.09e-11	Hemoglobin concentration;
LIHC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg03970086	chr16:88974840	CBFA2T3	-0.36	-7.27	-0.37	2.51e-12	Social autistic-like traits;
LIHC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.51	7.96	0.4	2.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.51	7.99	0.4	2.14e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.58	8.65	0.42	2.09e-16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LIHC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	trans	rs2073499	0.935	rs2526394	chr3:50189057	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-7.27	-0.37	2.41e-12	Schizophrenia;
LIHC	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg08992911	chr2:238395768	MLPH	0.49	5.98	0.31	5.74e-9	Prostate cancer;
LIHC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.41	0.37	1e-12	Lung cancer;
LIHC	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.38	-8.74	-0.43	1.06e-16	Educational attainment (years of education);
LIHC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.74	11.16	0.52	7.13e-25	Corneal astigmatism;
LIHC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.43	-6.54	-0.33	2.24e-10	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19302970	chr18:9102753	NDUFV2	-0.4	-6.16	-0.32	2e-9	Pancreatic cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22068822	chr5:171682568	UBTD2	-0.45	-6.44	-0.33	4.13e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17074213	chr1:92351695	TGFBR3	0.51	6.58	0.34	1.76e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg11441379	chr12:63026424	NA	0.61	6.22	0.32	1.45e-9	IgG glycosylation;
LIHC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.79	-15.9	-0.65	5.27e-43	Refractive error;
LIHC	cis	rs986417	0.686	rs6573322	chr14:61117882	T/C	cg27398547	chr14:60952738	C14orf39	0.64	6.16	0.32	2.07e-9	Gut microbiota (bacterial taxa);
LIHC	trans	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06710121	chr8:12235606	FAM66A	0.39	6.29	0.32	9.81e-10	Mood instability;
LIHC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.87	-0.35	3.1e-11	Bipolar disorder;
LIHC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.46	7.11	0.36	6.81e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg08668510	chr10:1095578	IDI1	0.67	6.81	0.35	4.33e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7945071	0.507	rs4753891	chr11:110298547	A/G	cg04157658	chr11:110243994	NA	-0.34	-6.3	-0.32	9.37e-10	Cognitive function;
LIHC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg15269541	chr15:43626905	ADAL	-0.3	-5.76	-0.3	1.9e-8	Lung cancer in ever smokers;
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.75	9.29	0.45	1.82e-18	Morning vs. evening chronotype;
LIHC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.69	-6.73	-0.34	7.01e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	6.77	0.34	5.55e-11	Menopause (age at onset);
LIHC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.91	-0.3	8.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.13	9.88	0.47	2.1e-20	Schizophrenia;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg07133347	chr1:107600762	PRMT6	-0.45	-6.85	-0.35	3.55e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9527	0.518	rs12776863	chr10:104641679	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-5.76	-0.3	1.88e-8	Arsenic metabolism;
LIHC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg05590025	chr7:65112418	INTS4L2	-0.66	-7.2	-0.36	3.94e-12	Diabetic kidney disease;
LIHC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-0.97	-22.75	-0.78	1.95e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg13919466	chr1:32135498	COL16A1	-0.34	-6.33	-0.32	7.68e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4934494	0.768	rs72818784	chr10:91549414	A/G	cg19698084	chr10:91461284	KIF20B	-0.47	-5.97	-0.31	5.82e-9	Red blood cell count;
LIHC	cis	rs2274273	1.000	rs57970196	chr14:55600405	C/T	cg01864836	chr14:55583639	NA	-0.36	-6.15	-0.32	2.14e-9	Protein biomarker;
LIHC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.37	-0.49	4.4e-22	Blood metabolite levels;
LIHC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg17724175	chr1:150552817	MCL1	0.41	8.17	0.4	6.08e-15	Melanoma;
LIHC	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.92	-0.35	2.28e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.26	-0.32	1.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.18	-0.32	1.87e-9	Tuberculosis;
LIHC	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.19	-10.09	-0.48	4.01e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs9473924	0.505	rs9473931	chr6:50851411	C/G	cg14470998	chr6:50812995	TFAP2B	0.89	10.6	0.5	6.74e-23	Body mass index;
LIHC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.49	-0.38	5.95e-13	Platelet distribution width;
LIHC	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	0.92	22.66	0.77	4.62e-70	Multiple myeloma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.3.1245645R	chr3:56681254	C3orf63	-0.29	-6.05	-0.31	3.91e-9	Cognitive function;
LIHC	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.36	3.49e-12	Protein C levels;
LIHC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.48	7.81	0.39	6.89e-14	Schizophrenia;
LIHC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.59	-6.86	-0.35	3.28e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.69	0.46	9.12e-20	Corneal astigmatism;
LIHC	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.78	14.69	0.62	3.25e-38	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg25024717	chr12:54324583	NA	-0.28	-5.87	-0.3	1.03e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs6445975	0.715	rs4681836	chr3:58267287	C/T	cg23715586	chr3:58305044	RPP14	-0.37	-6.22	-0.32	1.45e-9	Systemic lupus erythematosus;
LIHC	cis	rs7619427	0.544	rs9848662	chr3:43962778	T/C	cg24966902	chr3:44043705	NA	0.46	7.08	0.36	7.99e-12	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.53	9.57	0.46	2.2e-19	Total cholesterol levels;
LIHC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.48	-7.35	-0.37	1.46e-12	Height;
LIHC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg14222432	chr12:29376421	FAR2	0.34	6.62	0.34	1.35e-10	QT interval;
LIHC	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg02023728	chr11:77925099	USP35	0.34	6.11	0.31	2.67e-9	Alzheimer's disease (survival time);
LIHC	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg10820045	chr2:198174542	NA	0.5	7.59	0.38	3.04e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.27	-6.48	-0.33	3.16e-10	Cutaneous nevi;
LIHC	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.62	9.27	0.45	2.14e-18	Menopause (age at onset);
LIHC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.69	12.59	0.56	4.11e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg21466736	chr12:48725269	NA	-0.7	-10.49	-0.49	1.71e-22	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg18944383	chr4:111397179	ENPEP	0.34	7.99	0.4	2.08e-14	Height;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04282497	chr4:82350883	RASGEF1B	0.45	6.98	0.35	1.51e-11	Bilirubin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04219446	chr17:73629082	RECQL5;LOC643008	0.49	6.65	0.34	1.18e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.62	7.9	0.39	3.77e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.38	-0.37	1.23e-12	Testicular germ cell tumor;
LIHC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg18478394	chr8:109455254	TTC35	0.42	7.21	0.36	3.52e-12	Dupuytren's disease;
LIHC	cis	rs753955	0.567	rs11617286	chr13:24409348	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-7.14	-0.36	5.69e-12	Lung cancer;
LIHC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-7.51	-0.38	5.17e-13	Cognitive test performance;
LIHC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs74233809	1.000	rs12220743	chr10:104851912	C/T	cg03493300	chr10:104813866	CNNM2	0.47	6.32	0.32	8.08e-10	Birth weight;
LIHC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.79	-0.34	5.08e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg01256987	chr12:42539512	GXYLT1	-0.43	-7.15	-0.36	5.19e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg08566640	chr11:64091735	NA	0.68	11.9	0.54	1.49e-27	Height;
LIHC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.69	0.57	1.64e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02985541	chr2:219472218	PLCD4	-0.39	-6.51	-0.33	2.65e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg21467203	chr3:49911342	NA	-0.42	-5.75	-0.3	2.03e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.62	-6.89	-0.35	2.77e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.34	0.32	7.38e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs11673344	0.670	rs35011739	chr19:37434230	A/C	cg27390819	chr19:37464633	NA	-0.49	-5.84	-0.3	1.23e-8	Obesity-related traits;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.7	-10.64	-0.5	4.95e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg25588787	chr5:154027256	NA	0.38	5.9	0.3	8.9e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.53	5.87	0.3	1.04e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs4853036	0.951	rs10496175	chr2:70153848	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.14	-0.32	2.28e-9	Colorectal or endometrial cancer;
LIHC	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.53	8.62	0.42	2.44e-16	Blood protein levels;
LIHC	cis	rs4908768	0.906	rs12145445	chr1:8604370	C/G	cg25722041	chr1:8623473	RERE	0.42	5.91	0.3	8.17e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	6.39	0.33	5.41e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.15	-0.36	5.28e-12	Response to antipsychotic treatment;
LIHC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.97	-7.09	-0.36	7.81e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.79	12.54	0.56	5.98e-30	Corneal astigmatism;
LIHC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.34e-11	Cognitive function;
LIHC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg10360323	chr17:41437877	NA	0.41	6.07	0.31	3.33e-9	Menopause (age at onset);
LIHC	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.38	-6.75	-0.34	6.32e-11	Asthma;
LIHC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.61	9.24	0.45	2.72e-18	Longevity;
LIHC	cis	rs4908768	0.911	rs79769442	chr1:8658477	C/T	cg20416874	chr1:8611966	RERE	0.53	6.77	0.34	5.75e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.75	0.57	1.04e-30	Prudent dietary pattern;
LIHC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.64	8.83	0.43	5.54e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16434002	chr17:42200994	HDAC5	-0.47	-7.14	-0.36	5.61e-12	Total body bone mineral density;
LIHC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.26	0.37	2.59e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.54	8.5	0.42	6.03e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9434723	0.844	rs2239561	chr1:9304205	C/T	cg04199779	chr1:9294473	H6PD	-0.58	-6.67	-0.34	1.02e-10	Height;
LIHC	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.51	8.09	0.4	1.08e-14	Lipoprotein (a) levels;
LIHC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.51	5.72	0.3	2.33e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg25039879	chr17:56429692	SUPT4H1	0.76	8.73	0.43	1.17e-16	Cognitive test performance;
LIHC	cis	rs3015497	0.789	rs923908	chr14:51123595	C/T	cg09863266	chr14:51125203	SAV1	-0.42	-6.87	-0.35	3.11e-11	Mean platelet volume;
LIHC	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.38	-0.33	5.71e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.39	6.34	0.32	7.21e-10	IgG glycosylation;
LIHC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg18887096	chr2:219472410	PLCD4	0.35	6.22	0.32	1.49e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.53	-7.25	-0.37	2.79e-12	Ulcerative colitis;
LIHC	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.47	6.25	0.32	1.24e-9	Glioblastoma;Glioma;
LIHC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-5.72	-0.3	2.28e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.51	8.31	0.41	2.31e-15	Schizophrenia;
LIHC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg08125733	chr17:73851984	WBP2	0.51	8.23	0.41	4.1e-15	White matter hyperintensity burden;
LIHC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg07959070	chr22:50026188	C22orf34	-0.33	-8.37	-0.41	1.47e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg14132834	chr19:41945861	ATP5SL	0.45	6.61	0.34	1.48e-10	Height;
LIHC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.34	0.32	7.45e-10	Tonsillectomy;
LIHC	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.52	-7.48	-0.37	6.53e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg20607798	chr8:58055168	NA	0.64	8.21	0.41	4.61e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.97	16.89	0.67	5.92e-47	Subjective well-being;
LIHC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	trans	rs73245065	0.558	rs68032173	chr10:30911030	C/A	cg21500456	chr14:21190377	NA	0.45	6.23	0.32	1.37e-9	Bone mineral density (femoral neck);
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.24	-0.32	1.27e-9	Total body bone mineral density;
LIHC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.57	-8.5	-0.42	5.75e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04504578	chr17:36831313	C17orf96	0.45	6.05	0.31	3.88e-9	Hepatitis;
LIHC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.34	18.69	0.71	3.43e-54	Gout;
LIHC	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg18898632	chr2:242989856	NA	-0.51	-7.1	-0.36	7.24e-12	Obesity-related traits;
LIHC	cis	rs7534824	0.543	rs61780295	chr1:101400264	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	6.9	0.35	2.61e-11	Refractive astigmatism;
LIHC	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg10820045	chr2:198174542	NA	0.46	6.99	0.35	1.42e-11	Intracranial aneurysm;
LIHC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg11764359	chr7:65958608	NA	0.57	6.0	0.31	4.9e-9	Diabetic kidney disease;
LIHC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.63	-7.84	-0.39	5.83e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.07e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.65	7.05	0.36	1.01e-11	Type 2 diabetes;
LIHC	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg17074339	chr11:11642133	GALNTL4	0.4	6.09	0.31	3.09e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.76	-11.6	-0.53	1.87e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.75	-9.04	-0.44	1.18e-17	Schizophrenia;
LIHC	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.39	-0.33	5.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg21231739	chr4:1642635	FAM53A	-0.37	-5.96	-0.31	6.22e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.55	-0.42	4.19e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.0	-19.45	-0.72	2.83e-57	Exhaled nitric oxide output;
LIHC	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg03934865	chr2:198174659	NA	0.46	6.58	0.34	1.74e-10	Intracranial aneurysm;
LIHC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.75	13.71	0.6	2.07e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-7.4	-0.37	1.09e-12	Post bronchodilator FEV1;
LIHC	cis	rs9322817	0.715	rs6918700	chr6:105244526	A/T	cg02098413	chr6:105308735	HACE1	-0.42	-7.71	-0.38	1.42e-13	Thyroid stimulating hormone;
LIHC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg25902810	chr10:99078978	FRAT1	0.64	9.17	0.44	4.39e-18	Monocyte count;
LIHC	cis	rs1419980	0.730	rs11533525	chr12:7750251	G/A	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.84	0.51	1.02e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-11.54	-0.53	3e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.73	8.05	0.4	1.36e-14	Height;
LIHC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.39	-0.33	5.51e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.14e-14	Mean platelet volume;
LIHC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs7106204	0.609	rs11821417	chr11:24279139	G/T	ch.11.24196551F	chr11:24239977	NA	0.66	5.94	0.31	6.93e-9	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06634786	chr22:41940651	POLR3H	0.57	6.21	0.32	1.57e-9	Vitiligo;
LIHC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.47	7.04	0.36	1.07e-11	Aortic root size;
LIHC	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg03934865	chr2:198174659	NA	0.46	6.66	0.34	1.08e-10	Dermatomyositis;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09429435	chr19:12914994	NA	0.41	6.31	0.32	8.56e-10	Bilirubin levels;
LIHC	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.29	6.19	0.32	1.72e-9	Pulmonary function;
LIHC	trans	rs1624005	0.967	rs1667656	chr14:43392902	G/C	cg11960719	chr5:1510684	LPCAT1	-0.37	-6.5	-0.33	2.81e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LIHC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg16479474	chr6:28041457	NA	0.47	7.15	0.36	5.22e-12	Parkinson's disease;
LIHC	cis	rs716804	0.703	rs11042687	chr11:10265036	G/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.12e-8	Neuroticism;
LIHC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	cis	rs3823572	0.542	rs11773892	chr7:133626334	G/T	cg03336402	chr7:133662267	EXOC4	0.56	6.62	0.34	1.36e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06420487	chr17:61919686	SMARCD2	0.42	5.78	0.3	1.66e-8	Height;
LIHC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg20607798	chr8:58055168	NA	0.48	5.96	0.31	6.18e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.56	-8.53	-0.42	4.8e-16	White matter hyperintensity burden;
LIHC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg21573476	chr21:45109991	RRP1B	0.51	9.11	0.44	7.06e-18	Mean corpuscular volume;
LIHC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.5	-8.32	-0.41	2.08e-15	Longevity;Endometriosis;
LIHC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg00277334	chr10:82204260	NA	-0.55	-6.83	-0.35	3.86e-11	Post bronchodilator FEV1;
LIHC	cis	rs4716602	0.550	rs12672151	chr7:156159053	A/G	cg16983916	chr7:156159713	NA	-0.32	-5.87	-0.3	1.02e-8	Anti-saccade response;
LIHC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.98e-10	Personality dimensions;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg12458913	chr13:53173898	NA	0.51	8.33	0.41	1.92e-15	Lewy body disease;
LIHC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.83	0.39	5.99e-14	Platelet count;
LIHC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.07	-0.31	3.35e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.72	-0.34	7.63e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.88	0.3	9.85e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg06212747	chr3:49208901	KLHDC8B	0.48	6.2	0.32	1.66e-9	Resting heart rate;
LIHC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-12.29	-0.55	5.32e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.24	-0.41	3.62e-15	Chronic sinus infection;
LIHC	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.36	5.97	0.31	5.9e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.56	9.12	0.44	6.64e-18	Body mass index;
LIHC	trans	rs9641123	0.608	rs2528539	chr7:93248951	G/A	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg13629201	chr9:5111420	JAK2	0.41	6.32	0.32	8.08e-10	Alopecia areata;
LIHC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.79	12.54	0.56	6.18e-30	Corneal astigmatism;
LIHC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.54	7.63	0.38	2.33e-13	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg15208524	chr1:10270712	KIF1B	0.37	5.76	0.3	1.86e-8	Hepatocellular carcinoma;
LIHC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg06466757	chr4:1255808	NA	0.34	5.79	0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	8.15	0.4	7e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-6.23	-0.32	1.4e-9	Subjective well-being;
LIHC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.38	-5.76	-0.3	1.9e-8	Menopause (age at onset);
LIHC	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg03037974	chr15:76606532	NA	-0.66	-10.84	-0.51	9.89e-24	Blood metabolite levels;
LIHC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.55	9.15	0.44	5.33e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg06565975	chr8:143823917	SLURP1	0.33	6.14	0.32	2.24e-9	Urinary tract infection frequency;
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.85	0.39	5.46e-14	Height;
LIHC	trans	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg24112000	chr20:60950667	NA	-0.6	-8.97	-0.44	2.05e-17	Colorectal cancer;
LIHC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.55	8.35	0.41	1.73e-15	Longevity;Endometriosis;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23788167	chr9:74979561	ZFAND5	0.5	6.52	0.33	2.47e-10	Lung function (FEV1);
LIHC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg19743168	chr1:23544995	NA	0.34	5.72	0.3	2.33e-8	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04903962	chr12:53615479	RARG	0.53	7.27	0.37	2.41e-12	Lung function (FEV1/FVC);
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg10299061	chr3:53078990	SFMBT1	-0.59	-6.45	-0.33	3.89e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg14515779	chr1:101123966	NA	0.63	12.13	0.55	2.12e-28	Monocyte count;
LIHC	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.48	6.98	0.35	1.57e-11	Dermatomyositis;
LIHC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs6960043	1.000	rs6960043	chr7:15052860	C/T	cg19272540	chr7:15055459	NA	0.21	5.84	0.3	1.22e-8	Type 2 diabetes;
LIHC	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.32	-6.49	-0.33	3.02e-10	Platelet distribution width;
LIHC	cis	rs1144333	0.510	rs1146652	chr1:76273708	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-7.49	-0.38	5.75e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg21724239	chr8:58056113	NA	0.49	6.52	0.33	2.55e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg15691649	chr6:25882328	NA	0.47	6.58	0.34	1.75e-10	Blood metabolite levels;
LIHC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.66	11.61	0.53	1.75e-26	Colorectal cancer;
LIHC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.39	-6.11	-0.31	2.68e-9	Mortality in heart failure;
LIHC	cis	rs6450176	0.564	rs31228	chr5:53325994	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.45	-0.59	2.1e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.36	5.93	0.31	7.45e-9	Platelet distribution width;
LIHC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.32	6.28	0.32	9.99e-10	Monocyte count;
LIHC	cis	rs11098699	0.821	rs11731898	chr4:124220979	C/A	cg09941581	chr4:124220074	SPATA5	0.33	6.64	0.34	1.23e-10	Mosquito bite size;
LIHC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	7.81	0.39	6.85e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg01518246	chr11:63870912	FLRT1;MACROD1	0.45	6.19	0.32	1.7e-9	Mean platelet volume;
LIHC	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.44	8.62	0.42	2.58e-16	Testicular germ cell tumor;
LIHC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg17724175	chr1:150552817	MCL1	-0.34	-6.37	-0.33	6.1e-10	Tonsillectomy;
LIHC	cis	rs12079745	0.793	rs12074492	chr1:169215363	C/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.75	-6.98	-0.35	1.53e-11	QT interval;
LIHC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.34	5.82	0.3	1.39e-8	Body mass index;
LIHC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	5.87	0.3	1.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2.07e-9	Ulcerative colitis;
LIHC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-8.58	-0.42	3.42e-16	Morning vs. evening chronotype;
LIHC	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.47	6.29	0.32	9.64e-10	Cognitive test performance;
LIHC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.4	7.59	0.38	3.01e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	5.98	0.31	5.48e-9	Schizophrenia;
LIHC	cis	rs1982963	0.627	rs8020559	chr14:52490690	T/G	cg10843707	chr14:52510701	NID2	0.37	6.2	0.32	1.67e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.74	-0.81	4.9e-82	Myeloid white cell count;
LIHC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.35	-5.82	-0.3	1.39e-8	IgG glycosylation;
LIHC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.51	7.32	0.37	1.8e-12	Schizophrenia;
LIHC	trans	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg14222432	chr12:29376421	FAR2	0.34	6.69	0.34	9.16e-11	QT interval;
LIHC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.41	6.51	0.33	2.67e-10	Height;
LIHC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.69	-0.5	3.22e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.58	9.54	0.46	2.83e-19	Colorectal cancer;
LIHC	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.17	0.32	1.95e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1432089	0.773	rs62344302	chr4:171785314	C/T	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.64	9.06	0.44	1.05e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.85	-0.3	1.17e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.76	11.03	0.51	2.02e-24	Obesity-related traits;
LIHC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg03037974	chr15:76606532	NA	0.8	16.57	0.67	1.05e-45	Blood metabolite levels;
LIHC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.87	12.39	0.56	2.17e-29	Menarche (age at onset);
LIHC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg06115741	chr20:33292138	TP53INP2	0.49	5.92	0.3	7.78e-9	Protein C levels;
LIHC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.47	10.8	0.5	1.37e-23	Diastolic blood pressure;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05208895	chr7:100276062	GNB2	0.42	6.25	0.32	1.23e-9	Bilirubin levels;
LIHC	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.55	-8.3	-0.41	2.41e-15	Response to antidepressants and depression;
LIHC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg15691649	chr6:25882328	NA	-0.61	-8.18	-0.4	5.76e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.48	8.19	0.41	5.09e-15	Response to temozolomide;
LIHC	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.47	7.36	0.37	1.34e-12	Adiposity;
LIHC	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.56	10.31	0.49	7e-22	Lewy body disease;
LIHC	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.49	7.87	0.39	4.6e-14	Endometrial cancer;
LIHC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg13047869	chr3:10149882	C3orf24	0.5	5.94	0.31	7e-9	Alzheimer's disease;
LIHC	cis	rs4934494	0.768	rs768805	chr10:91455205	C/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.51	-0.33	2.69e-10	Red blood cell count;
LIHC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg19680672	chr10:131412579	MGMT	-0.45	-7.02	-0.35	1.22e-11	Response to temozolomide;
LIHC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	7.66	0.38	1.95e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.57	-8.65	-0.42	2e-16	Menarche (age at onset);
LIHC	trans	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.61	-9.54	-0.46	2.8e-19	Eotaxin levels;
LIHC	cis	rs963731	0.649	rs2060989	chr2:39293530	G/A	cg04010122	chr2:39346883	SOS1	-0.61	-6.06	-0.31	3.69e-9	Corticobasal degeneration;
LIHC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.99	-0.4	2.03e-14	Monocyte percentage of white cells;
LIHC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.67	8.44	0.42	9.11e-16	Gut microbiome composition (summer);
LIHC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg05552183	chr6:42928497	GNMT	0.68	10.09	0.48	3.89e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-12.53	-0.56	6.65e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.78	12.4	0.56	2.1e-29	Colorectal cancer;
LIHC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg08676812	chr11:65308423	LTBP3	0.92	6.44	0.33	4.05e-10	Height;
LIHC	cis	rs1494950	1.000	rs2643083	chr4:14995589	G/T	cg12377275	chr4:15005593	CPEB2	-0.79	-6.68	-0.34	9.6e-11	Political ideology;
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-0.92	-14.65	-0.62	4.62e-38	Longevity;
LIHC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg16586182	chr3:47516702	SCAP	-0.58	-11.33	-0.52	1.75e-25	Colorectal cancer;
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg12903224	chr12:29470962	FAR2	-0.37	-5.93	-0.31	7.47e-9	QT interval;
LIHC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg03929089	chr4:120376271	NA	-0.41	-6.1	-0.31	2.91e-9	HDL cholesterol;
LIHC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg14580859	chr9:123691850	NA	0.39	6.85	0.35	3.45e-11	Rheumatoid arthritis;
LIHC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.57	8.35	0.41	1.73e-15	Emphysema distribution in smoking;
LIHC	cis	rs903552	0.932	rs11858490	chr15:102007443	G/T	cg25677261	chr15:102009856	PCSK6	0.44	6.02	0.31	4.41e-9	Diabetic kidney disease;
LIHC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg05941027	chr17:61774174	LIMD2	0.35	7.37	0.37	1.32e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7923837	0.651	rs3824735	chr10:94354204	T/G	cg25506282	chr10:94462361	NA	0.34	5.84	0.3	1.23e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs1712517	0.771	rs61869827	chr10:105079439	T/C	cg05636881	chr10:105038444	INA	0.48	7.58	0.38	3.19e-13	Migraine;
LIHC	cis	rs8084351	0.599	rs12605603	chr18:50679866	C/G	cg24270629	chr18:50823537	DCC	-0.45	-6.78	-0.34	5.39e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg13409248	chr3:40428643	ENTPD3	0.5	8.3	0.41	2.42e-15	Renal cell carcinoma;
LIHC	trans	rs1347297	0.774	rs9973732	chr2:179281435	A/G	cg14011486	chr1:26737247	LIN28	0.45	7.14	0.36	5.5e-12	Alzheimer disease and age of onset;
LIHC	trans	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg09045935	chr12:6379348	NA	0.8	6.58	0.34	1.8e-10	Blood metabolite levels;
LIHC	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.58	-8.33	-0.41	2.02e-15	Neuroblastoma;
LIHC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-8.94	-0.44	2.48e-17	Vitiligo;
LIHC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.7	-11.01	-0.51	2.49e-24	Coronary artery disease;
LIHC	trans	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg10756647	chr7:56101905	PSPH	0.63	8.66	0.42	1.86e-16	Corneal structure;
LIHC	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.48	7.7	0.38	1.48e-13	Longevity;Endometriosis;
LIHC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.65	-16.58	-0.67	9.67e-46	Breast cancer;
LIHC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.87	13.18	0.58	2.31e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.56	-8.87	-0.43	4.18e-17	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	ch.11.42038R	chr11:967971	AP2A2	0.53	9.72	0.47	7.06e-20	Alzheimer's disease (late onset);
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg15382696	chr6:118971807	C6orf204	-0.59	-6.6	-0.34	1.53e-10	Diastolic blood pressure;
LIHC	cis	rs3740540	0.530	rs2362507	chr10:126290820	A/G	cg04949429	chr10:126290192	LHPP	0.45	7.34	0.37	1.55e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.39	-6.25	-0.32	1.21e-9	Red blood cell count;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs507080	0.961	rs673770	chr11:118550601	T/G	cg04173919	chr11:118528438	PHLDB1	0.31	5.72	0.3	2.38e-8	Serum metabolite levels;
LIHC	cis	rs11663156	1.000	rs10515960	chr18:50913822	C/A	cg24270629	chr18:50823537	DCC	-0.46	-6.1	-0.31	2.89e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.609	rs10450664	chr11:71636655	A/G	cg26138937	chr11:71823887	C11orf51	-1.24	-9.79	-0.47	4.05e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs9918079	0.580	rs13120905	chr4:15612288	A/T	cg21329975	chr4:15471214	CC2D2A	0.41	6.23	0.32	1.38e-9	Obesity-related traits;
LIHC	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg07382826	chr16:28625726	SULT1A1	-0.43	-6.27	-0.32	1.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08280861	chr8:58055591	NA	0.49	6.13	0.31	2.38e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.24	0.32	1.3e-9	Asthma and hay fever;
LIHC	trans	rs7504990	0.802	rs56383134	chr18:50388655	G/A	cg08535148	chr4:26321143	RBPJ	0.52	6.14	0.32	2.26e-9	Gallbladder cancer;
LIHC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.49	-7.3	-0.37	2.08e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4407350	1.000	rs4823331	chr22:44923082	T/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.03	-0.31	4.3e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.54	6.96	0.35	1.77e-11	Economic and political preferences (feminism/equality);
LIHC	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg19676328	chr12:49525230	TUBA1B	-0.38	-6.2	-0.32	1.65e-9	Total cholesterol levels;
LIHC	cis	rs11229555	0.574	rs12272310	chr11:58186462	A/C	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6466055	0.666	rs12671047	chr7:104999535	C/A	cg04380332	chr7:105027541	SRPK2	-0.37	-6.95	-0.35	1.88e-11	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg11062466	chr8:58055876	NA	0.4	5.79	0.3	1.62e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10757852	chr3:141319363	RASA2	0.48	6.6	0.34	1.56e-10	Hepatitis;
LIHC	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg10820045	chr2:198174542	NA	0.47	6.97	0.35	1.6e-11	Dermatomyositis;
LIHC	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.78	12.91	0.57	2.53e-31	Tonsillectomy;
LIHC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.45	-9.22	-0.45	3.03e-18	Immature fraction of reticulocytes;
LIHC	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.39	6.48	0.33	3.28e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg12046867	chr14:103022105	NA	-0.53	-7.82	-0.39	6.55e-14	Platelet count;
LIHC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg14024328	chr4:719362	PCGF3	-0.47	-7.08	-0.36	8.46e-12	White blood cell count;
LIHC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.33	7.42	0.37	9.44e-13	Ulcerative colitis;
LIHC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.07	-0.31	3.46e-9	Total body bone mineral density;
LIHC	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.37	-6.73	-0.34	7.12e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.82	13.03	0.58	8.39e-32	Longevity;
LIHC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	6.49	0.33	3.04e-10	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs12500138	1.000	rs59353629	chr4:166218077	T/A	cg25064052	chr4:166216151	KLHL2	-0.61	-5.77	-0.3	1.8e-8	Cognitive function;
LIHC	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.61	-9.75	-0.47	5.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	8.3	0.41	2.37e-15	IgG glycosylation;
LIHC	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.7	0.38	1.46e-13	Systemic lupus erythematosus;
LIHC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	0.94	12.16	0.55	1.66e-28	Severe influenza A (H1N1) infection;
LIHC	cis	rs11031096	0.678	rs61899666	chr11:4178711	C/A	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-0.56	-6.21	-0.32	1.51e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7192750	0.586	rs7204708	chr16:71986946	C/T	cg06353428	chr16:71660113	MARVELD3	-0.77	-8.3	-0.41	2.43e-15	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.92	6.89	0.35	2.76e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.77	-14.11	-0.61	6.13e-36	Longevity;
LIHC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.35	14.76	0.62	1.75e-38	Eosinophil percentage of granulocytes;
LIHC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14850771	chr21:34775459	IFNGR2	-0.51	-6.14	-0.32	2.28e-9	Systolic blood pressure;
LIHC	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.36	7.98	0.4	2.27e-14	Blood metabolite ratios;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.86	-0.3	1.11e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.4	-5.83	-0.3	1.26e-8	Other erythrocyte phenotypes;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20261243	chr20:44718728	NCOA5	0.44	6.54	0.33	2.27e-10	Pancreatic cancer;
LIHC	cis	rs35883536	1.000	rs871151	chr1:101123737	G/A	cg14515779	chr1:101123966	NA	-0.69	-13.86	-0.6	5.63e-35	Monocyte count;
LIHC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.67	0.42	1.78e-16	Schizophrenia;
LIHC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.53	-6.5	-0.33	2.81e-10	Blood metabolite levels;
LIHC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg15448220	chr1:150897856	SETDB1	0.43	6.77	0.34	5.77e-11	Melanoma;
LIHC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs7534824	0.543	rs6693339	chr1:101424431	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.61	-7.37	-0.37	1.32e-12	Refractive astigmatism;
LIHC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.49	-7.45	-0.37	7.54e-13	Coronary artery disease;
LIHC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.53	-5.92	-0.3	7.85e-9	Menopause (age at onset);
LIHC	cis	rs712039	0.617	rs36081240	chr17:35785054	G/A	cg16670864	chr17:35848621	DUSP14	0.35	5.86	0.3	1.09e-8	Tuberculosis;
LIHC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.65	11.28	0.52	2.57e-25	Menopause (age at onset);
LIHC	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.65	0.56	2.48e-30	Prudent dietary pattern;
LIHC	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.41	-6.11	-0.31	2.71e-9	Educational attainment (college completion);
LIHC	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	9.18	0.44	4.16e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.61	0.34	1.51e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-0.62	-13.62	-0.59	4.95e-34	Obesity-related traits;
LIHC	trans	rs10411161	1.000	rs10402988	chr19:52363104	G/A	cg22319618	chr22:45562946	NUP50	-0.51	-6.83	-0.35	4.01e-11	Breast cancer;
LIHC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-6.92	-0.35	2.26e-11	IgG glycosylation;
LIHC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.94	-0.35	1.95e-11	Schizophrenia;
LIHC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Educational attainment;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg00280220	chr17:61926910	NA	0.41	6.78	0.34	5.24e-11	Prudent dietary pattern;
LIHC	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.7e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.72	-10.68	-0.5	3.68e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	10.54	0.5	1.13e-22	Platelet count;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	0.62	8.75	0.43	9.87e-17	Prudent dietary pattern;
LIHC	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.31	-0.32	8.46e-10	Post bronchodilator FEV1;
LIHC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.71	10.58	0.5	8.11e-23	Aortic root size;
LIHC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.75	13.56	0.59	8.27e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	0.94	17.02	0.68	1.71e-47	Coronary artery disease;
LIHC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.33	-0.74	8.13e-61	Height;
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.94	18.94	0.72	3.34e-55	Height;
LIHC	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.83	17.32	0.68	1.06e-48	Longevity;
LIHC	cis	rs911119	1.000	rs3088162	chr20:23607752	C/A	cg16589663	chr20:23618590	CST3	0.76	7.97	0.4	2.37e-14	Chronic kidney disease;
LIHC	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-6.27	-0.32	1.09e-9	Morning vs. evening chronotype;
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg08469215	chr1:156261351	TMEM79	0.4	6.59	0.34	1.68e-10	Tonsillectomy;
LIHC	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	11.25	0.52	3.35e-25	Coronary artery disease;
LIHC	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	10.83	0.51	1.03e-23	Alzheimer's disease (late onset);
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg02990361	chr1:107599529	PRMT6	0.59	9.58	0.46	2e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.64	10.83	0.51	1.07e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.2	0.32	1.61e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6489882	0.807	rs1859334	chr12:113367332	C/T	cg10175203	chr3:128143634	NA	0.38	6.12	0.31	2.6e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg06360820	chr2:242988706	NA	-0.84	-12.75	-0.57	9.57e-31	Obesity-related traits;
LIHC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg14779329	chr11:130786720	SNX19	0.42	6.38	0.33	5.83e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-1.01	-11.52	-0.53	3.46e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs507080	0.961	rs1784298	chr11:118548665	T/C	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.75	11.81	0.54	3.06e-27	Corneal astigmatism;
LIHC	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-8.36	-0.41	1.57e-15	Extraversion;
LIHC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.58	-8.61	-0.42	2.66e-16	Blood protein levels;
LIHC	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg14593290	chr7:50529359	DDC	-0.36	-6.23	-0.32	1.35e-9	Systemic sclerosis;
LIHC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-7.49	-0.38	5.75e-13	Morning vs. evening chronotype;
LIHC	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.42	8.05	0.4	1.4e-14	Testicular germ cell tumor;
LIHC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.21	-5.86	-0.3	1.07e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.86	-0.35	3.29e-11	Diabetic kidney disease;
LIHC	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.07e-8	Osteoarthritis;
LIHC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.52	6.08	0.31	3.27e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.76	12.99	0.57	1.23e-31	Mean platelet volume;
LIHC	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.43	6.18	0.32	1.82e-9	Pursuit maintenance gain;
LIHC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	1.11	13.68	0.59	2.68e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.48	-8.03	-0.4	1.61e-14	Blood metabolite levels;
LIHC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.95	-0.4	2.69e-14	Migraine;Coronary artery disease;
LIHC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.6	-8.79	-0.43	7.28e-17	Testicular germ cell tumor;
LIHC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	7.32	0.37	1.8e-12	Total body bone mineral density;
LIHC	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg09795085	chr6:101329169	ASCC3	0.53	7.48	0.37	6.49e-13	Neuroticism;
LIHC	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg27433088	chr4:174089019	GALNT7	0.39	7.18	0.36	4.26e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.66	9.17	0.44	4.39e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg05185784	chr16:90016020	DEF8	0.39	6.38	0.33	5.79e-10	Squamous cell carcinoma;
LIHC	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.25	6.14	0.32	2.26e-9	Obesity-related traits;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03181376	chr2:43454447	ZFP36L2;LOC100129726	-0.46	-6.24	-0.32	1.27e-9	Lung cancer in ever smokers;
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.39	-9.76	-0.47	5.32e-20	Longevity;Endometriosis;
LIHC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.81	7.12	0.36	6.54e-12	Arsenic metabolism;
LIHC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.57	8.23	0.41	4.12e-15	Platelet count;
LIHC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.91	13.3	0.58	8.36e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.02e-9	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs10411161	0.702	rs11879336	chr19:52389627	C/T	cg22319618	chr22:45562946	NUP50	-0.64	-8.58	-0.42	3.4e-16	Breast cancer;
LIHC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.67	12.05	0.55	3.99e-28	High light scatter reticulocyte count;
LIHC	cis	rs1664789	0.935	rs1694064	chr5:53279690	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.24	0.41	3.79e-15	Waist circumference adjusted for body mass index;
LIHC	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg00792783	chr2:198669748	PLCL1	0.44	6.41	0.33	4.85e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.45	7.33	0.37	1.64e-12	Corneal astigmatism;
LIHC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg19000871	chr14:103996768	TRMT61A	-0.4	-6.47	-0.33	3.37e-10	Reticulocyte count;
LIHC	cis	rs2274273	1.000	rs11621351	chr14:55616740	C/A	cg01864836	chr14:55583639	NA	-0.36	-6.14	-0.32	2.3e-9	Protein biomarker;
LIHC	trans	rs6489882	0.671	rs7135577	chr12:113358106	A/G	cg10175203	chr3:128143634	NA	0.39	6.4	0.33	5.08e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg04865290	chr3:52927548	TMEM110	-0.51	-5.81	-0.3	1.4e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.9	-0.3	8.53e-9	Tuberculosis;
LIHC	cis	rs12915845	0.545	rs4407042	chr15:89077885	T/A	cg05013243	chr15:89149849	MIR1179	-0.38	-6.79	-0.34	4.95e-11	Menarche (age at onset);
LIHC	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.59	-9.25	-0.45	2.53e-18	Corneal astigmatism;
LIHC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.64	-9.35	-0.45	1.14e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-10.82	-0.51	1.15e-23	Calcium levels;
LIHC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.05	-0.78	1.27e-71	Height;
LIHC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	0.79	5.86	0.3	1.08e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs672413	0.620	rs663646	chr5:78285778	G/A	cg04677158	chr5:78279841	ARSB	0.37	6.24	0.32	1.32e-9	Blood and toenail selenium levels;Blood protein levels;
LIHC	cis	rs507080	0.769	rs2077173	chr11:118492591	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	5.85	0.3	1.16e-8	Serum metabolite levels;
LIHC	cis	rs12464559	0.826	rs78355157	chr2:152632574	C/T	cg01189475	chr2:152685088	ARL5A	-0.71	-6.65	-0.34	1.2e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.62	10.96	0.51	3.57e-24	Testicular germ cell tumor;
LIHC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.78	11.86	0.54	2.06e-27	Response to antineoplastic agents;
LIHC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.2	-0.52	5.26e-25	Primary sclerosing cholangitis;
LIHC	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg04725166	chr1:7887271	PER3	-0.44	-7.82	-0.39	6.81e-14	Crohn's disease;
LIHC	cis	rs4908760	0.539	rs10864367	chr1:8847380	C/T	cg20416874	chr1:8611966	RERE	-0.55	-9.85	-0.47	2.53e-20	Vitiligo;
LIHC	cis	rs903552	0.932	rs11858490	chr15:102007443	G/T	cg06707286	chr15:102010195	PCSK6	0.47	6.77	0.34	5.48e-11	Diabetic kidney disease;
LIHC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.37	-0.33	6.26e-10	Height;
LIHC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	7.91	0.39	3.69e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.99	0.48	9e-21	Lung cancer;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.83	-15.17	-0.63	4.12e-40	Height;
LIHC	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs1403694	0.966	rs1656910	chr3:186438993	A/C	cg12454167	chr3:186435060	KNG1	0.29	7.05	0.36	1e-11	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs12188164	0.840	rs67665078	chr5:428754	G/A	cg19980199	chr5:480033	SLC9A3	0.34	5.76	0.3	1.91e-8	Cystic fibrosis severity;
LIHC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.15	-0.52	8.04e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4728302	0.869	rs7792546	chr7:133595502	G/T	cg10665199	chr7:133106180	EXOC4	0.37	6.53	0.33	2.4e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	10.65	0.5	4.5e-23	Lymphocyte counts;
LIHC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg18867708	chr6:26865862	GUSBL1	-0.5	-7.69	-0.38	1.59e-13	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.63	10.32	0.49	6.43e-22	Menopause (age at onset);
LIHC	cis	rs7212590	0.748	rs8074176	chr17:57861995	G/A	cg10252138	chr17:58120427	NA	-0.58	-5.89	-0.3	9.48e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.57e-21	Bladder cancer;
LIHC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg18016565	chr1:150552671	MCL1	0.56	10.28	0.49	9.21e-22	Melanoma;
LIHC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-21.24	-0.75	1.89e-64	Height;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	11.99	0.54	6.88e-28	Height;
LIHC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.59	10.77	0.5	1.69e-23	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.47	-7.56	-0.38	3.83e-13	Monobrow;
LIHC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.87	13.22	0.58	1.58e-32	Vitamin D levels;
LIHC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	0.85	7.04	0.36	1.09e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs57502260	0.790	rs7129320	chr11:68388220	G/A	cg20283391	chr11:68216788	NA	-0.48	-5.93	-0.31	7.56e-9	Total body bone mineral density (age 45-60);
LIHC	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.57	8.89	0.43	3.63e-17	Corneal astigmatism;
LIHC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.44	-8.01	-0.4	1.79e-14	Prudent dietary pattern;
LIHC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.65	7.82	0.39	6.73e-14	Heart rate;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00436174	chr2:128051630	ERCC3	0.41	6.34	0.32	7.11e-10	Calcium levels;
LIHC	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.48	8.77	0.43	8.45e-17	Hand grip strength;
LIHC	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.75	-0.3	2.03e-8	Response to amphetamines;
LIHC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	13.44	0.59	2.41e-33	Lung cancer in ever smokers;
LIHC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg24130564	chr14:104152367	KLC1	-0.54	-8.68	-0.42	1.66e-16	Reticulocyte count;
LIHC	cis	rs36051895	0.530	rs6476951	chr9:5221614	A/G	cg02405213	chr9:5042618	JAK2	-0.63	-10.05	-0.48	5.48e-21	Pediatric autoimmune diseases;
LIHC	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.85	-0.35	3.49e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.08e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg02269571	chr22:50332266	NA	-0.61	-8.37	-0.41	1.46e-15	Schizophrenia;
LIHC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.44	7.13	0.36	5.9e-12	Total body bone mineral density;
LIHC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.32	-0.32	8.12e-10	Bipolar disorder;
LIHC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.85	-0.39	5.42e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.61	11.07	0.51	1.47e-24	Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.95	0.31	6.66e-9	Renal cell carcinoma;
LIHC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.22	-6.95	-0.35	1.88e-11	Motion sickness;
LIHC	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.27	0.32	1.12e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.98	-17.78	-0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-8.42	-0.41	1.09e-15	Blood metabolite levels;
LIHC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	6.09	0.31	3.1e-9	Coronary artery disease;
LIHC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.79	-0.34	5e-11	Menarche (age at onset);
LIHC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg00204512	chr16:28754710	NA	0.34	6.95	0.35	1.86e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.35	0.32	6.93e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.43	6.12	0.31	2.55e-9	Longevity;Endometriosis;
LIHC	cis	rs611744	1.000	rs611744	chr8:109228008	A/G	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg05590025	chr7:65112418	INTS4L2	0.59	6.51	0.33	2.69e-10	Diabetic kidney disease;
LIHC	cis	rs36051895	0.502	rs12347799	chr9:5215954	G/A	cg02405213	chr9:5042618	JAK2	-0.59	-9.4	-0.45	7.97e-19	Pediatric autoimmune diseases;
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.94	-16.06	-0.66	1.24e-43	Longevity;
LIHC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg02990361	chr1:107599529	PRMT6	-0.6	-9.85	-0.47	2.54e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7534824	0.625	rs61780327	chr1:101449810	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.38	0.37	1.22e-12	Refractive astigmatism;
LIHC	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.74	12.67	0.57	2.06e-30	Menopause (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg09047884	chr22:43484984	TTLL1	-0.39	-6.1	-0.31	2.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg24693881	chr1:107596107	NA	0.54	9.41	0.45	7.51e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg26526709	chr7:35077807	DPY19L1	0.47	6.9	0.35	2.55e-11	Morning vs. evening chronotype;
LIHC	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.52	8.29	0.41	2.55e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27228074	chr10:104678015	CNNM2	0.49	6.11	0.31	2.67e-9	Hepatitis;
LIHC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16405210	chr4:1374714	KIAA1530	0.43	6.37	0.33	6.02e-10	Obesity-related traits;
LIHC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.41	8.42	0.41	1.08e-15	Cardiovascular disease risk factors;
LIHC	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg09795085	chr6:101329169	ASCC3	0.51	7.15	0.36	5.22e-12	Neuroticism;
LIHC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.57	9.3	0.45	1.75e-18	Multiple sclerosis;
LIHC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.25	0.32	1.2e-9	Glycated hemoglobin levels;
LIHC	cis	rs611744	0.967	rs686584	chr8:109192357	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.68	0.42	1.63e-16	Dupuytren's disease;
LIHC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-1.05	-19.89	-0.73	5.05e-59	Migraine;
LIHC	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.41	-6.39	-0.33	5.35e-10	Breast cancer;
LIHC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg20140201	chr2:241835670	C2orf54	-0.46	-6.16	-0.32	2.09e-9	Urinary metabolites;
LIHC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.38	7.87	0.39	4.79e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.49	-5.86	-0.3	1.08e-8	LDL cholesterol to HDL cholesterol ratio;
LIHC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.96	0.31	6.34e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.3	-7.04	-0.36	1.08e-11	Menarche (age at onset);
LIHC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.27e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.67	8.28	0.41	2.86e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.42	-5.97	-0.31	5.8e-9	Longevity;
LIHC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.76	-0.39	9.95e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.52	0.59	1.15e-33	Cognitive test performance;
LIHC	cis	rs1712517	0.873	rs7903004	chr10:105004101	G/A	cg05636881	chr10:105038444	INA	-0.39	-6.14	-0.32	2.27e-9	Migraine;
LIHC	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-14.51	-0.62	1.58e-37	Gut microbiome composition (summer);
LIHC	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.36	7.09	0.36	7.66e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.78	-0.3	1.64e-8	Type 2 diabetes;
LIHC	trans	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg07393940	chr7:158741817	NA	-0.57	-7.02	-0.35	1.21e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.75	12.92	0.57	2.25e-31	Mean platelet volume;
LIHC	cis	rs77637988	0.577	rs6705802	chr2:48603483	A/C	cg00032884	chr2:48540671	FOXN2	0.4	6.17	0.32	1.93e-9	Joint mobility (Beighton score);
LIHC	cis	rs17106184	1.000	rs12078434	chr1:51393645	C/G	cg07174182	chr1:51127561	FAF1	-0.72	-7.98	-0.4	2.29e-14	Type 2 diabetes;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg02990361	chr1:107599529	PRMT6	0.65	10.9	0.51	6.04e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11761441	0.669	rs13241486	chr7:79536	G/C	cg25149888	chr7:81075	NA	0.39	9.23	0.45	2.87e-18	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg12458913	chr13:53173898	NA	0.35	6.01	0.31	4.79e-9	Lewy body disease;
LIHC	cis	rs370915	0.890	rs1425952	chr4:187833545	A/G	cg19519643	chr4:187840862	NA	-0.55	-9.41	-0.45	7.27e-19	Gout;
LIHC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg15123519	chr2:136567270	LCT	0.41	8.58	0.42	3.34e-16	Mosquito bite size;
LIHC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg19635926	chr16:89946313	TCF25	0.46	6.0	0.31	5.11e-9	Skin colour saturation;
LIHC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.98	19.05	0.72	1.11e-55	Intelligence (multi-trait analysis);
LIHC	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.68	8.53	0.42	4.89e-16	Corneal astigmatism;
LIHC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.33	0.41	1.94e-15	Lung cancer in ever smokers;
LIHC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	7.56	0.38	3.86e-13	HDL cholesterol;
LIHC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg18306943	chr3:40428807	ENTPD3	0.34	5.74	0.3	2.07e-8	Renal cell carcinoma;
LIHC	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg25588787	chr5:154027256	NA	0.39	6.03	0.31	4.36e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4700695	0.920	rs251303	chr5:65248753	A/C	cg21114390	chr5:65439923	SFRS12	0.44	5.77	0.3	1.8e-8	Facial morphology (factor 19);
LIHC	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.03	-20.09	-0.74	7.46e-60	Exhaled nitric oxide output;
LIHC	cis	rs16828019	0.640	rs1140227	chr1:41493811	C/T	cg20697417	chr1:41786797	NA	0.31	5.78	0.3	1.71e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-15.89	-0.65	5.96e-43	Refractive error;
LIHC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	0.99	16.1	0.66	8.61e-44	Orofacial clefts;
LIHC	trans	rs13202860	0.730	rs55965170	chr6:87191762	C/A	cg27326224	chr7:950474	ADAP1	-0.57	-6.32	-0.32	8.05e-10	Sexual dysfunction (female);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02992252	chr1:23857546	E2F2	-0.39	-6.28	-0.32	1.03e-9	Pancreatic cancer;
LIHC	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.72	7.17	0.36	4.68e-12	Alzheimer's disease;
LIHC	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.53	0.33	2.42e-10	Lung cancer in ever smokers;
LIHC	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.17	17.26	0.68	1.82e-48	Corneal structure;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	0.59	8.53	0.42	4.8e-16	Prudent dietary pattern;
LIHC	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg17135325	chr3:160939158	NMD3	0.52	7.57	0.38	3.4e-13	Parkinson's disease;
LIHC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.58e-9	Childhood ear infection;
LIHC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg09222892	chr1:25734099	RHCE	-0.47	-8.68	-0.42	1.65e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs12286929	0.637	rs7125361	chr11:115080042	C/G	cg04055981	chr11:115044050	NA	0.36	5.91	0.3	8.48e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.73	0.54	5.99e-27	Coffee consumption (cups per day);
LIHC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.63	9.57	0.46	2.19e-19	Longevity;
LIHC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00152838	chr16:24741724	TNRC6A	0.46	6.18	0.32	1.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02985541	chr2:219472218	PLCD4	-0.42	-6.92	-0.35	2.24e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.32	6.41	0.33	4.95e-10	Renal cell carcinoma;
LIHC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg02462569	chr6:150064036	NUP43	-0.32	-6.9	-0.35	2.52e-11	Lung cancer;
LIHC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-23.04	-0.78	1.44e-71	Height;
LIHC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.48	7.25	0.36	2.8e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.58	9.17	0.44	4.45e-18	Height;
LIHC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.96	22.23	0.77	2.2e-68	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.26	-0.32	1.15e-9	Longevity;
LIHC	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.51	7.26	0.37	2.59e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.35	5.87	0.3	1.06e-8	Type 2 diabetes;
LIHC	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg05262829	chr1:226921576	ITPKB	0.41	7.8	0.39	7.81e-14	Parkinson's disease;
LIHC	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.24	0.55	8.17e-29	Mean platelet volume;
LIHC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.28	0.32	1.03e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-12.04	-0.55	4.49e-28	Plateletcrit;Platelet count;
LIHC	trans	rs2352908	0.786	rs10130392	chr14:49427345	A/G	cg00793774	chr10:104403707	TRIM8	0.5	6.05	0.31	3.84e-9	Social communication problems;
LIHC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	8.36	0.41	1.65e-15	Schizophrenia;
LIHC	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg24220031	chr2:73402428	NA	-0.27	-5.9	-0.3	8.62e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.6	-8.87	-0.43	4.16e-17	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.55	-0.33	2.15e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.69e-29	Prudent dietary pattern;
LIHC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg12140854	chr5:148520817	ABLIM3	-0.52	-5.97	-0.31	5.92e-9	Breast cancer;
LIHC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.35	0.32	6.86e-10	Morning vs. evening chronotype;
LIHC	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.55	-6.84	-0.35	3.57e-11	Opioid sensitivity;
LIHC	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.54	0.46	2.84e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.53	-10.22	-0.48	1.44e-21	Mean corpuscular volume;
LIHC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.53	-7.44	-0.37	8.18e-13	Body mass index;
LIHC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.29	7.05	0.36	1.02e-11	Primary biliary cholangitis;
LIHC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21467203	chr3:49911342	NA	0.51	9.2	0.45	3.72e-18	Body mass index;
LIHC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.74	0.3	2.07e-8	Schizophrenia;
LIHC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.0	-0.35	1.32e-11	Breast cancer;
LIHC	trans	rs73186030	0.920	rs2001548	chr3:122032789	C/T	cg13973942	chr17:977984	ABR	0.47	6.29	0.32	9.96e-10	Serum parathyroid hormone levels;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.57	7.5	0.38	5.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg12661370	chr5:149340060	SLC26A2	0.5	6.08	0.31	3.23e-9	HIV-1 control;
LIHC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.59	8.21	0.41	4.58e-15	Aortic root size;
LIHC	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.81	-0.39	7.25e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.8	-0.3	1.53e-8	Pulse pressure;
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.39	6.12	0.31	2.54e-9	Testicular germ cell tumor;
LIHC	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.43	-6.73	-0.34	7.16e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	trans	rs6489882	0.872	rs7132797	chr12:113375036	A/C	cg10175203	chr3:128143634	NA	0.38	6.17	0.32	1.96e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg04306507	chr14:55594613	LGALS3	0.32	5.97	0.31	5.93e-9	Protein biomarker;
LIHC	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.62	10.01	0.48	7.41e-21	Corneal astigmatism;
LIHC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.42	-6.63	-0.34	1.29e-10	Dental caries;
LIHC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.36	6.14	0.32	2.26e-9	Uric acid levels;
LIHC	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg08126542	chr6:37504118	NA	-0.36	-6.21	-0.32	1.5e-9	Cognitive performance;
LIHC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.6	-0.38	2.8e-13	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.05	0.44	1.07e-17	Coffee consumption (cups per day);
LIHC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.66	12.84	0.57	4.6e-31	Rheumatoid arthritis;
LIHC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.88	-0.3	9.6e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.6	8.78	0.43	7.73e-17	Prudent dietary pattern;
LIHC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.21	0.58	1.82e-32	Psoriasis;
LIHC	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.78	-0.5	1.56e-23	Inflammatory bowel disease;
LIHC	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.25	0.32	1.24e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg07952391	chr2:88470173	THNSL2	0.77	7.14	0.36	5.78e-12	Plasma clusterin levels;
LIHC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.84	14.75	0.62	1.81e-38	Body mass index (adult);
LIHC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.82	8.28	0.41	2.77e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.46	-6.36	-0.33	6.64e-10	Initial pursuit acceleration;
LIHC	trans	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg10756647	chr7:56101905	PSPH	1.1	13.4	0.59	3.3e-33	Diabetic kidney disease;
LIHC	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.23	0.48	1.34e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.89	0.3	9.45e-9	Longevity;
LIHC	cis	rs4407350	0.806	rs5765706	chr22:44909045	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.56	0.33	1.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.43	6.78	0.34	5.3e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.27	-0.52	2.84e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg13409248	chr3:40428643	ENTPD3	0.43	6.87	0.35	3.03e-11	Renal cell carcinoma;
LIHC	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-9.1	-0.44	7.77e-18	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg13175981	chr1:150552382	MCL1	-0.44	-5.99	-0.31	5.37e-9	Tonsillectomy;
LIHC	cis	rs288342	0.832	rs288283	chr2:183642628	C/T	cg02625481	chr2:183667124	NA	-0.29	-5.91	-0.3	8.39e-9	Recurrent major depressive disorder;
LIHC	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.0	15.34	0.64	8.56e-41	Corneal structure;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07677032	chr17:61819896	STRADA	-0.41	-5.93	-0.31	7.46e-9	Prudent dietary pattern;
LIHC	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.52	0.33	2.52e-10	Ileal carcinoids;
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg18470593	chr4:15471377	CC2D2A	0.4	6.06	0.31	3.69e-9	Obesity-related traits;
LIHC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.55	-9.4	-0.45	8.37e-19	Blood metabolite levels;
LIHC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg02290350	chr8:58132656	NA	-0.46	-9.0	-0.44	1.63e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.84	-12.26	-0.55	6.96e-29	Diastolic blood pressure;
LIHC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	1.03	9.61	0.46	1.58e-19	Diabetic retinopathy;
LIHC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.06	0.31	3.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.12	-0.4	8.62e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs4908768	0.501	rs11121199	chr1:8600192	G/A	cg20416874	chr1:8611966	RERE	-0.68	-14.63	-0.62	5.32e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.51	6.7	0.34	8.84e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs864643	0.945	rs583083	chr3:39550445	C/T	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg20651018	chr11:3035856	CARS	-0.38	-6.34	-0.32	7.19e-10	Longevity;
LIHC	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg03934865	chr2:198174659	NA	0.45	6.4	0.33	5.06e-10	Dermatomyositis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07454192	chr8:74888262	TMEM70	0.38	6.34	0.32	7.19e-10	Cognitive function;
LIHC	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.21	-0.41	4.6e-15	Response to antipsychotic treatment;
LIHC	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.6	-10.35	-0.49	5.1e-22	Diisocyanate-induced asthma;
LIHC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	8.52	0.42	5.17e-16	Red cell distribution width;Reticulocyte count;
LIHC	trans	rs1624005	1.000	rs2481764	chr14:43381455	T/A	cg11960719	chr5:1510684	LPCAT1	-0.35	-6.21	-0.32	1.54e-9	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LIHC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg15123519	chr2:136567270	LCT	0.44	9.02	0.44	1.35e-17	Mosquito bite size;
LIHC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.37	6.72	0.34	7.76e-11	Mean corpuscular volume;
LIHC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.64	0.38	2.15e-13	Bipolar disorder;
LIHC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg17724175	chr1:150552817	MCL1	0.38	7.47	0.37	6.67e-13	Melanoma;
LIHC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-15.25	-0.64	2.01e-40	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9834975	0.544	rs9917729	chr3:122285701	A/T	cg18228109	chr6:162684441	PARK2	0.34	6.07	0.31	3.48e-9	Diastolic blood pressure;
LIHC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg19680672	chr10:131412579	MGMT	0.43	6.53	0.33	2.4e-10	Response to temozolomide;
LIHC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.74	-13.18	-0.58	2.24e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.86e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg19318889	chr4:1322082	MAEA	0.47	6.69	0.34	8.94e-11	Obesity-related traits;
LIHC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.93	-17.16	-0.68	4.78e-48	Parkinson's disease;
LIHC	cis	rs12464559	0.579	rs11682909	chr2:152651592	A/G	cg01189475	chr2:152685088	ARL5A	0.64	7.48	0.38	6.16e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.55	-0.5	1.01e-22	Response to antipsychotic treatment;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26246133	chr11:93276703	C11orf75	0.47	6.58	0.34	1.8e-10	Immature fraction of reticulocytes;
LIHC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.91	-16.88	-0.67	6.07e-47	Aortic root size;
LIHC	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.31	-0.37	1.85e-12	Metabolite levels;
LIHC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.26	-0.32	1.16e-9	Lung cancer;
LIHC	cis	rs13161895	1.000	rs1102191	chr5:179416210	C/T	cg06664874	chr5:179499304	RNF130	0.57	7.02	0.35	1.21e-11	LDL cholesterol;
LIHC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.57	8.19	0.41	5.15e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs700651	0.789	rs892514	chr2:198905270	T/C	cg10820045	chr2:198174542	NA	0.44	6.47	0.33	3.38e-10	Intracranial aneurysm;
LIHC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.64	10.12	0.48	3.23e-21	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.52	8.5	0.42	6.06e-16	Corneal astigmatism;
LIHC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.69	-0.38	1.63e-13	Calcium levels;
LIHC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.53	-8.18	-0.4	5.63e-15	High light scatter reticulocyte count;
LIHC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.72	-0.39	1.27e-13	Neuroticism;
LIHC	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg23435118	chr5:141488016	NDFIP1	-0.43	-6.01	-0.31	4.86e-9	Crohn's disease;
LIHC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.83	-6.87	-0.35	3.07e-11	Breast cancer;
LIHC	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.58	10.69	0.5	3.2e-23	Leprosy;
LIHC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.44	5.75	0.3	1.94e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg18375707	chr11:64034959	PLCB3	-0.52	-7.89	-0.39	4.08e-14	Body mass index;
LIHC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.81	-6.56	-0.33	1.99e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.44	-6.08	-0.31	3.29e-9	Initial pursuit acceleration;
LIHC	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-7.62	-0.38	2.56e-13	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.77	-0.34	5.68e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg21724239	chr8:58056113	NA	0.46	6.2	0.32	1.64e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.7	-7.82	-0.39	6.64e-14	Neuroticism;
LIHC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-17.3	-0.68	1.29e-48	Height;
LIHC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg02269571	chr22:50332266	NA	0.59	8.4	0.41	1.23e-15	Schizophrenia;
LIHC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.99	0.51	2.87e-24	Platelet count;
LIHC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.42	-0.56	1.7e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	1.0	11.01	0.51	2.49e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.66	-0.42	1.85e-16	Gut microbiome composition (summer);
LIHC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.26	0.55	6.95e-29	Menopause (age at onset);
LIHC	cis	rs8081395	0.741	rs1292051	chr17:57963923	G/A	cg13753209	chr17:57696993	CLTC	0.38	5.71	0.3	2.43e-8	White blood cell count;
LIHC	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.63	-6.85	-0.35	3.54e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.35	-0.45	1.22e-18	Hemoglobin concentration;
LIHC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.46	0.33	3.6e-10	Morning vs. evening chronotype;
LIHC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	trans	rs465757	1.000	rs465757	chr20:15580283	A/G	cg18760920	chr15:68177265	NA	-0.49	-6.13	-0.31	2.39e-9	Interleukin-10 levels;
LIHC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-6.94	-0.35	1.98e-11	Prostate cancer;
LIHC	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27220681	chr17:685915	RNMTL1;GLOD4	0.51	7.64	0.38	2.16e-13	Lung function (FEV1/FVC);
LIHC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.94	0.31	7.12e-9	Bipolar disorder;
LIHC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.52	5.98	0.31	5.61e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8074751	0.625	rs6504335	chr17:63634508	G/A	cg04531363	chr17:63634484	CCDC46	0.32	5.75	0.3	1.95e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.65	9.39	0.45	8.52e-19	Initial pursuit acceleration;
LIHC	cis	rs10508774	1.000	rs12415588	chr10:32761592	C/A	cg01819863	chr10:32635814	EPC1	0.65	6.08	0.31	3.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.63	0.42	2.42e-16	Birth weight;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	cis	rs4240897	0.935	rs2236055	chr1:12042261	A/G	cg13216073	chr1:12042593	MFN2	0.51	8.27	0.41	2.98e-15	Tuberculosis;
LIHC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg21395723	chr22:39101663	GTPBP1	0.38	6.39	0.33	5.36e-10	Menopause (age at onset);
LIHC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg03987003	chr1:145516092	GNRHR2;PEX11B	-0.49	-6.1	-0.31	2.82e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.11	-0.44	7.04e-18	Exhaled nitric oxide output;
LIHC	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.28	-5.96	-0.31	6.22e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.25	0.55	7.78e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.69	-9.27	-0.45	2.16e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.96	0.4	2.61e-14	Triglyceride levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13552506	chr1:946444	NA	0.43	6.17	0.32	1.97e-9	Longevity;
LIHC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg01320579	chr17:75405842	SEPT9	0.54	7.72	0.39	1.31e-13	Airflow obstruction;
LIHC	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg09467607	chr2:36825704	FEZ2	0.49	7.21	0.36	3.51e-12	Height;
LIHC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.4	6.96	0.35	1.74e-11	Hepatocellular carcinoma;
LIHC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.68	-0.43	1.59e-16	Total cholesterol levels;
LIHC	cis	rs965469	1.000	rs6051808	chr20:3350697	A/T	cg25506879	chr20:3388711	C20orf194	-0.54	-6.51	-0.33	2.65e-10	IFN-related cytopenia;
LIHC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg26939375	chr7:64535504	NA	0.47	7.16	0.36	4.84e-12	Aortic root size;
LIHC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.67	-12.68	-0.57	1.77e-30	Neuroticism;
LIHC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg00529422	chr1:16285251	ZBTB17	0.34	6.49	0.33	3.04e-10	Systolic blood pressure;
LIHC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.65	13.64	0.59	3.82e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	7.9	0.39	3.85e-14	Platelet count;
LIHC	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.48	6.77	0.34	5.62e-11	Endometrial cancer;
LIHC	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.57	6.76	0.34	6.03e-11	Primary sclerosing cholangitis;
LIHC	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.77	11.58	0.53	2.15e-26	Subjective well-being;
LIHC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg05044414	chr3:183734942	ABCC5	0.34	5.99	0.31	5.34e-9	Anterior chamber depth;
LIHC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	13.92	0.6	3.22e-35	Chronic sinus infection;
LIHC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.82	13.59	0.59	5.99e-34	Multiple sclerosis;
LIHC	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.38	-6.72	-0.34	7.74e-11	Schizophrenia;
LIHC	cis	rs7103411	0.592	rs11030087	chr11:27646246	T/C	cg18117895	chr11:27722066	BDNF	-0.46	-6.59	-0.34	1.66e-10	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.62	0.34	1.4e-10	Bipolar disorder;
LIHC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.55	9.15	0.44	5.29e-18	Cognitive function;
LIHC	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.54	8.78	0.43	8.01e-17	Corneal astigmatism;
LIHC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.68	12.97	0.57	1.41e-31	Systemic lupus erythematosus;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10029411	chr13:50746245	FAM10A4	0.37	6.09	0.31	3.05e-9	Pancreatic cancer;
LIHC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg13395646	chr4:1353034	KIAA1530	0.42	6.54	0.33	2.23e-10	Obesity-related traits;
LIHC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.2	0.45	3.58e-18	Eosinophil percentage of white cells;
LIHC	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg10381502	chr11:71823885	C11orf51	-1.07	-9.09	-0.44	8.45e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.4	-8.69	-0.43	1.55e-16	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9899728	0.572	rs4365317	chr17:73059820	C/G	cg27626185	chr17:73056755	KCTD2	-0.66	-11.84	-0.54	2.44e-27	Alzheimer's disease or small vessel stroke;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg14195377	chr11:60928647	VPS37C	-0.4	-6.26	-0.32	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.79	-0.39	8.24e-14	Response to antipsychotic treatment;
LIHC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	10.36	0.49	4.53e-22	Alzheimer's disease;
LIHC	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg15841412	chr13:111365552	ING1	0.5	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg08125733	chr17:73851984	WBP2	0.54	8.41	0.41	1.12e-15	White matter hyperintensity burden;
LIHC	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg17771515	chr6:154831774	CNKSR3	0.59	6.25	0.32	1.19e-9	Lipoprotein (a) levels;
LIHC	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-15.19	-0.63	3.33e-40	Exhaled nitric oxide output;
LIHC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.52	-9.25	-0.45	2.48e-18	Diastolic blood pressure;
LIHC	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.39	-7.15	-0.36	5.27e-12	Height;
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08219700	chr8:58056026	NA	0.52	7.14	0.36	5.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg17135325	chr3:160939158	NMD3	0.56	7.77	0.39	9.21e-14	Parkinson's disease;
LIHC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.34	0.41	1.9e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.48	-5.91	-0.3	8.28e-9	Narcolepsy;
LIHC	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.72	-0.39	1.33e-13	Response to antipsychotic treatment;
LIHC	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg09918751	chr15:100517450	ADAMTS17	0.74	13.39	0.59	3.61e-33	Height;
LIHC	cis	rs28830936	0.934	rs2412641	chr15:42124399	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.09	-0.31	3.05e-9	Diastolic blood pressure;
LIHC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg21395723	chr22:39101663	GTPBP1	0.35	5.74	0.3	2.06e-8	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04650786	chr6:108395545	OSTM1	0.41	6.19	0.32	1.71e-9	Pancreatic cancer;
LIHC	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.51	8.82	0.43	5.97e-17	Coronary artery disease;
LIHC	cis	rs12980942	0.591	rs11879429	chr19:41757444	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.99	0.35	1.47e-11	Coronary artery disease;
LIHC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg14779329	chr11:130786720	SNX19	0.42	6.4	0.33	5.12e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09469394	chr2:61243988	PEX13;PUS10	0.44	6.29	0.32	9.61e-10	Cognitive function;
LIHC	cis	rs8016982	0.589	rs12586249	chr14:81701004	T/C	cg01989461	chr14:81687754	GTF2A1	-0.45	-7.48	-0.38	6.13e-13	Schizophrenia;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.42	6.25	0.32	1.22e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.6	8.81	0.43	6.55e-17	Blood metabolite levels;
LIHC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.49	0.33	2.97e-10	Lung cancer in ever smokers;
LIHC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg07599136	chr5:415885	AHRR	0.39	6.54	0.33	2.21e-10	Cystic fibrosis severity;
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08677398	chr8:58056175	NA	0.4	5.81	0.3	1.39e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.49	-7.4	-0.37	1.04e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg11783602	chr8:55087084	NA	-0.34	-6.57	-0.33	1.92e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs17102884	0.587	rs6574190	chr14:75167015	G/A	cg08847533	chr14:75593920	NEK9	0.43	6.61	0.34	1.44e-10	Neuroticism;
LIHC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.88	11.18	0.52	6.06e-25	Coronary artery disease;
LIHC	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg03934865	chr2:198174659	NA	0.54	8.26	0.41	3.32e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2273156	1.000	rs36112862	chr14:35478433	C/T	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs655641	1.000	rs528109	chr11:85715853	C/T	cg09030501	chr11:85779252	PICALM	-0.49	-6.07	-0.31	3.42e-9	Platelet count;
LIHC	cis	rs4788570	0.615	rs6499526	chr16:71648299	C/T	cg06353428	chr16:71660113	MARVELD3	1.4	13.93	0.6	2.91e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	0.94	19.04	0.72	1.27e-55	Schizophrenia;
LIHC	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.54	8.42	0.41	1.07e-15	Urinary tract infection frequency;
LIHC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.27	0.32	1.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.01	-0.35	1.31e-11	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.56	0.33	2.02e-10	Renal cell carcinoma;
LIHC	cis	rs4908768	0.539	rs922366	chr1:8653733	C/A	cg20416874	chr1:8611966	RERE	-0.62	-11.25	-0.52	3.49e-25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.47	5.75	0.3	1.94e-8	Alzheimer's disease;
LIHC	trans	rs6934970	1.000	rs9384846	chr6:113124583	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-6.09	-0.31	3.1e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.43	6.49	0.33	3.05e-10	Eosinophil percentage of white cells;
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg16509355	chr4:15471240	CC2D2A	0.5	7.82	0.39	6.46e-14	Obesity-related traits;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.36	5.99	0.31	5.44e-9	Height;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.61	8.94	0.44	2.57e-17	Prudent dietary pattern;
LIHC	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	8.79	0.43	7.51e-17	Lung cancer in ever smokers;
LIHC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.44	-0.33	3.98e-10	Personality dimensions;
LIHC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg12365402	chr11:9010492	NRIP3	0.33	8.5	0.42	5.86e-16	Hemoglobin concentration;
LIHC	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.61	-9.92	-0.47	1.51e-20	Resting heart rate;
LIHC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.66	7.88	0.39	4.28e-14	Eosinophilic esophagitis;
LIHC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.59	7.78	0.39	8.4e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.5	-7.91	-0.39	3.52e-14	Educational attainment;
LIHC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.27	-0.37	2.47e-12	Bipolar disorder;
LIHC	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.6	-11.96	-0.54	8.95e-28	Plateletcrit;Platelet count;
LIHC	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.49e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.37	-5.98	-0.31	5.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	1.0	18.93	0.72	3.6e-55	Breast cancer;
LIHC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-8.98	-0.44	1.89e-17	Morning vs. evening chronotype;
LIHC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg19920283	chr7:105172520	RINT1	0.67	6.04	0.31	3.95e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6594499	0.872	rs10059658	chr5:110452815	T/C	cg04022379	chr5:110408740	TSLP	0.49	8.16	0.4	6.26e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04098458	chr2:149402448	EPC2	-0.44	-6.29	-0.32	9.68e-10	Cognitive function;
LIHC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.36	-0.41	1.6e-15	Height;
LIHC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.79	0.3	1.6e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	0.86	8.64	0.42	2.17e-16	Type 2 diabetes nephropathy;
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg08916839	chr5:415575	AHRR	0.29	6.31	0.32	8.64e-10	Cystic fibrosis severity;
LIHC	cis	rs7635838	0.859	rs9869423	chr3:11459156	G/T	cg00170343	chr3:11313890	ATG7	0.44	6.76	0.34	5.97e-11	HDL cholesterol;
LIHC	cis	rs7617773	1.000	rs6442109	chr3:48192981	G/A	cg11946769	chr3:48343235	NME6	-0.65	-8.39	-0.41	1.34e-15	Coronary artery disease;
LIHC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.76	12.8	0.57	6.44e-31	Anterior chamber depth;
LIHC	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-7.51	-0.38	5.23e-13	Metabolite levels;
LIHC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.71	10.46	0.49	2.16e-22	Aortic root size;
LIHC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.34	-7.52	-0.38	4.97e-13	Type 2 diabetes;
LIHC	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.52	-7.08	-0.36	8.23e-12	Schizophrenia;
LIHC	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.84	17.59	0.69	9.04e-50	Longevity;
LIHC	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.44	8.09	0.4	1.03e-14	Platelet distribution width;
LIHC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.11	-0.31	2.7e-9	Tuberculosis;
LIHC	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	6.15	0.32	2.15e-9	Menopause (age at onset);
LIHC	cis	rs965469	0.779	rs2207995	chr20:3294484	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.49	-6.88	-0.35	2.88e-11	High light scatter reticulocyte count;
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.89	-14.62	-0.62	6.33e-38	Longevity;
LIHC	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.63	7.96	0.4	2.64e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg03934865	chr2:198174659	NA	0.54	8.3	0.41	2.38e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-8.51	-0.42	5.43e-16	Vitiligo;
LIHC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.55	-0.5	1.05e-22	Aortic root size;
LIHC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.64	11.08	0.51	1.39e-24	Lewy body disease;
LIHC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg14440974	chr22:39074834	NA	-0.38	-6.2	-0.32	1.62e-9	Menopause (age at onset);
LIHC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.36	5.76	0.3	1.89e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-1.12	-11.04	-0.51	2e-24	Acne (severe);
LIHC	cis	rs9303280	0.967	rs1031458	chr17:38072173	G/T	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.67	-0.34	1.02e-10	Self-reported allergy;
LIHC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	12.97	0.57	1.45e-31	Alzheimer's disease;
LIHC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	6.95	0.35	1.82e-11	Height;
LIHC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.77	11.61	0.53	1.68e-26	Monocyte percentage of white cells;
LIHC	trans	rs2270927	0.510	rs13188781	chr5:75580409	C/A	cg13563193	chr19:33072644	PDCD5	0.97	9.06	0.44	9.9e-18	Mean corpuscular volume;
LIHC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11635401	chr19:17322527	MYO9B	0.45	6.77	0.34	5.48e-11	Longevity;
LIHC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	6.93	0.35	2.16e-11	Renal cell carcinoma;
LIHC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.48	6.88	0.35	2.89e-11	Height;
LIHC	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.87	-12.95	-0.57	1.74e-31	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs2108622	0.727	rs12609468	chr19:15977814	A/G	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.69	11.23	0.52	4.11e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-0.63	-9.32	-0.45	1.46e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7129220	0.588	rs34984386	chr11:10095987	A/C	cg01453529	chr11:10209919	SBF2	-0.39	-6.91	-0.35	2.43e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.56	0.56	5.14e-30	Prudent dietary pattern;
LIHC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.65	11.01	0.51	2.5300000000000002e-24	Menopause (age at onset);
LIHC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.44	6.81	0.35	4.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.44	7.33	0.37	1.66e-12	Crohn's disease;
LIHC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg04455712	chr21:45112962	RRP1B	0.41	6.82	0.35	4.19e-11	Mean corpuscular volume;
LIHC	cis	rs36051895	0.659	rs7862042	chr9:5268139	G/A	cg02405213	chr9:5042618	JAK2	-0.57	-8.79	-0.43	7.22e-17	Pediatric autoimmune diseases;
LIHC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.71	-12.24	-0.55	8.01e-29	Refractive error;
LIHC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg19645103	chr12:69753606	YEATS4	-0.52	-7.84	-0.39	5.89e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17125944	0.506	rs7160285	chr14:53311400	A/C	cg00686598	chr14:53173677	PSMC6	-0.79	-9.37	-0.45	9.77e-19	Alzheimer's disease (late onset);
LIHC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg15269541	chr15:43626905	ADAL	-0.3	-5.91	-0.3	8.21e-9	Lung cancer in ever smokers;
LIHC	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg04610667	chr7:75704037	NA	0.35	6.2	0.32	1.61e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg23730037	chr7:158596552	ESYT2	-0.41	-6.37	-0.33	6.22e-10	Height;
LIHC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.79e-31	Breast cancer;
LIHC	cis	rs4742903	0.935	rs1889284	chr9:106926980	C/T	cg14250997	chr9:106856677	SMC2	0.36	6.14	0.32	2.27e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.69	6.52	0.33	2.57e-10	Schizophrenia;
LIHC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.42	-6.79	-0.34	5e-11	Height;
LIHC	cis	rs57590327	0.527	rs11917558	chr3:81610805	G/A	cg07356753	chr3:81810745	GBE1	-0.56	-8.5	-0.42	5.84e-16	Extraversion;
LIHC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	8.26	0.41	3.33e-15	Menarche (age at onset);
LIHC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.63	8.98	0.44	1.8e-17	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.39	6.2	0.32	1.61e-9	Mortality in heart failure;
LIHC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg10935138	chr17:73851978	WBP2	-0.45	-7.07	-0.36	8.78e-12	White matter hyperintensity burden;
LIHC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.58	-10.29	-0.49	8.43e-22	Platelet distribution width;
LIHC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-9.14	-0.44	5.77e-18	Parkinson's disease;
LIHC	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	10.43	0.49	2.63e-22	Personality dimensions;
LIHC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg07636037	chr3:49044803	WDR6	-0.61	-7.29	-0.37	2.14e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg19894588	chr14:64061835	NA	-0.48	-7.58	-0.38	3.17e-13	Fat distribution (HIV);
LIHC	trans	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg17675199	chr6:35436792	RPL10A	-0.44	-9.11	-0.44	7.26e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg12863693	chr15:85201151	NMB	0.48	6.87	0.35	3.13e-11	Schizophrenia;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04013166	chr16:89971882	TCF25	0.6	7.9	0.39	3.72e-14	Skin colour saturation;
LIHC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.57	0.42	3.51e-16	Motion sickness;
LIHC	cis	rs4700695	1.000	rs4700696	chr5:65412634	G/C	cg21114390	chr5:65439923	SFRS12	-0.47	-6.07	-0.31	3.36e-9	Facial morphology (factor 19);
LIHC	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.85	-0.54	2.23e-27	Coffee consumption (cups per day);
LIHC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.92	0.57	2.25e-31	Mean platelet volume;
LIHC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.48	-0.37	6.34e-13	Chronic sinus infection;
LIHC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.37	6.18	0.32	1.81e-9	Monobrow;
LIHC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.41	6.42	0.33	4.45e-10	Prostate cancer;
LIHC	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-0.51	-6.12	-0.31	2.52e-9	Blood pressure (smoking interaction);
LIHC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.37	-6.58	-0.34	1.76e-10	Immature fraction of reticulocytes;
LIHC	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.58	-7.63	-0.38	2.4e-13	Type 2 diabetes;
LIHC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg15534755	chr11:117069859	TAGLN	-0.39	-6.56	-0.33	1.96e-10	Blood protein levels;
LIHC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg22834771	chr12:69754056	YEATS4	0.39	6.36	0.33	6.48e-10	Blood protein levels;
LIHC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg07424592	chr7:64974309	NA	0.8	9.05	0.44	1.12e-17	Diabetic kidney disease;
LIHC	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.44	-0.37	8.28e-13	Bipolar disorder;
LIHC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.15	-0.32	2.12e-9	Colorectal cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24928681	chr11:74700231	NEU3	0.45	6.16	0.32	2.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg16102536	chr7:156981717	UBE3C	0.36	6.14	0.31	2.34e-9	Body mass index;
LIHC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg00204748	chr12:29376779	FAR2	0.4	7.5	0.38	5.68e-13	QT interval;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12230010	chr10:72163718	EIF4EBP2	0.39	6.09	0.31	3.1e-9	Cognitive function;
LIHC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.43	7.43	0.37	8.54e-13	Mean corpuscular volume;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.5	-8.49	-0.42	6.24e-16	Pubertal anthropometrics;
LIHC	cis	rs965469	0.779	rs2236119	chr20:3303576	G/T	cg25506879	chr20:3388711	C20orf194	-0.5	-6.18	-0.32	1.81e-9	IFN-related cytopenia;
LIHC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24229701	chr12:130821962	PIWIL1	-0.44	-6.77	-0.34	5.55e-11	Menopause (age at onset);
LIHC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	8.89	0.43	3.68e-17	Schizophrenia;
LIHC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg18305652	chr10:134549665	INPP5A	0.4	6.15	0.32	2.22e-9	Primary sclerosing cholangitis;
LIHC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.73	-0.34	7.3e-11	Electroencephalogram traits;
LIHC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg12751644	chr20:60527061	NA	-0.36	-6.08	-0.31	3.3e-9	Body mass index;
LIHC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.84	7.52	0.38	4.8e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.7	-0.38	1.43e-13	Total body bone mineral density;
LIHC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.39	-6.01	-0.31	4.64e-9	Menarche (age at onset);
LIHC	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.49	9.58	0.46	2.09e-19	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.69	6.99	0.35	1.49e-11	Alzheimer's disease;
LIHC	cis	rs244293	0.795	rs12940239	chr17:53068930	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.46	-6.54	-0.33	2.24e-10	Menarche (age at onset);
LIHC	trans	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg01596870	chr19:55963115	NA	-0.65	-9.51	-0.46	3.47e-19	Obesity-related traits;
LIHC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.27	-0.37	2.46e-12	Body mass index;
LIHC	cis	rs2191566	0.960	rs11083733	chr19:44520919	G/C	cg20607764	chr19:44506953	ZNF230	-0.41	-6.7	-0.34	8.82e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.3	-16.62	-0.67	6.84e-46	Diabetic kidney disease;
LIHC	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg10756647	chr7:56101905	PSPH	1.02	12.11	0.55	2.53e-28	Diabetic kidney disease;
LIHC	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.77	13.03	0.58	8.32e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.35	0.8	1.14e-76	Prudent dietary pattern;
LIHC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.46	10.68	0.5	3.48e-23	Iron status biomarkers (transferrin levels);
LIHC	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.04e-13	Vitiligo;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11955762	chr13:111268705	CARKD	0.5	6.34	0.32	7.22e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.53	-8.59	-0.42	3.15e-16	Cocaine dependence;
LIHC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.62	-0.38	2.47e-13	Monocyte percentage of white cells;
LIHC	cis	rs56146971	0.714	rs79810056	chr14:91852929	A/G	cg16433844	chr14:91963127	SMEK1	-0.52	-6.18	-0.32	1.87e-9	Alzheimer disease and age of onset;
LIHC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.7	8.33	0.41	2.02e-15	Morning vs. evening chronotype;
LIHC	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg10820045	chr2:198174542	NA	0.46	6.99	0.35	1.48e-11	Dermatomyositis;
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg19635926	chr16:89946313	TCF25	0.56	7.58	0.38	3.24e-13	Skin colour saturation;
LIHC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.19e-9	Bipolar disorder;
LIHC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.32	-6.06	-0.31	3.66e-9	Body mass index;
LIHC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.23	-0.45	2.94e-18	Diabetic kidney disease;
LIHC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-5.9	-0.3	8.83e-9	Pancreatic cancer;
LIHC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg20283391	chr11:68216788	NA	-0.38	-6.08	-0.31	3.14e-9	Total body bone mineral density;
LIHC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.36	0.45	1.06e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.45	6.57	0.33	1.85e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg07061783	chr6:25882402	NA	0.64	8.22	0.41	4.25e-15	Blood metabolite levels;
LIHC	cis	rs4474465	0.790	rs12363982	chr11:78229167	C/T	cg27205649	chr11:78285834	NARS2	0.38	5.82	0.3	1.32e-8	Alzheimer's disease (survival time);
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.37	7.35	0.37	1.48e-12	Renal cell carcinoma;
LIHC	cis	rs832187	0.704	rs704364	chr3:63874734	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.45	6.29	0.32	9.65e-10	Schizophrenia;
LIHC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.53	0.38	4.52e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	cis	rs6694270	0.529	rs11261065	chr1:19106254	A/C	cg26220594	chr1:19110978	NA	-0.35	-6.0	-0.31	5.15e-9	Drug-induced liver injury (nitrofurantoin);
LIHC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	11.16	0.52	7.19e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.47	-8.12	-0.4	8.73e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.65	0.34	1.15e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.66	10.76	0.5	1.88e-23	Platelet count;
LIHC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.42	0.41	1.07e-15	Motion sickness;
LIHC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.49	8.07	0.4	1.23e-14	Cognitive function;
LIHC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.67	11.86	0.54	2.04e-27	High light scatter reticulocyte count;
LIHC	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.43	-0.33	4.33e-10	Post bronchodilator FEV1;
LIHC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.87	-0.3	1.04e-8	Heart rate;
LIHC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.23	-0.41	3.99e-15	Schizophrenia;
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.61	9.28	0.45	1.97e-18	Longevity;Endometriosis;
LIHC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.9	-0.3	8.7e-9	Aortic root size;
LIHC	cis	rs4716602	0.596	rs10266659	chr7:156159278	A/G	cg16983916	chr7:156159713	NA	-0.32	-5.77	-0.3	1.82e-8	Anti-saccade response;
LIHC	cis	rs5015933	0.902	rs13291306	chr9:128124798	A/T	cg14078157	chr9:128172775	NA	-0.39	-6.51	-0.33	2.7e-10	Body mass index;
LIHC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	cis	rs611744	0.967	rs662714	chr8:109221659	C/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.19e-10	Dupuytren's disease;
LIHC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.52	0.38	4.81e-13	Schizophrenia;
LIHC	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg23978390	chr7:1156363	C7orf50	0.42	6.17	0.32	1.93e-9	Longevity;Endometriosis;
LIHC	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	11.51	0.53	3.93e-26	Post bronchodilator FEV1;
LIHC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.64	-0.42	2.18e-16	Primary biliary cholangitis;
LIHC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.76	11.74	0.54	5.79e-27	Corneal astigmatism;
LIHC	cis	rs2257205	0.667	rs16943200	chr17:56829611	A/G	cg12560992	chr17:57184187	TRIM37	0.71	7.78	0.39	8.76e-14	Pancreatic cancer;
LIHC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.63	11.29	0.52	2.36e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg10587741	chr22:38071170	LGALS1	0.45	8.05	0.4	1.42e-14	Fat distribution (HIV);
LIHC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg11784071	chr10:104629166	AS3MT	-0.35	-5.82	-0.3	1.32e-8	Arsenic metabolism;
LIHC	cis	rs722599	0.501	rs2286912	chr14:75385437	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-7.58	-0.38	3.37e-13	IgG glycosylation;
LIHC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.12	-0.36	6.56e-12	Heart rate;
LIHC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.69	7.28	0.37	2.3e-12	Alzheimer's disease;
LIHC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.77	-11.75	-0.54	5.24e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg14393609	chr7:65229607	NA	-0.37	-5.81	-0.3	1.4e-8	Aortic root size;
LIHC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg12751644	chr20:60527061	NA	-0.36	-6.08	-0.31	3.3e-9	Body mass index;
LIHC	cis	rs8084351	0.577	rs8083719	chr18:50638557	A/G	cg24270629	chr18:50823537	DCC	0.43	6.38	0.33	5.78e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.11e-18	Bipolar disorder;
LIHC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.47	-0.49	1.92e-22	Alzheimer's disease;
LIHC	cis	rs9896052	0.614	rs6501800	chr17:73446891	A/T	cg25649188	chr17:73499917	CASKIN2	-0.45	-6.83	-0.35	3.99e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.53	8.58	0.42	3.26e-16	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg05343316	chr1:45956843	TESK2	0.45	6.42	0.33	4.68e-10	High light scatter reticulocyte count;
LIHC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.44	7.0	0.35	1.38e-11	Breast cancer;
LIHC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.44	-9.89	-0.47	1.8899999999999998e-20	Urinary metabolites;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.55	8.3	0.41	2.42e-15	Longevity;Endometriosis;
LIHC	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg16275483	chr1:110013120	SYPL2	-0.49	-6.05	-0.31	3.85e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg22633049	chr21:46681294	NA	-0.38	-6.41	-0.33	4.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.21	-0.36	3.58e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13409248	chr3:40428643	ENTPD3	0.43	7.08	0.36	8.19e-12	Renal cell carcinoma;
LIHC	cis	rs4903214	0.895	rs10130040	chr14:74713682	A/C	cg11132536	chr14:74711944	VSX2	-0.24	-6.22	-0.32	1.45e-9	Inflammatory bowel disease;
LIHC	cis	rs1023500	1.000	rs7293091	chr22:42341308	A/G	cg04733989	chr22:42467013	NAGA	-0.49	-5.82	-0.3	1.32e-8	Schizophrenia;
LIHC	cis	rs7238033	0.624	rs8090908	chr18:43310187	A/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.46	0.33	3.55e-10	Bladder cancer;
LIHC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg04013166	chr16:89971882	TCF25	0.61	7.97	0.4	2.38e-14	Skin colour saturation;
LIHC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.51	-8.93	-0.43	2.68e-17	Total body bone mineral density;
LIHC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.46	-6.97	-0.35	1.67e-11	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00128877	chr1:47070178	MKNK1	0.4	6.38	0.33	5.71e-10	Cognitive function;
LIHC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.69	-10.04	-0.48	5.77e-21	Mosquito bite size;
LIHC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.15	-0.4	7.09e-15	Chronic sinus infection;
LIHC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02290350	chr8:58132656	NA	0.41	8.59	0.42	3.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7707921	1.000	rs749401	chr5:81561369	T/C	cg15871215	chr5:81402204	ATG10	-0.59	-5.85	-0.3	1.16e-8	Breast cancer;
LIHC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.69	0.34	9.35e-11	Diabetic kidney disease;
LIHC	cis	rs6450176	0.564	rs401449	chr5:53326735	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.41	-0.59	3.03e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg07959070	chr22:50026188	C22orf34	-0.32	-8.39	-0.41	1.3e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg03037974	chr15:76606532	NA	-0.6	-9.92	-0.47	1.52e-20	Blood metabolite levels;
LIHC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.47	-6.79	-0.34	5.07e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg23254163	chr1:152506842	NA	0.22	5.74	0.3	2.06e-8	Hair morphology;
LIHC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.74	5.89	0.3	9.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.63	-6.82	-0.35	4.1e-11	Blood protein levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00259882	chr11:70049130	FADD	0.57	7.59	0.38	3.06e-13	Lung function (FEV1/FVC);
LIHC	cis	rs72945132	0.882	rs59681006	chr11:70179401	T/C	cg00319359	chr11:70116639	PPFIA1	0.63	5.74	0.3	2.1e-8	Coronary artery disease;
LIHC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.65	-11.04	-0.51	1.98e-24	Crohn's disease;
LIHC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.35	7.43	0.37	9e-13	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-6.18	-0.32	1.82e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9980664	1.000	rs9978964	chr21:34736952	T/C	cg04842828	chr21:34696676	IFNAR1	0.46	6.15	0.32	2.21e-9	Cognitive decline (age-related);
LIHC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-12.52	-0.56	7.22e-30	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.27e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.26	0.8	2.39e-76	Prudent dietary pattern;
LIHC	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	6.91	0.35	2.35e-11	Exhaled nitric oxide output;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02576938	chr4:89442616	PIGY	0.37	6.23	0.32	1.36e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.68	-12.67	-0.57	1.96e-30	Refractive error;
LIHC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.39	-6.1	-0.31	2.91e-9	Morning vs. evening chronotype;
LIHC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg02079420	chr8:82753780	SNX16	0.37	6.8	0.34	4.77e-11	Diastolic blood pressure;
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg00656387	chr3:40428638	ENTPD3	-0.49	-8.03	-0.4	1.62e-14	Renal cell carcinoma;
LIHC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	9.23	0.45	2.9e-18	Lung cancer;
LIHC	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.55	7.21	0.36	3.58e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	7.99	0.4	2.16e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.33	6.99	0.35	1.44e-11	Facial morphology (factor 15, philtrum width);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15243024	chr2:27651571	NRBP1	-0.52	-6.41	-0.33	4.94e-10	Systolic blood pressure;
LIHC	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.5	-7.46	-0.37	6.99e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.9	0.3	8.97e-9	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.48	0.46	4.35e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg15605315	chr1:45957053	TESK2	0.44	5.93	0.31	7.27e-9	Platelet count;
LIHC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-0.97	-21.9	-0.76	4.6e-67	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.55	-7.88	-0.39	4.38e-14	Coronary artery disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07590584	chr13:113140145	TUBGCP3	0.39	6.32	0.32	8.19e-10	Longevity;
LIHC	cis	rs61440199	0.818	rs11128940	chr3:20159199	G/A	cg00235661	chr3:20228976	SGOL1	-0.44	-6.25	-0.32	1.2e-9	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	7.55	0.38	3.93e-13	Lymphocyte counts;
LIHC	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg03894339	chr8:19674705	INTS10	0.46	6.91	0.35	2.45e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10924970	0.934	rs2891026	chr1:235429907	A/C	cg26050004	chr1:235667680	B3GALNT2	0.4	5.86	0.3	1.07e-8	Asthma;
LIHC	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.51	-0.33	2.65e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.55	-7.77	-0.39	8.98e-14	Alzheimer's disease;
LIHC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.05	15.08	0.63	9.62e-40	Cognitive function;
LIHC	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16684958	chr7:75615977	POR	0.52	8.57	0.42	3.5e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg17135325	chr3:160939158	NMD3	0.56	8.24	0.41	3.62e-15	Parkinson's disease;
LIHC	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-7.72	-0.39	1.3e-13	Extraversion;
LIHC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	6.01	0.31	4.67e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.87	13.71	0.6	2.19e-34	Gastritis;
LIHC	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.76	0.39	9.61e-14	Corneal astigmatism;
LIHC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.53e-13	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.37	-0.41	1.51e-15	Chronic sinus infection;
LIHC	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.65	12.52	0.56	7.19e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.56	9.42	0.45	6.71e-19	Aortic root size;
LIHC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg25894440	chr7:65020034	NA	0.52	6.02	0.31	4.45e-9	Diabetic kidney disease;
LIHC	cis	rs8027181	0.606	rs12911743	chr15:73104935	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.43	6.56	0.33	1.98e-10	Triglyceride levels;
LIHC	cis	rs11671005	0.735	rs11881000	chr19:58932788	C/T	cg25952890	chr19:58913133	NA	0.67	7.2	0.36	3.89e-12	Mean platelet volume;
LIHC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.4	-0.41	1.21e-15	Cognitive function;
LIHC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-0.98	-9.79	-0.47	4.07e-20	Type 2 diabetes nephropathy;
LIHC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-8.36	-0.41	1.6e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24549020	chr5:56110836	MAP3K1	0.52	6.4	0.33	5.23e-10	Initial pursuit acceleration;
LIHC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg23435118	chr5:141488016	NDFIP1	-0.44	-6.12	-0.31	2.61e-9	Crohn's disease;
LIHC	cis	rs3770081	1.000	rs12621992	chr2:86345349	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-7.9	-0.39	3.9e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.63	12.64	0.56	2.58e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	1.06	14.27	0.61	1.38e-36	Body mass index;
LIHC	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.7	-0.34	8.45e-11	Migraine;Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.47	7.57	0.38	3.52e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.56	-10.3	-0.49	7.31e-22	Total body bone mineral density;
LIHC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-0.98	-22.24	-0.77	2.11e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-0.48	-6.35	-0.32	7e-10	Lung cancer;
LIHC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.64	-9.18	-0.44	4.09e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9503598	0.502	rs4959833	chr6:3435114	T/A	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.89	-0.3	9.42e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.75	15.06	0.63	1.09e-39	Menopause (age at onset);
LIHC	cis	rs8083850	0.603	rs11665094	chr18:50852319	A/G	cg24270629	chr18:50823537	DCC	0.53	7.97	0.4	2.39e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg19680485	chr15:31195859	MTMR15	-0.5	-5.79	-0.3	1.61e-8	Hypertriglyceridemia;
LIHC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.55	9.87	0.47	2.17e-20	Height;
LIHC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.74	12.47	0.56	1.14e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.82	15.96	0.65	3.14e-43	Response to diuretic therapy;
LIHC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg03859395	chr2:55845619	SMEK2	0.92	16.37	0.66	6.68e-45	Metabolic syndrome;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24504843	chr4:56896641	CEP135	0.47	7.08	0.36	8.48e-12	Longevity;
LIHC	cis	rs2637030	0.586	rs12521381	chr5:52846195	C/T	cg06476337	chr5:52856530	NDUFS4	0.38	6.31	0.32	8.8e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.48	-0.56	9.93e-30	Colorectal cancer;
LIHC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg06238570	chr21:40685208	BRWD1	0.56	6.79	0.34	4.99e-11	Cognitive function;
LIHC	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	7.47	0.37	6.75e-13	Systemic lupus erythematosus;
LIHC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg11342453	chr6:26196699	NA	0.52	5.8	0.3	1.55e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.67	11.75	0.54	5.21e-27	Menopause (age at onset);
LIHC	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.96	10.38	0.49	4.04e-22	Breast cancer;
LIHC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.66	13.06	0.58	6.68e-32	Schizophrenia;
LIHC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg26831259	chr4:1366826	KIAA1530	-0.37	-5.84	-0.3	1.22e-8	Longevity;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06656553	chr16:89960601	TCF25	-0.46	-5.86	-0.3	1.08e-8	Skin colour saturation;
LIHC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.21	0.32	1.55e-9	Heart rate;
LIHC	cis	rs12744310	0.887	rs12026404	chr1:41801912	C/A	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.93	0.35	2.04e-11	Personality dimensions;
LIHC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.42	-9.42	-0.45	7.17e-19	Arsenic metabolism;
LIHC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg07661805	chr8:143867942	LY6D	-0.27	-5.91	-0.3	8.48e-9	Urinary tract infection frequency;
LIHC	cis	rs12286929	0.839	rs12790574	chr11:115009145	C/T	cg04055981	chr11:115044050	NA	0.4	5.84	0.3	1.19e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.6	5.79	0.3	1.58e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg25344623	chr2:136566232	LCT	-0.38	-6.18	-0.32	1.78e-9	Corneal structure;
LIHC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.65	12.6	0.56	3.75e-30	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	1.02	12.21	0.55	1.02e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	trans	rs7668874	0.779	rs7698241	chr4:116805566	C/T	cg08917878	chr5:172668965	NA	-0.31	-6.07	-0.31	3.45e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.81	-0.3	1.39e-8	Urinary tract infection frequency;
LIHC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.63	6.9	0.35	2.49e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.76	-10.83	-0.51	1.08e-23	Colorectal cancer;
LIHC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.66	0.59	3.34e-34	Lung cancer in ever smokers;
LIHC	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.3	-6.84	-0.35	3.59e-11	Hip circumference;Waist circumference;
LIHC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.43	-7.01	-0.35	1.29e-11	Menarche (age at onset);
LIHC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.67	-11.26	-0.52	3.03e-25	Breast cancer;
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg10802521	chr3:52805072	NEK4	-0.37	-5.96	-0.31	6.25e-9	Bipolar disorder;
LIHC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.94	15.5	0.64	1.98e-41	Metabolic syndrome;
LIHC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.44	6.19	0.32	1.68e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2953174	0.507	rs4234123	chr2:241541640	C/T	cg07929629	chr2:241523174	NA	0.6	8.23	0.41	3.9e-15	Bipolar disorder;
LIHC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.43	5.99	0.31	5.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.82	0.39	6.61e-14	Height;
LIHC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.91	16.88	0.67	6.34e-47	Menopause (age at onset);
LIHC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.31e-20	Menopause (age at onset);
LIHC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	0.84	11.66	0.53	1.09e-26	Skin colour saturation;
LIHC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.32e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg15691649	chr6:25882328	NA	-0.63	-8.08	-0.4	1.13e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg03647239	chr10:116582469	FAM160B1	0.46	6.75	0.34	6.19e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg13753209	chr17:57696993	CLTC	0.76	12.01	0.54	5.85e-28	Hemoglobin concentration;
LIHC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg26831259	chr4:1366826	KIAA1530	-0.35	-5.84	-0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg04725166	chr1:7887271	PER3	-0.4	-7.05	-0.36	9.69e-12	Crohn's disease;
LIHC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.89	0.3	9.25e-9	Bipolar disorder;
LIHC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.64	-11.4	-0.52	9.9e-26	Dental caries;
LIHC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.45	-5.9	-0.3	8.54e-9	Menarche (age at onset);
LIHC	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.57	7.81	0.39	7.31e-14	Eotaxin levels;
LIHC	cis	rs9596863	0.898	rs68039282	chr13:54389435	C/A	ch.13.53330881F	chr13:54432880	NA	0.43	5.73	0.3	2.21e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.67	-9.44	-0.45	5.94e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.54	9.77	0.47	4.95e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg21466736	chr12:48725269	NA	0.34	6.0	0.31	5.02e-9	Plateletcrit;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.62	9.57	0.46	2.26e-19	Longevity;Endometriosis;
LIHC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.48	-6.94	-0.35	1.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.59	0.5	7.41e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.52	-9.16	-0.44	4.85e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs5753037	0.653	rs131277	chr22:30154101	C/A	cg01021169	chr22:30184971	ASCC2	-0.31	-5.76	-0.3	1.91e-8	Type 1 diabetes;
LIHC	cis	rs8083850	0.635	rs1367634	chr18:50864668	T/G	cg24270629	chr18:50823537	DCC	0.53	8.05	0.4	1.42e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.52	0.38	4.8e-13	Menarche (age at onset);
LIHC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	8.17	0.4	6.2e-15	Schizophrenia;
LIHC	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.63	-5.88	-0.3	9.6e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.49	9.35	0.45	1.21e-18	Testicular germ cell tumor;
LIHC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg03037974	chr15:76606532	NA	0.79	16.11	0.66	7.57e-44	Blood metabolite levels;
LIHC	cis	rs7129220	0.588	rs7938534	chr11:10105925	G/T	cg01453529	chr11:10209919	SBF2	-0.4	-6.97	-0.35	1.64e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	1.01	19.28	0.72	1.38e-56	Breast cancer;
LIHC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.6	-8.5	-0.42	6.02e-16	Blood pressure (smoking interaction);
LIHC	cis	rs11098699	0.821	rs11735364	chr4:124185679	T/C	cg09941581	chr4:124220074	SPATA5	0.31	6.16	0.32	2.01e-9	Mosquito bite size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03385846	chr16:77756558	NUDT7	0.44	6.1	0.31	2.91e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.56	-0.38	3.81e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.48	0.56	9.98e-30	Total body bone mineral density;
LIHC	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17507749	chr15:85114479	UBE2QP1	0.63	7.3	0.37	2e-12	Schizophrenia;
LIHC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg17135325	chr3:160939158	NMD3	0.59	8.4	0.41	1.18e-15	Parkinson's disease;
LIHC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.51	-8.56	-0.42	3.86e-16	Height;
LIHC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.42	-6.28	-0.32	1.02e-9	Cognitive function;
LIHC	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.32	7.29	0.37	2.14e-12	Blood metabolite ratios;
LIHC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.51	7.66	0.38	1.93e-13	High light scatter reticulocyte count;
LIHC	trans	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs4407350	0.870	rs4823327	chr22:44908708	T/C	cg04154583	chr22:44889756	LDOC1L	0.3	6.0	0.31	4.95e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Vitiligo;
LIHC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.77	0.3	1.82e-8	Menopause (age at onset);
LIHC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.91	0.35	2.41e-11	Lung cancer in ever smokers;
LIHC	cis	rs11966931	0.711	rs4945790	chr6:108109985	C/T	cg04749840	chr6:108095067	SCML4	-0.32	-5.75	-0.3	2.03e-8	Neutrophil percentage of white cells;
LIHC	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.72	-8.86	-0.43	4.33e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg03934865	chr2:198174659	NA	-0.57	-9.2	-0.45	3.7e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.72	-0.43	1.26e-16	Gut microbiome composition (summer);
LIHC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	0.81	11.24	0.52	3.56e-25	Skin colour saturation;
LIHC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.49	7.76	0.39	9.95e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2901460	0.509	rs56944298	chr2:62090001	A/G	cg02183531	chr2:62113199	CCT4	-0.4	-5.88	-0.3	1e-8	Mean corpuscular volume;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18713687	chr3:195489789	MUC4	0.67	10.26	0.49	1.02e-21	Lung disease severity in cystic fibrosis;
LIHC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.3	0.32	8.9e-10	Rheumatoid arthritis;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.68	12.98	0.57	1.38e-31	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.49	9.19	0.44	3.94e-18	Hemoglobin concentration;
LIHC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.16	0.36	5.07e-12	Electroencephalogram traits;
LIHC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Amyotrophic lateral sclerosis (age of onset);
LIHC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.59	7.58	0.38	3.25e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.71	-12.56	-0.56	5.15e-30	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg08847533	chr14:75593920	NEK9	-0.39	-6.55	-0.33	2.07e-10	Caffeine consumption;
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg16822855	chr3:40428330	ENTPD3	-0.31	-5.76	-0.3	1.87e-8	Renal cell carcinoma;
LIHC	cis	rs16958440	1.000	rs16958701	chr18:44655241	T/C	cg17192377	chr18:44677553	HDHD2	0.6	6.74	0.34	6.88e-11	Sitting height ratio;
LIHC	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg03146154	chr1:46216737	IPP	-0.39	-6.51	-0.33	2.69e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.73	-0.39	1.19e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	0.67	6.67	0.34	1.03e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-9.47	-0.46	4.73e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.33	0.58	6.41e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.62	0.34	1.43e-10	Renal cell carcinoma;
LIHC	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg03934865	chr2:198174659	NA	-0.56	-8.75	-0.43	9.76e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-7.97	-0.4	2.34e-14	Neuroticism;
LIHC	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.3	-6.42	-0.33	4.43e-10	Weight;
LIHC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.42	-6.04	-0.31	4.01e-9	Height;
LIHC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.59	9.11	0.44	7.08e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg15123519	chr2:136567270	LCT	-0.38	-5.84	-0.3	1.23e-8	Corneal structure;
LIHC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.68e-9	Life satisfaction;
LIHC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-8.39	-0.41	1.25e-15	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.4	-0.56	2.03e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.46	6.21	0.32	1.55e-9	Major depressive disorder;
LIHC	cis	rs3853824	1.000	rs6503765	chr17:54880572	C/T	cg13675837	chr17:54910204	DGKE	0.39	5.91	0.3	8.15e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	6.74	0.34	6.92e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg26338869	chr17:61819248	STRADA	0.53	7.18	0.36	4.41e-12	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.43	6.22	0.32	1.42e-9	Pancreatic cancer;
LIHC	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-15.98	-0.65	2.44e-43	Ulcerative colitis;
LIHC	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.71	10.43	0.49	2.77e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.51	8.7	0.43	1.42e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg20415828	chr12:123011764	RSRC2;KNTC1	-0.43	-6.52	-0.33	2.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6516091	0.778	rs62199231	chr20:6050133	C/T	cg25325723	chr20:6104886	FERMT1	-0.71	-5.88	-0.3	9.8e-9	Abdominal aortic aneurysm;
LIHC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg06466757	chr4:1255808	NA	0.34	5.82	0.3	1.32e-8	Obesity-related traits;
LIHC	cis	rs4907240	0.925	rs11164109	chr2:97300833	T/A	cg26665480	chr2:98280029	ACTR1B	-0.41	-6.02	-0.31	4.39e-9	Event-related brain oscillations;
LIHC	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg04374321	chr14:90722782	PSMC1	0.49	7.09	0.36	7.5e-12	Longevity;
LIHC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.53	-6.05	-0.31	3.8e-9	Corneal curvature;
LIHC	trans	rs1997066	0.920	rs11812127	chr10:106722433	T/C	cg21239439	chr6:170038665	WDR27	0.67	6.08	0.31	3.23e-9	Diabetic kidney disease;
LIHC	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.68	0.38	1.7e-13	Corneal astigmatism;
LIHC	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg23587288	chr2:27483067	SLC30A3	-0.33	-6.02	-0.31	4.49e-9	Blood metabolite levels;
LIHC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.42	-5.88	-0.3	9.59e-9	Height;
LIHC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.02e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.4	6.02	0.31	4.46e-9	Gout;
LIHC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.09	-0.36	7.81e-12	Vitiligo;
LIHC	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.69	-10.68	-0.5	3.52e-23	Urate levels in obese individuals;
LIHC	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.13	0.31	2.45e-9	Myopia (pathological);
LIHC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.24	6.19	0.32	1.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.22	-5.84	-0.3	1.21e-8	Hepatitis;
LIHC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.62	-11.86	-0.54	2.15e-27	Age at first birth;
LIHC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.32	-6.49	-0.33	3.02e-10	Platelet distribution width;
LIHC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.8	-10.64	-0.5	5.02e-23	Systemic lupus erythematosus;
LIHC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.38	-6.73	-0.34	7.21e-11	Aortic root size;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg03874509	chr1:107600012	PRMT6	-0.69	-10.64	-0.5	5.04e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.39	-6.54	-0.33	2.29e-10	Menopause (age at onset);
LIHC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.98	0.44	1.87e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg03146154	chr1:46216737	IPP	0.49	8.35	0.41	1.74e-15	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.55	9.64	0.46	1.26e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg14709524	chr16:89940631	TCF25	0.47	5.79	0.3	1.58e-8	Skin colour saturation;
LIHC	trans	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg17675199	chr6:35436792	RPL10A	-0.45	-9.16	-0.44	4.71e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg10381502	chr11:71823885	C11orf51	1.02	8.51	0.42	5.38e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs526821	0.553	rs295597	chr11:55470003	T/C	cg04317927	chr11:55418816	OR4S2	0.44	8.17	0.4	5.93e-15	Pediatric bone mineral density (spine);
LIHC	cis	rs4908768	0.911	rs12567592	chr1:8788907	C/T	cg20416874	chr1:8611966	RERE	0.52	7.59	0.38	3.01e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.41	5.92	0.31	7.62e-9	Height;
LIHC	cis	rs507080	0.663	rs523793	chr11:118570697	C/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-1.09	-10.06	-0.48	4.85e-21	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17427198	chr6:52529191	LOC730101	0.44	6.25	0.32	1.19e-9	Cognitive function;
LIHC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13395646	chr4:1353034	KIAA1530	0.63	9.11	0.44	7.15e-18	Obesity-related traits;
LIHC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.5	7.8	0.39	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8084351	0.577	rs9949889	chr18:50608436	A/G	cg24270629	chr18:50823537	DCC	-0.46	-7.04	-0.36	1.03e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.22	0.32	1.42e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.6	8.6	0.42	2.95e-16	Coronary artery disease;
LIHC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.91	-0.3	8.13e-9	IgG glycosylation;
LIHC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	13.15	0.58	3.07e-32	Lung cancer in ever smokers;
LIHC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg23791538	chr6:167370224	RNASET2	-0.51	-7.81	-0.39	6.86e-14	Crohn's disease;
LIHC	cis	rs9649465	1.000	rs1468656	chr7:123375505	G/C	cg03229431	chr7:123269106	ASB15	-0.37	-7.99	-0.4	2.03e-14	Migraine;
LIHC	cis	rs16958440	0.867	rs114475395	chr18:44691010	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs12286929	0.590	rs4936322	chr11:115061533	T/C	cg04055981	chr11:115044050	NA	0.39	6.46	0.33	3.56e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.53	7.93	0.39	3.05e-14	High light scatter reticulocyte count;
LIHC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.41	-7.27	-0.37	2.47e-12	Coronary artery disease;
LIHC	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg23352942	chr3:46931381	PTH1R	-0.29	-7.32	-0.37	1.84e-12	Birth weight;
LIHC	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.8	11.31	0.52	2.12e-25	Pediatric areal bone mineral density (radius);
LIHC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.85	15.59	0.64	8.92e-42	Multiple myeloma (IgH translocation);
LIHC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.71	0.3	2.45e-8	Schizophrenia;
LIHC	cis	rs16958440	0.867	rs80064497	chr18:44669653	A/G	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.78	-14.98	-0.63	2.41e-39	Mortality in heart failure;
LIHC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.42	6.81	0.35	4.49e-11	Red blood cell count;
LIHC	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.23	-0.32	1.41e-9	Metabolite levels;
LIHC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.59	-0.5	7.71e-23	Total cholesterol levels;
LIHC	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-0.76	-8.61	-0.42	2.66e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.54	7.74	0.39	1.16e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg16736954	chr20:23401023	NAPB	0.68	8.16	0.4	6.32e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	10.96	0.51	3.65e-24	Type 2 diabetes;
LIHC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.79	6.39	0.33	5.48e-10	Body mass index;
LIHC	cis	rs17428076	0.874	rs72885532	chr2:172684033	A/G	cg13550731	chr2:172543902	DYNC1I2	0.38	6.21	0.32	1.54e-9	Myopia;
LIHC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.79	11.27	0.52	2.85e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg10820045	chr2:198174542	NA	-0.47	-7.02	-0.36	1.17e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.41	-6.65	-0.34	1.13e-10	Menarche (age at onset);
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.49	6.55	0.33	2.1e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11003009	chr5:74632112	HMGCR	0.4	6.58	0.34	1.77e-10	Cognitive function;
LIHC	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.18	-0.4	5.53e-15	Colorectal cancer;
LIHC	cis	rs7395581	0.959	rs901746	chr11:47260319	A/G	cg25783544	chr11:47291846	MADD	0.43	6.21	0.32	1.52e-9	HDL cholesterol;
LIHC	cis	rs2806561	0.780	rs12751560	chr1:23407081	C/A	cg19743168	chr1:23544995	NA	-0.35	-6.28	-0.32	1.02e-9	Height;
LIHC	cis	rs4891159	0.790	rs690619	chr18:74108744	A/G	cg24786174	chr18:74118243	ZNF516	0.78	13.89	0.6	4.12e-35	Longevity;
LIHC	cis	rs970821	0.645	rs6470180	chr8:124751584	T/G	cg00283535	chr8:124749564	ANXA13	-0.42	-7.44	-0.37	8.14e-13	Breast cancer;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.48	-0.33	3.13e-10	Renal cell carcinoma;
LIHC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00287636	chr16:49892218	NA	0.42	6.19	0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.8e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2257205	0.667	rs75982345	chr17:56708836	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.24	-0.32	1.31e-9	Pancreatic cancer;
LIHC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.37	6.61	0.34	1.46e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.51	6.68	0.34	9.85e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12463550	chr7:65579703	CRCP	0.67	6.86	0.35	3.29e-11	Diabetic kidney disease;
LIHC	trans	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg14791747	chr16:20752902	THUMPD1	-0.49	-6.88	-0.35	2.94e-11	Dental caries;
LIHC	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.34	0.37	1.56e-12	Nonalcoholic fatty liver disease;
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27189623	chr16:705930	WDR90	0.42	6.91	0.35	2.43e-11	Height;
LIHC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg07636037	chr3:49044803	WDR6	-0.82	-8.32	-0.41	2.09e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.57	8.51	0.42	5.56e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22994272	chr14:104346241	NA	0.46	7.1	0.36	7.08e-12	Pancreatic cancer;
LIHC	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg23682824	chr7:23144976	KLHL7	0.42	6.23	0.32	1.37e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.48	-0.33	3.22e-10	Mood instability;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.49	7.65	0.38	2.01e-13	Testicular germ cell tumor;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg13395646	chr4:1353034	KIAA1530	0.41	5.8	0.3	1.51e-8	Longevity;
LIHC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	8.98	0.44	1.78e-17	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.29	-6.7	-0.34	8.84e-11	Crohn's disease;
LIHC	cis	rs1712517	0.740	rs4293062	chr10:105052624	G/A	cg05636881	chr10:105038444	INA	0.46	7.01	0.35	1.31e-11	Migraine;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08127460	chr7:156931776	UBE3C	-0.4	-6.08	-0.31	3.17e-9	Calcium levels;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg13152130	chr6:118910203	C6orf204	0.62	6.84	0.35	3.7e-11	Diastolic blood pressure;
LIHC	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.45	7.39	0.37	1.14e-12	Educational attainment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26316544	chr3:52188418	WDR51A	0.42	6.29	0.32	9.7e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg20129853	chr10:51489980	NA	-0.4	-8.6	-0.42	2.94e-16	Prostate-specific antigen levels;
LIHC	cis	rs2073300	1.000	rs6048825	chr20:23457671	T/C	cg12062639	chr20:23401060	NAPB	0.78	9.7	0.46	8.37e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg08824895	chr13:115047677	UPF3A	0.48	6.86	0.35	3.32e-11	Schizophrenia;
LIHC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.54	-8.6	-0.42	2.88e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.35	-7.57	-0.38	3.48e-13	Longevity;
LIHC	cis	rs3106136	0.678	rs7674215	chr4:95294145	C/A	cg11021082	chr4:95130006	SMARCAD1	0.34	5.9	0.3	8.94e-9	Capecitabine sensitivity;
LIHC	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.66	-6.31	-0.32	8.45e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.46	-7.22	-0.36	3.29e-12	Type 2 diabetes;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27543739	chr10:94334014	IDE	0.51	6.67	0.34	1.06e-10	Hepatitis;
LIHC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.79	-10.09	-0.48	4e-21	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg01191815	chr15:63084959	TLN2	-0.46	-6.66	-0.34	1.08e-10	Alcohol dependence;
LIHC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg14671364	chr1:107599128	PRMT6	0.45	6.17	0.32	1.9e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg25828445	chr12:7781288	NA	0.44	6.86	0.35	3.33e-11	HDL cholesterol levels;
LIHC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.59	10.68	0.5	3.59e-23	Mean corpuscular volume;
LIHC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.05	-0.78	1.27e-71	Height;
LIHC	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	9.7e-13	Putamen volume;
LIHC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.45	16.45	0.66	3.18e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.81	-11.39	-0.52	1.07e-25	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2242116	0.900	rs1001284	chr3:46933960	C/G	cg02527881	chr3:46936655	PTH1R	-0.54	-11.73	-0.54	6.07e-27	Birth weight;
LIHC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg07713946	chr22:31675144	LIMK2	-0.42	-7.41	-0.37	9.8e-13	Colorectal cancer;
LIHC	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.41	-0.33	4.94e-10	Coronary artery calcification;
LIHC	cis	rs4908768	0.539	rs1061039	chr1:8642588	T/C	cg20416874	chr1:8611966	RERE	-0.64	-12.59	-0.56	4.06e-30	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.36	5.73	0.3	2.17e-8	Cocaine dependence;
LIHC	cis	rs151997	0.925	rs28077	chr5:50191946	T/A	cg06027927	chr5:50259733	NA	0.57	7.72	0.39	1.28e-13	Callous-unemotional behaviour;
LIHC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.13	0.36	6.06e-12	Obesity-related traits;
LIHC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.58e-9	Childhood ear infection;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-6.74	-0.34	6.9e-11	Lymphocyte counts;
LIHC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.54	7.17	0.36	4.62e-12	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg24130564	chr14:104152367	KLC1	-0.54	-8.82	-0.43	6.01e-17	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.46e-25	Eye color traits;
LIHC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs2273669	0.588	rs111773102	chr6:109306480	C/T	cg05315195	chr6:109294784	ARMC2	-0.52	-5.76	-0.3	1.88e-8	Prostate cancer;
LIHC	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg05147244	chr20:61493195	TCFL5	1.23	10.37	0.49	4.35e-22	Obesity-related traits;
LIHC	cis	rs11233413	1.000	rs11233415	chr11:82725037	A/C	cg24227371	chr11:82718527	RAB30	-0.35	-7.74	-0.39	1.11e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.73	-0.3	2.19e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg10820045	chr2:198174542	NA	-0.51	-7.8	-0.39	7.41e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.8	0.35	4.73e-11	Red blood cell count;
LIHC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.44	6.17	0.32	1.94e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg01864836	chr14:55583639	NA	-0.41	-7.44	-0.37	8.07e-13	Protein biomarker;
LIHC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	5.91	0.3	8.19e-9	Bipolar disorder;
LIHC	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg01843034	chr6:37503916	NA	-0.46	-7.84	-0.39	5.95e-14	Cognitive performance;
LIHC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.35	-7.02	-0.35	1.2e-11	Colorectal cancer;
LIHC	cis	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.41	-0.41	1.09e-15	Extraversion;
LIHC	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.6	-7.02	-0.35	1.18e-11	Body mass index;
LIHC	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.89	11.15	0.52	8.01e-25	Coronary artery disease;
LIHC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg17279839	chr7:150038598	RARRES2	0.55	11.03	0.51	2.16e-24	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-9.62	-0.46	1.53e-19	Asthma;
LIHC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.4	-0.33	5.17e-10	Height;
LIHC	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.45	7.34	0.37	1.6e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.75	10.7	0.5	3.19e-23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.34	6.61	0.34	1.47e-10	Cancer;
LIHC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.97	-0.4	2.36e-14	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.68	10.88	0.51	7.27e-24	Breast cancer;
LIHC	cis	rs11888559	0.511	rs1560855	chr2:204036063	T/C	cg24605529	chr2:203879461	NBEAL1	0.76	5.81	0.3	1.44e-8	Height;
LIHC	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.6	-0.34	1.53e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.42	0.41	1.01e-15	Platelet count;
LIHC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg18016565	chr1:150552671	MCL1	0.55	10.29	0.49	7.91e-22	Melanoma;
LIHC	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg09597638	chr17:3907349	NA	0.55	6.75	0.34	6.32e-11	Type 2 diabetes;
LIHC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.61	-8.71	-0.43	1.33e-16	Aortic root size;
LIHC	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.4	6.37	0.33	6.05e-10	Sum eosinophil basophil counts;
LIHC	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg14515779	chr1:101123966	NA	0.49	6.75	0.34	6.22e-11	Monocyte count;
LIHC	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg06096015	chr1:231504339	EGLN1	0.42	7.17	0.36	4.68e-12	Red blood cell count;
LIHC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg00656387	chr3:40428638	ENTPD3	-0.37	-6.18	-0.32	1.79e-9	Renal cell carcinoma;
LIHC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.56	-8.06	-0.4	1.26e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02985541	chr2:219472218	PLCD4	0.42	6.88	0.35	2.87e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg05484376	chr2:27715224	FNDC4	0.36	5.93	0.31	7.33e-9	Total body bone mineral density;
LIHC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.32	6.73	0.34	7.35e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs2637030	0.533	rs7731940	chr5:52863638	A/T	cg06476337	chr5:52856530	NDUFS4	0.41	6.57	0.33	1.86e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg13482628	chr17:19912719	NA	0.38	6.21	0.32	1.5e-9	Schizophrenia;
LIHC	cis	rs611744	0.967	rs608115	chr8:109231948	T/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	trans	rs2352908	1.000	rs2352913	chr14:49453094	T/C	cg16568472	chr20:3190600	ITPA	-0.45	-6.07	-0.31	3.37e-9	Social communication problems;
LIHC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.42	8.8	0.43	7.09e-17	Coronary artery disease;
LIHC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09065629	chr16:1709722	CRAMP1L	0.32	5.74	0.3	2.09e-8	Coronary artery disease;
LIHC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg26441486	chr22:50317300	CRELD2	0.35	6.18	0.32	1.81e-9	Schizophrenia;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11987759	chr7:65425863	GUSB	-0.39	-6.12	-0.31	2.5e-9	Calcium levels;
LIHC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.5	-7.74	-0.39	1.13e-13	Pulse pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11489389	chr3:63849240	ATXN7;THOC7	0.43	6.3	0.32	9.06e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26347064	chr19:45211248	CEACAM16	0.37	6.2	0.32	1.64e-9	Immature fraction of reticulocytes;
LIHC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.14	-0.31	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18679886	chr7:107531975	DLD	0.41	6.07	0.31	3.44e-9	Pancreatic cancer;
LIHC	cis	rs7523273	0.512	rs2761435	chr1:207918466	C/G	cg22525895	chr1:207977042	MIR29B2	0.5	7.99	0.4	2.14e-14	Schizophrenia;
LIHC	trans	rs800082	1.000	rs1405597	chr3:144314276	A/C	cg24215973	chr2:240111563	HDAC4	-0.42	-6.18	-0.32	1.79e-9	Smoking behavior;
LIHC	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	0.69	7.32	0.37	1.75e-12	Arsenic metabolism;
LIHC	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.4	-5.77	-0.3	1.74e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.53	8.7	0.43	1.41e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.52	-10.61	-0.5	6.19e-23	Late-onset Alzheimer's disease;
LIHC	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.48	-6.51	-0.33	2.73e-10	Schizophrenia;
LIHC	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg15123519	chr2:136567270	LCT	-0.37	-5.86	-0.3	1.07e-8	Corneal structure;
LIHC	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.58	-0.5	8.4e-23	Pediatric autoimmune diseases;
LIHC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.26	-0.49	1.06e-21	Blood metabolite levels;
LIHC	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg14768367	chr16:72042858	DHODH	0.58	6.11	0.31	2.75e-9	LDL cholesterol levels;Total cholesterol levels;
LIHC	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.54	-8.14	-0.4	7.59e-15	Corneal astigmatism;
LIHC	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.39	6.41	0.33	4.85e-10	Mean arterial pressure;
LIHC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	15.18	0.63	3.93e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.38	6.28	0.32	9.99e-10	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.66	-9.94	-0.47	1.26e-20	Monocyte count;
LIHC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.46	-7.66	-0.38	1.98e-13	Orofacial clefts;
LIHC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.08	0.48	4.18e-21	Diisocyanate-induced asthma;
LIHC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.75	5.95	0.31	6.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.33	-6.69	-0.34	9.36e-11	Platelet distribution width;
LIHC	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg10820045	chr2:198174542	NA	0.46	6.99	0.35	1.41e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.67	9.97	0.47	1.02e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.96	0.31	6.25e-9	Menopause (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25494665	chr13:42623369	DGKH	0.4	6.13	0.31	2.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18123596	chr17:36956264	PIP4K2B	0.49	6.85	0.35	3.38e-11	Pancreatic cancer;
LIHC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.22	-0.32	1.43e-9	Body mass index;
LIHC	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.71	-8.73	-0.43	1.11e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4728302	0.869	rs958405	chr7:133597151	A/G	cg10665199	chr7:133106180	EXOC4	0.38	6.64	0.34	1.21e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.72	0.39	1.34e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs17152411	0.895	rs61872118	chr10:126583450	C/T	cg07906193	chr10:126599966	NA	0.43	6.84	0.35	3.73e-11	Height;
LIHC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.45	7.76	0.39	1.02e-13	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4684776	0.867	rs11706903	chr3:11343551	C/A	cg00170343	chr3:11313890	ATG7	-0.52	-7.21	-0.36	3.53e-12	Small vessel stroke;
LIHC	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg03146154	chr1:46216737	IPP	-0.37	-6.16	-0.32	1.99e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.47	-7.61	-0.38	2.62e-13	Longevity;Endometriosis;
LIHC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.56	0.53	2.57e-26	Tonsillectomy;
LIHC	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.46	6.79	0.34	4.87e-11	Nonalcoholic fatty liver disease;
LIHC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.31	-7.28	-0.37	2.25e-12	Menarche (age at onset);
LIHC	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs9918079	0.542	rs1789	chr4:15664535	G/A	cg04067612	chr4:15429572	C1QTNF7	-0.27	-5.78	-0.3	1.64e-8	Obesity-related traits;
LIHC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.18	-0.36	4.45e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.02	-0.31	4.45e-9	Tuberculosis;
LIHC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.65	9.54	0.46	2.75e-19	Mosquito bite size;
LIHC	cis	rs5030049	1	rs5030049	chr3:186450863	T/C	cg12454167	chr3:186435060	KNG1	0.34	6.09	0.31	3.11e-9	Blood protein levels;
LIHC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.92	0.65	4.32e-43	Breast cancer;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.55	0.62	1.1e-37	Prudent dietary pattern;
LIHC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.7	0.43	1.43e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs9810259	0.525	rs310749	chr3:12273768	A/C	cg23514324	chr3:12329213	PPARG	-0.45	-5.73	-0.3	2.19e-8	Platelet count;
LIHC	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs1198430	0.925	rs2510072	chr1:23769674	A/G	cg13183780	chr1:23809682	ASAP3	-0.55	-7.55	-0.38	3.91e-13	Total cholesterol levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14608199	chr11:2949963	PHLDA2	0.44	6.37	0.33	6.11e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16576597	chr16:28551801	NUPR1	0.46	7.02	0.35	1.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.07	-0.31	3.33e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg19318889	chr4:1322082	MAEA	0.42	6.5	0.33	2.78e-10	Obesity-related traits;
LIHC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	0.76	10.03	0.48	6.44e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg11367502	chr7:22862612	TOMM7	0.49	8.43	0.41	9.85e-16	Fibrinogen;
LIHC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.56	9.16	0.44	4.94e-18	Body mass index;
LIHC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.8	-14.64	-0.62	4.99e-38	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.23	-10.64	-0.5	5.12e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg26076054	chr5:421317	AHRR	0.27	5.84	0.3	1.24e-8	Cystic fibrosis severity;
LIHC	cis	rs11969893	0.737	rs9386262	chr6:101427687	G/T	cg12253828	chr6:101329408	ASCC3	1.05	11.41	0.52	9.39e-26	Economic and political preferences (immigration/crime);
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	-0.58	-8.52	-0.42	5.15e-16	Prudent dietary pattern;
LIHC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg23796481	chr11:64053134	BAD;GPR137	0.6	8.06	0.4	1.26e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.35	-6.1	-0.31	2.84e-9	IgG glycosylation;
LIHC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.43	7.29	0.37	2.2e-12	Hemoglobin concentration;
LIHC	cis	rs8044868	1.000	rs8052408	chr16:72158077	C/T	cg16558253	chr16:72132732	DHX38	-0.39	-6.27	-0.32	1.07e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.53	7.63	0.38	2.42e-13	Electrocardiographic conduction measures;
LIHC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.83	13.67	0.59	3.06e-34	Breast cancer;
LIHC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.41e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs76648483	0.672	rs1138357	chr15:80263406	C/T	cg11476254	chr16:89159666	ACSF3	-0.48	-6.15	-0.32	2.12e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	cis	rs963731	0.649	rs10439459	chr2:39236983	G/T	cg04010122	chr2:39346883	SOS1	-0.68	-5.76	-0.3	1.86e-8	Corticobasal degeneration;
LIHC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.57	-8.69	-0.43	1.56e-16	Blood protein levels;
LIHC	cis	rs722599	0.501	rs7158047	chr14:75388803	G/A	cg08847533	chr14:75593920	NEK9	0.59	10.35	0.49	4.97e-22	IgG glycosylation;
LIHC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	1.02	17.15	0.68	5.38e-48	Tonsillectomy;
LIHC	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02450064	chr17:40260053	DHX58	-0.3	-6.27	-0.32	1.07e-9	Fibrinogen levels;
LIHC	cis	rs10420951	0.535	rs78061871	chr19:18566637	G/A	cg10790698	chr19:18539756	SSBP4	-0.41	-5.81	-0.3	1.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg17980119	chr2:219472607	PLCD4	0.34	5.81	0.3	1.43e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02985541	chr2:219472218	PLCD4	-0.42	-6.47	-0.33	3.35e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg26545112	chr7:97833388	LMTK2	-0.41	-6.09	-0.31	3.11e-9	Alcohol dependence;
LIHC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	8.89	0.43	3.58e-17	Breast cancer;
LIHC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg04317338	chr11:64019027	PLCB3	0.49	6.76	0.34	5.88e-11	Platelet count;
LIHC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg02344993	chr17:57696989	CLTC	0.7	11.86	0.54	2.02e-27	Hemoglobin concentration;
LIHC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.04	-0.4	1.45e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg13114125	chr14:105738426	BRF1	-0.78	-10.02	-0.48	7.05e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.11	-0.36	7.03e-12	Diabetic kidney disease;
LIHC	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.26	-0.32	1.14e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-6.68	-0.34	9.72e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.63	9.71	0.46	7.82e-20	Tonsillectomy;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.63	0.53	1.49e-26	Monocyte percentage of white cells;
LIHC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.84	0.3	1.21e-8	Systolic blood pressure;
LIHC	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg06935464	chr4:38784597	TLR10	0.44	6.79	0.34	5.02e-11	Breast cancer;
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg01864069	chr14:103024347	NA	-0.57	-9.5	-0.46	3.73e-19	Platelet count;
LIHC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.46	-0.59	2.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1697938	0.875	rs323561	chr5:40871745	T/G	cg01087697	chr5:40835557	RPL37	-0.49	-6.05	-0.31	3.76e-9	Multiple system atrophy;
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.48	-7.47	-0.37	6.65e-13	Testicular germ cell tumor;
LIHC	trans	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04530015	chr2:215796436	ABCA12	0.49	9.01	0.44	1.46e-17	Neuroblastoma (high-risk);
LIHC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.31	-6.56	-0.33	2.05e-10	Blood metabolite levels;
LIHC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.54	-7.21	-0.36	3.57e-12	Dialysis-related mortality;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.55	8.3	0.41	2.52e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	16.31	0.66	1.18e-44	Platelet count;
LIHC	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.68	5.71	0.3	2.43e-8	HDL cholesterol;
LIHC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.5	-7.83	-0.39	6.38e-14	Bone mineral density (spine);
LIHC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.42	6.38	0.33	5.81e-10	Educational attainment;
LIHC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg12798992	chr6:167411361	FGFR1OP	0.6	9.9	0.47	1.8e-20	Crohn's disease;
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27297192	chr10:134578999	INPP5A	0.55	7.62	0.38	2.46e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.85	9.82	0.47	3.22e-20	Prostate cancer;
LIHC	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.83	-6.16	-0.32	2.05e-9	Mosquito bite size;
LIHC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.86	0.35	3.28e-11	Lung cancer in ever smokers;
LIHC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05771511	chr15:63340396	TPM1	0.47	6.97	0.35	1.63e-11	Platelet count;
LIHC	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.65	-7.13	-0.36	5.86e-12	Body mass index;
LIHC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.77	-10.63	-0.5	5.47e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.94	-0.35	1.96e-11	Acylcarnitine levels;
LIHC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg24879335	chr3:133465180	TF	0.28	6.33	0.32	7.84e-10	Iron status biomarkers;
LIHC	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.43	6.44	0.33	4.02e-10	Schizophrenia;
LIHC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	7.08	0.36	8.28e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.65	12.49	0.56	9.46e-30	Rheumatoid arthritis;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.36	-6.46	-0.33	3.67e-10	Paraoxonase activity;
LIHC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.5	6.79	0.34	5.11e-11	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09864156	chr10:70939728	SUPV3L1	0.38	6.66	0.34	1.12e-10	Cognitive function;
LIHC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.51	7.7	0.38	1.44e-13	Type 2 diabetes;
LIHC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg22079354	chr11:130786696	SNX19	0.42	5.99	0.31	5.23e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.5	6.02	0.31	4.6e-9	Heart rate;
LIHC	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.77	0.39	9.01e-14	Corneal astigmatism;
LIHC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.77	11.32	0.52	1.9e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs35883536	0.933	rs1409419	chr1:101183396	T/C	cg14515779	chr1:101123966	NA	-0.67	-12.76	-0.57	9.49e-31	Monocyte count;
LIHC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.22	0.52	4.31e-25	Colorectal cancer;
LIHC	cis	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg00251536	chr1:45205438	KIF2C	-0.48	-7.28	-0.37	2.26e-12	Eotaxin levels;
LIHC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.55	7.66	0.38	1.99e-13	Height;
LIHC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg05372495	chr19:1063624	ABCA7	-0.42	-6.7	-0.34	8.43e-11	Alzheimer's disease (late onset);
LIHC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.88	15.27	0.64	1.62e-40	Parkinson's disease;
LIHC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.62	-8.95	-0.44	2.34e-17	Aortic root size;
LIHC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	0.95	16.48	0.67	2.64e-45	Testicular germ cell tumor;
LIHC	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.57	8.27	0.41	3.08e-15	Urinary tract infection frequency;
LIHC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	9.78	0.47	4.55e-20	Total body bone mineral density;
LIHC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.16	0.36	4.87e-12	Self-reported allergy;
LIHC	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.59	7.34	0.37	1.58e-12	Macular telangiectasia type 2;
LIHC	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.52	-6.52	-0.33	2.52e-10	Major depressive disorder;
LIHC	cis	rs6449957	0.639	rs706711	chr5:67520226	G/A	cg23036683	chr5:67512108	NA	0.54	7.84	0.39	5.77e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs943466	0.955	rs2894342	chr6:33774394	C/A	cg25922239	chr6:33757077	LEMD2	-0.44	-6.07	-0.31	3.46e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.47	6.29	0.32	9.64e-10	Cognitive test performance;
LIHC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.06	0.31	3.52e-9	Cognitive ability;
LIHC	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-8.04	-0.4	1.44e-14	Vitamin D levels;
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.32	-7.0	-0.35	1.32e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.66	-0.46	1.15e-19	Response to antipsychotic treatment;
LIHC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg15123519	chr2:136567270	LCT	-0.36	-5.85	-0.3	1.14e-8	Corneal structure;
LIHC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.58	-8.38	-0.41	1.43e-15	Blood metabolite levels;
LIHC	trans	rs8113308	0.810	rs7254930	chr19:52451527	G/T	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.48	-8.68	-0.42	1.65e-16	Colorectal cancer;
LIHC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.56	8.05	0.4	1.37e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg02931644	chr1:25747376	RHCE	-0.32	-6.9	-0.35	2.57e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.52	-8.98	-0.44	1.79e-17	Total body bone mineral density;
LIHC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.6	7.42	0.37	9.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.45	7.41	0.37	1.02e-12	Mean corpuscular volume;
LIHC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.54	8.78	0.43	7.77e-17	Bipolar disorder;
LIHC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.65	-0.34	1.18e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.06e-25	Melanoma;
LIHC	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.52	7.95	0.39	2.76e-14	Corneal astigmatism;
LIHC	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.52	-7.92	-0.39	3.38e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9322817	0.691	rs2486135	chr6:105282263	C/T	cg02098413	chr6:105308735	HACE1	0.45	8.41	0.41	1.16e-15	Thyroid stimulating hormone;
LIHC	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.43	6.49	0.33	2.97e-10	Height;
LIHC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.65	-7.54	-0.38	4.3e-13	Type 2 diabetes;
LIHC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.42	7.02	0.35	1.24e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.91	-0.43	3.19e-17	Schizophrenia;
LIHC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.83e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7707921	0.752	rs34981833	chr5:81272732	T/C	cg15871215	chr5:81402204	ATG10	-0.64	-6.34	-0.32	7.41e-10	Breast cancer;
LIHC	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg19539972	chr4:7069911	GRPEL1	0.41	6.15	0.32	2.16e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.31	5.81	0.3	1.4e-8	Multiple system atrophy;
LIHC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.93	17.8	0.69	1.27e-50	Menopause (age at onset);
LIHC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.61	-8.86	-0.43	4.61e-17	Monocyte percentage of white cells;
LIHC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.59	7.62	0.38	2.57e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1144333	1.000	rs1890967	chr1:76459544	T/C	cg10523679	chr1:76189770	ACADM	0.45	6.43	0.33	4.19e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.94	-12.4	-0.56	2.09e-29	Obesity-related traits;
LIHC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg25801113	chr15:45476975	SHF	0.36	6.1	0.31	2.92e-9	Uric acid levels;
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.63	-0.42	2.3e-16	Lymphocyte counts;
LIHC	cis	rs970821	0.667	rs2891798	chr8:124744096	C/T	cg00283535	chr8:124749564	ANXA13	0.42	7.67	0.38	1.75e-13	Breast cancer;
LIHC	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg18478394	chr8:109455254	TTC35	0.4	6.79	0.34	4.92e-11	Dupuytren's disease;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.54	8.34	0.41	1.89e-15	Longevity;Endometriosis;
LIHC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-9.48	-0.46	4.49e-19	Bipolar disorder;
LIHC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.38	-5.81	-0.3	1.45e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs11888559	0.655	rs4328616	chr2:204007739	G/C	cg24605529	chr2:203879461	NBEAL1	0.78	5.92	0.31	7.62e-9	Height;
LIHC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	0.93	15.93	0.65	3.87e-43	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg00280220	chr17:61926910	NA	0.43	6.88	0.35	2.83e-11	Prudent dietary pattern;
LIHC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.26	-0.37	2.62e-12	Migraine;Coronary artery disease;
LIHC	cis	rs17106184	1.000	rs72904709	chr1:51306002	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Body mass index;
LIHC	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.34	-0.32	7.24e-10	Prevalent atrial fibrillation;
LIHC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.71	-9.74	-0.47	6.18e-20	Selective IgA deficiency;
LIHC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.51	7.98	0.4	2.18e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.59	6.86	0.35	3.17e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg21466736	chr12:48725269	NA	-0.63	-9.13	-0.44	6.16e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.38	0.56	2.38e-29	Prudent dietary pattern;
LIHC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	5.93e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.64	9.7	0.46	8.23e-20	Corneal astigmatism;
LIHC	trans	rs6600671	1.000	rs1986111	chr1:121204788	C/T	cg08727972	chr1:148025634	NBPF14	0.4	6.07	0.31	3.46e-9	Hip geometry;
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.01	0.44	1.44e-17	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08556938	chr17:58512855	NA	0.44	6.44	0.33	4.05e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11478273	chr8:128806682	PVT1	0.5	6.67	0.34	1.05e-10	Lung function (FEV1/FVC);
LIHC	trans	rs17083533	0.661	rs76715387	chr6:121750190	C/G	cg16423337	chr3:52828818	ITIH3	0.29	6.34	0.32	7.12e-10	Heart rate;
LIHC	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs16958440	0.708	rs62096465	chr18:44629624	C/T	cg17192377	chr18:44677553	HDHD2	0.52	6.53	0.33	2.38e-10	Sitting height ratio;
LIHC	cis	rs907683	0.584	rs12991025	chr2:220284779	C/T	cg15015639	chr2:220282977	DES	0.36	8.83	0.43	5.53e-17	Resting heart rate;
LIHC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.75	-12.39	-0.56	2.2e-29	Corneal astigmatism;
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.66	11.48	0.53	5.08e-26	Longevity;Endometriosis;
LIHC	trans	rs9914544	0.545	rs2892016	chr17:18786776	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.75e-10	Educational attainment (years of education);
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.76	0.39	1e-13	Prudent dietary pattern;
LIHC	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.43	6.75	0.34	6.19e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.75	-11.24	-0.52	3.6e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.4	6.67	0.34	1.04e-10	Red blood cell count;
LIHC	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.43	8.25	0.41	3.47e-15	Height;
LIHC	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.91	-0.3	8.46e-9	Diastolic blood pressure;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.85e-13	Lymphocyte counts;
LIHC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.48	-0.49	1.83e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.44	8.14	0.4	7.19e-15	Prudent dietary pattern;
LIHC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-9.58	-0.46	2.01e-19	Colorectal cancer;
LIHC	cis	rs10744422	0.800	rs1696320	chr12:123269814	A/G	cg18912006	chr12:123335444	HIP1R	-0.52	-6.03	-0.31	4.17e-9	Schizophrenia;
LIHC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.55	-0.5	1.05e-22	Aortic root size;
LIHC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg22563815	chr15:78856949	CHRNA5	0.36	6.57	0.33	1.9e-10	Sudden cardiac arrest;
LIHC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24110177	chr3:50126178	RBM5	0.42	6.47	0.33	3.43e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-6.19	-0.32	1.75e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.6	0.46	1.74e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg00204748	chr12:29376779	FAR2	0.39	7.24	0.36	3.03e-12	QT interval;
LIHC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	8.76	0.43	9.07e-17	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.66e-17	Prudent dietary pattern;
LIHC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.59	0.42	3.16e-16	Schizophrenia;
LIHC	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg27205649	chr11:78285834	NARS2	-0.38	-5.88	-0.3	9.86e-9	Alzheimer's disease (survival time);
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.55	7.05	0.36	9.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.8e-12	Waist circumference;Weight;
LIHC	cis	rs17152411	0.652	rs3845	chr10:126674093	T/C	cg07906193	chr10:126599966	NA	-0.31	-6.31	-0.32	8.84e-10	Height;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.21	-0.45	3.35e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.68	8.71	0.43	1.35e-16	Initial pursuit acceleration;
LIHC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.71	0.34	8.14e-11	Lung cancer;
LIHC	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.42	-0.33	4.43e-10	Metabolite levels;
LIHC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg03037974	chr15:76606532	NA	-0.65	-11.6	-0.53	1.8e-26	Blood metabolite levels;
LIHC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.56	5.74	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.38	12.35	0.56	3.16e-29	Uric acid levels;
LIHC	cis	rs10924970	0.625	rs10802624	chr1:235494971	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.74	0.3	2.14e-8	Asthma;
LIHC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-5.91	-0.3	8.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8050755	0.649	rs2516737	chr16:2101749	A/G	cg04515572	chr16:2107413	TSC2	0.82	6.83	0.35	3.98e-11	Major depressive disorder;
LIHC	cis	rs8084351	0.539	rs4638654	chr18:50640310	A/G	cg24270629	chr18:50823537	DCC	0.42	6.24	0.32	1.3e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	6.71	0.34	8.17e-11	IgG glycosylation;
LIHC	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-0.95	-12.16	-0.55	1.59e-28	Obesity-related traits;
LIHC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.47	7.83	0.39	6.15e-14	Longevity;Endometriosis;
LIHC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg23978390	chr7:1156363	C7orf50	0.53	8.02	0.4	1.68e-14	Longevity;Endometriosis;
LIHC	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.49	-7.21	-0.36	3.65e-12	Thyroid stimulating hormone;
LIHC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.23	-0.36	3.25e-12	Migraine;Coronary artery disease;
LIHC	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg19735590	chr5:154026979	NA	-0.48	-5.91	-0.3	8.18e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-7.04	-0.36	1.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg03945807	chr20:60948434	NA	-0.36	-6.44	-0.33	3.97e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg05941027	chr17:61774174	LIMD2	0.35	7.47	0.37	6.76e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07024458	chr16:56390600	GNAO1	0.45	7.35	0.37	1.52e-12	Cognitive function;
LIHC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.61	8.44	0.42	9.17e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04339246	chr15:89876433	POLG	-0.48	-6.91	-0.35	2.37e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600626	0.636	rs11236517	chr11:75452721	T/C	cg24262691	chr11:75473276	NA	0.39	5.88	0.3	9.79e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.4	-8.34	-0.41	1.83e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.64	-0.34	1.27e-10	Urate levels in overweight individuals;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg00280220	chr17:61926910	NA	-0.39	-6.3	-0.32	9.1e-10	Prudent dietary pattern;
LIHC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3e-11	Height;
LIHC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12016809	chr21:47604291	C21orf56	0.41	5.95	0.31	6.57e-9	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	6.15	0.32	2.15e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7587476	1.000	rs2121285	chr2:215656168	C/G	cg04004882	chr2:215674386	BARD1	-0.51	-6.79	-0.34	4.86e-11	Neuroblastoma;
LIHC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.27	0.32	1.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.82	-0.3	1.39e-8	Systolic blood pressure;
LIHC	cis	rs477692	0.637	rs7098627	chr10:131315866	C/T	cg05714579	chr10:131428358	MGMT	0.41	6.64	0.34	1.27e-10	Response to temozolomide;
LIHC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg04374321	chr14:90722782	PSMC1	0.52	8.41	0.41	1.09e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.53	-8.67	-0.42	1.73e-16	Blood metabolite levels;
LIHC	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg14515779	chr1:101123966	NA	0.59	11.42	0.53	8.03e-26	Monocyte count;
LIHC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.96	0.31	6.31e-9	Bipolar disorder;
LIHC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs61990749	0.511	rs7146020	chr14:78358319	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.38	6.2	0.32	1.64e-9	Fibroblast growth factor basic levels;
LIHC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04317338	chr11:64019027	PLCB3	0.48	6.73	0.34	7.08e-11	Platelet count;
LIHC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg02269571	chr22:50332266	NA	-0.66	-8.72	-0.43	1.27e-16	Schizophrenia;
LIHC	cis	rs2904967	0.568	rs531178	chr11:64852421	T/C	cg19545356	chr11:64851426	ZFPL1;CDCA5	1.06	6.82	0.35	4.15e-11	Mean corpuscular volume;
LIHC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg12560992	chr17:57184187	TRIM37	0.53	7.23	0.36	3.18e-12	Cognitive test performance;
LIHC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.71	8.04	0.4	1.52e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	7.39	0.37	1.12e-12	Lung cancer;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13409248	chr3:40428643	ENTPD3	0.49	8.33	0.41	1.95e-15	Renal cell carcinoma;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05787120	chr3:50365854	TUSC2	0.46	6.46	0.33	3.52e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.37	6.17	0.32	1.91e-9	Schizophrenia;
LIHC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.72	-10.98	-0.51	3.23e-24	Aortic root size;
LIHC	cis	rs61677309	1.000	rs67462512	chr11:118155336	G/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.77	0.57	8.09e-31	Alzheimer's disease;
LIHC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.97	14.7	0.62	3.06e-38	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg21605333	chr4:119757512	SEC24D	1.0	8.21	0.41	4.45e-15	Cannabis dependence symptom count;
LIHC	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg03934865	chr2:198174659	NA	0.43	6.2	0.32	1.62e-9	Dermatomyositis;
LIHC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-8.44	-0.42	9.35e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs151997	0.962	rs27256	chr5:50190264	G/C	cg06027927	chr5:50259733	NA	0.57	7.69	0.38	1.6e-13	Callous-unemotional behaviour;
LIHC	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.84	8.67	0.42	1.74e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.39	-6.11	-0.31	2.72e-9	Coronary artery disease;
LIHC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.86	12.17	0.55	1.45e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs712039	0.687	rs11656455	chr17:35771885	G/A	cg16670864	chr17:35848621	DUSP14	0.34	5.73	0.3	2.2e-8	Tuberculosis;
LIHC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg03037974	chr15:76606532	NA	-0.58	-9.79	-0.47	4.01e-20	Blood metabolite levels;
LIHC	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.99	0.6	1.73e-35	Coffee consumption (cups per day);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22016770	chr5:42468779	GHR	0.43	6.12	0.31	2.53e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg11062466	chr8:58055876	NA	0.51	7.61	0.38	2.72e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.4	6.47	0.33	3.39e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-8.68	-0.42	1.65e-16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg09182678	chr22:50328711	NA	-0.69	-7.62	-0.38	2.47e-13	Mean platelet volume;
LIHC	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg00209037	chr22:46443395	NA	-0.66	-8.05	-0.4	1.35e-14	Dupuytren's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25485084	chr12:118809325	TAOK3	0.42	6.39	0.33	5.54e-10	Pancreatic cancer;
LIHC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	11.41	0.53	8.93e-26	Multiple sclerosis;
LIHC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg02269571	chr22:50332266	NA	0.64	8.97	0.44	2.05e-17	Schizophrenia;
LIHC	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.5	-0.38	5.7e-13	Tuberculosis;
LIHC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.29	0.58	8.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs13201877	0.591	rs3850213	chr6:137655458	A/T	cg16624405	chr10:133607033	NA	-0.43	-6.28	-0.32	1.03e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs72627123	0.531	rs3742806	chr14:74532523	A/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	5.78	0.3	1.69e-8	Morning vs. evening chronotype;
LIHC	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.79	0.3	1.63e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs818427	0.681	rs469523	chr5:112294680	A/G	cg07820702	chr5:112228657	REEP5	0.4	6.2	0.32	1.62e-9	Total body bone mineral density;
LIHC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs10242455	0.571	rs45532337	chr7:99310319	A/G	cg18809830	chr7:99032528	PTCD1	-0.83	-6.67	-0.34	1.05e-10	Blood metabolite levels;
LIHC	cis	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg05927578	chr16:4029543	ADCY9	0.58	6.38	0.33	5.9e-10	Waist circumference;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09477006	chr4:6711267	MRFAP1L1	0.52	7.13	0.36	6.13e-12	Lung function (FEV1/FVC);
LIHC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.34	13.9	0.6	3.84e-35	Eosinophil percentage of granulocytes;
LIHC	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg19676328	chr12:49525230	TUBA1B	-0.46	-6.85	-0.35	3.54e-11	Total cholesterol levels;
LIHC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.25	0.55	7.29e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.45	6.22	0.32	1.43e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LIHC	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.31	-7.35	-0.37	1.46e-12	Blood protein levels;
LIHC	trans	rs530081	0.659	rs500903	chr18:32693303	C/T	cg26396443	chr14:99729005	BCL11B	0.34	6.12	0.31	2.53e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20887711	chr4:1340912	KIAA1530	0.6	9.28	0.45	2.04e-18	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.38	6.04	0.31	3.92e-9	Menopause (age at onset);
LIHC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.42	-0.71	3.99e-53	Ulcerative colitis;
LIHC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	8.01	0.4	1.85e-14	Blood metabolite levels;
LIHC	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.33	0.55	3.71e-29	Coffee consumption (cups per day);
LIHC	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.44	-7.38	-0.37	1.18e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18357526	chr6:26021779	HIST1H4A	0.57	8.54	0.42	4.61e-16	Schizophrenia;
LIHC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.48	8.07	0.4	1.22e-14	Obesity-related traits;
LIHC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.68	-9.11	-0.44	7.15e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg18887096	chr2:219472410	PLCD4	0.36	6.33	0.32	7.86e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7534824	0.625	rs17449022	chr1:101442367	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.4	0.37	1.08e-12	Refractive astigmatism;
LIHC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.91	0.39	3.69e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.37	-6.03	-0.31	4.34e-9	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.75	10.79	0.5	1.44e-23	Coronary artery disease;
LIHC	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg14930904	chr10:32216787	ARHGAP12	0.35	5.99	0.31	5.46e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.42	-5.82	-0.3	1.34e-8	Smoking behavior;
LIHC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.84	13.15	0.58	3.15e-32	Breast cancer;
LIHC	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.35	-5.79	-0.3	1.57e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs16828019	0.777	rs115916606	chr1:41642700	C/G	cg20697417	chr1:41786797	NA	0.35	6.59	0.34	1.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.56	-8.74	-0.43	1.04e-16	Dental caries;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.45e-13	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.74	13.06	0.58	6.84e-32	Eosinophil percentage of white cells;
LIHC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.65	-8.09	-0.4	1.07e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg04118878	chr10:71993077	PPA1	0.58	6.32	0.32	8.31e-10	Blood protein levels;
LIHC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg20607798	chr8:58055168	NA	0.49	6.17	0.32	1.93e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.84e-19	Waist circumference;Weight;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27189623	chr16:705930	WDR90	0.34	5.79	0.3	1.61e-8	Height;
LIHC	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.83	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.5	6.31	0.32	8.66e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-7.69	-0.38	1.62e-13	Schizophrenia;
LIHC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg18016565	chr1:150552671	MCL1	-0.49	-9.43	-0.45	6.5e-19	Tonsillectomy;
LIHC	cis	rs77741769	0.553	rs12372231	chr12:121351729	T/A	cg02419362	chr12:121203948	SPPL3	0.33	5.83	0.3	1.28e-8	Mean corpuscular volume;
LIHC	cis	rs9896052	0.649	rs6501798	chr17:73444647	C/T	cg25649188	chr17:73499917	CASKIN2	0.44	7.03	0.36	1.12e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Urate levels;
LIHC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-7.88	-0.39	4.46e-14	Extraversion;
LIHC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.68	0.34	9.97e-11	Platelet count;
LIHC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	0.62	6.25	0.32	1.22e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9918079	0.560	rs13147590	chr4:15621188	A/G	cg16509355	chr4:15471240	CC2D2A	0.43	6.68	0.34	9.44e-11	Obesity-related traits;
LIHC	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.3	-0.41	2.41e-15	Vitamin D levels;
LIHC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.99	0.35	1.49e-11	Diabetic kidney disease;
LIHC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.86	-0.69	7.5400000000000006e-51	Schizophrenia;
LIHC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6450176	0.564	rs391470	chr5:53332338	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.5	-0.59	1.4e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1144333	0.655	rs968018	chr1:76395662	G/A	cg22875332	chr1:76189707	ACADM	0.42	6.29	0.32	9.69e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7635838	0.855	rs9816564	chr3:11475297	T/C	cg00170343	chr3:11313890	ATG7	0.42	6.61	0.34	1.45e-10	HDL cholesterol;
LIHC	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.53	7.65	0.38	2.05e-13	Urinary tract infection frequency;
LIHC	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.53	-0.42	4.67e-16	Response to antipsychotic treatment;
LIHC	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg03934865	chr2:198174659	NA	0.54	8.54	0.42	4.61e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06002616	chr8:101225028	SPAG1	0.34	5.96	0.31	6.28e-9	Atrioventricular conduction;
LIHC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.39	-5.81	-0.3	1.45e-8	Menarche (age at onset);
LIHC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.32	-5.71	-0.3	2.43e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.58	-8.62	-0.42	2.58e-16	Height;
LIHC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.55	-7.66	-0.38	1.88e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-13.77	-0.6	1.21e-34	Headache;
LIHC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-1.04	-12.95	-0.57	1.75e-31	Intelligence (multi-trait analysis);
LIHC	trans	rs359466	0.720	rs12187599	chr5:173272518	C/T	cg22556143	chr10:134061604	STK32C	-0.4	-6.11	-0.31	2.79e-9	QRS complex (Sokolow-Lyon);
LIHC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.38	-0.33	5.67e-10	Personality dimensions;
LIHC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.73	11.85	0.54	2.24e-27	Mean platelet volume;
LIHC	cis	rs1620921	0.505	rs4709467	chr6:161203079	G/A	cg01280913	chr6:161186852	NA	-0.29	-5.75	-0.3	2e-8	Lipoprotein (a) - cholesterol levels;
LIHC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.46	6.22	0.32	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.72	12.54	0.56	6.36e-30	Platelet count;
LIHC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.45	7.26	0.37	2.59e-12	Total body bone mineral density;
LIHC	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.54	8.56	0.42	3.86e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg02023728	chr11:77925099	USP35	0.33	5.97	0.31	6.09e-9	Alzheimer's disease (survival time);
LIHC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.7	9.5	0.46	3.82e-19	Aortic root size;
LIHC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.15	-0.32	2.22e-9	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02985541	chr2:219472218	PLCD4	0.45	8.71	0.43	1.33e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.68	6.93	0.35	2.11e-11	Alzheimer's disease;
LIHC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27189623	chr16:705930	WDR90	0.42	6.95	0.35	1.85e-11	Height;
LIHC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08448040	chr3:13521693	HDAC11	0.44	6.28	0.32	1.01e-9	Pancreatic cancer;
LIHC	trans	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.69	-10.29	-0.49	8.01e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.35e-21	Alzheimer's disease (late onset);
LIHC	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	0.78	9.08	0.44	8.77e-18	Exhaled nitric oxide output;
LIHC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg03013999	chr17:37608204	MED1	0.36	5.9	0.3	8.71e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.98	-0.44	1.79e-17	Obesity-related traits;
LIHC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.3	-6.58	-0.34	1.82e-10	Longevity;
LIHC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.96	-0.31	6.34e-9	Uric acid levels;
LIHC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg19302996	chr17:73780495	UNK	-0.54	-6.65	-0.34	1.14e-10	Psoriasis;
LIHC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.77	0.5	1.73e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg16970926	chr12:29381810	FAR2	-0.28	-5.89	-0.3	9.12e-9	QT interval;
LIHC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.65	-12.09	-0.55	2.98e-28	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg10756647	chr7:56101905	PSPH	1.09	13.55	0.59	9.11e-34	Diabetic kidney disease;
LIHC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.54	-9.08	-0.44	8.92e-18	Colorectal cancer;
LIHC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.5	-6.84	-0.35	3.57e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-6.89	-0.35	2.63e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg12661370	chr5:149340060	SLC26A2	0.5	6.08	0.31	3.23e-9	HIV-1 control;
LIHC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	7.42	0.37	9.58e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.36	6.14	0.31	2.32e-9	Cognitive performance;
LIHC	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.94	-18.94	-0.72	3.09e-55	Schizophrenia;
LIHC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.58	6.25	0.32	1.21e-9	Systemic lupus erythematosus;
LIHC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.49	6.52	0.33	2.48e-10	Major depressive disorder;
LIHC	cis	rs4834770	0.685	rs4496567	chr4:120175625	A/T	cg09307838	chr4:120376055	NA	0.41	5.85	0.3	1.17e-8	Blood protein levels;
LIHC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.67	9.75	0.47	5.51e-20	Initial pursuit acceleration;
LIHC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.33	-0.32	7.61e-10	Total body bone mineral density;
LIHC	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.53	6.18	0.32	1.82e-9	Coronary artery disease;
LIHC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-8.67	-0.42	1.8e-16	Alzheimer's disease;
LIHC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg09222892	chr1:25734099	RHCE	0.48	8.89	0.43	3.55e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	0.86	11.92	0.54	1.23e-27	Skin colour saturation;
LIHC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.51	9.64	0.46	1.26e-19	Atrioventricular conduction;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08677398	chr8:58056175	NA	0.41	6.33	0.32	7.6e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.38	-9.59	-0.46	1.94e-19	Longevity;Endometriosis;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.57	-0.5	9.05e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	0.84	11.74	0.54	5.79e-27	Skin colour saturation;
LIHC	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.71	0.46	7.58e-20	Corneal astigmatism;
LIHC	cis	rs7635838	0.827	rs9848170	chr3:11495983	G/C	cg00170343	chr3:11313890	ATG7	0.4	6.17	0.32	1.94e-9	HDL cholesterol;
LIHC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs2386661	0.693	rs56226546	chr10:5659929	G/A	cg17085576	chr10:5658249	NA	-0.36	-6.44	-0.33	4.05e-10	Breast cancer;
LIHC	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg16275483	chr1:110013120	SYPL2	-0.49	-6.27	-0.32	1.11e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	0.83	5.84	0.3	1.23e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.48	-0.49	1.83e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.79	-0.34	4.84e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.33	-0.37	1.7e-12	Tuberculosis;
LIHC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.43	-6.7	-0.34	8.42e-11	Dental caries;
LIHC	trans	rs875971	0.545	rs316316	chr7:65614257	C/T	cg26939375	chr7:64535504	NA	-0.41	-6.41	-0.33	4.96e-10	Aortic root size;
LIHC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.44	6.24	0.32	1.32e-9	Morning vs. evening chronotype;
LIHC	cis	rs3099143	1.000	rs111908804	chr15:77123773	C/G	cg21673338	chr15:77095150	SCAPER	-0.52	-6.99	-0.35	1.49e-11	Recalcitrant atopic dermatitis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04600792	chr7:29256702	CHN2	0.37	6.07	0.31	3.45e-9	Cognitive function;
LIHC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg04013166	chr16:89971882	TCF25	0.54	6.81	0.35	4.53e-11	Skin colour saturation;
LIHC	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.32	6.99	0.35	1.45e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4407350	0.870	rs135627	chr22:44906402	A/G	cg11695653	chr22:44894386	LDOC1L	-0.35	-5.97	-0.31	6.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	7.98	0.4	2.31e-14	Coronary artery disease;
LIHC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.98	-10.01	-0.48	7.59e-21	Plasma clusterin levels;
LIHC	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg16275483	chr1:110013120	SYPL2	-0.49	-6.15	-0.32	2.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg03934865	chr2:198174659	NA	-0.6	-9.67	-0.46	1.04e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.43	-9.2	-0.45	3.59e-18	Rheumatoid arthritis;
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.06e-10	Renal cell carcinoma;
LIHC	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.96	-0.35	1.72e-11	IgG glycosylation;
LIHC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.87	13.13	0.58	3.59e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.42	-7.21	-0.36	3.58e-12	Lung cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19909895	chr3:128368930	RPN1	0.44	6.4	0.33	5.01e-10	Cognitive function;
LIHC	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg24542714	chr1:46669345	POMGNT1;C1orf190	0.44	7.23	0.36	3.11e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-0.91	-9.38	-0.45	9.4e-19	Magnesium levels;
LIHC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.53	7.15	0.36	5.17e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.41	0.52	9.38e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg23485639	chr6:28045615	ZNF165	0.41	6.38	0.33	5.68e-10	Cardiac Troponin-T levels;
LIHC	trans	rs2302464	1.000	rs57326588	chr4:15725436	G/C	cg17675199	chr6:35436792	RPL10A	-0.4	-6.42	-0.33	4.56e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg04310649	chr10:35416472	CREM	-0.42	-5.8	-0.3	1.48e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg18887096	chr2:219472410	PLCD4	0.4	6.94	0.35	1.95e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21956150	chr19:1438388	RPS15	-0.35	-6.1	-0.31	2.8e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12492359	chr2:203242268	BMPR2	0.44	6.13	0.31	2.42e-9	Migraine with aura;
LIHC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7129220	0.588	rs61878625	chr11:10123136	T/C	cg01453529	chr11:10209919	SBF2	-0.38	-6.8	-0.34	4.82e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.84	12.6	0.56	3.53e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.07	16.09	0.66	8.9e-44	Cognitive function;
LIHC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.65e-12	Breast cancer;
LIHC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.41	5.74	0.3	2.12e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg05347473	chr6:146136440	FBXO30	0.35	5.73	0.3	2.19e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3857067	1.000	rs3846291	chr4:95026735	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.1	-0.36	7.3e-12	QT interval;
LIHC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.5	7.83	0.39	6.08e-14	Total body bone mineral density;
LIHC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	0.72	8.17	0.4	6.16e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.77	-0.3	1.79e-8	Total body bone mineral density;
LIHC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.95	0.54	9.69e-28	Cognitive ability;
LIHC	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs77106637	0.585	rs10898870	chr11:72456218	A/C	cg03713592	chr11:72463424	ARAP1	0.57	6.07	0.31	3.36e-9	Type 2 diabetes;
LIHC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg23791538	chr6:167370224	RNASET2	0.49	7.96	0.4	2.5e-14	Primary biliary cholangitis;
LIHC	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg05926928	chr17:57297772	GDPD1	0.55	7.11	0.36	6.63e-12	Opioid sensitivity;
LIHC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.51	0.49	1.45e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.93	-0.31	7.52e-9	Diabetic kidney disease;
LIHC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.56	8.08	0.4	1.1e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg00612595	chr21:47717864	NA	-0.36	-5.86	-0.3	1.1e-8	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.58	8.26	0.41	3.26e-15	Bladder cancer;
LIHC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.38	6.06	0.31	3.67e-9	Menopause (age at onset);
LIHC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-1.03	-20.85	-0.75	7.21e-63	Breast cancer;
LIHC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.73	-0.39	1.2e-13	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.53	6.7	0.34	8.73e-11	Alzheimer's disease;
LIHC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.65	-8.03	-0.4	1.56e-14	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.43	-10.22	-0.48	1.44e-21	Reticulocyte fraction of red cells;Reticulocyte count;
LIHC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	14.26	0.61	1.56e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs243505	0.733	rs9987055	chr7:148501758	G/A	cg09806900	chr7:148480153	CUL1	0.43	6.37	0.33	5.99e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09051904	chr22:36635583	APOL2	0.45	6.15	0.32	2.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.54	-0.5	1.11e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs11958404	1.000	rs56175756	chr5:157391080	T/C	cg05962755	chr5:157440814	NA	1.06	11.58	0.53	2.25e-26	IgG glycosylation;
LIHC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg14580859	chr9:123691850	NA	0.39	6.96	0.35	1.73e-11	Rheumatoid arthritis;
LIHC	cis	rs10420951	0.617	rs79257623	chr19:18563714	G/A	cg10790698	chr19:18539756	SSBP4	-0.42	-6.03	-0.31	4.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	0.84	10.9	0.51	5.92e-24	Iron status biomarkers;
LIHC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.34e-11	Cognitive function;
LIHC	trans	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg10208301	chr11:6592745	DNHD1	-0.45	-6.39	-0.33	5.43e-10	Coronary artery calcification;
LIHC	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.41	7.5	0.38	5.68e-13	Testicular germ cell tumor;
LIHC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.77	13.93	0.6	2.94e-35	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16684958	chr7:75615977	POR	0.52	8.53	0.42	4.68e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.85	0.57	4.09e-31	Schizophrenia;
LIHC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg16989086	chr20:62203971	PRIC285	0.57	8.2	0.41	5.08e-15	Glioblastoma;
LIHC	cis	rs74233809	1.000	rs76752100	chr10:104794086	G/T	cg03493300	chr10:104813866	CNNM2	0.47	6.38	0.33	5.75e-10	Birth weight;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05025164	chr4:1340916	KIAA1530	0.53	8.05	0.4	1.39e-14	Obesity-related traits;
LIHC	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.2	0.48	1.73e-21	Diisocyanate-induced asthma;
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.8	12.77	0.57	8.46e-31	Longevity;
LIHC	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.35	6.03	0.31	4.36e-9	Mean corpuscular volume;
LIHC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg00334542	chr7:100209784	MOSPD3	-0.7	-7.68	-0.38	1.65e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	8.42	0.41	1.02e-15	Schizophrenia;
LIHC	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.47	6.0	0.31	4.97e-9	Alzheimer's disease;
LIHC	cis	rs2302777	0.507	rs1007655	chr17:38111419	G/A	cg17467752	chr17:38218738	THRA	0.4	5.81	0.3	1.42e-8	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.11	-0.44	7.26e-18	Bipolar disorder;
LIHC	cis	rs2274273	0.870	rs17741542	chr14:55805861	A/G	cg01864836	chr14:55583639	NA	0.38	6.75	0.34	6.47e-11	Protein biomarker;
LIHC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.5	6.26	0.32	1.18e-9	Pancreatic cancer;
LIHC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.75	13.71	0.6	2.07e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.77	-12.66	-0.57	2.08e-30	Breast cancer;
LIHC	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.44	7.01	0.35	1.25e-11	Metabolite levels;
LIHC	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.37	-5.91	-0.3	8.21e-9	Lewy body disease;
LIHC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-7.97	-0.4	2.43e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.41	-6.93	-0.35	2.16e-11	Platelet distribution width;
LIHC	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg00792783	chr2:198669748	PLCL1	0.45	6.56	0.33	2.04e-10	Intracranial aneurysm;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.43	-0.41	1e-15	Lymphocyte counts;
LIHC	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg15192750	chr16:69999425	NA	0.45	6.86	0.35	3.22e-11	IgE levels;
LIHC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.87	-11.21	-0.52	4.95e-25	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.1	-10.33	-0.49	5.84e-22	Breast cancer;
LIHC	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.49	7.28	0.37	2.36e-12	Thyroid stimulating hormone;
LIHC	cis	rs7116495	1.000	rs4943821	chr11:71813747	C/T	cg26138937	chr11:71823887	C11orf51	0.7	7.11	0.36	6.68e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.86	-6.54	-0.33	2.22e-10	Systolic blood pressure;
LIHC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	7.36	0.37	1.35e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.7	-12.85	-0.57	4.03e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs847649	1.000	rs11514917	chr7:102609221	A/C	cg18108683	chr7:102477205	FBXL13	-0.46	-6.88	-0.35	2.88e-11	Morning vs. evening chronotype;
LIHC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	1.01	18.11	0.7	6.87e-52	Multiple system atrophy;
LIHC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg07645718	chr20:61493192	TCFL5	0.76	6.37	0.33	6.14e-10	Obesity-related traits;
LIHC	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.54	9.96	0.47	1.12e-20	Multiple myeloma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18620298	chr10:76995799	COMTD1	-0.44	-6.13	-0.31	2.43e-9	Pancreatic cancer;
LIHC	cis	rs425535	0.619	rs2367443	chr4:74818406	T/C	cg02530824	chr4:74847766	PF4	-0.39	-6.31	-0.32	8.61e-10	Blood protein levels;
LIHC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-12.04	-0.55	4.67e-28	Alzheimer's disease (late onset);
LIHC	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.5e-11	Dermatomyositis;
LIHC	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.96	0.6	2.31e-35	Coffee consumption (cups per day);
LIHC	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.67	-11.7	-0.53	8.28e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	10.56	0.5	9.12e-23	Body mass index (adult);
LIHC	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg05025164	chr4:1340916	KIAA1530	-0.39	-5.84	-0.3	1.24e-8	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.39	6.16	0.32	2.01e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.72	-10.76	-0.5	1.82e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.55	6.42	0.33	4.62e-10	Mammographic density (dense area);
LIHC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.28	-0.41	2.8e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.34	7.75	0.39	1.03e-13	Blood metabolite ratios;
LIHC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg20607798	chr8:58055168	NA	0.49	6.94	0.35	2.02e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.38	6.11	0.31	2.67e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg05555928	chr11:63887634	MACROD1	0.51	6.58	0.34	1.81e-10	Mean platelet volume;
LIHC	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12826209	chr6:26865740	GUSBL1	0.57	5.84	0.3	1.2e-8	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-9.04	-0.44	1.16e-17	Exhaled nitric oxide output;
LIHC	cis	rs937213	0.573	rs2412464	chr15:40303842	G/A	cg20255370	chr15:40268687	EIF2AK4	-0.37	-6.33	-0.32	7.51e-10	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.0	12.74	0.57	1.07e-30	Body mass index;
LIHC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.65	9.87	0.47	2.22e-20	Neutrophil percentage of white cells;
LIHC	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	1.06	8.05	0.4	1.39e-14	Arsenic metabolism;
LIHC	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg06766960	chr11:133703094	NA	-0.41	-6.23	-0.32	1.4e-9	Childhood ear infection;
LIHC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.64	-6.66	-0.34	1.09e-10	Diabetic retinopathy;
LIHC	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-0.86	-14.36	-0.61	6.34e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.91	-0.3	8.14e-9	Life satisfaction;
LIHC	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg07451762	chr16:28383216	NA	-0.38	-6.42	-0.33	4.64e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1866706	0.896	rs7105759	chr11:12868817	T/A	cg25843174	chr11:12811716	TEAD1	-0.32	-6.87	-0.35	2.96e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs370915	1.000	rs9685837	chr4:187818466	C/T	cg12892747	chr4:187813459	NA	-0.38	-6.07	-0.31	3.34e-9	Gout;
LIHC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.74	-13.99	-0.6	1.75e-35	Mortality in heart failure;
LIHC	trans	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.49	6.71	0.34	8.25e-11	Morning vs. evening chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26628795	chr2:111435723	BUB1	0.41	6.39	0.33	5.35e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.81	9.38	0.45	9.51e-19	Cognitive function;
LIHC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.75e-8	Parkinson's disease;
LIHC	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.63	9.83	0.47	3.07e-20	Cognitive test performance;
LIHC	cis	rs9372498	0.505	rs1413630	chr6:118656434	A/G	cg01339444	chr6:118972232	C6orf204	0.73	6.24	0.32	1.28e-9	Diastolic blood pressure;
LIHC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.4	-0.49	3.45e-22	Hemoglobin concentration;
LIHC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.4	7.67	0.38	1.84e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23260255	chr3:187871479	LPP	0.47	6.76	0.34	5.84e-11	Pancreatic cancer;
LIHC	trans	rs9641123	0.608	rs6943527	chr7:93205706	T/C	cg09745688	chr16:2908918	PRSS22	-0.37	-6.35	-0.32	6.73e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs243505	0.559	rs2072408	chr7:148508197	A/G	cg09806900	chr7:148480153	CUL1	0.39	5.78	0.3	1.68e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.55	-0.42	4.1e-16	Type 2 diabetes;
LIHC	cis	rs4407350	0.967	rs4501045	chr22:44922321	G/A	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.08	-0.31	3.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg22890737	chr4:3514540	LRPAP1	0.43	7.07	0.36	8.57e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg01320579	chr17:75405842	SEPT9	0.52	7.49	0.38	5.86e-13	Airflow obstruction;
LIHC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.6	8.21	0.41	4.45e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.3	-6.23	-0.32	1.34e-9	Blood metabolite levels;
LIHC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.96	19.17	0.72	3.74e-56	Birth weight;
LIHC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.64	6.24	0.32	1.3e-9	Inflammatory bowel disease;
LIHC	trans	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg10756647	chr7:56101905	PSPH	-0.49	-7.23	-0.36	3.09e-12	Aortic root size;
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg21756720	chr8:11724777	CTSB	-0.57	-7.04	-0.36	1.08e-11	Monocyte count;
LIHC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.41	6.17	0.32	1.96e-9	Diastolic blood pressure;
LIHC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg07451762	chr16:28383216	NA	0.4	7.15	0.36	5.4e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.5	-9.05	-0.44	1.13e-17	Atrioventricular conduction;
LIHC	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.63	-10.23	-0.48	1.32e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.58	0.56	4.27e-30	Colorectal cancer;
LIHC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.85	0.3	1.14e-8	Bladder cancer;
LIHC	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg05535760	chr7:792225	HEATR2	-0.78	-5.83	-0.3	1.32e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg07884673	chr3:53033167	SFMBT1	0.92	6.74	0.34	6.85e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg05941027	chr17:61774174	LIMD2	0.35	7.39	0.37	1.13e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.54	-8.53	-0.42	4.86e-16	Menarche (age at onset);
LIHC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg16586182	chr3:47516702	SCAP	-0.54	-9.86	-0.47	2.43e-20	Colorectal cancer;
LIHC	cis	rs3823572	0.564	rs6949760	chr7:133676101	C/A	cg03336402	chr7:133662267	EXOC4	-0.48	-5.77	-0.3	1.76e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs55665837	0.540	rs4144487	chr11:14750451	C/G	cg25251204	chr11:14927456	NA	0.4	5.74	0.3	2.11e-8	Vitamin D levels;
LIHC	cis	rs61440199	0.818	rs76854494	chr3:20179496	G/C	cg00235661	chr3:20228976	SGOL1	-0.42	-5.79	-0.3	1.58e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg17279839	chr7:150038598	RARRES2	0.39	7.59	0.38	3.06e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.25	0.45	2.49e-18	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.75	-14.55	-0.62	1.13e-37	Iron status biomarkers;
LIHC	cis	rs11958404	0.860	rs7730844	chr5:157461208	C/T	cg05962755	chr5:157440814	NA	1.01	11.11	0.52	1.05e-24	IgG glycosylation;
LIHC	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.6	-8.85	-0.43	4.76e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.46	6.69	0.34	8.94e-11	Asthma;
LIHC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.53	7.01	0.35	1.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg18016565	chr1:150552671	MCL1	0.53	10.02	0.48	6.66e-21	Melanoma;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00428944	chr8:101963525	YWHAZ	0.35	6.48	0.33	3.21e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.36	5.89	0.3	9.2e-9	Menopause (age at onset);
LIHC	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.86	13.15	0.58	2.98e-32	Obesity-related traits;
LIHC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.62	-0.38	2.58e-13	Height;
LIHC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg14067834	chr17:29058358	SUZ12P	0.6	5.9	0.3	8.71e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg22800045	chr5:56110881	MAP3K1	-0.57	-6.79	-0.34	4.89e-11	Initial pursuit acceleration;
LIHC	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.52	-7.15	-0.36	5.3e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.49	7.45	0.37	7.66e-13	Diastolic blood pressure;
LIHC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	11.96	0.54	8.55e-28	Post bronchodilator FEV1;
LIHC	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg14930904	chr10:32216787	ARHGAP12	0.37	6.7	0.34	8.5e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.4	0.52	9.54e-26	Colorectal cancer;
LIHC	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.41	5.88	0.3	9.87e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs864643	1.000	rs816494	chr3:39556845	T/C	cg05136238	chr3:39556330	MOBP	0.32	5.78	0.3	1.65e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.35	-0.32	7.04e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.66	11.64	0.53	1.38e-26	Colorectal cancer;
LIHC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.66	-13.2	-0.58	1.87e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	8.01	0.4	1.83e-14	Lymphocyte counts;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16249105	chr10:120938029	PRDX3	-0.39	-6.03	-0.31	4.15e-9	Longevity;
LIHC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	8.27	0.41	2.98e-15	Post bronchodilator FEV1;
LIHC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-7.04	-0.36	1.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg23978390	chr7:1156363	C7orf50	0.47	6.63	0.34	1.3e-10	Longevity;Endometriosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05095774	chr18:52495848	RAB27B	0.45	6.35	0.32	6.99e-10	Lung function (FEV1/FVC);
LIHC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-7.54	-0.38	4.25e-13	Eosinophil percentage of white cells;
LIHC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg12798992	chr6:167411361	FGFR1OP	0.41	6.36	0.33	6.61e-10	Primary biliary cholangitis;
LIHC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.44	6.2	0.32	1.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4728302	0.869	rs7792492	chr7:133595316	C/T	cg10665199	chr7:133106180	EXOC4	0.33	5.88	0.3	9.78e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.62	5.79	0.3	1.58e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.47	-6.84	-0.35	3.58e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1144333	0.655	rs76735776	chr1:76455211	A/G	cg10523679	chr1:76189770	ACADM	0.45	5.99	0.31	5.31e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg25566285	chr7:158114605	PTPRN2	0.23	6.15	0.32	2.11e-9	Calcium levels;
LIHC	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.67	13.37	0.59	4.49e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.63	0.42	2.28e-16	Menarche (age at onset);
LIHC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.08	-0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs74181299	0.819	rs2723087	chr2:65298282	T/A	cg05010058	chr2:65284262	CEP68	0.38	6.39	0.33	5.38e-10	Pulse pressure;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.62	9.23	0.45	2.91e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.47	-0.49	1.91e-22	Platelet count;
LIHC	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.71	-9.88	-0.47	2.09e-20	Tonsillectomy;
LIHC	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg20636351	chr8:55087400	NA	-0.35	-7.27	-0.37	2.47e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-6.48	-0.33	3.22e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11683229	0.778	rs72811598	chr2:63326416	T/G	cg17519650	chr2:63277830	OTX1	-0.51	-5.79	-0.3	1.6e-8	Protein quantitative trait loci;
LIHC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.58	0.53	2.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.33	6.42	0.33	4.55e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.62	-0.46	1.5700000000000001e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.38	6.07	0.31	3.46e-9	Menopause (age at onset);
LIHC	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.68	11.96	0.54	8.99e-28	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.94	17.78	0.69	1.48e-50	Menopause (age at onset);
LIHC	cis	rs10838687	0.673	rs77532017	chr11:47284317	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.88	-0.3	9.67e-9	Proinsulin levels;
LIHC	cis	rs1185460	0.546	rs7114961	chr11:118914388	G/C	cg23280166	chr11:118938394	VPS11	-0.43	-5.99	-0.31	5.35e-9	Coronary artery disease;
LIHC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg05941027	chr17:61774174	LIMD2	0.32	6.53	0.33	2.43e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.68	0.43	1.6e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Macular telangiectasia type 2;
LIHC	cis	rs1113500	0.787	rs10881502	chr1:108641819	C/T	cg06207961	chr1:108661230	NA	-0.32	-6.1	-0.31	2.89e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.76	10.15	0.48	2.45e-21	Fat distribution (HIV);
LIHC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.83	-13.36	-0.59	4.91e-33	Breast cancer;
LIHC	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg14092571	chr14:90743983	NA	0.46	7.25	0.37	2.76e-12	Mortality in heart failure;
LIHC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg00086871	chr4:6988644	TBC1D14	0.89	6.27	0.32	1.07e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.69	-0.34	9.41e-11	Hip circumference;Waist circumference;
LIHC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	10.88	0.51	7.4e-24	Colorectal cancer;
LIHC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13401831	chr22:18593307	TUBA8	0.44	6.49	0.33	3.09e-10	Pancreatic cancer;
LIHC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.47	-9.59	-0.46	1.94e-19	Tonsillectomy;
LIHC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.0	-0.35	1.4e-11	Bipolar disorder;
LIHC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.77	0.34	5.5e-11	Alzheimer's disease (late onset);
LIHC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.99	-0.35	1.48e-11	Alzheimer's disease;
LIHC	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg06271696	chr7:157225062	NA	-0.47	-7.32	-0.37	1.84e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg12903224	chr12:29470962	FAR2	0.39	6.52	0.33	2.58e-10	QT interval;
LIHC	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg09597638	chr17:3907349	NA	0.55	6.74	0.34	6.86e-11	Type 2 diabetes;
LIHC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg21724239	chr8:58056113	NA	0.49	6.53	0.33	2.43e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17253792	0.545	rs12894368	chr14:56025178	C/A	cg01858014	chr14:56050164	KTN1	-0.67	-6.11	-0.31	2.74e-9	Putamen volume;
LIHC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg20283391	chr11:68216788	NA	-0.52	-7.97	-0.4	2.38e-14	Total body bone mineral density;
LIHC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.54	-0.33	2.26e-10	Longevity;Endometriosis;
LIHC	cis	rs55702914	0.809	rs2376407	chr2:198183465	A/G	cg10820045	chr2:198174542	NA	-0.4	-5.93	-0.31	7.39e-9	Major depression and alcohol dependence;
LIHC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.88	-0.35	2.88e-11	Coronary artery disease;
LIHC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.84	16.18	0.66	3.89e-44	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs151997	1.000	rs251043	chr5:50215997	A/G	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.69	-9.1	-0.44	7.83e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.74	0.39	1.16e-13	Mean platelet volume;
LIHC	cis	rs116248771	0.549	rs9849301	chr3:158444860	C/T	cg16708174	chr3:158430962	RARRES1	0.7	9.25	0.45	2.45e-18	diarrhoeal disease at age 2;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18125326	chr3:88112162	NA	0.28	6.17	0.32	1.92e-9	Cognitive function;
LIHC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg15691649	chr6:25882328	NA	-0.38	-5.97	-0.31	5.87e-9	Height;
LIHC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	1.0	16.0	0.65	2.04e-43	Metabolic syndrome;
LIHC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.51	-7.27	-0.37	2.53e-12	Blood metabolite levels;
LIHC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.45	-7.3	-0.37	2.09e-12	Response to temozolomide;
LIHC	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.73	-9.99	-0.48	8.45e-21	Body mass index;
LIHC	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.53	8.65	0.42	2.04e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.58	-8.27	-0.41	2.98e-15	Lymphocyte counts;
LIHC	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.35	-6.02	-0.31	4.52e-9	Cognitive performance;
LIHC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg14930904	chr10:32216787	ARHGAP12	0.37	6.4	0.33	5.1e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15724272	chr4:89513644	HERC3	-0.44	-6.2	-0.32	1.67e-9	Pancreatic cancer;
LIHC	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.59	-11.98	-0.54	7.63e-28	Plateletcrit;Platelet count;
LIHC	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.76	-0.3	1.89e-8	Mortality in heart failure;
LIHC	cis	rs3762637	0.882	rs9856011	chr3:122093570	G/A	cg24169773	chr3:122142474	KPNA1	-0.49	-9.58	-0.46	2.06e-19	LDL cholesterol levels;
LIHC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.0	18.68	0.71	3.43e-54	Monocyte percentage of white cells;
LIHC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg02079420	chr8:82753780	SNX16	-0.36	-6.59	-0.34	1.63e-10	Diastolic blood pressure;
LIHC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.71	7.24	0.36	3.06e-12	Bipolar disorder;
LIHC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.8	9.01	0.44	1.46e-17	Vitiligo;
LIHC	cis	rs1865721	0.804	rs4510115	chr18:73209635	G/A	cg26385618	chr18:73139727	C18orf62	-0.29	-7.4	-0.37	1.08e-12	Intelligence;
LIHC	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.54	-0.38	4.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16684958	chr7:75615977	POR	0.51	8.59	0.42	3.18e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.39	-0.33	5.39e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg06012730	chr15:75315579	PPCDC	0.37	6.86	0.35	3.32e-11	Blood trace element (Zn levels);
LIHC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.47	-7.11	-0.36	6.72e-12	White blood cell count;
LIHC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-6.23	-0.32	1.37e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg12042659	chr19:58951599	ZNF132	0.39	6.46	0.33	3.57e-10	Uric acid clearance;
LIHC	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	9.91	0.47	1.58e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.51	-5.73	-0.3	2.17e-8	Vitiligo;
LIHC	cis	rs4908768	0.539	rs6663123	chr1:8642931	T/C	cg20416874	chr1:8611966	RERE	-0.64	-12.92	-0.57	2.27e-31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-6.7	-0.34	8.46e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs11955398	0.716	rs1379117	chr5:59942309	T/C	cg02684056	chr5:59996105	DEPDC1B	0.4	5.92	0.3	7.95e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-8.03	-0.4	1.61e-14	Vitamin D levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg23174392	chr13:114009751	GRTP1	0.37	6.41	0.33	4.8e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12379764	chr21:47803548	PCNT	-0.54	-7.8	-0.39	7.58e-14	Testicular germ cell tumor;
LIHC	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg27005118	chr17:13972210	COX10	-0.38	-7.24	-0.36	2.91e-12	Temperament;
LIHC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg03264133	chr6:25882463	NA	-0.41	-6.22	-0.32	1.48e-9	Height;
LIHC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.07	9.91	0.47	1.57e-20	Diabetic retinopathy;
LIHC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg04166393	chr7:2884313	GNA12	0.43	6.02	0.31	4.48e-9	Height;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07685765	chr19:48964041	KCNJ14	-0.33	-6.38	-0.33	5.75e-10	Calcium levels;
LIHC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.25	-0.32	1.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25632853	chr15:73088954	NA	0.37	6.17	0.32	1.93e-9	Triglyceride levels;
LIHC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.25	13.52	0.59	1.15e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.18	-0.32	1.81e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg25894440	chr7:65020034	NA	-0.52	-5.79	-0.3	1.6e-8	Diabetic kidney disease;
LIHC	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.41e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.57	7.88	0.39	4.37e-14	Bladder cancer;
LIHC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.73	-13.59	-0.59	6.38e-34	Mortality in heart failure;
LIHC	cis	rs7238033	0.663	rs12454680	chr18:43321417	T/C	cg20610511	chr18:43302872	SLC14A1	0.35	5.82	0.3	1.37e-8	Bladder cancer;
LIHC	cis	rs7818688	0.697	rs74633621	chr8:95981037	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg01629716	chr15:45996671	NA	0.51	9.21	0.45	3.44e-18	Waist circumference;Weight;
LIHC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.85	0.35	3.49e-11	Lung cancer;
LIHC	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg14067834	chr17:29058358	SUZ12P	-0.65	-6.17	-0.32	1.9e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20689054	chr4:153457152	FBXW7	0.41	6.03	0.31	4.17e-9	Electrocardiographic conduction measures;
LIHC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04530015	chr2:215796436	ABCA12	-0.4	-6.57	-0.33	1.86e-10	Neuroblastoma;
LIHC	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg01864069	chr14:103024347	NA	0.36	5.96	0.31	6.38e-9	Platelet count;
LIHC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg22079354	chr11:130786696	SNX19	0.42	6.03	0.31	4.18e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-1.2	-16.23	-0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	9.41	0.45	7.48e-19	Total body bone mineral density;
LIHC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.34	0.55	3.52e-29	Alzheimer's disease;
LIHC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-1.02	-19.42	-0.72	3.74e-57	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04794120	chr7:48019205	HUS1	-0.48	-7.16	-0.36	4.99e-12	Pancreatic cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07551314	chr1:26190155	PAQR7	0.5	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12463550	chr7:65579703	CRCP	0.68	7.05	0.36	9.9e-12	Diabetic kidney disease;
LIHC	cis	rs6466055	0.720	rs6466064	chr7:105024217	T/C	cg04380332	chr7:105027541	SRPK2	-0.37	-6.88	-0.35	2.83e-11	Schizophrenia;
LIHC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.67	11.66	0.53	1.11e-26	Diastolic blood pressure;
LIHC	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.19	-0.32	1.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg25364880	chr3:44379878	C3orf23	0.42	5.89	0.3	9.11e-9	Depressive symptoms;
LIHC	cis	rs9322817	0.583	rs7741733	chr6:105182839	T/C	cg02098413	chr6:105308735	HACE1	-0.43	-7.78	-0.39	8.37e-14	Thyroid stimulating hormone;
LIHC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg16836995	chr17:43662488	NA	-0.76	-7.71	-0.38	1.41e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg04118878	chr10:71993077	PPA1	0.57	5.75	0.3	1.98e-8	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.23	0.61	1.96e-36	Chronic sinus infection;
LIHC	cis	rs2834188	1.000	rs2252930	chr21:34704201	C/G	cg04842828	chr21:34696676	IFNAR1	-0.49	-6.32	-0.32	7.97e-10	Narcolepsy;
LIHC	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00938859	chr5:1591904	SDHAP3	0.57	7.09	0.36	7.91e-12	Breast cancer;
LIHC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	9.69	0.46	9.09e-20	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg14067834	chr17:29058358	SUZ12P	0.72	7.34	0.37	1.56e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.38	6.24	0.32	1.29e-9	Blood metabolite levels;
LIHC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.31	5.76	0.3	1.91e-8	Height;
LIHC	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.57	10.04	0.48	5.69e-21	Schizophrenia;
LIHC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	0.99	10.63	0.5	5.22e-23	Vitiligo;
LIHC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.91	0.35	2.38e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.45	6.79	0.34	4.94e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20237920	chr15:76225808	FBXO22OS;FBXO22	0.38	6.08	0.31	3.17e-9	Myopia (pathological);
LIHC	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.54	7.99	0.4	2.1e-14	Recombination rate (females);
LIHC	trans	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg10756647	chr7:56101905	PSPH	1.0	11.4	0.52	9.84e-26	Diabetic kidney disease;
LIHC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.38	5.91	0.3	8.21e-9	Glioblastoma;
LIHC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.6	8.97	0.44	1.94e-17	Recombination rate (females);
LIHC	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg05535760	chr7:792225	HEATR2	0.79	11.07	0.51	1.51e-24	Cerebrospinal P-tau181p levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06348038	chr1:207038460	IL20	0.5	6.8	0.35	4.6e-11	Lung function (FEV1/FVC);
LIHC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.34	-5.97	-0.31	6.05e-9	IgG glycosylation;
LIHC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.59	0.5	7.6e-23	Alzheimer's disease;
LIHC	trans	rs4714291	0.832	rs6917417	chr6:40104628	T/C	cg02267698	chr19:7991119	CTXN1	-0.4	-6.6	-0.34	1.56e-10	Strep throat;
LIHC	cis	rs11229555	0.609	rs34133416	chr11:58184720	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.59	5.94	0.31	6.99e-9	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg19894588	chr14:64061835	NA	-0.62	-8.58	-0.42	3.38e-16	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.13e-14	Neuroticism;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02290350	chr8:58132656	NA	0.49	8.83	0.43	5.72e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg20607798	chr8:58055168	NA	0.62	7.23	0.36	3.17e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	8.98	0.44	1.89e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.52	7.57	0.38	3.55e-13	Obesity-related traits;
LIHC	cis	rs7818688	0.697	rs11783878	chr8:95979261	C/T	cg16049864	chr8:95962084	TP53INP1	-0.52	-5.95	-0.31	6.53e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.54	8.38	0.41	1.42e-15	Blood protein levels;
LIHC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.84	14.73	0.62	2.31e-38	Bone mineral density;
LIHC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02290350	chr8:58132656	NA	0.42	8.88	0.43	3.83e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs9648428	0.515	rs11974488	chr7:36202112	G/T	cg14708893	chr7:36124863	NA	-0.41	-6.18	-0.32	1.79e-9	Obesity-related traits;
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.56	9.46	0.46	5.21e-19	Aortic root size;
LIHC	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs17106184	0.786	rs1278518	chr1:50897841	T/C	cg07174182	chr1:51127561	FAF1	-0.6	-6.69	-0.34	9.09e-11	Type 2 diabetes;
LIHC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-11.05	-0.51	1.74e-24	Platelet count;
LIHC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.22	-0.32	1.43e-9	Longevity;Endometriosis;
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg12792011	chr19:58661915	ZNF329	0.96	8.01	0.4	1.76e-14	Cholesterol, total;
LIHC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.5	-6.35	-0.32	6.76e-10	Schizophrenia;
LIHC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.11	0.31	2.71e-9	Schizophrenia;
LIHC	cis	rs2845885	0.744	rs2701540	chr11:63869107	T/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.59	-7.67	-0.38	1.84e-13	Body mass index;
LIHC	cis	rs3018712	0.532	rs2510396	chr11:68417652	G/C	cg16797656	chr11:68205561	LRP5	-0.44	-5.79	-0.3	1.56e-8	Total body bone mineral density;
LIHC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.85	12.19	0.55	1.26e-28	Glomerular filtration rate (creatinine);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23394849	chr1:38006089	SNIP1	-0.48	-7.08	-0.36	8.27e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-10.2	-0.48	1.69e-21	Chronic sinus infection;
LIHC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg18944383	chr4:111397179	ENPEP	0.34	7.96	0.4	2.52e-14	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25417551	chr17:35767582	TADA2A;ACACA	0.5	6.89	0.35	2.7e-11	Lung function (FEV1/FVC);
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg15382696	chr6:118971807	C6orf204	0.62	6.03	0.31	4.36e-9	Renal cell carcinoma;
LIHC	cis	rs16828019	0.777	rs12023079	chr1:41470111	G/A	cg03962019	chr1:41807865	NA	0.52	7.06	0.36	9.17e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs970821	1.000	rs17349815	chr8:124746417	C/G	cg00283535	chr8:124749564	ANXA13	0.35	5.97	0.31	6.04e-9	Breast cancer;
LIHC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.21	-0.45	3.32e-18	Electroencephalogram traits;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg22528358	chr1:107598549	PRMT6	0.7	11.55	0.53	2.75e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.5	7.88	0.39	4.27e-14	Alzheimer's disease (survival time);
LIHC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.7	13.9	0.6	4.1e-35	Body mass index;
LIHC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-6.64	-0.34	1.25e-10	Morning vs. evening chronotype;
LIHC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg00074818	chr8:8560427	CLDN23	-0.34	-5.82	-0.3	1.38e-8	Obesity-related traits;
LIHC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.49	-7.61	-0.38	2.62e-13	Breast size;
LIHC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.41	-6.45	-0.33	3.71e-10	Crohn's disease;
LIHC	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.33e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg15051221	chr5:177434457	FAM153C	0.33	5.85	0.3	1.16e-8	Methadone dose in opioid dependence;
LIHC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.68	8.42	0.41	1.04e-15	Mean platelet volume;
LIHC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.6	9.69	0.46	8.97e-20	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg03037974	chr15:76606532	NA	-0.51	-8.06	-0.4	1.27e-14	Blood metabolite levels;
LIHC	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.28	0.37	2.24e-12	Airflow obstruction;
LIHC	cis	rs2997447	0.846	rs3008225	chr1:26390181	T/A	cg19633962	chr1:26362018	EXTL1	-0.52	-5.89	-0.3	9.2e-9	QRS complex (12-leadsum);
LIHC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg19318889	chr4:1322082	MAEA	0.44	5.91	0.3	8.3e-9	Longevity;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.83	13.89	0.6	4.12e-35	Height;
LIHC	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	1.06	11.57	0.53	2.42e-26	IgG glycosylation;
LIHC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.8	-0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.08	20.83	0.75	8.17e-63	Multiple system atrophy;
LIHC	cis	rs7116495	1.000	rs635442	chr11:71570982	A/G	cg26138937	chr11:71823887	C11orf51	0.7	6.64	0.34	1.25e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg15448220	chr1:150897856	SETDB1	0.44	6.84	0.35	3.63e-11	Tonsillectomy;
LIHC	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.58	-8.46	-0.42	8.15e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22168489	chr12:122356033	WDR66	-0.48	-8.05	-0.4	1.36e-14	Mean corpuscular volume;
LIHC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02290350	chr8:58132656	NA	0.38	7.79	0.39	8.16e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg11764359	chr7:65958608	NA	-0.58	-6.05	-0.31	3.88e-9	Diabetic kidney disease;
LIHC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	15.22	0.64	2.68e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg05973401	chr12:123451056	ABCB9	0.46	6.21	0.32	1.56e-9	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.79	-17.48	-0.69	2.43e-49	Urate levels in lean individuals;
LIHC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.52	9.22	0.45	3.03e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.65	6.57	0.33	1.84e-10	Lymphocyte counts;
LIHC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.76	0.47	5.3e-20	Platelet count;
LIHC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.41	6.71	0.34	7.86e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.36	-6.84	-0.35	3.55e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs7902334	1.000	rs7902334	chr10:12645941	A/C	cg26169081	chr10:12648338	CAMK1D	-0.81	-9.93	-0.47	1.37e-20	Coronary artery aneurysm in Kawasaki disease;
LIHC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.5	-5.98	-0.31	5.5e-9	Iron status biomarkers;
LIHC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg06238570	chr21:40685208	BRWD1	0.6	7.23	0.36	3.26e-12	Cognitive function;
LIHC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.56	8.7	0.43	1.44e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.81e-11	Aortic root size;
LIHC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.82	-9.0	-0.44	1.62e-17	Vitiligo;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg15848620	chr12:58087721	OS9	-0.55	-7.51	-0.38	5.32e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg01864069	chr14:103024347	NA	0.37	6.21	0.32	1.53e-9	Platelet count;
LIHC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.6	10.26	0.49	1.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg27433088	chr4:174089019	GALNT7	-0.39	-7.21	-0.36	3.67e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.75	0.43	9.91e-17	Prudent dietary pattern;
LIHC	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.59	9.9	0.47	1.7e-20	Dupuytren's disease;
LIHC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.48	7.28	0.37	2.31e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02985541	chr2:219472218	PLCD4	0.4	7.38	0.37	1.23e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs963731	0.649	rs10153761	chr2:39262068	C/T	cg04010122	chr2:39346883	SOS1	-0.68	-6.11	-0.31	2.73e-9	Corticobasal degeneration;
LIHC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.07	15.54	0.64	1.36e-41	Cognitive function;
LIHC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.29	17.34	0.68	9.06e-49	Diabetic kidney disease;
LIHC	cis	rs9816226	0.591	rs6809651	chr3:185814642	G/A	cg00760338	chr3:185826511	ETV5	-0.68	-5.71	-0.3	2.46e-8	Obesity;Body mass index;
LIHC	cis	rs7129556	0.539	rs6592728	chr11:77247260	A/G	cg03570279	chr11:77446074	RSF1	-0.35	-6.44	-0.33	4.08e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.44	-6.51	-0.33	2.74e-10	Survival in rectal cancer;
LIHC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.96	18.38	0.7	6.07e-53	Menopause (age at onset);
LIHC	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg22356347	chr1:167427500	CD247	-0.4	-6.64	-0.34	1.24e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.73	-9.61	-0.46	1.67e-19	Asthma;
LIHC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs3790844	0.876	rs3790845	chr1:200006861	C/T	cg13229857	chr1:200006247	NR5A2	0.44	7.19	0.36	4.2e-12	Pancreatic cancer;
LIHC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	7.42	0.37	9.63e-13	Schizophrenia;
LIHC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.89	-0.35	2.68e-11	Response to antipsychotic treatment;
LIHC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.56	9.16	0.44	4.94e-18	Body mass index;
LIHC	trans	rs10411161	1.000	rs6509581	chr19:52363882	T/C	cg22319618	chr22:45562946	NUP50	-0.51	-6.91	-0.35	2.31e-11	Breast cancer;
LIHC	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.38	7.38	0.37	1.2e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.57	10.14	0.48	2.62e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	11.08	0.51	1.42e-24	Myopia (pathological);
LIHC	trans	rs12960119	0.536	rs12964768	chr18:23742176	C/T	cg05333146	chr16:67183725	B3GNT9	0.64	6.09	0.31	3e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.44	6.25	0.32	1.22e-9	Ulcerative colitis;
LIHC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.6	8.04	0.4	1.47e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.42	-7.23	-0.36	3.13e-12	Coronary artery disease;
LIHC	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg19633962	chr1:26362018	EXTL1	-0.69	-6.29	-0.32	9.47e-10	QRS complex (12-leadsum);
LIHC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg25356066	chr3:128598488	ACAD9	0.56	7.75	0.39	1.08e-13	IgG glycosylation;
LIHC	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.73	7.52	0.38	4.76e-13	Bipolar disorder;
LIHC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg13047869	chr3:10149882	C3orf24	0.5	6.08	0.31	3.23e-9	Alzheimer's disease;
LIHC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg25039879	chr17:56429692	SUPT4H1	0.52	7.28	0.37	2.29e-12	Cognitive test performance;
LIHC	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.81	14.11	0.61	5.84e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg03945807	chr20:60948434	NA	-0.36	-6.49	-0.33	2.93e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg00091569	chr3:40428383	ENTPD3	0.39	6.57	0.33	1.89e-10	Renal cell carcinoma;
LIHC	cis	rs116248771	0.739	rs12488447	chr3:158421824	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.25	0.32	1.25e-9	diarrhoeal disease at age 2;
LIHC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-7.83	-0.39	6.02e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.28	17.42	0.69	4.2e-49	Diabetic kidney disease;
LIHC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg14067834	chr17:29058358	SUZ12P	0.68	6.69	0.34	9.29e-11	Body mass index;
LIHC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.24	0.32	1.26e-9	Renal cell carcinoma;
LIHC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.06	15.39	0.64	5.35e-41	Cognitive function;
LIHC	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	0.69	7.8	0.39	7.82e-14	Coronary artery disease;
LIHC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.41	-6.52	-0.33	2.47e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7937890	0.560	rs2597194	chr11:14497269	C/T	cg02886208	chr11:14281011	SPON1	-0.49	-6.56	-0.33	1.94e-10	Mitochondrial DNA levels;
LIHC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-8.95	-0.44	2.26e-17	Gut microbiome composition (summer);
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.73	-10.94	-0.51	4.49e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.33	-0.58	6.42e-33	Coffee consumption (cups per day);
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.32	6.18	0.32	1.83e-9	Tonsillectomy;
LIHC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.67	0.38	1.83e-13	Alzheimer's disease;
LIHC	cis	rs8081395	0.769	rs12449331	chr17:57883646	T/C	cg13753209	chr17:57696993	CLTC	-0.47	-7.33	-0.37	1.63e-12	White blood cell count;
LIHC	trans	rs17185553	1.000	rs17185553	chr9:17934120	C/G	cg11549972	chr12:103358649	NA	0.61	6.15	0.32	2.21e-9	Small cell lung carcinoma;
LIHC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.85	13.91	0.6	3.46e-35	Colorectal cancer;
LIHC	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.38	-7.09	-0.36	7.69e-12	Height;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.71	-0.34	8.16e-11	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg00656387	chr3:40428638	ENTPD3	0.5	8.29	0.41	2.68e-15	Renal cell carcinoma;
LIHC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.58	-6.91	-0.35	2.43e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg12798992	chr6:167411361	FGFR1OP	0.45	6.63	0.34	1.3e-10	Crohn's disease;
LIHC	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg08528486	chr13:113648767	MCF2L	-0.4	-6.39	-0.33	5.57e-10	Systolic blood pressure;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21668880	chr6:34759629	UHRF1BP1	-0.46	-6.35	-0.32	6.88e-10	Lung cancer in ever smokers;
LIHC	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.59	-11.97	-0.54	8.22e-28	Plateletcrit;Platelet count;
LIHC	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	10.23	0.48	1.33e-21	Obesity-related traits;
LIHC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.85	-0.3	1.15e-8	Calcium levels;
LIHC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.71	9.92	0.47	1.52e-20	Cardiac Troponin-T levels;
LIHC	cis	rs77637988	0.578	rs7576964	chr2:48601448	G/T	cg15846641	chr2:48541264	FOXN2	0.59	7.98	0.4	2.18e-14	Joint mobility (Beighton score);
LIHC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.59	-8.42	-0.41	1.08e-15	Initial pursuit acceleration;
LIHC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg12463550	chr7:65579703	CRCP	0.73	7.64	0.38	2.26e-13	Diabetic kidney disease;
LIHC	cis	rs17106184	0.892	rs72900922	chr1:51095195	G/A	cg07174182	chr1:51127561	FAF1	-0.65	-7.04	-0.36	1.03e-11	Type 2 diabetes;
LIHC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.62	-7.78	-0.39	8.5e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.66	-0.38	1.99e-13	Chronic sinus infection;
LIHC	cis	rs4908768	0.501	rs6577494	chr1:8576925	C/T	cg20416874	chr1:8611966	RERE	-0.68	-14.62	-0.62	6.18e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.58	8.22	0.41	4.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg05552183	chr6:42928497	GNMT	0.42	5.94	0.31	6.96e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg22842854	chr12:123319900	HIP1R	0.66	8.14	0.4	7.2e-15	Schizophrenia;
LIHC	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.45	7.44	0.37	8.16e-13	Endometrial cancer;
LIHC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.75	11.28	0.52	2.61e-25	Coronary artery disease;
LIHC	cis	rs6783573	0.535	rs6442006	chr3:46629382	C/G	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.6	-6.64	-0.34	1.2e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21171335	chr12:122356390	WDR66	-0.46	-7.5	-0.38	5.45e-13	Mean corpuscular volume;
LIHC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.6	10.28	0.49	8.9e-22	Longevity;Endometriosis;
LIHC	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.57	8.43	0.41	9.64e-16	Retinal vascular caliber;
LIHC	cis	rs11112613	0.609	rs11112632	chr12:106041887	A/G	cg03607813	chr12:105948248	NA	-0.49	-7.8	-0.39	7.76e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.54	9.2	0.45	3.73e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg03465714	chr1:152285911	FLG	-0.31	-6.21	-0.32	1.56e-9	Inflammatory skin disease;
LIHC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.43	-7.44	-0.37	8.11e-13	Lung cancer;
LIHC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	1.0	14.47	0.62	2.44e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg14092571	chr14:90743983	NA	0.42	5.77	0.3	1.8e-8	Mortality in heart failure;
LIHC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.41	-0.53	8.75e-26	Chronic sinus infection;
LIHC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg14132834	chr19:41945861	ATP5SL	0.45	6.61	0.34	1.5e-10	Height;
LIHC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.44	-6.29	-0.32	9.94e-10	Dental caries;
LIHC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg02269571	chr22:50332266	NA	-0.59	-8.06	-0.4	1.28e-14	Schizophrenia;
LIHC	cis	rs72653721	0.713	rs60197525	chr6:11053289	T/C	cg13562911	chr6:11044106	ELOVL2	0.52	7.41	0.37	1.03e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17164693	chr10:124913828	BUB3	0.51	7.15	0.36	5.2e-12	Pancreatic cancer;
LIHC	cis	rs9322817	0.691	rs12203954	chr6:105295647	C/T	cg02098413	chr6:105308735	HACE1	0.44	8.33	0.41	1.92e-15	Thyroid stimulating hormone;
LIHC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25072359	chr17:41440525	NA	0.37	5.84	0.3	1.2e-8	Menopause (age at onset);
LIHC	trans	rs72960926	0.744	rs72954341	chr6:74947167	A/G	cg07247405	chr1:2484626	LOC115110	0.53	6.41	0.33	4.83e-10	Metabolite levels (MHPG);
LIHC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.5	0.33	2.77e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	6.1	0.31	2.84e-9	IgG glycosylation;
LIHC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg23485639	chr6:28045615	ZNF165	0.4	6.3	0.32	9.03e-10	Cardiac Troponin-T levels;
LIHC	cis	rs151997	0.569	rs62367393	chr5:50270360	C/A	cg06027927	chr5:50259733	NA	0.54	6.61	0.34	1.46e-10	Callous-unemotional behaviour;
LIHC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg21724239	chr8:58056113	NA	0.48	6.28	0.32	1.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.45	-7.77	-0.39	9.52e-14	Total body bone mineral density;
LIHC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.95	0.51	3.9e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.7	11.42	0.53	8.24e-26	Night sleep phenotypes;
LIHC	cis	rs1144333	0.655	rs17097681	chr1:76376926	C/T	cg22875332	chr1:76189707	ACADM	0.41	6.03	0.31	4.24e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18252515	chr7:66147081	NA	-0.44	-6.38	-0.33	5.68e-10	Aortic root size;
LIHC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.5	-12.26	-0.55	7.1e-29	Alzheimer's disease (late onset);
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.36	6.09	0.31	2.96e-9	Height;
LIHC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg00677901	chr16:88017247	BANP	0.52	8.02	0.4	1.74e-14	Menopause (age at onset);
LIHC	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.08	0.31	3.26e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.32	6.96	0.35	1.76e-11	Blood metabolite ratios;
LIHC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.26	-0.32	1.14e-9	Menarche (age at onset);
LIHC	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg08126542	chr6:37504118	NA	-0.36	-6.24	-0.32	1.29e-9	Cognitive performance;
LIHC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg07061783	chr6:25882402	NA	-0.53	-6.99	-0.35	1.42e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	0.9	16.74	0.67	2.29e-46	Eosinophil percentage of white cells;
LIHC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.45	6.0	0.31	4.97e-9	Obesity-related traits;
LIHC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.67	14.18	0.61	3.14e-36	Sense of smell;
LIHC	cis	rs7614311	0.689	rs73122704	chr3:63841228	C/T	cg22134162	chr3:63841271	THOC7	-0.55	-6.33	-0.32	7.83e-10	Lung function (FVC);Lung function (FEV1);
LIHC	trans	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.26	0.32	1.17e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg12798992	chr6:167411361	FGFR1OP	0.45	6.75	0.34	6.53e-11	Crohn's disease;
LIHC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.4	-5.78	-0.3	1.66e-8	Cognitive function;
LIHC	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg18876405	chr7:65276391	NA	-0.56	-9.43	-0.45	6.31e-19	Calcium levels;
LIHC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16262614	chr3:133464971	TF	0.28	6.48	0.33	3.29e-10	Iron status biomarkers;
LIHC	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.41	-7.35	-0.37	1.5e-12	Glaucoma;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg01287788	chr2:86362935	SNORD94;PTCD3	-0.5	-6.11	-0.31	2.73e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.8	0.65	1.35e-42	Chronic sinus infection;
LIHC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.56	-7.72	-0.39	1.31e-13	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08677398	chr8:58056175	NA	0.38	5.73	0.3	2.21e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16164276	chr3:11034345	SLC6A1	0.41	6.69	0.34	8.91e-11	Pancreatic cancer;
LIHC	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	19.29	0.72	1.3e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.77	-11.54	-0.53	2.94e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg19635926	chr16:89946313	TCF25	0.46	6.0	0.31	5.11e-9	Skin colour saturation;
LIHC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg18887096	chr2:219472410	PLCD4	0.37	6.39	0.33	5.47e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.93	-14.33	-0.61	8.5e-37	Sudden cardiac arrest;
LIHC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.5	7.78	0.39	8.81e-14	Total body bone mineral density;
LIHC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.26	-0.37	2.56e-12	IgG glycosylation;
LIHC	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.37	6.0	0.31	5.05e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.41	6.18	0.32	1.82e-9	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.99	0.51	2.87e-24	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08436942	chr4:4249992	TMEM128	0.48	6.39	0.33	5.36e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8081395	0.899	rs2645477	chr17:57845624	A/C	cg13753209	chr17:57696993	CLTC	-0.46	-7.02	-0.35	1.23e-11	White blood cell count;
LIHC	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.32	-6.2	-0.32	1.58e-9	Cancer;
LIHC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.32	7.07	0.36	8.53e-12	Ulcerative colitis;
LIHC	trans	rs2211698	1.000	rs1003532	chr21:35834630	C/T	cg18044562	chr7:50468399	IKZF1	-0.5	-7.14	-0.36	5.74e-12	Cancer;
LIHC	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.52	8.86	0.43	4.51e-17	Lymphocyte percentage of white cells;
LIHC	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.49	-9.01	-0.44	1.44e-17	Reticulocyte fraction of red cells;
LIHC	trans	rs11689435	0.925	rs1478591	chr2:218346062	A/T	cg13544946	chr9:35729779	TLN1	-0.44	-6.35	-0.32	6.82e-10	Metabolite levels (MHPG);
LIHC	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.05	-0.4	1.38e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs9914544	0.545	rs2892015	chr17:18786849	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.57	-0.33	1.82e-10	Educational attainment (years of education);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17059624	chr11:85358760	TMEM126A	0.49	6.82	0.35	4.2e-11	Pancreatic cancer;
LIHC	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	5.74	0.3	2.14e-8	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs9473924	0.618	rs61236902	chr6:50813055	C/G	cg14470998	chr6:50812995	TFAP2B	0.98	11.12	0.52	9.6e-25	Body mass index;
LIHC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.45	6.07	0.31	3.43e-9	Major depressive disorder;
LIHC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18252515	chr7:66147081	NA	-0.43	-6.3	-0.32	9.36e-10	Aortic root size;
LIHC	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	7.94	0.39	3.03e-14	LDL cholesterol;
LIHC	cis	rs7674212	0.510	rs2720468	chr4:104085153	A/G	cg16532752	chr4:104119610	CENPE	-0.43	-6.75	-0.34	6.31e-11	Type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06157335	chr1:53164003	C1orf163	0.4	6.25	0.32	1.19e-9	Pancreatic cancer;
LIHC	cis	rs986417	1.000	rs8021348	chr14:60952777	G/T	cg27398547	chr14:60952738	C14orf39	0.82	9.57	0.46	2.22e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.05	-0.31	3.74e-9	Colorectal cancer;
LIHC	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg10381502	chr11:71823885	C11orf51	-0.54	-5.78	-0.3	1.73e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-5.99	-0.31	5.37e-9	Menarche (age at onset);
LIHC	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.64e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22509189	chr2:225307070	NA	-0.5	-7.42	-0.37	9.6e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	trans	rs4714291	0.775	rs2949019	chr6:40051200	C/T	cg02267698	chr19:7991119	CTXN1	-0.42	-7.22	-0.36	3.34e-12	Strep throat;
LIHC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.11	17.32	0.68	1.1e-48	Gut microbiome composition (summer);
LIHC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.65	8.72	0.43	1.2e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.64	-0.34	1.24e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.41	-5.75	-0.3	1.93e-8	Total body bone mineral density;
LIHC	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.76	0.47	5.25e-20	Corneal astigmatism;
LIHC	cis	rs7091068	0.659	rs10732241	chr10:95468573	T/C	cg20715218	chr10:95462985	C10orf4	0.59	6.61	0.34	1.45e-10	Urinary tract infection frequency;
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.2	-0.32	1.61e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg02640540	chr1:67518911	SLC35D1	-0.49	-6.49	-0.33	3.08e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.67	-10.35	-0.49	5.02e-22	Lung cancer;
LIHC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.17	0.32	1.88e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg18944383	chr4:111397179	ENPEP	0.24	6.13	0.31	2.47e-9	Height;
LIHC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-6.11	-0.31	2.68e-9	Total body bone mineral density;
LIHC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.25	0.45	2.57e-18	Gut microbiome composition (summer);
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.58	9.69	0.46	8.53e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	9.15	0.44	5.21e-18	Menarche (age at onset);
LIHC	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg09795085	chr6:101329169	ASCC3	-0.52	-7.21	-0.36	3.65e-12	Neuroticism;
LIHC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.57	-9.5	-0.46	3.65e-19	Cognitive function;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.35	0.59	5.02e-33	Prudent dietary pattern;
LIHC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.64	11.27	0.52	2.99e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg10319629	chr12:132285459	NA	0.46	8.2	0.41	5.07e-15	Migraine;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05352688	chr1:211643515	NA	0.18	6.12	0.31	2.63e-9	Cognitive function;
LIHC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg23205692	chr1:25664452	TMEM50A	0.38	6.1	0.31	2.86e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg07133347	chr1:107600762	PRMT6	-0.45	-6.8	-0.35	4.69e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.22	-0.52	4.4e-25	Response to antipsychotic treatment;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg06497051	chr1:156261200	TMEM79	0.38	6.09	0.31	3.04e-9	Tonsillectomy;
LIHC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg21395723	chr22:39101663	GTPBP1	0.36	6.11	0.31	2.71e-9	Menopause (age at onset);
LIHC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.7	0.38	1.45e-13	Diastolic blood pressure;
LIHC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.53	8.65	0.42	1.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg14146966	chr2:61757674	XPO1	-0.44	-7.4	-0.37	1.08e-12	Tuberculosis;
LIHC	trans	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg10756647	chr7:56101905	PSPH	1.03	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg24826892	chr11:71159390	DHCR7	0.47	6.17	0.32	1.91e-9	Vitamin D levels;
LIHC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.92	-0.3	8.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.47	-6.46	-0.33	3.62e-10	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.43	7.99	0.4	2.16e-14	Prudent dietary pattern;
LIHC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg02527881	chr3:46936655	PTH1R	0.35	6.78	0.34	5.38e-11	Colorectal cancer;
LIHC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.16	-0.44	4.85e-18	Schizophrenia;
LIHC	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.45	-0.37	7.81e-13	Breast cancer;
LIHC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.45	7.63	0.38	2.35e-13	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.57	-8.98	-0.44	1.88e-17	Response to antidepressants and depression;
LIHC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.44	0.33	4.13e-10	Cognitive test performance;
LIHC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.48	7.05	0.36	9.79e-12	Aortic root size;
LIHC	cis	rs1401454	1.000	rs1837095	chr11:16245692	T/A	cg10927848	chr11:16298618	SOX6	-0.33	-6.08	-0.31	3.24e-9	Blood pressure;
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.44	-0.37	8.36e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	9.51	0.46	3.53e-19	Lung cancer in ever smokers;
LIHC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.85	-0.43	4.75e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.63	6.87	0.35	2.99e-11	Alzheimer's disease;
LIHC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	19.73	0.73	2.23e-58	Smoking behavior;
LIHC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.57	7.02	0.35	1.22e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.76	0.3	1.89e-8	Tuberculosis;
LIHC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg26338869	chr17:61819248	STRADA	-0.52	-6.89	-0.35	2.62e-11	Height;
LIHC	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.29	6.52	0.33	2.51e-10	Weight;
LIHC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	1.02	11.85	0.54	2.29e-27	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg18944383	chr4:111397179	ENPEP	0.24	6.29	0.32	9.86e-10	Height;
LIHC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg05941027	chr17:61774174	LIMD2	0.37	7.85	0.39	5.23e-14	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	trans	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg10756647	chr7:56101905	PSPH	-1.1	-13.4	-0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.52	-0.38	4.84e-13	Schizophrenia;
LIHC	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.59	9.23	0.45	2.94e-18	Platelet distribution width;
LIHC	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.04	15.79	0.65	1.47e-42	Corneal structure;
LIHC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.86	-14.43	-0.62	3.52e-37	Post bronchodilator FEV1;
LIHC	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.55	-9.55	-0.46	2.49e-19	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.26	6.2	0.32	1.59e-9	Heart rate;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00249093	chr19:5804642	NA	0.46	6.14	0.32	2.33e-9	Hepatitis;
LIHC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.65	10.18	0.48	1.89e-21	Resting heart rate;
LIHC	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.54	7.06	0.36	9.48e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.76	9.01	0.44	1.49e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	13.71	0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.28	21.37	0.76	5.78e-65	Corneal structure;
LIHC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.62	-9.34	-0.45	1.23e-18	Lung disease severity in cystic fibrosis;
LIHC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.63	-0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg10820045	chr2:198174542	NA	0.44	6.48	0.33	3.18e-10	Intracranial aneurysm;
LIHC	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg20991723	chr1:152506922	NA	0.55	9.53	0.46	3.1e-19	Hair morphology;
LIHC	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg21625330	chr8:9911636	MSRA	0.55	7.28	0.37	2.27e-12	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg19735590	chr5:154026979	NA	0.47	5.9	0.3	8.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.36	-5.78	-0.3	1.7e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.78	0.39	8.75e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.48	6.91	0.35	2.42e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-9.78	-0.47	4.49e-20	Mean corpuscular volume;
LIHC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.83	-0.57	4.85e-31	Colorectal cancer;
LIHC	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19671926	chr4:122722719	EXOSC9	0.51	7.89	0.39	3.99e-14	Type 2 diabetes;
LIHC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg17834443	chr8:19674713	INTS10	0.49	7.4	0.37	1.06e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00049502	chr12:112280971	C12orf47;MAPKAPK5	0.38	6.16	0.32	2.05e-9	Cognitive function;
LIHC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-9.04	-0.44	1.21e-17	Electrocardiographic conduction measures;
LIHC	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg01843034	chr6:37503916	NA	-0.46	-7.98	-0.4	2.17e-14	Cognitive performance;
LIHC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg20607798	chr8:58055168	NA	0.47	6.42	0.33	4.58e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.15	0.55	1.79e-28	Prudent dietary pattern;
LIHC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg12698349	chr2:225449008	CUL3	0.44	5.77	0.3	1.73e-8	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.92	11.62	0.53	1.58e-26	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg07424592	chr7:64974309	NA	0.8	9.43	0.45	6.25e-19	Diabetic kidney disease;
LIHC	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.45	0.37	7.77e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.24	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	trans	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.1	-0.31	2.83e-9	Pulmonary function;
LIHC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.25	6.02	0.31	4.56e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-1.0	-11.51	-0.53	3.93e-26	Vitiligo;
LIHC	trans	rs792448	0.743	rs2516331	chr1:212416989	C/A	cg20223728	chr6:6006398	NRN1	0.35	6.12	0.31	2.51e-9	White blood cell count (basophil);
LIHC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	8.09	0.4	1.05e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17756712	0.697	rs2294669	chr6:625673	C/G	cg14374089	chr6:596013	EXOC2	0.45	6.49	0.33	2.99e-10	Vertical cup-disc ratio;
LIHC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.65	13.7	0.6	2.39e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg05361325	chr10:32636312	EPC1	-0.52	-6.41	-0.33	4.77e-10	Sexual dysfunction (female);
LIHC	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.23	0.36	3.25e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2573652	0.722	rs968412	chr15:100544512	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.64	-11.1	-0.51	1.16e-24	Height;
LIHC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg17796960	chr10:135278976	LOC619207	-0.35	-5.79	-0.3	1.63e-8	Systemic lupus erythematosus;
LIHC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.51	-6.57	-0.33	1.92e-10	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.27	-0.41	3.05e-15	Gut microbiome composition (summer);
LIHC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.69	12.2	0.55	1.15e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.42	-7.19	-0.36	4.16e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.61	-9.95	-0.47	1.19e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19671926	chr4:122722719	EXOSC9	0.46	6.61	0.34	1.49e-10	Type 2 diabetes;
LIHC	cis	rs1866706	1.000	rs10766000	chr11:12886870	G/C	cg25843174	chr11:12811716	TEAD1	0.32	6.5	0.33	2.78e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4920343	0.698	rs591009	chr1:19086869	A/G	cg19637330	chr1:19110922	NA	0.33	6.08	0.31	3.28e-9	Knee osteoarthritis;
LIHC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.45	6.78	0.34	5.45e-11	Mean platelet volume;
LIHC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	7.98	0.4	2.19e-14	Body mass index;
LIHC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.94	-0.35	1.97e-11	Response to antipsychotic treatment;
LIHC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.09	0.48	3.97e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.94	-0.35	1.99e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.7	10.83	0.51	1.07e-23	Phospholipid levels (plasma);
LIHC	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg24112000	chr20:60950667	NA	-0.61	-9.77	-0.47	4.91e-20	Colorectal cancer;
LIHC	cis	rs8081395	0.836	rs1292061	chr17:57911230	A/G	cg13753209	chr17:57696993	CLTC	-0.48	-7.44	-0.37	8.07e-13	White blood cell count;
LIHC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.44	-7.96	-0.4	2.61e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.55	9.01	0.44	1.46e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12379764	chr21:47803548	PCNT	-0.53	-7.69	-0.38	1.5700000000000001e-13	Testicular germ cell tumor;
LIHC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg05941027	chr17:61774174	LIMD2	0.37	7.75	0.39	1.07e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs6934970	1.000	rs6934785	chr6:113124239	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-6.09	-0.31	3.1e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.69	-11.97	-0.54	8.24e-28	Prudent dietary pattern;
LIHC	trans	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg10208301	chr11:6592745	DNHD1	0.47	6.28	0.32	1.01e-9	Coronary artery calcification;
LIHC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg02272795	chr19:15279244	NOTCH3	-0.31	-5.75	-0.3	2.02e-8	Pulse pressure;
LIHC	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg05197062	chr11:11642011	GALNTL4	0.46	6.75	0.34	6.16e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.32	0.32	8.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.87	14.16	0.61	3.69e-36	Colorectal cancer;
LIHC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.19	-0.45	3.86e-18	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.89	12.91	0.57	2.4e-31	Sudden cardiac arrest;
LIHC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2710642	0.525	rs1386401	chr2:62889906	C/G	cg17519650	chr2:63277830	OTX1	0.45	7.04	0.36	1.09e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.68e-15	Motion sickness;
LIHC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.6	-0.56	3.56e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg06453172	chr10:134556979	INPP5A	0.56	7.83	0.39	6.09e-14	Migraine;
LIHC	cis	rs16828019	0.852	rs71648540	chr1:41722295	G/A	cg03387723	chr1:41708464	SCMH1	-0.44	-7.21	-0.36	3.66e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.04e-8	Coronary artery disease;
LIHC	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg12698662	chr3:15914712	MIR563	-0.37	-6.72	-0.34	7.42e-11	Mean platelet volume;
LIHC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	1.02	19.58	0.73	8.67e-58	Breast cancer;
LIHC	trans	rs3176789	0.624	rs11052978	chr12:9920478	G/A	cg18988856	chr7:99425577	CYP3A43	0.2	6.18	0.32	1.78e-9	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LIHC	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.71	10.7	0.5	3.19e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-8.89	-0.43	3.58e-17	Body mass index (adult);
LIHC	cis	rs17106184	1.000	rs57095912	chr1:51356830	T/G	cg07174182	chr1:51127561	FAF1	-0.76	-7.66	-0.38	1.97e-13	Type 2 diabetes;
LIHC	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.53	-8.84	-0.43	5.17e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.15e-11	Prudent dietary pattern;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20929545	chr11:118958046	HMBS	0.37	6.23	0.32	1.41e-9	Longevity;
LIHC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.35	-7.16	-0.36	5.02e-12	Colorectal cancer;
LIHC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.95	-0.47	1.22e-20	Chronic sinus infection;
LIHC	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.26	-0.32	1.13e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.36	9.76	0.47	5.13e-20	Weight;
LIHC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.79	-17.43	-0.69	3.77e-49	Urate levels in lean individuals;
LIHC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.88	0.39	4.49e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.69	10.2	0.48	1.72e-21	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg00091569	chr3:40428383	ENTPD3	-0.38	-6.53	-0.33	2.36e-10	Renal cell carcinoma;
LIHC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg16145915	chr7:1198662	ZFAND2A	0.3	5.75	0.3	2.02e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.63	-0.42	2.4e-16	Response to antipsychotic treatment;
LIHC	cis	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg16589663	chr20:23618590	CST3	-0.62	-6.25	-0.32	1.24e-9	Chronic kidney disease;
LIHC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg05760424	chr2:242988095	NA	-0.54	-7.14	-0.36	5.49e-12	Obesity-related traits;
LIHC	trans	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg17675199	chr6:35436792	RPL10A	-0.44	-9.21	-0.45	3.25e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	6.94	0.35	2e-11	Aortic root size;
LIHC	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.45	5.92	0.3	7.74e-9	Obesity (extreme);
LIHC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.69e-10	Waist circumference;Weight;
LIHC	cis	rs34540877	0.793	rs36054879	chr19:33150858	T/C	cg22980127	chr19:33182716	NUDT19	0.86	5.98	0.31	5.74e-9	Red cell distribution width;
LIHC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.82	6.88	0.35	2.87e-11	Body mass index;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06679563	chr19:33622563	WDR88	0.43	6.97	0.35	1.59e-11	Longevity;
LIHC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.68	11.09	0.51	1.24e-24	Platelet count;
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20011983	chr2:74347215	NA	-0.39	-5.75	-0.3	2e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21448741	chr8:58168803	NA	0.36	6.72	0.34	7.69e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.14e-8	Pulmonary function;
LIHC	trans	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg10756647	chr7:56101905	PSPH	0.63	8.6	0.42	2.84e-16	Corneal structure;
LIHC	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.7	9.85	0.47	2.5e-20	Lymphocyte counts;
LIHC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.45	0.53	6.71e-26	Alzheimer's disease (late onset);
LIHC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.49	-6.75	-0.34	6.51e-11	High light scatter reticulocyte count;
LIHC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.23	-0.32	1.34e-9	Coronary artery disease;
LIHC	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg02527881	chr3:46936655	PTH1R	-0.54	-11.92	-0.54	1.2e-27	Birth weight;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.28	-0.32	1.01e-9	Total body bone mineral density;
LIHC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.7	-6.69	-0.34	8.91e-11	Red cell distribution width;
LIHC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.7	10.78	0.5	1.65e-23	Monocyte count;
LIHC	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.57	-0.33	1.83e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.59	-10.42	-0.49	3.02e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.31	-6.21	-0.32	1.58e-9	DNA methylation (variation);
LIHC	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg08126542	chr6:37504118	NA	-0.37	-6.3	-0.32	9.03e-10	Cognitive performance;
LIHC	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22509189	chr2:225307070	NA	-0.64	-7.55	-0.38	4.12e-13	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.35	6.1	0.31	2.95e-9	Cognitive function;
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08280861	chr8:58055591	NA	0.53	6.63	0.34	1.34e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7818688	0.546	rs13250762	chr8:95987570	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	5.77	0.3	1.81e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.51	8.07	0.4	1.19e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg26939375	chr7:64535504	NA	0.44	6.72	0.34	7.41e-11	Aortic root size;
LIHC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.36	-6.4	-0.33	5.16e-10	Aortic root size;
LIHC	cis	rs6691722	0.503	rs6692646	chr1:24707629	C/T	cg18323236	chr1:24743029	NIPAL3	0.41	7.41	0.37	9.79e-13	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.93	-10.18	-0.48	1.93e-21	Red cell distribution width;
LIHC	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg16589663	chr20:23618590	CST3	0.76	7.88	0.39	4.47e-14	Chronic kidney disease;
LIHC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.47	-17.98	-0.7	2.32e-51	Breast cancer;
LIHC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.35	-6.43	-0.33	4.3e-10	Platelet distribution width;
LIHC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.2	-0.41	4.92e-15	Chronic sinus infection;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg21304211	chr1:112281877	C1orf183	0.42	6.3	0.32	9.25e-10	Migraine with aura;
LIHC	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.7	-12.14	-0.55	1.84e-28	Pediatric autoimmune diseases;
LIHC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg07671805	chr5:74907694	NA	-0.47	-5.8	-0.3	1.49e-8	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	trans	rs6866721	0.791	rs7724649	chr5:116216985	T/G	cg07571379	chr11:134631427	NA	-0.28	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	1.08	14.69	0.62	3.18e-38	Heart rate;
LIHC	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-0.82	-9.65	-0.46	1.24e-19	Gut microbiota (bacterial taxa);
LIHC	trans	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg25214090	chr10:38739885	LOC399744	-0.4	-6.53	-0.33	2.38e-10	Diastolic blood pressure;
LIHC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg12365402	chr11:9010492	NRIP3	-0.31	-8.09	-0.4	1.03e-14	Hemoglobin concentration;
LIHC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.9	0.3	8.57e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.68	-8.31	-0.41	2.23e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg06207120	chr15:45996521	NA	0.32	6.02	0.31	4.55e-9	Waist circumference;Weight;
LIHC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.46	-0.49	2.12e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs9943465	0.688	rs318929	chr10:132071772	T/C	cg12765123	chr10:132100019	NA	0.43	6.12	0.31	2.64e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg03859395	chr2:55845619	SMEK2	0.9	15.68	0.65	3.88e-42	Metabolic syndrome;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17342834	chr11:535396	HRAS	0.61	7.64	0.38	2.26e-13	Hepatitis;
LIHC	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg10820045	chr2:198174542	NA	0.53	8.86	0.43	4.41e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.63	9.32	0.45	1.46e-18	Bipolar disorder;
LIHC	cis	rs8084351	0.599	rs12604508	chr18:50730441	A/G	cg24270629	chr18:50823537	DCC	-0.45	-6.59	-0.34	1.7e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.7	8.93	0.43	2.7e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.55	0.64	1.25e-41	Chronic sinus infection;
LIHC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.37	-6.22	-0.32	1.48e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.47	-7.55	-0.38	3.9e-13	Neurofibrillary tangles;
LIHC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.34	-0.32	7.15e-10	Schizophrenia;
LIHC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.61	-5.97	-0.31	5.9e-9	Urate levels in lean individuals;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27391037	chr22:18560705	PEX26	0.4	6.18	0.32	1.86e-9	Lung function (FEV1/FVC);
LIHC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.58	6.72	0.34	7.66e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19623624	chr10:135278901	LOC619207	-0.45	-6.99	-0.35	1.43e-11	Systemic lupus erythematosus;
LIHC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4699052	0.963	rs56144793	chr4:104150653	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-6.62	-0.34	1.43e-10	Testicular germ cell tumor;
LIHC	cis	rs35123781	0.696	rs13179952	chr5:139070573	C/G	cg10513866	chr5:139070639	NA	0.45	5.83	0.3	1.31e-8	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.95	0.35	1.91e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.45	-7.69	-0.38	1.56e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg15208524	chr1:10270712	KIF1B	0.46	6.79	0.34	5.07e-11	Hepatocellular carcinoma;
LIHC	cis	rs4908768	0.501	rs6577502	chr1:8615577	T/C	cg20416874	chr1:8611966	RERE	-0.7	-15.26	-0.64	1.9e-40	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13430225	chr1:53662423	CPT2	0.49	6.25	0.32	1.21e-9	Hepatitis;
LIHC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg17279839	chr7:150038598	RARRES2	0.59	11.97	0.54	7.99e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.77	-14.82	-0.63	9.88e-39	Mortality in heart failure;
LIHC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.65	13.64	0.59	3.82e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.15e-9	Mortality in heart failure;
LIHC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg26338869	chr17:61819248	STRADA	0.53	7.18	0.36	4.33e-12	Height;
LIHC	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.54	6.96	0.35	1.77e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs7106204	1.000	rs12798139	chr11:24220907	A/G	ch.11.24196551F	chr11:24239977	NA	0.69	6.98	0.35	1.51e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg03934865	chr2:198174659	NA	-0.48	-6.96	-0.35	1.72e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17497049	chr19:56110871	FIZ1;ZNF524	0.46	6.31	0.32	8.42e-10	Lung function (FEV1/FVC);
LIHC	cis	rs365132	0.875	rs353495	chr5:176430723	T/C	cg16309518	chr5:176445507	NA	-0.53	-9.89	-0.47	1.88e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg04998671	chr14:104000505	TRMT61A	-0.41	-5.75	-0.3	1.94e-8	Coronary artery disease;
LIHC	trans	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.69	7.27	0.37	2.52e-12	Exhaled nitric oxide output;
LIHC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.34	0.45	1.31e-18	Bipolar disorder;
LIHC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.11	0.58	4.33e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg18898632	chr2:242989856	NA	-0.59	-7.88	-0.39	4.46e-14	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.47	-7.83	-0.39	6.24e-14	Mean corpuscular volume;
LIHC	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.83	11.39	0.52	1.07e-25	Body mass index;
LIHC	trans	rs6600671	1.000	rs12047116	chr1:121185770	G/A	cg09829573	chr1:144692074	NBPF9	-0.43	-7.83	-0.39	6.27e-14	Hip geometry;
LIHC	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg20569855	chr1:109824440	PSRC1	0.52	6.63	0.34	1.3100000000000001e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.5	-8.59	-0.42	3.24e-16	Pubertal anthropometrics;
LIHC	cis	rs11229555	0.574	rs12272096	chr11:58186118	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04530015	chr2:215796436	ABCA12	-0.4	-6.43	-0.33	4.21e-10	Neuroblastoma;
LIHC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.5	-8.11	-0.4	9.41e-15	Crohn's disease;
LIHC	trans	rs6897795	1.000	rs6897795	chr5:177606419	G/A	cg19598605	chr2:70056955	GMCL1	-0.62	-7.57	-0.38	3.47e-13	Plateletcrit;
LIHC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.54	-0.46	2.84e-19	Obesity-related traits;
LIHC	cis	rs959260	1.000	rs2385264	chr17:73364992	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.83	-0.3	1.25e-8	Systemic lupus erythematosus;
LIHC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg16102536	chr7:156981717	UBE3C	-0.35	-5.9	-0.3	8.69e-9	Body mass index;
LIHC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.47	11.48	0.53	5.07e-26	Diastolic blood pressure;
LIHC	cis	rs17213078	0.505	rs6735859	chr2:106744603	T/C	cg16099169	chr2:106886729	NA	0.38	5.97	0.31	5.78e-9	Facial morphology (factor 23);
LIHC	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19671926	chr4:122722719	EXOSC9	0.49	7.25	0.36	2.83e-12	Type 2 diabetes;
LIHC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg26441486	chr22:50317300	CRELD2	0.35	6.17	0.32	1.88e-9	Schizophrenia;
LIHC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.74	-13.8	-0.6	1e-34	Height;
LIHC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	0.96	18.34	0.7	8.49e-53	Male-pattern baldness;
LIHC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.37e-18	Subjective well-being;
LIHC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.38	-0.49	3.9e-22	Lung cancer;
LIHC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00152838	chr16:24741724	TNRC6A	-0.49	-6.56	-0.33	2.01e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.74	0.3	2.07e-8	Height;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg01852063	chr16:1500567	CLCN7	0.34	6.07	0.31	3.49e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.55	7.01	0.35	1.26e-11	Initial pursuit acceleration;
LIHC	cis	rs6907629	0.704	rs879840	chr6:167558739	C/T	cg13805183	chr6:167554790	NA	-0.26	-6.07	-0.31	3.36e-9	Asthma (childhood onset);
LIHC	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.32	7.26	0.37	2.62e-12	Blood metabolite ratios;
LIHC	cis	rs12960505	0.506	rs878571	chr18:50960222	T/C	cg24270629	chr18:50823537	DCC	-0.49	-6.72	-0.34	7.53e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs56292044	0.706	rs10092669	chr8:138776004	A/G	cg05886954	chr16:3631570	BTBD12	0.32	6.13	0.31	2.47e-9	Post bronchodilator FEV1/FVC ratio in COPD;
LIHC	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg05372495	chr19:1063624	ABCA7	-0.42	-6.72	-0.34	7.79e-11	Alzheimer's disease (late onset);
LIHC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg18887096	chr2:219472410	PLCD4	0.35	6.06	0.31	3.63e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.29	5.85	0.3	1.12e-8	Bone mineral density;
LIHC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.38	-11.71	-0.53	7.6e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.75	-0.34	6.35e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.47	7.22	0.36	3.44e-12	Morning vs. evening chronotype;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.44	7.39	0.37	1.16e-12	Testicular germ cell tumor;
LIHC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.65	-11.8	-0.54	3.39e-27	Height;
LIHC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	trans	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg17675199	chr6:35436792	RPL10A	-0.45	-9.18	-0.44	4.25e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10878170	chr12:12764498	CREBL2	0.37	6.1	0.31	2.82e-9	Calcium levels;
LIHC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.42	8.37	0.41	1.51e-15	Cardiovascular disease risk factors;
LIHC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06050784	chr16:88016603	BANP	0.36	6.55	0.33	2.15e-10	Menopause (age at onset);
LIHC	cis	rs5769765	0.773	rs7410304	chr22:50316835	T/C	cg26441486	chr22:50317300	CRELD2	0.38	6.45	0.33	3.91e-10	Schizophrenia;
LIHC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.4e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg06238570	chr21:40685208	BRWD1	-0.38	-6.17	-0.32	1.89e-9	Menarche (age at onset);
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.42	7.06	0.36	9.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs17152411	0.947	rs733400	chr10:126594340	G/A	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.35	0.64	8.19e-41	Chronic sinus infection;
LIHC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.53	-0.42	4.85e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.63	9.82	0.47	3.29e-20	Longevity;Endometriosis;
LIHC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.01	0.35	1.3e-11	Height;
LIHC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11645453	chr3:52864694	ITIH4	-0.22	-5.73	-0.3	2.2e-8	Bipolar disorder;
LIHC	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.47	7.59	0.38	3.05e-13	Adiposity;
LIHC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.54	0.56	6.33e-30	Total body bone mineral density;
LIHC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs16828019	0.929	rs1032728	chr1:41679566	A/T	cg20697417	chr1:41786797	NA	0.34	6.5	0.33	2.78e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.9	8.78	0.43	7.76e-17	Inflammatory bowel disease;
LIHC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.41	5.81	0.3	1.41e-8	Blood protein levels;
LIHC	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.25	-6.15	-0.32	2.22e-9	Melanoma;
LIHC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.55	-5.97	-0.31	6.01e-9	Coronary artery disease;
LIHC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg15123519	chr2:136567270	LCT	0.44	8.85	0.43	4.86e-17	Mosquito bite size;
LIHC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.61	7.49	0.38	6.09e-13	Heart rate;
LIHC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.39	-6.49	-0.33	2.95e-10	Paraoxonase activity;
LIHC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.41	-6.5	-0.33	2.9e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.49	6.81	0.35	4.39e-11	Blood protein levels;
LIHC	cis	rs4934494	0.681	rs3740035	chr10:91476465	T/C	cg19698084	chr10:91461284	KIF20B	-0.47	-6.35	-0.32	6.84e-10	Red blood cell count;
LIHC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.33	5.72	0.3	2.38e-8	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.41	7.37	0.37	1.31e-12	Schizophrenia;
LIHC	cis	rs7945718	0.535	rs7114698	chr11:12707876	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.75	0.39	1.09e-13	Educational attainment (years of education);
LIHC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.71	6.85	0.35	3.54e-11	Breast cancer;
LIHC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.98	-0.31	5.68e-9	Colorectal cancer;
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11987759	chr7:65425863	GUSB	-0.39	-6.11	-0.31	2.75e-9	Aortic root size;
LIHC	cis	rs10949834	0.715	rs710968	chr7:73497728	A/G	cg07137043	chr7:73588983	EIF4H	0.56	6.19	0.32	1.71e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.66	13.77	0.6	1.21e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs787274	0.867	rs787279	chr9:115539514	T/C	cg13803584	chr9:115635662	SNX30	-0.56	-6.25	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.44	-5.94	-0.31	6.84e-9	Initial pursuit acceleration;
LIHC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.48	5.83	0.3	1.25e-8	Bladder cancer;
LIHC	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.61	9.83	0.47	2.95e-20	Response to antidepressants and depression;
LIHC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.46	7.2	0.36	3.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18691055	chr10:129924607	MKI67	-0.47	-6.24	-0.32	1.32e-9	Pancreatic cancer;
LIHC	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.38	-13.24	-0.58	1.4e-32	Psoriasis vulgaris;
LIHC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs965469	1.000	rs2281497	chr20:3258874	G/A	cg25506879	chr20:3388711	C20orf194	-0.59	-7.26	-0.37	2.67e-12	IFN-related cytopenia;
LIHC	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg17425144	chr1:10567563	PEX14	0.63	12.89	0.57	2.92e-31	Breast size;
LIHC	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.66	-0.42	1.95e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.29e-11	Prudent dietary pattern;
LIHC	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-5.85	-0.3	1.14e-8	Ulcerative colitis;
LIHC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg23250374	chr4:57253573	AASDH	-0.38	-6.05	-0.31	3.77e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.13	-0.31	2.37e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.24e-12	Post bronchodilator FEV1;
LIHC	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg14515779	chr1:101123966	NA	-0.46	-6.61	-0.34	1.46e-10	Monocyte count;
LIHC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.42	-8.44	-0.42	9.17e-16	Obesity-related traits;
LIHC	cis	rs9378688	0.654	rs2505678	chr6:2344158	A/G	cg12303981	chr6:2244766	GMDS	-0.45	-6.06	-0.31	3.62e-9	Caudate nucleus volume;
LIHC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg17135325	chr3:160939158	NMD3	0.52	7.46	0.37	7.39e-13	Parkinson's disease;
LIHC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.7	0.43	1.41e-16	Multiple sclerosis;
LIHC	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg17640201	chr16:30407289	ZNF48	0.47	7.5	0.38	5.49e-13	Tonsillectomy;
LIHC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg07451762	chr16:28383216	NA	0.35	6.43	0.33	4.19e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg16586182	chr3:47516702	SCAP	-0.54	-9.86	-0.47	2.43e-20	Colorectal cancer;
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.85	0.3	1.14e-8	Calcium levels;
LIHC	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.54	-7.56	-0.38	3.83e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.55	-7.15	-0.36	5.13e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	7.98	0.4	2.28e-14	Parkinson's disease;
LIHC	cis	rs16828019	0.929	rs35813191	chr1:41742800	T/C	cg03962019	chr1:41807865	NA	0.53	7.6	0.38	2.89e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg17466768	chr2:25194156	DNAJC27	-0.41	-5.98	-0.31	5.74e-9	Body mass index;
LIHC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.5	-7.64	-0.38	2.17e-13	Corneal astigmatism;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16684958	chr7:75615977	POR	-0.51	-8.48	-0.42	6.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.64	11.0	0.51	2.59e-24	Superior crus of antihelix expression;
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg11598736	chr3:195384522	SDHAP2	0.73	8.75	0.43	9.84e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2073300	1.000	rs6048826	chr20:23458050	C/A	cg12062639	chr20:23401060	NAPB	0.78	9.87	0.47	2.16e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.42	-0.45	7.09e-19	Blood metabolite levels;
LIHC	cis	rs1494950	0.661	rs72491263	chr4:15080600	C/T	cg12377275	chr4:15005593	CPEB2	-0.88	-7.56	-0.38	3.77e-13	Political ideology;
LIHC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.62	10.8	0.5	1.32e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.29	-5.86	-0.3	1.09e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.23	0.36	3.23e-12	Height;
LIHC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	5.97	0.31	5.84e-9	Schizophrenia;
LIHC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.86	10.41	0.49	3.1e-22	Cognitive function;
LIHC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.64	-0.38	2.19e-13	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	7.11	0.36	7.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.75	-11.12	-0.52	9.65e-25	Menarche (age at onset);
LIHC	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg03999872	chr20:62272968	STMN3	-0.44	-6.54	-0.33	2.3e-10	Atopic dermatitis;
LIHC	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.56	7.87	0.39	4.6e-14	Schizophrenia;
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.82	0.3	1.33e-8	Calcium levels;
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	0.96	8.25	0.41	3.52e-15	Lymphocyte counts;
LIHC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.67	11.39	0.52	1.1e-25	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02781704	chr3:194033517	NA	-0.51	-6.9	-0.35	2.48e-11	Pancreatic cancer;
LIHC	cis	rs9513627	0.920	rs2390280	chr13:100208802	A/G	cg25919922	chr13:100150906	NA	0.76	6.67	0.34	1.02e-10	Obesity-related traits;
LIHC	cis	rs903552	0.673	rs4965878	chr15:102009589	C/T	cg00659931	chr15:102010125	PCSK6	-0.52	-6.93	-0.35	2.07e-11	Diabetic kidney disease;
LIHC	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.93	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	cis	rs7756236	0.521	rs9462208	chr6:36627890	T/C	cg08179530	chr6:36648295	CDKN1A	0.41	6.07	0.31	3.41e-9	QRS duration;
LIHC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.48	6.97	0.35	1.68e-11	Bone mineral density;
LIHC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	6.43	0.33	4.35e-10	Parkinson's disease;
LIHC	cis	rs3790844	0.955	rs3790848	chr1:200006111	C/A	cg07208853	chr1:200005219	NR5A2	0.35	7.65	0.38	2.11e-13	Pancreatic cancer;
LIHC	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg03934865	chr2:198174659	NA	0.46	6.58	0.34	1.74e-10	Dermatomyositis;
LIHC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.04	14.53	0.62	1.36e-37	Sexual dysfunction (female);
LIHC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00152838	chr16:24741724	TNRC6A	-0.48	-6.43	-0.33	4.41e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1865721	1.000	rs17283454	chr18:73186619	G/A	cg26385618	chr18:73139727	C18orf62	-0.3	-7.75	-0.39	1.07e-13	Intelligence;
LIHC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.77	-13.25	-0.58	1.25e-32	Aortic root size;
LIHC	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	0.66	8.49	0.42	6.18e-16	Corneal structure;
LIHC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.36	-9.4	-0.45	7.95e-19	Longevity;Endometriosis;
LIHC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-8.44	-0.42	9.01e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2834188	1.000	rs2026254	chr21:34688032	C/T	cg14352951	chr21:34696688	IFNAR1	0.48	6.59	0.34	1.69e-10	Narcolepsy;
LIHC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.64	0.56	2.67e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg03037974	chr15:76606532	NA	0.74	14.52	0.62	1.56e-37	Blood metabolite levels;
LIHC	trans	rs6934970	0.860	rs12213194	chr6:112984943	C/T	cg09308777	chr6:169852575	NA	0.59	6.04	0.31	3.93e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.68e-9	Life satisfaction;
LIHC	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg13628971	chr7:2884303	GNA12	-0.33	-5.75	-0.3	1.96e-8	Plateletcrit;
LIHC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.42	0.41	1.02e-15	Coronary artery disease;
LIHC	trans	rs1814175	0.645	rs599890	chr11:49711718	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.44	-0.74	2.93e-61	Height;
LIHC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.56	-7.62	-0.38	2.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.25e-16	Schizophrenia;
LIHC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.11	-0.31	2.7e-9	Menarche (age at onset);
LIHC	cis	rs611744	0.967	rs653081	chr8:109230383	G/T	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.4	-0.37	1.05e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.75	10.44	0.49	2.39e-22	Lymphocyte counts;
LIHC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.19	0.32	1.72e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.88	-14.65	-0.62	4.75e-38	Gut microbiota (bacterial taxa);
LIHC	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg22563815	chr15:78856949	CHRNA5	0.36	6.45	0.33	3.9e-10	Sudden cardiac arrest;
LIHC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21448741	chr8:58168803	NA	0.38	6.12	0.31	2.54e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs62458065	1.000	rs6462363	chr7:32464759	T/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.64	-7.32	-0.37	1.77e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg25649188	chr17:73499917	CASKIN2	0.4	6.78	0.34	5.43e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.43	-6.72	-0.34	7.81e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs713477	1.000	rs8014526	chr14:55885054	C/G	cg13175173	chr14:55914753	NA	-0.32	-7.13	-0.36	5.98e-12	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.79	0.47	4.2e-20	Morning vs. evening chronotype;
LIHC	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-10.78	-0.5	1.64e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.31	-0.32	8.76e-10	Diabetic kidney disease;
LIHC	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg00204748	chr12:29376779	FAR2	-0.34	-6.36	-0.33	6.56e-10	QT interval;
LIHC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.32	-0.37	1.76e-12	Ulcerative colitis;
LIHC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg05941027	chr17:61774174	LIMD2	0.34	6.91	0.35	2.32e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.35	-5.72	-0.3	2.29e-8	Crohn's disease;
LIHC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.66	-9.28	-0.45	2.04e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.53	6.04	0.31	4.13e-9	Axial length;
LIHC	cis	rs1823913	0.895	rs10931491	chr2:192120813	G/A	cg12404831	chr2:192114017	MYO1B	-0.33	-6.5	-0.33	2.9e-10	Obesity-related traits;
LIHC	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.49	-7.43	-0.37	8.72e-13	Diastolic blood pressure;
LIHC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.27e-19	Initial pursuit acceleration;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-7.64	-0.38	2.17e-13	Lymphocyte counts;
LIHC	cis	rs12744310	1.000	rs36143444	chr1:41764310	C/T	cg03962019	chr1:41807865	NA	0.39	6.28	0.32	1.06e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25936770	chr7:122321411	CADPS2	0.41	6.35	0.32	6.84e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.56	-0.53	2.65e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.51	-7.69	-0.38	1.55e-13	HDL cholesterol;
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.28	-0.49	8.71e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.92	15.88	0.65	6.15e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg07817648	chr10:79422355	NA	-0.3	-6.1	-0.31	2.86e-9	Mortality in heart failure;
LIHC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.62	10.35	0.49	5.15e-22	Platelet count;
LIHC	cis	rs67257959	0.708	rs13343952	chr19:17197064	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.36	5.8	0.3	1.5e-8	Selective IgA deficiency;
LIHC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.43	-7.24	-0.36	2.9e-12	Height;
LIHC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.39	6.96	0.35	1.71e-11	Psoriasis;
LIHC	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.67	7.29	0.37	2.24e-12	Exhaled nitric oxide output;
LIHC	cis	rs965469	0.779	rs6133034	chr20:3337661	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-6.24	-0.32	1.27e-9	IFN-related cytopenia;
LIHC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg27432699	chr2:27873401	GPN1	-0.6	-8.59	-0.42	3.11e-16	Total body bone mineral density;
LIHC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.32	-7.18	-0.36	4.51e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.7	12.6	0.56	3.78e-30	Lewy body disease;
LIHC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.43	-6.11	-0.31	2.66e-9	Height;
LIHC	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.33	-5.92	-0.3	8.01e-9	Lewy body disease;
LIHC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.6	-9.84	-0.47	2.81e-20	Post bronchodilator FEV1;
LIHC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg10755058	chr3:40428713	ENTPD3	-0.35	-5.97	-0.31	6.06e-9	Renal cell carcinoma;
LIHC	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.47	0.46	4.91e-19	Corneal astigmatism;
LIHC	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.42	-6.3	-0.32	9.11e-10	Systemic sclerosis;
LIHC	cis	rs9309473	0.950	rs13427832	chr2:73844818	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.84	-0.35	3.61e-11	Metabolite levels;
LIHC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	8.49	0.42	6.55e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg22633049	chr21:46681294	NA	-0.36	-6.13	-0.31	2.47e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-11.82	-0.54	2.88e-27	Multiple sclerosis;
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.93	0.35	2.16e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg08499158	chr17:42289980	UBTF	0.48	7.95	0.4	2.66e-14	Total body bone mineral density;
LIHC	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.68	-0.46	9.29e-20	Morning vs. evening chronotype;
LIHC	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-0.76	-6.69	-0.34	9.24e-11	Blood protein levels;
LIHC	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	6.61	0.34	1.45e-10	Lymphocyte counts;
LIHC	trans	rs11614333	0.523	rs2098434	chr12:15004540	G/T	cg08449838	chr12:32112341	C12orf35	0.48	6.34	0.32	7.28e-10	Hand grip strength;
LIHC	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.89	9.97	0.47	1.02e-20	Alzheimer's disease (late onset);
LIHC	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.34	20.93	0.75	3.29e-63	Corneal structure;
LIHC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	6.82	0.35	4.11e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.26	-16.63	-0.67	6.04e-46	Diabetic kidney disease;
LIHC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.62	7.63	0.38	2.35e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.39	6.23	0.32	1.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg08847533	chr14:75593920	NEK9	-0.34	-5.72	-0.3	2.31e-8	Caffeine consumption;
LIHC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	9.61	0.46	1.59e-19	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg23978390	chr7:1156363	C7orf50	0.53	8.14	0.4	7.55e-15	Longevity;Endometriosis;
LIHC	cis	rs3736485	0.966	rs12592889	chr15:51795172	G/A	cg08986416	chr15:51914746	DMXL2	-0.4	-6.1	-0.31	2.91e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.55	-8.86	-0.43	4.34e-17	Brain structure;
LIHC	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.51	8.95	0.44	2.27e-17	Coronary artery disease;
LIHC	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.65	-9.39	-0.45	8.8e-19	White matter hyperintensity burden;
LIHC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02969873	chr4:1330999	MAEA	-0.41	-6.22	-0.32	1.47e-9	Longevity;
LIHC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21467203	chr3:49911342	NA	-0.53	-9.65	-0.46	1.16e-19	Body mass index;
LIHC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.22	0.36	3.37e-12	Obesity-related traits;
LIHC	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg10756647	chr7:56101905	PSPH	1.01	11.9	0.54	1.53e-27	Diabetic kidney disease;
LIHC	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-8.59	-0.42	3.24e-16	Total cholesterol levels;
LIHC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.73	8.06	0.4	1.25e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.19	0.58	2.12e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.71	0.38	1.35e-13	Prudent dietary pattern;
LIHC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.87	6.61	0.34	1.51e-10	IgG glycosylation;
LIHC	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.57	-9.16	-0.44	4.94e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg06565975	chr8:143823917	SLURP1	0.34	6.59	0.34	1.66e-10	Urinary tract infection frequency;
LIHC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19671926	chr4:122722719	EXOSC9	0.54	8.48	0.42	6.86e-16	Type 2 diabetes;
LIHC	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg08345082	chr10:99160200	RRP12	-0.36	-6.01	-0.31	4.74e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg10360323	chr17:41437877	NA	0.4	5.95	0.31	6.7e-9	Menopause (age at onset);
LIHC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg04013166	chr16:89971882	TCF25	0.49	5.91	0.3	8.48e-9	Skin colour saturation;
LIHC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.56	0.59	7.98e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08140343	chr19:37569236	ZNF420	-0.45	-6.45	-0.33	3.91e-10	Pancreatic cancer;
LIHC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	7.09	0.36	7.71e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg10756647	chr7:56101905	PSPH	1.02	12.09	0.55	2.84e-28	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02290350	chr8:58132656	NA	0.51	11.04	0.51	1.9e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.56	7.36	0.37	1.38e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs77637988	0.533	rs13398791	chr2:48622320	G/C	cg15846641	chr2:48541264	FOXN2	0.54	7.19	0.36	4.12e-12	Joint mobility (Beighton score);
LIHC	cis	rs11671005	0.735	rs35652377	chr19:58929200	A/C	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg02297831	chr4:17616191	MED28	0.4	6.47	0.33	3.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg16506815	chr2:162101123	NA	-0.41	-6.25	-0.32	1.21e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.97	0.35	1.61e-11	Morning vs. evening chronotype;
LIHC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.83	0.43	5.64e-17	Cognitive ability;
LIHC	cis	rs6782228	0.606	rs2811489	chr3:128337371	A/G	cg16766828	chr3:128327626	NA	0.41	6.46	0.33	3.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	1.07	14.92	0.63	3.91e-39	Heart rate;
LIHC	cis	rs9918079	0.560	rs4698402	chr4:15629803	G/A	cg16509355	chr4:15471240	CC2D2A	-0.44	-6.74	-0.34	6.83e-11	Obesity-related traits;
LIHC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg12661370	chr5:149340060	SLC26A2	-0.52	-6.38	-0.33	5.66e-10	HIV-1 control;
LIHC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg08132940	chr7:1081526	C7orf50	-0.84	-7.0	-0.35	1.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.65	0.38	2.03e-13	Height;
LIHC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.31	-0.32	8.59e-10	Response to antipsychotic treatment;
LIHC	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.45	6.0	0.31	4.93e-9	Obesity (extreme);
LIHC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.63	-9.72	-0.47	6.82e-20	Total body bone mineral density;
LIHC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg19680672	chr10:131412579	MGMT	-0.4	-6.09	-0.31	2.99e-9	Response to temozolomide;
LIHC	cis	rs1400745	0.756	rs3783316	chr14:35337192	A/G	cg16230307	chr14:35515116	FAM177A1	0.38	6.2	0.32	1.64e-9	Monocyte count;
LIHC	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.12	0.36	6.37e-12	Bipolar disorder;
LIHC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.87	-0.35	3.06e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg25952890	chr19:58913133	NA	0.71	7.81	0.39	7.16e-14	Mean platelet volume;
LIHC	trans	rs4596713	0.538	rs11145460	chr9:71766091	T/G	cg16512924	chr15:28394682	HERC2	0.4	6.41	0.33	4.8e-10	Headache;
LIHC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg18887096	chr2:219472410	PLCD4	0.35	6.01	0.31	4.75e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	7.86	0.39	5.1e-14	Schizophrenia;
LIHC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg14440974	chr22:39074834	NA	-0.34	-5.79	-0.3	1.63e-8	Menopause (age at onset);
LIHC	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.39	-7.76	-0.39	1e-13	Coronary artery disease or large artery stroke;
LIHC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.62	12.86	0.57	3.81e-31	Fat distribution (HIV);
LIHC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.95	12.51	0.56	7.7e-30	HIV-1 control;
LIHC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg24296786	chr1:45957014	TESK2	0.4	5.72	0.3	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1080261	0.504	rs6928183	chr6:110799201	A/G	cg22334665	chr6:110797497	SLC22A16	0.45	5.76	0.3	1.87e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
LIHC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.47	-6.81	-0.35	4.5e-11	Response to metformin (IC50);
LIHC	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19098793	chr7:1609793	KIAA1908;PSMG3	-0.46	-6.1	-0.31	2.87e-9	Pancreatic cancer;
LIHC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.11	12.98	0.57	1.32e-31	Vitiligo;
LIHC	cis	rs6584283	0.766	rs7911680	chr10:101293468	A/C	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.91	-0.3	8.25e-9	Ulcerative colitis;
LIHC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.62	5.86	0.3	1.1e-8	Vitiligo;
LIHC	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.44	-6.08	-0.31	3.28e-9	QT interval;
LIHC	cis	rs11229555	0.598	rs1893902	chr11:58190747	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.74	-0.39	1.12e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.62	7.29	0.37	2.12e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs16863064	0.660	rs1007308	chr3:187889723	C/T	cg02569115	chr17:76922138	TIMP2	0.34	6.09	0.31	3.04e-9	Schizophrenia;
LIHC	cis	rs922107	0.713	rs2061479	chr1:90044165	A/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.73	-0.39	1.24e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs77861329	1.000	rs2304505	chr3:52184760	T/C	cg08692210	chr3:52188851	WDR51A	0.84	7.96	0.4	2.65e-14	Macrophage inflammatory protein 1b levels;
LIHC	trans	rs2744203	1.000	rs60002471	chr6:104640064	C/G	cg27088726	chr16:83171155	CDH13	-0.46	-6.08	-0.31	3.14e-9	IgG glycosylation;
LIHC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg01364799	chr7:75623366	TMEM120A	0.51	7.54	0.38	4.14e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.32	-6.44	-0.33	4.16e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.08e-8	Coronary artery disease;
LIHC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.54	-9.54	-0.46	2.71e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.55	-7.8	-0.39	7.4e-14	Facial morphology (factor 19);
LIHC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.39	6.59	0.34	1.65e-10	Schizophrenia;
LIHC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg17980119	chr2:219472607	PLCD4	0.35	6.11	0.31	2.76e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.29	-0.32	9.9e-10	Breast cancer;
LIHC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.84	-0.39	5.62e-14	Personality dimensions;
LIHC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.54	-7.7	-0.38	1.5e-13	Body mass index;
LIHC	cis	rs10097731	0.901	rs28505206	chr8:82044410	A/G	cg25230327	chr8:82042993	NA	-0.6	-8.14	-0.4	7.31e-15	Serum total protein level;
LIHC	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-13.25	-0.58	1.21e-32	Coffee consumption (cups per day);
LIHC	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16684958	chr7:75615977	POR	0.52	8.59	0.42	3.22e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg25019722	chr6:37503610	NA	-0.32	-5.76	-0.3	1.87e-8	Cognitive performance;
LIHC	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.84	0.3	1.19e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg03146154	chr1:46216737	IPP	-0.4	-6.55	-0.33	2.11e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg07424592	chr7:64974309	NA	-0.81	-9.63	-0.46	1.45e-19	Diabetic kidney disease;
LIHC	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.5	-0.38	5.39e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg12437481	chr16:420112	MRPL28	-0.66	-9.76	-0.47	5.33e-20	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.48	-7.79	-0.39	7.99e-14	Longevity;Endometriosis;
LIHC	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.88	-10.38	-0.49	4.11e-22	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.91	0.57	2.5e-31	Prudent dietary pattern;
LIHC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.36	-8.66	-0.42	1.9e-16	Cutaneous nevi;
LIHC	cis	rs864643	1.000	rs572971	chr3:39561427	G/T	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs36051895	0.623	rs10283467	chr9:5244356	C/G	cg02405213	chr9:5042618	JAK2	0.63	10.18	0.48	1.93e-21	Pediatric autoimmune diseases;
LIHC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg26149184	chr10:133730230	NA	0.47	7.37	0.37	1.29e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.05	0.8	2.27e-79	Prudent dietary pattern;
LIHC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.72	-8.99	-0.44	1.7e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg05555928	chr11:63887634	MACROD1	0.56	7.57	0.38	3.5e-13	Mean platelet volume;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg23906291	chr17:37844223	PGAP3;ERBB2	-0.49	-6.82	-0.35	4.11e-11	Alopecia areata;
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.59	6.75	0.34	6.28e-11	Alzheimer's disease;
LIHC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-6.03	-0.31	4.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836950	0.501	rs1474490	chr21:40716136	C/A	cg11890956	chr21:40555474	PSMG1	-0.44	-7.08	-0.36	8.25e-12	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.88	-0.47	2.04e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03576123	chr11:487126	PTDSS2	-1.0	-7.02	-0.35	1.21e-11	Body mass index;
LIHC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.63e-9	Aortic root size;
LIHC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.14	0.36	5.5e-12	Bipolar disorder;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.5	-7.95	-0.39	2.74e-14	Testicular germ cell tumor;
LIHC	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.33	7.53	0.38	4.44e-13	Blood metabolite ratios;
LIHC	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.4	8.35	0.41	1.67e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg12863693	chr15:85201151	NMB	0.44	6.14	0.32	2.28e-9	Schizophrenia;
LIHC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.38	-5.88	-0.3	9.98e-9	Neurofibrillary tangles;
LIHC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.3	0.32	8.98e-10	Schizophrenia;
LIHC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.56	8.16	0.4	6.48e-15	Cognitive ability;
LIHC	cis	rs2997447	0.706	rs61776573	chr1:26429356	A/C	cg19633962	chr1:26362018	EXTL1	-0.62	-6.82	-0.35	4.03e-11	QRS complex (12-leadsum);
LIHC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.49	-0.33	3.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.57	-8.87	-0.43	4.04e-17	Dental caries;
LIHC	cis	rs4407350	1.000	rs4407350	chr22:44922275	G/A	cg12001887	chr22:44893917	LDOC1L	-0.34	-5.83	-0.3	1.28e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.93	-16.46	-0.66	3.06e-45	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.84	12.96	0.57	1.57e-31	Metabolic syndrome;
LIHC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.11	-0.31	2.78e-9	Ulcerative colitis;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.6	0.53	1.82e-26	Alzheimer's disease;
LIHC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.49	0.59	1.47e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.58	-9.64	-0.46	1.29e-19	Fibroblast growth factor basic levels;
LIHC	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.45	-7.2	-0.36	3.92e-12	Hepatocellular carcinoma;
LIHC	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.32	-8.87	-0.43	4.18e-17	Intelligence;
LIHC	cis	rs509477	0.718	rs273346	chr18:32603056	G/T	cg23791764	chr18:32556832	MAPRE2	0.45	6.1	0.31	2.81e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.81	0.57	5.9e-31	Prudent dietary pattern;
LIHC	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.19	0.4	5.37e-15	Morning vs. evening chronotype;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09256448	chr16:638327	NA	0.39	6.78	0.34	5.38e-11	Height;
LIHC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.48	0.46	4.54e-19	Electroencephalogram traits;
LIHC	cis	rs11229555	0.645	rs4347409	chr11:58176252	C/T	cg15696309	chr11:58395628	NA	0.64	7.51	0.38	5.04e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.01	0.58	1e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg03146154	chr1:46216737	IPP	-0.4	-6.54	-0.33	2.27e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg03387723	chr1:41708464	SCMH1	-0.44	-7.22	-0.36	3.35e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.53	7.98	0.4	2.29e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg03934865	chr2:198174659	NA	-0.45	-6.49	-0.33	2.96e-10	Intracranial aneurysm;
LIHC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg09238746	chr17:78121135	EIF4A3	-0.47	-7.06	-0.36	9.51e-12	Yeast infection;
LIHC	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.99	0.35	1.46e-11	Itch intensity from mosquito bite;
LIHC	cis	rs911119	0.955	rs55897275	chr20:23595953	A/T	cg16589663	chr20:23618590	CST3	0.72	7.6	0.38	2.88e-13	Chronic kidney disease;
LIHC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.52	8.86	0.43	4.58e-17	Coronary artery disease;
LIHC	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg09597638	chr17:3907349	NA	0.49	6.92	0.35	2.3e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.77	12.31	0.55	4.38e-29	Night sleep phenotypes;
LIHC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.76	0.47	5.25e-20	Tonsillectomy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14728310	chr19:9879317	ZNF846	0.51	7.1	0.36	7.11e-12	Lung function (FEV1/FVC);
LIHC	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.38	6.21	0.32	1.52e-9	Height;
LIHC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.28	-5.82	-0.3	1.33e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.38	-5.97	-0.31	5.82e-9	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03965827	chr15:50979356	TRPM7	0.44	6.12	0.31	2.52e-9	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.29	-0.32	9.65e-10	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.45	6.35	0.32	6.94e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.45	6.85	0.35	3.51e-11	Height;
LIHC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg04374321	chr14:90722782	PSMC1	0.48	6.75	0.34	6.26e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	8.01	0.4	1.84e-14	Hemoglobin concentration;
LIHC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07305463	chr2:136567211	LCT	0.41	7.68	0.38	1.64e-13	Mosquito bite size;
LIHC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.33	7.15	0.36	5.13e-12	Ulcerative colitis;
LIHC	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg11812906	chr14:75593930	NEK9	0.37	5.77	0.3	1.73e-8	IgG glycosylation;
LIHC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.87	12.84	0.57	4.42e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.28	6.19	0.32	1.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg04865290	chr3:52927548	TMEM110	-0.44	-6.35	-0.32	6.71e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg00091569	chr3:40428383	ENTPD3	0.42	6.93	0.35	2.12e-11	Renal cell carcinoma;
LIHC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-0.99	-22.02	-0.77	1.5e-67	Height;
LIHC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg01364799	chr7:75623366	TMEM120A	-0.47	-6.78	-0.34	5.29e-11	Eotaxin levels;
LIHC	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.64	-0.42	2.13e-16	Brugada syndrome;
LIHC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.72	9.28	0.45	1.97e-18	Fat distribution (HIV);
LIHC	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.28	-6.58	-0.34	1.74e-10	Alcohol dependence;
LIHC	trans	rs1146361	0.556	rs983760	chr1:116676668	C/G	cg20979128	chr1:16271176	ZBTB17	-0.46	-6.71	-0.34	8.1e-11	Fear of minor pain;
LIHC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00152838	chr16:24741724	TNRC6A	0.5	6.21	0.32	1.51e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.31	6.49	0.33	3e-10	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21448741	chr8:58168803	NA	0.33	5.86	0.3	1.11e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.39	6.45	0.33	3.84e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.61	-8.87	-0.43	4.15e-17	Parkinson's disease;
LIHC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-8.44	-0.42	9.35e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-13.46	-0.59	1.95e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.83	18.34	0.7	8.29e-53	Gestational age at birth (maternal effect);
LIHC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.67	-11.6	-0.53	1.92e-26	Crohn's disease;
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.54e-15	Prudent dietary pattern;
LIHC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.06	16.62	0.67	6.67e-46	Breast cancer;
LIHC	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.47	7.05	0.36	9.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg06609049	chr19:2785107	THOP1	0.61	9.61	0.46	1.69e-19	Total cholesterol levels;
LIHC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg08888203	chr3:10149979	C3orf24	0.61	6.59	0.34	1.65e-10	Alzheimer's disease;
LIHC	cis	rs1075232	1.000	rs9672214	chr15:31677775	A/T	cg01030201	chr15:31746330	NA	-0.78	-6.09	-0.31	3.07e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg08213375	chr14:104286397	PPP1R13B	0.51	9.64	0.46	1.34e-19	Schizophrenia;
LIHC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.77	-0.69	1.66e-50	Schizophrenia;
LIHC	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22509189	chr2:225307070	NA	-0.57	-7.17	-0.36	4.59e-12	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs600806	0.850	rs2303875	chr1:109955010	A/C	cg12613107	chr7:150069577	REPIN1	0.81	6.04	0.31	4.08e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.61	-10.92	-0.51	4.95e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.51	0.56	7.86e-30	Prudent dietary pattern;
LIHC	cis	rs9888615	0.624	rs12892879	chr14:53384621	G/A	cg00686598	chr14:53173677	PSMC6	-0.46	-6.17	-0.32	1.9e-9	Systolic blood pressure;
LIHC	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.56	-0.33	1.95e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.75	0.34	6.32e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg24115593	chr5:169010705	CCDC99	-0.39	-6.17	-0.32	1.97e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.94	17.84	0.69	8.48e-51	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23129613	chr7:150065255	REPIN1	0.43	6.35	0.32	6.94e-10	Pancreatic cancer;
LIHC	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.63	-9.17	-0.44	4.53e-18	Blood pressure (smoking interaction);
LIHC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.52	8.12	0.4	8.6e-15	Resting heart rate;
LIHC	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg10381502	chr11:71823885	C11orf51	1.08	9.2	0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02985541	chr2:219472218	PLCD4	0.47	9.08	0.44	8.56e-18	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.72	11.68	0.53	9.45e-27	Anterior chamber depth;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26534993	chr2:3291401	TSSC1	0.47	6.5	0.33	2.77e-10	Hepatitis;
LIHC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.47	-9.05	-0.44	1.13e-17	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.54	0.8	2.06e-77	Prudent dietary pattern;
LIHC	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.03	-0.31	4.14e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.71	-7.96	-0.4	2.52e-14	Neuroticism;
LIHC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-5.89	-0.3	9.16e-9	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18683720	chr19:7694563	XAB2;LOC100131801	-0.48	-6.66	-0.34	1.07e-10	Pancreatic cancer;
LIHC	cis	rs62179067	0.708	rs11896002	chr2:179935887	A/C	cg07532576	chr2:179544947	TTN	0.61	5.8	0.3	1.49e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.07	-0.31	3.37e-9	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03574736	chr2:98280624	ACTR1B	-0.57	-6.61	-0.34	1.49e-10	Systolic blood pressure;
LIHC	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.57	7.04	0.36	1.03e-11	Breast cancer;
LIHC	cis	rs6442522	0.678	rs878946	chr3:15509212	T/C	cg16303742	chr3:15540471	COLQ	0.47	7.85	0.39	5.45e-14	Uric acid levels;
LIHC	trans	rs875971	1.000	rs778706	chr7:65860424	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.38	6.17	0.32	1.95e-9	Prostate cancer;
LIHC	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-22.79	-0.78	1.35e-70	Colorectal cancer;
LIHC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.29	0.49	8.19e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs9641123	0.639	rs60811069	chr7:93212576	C/T	cg09745688	chr16:2908918	PRSS22	-0.34	-6.17	-0.32	1.88e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.61	12.1	0.55	2.67e-28	Plateletcrit;Platelet count;
LIHC	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg12046867	chr14:103022105	NA	0.44	7.01	0.35	1.26e-11	Platelet count;
LIHC	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.6	8.33	0.41	1.93e-15	Neuroticism;
LIHC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.18	-0.32	1.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7707921	0.881	rs2407153	chr5:81555328	T/G	cg15871215	chr5:81402204	ATG10	0.6	5.89	0.3	9.34e-9	Breast cancer;
LIHC	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg18081818	chr7:23246105	NA	0.44	6.75	0.34	6.49e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs4596713	0.538	rs11145484	chr9:71769857	G/C	cg16512924	chr15:28394682	HERC2	0.4	6.42	0.33	4.66e-10	Headache;
LIHC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg10360323	chr17:41437877	NA	0.4	5.99	0.31	5.26e-9	Menopause (age at onset);
LIHC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg12863693	chr15:85201151	NMB	0.45	6.52	0.33	2.56e-10	Schizophrenia;
LIHC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-7.95	-0.4	2.67e-14	Total body bone mineral density;
LIHC	cis	rs2292096	1.000	rs35687916	chr1:200725163	T/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.12	-0.31	2.57e-9	Epilepsy;
LIHC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.43	-8.04	-0.4	1.43e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.55	-7.86	-0.39	5.03e-14	Neuroticism;
LIHC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	11.01	0.51	2.56e-24	Menarche (age at onset);
LIHC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.02	0.35	1.21e-11	Aortic root size;
LIHC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.23e-16	Schizophrenia;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.1	-0.31	2.91e-9	Total body bone mineral density;
LIHC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	7.68	0.38	1.74e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.61	7.28	0.37	2.36e-12	Cognitive function;
LIHC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.71	-12.65	-0.56	2.36e-30	Prudent dietary pattern;
LIHC	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.76	7.89	0.39	4.24e-14	Chronic kidney disease;
LIHC	cis	rs10420951	0.617	rs8103520	chr19:18563970	A/C	cg10790698	chr19:18539756	SSBP4	-0.42	-6.03	-0.31	4.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.32	7.85	0.39	5.32e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.56	-8.52	-0.42	5.05e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg10820045	chr2:198174542	NA	0.54	8.58	0.42	3.33e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7619427	0.908	rs9882094	chr3:44081970	C/T	cg24966902	chr3:44043705	NA	0.42	6.15	0.32	2.15e-9	Schizophrenia;
LIHC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.71	-11.63	-0.53	1.39e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg02993280	chr1:107599747	PRMT6	0.68	11.1	0.51	1.19e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg22065733	chr8:11801320	NA	0.46	5.77	0.3	1.79e-8	Neuroticism;
LIHC	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.98	-0.31	5.76e-9	Coronary artery disease;
LIHC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.87	8.16	0.4	6.35e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.44	6.4	0.33	5.14e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16684958	chr7:75615977	POR	0.51	8.51	0.42	5.6e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	11.23	0.52	3.99e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.84	18.8	0.71	1.23e-54	Gestational age at birth (maternal effect);
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.71	12.2	0.55	1.17e-28	Prudent dietary pattern;
LIHC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.43	-6.03	-0.31	4.16e-9	Total body bone mineral density;
LIHC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08443851	chr16:85646773	KIAA0182	0.47	6.67	0.34	1e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.13	-0.4	8.14e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.57	0.33	1.92e-10	Schizophrenia;
LIHC	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg25783544	chr11:47291846	MADD	0.4	5.74	0.3	2.04e-8	HDL cholesterol;
LIHC	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.41	6.83	0.35	3.81e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.53	0.42	4.66e-16	Initial pursuit acceleration;
LIHC	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg16586182	chr3:47516702	SCAP	-0.39	-6.67	-0.34	1e-10	Birth weight;
LIHC	trans	rs7772697	0.635	rs4454159	chr6:149411908	A/C	cg04561327	chr14:23540794	ACIN1	-0.52	-6.49	-0.33	3.08e-10	Diabetic retinopathy;
LIHC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18357526	chr6:26021779	HIST1H4A	0.7	8.97	0.44	1.92e-17	Urate levels;
LIHC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg03959625	chr15:84868606	LOC388152	0.45	6.28	0.32	1.02e-9	Schizophrenia;
LIHC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg02269571	chr22:50332266	NA	-0.64	-8.36	-0.41	1.59e-15	Schizophrenia;
LIHC	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.59	8.69	0.43	1.53e-16	Recombination rate (females);
LIHC	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.55	-0.38	3.99e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg11766577	chr21:47581405	C21orf56	-0.38	-5.9	-0.3	8.51e-9	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.31	0.41	2.3e-15	Motion sickness;
LIHC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.5	-0.33	2.87e-10	Mean corpuscular volume;
LIHC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00152838	chr16:24741724	TNRC6A	0.49	6.12	0.31	2.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg21856205	chr7:94953877	PON1	-0.48	-6.17	-0.32	1.95e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg20991723	chr1:152506922	NA	-0.5	-8.6	-0.42	2.95e-16	Hair morphology;
LIHC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg27433088	chr4:174089019	GALNT7	-0.41	-6.59	-0.34	1.62e-10	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg03037974	chr15:76606532	NA	-0.59	-9.81	-0.47	3.43e-20	Blood metabolite levels;
LIHC	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.9	10.96	0.51	3.69e-24	Coronary artery disease;
LIHC	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.35	-6.06	-0.31	3.69e-9	Menopause (age at onset);
LIHC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg05697976	chr12:29376483	FAR2	0.3	6.15	0.32	2.12e-9	QT interval;
LIHC	cis	rs11645898	0.504	rs79489472	chr16:71870359	C/T	cg03805757	chr16:71968109	PKD1L3	-0.85	-8.64	-0.42	2.13e-16	Blood protein levels;
LIHC	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg04610667	chr7:75704037	NA	0.32	5.79	0.3	1.61e-8	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.76	-8.34	-0.41	1.89e-15	Exhaled nitric oxide output;
LIHC	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.45	-6.71	-0.34	7.96e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.37	8.12	0.4	8.5e-15	Educational attainment (years of education);
LIHC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.55	7.85	0.39	5.47e-14	Prostate cancer;
LIHC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.64	10.8	0.5	1.37e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.68	11.16	0.52	7.19e-25	Menopause (age at onset);
LIHC	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.77	-0.34	5.65e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg08847533	chr14:75593920	NEK9	0.44	6.88	0.35	2.8e-11	IgG glycosylation;
LIHC	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg03934865	chr2:198174659	NA	0.44	6.27	0.32	1.07e-9	Dermatomyositis;
LIHC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.86	0.35	3.29e-11	Aortic root size;
LIHC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.51	-7.05	-0.36	1.02e-11	Aortic root size;
LIHC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.7	12.72	0.57	1.29e-30	Iron status biomarkers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24924243	chr11:27528430	LIN7C;BDNFOS	-0.41	-6.12	-0.31	2.56e-9	Pancreatic cancer;
LIHC	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.82	-0.39	6.67e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Parkinson's disease;
LIHC	cis	rs1144333	0.655	rs76416835	chr1:76341511	G/T	cg22875332	chr1:76189707	ACADM	0.43	6.41	0.33	4.77e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12702595	0.589	rs6463662	chr7:7259477	G/A	cg04827551	chr7:7268805	C1GALT1	0.33	6.15	0.32	2.16e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22509189	chr2:225307070	NA	-0.54	-7.1	-0.36	7.19e-12	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg12253828	chr6:101329408	ASCC3	0.42	6.69	0.34	9.19e-11	Neuroticism;
LIHC	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.79	8.06	0.4	1.3e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.73	9.93	0.47	1.44e-20	Body mass index;
LIHC	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.47e-18	Coffee consumption (cups per day);
LIHC	cis	rs7326068	0.524	rs9506531	chr13:21232983	C/T	cg27499820	chr13:21296301	IL17D	-0.37	-5.74	-0.3	2.06e-8	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg05425664	chr17:57184151	TRIM37	0.48	6.06	0.31	3.58e-9	Vitamin D levels;
LIHC	cis	rs10420951	0.617	rs7251067	chr19:18600056	G/A	cg10790698	chr19:18539756	SSBP4	-0.42	-5.99	-0.31	5.44e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg24579218	chr15:68104479	NA	-0.34	-5.83	-0.3	1.27e-8	Restless legs syndrome;
LIHC	cis	rs11233413	0.559	rs10898067	chr11:82684697	T/C	cg24227371	chr11:82718527	RAB30	-0.35	-7.57	-0.38	3.59e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg25214090	chr10:38739885	LOC399744	-0.38	-6.16	-0.32	1.99e-9	Diastolic blood pressure;
LIHC	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg23091122	chr1:110024289	SYPL2	-0.48	-6.32	-0.32	8.33e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.59	10.51	0.49	1.41e-22	Dupuytren's disease;
LIHC	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg16583315	chr14:65563665	MAX	-0.42	-8.43	-0.41	9.65e-16	Obesity-related traits;
LIHC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.72	9.35	0.45	1.19e-18	Gut microbiome composition (summer);
LIHC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-9.21	-0.45	3.35e-18	Gut microbiome composition (summer);
LIHC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.14	13.44	0.59	2.41e-33	Vitiligo;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03729566	chr7:1059678	C7orf50	-0.41	-6.56	-0.33	1.97e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.53	0.33	2.33e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10216189	0.967	rs6962735	chr7:5526439	C/G	cg05318486	chr7:5553423	FBXL18	-0.58	-8.63	-0.42	2.28e-16	Relative hand skill in reading disability;
LIHC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.02	-0.31	4.51e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.21	-0.41	4.52e-15	Body mass index (adult);
LIHC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.86	13.15	0.58	2.91e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg15282417	chr9:129245246	FAM125B	0.41	6.86	0.35	3.25e-11	Intraocular pressure;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg04781839	chr16:1374937	UBE2I	0.36	6.05	0.31	3.75e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.41	-5.77	-0.3	1.78e-8	Total body bone mineral density;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26912877	chr1:6305344	HES3	-0.47	-6.17	-0.32	1.98e-9	Systolic blood pressure;
LIHC	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.63	6.4	0.33	5.07e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.71	-0.43	1.32e-16	Blood metabolite levels;
LIHC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg15352829	chr14:105391018	PLD4	-0.45	-9.36	-0.45	1.1e-18	Rheumatoid arthritis;
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg23601095	chr6:26197514	HIST1H3D	0.54	5.79	0.3	1.58e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.47	-0.33	3.43e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.42	-0.33	4.45e-10	Fear of minor pain;
LIHC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.4	7.71	0.38	1.38e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg09069446	chr16:4462122	CORO7	-0.35	-5.74	-0.3	2.04e-8	Schizophrenia;
LIHC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-8.61	-0.42	2.65e-16	Chronic sinus infection;
LIHC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.7	-7.57	-0.38	3.56e-13	Neuroticism;
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.42	-0.33	4.45e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.49	8.24	0.41	3.68e-15	Schizophrenia;
LIHC	cis	rs67981189	0.513	rs7154395	chr14:71566300	G/A	cg15816911	chr14:71606274	NA	0.43	6.87	0.35	3.01e-11	Schizophrenia;
LIHC	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	1.11	9.76	0.47	5.07e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.71	-0.3	2.46e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.15e-9	Mortality in heart failure;
LIHC	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.76	12.53	0.56	6.55e-30	Anterior chamber depth;
LIHC	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.74	7.66	0.38	1.99e-13	Opioid sensitivity;
LIHC	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.66	-10.06	-0.48	4.87e-21	Pediatric autoimmune diseases;
LIHC	trans	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg10208301	chr11:6592745	DNHD1	0.47	6.69	0.34	9.05e-11	Coronary artery calcification;
LIHC	cis	rs7187994	0.848	rs16974558	chr16:84787111	G/A	cg07647771	chr16:84786436	USP10	-0.32	-6.22	-0.32	1.47e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.4	0.33	5.11e-10	Axial length;
LIHC	cis	rs7395581	0.959	rs2279239	chr11:47281780	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.53	-0.42	4.94e-16	HDL cholesterol;
LIHC	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.84	-0.39	5.64e-14	Breast cancer;
LIHC	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg02795151	chr17:7402630	POLR2A	0.51	5.75	0.3	2e-8	Androgen levels;
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02290350	chr8:58132656	NA	-0.49	-10.63	-0.5	5.43e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.34	-0.32	7.32e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	0.61	6.14	0.32	2.26e-9	Obesity-related traits;
LIHC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-7.46	-0.37	7.44e-13	Platelet distribution width;
LIHC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg16479474	chr6:28041457	NA	0.39	6.68	0.34	9.59e-11	Cardiac Troponin-T levels;
LIHC	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.3	-0.37	2.08e-12	Morning vs. evening chronotype;
LIHC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.43	0.37	8.83e-13	Mean platelet volume;
LIHC	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.65	9.69	0.46	8.67e-20	Menarche (age at onset);
LIHC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.1	-0.4	1.01e-14	Chronic sinus infection;
LIHC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.61	-0.38	2.76e-13	Total body bone mineral density;
LIHC	cis	rs9473924	0.505	rs9473921	chr6:50828072	C/T	cg14470998	chr6:50812995	TFAP2B	0.9	10.14	0.48	2.67e-21	Body mass index;
LIHC	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.42	-6.39	-0.33	5.38e-10	Multiple sclerosis;
LIHC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.66	-8.93	-0.43	2.72e-17	Schizophrenia;
LIHC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.56	-7.57	-0.38	3.6e-13	Aortic root size;
LIHC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg18225595	chr11:63971243	STIP1	0.64	6.43	0.33	4.37e-10	Mean platelet volume;
LIHC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.07	18.56	0.71	1.07e-53	Testicular germ cell tumor;
LIHC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-9.21	-0.45	3.35e-18	Gut microbiome composition (summer);
LIHC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.6	10.26	0.49	1.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17106184	1.000	rs72900956	chr1:51143665	G/T	cg07174182	chr1:51127561	FAF1	-0.76	-8.12	-0.4	8.47e-15	Type 2 diabetes;
LIHC	trans	rs7336933	0.866	rs4941411	chr13:42471498	T/C	cg15665968	chr21:44527764	U2AF1	-0.78	-6.16	-0.32	2.08e-9	Calcium levels;
LIHC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06481639	chr22:41940642	POLR3H	0.7	7.01	0.35	1.28e-11	Vitiligo;
LIHC	cis	rs975210	1.000	rs975210	chr15:70364352	G/A	cg01666796	chr15:70364327	TLE3	-0.59	-7.69	-0.38	1.54e-13	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	7.05	0.36	9.84e-12	Bone mineral density;
LIHC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.87	-13.41	-0.59	3e-33	Body mass index;
LIHC	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.73	0.5	2.46e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07305463	chr2:136567211	LCT	0.39	7.25	0.37	2.76e-12	Mosquito bite size;
LIHC	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.86	12.19	0.55	1.29e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.76	0.34	5.99e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-8.34	-0.41	1.86e-15	Morning vs. evening chronotype;
LIHC	trans	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg03929089	chr4:120376271	NA	-0.48	-7.4	-0.37	1.08e-12	Pediatric bone mineral density (spine);
LIHC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.41	6.31	0.32	8.49e-10	Melanoma;
LIHC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.58	6.72	0.34	7.66e-11	Menarche (age at onset);
LIHC	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.41	-0.33	4.78e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.39	-0.33	5.51e-10	Total body bone mineral density;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02697074	chr17:40761760	FAM134C;TUBG1	0.38	6.05	0.31	3.72e-9	Metabolic traits;
LIHC	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.95	-0.39	2.81e-14	Capecitabine sensitivity;
LIHC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.55	0.33	2.13e-10	Obesity-related traits;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.89	-0.35	2.71e-11	Total body bone mineral density;
LIHC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg20090690	chr10:134436459	INPP5A	0.42	5.8	0.3	1.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.43	-7.4	-0.37	1.07e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.05	0.31	3.9e-9	Blood metabolite levels;
LIHC	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.88	-0.3	9.51e-9	Tuberculosis;
LIHC	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.06	0.48	4.93e-21	Coffee consumption (cups per day);
LIHC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.8	-0.3	1.51e-8	Menopause (age at onset);
LIHC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg14558114	chr2:88469736	THNSL2	-0.37	-5.76	-0.3	1.87e-8	Response to metformin (IC50);
LIHC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.02	-12.17	-0.55	1.5e-28	Primary sclerosing cholangitis;
LIHC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.74	-12.4	-0.56	2.13e-29	Systemic lupus erythematosus;
LIHC	cis	rs7617773	1.000	rs6771889	chr3:48194326	C/T	cg11946769	chr3:48343235	NME6	-0.66	-8.46	-0.42	7.79e-16	Coronary artery disease;
LIHC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.8	12.35	0.56	3.05e-29	Dental caries;
LIHC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.48	8.09	0.4	1.03e-14	Schizophrenia;
LIHC	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.32	-8.58	-0.42	3.37e-16	Intelligence;
LIHC	cis	rs61677309	1.000	rs56938099	chr11:118156688	A/G	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg05865280	chr17:75406074	SEPT9	0.6	15.82	0.65	1.06e-42	Airflow obstruction;
LIHC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg06598544	chr20:61472147	COL9A3	-0.85	-8.18	-0.4	5.58e-15	Obesity-related traits;
LIHC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.23	-7.17	-0.36	4.56e-12	Motion sickness;
LIHC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-10.26	-0.49	1.02e-21	Platelet count;
LIHC	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-0.71	-7.3	-0.37	1.98e-12	Putamen volume;
LIHC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-0.88	-9.6	-0.46	1.83e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19173666	chr17:80740808	TBCD	-0.33	-7.03	-0.36	1.13e-11	Calcium levels;
LIHC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.42	7.15	0.36	5.45e-12	Mean corpuscular volume;
LIHC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	1.25	14.78	0.62	1.38e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7116495	0.867	rs529567	chr11:71580537	G/A	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.3e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.93	19.5	0.73	1.81e-57	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.96	-0.35	1.73e-11	Breast cancer;
LIHC	cis	rs75908454	1.000	rs16888015	chr6:169829597	A/G	cg19338460	chr6:170058176	WDR27	-0.84	-7.59	-0.38	3.1e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.53	7.69	0.38	1.5700000000000001e-13	Urinary tract infection frequency;
LIHC	cis	rs2540917	0.904	rs2540916	chr2:60608930	T/C	cg00543073	chr2:60773386	BCL11A	-0.29	-5.83	-0.3	1.29e-8	Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.37	7.42	0.37	9.12e-13	Renal cell carcinoma;
LIHC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.03e-26	Chronic sinus infection;
LIHC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.15	0.52	8.08e-25	Type 2 diabetes;
LIHC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.64	-8.91	-0.43	3.18e-17	Schizophrenia;
LIHC	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.24	-0.32	1.27e-9	Tuberculosis;
LIHC	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg02376097	chr19:46275166	DMPK	-0.44	-6.82	-0.35	4.18e-11	Coronary artery disease;
LIHC	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.42	6.44	0.33	4.16e-10	Neuroticism;
LIHC	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg08668510	chr10:1095578	IDI1	0.68	6.62	0.34	1.41e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.31	-0.32	8.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.58	0.62	8.84e-38	Chronic sinus infection;
LIHC	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.64	6.09	0.31	2.95e-9	Schizophrenia;
LIHC	cis	rs13161895	1.000	rs34674199	chr5:179473900	G/A	cg02702477	chr5:179499311	RNF130	0.8	11.17	0.52	6.67e-25	LDL cholesterol;
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.53	-0.33	2.32e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.85	-0.35	3.36e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg20016023	chr10:99160130	RRP12	-0.4	-6.24	-0.32	1.27e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs10508774	0.929	rs56265142	chr10:32787643	A/G	cg01819863	chr10:32635814	EPC1	0.61	5.8	0.3	1.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.39	-6.01	-0.31	4.72e-9	Glioblastoma;
LIHC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg07382826	chr16:28625726	SULT1A1	0.49	7.52	0.38	4.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12079745	0.793	rs12565852	chr1:169369330	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06656553	chr16:89960601	TCF25	-0.44	-5.91	-0.3	8.11e-9	Skin colour saturation;
LIHC	trans	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg17830980	chr10:43048298	ZNF37B	0.43	7.86	0.39	5.08e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.6	6.67	0.34	1.06e-10	Vitiligo;
LIHC	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg05147654	chr7:157448565	PTPRN2	-0.3	-6.0	-0.31	5.11e-9	Colorectal cancer;
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.55	9.39	0.45	8.39e-19	Calcium levels;
LIHC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg23431851	chr1:46668822	C1orf190;POMGNT1	-0.49	-7.76	-0.39	1e-13	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.21	0.55	1.05e-28	Height;
LIHC	cis	rs9596863	1.000	rs9568943	chr13:54423065	G/T	ch.13.53330881F	chr13:54432880	NA	0.44	5.94	0.31	6.85e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15084945	chr3:39452455	SNORA62;RPSA	-0.43	-6.48	-0.33	3.23e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.02	-0.31	4.53e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.93	10.31	0.49	7.26e-22	Breast cancer;
LIHC	cis	rs3744061	0.520	rs9908979	chr17:74645486	T/G	cg13533061	chr17:74712429	JMJD6	-0.3	-5.99	-0.31	5.46e-9	Retinal arteriolar caliber;
LIHC	cis	rs1000083	0.651	rs56773447	chr5:96567642	G/T	ch.5.96698337R	chr5:96672581	NA	0.81	6.46	0.33	3.6e-10	Cisplatin-induced ototoxicity;
LIHC	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.63	7.13	0.36	5.82e-12	Obesity-related traits;
LIHC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.98	0.51	3.2e-24	Motion sickness;
LIHC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.57	0.42	3.56e-16	Motion sickness;
LIHC	cis	rs860295	0.812	rs12024257	chr1:155780536	G/A	cg02153340	chr1:155202674	NA	-0.34	-6.12	-0.31	2.56e-9	Body mass index;
LIHC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg18944383	chr4:111397179	ENPEP	0.24	6.15	0.32	2.16e-9	Height;
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg22907277	chr7:1156413	C7orf50	0.58	8.79	0.43	7.41e-17	Longevity;Endometriosis;
LIHC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	21.76	0.76	1.63e-66	Height;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.9	-0.3	8.56e-9	Longevity;Endometriosis;
LIHC	cis	rs2412488	0.853	rs10011394	chr4:54355067	C/T	cg22241045	chr4:54363911	LNX1	0.41	6.7	0.34	8.67e-11	DNA methylation (variation);
LIHC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-13.01	-0.58	1e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.51	8.07	0.4	1.17e-14	Testicular germ cell tumor;
LIHC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.89	0.43	3.51e-17	Lung cancer in ever smokers;
LIHC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-7.83	-0.39	6.2e-14	Chronic sinus infection;
LIHC	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.71	-12.31	-0.55	4.49e-29	Pediatric autoimmune diseases;
LIHC	trans	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg10756647	chr7:56101905	PSPH	-1.0	-12.98	-0.57	1.32e-31	Diabetic kidney disease;
LIHC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.41	-5.9	-0.3	8.71e-9	Height;
LIHC	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-10.79	-0.5	1.45e-23	Myopia (pathological);
LIHC	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg18700516	chr19:44507157	ZNF230	-0.36	-5.97	-0.31	6.07e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	9.58e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs17152411	0.793	rs7085829	chr10:126587142	A/G	cg07906193	chr10:126599966	NA	0.42	6.61	0.34	1.48e-10	Height;
LIHC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.49	-8.84	-0.43	5.11e-17	Neuroticism;
LIHC	cis	rs4407350	0.870	rs5765715	chr22:44915217	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.39	0.33	5.35e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs151997	0.925	rs26090	chr5:50170071	C/T	cg06027927	chr5:50259733	NA	-0.56	-7.51	-0.38	5.03e-13	Callous-unemotional behaviour;
LIHC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.47e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg26395211	chr5:140044315	WDR55	-0.4	-5.97	-0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg00204748	chr12:29376779	FAR2	0.4	7.48	0.38	6.14e-13	QT interval;
LIHC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.39	-0.41	1.27e-15	Mood instability;
LIHC	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.56	8.0	0.4	2.01e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg25344623	chr2:136566232	LCT	0.41	8.48	0.42	6.85e-16	Mosquito bite size;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.97	-22.38	-0.77	5.51e-69	Prudent dietary pattern;
LIHC	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.4	-6.07	-0.31	3.48e-9	Multiple myeloma;
LIHC	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-0.83	-6.43	-0.33	4.41e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.77	12.25	0.55	7.23e-29	Corneal astigmatism;
LIHC	trans	rs911555	0.755	rs975892	chr14:103883349	A/T	cg17675199	chr6:35436792	RPL10A	0.42	8.68	0.42	1.68e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.8	-0.3	1.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg02297831	chr4:17616191	MED28	0.42	5.8	0.3	1.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02290350	chr8:58132656	NA	0.44	9.28	0.45	2.02e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.06e-9	Primary biliary cholangitis;
LIHC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.92	0.39	3.36e-14	Mood instability;
LIHC	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.86	0.35	3.19e-11	Dermatomyositis;
LIHC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.34	-0.45	1.27e-18	Hemoglobin concentration;
LIHC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg23982607	chr1:1823379	GNB1	0.49	7.0	0.35	1.33e-11	Body mass index;
LIHC	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.78	14.41	0.61	3.99e-37	Longevity;
LIHC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg12046867	chr14:103022105	NA	-0.57	-8.43	-0.41	9.98e-16	Platelet count;
LIHC	cis	rs7961581	0.912	rs4760915	chr12:71634112	T/C	cg05756094	chr12:71608604	NA	0.37	5.77	0.3	1.82e-8	Type 2 diabetes;
LIHC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg10130564	chr11:117069849	TAGLN	0.35	6.01	0.31	4.84e-9	Blood protein levels;
LIHC	trans	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.67	0.34	1.05e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.26	-0.49	1.05e-21	Hemoglobin concentration;
LIHC	cis	rs17286411	0.787	rs1834036	chr16:71972060	G/A	cg06353428	chr16:71660113	MARVELD3	0.51	6.5	0.33	2.87e-10	Blood protein levels;
LIHC	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.3	-7.44	-0.37	8.33e-13	Gut microbiome composition (winter);
LIHC	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.9	-14.86	-0.63	6.84e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	0.67	7.41	0.37	1.03e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs7937890	0.668	rs12361851	chr11:14267668	C/T	cg02886208	chr11:14281011	SPON1	0.5	6.81	0.35	4.44e-11	Mitochondrial DNA levels;
LIHC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.86	13.38	0.59	3.95e-33	Vitamin D levels;
LIHC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs7716219	0.572	rs3898451	chr5:54875243	C/A	cg14753740	chr5:54468940	CDC20B;MIR449C	0.44	6.13	0.31	2.42e-9	Height;
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07677032	chr17:61819896	STRADA	0.41	6.04	0.31	4.02e-9	Prudent dietary pattern;
LIHC	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.49	7.35	0.37	1.46e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg25356066	chr3:128598488	ACAD9	0.55	7.7	0.38	1.51e-13	IgG glycosylation;
LIHC	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	0.89	12.81	0.57	6.08e-31	Post bronchodilator FEV1;
LIHC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg04469686	chr1:162760199	HSD17B7	-0.42	-6.42	-0.33	4.48e-10	Breast cancer;
LIHC	cis	rs7945071	0.507	rs12417004	chr11:110297827	T/C	cg04157658	chr11:110243994	NA	0.34	6.14	0.32	2.26e-9	Cognitive function;
LIHC	trans	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.43	-6.31	-0.32	8.59e-10	Endometrial cancer;
LIHC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.42	7.04	0.36	1.04e-11	IgG glycosylation;
LIHC	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.69	10.66	0.5	4.37e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.69	-0.34	8.95e-11	Schizophrenia;
LIHC	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-0.68	-11.22	-0.52	4.45e-25	Pediatric autoimmune diseases;
LIHC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg23422044	chr7:1970798	MAD1L1	-0.58	-9.01	-0.44	1.49e-17	Neuroticism;
LIHC	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.52	-8.41	-0.41	1.12e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.55	-0.46	2.59e-19	Blood metabolite levels;
LIHC	trans	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.62e-9	Pulmonary function;
LIHC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg02290350	chr8:58132656	NA	0.47	8.49	0.42	6.54e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.09	0.36	7.92e-12	Caffeine consumption;
LIHC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg16797656	chr11:68205561	LRP5	0.54	8.65	0.42	2.08e-16	Total body bone mineral density;
LIHC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.62	10.07	0.48	4.63e-21	Smoking initiation;
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-8.98	-0.44	1.79e-17	Total body bone mineral density;
LIHC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.45	6.0	0.31	4.97e-9	Obesity-related traits;
LIHC	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.39	-0.37	1.17e-12	Urate levels in overweight individuals;
LIHC	cis	rs4788570	0.697	rs11075904	chr16:71816899	G/A	cg06353428	chr16:71660113	MARVELD3	1.33	14.27	0.61	1.38e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.64	-10.3	-0.49	7.49e-22	Bipolar disorder;
LIHC	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.39	-6.3	-0.32	8.93e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg16226627	chr15:75307476	SCAMP5	0.56	9.81	0.47	3.65e-20	Lung cancer;
LIHC	cis	rs3736485	0.903	rs8039835	chr15:51865864	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.07	-0.31	3.46e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	1.01	12.03	0.55	4.92e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.43	-6.0	-0.31	4.91e-9	Initial pursuit acceleration;
LIHC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.61	-10.12	-0.48	3.11e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.13	-10.41	-0.49	3.17e-22	Schizophrenia;
LIHC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.34	0.37	1.57e-12	Lung cancer;
LIHC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.35	8.82	0.43	6.11e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg26692224	chr17:62915920	LRRC37A3	0.67	6.48	0.33	3.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg03037974	chr15:76606532	NA	0.74	14.5	0.62	1.86e-37	Blood metabolite levels;
LIHC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.77	-0.47	4.66e-20	Response to antipsychotic treatment;
LIHC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	0.92	7.72	0.39	1.26e-13	Cognitive function;
LIHC	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.62	9.5	0.46	3.91e-19	Electrocardiographic conduction measures;
LIHC	cis	rs10847980	0.590	rs75794148	chr12:123287329	C/G	cg22842854	chr12:123319900	HIP1R	0.91	9.9	0.47	1.79e-20	Adiponectin levels;
LIHC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.83	0.35	3.79e-11	Aortic root size;
LIHC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.6e-18	Bipolar disorder;
LIHC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg15691649	chr6:25882328	NA	-0.37	-5.9	-0.3	8.57e-9	Height;
LIHC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.87	-15.23	-0.64	2.51e-40	Colorectal cancer;
LIHC	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg04306507	chr14:55594613	LGALS3	0.32	5.94	0.31	7.04e-9	Protein biomarker;
LIHC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.61	-8.36	-0.41	1.65e-15	Body mass index;
LIHC	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.59	9.58	0.46	2.03e-19	Response to antidepressants and depression;
LIHC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.79	12.3	0.55	4.68e-29	Resting heart rate;
LIHC	cis	rs17106184	1.000	rs113611257	chr1:51221103	G/A	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg15208524	chr1:10270712	KIF1B	0.39	5.72	0.3	2.35e-8	Hepatocellular carcinoma;
LIHC	cis	rs716804	0.566	rs9645625	chr11:10070833	A/C	cg01453529	chr11:10209919	SBF2	-0.32	-6.12	-0.31	2.57e-9	Neuroticism;
LIHC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.64	0.56	2.6e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.52	7.98	0.4	2.16e-14	Corneal astigmatism;
LIHC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.46	-7.19	-0.36	4.17e-12	Mean corpuscular hemoglobin;
LIHC	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg03934865	chr2:198174659	NA	0.55	8.42	0.41	1.08e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg24209194	chr3:40518798	ZNF619	0.45	6.46	0.33	3.7e-10	Renal cell carcinoma;
LIHC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.49	6.58	0.34	1.75e-10	Height;
LIHC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24229701	chr12:130821962	PIWIL1	0.43	6.28	0.32	1e-9	Menopause (age at onset);
LIHC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.66	6.97	0.35	1.65e-11	Exhaled nitric oxide output;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.46	8.29	0.41	2.69e-15	Prudent dietary pattern;
LIHC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.34	0.58	5.79e-33	Cognitive test performance;
LIHC	cis	rs16958440	0.867	rs77615793	chr18:44684464	C/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.67	6.05	0.31	3.71e-9	Body mass index;
LIHC	trans	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg01596870	chr19:55963115	NA	-0.68	-9.92	-0.47	1.45e-20	Obesity-related traits;
LIHC	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.61	-0.38	2.69e-13	Prevalent atrial fibrillation;
LIHC	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.52	8.39	0.41	1.3e-15	Corneal astigmatism;
LIHC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.87	0.54	1.85e-27	Colorectal cancer;
LIHC	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg06265175	chr8:121136014	COL14A1	0.48	7.72	0.39	1.34e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21512275	chr2:157198069	NA	0.45	6.82	0.35	4.11e-11	Cognitive function;
LIHC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.99	0.57	1.28e-31	Glomerular filtration rate (creatinine);
LIHC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	9.65	0.46	1.24e-19	Resting heart rate;
LIHC	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08893839	chr5:154027129	NA	0.49	6.75	0.34	6.16e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.42	0.33	4.69e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg04709771	chr16:646395	RAB40C	0.44	8.02	0.4	1.7e-14	Height;
LIHC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg17135325	chr3:160939158	NMD3	0.57	7.96	0.4	2.62e-14	Parkinson's disease;
LIHC	cis	rs4950322	0.512	rs10736839	chr1:146842146	C/G	cg25205988	chr1:146714368	CHD1L	0.44	6.29	0.32	9.91e-10	Protein quantitative trait loci;
LIHC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.86	-14.44	-0.62	3.07e-37	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.41	-7.34	-0.37	1.58e-12	Aortic root size;
LIHC	cis	rs911119	0.955	rs6048952	chr20:23607257	A/G	cg16589663	chr20:23618590	CST3	0.71	7.51	0.38	5.15e-13	Chronic kidney disease;
LIHC	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg20737812	chr15:86336631	KLHL25	-0.42	-5.83	-0.3	1.27e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.73	-9.28	-0.45	1.95e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.4	0.37	1.09e-12	Cannabis dependence symptom count;
LIHC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg07424592	chr7:64974309	NA	0.79	9.1	0.44	7.54e-18	Diabetic kidney disease;
LIHC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.49	-6.05	-0.31	3.79e-9	Narcolepsy;
LIHC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.39	-8.48	-0.42	6.88e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.5	-8.47	-0.42	7.44e-16	Coronary artery disease;
LIHC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-8.71	-0.43	1.35e-16	Chronic sinus infection;
LIHC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.65	10.33	0.49	5.81e-22	Platelet count;
LIHC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.55	7.07	0.36	8.98e-12	Parkinson's disease;
LIHC	trans	rs5743467	1.000	rs5743467	chr8:6731529	C/G	cg14033944	chr8:11627058	NEIL2	-0.6	-6.4	-0.33	5.09e-10	Plasma kynurenine levels in major depressive disorder;Plasma kynurenine to tryptophan ratio in major depressive disorder;
LIHC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.41	-9.29	-0.45	1.79e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg18016565	chr1:150552671	MCL1	0.52	9.8	0.47	3.84e-20	Melanoma;
LIHC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg16102536	chr7:156981717	UBE3C	0.36	6.14	0.32	2.25e-9	Body mass index;
LIHC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.62	6.96	0.35	1.76e-11	Menarche (age at onset);
LIHC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.38	-0.41	1.35e-15	Atrioventricular conduction;
LIHC	cis	rs1892700	0.764	rs62227704	chr21:34910056	G/C	cg14850771	chr21:34775459	IFNGR2	-0.45	-5.96	-0.31	6.41e-9	Educational attainment;
LIHC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.76	13.0	0.58	1.09e-31	Anterior chamber depth;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07308232	chr7:1071921	C7orf50	-0.4	-6.36	-0.33	6.3e-10	Longevity;Endometriosis;
LIHC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-8.03	-0.4	1.57e-14	Body mass index;
LIHC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.56	9.76	0.47	5.34e-20	Mean corpuscular volume;
LIHC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.34	6.6	0.34	1.56e-10	Multiple system atrophy;
LIHC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.76	-0.34	6.06e-11	Mean corpuscular volume;
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.57	0.62	9.41e-38	Prudent dietary pattern;
LIHC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.38	-0.33	5.85e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6516091	0.640	rs6117070	chr20:6061606	A/G	cg25325723	chr20:6104886	FERMT1	-0.56	-5.8	-0.3	1.5e-8	Abdominal aortic aneurysm;
LIHC	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-12.48	-0.56	1.02e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.88	12.17	0.55	1.44e-28	Mitochondrial DNA levels;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.94	-0.39	2.86e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.37	0.33	6.03e-10	Cognitive ability;
LIHC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06212747	chr3:49208901	KLHDC8B	0.5	6.39	0.33	5.43e-10	Parkinson's disease;
LIHC	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg08034816	chr17:79219380	SLC38A10	0.42	6.85	0.35	3.34e-11	Frontotemporal dementia;
LIHC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg26939375	chr7:64535504	NA	-0.44	-6.66	-0.34	1.07e-10	Aortic root size;
LIHC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.28	21.09	0.75	7.5e-64	Corneal structure;
LIHC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-7.08	-0.36	8.48e-12	IgG glycosylation;
LIHC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.87	-0.35	3.1e-11	Fear of minor pain;
LIHC	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.5	-6.09	-0.31	3.09e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.82	0.43	6.02e-17	Menarche (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00014996	chr18:158348	USP14	-0.43	-6.35	-0.32	6.8e-10	Longevity;
LIHC	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-8.23	-0.41	3.94e-15	Blood pressure (smoking interaction);
LIHC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg07061783	chr6:25882402	NA	-0.48	-6.69	-0.34	9.05e-11	Blood metabolite levels;
LIHC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.57	8.48	0.42	6.76e-16	Cognitive function;
LIHC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.47	-7.84	-0.39	5.6e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.14	0.32	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.67	-7.04	-0.36	1.07e-11	Vitiligo;
LIHC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.4	-8.27	-0.41	3.1e-15	Immature fraction of reticulocytes;
LIHC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.26	0.45	2.33e-18	Bipolar disorder;
LIHC	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.7	-12.84	-0.57	4.62e-31	Mean platelet volume;
LIHC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00684032	chr4:1343700	KIAA1530	-0.35	-5.83	-0.3	1.31e-8	Obesity-related traits;
LIHC	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.4	6.61	0.34	1.46e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.21	-0.32	1.51e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.39	0.41	1.34e-15	Schizophrenia;
LIHC	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg05590025	chr7:65112418	INTS4L2	0.65	7.4	0.37	1.07e-12	Diabetic kidney disease;
LIHC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.41	-0.33	4.91e-10	Menopause (age at onset);
LIHC	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-7.12	-0.36	6.32e-12	Morning vs. evening chronotype;
LIHC	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg09260627	chr8:8243751	NA	-0.51	-6.5	-0.33	2.93e-10	Monocyte count;
LIHC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.03e-25	Tonsillectomy;
LIHC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.78	-0.5	1.62e-23	Eye color traits;
LIHC	cis	rs17102423	0.589	rs8011585	chr14:65522223	T/A	cg16583315	chr14:65563665	MAX	-0.37	-7.22	-0.36	3.39e-12	Obesity-related traits;
LIHC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18252515	chr7:66147081	NA	0.42	5.79	0.3	1.61e-8	Aortic root size;
LIHC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04530015	chr2:215796436	ABCA12	-0.39	-6.36	-0.33	6.61e-10	Neuroblastoma;
LIHC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.65	10.11	0.48	3.29e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.74	-0.3	2.1e-8	Uric acid levels;
LIHC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg19645103	chr12:69753606	YEATS4	0.46	6.3	0.32	9.07e-10	Response to diuretic therapy;
LIHC	cis	rs4755351	0.553	rs10836023	chr11:33125046	G/A	cg05567920	chr11:33183001	CSTF3	0.42	6.17	0.32	1.96e-9	Lung cancer in ever smokers;
LIHC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.53	-8.56	-0.42	4.01e-16	Fibrinogen levels;
LIHC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs4596713	0.538	rs10125494	chr9:71770861	C/G	cg16512924	chr15:28394682	HERC2	0.4	6.47	0.33	3.43e-10	Headache;
LIHC	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.21	-0.32	1.53e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.4	0.59	3.47e-33	Lung cancer in ever smokers;
LIHC	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.72	6.92	0.35	2.24e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs1974653	0.781	rs175164	chr22:20115562	C/T	cg20152630	chr19:46405944	MYPOP	0.47	6.07	0.31	3.37e-9	Schizophrenia;
LIHC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	7.57	0.38	3.6e-13	Schizophrenia;
LIHC	cis	rs17106184	1.000	rs1573012	chr1:51369991	T/C	cg07174182	chr1:51127561	FAF1	-0.75	-7.61	-0.38	2.74e-13	Type 2 diabetes;
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21747090	chr2:27597821	SNX17	-0.43	-6.36	-0.33	6.62e-10	Total body bone mineral density;
LIHC	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.61	-6.59	-0.34	1.64e-10	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg15605315	chr1:45957053	TESK2	0.49	6.93	0.35	2.12e-11	High light scatter reticulocyte count;
LIHC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.25	-0.32	1.21e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.52	7.48	0.37	6.3e-13	Obesity-related traits;
LIHC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.34	-0.32	7.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7095607	0.538	rs2255136	chr10:69921733	T/A	cg18986048	chr10:69913749	MYPN	0.47	7.06	0.36	9.14e-12	Lung function (FVC);
LIHC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.51	7.39	0.37	1.13e-12	Type 2 diabetes;
LIHC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg18357645	chr12:58087776	OS9	-0.45	-6.98	-0.35	1.49e-11	Multiple sclerosis;
LIHC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.61	0.34	1.51e-10	Renal cell carcinoma;
LIHC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02290350	chr8:58132656	NA	0.41	8.63	0.42	2.39e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1866706	1.000	rs2165283	chr11:12873035	G/A	cg25843174	chr11:12811716	TEAD1	-0.32	-6.75	-0.34	6.5e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg27209729	chr11:64428925	NRXN2	0.35	6.49	0.33	3.07e-10	Body mass index;Urate levels;
LIHC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.67	9.97	0.47	9.99e-21	Menopause (age at onset);
LIHC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.85	12.45	0.56	1.31e-29	Psoriasis;
LIHC	cis	rs2071426	1.000	rs2071426	chr10:96828323	T/C	cg09036531	chr10:96991505	NA	-0.49	-5.9	-0.3	8.78e-9	Blood metabolite levels;
LIHC	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg01864836	chr14:55583639	NA	-0.42	-8.08	-0.4	1.15e-14	Protein biomarker;
LIHC	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.0	14.38	0.61	5.37e-37	Chin dimples;
LIHC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.77	-11.42	-0.53	8.38e-26	Corneal astigmatism;
LIHC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.43	-6.66	-0.34	1.09e-10	Height;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg10217327	chr6:118973057	C6orf204	0.68	6.93	0.35	2.12e-11	Diastolic blood pressure;
LIHC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg07451762	chr16:28383216	NA	0.42	7.5	0.38	5.55e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs832187	0.603	rs7615475	chr3:63926661	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.45	-6.37	-0.33	6.13e-10	Schizophrenia;
LIHC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.91	0.7	4.35e-51	Mean corpuscular hemoglobin;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg02990361	chr1:107599529	PRMT6	-0.67	-11.2	-0.52	5.26e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg20140201	chr2:241835670	C2orf54	-0.46	-6.24	-0.32	1.31e-9	Urinary metabolites;
LIHC	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg17623882	chr6:41773611	USP49	-0.43	-5.8	-0.3	1.52e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.79	-12.16	-0.55	1.68e-28	Schizophrenia;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg07810114	chr1:12018622	PLOD1	-0.49	-6.32	-0.32	8.37e-10	Alcohol dependence;
LIHC	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8084351	0.577	rs4426414	chr18:50621741	G/C	cg24270629	chr18:50823537	DCC	0.44	6.65	0.34	1.15e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs57244997	0.725	rs58957516	chr6:162427889	C/A	cg17173639	chr6:162384350	PARK2	-0.5	-6.31	-0.32	8.79e-10	Mosquito bite size;
LIHC	cis	rs10733682	0.659	rs13287548	chr9:129466456	C/T	cg00232160	chr9:129468157	NA	0.37	6.41	0.33	4.89e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.43	-7.04	-0.36	1.09e-11	Schizophrenia;
LIHC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.36	7.2	0.36	3.91e-12	Renal cell carcinoma;
LIHC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	5.87e-9	Menopause (age at onset);
LIHC	cis	rs1144333	1.000	rs78223982	chr1:76465203	T/C	cg10523679	chr1:76189770	ACADM	0.42	5.97	0.31	6.09e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.48	-7.75	-0.39	1.08e-13	Response to temozolomide;
LIHC	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.56	6.49	0.33	2.99e-10	Eye color traits;
LIHC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg02290350	chr8:58132656	NA	0.44	8.72	0.43	1.21e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.64	-8.64	-0.42	2.19e-16	Educational attainment;
LIHC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.41	8.88	0.43	3.86e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg20129853	chr10:51489980	NA	-0.4	-8.76	-0.43	8.94e-17	Prostate-specific antigen levels;
LIHC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg27170947	chr2:26402098	FAM59B	0.67	8.3	0.41	2.37e-15	Gut microbiome composition (summer);
LIHC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	cis	rs4742903	0.935	rs1507513	chr9:106973857	A/G	cg14250997	chr9:106856677	SMC2	0.34	5.76	0.3	1.88e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.94	0.39	2.98e-14	Response to antipsychotic treatment;
LIHC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02969873	chr4:1330999	MAEA	-0.41	-6.25	-0.32	1.22e-9	Longevity;
LIHC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	7.12	0.36	6.57e-12	Parkinson's disease;
LIHC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.47	6.24	0.32	1.28e-9	Parkinson's disease;
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg12903224	chr12:29470962	FAR2	-0.37	-5.91	-0.3	8.31e-9	QT interval;
LIHC	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-8.98	-0.44	1.84e-17	Exhaled nitric oxide output;
LIHC	cis	rs4728302	0.934	rs2971963	chr7:133641505	A/G	cg10665199	chr7:133106180	EXOC4	-0.35	-5.84	-0.3	1.21e-8	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.42	-6.01	-0.31	4.69e-9	Systemic lupus erythematosus;
LIHC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.43	-7.36	-0.37	1.34e-12	Aortic root size;
LIHC	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	12.4	0.56	1.98e-29	Body mass index (adult);
LIHC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.55	10.34	0.49	5.68e-22	Multiple myeloma;
LIHC	trans	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.76e-11	Coronary artery disease;
LIHC	cis	rs9915021	0.623	rs9899860	chr17:33941120	C/T	cg20932281	chr17:33905541	PEX12	0.57	7.06	0.36	9.29e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.73	-0.39	1.23e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-5.92	-0.3	8.04e-9	Renal cell carcinoma;
LIHC	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.61	-11.04	-0.51	1.96e-24	Breast cancer;
LIHC	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27596707	chr10:65029168	JMJD1C	-0.36	-6.11	-0.31	2.78e-9	Cognitive function;
LIHC	cis	rs3770081	1.000	rs76081054	chr2:86285037	T/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.96	-11.41	-0.53	9.09e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.96	-0.51	3.81e-24	Crohn's disease;
LIHC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.9	-18.64	-0.71	5.02e-54	Height;
LIHC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.05e-17	Bipolar disorder;
LIHC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg26531700	chr6:26746687	NA	0.38	6.44	0.33	3.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg07706471	chr12:123319906	HIP1R	-0.63	-8.28	-0.41	2.88e-15	Schizophrenia;
LIHC	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-7.79	-0.39	8.3e-14	Exhaled nitric oxide output;
LIHC	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.81	0.5	1.29e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.38	-0.37	1.24e-12	Breast cancer;
LIHC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	1.06	13.86	0.6	5.48e-35	Red blood cell traits;
LIHC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	cis	rs10849893	0.538	rs10744762	chr12:121839701	A/C	cg01154721	chr12:121881891	KDM2B	0.36	5.99	0.31	5.46e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.58	-0.5	7.78e-23	Chronic sinus infection;
LIHC	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.1e-22	Hypertriglyceridemia;
LIHC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.56	-0.33	2.01e-10	Mean corpuscular volume;
LIHC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.67	12.33	0.55	3.73e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.56	9.53	0.46	3.1e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	11.53	0.53	3.25e-26	Coronary artery disease;
LIHC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-11.63	-0.53	1.45e-26	Platelet count;
LIHC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.56	9.53	0.46	2.96e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.8	8.45	0.42	8.66e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12976411	1.000	rs12976411	chr19:32882020	A/T	cg02282382	chr19:32836354	ZNF507	-0.47	-5.79	-0.3	1.6e-8	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.33	-18.21	-0.7	2.75e-52	Diabetic kidney disease;
LIHC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.79	9.36	0.45	1.06e-18	Cisplatin-induced ototoxicity;
LIHC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7078219	0.523	rs4129134	chr10:101284345	C/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.0	-0.31	5.16e-9	Dental caries;
LIHC	cis	rs13272623	0.502	rs268627	chr8:71561041	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.45	-5.99	-0.31	5.34e-9	IgG glycosylation;
LIHC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.69	0.34	8.87e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs17106184	0.551	rs11205718	chr1:50854466	C/T	cg07174182	chr1:51127561	FAF1	-0.44	-5.73	-0.3	2.19e-8	Type 2 diabetes;
LIHC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-8.23	-0.41	3.95e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.4	-5.94	-0.31	6.94e-9	Iron status biomarkers;
LIHC	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.74	10.66	0.5	4.27e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.63	9.66	0.46	1.14e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.39	6.3	0.32	9.1e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	6.58	0.34	1.72e-10	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.48	-5.91	-0.3	8.28e-9	Narcolepsy;
LIHC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	1.08	14.69	0.62	3.18e-38	Heart rate;
LIHC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.14	0.36	5.65e-12	Axial length;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05464589	chr10:134571599	INPP5A	0.45	6.04	0.31	3.91e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.73	-11.36	-0.52	1.41e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.48	6.82	0.35	4.17e-11	Bipolar disorder;
LIHC	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.59	-6.87	-0.35	3.07e-11	Metabolite levels;
LIHC	trans	rs61041384	0.661	rs4759411	chr12:123740843	C/G	cg07919128	chr17:18022025	MYO15A	0.68	6.77	0.34	5.61e-11	Schizophrenia;
LIHC	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg10756647	chr7:56101905	PSPH	-0.98	-11.62	-0.53	1.57e-26	Gout;
LIHC	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.32	-8.5	-0.42	6.16e-16	Intelligence;
LIHC	trans	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19894588	chr14:64061835	NA	-0.5	-6.49	-0.33	3.06e-10	Glioblastoma;Glioma;
LIHC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	1.03	11.72	0.54	6.64e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg25783544	chr11:47291846	MADD	0.41	5.95	0.31	6.8e-9	HDL cholesterol;
LIHC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.37	-0.37	1.27e-12	Type 2 diabetes;
LIHC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-9.98	-0.47	9.68e-21	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg14092571	chr14:90743983	NA	-0.37	-5.79	-0.3	1.59e-8	Mortality in heart failure;
LIHC	cis	rs11125080	0.735	rs11682326	chr2:46734550	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.55	-5.9	-0.3	8.84e-9	Anti-saccade response;Anti-saccade error rate in psychotic disorders;
LIHC	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg12179176	chr11:130786555	SNX19	-0.61	-9.21	-0.45	3.3e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.44	-7.28	-0.37	2.31e-12	Educational attainment;
LIHC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.57	8.24	0.41	3.71e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.58	10.67	0.5	4.02e-23	Total body bone mineral density;
LIHC	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.7	-12.39	-0.56	2.23e-29	Height;
LIHC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.78	-0.34	5.32e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs400736	0.702	rs225134	chr1:8098730	A/G	cg25007680	chr1:8021821	PARK7	0.63	9.77	0.47	4.77e-20	Response to antidepressants and depression;
LIHC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.45	7.76	0.39	1.02e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.68	9.89	0.47	1.95e-20	Menarche (age at onset);
LIHC	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.79	-7.32	-0.37	1.81e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.4	7.93	0.39	3.11e-14	Coronary artery disease or large artery stroke;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10845606	0.581	rs10772591	chr12:12834802	A/G	cg04607235	chr12:12878440	APOLD1	-0.44	-6.18	-0.32	1.85e-9	Systemic lupus erythematosus;
LIHC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg25329415	chr6:28076851	NA	0.27	5.75	0.3	1.97e-8	Cardiac Troponin-T levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17019285	chr8:11725104	CTSB	0.51	6.94	0.35	2e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg12698662	chr3:15914712	MIR563	-0.35	-6.52	-0.33	2.6e-10	Mean platelet volume;
LIHC	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.33	20.23	0.74	2.12e-60	Corneal structure;
LIHC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.8	6.84	0.35	3.69e-11	Body mass index;
LIHC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22433398	chr13:27825486	RPL21;RPL21P28	0.51	7.46	0.37	7.19e-13	Lung function (FEV1/FVC);
LIHC	cis	rs1712517	0.904	rs10883863	chr10:105161879	G/A	cg05636881	chr10:105038444	INA	-0.41	-6.32	-0.32	8.11e-10	Migraine;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08077726	chr17:74734280	SFRS2;MFSD11	0.51	7.61	0.38	2.64e-13	Pancreatic cancer;
LIHC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg15832292	chr6:96025679	MANEA	0.58	7.78	0.39	8.73e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.05	-19.07	-0.72	9.87e-56	Testicular germ cell tumor;
LIHC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06544989	chr22:39130855	UNC84B	0.38	6.17	0.32	1.96e-9	Menopause (age at onset);
LIHC	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.8	-0.39	7.42e-14	Obesity-related traits;
LIHC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg17135325	chr3:160939158	NMD3	0.49	7.23	0.36	3.19e-12	Morning vs. evening chronotype;
LIHC	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.68	7.23	0.36	3.16e-12	Exhaled nitric oxide output;
LIHC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.81	0.35	4.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg05941027	chr17:61774174	LIMD2	0.34	6.8	0.35	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.33	0.41	2.02e-15	Motion sickness;
LIHC	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg08345082	chr10:99160200	RRP12	-0.4	-6.71	-0.34	8.13e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs785830	0.636	rs601023	chr9:224693	A/G	cg14500300	chr9:211689	NA	0.28	5.93	0.31	7.39e-9	Platelet distribution width;
LIHC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.65	-11.25	-0.52	3.37e-25	Crohn's disease;
LIHC	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.5e-10	Asthma;
LIHC	cis	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21467203	chr3:49911342	NA	-0.48	-8.44	-0.42	9.04e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.21	0.41	4.57e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	13.6	0.59	5.75e-34	Psoriasis;
LIHC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg13957321	chr17:43675089	NA	0.44	7.15	0.36	5.18e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.82	-0.3	1.38e-8	Body mass index;
LIHC	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.83	13.42	0.59	2.78e-33	Monocyte count;
LIHC	trans	rs55986470	0.817	rs66895963	chr2:239403902	A/T	cg01134436	chr17:81009848	B3GNTL1	0.59	6.1	0.31	2.93e-9	Chronotype;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02641675	chr6:74363634	SLC17A5	-0.38	-6.17	-0.32	1.88e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg06238570	chr21:40685208	BRWD1	0.6	7.24	0.36	3.01e-12	Cognitive function;
LIHC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.43	-6.5	-0.33	2.82e-10	Iron status biomarkers;
LIHC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg08253296	chr5:74907592	NA	-0.47	-6.01	-0.31	4.67e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	1.13	14.64	0.62	5.12e-38	Body mass index;
LIHC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	0.71	7.42	0.37	9.12e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg17385448	chr1:15911702	AGMAT	0.38	6.13	0.31	2.4e-9	Systolic blood pressure;
LIHC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.89	19.41	0.72	4.15e-57	Blood protein levels;
LIHC	cis	rs6466055	0.777	rs3801278	chr7:104907017	C/T	cg04380332	chr7:105027541	SRPK2	0.36	6.71	0.34	8.15e-11	Schizophrenia;
LIHC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.51	-0.49	1.47e-22	Response to antipsychotic treatment;
LIHC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21467203	chr3:49911342	NA	-0.41	-7.25	-0.36	2.86e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.37	-6.11	-0.31	2.76e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg01818776	chr8:25202910	DOCK5	0.5	6.27	0.32	1.09e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	14.91	0.63	4.59e-39	Menarche (age at onset);
LIHC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.67	10.22	0.48	1.39e-21	Corneal astigmatism;
LIHC	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg09695851	chr17:3907499	NA	-0.54	-6.21	-0.32	1.5e-9	Type 2 diabetes;
LIHC	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.92e-25	Psoriasis vulgaris;
LIHC	cis	rs17428076	0.874	rs62182372	chr2:172684487	C/T	cg13550731	chr2:172543902	DYNC1I2	0.38	6.21	0.32	1.55e-9	Myopia;
LIHC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.28	-6.05	-0.31	3.91e-9	Ulcerative colitis;
LIHC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg17279839	chr7:150038598	RARRES2	0.41	8.17	0.4	5.86e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs882732	0.576	rs3827893	chr14:95033671	A/T	cg14866387	chr14:95027382	SERPINA4	-0.38	-6.34	-0.32	7.06e-10	Blood protein levels;
LIHC	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg07451762	chr16:28383216	NA	-0.33	-6.28	-0.32	1.03e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4517514	0.509	rs10765252	chr11:89875664	C/T	cg05041596	chr11:89867385	NAALAD2	0.41	6.59	0.34	1.69e-10	Trans fatty acid levels;
LIHC	trans	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg19894588	chr14:64061835	NA	-0.63	-8.76	-0.43	9.08e-17	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.77	-9.9	-0.47	1.79e-20	Body mass index;
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-7.36	-0.37	1.39e-12	Plasma homocysteine levels (post-methionine load test);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.41	6.68	0.34	9.77e-11	Cognitive function;
LIHC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg14222432	chr12:29376421	FAR2	0.38	7.31	0.37	1.89e-12	QT interval;
LIHC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg15192750	chr16:69999425	NA	0.47	7.0	0.35	1.38e-11	IgE levels;
LIHC	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27297192	chr10:134578999	INPP5A	0.55	7.59	0.38	3.1400000000000003e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.51	-0.38	5.11e-13	Mean platelet volume;
LIHC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.57	0.46	2.3e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.66	9.19	0.44	4.02e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9918079	0.580	rs13120905	chr4:15612288	A/T	cg21123203	chr4:15471301	CC2D2A	0.45	7.23	0.36	3.24e-12	Obesity-related traits;
LIHC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-0.62	-13.48	-0.59	1.63e-33	Obesity-related traits;
LIHC	cis	rs712039	0.652	rs853197	chr17:35848716	T/C	cg16670864	chr17:35848621	DUSP14	0.35	5.88	0.3	9.85e-9	Tuberculosis;
LIHC	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg22705602	chr4:152727874	NA	-0.31	-6.58	-0.34	1.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.71	-0.38	1.4e-13	Response to antipsychotic treatment;
LIHC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.33	6.59	0.34	1.67e-10	Renal cell carcinoma;
LIHC	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg20991723	chr1:152506922	NA	0.53	9.23	0.45	2.89e-18	Hair morphology;
LIHC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs72627509	0.629	rs1718824	chr4:57903747	A/C	cg26694713	chr4:57773883	REST	-0.44	-6.08	-0.31	3.15e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.86	-0.39	4.99e-14	Coronary artery disease;
LIHC	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg08462924	chr1:41848221	NA	0.35	5.93	0.31	7.21e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08122663	chr6:17706677	NUP153	0.37	6.04	0.31	3.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs61677309	1.000	rs4938501	chr11:118166497	A/G	cg06090739	chr11:118230722	UBE4A	0.32	5.93	0.31	7.5e-9	Lung cancer in ever smokers;
LIHC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.86	11.24	0.52	3.86e-25	Schizophrenia;
LIHC	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.23	-0.36	3.16e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg12698662	chr3:15914712	MIR563	-0.36	-6.67	-0.34	1e-10	Mean platelet volume;
LIHC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs797680	0.856	rs12044657	chr1:93639596	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.35	-6.07	-0.31	3.37e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.62	-9.41	-0.45	7.74e-19	Motion sickness;
LIHC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg18887096	chr2:219472410	PLCD4	-0.39	-6.69	-0.34	9.17e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.74	12.04	0.55	4.35e-28	Body mass index;
LIHC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.41	6.1	0.31	2.8e-9	Methadone dose in opioid dependence;
LIHC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.51	8.51	0.42	5.66e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.68	6.62	0.34	1.38e-10	Schizophrenia;
LIHC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.02	0.35	1.21e-11	Lung cancer;
LIHC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.17	-0.32	1.88e-9	Schizophrenia;
LIHC	trans	rs4596713	0.507	rs2275427	chr9:71792581	G/A	cg16512924	chr15:28394682	HERC2	0.38	6.17	0.32	1.97e-9	Headache;
LIHC	cis	rs1865721	0.958	rs11663060	chr18:73172806	T/C	cg26385618	chr18:73139727	C18orf62	-0.29	-7.28	-0.37	2.3e-12	Intelligence;
LIHC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.68	-0.34	9.46e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg00792783	chr2:198669748	PLCL1	0.42	5.99	0.31	5.18e-9	Dermatomyositis;
LIHC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.75	-0.3	1.98e-8	Subjective well-being;
LIHC	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.26	-0.32	1.16e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.23	0.52	4.11e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg03647239	chr10:116582469	FAM160B1	0.46	6.38	0.33	5.9e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg02376097	chr19:46275166	DMPK	-0.43	-6.69	-0.34	9.2e-11	Coronary artery disease;
LIHC	cis	rs4700695	0.764	rs152941	chr5:65241446	A/G	cg21114390	chr5:65439923	SFRS12	0.44	5.77	0.3	1.8e-8	Facial morphology (factor 19);
LIHC	trans	rs10761482	0.639	rs2067612	chr10:62212334	T/C	cg17314160	chr12:110399253	GIT2	-0.4	-6.05	-0.31	3.73e-9	Schizophrenia;
LIHC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-8.99	-0.44	1.67e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.45e-10	Prudent dietary pattern;
LIHC	cis	rs11229555	0.574	rs11603800	chr11:58202085	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.44	-7.24	-0.36	2.98e-12	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18040892	chr19:11144017	SMARCA4	-0.38	-6.44	-0.33	3.95e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg06664874	chr5:179499304	RNF130	-0.58	-7.22	-0.36	3.48e-12	LDL cholesterol;
LIHC	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	12.2	0.55	1.15e-28	Coffee consumption (cups per day);
LIHC	trans	rs1075232	0.655	rs77987193	chr15:31588258	C/G	cg04373760	chr16:53404718	NA	0.65	6.25	0.32	1.24e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.8	-12.02	-0.54	5.38e-28	Obesity-related traits;
LIHC	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg13175981	chr1:150552382	MCL1	-0.45	-6.32	-0.32	7.95e-10	Tonsillectomy;
LIHC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.11	-0.61	6.26e-36	Alzheimer's disease;
LIHC	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg00977110	chr5:151150581	G3BP1	0.55	6.98	0.35	1.56e-11	Preschool internalizing problems;
LIHC	cis	rs35883536	0.967	rs4908090	chr1:101135177	A/G	cg14515779	chr1:101123966	NA	-0.68	-13.54	-0.59	9.39e-34	Monocyte count;
LIHC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.0	0.51	2.63e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	1.17	13.75	0.6	1.47e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg18016565	chr1:150552671	MCL1	0.54	10.31	0.49	6.79e-22	Melanoma;
LIHC	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg24220031	chr2:73402428	NA	-0.28	-5.96	-0.31	6.36e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg14671364	chr1:107599128	PRMT6	-0.51	-7.54	-0.38	4.23e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	12.98	0.57	1.38e-31	Cognitive test performance;
LIHC	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg03037974	chr15:76606532	NA	0.64	11.26	0.52	3.2e-25	Blood metabolite levels;
LIHC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg03517284	chr6:25882590	NA	-0.44	-6.64	-0.34	1.21e-10	Height;
LIHC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg12365402	chr11:9010492	NRIP3	-0.3	-8.05	-0.4	1.39e-14	Hemoglobin concentration;
LIHC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17554472	chr22:41940697	POLR3H	0.56	6.08	0.31	3.2e-9	Vitiligo;
LIHC	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.25	0.41	3.56e-15	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08882882	chr6:84937375	KIAA1009	0.46	6.29	0.32	9.7e-10	Pancreatic cancer;
LIHC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.14	-0.7	5.33e-52	Coronary artery disease;
LIHC	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.85	-0.3	1.17e-8	Diastolic blood pressure;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27297192	chr10:134578999	INPP5A	0.55	8.06	0.4	1.3e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	6.61	0.34	1.48e-10	Response to antipsychotic treatment;
LIHC	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	9.99	0.48	8.38e-21	Colorectal cancer;
LIHC	cis	rs2710642	0.721	rs10177638	chr2:62887010	C/T	cg17519650	chr2:63277830	OTX1	0.47	6.83	0.35	3.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14154082	chr13:112174009	NA	0.29	6.17	0.32	1.94e-9	Menarche (age at onset);
LIHC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.57	11.51	0.53	3.79e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.24	-0.36	2.93e-12	Metabolite levels;
LIHC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.88	-0.3	9.77e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.72	10.23	0.48	1.34e-21	Menarche (age at onset);
LIHC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.16	-0.32	2.07e-9	Aortic root size;
LIHC	cis	rs7326068	0.504	rs7983020	chr13:21239941	C/T	cg27234864	chr13:21295941	IL17D	-0.39	-6.09	-0.31	3.01e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-7.14	-0.36	5.54e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.2	-0.41	4.89e-15	Obesity-related traits;
LIHC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.4	-6.46	-0.33	3.66e-10	Blood pressure (smoking interaction);
LIHC	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.77	10.99	0.51	2.84e-24	Response to hepatitis C treatment;
LIHC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-6.6	-0.34	1.54e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.48	8.02	0.4	1.73e-14	Obesity-related traits;
LIHC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-10.31	-0.49	6.86e-22	Arsenic metabolism;
LIHC	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.66	-9.4	-0.45	7.79e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20887711	chr4:1340912	KIAA1530	0.81	12.47	0.56	1.12e-29	Longevity;
LIHC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.8	13.23	0.58	1.47e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.66	7.23	0.36	3.2e-12	Exhaled nitric oxide output;
LIHC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg16736954	chr20:23401023	NAPB	0.71	8.21	0.41	4.5e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.97	-0.31	6.08e-9	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	0.84	9.82	0.47	3.16e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.47	-7.12	-0.36	6.6e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs1355223	0.867	rs3818514	chr11:34680053	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.17	-0.32	1.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg18944383	chr4:111397179	ENPEP	0.27	6.97	0.35	1.66e-11	Height;
LIHC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.29	0.49	7.98e-22	Vitiligo;
LIHC	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg26138937	chr11:71823887	C11orf51	-1.31	-10.34	-0.49	5.49e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	0.91	12.6	0.56	3.57e-30	Mitochondrial DNA levels;
LIHC	cis	rs4773330	1.000	rs1891958	chr13:111817665	C/T	cg26911804	chr13:111806221	ARHGEF7	-0.63	-6.47	-0.33	3.44e-10	Bilirubin levels;
LIHC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.63	8.78	0.43	7.88e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.97	-13.55	-0.59	9.21e-34	Breast cancer;
LIHC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.8	-0.3	1.53e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs61677309	1.000	rs894677	chr11:118172535	C/T	cg06090739	chr11:118230722	UBE4A	0.35	6.44	0.33	4.11e-10	Lung cancer in ever smokers;
LIHC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.53	0.33	2.36e-10	Cognitive ability;
LIHC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.42	-6.69	-0.34	8.95e-11	Schizophrenia;
LIHC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.49	7.71	0.38	1.38e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4700695	0.841	rs428880	chr5:65245133	C/A	cg21114390	chr5:65439923	SFRS12	0.44	5.77	0.3	1.8e-8	Facial morphology (factor 19);
LIHC	cis	rs1639906	0.895	rs6972752	chr7:2196551	G/A	cg04267008	chr7:1944627	MAD1L1	0.47	6.11	0.31	2.69e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg25204440	chr1:209979598	IRF6	0.43	6.56	0.33	2.04e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.87	0.39	4.6e-14	Motion sickness;
LIHC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-7.58	-0.38	3.23e-13	Prudent dietary pattern;
LIHC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15290081	chr7:76254647	POMZP3;LOC100133091	0.5	7.01	0.35	1.27e-11	Systolic blood pressure;
LIHC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg12798992	chr6:167411361	FGFR1OP	0.64	10.64	0.5	4.8e-23	Crohn's disease;
LIHC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.5	0.46	3.65e-19	Bipolar disorder;
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.54	7.57	0.38	3.4e-13	Lymphocyte counts;
LIHC	cis	rs9649465	1.000	rs13230294	chr7:123380821	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.19	-0.41	5.09e-15	Migraine;
LIHC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.21	-0.41	4.7e-15	Schizophrenia;
LIHC	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.58	-8.85	-0.43	4.92e-17	Smoking behavior;
LIHC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs507080	0.961	rs607527	chr11:118538187	A/C	cg04173919	chr11:118528438	PHLDB1	-0.31	-5.83	-0.3	1.27e-8	Serum metabolite levels;
LIHC	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	0.91	10.43	0.49	2.72e-22	Breast cancer;
LIHC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.47	-5.84	-0.3	1.21e-8	Breast cancer;
LIHC	cis	rs17106184	0.681	rs12058197	chr1:51284557	T/C	cg07174182	chr1:51127561	FAF1	-0.65	-7.21	-0.36	3.53e-12	Type 2 diabetes;
LIHC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.84	-14.85	-0.63	7.54e-39	Aortic root size;
LIHC	cis	rs7818688	0.697	rs11782590	chr8:95970158	G/C	cg16049864	chr8:95962084	TP53INP1	0.56	6.33	0.32	7.59e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.22	-6.13	-0.31	2.43e-9	Type 2 diabetes;
LIHC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.58	-8.53	-0.42	4.82e-16	Schizophrenia;
LIHC	cis	rs9948	1.000	rs6576986	chr2:97508320	G/C	cg01990225	chr2:97406019	LMAN2L	-0.59	-5.99	-0.31	5.19e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.54e-12	Corneal astigmatism;
LIHC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	cis	rs10197940	0.810	rs4664045	chr2:152267072	T/G	cg06191203	chr2:152266755	RIF1	-0.51	-9.65	-0.46	1.17e-19	Lung cancer;
LIHC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.52	6.68	0.34	9.48e-11	Initial pursuit acceleration;
LIHC	cis	rs263063	0.920	rs263057	chr19:5037351	A/G	cg18473234	chr19:5097819	KDM4B	-0.54	-6.72	-0.34	7.76e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.45	-7.69	-0.38	1.6e-13	Breast cancer;
LIHC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-13.62	-0.59	4.66e-34	Systemic lupus erythematosus;
LIHC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.8	-11.9	-0.54	1.46e-27	Blood metabolite levels;
LIHC	cis	rs600806	0.813	rs4970760	chr1:109985439	A/G	cg23091122	chr1:110024289	SYPL2	-0.49	-6.55	-0.33	2.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.36	5.8	0.3	1.49e-8	Menopause (age at onset);
LIHC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.89	18.83	0.71	8.72e-55	IgG glycosylation;
LIHC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.5	6.56	0.33	2.05e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.17	-0.4	6.13e-15	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.55	-9.37	-0.45	9.81e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg25344623	chr2:136566232	LCT	0.45	8.88	0.43	3.71e-17	Corneal structure;
LIHC	cis	rs9309473	0.607	rs1522927	chr2:73556155	T/G	cg20560298	chr2:73613845	ALMS1	-0.41	-6.4	-0.33	5.23e-10	Metabolite levels;
LIHC	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.7	0.34	8.37e-11	Exhaled nitric oxide output;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-14.18	-0.61	3.2e-36	Prudent dietary pattern;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	7.65	0.38	2.09e-13	Obesity-related traits;
LIHC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg16070018	chr6:26224392	HIST1H3E	-0.62	-7.5	-0.38	5.55e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg26138937	chr11:71823887	C11orf51	-1.33	-10.54	-0.5	1.07e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-10.1	-0.48	3.58e-21	Glomerular filtration rate (creatinine);
LIHC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.56	9.12	0.44	6.64e-18	Body mass index;
LIHC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg08668510	chr10:1095578	IDI1	0.74	7.38	0.37	1.18e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.71	-12.55	-0.56	5.82e-30	Refractive error;
LIHC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.85	0.3	1.17e-8	Rheumatoid arthritis;
LIHC	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg16684958	chr7:75615977	POR	0.51	8.49	0.42	6.55e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.6	0.67	8.6e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs2302190	0.882	rs9901693	chr17:56606915	C/T	cg12560992	chr17:57184187	TRIM37	0.69	8.88	0.43	3.9e-17	Vitamin D levels;
LIHC	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	7.14	0.36	5.5e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs116248771	0.690	rs10936149	chr3:158293893	T/G	cg16708174	chr3:158430962	RARRES1	0.47	6.21	0.32	1.54e-9	diarrhoeal disease at age 2;
LIHC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.47	7.68	0.38	1.72e-13	Alcohol dependence;
LIHC	cis	rs17776563	0.959	rs1348004	chr15:89113450	C/G	cg05013243	chr15:89149849	MIR1179	0.45	7.56	0.38	3.66e-13	Thyroid hormone levels;
LIHC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.52	7.85	0.39	5.41e-14	Longevity;Endometriosis;
LIHC	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.8	12.79	0.57	7e-31	Chronic lymphocytic leukemia;
LIHC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.16	-0.48	2.26e-21	Blood metabolite levels;
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.73	10.24	0.48	1.21e-21	Menarche (age at onset);
LIHC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.05	0.31	3.8e-9	Personality dimensions;
LIHC	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02450064	chr17:40260053	DHX58	-0.3	-6.15	-0.32	2.17e-9	Fibrinogen levels;
LIHC	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.81	-13.87	-0.6	5.03e-35	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2412488	0.893	rs2271558	chr4:54362833	A/G	cg22241045	chr4:54363911	LNX1	0.46	7.64	0.38	2.15e-13	DNA methylation (variation);
LIHC	cis	rs1914816	0.941	rs2460146	chr15:76554755	C/T	cg03037974	chr15:76606532	NA	-0.61	-6.4	-0.33	5.1e-10	Response to tocilizumab in rheumatoid arthritis;
LIHC	trans	rs9500256	0.966	rs1322446	chr6:58311950	C/T	cg03371099	chr6:57305889	PRIM2	-0.37	-6.43	-0.33	4.34e-10	Eosinophilic esophagitis (pediatric);
LIHC	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Educational attainment;
LIHC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.84	0.43	5.31e-17	Menarche (age at onset);
LIHC	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.55	-0.46	2.62e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08843001	chr8:30891486	WRN;PURG	0.51	6.49	0.33	2.98e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11053548	0.614	rs10505745	chr12:10176144	A/G	cg04314261	chr12:10163030	CLEC12B	-0.37	-5.8	-0.3	1.48e-8	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg04013166	chr16:89971882	TCF25	0.52	6.46	0.33	3.55e-10	Skin colour saturation;
LIHC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	9.69	0.46	8.64e-20	Platelet count;
LIHC	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg15282417	chr9:129245246	FAM125B	0.39	6.3	0.32	9.1e-10	Intraocular pressure;
LIHC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.93	-0.39	3.2e-14	Monocyte percentage of white cells;
LIHC	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	0.56	7.49	0.38	5.84e-13	Opioid sensitivity;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg11668770	chr19:56125740	NA	0.39	6.19	0.32	1.71e-9	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.27	-0.41	3e-15	Response to antipsychotic treatment;
LIHC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.19	-0.32	1.68e-9	Tonsillectomy;
LIHC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.55	-5.97	-0.31	5.9e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6782228	0.606	rs2001950	chr3:128419756	A/G	cg16766828	chr3:128327626	NA	-0.37	-5.93	-0.31	7.47e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7937890	0.559	rs2597197	chr11:14489832	G/A	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.5	7.99	0.4	2.07e-14	Lymphocyte counts;
LIHC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg18357526	chr6:26021779	HIST1H4A	0.54	6.68	0.34	9.93e-11	Blood metabolite levels;
LIHC	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg07636037	chr3:49044803	WDR6	-0.55	-6.38	-0.33	5.74e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.72	-9.28	-0.45	1.97e-18	Mean platelet volume;
LIHC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.46	-7.52	-0.38	4.91e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1775715	0.870	rs1251400	chr10:32235145	A/G	cg14930904	chr10:32216787	ARHGAP12	0.39	6.95	0.35	1.82e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.53	8.8	0.43	7.1e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12379764	chr21:47803548	PCNT	-0.55	-8.22	-0.41	4.2e-15	Testicular germ cell tumor;
LIHC	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.68e-11	Blood pressure;
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20887711	chr4:1340912	KIAA1530	0.6	9.29	0.45	1.82e-18	Obesity-related traits;
LIHC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.53	9.42	0.45	6.92e-19	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg07424592	chr7:64974309	NA	0.75	8.79	0.43	7.66e-17	Diabetic kidney disease;
LIHC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12826209	chr6:26865740	GUSBL1	0.46	5.72	0.3	2.36e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg02993280	chr1:107599747	PRMT6	-0.64	-10.02	-0.48	7.1e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.31	-6.78	-0.34	5.41e-11	Congenital heart disease (maternal effect);
LIHC	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg02795151	chr17:7402630	POLR2A	0.54	5.85	0.3	1.13e-8	Androgen levels;
LIHC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.75	6.01	0.31	4.86e-9	Blood protein levels;
LIHC	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg27206522	chr1:152595629	LCE3A	0.24	5.72	0.3	2.34e-8	Psoriasis;
LIHC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.39	-5.89	-0.3	9.04e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.88	0.39	4.43e-14	Lung cancer;
LIHC	cis	rs611744	0.836	rs684412	chr8:109210905	T/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.89	11.56	0.53	2.56e-26	Coronary artery disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04185861	chr1:154377809	IL6R	-0.46	-6.38	-0.33	5.82e-10	Systolic blood pressure;
LIHC	cis	rs11644362	0.966	rs12933348	chr16:12991081	C/T	cg06890432	chr16:12997467	SHISA9	-0.39	-6.72	-0.34	7.67e-11	Positive affect;Subjective well-being;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12445461	chr9:6681608	NA	0.46	6.52	0.33	2.6e-10	Pancreatic cancer;
LIHC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.54	8.67	0.42	1.78e-16	Total body bone mineral density;
LIHC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.28	6.82	0.35	4.23e-11	Primary biliary cholangitis;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27297192	chr10:134578999	INPP5A	0.52	6.97	0.35	1.66e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg20891283	chr12:69753455	YEATS4	0.47	6.52	0.33	2.49e-10	Response to diuretic therapy;
LIHC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.46	0.37	7.4e-13	IgG glycosylation;
LIHC	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.04	0.31	3.95e-9	Heart rate;
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg23605328	chr1:201951606	RNPEP	0.4	6.28	0.32	1e-9	Monocyte percentage of white cells;
LIHC	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.56	-8.32	-0.41	2.15e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.02	16.54	0.67	1.47e-45	Orofacial clefts;
LIHC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.66	6.18	0.32	1.86e-9	Urate levels in lean individuals;
LIHC	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02985541	chr2:219472218	PLCD4	0.38	6.58	0.34	1.8e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-7.93	-0.39	3.15e-14	Body mass index;
LIHC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	9.5	0.46	3.68e-19	Lung cancer in ever smokers;
LIHC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.78	-0.3	1.68e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.6	-0.34	1.58e-10	Type 2 diabetes;
LIHC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.46	6.31	0.32	8.42e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	2.97e-11	Renal cell carcinoma;
LIHC	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.44	0.33	4.1e-10	Lymphocyte counts;
LIHC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-7.8	-0.39	7.5e-14	Ulcerative colitis;
LIHC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.28	21.87	0.76	6.17e-67	Corneal structure;
LIHC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg23533926	chr12:111358616	MYL2	-0.32	-6.23	-0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.8	-0.35	4.59e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.55	7.72	0.39	1.27e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.33	-6.19	-0.32	1.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25742201	chr17:35306863	AATF	-0.53	-6.83	-0.35	3.81e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.41	-0.49	3.1e-22	Coronary artery disease;
LIHC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg23625390	chr15:77176239	SCAPER	0.34	5.92	0.3	7.76e-9	Blood metabolite levels;
LIHC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg24296786	chr1:45957014	TESK2	-0.4	-5.75	-0.3	1.99e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.46	7.05	0.36	1.02e-11	Blood protein levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08547432	chr19:50143419	RRAS	0.41	6.6	0.34	1.57e-10	Cognitive function;
LIHC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.59	8.94	0.44	2.45e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg27205649	chr11:78285834	NARS2	0.4	6.26	0.32	1.14e-9	Alzheimer's disease (survival time);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20546810	chr20:2489835	ZNF343	-0.42	-6.05	-0.31	3.77e-9	Immature fraction of reticulocytes;
LIHC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.38	0.37	1.21e-12	Protein C levels;
LIHC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.31e-18	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27658640	chr17:4843839	RNF167;SLC25A11	0.45	6.35	0.32	6.84e-10	Pancreatic cancer;
LIHC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.55	8.35	0.41	1.71e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.51	-8.1	-0.4	9.49e-15	Menarche (age at onset);
LIHC	cis	rs2302190	0.882	rs7216856	chr17:56472295	C/T	cg12560992	chr17:57184187	TRIM37	0.68	8.63	0.42	2.43e-16	Vitamin D levels;
LIHC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.27	16.79	0.67	1.38e-46	Diabetic kidney disease;
LIHC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.53	-8.48	-0.42	7.05e-16	Coronary artery disease;
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.25	-0.37	2.76e-12	Testicular germ cell tumor;
LIHC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02450064	chr17:40260053	DHX58	-0.3	-6.15	-0.32	2.17e-9	Fibrinogen levels;
LIHC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	7.74	0.39	1.15e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs16828019	0.777	rs12739052	chr1:41464455	C/A	cg03962019	chr1:41807865	NA	0.53	7.01	0.35	1.26e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs60752752	0.852	rs12040625	chr1:153365548	A/G	cg14901121	chr8:98817630	LAPTM4B	-0.41	-6.86	-0.35	3.31e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.61	-9.72	-0.47	7.19e-20	Inflammatory bowel disease;
LIHC	cis	rs6960043	0.620	rs11760782	chr7:15064788	A/T	cg19272540	chr7:15055459	NA	0.26	6.57	0.33	1.92e-10	Type 2 diabetes;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.68	-10.66	-0.5	4.19e-23	Skin colour saturation;
LIHC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.6	8.46	0.42	7.66e-16	Morning vs. evening chronotype;
LIHC	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg06453172	chr10:134556979	INPP5A	-0.62	-7.72	-0.39	1.34e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.63	-9.58	-0.46	2.14e-19	Colorectal cancer;
LIHC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.51	7.25	0.36	2.88e-12	Menopause (age at onset);
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.52	-15.89	-0.65	5.89e-43	Breast cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg20870372	chr13:99867982	UBAC2	0.32	6.09	0.31	2.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs6108011	0.659	rs6117882	chr20:7589465	C/T	cg13422339	chr21:47602486	C21orf56	0.5	6.21	0.32	1.57e-9	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.38	6.95	0.35	1.8e-11	IgG glycosylation;
LIHC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.3	0.37	1.98e-12	Obesity-related traits;
LIHC	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.07	0.31	3.47e-9	Mean corpuscular volume;
LIHC	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg18121669	chr1:26560928	CCDC21	-0.47	-7.08	-0.36	8.33e-12	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.66	10.11	0.48	3.38e-21	Prostate cancer;
LIHC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg14440974	chr22:39074834	NA	-0.38	-6.49	-0.33	3.05e-10	Menopause (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06030229	chr18:19321133	MIB1	0.51	6.26	0.32	1.15e-9	Hepatitis;
LIHC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.84	-17.28	-0.68	1.55e-48	Height;
LIHC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.48	-7.17	-0.36	4.73e-12	Fibrinogen levels;
LIHC	cis	rs9918079	0.560	rs4698409	chr4:15659766	G/A	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.14	-0.32	2.29e-9	Obesity-related traits;
LIHC	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2.05e-9	Ulcerative colitis;
LIHC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.03	14.59	0.62	7.75e-38	Cognitive function;
LIHC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	0.67	7.95	0.39	2.72e-14	Corneal curvature;
LIHC	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg01950434	chr2:97203154	ARID5A	-0.44	-6.42	-0.33	4.67e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.56	0.53	2.64e-26	Alzheimer's disease;
LIHC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	12.95	0.57	1.76e-31	Prudent dietary pattern;
LIHC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.83	0.3	1.28e-8	Self-reported allergy;
LIHC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.09	-0.4	1.02e-14	Body mass index;
LIHC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.81	0.54	3.03e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25457191	chr19:34895442	PDCD2L	0.46	6.21	0.32	1.53e-9	Lung function (FEV1/FVC);
LIHC	cis	rs748404	0.533	rs11632120	chr15:43415373	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.35	-5.71	-0.3	2.41e-8	Lung cancer;
LIHC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.64	7.73	0.39	1.22e-13	Heart rate;
LIHC	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.54	-8.64	-0.42	2.2e-16	Superior crus of antihelix expression;
LIHC	cis	rs7129556	0.520	rs4366508	chr11:77274999	C/T	cg03570279	chr11:77446074	RSF1	-0.36	-6.68	-0.34	9.43e-11	Weight loss (gastric bypass surgery);
LIHC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.75	0.3	1.99e-8	Bladder cancer;
LIHC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.74	-0.34	6.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-8.17	-0.4	6.23e-15	Corneal astigmatism;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02290350	chr8:58132656	NA	0.51	11.04	0.51	1.9e-24	Developmental language disorder (linguistic errors);
LIHC	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg19635926	chr16:89946313	TCF25	0.46	6.0	0.31	4.94e-9	Skin colour saturation;
LIHC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.52	-0.42	5.17e-16	Total cholesterol levels;
LIHC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.42	7.76	0.39	9.7e-14	Schizophrenia;
LIHC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.38	-5.74	-0.3	2.05e-8	Lung cancer;
LIHC	cis	rs7707921	0.881	rs6875409	chr5:81297077	A/G	cg15871215	chr5:81402204	ATG10	-0.63	-6.38	-0.33	5.7e-10	Breast cancer;
LIHC	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.5	-7.24	-0.36	2.93e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.02	0.31	4.58e-9	Menopause (age at onset);
LIHC	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.86e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.4	6.15	0.32	2.11e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs7188697	0.848	rs42947	chr16:58579158	A/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.25	-0.37	2.73e-12	QT interval;
LIHC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.31	-6.56	-0.33	2.05e-10	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.13	0.31	2.49e-9	Prudent dietary pattern;
LIHC	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg00012203	chr2:219082015	ARPC2	0.77	10.96	0.51	3.85e-24	Colorectal cancer;
LIHC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	0.96	18.44	0.71	3.27e-53	Bone mineral density;
LIHC	cis	rs2637266	0.756	rs846623	chr10:78542819	C/T	cg18941641	chr10:78392320	NA	0.28	6.03	0.31	4.24e-9	Pulmonary function;
LIHC	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg18305652	chr10:134549665	INPP5A	0.41	5.94	0.31	6.99e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8084351	0.539	rs7504413	chr18:50610528	T/C	cg24270629	chr18:50823537	DCC	0.44	6.73	0.34	7.31e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg23605328	chr1:201951606	RNPEP	0.39	6.2	0.32	1.66e-9	Monocyte percentage of white cells;
LIHC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.05	-0.4	1.42e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	cis	rs11083846	0.866	rs3786708	chr19:47248308	G/A	cg08230695	chr19:47220755	PRKD2	0.62	6.28	0.32	1.04e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.48	7.59	0.38	2.98e-13	Schizophrenia;
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg12923728	chr3:195709715	SDHAP1	-0.6	-6.93	-0.35	2.04e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.19e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-8.45	-0.42	8.33e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs611744	0.934	rs604698	chr8:109238721	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.38	-6.04	-0.31	4.02e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.67	6.44	0.33	3.98e-10	Breast cancer;
LIHC	trans	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg10756647	chr7:56101905	PSPH	-0.47	-7.06	-0.36	9.56e-12	Aortic root size;
LIHC	cis	rs7546668	0.895	rs10754894	chr1:15835234	G/A	cg11706911	chr1:15910989	AGMAT	0.45	6.9	0.35	2.6e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.89	-0.35	2.68e-11	Electroencephalogram traits;
LIHC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.43e-23	Personality dimensions;
LIHC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.88	0.39	4.36e-14	Motion sickness;
LIHC	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg25665528	chr16:2260870	C16orf79	-0.36	-6.32	-0.32	8.36e-10	Height;
LIHC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.58	8.65	0.42	2.01e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.29	-0.7	1.34e-52	Height;
LIHC	cis	rs11229555	0.645	rs7926682	chr11:58189495	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg09417038	chr21:47716443	C21orf57	-0.49	-7.21	-0.36	3.54e-12	Testicular germ cell tumor;
LIHC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.8	6.81	0.35	4.29e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.56	8.11	0.4	9.34e-15	Renal cell carcinoma;
LIHC	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.46	5.84	0.3	1.23e-8	Bipolar disorder;
LIHC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.83	12.68	0.57	1.84e-30	Metabolic syndrome;
LIHC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.0	0.31	5.11e-9	Tonsillectomy;
LIHC	cis	rs3015497	0.646	rs3015492	chr14:51124743	G/A	cg09863266	chr14:51125203	SAV1	-0.41	-5.8	-0.3	1.49e-8	Mean platelet volume;
LIHC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-8.06	-0.4	1.28e-14	Morning vs. evening chronotype;
LIHC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg21724239	chr8:58056113	NA	0.48	6.39	0.33	5.3e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.54	7.65	0.38	2.03e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg02993280	chr1:107599747	PRMT6	0.67	10.98	0.51	3.13e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.35	8.58	0.42	3.29e-16	Weight;
LIHC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	1.03	13.27	0.58	1.03e-32	Mosquito bite size;
LIHC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.31	0.41	2.3e-15	Motion sickness;
LIHC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg06565975	chr8:143823917	SLURP1	0.34	6.66	0.34	1.1e-10	Urinary tract infection frequency;
LIHC	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg25566285	chr7:158114605	PTPRN2	0.23	6.22	0.32	1.43e-9	Calcium levels;
LIHC	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg12798992	chr6:167411361	FGFR1OP	0.42	6.61	0.34	1.48e-10	Primary biliary cholangitis;
LIHC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.43	-6.68	-0.34	9.6e-11	Schizophrenia;
LIHC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg05941027	chr17:61774174	LIMD2	-0.32	-6.64	-0.34	1.25e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs895636	0.752	rs4245800	chr2:45189866	G/A	cg16198908	chr2:45192207	NA	0.39	5.94	0.31	6.97e-9	Metabolite levels;Fasting plasma glucose;
LIHC	cis	rs1866706	1.000	rs6486065	chr11:12870969	T/G	cg25843174	chr11:12811716	TEAD1	-0.29	-6.14	-0.31	2.34e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02290350	chr8:58132656	NA	0.42	8.88	0.43	3.83e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27343303	chr11:34380546	NA	0.47	6.63	0.34	1.32e-10	Pancreatic cancer;
LIHC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.81	12.02	0.55	5.2e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3823572	0.564	rs2346273	chr7:133659764	A/T	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg25364880	chr3:44379878	C3orf23	0.57	7.71	0.38	1.42e-13	Depressive symptoms;
LIHC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.87	10.83	0.51	1.04e-23	Mean platelet volume;
LIHC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.16	0.4	6.58e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.79	0.3	1.61e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg09182678	chr22:50328711	NA	-0.43	-6.17	-0.32	1.98e-9	Schizophrenia;
LIHC	cis	rs963731	0.579	rs1454219	chr2:39276957	C/T	cg04010122	chr2:39346883	SOS1	-0.61	-6.3	-0.32	9.37e-10	Corticobasal degeneration;
LIHC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-8.02	-0.4	1.72e-14	Cognitive function;
LIHC	cis	rs4407350	0.967	rs5765741	chr22:44924292	A/G	cg11695653	chr22:44894386	LDOC1L	-0.36	-5.98	-0.31	5.75e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.62	11.08	0.51	1.4e-24	Platelet distribution width;
LIHC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.82	0.47	3.18e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.22	0.36	3.39e-12	Bipolar disorder;
LIHC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.49	7.44	0.37	8.22e-13	Asthma (sex interaction);
LIHC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.43	-5.98	-0.31	5.54e-9	Height;
LIHC	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg11441379	chr12:63026424	NA	0.61	6.22	0.32	1.45e-9	IgG glycosylation;
LIHC	cis	rs16828019	0.852	rs12759050	chr1:41664204	T/A	cg03962019	chr1:41807865	NA	0.53	7.64	0.38	2.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.47	-7.02	-0.35	1.2e-11	Diastolic blood pressure;
LIHC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.24	0.55	7.91e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg14758556	chr20:62440591	NA	-0.41	-6.58	-0.34	1.74e-10	Atopic dermatitis;
LIHC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.77	-9.36	-0.45	1.08e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1144333	0.655	rs4949682	chr1:76443196	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-7.62	-0.38	2.44e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9322817	0.691	rs2499667	chr6:105319125	G/A	cg02098413	chr6:105308735	HACE1	0.42	7.71	0.38	1.35e-13	Thyroid stimulating hormone;
LIHC	trans	rs76485637	0.761	rs71374973	chr16:8000380	A/T	cg15006175	chr8:145698660	KIFC2	-0.33	-6.06	-0.31	3.54e-9	Pediatric bone mineral density (spine);
LIHC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg17980119	chr2:219472607	PLCD4	0.34	5.79	0.3	1.57e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9649465	1.000	rs6466881	chr7:123337734	G/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.04	-0.4	1.44e-14	Migraine;
LIHC	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.21	-0.32	1.52e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02895995	chr19:7554069	PEX11G	0.37	6.14	0.32	2.25e-9	Cognitive function;
LIHC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.72	11.61	0.53	1.73e-26	Oral cavity cancer;
LIHC	cis	rs9921222	0.500	rs12917907	chr16:405866	C/T	cg00101154	chr16:420108	MRPL28	-0.59	-8.44	-0.42	8.81e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.49	-6.86	-0.35	3.21e-11	Urate levels in overweight individuals;
LIHC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.36	5.93	0.31	7.52e-9	Height;
LIHC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.23	-0.36	3.28e-12	Body mass index;
LIHC	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.96	0.31	6.26e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LIHC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.67	10.41	0.49	3.25e-22	Height;
LIHC	trans	rs6600671	0.967	rs12069545	chr1:121172203	A/G	cg09829573	chr1:144692074	NBPF9	-0.45	-8.23	-0.41	4.12e-15	Hip geometry;
LIHC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.42	-6.14	-0.32	2.31e-9	Narcolepsy;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.61	8.84	0.43	5.28e-17	Prudent dietary pattern;
LIHC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.76	-0.3	1.93e-8	Aortic root size;
LIHC	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.06	-0.36	9.52e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.29	6.93	0.35	2.04e-11	Primary biliary cholangitis;
LIHC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.46	6.35	0.32	6.66e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.54	-8.36	-0.41	1.57e-15	Schizophrenia;
LIHC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.67	10.21	0.48	1.56e-21	Body mass index;
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13409248	chr3:40428643	ENTPD3	0.47	7.71	0.38	1.38e-13	Renal cell carcinoma;
LIHC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.4	6.51	0.33	2.72e-10	Red blood cell count;
LIHC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.46	0.56	1.24e-29	Cognitive test performance;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.58	10.12	0.48	3.02e-21	Longevity;Endometriosis;
LIHC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg23485639	chr6:28045615	ZNF165	0.39	5.94	0.31	7.13e-9	Parkinson's disease;
LIHC	cis	rs2176862	1.000	rs77406377	chr3:46620961	T/G	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.3	-0.32	9.3e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.68	-11.45	-0.53	6.43e-26	Blood trace element (Cu levels);
LIHC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.56	6.31	0.32	8.73e-10	Axial length;
LIHC	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg06353428	chr16:71660113	MARVELD3	0.67	7.29	0.37	2.15e-12	Blood protein levels;
LIHC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.99	-20.3	-0.74	1.06e-60	Breast cancer;
LIHC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.38	6.76	0.34	6.09e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7937890	0.559	rs2575838	chr11:14498221	C/G	cg02886208	chr11:14281011	SPON1	-0.44	-6.15	-0.32	2.17e-9	Mitochondrial DNA levels;
LIHC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.23	-0.41	3.86e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg04310649	chr10:35416472	CREM	0.42	5.78	0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4853036	0.951	rs35344582	chr2:70148093	C/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.25	-0.32	1.23e-9	Colorectal or endometrial cancer;
LIHC	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.63	-11.19	-0.52	5.74e-25	Breast cancer;
LIHC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.58	-10.2	-0.48	1.61e-21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18867708	chr6:26865862	GUSBL1	0.55	8.23	0.41	3.92e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg16797656	chr11:68205561	LRP5	0.59	7.79	0.39	8.34e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs58785573	0.504	rs13151185	chr4:38609196	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.55	7.81	0.39	7.13e-14	Lymphocyte percentage of white cells;
LIHC	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg14515779	chr1:101123966	NA	-0.59	-11.19	-0.52	5.49e-25	Monocyte count;
LIHC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg02290350	chr8:58132656	NA	0.47	9.18	0.44	4.15e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs3106136	0.649	rs6532486	chr4:95300390	C/T	cg11021082	chr4:95130006	SMARCAD1	0.35	5.9	0.3	8.71e-9	Capecitabine sensitivity;
LIHC	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg00647820	chr17:40259828	DHX58	-0.29	-6.11	-0.31	2.67e-9	Fibrinogen levels;
LIHC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.35	-5.78	-0.3	1.69e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14196211	chr17:79670206	MRPL12	0.39	6.06	0.31	3.52e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg17764715	chr19:33622953	WDR88	0.45	6.55	0.33	2.17e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.44	-6.0	-0.31	4.96e-9	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24991452	chr6:35996059	MAPK14	0.42	6.61	0.34	1.52e-10	Cognitive function;
LIHC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg02782426	chr3:40428986	ENTPD3	0.35	6.48	0.33	3.17e-10	Renal cell carcinoma;
LIHC	cis	rs10861661	0.963	rs10861662	chr12:107178653	A/C	cg15890332	chr12:107067104	RFX4	0.26	5.75	0.3	2.01e-8	Triglyceride levels;
LIHC	trans	rs1994321	1.000	rs1994321	chr11:12087313	G/T	cg20781238	chr11:787685	CEND1	-0.4	-6.35	-0.32	6.73e-10	Non-response to selective serotonin reuptake inhibitors and depression;
LIHC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.5	-6.65	-0.34	1.17e-10	Breast cancer;
LIHC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg09137382	chr11:130731461	NA	0.44	6.83	0.35	3.88e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-8.87	-0.43	4.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.43	-0.33	4.27e-10	Type 2 diabetes;
LIHC	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.46	6.61	0.34	1.48e-10	Pulse pressure;
LIHC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	10.1	0.48	3.53e-21	Resting heart rate;
LIHC	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg14593290	chr7:50529359	DDC	0.41	6.82	0.35	4.09e-11	Malaria;
LIHC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.88	0.39	4.36e-14	Motion sickness;
LIHC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.87	-0.35	3.12e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg22951263	chr5:87985283	NA	-0.39	-6.72	-0.34	7.43e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.34	0.56	3.48e-29	Prudent dietary pattern;
LIHC	trans	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg10756647	chr7:56101905	PSPH	-1.04	-12.56	-0.56	5.34e-30	Diabetic kidney disease;
LIHC	trans	rs11088226	0.709	rs55860967	chr21:33880018	G/A	cg09050820	chr6:167586206	TCP10L2	0.51	6.5	0.33	2.77e-10	Gastritis;
LIHC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.95	11.14	0.52	8.8e-25	Triglycerides;
LIHC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.45	6.24	0.32	1.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg16309518	chr5:176445507	NA	-0.52	-9.6	-0.46	1.8e-19	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.4	-6.7	-0.34	8.74e-11	Longevity;
LIHC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.53	5.84	0.3	1.23e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs16958440	1.000	rs60854219	chr18:44646664	G/A	cg17192377	chr18:44677553	HDHD2	0.6	6.76	0.34	5.88e-11	Sitting height ratio;
LIHC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.41	-6.55	-0.33	2.13e-10	Mortality in heart failure;
LIHC	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-7.06	-0.36	9.4e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg15105060	chr4:7024189	TBC1D14	-0.78	-6.59	-0.34	1.71e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-9.83	-0.47	3.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26734620	chr12:56694298	CS	1.28	10.93	0.51	4.77e-24	Psoriasis vulgaris;
LIHC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.2	-13.02	-0.58	9.8e-32	Plateletcrit;
LIHC	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg04725166	chr1:7887271	PER3	-0.39	-7.0	-0.35	1.33e-11	Crohn's disease;
LIHC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-1.01	-19.21	-0.72	2.67e-56	Breast cancer;
LIHC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.56	-8.1	-0.4	9.74e-15	Coronary artery disease;
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg00091569	chr3:40428383	ENTPD3	-0.38	-6.53	-0.33	2.36e-10	Renal cell carcinoma;
LIHC	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg01843034	chr6:37503916	NA	-0.48	-8.11	-0.4	9.22e-15	Cognitive performance;
LIHC	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.76	9.04	0.44	1.15e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.45	6.72	0.34	7.4e-11	Gout;
LIHC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.51	-9.41	-0.45	7.54e-19	Asthma;
LIHC	cis	rs546131	0.642	rs523246	chr11:34845011	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.26	0.37	2.69e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs907683	0.584	rs12621188	chr2:220287892	C/G	cg15015639	chr2:220282977	DES	0.36	8.46	0.42	7.95e-16	Resting heart rate;
LIHC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	17.56	0.69	1.15e-49	Nonalcoholic fatty liver disease;
LIHC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.58	-6.49	-0.33	3.03e-10	Axial length;
LIHC	cis	rs74181299	0.591	rs1894875	chr2:65363579	G/A	cg05010058	chr2:65284262	CEP68	-0.35	-5.81	-0.3	1.46e-8	Pulse pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25026715	chr17:26989248	SUPT6H;SDF2	-0.48	-6.71	-0.34	8.28e-11	Pancreatic cancer;
LIHC	cis	rs74233809	1.000	rs5011520	chr10:104697516	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.09	0.31	2.98e-9	Birth weight;
LIHC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.44	6.01	0.31	4.75e-9	Iron status biomarkers;
LIHC	cis	rs9513627	0.915	rs73556182	chr13:100122107	A/G	cg25919922	chr13:100150906	NA	-0.8	-7.07	-0.36	8.77e-12	Obesity-related traits;
LIHC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.43	7.24	0.36	3.08e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	7.13	0.36	5.97e-12	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.45	5.82	0.3	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.6	0.42	2.85e-16	Menarche (age at onset);
LIHC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.79	-0.43	7.33e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.75e-10	Depression;
LIHC	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg00977110	chr5:151150581	G3BP1	0.56	7.03	0.36	1.11e-11	Preschool internalizing problems;
LIHC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.7	10.93	0.51	4.55e-24	Corneal astigmatism;
LIHC	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.4	7.08	0.36	8.34e-12	Obesity;
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.97	0.31	5.88e-9	Tonsillectomy;
LIHC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg18867708	chr6:26865862	GUSBL1	-0.49	-7.46	-0.37	6.99e-13	Schizophrenia;
LIHC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-6.69	-0.34	8.89e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	cis	rs6466055	0.674	rs6967587	chr7:104744041	C/T	cg04380332	chr7:105027541	SRPK2	-0.34	-6.43	-0.33	4.3e-10	Schizophrenia;
LIHC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg14829360	chr17:73884958	NA	-0.51	-7.67	-0.38	1.77e-13	Psoriasis;
LIHC	cis	rs4853036	1.000	rs35002543	chr2:70091299	A/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-5.72	-0.3	2.26e-8	Colorectal or endometrial cancer;
LIHC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.2	-0.41	4.94e-15	Body mass index;
LIHC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.45	7.5	0.38	5.51e-13	Mean corpuscular volume;
LIHC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg04013166	chr16:89971882	TCF25	0.52	6.62	0.34	1.35e-10	Skin colour saturation;
LIHC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.37	0.33	6.08e-10	Cognitive test performance;
LIHC	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.72	0.47	6.91e-20	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.41	-9.37	-0.45	1.03e-18	Type 2 diabetes;
LIHC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg26395211	chr5:140044315	WDR55	0.4	5.88	0.3	9.85e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs273218	1.000	rs156438	chr5:53374120	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.67	10.78	0.5	1.59e-23	Migraine;
LIHC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	8.73	0.43	1.15e-16	Platelet count;
LIHC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.61	-0.34	1.49e-10	Bipolar disorder;
LIHC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.27	-0.32	1.06e-9	Mean corpuscular volume;
LIHC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03264133	chr6:25882463	NA	-0.45	-6.96	-0.35	1.72e-11	Height;
LIHC	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg02702477	chr5:179499311	RNF130	0.74	10.14	0.48	2.7e-21	LDL cholesterol;
LIHC	cis	rs1823913	1.000	rs4853565	chr2:192123746	C/T	cg12404831	chr2:192114017	MYO1B	-0.32	-6.54	-0.33	2.21e-10	Obesity-related traits;
LIHC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.39	-5.83	-0.3	1.3e-8	Rheumatoid arthritis;
LIHC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg15832292	chr6:96025679	MANEA	0.6	6.79	0.34	5.12e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	0.81	13.66	0.59	3.3e-34	Total cholesterol levels;
LIHC	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.46	6.28	0.32	1.04e-9	Longevity;
LIHC	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	1.11	9.22	0.45	3.09e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-7.9	-0.39	3.74e-14	Crohn's disease;
LIHC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.77	-0.69	1.69e-50	Gut microbiome composition (summer);
LIHC	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.68	11.19	0.52	5.8e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.33	-0.32	7.5e-10	Height;
LIHC	trans	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg14791747	chr16:20752902	THUMPD1	-0.48	-6.72	-0.34	7.47e-11	Dental caries;
LIHC	cis	rs12744310	0.945	rs72665690	chr1:41775236	C/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg18306943	chr3:40428807	ENTPD3	0.33	5.88	0.3	9.6e-9	Renal cell carcinoma;
LIHC	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.78	-7.24	-0.36	2.9e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.56	-8.82	-0.43	5.78e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.57	8.01	0.4	1.77e-14	Neuroticism;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.07	-0.31	3.31e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	6.99	0.35	1.43e-11	Height;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg11062466	chr8:58055876	NA	0.51	7.6	0.38	2.92e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.98	17.88	0.7	5.79e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	8.9	0.43	3.42e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.37	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04575087	chr11:46867195	CKAP5	0.47	6.39	0.33	5.54e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.59	6.89	0.35	2.63e-11	Bipolar disorder;
LIHC	trans	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg23605328	chr1:201951606	RNPEP	0.38	6.07	0.31	3.35e-9	Monocyte percentage of white cells;
LIHC	cis	rs9993613	1.000	rs2366302	chr4:73450550	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.38	-5.98	-0.31	5.75e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	7.83	0.39	6.09e-14	Eotaxin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03075683	chr16:11038168	CLEC16A	0.42	6.27	0.32	1.1e-9	Cognitive function;
LIHC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.34	-0.32	7.13e-10	Height;
LIHC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-9.34	-0.45	1.22e-18	Blood protein levels;
LIHC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.59	9.3	0.45	1.71e-18	Lymphocyte counts;
LIHC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.61e-14	Motion sickness;
LIHC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12463550	chr7:65579703	CRCP	-0.62	-6.65	-0.34	1.18e-10	Diabetic kidney disease;
LIHC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.46	0.37	7.27e-13	Glycated hemoglobin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24449302	chr15:66679100	MAP2K1	-0.52	-7.82	-0.39	6.74e-14	Cognitive function;
LIHC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.59	9.59	0.46	1.86e-19	Lymphocyte counts;
LIHC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.36	6.51	0.33	2.69e-10	Aortic root size;
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.42	0.37	9.09e-13	Renal cell carcinoma;
LIHC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.51	-9.04	-0.44	1.21e-17	Total body bone mineral density;
LIHC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg05110241	chr16:68378359	PRMT7	-0.5	-5.95	-0.31	6.56e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.92	16.56	0.67	1.21e-45	Bone mineral density;
LIHC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg17980119	chr2:219472607	PLCD4	0.35	6.07	0.31	3.39e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg22037779	chr5:139682734	PFDN1	-0.54	-6.48	-0.33	3.12e-10	Mean platelet volume;
LIHC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.52	8.12	0.4	8.73e-15	Lymphocyte counts;
LIHC	cis	rs244293	0.965	rs244369	chr17:53186061	C/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.38	-6.28	-0.32	1.05e-9	Educational attainment;
LIHC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg25281562	chr12:121454272	C12orf43	-0.36	-6.12	-0.31	2.57e-9	N-glycan levels;
LIHC	cis	rs4407350	0.721	rs131157	chr22:44891722	A/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.39	-0.33	5.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.51	-8.93	-0.43	2.59e-17	Longevity;
LIHC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.45	0.33	3.91e-10	Response to antipsychotic treatment;
LIHC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg01557791	chr16:72042693	DHODH	-0.43	-7.15	-0.36	5.22e-12	Fibrinogen levels;
LIHC	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg12560992	chr17:57184187	TRIM37	0.72	9.09	0.44	8.09e-18	Vitamin D levels;
LIHC	cis	rs1185460	0.565	rs657685	chr11:118912982	G/C	cg01677386	chr11:118938358	VPS11	0.44	5.89	0.3	9.22e-9	Coronary artery disease;
LIHC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.83	9.15	0.44	5.17e-18	Initial pursuit acceleration;
LIHC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.3	0.37	2e-12	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.88	-13.54	-0.59	9.85e-34	Myeloid white cell count;
LIHC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.66	-0.34	1.09e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.71e-10	Waist circumference;Weight;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.69	-10.51	-0.49	1.37e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	8.13	0.4	8.13e-15	Fuchs's corneal dystrophy;
LIHC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.38	7.11	0.36	6.85e-12	Schizophrenia;
LIHC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.45	8.07	0.4	1.2e-14	IgG glycosylation;
LIHC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.96	-0.51	3.76e-24	Primary sclerosing cholangitis;
LIHC	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.82	-0.3	1.34e-8	Tuberculosis;
LIHC	cis	rs3812111	0.605	rs1204845	chr6:116521190	G/A	cg08036074	chr6:116424633	NT5DC1	-0.41	-6.59	-0.34	1.66e-10	Age-related macular degeneration;
LIHC	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.47	-6.04	-0.31	4.06e-9	Response to amphetamines;
LIHC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg09182678	chr22:50328711	NA	-0.44	-6.23	-0.32	1.33e-9	Schizophrenia;
LIHC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.69	-0.34	9.33e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg14061069	chr19:46274453	DMPK	0.69	12.68	0.57	1.85e-30	Coronary artery disease;
LIHC	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg16070018	chr6:26224392	HIST1H3E	-0.67	-6.53	-0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.68	8.78	0.43	7.82e-17	Initial pursuit acceleration;
LIHC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	13.32	0.58	6.82e-33	Primary sclerosing cholangitis;
LIHC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.56	0.53	2.67e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.44	5.91	0.3	8.39e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	11.51	0.53	3.96e-26	Coronary artery disease;
LIHC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg14393609	chr7:65229607	NA	-0.42	-6.24	-0.32	1.31e-9	Aortic root size;
LIHC	cis	rs6545883	0.894	rs2600672	chr2:61536740	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.91	-0.3	8.27e-9	Tuberculosis;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg20709868	chr19:12992305	DNASE2	0.45	6.68	0.34	9.69e-11	Migraine with aura;
LIHC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	6.33	0.32	7.86e-10	Menarche (age at onset);
LIHC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.92	12.44	0.56	1.42e-29	Heart rate;
LIHC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.96	-0.31	6.29e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.88	15.53	0.64	1.53e-41	Colorectal cancer;
LIHC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg08213375	chr14:104286397	PPP1R13B	0.51	8.59	0.42	3.06e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg05197062	chr11:11642011	GALNTL4	0.43	6.06	0.31	3.61e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12500138	1.000	rs28407421	chr4:166169576	A/G	cg25064052	chr4:166216151	KLHL2	-0.64	-5.92	-0.31	7.68e-9	Cognitive function;
LIHC	cis	rs7635838	0.927	rs13082150	chr3:11437813	T/C	cg00170343	chr3:11313890	ATG7	0.45	7.04	0.36	1.08e-11	HDL cholesterol;
LIHC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	20.87	0.75	5.84e-63	Chronic sinus infection;
LIHC	trans	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg17675199	chr6:35436792	RPL10A	0.33	6.72	0.34	7.58e-11	Coronary artery disease;
LIHC	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg06935464	chr4:38784597	TLR10	0.44	6.58	0.34	1.77e-10	Breast cancer;
LIHC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.87	-12.43	-0.56	1.65e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.54	-0.38	4.21e-13	Mood instability;
LIHC	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg00142150	chr22:38071001	LGALS1	0.62	8.01	0.4	1.82e-14	Fat distribution (HIV);
LIHC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.56	-7.71	-0.38	1.43e-13	Ulcerative colitis;
LIHC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.86	0.3	1.11e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.41	-5.84	-0.3	1.22e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21467203	chr3:49911342	NA	0.61	11.29	0.52	2.54e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.78	0.54	4.15e-27	Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.95	0.35	1.82e-11	Height;
LIHC	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg21995068	chr20:25989032	LOC100134868	-0.61	-9.81	-0.47	3.64e-20	Colorectal or endometrial cancer;
LIHC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4845459	0.935	rs4845449	chr1:152591024	A/T	cg20634798	chr1:152595351	LCE3A	-0.31	-6.19	-0.32	1.73e-9	Psoriasis;
LIHC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.84	-0.57	4.5e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.31	7.8	0.39	7.42e-14	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6088813	1.000	rs6087705	chr20:34001250	C/T	cg14752227	chr20:34000481	UQCC	-0.4	-5.74	-0.3	2.1e-8	Height;
LIHC	cis	rs244293	0.931	rs2628323	chr17:53203097	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.24e-13	Menarche (age at onset);
LIHC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.63	8.12	0.4	8.29e-15	Morning vs. evening chronotype;
LIHC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.64	-10.74	-0.5	2.22e-23	Colorectal cancer;
LIHC	cis	rs4728302	1.000	rs4728302	chr7:133630463	C/T	cg10665199	chr7:133106180	EXOC4	-0.35	-5.89	-0.3	9.4e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg15654264	chr1:150340011	RPRD2	0.49	8.23	0.41	4.1e-15	Migraine;
LIHC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.71	0.38	1.39e-13	Mean platelet volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07489123	chr19:1812466	ATP8B3	0.42	6.06	0.31	3.56e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.38	-5.81	-0.3	1.4e-8	Platelet count;
LIHC	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.47	0.49	1.93e-22	Colorectal cancer;
LIHC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg16736954	chr20:23401023	NAPB	0.71	8.42	0.41	1.06e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.48	5.91	0.3	8.47e-9	Schizophrenia;
LIHC	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02985541	chr2:219472218	PLCD4	-0.36	-6.36	-0.33	6.34e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.79	-8.65	-0.42	2.06e-16	Vitiligo;
LIHC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.62	-7.77	-0.39	9.51e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.6	7.98	0.4	2.23e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-8.65	-0.42	2.09e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.53	8.11	0.4	9.15e-15	HDL cholesterol;
LIHC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-10.23	-0.48	1.36e-21	Chronic sinus infection;
LIHC	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.71	-11.04	-0.51	1.89e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.48	-18.36	-0.7	7.27e-53	Breast cancer;
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.27	-6.29	-0.32	9.46e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.62	-6.44	-0.33	4.09e-10	Lymphocyte counts;
LIHC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.29	-6.7	-0.34	8.84e-11	Crohn's disease;
LIHC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.41	6.5	0.33	2.91e-10	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.54	-6.01	-0.31	4.71e-9	IgG glycosylation;
LIHC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg02290350	chr8:58132656	NA	0.41	8.7	0.43	1.43e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-9.29	-0.45	1.88e-18	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08677398	chr8:58056175	NA	0.39	6.06	0.31	3.68e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs4714291	0.832	rs7764688	chr6:40115442	G/T	cg02267698	chr19:7991119	CTXN1	-0.4	-6.63	-0.34	1.3100000000000001e-10	Strep throat;
LIHC	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.38	-0.37	1.2e-12	Metabolite levels;
LIHC	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.36	6.66	0.34	1.11e-10	Height;
LIHC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg02640540	chr1:67518911	SLC35D1	0.44	6.08	0.31	3.12e-9	Lymphocyte percentage of white cells;
LIHC	trans	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs12464559	0.649	rs6708645	chr2:152620387	A/T	cg01189475	chr2:152685088	ARL5A	0.63	7.46	0.37	7.1e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-7.63	-0.38	2.36e-13	Height;
LIHC	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.78	-0.34	5.3e-11	Mean platelet volume;
LIHC	cis	rs1355223	0.902	rs11607035	chr11:34718911	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.38	-0.33	5.6e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.46	0.37	7.3e-13	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.83	-0.3	1.25e-8	Blood metabolite levels;
LIHC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.05	-0.31	3.88e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.44	6.16	0.32	2.06e-9	Monobrow;
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.36	6.03	0.31	4.25e-9	Height;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg16132339	chr22:24313637	DDTL;DDT	0.82	17.02	0.68	1.78e-47	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.49	0.33	2.95e-10	Renal cell carcinoma;
LIHC	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg09238746	chr17:78121135	EIF4A3	-0.53	-8.21	-0.41	4.46e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LIHC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg15848620	chr12:58087721	OS9	0.52	6.55	0.33	2.15e-10	Multiple sclerosis;
LIHC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-0.96	-17.64	-0.69	5.3e-50	IgG glycosylation;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg19568834	chr20:34252926	CPNE1;RBM12	-0.4	-6.05	-0.31	3.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07730007	chr12:107377277	MTERFD3	0.44	6.05	0.31	3.84e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05590025	chr7:65112418	INTS4L2	-0.45	-6.89	-0.35	2.62e-11	Calcium levels;
LIHC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.67e-9	Mortality in heart failure;
LIHC	cis	rs986417	0.818	rs1254325	chr14:60909689	A/G	cg27398547	chr14:60952738	C14orf39	-0.7	-8.45	-0.42	8.5e-16	Gut microbiota (bacterial taxa);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13286318	chr8:57906058	IMPAD1	0.49	6.73	0.34	7.05e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.33	20.83	0.75	8.23e-63	Corneal structure;
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.81	0.35	4.42e-11	Renal cell carcinoma;
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg23782820	chr8:58130467	NA	0.34	5.87	0.3	1.04e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04633058	chr17:48474099	LRRC59	0.49	7.42	0.37	9.52e-13	Pancreatic cancer;
LIHC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.16	0.55	1.65e-28	Mean platelet volume;
LIHC	cis	rs61677309	1.000	rs66832804	chr11:118157049	T/A	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs2274273	0.624	rs10141396	chr14:55816925	A/C	cg01864836	chr14:55583639	NA	-0.36	-5.86	-0.3	1.07e-8	Protein biomarker;
LIHC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg26149184	chr10:133730230	NA	0.47	7.5	0.38	5.69e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.12	25.1	0.81	1.47e-79	Cognitive ability;
LIHC	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.41	6.95	0.35	1.89e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01630199	chr7:66369076	NA	0.41	6.1	0.31	2.8e-9	Bilirubin levels;
LIHC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.83	0.35	3.95e-11	Height;
LIHC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.55	-9.1	-0.44	7.81e-18	Colorectal cancer;
LIHC	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.76	-9.07	-0.44	9.33e-18	Psoriasis vulgaris;
LIHC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.62	-11.22	-0.52	4.36e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs1152591	0.505	rs1152593	chr14:64675895	C/T	cg21174375	chr14:64681225	SYNE2	0.37	5.9	0.3	8.68e-9	Atrial fibrillation;
LIHC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.42	-8.46	-0.42	7.81e-16	Obesity-related traits;
LIHC	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.44	6.63	0.34	1.27e-10	Schizophrenia;
LIHC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.49	0.53	4.67e-26	Tonsillectomy;
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.91	-0.3	8.35e-9	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.88	0.35	2.9e-11	Renal cell carcinoma;
LIHC	cis	rs3736485	0.966	rs7170444	chr15:51890500	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.37	-0.33	5.94e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg26138937	chr11:71823887	C11orf51	-1.34	-10.79	-0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-9.93	-0.47	1.42e-20	Coronary artery disease;
LIHC	cis	rs2016586	0.802	rs5999975	chr22:36115911	G/A	cg26342177	chr22:36113512	APOL5	-0.39	-6.57	-0.33	1.82e-10	Body mass index;
LIHC	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.56	8.26	0.41	3.32e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.72	-10.27	-0.49	9.23e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.82	0.3	1.34e-8	Iron status biomarkers;
LIHC	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg24391279	chr8:1708526	NA	0.33	5.99	0.31	5.2e-9	Systolic blood pressure;
LIHC	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.77	-7.06	-0.36	9.29e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-9.68	-0.46	9.32e-20	Asthma;
LIHC	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.58	9.43	0.45	6.45e-19	Corneal astigmatism;
LIHC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs7911264	0.572	rs7071912	chr10:94416229	T/G	cg25506282	chr10:94462361	NA	0.38	6.39	0.33	5.33e-10	Inflammatory bowel disease;
LIHC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.26	0.41	3.32e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg24879335	chr3:133465180	TF	0.26	5.84	0.3	1.19e-8	Iron status biomarkers;
LIHC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.57	8.37	0.41	1.49e-15	Platelet count;
LIHC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.0	0.31	4.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.91	-0.3	8.14e-9	Life satisfaction;
LIHC	cis	rs2279817	0.780	rs77072467	chr1:17979675	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-7.14	-0.36	5.8e-12	Neuroticism;
LIHC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.11	0.4	9.35e-15	Response to antipsychotic treatment;
LIHC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05771511	chr15:63340396	TPM1	0.51	7.46	0.37	7.16e-13	Platelet count;
LIHC	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.42e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.89	-19.31	-0.72	1.07e-56	Height;
LIHC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.36	5.79	0.3	1.61e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg16479474	chr6:28041457	NA	0.39	6.52	0.33	2.57e-10	Cardiac Troponin-T levels;
LIHC	cis	rs3790645	1.000	rs3127013	chr1:26891360	T/G	cg23229016	chr1:26872525	RPS6KA1	0.23	5.73	0.3	2.26e-8	Glucose homeostasis traits;
LIHC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs1211375	0.628	rs3859141	chr16:245079	T/C	cg00126636	chr16:237282	NA	-0.41	-7.0	-0.35	1.39e-11	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.4	6.05	0.31	3.86e-9	Menarche (age at onset);
LIHC	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	6.26	0.32	1.15e-9	Reticulocyte fraction of red cells;
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg21522988	chr12:29376872	FAR2	0.3	6.86	0.35	3.28e-11	QT interval;
LIHC	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.37	12.47	0.56	1.08e-29	Uric acid levels;
LIHC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	0.9	8.01	0.4	1.83e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg24296786	chr1:45957014	TESK2	-0.39	-5.88	-0.3	9.77e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg26395211	chr5:140044315	WDR55	0.41	6.09	0.31	2.99e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs11014306	0.841	rs11014309	chr10:25224755	C/A	cg06869505	chr1:15527517	TMEM51	0.34	6.04	0.31	4.02e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs249954	0.512	rs249856	chr16:23658976	G/A	cg09867953	chr16:23706666	ERN2	0.38	6.37	0.33	6.15e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg03859395	chr2:55845619	SMEK2	0.9	15.58	0.64	9.6e-42	Metabolic syndrome;
LIHC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg25600027	chr14:23388339	RBM23	-0.41	-6.02	-0.31	4.4e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs4650994	0.550	rs12047530	chr1:178543407	A/G	cg05350800	chr1:178550844	NA	-0.35	-7.64	-0.38	2.26e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.11	0.58	4.33e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	12.39	0.56	2.21e-29	Alzheimer's disease;
LIHC	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.64	10.11	0.48	3.27e-21	Obesity-related traits;
LIHC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.95e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg16586182	chr3:47516702	SCAP	0.45	7.87	0.39	4.8e-14	Colorectal cancer;
LIHC	cis	rs3823572	0.548	rs2971981	chr7:133651555	T/C	cg03336402	chr7:133662267	EXOC4	-0.48	-5.85	-0.3	1.15e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.32	6.69	0.34	9.1e-11	Blood metabolite levels;
LIHC	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.36	-0.33	6.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	23.39	0.78	6.36e-73	Body mass index (adult);
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg14828511	chr1:107599125	PRMT6	-0.42	-6.01	-0.31	4.79e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.54	-6.87	-0.35	3.06e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18716194	chr12:110872950	ARPC3	0.47	6.94	0.35	1.98e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg05044414	chr3:183734942	ABCC5	0.34	5.99	0.31	5.23e-9	Anterior chamber depth;
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.26	-16.36	-0.66	7.9e-45	Diabetic kidney disease;
LIHC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.47	16.88	0.67	6.43e-47	Eosinophil percentage of granulocytes;
LIHC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg00204512	chr16:28754710	NA	0.37	6.77	0.34	5.79e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.67	-10.09	-0.48	3.96e-21	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17125944	0.686	rs4901305	chr14:53364271	C/T	cg00686598	chr14:53173677	PSMC6	-0.81	-8.99	-0.44	1.66e-17	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08219700	chr8:58056026	NA	0.52	7.16	0.36	4.94e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.53	8.56	0.42	3.84e-16	Height;
LIHC	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.34	7.75	0.39	1.03e-13	Blood metabolite ratios;
LIHC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg15123519	chr2:136567270	LCT	0.35	6.67	0.34	1.05e-10	Mosquito bite size;
LIHC	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.49	7.31	0.37	1.87e-12	Dialysis-related mortality;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14802876	chr6:34217098	C6orf1	-0.38	-6.13	-0.31	2.38e-9	Pancreatic cancer;
LIHC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.45	-7.55	-0.38	4.01e-13	Testicular germ cell tumor;
LIHC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	7.91	0.39	3.56e-14	Bipolar disorder lithium response (categorical) or schizophrenia;
LIHC	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg25174290	chr11:3078921	CARS	-0.44	-6.5	-0.33	2.79e-10	Calcium levels;
LIHC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.69	12.31	0.55	4.59e-29	Iron status biomarkers;
LIHC	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.22	-5.88	-0.3	9.86e-9	Hepatitis;
LIHC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.83	-8.77	-0.43	8.65e-17	Pancreatic cancer;
LIHC	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.47	7.15	0.36	5.39e-12	Adiposity;
LIHC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.6	7.16	0.36	4.99e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs36051895	0.530	rs10114531	chr9:5229116	A/G	cg02405213	chr9:5042618	JAK2	-0.6	-9.37	-0.45	1.01e-18	Pediatric autoimmune diseases;
LIHC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.46	7.73	0.39	1.24e-13	Response to temozolomide;
LIHC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.03	-7.25	-0.36	2.89e-12	Body mass index;
LIHC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	0.83	9.38	0.45	9.11e-19	Vitiligo;
LIHC	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg03999872	chr20:62272968	STMN3	-0.46	-6.78	-0.34	5.22e-11	Atopic dermatitis;
LIHC	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.63	-0.38	2.31e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	8.22	0.41	4.36e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.66	10.96	0.51	3.65e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.24	5.77	0.3	1.76e-8	Primary biliary cholangitis;
LIHC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-1.01	-19.24	-0.72	1.97e-56	Breast cancer;
LIHC	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg07424592	chr7:64974309	NA	-0.77	-8.94	-0.44	2.49e-17	Gout;
LIHC	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg10587741	chr22:38071170	LGALS1	0.47	8.48	0.42	6.84e-16	Fat distribution (HIV);
LIHC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.74	0.3	2.1e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14737905	chr2:128186178	PROC	0.46	6.86	0.35	3.21e-11	Immature fraction of reticulocytes;
LIHC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg18867708	chr6:26865862	GUSBL1	0.52	8.1	0.4	9.8e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs10491431	0.866	rs10461715	chr5:36002012	C/T	cg26557896	chr1:77165565	NA	-0.4	-6.59	-0.34	1.69e-10	Blood metabolite levels;
LIHC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.83	13.78	0.6	1.19e-34	Dental caries;
LIHC	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.77	0.39	9.01e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.58	11.25	0.52	3.32e-25	Coronary artery disease;
LIHC	cis	rs11229555	0.645	rs10896775	chr11:58175989	A/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.79	-0.54	3.69e-27	Type 2 diabetes;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	0.38	6.08	0.31	3.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.1	0.44	7.68e-18	Bipolar disorder;
LIHC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.44	7.32	0.37	1.82e-12	Response to temozolomide;
LIHC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.42	0.41	1.05e-15	Menarche (age at onset);
LIHC	cis	rs7487075	0.619	rs12314541	chr12:46794766	T/C	cg23829395	chr12:46796953	NA	0.35	6.28	0.32	1.06e-9	Itch intensity from mosquito bite;
LIHC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.53	5.81	0.3	1.45e-8	Menopause (age at onset);
LIHC	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	11.02	0.51	2.36e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg03934865	chr2:198174659	NA	0.45	6.47	0.33	3.42e-10	Dermatomyositis;
LIHC	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.6	7.96	0.4	2.6e-14	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.89	12.44	0.56	1.51e-29	Blood metabolite levels;
LIHC	cis	rs600806	0.778	rs491285	chr1:110019002	C/T	cg08911820	chr1:110026001	ATXN7L2	0.56	6.91	0.35	2.45e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg14169308	chr2:86850884	RNF103	0.63	6.08	0.31	3.24e-9	Hip geometry;
LIHC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.32	-0.49	6.71e-22	Pancreatic cancer;
LIHC	cis	rs4834770	0.792	rs7676969	chr4:120173724	C/T	cg09307838	chr4:120376055	NA	0.41	5.86	0.3	1.08e-8	Blood protein levels;
LIHC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.65	0.56	2.36e-30	Hip circumference adjusted for BMI;
LIHC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.83	9.1	0.44	7.39e-18	Vitiligo;
LIHC	cis	rs10847980	0.590	rs78462864	chr12:123365867	C/T	cg25930673	chr12:123319894	HIP1R	1.14	11.54	0.53	3.14e-26	Adiponectin levels;
LIHC	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg09911534	chr15:67153556	NA	-0.48	-5.94	-0.31	7.08e-9	Lung cancer (smoking interaction);
LIHC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.68	-9.82	-0.47	3.24e-20	Initial pursuit acceleration;
LIHC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.68	-0.43	1.61e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.61	-9.45	-0.46	5.37e-19	Retinal vascular caliber;
LIHC	cis	rs2073300	1.000	rs6048834	chr20:23462213	C/T	cg12062639	chr20:23401060	NAPB	0.78	9.81	0.47	3.62e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	9.13	0.44	6.03e-18	Monocyte count;
LIHC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	7.49	0.38	6.12e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.72	-0.43	1.27e-16	Schizophrenia;
LIHC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg19682013	chr15:45996608	NA	0.41	7.25	0.37	2.78e-12	Waist circumference;Weight;
LIHC	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.56	10.97	0.51	3.3e-24	Coronary artery disease;
LIHC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.79	-12.28	-0.55	6e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2540917	0.904	rs2668729	chr2:60608383	G/A	cg00543073	chr2:60773386	BCL11A	-0.29	-5.79	-0.3	1.6e-8	Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12315590	chr3:128997497	C3orf37	0.51	7.4	0.37	1.1e-12	Pancreatic cancer;
LIHC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.26	6.28	0.32	1.03e-9	Primary biliary cholangitis;
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg07133347	chr1:107600762	PRMT6	-0.41	-6.19	-0.32	1.72e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	0.74	8.04	0.4	1.5e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.63	-0.38	2.29e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg14773178	chr5:1868261	NA	0.26	6.72	0.34	7.55e-11	Cardiovascular disease risk factors;
LIHC	trans	rs1436334	1.000	rs6783422	chr3:104548890	A/G	cg27425383	chr3:125776273	SLC41A3	-0.34	-6.41	-0.33	4.75e-10	Initial pursuit acceleration;
LIHC	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.41	-0.37	1.02e-12	Tuberculosis;
LIHC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.66	-9.49	-0.46	4.16e-19	Testicular germ cell tumor;
LIHC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.97	14.95	0.63	3.11e-39	Metabolic syndrome;
LIHC	cis	rs74233809	0.892	rs11191447	chr10:104652323	C/T	cg03493300	chr10:104813866	CNNM2	0.45	5.9	0.3	8.78e-9	Birth weight;
LIHC	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.43	8.57	0.42	3.71e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs244293	0.965	rs171513	chr17:53190426	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.26e-13	Menarche (age at onset);
LIHC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-19.79	-0.73	1.21e-58	Height;
LIHC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg15448220	chr1:150897856	SETDB1	0.44	6.83	0.35	3.85e-11	Melanoma;
LIHC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.45	7.12	0.36	6.52e-12	HDL cholesterol levels;
LIHC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg12798992	chr6:167411361	FGFR1OP	0.52	8.07	0.4	1.24e-14	Crohn's disease;
LIHC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.6	10.38	0.49	3.91e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.08	-0.48	4.34e-21	Tonsillectomy;
LIHC	trans	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg04702396	chr17:15466718	FAM18B2	-0.44	-6.85	-0.35	3.46e-11	Educational attainment (years of education);
LIHC	trans	rs983392	0.709	rs11603507	chr11:59982470	T/A	cg17275991	chr19:58003312	ZNF419	0.44	6.26	0.32	1.12e-9	Alzheimer's disease (late onset);
LIHC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.52	8.34	0.41	1.9e-15	Height;
LIHC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg24826892	chr11:71159390	DHCR7	0.5	6.38	0.33	5.79e-10	Vitamin D levels;
LIHC	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg00977110	chr5:151150581	G3BP1	0.51	6.34	0.32	7.45e-10	Preschool internalizing problems;
LIHC	cis	rs2274273	0.588	rs17128145	chr14:55536406	G/T	cg01864836	chr14:55583639	NA	0.4	6.31	0.32	8.62e-10	Protein biomarker;
LIHC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg04013166	chr16:89971882	TCF25	0.49	6.08	0.31	3.24e-9	Skin colour saturation;
LIHC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.58	9.28	0.45	2.05e-18	Multiple sclerosis;
LIHC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg02640540	chr1:67518911	SLC35D1	-0.39	-5.86	-0.3	1.1e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg03934865	chr2:198174659	NA	0.53	8.07	0.4	1.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8067354	0.540	rs12600680	chr17:58037374	T/C	cg02344993	chr17:57696989	CLTC	0.65	10.28	0.49	8.95e-22	Hemoglobin concentration;
LIHC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg24203234	chr3:128598194	ACAD9	0.44	6.18	0.32	1.78e-9	IgG glycosylation;
LIHC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg00204512	chr16:28754710	NA	0.41	7.16	0.36	4.9e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg10360323	chr17:41437877	NA	0.4	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	cis	rs4919087	0.715	rs793524	chr10:99024572	A/G	cg25902810	chr10:99078978	FRAT1	-0.55	-6.29	-0.32	9.84e-10	Monocyte count;
LIHC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.37	-0.33	6.17e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.65	12.12	0.55	2.24e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.72	0.3	2.39e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs10411161	1.000	rs2867318	chr19:52363472	T/C	cg22319618	chr22:45562946	NUP50	-0.51	-6.83	-0.35	4.01e-11	Breast cancer;
LIHC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-8.14	-0.4	7.32e-15	Tonsillectomy;
LIHC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.44	0.53	7.19e-26	Platelet count;
LIHC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg24209194	chr3:40518798	ZNF619	-0.45	-6.61	-0.34	1.44e-10	Renal cell carcinoma;
LIHC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02290350	chr8:58132656	NA	0.5	8.99	0.44	1.74e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs724818	1.000	rs729243	chr4:121585651	C/T	cg16091981	chr1:17634543	PADI4	-0.5	-6.12	-0.31	2.6e-9	Monobrow thickness;
LIHC	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.73	11.1	0.51	1.15e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs16858210	0.607	rs59321941	chr3:183571024	A/G	cg25686905	chr3:183603175	PARL	-0.49	-8.6	-0.42	2.88e-16	Menopause (age at onset);
LIHC	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.44	-6.19	-0.32	1.68e-9	Schizophrenia;
LIHC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.81	0.3	1.42e-8	Platelet count;
LIHC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.9	12.0	0.54	6.13e-28	Post bronchodilator FEV1;
LIHC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.62	6.47	0.33	3.37e-10	Schizophrenia;
LIHC	cis	rs16854884	0.710	rs6782558	chr3:143817462	G/C	cg06585982	chr3:143692056	C3orf58	0.41	5.76	0.3	1.87e-8	Economic and political preferences (feminism/equality);
LIHC	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg25919922	chr13:100150906	NA	-0.75	-6.38	-0.33	5.91e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.57	7.53	0.38	4.56e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.77	13.3	0.58	7.81e-33	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.59	9.12	0.44	6.46e-18	Longevity;
LIHC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.57	8.65	0.42	2.1e-16	Height;
LIHC	cis	rs6088813	1.000	rs6088820	chr20:33987298	T/C	cg14752227	chr20:34000481	UQCC	-0.4	-5.75	-0.3	1.99e-8	Height;
LIHC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.65	-9.31	-0.45	1.57e-18	Blood metabolite levels;
LIHC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.99	0.48	9e-21	Lung cancer;
LIHC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.71	-11.66	-0.53	1.13e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.09	0.4	1.03e-14	Tonsillectomy;
LIHC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.35	8.11	0.4	9.26e-15	Crohn's disease;
LIHC	trans	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.36	6.57	0.33	1.83e-10	Blood metabolite levels;
LIHC	cis	rs1144333	0.655	rs4949681	chr1:76409828	C/T	cg22875332	chr1:76189707	ACADM	0.41	6.14	0.32	2.31e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.89	0.3	9.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg04162153	chr10:124029871	BTBD16	-0.43	-6.03	-0.31	4.28e-9	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.95	-0.31	6.78e-9	Breast cancer;
LIHC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.87	-0.35	3e-11	Mean corpuscular volume;
LIHC	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.82	8.4	0.41	1.17e-15	Blood protein levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14734630	chr12:29533564	ERGIC2	-0.53	-6.07	-0.31	3.41e-9	Systolic blood pressure;
LIHC	cis	rs959260	1.000	rs7226070	chr17:73372811	T/C	cg20590849	chr17:73267439	MIF4GD	-0.53	-5.75	-0.3	1.96e-8	Systemic lupus erythematosus;
LIHC	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.41	6.28	0.32	1.01e-9	HDL cholesterol;
LIHC	cis	rs1144333	0.737	rs1144331	chr1:76272357	G/A	cg03433033	chr1:76189801	ACADM	-0.56	-8.61	-0.42	2.7e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	6.37	0.33	5.99e-10	Platelet distribution width;
LIHC	trans	rs75804782	0.521	rs72994970	chr2:239426992	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	6.37	0.33	6.12e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.01e-8	Tonsillectomy;
LIHC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.58	-9.56	-0.46	2.43e-19	Colorectal cancer;
LIHC	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg22951263	chr5:87985283	NA	-0.41	-7.17	-0.36	4.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.74	-9.39	-0.45	8.5e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs7238033	0.624	rs8099449	chr18:43311696	T/C	cg20610511	chr18:43302872	SLC14A1	0.38	6.34	0.32	7.44e-10	Bladder cancer;
LIHC	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.56	8.26	0.41	3.22e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg15691649	chr6:25882328	NA	0.59	7.93	0.39	3.16e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg05501817	chr11:14380813	RRAS2	-0.45	-6.32	-0.32	8.29e-10	Sense of smell;
LIHC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-12.55	-0.56	5.8e-30	Coronary artery disease;
LIHC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.39	-0.33	5.54e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg07451762	chr16:28383216	NA	0.32	6.09	0.31	3.1e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-17.47	-0.69	2.6e-49	Height;
LIHC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.42	-6.66	-0.34	1.08e-10	Multiple myeloma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00226754	chr12:124068984	TMED2	-0.41	-6.71	-0.34	8.33e-11	Pancreatic cancer;
LIHC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.46	-7.56	-0.38	3.67e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.573	rs7101478	chr11:78272517	C/A	cg27205649	chr11:78285834	NARS2	0.43	6.78	0.34	5.36e-11	Alzheimer's disease (survival time);
LIHC	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg14092571	chr14:90743983	NA	0.44	7.06	0.36	9.47e-12	Mortality in heart failure;
LIHC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs6565180	0.888	rs13333093	chr16:30407269	C/A	cg17640201	chr16:30407289	ZNF48	0.8	13.74	0.6	1.58e-34	Tonsillectomy;
LIHC	cis	rs4788570	0.727	rs7204118	chr16:71833658	G/C	cg06353428	chr16:71660113	MARVELD3	1.3	13.62	0.59	4.58e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.58	6.95	0.35	1.85e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg11161837	chr1:110010384	SYPL2	0.45	6.15	0.32	2.11e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.67	-6.16	-0.32	2.04e-9	Red cell distribution width;
LIHC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg22532475	chr10:104410764	TRIM8	0.36	6.34	0.32	7.18e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-5.91	-0.3	8.23e-9	Renal cell carcinoma;
LIHC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.77	-0.3	1.8e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.64	-9.41	-0.45	7.21e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg13844804	chr7:814759	HEATR2	0.44	5.89	0.3	9.39e-9	Cerebrospinal P-tau181p levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17315132	chr17:27169875	C17orf63	-0.52	-6.08	-0.31	3.14e-9	Systolic blood pressure;
LIHC	cis	rs7106204	0.609	rs12790279	chr11:24286221	C/G	ch.11.24196551F	chr11:24239977	NA	0.61	6.65	0.34	1.17e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.34	0.37	1.56e-12	Nonalcoholic fatty liver disease;
LIHC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.76	0.3	1.86e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.7	12.05	0.55	4.21e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	7.14	0.36	5.5e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.04	-0.36	1.04e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs12928939	0.815	rs10500560	chr16:71681153	G/A	cg03805757	chr16:71968109	PKD1L3	-0.68	-7.41	-0.37	1.01e-12	Post bronchodilator FEV1;
LIHC	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.69	-12.34	-0.55	3.49e-29	Obesity-related traits;
LIHC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg03854865	chr6:26224070	HIST1H3E	0.59	6.43	0.33	4.36e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.87	10.8	0.5	1.34e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.5	7.74	0.39	1.14e-13	Testicular germ cell tumor;
LIHC	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	7.88	0.39	4.55e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.52	-7.75	-0.39	1.05e-13	Height;
LIHC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.82e-31	Breast cancer;
LIHC	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.58	-7.79	-0.39	7.88e-14	Type 2 diabetes;
LIHC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.37	-5.73	-0.3	2.22e-8	Glioblastoma;
LIHC	cis	rs986417	0.748	rs4141684	chr14:61069351	C/T	cg27398547	chr14:60952738	C14orf39	0.49	5.93	0.31	7.3e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-11.88	-0.54	1.78e-27	Eye color traits;
LIHC	cis	rs1983891	0.955	rs4714480	chr6:41520891	T/C	cg20194872	chr6:41519635	FOXP4	0.42	6.61	0.34	1.48e-10	Prostate cancer;
LIHC	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.42	-6.12	-0.31	2.49e-9	Blood protein levels;
LIHC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Blood protein levels;
LIHC	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.56	-6.18	-0.32	1.79e-9	Ulcerative colitis;
LIHC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.46	10.41	0.49	3.25e-22	Iron status biomarkers (transferrin levels);
LIHC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.74	10.16	0.48	2.23e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg07451762	chr16:28383216	NA	0.33	6.2	0.32	1.62e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.05e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.51	0.49	1.41e-22	Dupuytren's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04421424	chr19:57791681	ZNF460	0.45	6.19	0.32	1.68e-9	Pancreatic cancer;
LIHC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs75908454	1.000	rs74665543	chr6:169799665	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.52	-0.38	4.91e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.86	15.7	0.65	3.3e-42	Dental caries;
LIHC	cis	rs12744310	0.830	rs12045184	chr1:41799611	G/A	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16426870	chr16:23652487	PALB2;DCTN5	-0.48	-6.45	-0.33	3.91e-10	Pancreatic cancer;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg22663859	chr13:21900854	NA	0.44	7.24	0.36	3.07e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06002616	chr8:101225028	SPAG1	0.36	5.95	0.31	6.53e-9	Atrioventricular conduction;
LIHC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.42	-6.47	-0.33	3.42e-10	Cognitive test performance;
LIHC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.44	7.63	0.38	2.42e-13	Mean corpuscular volume;
LIHC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.89	16.15	0.66	5.35e-44	Aortic root size;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.04	-0.31	3.95e-9	Total body bone mineral density;
LIHC	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.74	0.39	1.13e-13	Mean platelet volume;
LIHC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.75	14.46	0.62	2.57e-37	Mortality in heart failure;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.27	-0.37	2.51e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg22903471	chr2:27725779	GCKR	-0.43	-6.29	-0.32	9.47e-10	Blood metabolite levels;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07677032	chr17:61819896	STRADA	0.42	5.81	0.3	1.43e-8	Prudent dietary pattern;
LIHC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.66	11.85	0.54	2.32e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg04610667	chr7:75704037	NA	-0.35	-6.37	-0.33	6.11e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1624005	1.000	rs1624005	chr14:43382362	A/G	cg11960719	chr5:1510684	LPCAT1	-0.36	-6.39	-0.33	5.29e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LIHC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-9.47	-0.46	4.59e-19	Tonsillectomy;
LIHC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	11.63	0.53	1.43e-26	Cognitive test performance;
LIHC	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg18964960	chr10:1102726	WDR37	-0.68	-6.55	-0.33	2.14e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.41	-0.33	4.8e-10	Height;
LIHC	cis	rs2625529	0.824	rs16956328	chr15:72143855	A/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.73	-0.3	2.16e-8	Red blood cell count;
LIHC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg25894440	chr7:65020034	NA	-0.53	-6.17	-0.32	1.93e-9	Diabetic kidney disease;
LIHC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.09	-0.4	1.03e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.55	0.33	2.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3743104	0.534	rs11854391	chr15:33022582	A/T	cg07179000	chr15:33023586	GREM1	-0.52	-8.19	-0.4	5.32e-15	Hypospadias;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg01546424	chr6:149721457	MAP3K7IP2;SUMO4	0.64	6.4	0.33	5.08e-10	Mean platelet volume;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.22	0.55	9.58e-29	Alzheimer's disease;
LIHC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.69	0.38	1.59e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.76	-0.5	1.82e-23	Response to antipsychotic treatment;
LIHC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.8	-0.35	4.74e-11	Coronary artery disease;
LIHC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-11.37	-0.52	1.22e-25	Monocyte percentage of white cells;
LIHC	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-8.57	-0.42	3.74e-16	Body mass index;
LIHC	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.96	-16.76	-0.67	1.89e-46	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.88	0.3	9.67e-9	Birth weight;
LIHC	cis	rs10106298	0.901	rs1434281	chr8:103671080	G/A	cg10187029	chr8:103597600	NA	0.52	6.79	0.34	5.1e-11	Schizophrenia;
LIHC	cis	rs507080	0.922	rs508640	chr11:118564413	A/G	cg04173919	chr11:118528438	PHLDB1	0.35	6.57	0.33	1.89e-10	Serum metabolite levels;
LIHC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg23262073	chr20:60523788	NA	-0.29	-5.94	-0.31	6.89e-9	Body mass index;
LIHC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.91	0.43	3.13e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg20368463	chr18:77673604	PQLC1	0.46	5.77	0.3	1.74e-8	Opioid sensitivity;
LIHC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.28	15.64	0.65	5.7700000000000006e-42	Alzheimer's disease (late onset);
LIHC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-5.87	-0.3	1.01e-8	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04530015	chr2:215796436	ABCA12	-0.39	-6.36	-0.33	6.61e-10	Neuroblastoma;
LIHC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.56	11.04	0.51	1.99e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs4934494	1.000	rs4934494	chr10:91447419	G/A	cg19698084	chr10:91461284	KIF20B	-0.45	-6.09	-0.31	2.97e-9	Red blood cell count;
LIHC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.59	-10.79	-0.5	1.5e-23	Alzheimer's disease (late onset);
LIHC	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18501264	chr19:33555827	RHPN2	-0.44	-6.13	-0.31	2.39e-9	Hepatitis;
LIHC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.36	5.95	0.31	6.53e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg06360820	chr2:242988706	NA	-0.81	-11.16	-0.52	6.97e-25	Obesity-related traits;
LIHC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10276381	0.901	rs73300638	chr7:28187344	A/C	cg23620719	chr7:28220237	JAZF1	0.63	7.88	0.39	4.49e-14	Crohn's disease;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.23	0.81	4.46e-80	Prudent dietary pattern;
LIHC	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.53	8.33	0.41	2.02e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.77	12.76	0.57	9.08e-31	Phospholipid levels (plasma);
LIHC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.05	-0.36	9.88e-12	Reticulocyte count;
LIHC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.63	-0.5	5.24e-23	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg25952890	chr19:58913133	NA	0.55	6.29	0.32	9.86e-10	Mean platelet volume;
LIHC	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-9.34	-0.45	1.27e-18	Blood metabolite levels;
LIHC	cis	rs6750047	0.605	rs1374191	chr2:38265420	T/G	cg07380506	chr2:38303506	CYP1B1	-0.58	-7.41	-0.37	1.02e-12	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs7534824	0.625	rs55693426	chr1:101466859	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.48	0.37	6.36e-13	Refractive astigmatism;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.45	8.8	0.43	7.12e-17	Testicular germ cell tumor;
LIHC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.49	9.18	0.44	4.06e-18	Hemoglobin concentration;
LIHC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.53	-7.04	-0.36	1.06e-11	Birth weight;
LIHC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.64	0.34	1.25e-10	Bipolar disorder;
LIHC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.52	8.19	0.41	5.16e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.55	0.42	4.3e-16	Lymphocyte counts;
LIHC	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.52	9.78	0.47	4.38e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.61e-9	Schizophrenia;
LIHC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.95	-0.31	6.76e-9	Tonsillectomy;
LIHC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-10.9	-0.51	6.27e-24	Total body bone mineral density;
LIHC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.99	0.48	9e-21	Lung cancer;
LIHC	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.39e-8	Lewy body disease;
LIHC	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7487075	0.619	rs6582658	chr12:46856095	G/A	cg23829395	chr12:46796953	NA	0.34	6.06	0.31	3.54e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg15744005	chr10:104629667	AS3MT	0.39	8.68	0.42	1.64e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.42	-0.49	2.92e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.16	-8.66	-0.42	1.9e-16	Body mass index;
LIHC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.71	0.43	1.35e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg05941027	chr17:61774174	LIMD2	0.34	6.91	0.35	2.32e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.66	10.04	0.48	6.06e-21	Body mass index;
LIHC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg18478394	chr8:109455254	TTC35	0.42	7.24	0.36	2.98e-12	Dupuytren's disease;
LIHC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.22	0.41	4.31e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg03264133	chr6:25882463	NA	-0.42	-6.26	-0.32	1.17e-9	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08204369	chr17:73150733	HN1	0.43	7.14	0.36	5.65e-12	Cognitive function;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.59	-9.04	-0.44	1.18e-17	Height;
LIHC	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.49	7.55	0.38	4.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.52	7.35	0.37	1.46e-12	Body mass index;
LIHC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.59	5.99	0.31	5.46e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.42	0.37	9.46e-13	Glycated hemoglobin levels;
LIHC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.34	-10.6	-0.5	6.85e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.52	9.27	0.45	2.15e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.52	8.25	0.41	3.56e-15	HDL cholesterol;
LIHC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26913058	chr16:419975	MRPL28	0.43	5.92	0.3	7.97e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.59	11.56	0.53	2.67e-26	Melanoma;
LIHC	cis	rs61677309	1.000	rs56785719	chr11:118176623	C/G	cg06090739	chr11:118230722	UBE4A	0.34	6.14	0.32	2.27e-9	Lung cancer in ever smokers;
LIHC	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	14.42	0.61	3.81e-37	Coffee consumption (cups per day);
LIHC	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.59	-8.78	-0.43	7.9e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.22	-0.32	1.44e-9	Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19684392	chr10:44144386	ZNF32	0.48	6.34	0.32	7.4e-10	Lung function (FEV1/FVC);
LIHC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.78	11.75	0.54	5.36e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.44	-0.42	9.07e-16	Colorectal cancer;
LIHC	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.6	6.67	0.34	1.03e-10	Schizophrenia;
LIHC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.74	9.25	0.45	2.43e-18	Schizophrenia;
LIHC	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.46	7.13	0.36	5.99e-12	Coronary artery disease;
LIHC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg14222432	chr12:29376421	FAR2	0.36	6.93	0.35	2.16e-11	QT interval;
LIHC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.52	6.87	0.35	3.02e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.02	-0.35	1.22e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.94	17.91	0.7	4.61e-51	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	11.7	0.53	8.25e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05665937	chr4:1216051	CTBP1	-0.45	-6.07	-0.31	3.35e-9	Obesity-related traits;
LIHC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.7	0.73	2.92e-58	Smoking behavior;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg14671364	chr1:107599128	PRMT6	0.49	7.38	0.37	1.25e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	5.93	0.31	7.43e-9	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.37	0.33	6.13e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg12310025	chr6:25882481	NA	-0.41	-6.11	-0.31	2.68e-9	Height;
LIHC	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg07636037	chr3:49044803	WDR6	-0.58	-6.51	-0.33	2.63e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg07862535	chr7:139043722	LUC7L2	0.58	10.03	0.48	6.11e-21	Diisocyanate-induced asthma;
LIHC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.01	-0.35	1.24e-11	Bipolar disorder;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.68	-0.34	9.67e-11	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05038121	chr15:80444758	FAH	0.51	6.85	0.35	3.46e-11	Pancreatic cancer;
LIHC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20307385	chr11:47447363	PSMC3	-0.46	-6.13	-0.31	2.48e-9	Subjective well-being;
LIHC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.68e-17	Prudent dietary pattern;
LIHC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg16226627	chr15:75307476	SCAMP5	0.36	6.95	0.35	1.81e-11	Blood trace element (Zn levels);
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg23601095	chr6:26197514	HIST1H3D	0.54	5.79	0.3	1.58e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.7	-0.5	3.15e-23	Breast cancer;
LIHC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.36	1.17e-11	Diabetic kidney disease;
LIHC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.61	9.71	0.47	7.37e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs17286411	0.671	rs9936903	chr16:71727571	A/T	cg06353428	chr16:71660113	MARVELD3	0.45	6.66	0.34	1.06e-10	Blood protein levels;
LIHC	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.63	-9.01	-0.44	1.5e-17	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.68	-9.88	-0.47	2e-20	Initial pursuit acceleration;
LIHC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.41	6.61	0.34	1.51e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.73	-11.01	-0.51	2.42e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.07	-0.36	9.02e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg00564555	chr16:1970112	NA	0.26	6.14	0.32	2.24e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg06611532	chr13:114900021	NA	0.38	7.04	0.36	1.06e-11	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg22633049	chr21:46681294	NA	-0.36	-6.12	-0.31	2.5e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.9	0.54	1.49e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.79	-14.05	-0.6	1.07e-35	Refractive error;
LIHC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.32	-6.8	-0.35	4.58e-11	Longevity;
LIHC	cis	rs4407350	1.000	rs4386428	chr22:44922359	T/G	cg26276947	chr22:44892394	LDOC1L	0.35	6.35	0.32	6.81e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs783540	0.967	rs4779044	chr15:83339353	A/C	cg18393722	chr15:85113863	UBE2QP1	0.38	6.6	0.34	1.56e-10	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.86	-0.3	1.07e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.34	-0.32	7.42e-10	Menopause (age at onset);
LIHC	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.93	-0.35	2.11e-11	Blood pressure;
LIHC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg07090678	chr1:91966139	CDC7	0.51	6.96	0.35	1.72e-11	Breast cancer;
LIHC	cis	rs16912285	0.748	rs58504811	chr11:24252020	T/G	ch.11.24196551F	chr11:24239977	NA	0.74	9.5	0.46	3.66e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.7	-12.3	-0.55	4.76e-29	Refractive error;
LIHC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.43	6.59	0.34	1.69e-10	Educational attainment;
LIHC	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.1	-0.44	7.45e-18	Colorectal cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05610740	chr12:96794311	CDK17	0.48	6.75	0.34	6.51e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.49	8.49	0.42	6.33e-16	Coronary artery disease;
LIHC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg15832292	chr6:96025679	MANEA	-0.73	-9.17	-0.44	4.46e-18	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7923837	0.713	rs10882099	chr10:94460650	T/C	cg25093409	chr10:94429542	NA	0.33	5.82	0.3	1.34e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg14146966	chr2:61757674	XPO1	0.48	8.51	0.42	5.64e-16	Tuberculosis;
LIHC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.28	0.37	2.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg23262073	chr20:60523788	NA	-0.28	-5.73	-0.3	2.24e-8	Body mass index;
LIHC	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.86	0.3	1.08e-8	Platelet distribution width;
LIHC	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.5e-11	Dermatomyositis;
LIHC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	2.97e-30	Menopause (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13749424	chr17:80416444	NARF	0.54	6.79	0.34	5.09e-11	Hepatitis;
LIHC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.51	6.7	0.34	8.84e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02985541	chr2:219472218	PLCD4	-0.38	-6.58	-0.34	1.8e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs3736485	0.934	rs114641722	chr15:51863572	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25632853	chr15:73088954	NA	0.36	6.05	0.31	3.77e-9	Triglyceride levels;
LIHC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.7	11.58	0.53	2.14e-26	Menopause (age at onset);
LIHC	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg15711740	chr2:61764176	XPO1	0.43	5.8	0.3	1.52e-8	Tuberculosis;
LIHC	cis	rs7546668	1.000	rs9298	chr1:15897020	C/T	cg11706911	chr1:15910989	AGMAT	0.44	6.72	0.34	7.78e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.4	-5.79	-0.3	1.57e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.53	7.07	0.36	8.71e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg13395646	chr4:1353034	KIAA1530	0.39	5.85	0.3	1.15e-8	Longevity;
LIHC	trans	rs2363709	0.892	rs2087553	chr3:67428164	G/A	cg25028035	chr6:42016671	CCND3	-0.85	-6.09	-0.31	3.07e-9	IgE levels;
LIHC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.47	-5.75	-0.3	1.93e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.57	6.74	0.34	6.76e-11	Ulcerative colitis;
LIHC	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg08131848	chr9:88420837	LOC389765	0.36	6.06	0.31	3.57e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.56	-8.33	-0.41	1.96e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.68	-8.68	-0.42	1.67e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.58	6.76	0.34	5.8e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg12903224	chr12:29470962	FAR2	-0.37	-5.97	-0.31	5.9e-9	QT interval;
LIHC	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg27417294	chr10:81904244	PLAC9	0.35	6.03	0.31	4.37e-9	Sarcoidosis;
LIHC	cis	rs72627123	0.867	rs8015927	chr14:74465756	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.9	-8.3	-0.41	2.37e-15	Morning vs. evening chronotype;
LIHC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.67	-0.38	1.86e-13	Ulcerative colitis;
LIHC	cis	rs7651039	0.641	rs2455823	chr3:15666856	T/C	cg16303742	chr3:15540471	COLQ	0.4	6.48	0.33	3.29e-10	Coronary heart disease;
LIHC	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.77	0.3	1.75e-8	Lung cancer;
LIHC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.62	-0.46	1.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.45	7.92	0.39	3.41e-14	Coronary artery disease;
LIHC	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.62	11.27	0.52	2.97e-25	Airflow obstruction;
LIHC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.36	6.44	0.33	3.96e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg21522988	chr12:29376872	FAR2	0.29	6.69	0.34	9.32e-11	QT interval;
LIHC	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg10820045	chr2:198174542	NA	0.56	9.33	0.45	1.41e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.5	7.68	0.38	1.73e-13	Diastolic blood pressure;
LIHC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	0.85	7.64	0.38	2.25e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.87	-0.3	1.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.73	-10.26	-0.49	1.02e-21	Dilated cardiomyopathy;
LIHC	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg18081818	chr7:23246105	NA	-0.39	-5.75	-0.3	1.95e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg20636351	chr8:55087400	NA	0.29	5.93	0.31	7.36e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.32	6.21	0.32	1.56e-9	DNA methylation (variation);
LIHC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.41	-6.92	-0.35	2.23e-11	Blood metabolite levels;
LIHC	cis	rs13161895	1.000	rs34674199	chr5:179473900	G/A	cg06664874	chr5:179499304	RNF130	0.61	7.56	0.38	3.66e-13	LDL cholesterol;
LIHC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.66	-10.76	-0.5	1.91e-23	Childhood ear infection;
LIHC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg00204748	chr12:29376779	FAR2	0.42	7.7	0.38	1.44e-13	QT interval;
LIHC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10556349	chr10:835070	NA	0.67	5.85	0.3	1.13e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.48	7.81	0.39	7.2e-14	Metabolite levels;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg15654264	chr1:150340011	RPRD2	0.49	8.15	0.4	7.03e-15	Migraine;
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.93	13.32	0.58	6.93e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg08539965	chr1:21396338	EIF4G3	0.35	6.21	0.32	1.57e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.44	7.39	0.37	1.15e-12	Bipolar disorder;
LIHC	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.33	-6.34	-0.32	7.21e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.51	8.91	0.43	3.11e-17	N-glycan levels;
LIHC	cis	rs16912285	0.688	rs7126291	chr11:24312936	A/C	ch.11.24196551F	chr11:24239977	NA	0.78	10.54	0.5	1.14e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-8.54	-0.42	4.49e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	10.27	0.49	9.84e-22	LDL cholesterol;
LIHC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg20195005	chr22:42527684	CYP2D6	0.32	6.15	0.32	2.19e-9	Birth weight;
LIHC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg06565975	chr8:143823917	SLURP1	0.34	6.65	0.34	1.17e-10	Urinary tract infection frequency;
LIHC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.44	-7.98	-0.4	2.22e-14	Mean corpuscular volume;
LIHC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-6.23	-0.32	1.39e-9	Migraine;Coronary artery disease;
LIHC	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.71	-10.3	-0.49	7.76e-22	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20174699	chr12:50222232	LOC100286844;NCKAP5L	0.48	6.79	0.34	5.08e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.7	-0.34	8.38e-11	Mood instability;
LIHC	cis	rs35791980	0.560	rs4729347	chr7:76982480	C/T	cg12876866	chr7:77025528	PION	-0.46	-6.72	-0.34	7.51e-11	Pursuit maintenance gain;
LIHC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg18887096	chr2:219472410	PLCD4	0.37	5.78	0.3	1.64e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.1	-0.4	9.8e-15	Response to antipsychotic treatment;
LIHC	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.54	-6.31	-0.32	8.46e-10	IFN-related cytopenia;
LIHC	cis	rs9649465	1.000	rs2109724	chr7:123325391	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.02e-15	Migraine;
LIHC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.63	-16.46	-0.66	2.95e-45	Breast cancer;
LIHC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.63	9.88	0.47	2.06e-20	Corneal astigmatism;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg13799429	chr6:90582589	CASP8AP2	0.59	6.08	0.31	3.12e-9	Mean platelet volume;
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.51	7.56	0.38	3.76e-13	Longevity;
LIHC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.69	13.3	0.58	8.38e-33	Systemic lupus erythematosus;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08078137	chr12:19593453	AEBP2	0.37	6.14	0.32	2.35e-9	Calcium levels;
LIHC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.46	-0.37	7.22e-13	Initial pursuit acceleration;
LIHC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.65	8.77	0.43	8.85e-17	Sudden cardiac arrest;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23218665	chr1:11159850	EXOSC10	0.45	6.13	0.31	2.43e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.63	9.81	0.47	3.63e-20	Tuberculosis;
LIHC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg19635926	chr16:89946313	TCF25	0.48	6.17	0.32	1.97e-9	Skin colour saturation;
LIHC	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.9	-0.51	6.09e-24	Eye color traits;
LIHC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	11.99	0.54	6.58e-28	Platelet count;
LIHC	cis	rs6466055	0.739	rs7806591	chr7:104927776	C/T	cg04380332	chr7:105027541	SRPK2	0.37	6.86	0.35	3.2e-11	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.92	0.35	2.26e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-19.36	-0.72	6.61e-57	Coronary artery disease;
LIHC	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.49	8.84	0.43	5.32e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.64	11.08	0.51	1.44e-24	Diisocyanate-induced asthma;
LIHC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17554472	chr22:41940697	POLR3H	0.54	5.93	0.31	7.29e-9	Vitiligo;
LIHC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.97	-0.31	5.8e-9	Vitamin D levels;
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.88	13.04	0.58	8.16e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7577696	0.524	rs61399065	chr2:32208554	G/A	cg02381751	chr2:32503542	YIPF4	-0.45	-6.13	-0.31	2.46e-9	Inflammatory biomarkers;
LIHC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.52	7.65	0.38	2.02e-13	Initial pursuit acceleration;
LIHC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.5	0.33	2.76e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg10756647	chr7:56101905	PSPH	0.62	8.48	0.42	6.65e-16	Corneal structure;
LIHC	trans	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg07393940	chr7:158741817	NA	0.55	6.56	0.33	1.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.72	11.13	0.52	9.27e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.92	-11.61	-0.53	1.71e-26	Body mass index;
LIHC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.52	5.98	0.31	5.66e-9	Alzheimer's disease;
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.84	-0.3	1.22e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.56	-7.89	-0.39	4.18e-14	Corneal structure;
LIHC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	7.71	0.38	1.4e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03864326	chr16:67927170	PSKH1	-0.49	-7.21	-0.36	3.73e-12	Cognitive function;
LIHC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg03732007	chr1:2071316	PRKCZ	0.34	5.73	0.3	2.23e-8	Height;
LIHC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg10792982	chr14:105748885	BRF1	0.46	6.25	0.32	1.24e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.33	-5.95	-0.31	6.48e-9	Platelet distribution width;
LIHC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.21	0.55	1.08e-28	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22529720	chr7:139044624	LUC7L2	-0.43	-6.32	-0.32	8.06e-10	Pancreatic cancer;
LIHC	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg27090078	chr2:85622094	CAPG	-0.33	-5.79	-0.3	1.62e-8	Ear protrusion;
LIHC	trans	rs1421898	0.509	rs62385365	chr5:158306962	G/A	cg10462998	chr5:175976188	PCDH24	-0.71	-6.08	-0.31	3.22e-9	Inflammatory skin disease;
LIHC	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.48	0.53	4.98e-26	Coffee consumption (cups per day);
LIHC	cis	rs7119038	0.818	rs6589685	chr11:118612197	T/C	cg19308663	chr11:118741387	NA	0.4	6.27	0.32	1.08e-9	Sjögren's syndrome;
LIHC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.8	-0.39	7.82e-14	Pediatric bone mineral density (spine);
LIHC	trans	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg10096035	chr12:96392698	NA	0.4	6.36	0.33	6.28e-10	Schizophrenia;
LIHC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg12365402	chr11:9010492	NRIP3	-0.33	-8.58	-0.42	3.38e-16	Hemoglobin concentration;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg16189644	chr5:96271684	LNPEP	-0.49	-7.45	-0.37	7.55e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-9.72	-0.47	7.1e-20	Obesity-related traits;
LIHC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.76	-0.43	9.03e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.45	-6.81	-0.35	4.27e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg12798992	chr6:167411361	FGFR1OP	0.46	7.16	0.36	5.01e-12	Crohn's disease;
LIHC	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	5.01e-12	Corneal astigmatism;
LIHC	trans	rs1864585	0.552	rs73208794	chr8:10681248	C/G	cg20373634	chr10:103911536	NOLC1	-0.47	-6.17	-0.32	1.93e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg08345082	chr10:99160200	RRP12	-0.39	-6.63	-0.34	1.3e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.61	-10.15	-0.48	2.53e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg25019722	chr6:37503610	NA	-0.37	-6.25	-0.32	1.24e-9	Cognitive performance;
LIHC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg18944383	chr4:111397179	ENPEP	0.27	7.06	0.36	9.34e-12	Height;
LIHC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg24209194	chr3:40518798	ZNF619	0.47	7.01	0.35	1.29e-11	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11087358	chr12:57940980	DCTN2	0.4	6.27	0.32	1.11e-9	Cognitive function;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.54	8.28	0.41	2.89e-15	Longevity;Endometriosis;
LIHC	cis	rs6545883	0.894	rs2600672	chr2:61536740	A/G	cg14146966	chr2:61757674	XPO1	0.44	7.39	0.37	1.13e-12	Tuberculosis;
LIHC	cis	rs61712019	0.679	rs2204916	chr2:77730014	A/G	cg11252801	chr2:77748917	LRRTM4	0.54	7.5	0.38	5.71e-13	Schizophrenia;
LIHC	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-12.25	-0.55	7.35e-29	Response to antipsychotic treatment;
LIHC	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.5	7.68	0.38	1.73e-13	Diastolic blood pressure;
LIHC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	cis	rs8081395	0.580	rs180515	chr17:58024275	A/G	cg13753209	chr17:57696993	CLTC	0.49	7.79	0.39	7.91e-14	White blood cell count;
LIHC	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-6.62	-0.34	1.4e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.57	9.41	0.45	7.47e-19	Colorectal cancer;
LIHC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.51	-7.92	-0.39	3.26e-14	Lymphocyte counts;
LIHC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.68	13.23	0.58	1.46e-32	High light scatter reticulocyte count;
LIHC	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.09	0.48	4.09e-21	Colorectal cancer;
LIHC	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.32	7.25	0.36	2.89e-12	Blood metabolite ratios;
LIHC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.68	0.53	9.06e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.73	0.43	1.12e-16	Lung cancer in ever smokers;
LIHC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg07636037	chr3:49044803	WDR6	-0.7	-7.35	-0.37	1.49e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg10820045	chr2:198174542	NA	-0.47	-7.22	-0.36	3.29e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.08	18.76	0.71	1.68e-54	Testicular germ cell tumor;
LIHC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.78	-18.21	-0.7	2.89e-52	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.58	9.64	0.46	1.26e-19	Pelvic organ prolapse;
LIHC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg22079354	chr11:130786696	SNX19	0.41	5.82	0.3	1.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.44	6.37	0.33	5.98e-10	Longevity;
LIHC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.43e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.2	0.32	1.61e-9	Prudent dietary pattern;
LIHC	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.22	0.58	1.62e-32	Coffee consumption (cups per day);
LIHC	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.46	-0.42	7.82e-16	Colorectal cancer;
LIHC	cis	rs7523273	0.565	rs2796250	chr1:207903654	T/C	cg22525895	chr1:207977042	MIR29B2	-0.55	-8.32	-0.41	2.11e-15	Schizophrenia;
LIHC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.5	0.59	1.38e-33	Cognitive test performance;
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07308232	chr7:1071921	C7orf50	-0.38	-6.07	-0.31	3.44e-9	Longevity;Endometriosis;
LIHC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.46	-7.54	-0.38	4.22e-13	Alzheimer's disease (late onset);
LIHC	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.68	8.74	0.43	1.06e-16	Macular telangiectasia type 2;
LIHC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-9.12	-0.44	6.57e-18	Tonsillectomy;
LIHC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs1419980	0.730	rs11054884	chr12:7772906	A/T	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.73	0.5	2.41e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg20016023	chr10:99160130	RRP12	-0.41	-6.48	-0.33	3.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.53	-7.73	-0.39	1.24e-13	Facial morphology (factor 19);
LIHC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.35	6.15	0.32	2.15e-9	Schizophrenia;
LIHC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09256448	chr16:638327	NA	0.39	6.66	0.34	1.1e-10	Height;
LIHC	trans	rs8117834	0.574	rs6108106	chr20:8086361	G/A	cg00593689	chr4:53575888	NA	0.38	6.44	0.33	3.98e-10	Chronic kidney disease;
LIHC	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg01444801	chr10:135216882	MTG1	0.66	9.88	0.47	2.12e-20	Systemic lupus erythematosus;
LIHC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg04310649	chr10:35416472	CREM	-0.43	-5.85	-0.3	1.13e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.29	-6.73	-0.34	7.11e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.45	6.04	0.31	3.97e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.71	11.58	0.53	2.17e-26	Oral cavity cancer;
LIHC	cis	rs2257205	0.667	rs7207254	chr17:56912572	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-6.13	-0.31	2.36e-9	Pancreatic cancer;
LIHC	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.79	-8.82	-0.43	5.87e-17	Exhaled nitric oxide output;
LIHC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg02580895	chr19:2754563	NA	-0.46	-6.86	-0.35	3.14e-11	Total cholesterol levels;
LIHC	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.63	6.68	0.34	9.58e-11	Homocysteine levels;
LIHC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.9	-17.93	-0.7	3.7700000000000003e-51	Coronary artery disease;
LIHC	cis	rs238295	0.805	rs1053399	chr20:5525986	T/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.95	-0.35	1.89e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg00800038	chr16:89945340	TCF25	-0.59	-9.64	-0.46	1.28e-19	Skin colour saturation;
LIHC	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.91	-0.43	3.16e-17	Brugada syndrome;
LIHC	trans	rs12753920	0.642	rs2209337	chr1:92623079	C/G	cg15668468	chr10:118892869	VAX1	0.43	6.11	0.31	2.72e-9	Systemic lupus erythematosus;
LIHC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.48	-10.29	-0.49	8.26e-22	White blood cell count (basophil);
LIHC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.51	8.89	0.43	3.66e-17	Total body bone mineral density;
LIHC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg03013999	chr17:37608204	MED1	0.35	5.78	0.3	1.71e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.8	6.06	0.31	3.67e-9	Systolic blood pressure;
LIHC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.56	7.46	0.37	7.29e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.45	-7.4	-0.37	1.03e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg12053284	chr18:40857256	SYT4	-0.52	-6.17	-0.32	1.95e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.46	-7.24	-0.36	2.99e-12	Lymphocyte counts;
LIHC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-6.05	-0.31	3.76e-9	Mean corpuscular volume;
LIHC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.66	-9.85	-0.47	2.49e-20	Testicular germ cell tumor;
LIHC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.6	-8.93	-0.43	2.69e-17	Heart rate;
LIHC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-8.03	-0.4	1.64e-14	Electroencephalogram traits;
LIHC	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg00792783	chr2:198669748	PLCL1	0.42	6.05	0.31	3.81e-9	Dermatomyositis;
LIHC	cis	rs8056893	0.714	rs1868159	chr16:68387496	G/T	cg02226672	chr16:68398533	SMPD3	-0.45	-6.22	-0.32	1.42e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg18887096	chr2:219472410	PLCD4	0.37	6.34	0.32	7.16e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-7.28	-0.37	2.26e-12	Putamen volume;
LIHC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	0.91	7.34	0.37	1.54e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.79	-8.69	-0.43	1.55e-16	Vitiligo;
LIHC	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.41	-6.27	-0.32	1.11e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg11812906	chr14:75593930	NEK9	0.41	6.32	0.32	8.3e-10	IgG glycosylation;
LIHC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.82	-7.95	-0.4	2.7e-14	Diabetic retinopathy;
LIHC	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.49	7.44	0.37	7.99e-13	Adiposity;
LIHC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.7	-0.38	1.43e-13	Total body bone mineral density;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg14709524	chr16:89940631	TCF25	-0.54	-7.45	-0.37	7.48e-13	Skin colour saturation;
LIHC	trans	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	7.9	0.39	3.87e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg09592244	chr17:37024020	NA	0.36	5.98	0.31	5.56e-9	Height;
LIHC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg23517279	chr6:96025343	MANEA	0.54	6.03	0.31	4.26e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.79	0.43	7.64e-17	Lung cancer in ever smokers;
LIHC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-1.13	-12.63	-0.56	2.88e-30	White matter hyperintensity burden;
LIHC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.9	8.69	0.43	1.54e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg10755058	chr3:40428713	ENTPD3	0.4	6.88	0.35	2.79e-11	Renal cell carcinoma;
LIHC	cis	rs7598759	0.548	rs6750795	chr2:232378231	T/C	cg19187155	chr2:232395269	NMUR1	0.59	9.01	0.44	1.48e-17	Noise-induced hearing loss;
LIHC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.69	11.15	0.52	8.1e-25	Corneal astigmatism;
LIHC	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.14	-0.32	2.23e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs7188697	0.922	rs37041	chr16:58579886	T/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.28	-0.37	2.35e-12	QT interval;
LIHC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.61	-8.89	-0.43	3.66e-17	Blood metabolite levels;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21384971	chr17:46114574	COPZ2;MIR152	-0.51	-6.84	-0.35	3.67e-11	Lung cancer in ever smokers;
LIHC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg26818010	chr10:134567672	INPP5A	0.62	8.4	0.41	1.21e-15	Migraine;
LIHC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.53	-0.33	2.39e-10	Total cholesterol levels;
LIHC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg21361702	chr7:150065534	REPIN1	0.47	6.66	0.34	1.12e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.39	5.8	0.3	1.47e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7534824	0.625	rs12561853	chr1:101457863	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.67	-7.85	-0.39	5.43e-14	Refractive astigmatism;
LIHC	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.65	7.78	0.39	8.4e-14	Homocysteine levels;
LIHC	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.6	-8.81	-0.43	6.19e-17	Parkinson's disease;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg14393609	chr7:65229607	NA	-0.39	-6.52	-0.33	2.46e-10	Calcium levels;
LIHC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.48	7.53	0.38	4.68e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-11.64	-0.53	1.36e-26	Vitiligo;
LIHC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.53	-8.58	-0.42	3.31e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.24	-7.47	-0.37	6.94e-13	Mean corpuscular volume;
LIHC	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg16509355	chr4:15471240	CC2D2A	-0.47	-7.59	-0.38	2.98e-13	Obesity-related traits;
LIHC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.96	0.31	6.39e-9	Heart rate;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg20990694	chr7:150417431	GIMAP1	0.37	6.14	0.32	2.24e-9	Electroencephalogram traits;
LIHC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	6e-11	Prudent dietary pattern;
LIHC	cis	rs903552	0.736	rs9806495	chr15:102008059	G/A	cg00659931	chr15:102010125	PCSK6	-0.52	-7.0	-0.35	1.32e-11	Diabetic kidney disease;
LIHC	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.5	-7.5	-0.38	5.59e-13	Diastolic blood pressure;
LIHC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.82	-13.9	-0.6	4.01e-35	Aortic root size;
LIHC	cis	rs10845606	0.581	rs9971854	chr12:12834186	A/G	cg09462578	chr12:12878428	APOLD1	0.46	6.74	0.34	6.71e-11	Systemic lupus erythematosus;
LIHC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.42	-0.45	6.74e-19	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.95	-12.12	-0.55	2.25e-28	Body mass index;
LIHC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.51	-8.47	-0.42	7.25e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.74	0.43	1.09e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.94	0.31	7.06e-9	Obesity-related traits;
LIHC	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.48	7.99	0.4	2.04e-14	Endometrial cancer;
LIHC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	7.94e-10	Red blood cell count;
LIHC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	1.02	10.16	0.48	2.32e-21	Eosinophil percentage of granulocytes;
LIHC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.85	16.21	0.66	2.92e-44	Response to diuretic therapy;
LIHC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg15448220	chr1:150897856	SETDB1	0.43	6.73	0.34	6.96e-11	Tonsillectomy;
LIHC	cis	rs7116495	0.609	rs1541304	chr11:71714078	T/C	cg10381502	chr11:71823885	C11orf51	-1.06	-9.3	-0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.43	5.8	0.3	1.54e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.38	-6.45	-0.33	3.89e-10	Menopause (age at onset);
LIHC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.54	-8.22	-0.41	4.33e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg11057378	chr10:81107060	PPIF	0.37	6.06	0.31	3.63e-9	Height;
LIHC	cis	rs10508774	1.000	rs72795567	chr10:32896509	T/C	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.8	6.81	0.35	4.29e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.44	-0.33	3.95e-10	Bipolar disorder;
LIHC	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	0.39	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.63	10.68	0.5	3.48e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.61	9.13	0.44	6.16e-18	Recombination rate (females);
LIHC	cis	rs2274273	0.901	rs17674563	chr14:55831125	G/A	cg01864836	chr14:55583639	NA	-0.38	-6.58	-0.34	1.72e-10	Protein biomarker;
LIHC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.91	0.65	4.82e-43	White blood cell count;
LIHC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.36	5.99	0.31	5.36e-9	Alcohol dependence;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	25.04	0.8	2.33e-79	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02257712	chr5:150080478	RBM22	0.44	6.1	0.31	2.85e-9	Pancreatic cancer;
LIHC	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-0.58	-6.74	-0.34	6.58e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.46	8.2	0.41	4.95e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg25344623	chr2:136566232	LCT	-0.41	-8.45	-0.42	8.43e-16	Mosquito bite size;
LIHC	trans	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg01148741	chr2:96811453	DUSP2	-0.39	-6.3	-0.32	9.41e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg01788221	chr16:89496183	ANKRD11	-0.42	-6.48	-0.33	3.14e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.5	-0.38	5.5e-13	Aortic root size;
LIHC	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.51	-0.33	2.64e-10	Metabolite levels;
LIHC	cis	rs9377188	0.744	rs2486419	chr6:149329771	G/T	cg03945663	chr6:149309952	UST	0.26	6.0	0.31	4.97e-9	Cancer;
LIHC	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.42	5.87	0.3	1.03e-8	Kawasaki disease;
LIHC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12463550	chr7:65579703	CRCP	0.68	7.11	0.36	6.92e-12	Diabetic kidney disease;
LIHC	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.8	9.43	0.45	6.45e-19	Ulcerative colitis;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg23782820	chr8:58130467	NA	0.34	5.85	0.3	1.13e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.03	9.27	0.45	2.19e-18	Diabetic retinopathy;
LIHC	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg16394018	chr11:14927549	NA	0.4	5.81	0.3	1.39e-8	Vitamin D levels;
LIHC	cis	rs11673344	0.864	rs2263167	chr19:37520927	A/G	cg27390819	chr19:37464633	NA	-0.52	-6.34	-0.32	7.35e-10	Obesity-related traits;
LIHC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.81	0.54	3.03e-27	Cognitive test performance;
LIHC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	21.33	0.76	8.61e-65	Chronic sinus infection;
LIHC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.66	-9.07	-0.44	9.22e-18	Schizophrenia;
LIHC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg24826892	chr11:71159390	DHCR7	0.47	6.01	0.31	4.84e-9	Vitamin D levels;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.6	8.83	0.43	5.67e-17	Prudent dietary pattern;
LIHC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg02640540	chr1:67518911	SLC35D1	0.41	6.42	0.33	4.48e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.58	6.93	0.35	2.09e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.51	7.93	0.39	3.04e-14	Alzheimer's disease (survival time);
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.4	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.09e-18	Hemoglobin concentration;
LIHC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	1.06	14.27	0.61	1.46e-36	Heart rate;
LIHC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.49	-8.69	-0.43	1.55e-16	Longevity;
LIHC	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.39	6.46	0.33	3.68e-10	Lewy body disease;
LIHC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.86	-16.93	-0.68	3.93e-47	Height;
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.37	6.79	0.34	5.04e-11	Sudden cardiac arrest;
LIHC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.36	5.73	0.3	2.16e-8	Schizophrenia;
LIHC	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.82	-13.76	-0.6	1.32e-34	Multiple sclerosis;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.63	-8.09	-0.4	1.05e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	0.54	10.34	0.49	5.34e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.6	8.26	0.41	3.12e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.43	0.56	1.65e-29	Menopause (age at onset);
LIHC	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.84	6.96	0.35	1.73e-11	Blood protein levels;
LIHC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.42	6.72	0.34	7.81e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.97e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-7.41	-0.37	1e-12	Longevity;Endometriosis;
LIHC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-15.49	-0.64	2.29e-41	Gut microbiome composition (summer);
LIHC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.09	-0.55	2.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	8.42	0.41	1.08e-15	Coronary artery disease;
LIHC	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg13482628	chr17:19912719	NA	0.49	7.98	0.4	2.24e-14	Schizophrenia;
LIHC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.52	-9.3	-0.45	1.7e-18	Diastolic blood pressure;
LIHC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.48	8.16	0.4	6.3e-15	Response to temozolomide;
LIHC	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.56	8.7	0.43	1.44e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.54	8.71	0.43	1.3e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.91	0.57	2.5e-31	Prudent dietary pattern;
LIHC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.94	0.31	7.05e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg08135965	chr6:41755394	TOMM6	0.45	5.95	0.31	6.46e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.84	0.35	3.58e-11	Cognitive function;
LIHC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.41	-6.68	-0.34	9.73e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00958927	chr1:175162553	KIAA0040	0.39	6.51	0.33	2.67e-10	Alcohol dependence;
LIHC	cis	rs2574704	1.000	rs11711892	chr3:11650787	T/C	cg15876825	chr3:11651881	VGLL4	-0.49	-8.2	-0.41	4.95e-15	Body mass index;
LIHC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.66	9.5	0.46	3.9e-19	Schizophrenia;
LIHC	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg14345882	chr6:26364793	BTN3A2	0.34	5.73	0.3	2.23e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.51	-8.0	-0.4	1.99e-14	Lymphocyte counts;
LIHC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg25344623	chr2:136566232	LCT	-0.4	-8.15	-0.4	7.08e-15	Mosquito bite size;
LIHC	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.3	6.37	0.33	6.14e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.33	-0.37	1.67e-12	IgG glycosylation;
LIHC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	0.81	6.76	0.34	6.07e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.35	-7.27	-0.37	2.4e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.36	0.56	3.01e-29	Prudent dietary pattern;
LIHC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg00277334	chr10:82204260	NA	0.49	5.96	0.31	6.26e-9	Post bronchodilator FEV1;
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.38	0.33	5.67e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.39	-7.8	-0.39	7.81e-14	Renal cell carcinoma;
LIHC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.62	9.88	0.47	2.05e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.44	8.36	0.41	1.63e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs903552	1.000	rs4965872	chr15:102004002	C/T	cg25677261	chr15:102009856	PCSK6	-0.46	-6.19	-0.32	1.68e-9	Diabetic kidney disease;
LIHC	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.63	-10.36	-0.49	4.75e-22	Bipolar disorder;
LIHC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.73	12.31	0.55	4.35e-29	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg26939375	chr7:64535504	NA	-0.45	-6.87	-0.35	3.05e-11	Aortic root size;
LIHC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18867708	chr6:26865862	GUSBL1	-0.57	-8.61	-0.42	2.71e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.29	-0.37	2.16e-12	Bipolar disorder;
LIHC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.45	-0.33	3.83e-10	Longevity;Endometriosis;
LIHC	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.94	-18.48	-0.71	2.22e-53	Schizophrenia;
LIHC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-7.03	-0.36	1.11e-11	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg17724175	chr1:150552817	MCL1	0.41	8.17	0.4	6.08e-15	Melanoma;
LIHC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-9.35	-0.45	1.21e-18	Parkinson's disease;
LIHC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.7	6.75	0.34	6.43e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.19	0.55	1.22e-28	Cognitive test performance;
LIHC	cis	rs16828019	0.852	rs12045171	chr1:41528805	G/A	cg20697417	chr1:41786797	NA	0.3	5.9	0.3	8.86e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17036023	1	rs17036023	chr1:117129711	C/T	cg01558040	chr1:116184423	VANGL1	-0.59	-5.77	-0.3	1.76e-8	Asthma (childhood onset);
LIHC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.34e-9	Aortic root size;
LIHC	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.65	-9.81	-0.47	3.6e-20	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	7.87	0.39	4.84e-14	Motion sickness;
LIHC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.21	0.52	4.66e-25	Colorectal cancer;
LIHC	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	-0.41	-5.76	-0.3	1.85e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs74181299	0.927	rs2723064	chr2:65279805	T/C	cg05010058	chr2:65284262	CEP68	0.4	6.78	0.34	5.3e-11	Pulse pressure;
LIHC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-9.16	-0.44	4.98e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.67	-0.42	1.8e-16	Colorectal cancer;
LIHC	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.11	-0.44	7.04e-18	Type 2 diabetes;
LIHC	cis	rs6967414	0.786	rs6948965	chr7:6758547	G/A	cg00387323	chr7:6746715	ZNF12	0.67	7.47	0.37	6.56e-13	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg08528486	chr13:113648767	MCF2L	-0.41	-6.43	-0.33	4.22e-10	Systolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12857786	chr4:83934023	LIN54	0.42	6.13	0.31	2.47e-9	Pancreatic cancer;
LIHC	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg06359132	chr10:99160096	RRP12	-0.39	-6.17	-0.32	1.89e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs11098699	0.784	rs6835971	chr4:124230999	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.43	0.33	4.22e-10	Mosquito bite size;
LIHC	cis	rs7712401	0.791	rs9327279	chr5:122122160	T/G	cg18764291	chr5:122110994	SNX2	0.35	6.1	0.31	2.87e-9	Mean platelet volume;
LIHC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.59	-11.47	-0.53	5.28e-26	Tonsillectomy;
LIHC	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg18470593	chr4:15471377	CC2D2A	0.39	5.82	0.3	1.35e-8	Obesity-related traits;
LIHC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.9	19.5	0.73	1.79e-57	Blood protein levels;
LIHC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.47	7.61	0.38	2.63e-13	Mean corpuscular volume;
LIHC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.46	6.13	0.31	2.41e-9	Crohn's disease;
LIHC	trans	rs11165623	0.602	rs7517055	chr1:97007781	C/G	cg10631902	chr5:14652156	NA	-0.26	-6.51	-0.33	2.7e-10	Hip circumference;Waist circumference;
LIHC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08392591	chr16:89556376	ANKRD11	0.39	5.84	0.3	1.23e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs2629540	0.543	rs2559515	chr10:126513925	A/G	cg08799069	chr10:126477246	METTL10	0.43	6.2	0.32	1.65e-9	Cocaine dependence;
LIHC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.63	-10.17	-0.48	2.06e-21	Obesity-related traits;
LIHC	cis	rs516243	0.703	rs169538	chr1:10737045	T/C	cg02903756	chr1:10750680	CASZ1	-0.35	-6.34	-0.32	7.24e-10	Migraine - clinic-based;
LIHC	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg22705602	chr4:152727874	NA	-0.3	-6.12	-0.31	2.59e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06420487	chr17:61919686	SMARCD2	0.44	5.95	0.31	6.71e-9	Height;
LIHC	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.45	6.39	0.33	5.49e-10	Asthma;
LIHC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.23e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg10210624	chr19:58662595	ZNF329	0.72	7.14	0.36	5.58e-12	Cholesterol, total;
LIHC	cis	rs611744	0.967	rs677288	chr8:109177539	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.69	-8.39	-0.41	1.31e-15	Homocysteine levels;
LIHC	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.87	15.81	0.65	1.15e-42	Body mass index;
LIHC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-8.58	-0.42	3.41e-16	IgG glycosylation;
LIHC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg06598544	chr20:61472147	COL9A3	-0.91	-8.62	-0.42	2.49e-16	Obesity-related traits;
LIHC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.61e-9	Schizophrenia;
LIHC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.54	8.05	0.4	1.37e-14	High light scatter reticulocyte count;
LIHC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.68	-0.42	1.68e-16	Gut microbiome composition (summer);
LIHC	cis	rs1000083	0.748	rs3104166	chr5:96656684	A/T	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15065896	chr3:37285038	GOLGA4	0.52	7.38	0.37	1.21e-12	Pancreatic cancer;
LIHC	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg17927777	chr20:33865990	NA	0.52	5.86	0.3	1.07e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg04610667	chr7:75704037	NA	0.33	5.98	0.31	5.49e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	6.67	0.34	1.03e-10	Renal cell carcinoma;
LIHC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.56	8.46	0.42	7.75e-16	Resting heart rate;
LIHC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.46	-0.33	3.5e-10	Bipolar disorder;
LIHC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.98	-0.31	5.65e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-8.67	-0.42	1.71e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.1e-9	Tonsillectomy;
LIHC	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.37	5.98	0.31	5.5e-9	Height;
LIHC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.4	7.59	0.38	3.06e-13	Schizophrenia;
LIHC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.34	8.67	0.42	1.81e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg04310649	chr10:35416472	CREM	-0.44	-5.87	-0.3	1e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg07424592	chr7:64974309	NA	0.82	9.53	0.46	2.98e-19	Diabetic kidney disease;
LIHC	cis	rs11098699	0.821	rs2047585	chr4:124231984	C/T	cg09941581	chr4:124220074	SPATA5	-0.31	-6.29	-0.32	9.66e-10	Mosquito bite size;
LIHC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg23939001	chr4:940644	TMEM175	-0.4	-7.29	-0.37	2.18e-12	Systemic sclerosis;
LIHC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg14067834	chr17:29058358	SUZ12P	0.62	6.44	0.33	4.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.82	0.3	1.38e-8	Eosinophil percentage of white cells;
LIHC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	8.35	0.41	1.71e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.96	17.49	0.69	2.23e-49	Breast cancer;
LIHC	cis	rs963731	0.649	rs2924714	chr2:39333288	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-6.01	-0.31	4.7e-9	Corticobasal degeneration;
LIHC	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.46	6.07	0.31	3.35e-9	Glioblastoma;Glioma;
LIHC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg17980119	chr2:219472607	PLCD4	0.34	5.86	0.3	1.06e-8	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-21.37	-0.76	5.99e-65	Height;
LIHC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.42	6.15	0.32	2.18e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs5753037	0.809	rs5752964	chr22:30208608	C/T	cg01021169	chr22:30184971	ASCC2	-0.37	-6.92	-0.35	2.24e-11	Type 1 diabetes;
LIHC	cis	rs903552	0.932	rs9806551	chr15:102008206	C/T	cg06707286	chr15:102010195	PCSK6	-0.52	-7.61	-0.38	2.61e-13	Diabetic kidney disease;
LIHC	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.73	-11.03	-0.51	2.14e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs539514	0.690	rs480929	chr13:76312773	G/A	cg04757411	chr13:76259545	LMO7	-0.47	-8.18	-0.4	5.52e-15	Type 1 diabetes;
LIHC	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.74	-0.34	6.66e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.59	6.44	0.33	4.08e-10	Alzheimer's disease;
LIHC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg16506815	chr2:162101123	NA	0.46	7.46	0.37	6.99e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.85	-0.35	3.48e-11	Metabolite levels;
LIHC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-18.84	-0.71	8.05e-55	Height;
LIHC	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.62	6.2	0.32	1.62e-9	Carotid intima media thickness;
LIHC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.45	6.29	0.32	9.6e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2236918	0.901	rs1635502	chr1:242039382	A/G	cg17736920	chr1:242011382	EXO1	0.5	7.21	0.36	3.56e-12	Menopause (age at onset);
LIHC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.42	0.45	7.02e-19	Bipolar disorder;
LIHC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg22633049	chr21:46681294	NA	-0.37	-6.29	-0.32	9.62e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4800452	0.956	rs4369779	chr18:20735408	T/C	cg26136497	chr18:20735537	CABLES1	-0.44	-5.83	-0.3	1.26e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg03013999	chr17:37608204	MED1	0.36	6.05	0.31	3.9e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg09795085	chr6:101329169	ASCC3	0.52	7.33	0.37	1.66e-12	Neuroticism;
LIHC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.08	-0.44	8.74e-18	Aortic root size;
LIHC	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-9.7	-0.46	8.11e-20	Platelet distribution width;
LIHC	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.41	5.72	0.3	2.35e-8	Tuberculosis;
LIHC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg21466736	chr12:48725269	NA	-0.7	-10.65	-0.5	4.47e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs1144333	1.000	rs12078893	chr1:76370862	T/C	cg22875332	chr1:76189707	ACADM	0.4	6.27	0.32	1.07e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.04	15.21	0.64	2.8e-40	Cognitive function;
LIHC	cis	rs2625529	0.824	rs7183749	chr15:72377278	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.87	-0.3	1.02e-8	Red blood cell count;
LIHC	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	0.91	7.34	0.37	1.54e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08280861	chr8:58055591	NA	0.49	6.05	0.31	3.9e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.25	-13.43	-0.59	2.45e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.37	-6.6	-0.34	1.55e-10	Aortic root size;
LIHC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg23262073	chr20:60523788	NA	-0.29	-6.02	-0.31	4.47e-9	Body mass index;
LIHC	cis	rs6141769	0.542	rs28548407	chr20:31301495	T/C	cg13636640	chr20:31349939	DNMT3B	-0.32	-5.74	-0.3	2.09e-8	Subjective well-being;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05119084	chr18:46477127	SMAD7	0.44	6.08	0.31	3.27e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs273218	1.000	rs273217	chr5:53380938	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.64	10.13	0.48	2.8e-21	Migraine;
LIHC	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg09876464	chr15:85330779	ZNF592	0.37	6.11	0.31	2.64e-9	P wave terminal force;
LIHC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.33e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.05	0.4	1.37e-14	Renal cell carcinoma;
LIHC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.46	7.24	0.36	2.97e-12	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.17	0.44	4.42e-18	IgG glycosylation;
LIHC	cis	rs17094222	0.504	rs4917904	chr10:102447292	G/A	cg26540559	chr10:102447443	NA	0.39	7.66	0.38	1.98e-13	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.07	-0.36	8.62e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.52	-7.82	-0.39	6.43e-14	Red cell distribution width;
LIHC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.77	0.39	9.01e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg20651018	chr11:3035856	CARS	0.36	5.86	0.3	1.06e-8	Longevity;
LIHC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.62	-9.98	-0.47	9.33e-21	Obesity-related traits;
LIHC	trans	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg01134436	chr17:81009848	B3GNTL1	0.73	6.36	0.33	6.57e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg22633049	chr21:46681294	NA	-0.38	-6.32	-0.32	8.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.5e-16	Platelet count;
LIHC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02244288	chr16:89573955	SPG7	-0.3	-5.73	-0.3	2.2e-8	Multiple myeloma (IgH translocation);
LIHC	trans	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg07393940	chr7:158741817	NA	0.54	6.25	0.32	1.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg23422044	chr7:1970798	MAD1L1	-0.69	-10.63	-0.5	5.58e-23	Bipolar disorder;
LIHC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.57	9.86	0.47	2.46e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.56	6.08	0.31	3.24e-9	Alzheimer's disease;
LIHC	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg16691251	chr5:66510806	NA	-0.47	-6.81	-0.35	4.38e-11	Breast cancer;
LIHC	cis	rs4700695	0.614	rs437399	chr5:65208533	A/G	cg21114390	chr5:65439923	SFRS12	0.46	5.83	0.3	1.3e-8	Facial morphology (factor 19);
LIHC	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.66	10.76	0.5	1.87e-23	Obesity-related traits;
LIHC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg27494647	chr7:150038898	RARRES2	0.3	5.85	0.3	1.16e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.78	-0.34	5.38e-11	Height;
LIHC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.25	-0.7	1.98e-52	Height;
LIHC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.53	8.17	0.4	6.14e-15	Menarche (age at onset);
LIHC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.51	-0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.59	8.6	0.42	2.91e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg14828511	chr1:107599125	PRMT6	0.41	5.79	0.3	1.58e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	1.02e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-8.13	-0.4	8.08e-15	Tonsillectomy;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg11143796	chr4:178363279	AGA	-0.43	-6.21	-0.32	1.58e-9	Alopecia areata;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.5	6.74	0.34	6.56e-11	Pancreatic cancer;
LIHC	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.29	-0.45	1.85e-18	Red blood cell count;
LIHC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg26441486	chr22:50317300	CRELD2	-0.34	-5.98	-0.31	5.62e-9	Schizophrenia;
LIHC	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg09003973	chr2:102972529	NA	0.82	7.15	0.36	5.19e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs7714584	1.000	rs3906528	chr5:150266718	G/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs7238033	0.663	rs11877720	chr18:43318255	A/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.48	0.33	3.26e-10	Bladder cancer;
LIHC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Body mass index;
LIHC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.45	7.91	0.39	3.66e-14	IgG glycosylation;
LIHC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.22	0.41	4.37e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4650994	0.550	rs10913573	chr1:178530455	G/A	cg05350800	chr1:178550844	NA	-0.34	-7.35	-0.37	1.48e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg10820045	chr2:198174542	NA	0.48	7.19	0.36	4.17e-12	Dermatomyositis;
LIHC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.26	-7.04	-0.36	1.04e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14217534	chr12:49525474	TUBA1B	0.45	6.29	0.32	9.7e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.43	-6.86	-0.35	3.25e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.54	7.91	0.39	3.53e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.15	0.32	2.11e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs3740540	0.530	rs2362503	chr10:126290538	T/C	cg04949429	chr10:126290192	LHPP	0.45	7.34	0.37	1.55e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg14440974	chr22:39074834	NA	0.44	6.98	0.35	1.51e-11	Menopause (age at onset);
LIHC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.65	7.92	0.39	3.26e-14	Gut microbiome composition (summer);
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg08687515	chr19:58661962	ZNF329	0.99	7.72	0.39	1.32e-13	Cholesterol, total;
LIHC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.48	6.06	0.31	3.59e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.85	-9.7	-0.46	8.45e-20	Triglycerides;
LIHC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-11.04	-0.51	1.96e-24	Platelet count;
LIHC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.44	8.03	0.4	1.6e-14	IgG glycosylation;
LIHC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-12.26	-0.55	6.98e-29	Vitiligo;
LIHC	cis	rs6695567	1.000	rs6588467	chr1:53630304	G/A	cg20326410	chr1:53600821	SLC1A7	0.3	6.31	0.32	8.6e-10	Systemic lupus erythematosus;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.72	-10.32	-0.49	6.42e-22	Menarche (age at onset);
LIHC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.84	0.35	3.67e-11	Dermatomyositis;
LIHC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.25e-12	Bipolar disorder;
LIHC	trans	rs12935229	0.756	rs11149981	chr16:77370138	G/T	cg11525352	chr7:43351604	HECW1	0.31	6.12	0.31	2.51e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LIHC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg03037974	chr15:76606532	NA	0.61	10.3	0.49	7.73e-22	Blood metabolite levels;
LIHC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg15123519	chr2:136567270	LCT	-0.45	-9.16	-0.44	4.74e-18	Mosquito bite size;
LIHC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	0.88	15.16	0.63	4.7e-40	Parkinson's disease;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg07342512	chr1:65886002	LEPROT;LEPR	-0.46	-6.45	-0.33	3.84e-10	Eotaxin levels;
LIHC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.55	5.9	0.3	8.56e-9	Alzheimer's disease;
LIHC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.33	6.15	0.32	2.12e-9	Total body bone mineral density;
LIHC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.5	16.55	0.67	1.29e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs55665837	0.540	rs1007392	chr11:14774591	A/G	cg25251204	chr11:14927456	NA	0.41	5.85	0.3	1.12e-8	Vitamin D levels;
LIHC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.49	-6.61	-0.34	1.48e-10	Interleukin-18 levels;
LIHC	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg25686905	chr3:183603175	PARL	-0.49	-9.24	-0.45	2.73e-18	Menopause (age at onset);
LIHC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-12.27	-0.55	6.15e-29	Vitiligo;
LIHC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.58	9.94	0.47	1.33e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	5.96	0.31	6.22e-9	Bipolar disorder;
LIHC	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.71	-0.38	1.36e-13	Response to antipsychotic treatment;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg14393609	chr7:65229607	NA	-0.41	-6.87	-0.35	3e-11	Calcium levels;
LIHC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.41	6.32	0.32	8.35e-10	Post bronchodilator FEV1;
LIHC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.8	12.99	0.57	1.23e-31	Colorectal cancer;
LIHC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg27478167	chr7:817139	HEATR2	-0.42	-5.97	-0.31	5.86e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10847980	0.590	rs58182048	chr12:123287708	C/T	cg07706471	chr12:123319906	HIP1R	0.75	8.16	0.4	6.55e-15	Adiponectin levels;
LIHC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.57	6.34	0.32	7.3e-10	Axial length;
LIHC	cis	rs7523273	0.565	rs1359147	chr1:207886150	C/T	cg22525895	chr1:207977042	MIR29B2	0.52	7.69	0.38	1.58e-13	Schizophrenia;
LIHC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg23625390	chr15:77176239	SCAPER	0.34	5.88	0.3	9.59e-9	Blood metabolite levels;
LIHC	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.45	-0.37	7.92e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg15017067	chr4:17643749	FAM184B	0.34	5.84	0.3	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg17623882	chr6:41773611	USP49	-0.43	-5.85	-0.3	1.13e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.33	6.29	0.32	9.82e-10	Aortic root size;
LIHC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg02079420	chr8:82753780	SNX16	0.34	6.06	0.31	3.6e-9	Diastolic blood pressure;
LIHC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg18306943	chr3:40428807	ENTPD3	0.33	5.87	0.3	1.04e-8	Renal cell carcinoma;
LIHC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg00204748	chr12:29376779	FAR2	0.4	7.41	0.37	1.03e-12	QT interval;
LIHC	cis	rs10411936	0.720	rs7252649	chr19:16582785	G/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	6.41	0.33	4.7e-10	White blood cell count;Multiple sclerosis;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg05484376	chr2:27715224	FNDC4	0.38	6.46	0.33	3.59e-10	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg25894440	chr7:65020034	NA	0.52	5.88	0.3	9.54e-9	Diabetic kidney disease;
LIHC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-6.6	-0.34	1.61e-10	Fibrinogen levels;
LIHC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.55	10.59	0.5	7.63e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.11	-0.48	3.42e-21	Type 2 diabetes;
LIHC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.68	-9.78	-0.47	4.57e-20	Initial pursuit acceleration;
LIHC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg18887096	chr2:219472410	PLCD4	0.35	5.97	0.31	6.11e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.53	9.06	0.44	1.05e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	7.0	0.35	1.33e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg03859395	chr2:55845619	SMEK2	0.91	16.07	0.66	1.1e-43	Metabolic syndrome;
LIHC	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg03037974	chr15:76606532	NA	0.61	10.74	0.5	2.21e-23	Blood metabolite levels;
LIHC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg14593290	chr7:50529359	DDC	-0.35	-6.14	-0.31	2.35e-9	Systemic sclerosis;
LIHC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-9.6	-0.46	1.79e-19	Parkinson's disease;
LIHC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-8.41	-0.41	1.14e-15	Type 2 diabetes;
LIHC	cis	rs11702148	0.552	rs2834235	chr21:34901423	C/T	cg14850771	chr21:34775459	IFNGR2	-0.44	-7.08	-0.36	8.04e-12	Mean corpuscular hemoglobin;
LIHC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.58	-9.65	-0.46	1.24e-19	Cognitive function;
LIHC	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.59	-6.59	-0.34	1.63e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.32	-8.24	-0.41	3.65e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.6	9.38	0.45	9.65e-19	Menarche (age at onset);
LIHC	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.75	11.45	0.53	6.52e-26	Eye color traits;
LIHC	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.6	7.25	0.36	2.86e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.84	7.73	0.39	1.25e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs1664789	1.000	rs787544	chr5:53273342	G/T	ch.5.1024479R	chr5:53302184	ARL15	0.49	7.92	0.39	3.26e-14	Waist circumference adjusted for body mass index;
LIHC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.66	0.42	1.91e-16	Motion sickness;
LIHC	cis	rs77637988	0.604	rs17855177	chr2:48602252	C/T	cg15846641	chr2:48541264	FOXN2	0.57	7.63	0.38	2.36e-13	Joint mobility (Beighton score);
LIHC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.98	0.51	3.15e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.5	0.49	1.59e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.59	-0.42	3.14e-16	Total body bone mineral density;
LIHC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg18225595	chr11:63971243	STIP1	0.63	9.41	0.45	7.61e-19	Platelet count;
LIHC	cis	rs2637030	0.515	rs2130744	chr5:52896723	C/T	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.8	6.81	0.35	4.29e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg09182678	chr22:50328711	NA	-0.7	-7.38	-0.37	1.19e-12	Acne (severe);
LIHC	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.34	0.37	1.57e-12	Lung cancer;
LIHC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05025164	chr4:1340916	KIAA1530	0.39	5.98	0.31	5.73e-9	Obesity-related traits;
LIHC	trans	rs597503	1.000	rs530612	chr18:6942997	A/G	cg12380209	chr10:120515094	C10orf46	0.6	6.17	0.32	1.97e-9	Sudden cardiac arrest;
LIHC	cis	rs943466	1.000	rs12524835	chr6:33730843	G/C	cg25922239	chr6:33757077	LEMD2	-0.5	-5.89	-0.3	9.34e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.87	-0.43	4.13e-17	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.59	-9.85	-0.47	2.48e-20	Height;
LIHC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.78	-0.3	1.71e-8	Menopause (age at onset);
LIHC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	0.56	9.98	0.47	9.72e-21	Methadone dose in opioid dependence;
LIHC	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.93	0.51	4.56e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-6.97	-0.35	1.68e-11	Vitiligo;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15055890	chr3:11747650	VGLL4	-0.33	-7.09	-0.36	7.64e-12	Calcium levels;
LIHC	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.36	-6.35	-0.32	6.8e-10	Total cholesterol levels;
LIHC	cis	rs10508774	1.000	rs12415699	chr10:32749404	A/C	cg01819863	chr10:32635814	EPC1	0.65	6.09	0.31	3.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	5.84	0.3	1.19e-8	Schizophrenia;
LIHC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg14709524	chr16:89940631	TCF25	0.49	6.0	0.31	5.09e-9	Skin colour saturation;
LIHC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.89	-0.39	4.04e-14	Chronic sinus infection;
LIHC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg20194872	chr6:41519635	FOXP4	0.44	6.89	0.35	2.67e-11	Prostate cancer;
LIHC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg15105060	chr4:7024189	TBC1D14	-0.74	-6.56	-0.33	2.04e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4862307	0.623	rs11730046	chr4:184988245	C/G	cg22054328	chr4:184930219	STOX2	0.36	5.84	0.3	1.2e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.63	7.52	0.38	4.92e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.47	-0.76	2.4e-65	Height;
LIHC	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	0.98	14.81	0.63	1.08e-38	Corneal structure;
LIHC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.95	17.38	0.68	6.34e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.54	7.77	0.39	9.01e-14	Height;
LIHC	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg04034577	chr2:241836375	C2orf54	-0.48	-11.27	-0.52	2.8e-25	Urinary metabolites;
LIHC	trans	rs75804782	0.521	rs72993034	chr2:239385895	C/T	cg01134436	chr17:81009848	B3GNTL1	0.86	7.2	0.36	3.82e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs28595532	0.748	rs72670246	chr4:119335061	G/A	cg21605333	chr4:119757512	SEC24D	0.96	7.4	0.37	1.04e-12	Cannabis dependence symptom count;
LIHC	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg11642891	chr2:3452563	TTC15	-0.42	-6.73	-0.34	6.99e-11	Obesity-related traits;
LIHC	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.5	-9.41	-0.45	7.37e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs2302190	0.882	rs12942018	chr17:56613277	C/T	cg12560992	chr17:57184187	TRIM37	0.69	8.88	0.43	3.9e-17	Vitamin D levels;
LIHC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg14440974	chr22:39074834	NA	-0.34	-5.81	-0.3	1.43e-8	Menopause (age at onset);
LIHC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.84	13.36	0.59	4.6e-33	Colorectal cancer;
LIHC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.58	7.55	0.38	4.11e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.67	-7.8	-0.39	7.53e-14	Cognitive function;
LIHC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.6	-10.6	-0.5	6.66e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.71	9.19	0.45	3.84e-18	Body mass index;
LIHC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	0.84	11.03	0.51	2.02e-24	Skin colour saturation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21215811	chr17:40925428	VPS25	0.48	6.84	0.35	3.72e-11	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.8	11.23	0.52	3.98e-25	Pediatric areal bone mineral density (radius);
LIHC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.52	8.53	0.42	4.91e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	13.3	0.58	7.74e-33	Chronic sinus infection;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg09331995	chr7:27309021	NA	0.56	6.47	0.33	3.35e-10	Mean platelet volume;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27380774	chr11:1000560	AP2A2	0.44	6.64	0.34	1.21e-10	Longevity;
LIHC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.58	11.56	0.53	2.56e-26	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.23	-0.32	1.35e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.48e-9	Resting heart rate;
LIHC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.51	7.19	0.36	4.08e-12	Obesity-related traits;
LIHC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.51	-7.48	-0.37	6.52e-13	Bone mineral density (spine);
LIHC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.64	-12.5	-0.56	8.88e-30	High light scatter reticulocyte count;
LIHC	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.47	6.9	0.35	2.46e-11	Asthma;
LIHC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.95	-9.26	-0.45	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-10.62	-0.5	5.79e-23	Alzheimer's disease (late onset);
LIHC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7587476	0.861	rs17488049	chr2:215651750	G/A	cg04004882	chr2:215674386	BARD1	0.52	6.32	0.32	8.02e-10	Neuroblastoma;
LIHC	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg17385448	chr1:15911702	AGMAT	0.38	6.39	0.33	5.34e-10	Systolic blood pressure;
LIHC	cis	rs3820500	0.543	rs2211130	chr1:118014894	C/T	cg20383390	chr1:117909022	MAN1A2	0.46	5.91	0.3	8.43e-9	Pneumonia;
LIHC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg06951627	chr6:26196580	NA	-0.52	-5.98	-0.31	5.48e-9	Gout;Renal underexcretion gout;
LIHC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21448741	chr8:58168803	NA	0.35	6.51	0.33	2.73e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg04865290	chr3:52927548	TMEM110	-0.43	-5.76	-0.3	1.93e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs6565180	0.926	rs4788413	chr16:30410445	C/T	cg17640201	chr16:30407289	ZNF48	0.78	12.61	0.56	3.38e-30	Tonsillectomy;
LIHC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg27490568	chr2:178487706	NA	1.1	11.84	0.54	2.52e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg15704280	chr7:45808275	SEPT13	0.62	6.49	0.33	2.96e-10	Axial length;
LIHC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.61	0.5	6.31e-23	Vitiligo;
LIHC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.91	-0.43	3.16e-17	Monocyte count;
LIHC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.63	-10.01	-0.48	7.61e-21	Dental caries;
LIHC	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	15.53	0.64	1.49e-41	Exhaled nitric oxide output;
LIHC	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.55	9.68	0.46	9.7e-20	Total cholesterol levels;
LIHC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.34	8.25	0.41	3.46e-15	Immature fraction of reticulocytes;
LIHC	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.31	-6.42	-0.33	4.63e-10	Sitting height ratio;
LIHC	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.47	0.53	5.44e-26	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.26	-0.32	1.12e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.97	15.07	0.63	1.01e-39	Breast cancer;
LIHC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.31	0.45	1.6e-18	Hemoglobin concentration;
LIHC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-7.62	-0.38	2.45e-13	Response to bleomycin (chromatid breaks);
LIHC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-7.05	-0.36	1.02e-11	Bladder cancer;
LIHC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.24	0.41	3.84e-15	Motion sickness;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-7.93	-0.39	3.21e-14	Lymphocyte counts;
LIHC	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.79	-0.3	1.63e-8	Red blood cell count;
LIHC	trans	rs1432089	0.773	rs6845629	chr4:171784030	C/G	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24110177	chr3:50126178	RBM5	-0.46	-7.23	-0.36	3.19e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18357526	chr6:26021779	HIST1H4A	0.9	12.0	0.54	6.54e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.55	-0.42	4.1e-16	Type 2 diabetes;
LIHC	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.97	0.35	1.66e-11	Height;
LIHC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.55	0.38	3.88e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs9377188	0.707	rs2500540	chr6:149330806	A/T	cg03945663	chr6:149309952	UST	-0.27	-6.36	-0.33	6.59e-10	Cancer;
LIHC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.81	-0.3	1.4e-8	Personality dimensions;
LIHC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-6.05	-0.31	3.79e-9	Schizophrenia;
LIHC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.33	-0.32	7.79e-10	Diabetic kidney disease;
LIHC	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.35	-7.51	-0.38	5.04e-13	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-12.93	-0.57	2.05e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.76	13.98	0.6	1.96e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.09	0.4	1.05e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.12	-0.4	8.7e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs74233809	1.000	rs11191515	chr10:104776527	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.4e-9	Birth weight;
LIHC	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.5	7.77	0.39	9.22e-14	Alzheimer's disease (survival time);
LIHC	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.87	-8.21	-0.41	4.66e-15	White matter integrity;
LIHC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.09e-10	Bipolar disorder;
LIHC	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1075232	1.000	rs16956707	chr15:31641633	G/A	cg01030201	chr15:31746330	NA	-0.78	-6.0	-0.31	5.07e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.54	-8.75	-0.43	9.98e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	6.96	0.35	1.74e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22619719	chr1:1891578	KIAA1751	0.45	6.19	0.32	1.69e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.7	7.1	0.36	7.09e-12	Alzheimer's disease;
LIHC	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.69	-0.5	3.32e-23	Pediatric autoimmune diseases;
LIHC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00166722	chr3:10149974	C3orf24	0.52	5.79	0.3	1.63e-8	Alzheimer's disease;
LIHC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.79	-0.34	4.84e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg11953164	chr1:23521307	HTR1D	0.29	5.85	0.3	1.15e-8	Height;
LIHC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.32	14.21	0.61	2.44e-36	Eosinophil percentage of granulocytes;
LIHC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg23280166	chr11:118938394	VPS11	0.56	7.4	0.37	1.07e-12	Coronary artery disease;
LIHC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.24	-0.55	7.9e-29	Primary sclerosing cholangitis;
LIHC	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.69	-9.95	-0.47	1.22e-20	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs903552	1.000	rs8027380	chr15:102005810	T/C	cg06707286	chr15:102010195	PCSK6	-0.44	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.43	6.38	0.33	5.63e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-12.21	-0.55	1.01e-28	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9783347	1.000	rs7947378	chr11:18381327	T/C	cg15585147	chr11:18324498	HPS5	0.43	6.58	0.34	1.78e-10	Pancreatic cancer;
LIHC	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg10820045	chr2:198174542	NA	0.48	7.31	0.37	1.91e-12	Dermatomyositis;
LIHC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg23533926	chr12:111358616	MYL2	0.32	6.41	0.33	4.96e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.29	-0.45	1.91e-18	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.43	6.62	0.34	1.36e-10	Neuroticism;
LIHC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.4	-0.41	1.22e-15	Schizophrenia;
LIHC	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.3	-5.71	-0.3	2.41e-8	Red blood cell count;
LIHC	cis	rs2191566	0.887	rs55703004	chr19:44504781	T/G	cg20607764	chr19:44506953	ZNF230	-0.4	-6.16	-0.32	1.99e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.03	15.95	0.65	3.18e-43	Breast cancer;
LIHC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.64	10.53	0.49	1.16e-22	Breast cancer;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.23	-0.32	1.36e-9	Total body bone mineral density;
LIHC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg19635926	chr16:89946313	TCF25	0.48	6.04	0.31	3.95e-9	Skin colour saturation;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.6	0.62	6.99e-38	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.29	-0.45	1.82e-18	Diabetic kidney disease;
LIHC	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg19671926	chr4:122722719	EXOSC9	0.46	6.76	0.34	6.06e-11	Type 2 diabetes;
LIHC	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg03934865	chr2:198174659	NA	0.47	6.92	0.35	2.24e-11	Intracranial aneurysm;
LIHC	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.56	8.17	0.4	6.14e-15	Heschl's gyrus morphology;
LIHC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.87	-9.86	-0.47	2.36e-20	Red cell distribution width;
LIHC	cis	rs7539624	0.541	rs10916601	chr1:223897416	G/A	cg07395969	chr1:223900822	CAPN2	0.49	5.82	0.3	1.38e-8	Schizophrenia;
LIHC	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.88	-14.63	-0.62	5.34e-38	Schizophrenia;
LIHC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.4	-5.77	-0.3	1.79e-8	Morning vs. evening chronotype;
LIHC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.44	6.71	0.34	8.05e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.85	14.45	0.62	2.94e-37	Menopause (age at onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01854420	chr3:99536702	MIR548G;C3orf26	-0.52	-6.4	-0.33	5.1e-10	Systolic blood pressure;
LIHC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.1e-9	Tonsillectomy;
LIHC	trans	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.89e-11	Aortic root size;
LIHC	cis	rs12744310	0.887	rs1892420	chr1:41781410	C/T	cg03962019	chr1:41807865	NA	0.39	6.23	0.32	1.36e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08280861	chr8:58055591	NA	0.51	6.39	0.33	5.56e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19349861	chr11:133402246	OPCML	-0.41	-6.21	-0.32	1.56e-9	Cognitive function;
LIHC	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.19	13.15	0.58	2.9e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.53	-7.45	-0.37	7.8e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.32	-7.21	-0.36	3.56e-12	Menarche (age at onset);
LIHC	cis	rs7677751	1.000	rs7677751	chr4:55124460	C/T	cg17187183	chr4:55093834	PDGFRA	0.66	7.82	0.39	6.61e-14	Corneal astigmatism;
LIHC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.62	10.58	0.5	8.27e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.33	-8.76	-0.43	8.93e-17	Hemoglobin concentration;
LIHC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.8	11.86	0.54	2.01e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.48	6.49	0.33	3.1e-10	Breast cancer;
LIHC	cis	rs67981189	0.593	rs10132789	chr14:71480279	G/T	cg15816911	chr14:71606274	NA	0.39	6.24	0.32	1.29e-9	Schizophrenia;
LIHC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.62	-0.42	2.6e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg25919922	chr13:100150906	NA	-0.75	-6.38	-0.33	5.91e-10	Obesity-related traits;
LIHC	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg18367735	chr17:79674897	NA	0.64	7.83	0.39	6.13e-14	Dental caries;
LIHC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.75	0.3	1.93e-8	Parkinson's disease;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.8	-0.34	4.82e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.77	0.3	1.73e-8	Longevity;
LIHC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	8.06	0.4	1.32e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg09695851	chr17:3907499	NA	0.46	5.82	0.3	1.37e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg14709524	chr16:89940631	TCF25	0.49	6.05	0.31	3.85e-9	Skin colour saturation;
LIHC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg26441486	chr22:50317300	CRELD2	-0.36	-6.65	-0.34	1.17e-10	Schizophrenia;
LIHC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.67	10.24	0.48	1.18e-21	Total body bone mineral density;
LIHC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	1.07	12.08	0.55	3.31e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs918629	0.761	rs6898371	chr5:95289333	A/G	cg10483112	chr5:95245456	ELL2	-0.37	-6.48	-0.33	3.23e-10	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08219700	chr8:58056026	NA	0.51	6.86	0.35	3.14e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.66	6.81	0.35	4.32e-11	Alzheimer's disease;
LIHC	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg08824895	chr13:115047677	UPF3A	0.5	7.25	0.37	2.71e-12	Schizophrenia;
LIHC	cis	rs546131	0.642	rs1949048	chr11:34836974	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.28	-0.32	1.01e-9	Lung disease severity in cystic fibrosis;
LIHC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.66	9.7	0.46	8.07e-20	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	8.44	0.42	9.2e-16	Platelet count;
LIHC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg04719120	chr6:96025338	MANEA	0.55	6.49	0.33	3.03e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.19e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.78	0.3	1.68e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.45	7.48	0.37	6.36e-13	Aortic root size;
LIHC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.54	-7.37	-0.37	1.27e-12	HIV-1 control;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00586367	chr8:74790437	UBE2W	0.49	7.05	0.36	9.93e-12	Cognitive function;
LIHC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.77	12.56	0.56	5.28e-30	Fat distribution (HIV);
LIHC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-10.95	-0.51	3.89e-24	Type 2 diabetes;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.66	9.61	0.46	1.59e-19	Menarche (age at onset);
LIHC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.93e-9	Life satisfaction;
LIHC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.06	0.55	3.67e-28	Alzheimer's disease;
LIHC	cis	rs860295	1.000	rs7541060	chr1:155728088	A/T	cg02153340	chr1:155202674	NA	-0.31	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.56	-10.56	-0.5	9.29e-23	Mean corpuscular volume;
LIHC	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg19752551	chr11:57585705	CTNND1	-0.5	-6.88	-0.35	2.87e-11	Schizophrenia;
LIHC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.48	-6.23	-0.32	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19040509	chr17:72199640	RPL38	0.41	6.04	0.31	3.98e-9	Pancreatic cancer;
LIHC	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.43	5.84	0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.52	-8.36	-0.41	1.63e-15	Coronary artery disease;
LIHC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.23	-0.48	1.32e-21	Response to antipsychotic treatment;
LIHC	cis	rs11696739	0.835	rs6074894	chr20:1597050	G/A	cg15722679	chr20:1638393	SIRPG	0.41	7.83	0.39	5.98e-14	Mean platelet volume;
LIHC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.1	-0.31	2.92e-9	Headache;
LIHC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.61	-0.38	2.66e-13	Schizophrenia;
LIHC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg00343986	chr7:65444356	GUSB	-0.41	-6.04	-0.31	4.1e-9	Aortic root size;
LIHC	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.06e-34	Gastritis;
LIHC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg19743168	chr1:23544995	NA	0.36	6.05	0.31	3.74e-9	Height;
LIHC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.54	0.53	3.17e-26	Motion sickness;
LIHC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.91	0.35	2.34e-11	Gut microbiome composition (summer);
LIHC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg07713946	chr22:31675144	LIMK2	-0.42	-7.55	-0.38	3.89e-13	Colorectal cancer;
LIHC	cis	rs9464760	0.527	rs9476759	chr6:15158709	T/C	cg15799072	chr6:15248335	JARID2	0.58	5.75	0.3	1.97e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.41	7.57	0.38	3.56e-13	Electrocardiographic conduction measures;
LIHC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.9	0.35	2.48e-11	Bipolar disorder;
LIHC	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg02023728	chr11:77925099	USP35	-0.34	-6.01	-0.31	4.72e-9	Alzheimer's disease (survival time);
LIHC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.88	11.47	0.53	5.27e-26	Heart rate;
LIHC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.83	7.63	0.38	2.42e-13	Lymphocyte counts;
LIHC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.58	7.45	0.37	7.53e-13	Post bronchodilator FEV1;
LIHC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.94	-13.65	-0.59	3.67e-34	Blood metabolite levels;
LIHC	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.12	-0.36	6.35e-12	Bipolar disorder;
LIHC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.35	5.77	0.3	1.79e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg25344623	chr2:136566232	LCT	-0.37	-5.97	-0.31	5.89e-9	Corneal structure;
LIHC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg23205692	chr1:25664452	TMEM50A	0.4	6.35	0.32	6.75e-10	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs10612751	1	rs10612751	chr13:107646032	CTG/C	cg06614754	chr13:107569395	NA	0.33	6.23	0.32	1.34e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.62	-9.35	-0.45	1.2e-18	Skin colour saturation;
LIHC	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19906760	chr14:78227687	SNW1;C14orf178	0.42	6.62	0.34	1.35e-10	Pancreatic cancer;
LIHC	cis	rs3770081	0.590	rs6747424	chr2:86176224	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.83	0.3	1.27e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs11229555	0.645	rs7945992	chr11:58187755	T/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs79387448	0.745	rs72993754	chr2:103151136	A/G	cg09003973	chr2:102972529	NA	0.8	7.05	0.36	1.02e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07677032	chr17:61819896	STRADA	0.43	6.2	0.32	1.62e-9	Prudent dietary pattern;
LIHC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg00277334	chr10:82204260	NA	-0.49	-5.85	-0.3	1.13e-8	Post bronchodilator FEV1;
LIHC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.39	-5.72	-0.3	2.33e-8	Other erythrocyte phenotypes;
LIHC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg15902774	chr15:75289873	SCAMP5	0.4	5.99	0.31	5.3300000000000004e-09	Lung cancer;
LIHC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg03037974	chr15:76606532	NA	0.79	16.37	0.66	6.87e-45	Blood metabolite levels;
LIHC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg06664874	chr5:179499304	RNF130	0.58	7.08	0.36	8.06e-12	LDL cholesterol;
LIHC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg20387954	chr3:183756860	HTR3D	0.28	5.9	0.3	8.59e-9	Anterior chamber depth;
LIHC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg25894440	chr7:65020034	NA	-0.53	-6.04	-0.31	4.05e-9	Diabetic kidney disease;
LIHC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21467203	chr3:49911342	NA	-0.46	-8.54	-0.42	4.46e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02978959	chr19:57791520	ZNF460	0.46	6.39	0.33	5.56e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.37	2.22e-12	Migraine;Coronary artery disease;
LIHC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg03959625	chr15:84868606	LOC388152	0.43	5.89	0.3	9.45e-9	Schizophrenia;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.64	12.19	0.55	1.22e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.81	12.96	0.57	1.6e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg24130564	chr14:104152367	KLC1	-0.44	-7.26	-0.37	2.63e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.46	6.67	0.34	1.03e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.22	0.32	1.49e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22455342	chr2:225449267	CUL3	0.47	6.1	0.31	2.95e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12016809	chr21:47604291	C21orf56	0.4	5.95	0.31	6.75e-9	Testicular germ cell tumor;
LIHC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.46	6.85	0.35	3.38e-11	Gout;
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26076054	chr5:421317	AHRR	0.27	5.97	0.31	5.91e-9	Cystic fibrosis severity;
LIHC	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	8.17	0.4	6.2e-15	Eotaxin levels;
LIHC	cis	rs3790844	0.613	rs12030331	chr1:200001547	G/A	cg13229857	chr1:200006247	NR5A2	0.37	6.07	0.31	3.35e-9	Pancreatic cancer;
LIHC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg06804625	chr1:109812012	CELSR2	0.41	6.02	0.31	4.53e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.98	17.9	0.7	4.83e-51	Subjective well-being;
LIHC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.66	-10.62	-0.5	5.96e-23	Lung cancer;
LIHC	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.41	7.33	0.37	1.69e-12	Testicular germ cell tumor;
LIHC	cis	rs11663156	0.534	rs12957181	chr18:50901617	A/G	cg24270629	chr18:50823537	DCC	0.45	6.17	0.32	1.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg07382826	chr16:28625726	SULT1A1	-0.45	-6.49	-0.33	3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.99	-0.35	1.4e-11	Eosinophil percentage of white cells;
LIHC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	1.18	12.71	0.57	1.35e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg24209194	chr3:40518798	ZNF619	0.53	7.52	0.38	4.8e-13	Renal cell carcinoma;
LIHC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.66	-9.99	-0.48	8.62e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12516959	chr21:47718080	NA	-0.36	-5.84	-0.3	1.21e-8	Testicular germ cell tumor;
LIHC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg17279839	chr7:150038598	RARRES2	0.47	10.01	0.48	7.46e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.71	-9.61	-0.46	1.67e-19	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.54	10.8	0.5	1.35e-23	Myopia (pathological);
LIHC	trans	rs72960926	0.744	rs11759133	chr6:74932518	A/G	cg07247405	chr1:2484626	LOC115110	0.55	6.58	0.34	1.75e-10	Metabolite levels (MHPG);
LIHC	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.59	9.54	0.46	2.85e-19	Multiple sclerosis;
LIHC	cis	rs6708331	0.517	rs12992553	chr2:70360262	A/G	cg01613454	chr2:70366299	NA	0.38	6.11	0.31	2.75e-9	Obesity-related traits;
LIHC	cis	rs7238033	0.602	rs8088163	chr18:43309809	T/C	cg20610511	chr18:43302872	SLC14A1	0.39	6.46	0.33	3.55e-10	Bladder cancer;
LIHC	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16684958	chr7:75615977	POR	-0.51	-8.37	-0.41	1.45e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21107223	chr15:75182455	MPI	-0.44	-6.33	-0.32	7.79e-10	Cognitive function;
LIHC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	ch.11.42038R	chr11:967971	AP2A2	0.55	10.02	0.48	7.03e-21	Alzheimer's disease (late onset);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24588891	chr3:9848638	ARPC4	0.39	6.07	0.31	3.49e-9	Immature fraction of reticulocytes;
LIHC	trans	rs668210	0.793	rs522553	chr11:65771669	T/C	cg17712092	chr4:129076599	LARP1B	0.6	6.43	0.33	4.34e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.51	-7.94	-0.39	2.84e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9896052	0.614	rs4789201	chr17:73440579	A/G	cg25649188	chr17:73499917	CASKIN2	0.43	6.81	0.35	4.32e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.38	-0.33	5.62e-10	Blood protein levels;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg19139277	chr8:28243953	ZNF395	-0.56	-6.09	-0.31	3.01e-9	Preeclampsia;
LIHC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10869401	chr11:129802046	PRDM10	-0.39	-6.12	-0.31	2.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.889	rs585545	chr1:109841662	A/T	cg16275483	chr1:110013120	SYPL2	-0.5	-6.16	-0.32	2.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg07645718	chr20:61493192	TCFL5	0.79	6.56	0.33	2.03e-10	Obesity-related traits;
LIHC	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.71	8.2	0.41	5.03e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg21724239	chr8:58056113	NA	0.48	5.78	0.3	1.66e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg05197062	chr11:11642011	GALNTL4	0.42	6.08	0.31	3.17e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9528384	0.927	rs4886357	chr13:62234016	G/C	cg20705804	chr7:43590176	HECW1	0.55	6.1	0.31	2.82e-9	Verbal declarative memory;
LIHC	cis	rs10420951	0.617	rs8101992	chr19:18614423	A/G	cg10790698	chr19:18539756	SSBP4	-0.42	-5.92	-0.3	7.93e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.58	0.42	3.3e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7187994	0.848	rs16974515	chr16:84782510	T/G	cg07647771	chr16:84786436	USP10	-0.33	-6.46	-0.33	3.51e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.08	-0.48	4.34e-21	Tonsillectomy;
LIHC	trans	rs2363709	1.000	rs2363714	chr3:67421846	C/G	cg22969669	chr19:19613165	GATAD2A	-0.66	-6.13	-0.31	2.48e-9	IgE levels;
LIHC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.82	13.57	0.59	7.62e-34	Multiple sclerosis;
LIHC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.4	0.37	1.08e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.88	16.12	0.66	6.65e-44	Coronary artery disease;
LIHC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.36	6.65	0.34	1.19e-10	Ewing sarcoma;
LIHC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.37	0.33	5.96e-10	Rheumatoid arthritis;
LIHC	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.31	-0.37	1.87e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg03037974	chr15:76606532	NA	0.71	13.87	0.6	5.27e-35	Blood metabolite levels;
LIHC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.53	-7.93	-0.39	3.07e-14	Metabolic syndrome;
LIHC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	7.55	0.38	3.97e-13	Tonsillectomy;
LIHC	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-8.74	-0.43	1.09e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg26531700	chr6:26746687	NA	0.37	6.15	0.32	2.21e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.4	-6.17	-0.32	1.91e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.3	0.45	1.74e-18	Bipolar disorder;
LIHC	cis	rs17776563	0.887	rs28773595	chr15:89128232	A/G	cg05013243	chr15:89149849	MIR1179	0.4	6.65	0.34	1.19e-10	Thyroid hormone levels;
LIHC	cis	rs9649465	1.000	rs3807640	chr7:123338713	G/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.18e-15	Migraine;
LIHC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg00204748	chr12:29376779	FAR2	0.41	7.6	0.38	2.81e-13	QT interval;
LIHC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.25	0.32	1.24e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg26149184	chr10:133730230	NA	0.45	7.16	0.36	4.83e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg12365402	chr11:9010492	NRIP3	-0.24	-6.19	-0.32	1.72e-9	Hemoglobin concentration;
LIHC	trans	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04565464	chr8:145669602	NFKBIL2	0.38	6.12	0.31	2.54e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.2	0.32	1.58e-9	Tonsillectomy;
LIHC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.13	0.66	6.33e-44	Electrocardiographic conduction measures;
LIHC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.58	0.38	3.31e-13	IgG glycosylation;
LIHC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.76	10.97	0.51	3.3e-24	Coronary artery disease;
LIHC	cis	rs116248771	0.739	rs6768636	chr3:158347565	C/T	cg16708174	chr3:158430962	RARRES1	-0.49	-6.55	-0.33	2.18e-10	diarrhoeal disease at age 2;
LIHC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.12	0.48	3.02e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.43	7.22	0.36	3.31e-12	Hemoglobin concentration;
LIHC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.8	0.3	1.49e-8	Schizophrenia;
LIHC	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1403694	1.000	rs2689197	chr3:186438346	C/T	cg12454167	chr3:186435060	KNG1	0.29	7.05	0.36	1.02e-11	Blood protein levels;
LIHC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.52	7.69	0.38	1.56e-13	Height;
LIHC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg00656387	chr3:40428638	ENTPD3	0.44	7.46	0.37	7.03e-13	Renal cell carcinoma;
LIHC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg14440974	chr22:39074834	NA	-0.44	-6.98	-0.35	1.58e-11	Menopause (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14279899	chr6:137540774	IFNGR1	-0.41	-6.12	-0.31	2.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.1	0.4	9.79e-15	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27130769	chr7:5417105	TNRC18	0.45	6.68	0.34	9.81e-11	Pancreatic cancer;
LIHC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg20607798	chr8:58055168	NA	0.5	6.24	0.32	1.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.62	7.22	0.36	3.39e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.4	-5.91	-0.3	8.46e-9	P wave terminal force;
LIHC	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.75	10.9	0.51	6e-24	Corneal astigmatism;
LIHC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.14e-14	Mean platelet volume;
LIHC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.31	0.52	2.11e-25	Lung cancer in ever smokers;
LIHC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.7	10.61	0.5	6.25e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.76	-13.64	-0.59	3.94e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg00204512	chr16:28754710	NA	0.42	7.12	0.36	6.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	8.03	0.4	1.57e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.69	7.05	0.36	1.01e-11	Alzheimer's disease;
LIHC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.13	0.61	5.14e-36	Chronic sinus infection;
LIHC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.52	0.42	5.06e-16	Schizophrenia;
LIHC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.86	14.88	0.63	5.89e-39	Monocyte count;
LIHC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.79	6.64	0.34	1.22e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7577696	0.525	rs2366547	chr2:32251109	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-5.96	-0.31	6.12e-9	Inflammatory biomarkers;
LIHC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.05	0.4	1.38e-14	Platelet count;
LIHC	cis	rs1664789	1.000	rs1664787	chr5:53282149	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.68	0.42	1.61e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg06096015	chr1:231504339	EGLN1	-0.43	-7.26	-0.37	2.64e-12	Red blood cell count;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg05484376	chr2:27715224	FNDC4	0.39	6.5	0.33	2.78e-10	Menopause (age at onset);
LIHC	cis	rs10242455	0.571	rs55830753	chr7:99292222	A/G	cg18809830	chr7:99032528	PTCD1	-0.83	-6.62	-0.34	1.42e-10	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg00292662	chr22:38071168	LGALS1	0.39	6.63	0.34	1.35e-10	Fat distribution (HIV);
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg09835421	chr16:68378352	PRMT7	-0.88	-10.26	-0.48	1.07e-21	Magnesium levels;
LIHC	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.65	9.5	0.46	3.68e-19	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02895995	chr19:7554069	PEX11G	0.43	6.61	0.34	1.48e-10	Pancreatic cancer;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.7	7.21	0.36	3.69e-12	Alzheimer's disease;
LIHC	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.88	10.89	0.51	6.3e-24	Prostate cancer;
LIHC	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.7	13.13	0.58	3.66e-32	Mean platelet volume;
LIHC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.33	0.55	3.63e-29	Menopause (age at onset);
LIHC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	6.83	0.35	3.85e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.6	-7.53	-0.38	4.49e-13	Post bronchodilator FEV1;
LIHC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-6.05	-0.31	3.71e-9	Breast cancer;
LIHC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg00529422	chr1:16285251	ZBTB17	0.33	6.0	0.31	4.92e-9	Systolic blood pressure;
LIHC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-15.36	-0.64	7.65e-41	Body mass index;
LIHC	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	7.84	0.39	5.65e-14	LDL cholesterol;
LIHC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg05110241	chr16:68378359	PRMT7	0.88	9.97	0.47	1e-20	Schizophrenia;
LIHC	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.48	0.33	3.25e-10	Educational attainment;
LIHC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.57	9.56	0.46	2.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.64	9.02	0.44	1.34e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.48	6.21	0.32	1.58e-9	Parkinson's disease;
LIHC	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.39	6.33	0.32	7.68e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.54	-6.66	-0.34	1.1e-10	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.67	8.37	0.41	1.5e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.63	12.77	0.57	8.51e-31	Schizophrenia;
LIHC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.9	-0.3	8.79e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg02290350	chr8:58132656	NA	0.32	6.91	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg05527609	chr1:210001259	C1orf107	-0.54	-7.52	-0.38	4.9e-13	Red blood cell count;
LIHC	cis	rs8067354	0.957	rs9896742	chr17:57826530	T/G	cg02344993	chr17:57696989	CLTC	0.55	8.79	0.43	7.41e-17	Hemoglobin concentration;
LIHC	cis	rs151997	0.962	rs56170692	chr5:50247928	G/A	cg06027927	chr5:50259733	NA	0.6	7.87	0.39	4.86e-14	Callous-unemotional behaviour;
LIHC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.49	6.38	0.33	5.82e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.44	5.99	0.31	5.44e-9	Initial pursuit acceleration;
LIHC	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg02269571	chr22:50332266	NA	-0.59	-7.97	-0.4	2.32e-14	Schizophrenia;
LIHC	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg06611532	chr13:114900021	NA	-0.37	-6.88	-0.35	2.83e-11	Schizophrenia;
LIHC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	0.75	8.12	0.4	8.49e-15	Testicular germ cell tumor;
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg21486233	chr12:29375141	FAR2	0.29	5.72	0.3	2.27e-8	QT interval;
LIHC	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.82	9.13	0.44	6.29e-18	Breast cancer;
LIHC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.47	7.01	0.35	1.25e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.53	-0.33	2.39e-10	Eosinophil percentage of white cells;
LIHC	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.41	6.34	0.32	7.23e-10	Neutrophil percentage of white cells;
LIHC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-7.52	-0.38	4.74e-13	Lymphocyte counts;
LIHC	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs1144333	0.655	rs77244403	chr1:76304872	A/G	cg22875332	chr1:76189707	ACADM	0.44	6.62	0.34	1.42e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.8	9.65	0.46	1.16e-19	Cognitive function;
LIHC	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg10665199	chr7:133106180	EXOC4	0.35	6.09	0.31	3.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.61	0.8	1.12e-77	Prudent dietary pattern;
LIHC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.65	-7.72	-0.39	1.3e-13	Neuroticism;
LIHC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.48	-0.46	4.56e-19	Alzheimer's disease;
LIHC	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.4	6.02	0.31	4.43e-9	Superior crus of antihelix expression;
LIHC	trans	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg10208301	chr11:6592745	DNHD1	0.48	6.53	0.33	2.33e-10	Coronary artery calcification;
LIHC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.52	8.46	0.42	7.64e-16	Schizophrenia;
LIHC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.46	6.18	0.32	1.84e-9	Initial pursuit acceleration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26011156	chr1:156183096	PMF1	0.45	6.25	0.32	1.23e-9	Pancreatic cancer;
LIHC	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.33	-7.47	-0.37	6.93e-13	Educational attainment (years of education);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20340149	chr2:122407145	CLASP1	0.41	6.17	0.32	1.9e-9	Lung function (FEV1/FVC);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg11317705	chr7:6693838	NA	0.39	6.18	0.32	1.83e-9	Calcium levels;
LIHC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-6.28	-0.32	1.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7091068	0.518	rs4144097	chr10:95432480	A/C	cg20715218	chr10:95462985	C10orf4	0.52	7.45	0.37	7.83e-13	Urinary tract infection frequency;
LIHC	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.41	-6.39	-0.33	5.35e-10	Breast cancer;
LIHC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg18944383	chr4:111397179	ENPEP	0.31	7.29	0.37	2.14e-12	Coronary artery disease;
LIHC	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.65	-10.24	-0.48	1.19e-21	Nonalcoholic fatty liver disease;
LIHC	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.45	8.56	0.42	3.97e-16	Schizophrenia;
LIHC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.48	-8.35	-0.41	1.68e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs238295	0.766	rs6085197	chr20:5511010	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.44	-5.99	-0.31	5.36e-9	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.37	-6.23	-0.32	1.34e-9	Educational attainment;
LIHC	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Hypertriglyceridemia;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.38	-0.33	5.62e-10	Menopause (age at onset);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24474622	chr7:1103876	C7orf50	0.5	6.29	0.32	9.85e-10	Lung function (FEV1);
LIHC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.58	0.56	4.54e-30	Menopause (age at onset);
LIHC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.91	-0.47	1.62e-20	Total cholesterol levels;
LIHC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg25894440	chr7:65020034	NA	-0.54	-6.35	-0.32	6.76e-10	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg07424592	chr7:64974309	NA	0.79	9.32	0.45	1.43e-18	Diabetic kidney disease;
LIHC	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.73	12.35	0.56	3.06e-29	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs74181299	0.684	rs2302631	chr2:65331659	T/G	cg05010058	chr2:65284262	CEP68	-0.4	-6.75	-0.34	6.53e-11	Pulse pressure;
LIHC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.25	0.55	7.28e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg14580859	chr9:123691850	NA	0.37	6.55	0.33	2.11e-10	Rheumatoid arthritis;
LIHC	cis	rs151997	0.962	rs27612	chr5:50179120	G/A	cg06027927	chr5:50259733	NA	0.57	7.61	0.38	2.61e-13	Callous-unemotional behaviour;
LIHC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.85	14.72	0.62	2.4e-38	Monocyte count;
LIHC	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	0.29	6.94	0.35	1.93e-11	Gut microbiome composition (winter);
LIHC	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.75	10.68	0.5	3.6e-23	Obesity-related traits;
LIHC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	7.23	0.36	3.09e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06634786	chr22:41940651	POLR3H	0.56	6.08	0.31	3.22e-9	Vitiligo;
LIHC	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22197824	chr11:65431114	RELA	0.45	6.17	0.32	1.96e-9	Lung function (FEV1/FVC);
LIHC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.09	-0.44	8.46e-18	Bipolar disorder and schizophrenia;
LIHC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.53	6.13	0.31	2.36e-9	Axial length;
LIHC	trans	rs1421898	0.509	rs62385378	chr5:158327312	G/A	cg10462998	chr5:175976188	PCDH24	-0.71	-6.08	-0.31	3.22e-9	Inflammatory skin disease;
LIHC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.9	-18.38	-0.7	5.63e-53	Height;
LIHC	cis	rs7945718	0.591	rs7937898	chr11:12703561	G/T	cg25843174	chr11:12811716	TEAD1	-0.32	-7.27	-0.37	2.39e-12	Educational attainment (years of education);
LIHC	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg08126542	chr6:37504118	NA	-0.37	-6.37	-0.33	5.94e-10	Cognitive performance;
LIHC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.53	-6.98	-0.35	1.58e-11	Pancreatic cancer;
LIHC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.68	9.92	0.47	1.53e-20	Testicular germ cell tumor;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03277652	chr8:142011117	PTK2	0.39	6.23	0.32	1.36e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22509189	chr2:225307070	NA	0.54	7.13	0.36	5.82e-12	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.47	7.12	0.36	6.44e-12	Blood protein levels;
LIHC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-0.9	-9.88	-0.47	2.02e-20	Magnesium levels;
LIHC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.68	12.7	0.57	1.57e-30	Coronary artery disease;
LIHC	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.65	10.12	0.48	3.11e-21	Type 2 diabetes;
LIHC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.29e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs7945718	0.621	rs12281511	chr11:12677295	A/C	cg25843174	chr11:12811716	TEAD1	0.33	7.71	0.38	1.42e-13	Educational attainment (years of education);
LIHC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.2	-0.32	1.62e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg03999872	chr20:62272968	STMN3	0.4	6.07	0.31	3.41e-9	Prostate cancer;
LIHC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg02297831	chr4:17616191	MED28	-0.46	-7.43	-0.37	8.85e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg05294307	chr14:35346193	BAZ1A	-0.43	-6.38	-0.33	5.83e-10	Psoriasis;
LIHC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.5	0.33	2.88e-10	Response to antipsychotic treatment;
LIHC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	6.5	0.33	2.86e-10	Body mass index;
LIHC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.21	-6.02	-0.31	4.53e-9	Calcium levels;
LIHC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg05896524	chr21:47604654	C21orf56	0.44	6.62	0.34	1.38e-10	Testicular germ cell tumor;
LIHC	cis	rs748404	0.578	rs2012467	chr15:43690565	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.69	0.43	1.48e-16	Lung cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20676401	chr10:5726466	C10orf18	-0.46	-6.53	-0.33	2.41e-10	Pancreatic cancer;
LIHC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.4	-6.06	-0.31	3.56e-9	Height;
LIHC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.86	-0.3	1.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.83	13.58	0.59	6.5e-34	Monocyte count;
LIHC	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.61	6.06	0.31	3.51e-9	Carotid intima media thickness;
LIHC	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.59	8.65	0.42	2.05e-16	Menopause (age at onset);
LIHC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg20607798	chr8:58055168	NA	0.67	7.83	0.39	6.21e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.37e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs7777677	0.925	rs4726547	chr7:142370582	C/T	cg21680980	chr1:221069572	NA	-0.48	-6.08	-0.31	3.27e-9	Alcoholic chronic pancreatitis;
LIHC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.63	0.34	1.29e-10	Cognitive test performance;
LIHC	cis	rs6066825	0.644	rs6095248	chr20:47320932	A/G	cg18078177	chr20:47281410	PREX1	0.42	6.97	0.35	1.65e-11	Colorectal cancer;
LIHC	cis	rs2637266	0.783	rs2395436	chr10:78488513	G/T	cg18941641	chr10:78392320	NA	0.27	5.81	0.3	1.42e-8	Pulmonary function;
LIHC	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg14146966	chr2:61757674	XPO1	0.48	8.45	0.42	8.6e-16	Tuberculosis;
LIHC	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.46	6.25	0.32	1.23e-9	Pulse pressure;
LIHC	cis	rs7602441	0.521	rs8849	chr2:14780131	A/G	cg06545361	chr2:14773388	FAM84A	0.55	6.29	0.32	9.56e-10	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.05e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs12602486	1.000	rs76971031	chr17:42242724	T/G	cg13607699	chr17:42295918	UBTF	-0.75	-6.42	-0.33	4.46e-10	Glycated hemoglobin levels;
LIHC	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.37	-6.09	-0.31	3e-9	Total cholesterol levels;
LIHC	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.62	8.92	0.43	2.88e-17	Menopause (age at onset);
LIHC	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.58	6.38	0.33	5.85e-10	Itch intensity from mosquito bite;
LIHC	cis	rs28489187	0.683	rs11161607	chr1:85855855	T/C	cg16011679	chr1:85725395	C1orf52	0.46	5.82	0.3	1.36e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.31	-0.37	1.89e-12	Blood metabolite levels;
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.64	-8.01	-0.4	1.81e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.43	-0.33	4.29e-10	Axial length;
LIHC	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg15704280	chr7:45808275	SEPT13	0.61	6.36	0.33	6.55e-10	Axial length;
LIHC	cis	rs3736485	0.966	rs11636170	chr15:51767087	G/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.95	-0.31	6.79e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg09417038	chr21:47716443	C21orf57	0.5	7.65	0.38	2.04e-13	Testicular germ cell tumor;
LIHC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg02269571	chr22:50332266	NA	-1.03	-10.62	-0.5	6.05e-23	Schizophrenia;
LIHC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-7.98	-0.4	2.22e-14	Gut microbiome composition (summer);
LIHC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.46	-6.55	-0.33	2.1e-10	Other erythrocyte phenotypes;
LIHC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.6	-11.82	-0.54	2.81e-27	Coronary artery disease;
LIHC	trans	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04565464	chr8:145669602	NFKBIL2	-0.4	-6.69	-0.34	8.99e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04127825	chr1:167503222	NA	0.49	7.04	0.36	1.08e-11	Pancreatic cancer;
LIHC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg25039879	chr17:56429692	SUPT4H1	0.75	8.41	0.41	1.1e-15	Cognitive test performance;
LIHC	cis	rs3789045	0.774	rs898388	chr1:204500257	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.4	-6.26	-0.32	1.13e-9	Educational attainment (college completion);
LIHC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg18944383	chr4:111397179	ENPEP	0.28	7.08	0.36	8.31e-12	Height;
LIHC	trans	rs12960119	0.536	rs12968175	chr18:23716392	A/G	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.4	-7.06	-0.36	9.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.07e-22	Colorectal cancer;
LIHC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	8.26	0.41	3.32e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-10.49	-0.49	1.7e-22	Platelet count;
LIHC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.5	6.86	0.35	3.24e-11	Mean platelet volume;
LIHC	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.57	-10.24	-0.48	1.18e-21	Neurofibrillary tangles;
LIHC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.39	6.32	0.32	8.29e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.62	9.27	0.45	2.19e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg17750252	chr2:136567154	LCT	0.35	6.11	0.31	2.68e-9	Mosquito bite size;
LIHC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.6	-11.47	-0.53	5.39e-26	Mean corpuscular volume;
LIHC	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	0.67	7.56	0.38	3.69e-13	Coronary artery disease;
LIHC	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.57	9.74	0.47	5.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.6	9.85	0.47	2.53e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.57	7.66	0.38	1.94e-13	Opioid sensitivity;
LIHC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg05697976	chr12:29376483	FAR2	0.3	6.17	0.32	1.9e-9	QT interval;
LIHC	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg13903917	chr12:124904514	NCOR2	0.35	6.14	0.32	2.25e-9	Oropharynx cancer;
LIHC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.81	15.37	0.64	6.44e-41	Blood protein levels;
LIHC	cis	rs1355223	0.872	rs1258466	chr11:34730066	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.32	-0.32	8.28e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg01864836	chr14:55583639	NA	-0.41	-7.67	-0.38	1.79e-13	Protein biomarker;
LIHC	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.49	-0.42	6.3e-16	Endometrial cancer;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.21	0.58	1.74e-32	Prudent dietary pattern;
LIHC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.55	8.66	0.42	1.92e-16	Neuroticism;
LIHC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.53e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs11031096	0.563	rs12289940	chr11:4224589	T/A	cg18678763	chr11:4115507	RRM1	-0.43	-6.45	-0.33	3.87e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg02993280	chr1:107599747	PRMT6	0.58	9.27	0.45	2.16e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs11760633	0.607	rs11760284	chr7:1827569	C/T	cg00395210	chr12:48592465	NA	0.34	6.06	0.31	3.5e-9	Coronary artery disease;
LIHC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.84	18.33	0.7	9.26e-53	Gestational age at birth (maternal effect);
LIHC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.24	-0.41	3.62e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg05110241	chr16:68378359	PRMT7	-0.9	-10.01	-0.48	7.42e-21	Schizophrenia;
LIHC	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2599510	0.703	rs58852184	chr2:32729763	A/T	cg02381751	chr2:32503542	YIPF4	0.45	5.88	0.3	9.98e-9	Interleukin-18 levels;
LIHC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.63	-9.92	-0.47	1.45e-20	Obesity-related traits;
LIHC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.7	-0.34	8.5e-11	Morning vs. evening chronotype;
LIHC	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2176862	1.000	rs2280414	chr3:46621215	T/C	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.3	-0.32	9.3e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg03517284	chr6:25882590	NA	-0.44	-6.65	-0.34	1.17e-10	Height;
LIHC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.93	0.54	1.12e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.65e-12	Breast cancer;
LIHC	cis	rs1499280	0.920	rs1157137	chr5:52099093	G/T	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.48	6.3	0.32	9.36e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16346588	chr10:242978	ZMYND11	0.42	6.34	0.32	7.35e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg14250997	chr9:106856677	SMC2	0.42	7.45	0.37	7.54e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.77	9.41	0.45	7.37e-19	Heart rate;
LIHC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.72	10.35	0.49	5.28e-22	Diastolic blood pressure;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg22771759	chr13:24902376	NA	0.32	6.7	0.34	8.43e-11	Obesity-related traits;
LIHC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-13.43	-0.59	2.45e-33	Monocyte percentage of white cells;
LIHC	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg09003973	chr2:102972529	NA	0.87	7.47	0.37	6.66e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg02503808	chr4:7069936	GRPEL1	0.76	11.43	0.53	7.6e-26	Monocyte percentage of white cells;
LIHC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.03	0.31	4.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16517634	chr2:8977876	KIDINS220	0.42	6.08	0.31	3.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02290350	chr8:58132656	NA	0.47	8.61	0.42	2.81e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.79	0.39	8.09e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.94	0.51	4.41e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs903552	1.000	rs8043205	chr15:102005749	A/G	cg25677261	chr15:102009856	PCSK6	-0.46	-6.22	-0.32	1.44e-9	Diabetic kidney disease;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/T	cg03715129	chr7:2117724	MAD1L1	-0.77	-5.82	-0.3	1.36e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2629751	0.512	rs2722169	chr12:104415450	C/T	cg14987745	chr12:104360022	TDG	-0.69	-6.84	-0.35	3.56e-11	Hepatitis C induced liver fibrosis;
LIHC	cis	rs2607426	1.000	rs2249854	chr19:41269481	T/C	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.48	-5.82	-0.3	1.36e-8	Blood protein levels;
LIHC	trans	rs4342066	0.736	rs1599951	chr3:28359788	G/A	cg11103623	chr3:57235255	HESX1	0.38	6.2	0.32	1.65e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1461503	0.900	rs7119398	chr11:122832492	C/A	cg25161029	chr11:122845972	NA	0.4	6.7	0.34	8.39e-11	Menarche (age at onset);
LIHC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.99	10.76	0.5	1.9e-23	Triglycerides;
LIHC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.39	0.61	4.74e-37	Chronic sinus infection;
LIHC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg00750074	chr16:89608354	SPG7	-0.48	-7.84	-0.39	5.63e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.64	9.96	0.47	1.13e-20	Testicular germ cell tumor;
LIHC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.49	6.46	0.33	3.65e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.55	-0.42	4.12e-16	Total body bone mineral density;
LIHC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg07061783	chr6:25882402	NA	-0.53	-6.44	-0.33	3.95e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.23	-0.45	2.96e-18	Colorectal cancer;
LIHC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	0.85	7.04	0.36	1.09e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.72	-11.97	-0.54	8.1e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg14791747	chr16:20752902	THUMPD1	-0.46	-6.49	-0.33	3.01e-10	Dental caries;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg18658371	chr14:91527208	RPS6KA5	-0.83	-6.3	-0.32	9.32e-10	Mild influenza (H1N1) infection;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.73	-0.43	1.15e-16	Renal cell carcinoma;
LIHC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.61	0.65	7.25e-42	Chronic sinus infection;
LIHC	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-5.98	-0.31	5.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.64	12.25	0.55	7.35e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.46	6.55	0.33	2.07e-10	Schizophrenia;
LIHC	cis	rs3736485	0.808	rs28576876	chr15:51951252	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-5.85	-0.3	1.18e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.39	6.56	0.33	1.97e-10	Type 2 diabetes;
LIHC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.97	19.09	0.72	8.38e-56	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-7.09	-0.36	7.55e-12	Vitiligo;
LIHC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	5.96	0.31	6.26e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg00277334	chr10:82204260	NA	-0.55	-6.91	-0.35	2.43e-11	Post bronchodilator FEV1;
LIHC	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.45	-6.05	-0.31	3.85e-9	Colorectal cancer;
LIHC	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.8	12.14	0.55	1.92e-28	Subjective well-being;
LIHC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.75	11.62	0.53	1.58e-26	Corneal astigmatism;
LIHC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg10360323	chr17:41437877	NA	0.39	5.84	0.3	1.22e-8	Menopause (age at onset);
LIHC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.1	0.4	9.65e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.17	15.21	0.64	2.92e-40	Blood protein levels;
LIHC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.72	-11.77	-0.54	4.33e-27	Body mass index;
LIHC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.51	7.17	0.36	4.52e-12	Menopause (age at onset);
LIHC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg11812906	chr14:75593930	NEK9	0.44	6.64	0.34	1.22e-10	IgG glycosylation;
LIHC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.93	0.51	4.75e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3736485	0.932	rs2899477	chr15:51937701	C/T	cg08986416	chr15:51914746	DMXL2	-0.43	-6.12	-0.31	2.5e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	0.84	10.93	0.51	4.91e-24	Skin colour saturation;
LIHC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18357526	chr6:26021779	HIST1H4A	0.46	6.83	0.35	3.96e-11	Height;
LIHC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-6.99	-0.35	1.49e-11	Personality dimensions;
LIHC	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg20991723	chr1:152506922	NA	0.59	10.51	0.49	1.45e-22	Hair morphology;
LIHC	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.54	7.85	0.39	5.45e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg25566285	chr7:158114605	PTPRN2	0.23	6.21	0.32	1.5e-9	Calcium levels;
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.63	9.65	0.46	1.17e-19	Renal cell carcinoma;
LIHC	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	10.29	0.49	8.26e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.43	-8.53	-0.42	4.8e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.43	6.49	0.33	3.09e-10	Personality dimensions;
LIHC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	8.32	0.41	2.19e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.43	7.7	0.38	1.51e-13	Total body bone mineral density;
LIHC	cis	rs57244997	0.725	rs61574422	chr6:162425056	T/C	cg17173639	chr6:162384350	PARK2	-0.56	-7.09	-0.36	7.55e-12	Mosquito bite size;
LIHC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.5	7.68	0.38	1.67e-13	Corneal astigmatism;
LIHC	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.28e-27	Motion sickness;
LIHC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.59	-0.34	1.7e-10	Testicular germ cell tumor;
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.76	0.78	1.78e-70	Height;
LIHC	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg25364880	chr3:44379878	C3orf23	0.54	7.35	0.37	1.48e-12	Depressive symptoms;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10620100	chr15:40714174	NA	0.43	6.13	0.31	2.36e-9	Pancreatic cancer;
LIHC	cis	rs11023332	0.650	rs2122942	chr11:14807375	T/G	cg19336497	chr11:14380999	RRAS2	-0.35	-6.18	-0.32	1.78e-9	Adiponectin levels;Vitamin D levels;
LIHC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.6	-10.0	-0.48	8.01e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.43e-11	Height;
LIHC	trans	rs859980	0.514	rs9386402	chr6:104519786	C/T	cg11635524	chr19:46850777	PPP5C	-0.45	-6.31	-0.32	8.44e-10	Tourette's syndrome or obsessive-compulsive disorder;
LIHC	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg08135965	chr6:41755394	TOMM6	0.44	5.72	0.3	2.34e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg20818283	chr2:191399100	TMEM194B	0.46	6.16	0.32	2.1e-9	Pulse pressure;
LIHC	cis	rs10792665	0.640	rs1904426	chr11:82620122	G/C	cg24227371	chr11:82718527	RAB30	-0.27	-6.13	-0.31	2.41e-9	Obesity-related traits;
LIHC	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg02023728	chr11:77925099	USP35	-0.35	-6.17	-0.32	1.92e-9	Alzheimer's disease (survival time);
LIHC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00958927	chr1:175162553	KIAA0040	0.39	6.37	0.33	5.98e-10	Alcohol dependence;
LIHC	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.38	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4908768	0.579	rs55840223	chr1:8862787	G/C	cg20416874	chr1:8611966	RERE	0.4	5.77	0.3	1.75e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.74	11.27	0.52	3e-25	Corneal astigmatism;
LIHC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.37	0.33	6.27e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs4759375	1.000	rs11057224	chr12:123755179	A/G	cg00376283	chr12:123451042	ABCB9	-0.5	-6.24	-0.32	1.27e-9	HDL cholesterol;
LIHC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.76e-46	Parkinson's disease;
LIHC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.16	-0.36	5.06e-12	Vitiligo;
LIHC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.52	-6.63	-0.34	1.33e-10	Pancreatic cancer;
LIHC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20011983	chr2:74347215	NA	-0.43	-6.28	-0.32	1.01e-9	Gestational age at birth (maternal effect);
LIHC	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg08824895	chr13:115047677	UPF3A	0.48	6.74	0.34	6.74e-11	Schizophrenia;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.67	0.57	2.05e-30	Prudent dietary pattern;
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.76	-11.82	-0.54	3e-27	Longevity;
LIHC	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.84	0.54	2.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs9378688	1.000	rs9392374	chr6:2223002	T/G	cg12303981	chr6:2244766	GMDS	-0.49	-6.22	-0.32	1.48e-9	Caudate nucleus volume;
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.49	8.09	0.4	1.03e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.58	6.42	0.33	4.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10411936	0.750	rs8112401	chr19:16593012	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	6.41	0.33	4.8e-10	White blood cell count;Multiple sclerosis;
LIHC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.87	-13.34	-0.59	5.45e-33	Lymphocyte percentage of white cells;
LIHC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.07	0.31	3.4e-9	Subjective well-being;
LIHC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	1.02	10.59	0.5	7.69e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.69	-8.87	-0.43	4.17e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.69	10.0	0.48	7.85e-21	Testicular germ cell tumor;
LIHC	cis	rs963731	0.649	rs2924710	chr2:39302757	G/C	cg04010122	chr2:39346883	SOS1	-0.7	-6.32	-0.32	8.07e-10	Corticobasal degeneration;
LIHC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.82	15.31	0.64	1.17e-40	Blood protein levels;
LIHC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	trans	rs6073597	0.967	rs2284276	chr20:43682124	C/T	cg14213297	chr9:130870109	SLC25A25	0.34	6.08	0.31	3.19e-9	Positive affect;
LIHC	cis	rs11673344	0.764	rs547483	chr19:37441365	C/T	cg27390819	chr19:37464633	NA	0.53	6.47	0.33	3.34e-10	Obesity-related traits;
LIHC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-8.5	-0.42	5.79e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg10790698	chr19:18539756	SSBP4	-0.36	-7.53	-0.38	4.6e-13	Breast cancer;
LIHC	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.36	0.33	6.31e-10	Lung cancer;
LIHC	cis	rs7106204	0.514	rs7123539	chr11:24272000	G/A	ch.11.24196551F	chr11:24239977	NA	-0.73	-8.88	-0.43	3.8e-17	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.66	9.79	0.47	4.08e-20	Menarche (age at onset);
LIHC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.75	-11.37	-0.52	1.26e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.68	-9.28	-0.45	1.97e-18	Corneal structure;
LIHC	cis	rs7319311	0.748	rs9515198	chr13:111029065	C/T	cg05272587	chr13:111038400	COL4A2	0.38	7.71	0.38	1.41e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs4728302	0.869	rs10253633	chr7:133590869	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg01021169	chr22:30184971	ASCC2	-0.37	-7.04	-0.36	1.07e-11	Type 1 diabetes;
LIHC	cis	rs831571	0.774	rs40610	chr3:64009508	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.49	-6.48	-0.33	3.16e-10	Type 2 diabetes;
LIHC	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg18898632	chr2:242989856	NA	-0.7	-8.69	-0.43	1.5e-16	Obesity-related traits;
LIHC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.75	-7.8	-0.39	7.76e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.49	-0.42	6.54e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.02	-0.4	1.75e-14	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.74	7.51	0.38	5.16e-13	Alzheimer's disease;
LIHC	cis	rs16912285	0.748	rs12786638	chr11:24346006	A/G	ch.11.24196551F	chr11:24239977	NA	0.72	8.45	0.42	8.51e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.36	5.98	0.31	5.76e-9	Monocyte count;
LIHC	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.11	0.44	7.14e-18	Response to antipsychotic treatment;
LIHC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.0	-8.14	-0.4	7.3e-15	Body mass index;
LIHC	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.95	0.35	1.8e-11	Breast cancer;
LIHC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.85	13.94	0.6	2.63e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg08992911	chr2:238395768	MLPH	0.48	5.93	0.31	7.32e-9	Prostate cancer;
LIHC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg27432699	chr2:27873401	GPN1	-0.48	-6.92	-0.35	2.3e-11	Total body bone mineral density;
LIHC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg06199346	chr11:14280333	SPON1	0.34	5.75	0.3	2.02e-8	Mitochondrial DNA levels;
LIHC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-8.62	-0.42	2.53e-16	Lung cancer;
LIHC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19623624	chr10:135278901	LOC619207	-0.42	-6.56	-0.33	2.05e-10	Systemic lupus erythematosus;
LIHC	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	2.01e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.65	-6.47	-0.33	3.4e-10	Multiple sclerosis;
LIHC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.63	9.49	0.46	4.2e-19	Corneal astigmatism;
LIHC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.67	8.88	0.43	3.94e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	trans	rs13202860	1.000	rs13193345	chr6:87187922	G/A	cg27326224	chr7:950474	ADAP1	-0.57	-6.32	-0.32	8.05e-10	Sexual dysfunction (female);
LIHC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg06466757	chr4:1255808	NA	0.3	5.77	0.3	1.8e-8	Obesity-related traits;
LIHC	cis	rs17152411	0.895	rs11245422	chr10:126588143	T/C	cg07906193	chr10:126599966	NA	0.42	6.6	0.34	1.61e-10	Height;
LIHC	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.33	-12.81	-0.57	5.98e-31	Psoriasis vulgaris;
LIHC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.49	7.78	0.39	8.72e-14	Dental caries;
LIHC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.5	7.43	0.37	8.55e-13	Total body bone mineral density;
LIHC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.51	-7.33	-0.37	1.65e-12	Breast cancer;
LIHC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.27	-6.83	-0.35	3.96e-11	Mean corpuscular volume;
LIHC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.06	16.75	0.67	2.08e-46	Breast cancer;
LIHC	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.58	9.18	0.44	4.22e-18	Corneal astigmatism;
LIHC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.99	-0.4	2.15e-14	Total body bone mineral density;
LIHC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	1.02	19.53	0.73	1.39e-57	Breast cancer;
LIHC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.62	9.32	0.45	1.51e-18	Mean corpuscular volume;
LIHC	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.4	8.57	0.42	3.51e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.97	-0.31	5.83e-9	Breast cancer;
LIHC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.39	-8.94	-0.44	2.39e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.65	0.34	1.17e-10	Neuroticism;
LIHC	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.05	0.31	3.85e-9	Axial length;
LIHC	cis	rs7539624	0.588	rs1892077	chr1:223895116	A/G	cg07395969	chr1:223900822	CAPN2	0.49	5.77	0.3	1.76e-8	Schizophrenia;
LIHC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.56	0.38	3.79e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.53	-7.58	-0.38	3.27e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg13903179	chr13:21900392	NA	0.35	5.9	0.3	8.58e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-7.34	-0.37	1.6e-12	Longevity;Endometriosis;
LIHC	cis	rs72772090	0.908	rs6864233	chr5:96044681	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.52	6.17	0.32	1.97e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg26566898	chr11:117069891	TAGLN	0.39	5.99	0.31	5.25e-9	Blood protein levels;
LIHC	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.8	-0.3	1.53e-8	Alcohol dependence;
LIHC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.57	-7.59	-0.38	3.03e-13	Response to antineoplastic agents;
LIHC	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.54	-8.54	-0.42	4.51e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.48	0.53	5.13e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.49	-6.73	-0.34	6.97e-11	Height;
LIHC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.02	-0.51	2.23e-24	Crohn's disease;
LIHC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.89	-15.56	-0.64	1.14e-41	Colorectal cancer;
LIHC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.44	0.49	2.57e-22	Obesity-related traits;
LIHC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-5.91	-0.3	8.43e-9	Schizophrenia;
LIHC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.92	-15.27	-0.64	1.67e-40	Lymphocyte percentage of white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21692936	chr11:62623994	SLC3A2;SNORD27;SNHG1;SNORD25;SNORD26	0.41	6.08	0.31	3.2e-9	Pancreatic cancer;
LIHC	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.69	11.21	0.52	4.77e-25	Diisocyanate-induced asthma;
LIHC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.38	5.83	0.3	1.26e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	0.8	5.72	0.3	2.37e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-8.46	-0.42	7.87e-16	Chronic sinus infection;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg22586474	chr7:931148	C7orf20	0.5	6.42	0.33	4.67e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.54	-7.04	-0.36	1.07e-11	Coronary artery calcification;
LIHC	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.58	-8.43	-0.41	9.61e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.5	-0.46	3.88e-19	Bipolar disorder;
LIHC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.74	-0.3	2.12e-8	Uric acid levels;
LIHC	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg10820045	chr2:198174542	NA	0.49	7.5	0.38	5.48e-13	Intracranial aneurysm;
LIHC	cis	rs5753037	0.834	rs713656	chr22:30212194	C/G	cg01021169	chr22:30184971	ASCC2	-0.35	-6.62	-0.34	1.4e-10	Type 1 diabetes;
LIHC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg12560992	chr17:57184187	TRIM37	0.55	7.69	0.38	1.63e-13	Cognitive test performance;
LIHC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.44	7.14	0.36	5.56e-12	Methadone dose in opioid dependence;
LIHC	trans	rs13201877	0.591	rs3850212	chr6:137655120	A/G	cg16624405	chr10:133607033	NA	-0.43	-6.28	-0.32	1.03e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg09876464	chr15:85330779	ZNF592	0.35	5.97	0.31	5.87e-9	P wave terminal force;
LIHC	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg20159608	chr7:32802032	NA	-0.49	-5.72	-0.3	2.3e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.38	6.1	0.31	2.85e-9	Menopause (age at onset);
LIHC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.24e-9	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.15	0.55	1.79e-28	Prudent dietary pattern;
LIHC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.39	-7.06	-0.36	9.43e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.75	0.57	1.03e-30	Colorectal cancer;
LIHC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-7.75	-0.39	1.05e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.47	0.33	3.37e-10	Mean corpuscular volume;
LIHC	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.51	7.97	0.4	2.39e-14	Extraversion;
LIHC	cis	rs4722166	0.599	rs7776857	chr7:22754768	G/T	cg05472934	chr7:22766657	IL6	0.6	8.7	0.43	1.4e-16	Lung cancer;
LIHC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg05343316	chr1:45956843	TESK2	0.45	6.6	0.34	1.53e-10	High light scatter reticulocyte count;
LIHC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.14	-0.4	7.64e-15	Monocyte count;
LIHC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-10.7	-0.5	3.14e-23	Breast cancer;
LIHC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-7.7	-0.38	1.5e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.47	11.34	0.52	1.63e-25	Alcohol dependence;
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg19635926	chr16:89946313	TCF25	0.48	6.46	0.33	3.67e-10	Skin colour saturation;
LIHC	cis	rs17106184	1.000	rs72900932	chr1:51107959	T/C	cg07174182	chr1:51127561	FAF1	-0.65	-7.04	-0.36	1.03e-11	Type 2 diabetes;
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02290350	chr8:58132656	NA	0.52	10.83	0.51	1.03e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-11.29	-0.52	2.44e-25	Chronic sinus infection;
LIHC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.18	-0.78	3.99e-72	Height;
LIHC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg09222892	chr1:25734099	RHCE	-0.47	-8.77	-0.43	8.75e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs2997447	0.761	rs61776618	chr1:26456709	A/G	cg19633962	chr1:26362018	EXTL1	-0.65	-5.76	-0.3	1.87e-8	QRS complex (12-leadsum);
LIHC	cis	rs77637988	0.603	rs72820445	chr2:48607856	T/C	cg15846641	chr2:48541264	FOXN2	0.58	7.93	0.39	3.05e-14	Joint mobility (Beighton score);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12880967	chr11:63804044	MACROD1	0.46	6.05	0.31	3.9e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.79	-0.3	1.56e-8	Morning vs. evening chronotype;
LIHC	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.7	-10.7	-0.5	3.16e-23	Eosinophil percentage of white cells;
LIHC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	5.81	0.3	1.42e-8	Schizophrenia;
LIHC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg00292662	chr22:38071168	LGALS1	0.4	6.7	0.34	8.65e-11	Fat distribution (HIV);
LIHC	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.89	-0.3	9.1e-9	Response to antipsychotic treatment;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-7.21	-0.36	3.59e-12	Prudent dietary pattern;
LIHC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg11062466	chr8:58055876	NA	0.4	5.8	0.3	1.53e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.85	0.3	1.12e-8	Menopause (age at onset);
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.58	8.67	0.42	1.75e-16	Menarche (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg15803506	chr10:135125704	ZNF511	0.4	6.17	0.32	1.95e-9	Longevity;
LIHC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.27	-6.13	-0.31	2.38e-9	Migraine;
LIHC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17708016	chr12:54321992	NA	0.42	7.3	0.37	2e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.71	-0.3	2.43e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	18.52	0.71	1.52e-53	Tonsillectomy;
LIHC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.58	-0.34	1.79e-10	Gut microbiome composition (summer);
LIHC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg00012203	chr2:219082015	ARPC2	0.51	6.69	0.34	9.33e-11	Ulcerative colitis;
LIHC	cis	rs36051895	0.623	rs2146041	chr9:5262911	A/G	cg02405213	chr9:5042618	JAK2	-0.65	-10.79	-0.5	1.5e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9443189	1.000	rs6906615	chr6:76489774	A/G	cg01950844	chr6:76311363	SENP6	0.47	5.78	0.3	1.69e-8	Prostate cancer;
LIHC	cis	rs9328573	0.685	rs2006990	chr15:100508462	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.42	-6.43	-0.33	4.31e-10	Urate levels in lean individuals;
LIHC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.24	-0.48	1.19e-21	Response to antipsychotic treatment;
LIHC	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.63	-8.98	-0.44	1.8e-17	White matter hyperintensity burden;
LIHC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.73	0.3	2.26e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.78	0.3	1.69e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3736757	0.664	rs12567225	chr1:184678272	A/G	cg07817967	chr1:184721222	EDEM3	-0.35	-5.78	-0.3	1.7e-8	Obesity-related traits;
LIHC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.58	-0.38	3.24e-13	Morning vs. evening chronotype;
LIHC	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.42	-5.86	-0.3	1.07e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.58	10.46	0.49	2.14e-22	Coronary heart disease;
LIHC	cis	rs12493885	0.818	rs10935970	chr3:153770237	C/G	cg10247383	chr3:153839028	SGEF	0.65	6.13	0.31	2.41e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.3	16.95	0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs11098699	0.950	rs11098700	chr4:124193531	G/C	cg09941581	chr4:124220074	SPATA5	0.3	5.72	0.3	2.29e-8	Mosquito bite size;
LIHC	cis	rs12188164	0.812	rs9313065	chr5:423426	T/C	cg10655629	chr5:480253	SLC9A3	0.36	5.77	0.3	1.77e-8	Cystic fibrosis severity;
LIHC	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.57	7.45	0.37	7.55e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.52	9.96	0.47	1.13e-20	Testicular germ cell tumor;
LIHC	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.71	-9.87	-0.47	2.25e-20	Personality dimensions;
LIHC	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.67	-8.1	-0.4	9.91e-15	Mean platelet volume;
LIHC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg18944383	chr4:111397179	ENPEP	0.25	6.33	0.32	7.77e-10	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.27	16.79	0.67	1.38e-46	Diabetic kidney disease;
LIHC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-0.91	-10.28	-0.49	8.74e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs507080	0.922	rs4474473	chr11:118553889	T/G	cg04173919	chr11:118528438	PHLDB1	0.33	6.24	0.32	1.33e-9	Serum metabolite levels;
LIHC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.46	6.82	0.35	4.19e-11	Personality dimensions;
LIHC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.52	7.39	0.37	1.15e-12	Menopause (age at onset);
LIHC	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg17623882	chr6:41773611	USP49	-0.43	-5.85	-0.3	1.13e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.22	0.48	1.39e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.48	-7.37	-0.37	1.28e-12	Pubertal anthropometrics;
LIHC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.47	6.81	0.35	4.34e-11	Bone mineral density;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.72	-11.98	-0.54	7.39e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.35	5.81	0.3	1.46e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.47	-7.67	-0.38	1.86e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.44	-6.1	-0.31	2.8e-9	Cleft lip with or without cleft palate;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg13700589	chr9:15511220	PSIP1	-0.51	-6.55	-0.33	2.13e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	10.33	0.49	6.02e-22	Response to antipsychotic treatment;
LIHC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.46	-0.37	7e-13	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.7	-12.65	-0.56	2.45e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg19336497	chr11:14380999	RRAS2	-0.34	-5.74	-0.3	2.14e-8	Vitamin D levels;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06634786	chr22:41940651	POLR3H	0.56	6.18	0.32	1.87e-9	Cannabis dependence symptom count;
LIHC	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.41	6.1	0.31	2.81e-9	Height;
LIHC	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.53	-6.59	-0.34	1.65e-10	Schizophrenia;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg00703542	chr5:145583510	RBM27	0.47	6.36	0.33	6.62e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-19.73	-0.73	2.22e-58	Height;
LIHC	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs7238033	0.624	rs4310958	chr18:43309355	C/G	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.54	9.16	0.44	4.81e-18	Breast cancer;
LIHC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.58	-6.12	-0.31	2.53e-9	Multiple sclerosis;
LIHC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg07451762	chr16:28383216	NA	0.4	7.29	0.37	2.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg08645402	chr16:4508243	NA	0.38	6.37	0.33	6.16e-10	Schizophrenia;
LIHC	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.37	0.33	6.09e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	8.88	0.43	3.73e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.63	9.26	0.45	2.28e-18	Corneal astigmatism;
LIHC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.38	5.99	0.31	5.34e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg00935119	chr6:36647544	CDKN1A	-0.45	-6.39	-0.33	5.46e-10	QRS duration;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg11953164	chr1:23521307	HTR1D	0.29	5.78	0.3	1.68e-8	Height;
LIHC	cis	rs6693567	0.826	rs1260387	chr1:150371448	T/C	cg15654264	chr1:150340011	RPRD2	0.43	6.26	0.32	1.14e-9	Migraine;
LIHC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.98	13.29	0.58	8.46e-33	Heart rate;
LIHC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-11.94	-0.54	1.04e-27	Vitiligo;
LIHC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.82	0.3	1.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	10.92	0.51	5.28e-24	Alzheimer's disease (late onset);
LIHC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.96	-0.35	1.79e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.96	-0.35	1.79e-11	IFN-related cytopenia;
LIHC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	8.73	0.43	1.13e-16	Platelet count;
LIHC	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs15676	0.783	rs2977995	chr9:131584245	A/G	cg00228799	chr9:131580591	ENDOG	0.48	6.99	0.35	1.44e-11	Blood metabolite levels;
LIHC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.48	-8.67	-0.42	1.75e-16	Asthma;
LIHC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.41	6.31	0.32	8.62e-10	Educational attainment;
LIHC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.47	-7.32	-0.37	1.8e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.85	0.51	9.05e-24	Colorectal cancer;
LIHC	cis	rs73206853	0.640	rs3825390	chr12:110976409	A/C	cg12870014	chr12:110450643	ANKRD13A	0.77	8.87	0.43	4e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.55	9.16	0.44	4.79e-18	Fibroblast growth factor basic levels;
LIHC	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	1.0	11.73	0.54	6.05e-27	IgG glycosylation;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22280406	chr17:78582647	RPTOR	0.45	6.18	0.32	1.81e-9	Hepatitis;
LIHC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.88	-0.3	9.59e-9	Heart rate;
LIHC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.05	-0.36	9.9e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.91	10.22	0.48	1.37e-21	IgG glycosylation;
LIHC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.7	-0.38	1.45e-13	Tonsillectomy;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03248799	chr12:56510114	RPL41	0.39	6.29	0.32	9.76e-10	Metabolic traits;
LIHC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	5.97	0.31	5.96e-9	Coronary artery disease;
LIHC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.52	0.49	1.35e-22	Bladder cancer;
LIHC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.57	8.34	0.41	1.85e-15	Platelet count;
LIHC	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.5	8.31	0.41	2.32e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	cis	rs15676	0.783	rs2997917	chr9:131586918	G/A	cg00228799	chr9:131580591	ENDOG	0.48	6.92	0.35	2.19e-11	Blood metabolite levels;
LIHC	cis	rs7523273	0.925	rs4844394	chr1:208000625	C/T	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.59	-0.5	7.74e-23	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.03	0.31	4.21e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg00656387	chr3:40428638	ENTPD3	0.43	6.96	0.35	1.7e-11	Renal cell carcinoma;
LIHC	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	0.55	10.39	0.49	3.56e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg20399509	chr21:47717575	C21orf57	-0.37	-5.96	-0.31	6.22e-9	Testicular germ cell tumor;
LIHC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg00204512	chr16:28754710	NA	0.43	7.45	0.37	7.78e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	13.07	0.58	6.15e-32	Hip circumference adjusted for BMI;
LIHC	cis	rs11958404	0.615	rs10053795	chr5:157449185	T/C	cg05962755	chr5:157440814	NA	0.54	6.73	0.34	6.97e-11	IgG glycosylation;
LIHC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg19006947	chr11:64034861	PLCB3	-0.59	-8.5	-0.42	5.97e-16	Body mass index;
LIHC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg12798992	chr6:167411361	FGFR1OP	-0.47	-7.68	-0.38	1.73e-13	Crohn's disease;
LIHC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.58	9.64	0.46	1.27e-19	Height;
LIHC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.45	6.29	0.32	9.72e-10	Obesity-related traits;
LIHC	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.54	-6.97	-0.35	1.6e-11	Type 2 diabetes;
LIHC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	13.05	0.58	7.2e-32	Prudent dietary pattern;
LIHC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.78	0.39	8.74e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.39	-6.93	-0.35	2.16e-11	Schizophrenia;
LIHC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.54	8.42	0.41	1.04e-15	Tumor biomarkers;
LIHC	cis	rs4788570	0.615	rs8053745	chr16:71689693	A/G	cg06353428	chr16:71660113	MARVELD3	1.43	14.99	0.63	2.2e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.79	12.59	0.56	4.04e-30	Breast cancer;
LIHC	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.88	0.57	3.23e-31	Colorectal cancer;
LIHC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg05084668	chr3:125655381	ALG1L	-0.41	-6.39	-0.33	5.28e-10	Blood pressure (smoking interaction);
LIHC	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.47	7.16	0.36	4.9e-12	Cocaine dependence;
LIHC	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	5.74	0.3	2.12e-8	Coronary artery disease;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg15382696	chr6:118971807	C6orf204	0.64	6.24	0.32	1.28e-9	Diastolic blood pressure;
LIHC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23043544	chr7:2124092	MAD1L1	-0.4	-6.3	-0.32	9.28e-10	Bipolar disorder;
LIHC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.83	9.16	0.44	4.85e-18	Vitiligo;
LIHC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg10932868	chr11:921992	NA	0.39	7.27	0.37	2.53e-12	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.21	0.55	1.08e-28	Prudent dietary pattern;
LIHC	trans	rs783540	0.867	rs7167880	chr15:83294436	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.27	-0.32	1.06e-9	Schizophrenia;
LIHC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.53	6.85	0.35	3.35e-11	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.12e-18	Schizophrenia;
LIHC	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	6.94	0.35	1.93e-11	Glycated hemoglobin levels;
LIHC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-6.96	-0.35	1.72e-11	Morning vs. evening chronotype;
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.45	7.23	0.36	3.28e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.42	-0.45	7.15e-19	Electroencephalogram traits;
LIHC	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg06360820	chr2:242988706	NA	-0.91	-12.87	-0.57	3.43e-31	Obesity-related traits;
LIHC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.49	-7.0	-0.35	1.33e-11	Life satisfaction;
LIHC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.54	0.5	1.07e-22	Alzheimer's disease;
LIHC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg04369109	chr6:150039330	LATS1	-0.37	-5.89	-0.3	9.1e-9	Lung cancer;
LIHC	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.57	7.36	0.37	1.42e-12	Schizophrenia;
LIHC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.61	11.47	0.53	5.46e-26	Alzheimer's disease (late onset);
LIHC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-7.43	-0.37	8.85e-13	Cognitive function;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17445840	chr3:101546486	FAM55C;NFKBIZ	0.46	6.94	0.35	1.93e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21467203	chr3:49911342	NA	0.39	6.64	0.34	1.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs273218	1.000	rs274366	chr5:53374636	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.68	10.92	0.51	5.17e-24	Migraine;
LIHC	cis	rs1401454	1.000	rs1401454	chr11:16250183	C/T	cg10927848	chr11:16298618	SOX6	-0.33	-6.15	-0.32	2.21e-9	Blood pressure;
LIHC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.87e-10	Aortic root size;
LIHC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	7.45	0.37	7.9e-13	Schizophrenia;
LIHC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.1	7.92	0.39	3.47e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg26939375	chr7:64535504	NA	0.47	7.13	0.36	5.83e-12	Aortic root size;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg15893493	chr8:124194847	FAM83A	0.89	8.19	0.4	5.44e-15	Urinary uromodulin levels;
LIHC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.7	-0.34	8.85e-11	Migraine;Coronary artery disease;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg11070056	chr1:107600091	PRMT6	0.61	9.62	0.46	1.54e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-6.24	-0.32	1.33e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-23.71	-0.79	3.38e-74	Height;
LIHC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.48	-7.95	-0.4	2.66e-14	Menarche (age at onset);
LIHC	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.23	-5.86	-0.3	1.11e-8	Schizophrenia;
LIHC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg10790698	chr19:18539756	SSBP4	-0.36	-7.35	-0.37	1.49e-12	Breast cancer;
LIHC	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.29	6.06	0.31	3.54e-9	Pulmonary function;
LIHC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.89	-0.39	4.23e-14	Schizophrenia;
LIHC	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.66	8.34	0.41	1.85e-15	Corneal astigmatism;
LIHC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.88	-0.47	2.03e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.91	11.44	0.53	7.06e-26	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09755102	chr1:33283495	S100PBP;YARS	0.42	6.56	0.33	1.98e-10	Pancreatic cancer;
LIHC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.95	0.31	6.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg05941027	chr17:61774174	LIMD2	0.29	5.81	0.3	1.46e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.44	6.79	0.34	4.88e-11	Methadone dose in opioid dependence;
LIHC	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg00277334	chr10:82204260	NA	-0.55	-6.98	-0.35	1.53e-11	Post bronchodilator FEV1;
LIHC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.48	7.46	0.37	7.41e-13	Blood protein levels;
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.38	-5.83	-0.3	1.31e-8	Testicular germ cell tumor;
LIHC	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	5.97	0.31	5.96e-9	Response to antipsychotic treatment;
LIHC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21467203	chr3:49911342	NA	0.44	7.83	0.39	6.17e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.76	-10.14	-0.48	2.66e-21	Schizophrenia;
LIHC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.58	5.86	0.3	1.09e-8	Crohn's disease;
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.49	7.87	0.39	4.75e-14	Testicular germ cell tumor;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20132801	chr8:48172283	KIAA0146	0.43	6.52	0.33	2.55e-10	Immature fraction of reticulocytes;
LIHC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.74	7.71	0.38	1.41e-13	Vitiligo;
LIHC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	trans	rs36022378	0.504	rs4688688	chr3:50042690	C/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.66	-0.34	1.1e-10	Diastolic blood pressure;
LIHC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	1.03	15.33	0.64	9.68e-41	Breast cancer;
LIHC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg18944383	chr4:111397179	ENPEP	-0.34	-7.82	-0.39	6.4e-14	Height;
LIHC	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg27205649	chr11:78285834	NARS2	0.38	5.94	0.31	6.97e-9	Alzheimer's disease (survival time);
LIHC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-1.01	-20.16	-0.74	4.04e-60	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.25	0.32	1.23e-9	Renal cell carcinoma;
LIHC	trans	rs62103177	0.564	rs59188178	chr18:77723435	T/C	cg05926928	chr17:57297772	GDPD1	0.65	6.95	0.35	1.83e-11	Opioid sensitivity;
LIHC	cis	rs7818688	0.654	rs75680386	chr8:95986148	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	6.49	0.33	2.99e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.57	-0.46	2.16e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg00142150	chr22:38071001	LGALS1	0.63	8.18	0.4	5.5e-15	Fat distribution (HIV);
LIHC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.32	6.41	0.33	4.74e-10	Renal cell carcinoma;
LIHC	trans	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.58	-6.05	-0.31	3.88e-9	Hair shape;
LIHC	trans	rs3783890	1.000	rs12885232	chr14:93771020	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.25	0.32	1.24e-9	Body mass index;
LIHC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.31	-0.32	8.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.37	-0.41	1.53e-15	Total cholesterol levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17513182	chr1:153894941	GATAD2B	0.46	6.76	0.34	6.01e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.69	11.65	0.53	1.22e-26	Crohn's disease;
LIHC	cis	rs1144333	0.655	rs11162053	chr1:76470267	A/C	cg10523679	chr1:76189770	ACADM	0.44	6.19	0.32	1.73e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-7.9	-0.39	3.81e-14	Longevity;
LIHC	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg17456097	chr1:26900765	RPS6KA1	0.39	5.83	0.3	1.26e-8	Glucose homeostasis traits;
LIHC	cis	rs57590327	0.679	rs35395999	chr3:81613013	T/C	cg07356753	chr3:81810745	GBE1	-0.48	-6.5	-0.33	2.89e-10	Extraversion;
LIHC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.56	-9.29	-0.45	1.79e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg02344993	chr17:57696989	CLTC	0.73	12.38	0.56	2.54e-29	Hemoglobin concentration;
LIHC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.02	-15.06	-0.63	1.13e-39	Ulcerative colitis;
LIHC	cis	rs36051895	0.623	rs1120679	chr9:5248073	C/G	cg02405213	chr9:5042618	JAK2	-0.63	-10.38	-0.49	3.95e-22	Pediatric autoimmune diseases;
LIHC	cis	rs2637266	0.655	rs846628	chr10:78538392	G/A	cg18941641	chr10:78392320	NA	0.29	6.21	0.32	1.53e-9	Pulmonary function;
LIHC	cis	rs4575098	0.681	rs10797093	chr1:161103445	T/G	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.4	7.4	0.37	1.03e-12	Monocyte percentage of white cells;
LIHC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.79	-14.05	-0.6	1.01e-35	Coronary artery disease;
LIHC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.2e-8	Vitiligo;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18905668	chr11:18388147	GTF2H1	0.41	7.03	0.36	1.16e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.46	-0.74	2.51e-61	Height;
LIHC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.42	5.77	0.3	1.76e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.42	0.45	7.2e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs55665837	0.701	rs11023272	chr11:14630370	T/C	cg00085434	chr11:14927489	NA	0.43	6.03	0.31	4.36e-9	Vitamin D levels;
LIHC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.56	0.56	4.96e-30	Schizophrenia;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg16103275	chr6:290800	DUSP22	0.51	6.58	0.34	1.81e-10	Menopause (age at onset);
LIHC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.29	0.66	1.51e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-7.62	-0.38	2.51e-13	Lymphocyte counts;
LIHC	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.52	-8.64	-0.42	2.2e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.57	9.47	0.46	4.9e-19	Colorectal cancer;
LIHC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs9921222	0.692	rs11860497	chr16:405416	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.54	11.29	0.52	2.51e-25	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.62	0.38	2.49e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.98	0.54	7.2e-28	Prudent dietary pattern;
LIHC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.47	-6.82	-0.35	4.17e-11	Corneal structure;
LIHC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16346588	chr10:242978	ZMYND11	0.38	5.88	0.3	9.83e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	6.24	0.32	1.33e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.47	6.23	0.32	1.36e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg17509989	chr5:176798049	RGS14	0.82	11.51	0.53	4.01e-26	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.2e-22	Cognitive function;
LIHC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs6466055	0.777	rs3779210	chr7:104828098	C/T	cg04380332	chr7:105027541	SRPK2	-0.35	-6.68	-0.34	9.74e-11	Schizophrenia;
LIHC	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.88	0.43	3.74e-17	Exhaled nitric oxide output;
LIHC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.8	-14.37	-0.61	5.82e-37	Refractive error;
LIHC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg17135325	chr3:160939158	NMD3	0.57	8.15	0.4	6.73e-15	Parkinson's disease;
LIHC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.49	-7.27	-0.37	2.5e-12	Breast size;
LIHC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.52	8.01	0.4	1.82e-14	Resting heart rate;
LIHC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.38	-8.13	-0.4	7.79e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.25	0.32	1.2e-9	Renal cell carcinoma;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg21522988	chr12:29376872	FAR2	0.3	6.84	0.35	3.59e-11	QT interval;
LIHC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.56	7.49	0.38	6.02e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs1865721	1.000	rs8094181	chr18:73193976	T/A	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg18180155	chr22:45809454	SMC1B;RIBC2	0.56	6.21	0.32	1.54e-9	Tonsillectomy;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.73	-10.74	-0.5	2.19e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19404433	chr20:21695773	PAX1	0.39	6.19	0.32	1.68e-9	Pancreatic cancer;
LIHC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.67	11.26	0.52	3.25e-25	Menopause (age at onset);
LIHC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg18306943	chr3:40428807	ENTPD3	0.34	5.77	0.3	1.81e-8	Renal cell carcinoma;
LIHC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.82	12.99	0.57	1.28e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.8	8.26	0.41	3.22e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.38	6.54	0.33	2.31e-10	Schizophrenia;
LIHC	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg27205649	chr11:78285834	NARS2	0.4	6.11	0.31	2.71e-9	Alzheimer's disease (survival time);
LIHC	cis	rs12702595	0.875	rs2108783	chr7:7266867	A/C	cg04827551	chr7:7268805	C1GALT1	-0.36	-6.64	-0.34	1.26e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.53	12.32	0.55	4.1e-29	Skin aging (microtopography measurement);
LIHC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-7.89	-0.39	4.11e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.58	10.28	0.49	8.6e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg21466736	chr12:48725269	NA	-0.7	-10.65	-0.5	4.47e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	10.8	0.5	1.33e-23	Personality dimensions;
LIHC	cis	rs7487075	0.554	rs7957777	chr12:46628789	A/C	cg15584813	chr12:47219626	SLC38A4	0.31	5.72	0.3	2.32e-8	Itch intensity from mosquito bite;
LIHC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.95	20.48	0.74	2.05e-61	Blood protein levels;
LIHC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.11	13.05	0.58	7.07e-32	Vitiligo;
LIHC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.72	10.26	0.48	1.07e-21	Selective IgA deficiency;
LIHC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-9.78	-0.47	4.42e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.39	7.07	0.36	8.62e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs114532231	0.661	rs12617962	chr2:86513102	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.67	6.97	0.35	1.65e-11	Asymmetrical dimethylarginine levels;
LIHC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg22532475	chr10:104410764	TRIM8	0.36	6.37	0.33	6.16e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.74	10.9	0.51	6.12e-24	Corneal astigmatism;
LIHC	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg07636037	chr3:49044803	WDR6	-0.55	-6.19	-0.32	1.77e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.38	-7.06	-0.36	9.22e-12	Height;
LIHC	cis	rs11687659	0.515	rs6725611	chr2:191579025	G/A	cg10560079	chr2:191398806	TMEM194B	-0.41	-5.72	-0.3	2.35e-8	Immature fraction of reticulocytes;
LIHC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.25	5.96	0.31	6.16e-9	Primary biliary cholangitis;
LIHC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.37	5.96	0.31	6.32e-9	Menopause (age at onset);
LIHC	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg00091569	chr3:40428383	ENTPD3	-0.4	-6.79	-0.34	4.83e-11	Renal cell carcinoma;
LIHC	cis	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg01864836	chr14:55583639	NA	-0.38	-6.37	-0.33	6.03e-10	Protein biomarker;
LIHC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg03013999	chr17:37608204	MED1	-0.34	-5.76	-0.3	1.91e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg09835421	chr16:68378352	PRMT7	-0.8	-9.62	-0.46	1.46e-19	Schizophrenia;
LIHC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.74	-0.3	2.04e-8	Colorectal cancer;
LIHC	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.68	8.49	0.42	6.36e-16	Corneal astigmatism;
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.66	-10.12	-0.48	3.1e-21	Renal cell carcinoma;
LIHC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.66	-0.34	1.1e-10	Bipolar disorder;
LIHC	cis	rs509477	0.718	rs273342	chr18:32604956	G/A	cg23791764	chr18:32556832	MAPRE2	0.45	6.16	0.32	2.08e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg13409248	chr3:40428643	ENTPD3	0.5	8.43	0.41	9.5e-16	Renal cell carcinoma;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.68	-0.42	1.69e-16	Lymphocyte counts;
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg20399509	chr21:47717575	C21orf57	-0.36	-5.87	-0.3	1.04e-8	Testicular germ cell tumor;
LIHC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.89	0.35	2.62e-11	Heart rate;
LIHC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg22633049	chr21:46681294	NA	-0.37	-6.48	-0.33	3.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs807029	0.577	rs3740488	chr10:102754033	A/T	cg25179470	chr10:102756915	LZTS2	0.45	6.41	0.33	4.93e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.97	-0.44	1.96e-17	Skin colour saturation;
LIHC	cis	rs10242455	0.850	rs57367781	chr7:99116819	G/A	cg18809830	chr7:99032528	PTCD1	-0.83	-6.45	-0.33	3.72e-10	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17562763	chr11:67398026	NUDT8	0.57	7.42	0.37	9.44e-13	Lung function (FEV1/FVC);
LIHC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.43	11.34	0.52	1.6e-25	Cutaneous nevi;
LIHC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.66	-13.05	-0.58	7.23e-32	Body mass index;
LIHC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.76	-13.09	-0.58	4.99e-32	QRS duration;
LIHC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.23	0.52	3.93e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg06289844	chr6:126071538	HEY2	0.36	6.44	0.33	3.93e-10	Brugada syndrome;
LIHC	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	0.66	6.53	0.33	2.32e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg25364880	chr3:44379878	C3orf23	0.59	8.13	0.4	7.83e-15	Depressive symptoms;
LIHC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.37	-6.23	-0.32	1.34e-9	Educational attainment;
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.4	0.33	5.22e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.53	0.59	1.05e-33	Coffee consumption (cups per day);
LIHC	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.93	-12.67	-0.57	2.02e-30	Post bronchodilator FEV1;
LIHC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.55	9.8	0.47	3.91e-20	Coronary artery disease;
LIHC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.07	-0.4	1.21e-14	Monocyte percentage of white cells;
LIHC	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg10820045	chr2:198174542	NA	0.47	6.97	0.35	1.6e-11	Dermatomyositis;
LIHC	cis	rs16828019	0.852	rs71648536	chr1:41632008	T/A	cg03962019	chr1:41807865	NA	0.53	7.73	0.39	1.25e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.8	17.31	0.68	1.18e-48	Gestational age at birth (maternal effect);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27120934	chr6:129480619	LAMA2	0.35	6.39	0.33	5.33e-10	Cognitive function;
LIHC	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg26931527	chr16:83979911	NA	0.61	5.8	0.3	1.54e-8	Pursuit maintenance gain;
LIHC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-5.77	-0.3	1.8e-8	Personality dimensions;
LIHC	cis	rs400736	0.637	rs2300428	chr1:7996894	A/G	cg25007680	chr1:8021821	PARK7	-0.44	-6.88	-0.35	2.82e-11	Response to antidepressants and depression;
LIHC	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg10820045	chr2:198174542	NA	0.48	7.29	0.37	2.18e-12	Dermatomyositis;
LIHC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	7.47	0.37	6.8e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	trans	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg26939375	chr7:64535504	NA	-0.43	-6.63	-0.34	1.3e-10	Aortic root size;
LIHC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.69	10.52	0.49	1.34e-22	Urate levels in obese individuals;
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.19	-0.32	1.72e-9	Total body bone mineral density;
LIHC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg09835421	chr16:68378352	PRMT7	0.83	9.8	0.47	3.91e-20	Schizophrenia;
LIHC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	6.23	0.32	1.37e-9	Coronary artery disease;
LIHC	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.84	-0.3	1.19e-8	Neuroticism;
LIHC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.57	7.82	0.39	6.75e-14	Blood metabolite levels;
LIHC	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.3	6.42	0.33	4.64e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	8.65	0.42	2.01e-16	Obesity-related traits;
LIHC	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.17	-0.32	1.98e-9	Coronary artery disease;
LIHC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	6.06e-9	Menopause (age at onset);
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.61	11.29	0.52	2.36e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02996314	chr1:32479425	KHDRBS1	0.45	6.36	0.33	6.56e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-6.71	-0.34	7.87e-11	Breast cancer;
LIHC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.97	-9.8	-0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.86e-11	Dermatomyositis;
LIHC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.86	12.95	0.57	1.73e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.45	0.42	8.22e-16	Platelet count;
LIHC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.82	-0.35	4.15e-11	Height;
LIHC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg00612595	chr21:47717864	NA	-0.37	-5.99	-0.31	5.44e-9	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.33	2.39e-10	Vitiligo;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.09	-0.4	1.07e-14	Lymphocyte counts;
LIHC	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.48e-9	Cognitive performance;
LIHC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.35	-5.94	-0.31	6.99e-9	Alzheimer's disease (late onset);
LIHC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.54	6.71	0.34	7.89e-11	Menarche (age at onset);
LIHC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.93	0.51	4.9e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.93	-16.28	-0.66	1.63e-44	Oral cavity cancer;
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg26570765	chr4:1273065	NA	0.29	5.73	0.3	2.19e-8	Obesity-related traits;
LIHC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg16226627	chr15:75307476	SCAMP5	0.55	9.62	0.46	1.49e-19	Lung cancer;
LIHC	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.52	10.04	0.48	5.86e-21	Multiple myeloma;
LIHC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.85	10.18	0.48	1.99e-21	Cognitive function;
LIHC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.73	-0.34	7.14e-11	Response to antipsychotic treatment;
LIHC	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg12560992	chr17:57184187	TRIM37	0.65	8.2	0.41	4.87e-15	Vitamin D levels;
LIHC	cis	rs903552	1.000	rs8043379	chr15:102005837	A/G	cg25677261	chr15:102009856	PCSK6	-0.46	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg11161837	chr1:110010384	SYPL2	0.47	6.35	0.32	6.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg05714579	chr10:131428358	MGMT	0.41	6.67	0.34	1.01e-10	Response to temozolomide;
LIHC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.69	11.89	0.54	1.58e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02732134	chr10:101732382	DNMBP	-0.52	-8.05	-0.4	1.34e-14	Lung function (FEV1/FVC);
LIHC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.46	0.59	2.05e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.69	11.66	0.53	1.08e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg09990169	chr2:241835740	C2orf54	-0.71	-11.47	-0.53	5.37e-26	Urinary metabolites;
LIHC	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg04450003	chr12:50355995	AQP5	0.59	7.17	0.36	4.76e-12	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.53	8.54	0.42	4.35e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg05043794	chr9:111880884	C9orf5	-0.23	-5.91	-0.3	8.44e-9	Menarche (age at onset);
LIHC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.61	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	trans	rs2209875	1.000	rs7850776	chr9:91817364	T/C	cg26057616	chr1:222234397	NA	0.37	6.18	0.32	1.8e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs903552	0.736	rs9806495	chr15:102008059	G/A	cg04789225	chr15:102009795	PCSK6	-0.46	-6.04	-0.31	3.94e-9	Diabetic kidney disease;
LIHC	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.42	6.42	0.33	4.56e-10	Neutrophil percentage of white cells;
LIHC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3015497	0.653	rs2356456	chr14:51093216	A/T	cg09863266	chr14:51125203	SAV1	-0.4	-6.43	-0.33	4.26e-10	Mean platelet volume;
LIHC	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg26395211	chr5:140044315	WDR55	-0.43	-6.35	-0.32	6.88e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-5.8	-0.3	1.54e-8	Monocyte percentage of white cells;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12516959	chr21:47718080	NA	-0.37	-5.86	-0.3	1.06e-8	Testicular germ cell tumor;
LIHC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.59	-0.34	1.66e-10	Response to antipsychotic treatment;
LIHC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.62	8.28	0.41	2.83e-15	Neutrophil percentage of white cells;
LIHC	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-6.48	-0.33	3.13e-10	Intracranial aneurysm;
LIHC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.31	-0.45	1.65e-18	Bipolar disorder;
LIHC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.78	13.45	0.59	2.21e-33	Aortic root size;
LIHC	cis	rs963731	0.649	rs79361942	chr2:39336315	G/A	cg04010122	chr2:39346883	SOS1	0.67	5.99	0.31	5.28e-9	Corticobasal degeneration;
LIHC	cis	rs9443189	0.762	rs2748955	chr6:76464302	C/G	cg01950844	chr6:76311363	SENP6	-0.53	-6.39	-0.33	5.34e-10	Prostate cancer;
LIHC	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.27	6.4	0.33	5.23e-10	Heart rate;
LIHC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg25356066	chr3:128598488	ACAD9	0.56	7.77	0.39	8.97e-14	IgG glycosylation;
LIHC	cis	rs9543976	1.000	rs2296146	chr13:76143572	T/C	cg01531495	chr13:76123901	UCHL3	-0.52	-6.16	-0.32	1.99e-9	Diabetic retinopathy;
LIHC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg02297831	chr4:17616191	MED28	0.43	6.79	0.34	5.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg08126542	chr6:37504118	NA	-0.37	-6.32	-0.32	8.26e-10	Cognitive performance;
LIHC	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.42	6.43	0.33	4.25e-10	Neutrophil percentage of white cells;
LIHC	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg06598544	chr20:61472147	COL9A3	-0.68	-6.68	-0.34	9.92e-11	Obesity-related traits;
LIHC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.78	0.43	8.02e-17	Eosinophil percentage of white cells;
LIHC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.23	-0.45	2.95e-18	Heart rate;
LIHC	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.38	6.11	0.31	2.71e-9	Metabolite levels;
LIHC	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	1.11	9.76	0.47	5.07e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.41	-5.72	-0.3	2.27e-8	Menopause (age at onset);
LIHC	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.68	-0.5	3.47e-23	Inflammatory bowel disease;
LIHC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.73	0.3	2.25e-8	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11347316	chr11:18343657	GTF2H1;HPS5	0.51	7.22	0.36	3.5e-12	Lung function (FEV1/FVC);
LIHC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.22	-0.36	3.3e-12	Longevity;
LIHC	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.58	9.59	0.46	1.9e-19	Corneal astigmatism;
LIHC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-1.13	-12.71	-0.57	1.4e-30	White matter hyperintensity burden;
LIHC	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg27205649	chr11:78285834	NARS2	0.43	6.34	0.32	7.15e-10	Alzheimer's disease (survival time);
LIHC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.87	0.39	4.6e-14	Motion sickness;
LIHC	cis	rs12744310	0.887	rs28541673	chr1:41781994	A/G	cg03962019	chr1:41807865	NA	0.39	6.23	0.32	1.36e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.6	7.67	0.38	1.83e-13	Morning vs. evening chronotype;
LIHC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	10.78	0.5	1.56e-23	Menarche (age at onset);
LIHC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg17724175	chr1:150552817	MCL1	0.41	8.05	0.4	1.34e-14	Melanoma;
LIHC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.92	0.3	7.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.34	-5.97	-0.31	6.05e-9	IgG glycosylation;
LIHC	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	8.86	0.43	4.35e-17	Electroencephalogram traits;
LIHC	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.73	-9.98	-0.47	9.57e-21	Personality dimensions;
LIHC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.86	0.3	1.09e-8	Bipolar disorder;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.67	0.53	1.03e-26	Prudent dietary pattern;
LIHC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.7	12.84	0.57	4.75e-31	Dental caries;
LIHC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	15.91	0.65	4.72e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.62	-10.04	-0.48	5.81e-21	Platelet count;
LIHC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.54	-7.66	-0.38	1.92e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LIHC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-6.63	-0.34	1.3100000000000001e-10	Blood metabolite levels;
LIHC	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.27	-6.5	-0.33	2.8e-10	Colorectal cancer;
LIHC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.79	-0.5	1.51e-23	Mean corpuscular volume;
LIHC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	trans	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs11627756	0.915	rs11850368	chr14:103131770	G/C	cg12046867	chr14:103022105	NA	0.39	5.93	0.31	7.27e-9	Mean platelet volume;
LIHC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg18357526	chr6:26021779	HIST1H4A	0.58	8.01	0.4	1.85e-14	Blood metabolite levels;
LIHC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.17	-0.32	1.92e-9	Menarche (age at onset);
LIHC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.56	-7.65	-0.38	2.09e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.73	0.3	2.18e-8	Electroencephalogram traits;
LIHC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	0.94	9.16	0.44	4.77e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.2	-0.32	1.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg20991723	chr1:152506922	NA	0.52	8.81	0.43	6.54e-17	Hair morphology;
LIHC	cis	rs2073300	1.000	rs59283536	chr20:23457575	A/T	cg12062639	chr20:23401060	NAPB	0.78	9.7	0.46	8.37e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	5.78	0.3	1.69e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.61	-8.76	-0.43	9.02e-17	Response to antineoplastic agents;
LIHC	cis	rs17253792	0.545	rs71412688	chr14:56021539	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-6.11	-0.31	2.74e-9	Putamen volume;
LIHC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.65	-0.5	4.52e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.43	-5.96	-0.31	6.12e-9	Total body bone mineral density;
LIHC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.62	10.58	0.5	8.03e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2386661	0.826	rs1317516	chr10:5672720	A/G	cg17085576	chr10:5658249	NA	0.36	5.82	0.3	1.39e-8	Breast cancer;
LIHC	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.67	-11.34	-0.52	1.65e-25	Pediatric autoimmune diseases;
LIHC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.7	0.43	1.39e-16	Menarche (age at onset);
LIHC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.46	0.49	2.1e-22	Bladder cancer;
LIHC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.33	-0.37	1.64e-12	Type 2 diabetes;
LIHC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.54	7.92	0.39	3.36e-14	Longevity;Endometriosis;
LIHC	cis	rs6445525	0.967	rs2060022	chr3:65999755	A/G	cg06109867	chr3:66002991	MAGI1	-0.32	-5.76	-0.3	1.83e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs12980942	0.591	rs3760660	chr19:41769025	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.58	7.08	0.36	8.28e-12	Coronary artery disease;
LIHC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-1.06	-12.94	-0.57	1.97e-31	Eosinophil percentage of granulocytes;
LIHC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg03037974	chr15:76606532	NA	0.76	14.82	0.63	1.04e-38	Blood metabolite levels;
LIHC	trans	rs13325613	0.915	rs34677490	chr3:46270748	G/T	cg26337592	chr1:153642686	ILF2	0.68	6.18	0.32	1.81e-9	Monocyte count;
LIHC	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg05110241	chr16:68378359	PRMT7	-0.49	-5.96	-0.31	6.44e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21747090	chr2:27597821	SNX17	-0.47	-7.19	-0.36	4.15e-12	Total body bone mineral density;
LIHC	trans	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.22e-9	Lewy body disease;
LIHC	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.28	-0.32	1.06e-9	Gout;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06500355	chr6:111804104	REV3L	-0.38	-6.5	-0.33	2.91e-10	Triglycerides;
LIHC	cis	rs1475718	0.526	rs7848481	chr9:137120661	T/C	cg21243944	chr9:137118148	NA	-0.44	-6.07	-0.31	3.42e-9	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.84	11.33	0.52	1.72e-25	Blood metabolite levels;
LIHC	cis	rs10508774	0.810	rs13377150	chr10:32855857	A/G	cg01819863	chr10:32635814	EPC1	0.61	5.83	0.3	1.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg18219878	chr12:19459468	PLEKHA5	0.41	6.17	0.32	1.89e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.48	-7.01	-0.35	1.29e-11	Height;
LIHC	cis	rs11958404	0.615	rs10058832	chr5:157431866	T/A	cg05962755	chr5:157440814	NA	0.63	8.24	0.41	3.77e-15	IgG glycosylation;
LIHC	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.27	5.93	0.31	7.36e-9	Pulmonary function;
LIHC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	trans	rs75804782	0.521	rs55973123	chr2:239416264	G/A	cg01134436	chr17:81009848	B3GNTL1	0.62	6.24	0.32	1.26e-9	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.34	-0.45	1.31e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.53	6.85	0.35	3.43e-11	Resting heart rate;
LIHC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.8	0.35	4.74e-11	Ileal carcinoids;
LIHC	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg17623882	chr6:41773611	USP49	0.44	6.02	0.31	4.48e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs9549328	0.879	rs12428058	chr13:113636504	G/A	cg18289306	chr13:113640169	MCF2L	0.43	6.87	0.35	3.05e-11	Systolic blood pressure;
LIHC	trans	rs7874142	0.606	rs10776904	chr9:137689624	C/A	cg18109838	chr5:88185987	MEF2C	-0.38	-7.48	-0.37	6.52e-13	Longevity;
LIHC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.72	-12.37	-0.56	2.74e-29	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.22	6.02	0.31	4.4e-9	Calcium levels;
LIHC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21448741	chr8:58168803	NA	0.38	6.12	0.31	2.54e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.55	-9.47	-0.46	4.82e-19	Reticulocyte count;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.52	8.07	0.4	1.19e-14	Longevity;Endometriosis;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.7	10.89	0.51	6.51e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.46	7.06	0.36	9.36e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg11764359	chr7:65958608	NA	0.59	5.84	0.3	1.21e-8	Diabetic kidney disease;
LIHC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg10096929	chr1:156261403	TMEM79	0.35	5.79	0.3	1.56e-8	Tonsillectomy;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.31	-0.37	1.96e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.53	0.42	4.87e-16	Initial pursuit acceleration;
LIHC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg19635926	chr16:89946313	TCF25	0.49	6.21	0.32	1.5e-9	Skin colour saturation;
LIHC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.48	7.18	0.36	4.44e-12	Platelet distribution width;
LIHC	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06360820	chr2:242988706	NA	-0.83	-13.0	-0.57	1.16e-31	Obesity-related traits;
LIHC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7.06e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.15	0.58	2.92e-32	Prudent dietary pattern;
LIHC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.53	-0.53	3.3e-26	Chronic sinus infection;
LIHC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.58	0.5	8.39e-23	Total body bone mineral density;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.45	-6.22	-0.32	1.49e-9	Total body bone mineral density;
LIHC	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.25	-0.32	1.21e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.98	-0.35	1.55e-11	Obesity-related traits;
LIHC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.71	9.3	0.45	1.76e-18	Gut microbiome composition (summer);
LIHC	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.25	6.31	0.32	8.63e-10	Menarche (age at onset);
LIHC	trans	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg15676719	chr1:167598521	RCSD1	0.34	6.3	0.32	9.17e-10	Systemic lupus erythematosus;
LIHC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.49	-5.91	-0.3	8.14e-9	Parkinson's disease;
LIHC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	trans	rs7721647	0.810	rs72771538	chr5:90797727	G/A	cg10859192	chr12:54071672	ATP5G2	-0.41	-6.07	-0.31	3.34e-9	Breast cancer;
LIHC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.77	12.92	0.57	2.32e-31	Oral cavity cancer;
LIHC	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.5	9.49	0.46	4.03e-19	Testicular germ cell tumor;
LIHC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.69	0.59	2.64e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs11233413	0.508	rs10898066	chr11:82680867	A/C	cg24227371	chr11:82718527	RAB30	0.3	6.72	0.34	7.42e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg14440974	chr22:39074834	NA	0.43	7.15	0.36	5.38e-12	Menopause (age at onset);
LIHC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.89	-15.52	-0.64	1.66e-41	Aortic root size;
LIHC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.84	0.35	3.7e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.62	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg00800038	chr16:89945340	TCF25	-0.63	-9.48	-0.46	4.32e-19	Skin colour saturation;
LIHC	cis	rs611744	0.967	rs598022	chr8:109187759	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg11693508	chr17:37793320	STARD3	0.73	7.38	0.37	1.23e-12	Bipolar disorder;
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.3	0.37	2e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg18016565	chr1:150552671	MCL1	0.54	10.05	0.48	5.25e-21	Melanoma;
LIHC	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	6.17	0.32	1.92e-9	Ileal carcinoids;
LIHC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.56	0.64	1.2e-41	Chronic sinus infection;
LIHC	trans	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18070394	chr4:2470786	RNF4	0.39	6.1	0.31	2.92e-9	Height;
LIHC	cis	rs4908768	0.817	rs11587482	chr1:8743195	T/G	cg20416874	chr1:8611966	RERE	0.51	7.27	0.37	2.48e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.72	-0.5	2.52e-23	Total cholesterol levels;
LIHC	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg01364799	chr7:75623366	TMEM120A	0.51	7.81	0.39	6.99e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	1.0	16.01	0.65	1.95e-43	Body mass index;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg15383120	chr6:291909	DUSP22	-0.48	-6.31	-0.32	8.68e-10	Menopause (age at onset);
LIHC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg14222432	chr12:29376421	FAR2	-0.38	-7.34	-0.37	1.55e-12	QT interval;
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg03785755	chr6:26196794	NA	0.5	5.88	0.3	9.89e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg19752551	chr11:57585705	CTNND1	-0.47	-6.04	-0.31	4.02e-9	Schizophrenia;
LIHC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	8.59	0.42	3.12e-16	Platelet count;
LIHC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.5	9.55	0.46	2.63e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	7.77	0.39	9.12e-14	Schizophrenia;
LIHC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.79	-0.3	1.63e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	7.04	0.36	1.06e-11	Lung cancer;
LIHC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.86	12.96	0.57	1.53e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	13.38	0.59	3.93e-33	Primary sclerosing cholangitis;
LIHC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.6	10.72	0.5	2.54e-23	Mean corpuscular volume;
LIHC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs273218	1.000	rs156442	chr5:53373029	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.67	10.92	0.51	5.1e-24	Migraine;
LIHC	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg07423050	chr13:99094983	FARP1	0.34	5.75	0.3	1.96e-8	Longevity;
LIHC	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg27432699	chr2:27873401	GPN1	-0.81	-13.22	-0.58	1.68e-32	Oral cavity cancer;
LIHC	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.11e-27	IgG glycosylation;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.95	14.57	0.62	9.87e-38	Skin colour saturation;
LIHC	cis	rs611744	0.967	rs684093	chr8:109199355	G/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.85	-0.3	1.15e-8	Pulse pressure;
LIHC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.71	11.58	0.53	2.13e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs17428076	0.793	rs56275355	chr2:172710180	G/A	cg13550731	chr2:172543902	DYNC1I2	0.39	6.34	0.32	7.36e-10	Myopia;
LIHC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26897989	chr16:1907736	C16orf73	-0.5	-6.43	-0.33	4.3e-10	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.81	0.43	6.36e-17	Lung cancer;
LIHC	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	0.83	11.92	0.54	1.27e-27	Left atrial antero-posterior diameter;
LIHC	cis	rs7165170	0.678	rs12593759	chr15:91202601	C/T	cg26821196	chr15:91095069	CRTC3	0.39	7.09	0.36	7.85e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.63	0.53	1.49e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg10621924	chr7:39171070	POU6F2	0.37	5.81	0.3	1.44e-8	IgG glycosylation;
LIHC	cis	rs11191270	0.554	rs11191274	chr10:104140350	G/A	cg15320455	chr10:103880129	LDB1	1.05	7.74	0.39	1.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	1.000	rs10793016	chr11:71755063	A/G	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg00612595	chr21:47717864	NA	0.38	6.24	0.32	1.27e-9	Testicular germ cell tumor;
LIHC	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.6	9.54	0.46	2.82e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs9993613	0.967	rs6834847	chr4:73436595	T/G	cg15102770	chr4:73434591	ADAMTS3	-0.39	-6.21	-0.32	1.5e-9	Hip circumference adjusted for BMI;Height;
LIHC	trans	rs783540	0.846	rs2099259	chr15:83323688	C/T	cg18393722	chr15:85113863	UBE2QP1	0.38	6.49	0.33	2.94e-10	Schizophrenia;
LIHC	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg20129853	chr10:51489980	NA	-0.42	-9.1	-0.44	7.71e-18	Prostate-specific antigen levels;
LIHC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.49	6.27	0.32	1.09e-9	Alzheimer's disease;
LIHC	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg20636351	chr8:55087400	NA	-0.37	-7.58	-0.38	3.26e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg16797656	chr11:68205561	LRP5	0.55	8.78	0.43	7.81e-17	Total body bone mineral density;
LIHC	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.84	-0.3	1.24e-8	Biliary atresia;
LIHC	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.79	0.71	1.31e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.7	-9.09	-0.44	8.25e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg00908766	chr1:109817496	CELSR2	0.44	7.67	0.38	1.75e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.56	8.46	0.42	7.75e-16	Resting heart rate;
LIHC	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.34	7.69	0.38	1.61e-13	Blood metabolite ratios;
LIHC	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.41	-5.78	-0.3	1.71e-8	Large artery stroke;
LIHC	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08555112	chr17:48942811	TOB1	0.46	6.38	0.33	5.68e-10	Pancreatic cancer;
LIHC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg05110241	chr16:68378359	PRMT7	-0.63	-6.85	-0.35	3.34e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	-0.46	-7.21	-0.36	3.51e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.25	-0.36	2.89e-12	Longevity;
LIHC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg12560992	chr17:57184187	TRIM37	0.54	7.38	0.37	1.19e-12	Cognitive test performance;
LIHC	cis	rs9341808	0.529	rs9352826	chr6:81059371	C/T	cg08355045	chr6:80787529	NA	0.35	6.98	0.35	1.53e-11	Sitting height ratio;
LIHC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	5.8e-20	Corneal astigmatism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10668512	chr15:42565522	GANC;TMEM87A	0.45	7.05	0.36	1.01e-11	Cognitive function;
LIHC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs8081395	0.801	rs12938273	chr17:57901652	G/A	cg13753209	chr17:57696993	CLTC	-0.48	-7.45	-0.37	7.59e-13	White blood cell count;
LIHC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.34	0.52	1.59e-25	Coronary artery disease;
LIHC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-9.0	-0.44	1.61e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg25358938	chr8:29940886	TMEM66	-0.56	-6.09	-0.31	3.05e-9	Obesity-related traits;
LIHC	cis	rs1211375	0.606	rs1203977	chr16:256278	A/C	cg08400316	chr16:204221	HBZ	-0.37	-6.03	-0.31	4.21e-9	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg22771759	chr13:24902376	NA	0.35	6.67	0.34	1e-10	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.33	-6.81	-0.35	4.5e-11	Renal cell carcinoma;
LIHC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.59	-0.38	3.1e-13	Chronic sinus infection;
LIHC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.67	-10.11	-0.48	3.36e-21	Parkinson's disease;
LIHC	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.54	-12.93	-0.57	2.05e-31	White blood cell count (basophil);
LIHC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg12798992	chr6:167411361	FGFR1OP	0.42	6.37	0.33	6.06e-10	Primary biliary cholangitis;
LIHC	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.12	8.54	0.42	4.32e-16	Arsenic metabolism;
LIHC	cis	rs7474896	1.000	rs11011339	chr10:37996346	C/A	cg25427524	chr10:38739819	LOC399744	-0.5	-6.27	-0.32	1.07e-9	Obesity (extreme);
LIHC	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.74	12.97	0.57	1.44e-31	Eosinophil percentage of white cells;
LIHC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.59	0.34	1.62e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs918629	0.567	rs4642392	chr5:95255379	A/G	cg10483112	chr5:95245456	ELL2	0.37	7.0	0.35	1.34e-11	IgG glycosylation;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.1	0.36	7.42e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.86	-0.3	1.09e-8	Calcium levels;
LIHC	cis	rs273218	0.951	rs428213	chr5:53382790	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.61	-9.6	-0.46	1.78e-19	Migraine;
LIHC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.6	11.78	0.54	4.02e-27	Tonsillectomy;
LIHC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.86	14.94	0.63	3.27e-39	Headache;
LIHC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg00142150	chr22:38071001	LGALS1	0.43	7.31	0.37	1.95e-12	Fat distribution (HIV);
LIHC	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	9.47	0.46	4.92e-19	Schizophrenia;
LIHC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs1712517	0.771	rs11191676	chr10:105155066	C/A	cg05636881	chr10:105038444	INA	0.48	7.41	0.37	9.96e-13	Migraine;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06434972	chr7:44122219	POLM	0.46	7.45	0.37	7.54e-13	Cognitive function;
LIHC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.62	-0.34	1.4e-10	Morning vs. evening chronotype;
LIHC	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg16275483	chr1:110013120	SYPL2	-0.5	-6.22	-0.32	1.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	trans	rs6058796	1.000	rs35220493	chr20:31267831	G/A	cg02600331	chr11:130417168	NA	0.36	7.49	0.38	5.93e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs10792665	0.611	rs12277804	chr11:82621549	A/G	cg24227371	chr11:82718527	RAB30	-0.28	-6.54	-0.33	2.23e-10	Obesity-related traits;
LIHC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg16102536	chr7:156981717	UBE3C	-0.36	-6.14	-0.32	2.25e-9	Body mass index;
LIHC	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.61	-9.7	-0.46	8.32e-20	Pediatric autoimmune diseases;
LIHC	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg26139080	chr11:47293733	MADD	-0.5	-8.44	-0.42	8.85e-16	HDL cholesterol;
LIHC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.94	20.44	0.74	3.16e-61	Blood protein levels;
LIHC	cis	rs3736485	0.966	rs1031664	chr15:51754897	C/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.38	-0.33	5.75e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg23461800	chr14:103021989	NA	0.45	6.31	0.32	8.6e-10	Platelet count;
LIHC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.74	11.19	0.52	5.54e-25	Subjective well-being;
LIHC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	9.19	0.45	3.82e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21448741	chr8:58168803	NA	0.36	6.59	0.34	1.64e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.48	7.84	0.39	5.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg02811702	chr13:24901961	NA	0.27	6.38	0.33	5.75e-10	Obesity-related traits;
LIHC	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg12379764	chr21:47803548	PCNT	-0.52	-7.42	-0.37	9.07e-13	Testicular germ cell tumor;
LIHC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.44	-7.11	-0.36	6.81e-12	Menarche (age at onset);
LIHC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.61	-10.46	-0.49	2.16e-22	Colorectal cancer;
LIHC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.4	-0.33	5.06e-10	Longevity;
LIHC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.69	-11.51	-0.53	3.96e-26	Colorectal cancer;
LIHC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.26e-9	Menopause (age at onset);
LIHC	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.44	-7.25	-0.37	2.74e-12	Pelvic organ prolapse;
LIHC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.41	-6.96	-0.35	1.73e-11	Type 2 diabetes;
LIHC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	7.44	0.37	8.45e-13	Lymphocyte counts;
LIHC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.44	0.37	8.37e-13	Airflow obstruction;
LIHC	cis	rs972578	0.967	rs6002985	chr22:43333427	C/T	cg01576275	chr22:43409880	NA	-0.33	-5.77	-0.3	1.75e-8	Mean platelet volume;
LIHC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.98	0.44	1.86e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg10932868	chr11:921992	NA	0.4	7.48	0.38	6.23e-13	Alzheimer's disease (late onset);
LIHC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.42	-8.82	-0.43	5.96e-17	Obesity-related traits;
LIHC	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg04610667	chr7:75704037	NA	-0.33	-5.85	-0.3	1.16e-8	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.44	0.64	3.51e-41	Tonsillectomy;
LIHC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.87	-0.3	1.03e-8	Tonsillectomy;
LIHC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27297192	chr10:134578999	INPP5A	0.53	7.42	0.37	9.64e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.46	7.38	0.37	1.24e-12	Cleft lip with or without cleft palate;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07148452	chr15:90176987	KIF7	0.46	6.59	0.34	1.63e-10	Bilirubin levels;
LIHC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg07706471	chr12:123319906	HIP1R	-0.59	-7.74	-0.39	1.13e-13	Schizophrenia;
LIHC	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg09918751	chr15:100517450	ADAMTS17	0.69	12.01	0.54	5.91e-28	Height;
LIHC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.86	0.63	6.96e-39	Chronic sinus infection;
LIHC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg06064525	chr11:970664	AP2A2	-0.44	-10.72	-0.5	2.54e-23	Alzheimer's disease (late onset);
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg02990361	chr1:107599529	PRMT6	-0.59	-9.56	-0.46	2.42e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17309827	0.965	rs13206690	chr6:3433340	T/G	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.81	-0.3	1.45e-8	Crohn's disease;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.65	-11.61	-0.53	1.7e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-6.21	-0.32	1.57e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1494950	1.000	rs28520420	chr4:15007619	C/T	cg12377275	chr4:15005593	CPEB2	-0.84	-7.53	-0.38	4.59e-13	Political ideology;
LIHC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	6.36	0.33	6.5e-10	Lymphocyte counts;
LIHC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.7	11.92	0.54	1.26e-27	Hemoglobin concentration;
LIHC	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	14.0	0.6	1.67e-35	Coffee consumption (cups per day);
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.44	0.33	4.11e-10	Total body bone mineral density;
LIHC	trans	rs875971	0.638	rs801216	chr7:66011667	T/C	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12963096	chr13:39612675	NHLRC3;C13orf23	0.53	7.42	0.37	9.6e-13	Lung function (FEV1/FVC);
LIHC	trans	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg19680672	chr10:131412579	MGMT	0.42	6.53	0.33	2.39e-10	Response to temozolomide;
LIHC	cis	rs4908760	0.827	rs7556169	chr1:8741401	C/T	cg20416874	chr1:8611966	RERE	0.67	14.11	0.61	6.18e-36	Vitiligo;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02816363	chr19:55963123	NA	0.43	6.14	0.32	2.29e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs787274	0.619	rs10115576	chr9:115617822	T/C	cg13803584	chr9:115635662	SNX30	-0.57	-6.29	-0.32	9.68e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs876084	0.505	rs4871044	chr8:121158773	C/T	cg06265175	chr8:121136014	COL14A1	0.42	6.58	0.34	1.8e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07951810	chr12:65153561	GNS	0.5	7.3	0.37	2.05e-12	Cognitive function;
LIHC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02581963	chr10:102133317	C10orf75	-0.42	-6.93	-0.35	2.15e-11	Metabolic traits;
LIHC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.25	0.66	2.13e-44	Smoking behavior;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg07133347	chr1:107600762	PRMT6	0.46	6.83	0.35	3.87e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.35	-6.88	-0.35	2.82e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg22809023	chr3:195622598	TNK2	-0.43	-6.41	-0.33	4.75e-10	Pancreatic cancer;
LIHC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg10820045	chr2:198174542	NA	-0.61	-10.38	-0.49	4.04e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.64	12.21	0.55	1.03e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.67	13.33	0.58	6e-33	Leprosy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27454894	chr16:88878596	APRT	0.46	6.77	0.34	5.61e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg12463550	chr7:65579703	CRCP	0.72	6.85	0.35	3.35e-11	Diabetic kidney disease;
LIHC	cis	rs1982963	0.627	rs77101097	chr14:52494300	C/T	cg10843707	chr14:52510701	NID2	0.37	5.98	0.31	5.77e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Amyotrophic lateral sclerosis (age of onset);
LIHC	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.6	12.04	0.55	4.52e-28	Plateletcrit;Platelet count;
LIHC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.65	-8.3	-0.41	2.48e-15	Initial pursuit acceleration;
LIHC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.88	-0.3	9.96e-9	Personality dimensions;
LIHC	cis	rs10106298	0.904	rs7835270	chr8:103668320	A/G	cg10187029	chr8:103597600	NA	0.53	6.79	0.34	4.93e-11	Schizophrenia;
LIHC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg16797656	chr11:68205561	LRP5	0.51	8.1	0.4	9.54e-15	Total body bone mineral density;
LIHC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.43e-23	Personality dimensions;
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg07133347	chr1:107600762	PRMT6	-0.45	-6.73	-0.34	7.27e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.98	0.54	7.38e-28	Prudent dietary pattern;
LIHC	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg05527609	chr1:210001259	C1orf107	-0.58	-7.83	-0.39	6.22e-14	Red blood cell count;
LIHC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.62	-10.32	-0.49	6.59e-22	Obesity-related traits;
LIHC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02290350	chr8:58132656	NA	0.49	9.23	0.45	2.88e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-11.02	-0.51	2.32e-24	Primary sclerosing cholangitis;
LIHC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.56	-9.22	-0.45	3.17e-18	Longevity;Endometriosis;
LIHC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.24	0.36	3.03e-12	Aortic root size;
LIHC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.76	11.22	0.52	4.41e-25	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.78	14.59	0.62	8.18e-38	Recombination rate (males);
LIHC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.51	-7.08	-0.36	8.1e-12	Aortic root size;
LIHC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.4	6.39	0.33	5.42e-10	Obesity-related traits;
LIHC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg05044414	chr3:183734942	ABCC5	0.35	6.15	0.32	2.2e-9	Anterior chamber depth;
LIHC	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-9.97	-0.47	1.01e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.49	0.64	2.17e-41	Chronic sinus infection;
LIHC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.46	-6.0	-0.31	5.1e-9	Subjective well-being;
LIHC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.2	12.94	0.57	1.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	18.26	0.7	1.79e-52	Colorectal cancer;
LIHC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	7.95	0.39	2.76e-14	Hemoglobin concentration;
LIHC	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg05110241	chr16:68378359	PRMT7	-0.49	-5.88	-0.3	9.56e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.04	0.31	3.96e-9	Cognitive ability;
LIHC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.95	17.96	0.7	2.95e-51	Menopause (age at onset);
LIHC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.12	-0.36	6.4e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-13.29	-0.58	9.19e-33	Total body bone mineral density;
LIHC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.01	0.35	1.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.71	0.43	1.28e-16	Coffee consumption (cups per day);
LIHC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	7.61	0.38	2.62e-13	IgG glycosylation;
LIHC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	0.92	7.72	0.39	1.26e-13	Cognitive function;
LIHC	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.71	-12.19	-0.55	1.2e-28	Pediatric autoimmune diseases;
LIHC	trans	rs783540	1.000	rs698500	chr15:83237769	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-7.05	-0.36	1.02e-11	Schizophrenia;
LIHC	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg00977110	chr5:151150581	G3BP1	0.52	6.54	0.33	2.3e-10	Preschool internalizing problems;
LIHC	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.81	14.11	0.61	5.84e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.58	10.1	0.48	3.54e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.78e-15	Body mass index;
LIHC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.37	7.0	0.35	1.34e-11	Schizophrenia;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.46	8.29	0.41	2.55e-15	Prudent dietary pattern;
LIHC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg21003380	chr1:156261207	TMEM79	0.34	5.76	0.3	1.93e-8	Tonsillectomy;
LIHC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.47	-5.86	-0.3	1.09e-8	Breast cancer;
LIHC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.76	9.8	0.47	3.86e-20	Schizophrenia;
LIHC	trans	rs12753920	0.642	rs7533077	chr1:92584519	C/T	cg15668468	chr10:118892869	VAX1	-0.41	-6.07	-0.31	3.48e-9	Systemic lupus erythematosus;
LIHC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.49	7.15	0.36	5.16e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-0.74	-9.28	-0.45	2.03e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.44	5.79	0.3	1.56e-8	Pulse pressure;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.48	-7.44	-0.37	8.36e-13	Testicular germ cell tumor;
LIHC	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.52	-10.94	-0.51	4.52e-24	Birth weight;
LIHC	cis	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg19680485	chr15:31195859	MTMR15	-0.56	-6.01	-0.31	4.83e-9	Hypertriglyceridemia;
LIHC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg23791538	chr6:167370224	RNASET2	-0.39	-6.19	-0.32	1.73e-9	Primary biliary cholangitis;
LIHC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.0	0.35	1.34e-11	Aortic root size;
LIHC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-13.35	-0.59	5.14e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg09182678	chr22:50328711	NA	0.43	6.16	0.32	2.04e-9	Schizophrenia;
LIHC	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.85	-0.3	1.18e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs8081395	0.834	rs2665397	chr17:57826731	C/A	cg02344993	chr17:57696989	CLTC	-0.45	-7.29	-0.37	2.22e-12	White blood cell count;
LIHC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.47	-8.12	-0.4	8.73e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10792665	0.640	rs2086298	chr11:82619218	C/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.09	-0.31	3.09e-9	Obesity-related traits;
LIHC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-8.24	-0.41	3.69e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.94	19.09	0.72	7.75e-56	Bone mineral density;
LIHC	cis	rs3981351	0.797	rs61866461	chr10:115454862	C/A	cg24846397	chr10:115438155	CASP7	-0.45	-6.84	-0.35	3.65e-11	Obesity-related traits;
LIHC	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.86	-0.3	1.1e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.24	-15.85	-0.65	7.92e-43	Diabetic kidney disease;
LIHC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.46	-0.33	3.52e-10	Bipolar disorder;
LIHC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.5	7.8	0.39	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.77e-11	Schizophrenia;
LIHC	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.76	-0.43	9.19e-17	Coffee consumption (cups per day);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03359468	chr8:26240463	BNIP3L	-0.56	-6.56	-0.33	1.98e-10	Systolic blood pressure;
LIHC	cis	rs2292096	1.000	rs16830092	chr1:200823498	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-6.12	-0.31	2.61e-9	Epilepsy;
LIHC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.56	-9.11	-0.44	6.87e-18	Lymphocyte counts;
LIHC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-17.0	-0.68	2.02e-47	Ulcerative colitis;
LIHC	trans	rs10411161	0.702	rs8110531	chr19:52383510	C/T	cg22319618	chr22:45562946	NUP50	-0.6	-8.08	-0.4	1.13e-14	Breast cancer;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.37	6.17	0.32	1.91e-9	Mood instability;
LIHC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.73	11.66	0.53	1.11e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.9	-0.39	3.82e-14	Blood metabolite levels;
LIHC	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.72	10.68	0.5	3.75e-23	Subjective well-being;
LIHC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg18016565	chr1:150552671	MCL1	-0.49	-9.73	-0.47	6.75e-20	Tonsillectomy;
LIHC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.34	9.88e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.6	-8.56	-0.42	4e-16	Coronary artery disease;
LIHC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg18016565	chr1:150552671	MCL1	-0.54	-10.52	-0.49	1.32e-22	Melanoma;
LIHC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.69	-6.4	-0.33	5.12e-10	Breast cancer;
LIHC	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.56	-8.29	-0.41	2.55e-15	White matter hyperintensity burden;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21747090	chr2:27597821	SNX17	-0.41	-6.02	-0.31	4.53e-9	Total body bone mineral density;
LIHC	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.96	-0.31	6.13e-9	Systemic lupus erythematosus;
LIHC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.22	-0.36	3.42e-12	Bipolar disorder;
LIHC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.41	6.78	0.34	5.45e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.45	-0.42	8.54e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.88	-0.51	7.02e-24	Body mass index;
LIHC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg25114630	chr15:101792522	CHSY1	0.55	6.95	0.35	1.81e-11	Corneal structure;
LIHC	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.41	7.77	0.39	9.21e-14	Testicular germ cell tumor;
LIHC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg08539965	chr1:21396338	EIF4G3	0.34	6.0	0.31	5.13e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.53	0.56	6.63e-30	Platelet count;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.76	12.03	0.55	4.98e-28	Longevity;
LIHC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg12046867	chr14:103022105	NA	-0.47	-6.78	-0.34	5.25e-11	Platelet count;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.85e-11	Prudent dietary pattern;
LIHC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	8.14	0.4	7.21e-15	Platelet count;
LIHC	cis	rs4908768	0.657	rs4908510	chr1:8806345	C/G	cg20416874	chr1:8611966	RERE	-0.45	-6.93	-0.35	2.1e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.33	6.51	0.33	2.63e-10	Renal cell carcinoma;
LIHC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.66	6.54	0.33	2.22e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00802000	chr16:706648	WDR90	-0.38	-6.22	-0.32	1.49e-9	Height;
LIHC	cis	rs831571	0.703	rs831566	chr3:64075938	G/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.51	6.43	0.33	4.31e-10	Type 2 diabetes;
LIHC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.44	7.23	0.36	3.16e-12	Red blood cell count;
LIHC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-7.54	-0.38	4.39e-13	Lymphocyte counts;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.94	-16.17	-0.66	4.57e-44	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg19680672	chr10:131412579	MGMT	-0.47	-7.23	-0.36	3.18e-12	Response to temozolomide;
LIHC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	1.0	19.11	0.72	6.53e-56	Breast cancer;
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.69	0.62	3.3e-38	Prudent dietary pattern;
LIHC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.34	5.84	0.3	1.25e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg10241871	chr14:102965420	TECPR2	-0.5	-7.86	-0.39	5.1e-14	Plateletcrit;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg13627451	chr15:52043674	TMOD2;LYSMD2	-0.43	-6.09	-0.31	3.08e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	cis	rs10792665	0.512	rs4280021	chr11:82582563	C/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.56	-0.33	1.96e-10	Obesity-related traits;
LIHC	cis	rs2637266	0.626	rs724113	chr10:78557309	C/T	cg18941641	chr10:78392320	NA	0.3	6.46	0.33	3.58e-10	Pulmonary function;
LIHC	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.6	8.93	0.43	2.6e-17	Recombination rate (females);
LIHC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.2	-0.36	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg11700415	chr19:49140818	SEC1;DBP	-0.38	-6.08	-0.31	3.13e-9	Eotaxin levels;
LIHC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg22777020	chr22:31556080	RNF185	-0.55	-6.24	-0.32	1.26e-9	Colorectal cancer;
LIHC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.61	0.67	7.88e-46	Smoking behavior;
LIHC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.47	5.85	0.3	1.16e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.38	-7.33	-0.37	1.7e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.0	-0.54	6.29e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1322512	0.959	rs2623954	chr6:152966001	G/A	cg03415253	chr6:152958462	SYNE1	-0.33	-6.22	-0.32	1.47e-9	Tonometry;
LIHC	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	19.77	0.73	1.47e-58	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.8	-18.23	-0.7	2.41e-52	Urate levels in lean individuals;
LIHC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg23262073	chr20:60523788	NA	-0.29	-6.12	-0.31	2.51e-9	Body mass index;
LIHC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.24	6.15	0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.47	-7.55	-0.38	3.9e-13	Neurofibrillary tangles;
LIHC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.67	9.57	0.46	2.15e-19	Schizophrenia;
LIHC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.75	11.4	0.52	9.67e-26	Corneal astigmatism;
LIHC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.85	10.51	0.49	1.41e-22	Cognitive function;
LIHC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.85	13.71	0.6	2.23e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04004882	chr2:215674386	BARD1	0.51	6.23	0.32	1.4e-9	Neuroblastoma;
LIHC	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.67	11.86	0.54	2.09e-27	Pediatric autoimmune diseases;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.71	-0.38	1.36e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg13175981	chr1:150552382	MCL1	-0.45	-6.19	-0.32	1.76e-9	Blood protein levels;
LIHC	cis	rs7937890	0.561	rs2575849	chr11:14539639	T/A	cg02886208	chr11:14281011	SPON1	-0.44	-6.16	-0.32	2.08e-9	Mitochondrial DNA levels;
LIHC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg18196295	chr10:418757	DIP2C	-0.5	-5.89	-0.3	8.99e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.5	7.21	0.36	3.61e-12	Initial pursuit acceleration;
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	7.11	0.36	6.65e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.47	8.52	0.42	5.13e-16	Colorectal cancer;
LIHC	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.74	10.66	0.5	4.27e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg21724239	chr8:58056113	NA	0.46	6.08	0.31	3.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg22705602	chr4:152727874	NA	-0.31	-6.33	-0.32	7.6e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.63	-12.45	-0.56	1.38e-29	Prudent dietary pattern;
LIHC	cis	rs7238033	0.663	rs11877630	chr18:43317977	A/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.5	0.33	2.89e-10	Bladder cancer;
LIHC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.64	10.66	0.5	4.34e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.17	0.32	1.91e-9	Renal cell carcinoma;
LIHC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Morning vs. evening chronotype;
LIHC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg16434002	chr17:42200994	HDAC5	0.4	5.86	0.3	1.1e-8	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.71	10.74	0.5	2.24e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs4919087	0.590	rs1253397	chr10:99045556	C/T	cg25902810	chr10:99078978	FRAT1	-0.61	-6.72	-0.34	7.57e-11	Monocyte count;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.26e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.53	8.69	0.43	1.52e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.27	6.28	0.32	1.02e-9	Heart rate;
LIHC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	8.79	0.43	7.55e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	trans	rs6489882	0.902	rs4767037	chr12:113372804	A/C	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg19139277	chr8:28243953	ZNF395	0.7	6.16	0.32	2.06e-9	Musician's dystonia;
LIHC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-5.83	-0.3	1.3e-8	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.37	0.41	1.51e-15	Motion sickness;
LIHC	cis	rs2274273	0.588	rs7155054	chr14:55750662	A/G	cg01864836	chr14:55583639	NA	-0.34	-5.77	-0.3	1.76e-8	Protein biomarker;
LIHC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.67	10.13	0.48	2.9e-21	Platelet count;
LIHC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.58	-11.35	-0.52	1.45e-25	Body mass index;
LIHC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.36	1.17e-11	Diabetic kidney disease;
LIHC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.52	-5.97	-0.31	5.83e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.36	5.87	0.3	1.02e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.85	-9.74	-0.47	5.97e-20	Ulcerative colitis;
LIHC	cis	rs4788570	0.566	rs61171207	chr16:71504798	C/T	cg06353428	chr16:71660113	MARVELD3	-1.01	-9.39	-0.45	8.54e-19	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.7	-10.26	-0.49	1e-21	Coronary artery disease;
LIHC	cis	rs9372498	0.505	rs1626650	chr6:118654588	C/T	cg01339444	chr6:118972232	C6orf204	0.78	6.0	0.31	5.03e-9	Diastolic blood pressure;
LIHC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg18357645	chr12:58087776	OS9	-0.45	-6.91	-0.35	2.45e-11	Multiple sclerosis;
LIHC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.72	-0.39	1.26e-13	Total body bone mineral density;
LIHC	trans	rs17051917	0.841	rs4943284	chr13:35480729	A/C	cg01231434	chr16:23607392	NDUFAB1	-0.93	-6.4	-0.33	5.05e-10	Migraine with aura;
LIHC	cis	rs16958440	1.000	rs62096468	chr18:44637566	C/A	cg17192377	chr18:44677553	HDHD2	0.61	6.8	0.35	4.62e-11	Sitting height ratio;
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.79	12.8	0.57	6.29e-31	Longevity;
LIHC	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg18944383	chr4:111397179	ENPEP	0.25	6.21	0.32	1.51e-9	Coronary artery disease;
LIHC	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg01843034	chr6:37503916	NA	-0.4	-6.53	-0.33	2.31e-10	Cognitive performance;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00620304	chr6:34231334	NA	0.43	6.32	0.32	8.39e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.63	9.83	0.47	3.06e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1789	0.903	rs4470622	chr4:15674175	T/G	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.91	-0.3	8.38e-9	Blood protein levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14782266	chr2:42565367	NA	0.43	6.17	0.32	1.96e-9	Longevity;
LIHC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.64	-9.67	-0.46	1.03e-19	Schizophrenia;
LIHC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-10.92	-0.51	4.99e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.06	19.2	0.72	2.91e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs11955398	0.692	rs897672	chr5:59996101	C/G	cg02684056	chr5:59996105	DEPDC1B	0.46	6.76	0.34	5.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.66	-13.63	-0.59	4.44e-34	Brugada syndrome;
LIHC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg09222892	chr1:25734099	RHCE	-0.44	-7.92	-0.39	3.48e-14	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs6066825	0.605	rs4325821	chr20:47224787	T/C	cg18078177	chr20:47281410	PREX1	0.49	8.21	0.41	4.53e-15	Colorectal cancer;
LIHC	cis	rs7677751	0.806	rs4864847	chr4:55071953	G/A	cg17187183	chr4:55093834	PDGFRA	0.57	7.22	0.36	3.33e-12	Corneal astigmatism;
LIHC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.38	-6.12	-0.31	2.5e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.57	9.21	0.45	3.36e-18	Eosinophilic esophagitis;
LIHC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.12	-0.44	6.62e-18	Gut microbiome composition (summer);
LIHC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.58	8.92	0.43	2.79e-17	Longevity;
LIHC	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg07636037	chr3:49044803	WDR6	-0.57	-6.39	-0.33	5.32e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg00792783	chr2:198669748	PLCL1	0.41	5.92	0.31	7.71e-9	Dermatomyositis;
LIHC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.02	-0.44	1.33e-17	Bipolar disorder;
LIHC	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg00977110	chr5:151150581	G3BP1	-0.56	-7.03	-0.36	1.12e-11	Preschool internalizing problems;
LIHC	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.54	-0.33	2.26e-10	Neuroticism;
LIHC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.88	-0.3	9.77e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7534824	0.625	rs2391574	chr1:101373298	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.94	0.35	1.96e-11	Refractive astigmatism;
LIHC	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg26597838	chr10:835615	NA	1.08	12.47	0.56	1.14e-29	Eosinophil percentage of granulocytes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15985400	chr11:76091674	PRKRIR	0.41	6.2	0.32	1.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.43	6.97	0.35	1.6e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-0.9	-9.98	-0.47	9.4e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg26536354	chr8:144654954	C8orf73	0.52	5.98	0.31	5.56e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.5	8.82	0.43	6.12e-17	Colorectal cancer;
LIHC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.41	7.3	0.37	1.98e-12	Platelet distribution width;
LIHC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.6	10.94	0.51	4.22e-24	Mean corpuscular volume;
LIHC	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.43	-8.67	-0.42	1.76e-16	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.04	0.58	8.2e-32	Prudent dietary pattern;
LIHC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.08	-0.51	1.35e-24	Alzheimer's disease;
LIHC	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.56	-6.34	-0.32	7.15e-10	Ulcerative colitis;
LIHC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.42e-20	Height;
LIHC	trans	rs983392	0.709	rs7939882	chr11:59973929	A/C	cg17275991	chr19:58003312	ZNF419	0.43	6.14	0.32	2.33e-9	Alzheimer's disease (late onset);
LIHC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.46	8.17	0.4	6.03e-15	IgG glycosylation;
LIHC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.61	10.66	0.5	4.23e-23	Colorectal cancer;
LIHC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	5.94	0.31	7.14e-9	Menopause (age at onset);
LIHC	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.68	-10.62	-0.5	5.66e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.49	7.73	0.39	1.23e-13	Dental caries;
LIHC	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg16275483	chr1:110013120	SYPL2	-0.52	-6.38	-0.33	5.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	7.16	0.36	4.87e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs1789	0.653	rs13142069	chr4:15593692	C/T	cg16509355	chr4:15471240	CC2D2A	0.41	6.58	0.34	1.73e-10	Blood protein levels;
LIHC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg18912006	chr12:123335444	HIP1R	-0.6	-7.2	-0.36	3.76e-12	Schizophrenia;
LIHC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.1	0.55	2.66e-28	Cognitive test performance;
LIHC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg11861562	chr11:117069780	TAGLN	0.48	7.98	0.4	2.17e-14	Blood protein levels;
LIHC	cis	rs67981189	0.593	rs2810072	chr14:71387193	A/G	cg15816911	chr14:71606274	NA	-0.41	-6.49	-0.33	2.99e-10	Schizophrenia;
LIHC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.45	-8.38	-0.41	1.35e-15	Glycated hemoglobin levels;
LIHC	cis	rs7578199	0.814	rs7570017	chr2:242261434	A/G	cg19372975	chr2:242212901	HDLBP	-0.59	-5.73	-0.3	2.2e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.4	-7.62	-0.38	2.59e-13	Testicular germ cell tumor;
LIHC	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.95	11.97	0.54	8.26e-28	Economic and political preferences (immigration/crime);
LIHC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.47	-7.68	-0.38	1.64e-13	Cognitive function;
LIHC	cis	rs611744	0.935	rs661036	chr8:109213088	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs2625529	0.775	rs2723342	chr15:72107699	G/C	cg16672083	chr15:72433130	SENP8	-0.33	-6.04	-0.31	4.08e-9	Red blood cell count;
LIHC	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.66	9.42	0.45	6.99e-19	Response to hepatitis C treatment;
LIHC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.45	-9.08	-0.44	9.1e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.49e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.61	0.5	6.17e-23	Lymphocyte counts;
LIHC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-6.18	-0.32	1.83e-9	Testicular germ cell tumor;
LIHC	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	cis	rs12744310	1.000	rs12037588	chr1:41763955	C/G	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.71	0.46	7.76e-20	Electroencephalogram traits;
LIHC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21467203	chr3:49911342	NA	-0.57	-10.52	-0.49	1.27e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs67981189	0.634	rs221896	chr14:71606668	C/G	cg15816911	chr14:71606274	NA	-0.41	-6.62	-0.34	1.39e-10	Schizophrenia;
LIHC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.73	5.86	0.3	1.08e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg02290350	chr8:58132656	NA	0.51	9.71	0.46	7.47e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg18887096	chr2:219472410	PLCD4	0.37	6.34	0.32	7.35e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.77	-0.3	1.78e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.92	-10.66	-0.5	4.12e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.45	6.56	0.33	2e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.65	6.88	0.35	2.89e-11	Type 2 diabetes;
LIHC	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.05	-0.36	9.94e-12	Total cholesterol levels;
LIHC	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00802000	chr16:706648	WDR90	-0.36	-6.07	-0.31	3.32e-9	Height;
LIHC	cis	rs1664789	0.935	rs787545	chr5:53274292	G/A	ch.5.1024479R	chr5:53302184	ARL15	0.51	7.81	0.39	7.25e-14	Waist circumference adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.61	11.82	0.54	2.92e-27	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg26338869	chr17:61819248	STRADA	0.53	7.11	0.36	6.79e-12	Height;
LIHC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.53	-8.03	-0.4	1.6e-14	Crohn's disease;
LIHC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg02269571	chr22:50332266	NA	-0.63	-8.94	-0.44	2.44e-17	Schizophrenia;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg07384357	chr20:62499359	TPD52L2	0.38	6.59	0.34	1.64e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs4764124	0.652	rs6488712	chr12:14939332	G/A	cg19759883	chr12:14956454	WBP11;C12orf60	0.37	6.7	0.34	8.61e-11	Pubertal anthropometrics;
LIHC	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.75	5.88	0.3	9.51e-9	Blood protein levels;
LIHC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.12e-9	Coronary artery disease;
LIHC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.3	-6.26	-0.32	1.12e-9	Blood metabolite levels;
LIHC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.61	-6.99	-0.35	1.43e-11	Menarche (age at onset);
LIHC	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.43	0.41	9.72e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2191566	0.639	rs62119176	chr19:44539272	C/T	cg20607764	chr19:44506953	ZNF230	-0.38	-6.27	-0.32	1.07e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.13	9.9	0.47	1.74e-20	Schizophrenia;
LIHC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.77	12.34	0.56	3.42e-29	Corneal astigmatism;
LIHC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.38	6.0	0.31	5.13e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.5	-8.57	-0.42	3.74e-16	White blood cell count;
LIHC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.92	16.68	0.67	3.87e-46	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.39	-0.45	8.75e-19	Colorectal cancer;
LIHC	cis	rs1274963	0.601	rs811970	chr3:39196552	A/G	cg02254461	chr3:39195904	CSRNP1	-0.52	-6.65	-0.34	1.13e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs9625935	0.518	rs713718	chr22:30314092	A/C	cg01021169	chr22:30184971	ASCC2	0.36	6.31	0.32	8.75e-10	Tonsillectomy;
LIHC	trans	rs13381277	1.000	rs9956321	chr18:74328477	C/T	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.41	-0.33	4.77e-10	Dental caries;
LIHC	cis	rs7945718	0.621	rs6485989	chr11:12695171	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.74	0.39	1.13e-13	Educational attainment (years of education);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17403046	chr12:113596797	DDX54;CCDC42B	0.57	6.93	0.35	2.05e-11	Lung function (FEV1);
LIHC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg12798992	chr6:167411361	FGFR1OP	0.5	7.57	0.38	3.54e-13	Crohn's disease;
LIHC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.55	8.25	0.41	3.42e-15	Gout;
LIHC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.79	0.6	1.01e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.6	10.59	0.5	7.58e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.51	9.05	0.44	1.09e-17	N-glycan levels;
LIHC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.34	-5.74	-0.3	2.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.72	9.29	0.45	1.86e-18	Gut microbiome composition (summer);
LIHC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	11.83	0.54	2.74e-27	Platelet count;
LIHC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.54	7.77	0.39	9.49e-14	Height;
LIHC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.65	10.92	0.51	5.03e-24	Fat distribution (HIV);
LIHC	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.55	-0.42	4.18e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18030105	chr11:3396237	ZNF195	0.47	6.47	0.33	3.35e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.02	-0.31	4.55e-9	Ulcerative colitis;
LIHC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg11952622	chr19:58962976	ZNF324B	0.48	7.21	0.36	3.66e-12	Uric acid clearance;
LIHC	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg00601450	chr5:74908170	NA	0.55	6.36	0.33	6.46e-10	Coronary artery disease;
LIHC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg13647721	chr17:30228624	UTP6	0.8	7.65	0.38	2.07e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.64	-9.16	-0.44	5.03e-18	White matter hyperintensity burden;
LIHC	trans	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg01134436	chr17:81009848	B3GNTL1	0.8	6.95	0.35	1.89e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.73	-0.47	6.6e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.21	0.41	4.55e-15	Lymphocyte counts;
LIHC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-9.01	-0.44	1.52e-17	Vitiligo;
LIHC	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg09695851	chr17:3907499	NA	0.56	7.41	0.37	9.66e-13	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.48	7.25	0.36	2.84e-12	Height;
LIHC	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.47	-5.74	-0.3	2.13e-8	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg24449463	chr1:168025552	DCAF6	-0.49	-6.18	-0.32	1.78e-9	Schizophrenia;
LIHC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.09	0.36	7.56e-12	Aortic root size;
LIHC	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.47	6.9	0.35	2.46e-11	Asthma;
LIHC	trans	rs6934970	1.000	rs12204540	chr6:113033306	A/G	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.83	-0.3	1.29e-8	Coronary artery disease;
LIHC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg16226627	chr15:75307476	SCAMP5	0.54	9.71	0.46	7.59e-20	Lung cancer;
LIHC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.74	7.67	0.38	1.78e-13	Vitiligo;
LIHC	cis	rs6728642	0.519	rs6721921	chr2:97566501	G/A	cg26665480	chr2:98280029	ACTR1B	-0.6	-6.44	-0.33	3.96e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.0	0.4	1.99e-14	Motion sickness;
LIHC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	8.13	0.4	7.86e-15	Platelet count;
LIHC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg14092571	chr14:90743983	NA	0.41	6.56	0.33	1.99e-10	Mortality in heart failure;
LIHC	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.6	8.26	0.41	3.23e-15	Coronary artery disease;
LIHC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17507749	chr15:85114479	UBE2QP1	0.63	7.18	0.36	4.38e-12	Schizophrenia;
LIHC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.87	13.22	0.58	1.58e-32	Vitamin D levels;
LIHC	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	8.17	0.4	6.2e-15	Eotaxin levels;
LIHC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.43	5.85	0.3	1.14e-8	Life satisfaction;
LIHC	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg22153463	chr1:85462885	MCOLN2	0.52	5.93	0.31	7.54e-9	Serum sulfate level;
LIHC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg09182678	chr22:50328711	NA	-0.38	-5.79	-0.3	1.63e-8	Schizophrenia;
LIHC	cis	rs7961581	0.748	rs1390201	chr12:71608527	C/T	cg05756094	chr12:71608604	NA	0.41	6.67	0.34	1.02e-10	Type 2 diabetes;
LIHC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.95e-11	Rheumatoid arthritis;
LIHC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.69	7.28	0.37	2.3e-12	Alzheimer's disease;
LIHC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.75e-10	Uric acid levels;
LIHC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01200585	chr1:228362443	C1orf69	-0.4	-5.82	-0.3	1.34e-8	Diastolic blood pressure;
LIHC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02985541	chr2:219472218	PLCD4	-0.39	-5.98	-0.31	5.63e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg05714579	chr10:131428358	MGMT	0.41	6.63	0.34	1.3100000000000001e-10	Response to temozolomide;
LIHC	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg10127483	chr1:110009974	SYPL2	0.5	6.26	0.32	1.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg14067834	chr17:29058358	SUZ12P	0.73	7.42	0.37	9.65e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.14	-0.32	2.23e-9	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17776324	chr12:9903429	NA	-0.37	-6.12	-0.31	2.57e-9	Pancreatic cancer;
LIHC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.85	0.35	3.39e-11	Height;
LIHC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.74	11.0	0.51	2.76e-24	Corneal astigmatism;
LIHC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.81	11.03	0.51	2.02e-24	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.02	-0.31	4.6e-9	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05393045	chr10:119256233	EMX2OS	0.42	6.47	0.33	3.43e-10	Cognitive function;
LIHC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.59	8.56	0.42	3.94e-16	Platelet count;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20451727	chr4:83931713	LIN54	-0.56	-6.74	-0.34	6.6e-11	Systolic blood pressure;
LIHC	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.59	8.65	0.42	1.97e-16	Recombination rate (females);
LIHC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	11.55	0.53	2.71e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.5	-7.53	-0.38	4.55e-13	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.5	7.88	0.39	4.5e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.91	8.23	0.41	3.86e-15	LDL cholesterol;
LIHC	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg07322936	chr10:88137208	NA	-0.46	-6.02	-0.31	4.55e-9	Schizophrenia;
LIHC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.53	-6.57	-0.33	1.83e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg26441486	chr22:50317300	CRELD2	0.35	6.33	0.32	7.65e-10	Schizophrenia;
LIHC	cis	rs1144333	0.510	rs1146652	chr1:76273708	A/G	cg22875332	chr1:76189707	ACADM	-0.43	-6.54	-0.33	2.18e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.73	-11.25	-0.52	3.39e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg21559469	chr19:19431446	KIAA0892;SF4	0.41	5.74	0.3	2.09e-8	Tonsillectomy;
LIHC	trans	rs950169	0.579	rs881983	chr15:84647308	C/T	cg00571809	chr1:3397113	ARHGEF16	0.38	6.29	0.32	9.5e-10	Schizophrenia;
LIHC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.59	-9.29	-0.45	1.89e-18	High light scatter reticulocyte count;
LIHC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.56	8.03	0.4	1.55e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08219700	chr8:58056026	NA	0.52	6.21	0.32	1.56e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	0.71	7.81	0.39	7.23e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.69	11.31	0.52	1.99e-25	Platelet count;
LIHC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg25894440	chr7:65020034	NA	-0.54	-6.2	-0.32	1.59e-9	Diabetic kidney disease;
LIHC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.93	-12.35	-0.56	3.04e-29	Schizophrenia;
LIHC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-6.71	-0.34	7.96e-11	Arsenic metabolism;
LIHC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.4	6.32	0.32	8.06e-10	Multiple sclerosis;
LIHC	cis	rs365132	0.517	rs3762974	chr5:176328336	G/A	cg16309518	chr5:176445507	NA	0.52	9.85	0.47	2.59e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs17106184	0.892	rs12098132	chr1:51127524	C/A	cg07174182	chr1:51127561	FAF1	-0.75	-8.13	-0.4	7.8e-15	Type 2 diabetes;
LIHC	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg08992911	chr2:238395768	MLPH	0.67	6.98	0.35	1.58e-11	Prostate cancer;
LIHC	trans	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg24036039	chr1:3397125	ARHGEF16	0.4	6.59	0.34	1.66e-10	Schizophrenia;
LIHC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg02290350	chr8:58132656	NA	0.31	6.9	0.35	2.57e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.5	-8.72	-0.43	1.25e-16	Narcolepsy;
LIHC	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.51	-6.05	-0.31	3.91e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-8.04	-0.4	1.45e-14	Gut microbiome composition (summer);
LIHC	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.64	9.34	0.45	1.27e-18	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.43	6.29	0.32	9.78e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	6.6	0.34	1.54e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg14222797	chr10:16859974	RSU1	0.49	6.04	0.31	4.04e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.13	-0.36	6.19e-12	Personality dimensions;
LIHC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.44	0.45	6e-19	Bipolar disorder;
LIHC	cis	rs80282103	0.867	rs7099063	chr10:1078547	C/G	cg08668510	chr10:1095578	IDI1	0.59	6.09	0.31	3.04e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs78062588	0.892	rs3811450	chr1:154551032	C/T	cg24304309	chr1:154577895	ADAR	-0.56	-6.3	-0.32	9.35e-10	Lung cancer;
LIHC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.6	9.02	0.44	1.36e-17	Recombination rate (females);
LIHC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.5e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.58	0.53	2.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs13201877	0.591	rs3843990	chr6:137654515	T/C	cg16624405	chr10:133607033	NA	-0.42	-6.18	-0.32	1.87e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.37	-6.45	-0.33	3.85e-10	Asthma;
LIHC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.19	-25.85	-0.81	2.01e-82	Myeloid white cell count;
LIHC	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg15490075	chr13:100150979	NA	0.52	5.77	0.3	1.79e-8	Obesity-related traits;
LIHC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg00343986	chr7:65444356	GUSB	0.4	5.99	0.31	5.21e-9	Aortic root size;
LIHC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	1.03	18.02	0.7	1.7e-51	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-8.97	-0.44	2.04e-17	Gut microbiome composition (summer);
LIHC	cis	rs600806	0.889	rs585545	chr1:109841662	A/T	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.73	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.56	7.22	0.36	3.44e-12	Parkinson's disease;
LIHC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.37	0.33	6.14e-10	Renal cell carcinoma;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00061764	chr3:67564432	SUCLG2	0.43	6.45	0.33	3.9e-10	Bilirubin levels;
LIHC	cis	rs507080	0.922	rs625513	chr11:118555719	A/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.57	0.33	1.9e-10	Serum metabolite levels;
LIHC	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.41	6.65	0.34	1.16e-10	Inhibitory control;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21432158	chr12:104530941	NFYB	0.43	6.48	0.33	3.25e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-8.16	-0.4	6.53e-15	Osteoporosis;
LIHC	cis	rs1555322	0.530	rs2425044	chr20:33869735	C/T	cg17927777	chr20:33865990	NA	0.55	6.5	0.33	2.77e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08219700	chr8:58056026	NA	0.46	5.79	0.3	1.63e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.63	11.3	0.52	2.29e-25	Breast cancer;
LIHC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.44	-0.37	8.39e-13	Platelet distribution width;
LIHC	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-0.84	-9.29	-0.45	1.86e-18	Exhaled nitric oxide output;
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12016809	chr21:47604291	C21orf56	0.43	6.37	0.33	6.08e-10	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg00091569	chr3:40428383	ENTPD3	-0.38	-6.53	-0.33	2.36e-10	Renal cell carcinoma;
LIHC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.17	-0.32	1.95e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg05185784	chr16:90016020	DEF8	-0.48	-6.18	-0.32	1.84e-9	Skin colour saturation;
LIHC	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.73	-0.34	7.17e-11	Schizophrenia;
LIHC	cis	rs6450176	0.564	rs31227	chr5:53326467	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.75	-13.51	-0.59	1.27e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14509581	chr15:68522181	CLN6	0.45	6.09	0.31	3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21448741	chr8:58168803	NA	0.35	6.55	0.33	2.1e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.17	-0.36	4.8e-12	Coronary artery disease;
LIHC	cis	rs10878977	0.565	rs11177657	chr12:69809909	T/C	cg17330252	chr12:69809627	NA	0.37	5.83	0.3	1.3e-8	Colorectal cancer;
LIHC	cis	rs11195062	0.766	rs1935465	chr10:112029300	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.75	-0.3	2.01e-8	Multiple myeloma;
LIHC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.53	7.41	0.37	1.03e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	8.31	0.41	2.31e-15	Mean corpuscular hemoglobin;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14504603	chr2:211341483	LANCL1;CPS1	0.36	6.23	0.32	1.36e-9	Calcium levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19502932	chr11:6640663	TPP1	0.42	6.03	0.31	4.14e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.33	-6.59	-0.34	1.66e-10	Breast cancer;
LIHC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.75	0.43	9.55e-17	Motion sickness;
LIHC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.57	7.8	0.39	7.33e-14	Neuroblastoma;
LIHC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	20.79	0.75	1.21e-62	Chronic sinus infection;
LIHC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.79	-0.34	4.91e-11	Height;
LIHC	trans	rs79389047	0.850	rs10000631	chr4:157662289	C/T	cg18148021	chr14:56616059	PELI2	0.41	6.26	0.32	1.15e-9	Plateletcrit;
LIHC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.05	-0.74	1.13e-59	Height;
LIHC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg02869306	chr7:64672164	INTS4L1	0.28	6.16	0.32	2e-9	Calcium levels;
LIHC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.48	6.3	0.32	9.01e-10	Major depressive disorder;
LIHC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg19045956	chr2:200819837	C2orf60;C2orf47	0.33	5.79	0.3	1.57e-8	Osteoporosis;
LIHC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.46	-7.25	-0.37	2.74e-12	Superior crus of antihelix expression;
LIHC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.57	7.63	0.38	2.42e-13	Hemoglobin concentration;Hematocrit;
LIHC	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	6.69	0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg16586182	chr3:47516702	SCAP	0.6	11.76	0.54	4.7e-27	Colorectal cancer;
LIHC	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs17152411	1.000	rs17152433	chr10:126670356	G/A	cg07906193	chr10:126599966	NA	0.36	6.04	0.31	4.01e-9	Height;
LIHC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.81	6.81	0.35	4.33e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2901460	0.527	rs10167456	chr2:62112839	G/A	cg02183531	chr2:62113199	CCT4	-0.41	-6.04	-0.31	4e-9	Mean corpuscular volume;
LIHC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg25356066	chr3:128598488	ACAD9	0.56	7.74	0.39	1.1e-13	IgG glycosylation;
LIHC	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-8.95	-0.44	2.24e-17	Bipolar disorder;
LIHC	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg23533926	chr12:111358616	MYL2	0.33	6.4	0.33	4.98e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg13957321	chr17:43675089	NA	0.49	7.72	0.39	1.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg16275483	chr1:110013120	SYPL2	-0.52	-6.3	-0.32	9.12e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	0.75	9.4	0.45	8.12e-19	Corneal structure;
LIHC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.42	-7.02	-0.35	1.22e-11	Breast cancer;
LIHC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.51	7.24	0.36	2.99e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24229701	chr12:130821962	PIWIL1	0.46	6.97	0.35	1.63e-11	Menopause (age at onset);
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.37	-5.91	-0.3	8.21e-9	Testicular germ cell tumor;
LIHC	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.2e-9	Lymphocyte counts;
LIHC	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.85	0.3	1.12e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-0.91	-11.69	-0.53	8.72e-27	Mitochondrial DNA levels;
LIHC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.92	16.92	0.67	4.48e-47	Menopause (age at onset);
LIHC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.24	-0.45	2.77e-18	Ulcerative colitis;
LIHC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.13	0.44	6.09e-18	Bipolar disorder;
LIHC	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.71	-0.38	1.41e-13	Coronary artery disease;
LIHC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.59	6.47	0.33	3.34e-10	Gut microbiome composition (summer);
LIHC	trans	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg15676719	chr1:167598521	RCSD1	-0.38	-7.17	-0.36	4.59e-12	Systemic lupus erythematosus;
LIHC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg09417038	chr21:47716443	C21orf57	-0.58	-8.58	-0.42	3.47e-16	Testicular germ cell tumor;
LIHC	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg08992911	chr2:238395768	MLPH	0.55	6.44	0.33	4.12e-10	Prostate cancer;
LIHC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.93	0.43	2.68e-17	Motion sickness;
LIHC	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.75	0.3	1.97e-8	Morning vs. evening chronotype;
LIHC	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.49	7.67	0.38	1.76e-13	Alzheimer's disease (survival time);
LIHC	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg07117364	chr1:16154769	NA	-0.42	-7.34	-0.37	1.62e-12	Dilated cardiomyopathy;
LIHC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.66	0.38	1.9e-13	IgG glycosylation;
LIHC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.75	-10.74	-0.5	2.21e-23	Dilated cardiomyopathy;
LIHC	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.7	-7.28	-0.37	2.32e-12	Putamen volume;
LIHC	trans	rs2288327	0.591	rs2562845	chr2:179514433	T/C	cg14011486	chr1:26737247	LIN28	0.43	6.2	0.32	1.59e-9	Atrial fibrillation;
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.72	-0.3	2.3e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.57	8.19	0.4	5.28e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.53	-0.38	4.67e-13	Morning vs. evening chronotype;
LIHC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	8.88	0.43	3.97e-17	Mood instability;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07077080	chr8:30585289	GSR	0.42	6.92	0.35	2.18e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	16.23	0.66	2.46e-44	Nonalcoholic fatty liver disease;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07308232	chr7:1071921	C7orf50	-0.44	-7.03	-0.36	1.14e-11	Longevity;Endometriosis;
LIHC	trans	rs9687065	1.000	rs10078963	chr5:148400424	G/A	cg00646241	chr11:70563878	SHANK2	0.36	6.04	0.31	3.94e-9	Diastolic blood pressure;
LIHC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.48	7.56	0.38	3.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3736485	0.966	rs4775944	chr15:51775610	T/C	cg08986416	chr15:51914746	DMXL2	-0.41	-6.15	-0.32	2.11e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-6.05	-0.31	3.74e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.55	8.77	0.43	8.44e-17	Menarche (age at onset);
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg21522988	chr12:29376872	FAR2	0.3	6.99	0.35	1.44e-11	QT interval;
LIHC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg15832292	chr6:96025679	MANEA	0.62	7.17	0.36	4.71e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.78	-0.54	3.97e-27	Alzheimer's disease;
LIHC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.08	0.4	1.15e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.44	-6.62	-0.34	1.41e-10	Neutrophil percentage of white cells;
LIHC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg15704280	chr7:45808275	SEPT13	0.69	7.22	0.36	3.41e-12	Body mass index;
LIHC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.69	-7.66	-0.38	1.97e-13	Bronchopulmonary dysplasia;
LIHC	trans	rs10411161	0.702	rs2867319	chr19:52397160	T/C	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.6	9.01	0.44	1.51e-17	Platelet count;
LIHC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg18016565	chr1:150552671	MCL1	0.56	10.27	0.49	9.3e-22	Melanoma;
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.78	-0.3	1.69e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg10411590	chr13:21900810	NA	0.42	6.83	0.35	3.88e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs965469	0.779	rs6133039	chr20:3385006	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-6.36	-0.33	6.5e-10	IFN-related cytopenia;
LIHC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	9.26	0.45	2.24e-18	Schizophrenia;
LIHC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg14440974	chr22:39074834	NA	-0.44	-7.1	-0.36	7.19e-12	Menopause (age at onset);
LIHC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.46	6.04	0.31	4e-9	Primary sclerosing cholangitis;
LIHC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-7.42	-0.37	9.06e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-9.68	-0.46	9.39e-20	Parkinson's disease;
LIHC	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.06	-0.31	3.53e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.65	-11.98	-0.54	7.41e-28	Lymphocyte percentage of white cells;
LIHC	cis	rs3106136	0.678	rs6532484	chr4:95297118	C/T	cg11021082	chr4:95130006	SMARCAD1	0.36	6.14	0.32	2.27e-9	Capecitabine sensitivity;
LIHC	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.36	-8.43	-0.41	9.85e-16	Corneal astigmatism;
LIHC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.88	-0.51	7.1e-24	Schizophrenia;
LIHC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.57	8.7	0.43	1.42e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.44	-6.0	-0.31	5.08e-9	Obesity-related traits;
LIHC	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	0.7	7.88	0.39	4.55e-14	Coronary artery disease;
LIHC	cis	rs3770081	0.590	rs79329534	chr2:86458631	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.74	-7.23	-0.36	3.13e-12	Facial emotion recognition (sad faces);
LIHC	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.6	8.29	0.41	2.71e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg11062466	chr8:58055876	NA	0.51	7.61	0.38	2.72e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg16926213	chr1:1841314	NA	0.32	5.93	0.31	7.41e-9	Body mass index;
LIHC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.91	13.85	0.6	6.07e-35	Obesity-related traits;
LIHC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.57	-0.5	8.56e-23	Waist circumference;Body mass index;
LIHC	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.04e-8	Coronary artery disease;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.15	-0.32	2.19e-9	Aortic root size;
LIHC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.62	9.91	0.47	1.64e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.11	-0.31	2.72e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.64	0.53	1.34e-26	Platelet count;
LIHC	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg07451762	chr16:28383216	NA	0.39	6.87	0.35	3.05e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19553056	chr4:142142166	ZNF330	0.46	6.59	0.34	1.68e-10	Pancreatic cancer;
LIHC	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-6.8	-0.35	4.74e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2834188	0.961	rs8130807	chr21:34690013	A/G	cg04842828	chr21:34696676	IFNAR1	0.45	6.14	0.32	2.31e-9	Narcolepsy;
LIHC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.44	-6.5	-0.33	2.82e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.51	7.9	0.39	3.83e-14	Corneal astigmatism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27305525	chr1:154955752	FLAD1	0.38	6.37	0.33	5.96e-10	Cognitive function;
LIHC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.91	8.21	0.41	4.74e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.75	9.73	0.47	6.53e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	18.36	0.7	6.84e-53	Tonsillectomy;
LIHC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.76	13.09	0.58	5.08e-32	Mean platelet volume;
LIHC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.39	-6.35	-0.32	6.69e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.7	12.46	0.56	1.2e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	8.11	0.4	9.44e-15	Platelet count;
LIHC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.59	7.89	0.39	4.14e-14	Coronary artery disease;
LIHC	cis	rs988712	0.516	rs6484320	chr11:27703188	T/A	cg18117895	chr11:27722066	BDNF	-0.51	-7.13	-0.36	6.04e-12	Obesity;
LIHC	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-5.8	-0.3	1.48e-8	Diastolic blood pressure;
LIHC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg18912006	chr12:123335444	HIP1R	-0.63	-7.58	-0.38	3.18e-13	Schizophrenia;
LIHC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.46	6.89	0.35	2.65e-11	Blood protein levels;
LIHC	cis	rs7165170	0.678	rs10083558	chr15:91202504	C/A	cg26821196	chr15:91095069	CRTC3	-0.36	-6.52	-0.33	2.49e-10	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.57	7.89	0.39	4.18e-14	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg26338869	chr17:61819248	STRADA	0.54	7.42	0.37	9.33e-13	Height;
LIHC	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.41	-0.37	1.03e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.74	-0.5	2.15e-23	Alzheimer's disease (late onset);
LIHC	trans	rs9834975	0.565	rs4677957	chr3:122257767	G/A	cg18228109	chr6:162684441	PARK2	0.33	6.09	0.31	3.04e-9	Diastolic blood pressure;
LIHC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	11.67	0.53	1.02e-26	Mean platelet volume;
LIHC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.6	7.87	0.39	4.57e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.5	9.15	0.44	5.35e-18	Height;
LIHC	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	6.02	0.31	4.54e-9	Lung cancer;
LIHC	cis	rs11166927	1.000	rs13256946	chr8:140805101	G/A	cg16909799	chr8:140841666	TRAPPC9	0.51	8.05	0.4	1.38e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.61	7.15	0.36	5.42e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.93	8.18	0.4	5.53e-15	Breast cancer;
LIHC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.43	7.0	0.35	1.34e-11	Bipolar disorder;
LIHC	cis	rs11098699	0.898	rs2047202	chr4:124233100	C/G	cg09941581	chr4:124220074	SPATA5	-0.3	-5.72	-0.3	2.3e-8	Mosquito bite size;
LIHC	cis	rs2574704	0.851	rs3856795	chr3:11630484	G/A	cg15876825	chr3:11651881	VGLL4	-0.48	-7.78	-0.39	8.62e-14	Body mass index;
LIHC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.53	-8.42	-0.41	1.01e-15	Colorectal cancer;
LIHC	cis	rs67981189	0.552	rs9323556	chr14:71469512	T/C	cg15816911	chr14:71606274	NA	0.41	6.54	0.33	2.2e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00011284	chr16:53469344	RBL2	0.5	7.71	0.38	1.43e-13	Cognitive function;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg02869306	chr7:64672164	INTS4L1	-0.3	-6.41	-0.33	4.69e-10	Calcium levels;
LIHC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.92	9.63	0.46	1.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.64	6.95	0.35	1.88e-11	Alzheimer's disease;
LIHC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.79	13.09	0.58	5.05e-32	Breast cancer;
LIHC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.68	0.59	2.85e-34	Lung cancer in ever smokers;
LIHC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.2	-0.36	3.88e-12	Axial length;
LIHC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.6	-0.34	1.57e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.81	8.24	0.41	3.73e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.31	0.41	2.33e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs903552	0.736	rs9806495	chr15:102008059	G/A	cg06707286	chr15:102010195	PCSK6	-0.53	-7.57	-0.38	3.43e-13	Diabetic kidney disease;
LIHC	cis	rs244293	0.673	rs12944690	chr17:53029614	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-5.96	-0.31	6.18e-9	Menarche (age at onset);
LIHC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.1	0.31	2.86e-9	Rheumatoid arthritis;
LIHC	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.54	9.26	0.45	2.31e-18	Obesity-related traits;
LIHC	cis	rs263063	0.834	rs710957	chr19:5054345	G/C	cg18473234	chr19:5097819	KDM4B	0.56	6.98	0.35	1.5e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.61	-10.93	-0.51	4.92e-24	Gestational age at birth (maternal effect);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.38	6.57	0.33	1.89e-10	Cognitive function;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.82	0.39	6.59e-14	Height;
LIHC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.59	9.25	0.45	2.45e-18	High light scatter reticulocyte count;
LIHC	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	0.99	7.88	0.39	4.4e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.16	0.32	2.08e-9	Glycated hemoglobin levels;
LIHC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.55	0.53	2.81e-26	Lung cancer in ever smokers;
LIHC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.54	-0.33	2.3e-10	Lung cancer in ever smokers;
LIHC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.25	-0.61	1.78e-36	Alzheimer's disease;
LIHC	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.22	0.58	1.62e-32	Coffee consumption (cups per day);
LIHC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.51	9.06	0.44	1.04e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7937890	0.587	rs11023204	chr11:14411223	C/A	cg02886208	chr11:14281011	SPON1	-0.51	-7.22	-0.36	3.34e-12	Mitochondrial DNA levels;
LIHC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg12140854	chr5:148520817	ABLIM3	0.52	5.97	0.31	6.08e-9	Breast cancer;
LIHC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.45	-0.45	5.63e-19	Colorectal cancer;
LIHC	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg02702477	chr5:179499311	RNF130	0.9	11.93	0.54	1.11e-27	LDL cholesterol;
LIHC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.6	6.58	0.33	1.82e-10	Alzheimer's disease;
LIHC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.3e-9	Aortic root size;
LIHC	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.63	10.59	0.5	7.25e-23	Coronary artery disease;
LIHC	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.28	-6.99	-0.35	1.45e-11	Gut microbiome composition (winter);
LIHC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.69	-0.5	3.32e-23	Alcohol dependence;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.33	-0.37	1.71e-12	Bipolar disorder;
LIHC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.98	-10.03	-0.48	6.22e-21	Breast cancer;
LIHC	trans	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg26939375	chr7:64535504	NA	0.4	6.29	0.32	9.67e-10	Aortic root size;
LIHC	cis	rs3762637	0.941	rs79493664	chr3:122109546	T/A	cg24169773	chr3:122142474	KPNA1	-0.47	-9.16	-0.44	4.72e-18	LDL cholesterol levels;
LIHC	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.19	0.52	5.57e-25	Cognitive test performance;
LIHC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	7.99	0.4	2.08e-14	IgG glycosylation;
LIHC	cis	rs2073300	1.000	rs2236021	chr20:23432528	A/G	cg12062639	chr20:23401060	NAPB	0.81	9.68	0.46	9.91e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.72	-9.63	-0.46	1.44e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.77	-12.97	-0.57	1.48e-31	Hip circumference adjusted for BMI;
LIHC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.6	10.26	0.49	1.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.82	0.65	1.12e-42	Chronic sinus infection;
LIHC	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg23254163	chr1:152506842	NA	0.23	5.98	0.31	5.64e-9	Hair morphology;
LIHC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.18	-0.32	1.83e-9	Arsenic metabolism;
LIHC	cis	rs7250872	0.606	rs2304616	chr19:1826164	G/T	cg18850929	chr19:1828978	REXO1	0.39	6.29	0.32	9.44e-10	Bipolar disorder;
LIHC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.84	14.61	0.62	6.92e-38	Headache;
LIHC	trans	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg26939375	chr7:64535504	NA	-0.43	-6.98	-0.35	1.52e-11	Aortic root size;
LIHC	cis	rs74233809	1.000	rs1060240	chr10:104883337	A/G	cg03493300	chr10:104813866	CNNM2	0.47	6.34	0.32	7.15e-10	Birth weight;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.37	-6.11	-0.31	2.76e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.59	9.94	0.47	1.31e-20	Bipolar disorder;
LIHC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.76	-12.53	-0.56	6.92e-30	Breast cancer;
LIHC	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.94	-0.31	6.88e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.77	6.47	0.33	3.44e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.75	10.9	0.51	5.9e-24	Corneal astigmatism;
LIHC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.84	10.57	0.5	8.49e-23	Cognitive function;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg02990361	chr1:107599529	PRMT6	0.65	10.94	0.51	4.43e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08706837	chr1:37940090	ZC3H12A	-0.48	-6.2	-0.32	1.64e-9	Systolic blood pressure;
LIHC	trans	rs75804782	0.521	rs58568091	chr2:239430582	G/A	cg01134436	chr17:81009848	B3GNTL1	0.74	6.4	0.33	5.04e-10	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25373372	chr6:82462656	FAM46A	0.38	6.1	0.31	2.84e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg05941027	chr17:61774174	LIMD2	0.35	7.47	0.37	6.81e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg16989086	chr20:62203971	PRIC285	0.57	8.23	0.41	3.97e-15	Glioblastoma;
LIHC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-10.55	-0.5	1.06e-22	Crohn's disease;
LIHC	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.91	-0.3	8.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg12863693	chr15:85201151	NMB	0.48	6.86	0.35	3.31e-11	Schizophrenia;
LIHC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21545522	chr1:205238299	TMCC2	0.42	7.89	0.39	4.1e-14	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg06012730	chr15:75315579	PPCDC	-0.35	-6.32	-0.32	7.99e-10	Blood trace element (Zn levels);
LIHC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.39	6.98	0.35	1.51e-11	Schizophrenia;
LIHC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.42	0.56	1.67e-29	Chronic sinus infection;
LIHC	cis	rs7119038	0.865	rs4938573	chr11:118741842	C/T	cg19308663	chr11:118741387	NA	-0.47	-6.13	-0.31	2.38e-9	Sjögren's syndrome;
LIHC	cis	rs28475163	0.958	rs7395116	chr11:324880	C/G	cg03071500	chr11:325964	NA	0.46	7.56	0.38	3.84e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.98	-0.31	5.65e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.95	-0.35	1.8e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.36	0.37	1.4e-12	Prudent dietary pattern;
LIHC	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-20.36	-0.74	6.4e-61	Exhaled nitric oxide output;
LIHC	cis	rs4742903	0.935	rs10991168	chr9:106974902	C/T	cg14250997	chr9:106856677	SMC2	0.35	5.83	0.3	1.32e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg10756647	chr7:56101905	PSPH	0.63	8.62	0.42	2.51e-16	Corneal structure;
LIHC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.14	0.52	8.66e-25	Hemoglobin concentration;
LIHC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.41	5.81	0.3	1.45e-8	Schizophrenia;
LIHC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg09182678	chr22:50328711	NA	-0.43	-6.11	-0.31	2.72e-9	Schizophrenia;
LIHC	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.41	-6.07	-0.31	3.45e-9	Height;
LIHC	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.69	-12.54	-0.56	5.98e-30	Mean platelet volume;
LIHC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg07117364	chr1:16154769	NA	-0.39	-6.96	-0.35	1.77e-11	Dilated cardiomyopathy;
LIHC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.72	-9.56	-0.46	2.48e-19	Body mass index;
LIHC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.58	-10.01	-0.48	7.69e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg22676075	chr6:135203613	NA	0.38	6.3	0.32	9.22e-10	Red blood cell count;
LIHC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.66	0.53	1.12e-26	Colorectal cancer;
LIHC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg16070018	chr6:26224392	HIST1H3E	0.56	6.67	0.34	1.06e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12463550	chr7:65579703	CRCP	-0.68	-7.09	-0.36	7.77e-12	Diabetic kidney disease;
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.65	-9.05	-0.44	1.14e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.56	-9.46	-0.46	5e-19	Paraoxonase activity;
LIHC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg21724239	chr8:58056113	NA	0.48	6.36	0.33	6.53e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	8.24	0.41	3.81e-15	Coronary artery disease;
LIHC	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg16275483	chr1:110013120	SYPL2	-0.47	-5.77	-0.3	1.78e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.26	-14.53	-0.62	1.32e-37	Diabetic kidney disease;
LIHC	cis	rs7945718	0.592	rs6416153	chr11:12684263	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.48e-11	Height;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.25	0.75	1.7600000000000002e-64	Prudent dietary pattern;
LIHC	cis	rs986417	1.000	rs2350900	chr14:60938681	T/A	cg27398547	chr14:60952738	C14orf39	0.88	10.26	0.49	1.06e-21	Gut microbiota (bacterial taxa);
LIHC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.71	13.15	0.58	2.99e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.65	0.42	2.06e-16	Initial pursuit acceleration;
LIHC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg05347473	chr6:146136440	FBXO30	0.37	5.99	0.31	5.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.53	8.19	0.4	5.39e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg16479474	chr6:28041457	NA	0.47	7.15	0.36	5.22e-12	Parkinson's disease;
LIHC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.74	0.3	2.11e-8	Bladder cancer;
LIHC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	1.17	10.91	0.51	5.5e-24	Obesity-related traits;
LIHC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	7.75	0.39	1.03e-13	Schizophrenia;
LIHC	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg02640540	chr1:67518911	SLC35D1	-0.44	-7.03	-0.36	1.13e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs151997	0.962	rs28090	chr5:50177509	T/C	cg06027927	chr5:50259733	NA	0.57	7.59	0.38	3.05e-13	Callous-unemotional behaviour;
LIHC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01812927	chr12:124901281	NCOR2	0.43	6.7	0.34	8.56e-11	Bilirubin levels;
LIHC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg00343986	chr7:65444356	GUSB	-0.38	-5.71	-0.3	2.45e-8	Aortic root size;
LIHC	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.51	8.02	0.4	1.7e-14	Total body bone mineral density;
LIHC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg27523141	chr10:43048294	ZNF37B	0.37	6.47	0.33	3.32e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.86	-0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.49	6.65	0.34	1.16e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.51	-8.54	-0.42	4.46e-16	Blood metabolite levels;
LIHC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg18357645	chr12:58087776	OS9	-0.45	-6.98	-0.35	1.49e-11	Multiple sclerosis;
LIHC	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.43	-0.33	4.26e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs992157	0.764	rs2891077	chr2:219184430	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.15	0.48	2.48e-21	Colorectal cancer;
LIHC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21467203	chr3:49911342	NA	0.5	9.0	0.44	1.63e-17	Body mass index;
LIHC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg01557791	chr16:72042693	DHODH	-0.4	-6.72	-0.34	7.74e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.69	11.33	0.52	1.78e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22828147	chr6:4776490	CDYL	0.43	6.52	0.33	2.54e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20135002	chr11:47629003	NA	-0.51	-8.75	-0.43	9.91e-17	Subjective well-being;
LIHC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.58	-8.18	-0.4	5.57e-15	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg07424592	chr7:64974309	NA	0.79	9.19	0.44	4.01e-18	Diabetic kidney disease;
LIHC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.78	-11.72	-0.54	6.46e-27	Breast cancer;
LIHC	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg24449463	chr1:168025552	DCAF6	-0.5	-6.23	-0.32	1.34e-9	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.25	-0.36	2.82e-12	Migraine;Coronary artery disease;
LIHC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg03934865	chr2:198174659	NA	0.57	8.76	0.43	9.31e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg16088116	chr21:44841560	SIK1	-0.42	-6.52	-0.33	2.59e-10	Coronary artery disease;
LIHC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.86	15.21	0.64	2.93e-40	Headache;
LIHC	cis	rs243505	0.660	rs3807450	chr7:148522269	C/A	cg09806900	chr7:148480153	CUL1	0.43	6.12	0.31	2.59e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.45	-7.39	-0.37	1.13e-12	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LIHC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.83	-13.27	-0.58	1.01e-32	Coronary artery disease;
LIHC	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.87	0.3	1.05e-8	Educational attainment;
LIHC	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg16724585	chr3:197361211	NA	-0.48	-6.77	-0.34	5.65e-11	Pancreatic cancer;
LIHC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg06627628	chr2:24431161	ITSN2	-0.66	-7.74	-0.39	1.16e-13	Lymphocyte counts;
LIHC	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	11.37	0.52	1.22e-25	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.38	6.09	0.31	2.98e-9	Melanoma;
LIHC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.78	0.39	8.78e-14	Height;
LIHC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg24209194	chr3:40518798	ZNF619	-0.44	-6.27	-0.32	1.09e-9	Renal cell carcinoma;
LIHC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.56	-0.33	2e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs7619427	0.908	rs7617917	chr3:44081434	G/A	cg24966902	chr3:44043705	NA	0.42	6.09	0.31	3e-9	Schizophrenia;
LIHC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	0.84	11.66	0.53	1.09e-26	Skin colour saturation;
LIHC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.29	0.45	1.86e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.51	-8.56	-0.42	3.8e-16	Bipolar disorder;
LIHC	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.6	-10.26	-0.49	1.03e-21	Pediatric autoimmune diseases;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.81	0.5	1.29e-23	Lymphocyte counts;
LIHC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.37	5.92	0.3	7.76e-9	Age at first birth;
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26076054	chr5:421317	AHRR	0.27	5.94	0.31	6.88e-9	Cystic fibrosis severity;
LIHC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.08	9.8	0.47	3.72e-20	Diabetic retinopathy;
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.79	-9.64	-0.46	1.28e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.65	8.36	0.41	1.64e-15	Gut microbiome composition (summer);
LIHC	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.34	-8.06	-0.4	1.33e-14	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01353569	chr7:106810328	HBP1	0.4	6.4	0.33	5.12e-10	Cognitive function;
LIHC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	6.04e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.52	-5.97	-0.31	5.83e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02450064	chr17:40260053	DHX58	-0.3	-6.15	-0.32	2.17e-9	Fibrinogen levels;
LIHC	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.37	-7.13	-0.36	5.82e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.35	0.37	1.51e-12	Prudent dietary pattern;
LIHC	cis	rs1570989	0.841	rs9349054	chr6:12029312	C/T	cg17804551	chr6:12015979	HIVEP1	-0.41	-6.26	-0.32	1.14e-9	Alcohol and nicotine co-dependence;
LIHC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.68	-8.84	-0.43	5.19e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg19680672	chr10:131412579	MGMT	-0.38	-5.8	-0.3	1.49e-8	Response to temozolomide;
LIHC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg05425664	chr17:57184151	TRIM37	-0.45	-6.24	-0.32	1.3e-9	Testicular germ cell tumor;
LIHC	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg12698662	chr3:15914712	MIR563	-0.39	-7.23	-0.36	3.12e-12	Mean platelet volume;
LIHC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.26	0.58	1.16e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.77	6.54	0.33	2.24e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	cis	rs9596863	1.000	rs1545659	chr13:54433788	G/A	ch.13.53330881F	chr13:54432880	NA	-0.45	-6.43	-0.33	4.18e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.47e-9	Cognitive performance;
LIHC	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg00277334	chr10:82204260	NA	-0.51	-6.37	-0.33	6.11e-10	Post bronchodilator FEV1;
LIHC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.52	6.71	0.34	7.93e-11	Orofacial clefts;
LIHC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.62	7.51	0.38	5.29e-13	Cognitive function;
LIHC	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	0.94	19.26	0.72	1.66e-56	Schizophrenia;
LIHC	cis	rs2412488	0.815	rs13150384	chr4:54357457	T/A	cg22241045	chr4:54363911	LNX1	0.41	6.61	0.34	1.44e-10	DNA methylation (variation);
LIHC	cis	rs9309473	0.607	rs58962779	chr2:73555801	T/C	cg20560298	chr2:73613845	ALMS1	-0.41	-6.43	-0.33	4.32e-10	Metabolite levels;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg07725925	chr16:89976287	TCF25	-0.4	-5.82	-0.3	1.33e-8	Skin colour saturation;
LIHC	cis	rs7487075	0.780	rs10785624	chr12:46766787	C/T	cg21428710	chr12:47219797	SLC38A4	0.28	5.92	0.31	7.71e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2637266	0.626	rs846619	chr10:78545449	A/G	cg18941641	chr10:78392320	NA	0.3	6.37	0.33	6.08e-10	Pulmonary function;
LIHC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg14440974	chr22:39074834	NA	0.42	6.65	0.34	1.13e-10	Menopause (age at onset);
LIHC	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg06359132	chr10:99160096	RRP12	-0.4	-6.22	-0.32	1.45e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg00280220	chr17:61926910	NA	0.41	6.27	0.32	1.09e-9	Prudent dietary pattern;
LIHC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.5	6.64	0.34	1.25e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2274273	0.967	rs8013027	chr14:55610940	C/G	cg01864836	chr14:55583639	NA	-0.39	-7.25	-0.37	2.76e-12	Protein biomarker;
LIHC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.49	8.75	0.43	9.76e-17	HDL cholesterol levels;
LIHC	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg09572067	chr16:29127029	RRN3P2	0.51	8.06	0.4	1.3e-14	Menopause (age at onset);
LIHC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	1.07	14.56	0.62	1.06e-37	Heart rate;
LIHC	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg08345082	chr10:99160200	RRP12	-0.4	-7.06	-0.36	9.47e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.45	7.03	0.36	1.13e-11	Melanoma;
LIHC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg17764715	chr19:33622953	WDR88	0.41	5.79	0.3	1.61e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.65	11.63	0.53	1.39e-26	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg02023728	chr11:77925099	USP35	-0.33	-5.86	-0.3	1.09e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.93	0.31	7.49e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs61041384	0.661	rs74240768	chr12:123683976	T/C	cg00376283	chr12:123451042	ABCB9	-0.55	-6.14	-0.32	2.28e-9	Schizophrenia;
LIHC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg12863693	chr15:85201151	NMB	0.44	6.31	0.32	8.81e-10	Schizophrenia;
LIHC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.36	-18.54	-0.71	1.3e-53	Gout;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.49	7.25	0.37	2.78e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.82	0.54	2.99e-27	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.55	0.33	2.09e-10	Prudent dietary pattern;
LIHC	cis	rs15676	0.947	rs2977994	chr9:131585216	G/T	cg00228799	chr9:131580591	ENDOG	0.47	7.15	0.36	5.46e-12	Blood metabolite levels;
LIHC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.71	-10.55	-0.5	1.05e-22	Aortic root size;
LIHC	cis	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg16684958	chr7:75615977	POR	0.44	6.67	0.34	1.05e-10	Eotaxin levels;
LIHC	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg23254163	chr1:152506842	NA	0.24	6.23	0.32	1.34e-9	Hair morphology;
LIHC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.53	10.32	0.49	6.35e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.45	8.37	0.41	1.55e-15	Prudent dietary pattern;
LIHC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.6	11.19	0.52	5.83e-25	Systemic lupus erythematosus;
LIHC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.37	-5.8	-0.3	1.48e-8	Breast cancer;
LIHC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	9.92	0.47	1.48e-20	Electrocardiographic conduction measures;
LIHC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg16226627	chr15:75307476	SCAMP5	0.52	8.84	0.43	5.23e-17	Lung cancer;
LIHC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15541040	chr2:3486749	NA	-0.43	-6.49	-0.33	2.94e-10	Neurofibrillary tangles;
LIHC	trans	rs9641123	0.639	rs2251307	chr7:93207036	A/G	cg09745688	chr16:2908918	PRSS22	-0.37	-6.43	-0.33	4.22e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	0.89	6.49	0.33	3.1e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg12661370	chr5:149340060	SLC26A2	0.51	6.18	0.32	1.8e-9	HIV-1 control;
LIHC	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.84	-0.3	1.23e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.29	-6.22	-0.32	1.43e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.25	0.32	1.24e-9	Schizophrenia;
LIHC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.44	-7.8	-0.39	7.5e-14	Aortic root size;
LIHC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.66	10.11	0.48	3.4e-21	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2108622	0.727	rs62107770	chr19:15985425	A/G	cg13772218	chr19:15982569	NA	0.37	7.57	0.38	3.48e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg22834771	chr12:69754056	YEATS4	-0.39	-6.38	-0.33	5.79e-10	Response to diuretic therapy;
LIHC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.84	-0.39	5.94e-14	Electroencephalogram traits;
LIHC	trans	rs9475752	0.564	rs7744799	chr6:56743843	C/T	cg25726699	chr6:135826776	C6orf217	0.41	6.16	0.32	2.05e-9	Menarche (age at onset);
LIHC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg23791538	chr6:167370224	RNASET2	0.43	7.12	0.36	6.48e-12	Primary biliary cholangitis;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.0	0.58	1.11e-31	Prudent dietary pattern;
LIHC	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.57	9.33	0.45	1.34e-18	Schizophrenia;
LIHC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.95	20.5	0.74	1.68e-61	Blood protein levels;
LIHC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.6	-10.47	-0.49	1.94e-22	Dental caries;
LIHC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.69	-9.54	-0.46	2.69e-19	Corneal structure;
LIHC	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.29	0.37	2.15e-12	Fuchs's corneal dystrophy;
LIHC	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18898632	chr2:242989856	NA	-0.47	-6.68	-0.34	9.56e-11	Obesity-related traits;
LIHC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-10.12	-0.48	3.12e-21	Lung cancer;
LIHC	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg07451762	chr16:28383216	NA	0.36	6.21	0.32	1.56e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg10978503	chr1:24200527	CNR2	0.29	6.94	0.35	2.01e-11	Immature fraction of reticulocytes;
LIHC	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.75	13.07	0.58	6.06e-32	Tonsillectomy;
LIHC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg25828445	chr12:7781288	NA	0.44	6.75	0.34	6.36e-11	HDL cholesterol levels;
LIHC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.44e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.69	-9.97	-0.47	9.86e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.53	-0.38	4.6e-13	Post bronchodilator FEV1;
LIHC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.32	-7.33	-0.37	1.7e-12	Menarche (age at onset);
LIHC	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg00204512	chr16:28754710	NA	0.29	5.75	0.3	1.97e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-7.29	-0.37	2.14e-12	Renal cell carcinoma;
LIHC	cis	rs9467160	0.520	rs9379660	chr6:24441635	C/G	cg20631270	chr6:24437470	GPLD1	0.43	6.62	0.34	1.42e-10	Liver enzyme levels;
LIHC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.16	-8.65	-0.42	2.07e-16	Body mass index;
LIHC	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.57	-8.18	-0.4	5.49e-15	Blood pressure (smoking interaction);
LIHC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-17.69	-0.69	3.63e-50	Height;
LIHC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.89	0.39	4.02e-14	Multiple sclerosis;
LIHC	trans	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.01	0.35	1.29e-11	Ulcerative colitis;
LIHC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.42	-9.79	-0.47	4.01e-20	Type 2 diabetes;
LIHC	cis	rs13161895	1.000	rs12656814	chr5:179471556	G/A	cg02702477	chr5:179499311	RNF130	0.8	11.17	0.52	6.67e-25	LDL cholesterol;
LIHC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.62	10.89	0.51	6.47e-24	Extrinsic epigenetic age acceleration;
LIHC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.16	-0.32	1.99e-9	Height;
LIHC	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg17425144	chr1:10567563	PEX14	0.63	13.11	0.58	4.31e-32	Breast size;
LIHC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-0.92	-10.38	-0.49	4.13e-22	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.31	0.7	1.07e-52	Smoking behavior;
LIHC	cis	rs77861329	1.000	rs352149	chr3:52209530	C/A	cg08692210	chr3:52188851	WDR51A	0.83	7.96	0.4	2.61e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs9980664	0.591	rs58886971	chr21:34678942	G/A	cg04842828	chr21:34696676	IFNAR1	0.48	5.89	0.3	9.09e-9	Cognitive decline (age-related);
LIHC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg21466736	chr12:48725269	NA	0.63	9.01	0.44	1.43e-17	Glycated hemoglobin levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23861889	chr2:45878066	PRKCE	0.44	6.04	0.31	4.02e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg12863693	chr15:85201151	NMB	-0.4	-5.86	-0.3	1.08e-8	Schizophrenia;
LIHC	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.8	-0.39	7.43e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.96	0.35	1.72e-11	Red blood cell count;
LIHC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.88	0.3	9.6e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg06951627	chr6:26196580	NA	0.55	6.43	0.33	4.39e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	0.98	6.47	0.33	3.34e-10	Mitochondrial DNA levels;
LIHC	cis	rs6565189	0.865	rs4500746	chr16:30504344	T/C	cg17640201	chr16:30407289	ZNF48	0.54	6.23	0.32	1.37e-9	Tonsillectomy;
LIHC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15153026	chr7:143058944	FAM131B	-0.42	-6.13	-0.31	2.38e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.66	0.53	1.09e-26	Prudent dietary pattern;
LIHC	cis	rs17106184	1.000	rs72900957	chr1:51145808	A/G	cg07174182	chr1:51127561	FAF1	-0.61	-6.54	-0.33	2.25e-10	Type 2 diabetes;
LIHC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.52	6.69	0.34	9.28e-11	Initial pursuit acceleration;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19226647	chr10:114710611	TCF7L2	-0.48	-6.7	-0.34	8.64e-11	Migraine with aura;
LIHC	cis	rs273218	0.724	rs392714	chr5:53382703	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.52	8.43	0.41	9.87e-16	Migraine;
LIHC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.98	0.44	1.83e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.76	11.6	0.53	1.88e-26	Corneal astigmatism;
LIHC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.54e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.84	0.43	5.14e-17	Platelet count;
LIHC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.36	0.37	1.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23104823	chr14:45553408	PRPF39	0.39	6.51	0.33	2.68e-10	Cognitive function;
LIHC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.9	-0.35	2.54e-11	Response to antipsychotic treatment;
LIHC	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	5.72	0.3	2.39e-8	Breast cancer;
LIHC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.81	0.35	4.38e-11	Coronary artery disease;
LIHC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02985541	chr2:219472218	PLCD4	0.42	6.63	0.34	1.3e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.51	-0.53	3.76e-26	Coronary artery disease;
LIHC	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.3	-6.65	-0.34	1.15e-10	DNA methylation (variation);
LIHC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.58	11.32	0.52	1.93e-25	Coronary artery disease;
LIHC	cis	rs10411936	0.712	rs3810198	chr19:16601194	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.91	0.35	2.32e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs2758596	0.826	rs2758606	chr1:156201920	G/A	cg24450063	chr1:156163899	SLC25A44	1.0	10.59	0.5	7.7e-23	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.63	8.12	0.4	8.29e-15	Morning vs. evening chronotype;
LIHC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-6.59	-0.34	1.63e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2741335	0.876	rs2565055	chr8:27337380	G/T	cg07150473	chr8:27338183	CHRNA2	-0.47	-6.67	-0.34	1.02e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg14393609	chr7:65229607	NA	0.36	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.59	8.57	0.42	3.56e-16	Schizophrenia;
LIHC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.87	10.79	0.5	1.54e-23	Bladder cancer;
LIHC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.58	10.38	0.49	4.09e-22	Mean corpuscular volume;
LIHC	cis	rs2978263	0.628	rs1010054	chr8:30309947	C/T	cg05780722	chr8:30327988	RBPMS	0.32	6.13	0.31	2.49e-9	Cognitive performance;
LIHC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.93	-17.61	-0.69	7.14e-50	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.72	-0.39	1.28e-13	Total body bone mineral density;
LIHC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.41	7.19	0.36	4.1e-12	Schizophrenia;
LIHC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.77	9.68	0.46	9.51e-20	Cognitive function;
LIHC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.66	9.13	0.44	6.3e-18	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg19645103	chr12:69753606	YEATS4	-0.46	-6.32	-0.32	8.13e-10	Response to diuretic therapy;
LIHC	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.52	6.24	0.32	1.32e-9	Serum sulfate level;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.54	-7.22	-0.36	3.41e-12	Menopause (age at onset);
LIHC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.96	15.52	0.64	1.69e-41	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09071838	chr13:25497213	CENPJ	0.45	6.85	0.35	3.47e-11	Lung function (FEV1/FVC);
LIHC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.42	-7.92	-0.39	3.44e-14	Diastolic blood pressure;
LIHC	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.45	-6.37	-0.33	5.93e-10	Economic and political preferences (feminism/equality);
LIHC	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.23	-0.32	1.35e-9	Response to antipsychotic treatment;
LIHC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.25	0.48	1.14e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.53	9.98	0.48	9.08e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs1198430	0.925	rs2811975	chr1:23801081	A/T	cg13183780	chr1:23809682	ASAP3	-0.56	-7.9	-0.39	3.86e-14	Total cholesterol levels;
LIHC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.51	7.93	0.39	3.15e-14	High light scatter reticulocyte count;
LIHC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.34e-17	Gut microbiome composition (summer);
LIHC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg20887711	chr4:1340912	KIAA1530	0.46	7.04	0.36	1.05e-11	Obesity-related traits;
LIHC	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.58	-7.96	-0.4	2.62e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.67	8.87	0.43	4.23e-17	Blood metabolite levels;
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.58	10.64	0.5	5.14e-23	Height;
LIHC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg11839771	chr15:80205821	ST20	-0.28	-5.73	-0.3	2.25e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg12798992	chr6:167411361	FGFR1OP	0.46	6.9	0.35	2.51e-11	Primary biliary cholangitis;
LIHC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.71	-12.94	-0.57	1.89e-31	Crohn's disease;
LIHC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg20278634	chr1:36274212	EIF2C4	0.4	6.1	0.31	2.89e-9	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00938859	chr5:1591904	SDHAP3	0.59	7.22	0.36	3.33e-12	Breast cancer;
LIHC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.55	-0.33	2.1e-10	Response to antipsychotic treatment;
LIHC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.33	-6.51	-0.33	2.6200000000000003e-10	Multiple sclerosis;
LIHC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.46	8.4	0.41	1.22e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.62	-9.89	-0.47	1.88e-20	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11079354	chr6:27740361	NA	0.46	7.05	0.36	9.7e-12	Pancreatic cancer;
LIHC	cis	rs2257205	0.588	rs7219856	chr17:56941020	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-6.69	-0.34	9.14e-11	Pancreatic cancer;
LIHC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.67	0.57	1.98e-30	Total body bone mineral density;
LIHC	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg16914508	chr2:239161102	PER2	0.83	5.97	0.31	5.94e-9	Irritable bowel syndrome;
LIHC	cis	rs17102884	0.506	rs10873274	chr14:75407372	G/T	cg11812906	chr14:75593930	NEK9	-0.48	-8.06	-0.4	1.3e-14	Neuroticism;
LIHC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.33	-0.37	1.63e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.55	-9.98	-0.47	9.62e-21	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.55	-9.46	-0.46	5.3e-19	Age at first birth;
LIHC	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.92	9.76	0.47	5.28e-20	Morning vs. evening chronotype;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.64	10.07	0.48	4.57e-21	Longevity;
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.61	0.8	1.06e-77	Prudent dietary pattern;
LIHC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.15	0.36	5.31e-12	Parkinson's disease;
LIHC	trans	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.63	-0.38	2.36e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.89	15.59	0.64	9.3e-42	Colorectal cancer;
LIHC	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.46	-6.13	-0.31	2.47e-9	Psoriasis;
LIHC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg26939375	chr7:64535504	NA	0.47	7.95	0.39	2.81e-14	Calcium levels;
LIHC	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.91	-0.3	8.3e-9	Coronary artery disease;
LIHC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.55	-8.43	-0.41	9.93e-16	Height;
LIHC	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.28	-7.01	-0.35	1.27e-11	Gut microbiome composition (winter);
LIHC	cis	rs7106204	1.000	rs35876423	chr11:24214859	G/T	ch.11.24196551F	chr11:24239977	NA	0.68	6.83	0.35	3.89e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.65	5.84	0.3	1.21e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.47	6.27	0.32	1.1e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.37	-6.07	-0.31	3.38e-9	Melanoma;
LIHC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg11861562	chr11:117069780	TAGLN	0.49	8.01	0.4	1.82e-14	Blood protein levels;
LIHC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.07e-40	Aortic root size;
LIHC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.75	7.61	0.38	2.61e-13	Alzheimer's disease;
LIHC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg12297030	chr17:43662878	NA	-0.63	-6.06	-0.31	3.69e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	0.89	12.39	0.56	2.18e-29	Skin colour saturation;
LIHC	trans	rs2284367	0.505	rs4756151	chr11:34495358	C/A	cg02390588	chr12:53722253	SP7	-0.4	-6.06	-0.31	3.55e-9	Blood protein levels;
LIHC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.68	-12.27	-0.55	6.1e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	6.06	0.31	3.67e-9	Renal cell carcinoma;
LIHC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02290350	chr8:58132656	NA	0.38	8.15	0.4	6.86e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg08213375	chr14:104286397	PPP1R13B	0.56	9.76	0.47	5.21e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	8.04	0.4	1.52e-14	Mean platelet volume;
LIHC	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg22676075	chr6:135203613	NA	0.41	6.5	0.33	2.93e-10	Red blood cell count;
LIHC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.45	-7.25	-0.36	2.82e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.55	-9.05	-0.44	1.12e-17	Obesity-related traits;
LIHC	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg24060327	chr5:131705240	SLC22A5	0.55	7.44	0.37	8.01e-13	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	9.39	0.45	8.53e-19	Response to antipsychotic treatment;
LIHC	cis	rs4908768	0.501	rs1473420	chr1:8616838	T/G	cg20416874	chr1:8611966	RERE	-0.7	-15.26	-0.64	1.9e-40	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.06	19.53	0.73	1.43e-57	Mitochondrial DNA levels;
LIHC	cis	rs6761276	0.505	rs13019891	chr2:113829869	G/T	cg12858261	chr2:113808755	IL1F8	0.42	6.64	0.34	1.21e-10	Protein quantitative trait loci;
LIHC	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.48	-0.33	3.16e-10	Neuroticism;
LIHC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.7	10.44	0.49	2.52e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6545883	0.525	rs1177274	chr2:61368532	T/G	cg15711740	chr2:61764176	XPO1	-0.41	-5.91	-0.3	8.17e-9	Tuberculosis;
LIHC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.66e-9	Bipolar disorder;
LIHC	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.38	8.06	0.4	1.27e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18252515	chr7:66147081	NA	-0.42	-5.87	-0.3	1.01e-8	Aortic root size;
LIHC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.5	-6.41	-0.33	4.76e-10	Pancreatic cancer;
LIHC	cis	rs3791556	1.000	rs3791556	chr2:240112972	G/A	cg03281426	chr2:240109471	HDAC4	0.41	6.17	0.32	1.88e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.25	0.48	1.12e-21	Melanoma;
LIHC	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.27	-5.87	-0.3	1.04e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg05041596	chr11:89867385	NAALAD2	0.44	7.45	0.37	7.46e-13	White blood cell types;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08219700	chr8:58056026	NA	0.53	7.18	0.36	4.45e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs72772090	1.000	rs72772090	chr5:96036311	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-6.47	-0.33	3.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg10932868	chr11:921992	NA	0.38	7.32	0.37	1.83e-12	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg00656387	chr3:40428638	ENTPD3	0.5	8.37	0.41	1.44e-15	Renal cell carcinoma;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.75	0.8	3.17e-78	Prudent dietary pattern;
LIHC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg06565975	chr8:143823917	SLURP1	-0.33	-6.44	-0.33	4.16e-10	Urinary tract infection frequency;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg21486233	chr12:29375141	FAR2	0.3	5.8	0.3	1.48e-8	QT interval;
LIHC	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.68	-12.68	-0.57	1.85e-30	Height;
LIHC	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs17106184	1.000	rs56298082	chr1:50949727	C/T	cg07174182	chr1:51127561	FAF1	-0.58	-6.59	-0.34	1.64e-10	Type 2 diabetes;
LIHC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.68e-9	Life satisfaction;
LIHC	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.56	9.82	0.47	3.32e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.09	-0.31	3.12e-9	Total body bone mineral density;
LIHC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.83	0.35	3.81e-11	Morning vs. evening chronotype;
LIHC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.55	-0.53	2.82e-26	Platelet distribution width;
LIHC	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.09	-0.36	7.73e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.66	6.15	0.32	2.2e-9	Birth weight;
LIHC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.8	0.3	1.48e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg18478394	chr8:109455254	TTC35	-0.41	-6.87	-0.35	3.01e-11	Dupuytren's disease;
LIHC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg10587741	chr22:38071170	LGALS1	0.72	12.65	0.56	2.46e-30	Fat distribution (HIV);
LIHC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.4	0.37	1.08e-12	Neutrophil percentage of white cells;
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27297192	chr10:134578999	INPP5A	0.53	7.42	0.37	9.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs965469	1.000	rs6051732	chr20:3294182	G/A	cg25506879	chr20:3388711	C20orf194	-0.6	-6.91	-0.35	2.43e-11	IFN-related cytopenia;
LIHC	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	7.94	0.39	2.96e-14	Monocyte percentage of white cells;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07308232	chr7:1071921	C7orf50	-0.4	-6.48	-0.33	3.18e-10	Longevity;Endometriosis;
LIHC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-0.89	-9.69	-0.46	8.77e-20	Type 2 diabetes nephropathy;
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg00204748	chr12:29376779	FAR2	0.44	8.32	0.41	2.08e-15	QT interval;
LIHC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.62	-7.31	-0.37	1.88e-12	Lymphocyte counts;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.65	-9.68	-0.46	9.66e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	16.08	0.66	1.01e-43	Electrocardiographic conduction measures;
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.4	8.3	0.41	2.47e-15	Renal cell carcinoma;
LIHC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg22777020	chr22:31556080	RNF185	-0.56	-6.48	-0.33	3.19e-10	Colorectal cancer;
LIHC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	8.24	0.41	3.74e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.37	7.16	0.36	4.91e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	8.46	0.42	7.83e-16	HIV-1 control;
LIHC	cis	rs8048589	0.526	rs71388721	chr16:12212164	G/A	cg02910054	chr16:12241554	SNX29	0.28	6.83	0.35	3.92e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LIHC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.2	14.61	0.62	6.57e-38	Alzheimer's disease (late onset);
LIHC	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.17	0.4	5.93e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.66	-0.42	1.95e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg25828445	chr12:7781288	NA	0.45	6.93	0.35	2.09e-11	HDL cholesterol levels;
LIHC	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg15605315	chr1:45957053	TESK2	-0.49	-6.92	-0.35	2.27e-11	High light scatter reticulocyte count;
LIHC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-7.53	-0.38	4.6e-13	Vitiligo;
LIHC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.02	0.4	1.71e-14	Lung cancer;
LIHC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Body mass index;
LIHC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.43	7.31	0.37	1.92e-12	Educational attainment;
LIHC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-8.96	-0.44	2.07e-17	Body mass index (adult);
LIHC	cis	rs926392	0.896	rs1569538	chr20:37685216	A/G	cg16355469	chr20:37678765	NA	-0.39	-6.38	-0.33	5.65e-10	Dialysis-related mortality;
LIHC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.38	-5.88	-0.3	1e-8	Cognitive function;
LIHC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.4	5.84	0.3	1.24e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg00469287	chr7:23338798	C7orf30	0.49	6.61	0.34	1.46e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.6	-0.46	1.83e-19	Morning vs. evening chronotype;
LIHC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg05590025	chr7:65112418	INTS4L2	0.67	7.36	0.37	1.34e-12	Diabetic kidney disease;
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg02290350	chr8:58132656	NA	0.37	8.5	0.42	5.81e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.49	-7.75	-0.39	1.08e-13	Blood protein levels;
LIHC	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.3	-0.32	9.22e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.46	0.46	5.05e-19	Coffee consumption (cups per day);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg11313997	chr5:177027589	B4GALT7	0.41	6.43	0.33	4.18e-10	Morning vs. evening chronotype;
LIHC	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg16226627	chr15:75307476	SCAMP5	0.52	9.74	0.47	6.22e-20	Lung cancer;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	0.58	8.45	0.42	8.29e-16	Prudent dietary pattern;
LIHC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.51	6.33	0.32	7.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg16945685	chr11:120038821	NA	-0.38	-6.58	-0.34	1.75e-10	Stroke (pediatric);
LIHC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.38	5.76	0.3	1.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	1.01	16.52	0.67	1.68e-45	Body mass index;
LIHC	trans	rs8117834	0.574	rs73076256	chr20:8089458	A/C	cg00593689	chr4:53575888	NA	0.38	6.38	0.33	5.83e-10	Chronic kidney disease;
LIHC	cis	rs10838687	0.932	rs4752973	chr11:47269159	T/C	cg26139080	chr11:47293733	MADD	-0.44	-6.49	-0.33	3.06e-10	Proinsulin levels;
LIHC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.42	0.56	1.7e-29	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05968270	chr1:65533502	NA	0.46	6.2	0.32	1.67e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.7	-9.36	-0.45	1.08e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.52	8.02	0.4	1.67e-14	Left atrial antero-posterior diameter;
LIHC	trans	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg00571809	chr1:3397113	ARHGEF16	0.38	6.29	0.32	9.5e-10	Schizophrenia;
LIHC	cis	rs6466055	0.777	rs2240463	chr7:104844328	C/T	cg04380332	chr7:105027541	SRPK2	-0.36	-6.85	-0.35	3.46e-11	Schizophrenia;
LIHC	cis	rs11628318	0.572	rs7142319	chr14:103119425	C/T	cg12046867	chr14:103022105	NA	0.38	5.87	0.3	1.03e-8	Platelet count;
LIHC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-7.82	-0.39	6.54e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	9.02	0.44	1.34e-17	Exhaled nitric oxide output;
LIHC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.62	0.38	2.46e-13	Lung cancer in ever smokers;
LIHC	cis	rs3790645	1.000	rs383913	chr1:26893306	A/G	cg17456097	chr1:26900765	RPS6KA1	0.41	5.88	0.3	9.94e-9	Glucose homeostasis traits;
LIHC	cis	rs732505	1.000	rs4807789	chr19:5584448	T/C	cg26242866	chr19:5711310	LONP1	0.88	6.48	0.33	3.28e-10	vWF and FVIII levels;
LIHC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.57	-0.38	3.54e-13	Schizophrenia;
LIHC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.64	0.38	2.28e-13	Schizophrenia;
LIHC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.48	6.28	0.32	1.03e-9	Initial pursuit acceleration;
LIHC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg03037974	chr15:76606532	NA	-0.61	-10.2	-0.48	1.73e-21	Blood metabolite levels;
LIHC	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg02187348	chr16:89574699	SPG7	0.45	6.43	0.33	4.22e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	11.08	0.51	1.43e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.54	-10.04	-0.48	5.83e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08677398	chr8:58056175	NA	0.39	5.75	0.3	1.95e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg21724239	chr8:58056113	NA	0.49	6.43	0.33	4.17e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.52	-7.38	-0.37	1.22e-12	Body mass index;
LIHC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.95	22.45	0.77	3.15e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.58	9.51	0.46	3.51e-19	Menarche (age at onset);
LIHC	cis	rs11822910	0.737	rs2729389	chr11:57211646	A/G	cg00522883	chr11:57194120	SLC43A3	-0.55	-7.67	-0.38	1.81e-13	Platelet distribution width;
LIHC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.93	-0.47	1.41e-20	Crohn's disease;
LIHC	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.37	9.02	0.44	1.35e-17	Resting heart rate;
LIHC	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg23091122	chr1:110024289	SYPL2	-0.51	-6.81	-0.35	4.42e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12980942	0.810	rs16958999	chr19:41825186	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.47	5.91	0.3	8.07e-9	Coronary artery disease;
LIHC	cis	rs6847149	1.000	rs6852679	chr4:110804414	T/C	cg07850274	chr4:110748770	RRH	0.43	6.02	0.31	4.59e-9	Exercise treadmill test traits;
LIHC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.46	5.94	0.31	6.97e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs61677309	1.000	rs3825051	chr11:118174629	A/G	cg06090739	chr11:118230722	UBE4A	0.35	6.44	0.33	4.11e-10	Lung cancer in ever smokers;
LIHC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.67	0.42	1.82e-16	Alzheimer's disease;
LIHC	trans	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg26939375	chr7:64535504	NA	0.43	7.0	0.35	1.36e-11	Aortic root size;
LIHC	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.83	-0.3	1.29e-8	Coronary artery disease;
LIHC	cis	rs918629	0.716	rs12055262	chr5:95274632	T/C	cg10483112	chr5:95245456	ELL2	-0.35	-6.02	-0.31	4.47e-9	IgG glycosylation;
LIHC	cis	rs4575098	0.681	rs11589567	chr1:161116022	G/T	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.43	7.72	0.39	1.29e-13	Monocyte percentage of white cells;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg03721293	chr16:90014378	DEF8	0.37	6.2	0.32	1.64e-9	Skin colour saturation;
LIHC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg21734168	chr11:67353974	GSTP1	-0.28	-6.79	-0.34	4.99e-11	Mean corpuscular volume;
LIHC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg17135325	chr3:160939158	NMD3	0.42	6.09	0.31	3.06e-9	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.69	8.23	0.41	3.93e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg27386326	chr11:61587980	NA	0.34	6.15	0.32	2.21e-9	Trans fatty acid levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10920230	chr7:150757210	SLC4A2	-0.43	-6.28	-0.32	1.02e-9	Calcium levels;
LIHC	trans	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg17675199	chr6:35436792	RPL10A	0.32	6.33	0.32	7.48e-10	Coronary artery disease;
LIHC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.52	8.44	0.42	8.87e-16	Anterior chamber depth;
LIHC	cis	rs4650994	0.593	rs6700266	chr1:178508930	A/G	cg05350800	chr1:178550844	NA	0.3	6.39	0.33	5.51e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9649465	0.967	rs13230230	chr7:123329603	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.18	-0.4	5.61e-15	Migraine;
LIHC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.52	7.63	0.38	2.37e-13	Type 2 diabetes;
LIHC	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.24	0.45	2.75e-18	Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-22.37	-0.77	6.28e-69	Height;
LIHC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg13482628	chr17:19912719	NA	0.41	6.65	0.34	1.13e-10	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12463550	chr7:65579703	CRCP	0.67	7.03	0.36	1.15e-11	Diabetic kidney disease;
LIHC	trans	rs7721647	0.778	rs1596055	chr5:90886601	A/T	cg11567849	chr6:111751012	REV3L	-0.5	-6.04	-0.31	3.95e-9	Breast cancer;
LIHC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.68	-9.88	-0.47	2e-20	Initial pursuit acceleration;
LIHC	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg10978503	chr1:24200527	CNR2	0.26	6.36	0.33	6.59e-10	Immature fraction of reticulocytes;
LIHC	trans	rs7232775	0.818	rs1872357	chr18:43186262	A/G	cg21675030	chr3:111697974	ABHD10	0.52	6.04	0.31	4.05e-9	Metabolite levels;
LIHC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg16434002	chr17:42200994	HDAC5	-0.55	-7.99	-0.4	2.11e-14	Total body bone mineral density;
LIHC	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.57	-7.47	-0.37	6.63e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7188697	0.743	rs11859781	chr16:58602589	T/A	cg02549819	chr16:58548995	SETD6	0.48	7.49	0.38	5.75e-13	QT interval;
LIHC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.22e-34	Aortic root size;
LIHC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.08	-0.4	1.15e-14	Morning vs. evening chronotype;
LIHC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-8.95	-0.44	2.26e-17	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23115136	chr7:100281759	GIGYF1	0.45	6.72	0.34	7.6e-11	Pancreatic cancer;
LIHC	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.22	-0.41	4.22e-15	Body mass index;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg27262702	chr16:88878803	APRT	-0.48	-6.34	-0.32	7.2e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.63	11.88	0.54	1.81e-27	Temperament;
LIHC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-7.35	-0.37	1.46e-12	Hepatocellular carcinoma;
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.27	-0.55	6.47e-29	Alzheimer's disease;
LIHC	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	0.75	6.33	0.32	7.84e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs253664	0.796	rs799328	chr3:138082705	T/G	cg17918682	chr3:137893718	DBR1	-0.54	-5.72	-0.3	2.38e-8	Body mass index;
LIHC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02985541	chr2:219472218	PLCD4	0.45	8.71	0.43	1.33e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.58	8.49	0.42	6.21e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.37	5.97	0.31	6.02e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.07	19.01	0.72	1.71e-55	Testicular germ cell tumor;
LIHC	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.46e-25	Eye color traits;
LIHC	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.36	7.04	0.36	1.04e-11	Multiple sclerosis;
LIHC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	9.22	0.45	3.06e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.93	0.31	7.23e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.97	-0.31	6.06e-9	Life satisfaction;
LIHC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	-0.62	-9.93	-0.47	1.44e-20	Inflammatory bowel disease;
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.56	-7.83	-0.39	6.18e-14	Coronary artery disease;
LIHC	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09597638	chr17:3907349	NA	0.54	7.8	0.39	7.61e-14	Type 2 diabetes;
LIHC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg02023728	chr11:77925099	USP35	-0.34	-5.97	-0.31	5.95e-9	Alzheimer's disease (survival time);
LIHC	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.54	8.95	0.44	2.32e-17	Superior crus of antihelix expression;
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.44	-6.02	-0.31	4.43e-9	Total body bone mineral density;
LIHC	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.82	8.97	0.44	1.97e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.65	9.16	0.44	4.8e-18	Menopause (age at onset);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00164150	chr2:20101139	TTC32	0.43	6.06	0.31	3.67e-9	Morning vs. evening chronotype;
LIHC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg16797656	chr11:68205561	LRP5	0.54	8.61	0.42	2.63e-16	Total body bone mineral density;
LIHC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-6.77	-0.34	5.7e-11	Renal function-related traits (BUN);
LIHC	cis	rs11124272	0.868	rs477517	chr2:31848637	C/T	cg02381751	chr2:32503542	YIPF4	0.42	5.77	0.3	1.75e-8	Interleukin-18 levels;
LIHC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.54	-8.28	-0.41	2.72e-15	Height;
LIHC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.68	-11.03	-0.51	2.15e-24	Lung cancer;
LIHC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs244293	1.000	rs244288	chr17:53231841	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.16	-0.36	4.99e-12	Menarche (age at onset);
LIHC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.65	11.75	0.54	5.34e-27	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg04373760	chr16:53404718	NA	0.6	8.28	0.41	2.82e-15	Hypertriglyceridemia;
LIHC	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.41	-7.46	-0.37	7.26e-13	Hepatocellular carcinoma;
LIHC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.65	0.34	1.16e-10	Diabetic kidney disease;
LIHC	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-8.17	-0.4	5.98e-15	Body mass index;
LIHC	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.16	0.44	4.86e-18	Coffee consumption (cups per day);
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.45	0.56	1.3e-29	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.36	-7.38	-0.37	1.22e-12	Renal cell carcinoma;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.36	0.45	1.08e-18	Height;
LIHC	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg16583315	chr14:65563665	MAX	-0.38	-7.85	-0.39	5.55e-14	Obesity-related traits;
LIHC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.76	-10.67	-0.5	3.99e-23	Systemic lupus erythematosus;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14817848	chr12:12715558	DUSP16	-0.48	-6.42	-0.33	4.53e-10	Systolic blood pressure;
LIHC	cis	rs10861342	1.000	rs2888841	chr12:105493750	C/T	cg23923672	chr12:105501055	KIAA1033	0.65	7.59	0.38	2.99e-13	IgG glycosylation;
LIHC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg05973401	chr12:123451056	ABCB9	0.41	6.33	0.32	7.53e-10	Platelet count;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.44	0.33	4.01e-10	Prudent dietary pattern;
LIHC	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg05110241	chr16:68378359	PRMT7	-0.54	-6.51	-0.33	2.67e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.93	-0.39	3.04e-14	Capecitabine sensitivity;
LIHC	cis	rs11628318	0.515	rs60573537	chr14:103150407	A/G	cg12046867	chr14:103022105	NA	0.39	5.95	0.31	6.78e-9	Platelet count;
LIHC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	6.6	0.34	1.55e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.57	9.86	0.47	2.31e-20	Dupuytren's disease;
LIHC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.26	0.37	2.71e-12	Lung cancer in ever smokers;
LIHC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.43	-0.37	9.04e-13	Platelet distribution width;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg16070018	chr6:26224392	HIST1H3E	0.59	7.45	0.37	7.55e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs965469	1.000	rs2236098	chr20:3267133	A/G	cg25506879	chr20:3388711	C20orf194	-0.58	-7.06	-0.36	9.15e-12	IFN-related cytopenia;
LIHC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-11.21	-0.52	4.6e-25	Height;
LIHC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg15832292	chr6:96025679	MANEA	0.61	8.01	0.4	1.76e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.52	-6.11	-0.31	2.65e-9	Menarche (age at onset);
LIHC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.76	-0.3	1.83e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs818427	1.000	rs514763	chr5:112215156	C/T	cg07820702	chr5:112228657	REEP5	-0.36	-5.77	-0.3	1.79e-8	Total body bone mineral density;
LIHC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.39	0.37	1.15e-12	Obesity-related traits;
LIHC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-8.82	-0.43	6.16e-17	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg04373760	chr16:53404718	NA	0.62	8.19	0.4	5.18e-15	Hypertriglyceridemia;
LIHC	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg12698662	chr3:15914712	MIR563	-0.39	-7.23	-0.36	3.24e-12	Mean platelet volume;
LIHC	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.47	8.66	0.42	1.93e-16	Testicular germ cell tumor;
LIHC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.62	0.38	2.47e-13	Diastolic blood pressure;
LIHC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.46	6.1	0.31	2.92e-9	Height;
LIHC	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-5.76	-0.3	1.83e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs918629	0.679	rs56002885	chr5:95269602	A/G	cg10483112	chr5:95245456	ELL2	-0.37	-6.28	-0.32	1.02e-9	IgG glycosylation;
LIHC	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.81	-10.57	-0.5	8.43e-23	Blood pressure (smoking interaction);
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.18	0.36	4.33e-12	Cognitive function;
LIHC	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.71	11.53	0.53	3.24e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.42	-7.39	-0.37	1.12e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.58	8.66	0.42	1.85e-16	Recombination rate (females);
LIHC	cis	rs10792665	0.575	rs7113058	chr11:82559902	C/T	cg24227371	chr11:82718527	RAB30	-0.26	-6.25	-0.32	1.19e-9	Obesity-related traits;
LIHC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg14132834	chr19:41945861	ATP5SL	-0.45	-6.54	-0.33	2.2e-10	Height;
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg21466736	chr12:48725269	NA	-0.4	-5.93	-0.31	7.35e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg06359132	chr10:99160096	RRP12	-0.42	-6.51	-0.33	2.73e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.25	0.32	1.23e-9	Prudent dietary pattern;
LIHC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.69	12.39	0.56	2.24e-29	Menopause (age at onset);
LIHC	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg10820045	chr2:198174542	NA	0.48	7.27	0.37	2.45e-12	Dermatomyositis;
LIHC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.07e-18	Schizophrenia;
LIHC	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.49e-15	Facial morphology (factor 19);
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg15362194	chr2:98262546	COX5B	0.51	6.14	0.32	2.31e-9	Glycated hemoglobin levels;
LIHC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.05	0.4	1.38e-14	Menarche (age at onset);
LIHC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02985541	chr2:219472218	PLCD4	0.45	8.74	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7503168	1.000	rs10512472	chr17:33884804	A/G	cg20932281	chr17:33905541	PEX12	0.57	7.49	0.38	5.74e-13	Plateletcrit;
LIHC	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.79	-0.34	5.08e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg04310649	chr10:35416472	CREM	-0.43	-5.86	-0.3	1.11e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.86	0.35	3.29e-11	Aortic root size;
LIHC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg15902774	chr15:75289873	SCAMP5	0.41	6.15	0.32	2.14e-9	Lung cancer;
LIHC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg08847533	chr14:75593920	NEK9	0.38	6.38	0.33	5.68e-10	Caffeine consumption;
LIHC	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.34	21.12	0.75	5.59e-64	Corneal structure;
LIHC	cis	rs4908768	0.501	rs7551849	chr1:8539463	A/G	cg20416874	chr1:8611966	RERE	-0.69	-14.74	-0.62	2.15e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg07382826	chr16:28625726	SULT1A1	0.48	7.5	0.38	5.46e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	trans	rs13325613	0.915	rs34005848	chr3:46263745	C/T	cg26337592	chr1:153642686	ILF2	0.68	6.2	0.32	1.66e-9	Monocyte count;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.9	18.55	0.71	1.18e-53	Height;
LIHC	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg20568497	chr10:133558893	NA	0.4	6.07	0.31	3.39e-9	Survival in rectal cancer;
LIHC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.6	-7.08	-0.36	8.41e-12	Menarche (age at onset);
LIHC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.0	-0.44	1.62e-17	Bladder cancer;
LIHC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02985541	chr2:219472218	PLCD4	-0.44	-7.18	-0.36	4.25e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.37	5.82	0.3	1.34e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.75	-0.3	1.94e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-7.43	-0.37	8.78e-13	Cognitive function;
LIHC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.3	-0.32	9.41e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06476606	chr10:91061728	IFIT2	0.49	7.28	0.37	2.34e-12	Cognitive function;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg14828511	chr1:107599125	PRMT6	0.4	5.79	0.3	1.59e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	8.86	0.43	4.52e-17	Multiple sclerosis;
LIHC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.58	-8.8	-0.43	6.86e-17	Prostate cancer;
LIHC	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.7	7.37	0.37	1.33e-12	Diabetic kidney disease;
LIHC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.36	-6.22	-0.32	1.47e-9	Body mass index;
LIHC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.31	0.68	1.13e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.88	-18.16	-0.7	4.3e-52	Height;
LIHC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.04	9.48	0.46	4.29e-19	Diabetic retinopathy;
LIHC	cis	rs4684776	0.867	rs60056696	chr3:11331944	C/T	cg00170343	chr3:11313890	ATG7	-0.52	-7.15	-0.36	5.22e-12	Small vessel stroke;
LIHC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.24	0.55	8.15e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.41	-0.59	2.95e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.36	8.24	0.41	3.64e-15	Educational attainment (years of education);
LIHC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.26	0.37	2.62e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7095607	0.606	rs4746737	chr10:69959779	T/C	cg18986048	chr10:69913749	MYPN	0.39	5.85	0.3	1.12e-8	Lung function (FVC);
LIHC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg08392591	chr16:89556376	ANKRD11	0.54	8.52	0.42	5.13e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs11888559	0.511	rs1975211	chr2:204035715	T/C	cg24605529	chr2:203879461	NBEAL1	0.76	5.81	0.3	1.44e-8	Height;
LIHC	trans	rs6489882	0.966	rs6489879	chr12:113377822	G/A	cg10175203	chr3:128143634	NA	0.38	6.18	0.32	1.8e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg07689907	chr11:61582574	FADS1	-0.39	-5.81	-0.3	1.39e-8	Trans fatty acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19424078	chr11:747111	TALDO1	-0.44	-6.17	-0.32	1.94e-9	Pancreatic cancer;
LIHC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg06046430	chr4:77819534	ANKRD56	0.51	6.29	0.32	9.49e-10	Emphysema distribution in smoking;
LIHC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.98	-0.51	3.07e-24	Colorectal cancer;
LIHC	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg00601450	chr5:74908170	NA	0.56	6.43	0.33	4.25e-10	Coronary artery disease;
LIHC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg20435097	chr10:126320824	FAM53B	-0.41	-6.16	-0.32	2.02e-9	Cocaine dependence;
LIHC	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.39	-6.27	-0.32	1.08e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.82	-0.35	4.24e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg00343986	chr7:65444356	GUSB	-0.39	-5.83	-0.3	1.26e-8	Aortic root size;
LIHC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.26	0.48	1.07e-21	Colorectal cancer;
LIHC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08392591	chr16:89556376	ANKRD11	0.43	6.45	0.33	3.92e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg14146966	chr2:61757674	XPO1	-0.43	-7.29	-0.37	2.12e-12	Tuberculosis;
LIHC	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.4	0.52	1.01e-25	Motion sickness;
LIHC	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-12.9	-0.57	2.79e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21467203	chr3:49911342	NA	-0.43	-7.71	-0.38	1.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg20387954	chr3:183756860	HTR3D	0.28	6.07	0.31	3.32e-9	Anterior chamber depth;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg03721293	chr16:90014378	DEF8	0.38	6.35	0.32	6.72e-10	Skin colour saturation;
LIHC	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.41	7.38	0.37	1.21e-12	Testicular germ cell tumor;
LIHC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.73	12.68	0.57	1.81e-30	Mean platelet volume;
LIHC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.82	-0.63	1.03e-38	Chronic sinus infection;
LIHC	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.85	-0.35	3.49e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.39	0.41	1.28e-15	Lung cancer;
LIHC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg11632617	chr15:75315747	PPCDC	0.47	6.83	0.35	3.86e-11	Blood trace element (Zn levels);
LIHC	cis	rs2380220	0.808	rs2613548	chr6:95910559	C/T	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.47	6.92	0.35	2.31e-11	Pulse pressure;
LIHC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-8.96	-0.44	2.11e-17	Gut microbiome composition (summer);
LIHC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.24	16.09	0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-17.87	-0.69	6.79e-51	Height;
LIHC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.6	9.02	0.44	1.36e-17	Recombination rate (females);
LIHC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.85	11.62	0.53	1.51e-26	Post bronchodilator FEV1;
LIHC	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg02023728	chr11:77925099	USP35	0.36	6.24	0.32	1.3e-9	Alzheimer's disease (survival time);
LIHC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.75	9.7	0.46	8.48e-20	Body mass index;
LIHC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.95	17.58	0.69	9.65e-50	Menopause (age at onset);
LIHC	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg12923728	chr3:195709715	SDHAP1	-0.74	-9.86	-0.47	2.43e-20	Pancreatic cancer;
LIHC	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.5	7.53	0.38	4.44e-13	Resting heart rate;
LIHC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.39	-6.67	-0.34	1.01e-10	Monocyte percentage of white cells;
LIHC	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs11229555	0.645	rs11560908	chr11:58434545	A/C	cg15696309	chr11:58395628	NA	0.63	6.07	0.31	3.32e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.43	6.68	0.34	9.84e-11	Prostate cancer;
LIHC	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.98	0.31	5.56e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08280861	chr8:58055591	NA	0.52	6.5	0.33	2.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.31	0.41	2.3e-15	Motion sickness;
LIHC	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.28	0.32	1.06e-9	Schizophrenia;
LIHC	cis	rs965469	0.744	rs6139093	chr20:3334838	A/G	cg25506879	chr20:3388711	C20orf194	-0.52	-6.41	-0.33	4.8e-10	IFN-related cytopenia;
LIHC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.55	-0.38	3.9e-13	Body mass index;
LIHC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12463550	chr7:65579703	CRCP	0.69	7.12	0.36	6.23e-12	Diabetic kidney disease;
LIHC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.34	-5.9	-0.3	8.75e-9	IgG glycosylation;
LIHC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26897989	chr16:1907736	C16orf73	0.49	6.18	0.32	1.87e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.77	-14.06	-0.61	9.76e-36	Longevity;
LIHC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg14132834	chr19:41945861	ATP5SL	-0.45	-6.6	-0.34	1.61e-10	Height;
LIHC	trans	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04565464	chr8:145669602	NFKBIL2	0.39	6.51	0.33	2.63e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6466055	0.777	rs11765045	chr7:104922115	T/A	cg04380332	chr7:105027541	SRPK2	0.37	6.86	0.35	3.2e-11	Schizophrenia;
LIHC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg27124370	chr19:33622961	WDR88	0.47	7.09	0.36	7.77e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.69	8.66	0.42	1.89e-16	Initial pursuit acceleration;
LIHC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.57	8.53	0.42	4.87e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.75	12.48	0.56	9.93e-30	Schizophrenia;
LIHC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.58	11.61	0.53	1.71e-26	Colorectal cancer;
LIHC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg07636037	chr3:49044803	WDR6	-0.8	-8.16	-0.4	6.27e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	9.12	0.44	6.35e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.4	0.33	5.2400000000000005e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs922107	0.967	rs2045583	chr1:90018974	G/T	cg15422784	chr1:90023713	LRRC8B	0.49	8.08	0.4	1.11e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	ch.8.15787776F	chr8:15743405	NA	-0.52	-6.16	-0.32	2.05e-9	Preeclampsia;
LIHC	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg08345082	chr10:99160200	RRP12	-0.39	-6.72	-0.34	7.76e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.73	13.33	0.58	6.02e-33	Prudent dietary pattern;
LIHC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.31	7.09	0.36	7.82e-12	Crohn's disease;
LIHC	cis	rs2282032	0.527	rs55664487	chr14:90765880	C/T	cg04374321	chr14:90722782	PSMC1	0.49	7.07	0.36	8.56e-12	Longevity;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.3	0.32	9.29e-10	Prudent dietary pattern;
LIHC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.0	-0.35	1.34e-11	Aortic root size;
LIHC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-5.91	-0.3	8.14e-9	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.79	12.54	0.56	5.98e-30	Corneal astigmatism;
LIHC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg23461800	chr14:103021989	NA	-0.42	-5.87	-0.3	1.03e-8	Platelet count;
LIHC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.48	6.39	0.33	5.31e-10	Mean platelet volume;
LIHC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.86	0.35	3.25e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.56	7.71	0.38	1.4e-13	Heart rate;
LIHC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg07424592	chr7:64974309	NA	0.78	9.13	0.44	5.98e-18	Diabetic kidney disease;
LIHC	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.79	0.34	5.12e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg18196295	chr10:418757	DIP2C	-0.51	-5.89	-0.3	9.07e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs9993613	0.967	rs6446841	chr4:73437856	C/G	cg15102770	chr4:73434591	ADAMTS3	-0.38	-6.02	-0.31	4.55e-9	Hip circumference adjusted for BMI;Height;
LIHC	trans	rs10761482	0.500	rs10821779	chr10:62274525	A/G	cg14898824	chr12:64851143	TBK1	-0.33	-6.23	-0.32	1.36e-9	Schizophrenia;
LIHC	cis	rs15676	0.783	rs2977998	chr9:131580570	A/G	cg00228799	chr9:131580591	ENDOG	0.49	7.0	0.35	1.35e-11	Blood metabolite levels;
LIHC	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.52	0.38	4.95e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg24101359	chr6:42928495	GNMT	0.44	5.96	0.31	6.43e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg24296786	chr1:45957014	TESK2	-0.47	-6.31	-0.32	8.88e-10	Platelet count;
LIHC	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs9810089	0.777	rs2688601	chr3:136252601	G/A	cg21827317	chr3:136751795	NA	0.45	6.03	0.31	4.34e-9	Gestational age at birth (child effect);
LIHC	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	0.93	10.4	0.49	3.5e-22	Breast cancer;
LIHC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.89	-0.3	9.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7095607	0.538	rs2255027	chr10:69920911	T/C	cg18986048	chr10:69913749	MYPN	0.49	7.33	0.37	1.65e-12	Lung function (FVC);
LIHC	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.69	10.6	0.5	6.92e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1144333	0.737	rs1144339	chr1:76280543	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.73	-0.34	7.26e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.77	8.2	0.41	4.92e-15	Chronic kidney disease;
LIHC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.75e-10	Depression;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.78	-0.34	5.36e-11	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17839278	chr11:47664375	MTCH2	0.47	6.33	0.32	7.88e-10	Pancreatic cancer;
LIHC	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.46e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.79	-0.34	4.85e-11	IgG glycosylation;
LIHC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.23	6.2	0.32	1.66e-9	Calcium levels;
LIHC	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.39	-6.35	-0.32	6.91e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.51	-9.23	-0.45	2.94e-18	Colorectal cancer;
LIHC	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.68	10.69	0.5	3.3e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg18944383	chr4:111397179	ENPEP	0.26	6.25	0.32	1.23e-9	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-7.37	-0.37	1.27e-12	Initial pursuit acceleration;
LIHC	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg13679303	chr9:96623674	NA	-0.28	-6.09	-0.31	3.03e-9	DNA methylation (variation);
LIHC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg18887096	chr2:219472410	PLCD4	0.39	5.96	0.31	6.15e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg08890338	chr13:113700818	MCF2L	-0.36	-5.83	-0.3	1.3e-8	Systolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07372840	chr5:180296196	NA	0.42	6.25	0.32	1.19e-9	Cognitive function;
LIHC	cis	rs6752107	0.967	rs10203952	chr2:234153366	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.73	0.39	1.21e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.86	-0.35	3.24e-11	Body mass index;
LIHC	cis	rs7684446	1	rs7684446	chr4:15592864	C/T	cg16509355	chr4:15471240	CC2D2A	0.41	6.58	0.34	1.73e-10	Red blood cell count;
LIHC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.45	8.57	0.42	3.63e-16	Schizophrenia;
LIHC	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.79	-0.3	1.61e-8	Pulse pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13396037	chr8:42996139	HGSNAT	0.48	6.62	0.34	1.42e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs77633900	0.772	rs284902	chr15:76745687	G/C	cg21673338	chr15:77095150	SCAPER	-0.53	-5.93	-0.31	7.23e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2070433	0.851	rs8129793	chr21:47925719	T/C	cg12379764	chr21:47803548	PCNT	0.59	8.4	0.41	1.17e-15	Lymphocyte counts;
LIHC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.96	-15.12	-0.63	6.68e-40	Body mass index;
LIHC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.6	-6.97	-0.35	1.69e-11	Menarche (age at onset);
LIHC	cis	rs55702914	0.710	rs1429419	chr2:198154547	G/A	cg10820045	chr2:198174542	NA	-0.4	-6.03	-0.31	4.23e-9	Major depression and alcohol dependence;
LIHC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg25364880	chr3:44379878	C3orf23	0.5	7.17	0.36	4.61e-12	Depressive symptoms;
LIHC	cis	rs546131	0.642	rs1039841	chr11:34833139	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.34	1.66e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.76	11.82	0.54	2.78e-27	Longevity;
LIHC	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg20826740	chr17:37024042	NA	0.41	6.9	0.35	2.6e-11	Height;
LIHC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.27	-7.03	-0.36	1.1e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	12.3	0.55	4.89e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg16070018	chr6:26224392	HIST1H3E	0.6	7.53	0.38	4.45e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	6.98e-23	Hemoglobin concentration;
LIHC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.43	5.73	0.3	2.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.76	0.3	1.92e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs986417	0.818	rs2057135	chr14:61077022	G/A	cg27398547	chr14:60952738	C14orf39	0.66	7.31	0.37	1.93e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg20487152	chr13:99095054	FARP1	-0.36	-6.14	-0.32	2.28e-9	Longevity;
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-6.99	-0.35	1.45e-11	Vitiligo;
LIHC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	0.83	7.39	0.37	1.13e-12	Type 2 diabetes nephropathy;
LIHC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.45	8.07	0.4	1.2e-14	IgG glycosylation;
LIHC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.86	0.35	3.29e-11	Aortic root size;
LIHC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.6	0.46	1.72e-19	Tonsillectomy;
LIHC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.7	10.64	0.5	4.85e-23	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg05555928	chr11:63887634	MACROD1	0.5	6.53	0.33	2.34e-10	Mean platelet volume;
LIHC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.86	0.35	3.29e-11	Aortic root size;
LIHC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.1	11.28	0.52	2.73e-25	Opioid sensitivity;
LIHC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01151424	chr11:17411006	KCNJ11	0.47	7.0	0.35	1.34e-11	Lung function (FEV1/FVC);
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.65	9.71	0.46	7.5599999999999994e-20	Menarche (age at onset);
LIHC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.55	-7.76	-0.39	9.73e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg14092571	chr14:90743983	NA	-0.38	-5.97	-0.31	5.93e-9	Mortality in heart failure;
LIHC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.48	7.47	0.37	6.73e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-8.76	-0.43	9.07e-17	Height;
LIHC	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg24296786	chr1:45957014	TESK2	0.42	5.78	0.3	1.64e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12744310	1.000	rs12032162	chr1:41762935	T/C	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.75	-0.3	1.98e-8	Red blood cell count;
LIHC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.75	-0.34	6.19e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.63	9.88	0.47	2.07e-20	Educational attainment;
LIHC	cis	rs9473924	0.542	rs2857514	chr6:50811283	C/T	cg14470998	chr6:50812995	TFAP2B	1.05	8.9	0.43	3.3e-17	Body mass index;
LIHC	trans	rs12752401	0.867	rs67349818	chr1:103030560	T/C	cg24921808	chr19:740313	PALM	0.49	6.43	0.33	4.21e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13409248	chr3:40428643	ENTPD3	0.49	8.24	0.41	3.69e-15	Renal cell carcinoma;
LIHC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg15691649	chr6:25882328	NA	-0.39	-6.22	-0.32	1.44e-9	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05793409	chr1:35658810	SFPQ	0.42	6.15	0.32	2.13e-9	Pancreatic cancer;
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.95	-0.31	6.46e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs882732	1.000	rs875958	chr14:95028667	A/T	cg14866387	chr14:95027382	SERPINA4	-0.44	-6.36	-0.33	6.61e-10	Blood protein levels;
LIHC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.67	0.53	1.02e-26	Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04318546	chr15:101147087	ASB7	-0.41	-6.22	-0.32	1.44e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.82e-31	Breast cancer;
LIHC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.48	-9.29	-0.45	1.91e-18	Tuberculosis;
LIHC	cis	rs1046896	0.961	rs7208565	chr17:80696692	C/T	cg00809820	chr17:80708513	TBCD;FN3K	0.34	5.93	0.31	7.53e-9	Glycated hemoglobin levels;
LIHC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.85	0.3	1.14e-8	Bladder cancer;
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs963731	0.649	rs297143	chr2:39320067	T/C	cg04010122	chr2:39346883	SOS1	-0.68	-6.03	-0.31	4.15e-9	Corticobasal degeneration;
LIHC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg15017067	chr4:17643749	FAM184B	0.34	5.75	0.3	2.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.67	13.32	0.58	6.74e-33	Coronary artery disease;
LIHC	trans	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg10756647	chr7:56101905	PSPH	0.47	6.81	0.35	4.38e-11	Aortic root size;
LIHC	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-8.01	-0.4	1.81e-14	Extraversion;
LIHC	cis	rs3812111	0.774	rs482012	chr6:116430533	G/T	cg08036074	chr6:116424633	NT5DC1	0.66	11.82	0.54	2.97e-27	Age-related macular degeneration;
LIHC	cis	rs3731896	0.848	rs4485556	chr2:220157418	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.57	7.51	0.38	5.05e-13	Educational attainment;
LIHC	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.46	-6.74	-0.34	6.89e-11	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	9.73	0.47	6.35e-20	Lung cancer;
LIHC	cis	rs4700695	0.534	rs153394	chr5:65426676	T/A	cg21114390	chr5:65439923	SFRS12	-0.52	-6.06	-0.31	3.63e-9	Facial morphology (factor 19);
LIHC	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.3	-7.88	-0.39	4.27e-14	Intelligence;
LIHC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-8.27	-0.41	2.98e-15	Blood metabolite levels;
LIHC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.24	0.32	1.31e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.47	6.07	0.31	3.48e-9	Panic disorder;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.78	10.6	0.5	6.72e-23	Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.77	0.62	1.56e-38	Prudent dietary pattern;
LIHC	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.76	10.92	0.51	5.27e-24	Lymphocyte counts;
LIHC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg25894440	chr7:65020034	NA	-0.6	-6.45	-0.33	3.93e-10	Diabetic kidney disease;
LIHC	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	5.99	0.31	5.3e-9	Schizophrenia;
LIHC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.33	-7.2	-0.36	3.87e-12	Ulcerative colitis;
LIHC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.43	6.68	0.34	9.5e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg14515779	chr1:101123966	NA	0.63	12.13	0.55	2.12e-28	Monocyte count;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.73	0.57	1.17e-30	Prudent dietary pattern;
LIHC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.45	-6.14	-0.32	2.27e-9	Longevity;
LIHC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.4	-6.04	-0.31	4.12e-9	Blood pressure (smoking interaction);
LIHC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.68	-9.37	-0.45	9.78e-19	Red blood cell count;
LIHC	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.32e-14	Corneal astigmatism;
LIHC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.4	6.74	0.34	6.57e-11	Blood metabolite levels;
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.25	-0.48	1.14e-21	Longevity;Endometriosis;
LIHC	trans	rs783540	0.967	rs1269134	chr15:83282628	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.69	-0.34	8.99e-11	Schizophrenia;
LIHC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.43	-0.76	3.5e-65	Height;
LIHC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.26	6.17	0.32	1.9e-9	Crohn's disease;
LIHC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs922107	0.738	rs12135419	chr1:90053245	C/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.69	-0.38	1.58e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.74	-13.72	-0.6	1.97e-34	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.6	-0.34	1.57e-10	Mean corpuscular volume;
LIHC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.92	-0.39	3.35e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21448741	chr8:58168803	NA	0.34	6.13	0.31	2.42e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21467203	chr3:49911342	NA	-0.49	-8.59	-0.42	3.1e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.11	-0.31	2.77e-9	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.77	0.8	2.76e-78	Prudent dietary pattern;
LIHC	cis	rs2637266	0.756	rs846631	chr10:78536928	T/G	cg18941641	chr10:78392320	NA	0.28	5.96	0.31	6.3e-9	Pulmonary function;
LIHC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-9.45	-0.46	5.47e-19	Body mass index;
LIHC	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.73	-11.06	-0.51	1.66e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.5	-5.82	-0.3	1.33e-8	Orofacial clefts;
LIHC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.56	8.21	0.41	4.64e-15	Prostate cancer;
LIHC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.45	7.15	0.36	5.21e-12	Height;
LIHC	trans	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.89e-11	Aortic root size;
LIHC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	1.01	16.82	0.67	1.09e-46	Obesity-related traits;
LIHC	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg19680672	chr10:131412579	MGMT	-0.38	-5.8	-0.3	1.47e-8	Response to temozolomide;
LIHC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.55	-6.56	-0.33	1.97e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.67	-0.38	1.81e-13	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg07451762	chr16:28383216	NA	0.39	6.89	0.35	2.72e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.89	0.3	9.27e-9	Bladder cancer;
LIHC	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.8	-10.62	-0.5	6.05e-23	Blood pressure (smoking interaction);
LIHC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.71	-13.9	-0.6	3.76e-35	Menopause (age at onset);
LIHC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.2e-13	Electroencephalogram traits;
LIHC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.62	11.42	0.53	8.58e-26	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21227347	chr9:117374170	C9orf91	0.43	6.68	0.34	9.53e-11	Pancreatic cancer;
LIHC	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.7	11.58	0.53	2.26e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.34	-0.45	1.3e-18	Colorectal cancer;
LIHC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg13919466	chr1:32135498	COL16A1	-0.38	-7.29	-0.37	2.11e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4699052	0.963	rs11097804	chr4:104215137	A/T	cg16532752	chr4:104119610	CENPE	-0.4	-6.37	-0.33	6.09e-10	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.86	0.39	5.21e-14	Prudent dietary pattern;
LIHC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.42	-6.69	-0.34	9.14e-11	Platelet count;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg00280220	chr17:61926910	NA	0.42	6.89	0.35	2.73e-11	Prudent dietary pattern;
LIHC	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.61	-9.62	-0.46	1.48e-19	Malaria;
LIHC	cis	rs9473924	0.542	rs2817378	chr6:50789197	G/A	cg14470998	chr6:50812995	TFAP2B	0.99	11.04	0.51	1.92e-24	Body mass index;
LIHC	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.12	9.94	0.47	1.24e-20	Schizophrenia;
LIHC	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-6.14	-0.32	2.31e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg18225595	chr11:63971243	STIP1	-0.46	-7.35	-0.37	1.49e-12	Platelet count;
LIHC	cis	rs7487075	0.619	rs12822345	chr12:46834677	G/C	cg23829395	chr12:46796953	NA	0.35	6.19	0.32	1.76e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg04013166	chr16:89971882	TCF25	0.56	7.0	0.35	1.35e-11	Skin colour saturation;
LIHC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg22633049	chr21:46681294	NA	-0.37	-6.36	-0.33	6.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.59	8.84	0.43	5.17e-17	Platelet count;
LIHC	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg16652328	chr3:33138982	GLB1;TMPPE	-0.55	-7.04	-0.36	1.08e-11	Major depressive disorder;
LIHC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.81	-6.59	-0.34	1.63e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg26441486	chr22:50317300	CRELD2	0.37	5.96	0.31	6.29e-9	Schizophrenia;
LIHC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	12.75	0.57	1.01e-30	Electrocardiographic conduction measures;
LIHC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg16226627	chr15:75307476	SCAMP5	0.55	9.7	0.46	8.07e-20	Lung cancer;
LIHC	cis	rs6137287	0.722	rs1007226	chr20:21103987	A/G	cg04219410	chr20:21106687	PLK1S1	0.34	5.9	0.3	8.59e-9	Height;
LIHC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg16970926	chr12:29381810	FAR2	-0.28	-5.8	-0.3	1.48e-8	QT interval;
LIHC	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14396892	chr9:96623032	NA	-0.33	-6.3	-0.32	9.01e-10	DNA methylation (variation);
LIHC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.37	-7.11	-0.36	6.84e-12	Body mass index;
LIHC	cis	rs35791980	0.820	rs11764672	chr7:76949191	C/T	cg12876866	chr7:77025528	PION	-0.48	-6.54	-0.33	2.19e-10	Pursuit maintenance gain;
LIHC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg10820045	chr2:198174542	NA	0.5	7.88	0.39	4.49e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4908760	0.827	rs10864360	chr1:8724522	C/T	cg20416874	chr1:8611966	RERE	-0.64	-12.62	-0.56	3.04e-30	Vitiligo;
LIHC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.43	-6.14	-0.32	2.27e-9	Height;
LIHC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.35	-7.06	-0.36	9.2e-12	Body mass index;
LIHC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg17750252	chr2:136567154	LCT	0.33	5.93	0.31	7.44e-9	Mosquito bite size;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.44	6.44	0.33	3.99e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.52	0.33	2.51e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	7.6	0.38	2.93e-13	Tonsillectomy;
LIHC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-7.62	-0.38	2.55e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.22	-0.41	4.17e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03347828	chr17:7739579	NA	0.45	6.91	0.35	2.37e-11	Cognitive function;
LIHC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg01629716	chr15:45996671	NA	0.52	9.65	0.46	1.25e-19	Waist circumference;Weight;
LIHC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.34	-18.13	-0.7	5.81e-52	Gout;
LIHC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.13	0.36	5.9e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.22	-0.36	3.41e-12	Bipolar disorder;
LIHC	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg26441486	chr22:50317300	CRELD2	0.35	6.29	0.32	9.96e-10	Schizophrenia;
LIHC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-9.23	-0.45	2.92e-18	Personality dimensions;
LIHC	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.81	12.45	0.56	1.35e-29	Body mass index;
LIHC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.69	13.72	0.6	1.95e-34	Coronary artery disease;
LIHC	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg04374321	chr14:90722782	PSMC1	0.49	7.07	0.36	8.63e-12	Longevity;
LIHC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.41	-6.0	-0.31	5.08e-9	Height;
LIHC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.74	0.3	2.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.69	-8.56	-0.42	3.78e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg22705602	chr4:152727874	NA	0.29	6.18	0.32	1.8e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.8	12.8	0.57	6.64e-31	Chronic lymphocytic leukemia;
LIHC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.69	-13.2	-0.58	1.92e-32	Height;
LIHC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.57	-8.5	-0.42	6.08e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.65	11.07	0.51	1.52e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.29	-0.41	2.57e-15	Exhaled nitric oxide output;
LIHC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.83	8.89	0.43	3.5e-17	Vitiligo;
LIHC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg26441486	chr22:50317300	CRELD2	0.37	6.35	0.32	6.78e-10	Schizophrenia;
LIHC	cis	rs11951515	0.509	rs12521249	chr5:43558629	T/C	cg01983248	chr5:43482804	C5orf28	0.37	6.18	0.32	1.87e-9	Metabolite levels  (X-11787);
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.58	-7.84	-0.39	5.71e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.63	-0.38	2.4e-13	Total cholesterol levels;
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.47	0.33	3.38e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg18809830	chr7:99032528	PTCD1	-0.83	-6.66	-0.34	1.07e-10	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01148728	chr11:117198424	CEP164	0.45	6.52	0.33	2.54e-10	Cognitive function;
LIHC	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.64	8.84	0.43	5.05e-17	Coronary artery disease;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.64	-9.15	-0.44	5.41e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.74	11.45	0.53	6.53e-26	Gastritis;
LIHC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.08e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-6.75	-0.34	6.17e-11	Lymphocyte counts;
LIHC	cis	rs7116495	0.609	rs1791449	chr11:71579662	C/T	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.27e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs546131	0.642	rs34191151	chr11:34850509	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.55	-0.33	2.17e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1712517	0.838	rs1891293	chr10:105001797	C/T	cg05636881	chr10:105038444	INA	-0.42	-6.72	-0.34	7.63e-11	Migraine;
LIHC	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.58	8.62	0.42	2.55e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.49	5.71	0.3	2.4e-8	Alzheimer's disease;
LIHC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg23690444	chr14:81902736	NA	0.68	9.42	0.45	7.17e-19	Prudent dietary pattern;
LIHC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.84	-14.07	-0.61	8.63e-36	Body mass index;
LIHC	cis	rs56146971	0.714	rs55709253	chr14:91853363	T/C	cg16433844	chr14:91963127	SMEK1	-0.53	-6.28	-0.32	1.02e-9	Alzheimer disease and age of onset;
LIHC	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.47	7.42	0.37	9.14e-13	Menopause (age at onset);
LIHC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.86	0.51	8.06e-24	Lung cancer in ever smokers;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.58	8.09	0.4	1.03e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg10820045	chr2:198174542	NA	0.47	7.05	0.36	1.01e-11	Dermatomyositis;
LIHC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.86	0.3	1.11e-8	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.37	6.84	0.35	3.57e-11	Schizophrenia;
LIHC	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg18289306	chr13:113640169	MCF2L	0.42	6.27	0.32	1.12e-9	Systolic blood pressure;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.98	-0.35	1.53e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.07	-0.36	8.75e-12	Personality dimensions;
LIHC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.68	-12.48	-0.56	1.02e-29	Iron status biomarkers;
LIHC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg26441486	chr22:50317300	CRELD2	0.38	6.46	0.33	3.7e-10	Schizophrenia;
LIHC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg12253828	chr6:101329408	ASCC3	0.44	7.08	0.36	8.31e-12	Neuroticism;
LIHC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.49	5.74	0.3	2.11e-8	Bladder cancer;
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.39	8.05	0.4	1.42e-14	Renal cell carcinoma;
LIHC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	7.52	0.38	4.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-7.01	-0.35	1.29e-11	HDL cholesterol;
LIHC	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.24	-0.32	1.26e-9	Tuberculosis;
LIHC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.02	0.35	1.24e-11	Vitiligo;
LIHC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.6	-0.34	1.58e-10	Mean corpuscular volume;
LIHC	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.41	6.4	0.33	5.11e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04004882	chr2:215674386	BARD1	0.56	7.6	0.38	2.86e-13	Neuroblastoma;
LIHC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.49	-6.98	-0.35	1.58e-11	Body mass index;
LIHC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26913058	chr16:419975	MRPL28	-0.52	-7.36	-0.37	1.36e-12	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg03146154	chr1:46216737	IPP	0.48	8.08	0.4	1.12e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.45	-6.66	-0.34	1.09e-10	Dermatomyositis;
LIHC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.88	12.08	0.55	3.18e-28	Post bronchodilator FEV1;
LIHC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.71	0.3	2.39e-8	Bipolar disorder;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.52	5.97	0.31	5.86e-9	Alzheimer's disease;
LIHC	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.92	-0.35	2.17e-11	Metabolite levels;
LIHC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.5	-6.22	-0.32	1.46e-9	Parkinson's disease;
LIHC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.62	9.83	0.47	3e-20	Corneal astigmatism;
LIHC	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.23	-0.36	3.14e-12	Response to antipsychotic treatment;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg08556938	chr17:58512855	NA	0.43	6.49	0.33	3.05e-10	Electroencephalogram traits;
LIHC	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00938859	chr5:1591904	SDHAP3	0.57	7.07	0.36	8.57e-12	Breast cancer;
LIHC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg01256987	chr12:42539512	GXYLT1	-0.35	-5.71	-0.3	2.39e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.75	0.8	3.26e-78	Prudent dietary pattern;
LIHC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.5	-8.17	-0.4	5.97e-15	Cognitive function;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.55	8.22	0.41	4.42e-15	Longevity;
LIHC	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg22153463	chr1:85462885	MCOLN2	0.54	6.42	0.33	4.69e-10	Serum sulfate level;
LIHC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	11.02	0.51	2.34e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg08499158	chr17:42289980	UBTF	0.49	8.29	0.41	2.68e-15	Total body bone mineral density;
LIHC	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.65	0.38	2.11e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.99	0.44	1.68e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07677032	chr17:61819896	STRADA	0.41	6.09	0.31	3.04e-9	Prudent dietary pattern;
LIHC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg10932868	chr11:921992	NA	0.35	6.63	0.34	1.3100000000000001e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.33	-0.32	7.79e-10	Diabetic kidney disease;
LIHC	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg19000871	chr14:103996768	TRMT61A	-0.55	-8.9	-0.43	3.3e-17	Coronary artery disease;
LIHC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg16989086	chr20:62203971	PRIC285	0.57	8.25	0.41	3.51e-15	Glioblastoma;
LIHC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.49	7.41	0.37	9.94e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg26441486	chr22:50317300	CRELD2	-0.33	-5.92	-0.31	7.71e-9	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg02297831	chr4:17616191	MED28	0.42	6.67	0.34	1.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.94	18.09	0.7	8.44e-52	Menopause (age at onset);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01172785	chr16:50092553	NA	0.4	6.46	0.33	3.5e-10	Immature fraction of reticulocytes;
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27297192	chr10:134578999	INPP5A	0.53	7.42	0.37	9.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.61	9.05	0.44	1.11e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg12798992	chr6:167411361	FGFR1OP	0.49	7.08	0.36	8.35e-12	Crohn's disease;
LIHC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-6.6	-0.34	1.52e-10	Plateletcrit;
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg18279126	chr7:2041391	MAD1L1	0.36	5.73	0.3	2.26e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg13844804	chr7:814759	HEATR2	0.45	5.99	0.31	5.46e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.85e-11	Dermatomyositis;
LIHC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.78	8.86	0.43	4.35e-17	Cognitive function;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.45	8.11	0.4	8.96e-15	Prudent dietary pattern;
LIHC	cis	rs7945718	0.621	rs4514397	chr11:12689768	G/T	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.46	16.71	0.67	3.08e-46	Eosinophil percentage of granulocytes;
LIHC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs1865721	0.682	rs1561080	chr18:73145847	A/G	cg26385618	chr18:73139727	C18orf62	-0.26	-7.26	-0.37	2.56e-12	Intelligence;
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.52	6.92	0.35	2.19e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg14393609	chr7:65229607	NA	0.38	5.91	0.3	8.22e-9	Aortic root size;
LIHC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg16970926	chr12:29381810	FAR2	0.27	5.75	0.3	1.94e-8	QT interval;
LIHC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-8.73	-0.43	1.12e-16	Gut microbiome composition (summer);
LIHC	cis	rs9596863	1.000	rs9596856	chr13:54409401	C/T	ch.13.53330881F	chr13:54432880	NA	0.44	5.98	0.31	5.48e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.55	7.21	0.36	3.58e-12	Economic and political preferences (feminism/equality);
LIHC	trans	rs745109	0.816	rs74443614	chr2:86845509	G/C	cg24539459	chr1:146658275	FMO5	-0.61	-6.39	-0.33	5.4e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LIHC	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg13397359	chr6:42928475	GNMT	0.46	6.44	0.33	3.96e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.6	-9.17	-0.44	4.61e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.39	-6.97	-0.35	1.67e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.55	8.35	0.41	1.67e-15	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05301818	chr8:125385252	TMEM65	0.48	6.47	0.33	3.47e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.41	-6.16	-0.32	2.01e-9	Prostate cancer;
LIHC	cis	rs600806	0.778	rs12145677	chr1:110023610	G/A	cg08911820	chr1:110026001	ATXN7L2	0.52	6.35	0.32	6.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9322817	0.583	rs6941988	chr6:105146656	C/T	cg02098413	chr6:105308735	HACE1	0.4	8.09	0.4	1.06e-14	Thyroid stimulating hormone;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg00280220	chr17:61926910	NA	0.43	6.81	0.35	4.41e-11	Prudent dietary pattern;
LIHC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-14.91	-0.63	4.45e-39	Primary sclerosing cholangitis;
LIHC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-11.46	-0.53	6.04e-26	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6691722	0.583	rs7537875	chr1:24695151	A/T	cg18323236	chr1:24743029	NIPAL3	0.32	6.02	0.31	4.45e-9	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs151997	0.629	rs152808	chr5:50207382	G/C	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.04	0.31	4.11e-9	Coronary artery disease;
LIHC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.84	0.65	9.42e-43	Nonalcoholic fatty liver disease;
LIHC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg20887711	chr4:1340912	KIAA1530	0.48	6.03	0.31	4.23e-9	Recombination rate (females);
LIHC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.56	-8.79	-0.43	7.45e-17	Menarche (age at onset);
LIHC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg16102536	chr7:156981717	UBE3C	0.37	6.16	0.32	2.02e-9	Body mass index;
LIHC	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.21e-9	Mean corpuscular volume;
LIHC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.56	-9.1	-0.44	7.76e-18	Longevity;Endometriosis;
LIHC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.9	-10.13	-0.48	2.79e-21	Schizophrenia;
LIHC	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.8	8.18	0.4	5.71e-15	Height;
LIHC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.49	8.75	0.43	1.02e-16	Height;
LIHC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg17135325	chr3:160939158	NMD3	0.55	7.82	0.39	6.82e-14	Parkinson's disease;
LIHC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.48	6.92	0.35	2.27e-11	Corneal structure;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.66	11.7	0.53	7.97e-27	Colorectal cancer;
LIHC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.47	-6.26	-0.32	1.14e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7520050	0.933	rs6694340	chr1:46289416	C/T	cg03146154	chr1:46216737	IPP	-0.37	-5.98	-0.31	5.62e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	6.17	0.32	1.92e-9	Ileal carcinoids;
LIHC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Vitiligo;
LIHC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21747090	chr2:27597821	SNX17	0.42	6.37	0.33	6.06e-10	Total body bone mineral density;
LIHC	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg18964960	chr10:1102726	WDR37	0.69	6.33	0.32	7.61e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg04013166	chr16:89971882	TCF25	0.59	7.58	0.38	3.25e-13	Skin colour saturation;
LIHC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.44	6.98	0.35	1.51e-11	Cognitive function;
LIHC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.73	7.66	0.38	1.93e-13	Schizophrenia;
LIHC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg18225595	chr11:63971243	STIP1	0.61	7.88	0.39	4.42e-14	Mean platelet volume;
LIHC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg04160030	chr1:24195659	FUCA1	-0.36	-5.88	-0.3	9.82e-9	Immature fraction of reticulocytes;
LIHC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.74	0.3	2.05e-8	Coronary artery disease;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.48	-8.39	-0.41	1.28e-15	Total body bone mineral density;
LIHC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.84	0.47	2.7e-20	Crohn's disease;
LIHC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.59	5.72	0.3	2.3e-8	Plasma clusterin levels;
LIHC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.66	-8.72	-0.43	1.21e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.51	8.47	0.42	7.41e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg05484376	chr2:27715224	FNDC4	0.34	5.74	0.3	2.12e-8	Total body bone mineral density;
LIHC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.46	-6.5	-0.33	2.84e-10	Obesity-related traits;
LIHC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg12046867	chr14:103022105	NA	0.49	6.87	0.35	2.96e-11	Platelet count;
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.41	-0.33	4.74e-10	Total body bone mineral density;
LIHC	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.5	5.73	0.3	2.21e-8	Coronary artery disease;
LIHC	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg04733989	chr22:42467013	NAGA	0.66	9.48	0.46	4.36e-19	Schizophrenia;
LIHC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.4	-6.54	-0.33	2.22e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.4	8.1	0.4	9.64e-15	Renal cell carcinoma;
LIHC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.73	0.43	1.13e-16	Lung cancer in ever smokers;
LIHC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.66	12.71	0.57	1.42e-30	Rheumatoid arthritis;
LIHC	cis	rs74233809	1.000	rs11191514	chr10:104773364	C/T	cg03493300	chr10:104813866	CNNM2	0.45	6.06	0.31	3.62e-9	Birth weight;
LIHC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-13.16	-0.58	2.85e-32	Alzheimer's disease;
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.37	-6.29	-0.32	9.56e-10	Paraoxonase activity;
LIHC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.51	7.52	0.38	4.89e-13	Platelet count;
LIHC	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.55	5.82	0.3	1.32e-8	IgG glycosylation;
LIHC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.7	-0.79	3.61e-74	Height;
LIHC	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.43	-6.13	-0.31	2.41e-9	Blood protein levels;
LIHC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.31	-0.58	7.63e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg03517284	chr6:25882590	NA	-0.38	-5.72	-0.3	2.27e-8	Height;
LIHC	cis	rs3820500	0.543	rs7514323	chr1:118002719	A/G	cg20383390	chr1:117909022	MAN1A2	0.46	6.02	0.31	4.4e-9	Pneumonia;
LIHC	cis	rs712039	0.652	rs11656503	chr17:35772021	G/T	cg16670864	chr17:35848621	DUSP14	0.34	5.76	0.3	1.9e-8	Tuberculosis;
LIHC	cis	rs11663156	1.000	rs2339639	chr18:50928022	A/T	cg24270629	chr18:50823537	DCC	-0.47	-6.42	-0.33	4.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.42e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg08911820	chr1:110026001	ATXN7L2	0.6	7.38	0.37	1.23e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.77	9.12	0.44	6.79e-18	Bladder cancer;
LIHC	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.49	6.59	0.34	1.69e-10	Glioblastoma;Glioma;
LIHC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.59	-0.5	7.71e-23	Total cholesterol levels;
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11987759	chr7:65425863	GUSB	0.38	6.06	0.31	3.61e-9	Calcium levels;
LIHC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg22633049	chr21:46681294	NA	-0.35	-5.77	-0.3	1.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.11	0.4	9.34e-15	Schizophrenia;
LIHC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	6.13	0.31	2.43e-9	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.31	0.58	7.32e-33	Diabetic kidney disease;
LIHC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	18.56	0.71	1.07e-53	Testicular germ cell tumor;
LIHC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21467203	chr3:49911342	NA	0.43	7.54	0.38	4.31e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.94	-16.87	-0.67	6.63e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	7.01	0.35	1.31e-11	Lung cancer in ever smokers;
LIHC	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.33	5.8	0.3	1.53e-8	Metabolite levels (small molecules and protein measures);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13713052	chr3:122102218	FAM162A;CCDC58	0.55	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.58	10.25	0.48	1.1e-21	Dupuytren's disease;
LIHC	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.39	6.14	0.32	2.27e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg07133347	chr1:107600762	PRMT6	0.46	6.83	0.35	3.87e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	11.21	0.52	4.73e-25	Cognitive test performance;
LIHC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg16970926	chr12:29381810	FAR2	0.28	5.97	0.31	6.02e-9	QT interval;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg19635926	chr16:89946313	TCF25	0.5	7.04	0.36	1.04e-11	Interleukin-17 levels;
LIHC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.51	-0.33	2.68e-10	Type 2 diabetes;
LIHC	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.18	-0.4	5.45e-15	Capecitabine sensitivity;
LIHC	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.38	9.1	0.44	7.47e-18	Blood metabolite ratios;
LIHC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.37	6.48	0.33	3.16e-10	Psoriasis;
LIHC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.25	-0.36	2.84e-12	HDL cholesterol;
LIHC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.54	-7.7	-0.38	1.48e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.29	7.2	0.36	3.93e-12	Cutaneous nevi;
LIHC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.71	0.38	1.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.31	6.52	0.33	2.59e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs116248771	0.739	rs16829290	chr3:158392278	T/C	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.32e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.35	6.55	0.33	2.07e-10	Testicular germ cell tumor;
LIHC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.47	-6.92	-0.35	2.27e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs16958440	0.867	rs12326221	chr18:44682893	G/T	cg17192377	chr18:44677553	HDHD2	0.9	8.34	0.41	1.78e-15	Sitting height ratio;
LIHC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.55	6.41	0.33	4.71e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.89	-0.54	1.66e-27	Total cholesterol levels;
LIHC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.52	-6.56	-0.33	2.03e-10	Coronary artery calcification;
LIHC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg17279839	chr7:150038598	RARRES2	0.51	10.65	0.5	4.77e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.73	11.2	0.52	5.32e-25	Metabolite levels;
LIHC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.56	-9.66	-0.46	1.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.6	11.91	0.54	1.36e-27	Plateletcrit;Platelet count;
LIHC	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.86	-6.4	-0.33	5.02e-10	Platelet distribution width;
LIHC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	9.66	0.46	1.15e-19	Total body bone mineral density;
LIHC	cis	rs12744310	1.000	rs12031417	chr1:41763028	A/G	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.71	9.07	0.44	9.29e-18	Gut microbiome composition (summer);
LIHC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-7.5	-0.38	5.62e-13	Lymphocyte counts;
LIHC	cis	rs6604026	0.740	rs10874747	chr1:93352491	A/G	cg17283838	chr1:93427260	FAM69A	-0.42	-5.8	-0.3	1.48e-8	Multiple sclerosis;
LIHC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	7.06	0.36	9.58e-12	Menopause (age at onset);
LIHC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.57	8.29	0.41	2.61e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg02297831	chr4:17616191	MED28	0.43	6.8	0.35	4.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.76	0.43	9.46e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.62	-0.81	1.41e-81	Myeloid white cell count;
LIHC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.27	-13.88	-0.6	4.83e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9918079	0.580	rs13120905	chr4:15612288	A/T	cg16509355	chr4:15471240	CC2D2A	0.46	7.1	0.36	7.27e-12	Obesity-related traits;
LIHC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.33	5.98	0.31	5.61e-9	Alopecia areata;
LIHC	cis	rs3770081	1.000	rs3770087	chr2:86267068	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.72	0.3	2.29e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg19508488	chr2:152266495	RIF1	-0.49	-7.21	-0.36	3.59e-12	Squamous cell lung carcinoma;
LIHC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.57	8.5	0.42	6.04e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg02290350	chr8:58132656	NA	0.47	8.61	0.42	2.69e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.58	7.92	0.39	3.33e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.62	11.64	0.53	1.29e-26	Age at first birth;
LIHC	cis	rs3823572	0.542	rs10269665	chr7:133630418	A/G	cg03336402	chr7:133662267	EXOC4	0.46	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.44	6.22	0.32	1.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	cis	rs34375054	0.573	rs35698828	chr12:125658603	C/T	cg25124228	chr12:125621409	AACS	-0.43	-6.61	-0.34	1.47e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.81	0.5	1.24e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.42	-0.33	4.59e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.68	0.34	9.97e-11	Platelet count;
LIHC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.09e-10	Aortic root size;
LIHC	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-7.64	-0.38	2.21e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.07	24.52	0.8	2.44e-77	IgG glycosylation;
LIHC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.57	11.03	0.51	2.04e-24	Coronary artery disease;
LIHC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg02344993	chr17:57696989	CLTC	0.7	11.89	0.54	1.66e-27	Hemoglobin concentration;
LIHC	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.79	8.97	0.44	1.94e-17	Exhaled nitric oxide levels;
LIHC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.57	9.3	0.45	1.74e-18	Lymphocyte counts;
LIHC	cis	rs77106637	0.585	rs67260737	chr11:72458196	A/G	cg03713592	chr11:72463424	ARAP1	0.6	6.61	0.34	1.44e-10	Type 2 diabetes;
LIHC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.35	6.07	0.31	3.37e-9	Psoriasis;
LIHC	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.28	0.32	1.04e-9	Ileal carcinoids;
LIHC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg20607798	chr8:58055168	NA	0.52	6.56	0.33	1.98e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.36	8.28	0.41	2.72e-15	Educational attainment (years of education);
LIHC	cis	rs943466	1.000	rs11754690	chr6:33744157	G/A	cg25922239	chr6:33757077	LEMD2	-0.47	-5.77	-0.3	1.75e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.57	6.81	0.35	4.35e-11	Alzheimer's disease;
LIHC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.06	9.55	0.46	2.59e-19	Diabetic retinopathy;
LIHC	cis	rs35955747	0.871	rs2013254	chr22:31690803	G/A	cg22777020	chr22:31556080	RNF185	-0.49	-5.76	-0.3	1.91e-8	Neutrophil count;Sum basophil neutrophil counts;
LIHC	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.41	0.45	7.21e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	11.24	0.52	3.73e-25	Schizophrenia;
LIHC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.82	-13.6	-0.59	5.83e-34	Aortic root size;
LIHC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg25894440	chr7:65020034	NA	-0.54	-6.13	-0.31	2.37e-9	Diabetic kidney disease;
LIHC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	8.27	0.41	2.93e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	10.23	0.48	1.27e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg27478167	chr7:817139	HEATR2	-0.51	-6.82	-0.35	4.1e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.25	0.41	3.5e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.66	11.57	0.53	2.41e-26	Colorectal cancer;
LIHC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.1	-10.33	-0.49	5.84e-22	Breast cancer;
LIHC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-7.09	-0.36	7.82e-12	Birth weight;
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg20090690	chr10:134436459	INPP5A	0.44	6.02	0.31	4.42e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.54	-7.16	-0.36	5.11e-12	Lung cancer;
LIHC	cis	rs2224391	1.000	rs9504369	chr6:5261575	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.41	-6.24	-0.32	1.32e-9	Height;
LIHC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.78	-0.54	4.13e-27	Total cholesterol levels;
LIHC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.6	0.56	3.51e-30	Cognitive test performance;
LIHC	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.48	0.33	3.15e-10	Response to antipsychotic treatment;
LIHC	cis	rs11031096	0.587	rs2920145	chr11:4070552	G/T	cg18678763	chr11:4115507	RRM1	0.45	6.69	0.34	9.2e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.37	6.78	0.34	5.14e-11	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.27	0.58	1.02e-32	Diabetic kidney disease;
LIHC	cis	rs2191566	0.960	rs7255315	chr19:44510933	A/T	cg20607764	chr19:44506953	ZNF230	-0.41	-6.66	-0.34	1.1e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg26951091	chr14:76844913	ESRRB	0.59	6.48	0.33	3.28e-10	Putamen volume;
LIHC	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.19	0.61	3.05e-36	Bipolar disorder;
LIHC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.84	0.3	1.23e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-7.1	-0.36	7.3e-12	Life satisfaction;
LIHC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg25329415	chr6:28076851	NA	0.27	5.74	0.3	2.13e-8	Cardiac Troponin-T levels;
LIHC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg17135325	chr3:160939158	NMD3	0.56	8.07	0.4	1.22e-14	Parkinson's disease;
LIHC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.73	9.55	0.46	2.58e-19	Eosinophilic esophagitis;
LIHC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.49	9.85	0.47	2.67e-20	Tonsillectomy;
LIHC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-9.3	-0.45	1.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg07451762	chr16:28383216	NA	0.32	6.14	0.31	2.33e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.6e-18	Bipolar disorder;
LIHC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg03013999	chr17:37608204	MED1	-0.36	-5.97	-0.31	5.89e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.85	-13.22	-0.58	1.67e-32	Obesity-related traits;
LIHC	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.41	0.49	3.12e-22	Colorectal cancer;
LIHC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg16586182	chr3:47516702	SCAP	0.57	10.4	0.49	3.34e-22	Colorectal cancer;
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg24101359	chr6:42928495	GNMT	0.43	5.91	0.3	8.14e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg09094615	chr8:17779997	PCM1	0.42	6.14	0.32	2.31e-9	Myopia (pathological);
LIHC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.47	-8.19	-0.4	5.33e-15	Mean corpuscular volume;
LIHC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.78	-15.64	-0.65	5.53e-42	Height;
LIHC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-10.77	-0.5	1.79e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs332507	0.601	rs11707114	chr3:124375799	C/T	cg05980111	chr3:124395277	KALRN	0.32	6.21	0.32	1.57e-9	Plateletcrit;
LIHC	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg18898632	chr2:242989856	NA	-0.47	-6.52	-0.33	2.58e-10	Obesity-related traits;
LIHC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.35	6.2	0.32	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.63	12.49	0.56	9.39e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg25214090	chr10:38739885	LOC399744	-0.4	-6.41	-0.33	4.85e-10	Diastolic blood pressure;
LIHC	cis	rs9473924	1.000	rs9473924	chr6:50834157	A/C	cg14470998	chr6:50812995	TFAP2B	-0.41	-6.32	-0.32	8.34e-10	Body mass index;
LIHC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.35	-6.06	-0.31	3.55e-9	Schizophrenia;
LIHC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.0	-0.44	1.63e-17	Gut microbiome composition (summer);
LIHC	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg02023728	chr11:77925099	USP35	-0.36	-6.37	-0.33	6.12e-10	Alzheimer's disease (survival time);
LIHC	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-6.52	-0.33	2.58e-10	Neuroticism;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.58	6.83	0.35	3.99e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-10.09	-0.48	3.92e-21	Platelet count;
LIHC	cis	rs3112357	0.901	rs13307412	chr7:135388142	A/G	cg20392616	chr7:135392013	SLC13A4	0.42	6.88	0.35	2.83e-11	Plantar warts;
LIHC	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-9.49	-0.46	4.24e-19	Platelet distribution width;
LIHC	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg00792783	chr2:198669748	PLCL1	0.45	6.68	0.34	9.45e-11	Dermatomyositis;
LIHC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.73	-0.43	1.18e-16	Skin colour saturation;
LIHC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.63	10.23	0.48	1.35e-21	Resting heart rate;
LIHC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.35	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.54	-7.02	-0.35	1.19e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs10213084	1.000	rs10010958	chr4:147511918	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.47	6.32	0.32	8.15e-10	Heart rate;
LIHC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.56	-0.46	2.35e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs11673344	0.764	rs10403679	chr19:37471712	G/C	cg27390819	chr19:37464633	NA	-0.49	-5.91	-0.3	8.23e-9	Obesity-related traits;
LIHC	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.99	-0.54	6.78e-28	Response to antipsychotic treatment;
LIHC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.49	7.76	0.39	9.79e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.25	-0.55	7.24e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.62	-0.38	2.44e-13	Body mass index;
LIHC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.32	0.58	6.85e-33	Chronic sinus infection;
LIHC	cis	rs4930561	0.714	rs10896300	chr11:67953772	C/T	cg04465784	chr11:67976953	SUV420H1	0.3	5.78	0.3	1.71e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LIHC	trans	rs890100	0.640	rs2193484	chr2:56687813	A/G	cg27252696	chr6:100912940	SIM1	0.35	6.08	0.31	3.17e-9	Gut microbiome composition (summer);
LIHC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.4	6.48	0.33	3.17e-10	Bipolar disorder;
LIHC	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.79	12.61	0.56	3.36e-30	Eye color traits;
LIHC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.78	-13.66	-0.59	3.21e-34	Coronary artery disease;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	9.44	0.45	5.93e-19	Lymphocyte counts;
LIHC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.28	0.52	2.74e-25	Motion sickness;
LIHC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.88	-0.35	2.82e-11	Response to antipsychotic treatment;
LIHC	cis	rs1892700	0.840	rs74730233	chr21:34864391	G/T	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg13409248	chr3:40428643	ENTPD3	-0.44	-7.39	-0.37	1.11e-12	Renal cell carcinoma;
LIHC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.65e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg16506815	chr2:162101123	NA	-0.42	-6.33	-0.32	7.64e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs2723064	0.526	rs4671120	chr2:65371112	G/A	cg05010058	chr2:65284262	CEP68	-0.36	-5.8	-0.3	1.51e-8	Atrial fibrillation;
LIHC	cis	rs8084351	0.577	rs12965244	chr18:50663864	A/G	cg24270629	chr18:50823537	DCC	-0.44	-6.48	-0.33	3.12e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.42	-6.09	-0.31	3.07e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.57	0.59	7.69e-34	Lung cancer in ever smokers;
LIHC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.78	-13.63	-0.59	4.46e-34	Aortic root size;
LIHC	cis	rs10857712	0.851	rs7913420	chr10:135213854	C/T	cg01444801	chr10:135216882	MTG1	-0.66	-9.86	-0.47	2.39e-20	Systemic lupus erythematosus;
LIHC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.83	-13.21	-0.58	1.76e-32	Colorectal cancer;
LIHC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-12.01	-0.54	6.02e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.49	-6.95	-0.35	1.84e-11	Prostate cancer;
LIHC	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg27561452	chr16:68573240	ZFP90	-0.41	-6.21	-0.32	1.58e-9	Brugada syndrome;
LIHC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.72	-0.3	2.34e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1459104	0.673	rs7118132	chr11:55126517	C/T	cg15704280	chr7:45808275	SEPT13	0.58	8.03	0.4	1.57e-14	Body mass index;
LIHC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10065203	0.527	rs173948	chr5:14347771	A/G	cg26595256	chr5:14380529	TRIO	-0.4	-6.06	-0.31	3.57e-9	Paclitaxel-induced neuropathy;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg09779027	chr19:7224513	INSR	0.3	6.76	0.34	6.07e-11	Hypothyroidism;
LIHC	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.83	8.63	0.42	2.35e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg25039879	chr17:56429692	SUPT4H1	0.86	9.69	0.46	9e-20	Cognitive test performance;
LIHC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg06115741	chr20:33292138	TP53INP2	0.48	5.72	0.3	2.32e-8	Protein C levels;
LIHC	cis	rs7091068	0.802	rs10786121	chr10:95419796	G/A	cg20715218	chr10:95462985	C10orf4	0.56	6.2	0.32	1.67e-9	Urinary tract infection frequency;
LIHC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg02290350	chr8:58132656	NA	0.39	8.4	0.41	1.23e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04565464	chr8:145669602	NFKBIL2	0.37	6.1	0.31	2.85e-9	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.69	0.5	3.24e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.59	-8.0	-0.4	1.95e-14	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	7.69	0.38	1.61e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.28	-0.32	1.01e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.42	-0.45	6.98e-19	Obesity-related traits;
LIHC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.98	0.35	1.53e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg17724175	chr1:150552817	MCL1	0.41	8.0	0.4	1.98e-14	Tonsillectomy;
LIHC	cis	rs6669384	0.774	rs61821318	chr1:208033706	C/T	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.96	-0.31	6.45e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.48	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.68	12.01	0.54	5.77e-28	Bone mineral density;
LIHC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.53	8.15	0.4	6.85e-15	Resting heart rate;
LIHC	cis	rs2710642	0.927	rs1468748	chr2:63204611	C/T	cg17519650	chr2:63277830	OTX1	0.48	7.38	0.37	1.22e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05590025	chr7:65112418	INTS4L2	0.44	6.6	0.34	1.6e-10	Calcium levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11823463	chr1:156629982	NA	-0.56	-6.76	-0.34	6.11e-11	Systolic blood pressure;
LIHC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	0.65	6.51	0.33	2.7e-10	Hip circumference adjusted for BMI;
LIHC	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.63	10.15	0.48	2.56e-21	Corneal astigmatism;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10137979	chr8:110346498	ENY2;NUDCD1	0.43	6.62	0.34	1.37e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg13535736	chr9:111863775	C9orf5	-0.38	-5.71	-0.3	2.41e-8	Menarche (age at onset);
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.82	15.01	0.63	1.72e-39	Prudent dietary pattern;
LIHC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.38	12.24	0.55	7.87e-29	Uric acid levels;
LIHC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg27572855	chr1:25598939	RHD	0.39	8.51	0.42	5.67e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.56	9.1	0.44	7.5e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-1.07	-13.64	-0.59	4.14e-34	Dilated cardiomyopathy;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg04013166	chr16:89971882	TCF25	0.58	7.84	0.39	5.71e-14	Skin colour saturation;
LIHC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.67	11.89	0.54	1.54e-27	Longevity;Endometriosis;
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg03721293	chr16:90014378	DEF8	0.41	6.95	0.35	1.83e-11	Skin colour saturation;
LIHC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.68	8.34	0.41	1.84e-15	Morning vs. evening chronotype;
LIHC	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg22842854	chr12:123319900	HIP1R	0.83	9.26	0.45	2.24e-18	Adiponectin levels;
LIHC	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-8.69	-0.43	1.56e-16	Vitamin D levels;
LIHC	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.82	-14.77	-0.62	1.55e-38	Height;
LIHC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.58	0.56	4.39e-30	Colorectal cancer;
LIHC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.65	-0.34	1.14e-10	Metabolite levels;
LIHC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.44	-7.18	-0.36	4.38e-12	Menarche (age at onset);
LIHC	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg00204748	chr12:29376779	FAR2	0.35	6.61	0.34	1.47e-10	QT interval;
LIHC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	8.06	0.4	1.27e-14	Diastolic blood pressure;
LIHC	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.41	6.66	0.34	1.08e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs3736485	0.934	rs1902592	chr15:51881980	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.79	-12.45	-0.56	1.38e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg18375707	chr11:64034959	PLCB3	-0.51	-7.83	-0.39	6.39e-14	Body mass index;
LIHC	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.72	9.25	0.45	2.55e-18	Eosinophilic esophagitis;
LIHC	cis	rs4684776	0.676	rs11714563	chr3:11313214	A/G	cg00170343	chr3:11313890	ATG7	-0.51	-6.95	-0.35	1.85e-11	Small vessel stroke;
LIHC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg25894440	chr7:65020034	NA	-0.54	-6.1	-0.31	2.79e-9	Diabetic kidney disease;
LIHC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.8	13.34	0.59	5.55e-33	Psoriasis;
LIHC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.92	16.59	0.67	9.39e-46	Colorectal cancer;
LIHC	cis	rs3790844	0.678	rs3790854	chr1:200000125	C/T	cg13229857	chr1:200006247	NR5A2	-0.36	-5.98	-0.31	5.53e-9	Pancreatic cancer;
LIHC	cis	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg16684958	chr7:75615977	POR	0.4	5.96	0.31	6.36e-9	Eotaxin levels;
LIHC	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.44	6.81	0.35	4.52e-11	Glioblastoma;
LIHC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.32	-0.74	9.46e-61	Height;
LIHC	cis	rs9513627	1.000	rs9517758	chr13:100179397	T/A	cg25919922	chr13:100150906	NA	0.77	7.04	0.36	1.08e-11	Obesity-related traits;
LIHC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.44	7.06	0.36	9.58e-12	Total body bone mineral density;
LIHC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.4	-6.31	-0.32	8.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs78049276	0.736	rs6841581	chr4:148401190	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.37	-0.37	1.27e-12	Pulse pressure;
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.31	-6.37	-0.33	6.07e-10	Renal cell carcinoma;
LIHC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg09222892	chr1:25734099	RHCE	-0.48	-8.65	-0.42	2.03e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.72	-0.3	2.34e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	5.93	0.31	7.43e-9	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.37	6.5	0.33	2.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8081395	0.866	rs2777899	chr17:57832391	T/G	cg02344993	chr17:57696989	CLTC	-0.45	-7.29	-0.37	2.22e-12	White blood cell count;
LIHC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.49	7.59	0.38	3.13e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.05	-0.44	1.09e-17	Birth weight;
LIHC	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.52	8.89	0.43	3.48e-17	Breast cancer;
LIHC	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.93	16.47	0.66	2.86e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs8064024	0.680	rs3747613	chr16:4908504	C/G	cg08329684	chr16:4932620	PPL	-0.34	-5.93	-0.31	7.35e-9	Cancer;
LIHC	cis	rs11212260	0.655	rs76734158	chr11:107204517	A/G	cg25435332	chr11:107328525	CWF19L2	0.75	6.93	0.35	2.12e-11	IgG glycosylation;
LIHC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.62	-0.34	1.43e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.29	-0.32	9.77e-10	Height;
LIHC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.4	-6.19	-0.32	1.74e-9	Lung cancer;
LIHC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.43	-6.58	-0.34	1.78e-10	Height;
LIHC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.38	-6.0	-0.31	4.97e-9	Neurofibrillary tangles;
LIHC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg21486233	chr12:29375141	FAR2	0.32	6.51	0.33	2.72e-10	QT interval;
LIHC	cis	rs243505	0.559	rs7802887	chr7:148494758	C/T	cg09806900	chr7:148480153	CUL1	0.42	6.22	0.32	1.49e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg05535760	chr7:792225	HEATR2	0.49	6.77	0.34	5.77e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.9	0.35	2.58e-11	Testicular germ cell tumor;
LIHC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.68	-0.38	1.67e-13	Electroencephalogram traits;
LIHC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.57	7.81	0.39	6.92e-14	Neuroblastoma;
LIHC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.8	7.56	0.38	3.78e-13	Plasma clusterin levels;
LIHC	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg17385448	chr1:15911702	AGMAT	0.4	6.81	0.35	4.41e-11	Systolic blood pressure;
LIHC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.95	-0.31	6.69e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.41	-6.94	-0.35	1.99e-11	Lung cancer;
LIHC	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.51	9.77	0.47	4.85e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.6	-9.9	-0.47	1.77e-20	Schizophrenia;
LIHC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.47	7.97	0.4	2.37e-14	Obesity-related traits;
LIHC	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.83	0.35	3.82e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.74	-11.69	-0.53	8.9e-27	Personality dimensions;
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.48	6.52	0.33	2.55e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.22	0.32	1.45e-9	Electroencephalogram traits;
LIHC	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.69	-7.63	-0.38	2.29e-13	Exhaled nitric oxide output;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09034795	chr11:63676760	MARK2	0.41	6.36	0.33	6.66e-10	Longevity;
LIHC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.85	0.57	4.05e-31	Colorectal cancer;
LIHC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-6.93	-0.35	2.13e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg04455712	chr21:45112962	RRP1B	0.43	6.96	0.35	1.8e-11	Mean corpuscular volume;
LIHC	cis	rs7712401	0.686	rs185007	chr5:122199318	C/T	cg18764291	chr5:122110994	SNX2	0.33	5.82	0.3	1.37e-8	Mean platelet volume;
LIHC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00152838	chr16:24741724	TNRC6A	0.5	6.23	0.32	1.37e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-9.17	-0.44	4.37e-18	Response to antipsychotic treatment;
LIHC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.59	0.53	2.03e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg03037974	chr15:76606532	NA	0.88	22.77	0.78	1.74e-70	Blood metabolite levels;
LIHC	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.46	-10.6	-0.5	6.67e-23	Diastolic blood pressure;
LIHC	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.49	7.79	0.39	7.92e-14	Blood protein levels;
LIHC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.41	-8.36	-0.41	1.55e-15	Immature fraction of reticulocytes;
LIHC	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.02e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg05527609	chr1:210001259	C1orf107	-0.57	-7.65	-0.38	2.13e-13	Red blood cell count;
LIHC	cis	rs6466055	0.748	rs9640686	chr7:104867330	T/G	cg04380332	chr7:105027541	SRPK2	0.36	6.71	0.34	8.29e-11	Schizophrenia;
LIHC	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16684958	chr7:75615977	POR	-0.51	-8.59	-0.42	3.22e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.51	-7.61	-0.38	2.73e-13	Total body bone mineral density;
LIHC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg19513890	chr22:42538836	CYP2D7P1	0.42	8.46	0.42	8.17e-16	Cognitive function;
LIHC	cis	rs9473924	1.000	rs6923215	chr6:50889848	G/A	cg14470998	chr6:50812995	TFAP2B	0.49	7.35	0.37	1.52e-12	Body mass index;
LIHC	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.61	-12.02	-0.54	5.41e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7129556	0.520	rs10793257	chr11:77309533	T/C	cg03570279	chr11:77446074	RSF1	-0.35	-6.47	-0.33	3.43e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-1.02	-20.83	-0.75	8.16e-63	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs713477	1.000	rs12893000	chr14:55912280	G/T	cg13175173	chr14:55914753	NA	-0.36	-8.26	-0.41	3.34e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.42	6.81	0.35	4.49e-11	Red blood cell count;
LIHC	trans	rs783540	0.934	rs7182403	chr15:83297613	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.24	-0.32	1.33e-9	Schizophrenia;
LIHC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.56	-7.86	-0.39	5.16e-14	Total body bone mineral density;
LIHC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.97	18.36	0.7	6.68e-53	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	6.81e-47	Diabetic kidney disease;
LIHC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.68	0.5	3.65e-23	Type 2 diabetes;
LIHC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-8.03	-0.4	1.57e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.66	9.53	0.46	2.96e-19	Monocyte percentage of white cells;
LIHC	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg04610667	chr7:75704037	NA	-0.35	-6.18	-0.32	1.86e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.6	-8.03	-0.4	1.55e-14	Diastolic blood pressure;
LIHC	cis	rs3762637	0.941	rs9810999	chr3:122074391	G/A	cg24169773	chr3:122142474	KPNA1	-0.49	-9.52	-0.46	3.18e-19	LDL cholesterol levels;
LIHC	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-10.8	-0.5	1.35e-23	Pediatric autoimmune diseases;
LIHC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	7.63	0.38	2.35e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.73	-0.3	2.23e-8	Obesity-related traits;
LIHC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.65	-7.57	-0.38	3.45e-13	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.97	9.8	0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.58	6.29	0.32	9.7e-10	Gut microbiome composition (summer);
LIHC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg10932868	chr11:921992	NA	0.35	6.4	0.33	5.15e-10	Alzheimer's disease (late onset);
LIHC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg03517284	chr6:25882590	NA	-0.38	-5.76	-0.3	1.83e-8	Height;
LIHC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-8.52	-0.42	5.35e-16	Total body bone mineral density;
LIHC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.37	5.75	0.3	1.94e-8	Total body bone mineral density;
LIHC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.47	6.84	0.35	3.7e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg05930370	chr1:224545104	CNIH4	-0.44	-6.09	-0.31	3.07e-9	Alopecia areata;
LIHC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.94	20.21	0.74	2.5e-60	Blood protein levels;
LIHC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg12373951	chr3:133503437	NA	0.46	7.65	0.38	2.03e-13	Iron status biomarkers;
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.83	12.2	0.55	1.1e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.78	13.24	0.58	1.39e-32	Psoriasis;
LIHC	cis	rs61677309	1.000	rs56140791	chr11:118167190	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.41	0.33	4.8e-10	Lung cancer in ever smokers;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg09417038	chr21:47716443	C21orf57	-0.54	-8.07	-0.4	1.19e-14	Testicular germ cell tumor;
LIHC	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.38	6.44	0.33	4.04e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	6.06	0.31	3.63e-9	Height;
LIHC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.42	0.41	1.03e-15	Resting heart rate;
LIHC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg03013999	chr17:37608204	MED1	-0.35	-5.8	-0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9473924	0.542	rs2245173	chr6:50810540	T/C	cg14470998	chr6:50812995	TFAP2B	0.98	11.36	0.52	1.42e-25	Body mass index;
LIHC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.42	6.95	0.35	1.91e-11	Red blood cell count;
LIHC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.48	7.94	0.39	2.86e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.67	12.77	0.57	8.25e-31	Menopause (age at onset);
LIHC	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-8.08	-0.4	1.1e-14	Putamen volume;
LIHC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-9.15	-0.44	5.23e-18	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.63	7.96	0.4	2.64e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9392556	0.510	rs613028	chr6:4102139	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.31	-5.86	-0.3	1.08e-8	Blood metabolite levels;
LIHC	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.32	8.18	0.4	5.75e-15	Gut microbiome composition (winter);
LIHC	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.08	-0.36	8.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.31	-0.32	8.7e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs623264	0.920	rs415427	chr19:5470637	T/G	cg03088458	chr19:5478473	NA	-0.35	-6.04	-0.31	4.05e-9	Interleukin-2 receptor antagonist levels;
LIHC	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg19513890	chr22:42538836	CYP2D7P1	0.42	8.25	0.41	3.58e-15	Cognitive function;
LIHC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	cis	rs2834188	1.000	rs2834188	chr21:34689253	A/G	cg04842828	chr21:34696676	IFNAR1	0.45	6.14	0.32	2.31e-9	Narcolepsy;
LIHC	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg00012203	chr2:219082015	ARPC2	-0.46	-5.83	-0.3	1.31e-8	Ulcerative colitis;
LIHC	cis	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg01231543	chr16:68741748	NA	0.36	5.72	0.3	2.32e-8	Colorectal cancer;
LIHC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-14.3	-0.61	1.07e-36	Height;
LIHC	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg20335179	chr10:1068567	C10orf110;IDI2	-0.54	-5.72	-0.3	2.35e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg05941027	chr17:61774174	LIMD2	0.31	6.34	0.32	7.07e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.87	-0.3	1.01e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.32	7.58	0.38	3.28e-13	Corneal astigmatism;
LIHC	cis	rs1982963	0.950	rs2645738	chr14:52513202	G/A	cg10843707	chr14:52510701	NID2	-0.48	-8.55	-0.42	4.22e-16	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.28	16.92	0.68	4.2e-47	Diabetic kidney disease;
LIHC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.85	-0.47	2.6e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.75	13.33	0.58	6.41e-33	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.71	11.88	0.54	1.68e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06481639	chr22:41940642	POLR3H	-0.53	-5.75	-0.3	2.01e-8	Neuroticism;
LIHC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg25894440	chr7:65020034	NA	0.53	6.04	0.31	4.03e-9	Diabetic kidney disease;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01719141	chr9:140513215	C9orf37;EHMT1	-0.41	-6.5	-0.33	2.87e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.55	-10.43	-0.49	2.66e-22	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.21	-0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs2292096	0.850	rs12760892	chr1:200802901	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-6.07	-0.31	3.33e-9	Epilepsy;
LIHC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.46	7.32	0.37	1.8e-12	Mortality in heart failure;
LIHC	cis	rs9322817	0.691	rs2499660	chr6:105285750	T/C	cg02098413	chr6:105308735	HACE1	0.44	8.27	0.41	3.04e-15	Thyroid stimulating hormone;
LIHC	cis	rs903552	0.932	rs9806551	chr15:102008206	C/T	cg25677261	chr15:102009856	PCSK6	-0.5	-6.83	-0.35	3.88e-11	Diabetic kidney disease;
LIHC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	9.83	0.47	3.02e-20	Personality dimensions;
LIHC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg11812906	chr14:75593930	NEK9	0.42	6.36	0.33	6.53e-10	Neuroticism (multi-trait analysis);
LIHC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg10628098	chr11:65292300	SCYL1	-0.37	-5.88	-0.3	9.7e-9	Bone mineral density;
LIHC	trans	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg16011800	chr17:1958478	HIC1	-0.5	-7.33	-0.37	1.67e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.64	9.73	0.47	6.66e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg15123519	chr2:136567270	LCT	-0.43	-8.67	-0.42	1.8e-16	Mosquito bite size;
LIHC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.46	16.4	0.66	5.12e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.4	-6.41	-0.33	4.78e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs8081395	0.775	rs2526355	chr17:57953233	G/C	cg13753209	chr17:57696993	CLTC	0.38	5.83	0.3	1.27e-8	White blood cell count;
LIHC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.93	-0.81	1e-82	Myeloid white cell count;
LIHC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.49	6.45	0.33	3.82e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.93	-0.35	2.08e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Bone mineral density;
LIHC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.78	9.16	0.44	4.82e-18	Small cell lung carcinoma;
LIHC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.95	-0.35	1.88e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.96	-12.59	-0.56	4.07e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.77e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.71	0.34	8.14e-11	Lung cancer;
LIHC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.76	0.47	5.11e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg01629716	chr15:45996671	NA	0.52	9.65	0.46	1.25e-19	Waist circumference;Weight;
LIHC	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.41	6.29	0.32	9.87e-10	Diastolic blood pressure;
LIHC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.47	8.02	0.4	1.65e-14	Mean corpuscular volume;
LIHC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg24130564	chr14:104152367	KLC1	-0.55	-8.9	-0.43	3.42e-17	Reticulocyte count;
LIHC	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg26031613	chr14:104095156	KLC1	1.16	15.38	0.64	6.25e-41	Body mass index;
LIHC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.51	0.33	2.7e-10	Hemoglobin concentration;
LIHC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.97	9.47	0.46	4.69e-19	Cognitive function;
LIHC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.65	0.46	1.24e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.32	-5.94	-0.31	6.87e-9	Tonsillectomy;
LIHC	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.08	-0.31	3.22e-9	Response to antipsychotic treatment;
LIHC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.62	9.76	0.47	5.15e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.48	7.51	0.38	5.23e-13	Methadone dose in opioid dependence;
LIHC	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg01858014	chr14:56050164	KTN1	-0.63	-5.89	-0.3	9.13e-9	Putamen volume;
LIHC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.43	-0.37	8.66e-13	Schizophrenia;
LIHC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.48	-0.42	6.86e-16	Schizophrenia;
LIHC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg22676075	chr6:135203613	NA	0.4	6.45	0.33	3.87e-10	Red blood cell count;
LIHC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.27	-0.45	2.12e-18	Bipolar disorder;
LIHC	cis	rs4450131	0.522	rs11245328	chr10:126358413	G/A	cg20435097	chr10:126320824	FAM53B	0.67	12.33	0.55	3.71e-29	White blood cell count (basophil);
LIHC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.72	-0.3	2.34e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.49e-29	Menopause (age at onset);
LIHC	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.85	12.35	0.56	3.15e-29	Post bronchodilator FEV1;
LIHC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.75	11.09	0.51	1.3e-24	Response to antineoplastic agents;
LIHC	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.73	-0.43	1.11e-16	Total cholesterol levels;
LIHC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.55	8.86	0.43	4.49e-17	Longevity;Endometriosis;
LIHC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.52	7.67	0.38	1.77e-13	Initial pursuit acceleration;
LIHC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg02269571	chr22:50332266	NA	-0.98	-10.11	-0.48	3.45e-21	Mean platelet volume;
LIHC	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs965469	1.000	rs6051807	chr20:3350485	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-6.24	-0.32	1.32e-9	IFN-related cytopenia;
LIHC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.77	-9.41	-0.45	7.23e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.45e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.07e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.61	10.03	0.48	6.27e-21	Schizophrenia;
LIHC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.54	-8.45	-0.42	8.72e-16	Breast size;
LIHC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.57	-0.38	3.62e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg05185784	chr16:90016020	DEF8	0.38	6.24	0.32	1.28e-9	Squamous cell carcinoma;
LIHC	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg26031613	chr14:104095156	KLC1	1.03	12.95	0.57	1.77e-31	Body mass index;
LIHC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.56	8.4	0.41	1.21e-15	HIV-1 control;
LIHC	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.45	6.59	0.34	1.63e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.41	-5.75	-0.3	2e-8	Aortic root size;
LIHC	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.55	7.32	0.37	1.84e-12	Vitiligo;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.39	7.83	0.39	6.2e-14	Renal cell carcinoma;
LIHC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.67	-11.22	-0.52	4.23e-25	Pulse pressure;
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.76	-0.39	1e-13	Lymphocyte counts;
LIHC	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.59	0.46	1.84e-19	Corneal astigmatism;
LIHC	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	1.04	14.23	0.61	1.99e-36	Corneal structure;
LIHC	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.9	17.17	0.68	4.23e-48	Body mass index;
LIHC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg04727924	chr7:799746	HEATR2	0.41	6.28	0.32	1.01e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs2108622	0.727	rs62107764	chr19:15982658	A/G	cg13772218	chr19:15982569	NA	0.37	7.75	0.39	1.06e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg14067834	chr17:29058358	SUZ12P	0.67	6.48	0.33	3.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1914816	0.941	rs2469544	chr15:76484947	A/T	cg03037974	chr15:76606532	NA	-0.59	-6.11	-0.31	2.67e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-8.59	-0.42	3.04e-16	Initial pursuit acceleration;
LIHC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.07	16.7	0.67	3.25e-46	Breast cancer;
LIHC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.77	9.89	0.47	1.92e-20	Gut microbiome composition (summer);
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.72	-11.2	-0.52	5.23e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.63	8.63	0.42	2.28e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg06497051	chr1:156261200	TMEM79	0.38	6.19	0.32	1.77e-9	Tonsillectomy;
LIHC	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.71	0.46	7.58e-20	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22807378	chr6:170151601	TCTE3;C6orf70	-0.48	-6.6	-0.34	1.57e-10	Pancreatic cancer;
LIHC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.75	-0.34	6.16e-11	Hepatocellular carcinoma;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg00684032	chr4:1343700	KIAA1530	0.4	6.85	0.35	3.34e-11	Obesity-related traits;
LIHC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.49	0.33	2.98e-10	Menarche (age at onset);
LIHC	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-1.09	-13.71	-0.6	2.13e-34	Blood protein levels;
LIHC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.6	7.26	0.37	2.58e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.98	-0.35	1.55e-11	Vitiligo;
LIHC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.78	-12.42	-0.56	1.75e-29	Tonsillectomy;
LIHC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.42	8.48	0.42	6.71e-16	Renal cell carcinoma;
LIHC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg20607798	chr8:58055168	NA	0.49	6.21	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.42	-7.16	-0.36	5.08e-12	Platelet distribution width;
LIHC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg05501817	chr11:14380813	RRAS2	0.43	5.87	0.3	1.03e-8	Sense of smell;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18110333	chr6:292329	DUSP22	-0.53	-6.9	-0.35	2.49e-11	Menopause (age at onset);
LIHC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.6	10.26	0.49	1.05e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.83	0.3	1.25e-8	Blood metabolite levels;
LIHC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.58	7.48	0.38	6.22e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.45	-7.49	-0.38	5.97e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg19680485	chr15:31195859	MTMR15	-0.54	-5.97	-0.31	5.95e-9	Hypertriglyceridemia;
LIHC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg16797656	chr11:68205561	LRP5	0.51	8.04	0.4	1.47e-14	Total body bone mineral density;
LIHC	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg13837822	chr10:26931731	LOC731789	0.36	6.66	0.34	1.1e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.38	-0.37	1.22e-12	Total body bone mineral density;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.27	-0.37	2.51e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.9	-0.63	4.91e-39	Chronic sinus infection;
LIHC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.85	-9.91	-0.47	1.66e-20	Primary sclerosing cholangitis;
LIHC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.52	-6.56	-0.33	2.03e-10	Coronary artery calcification;
LIHC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.42e-30	Alzheimer's disease;
LIHC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	0.87	6.33	0.32	7.7e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg26138144	chr22:38071188	LGALS1	0.42	7.83	0.39	6.21e-14	Fat distribution (HIV);
LIHC	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.14	-10.21	-0.48	1.54e-21	Schizophrenia;
LIHC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.81	-12.39	-0.56	2.19e-29	Breast cancer;
LIHC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.74	11.27	0.52	3e-25	Corneal astigmatism;
LIHC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.65	-0.38	2.04e-13	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06009330	chr2:70485380	PCYOX1	-0.43	-6.3	-0.32	8.99e-10	Cognitive function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg06795559	chr20:5931181	MCM8;TRMT6	0.41	6.12	0.31	2.52e-9	Calcium levels;
LIHC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.91	0.35	2.32e-11	Renal cell carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04873026	chr21:30365177	RNF160	0.44	6.05	0.31	3.84e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.39	7.16	0.36	4.85e-12	Schizophrenia;
LIHC	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.85	-0.3	1.17e-8	Systolic blood pressure;
LIHC	cis	rs4407350	0.837	rs5765707	chr22:44909507	A/T	cg26276947	chr22:44892394	LDOC1L	0.35	6.55	0.33	2.13e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg26138937	chr11:71823887	C11orf51	-1.32	-10.43	-0.49	2.71e-22	Severe influenza A (H1N1) infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18525740	chr5:176449647	ZNF346	0.4	6.06	0.31	3.63e-9	Cognitive function;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.51	7.64	0.38	2.2e-13	Platelet count;
LIHC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.94	0.31	6.89e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	0.71	7.87	0.39	4.71e-14	Dental caries;
LIHC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-7.28	-0.37	2.37e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs668210	0.793	rs502363	chr11:65775592	C/T	cg17712092	chr4:129076599	LARP1B	0.59	6.56	0.33	1.95e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17102884	0.587	rs10162454	chr14:75144618	T/C	cg08847533	chr14:75593920	NEK9	0.42	6.29	0.32	9.82e-10	Neuroticism;
LIHC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg12501888	chr15:85177176	SCAND2	-0.51	-8.02	-0.4	1.71e-14	P wave terminal force;
LIHC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.02	0.36	1.18e-11	Bladder cancer;
LIHC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.56	9.48	0.46	4.51e-19	HDL cholesterol;
LIHC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	9.41	0.45	7.28e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg23114964	chr1:42217077	HIVEP3	0.43	6.5	0.33	2.89e-10	Chronic kidney disease;
LIHC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg12560992	chr17:57184187	TRIM37	0.54	7.34	0.37	1.56e-12	Cognitive test performance;
LIHC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.42	-7.0	-0.35	1.32e-11	Breast cancer;
LIHC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.41	8.09	0.4	1.07e-14	Cardiovascular disease risk factors;
LIHC	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	8.04	0.4	1.48e-14	Mean platelet volume;
LIHC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs8084351	0.599	rs12454142	chr18:50676918	G/A	cg24270629	chr18:50823537	DCC	-0.45	-6.67	-0.34	1.01e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.3	-0.37	2.09e-12	Tuberculosis;
LIHC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.21	-0.36	3.7e-12	Personality dimensions;
LIHC	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.36	-6.03	-0.31	4.33e-9	Menopause (age at onset);
LIHC	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.55	-8.37	-0.41	1.48e-15	Blood trace element (Cu levels);
LIHC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.48	-8.24	-0.41	3.68e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg02640540	chr1:67518911	SLC35D1	0.45	6.02	0.31	4.6e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg09592903	chr2:55203963	RTN4	0.63	11.58	0.53	2.24e-26	Mean platelet volume;
LIHC	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg27206522	chr1:152595629	LCE3A	-0.25	-5.86	-0.3	1.12e-8	Psoriasis;
LIHC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.3	15.42	0.64	4.11e-41	Psoriasis vulgaris;
LIHC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.5	7.94	0.39	3.03e-14	Height;
LIHC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.72	-0.34	7.77e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.79	-9.81	-0.47	3.51e-20	Gut microbiome composition (summer);
LIHC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.79	-7.68	-0.38	1.74e-13	Diabetic retinopathy;
LIHC	cis	rs12079745	0.793	rs3766082	chr1:169215068	A/T	cg09363564	chr1:169337483	NME7;BLZF1	0.66	6.49	0.33	3.02e-10	QT interval;
LIHC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	6.9	0.35	2.46e-11	Axial length;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26815147	chr15:45879302	PLDN	-0.51	-6.34	-0.32	7.29e-10	Systolic blood pressure;
LIHC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.69	-10.17	-0.48	2.15e-21	Coronary artery disease;
LIHC	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.79	-0.3	1.63e-8	Red blood cell count;
LIHC	cis	rs17106184	0.892	rs12090545	chr1:51193984	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-7.22	-0.36	3.38e-12	Type 2 diabetes;
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.1	0.4	9.76e-15	Height;
LIHC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.58	10.54	0.5	1.16e-22	Diastolic blood pressure;
LIHC	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.71	-0.34	7.92e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.21	5.77	0.3	1.79e-8	Hepatitis;
LIHC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.96	-0.35	1.74e-11	Self-reported allergy;
LIHC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	8.97	0.44	2.05e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.58	-8.55	-0.42	4.11e-16	Longevity;
LIHC	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.4	-7.26	-0.37	2.7e-12	Asthma;
LIHC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.91	11.33	0.52	1.82e-25	Blood protein levels;
LIHC	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.65	-10.41	-0.49	3.22e-22	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	10.28	0.49	9.2e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04221910	chr5:616842	CEP72	0.41	7.29	0.37	2.19e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01947930	chr5:141016379	RELL2;HDAC3	-0.43	-6.61	-0.34	1.51e-10	Pancreatic cancer;
LIHC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.71	-8.35	-0.41	1.68e-15	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.77	13.41	0.59	3.06e-33	Aortic root size;
LIHC	cis	rs986417	1.000	rs9989167	chr14:60942374	T/C	cg27398547	chr14:60952738	C14orf39	0.81	9.39	0.45	8.69e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.49	-0.42	6.54e-16	Bipolar disorder and schizophrenia;
LIHC	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg07359730	chr1:67896138	SERBP1	0.5	6.4	0.33	5.07e-10	Morning vs. evening chronotype;
LIHC	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg06640241	chr16:89574553	SPG7	0.62	8.81	0.43	6.39e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.71	0.38	1.42e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.71	-10.74	-0.5	2.3e-23	Aortic root size;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.6	9.32	0.45	1.51e-18	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19487717	chr11:70263216	CTTN	0.49	6.93	0.35	2.17e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.38	6.05	0.31	3.72e-9	Diastolic blood pressure;
LIHC	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.52	8.14	0.4	7.57e-15	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.04	-0.4	1.53e-14	Chronic sinus infection;
LIHC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg14440974	chr22:39074834	NA	-0.4	-6.26	-0.32	1.18e-9	Menopause (age at onset);
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg13152130	chr6:118910203	C6orf204	-0.62	-6.99	-0.35	1.49e-11	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08219700	chr8:58056026	NA	0.52	7.14	0.36	5.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg15208524	chr1:10270712	KIF1B	-0.38	-5.88	-0.3	9.55e-9	Hepatocellular carcinoma;
LIHC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.48	11.13	0.52	9.45e-25	Iron status biomarkers (transferrin levels);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01261044	chr14:35451962	SRP54	0.44	6.27	0.32	1.09e-9	Pancreatic cancer;
LIHC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.67	13.22	0.58	1.57e-32	High light scatter reticulocyte count;
LIHC	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	0.68	8.7	0.43	1.41e-16	Corneal structure;
LIHC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg17135325	chr3:160939158	NMD3	0.56	8.07	0.4	1.22e-14	Morning vs. evening chronotype;
LIHC	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-7.79	-0.39	7.89e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.94	-0.31	7.11e-9	Menopause (age at onset);
LIHC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.29	-7.09	-0.36	7.62e-12	Longevity;Endometriosis;
LIHC	trans	rs8033655	1.000	rs8033655	chr15:50308950	A/G	cg10099229	chr12:6960622	USP5;CDCA3	0.42	6.09	0.31	3.1e-9	Skin pigmentation;
LIHC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg24209194	chr3:40518798	ZNF619	0.44	6.28	0.32	1.05e-9	Renal cell carcinoma;
LIHC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	11.48	0.53	5.17e-26	Electrocardiographic conduction measures;
LIHC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg20568497	chr10:133558893	NA	0.41	6.17	0.32	1.88e-9	Survival in rectal cancer;
LIHC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	cis	rs7503168	1.000	rs12604067	chr17:33952103	C/G	cg20932281	chr17:33905541	PEX12	0.54	7.01	0.35	1.25e-11	Plateletcrit;
LIHC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.38	6.15	0.32	2.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12516959	chr21:47718080	NA	0.36	5.85	0.3	1.17e-8	Testicular germ cell tumor;
LIHC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.0	-0.54	6.29e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg24675879	chr17:28444056	MIR423;CCDC55	-0.55	-6.31	-0.32	8.83e-10	Bronchial neuroendocrine tumor;
LIHC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg16926213	chr1:1841314	NA	0.32	5.88	0.3	9.98e-9	Body mass index;
LIHC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.34	6.54	0.33	2.22e-10	HDL cholesterol levels;
LIHC	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	7.88	0.39	4.51e-14	Height;
LIHC	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.82	0.3	1.33e-8	Body mass index;
LIHC	cis	rs17384381	0.636	rs11161615	chr1:85906816	A/G	cg16011679	chr1:85725395	C1orf52	-0.49	-6.28	-0.32	9.99e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.01	-0.44	1.48e-17	Bipolar disorder;
LIHC	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.62	-6.76	-0.34	6.02e-11	Putamen volume;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs744487	1.000	rs11581667	chr1:234726356	C/T	cg09691134	chr1:234734475	NA	0.4	6.5	0.33	2.83e-10	LDL cholesterol;
LIHC	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-8.1	-0.4	9.48e-15	Response to antipsychotic treatment;
LIHC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs729050	0.961	rs2148564	chr14:94073093	A/G	cg00587042	chr7:42927968	NA	-0.46	-6.06	-0.31	3.65e-9	Body mass index;
LIHC	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.75	-8.43	-0.41	1e-15	Exhaled nitric oxide output;
LIHC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.72	-9.56	-0.46	2.48e-19	Body mass index;
LIHC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.5	-7.28	-0.37	2.35e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.69e-10	Waist circumference;Weight;
LIHC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg12863693	chr15:85201151	NMB	0.47	6.84	0.35	3.59e-11	Schizophrenia;
LIHC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg16586182	chr3:47516702	SCAP	-0.58	-11.15	-0.52	7.83e-25	Colorectal cancer;
LIHC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.34	0.45	1.31e-18	Bipolar disorder;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg09455208	chr3:40491958	NA	-0.38	-7.74	-0.39	1.15e-13	Renal cell carcinoma;
LIHC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg16070018	chr6:26224392	HIST1H3E	0.55	6.54	0.33	2.28e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.38	-6.41	-0.33	4.94e-10	Tuberculosis;
LIHC	cis	rs13161895	0.646	rs77997852	chr5:179504925	T/C	cg06664874	chr5:179499304	RNF130	0.7	7.4	0.37	1.1e-12	LDL cholesterol;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14465769	chr3:197021243	DLG1	-0.29	-6.24	-0.32	1.32e-9	Calcium levels;
LIHC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.59	-6.83	-0.35	3.83e-11	Menarche (age at onset);
LIHC	cis	rs6459788	1.000	rs6459788	chr7:157260190	G/A	cg06271696	chr7:157225062	NA	-0.38	-6.73	-0.34	7.3e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.55	-10.42	-0.49	2.96e-22	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12062639	chr20:23401060	NAPB	0.85	10.27	0.49	9.25e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.5	7.24	0.36	2.96e-12	Asthma;
LIHC	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	6.51	0.33	2.74e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.5	-7.24	-0.36	2.93e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.77	0.54	4.4e-27	Motion sickness;
LIHC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.39	6.27	0.32	1.11e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg19773385	chr1:10388646	KIF1B	-0.48	-8.4	-0.41	1.18e-15	Hepatocellular carcinoma;
LIHC	cis	rs4742903	0.935	rs7872170	chr9:106957103	G/A	cg14250997	chr9:106856677	SMC2	0.36	6.07	0.31	3.36e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs9443189	0.950	rs6453845	chr6:76576527	G/T	cg01950844	chr6:76311363	SENP6	-0.52	-6.71	-0.34	8.18e-11	Prostate cancer;
LIHC	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg00204512	chr16:28754710	NA	0.34	6.3	0.32	9.02e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.97	-13.89	-0.6	4.16e-35	Breast cancer;
LIHC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.19	-0.4	5.24e-15	Longevity;
LIHC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg24060327	chr5:131705240	SLC22A5	-0.44	-5.73	-0.3	2.18e-8	Breast cancer;
LIHC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.57	-7.56	-0.38	3.78e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs1712517	0.844	rs1163081	chr10:105029840	G/C	cg05636881	chr10:105038444	INA	0.38	5.91	0.3	8.15e-9	Migraine;
LIHC	cis	rs4919087	0.748	rs793517	chr10:98987522	A/G	cg25902810	chr10:99078978	FRAT1	-0.53	-6.1	-0.31	2.92e-9	Monocyte count;
LIHC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.48	-18.11	-0.7	6.78e-52	Breast cancer;
LIHC	cis	rs2304069	0.826	rs184960	chr5:149343370	C/T	cg12661370	chr5:149340060	SLC26A2	-0.54	-7.35	-0.37	1.43e-12	HIV-1 control;
LIHC	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.93	-19.59	-0.73	8e-58	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.03	0.44	1.27e-17	Coffee consumption (cups per day);
LIHC	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.36	0.45	1.08e-18	Corneal astigmatism;
LIHC	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg17085576	chr10:5658249	NA	0.35	6.21	0.32	1.55e-9	Breast cancer;
LIHC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-9.3	-0.45	1.75e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.59	8.76	0.43	9.33e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs62179067	0.708	rs77046457	chr2:179940751	C/T	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.32	-5.85	-0.3	1.15e-8	IgG glycosylation;
LIHC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg24130564	chr14:104152367	KLC1	-0.54	-8.7	-0.43	1.44e-16	Reticulocyte count;
LIHC	cis	rs911119	0.955	rs7265178	chr20:23603382	C/G	cg16589663	chr20:23618590	CST3	0.75	7.88	0.39	4.28e-14	Chronic kidney disease;
LIHC	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.65	-6.85	-0.35	3.5e-11	Hair shape;
LIHC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.6	8.39	0.41	1.28e-15	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.97	7.09	0.36	7.81e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.54	-9.18	-0.44	4.27e-18	Myeloid white cell count;
LIHC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.58	9.47	0.46	4.75e-19	Resting heart rate;
LIHC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.65	0.34	1.13e-10	Educational attainment;
LIHC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.43	5.98	0.31	5.51e-9	Coronary artery disease;
LIHC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-11.17	-0.52	6.65e-25	Platelet count;
LIHC	cis	rs818427	0.964	rs495794	chr5:112201094	A/G	cg07820702	chr5:112228657	REEP5	0.36	5.79	0.3	1.62e-8	Total body bone mineral density;
LIHC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.59	-8.82	-0.43	5.83e-17	Platelet count;
LIHC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg14690197	chr8:22456421	C8orf58	-0.36	-5.76	-0.3	1.89e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.7	11.87	0.54	1.97e-27	Monocyte count;
LIHC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21016266	chr12:122356598	WDR66	0.39	5.86	0.3	1.11e-8	Mean corpuscular volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21850239	chr11:62528988	POLR2G	0.5	6.32	0.32	8.38e-10	Lung function (FEV1/FVC);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08935602	chr16:2509817	C16orf59	0.34	6.14	0.32	2.23e-9	Metabolic traits;
LIHC	trans	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg10756647	chr7:56101905	PSPH	-1.09	-13.61	-0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-7.0	-0.35	1.36e-11	Obesity-related traits;
LIHC	trans	rs10242455	0.571	rs45593341	chr7:99304911	C/A	cg09045935	chr12:6379348	NA	0.73	6.13	0.31	2.43e-9	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26614578	chr12:113623930	C12orf52;DDX54	0.53	7.73	0.39	1.19e-13	Pancreatic cancer;
LIHC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.12	17.17	0.68	4.25e-48	Corneal structure;
LIHC	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg03934865	chr2:198174659	NA	0.47	6.74	0.34	6.87e-11	Dermatomyositis;
LIHC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.42	0.41	1.01e-15	Platelet count;
LIHC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	12.22	0.55	9.59e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.51	-0.33	2.7e-10	Height;
LIHC	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.42	-6.81	-0.35	4.33e-11	Schizophrenia;
LIHC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	13.24	0.58	1.39e-32	Response to antipsychotic treatment;
LIHC	cis	rs6442522	0.640	rs28632773	chr3:15515918	C/G	cg16303742	chr3:15540471	COLQ	0.4	6.55	0.33	2.06e-10	Uric acid levels;
LIHC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg13753209	chr17:57696993	CLTC	-0.59	-8.95	-0.44	2.27e-17	Hemoglobin concentration;
LIHC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.38	7.63	0.38	2.34e-13	Renal cell carcinoma;
LIHC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.39	-0.33	5.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.65	10.74	0.5	2.24e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	5.74	0.3	2.11e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg21466736	chr12:48725269	NA	-0.63	-9.18	-0.44	4.2e-18	Glycated hemoglobin levels;
LIHC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.25	0.32	1.22e-9	Melanoma;
LIHC	cis	rs7395581	0.959	rs7129661	chr11:47268550	T/G	cg25783544	chr11:47291846	MADD	0.43	6.34	0.32	7.24e-10	HDL cholesterol;
LIHC	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.78	10.31	0.49	7.09e-22	Post bronchodilator FEV1;
LIHC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.51	-17.84	-0.69	8.44e-51	Breast cancer;
LIHC	trans	rs1864585	0.520	rs73200724	chr8:10592331	G/T	cg26278703	chr11:58910052	FAM111A	0.74	6.46	0.33	3.56e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.7	-0.34	8.48e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.36	-7.14	-0.36	5.68e-12	Schizophrenia;
LIHC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.58	9.68	0.46	9.8e-20	Colorectal cancer;
LIHC	cis	rs760762	0.636	rs6065332	chr20:39946922	C/G	cg06424997	chr20:39929561	ZHX3	0.36	5.93	0.31	7.22e-9	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LIHC	cis	rs1881396	0.531	rs72613829	chr2:27902987	C/T	cg27432699	chr2:27873401	GPN1	0.47	6.66	0.34	1.1e-10	Nonalcoholic fatty liver disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19514765	chr6:27805693	HIST1H2BN;HIST1H2AK	0.42	6.18	0.32	1.81e-9	Cognitive function;
LIHC	cis	rs55665837	0.701	rs11023265	chr11:14616038	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-6.16	-0.32	2.03e-9	Vitamin D levels;
LIHC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	1.02	19.57	0.73	9.42e-58	Breast cancer;
LIHC	cis	rs2273156	1.000	rs56686328	chr14:35458070	G/A	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.46	5.82	0.3	1.38e-8	Blood protein levels;
LIHC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-11.3	-0.52	2.34e-25	Coronary artery disease;
LIHC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.84	10.53	0.49	1.18e-22	Cognitive function;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	6.81	0.35	4.42e-11	Obesity-related traits;
LIHC	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.46	0.33	3.62e-10	Mammographic density (dense area);
LIHC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	5.99	0.31	5.4e-9	Coronary artery disease;
LIHC	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs10508774	1.000	rs11008970	chr10:32835635	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.06	0.31	3.66e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.52	-8.05	-0.4	1.39e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.52	8.46	0.42	7.74e-16	Schizophrenia;
LIHC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.35	8.98	0.44	1.81e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg02269571	chr22:50332266	NA	-0.66	-8.9	-0.43	3.32e-17	Schizophrenia;
LIHC	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg20991723	chr1:152506922	NA	-0.4	-6.35	-0.32	6.72e-10	Hair morphology;
LIHC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.55	7.93	0.39	3.2e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.54	-8.34	-0.41	1.9e-15	High light scatter reticulocyte count;
LIHC	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg20991723	chr1:152506922	NA	-0.52	-8.83	-0.43	5.63e-17	Hair morphology;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg14709524	chr16:89940631	TCF25	0.5	6.53	0.33	2.36e-10	Skin colour saturation;
LIHC	cis	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg02972257	chr16:68554789	NA	0.6	6.2	0.32	1.62e-9	Ulcerative colitis;
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg15664640	chr17:80829946	TBCD	-0.37	-5.9	-0.3	8.91e-9	Glycated hemoglobin levels;
LIHC	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.83	-0.3	1.29e-8	Coronary artery disease;
LIHC	cis	rs78062588	1.000	rs61300392	chr1:154575685	A/T	cg24304309	chr1:154577895	ADAR	-0.51	-5.87	-0.3	1.01e-8	Lung cancer;
LIHC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.7	-12.3	-0.55	4.96e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2292030	1	rs2292030	chr5:132161294	G/A	cg02081065	chr5:132209139	LEAP2	0.28	5.77	0.3	1.81e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.04	-0.44	1.15e-17	Type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.7	8.53	0.42	4.82e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.55	0.33	2.12e-10	Renal cell carcinoma;
LIHC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.78e-13	Bone mineral density;
LIHC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.82	-9.66	-0.46	1.13e-19	Vitiligo;
LIHC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg06289844	chr6:126071538	HEY2	-0.35	-6.14	-0.31	2.35e-9	Brugada syndrome;
LIHC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.84	15.6	0.64	8.46e-42	Multiple myeloma (IgH translocation);
LIHC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-6.32	-0.32	8.18e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.54	-7.6	-0.38	2.79e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.46	6.95	0.35	1.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.54	8.06	0.4	1.34e-14	HIV-1 control;
LIHC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21607453	chr9:98783545	NCRNA00092	0.39	6.47	0.33	3.3e-10	Pancreatic cancer;
LIHC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.49	0.46	4.14e-19	Electroencephalogram traits;
LIHC	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.34	-5.97	-0.31	5.9e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg14515779	chr1:101123966	NA	-0.49	-7.03	-0.36	1.16e-11	Monocyte count;
LIHC	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.27	-0.41	3.06e-15	Response to antipsychotic treatment;
LIHC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Body mass index;
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.05	-0.31	3.76e-9	Longevity;
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg00656387	chr3:40428638	ENTPD3	0.5	8.52	0.42	5.28e-16	Renal cell carcinoma;
LIHC	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.47	-6.58	-0.34	1.8e-10	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.72	-11.29	-0.52	2.43e-25	Obesity-related traits;
LIHC	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.4	-0.41	1.22e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg00129232	chr17:37814104	STARD3	-0.35	-5.74	-0.3	2.07e-8	Self-reported allergy;
LIHC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.54	-11.11	-0.51	1.1e-24	Lung cancer;
LIHC	trans	rs1814175	0.615	rs7113020	chr11:49746540	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.06	0.36	9.47e-12	Height;
LIHC	cis	rs922107	1.000	rs922107	chr1:90022796	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.82	-0.39	6.62e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.25	6.74	0.34	6.88e-11	Type 2 diabetes;
LIHC	cis	rs7535752	0.519	rs11583012	chr1:8440132	G/A	cg20416874	chr1:8611966	RERE	0.5	5.93	0.31	7.5e-9	Breast cancer;
LIHC	trans	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.49	6.11	0.31	2.65e-9	Ulcerative colitis;
LIHC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.66	-9.5	-0.46	3.88e-19	Blood metabolite levels;
LIHC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.5	6.04	0.31	4.02e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.59	10.3	0.49	7.75e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.01	0.31	4.81e-9	Blood metabolite levels;
LIHC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.4	6.41	0.33	4.8e-10	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15130565	chr3:61546275	PTPRG	0.41	6.15	0.32	2.21e-9	Pancreatic cancer;
LIHC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.77	11.95	0.54	9.51e-28	Corneal astigmatism;
LIHC	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg24296786	chr1:45957014	TESK2	0.5	7.47	0.37	6.63e-13	Platelet count;
LIHC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg13114125	chr14:105738426	BRF1	-0.76	-10.14	-0.48	2.69e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.5	9.46	0.46	5.31e-19	Hemoglobin concentration;
LIHC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg09238746	chr17:78121135	EIF4A3	-0.54	-8.2	-0.41	5.07e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LIHC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg01629716	chr15:45996671	NA	0.52	9.56	0.46	2.42e-19	Waist circumference;Weight;
LIHC	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.46	9.02	0.44	1.4e-17	Testicular germ cell tumor;
LIHC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.71	-12.54	-0.56	5.96e-30	Refractive error;
LIHC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.73	0.39	1.23e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.48	-6.64	-0.34	1.24e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg07234388	chr1:156261841	TMEM79	0.51	9.26	0.45	2.32e-18	Tonsillectomy;
LIHC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.61	-8.41	-0.41	1.15e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg01364799	chr7:75623366	TMEM120A	-0.41	-6.19	-0.32	1.7e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.73	14.82	0.63	9.9e-39	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.31	0.49	7.06e-22	Vitiligo;
LIHC	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg20578329	chr17:80767326	TBCD	-0.64	-6.52	-0.33	2.54e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.86	0.8	1.15e-78	Prudent dietary pattern;
LIHC	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.68	10.72	0.5	2.61e-23	Colorectal adenoma (advanced);
LIHC	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.63	0.34	1.34e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03888365	chr8:123792680	ZHX2	0.44	6.26	0.32	1.15e-9	Pancreatic cancer;
LIHC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg24203234	chr3:128598194	ACAD9	0.44	6.19	0.32	1.77e-9	IgG glycosylation;
LIHC	cis	rs903552	0.800	rs1587107	chr15:102006485	T/C	cg25677261	chr15:102009856	PCSK6	-0.5	-6.65	-0.34	1.14e-10	Diabetic kidney disease;
LIHC	trans	rs1912702	0.592	rs4644672	chr11:79174777	A/G	cg18020480	chr1:174186816	RABGAP1L	0.45	6.21	0.32	1.5e-9	Hair greying;
LIHC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.44	0.37	8.16e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.47	0.49	1.98e-22	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.8	-7.45	-0.37	7.84e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.85	-9.57	-0.46	2.24e-19	Ulcerative colitis;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg16358155	chr3:195490169	MUC4	0.42	6.34	0.32	7.24e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.62	-9.15	-0.44	5.43e-18	Blood metabolite levels;
LIHC	cis	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg01231543	chr16:68741748	NA	0.38	6.17	0.32	1.97e-9	Colorectal cancer;
LIHC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.38	5.77	0.3	1.77e-8	Mean corpuscular volume;
LIHC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.43	-6.34	-0.32	7.35e-10	Blood trace element (Zn levels);
LIHC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.39	6.45	0.33	3.74e-10	Red blood cell count;
LIHC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.7	10.06	0.48	4.86e-21	Menarche (age at onset);
LIHC	cis	rs611744	0.781	rs75534351	chr8:109118714	A/T	cg21045802	chr8:109455806	TTC35	0.5	8.44	0.42	9.1e-16	Dupuytren's disease;
LIHC	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg01145232	chr6:150245071	RAET1G	-0.42	-7.94	-0.39	2.93e-14	Lung cancer;
LIHC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-8.08	-0.4	1.14e-14	Blood metabolite levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02464098	chr8:26240309	BNIP3L	-0.53	-6.52	-0.33	2.56e-10	Systolic blood pressure;
LIHC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.57e-21	Bladder cancer;
LIHC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.47	6.58	0.34	1.8e-10	Schizophrenia;
LIHC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg18944383	chr4:111397179	ENPEP	0.24	6.28	0.32	1.02e-9	Height;
LIHC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg08896387	chr1:24191740	FUCA1	0.37	6.02	0.31	4.39e-9	Immature fraction of reticulocytes;
LIHC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.99	-0.4	2.02e-14	Type 2 diabetes;
LIHC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.49	8.38	0.41	1.37e-15	Response to temozolomide;
LIHC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.59	8.88	0.43	3.75e-17	Gout;
LIHC	cis	rs943466	1.000	rs61662306	chr6:33746697	G/A	cg25922239	chr6:33757077	LEMD2	-0.47	-5.77	-0.3	1.75e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.44	-8.65	-0.42	1.97e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg19636519	chr7:99541626	NA	0.3	5.74	0.3	2.07e-8	Coronary artery disease;
LIHC	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.31	-8.01	-0.4	1.85e-14	Intelligence;
LIHC	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg02251663	chr11:14281053	SPON1	-0.43	-5.71	-0.3	2.45e-8	Mitochondrial DNA levels;
LIHC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg12751644	chr20:60527061	NA	-0.35	-5.87	-0.3	1.03e-8	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12958836	chr12:8185024	FOXJ2	0.46	6.91	0.35	2.32e-11	Lung function (FEV1/FVC);
LIHC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	13.98	0.6	1.85e-35	Multiple sclerosis;
LIHC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.79	0.3	1.59e-8	Schizophrenia;
LIHC	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.59	-0.34	1.66e-10	Neuroticism;
LIHC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.79	-15.91	-0.65	4.7e-43	Refractive error;
LIHC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg00204748	chr12:29376779	FAR2	0.44	8.15	0.4	6.89e-15	QT interval;
LIHC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	1.08	14.71	0.62	2.81e-38	Heart rate;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20332866	chr1:100678932	DBT	0.39	6.75	0.34	6.34e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.28	0.32	1.03e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.4	-6.76	-0.34	5.92e-11	Aortic root size;
LIHC	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.42	6.53	0.33	2.42e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg14473756	chr11:122847823	NA	-0.32	-5.75	-0.3	1.98e-8	Menarche (age at onset);
LIHC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	0.93	6.59	0.34	1.7e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.49	8.01	0.4	1.87e-14	Longevity;Endometriosis;
LIHC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	1.01	18.6	0.71	7.45e-54	Breast cancer;
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.46	-7.85	-0.39	5.35e-14	Menopause (age at onset);
LIHC	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-0.84	-12.87	-0.57	3.59e-31	Obesity-related traits;
LIHC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.29	6.8	0.35	4.61e-11	Primary biliary cholangitis;
LIHC	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg16275483	chr1:110013120	SYPL2	-0.51	-6.33	-0.32	7.5e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26476595	chr16:2284284	E4F1	0.48	6.7	0.34	8.8e-11	Hepatitis;
LIHC	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg18357645	chr12:58087776	OS9	-0.42	-6.12	-0.31	2.62e-9	Multiple sclerosis;
LIHC	cis	rs911119	0.955	rs8121283	chr20:23605002	G/C	cg16589663	chr20:23618590	CST3	0.76	8.04	0.4	1.44e-14	Chronic kidney disease;
LIHC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.41	6.28	0.32	1.02e-9	Platelet count;
LIHC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.58	-0.34	1.76e-10	Gut microbiome composition (summer);
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.99	-0.35	1.42e-11	Total body bone mineral density;
LIHC	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.92	11.74	0.54	5.69e-27	Coronary artery disease;
LIHC	cis	rs2176862	1.000	rs116786372	chr3:46610126	C/G	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.34	-0.32	7.42e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg02869306	chr7:64672164	INTS4L1	0.28	5.71	0.3	2.42e-8	Aortic root size;
LIHC	cis	rs4919087	0.715	rs1253387	chr10:99032968	G/A	cg25902810	chr10:99078978	FRAT1	-0.6	-6.85	-0.35	3.38e-11	Monocyte count;
LIHC	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.58	6.37	0.33	6.07e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.38	6.07	0.31	3.49e-9	Lung cancer;
LIHC	cis	rs8010715	0.816	rs6573573	chr14:24599257	T/C	cg23112188	chr14:24563095	PCK2	-0.29	-6.13	-0.31	2.38e-9	IgG glycosylation;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg04610667	chr7:75704037	NA	-0.35	-6.35	-0.32	6.75e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.98	0.57	1.39e-31	Platelet count;
LIHC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-7.4	-0.37	1.03e-12	Platelet distribution width;
LIHC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg18769074	chr3:133464867	TF	0.27	6.09	0.31	3.02e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.5	-6.35	-0.32	6.85e-10	Schizophrenia;
LIHC	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.59	-6.59	-0.34	1.63e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.49	6.36	0.33	6.37e-10	Large artery stroke;
LIHC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.84	-14.71	-0.62	2.69e-38	Aortic root size;
LIHC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg16127683	chr15:40268777	EIF2AK4	-0.6	-8.08	-0.4	1.13e-14	Response to haloperidol in psychosis;
LIHC	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.32	5.79	0.3	1.57e-8	Parkinson's disease;
LIHC	cis	rs3780378	0.875	rs7032785	chr9:5042046	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-9.87	-0.47	2.18e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg10755058	chr3:40428713	ENTPD3	0.41	7.13	0.36	6.01e-12	Renal cell carcinoma;
LIHC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.62	9.34	0.45	1.31e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg15534755	chr11:117069859	TAGLN	0.4	6.75	0.34	6.42e-11	Blood protein levels;
LIHC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	6.41	0.33	4.92e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	1.02	19.59	0.73	8.04e-58	Breast cancer;
LIHC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-1.03	-13.51	-0.59	1.28e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg14709524	chr16:89940631	TCF25	0.47	5.72	0.3	2.28e-8	Skin colour saturation;
LIHC	cis	rs797680	0.820	rs10874773	chr1:93798496	T/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.33	-5.75	-0.3	1.94e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg15208524	chr1:10270712	KIF1B	0.41	6.04	0.31	4.04e-9	Hepatocellular carcinoma;
LIHC	cis	rs7487075	0.619	rs9971879	chr12:46806773	T/C	cg23829395	chr12:46796953	NA	0.35	6.26	0.32	1.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.67	7.29	0.37	2.24e-12	Exhaled nitric oxide output;
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.87	-0.35	3.07e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs10916814	1.000	rs12145351	chr1:20901181	C/A	cg24502330	chr1:20914028	CDA	-0.28	-5.87	-0.3	1.05e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs6073597	0.967	rs6031972	chr20:43704943	T/C	cg14213297	chr9:130870109	SLC25A25	-0.35	-6.05	-0.31	3.73e-9	Positive affect;
LIHC	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-11.18	-0.52	6.02e-25	Colorectal cancer;
LIHC	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.35	23.15	0.78	5.47e-72	Corneal structure;
LIHC	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.53	-0.38	4.7e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs61677309	1.000	rs55806415	chr11:118162862	G/A	cg06090739	chr11:118230722	UBE4A	0.34	6.38	0.33	5.86e-10	Lung cancer in ever smokers;
LIHC	cis	rs1211375	0.606	rs1203977	chr16:256278	A/C	cg00126636	chr16:237282	NA	0.37	6.39	0.33	5.35e-10	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.84	0.47	2.78e-20	Lymphocyte counts;
LIHC	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg23587288	chr2:27483067	SLC30A3	-0.31	-5.8	-0.3	1.51e-8	Blood metabolite levels;
LIHC	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.86	-10.58	-0.5	7.87e-23	Prostate cancer;
LIHC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-7.14	-0.36	5.64e-12	Diabetic kidney disease;
LIHC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	8.06	0.4	1.28e-14	Coronary artery disease;
LIHC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg02248941	chr16:2239361	CASKIN1	0.35	6.74	0.34	6.95e-11	Height;
LIHC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.91	10.27	0.49	9.28e-22	Eosinophil percentage of granulocytes;
LIHC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.42	-6.13	-0.31	2.41e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.45	7.93	0.39	3.07e-14	Neurofibrillary tangles;
LIHC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.45	-7.5	-0.38	5.38e-13	Aortic root size;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.8	14.21	0.61	2.52e-36	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg09990169	chr2:241835740	C2orf54	-0.64	-10.18	-0.48	1.88e-21	Urinary metabolites;
LIHC	cis	rs611744	0.870	rs638905	chr8:109203406	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg18944383	chr4:111397179	ENPEP	-0.25	-6.04	-0.31	4.02e-9	Coronary artery disease;
LIHC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.36	6.07	0.31	3.37e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg03037974	chr15:76606532	NA	0.76	14.87	0.63	6.3e-39	Blood metabolite levels;
LIHC	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.54	9.46	0.46	5.32e-19	Breast cancer;
LIHC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21467203	chr3:49911342	NA	0.43	7.65	0.38	2.09e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg21467203	chr3:49911342	NA	-0.45	-5.96	-0.31	6.37e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.26	-0.32	1.15e-9	Ulcerative colitis;
LIHC	cis	rs3853824	0.965	rs1052227	chr17:54906137	C/T	cg13675837	chr17:54910204	DGKE	-0.41	-5.9	-0.3	8.98e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg04306507	chr14:55594613	LGALS3	0.32	5.96	0.31	6.19e-9	Protein biomarker;
LIHC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.43	-7.31	-0.37	1.95e-12	IgG glycosylation;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.48	-6.79	-0.34	5.04e-11	Lymphocyte counts;
LIHC	cis	rs288342	0.797	rs288310	chr2:183650229	G/A	cg02625481	chr2:183667124	NA	-0.29	-6.02	-0.31	4.55e-9	Recurrent major depressive disorder;
LIHC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.69	-8.57	-0.42	3.65e-16	Gut microbiome composition (summer);
LIHC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	15.76	0.65	1.93e-42	Tonsillectomy;
LIHC	cis	rs57502260	0.915	rs75202638	chr11:68210421	C/T	cg16797656	chr11:68205561	LRP5	0.62	8.35	0.41	1.75e-15	Total body bone mineral density (age 45-60);
LIHC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.4	-6.22	-0.32	1.43e-9	Morning vs. evening chronotype;
LIHC	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.3	-0.37	2.03e-12	Bipolar disorder;
LIHC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.61	7.29	0.37	2.11e-12	Cognitive function;
LIHC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	13.46	0.59	1.93e-33	Menopause (age at onset);
LIHC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.72	-0.43	1.24e-16	Obesity-related traits;
LIHC	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.79	8.97	0.44	1.94e-17	Exhaled nitric oxide levels;
LIHC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.49	8.0	0.4	1.96e-14	Total body bone mineral density;
LIHC	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg17385448	chr1:15911702	AGMAT	0.36	5.97	0.31	5.91e-9	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.7	8.51	0.42	5.36e-16	IgG glycosylation;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07021052	chr2:20871279	NA	0.37	7.09	0.36	7.67e-12	Abdominal aortic aneurysm;
LIHC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.6	8.59	0.42	3.17e-16	Obesity-related traits;
LIHC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.08	-0.31	3.14e-9	Obesity-related traits;
LIHC	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.51	8.35	0.41	1.67e-15	Diastolic blood pressure;
LIHC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg21573476	chr21:45109991	RRP1B	-0.52	-9.74	-0.47	6.01e-20	Mean corpuscular volume;
LIHC	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.69	10.76	0.5	1.93e-23	Diisocyanate-induced asthma;
LIHC	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg03689076	chr20:33865952	NA	0.55	6.17	0.32	1.92e-9	Attention deficit hyperactivity disorder;
LIHC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.88	-18.26	-0.7	1.79e-52	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21792150	chr3:101567884	NFKBIZ	-0.51	-6.4	-0.33	5.2400000000000005e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.16	0.36	4.86e-12	Vitiligo;
LIHC	cis	rs9918079	0.560	rs7685083	chr4:15610771	G/A	cg04067612	chr4:15429572	C1QTNF7	0.28	5.88	0.3	1e-8	Obesity-related traits;
LIHC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.91	0.47	1.6e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.63	-16.72	-0.67	2.82e-46	Breast cancer;
LIHC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg00149659	chr3:10157352	C3orf10	0.65	6.37	0.33	6.04e-10	Alzheimer's disease;
LIHC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	10.19	0.48	1.76e-21	Personality dimensions;
LIHC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg19635926	chr16:89946313	TCF25	0.49	6.24	0.32	1.28e-9	Skin colour saturation;
LIHC	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.48	-7.1	-0.36	7.34e-12	Mortality in heart failure;
LIHC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.91	11.46	0.53	6.1e-26	Schizophrenia;
LIHC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.39	-6.85	-0.35	3.53e-11	Aortic root size;
LIHC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	6.52	0.33	2.55e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.85	15.31	0.64	1.2e-40	Aortic root size;
LIHC	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg19773385	chr1:10388646	KIF1B	-0.48	-8.38	-0.41	1.35e-15	Hepatocellular carcinoma;
LIHC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg09003973	chr2:102972529	NA	0.54	6.06	0.31	3.63e-9	Blood protein levels;
LIHC	cis	rs400736	0.740	rs225118	chr1:8108754	G/A	cg25007680	chr1:8021821	PARK7	0.53	8.1	0.4	9.58e-15	Response to antidepressants and depression;
LIHC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-6.94	-0.35	1.99e-11	Chronic sinus infection;
LIHC	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.85	9.65	0.46	1.2e-19	Facial emotion recognition (sad faces);
LIHC	trans	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg17675199	chr6:35436792	RPL10A	-0.41	-8.35	-0.41	1.7e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg02023728	chr11:77925099	USP35	0.34	6.11	0.31	2.67e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.34	-0.32	7.13e-10	Height;
LIHC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg17724175	chr1:150552817	MCL1	0.47	9.05	0.44	1.11e-17	Melanoma;
LIHC	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.64	12.12	0.55	2.19e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.44	8.05	0.4	1.36e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs16912285	0.748	rs7104694	chr11:24280281	A/C	ch.11.24196551F	chr11:24239977	NA	0.77	10.62	0.5	5.73e-23	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.72	0.3	2.38e-8	Vitiligo;
LIHC	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg24069376	chr3:38537580	EXOG	0.43	7.73	0.39	1.24e-13	Electrocardiographic conduction measures;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.76	-0.34	6.07e-11	Total body bone mineral density;
LIHC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11671005	0.611	rs56026876	chr19:59006157	G/C	cg25952890	chr19:58913133	NA	0.68	6.95	0.35	1.86e-11	Mean platelet volume;
LIHC	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg26138937	chr11:71823887	C11orf51	-0.78	-7.92	-0.39	3.26e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00152838	chr16:24741724	TNRC6A	-0.49	-6.56	-0.33	2.01e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.89	-0.35	2.65e-11	IgG glycosylation;
LIHC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16574807	chr4:6945745	TBC1D14	-0.4	-6.57	-0.33	1.83e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.75	-13.84	-0.6	6.67e-35	Height;
LIHC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg12365402	chr11:9010492	NRIP3	-0.26	-6.72	-0.34	7.65e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.37	6.93	0.35	2.07e-11	IgG glycosylation;
LIHC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	8.71	0.43	1.35e-16	Eotaxin levels;
LIHC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.92	12.98	0.57	1.38e-31	Primary sclerosing cholangitis;
LIHC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08504806	chr7:2027239	MAD1L1	0.42	6.23	0.32	1.36e-9	Pancreatic cancer;
LIHC	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.39	5.97	0.31	6.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg20991723	chr1:152506922	NA	0.55	9.52	0.46	3.34e-19	Hair morphology;
LIHC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.37	5.73	0.3	2.19e-8	Prostate cancer;
LIHC	cis	rs244293	0.701	rs4793783	chr17:53025480	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.03	-0.31	4.32e-9	Menarche (age at onset);
LIHC	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.49	-7.43	-0.37	9.04e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.17	0.36	4.8e-12	Vitiligo;
LIHC	cis	rs12602486	1.000	rs74635090	chr17:42219267	G/A	cg13607699	chr17:42295918	UBTF	-0.72	-6.27	-0.32	1.12e-9	Glycated hemoglobin levels;
LIHC	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.38	7.03	0.36	1.13e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg07061783	chr6:25882402	NA	-0.43	-6.03	-0.31	4.14e-9	Blood metabolite levels;
LIHC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.42	6.27	0.32	1.1e-9	Height;
LIHC	cis	rs2297441	0.550	rs6011097	chr20:62398825	G/A	cg14758556	chr20:62440591	NA	-0.45	-7.22	-0.36	3.39e-12	Ulcerative colitis;
LIHC	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.49	0.53	4.74e-26	Personality dimensions;
LIHC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.32	-0.37	1.77e-12	Height;
LIHC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.86	0.35	3.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9513627	0.920	rs7334943	chr13:100121287	C/G	cg25919922	chr13:100150906	NA	0.73	6.56	0.33	1.97e-10	Obesity-related traits;
LIHC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.36	-6.49	-0.33	3.04e-10	Aortic root size;
LIHC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.79	0.54	3.62e-27	Response to antipsychotic treatment;
LIHC	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs332507	0.830	rs1846891	chr3:124399397	A/G	cg05980111	chr3:124395277	KALRN	0.45	7.05	0.36	9.91e-12	Plateletcrit;
LIHC	cis	rs11671005	0.569	rs73068335	chr19:59089308	C/G	cg25952890	chr19:58913133	NA	0.66	6.75	0.34	6.52e-11	Mean platelet volume;
LIHC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.72	10.66	0.5	4.1000000000000003e-23	Corneal astigmatism;
LIHC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.16	0.48	2.37e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg02795151	chr17:7402630	POLR2A	0.55	5.8	0.3	1.52e-8	Androgen levels;
LIHC	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.46	8.28	0.41	2.75e-15	Platelet distribution width;
LIHC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg20302533	chr7:39170763	POU6F2	0.38	6.98	0.35	1.52e-11	IgG glycosylation;
LIHC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.87	10.79	0.5	1.46e-23	Bladder cancer;
LIHC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.05	0.55	4.26e-28	Body mass index;
LIHC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.42e-30	Alzheimer's disease;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.64	-0.42	2.21e-16	Lymphocyte counts;
LIHC	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.24e-12	Post bronchodilator FEV1;
LIHC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.58	9.58	0.46	2.08e-19	Post bronchodilator FEV1;
LIHC	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-10.74	-0.5	2.19e-23	Colorectal cancer;
LIHC	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.36	-6.17	-0.32	1.9e-9	High light scatter reticulocyte count;
LIHC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.63	8.78	0.43	7.88e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05665937	chr4:1216051	CTBP1	-0.45	-5.98	-0.31	5.57e-9	Obesity-related traits;
LIHC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.38	5.87	0.3	1.05e-8	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.45	8.12	0.4	8.63e-15	Prudent dietary pattern;
LIHC	trans	rs4753788	0.511	rs12224337	chr11:107140077	G/A	cg09581611	chr16:67978158	SLC12A4;LCAT	0.3	6.06	0.31	3.63e-9	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26309655	chr1:150459725	TARS2	0.44	6.18	0.32	1.83e-9	Lung function (FEV1/FVC);
LIHC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.15	0.36	5.31e-12	Self-reported allergy;
LIHC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.4	-6.02	-0.31	4.54e-9	Total body bone mineral density;
LIHC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg03476357	chr21:30257390	N6AMT1	0.55	8.01	0.4	1.84e-14	Cognitive test performance;
LIHC	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.87	-14.54	-0.62	1.25e-37	Schizophrenia;
LIHC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Life satisfaction;
LIHC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.85	-0.3	1.17e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg03037974	chr15:76606532	NA	0.67	12.5	0.56	8.94e-30	Blood metabolite levels;
LIHC	cis	rs611744	0.967	rs678387	chr8:109242730	G/C	cg21045802	chr8:109455806	TTC35	0.5	8.65	0.42	2.05e-16	Dupuytren's disease;
LIHC	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.58	9.57	0.46	2.23e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.45	6.98	0.35	1.5e-11	Height;
LIHC	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.47	7.23	0.36	3.23e-12	Alzheimer's disease (survival time);
LIHC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.1	11.28	0.52	2.73e-25	Opioid sensitivity;
LIHC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.47	6.34	0.32	7.42e-10	Morning vs. evening chronotype;
LIHC	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg01843034	chr6:37503916	NA	-0.48	-8.26	-0.41	3.26e-15	Cognitive performance;
LIHC	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.5	-0.38	5.47e-13	Parkinson's disease;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.45	8.31	0.41	2.33e-15	Prudent dietary pattern;
LIHC	cis	rs11239930	1.000	rs11239930	chr1:146560564	C/T	cg25205988	chr1:146714368	CHD1L	-0.37	-5.83	-0.3	1.32e-8	AIDS progression;
LIHC	cis	rs16912285	0.748	rs7952223	chr11:24256443	G/C	ch.11.24196551F	chr11:24239977	NA	0.7	8.65	0.42	2.06e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg08424446	chr12:133381374	GOLGA3	0.43	6.43	0.33	4.4e-10	Electroencephalogram traits;
LIHC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.83	0.39	6.06e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.46	6.55	0.33	2.17e-10	Schizophrenia;
LIHC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.81	-0.3	1.41e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.12	0.58	4.01e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg12560992	chr17:57184187	TRIM37	0.73	9.14	0.44	5.78e-18	Vitamin D levels;
LIHC	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	12.4	0.56	2.13e-29	Coffee consumption (cups per day);
LIHC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.31	0.49	6.73e-22	Melanoma;
LIHC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.77	-0.5	1.68e-23	Platelet count;
LIHC	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.23	-6.3	-0.32	9.34e-10	Type 2 diabetes;
LIHC	cis	rs2531992	0.686	rs933392	chr16:4032716	T/G	cg05927578	chr16:4029543	ADCY9	0.52	7.12	0.36	6.38e-12	Waist circumference;
LIHC	trans	rs801193	0.660	rs974239	chr7:66213491	G/A	cg10756647	chr7:56101905	PSPH	0.47	6.95	0.35	1.88e-11	Aortic root size;
LIHC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg17724175	chr1:150552817	MCL1	-0.38	-7.85	-0.39	5.49e-14	Tonsillectomy;
LIHC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.43	5.95	0.31	6.76e-9	Life satisfaction;
LIHC	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-8.58	-0.42	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.69	-11.73	-0.54	5.95e-27	Crohn's disease;
LIHC	cis	rs11822910	0.906	rs11822095	chr11:57194155	G/A	cg00522883	chr11:57194120	SLC43A3	0.7	8.35	0.41	1.67e-15	Platelet distribution width;
LIHC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.21	-0.32	1.5e-9	Total body bone mineral density;
LIHC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-8.97	-0.44	2.04e-17	Bipolar disorder;
LIHC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg27170947	chr2:26402098	FAM59B	-0.72	-8.67	-0.42	1.7e-16	Gut microbiome composition (summer);
LIHC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	13.24	0.58	1.41e-32	Birth weight;
LIHC	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg20607798	chr8:58055168	NA	0.49	6.13	0.31	2.37e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1494950	1.000	rs10212717	chr4:14990560	T/C	cg12377275	chr4:15005593	CPEB2	-0.79	-6.68	-0.34	9.49e-11	Political ideology;
LIHC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.67	-8.3	-0.41	2.49e-15	Gut microbiome composition (summer);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13898564	chr9:78504994	PCSK5	-0.48	-6.16	-0.32	2.09e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2257205	0.588	rs7214266	chr17:56851920	C/T	cg12560992	chr17:57184187	TRIM37	0.68	7.44	0.37	8.24e-13	Pancreatic cancer;
LIHC	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.41	-5.94	-0.31	7.17e-9	Red blood cell traits;
LIHC	cis	rs9896052	0.580	rs7406977	chr17:73460417	T/G	cg25649188	chr17:73499917	CASKIN2	0.44	6.85	0.35	3.37e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.46	6.0	0.31	5.04e-9	Major depressive disorder;
LIHC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.12	-16.58	-0.67	9.59e-46	Sexual dysfunction (female);
LIHC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.97	20.41	0.74	3.92e-61	Blood protein levels;
LIHC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.28	7.01	0.35	1.28e-11	Schizophrenia;
LIHC	cis	rs3790844	0.678	rs3790854	chr1:200000125	C/T	cg07208853	chr1:200005219	NR5A2	-0.38	-8.56	-0.42	3.75e-16	Pancreatic cancer;
LIHC	cis	rs1030268	0.651	rs13222377	chr7:133466346	C/T	cg03336402	chr7:133662267	EXOC4	-0.51	-6.2	-0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2997447	0.706	rs12062488	chr1:26466253	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.86	-0.3	1.06e-8	QRS complex (12-leadsum);
LIHC	cis	rs4908768	0.911	rs953535	chr1:8776719	A/C	cg20416874	chr1:8611966	RERE	0.52	7.84	0.39	5.6e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs965469	1.000	rs6133036	chr20:3349682	A/G	cg25506879	chr20:3388711	C20orf194	-0.54	-6.52	-0.33	2.58e-10	IFN-related cytopenia;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg05481257	chr2:20870211	GDF7	0.4	8.14	0.4	7.53e-15	Abdominal aortic aneurysm;
LIHC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.92	0.3	7.8e-9	Self-reported allergy;
LIHC	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-0.86	-10.47	-0.49	2.03e-22	Blood pressure (smoking interaction);
LIHC	cis	rs1322512	1.000	rs2758812	chr6:152965908	C/T	cg03415253	chr6:152958462	SYNE1	-0.33	-6.22	-0.32	1.47e-9	Tonometry;
LIHC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.14	0.4	7.21e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg02447239	chr2:235936137	SH3BP4	-0.36	-6.28	-0.32	1.01e-9	Dialysis-related mortality;
LIHC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.58	8.03	0.4	1.62e-14	Height;
LIHC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.33	5.97	0.31	5.9e-9	Aortic root size;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08219700	chr8:58056026	NA	0.52	7.15	0.36	5.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.72	-10.75	-0.5	2.11e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.69	0.43	1.55e-16	Schizophrenia;
LIHC	cis	rs10792665	0.512	rs7106981	chr11:82600876	C/T	cg24227371	chr11:82718527	RAB30	-0.28	-6.56	-0.33	1.97e-10	Obesity-related traits;
LIHC	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-6.08	-0.31	3.26e-9	Systolic blood pressure;
LIHC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	14.24	0.61	1.92e-36	Coffee consumption (cups per day);
LIHC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.37	5.86	0.3	1.07e-8	Menopause (age at onset);
LIHC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.24	6.09	0.31	3.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9918079	0.560	rs7662032	chr4:15635414	C/G	cg21329975	chr4:15471214	CC2D2A	-0.41	-6.19	-0.32	1.73e-9	Obesity-related traits;
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.85	12.58	0.56	4.47e-30	Menarche (age at onset);
LIHC	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs67981189	0.593	rs2526847	chr14:71422274	G/A	cg15816911	chr14:71606274	NA	-0.4	-6.48	-0.33	3.12e-10	Schizophrenia;
LIHC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-10.48	-0.49	1.84e-22	Schizophrenia;
LIHC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.23	-6.14	-0.31	2.34e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg14515779	chr1:101123966	NA	-0.46	-6.54	-0.33	2.19e-10	Monocyte count;
LIHC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.43	0.53	7.94e-26	Coronary artery disease;
LIHC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.38	6.15	0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	0.98	10.67	0.5	4.01e-23	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg17279839	chr7:150038598	RARRES2	0.48	10.02	0.48	6.83e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg05110241	chr16:68378359	PRMT7	-0.56	-6.12	-0.31	2.62e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.07e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.54	-9.98	-0.47	9.3e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	11.09	0.51	1.3e-24	Lung cancer in ever smokers;
LIHC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.66	-7.38	-0.37	1.23e-12	Neutrophil percentage of white cells;
LIHC	cis	rs17286411	0.750	rs4788561	chr16:71878255	G/A	cg06353428	chr16:71660113	MARVELD3	0.55	6.92	0.35	2.18e-11	Blood protein levels;
LIHC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.47	6.89	0.35	2.67e-11	Aortic root size;
LIHC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.58	-9.38	-0.45	9.16e-19	Diastolic blood pressure;
LIHC	cis	rs1144333	0.850	rs1251273	chr1:76288617	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.66	-0.34	1.13e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg03934865	chr2:198174659	NA	-0.57	-8.99	-0.44	1.71e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.43	5.75	0.3	1.99e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg14580859	chr9:123691850	NA	0.38	6.66	0.34	1.12e-10	Rheumatoid arthritis;
LIHC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.56	-11.51	-0.53	3.86e-26	Urate levels;
LIHC	cis	rs72653721	0.838	rs911196	chr6:10990751	T/G	cg13562911	chr6:11044106	ELOVL2	0.52	7.41	0.37	1.03e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg09572067	chr16:29127029	RRN3P2	0.51	8.16	0.4	6.36e-15	Menopause (age at onset);
LIHC	cis	rs11229030	0.893	rs2584859	chr11:57207447	A/G	cg00522883	chr11:57194120	SLC43A3	0.43	6.13	0.31	2.44e-9	Crohn's disease;
LIHC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.43	8.09	0.4	1.05e-14	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.77	9.67	0.46	9.97e-20	Cognitive function;
LIHC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg14092571	chr14:90743983	NA	-0.38	-6.04	-0.31	4.12e-9	Mortality in heart failure;
LIHC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs2286503	0.839	rs10276099	chr7:22862950	G/A	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.53	-6.5	-0.33	2.9e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.55	7.55	0.38	4.06e-13	Eosinophil percentage of white cells;
LIHC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.6	0.34	1.59e-10	Hemoglobin concentration;
LIHC	cis	rs17125944	0.615	rs6572867	chr14:53319283	C/T	cg00686598	chr14:53173677	PSMC6	-0.84	-9.84	-0.47	2.68e-20	Alzheimer's disease (late onset);
LIHC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg13385521	chr17:29058706	SUZ12P	0.58	5.8	0.3	1.54e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.72	0.43	1.19e-16	Alzheimer's disease;
LIHC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.38	7.54	0.38	4.2e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	1.05	14.05	0.6	1.05e-35	Heart rate;
LIHC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.61	-10.3	-0.49	7.37e-22	Mean platelet volume;
LIHC	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00938859	chr5:1591904	SDHAP3	0.57	7.07	0.36	8.57e-12	Breast cancer;
LIHC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	8.06	0.4	1.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg25364880	chr3:44379878	C3orf23	0.59	8.22	0.41	4.39e-15	Depressive symptoms;
LIHC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	8.79	0.43	7.16e-17	Platelet count;
LIHC	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.26	7.15	0.36	5.38e-12	Type 2 diabetes;
LIHC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.85	0.3	1.18e-8	Schizophrenia;
LIHC	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg17724175	chr1:150552817	MCL1	-0.37	-7.47	-0.37	6.62e-13	Tonsillectomy;
LIHC	cis	rs6977660	1.000	rs2892940	chr7:19794750	G/A	cg07541023	chr7:19748670	TWISTNB	0.42	6.34	0.32	7.3e-10	Thyroid stimulating hormone;
LIHC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	5.76	0.3	1.89e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.74	11.01	0.51	2.56e-24	Menarche (age at onset);
LIHC	cis	rs611744	0.967	rs671139	chr8:109191260	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.16	0.77	4.33e-68	Chronic sinus infection;
LIHC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.42	6.49	0.33	3.07e-10	Smoking behavior;
LIHC	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.53	8.17	0.4	5.97e-15	Diastolic blood pressure;
LIHC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.6	-0.38	2.79e-13	Response to antipsychotic treatment;
LIHC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg23791538	chr6:167370224	RNASET2	-0.52	-7.72	-0.39	1.31e-13	Crohn's disease;
LIHC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	0.93	16.95	0.68	3.21e-47	Parkinson's disease;
LIHC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg05110241	chr16:68378359	PRMT7	-0.58	-6.84	-0.35	3.64e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LIHC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg18887096	chr2:219472410	PLCD4	0.37	6.39	0.33	5.47e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3736485	0.966	rs11634039	chr15:51895575	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.29	-0.32	9.52e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs9500256	0.967	rs4928431	chr6:58306258	A/G	cg03371099	chr6:57305889	PRIM2	0.36	6.47	0.33	3.41e-10	Eosinophilic esophagitis (pediatric);
LIHC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.52	-10.32	-0.49	6.69e-22	Prostate cancer;
LIHC	trans	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg05926928	chr17:57297772	GDPD1	0.64	6.74	0.34	6.76e-11	Opioid sensitivity;
LIHC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.45	6.51	0.33	2.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg01864069	chr14:103024347	NA	-0.57	-9.1	-0.44	7.59e-18	Platelet count;
LIHC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.8	0.65	1.35e-42	Chronic sinus infection;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.72	0.39	1.26e-13	Prudent dietary pattern;
LIHC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg14690197	chr8:22456421	C8orf58	-0.42	-6.27	-0.32	1.07e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.0	14.18	0.61	3.28e-36	Cognitive function;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20349687	chr2:88927127	EIF2AK3	-0.48	-6.18	-0.32	1.86e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.6	9.27	0.45	2.14e-18	Chronic sinus infection;
LIHC	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.76	11.46	0.53	5.87e-26	Neuroticism;
LIHC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-8.33	-0.41	1.96e-15	Urinary tract infection frequency;
LIHC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg15691649	chr6:25882328	NA	-0.51	-7.43	-0.37	8.62e-13	Blood metabolite levels;
LIHC	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.46	-6.36	-0.33	6.48e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg27203090	chr3:33138513	GLB1;TMPPE	0.52	6.53	0.33	2.31e-10	Major depressive disorder;
LIHC	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg23352942	chr3:46931381	PTH1R	-0.28	-7.16	-0.36	4.99e-12	Birth weight;
LIHC	cis	rs11958404	0.615	rs10475649	chr5:157447301	T/C	cg05962755	chr5:157440814	NA	0.59	7.83	0.39	6.15e-14	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19877205	chr20:52824603	PFDN4	-0.4	-6.13	-0.31	2.43e-9	Pancreatic cancer;
LIHC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg03037974	chr15:76606532	NA	0.49	7.74	0.39	1.13e-13	Blood metabolite levels;
LIHC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.44	-6.87	-0.35	3.04e-11	Schizophrenia;
LIHC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.77	-11.86	-0.54	2.07e-27	Acylcarnitine levels;
LIHC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.57	8.02	0.4	1.69e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.59	10.28	0.49	8.62e-22	Height;
LIHC	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.7	0.34	8.52e-11	Systolic blood pressure;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18000306	chr6:288505	NA	0.36	6.91	0.35	2.35e-11	Menopause (age at onset);
LIHC	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg07451762	chr16:28383216	NA	0.34	6.17	0.32	1.9e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.59	7.89	0.39	4.26e-14	Coronary artery disease;
LIHC	cis	rs17095355	1.000	rs11194933	chr10:111725862	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.96	-0.31	6.19e-9	Biliary atresia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00419759	chr1:114301964	PHTF1	0.41	6.25	0.32	1.23e-9	Pancreatic cancer;
LIHC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	2.97e-9	Mortality in heart failure;
LIHC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.18	0.36	4.3e-12	Self-reported allergy;
LIHC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.29	0.55	5.2e-29	Schizophrenia;
LIHC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.8	-0.39	7.74e-14	Total body bone mineral density;
LIHC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg15664640	chr17:80829946	TBCD	-0.55	-5.86	-0.3	1.1e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.5	8.02	0.4	1.69e-14	Age at first birth;
LIHC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.77e-22	Hemoglobin concentration;
LIHC	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	0.82	9.31	0.45	1.55e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.86	12.93	0.57	2.02e-31	Lymphocyte percentage of white cells;
LIHC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.29	-19.32	-0.72	9.82e-57	Type 1 diabetes nephropathy;
LIHC	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.78	13.16	0.58	2.73e-32	Gastritis;
LIHC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.92	15.08	0.63	9.68e-40	Colorectal cancer;
LIHC	cis	rs17106184	1.000	rs12089749	chr1:51306329	C/A	cg07174182	chr1:51127561	FAF1	-0.62	-6.59	-0.34	1.68e-10	Type 2 diabetes;
LIHC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.9	0.3	8.78e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.72	-10.28	-0.49	9.19e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.04	0.36	1.04e-11	Exhaled nitric oxide output;
LIHC	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg27129171	chr3:47204927	SETD2	0.49	7.88	0.39	4.48e-14	Birth weight;
LIHC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.02	-0.44	1.4e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.77	-0.39	9.19e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.47	7.07	0.36	8.74e-12	Cystic fibrosis severity;
LIHC	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.62	-12.58	-0.56	4.45e-30	Plateletcrit;Platelet count;
LIHC	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.85	-0.35	3.4e-11	Metabolite levels;
LIHC	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.85	-12.67	-0.57	1.93e-30	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.67	-10.63	-0.5	5.43e-23	Lung cancer;
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg03785755	chr6:26196794	NA	0.5	5.88	0.3	9.89e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.61	5.87	0.3	1.02e-8	Vitiligo;
LIHC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.07	0.31	3.35e-9	Cognitive ability;
LIHC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg15208524	chr1:10270712	KIF1B	0.41	6.09	0.31	3.05e-9	Hepatocellular carcinoma;
LIHC	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg11839771	chr15:80205821	ST20	-0.31	-6.46	-0.33	3.55e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	trans	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg26939375	chr7:64535504	NA	0.43	6.59	0.34	1.64e-10	Aortic root size;
LIHC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-8.55	-0.42	4.22e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg07061783	chr6:25882402	NA	-0.53	-6.73	-0.34	7.08e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-9.81	-0.47	3.45e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-0.89	-9.98	-0.47	9.65e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.46	-6.29	-0.32	9.69e-10	Initial pursuit acceleration;
LIHC	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.38	0.33	5.76e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.66	-12.61	-0.56	3.33e-30	Refractive error;
LIHC	cis	rs420259	0.681	rs249868	chr16:23666797	A/G	cg05131483	chr16:23706242	ERN2	0.34	5.8	0.3	1.55e-8	Bipolar disorder;
LIHC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.46	-0.59	2.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.04	-0.48	5.74e-21	Response to antipsychotic treatment;
LIHC	cis	rs6815814	0.950	rs9306967	chr4:38807911	G/C	cg06935464	chr4:38784597	TLR10	0.4	6.54	0.33	2.18e-10	Breast cancer;
LIHC	cis	rs12611088	0.538	rs2599435	chr19:43975299	A/G	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.18	-0.32	1.87e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.71	-0.43	1.28e-16	Primary biliary cholangitis;
LIHC	cis	rs1000083	0.834	rs2351506	chr5:96585715	A/G	ch.5.96698337R	chr5:96672581	NA	0.84	6.84	0.35	3.68e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	14.01	0.6	1.53e-35	Cognitive test performance;
LIHC	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.32	-6.34	-0.32	7.31e-10	Alcohol dependence;
LIHC	trans	rs60752752	0.852	rs59678238	chr1:153370659	C/G	cg14901121	chr8:98817630	LAPTM4B	-0.44	-7.28	-0.37	2.35e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.36	6.68	0.34	9.79e-11	Ewing sarcoma;
LIHC	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.54e-12	Corneal astigmatism;
LIHC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.81	7.73	0.39	1.19e-13	Diabetic retinopathy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25759457	chr1:172502420	C1orf9	0.42	6.06	0.31	3.55e-9	Pancreatic cancer;
LIHC	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg14515779	chr1:101123966	NA	-0.45	-6.38	-0.33	5.67e-10	Monocyte count;
LIHC	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.31	7.78	0.39	8.59e-14	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	0.97	10.17	0.48	2.11e-21	Vitiligo;
LIHC	cis	rs3736594	0.513	rs76013440	chr2:27816315	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.69	0.34	9.33e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.71	0.5	2.77e-23	Bladder cancer;
LIHC	cis	rs35160687	0.644	rs11676515	chr2:86496057	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.35	5.74	0.3	2.12e-8	Night sleep phenotypes;
LIHC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.32	5.89	0.3	9.03e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.46	-7.27	-0.37	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9543976	1.000	rs7339146	chr13:76173719	G/A	cg01531495	chr13:76123901	UCHL3	-0.49	-5.89	-0.3	9.07e-9	Diabetic retinopathy;
LIHC	cis	rs4920343	0.698	rs851121	chr1:19087765	C/T	cg19637330	chr1:19110922	NA	0.33	6.08	0.31	3.28e-9	Knee osteoarthritis;
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.69	8.4	0.41	1.18e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg09165964	chr15:75287851	SCAMP5	0.47	6.86	0.35	3.14e-11	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.53	7.83	0.39	5.99e-14	Diastolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05379784	chr14:74111382	DNAL1	0.44	6.66	0.34	1.11e-10	Cognitive function;
LIHC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.51	-8.91	-0.43	2.98e-17	Longevity;
LIHC	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg25783544	chr11:47291846	MADD	0.43	6.27	0.32	1.1e-9	HDL cholesterol;
LIHC	cis	rs7188697	0.922	rs37061	chr16:58566671	A/G	cg02549819	chr16:58548995	SETD6	-0.45	-7.16	-0.36	5.04e-12	QT interval;
LIHC	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs712039	0.652	rs829161	chr17:35763863	C/T	cg16670864	chr17:35848621	DUSP14	-0.36	-6.01	-0.31	4.86e-9	Tuberculosis;
LIHC	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.61	8.27	0.41	2.92e-15	Breast cancer;
LIHC	cis	rs6967414	0.579	rs6968879	chr7:6757886	T/G	cg00387323	chr7:6746715	ZNF12	0.67	7.47	0.37	6.89e-13	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.79	8.15	0.4	6.92e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16828019	0.852	rs12045171	chr1:41528805	G/A	cg03962019	chr1:41807865	NA	0.49	7.32	0.37	1.81e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg16822855	chr3:40428330	ENTPD3	0.34	6.16	0.32	1.99e-9	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01261044	chr14:35451962	SRP54	0.41	6.38	0.33	5.64e-10	Cognitive function;
LIHC	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.43	-6.75	-0.34	6.46e-11	Response to antidepressants and depression;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.85	0.43	4.64e-17	Prudent dietary pattern;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08989290	chr16:615782	NHLRC4	0.31	6.12	0.31	2.53e-9	Height;
LIHC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.65	12.6	0.56	3.58e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02290350	chr8:58132656	NA	0.4	8.41	0.41	1.15e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.48	6.68	0.34	9.58e-11	Schizophrenia;
LIHC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	5.91	0.3	8.27e-9	Menopause (age at onset);
LIHC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	1.01	10.92	0.51	4.9299999999999996e-24	Triglycerides;
LIHC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg12454167	chr3:186435060	KNG1	0.39	9.09	0.44	7.92e-18	Blood protein levels;
LIHC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.54	6.88	0.35	2.9100000000000002e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.63	-9.96	-0.47	1.12e-20	Lung cancer;
LIHC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-7.94	-0.39	2.9e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.67	8.37	0.41	1.5e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.72	10.39	0.49	3.79e-22	Diastolic blood pressure;
LIHC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	1.06	14.16	0.61	3.86e-36	Body mass index;
LIHC	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.25	-0.36	2.87e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs11628318	0.515	rs1190343	chr14:103100348	G/A	cg12046867	chr14:103022105	NA	-0.37	-5.74	-0.3	2.08e-8	Platelet count;
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg20090690	chr10:134436459	INPP5A	0.46	5.78	0.3	1.69e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.75	-0.3	1.96e-8	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08953461	chr5:157158882	THG1L	0.45	6.86	0.35	3.23e-11	Cognitive function;
LIHC	cis	rs35955747	0.902	rs2413048	chr22:31686102	G/A	cg22777020	chr22:31556080	RNF185	-0.49	-5.76	-0.3	1.91e-8	Neutrophil count;Sum basophil neutrophil counts;
LIHC	trans	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg17675199	chr6:35436792	RPL10A	-0.41	-8.45	-0.42	8.67e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.05	-0.4	1.37e-14	Capecitabine sensitivity;
LIHC	cis	rs400736	0.562	rs10864331	chr1:8172178	A/G	cg25007680	chr1:8021821	PARK7	-0.44	-6.53	-0.33	2.44e-10	Response to antidepressants and depression;
LIHC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.61	10.41	0.49	3.2e-22	Height;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg15382696	chr6:118971807	C6orf204	0.63	6.37	0.33	6.05e-10	Diastolic blood pressure;
LIHC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg13628971	chr7:2884303	GNA12	0.37	6.07	0.31	3.49e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.48	6.78	0.34	5.2e-11	Diastolic blood pressure;
LIHC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14580859	chr9:123691850	NA	0.38	6.6	0.34	1.61e-10	Rheumatoid arthritis;
LIHC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	1.06	16.09	0.66	9.03e-44	Breast cancer;
LIHC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg05973401	chr12:123451056	ABCB9	0.44	6.03	0.31	4.15e-9	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.15e-22	Colorectal cancer;
LIHC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.82	0.35	4.22e-11	Body mass index;
LIHC	cis	rs903552	0.935	rs4965387	chr15:102003209	G/A	cg00659931	chr15:102010125	PCSK6	-0.45	-6.15	-0.32	2.2e-9	Diabetic kidney disease;
LIHC	cis	rs6750047	0.625	rs336037	chr2:38261124	T/C	cg07380506	chr2:38303506	CYP1B1	-0.59	-7.45	-0.37	7.81e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg03934865	chr2:198174659	NA	0.54	8.24	0.41	3.72e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.43	9.14	0.44	5.59e-18	Migraine;
LIHC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs2540917	0.654	rs11125842	chr2:60640807	A/G	cg00543073	chr2:60773386	BCL11A	-0.33	-6.5	-0.33	2.85e-10	Mean corpuscular volume;
LIHC	cis	rs1008375	1.000	rs13149474	chr4:17688582	G/A	cg16339924	chr4:17578868	LAP3	-0.49	-6.13	-0.31	2.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg25952890	chr19:58913133	NA	-0.7	-7.72	-0.39	1.31e-13	Mean platelet volume;
LIHC	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg11987759	chr7:65425863	GUSB	0.38	5.92	0.3	7.82e-9	Calcium levels;
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-9.62	-0.46	1.5e-19	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.48	0.46	4.54e-19	Electroencephalogram traits;
LIHC	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.81	-0.3	1.44e-8	Systolic blood pressure;
LIHC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.87	13.05	0.58	7.09e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.69	12.03	0.55	4.8e-28	Prudent dietary pattern;
LIHC	cis	rs739401	0.619	rs10766481	chr11:2961512	G/C	cg20651018	chr11:3035856	CARS	-0.34	-5.76	-0.3	1.92e-8	Longevity;
LIHC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.29	0.55	5.1e-29	Cognitive test performance;
LIHC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg09163369	chr1:210001066	C1orf107	0.48	6.28	0.32	1.04e-9	Orofacial clefts;
LIHC	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.16	-0.4	6.42e-15	Response to antipsychotic treatment;
LIHC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.6	8.36	0.41	1.64e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11264799	0.520	rs2779159	chr1:157550357	C/T	cg18268488	chr1:157545234	FCRL4	0.21	5.73	0.3	2.25e-8	IgA nephropathy;
LIHC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.76	0.3	1.86e-8	Schizophrenia;
LIHC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-10.46	-0.49	2.15e-22	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.63	-9.62	-0.46	1.47e-19	Uric acid clearance;
LIHC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.77	12.34	0.56	3.42e-29	Corneal astigmatism;
LIHC	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg19920283	chr7:105172520	RINT1	0.48	6.13	0.31	2.49e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02985541	chr2:219472218	PLCD4	0.42	6.84	0.35	3.73e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.32	-6.38	-0.33	5.82e-10	Platelet distribution width;
LIHC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.69	11.6	0.53	1.81e-26	Crohn's disease;
LIHC	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.35	8.26	0.41	3.19e-15	Weight;
LIHC	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.13	-0.36	6.2e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg06598544	chr20:61472147	COL9A3	-0.9	-8.42	-0.41	1.07e-15	Obesity-related traits;
LIHC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-9.03	-0.44	1.24e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.75	-0.69	2.03e-50	Schizophrenia;
LIHC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.35	0.32	7.02e-10	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	0.42	6.19	0.32	1.71e-9	Pancreatic cancer;
LIHC	cis	rs4934494	0.768	rs12572608	chr10:91406927	A/G	cg19698084	chr10:91461284	KIF20B	0.49	6.53	0.33	2.4e-10	Red blood cell count;
LIHC	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg11204139	chr17:3907470	NA	0.57	6.62	0.34	1.36e-10	Type 2 diabetes;
LIHC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-11.49	-0.53	4.66e-26	Electrocardiographic conduction measures;
LIHC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-5.98	-0.31	5.66e-9	Mood instability;
LIHC	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.76	8.18	0.4	5.78e-15	Chronic kidney disease;
LIHC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg07645718	chr20:61493192	TCFL5	0.75	6.14	0.32	2.31e-9	Obesity-related traits;
LIHC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03517284	chr6:25882590	NA	-0.5	-6.46	-0.33	3.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.54	-7.66	-0.38	1.95e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.71	7.37	0.37	1.27e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg18867708	chr6:26865862	GUSBL1	0.48	5.84	0.3	1.22e-8	Small cell lung carcinoma;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.06	-0.4	1.31e-14	Capecitabine sensitivity;
LIHC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7091068	0.566	rs7082701	chr10:95501042	G/T	cg20715218	chr10:95462985	C10orf4	0.57	5.86	0.3	1.07e-8	Urinary tract infection frequency;
LIHC	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg08345082	chr10:99160200	RRP12	0.39	6.81	0.35	4.47e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg25919922	chr13:100150906	NA	-0.75	-6.36	-0.32	6.66e-10	Obesity-related traits;
LIHC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.79	-0.3	1.58e-8	Ulcerative colitis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg00715988	chr14:96968640	PAPOLA	-0.46	-6.79	-0.34	4.95e-11	Systolic blood pressure;
LIHC	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.88	-14.62	-0.62	6.16e-38	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs57590327	0.679	rs35942842	chr3:81588362	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-6.43	-0.33	4.29e-10	Extraversion;
LIHC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.61	7.29	0.37	2.11e-12	Cognitive function;
LIHC	trans	rs6058796	1.000	rs9636547	chr20:31262033	T/A	cg02600331	chr11:130417168	NA	0.36	7.86	0.39	4.98e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs6977660	1.000	rs13230910	chr7:19806003	A/G	cg07541023	chr7:19748670	TWISTNB	-0.39	-6.09	-0.31	3.05e-9	Thyroid stimulating hormone;
LIHC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg03013999	chr17:37608204	MED1	-0.34	-5.76	-0.3	1.91e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.66	10.95	0.51	4.11e-24	Pulse pressure;
LIHC	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.85	-15.09	-0.63	8.79e-40	Aortic root size;
LIHC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.61	-6.96	-0.35	1.78e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs12986413	0.967	rs1015670	chr19:2171490	G/A	cg09261902	chr19:2140048	AP3D1	0.37	6.38	0.33	5.85e-10	Height;
LIHC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.71	11.01	0.51	2.43e-24	Corneal astigmatism;
LIHC	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.53	-5.93	-0.31	7.57e-9	Ulcerative colitis;
LIHC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.39	5.93	0.31	7.38e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.59	10.37	0.49	4.3e-22	Mean corpuscular volume;
LIHC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-6.53	-0.33	2.34e-10	Electroencephalogram traits;
LIHC	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg24112000	chr20:60950667	NA	-0.6	-9.72	-0.47	6.86e-20	Colorectal cancer;
LIHC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.7	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02475777	chr4:1388615	CRIPAK	0.52	7.55	0.38	4.12e-13	Longevity;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg19362124	chr8:42912008	FNTA	-0.4	-6.47	-0.33	3.35e-10	Eotaxin levels;
LIHC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.5	-6.54	-0.33	2.21e-10	Breast cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06503243	chr13:42006994	OR7E37P	0.36	6.15	0.32	2.22e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs1144333	0.655	rs76992868	chr1:76418916	G/A	cg10154597	chr10:134910271	GPR123	0.31	6.11	0.31	2.69e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.32	-8.29	-0.41	2.68e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.62	-11.07	-0.51	1.49e-24	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs10744422	0.800	rs839363	chr12:123276924	C/T	cg07706471	chr12:123319906	HIP1R	-0.6	-7.65	-0.38	2.02e-13	Schizophrenia;
LIHC	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.05	-0.36	1.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg14067834	chr17:29058358	SUZ12P	0.69	6.72	0.34	7.71e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.36	0.49	4.71e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.71	13.67	0.59	3.13e-34	Menopause (age at onset);
LIHC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg23109721	chr2:106886537	NA	-0.73	-7.03	-0.36	1.13e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LIHC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.5	0.53	4.37e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.95	0.54	9.69e-28	Cognitive ability;
LIHC	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg04610667	chr7:75704037	NA	-0.35	-6.33	-0.32	7.67e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.67	-11.63	-0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.31	-0.41	2.27e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.47	7.66	0.38	1.88e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg12374095	chr12:54320830	NA	0.44	6.36	0.33	6.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	trans	rs875971	1.000	rs875971	chr7:65617595	A/G	cg10756647	chr7:56101905	PSPH	-0.43	-6.08	-0.31	3.21e-9	Aortic root size;
LIHC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.33	6.7	0.34	8.61e-11	Cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06425136	chr16:31040922	NA	-0.41	-6.33	-0.32	7.7e-10	Systolic blood pressure;
LIHC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.08	0.44	9.16e-18	Platelet count;
LIHC	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.72	-0.47	7.19e-20	Ulcerative colitis;
LIHC	cis	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg18809830	chr7:99032528	PTCD1	-0.79	-6.22	-0.32	1.46e-9	Blood metabolite levels;
LIHC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.43	-6.34	-0.32	7.41e-10	Height;
LIHC	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-6.4	-0.33	5.12e-10	Schizophrenia;
LIHC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	0.83	7.04	0.36	1.05e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg21522988	chr12:29376872	FAR2	0.3	6.86	0.35	3.28e-11	QT interval;
LIHC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.91	-10.95	-0.51	3.86e-24	Primary sclerosing cholangitis;
LIHC	trans	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg19955956	chr7:72299837	SBDSP;TYW1B	0.38	7.08	0.36	8.01e-12	Blood metabolite levels;
LIHC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg11057378	chr10:81107060	PPIF	0.37	6.06	0.31	3.63e-9	Height;
LIHC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.47	-0.76	2.4e-65	Height;
LIHC	trans	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg23598604	chr1:99732472	LPPR4	-0.31	-6.5	-0.33	2.86e-10	Multiple myeloma;
LIHC	cis	rs9783347	1.000	rs4150564	chr11:18355308	G/A	cg15585147	chr11:18324498	HPS5	0.43	6.73	0.34	6.95e-11	Pancreatic cancer;
LIHC	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg15208524	chr1:10270712	KIF1B	0.45	6.53	0.33	2.31e-10	Hepatocellular carcinoma;
LIHC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.48	-7.92	-0.39	3.41e-14	Mean corpuscular volume;
LIHC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg10790698	chr19:18539756	SSBP4	-0.34	-7.22	-0.36	3.38e-12	Breast cancer;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22352273	chr2:238969464	SCLY	-0.43	-6.3	-0.32	9.2e-10	Cognitive function;
LIHC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.58	9.39	0.45	8.68e-19	Lymphocyte counts;
LIHC	cis	rs2257205	0.667	rs79155614	chr17:56722496	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-9.75	-0.47	5.41e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.32	6.04	0.31	3.94e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg18121669	chr1:26560928	CCDC21	0.51	7.96	0.4	2.58e-14	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.8	11.94	0.54	1.04e-27	Coronary artery disease;
LIHC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.51	-7.05	-0.36	9.75e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg24069376	chr3:38537580	EXOG	0.43	8.13	0.4	8.1e-15	Electrocardiographic conduction measures;
LIHC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.22	6.07	0.31	3.42e-9	Calcium levels;
LIHC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.76	10.14	0.48	2.64e-21	Selective IgA deficiency;
LIHC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-5.99	-0.31	5.26e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg14393609	chr7:65229607	NA	0.44	6.57	0.33	1.84e-10	Aortic root size;
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg22325292	chr17:80708367	FN3K	0.39	6.27	0.32	1.08e-9	Glycated hemoglobin levels;
LIHC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.39	7.78	0.39	8.72e-14	Renal cell carcinoma;
LIHC	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	12.01	0.54	5.59e-28	Post bronchodilator FEV1;
LIHC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg07382826	chr16:28625726	SULT1A1	0.52	8.01	0.4	1.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.25	-0.45	2.55e-18	Bipolar disorder;
LIHC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.45	6.03	0.31	4.22e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21448741	chr8:58168803	NA	0.36	6.29	0.32	9.57e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.53	-10.18	-0.48	1.95e-21	Asthma;
LIHC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.47	7.78	0.39	8.57e-14	Multiple sclerosis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14552441	chr12:4650518	RAD51AP1	0.36	6.09	0.31	2.99e-9	Hepatitis;
LIHC	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.73	10.54	0.5	1.1e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-10.49	-0.49	1.71e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.14	-0.31	2.34e-9	Aortic root size;
LIHC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg17385448	chr1:15911702	AGMAT	0.35	6.23	0.32	1.4e-9	Systolic blood pressure;
LIHC	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.87	-10.73	-0.5	2.32e-23	Prostate cancer;
LIHC	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.77	11.98	0.54	7.27e-28	Corneal astigmatism;
LIHC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg00225070	chr15:80189496	MTHFS	0.45	7.42	0.37	9.31e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-7.41	-0.37	9.72e-13	Initial pursuit acceleration;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg00612595	chr21:47717864	NA	-0.35	-5.76	-0.3	1.85e-8	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.3	-7.07	-0.36	8.93e-12	Menarche (age at onset);
LIHC	cis	rs77637988	0.516	rs55744465	chr2:48632455	G/T	cg15846641	chr2:48541264	FOXN2	0.5	6.53	0.33	2.41e-10	Joint mobility (Beighton score);
LIHC	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.52	-6.33	-0.32	7.91e-10	Vitiligo;
LIHC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.41	6.16	0.32	2e-9	Menarche (age at onset);
LIHC	cis	rs743757	1.000	rs762897	chr3:50428766	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.46	6.93	0.35	2.16e-11	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	8.89e-15	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs2412488	0.893	rs6825364	chr4:54340881	T/C	cg22241045	chr4:54363911	LNX1	-0.41	-6.59	-0.34	1.71e-10	DNA methylation (variation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01297674	chr2:122406765	CLASP1	0.49	6.72	0.34	7.54e-11	Pancreatic cancer;
LIHC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.57	7.39	0.37	1.11e-12	Parkinson's disease;
LIHC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.66	8.41	0.41	1.12e-15	Initial pursuit acceleration;
LIHC	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.41	-6.58	-0.34	1.78e-10	Neutrophil percentage of white cells;
LIHC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-6.77	-0.34	5.72e-11	Lymphocyte counts;
LIHC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.6	-8.59	-0.42	3.09e-16	Blood pressure (smoking interaction);
LIHC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.66	13.04	0.58	7.61e-32	High light scatter reticulocyte count;
LIHC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg03735888	chr19:58951602	ZNF132	0.35	5.76	0.3	1.83e-8	Uric acid clearance;
LIHC	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	11.02	0.51	2.36e-24	Colorectal cancer;
LIHC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg05484376	chr2:27715224	FNDC4	0.35	5.8	0.3	1.49e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07305463	chr2:136567211	LCT	-0.4	-7.68	-0.38	1.65e-13	Mosquito bite size;
LIHC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.55	7.25	0.36	2.82e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg16736954	chr20:23401023	NAPB	0.72	8.46	0.42	7.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.6	-0.34	1.59e-10	Bipolar disorder;
LIHC	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.52	-0.38	4.95e-13	Coronary artery disease;
LIHC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.39	5.85	0.3	1.15e-8	Menarche (age at onset);
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.49	-0.33	3.03e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs244293	0.965	rs244311	chr17:53212803	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.37	-0.37	1.27e-12	Menarche (age at onset);
LIHC	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	0.94	19.01	0.72	1.66e-55	Schizophrenia;
LIHC	trans	rs7374732	0.692	rs6800955	chr3:23139179	C/T	cg19691163	chr5:96304288	LNPEP	0.42	6.45	0.33	3.8e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05025164	chr4:1340916	KIAA1530	0.75	11.61	0.53	1.73e-26	Longevity;
LIHC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	9.94	0.47	1.3e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.8	-12.29	-0.55	5.27e-29	Smoking behavior;
LIHC	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg13482628	chr17:19912719	NA	0.42	7.06	0.36	9.53e-12	Schizophrenia;
LIHC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg03146154	chr1:46216737	IPP	0.5	8.34	0.41	1.86e-15	Red blood cell count;Reticulocyte count;
LIHC	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg25019722	chr6:37503610	NA	-0.32	-5.74	-0.3	2.14e-8	Cognitive performance;
LIHC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.43	-7.55	-0.38	3.92e-13	Aortic root size;
LIHC	cis	rs2637266	0.685	rs7098713	chr10:78452828	C/T	cg18941641	chr10:78392320	NA	0.27	5.87	0.3	1.02e-8	Pulmonary function;
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.54	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.09	-0.36	7.66e-12	Personality dimensions;
LIHC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.46	7.33	0.37	1.66e-12	Height;
LIHC	cis	rs17310467	0.541	rs764598	chr20:33161150	C/G	cg08999081	chr20:33150536	PIGU	0.56	5.84	0.3	1.24e-8	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-5.84	-0.3	1.18e-8	Bipolar disorder;
LIHC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg17135325	chr3:160939158	NMD3	0.5	7.46	0.37	7.22e-13	Morning vs. evening chronotype;
LIHC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.41	-6.73	-0.34	7.25e-11	Facial morphology (factor 20);
LIHC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg25894440	chr7:65020034	NA	-0.55	-6.21	-0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg03387723	chr1:41708464	SCMH1	-0.42	-6.93	-0.35	2.14e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.79	0.34	4.83e-11	Ileal carcinoids;
LIHC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.84	9.17	0.44	4.43e-18	Initial pursuit acceleration;
LIHC	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.61	-9.53	-0.46	2.99e-19	Neuroblastoma (high-risk);
LIHC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.42e-17	Lung cancer in ever smokers;
LIHC	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.71	-0.79	3.38e-74	Height;
LIHC	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.07	-0.4	1.22e-14	Response to antipsychotic treatment;
LIHC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.62	6.86	0.35	3.31e-11	Alzheimer's disease;
LIHC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.93	-0.31	7.23e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14978174	chr3:156391939	TIPARP;LOC100287227	0.46	6.23	0.32	1.4e-9	Pancreatic cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09604110	chr6:116422028	NT5DC1	-0.39	-6.19	-0.32	1.74e-9	Pancreatic cancer;
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.64	-8.17	-0.4	6.07e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.77	-0.34	5.46e-11	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06130371	chr15:65578830	PARP16	-0.42	-6.38	-0.33	5.75e-10	Pancreatic cancer;
LIHC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.42	6.38	0.33	5.61e-10	Mean platelet volume;
LIHC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.76	0.3	1.88e-8	Bladder cancer;
LIHC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg24209194	chr3:40518798	ZNF619	0.49	7.36	0.37	1.37e-12	Renal cell carcinoma;
LIHC	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg25182066	chr10:30743637	MAP3K8	0.42	6.9	0.35	2.56e-11	Inflammatory bowel disease;
LIHC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg12253828	chr6:101329408	ASCC3	-0.39	-5.97	-0.31	6.04e-9	Neuroticism;
LIHC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.95	0.35	1.9e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg03013999	chr17:37608204	MED1	-0.36	-6.07	-0.31	3.33e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg16606324	chr3:10149918	C3orf24	0.49	5.86	0.3	1.11e-8	Alzheimer's disease;
LIHC	trans	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg26939375	chr7:64535504	NA	-0.43	-7.32	-0.37	1.77e-12	Aortic root size;
LIHC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.55	-8.51	-0.42	5.47e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg16589663	chr20:23618590	CST3	0.68	7.33	0.37	1.66e-12	Chronic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01074676	chr14:60601069	C14orf135	0.3	6.57	0.33	1.89e-10	Cognitive function;
LIHC	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.64	9.41	0.45	7.22e-19	Monocyte count;
LIHC	cis	rs10411936	0.682	rs8103805	chr19:16598433	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.95	0.35	1.81e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.45	6.37	0.33	6.08e-10	Diastolic blood pressure;
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.93	0.39	3.18e-14	Height;
LIHC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg03258749	chr1:151040405	MLLT11	-0.39	-6.4	-0.33	5.14e-10	Childhood ear infection;
LIHC	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg27205649	chr11:78285834	NARS2	-0.38	-5.78	-0.3	1.68e-8	Alzheimer's disease (survival time);
LIHC	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg06096015	chr1:231504339	EGLN1	0.5	9.22	0.45	3.12e-18	Hemoglobin concentration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12922032	chr2:32582209	BIRC6	0.49	6.49	0.33	3.1e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.21e-8	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg12463550	chr7:65579703	CRCP	0.69	7.15	0.36	5.29e-12	Diabetic kidney disease;
LIHC	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.84	-0.35	3.68e-11	Metabolite levels;
LIHC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22168489	chr12:122356033	WDR66	0.45	6.75	0.34	6.16e-11	Mean corpuscular volume;
LIHC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	0.85	11.67	0.53	1.03e-26	Skin colour saturation;
LIHC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.27	-0.32	1.08e-9	IgG glycosylation;
LIHC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.9	-17.95	-0.7	3.1e-51	Coronary artery disease;
LIHC	trans	rs2363709	1.000	rs2363709	chr3:67417105	G/A	cg13681781	chr9:139102396	QSOX2	0.81	6.33	0.32	7.66e-10	IgE levels;
LIHC	trans	rs13202860	0.908	rs11752790	chr6:87183280	C/A	cg27326224	chr7:950474	ADAP1	-0.57	-6.33	-0.32	7.69e-10	Sexual dysfunction (female);
LIHC	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.16	16.12	0.66	6.66e-44	Corneal structure;
LIHC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.47	6.34	0.32	7.12e-10	Height;
LIHC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg17771515	chr6:154831774	CNKSR3	0.59	6.49	0.33	2.96e-10	Lipoprotein (a) levels;
LIHC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.69	-11.81	-0.54	3.18e-27	Colorectal cancer;
LIHC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.58	-0.42	3.44e-16	Magnesium levels;
LIHC	trans	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg24036039	chr1:3397125	ARHGEF16	0.4	6.53	0.33	2.43e-10	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07822143	chr4:146019674	ABCE1;ANAPC10	0.4	6.35	0.32	6.67e-10	Pancreatic cancer;
LIHC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.96	-12.85	-0.57	4.02e-31	Bladder cancer;
LIHC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg14558114	chr2:88469736	THNSL2	-0.37	-5.82	-0.3	1.32e-8	Response to metformin (IC50);
LIHC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg22563815	chr15:78856949	CHRNA5	-0.35	-6.28	-0.32	1.03e-9	Sudden cardiac arrest;
LIHC	cis	rs12086130	0.892	rs72906860	chr1:51499822	G/A	cg07174182	chr1:51127561	FAF1	-0.88	-9.84	-0.47	2.7e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs1461503	0.934	rs7119533	chr11:122832683	A/T	cg25161029	chr11:122845972	NA	0.4	6.7	0.34	8.39e-11	Menarche (age at onset);
LIHC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.55	-8.3	-0.41	2.36e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.75	10.59	0.5	7.73e-23	Obesity-related traits;
LIHC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.6	5.9	0.3	8.91e-9	Vitiligo;
LIHC	cis	rs8081395	0.836	rs1292061	chr17:57911230	A/G	cg02344993	chr17:57696989	CLTC	-0.46	-7.57	-0.38	3.5e-13	White blood cell count;
LIHC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	trans	rs2288327	0.630	rs16866400	chr2:179448911	G/A	cg14011486	chr1:26737247	LIN28	0.46	6.28	0.32	1e-9	Atrial fibrillation;
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.84	0.39	5.82e-14	Height;
LIHC	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.67	-0.62	3.81e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.8	15.14	0.63	5.42e-40	IgG glycosylation;
LIHC	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.34	5.9	0.3	8.89e-9	HIV-1 susceptibility;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07810114	chr1:12018622	PLOD1	0.39	6.32	0.32	8.25e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg05484376	chr2:27715224	FNDC4	0.37	6.31	0.32	8.8e-10	Total body bone mineral density;
LIHC	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg04592579	chr7:75616294	TMEM120A	0.39	6.79	0.34	4.9e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.21e-8	Menopause (age at onset);
LIHC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.05	-0.4	1.43e-14	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg12463550	chr7:65579703	CRCP	0.68	7.09	0.36	7.52e-12	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.31	0.45	1.6e-18	Hemoglobin concentration;
LIHC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.34	0.58	5.8e-33	Colorectal cancer;
LIHC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.85	-14.78	-0.62	1.38e-38	Aortic root size;
LIHC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.34	-5.71	-0.3	2.42e-8	Lung cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14331148	chr19:47551893	TMEM160	-0.46	-6.92	-0.35	2.27e-11	Cognitive function;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.81	16.72	0.67	2.73e-46	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.53	-8.22	-0.41	4.13e-15	White matter hyperintensity burden;
LIHC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.18e-31	Sense of smell;
LIHC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-10.62	-0.5	5.97e-23	Bladder cancer;
LIHC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-1.13	-12.71	-0.57	1.4e-30	White matter hyperintensity burden;
LIHC	cis	rs546131	0.614	rs35357012	chr11:34793384	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-6.23	-0.32	1.4e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs476633	0.595	rs11857726	chr15:41530359	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.82	-0.3	1.36e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.64	9.75	0.47	5.54e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.05	0.44	1.08e-17	Corneal astigmatism;
LIHC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.24	0.52	3.62e-25	Coronary artery disease;
LIHC	cis	rs249954	0.512	rs34514	chr16:23670597	G/A	cg09867953	chr16:23706666	ERN2	0.37	6.19	0.32	1.76e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.12	-0.44	6.77e-18	Bipolar disorder;
LIHC	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.56	-7.97	-0.4	2.43e-14	Facial morphology (factor 19);
LIHC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.48	-7.68	-0.38	1.67e-13	Diastolic blood pressure;
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	5.96	0.31	6.29e-9	Aortic root size;
LIHC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs832187	0.629	rs6798742	chr3:63903759	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.42	-5.98	-0.31	5.68e-9	Schizophrenia;
LIHC	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-20.7	-0.75	2.84e-62	Exhaled nitric oxide output;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.56	-7.78	-0.39	8.55e-14	Menopause (age at onset);
LIHC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.3	-6.38	-0.33	5.67e-10	Blood metabolite levels;
LIHC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.42	5.96	0.31	6.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.62	9.79	0.47	4.25e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs11958404	0.615	rs7711271	chr5:157452268	C/G	cg05962755	chr5:157440814	NA	0.61	7.93	0.39	3.16e-14	IgG glycosylation;
LIHC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.35	-5.85	-0.3	1.17e-8	Atrioventricular conduction;
LIHC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs611744	0.967	rs666821	chr8:109204313	T/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.73	0.34	6.96e-11	Renal cell carcinoma;
LIHC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.28	0.41	2.8e-15	Lung cancer;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.56	8.34	0.41	1.81e-15	Height;
LIHC	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08280861	chr8:58055591	NA	0.48	5.99	0.31	5.37e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.45	-6.04	-0.31	4.07e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.59	-8.47	-0.42	7.24e-16	Initial pursuit acceleration;
LIHC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-9.98	-0.48	9.07e-21	Platelet count;
LIHC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg04709771	chr16:646395	RAB40C	0.46	8.19	0.41	5.1e-15	Height;
LIHC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.68	0.34	9.86e-11	Lung cancer;
LIHC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.41	6.72	0.34	7.67e-11	Red blood cell count;
LIHC	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.35	-5.76	-0.3	1.87e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.38	8.91	0.43	3.18e-17	Blood protein levels;
LIHC	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.53	-7.03	-0.36	1.1e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg01238044	chr22:24384105	GSTT1	-0.44	-5.98	-0.31	5.57e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.88	-0.35	2.85e-11	Bipolar disorder;
LIHC	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	8.93	0.43	2.63e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.48	-0.46	4.24e-19	Blood metabolite levels;
LIHC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.88	-0.51	6.88e-24	Platelet count;
LIHC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.46	6.32	0.32	8.07e-10	Body mass index;
LIHC	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.52	-8.67	-0.42	1.75e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.67	9.34	0.45	1.3e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.82	-0.3	1.32e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.76	-11.01	-0.51	2.41e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg11657440	chr19:46296263	DMWD	-0.54	-8.53	-0.42	4.7e-16	Coronary artery disease;
LIHC	cis	rs7212590	0.581	rs8070961	chr17:57813168	A/G	cg10252138	chr17:58120427	NA	-0.62	-6.01	-0.31	4.72e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2274273	0.868	rs9919926	chr14:55813890	G/C	cg01864836	chr14:55583639	NA	-0.37	-6.55	-0.33	2.07e-10	Protein biomarker;
LIHC	cis	rs918629	0.761	rs6881872	chr5:95286726	A/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.22	-0.32	1.42e-9	IgG glycosylation;
LIHC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg01557791	chr16:72042693	DHODH	-0.45	-7.51	-0.38	5.08e-13	Fibrinogen levels;
LIHC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.86	12.65	0.56	2.29e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.2	0.52	4.96e-25	Colorectal cancer;
LIHC	cis	rs9917256	0.831	rs908594	chr2:169133796	A/G	cg07857142	chr2:169103971	STK39	0.54	6.02	0.31	4.41e-9	Parkinson's disease;
LIHC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.74	12.17	0.55	1.48e-28	Menarche (age at onset);
LIHC	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.83	8.38	0.41	1.36e-15	Facial emotion recognition (sad faces);
LIHC	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.32	6.79	0.34	4.85e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.48	0.33	3.16e-10	Mean platelet volume;
LIHC	cis	rs1434579	0.897	rs12610672	chr19:44945571	G/T	cg15540054	chr19:45004280	ZNF180	-0.51	-7.19	-0.36	4.24e-12	Tuberculosis;
LIHC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.63	-0.53	1.48e-26	Platelet distribution width;
LIHC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.84	-0.3	1.21e-8	Type 2 diabetes;
LIHC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.54	-0.46	2.77e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9513627	0.915	rs80270035	chr13:100121784	C/T	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.69	0.38	1.53e-13	Height;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg12311636	chr6:118886798	C6orf204	0.51	5.89	0.3	9.24e-9	Diastolic blood pressure;
LIHC	cis	rs62179067	0.708	rs11885450	chr2:179936317	G/A	cg07532576	chr2:179544947	TTN	0.61	5.8	0.3	1.49e-8	Late-onset Alzheimer's disease;
LIHC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.86	13.43	0.59	2.47e-33	Height;
LIHC	cis	rs6088813	1.000	rs6088812	chr20:33974163	T/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.83	-0.3	1.25e-8	Height;
LIHC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.29	6.86	0.35	3.3e-11	Primary biliary cholangitis;
LIHC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg24112000	chr20:60950667	NA	-0.59	-8.79	-0.43	7.64e-17	Colorectal cancer;
LIHC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.73	-0.3	2.23e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg21229253	chr9:134406525	UCK1	-0.41	-6.16	-0.32	2.01e-9	Neuroblastoma;
LIHC	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.37	6.7	0.34	8.81e-11	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg01652190	chr22:50026171	C22orf34	-0.35	-7.83	-0.39	6.32e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.43	6.16	0.32	2.1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.19	-0.32	1.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs263063	0.506	rs12611002	chr19:5051655	C/T	cg18473234	chr19:5097819	KDM4B	0.65	7.7	0.38	1.44e-13	Periodontitis (CDC/AAP);
LIHC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg15534755	chr11:117069859	TAGLN	0.37	6.24	0.32	1.28e-9	Blood protein levels;
LIHC	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.33	-0.32	7.6e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.49	7.92	0.39	3.35e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.4	-6.61	-0.34	1.44e-10	Colorectal or endometrial cancer;
LIHC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	0.74	10.53	0.49	1.17e-22	Initial pursuit acceleration;
LIHC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.36	-7.15	-0.36	5.34e-12	Body mass index;
LIHC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.37e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06420487	chr17:61919686	SMARCD2	0.44	6.02	0.31	4.5e-9	Height;
LIHC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.76	11.06	0.51	1.66e-24	Vitamin D levels;
LIHC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.54	7.67	0.38	1.86e-13	Ulcerative colitis;
LIHC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg11861562	chr11:117069780	TAGLN	0.48	7.96	0.4	2.5e-14	Blood protein levels;
LIHC	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.53	0.33	2.33e-10	Height;
LIHC	cis	rs4728302	0.869	rs13233690	chr7:133587328	C/T	cg10665199	chr7:133106180	EXOC4	0.36	6.3	0.32	8.9e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02290350	chr8:58132656	NA	0.41	8.5	0.42	5.9e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs716804	0.740	rs12279861	chr11:10263225	C/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.11e-8	Neuroticism;
LIHC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.66	-9.21	-0.45	3.36e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg16583315	chr14:65563665	MAX	-0.4	-8.24	-0.41	3.64e-15	Obesity-related traits;
LIHC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.26e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.72	-10.13	-0.48	2.83e-21	Initial pursuit acceleration;
LIHC	cis	rs7911264	0.905	rs7918084	chr10:94429467	C/T	cg25093409	chr10:94429542	NA	0.39	5.94	0.31	6.84e-9	Inflammatory bowel disease;
LIHC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.48	-6.3	-0.32	9.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs807029	0.533	rs12571302	chr10:102742763	C/A	cg25179470	chr10:102756915	LZTS2	0.45	6.36	0.32	6.65e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.34	6.13	0.31	2.45e-9	Aortic root size;
LIHC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-5.87	-0.3	1.02e-8	Height;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg10962125	chr10:99094715	FRAT2	-0.39	-6.09	-0.31	2.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03045169	chr17:62503007	CCDC45;DDX5	0.41	6.61	0.34	1.48e-10	Cognitive function;
LIHC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.61	8.51	0.42	5.36e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg16736954	chr20:23401023	NAPB	0.7	8.15	0.4	6.87e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.12	12.8	0.57	6.57e-31	Vitiligo;
LIHC	cis	rs611744	0.870	rs381742	chr8:109142079	G/T	cg21045802	chr8:109455806	TTC35	0.49	8.36	0.41	1.56e-15	Dupuytren's disease;
LIHC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.48e-8	Axial length;
LIHC	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.66	-0.38	1.89e-13	Schizophrenia;
LIHC	cis	rs9322817	0.691	rs7769270	chr6:105230729	C/A	cg02098413	chr6:105308735	HACE1	-0.43	-7.85	-0.39	5.55e-14	Thyroid stimulating hormone;
LIHC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.61	7.14	0.36	5.63e-12	Lymphocyte counts;
LIHC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-6.38	-0.33	5.84e-10	Blood trace element (Zn levels);
LIHC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00149659	chr3:10157352	C3orf10	0.49	5.85	0.3	1.12e-8	Alzheimer's disease;
LIHC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.5	-8.6	-0.42	2.94e-16	White blood cell count;
LIHC	cis	rs8016982	0.589	rs4640110	chr14:81692191	A/G	cg01989461	chr14:81687754	GTF2A1	-0.47	-8.07	-0.4	1.22e-14	Schizophrenia;
LIHC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg21782813	chr7:2030301	MAD1L1	0.46	7.91	0.39	3.61e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg15848620	chr12:58087721	OS9	-0.58	-8.03	-0.4	1.54e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.64	-0.34	1.25e-10	Mean platelet volume;
LIHC	cis	rs1198430	0.925	rs1207124	chr1:23760408	A/G	cg13183780	chr1:23809682	ASAP3	-0.5	-7.43	-0.37	8.7e-13	Total cholesterol levels;
LIHC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.34	13.9	0.6	3.84e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.09	13.26	0.58	1.11e-32	Primary sclerosing cholangitis;
LIHC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-6.24	-0.32	1.3e-9	Morning vs. evening chronotype;
LIHC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-7.15	-0.36	5.45e-12	Electroencephalogram traits;
LIHC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.35	-0.37	1.46e-12	Breast cancer;
LIHC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.3	-5.76	-0.3	1.86e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg07134254	chr20:33865797	NA	0.5	5.71	0.3	2.4e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg12863693	chr15:85201151	NMB	0.4	5.8	0.3	1.47e-8	Schizophrenia;
LIHC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-5.91	-0.3	8.17e-9	Subjective well-being;
LIHC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.56	8.39	0.41	1.3e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg12310025	chr6:25882481	NA	-0.4	-6.02	-0.31	4.44e-9	Height;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.55	-6.53	-0.33	2.39e-10	Diastolic blood pressure;
LIHC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-14.12	-0.61	5.56e-36	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg15704280	chr7:45808275	SEPT13	0.58	6.07	0.31	3.4e-9	Axial length;
LIHC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg16586182	chr3:47516702	SCAP	-0.53	-9.5	-0.46	3.72e-19	Colorectal cancer;
LIHC	cis	rs61677309	0.638	rs7940554	chr11:118142930	C/T	cg06090739	chr11:118230722	UBE4A	0.3	5.72	0.3	2.31e-8	Lung cancer in ever smokers;
LIHC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-19.33	-0.72	8.85e-57	Coronary artery disease;
LIHC	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-12.18	-0.55	1.38e-28	Eye color traits;
LIHC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.41	-5.75	-0.3	1.93e-8	Cotinine glucuronidation;
LIHC	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.69	-10.23	-0.48	1.34e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs400736	0.740	rs225129	chr1:8094164	T/A	cg25007680	chr1:8021821	PARK7	0.63	9.92	0.47	1.46e-20	Response to antidepressants and depression;
LIHC	cis	rs16828019	0.852	rs12045171	chr1:41528805	G/A	cg03387723	chr1:41708464	SCMH1	-0.4	-6.82	-0.35	4.05e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.66	9.77	0.47	4.81e-20	Breast cancer;
LIHC	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.79	13.9	0.6	4.01e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg00280220	chr17:61926910	NA	0.44	7.15	0.36	5.34e-12	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs11098699	1.000	rs11940736	chr4:124171702	A/G	cg09941581	chr4:124220074	SPATA5	0.35	6.52	0.33	2.57e-10	Mosquito bite size;
LIHC	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.22	5.84	0.3	1.19e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.86	-0.35	3.29e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.06	-0.31	3.58e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.4	-0.37	1.07e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.55	-6.01	-0.31	4.74e-9	IgG glycosylation;
LIHC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	16.13	0.66	6.25e-44	Nonalcoholic fatty liver disease;
LIHC	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.35	-8.61	-0.42	2.7e-16	Breast cancer;
LIHC	cis	rs7106204	0.514	rs11027789	chr11:24260906	T/C	ch.11.24196551F	chr11:24239977	NA	0.75	9.4	0.45	7.88e-19	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.3	0.41	2.45e-15	IgG glycosylation;
LIHC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-6.1	-0.31	2.9e-9	Body mass index;
LIHC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.61	-11.11	-0.51	1.12e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.37	-6.1	-0.31	2.86e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.52	-8.42	-0.41	1.03e-15	Vitiligo;
LIHC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.79	-15.9	-0.65	5.27e-43	Refractive error;
LIHC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.64	10.67	0.5	4.01e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg19635926	chr16:89946313	TCF25	0.54	7.33	0.37	1.68e-12	Skin colour saturation;
LIHC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg16586182	chr3:47516702	SCAP	-0.5	-8.93	-0.43	2.66e-17	Colorectal cancer;
LIHC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.95	0.35	1.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.6	-10.24	-0.48	1.19e-21	HDL cholesterol;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.51	6.13	0.31	2.46e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16456337	chr5:112312164	DCP2	0.4	6.09	0.31	3.01e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.73	-0.47	6.67e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.76	-0.3	1.83e-8	Mortality in heart failure;
LIHC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.98	21.52	0.76	1.48e-65	Bone mineral density;
LIHC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-1.16	-11.12	-0.52	1.01e-24	Obesity-related traits;
LIHC	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-7.64	-0.38	2.14e-13	Body mass index;
LIHC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.66	-0.38	1.96e-13	Schizophrenia;
LIHC	cis	rs963731	0.579	rs6544195	chr2:39288486	A/G	cg04010122	chr2:39346883	SOS1	-0.66	-5.94	-0.31	6.92e-9	Corticobasal degeneration;
LIHC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg19635926	chr16:89946313	TCF25	0.5	6.47	0.33	3.38e-10	Skin colour saturation;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.14	0.55	1.93e-28	Prudent dietary pattern;
LIHC	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.76	13.21	0.58	1.83e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1551570	0.755	rs7401	chr19:10225777	A/G	cg16327482	chr19:10226339	EIF3G	0.49	8.42	0.41	1.06e-15	Narcolepsy;
LIHC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg23387056	chr11:14280742	SPON1	0.44	6.13	0.31	2.37e-9	Mitochondrial DNA levels;
LIHC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.49	0.42	6.44e-16	Lung cancer;
LIHC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg11812906	chr14:75593930	NEK9	-0.45	-7.22	-0.36	3.36e-12	IgG glycosylation;
LIHC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.65	7.92	0.39	3.4e-14	Iron status biomarkers;
LIHC	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.58	0.5	8.23e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	12.84	0.57	4.49e-31	Cognitive test performance;
LIHC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	8.15	0.4	7.08e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.59	11.28	0.52	2.66e-25	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg13409248	chr3:40428643	ENTPD3	0.41	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	cis	rs12618769	0.652	rs1516085	chr2:99232312	G/A	cg10123293	chr2:99228465	UNC50	0.37	5.78	0.3	1.68e-8	Bipolar disorder;
LIHC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.45	6.56	0.33	1.97e-10	Aortic root size;
LIHC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.51e-29	Menopause (age at onset);
LIHC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg17294928	chr15:75287854	SCAMP5	-0.51	-6.36	-0.33	6.43e-10	Lung cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23524709	chr19:4636345	NA	0.53	6.91	0.35	2.32e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg19302996	chr17:73780495	UNK	0.48	6.75	0.34	6.31e-11	White matter hyperintensity burden;
LIHC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.69	11.8	0.54	3.53e-27	Lymphocyte counts;
LIHC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4575098	0.681	rs11591206	chr1:161111363	C/T	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.4	7.29	0.37	2.13e-12	Monocyte percentage of white cells;
LIHC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.97	-15.09	-0.63	8.46e-40	Urate levels;
LIHC	cis	rs11779988	0.545	rs415840	chr8:17782134	C/T	cg01800426	chr8:17659068	MTUS1	-0.42	-5.96	-0.31	6.2e-9	Breast cancer;
LIHC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg23149560	chr2:74406255	MOBKL1B	-0.43	-6.18	-0.32	1.82e-9	Gestational age at birth (maternal effect);
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	7.98	0.4	2.17e-14	Height;
LIHC	cis	rs16828019	0.929	rs1032728	chr1:41679566	A/T	cg03387723	chr1:41708464	SCMH1	-0.44	-7.18	-0.36	4.42e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.77	13.3	0.58	7.81e-33	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs797680	0.856	rs12030549	chr1:93669218	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.33	-5.84	-0.3	1.23e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	1.02	21.13	0.75	5.31e-64	Height;
LIHC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg25039879	chr17:56429692	SUPT4H1	0.75	8.41	0.41	1.1e-15	Cognitive test performance;
LIHC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4668356	0.543	rs1989613	chr2:172034292	A/G	cg13882835	chr2:172017928	TLK1	-0.45	-6.03	-0.31	4.2e-9	Cognitive performance;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20623868	chr19:15666885	NA	0.42	6.17	0.32	1.91e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.85	-0.57	3.99e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.43	8.03	0.4	1.6e-14	Schizophrenia;
LIHC	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15664640	chr17:80829946	TBCD	0.64	10.03	0.48	6.52e-21	Breast cancer;
LIHC	cis	rs9500256	0.967	rs1012500	chr6:58304669	G/A	cg03371099	chr6:57305889	PRIM2	-0.4	-7.09	-0.36	7.65e-12	Eosinophilic esophagitis (pediatric);
LIHC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.47	6.67	0.34	1.02e-10	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.71	-10.72	-0.5	2.53e-23	Aortic root size;
LIHC	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.58	9.45	0.46	5.71e-19	Corneal astigmatism;
LIHC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg06565975	chr8:143823917	SLURP1	-0.4	-6.68	-0.34	9.6e-11	Urinary tract infection frequency;
LIHC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.44	8.34	0.41	1.82e-15	Schizophrenia;
LIHC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg06096015	chr1:231504339	EGLN1	-0.39	-7.08	-0.36	8.42e-12	Red blood cell count;
LIHC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg19318889	chr4:1322082	MAEA	0.43	5.95	0.31	6.65e-9	Obesity-related traits;
LIHC	cis	rs13161895	1.000	rs394616	chr5:179418134	T/G	cg06664874	chr5:179499304	RNF130	0.57	7.03	0.36	1.16e-11	LDL cholesterol;
LIHC	trans	rs1814175	0.646	rs10839335	chr11:49715265	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-20.66	-0.75	4.12e-62	Height;
LIHC	cis	rs11888559	0.655	rs6435172	chr2:203953234	G/C	cg24605529	chr2:203879461	NBEAL1	0.75	5.78	0.3	1.66e-8	Height;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.05	0.55	4.17e-28	Prudent dietary pattern;
LIHC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.73	-9.22	-0.45	3.12e-18	Gut microbiome composition (summer);
LIHC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.75	13.78	0.6	1.12e-34	Iron status biomarkers;
LIHC	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.89	14.94	0.63	3.3e-39	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs72843506	0.656	rs73984573	chr17:19985340	A/G	cg12065943	chr17:19881925	AKAP10	-0.33	-5.76	-0.3	1.9e-8	Schizophrenia;
LIHC	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7188697	0.922	rs37051	chr16:58558102	C/T	cg02549819	chr16:58548995	SETD6	-0.45	-7.11	-0.36	6.73e-12	QT interval;
LIHC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	8.24	0.41	3.74e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.62	-7.16	-0.36	5.07e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-10.82	-0.51	1.12e-23	Chronic sinus infection;
LIHC	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg12826209	chr6:26865740	GUSBL1	0.59	5.83	0.3	1.28e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg21157115	chr9:33001303	APTX	-0.57	-6.33	-0.32	7.53e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.65	0.38	2.13e-13	Mean platelet volume;
LIHC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg15711740	chr2:61764176	XPO1	0.42	5.78	0.3	1.69e-8	Tuberculosis;
LIHC	trans	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg01134436	chr17:81009848	B3GNTL1	0.73	6.11	0.31	2.67e-9	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.64	0.42	2.12e-16	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15779458	chr2:233415951	TIGD1;EIF4E2	0.46	6.6	0.34	1.52e-10	Cognitive function;
LIHC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.65	-0.5	4.68e-23	Bipolar disorder and schizophrenia;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg27539721	chr12:102133366	SYCP3	-0.47	-6.43	-0.33	4.33e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.31	-17.08	-0.68	1.01e-47	Diabetic kidney disease;
LIHC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	8.93	0.43	2.62e-17	Platelet count;
LIHC	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg00142150	chr22:38071001	LGALS1	0.44	7.48	0.38	6.14e-13	Fat distribution (HIV);
LIHC	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.57	-10.85	-0.51	9.37e-24	Neurofibrillary tangles;
LIHC	cis	rs611744	0.967	rs584716	chr8:109178634	A/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	6.5	0.33	2.78e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.06	14.13	0.61	5.04e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03705947	chr1:68152081	GADD45A	0.42	6.7	0.34	8.5e-11	Pancreatic cancer;
LIHC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.07	0.31	3.46e-9	Schizophrenia;
LIHC	cis	rs8014671	0.553	rs11628785	chr14:70908217	G/A	cg25576086	chr14:70833871	SYNJ2BP	-0.46	-7.15	-0.36	5.34e-12	Prostate cancer;
LIHC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.41	-5.87	-0.3	1.03e-8	Blood protein levels;
LIHC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.89	-17.97	-0.7	2.53e-51	Height;
LIHC	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.73	0.47	6.3e-20	Corneal astigmatism;
LIHC	cis	rs17152411	1.000	rs10901837	chr10:126614618	G/A	cg07906193	chr10:126599966	NA	0.47	7.36	0.37	1.34e-12	Height;
LIHC	trans	rs4714291	0.862	rs2984445	chr6:40069935	C/T	cg02267698	chr19:7991119	CTXN1	-0.4	-6.78	-0.34	5.43e-11	Strep throat;
LIHC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg16479474	chr6:28041457	NA	0.46	6.44	0.33	4.04e-10	Depression;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.47	-6.41	-0.33	4.92e-10	Total body bone mineral density;
LIHC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-15.49	-0.64	2.2e-41	Headache;
LIHC	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.51	9.68	0.46	9.91e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.73	-7.29	-0.37	2.18e-12	Vitiligo;
LIHC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.33	6.15	0.32	2.16e-9	Mean corpuscular volume;
LIHC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.93	16.4	0.66	5.29e-45	Intelligence (multi-trait analysis);
LIHC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg04025307	chr7:1156635	C7orf50	0.46	6.19	0.32	1.71e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs965469	1.000	rs6037538	chr20:3282978	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.71	-0.34	7.86e-11	IFN-related cytopenia;
LIHC	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.59	-5.97	-0.31	5.8e-9	Lymphocyte counts;
LIHC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.45	6.91	0.35	2.39e-11	Diastolic blood pressure;
LIHC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	6.01	0.31	4.75e-9	Iron status biomarkers;
LIHC	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg19000871	chr14:103996768	TRMT61A	-0.57	-9.06	-0.44	1.02e-17	Coronary artery disease;
LIHC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.18	-0.52	6.26e-25	Diastolic blood pressure;
LIHC	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg01364799	chr7:75623366	TMEM120A	0.52	7.83	0.39	6.35e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.65	0.38	2.03e-13	Triglyceride levels;
LIHC	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.17	27.25	0.83	1.06e-87	Schizophrenia;
LIHC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.63	11.3	0.52	2.2e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-6.79	-0.34	5.1e-11	Electroencephalogram traits;
LIHC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02886208	chr11:14281011	SPON1	0.58	8.52	0.42	5.24e-16	Mitochondrial DNA levels;
LIHC	cis	rs11888559	0.655	rs4675316	chr2:204019331	T/C	cg24605529	chr2:203879461	NBEAL1	0.77	5.85	0.3	1.16e-8	Height;
LIHC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.7e-9	Blood metabolite levels;
LIHC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-8.53	-0.42	4.7e-16	Glaucoma (primary open-angle);
LIHC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg12365402	chr11:9010492	NRIP3	-0.23	-5.88	-0.3	9.54e-9	Hemoglobin concentration;
LIHC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.55	-7.57	-0.38	3.47e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.39	-7.52	-0.38	4.91e-13	Testicular germ cell tumor;
LIHC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.34	0.32	7.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.52e-9	Vitamin D levels;
LIHC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.7	-8.71	-0.43	1.31e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg16586182	chr3:47516702	SCAP	-0.4	-6.7	-0.34	8.61e-11	Birth weight;
LIHC	cis	rs797680	0.856	rs682514	chr1:93719430	A/C	cg15093775	chr1:93646470	TMED5;CCDC18	0.34	5.96	0.31	6.39e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg00495681	chr13:53174319	NA	0.38	5.77	0.3	1.75e-8	Lewy body disease;
LIHC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg00529422	chr1:16285251	ZBTB17	0.35	6.72	0.34	7.46e-11	Systolic blood pressure;
LIHC	cis	rs6586163	1.000	rs6586165	chr10:90755056	T/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-8.36	-0.41	1.64e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.12	0.44	6.46e-18	Platelet count;
LIHC	cis	rs75908454	1.000	rs78088663	chr6:169844298	C/T	cg19338460	chr6:170058176	WDR27	-0.84	-7.39	-0.37	1.15e-12	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.84	0.63	8.42e-39	Prudent dietary pattern;
LIHC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.44	5.97	0.31	5.92e-9	Life satisfaction;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.61	11.12	0.52	9.99e-25	Schizophrenia;
LIHC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.71	0.34	7.94e-11	Lung cancer in ever smokers;
LIHC	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.69	-8.57	-0.42	3.65e-16	Gut microbiome composition (summer);
LIHC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.49	5.85	0.3	1.18e-8	Schizophrenia;
LIHC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.4	-8.11	-0.4	9.08e-15	Urinary metabolites;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.72	-0.34	7.74e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.86	0.43	4.51e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	8.57	0.42	3.5e-16	Hip circumference adjusted for BMI;
LIHC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.81	7.14	0.36	5.64e-12	Arsenic metabolism;
LIHC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.56	-11.21	-0.52	4.68e-25	Tonsillectomy;
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.75	11.07	0.51	1.51e-24	Menarche (age at onset);
LIHC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg21724239	chr8:58056113	NA	0.44	5.87	0.3	1.02e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7188697	0.922	rs2243463	chr16:58571189	T/C	cg02549819	chr16:58548995	SETD6	-0.45	-7.18	-0.36	4.43e-12	QT interval;
LIHC	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.24	6.4	0.33	5.17e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.71	-0.38	1.41e-13	Coronary artery disease;
LIHC	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg10241871	chr14:102965420	TECPR2	-0.48	-7.59	-0.38	3.13e-13	Blood protein levels;
LIHC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.73	-0.34	6.95e-11	Metabolite levels;
LIHC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.47	-7.82	-0.39	6.57e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.86	0.35	3.14e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	0.59	10.09	0.48	4.07e-21	Testicular germ cell tumor;
LIHC	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	1.03	20.93	0.75	3.47e-63	Breast cancer;
LIHC	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg00529422	chr1:16285251	ZBTB17	0.34	6.41	0.33	4.83e-10	Systolic blood pressure;
LIHC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.56	0.42	3.99e-16	Height;
LIHC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.72	8.3	0.41	2.5e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.53	-8.65	-0.42	2.02e-16	Body mass index;
LIHC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.52	8.31	0.41	2.22e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.69	0.34	8.89e-11	Renal cell carcinoma;
LIHC	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.33	-0.41	1.93e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.16e-11	Ileal carcinoids;
LIHC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-10.53	-0.49	1.21e-22	Body mass index;
LIHC	cis	rs1789	0.786	rs6449161	chr4:15692954	A/G	cg24225360	chr4:15471699	CC2D2A	-0.39	-5.95	-0.31	6.5e-9	Blood protein levels;
LIHC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.87	0.35	3.12e-11	Red blood cell count;
LIHC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.99	11.35	0.52	1.46e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.28	6.03	0.31	4.19e-9	Pulmonary function;
LIHC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.17	0.32	1.92e-9	Heart rate;
LIHC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg05941027	chr17:61774174	LIMD2	-0.34	-7.12	-0.36	6.23e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg08668510	chr10:1095578	IDI1	0.66	6.47	0.33	3.44e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs4596713	0.507	rs10115283	chr9:71801162	T/G	cg16512924	chr15:28394682	HERC2	0.38	6.17	0.32	1.94e-9	Headache;
LIHC	cis	rs11212737	0.818	rs2624135	chr11:108513693	T/G	cg22776369	chr11:108536276	DDX10	0.37	6.19	0.32	1.69e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.48	7.74	0.39	1.17e-13	Lung cancer;
LIHC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg03859395	chr2:55845619	SMEK2	-0.5	-8.21	-0.41	4.57e-15	Metabolic syndrome;
LIHC	cis	rs7106204	0.748	rs7947388	chr11:24224903	A/G	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.04e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	0.87	14.32	0.61	8.96e-37	Left atrial antero-posterior diameter;
LIHC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.67	9.94	0.47	1.32e-20	Mosquito bite size;
LIHC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.55	-8.3	-0.41	2.45e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.69	-9.29	-0.45	1.84e-18	Calcium levels;
LIHC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.21	0.36	3.61e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2257205	0.667	rs7209498	chr17:56680642	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-6.69	-0.34	8.94e-11	Pancreatic cancer;
LIHC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.83e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	1.17	9.75	0.47	5.68e-20	Gut microbiota (bacterial taxa);
LIHC	trans	rs12752401	0.717	rs12751268	chr1:103002533	C/T	cg17681729	chr19:740608	PALM	0.45	6.35	0.32	6.67e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.34	-8.46	-0.42	7.92e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg11057378	chr10:81107060	PPIF	0.36	5.93	0.31	7.51e-9	Height;
LIHC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.86	0.67	7.3e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.48	6.15	0.32	2.17e-9	Initial pursuit acceleration;
LIHC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg13409248	chr3:40428643	ENTPD3	-0.43	-7.27	-0.37	2.47e-12	Renal cell carcinoma;
LIHC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-13.69	-0.59	2.61e-34	Height;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.62	7.9	0.39	3.77e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs17152411	1.000	rs11245440	chr10:126634572	C/T	cg07906193	chr10:126599966	NA	0.47	7.05	0.36	9.93e-12	Height;
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg21294424	chr19:58662284	ZNF329	0.92	7.09	0.36	7.8e-12	Cholesterol, total;
LIHC	cis	rs7534824	0.625	rs17449022	chr1:101442367	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	7.24	0.36	2.99e-12	Refractive astigmatism;
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.51	8.06	0.4	1.31e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.76	12.64	0.56	2.58e-30	Menarche (age at onset);
LIHC	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.62	10.38	0.49	3.89e-22	Recombination rate (males);
LIHC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg15123519	chr2:136567270	LCT	-0.36	-5.77	-0.3	1.76e-8	Corneal structure;
LIHC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg03013999	chr17:37608204	MED1	-0.36	-6.07	-0.31	3.33e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.61	10.23	0.48	1.37e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.69	-6.23	-0.32	1.38e-9	Blood protein levels;
LIHC	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg22842854	chr12:123319900	HIP1R	-0.59	-6.9	-0.35	2.48e-11	Schizophrenia;
LIHC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg17750252	chr2:136567154	LCT	-0.34	-6.31	-0.32	8.56e-10	Mosquito bite size;
LIHC	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.41	7.41	0.37	1e-12	Glaucoma;
LIHC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21467203	chr3:49911342	NA	-0.52	-9.03	-0.44	1.29e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs903552	0.736	rs2412008	chr15:102006841	C/T	cg25677261	chr15:102009856	PCSK6	-0.51	-6.86	-0.35	3.2e-11	Diabetic kidney disease;
LIHC	cis	rs4934494	0.768	rs58163515	chr10:91397564	T/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.68	-0.34	9.61e-11	Red blood cell count;
LIHC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.56	8.09	0.4	1.03e-14	Height;
LIHC	cis	rs5770917	1.000	rs3213445	chr22:51015838	T/C	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.44	-6.4	-0.33	5.07e-10	Narcolepsy;
LIHC	cis	rs6808694	0.568	rs6550401	chr3:20219694	A/C	cg00235661	chr3:20228976	SGOL1	0.36	6.35	0.32	6.99e-10	Ischemic stroke;
LIHC	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.66	9.81	0.47	3.41e-20	Lymphocyte percentage of white cells;
LIHC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg14092571	chr14:90743983	NA	0.4	6.25	0.32	1.19e-9	Mortality in heart failure;
LIHC	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.48	7.04	0.36	1.04e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.5	-0.33	2.91e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg16275483	chr1:110013120	SYPL2	-0.5	-6.28	-0.32	1.03e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg00536792	chr6:53530503	KLHL31	-1.01	-7.33	-0.37	1.72e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.3e-14	Height;
LIHC	cis	rs3790844	0.876	rs3790847	chr1:200006217	G/T	cg07208853	chr1:200005219	NR5A2	0.4	8.71	0.43	1.3e-16	Pancreatic cancer;
LIHC	cis	rs10744422	0.800	rs1696320	chr12:123269814	A/G	cg25930673	chr12:123319894	HIP1R	-0.81	-10.05	-0.48	5.43e-21	Schizophrenia;
LIHC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.32	0.41	2.13e-15	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.36	-0.33	6.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07491203	chr7:155089714	INSIG1	-0.44	-6.81	-0.35	4.51e-11	Cognitive function;
LIHC	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.23	-0.64	2.38e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.51	6.35	0.32	6.77e-10	Bipolar disorder;
LIHC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.22	-0.45	3.09e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.44	0.37	8.19e-13	Prudent dietary pattern;
LIHC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.86	-0.43	4.45e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	7.61	0.38	2.62e-13	Response to antipsychotic treatment;
LIHC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.51	7.7	0.38	1.51e-13	Cognitive function;
LIHC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.49	-0.56	9.73e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.57	9.57	0.46	2.15e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.86	13.15	0.58	2.98e-32	Obesity-related traits;
LIHC	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.78	-0.3	1.69e-8	Resting heart rate;
LIHC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg13152130	chr6:118910203	C6orf204	-0.65	-7.34	-0.37	1.61e-12	Diastolic blood pressure;
LIHC	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.69	11.35	0.52	1.55e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.51	-0.42	5.73e-16	Schizophrenia;
LIHC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.7	10.49	0.49	1.72e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21864845	chr1:1208426	UBE2J2	0.41	6.69	0.34	8.92e-11	Cognitive function;
LIHC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	9.39	0.45	8.54e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg21395723	chr22:39101663	GTPBP1	0.35	5.79	0.3	1.61e-8	Menopause (age at onset);
LIHC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	6.51	0.33	2.7e-10	Parkinson's disease;
LIHC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-8.93	-0.43	2.6e-17	Asthma;
LIHC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.25	-0.55	7.24e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.44	-7.73	-0.39	1.2e-13	Schizophrenia;
LIHC	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.57	7.02	0.35	1.18e-11	Mean platelet volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18053345	chr5:37370947	NUP155	0.45	6.63	0.34	1.33e-10	Cognitive function;
LIHC	cis	rs62179067	0.708	rs17363057	chr2:179936172	A/C	cg07532576	chr2:179544947	TTN	0.62	5.8	0.3	1.5e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.57	9.41	0.45	7.47e-19	Colorectal cancer;
LIHC	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.64	-0.5	5.15e-23	Eye color traits;
LIHC	trans	rs783540	0.835	rs8030185	chr15:83391537	G/A	cg18393722	chr15:85113863	UBE2QP1	0.37	6.47	0.33	3.34e-10	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.62	7.85	0.39	5.52e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs12928939	0.727	rs8053623	chr16:71647529	A/G	cg03805757	chr16:71968109	PKD1L3	-0.54	-6.3	-0.32	8.95e-10	Post bronchodilator FEV1;
LIHC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg06640241	chr16:89574553	SPG7	0.66	10.45	0.49	2.34e-22	Multiple myeloma (IgH translocation);
LIHC	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg26939375	chr7:64535504	NA	0.43	6.82	0.35	4.11e-11	Aortic root size;
LIHC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg14132834	chr19:41945861	ATP5SL	-0.39	-5.76	-0.3	1.86e-8	Height;
LIHC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg18107078	chr1:162760321	HSD17B7	0.4	6.41	0.33	4.89e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs611744	0.870	rs57723916	chr8:109191433	A/T	cg18478394	chr8:109455254	TTC35	0.39	6.8	0.35	4.67e-11	Dupuytren's disease;
LIHC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.94	-0.44	2.52e-17	Skin colour saturation;
LIHC	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.55	0.5	1e-22	Hypertriglyceridemia;
LIHC	cis	rs2737618	0.674	rs2258280	chr1:200097648	G/A	cg21825944	chr1:200113062	NR5A2	-0.45	-7.69	-0.38	1.56e-13	Uric acid levels;
LIHC	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.2	-0.32	1.62e-9	Tuberculosis;
LIHC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	6.43	0.33	4.24e-10	Red cell distribution width;
LIHC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.61	0.38	2.76e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.02	0.31	4.58e-9	Menopause (age at onset);
LIHC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.41	0.56	1.91e-29	Cognitive test performance;
LIHC	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg01843034	chr6:37503916	NA	-0.47	-7.37	-0.37	1.33e-12	Cognitive performance;
LIHC	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.55	5.9	0.3	8.61e-9	Hip geometry;
LIHC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg24826892	chr11:71159390	DHCR7	-0.51	-6.7	-0.34	8.75e-11	Vitamin D levels;
LIHC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.75	0.34	6.39e-11	Lung cancer in ever smokers;
LIHC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.76	13.88	0.6	4.65e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.45	-5.94	-0.31	7.19e-9	Psoriasis;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg18306943	chr3:40428807	ENTPD3	-0.44	-7.82	-0.39	6.78e-14	Renal cell carcinoma;
LIHC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg03037974	chr15:76606532	NA	0.74	14.64	0.62	5.01e-38	Blood metabolite levels;
LIHC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg19318889	chr4:1322082	MAEA	0.44	5.86	0.3	1.07e-8	Obesity-related traits;
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.79	-9.59	-0.46	1.84e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.24e-9	Bipolar disorder;
LIHC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg05697976	chr12:29376483	FAR2	0.31	6.24	0.32	1.33e-9	QT interval;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg00091569	chr3:40428383	ENTPD3	0.39	6.57	0.33	1.87e-10	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	ch.3.96438232F	chr3:94955542	NA	-0.37	-6.26	-0.32	1.16e-9	Pancreatic cancer;
LIHC	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-0.86	-14.41	-0.61	4.08e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	11.13	0.52	9.21e-25	HIV-1 control;
LIHC	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.2	-0.36	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.5	-0.33	2.9e-10	Bipolar disorder;
LIHC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.44	-6.21	-0.32	1.55e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.48e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17467752	chr17:38218738	THRA	-0.54	-9.29	-0.45	1.86e-18	Myeloid white cell count;
LIHC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.13	0.58	3.52e-32	Cognitive test performance;
LIHC	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.51	-0.49	1.47e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.99	0.63	2.13e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10861342	1.000	rs1444608	chr12:105559157	A/G	cg23923672	chr12:105501055	KIAA1033	0.65	7.57	0.38	3.52e-13	IgG glycosylation;
LIHC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg15691649	chr6:25882328	NA	-0.47	-6.28	-0.32	1.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	1.03	7.36	0.37	1.36e-12	Arsenic metabolism;
LIHC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.39	6.38	0.33	5.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72627123	0.867	rs74492048	chr14:74439895	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.48	0.42	6.78e-16	Morning vs. evening chronotype;
LIHC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.52	7.09	0.36	7.61e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-7.4	-0.37	1.1e-12	Psoriasis;
LIHC	trans	rs10411161	1.000	rs72626249	chr19:52364875	C/T	cg22319618	chr22:45562946	NUP50	-0.54	-7.23	-0.36	3.26e-12	Breast cancer;
LIHC	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.84	11.07	0.51	1.52e-24	Menopause (age at onset);
LIHC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.87	10.81	0.5	1.21e-23	Bladder cancer;
LIHC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.51	9.64	0.46	1.3e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.78	-0.5	1.56e-23	Inflammatory bowel disease;
LIHC	cis	rs965469	0.779	rs6037544	chr20:3290570	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs2637266	1.000	rs755824	chr10:78381348	A/G	cg18941641	chr10:78392320	NA	0.3	6.53	0.33	2.43e-10	Pulmonary function;
LIHC	cis	rs6466055	0.777	rs3801282	chr7:104881530	A/G	cg04380332	chr7:105027541	SRPK2	0.36	6.87	0.35	3.07e-11	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-7.14	-0.36	5.56e-12	Schizophrenia;
LIHC	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg00792783	chr2:198669748	PLCL1	0.45	6.47	0.33	3.45e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.4	6.79	0.34	5e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg10551016	chr22:41252963	ST13;XPNPEP3	-0.45	-6.47	-0.33	3.42e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg03805757	chr16:71968109	PKD1L3	-0.51	-5.84	-0.3	1.22e-8	Post bronchodilator FEV1;
LIHC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.67	-0.57	1.95e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.49	7.33	0.37	1.66e-12	Blood pressure (smoking interaction);
LIHC	cis	rs7551222	0.749	rs6594019	chr1:204568610	T/C	cg20240347	chr1:204465584	NA	-0.31	-6.26	-0.32	1.18e-9	Schizophrenia;
LIHC	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg02795151	chr17:7402630	POLR2A	-0.54	-6.81	-0.35	4.38e-11	Androgen levels;
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.94	-14.12	-0.61	5.32e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.78	-8.49	-0.42	6.46e-16	Putamen volume;
LIHC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.64	-9.06	-0.44	9.93e-18	Blood metabolite levels;
LIHC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.84	-0.39	5.87e-14	Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.51e-21	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.6	8.99	0.44	1.67e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	4.12e-15	Schizophrenia;
LIHC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	11.06	0.51	1.58e-24	Platelet count;
LIHC	trans	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg26939375	chr7:64535504	NA	-0.42	-6.84	-0.35	3.73e-11	Aortic root size;
LIHC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.42	0.45	7.01e-19	Melanoma;
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.73	-0.3	2.25e-8	Total body bone mineral density;
LIHC	trans	rs9914544	0.545	rs2386404	chr17:18769349	T/C	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.79	-0.34	5.11e-11	Educational attainment (years of education);
LIHC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.06	16.62	0.67	6.67e-46	Breast cancer;
LIHC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	11.16	0.52	7.29e-25	Lung cancer in ever smokers;
LIHC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.07	0.4	1.24e-14	Motion sickness;
LIHC	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.33	-6.41	-0.33	4.73e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.4	-0.33	5.13e-10	Height;
LIHC	cis	rs600626	0.636	rs10899109	chr11:75451201	G/A	cg24262691	chr11:75473276	NA	0.4	5.95	0.31	6.74e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.48	0.59	1.62e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs7759633	0.800	rs41272110	chr6:161006172	T/G	cg06341590	chr4:57624431	NA	-0.59	-6.53	-0.33	2.35e-10	Triglycerides;
LIHC	cis	rs11671005	0.610	rs11669345	chr19:59062259	C/T	cg25952890	chr19:58913133	NA	0.67	6.86	0.35	3.3e-11	Mean platelet volume;
LIHC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.58	0.46	2.02e-19	Alzheimer's disease;
LIHC	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.05e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-6.63	-0.34	1.33e-10	IgG glycosylation;
LIHC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.48	7.59	0.38	3.06e-13	Schizophrenia;
LIHC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.37	-0.37	1.3e-12	Bipolar disorder;
LIHC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	0.76	8.22	0.41	4.36e-15	Testicular germ cell tumor;
LIHC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.38	-5.87	-0.3	1.01e-8	Mean platelet volume;
LIHC	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.48	7.01	0.35	1.26e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.57	9.89	0.47	1.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg03874509	chr1:107600012	PRMT6	-0.71	-10.77	-0.5	1.76e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg24693881	chr1:107596107	NA	-0.47	-7.73	-0.39	1.24e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.7	8.97	0.44	2.06e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs5753037	0.702	rs36576	chr22:30206291	C/A	cg01021169	chr22:30184971	ASCC2	-0.35	-6.67	-0.34	1.04e-10	Type 1 diabetes;
LIHC	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.48	0.38	6.13e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg10381502	chr11:71823885	C11orf51	-1.02	-8.51	-0.42	5.38e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.47	-0.33	3.43e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.52	8.55	0.42	4.15e-16	Alzheimer's disease;
LIHC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg12160578	chr15:63334699	TPM1	-0.6	-8.6	-0.42	2.96e-16	Platelet count;
LIHC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.88	13.26	0.58	1.1e-32	Vitamin D levels;
LIHC	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	10.64	0.5	5.14e-23	Lung cancer in ever smokers;
LIHC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.81	0.47	3.53e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.4	-0.33	5.09e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.48	-7.92	-0.39	3.41e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs12079745	0.623	rs12091844	chr1:169433273	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.7	-6.66	-0.34	1.09e-10	QT interval;
LIHC	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.01	17.61	0.69	7.65e-50	Triglycerides;
LIHC	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.65	-8.94	-0.44	2.54e-17	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.57	0.42	3.57e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg03721293	chr16:90014378	DEF8	0.39	6.59	0.34	1.63e-10	Skin colour saturation;
LIHC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg18016565	chr1:150552671	MCL1	0.55	10.74	0.5	2.14e-23	Tonsillectomy;
LIHC	cis	rs11673344	0.864	rs55792845	chr19:37498685	T/C	cg27390819	chr19:37464633	NA	-0.51	-6.21	-0.32	1.57e-9	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	6.32	0.32	8.08e-10	Renal cell carcinoma;
LIHC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21467203	chr3:49911342	NA	0.45	8.27	0.41	3.02e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.46	9.09	0.44	7.98e-18	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg01864069	chr14:103024347	NA	-0.57	-9.52	-0.46	3.36e-19	Platelet count;
LIHC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.44	7.06	0.36	9.58e-12	Total body bone mineral density;
LIHC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg05272587	chr13:111038400	COL4A2	0.32	6.73	0.34	7.37e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg23091122	chr1:110024289	SYPL2	-0.44	-5.78	-0.3	1.7e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg16736954	chr20:23401023	NAPB	0.73	8.63	0.42	2.36e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.72	8.08	0.4	1.15e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.32	6.67	0.34	1.01e-10	Schizophrenia;
LIHC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.84	-0.3	1.18e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.88	-0.39	4.53e-14	Coronary artery disease;
LIHC	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	12.4	0.56	2.07e-29	Coronary artery disease;
LIHC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.66	-9.79	-0.47	4.16e-20	Menopause (age at onset);
LIHC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.15e-11	Height;
LIHC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg20195005	chr22:42527684	CYP2D6	0.31	5.83	0.3	1.29e-8	Birth weight;
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.92	0.35	2.28e-11	Renal cell carcinoma;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.21	-0.32	1.52e-9	Schizophrenia;
LIHC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.6	7.2	0.36	3.87e-12	Cognitive function;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11283100	chr3:138634282	NA	0.48	6.56	0.33	1.94e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg18270830	chr10:32634957	EPC1	0.53	6.44	0.33	4.04e-10	Sexual dysfunction (female);
LIHC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	0.97	7.19	0.36	4.02e-12	Diabetic retinopathy;
LIHC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.59	-7.46	-0.37	7.01e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	6.27	0.32	1.08e-9	Type 2 diabetes;
LIHC	cis	rs57244997	0.685	rs2226770	chr6:162447251	C/T	cg17173639	chr6:162384350	PARK2	0.6	7.45	0.37	7.65e-13	Mosquito bite size;
LIHC	cis	rs10792665	0.575	rs3793983	chr11:82554176	T/A	cg24227371	chr11:82718527	RAB30	-0.25	-5.88	-0.3	1e-8	Obesity-related traits;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.63	-9.29	-0.45	1.91e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg01557791	chr16:72042693	DHODH	0.39	6.62	0.34	1.42e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.52	7.07	0.36	9e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs74544699	1.000	rs499141	chr4:74768970	A/C	cg02530824	chr4:74847766	PF4	0.62	6.49	0.33	3.11e-10	Growth-regulated protein alpha levels;
LIHC	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.52	-12.22	-0.55	9.94e-29	White blood cell count (basophil);
LIHC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.05	0.44	1.07e-17	Electroencephalogram traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26301639	chr3:93781795	NSUN3;DHFRL1	0.43	6.15	0.32	2.21e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16346588	chr10:242978	ZMYND11	0.38	5.85	0.3	1.15e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.11e-13	Lung cancer;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.04e-14	Height;
LIHC	cis	rs6782228	0.675	rs9841987	chr3:128385142	G/T	cg16766828	chr3:128327626	NA	-0.43	-6.77	-0.34	5.68e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs860295	1.000	rs10908482	chr1:155713873	T/C	cg02153340	chr1:155202674	NA	-0.31	-5.79	-0.3	1.56e-8	Body mass index;
LIHC	cis	rs12980942	0.935	rs12980480	chr19:41804655	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.18	0.32	1.8e-9	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.39	6.07	0.31	3.4e-9	Height;
LIHC	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-0.74	-10.55	-0.5	1e-22	White blood cell count;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.76	9.54	0.46	2.75e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs963731	0.579	rs12712630	chr2:39284582	A/G	cg04010122	chr2:39346883	SOS1	-0.7	-6.19	-0.32	1.71e-9	Corticobasal degeneration;
LIHC	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	6.68	0.34	9.76e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs8032158	0.502	rs2136385	chr15:56235245	C/A	cg24530489	chr15:56299380	NA	0.4	5.82	0.3	1.37e-8	Keloid;
LIHC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.58	-9.05	-0.44	1.1e-17	Serum sulfate level;
LIHC	trans	rs783540	0.521	rs28719490	chr15:83389440	A/G	cg18393722	chr15:85113863	UBE2QP1	0.46	6.62	0.34	1.42e-10	Schizophrenia;
LIHC	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.6	6.94	0.35	2e-11	Height;
LIHC	trans	rs11958034	0.539	rs7736963	chr5:18925343	T/G	cg08248751	chr6:44043192	NA	-0.34	-6.06	-0.31	3.61e-9	Mitochondrial DNA levels;
LIHC	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg10483660	chr13:112241077	NA	-0.23	-6.09	-0.31	3.03e-9	Hepatitis;
LIHC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg06466757	chr4:1255808	NA	0.34	5.73	0.3	2.16e-8	Obesity-related traits;
LIHC	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.89	0.3	9.23e-9	Platelet distribution width;
LIHC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.34	0.41	1.84e-15	Birth weight;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg02951695	chr10:134400351	INPP5A	0.43	6.25	0.32	1.24e-9	Longevity;
LIHC	trans	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05926928	chr17:57297772	GDPD1	-0.41	-6.14	-0.32	2.32e-9	Schizophrenia;
LIHC	cis	rs8056893	0.879	rs3961282	chr16:68365157	A/G	cg02226672	chr16:68398533	SMPD3	0.46	6.26	0.32	1.14e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-8.47	-0.42	7.14e-16	Gut microbiome composition (summer);
LIHC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg16586182	chr3:47516702	SCAP	0.45	7.75	0.39	1.04e-13	Colorectal cancer;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.72	8.08	0.4	1.15e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.32	7.48e-10	Ulcerative colitis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07920855	chr1:185286635	IVNS1ABP	-0.45	-6.56	-0.33	2e-10	Cognitive function;
LIHC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	0.82	6.83	0.35	3.94e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.65	0.34	1.19e-10	Mean corpuscular volume;
LIHC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg03037974	chr15:76606532	NA	0.76	14.77	0.62	1.62e-38	Blood metabolite levels;
LIHC	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.68	11.01	0.51	2.43e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.67	11.43	0.53	7.51e-26	Lymphocyte counts;
LIHC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg17771515	chr6:154831774	CNKSR3	0.56	5.85	0.3	1.15e-8	Lipoprotein (a) levels;
LIHC	cis	rs4742903	0.870	rs1354894	chr9:106975237	G/A	cg14250997	chr9:106856677	SMC2	0.35	5.83	0.3	1.31e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs116248771	0.739	rs1051109	chr3:158415344	T/C	cg16708174	chr3:158430962	RARRES1	0.49	6.48	0.33	3.25e-10	diarrhoeal disease at age 2;
LIHC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.63	0.38	2.35e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1814175	0.588	rs34449937	chr11:49756013	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.37	-0.74	5.91e-61	Height;
LIHC	cis	rs7539624	0.588	rs7555491	chr1:223894889	C/T	cg07395969	chr1:223900822	CAPN2	-0.48	-5.79	-0.3	1.59e-8	Schizophrenia;
LIHC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.76	0.5	1.86e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs9649465	0.935	rs1506641	chr7:123390143	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.04	-0.4	1.47e-14	Migraine;
LIHC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg27523141	chr10:43048294	ZNF37B	-0.37	-6.4	-0.33	5.12e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04530015	chr2:215796436	ABCA12	-0.39	-6.36	-0.33	6.61e-10	Neuroblastoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24222377	chr18:55254128	FECH	0.46	6.38	0.33	5.81e-10	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.35	-0.37	1.45e-12	Bipolar disorder;
LIHC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg26566898	chr11:117069891	TAGLN	0.43	6.75	0.34	6.47e-11	Blood protein levels;
LIHC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.63	-10.74	-0.5	2.21e-23	Multiple sclerosis;
LIHC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.61	9.27	0.45	2.2e-18	Longevity;
LIHC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	8.49	0.42	6.29e-16	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00587304	chr3:172468157	NA	0.41	6.55	0.33	2.13e-10	Cognitive function;
LIHC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg16970926	chr12:29381810	FAR2	0.29	6.01	0.31	4.78e-9	QT interval;
LIHC	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg07451762	chr16:28383216	NA	0.33	6.13	0.31	2.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.66	7.73	0.39	1.24e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.44	-7.5	-0.38	5.62e-13	Educational attainment;
LIHC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.71	12.09	0.55	2.96e-28	Menopause (age at onset);
LIHC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.43	-7.27	-0.37	2.41e-12	Alzheimer's disease (late onset);
LIHC	cis	rs16858210	0.607	rs60244260	chr3:183570734	G/A	cg25686905	chr3:183603175	PARL	-0.49	-8.57	-0.42	3.53e-16	Menopause (age at onset);
LIHC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.36	7.37	0.37	1.31e-12	Cancer;
LIHC	cis	rs62179067	0.708	rs11895391	chr2:179940586	A/G	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.11	-0.44	6.87e-18	Colorectal cancer;
LIHC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.12	0.31	2.53e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.73	-12.94	-0.57	1.97e-31	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.79	-13.44	-0.59	2.35e-33	Platelet distribution width;
LIHC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.59	-9.7	-0.46	8.44e-20	Post bronchodilator FEV1;
LIHC	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.36	8.24	0.41	3.64e-15	Educational attainment (years of education);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07395075	chr16:56642428	MT2A	0.39	6.07	0.31	3.32e-9	Pancreatic cancer;
LIHC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.45	-6.82	-0.35	4.05e-11	Height;
LIHC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.46	-8.44	-0.42	9.35e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.83	15.24	0.64	2.14e-40	IgG glycosylation;
LIHC	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	0.96	14.01	0.6	1.41e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.54	5.86	0.3	1.06e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.54	8.02	0.4	1.73e-14	Multiple sclerosis;
LIHC	cis	rs17125944	0.686	rs2025634	chr14:53336017	C/T	cg00686598	chr14:53173677	PSMC6	-0.74	-8.52	-0.42	5.34e-16	Alzheimer's disease (late onset);
LIHC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg08694578	chr2:241835147	C2orf54	-0.52	-8.06	-0.4	1.32e-14	Urinary metabolites;
LIHC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.57	9.89	0.47	1.96e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs861318	0.702	rs12098223	chr1:159011694	C/T	cg11003133	chr1:159046391	AIM2	-0.32	-6.46	-0.33	3.62e-10	Obesity-related traits;
LIHC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.51	9.69	0.46	8.57e-20	Schizophrenia;
LIHC	cis	rs8084351	0.539	rs4129323	chr18:50605360	G/C	cg24270629	chr18:50823537	DCC	0.46	7.05	0.36	9.72e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.58	-6.71	-0.34	8.18e-11	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs9942416	0.503	rs253393	chr5:74929647	G/A	cg19683494	chr5:74908142	NA	-0.48	-6.21	-0.32	1.55e-9	Age-related disease endophenotypes;
LIHC	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.4	7.67	0.38	1.8e-13	Height;
LIHC	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.32	0.55	4.05e-29	Coffee consumption (cups per day);
LIHC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-6.05	-0.31	3.72e-9	Colorectal cancer;
LIHC	cis	rs16958440	1.000	rs57928699	chr18:44645593	T/A	cg17192377	chr18:44677553	HDHD2	0.6	6.76	0.34	5.88e-11	Sitting height ratio;
LIHC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg24296786	chr1:45957014	TESK2	-0.4	-5.88	-0.3	9.62e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs8064454	0.764	rs11658063	chr17:36103872	C/G	cg04198914	chr17:36106025	HNF1B	0.36	6.1	0.31	2.89e-9	Prostate cancer;
LIHC	cis	rs8016982	0.520	rs17111601	chr14:81717808	C/T	cg01989461	chr14:81687754	GTF2A1	-0.39	-6.27	-0.32	1.08e-9	Schizophrenia;
LIHC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.68	0.53	9.79e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.74	-0.3	2.11e-8	Alcohol dependence;
LIHC	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg10241871	chr14:102965420	TECPR2	-0.47	-7.46	-0.37	7.03e-13	Plateletcrit;
LIHC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.47	6.81	0.35	4.45e-11	Multiple sclerosis;
LIHC	cis	rs67981189	0.574	rs2526884	chr14:71367967	G/A	cg15816911	chr14:71606274	NA	-0.4	-6.41	-0.33	4.76e-10	Schizophrenia;
LIHC	cis	rs10847980	0.590	rs75794148	chr12:123287329	C/G	cg25930673	chr12:123319894	HIP1R	1.09	11.71	0.53	7.59e-27	Adiponectin levels;
LIHC	cis	rs7116495	0.867	rs562621	chr11:71579213	C/G	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.27e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg10978503	chr1:24200527	CNR2	-0.38	-8.92	-0.43	2.83e-17	Immature fraction of reticulocytes;
LIHC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg22079354	chr11:130786696	SNX19	0.41	5.9	0.3	8.98e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg27386326	chr11:61587980	NA	0.68	13.74	0.6	1.64e-34	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.38	6.4	0.33	5.17e-10	Schizophrenia;
LIHC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.61	-0.34	1.49e-10	Personality dimensions;
LIHC	cis	rs16944613	0.588	rs6416553	chr15:91135411	A/G	cg26821196	chr15:91095069	CRTC3	-0.44	-7.31	-0.37	1.86e-12	Colorectal cancer;
LIHC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.55	9.23	0.45	2.92e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.4	0.45	8.21e-19	Platelet count;
LIHC	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg03859395	chr2:55845619	SMEK2	0.9	15.68	0.65	3.88e-42	Metabolic syndrome;
LIHC	cis	rs4970966	0.855	rs11204701	chr1:150662179	A/T	cg18016565	chr1:150552671	MCL1	-0.43	-6.45	-0.33	3.87e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.59	0.34	1.63e-10	Height;
LIHC	trans	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg01596870	chr19:55963115	NA	-0.67	-10.74	-0.5	2.18e-23	Obesity-related traits;
LIHC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.19	0.4	5.35e-15	Motion sickness;
LIHC	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg20240347	chr1:204465584	NA	-0.31	-6.25	-0.32	1.21e-9	Schizophrenia;
LIHC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17507749	chr15:85114479	UBE2QP1	0.77	8.63	0.42	2.34e-16	Schizophrenia;
LIHC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-12.71	-0.57	1.42e-30	Morning vs. evening chronotype;
LIHC	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.91	6.85	0.35	3.55e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-8.28	-0.41	2.88e-15	Waist circumference;Body mass index;
LIHC	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2637266	1.000	rs2130799	chr10:78322922	C/T	cg18941641	chr10:78392320	NA	0.28	6.01	0.31	4.86e-9	Pulmonary function;
LIHC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.68	-0.42	1.68e-16	Gut microbiome composition (summer);
LIHC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.18	0.52	5.88e-25	Lung cancer in ever smokers;
LIHC	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.4	7.77	0.39	9.55e-14	White blood cell count (basophil);
LIHC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.5	-6.96	-0.35	1.74e-11	Height;
LIHC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.71	-0.34	8.2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.93	-0.54	1.11e-27	Urate levels in overweight individuals;
LIHC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.03	14.83	0.63	8.98e-39	Cognitive function;
LIHC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.48	-6.83	-0.35	3.85e-11	Height;
LIHC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02767759	chr16:30366751	CD2BP2	0.47	7.2	0.36	3.79e-12	Cognitive function;
LIHC	cis	rs477692	0.618	rs7080419	chr10:131455235	A/G	cg19680672	chr10:131412579	MGMT	-0.43	-6.59	-0.34	1.68e-10	Response to temozolomide;
LIHC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.29	21.48	0.76	2.15e-65	Corneal structure;
LIHC	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.5	-7.39	-0.37	1.12e-12	Mortality in heart failure;
LIHC	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.79	14.47	0.62	2.41e-37	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.57	-7.59	-0.38	3.17e-13	Gut microbiome composition (summer);
LIHC	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.66	9.7	0.46	8.37e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.55	-9.08	-0.44	9e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	7.21	0.36	3.58e-12	Protein C levels;
LIHC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.47	-8.41	-0.41	1.13e-15	Mean corpuscular volume;
LIHC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.72	-8.14	-0.4	7.37e-15	Neuroticism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20824237	chr3:99979579	TBC1D23	0.39	6.07	0.31	3.47e-9	Cognitive function;
LIHC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg13844804	chr7:814759	HEATR2	0.45	6.04	0.31	3.99e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.33	-6.7	-0.34	8.68e-11	Immature fraction of reticulocytes;
LIHC	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.31	2.7e-9	Mean corpuscular volume;
LIHC	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12463550	chr7:65579703	CRCP	0.67	6.9	0.35	2.49e-11	Diabetic kidney disease;
LIHC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	0.99	8.7	0.43	1.39e-16	Lymphocyte counts;
LIHC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg05044414	chr3:183734942	ABCC5	0.35	6.07	0.31	3.47e-9	Anterior chamber depth;
LIHC	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.57	7.0	0.35	1.38e-11	QRS duration;
LIHC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20307385	chr11:47447363	PSMC3	-0.44	-5.74	-0.3	2.04e-8	Subjective well-being;
LIHC	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.86	-0.3	1.09e-8	Response to antipsychotic treatment;
LIHC	trans	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg10756647	chr7:56101905	PSPH	-1.07	-13.17	-0.58	2.44e-32	Diabetic kidney disease;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg20078067	chr8:12612870	LONRF1	0.71	6.66	0.34	1.12e-10	Musician's dystonia;
LIHC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.52	6.16	0.32	2.06e-9	Coronary artery disease;
LIHC	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg05110241	chr16:68378359	PRMT7	-0.56	-6.77	-0.34	5.72e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg17385448	chr1:15911702	AGMAT	0.36	6.11	0.31	2.74e-9	Systolic blood pressure;
LIHC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg16479474	chr6:28041457	NA	0.45	6.68	0.34	9.73e-11	Parkinson's disease;
LIHC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.6	10.67	0.5	3.87e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.77	10.08	0.48	4.37e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.31	7.2	0.36	3.98e-12	Blood metabolite ratios;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg16600020	chr8:30210405	NA	0.31	6.07	0.31	3.35e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.9	18.08	0.7	9.01e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.72	9.81	0.47	3.57e-20	Asthma;
LIHC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.28	-0.32	1.06e-9	Obesity-related traits;
LIHC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15001132	chr13:25875890	NUPL1	0.5	6.72	0.34	7.69e-11	Lung function (FEV1/FVC);
LIHC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.78	-9.56	-0.46	2.43e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7534824	0.625	rs17448356	chr1:101345093	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.67	0.34	1.01e-10	Refractive astigmatism;
LIHC	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.31	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.36	6.45	0.33	3.8e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs332507	0.830	rs13069961	chr3:124358715	A/G	cg05980111	chr3:124395277	KALRN	0.4	6.15	0.32	2.2e-9	Plateletcrit;
LIHC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.78	-9.65	-0.46	1.18e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-10.44	-0.49	2.56e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg18016565	chr1:150552671	MCL1	0.58	11.01	0.51	2.38e-24	Blood protein levels;
LIHC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.89	-0.3	9.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg15192750	chr16:69999425	NA	0.46	6.56	0.33	1.95e-10	IgE levels;
LIHC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.31	-0.32	8.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg03037974	chr15:76606532	NA	0.88	22.87	0.78	7.02e-71	Blood metabolite levels;
LIHC	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	0.84	7.15	0.36	5.41e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.31e-12	HDL cholesterol levels;
LIHC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.5	8.18	0.4	5.77e-15	Schizophrenia;
LIHC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.72	0.47	7.14e-20	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.32	-6.55	-0.33	2.14e-10	Blood metabolite levels;
LIHC	trans	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg25214090	chr10:38739885	LOC399744	0.4	6.61	0.34	1.48e-10	Diastolic blood pressure;
LIHC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg22633049	chr21:46681294	NA	-0.35	-5.79	-0.3	1.6e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-0.9	-9.03	-0.44	1.28e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23043544	chr7:2124092	MAD1L1	-0.39	-6.35	-0.32	6.8e-10	Neuroticism;
LIHC	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg07541023	chr7:19748670	TWISTNB	0.36	5.72	0.3	2.33e-8	Thyroid stimulating hormone;
LIHC	cis	rs539514	0.690	rs776527	chr13:76317794	G/A	cg04757411	chr13:76259545	LMO7	-0.47	-8.25	-0.41	3.5e-15	Type 1 diabetes;
LIHC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.04	0.4	1.5e-14	Motion sickness;
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.59	8.92	0.43	2.96e-17	Longevity;Endometriosis;
LIHC	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.73	-9.83	-0.47	2.91e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg18081818	chr7:23246105	NA	-0.39	-5.8	-0.3	1.48e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs11951515	0.508	rs1366410	chr5:43601610	C/A	cg01983248	chr5:43482804	C5orf28	-0.37	-6.12	-0.31	2.54e-9	Metabolite levels  (X-11787);
LIHC	cis	rs2607426	0.681	rs2233156	chr19:41281700	C/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-6.03	-0.31	4.26e-9	Blood protein levels;
LIHC	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.93	0.51	4.56e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.7	0.38	1.44e-13	Nonalcoholic fatty liver disease;
LIHC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.79	-11.79	-0.54	3.75e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.47	-6.37	-0.33	6.12e-10	Serum sulfate level;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.4	-0.33	5e-10	Total body bone mineral density;
LIHC	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.43	-6.28	-0.32	1.01e-9	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg25124228	chr12:125621409	AACS	-0.43	-6.66	-0.34	1.09e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg24296786	chr1:45957014	TESK2	-0.39	-5.88	-0.3	9.88e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg25024717	chr12:54324583	NA	-0.32	-6.3	-0.32	8.9e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg12661370	chr5:149340060	SLC26A2	-0.57	-6.8	-0.35	4.61e-11	HIV-1 control;
LIHC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg23533926	chr12:111358616	MYL2	-0.33	-6.26	-0.32	1.12e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.14	0.32	2.24e-9	Systolic blood pressure;
LIHC	cis	rs2901460	0.509	rs17573253	chr2:62101915	C/T	cg02183531	chr2:62113199	CCT4	0.42	6.21	0.32	1.53e-9	Mean corpuscular volume;
LIHC	cis	rs3770081	0.793	rs7608262	chr2:86225471	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.04	-0.4	1.46e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-6.73	-0.34	7.17e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg17675199	chr6:35436792	RPL10A	0.34	6.63	0.34	1.32e-10	Coronary artery disease;
LIHC	cis	rs2412488	0.815	rs6843529	chr4:54355854	T/C	cg22241045	chr4:54363911	LNX1	0.42	6.78	0.34	5.45e-11	DNA methylation (variation);
LIHC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.34	0.58	5.91e-33	Cognitive test performance;
LIHC	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.56	6.59	0.34	1.7e-10	QRS duration;
LIHC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg16836995	chr17:43662488	NA	-0.69	-7.21	-0.36	3.64e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-12.83	-0.57	5.1e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.51	-7.66	-0.38	1.97e-13	Total body bone mineral density;
LIHC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg21522988	chr12:29376872	FAR2	0.26	5.95	0.31	6.61e-9	QT interval;
LIHC	cis	rs13217239	0.597	rs9467978	chr6:27024558	A/G	cg12292205	chr6:26970375	C6orf41	-0.44	-7.41	-0.37	9.95e-13	Schizophrenia;
LIHC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-8.76	-0.43	9.02e-17	Schizophrenia;
LIHC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.94	12.82	0.57	5.38e-31	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs16958440	0.867	rs78585258	chr18:44677729	T/A	cg17192377	chr18:44677553	HDHD2	0.93	8.75	0.43	1.01e-16	Sitting height ratio;
LIHC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.76	15.2	0.63	3.14e-40	Height;
LIHC	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.03	-0.36	1.09e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg19318889	chr4:1322082	MAEA	0.41	5.94	0.31	6.9e-9	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg11764359	chr7:65958608	NA	0.6	6.1	0.31	2.92e-9	Diabetic kidney disease;
LIHC	cis	rs2051211	0.947	rs73065216	chr3:38524194	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-6.28	-0.32	1.01e-9	QRS duration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09337544	chr22:38857452	NA	0.43	6.36	0.33	6.31e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.84	13.6	0.59	5.67e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.62	-6.34	-0.32	7.1e-10	Carotid intima media thickness;
LIHC	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.71	11.89	0.54	1.63e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg12374095	chr12:54320830	NA	0.4	5.79	0.3	1.6e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.37	0.41	1.53e-15	Motion sickness;
LIHC	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs2395128	0.765	rs1880690	chr10:76664682	G/A	cg24341800	chr11:107992076	ACAT1	0.49	6.04	0.31	3.95e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.33	-7.16	-0.36	4.97e-12	Ulcerative colitis;
LIHC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg17834443	chr8:19674713	INTS10	-0.48	-7.28	-0.37	2.31e-12	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs9460578	0.634	rs9465912	chr6:20826011	G/A	cg07086918	chr5:176784688	RGS14	-0.43	-6.07	-0.31	3.32e-9	Breast cancer;
LIHC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.17	-0.32	1.95e-9	Pancreatic cancer;
LIHC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg06565975	chr8:143823917	SLURP1	-0.41	-7.72	-0.39	1.27e-13	Urinary tract infection frequency;
LIHC	cis	rs15676	0.783	rs7858732	chr9:131563540	A/G	cg00228799	chr9:131580591	ENDOG	-0.46	-6.51	-0.33	2.7e-10	Blood metabolite levels;
LIHC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.59	10.09	0.48	3.98e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs6866721	0.791	rs35637069	chr5:116216123	C/G	cg07571379	chr11:134631427	NA	-0.28	-6.07	-0.31	3.31e-9	Body mass index;
LIHC	cis	rs611744	0.967	rs686584	chr8:109192357	G/A	cg18478394	chr8:109455254	TTC35	0.4	6.87	0.35	3.09e-11	Dupuytren's disease;
LIHC	cis	rs150647904	1	rs150647904	chr1:54839485	T/TCAG	cg17417004	chr1:54819992	SSBP3	0.56	7.56	0.38	3.67e-13	Platelet distribution width;
LIHC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.81e-14	Motion sickness;
LIHC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.56	0.5	9.48e-23	Bladder cancer;
LIHC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg03959625	chr15:84868606	LOC388152	0.48	6.02	0.31	4.4e-9	Schizophrenia;
LIHC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21582582	chr3:182698605	DCUN1D1	0.53	6.91	0.35	2.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.33	-6.46	-0.33	3.68e-10	Body mass index;
LIHC	trans	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg02418909	chr7:4811322	NA	-0.45	-6.11	-0.31	2.69e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs986417	0.748	rs4899011	chr14:60986698	A/G	cg27398547	chr14:60952738	C14orf39	0.76	8.99	0.44	1.74e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs903552	0.736	rs2132196	chr15:102007089	A/G	cg06707286	chr15:102010195	PCSK6	-0.52	-7.48	-0.37	6.46e-13	Diabetic kidney disease;
LIHC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.97	13.24	0.58	1.36e-32	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21545522	chr1:205238299	TMCC2	0.37	7.08	0.36	8.15e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg01864836	chr14:55583639	NA	-0.41	-7.61	-0.38	2.63e-13	Protein biomarker;
LIHC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.15	-0.32	2.17e-9	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.46	-11.99	-0.54	6.92e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.37	-0.33	6.27e-10	Metabolite levels;
LIHC	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.49	7.48	0.38	6.27e-13	Adiposity;
LIHC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.86	12.47	0.56	1.13e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	10.52	0.49	1.36e-22	Monocyte percentage of white cells;
LIHC	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.25	11.14	0.52	8.51e-25	Uric acid levels;
LIHC	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-0.78	-8.41	-0.41	1.15e-15	Exhaled nitric oxide output;
LIHC	trans	rs1814175	0.615	rs7113020	chr11:49746540	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-20.89	-0.75	4.61e-63	Height;
LIHC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.31	7.69	0.38	1.56e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg04317338	chr11:64019027	PLCB3	-0.55	-7.44	-0.37	8.16e-13	Platelet count;
LIHC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.31	-5.72	-0.3	2.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg14593290	chr7:50529359	DDC	0.62	9.77	0.47	4.77e-20	Malaria;
LIHC	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg01339444	chr6:118972232	C6orf204	-0.6	-5.77	-0.3	1.75e-8	Diastolic blood pressure;
LIHC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.1	-0.31	2.8e-9	IgG glycosylation;
LIHC	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.58	-8.18	-0.4	5.5e-15	Neuroblastoma;
LIHC	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.39e-18	Subjective well-being;
LIHC	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg01864836	chr14:55583639	NA	-0.34	-6.3	-0.32	9.41e-10	Protein biomarker;
LIHC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs3814244	0.515	rs2906862	chr12:68399151	T/C	cg15249341	chr12:68405565	NA	0.34	7.06	0.36	9.47e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.7	11.21	0.52	4.86e-25	Colorectal adenoma (advanced);
LIHC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg16989086	chr20:62203971	PRIC285	0.57	8.25	0.41	3.51e-15	Glioblastoma;
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.56	7.39	0.37	1.1e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.71	11.0	0.51	2.56e-24	Corneal astigmatism;
LIHC	cis	rs12980942	0.872	rs12972949	chr19:41774935	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.9	0.35	2.48e-11	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1434579	0.897	rs2037904	chr19:44945091	A/G	cg15540054	chr19:45004280	ZNF180	0.56	7.87	0.39	4.59e-14	Tuberculosis;
LIHC	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg05941027	chr17:61774174	LIMD2	-0.31	-5.72	-0.3	2.31e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-9.58	-0.46	2.02e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17760058	chr19:2321626	LSM7	0.41	6.08	0.31	3.13e-9	Longevity;
LIHC	cis	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg16797762	chr3:3221439	CRBN	0.79	8.11	0.4	8.9e-15	White matter integrity;
LIHC	trans	rs6934970	1.000	rs12196496	chr6:113021779	T/A	cg02620054	chr10:133946674	JAKMIP3	0.53	6.05	0.31	3.73e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg00280220	chr17:61926910	NA	0.43	6.73	0.34	7.1e-11	Prudent dietary pattern;
LIHC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.56	9.51	0.46	3.56e-19	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-7.89	-0.39	4.25e-14	Neuroticism;
LIHC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	1e-16	Reticulocyte count;
LIHC	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	0.71	12.28	0.55	5.83e-29	Testicular germ cell tumor;
LIHC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg10360323	chr17:41437877	NA	0.4	6.02	0.31	4.45e-9	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12463550	chr7:65579703	CRCP	0.59	5.93	0.31	7.32e-9	Diabetic kidney disease;
LIHC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.23	-6.15	-0.32	2.16e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg20991723	chr1:152506922	NA	0.4	6.14	0.32	2.29e-9	Hair morphology;
LIHC	cis	rs1113500	0.787	rs11185266	chr1:108642664	G/A	cg06207961	chr1:108661230	NA	0.31	6.01	0.31	4.74e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.35	-7.28	-0.37	2.33e-12	Bone mineral density;
LIHC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	8.17	0.4	5.97e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg00318621	chr2:106887213	NA	-0.58	-5.96	-0.31	6.17e-9	Facial morphology (factor 23);
LIHC	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg09003973	chr2:102972529	NA	1.22	9.91	0.47	1.63e-20	Gut microbiota (bacterial taxa);
LIHC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.29	0.37	2.14e-12	Morning vs. evening chronotype;
LIHC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.82	-10.64	-0.5	4.93e-23	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4407350	0.967	rs4522715	chr22:44922347	G/A	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.08	-0.31	3.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg01444801	chr10:135216882	MTG1	-0.66	-9.88	-0.47	2.12e-20	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.0	0.4	2e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.64	-9.92	-0.47	1.54e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.33	0.41	1.93e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg13815390	chr20:61568896	DIDO1;C20orf11	-0.42	-6.09	-0.31	3.1e-9	Triglycerides;
LIHC	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg11204139	chr17:3907470	NA	0.69	8.71	0.43	1.32e-16	Type 2 diabetes;
LIHC	cis	rs11871801	1.000	rs72823064	chr17:40569974	T/C	cg14558262	chr17:40713999	COASY	0.46	5.74	0.3	2.04e-8	Crohn's disease;
LIHC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-8.12	-0.4	8.58e-15	Mood instability;
LIHC	trans	rs11760633	0.607	rs11761457	chr7:1829228	C/T	cg00395210	chr12:48592465	NA	0.34	6.06	0.31	3.53e-9	Coronary artery disease;
LIHC	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.53	-8.07	-0.4	1.17e-14	Schizophrenia;
LIHC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-10.99	-0.51	2.79e-24	Response to antipsychotic treatment;
LIHC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.61	8.0	0.4	1.99e-14	Bladder cancer;
LIHC	cis	rs45544231	0.569	rs9923558	chr16:52548183	A/T	cg09051775	chr16:52580266	TOX3	-0.32	-5.77	-0.3	1.81e-8	Restless legs syndrome;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10491242	chr19:50366052	PNKP	0.43	6.29	0.32	9.62e-10	Pancreatic cancer;
LIHC	cis	rs17106184	0.688	rs10788930	chr1:51118253	C/T	cg07174182	chr1:51127561	FAF1	-0.46	-6.11	-0.31	2.73e-9	Type 2 diabetes;
LIHC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02711726	chr17:80685570	FN3KRP	-0.44	-7.99	-0.4	2.13e-14	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-7.05	-0.36	1.02e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg17834443	chr8:19674713	INTS10	0.48	7.19	0.36	4.13e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs965469	0.779	rs2236115	chr20:3296279	G/A	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.79	-9.6	-0.46	1.81e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.96	10.52	0.49	1.28e-22	IgG glycosylation;
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.55	8.71	0.43	1.29e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.5	6.77	0.34	5.59e-11	Interleukin-17 levels;
LIHC	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-9.31	-0.45	1.61e-18	Mean platelet volume;
LIHC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02450064	chr17:40260053	DHX58	-0.3	-6.14	-0.32	2.24e-9	Fibrinogen levels;
LIHC	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg01364799	chr7:75623366	TMEM120A	0.43	6.48	0.33	3.22e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7149242	1.000	rs7149242	chr14:101159416	G/T	cg11726507	chr14:101155519	NA	0.27	6.01	0.31	4.81e-9	Platelet count;
LIHC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06530028	chr7:143078179	ZYX	0.46	6.44	0.33	3.93e-10	Pancreatic cancer;
LIHC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.84	-0.35	3.69e-11	Psoriasis;
LIHC	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg15282417	chr9:129245246	FAM125B	0.39	6.22	0.32	1.46e-9	Intraocular pressure;
LIHC	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg03945807	chr20:60948434	NA	-0.39	-6.89	-0.35	2.67e-11	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.31	0.32	8.5e-10	Prudent dietary pattern;
LIHC	cis	rs7116495	0.609	rs1791456	chr11:71594888	G/C	cg26138937	chr11:71823887	C11orf51	1.19	9.52	0.46	3.37e-19	Severe influenza A (H1N1) infection;
LIHC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg08694578	chr2:241835147	C2orf54	-0.51	-7.16	-0.36	4.88e-12	Urinary metabolites;
LIHC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.95	9.7	0.46	8.02e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.78	12.91	0.57	2.53e-31	Tonsillectomy;
LIHC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.98	22.84	0.78	9.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.49	8.27	0.41	3.05e-15	Obesity-related traits;
LIHC	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg25124228	chr12:125621409	AACS	-0.4	-6.57	-0.33	1.89e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	trans	rs12476592	0.530	rs77804166	chr2:64160237	G/A	cg06077443	chr18:10457385	APCDD1	0.36	6.09	0.31	3.07e-9	Childhood ear infection;
LIHC	cis	rs4407350	0.870	rs2213373	chr22:44911669	C/T	cg26276947	chr22:44892394	LDOC1L	0.34	6.56	0.33	1.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.5	7.66	0.38	1.93e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.16	0.4	6.31e-15	Lymphocyte counts;
LIHC	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.51	9.53	0.46	3.06e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	6.27	0.32	1.06e-9	Bipolar disorder;
LIHC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.36	6.35	0.32	6.76e-10	Platelet distribution width;
LIHC	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg01364799	chr7:75623366	TMEM120A	-0.45	-6.81	-0.35	4.5e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg22951263	chr5:87985283	NA	-0.39	-6.72	-0.34	7.43e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-7.29	-0.37	2.18e-12	Hepatocellular carcinoma;
LIHC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.71	-0.34	7.98e-11	Personality dimensions;
LIHC	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg08126542	chr6:37504118	NA	-0.37	-6.3	-0.32	9.03e-10	Cognitive performance;
LIHC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	18.36	0.7	6.84e-53	Tonsillectomy;
LIHC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-7.73	-0.39	1.2e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.8	0.39	7.44e-14	Fibroblast growth factor basic levels;
LIHC	trans	rs3743102	0.591	rs12148608	chr15:83382102	A/G	cg01542190	chr22:50604728	NA	0.55	7.43	0.37	8.98e-13	Colorectal adenoma (advanced);
LIHC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg04498913	chr7:1135747	C7orf50	0.39	5.84	0.3	1.22e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs78545713	1.000	rs3734534	chr6:26240649	A/G	cg16070018	chr6:26224392	HIST1H3E	-0.59	-6.5	-0.33	2.9e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg13647721	chr17:30228624	UTP6	0.69	6.72	0.34	7.39e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08893839	chr5:154027129	NA	-0.51	-7.1	-0.36	7.49e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.51	0.53	4.02e-26	Motion sickness;
LIHC	cis	rs9649465	1.000	rs10215466	chr7:123326044	G/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.02e-15	Migraine;
LIHC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs965469	1.000	rs2236108	chr20:3286331	A/C	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10285711	chr2:135762012	YSK4	0.48	6.17	0.32	1.88e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7078219	0.505	rs7908704	chr10:101293318	G/A	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.09	-0.31	3.12e-9	Dental caries;
LIHC	trans	rs783540	0.967	rs1259183	chr15:83279433	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.66	-0.34	1.1e-10	Schizophrenia;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg27586682	chr1:26437624	PDIK1L	0.45	6.19	0.32	1.76e-9	Alopecia areata;
LIHC	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.75	8.18	0.4	5.53e-15	Height;
LIHC	cis	rs17106184	1.000	rs11205777	chr1:51286954	T/A	cg07174182	chr1:51127561	FAF1	-0.59	-6.78	-0.34	5.2e-11	Type 2 diabetes;
LIHC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.44	-6.42	-0.33	4.54e-10	Narcolepsy;
LIHC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.72	-9.65	-0.46	1.2e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.59	10.15	0.48	2.53e-21	Alcohol dependence;
LIHC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg03934865	chr2:198174659	NA	-0.6	-9.62	-0.46	1.5700000000000001e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21448741	chr8:58168803	NA	0.35	6.24	0.32	1.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.57e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg03874509	chr1:107600012	PRMT6	-0.7	-10.98	-0.51	3.17e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3770081	1.000	rs12612513	chr2:86301225	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.87	-8.58	-0.42	3.25e-16	Facial emotion recognition (sad faces);
LIHC	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.37	6.39	0.33	5.51e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02290350	chr8:58132656	NA	0.4	8.5	0.42	6.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg05973401	chr12:123451056	ABCB9	0.49	7.48	0.38	6.16e-13	Platelet count;
LIHC	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.7	-10.38	-0.49	4.06e-22	Diisocyanate-induced asthma;
LIHC	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.52	-10.94	-0.51	4.43e-24	Late-onset Alzheimer's disease;
LIHC	trans	rs6467710	0.744	rs834093	chr7:137210014	T/C	cg04467748	chr15:79760772	KIAA1024	0.44	6.42	0.33	4.52e-10	AIDS progression;
LIHC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.42	-7.12	-0.36	6.32e-12	Lewy body disease;
LIHC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg11212589	chr17:38028394	ZPBP2	-0.33	-6.91	-0.35	2.31e-11	Self-reported allergy;
LIHC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg19682013	chr15:45996608	NA	0.4	7.12	0.36	6.25e-12	Waist circumference;Weight;
LIHC	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-6.7	-0.34	8.84e-11	Obesity (extreme);
LIHC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg07424592	chr7:64974309	NA	0.79	9.05	0.44	1.09e-17	Diabetic kidney disease;
LIHC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.85	-0.39	5.42e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.39	-6.24	-0.32	1.27e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.51	8.89	0.43	3.63e-17	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67981189	0.593	rs7154437	chr14:71441385	A/G	cg15816911	chr14:71606274	NA	0.42	6.65	0.34	1.14e-10	Schizophrenia;
LIHC	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg02023728	chr11:77925099	USP35	0.32	5.76	0.3	1.89e-8	Alzheimer's disease (survival time);
LIHC	cis	rs10792665	0.575	rs1939136	chr11:82558046	A/T	cg24227371	chr11:82718527	RAB30	-0.25	-5.99	-0.31	5.19e-9	Obesity-related traits;
LIHC	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.4	-0.33	4.98e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.46	0.66	3.08e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-8.35	-0.41	1.74e-15	Putamen volume;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.19	0.55	1.26e-28	Height;
LIHC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.15	0.68	5.4e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.63	8.56	0.42	3.87e-16	Vitamin D levels;
LIHC	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.85	0.3	1.17e-8	Rheumatoid arthritis;
LIHC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg12310025	chr6:25882481	NA	-0.47	-7.17	-0.36	4.57e-12	Height;
LIHC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.61	7.74	0.39	1.11e-13	Initial pursuit acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16490470	chr1:208390388	PLXNA2	0.41	6.18	0.32	1.82e-9	Longevity;
LIHC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.67	9.85	0.47	2.54e-20	Menopause (age at onset);
LIHC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg12365402	chr11:9010492	NRIP3	0.31	7.91	0.39	3.7e-14	Hemoglobin concentration;
LIHC	cis	rs7129220	0.588	rs16907481	chr11:10144108	A/T	cg01453529	chr11:10209919	SBF2	-0.37	-6.68	-0.34	9.53e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	7.03	0.36	1.15e-11	Renal cell carcinoma;
LIHC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.43	-7.39	-0.37	1.16e-12	Aortic root size;
LIHC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.55	-0.5	1.05e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg04610667	chr7:75704037	NA	0.35	6.0	0.31	4.91e-9	Eotaxin levels;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg24693881	chr1:107596107	NA	-0.49	-8.0	-0.4	2e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.22	0.36	3.4e-12	Aortic root size;
LIHC	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.5	-7.94	-0.39	2.91e-14	Diastolic blood pressure;
LIHC	cis	rs10508774	1.000	rs12416352	chr10:32919749	T/G	cg01819863	chr10:32635814	EPC1	0.63	5.88	0.3	9.9e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs797680	0.796	rs797661	chr1:93687091	G/T	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.88	0.3	1e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LIHC	trans	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg10756647	chr7:56101905	PSPH	1.08	13.46	0.59	2e-33	Diabetic kidney disease;
LIHC	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07368265	chr1:219375142	LYPLAL1	-0.35	-6.08	-0.31	3.21e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20011983	chr2:74347215	NA	-0.39	-5.78	-0.3	1.68e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.19	0.45	3.83e-18	Electroencephalogram traits;
LIHC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.6	7.74	0.39	1.12e-13	Diastolic blood pressure;
LIHC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.73	-11.29	-0.52	2.5e-25	Coronary artery disease;
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.51	9.1	0.44	7.83e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.39	5.76	0.3	1.88e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg22705602	chr4:152727874	NA	0.3	6.24	0.32	1.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.96	0.44	2.2e-17	Lung cancer in ever smokers;
LIHC	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg06265175	chr8:121136014	COL14A1	0.49	7.99	0.4	2.09e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14729855	chr6:34204698	HMGA1	0.46	6.44	0.33	3.96e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.6	0.34	1.53e-10	Cognitive ability;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.84	0.54	2.44e-27	Prudent dietary pattern;
LIHC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg11204139	chr17:3907470	NA	0.64	10.85	0.51	9.42e-24	Type 2 diabetes;
LIHC	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg06359132	chr10:99160096	RRP12	-0.4	-6.04	-0.31	4.02e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs959260	1.000	rs2033609	chr17:73367021	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.83	-0.3	1.25e-8	Systemic lupus erythematosus;
LIHC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.51	-6.53	-0.33	2.33e-10	Coronary artery calcification;
LIHC	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.63	6.8	0.35	4.73e-11	Homocysteine levels;
LIHC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.97	0.4	2.4e-14	Response to antipsychotic treatment;
LIHC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg10130564	chr11:117069849	TAGLN	0.37	6.32	0.32	8.3e-10	Blood protein levels;
LIHC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.67	13.13	0.58	3.52e-32	Lymphocyte percentage of white cells;
LIHC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg00071026	chr13:113650936	MCF2L	-0.37	-5.72	-0.3	2.28e-8	Systolic blood pressure;
LIHC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.63	-0.34	1.28e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	1.04	15.0	0.63	1.95e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.61	-9.83	-0.47	3.08e-20	Obesity-related traits;
LIHC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.6	7.74	0.39	1.15e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.53	8.8	0.43	7.1e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg16797656	chr11:68205561	LRP5	0.49	7.79	0.39	7.88e-14	Total body bone mineral density;
LIHC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-8.87	-0.43	4.17e-17	Parkinson's disease;
LIHC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.82	13.49	0.59	1.54e-33	Monocyte count;
LIHC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.29	-7.26	-0.37	2.62e-12	Longevity;Endometriosis;
LIHC	cis	rs11212260	0.655	rs11212215	chr11:107287405	G/A	cg25435332	chr11:107328525	CWF19L2	0.8	8.18	0.4	5.7e-15	IgG glycosylation;
LIHC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg14067834	chr17:29058358	SUZ12P	0.72	7.12	0.36	6.39e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	0.77	5.9	0.3	8.85e-9	IgG glycosylation;
LIHC	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.78	-12.18	-0.55	1.4e-28	Corneal astigmatism;
LIHC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.6	-7.97	-0.4	2.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01585758	chr2:203102753	SUMO1	0.45	6.53	0.33	2.32e-10	Pancreatic cancer;
LIHC	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	0.57	9.46	0.46	5.2e-19	Testicular germ cell tumor;
LIHC	cis	rs4908768	0.539	rs11121204	chr1:8654305	A/G	cg20416874	chr1:8611966	RERE	0.62	11.1	0.51	1.15e-24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.21	-0.36	3.63e-12	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.84	0.54	2.39e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg17845761	chr1:175162550	KIAA0040	-0.37	-6.14	-0.31	2.35e-9	Alcohol dependence;
LIHC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg02269571	chr22:50332266	NA	-0.87	-10.37	-0.49	4.28e-22	Schizophrenia;
LIHC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg14067834	chr17:29058358	SUZ12P	-0.73	-7.21	-0.36	3.53e-12	Body mass index;
LIHC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.81	-12.18	-0.55	1.37e-28	Cognitive test performance;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.59	10.89	0.51	6.49e-24	Height;
LIHC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.49	5.99	0.31	5.24e-9	Schizophrenia;
LIHC	cis	rs17094222	0.504	rs12267029	chr10:102458677	C/A	cg26540559	chr10:102447443	NA	0.4	7.71	0.38	1.4e-13	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.12	24.8	0.8	2.06e-78	Cognitive ability;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02290350	chr8:58132656	NA	0.49	10.59	0.5	7.41e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.66	0.34	1.08e-10	Rheumatoid arthritis;
LIHC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg14580859	chr9:123691850	NA	0.38	6.52	0.33	2.48e-10	Rheumatoid arthritis;
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.71	-11.67	-0.53	1.06e-26	Smoking behavior;
LIHC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg14779329	chr11:130786720	SNX19	0.38	5.89	0.3	9.28e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg24296786	chr1:45957014	TESK2	0.43	6.25	0.32	1.2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.52	5.82	0.3	1.37e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.22	6.03	0.31	4.27e-9	Hepatitis;
LIHC	cis	rs80282103	0.618	rs57514701	chr10:1146169	G/A	cg08668510	chr10:1095578	IDI1	0.62	6.07	0.31	3.45e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.54	-8.66	-0.42	1.86e-16	Colorectal cancer;
LIHC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg10774155	chr7:65338427	VKORC1L1	0.47	6.97	0.35	1.6e-11	Calcium levels;
LIHC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.13	0.31	2.41e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.62	-0.5	6.07e-23	Platelet count;
LIHC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.45	6.63	0.34	1.32e-10	Aortic root size;
LIHC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-8.89	-0.43	3.58e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13198984	chr17:80129470	CCDC57	-0.33	-5.8	-0.3	1.54e-8	Life satisfaction;
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.69	-0.38	1.53e-13	Obesity-related traits;
LIHC	cis	rs963731	0.579	rs6739807	chr2:39287668	G/A	cg04010122	chr2:39346883	SOS1	-0.59	-6.0	-0.31	5.04e-9	Corticobasal degeneration;
LIHC	cis	rs11229555	0.645	rs11229429	chr11:58180872	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.77	-0.34	5.68e-11	Diabetic kidney disease;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg16070018	chr6:26224392	HIST1H3E	0.6	7.53	0.38	4.45e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.25	-0.32	1.25e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.32	-0.41	2.07e-15	Exhaled nitric oxide output;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26011197	chr5:175970570	NA	-0.48	-6.36	-0.33	6.58e-10	Systolic blood pressure;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09430954	chr19:46236890	NA	0.44	6.13	0.31	2.36e-9	Bilirubin levels;
LIHC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.38	-6.66	-0.34	1.08e-10	Aortic root size;
LIHC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.39	-5.92	-0.3	7.86e-9	Menarche (age at onset);
LIHC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.66	8.19	0.4	5.24e-15	Mean platelet volume;
LIHC	trans	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.42	5.76	0.3	1.83e-8	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.46	0.37	7.18e-13	Renal cell carcinoma;
LIHC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16684958	chr7:75615977	POR	0.51	8.61	0.42	2.78e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.44	0.33	4.09e-10	Lymphocyte counts;
LIHC	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg12798992	chr6:167411361	FGFR1OP	0.59	9.73	0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs2834188	1.000	rs1018741	chr21:34686345	G/A	cg04842828	chr21:34696676	IFNAR1	0.44	5.98	0.31	5.73e-9	Narcolepsy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11786013	chr1:36622167	MAP7D1	0.43	6.04	0.31	4.11e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs16828019	0.777	rs115916606	chr1:41642700	C/G	cg03962019	chr1:41807865	NA	0.53	7.64	0.38	2.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.57	-8.49	-0.42	6.44e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.7	-10.65	-0.5	4.56e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	0.79	6.02	0.31	4.58e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11083846	0.913	rs11668987	chr19:47227821	A/G	cg08230695	chr19:47220755	PRKD2	-0.54	-5.81	-0.3	1.4e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.43	8.14	0.4	7.32e-15	Platelet distribution width;
LIHC	cis	rs699	0.556	rs2478525	chr1:230865350	C/G	cg07502417	chr1:230849801	AGT	0.3	6.56	0.33	2.05e-10	Coronary artery disease;
LIHC	cis	rs7119	0.643	rs12904384	chr15:77410878	T/G	cg17802220	chr15:77601643	NA	-0.36	-6.92	-0.35	2.3e-11	Type 2 diabetes;
LIHC	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.55	-8.54	-0.42	4.36e-16	Smoking behavior;
LIHC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.48	7.62	0.38	2.51e-13	Multiple sclerosis;
LIHC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.62	9.05	0.44	1.13e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs56145559	1	rs56145559	chr2:73623439	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-5.97	-0.31	6.02e-9	Schizophrenia;
LIHC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.73	-0.5	2.4e-23	Primary sclerosing cholangitis;
LIHC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.39	-7.51	-0.38	5.17e-13	Schizophrenia;
LIHC	cis	rs10503871	0.690	rs7840384	chr8:30349914	A/G	cg26383811	chr8:30366931	RBPMS	0.43	7.52	0.38	4.88e-13	Metabolite levels  (X-11787);
LIHC	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16576597	chr16:28551801	NUPR1	0.47	7.11	0.36	6.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	9.72	0.47	7.23e-20	Tonsillectomy;
LIHC	trans	rs783540	0.874	rs10468217	chr15:83248079	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.11	-0.31	2.7e-9	Schizophrenia;
LIHC	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.28	6.28	0.32	1.04e-9	Weight;
LIHC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.54	-8.34	-0.41	1.91e-15	Coronary artery disease;
LIHC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.57	-8.7	-0.43	1.45e-16	Longevity;Endometriosis;
LIHC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	7.57	0.38	3.41e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg10932868	chr11:921992	NA	0.35	6.57	0.33	1.93e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02251663	chr11:14281053	SPON1	-0.43	-6.02	-0.31	4.49e-9	Mitochondrial DNA levels;
LIHC	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.71	-0.38	1.42e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.06	0.36	9.23e-12	Hemoglobin concentration;
LIHC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.84	-0.65	9.44e-43	Chronic sinus infection;
LIHC	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg24083324	chr1:214162604	PROX1	-0.56	-8.55	-0.42	4.16e-16	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.26	-0.32	1.18e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.83	0.3	1.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.24	-0.32	1.29e-9	Schizophrenia;
LIHC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.72	10.61	0.5	6.25e-23	Corneal astigmatism;
LIHC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg17135325	chr3:160939158	NMD3	0.5	6.66	0.34	1.12e-10	Parkinson's disease;
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.47	-6.96	-0.35	1.69e-11	Longevity;Endometriosis;
LIHC	cis	rs7551222	0.646	rs7556371	chr1:204457336	A/G	cg20240347	chr1:204465584	NA	0.31	6.61	0.34	1.52e-10	Schizophrenia;
LIHC	cis	rs7224668	0.647	rs2271090	chr17:79246605	A/G	cg08034816	chr17:79219380	SLC38A10	0.39	5.95	0.31	6.48e-9	IgG glycosylation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01910272	chr3:52489346	TNNC1;NISCH	0.46	6.59	0.34	1.63e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.52	-7.57	-0.38	3.56e-13	Platelet count;
LIHC	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.21	-0.41	4.65e-15	Vitamin D levels;
LIHC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg07424592	chr7:64974309	NA	0.82	9.56	0.46	2.49e-19	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12790134	chr8:67578787	VCPIP1	-0.5	-6.07	-0.31	3.38e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg08923669	chr16:420230	MRPL28	-0.47	-6.2	-0.32	1.64e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.41	-6.07	-0.31	3.45e-9	Height;
LIHC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	13.94	0.6	2.8e-35	Chronic sinus infection;
LIHC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-6.95	-0.35	1.8e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg10756647	chr7:56101905	PSPH	1.1	13.62	0.59	4.65e-34	Diabetic kidney disease;
LIHC	cis	rs611744	0.967	rs650968	chr8:109211055	C/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02941728	chr11:60617807	CCDC86	0.42	6.59	0.34	1.68e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.73	-10.92	-0.51	5.01e-24	Aortic root size;
LIHC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.92	15.61	0.65	7.13e-42	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg16822855	chr3:40428330	ENTPD3	-0.32	-5.79	-0.3	1.63e-8	Renal cell carcinoma;
LIHC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg00684032	chr4:1343700	KIAA1530	-0.35	-5.83	-0.3	1.3e-8	Obesity-related traits;
LIHC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.63	-11.36	-0.52	1.37e-25	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2270927	0.510	rs2937748	chr5:75572032	T/G	cg13563193	chr19:33072644	PDCD5	0.84	7.97	0.4	2.38e-14	Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.5	7.42	0.37	9.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12379764	chr21:47803548	PCNT	-0.52	-7.71	-0.38	1.43e-13	Testicular germ cell tumor;
LIHC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.39	6.27	0.32	1.11e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.63	10.82	0.5	1.19e-23	Uric acid clearance;
LIHC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.4	7.39	0.37	1.14e-12	Methadone dose in opioid dependence;
LIHC	cis	rs988712	0.662	rs11030100	chr11:27677586	G/T	cg18117895	chr11:27722066	BDNF	0.5	6.81	0.35	4.4e-11	Obesity;
LIHC	cis	rs713477	0.967	rs10150596	chr14:55916167	A/G	cg13175173	chr14:55914753	NA	0.36	8.67	0.42	1.77e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.22	-0.36	3.41e-12	Bipolar disorder;
LIHC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.84	12.66	0.56	2.25e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05834845	chr3:195489306	MUC4	0.65	9.84	0.47	2.84e-20	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.7	-0.5	3.03e-23	Chronic sinus infection;
LIHC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21545522	chr1:205238299	TMCC2	0.32	6.15	0.32	2.13e-9	Red blood cell count;
LIHC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.53	-7.4	-0.37	1.09e-12	Body mass index;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-10.37	-0.49	4.36e-22	Schizophrenia;
LIHC	cis	rs2279817	0.820	rs76593741	chr1:18010067	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.76	-0.39	9.68e-14	Neuroticism;
LIHC	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.38	5.89	0.3	9.1e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LIHC	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.4	0.37	1.06e-12	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.64	-0.38	2.22e-13	Fibroblast growth factor basic levels;
LIHC	trans	rs2537594	0.936	rs1404418	chr7:17814085	A/T	cg10150615	chr22:24372951	LOC391322	0.43	6.43	0.33	4.3e-10	Mean corpuscular hemoglobin;
LIHC	trans	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg23598604	chr1:99732472	LPPR4	-0.3	-6.41	-0.33	4.92e-10	Multiple myeloma;
LIHC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	7.0	0.35	1.35e-11	Menopause (age at onset);
LIHC	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.8	-10.56	-0.5	9.41e-23	Body mass index;
LIHC	cis	rs13020137	1	rs13020137	chr2:130757304	A/G	cg08790550	chr2:130955686	TUBA3E	0.45	7.53	0.38	4.61e-13	Schizophrenia;
LIHC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.15	-0.32	2.17e-9	IgG glycosylation;
LIHC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-1.0	-11.32	-0.52	1.98e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-7.24	-0.36	3.02e-12	Cognitive function;
LIHC	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.56	-7.08	-0.36	8.39e-12	Post bronchodilator FEV1;
LIHC	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg19623624	chr10:135278901	LOC619207	-0.42	-6.52	-0.33	2.55e-10	Systemic lupus erythematosus;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.7	0.38	1.5e-13	Prudent dietary pattern;
LIHC	cis	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg03999872	chr20:62272968	STMN3	0.43	6.54	0.33	2.24e-10	Atopic dermatitis;
LIHC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.74	14.42	0.61	3.67e-37	Mortality in heart failure;
LIHC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.58	-9.43	-0.45	6.59e-19	Lymphocyte counts;
LIHC	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg08330972	chr4:2403930	ZFYVE28	0.52	6.14	0.31	2.33e-9	Influenza A (H1N1) severity;
LIHC	trans	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg10208301	chr11:6592745	DNHD1	-0.45	-6.48	-0.33	3.29e-10	Coronary artery calcification;
LIHC	cis	rs9596863	1.000	rs1379833	chr13:54443167	C/T	ch.13.53330881F	chr13:54432880	NA	0.44	5.86	0.3	1.07e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.36	-0.33	6.52e-10	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.27	0.61	1.39e-36	Prudent dietary pattern;
LIHC	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.5	9.55	0.46	2.56e-19	Testicular germ cell tumor;
LIHC	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.48	6.06	0.31	3.64e-9	Panic disorder;
LIHC	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.54	-13.09	-0.58	5.17e-32	White blood cell count (basophil);
LIHC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.77	0.34	5.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.98	-0.31	5.61e-9	Neuroticism;
LIHC	cis	rs243505	0.632	rs887571	chr7:148505253	G/A	cg09806900	chr7:148480153	CUL1	0.44	6.52	0.33	2.52e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.17	-0.32	1.91e-9	Blood metabolite levels;
LIHC	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.75	-8.43	-0.41	1.01e-15	Exhaled nitric oxide output;
LIHC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-1.02	-10.72	-0.5	2.53e-23	Vitiligo;
LIHC	cis	rs4450131	0.868	rs10794175	chr10:126358073	G/T	cg20435097	chr10:126320824	FAM53B	0.51	9.01	0.44	1.44e-17	White blood cell count (basophil);
LIHC	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.5	7.66	0.38	1.97e-13	Cocaine dependence;
LIHC	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.53	-0.42	4.87e-16	Body mass index;
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg05527609	chr1:210001259	C1orf107	0.4	6.33	0.32	7.83e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.54	6.32	0.32	8.27e-10	Alzheimer's disease;
LIHC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.89	11.14	0.52	8.2e-25	Coronary artery disease;
LIHC	cis	rs116248771	0.739	rs2082159	chr3:158359667	C/T	cg16708174	chr3:158430962	RARRES1	0.48	6.42	0.33	4.46e-10	diarrhoeal disease at age 2;
LIHC	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg06565975	chr8:143823917	SLURP1	-0.31	-5.85	-0.3	1.14e-8	Urinary tract infection frequency;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg07568779	chr8:15398233	TUSC3	-0.44	-6.16	-0.32	2e-9	Monocyte count;
LIHC	cis	rs6545883	0.894	rs6734628	chr2:61451260	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.29	-0.37	2.16e-12	Tuberculosis;
LIHC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.57	-0.42	3.73e-16	Primary biliary cholangitis;
LIHC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.02	0.48	6.67e-21	Crohn's disease;
LIHC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.76	0.34	6.12e-11	Alzheimer's disease (late onset);
LIHC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.4	6.53	0.33	2.32e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg05025164	chr4:1340916	KIAA1530	-0.39	-5.84	-0.3	1.24e-8	Obesity-related traits;
LIHC	cis	rs5771242	1.000	rs5771242	chr22:50661869	T/C	cg16473166	chr22:50639996	SELO	0.61	7.08	0.36	8.18e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LIHC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-30.24	-0.85	1.18e-98	Myeloid white cell count;
LIHC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.57	8.62	0.42	2.56e-16	Longevity;Endometriosis;
LIHC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg08888203	chr3:10149979	C3orf24	0.62	6.74	0.34	6.91e-11	Alzheimer's disease;
LIHC	cis	rs3770081	1.000	rs76297018	chr2:86227007	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.52	-0.42	5.32e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg20818283	chr2:191399100	TMEM194B	-0.45	-6.1	-0.31	2.91e-9	Pulse pressure;
LIHC	cis	rs2834188	0.924	rs2834177	chr21:34676806	T/C	cg14352951	chr21:34696688	IFNAR1	0.48	6.7	0.34	8.71e-11	Narcolepsy;
LIHC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17410650	chr12:54324560	NA	-0.42	-8.26	-0.41	3.21e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.24	-0.55	7.9e-29	Primary sclerosing cholangitis;
LIHC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.19	-0.32	1.73e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05108160	chr13:110790284	NA	0.43	6.92	0.35	2.23e-11	Cognitive function;
LIHC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.28	0.32	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.05	-0.31	3.81e-9	Headache;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg09835421	chr16:68378352	PRMT7	0.67	8.27	0.41	3.08e-15	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.46	0.42	7.87e-16	Motion sickness;
LIHC	trans	rs1509701	0.898	rs11802622	chr1:239195698	A/T	cg02310027	chr17:77704741	ENPP7	0.4	6.2	0.32	1.62e-9	Shingles;
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02359409	chr6:42947317	PEX6	-0.48	-6.78	-0.34	5.42e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.88	-0.39	4.27e-14	Capecitabine sensitivity;
LIHC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00958927	chr1:175162553	KIAA0040	0.39	6.55	0.33	2.06e-10	Diastolic blood pressure;
LIHC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.43	-0.41	9.44e-16	Calcium levels;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.49	-7.65	-0.38	2.06e-13	Coronary artery disease;
LIHC	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.6	-8.59	-0.42	3.16e-16	Blood pressure (smoking interaction);
LIHC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23422044	chr7:1970798	MAD1L1	0.57	6.82	0.35	4.19e-11	Bipolar disorder;
LIHC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg19682013	chr15:45996608	NA	0.39	6.63	0.34	1.29e-10	Waist circumference;Weight;
LIHC	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.51	-8.69	-0.43	1.49e-16	Hepatocellular carcinoma;
LIHC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.52	8.38	0.41	1.43e-15	Total body bone mineral density;
LIHC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.86	-0.51	8.4e-24	Hemoglobin concentration;
LIHC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg05555928	chr11:63887634	MACROD1	-0.46	-6.0	-0.31	5.13e-9	Body mass index;
LIHC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.56	8.32	0.41	2.16e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-6.47	-0.33	3.45e-10	Response to antipsychotic treatment;
LIHC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg18016565	chr1:150552671	MCL1	-0.49	-9.43	-0.45	6.5e-19	Tonsillectomy;
LIHC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.97	-0.31	5.92e-9	Colorectal cancer;
LIHC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.16	-0.36	4.84e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs990171	0.571	rs3771202	chr2:102772669	C/G	cg22835712	chr2:102737379	NA	0.5	7.09	0.36	7.95e-12	Lymphocyte counts;
LIHC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.9	-0.3	8.96e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.5	0.38	5.37e-13	Electroencephalogram traits;
LIHC	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg10241871	chr14:102965420	TECPR2	-0.49	-7.6	-0.38	2.94e-13	Blood protein levels;
LIHC	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00495681	chr13:53174319	NA	-0.39	-5.99	-0.31	5.19e-9	Lewy body disease;
LIHC	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.29	7.75	0.39	1.08e-13	Intelligence;
LIHC	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.98	11.39	0.52	1.1e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.32	-17.62	-0.69	6.64e-50	Diabetic kidney disease;
LIHC	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.54	9.23	0.45	2.97e-18	Schizophrenia;
LIHC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.59	7.13	0.36	6.07e-12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11760633	0.502	rs36020539	chr7:1823203	A/T	cg23422044	chr7:1970798	MAD1L1	-0.36	-5.73	-0.3	2.16e-8	Coronary artery disease;
LIHC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-8.6	-0.42	2.89e-16	Gut microbiome composition (summer);
LIHC	cis	rs2895526	0.521	rs6602606	chr10:12713901	C/T	cg00115178	chr10:12648176	CAMK1D	-0.38	-6.54	-0.33	2.23e-10	Headache;
LIHC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.65	-9.74	-0.47	5.86e-20	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.79	-0.3	1.61e-8	Colorectal cancer;
LIHC	trans	rs60752752	0.852	rs61803340	chr1:153369833	A/C	cg14901121	chr8:98817630	LAPTM4B	-0.43	-7.17	-0.36	4.6e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.6	8.38	0.41	1.39e-15	Lung cancer;
LIHC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.68	8.75	0.43	1.02e-16	Initial pursuit acceleration;
LIHC	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	9.81	0.47	3.65e-20	Colorectal cancer;
LIHC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.51	0.33	2.69e-10	Schizophrenia;
LIHC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.5	-6.0	-0.31	5e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.56	-6.53	-0.33	2.35e-10	Cognitive function;
LIHC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.48	6.78	0.34	5.2e-11	Diastolic blood pressure;
LIHC	cis	rs57590327	0.679	rs1907880	chr3:81567861	C/T	cg07356753	chr3:81810745	GBE1	-0.45	-6.14	-0.32	2.28e-9	Extraversion;
LIHC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg03013999	chr17:37608204	MED1	0.36	6.03	0.31	4.18e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.49	-9.52	-0.46	3.32e-19	Endometriosis;
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.42	8.51	0.42	5.4e-16	Renal cell carcinoma;
LIHC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.65	-6.6	-0.34	1.57e-10	Vitiligo;
LIHC	cis	rs10431058	0.965	rs1939895	chr11:107483469	C/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.39	6.24	0.32	1.3e-9	Common traits (Other);
LIHC	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	7.22	0.36	3.34e-12	Bipolar disorder;
LIHC	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	7.79	0.39	8.15e-14	Systemic lupus erythematosus;
LIHC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.06	15.78	0.65	1.58e-42	Cognitive function;
LIHC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-6.56	-0.33	1.95e-10	IgG glycosylation;
LIHC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg05555928	chr11:63887634	MACROD1	0.54	7.16	0.36	4.95e-12	Mean platelet volume;
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg27432699	chr2:27873401	GPN1	-0.53	-7.59	-0.38	2.98e-13	Total body bone mineral density;
LIHC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-7.56	-0.38	3.86e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	17.03	0.68	1.64e-47	Lung cancer in ever smokers;
LIHC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg16724585	chr3:197361211	NA	-0.47	-6.61	-0.34	1.46e-10	Pancreatic cancer;
LIHC	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.59	6.83	0.35	3.85e-11	Bipolar disorder;
LIHC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg22633049	chr21:46681294	NA	-0.37	-6.31	-0.32	8.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00938859	chr5:1591904	SDHAP3	0.56	7.15	0.36	5.34e-12	Breast cancer;
LIHC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21467203	chr3:49911342	NA	-0.61	-11.17	-0.52	6.36e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs61440199	1.000	rs73818808	chr3:20136085	T/C	cg00235661	chr3:20228976	SGOL1	-0.41	-5.8	-0.3	1.48e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs8056893	0.714	rs1465468	chr16:68398290	A/G	cg02226672	chr16:68398533	SMPD3	0.43	6.13	0.31	2.42e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs9322817	0.691	rs9391241	chr6:105223663	T/C	cg02098413	chr6:105308735	HACE1	-0.42	-7.55	-0.38	4.01e-13	Thyroid stimulating hormone;
LIHC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.69	9.96	0.47	1.06e-20	Monocyte percentage of white cells;
LIHC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg10932868	chr11:921992	NA	-0.31	-5.79	-0.3	1.61e-8	Alzheimer's disease (late onset);
LIHC	cis	rs7395581	0.918	rs7124955	chr11:47315274	A/T	cg26139080	chr11:47293733	MADD	-0.49	-8.03	-0.4	1.57e-14	HDL cholesterol;
LIHC	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg16583315	chr14:65563665	MAX	-0.38	-7.26	-0.37	2.6e-12	Obesity-related traits;
LIHC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	11.16	0.52	6.93e-25	Lung cancer in ever smokers;
LIHC	cis	rs903552	1.000	rs12906575	chr15:102003617	G/A	cg00659931	chr15:102010125	PCSK6	-0.44	-5.96	-0.31	6.15e-9	Diabetic kidney disease;
LIHC	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.42	-5.89	-0.3	9.11e-9	Stearic acid (18:0) levels;
LIHC	cis	rs17152411	0.600	rs7902120	chr10:126679739	C/T	cg07906193	chr10:126599966	NA	-0.29	-5.74	-0.3	2.07e-8	Height;
LIHC	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg18478394	chr8:109455254	TTC35	0.42	7.24	0.36	2.98e-12	Dupuytren's disease;
LIHC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	ch.11.42038R	chr11:967971	AP2A2	0.55	10.0	0.48	7.97e-21	Alzheimer's disease (late onset);
LIHC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.6	8.18	0.4	5.48e-15	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.57	-9.88	-0.47	2.02e-20	Systemic lupus erythematosus;
LIHC	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.76	0.34	5.97e-11	Type 2 diabetes;
LIHC	cis	rs778371	0.788	rs2675959	chr2:233791988	T/A	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.89	-0.39	4.02e-14	Schizophrenia;
LIHC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.53	7.53	0.38	4.48e-13	Prostate cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13494355	chr1:1274420	DVL1	0.42	6.47	0.33	3.42e-10	Longevity;
LIHC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg07148914	chr20:33460835	GGT7	0.44	5.89	0.3	9.1e-9	Coronary artery disease;
LIHC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.84	0.35	3.73e-11	Bipolar disorder;
LIHC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.65	7.4	0.37	1.08e-12	Neutrophil percentage of white cells;
LIHC	cis	rs4788570	0.615	rs10852503	chr16:71652227	G/C	cg06353428	chr16:71660113	MARVELD3	1.45	15.74	0.65	2.22e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-9.78	-0.47	4.28e-20	Asthma;
LIHC	cis	rs10508774	1.000	rs957219	chr10:32931910	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.65	10.61	0.5	6.14e-23	Platelet count;
LIHC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.26	-6.37	-0.33	6.24e-10	Crohn's disease;
LIHC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21467203	chr3:49911342	NA	0.44	7.76	0.39	1.01e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg03037974	chr15:76606532	NA	0.65	11.45	0.53	6.56e-26	Blood metabolite levels;
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.67	0.34	1.04e-10	Obesity-related traits;
LIHC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09695851	chr17:3907499	NA	0.67	11.13	0.52	8.99e-25	Type 2 diabetes;
LIHC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.56	-9.09	-0.44	8.42e-18	Cognitive function;
LIHC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.82	-13.9	-0.6	4.09e-35	Aortic root size;
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.55	8.29	0.41	2.62e-15	Longevity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18593717	chr1:156722068	HDGF	-0.43	-6.34	-0.32	7.17e-10	Pancreatic cancer;
LIHC	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg04359351	chr2:3481828	TTC15	-0.29	-5.8	-0.3	1.48e-8	Neurofibrillary tangles;
LIHC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.5	-8.05	-0.4	1.39e-14	Cognitive function;
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.62	0.56	3.02e-30	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.29	-0.45	1.82e-18	Diabetic kidney disease;
LIHC	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.69	7.21	0.36	3.66e-12	Blood protein levels;
LIHC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-7.24	-0.36	3.04e-12	Obesity (extreme);
LIHC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.57	0.38	3.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.9	19.37	0.72	6.1900000000000006e-57	Blood protein levels;
LIHC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	10.19	0.48	1.85e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg18016565	chr1:150552671	MCL1	0.54	10.05	0.48	5.25e-21	Melanoma;
LIHC	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.56	8.47	0.42	7.28e-16	Height;
LIHC	trans	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg01596870	chr19:55963115	NA	-0.67	-9.82	-0.47	3.31e-20	Obesity-related traits;
LIHC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg08896387	chr1:24191740	FUCA1	0.42	6.75	0.34	6.43e-11	Immature fraction of reticulocytes;
LIHC	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.8	-12.68	-0.57	1.78e-30	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.22	-0.32	1.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16958440	1.000	rs2289131	chr18:44602864	G/A	cg17192377	chr18:44677553	HDHD2	0.59	6.52	0.33	2.56e-10	Sitting height ratio;
LIHC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg22563815	chr15:78856949	CHRNA5	0.36	6.45	0.33	3.9e-10	Sudden cardiac arrest;
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg27432699	chr2:27873401	GPN1	-0.49	-7.07	-0.36	8.55e-12	Total body bone mineral density;
LIHC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.48	7.45	0.37	7.7e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.07	0.51	1.49e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg05361325	chr10:32636312	EPC1	-0.48	-5.87	-0.3	1e-8	Sexual dysfunction (female);
LIHC	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.7	-10.83	-0.51	1.06e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.74	-9.61	-0.46	1.59e-19	Morning vs. evening chronotype;
LIHC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.34	9.12	0.44	6.58e-18	Birth weight;
LIHC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.63	-8.95	-0.44	2.26e-17	Initial pursuit acceleration;
LIHC	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.75	8.03	0.4	1.61e-14	Schizophrenia;
LIHC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18867708	chr6:26865862	GUSBL1	-0.57	-8.61	-0.42	2.71e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.09e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-9.98	-0.47	9.42e-21	Body mass index;
LIHC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg14067834	chr17:29058358	SUZ12P	0.63	6.65	0.34	1.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.76e-11	Coronary artery disease;
LIHC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.73	-10.28	-0.49	9.12e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg18306943	chr3:40428807	ENTPD3	-0.44	-7.81	-0.39	6.94e-14	Renal cell carcinoma;
LIHC	cis	rs9309473	0.528	rs11126395	chr2:73564964	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.32	-0.37	1.82e-12	Metabolite levels;
LIHC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.62	-9.08	-0.44	8.74e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg11764359	chr7:65958608	NA	0.56	6.0	0.31	5.17e-9	Diabetic kidney disease;
LIHC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.56e-16	Crohn's disease;
LIHC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.99	0.4	2.13e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.15	16.08	0.66	9.8e-44	Corneal structure;
LIHC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.56	7.03	0.36	1.1e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.25	0.45	2.51e-18	Hemoglobin concentration;
LIHC	trans	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg05926928	chr17:57297772	GDPD1	0.71	8.98	0.44	1.82e-17	Schizophrenia;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg09148494	chr19:55866345	COX6B2;FAM71E2	0.43	6.16	0.32	2.01e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.66	-0.42	1.92e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg10935138	chr17:73851978	WBP2	-0.5	-7.38	-0.37	1.23e-12	White matter hyperintensity burden;
LIHC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.5	6.58	0.34	1.81e-10	Parkinson's disease;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15212038	chr4:7032128	TBC1D14	0.52	6.24	0.32	1.27e-9	Lung function (FEV1);
LIHC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.46	-6.79	-0.34	5e-11	Blood protein levels;
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.66	9.68	0.46	9.45e-20	Menarche (age at onset);
LIHC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02359409	chr6:42947317	PEX6	-0.47	-6.23	-0.32	1.39e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.59	10.12	0.48	3.02e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4690686	0.731	rs11941845	chr4:177276526	G/A	cg17059388	chr4:177262070	NA	0.36	6.61	0.34	1.46e-10	Essential tremor;
LIHC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.74	11.81	0.54	3.2e-27	Colorectal cancer;
LIHC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.87	15.47	0.64	2.69e-41	Dental caries;
LIHC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.77	12.02	0.55	5.25e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg18357526	chr6:26021779	HIST1H4A	0.58	8.01	0.4	1.85e-14	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07192821	chr15:45003560	B2M	0.43	6.28	0.32	1.01e-9	Cognitive function;
LIHC	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg27205649	chr11:78285834	NARS2	0.38	5.77	0.3	1.74e-8	Alzheimer's disease (survival time);
LIHC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.67	11.48	0.53	4.92e-26	Menopause (age at onset);
LIHC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.49	6.57	0.33	1.88e-10	Coronary artery disease;
LIHC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.33	6.02	0.31	4.54e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.45	6.81	0.35	4.47e-11	Type 2 diabetes;
LIHC	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg02219949	chr17:45927392	SP6	0.43	5.73	0.3	2.26e-8	Ease of getting up in the morning;
LIHC	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.82	10.27	0.49	9.58e-22	IgG glycosylation;
LIHC	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.33	-5.74	-0.3	2.08e-8	IgG glycosylation;
LIHC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.68	-12.74	-0.57	1.0500000000000001e-30	Refractive error;
LIHC	cis	rs9649465	0.967	rs12537072	chr7:123377213	A/G	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.25e-15	Migraine;
LIHC	cis	rs3823572	0.504	rs2346266	chr7:133639533	A/G	cg03336402	chr7:133662267	EXOC4	0.46	5.75	0.3	2e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.45	7.81	0.39	6.97e-14	Mean corpuscular volume;
LIHC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-6.57	-0.33	1.84e-10	Total cholesterol levels;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.43	6.06	0.31	3.52e-9	Longevity;Endometriosis;
LIHC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.58	-8.7	-0.43	1.37e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2607426	0.681	rs1455434	chr19:41257046	G/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.53	-5.82	-0.3	1.32e-8	Blood protein levels;
LIHC	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.05	-0.31	3.71e-9	Bipolar disorder;
LIHC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	0.91	16.41	0.66	5.02e-45	Parkinson's disease;
LIHC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg12042659	chr19:58951599	ZNF132	0.36	5.94	0.31	6.89e-9	Uric acid clearance;
LIHC	cis	rs12808519	0.646	rs12361755	chr11:69602646	C/T	cg19831575	chr11:69590090	FGF4	0.47	6.55	0.33	2.11e-10	Urate levels in overweight individuals;
LIHC	cis	rs546131	0.600	rs7946699	chr11:34820069	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.56	8.36	0.41	1.61e-15	Lung disease severity in cystic fibrosis;
LIHC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.5	7.61	0.38	2.65e-13	Red cell distribution width;
LIHC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.51	7.97	0.4	2.32e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.49	7.7	0.38	1.48e-13	Testicular germ cell tumor;
LIHC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.62	7.9	0.39	3.79e-14	Initial pursuit acceleration;
LIHC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.56	10.16	0.48	2.36e-21	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.65	7.88	0.39	4.33e-14	Heart rate;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.34	0.58	5.88e-33	Prudent dietary pattern;
LIHC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.37	-6.7	-0.34	8.6e-11	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.63	-0.46	1.43e-19	Platelet count;
LIHC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.59	-11.09	-0.51	1.25e-24	Mean corpuscular volume;
LIHC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.57	8.96	0.44	2.18e-17	Menarche (age at onset);
LIHC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.87	-0.3	1.01e-8	Axial length;
LIHC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg05361325	chr10:32636312	EPC1	-0.52	-6.4	-0.33	5.13e-10	Sexual dysfunction (female);
LIHC	cis	rs6952808	0.743	rs10266703	chr7:1918941	C/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.09	0.36	7.86e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	7.35	0.37	1.49e-12	Refractive astigmatism;
LIHC	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg05163923	chr11:71159392	DHCR7	-0.59	-7.27	-0.37	2.51e-12	Vitamin D levels;
LIHC	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.56	7.48	0.37	6.26e-13	Eotaxin levels;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.99	0.31	5.4e-9	Menopause (age at onset);
LIHC	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg17410650	chr12:54324560	NA	-0.4	-7.22	-0.36	3.4e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11388866	chr21:40752116	WRB	-0.45	-6.12	-0.31	2.5e-9	Hepatitis;
LIHC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Vitiligo;
LIHC	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.36	5.82	0.3	1.32e-8	Height;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg05484376	chr2:27715224	FNDC4	0.37	6.26	0.32	1.16e-9	Total body bone mineral density;
LIHC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.72	-0.43	1.26e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.48	8.34	0.41	1.84e-15	Lymphocyte percentage of white cells;
LIHC	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.91	18.37	0.7	6.44e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg03037974	chr15:76606532	NA	-0.6	-10.01	-0.48	7.34e-21	Blood metabolite levels;
LIHC	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg26395211	chr5:140044315	WDR55	-0.44	-6.49	-0.33	2.98e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.73	12.54	0.56	6.41e-30	Aortic root size;
LIHC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg11764359	chr7:65958608	NA	0.55	5.82	0.3	1.35e-8	Diabetic kidney disease;
LIHC	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.9	-0.35	2.49e-11	Endometrial cancer;
LIHC	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	5.76	0.3	1.84e-8	Response to antipsychotic treatment;
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.71	10.36	0.49	4.7e-22	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg23625390	chr15:77176239	SCAPER	0.34	5.9	0.3	8.63e-9	Blood metabolite levels;
LIHC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.69	11.64	0.53	1.36e-26	Crohn's disease;
LIHC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg22633049	chr21:46681294	NA	-0.35	-6.31	-0.32	8.69e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.39	7.45	0.37	7.91e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.59	8.43	0.41	9.64e-16	Aortic root size;
LIHC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.34	-0.32	7.41e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg02023728	chr11:77925099	USP35	0.37	6.5	0.33	2.9e-10	Alzheimer's disease (survival time);
LIHC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.97	11.23	0.52	4.15e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs3015497	0.648	rs10144512	chr14:51082271	A/C	cg09863266	chr14:51125203	SAV1	-0.38	-6.08	-0.31	3.15e-9	Mean platelet volume;
LIHC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.33	-0.32	7.63e-10	Longevity;
LIHC	cis	rs8067354	0.574	rs7219089	chr17:58032865	C/T	cg13753209	chr17:57696993	CLTC	0.71	10.58	0.5	8.01e-23	Hemoglobin concentration;
LIHC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.43	-6.97	-0.35	1.61e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg08477640	chr19:41863820	B9D2	0.36	6.08	0.31	3.27e-9	Colorectal cancer;
LIHC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.46	-5.74	-0.3	2.05e-8	Breast cancer;
LIHC	cis	rs244293	0.831	rs11079147	chr17:53094754	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.51	0.38	5.12e-13	Menarche (age at onset);
LIHC	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.48	7.42	0.37	9.58e-13	Diastolic blood pressure;
LIHC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	0.82	16.35	0.66	8.67e-45	Longevity;
LIHC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg06784218	chr1:46089804	CCDC17	0.35	5.75	0.3	1.97e-8	Platelet count;
LIHC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg08847533	chr14:75593920	NEK9	0.35	5.91	0.3	8.21e-9	Caffeine consumption;
LIHC	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.85	6.26	0.32	1.14e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.6	0.67	8.33e-46	Smoking behavior;
LIHC	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.32e-10	Pulmonary function;
LIHC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.5	-7.96	-0.4	2.59e-14	Cognitive function;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.56	10.27	0.49	9.91e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.68	12.15	0.55	1.69e-28	Lewy body disease;
LIHC	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.53	7.85	0.39	5.46e-14	Body mass index;
LIHC	cis	rs4759375	1.000	rs10773003	chr12:123775127	A/G	cg00376283	chr12:123451042	ABCB9	0.46	5.83	0.3	1.28e-8	HDL cholesterol;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg03721293	chr16:90014378	DEF8	0.4	6.78	0.34	5.4e-11	Skin colour saturation;
LIHC	cis	rs3018712	0.532	rs2510398	chr11:68421416	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.17e-8	Total body bone mineral density;
LIHC	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg19773385	chr1:10388646	KIF1B	-0.42	-7.38	-0.37	1.2e-12	Hepatocellular carcinoma;
LIHC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg19645103	chr12:69753606	YEATS4	-0.44	-5.81	-0.3	1.44e-8	Response to diuretic therapy;
LIHC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	10.87	0.51	7.73e-24	Response to antipsychotic treatment;
LIHC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.49	-7.09	-0.36	7.64e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs45544231	0.569	rs12443621	chr16:52548037	A/G	cg09051775	chr16:52580266	TOX3	-0.32	-5.77	-0.3	1.81e-8	Restless legs syndrome;
LIHC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.46	6.24	0.32	1.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.42	6.77	0.34	5.73e-11	Menopause (age at onset);
LIHC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.09	-0.4	1.04e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.89	-17.31	-0.68	1.19e-48	Height;
LIHC	cis	rs2108622	0.727	rs9305069	chr19:15983386	A/G	cg13772218	chr19:15982569	NA	0.37	7.61	0.38	2.7e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-8.03	-0.4	1.57e-14	Body mass index;
LIHC	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.07	0.48	4.47e-21	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.42	8.35	0.41	1.76e-15	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.2	16.12	0.66	6.97e-44	Diabetic kidney disease;
LIHC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02985541	chr2:219472218	PLCD4	-0.44	-7.99	-0.4	2.04e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg16405210	chr4:1374714	KIAA1530	0.45	5.71	0.3	2.39e-8	Obesity-related traits;
LIHC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.69	10.75	0.5	1.98e-23	Body mass index;
LIHC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.57	11.35	0.52	1.45e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.52	6.62	0.34	1.38e-10	Menarche (age at onset);
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.64	9.34	0.45	1.24e-18	Menarche (age at onset);
LIHC	trans	rs2744203	1.000	rs2473166	chr6:104643048	G/A	cg27088726	chr16:83171155	CDH13	-0.45	-6.2	-0.32	1.66e-9	IgG glycosylation;
LIHC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.53	6.98	0.35	1.57e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.33	2.47e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.56	8.12	0.4	8.62e-15	Alzheimer's disease;
LIHC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg15691649	chr6:25882328	NA	0.48	6.72	0.34	7.63e-11	Blood metabolite levels;
LIHC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.72	8.48	0.42	6.69e-16	Menarche (age at onset);
LIHC	cis	rs6466055	0.932	rs7811681	chr7:104928869	A/G	cg04380332	chr7:105027541	SRPK2	0.34	6.4	0.33	5.02e-10	Schizophrenia;
LIHC	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg16275483	chr1:110013120	SYPL2	-0.5	-6.2	-0.32	1.65e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7707921	0.881	rs60733727	chr5:81448283	G/A	cg15871215	chr5:81402204	ATG10	-0.61	-5.93	-0.31	7.3e-9	Breast cancer;
LIHC	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.46	-7.2	-0.36	3.81e-12	Type 2 diabetes;
LIHC	cis	rs4853525	0.522	rs62179717	chr2:191590813	T/G	cg10560079	chr2:191398806	TMEM194B	-0.42	-5.75	-0.3	2.03e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs7668874	0.779	rs7656260	chr4:116809546	T/G	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg20991723	chr1:152506922	NA	-0.5	-8.84	-0.43	5.15e-17	Hair morphology;
LIHC	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	8.84	0.43	5.11e-17	Total cholesterol levels;
LIHC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.19	0.36	4.06e-12	Parkinson's disease;
LIHC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.64	7.32	0.37	1.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.57	-0.33	1.89e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-0.68	-11.7	-0.53	8.04e-27	Pediatric autoimmune diseases;
LIHC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg08992911	chr2:238395768	MLPH	0.55	6.44	0.33	4.12e-10	Prostate cancer;
LIHC	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.04	-0.36	1.05e-11	Major depressive disorder;
LIHC	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.54	-8.2	-0.41	5.01e-15	Schizophrenia;
LIHC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg27124370	chr19:33622961	WDR88	0.47	7.07	0.36	8.6e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.47	-0.42	7.47e-16	Exhaled nitric oxide output;
LIHC	cis	rs6466055	0.720	rs1204060	chr7:104963064	T/C	cg04380332	chr7:105027541	SRPK2	0.37	6.88	0.35	2.84e-11	Schizophrenia;
LIHC	cis	rs7106204	0.858	rs2403889	chr11:24210226	T/C	ch.11.24196551F	chr11:24239977	NA	0.76	10.13	0.48	2.98e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs7131987	0.630	rs1006409	chr12:29435675	A/G	cg14222432	chr12:29376421	FAR2	0.31	6.49	0.33	2.95e-10	QT interval;
LIHC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-8.0	-0.4	1.92e-14	Crohn's disease;
LIHC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg07527105	chr16:88053339	BANP	-0.4	-5.75	-0.3	1.97e-8	Menopause (age at onset);
LIHC	cis	rs12960505	0.506	rs1039452	chr18:50953078	C/T	cg24270629	chr18:50823537	DCC	-0.48	-6.72	-0.34	7.41e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs16828019	0.852	rs12044539	chr1:41661732	A/C	cg03387723	chr1:41708464	SCMH1	-0.44	-7.13	-0.36	5.91e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6540556	0.723	rs6672256	chr1:209894043	A/T	cg05527609	chr1:210001259	C1orf107	0.53	6.86	0.35	3.23e-11	Red blood cell count;
LIHC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg01864836	chr14:55583639	NA	-0.39	-7.27	-0.37	2.51e-12	Protein biomarker;
LIHC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.62	-8.92	-0.43	2.89e-17	Coronary artery disease;
LIHC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg05084668	chr3:125655381	ALG1L	-0.39	-6.13	-0.31	2.43e-9	Blood pressure (smoking interaction);
LIHC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.92	0.39	3.35e-14	Mean platelet volume;
LIHC	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg09572067	chr16:29127029	RRN3P2	0.57	8.61	0.42	2.77e-16	Menopause (age at onset);
LIHC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg20487152	chr13:99095054	FARP1	0.41	6.99	0.35	1.42e-11	Educational attainment (years of education);
LIHC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.69	13.42	0.59	2.86e-33	Coronary artery disease;
LIHC	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	0.73	12.64	0.56	2.55e-30	Testicular germ cell tumor;
LIHC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-6.83	-0.35	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	0.9	12.82	0.57	5.22e-31	Mitochondrial DNA levels;
LIHC	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg20991723	chr1:152506922	NA	0.54	9.1	0.44	7.75e-18	Hair morphology;
LIHC	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.29	-0.37	2.17e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg04374321	chr14:90722782	PSMC1	0.48	6.55	0.33	2.14e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg02081065	chr5:132209139	LEAP2	0.26	5.73	0.3	2.23e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	0.77	9.19	0.45	3.89e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	7.2	0.36	3.8e-12	Protein C levels;
LIHC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.11e-31	Sense of smell;
LIHC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.64	0.34	1.25e-10	Rheumatoid arthritis;
LIHC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs4388979	0.894	rs10850589	chr12:109499490	C/T	cg03220751	chr12:109490328	USP30	0.87	13.09	0.58	5.04e-32	Plateletcrit;Platelet count;
LIHC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.84	-12.28	-0.55	5.99e-29	Diastolic blood pressure;
LIHC	cis	rs35150201	0.818	rs7810260	chr7:135311120	G/A	cg23117316	chr7:135346802	PL-5283	-0.28	-5.85	-0.3	1.13e-8	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg12311636	chr6:118886798	C6orf204	-0.53	-6.22	-0.32	1.44e-9	Diastolic blood pressure;
LIHC	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.61	9.77	0.47	4.92e-20	Resting heart rate;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04237075	chr9:34637949	SIGMAR1	0.41	6.18	0.32	1.85e-9	Pancreatic cancer;
LIHC	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg27205649	chr11:78285834	NARS2	-0.4	-5.73	-0.3	2.2e-8	Alzheimer's disease (survival time);
LIHC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.07e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2292096	1.000	rs10494818	chr1:200749160	A/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-6.17	-0.32	1.96e-9	Epilepsy;
LIHC	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.56	7.45	0.37	7.45e-13	Body mass index (adult);
LIHC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.78	12.48	0.56	9.9e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.45	0.33	3.74e-10	Menarche (age at onset);
LIHC	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.48	-6.46	-0.33	3.53e-10	Alzheimer's disease biomarkers;
LIHC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.34	6.23	0.32	1.39e-9	Mean corpuscular volume;
LIHC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.58	9.27	0.45	2.11e-18	Lymphocyte counts;
LIHC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.57	8.59	0.42	3.12e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.05	-0.31	3.78e-9	Total body bone mineral density;
LIHC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg24130564	chr14:104152367	KLC1	-0.55	-9.16	-0.44	4.73e-18	Reticulocyte count;
LIHC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.41	0.56	1.91e-29	Cognitive test performance;
LIHC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	10.86	0.51	8.58e-24	Colorectal cancer;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.42	-5.73	-0.3	2.19e-8	Total body bone mineral density;
LIHC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	5.91	0.3	8.32e-9	Platelet count;
LIHC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg03013999	chr17:37608204	MED1	0.35	5.9	0.3	8.82e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.25	0.45	2.4e-18	Bipolar disorder;
LIHC	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg27205649	chr11:78285834	NARS2	0.39	5.96	0.31	6.31e-9	Alzheimer's disease (survival time);
LIHC	trans	rs1920116	0.778	rs2421829	chr3:169554264	T/C	cg00669760	chr2:44735195	C2orf34	0.38	6.05	0.31	3.79e-9	Glioma (high-grade);
LIHC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	1.05	15.56	0.64	1.18e-41	Breast cancer;
LIHC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.45	7.46	0.37	7.34e-13	Breast cancer;
LIHC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11645453	chr3:52864694	ITIH4	0.22	5.96	0.31	6.38e-9	Bipolar disorder;
LIHC	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg22138327	chr13:27999177	GTF3A	0.75	5.89	0.3	9.31e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs4650994	0.593	rs2811297	chr1:178551472	C/T	cg05350800	chr1:178550844	NA	-0.31	-6.89	-0.35	2.77e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs918629	0.761	rs10073752	chr5:95279233	A/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.1	-0.31	2.85e-9	IgG glycosylation;
LIHC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.18	-0.68	3.93e-48	Gut microbiome composition (summer);
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.23	-0.32	1.36e-9	Longevity;Endometriosis;
LIHC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.77	-0.5	1.68e-23	Platelet count;
LIHC	cis	rs17106184	0.892	rs111701702	chr1:51284446	T/C	cg07174182	chr1:51127561	FAF1	-0.65	-7.17	-0.36	4.69e-12	Type 2 diabetes;
LIHC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.64	0.53	1.27e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg14930904	chr10:32216787	ARHGAP12	0.4	7.07	0.36	8.68e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-8.84	-0.43	5.16e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.63	0.5	5.46e-23	Platelet count;
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.54e-79	Prudent dietary pattern;
LIHC	cis	rs332507	0.830	rs11714527	chr3:124422722	G/A	cg05980111	chr3:124395277	KALRN	0.42	6.53	0.33	2.44e-10	Plateletcrit;
LIHC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.32	-0.52	1.95e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg25894440	chr7:65020034	NA	0.54	6.25	0.32	1.23e-9	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09774412	chr22:50902130	SBF1	0.43	6.28	0.32	1.04e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.7	12.63	0.56	2.87e-30	Longevity;
LIHC	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.38	7.2	0.36	3.94e-12	Testicular germ cell tumor;
LIHC	cis	rs981946	0.544	rs10498660	chr6:3343544	C/T	cg18842474	chr6:3356384	SLC22A23	0.36	5.8	0.3	1.5e-8	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.83	-0.3	1.3e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs785830	0.717	rs617453	chr9:223339	A/G	cg14500300	chr9:211689	NA	0.29	6.7	0.34	8.67e-11	Platelet distribution width;
LIHC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.41	-7.29	-0.37	2.21e-12	Coronary artery disease;
LIHC	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.5	9.39	0.45	8.76e-19	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.46	-7.12	-0.36	6.59e-12	Cognitive function;
LIHC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	0.87	11.88	0.54	1.69e-27	Skin colour saturation;
LIHC	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.74	11.24	0.52	3.75e-25	Eye color traits;
LIHC	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.77	-9.82	-0.47	3.38e-20	Body mass index;
LIHC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.62	-10.39	-0.49	3.69e-22	Alcohol dependence;
LIHC	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg25039879	chr17:56429692	SUPT4H1	0.76	8.29	0.41	2.66e-15	Cognitive test performance;
LIHC	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.57	9.44	0.45	6.19e-19	Corneal astigmatism;
LIHC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg01629716	chr15:45996671	NA	0.51	9.12	0.44	6.75e-18	Waist circumference;Weight;
LIHC	trans	rs4596713	0.538	rs10781456	chr9:71782869	G/A	cg16512924	chr15:28394682	HERC2	0.39	6.26	0.32	1.18e-9	Headache;
LIHC	cis	rs7091068	0.616	rs7920366	chr10:95497178	A/T	cg20715218	chr10:95462985	C10orf4	0.59	6.15	0.32	2.22e-9	Urinary tract infection frequency;
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	8.68	0.42	1.62e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.53	7.98	0.4	2.31e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07147234	chr12:56522077	ESYT1	0.43	6.09	0.31	3.05e-9	Pancreatic cancer;
LIHC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.45	6.56	0.33	1.97e-10	Aortic root size;
LIHC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg03037974	chr15:76606532	NA	0.78	15.94	0.65	3.71e-43	Blood metabolite levels;
LIHC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.93	-0.39	3.22e-14	Type 2 diabetes;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.83	0.3	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg26939375	chr7:64535504	NA	0.47	7.17	0.36	4.73e-12	Aortic root size;
LIHC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-8.03	-0.4	1.64e-14	Schizophrenia;
LIHC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.26	-0.32	1.17e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.67	-10.07	-0.48	4.72e-21	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.39	6.28	0.32	1.02e-9	Menopause (age at onset);
LIHC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg00142150	chr22:38071001	LGALS1	0.7	11.36	0.52	1.42e-25	Fat distribution (HIV);
LIHC	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg15472797	chr10:135243109	NA	-0.4	-6.59	-0.34	1.63e-10	Systemic lupus erythematosus;
LIHC	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.71	8.9	0.43	3.28e-17	Migraine;
LIHC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	12.34	0.56	3.48e-29	Cognitive test performance;
LIHC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.06	0.48	5.15e-21	Colorectal cancer;
LIHC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.55	7.49	0.38	6.01e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7429990	0.901	rs6442102	chr3:48152562	A/G	cg11946769	chr3:48343235	NME6	-0.48	-6.41	-0.33	4.81e-10	Educational attainment (years of education);
LIHC	cis	rs2531992	1.000	rs2531992	chr16:4021734	A/G	cg05927578	chr16:4029543	ADCY9	0.58	6.81	0.35	4.31e-11	Waist circumference;
LIHC	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.62	-6.98	-0.35	1.53e-11	Opioid sensitivity;
LIHC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02290350	chr8:58132656	NA	0.42	8.78	0.43	7.73e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-7.24	-0.36	2.93e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1892700	0.764	rs1804385	chr21:34896962	C/G	cg14850771	chr21:34775459	IFNGR2	-0.46	-6.15	-0.32	2.11e-9	Educational attainment;
LIHC	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	5.77	0.3	1.81e-8	Birth weight;
LIHC	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.37	6.22	0.32	1.49e-9	Mean corpuscular volume;
LIHC	cis	rs965469	1.000	rs2236123	chr20:3305305	C/G	cg25506879	chr20:3388711	C20orf194	0.51	5.84	0.3	1.23e-8	IFN-related cytopenia;
LIHC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.13	0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg01236616	chr12:121019343	POP5	-1.32	-17.01	-0.68	1.81e-47	Type 1 diabetes nephropathy;
LIHC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	1.06	12.64	0.56	2.63e-30	Vitiligo;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22481253	chr6:34204911	HMGA1	0.45	6.35	0.32	6.96e-10	Triglycerides;
LIHC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.47	7.37	0.37	1.31e-12	Height;
LIHC	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg26031613	chr14:104095156	KLC1	-0.4	-5.83	-0.3	1.26e-8	Coronary artery disease;
LIHC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.2	-0.36	3.77e-12	Height;
LIHC	cis	rs986417	0.748	rs11158289	chr14:61032390	C/T	cg27398547	chr14:60952738	C14orf39	0.57	7.05	0.36	9.75e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.35	5.72	0.3	2.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.32	5.77	0.3	1.77e-8	Diastolic blood pressure;
LIHC	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.26	-0.32	1.17e-9	Coronary artery disease;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg02902477	chr6:26197071	HIST1H3D	0.53	5.87	0.3	1.01e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.58	9.76	0.47	5.19e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4979906	1.000	rs7923587	chr10:79453218	C/T	cg07817648	chr10:79422355	NA	0.29	6.33	0.32	7.81e-10	Mortality in heart failure;
LIHC	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.73	10.46	0.49	2.09e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.6	8.48	0.42	6.68e-16	Blood metabolite levels;
LIHC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.35	-7.7	-0.38	1.45e-13	Longevity;
LIHC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.54	-0.5	1.08e-22	Hemoglobin concentration;
LIHC	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg27561452	chr16:68573240	ZFP90	0.42	6.34	0.32	7.29e-10	Brugada syndrome;
LIHC	cis	rs10818894	0.772	rs10120705	chr9:126692600	T/G	cg16191174	chr9:126692580	DENND1A	0.62	7.08	0.36	8.11e-12	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LIHC	cis	rs1144333	0.510	rs12408897	chr1:76448102	T/C	cg03433033	chr1:76189801	ACADM	0.54	7.46	0.37	7.27e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.86	15.56	0.64	1.14e-41	Body mass index;
LIHC	cis	rs74181299	0.533	rs12713533	chr2:65364702	G/T	cg05010058	chr2:65284262	CEP68	-0.37	-5.94	-0.31	6.83e-9	Pulse pressure;
LIHC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.79	-0.34	5.05e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg23485639	chr6:28045615	ZNF165	0.39	6.11	0.31	2.72e-9	Parkinson's disease;
LIHC	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg18225595	chr11:63971243	STIP1	-0.64	-9.7	-0.46	8.27e-20	Platelet count;
LIHC	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.56	8.16	0.4	6.33e-15	Obesity-related traits;
LIHC	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.41	5.78	0.3	1.67e-8	Systolic blood pressure;
LIHC	cis	rs11229555	0.645	rs11229442	chr11:58196790	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg22481606	chr17:56429567	SUPT4H1	-0.47	-6.09	-0.31	2.98e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.7	-9.32	-0.45	1.49e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.4	8.04	0.4	1.49e-14	Cardiovascular disease risk factors;
LIHC	cis	rs7212590	0.618	rs7217337	chr17:58023417	C/T	cg10252138	chr17:58120427	NA	-0.58	-5.91	-0.3	8.12e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg08847533	chr14:75593920	NEK9	0.54	8.35	0.41	1.67e-15	IgG glycosylation;
LIHC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.34	-8.83	-0.43	5.38e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.74	-9.75	-0.47	5.47e-20	Schizophrenia;
LIHC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.51	7.94	0.39	2.95e-14	Adiposity;
LIHC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.81	-0.39	7.04e-14	Response to antipsychotic treatment;
LIHC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.74	-0.43	1.1e-16	Total cholesterol levels;
LIHC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.85	-0.3	1.18e-8	Subjective well-being;
LIHC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.62	-9.49	-0.46	4.18e-19	Aortic root size;
LIHC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	11.8	0.54	3.45e-27	Colorectal cancer;
LIHC	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg18081818	chr7:23246105	NA	-0.4	-5.93	-0.31	7.36e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	12.61	0.56	3.21e-30	Mean platelet volume;
LIHC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.99	-0.31	5.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg17830980	chr10:43048298	ZNF37B	0.34	6.27	0.32	1.07e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.43	8.06	0.4	1.28e-14	Red cell distribution width;
LIHC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg02079420	chr8:82753780	SNX16	0.34	5.86	0.3	1.06e-8	Diastolic blood pressure;
LIHC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-8.04	-0.4	1.45e-14	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.29	-0.45	1.82e-18	Diabetic kidney disease;
LIHC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.78	-0.82	6.04e-86	Myeloid white cell count;
LIHC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.83	0.35	3.91e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	7.79	0.39	8.15e-14	Blood protein levels;
LIHC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	10.53	0.49	1.2e-22	Lung cancer;
LIHC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg24826892	chr11:71159390	DHCR7	0.5	6.48	0.33	3.15e-10	Vitamin D levels;
LIHC	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.52	8.01	0.4	1.83e-14	Type 2 diabetes;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.6	6.01	0.31	4.64e-9	Carotid intima media thickness;
LIHC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.18	0.4	5.73e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06942197	chr17:38804076	SMARCE1	-0.48	-6.77	-0.34	5.57e-11	Pancreatic cancer;
LIHC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg17750252	chr2:136567154	LCT	0.35	6.0	0.31	5.07e-9	Mosquito bite size;
LIHC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	9.68	0.46	9.36e-20	Body mass index;
LIHC	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.4	5.97	0.31	5.9e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg18081818	chr7:23246105	NA	-0.39	-5.99	-0.31	5.35e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.96	15.09	0.63	8.93e-40	Skin colour saturation;
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg08916839	chr5:415575	AHRR	0.29	6.18	0.32	1.87e-9	Cystic fibrosis severity;
LIHC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.83	0.35	3.94e-11	Personality dimensions;
LIHC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.9	-0.39	3.88e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.42	-0.33	4.57e-10	Diabetic kidney disease;
LIHC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.07e-18	Schizophrenia;
LIHC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-8.72	-0.43	1.2e-16	Atrioventricular conduction;
LIHC	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.71	8.11	0.4	8.94e-15	Schizophrenia;
LIHC	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.36	-5.88	-0.3	9.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.72	-0.3	2.35e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.5	-10.73	-0.5	2.4e-23	Birth weight;
LIHC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.35	0.77	7.7e-69	Chronic sinus infection;
LIHC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.4	-7.3	-0.37	2.08e-12	Aortic root size;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg12376772	chr13:32526694	EEF1DP3	0.63	6.55	0.33	2.09e-10	Mean platelet volume;
LIHC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.71	11.17	0.52	6.58e-25	Corneal astigmatism;
LIHC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.47	-7.09	-0.36	7.77e-12	Height;
LIHC	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg14593290	chr7:50529359	DDC	-0.46	-7.44	-0.37	8.02e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.7	12.35	0.56	3.04e-29	Colorectal cancer;
LIHC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg03859395	chr2:55845619	SMEK2	0.78	13.22	0.58	1.57e-32	Metabolic syndrome;
LIHC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg04709771	chr16:646395	RAB40C	0.47	8.3	0.41	2.44e-15	Height;
LIHC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg27523141	chr10:43048294	ZNF37B	0.38	6.53	0.33	2.43e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.36	6.0	0.31	5.07e-9	Blood metabolite levels;
LIHC	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg25783544	chr11:47291846	MADD	0.41	5.82	0.3	1.33e-8	HDL cholesterol;
LIHC	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-6.88	-0.35	2.95e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.32	-5.75	-0.3	2.03e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.45	-0.37	7.76e-13	Obesity-related traits;
LIHC	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.75e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.77	11.52	0.53	3.61e-26	Coronary artery disease;
LIHC	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.27	6.25	0.32	1.21e-9	Heart rate;
LIHC	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg20129853	chr10:51489980	NA	-0.41	-8.96	-0.44	2.13e-17	Prostate-specific antigen levels;
LIHC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.67	8.61	0.42	2.62e-16	Initial pursuit acceleration;
LIHC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.72	0.54	6.76e-27	Motion sickness;
LIHC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.06	-0.36	9.18e-12	IgG glycosylation;
LIHC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-7.9	-0.39	3.86e-14	Vitiligo;
LIHC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-10.4	-0.49	3.41e-22	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.85	0.35	3.39e-11	Height;
LIHC	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg09795085	chr6:101329169	ASCC3	0.51	7.19	0.36	4.11e-12	Neuroticism;
LIHC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.34	0.45	1.22e-18	Hemoglobin concentration;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.96	0.54	8.7300000000000009e-28	Prudent dietary pattern;
LIHC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.47	-6.94	-0.35	2e-11	Response to metformin (IC50);
LIHC	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.91	-0.3	8.19e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg06289844	chr6:126071538	HEY2	0.38	6.62	0.34	1.42e-10	Brugada syndrome;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.59	-8.32	-0.41	2.15e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.41	-7.45	-0.37	7.78e-13	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08219700	chr8:58056026	NA	0.52	7.15	0.36	5.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.54	9.98	0.47	9.5e-21	Bipolar disorder and schizophrenia;
LIHC	trans	rs3742264	0.656	rs6561275	chr13:46518299	A/T	cg08762273	chr6:26247270	HIST1H4G	0.3	6.04	0.31	4.08e-9	Blood protein levels;
LIHC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.65	-11.57	-0.53	2.47e-26	Coronary artery disease;
LIHC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg17724175	chr1:150552817	MCL1	0.38	7.45	0.37	7.66e-13	Melanoma;
LIHC	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-12.24	-0.55	8.19e-29	Coronary artery disease;
LIHC	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.52	9.44	0.45	6.17e-19	Coronary heart disease;
LIHC	cis	rs11822910	0.871	rs2581928	chr11:57202790	A/G	cg00522883	chr11:57194120	SLC43A3	-0.67	-8.89	-0.43	3.61e-17	Platelet distribution width;
LIHC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-9.55	-0.46	2.56e-19	Colorectal cancer;
LIHC	cis	rs6747952	0.899	rs2121404	chr2:239083826	A/G	cg17459225	chr2:239074497	NA	0.37	5.93	0.31	7.42e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.3	23.54	0.79	1.63e-73	Corneal structure;
LIHC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.53	-8.0	-0.4	2e-14	Metabolic syndrome;
LIHC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.45	6.41	0.33	4.71e-10	Morning vs. evening chronotype;
LIHC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.75	-11.19	-0.52	5.54e-25	Subjective well-being;
LIHC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.23	0.41	4.09e-15	Platelet count;
LIHC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg03945807	chr20:60948434	NA	0.4	6.5	0.33	2.86e-10	Colorectal cancer;
LIHC	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg01231543	chr16:68741748	NA	0.39	6.02	0.31	4.51e-9	Colorectal cancer;
LIHC	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.64	-11.26	-0.52	3.11e-25	Breast cancer;
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27297192	chr10:134578999	INPP5A	0.51	6.88	0.35	2.86e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12379764	chr21:47803548	PCNT	0.56	8.12	0.4	8.31e-15	Testicular germ cell tumor;
LIHC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.27	0.52	2.88e-25	Menopause (age at onset);
LIHC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.6	9.06	0.44	1e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.53	-7.46	-0.37	7.12e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs10838687	0.800	rs2290146	chr11:47353498	G/A	cg26139080	chr11:47293733	MADD	-0.41	-5.73	-0.3	2.19e-8	Proinsulin levels;
LIHC	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.55	0.5	1e-22	Hypertriglyceridemia;
LIHC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.66	-11.05	-0.51	1.73e-24	Childhood ear infection;
LIHC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.46	-0.37	7.3e-13	Breast cancer;
LIHC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg17519650	chr2:63277830	OTX1	-0.42	-6.69	-0.34	9.2e-11	Coronary artery disease;
LIHC	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg16589663	chr20:23618590	CST3	0.72	7.58	0.38	3.35e-13	Chronic kidney disease;
LIHC	cis	rs116248771	0.739	rs73156428	chr3:158346471	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.26	0.32	1.14e-9	diarrhoeal disease at age 2;
LIHC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg22834771	chr12:69754056	YEATS4	-0.38	-5.84	-0.3	1.22e-8	Response to diuretic therapy;
LIHC	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.83	16.3	0.66	1.31e-44	Testicular germ cell tumor;
LIHC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg13385521	chr17:29058706	SUZ12P	0.58	5.8	0.3	1.54e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-7.18	-0.36	4.42e-12	Obesity-related traits;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.65	0.42	2e-16	Prudent dietary pattern;
LIHC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.53	6.35	0.32	6.99e-10	Morning vs. evening chronotype;
LIHC	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.64	9.92	0.47	1.55e-20	Lymphocyte counts;
LIHC	cis	rs2737618	0.651	rs2816976	chr1:200081021	A/T	cg21825944	chr1:200113062	NR5A2	-0.46	-7.95	-0.4	2.67e-14	Uric acid levels;
LIHC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.61	-9.99	-0.48	8.77e-21	Post bronchodilator FEV1;
LIHC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.59	8.62	0.42	2.54e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-8.31	-0.41	2.25e-15	Morning vs. evening chronotype;
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.64	9.7	0.46	8.44e-20	Renal cell carcinoma;
LIHC	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-12.08	-0.55	3.32e-28	Alzheimer's disease (late onset);
LIHC	cis	rs10845606	0.560	rs7973428	chr12:12828050	C/T	cg09462578	chr12:12878428	APOLD1	-0.42	-6.11	-0.31	2.7e-9	Systemic lupus erythematosus;
LIHC	cis	rs3741798	1.000	rs3825259	chr12:12496635	A/G	cg08615371	chr12:12503544	MANSC1	0.9	7.31	0.37	1.85e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-11.18	-0.52	6.23e-25	Longevity;Endometriosis;
LIHC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	trans	rs73198271	0.515	rs17629935	chr8:8619381	A/T	cg06710121	chr8:12235606	FAM66A	0.63	6.23	0.32	1.35e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.68	0.34	9.72e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17776563	0.853	rs72763825	chr15:89149872	A/G	cg05013243	chr15:89149849	MIR1179	0.42	6.81	0.35	4.5e-11	Thyroid hormone levels;
LIHC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.09	-0.31	3.1e-9	Longevity;
LIHC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg24296786	chr1:45957014	TESK2	0.42	6.1	0.31	2.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-8.07	-0.4	1.17e-14	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.47	7.52	0.38	5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	10.45	0.49	2.23e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	8.5	0.42	6.02e-16	Blood metabolite levels;
LIHC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.62	11.09	0.51	1.26e-24	Dupuytren's disease;
LIHC	cis	rs2302190	0.882	rs8073754	chr17:56618030	C/T	cg12560992	chr17:57184187	TRIM37	0.7	8.94	0.44	2.45e-17	Vitamin D levels;
LIHC	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.51	9.35	0.45	1.14e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg09222892	chr1:25734099	RHCE	0.48	8.89	0.43	3.55e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.05	-0.55	4.07e-28	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.62	7.25	0.36	2.84e-12	Crohn's disease;
LIHC	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg05760424	chr2:242988095	NA	-0.5	-6.77	-0.34	5.51e-11	Obesity-related traits;
LIHC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.17	-13.04	-0.58	7.98e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.62	-10.87	-0.51	7.67e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg25665528	chr16:2260870	C16orf79	0.37	6.5	0.33	2.92e-10	Height;
LIHC	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg04306507	chr14:55594613	LGALS3	-0.31	-6.06	-0.31	3.62e-9	Protein biomarker;
LIHC	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.06	-0.31	3.67e-9	Tuberculosis;
LIHC	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.4	7.67	0.38	1.77e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	1.000	rs17097836	chr1:76462006	T/A	cg10523679	chr1:76189770	ACADM	0.42	5.96	0.31	6.4e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.39	-5.95	-0.31	6.57e-9	Educational attainment;
LIHC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	7.88	0.39	4.34e-14	IgG glycosylation;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg06535952	chr19:56126775	NA	0.43	6.4	0.33	5.03e-10	Alopecia areata;
LIHC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.47	7.58	0.38	3.32e-13	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	0.85	9.96	0.47	1.06e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.28	-7.17	-0.36	4.77e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.38	-6.35	-0.32	6.72e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg03934865	chr2:198174659	NA	0.51	7.99	0.4	2.06e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.45	-6.76	-0.34	6.04e-11	Asthma;
LIHC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.76	0.54	4.85e-27	Post bronchodilator FEV1;
LIHC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg16226627	chr15:75307476	SCAMP5	0.52	9.74	0.47	6.21e-20	Lung cancer;
LIHC	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.93	0.51	4.56e-24	Colorectal cancer;
LIHC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	9.61	0.46	1.59e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	0.94	10.21	0.48	1.51e-21	Vitiligo;
LIHC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.31	6.7	0.34	8.77e-11	Bone mineral density;
LIHC	cis	rs600806	0.676	rs573491	chr1:110026891	T/G	cg08911820	chr1:110026001	ATXN7L2	0.55	6.8	0.35	4.67e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.51	-0.33	2.7e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.78	-0.3	1.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.62	8.15	0.4	6.8e-15	Motion sickness;
LIHC	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma;
LIHC	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.37	-8.09	-0.4	1.02e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg17749961	chr2:30669863	LCLAT1	0.46	5.9	0.3	8.95e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg27211696	chr2:191398769	TMEM194B	-0.49	-6.45	-0.33	3.85e-10	Diastolic blood pressure;
LIHC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.59	9.6	0.46	1.74e-19	Type 2 diabetes;
LIHC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	6.27	0.32	1.06e-9	Initial pursuit acceleration;
LIHC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.82	10.34	0.49	5.56e-22	Cognitive function;
LIHC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.35	-7.25	-0.36	2.88e-12	Bone mineral density;
LIHC	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	7.0	0.35	1.33e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg20435097	chr10:126320824	FAM53B	-0.41	-5.98	-0.31	5.5e-9	Cocaine dependence;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg02869306	chr7:64672164	INTS4L1	0.28	6.05	0.31	3.73e-9	Calcium levels;
LIHC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	8.74	0.43	1.04e-16	Menarche (age at onset);
LIHC	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.13	-0.36	5.91e-12	Metabolite levels;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11905131	chr22:24372483	LOC391322	0.65	8.54	0.42	4.46e-16	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg04702396	chr17:15466718	FAM18B2	0.44	6.72	0.34	7.43e-11	Educational attainment (years of education);
LIHC	cis	rs9473924	0.505	rs9463663	chr6:50902266	G/A	cg14470998	chr6:50812995	TFAP2B	0.93	10.85	0.51	9.2e-24	Body mass index;
LIHC	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.07e-8	Osteoarthritis;
LIHC	cis	rs2997447	0.723	rs2802336	chr1:26473758	A/C	cg19633962	chr1:26362018	EXTL1	-0.54	-6.31	-0.32	8.46e-10	QRS complex (12-leadsum);
LIHC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.34	-5.99	-0.31	5.25e-9	Schizophrenia;
LIHC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.43	5.84	0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.04e-8	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg10664184	chr19:17420304	DDA1	0.45	5.74	0.3	2.12e-8	Systemic lupus erythematosus;
LIHC	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg06265175	chr8:121136014	COL14A1	0.48	7.72	0.39	1.34e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7487075	0.930	rs11183468	chr12:46806261	A/T	cg22049899	chr12:47219821	SLC38A4	0.34	6.02	0.31	4.6e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	2.04e-10	Personality dimensions;
LIHC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13126279	chr21:47581558	C21orf56	-0.38	-5.95	-0.31	6.52e-9	Testicular germ cell tumor;
LIHC	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.77	13.03	0.58	8.91e-32	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg24209194	chr3:40518798	ZNF619	0.42	5.97	0.31	6.06e-9	Renal cell carcinoma;
LIHC	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09140114	chr16:29324813	RUNDC2C	-0.44	-6.1	-0.31	2.82e-9	Menopause (age at onset);
LIHC	cis	rs831571	0.703	rs55714137	chr3:64076779	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.58	-6.62	-0.34	1.35e-10	Type 2 diabetes;
LIHC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg18944383	chr4:111397179	ENPEP	0.26	6.3	0.32	9.32e-10	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20211779	chr11:34378921	ABTB2	0.45	6.05	0.31	3.78e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg03945807	chr20:60948434	NA	0.44	6.72	0.34	7.46e-11	Colorectal cancer;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-14.86	-0.63	6.95e-39	Prudent dietary pattern;
LIHC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02475777	chr4:1388615	CRIPAK	0.39	5.83	0.3	1.31e-8	Longevity;
LIHC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.35	5.76	0.3	1.88e-8	Blood metabolite levels;
LIHC	cis	rs4728302	0.869	rs12707129	chr7:133593177	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.38	-6.06	-0.31	3.58e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.49	7.19	0.36	3.98e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	1.01	11.68	0.53	9.69e-27	IgG glycosylation;
LIHC	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.29	-0.45	1.9e-18	Type 2 diabetes;
LIHC	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.22e-9	Mean corpuscular volume;
LIHC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.81	-8.96	-0.44	2.15e-17	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11587315	chr1:223254976	NA	-0.47	-6.32	-0.32	8.33e-10	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg07424592	chr7:64974309	NA	-0.8	-9.29	-0.45	1.82e-18	Diabetic kidney disease;
LIHC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg07713946	chr22:31675144	LIMK2	-0.43	-7.81	-0.39	7.12e-14	Colorectal cancer;
LIHC	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	1.18	11.4	0.52	1.02e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg12560992	chr17:57184187	TRIM37	0.68	8.8	0.43	7e-17	Vitamin D levels;
LIHC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.46	-8.2	-0.41	4.95e-15	Prudent dietary pattern;
LIHC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.86	10.36	0.49	4.56e-22	Cognitive function;
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.83	-0.35	3.88e-11	Testicular germ cell tumor;
LIHC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg16486109	chr11:613632	IRF7	0.61	6.81	0.35	4.44e-11	Systemic lupus erythematosus;
LIHC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.22	0.32	1.43e-9	Tonsillectomy;
LIHC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg05590025	chr7:65112418	INTS4L2	-0.67	-7.36	-0.37	1.34e-12	Diabetic kidney disease;
LIHC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg14779329	chr11:130786720	SNX19	0.38	5.86	0.3	1.11e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.12	-0.44	6.36e-18	Bipolar disorder;
LIHC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.44	0.37	8.24e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.61	-10.59	-0.5	7.65e-23	Mean corpuscular volume;
LIHC	cis	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg20560298	chr2:73613845	ALMS1	0.36	5.73	0.3	2.16e-8	Schizophrenia;
LIHC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.86	0.43	4.31e-17	Lung cancer;
LIHC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg05941027	chr17:61774174	LIMD2	-0.31	-6.26	-0.32	1.14e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-12.37	-0.56	2.76e-29	Alzheimer's disease;
LIHC	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	8.07	0.4	1.19e-14	Electrocardiographic conduction measures;
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.52	-0.33	2.5e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs10847980	0.590	rs75217947	chr12:123346177	G/C	cg22842854	chr12:123319900	HIP1R	0.93	10.51	0.49	1.41e-22	Adiponectin levels;
LIHC	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.48	6.41	0.33	4.91e-10	Plateletcrit;
LIHC	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.39	-7.0	-0.35	1.35e-11	Asthma;
LIHC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg04756594	chr16:24857601	SLC5A11	0.44	6.89	0.35	2.64e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.38	0.37	1.22e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.15	-0.52	7.67e-25	Eye color traits;
LIHC	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.72	-0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.63	0.34	1.29e-10	Blood metabolite levels;
LIHC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg06050784	chr16:88016603	BANP	0.4	7.28	0.37	2.36e-12	Menopause (age at onset);
LIHC	cis	rs9303280	0.901	rs7219923	chr17:38074518	C/T	cg11212589	chr17:38028394	ZPBP2	-0.33	-6.66	-0.34	1.11e-10	Self-reported allergy;
LIHC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.46	-6.08	-0.31	3.21e-9	Blood metabolite levels;
LIHC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.23	0.45	2.83e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.92	0.39	3.47e-14	Lung cancer;
LIHC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.66	11.74	0.54	5.54e-27	High light scatter reticulocyte count;
LIHC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.85	13.94	0.6	2.63e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.82	13.71	0.6	2.07e-34	Monocyte count;
LIHC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.95	13.02	0.58	9.71e-32	Heart rate;
LIHC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12493885	0.818	rs60023390	chr3:153771056	C/T	cg10247383	chr3:153839028	SGEF	0.65	6.13	0.31	2.41e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7534824	0.625	rs72736234	chr1:101526098	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	7.12	0.36	6.25e-12	Refractive astigmatism;
LIHC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.46	-10.54	-0.5	1.15e-22	Arsenic metabolism;
LIHC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-10.44	-0.49	2.57e-22	Asthma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22672078	chr12:132628386	DDX51;NOC4L	-0.42	-6.19	-0.32	1.68e-9	Pancreatic cancer;
LIHC	trans	rs13381277	1.000	rs9959129	chr18:74329661	A/G	cg17352830	chr21:37617589	DOPEY2	0.54	6.47	0.33	3.46e-10	Dental caries;
LIHC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	6.42	0.33	4.51e-10	Lung cancer in ever smokers;
LIHC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.73	0.39	1.24e-13	Platelet count;
LIHC	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.58	9.43	0.45	6.45e-19	Corneal astigmatism;
LIHC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.58	8.88	0.43	3.78e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.45e-13	Prudent dietary pattern;
LIHC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg18912006	chr12:123335444	HIP1R	-0.61	-7.29	-0.37	2.1e-12	Schizophrenia;
LIHC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.46	7.34	0.37	1.56e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs507080	0.922	rs4938524	chr11:118552074	G/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.17	0.32	1.92e-9	Serum metabolite levels;
LIHC	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.22	-0.32	1.44e-9	Metabolite levels;
LIHC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.77	-10.9	-0.51	6.08e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02985541	chr2:219472218	PLCD4	0.45	8.68	0.42	1.62e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg16736954	chr20:23401023	NAPB	0.71	8.28	0.41	2.86e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg05044414	chr3:183734942	ABCC5	0.31	5.81	0.3	1.42e-8	Anterior chamber depth;
LIHC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.35	6.43	0.33	4.22e-10	Aortic root size;
LIHC	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg23461800	chr14:103021989	NA	0.45	6.3	0.32	8.99e-10	Platelet count;
LIHC	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.85	15.96	0.65	3.1e-43	Blood protein levels;
LIHC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.45	7.14	0.36	5.48e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.87	0.54	1.95e-27	Colorectal cancer;
LIHC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.8	8.77	0.43	8.83e-17	Vitiligo;
LIHC	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg25182066	chr10:30743637	MAP3K8	-0.6	-9.61	-0.46	1.59e-19	Inflammatory bowel disease;
LIHC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	21.03	0.75	1.37e-63	Smoking behavior;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg10150615	chr22:24372951	LOC391322	0.55	7.22	0.36	3.3e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03532005	chr7:56119028	CCT6A;PSPH	-0.41	-6.32	-0.32	8.29e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	8.24	0.41	3.74e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg11530693	chr1:120165357	ZNF697	0.47	7.53	0.38	4.59e-13	Systemic lupus erythematosus;
LIHC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.48	-7.84	-0.39	5.71e-14	Cognitive function;
LIHC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.94	-0.47	1.26e-20	Crohn's disease;
LIHC	cis	rs61712019	0.643	rs12997025	chr2:77711560	G/T	cg11252801	chr2:77748917	LRRTM4	0.55	7.59	0.38	3.17e-13	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	11.46	0.53	6.18e-26	Height;
LIHC	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.42	-8.29	-0.41	2.67e-15	Testicular germ cell tumor;
LIHC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	8.61	0.42	2.7e-16	Lymphocyte counts;
LIHC	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	0.78	9.07	0.44	9.76e-18	Exhaled nitric oxide output;
LIHC	cis	rs8081395	0.834	rs11650106	chr17:57850251	C/T	cg02344993	chr17:57696989	CLTC	-0.43	-6.96	-0.35	1.72e-11	White blood cell count;
LIHC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.52	-8.73	-0.43	1.18e-16	Cognitive function;
LIHC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.65	11.63	0.53	1.39e-26	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.62	-8.41	-0.41	1.1e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg25024717	chr12:54324583	NA	-0.32	-6.33	-0.32	7.9e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.76	11.64	0.53	1.36e-26	Vitamin D levels;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg19635926	chr16:89946313	TCF25	0.51	7.16	0.36	4.96e-12	Skin colour saturation;
LIHC	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.61	9.92	0.47	1.46e-20	Response to antidepressants and depression;
LIHC	cis	rs3733606	0.503	rs11734132	chr4:6891519	C/G	cg05012661	chr4:6891264	NA	-0.41	-6.75	-0.34	6.53e-11	Platelet count;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.72	-9.19	-0.44	3.97e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1029738	0.659	rs1608553	chr7:22896231	G/C	cg22407942	chr7:22894828	SNORD93	-0.34	-6.46	-0.33	3.68e-10	Fibrinogen levels;
LIHC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-8.53	-0.42	4.75e-16	Morning vs. evening chronotype;
LIHC	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.47	6.67	0.34	1.06e-10	Pulse pressure;
LIHC	cis	rs3736485	0.966	rs10467924	chr15:51787579	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.21	-0.32	1.5e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg26939375	chr7:64535504	NA	-0.43	-6.89	-0.35	2.67e-11	Aortic root size;
LIHC	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.31	7.57	0.38	3.48e-13	Gut microbiome composition (winter);
LIHC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25958857	chr12:53448399	TENC1	-0.44	-6.34	-0.32	7.07e-10	Cognitive function;
LIHC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.55	8.88	0.43	3.76e-17	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.61	-0.46	1.6e-19	Mean platelet volume;
LIHC	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.76	14.21	0.61	2.5e-36	Mean platelet volume;
LIHC	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs12144094	0.882	rs10218713	chr1:120247899	A/G	cg20995928	chr1:120229863	NA	0.42	7.29	0.37	2.2e-12	Height;
LIHC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg13844804	chr7:814759	HEATR2	0.44	5.89	0.3	9.46e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.64	8.01	0.4	1.81e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs7818688	0.745	rs16917117	chr8:95909498	C/T	cg16049864	chr8:95962084	TP53INP1	-0.51	-5.98	-0.31	5.72e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.82	12.15	0.55	1.81e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg15123519	chr2:136567270	LCT	-0.32	-5.72	-0.3	2.29e-8	Corneal structure;
LIHC	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg26395211	chr5:140044315	WDR55	0.41	6.15	0.32	2.17e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.11	-0.4	9.12e-15	Exhaled nitric oxide output;
LIHC	cis	rs12458462	0.851	rs62097746	chr18:77487508	G/A	cg11879182	chr18:77439856	CTDP1	0.83	13.38	0.59	4.01e-33	Monocyte count;
LIHC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.45	-0.37	7.77e-13	Type 2 diabetes;
LIHC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg25344623	chr2:136566232	LCT	-0.39	-7.89	-0.39	4.09e-14	Mosquito bite size;
LIHC	cis	rs36051895	0.589	rs7850294	chr9:5191128	C/T	cg02405213	chr9:5042618	JAK2	0.69	11.68	0.53	9.14e-27	Pediatric autoimmune diseases;
LIHC	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg12698662	chr3:15914712	MIR563	-0.39	-7.17	-0.36	4.54e-12	Mean platelet volume;
LIHC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.41	-5.72	-0.3	2.37e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg20291162	chr17:40259547	DHX58	-0.38	-5.75	-0.3	1.97e-8	Fibrinogen levels;
LIHC	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg12160578	chr15:63334699	TPM1	0.67	8.87	0.43	4.13e-17	Orofacial clefts;
LIHC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.88	12.06	0.55	3.77e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.46	-6.68	-0.34	9.68e-11	Height;
LIHC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.7	-9.52	-0.46	3.31e-19	Corneal structure;
LIHC	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02707576	chr5:139682775	PFDN1	0.38	6.09	0.31	2.98e-9	Calcium levels;
LIHC	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg18898632	chr2:242989856	NA	0.52	7.02	0.35	1.22e-11	Obesity-related traits;
LIHC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.49	0.56	9.2e-30	Cognitive test performance;
LIHC	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.77	11.13	0.52	8.89e-25	Obesity-related traits;
LIHC	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.1	-0.31	2.83e-9	Ulcerative colitis;
LIHC	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.66	9.13	0.44	6.3e-18	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg15848620	chr12:58087721	OS9	-0.58	-7.88	-0.39	4.52e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-6.13	-0.31	2.37e-9	Menarche (age at onset);
LIHC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.54	-9.21	-0.45	3.28e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.42	0.41	1.09e-15	Lung cancer in ever smokers;
LIHC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-5.79	-0.3	1.6e-8	Schizophrenia;
LIHC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.37	-0.41	1.51e-15	Aortic root size;
LIHC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.64	10.83	0.51	1.07e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.34e-24	Subjective well-being;
LIHC	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.8	9.11	0.44	7.17e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg16586182	chr3:47516702	SCAP	0.58	10.74	0.5	2.14e-23	Colorectal cancer;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17842912	chr5:139060919	CXXC5	0.5	6.37	0.33	6.22e-10	Lung function (FEV1);
LIHC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	6.67	0.34	1.01e-10	Schizophrenia;
LIHC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.89	0.39	4.22e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg18192155	chr21:44258298	NA	0.4	6.27	0.32	1.09e-9	Information processing speed;
LIHC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.63	10.34	0.49	5.59e-22	Smoking initiation;
LIHC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	6.38	0.33	5.76e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.79	-10.94	-0.51	4.42e-24	Uric acid levels;
LIHC	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg13877915	chr19:58951672	ZNF132	0.59	9.06	0.44	9.94e-18	Uric acid clearance;
LIHC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.68	-11.3	-0.52	2.24e-25	Menopause (age at onset);
LIHC	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.47e-18	Coffee consumption (cups per day);
LIHC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15541040	chr2:3486749	NA	-0.45	-6.89	-0.35	2.71e-11	Neurofibrillary tangles;
LIHC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.52	-8.15	-0.4	7.01e-15	Fibrinogen levels;
LIHC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.41	-8.36	-0.41	1.56e-15	Obesity-related traits;
LIHC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.02	0.31	4.49e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.53	-6.13	-0.31	2.39e-9	Ulcerative colitis;
LIHC	cis	rs965469	1.000	rs2236087	chr20:3255905	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-6.14	-0.32	2.23e-9	IFN-related cytopenia;
LIHC	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.83	14.94	0.63	3.5e-39	Adiposity;
LIHC	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-6.59	-0.34	1.71e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.66	-13.1	-0.58	4.72e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.66	10.14	0.48	2.7e-21	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21775445	chr20:1373916	FKBP1A	0.46	6.57	0.33	1.83e-10	Pancreatic cancer;
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-5.73	-0.3	2.17e-8	Diastolic blood pressure;
LIHC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.48	-7.68	-0.38	1.72e-13	Cognitive function;
LIHC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg10210624	chr19:58662595	ZNF329	0.74	7.48	0.38	6.2800000000000005e-13	Cholesterol, total;
LIHC	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.29e-24	Subjective well-being;
LIHC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg07713946	chr22:31675144	LIMK2	-0.42	-7.38	-0.37	1.18e-12	Colorectal cancer;
LIHC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.95	0.31	6.78e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.95	22.46	0.77	2.7e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.33	6.78	0.34	5.41e-11	Renal cell carcinoma;
LIHC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	7.06	0.36	9.1e-12	Hemoglobin concentration;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg12154153	chr1:168195108	SFT2D2	0.61	6.07	0.31	3.41e-9	Mean platelet volume;
LIHC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	8.05	0.4	1.4e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs965469	1.000	rs8123289	chr20:3253831	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.36	-0.33	6.36e-10	IFN-related cytopenia;
LIHC	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg22771759	chr13:24902376	NA	0.32	6.7	0.34	8.43e-11	Obesity-related traits;
LIHC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg17724175	chr1:150552817	MCL1	-0.39	-7.88	-0.39	4.26e-14	Tonsillectomy;
LIHC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.74	-9.3	-0.45	1.72e-18	Gut microbiome composition (summer);
LIHC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg18944383	chr4:111397179	ENPEP	0.28	6.52	0.33	2.56e-10	Coronary artery disease;
LIHC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg06096015	chr1:231504339	EGLN1	-0.43	-8.47	-0.42	7.37e-16	Hemoglobin concentration;
LIHC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.0	0.31	5.05e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.72	-14.26	-0.61	1.58e-36	Extrinsic epigenetic age acceleration;
LIHC	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-7.79	-0.39	8.37e-14	Exhaled nitric oxide output;
LIHC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.12	0.52	9.88e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.46	-6.8	-0.35	4.55e-11	Aortic root size;
LIHC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26336594	chr4:152330339	FAM160A1	-0.43	-6.25	-0.32	1.24e-9	Cognitive function;
LIHC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.36	-5.85	-0.3	1.13e-8	Cystic fibrosis severity;
LIHC	cis	rs6466055	0.777	rs10238507	chr7:104807207	G/T	cg04380332	chr7:105027541	SRPK2	0.35	6.6	0.34	1.58e-10	Schizophrenia;
LIHC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg00612595	chr21:47717864	NA	-0.36	-5.86	-0.3	1.1e-8	Testicular germ cell tumor;
LIHC	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.47	-7.16	-0.36	5.09e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22694153	chr1:46768912	LRRC41;UQCRH	0.43	6.87	0.35	3.05e-11	Calcium levels;
LIHC	cis	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg01364799	chr7:75623366	TMEM120A	0.54	7.71	0.38	1.42e-13	Eotaxin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13095604	chr12:12966124	DDX47	0.45	6.23	0.32	1.34e-9	Pancreatic cancer;
LIHC	cis	rs7635838	0.892	rs9310379	chr3:11434143	C/T	cg00170343	chr3:11313890	ATG7	-0.45	-7.17	-0.36	4.71e-12	HDL cholesterol;
LIHC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg07817648	chr10:79422355	NA	-0.31	-6.68	-0.34	9.56e-11	Bone mineral density;
LIHC	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.32	-5.91	-0.3	8.38e-9	Lewy body disease;
LIHC	cis	rs4478037	0.818	rs17522946	chr3:33138777	A/G	cg27203090	chr3:33138513	GLB1;TMPPE	-0.48	-6.04	-0.31	3.95e-9	Major depressive disorder;
LIHC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.41	6.78	0.34	5.32e-11	IgG glycosylation;
LIHC	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg08539965	chr1:21396338	EIF4G3	0.34	6.07	0.31	3.31e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs3018712	0.532	rs948863	chr11:68420974	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.17e-8	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg10360323	chr17:41437877	NA	0.4	5.99	0.31	5.25e-9	Menopause (age at onset);
LIHC	cis	rs35160687	0.644	rs1863061	chr2:86512907	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.36	5.83	0.3	1.26e-8	Night sleep phenotypes;
LIHC	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.93	0.31	7.33e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg11062466	chr8:58055876	NA	0.49	7.01	0.35	1.27e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	5.74	0.3	2.06e-8	Renal cell carcinoma;
LIHC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.9	0.43	3.29e-17	Menarche (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg08434171	chr17:16284988	UBB	-0.36	-6.42	-0.33	4.45e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-1.1	-17.57	-0.69	1.08e-49	Urate levels;
LIHC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.63	0.42	2.28e-16	Height;
LIHC	cis	rs999943	0.810	rs57088429	chr6:33644189	G/A	cg14003231	chr6:33640908	ITPR3	0.33	6.31	0.32	8.51e-10	Obesity (extreme);
LIHC	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	6.93	0.35	2.04e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.6	10.43	0.49	2.61e-22	Longevity;Endometriosis;
LIHC	cis	rs55665837	0.665	rs11023273	chr11:14630819	G/A	cg25251204	chr11:14927456	NA	0.43	6.01	0.31	4.84e-9	Vitamin D levels;
LIHC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs7395581	0.959	rs59663860	chr11:47276350	G/C	cg25783544	chr11:47291846	MADD	0.45	6.66	0.34	1.06e-10	HDL cholesterol;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.89	0.57	2.82e-31	Prudent dietary pattern;
LIHC	trans	rs11014306	1.000	rs16925145	chr10:25198782	G/A	cg17214381	chr4:188916668	ZFP42	-0.55	-6.24	-0.32	1.29e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg01987224	chr1:201084466	NA	-0.33	-6.03	-0.31	4.3e-9	Permanent tooth development;
LIHC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.48	-8.0	-0.4	2.01e-14	Blood metabolite levels;
LIHC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg03854865	chr6:26224070	HIST1H3E	0.63	7.07	0.36	8.82e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs8023580	1.000	rs4984512	chr15:96704448	T/G	cg01739960	chr15:96715164	NA	0.36	5.79	0.3	1.62e-8	Sex hormone-binding globulin levels;
LIHC	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg03934865	chr2:198174659	NA	-0.57	-8.94	-0.44	2.54e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg05110241	chr16:68378359	PRMT7	-0.88	-9.93	-0.47	1.39e-20	Schizophrenia;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg27432699	chr2:27873401	GPN1	-0.54	-7.69	-0.38	1.5700000000000001e-13	Total body bone mineral density;
LIHC	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.33	-0.37	1.63e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.3	-6.94	-0.35	1.97e-11	Menarche (age at onset);
LIHC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg27490568	chr2:178487706	NA	0.36	5.75	0.3	1.98e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg18944383	chr4:111397179	ENPEP	0.31	7.29	0.37	2.14e-12	Coronary artery disease;
LIHC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.48	0.42	6.79e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.44	-0.33	3.99e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs17102423	0.723	rs11158573	chr14:65579370	A/G	cg11161011	chr14:65562177	MAX	-0.57	-7.91	-0.39	3.55e-14	Obesity-related traits;
LIHC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.75	0.3	1.99e-8	Bladder cancer;
LIHC	cis	rs2073300	1.000	rs6036424	chr20:23459976	A/C	cg12062639	chr20:23401060	NAPB	-0.76	-9.49	-0.46	4.23e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.37	6.65	0.34	1.14e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs17125944	0.686	rs7145242	chr14:53349842	G/A	cg00686598	chr14:53173677	PSMC6	-0.77	-8.63	-0.42	2.29e-16	Alzheimer's disease (late onset);
LIHC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.33	-5.93	-0.31	7.52e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.44	-0.37	8.14e-13	Response to antipsychotic treatment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06905970	chr19:41222748	ADCK4;ITPKC	0.39	6.14	0.32	2.32e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.39	6.24	0.32	1.3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11987759	chr7:65425863	GUSB	-0.39	-6.17	-0.32	1.88e-9	Calcium levels;
LIHC	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg09795085	chr6:101329169	ASCC3	-0.49	-6.61	-0.34	1.49e-10	Neuroticism;
LIHC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.71	10.6	0.5	6.78e-23	Aortic root size;
LIHC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.53	-7.7	-0.38	1.52e-13	Total body bone mineral density;
LIHC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.42	0.33	4.44e-10	Mood instability;
LIHC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.53	6.1	0.31	2.86e-9	Pancreatic cancer;
LIHC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.81	0.3	1.45e-8	Bipolar disorder;
LIHC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.42	-6.74	-0.34	6.64e-11	Menarche (age at onset);
LIHC	cis	rs10845606	0.781	rs7972866	chr12:12828320	C/T	cg04607235	chr12:12878440	APOLD1	-0.47	-6.64	-0.34	1.23e-10	Systemic lupus erythematosus;
LIHC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.87	-0.35	3.1e-11	Diabetic kidney disease;
LIHC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg10587741	chr22:38071170	LGALS1	0.73	12.78	0.57	7.83e-31	Fat distribution (HIV);
LIHC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	1.05	12.79	0.57	7.17e-31	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.35	-0.32	6.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.77	7.53	0.38	4.6e-13	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.12	0.36	6.48e-12	Renal cell carcinoma;
LIHC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.85	-0.35	3.34e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.56	9.34	0.45	1.23e-18	Cognitive function;
LIHC	cis	rs2412488	0.850	rs9312639	chr4:54226228	A/T	cg22241045	chr4:54363911	LNX1	-0.38	-6.21	-0.32	1.56e-9	DNA methylation (variation);
LIHC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.36	-7.72	-0.39	1.27e-13	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg17385448	chr1:15911702	AGMAT	-0.36	-5.78	-0.3	1.7e-8	Systolic blood pressure;
LIHC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg04610667	chr7:75704037	NA	0.35	6.23	0.32	1.34e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.71	8.14	0.4	7.58e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	6.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.78	11.25	0.52	3.36e-25	Longevity;
LIHC	cis	rs238295	0.766	rs6139759	chr20:5511742	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	0.42	5.71	0.3	2.43e-8	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs3741798	1.000	rs77559638	chr12:12499909	T/A	cg08615371	chr12:12503544	MANSC1	0.9	7.29	0.37	2.18e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg14222432	chr12:29376421	FAR2	0.36	7.05	0.36	9.82e-12	QT interval;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21989094	chr19:39421295	MRPS12;SARS2	0.43	6.49	0.33	2.95e-10	Cognitive function;
LIHC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.6	8.36	0.41	1.59e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25152348	chr22:50946712	NCAPH2;LMF2	-0.51	-7.5	-0.38	5.42e-13	Cognitive function;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.65	10.87	0.51	7.89e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	6.54	0.33	2.24e-10	Homocysteine levels;
LIHC	cis	rs10508774	0.866	rs72784062	chr10:33194851	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.77	0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.56	10.16	0.48	2.36e-21	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs12752401	0.867	rs67349818	chr1:103030560	T/C	cg17681729	chr19:740608	PALM	0.44	6.24	0.32	1.27e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs7551222	0.752	rs12133735	chr1:204556836	G/T	cg20240347	chr1:204465584	NA	-0.31	-6.34	-0.32	7.1e-10	Schizophrenia;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.26	-0.32	1.13e-9	Longevity;
LIHC	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.13	-10.41	-0.49	3.17e-22	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.24	-0.32	1.32e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs832187	1.000	rs832187	chr3:63833050	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.55	8.02	0.4	1.69e-14	Schizophrenia;
LIHC	cis	rs7818688	0.614	rs12056517	chr8:95877285	C/T	cg16049864	chr8:95962084	TP53INP1	0.53	5.99	0.31	5.28e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.7	-10.14	-0.48	2.74e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.45	6.67	0.34	1.02e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.42	5.8	0.3	1.53e-8	Multiple sclerosis;
LIHC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.6	7.71	0.38	1.37e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.47	6.97	0.35	1.68e-11	QT interval;
LIHC	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.47	9.51	0.46	3.45e-19	Tonsillectomy;
LIHC	cis	rs3770081	1.000	rs76052260	chr2:86328727	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-9.26	-0.45	2.39e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.95	-0.35	1.82e-11	Endometrial cancer;
LIHC	cis	rs244293	0.965	rs2787488	chr17:53208151	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs243505	0.691	rs243486	chr7:148448221	A/C	cg09806900	chr7:148480153	CUL1	-0.43	-6.01	-0.31	4.89e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.74	-9.59	-0.46	1.96e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02290350	chr8:58132656	NA	0.47	9.29	0.45	1.8e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.65	10.91	0.51	5.77e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.17	0.55	1.53e-28	Mean platelet volume;
LIHC	cis	rs611744	0.967	rs651814	chr8:109196571	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.23e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.74	-6.79	-0.34	4.9e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LIHC	cis	rs10792665	0.611	rs6592088	chr11:82624487	G/A	cg24227371	chr11:82718527	RAB30	-0.27	-6.13	-0.31	2.41e-9	Obesity-related traits;
LIHC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.87	15.77	0.65	1.66e-42	Body mass index;
LIHC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.82	0.35	4.14e-11	Red blood cell count;
LIHC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg25039879	chr17:56429692	SUPT4H1	0.79	8.95	0.44	2.32e-17	Cognitive test performance;
LIHC	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg22153745	chr1:153894579	GATAD2B	-0.39	-6.04	-0.31	4.06e-9	Total cholesterol levels;
LIHC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg10932868	chr11:921992	NA	0.34	6.42	0.33	4.67e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-1.07	-11.09	-0.51	1.23e-24	Breast cancer;
LIHC	trans	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg06175025	chr14:78082992	SPTLC2	0.42	6.12	0.31	2.51e-9	Urate levels in overweight individuals;Urate levels in obese individuals;
LIHC	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-12.72	-0.57	1.27e-30	Coffee consumption (cups per day);
LIHC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.48	-0.38	6.22e-13	Bipolar disorder;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg22882523	chr8:145107012	OPLAH	-0.29	-6.34	-0.32	7.17e-10	Systolic blood pressure;
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg20469419	chr4:1232170	CTBP1	-0.32	-5.82	-0.3	1.32e-8	Obesity-related traits;
LIHC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg12365402	chr11:9010492	NRIP3	-0.29	-7.8	-0.39	7.62e-14	Hemoglobin concentration;
LIHC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.75	-15.34	-0.64	8.88e-41	Body mass index;
LIHC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.27e-12	Bipolar disorder;
LIHC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg03859395	chr2:55845619	SMEK2	0.85	15.02	0.63	1.56e-39	Metabolic syndrome;
LIHC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.05	-0.31	3.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.06	0.44	1.02e-17	Electroencephalogram traits;
LIHC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.09	-0.36	7.75e-12	Personality dimensions;
LIHC	cis	rs2224391	0.784	rs35048711	chr6:5262235	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-5.96	-0.31	6.36e-9	Height;
LIHC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg14440974	chr22:39074834	NA	-0.36	-5.98	-0.31	5.65e-9	Menopause (age at onset);
LIHC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg00204512	chr16:28754710	NA	0.35	6.4	0.33	4.98e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg26939375	chr7:64535504	NA	0.42	6.77	0.34	5.56e-11	Aortic root size;
LIHC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.77	-8.37	-0.41	1.53e-15	Vitiligo;
LIHC	cis	rs722599	0.501	rs7158047	chr14:75388803	G/A	cg11812906	chr14:75593930	NEK9	0.46	7.8	0.39	7.74e-14	IgG glycosylation;
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.33	0.32	7.68e-10	Total body bone mineral density;
LIHC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.35	7.43	0.37	9e-13	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.56	-8.45	-0.42	8.7e-16	Height;
LIHC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.69	-10.15	-0.48	2.57e-21	Coronary artery disease;
LIHC	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg26138937	chr11:71823887	C11orf51	1.19	9.95	0.47	1.14e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.69	10.98	0.51	3.03e-24	Response to diuretic therapy;
LIHC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.7	9.97	0.47	1.01e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.46	7.08	0.36	8.47e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.64	0.34	1.27e-10	Height;
LIHC	trans	rs7504990	0.722	rs34923505	chr18:50372170	G/A	cg08535148	chr4:26321143	RBPJ	0.56	6.99	0.35	1.42e-11	Gallbladder cancer;
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.6	-6.16	-0.32	2.05e-9	Diastolic blood pressure;
LIHC	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.73	-0.3	2.19e-8	Neuroticism;
LIHC	cis	rs864643	1.000	rs1340223	chr3:39549699	T/G	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.02	-0.4	1.67e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg16088116	chr21:44841560	SIK1	-0.42	-6.34	-0.32	7.23e-10	Coronary artery disease;
LIHC	cis	rs5753037	0.639	rs5997534	chr22:30220190	G/A	cg01021169	chr22:30184971	ASCC2	-0.41	-8.2	-0.41	4.77e-15	Type 1 diabetes;
LIHC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.65	-10.47	-0.49	1.93e-22	Colorectal cancer;
LIHC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.47	7.24	0.36	3.01e-12	Height;
LIHC	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.64	-10.69	-0.5	3.32e-23	Pediatric autoimmune diseases;
LIHC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.68	11.97	0.54	7.99e-28	Colorectal cancer;
LIHC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.49	0.46	3.97e-19	Bipolar disorder;
LIHC	cis	rs11673344	0.504	rs2595555	chr19:37491121	C/T	cg27390819	chr19:37464633	NA	-0.47	-6.15	-0.32	2.22e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.57	7.02	0.35	1.19e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.77	0.3	1.82e-8	Electroencephalogram traits;
LIHC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	11.42	0.53	8.51e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg22842854	chr12:123319900	HIP1R	-0.73	-9.7	-0.46	8.21e-20	Schizophrenia;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.87	-15.07	-0.63	1.04e-39	Height;
LIHC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.77	6.32	0.32	8.14e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.83	9.56	0.46	2.43e-19	Primary sclerosing cholangitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24452069	chr19:4867631	PLIN3	0.48	6.16	0.32	2e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg25039879	chr17:56429692	SUPT4H1	0.79	8.97	0.44	1.98e-17	Cognitive test performance;
LIHC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02985541	chr2:219472218	PLCD4	-0.41	-6.55	-0.33	2.13e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-7.72	-0.39	1.27e-13	Prudent dietary pattern;
LIHC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.08	0.36	8.35e-12	Heart rate;
LIHC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.79	9.37	0.45	9.99e-19	Small cell lung carcinoma;
LIHC	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.16	-0.32	2.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.73	0.34	6.98e-11	Tonsillectomy;
LIHC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.41	0.52	9.28e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.34	0.56	3.48e-29	Prudent dietary pattern;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg02993280	chr1:107599747	PRMT6	-0.69	-11.16	-0.52	6.98e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.65	-6.62	-0.34	1.36e-10	Migraine;Coronary artery disease;
LIHC	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.51	7.54	0.38	4.41e-13	Multiple sclerosis;
LIHC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.32	-5.86	-0.3	1.08e-8	Aortic root size;
LIHC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-7.31	-0.37	1.86e-12	Schizophrenia;
LIHC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.45	7.64	0.38	2.24e-13	Response to temozolomide;
LIHC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Vitiligo;
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.11	-0.31	2.69e-9	Menopause (age at onset);
LIHC	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.68	7.94	0.39	2.98e-14	Primary sclerosing cholangitis;
LIHC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-11.17	-0.52	6.65e-25	Platelet count;
LIHC	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.39	6.18	0.32	1.87e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4407350	1.000	rs5764886	chr22:44925334	C/T	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.02	-0.31	4.39e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10508774	0.866	rs11009070	chr10:33054285	C/A	cg01819863	chr10:32635814	EPC1	0.63	5.78	0.3	1.68e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.79	11.84	0.54	2.4200000000000002e-27	Metabolic syndrome;
LIHC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.42	7.39	0.37	1.16e-12	Aortic root size;
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg01788221	chr16:89496183	ANKRD11	0.41	6.51	0.33	2.69e-10	Multiple myeloma (IgH translocation);
LIHC	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25789201	chr7:72395803	POM121	0.46	6.42	0.33	4.53e-10	Pancreatic cancer;
LIHC	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.57	-0.42	3.57e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs965469	0.779	rs6051683	chr20:3237822	G/C	cg25506879	chr20:3388711	C20orf194	-0.52	-6.33	-0.32	7.92e-10	IFN-related cytopenia;
LIHC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	6.21	0.32	1.52e-9	Renal cell carcinoma;
LIHC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs2839627	0.638	rs7276320	chr21:44269588	A/G	cg18192155	chr21:44258298	NA	-0.48	-6.3	-0.32	9.02e-10	Information processing speed;
LIHC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.77	-12.71	-0.57	1.44e-30	Breast cancer;
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.94	-15.95	-0.65	3.21e-43	Longevity;
LIHC	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05771511	chr15:63340396	TPM1	0.47	6.97	0.35	1.63e-11	Platelet count;
LIHC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.67	-11.05	-0.51	1.75e-24	Inflammatory bowel disease;
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg05527609	chr1:210001259	C1orf107	-0.41	-5.99	-0.31	5.31e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs74181299	0.750	rs2723067	chr2:65277951	A/G	cg05010058	chr2:65284262	CEP68	0.35	5.94	0.31	7.07e-9	Pulse pressure;
LIHC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.61	12.64	0.56	2.53e-30	Fat distribution (HIV);
LIHC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.35e-16	Motion sickness;
LIHC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.99	0.44	1.75e-17	Cognitive ability;
LIHC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg03013999	chr17:37608204	MED1	0.36	5.91	0.3	8.43e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.48	8.2	0.41	4.83e-15	Obesity-related traits;
LIHC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.6	-10.18	-0.48	1.93e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.43	6.41	0.33	4.81e-10	Obesity-related traits;
LIHC	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.67	-13.21	-0.58	1.8e-32	Leprosy;
LIHC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.37	-0.33	6.02e-10	Schizophrenia;
LIHC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg10360323	chr17:41437877	NA	0.4	5.96	0.31	6.14e-9	Menopause (age at onset);
LIHC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	9.08	0.44	8.83e-18	Exhaled nitric oxide output;
LIHC	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.63	-10.01	-0.48	7.62e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.76e-9	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.54	8.27	0.41	3.07e-15	Height;
LIHC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.18	0.32	1.82e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.64	-9.52	-0.46	3.19e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-8.15	-0.4	7.18e-15	Ulcerative colitis;
LIHC	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.94	0.54	1.01e-27	Eye color traits;
LIHC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.64	11.59	0.53	2.03e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.66	-9.29	-0.45	1.81e-18	Body mass index;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25951811	chr14:96858416	AK7	0.38	6.08	0.31	3.19e-9	Calcium levels;
LIHC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg00750074	chr16:89608354	SPG7	-0.39	-5.89	-0.3	9.06e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs16870629	0.567	rs35661060	chr5:1060379	G/A	cg08382946	chr5:1082689	SLC12A7	-0.43	-6.29	-0.32	9.61e-10	QT interval;
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.77	-0.3	1.82e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs600806	0.854	rs367586	chr1:109850122	C/A	cg23091122	chr1:110024289	SYPL2	-0.45	-5.71	-0.3	2.44e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg03859395	chr2:55845619	SMEK2	0.9	15.35	0.64	8.28e-41	Metabolic syndrome;
LIHC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.87	9.48	0.46	4.34e-19	Vitiligo;
LIHC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.7	6.73	0.34	7.09e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	1.02	12.11	0.55	2.4e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg09307838	chr4:120376055	NA	-0.41	-6.12	-0.31	2.56e-9	Diastolic blood pressure;
LIHC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.9	-0.35	2.52e-11	Height;
LIHC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-12.22	-0.55	9.28e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg07424592	chr7:64974309	NA	0.83	9.5	0.46	3.78e-19	Diabetic kidney disease;
LIHC	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.84	14.74	0.62	1.99e-38	Body mass index;
LIHC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	9.43	0.45	6.44e-19	Schizophrenia;
LIHC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.5	-8.49	-0.42	6.42e-16	White blood cell count;
LIHC	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.32	7.35	0.37	1.43e-12	Blood metabolite ratios;
LIHC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.2	-0.32	1.66e-9	Breast cancer;
LIHC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.54	8.53	0.42	4.69e-16	Total body bone mineral density;
LIHC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	8.05	0.4	1.43e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08219700	chr8:58056026	NA	0.52	6.7	0.34	8.83e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1712517	0.771	rs10883857	chr10:105127587	A/C	cg05636881	chr10:105038444	INA	-0.48	-7.38	-0.37	1.21e-12	Migraine;
LIHC	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg20560298	chr2:73613845	ALMS1	0.36	5.83	0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg07382826	chr16:28625726	SULT1A1	0.5	7.74	0.39	1.13e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.43	-6.02	-0.31	4.41e-9	Crohn's disease;
LIHC	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg26138937	chr11:71823887	C11orf51	-1.28	-10.45	-0.49	2.31e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.52	-9.47	-0.46	4.75e-19	Asthma;
LIHC	cis	rs611744	0.967	rs635219	chr8:109229243	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19346786	chr7:2764209	NA	-0.36	-5.78	-0.3	1.65e-8	Height;
LIHC	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.38	-6.11	-0.31	2.68e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg15841412	chr13:111365552	ING1	0.48	6.04	0.31	4.06e-9	Coronary artery disease;
LIHC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.9	0.3	8.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	15.49	0.64	2.32e-41	Tonsillectomy;
LIHC	cis	rs9921222	0.565	rs1805105	chr16:396264	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.54	10.82	0.51	1.13e-23	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7707921	0.881	rs57621982	chr5:81406770	C/T	cg15871215	chr5:81402204	ATG10	-0.61	-5.92	-0.3	7.81e-9	Breast cancer;
LIHC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.44	0.66	3.7e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg23782820	chr8:58130467	NA	0.33	5.95	0.31	6.66e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg06115741	chr20:33292138	TP53INP2	0.49	5.83	0.3	1.3e-8	Protein C levels;
LIHC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.6	10.2	0.48	1.62e-21	Height;
LIHC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.39	0.49	3.81e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	6.8	0.34	4.8e-11	Homocysteine levels;
LIHC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg10360323	chr17:41437877	NA	0.4	6.05	0.31	3.83e-9	Menopause (age at onset);
LIHC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	16.43	0.66	4.17e-45	Lung cancer in ever smokers;
LIHC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.82e-10	Fibrinogen levels;
LIHC	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.83	-0.3	1.32e-8	Lewy body disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05531134	chr21:19192027	C21orf91	-0.51	-7.05	-0.36	9.96e-12	Pancreatic cancer;
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg00612595	chr21:47717864	NA	-0.38	-6.43	-0.33	4.19e-10	Testicular germ cell tumor;
LIHC	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.4	0.41	1.24e-15	Eosinophil percentage of white cells;
LIHC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-1.05	-11.95	-0.54	9.56e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg25566285	chr7:158114605	PTPRN2	0.23	6.19	0.32	1.74e-9	Calcium levels;
LIHC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.87	0.39	4.62e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.29	-0.41	2.62e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.87	0.3	1.02e-8	Body mass index;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.64	0.38	2.21e-13	Prudent dietary pattern;
LIHC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.65	-9.37	-0.45	1.05e-18	Obesity-related traits;
LIHC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.56	11.01	0.51	2.43e-24	Prostate cancer;
LIHC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg00071026	chr13:113650936	MCF2L	-0.4	-6.04	-0.31	4e-9	Systolic blood pressure;
LIHC	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg01652190	chr22:50026171	C22orf34	-0.29	-6.3	-0.32	9.2e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs4566648	0.593	rs7683410	chr4:84183908	T/C	cg06219686	chr17:29421884	NF1	-0.53	-6.11	-0.31	2.71e-9	Monocyte count;
LIHC	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.83	-0.3	1.27e-8	Resting heart rate;
LIHC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg22676075	chr6:135203613	NA	0.41	6.75	0.34	6.45e-11	Red blood cell count;
LIHC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.45	0.56	1.34e-29	Cognitive test performance;
LIHC	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg00792783	chr2:198669748	PLCL1	-0.43	-6.28	-0.32	1.01e-9	Intracranial aneurysm;
LIHC	cis	rs2273669	0.667	rs11757168	chr6:109301091	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.88	-0.3	9.87e-9	Prostate cancer;
LIHC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.04	0.31	3.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7818688	0.697	rs35032356	chr8:95977484	G/T	cg16049864	chr8:95962084	TP53INP1	0.62	6.74	0.34	6.69e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg10820045	chr2:198174542	NA	0.41	6.01	0.31	4.72e-9	Dermatomyositis;
LIHC	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	0.39	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.78	13.52	0.59	1.17e-33	Aortic root size;
LIHC	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.86	14.74	0.62	2.01e-38	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27189623	chr16:705930	WDR90	0.42	6.91	0.35	2.43e-11	Height;
LIHC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.75	-0.3	2.01e-8	Obesity-related traits;
LIHC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.23	-7.37	-0.37	1.3e-12	Mean corpuscular volume;
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.45	6.08	0.31	3.23e-9	Life satisfaction;
LIHC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.7	-11.22	-0.52	4.45e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.03	-0.31	4.22e-9	Bladder cancer;
LIHC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.75e-12	IgG glycosylation;
LIHC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg12798992	chr6:167411361	FGFR1OP	0.45	6.94	0.35	2.01e-11	Crohn's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20033557	chr15:63414489	LACTB	-0.59	-6.72	-0.34	7.56e-11	Systolic blood pressure;
LIHC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	8.9	0.43	3.33e-17	Initial pursuit acceleration;
LIHC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg25039879	chr17:56429692	SUPT4H1	0.81	9.04	0.44	1.2e-17	Cognitive test performance;
LIHC	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.87	-0.51	7.97e-24	Eye color traits;
LIHC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg08949735	chr16:89699720	DPEP1	-0.41	-8.09	-0.4	1.06e-14	Vitiligo;
LIHC	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10477989	chr11:68039601	C11orf24	-0.47	-6.82	-0.35	4.14e-11	Triglycerides;
LIHC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01200585	chr1:228362443	C1orf69	-0.4	-5.86	-0.3	1.08e-8	Diastolic blood pressure;
LIHC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.98	-0.44	1.85e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.6	8.64	0.42	2.26e-16	Coronary artery disease;
LIHC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.51	0.33	2.68e-10	Ileal carcinoids;
LIHC	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.43	-6.75	-0.34	6.33e-11	Multiple sclerosis;
LIHC	cis	rs797680	0.856	rs531358	chr1:93676011	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.65e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.97	20.97	0.75	2.32e-63	Bone mineral density;
LIHC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.48	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23191292	chr6:157099924	ARID1B	0.42	6.4	0.33	5.03e-10	Cognitive function;
LIHC	cis	rs3736594	0.513	rs62138968	chr2:27824485	C/G	cg27432699	chr2:27873401	GPN1	0.46	6.92	0.35	2.29e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.59	-7.07	-0.36	8.73e-12	Blood metabolite levels;
LIHC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg16586182	chr3:47516702	SCAP	0.61	11.88	0.54	1.68e-27	Colorectal cancer;
LIHC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg17724175	chr1:150552817	MCL1	0.49	9.58	0.46	2.01e-19	Melanoma;
LIHC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	4.04e-13	Bipolar disorder;
LIHC	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.21	0.55	1.01e-28	Coffee consumption (cups per day);
LIHC	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg05425664	chr17:57184151	TRIM37	0.55	7.8	0.39	7.78e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg14067834	chr17:29058358	SUZ12P	0.68	6.68	0.34	9.52e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.73	12.86	0.57	3.9e-31	Breast cancer;
LIHC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.69	11.97	0.54	8.25e-28	Menopause (age at onset);
LIHC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.81	-0.75	9.66e-63	Height;
LIHC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg13319975	chr6:146136371	FBXO30	-0.36	-6.03	-0.31	4.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.39	-0.41	1.3e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4586057	0.514	rs12254390	chr10:92620148	G/C	cg14313238	chr10:92632228	RPP30	0.36	5.99	0.31	5.4e-9	Economic and political preferences (time);
LIHC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.55	9.25	0.45	2.5e-18	Bipolar disorder;
LIHC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.52	6.17	0.32	1.95e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs600806	0.888	rs443345	chr1:109849254	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.56	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-7.15	-0.36	5.38e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-7.76	-0.39	9.66e-14	Neuranatomic and neurocognitive phenotypes;
LIHC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.89	-0.35	2.77e-11	Alcohol dependence;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.29	0.32	9.76e-10	Renal cell carcinoma;
LIHC	cis	rs7116495	0.737	rs670802	chr11:71799668	A/C	cg26138937	chr11:71823887	C11orf51	-0.81	-7.98	-0.4	2.23e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.68	0.57	1.91e-30	Alzheimer's disease;
LIHC	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.62	-9.01	-0.44	1.48e-17	White matter hyperintensity burden;
LIHC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.62	9.02	0.44	1.42e-17	Menarche (age at onset);
LIHC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg11212589	chr17:38028394	ZPBP2	0.33	6.65	0.34	1.18e-10	Self-reported allergy;
LIHC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.45	-0.37	7.54e-13	IgG glycosylation;
LIHC	cis	rs7072216	0.650	rs10883089	chr10:100163120	A/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.44	-0.33	4.04e-10	Metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22141780	chr2:132233726	TUBA3D	0.39	6.12	0.31	2.62e-9	Pancreatic cancer;
LIHC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.43	6.09	0.31	3.07e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1198430	0.929	rs1210852	chr1:23753533	T/C	cg19827787	chr1:23763612	ASAP3	0.34	6.0	0.31	5.07e-9	Total cholesterol levels;
LIHC	cis	rs6449957	0.832	rs12660017	chr5:67450350	T/C	cg23036683	chr5:67512108	NA	0.43	6.06	0.31	3.68e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg16479474	chr6:28041457	NA	0.35	5.77	0.3	1.79e-8	Cardiac Troponin-T levels;
LIHC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.75	-10.71	-0.5	2.87e-23	Mosquito bite size;
LIHC	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.53	-6.92	-0.35	2.19e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.72	-0.57	1.31e-30	Schizophrenia;
LIHC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.82	0.3	1.38e-8	Eosinophil percentage of white cells;
LIHC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.4	7.07	0.36	8.71e-12	Hepatocellular carcinoma;
LIHC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.45	6.03	0.31	4.22e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.46	7.7	0.38	1.51e-13	Height;
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg14257396	chr1:107603778	NA	0.36	5.93	0.31	7.41e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg26939375	chr7:64535504	NA	0.42	6.75	0.34	6.45e-11	Aortic root size;
LIHC	cis	rs6973256	0.605	rs12707114	chr7:133345207	C/G	cg10665199	chr7:133106180	EXOC4	0.34	5.83	0.3	1.26e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg13903179	chr13:21900392	NA	0.37	6.39	0.33	5.29e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.8	-0.3	1.53e-8	Alcohol dependence;
LIHC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.16	-0.4	6.41e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg20240347	chr1:204465584	NA	-0.36	-7.54	-0.38	4.16e-13	Schizophrenia;
LIHC	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.62	-7.15	-0.36	5.27e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-7.5	-0.38	5.53e-13	Lymphocyte counts;
LIHC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.56	-8.61	-0.42	2.72e-16	Menarche (age at onset);
LIHC	trans	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	0.79	11.71	0.54	7.15e-27	Monocyte percentage of white cells;
LIHC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.67	9.68	0.46	9.29e-20	Monocyte percentage of white cells;
LIHC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.52	7.91	0.39	3.48e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.38	0.33	5.84e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg13844804	chr7:814759	HEATR2	-0.42	-5.73	-0.3	2.16e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-9.5	-0.46	3.93e-19	Bronchopulmonary dysplasia;
LIHC	cis	rs3736485	1.000	rs11631408	chr15:51746236	A/G	cg08986416	chr15:51914746	DMXL2	-0.39	-5.78	-0.3	1.66e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.63	12.73	0.57	1.19e-30	Airflow obstruction;
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg20090690	chr10:134436459	INPP5A	0.45	6.07	0.31	3.45e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21545522	chr1:205238299	TMCC2	0.32	6.14	0.32	2.29e-9	Red blood cell count;
LIHC	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg19302996	chr17:73780495	UNK	-0.47	-6.7	-0.34	8.5e-11	White matter hyperintensity burden;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08280861	chr8:58055591	NA	0.48	5.94	0.31	7.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg16652328	chr3:33138982	GLB1;TMPPE	-0.59	-7.93	-0.39	3.25e-14	Major depressive disorder;
LIHC	cis	rs6599636	1	rs6599636	chr10:124677899	T/G	cg05252487	chr10:124670562	FAM24A	-0.32	-5.87	-0.3	1.03e-8	Red cell distribution width;
LIHC	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.39	9.29	0.45	1.81e-18	Blood metabolite ratios;
LIHC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.58	0.42	3.38e-16	Birth weight;
LIHC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.88	-0.3	9.92e-9	Vitiligo;
LIHC	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.63	-8.51	-0.42	5.74e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05771511	chr15:63340396	TPM1	0.47	7.04	0.36	1.05e-11	Platelet count;
LIHC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-6.18	-0.32	1.87e-9	Crohn's disease;
LIHC	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.56	-5.92	-0.3	7.82e-9	Vitiligo;
LIHC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.61	5.82	0.3	1.37e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.83	-0.3	1.3e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.39	-6.84	-0.35	3.64e-11	Schizophrenia;
LIHC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-11.41	-0.53	9.22e-26	Electrocardiographic conduction measures;
LIHC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-6.63	-0.34	1.3100000000000001e-10	Blood metabolite levels;
LIHC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17507749	chr15:85114479	UBE2QP1	0.75	8.74	0.43	1.06e-16	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.15	26.51	0.82	6.09e-85	Myeloid white cell count;
LIHC	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg27203090	chr3:33138513	GLB1;TMPPE	-0.57	-7.49	-0.38	5.79e-13	Major depressive disorder;
LIHC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.42	6.27	0.32	1.1e-9	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.64	8.35	0.41	1.77e-15	Motion sickness;
LIHC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.74	0.39	1.14e-13	Mean platelet volume;
LIHC	cis	rs11673344	0.764	rs16971873	chr19:37469423	C/T	cg27390819	chr19:37464633	NA	-0.49	-5.92	-0.31	7.65e-9	Obesity-related traits;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.77	13.3	0.58	7.81e-33	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	0.79	12.62	0.56	3.12e-30	Yeast infection;
LIHC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.8	-0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.5	7.78	0.39	8.94e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.36	6.01	0.31	4.7e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.44	-6.02	-0.31	4.51e-9	Obesity-related traits;
LIHC	cis	rs11893307	0.566	rs62179714	chr2:191567541	G/C	cg10560079	chr2:191398806	TMEM194B	-0.41	-5.75	-0.3	2e-8	Mean platelet volume;
LIHC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.33	-5.86	-0.3	1.12e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg14930904	chr10:32216787	ARHGAP12	0.36	6.47	0.33	3.39e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg14593290	chr7:50529359	DDC	0.62	9.67	0.46	1.01e-19	Malaria;
LIHC	cis	rs142472947	1	rs142472947	chr1:8520487	AAAG/A	cg20416874	chr1:8611966	RERE	0.58	9.29	0.45	1.83e-18	White blood cell count;
LIHC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.96	13.84	0.6	6.93e-35	Nonalcoholic fatty liver disease;
LIHC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.35	0.32	6.93e-10	Red blood cell count;Reticulocyte count;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09380000	chr7:2650132	IQCE	0.35	6.45	0.33	3.89e-10	Longevity;
LIHC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg02640540	chr1:67518911	SLC35D1	0.44	6.02	0.31	4.59e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.6	11.2	0.52	5.04e-25	Systemic lupus erythematosus;
LIHC	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.67	12.06	0.55	3.94e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.8	-12.68	-0.57	1.78e-30	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.42	-5.9	-0.3	8.69e-9	Height;
LIHC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.37	6.05	0.31	3.79e-9	Blood metabolite levels;
LIHC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.63	0.42	2.42e-16	Birth weight;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.89	14.26	0.61	1.59e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.38	8.13	0.4	7.79e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.66	-11.21	-0.52	4.64e-25	Menarche (age at onset);
LIHC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00815214	chr21:47717953	NA	-0.38	-5.95	-0.31	6.76e-9	Testicular germ cell tumor;
LIHC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg17279839	chr7:150038598	RARRES2	0.49	10.25	0.48	1.16e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.58	9.27	0.45	2.11e-18	Lymphocyte counts;
LIHC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.73	-0.3	2.16e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg01864836	chr14:55583639	NA	-0.4	-7.52	-0.38	4.98e-13	Protein biomarker;
LIHC	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.94	-0.31	6.97e-9	Red blood cell count;
LIHC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.64	0.53	1.34e-26	Lung cancer in ever smokers;
LIHC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	9.57	0.46	2.28e-19	Eosinophilic esophagitis;
LIHC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.33	-8.76	-0.43	8.93e-17	Hemoglobin concentration;
LIHC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.27	0.41	3.04e-15	Birth weight;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg20607798	chr8:58055168	NA	0.62	7.92	0.39	3.38e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.59	-8.9	-0.43	3.42e-17	White matter hyperintensity burden;
LIHC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg15744005	chr10:104629667	AS3MT	-0.4	-9.05	-0.44	1.08e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.12	-15.49	-0.64	2.23e-41	Gut microbiome composition (summer);
LIHC	cis	rs9590974	0.663	rs1216860	chr13:47232268	C/T	cg04092803	chr13:47240378	LRCH1	0.27	5.93	0.31	7.57e-9	PR segment;
LIHC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.56	-0.33	1.97e-10	Mean corpuscular volume;
LIHC	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.78e-10	Obesity-related traits;
LIHC	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg03934865	chr2:198174659	NA	0.46	6.67	0.34	1.04e-10	Dermatomyositis;
LIHC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.44	-0.33	3.94e-10	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.46	-6.6	-0.34	1.53e-10	Lymphocyte counts;
LIHC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.41	0.59	3.07e-33	Airflow obstruction;
LIHC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.53	0.38	4.53e-13	Bone mineral density;
LIHC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.83	-15.84	-0.65	8.89e-43	Height;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23854747	chr20:62612705	PRPF6	-0.54	-6.26	-0.32	1.15e-9	Systolic blood pressure;
LIHC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.52	0.42	5.05e-16	Coronary artery disease;
LIHC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.11	-0.36	6.66e-12	Schizophrenia;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg18306943	chr3:40428807	ENTPD3	-0.43	-7.57	-0.38	3.56e-13	Renal cell carcinoma;
LIHC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.49	-6.07	-0.31	3.34e-9	Narcolepsy;
LIHC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.56	10.21	0.48	1.51e-21	Methadone dose in opioid dependence;
LIHC	cis	rs9590974	0.705	rs1408224	chr13:47215218	G/A	cg04092803	chr13:47240378	LRCH1	0.28	5.96	0.31	6.24e-9	PR segment;
LIHC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.54	7.88	0.39	4.44e-14	Lung cancer;
LIHC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.79	0.65	1.41e-42	White blood cell count;
LIHC	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.74	13.06	0.58	6.76e-32	Eosinophil percentage of white cells;
LIHC	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg05110241	chr16:68378359	PRMT7	-0.63	-6.46	-0.33	3.57e-10	Schizophrenia;
LIHC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.47	6.64	0.34	1.2e-10	Morning vs. evening chronotype;
LIHC	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.95	0.35	1.88e-11	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg11764359	chr7:65958608	NA	0.59	6.29	0.32	9.54e-10	Diabetic kidney disease;
LIHC	trans	rs2270221	0.812	rs11761300	chr7:31908052	G/C	cg06873401	chr5:77792105	LHFPL2	0.5	6.13	0.31	2.4e-9	Endometriosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19988671	chr7:155589783	NA	0.42	6.38	0.33	5.82e-10	Pancreatic cancer;
LIHC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.73	-9.76	-0.47	5.02e-20	Asthma;
LIHC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.57	9.31	0.45	1.64e-18	Longevity;Endometriosis;
LIHC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-6.75	-0.34	6.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.04	-0.31	4.03e-9	Response to antipsychotic treatment;
LIHC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.91	0.51	5.6e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.73	11.8	0.54	3.43e-27	Corneal astigmatism;
LIHC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	1.0	11.23	0.52	3.93e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.95	-0.31	6.51e-9	Total body bone mineral density;
LIHC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.19	0.48	1.8e-21	Morning vs. evening chronotype;
LIHC	cis	rs7131987	0.641	rs2015599	chr12:29435480	G/A	cg14222432	chr12:29376421	FAR2	0.31	6.49	0.33	2.95e-10	QT interval;
LIHC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg07424592	chr7:64974309	NA	-0.75	-8.71	-0.43	1.32e-16	Diabetic kidney disease;
LIHC	cis	rs17776563	0.959	rs17197194	chr15:89111610	G/A	cg05013243	chr15:89149849	MIR1179	0.46	7.61	0.38	2.62e-13	Thyroid hormone levels;
LIHC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.76	0.34	5.88e-11	Personality dimensions;
LIHC	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.51	-7.74	-0.39	1.1e-13	Menarche (age at onset);
LIHC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	1.03	11.15	0.52	7.78e-25	Triglycerides;
LIHC	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.26	6.06	0.31	3.63e-9	Heart rate;
LIHC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.69	0.46	9.05e-20	Bipolar disorder;
LIHC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg14004847	chr7:1930337	MAD1L1	0.46	6.56	0.33	2.05e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.34	5.81	0.3	1.42e-8	Schizophrenia;
LIHC	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.5	6.84	0.35	3.65e-11	Asthma (bronchodilator response);
LIHC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.38	-5.85	-0.3	1.12e-8	Cognitive function;
LIHC	cis	rs7937890	0.559	rs2575837	chr11:14498001	A/G	cg02886208	chr11:14281011	SPON1	-0.44	-6.15	-0.32	2.17e-9	Mitochondrial DNA levels;
LIHC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.57	8.66	0.42	1.9e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.8	-12.7	-0.57	1.58e-30	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg07424592	chr7:64974309	NA	-0.8	-9.31	-0.45	1.58e-18	Diabetic kidney disease;
LIHC	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.41	7.4	0.37	1.08e-12	Response to antipsychotic treatment;
LIHC	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg03989125	chr22:38214979	NA	-0.44	-6.03	-0.31	4.34e-9	Glioblastoma;Glioma;
LIHC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-7.46	-0.37	7.07e-13	P wave terminal force;
LIHC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg25024717	chr12:54324583	NA	0.31	6.17	0.32	1.91e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs12086130	0.892	rs72904801	chr1:51442137	A/G	cg07174182	chr1:51127561	FAF1	-0.76	-8.17	-0.4	6.13e-15	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs924607	0.510	rs1709542	chr5:662543	A/G	cg24163568	chr5:669837	TPPP	0.29	5.94	0.31	7.02e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.32	6.53	0.33	2.33e-10	Renal cell carcinoma;
LIHC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg01256987	chr12:42539512	GXYLT1	-0.36	-5.91	-0.3	8.5e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.39	7.24	0.36	3.03e-12	Schizophrenia;
LIHC	cis	rs10508774	1.000	rs72793595	chr10:32737215	C/G	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1499280	1.000	rs1499280	chr5:52096889	C/A	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.76	-0.3	1.86e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.63	0.34	1.34e-10	Bipolar disorder;
LIHC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.64	-9.06	-0.44	9.93e-18	Blood metabolite levels;
LIHC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.85	11.49	0.53	4.66e-26	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.42	0.41	1.07e-15	Motion sickness;
LIHC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	1.07	14.89	0.63	5.24e-39	Heart rate;
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.24	-0.36	2.92e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs6788895	1.000	rs7636866	chr3:150461568	A/T	cg09723797	chr3:150481914	SIAH2	0.85	11.59	0.53	2e-26	Breast cancer;
LIHC	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.5	6.73	0.34	7.05e-11	Interstitial lung disease;
LIHC	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-0.57	-7.94	-0.39	2.99e-14	Obesity-related traits;
LIHC	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg26149184	chr10:133730230	NA	0.38	5.84	0.3	1.24e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.79	-0.34	4.84e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg07706471	chr12:123319906	HIP1R	-0.57	-7.62	-0.38	2.57e-13	Schizophrenia;
LIHC	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16684958	chr7:75615977	POR	0.48	8.12	0.4	8.54e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg20607798	chr8:58055168	NA	0.64	8.21	0.41	4.61e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14103574	chr5:162932455	MAT2B	0.46	7.62	0.38	2.54e-13	Cognitive function;
LIHC	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg01652190	chr22:50026171	C22orf34	-0.34	-7.63	-0.38	2.35e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg08916839	chr5:415575	AHRR	0.29	6.27	0.32	1.08e-9	Cystic fibrosis severity;
LIHC	cis	rs2607426	1.000	rs2607422	chr19:41276990	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.48	-5.8	-0.3	1.5e-8	Blood protein levels;
LIHC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.42	-7.16	-0.36	5.08e-12	Platelet distribution width;
LIHC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.87	13.09	0.58	4.92e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.8	-13.53	-0.59	1.1e-33	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15254786	chr2:207630414	MDH1B;FASTKD2	0.38	6.11	0.31	2.73e-9	Cognitive function;
LIHC	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	0.59	6.19	0.32	1.71e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.64	8.99	0.44	1.71e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.63	-7.73	-0.39	1.21e-13	Itch intensity from mosquito bite;
LIHC	trans	rs9531686	1.000	rs9546999	chr13:85549012	G/C	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.31	6.24	0.32	1.26e-9	Anorexia nervosa;
LIHC	cis	rs8017423	0.967	rs61989980	chr14:90727635	C/T	cg04374321	chr14:90722782	PSMC1	0.78	15.15	0.63	4.85e-40	Mortality in heart failure;
LIHC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg00204748	chr12:29376779	FAR2	0.4	7.48	0.38	6.14e-13	QT interval;
LIHC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21467203	chr3:49911342	NA	-0.43	-7.59	-0.38	3.09e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.59	9.06	0.44	1e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg10756647	chr7:56101905	PSPH	1.07	13.4	0.59	3.25e-33	Diabetic kidney disease;
LIHC	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.85	0.39	5.57e-14	Lung cancer;
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg06497051	chr1:156261200	TMEM79	0.37	5.9	0.3	8.83e-9	Tonsillectomy;
LIHC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21467203	chr3:49911342	NA	0.36	6.23	0.32	1.37e-9	Menarche (age at onset);
LIHC	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg20129853	chr10:51489980	NA	-0.43	-9.29	-0.45	1.82e-18	Prostate-specific antigen levels;
LIHC	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg27255678	chr10:102756921	LZTS2	0.52	7.24	0.36	2.99e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.59	-10.38	-0.49	4.03e-22	Diisocyanate-induced asthma;
LIHC	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg27205649	chr11:78285834	NARS2	-0.38	-5.84	-0.3	1.22e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17808901	chr3:39093368	WDR48	0.42	6.36	0.33	6.44e-10	Cognitive function;
LIHC	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.94	-8.33	-0.41	2e-15	White matter integrity;
LIHC	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.44	5.72	0.3	2.37e-8	Psoriasis;
LIHC	cis	rs3823572	0.542	rs2953636	chr7:133637904	A/G	cg03336402	chr7:133662267	EXOC4	0.47	5.89	0.3	9.49e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.89	-0.3	9.33e-9	Type 2 diabetes;
LIHC	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.81	-0.3	1.4e-8	Diastolic blood pressure;
LIHC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg12798992	chr6:167411361	FGFR1OP	0.36	5.73	0.3	2.2e-8	Crohn's disease;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg05010058	chr2:65284262	CEP68	0.39	6.68	0.34	9.98e-11	Pulse pressure;
LIHC	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.45	-8.89	-0.43	3.7e-17	LDL cholesterol levels;
LIHC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.63e-18	Bipolar disorder;
LIHC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg03854865	chr6:26224070	HIST1H3E	0.56	7.03	0.36	1.15e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg07541023	chr7:19748670	TWISTNB	0.42	6.13	0.31	2.42e-9	Thyroid stimulating hormone;
LIHC	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-17.14	-0.68	5.47e-48	Schizophrenia;
LIHC	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.34	0.49	5.62e-22	Hypertriglyceridemia;
LIHC	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.32	5.83	0.3	1.27e-8	HDL cholesterol;
LIHC	cis	rs15676	0.947	rs2997913	chr9:131589033	C/T	cg13708974	chr9:131466143	PKN3	0.38	5.91	0.3	8.24e-9	Blood metabolite levels;
LIHC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.45	-0.37	7.47e-13	HDL cholesterol;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01056903	chr20:44601024	ZNF335	0.44	6.61	0.34	1.49e-10	Cognitive function;
LIHC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg21724239	chr8:58056113	NA	0.47	6.24	0.32	1.32e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.46	-6.33	-0.32	7.85e-10	QT interval;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26240231	chr7:1148101	C7orf50	-0.37	-5.71	-0.3	2.45e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.75	12.68	0.57	1.77e-30	Aortic root size;
LIHC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	6.27	0.32	1.11e-9	Lymphocyte percentage of white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13410877	chr18:55712976	NEDD4L	0.45	7.03	0.36	1.15e-11	Cognitive function;
LIHC	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	0.75	9.36	0.45	1.1e-18	Corneal structure;
LIHC	trans	rs7178375	0.678	rs34678577	chr15:31177465	A/C	cg04373760	chr16:53404718	NA	0.66	8.85	0.43	4.94e-17	Hypertriglyceridemia;
LIHC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.52	-0.76	1.46e-65	Height;
LIHC	cis	rs882732	1.000	rs5511	chr14:95033595	A/T	cg14866387	chr14:95027382	SERPINA4	0.46	6.43	0.33	4.38e-10	Blood protein levels;
LIHC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.33	6.19	0.32	1.7e-9	Total body bone mineral density;
LIHC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.94	-0.51	4.52e-24	Hemoglobin concentration;
LIHC	cis	rs1593	0.641	rs28690003	chr4:187224562	G/A	cg14349977	chr4:187219430	NA	0.47	6.74	0.34	6.73e-11	Activated partial thromboplastin time;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13686143	chr2:201828163	ORC2L	0.42	6.06	0.31	3.57e-9	Pancreatic cancer;
LIHC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg14393609	chr7:65229607	NA	-0.35	-5.75	-0.3	2.01e-8	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs74181299	0.684	rs60136636	chr2:65338422	G/A	cg05010058	chr2:65284262	CEP68	-0.4	-6.68	-0.34	9.55e-11	Pulse pressure;
LIHC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.43	-7.68	-0.38	1.65e-13	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21747090	chr2:27597821	SNX17	-0.39	-5.77	-0.3	1.79e-8	Total body bone mineral density;
LIHC	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg25588787	chr5:154027256	NA	0.38	5.71	0.3	2.45e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.51	7.33	0.37	1.73e-12	Body mass index;
LIHC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.39	-6.93	-0.35	2.08e-11	Aortic root size;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.6	8.36	0.41	1.61e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.42	6.25	0.32	1.23e-9	Height;
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.63	7.33	0.37	1.62e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11822910	1.000	rs11820985	chr11:57200414	T/C	cg00522883	chr11:57194120	SLC43A3	0.69	8.7	0.43	1.41e-16	Platelet distribution width;
LIHC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg21395723	chr22:39101663	GTPBP1	0.38	6.17	0.32	1.91e-9	Menopause (age at onset);
LIHC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-8.97	-0.44	1.94e-17	Bipolar disorder;
LIHC	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg25038773	chr8:6638180	NA	-0.3	-6.28	-0.32	1.04e-9	Monocyte count;
LIHC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs11627756	0.915	rs12100848	chr14:103127449	T/C	cg12046867	chr14:103022105	NA	0.39	5.92	0.3	7.82e-9	Mean platelet volume;
LIHC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.88	-0.57	3.09e-31	Breast cancer;
LIHC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.94e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg05941027	chr17:61774174	LIMD2	0.29	5.75	0.3	1.98e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.57	-8.28	-0.41	2.85e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.44	6.44	0.33	4.17e-10	Crohn's disease;
LIHC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.59	7.58	0.38	3.25e-13	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09060316	chr2:26467451	HADHB;HADHA	-0.53	-6.76	-0.34	6.12e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.06	15.28	0.64	1.54e-40	Cognitive function;
LIHC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.47	5.96	0.31	6.44e-9	Mean platelet volume;
LIHC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.51	8.71	0.43	1.34e-16	Obesity-related traits;
LIHC	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-0.67	-11.47	-0.53	5.58e-26	Pediatric autoimmune diseases;
LIHC	trans	rs4290604	0.748	rs4663241	chr2:238085960	T/C	cg15676719	chr1:167598521	RCSD1	-0.46	-6.21	-0.32	1.57e-9	Asthma;
LIHC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.1	0.44	7.64e-18	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.42	7.35	0.37	1.52e-12	Aortic root size;
LIHC	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg00977110	chr5:151150581	G3BP1	-0.56	-6.98	-0.35	1.58e-11	Preschool internalizing problems;
LIHC	trans	rs7874142	0.616	rs10776902	chr9:137688048	C/T	cg18109838	chr5:88185987	MEF2C	0.39	7.69	0.38	1.5700000000000001e-13	Longevity;
LIHC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05771511	chr15:63340396	TPM1	0.47	7.04	0.36	1.05e-11	Platelet count;
LIHC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg06207120	chr15:45996521	NA	0.34	6.62	0.34	1.39e-10	Waist circumference;Weight;
LIHC	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.47	7.24	0.36	3.08e-12	Breast cancer;
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	cis	rs11212737	0.765	rs2062116	chr11:108514951	C/T	cg22776369	chr11:108536276	DDX10	0.38	6.33	0.32	7.65e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27359949	chr3:14220525	XPC;LSM3	0.3	6.08	0.31	3.28e-9	Calcium levels;
LIHC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg07438165	chr14:95942775	C14orf49	0.63	6.24	0.32	1.31e-9	Mild influenza (H1N1) infection;
LIHC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.67	-14.13	-0.61	4.85e-36	Sense of smell;
LIHC	trans	rs3783890	1.000	rs12889579	chr14:93789660	G/A	cg02802420	chr16:69363236	PDF;COG8	0.32	6.32	0.32	8.12e-10	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16293631	chr17:38020606	IKZF3	-0.39	-6.06	-0.31	3.67e-9	Cognitive function;
LIHC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-12.96	-0.57	1.63e-31	Urinary metabolites;
LIHC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	0.85	7.15	0.36	5.38e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.38	-6.26	-0.32	1.12e-9	Corneal astigmatism;
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.66	9.61	0.46	1.59e-19	Menarche (age at onset);
LIHC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg20607798	chr8:58055168	NA	0.46	6.23	0.32	1.34e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.9	-0.43	3.28e-17	Bipolar disorder;
LIHC	cis	rs7091068	0.522	rs10748612	chr10:95494458	G/A	cg20715218	chr10:95462985	C10orf4	0.58	6.41	0.33	4.75e-10	Urinary tract infection frequency;
LIHC	cis	rs7116495	1.000	rs11235440	chr11:71826644	A/G	cg26138937	chr11:71823887	C11orf51	0.84	8.54	0.42	4.41e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg07061783	chr6:25882402	NA	-0.47	-5.8	-0.3	1.49e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg12062639	chr20:23401060	NAPB	0.85	10.27	0.49	9.84e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg25179470	chr10:102756915	LZTS2	0.45	6.32	0.32	8.06e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg04632378	chr13:21900426	NA	0.38	6.49	0.33	2.94e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg04352962	chr1:209979756	IRF6	0.39	5.99	0.31	5.35e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.56	-9.05	-0.44	1.09e-17	Birth weight;
LIHC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	10.83	0.51	1.04e-23	Platelet count;
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12379764	chr21:47803548	PCNT	-0.54	-7.76	-0.39	9.58e-14	Testicular germ cell tumor;
LIHC	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.71	10.58	0.5	7.85e-23	Subjective well-being;
LIHC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.43	-0.37	8.68e-13	Breast cancer;
LIHC	cis	rs11229555	0.645	rs61903159	chr11:58184475	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg17980119	chr2:219472607	PLCD4	0.33	5.72	0.3	2.31e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-7.58	-0.38	3.34e-13	Initial pursuit acceleration;
LIHC	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	0.55	8.56	0.42	3.82e-16	Atopic dermatitis;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22082706	chr11:70001938	ANO1	0.44	6.53	0.33	2.41e-10	Bilirubin levels;
LIHC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.06	-13.58	-0.59	6.77e-34	Primary sclerosing cholangitis;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.81	12.72	0.57	1.25e-30	Longevity;
LIHC	trans	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg01596870	chr19:55963115	NA	-0.66	-9.36	-0.45	1.1e-18	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg00280220	chr17:61926910	NA	0.42	6.79	0.34	4.88e-11	Prudent dietary pattern;
LIHC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.57	11.34	0.52	1.58e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs539514	0.550	rs2328956	chr13:76294595	G/A	cg04757411	chr13:76259545	LMO7	-0.46	-8.22	-0.41	4.39e-15	Type 1 diabetes;
LIHC	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.63	7.55	0.38	3.93e-13	Height;
LIHC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.66	-11.13	-0.52	8.89e-25	Childhood ear infection;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26755097	chr6:30711844	FLOT1;IER3	0.45	6.45	0.33	3.78e-10	Hepatitis;
LIHC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.6	10.28	0.49	9.16e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.48	-6.1	-0.31	2.89e-9	Ulcerative colitis;
LIHC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.44	-8.65	-0.42	1.97e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4706831	0.647	rs627240	chr6:80985885	C/A	cg08355045	chr6:80787529	NA	-0.29	-5.78	-0.3	1.66e-8	Joint mobility (Beighton score);
LIHC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg24826892	chr11:71159390	DHCR7	0.56	7.13	0.36	5.91e-12	Vitamin D levels;
LIHC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.64	-9.18	-0.44	4.09e-18	Schizophrenia;
LIHC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	8.87	0.43	4.26e-17	Blood metabolite levels;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.11	-0.31	2.69e-9	Total body bone mineral density;
LIHC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-6.33	-0.32	7.49e-10	Ulcerative colitis;
LIHC	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg20651018	chr11:3035856	CARS	-0.35	-5.8	-0.3	1.51e-8	Longevity;
LIHC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.6	-8.77	-0.43	8.27e-17	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.67	-5.87	-0.3	1.03e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-0.81	-12.21	-0.55	1.02e-28	Obesity-related traits;
LIHC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.47	7.66	0.38	1.88e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-12.3	-0.55	4.71e-29	Vitiligo;
LIHC	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg25038773	chr8:6638180	NA	0.32	6.84	0.35	3.55e-11	Myopia (pathological);
LIHC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.3	-16.6	-0.67	8.39e-46	Diabetic kidney disease;
LIHC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.47	-8.45	-0.42	8.76e-16	Colorectal cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10175688	chr17:6544015	TXNDC17;KIAA0753	-0.52	-6.58	-0.34	1.74e-10	Systolic blood pressure;
LIHC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.8	-7.7	-0.38	1.47e-13	Diabetic retinopathy;
LIHC	cis	rs4684776	0.935	rs6772675	chr3:11376080	C/G	cg00170343	chr3:11313890	ATG7	-0.51	-6.83	-0.35	3.93e-11	Small vessel stroke;
LIHC	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.44	6.56	0.33	1.97e-10	Survival in rectal cancer;
LIHC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.63	8.43	0.41	9.770000000000001e-16	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs838721	0.574	rs34332006	chr2:234257452	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	5.83	0.3	1.25e-8	Total body bone mineral density;
LIHC	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg11812906	chr14:75593930	NEK9	0.38	5.88	0.3	9.97e-9	Neuroticism;
LIHC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.55	10.23	0.48	1.31e-21	Methadone dose in opioid dependence;
LIHC	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-7.22	-0.36	3.41e-12	IFN-related cytopenia;
LIHC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.66	-9.45	-0.45	5.64e-19	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00930347	chr6:110012366	AKD1;FIG4	0.48	6.4	0.33	5.18e-10	Pancreatic cancer;
LIHC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.03	-18.01	-0.7	1.74e-51	Body mass index;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.63	11.23	0.52	4.05e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19671926	chr4:122722719	EXOSC9	0.48	6.97	0.35	1.69e-11	Type 2 diabetes;
LIHC	cis	rs1144333	0.655	rs1417402	chr1:76437196	C/T	cg10523679	chr1:76189770	ACADM	0.46	6.05	0.31	3.77e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg19623624	chr10:135278901	LOC619207	-0.44	-6.86	-0.35	3.31e-11	Systemic lupus erythematosus;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.58	-8.22	-0.41	4.19e-15	Testicular germ cell tumor;
LIHC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.53	-0.38	4.65e-13	Blood metabolite levels;
LIHC	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.34	23.21	0.78	3.04e-72	Corneal structure;
LIHC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg06096015	chr1:231504339	EGLN1	0.5	9.2	0.45	3.56e-18	Hemoglobin concentration;
LIHC	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	12.33	0.55	3.91e-29	Birth weight;
LIHC	cis	rs16854884	0.739	rs1075113	chr3:143760535	C/T	cg06585982	chr3:143692056	C3orf58	0.45	6.34	0.32	7.4e-10	Economic and political preferences (feminism/equality);
LIHC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.09	-0.4	1.05e-14	Monocyte percentage of white cells;
LIHC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.78	11.77	0.54	4.55e-27	Coronary artery disease;
LIHC	cis	rs10792665	0.512	rs10792660	chr11:82597704	C/G	cg24227371	chr11:82718527	RAB30	0.27	6.39	0.33	5.53e-10	Obesity-related traits;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.52	7.68	0.38	1.64e-13	Height;
LIHC	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg03934865	chr2:198174659	NA	0.54	8.19	0.41	5.11e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.03	-7.25	-0.36	2.89e-12	Body mass index;
LIHC	cis	rs35892873	0.920	rs9865702	chr3:126092351	A/G	cg15490784	chr3:126061950	KLF15	0.45	6.72	0.34	7.6e-11	Male-pattern baldness;
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg02782426	chr3:40428986	ENTPD3	-0.32	-6.06	-0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LIHC	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.92	-0.47	1.51e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg12365402	chr11:9010492	NRIP3	0.24	5.84	0.3	1.19e-8	Hemoglobin concentration;
LIHC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.64	-0.69	5.52e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.81	-15.07	-0.63	9.98e-40	Refractive error;
LIHC	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-5.92	-0.3	7.83e-9	Red cell distribution width;
LIHC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg18944383	chr4:111397179	ENPEP	0.26	6.37	0.33	6.02e-10	Coronary artery disease;
LIHC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg12863693	chr15:85201151	NMB	0.45	6.33	0.32	7.53e-10	Schizophrenia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg20284773	chr1:156736924	PRCC	-0.38	-6.15	-0.32	2.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2257205	0.667	rs7211439	chr17:56847832	A/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.61	-0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.2e-10	Renal cell carcinoma;
LIHC	cis	rs74233809	0.901	rs3824754	chr10:104614350	C/T	cg03493300	chr10:104813866	CNNM2	0.42	5.82	0.3	1.38e-8	Birth weight;
LIHC	cis	rs600806	0.778	rs4970761	chr1:109995398	C/T	cg23091122	chr1:110024289	SYPL2	-0.52	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-10.7	-0.5	3.15e-23	Breast cancer;
LIHC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.55	7.86	0.39	4.94e-14	Eosinophil percentage of white cells;
LIHC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg12297030	chr17:43662878	NA	-0.63	-6.09	-0.31	3.08e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2242116	0.900	rs1001284	chr3:46933960	C/G	cg27129171	chr3:47204927	SETD2	0.48	7.57	0.38	3.52e-13	Birth weight;
LIHC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg19318889	chr4:1322082	MAEA	-0.48	-6.63	-0.34	1.3100000000000001e-10	Obesity-related traits;
LIHC	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.54e-11	Type 2 diabetes;
LIHC	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg19508488	chr2:152266495	RIF1	0.5	7.05	0.36	9.83e-12	Squamous cell lung carcinoma;
LIHC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.62	-9.65	-0.46	1.16e-19	Height;
LIHC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.89	0.35	2.77e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg20991723	chr1:152506922	NA	0.59	10.28	0.49	8.92e-22	Hair morphology;
LIHC	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.36	-0.33	6.41e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.61e-9	Schizophrenia;
LIHC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	6.24	0.32	1.27e-9	Neuroticism;
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.27	0.32	1.12e-9	Obesity-related traits;
LIHC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20135002	chr11:47629003	NA	-0.51	-8.59	-0.42	3.23e-16	Subjective well-being;
LIHC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00166722	chr3:10149974	C3orf24	0.51	5.92	0.3	7.85e-9	Alzheimer's disease;
LIHC	cis	rs7116495	0.867	rs597513	chr11:71797422	T/A	cg26138937	chr11:71823887	C11orf51	-0.68	-6.85	-0.35	3.36e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	7.67	0.38	1.81e-13	Blood protein levels;
LIHC	cis	rs4950322	0.576	rs4950427	chr1:146862903	T/C	cg25205988	chr1:146714368	CHD1L	0.42	5.92	0.3	7.97e-9	Protein quantitative trait loci;
LIHC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg24296786	chr1:45957014	TESK2	0.4	5.71	0.3	2.44e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2209875	1.000	rs10867159	chr9:91800566	A/G	cg26057616	chr1:222234397	NA	0.38	6.32	0.32	8.33e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.58	8.47	0.42	7.29e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.5	-9.29	-0.45	1.8e-18	Asthma;
LIHC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs3781684	1.000	rs7122312	chr11:76812827	C/G	cg19164997	chr11:76818702	CAPN5	0.48	6.59	0.34	1.64e-10	Cognitive performance;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12187049	chr5:70882888	MCCC2	0.48	7.45	0.37	7.55e-13	Cognitive function;
LIHC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.45	-6.95	-0.35	1.86e-11	Cognitive function;
LIHC	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.6	-0.62	7.2e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.86	13.41	0.59	2.92e-33	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.63	10.54	0.5	1.1e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	8.54	0.42	4.52e-16	Platelet count;
LIHC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.57	9.86	0.47	2.36e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.49	7.17	0.36	4.77e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.84	0.3	1.23e-8	Renal cell carcinoma;
LIHC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg18867708	chr6:26865862	GUSBL1	0.51	7.86	0.39	4.95e-14	Schizophrenia;
LIHC	cis	rs4699052	1.000	rs4699052	chr4:104137790	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-6.65	-0.34	1.18e-10	Testicular germ cell tumor;
LIHC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.31	-5.78	-0.3	1.68e-8	HDL cholesterol;
LIHC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.67	8.32	0.41	2.18e-15	Gut microbiome composition (summer);
LIHC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.36	-6.09	-0.31	3.02e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs654384	0.898	rs1077472	chr7:4175323	G/A	cg26675336	chr15:86133334	AKAP13	0.3	6.16	0.32	2.08e-9	Positive affect;
LIHC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.85	-0.3	1.15e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-0.78	-13.63	-0.59	4.37e-34	Total body bone mineral density;
LIHC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	7.5	0.38	5.53e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1509123	0.609	rs7224971	chr17:6713999	A/T	cg12642237	chr17:6703447	TEKT1	0.89	7.63	0.38	2.38e-13	Blood metabolite levels;
LIHC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.63	-0.42	2.42e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1434579	0.865	rs35813988	chr19:44940420	G/A	cg15540054	chr19:45004280	ZNF180	0.57	7.95	0.39	2.8e-14	Tuberculosis;
LIHC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.53	6.85	0.35	3.39e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.71	9.53	0.46	3e-19	Body mass index;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22164250	chr7:139256604	HIPK2	0.51	6.18	0.32	1.85e-9	Lung function (FEV1);
LIHC	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg00071026	chr13:113650936	MCF2L	-0.37	-5.82	-0.3	1.36e-8	Systolic blood pressure;
LIHC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.8	12.5	0.56	9.03e-30	Breast cancer;
LIHC	cis	rs151997	1.000	rs72758246	chr5:50246783	G/C	cg06027927	chr5:50259733	NA	0.6	7.96	0.4	2.56e-14	Callous-unemotional behaviour;
LIHC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.45	-10.37	-0.49	4.36e-22	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.67	0.42	1.73e-16	Platelet count;
LIHC	cis	rs12702595	0.818	rs7787942	chr7:7270012	A/T	cg04827551	chr7:7268805	C1GALT1	0.37	6.7	0.34	8.49e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.61	8.58	0.42	3.44e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg16576597	chr16:28551801	NUPR1	0.38	6.21	0.32	1.57e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs918629	0.567	rs1458018	chr5:95253295	G/T	cg10483112	chr5:95245456	ELL2	-0.38	-7.17	-0.36	4.8e-12	IgG glycosylation;
LIHC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3736485	0.932	rs2278989	chr15:51914716	T/C	cg08986416	chr15:51914746	DMXL2	-0.47	-7.01	-0.35	1.28e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.94	17.6	0.69	7.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg24579218	chr15:68104479	NA	-0.34	-5.81	-0.3	1.42e-8	Restless legs syndrome;
LIHC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.5	0.46	3.68e-19	Bipolar disorder;
LIHC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.71	10.26	0.49	1e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.17	15.19	0.63	3.36e-40	Blood protein levels;
LIHC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg00204512	chr16:28754710	NA	0.42	7.09	0.36	7.97e-12	Body mass index;
LIHC	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.62	-9.95	-0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.47	6.19	0.32	1.69e-9	Parkinson's disease;
LIHC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	7.96	0.4	2.5e-14	Schizophrenia;
LIHC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-10.36	-0.49	4.88e-22	Breast cancer;
LIHC	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.37	7.69	0.38	1.59e-13	Optic cup area;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg00280220	chr17:61926910	NA	0.42	6.81	0.35	4.44e-11	Prudent dietary pattern;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg14393609	chr7:65229607	NA	0.41	6.91	0.35	2.43e-11	Calcium levels;
LIHC	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.39	-5.9	-0.3	8.9e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.64	8.77	0.43	8.83e-17	Skin colour saturation;
LIHC	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	-0.53	-10.13	-0.48	2.85e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-8.6	-0.42	2.88e-16	Primary biliary cholangitis;
LIHC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg18016565	chr1:150552671	MCL1	0.58	11.47	0.53	5.62e-26	Tonsillectomy;
LIHC	trans	rs2363709	1.000	rs2363709	chr3:67417105	G/A	cg25028035	chr6:42016671	CCND3	-0.83	-6.16	-0.32	2.04e-9	IgE levels;
LIHC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.56	-0.33	2.05e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.43	6.49	0.33	3.08e-10	Post bronchodilator FEV1;
LIHC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg00091569	chr3:40428383	ENTPD3	-0.35	-6.09	-0.31	2.96e-9	Renal cell carcinoma;
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.71	0.76	2.62e-66	Height;
LIHC	cis	rs4780401	0.967	rs11075012	chr16:11831030	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-6.07	-0.31	3.44e-9	Rheumatoid arthritis;
LIHC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	9.43	0.45	6.63e-19	IgG glycosylation;
LIHC	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.74	13.11	0.58	4.34e-32	Eosinophil percentage of white cells;
LIHC	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg16583315	chr14:65563665	MAX	-0.39	-7.93	-0.39	3.14e-14	Obesity-related traits;
LIHC	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg04118878	chr10:71993077	PPA1	-0.57	-5.99	-0.31	5.38e-9	Blood protein levels;
LIHC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26897989	chr16:1907736	C16orf73	-0.5	-5.79	-0.3	1.61e-8	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9322817	0.902	rs7773123	chr6:105173726	A/G	cg02098413	chr6:105308735	HACE1	0.43	7.07	0.36	9.01e-12	Thyroid stimulating hormone;
LIHC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18225595	chr11:63971243	STIP1	0.64	7.86	0.39	4.95e-14	Mean platelet volume;
LIHC	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.77	0.34	5.55e-11	Renal cell carcinoma;
LIHC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.34	6.18	0.32	1.8e-9	Aortic root size;
LIHC	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.5	7.24	0.36	2.96e-12	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.03	-0.36	1.13e-11	Migraine;Coronary artery disease;
LIHC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.61	9.71	0.46	7.77e-20	Age at first birth;
LIHC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.66	-9.47	-0.46	4.7e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg27366882	chr3:133540807	NA	0.42	7.26	0.37	2.63e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs778371	0.748	rs1878287	chr2:233790649	G/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.84	-0.39	5.72e-14	Schizophrenia;
LIHC	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	12.89	0.57	3.03e-31	Coffee consumption (cups per day);
LIHC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.68	11.6	0.53	1.83e-26	Colorectal cancer;
LIHC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.39	5.91	0.3	8.17e-9	Mean corpuscular volume;
LIHC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.77	9.78	0.47	4.37e-20	Tonsillectomy;
LIHC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.33	0.49	5.93e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	7.18	0.36	4.26e-12	Morning vs. evening chronotype;
LIHC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.43	-6.07	-0.31	3.45e-9	Morning vs. evening chronotype;
LIHC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.59	8.34	0.41	1.79e-15	Blood metabolite levels;
LIHC	cis	rs4908768	1.000	rs7523186	chr1:8655495	C/T	cg20416874	chr1:8611966	RERE	-0.56	-7.44	-0.37	8.06e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.69	-14.61	-0.62	6.62e-38	Brugada syndrome;
LIHC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.47e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.63	0.38	2.34e-13	Schizophrenia;
LIHC	cis	rs965469	0.779	rs6139048	chr20:3239753	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-6.33	-0.32	7.92e-10	IFN-related cytopenia;
LIHC	cis	rs4788570	0.538	rs16973260	chr16:71534853	A/G	cg06353428	chr16:71660113	MARVELD3	1.08	9.57	0.46	2.23e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs6066825	0.644	rs6019386	chr20:47326440	T/G	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.84e-12	Colorectal cancer;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg14196208	chr9:127020110	NEK6	-0.4	-6.1	-0.31	2.93e-9	Neuroblastoma;
LIHC	trans	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg25214090	chr10:38739885	LOC399744	0.44	6.93	0.35	2.08e-11	Diastolic blood pressure;
LIHC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.52	-0.49	1.27e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.32	-7.34	-0.37	1.6e-12	Breast cancer;
LIHC	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.72	11.25	0.52	3.55e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.97	-0.47	1e-20	Response to antipsychotic treatment;
LIHC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.56	9.01	0.44	1.47e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.51	8.87	0.43	4.13e-17	Coronary artery disease;
LIHC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg10978503	chr1:24200527	CNR2	0.29	6.94	0.35	1.94e-11	Immature fraction of reticulocytes;
LIHC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.23	-0.32	1.35e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2412488	0.927	rs3811785	chr4:54327235	T/C	cg22241045	chr4:54363911	LNX1	-0.42	-6.77	-0.34	5.69e-11	DNA methylation (variation);
LIHC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.42	6.72	0.34	7.57e-11	Height;
LIHC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.54	7.13	0.36	6.04e-12	Body mass index;
LIHC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.88	-15.33	-0.64	9.23e-41	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.62	10.4	0.49	3.54e-22	Alcohol dependence;
LIHC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.63	-11.96	-0.54	8.62e-28	Menopause (age at onset);
LIHC	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.95	-0.35	1.88e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.37	-5.92	-0.3	7.8e-9	Mortality in heart failure;
LIHC	cis	rs78062588	1.000	rs72999485	chr1:154559360	G/C	cg24304309	chr1:154577895	ADAR	-0.56	-6.41	-0.33	4.88e-10	Lung cancer;
LIHC	cis	rs12467847	0.931	rs2708931	chr2:113693878	C/G	cg12858261	chr2:113808755	IL1F8	-0.39	-6.77	-0.34	5.58e-11	Response to amphetamines;
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.55	6.5	0.33	2.83e-10	Alzheimer's disease;
LIHC	cis	rs17817600	0.929	rs11234483	chr11:85644400	A/G	cg03102841	chr11:85646010	NA	-0.45	-5.92	-0.3	7.85e-9	Alzheimer's disease;
LIHC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	10.6	0.5	6.89e-23	Chronic sinus infection;
LIHC	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.73	0.34	7.17e-11	Type 2 diabetes;
LIHC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.15	0.52	7.48e-25	Coronary artery disease;
LIHC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.54	0.46	2.74e-19	Platelet count;
LIHC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.37	5.78	0.3	1.67e-8	Coronary artery disease;
LIHC	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg10756647	chr7:56101905	PSPH	1.01	11.98	0.54	7.24e-28	Diabetic kidney disease;
LIHC	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.19	0.55	1.29e-28	Coffee consumption (cups per day);
LIHC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.08	-0.31	3.22e-9	Total body bone mineral density;
LIHC	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.88	-11.12	-0.52	9.58e-25	Coronary artery disease;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-7.48	-0.37	6.49e-13	Longevity;Endometriosis;
LIHC	trans	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg04373760	chr16:53404718	NA	0.57	7.42	0.37	9.58e-13	Hypertriglyceridemia;
LIHC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg09182678	chr22:50328711	NA	-0.41	-6.08	-0.31	3.15e-9	Schizophrenia;
LIHC	cis	rs244293	0.965	rs2529508	chr17:53212572	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.6	5.78	0.3	1.64e-8	Vitiligo;
LIHC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.35	0.52	1.49e-25	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.47	6.56	0.33	2.03e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4294134	0.832	rs12707241	chr7:135259183	T/C	cg20392616	chr7:135392013	SLC13A4	0.38	5.98	0.31	5.63e-9	Paget's disease;
LIHC	cis	rs12744310	0.945	rs72665696	chr1:41775429	G/T	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.4	-6.38	-0.33	5.79e-10	Coronary artery disease;
LIHC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.76	13.98	0.6	1.96e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.61	0.34	1.46e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.63	8.96	0.44	2.12e-17	Coronary artery disease;
LIHC	cis	rs1664789	0.967	rs1694060	chr5:53278158	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.51	8.26	0.41	3.17e-15	Waist circumference adjusted for body mass index;
LIHC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg23517279	chr6:96025343	MANEA	0.54	6.33	0.32	7.53e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18252515	chr7:66147081	NA	-0.45	-6.5	-0.33	2.83e-10	Aortic root size;
LIHC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg20607798	chr8:58055168	NA	0.46	5.81	0.3	1.44e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.57	-6.23	-0.32	1.38e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg02228329	chr11:64053129	BAD;GPR137	0.7	9.56	0.46	2.49e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs10847980	0.623	rs28613486	chr12:123867268	T/C	cg07919128	chr17:18022025	MYO15A	-0.76	-7.56	-0.38	3.75e-13	Adiponectin levels;
LIHC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.26	-6.06	-0.31	3.65e-9	Subjective well-being;
LIHC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.82	13.51	0.59	1.21e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17467752	chr17:38218738	THRA	-0.55	-9.31	-0.45	1.57e-18	Myeloid white cell count;
LIHC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.33	8.29	0.41	2.6e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.83	9.41	0.45	7.7e-19	Cognitive test performance;
LIHC	cis	rs5753037	0.676	rs737945	chr22:30202774	G/C	cg01021169	chr22:30184971	ASCC2	-0.42	-8.34	-0.41	1.81e-15	Type 1 diabetes;
LIHC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg25894440	chr7:65020034	NA	-0.54	-6.22	-0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.4	8.03	0.4	1.56e-14	Renal cell carcinoma;
LIHC	cis	rs72627509	0.638	rs12642622	chr4:57902276	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.53	-6.9	-0.35	2.52e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.51	7.34	0.37	1.57e-12	Body mass index;
LIHC	cis	rs9783347	0.961	rs4150653	chr11:18374782	G/A	cg15585147	chr11:18324498	HPS5	0.38	5.99	0.31	5.39e-9	Pancreatic cancer;
LIHC	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.87	15.75	0.65	2.09e-42	Body mass index;
LIHC	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg24097872	chr10:5724021	NA	0.68	10.74	0.5	2.25e-23	Childhood ear infection;
LIHC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.54	8.02	0.4	1.69e-14	Multiple sclerosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22828804	chr20:3140466	UBOX5;FASTKD5	0.44	6.15	0.32	2.19e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg18289306	chr13:113640169	MCF2L	0.42	6.61	0.34	1.49e-10	Systolic blood pressure;
LIHC	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.86	17.67	0.69	4.33e-50	Longevity;
LIHC	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.79	0.3	1.56e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.43	-7.77	-0.39	9.37e-14	Aortic root size;
LIHC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.3	6.44	0.33	3.94e-10	Pulmonary function;
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg00049323	chr5:472564	LOC25845	0.35	5.82	0.3	1.38e-8	Cystic fibrosis severity;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	13.62	0.59	4.94e-34	Menopause (age at onset);
LIHC	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.77	-11.8	-0.54	3.39e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.9e-38	Blood metabolite levels;
LIHC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20135002	chr11:47629003	NA	-0.54	-9.25	-0.45	2.57e-18	Subjective well-being;
LIHC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27297192	chr10:134578999	INPP5A	0.53	8.02	0.4	1.75e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg13409248	chr3:40428643	ENTPD3	0.46	7.65	0.38	2.01e-13	Renal cell carcinoma;
LIHC	cis	rs77861329	1.000	rs9811707	chr3:52190657	G/A	cg08692210	chr3:52188851	WDR51A	0.82	7.74	0.39	1.14e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.58	10.31	0.49	6.89e-22	Dupuytren's disease;
LIHC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.37	6.83	0.35	4.01e-11	Ewing sarcoma;
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-8.03	-0.4	1.6e-14	Total body bone mineral density;
LIHC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.69	0.43	1.58e-16	Lung cancer in ever smokers;
LIHC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg15208524	chr1:10270712	KIF1B	0.41	6.09	0.31	3.05e-9	Hepatocellular carcinoma;
LIHC	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	cg06064525	chr11:970664	AP2A2	-0.44	-10.79	-0.5	1.47e-23	Alzheimer's disease (late onset);
LIHC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.93	0.35	2.11e-11	Lung cancer in ever smokers;
LIHC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg16822855	chr3:40428330	ENTPD3	0.35	6.38	0.33	5.91e-10	Renal cell carcinoma;
LIHC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.59	8.5	0.42	5.97e-16	Lung cancer;
LIHC	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg01145232	chr6:150245071	RAET1G	0.39	7.39	0.37	1.14e-12	Lung cancer;
LIHC	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02985541	chr2:219472218	PLCD4	-0.36	-6.22	-0.32	1.45e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21611145	chr19:13261629	IER2;STX10	0.49	6.12	0.31	2.53e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.8	6.9	0.35	2.59e-11	Arsenic metabolism;
LIHC	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.51	-8.58	-0.42	3.4e-16	Pubertal anthropometrics;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05980081	chr15:64385876	FAM96A	-0.55	-7.01	-0.35	1.29e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10733682	0.659	rs4358894	chr9:129464802	C/G	cg00232160	chr9:129468157	NA	0.36	6.26	0.32	1.16e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg19645103	chr12:69753606	YEATS4	-0.4	-5.92	-0.3	7.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.3	-0.37	2e-12	Tonsillectomy;
LIHC	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.47	-0.49	1.97e-22	Rheumatoid arthritis;
LIHC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg16506815	chr2:162101123	NA	-0.47	-7.78	-0.39	8.46e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26627956	chr2:202004766	CFLAR	0.39	6.21	0.32	1.55e-9	Pancreatic cancer;
LIHC	cis	rs12220238	0.915	rs12217890	chr10:76024496	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.24	0.32	1.28e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1198430	1.000	rs1198430	chr1:23755513	C/T	cg19827787	chr1:23763612	ASAP3	-0.32	-6.1	-0.31	2.94e-9	Total cholesterol levels;
LIHC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.41	-7.83	-0.39	6.07e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg02023728	chr11:77925099	USP35	-0.33	-5.94	-0.31	7.02e-9	Alzheimer's disease (survival time);
LIHC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	7.13	0.36	5.96e-12	Response to bleomycin (chromatid breaks);
LIHC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.62	9.83	0.47	3e-20	Corneal astigmatism;
LIHC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.42	6.77	0.34	5.56e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3736228	0.522	rs111564249	chr11:68404220	G/A	cg16797656	chr11:68205561	LRP5	0.49	6.24	0.32	1.3e-9	Bone mineral density;
LIHC	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10242455	0.571	rs73713595	chr7:99326659	G/A	cg18809830	chr7:99032528	PTCD1	-0.85	-6.8	-0.34	4.79e-11	Blood metabolite levels;
LIHC	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.43	6.53	0.33	2.32e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.7	-7.81	-0.39	7.21e-14	Exhaled nitric oxide output;
LIHC	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.6	-9.33	-0.45	1.39e-18	White matter hyperintensity burden;
LIHC	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.52	-8.31	-0.41	2.22e-15	Anterior chamber depth;
LIHC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.86	-0.35	3.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.93	-0.39	3.14e-14	Type 2 diabetes;
LIHC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.75	-11.28	-0.52	2.65e-25	Response to antineoplastic agents;
LIHC	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.69	-0.46	9.09e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg17279839	chr7:150038598	RARRES2	0.5	10.58	0.5	8.39e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	15.1	0.63	8.08e-40	Monocyte count;
LIHC	cis	rs600806	0.888	rs3768497	chr1:109866230	T/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.93	-0.31	7.4e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07631383	chr7:131012765	MKLN1	0.42	6.44	0.33	4.02e-10	Cognitive function;
LIHC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.86	14.26	0.61	1.62e-36	Colorectal cancer;
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.51	6.48	0.33	3.23e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.06	0.31	3.5e-9	Morning vs. evening chronotype;
LIHC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.58	8.04	0.4	1.5e-14	Bladder cancer;
LIHC	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg13482628	chr17:19912719	NA	0.49	8.03	0.4	1.6e-14	Schizophrenia;
LIHC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.66	10.79	0.5	1.51e-23	Platelet count;
LIHC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.76	11.71	0.54	7.22e-27	Corneal astigmatism;
LIHC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-6.78	-0.34	5.45e-11	Migraine;Coronary artery disease;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17498856	chr1:1457042	ATAD3A	0.39	6.06	0.31	3.67e-9	Alopecia areata;
LIHC	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg01858014	chr14:56050164	KTN1	-0.73	-8.35	-0.41	1.74e-15	Putamen volume;
LIHC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.68	13.19	0.58	2.17e-32	High light scatter reticulocyte count;
LIHC	trans	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg10208301	chr11:6592745	DNHD1	0.45	6.04	0.31	3.92e-9	Coronary artery calcification;
LIHC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.26	-0.49	1.06e-21	Response to antipsychotic treatment;
LIHC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-8.19	-0.4	5.34e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg13409248	chr3:40428643	ENTPD3	0.43	7.21	0.36	3.51e-12	Renal cell carcinoma;
LIHC	cis	rs1144333	0.510	rs12408897	chr1:76448102	T/C	cg22875332	chr1:76189707	ACADM	0.41	6.01	0.31	4.79e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.9	-11.74	-0.54	5.66e-27	Alzheimer's disease;
LIHC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	8.86	0.43	4.49e-17	Initial pursuit acceleration;
LIHC	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.27	0.61	1.4e-36	Bipolar disorder;
LIHC	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg03934865	chr2:198174659	NA	-0.48	-7.03	-0.36	1.11e-11	Intracranial aneurysm;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16150678	chr8:101170369	SPAG1	0.41	6.06	0.31	3.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7872515	1.000	rs7872515	chr9:94822540	A/G	cg01248375	chr9:94877805	SPTLC1	-0.54	-7.53	-0.38	4.43e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.43	6.64	0.34	1.24e-10	Methadone dose in opioid dependence;
LIHC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.31	-0.32	8.76e-10	Diabetic kidney disease;
LIHC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.37	5.79	0.3	1.58e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg00750074	chr16:89608354	SPG7	-0.38	-5.8	-0.3	1.5e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg13628971	chr7:2884303	GNA12	0.38	5.88	0.3	9.73e-9	Height;
LIHC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.45	7.33	0.37	1.66e-12	Alcohol dependence;
LIHC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg05044414	chr3:183734942	ABCC5	0.34	5.97	0.31	5.79e-9	Anterior chamber depth;
LIHC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.71	-0.3	2.43e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.54	-8.74	-0.43	1.08e-16	Longevity;Endometriosis;
LIHC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.47	7.67	0.38	1.83e-13	Tuberculosis;
LIHC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	1.05	15.38	0.64	6.23e-41	Breast cancer;
LIHC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.12	0.52	9.62e-25	Platelet count;
LIHC	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.56	-6.8	-0.35	4.55e-11	Breast cancer;
LIHC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.57	-0.5	9e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.68	9.98	0.47	9.65e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs3813359	0.614	rs17059066	chr6:130769858	C/T	cg12097325	chr1:1076431	NA	-0.74	-6.04	-0.31	4.05e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg21522988	chr12:29376872	FAR2	0.29	6.73	0.34	7.11e-11	QT interval;
LIHC	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.63	10.59	0.5	7.19e-23	Breast cancer;
LIHC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.3	0.41	2.45e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.88e-14	Total body bone mineral density;
LIHC	cis	rs2204008	0.615	rs11495468	chr12:38024633	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.44	0.45	5.99e-19	Bladder cancer;
LIHC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.62	0.42	2.52e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg19743168	chr1:23544995	NA	0.34	5.72	0.3	2.33e-8	Height;
LIHC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.79	12.44	0.56	1.43e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg22563815	chr15:78856949	CHRNA5	0.35	6.31	0.32	8.54e-10	Sudden cardiac arrest;
LIHC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.38	-5.96	-0.31	6.38e-9	Testicular germ cell tumor;
LIHC	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.66	5.99	0.31	5.18e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg12253828	chr6:101329408	ASCC3	-0.39	-5.97	-0.31	6.04e-9	Neuroticism;
LIHC	trans	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg10756647	chr7:56101905	PSPH	-1.1	-13.4	-0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs9303280	0.806	rs9303279	chr17:38073968	G/C	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.64	-0.34	1.21e-10	Self-reported allergy;
LIHC	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.74	8.7	0.43	1.46e-16	Exhaled nitric oxide output;
LIHC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.02	14.54	0.62	1.3e-37	Cognitive function;
LIHC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	5.86	0.3	1.11e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs74181299	0.684	rs6736728	chr2:65305499	A/G	cg05010058	chr2:65284262	CEP68	0.4	6.61	0.34	1.51e-10	Pulse pressure;
LIHC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.66	-6.28	-0.32	1.02e-9	Breast cancer;
LIHC	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs7188697	0.885	rs1646010	chr16:58549204	G/C	cg02549819	chr16:58548995	SETD6	-0.49	-7.74	-0.39	1.14e-13	QT interval;
LIHC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg13175981	chr1:150552382	MCL1	-0.43	-5.9	-0.3	8.63e-9	Tonsillectomy;
LIHC	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.06	0.48	4.99e-21	Coffee consumption (cups per day);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10408731	chr7:65214843	CCT6P1	-0.34	-6.35	-0.32	7.04e-10	Calcium levels;
LIHC	cis	rs11951515	0.508	rs67261887	chr5:43612441	T/A	cg01983248	chr5:43482804	C5orf28	-0.4	-6.55	-0.33	2.06e-10	Metabolite levels  (X-11787);
LIHC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.76	13.14	0.58	3.4e-32	Mean platelet volume;
LIHC	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg22705602	chr4:152727874	NA	-0.34	-7.17	-0.36	4.67e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.43	-6.25	-0.32	1.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg24826892	chr11:71159390	DHCR7	-0.44	-5.75	-0.3	1.98e-8	Vitamin D levels;
LIHC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.3	0.32	9.16e-10	Height;
LIHC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg05973401	chr12:123451056	ABCB9	0.47	5.97	0.31	6.06e-9	Neutrophil percentage of white cells;
LIHC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.02	0.31	4.43e-9	Menopause (age at onset);
LIHC	trans	rs1814175	0.530	rs11040482	chr11:49727068	T/C	cg03929089	chr4:120376271	NA	-0.86	-16.65	-0.67	5.35e-46	Height;
LIHC	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg02811702	chr13:24901961	NA	0.25	6.38	0.33	5.7e-10	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs365132	1.000	rs353468	chr5:176445494	A/T	cg16309518	chr5:176445507	NA	-0.58	-11.34	-0.52	1.62e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs400736	0.896	rs225126	chr1:8090615	A/G	cg25007680	chr1:8021821	PARK7	0.6	9.52	0.46	3.23e-19	Response to antidepressants and depression;
LIHC	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg25566285	chr7:158114605	PTPRN2	0.22	6.06	0.31	3.56e-9	Calcium levels;
LIHC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg23091122	chr1:110024289	SYPL2	-0.52	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.69	13.79	0.6	1.05e-34	Coronary artery disease;
LIHC	cis	rs4716602	0.572	rs10271030	chr7:156159796	T/C	cg16983916	chr7:156159713	NA	-0.32	-5.73	-0.3	2.17e-8	Anti-saccade response;
LIHC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.79	12.06	0.55	3.87e-28	Total body bone mineral density;
LIHC	cis	rs13161895	0.941	rs438050	chr5:179414645	T/C	cg02702477	chr5:179499311	RNF130	0.75	10.32	0.49	6.59e-22	LDL cholesterol;
LIHC	cis	rs4407350	0.694	rs131163	chr22:44892135	A/G	cg11695653	chr22:44894386	LDOC1L	-0.35	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-10.07	-0.48	4.6e-21	Initial pursuit acceleration;
LIHC	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.26	-6.1	-0.31	2.85e-9	Heart rate;
LIHC	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg14440974	chr22:39074834	NA	-0.38	-6.44	-0.33	4.04e-10	Menopause (age at onset);
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg18279126	chr7:2041391	MAD1L1	0.37	6.12	0.31	2.62e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.84	-15.82	-0.65	1.12e-42	Height;
LIHC	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.28	5.84	0.3	1.2e-8	Pulmonary function;
LIHC	cis	rs244293	0.868	rs12453779	chr17:53172109	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.55	0.38	4.05e-13	Menarche (age at onset);
LIHC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.5	8.51	0.42	5.47e-16	Hepatocellular carcinoma;
LIHC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg16226627	chr15:75307476	SCAMP5	0.49	8.67	0.42	1.75e-16	Lung cancer;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg19074533	chr20:25604700	NANP	-0.44	-6.09	-0.31	3.12e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.08	0.31	3.18e-9	Neutrophil percentage of white cells;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00838250	chr3:186287958	TBCCD1;DNAJB11	0.42	6.13	0.31	2.47e-9	Morning vs. evening chronotype;
LIHC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.7	9.12	0.44	6.58e-18	Gut microbiome composition (summer);
LIHC	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.96	19.23	0.72	2.28e-56	Birth weight;
LIHC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.58	-9.9	-0.47	1.7e-20	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg00091569	chr3:40428383	ENTPD3	0.39	6.74	0.34	6.75e-11	Renal cell carcinoma;
LIHC	trans	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg17675199	chr6:35436792	RPL10A	0.41	8.39	0.41	1.34e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.41	6.65	0.34	1.19e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.9	8.51	0.42	5.42e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs57590327	0.612	rs820272	chr3:81554345	T/C	cg07356753	chr3:81810745	GBE1	0.42	5.77	0.3	1.74e-8	Extraversion;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15464645	chr15:28380110	HERC2	0.41	6.08	0.31	3.24e-9	Pancreatic cancer;
LIHC	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.85	0.47	2.6e-20	Corneal astigmatism;
LIHC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.45	-0.72	2.74e-57	Coronary artery disease;
LIHC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.6	-0.34	1.56e-10	Personality dimensions;
LIHC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	9.08	0.44	8.77e-18	Motion sickness;
LIHC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg11812906	chr14:75593930	NEK9	0.4	5.88	0.3	9.68e-9	IgG glycosylation;
LIHC	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg15893493	chr8:124194847	FAM83A	-0.83	-7.9	-0.39	3.77e-14	Urinary uromodulin levels;
LIHC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.48	7.8	0.39	7.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.4	7.16	0.36	5.01e-12	Hepatocellular carcinoma;
LIHC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	9.85	0.47	2.5e-20	Personality dimensions;
LIHC	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.9	-0.3	8.7e-9	Coronary artery disease;
LIHC	cis	rs7095607	0.606	rs4746739	chr10:69960091	C/T	cg18986048	chr10:69913749	MYPN	-0.38	-5.74	-0.3	2.1e-8	Lung function (FVC);
LIHC	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.6	9.65	0.46	1.25e-19	Anterior chamber depth;
LIHC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.82	0.43	5.99e-17	Eosinophil percentage of white cells;
LIHC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.74	-0.39	1.11e-13	Chronic sinus infection;
LIHC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.88	14.59	0.62	7.91e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	6.45	0.33	3.92e-10	Bipolar disorder;
LIHC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	1.04	13.79	0.6	1.09e-34	Heart rate;
LIHC	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.41	6.07	0.31	3.41e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.75	0.43	1.02e-16	Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.84	8.6	0.42	2.96e-16	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01939414	chr2:103353548	MFSD9	0.47	6.47	0.33	3.39e-10	Pancreatic cancer;
LIHC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-7.94	-0.39	2.89e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg17130504	chr10:102756923	LZTS2	0.55	7.56	0.38	3.84e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4450131	0.569	rs7917674	chr10:126340267	C/A	cg20435097	chr10:126320824	FAM53B	-0.62	-11.66	-0.53	1.14e-26	White blood cell count (basophil);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg02375201	chr1:27114675	PIGV	-0.52	-6.3	-0.32	9.09e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg03934865	chr2:198174659	NA	-0.48	-7.01	-0.35	1.27e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.65	10.1	0.48	3.62e-21	Type 2 diabetes;
LIHC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	11.88	0.54	1.79e-27	Lung cancer in ever smokers;
LIHC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg22079354	chr11:130786696	SNX19	0.42	5.95	0.31	6.52e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	1.04	12.44	0.56	1.48e-29	Red blood cell traits;
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg13752114	chr3:195489708	MUC4	0.7	11.48	0.53	5.24e-26	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.42	-6.71	-0.34	8.06e-11	Inhibitory control;
LIHC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.49	-0.33	3.09e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4934494	0.727	rs55823491	chr10:91517355	A/G	cg19698084	chr10:91461284	KIF20B	-0.44	-5.83	-0.3	1.31e-8	Red blood cell count;
LIHC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18357526	chr6:26021779	HIST1H4A	0.41	6.13	0.31	2.36e-9	Height;
LIHC	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.78	11.99	0.54	6.63e-28	Breast cancer;
LIHC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.55	-0.56	5.53e-30	Response to antipsychotic treatment;
LIHC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.4	7.68	0.38	1.66e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1198430	0.714	rs946265	chr1:23775296	T/G	cg19827787	chr1:23763612	ASAP3	0.3	6.45	0.33	3.74e-10	Total cholesterol levels;
LIHC	cis	rs2016586	0.767	rs879680	chr22:36130527	T/C	cg26342177	chr22:36113512	APOL5	-0.36	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg23806715	chr17:73775811	H3F3B	0.54	7.63	0.38	2.39e-13	Psoriasis;
LIHC	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.88	13.01	0.58	1.06e-31	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-10.55	-0.5	1.05e-22	Crohn's disease;
LIHC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg25894440	chr7:65020034	NA	-0.51	-5.78	-0.3	1.69e-8	Diabetic kidney disease;
LIHC	trans	rs1814175	0.616	rs6486011	chr11:49740230	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-20.37	-0.74	5.91e-61	Height;
LIHC	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.43	6.52	0.33	2.47e-10	Nonalcoholic fatty liver disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09581848	chr17:37909335	NA	0.43	6.44	0.33	4.02e-10	Immature fraction of reticulocytes;
LIHC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.58	-10.57	-0.5	8.45e-23	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03513682	chr16:85542749	NA	0.46	6.74	0.34	6.95e-11	Longevity;
LIHC	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.67	-7.15	-0.36	5.45e-12	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.69	0.38	1.59e-13	Lymphocyte counts;
LIHC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.6	10.44	0.49	2.46e-22	Mean corpuscular volume;
LIHC	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.54	6.68	0.34	9.59e-11	Coronary artery disease;
LIHC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.45	5.95	0.31	6.7e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg27478167	chr7:817139	HEATR2	-0.5	-6.78	-0.34	5.4e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.1	-0.48	3.7e-21	Response to antipsychotic treatment;
LIHC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.32	6.43	0.33	4.19e-10	Platelet distribution width;
LIHC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.46	-6.36	-0.33	6.64e-10	Initial pursuit acceleration;
LIHC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.39	5.92	0.3	8e-9	Tuberculosis;
LIHC	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.78	-0.69	1.57e-50	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.44	6.74	0.34	6.63e-11	Melanoma;
LIHC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	11.37	0.52	1.22e-25	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	trans	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg10208301	chr11:6592745	DNHD1	0.47	6.89	0.35	2.68e-11	Coronary artery calcification;
LIHC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg05555928	chr11:63887634	MACROD1	0.53	7.08	0.36	8.01e-12	Mean platelet volume;
LIHC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	0.6	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs4716602	0.596	rs10265909	chr7:156158095	T/C	cg16983916	chr7:156159713	NA	-0.32	-5.87	-0.3	1.03e-8	Anti-saccade response;
LIHC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.42	7.07	0.36	8.58e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-5.74	-0.3	2.14e-8	Neuroticism;
LIHC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg19680672	chr10:131412579	MGMT	-0.45	-6.86	-0.35	3.33e-11	Response to temozolomide;
LIHC	cis	rs747782	0.527	rs1044269	chr11:47487740	G/A	cg20307385	chr11:47447363	PSMC3	0.59	6.89	0.35	2.63e-11	Intraocular pressure;
LIHC	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.37	7.76	0.39	9.77e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.7	-11.44	-0.53	6.83e-26	Childhood ear infection;
LIHC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.54	8.89	0.43	3.5e-17	Obesity-related traits;
LIHC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-10.84	-0.51	1.01e-23	Vitiligo;
LIHC	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg17623882	chr6:41773611	USP49	-0.43	-5.8	-0.3	1.53e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.62	10.72	0.5	2.68e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.45	6.12	0.31	2.5e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9513627	1.000	rs7338537	chr13:100119581	C/A	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs7116495	1.000	rs562469	chr11:71569843	A/T	cg26138937	chr11:71823887	C11orf51	0.7	6.7	0.34	8.52e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.55	-7.22	-0.36	3.48e-12	Lung cancer;
LIHC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.45	0.37	7.57e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg02297831	chr4:17616191	MED28	0.43	6.8	0.35	4.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.13	0.31	2.38e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs709400	0.663	rs1022736	chr14:103998423	G/C	cg26031613	chr14:104095156	KLC1	0.77	9.35	0.45	1.2e-18	Body mass index;
LIHC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg05044414	chr3:183734942	ABCC5	0.35	6.11	0.31	2.76e-9	Anterior chamber depth;
LIHC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg02269571	chr22:50332266	NA	0.59	8.34	0.41	1.83e-15	Schizophrenia;
LIHC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-8.62	-0.42	2.56e-16	Total body bone mineral density;
LIHC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.86	-10.82	-0.51	1.16e-23	Cognitive test performance;
LIHC	cis	rs1144333	0.655	rs76612182	chr1:76451889	C/T	cg22875332	chr1:76189707	ACADM	0.43	6.43	0.33	4.35e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.57	-7.85	-0.39	5.52e-14	Menopause (age at onset);
LIHC	cis	rs2412488	0.927	rs7690908	chr4:54339423	A/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.71	-0.34	8.2e-11	DNA methylation (variation);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22109331	chr1:212003961	LPGAT1	0.45	6.08	0.31	3.21e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6788895	1.000	rs2014279	chr3:150487945	G/T	cg07663535	chr3:150480033	SIAH2	0.5	6.42	0.33	4.51e-10	Breast cancer;
LIHC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg27211696	chr2:191398769	TMEM194B	-0.52	-6.84	-0.35	3.71e-11	Diastolic blood pressure;
LIHC	cis	rs9534463	0.667	rs1747224	chr13:47223102	G/A	cg04092803	chr13:47240378	LRCH1	0.27	5.74	0.3	2.11e-8	Platelet distribution width;
LIHC	cis	rs17152411	0.793	rs12569669	chr10:126592671	A/G	cg07906193	chr10:126599966	NA	0.47	7.25	0.37	2.75e-12	Height;
LIHC	cis	rs9918079	0.542	rs12499412	chr4:15602252	G/C	cg04067612	chr4:15429572	C1QTNF7	0.28	5.87	0.3	1.03e-8	Obesity-related traits;
LIHC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.68	9.31	0.45	1.57e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg17927777	chr20:33865990	NA	0.53	6.1	0.31	2.87e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.63	0.34	1.3e-10	Obesity-related traits;
LIHC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.71	-0.3	2.41e-8	Breast cancer;
LIHC	cis	rs8081395	0.805	rs2645485	chr17:57944281	C/G	cg13753209	chr17:57696993	CLTC	0.39	5.81	0.3	1.44e-8	White blood cell count;
LIHC	cis	rs3018712	0.547	rs4930583	chr11:68411179	G/A	cg16797656	chr11:68205561	LRP5	-0.44	-5.83	-0.3	1.28e-8	Total body bone mineral density;
LIHC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.5	6.28	0.32	1.01e-9	Chronic sinus infection;
LIHC	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.55	-8.63	-0.42	2.35e-16	White matter hyperintensity burden;
LIHC	cis	rs509477	1.000	rs7236052	chr18:32574540	A/G	cg23791764	chr18:32556832	MAPRE2	-0.49	-6.76	-0.34	6.07e-11	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.12	13.15	0.58	2.97e-32	Psoriasis vulgaris;
LIHC	trans	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg25214090	chr10:38739885	LOC399744	0.44	6.88	0.35	2.86e-11	Diastolic blood pressure;
LIHC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.62	-0.38	2.48e-13	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg09904177	chr6:26538194	HMGN4	-0.53	-5.72	-0.3	2.37e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg08847533	chr14:75593920	NEK9	0.48	7.44	0.37	8.33e-13	Platelet count;
LIHC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.82	9.35	0.45	1.15e-18	Vitiligo;
LIHC	trans	rs71658797	0.505	rs12041509	chr1:77969621	T/G	cg04606550	chr5:14226569	TRIO	0.39	6.04	0.31	4.06e-9	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
LIHC	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg05760424	chr2:242988095	NA	-0.53	-6.98	-0.35	1.51e-11	Obesity-related traits;
LIHC	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.97	-0.54	7.97e-28	Coffee consumption (cups per day);
LIHC	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg04306507	chr14:55594613	LGALS3	0.35	6.54	0.33	2.24e-10	Protein biomarker;
LIHC	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.5	-7.74	-0.39	1.16e-13	Breast size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21395782	chr19:19626814	NDUFA13;TSSK6	0.41	6.32	0.32	8.34e-10	Cognitive function;
LIHC	cis	rs1866706	1.000	rs6486063	chr11:12869497	C/G	cg25843174	chr11:12811716	TEAD1	0.29	6.2	0.32	1.59e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.15	0.4	6.94e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg24296786	chr1:45957014	TESK2	0.48	6.91	0.35	2.35e-11	Platelet count;
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg27094323	chr7:1216898	NA	-0.4	-5.8	-0.3	1.53e-8	Longevity;Endometriosis;
LIHC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7546668	1.000	rs4233537	chr1:15849700	T/A	cg11706911	chr1:15910989	AGMAT	0.44	6.83	0.35	3.91e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.77	11.58	0.53	2.15e-26	Subjective well-being;
LIHC	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg14515779	chr1:101123966	NA	0.49	7.06	0.36	9.19e-12	Monocyte count;
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.53	5.8	0.3	1.55e-8	Alzheimer's disease;
LIHC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.28	0.58	9.81e-33	Cognitive test performance;
LIHC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.81	-0.3	1.42e-8	Menopause (age at onset);
LIHC	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg11642891	chr2:3452563	TTC15	-0.45	-7.2	-0.36	3.8e-12	Obesity-related traits;
LIHC	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg09307838	chr4:120376055	NA	0.69	9.83	0.47	2.99e-20	Corneal astigmatism;
LIHC	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg06565975	chr8:143823917	SLURP1	0.33	6.27	0.32	1.11e-9	Urinary tract infection frequency;
LIHC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.72	14.0	0.6	1.6e-35	Height;
LIHC	cis	rs10508774	1.000	rs10159899	chr10:32955315	T/G	cg01819863	chr10:32635814	EPC1	0.64	5.95	0.31	6.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.56	-7.92	-0.39	3.36e-14	Facial morphology (factor 19);
LIHC	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.65	8.02	0.4	1.71e-14	Neuroticism;
LIHC	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	-0.52	-8.01	-0.4	1.82e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg18357526	chr6:26021779	HIST1H4A	0.58	8.01	0.4	1.85e-14	Blood metabolite levels;
LIHC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg09182678	chr22:50328711	NA	-0.43	-6.17	-0.32	1.98e-9	Schizophrenia;
LIHC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.66	-0.38	1.91e-13	Morning vs. evening chronotype;
LIHC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.49	7.49	0.38	5.73e-13	Resting heart rate;
LIHC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.1	-0.44	7.84e-18	Alzheimer's disease;
LIHC	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs9326778	0.520	rs17161799	chr5:108826124	A/G	cg17395555	chr5:108820864	NA	-0.36	-6.26	-0.32	1.19e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg05697976	chr12:29376483	FAR2	0.31	6.17	0.32	1.9e-9	QT interval;
LIHC	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg10820045	chr2:198174542	NA	-0.61	-10.23	-0.48	1.37e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg03146154	chr1:46216737	IPP	-0.37	-6.14	-0.31	2.32e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.28	0.37	2.24e-12	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13409248	chr3:40428643	ENTPD3	0.47	7.67	0.38	1.84e-13	Renal cell carcinoma;
LIHC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.67	-11.15	-0.52	7.7e-25	Childhood ear infection;
LIHC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.56	-0.33	2.03e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7075426	0.669	rs10887607	chr10:88190354	A/G	cg07322936	chr10:88137208	NA	0.48	6.14	0.31	2.35e-9	Migraine without aura;
LIHC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17507749	chr15:85114479	UBE2QP1	0.61	6.79	0.34	5.09e-11	Schizophrenia;
LIHC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.85	12.11	0.55	2.57e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.12	0.36	6.28e-12	Monocyte percentage of white cells;
LIHC	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg22705602	chr4:152727874	NA	-0.3	-6.23	-0.32	1.35e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.89	-13.83	-0.6	7.09e-35	Body mass index;
LIHC	cis	rs10022260	1	rs10022260	chr4:83793921	C/T	cg00595051	chr4:83955429	COPS4	-0.48	-6.74	-0.34	6.69e-11	Adult asthma;
LIHC	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	7.61	0.38	2.65e-13	LDL cholesterol;
LIHC	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg09165964	chr15:75287851	SCAMP5	0.5	6.96	0.35	1.76e-11	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs61990749	0.571	rs4903655	chr14:78306326	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.49	7.39	0.37	1.12e-12	Fibroblast growth factor basic levels;
LIHC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.46	6.31	0.32	8.55e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs742115	0.563	rs12663475	chr6:11297296	T/C	cg25250968	chr6:11318770	NEDD9	-0.42	-6.55	-0.33	2.13e-10	Coronary artery disease;
LIHC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	ch.11.42038R	chr11:967971	AP2A2	0.54	9.76	0.47	5.28e-20	Alzheimer's disease (late onset);
LIHC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.71	0.34	8.08e-11	Bipolar disorder;
LIHC	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg24060327	chr5:131705240	SLC22A5	0.55	7.44	0.37	8.01e-13	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs7487075	0.930	rs4076484	chr12:46833912	C/G	cg11331445	chr12:47219877	SLC38A4	0.27	5.79	0.3	1.63e-8	Itch intensity from mosquito bite;
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.37	0.37	1.31e-12	Renal cell carcinoma;
LIHC	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.95	-0.44	2.37e-17	Colorectal cancer;
LIHC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg00800038	chr16:89945340	TCF25	-0.62	-9.43	-0.45	6.49e-19	Skin colour saturation;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.53	5.77	0.3	1.73e-8	Alzheimer's disease;
LIHC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.92	9.63	0.46	1.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs4908768	0.501	rs2045820	chr1:8738135	A/G	cg20416874	chr1:8611966	RERE	-0.63	-12.77	-0.57	8.45e-31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	6.8	0.35	4.63e-11	Renal cell carcinoma;
LIHC	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.64	6.77	0.34	5.66e-11	Type 2 diabetes;
LIHC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.48	8.16	0.4	6.37e-15	Response to temozolomide;
LIHC	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg20607764	chr19:44506953	ZNF230	0.42	6.71	0.34	7.99e-11	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.04	0.72	1.3e-55	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.68	0.8	5.83e-78	Prudent dietary pattern;
LIHC	cis	rs16858210	0.529	rs10937154	chr3:183569489	C/T	cg25686905	chr3:183603175	PARL	-0.47	-8.35	-0.41	1.76e-15	Menopause (age at onset);
LIHC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.82	-0.35	4.11e-11	Personality dimensions;
LIHC	cis	rs12980942	0.872	rs3816052	chr19:41773797	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.51	6.38	0.33	5.74e-10	Coronary artery disease;
LIHC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.87	-0.3	1.01e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.8	11.36	0.52	1.4e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.89	18.09	0.7	8.88e-52	Height;
LIHC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg23978390	chr7:1156363	C7orf50	0.48	6.83	0.35	3.86e-11	Longevity;Endometriosis;
LIHC	cis	rs4407350	0.870	rs2213373	chr22:44911669	C/T	cg04154583	chr22:44889756	LDOC1L	0.3	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	8.02	0.4	1.66e-14	Mean platelet volume;
LIHC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.67	7.23	0.36	3.09e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.36	-0.33	6.5e-10	Heart rate;
LIHC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.38	7.78	0.39	8.76e-14	Immature fraction of reticulocytes;
LIHC	trans	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg24036039	chr1:3397125	ARHGEF16	0.39	6.45	0.33	3.82e-10	Schizophrenia;
LIHC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.92	0.3	7.95e-9	Schizophrenia;
LIHC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg00792783	chr2:198669748	PLCL1	-0.46	-6.77	-0.34	5.68e-11	Dermatomyositis;
LIHC	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg24083324	chr1:214162604	PROX1	0.55	8.61	0.42	2.8e-16	Schizophrenia;
LIHC	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg24220031	chr2:73402428	NA	0.27	5.77	0.3	1.76e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.95	15.67	0.65	4.22e-42	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.75	-7.7	-0.38	1.49e-13	Vitiligo;
LIHC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.9	-0.39	3.85e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.7	-9.81	-0.47	3.58e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.86	15.36	0.64	7.44e-41	Body mass index;
LIHC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.8	0.34	4.81e-11	Primary biliary cholangitis;
LIHC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.78	-0.3	1.64e-8	Life satisfaction;
LIHC	trans	rs12220238	0.841	rs10824161	chr10:76133762	C/G	cg15970666	chr2:162095662	NA	-0.55	-6.27	-0.32	1.09e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-10.49	-0.49	1.7e-22	Platelet count;
LIHC	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.44	6.89	0.35	2.66e-11	Coronary artery disease;
LIHC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.56	-9.56	-0.46	2.38e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.45	0.33	3.79e-10	Mean platelet volume;
LIHC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.22	6.02	0.31	4.4e-9	Calcium levels;
LIHC	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.78e-10	Obesity-related traits;
LIHC	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.48	7.56	0.38	3.75e-13	Cocaine dependence;
LIHC	cis	rs716804	0.703	rs11042703	chr11:10288235	G/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.87	-0.3	1.01e-8	Neuroticism;
LIHC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.81	-0.3	1.46e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.74	-13.34	-0.59	5.69e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.53	6.07	0.31	3.4e-9	Alzheimer's disease;
LIHC	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.08	0.31	3.28e-9	Ulcerative colitis;
LIHC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.43	-6.09	-0.31	3.07e-9	Height;
LIHC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg02269571	chr22:50332266	NA	-0.54	-7.41	-0.37	9.94e-13	Schizophrenia;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs244293	0.965	rs244287	chr17:53232036	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.18	0.36	4.37e-12	Menarche (age at onset);
LIHC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.54	8.13	0.4	8.1e-15	Longevity;Endometriosis;
LIHC	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg21231739	chr4:1642635	FAM53A	-0.38	-5.98	-0.31	5.67e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.47	-7.65	-0.38	2.13e-13	Cognitive function;
LIHC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg22834771	chr12:69754056	YEATS4	0.39	5.97	0.31	6.04e-9	Response to diuretic therapy;
LIHC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.64	8.71	0.43	1.31e-16	Aortic root size;
LIHC	cis	rs922107	0.713	rs10922668	chr1:90043236	A/G	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.6	-0.38	2.96e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg12373951	chr3:133503437	NA	0.43	7.16	0.36	4.83e-12	Iron status biomarkers;
LIHC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg16309518	chr5:176445507	NA	-0.52	-9.6	-0.46	1.78e-19	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.71	-6.72	-0.34	7.52e-11	Bipolar disorder;
LIHC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg13319975	chr6:146136371	FBXO30	-0.35	-5.9	-0.3	8.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.27	-0.37	2.4e-12	Ulcerative colitis;
LIHC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.06	-0.48	4.98e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg03859395	chr2:55845619	SMEK2	0.77	13.24	0.58	1.4e-32	Metabolic syndrome;
LIHC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.46	10.69	0.5	3.32e-23	Iron status biomarkers (transferrin levels);
LIHC	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg03645007	chr3:50255295	SLC38A3	0.53	7.13	0.36	5.91e-12	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-9.76	-0.47	5.37e-20	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07016325	chr14:96968745	PAPOLA	-0.43	-6.22	-0.32	1.45e-9	Cognitive function;
LIHC	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.4	-5.89	-0.3	9.38e-9	Red blood cell traits;
LIHC	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.72	9.64	0.46	1.33e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg11204139	chr17:3907470	NA	0.67	11.3	0.52	2.3e-25	Type 2 diabetes;
LIHC	cis	rs829883	0.668	rs829882	chr12:98880099	A/G	cg23471612	chr12:98897216	NA	0.31	5.9	0.3	8.8e-9	Colorectal adenoma (advanced);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10477989	chr11:68039601	C11orf24	0.5	6.96	0.35	1.75e-11	Lung function (FEV1/FVC);
LIHC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.78	-0.67	1.55e-46	Ulcerative colitis;
LIHC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.45	-9.09	-0.44	8.22e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.5	6.21	0.32	1.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg13647721	chr17:30228624	UTP6	0.67	6.62	0.34	1.38e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg27211696	chr2:191398769	TMEM194B	-0.62	-7.86	-0.39	5.06e-14	Diastolic blood pressure;
LIHC	trans	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg07393940	chr7:158741817	NA	-0.57	-6.73	-0.34	7.07e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg10811681	chr14:69259722	ZFP36L1	-0.81	-6.24	-0.32	1.29e-9	Mild influenza (H1N1) infection;
LIHC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.6	10.34	0.49	5.56e-22	Lung cancer in ever smokers;
LIHC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg03037974	chr15:76606532	NA	0.77	15.52	0.64	1.78e-41	Blood metabolite levels;
LIHC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3917254	0.596	rs6754776	chr2:102764778	C/G	cg22835712	chr2:102737379	NA	-0.5	-5.74	-0.3	2.11e-8	Blood protein levels;
LIHC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.57	-0.33	1.83e-10	Bipolar disorder;
LIHC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg14440974	chr22:39074834	NA	-0.36	-6.04	-0.31	4.04e-9	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.86	12.87	0.57	3.46e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4474465	1.000	rs4944202	chr11:78189558	T/C	cg02023728	chr11:77925099	USP35	0.33	5.85	0.3	1.13e-8	Alzheimer's disease (survival time);
LIHC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.42	-0.45	6.74e-19	Gut microbiome composition (summer);
LIHC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.81	-6.58	-0.34	1.77e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.65	9.77	0.47	4.95e-20	Height;
LIHC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.4	7.95e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	8.94	0.44	2.54e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.65	6.97	0.35	1.63e-11	Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13645767	chr9:97766849	C9orf3	0.43	6.21	0.32	1.52e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-7.3	-0.37	2.02e-12	Initial pursuit acceleration;
LIHC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg18944383	chr4:111397179	ENPEP	0.25	6.14	0.32	2.28e-9	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.51	-7.82	-0.39	6.69e-14	Renal cell carcinoma;
LIHC	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.39	8.14	0.4	7.25e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg06060754	chr5:176797920	RGS14	0.7	10.64	0.5	4.98e-23	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	7.68	0.38	1.71e-13	Coffee consumption (cups per day);
LIHC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.89	12.67	0.57	1.99e-30	Alzheimer's disease;
LIHC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.46	6.63	0.34	1.28e-10	Bone mineral density;
LIHC	cis	rs7703744	0.747	rs6896559	chr5:118678718	G/C	cg04195774	chr5:118677172	TNFAIP8	-0.4	-5.72	-0.3	2.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1198430	0.852	rs909537	chr1:23810063	C/G	cg13183780	chr1:23809682	ASAP3	-0.56	-8.08	-0.4	1.14e-14	Total cholesterol levels;
LIHC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.39	-7.1	-0.36	7.48e-12	Psoriasis;
LIHC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.56	9.96	0.47	1.05e-20	Neuroticism;
LIHC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.73	0.34	7.34e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-8.95	-0.44	2.35e-17	Bipolar disorder;
LIHC	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	20.34	0.74	7.47e-61	Colorectal cancer;
LIHC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.71	-0.43	1.31e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	trans	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg19894588	chr14:64061835	NA	-0.63	-8.76	-0.43	9.13e-17	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	9.01	0.44	1.52e-17	Post bronchodilator FEV1;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.62	-0.42	2.55e-16	Lymphocyte counts;
LIHC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.49	-7.7	-0.38	1.44e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02439053	chr19:18390991	JUND	0.43	6.05	0.31	3.81e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs2274273	0.624	rs7151581	chr14:55788445	A/G	cg01864836	chr14:55583639	NA	0.37	6.02	0.31	4.45e-9	Protein biomarker;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.15e-11	Prudent dietary pattern;
LIHC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21467203	chr3:49911342	NA	-0.44	-7.79	-0.39	7.94e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg03785755	chr6:26196794	NA	0.52	5.82	0.3	1.37e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.67	-0.38	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.95	-0.51	4.11e-24	Hemoglobin concentration;
LIHC	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.61	12.1	0.55	2.67e-28	Plateletcrit;Platelet count;
LIHC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg03959625	chr15:84868606	LOC388152	0.47	6.76	0.34	6.14e-11	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06584407	chr1:11907324	NPPA	0.45	6.67	0.34	1.02e-10	Pancreatic cancer;
LIHC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.47	6.32	0.32	8.04e-10	Total body bone mineral density;
LIHC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.52	-9.23	-0.45	2.82e-18	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.25	-16.77	-0.67	1.7e-46	Diabetic kidney disease;
LIHC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17467752	chr17:38218738	THRA	0.64	11.78	0.54	4.19e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.74	11.52	0.53	3.52e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.06	-0.31	3.58e-9	IgG glycosylation;
LIHC	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.48	-6.6	-0.34	1.59e-10	Asthma (bronchodilator response);
LIHC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	1.04	18.97	0.72	2.46e-55	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.8	8.9	0.43	3.22e-17	Vitiligo;
LIHC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg23205692	chr1:25664452	TMEM50A	0.39	6.32	0.32	7.94e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.66	8.41	0.41	1.15e-15	Exhaled nitric oxide output;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.19	0.32	1.7e-9	Aortic root size;
LIHC	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.76	10.85	0.51	9.46e-24	Lymphocyte counts;
LIHC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.6	-8.83	-0.43	5.43e-17	Blood pressure (smoking interaction);
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.64	-9.72	-0.47	6.96e-20	Renal cell carcinoma;
LIHC	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.79	10.37	0.49	4.24e-22	Ear protrusion;
LIHC	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg09990169	chr2:241835740	C2orf54	-0.7	-11.19	-0.52	5.69e-25	Urinary metabolites;
LIHC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.54	8.14	0.4	7.45e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.11	10.18	0.48	1.9e-21	Uric acid levels;
LIHC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.24	0.36	2.93e-12	Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.588	rs7481648	chr11:49754910	A/G	cg03929089	chr4:120376271	NA	-0.85	-16.54	-0.67	1.44e-45	Height;
LIHC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.58	11.38	0.52	1.2e-25	Glomerular filtration rate (creatinine);
LIHC	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.38	5.96	0.31	6.36e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21448741	chr8:58168803	NA	0.33	5.86	0.3	1.11e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3018712	0.590	rs4930236	chr11:68414000	C/A	cg16797656	chr11:68205561	LRP5	-0.43	-5.74	-0.3	2.05e-8	Total body bone mineral density;
LIHC	cis	rs12220238	0.915	rs11001003	chr10:76099944	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.54	-8.27	-0.41	3.07e-15	P wave terminal force;
LIHC	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.45	6.35	0.32	6.97e-10	Kawasaki disease;
LIHC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.24	-0.41	3.62e-15	Chronic sinus infection;
LIHC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.54	9.3	0.45	1.65e-18	Mean corpuscular volume;
LIHC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg00012203	chr2:219082015	ARPC2	-0.83	-13.16	-0.58	2.79e-32	Colorectal cancer;
LIHC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	11.18	0.52	6.17e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.15	-16.95	-0.68	3.18e-47	Chronic sinus infection;
LIHC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.85	0.35	3.39e-11	Height;
LIHC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.54	10.5	0.49	1.53e-22	Methadone dose in opioid dependence;
LIHC	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg15192750	chr16:69999425	NA	0.45	7.05	0.36	1.02e-11	IgE levels;
LIHC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.43	-6.99	-0.35	1.4e-11	Bipolar disorder;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.75	13.58	0.59	6.97e-34	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04109349	chr1:245317172	KIF26B	0.41	6.71	0.34	8.2e-11	Cognitive function;
LIHC	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.66	10.88	0.51	6.96e-24	Pulse pressure;
LIHC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	7.17	0.36	4.57e-12	Longevity;
LIHC	cis	rs539514	0.587	rs689418	chr13:76322977	G/A	cg04757411	chr13:76259545	LMO7	-0.41	-6.83	-0.35	3.79e-11	Type 1 diabetes;
LIHC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg24296786	chr1:45957014	TESK2	0.4	5.71	0.3	2.44e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.5	6.49	0.33	3.09e-10	Initial pursuit acceleration;
LIHC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6449957	0.590	rs7713645	chr5:67527326	A/C	cg23036683	chr5:67512108	NA	0.4	5.83	0.3	1.28e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.78	-10.44	-0.49	2.47e-22	Systemic lupus erythematosus;
LIHC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.37	6.64	0.34	1.22e-10	Aortic root size;
LIHC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.43	-8.0	-0.4	1.98e-14	Electrocardiographic conduction measures;
LIHC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.26	-0.32	1.16e-9	Morning vs. evening chronotype;
LIHC	trans	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.76e-11	Coronary artery disease;
LIHC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.25	-7.55	-0.38	4.09e-13	Calcium levels;
LIHC	cis	rs965469	0.779	rs6051771	chr20:3328271	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.14	-0.48	2.63e-21	Response to antipsychotic treatment;
LIHC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	5.93e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.13	0.36	6.18e-12	Axial length;
LIHC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.49	7.89	0.39	4.13e-14	HDL cholesterol;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02737830	chr12:64616354	C12orf66	0.41	6.78	0.34	5.39e-11	Cognitive function;
LIHC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	1.08	12.16	0.55	1.63e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs600806	0.778	rs4970731	chr1:109995459	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.11	-0.36	6.87e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-19.53	-0.73	1.37e-57	Height;
LIHC	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg23091122	chr1:110024289	SYPL2	-0.48	-6.46	-0.33	3.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs965469	0.843	rs6051698	chr20:3248983	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-6.5	-0.33	2.84e-10	IFN-related cytopenia;
LIHC	cis	rs9322817	0.902	rs9391238	chr6:105197874	A/G	cg02098413	chr6:105308735	HACE1	-0.37	-6.03	-0.31	4.33e-9	Thyroid stimulating hormone;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg14257396	chr1:107603778	NA	-0.38	-6.22	-0.32	1.41e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs7668874	0.779	rs6848473	chr4:116811112	C/T	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs7534824	0.625	rs61780321	chr1:101428304	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	7.04	0.36	1.05e-11	Refractive astigmatism;
LIHC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.4	0.45	7.89e-19	Hemoglobin concentration;
LIHC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.45	-7.88	-0.39	4.37e-14	Aortic root size;
LIHC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg18225595	chr11:63971243	STIP1	-0.48	-6.34	-0.32	7.39e-10	Platelet count;
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.3	0.41	2.38e-15	Renal cell carcinoma;
LIHC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	16.09	0.66	9.11e-44	Platelet count;
LIHC	cis	rs2010672	0.500	rs7171218	chr15:91152085	T/G	cg26821196	chr15:91095069	CRTC3	0.34	6.27	0.32	1.08e-9	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LIHC	cis	rs16958440	0.867	rs79420880	chr18:44663687	C/T	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.54	7.0	0.35	1.36e-11	Pancreatic cancer;
LIHC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.74	-0.3	2.08e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg25894440	chr7:65020034	NA	-0.51	-5.74	-0.3	2.09e-8	Diabetic kidney disease;
LIHC	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.45	-0.42	8.46e-16	HDL cholesterol;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14022721	chr22:25507536	KIAA1671	0.37	6.11	0.31	2.67e-9	Cognitive function;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.01	-0.4	1.84e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg14393609	chr7:65229607	NA	-0.38	-6.04	-0.31	4.02e-9	Aortic root size;
LIHC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.83	7.99	0.4	2.07e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07305463	chr2:136567211	LCT	0.41	7.33	0.37	1.72e-12	Mosquito bite size;
LIHC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	0.97	13.01	0.58	1.05e-31	Cognitive function;
LIHC	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.63	7.9	0.39	3.98e-14	Macular telangiectasia type 2;
LIHC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.32	7.14	0.36	5.68e-12	Crohn's disease;
LIHC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.76	-17.49	-0.69	2.24e-49	Brugada syndrome;
LIHC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg15676719	chr1:167598521	RCSD1	-0.39	-6.91	-0.35	2.42e-11	Systemic lupus erythematosus;
LIHC	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.63	-6.76	-0.34	5.79e-11	Hair shape;
LIHC	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.69	10.11	0.48	3.39e-21	Lymphocyte counts;
LIHC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-10.89	-0.51	6.65e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11888559	0.511	rs1351826	chr2:203850508	G/A	cg24605529	chr2:203879461	NBEAL1	0.72	5.77	0.3	1.74e-8	Height;
LIHC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg00990874	chr7:1149470	C7orf50	-0.66	-9.21	-0.45	3.26e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17467752	chr17:38218738	THRA	0.4	6.05	0.31	3.79e-9	Myeloid white cell count;
LIHC	cis	rs11229555	0.645	rs11229435	chr11:58185796	G/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg20240347	chr1:204465584	NA	-0.35	-7.48	-0.37	6.51e-13	Schizophrenia;
LIHC	cis	rs12144094	0.882	rs1853048	chr1:120240114	C/A	cg20995928	chr1:120229863	NA	0.42	7.26	0.37	2.59e-12	Height;
LIHC	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.49	-8.95	-0.44	2.25e-17	Atrioventricular conduction;
LIHC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.84	12.11	0.55	2.51e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg19680672	chr10:131412579	MGMT	-0.45	-6.94	-0.35	2.02e-11	Response to temozolomide;
LIHC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	trans	rs4819388	0.915	rs6518352	chr21:45646698	A/G	cg17383793	chr5:52405638	MOCS2	0.4	6.05	0.31	3.88e-9	Celiac disease;
LIHC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	15.2	0.63	3.22e-40	Tonsillectomy;
LIHC	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.39	-6.27	-0.32	1.08e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs611744	0.967	rs569701	chr8:109239207	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.5	6.24	0.32	1.3e-9	Menarche (age at onset);
LIHC	cis	rs1144333	0.737	rs1144331	chr1:76272357	G/A	cg22875332	chr1:76189707	ACADM	-0.43	-6.91	-0.35	2.45e-11	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg18944383	chr4:111397179	ENPEP	0.28	6.42	0.33	4.47e-10	Coronary artery disease;
LIHC	cis	rs77637988	0.631	rs7573316	chr2:48600692	C/T	cg15846641	chr2:48541264	FOXN2	0.59	8.0	0.4	1.97e-14	Joint mobility (Beighton score);
LIHC	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.35	-6.04	-0.31	4.04e-9	Lewy body disease;
LIHC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg12560992	chr17:57184187	TRIM37	0.74	10.96	0.51	3.56e-24	Cognitive test performance;
LIHC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.69	11.63	0.53	1.44e-26	Hemoglobin concentration;
LIHC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04221910	chr5:616842	CEP72	0.41	7.33	0.37	1.68e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg27478167	chr7:817139	HEATR2	-0.41	-5.83	-0.3	1.26e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg07895657	chr22:50616420	PANX2	-0.39	-6.74	-0.34	6.65e-11	Obesity-related traits;
LIHC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3e-11	Height;
LIHC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.67	0.5	4.01e-23	Vitiligo;
LIHC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	13.5	0.59	1.32e-33	Post bronchodilator FEV1;
LIHC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.35	8.63	0.42	2.4e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg01864836	chr14:55583639	NA	-0.36	-6.58	-0.34	1.73e-10	Protein biomarker;
LIHC	cis	rs17106184	1.000	rs72898921	chr1:50928775	C/T	cg07174182	chr1:51127561	FAF1	-0.6	-6.7	-0.34	8.43e-11	Type 2 diabetes;
LIHC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.98	19.41	0.72	4.17e-57	Ewing sarcoma;
LIHC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17554472	chr22:41940697	POLR3H	0.58	6.32	0.32	8.02e-10	Vitiligo;
LIHC	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.6	8.92	0.43	2.84e-17	Recombination rate (females);
LIHC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.58	7.91	0.39	3.71e-14	Coronary artery disease;
LIHC	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.32	6.7	0.34	8.6e-11	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.57	7.8	0.39	7.48e-14	Eotaxin levels;
LIHC	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.25	6.4	0.33	5.04e-10	Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.72	13.05	0.58	7.43e-32	Prudent dietary pattern;
LIHC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.88	17.07	0.68	1.12e-47	Blood protein levels;
LIHC	cis	rs1190552	0.761	rs12896625	chr14:102838957	T/C	cg10241871	chr14:102965420	TECPR2	0.39	5.78	0.3	1.66e-8	Blood protein levels;
LIHC	cis	rs17854409	0.764	rs12625513	chr20:61475661	G/A	cg06598544	chr20:61472147	COL9A3	-0.9	-7.65	-0.38	2.11e-13	Obesity-related traits;
LIHC	trans	rs3858145	0.588	rs736535	chr10:70043916	G/A	cg04882175	chr6:131122610	NA	-0.51	-6.14	-0.32	2.31e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-8.12	-0.4	8.33e-15	Putamen volume;
LIHC	cis	rs747782	0.646	rs4752839	chr11:47495202	G/A	cg20307385	chr11:47447363	PSMC3	-0.56	-6.35	-0.32	6.7e-10	Intraocular pressure;
LIHC	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.85	13.46	0.59	1.88e-33	Gastritis;
LIHC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.69	6.75	0.34	6.46e-11	Schizophrenia;
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.68	0.8	5.83e-78	Prudent dietary pattern;
LIHC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.85	10.22	0.48	1.42e-21	Cognitive function;
LIHC	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg10381502	chr11:71823885	C11orf51	1.06	9.3	0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.44	8.37	0.41	1.46e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.98	0.54	7.79e-28	Coffee consumption (cups per day);
LIHC	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.34	7.02	0.35	1.23e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.54	5.82	0.3	1.39e-8	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.46	0.33	3.66e-10	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18779695	chr6:36164024	BRPF3	0.43	6.07	0.31	3.38e-9	Pancreatic cancer;
LIHC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.31	7.03	0.36	1.1e-11	Crohn's disease;
LIHC	trans	rs10411161	0.580	rs10409620	chr19:52371176	A/G	cg22319618	chr22:45562946	NUP50	-0.51	-7.39	-0.37	1.17e-12	Breast cancer;
LIHC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.67	-0.42	1.8e-16	Blood pressure (smoking interaction);
LIHC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.28	6.82	0.35	4.24e-11	Primary biliary cholangitis;
LIHC	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg22963979	chr7:1858916	MAD1L1	0.4	5.74	0.3	2.12e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.39	-5.83	-0.3	1.31e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg22787604	chr8:1509810	DLGAP2	-0.36	-6.3	-0.32	9.23e-10	Lung cancer;
LIHC	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.41	7.07	0.36	8.86e-12	Monocyte percentage of white cells;
LIHC	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-5.97	-0.31	5.81e-9	Ulcerative colitis;
LIHC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.12	-22.19	-0.77	3.15e-68	Myeloid white cell count;
LIHC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.95	-0.65	3.17e-43	Height;
LIHC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.89	-13.87	-0.6	4.92e-35	Body mass index;
LIHC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.7	-11.52	-0.53	3.71e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg13647721	chr17:30228624	UTP6	0.73	8.08	0.4	1.13e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.04	0.55	4.52e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02985541	chr2:219472218	PLCD4	0.43	6.95	0.35	1.84e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.88	7.4	0.37	1.04e-12	Cognitive function;
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.31e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg17218026	chr1:154582156	ADAR	0.3	5.9	0.3	8.88e-9	Blood protein levels;
LIHC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg21573476	chr21:45109991	RRP1B	-0.5	-9.27	-0.45	2.15e-18	Mean corpuscular volume;
LIHC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.44	6.45	0.33	3.78e-10	Crohn's disease;
LIHC	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg11005552	chr10:105648138	OBFC1	0.38	6.09	0.31	3.03e-9	Coronary artery disease;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27297192	chr10:134578999	INPP5A	0.55	7.59	0.38	3.1400000000000003e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.76e-46	Parkinson's disease;
LIHC	cis	rs4407350	0.756	rs131168	chr22:44896225	T/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.63	0.34	1.34e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11381792	chr21:45432451	TRAPPC10	-0.45	-6.07	-0.31	3.45e-9	Triglycerides;
LIHC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.54	-7.94	-0.39	2.94e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg02344993	chr17:57696989	CLTC	0.73	12.38	0.56	2.54e-29	Hemoglobin concentration;
LIHC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.59	8.58	0.42	3.45e-16	Height;
LIHC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.96	-0.51	3.76e-24	Primary sclerosing cholangitis;
LIHC	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.4	-6.92	-0.35	2.23e-11	Breast cancer;
LIHC	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs36051895	0.587	rs7036761	chr9:5198781	A/C	cg02405213	chr9:5042618	JAK2	0.68	10.86	0.51	8.24e-24	Pediatric autoimmune diseases;
LIHC	cis	rs2073499	0.935	rs57842657	chr3:50227787	T/A	cg03645007	chr3:50255295	SLC38A3	0.47	6.25	0.32	1.22e-9	Schizophrenia;
LIHC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.66	-10.81	-0.5	1.31e-23	Bipolar disorder;
LIHC	trans	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.22	-0.32	1.42e-9	Educational attainment (years of education);
LIHC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg24044564	chr13:99115944	STK24	0.48	6.88	0.35	2.84e-11	Obesity-related traits;
LIHC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.66	-10.57	-0.5	8.58e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.08	-0.36	8.12e-12	Fear of minor pain;
LIHC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.54	-9.87	-0.47	2.23e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.91	-16.76	-0.67	1.97e-46	Schizophrenia;
LIHC	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.5	9.71	0.47	7.35e-20	Testicular germ cell tumor;
LIHC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.37	-5.76	-0.3	1.84e-8	Breast cancer;
LIHC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.56	-7.87	-0.39	4.62e-14	Total body bone mineral density;
LIHC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.7	-12.15	-0.55	1.72e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.6	-0.34	1.55e-10	Menarche (age at onset);
LIHC	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg23043544	chr7:2124092	MAD1L1	-0.4	-6.52	-0.33	2.49e-10	Neuroticism;
LIHC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.98	-17.72	-0.69	2.56e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.75	-11.23	-0.52	3.97e-25	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.78	14.69	0.62	3.25e-38	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	9.77	0.47	4.85e-20	Personality dimensions;
LIHC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.63	-11.24	-0.52	3.79e-25	Dental caries;
LIHC	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.18	0.32	1.83e-9	Mean corpuscular volume;
LIHC	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.43	7.09	0.36	7.79e-12	Schizophrenia;
LIHC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.32e-37	Blood metabolite levels;
LIHC	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.33	-0.37	1.7e-12	Tuberculosis;
LIHC	cis	rs12022452	0.556	rs12037288	chr1:40996297	G/A	cg25568243	chr1:40974465	DEM1	0.45	5.9	0.3	8.79e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.28	-0.32	1.04e-9	Coronary artery disease;
LIHC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.51	-8.94	-0.44	2.52e-17	Longevity;
LIHC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg16586182	chr3:47516702	SCAP	-0.51	-9.25	-0.45	2.44e-18	Colorectal cancer;
LIHC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.54	9.74	0.47	5.84e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01200585	chr1:228362443	C1orf69	0.39	6.05	0.31	3.76e-9	Diastolic blood pressure;
LIHC	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-7.26	-0.37	2.56e-12	Uric acid levels;
LIHC	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.93	-0.35	2.09e-11	Response to antipsychotic treatment;
LIHC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.41	6.94	0.35	1.96e-11	IgG glycosylation;
LIHC	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	0.92	11.9	0.54	1.49e-27	Post bronchodilator FEV1;
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.71	-9.04	-0.44	1.2e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.09	-0.31	3.12e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.19	-18.27	-0.7	1.62e-52	Type 1 diabetes nephropathy;
LIHC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.7e-10	Uric acid levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22517316	chr8:42128500	IKBKB	0.47	6.04	0.31	4.02e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7116495	0.867	rs1612492	chr11:71583865	T/G	cg26138937	chr11:71823887	C11orf51	0.68	6.53	0.33	2.4e-10	Severe influenza A (H1N1) infection;
LIHC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.1	-0.31	2.91e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.49	6.65	0.34	1.15e-10	High light scatter reticulocyte count;
LIHC	trans	rs1555543	0.517	rs2391766	chr1:96909240	T/C	cg10631902	chr5:14652156	NA	-0.32	-6.59	-0.34	1.64e-10	Body mass index;
LIHC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00802000	chr16:706648	WDR90	-0.38	-6.2	-0.32	1.62e-9	Height;
LIHC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.66	9.93	0.47	1.37e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.58	9.47	0.46	4.65e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.57	8.3	0.41	2.47e-15	Heschl's gyrus morphology;
LIHC	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.4	6.67	0.34	1.04e-10	Red blood cell count;
LIHC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg08888203	chr3:10149979	C3orf24	0.56	6.45	0.33	3.89e-10	Alzheimer's disease;
LIHC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.79	12.76	0.57	9.36e-31	Colorectal cancer;
LIHC	cis	rs2304456	1.000	rs5030044	chr3:186449122	A/G	cg12454167	chr3:186435060	KNG1	0.34	6.06	0.31	3.61e-9	Blood protein levels;
LIHC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.04	14.97	0.63	2.54e-39	Cognitive function;
LIHC	cis	rs10847980	0.590	rs77970074	chr12:123292186	T/G	cg07706471	chr12:123319906	HIP1R	0.75	8.19	0.4	5.21e-15	Adiponectin levels;
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.5	7.99	0.4	2.1e-14	Testicular germ cell tumor;
LIHC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.75	11.31	0.52	2.08e-25	Subjective well-being;
LIHC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.45	-6.6	-0.34	1.61e-10	Mean platelet volume;
LIHC	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg06664874	chr5:179499304	RNF130	0.67	7.7	0.38	1.51e-13	LDL cholesterol;
LIHC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg17420585	chr12:42539391	GXYLT1	0.35	5.71	0.3	2.39e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-8.1	-0.4	9.81e-15	Schizophrenia;
LIHC	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg26338869	chr17:61819248	STRADA	0.52	7.0	0.35	1.36e-11	Height;
LIHC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.42	6.82	0.35	4.14e-11	Red blood cell count;
LIHC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.76	-0.3	1.85e-8	Subjective well-being;
LIHC	cis	rs7872515	0.887	rs58129324	chr9:94839105	T/C	cg01248375	chr9:94877805	SPTLC1	0.56	8.27	0.41	2.99e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.57	0.46	2.19e-19	Height;
LIHC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.28e-18	Bipolar disorder;
LIHC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg11204139	chr17:3907470	NA	-0.57	-8.36	-0.41	1.6e-15	Type 2 diabetes;
LIHC	cis	rs965469	0.779	rs2236103	chr20:3276821	A/G	cg25506879	chr20:3388711	C20orf194	0.5	6.21	0.32	1.55e-9	IFN-related cytopenia;
LIHC	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.64	10.56	0.5	9.32e-23	Recombination rate (males);
LIHC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.47	7.72	0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.36	-8.26	-0.41	3.34e-15	Congenital heart disease (maternal effect);
LIHC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.42	-0.49	2.92e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.35	5.78	0.3	1.65e-8	Longevity;
LIHC	cis	rs2637266	0.749	rs4979830	chr10:78457484	C/T	cg18941641	chr10:78392320	NA	0.28	6.0	0.31	5.14e-9	Pulmonary function;
LIHC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.94	0.7	3.47e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs2901460	0.509	rs6750080	chr2:62071542	C/T	cg02183531	chr2:62113199	CCT4	-0.41	-6.13	-0.31	2.42e-9	Mean corpuscular volume;
LIHC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.51	10.2	0.48	1.61e-21	Melanoma;
LIHC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.08	0.66	9.77e-44	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25118631	chr4:120206103	USP53	-0.39	-6.93	-0.35	2.11e-11	Cognitive function;
LIHC	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.01e-22	Hypertriglyceridemia;
LIHC	cis	rs912330	0.500	rs9556967	chr13:99186751	G/T	cg07423050	chr13:99094983	FARP1	-0.33	-6.05	-0.31	3.83e-9	Alzheimer's disease;
LIHC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.09	-0.36	7.75e-12	Bipolar disorder;
LIHC	cis	rs903552	1.000	rs12908079	chr15:102003820	C/A	cg25677261	chr15:102009856	PCSK6	-0.45	-6.36	-0.33	6.57e-10	Diabetic kidney disease;
LIHC	cis	rs7786877	0.723	rs62482237	chr7:100213476	A/G	cg00334542	chr7:100209784	MOSPD3	-0.69	-6.52	-0.33	2.57e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1144333	0.655	rs17097695	chr1:76387258	A/C	cg03433033	chr1:76189801	ACADM	0.53	7.45	0.37	7.73e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-0.82	-12.21	-0.55	1.01e-28	Obesity-related traits;
LIHC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.58	0.56	4.44e-30	Cognitive test performance;
LIHC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg26531700	chr6:26746687	NA	0.39	6.5	0.33	2.92e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.95	0.31	6.57e-9	Morning vs. evening chronotype;
LIHC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.24	0.55	8.47e-29	Motion sickness;
LIHC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	1.06	14.27	0.61	1.46e-36	Heart rate;
LIHC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.19	-0.36	4.21e-12	Menopause (age at onset);
LIHC	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.9	11.49	0.53	4.75e-26	Bladder cancer;
LIHC	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg17182837	chr8:41585554	ANK1	-0.23	-5.83	-0.3	1.3e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs12602486	1.000	rs16940539	chr17:42224581	C/G	cg13607699	chr17:42295918	UBTF	-0.74	-6.35	-0.32	6.99e-10	Glycated hemoglobin levels;
LIHC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg04756594	chr16:24857601	SLC5A11	0.45	7.16	0.36	4.94e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.54	-8.41	-0.41	1.13e-15	Extraversion;
LIHC	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-10.75	-0.5	2.03e-23	Morning vs. evening chronotype;
LIHC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.03	0.31	4.3e-9	Rheumatoid arthritis;
LIHC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg16797656	chr11:68205561	LRP5	0.59	7.83	0.39	6.36e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.88	12.22	0.55	9.76e-29	Blood metabolite levels;
LIHC	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg03934865	chr2:198174659	NA	0.42	5.93	0.31	7.6e-9	Dermatomyositis;
LIHC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.67	-9.12	-0.44	6.42e-18	Blood metabolite levels;
LIHC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg27494647	chr7:150038898	RARRES2	0.37	7.0	0.35	1.32e-11	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs8117834	0.574	rs6118061	chr20:8087343	T/C	cg00593689	chr4:53575888	NA	0.41	6.84	0.35	3.77e-11	Chronic kidney disease;
LIHC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.83e-10	Aortic root size;
LIHC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.67	0.5	4.05e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg02023728	chr11:77925099	USP35	-0.35	-5.97	-0.31	6e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.59	-7.05	-0.36	1.02e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.37	-5.94	-0.31	7.08e-9	Primary biliary cholangitis;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg20470467	chr16:30886130	NA	0.39	6.16	0.32	2.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-6.93	-0.35	2.07e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.3	-0.32	9.01e-10	Longevity;Endometriosis;
LIHC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg15691649	chr6:25882328	NA	-0.37	-5.86	-0.3	1.07e-8	Height;
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.51	8.3	0.41	2.49e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.92	-0.54	1.19e-27	Alzheimer's disease;
LIHC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.06	-0.31	3.53e-9	Tonsillectomy;
LIHC	cis	rs7818688	0.614	rs12056808	chr8:95876868	G/A	cg16049864	chr8:95962084	TP53INP1	0.51	5.83	0.3	1.27e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg16070123	chr10:51489643	NA	-0.37	-5.92	-0.3	7.9e-9	Prostate-specific antigen levels;
LIHC	trans	rs9914544	0.564	rs9907723	chr17:18758853	T/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.68e-10	Educational attainment (years of education);
LIHC	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg12501888	chr15:85177176	SCAND2	-0.5	-7.79	-0.39	7.99e-14	P wave terminal force;
LIHC	trans	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.21	-0.48	1.51e-21	Hemoglobin concentration;
LIHC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg03037974	chr15:76606532	NA	0.74	14.52	0.62	1.54e-37	Blood metabolite levels;
LIHC	cis	rs2710642	0.611	rs6752010	chr2:62859042	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-6.91	-0.35	2.38e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.47	7.56	0.38	3.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.41	-0.33	4.78e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.65	0.53	1.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.59	10.21	0.48	1.6e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.92	11.62	0.53	1.58e-26	Coronary artery disease;
LIHC	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	6.13	0.31	2.36e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.4	-0.45	7.89e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg05084668	chr3:125655381	ALG1L	-0.34	-6.13	-0.31	2.39e-9	Blood pressure (smoking interaction);
LIHC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.77	12.75	0.57	9.66e-31	Psoriasis;
LIHC	cis	rs400736	0.729	rs2493215	chr1:8007716	C/T	cg25007680	chr1:8021821	PARK7	0.46	7.28	0.37	2.27e-12	Response to antidepressants and depression;
LIHC	cis	rs8067354	0.574	rs2526353	chr17:57988607	G/T	cg13753209	chr17:57696993	CLTC	0.71	10.57	0.5	8.45e-23	Hemoglobin concentration;
LIHC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.5	8.05	0.4	1.38e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4699052	0.963	rs7672802	chr4:104212233	A/T	cg16532752	chr4:104119610	CENPE	-0.39	-6.29	-0.32	9.82e-10	Testicular germ cell tumor;
LIHC	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.52	-7.04	-0.36	1.08e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.39	7.92	0.39	3.4e-14	Renal cell carcinoma;
LIHC	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.31	-5.8	-0.3	1.51e-8	Red blood cell count;
LIHC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.49	0.46	4.06e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs965469	1.000	rs6139103	chr20:3361140	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.7	-0.34	8.46e-11	IFN-related cytopenia;
LIHC	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.83	16.16	0.66	4.75e-44	Testicular germ cell tumor;
LIHC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-9.28	-0.45	1.97e-18	Reticulocyte count;
LIHC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	1.07	14.54	0.62	1.24e-37	Heart rate;
LIHC	trans	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg25214090	chr10:38739885	LOC399744	0.47	7.75	0.39	1.03e-13	Diastolic blood pressure;
LIHC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.92	13.14	0.58	3.26e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2574704	0.886	rs13066755	chr3:11632089	C/T	cg15876825	chr3:11651881	VGLL4	-0.46	-7.47	-0.37	6.74e-13	Body mass index;
LIHC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	13.09	0.58	5.08e-32	Mean platelet volume;
LIHC	cis	rs600626	0.529	rs58411334	chr11:75467350	G/T	cg24262691	chr11:75473276	NA	0.42	5.93	0.31	7.39e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.04	-0.31	4.1e-9	Tuberculosis;
LIHC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg08499158	chr17:42289980	UBTF	-0.48	-7.81	-0.39	7.17e-14	Total body bone mineral density;
LIHC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.46	-5.81	-0.3	1.45e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs10170846	0.572	rs12620873	chr2:223419528	A/C	cg25565276	chr2:223520875	FARSB	0.77	10.94	0.51	4.46e-24	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.53	6.43	0.33	4.31e-10	Menarche (age at onset);
LIHC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg03037974	chr15:76606532	NA	0.89	23.03	0.78	1.59e-71	Blood metabolite levels;
LIHC	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.58	0.5	8.05e-23	Coffee consumption (cups per day);
LIHC	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.22	-6.79	-0.34	4.99e-11	Mean corpuscular volume;
LIHC	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.33	7.01	0.35	1.28e-11	Immature fraction of reticulocytes;
LIHC	cis	rs6722750	0.818	rs12104940	chr2:64385774	A/G	cg22352474	chr2:64371530	PELI1	0.46	6.59	0.34	1.67e-10	Neuroticism;
LIHC	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.86	0.39	4.95e-14	Corneal astigmatism;
LIHC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.95	0.39	2.79e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.47	6.57	0.33	1.86e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.32	6.73	0.34	7.35e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.54	9.54	0.46	2.74e-19	Mean corpuscular volume;
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.05	0.44	1.08e-17	Bipolar disorder;
LIHC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.67	10.52	0.49	1.27e-22	Corneal astigmatism;
LIHC	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.4	6.21	0.32	1.58e-9	Alzheimer's disease (survival time);
LIHC	cis	rs116248771	0.739	rs73156426	chr3:158346289	G/A	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.75e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.72	10.82	0.5	1.19e-23	Subjective well-being;
LIHC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg00204512	chr16:28754710	NA	0.36	6.43	0.33	4.28e-10	Tonsillectomy;Mean corpuscular volume;
LIHC	cis	rs4407350	0.756	rs131155	chr22:44891247	A/G	cg26276947	chr22:44892394	LDOC1L	0.33	6.39	0.33	5.36e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.46	6.6	0.34	1.54e-10	Breast cancer;
LIHC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.6	12.72	0.57	1.25e-30	Fat distribution (HIV);
LIHC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg14709524	chr16:89940631	TCF25	0.47	5.85	0.3	1.13e-8	Skin colour saturation;
LIHC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg09222892	chr1:25734099	RHCE	0.45	8.25	0.41	3.54e-15	Erythrocyte sedimentation rate;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16718920	chr1:21113643	HP1BP3	-0.52	-6.84	-0.35	3.59e-11	Systolic blood pressure;
LIHC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.78	12.4	0.56	2.14e-29	Corneal astigmatism;
LIHC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	11.36	0.52	1.36e-25	Platelet count;
LIHC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.77	-0.5	1.69e-23	Chronic sinus infection;
LIHC	trans	rs10242455	0.557	rs57830676	chr7:99281363	C/T	cg09045935	chr12:6379348	NA	0.74	6.16	0.32	2.03e-9	Blood metabolite levels;
LIHC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.88	-18.26	-0.7	1.79e-52	Height;
LIHC	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.54	-0.38	4.14e-13	Body mass index;
LIHC	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg18252515	chr7:66147081	NA	-1.34	-15.89	-0.65	5.54e-43	Gout;
LIHC	cis	rs6442522	0.560	rs2305614	chr3:15517318	C/G	cg16303742	chr3:15540471	COLQ	0.37	6.04	0.31	4.01e-9	Uric acid levels;
LIHC	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.45	7.39	0.37	1.14e-12	Corneal astigmatism;
LIHC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.65	-7.58	-0.38	3.21e-13	Lymphocyte counts;
LIHC	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.38	6.66	0.34	1.08e-10	Schizophrenia;
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.72	-0.34	7.76e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	0.55	10.48	0.49	1.84e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.92e-25	Psoriasis vulgaris;
LIHC	cis	rs11864453	0.616	rs9938025	chr16:72022041	A/G	cg01557791	chr16:72042693	DHODH	0.4	6.03	0.31	4.33e-9	Fibrinogen levels;
LIHC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	1.03	18.02	0.7	1.7e-51	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg22528358	chr1:107598549	PRMT6	0.72	11.91	0.54	1.35e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.38	5.99	0.31	5.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.88	-11.03	-0.51	2.16e-24	Dilated cardiomyopathy;
LIHC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.55	7.62	0.38	2.53e-13	Pancreatic cancer;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg02344993	chr17:57696989	CLTC	0.71	11.85	0.54	2.25e-27	Hemoglobin concentration;
LIHC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	1.01	19.45	0.72	2.77e-57	Breast cancer;
LIHC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.41	-7.36	-0.37	1.38e-12	Coronary artery disease;
LIHC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.53	0.56	6.44e-30	Mean platelet volume;
LIHC	cis	rs12702595	0.818	rs10259085	chr7:7268431	C/T	cg04827551	chr7:7268805	C1GALT1	0.38	6.86	0.35	3.26e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.74	0.54	5.78e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.39	5.81	0.3	1.41e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.7	-0.38	1.44e-13	Monocyte percentage of white cells;
LIHC	cis	rs4676482	0.578	rs784504	chr3:39195260	G/C	cg02254461	chr3:39195904	CSRNP1	-0.61	-6.31	-0.32	8.65e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	12.62	0.56	3.06e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02400128	chr5:114849010	NA	0.34	6.12	0.31	2.51e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.6e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	0.79	6.83	0.35	3.89e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-15.39	-0.64	5.49e-41	Longevity;
LIHC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg10756647	chr7:56101905	PSPH	0.49	7.26	0.37	2.6e-12	Aortic root size;
LIHC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.77	-0.5	1.77e-23	Hemoglobin concentration;
LIHC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.27e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs655641	0.911	rs682366	chr11:85701741	T/C	cg09030501	chr11:85779252	PICALM	-0.54	-6.32	-0.32	8.19e-10	Platelet count;
LIHC	cis	rs11673344	0.864	rs7256876	chr19:37579472	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.19	-0.32	1.73e-9	Obesity-related traits;
LIHC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.63	9.16	0.44	4.88e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2108622	0.711	rs12609820	chr19:15978057	T/C	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.87e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs7619427	0.544	rs59081044	chr3:43967628	C/T	cg24966902	chr3:44043705	NA	0.43	6.51	0.33	2.64e-10	Schizophrenia;
LIHC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02985541	chr2:219472218	PLCD4	0.45	8.42	0.41	1.05e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.15e-9	Tonsillectomy;
LIHC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02985541	chr2:219472218	PLCD4	-0.41	-6.58	-0.34	1.77e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26512142	chr11:2554198	KCNQ1	0.36	6.17	0.32	1.97e-9	Cognitive function;
LIHC	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.65	7.88	0.39	4.31e-14	Systemic lupus erythematosus;
LIHC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg01320579	chr17:75405842	SEPT9	0.51	6.93	0.35	2.09e-11	Airflow obstruction;
LIHC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.23	-10.64	-0.5	5.12e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs600806	0.778	rs2152924	chr1:110011701	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.48	-0.38	6.2e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg03645007	chr3:50255295	SLC38A3	0.49	6.22	0.32	1.46e-9	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.36	0.59	4.74e-33	Diabetic kidney disease;
LIHC	cis	rs9326778	0.520	rs11954116	chr5:108823033	A/G	cg17395555	chr5:108820864	NA	-0.37	-6.27	-0.32	1.09e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02097843	chr10:33269812	NA	-0.46	-6.31	-0.32	8.51e-10	Pancreatic cancer;
LIHC	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.49	-0.33	2.97e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs244293	0.965	rs11079153	chr17:53176023	C/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs11112613	0.609	rs2374534	chr12:106047897	A/T	cg03607813	chr12:105948248	NA	0.4	6.27	0.32	1.11e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.31	-0.7	1.14e-52	Ulcerative colitis;
LIHC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg08694578	chr2:241835147	C2orf54	-0.51	-7.84	-0.39	5.66e-14	Urinary metabolites;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20704215	chr1:35658192	SFPQ	-0.53	-6.22	-0.32	1.49e-9	Systolic blood pressure;
LIHC	cis	rs15676	0.947	rs1572912	chr9:131565554	T/C	cg13708974	chr9:131466143	PKN3	-0.38	-5.83	-0.3	1.29e-8	Blood metabolite levels;
LIHC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.85	12.38	0.56	2.46e-29	Glomerular filtration rate (creatinine);
LIHC	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	8.8	0.43	6.75e-17	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-7.74	-0.39	1.13e-13	Body mass index;
LIHC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg14440974	chr22:39074834	NA	-0.34	-5.72	-0.3	2.28e-8	Menopause (age at onset);
LIHC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.86	10.72	0.5	2.7e-23	Bladder cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19874450	chr17:34900926	GGNBP2	0.52	6.95	0.35	1.81e-11	Lung function (FEV1/FVC);
LIHC	cis	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg01364799	chr7:75623366	TMEM120A	0.5	7.17	0.36	4.8e-12	Eotaxin levels;
LIHC	trans	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg10756647	chr7:56101905	PSPH	1.07	13.24	0.58	1.32e-32	Diabetic kidney disease;
LIHC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21467203	chr3:49911342	NA	-0.43	-7.65	-0.38	2.01e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1385374	0.841	rs11059929	chr12:129296893	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.67	8.01	0.4	1.81e-14	Systemic lupus erythematosus;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09807979	chr1:154909529	PMVK	0.42	6.07	0.31	3.33e-9	Cognitive function;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-9.77	-0.47	4.91e-20	Longevity;Endometriosis;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.72	0.57	1.24e-30	Prudent dietary pattern;
LIHC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.6	8.12	0.4	8.39e-15	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.59	-7.99	-0.4	2.03e-14	Motion sickness;
LIHC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.48	-8.11	-0.4	8.88e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.59	8.01	0.4	1.8e-14	Gut microbiome composition (summer);
LIHC	cis	rs7945071	0.507	rs4753892	chr11:110302643	C/T	cg04157658	chr11:110243994	NA	0.32	5.89	0.3	9.1e-9	Cognitive function;
LIHC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-10.39	-0.49	3.78e-22	Longevity;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.47	0.62	2.36e-37	Prudent dietary pattern;
LIHC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	0.75	5.77	0.3	1.79e-8	IgG glycosylation;
LIHC	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-7.66	-0.38	1.97e-13	Homocysteine levels;
LIHC	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg14345882	chr6:26364793	BTN3A2	0.39	5.81	0.3	1.45e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.37	5.84	0.3	1.23e-8	Coronary artery disease;
LIHC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.75	13.4	0.59	3.22e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.31	0.37	1.94e-12	Vitiligo;
LIHC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.55	-9.34	-0.45	1.26e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	16.75	0.67	2.13e-46	Cognitive ability;
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.5	-6.2	-0.32	1.66e-9	Diastolic blood pressure;
LIHC	cis	rs8081395	0.651	rs1292067	chr17:57930646	A/C	cg02344993	chr17:57696989	CLTC	-0.51	-9.06	-0.44	1.06e-17	White blood cell count;
LIHC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.49	-6.94	-0.35	1.98e-11	Height;
LIHC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06002616	chr8:101225028	SPAG1	-0.35	-6.25	-0.32	1.23e-9	Atrioventricular conduction;
LIHC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.01	-20.39	-0.74	4.61e-61	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09326324	chr1:161123937	UFC1	0.46	6.41	0.33	4.82e-10	Pancreatic cancer;
LIHC	trans	rs8058130	0.566	rs9926510	chr16:64327067	A/C	cg08997518	chr6:116601248	DSE;TSPYL1	-0.44	-6.2	-0.32	1.59e-9	Schizophrenia;
LIHC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg00800038	chr16:89945340	TCF25	-0.62	-9.42	-0.45	7.05e-19	Interleukin-17 levels;
LIHC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.68	7.11	0.36	6.86e-12	Alzheimer's disease;
LIHC	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg10820045	chr2:198174542	NA	0.47	7.03	0.36	1.12e-11	Intracranial aneurysm;
LIHC	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.19	0.36	4.17e-12	Morning vs. evening chronotype;
LIHC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.63	9.86	0.47	2.34e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.83	13.71	0.6	2.09e-34	Monocyte count;
LIHC	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.25	6.72	0.34	7.75e-11	Type 2 diabetes;
LIHC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	8.35	0.41	1.69e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1144333	0.655	rs4949682	chr1:76443196	C/T	cg22875332	chr1:76189707	ACADM	-0.4	-5.87	-0.3	1.01e-8	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.52	9.83	0.47	2.95e-20	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.61	0.42	2.75e-16	Motion sickness;
LIHC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg11952622	chr19:58962976	ZNF324B	0.48	7.16	0.36	4.86e-12	Uric acid clearance;
LIHC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg21395723	chr22:39101663	GTPBP1	0.41	6.94	0.35	1.98e-11	Menopause (age at onset);
LIHC	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg23730037	chr7:158596552	ESYT2	-0.41	-6.27	-0.32	1.06e-9	Height;
LIHC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg27523141	chr10:43048294	ZNF37B	0.38	6.51	0.33	2.61e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.34	6.54	0.33	2.23e-10	Multiple system atrophy;
LIHC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg06598544	chr20:61472147	COL9A3	0.58	5.77	0.3	1.8e-8	Obesity-related traits;
LIHC	trans	rs2273156	0.929	rs12050171	chr14:35395451	T/A	cg20620338	chr15:102077239	NA	-0.41	-6.07	-0.31	3.35e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-6.63	-0.34	1.34e-10	Mosquito bite size;
LIHC	cis	rs3781458	0.806	rs3781466	chr10:126328689	A/G	cg20435097	chr10:126320824	FAM53B	-0.71	-13.87	-0.6	5.36e-35	Male-pattern baldness;
LIHC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.76	-0.73	1.56e-58	Height;
LIHC	cis	rs4853525	0.522	rs10490538	chr2:191590066	C/T	cg10560079	chr2:191398806	TMEM194B	0.41	5.82	0.3	1.38e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.71	-7.29	-0.37	2.16e-12	Putamen volume;
LIHC	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.77	0.34	5.49e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.64	11.08	0.51	1.44e-24	Diisocyanate-induced asthma;
LIHC	cis	rs7700895	0.578	rs147295	chr5:95219261	A/G	cg10483112	chr5:95245456	ELL2	0.32	5.75	0.3	2.03e-8	IgG glycosylation;
LIHC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg00091569	chr3:40428383	ENTPD3	0.41	6.98	0.35	1.5e-11	Renal cell carcinoma;
LIHC	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.51	-8.58	-0.42	3.4e-16	Pubertal anthropometrics;
LIHC	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg00085434	chr11:14927489	NA	0.41	5.81	0.3	1.41e-8	Vitamin D levels;
LIHC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg20607798	chr8:58055168	NA	0.46	5.94	0.31	6.85e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.71	-10.6	-0.5	6.64e-23	Lymphocyte counts;
LIHC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.22	0.41	4.21e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.02	-0.31	4.41e-9	Total body bone mineral density;
LIHC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.66	8.28	0.41	2.87e-15	Mean platelet volume;
LIHC	cis	rs72772090	0.710	rs113710451	chr5:96060306	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.2	-0.36	3.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.53	8.5	0.42	5.81e-16	Dialysis-related mortality;
LIHC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.48	-7.59	-0.38	3.02e-13	Cognitive function;
LIHC	cis	rs11098699	0.848	rs302540	chr4:124218602	T/C	cg09941581	chr4:124220074	SPATA5	0.31	5.81	0.3	1.4e-8	Mosquito bite size;
LIHC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.66	10.87	0.51	7.46e-24	Eosinophil percentage of white cells;
LIHC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.85	-13.76	-0.6	1.32e-34	Colorectal cancer;
LIHC	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg09795085	chr6:101329169	ASCC3	0.53	7.15	0.36	5.15e-12	Neuroticism;
LIHC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.48	-0.37	6.41e-13	Psoriasis;
LIHC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.19	-0.48	1.77e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.44	5.84	0.3	1.24e-8	Ulcerative colitis;
LIHC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.56	-0.38	3.8e-13	Chronic sinus infection;
LIHC	trans	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	Androgen levels;
LIHC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg12193833	chr17:30244370	NA	-0.54	-5.87	-0.3	1.01e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.47	0.37	6.94e-13	Aortic root size;
LIHC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.85	-0.43	4.65e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.51e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg20016023	chr10:99160130	RRP12	-0.4	-6.41	-0.33	4.86e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg21665744	chr7:39171113	POU6F2	0.32	5.84	0.3	1.22e-8	IgG glycosylation;
LIHC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24229701	chr12:130821962	PIWIL1	0.45	6.86	0.35	3.2e-11	Menopause (age at onset);
LIHC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.56	-8.12	-0.4	8.28e-15	Asthma;
LIHC	trans	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg17675199	chr6:35436792	RPL10A	0.43	8.8	0.43	7.09e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.82	-0.3	1.38e-8	Body mass index;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02359409	chr6:42947317	PEX6	-0.47	-6.59	-0.34	1.64e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs918629	0.530	rs1458019	chr5:95253489	A/G	cg10483112	chr5:95245456	ELL2	-0.38	-6.91	-0.35	2.38e-11	IgG glycosylation;
LIHC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16262614	chr3:133464971	TF	0.28	6.4	0.33	5.13e-10	Iron status biomarkers;
LIHC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg20194872	chr6:41519635	FOXP4	0.4	6.3	0.32	9.41e-10	Prostate cancer;
LIHC	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg11946769	chr3:48343235	NME6	-0.47	-6.24	-0.32	1.28e-9	Educational attainment (years of education);
LIHC	cis	rs17152411	0.947	rs55674450	chr10:126592153	G/T	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg26536354	chr8:144654954	C8orf73	0.52	6.06	0.31	3.55e-9	Attention deficit hyperactivity disorder;
LIHC	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.45	0.46	5.55e-19	Corneal astigmatism;
LIHC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.87	-0.35	3.12e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs847649	0.599	rs13232194	chr7:102742554	T/A	cg18108683	chr7:102477205	FBXL13	0.43	6.47	0.33	3.35e-10	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09366861	chr1:211556286	C1orf97	0.49	6.74	0.34	6.5500000000000006e-11	Pancreatic cancer;
LIHC	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.34	6.32	0.32	8.02e-10	Protein biomarker;
LIHC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.42	-0.56	1.74e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg07061783	chr6:25882402	NA	-0.51	-6.19	-0.32	1.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.57	0.38	3.4e-13	Corneal astigmatism;
LIHC	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg18898632	chr2:242989856	NA	-0.47	-6.5	-0.33	2.86e-10	Obesity-related traits;
LIHC	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	0.7	7.82	0.39	6.8e-14	Coronary artery disease;
LIHC	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs10792665	0.640	rs1114961	chr11:82622999	G/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.13	-0.31	2.41e-9	Obesity-related traits;
LIHC	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.7	-7.68	-0.38	1.73e-13	Exhaled nitric oxide output;
LIHC	cis	rs1144333	0.655	rs5745465	chr1:76346832	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.21	0.36	3.51e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.7	0.34	8.52e-11	Renal cell carcinoma;
LIHC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.73	-0.3	2.16e-8	Mortality in heart failure;
LIHC	cis	rs2637030	0.515	rs449160	chr5:53005969	A/G	cg06476337	chr5:52856530	NDUFS4	0.42	6.71	0.34	8.25e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.72	-0.34	7.84e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.38	0.37	1.23e-12	Vitiligo;
LIHC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.95	9.79	0.47	4.22e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18252515	chr7:66147081	NA	-0.43	-6.02	-0.31	4.43e-9	Aortic root size;
LIHC	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg20560298	chr2:73613845	ALMS1	0.36	5.83	0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.27	7.06	0.36	9.08e-12	Cardiovascular disease risk factors;
LIHC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.92	-0.31	7.69e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.61	0.46	1.6e-19	Platelet count;
LIHC	cis	rs3770081	1.000	rs78646493	chr2:86283195	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.95	-11.58	-0.53	2.24e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg00142150	chr22:38071001	LGALS1	0.44	7.48	0.38	6.14e-13	Fat distribution (HIV);
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.66	7.89	0.39	4e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.38	5.77	0.3	1.76e-8	Mean corpuscular volume;
LIHC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.87	0.54	1.95e-27	Colorectal cancer;
LIHC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-8.13	-0.4	8.1e-15	Menarche (age at onset);
LIHC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.75	-14.19	-0.61	2.96e-36	Height;
LIHC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg11632617	chr15:75315747	PPCDC	-0.43	-6.28	-0.32	1.04e-9	Blood trace element (Zn levels);
LIHC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg15192750	chr16:69999425	NA	0.48	6.98	0.35	1.53e-11	IgE levels;
LIHC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.37	-5.98	-0.31	5.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.67	11.41	0.53	8.95e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7546668	1.000	rs6685648	chr1:15825195	T/C	cg11706911	chr1:15910989	AGMAT	0.44	6.8	0.34	4.75e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs963731	0.649	rs4670905	chr2:39266134	A/T	cg04010122	chr2:39346883	SOS1	-0.68	-6.11	-0.31	2.73e-9	Corticobasal degeneration;
LIHC	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.43	6.24	0.32	1.31e-9	Lipoprotein (a) levels;
LIHC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.77	0.3	1.79e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg04374321	chr14:90722782	PSMC1	0.47	6.5	0.33	2.85e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.59	8.99	0.44	1.74e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12788078	chr18:43546845	KIAA1632	0.51	6.77	0.34	5.45e-11	Pancreatic cancer;
LIHC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.78	-0.34	5.38e-11	Height;
LIHC	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg10820045	chr2:198174542	NA	-0.5	-7.58	-0.38	3.35e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs722599	0.501	rs2286914	chr14:75387012	T/C	cg11812906	chr14:75593930	NEK9	-0.46	-7.64	-0.38	2.13e-13	IgG glycosylation;
LIHC	cis	rs7534824	0.625	rs61782078	chr1:101498212	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.22	0.36	3.37e-12	Refractive astigmatism;
LIHC	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	9.12	0.44	6.73e-18	Mean corpuscular hemoglobin;
LIHC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.69	10.79	0.5	1.45e-23	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.66	6.37	0.33	6.03e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-13.7	-0.6	2.39e-34	Primary sclerosing cholangitis;
LIHC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg18375707	chr11:64034959	PLCB3	-0.42	-5.77	-0.3	1.74e-8	Body mass index;
LIHC	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.68	11.08	0.51	1.41e-24	Diisocyanate-induced asthma;
LIHC	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.66	8.34	0.41	1.85e-15	Corneal astigmatism;
LIHC	cis	rs17106184	1.000	rs72900938	chr1:51118527	T/C	cg07174182	chr1:51127561	FAF1	-0.71	-7.56	-0.38	3.65e-13	Type 2 diabetes;
LIHC	cis	rs963731	0.649	rs297125	chr2:39314969	G/A	cg04010122	chr2:39346883	SOS1	-0.68	-6.03	-0.31	4.15e-9	Corticobasal degeneration;
LIHC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg13628971	chr7:2884303	GNA12	0.48	8.45	0.42	8.43e-16	Height;
LIHC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.38	-5.74	-0.3	2.1e-8	Heart rate;
LIHC	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg14146966	chr2:61757674	XPO1	0.44	7.55	0.38	3.97e-13	Tuberculosis;
LIHC	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.49	-5.72	-0.3	2.38e-8	Coronary artery disease;
LIHC	cis	rs922107	0.576	rs1563786	chr1:89952557	A/C	cg15422784	chr1:90023713	LRRC8B	-0.41	-6.31	-0.32	8.63e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.8	-12.74	-0.57	1.0500000000000001e-30	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	0.76	8.22	0.41	4.36e-15	Testicular germ cell tumor;
LIHC	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-7.68	-0.38	1.64e-13	Prudent dietary pattern;
LIHC	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.9	0.35	2.48e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22605943	chr3:107243790	BBX	0.47	6.14	0.32	2.3e-9	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.57	0.33	1.88e-10	Bipolar disorder;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg05527609	chr1:210001259	C1orf107	0.41	6.09	0.31	3.12e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.47	-8.67	-0.42	1.7e-16	Hand grip strength;
LIHC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg11764359	chr7:65958608	NA	0.57	6.01	0.31	4.66e-9	Diabetic kidney disease;
LIHC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-8.43	-0.41	9.45e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7619427	0.544	rs62252204	chr3:43965558	G/A	cg24966902	chr3:44043705	NA	0.43	6.52	0.33	2.47e-10	Schizophrenia;
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.43	-6.42	-0.33	4.49e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.95	-0.35	1.8e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.85	12.45	0.56	1.31e-29	Psoriasis;
LIHC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg20140201	chr2:241835670	C2orf54	-0.5	-7.58	-0.38	3.32e-13	Urinary metabolites;
LIHC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.57	7.63	0.38	2.34e-13	Vitiligo;
LIHC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.49	-8.0	-0.4	1.94e-14	Menarche (age at onset);
LIHC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.84	14.73	0.62	2.23e-38	Headache;
LIHC	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg05044414	chr3:183734942	ABCC5	0.32	5.87	0.3	1.05e-8	Anterior chamber depth;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg00496025	chr7:73038982	MLXIPL	-0.54	-6.78	-0.34	5.19e-11	Systolic blood pressure;
LIHC	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.3	-0.45	1.73e-18	QT interval;
LIHC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.77	-0.3	1.76e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-14.26	-0.61	1.58e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.29	-0.32	9.88e-10	Response to antipsychotic treatment;
LIHC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.82	12.91	0.57	2.4e-31	Height;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.47	-0.49	1.97e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.39	5.76	0.3	1.89e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg15123519	chr2:136567270	LCT	-0.39	-6.61	-0.34	1.44e-10	Corneal structure;
LIHC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.81	-18.21	-0.7	2.71e-52	Urate levels in lean individuals;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10446143	chr21:44394730	PKNOX1	0.43	6.35	0.32	6.68e-10	Pancreatic cancer;
LIHC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	13.46	0.59	2.04e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-9.41	-0.45	7.39e-19	Alzheimer's disease;
LIHC	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.56	-13.8	-0.6	9.24e-35	White blood cell count (basophil);
LIHC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg18944383	chr4:111397179	ENPEP	0.26	6.32	0.32	8.37e-10	Coronary artery disease;
LIHC	cis	rs7551222	0.614	rs7519417	chr1:204449952	T/C	cg20240347	chr1:204465584	NA	-0.33	-6.84	-0.35	3.6e-11	Schizophrenia;
LIHC	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.42	-7.31	-0.37	1.87e-12	Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.04e-16	Motion sickness;
LIHC	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	6.29	0.32	9.6e-10	Monocyte percentage of white cells;
LIHC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs12744310	0.887	rs12026778	chr1:41792274	C/T	cg03962019	chr1:41807865	NA	0.38	6.09	0.31	2.99e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg18404041	chr3:52824283	ITIH1	0.43	6.42	0.33	4.56e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg02290350	chr8:58132656	NA	0.47	9.16	0.44	4.93e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.04	-0.36	1.04e-11	Myeloid white cell count;
LIHC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg15902774	chr15:75289873	SCAMP5	0.43	6.2	0.32	1.6e-9	Lung cancer;
LIHC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.22	0.58	1.66e-32	Prudent dietary pattern;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.65e-11	Ileal carcinoids;
LIHC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	1.03	13.28	0.58	9.93e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.79	9.74	0.47	6.09e-20	Cognitive function;
LIHC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg21466736	chr12:48725269	NA	-0.71	-10.73	-0.5	2.36e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs1144333	0.850	rs1144342	chr1:76284364	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-8.51	-0.42	5.6e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.43	7.52	0.38	4.82e-13	Lung cancer;
LIHC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg10978503	chr1:24200527	CNR2	-0.38	-8.97	-0.44	2.02e-17	Immature fraction of reticulocytes;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.66	-9.87	-0.47	2.18e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg20129853	chr10:51489980	NA	-0.4	-8.57	-0.42	3.67e-16	Prostate-specific antigen levels;
LIHC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg02269571	chr22:50332266	NA	0.6	8.49	0.42	6.17e-16	Schizophrenia;
LIHC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20135002	chr11:47629003	NA	-0.58	-10.07	-0.48	4.5e-21	Subjective well-being;
LIHC	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.91	18.79	0.71	1.31e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg06238570	chr21:40685208	BRWD1	0.56	6.79	0.34	4.99e-11	Cognitive function;
LIHC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	9.41	0.45	7.65e-19	Total body bone mineral density;
LIHC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	8.14	0.4	7.23e-15	Tonsillectomy;
LIHC	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg20991723	chr1:152506922	NA	0.59	10.53	0.49	1.17e-22	Hair morphology;
LIHC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-6.54	-0.33	2.3e-10	Breast cancer;
LIHC	cis	rs17106184	0.681	rs12354253	chr1:51148711	G/A	cg07174182	chr1:51127561	FAF1	-0.6	-6.61	-0.34	1.5e-10	Type 2 diabetes;
LIHC	cis	rs8067354	0.574	rs1296279	chr17:57965731	G/A	cg13753209	chr17:57696993	CLTC	0.7	10.42	0.49	3.02e-22	Hemoglobin concentration;
LIHC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.98	-0.31	5.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-9.8	-0.47	3.72e-20	Asthma;
LIHC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.54	7.72	0.39	1.32e-13	Response to diuretic therapy;
LIHC	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.36	-0.41	1.59e-15	HDL cholesterol;
LIHC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.47	-7.62	-0.38	2.58e-13	Fibrinogen levels;
LIHC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg16586182	chr3:47516702	SCAP	0.58	10.74	0.5	2.14e-23	Colorectal cancer;
LIHC	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.31	6.0	0.31	5.12e-9	DNA methylation (variation);
LIHC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg12798992	chr6:167411361	FGFR1OP	0.53	8.75	0.43	9.73e-17	Crohn's disease;
LIHC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.78	-0.67	1.55e-46	Ulcerative colitis;
LIHC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg19920283	chr7:105172520	RINT1	0.68	6.26	0.32	1.15e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	5.8e-20	Corneal astigmatism;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.64	9.72	0.47	7.11e-20	Renal cell carcinoma;
LIHC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.33	-0.32	7.83e-10	Colorectal cancer;
LIHC	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.5	5.93	0.31	7.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.59	8.43	0.41	9.78e-16	Lymphocyte counts;
LIHC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.87	10.83	0.51	1.06e-23	Bladder cancer;
LIHC	trans	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg26939375	chr7:64535504	NA	0.4	6.45	0.33	3.81e-10	Aortic root size;
LIHC	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg04610667	chr7:75704037	NA	0.33	5.94	0.31	6.91e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs807029	0.533	rs67692077	chr10:102740271	T/C	cg27255678	chr10:102756921	LZTS2	0.52	7.41	0.37	9.92e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg25894440	chr7:65020034	NA	-0.56	-6.51	-0.33	2.69e-10	Diabetic kidney disease;
LIHC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.94	6.76	0.34	5.92e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.46	-7.75	-0.39	1.07e-13	Educational attainment;
LIHC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12463550	chr7:65579703	CRCP	0.68	7.32	0.37	1.82e-12	Diabetic kidney disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14984255	chr18:11908827	MPPE1	-0.43	-6.22	-0.32	1.42e-9	Systolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21705394	chr11:30344510	C11orf46	0.43	6.25	0.32	1.23e-9	Cognitive function;
LIHC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6594499	0.872	rs6881147	chr5:110451936	G/C	cg04022379	chr5:110408740	TSLP	0.49	8.19	0.4	5.39e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.7	10.17	0.48	2.07e-21	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.53	6.8	0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7116495	1.000	rs73543609	chr11:71816619	G/T	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.69	-10.63	-0.5	5.38e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.95	12.41	0.56	1.92e-29	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg24296786	chr1:45957014	TESK2	-0.49	-7.28	-0.37	2.34e-12	Platelet count;
LIHC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.5	8.83	0.43	5.53e-17	Colorectal cancer;
LIHC	cis	rs6442522	0.560	rs924811	chr3:15516820	C/T	cg16303742	chr3:15540471	COLQ	0.36	5.88	0.3	9.85e-9	Uric acid levels;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-6.0	-0.31	5.05e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.7	-12.35	-0.56	3.18e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs911119	0.955	rs8116859	chr20:23590703	A/T	cg16589663	chr20:23618590	CST3	0.72	7.54	0.38	4.32e-13	Chronic kidney disease;
LIHC	cis	rs9549328	0.879	rs12428058	chr13:113636504	G/A	cg00071026	chr13:113650936	MCF2L	-0.37	-5.85	-0.3	1.17e-8	Systolic blood pressure;
LIHC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.6	6.57	0.33	1.84e-10	Vitiligo;
LIHC	trans	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg18393722	chr15:85113863	UBE2QP1	0.44	7.41	0.37	9.92e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21438664	chr14:21738093	HNRNPC	-0.48	-6.22	-0.32	1.47e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg13607699	chr17:42295918	UBTF	-0.75	-15.01	-0.63	1.71e-39	Total body bone mineral density;
LIHC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg09990169	chr2:241835740	C2orf54	-0.71	-11.43	-0.53	7.88e-26	Urinary metabolites;
LIHC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-10.99	-0.51	2.84e-24	Personality dimensions;
LIHC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25120630	chr11:14380003	RRAS2	0.45	6.25	0.32	1.24e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.4	5.78	0.3	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	12.33	0.55	3.61e-29	Response to bleomycin (chromatid breaks);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg16993936	chr10:13146903	OPTN	0.59	6.43	0.33	4.31e-10	Mean platelet volume;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg17713864	chr17:48784765	ANKRD40	-0.46	-6.89	-0.35	2.71e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs434216	0.526	rs2270501	chr16:85932988	A/G	cg13603099	chr10:45454574	RASSF4	-0.55	-6.06	-0.31	3.67e-9	Monocyte count;
LIHC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg08499158	chr17:42289980	UBTF	0.5	8.13	0.4	8.04e-15	Total body bone mineral density;
LIHC	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.59	0.46	1.92e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg03854865	chr6:26224070	HIST1H3E	0.62	7.11	0.36	6.65e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.54	0.5	1.12e-22	Colorectal cancer;
LIHC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.42	0.33	4.6e-10	Morning vs. evening chronotype;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-9.43	-0.45	6.2800000000000005e-19	Schizophrenia;
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg10217327	chr6:118973057	C6orf204	0.63	6.07	0.31	3.46e-9	Diastolic blood pressure;
LIHC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.25	-0.32	1.22e-9	Bipolar disorder;
LIHC	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.6	-10.47	-0.49	1.94e-22	Dental caries;
LIHC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.9	8.67	0.42	1.7e-16	Plasma clusterin levels;
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg08687515	chr19:58661962	ZNF329	0.98	7.56	0.38	3.82e-13	Cholesterol, total;
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27297192	chr10:134578999	INPP5A	0.55	7.56	0.38	3.74e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg01134436	chr17:81009848	B3GNTL1	0.81	6.6	0.34	1.61e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	5.83	0.3	1.3e-8	Schizophrenia;
LIHC	trans	rs783540	1.000	rs11637433	chr15:83321336	A/G	cg18393722	chr15:85113863	UBE2QP1	0.39	6.86	0.35	3.19e-11	Schizophrenia;
LIHC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.62	9.84	0.47	2.87e-20	Corneal astigmatism;
LIHC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.44	7.26	0.37	2.68e-12	Height;
LIHC	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.78	9.0	0.44	1.62e-17	Exhaled nitric oxide output;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00907843	chr7:73038888	MLXIPL	0.47	6.56	0.33	2.04e-10	Hepatitis;
LIHC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg18478394	chr8:109455254	TTC35	0.39	6.78	0.34	5.24e-11	Dupuytren's disease;
LIHC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.29	0.37	2.14e-12	Lung cancer in ever smokers;
LIHC	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg14250997	chr9:106856677	SMC2	0.43	7.47	0.37	6.91e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs2045966	0.881	rs528412	chr8:98473089	T/C	cg21278164	chr1:226127694	LEFTY2	-0.64	-6.18	-0.32	1.84e-9	nicotine metabolite ratio in current smokers;
LIHC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.92	-0.3	8.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2412488	0.927	rs17520800	chr4:54338721	A/C	cg22241045	chr4:54363911	LNX1	-0.42	-6.77	-0.34	5.53e-11	DNA methylation (variation);
LIHC	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.76	0.34	5.97e-11	Type 2 diabetes;
LIHC	cis	rs3823572	0.586	rs2001282	chr7:133663287	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.39	0.37	1.12e-12	Menarche (age at onset);
LIHC	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	0.87	6.38	0.33	5.92e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs965469	1.000	rs2236104	chr20:3277602	C/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.83	-0.35	3.86e-11	IFN-related cytopenia;
LIHC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	7.93	0.39	3.19e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.36	-5.84	-0.3	1.2e-8	Body mass index;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.29	0.58	8.47e-33	Prudent dietary pattern;
LIHC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.53	-7.38	-0.37	1.22e-12	Pulse pressure;
LIHC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	1.04	11.8	0.54	3.36e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg01864069	chr14:103024347	NA	0.45	6.97	0.35	1.62e-11	Platelet count;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg11070056	chr1:107600091	PRMT6	0.63	10.75	0.5	2.04e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.01	0.31	4.81e-9	HDL cholesterol;
LIHC	cis	rs3736485	0.966	rs8041514	chr15:51866054	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.86	-14.98	-0.63	2.28e-39	Height;
LIHC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg00204512	chr16:28754710	NA	0.4	7.12	0.36	6.43e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6061231	0.958	rs2379126	chr20:60953005	C/A	cg03945807	chr20:60948434	NA	0.44	6.81	0.35	4.32e-11	Colorectal cancer;
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08219700	chr8:58056026	NA	0.51	6.92	0.35	2.3e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg09417038	chr21:47716443	C21orf57	-0.51	-7.56	-0.38	3.78e-13	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.77	11.82	0.54	2.95e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.17	0.4	6.23e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg08126542	chr6:37504118	NA	-0.37	-6.29	-0.32	9.51e-10	Cognitive performance;
LIHC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.39	-0.33	5.28e-10	Menarche (age at onset);
LIHC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg12798992	chr6:167411361	FGFR1OP	0.43	6.73	0.34	7.25e-11	Primary biliary cholangitis;
LIHC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.88	-0.35	2.82e-11	Response to antipsychotic treatment;
LIHC	cis	rs332507	0.830	rs62265580	chr3:124359842	C/T	cg05980111	chr3:124395277	KALRN	0.4	6.15	0.32	2.2e-9	Plateletcrit;
LIHC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.47	7.37	0.37	1.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg05044414	chr3:183734942	ABCC5	0.34	5.95	0.31	6.7e-9	Anterior chamber depth;
LIHC	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.77	10.74	0.5	2.21e-23	Response to hepatitis C treatment;
LIHC	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-5.74	-0.3	2.11e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06634786	chr22:41940651	POLR3H	-0.59	-6.69	-0.34	8.93e-11	Vitiligo;
LIHC	cis	rs7106204	0.590	rs28864378	chr11:24206582	C/A	ch.11.24196551F	chr11:24239977	NA	0.77	9.51	0.46	3.42e-19	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.89	0.3	9.25e-9	Tuberculosis;
LIHC	cis	rs3736757	0.664	rs12567226	chr1:184678290	C/T	cg07817967	chr1:184721222	EDEM3	0.38	6.04	0.31	4.05e-9	Obesity-related traits;
LIHC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.29	0.66	1.46e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs2274273	0.837	rs11625968	chr14:55801004	G/C	cg01864836	chr14:55583639	NA	-0.4	-7.32	-0.37	1.79e-12	Protein biomarker;
LIHC	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.47	-5.88	-0.3	9.72e-9	Serum sulfate level;
LIHC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg21724239	chr8:58056113	NA	0.49	6.46	0.33	3.6e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05025164	chr4:1340916	KIAA1530	0.74	11.21	0.52	4.89e-25	Longevity;
LIHC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.38	-6.18	-0.32	1.79e-9	Response to antipsychotic treatment;
LIHC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.37	0.37	1.29e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11671005	0.779	rs11670125	chr19:58987390	G/T	cg25952890	chr19:58913133	NA	0.73	7.37	0.37	1.26e-12	Mean platelet volume;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14828511	chr1:107599125	PRMT6	-0.44	-6.28	-0.32	1.05e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg05163923	chr11:71159392	DHCR7	-0.61	-7.49	-0.38	6.04e-13	Vitamin D levels;
LIHC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.48	7.85	0.39	5.49e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	6.1e-11	Prudent dietary pattern;
LIHC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg02931644	chr1:25747376	RHCE	-0.33	-7.06	-0.36	9.29e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.74	15.44	0.64	3.6e-41	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.49	9.39	0.45	8.68e-19	Testicular germ cell tumor;
LIHC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.65	0.5	4.64e-23	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg13047869	chr3:10149882	C3orf24	0.5	6.41	0.33	4.96e-10	Alzheimer's disease;
LIHC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg03983715	chr16:68378420	PRMT7	-0.52	-6.13	-0.31	2.43e-9	Schizophrenia;
LIHC	cis	rs4853036	0.951	rs6718298	chr2:70145450	A/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.95	-0.35	1.91e-11	Colorectal or endometrial cancer;
LIHC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.62	7.4	0.37	1.09e-12	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.48	0.46	4.51e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs4834770	1.000	rs2282688	chr4:120243722	T/C	cg09307838	chr4:120376055	NA	0.43	6.5	0.33	2.87e-10	Blood protein levels;
LIHC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-10.96	-0.51	3.74e-24	Mean corpuscular volume;
LIHC	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg25930673	chr12:123319894	HIP1R	1.04	11.55	0.53	2.78e-26	Adiponectin levels;
LIHC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-8.69	-0.43	1.51e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg10932868	chr11:921992	NA	0.4	7.66	0.38	1.99e-13	Alzheimer's disease (late onset);
LIHC	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.23	-5.86	-0.3	1.08e-8	Schizophrenia;
LIHC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2412488	1.000	rs6554106	chr4:54292791	A/G	cg22241045	chr4:54363911	LNX1	-0.47	-7.48	-0.37	6.52e-13	DNA methylation (variation);
LIHC	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.33	-0.37	1.67e-12	Bipolar disorder;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09100988	chr11:66725961	PC	0.51	6.79	0.34	5.11e-11	Hepatitis;
LIHC	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.43	-0.33	4.39e-10	Body mass index;
LIHC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18357526	chr6:26021779	HIST1H4A	0.46	6.79	0.34	5.03e-11	Height;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg13692902	chr5:34915868	BRIX1;RAD1	-0.37	-6.14	-0.32	2.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.64	-0.38	2.14e-13	Morning vs. evening chronotype;
LIHC	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	0.98	11.65	0.53	1.24e-26	Red blood cell traits;
LIHC	cis	rs55702914	0.905	rs787988	chr2:198200802	C/T	cg10820045	chr2:198174542	NA	-0.38	-5.79	-0.3	1.63e-8	Major depression and alcohol dependence;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-10.63	-0.5	5.19e-23	Skin colour saturation;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg09171127	chr8:8751325	MFHAS1	0.69	6.07	0.31	3.39e-9	Musician's dystonia;
LIHC	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.7	11.21	0.52	4.79e-25	Colorectal adenoma (advanced);
LIHC	cis	rs9309473	1.000	rs11689392	chr2:73622026	T/C	cg20560298	chr2:73613845	ALMS1	-0.58	-7.14	-0.36	5.59e-12	Metabolite levels;
LIHC	trans	rs10483554	0.607	rs2816787	chr14:49721727	A/G	cg21853235	chr3:50388532	TUSC4;CYB561D2	-0.51	-6.24	-0.32	1.26e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LIHC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-7.84	-0.39	5.82e-14	Rheumatoid arthritis;
LIHC	cis	rs2273156	0.706	rs7153331	chr14:35501670	A/G	cg16230307	chr14:35515116	FAM177A1	-0.43	-6.16	-0.32	2.01e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.56	-12.11	-0.55	2.43e-28	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6442522	0.606	rs13093164	chr3:15493818	C/T	cg16303742	chr3:15540471	COLQ	0.39	6.41	0.33	4.81e-10	Uric acid levels;
LIHC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.62	-0.34	1.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.35	-6.93	-0.35	2.09e-11	Colorectal cancer;
LIHC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.81e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.77	10.43	0.49	2.66e-22	Coronary artery disease;
LIHC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.88	-0.3	9.93e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.67	-9.77	-0.47	4.9e-20	IgG glycosylation;
LIHC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg22842854	chr12:123319900	HIP1R	-0.68	-8.81	-0.43	6.39e-17	Schizophrenia;
LIHC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	8.49	0.42	6.2e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.44	6.53	0.33	2.32e-10	Obesity-related traits;
LIHC	cis	rs4920343	0.698	rs510843	chr1:19090080	C/T	cg19637330	chr1:19110922	NA	-0.32	-5.85	-0.3	1.16e-8	Knee osteoarthritis;
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.47	7.78	0.39	8.92e-14	Testicular germ cell tumor;
LIHC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.57	9.95	0.47	1.17e-20	Methadone dose in opioid dependence;
LIHC	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-9.09	-0.44	8.15e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	0.64	6.54	0.33	2.27e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.49	7.18	0.36	4.4e-12	Lymphocyte counts;
LIHC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.54	9.75	0.47	5.8e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.48	-7.39	-0.37	1.13e-12	Schizophrenia;
LIHC	cis	rs80234489	1	rs80234489	chr12:31441179	A/C	cg15935736	chr12:31476933	FAM60A;FLJ13224	0.65	6.05	0.31	3.75e-9	Body mass index;
LIHC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.43	-0.56	1.59e-29	Alzheimer's disease;
LIHC	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	0.74	8.26	0.41	3.28e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs1046896	0.961	rs7208565	chr17:80696692	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	6.95	0.35	1.81e-11	Glycated hemoglobin levels;
LIHC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.59	8.8	0.43	6.85e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.71	-8.88	-0.43	3.75e-17	Blood protein levels;
LIHC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	9.74	0.47	6.23e-20	Response to antipsychotic treatment;
LIHC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1e-57	Breast cancer;
LIHC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg24203234	chr3:128598194	ACAD9	0.45	6.29	0.32	9.77e-10	IgG glycosylation;
LIHC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	1.01	19.04	0.72	1.3e-55	Breast cancer;
LIHC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.44	-10.06	-0.48	5.14e-21	Urinary metabolites;
LIHC	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.37	-13.18	-0.58	2.33e-32	Psoriasis vulgaris;
LIHC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.48	7.46	0.37	7.27e-13	Methadone dose in opioid dependence;
LIHC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02359409	chr6:42947317	PEX6	-0.47	-6.27	-0.32	1.11e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg10756647	chr7:56101905	PSPH	1.11	13.62	0.59	4.91e-34	Diabetic kidney disease;
LIHC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.16	0.36	4.83e-12	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg04711526	chr14:92582519	NDUFB1	0.43	6.91	0.35	2.44e-11	Alopecia areata;
LIHC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.44	-0.33	3.95e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	5.99	0.31	5.35e-9	Cognitive ability;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13475977	chr13:21047397	CRYL1	0.4	6.27	0.32	1.09e-9	Longevity;
LIHC	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg22771759	chr13:24902376	NA	0.32	6.69	0.34	9.05e-11	Obesity-related traits;
LIHC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.1e-13	Lung cancer;
LIHC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.67	9.47	0.46	4.65e-19	Coronary artery disease;
LIHC	cis	rs988712	0.705	rs35051342	chr11:27634373	G/C	cg18117895	chr11:27722066	BDNF	0.44	5.85	0.3	1.16e-8	Obesity;
LIHC	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.67	11.01	0.51	2.37e-24	White matter hyperintensity burden;
LIHC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.85	-0.3	1.13e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	13.96	0.6	2.37e-35	Coffee consumption (cups per day);
LIHC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.29	0.45	1.87e-18	Melanoma;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg14393609	chr7:65229607	NA	-0.37	-5.74	-0.3	2.06e-8	Aortic root size;
LIHC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.44	7.31	0.37	1.94e-12	Mean corpuscular volume;
LIHC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.2	0.52	5.37e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.9	0.43	3.44e-17	Motion sickness;
LIHC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-12.35	-0.56	3.03e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.68e-15	Motion sickness;
LIHC	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.79	-11.13	-0.52	9.43e-25	Response to hepatitis C treatment;
LIHC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	9.46	0.46	5.24e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.85	-0.35	3.51e-11	Diastolic blood pressure;
LIHC	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.47	-8.06	-0.4	1.32e-14	Pubertal anthropometrics;
LIHC	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.79	11.14	0.52	8.15e-25	Cerebrospinal P-tau181p levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13129888	chr1:28415099	EYA3	0.43	6.05	0.31	3.85e-9	Cognitive function;
LIHC	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg14593290	chr7:50529359	DDC	0.61	9.74	0.47	5.81e-20	Malaria;
LIHC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.41	-0.41	1.13e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.83	16.0	0.65	2.01e-43	Testicular germ cell tumor;
LIHC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.04e-8	Menopause (age at onset);
LIHC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.65	10.52	0.49	1.27e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.6	10.26	0.49	1.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.6	-8.7	-0.43	1.37e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs713477	0.654	rs11158040	chr14:55914607	T/C	cg13175173	chr14:55914753	NA	-0.31	-7.19	-0.36	4.03e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-0.8	-6.33	-0.32	7.5e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg22079354	chr11:130786696	SNX19	0.43	6.19	0.32	1.73e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg15123519	chr2:136567270	LCT	-0.37	-5.82	-0.3	1.33e-8	Corneal structure;
LIHC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.07e-8	Body mass index;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.65	0.62	4.71e-38	Prudent dietary pattern;
LIHC	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg02702477	chr5:179499311	RNF130	-0.74	-10.27	-0.49	9.85e-22	LDL cholesterol;
LIHC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg03395511	chr6:291903	DUSP22	-0.5	-6.54	-0.33	2.2e-10	Menopause (age at onset);
LIHC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.59	-10.14	-0.48	2.72e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	10.17	0.48	2.13e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1816752	0.905	rs7317850	chr13:24994037	C/G	cg22771759	chr13:24902376	NA	0.33	6.57	0.33	1.87e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg11764359	chr7:65958608	NA	-0.58	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.86	0.3	1.06e-8	Morning vs. evening chronotype;
LIHC	trans	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg26939375	chr7:64535504	NA	-0.43	-7.32	-0.37	1.77e-12	Aortic root size;
LIHC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.97	10.96	0.51	3.66e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.63	11.57	0.53	2.45e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg03732007	chr1:2071316	PRKCZ	0.36	6.19	0.32	1.75e-9	Height;
LIHC	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09572067	chr16:29127029	RRN3P2	0.62	9.66	0.46	1.1e-19	Menopause (age at onset);
LIHC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.45	7.77	0.39	9.2e-14	Schizophrenia;
LIHC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg15744005	chr10:104629667	AS3MT	0.38	8.44	0.42	8.93e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.54	8.63	0.42	2.32e-16	Body mass index;
LIHC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	2.97e-9	Mortality in heart failure;
LIHC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.45	6.07	0.31	3.33e-9	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12196473	chr3:99536614	MIR548G;C3orf26	0.43	6.3	0.32	9.05e-10	Pancreatic cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18954051	chr12:66554863	TMBIM4	0.45	6.53	0.33	2.33e-10	Hepatitis;
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.64	0.46	1.3e-19	Height;
LIHC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	7.68	0.38	1.74e-13	Alzheimer's disease;
LIHC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.62	6.97	0.35	1.65e-11	Menarche (age at onset);
LIHC	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg15208524	chr1:10270712	KIF1B	0.38	5.85	0.3	1.15e-8	Hepatocellular carcinoma;
LIHC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg11764359	chr7:65958608	NA	-0.58	-6.04	-0.31	3.97e-9	Diabetic kidney disease;
LIHC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg25344623	chr2:136566232	LCT	0.44	8.82	0.43	5.85e-17	Mosquito bite size;
LIHC	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg25251204	chr11:14927456	NA	0.41	5.87	0.3	1.03e-8	Vitamin D levels;
LIHC	cis	rs6782228	0.606	rs58977394	chr3:128337917	C/T	cg16766828	chr3:128327626	NA	-0.41	-6.46	-0.33	3.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.78	-0.3	1.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.42e-30	Alzheimer's disease;
LIHC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.39	8.94	0.44	2.53e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg23533926	chr12:111358616	MYL2	-0.32	-6.23	-0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg12365402	chr11:9010492	NRIP3	-0.31	-7.87	-0.39	4.67e-14	Hemoglobin concentration;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg26429905	chr20:35917924	MANBAL	-0.55	-6.05	-0.31	3.88e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg02990361	chr1:107599529	PRMT6	-0.58	-9.49	-0.46	4.01e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs903552	1.000	rs12719737	chr15:101999126	C/G	cg19295451	chr15:102010161	PCSK6	-0.43	-6.04	-0.31	4.03e-9	Diabetic kidney disease;
LIHC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.96	13.83	0.6	7.62e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg20735989	chr4:730612	PCGF3	-0.66	-8.72	-0.43	1.23e-16	White blood cell count;
LIHC	cis	rs797680	0.856	rs687394	chr1:93713917	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.46	6.52	0.33	2.49e-10	Longevity;Endometriosis;
LIHC	cis	rs8067354	0.527	rs1292039	chr17:57974913	A/T	cg02344993	chr17:57696989	CLTC	0.67	10.55	0.5	1.04e-22	Hemoglobin concentration;
LIHC	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.87	0.35	3.01e-11	Mean corpuscular volume;
LIHC	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.87e-10	Asthma;
LIHC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg05425664	chr17:57184151	TRIM37	-0.46	-5.79	-0.3	1.58e-8	Vitamin D levels;
LIHC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.54	0.46	2.83e-19	Tonsillectomy;
LIHC	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.75	-0.6	1.56e-34	Coffee consumption (cups per day);
LIHC	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.59	-5.8	-0.3	1.53e-8	Carotid intima media thickness;
LIHC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg04166393	chr7:2884313	GNA12	0.37	6.06	0.31	3.62e-9	Height;
LIHC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.48	-7.85	-0.39	5.49e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.51	6.15	0.32	2.11e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-6.94	-0.35	1.99e-11	Chronic sinus infection;
LIHC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg02290350	chr8:58132656	NA	0.31	7.15	0.36	5.41e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg22705602	chr4:152727874	NA	-0.31	-6.53	-0.33	2.38e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg13409248	chr3:40428643	ENTPD3	0.42	7.09	0.36	7.87e-12	Renal cell carcinoma;
LIHC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.29	-0.37	2.22e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.64	8.72	0.43	1.23e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg11861562	chr11:117069780	TAGLN	0.48	7.89	0.39	4.2e-14	Blood protein levels;
LIHC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.26e-34	Aortic root size;
LIHC	trans	rs10213084	0.915	rs10212988	chr4:147501000	A/G	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.92	-10.19	-0.48	1.83e-21	Red cell distribution width;
LIHC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-9.29	-0.45	1.79e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20011983	chr2:74347215	NA	-0.39	-5.74	-0.3	2.11e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg18279126	chr7:2041391	MAD1L1	-0.39	-6.72	-0.34	7.48e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.62	9.51	0.46	3.57e-19	Eotaxin levels;
LIHC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg21522988	chr12:29376872	FAR2	0.28	6.22	0.32	1.45e-9	QT interval;
LIHC	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.82	-11.43	-0.53	7.73e-26	Obesity-related traits;
LIHC	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.4	7.67	0.38	1.8e-13	Height;
LIHC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12286929	0.609	rs11602686	chr11:115100638	G/A	cg04055981	chr11:115044050	NA	0.43	6.23	0.32	1.4e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.72	9.71	0.46	7.42e-20	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20840002	chr11:105924441	KBTBD3	0.34	6.5	0.33	2.92e-10	Cognitive function;
LIHC	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.41	0.33	4.72e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LIHC	cis	rs2834256	0.517	rs7280365	chr21:34952583	G/C	cg14850771	chr21:34775459	IFNGR2	0.45	7.09	0.36	7.93e-12	Red cell distribution width;
LIHC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.1	-0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg12310025	chr6:25882481	NA	-0.39	-5.85	-0.3	1.15e-8	Height;
LIHC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.56	0.53	2.57e-26	Tonsillectomy;
LIHC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.4	-0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg02297831	chr4:17616191	MED28	0.44	6.81	0.35	4.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.81	11.71	0.54	7.16e-27	Coronary artery disease;
LIHC	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.45	9.11	0.44	6.97e-18	Late-onset Alzheimer's disease;
LIHC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.43	5.73	0.3	2.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.6	7.16	0.36	4.89e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg11764359	chr7:65958608	NA	0.91	16.72	0.67	2.66e-46	Aortic root size;
LIHC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.53	0.53	3.21e-26	Motion sickness;
LIHC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg07090678	chr1:91966139	CDC7	0.53	7.26	0.37	2.61e-12	Breast cancer;
LIHC	trans	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	7.19	0.36	4.11e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.68	-12.8	-0.57	6.55e-31	Body mass index;
LIHC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.23	-0.32	1.37e-9	IgG glycosylation;
LIHC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.61	7.35	0.37	1.45e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11229555	0.598	rs12276438	chr11:58185419	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.67	-5.88	-0.3	9.85e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs55665837	0.701	rs12787709	chr11:14639257	G/A	cg25251204	chr11:14927456	NA	0.44	5.89	0.3	9.34e-9	Vitamin D levels;
LIHC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20135002	chr11:47629003	NA	0.5	8.61	0.42	2.76e-16	Subjective well-being;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.51	7.68	0.38	1.69e-13	Height;
LIHC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.24e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.48	6.59	0.34	1.62e-10	Obesity-related traits;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02279591	chr5:94989328	RFESD	-0.26	-6.38	-0.33	5.68e-10	Calcium levels;
LIHC	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg15704280	chr7:45808275	SEPT13	0.64	6.11	0.31	2.72e-9	Myopia (pathological);
LIHC	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.32	-0.45	1.52e-18	Capecitabine sensitivity;
LIHC	cis	rs4728302	0.838	rs13231095	chr7:133604436	A/G	cg10665199	chr7:133106180	EXOC4	0.39	6.81	0.35	4.51e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.72e-12	IgG glycosylation;
LIHC	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.3	-0.32	9.41e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg18887096	chr2:219472410	PLCD4	0.35	6.26	0.32	1.13e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.47	0.37	6.91e-13	Prudent dietary pattern;
LIHC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.8	-8.98	-0.44	1.8e-17	Schizophrenia;
LIHC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.41	6.03	0.31	4.22e-9	Coronary artery disease;
LIHC	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.74	8.23	0.41	3.88e-15	Height;
LIHC	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg07541023	chr7:19748670	TWISTNB	0.4	5.95	0.31	6.56e-9	Thyroid stimulating hormone;
LIHC	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg24209194	chr3:40518798	ZNF619	-0.54	-8.06	-0.4	1.26e-14	Renal cell carcinoma;
LIHC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.06	-0.51	1.7e-24	Chronic sinus infection;
LIHC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.6	-10.9	-0.51	6.06e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.5	-0.46	3.65e-19	Obesity-related traits;
LIHC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.59	0.5	7.6e-23	Alzheimer's disease;
LIHC	cis	rs3743104	0.510	rs16973303	chr15:33020928	A/C	cg07179000	chr15:33023586	GREM1	-0.51	-8.1	-0.4	9.53e-15	Hypospadias;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg27187586	chr4:83932193	LIN54	-0.32	-6.44	-0.33	3.96e-10	Oropharynx cancer;
LIHC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.12	0.31	2.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	14.38	0.61	5.17e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg23485639	chr6:28045615	ZNF165	0.38	5.87	0.3	1.02e-8	Parkinson's disease;
LIHC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg18357526	chr6:26021779	HIST1H4A	0.42	6.33	0.32	7.66e-10	Height;
LIHC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg00901687	chr17:48585270	MYCBPAP	-0.53	-7.6	-0.38	2.92e-13	Visceral fat;
LIHC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.22	5.94	0.31	7.09e-9	Age-related hearing impairment;
LIHC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.53e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.85e-11	Dermatomyositis;
LIHC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.51	7.7	0.38	1.49e-13	Systemic lupus erythematosus;
LIHC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.74	13.67	0.59	3.08e-34	Height;
LIHC	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.36	-8.22	-0.41	4.14e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.52	-7.07	-0.36	8.71e-12	Pancreatic cancer;
LIHC	cis	rs2569991	0.636	rs2600222	chr3:12937617	C/G	cg22481960	chr3:13008800	IQSEC1	-0.43	-7.45	-0.37	7.57e-13	Periodontitis (DPAL);
LIHC	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.32	21.74	0.76	2.04e-66	Corneal structure;
LIHC	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg02359409	chr6:42947317	PEX6	-0.41	-5.91	-0.3	8.38e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.17	-0.32	1.97e-9	Diastolic blood pressure;
LIHC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg05044414	chr3:183734942	ABCC5	0.34	5.91	0.3	8.16e-9	Anterior chamber depth;
LIHC	cis	rs9648428	0.515	rs17172276	chr7:36202416	A/G	cg14708893	chr7:36124863	NA	-0.41	-6.18	-0.32	1.79e-9	Obesity-related traits;
LIHC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.35	5.77	0.3	1.76e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.9	13.21	0.58	1.73e-32	Sudden cardiac arrest;
LIHC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	8.21	0.41	4.6e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.25	-0.41	3.57e-15	Schizophrenia;
LIHC	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs3770081	0.826	rs76780449	chr2:86222811	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-5.91	-0.3	8.06e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.68	0.34	9.75e-11	Height;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg24693881	chr1:107596107	NA	0.52	8.99	0.44	1.77e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg09165964	chr15:75287851	SCAMP5	0.48	6.93	0.35	2.12e-11	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg15848620	chr12:58087721	OS9	-0.57	-7.55	-0.38	4.1e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4788570	0.543	rs4788820	chr16:71660115	G/C	cg06353428	chr16:71660113	MARVELD3	1.46	15.47	0.64	2.73e-41	Intelligence (multi-trait analysis);
LIHC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.3	0.37	2.01e-12	Lung cancer;
LIHC	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-9.26	-0.45	2.4e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1204798	0.589	rs10223646	chr6:116617399	C/T	cg23214565	chr6:116600728	DSE;TSPYL1	-0.42	-6.2	-0.32	1.63e-9	Dental caries;
LIHC	cis	rs4407350	0.837	rs4823326	chr22:44908678	C/T	cg04154583	chr22:44889756	LDOC1L	0.29	5.75	0.3	2.02e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs75887402	0.744	rs4836002	chr5:122676161	A/G	cg27033705	chr5:122759302	CEP120	-0.8	-5.71	-0.3	2.46e-8	Breast cancer;
LIHC	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg25114630	chr15:101792522	CHSY1	0.55	6.85	0.35	3.37e-11	Corneal structure;
LIHC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.73	-0.34	7.2e-11	Arsenic metabolism;
LIHC	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.69	11.33	0.52	1.78e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs17106184	1.000	rs11205788	chr1:51363096	G/A	cg07174182	chr1:51127561	FAF1	-0.75	-7.7	-0.38	1.44e-13	Type 2 diabetes;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07777156	chr17:22022000	NA	0.5	6.45	0.33	3.73e-10	Hepatitis;
LIHC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	10.11	0.48	3.46e-21	Menarche (age at onset);
LIHC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.64	-7.66	-0.38	1.87e-13	Migraine;Coronary artery disease;
LIHC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.83	13.84	0.6	6.62e-35	Aortic root size;
LIHC	cis	rs17102884	0.541	rs8004430	chr14:75171683	C/T	cg08847533	chr14:75593920	NEK9	0.45	7.0	0.35	1.35e-11	Neuroticism;
LIHC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.17	-0.32	1.9e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg11645453	chr3:52864694	ITIH4	0.22	5.96	0.31	6.39e-9	Bipolar disorder;
LIHC	cis	rs1564271	1.000	rs1564271	chr10:27011112	G/A	cg13837822	chr10:26931731	LOC731789	0.34	6.08	0.31	3.15e-9	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.32	6.35	0.32	6.83e-10	Testicular germ cell tumor;
LIHC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.59	-10.13	-0.48	2.93e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21448741	chr8:58168803	NA	0.35	6.09	0.31	3.02e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg11764359	chr7:65958608	NA	-0.58	-5.98	-0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs11955398	0.563	rs4700385	chr5:60032599	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.4	-5.71	-0.3	2.46e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg27205649	chr11:78285834	NARS2	0.38	5.86	0.3	1.09e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.61	8.01	0.4	1.76e-14	Exhaled nitric oxide output;
LIHC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.89	0.65	5.71e-43	White blood cell count;
LIHC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg02551604	chr5:131831745	NA	-0.5	-7.01	-0.35	1.27e-11	Asthma (sex interaction);
LIHC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.66	-9.88	-0.47	2e-20	Schizophrenia;
LIHC	cis	rs3106136	0.678	rs6532485	chr4:95297120	C/T	cg11021082	chr4:95130006	SMARCAD1	0.36	6.14	0.32	2.27e-9	Capecitabine sensitivity;
LIHC	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.76	-0.3	1.83e-8	Biliary atresia;
LIHC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.12	0.44	6.49e-18	Eosinophil percentage of white cells;
LIHC	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.16	-0.4	6.37e-15	Capecitabine sensitivity;
LIHC	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.38	0.33	5.6e-10	HDL cholesterol;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20638626	chr8:12523153	NA	0.54	6.85	0.35	3.4e-11	Hepatitis;
LIHC	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.37	-7.81	-0.39	7.04e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-6.03	-0.31	4.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg04374321	chr14:90722782	PSMC1	0.47	6.53	0.33	2.34e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.21	-0.36	3.68e-12	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-0.58	-6.79	-0.34	4.87e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs655641	0.834	rs2458496	chr11:85718816	C/G	cg09030501	chr11:85779252	PICALM	-0.52	-6.14	-0.32	2.23e-9	Platelet count;
LIHC	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg05110241	chr16:68378359	PRMT7	-0.5	-6.11	-0.31	2.75e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.94	-0.31	6.88e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.56	0.42	3.83e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.74	12.06	0.55	3.69e-28	Anterior chamber depth;
LIHC	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.35	-0.32	6.94e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.48	7.85	0.39	5.31e-14	Methadone dose in opioid dependence;
LIHC	cis	rs8084351	0.569	rs16956411	chr18:50775428	A/G	cg24270629	chr18:50823537	DCC	-0.48	-7.14	-0.36	5.59e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg00815214	chr21:47717953	NA	0.34	5.72	0.3	2.37e-8	Testicular germ cell tumor;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg14393609	chr7:65229607	NA	0.45	6.59	0.34	1.63e-10	Aortic root size;
LIHC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	9.93	0.47	1.38e-20	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2569991	1.000	rs2569991	chr3:12923197	C/A	cg22481960	chr3:13008800	IQSEC1	-0.38	-6.61	-0.34	1.45e-10	Periodontitis (DPAL);
LIHC	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg12140854	chr5:148520817	ABLIM3	0.45	6.16	0.32	2.01e-9	Breast cancer;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.5	-6.2	-0.32	1.66e-9	Diastolic blood pressure;
LIHC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.36	0.45	1.1e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.52	-6.5	-0.33	2.9e-10	Schizophrenia;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.49	-8.41	-0.41	1.12e-15	Total body bone mineral density;
LIHC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.48	7.46	0.37	7.27e-13	Methadone dose in opioid dependence;
LIHC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-6.54	-0.33	2.25e-10	Initial pursuit acceleration;
LIHC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.4	0.45	8.18e-19	Platelet count;
LIHC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-12.81	-0.57	5.96e-31	Vitiligo;
LIHC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.77	10.93	0.51	4.74e-24	Selective IgA deficiency;
LIHC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	6.91e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9641123	0.639	rs2677079	chr7:93256401	C/G	cg09745688	chr16:2908918	PRSS22	-0.39	-6.85	-0.35	3.42e-11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs7220401	0.521	rs11080105	chr17:27904711	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	7.31	0.37	1.86e-12	Coronary artery disease;
LIHC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-8.69	-0.43	1.5e-16	Menarche (age at onset);
LIHC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	0.96	16.24	0.66	2.23e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.99	-0.4	2.13e-14	Lymphocyte counts;
LIHC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg02269571	chr22:50332266	NA	0.61	8.63	0.42	2.37e-16	Schizophrenia;
LIHC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg12365402	chr11:9010492	NRIP3	0.29	7.4	0.37	1.07e-12	Hemoglobin concentration;
LIHC	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.49	-6.66	-0.34	1.1e-10	Schizophrenia;
LIHC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg22079354	chr11:130786696	SNX19	0.42	6.08	0.31	3.18e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6750047	0.605	rs2121260	chr2:38268763	T/G	cg07380506	chr2:38303506	CYP1B1	0.58	7.29	0.37	2.22e-12	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.5	-8.01	-0.4	1.81e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs7191868	1	rs7191868	chr16:536090	G/C	cg06259664	chr16:537672	RAB11FIP3	0.52	6.12	0.31	2.5e-9	Platelet distribution width;
LIHC	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.75	8.71	0.43	1.33e-16	Exhaled nitric oxide output;
LIHC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21582582	chr3:182698605	DCUN1D1	0.54	7.01	0.35	1.24e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.94	0.39	2.95e-14	Motion sickness;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.78	-0.34	5.13e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.59	8.93	0.43	2.6e-17	Recombination rate (females);
LIHC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.47	6.61	0.34	1.43e-10	Morning vs. evening chronotype;
LIHC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	0.85	11.71	0.53	7.62e-27	Skin colour saturation;
LIHC	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.68	11.21	0.52	4.66e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.63	-6.52	-0.33	2.54e-10	Migraine;Coronary artery disease;
LIHC	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.6	-9.41	-0.45	7.76e-19	Red cell distribution width;
LIHC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6466055	0.867	rs10241415	chr7:104948076	A/G	cg04380332	chr7:105027541	SRPK2	0.37	6.88	0.35	2.88e-11	Schizophrenia;
LIHC	cis	rs4759375	1.000	rs1109560	chr12:123757905	C/A	cg00376283	chr12:123451042	ABCB9	-0.49	-6.26	-0.32	1.17e-9	HDL cholesterol;
LIHC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.49	5.75	0.3	1.99e-8	Bladder cancer;
LIHC	cis	rs7546668	1.000	rs7515244	chr1:15873386	A/G	cg11706911	chr1:15910989	AGMAT	0.44	6.63	0.34	1.3100000000000001e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.37	9.92	0.47	1.53e-20	Weight;
LIHC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.28	0.41	2.8e-15	Lung cancer;
LIHC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg00204512	chr16:28754710	NA	0.42	7.37	0.37	1.3e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg05941027	chr17:61774174	LIMD2	0.33	6.71	0.34	8.24e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.75	10.44	0.49	2.53e-22	Lymphocyte counts;
LIHC	trans	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17183009	chr3:120277827	NA	0.52	6.06	0.31	3.65e-9	Corneal astigmatism;
LIHC	cis	rs12220238	0.841	rs10824161	chr10:76133762	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.63	-6.41	-0.33	4.8e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.48	6.06	0.31	3.64e-9	Panic disorder;
LIHC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	10.11	0.48	3.28e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg24879335	chr3:133465180	TF	0.31	7.02	0.35	1.19e-11	Iron status biomarkers;
LIHC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg21724239	chr8:58056113	NA	0.47	6.24	0.32	1.32e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.37	0.66	6.68e-45	Smoking behavior;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.17	-0.32	1.91e-9	Total body bone mineral density;
LIHC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12463550	chr7:65579703	CRCP	0.69	7.33	0.37	1.68e-12	Diabetic kidney disease;
LIHC	cis	rs742115	0.510	rs9468839	chr6:11308035	A/T	cg25250968	chr6:11318770	NEDD9	0.38	6.03	0.31	4.2e-9	Coronary artery disease;
LIHC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.47	-7.22	-0.36	3.45e-12	Coronary artery disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00006032	chr14:66974439	GPHN	0.49	7.72	0.39	1.3e-13	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08247611	chr16:71928811	KIAA0174	0.42	6.04	0.31	4.09e-9	Pancreatic cancer;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.87	0.78	6.99e-71	Height;
LIHC	cis	rs17776563	0.959	rs1348002	chr15:89113138	C/G	cg05013243	chr15:89149849	MIR1179	0.38	6.57	0.33	1.85e-10	Thyroid hormone levels;
LIHC	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.55	0.33	2.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg14067834	chr17:29058358	SUZ12P	0.72	7.12	0.36	6.39e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17125944	0.686	rs6572869	chr14:53353454	C/T	cg00686598	chr14:53173677	PSMC6	0.78	8.7	0.43	1.43e-16	Alzheimer's disease (late onset);
LIHC	trans	rs6489882	0.703	rs6489865	chr12:113360302	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg00750074	chr16:89608354	SPG7	-0.37	-5.72	-0.3	2.28e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.47	8.3	0.41	2.39e-15	QT interval;
LIHC	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.37	8.47	0.42	7.26e-16	Educational attainment (years of education);
LIHC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.68	-8.34	-0.41	1.88e-15	Gut microbiome composition (summer);
LIHC	cis	rs11673344	0.670	rs568654	chr19:37431187	G/A	cg27390819	chr19:37464633	NA	-0.5	-6.01	-0.31	4.88e-9	Obesity-related traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01623343	chr16:354374	AXIN1	-0.39	-6.2	-0.32	1.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.29	-0.32	9.95e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg23112188	chr14:24563095	PCK2	-0.29	-5.9	-0.3	8.87e-9	IgG glycosylation;
LIHC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.28	0.45	2.02e-18	Lung cancer in ever smokers;
LIHC	cis	rs920590	0.921	rs4922099	chr8:19648486	T/C	cg03894339	chr8:19674705	INTS10	0.44	6.63	0.34	1.28e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg24203234	chr3:128598194	ACAD9	-0.43	-6.1	-0.31	2.85e-9	IgG glycosylation;
LIHC	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	cis	rs4742903	0.935	rs12351370	chr9:106928940	G/A	cg14250997	chr9:106856677	SMC2	0.36	6.02	0.31	4.43e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.43	7.48	0.37	6.44e-13	Aortic root size;
LIHC	cis	rs6594499	0.872	rs7732974	chr5:110455381	T/C	cg04022379	chr5:110408740	TSLP	0.49	8.28	0.41	2.79e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.41	-7.35	-0.37	1.46e-12	Crohn's disease;
LIHC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.51	9.16	0.44	4.83e-18	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.63	8.52	0.42	5.31e-16	Skin colour saturation;
LIHC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2932538	0.583	rs2279500	chr1:113244433	T/C	cg22162597	chr1:113214053	CAPZA1	-0.68	-8.06	-0.4	1.25e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	cg25843174	chr11:12811716	TEAD1	0.29	6.68	0.34	9.78e-11	Educational attainment (years of education);
LIHC	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg06533319	chr4:3265114	C4orf44	0.34	6.51	0.33	2.63e-10	Parental longevity (mother's age at death);
LIHC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.37	-0.41	1.52e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg22633049	chr21:46681294	NA	-0.36	-6.11	-0.31	2.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg12923728	chr3:195709715	SDHAP1	-0.55	-6.24	-0.32	1.3e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10916814	0.655	rs4291476	chr1:20897019	A/G	cg24502330	chr1:20914028	CDA	-0.31	-6.82	-0.35	4.1e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs6058796	0.792	rs35938376	chr20:31270536	G/A	cg02600331	chr11:130417168	NA	0.36	7.59	0.38	2.98e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg23533926	chr12:111358616	MYL2	0.34	6.83	0.35	3.88e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.28	0.45	1.99e-18	Schizophrenia;
LIHC	trans	rs13098911	0.540	rs35477280	chr3:45974092	G/A	cg21656520	chr2:210867290	RPE	0.86	6.09	0.31	3.09e-9	Celiac disease;
LIHC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	0.79	11.81	0.54	3.14e-27	Monocyte percentage of white cells;
LIHC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg01444801	chr10:135216882	MTG1	-0.64	-9.68	-0.46	9.5e-20	Systemic lupus erythematosus;
LIHC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.6	5.8	0.3	1.55e-8	Vitiligo;
LIHC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.48	6.74	0.34	6.86e-11	Schizophrenia;
LIHC	cis	rs867186	0.614	rs74358111	chr20:33399077	C/A	cg08999081	chr20:33150536	PIGU	0.61	5.98	0.31	5.59e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.79	12.62	0.56	3.16e-30	Chronic lymphocytic leukemia;
LIHC	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	0.92	22.35	0.77	7.64e-69	Multiple myeloma;
LIHC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	12.56	0.56	4.96e-30	Schizophrenia;
LIHC	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg01092361	chr6:42185687	MRPS10	0.9	8.91	0.43	2.99e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs11696739	1.000	rs11696739	chr20:1600925	A/G	cg15722679	chr20:1638393	SIRPG	-0.34	-6.55	-0.33	2.07e-10	Mean platelet volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23800573	chr21:45114399	RRP1B	0.43	6.48	0.33	3.17e-10	Pancreatic cancer;
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.1	-0.44	7.62e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	5.77	0.3	1.81e-8	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs864643	1.000	rs581691	chr3:39550735	T/C	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs1664789	0.904	rs1694058	chr5:53277415	G/A	ch.5.1024479R	chr5:53302184	ARL15	0.54	8.37	0.41	1.45e-15	Waist circumference adjusted for body mass index;
LIHC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.28	-0.49	8.82e-22	Type 2 diabetes;
LIHC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg20607798	chr8:58055168	NA	0.49	6.2	0.32	1.6e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg15658676	chr6:53530538	KLHL31	-1.1	-7.88	-0.39	4.36e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.15	0.36	5.42e-12	Lung cancer;
LIHC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-22.17	-0.77	3.95e-68	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21813546	chr1:182808991	DHX9	0.44	6.73	0.34	7.04e-11	Pancreatic cancer;
LIHC	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.61	10.1	0.48	3.67e-21	Schizophrenia;
LIHC	cis	rs4979906	1.000	rs4979910	chr10:79456561	T/C	cg07817648	chr10:79422355	NA	-0.33	-6.85	-0.35	3.4e-11	Mortality in heart failure;
LIHC	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg15208524	chr1:10270712	KIF1B	0.45	6.53	0.33	2.4e-10	Hepatocellular carcinoma;
LIHC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg12923728	chr3:195709715	SDHAP1	-0.57	-6.61	-0.34	1.52e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.21	-5.74	-0.3	2.05e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.89	11.17	0.52	6.49e-25	Prostate cancer;
LIHC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.6	8.41	0.41	1.13e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg18357526	chr6:26021779	HIST1H4A	0.43	6.31	0.32	8.89e-10	Height;
LIHC	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.52	8.86	0.43	4.58e-17	Breast cancer;
LIHC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.58	6.93	0.35	2.07e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.67	-9.97	-0.47	9.98e-21	Mosquito bite size;
LIHC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11645453	chr3:52864694	ITIH4	0.22	5.73	0.3	2.23e-8	Bipolar disorder;
LIHC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	6.11e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.51	9.06	0.44	1.04e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.6	-0.46	1.8e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.93	6.95	0.35	1.87e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	trans	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg26939375	chr7:64535504	NA	0.39	6.19	0.32	1.69e-9	Aortic root size;
LIHC	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg00277334	chr10:82204260	NA	-0.54	-6.68	-0.34	9.51e-11	Post bronchodilator FEV1;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg25321988	chr19:49946433	NA	-0.49	-6.18	-0.32	1.85e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-7.11	-0.36	6.71e-12	Longevity;Endometriosis;
LIHC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.4	-0.33	5.17e-10	Height;
LIHC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.7	-10.36	-0.49	4.77e-22	Aortic root size;
LIHC	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.18	-0.4	5.53e-15	Colorectal cancer;
LIHC	cis	rs7776786	0.870	rs12540224	chr7:18830489	C/T	cg13420273	chr7:18810212	HDAC9	-0.26	-5.78	-0.3	1.67e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs7187994	0.848	rs8051512	chr16:84781101	C/G	cg07647771	chr16:84786436	USP10	-0.33	-6.55	-0.33	2.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10220309	0.628	rs10138520	chr14:80572248	T/C	cg08183125	chr14:80678293	DIO2	0.38	5.88	0.3	9.78e-9	Lung function (FEV1);
LIHC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.69	-10.11	-0.48	3.45e-21	Monocyte percentage of white cells;
LIHC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.06e-10	Menopause (age at onset);
LIHC	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.32	7.15	0.36	5.27e-12	Crohn's disease;
LIHC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.66	-0.38	1.93e-13	Electroencephalogram traits;
LIHC	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg19735590	chr5:154026979	NA	0.47	5.82	0.3	1.39e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.39	7.51	0.38	5.1e-13	Methadone dose in opioid dependence;
LIHC	trans	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg07393940	chr7:158741817	NA	0.56	6.73	0.34	7.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02985541	chr2:219472218	PLCD4	0.43	7.15	0.36	5.37e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.47	-7.68	-0.38	1.69e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7818688	0.697	rs11787303	chr8:95972864	C/T	cg16049864	chr8:95962084	TP53INP1	0.57	6.33	0.32	7.64e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6788895	1.000	rs73006998	chr3:150464271	G/A	cg07663535	chr3:150480033	SIAH2	0.59	7.07	0.36	8.65e-12	Breast cancer;
LIHC	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.72	-10.87	-0.51	7.91e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.42	-8.3	-0.41	2.43e-15	Testicular germ cell tumor;
LIHC	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.38	-7.4	-0.37	1.08e-12	Testicular germ cell tumor;
LIHC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.89	-15.52	-0.64	1.66e-41	Aortic root size;
LIHC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg14456004	chr13:21872349	NA	1.19	13.34	0.58	5.74e-33	White matter hyperintensity burden;
LIHC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.47	8.27	0.41	3.07e-15	N-glycan levels;
LIHC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.98	-18.56	-0.71	1.1e-53	Breast cancer;
LIHC	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.51	-8.19	-0.4	5.22e-15	Superior crus of antihelix expression;
LIHC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg16434002	chr17:42200994	HDAC5	-0.48	-7.17	-0.36	4.64e-12	Total body bone mineral density;
LIHC	cis	rs3106136	0.843	rs1344612	chr4:95265228	G/A	cg11021082	chr4:95130006	SMARCAD1	0.4	7.24	0.36	3.08e-12	Capecitabine sensitivity;
LIHC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00612595	chr21:47717864	NA	-0.4	-6.31	-0.32	8.87e-10	Testicular germ cell tumor;
LIHC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-0.86	-9.83	-0.47	2.93e-20	Schizophrenia;
LIHC	trans	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.44	6.0	0.31	5.17e-9	Alzheimer's disease;
LIHC	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.62	-8.78	-0.43	8.07e-17	Blood metabolite levels;
LIHC	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.21e-9	Mean corpuscular volume;
LIHC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-8.74	-0.43	1.05e-16	Height;
LIHC	cis	rs611744	0.624	rs2514844	chr8:109064809	A/G	cg21045802	chr8:109455806	TTC35	0.43	7.22	0.36	3.39e-12	Dupuytren's disease;
LIHC	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.35	-8.08	-0.4	1.12e-14	Congenital heart disease (maternal effect);
LIHC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg12160578	chr15:63334699	TPM1	-0.62	-8.73	-0.43	1.18e-16	Platelet count;
LIHC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.55	9.12	0.44	6.66e-18	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25777971	chr15:22945134	CYFIP1	0.42	6.34	0.32	7.47e-10	Pancreatic cancer;
LIHC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.8	10.21	0.48	1.6e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.78	13.62	0.59	4.71e-34	Aortic root size;
LIHC	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg10978503	chr1:24200527	CNR2	-0.38	-9.0	-0.44	1.64e-17	Immature fraction of reticulocytes;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01301323	chr12:77252588	CSRP2	0.44	6.71	0.34	7.87e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs17301259	0.729	rs2519923	chr7:88380200	G/A	cg07470830	chr6:76000847	NA	0.36	6.05	0.31	3.75e-9	Heschl's gyrus morphology;
LIHC	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg09795085	chr6:101329169	ASCC3	-0.49	-6.67	-0.34	1.04e-10	Neuroticism;
LIHC	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg01990225	chr2:97406019	LMAN2L	-0.7	-6.4	-0.33	5.17e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.48	7.24	0.36	2.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.33	-0.32	7.5e-10	Aortic root size;
LIHC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.2	0.36	3.84e-12	Exhaled nitric oxide output;
LIHC	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.53	8.35	0.41	1.68e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.23e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg06207120	chr15:45996521	NA	0.33	6.44	0.33	4.12e-10	Waist circumference;Weight;
LIHC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.21	-0.32	1.58e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg12826209	chr6:26865740	GUSBL1	0.52	6.45	0.33	3.77e-10	Small cell lung carcinoma;
LIHC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg08499158	chr17:42289980	UBTF	-0.52	-8.46	-0.42	8.13e-16	Total body bone mineral density;
LIHC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.55	8.05	0.4	1.41e-14	Longevity;Endometriosis;
LIHC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.43	0.45	6.42e-19	Morning vs. evening chronotype;
LIHC	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.51	7.55	0.38	3.9e-13	Schizophrenia;
LIHC	cis	rs9918079	0.560	rs13147590	chr4:15621188	A/G	cg04067612	chr4:15429572	C1QTNF7	0.28	5.88	0.3	1e-8	Obesity-related traits;
LIHC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-8.37	-0.41	1.53e-15	Gut microbiome composition (summer);
LIHC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.06	-0.31	3.5e-9	Ulcerative colitis;
LIHC	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.57	-0.42	3.54e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.52	7.53	0.38	4.63e-13	Glycated hemoglobin levels;
LIHC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg16226627	chr15:75307476	SCAMP5	-0.55	-9.69	-0.46	9.17e-20	Lung cancer;
LIHC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.55	-8.93	-0.43	2.64e-17	Blood trace element (Zn levels);
LIHC	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.34	-5.87	-0.3	1.02e-8	Response to antipsychotic treatment;
LIHC	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg03934865	chr2:198174659	NA	-0.48	-6.89	-0.35	2.76e-11	Dermatomyositis;
LIHC	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-7.03	-0.36	1.12e-11	Lung cancer;
LIHC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.6	10.38	0.49	4.14e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg01788221	chr16:89496183	ANKRD11	0.41	6.33	0.32	7.83e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00339695	chr16:24857497	SLC5A11	0.51	7.78	0.39	8.58e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-7.77	-0.39	9.35e-14	Homocysteine levels;
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg15463628	chr8:11872659	NA	-0.48	-6.51	-0.33	2.63e-10	Monocyte count;
LIHC	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg00387323	chr7:6746715	ZNF12	0.64	7.04	0.36	1.07e-11	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg22528358	chr1:107598549	PRMT6	-0.69	-11.36	-0.52	1.32e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.46	6.8	0.35	4.67e-11	Aortic root size;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg00612595	chr21:47717864	NA	-0.36	-5.85	-0.3	1.12e-8	Testicular germ cell tumor;
LIHC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.49	-7.53	-0.38	4.65e-13	Pulse pressure;
LIHC	trans	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg01134436	chr17:81009848	B3GNTL1	0.81	6.6	0.34	1.61e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.2	16.23	0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg13753209	chr17:57696993	CLTC	0.56	8.63	0.42	2.34e-16	Hemoglobin concentration;
LIHC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg17980119	chr2:219472607	PLCD4	0.34	5.79	0.3	1.62e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.39	6.98	0.35	1.58e-11	Response to antipsychotic treatment;
LIHC	trans	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-6.03	-0.31	4.17e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.84	15.1	0.63	8.03e-40	IgG glycosylation;
LIHC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.68e-14	Mean platelet volume;
LIHC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg12863693	chr15:85201151	NMB	0.47	6.84	0.35	3.59e-11	Schizophrenia;
LIHC	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.58e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.44	7.17	0.36	4.53e-12	Response to temozolomide;
LIHC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.29	-0.32	9.84e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg15123519	chr2:136567270	LCT	-0.38	-5.82	-0.3	1.38e-8	Corneal structure;
LIHC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.39	-6.03	-0.31	4.23e-9	Glioblastoma;
LIHC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.65	10.52	0.49	1.36e-22	Type 2 diabetes;
LIHC	cis	rs5769707	0.681	rs916360	chr22:50041972	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.34	-0.41	1.8e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.17	0.32	1.89e-9	Menopause (age at onset);
LIHC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02359409	chr6:42947317	PEX6	0.39	5.8	0.3	1.52e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.46	-0.37	7.36e-13	Renal cell carcinoma;
LIHC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg16797656	chr11:68205561	LRP5	0.53	8.46	0.42	7.99e-16	Total body bone mineral density (age 0-15);
LIHC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.85	13.68	0.59	2.7200000000000002e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.58	9.48	0.46	4.31e-19	Resting heart rate;
LIHC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs832187	0.640	rs56293138	chr3:63888935	G/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.48	-6.83	-0.35	3.85e-11	Schizophrenia;
LIHC	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg00935119	chr6:36647544	CDKN1A	0.46	6.63	0.34	1.34e-10	QRS duration;
LIHC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.46	10.36	0.49	4.53e-22	Iron status biomarkers (transferrin levels);
LIHC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.73	6.42	0.33	4.6e-10	IgG glycosylation;
LIHC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.64	0.42	2.15e-16	Exhaled nitric oxide output;
LIHC	cis	rs3106136	0.678	rs11944941	chr4:95298169	C/T	cg11021082	chr4:95130006	SMARCAD1	0.36	6.13	0.31	2.4e-9	Capecitabine sensitivity;
LIHC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.68	12.07	0.55	3.36e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4906332	0.782	rs7161305	chr14:104002234	G/A	cg19000871	chr14:103996768	TRMT61A	-0.54	-8.44	-0.42	8.89e-16	Coronary artery disease;
LIHC	cis	rs3736485	0.934	rs8036609	chr15:51861426	C/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.6	-7.39	-0.37	1.1e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	17.45	0.69	3.33e-49	Lung cancer in ever smokers;
LIHC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg00280220	chr17:61926910	NA	0.44	7.15	0.36	5.34e-12	Prudent dietary pattern;
LIHC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.05	19.42	0.72	3.87e-57	Multiple system atrophy;
LIHC	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.43	-7.25	-0.36	2.81e-12	Squamous cell lung carcinoma;
LIHC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18867708	chr6:26865862	GUSBL1	0.55	8.29	0.41	2.54e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.48	7.85	0.39	5.23e-14	Methadone dose in opioid dependence;
LIHC	cis	rs4919087	0.748	rs701813	chr10:98975632	C/T	cg25902810	chr10:99078978	FRAT1	-0.54	-6.25	-0.32	1.22e-9	Monocyte count;
LIHC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg11812906	chr14:75593930	NEK9	-0.67	-11.67	-0.53	1.05e-26	Coronary artery disease;
LIHC	cis	rs922107	0.713	rs6702712	chr1:89947493	T/C	cg15422784	chr1:90023713	LRRC8B	0.46	7.26	0.37	2.62e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs11031096	0.505	rs10835743	chr11:4226692	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.5	-0.33	2.91e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg08997518	chr6:116601248	DSE;TSPYL1	0.44	6.32	0.32	7.99e-10	Positive affect;
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.56	8.97	0.44	2.04e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.13	-0.4	8.12e-15	Colorectal cancer;
LIHC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.42	-6.25	-0.32	1.24e-9	Iron status biomarkers;
LIHC	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	cis	rs3820500	0.543	rs2622362	chr1:118089166	T/G	cg20383390	chr1:117909022	MAN1A2	-0.46	-5.84	-0.3	1.2e-8	Pneumonia;
LIHC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.21	-0.36	3.53e-12	Migraine;Coronary artery disease;
LIHC	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg14092571	chr14:90743983	NA	-0.36	-5.76	-0.3	1.85e-8	Mortality in heart failure;
LIHC	cis	rs868943	0.582	rs34001069	chr6:116483014	T/C	cg08036074	chr6:116424633	NT5DC1	-0.62	-6.91	-0.35	2.32e-11	Total cholesterol levels;
LIHC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.66	0.5	4.09e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.58	-0.34	1.8e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs965469	0.779	rs6037581	chr20:3351595	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-6.27	-0.32	1.06e-9	IFN-related cytopenia;
LIHC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.47	6.83	0.35	3.78e-11	Body mass index;
LIHC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg27433088	chr4:174089019	GALNT7	0.4	7.31	0.37	1.87e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg14671364	chr1:107599128	PRMT6	0.48	6.99	0.35	1.45e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg05555928	chr11:63887634	MACROD1	0.47	6.13	0.31	2.41e-9	Mean platelet volume;
LIHC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg02527881	chr3:46936655	PTH1R	0.33	6.43	0.33	4.2e-10	Colorectal cancer;
LIHC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg16558253	chr16:72132732	DHX38	-0.51	-8.1	-0.4	9.86e-15	Fibrinogen levels;
LIHC	cis	rs3823572	0.526	rs2971967	chr7:133642595	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.81	-0.3	1.4e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.86	0.39	5.18e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg14393609	chr7:65229607	NA	0.41	6.87	0.35	3.13e-11	Calcium levels;
LIHC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.51	9.28	0.45	1.98e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg18305652	chr10:134549665	INPP5A	-0.39	-6.3	-0.32	9.2e-10	Migraine;
LIHC	cis	rs7432375	0.901	rs900818	chr3:136471815	C/T	cg21827317	chr3:136751795	NA	-0.44	-5.75	-0.3	2.01e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs1023500	1.000	rs1023498	chr22:42340569	C/T	cg04733989	chr22:42467013	NAGA	-0.5	-5.85	-0.3	1.17e-8	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18541421	chr13:111768813	ARHGEF7	0.5	6.95	0.35	1.88e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.24	-0.48	1.25e-21	Schizophrenia;
LIHC	trans	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.84	-0.35	3.64e-11	Aortic root size;
LIHC	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.38	-6.25	-0.32	1.22e-9	Corneal astigmatism;
LIHC	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.39	5.93	0.31	7.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.75	6.44	0.33	4.08e-10	Blood protein levels;
LIHC	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg20636351	chr8:55087400	NA	-0.37	-7.65	-0.38	2.13e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg24296786	chr1:45957014	TESK2	-0.5	-7.22	-0.36	3.42e-12	Platelet count;
LIHC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg16506815	chr2:162101123	NA	-0.41	-6.25	-0.32	1.21e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	2.97e-11	Renal cell carcinoma;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.47	-7.07	-0.36	8.88e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.45	5.74	0.3	2.1e-8	Mean platelet volume;
LIHC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.42	0.33	4.42e-10	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11353984	chr5:65439984	SFRS12	-0.41	-6.08	-0.31	3.23e-9	Pancreatic cancer;
LIHC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg17135325	chr3:160939158	NMD3	0.47	7.11	0.36	6.79e-12	Morning vs. evening chronotype;
LIHC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.5	7.6	0.38	2.89e-13	Alzheimer's disease (survival time);
LIHC	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg12698662	chr3:15914712	MIR563	-0.38	-7.01	-0.35	1.32e-11	Mean platelet volume;
LIHC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.38	6.95	0.35	1.8e-11	IgG glycosylation;
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.51	0.33	2.74e-10	Total body bone mineral density;
LIHC	cis	rs13217239	0.597	rs9467978	chr6:27024558	A/G	cg18867708	chr6:26865862	GUSBL1	-0.52	-7.79	-0.39	7.87e-14	Schizophrenia;
LIHC	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg19683494	chr5:74908142	NA	0.57	7.53	0.38	4.58e-13	Age-related disease endophenotypes;
LIHC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.33	7.36	0.37	1.42e-12	Ulcerative colitis;
LIHC	trans	rs6934970	0.932	rs10456881	chr6:113052347	G/A	cg09308777	chr6:169852575	NA	0.58	6.06	0.31	3.67e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.42	-0.37	9.12e-13	Metabolite levels;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.01	-0.31	4.63e-9	Longevity;
LIHC	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.02	0.35	1.22e-11	Bipolar disorder;
LIHC	cis	rs4453791	1.000	rs13094414	chr3:38930568	A/G	cg02254461	chr3:39195904	CSRNP1	0.67	6.01	0.31	4.89e-9	Social communication problems;
LIHC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.98	0.47	9.61e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.55	9.08	0.44	8.95e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4908768	0.871	rs4908508	chr1:8800780	T/C	cg20416874	chr1:8611966	RERE	0.48	6.63	0.34	1.3100000000000001e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.75	0.39	1.05e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg05527609	chr1:210001259	C1orf107	0.42	6.31	0.32	8.56e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.48	-7.97	-0.4	2.43e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.49	5.97	0.31	6.04e-9	Schizophrenia;
LIHC	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.7	-7.81	-0.39	7.21e-14	Exhaled nitric oxide output;
LIHC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.42	-6.54	-0.33	2.29e-10	Height;
LIHC	cis	rs903552	1.000	rs4965386	chr15:102003207	G/A	cg19295451	chr15:102010161	PCSK6	-0.45	-6.36	-0.32	6.65e-10	Diabetic kidney disease;
LIHC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.4	-5.72	-0.3	2.32e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10503871	1.000	rs10503871	chr8:30436852	A/G	cg26383811	chr8:30366931	RBPMS	-0.43	-7.53	-0.38	4.58e-13	Metabolite levels  (X-11787);
LIHC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.56	9.14	0.44	5.52e-18	Lymphocyte counts;
LIHC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.32	0.58	6.47e-33	Cognitive test performance;
LIHC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.6	-8.57	-0.42	3.56e-16	Blood metabolite levels;
LIHC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.6	-9.43	-0.45	6.39e-19	Breast cancer;
LIHC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.89	13.24	0.58	1.41e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.78	11.18	0.52	6.31e-25	Blood metabolite levels;
LIHC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg03013999	chr17:37608204	MED1	0.35	5.89	0.3	9.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.05	9.49	0.46	4.21e-19	Diabetic retinopathy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12492359	chr2:203242268	BMPR2	0.51	6.89	0.35	2.64e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	0.87	15.3	0.64	1.28e-40	Blood trace element (Cu levels);
LIHC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.91	-0.3	8.35e-9	Subjective well-being;
LIHC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg03859395	chr2:55845619	SMEK2	0.87	15.3	0.64	1.26e-40	Metabolic syndrome;
LIHC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.62	10.35	0.49	5.15e-22	Platelet count;
LIHC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg05555928	chr11:63887634	MACROD1	-0.52	-6.43	-0.33	4.25e-10	Body mass index;
LIHC	trans	rs7504990	0.754	rs1030594	chr18:50374030	T/C	cg08535148	chr4:26321143	RBPJ	0.57	7.12	0.36	6.5e-12	Gallbladder cancer;
LIHC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	19.25	0.72	1.76e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.21	0.32	1.57e-9	Cognitive ability;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.23	-0.32	1.38e-9	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.19	-0.32	1.7e-9	Total body bone mineral density;
LIHC	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.16	-0.36	5.13e-12	Metabolite levels;
LIHC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg12863693	chr15:85201151	NMB	0.48	6.87	0.35	3.13e-11	Schizophrenia;
LIHC	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg08345082	chr10:99160200	RRP12	-0.4	-6.6	-0.34	1.6e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.49e-10	Alzheimer's disease;
LIHC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg24296786	chr1:45957014	TESK2	0.49	7.15	0.36	5.36e-12	Platelet count;
LIHC	trans	rs12780046	0.656	rs5025590	chr10:100820860	C/T	cg05980083	chr9:112191166	PTPN3	-0.49	-6.27	-0.32	1.11e-9	Non-glioblastoma glioma;
LIHC	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-16.96	-0.68	3.02e-47	Schizophrenia;
LIHC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.81	0.39	7.29e-14	Triglyceride levels;
LIHC	cis	rs72843506	0.586	rs113833946	chr17:19858906	T/C	cg12065943	chr17:19881925	AKAP10	-0.4	-6.56	-0.33	2.02e-10	Schizophrenia;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg05185784	chr16:90016020	DEF8	-0.46	-5.93	-0.31	7.39e-9	Skin colour saturation;
LIHC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.84	-15.12	-0.63	6.77e-40	Height;
LIHC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.54	-8.0	-0.4	1.89e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.63	-0.34	1.32e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.55	9.19	0.45	3.87e-18	Prudent dietary pattern;
LIHC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	0.72	8.19	0.4	5.38e-15	Testicular germ cell tumor;
LIHC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.44	6.49	0.33	3.01e-10	Birth weight;
LIHC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	6.08	0.31	3.3e-9	Rheumatoid arthritis;
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.88	0.3	9.7e-9	Tonsillectomy;
LIHC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.51	6.46	0.33	3.68e-10	Menarche (age at onset);
LIHC	cis	rs12079745	0.793	rs12063863	chr1:169269557	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-7.11	-0.36	6.7e-12	QT interval;
LIHC	cis	rs9596863	1.000	rs9568940	chr13:54419251	C/A	ch.13.53330881F	chr13:54432880	NA	0.44	5.97	0.31	5.84e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg18016565	chr1:150552671	MCL1	0.54	10.05	0.48	5.25e-21	Melanoma;
LIHC	trans	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg25427524	chr10:38739819	LOC399744	0.39	6.29	0.32	9.75e-10	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.61	8.78	0.43	8.07e-17	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg18306943	chr3:40428807	ENTPD3	-0.34	-5.94	-0.31	7.1e-9	Renal cell carcinoma;
LIHC	cis	rs9309473	0.861	rs6546857	chr2:73837955	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.48	-0.33	3.17e-10	Metabolite levels;
LIHC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04004882	chr2:215674386	BARD1	-0.59	-8.49	-0.42	6.61e-16	Neuroblastoma;
LIHC	trans	rs11157436	0.918	rs1983518	chr14:22617290	A/T	cg13567813	chr19:50879636	NR1H2	0.43	6.31	0.32	8.75e-10	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.55	-16.34	-0.66	8.8e-45	Breast cancer;
LIHC	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.46	-6.84	-0.35	3.68e-11	Blood protein levels;
LIHC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.55	-11.0	-0.51	2.76e-24	Urate levels;
LIHC	trans	rs4596713	0.507	rs10217120	chr9:71794919	A/G	cg16512924	chr15:28394682	HERC2	0.38	6.17	0.32	1.92e-9	Headache;
LIHC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg08132940	chr7:1081526	C7orf50	-0.74	-6.33	-0.32	7.56e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.55	-13.52	-0.59	1.17e-33	White blood cell count (basophil);
LIHC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.74	-7.1	-0.36	7.45e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.79	0.3	1.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.94	18.73	0.71	2.27e-54	Height;
LIHC	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg10820045	chr2:198174542	NA	0.49	7.78	0.39	8.43e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.68	0.57	1.87e-30	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.35	0.45	1.21e-18	Hemoglobin concentration;
LIHC	trans	rs859980	0.514	rs9386402	chr6:104519786	C/T	cg22481606	chr17:56429567	SUPT4H1	0.43	6.6	0.34	1.52e-10	Tourette's syndrome or obsessive-compulsive disorder;
LIHC	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.76	11.69	0.53	8.69e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg16970926	chr12:29381810	FAR2	0.27	5.75	0.3	1.94e-8	QT interval;
LIHC	cis	rs1144333	0.655	rs76794487	chr1:76384055	G/A	cg22875332	chr1:76189707	ACADM	0.41	6.16	0.32	2.05e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.66	0.46	1.08e-19	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.64	8.78	0.43	7.74e-17	Skin colour saturation;
LIHC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.47	7.01	0.35	1.25e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.56	6.8	0.35	4.63e-11	Coronary artery disease;
LIHC	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg00792783	chr2:198669748	PLCL1	0.42	5.99	0.31	5.18e-9	Dermatomyositis;
LIHC	cis	rs365132	0.715	rs181330	chr5:176404962	A/G	cg16309518	chr5:176445507	NA	-0.53	-9.96	-0.47	1.06e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.38	-6.06	-0.31	3.5e-9	Menarche (age at onset);
LIHC	cis	rs61712019	0.679	rs11126610	chr2:77714036	C/G	cg11252801	chr2:77748917	LRRTM4	0.55	7.61	0.38	2.76e-13	Schizophrenia;
LIHC	cis	rs712039	0.617	rs853201	chr17:35804187	C/A	cg16670864	chr17:35848621	DUSP14	0.34	5.73	0.3	2.21e-8	Tuberculosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12191964	chr2:43823338	THADA	-0.42	-6.37	-0.33	6.06e-10	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08779779	chr2:200322566	SATB2	-0.45	-6.24	-0.32	1.27e-9	Pancreatic cancer;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.76	0.39	1e-13	Prudent dietary pattern;
LIHC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.73	-12.41	-0.56	1.96e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.34	6.6	0.34	1.6e-10	Multiple system atrophy;
LIHC	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	0.72	8.44	0.42	9.1e-16	Dental caries;
LIHC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg18512352	chr11:47633146	NA	-0.25	-5.78	-0.3	1.71e-8	Subjective well-being;
LIHC	cis	rs74544699	1.000	rs585778	chr4:74779005	G/T	cg02530824	chr4:74847766	PF4	0.54	6.2	0.32	1.66e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.45	-8.05	-0.4	1.36e-14	Colorectal cancer;
LIHC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg00204512	chr16:28754710	NA	0.35	6.42	0.33	4.5e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-8.32	-0.41	2.14e-15	Vitiligo;
LIHC	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.42	5.83	0.3	1.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.59	10.81	0.5	1.25e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.52	9.22	0.45	3.21e-18	Total body bone mineral density;
LIHC	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.39	9.53	0.46	2.97e-19	Blood metabolite ratios;
LIHC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.52	-7.28	-0.37	2.27e-12	Body mass index;
LIHC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.89	-0.35	2.67e-11	Body mass index;
LIHC	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.75	10.91	0.51	5.57e-24	Response to antineoplastic agents;
LIHC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.71	-0.71	2.82e-54	Height;
LIHC	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.36	0.33	6.38e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	7.84	0.39	5.92e-14	Monocyte percentage of white cells;
LIHC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.52	-0.42	5.1e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12702595	1.000	rs12702595	chr7:7259270	C/A	cg04827551	chr7:7268805	C1GALT1	0.36	6.6	0.34	1.61e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.78	-0.67	1.55e-46	Ulcerative colitis;
LIHC	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.73	11.66	0.53	1.11e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.44	-7.87	-0.39	4.64e-14	Coronary artery disease;
LIHC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.42	0.66	4.33e-45	Smoking behavior;
LIHC	cis	rs7523273	0.626	rs2466572	chr1:207934487	A/C	cg22525895	chr1:207977042	MIR29B2	0.64	7.42	0.37	9.11e-13	Schizophrenia;
LIHC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-13.09	-0.58	5.11e-32	Colorectal cancer;
LIHC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.34	-5.97	-0.31	6.05e-9	IgG glycosylation;
LIHC	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.58	-8.62	-0.42	2.46e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.57e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.21	5.72	0.3	2.34e-8	Rheumatoid arthritis;
LIHC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.82	0.65	1.11e-42	White blood cell count;
LIHC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.48e-11	IgG glycosylation;
LIHC	trans	rs56341938	0.757	rs1420465	chr3:168715138	C/G	cg03582793	chr3:141162020	ZBTB38	-0.26	-6.34	-0.32	7.32e-10	Lung function (FEV1/FVC);
LIHC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.8	9.89	0.47	1.85e-20	Morning vs. evening chronotype;
LIHC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.46	6.19	0.32	1.77e-9	Major depressive disorder;
LIHC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.66	10.66	0.5	4.2e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.71	-0.3	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.16	17.26	0.68	1.87e-48	Corneal structure;
LIHC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20135002	chr11:47629003	NA	-0.56	-9.7	-0.46	8.06e-20	Subjective well-being;
LIHC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	0.94	15.95	0.65	3.43e-43	Testicular germ cell tumor;
LIHC	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.42	-0.37	9.23e-13	Adiposity;
LIHC	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.54	6.88	0.35	2.9100000000000002e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-7.78	-0.39	8.38e-14	Cognitive function;
LIHC	cis	rs36051895	0.659	rs72699590	chr9:5041690	C/G	cg02405213	chr9:5042618	JAK2	-0.72	-12.59	-0.56	4.13e-30	Pediatric autoimmune diseases;
LIHC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-11.07	-0.51	1.46e-24	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.12	0.31	2.5e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.73	-9.13	-0.44	6.31e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg24296786	chr1:45957014	TESK2	-0.5	-7.48	-0.38	6.21e-13	Platelet count;
LIHC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.23e-16	Motion sickness;
LIHC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	5.94	0.31	7.07e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs8117834	0.574	rs1079777	chr20:8084404	C/T	cg00593689	chr4:53575888	NA	0.38	6.54	0.33	2.22e-10	Chronic kidney disease;
LIHC	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	19.76	0.73	1.68e-58	Colorectal cancer;
LIHC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.44	7.64	0.38	2.25e-13	Schizophrenia;
LIHC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.72	-0.34	7.71e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.51	-7.19	-0.36	4.11e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg11764359	chr7:65958608	NA	0.58	6.01	0.31	4.64e-9	Diabetic kidney disease;
LIHC	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg09035930	chr12:129282057	SLC15A4	-0.48	-5.86	-0.3	1.11e-8	Systemic lupus erythematosus;
LIHC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.59	0.56	4.07e-30	Electrocardiographic conduction measures;
LIHC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.59	10.39	0.49	3.68e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs738321	0.690	rs11570750	chr22:38513138	G/A	cg25457927	chr22:38595422	NA	-0.29	-6.46	-0.33	3.53e-10	Breast cancer;
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg12903224	chr12:29470962	FAR2	-0.37	-5.96	-0.31	6.28e-9	QT interval;
LIHC	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg03934865	chr2:198174659	NA	0.45	6.97	0.35	1.65e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	11.84	0.54	2.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.85	13.54	0.59	1.01e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.6	-0.34	1.54e-10	Metabolite levels (Pyroglutamine);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg07614371	chr15:38746870	FAM98B	-0.42	-6.29	-0.32	9.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg10360323	chr17:41437877	NA	0.4	5.98	0.31	5.76e-9	Menopause (age at onset);
LIHC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.21	0.41	4.57e-15	Bladder cancer;
LIHC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	3.96e-13	Electroencephalogram traits;
LIHC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg10360323	chr17:41437877	NA	0.39	5.75	0.3	1.98e-8	Menopause (age at onset);
LIHC	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.56	8.64	0.42	2.2e-16	Corneal astigmatism;
LIHC	cis	rs10508774	1.000	rs72795564	chr10:32888300	T/A	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.54	-7.61	-0.38	2.76e-13	Multiple sclerosis;
LIHC	cis	rs4294134	0.832	rs11768962	chr7:135254692	C/T	cg20392616	chr7:135392013	SLC13A4	-0.37	-5.88	-0.3	9.51e-9	Paget's disease;
LIHC	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.21	0.32	1.49e-9	Protein biomarker;
LIHC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg20933634	chr6:27740509	NA	0.45	5.85	0.3	1.15e-8	Parkinson's disease;
LIHC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.74	0.34	6.77e-11	Ileal carcinoids;
LIHC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.45	-7.3	-0.37	2e-12	Corneal astigmatism;
LIHC	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.57	-13.93	-0.6	2.98e-35	White blood cell count (basophil);
LIHC	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.37	2.22e-12	Migraine;Coronary artery disease;
LIHC	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.76	10.87	0.51	7.95e-24	Response to hepatitis C treatment;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg05552183	chr6:42928497	GNMT	0.83	12.16	0.55	1.59e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs16958440	0.867	rs28578518	chr18:44687548	A/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-8.25	-0.41	3.39e-15	Waist circumference;Body mass index;
LIHC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06026331	chr20:60912101	LAMA5	0.41	5.98	0.31	5.65e-9	Colorectal cancer;
LIHC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-11.66	-0.53	1.12e-26	Urate levels in overweight individuals;
LIHC	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.66	10.7	0.5	3.06e-23	Schizophrenia;
LIHC	cis	rs4788570	0.667	rs9302630	chr16:71789529	A/C	cg06353428	chr16:71660113	MARVELD3	1.38	14.61	0.62	6.7e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.45	0.42	8.25e-16	Schizophrenia;
LIHC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.42	-6.65	-0.34	1.19e-10	Dental caries;
LIHC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.74e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg12064134	chr16:90016061	DEF8	-0.43	-5.89	-0.3	9.2e-9	Skin colour saturation;
LIHC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.51	-7.43	-0.37	8.88e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-6.63	-0.34	1.29e-10	Acne (severe);
LIHC	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg10820045	chr2:198174542	NA	-0.47	-7.2	-0.36	3.92e-12	Dermatomyositis;
LIHC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs922107	0.967	rs922105	chr1:90025657	C/T	cg15422784	chr1:90023713	LRRC8B	0.5	8.07	0.4	1.24e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg16070123	chr10:51489643	NA	-0.38	-6.03	-0.31	4.34e-9	Prostate-specific antigen levels;
LIHC	cis	rs7589728	0.688	rs76734941	chr2:88530454	T/C	cg04511125	chr2:88470314	THNSL2	0.79	6.89	0.35	2.76e-11	Plasma clusterin levels;
LIHC	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.48	-0.46	4.39e-19	Colorectal cancer;
LIHC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg01256987	chr12:42539512	GXYLT1	-0.36	-5.96	-0.31	6.23e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg04013166	chr16:89971882	TCF25	0.61	7.92	0.39	3.34e-14	Skin colour saturation;
LIHC	cis	rs716804	0.740	rs55933041	chr11:10263554	C/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.12e-8	Neuroticism;
LIHC	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.46	-0.33	3.62e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg10360323	chr17:41437877	NA	0.4	5.96	0.31	6.4e-9	Menopause (age at onset);
LIHC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-13.98	-0.6	1.99e-35	Systemic lupus erythematosus;
LIHC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg16145915	chr7:1198662	ZFAND2A	0.3	5.91	0.3	8.05e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg22633049	chr21:46681294	NA	-0.36	-6.14	-0.32	2.31e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.46	-7.47	-0.37	6.88e-13	Menarche (age at onset);
LIHC	trans	rs6934970	1.000	rs12201997	chr6:113098589	C/T	cg09308777	chr6:169852575	NA	0.62	6.16	0.32	2.08e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg03037974	chr15:76606532	NA	0.72	13.93	0.6	2.96e-35	Blood metabolite levels;
LIHC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.72	-0.43	1.26e-16	Gut microbiome composition (summer);
LIHC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg03037974	chr15:76606532	NA	-0.59	-10.13	-0.48	2.91e-21	Blood metabolite levels;
LIHC	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.79	0.43	7.58e-17	Exhaled nitric oxide levels;
LIHC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.67	11.37	0.52	1.29e-25	Lymphocyte counts;
LIHC	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg08992911	chr2:238395768	MLPH	0.49	5.96	0.31	6.24e-9	Prostate cancer;
LIHC	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.34	-0.37	1.53e-12	Tuberculosis;
LIHC	trans	rs10411161	0.702	rs8113685	chr19:52383890	C/T	cg22319618	chr22:45562946	NUP50	-0.6	-8.17	-0.4	6.12e-15	Breast cancer;
LIHC	cis	rs9918079	0.560	rs4557256	chr4:15626647	A/C	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.84	-0.3	1.21e-8	Obesity-related traits;
LIHC	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.54	-0.42	4.44e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg14343924	chr8:8086146	FLJ10661	-0.45	-5.77	-0.3	1.8e-8	Mood instability;
LIHC	trans	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg01596870	chr19:55963115	NA	-0.61	-7.22	-0.36	3.5e-12	Obesity-related traits;
LIHC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg19635926	chr16:89946313	TCF25	0.51	6.5	0.33	2.78e-10	Skin colour saturation;
LIHC	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.34	-6.29	-0.32	9.69e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	7.52	0.38	4.81e-13	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15087520	chr3:187871600	LPP	0.43	6.05	0.31	3.87e-9	Pancreatic cancer;
LIHC	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04530015	chr2:215796436	ABCA12	0.46	7.7	0.38	1.51e-13	Neuroblastoma;
LIHC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg16586182	chr3:47516702	SCAP	-0.52	-9.52	-0.46	3.26e-19	Colorectal cancer;
LIHC	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg00204748	chr12:29376779	FAR2	0.37	6.91	0.35	2.36e-11	QT interval;
LIHC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg15534755	chr11:117069859	TAGLN	0.39	6.67	0.34	1e-10	Blood protein levels;
LIHC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.79	-12.03	-0.55	4.69e-28	Coronary artery disease;
LIHC	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.29	-6.08	-0.31	3.18e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.38	6.39	0.33	5.42e-10	IgG glycosylation;
LIHC	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.61	6.15	0.32	2.15e-9	Type 2 diabetes;
LIHC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.5	7.19	0.36	4.15e-12	Obesity-related traits;
LIHC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.78	-0.43	8.15e-17	Monocyte count;
LIHC	cis	rs918629	0.567	rs2270554	chr5:95246134	G/T	cg10483112	chr5:95245456	ELL2	0.37	6.98	0.35	1.52e-11	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.07	0.55	3.41e-28	Motion sickness;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg00035636	chr13:21900591	NA	0.38	6.53	0.33	2.33e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.88	20.03	0.73	1.35e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg02297831	chr4:17616191	MED28	0.42	6.81	0.35	4.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.16	0.32	2.03e-9	Schizophrenia;
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.39	-0.33	5.42e-10	Schizophrenia;
LIHC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.43	5.94	0.31	6.99e-9	Uric acid clearance;
LIHC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.47	-7.81	-0.39	7e-14	Menarche (age at onset);
LIHC	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.65	8.07	0.4	1.18e-14	Bipolar disorder;
LIHC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.48	7.37	0.37	1.27e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.1	-0.78	8.79e-72	Height;
LIHC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	10.05	0.48	5.63e-21	Menarche (age at onset);
LIHC	trans	rs9641123	0.639	rs2528542	chr7:93266368	T/C	cg09745688	chr16:2908918	PRSS22	-0.37	-6.52	-0.33	2.58e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg12560992	chr17:57184187	TRIM37	0.69	8.91	0.43	3.17e-17	Vitamin D levels;
LIHC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.15	0.36	5.37e-12	Axial length;
LIHC	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg02023728	chr11:77925099	USP35	-0.33	-5.84	-0.3	1.2e-8	Alzheimer's disease (survival time);
LIHC	cis	rs57920188	0.535	rs4295855	chr1:4094993	C/T	cg20703997	chr1:4087676	NA	0.55	6.47	0.33	3.46e-10	Interleukin-17 levels;
LIHC	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg03146154	chr1:46216737	IPP	-0.37	-6.17	-0.32	1.96e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25437947	chr8:17941982	ASAH1	0.45	6.2	0.32	1.59e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.87	15.88	0.65	6.07e-43	Dental caries;
LIHC	cis	rs3823572	0.542	rs62470445	chr7:133630961	T/C	cg03336402	chr7:133662267	EXOC4	0.47	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.7	-10.19	-0.48	1.77e-21	Mosquito bite size;
LIHC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.76	0.65	1.97e-42	Electrocardiographic conduction measures;
LIHC	trans	rs4714291	0.832	rs2984431	chr6:39980900	T/A	cg02267698	chr19:7991119	CTXN1	-0.39	-6.51	-0.33	2.68e-10	Strep throat;
LIHC	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.83	0.3	1.32e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg14440974	chr22:39074834	NA	-0.46	-7.35	-0.37	1.52e-12	Menopause (age at onset);
LIHC	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.65	6.82	0.35	4.18e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.48	7.71	0.39	1.34e-13	Blood protein levels;
LIHC	cis	rs6060717	0.610	rs2794383	chr20:34615152	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.99	-0.4	2.14e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.24e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8072100	0.905	rs8078686	chr17:45735706	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	6.23	0.32	1.36e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.43	6.49	0.33	2.93e-10	Heart rate;
LIHC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.75	11.16	0.52	7.39e-25	Corneal astigmatism;
LIHC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.58	-0.34	1.76e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg05110241	chr16:68378359	PRMT7	-0.63	-6.85	-0.35	3.34e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11031096	0.655	rs1372806	chr11:4212308	C/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.91	-0.3	8.4e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg26677602	chr1:167035992	GPA33	0.43	6.77	0.34	5.61e-11	Calcium levels;
LIHC	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-16.42	-0.66	4.18e-45	Schizophrenia;
LIHC	cis	rs9443189	1.000	rs3822957	chr6:76607280	A/G	cg01950844	chr6:76311363	SENP6	-0.49	-6.23	-0.32	1.4e-9	Prostate cancer;
LIHC	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg10483660	chr13:112241077	NA	-0.22	-5.97	-0.31	5.95e-9	Hepatitis;
LIHC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-5.86	-0.3	1.09e-8	Breast cancer;
LIHC	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.03	-0.44	1.26e-17	Schizophrenia;
LIHC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.27e-19	Initial pursuit acceleration;
LIHC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.02	-14.24	-0.61	1.8e-36	Ulcerative colitis;
LIHC	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg15123519	chr2:136567270	LCT	-0.37	-5.75	-0.3	1.98e-8	Corneal structure;
LIHC	cis	rs2834188	1.000	rs13050445	chr21:34703597	C/T	cg14352951	chr21:34696688	IFNAR1	-0.51	-6.73	-0.34	7.03e-11	Narcolepsy;
LIHC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.35	6.45	0.33	3.83e-10	Aortic root size;
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg16970926	chr12:29381810	FAR2	0.28	5.94	0.31	6.84e-9	QT interval;
LIHC	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg16684958	chr7:75615977	POR	0.47	7.84	0.39	5.69e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg23422044	chr7:1970798	MAD1L1	-0.52	-5.8	-0.3	1.48e-8	Bipolar disorder;
LIHC	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs8067354	0.540	rs12600680	chr17:58037374	T/C	cg13753209	chr17:57696993	CLTC	0.71	10.58	0.5	8.01e-23	Hemoglobin concentration;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.65	9.69	0.46	8.67e-20	Menarche (age at onset);
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.62	-10.33	-0.49	5.78e-22	Glycated hemoglobin levels;
LIHC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-8.65	-0.42	2.09e-16	Skin colour saturation;
LIHC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.5	0.53	4.37e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg04155231	chr12:9217510	LOC144571	0.31	5.75	0.3	1.99e-8	Sjögren's syndrome;
LIHC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	7.75	0.39	1.03e-13	Schizophrenia;
LIHC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.43	6.37	0.33	6.12e-10	Obesity-related traits;
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg00612595	chr21:47717864	NA	-0.36	-5.93	-0.31	7.48e-9	Testicular germ cell tumor;
LIHC	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.42e-11	Dermatomyositis;
LIHC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.16	0.36	5.12e-12	Axial length;
LIHC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.59	10.08	0.48	4.29e-21	Platelet distribution width;
LIHC	cis	rs35955747	0.869	rs7286648	chr22:31539614	A/T	cg22777020	chr22:31556080	RNF185	0.53	6.32	0.32	8.03e-10	Neutrophil count;Sum basophil neutrophil counts;
LIHC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.96	0.35	1.71e-11	Body mass index;
LIHC	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg09795085	chr6:101329169	ASCC3	0.5	6.75	0.34	6.2e-11	Neuroticism;
LIHC	cis	rs62179067	0.708	rs11885227	chr2:179935847	G/A	cg07532576	chr2:179544947	TTN	0.61	5.8	0.3	1.49e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.42e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-7.49	-0.38	6.06e-13	Cognitive test performance;
LIHC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.64	10.95	0.51	4.12e-24	Colorectal cancer;
LIHC	cis	rs34245846	0.704	rs11264280	chr1:154862952	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.87	12.54	0.56	6.33e-30	Atrial fibrillation;
LIHC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	0.61	6.14	0.32	2.29e-9	Obesity-related traits;
LIHC	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.57	0.33	1.85e-10	Resting heart rate;
LIHC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-10.14	-0.48	2.72e-21	Body mass index;
LIHC	cis	rs3823572	0.564	rs2346274	chr7:133660841	G/A	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	1.05	13.93	0.6	2.88e-35	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17106184	1.000	rs57183177	chr1:51379945	A/G	cg07174182	chr1:51127561	FAF1	-0.77	-7.84	-0.39	5.73e-14	Type 2 diabetes;
LIHC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.64	13.1	0.58	4.87e-32	Airflow obstruction;
LIHC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.1	-0.44	7.75e-18	Alzheimer's disease;
LIHC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02985541	chr2:219472218	PLCD4	-0.43	-7.22	-0.36	3.44e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.66	7.07	0.36	8.62e-12	Exhaled nitric oxide output;
LIHC	cis	rs4699052	0.893	rs4699058	chr4:104171321	T/A	cg16532752	chr4:104119610	CENPE	-0.39	-6.14	-0.32	2.23e-9	Testicular germ cell tumor;
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06420487	chr17:61919686	SMARCD2	0.44	5.88	0.3	9.71e-9	Height;
LIHC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.66	0.46	1.13e-19	Bipolar disorder;
LIHC	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg14828511	chr1:107599125	PRMT6	-0.44	-6.25	-0.32	1.2e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg07636037	chr3:49044803	WDR6	-0.86	-7.19	-0.36	4.01e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg05697976	chr12:29376483	FAR2	0.34	6.91	0.35	2.39e-11	QT interval;
LIHC	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.02	0.44	1.38e-17	Platelet count;
LIHC	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.45	6.59	0.34	1.63e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs10503871	0.526	rs67817462	chr8:30483031	C/T	cg26383811	chr8:30366931	RBPMS	0.43	6.91	0.35	2.43e-11	Metabolite levels  (X-11787);
LIHC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.87	0.3	1.05e-8	Tonsillectomy;
LIHC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.12	0.68	6.77e-48	Gut microbiome composition (summer);
LIHC	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg16275483	chr1:110013120	SYPL2	-0.49	-6.18	-0.32	1.8e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg02269571	chr22:50332266	NA	-0.48	-6.93	-0.35	2.12e-11	Schizophrenia;
LIHC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.72	8.23	0.41	3.95e-15	Testicular germ cell tumor;
LIHC	cis	rs6782228	0.585	rs6774515	chr3:128415878	C/T	cg16766828	chr3:128327626	NA	-0.38	-6.01	-0.31	4.71e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.77	-0.5	1.68e-23	Platelet count;
LIHC	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg21734168	chr11:67353974	GSTP1	-0.26	-6.39	-0.33	5.56e-10	Mean corpuscular volume;
LIHC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-6.92	-0.35	2.22e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg15123519	chr2:136567270	LCT	-0.38	-6.14	-0.32	2.25e-9	Corneal structure;
LIHC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.91	0.3	8.37e-9	Obesity-related traits;
LIHC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.6	-0.5	7.13e-23	Response to antipsychotic treatment;
LIHC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	14.71	0.62	2.66e-38	Menopause (age at onset);
LIHC	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	0.74	8.19	0.4	5.33e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg05697976	chr12:29376483	FAR2	0.31	6.38	0.33	5.76e-10	QT interval;
LIHC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	0.87	13.62	0.59	4.87e-34	Testicular germ cell tumor;
LIHC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg14222432	chr12:29376421	FAR2	0.36	6.93	0.35	2.16e-11	QT interval;
LIHC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-8.13	-0.4	8.1e-15	Longevity;Endometriosis;
LIHC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg27478167	chr7:817139	HEATR2	-0.41	-5.91	-0.3	8.35e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg07706471	chr12:123319906	HIP1R	-0.63	-8.28	-0.41	2.88e-15	Schizophrenia;
LIHC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.2	5.73	0.3	2.15e-8	Calcium levels;
LIHC	cis	rs1434579	0.865	rs12983645	chr19:44943239	A/G	cg15540054	chr19:45004280	ZNF180	0.57	7.91	0.39	3.48e-14	Tuberculosis;
LIHC	cis	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg03999872	chr20:62272968	STMN3	0.43	6.33	0.32	7.48e-10	Atopic dermatitis;
LIHC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-6.98	-0.35	1.53e-11	Diabetic kidney disease;
LIHC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10838687	0.800	rs4752977	chr11:47300429	T/C	cg26139080	chr11:47293733	MADD	-0.41	-5.76	-0.3	1.87e-8	Proinsulin levels;
LIHC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.39	5.9	0.3	8.77e-9	Height;
LIHC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.66	0.5	4.38e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.34	0.37	1.56e-12	Bone mineral density;
LIHC	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.55	5.86	0.3	1.08e-8	IgG glycosylation;
LIHC	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.07	0.31	3.38e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.52	-9.25	-0.45	2.51e-18	Colorectal cancer;
LIHC	trans	rs75804782	0.521	rs55713398	chr2:239419933	A/G	cg01134436	chr17:81009848	B3GNTL1	0.76	6.53	0.33	2.37e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.33	0.32	7.58e-10	Platelet count;
LIHC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	1.01	11.73	0.54	6.26e-27	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-12.17	-0.55	1.5e-28	Alzheimer's disease (late onset);
LIHC	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg14393609	chr7:65229607	NA	-0.43	-6.4	-0.33	5.1e-10	Calcium levels;
LIHC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.33	6.37	0.33	5.93e-10	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.58	8.19	0.4	5.41e-15	Motion sickness;
LIHC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg21466736	chr12:48725269	NA	0.63	9.2	0.45	3.67e-18	Glycated hemoglobin levels;
LIHC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.39	7.61	0.38	2.68e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg11693508	chr17:37793320	STARD3	-0.7	-7.56	-0.38	3.84e-13	Bipolar disorder;
LIHC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.97	-0.31	5.91e-9	Mean corpuscular volume;
LIHC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.69	-6.46	-0.33	3.5e-10	Red cell distribution width;
LIHC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs7208859	0.673	rs57432042	chr17:29241038	T/C	cg14067834	chr17:29058358	SUZ12P	0.67	6.39	0.33	5.57e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.47	7.13	0.36	5.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.6	0.46	1.76e-19	Bipolar disorder;
LIHC	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg18289306	chr13:113640169	MCF2L	0.42	6.49	0.33	3.02e-10	Systolic blood pressure;
LIHC	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02228675	chr17:40259724	DHX58	-0.25	-5.8	-0.3	1.5e-8	Fibrinogen levels;
LIHC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.43	-6.29	-0.32	9.72e-10	Schizophrenia;
LIHC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.52	0.42	5.17e-16	Lung cancer in ever smokers;
LIHC	cis	rs238295	0.805	rs1983694	chr20:5574134	T/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-7.02	-0.35	1.22e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs2257205	0.600	rs8071081	chr17:56709055	T/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.5	-0.33	2.86e-10	Pancreatic cancer;
LIHC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18867708	chr6:26865862	GUSBL1	0.54	8.16	0.4	6.42e-15	Schizophrenia;
LIHC	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.51	-6.8	-0.35	4.66e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	7.0	0.35	1.32e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg11632617	chr15:75315747	PPCDC	-0.48	-6.79	-0.34	4.94e-11	Blood trace element (Zn levels);
LIHC	trans	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg10756647	chr7:56101905	PSPH	-1.03	-12.6	-0.56	3.61e-30	Diabetic kidney disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07097722	chr20:43247325	PKIG	0.38	6.29	0.32	9.87e-10	Longevity;
LIHC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.81e-9	Blood metabolite levels;
LIHC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	0.77	10.52	0.49	1.35e-22	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.92	-0.39	3.33e-14	Coronary artery disease;
LIHC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-10.72	-0.5	2.64e-23	Obesity-related traits;
LIHC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.08	-8.06	-0.4	1.26e-14	Body mass index;
LIHC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.56	7.48	0.38	6.18e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.49	-7.74	-0.39	1.16e-13	Schizophrenia;
LIHC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-8.35	-0.41	1.73e-15	Schizophrenia;
LIHC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg12193833	chr17:30244370	NA	-0.53	-6.1	-0.31	2.94e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg09911534	chr15:67153556	NA	-0.49	-5.98	-0.31	5.72e-9	Lung cancer (smoking interaction);
LIHC	cis	rs2292096	1.000	rs34596352	chr1:200785330	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-5.87	-0.3	1.02e-8	Epilepsy;
LIHC	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08052428	chr9:135996421	RALGDS	0.47	7.44	0.37	8.16e-13	Pancreatic cancer;
LIHC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.75	0.5	2.1e-23	Bladder cancer;
LIHC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.64	9.82	0.47	3.19e-20	Longevity;
LIHC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.35	7.86	0.39	5.17e-14	Crohn's disease;
LIHC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg12365402	chr11:9010492	NRIP3	0.29	7.4	0.37	1.07e-12	Hemoglobin concentration;
LIHC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.57	11.02	0.51	2.3e-24	Coronary artery disease;
LIHC	cis	rs17152411	0.652	rs7070792	chr10:126611155	G/A	cg07906193	chr10:126599966	NA	-0.29	-5.74	-0.3	2.05e-8	Height;
LIHC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.54	-7.37	-0.37	1.27e-12	Lung cancer in ever smokers;
LIHC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg12903224	chr12:29470962	FAR2	-0.41	-6.66	-0.34	1.12e-10	QT interval;
LIHC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.5	7.45	0.37	7.79e-13	Lymphocyte counts;
LIHC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs12144094	0.832	rs6683122	chr1:120242179	G/T	cg20995928	chr1:120229863	NA	0.42	7.13	0.36	5.88e-12	Height;
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg08358671	chr1:185286807	IVNS1ABP	-0.6	-6.69	-0.34	9.08e-11	Bronchial neuroendocrine tumor;
LIHC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.52	-9.53	-0.46	3.11e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs4800452	0.956	rs4308051	chr18:20735461	T/G	cg26136497	chr18:20735537	CABLES1	-0.44	-5.84	-0.3	1.22e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12079745	0.793	rs12076519	chr1:169283540	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-6.91	-0.35	2.36e-11	QT interval;
LIHC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.04	-0.58	8.18e-32	Vitiligo;
LIHC	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.42	6.4	0.33	5e-10	Red blood cell count;Reticulocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25365794	chr17:8022404	ALOXE3	0.52	7.27	0.37	2.47e-12	Pancreatic cancer;
LIHC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg14078730	chr11:63896557	MACROD1	0.33	6.11	0.31	2.75e-9	Platelet count;
LIHC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.73	-9.94	-0.47	1.24e-20	Monocyte percentage of white cells;
LIHC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.89	12.0	0.54	6.2e-28	Blood metabolite levels;
LIHC	cis	rs17106184	0.892	rs3789581	chr1:51019450	T/C	cg07174182	chr1:51127561	FAF1	-0.66	-7.07	-0.36	8.68e-12	Type 2 diabetes;
LIHC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.97	16.16	0.66	4.83e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.65	12.08	0.55	3.09e-28	Gestational age at birth (maternal effect);
LIHC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.61	6.88	0.35	2.89e-11	Menarche (age at onset);
LIHC	cis	rs12744310	0.943	rs35502198	chr1:41768541	T/G	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.6	7.32	0.37	1.82e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg03934865	chr2:198174659	NA	0.45	6.53	0.33	2.35e-10	Dermatomyositis;
LIHC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-10.86	-0.51	8.3e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg11764359	chr7:65958608	NA	0.6	6.38	0.33	5.71e-10	Diabetic kidney disease;
LIHC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.96	20.74	0.75	1.88e-62	Blood protein levels;
LIHC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg00204748	chr12:29376779	FAR2	-0.4	-7.31	-0.37	1.87e-12	QT interval;
LIHC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-12.09	-0.55	2.99e-28	Height;
LIHC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.71	-0.38	1.37e-13	Gut microbiome composition (summer);
LIHC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.72	11.74	0.54	5.62e-27	Body mass index;
LIHC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg13872831	chr3:50377988	RASSF1	0.26	6.5	0.33	2.91e-10	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.45	-6.26	-0.32	1.12e-9	Resting heart rate;
LIHC	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.93	0.31	7.49e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-7.24	-0.36	2.95e-12	Insulin-like growth factors;
LIHC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.41	6.68	0.34	9.85e-11	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.69	12.1	0.55	2.64e-28	Colorectal cancer;
LIHC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.22	0.32	1.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.88	0.39	4.43e-14	Lung cancer;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.57	0.76	9.39e-66	Prudent dietary pattern;
LIHC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.6	10.08	0.48	4.41e-21	Height;
LIHC	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.86	18.09	0.7	8.49e-52	Longevity;
LIHC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	8.49	0.42	6.46e-16	HIV-1 control;
LIHC	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.44	-8.12	-0.4	8.51e-15	Vitamin D levels;
LIHC	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.54	-0.69	1.36e-49	Schizophrenia;
LIHC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg08694578	chr2:241835147	C2orf54	-0.51	-8.02	-0.4	1.67e-14	Urinary metabolites;
LIHC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.81	0.54	3.03e-27	Cognitive test performance;
LIHC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.59	-6.61	-0.34	1.5e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg06115741	chr20:33292138	TP53INP2	0.5	5.72	0.3	2.34e-8	Protein C levels;
LIHC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.65	-9.8	-0.47	3.72e-20	Mosquito bite size;
LIHC	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.13	-10.41	-0.49	3.17e-22	Schizophrenia;
LIHC	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.42	5.76	0.3	1.92e-8	Tuberculosis;
LIHC	trans	rs13309098	0.793	rs17092951	chr7:48789477	A/T	cg01806741	chr6:1527072	NA	0.55	6.1	0.31	2.86e-9	QT interval (ambient particulate matter interaction);
LIHC	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg18678763	chr11:4115507	RRM1	0.47	6.5	0.33	2.81e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg05564831	chr3:52568323	NT5DC2	0.38	6.15	0.32	2.19e-9	Bipolar disorder;
LIHC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg11861562	chr11:117069780	TAGLN	0.5	8.2	0.41	5.05e-15	Blood protein levels;
LIHC	cis	rs600806	0.778	rs4970766	chr1:110013955	A/G	cg08911820	chr1:110026001	ATXN7L2	0.58	7.33	0.37	1.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg03037974	chr15:76606532	NA	-0.6	-10.29	-0.49	8.21e-22	Blood metabolite levels;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.73	-11.22	-0.52	4.2e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.55	6.44	0.33	3.94e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.75	10.46	0.49	2.08e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.21	0.61	2.47e-36	Chronic sinus infection;
LIHC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.43	6.49	0.33	3.09e-10	Personality dimensions;
LIHC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.51	7.33	0.37	1.67e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.44	7.31	0.37	1.85e-12	Response to temozolomide;
LIHC	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.52	8.44	0.42	9.17e-16	Corneal astigmatism;
LIHC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.42	-6.01	-0.31	4.75e-9	Motion sickness;
LIHC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.49	-9.42	-0.45	7.07e-19	Schizophrenia;
LIHC	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.25	6.15	0.32	2.11e-9	Primary biliary cholangitis;
LIHC	cis	rs2274273	0.870	rs3783652	chr14:55854208	A/G	cg01864836	chr14:55583639	NA	-0.38	-6.66	-0.34	1.08e-10	Protein biomarker;
LIHC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg04610667	chr7:75704037	NA	-0.33	-6.0	-0.31	5.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.31	6.42	0.33	4.56e-10	Crohn's disease;
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg13126279	chr21:47581558	C21orf56	-0.38	-5.91	-0.3	8.16e-9	Testicular germ cell tumor;
LIHC	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	1.04	13.07	0.58	5.89e-32	Economic and political preferences (immigration/crime);
LIHC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.49	-7.61	-0.38	2.62e-13	Breast size;
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg05697976	chr12:29376483	FAR2	0.31	6.38	0.33	5.76e-10	QT interval;
LIHC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-18.99	-0.72	2.08e-55	Height;
LIHC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg03859395	chr2:55845619	SMEK2	0.93	16.34	0.66	9.46e-45	Metabolic syndrome;
LIHC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.94	0.31	7.02e-9	Electroencephalogram traits;
LIHC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg07382826	chr16:28625726	SULT1A1	0.52	7.84	0.39	5.68e-14	Body mass index;
LIHC	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.53	8.51	0.42	5.39e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2906856	0.921	rs1019076	chr12:68398118	C/T	cg15249341	chr12:68405565	NA	0.34	7.06	0.36	9.47e-12	Mosquito bite size;
LIHC	cis	rs10416265	0.528	rs10420258	chr19:33602757	C/T	cg27124370	chr19:33622961	WDR88	0.49	6.86	0.35	3.18e-11	Bone properties (heel);
LIHC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.23	-0.36	3.26e-12	Vitiligo;
LIHC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.39	5.85	0.3	1.17e-8	Melanoma;
LIHC	cis	rs1559088	0.501	rs35492529	chr19:33597495	C/G	cg17764715	chr19:33622953	WDR88	0.49	6.41	0.33	4.71e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7534824	0.625	rs61782084	chr1:101515298	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.76	7.15	0.36	5.43e-12	Refractive astigmatism;
LIHC	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	8.4	0.41	1.22e-15	Schizophrenia;
LIHC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.06	-0.31	3.68e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.29	-0.41	2.63e-15	Height;
LIHC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.08	0.4	1.1e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.26	-0.37	2.71e-12	Blood pressure;
LIHC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg05044414	chr3:183734942	ABCC5	0.31	5.82	0.3	1.37e-8	Anterior chamber depth;
LIHC	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.45	6.19	0.32	1.73e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.74	10.03	0.48	6.13e-21	Body mass index;
LIHC	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.29	0.37	2.15e-12	Neuroticism;
LIHC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg17385448	chr1:15911702	AGMAT	0.34	6.03	0.31	4.2e-9	Systolic blood pressure;
LIHC	cis	rs797680	0.856	rs10874759	chr1:93630172	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.67e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs875971	1.000	rs778699	chr7:65868290	G/A	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs7799006	0.723	rs12673108	chr7:2286487	C/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.11	-0.31	2.7e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.33	-0.32	7.56e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.45e-11	Height;
LIHC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.77	-0.3	1.78e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.56	-0.46	2.35e-19	Response to antipsychotic treatment;
LIHC	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg22705602	chr4:152727874	NA	-0.31	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.1	10.02	0.48	6.65e-21	Diabetic retinopathy;
LIHC	trans	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg10208301	chr11:6592745	DNHD1	0.47	6.25	0.32	1.21e-9	Coronary artery calcification;
LIHC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.6	-10.89	-0.51	6.68e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-8.17	-0.4	6.17e-15	Gut microbiome composition (summer);
LIHC	cis	rs507080	0.922	rs519982	chr11:118565231	C/T	cg04173919	chr11:118528438	PHLDB1	0.36	6.6	0.34	1.53e-10	Serum metabolite levels;
LIHC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.4	6.71	0.34	7.92e-11	Atrioventricular conduction;
LIHC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.39	5.85	0.3	1.15e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.39	-7.78	-0.39	8.67e-14	Renal cell carcinoma;
LIHC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-12.47	-0.56	1.15e-29	Vitiligo;
LIHC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.56	7.52	0.38	4.81e-13	Emphysema distribution in smoking;
LIHC	cis	rs6782228	0.606	rs10048945	chr3:128409680	C/T	cg16766828	chr3:128327626	NA	-0.4	-6.39	-0.33	5.36e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	trans	rs13381277	1.000	rs9952875	chr18:74327943	G/C	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.41	-0.33	4.77e-10	Dental caries;
LIHC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.52	6.87	0.35	3.02e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs950169	0.690	rs12901166	chr15:84699113	G/A	cg24036039	chr1:3397125	ARHGEF16	0.39	6.21	0.32	1.57e-9	Schizophrenia;
LIHC	cis	rs4908768	0.906	rs12568293	chr1:8540912	C/T	cg20416874	chr1:8611966	RERE	-0.56	-9.0	-0.44	1.56e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.6	-10.48	-0.49	1.77e-22	Dental caries;
LIHC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.7e-9	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.1e-31	Prudent dietary pattern;
LIHC	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg00564555	chr16:1970112	NA	0.26	6.08	0.31	3.28e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs1865721	1.000	rs62089507	chr18:73179019	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.67	-0.38	1.77e-13	Intelligence;
LIHC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	8.68	0.42	1.61e-16	Lung cancer;
LIHC	cis	rs400736	0.729	rs9434948	chr1:8004963	A/C	cg25007680	chr1:8021821	PARK7	-0.46	-7.29	-0.37	2.13e-12	Response to antidepressants and depression;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12016809	chr21:47604291	C21orf56	0.42	6.21	0.32	1.5e-9	Testicular germ cell tumor;
LIHC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg21466736	chr12:48725269	NA	0.71	10.78	0.5	1.62e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.98	-0.4	2.21e-14	Monocyte percentage of white cells;
LIHC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.32	0.58	6.47e-33	Cognitive test performance;
LIHC	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg25783544	chr11:47291846	MADD	0.41	5.95	0.31	6.8e-9	HDL cholesterol;
LIHC	cis	rs6466055	0.720	rs2030776	chr7:105008458	C/G	cg04380332	chr7:105027541	SRPK2	-0.37	-6.96	-0.35	1.8e-11	Schizophrenia;
LIHC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.83	13.75	0.6	1.53e-34	Monocyte count;
LIHC	trans	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.54	8.04	0.4	1.48e-14	Body mass index;
LIHC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.51	0.33	2.66e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.66	-10.56	-0.5	9.4e-23	Skin colour saturation;
LIHC	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.5	-7.62	-0.38	2.56e-13	Liver enzyme levels;
LIHC	cis	rs7534824	0.625	rs12563134	chr1:101468558	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.71	-7.54	-0.38	4.22e-13	Refractive astigmatism;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg03862414	chr17:40824241	PLEKHH3	0.36	6.07	0.31	3.41e-9	Alopecia areata;
LIHC	trans	rs10411161	0.702	rs11878580	chr19:52388485	C/T	cg22319618	chr22:45562946	NUP50	-0.62	-8.49	-0.42	6.32e-16	Breast cancer;
LIHC	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.63	5.84	0.3	1.23e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.51e-13	Uric acid levels;
LIHC	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.68	-0.34	9.73e-11	Diastolic blood pressure;
LIHC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg02376097	chr19:46275166	DMPK	0.51	8.73	0.43	1.12e-16	Coronary artery disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08635118	chr7:6144369	USP42	-0.48	-6.16	-0.32	1.99e-9	Systolic blood pressure;
LIHC	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.35	-8.13	-0.4	8e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.56	-7.59	-0.38	3.03e-13	Body mass index;
LIHC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-7.98	-0.4	2.18e-14	Gut microbiome composition (summer);
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg21003380	chr1:156261207	TMEM79	0.38	6.07	0.31	3.49e-9	Tonsillectomy;
LIHC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.42	6.95	0.35	1.86e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.35	7.15	0.36	5.14e-12	Alcohol dependence;
LIHC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-8.03	-0.4	1.61e-14	Putamen volume;
LIHC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08392591	chr16:89556376	ANKRD11	0.41	6.16	0.32	2e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.18	0.4	5.73e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs477692	0.569	rs10764884	chr10:131308370	G/C	cg05714579	chr10:131428358	MGMT	0.4	6.47	0.33	3.47e-10	Response to temozolomide;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg18279126	chr7:2041391	MAD1L1	0.38	6.24	0.32	1.31e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1789	0.903	rs4453929	chr4:15672173	T/G	cg21329975	chr4:15471214	CC2D2A	-0.4	-5.99	-0.31	5.2e-9	Blood protein levels;
LIHC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.51	8.68	0.43	1.59e-16	Mean corpuscular volume;
LIHC	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	7.01	0.35	1.31e-11	Blood protein levels;
LIHC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg01320579	chr17:75405842	SEPT9	-0.44	-6.42	-0.33	4.43e-10	Airflow obstruction;
LIHC	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.37	0.33	5.99e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg23387056	chr11:14280742	SPON1	-0.42	-5.84	-0.3	1.21e-8	Mitochondrial DNA levels;
LIHC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.31	-5.83	-0.3	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.54	-14.57	-0.62	9.94e-38	Alzheimer's disease (late onset);
LIHC	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg16583315	chr14:65563665	MAX	-0.39	-7.88	-0.39	4.33e-14	Obesity-related traits;
LIHC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-14.02	-0.6	1.36e-35	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-1.21	-12.9	-0.57	2.75e-31	White matter hyperintensity burden;
LIHC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.43	0.49	2.7e-22	Obesity-related traits;
LIHC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg02297831	chr4:17616191	MED28	0.41	5.73	0.3	2.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.07	-0.4	1.19e-14	Monocyte percentage of white cells;
LIHC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.99	0.4	2.09e-14	Motion sickness;
LIHC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	21.13	0.75	5.53e-64	Chronic sinus infection;
LIHC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.75	14.43	0.62	3.24e-37	Mortality in heart failure;
LIHC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.39	6.21	0.32	1.52e-9	Melanoma;
LIHC	cis	rs2412488	0.893	rs6822201	chr4:54359743	T/C	cg22241045	chr4:54363911	LNX1	0.47	7.65	0.38	2e-13	DNA methylation (variation);
LIHC	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg15202627	chr4:1685555	FAM53A	-0.5	-5.79	-0.3	1.58e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.18	0.32	1.77e-9	Response to antipsychotic treatment;
LIHC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.6	7.84	0.39	5.68e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08219700	chr8:58056026	NA	0.51	6.24	0.32	1.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.54e-9	Aortic root size;
LIHC	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.98	-0.4	2.21e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-7.96	-0.4	2.63e-14	Alzheimer's disease;
LIHC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.64	-11.38	-0.52	1.19e-25	Dental caries;
LIHC	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.48	-8.0	-0.4	2.01e-14	Blood metabolite levels;
LIHC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.13	0.4	8.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs13401104	0.796	rs1466204	chr2:237121154	C/A	cg19324714	chr2:237145437	ASB18	0.37	5.85	0.3	1.13e-8	Educational attainment;
LIHC	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.1	-0.36	7.05e-12	Prevalent atrial fibrillation;
LIHC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.99	23.08	0.78	1.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.05	14.67	0.62	3.99e-38	Heart rate;
LIHC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg19680672	chr10:131412579	MGMT	-0.43	-6.64	-0.34	1.21e-10	Response to temozolomide;
LIHC	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg00071026	chr13:113650936	MCF2L	-0.37	-5.86	-0.3	1.11e-8	Systolic blood pressure;
LIHC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg15848620	chr12:58087721	OS9	-0.58	-7.66	-0.38	1.93e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.77	12.25	0.55	7.23e-29	Corneal astigmatism;
LIHC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.94	-0.35	1.92e-11	IgG glycosylation;
LIHC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.34	6.3	0.32	9.34e-10	Total body bone mineral density;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg14393609	chr7:65229607	NA	-0.44	-6.57	-0.33	1.83e-10	Aortic root size;
LIHC	cis	rs2607426	0.681	rs2607411	chr19:41268555	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-6.39	-0.33	5.5e-10	Blood protein levels;
LIHC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.23	-5.78	-0.3	1.65e-8	Schizophrenia;
LIHC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.48	-8.79	-0.43	7.41e-17	Mean corpuscular volume;
LIHC	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-6.49	-0.33	3.1e-10	Breast cancer;
LIHC	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.58	-6.63	-0.34	1.32e-10	Opioid sensitivity;
LIHC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.72	-0.3	2.31e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs926392	0.932	rs4812360	chr20:37689259	A/G	cg16355469	chr20:37678765	NA	0.38	5.99	0.31	5.36e-9	Dialysis-related mortality;
LIHC	cis	rs74233809	1.000	rs9633712	chr10:104873761	G/C	cg03493300	chr10:104813866	CNNM2	0.47	6.34	0.32	7.15e-10	Birth weight;
LIHC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.48e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02520104	chr13:80055217	NDFIP2	0.44	6.13	0.31	2.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.99	-19.64	-0.73	4.88e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.07	-8.63	-0.42	2.28e-16	Body mass index;
LIHC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.89	0.39	4.16e-14	Schizophrenia;
LIHC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.04	0.51	1.88e-24	Colorectal cancer;
LIHC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg03959625	chr15:84868606	LOC388152	0.46	6.63	0.34	1.33e-10	Schizophrenia;
LIHC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.56	7.65	0.38	2.11e-13	Blood metabolite levels;
LIHC	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.62	7.55	0.38	3.92e-13	Coronary artery disease;
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.38	-9.31	-0.45	1.58e-18	Longevity;Endometriosis;
LIHC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.48	-0.33	3.23e-10	Mean corpuscular volume;
LIHC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1000083	0.834	rs1845656	chr5:96614105	C/T	ch.5.96698337R	chr5:96672581	NA	0.93	7.47	0.37	6.95e-13	Cisplatin-induced ototoxicity;
LIHC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.49	-7.7	-0.38	1.43e-13	Bone mineral density (spine);
LIHC	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.2	-0.32	1.6e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-5.97	-0.31	6.02e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.51	5.74	0.3	2.11e-8	Primary sclerosing cholangitis;
LIHC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-7.94	-0.39	2.91e-14	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06441946	chr5:145583671	RBM27	0.42	6.41	0.33	4.73e-10	Cognitive function;
LIHC	trans	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-8.12	-0.4	8.51e-15	Obesity-related traits;
LIHC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.45	0.53	6.57e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg03013999	chr17:37608204	MED1	-0.36	-6.06	-0.31	3.64e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.78	0.57	7.68e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-8.27	-0.41	3.05e-15	Gut microbiome composition (summer);
LIHC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.54	5.8	0.3	1.55e-8	Menopause (age at onset);
LIHC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.61	-6.69	-0.34	9.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.64	-10.19	-0.48	1.8e-21	Uric acid clearance;
LIHC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.74	8.98	0.44	1.92e-17	Cognitive function;
LIHC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg03037974	chr15:76606532	NA	0.66	11.84	0.54	2.44e-27	Blood metabolite levels;
LIHC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.2	0.45	3.71e-18	Schizophrenia;
LIHC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.07e-18	Schizophrenia;
LIHC	cis	rs2302190	0.882	rs7221464	chr17:56552353	A/T	cg05425664	chr17:57184151	TRIM37	-0.49	-5.94	-0.31	6.91e-9	Vitamin D levels;
LIHC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg02297831	chr4:17616191	MED28	0.49	7.61	0.38	2.63e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.64	-0.38	2.25e-13	Total body bone mineral density;
LIHC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.86	-0.3	1.1e-8	Colorectal cancer;
LIHC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg08847533	chr14:75593920	NEK9	-0.43	-7.07	-0.36	8.98e-12	IgG glycosylation;
LIHC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	0.9	19.88	0.73	5.43e-59	Night sleep phenotypes;
LIHC	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.32	0.37	1.83e-12	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.84	0.6	6.95e-35	Bipolar disorder;
LIHC	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.7e-11	Dermatomyositis;
LIHC	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg20636351	chr8:55087400	NA	-0.38	-7.71	-0.38	1.41e-13	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10130860	chr1:43124230	PPIH	0.49	6.59	0.34	1.65e-10	Lung function (FEV1/FVC);
LIHC	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.88	-0.3	9.54e-9	Systolic blood pressure;
LIHC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.96	-0.31	6.36e-9	Personality dimensions;
LIHC	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.68	7.38	0.37	1.22e-12	Exhaled nitric oxide output;
LIHC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-7.15	-0.36	5.23e-12	Personality dimensions;
LIHC	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.72	0.5	2.63e-23	Bladder cancer;
LIHC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.76	-16.52	-0.67	1.77e-45	Systemic lupus erythematosus;
LIHC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.68	10.58	0.5	8e-23	Blood protein levels;
LIHC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-8.18	-0.4	5.51e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	1.15	8.97	0.44	2.04e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-16.01	-0.65	1.99e-43	Chronic sinus infection;
LIHC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg07959070	chr22:50026188	C22orf34	-0.33	-8.63	-0.42	2.4e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg19773385	chr1:10388646	KIF1B	-0.51	-8.69	-0.43	1.49e-16	Hepatocellular carcinoma;
LIHC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.35	6.32	0.32	7.96e-10	Aortic root size;
LIHC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.23	6.34	0.32	7.13e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05787193	chr1:84543369	PRKACB	-0.45	-6.05	-0.31	3.71e-9	Pancreatic cancer;
LIHC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.34	-6.45	-0.33	3.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	trans	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.21	-0.41	4.62e-15	Obesity-related traits;
LIHC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.45	6.33	0.32	7.81e-10	Morning vs. evening chronotype;
LIHC	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.83	-0.35	3.8e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg14440974	chr22:39074834	NA	-0.42	-6.78	-0.34	5.18e-11	Menopause (age at onset);
LIHC	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.13	0.36	5.95e-12	Eosinophil percentage of white cells;
LIHC	cis	rs7635838	0.722	rs6773963	chr3:11511975	G/A	cg00170343	chr3:11313890	ATG7	0.41	6.33	0.32	7.73e-10	HDL cholesterol;
LIHC	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.71	-11.17	-0.52	6.51e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.36	8.73	0.43	1.13e-16	Crohn's disease;
LIHC	cis	rs6001982	0.512	rs12159200	chr22:41042091	A/C	cg14879645	chr22:41048474	NA	0.4	5.95	0.31	6.5e-9	Breast cancer;
LIHC	cis	rs2710642	0.611	rs974345	chr2:62882774	C/T	cg17519650	chr2:63277830	OTX1	0.52	7.52	0.38	4.73e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21618040	chr12:123921306	RILPL2	0.5	6.31	0.32	8.53e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg00071026	chr13:113650936	MCF2L	-0.38	-5.93	-0.31	7.3e-9	Systolic blood pressure;
LIHC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	8.03	0.4	1.57e-14	Diastolic blood pressure;
LIHC	cis	rs16958440	0.867	rs79395141	chr18:44695680	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	11.19	0.52	5.77e-25	Chronic sinus infection;
LIHC	cis	rs12980942	0.591	rs2304231	chr19:41762670	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	7.09	0.36	7.88e-12	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19104784	chr15:81616677	STARD5	0.52	6.6	0.34	1.56e-10	Hepatitis;
LIHC	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.5	7.6	0.38	2.84e-13	Adiposity;
LIHC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.13	13.08	0.58	5.61e-32	Vitiligo;
LIHC	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.18	-0.32	1.78e-9	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05617927	chr15:83654886	FAM103A1	0.43	6.55	0.33	2.07e-10	Pancreatic cancer;
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.87	-0.3	1.01e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.91	-0.3	8.3e-9	Coronary artery disease;
LIHC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg03959625	chr15:84868606	LOC388152	0.44	6.02	0.31	4.52e-9	Schizophrenia;
LIHC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.67	13.22	0.58	1.57e-32	High light scatter reticulocyte count;
LIHC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg22903471	chr2:27725779	GCKR	-0.44	-6.42	-0.33	4.43e-10	Blood metabolite levels;
LIHC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.77	11.66	0.53	1.15e-26	Coronary artery disease;
LIHC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.65	-7.98	-0.4	2.22e-14	Gut microbiome composition (summer);
LIHC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-6.55	-0.33	2.08e-10	Initial pursuit acceleration;
LIHC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.6	10.46	0.49	2.08e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.46	6.38	0.33	5.7e-10	Aortic root size;
LIHC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.8	0.34	4.8e-11	Educational attainment;
LIHC	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg19680672	chr10:131412579	MGMT	-0.38	-5.8	-0.3	1.47e-8	Response to temozolomide;
LIHC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.87	16.22	0.66	2.71e-44	Multiple myeloma (IgH translocation);
LIHC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.95	-9.36	-0.45	1.09e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2694917	0.625	rs799261	chr12:56924389	C/G	cg15380473	chr2:11864427	NA	0.51	6.26	0.32	1.16e-9	Blood metabolite ratios;
LIHC	trans	rs2009579	1	rs2009579	chr20:37881482	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.42	-6.05	-0.31	3.73e-9	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg01629716	chr15:45996671	NA	0.52	9.6	0.46	1.77e-19	Waist circumference;Weight;
LIHC	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.49	-0.42	6.4e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.17	16.32	0.66	1.13e-44	Corneal structure;
LIHC	cis	rs12086130	0.892	rs72906810	chr1:51457200	A/G	cg07174182	chr1:51127561	FAF1	-0.92	-9.85	-0.47	2.66e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.31	0.81	2.24e-80	Prudent dietary pattern;
LIHC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	7.97	0.4	2.46e-14	Schizophrenia;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg16219491	chr6:26197733	HIST1H3D	0.53	5.72	0.3	2.34e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs77669868	0.929	rs3782002	chr11:114070563	A/T	cg01914181	chr11:114070210	ZBTB16	0.65	9.07	0.44	9.62e-18	Monocyte percentage of white cells;
LIHC	trans	rs4566648	0.593	rs28425691	chr4:84174626	A/G	cg06219686	chr17:29421884	NF1	-0.52	-6.12	-0.31	2.53e-9	Monocyte count;
LIHC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.41	-0.45	7.59e-19	Schizophrenia;
LIHC	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.59	8.65	0.42	2.08e-16	Breast cancer;
LIHC	cis	rs16958440	0.867	rs75481537	chr18:44719946	C/T	cg17192377	chr18:44677553	HDHD2	0.91	8.68	0.42	1.64e-16	Sitting height ratio;
LIHC	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.52	-0.42	5.04e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg14222432	chr12:29376421	FAR2	0.37	7.11	0.36	6.68e-12	QT interval;
LIHC	cis	rs970821	0.966	rs1946585	chr8:124750741	A/G	cg00283535	chr8:124749564	ANXA13	0.35	5.88	0.3	9.98e-9	Breast cancer;
LIHC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.96	0.31	6.44e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs12431939	0.947	rs55974960	chr14:51633742	T/C	cg23942311	chr14:51606299	NA	-0.36	-5.92	-0.3	7.73e-9	Cancer;
LIHC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.49	-7.01	-0.35	1.27e-11	Uric acid levels;
LIHC	cis	rs4908768	0.501	rs1463050	chr1:8597042	G/A	cg20416874	chr1:8611966	RERE	-0.71	-15.65	-0.65	5.22e-42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	trans	rs4322600	0.963	rs12884672	chr14:88286529	A/G	cg16008221	chr8:17823628	PCM1	-0.41	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.42	-6.8	-0.35	4.72e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.63	-10.01	-0.48	7.61e-21	Dental caries;
LIHC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.95	-0.31	6.76e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.55	7.59	0.38	3.12e-13	Bladder cancer;
LIHC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg02376097	chr19:46275166	DMPK	0.52	9.09	0.44	8.49e-18	Coronary artery disease;
LIHC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg00204748	chr12:29376779	FAR2	0.4	7.38	0.37	1.2e-12	QT interval;
LIHC	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg17830980	chr10:43048298	ZNF37B	0.42	7.94	0.39	3.02e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.4	-6.09	-0.31	3.03e-9	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.24e-17	Arsenic metabolism;
LIHC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.5	-8.32	-0.41	2.06e-15	Vitiligo;
LIHC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.83	-0.51	1.06e-23	Hemoglobin concentration;
LIHC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	10.19	0.48	1.83e-21	Hemoglobin concentration;
LIHC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	6.92	0.35	2.24e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10508774	1.000	rs12266925	chr10:32856445	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg03611732	chr10:21785697	C10orf114;MIR1915	0.5	6.09	0.31	3.03e-9	Glycated hemoglobin levels;
LIHC	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.46	-6.02	-0.31	4.46e-9	Testicular germ cell tumor;Testicular germ cell cancer;
LIHC	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26031613	chr14:104095156	KLC1	1.13	14.74	0.62	2.07e-38	Body mass index;
LIHC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-16.18	-0.66	3.9e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.12	0.4	8.83e-15	Platelet count;
LIHC	trans	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.52	0.59	1.17e-33	Diabetic kidney disease;
LIHC	trans	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg10208301	chr11:6592745	DNHD1	0.45	6.54	0.33	2.3e-10	Coronary artery calcification;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03940137	chr1:200708937	CAMSAP1L1	0.42	6.11	0.31	2.74e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088813	1.000	rs6141548	chr20:33971085	A/G	cg14752227	chr20:34000481	UQCC	-0.4	-5.8	-0.3	1.53e-8	Height;
LIHC	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.27	0.45	2.1e-18	Hemoglobin concentration;
LIHC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.1	-0.36	7.39e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.52	-7.87	-0.39	4.63e-14	Total body bone mineral density;
LIHC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.66	11.68	0.53	9.17e-27	Total body bone mineral density;
LIHC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.16	-0.32	2.08e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.76e-11	Coronary artery disease;
LIHC	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs2108622	0.727	rs3093193	chr19:15991914	C/G	cg13772218	chr19:15982569	NA	0.37	7.51	0.38	5.06e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs9309473	1.000	rs10186501	chr2:73697844	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.87	-0.35	3.04e-11	Metabolite levels;
LIHC	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg10820045	chr2:198174542	NA	0.46	7.2	0.36	3.84e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.89	0.43	3.47e-17	Platelet count;
LIHC	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.55	-8.45	-0.42	8.43e-16	Blood protein levels;
LIHC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17152411	1.000	rs10901843	chr10:126638020	A/G	cg07906193	chr10:126599966	NA	0.47	7.53	0.38	4.62e-13	Height;
LIHC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.31	0.41	2.24e-15	Alzheimer's disease;
LIHC	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.52	6.2	0.32	1.59e-9	Exhaled nitric oxide output;
LIHC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.31	0.58	7.24e-33	Cognitive test performance;
LIHC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.02	0.31	4.58e-9	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	6.19	0.32	1.74e-9	Height;
LIHC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.48e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	10.53	0.49	1.19e-22	Resting heart rate;
LIHC	cis	rs539514	0.690	rs504273	chr13:76310850	C/T	cg04757411	chr13:76259545	LMO7	-0.47	-8.3	-0.41	2.43e-15	Type 1 diabetes;
LIHC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.55	-8.88	-0.43	3.91e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs600806	0.778	rs11101962	chr1:110014187	A/T	cg02415029	chr1:110025642	ATXN7L2	-0.44	-5.75	-0.3	1.95e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.42	-8.45	-0.42	8.33e-16	Testicular germ cell tumor;
LIHC	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.81	-8.07	-0.4	1.19e-14	Facial morphology (factor 23);
LIHC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.09e-27	Obesity-related traits;
LIHC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.48	0.42	6.79e-16	Bladder cancer;
LIHC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.51	-8.45	-0.42	8.61e-16	Blood protein levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11240439	chr6:57087088	RAB23	-0.43	-6.17	-0.32	1.96e-9	Pancreatic cancer;
LIHC	cis	rs75908454	1.000	rs74400382	chr6:169803042	T/C	cg19338460	chr6:170058176	WDR27	-0.83	-7.52	-0.38	4.91e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.68	8.0	0.4	1.95e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.36	-0.37	1.4e-12	Body mass index;
LIHC	cis	rs903552	1.000	rs8041563	chr15:102005824	G/C	cg06707286	chr15:102010195	PCSK6	-0.44	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.63	0.42	2.33e-16	Schizophrenia;
LIHC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-10.88	-0.51	6.88e-24	Mosquito bite size;
LIHC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg02251663	chr11:14281053	SPON1	0.46	6.38	0.33	5.9e-10	Mitochondrial DNA levels;
LIHC	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.21	0.32	1.5e-9	Rheumatoid arthritis;
LIHC	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.96e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.52	8.13	0.4	7.98e-15	Lymphocyte counts;
LIHC	cis	rs3018712	0.590	rs4930585	chr11:68411347	T/C	cg16797656	chr11:68205561	LRP5	-0.44	-5.83	-0.3	1.28e-8	Total body bone mineral density;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg21097698	chr4:76932399	ART3	-0.48	-6.81	-0.35	4.54e-11	Alcohol dependence;
LIHC	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg14146966	chr2:61757674	XPO1	0.47	8.17	0.4	5.97e-15	Tuberculosis;
LIHC	cis	rs17106184	1.000	rs72902763	chr1:51255320	T/C	cg07174182	chr1:51127561	FAF1	-0.64	-6.89	-0.35	2.74e-11	Type 2 diabetes;
LIHC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.5	7.35	0.37	1.5e-12	Total body bone mineral density;
LIHC	cis	rs4853036	0.951	rs10165061	chr2:70146363	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.75	-0.34	6.19e-11	Colorectal or endometrial cancer;
LIHC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.5	-7.06	-0.36	9.45e-12	Body mass index;
LIHC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg14393609	chr7:65229607	NA	0.38	6.0	0.31	4.99e-9	Aortic root size;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-7.77	-0.39	9.43e-14	Lymphocyte counts;
LIHC	cis	rs79040073	1.000	rs79040073	chr15:49330854	C/T	cg04482760	chr15:49339272	SECISBP2L	-0.49	-5.88	-0.3	9.76e-9	Lung cancer in ever smokers;
LIHC	cis	rs7551222	0.634	rs11801289	chr1:204528969	G/C	cg20240347	chr1:204465584	NA	-0.35	-7.41	-0.37	1e-12	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23284646	chr4:17616339	MED28	0.45	6.17	0.32	1.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg19302996	chr17:73780495	UNK	-0.6	-9.48	-0.46	4.46e-19	White matter hyperintensity burden;
LIHC	cis	rs273218	1.000	rs156384	chr5:53371333	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.66	10.68	0.5	3.48e-23	Migraine;
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg11342453	chr6:26196699	NA	0.53	5.92	0.3	7.83e-9	Gout;Renal underexcretion gout;
LIHC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.58	8.97	0.44	1.93e-17	Uric acid clearance;
LIHC	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg07929629	chr2:241523174	NA	0.57	7.12	0.36	6.45e-12	Bipolar disorder;
LIHC	cis	rs8049040	1.000	rs8049040	chr16:71472704	A/G	cg06353428	chr16:71660113	MARVELD3	-0.55	-5.85	-0.3	1.16e-8	Blood protein levels;
LIHC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg00343986	chr7:65444356	GUSB	0.39	5.76	0.3	1.85e-8	Aortic root size;
LIHC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.35	-0.37	1.45e-12	Pancreatic cancer;
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00399650	chr7:141402322	KIAA1147	0.42	6.91	0.35	2.4e-11	Cognitive function;
LIHC	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.99	-0.35	1.47e-11	Blood pressure;
LIHC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	21.11	0.75	6.65e-64	Smoking behavior;
LIHC	cis	rs6952809	0.692	rs10244138	chr7:2439587	C/A	cg23289794	chr7:2394357	EIF3B	-0.6	-5.95	-0.31	6.67e-9	Multiple sclerosis;
LIHC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg08923669	chr16:420230	MRPL28	-0.45	-6.29	-0.32	9.89e-10	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.55	0.38	4.05e-13	Corneal astigmatism;
LIHC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01200585	chr1:228362443	C1orf69	0.41	6.37	0.33	6.08e-10	Diastolic blood pressure;
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	6.46	0.33	3.65e-10	Renal cell carcinoma;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg05560165	chr5:133450315	TCF7	-0.34	-6.1	-0.31	2.84e-9	Eotaxin levels;
LIHC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.18	0.44	4.05e-18	Lung cancer in ever smokers;
LIHC	trans	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.6e-9	Coronary artery disease;
LIHC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.51	7.48	0.38	6.2e-13	High light scatter reticulocyte count;
LIHC	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21659725	chr3:3221576	CRBN	-0.73	-12.03	-0.55	4.69e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs7326068	0.524	rs2497488	chr13:21201476	A/T	cg27234864	chr13:21295941	IL17D	0.38	6.27	0.32	1.06e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs12744310	0.830	rs12028010	chr1:41764471	T/C	cg03962019	chr1:41807865	NA	0.38	6.18	0.32	1.79e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	7.28	0.37	2.35e-12	Platelet count;
LIHC	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg08345082	chr10:99160200	RRP12	-0.37	-6.13	-0.31	2.37e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg25182066	chr10:30743637	MAP3K8	0.69	9.45	0.45	5.62e-19	Itch intensity from mosquito bite;
LIHC	cis	rs2073300	1.000	rs2236021	chr20:23432528	A/G	cg16736954	chr20:23401023	NAPB	0.51	5.73	0.3	2.26e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.46	16.71	0.67	3.08e-46	Eosinophil percentage of granulocytes;
LIHC	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04530015	chr2:215796436	ABCA12	0.46	7.7	0.38	1.51e-13	Neuroblastoma;
LIHC	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.46	-0.33	3.55e-10	Multiple sclerosis;
LIHC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	10.57	0.5	9.04e-23	Response to antipsychotic treatment;
LIHC	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.94	-0.35	2.02e-11	Total cholesterol levels;
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.57	8.71	0.43	1.35e-16	Height;
LIHC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.76	9.88	0.47	2.05e-20	Selective IgA deficiency;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.3e-14	Height;
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.1	-0.61	6.3e-36	Alzheimer's disease;
LIHC	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.58	-10.25	-0.48	1.12e-21	Colorectal cancer;
LIHC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg03146154	chr1:46216737	IPP	-0.39	-6.38	-0.33	5.88e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.08e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.37	6.02	0.31	4.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	11.13	0.52	9.02e-25	Type 2 diabetes;
LIHC	trans	rs13325613	0.915	rs34745455	chr3:46267333	T/C	cg26337592	chr1:153642686	ILF2	0.68	6.18	0.32	1.81e-9	Monocyte count;
LIHC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.87	14.22	0.61	2.22e-36	Colorectal cancer;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.53	-7.65	-0.38	2.03e-13	Menopause (age at onset);
LIHC	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg25600027	chr14:23388339	RBM23	-0.41	-5.88	-0.3	9.6e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.42	6.82	0.35	4.14e-11	Red blood cell count;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08280861	chr8:58055591	NA	0.49	6.13	0.31	2.38e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16828019	0.929	rs10524	chr1:41726473	T/C	cg03387723	chr1:41708464	SCMH1	-0.44	-7.17	-0.36	4.67e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.61	-0.38	2.72e-13	Tuberculosis;
LIHC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-7.82	-0.39	6.54e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs11673344	0.523	rs1667379	chr19:37492094	A/T	cg27390819	chr19:37464633	NA	-0.47	-6.15	-0.32	2.22e-9	Obesity-related traits;
LIHC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.25	-0.41	3.44e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.48	6.15	0.32	2.14e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg05590025	chr7:65112418	INTS4L2	-0.57	-6.25	-0.32	1.2e-9	Diabetic kidney disease;
LIHC	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.48	6.23	0.32	1.34e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg18478394	chr8:109455254	TTC35	0.42	7.24	0.36	3.07e-12	Dupuytren's disease;
LIHC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.41	8.94	0.44	2.46e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs10420951	0.617	rs3746176	chr19:18568951	C/G	cg10790698	chr19:18539756	SSBP4	-0.42	-5.93	-0.31	7.23e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.69	-0.34	9.06e-11	Fear of minor pain;
LIHC	cis	rs2933343	0.859	rs789245	chr3:128583580	C/A	cg25356066	chr3:128598488	ACAD9	0.55	7.01	0.35	1.29e-11	IgG glycosylation;
LIHC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.39e-27	Body mass index;
LIHC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.48	5.71	0.3	2.42e-8	Bladder cancer;
LIHC	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg14222432	chr12:29376421	FAR2	0.34	6.68	0.34	9.74e-11	QT interval;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg13409248	chr3:40428643	ENTPD3	0.46	7.91	0.39	3.64e-14	Renal cell carcinoma;
LIHC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Parkinson's disease;
LIHC	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg06935464	chr4:38784597	TLR10	0.39	5.82	0.3	1.38e-8	Breast cancer;
LIHC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.46	-6.5	-0.33	2.86e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs879568	0.789	rs4799432	chr18:34315042	C/T	cg16486109	chr11:613632	IRF7	-0.42	-6.12	-0.31	2.5e-9	QRS duration;
LIHC	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.71	0.34	7.96e-11	Mean corpuscular volume;
LIHC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.6	-10.31	-0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg00815214	chr21:47717953	NA	0.34	5.72	0.3	2.36e-8	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.99	0.31	5.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4908768	0.501	rs6577513	chr1:8702753	G/A	cg20416874	chr1:8611966	RERE	-0.62	-12.53	-0.56	6.54e-30	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs61712019	0.679	rs2861055	chr2:77716557	C/T	cg11252801	chr2:77748917	LRRTM4	0.55	7.73	0.39	1.25e-13	Schizophrenia;
LIHC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg11861562	chr11:117069780	TAGLN	0.48	8.03	0.4	1.59e-14	Blood protein levels;
LIHC	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.36	-6.25	-0.32	1.22e-9	Menopause (age at onset);
LIHC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.88	0.3	9.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.45	8.76	0.43	9.18e-17	Testicular germ cell tumor;
LIHC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.08e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg17845761	chr1:175162550	KIAA0040	-0.36	-5.88	-0.3	9.9e-9	Alcohol dependence;
LIHC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.63	-0.38	2.34e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-1.16	-13.08	-0.58	5.77e-32	White matter hyperintensity burden;
LIHC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg11764359	chr7:65958608	NA	-0.57	-5.93	-0.31	7.25e-9	Diabetic kidney disease;
LIHC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.86	-17.71	-0.69	3.01e-50	Height;
LIHC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.41	7.48	0.37	6.42e-13	Electrocardiographic conduction measures;
LIHC	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg12379764	chr21:47803548	PCNT	0.75	10.53	0.49	1.18e-22	Lymphocyte counts;
LIHC	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.89	-0.43	3.7e-17	Total cholesterol levels;
LIHC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg17135325	chr3:160939158	NMD3	0.55	7.88	0.39	4.38e-14	Parkinson's disease;
LIHC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg18121669	chr1:26560928	CCDC21	0.51	8.04	0.4	1.5e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8108269	1.000	rs8107236	chr19:46158436	A/G	cg13320842	chr19:46175254	GIPR	0.41	7.74	0.39	1.16e-13	Type 2 diabetes;
LIHC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Vitiligo;
LIHC	cis	rs7078219	0.505	rs7893840	chr10:101293341	T/C	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.09	-0.31	3.12e-9	Dental caries;
LIHC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs7953508	0.711	rs11107120	chr12:93985482	T/C	cg18151635	chr12:93972918	NA	-0.49	-7.6	-0.38	2.85e-13	Pubertal anthropometrics;
LIHC	cis	rs3015497	0.624	rs3015488	chr14:51135309	A/G	cg09863266	chr14:51125203	SAV1	-0.42	-5.85	-0.3	1.13e-8	Mean platelet volume;
LIHC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-7.58	-0.38	3.3e-13	Chronic sinus infection;
LIHC	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg19773385	chr1:10388646	KIF1B	-0.48	-8.34	-0.41	1.79e-15	Hepatocellular carcinoma;
LIHC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg25356066	chr3:128598488	ACAD9	0.54	7.39	0.37	1.11e-12	IgG glycosylation;
LIHC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.86	0.47	2.43e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6137287	0.643	rs6047259	chr20:21098319	A/G	cg04219410	chr20:21106687	PLK1S1	-0.33	-5.81	-0.3	1.41e-8	Height;
LIHC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.58	-6.63	-0.34	1.3e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.52	9.06	0.44	1.01e-17	Coronary artery disease;
LIHC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.41	5.71	0.3	2.46e-8	Longevity;Endometriosis;
LIHC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.49	7.16	0.36	4.9e-12	Multiple sclerosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20679082	chr17:1090548	ABR	0.44	6.24	0.32	1.33e-9	Lung function (FEV1/FVC);
LIHC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.67	-0.38	1.86e-13	Chronic sinus infection;
LIHC	cis	rs3106136	0.586	rs28474924	chr4:95086345	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.71	-0.3	2.45e-8	Capecitabine sensitivity;
LIHC	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.0	-0.31	5.02e-9	Vitiligo;
LIHC	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg03037974	chr15:76606532	NA	-0.51	-8.04	-0.4	1.44e-14	Blood metabolite levels;
LIHC	trans	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg10756647	chr7:56101905	PSPH	1.1	13.4	0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg02527881	chr3:46936655	PTH1R	0.35	6.78	0.34	5.38e-11	Colorectal cancer;
LIHC	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-8.19	-0.41	5.14e-15	Hepatocellular carcinoma;
LIHC	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg05621596	chr22:47072043	GRAMD4	-0.75	-11.97	-0.54	8e-28	Urate levels in obese individuals;
LIHC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.94	-0.31	6.87e-9	Bronchopulmonary dysplasia;
LIHC	trans	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg09872104	chr7:134855509	C7orf49	-0.76	-6.18	-0.32	1.85e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.61	5.89	0.3	9.45e-9	Vitiligo;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01505148	chr19:56170617	U2AF2	-0.41	-6.21	-0.32	1.5e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.09	-0.36	7.61e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs16828019	0.850	rs12027691	chr1:41462032	C/T	cg03387723	chr1:41708464	SCMH1	-0.45	-6.66	-0.34	1.07e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.34	6.3	0.32	9.34e-10	Total body bone mineral density;
LIHC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.88	0.43	3.76e-17	Motion sickness;
LIHC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.78	-0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.87	0.35	3.12e-11	Colorectal cancer;
LIHC	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg27523141	chr10:43048294	ZNF37B	0.37	6.51	0.33	2.74e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.9	-0.3	8.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg25039879	chr17:56429692	SUPT4H1	0.81	9.27	0.45	2.19e-18	Cognitive test performance;
LIHC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-6.62	-0.34	1.38e-10	Platelet distribution width;
LIHC	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg04592579	chr7:75616294	TMEM120A	0.38	6.71	0.34	8.09e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg01021169	chr22:30184971	ASCC2	-0.36	-6.94	-0.35	1.94e-11	Type 1 diabetes;
LIHC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.48	-8.04	-0.4	1.45e-14	Blood metabolite levels;
LIHC	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	6.61	0.34	1.51e-10	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.86	-0.3	1.08e-8	Diabetic kidney disease;
LIHC	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg03934865	chr2:198174659	NA	0.51	7.74	0.39	1.15e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg03037974	chr15:76606532	NA	-0.51	-7.94	-0.39	2.92e-14	Blood metabolite levels;
LIHC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg06533319	chr4:3265114	C4orf44	0.32	6.15	0.32	2.19e-9	Parental longevity (mother's age at death);
LIHC	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.82	11.41	0.52	9.22e-26	Body mass index;
LIHC	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg22771759	chr13:24902376	NA	0.31	6.54	0.33	2.3e-10	Obesity-related traits;
LIHC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.25	6.19	0.32	1.76e-9	Age-related hearing impairment;
LIHC	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.8	-0.39	7.43e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08677398	chr8:58056175	NA	0.41	6.32	0.32	8.32e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	0.87	11.96	0.54	8.55e-28	Post bronchodilator FEV1;
LIHC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.6	6.85	0.35	3.53e-11	Menarche (age at onset);
LIHC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-6.87	-0.35	2.96e-11	Mean platelet volume;
LIHC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.11	0.44	6.98e-18	Schizophrenia;
LIHC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.84	-15.18	-0.63	3.68e-40	Coronary artery disease;
LIHC	trans	rs1414896	0.692	rs4949948	chr1:95729060	A/T	cg24483554	chr1:179544584	NPHS2	0.26	6.13	0.31	2.4e-9	Non-alcoholic fatty liver disease histology (AST);
LIHC	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs9596863	0.851	rs9568923	chr13:54357573	G/A	ch.13.53330881F	chr13:54432880	NA	0.45	6.03	0.31	4.21e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg22771759	chr13:24902376	NA	0.33	6.67	0.34	1.01e-10	Obesity-related traits;
LIHC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg03037974	chr15:76606532	NA	0.86	21.24	0.75	2.02e-64	Blood metabolite levels;
LIHC	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.54	10.25	0.48	1.12e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs1355223	0.902	rs12802120	chr11:34747650	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.46	-0.33	3.61e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.68	9.89	0.47	1.95e-20	Menarche (age at onset);
LIHC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.5	-6.05	-0.31	3.86e-9	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg17294928	chr15:75287854	SCAMP5	-0.52	-6.62	-0.34	1.38e-10	Lung cancer;
LIHC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.04	0.31	3.92e-9	Lung cancer in ever smokers;
LIHC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-7.66	-0.38	1.89e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg02376097	chr19:46275166	DMPK	-0.46	-6.95	-0.35	1.82e-11	Coronary artery disease;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.6	-0.38	2.85e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18268492	chr10:99185986	PGAM1	-0.42	-6.27	-0.32	1.07e-9	Pancreatic cancer;
LIHC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.79	0.3	1.61e-8	Schizophrenia;
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.67	11.85	0.54	2.32e-27	Longevity;Endometriosis;
LIHC	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.03e-40	Aortic root size;
LIHC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.57	0.38	3.5e-13	Schizophrenia;
LIHC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg21466736	chr12:48725269	NA	-0.64	-9.2	-0.45	3.68e-18	Glycated hemoglobin levels;
LIHC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.57	8.75	0.43	1.01e-16	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs7937890	0.559	rs2167160	chr11:14507449	C/A	cg02886208	chr11:14281011	SPON1	-0.44	-6.17	-0.32	1.92e-9	Mitochondrial DNA levels;
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg05255149	chr17:80675120	FN3KRP	0.42	6.06	0.31	3.59e-9	Glycated hemoglobin levels;
LIHC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.59e-14	Parkinson's disease;
LIHC	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.48	-6.27	-0.32	1.1e-9	Pursuit maintenance gain;
LIHC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.58	-0.34	1.76e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.43	6.37	0.33	6.24e-10	Survival in rectal cancer;
LIHC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.17	0.32	1.92e-9	Schizophrenia;
LIHC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.19e-12	HDL cholesterol levels;
LIHC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.02	-0.35	1.23e-11	Personality dimensions;
LIHC	cis	rs1029738	0.500	rs10264441	chr7:22885014	C/A	cg11367502	chr7:22862612	TOMM7	-0.37	-6.16	-0.32	2.02e-9	Fibrinogen levels;
LIHC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.45	5.78	0.3	1.64e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg01411142	chr8:19674711	INTS10	0.51	7.95	0.4	2.7e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.01e-12	HDL cholesterol levels;
LIHC	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.51	-5.97	-0.31	5.78e-9	Coronary artery calcification;
LIHC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.53e-9	Menopause (age at onset);
LIHC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.29	21.31	0.76	1.03e-64	Corneal structure;
LIHC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05505450	chr2:58273643	VRK2	0.43	6.55	0.33	2.14e-10	Pancreatic cancer;
LIHC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-6.36	-0.33	6.49e-10	Blood pressure (smoking interaction);
LIHC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.26	-0.37	2.55e-12	Response to antipsychotic treatment;
LIHC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg12658694	chr1:38397304	INPP5B	0.52	7.75	0.39	1.05e-13	Coronary artery disease;
LIHC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.55	6.84	0.35	3.77e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	0.902	rs12802323	chr11:34747739	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.46	-0.33	3.61e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs907683	0.583	rs10932803	chr2:220292739	A/T	cg15015639	chr2:220282977	DES	0.35	8.4	0.41	1.19e-15	Resting heart rate;
LIHC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.39	6.52	0.33	2.46e-10	Red blood cell count;
LIHC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.24	-0.32	1.31e-9	Total body bone mineral density;
LIHC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.51	8.78	0.43	8.13e-17	Mean corpuscular volume;
LIHC	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.86	0.3	1.08e-8	Rheumatoid arthritis;
LIHC	trans	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs2257205	0.667	rs4453568	chr17:56934543	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-6.67	-0.34	1.05e-10	Pancreatic cancer;
LIHC	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.32	7.36	0.37	1.41e-12	Corneal astigmatism;
LIHC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg15691649	chr6:25882328	NA	-0.56	-8.21	-0.41	4.44e-15	Blood metabolite levels;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.73	13.83	0.6	7.65e-35	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.52	7.47	0.37	6.87e-13	Cognitive function;
LIHC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	6.45	0.33	3.92e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24447660	chr3:127872092	EEFSEC	0.45	6.55	0.33	2.11e-10	Cognitive function;
LIHC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.91	-0.3	8.11e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg12311636	chr6:118886798	C6orf204	-0.54	-6.38	-0.33	5.74e-10	Diastolic blood pressure;
LIHC	cis	rs3981351	0.797	rs3814231	chr10:115481018	A/G	cg24846397	chr10:115438155	CASP7	0.44	6.65	0.34	1.13e-10	Obesity-related traits;
LIHC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.75	12.68	0.57	1.77e-30	Aortic root size;
LIHC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.65	0.38	2e-13	Bipolar disorder;
LIHC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.54	-9.01	-0.44	1.46e-17	Blood metabolite levels;
LIHC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg23461800	chr14:103021989	NA	0.42	5.83	0.3	1.31e-8	Platelet count;
LIHC	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg04719120	chr6:96025338	MANEA	-0.7	-7.91	-0.39	3.52e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.12	0.52	1.02e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	8.05	0.4	1.41e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.66	-11.72	-0.54	6.8e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg05941027	chr17:61774174	LIMD2	0.32	6.53	0.33	2.43e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.84	13.87	0.6	5.23e-35	Multiple system atrophy;
LIHC	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.9	18.67	0.71	3.79e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.51	-0.38	5.05e-13	Lymphocyte counts;
LIHC	cis	rs3770081	1.000	rs57083584	chr2:86283648	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.84	-8.17	-0.4	6.05e-15	Facial emotion recognition (sad faces);
LIHC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.39	6.23	0.32	1.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs875971	1.000	rs778726	chr7:65828731	C/T	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.46	-8.5	-0.42	5.91e-16	Vitamin D levels;
LIHC	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg00204512	chr16:28754710	NA	-0.33	-6.13	-0.31	2.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.67	-0.42	1.8e-16	Colorectal cancer;
LIHC	cis	rs2257205	0.667	rs7342862	chr17:56816561	A/G	cg12560992	chr17:57184187	TRIM37	0.71	7.78	0.39	8.76e-14	Pancreatic cancer;
LIHC	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.57	-0.33	1.83e-10	Exhaled nitric oxide output;
LIHC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.58	6.93	0.35	2.09e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.6	0.34	1.58e-10	Ileal carcinoids;
LIHC	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg10820045	chr2:198174542	NA	0.48	7.47	0.37	6.93e-13	Dermatomyositis;
LIHC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	7.18	0.36	4.49e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.05e-8	Menopause (age at onset);
LIHC	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.33	0.32	7.62e-10	Ulcerative colitis;
LIHC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.56	-0.38	3.65e-13	Chronic sinus infection;
LIHC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.9	0.3	8.77e-9	Height;
LIHC	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-7.36	-0.37	1.34e-12	Neuroticism;
LIHC	cis	rs243505	0.762	rs734004	chr7:148505460	C/G	cg09806900	chr7:148480153	CUL1	0.44	6.73	0.34	7e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg05973401	chr12:123451056	ABCB9	0.41	6.28	0.32	1.02e-9	Platelet count;
LIHC	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.23e-9	Blood pressure;
LIHC	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg14146966	chr2:61757674	XPO1	0.48	8.51	0.42	5.37e-16	Tuberculosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27113440	chr11:22214386	ANO5	-0.45	-6.04	-0.31	4.04e-9	Pancreatic cancer;
LIHC	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.71	-0.34	8.07e-11	Blood pressure;
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.49	0.53	4.8e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08052302	chr7:76178628	LOC100133091	0.51	6.23	0.32	1.33e-9	Hepatitis;
LIHC	trans	rs11088226	0.541	rs75873023	chr21:33910658	G/A	cg09050820	chr6:167586206	TCP10L2	0.6	10.13	0.48	2.83e-21	Gastritis;
LIHC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.13	-0.66	6.34e-44	Diabetic kidney disease;
LIHC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.78	11.77	0.54	4.55e-27	Coronary artery disease;
LIHC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.64	-0.79	6.27e-74	Height;
LIHC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.78	15.26	0.64	1.75e-40	Mortality in heart failure;
LIHC	cis	rs611744	0.967	rs597992	chr8:109193808	A/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.43	7.23	0.36	3.27e-12	Blood metabolite levels;
LIHC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg00155535	chr12:132671473	NA	0.34	6.18	0.32	1.78e-9	Anti-saccade response;
LIHC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09835421	chr16:68378352	PRMT7	-0.52	-5.98	-0.31	5.58e-9	Schizophrenia;
LIHC	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.23	-0.52	4.16e-25	Eye color traits;
LIHC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.43	-10.27	-0.49	9.53e-22	Type 2 diabetes;
LIHC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.72	7.43	0.37	8.51e-13	Vitiligo;
LIHC	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg06634786	chr22:41940651	POLR3H	-0.58	-6.25	-0.32	1.23e-9	Neuroticism;
LIHC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.27	16.79	0.67	1.38e-46	Diabetic kidney disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19912883	chr2:87140809	RGPD2	-0.39	-6.18	-0.32	1.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.56	8.99	0.44	1.78e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.51	-0.49	1.47e-22	Breast cancer;
LIHC	cis	rs8192282	0.739	rs4845648	chr1:154514338	A/T	cg16683920	chr1:154474344	TDRD10;SHE	0.52	6.33	0.32	7.65e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LIHC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.12	0.31	2.57e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02985541	chr2:219472218	PLCD4	0.44	8.29	0.41	2.53e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs79387448	0.745	rs7576324	chr2:103142994	G/A	cg09003973	chr2:102972529	NA	0.82	7.18	0.36	4.41e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg14222432	chr12:29376421	FAR2	0.37	7.02	0.35	1.23e-11	QT interval;
LIHC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.33	2.99e-10	Alzheimer's disease;
LIHC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg23205692	chr1:25664452	TMEM50A	0.39	6.23	0.32	1.37e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg09417038	chr21:47716443	C21orf57	-0.56	-8.63	-0.42	2.41e-16	Testicular germ cell tumor;
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg27478167	chr7:817139	HEATR2	-0.51	-6.79	-0.34	4.99e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.84	-14.14	-0.61	4.46e-36	Body mass index;
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.52	-0.42	5.08e-16	Obesity-related traits;
LIHC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.72	-0.54	7e-27	Chronic sinus infection;
LIHC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.68	11.08	0.51	1.43e-24	Smoking initiation;
LIHC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.86	-0.35	3.23e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.47	-7.84	-0.39	5.6e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.75	8.93	0.43	2.65e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs2016586	0.929	rs4821439	chr22:36114263	C/T	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	cis	rs882732	1.000	rs12586297	chr14:95032394	G/A	cg14866387	chr14:95027382	SERPINA4	-0.46	-6.82	-0.35	4.04e-11	Blood protein levels;
LIHC	cis	rs16828019	0.852	rs12742803	chr1:41648131	G/A	cg03387723	chr1:41708464	SCMH1	-0.45	-7.23	-0.36	3.13e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21448741	chr8:58168803	NA	0.38	6.12	0.31	2.54e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg14473756	chr11:122847823	NA	-0.35	-6.22	-0.32	1.42e-9	Menarche (age at onset);
LIHC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	14.25	0.61	1.74e-36	Multiple sclerosis;
LIHC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg21573476	chr21:45109991	RRP1B	-0.48	-9.39	-0.45	8.68e-19	Mean corpuscular volume;
LIHC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.69	11.31	0.52	1.99e-25	Platelet count;
LIHC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg04226365	chr6:44355287	CDC5L	0.39	6.21	0.32	1.53e-9	Total body bone mineral density;
LIHC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.58	-10.1	-0.48	3.65e-21	Alcohol dependence;
LIHC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg07424592	chr7:64974309	NA	-0.8	-9.08	-0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs6504950	0.800	rs7208123	chr17:53006339	G/A	cg10237252	chr17:52977213	TOM1L1	-0.35	-6.15	-0.32	2.15e-9	Breast cancer;
LIHC	cis	rs3781458	0.803	rs7088656	chr10:126324077	G/A	cg20435097	chr10:126320824	FAM53B	0.72	13.39	0.59	3.75e-33	Male-pattern baldness;
LIHC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.48	-8.07	-0.4	1.22e-14	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07562458	chr1:224622430	WDR26	0.51	6.39	0.33	5.55e-10	Lung function (FEV1/FVC);
LIHC	cis	rs611744	0.967	rs584716	chr8:109178634	A/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.75	12.41	0.56	1.92e-29	Menarche (age at onset);
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.42	-5.76	-0.3	1.83e-8	Total body bone mineral density;
LIHC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.72	0.67	2.8e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg25356066	chr3:128598488	ACAD9	0.55	7.69	0.38	1.55e-13	IgG glycosylation;
LIHC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.84	0.39	5.6e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13047869	chr3:10149882	C3orf24	0.41	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-11.47	-0.53	5.68e-26	Platelet distribution width;
LIHC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.29	-12.91	-0.57	2.55e-31	Plateletcrit;
LIHC	cis	rs7911264	0.905	rs7918084	chr10:94429467	C/T	cg25506282	chr10:94462361	NA	0.39	5.91	0.3	8.45e-9	Inflammatory bowel disease;
LIHC	cis	rs9303280	0.967	rs1031460	chr17:38072247	T/G	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.65	-0.34	1.16e-10	Self-reported allergy;
LIHC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.37	5.95	0.31	6.5e-9	Menopause (age at onset);
LIHC	trans	rs12753920	0.562	rs7549158	chr1:92610211	A/T	cg15668468	chr10:118892869	VAX1	0.42	6.1	0.31	2.79e-9	Systemic lupus erythematosus;
LIHC	cis	rs9309473	1.000	rs10496193	chr2:73773503	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.67	-0.34	1.04e-10	Metabolite levels;
LIHC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.84	-0.57	4.5e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg08888203	chr3:10149979	C3orf24	0.55	6.09	0.31	3.05e-9	Alzheimer's disease;
LIHC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.86	9.62	0.46	1.53e-19	Initial pursuit acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04324509	chr3:101295624	PCNP	0.38	6.5	0.33	2.85e-10	Longevity;
LIHC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.62	-7.87	-0.39	4.85e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.87	-10.69	-0.5	3.27e-23	Mitochondrial DNA levels;
LIHC	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg17385448	chr1:15911702	AGMAT	0.37	6.24	0.32	1.27e-9	Systolic blood pressure;
LIHC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.69	-0.38	1.58e-13	Breast cancer;
LIHC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.1	-0.31	2.92e-9	Obesity-related traits;
LIHC	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.21	11.49	0.53	4.56e-26	Uric acid levels;
LIHC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.0	12.18	0.55	1.36e-28	Body mass index;
LIHC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1882538	0.901	rs35284403	chr7:132948884	T/C	cg10665199	chr7:133106180	EXOC4	0.51	7.94	0.39	2.87e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.93	18.77	0.71	1.5e-54	Bone mineral density;
LIHC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg18944383	chr4:111397179	ENPEP	-0.27	-6.09	-0.31	3.07e-9	Coronary artery disease;
LIHC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.22	-0.55	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-0.79	-9.02	-0.44	1.36e-17	Gut microbiota (bacterial taxa);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21194911	chr19:44716733	ZNF227	0.46	6.18	0.32	1.86e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg15208524	chr1:10270712	KIF1B	0.46	6.75	0.34	6.34e-11	Hepatocellular carcinoma;
LIHC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.92	17.07	0.68	1.09e-47	Menopause (age at onset);
LIHC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.77	11.96	0.54	9e-28	Fibrinogen levels;
LIHC	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs10131894	0.575	rs1860935	chr14:75432464	G/A	cg11812906	chr14:75593930	NEK9	0.63	10.82	0.51	1.14e-23	Coronary artery disease;
LIHC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.37	0.41	1.55e-15	Platelet count;
LIHC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.5	-10.71	-0.5	2.79e-23	White blood cell count (basophil);
LIHC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-7.08	-0.36	8.37e-12	Hemoglobin concentration;
LIHC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.88	14.01	0.6	1.47e-35	Metabolic syndrome;
LIHC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-8.52	-0.42	5.22e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.45	8.27	0.41	3.05e-15	Prudent dietary pattern;
LIHC	cis	rs3823572	0.564	rs1986870	chr7:133660109	A/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-6.47	-0.33	3.41e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.86	0.3	1.12e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	11.56	0.53	2.6e-26	Lung cancer in ever smokers;
LIHC	trans	rs8099121	0.585	rs9951289	chr18:4982797	G/C	cg15792134	chr6:169051418	SMOC2	-0.36	-6.13	-0.31	2.42e-9	Schizophrenia;
LIHC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.65	0.59	3.69e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-12.17	-0.55	1.5e-28	Alzheimer's disease (late onset);
LIHC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.52	-7.4	-0.37	1.07e-12	Body mass index;
LIHC	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg10381502	chr11:71823885	C11orf51	-1.06	-9.3	-0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.61	8.96	0.44	2.1e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.37	0.56	2.77e-29	Menopause (age at onset);
LIHC	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.46	-0.33	3.56e-10	Schizophrenia;
LIHC	trans	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.82	6.89	0.35	2.67e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-0.95	-12.58	-0.56	4.19e-30	Obesity-related traits;
LIHC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.67	-11.62	-0.53	1.52e-26	Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg18306943	chr3:40428807	ENTPD3	-0.4	-7.21	-0.36	3.61e-12	Renal cell carcinoma;
LIHC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.55	-10.34	-0.49	5.52e-22	Sense of smell;
LIHC	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.6	8.24	0.41	3.81e-15	Eotaxin levels;
LIHC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-6.03	-0.31	4.34e-9	Morning vs. evening chronotype;
LIHC	cis	rs4407350	0.721	rs3827402	chr22:44890651	T/C	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.45	-0.33	3.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.8	-11.1	-0.51	1.2e-24	Orofacial clefts;
LIHC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.35	6.93	0.35	2.14e-11	Alcohol dependence;
LIHC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.06	0.4	1.29e-14	Tonsillectomy;
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg08916839	chr5:415575	AHRR	0.28	6.13	0.31	2.36e-9	Cystic fibrosis severity;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.59	-8.43	-0.41	1e-15	Menopause (age at onset);
LIHC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg17724175	chr1:150552817	MCL1	-0.38	-7.69	-0.38	1.62e-13	Tonsillectomy;
LIHC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.62	0.38	2.59e-13	Heart rate;
LIHC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.92	13.39	0.59	3.72e-33	Primary sclerosing cholangitis;
LIHC	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.39e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg12798992	chr6:167411361	FGFR1OP	-0.61	-9.79	-0.47	4.11e-20	Crohn's disease;
LIHC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.42	-6.12	-0.31	2.57e-9	Narcolepsy;
LIHC	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12923728	chr3:195709715	SDHAP1	-0.74	-9.86	-0.47	2.43e-20	Pancreatic cancer;
LIHC	cis	rs7757419	1.000	rs7773328	chr6:34435162	A/T	cg17518776	chr6:34434842	PACSIN1	-0.28	-5.84	-0.3	1.23e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
LIHC	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.64	-7.45	-0.37	7.56e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.52	-8.23	-0.41	4.01e-15	Menarche (age at onset);
LIHC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.76	-14.33	-0.61	8.03e-37	Recombination rate (males);
LIHC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.35	5.96	0.31	6.19e-9	Permanent tooth development;
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02359409	chr6:42947317	PEX6	-0.48	-6.76	-0.34	6.06e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.78	-0.3	1.73e-8	Red blood cell count;
LIHC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.21	-0.36	3.53e-12	Platelet count;
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg21294424	chr19:58662284	ZNF329	0.94	7.38	0.37	1.23e-12	Cholesterol, total;
LIHC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.69	11.0	0.51	2.63e-24	Prostate cancer;
LIHC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.03	-9.42	-0.45	6.78e-19	Diabetic retinopathy;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14528756	chr2:176862893	KIAA1715	-0.28	-6.14	-0.32	2.31e-9	Calcium levels;
LIHC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.01	0.35	1.25e-11	Bipolar disorder;
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg00809820	chr17:80708513	TBCD;FN3K	0.4	7.01	0.35	1.3e-11	Glycated hemoglobin levels;
LIHC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.91	0.39	3.59e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs1144333	0.655	rs11162053	chr1:76470267	A/C	cg22875332	chr1:76189707	ACADM	0.4	6.26	0.32	1.14e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs918629	0.567	rs17085266	chr5:95247634	A/C	cg10483112	chr5:95245456	ELL2	-0.38	-7.13	-0.36	5.87e-12	IgG glycosylation;
LIHC	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20994686	chr17:71306668	CDC42EP4	0.47	6.36	0.33	6.35e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.76	11.6	0.53	1.88e-26	Corneal astigmatism;
LIHC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.56	7.82	0.39	6.52e-14	Morning vs. evening chronotype;
LIHC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg24826892	chr11:71159390	DHCR7	0.47	6.17	0.32	1.91e-9	Vitamin D levels;
LIHC	cis	rs539514	0.591	rs1323710	chr13:76297887	A/G	cg04757411	chr13:76259545	LMO7	-0.43	-7.26	-0.37	2.62e-12	Type 1 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18278596	chr14:105915860	MTA1	-0.4	-6.05	-0.31	3.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08856378	chr17:560590	VPS53	0.54	6.68	0.34	9.75e-11	Systolic blood pressure;
LIHC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-5.91	-0.3	8.31e-9	Fibrinogen levels;
LIHC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.68	-8.47	-0.42	7.14e-16	Gut microbiome composition (summer);
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.38	6.2	0.32	1.6e-9	Obesity-related traits;
LIHC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.85	12.96	0.57	1.62e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.01	-0.31	4.86e-9	Longevity;Endometriosis;
LIHC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.57	-8.14	-0.4	7.5e-15	Coronary artery disease;
LIHC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg05714579	chr10:131428358	MGMT	0.45	7.35	0.37	1.44e-12	Response to temozolomide;
LIHC	cis	rs12744310	1.000	rs1343775	chr1:41757993	A/G	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg14671364	chr1:107599128	PRMT6	0.5	7.21	0.36	3.73e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7212590	0.748	rs62081818	chr17:57890629	C/T	cg10252138	chr17:58120427	NA	-0.62	-6.11	-0.31	2.66e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.87	-0.39	4.69e-14	Total cholesterol levels;
LIHC	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.58	-7.89	-0.39	4.24e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-14.44	-0.62	3.01e-37	Height;
LIHC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.52	6.13	0.31	2.45e-9	Schizophrenia;
LIHC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg23533926	chr12:111358616	MYL2	0.33	6.42	0.33	4.5e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.15	-0.48	2.54e-21	Total cholesterol levels;
LIHC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg26441486	chr22:50317300	CRELD2	0.36	6.4	0.33	4.99e-10	Schizophrenia;
LIHC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg22079354	chr11:130786696	SNX19	0.43	6.14	0.31	2.34e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.79	11.21	0.52	4.9e-25	Obesity-related traits;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg18279126	chr7:2041391	MAD1L1	0.37	6.17	0.32	1.95e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.82	0.43	5.79e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9322817	0.540	rs2034823	chr6:105219573	A/T	cg02098413	chr6:105308735	HACE1	-0.42	-7.55	-0.38	4.01e-13	Thyroid stimulating hormone;
LIHC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg23461800	chr14:103021989	NA	-0.5	-7.15	-0.36	5.28e-12	Platelet count;
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	cis	rs2723064	0.516	rs2901749	chr2:65292570	G/T	cg05010058	chr2:65284262	CEP68	0.37	5.96	0.31	6.13e-9	Atrial fibrillation;
LIHC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.34	8.74	0.43	1.09e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08392591	chr16:89556376	ANKRD11	0.42	6.34	0.32	7.28e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs6788895	1.000	rs73010967	chr3:150498056	T/C	cg09723797	chr3:150481914	SIAH2	0.85	11.79	0.54	3.65e-27	Breast cancer;
LIHC	trans	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg21659725	chr3:3221576	CRBN	0.6	6.47	0.33	3.48e-10	Schizophrenia;
LIHC	cis	rs4788570	0.615	rs889568	chr16:71772399	T/C	cg06353428	chr16:71660113	MARVELD3	1.39	14.99	0.63	2.11e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs798766	0.868	rs4507432	chr4:1748200	A/G	cg21231739	chr4:1642635	FAM53A	-0.37	-5.95	-0.31	6.69e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg07541023	chr7:19748670	TWISTNB	0.39	5.76	0.3	1.88e-8	Thyroid stimulating hormone;
LIHC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.35	6.27	0.32	1.12e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.42	6.85	0.35	3.45e-11	Menopause (age at onset);
LIHC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	7.75	0.39	1.04e-13	Schizophrenia;
LIHC	cis	rs7940866	0.817	rs961491	chr11:130866090	G/T	cg12179176	chr11:130786555	SNX19	0.53	7.73	0.39	1.22e-13	Schizophrenia;
LIHC	cis	rs8084351	0.577	rs4270245	chr18:50621050	A/G	cg24270629	chr18:50823537	DCC	0.44	6.76	0.34	5.88e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.29	-0.32	9.81e-10	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07677032	chr17:61819896	STRADA	0.44	6.5	0.33	2.88e-10	Prudent dietary pattern;
LIHC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	1.01	19.34	0.72	8.03e-57	Breast cancer;
LIHC	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg20991723	chr1:152506922	NA	0.49	8.85	0.43	4.81e-17	Hair morphology;
LIHC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg05697976	chr12:29376483	FAR2	0.3	5.93	0.31	7.62e-9	QT interval;
LIHC	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.52	8.65	0.42	2.02e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.47	-7.35	-0.37	1.49e-12	Multiple myeloma;
LIHC	cis	rs3736485	0.966	rs10519312	chr15:51912971	A/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.56e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg06466757	chr4:1255808	NA	0.3	5.77	0.3	1.8e-8	Obesity-related traits;
LIHC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.21	0.41	4.55e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.2	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg01231543	chr16:68741748	NA	0.39	6.13	0.31	2.4e-9	Colorectal cancer;
LIHC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg20016023	chr10:99160130	RRP12	-0.4	-6.28	-0.32	1.02e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.76	7.04	0.36	1.03e-11	Plasma clusterin levels;
LIHC	cis	rs55665837	0.701	rs10766188	chr11:14660826	T/C	cg25251204	chr11:14927456	NA	0.42	5.76	0.3	1.92e-8	Vitamin D levels;
LIHC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.98	0.31	5.56e-9	Eosinophil percentage of white cells;
LIHC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg18016565	chr1:150552671	MCL1	0.49	9.43	0.45	6.57e-19	Melanoma;
LIHC	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg09904177	chr6:26538194	HMGN4	0.51	5.92	0.3	7.88e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.62	9.89	0.47	1.93e-20	Corneal astigmatism;
LIHC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.8	9.65	0.46	1.16e-19	Cognitive function;
LIHC	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.38	-5.98	-0.31	5.56e-9	Bipolar disorder;
LIHC	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg16006841	chr5:176797999	RGS14	0.79	11.54	0.53	3.12e-26	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.69	11.56	0.53	2.49e-26	Menopause (age at onset);
LIHC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.73	0.39	1.23e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg00277334	chr10:82204260	NA	-0.55	-6.87	-0.35	3.02e-11	Post bronchodilator FEV1;
LIHC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg00343986	chr7:65444356	GUSB	0.4	5.99	0.31	5.42e-9	Aortic root size;
LIHC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.49	6.72	0.34	7.44e-11	High light scatter reticulocyte count;
LIHC	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg12903224	chr12:29470962	FAR2	-0.39	-6.34	-0.32	7.44e-10	QT interval;
LIHC	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.54	6.21	0.32	1.51e-9	Sitting height ratio;
LIHC	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.56	-6.86	-0.35	3.22e-11	Breast cancer;
LIHC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.65	0.38	2.09e-13	Tonsillectomy;
LIHC	cis	rs17286411	0.750	rs35619990	chr16:71949266	C/T	cg03805757	chr16:71968109	PKD1L3	0.42	5.82	0.3	1.35e-8	Blood protein levels;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg03721293	chr16:90014378	DEF8	0.41	6.89	0.35	2.62e-11	Skin colour saturation;
LIHC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.34	5.86	0.3	1.07e-8	Body mass index;
LIHC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.4	-0.33	5.08e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg18116418	chr1:152553244	LCE3D	-0.31	-5.74	-0.3	2.14e-8	Psoriasis;
LIHC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.26	-0.41	3.18e-15	Chronic sinus infection;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.75e-9	Prudent dietary pattern;
LIHC	cis	rs36051895	0.589	rs6476950	chr9:5218416	A/T	cg02405213	chr9:5042618	JAK2	-0.66	-10.46	-0.49	2.15e-22	Pediatric autoimmune diseases;
LIHC	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg26031613	chr14:104095156	KLC1	-0.41	-5.78	-0.3	1.66e-8	Coronary artery disease;
LIHC	trans	rs654384	0.898	rs11766511	chr7:4173613	A/G	cg26675336	chr15:86133334	AKAP13	0.29	6.18	0.32	1.8e-9	Positive affect;
LIHC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04317338	chr11:64019027	PLCB3	0.52	7.11	0.36	6.98e-12	Platelet count;
LIHC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.28	0.49	8.95e-22	Diabetic retinopathy;
LIHC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.7	9.57	0.46	2.22e-19	Sudden cardiac arrest;
LIHC	cis	rs4407350	1.000	rs4407350	chr22:44922275	G/A	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.16	-0.32	2.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9322817	0.691	rs2168394	chr6:105259152	C/T	cg02098413	chr6:105308735	HACE1	-0.43	-8.06	-0.4	1.28e-14	Thyroid stimulating hormone;
LIHC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.72	0.3	2.28e-8	Parkinson's disease;
LIHC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	5.93	0.31	7.59e-9	IgG glycosylation;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15089892	chr3:101568188	NFKBIZ	0.51	6.81	0.35	4.32e-11	Myopia (pathological);
LIHC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.36	5.86	0.3	1.11e-8	Height;
LIHC	cis	rs244293	0.657	rs4829	chr17:53039315	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.13	-0.31	2.47e-9	Menarche (age at onset);
LIHC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.98	-0.31	5.68e-9	Colorectal cancer;
LIHC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.26	0.55	7.01e-29	Cognitive test performance;
LIHC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10431058	0.930	rs11212297	chr11:107475371	T/C	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.41	6.44	0.33	4.1e-10	Common traits (Other);
LIHC	cis	rs600626	0.529	rs11236525	chr11:75467545	C/G	cg24262691	chr11:75473276	NA	0.43	6.49	0.33	3.06e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs72627123	0.867	rs73301479	chr14:74467757	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.63	0.42	2.42e-16	Morning vs. evening chronotype;
LIHC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.48	0.53	4.87e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8049603	1.000	rs4968046	chr16:23078389	C/T	cg16484020	chr16:23217411	SCNN1G	-0.25	-5.71	-0.3	2.44e-8	Multiple sclerosis;
LIHC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.54	7.8	0.39	7.76e-14	Obesity-related traits;
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-7.21	-0.36	3.55e-12	Longevity;Endometriosis;
LIHC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg04450456	chr4:17643702	FAM184B	0.34	5.74	0.3	2.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.69	11.25	0.52	3.29e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg08499158	chr17:42289980	UBTF	-0.5	-8.13	-0.4	7.94e-15	Total body bone mineral density;
LIHC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.5e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs249954	0.512	rs249856	chr16:23658976	G/A	cg01460202	chr16:23706506	ERN2	0.35	5.75	0.3	1.97e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.86	15.52	0.64	1.73e-41	Body mass index;
LIHC	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.52	-10.45	-0.49	2.3e-22	Plateletcrit;Platelet count;
LIHC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg18944383	chr4:111397179	ENPEP	0.25	6.16	0.32	2.02e-9	Coronary artery disease;
LIHC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.57	9.68	0.46	9.89e-20	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs13190036	0.792	rs6874206	chr5:176650971	G/T	cg06532880	chr5:176731545	PRELID1;RAB24	0.43	5.86	0.3	1.09e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.52	7.63	0.38	2.37e-13	Initial pursuit acceleration;
LIHC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg02931644	chr1:25747376	RHCE	0.35	7.67	0.38	1.78e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg05590025	chr7:65112418	INTS4L2	-0.59	-6.58	-0.34	1.81e-10	Diabetic kidney disease;
LIHC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.68	10.27	0.49	9.42e-22	Response to diuretic therapy;
LIHC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg14440974	chr22:39074834	NA	-0.33	-5.79	-0.3	1.58e-8	Menopause (age at onset);
LIHC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.61	10.36	0.49	4.77e-22	Alcohol dependence;
LIHC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.34	7.96	0.4	2.48e-14	Longevity;Endometriosis;
LIHC	cis	rs7945718	0.621	rs10831895	chr11:12683327	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.78	0.39	8.58e-14	Educational attainment (years of education);
LIHC	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.49	7.64	0.38	2.14e-13	Schizophrenia;
LIHC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.46	-17.49	-0.69	2.16e-49	Breast cancer;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.73	14.5	0.62	1.78e-37	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.9	-10.5	-0.49	1.52e-22	Vitiligo;
LIHC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.59	-10.39	-0.49	3.84e-22	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15457276	chr19:4832024	TICAM1	0.4	6.08	0.31	3.22e-9	Cognitive function;
LIHC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11645453	chr3:52864694	ITIH4	-0.22	-5.77	-0.3	1.78e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg05896524	chr21:47604654	C21orf56	0.49	7.37	0.37	1.29e-12	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg00280220	chr17:61926910	NA	0.41	6.5	0.33	2.79e-10	Prudent dietary pattern;
LIHC	cis	rs1198430	0.568	rs1119439	chr1:23828904	A/T	cg13183780	chr1:23809682	ASAP3	-0.59	-7.82	-0.39	6.8e-14	Total cholesterol levels;
LIHC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.97	-0.35	1.6e-11	Morning vs. evening chronotype;
LIHC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.6	5.99	0.31	5.39e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.12	0.4	8.32e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.07e-40	Aortic root size;
LIHC	trans	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg17675199	chr6:35436792	RPL10A	0.34	6.61	0.34	1.44e-10	Coronary artery disease;
LIHC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	11.93	0.54	1.17e-27	Total cholesterol levels;
LIHC	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg14515779	chr1:101123966	NA	-0.66	-13.12	-0.58	3.93e-32	Monocyte count;
LIHC	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.5	7.5	0.38	5.51e-13	Lymphocyte counts;
LIHC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg22663859	chr13:21900854	NA	0.46	7.32	0.37	1.79e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.35	6.0	0.31	4.97e-9	Mean corpuscular volume;
LIHC	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg19633962	chr1:26362018	EXTL1	-0.71	-6.2	-0.32	1.61e-9	QRS complex (12-leadsum);
LIHC	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.31	0.55	4.57e-29	Coffee consumption (cups per day);
LIHC	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.53	9.01	0.44	1.51e-17	Schizophrenia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12830829	chr14:51707081	TMX1	-0.35	-6.15	-0.32	2.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.94	14.45	0.62	2.7e-37	Sudden cardiac arrest;
LIHC	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg10820045	chr2:198174542	NA	0.46	7.25	0.37	2.8e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs526821	0.553	rs519637	chr11:55295935	A/T	cg04317927	chr11:55418816	OR4S2	0.47	8.95	0.44	2.33e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg14222432	chr12:29376421	FAR2	0.35	6.72	0.34	7.42e-11	QT interval;
LIHC	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg16583315	chr14:65563665	MAX	-0.4	-8.2	-0.41	5.07e-15	Obesity-related traits;
LIHC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg23262073	chr20:60523788	NA	-0.28	-6.02	-0.31	4.44e-9	Body mass index;
LIHC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.6	0.67	8.33e-46	Smoking behavior;
LIHC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.54	-6.87	-0.35	3.06e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	12.04	0.55	4.45e-28	Cognitive test performance;
LIHC	cis	rs3758785	0.623	rs13447720	chr11:94165326	T/C	cg21580213	chr11:94231278	ANKRD49	-0.38	-6.43	-0.33	4.38e-10	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LIHC	cis	rs757081	0.671	rs214070	chr11:17305317	T/A	cg15432903	chr11:17409602	KCNJ11	-0.45	-5.96	-0.31	6.28e-9	Systolic blood pressure;
LIHC	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg22951263	chr5:87985283	NA	-0.37	-6.41	-0.33	4.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	6.36	0.33	6.3e-10	Neuroticism;
LIHC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.75	11.88	0.54	1.71e-27	Corneal astigmatism;
LIHC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg24130564	chr14:104152367	KLC1	-0.55	-8.9	-0.43	3.42e-17	Reticulocyte count;
LIHC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg05941027	chr17:61774174	LIMD2	-0.3	-6.04	-0.31	4.01e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.54	6.41	0.33	4.82e-10	Alzheimer's disease;
LIHC	trans	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg26939375	chr7:64535504	NA	0.41	6.47	0.33	3.36e-10	Aortic root size;
LIHC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.83	-0.35	3.88e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.32	5.75	0.3	1.93e-8	Aortic root size;
LIHC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	1.02	12.94	0.57	1.96e-31	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.26e-23	Hemoglobin concentration;
LIHC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.45	6.67	0.34	1.02e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.01	-0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	6.93	0.35	2.04e-11	Renal cell carcinoma;
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg03721293	chr16:90014378	DEF8	0.39	6.59	0.34	1.63e-10	Skin colour saturation;
LIHC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.7	-12.73	-0.57	1.14e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12464559	0.649	rs11894672	chr2:152657055	C/T	cg01189475	chr2:152685088	ARL5A	0.64	7.48	0.38	6.16e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.36	-6.06	-0.31	3.57e-9	IgG glycosylation;
LIHC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.83	-0.47	2.99e-20	Schizophrenia;
LIHC	cis	rs2997447	0.723	rs2259849	chr1:26474251	A/T	cg19633962	chr1:26362018	EXTL1	-0.54	-6.37	-0.33	6.17e-10	QRS complex (12-leadsum);
LIHC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17467752	chr17:38218738	THRA	0.4	6.05	0.31	3.79e-9	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs1144333	0.655	rs76992868	chr1:76418916	G/A	cg10523679	chr1:76189770	ACADM	0.45	6.08	0.31	3.19e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02359409	chr6:42947317	PEX6	-0.45	-6.0	-0.31	5.07e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1355223	1.000	rs35365094	chr11:34767790	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.35	-0.32	6.83e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.76	-0.5	1.82e-23	Response to antipsychotic treatment;
LIHC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.63	9.45	0.46	5.47e-19	Platelet count;
LIHC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.13	-0.36	5.89e-12	Migraine;Coronary artery disease;
LIHC	trans	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg21522988	chr12:29376872	FAR2	0.28	6.42	0.33	4.61e-10	QT interval;
LIHC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	1.03	21.81	0.76	1.01e-66	Height;
LIHC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.33	6.48	0.33	3.25e-10	Renal cell carcinoma;
LIHC	cis	rs9443189	0.950	rs276698	chr6:76473071	T/C	cg01950844	chr6:76311363	SENP6	0.49	5.86	0.3	1.11e-8	Prostate cancer;
LIHC	cis	rs4450131	0.522	rs4465331	chr10:126400357	C/T	cg20435097	chr10:126320824	FAM53B	0.65	11.83	0.54	2.71e-27	White blood cell count (basophil);
LIHC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.31	0.32	8.83e-10	Major depressive disorder;
LIHC	cis	rs17094448	0.557	rs117276277	chr14:74497463	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.99	0.44	1.76e-17	Blood protein levels;
LIHC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.78	0.69	1.56e-50	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.81e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.93	-0.43	2.74e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06002616	chr8:101225028	SPAG1	0.34	5.72	0.3	2.36e-8	Atrioventricular conduction;
LIHC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.48	-6.0	-0.31	5.01e-9	Menarche (age at onset);
LIHC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.53	6.8	0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	1.07	12.48	0.56	9.98e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-0.89	-10.59	-0.5	7.24e-23	Mitochondrial DNA levels;
LIHC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.42	0.45	7.19e-19	Bipolar disorder;
LIHC	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.67	8.25	0.41	3.55e-15	Morning vs. evening chronotype;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.99	0.63	2.09e-39	Prudent dietary pattern;
LIHC	cis	rs16828019	0.852	rs71648536	chr1:41632008	T/A	cg20697417	chr1:41786797	NA	0.34	6.57	0.33	1.92e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07609388	chr8:89341103	MMP16	0.45	6.94	0.35	1.95e-11	Pancreatic cancer;
LIHC	cis	rs7129220	0.512	rs1867138	chr11:10228728	A/G	cg01453529	chr11:10209919	SBF2	-0.36	-5.87	-0.3	1.05e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg24826892	chr11:71159390	DHCR7	0.52	6.85	0.35	3.5e-11	Vitamin D levels;
LIHC	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg12193833	chr17:30244370	NA	-0.51	-5.9	-0.3	8.77e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs16858210	0.657	rs73177515	chr3:183566825	T/A	cg25686905	chr3:183603175	PARL	-0.48	-8.4	-0.41	1.21e-15	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.85	-0.39	5.42e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9303280	0.617	rs4795406	chr17:38100134	G/C	cg17467752	chr17:38218738	THRA	0.37	6.02	0.31	4.53e-9	Self-reported allergy;
LIHC	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.72	0.5	2.59e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg20291162	chr17:40259547	DHX58	-0.41	-6.74	-0.34	6.92e-11	Fibrinogen levels;
LIHC	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.27	6.31	0.32	8.77e-10	Heart rate;
LIHC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.56	-8.21	-0.41	4.58e-15	Blood metabolite levels;
LIHC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.45	-5.89	-0.3	9.47e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.9	18.37	0.7	6.22e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.48	-6.76	-0.34	5.85e-11	Schizophrenia;
LIHC	cis	rs12997796	0.556	rs7558827	chr2:86923178	A/G	cg25203885	chr2:87302643	LOC285074	-0.62	-5.8	-0.3	1.55e-8	Schizophrenia;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg26939375	chr7:64535504	NA	0.48	7.22	0.36	3.46e-12	Calcium levels;
LIHC	cis	rs611744	0.967	rs635624	chr8:109197799	G/C	cg18478394	chr8:109455254	TTC35	0.4	6.94	0.35	1.93e-11	Dupuytren's disease;
LIHC	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.21	5.74	0.3	2.06e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.32	-0.41	2.16e-15	Body mass index;
LIHC	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.65	12.44	0.56	1.43e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.46	-6.55	-0.33	2.14e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.77	-0.34	5.62e-11	Hip circumference;Waist circumference;
LIHC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-9.58	-0.46	2.02e-19	Reticulocyte count;
LIHC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.55	7.56	0.38	3.71e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs8083850	0.635	rs9950970	chr18:50863808	T/C	cg24270629	chr18:50823537	DCC	-0.56	-8.58	-0.42	3.47e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.35	0.37	1.48e-12	Monocyte percentage of white cells;
LIHC	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.98	-0.35	1.57e-11	Prevalent atrial fibrillation;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-7.93	-0.39	3.16e-14	Vitamin D levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05611805	chr7:120498369	TSPAN12	0.38	6.22	0.32	1.46e-9	Cognitive function;
LIHC	cis	rs11031096	0.628	rs10835735	chr11:4211865	G/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.76	-0.3	1.85e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-6.46	-0.33	3.5e-10	Red cell distribution width;
LIHC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.83	-0.3	1.26e-8	Breast cancer;
LIHC	trans	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg05791018	chr13:19965014	NA	-0.28	-6.39	-0.33	5.49e-10	Schizophrenia;
LIHC	cis	rs4689642	0.756	rs4689091	chr4:7226892	G/A	cg21353189	chr4:7228343	SORCS2	0.37	6.14	0.32	2.28e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.46	-0.33	3.65e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.94	-12.02	-0.54	5.51e-28	Body mass index;
LIHC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.34	-6.15	-0.32	2.22e-9	Alzheimer's disease (late onset);
LIHC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.79	-12.71	-0.57	1.47e-30	Parkinson's disease;
LIHC	cis	rs10883723	0.579	rs1967815	chr10:104287051	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.23	0.32	1.35e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg12046867	chr14:103022105	NA	-0.47	-6.79	-0.34	4.94e-11	Platelet count;
LIHC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.71	12.09	0.55	2.96e-28	Menopause (age at onset);
LIHC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.9	-0.3	8.53e-9	Systemic lupus erythematosus;
LIHC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.44	6.17	0.32	1.96e-9	Height;
LIHC	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg14515779	chr1:101123966	NA	-0.6	-11.37	-0.52	1.21e-25	Monocyte count;
LIHC	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	14.03	0.6	1.23e-35	Cognitive test performance;
LIHC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.71	-0.3	2.41e-8	Breast cancer;
LIHC	cis	rs1865721	1.000	rs3813080	chr18:73186227	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.78	-0.39	8.81e-14	Intelligence;
LIHC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg24826892	chr11:71159390	DHCR7	0.47	6.11	0.31	2.68e-9	Vitamin D levels;
LIHC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-9.43	-0.45	6.36e-19	Initial pursuit acceleration;
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-7.0	-0.35	1.36e-11	Obesity-related traits;
LIHC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.54e-11	Ileal carcinoids;
LIHC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.51	5.73	0.3	2.25e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.63	7.42	0.37	9.21e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.56e-9	Aortic root size;
LIHC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.14e-25	Corneal astigmatism;
LIHC	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24633967	chr5:134195255	C5orf24	-0.3	-6.39	-0.33	5.33e-10	Calcium levels;
LIHC	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.6	-7.45	-0.37	7.5e-13	Blood metabolite levels;
LIHC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs11098699	0.718	rs13116874	chr4:124212211	T/C	cg09941581	chr4:124220074	SPATA5	0.33	6.6	0.34	1.57e-10	Mosquito bite size;
LIHC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-0.49	-6.05	-0.31	3.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.49	-0.33	2.94e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05347473	chr6:146136440	FBXO30	0.34	5.76	0.3	1.9e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2997447	0.846	rs3008235	chr1:26408409	T/C	cg19633962	chr1:26362018	EXTL1	-0.53	-6.2	-0.32	1.59e-9	QRS complex (12-leadsum);
LIHC	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-11.83	-0.54	2.75e-27	Morning vs. evening chronotype;
LIHC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg10820045	chr2:198174542	NA	0.53	8.93	0.43	2.67e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	0.98	10.31	0.49	7.06e-22	Vitiligo;
LIHC	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg20991723	chr1:152506922	NA	0.57	10.06	0.48	4.84e-21	Hair morphology;
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.63	6.55	0.33	2.14e-10	Alzheimer's disease;
LIHC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.3	0.45	1.77e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs903552	1.000	rs12908079	chr15:102003820	C/A	cg19295451	chr15:102010161	PCSK6	-0.45	-6.44	-0.33	4.11e-10	Diabetic kidney disease;
LIHC	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.48	-7.35	-0.37	1.52e-12	Gastritis;
LIHC	cis	rs13126513	0.708	rs883028	chr4:100451375	A/G	cg05468953	chr4:100565104	NA	0.32	6.35	0.32	7e-10	Metabolite levels (MHPG);
LIHC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.52	8.53	0.42	4.81e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.16	0.52	7.3e-25	Cognitive test performance;
LIHC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.62	-0.81	1.41e-81	Myeloid white cell count;
LIHC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.68	-6.52	-0.33	2.48e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.16	-0.4	6.4e-15	Glycated hemoglobin levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13027571	chr2:219081765	ARPC2	-0.62	-7.12	-0.36	6.59e-12	Systolic blood pressure;
LIHC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.48	6.43	0.33	4.24e-10	Coronary artery disease;
LIHC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg14222432	chr12:29376421	FAR2	0.35	6.84	0.35	3.66e-11	QT interval;
LIHC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21545522	chr1:205238299	TMCC2	-0.37	-7.1	-0.36	7.49e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg18306943	chr3:40428807	ENTPD3	0.34	6.06	0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-10.32	-0.49	6.31e-22	Alzheimer's disease;
LIHC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.51	6.49	0.33	3.08e-10	Menarche (age at onset);
LIHC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-11.88	-0.54	1.68e-27	Alzheimer's disease;
LIHC	cis	rs7301016	0.846	rs17732182	chr12:63026131	C/T	cg11441379	chr12:63026424	NA	0.61	6.26	0.32	1.15e-9	IgG glycosylation;
LIHC	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg24220031	chr2:73402428	NA	-0.27	-5.77	-0.3	1.76e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.4	-8.48	-0.42	6.68e-16	Obesity-related traits;
LIHC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg07959070	chr22:50026188	C22orf34	-0.32	-8.42	-0.41	1.03e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.25	-13.18	-0.58	2.36e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.45	-7.63	-0.38	2.4e-13	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.23	-0.32	1.4e-9	Mean corpuscular volume;
LIHC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg06238570	chr21:40685208	BRWD1	0.6	7.11	0.36	6.92e-12	Cognitive function;
LIHC	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	7.24	0.36	3.07e-12	Diastolic blood pressure;
LIHC	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg12253828	chr6:101329408	ASCC3	-0.39	-5.95	-0.31	6.78e-9	Neuroticism;
LIHC	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg10820045	chr2:198174542	NA	0.46	7.01	0.35	1.3e-11	Dermatomyositis;
LIHC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs918629	0.724	rs55841351	chr5:95278019	A/G	cg10483112	chr5:95245456	ELL2	-0.35	-6.02	-0.31	4.47e-9	IgG glycosylation;
LIHC	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.36	-6.1	-0.31	2.88e-9	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	7.99	0.4	2.15e-14	Height;
LIHC	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.47	-7.88	-0.39	4.39e-14	Longevity;
LIHC	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg20240347	chr1:204465584	NA	-0.35	-7.48	-0.37	6.4e-13	Schizophrenia;
LIHC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg12863693	chr15:85201151	NMB	0.41	5.73	0.3	2.25e-8	Schizophrenia;
LIHC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.89	-0.3	9.2e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.76	-0.43	9.46e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.4	0.37	1.1e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.49	-7.27	-0.37	2.5e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg15664640	chr17:80829946	TBCD	0.38	5.99	0.31	5.25e-9	Glycated hemoglobin levels;
LIHC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.45	6.1	0.31	2.91e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2016586	0.802	rs5999974	chr22:36115897	C/A	cg26342177	chr22:36113512	APOL5	-0.39	-6.57	-0.33	1.82e-10	Body mass index;
LIHC	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.5	-7.38	-0.37	1.19e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.61	-12.74	-0.57	1.08e-30	Plateletcrit;Platelet count;
LIHC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.4	7.68	0.38	1.68e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg03934865	chr2:198174659	NA	0.53	8.07	0.4	1.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg21395723	chr22:39101663	GTPBP1	0.37	6.17	0.32	1.92e-9	Menopause (age at onset);
LIHC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg18225595	chr11:63971243	STIP1	-0.46	-6.06	-0.31	3.59e-9	Platelet count;
LIHC	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg20991723	chr1:152506922	NA	0.54	9.36	0.45	1.13e-18	Hair morphology;
LIHC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	8.54	0.42	4.36e-16	Obesity-related traits;
LIHC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg12863693	chr15:85201151	NMB	0.49	7.11	0.36	6.72e-12	Schizophrenia;
LIHC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg18357526	chr6:26021779	HIST1H4A	0.42	6.28	0.32	1.03e-9	Height;
LIHC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg03037974	chr15:76606532	NA	-0.6	-9.96	-0.47	1.13e-20	Blood metabolite levels;
LIHC	cis	rs12095069	1	rs12095069	chr1:76463072	T/C	cg22875332	chr1:76189707	ACADM	0.4	6.24	0.32	1.26e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06217312	chr1:150552348	MCL1	-0.44	-6.1	-0.31	2.84e-9	Pancreatic cancer;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg05484376	chr2:27715224	FNDC4	0.37	6.33	0.32	7.68e-10	Total body bone mineral density;
LIHC	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg17385448	chr1:15911702	AGMAT	0.35	6.15	0.32	2.21e-9	Systolic blood pressure;
LIHC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg09222892	chr1:25734099	RHCE	-0.47	-8.74	-0.43	1.07e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.43	-7.49	-0.38	6.02e-13	Coronary artery disease;
LIHC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.96	-18.04	-0.7	1.31e-51	Breast cancer;
LIHC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.03	0.44	1.32e-17	Schizophrenia;
LIHC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.48	5.81	0.3	1.42e-8	Testicular germ cell tumor;
LIHC	cis	rs11786130	1.000	rs3815871	chr8:129008578	G/C	cg01765152	chr8:129005526	PVT1	-0.3	-6.33	-0.32	7.77e-10	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.19	15.39	0.64	5.81e-41	Alzheimer's disease (late onset);
LIHC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg10932868	chr11:921992	NA	0.36	6.61	0.34	1.48e-10	Alzheimer's disease (late onset);
LIHC	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.77	10.87	0.51	7.86e-24	Response to hepatitis C treatment;
LIHC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.78	-7.56	-0.38	3.8e-13	Diabetic retinopathy;
LIHC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.39	6.07	0.31	3.42e-9	Menopause (age at onset);
LIHC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.51	-9.53	-0.46	3e-19	Atrioventricular conduction;
LIHC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.55	-8.15	-0.4	7.18e-15	Ulcerative colitis;
LIHC	cis	rs2412488	0.927	rs1021099	chr4:54245775	A/G	cg22241045	chr4:54363911	LNX1	-0.4	-6.48	-0.33	3.15e-10	DNA methylation (variation);
LIHC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg12798992	chr6:167411361	FGFR1OP	0.52	8.03	0.4	1.59e-14	Crohn's disease;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.57	8.69	0.43	1.48e-16	Renal cell carcinoma;
LIHC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg19500275	chr17:80737654	TBCD	0.41	5.78	0.3	1.72e-8	Glycated hemoglobin levels;
LIHC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.51	-7.75	-0.39	1.07e-13	Longevity;Endometriosis;
LIHC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12463550	chr7:65579703	CRCP	0.67	7.18	0.36	4.48e-12	Diabetic kidney disease;
LIHC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.63	0.53	1.49e-26	Platelet count;
LIHC	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg03934865	chr2:198174659	NA	0.53	7.94	0.39	2.92e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.5	7.74	0.39	1.1e-13	Tonsillectomy;
LIHC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-7.11	-0.36	6.85e-12	Osteoporosis;
LIHC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.19	-0.32	1.73e-9	Schizophrenia;
LIHC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.48	6.54	0.33	2.24e-10	High light scatter reticulocyte count;
LIHC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg13251533	chr12:132286017	NA	0.39	6.52	0.33	2.47e-10	Migraine;
LIHC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg01864836	chr14:55583639	NA	-0.4	-7.62	-0.38	2.49e-13	Protein biomarker;
LIHC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.2e-9	Tonsillectomy;
LIHC	cis	rs7187994	0.848	rs12933228	chr16:84770691	G/A	cg07647771	chr16:84786436	USP10	-0.34	-6.17	-0.32	1.9e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.45	6.78	0.34	5.17e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04696171	chr16:89787876	C16orf7;ZNF276	0.38	6.15	0.32	2.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg14067834	chr17:29058358	SUZ12P	0.6	5.78	0.3	1.72e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.35	8.96	0.44	2.08e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.27	-16.34	-0.66	9.2e-45	Diabetic kidney disease;
LIHC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.7	6.85	0.35	3.35e-11	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.14	0.31	2.34e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.44	-8.11	-0.4	9.27e-15	Red cell distribution width;
LIHC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs1559088	0.501	rs35599132	chr19:33570554	G/A	cg27124370	chr19:33622961	WDR88	0.49	6.9	0.35	2.56e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.64	-9.88	-0.47	2.06e-20	Glaucoma (primary open-angle);
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.2	0.55	1.12e-28	Prudent dietary pattern;
LIHC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-8.42	-0.41	1.04e-15	Primary biliary cholangitis;
LIHC	cis	rs6066825	0.644	rs6066823	chr20:47338768	C/G	cg18078177	chr20:47281410	PREX1	0.4	6.49	0.33	2.98e-10	Colorectal cancer;
LIHC	cis	rs600806	0.665	rs1368988	chr1:110012123	A/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.25	-0.32	1.22e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4700695	0.841	rs36303	chr5:65350374	A/G	cg21114390	chr5:65439923	SFRS12	-0.45	-5.71	-0.3	2.43e-8	Facial morphology (factor 19);
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08677398	chr8:58056175	NA	0.41	5.99	0.31	5.21e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.74	0.3	2.07e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg14067834	chr17:29058358	SUZ12P	0.64	6.31	0.32	8.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.54	8.11	0.4	8.92e-15	Corneal astigmatism;
LIHC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.63	-7.84	-0.39	5.63e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-9.64	-0.46	1.27e-19	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.31	-7.74	-0.39	1.11e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.66	9.79	0.47	4.16e-20	Menopause (age at onset);
LIHC	cis	rs7116495	0.867	rs609492	chr11:71563123	T/C	cg26138937	chr11:71823887	C11orf51	0.63	6.11	0.31	2.64e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg03934865	chr2:198174659	NA	0.46	6.64	0.34	1.2e-10	Dermatomyositis;
LIHC	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.57	7.63	0.38	2.41e-13	Plateletcrit;
LIHC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.48	6.06	0.31	3.66e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.62	0.38	2.59e-13	Heart rate;
LIHC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg00142150	chr22:38071001	LGALS1	0.69	11.05	0.51	1.84e-24	Fat distribution (HIV);
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.85	-0.35	3.51e-11	Diastolic blood pressure;
LIHC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg08822215	chr16:89438651	ANKRD11	0.45	7.41	0.37	1.03e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.12	-0.31	2.5e-9	Schizophrenia;
LIHC	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg17385448	chr1:15911702	AGMAT	0.41	6.8	0.35	4.65e-11	Systolic blood pressure;
LIHC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	11.1	0.51	1.19e-24	Monocyte percentage of white cells;
LIHC	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.72	-11.15	-0.52	7.6e-25	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg03037974	chr15:76606532	NA	0.8	16.38	0.66	6.39e-45	Blood metabolite levels;
LIHC	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.62	9.4	0.45	8.03e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.73	8.92	0.43	2.91e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	3.15e-30	Menopause (age at onset);
LIHC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.33	0.41	2.02e-15	Motion sickness;
LIHC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.44	-0.59	2.29e-33	Aortic root size;
LIHC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.84	14.88	0.63	5.67e-39	Headache;
LIHC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.84	10.53	0.49	1.23e-22	Mean platelet volume;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.73	-10.91	-0.51	5.54e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.08	0.36	8.26e-12	Renal cell carcinoma;
LIHC	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.5	7.33	0.37	1.73e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.31	-0.32	8.87e-10	Diabetic kidney disease;
LIHC	cis	rs4407350	0.756	rs135622	chr22:44890658	T/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.43	0.33	4.31e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.35	-0.41	1.69e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg00280220	chr17:61926910	NA	0.42	6.74	0.34	6.72e-11	Prudent dietary pattern;
LIHC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.72	-11.15	-0.52	7.92e-25	Corneal astigmatism;
LIHC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.5	-7.27	-0.37	2.41e-12	Breast size;
LIHC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.58	-8.61	-0.42	2.7e-16	Cerebrospinal P-tau181p levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17152101	chr1:32509371	KHDRBS1	-0.25	-6.18	-0.32	1.87e-9	Calcium levels;
LIHC	cis	rs1144333	0.655	rs58722308	chr1:76423525	A/G	cg10523679	chr1:76189770	ACADM	0.45	6.08	0.31	3.19e-9	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg25195416	chr21:46696626	POFUT2	0.6	6.54	0.33	2.22e-10	Mean platelet volume;
LIHC	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-7.81	-0.39	7.1e-14	Endometrial cancer;
LIHC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs600806	0.676	rs573491	chr1:110026891	T/G	cg02415029	chr1:110025642	ATXN7L2	0.46	6.05	0.31	3.75e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.31	6.54	0.33	2.22e-10	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06714086	chr11:33182787	CSTF3	0.46	6.9	0.35	2.57e-11	Cognitive function;
LIHC	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg09904177	chr6:26538194	HMGN4	-0.38	-6.11	-0.31	2.72e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01822624	chr5:32710882	NPR3	-0.43	-6.21	-0.32	1.56e-9	Body mass index;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15216925	chr5:179921655	CNOT6	0.45	6.82	0.35	4.22e-11	Calcium levels;
LIHC	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg23091122	chr1:110024289	SYPL2	-0.52	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.75	5.9	0.3	8.88e-9	Blood protein levels;
LIHC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.33	6.75	0.34	6.52e-11	Bone mineral density;
LIHC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg26149184	chr10:133730230	NA	0.47	7.41	0.37	1.03e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.55	-0.38	3.92e-13	Morning vs. evening chronotype;
LIHC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.49	6.02	0.31	4.41e-9	Childhood ear infection;
LIHC	cis	rs12220238	0.915	rs2894235	chr10:76082945	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-8.42	-0.41	1.08e-15	Schizophrenia;
LIHC	cis	rs1144333	0.655	rs1146649	chr1:76268803	A/G	cg03433033	chr1:76189801	ACADM	-0.54	-7.67	-0.38	1.78e-13	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs11039100	1.000	rs11039100	chr11:5827003	C/T	cg11650987	chr12:10280440	CLEC7A	-0.4	-6.15	-0.32	2.17e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07677032	chr17:61819896	STRADA	0.41	5.97	0.31	6.09e-9	Prudent dietary pattern;
LIHC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.39	5.79	0.3	1.63e-8	Melanoma;
LIHC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg22676075	chr6:135203613	NA	0.39	6.31	0.32	8.89e-10	Red blood cell count;
LIHC	cis	rs17152411	1.000	rs7097282	chr10:126593492	T/C	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.42e-12	Height;
LIHC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.96	0.44	2.11e-17	Electroencephalogram traits;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.36	-6.07	-0.31	3.33e-9	Paraoxonase activity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01634057	chr4:123843788	NUDT6;SPATA5	0.49	6.22	0.32	1.45e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg11764359	chr7:65958608	NA	-0.63	-8.3	-0.41	2.41e-15	Calcium levels;
LIHC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.58	-11.0	-0.51	2.62e-24	Type 2 diabetes;
LIHC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.53	8.43	0.41	9.67e-16	Anterior chamber depth;
LIHC	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.71	-8.32	-0.41	2.17e-15	Exhaled nitric oxide output;
LIHC	cis	rs55665837	0.540	rs10832294	chr11:14747427	C/A	cg25251204	chr11:14927456	NA	0.41	5.83	0.3	1.25e-8	Vitamin D levels;
LIHC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg10360323	chr17:41437877	NA	0.39	5.83	0.3	1.27e-8	Menopause (age at onset);
LIHC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.36	5.72	0.3	2.36e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6489882	0.867	rs6489867	chr12:113363550	C/T	cg10175203	chr3:128143634	NA	0.38	6.13	0.31	2.38e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02985541	chr2:219472218	PLCD4	0.44	7.27	0.37	2.42e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.97	0.78	2.82e-71	Chronic sinus infection;
LIHC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg03037974	chr15:76606532	NA	0.74	14.58	0.62	8.64e-38	Blood metabolite levels;
LIHC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.88	11.87	0.54	1.9e-27	Blood metabolite levels;
LIHC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.88	-17.28	-0.68	1.62e-48	Height;
LIHC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg00601450	chr5:74908170	NA	-0.73	-9.42	-0.45	7.03e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg00318621	chr2:106887213	NA	-0.59	-5.92	-0.3	7.99e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14671364	chr1:107599128	PRMT6	-0.53	-7.65	-0.38	2.01e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs74233809	1.000	rs79668541	chr10:104793904	C/T	cg03493300	chr10:104813866	CNNM2	0.47	6.17	0.32	1.97e-9	Birth weight;
LIHC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20135002	chr11:47629003	NA	-0.53	-8.97	-0.44	1.94e-17	Subjective well-being;
LIHC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.21	0.55	1.02e-28	Cognitive test performance;
LIHC	cis	rs4742903	0.967	rs4743689	chr9:106909300	G/A	cg14250997	chr9:106856677	SMC2	0.4	7.1	0.36	7.46e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6442522	1.000	rs6442522	chr3:15440556	C/T	cg16303742	chr3:15540471	COLQ	0.42	6.99	0.35	1.48e-11	Uric acid levels;
LIHC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.7	10.64	0.5	4.85e-23	Neutrophil percentage of white cells;
LIHC	trans	rs9409565	0.513	rs16912862	chr9:97050005	A/G	cg05679027	chr9:99775184	HIATL2	-0.38	-6.52	-0.33	2.52e-10	Colorectal cancer (alcohol consumption interaction);
LIHC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.48	7.14	0.36	5.51e-12	Red cell distribution width;
LIHC	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.47	0.49	2e-22	Colorectal cancer;
LIHC	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.87	10.9	0.51	6.08e-24	Prostate cancer;
LIHC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.66	-9.86	-0.47	2.31e-20	Coronary artery disease;
LIHC	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-5.97	-0.31	5.79e-9	Homocysteine levels;
LIHC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.59	8.54	0.42	4.33e-16	Platelet count;
LIHC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.82	0.39	6.61e-14	Motion sickness;
LIHC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	8.12	0.4	8.8e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.48	6.43	0.33	4.42e-10	Major depressive disorder;
LIHC	trans	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg25214090	chr10:38739885	LOC399744	0.39	6.51	0.33	2.7e-10	Diastolic blood pressure;
LIHC	cis	rs7103411	0.637	rs6416056	chr11:27646745	A/G	cg18117895	chr11:27722066	BDNF	0.44	6.34	0.32	7.12e-10	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.85	-15.39	-0.64	5.63e-41	Aortic root size;
LIHC	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.48	-7.08	-0.36	8.41e-12	Mortality in heart failure;
LIHC	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg13482628	chr17:19912719	NA	0.56	9.33	0.45	1.36e-18	Schizophrenia;
LIHC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.6	-10.51	-0.49	1.39e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.54	7.29	0.37	2.14e-12	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	15.39	0.64	5.52e-41	Exhaled nitric oxide output;
LIHC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.12	0.4	8.8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.69	0.57	1.62e-30	Monocyte count;
LIHC	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg27129171	chr3:47204927	SETD2	0.48	7.67	0.38	1.79e-13	Birth weight;
LIHC	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg14675211	chr2:100938903	LONRF2	-0.46	-7.08	-0.36	8.3e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.5	7.7	0.38	1.48e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.57	6.69	0.34	9.33e-11	Bipolar disorder;
LIHC	cis	rs864643	1.000	rs1707988	chr3:39551526	G/A	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs526231	0.853	rs1991797	chr5:102622453	G/T	cg05225461	chr5:102596755	C5orf30	0.38	5.9	0.3	8.85e-9	Primary biliary cholangitis;
LIHC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04221910	chr5:616842	CEP72	0.41	7.33	0.37	1.63e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs59901009	0.863	rs56758314	chr11:10192648	C/T	cg01453529	chr11:10209919	SBF2	-0.32	-6.39	-0.33	5.55e-10	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.77	0.39	9.57e-14	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg13482628	chr17:19912719	NA	0.49	7.98	0.4	2.24e-14	Schizophrenia;
LIHC	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.13	-10.08	-0.48	4.44e-21	Schizophrenia;
LIHC	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.83	-0.35	3.86e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg18335740	chr13:41363409	SLC25A15	0.35	6.12	0.31	2.55e-9	Lewy body disease;
LIHC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.35	5.73	0.3	2.21e-8	Blood metabolite levels;
LIHC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.26	-0.37	2.64e-12	Psoriasis;
LIHC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.73	10.43	0.49	2.65e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg22777020	chr22:31556080	RNF185	-0.55	-6.32	-0.32	8.03e-10	Colorectal cancer;
LIHC	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	6.91	0.35	2.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.55	8.28	0.41	2.73e-15	Gout;
LIHC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.6	-0.46	1.78e-19	Obesity-related traits;
LIHC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg12863693	chr15:85201151	NMB	0.48	6.98	0.35	1.52e-11	Schizophrenia;
LIHC	cis	rs244293	0.965	rs244357	chr17:53193181	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.54	-0.38	4.15e-13	Menarche (age at onset);
LIHC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.97	0.31	6.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg00091569	chr3:40428383	ENTPD3	0.37	6.04	0.31	4.03e-9	Renal cell carcinoma;
LIHC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.43	0.45	6.65e-19	Morning vs. evening chronotype;
LIHC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.75	9.98	0.47	9.57e-21	Coronary artery disease;
LIHC	cis	rs8084351	0.599	rs948524	chr18:50677159	T/C	cg24270629	chr18:50823537	DCC	-0.45	-6.73	-0.34	7.1e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.26	-0.41	3.27e-15	Chronic sinus infection;
LIHC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg17135325	chr3:160939158	NMD3	0.6	8.63	0.42	2.32e-16	Parkinson's disease;
LIHC	cis	rs6065325	0.514	rs4812512	chr20:40094515	C/A	cg06610464	chr20:40243608	CHD6	0.38	6.16	0.32	2.07e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg05185784	chr16:90016020	DEF8	-0.44	-5.96	-0.31	6.27e-9	Skin colour saturation;
LIHC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg19680672	chr10:131412579	MGMT	-0.43	-6.61	-0.34	1.44e-10	Response to temozolomide;
LIHC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.97	0.35	1.65e-11	Self-reported allergy;
LIHC	cis	rs16828019	0.852	rs12406620	chr1:41512664	A/T	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.43	-6.96	-0.35	1.8e-11	Mitral valve prolapse;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19531713	chr17:41277059	BRCA1;NBR2	0.46	6.67	0.34	1.03e-10	Pancreatic cancer;
LIHC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-6.87	-0.35	3.01e-11	Hepatocellular carcinoma;
LIHC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04317338	chr11:64019027	PLCB3	0.49	6.73	0.34	7.06e-11	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11601666	chr17:8286754	RPL26	0.43	6.08	0.31	3.16e-9	Lung function (FEV1/FVC);
LIHC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs61677309	1.000	rs59450866	chr11:118167707	C/T	cg06090739	chr11:118230722	UBE4A	0.35	6.44	0.33	4.14e-10	Lung cancer in ever smokers;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12565055	chr22:29076175	TTC28	-0.41	-6.39	-0.33	5.33e-10	Systolic blood pressure;
LIHC	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.71	-7.72	-0.39	1.28e-13	Opioid sensitivity;
LIHC	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg06627628	chr2:24431161	ITSN2	-0.64	-7.48	-0.37	6.51e-13	Lymphocyte counts;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg09417038	chr21:47716443	C21orf57	0.49	7.58	0.38	3.31e-13	Testicular germ cell tumor;
LIHC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.46	6.19	0.32	1.76e-9	Major depressive disorder;
LIHC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.52	9.0	0.44	1.58e-17	Height;
LIHC	cis	rs17125944	0.615	rs7146915	chr14:53316039	C/T	cg00686598	chr14:53173677	PSMC6	-0.76	-9.19	-0.45	3.83e-18	Alzheimer's disease (late onset);
LIHC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg20651018	chr11:3035856	CARS	-0.36	-6.18	-0.32	1.81e-9	Longevity;
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.72	-11.13	-0.52	9.29e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.03	14.11	0.61	6.12e-36	Cognitive function;
LIHC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.41	7.96	0.4	2.54e-14	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg20636351	chr8:55087400	NA	-0.37	-7.58	-0.38	3.26e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.9e-38	Blood metabolite levels;
LIHC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg12798992	chr6:167411361	FGFR1OP	0.6	10.02	0.48	6.67e-21	Crohn's disease;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08949621	chr15:42265044	EHD4	-0.43	-6.04	-0.31	3.99e-9	Triglycerides;
LIHC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.57	-8.48	-0.42	6.85e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg19743168	chr1:23544995	NA	-0.36	-6.64	-0.34	1.26e-10	Height;
LIHC	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg18898632	chr2:242989856	NA	-0.57	-7.68	-0.38	1.66e-13	Obesity-related traits;
LIHC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.85	10.78	0.5	1.6e-23	Cognitive function;
LIHC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.48	7.46	0.37	7.01e-13	Blood protein levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02046226	chr10:121410475	BAG3	0.47	6.19	0.32	1.74e-9	Hepatitis;
LIHC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.56	-0.82	4.07e-85	Myeloid white cell count;
LIHC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.9	-0.47	1.81e-20	Total cholesterol levels;
LIHC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.21	-0.58	1.83e-32	Type 2 diabetes;
LIHC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg19743168	chr1:23544995	NA	0.36	6.12	0.31	2.5e-9	Height;
LIHC	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg11783602	chr8:55087084	NA	-0.31	-6.15	-0.32	2.19e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.71	12.1	0.55	2.59e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.33	-5.93	-0.31	7.5e-9	Lewy body disease;
LIHC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.75	15.33	0.64	9.55e-41	Menopause (age at onset);
LIHC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.39	-10.14	-0.48	2.65e-21	Asthma (sex interaction);
LIHC	cis	rs11718455	0.585	rs6789465	chr3:43932045	G/A	cg08738300	chr3:44038990	NA	0.37	6.34	0.32	7.23e-10	Coronary artery disease;
LIHC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.44	6.34	0.32	7.38e-10	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.22e-11	Aortic root size;
LIHC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.25e-16	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.82	-0.35	4.26e-11	Diabetic kidney disease;
LIHC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.89	13.62	0.59	4.7e-34	Vitamin D levels;
LIHC	cis	rs11630290	0.592	rs4777332	chr15:64158112	A/G	cg12036633	chr15:63758958	NA	0.63	6.81	0.35	4.47e-11	Iris characteristics;
LIHC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg10978503	chr1:24200527	CNR2	0.29	6.76	0.34	5.86e-11	Immature fraction of reticulocytes;
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.29	-0.32	9.49e-10	Renal cell carcinoma;
LIHC	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.48	-7.31	-0.37	1.89e-12	Diastolic blood pressure;
LIHC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg00204748	chr12:29376779	FAR2	0.35	6.61	0.34	1.47e-10	QT interval;
LIHC	cis	rs11673344	0.864	rs8110696	chr19:37500351	G/T	cg27390819	chr19:37464633	NA	-0.53	-6.16	-0.32	2.09e-9	Obesity-related traits;
LIHC	cis	rs7674212	0.510	rs6856593	chr4:104177699	T/C	cg16532752	chr4:104119610	CENPE	-0.4	-6.29	-0.32	9.89e-10	Type 2 diabetes;
LIHC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07627390	chr16:23652638	PALB2;DCTN5	0.53	6.89	0.35	2.65e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.95	16.4	0.66	5.36e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg01557791	chr16:72042693	DHODH	-0.43	-7.09	-0.36	7.59e-12	Fibrinogen levels;
LIHC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	0.83	9.36	0.45	1.07e-18	Vitiligo;
LIHC	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg23091122	chr1:110024289	SYPL2	-0.5	-6.69	-0.34	9.06e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.38	6.55	0.33	2.05e-10	Methadone dose in opioid dependence;
LIHC	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.28	6.33	0.32	7.48e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg23933602	chr10:16859644	RSU1	0.62	6.04	0.31	4.05e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.66	-0.34	1.11e-10	Testicular germ cell tumor;
LIHC	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg03934865	chr2:198174659	NA	0.55	8.38	0.41	1.42e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.88	0.39	4.27e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.39	6.8	0.35	4.58e-11	Platelet distribution width;
LIHC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.88	-0.3	9.72e-9	Body mass index;
LIHC	cis	rs4450131	1.000	rs10901802	chr10:126354554	C/G	cg20435097	chr10:126320824	FAM53B	-0.5	-9.1	-0.44	7.69e-18	White blood cell count (basophil);
LIHC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.39	6.26	0.32	1.17e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.59e-14	Platelet count;
LIHC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg19682013	chr15:45996608	NA	0.4	7.12	0.36	6.34e-12	Waist circumference;Weight;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10950113	chr16:69166907	CHTF8;CIRH1A	0.46	6.25	0.32	1.19e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.51	6.7	0.34	8.62e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	0.81	9.25	0.45	2.56e-18	Exhaled nitric oxide output;
LIHC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21171335	chr12:122356390	WDR66	0.43	6.64	0.34	1.24e-10	Mean corpuscular volume;
LIHC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg18357645	chr12:58087776	OS9	-0.44	-6.93	-0.35	2.07e-11	Multiple sclerosis;
LIHC	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.58	-0.34	1.82e-10	Body mass index;
LIHC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.57	-7.11	-0.36	6.67e-12	Ankle injury;
LIHC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.74	-13.79	-0.6	1.05e-34	Height;
LIHC	cis	rs13161895	1.000	rs35135297	chr5:179469532	T/C	cg06664874	chr5:179499304	RNF130	0.61	7.56	0.38	3.66e-13	LDL cholesterol;
LIHC	cis	rs6977660	1.000	rs35784097	chr7:19818848	A/G	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.53	-8.6	-0.42	2.82e-16	Body mass index;
LIHC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02985541	chr2:219472218	PLCD4	0.39	6.45	0.33	3.72e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg26395211	chr5:140044315	WDR55	0.41	6.12	0.31	2.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	10.0	0.48	7.94e-21	Personality dimensions;
LIHC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg12798992	chr6:167411361	FGFR1OP	-0.54	-8.28	-0.41	2.76e-15	Crohn's disease;
LIHC	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg06766960	chr11:133703094	NA	-0.59	-9.44	-0.45	5.84e-19	Childhood ear infection;
LIHC	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg26395211	chr5:140044315	WDR55	-0.44	-6.56	-0.33	2.03e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-10.19	-0.48	1.76e-21	Asthma;
LIHC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.51	-8.97	-0.44	1.97e-17	White blood cell count;
LIHC	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg08847533	chr14:75593920	NEK9	0.48	7.44	0.37	8.33e-13	IgG glycosylation;
LIHC	cis	rs4728302	0.869	rs7805864	chr7:133610390	G/A	cg10665199	chr7:133106180	EXOC4	0.38	6.71	0.34	8.17e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs1000083	0.834	rs1833875	chr5:96594277	G/A	ch.5.96698337R	chr5:96672581	NA	0.86	6.94	0.35	2.02e-11	Cisplatin-induced ototoxicity;
LIHC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.56	-10.22	-0.48	1.42e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05025164	chr4:1340916	KIAA1530	0.41	6.28	0.32	1.02e-9	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.78	12.88	0.57	3.24e-31	Anterior chamber depth;
LIHC	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.27e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg15202627	chr4:1685555	FAM53A	0.48	5.75	0.3	1.95e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.46	-5.81	-0.3	1.45e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-14.11	-0.61	6.07e-36	Height;
LIHC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.1	-23.95	-0.79	4.1e-75	Cognitive ability;
LIHC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.44	6.59	0.34	1.71e-10	Schizophrenia;
LIHC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.71	10.5	0.49	1.5e-22	Aortic root size;
LIHC	trans	rs4596713	0.507	rs10115134	chr9:71800562	T/C	cg16512924	chr15:28394682	HERC2	0.39	6.28	0.32	1e-9	Headache;
LIHC	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.65	7.55	0.38	4.07e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.52	7.23	0.36	3.13e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg07645718	chr20:61493192	TCFL5	0.74	6.16	0.32	2.03e-9	Obesity-related traits;
LIHC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.16	0.36	4.94e-12	Axial length;
LIHC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.47	6.42	0.33	4.67e-10	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.61	6.92	0.35	2.29e-11	Alzheimer's disease;
LIHC	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg03970086	chr16:88974840	CBFA2T3	0.37	7.43	0.37	8.53e-13	Social autistic-like traits;
LIHC	cis	rs12365397	0.775	rs11037365	chr11:43243675	C/T	cg16667275	chr11:43333495	API5	0.41	6.13	0.31	2.36e-9	Migraine;
LIHC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.56	-9.19	-0.45	3.87e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12220238	0.915	rs11000945	chr10:76030739	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.99	0.31	5.26e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.83	-0.35	3.86e-11	Hepatocellular carcinoma;
LIHC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg12798992	chr6:167411361	FGFR1OP	0.48	7.32	0.37	1.77e-12	Crohn's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06221861	chr7:100425075	EPHB4	0.43	6.53	0.33	2.38e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.92	16.75	0.67	2.14e-46	Colorectal cancer;
LIHC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	6.13	0.31	2.45e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4759375	1.000	rs28660993	chr12:123875394	C/T	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.6e-10	HDL cholesterol;
LIHC	trans	rs875971	0.617	rs810400	chr7:66022889	G/C	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg13047869	chr3:10149882	C3orf24	0.5	6.16	0.32	2.08e-9	Alzheimer's disease;
LIHC	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.73	11.96	0.54	9.11e-28	Body mass index;
LIHC	cis	rs7937890	0.572	rs2597218	chr11:14532338	C/T	cg02886208	chr11:14281011	SPON1	-0.48	-6.54	-0.33	2.28e-10	Mitochondrial DNA levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18363668	chr6:26026694	NA	0.39	6.05	0.31	3.9e-9	Cognitive function;
LIHC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg26441486	chr22:50317300	CRELD2	-0.35	-6.33	-0.32	7.6e-10	Schizophrenia;
LIHC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg07636037	chr3:49044803	WDR6	-0.59	-6.74	-0.34	6.5500000000000006e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.88	9.88	0.47	2.04e-20	Triglycerides;
LIHC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.64	-8.98	-0.44	1.92e-17	Blood metabolite levels;
LIHC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg23205692	chr1:25664452	TMEM50A	0.4	6.42	0.33	4.45e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-8.92	-0.43	2.79e-17	Atrioventricular conduction;
LIHC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.22	-0.36	3.45e-12	Response to antipsychotic treatment;
LIHC	cis	rs988712	0.576	rs6265	chr11:27679916	C/T	cg18117895	chr11:27722066	BDNF	0.51	6.73	0.34	7.36e-11	Obesity;
LIHC	cis	rs600806	0.888	rs12046539	chr1:109875415	C/T	cg23091122	chr1:110024289	SYPL2	-0.45	-5.93	-0.31	7.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg17135325	chr3:160939158	NMD3	0.42	6.09	0.31	3.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.47	7.77	0.39	9.48e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.56	10.28	0.49	8.91e-22	Methadone dose in opioid dependence;
LIHC	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg26939375	chr7:64535504	NA	0.47	7.18	0.36	4.4e-12	Aortic root size;
LIHC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg19338460	chr6:170058176	WDR27	-0.38	-5.9	-0.3	8.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg26939375	chr7:64535504	NA	-0.42	-7.27	-0.37	2.4e-12	Calcium levels;
LIHC	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7945718	0.591	rs10466378	chr11:12841992	G/A	cg25843174	chr11:12811716	TEAD1	0.35	7.92	0.39	3.42e-14	Educational attainment (years of education);
LIHC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.6	-10.42	-0.49	2.88e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	16.09	0.66	9.11e-44	Platelet count;
LIHC	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.58	-8.61	-0.42	2.66e-16	Blood protein levels;
LIHC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg20607798	chr8:58055168	NA	0.5	5.81	0.3	1.4e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.36	-0.41	1.57e-15	Gut microbiome composition (summer);
LIHC	trans	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg17675199	chr6:35436792	RPL10A	-0.43	-8.59	-0.42	3.14e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.99	-0.35	1.43e-11	Blood pressure;
LIHC	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.57	7.83	0.39	6.29e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs78545713	0.881	rs74608402	chr6:26240474	C/T	cg16070018	chr6:26224392	HIST1H3E	0.76	7.64	0.38	2.16e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.49	0.56	9.6e-30	Prudent dietary pattern;
LIHC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.6	0.38	2.95e-13	Response to antipsychotic treatment;
LIHC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg05941027	chr17:61774174	LIMD2	0.36	7.5	0.38	5.41e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02952972	chr11:972247	AP2A2	-0.45	-6.52	-0.33	2.55e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.86	13.2	0.58	1.88e-32	Vitamin D levels;
LIHC	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.49	-7.33	-0.37	1.71e-12	Adiposity;
LIHC	trans	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.2	0.32	1.59e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.84	9.29	0.45	1.85e-18	Cognitive test performance;
LIHC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.66	12.71	0.57	1.45e-30	High light scatter reticulocyte count;
LIHC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.76	0.43	9.13e-17	Height;
LIHC	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.9	-0.67	5.3e-47	Diabetic kidney disease;
LIHC	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.48	-0.76	2.13e-65	Coronary artery disease;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg14671364	chr1:107599128	PRMT6	0.48	7.2	0.36	3.8e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.35	-0.37	1.49e-12	Renal cell carcinoma;
LIHC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.75	9.4	0.45	7.99e-19	Systemic lupus erythematosus;
LIHC	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.6	9.81	0.47	3.5e-20	Corneal astigmatism;
LIHC	cis	rs7523273	0.565	rs4081159	chr1:207885479	G/A	cg22525895	chr1:207977042	MIR29B2	0.49	7.26	0.37	2.6e-12	Schizophrenia;
LIHC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.61	-0.42	2.77e-16	Morning vs. evening chronotype;
LIHC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-10.27	-0.49	9.66e-22	Dental caries;
LIHC	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.44	7.91	0.39	3.66e-14	Testicular germ cell tumor;
LIHC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	8.0	0.4	2e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.39	-7.85	-0.39	5.28e-14	Tonsillectomy;
LIHC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.43	-8.53	-0.42	4.94e-16	Testicular germ cell tumor;
LIHC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.8	-0.67	1.3e-46	Systemic lupus erythematosus;
LIHC	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.24	-0.41	3.72e-15	Exhaled nitric oxide output;
LIHC	cis	rs11246807	1	rs11246807	chr12:132275765	C/T	cg13251533	chr12:132286017	NA	0.54	6.57	0.33	1.89e-10	Psychosis proneness (perceptual aberration scale);
LIHC	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg11657440	chr19:46296263	DMWD	-0.53	-8.29	-0.41	2.56e-15	Coronary artery disease;
LIHC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.44	6.84	0.35	3.62e-11	Melanoma;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.17	0.32	1.96e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.26	6.07	0.31	3.33e-9	Heart rate;
LIHC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.7	-12.51	-0.56	8.05e-30	Refractive error;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg08251337	chr16:81040389	C16orf61;CENPN	-0.38	-6.19	-0.32	1.69e-9	Neuroblastoma;
LIHC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.45	7.27	0.37	2.4e-12	Platelet count;
LIHC	cis	rs151997	0.925	rs27579	chr5:50165147	G/A	cg06027927	chr5:50259733	NA	0.56	7.31	0.37	1.88e-12	Callous-unemotional behaviour;
LIHC	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25632853	chr15:73088954	NA	0.36	5.93	0.31	7.48e-9	Triglyceride levels;
LIHC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	9.06	0.44	1.04e-17	Initial pursuit acceleration;
LIHC	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg01320579	chr17:75405842	SEPT9	0.49	8.77	0.43	8.4e-17	Airflow obstruction;
LIHC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.22	7.25	0.37	2.71e-12	Motion sickness;
LIHC	trans	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.21	-0.41	4.62e-15	Obesity-related traits;
LIHC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.68	-9.47	-0.46	4.79e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg04013166	chr16:89971882	TCF25	0.48	6.08	0.31	3.28e-9	Skin colour saturation;
LIHC	cis	rs1986734	0.576	rs12503749	chr4:77418383	T/C	cg24201034	chr4:77507246	SHROOM3	-0.38	-6.12	-0.31	2.56e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.07e-26	Alzheimer's disease;
LIHC	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg04610667	chr7:75704037	NA	-0.35	-6.25	-0.32	1.23e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.46	6.22	0.32	1.42e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.1	0.36	7.46e-12	Diabetic kidney disease;
LIHC	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg03962019	chr1:41807865	NA	0.51	7.43	0.37	8.87e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.43	6.2	0.32	1.63e-9	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg08951907	chr17:18218556	TOP3A;SMCR8	-0.41	-6.09	-0.31	3.09e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.34e-11	Aortic root size;
LIHC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-12.1	-0.55	2.75e-28	Alzheimer's disease;
LIHC	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.49	8.03	0.4	1.55e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg13919466	chr1:32135498	COL16A1	-0.34	-6.33	-0.32	7.68e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.86	-0.3	1.09e-8	Colorectal cancer;
LIHC	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.56	10.42	0.49	2.84e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.51	-9.37	-0.45	1.04e-18	Asthma;
LIHC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.05	-0.31	3.75e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg05527609	chr1:210001259	C1orf107	-0.54	-7.52	-0.38	4.9e-13	Red blood cell count;
LIHC	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	10.3	0.49	7.75e-22	Response to antipsychotic treatment;
LIHC	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-0.66	-10.97	-0.51	3.34e-24	Pediatric autoimmune diseases;
LIHC	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.62	-0.34	1.41e-10	Total cholesterol levels;
LIHC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.24	0.41	3.8e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs3783890	0.887	rs11626995	chr14:93815892	C/T	cg02802420	chr16:69363236	PDF;COG8	0.32	6.19	0.32	1.69e-9	Body mass index;
LIHC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.74	-0.6	1.69e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs3812111	0.676	rs2351141	chr6:116501983	G/A	cg08036074	chr6:116424633	NT5DC1	-0.52	-8.71	-0.43	1.33e-16	Age-related macular degeneration;
LIHC	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.29	-0.41	2.53e-15	Vitamin D levels;
LIHC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.96	-17.53	-0.69	1.56e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.43	7.91	0.39	3.59e-14	Electrocardiographic conduction measures;
LIHC	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.44	7.34	0.37	1.57e-12	Crohn's disease;
LIHC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.43	0.41	9.85e-16	Motion sickness;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.12	0.4	8.4e-15	Height;
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07308232	chr7:1071921	C7orf50	-0.48	-7.7	-0.38	1.51e-13	Longevity;Endometriosis;
LIHC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.44	6.45	0.33	3.77e-10	Methadone dose in opioid dependence;
LIHC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	9.05	0.44	1.1e-17	Electroencephalogram traits;
LIHC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.85	12.19	0.55	1.26e-28	Glomerular filtration rate (creatinine);
LIHC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.65	6.55	0.33	2.07e-10	Bipolar disorder;
LIHC	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.49	-7.57	-0.38	3.46e-13	Blood pressure (smoking interaction);
LIHC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.86	12.81	0.57	5.99e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.42	6.36	0.33	6.51e-10	Tuberculosis;
LIHC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.27	-0.78	1.78e-72	Height;
LIHC	cis	rs611744	0.934	rs624311	chr8:109204437	A/G	cg18478394	chr8:109455254	TTC35	0.4	6.97	0.35	1.63e-11	Dupuytren's disease;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.54	9.34	0.45	1.26e-18	Systemic lupus erythematosus;
LIHC	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.42	-0.33	4.43e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs600806	0.778	rs2152924	chr1:110011701	G/A	cg11161837	chr1:110010384	SYPL2	0.46	6.32	0.32	8.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14838474	chr12:21654441	RECQL;GOLT1B	-0.39	-6.07	-0.31	3.42e-9	Bilirubin levels;
LIHC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-14.31	-0.61	1e-36	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.8	-9.8	-0.47	3.9e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2257205	0.667	rs28605629	chr17:56906157	C/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.46	-0.33	3.5e-10	Pancreatic cancer;
LIHC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg03959625	chr15:84868606	LOC388152	0.42	5.94	0.31	7.06e-9	Schizophrenia;
LIHC	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02290350	chr8:58132656	NA	0.46	9.4	0.45	8.2e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg14343924	chr8:8086146	FLJ10661	0.47	6.43	0.33	4.32e-10	Neuroticism;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.28	-0.32	1e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg15841412	chr13:111365552	ING1	0.48	5.88	0.3	9.67e-9	Coronary artery disease;
LIHC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.66	9.19	0.45	3.9e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.58	-0.53	2.12e-26	Chronic sinus infection;
LIHC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24549020	chr5:56110836	MAP3K1	0.54	6.8	0.35	4.63e-11	Initial pursuit acceleration;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-7.11	-0.36	6.62e-12	Prudent dietary pattern;
LIHC	cis	rs4714291	0.963	rs2395543	chr6:39965020	A/G	cg16345906	chr6:40101885	NA	-0.29	-5.84	-0.3	1.23e-8	Strep throat;
LIHC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20011983	chr2:74347215	NA	-0.39	-5.75	-0.3	2e-8	Gestational age at birth (maternal effect);
LIHC	trans	rs6489882	0.703	rs10774672	chr12:113360737	G/T	cg10175203	chr3:128143634	NA	0.4	6.46	0.33	3.53e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.89	18.32	0.7	1.06e-52	Height;
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg08392591	chr16:89556376	ANKRD11	0.56	8.96	0.44	2.22e-17	Multiple myeloma (IgH translocation);
LIHC	trans	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg08566640	chr11:64091735	NA	-0.69	-6.15	-0.32	2.14e-9	Androgen levels;
LIHC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.24	0.41	3.62e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.87	0.57	3.48e-31	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.78	0.8	2.34e-78	Prudent dietary pattern;
LIHC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.49	7.79	0.39	7.98e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7700895	0.737	rs6879652	chr5:95227462	T/C	cg10483112	chr5:95245456	ELL2	-0.33	-5.82	-0.3	1.38e-8	IgG glycosylation;
LIHC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.76	8.53	0.42	4.87e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.69	6.4	0.33	5.12e-10	Breast cancer;
LIHC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	9.37	0.45	9.76e-19	Mean platelet volume;
LIHC	cis	rs4699052	0.963	rs7657390	chr4:104213114	T/A	cg16532752	chr4:104119610	CENPE	-0.39	-6.29	-0.32	9.82e-10	Testicular germ cell tumor;
LIHC	cis	rs8192917	1.000	rs8192917	chr14:25102160	C/T	cg08766149	chr14:25103301	GZMB	-0.34	-7.87	-0.39	4.81e-14	Vitiligo;
LIHC	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16684958	chr7:75615977	POR	0.51	8.59	0.42	3.18e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg07424592	chr7:64974309	NA	-0.8	-9.31	-0.45	1.58e-18	Diabetic kidney disease;
LIHC	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	10.19	0.48	1.84e-21	LDL cholesterol;
LIHC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.51	8.32	0.41	2.06e-15	Schizophrenia;
LIHC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.89	0.3	9.39e-9	Body mass index;
LIHC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.75	14.41	0.61	4.2e-37	Mortality in heart failure;
LIHC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.63	-6.29	-0.32	9.81e-10	Red cell distribution width;
LIHC	trans	rs8117834	0.574	rs73076234	chr20:8081654	A/C	cg00593689	chr4:53575888	NA	0.37	6.17	0.32	1.89e-9	Chronic kidney disease;
LIHC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.46	5.84	0.3	1.22e-8	Blood protein levels;
LIHC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg22532475	chr10:104410764	TRIM8	0.37	6.49	0.33	3.06e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs861318	0.702	rs2814770	chr1:159012772	A/G	cg11003133	chr1:159046391	AIM2	0.33	6.73	0.34	7.27e-11	Obesity-related traits;
LIHC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.9	0.39	3.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2292096	0.929	rs6667419	chr1:200756197	G/C	cg07580975	chr1:200843333	NA	0.43	6.13	0.31	2.47e-9	Epilepsy;
LIHC	trans	rs4619890	0.641	rs6446622	chr4:7812674	G/A	cg12868349	chr11:71639594	RNF121;LOC100133315	-0.51	-6.4	-0.33	5.27e-10	Glaucoma (primary open-angle);
LIHC	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.3	7.45	0.37	7.61e-13	Gut microbiome composition (winter);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24926775	chr1:151584391	SNX27	0.46	6.66	0.34	1.11e-10	Pancreatic cancer;
LIHC	cis	rs9590974	0.663	rs1216859	chr13:47231911	G/A	cg04092803	chr13:47240378	LRCH1	0.26	5.74	0.3	2.04e-8	PR segment;
LIHC	trans	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg25214090	chr10:38739885	LOC399744	-0.37	-6.1	-0.31	2.85e-9	Diastolic blood pressure;
LIHC	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.55	6.95	0.35	1.86e-11	Mosquito bite size;
LIHC	cis	rs4423214	0.524	rs4944046	chr11:71123794	C/G	cg05163923	chr11:71159392	DHCR7	0.57	8.28	0.41	2.9e-15	Vitamin D levels;
LIHC	cis	rs74181299	0.684	rs6713746	chr2:65324492	G/C	cg05010058	chr2:65284262	CEP68	-0.4	-6.71	-0.34	8.22e-11	Pulse pressure;
LIHC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg15534755	chr11:117069859	TAGLN	0.36	6.04	0.31	4.05e-9	Blood protein levels;
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20570016	chr1:156261298	TMEM79	0.37	6.02	0.31	4.54e-9	Tonsillectomy;
LIHC	cis	rs74233809	0.786	rs11191564	chr10:104878543	C/T	cg03493300	chr10:104813866	CNNM2	0.47	6.34	0.32	7.15e-10	Birth weight;
LIHC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14067834	chr17:29058358	SUZ12P	-0.67	-6.83	-0.35	3.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2380220	0.872	rs115871915	chr6:95934180	T/C	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.53e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg05896524	chr21:47604654	C21orf56	0.44	6.62	0.34	1.38e-10	Testicular germ cell tumor;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.6	10.22	0.48	1.4e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.49	0.42	6.45e-16	Birth weight;
LIHC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.5	-0.38	5.38e-13	Chronic sinus infection;
LIHC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.48	0.46	4.48e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.65	10.25	0.48	1.16e-21	Longevity;
LIHC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.07	16.77	0.67	1.67e-46	Breast cancer;
LIHC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg21361702	chr7:150065534	REPIN1	0.46	6.42	0.33	4.55e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.74	-13.56	-0.59	8.03e-34	Facial morphology (factor 23);
LIHC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.63	-0.38	2.35e-13	Monocyte percentage of white cells;
LIHC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-8.29	-0.41	2.65e-15	Total body bone mineral density;
LIHC	cis	rs3812111	0.615	rs9320557	chr6:116462083	A/C	cg08036074	chr6:116424633	NT5DC1	-0.5	-8.64	-0.42	2.14e-16	Age-related macular degeneration;
LIHC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.34	-6.84	-0.35	3.76e-11	DNA methylation (variation);
LIHC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.52	0.38	4.82e-13	Morning vs. evening chronotype;
LIHC	trans	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg26113512	chr3:38035601	VILL	-0.53	-6.12	-0.31	2.56e-9	Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26618056	chr16:25043323	NA	0.55	7.69	0.38	1.63e-13	Lung function (FEV1/FVC);
LIHC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.5	7.8	0.39	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-9.04	-0.44	1.23e-17	Blood metabolite levels;
LIHC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.22e-11	Body mass index;
LIHC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27297192	chr10:134578999	INPP5A	-0.52	-8.25	-0.41	3.58e-15	Migraine;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg12334488	chr2:20871173	GDF7	-0.47	-8.98	-0.44	1.88e-17	Abdominal aortic aneurysm;
LIHC	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.06e-10	Renal cell carcinoma;
LIHC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.85	15.13	0.63	5.92e-40	Body mass index (adult);
LIHC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.98	0.31	5.51e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7326068	0.524	rs7998500	chr13:21159000	A/G	cg27234864	chr13:21295941	IL17D	0.37	5.89	0.3	9.32e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.54	7.49	0.38	5.86e-13	Lung disease severity in cystic fibrosis;
LIHC	trans	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg26939375	chr7:64535504	NA	-0.42	-6.74	-0.34	6.89e-11	Aortic root size;
LIHC	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.46e-25	Eye color traits;
LIHC	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.74	0.34	6.66e-11	Bipolar disorder;
LIHC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	6.26	0.32	1.15e-9	Bipolar disorder;
LIHC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.81	0.39	6.88e-14	Motion sickness;
LIHC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg19729930	chr2:74357872	NA	0.8	17.48	0.69	2.36e-49	Gestational age at birth (maternal effect);
LIHC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.97	12.61	0.56	3.25e-30	HIV-1 control;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg00091569	chr3:40428383	ENTPD3	-0.4	-6.83	-0.35	3.97e-11	Renal cell carcinoma;
LIHC	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.74	0.39	1.1e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.48	7.56	0.38	3.71e-13	Cocaine dependence;
LIHC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	12.37	0.56	2.58e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs244293	0.965	rs2628326	chr17:53178283	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.54	0.38	4.36e-13	Menarche (age at onset);
LIHC	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07080220	chr10:102295463	HIF1AN	0.52	7.0	0.35	1.4e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs11212260	0.655	rs11212208	chr11:107278690	C/A	cg25435332	chr11:107328525	CWF19L2	0.81	8.77	0.43	8.76e-17	IgG glycosylation;
LIHC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.22e-11	Body mass index;
LIHC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.5	7.26	0.37	2.59e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.32	-0.32	8.17e-10	Diastolic blood pressure;
LIHC	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.48	6.37	0.33	6.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	7.17	0.36	4.57e-12	Systemic lupus erythematosus;
LIHC	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg09165964	chr15:75287851	SCAMP5	0.48	6.58	0.34	1.74e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.76	10.98	0.51	3.13e-24	Response to hepatitis C treatment;
LIHC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.83	10.51	0.49	1.38e-22	Cognitive function;
LIHC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.24	-7.62	-0.38	2.56e-13	Mean corpuscular volume;
LIHC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.05	14.07	0.61	8.82e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11098699	0.784	rs11947137	chr4:124205966	C/G	cg09941581	chr4:124220074	SPATA5	0.32	6.38	0.33	5.62e-10	Mosquito bite size;
LIHC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.86	-0.3	1.08e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg09137382	chr11:130731461	NA	0.41	6.13	0.31	2.46e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg10790698	chr19:18539756	SSBP4	-0.34	-7.06	-0.36	9.39e-12	Breast cancer;
LIHC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.57	0.38	3.5e-13	Schizophrenia;
LIHC	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.55	-8.24	-0.41	3.63e-15	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg23978390	chr7:1156363	C7orf50	0.43	6.09	0.31	3.05e-9	Longevity;Endometriosis;
LIHC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.94	17.99	0.7	2.25e-51	Menopause (age at onset);
LIHC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.85	10.57	0.5	8.9e-23	Mean platelet volume;
LIHC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	0.65	7.25	0.37	2.79e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.38	8.73	0.43	1.11e-16	Blood protein levels;
LIHC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-6.29	-0.32	9.61e-10	Chronic sinus infection;
LIHC	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.85	-0.35	3.49e-11	Adiposity;
LIHC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg19635926	chr16:89946313	TCF25	0.55	6.84	0.35	3.57e-11	Skin colour saturation;
LIHC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.94	9.82	0.47	3.2e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2251381	0.640	rs2183568	chr21:30484782	A/T	cg24692254	chr21:30365293	RNF160	-0.76	-11.65	-0.53	1.17e-26	Selective IgA deficiency;
LIHC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg18016565	chr1:150552671	MCL1	0.62	12.27	0.55	6.11e-29	Urate levels;
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg07451762	chr16:28383216	NA	0.4	6.99	0.35	1.42e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.53	-8.24	-0.41	3.74e-15	Coronary artery disease;
LIHC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.54	7.64	0.38	2.27e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.54	8.3	0.41	2.52e-15	Longevity;Endometriosis;
LIHC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.48	7.09	0.36	7.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.15	0.32	2.11e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs2286503	0.780	rs12113458	chr7:22855628	G/T	cg11367502	chr7:22862612	TOMM7	0.46	8.04	0.4	1.49e-14	Fibrinogen;
LIHC	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.58	10.81	0.5	1.24e-23	Urate levels in overweight individuals;
LIHC	cis	rs7116495	1.000	rs7128317	chr11:71701367	C/T	cg26138937	chr11:71823887	C11orf51	0.8	8.03	0.4	1.6e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.51	8.49	0.42	6.6e-16	Blood metabolite levels;
LIHC	trans	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg09045935	chr12:6379348	NA	0.83	6.85	0.35	3.36e-11	Blood metabolite levels;
LIHC	cis	rs17021463	0.676	rs62320932	chr4:95307037	C/T	cg11021082	chr4:95130006	SMARCAD1	0.43	7.2	0.36	3.74e-12	Testicular germ cell tumor;
LIHC	cis	rs333960	0.597	rs333966	chr1:110441792	A/G	cg09167608	chr1:110449308	NA	0.43	6.02	0.31	4.49e-9	Obesity-related traits;
LIHC	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.02e-17	Arsenic metabolism;
LIHC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.87	13.09	0.58	4.92e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs8084351	0.577	rs4548946	chr18:50651671	C/T	cg24270629	chr18:50823537	DCC	-0.44	-6.49	-0.33	3.03e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.72	13.68	0.59	2.88e-34	Height;
LIHC	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.45	7.49	0.38	5.81e-13	Diastolic blood pressure;
LIHC	cis	rs965469	0.817	rs6515806	chr20:3359138	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-6.12	-0.31	2.51e-9	IFN-related cytopenia;
LIHC	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.59	11.03	0.51	2.01e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.52	0.42	5.1e-16	Exhaled nitric oxide output;
LIHC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.16	0.44	4.82e-18	Cognitive ability;
LIHC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.25	-16.45	-0.66	3.21e-45	Diabetic kidney disease;
LIHC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.82	0.69	1.01e-50	Smoking behavior;
LIHC	trans	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg10756647	chr7:56101905	PSPH	0.64	8.81	0.43	6.36e-17	Corneal structure;
LIHC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.38	6.13	0.31	2.48e-9	Melanoma;
LIHC	cis	rs116248771	0.739	rs73156455	chr3:158367557	A/G	cg16708174	chr3:158430962	RARRES1	0.48	6.38	0.33	5.61e-10	diarrhoeal disease at age 2;
LIHC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19811296	chr10:99161148	RRP12	0.4	6.33	0.32	7.58e-10	Calcium levels;
LIHC	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.88	9.25	0.45	2.46e-18	Facial morphology (factor 23);
LIHC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.74	-0.3	2.12e-8	Tonsillectomy;
LIHC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg22633049	chr21:46681294	NA	-0.4	-6.91	-0.35	2.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	0.76	8.46	0.42	8.18e-16	Gut microbiota (bacterial taxa);
LIHC	trans	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg26939375	chr7:64535504	NA	0.4	6.39	0.33	5.49e-10	Aortic root size;
LIHC	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg08126542	chr6:37504118	NA	-0.37	-6.26	-0.32	1.13e-9	Cognitive performance;
LIHC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02985541	chr2:219472218	PLCD4	0.44	8.5	0.42	5.86e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.13	0.31	2.46e-9	Educational attainment;
LIHC	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg13263691	chr18:77568018	NA	0.24	6.55	0.33	2.09e-10	Schizophrenia;
LIHC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.83	15.26	0.64	1.82e-40	Response to diuretic therapy;
LIHC	trans	rs11039100	1.000	rs35863965	chr11:5824256	G/T	cg11650987	chr12:10280440	CLEC7A	0.4	6.06	0.31	3.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.91	-16.9	-0.67	5.28e-47	Aortic root size;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27338377	chr3:5068433	NA	0.41	6.37	0.33	5.93e-10	Calcium levels;
LIHC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.01e-19	Renal cell carcinoma;
LIHC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.5	7.49	0.38	5.8e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.68	0.42	1.65e-16	Schizophrenia;
LIHC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.88	15.8	0.65	1.25e-42	Aortic root size;
LIHC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.44	7.21	0.36	3.56e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-8.74	-0.43	1.08e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.48	-0.33	3.13e-10	Renal cell carcinoma;
LIHC	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.34	-6.52	-0.33	2.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.13	-0.31	2.48e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg25356066	chr3:128598488	ACAD9	0.52	6.76	0.34	5.8e-11	IgG glycosylation;
LIHC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.41	-5.97	-0.31	5.89e-9	Other erythrocyte phenotypes;
LIHC	cis	rs10792665	0.618	rs7949388	chr11:82656251	A/T	cg24227371	chr11:82718527	RAB30	-0.31	-7.11	-0.36	6.78e-12	Obesity-related traits;
LIHC	cis	rs6788895	0.661	rs77431731	chr3:150489911	T/G	cg09723797	chr3:150481914	SIAH2	0.81	10.99	0.51	2.93e-24	Breast cancer;
LIHC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.56	8.42	0.41	1.03e-15	Resting heart rate;
LIHC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg18016565	chr1:150552671	MCL1	0.55	10.98	0.51	3.21e-24	Tonsillectomy;
LIHC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.6	-0.38	2.82e-13	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.34	23.26	0.78	1.98e-72	Corneal structure;
LIHC	cis	rs7429990	0.932	rs12486714	chr3:48148700	C/G	cg11946769	chr3:48343235	NME6	-0.47	-6.24	-0.32	1.28e-9	Educational attainment (years of education);
LIHC	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.53	7.63	0.38	2.31e-13	Schizophrenia;
LIHC	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.15	-0.4	7.17e-15	Brugada syndrome;
LIHC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-7.54	-0.38	4.41e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.87	13.18	0.58	2.31e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.78	12.94	0.57	1.94e-31	Anterior chamber depth;
LIHC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.34	0.37	1.55e-12	Monocyte percentage of white cells;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-6.77	-0.34	5.6e-11	Lymphocyte counts;
LIHC	cis	rs2273156	1.000	rs74046408	chr14:35467135	T/C	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.59	-9.54	-0.46	2.81e-19	Lymphocyte counts;
LIHC	trans	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg14222797	chr10:16859974	RSU1	-0.52	-6.08	-0.31	3.25e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-5.99	-0.31	5.25e-9	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg11599414	chr15:65399621	LOC390595	-0.27	-6.52	-0.33	2.6e-10	Calcium levels;
LIHC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.38	6.7	0.34	8.78e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.51	-8.17	-0.4	6.09e-15	Longevity;Endometriosis;
LIHC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-9.85	-0.47	2.63e-20	Obesity-related traits;
LIHC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.58	-8.61	-0.42	2.65e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07176146	chr1:35325364	C1orf212	-0.44	-6.05	-0.31	3.72e-9	Pancreatic cancer;
LIHC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.99	23.08	0.78	1.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.31	-0.7	1.15e-52	Height;
LIHC	cis	rs7116495	1.000	rs488799	chr11:71561686	A/G	cg26138937	chr11:71823887	C11orf51	0.69	6.7	0.34	8.74e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.48	6.41	0.33	4.93e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.33	-18.17	-0.7	3.94e-52	Diabetic kidney disease;
LIHC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg01256987	chr12:42539512	GXYLT1	-0.43	-7.06	-0.36	9.46e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.04	-0.31	4.07e-9	Longevity;
LIHC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.68	7.11	0.36	6.86e-12	Alzheimer's disease;
LIHC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.81	13.13	0.58	3.65e-32	Cognitive test performance;
LIHC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.69e-11	Blood pressure;
LIHC	cis	rs61542988	0.570	rs62448267	chr7:22822501	T/C	cg11367502	chr7:22862612	TOMM7	0.53	8.68	0.43	1.61e-16	Fibrinogen levels;
LIHC	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg19683494	chr5:74908142	NA	0.58	7.59	0.38	3.05e-13	Age-related disease endophenotypes;
LIHC	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.67	-10.86	-0.51	8.12e-24	Oral cavity cancer;
LIHC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg13114125	chr14:105738426	BRF1	-0.8	-10.07	-0.48	4.54e-21	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.81	12.09	0.55	2.84e-28	Coronary artery disease;
LIHC	cis	rs3818285	0.959	rs3740137	chr10:111630917	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.94	-0.31	7.18e-9	Superior crus of antihelix expression;
LIHC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.09	12.91	0.57	2.49e-31	Vitiligo;
LIHC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-6.63	-0.34	1.29e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.06	0.44	1.02e-17	Height;
LIHC	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.46	-6.79	-0.34	4.9e-11	Body mass index;
LIHC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.73	-12.07	-0.55	3.51e-28	Systemic lupus erythematosus;
LIHC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.52	-0.64	1.77e-41	Chronic sinus infection;
LIHC	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.71	10.08	0.48	4.15e-21	Corneal astigmatism;
LIHC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.44	7.02	0.35	1.2e-11	Blood protein levels;
LIHC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.13	-0.36	5.98e-12	Body mass index;
LIHC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.44	-6.78	-0.34	5.2e-11	Schizophrenia;
LIHC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-6.14	-0.31	2.32e-9	Testicular germ cell tumor;
LIHC	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-0.54	-8.63	-0.42	2.38e-16	Prostate cancer;
LIHC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.98	0.4	2.3e-14	Motion sickness;
LIHC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs932287	0.651	rs1111010	chr11:9049935	A/G	cg12365402	chr11:9010492	NRIP3	0.25	5.86	0.3	1.07e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.51	7.17	0.36	4.52e-12	Menopause (age at onset);
LIHC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.86	0.43	4.49e-17	Cognitive ability;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.69	9.32	0.45	1.45e-18	Aortic root size;
LIHC	cis	rs7818688	0.697	rs11776186	chr8:95971968	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	6.33	0.32	7.64e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs244293	0.931	rs244306	chr17:53237683	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.19	-0.36	4.2e-12	Menarche (age at onset);
LIHC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.71	-0.39	1.34e-13	Monocyte percentage of white cells;
LIHC	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.74	-9.51	-0.46	3.38e-19	Type 2 diabetes;
LIHC	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs6604026	0.740	rs2893225	chr1:93368496	G/C	cg17283838	chr1:93427260	FAM69A	-0.42	-5.77	-0.3	1.81e-8	Multiple sclerosis;
LIHC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-7.11	-0.36	6.65e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-14.3	-0.61	1.07e-36	Schizophrenia;
LIHC	cis	rs6723226	0.557	rs62136260	chr2:32575447	T/C	cg02381751	chr2:32503542	YIPF4	-0.47	-6.25	-0.32	1.19e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.64	-0.34	1.27e-10	Type 2 diabetes;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg00221035	chr7:7222342	C1GALT1	-0.57	-7.09	-0.36	7.55e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6442522	0.644	rs6442528	chr3:15505224	C/G	cg16303742	chr3:15540471	COLQ	0.44	7.46	0.37	7.43e-13	Uric acid levels;
LIHC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.21	0.52	4.79e-25	Motion sickness;
LIHC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg03934865	chr2:198174659	NA	0.46	6.58	0.34	1.74e-10	Dermatomyositis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15555402	chr12:19593456	AEBP2	0.42	6.17	0.32	1.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.21	0.55	1.05e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg03013999	chr17:37608204	MED1	0.36	6.07	0.31	3.41e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg00274965	chr21:34405681	NA	0.33	5.85	0.3	1.17e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs2579103	0.767	rs2118804	chr12:90665966	C/T	cg00091569	chr3:40428383	ENTPD3	0.37	6.05	0.31	3.8e-9	Body mass index;
LIHC	cis	rs12464559	0.522	rs4300824	chr2:152581866	T/C	cg01189475	chr2:152685088	ARL5A	0.72	9.02	0.44	1.41e-17	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.2	-0.52	5.15e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.59	7.39	0.37	1.11e-12	Vitamin D levels;
LIHC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-10.48	-0.49	1.83e-22	Monocyte percentage of white cells;
LIHC	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.89	0.6	4.42e-35	Bipolar disorder;
LIHC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.53	-6.95	-0.35	1.84e-11	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg00280220	chr17:61926910	NA	0.43	7.05	0.36	1.03e-11	Prudent dietary pattern;
LIHC	trans	rs10411161	0.702	rs1433081	chr19:52390710	A/C	cg22319618	chr22:45562946	NUP50	-0.63	-8.59	-0.42	3.15e-16	Breast cancer;
LIHC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.37	-6.23	-0.32	1.34e-9	Educational attainment;
LIHC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.23	0.32	1.37e-9	Schizophrenia;
LIHC	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.56	-0.42	3.94e-16	Coronary artery disease;
LIHC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.68	-9.77	-0.47	4.87e-20	Cholesterol, total;
LIHC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.57e-21	Bladder cancer;
LIHC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18252515	chr7:66147081	NA	-0.44	-6.38	-0.33	5.78e-10	Aortic root size;
LIHC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.46	-6.85	-0.35	3.46e-11	Cognitive function;
LIHC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg08888203	chr3:10149979	C3orf24	0.56	6.8	0.35	4.62e-11	Alzheimer's disease;
LIHC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-7.91	-0.39	3.7e-14	Blood metabolite levels;
LIHC	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.14	-0.32	2.31e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.13	-0.68	6.09e-48	Systemic lupus erythematosus;
LIHC	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.64	11.4	0.52	9.44e-26	Breast cancer;
LIHC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.09	0.31	2.99e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Intracranial aneurysm;
LIHC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.93	16.94	0.68	3.74e-47	Parkinson's disease;
LIHC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg03859395	chr2:55845619	SMEK2	0.73	11.77	0.54	4.47e-27	Metabolic syndrome;
LIHC	cis	rs8081395	0.711	rs11368	chr17:58031412	A/G	cg13753209	chr17:57696993	CLTC	0.39	5.93	0.31	7.57e-9	White blood cell count;
LIHC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.09	-12.74	-0.57	1.09e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17106184	1.000	rs9701805	chr1:51356810	G/C	cg07174182	chr1:51127561	FAF1	-0.74	-8.05	-0.4	1.35e-14	Type 2 diabetes;
LIHC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.84	0.39	5.77e-14	Morning vs. evening chronotype;
LIHC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.76	14.49	0.62	1.96e-37	Iron status biomarkers;
LIHC	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg14146966	chr2:61757674	XPO1	0.49	8.62	0.42	2.6e-16	Tuberculosis;
LIHC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	7.05	0.36	1e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.69	7.17	0.36	4.64e-12	Cannabis dependence symptom count;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.66	11.64	0.53	1.31e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg09417038	chr21:47716443	C21orf57	-0.54	-8.04	-0.4	1.45e-14	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.2	0.32	1.62e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.41	6.56	0.33	1.97e-10	Height;
LIHC	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg02869306	chr7:64672164	INTS4L1	-0.3	-6.62	-0.34	1.37e-10	Calcium levels;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.63	-7.94	-0.39	2.98e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	1.04	12.43	0.56	1.53e-29	Red blood cell traits;
LIHC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg02290350	chr8:58132656	NA	0.41	8.7	0.43	1.43e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.77	-0.39	9.55e-14	Coronary artery disease;
LIHC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.41	6.67	0.34	1.02e-10	Mood instability;
LIHC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.38	0.41	1.44e-15	Body mass index;
LIHC	cis	rs67981189	0.593	rs2251394	chr14:71436074	A/G	cg15816911	chr14:71606274	NA	-0.4	-6.42	-0.33	4.59e-10	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.36	-0.33	6.29e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs6466055	0.720	rs3801999	chr7:105027646	G/A	cg04380332	chr7:105027541	SRPK2	0.36	6.76	0.34	5.87e-11	Schizophrenia;
LIHC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.39	6.27	0.32	1.1e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.42	-6.39	-0.33	5.44e-10	Heart rate;
LIHC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.59	-8.54	-0.42	4.41e-16	Blood metabolite levels;
LIHC	cis	rs1555399	1.000	rs1555399	chr14:67984370	T/A	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.76	-0.3	1.85e-8	Parkinson's disease;
LIHC	cis	rs3815308	0.530	rs12973409	chr19:2196963	A/G	cg09261902	chr19:2140048	AP3D1	0.35	6.05	0.31	3.9e-9	Breast cancer;
LIHC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.73e-12	Personality dimensions;
LIHC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17507749	chr15:85114479	UBE2QP1	0.49	5.8	0.3	1.55e-8	Schizophrenia;
LIHC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.44	5.78	0.3	1.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.76	-0.62	1.8e-38	Alzheimer's disease (late onset);
LIHC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg22842854	chr12:123319900	HIP1R	-0.72	-9.02	-0.44	1.39e-17	Schizophrenia;
LIHC	trans	rs6489882	0.867	rs6489869	chr12:113363922	A/C	cg10175203	chr3:128143634	NA	0.39	6.39	0.33	5.57e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs2016586	0.543	rs5755906	chr22:36096091	T/C	cg26342177	chr22:36113512	APOL5	-0.36	-5.93	-0.31	7.46e-9	Body mass index;
LIHC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg07451762	chr16:28383216	NA	0.31	5.96	0.31	6.17e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg05555928	chr11:63887634	MACROD1	-0.5	-7.02	-0.36	1.17e-11	Body mass index;
LIHC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.61	-0.38	2.66e-13	Schizophrenia;
LIHC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.62	-5.93	-0.31	7.49e-9	Vitiligo;
LIHC	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.34	-7.15	-0.36	5.42e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs3015497	0.653	rs2356455	chr14:51093142	G/A	cg09863266	chr14:51125203	SAV1	-0.39	-6.16	-0.32	2.03e-9	Mean platelet volume;
LIHC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.37	6.48	0.33	3.16e-10	Psoriasis;
LIHC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg11764359	chr7:65958608	NA	-0.57	-5.89	-0.3	9.17e-9	Diabetic kidney disease;
LIHC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg11062466	chr8:58055876	NA	0.48	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18043075	chr10:115933939	MIR2110;C10orf118	-0.43	-6.07	-0.31	3.33e-9	Pancreatic cancer;
LIHC	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg07541023	chr7:19748670	TWISTNB	0.42	6.13	0.31	2.42e-9	Thyroid stimulating hormone;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.97	-0.35	1.59e-11	Total body bone mineral density;
LIHC	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.45	8.04	0.4	1.49e-14	Monocyte percentage of white cells;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg04161413	chr2:99225218	C2orf64;UNC50	-0.39	-6.11	-0.31	2.74e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.54	-0.33	2.23e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.97e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.49	-8.66	-0.42	1.91e-16	Schizophrenia;
LIHC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.5	-8.76	-0.43	9.11e-17	White blood cell count;
LIHC	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.69	11.98	0.54	7.23e-28	Colorectal cancer;
LIHC	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-29.5	-0.85	5.6e-96	Myeloid white cell count;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg17918875	chr8:17780190	PCM1	-0.38	-6.33	-0.32	7.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg04709771	chr16:646395	RAB40C	0.46	8.26	0.41	3.16e-15	Height;
LIHC	cis	rs77861329	1.000	rs9809254	chr3:52111474	T/C	cg08692210	chr3:52188851	WDR51A	0.83	8.32	0.41	2.05e-15	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.06	-0.31	3.66e-9	Total body bone mineral density;
LIHC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.52	8.36	0.41	1.57e-15	Height;
LIHC	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg11062466	chr8:58055876	NA	0.43	5.77	0.3	1.8e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.54	-8.81	-0.43	6.63e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	11.53	0.53	3.38e-26	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.56	9.04	0.44	1.18e-17	Longevity;Endometriosis;
LIHC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.39	5.73	0.3	2.17e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4294134	1.000	rs10234309	chr7:135311167	G/A	cg20392616	chr7:135392013	SLC13A4	-0.41	-6.72	-0.34	7.52e-11	Paget's disease;
LIHC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg18016565	chr1:150552671	MCL1	0.52	9.73	0.47	6.77e-20	Melanoma;
LIHC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.62	-8.52	-0.42	5.26e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19478983	chr7:120590592	ING3	-0.51	-6.48	-0.33	3.15e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.63	10.48	0.49	1.77e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.68	-11.73	-0.54	5.98e-27	Prudent dietary pattern;
LIHC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.37	-0.37	1.25e-12	Body mass index;
LIHC	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.49	8.03	0.4	1.54e-14	Schizophrenia;
LIHC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.68	9.51	0.46	3.46e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.54	-9.36	-0.45	1.06e-18	Gout;
LIHC	cis	rs74181299	0.750	rs58342673	chr2:65347584	T/C	cg05010058	chr2:65284262	CEP68	-0.39	-6.42	-0.33	4.56e-10	Pulse pressure;
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.27	0.41	3.08e-15	Renal cell carcinoma;
LIHC	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg07959070	chr22:50026188	C22orf34	-0.35	-8.56	-0.42	3.79e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7091068	0.671	rs1096025	chr10:95404701	T/C	cg20715218	chr10:95462985	C10orf4	-0.63	-7.05	-0.36	9.84e-12	Urinary tract infection frequency;
LIHC	cis	rs4700695	0.841	rs706681	chr5:65317913	G/T	cg21114390	chr5:65439923	SFRS12	0.45	5.71	0.3	2.4e-8	Facial morphology (factor 19);
LIHC	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.15	-0.52	7.69e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.06	-0.31	3.62e-9	Diastolic blood pressure;
LIHC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.43	0.37	8.56e-13	Bipolar disorder;
LIHC	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.85	12.01	0.54	5.59e-28	Post bronchodilator FEV1;
LIHC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	12.89	0.57	2.92e-31	Response to antipsychotic treatment;
LIHC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.63	-10.29	-0.49	8.04e-22	Age at first birth;
LIHC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.87	10.83	0.51	1.06e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg14393609	chr7:65229607	NA	0.44	6.55	0.33	2.08e-10	Aortic root size;
LIHC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.62	0.62	5.83e-38	Chronic sinus infection;
LIHC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.44	6.29	0.32	9.67e-10	Coronary artery disease;
LIHC	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.67	-11.52	-0.53	3.53e-26	Pediatric autoimmune diseases;
LIHC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.79	-14.35	-0.61	6.91e-37	Longevity;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16217313	chr6:107077344	RTN4IP1;QRSL1	-0.54	-6.28	-0.32	1.01e-9	Systolic blood pressure;
LIHC	cis	rs797680	0.856	rs7512911	chr1:93715818	C/G	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.69	12.1	0.55	2.64e-28	Colorectal cancer;
LIHC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.55	-0.38	3.97e-13	Mean platelet volume;
LIHC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.43	-5.77	-0.3	1.79e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	1.17	13.75	0.6	1.47e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.48	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs1823913	1.000	rs1840377	chr2:192122718	T/C	cg12404831	chr2:192114017	MYO1B	-0.32	-6.54	-0.33	2.21e-10	Obesity-related traits;
LIHC	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.41	0.45	7.5e-19	Coffee consumption (cups per day);
LIHC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02985541	chr2:219472218	PLCD4	0.42	6.92	0.35	2.24e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.34	-0.45	1.26e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.26	7.06	0.36	9.39e-12	Type 2 diabetes;
LIHC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.67	-10.09	-0.48	4.07e-21	Mosquito bite size;
LIHC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg19645103	chr12:69753606	YEATS4	0.4	5.99	0.31	5.19e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02985541	chr2:219472218	PLCD4	-0.43	-7.02	-0.35	1.19e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg12501888	chr15:85177176	SCAND2	-0.47	-7.19	-0.36	4e-12	P wave terminal force;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.54	-10.61	-0.5	6.17e-23	Prudent dietary pattern;
LIHC	trans	rs800082	0.934	rs6788831	chr3:144290498	G/T	cg24215973	chr2:240111563	HDAC4	-0.49	-7.1	-0.36	7.23e-12	Smoking behavior;
LIHC	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg18081818	chr7:23246105	NA	-0.42	-6.26	-0.32	1.14e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2540917	0.631	rs12104736	chr2:60650716	C/G	cg00543073	chr2:60773386	BCL11A	-0.32	-6.4	-0.33	5.21e-10	Mean corpuscular volume;
LIHC	trans	rs9914544	0.545	rs1037037	chr17:18765021	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Educational attainment (years of education);
LIHC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.12	0.4	8.77e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.22	0.32	1.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.48	7.48	0.37	6.43e-13	Testicular germ cell tumor;
LIHC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20135002	chr11:47629003	NA	-0.56	-9.52	-0.46	3.25e-19	Subjective well-being;
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.35	-0.32	6.81e-10	Total body bone mineral density;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01008834	chr1:150207620	ANP32E	0.51	6.57	0.33	1.86e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg25356066	chr3:128598488	ACAD9	0.56	7.65	0.38	2.06e-13	IgG glycosylation;
LIHC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.49	-6.2	-0.32	1.66e-9	Menarche (age at onset);
LIHC	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.47	-6.48	-0.33	3.28e-10	Initial pursuit acceleration;
LIHC	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.87	15.77	0.65	1.66e-42	Body mass index;
LIHC	trans	rs763512	0.532	rs1416	chr17:35894811	T/C	cg21037784	chr14:101351511	RTL1	-0.27	-6.08	-0.31	3.22e-9	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg21724239	chr8:58056113	NA	0.47	6.24	0.32	1.32e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.83	-0.3	1.26e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2274273	0.870	rs66696758	chr14:55766509	G/A	cg01864836	chr14:55583639	NA	-0.37	-6.63	-0.34	1.35e-10	Protein biomarker;
LIHC	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg20607798	chr8:58055168	NA	0.51	6.37	0.33	5.93e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.46	-0.33	3.56e-10	Height;
LIHC	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.52	7.09	0.36	7.61e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg25039879	chr17:56429692	SUPT4H1	0.74	8.03	0.4	1.62e-14	Cognitive test performance;
LIHC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg19920283	chr7:105172520	RINT1	0.66	6.02	0.31	4.39e-9	Bipolar disorder (body mass index interaction);
LIHC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.54	6.86	0.35	3.33e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs11098699	0.821	rs17006775	chr4:124214850	A/G	cg09941581	chr4:124220074	SPATA5	-0.35	-7.16	-0.36	4.96e-12	Mosquito bite size;
LIHC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs2257205	0.667	rs7342841	chr17:56916156	G/A	cg12560992	chr17:57184187	TRIM37	0.67	7.22	0.36	3.29e-12	Pancreatic cancer;
LIHC	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	0.86	6.16	0.32	2e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.35	0.37	1.47e-12	Multiple sclerosis;
LIHC	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27297192	chr10:134578999	INPP5A	0.52	7.1	0.36	7.07e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13470557	chr20:61431876	C20orf20	0.42	6.11	0.31	2.69e-9	Hepatitis;
LIHC	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg02269571	chr22:50332266	NA	0.74	8.22	0.41	4.23e-15	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-8.51	-0.42	5.65e-16	Primary biliary cholangitis;
LIHC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.98	-20.13	-0.74	5.24e-60	Coronary artery disease;
LIHC	cis	rs11958404	0.929	rs80162289	chr5:157354639	T/C	cg05962755	chr5:157440814	NA	0.97	9.4	0.45	7.84e-19	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg05590025	chr7:65112418	INTS4L2	0.66	7.39	0.37	1.12e-12	Diabetic kidney disease;
LIHC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg05110241	chr16:68378359	PRMT7	-0.48	-5.83	-0.3	1.27e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs963731	0.649	rs212322	chr2:39305928	C/T	cg04010122	chr2:39346883	SOS1	-0.61	-6.18	-0.32	1.82e-9	Corticobasal degeneration;
LIHC	cis	rs2380220	0.808	rs2613551	chr6:95914740	G/A	cg04719120	chr6:96025338	MANEA	-0.58	-6.24	-0.32	1.33e-9	Behavioural disinhibition (generation interaction);
LIHC	trans	rs2019216	0.605	rs11654492	chr17:22008649	A/C	cg14296220	chr9:32431791	ACO1	0.39	6.28	0.32	1.01e-9	Pelvic organ prolapse;
LIHC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.2	-0.32	1.66e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2096176	0.606	rs1339813	chr10:26313980	G/A	cg01396774	chr2:218299024	DIRC3	-0.31	-6.09	-0.31	3.07e-9	Obesity-related traits;
LIHC	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.48	-7.75	-0.39	1.04e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg04374321	chr14:90722782	PSMC1	0.48	6.57	0.33	1.91e-10	Gut microbiota (bacterial taxa);
LIHC	trans	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg17675199	chr6:35436792	RPL10A	0.39	8.01	0.4	1.87e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.57	6.32	0.32	8.19e-10	Axial length;
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg18306943	chr3:40428807	ENTPD3	0.4	7.05	0.36	9.77e-12	Renal cell carcinoma;
LIHC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.57	11.31	0.52	2.16e-25	Tonsillectomy;
LIHC	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25632853	chr15:73088954	NA	0.39	6.34	0.32	7.1e-10	Triglyceride levels;
LIHC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.45	-7.27	-0.37	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg17469321	chr7:55412551	NA	0.51	7.34	0.37	1.58e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.71	7.06	0.36	9.26e-12	Vitiligo;
LIHC	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.54	5.81	0.3	1.4e-8	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg11764359	chr7:65958608	NA	-0.57	-5.95	-0.31	6.77e-9	Diabetic kidney disease;
LIHC	cis	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg08029281	chr1:67600428	NA	-0.35	-6.05	-0.31	3.84e-9	Psoriasis;
LIHC	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.47	-0.37	6.67e-13	IgG glycosylation;
LIHC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg10978503	chr1:24200527	CNR2	-0.35	-8.43	-0.41	1.01e-15	Immature fraction of reticulocytes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00930347	chr6:110012366	AKD1;FIG4	0.48	7.02	0.35	1.19e-11	Cognitive function;
LIHC	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.48	-6.12	-0.31	2.5e-9	Response to amphetamines;
LIHC	cis	rs965469	0.779	rs6051717	chr20:3270242	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-6.5	-0.33	2.85e-10	IFN-related cytopenia;
LIHC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.58	10.04	0.48	5.89e-21	Mean corpuscular volume;
LIHC	cis	rs6662572	0.853	rs2065708	chr1:45977685	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.6	6.38	0.33	5.74e-10	Blood protein levels;
LIHC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26476595	chr16:2284284	E4F1	0.43	6.52	0.33	2.53e-10	Pancreatic cancer;
LIHC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.51	7.0	0.35	1.34e-11	Aortic root size;
LIHC	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.36	7.6	0.38	2.95e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.53	7.86	0.39	4.91e-14	Total body bone mineral density;
LIHC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.52	9.01	0.44	1.45e-17	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.29	6.86	0.35	3.3e-11	Primary biliary cholangitis;
LIHC	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-6.18	-0.32	1.79e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2334880	0.602	rs12444212	chr16:71437689	T/C	cg06353428	chr16:71660113	MARVELD3	-0.83	-7.85	-0.39	5.31e-14	Malaria;
LIHC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.46	-7.77	-0.39	9.44e-14	Response to temozolomide;
LIHC	cis	rs4820539	0.802	rs5759587	chr22:23441515	C/G	cg21100191	chr22:23484243	RTDR1	0.76	12.2	0.55	1.14e-28	Bone mineral density;
LIHC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.71	11.35	0.52	1.47e-25	Corneal astigmatism;
LIHC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg12798992	chr6:167411361	FGFR1OP	0.44	6.8	0.34	4.81e-11	Primary biliary cholangitis;
LIHC	cis	rs1403694	1.000	rs2304451	chr3:186437661	G/C	cg12454167	chr3:186435060	KNG1	0.3	7.28	0.37	2.25e-12	Blood protein levels;
LIHC	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.1	-0.31	2.91e-9	Tuberculosis;
LIHC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg00343986	chr7:65444356	GUSB	-0.41	-6.06	-0.31	3.68e-9	Aortic root size;
LIHC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg05590025	chr7:65112418	INTS4L2	-0.53	-5.75	-0.3	2.01e-8	Diabetic kidney disease;
LIHC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.22	-0.32	1.42e-9	Fear of minor pain;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg07424592	chr7:64974309	NA	0.81	9.45	0.45	5.58e-19	Diabetic kidney disease;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.72	-11.92	-0.54	1.24e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.61	8.99	0.44	1.72e-17	Recombination rate (females);
LIHC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-6.02	-0.31	4.51e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1982963	1.000	rs10139288	chr14:52506486	T/C	cg10843707	chr14:52510701	NID2	-0.44	-7.7	-0.38	1.51e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	9.37	0.45	1.04e-18	Platelet count;
LIHC	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.87	17.73	0.69	2.5e-50	Testicular germ cell tumor;
LIHC	cis	rs2737618	0.722	rs1986405	chr1:200095935	C/G	cg21825944	chr1:200113062	NR5A2	-0.46	-7.73	-0.39	1.24e-13	Uric acid levels;
LIHC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.23	-7.15	-0.36	5.22e-12	Motion sickness;
LIHC	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.43	9.0	0.44	1.59e-17	Optic cup area;
LIHC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg03037974	chr15:76606532	NA	0.74	14.39	0.61	4.85e-37	Blood metabolite levels;
LIHC	cis	rs3823572	0.542	rs62470443	chr7:133627499	G/A	cg03336402	chr7:133662267	EXOC4	0.52	6.2	0.32	1.65e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	8.42	0.41	1.04e-15	Schizophrenia;
LIHC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.38	6.71	0.34	7.86e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg24296786	chr1:45957014	TESK2	0.51	7.54	0.38	4.31e-13	High light scatter reticulocyte count;
LIHC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.63	6.03	0.31	4.24e-9	Inflammatory bowel disease;
LIHC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.56e-48	Diabetic kidney disease;
LIHC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18252515	chr7:66147081	NA	0.42	6.05	0.31	3.83e-9	Aortic root size;
LIHC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.64	-9.08	-0.44	8.7e-18	Blood metabolite levels;
LIHC	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs6066825	0.555	rs717709	chr20:47305959	G/A	cg18078177	chr20:47281410	PREX1	0.41	6.78	0.34	5.28e-11	Colorectal cancer;
LIHC	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.27	-0.37	2.4e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.89	-0.39	4.01e-14	Metabolite levels;
LIHC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.55	8.28	0.41	2.9e-15	Heart rate;
LIHC	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.82	-0.35	4.2e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.68	0.78	3.75e-70	Chronic sinus infection;
LIHC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.42	8.35	0.41	1.73e-15	Cognitive function;
LIHC	cis	rs6545883	0.894	rs2167566	chr2:61519408	G/T	cg14146966	chr2:61757674	XPO1	0.4	6.82	0.35	4.04e-11	Tuberculosis;
LIHC	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg19680672	chr10:131412579	MGMT	-0.39	-6.02	-0.31	4.39e-9	Response to temozolomide;
LIHC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.43	5.95	0.31	6.75e-9	Tuberculosis;
LIHC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.58	6.39	0.33	5.34e-10	Axial length;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21564803	chr22:43485544	TTLL1	0.43	6.44	0.33	4.02e-10	Cognitive function;
LIHC	cis	rs9596863	0.784	rs4242932	chr13:54448513	A/C	ch.13.53330881F	chr13:54432880	NA	-0.35	-5.89	-0.3	9.11e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.24	-0.41	3.59e-15	Response to antipsychotic treatment;
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.84	-0.54	2.51e-27	Alzheimer's disease;
LIHC	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg14146966	chr2:61757674	XPO1	0.48	8.57	0.42	3.61e-16	Tuberculosis;
LIHC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.43e-16	Motion sickness;
LIHC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.72	-14.11	-0.61	5.78e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10851411	0.697	rs17766258	chr15:42785137	A/G	cg21293051	chr15:42870591	STARD9	-0.67	-5.91	-0.3	8.28e-9	Glucose homeostasis traits;
LIHC	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg23587288	chr2:27483067	SLC30A3	0.32	5.96	0.31	6.26e-9	Blood metabolite levels;
LIHC	cis	rs240764	0.725	rs239212	chr6:101145178	G/A	cg09795085	chr6:101329169	ASCC3	0.45	6.18	0.32	1.87e-9	Neuroticism;
LIHC	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.23e-9	Blood pressure;
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg00809820	chr17:80708513	TBCD;FN3K	0.4	7.13	0.36	5.86e-12	Glycated hemoglobin levels;
LIHC	cis	rs12980942	0.872	rs66724427	chr19:41776257	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.29	0.32	9.54e-10	Coronary artery disease;
LIHC	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.34	-0.32	7.12e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg17724175	chr1:150552817	MCL1	0.41	7.8	0.39	7.32e-14	Melanoma;
LIHC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg13409248	chr3:40428643	ENTPD3	0.42	6.76	0.34	6.05e-11	Renal cell carcinoma;
LIHC	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg03934865	chr2:198174659	NA	0.47	6.85	0.35	3.51e-11	Dermatomyositis;
LIHC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.49	-7.64	-0.38	2.15e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11628318	0.614	rs4906254	chr14:103209153	C/T	cg01864069	chr14:103024347	NA	-0.34	-5.77	-0.3	1.81e-8	Platelet count;
LIHC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.27	-18.69	-0.71	3.23e-54	Ulcerative colitis;
LIHC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.8	0.35	4.66e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	12.16	0.55	1.57e-28	Colorectal cancer;
LIHC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	1.08	16.2	0.66	3.28e-44	Corneal structure;
LIHC	cis	rs12079745	0.793	rs12063056	chr1:169264107	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-7.12	-0.36	6.6e-12	QT interval;
LIHC	cis	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg26799834	chr8:12899921	NA	-0.53	-5.79	-0.3	1.61e-8	Obesity-related traits;
LIHC	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.37	12.28	0.55	5.73e-29	Uric acid levels;
LIHC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	0.83	9.31	0.45	1.54e-18	Vitiligo;
LIHC	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.48	-7.31	-0.37	1.89e-12	Triglyceride levels;
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg08847533	chr14:75593920	NEK9	-0.44	-7.11	-0.36	7.01e-12	Caffeine consumption;
LIHC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.58	-7.1	-0.36	7.38e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.31	-0.32	8.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18357526	chr6:26021779	HIST1H4A	0.41	6.09	0.31	3.01e-9	Height;
LIHC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg23205692	chr1:25664452	TMEM50A	0.38	6.05	0.31	3.9e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs9322817	0.691	rs9377679	chr6:105345036	C/T	cg02098413	chr6:105308735	HACE1	0.42	8.06	0.4	1.3e-14	Thyroid stimulating hormone;
LIHC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.87	0.3	1.01e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.13	-0.4	8.04e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs1075232	0.655	rs78959602	chr15:31560784	A/G	cg04373760	chr16:53404718	NA	0.67	6.43	0.33	4.22e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.73	0.3	2.23e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.34	-0.37	1.61e-12	Lung cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25743719	chr2:10443138	HPCAL1	0.48	6.33	0.32	7.59e-10	Lung function (FEV1/FVC);
LIHC	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.55	6.51	0.33	2.6200000000000003e-10	Mammographic density (dense area);
LIHC	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg05527609	chr1:210001259	C1orf107	-0.58	-7.83	-0.39	6.21e-14	Red blood cell count;
LIHC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.88	-0.35	2.87e-11	Personality dimensions;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11153505	chr13:113378377	ATP11A	-0.4	-6.17	-0.32	1.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.87	0.3	1.01e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.17	-0.44	4.37e-18	Alzheimer's disease;
LIHC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.78	0.3	1.69e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.41	-0.53	8.75e-26	Chronic sinus infection;
LIHC	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.13	-9.96	-0.47	1.12e-20	Schizophrenia;
LIHC	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.24	-0.48	1.21e-21	Eye color traits;
LIHC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.49	6.17	0.32	1.92e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.68	-9.84	-0.47	2.78e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.64	-7.36	-0.37	1.38e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.53	-6.55	-0.33	2.05e-10	Monobrow;
LIHC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.56	10.32	0.49	6.24e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4407350	0.609	rs1962220	chr22:44888063	G/A	cg11695653	chr22:44894386	LDOC1L	0.36	6.03	0.31	4.34e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-9.06	-0.44	1.06e-17	Obesity-related traits;
LIHC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.38	0.59	3.85e-33	Chronic sinus infection;
LIHC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	0.98	11.65	0.53	1.24e-26	Red blood cell traits;
LIHC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.48	7.37	0.37	1.27e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs6977660	1.000	rs6959889	chr7:19822024	A/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.57	9.86	0.47	2.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.61	6.3	0.32	9.42e-10	Smoking initiation;
LIHC	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg20194872	chr6:41519635	FOXP4	0.4	6.48	0.33	3.25e-10	Prostate cancer;
LIHC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.37	-5.74	-0.3	2.12e-8	Bipolar disorder;
LIHC	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg25114630	chr15:101792522	CHSY1	-0.6	-7.78	-0.39	8.49e-14	Corneal structure;
LIHC	cis	rs11062517	1	rs11062517	chr12:3235839	C/T	cg07248242	chr12:3281520	TSPAN9	-0.29	-5.79	-0.3	1.63e-8	Platelet distribution width;
LIHC	cis	rs7503168	0.908	rs9907772	chr17:34000628	G/A	cg20932281	chr17:33905541	PEX12	0.54	7.08	0.36	8.39e-12	Plateletcrit;
LIHC	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.75	12.5	0.56	8.42e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	trans	rs8113308	0.810	rs8104323	chr19:52443245	C/T	cg14959425	chr7:20447707	ITGB8	-0.48	-6.15	-0.32	2.22e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.32	7.44	0.37	8.48e-13	Corneal astigmatism;
LIHC	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.3	0.32	9.42e-10	Response to antipsychotic treatment;
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.83	-0.3	1.28e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.2	0.55	1.11e-28	Cognitive test performance;
LIHC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.59	-8.54	-0.42	4.39e-16	Schizophrenia;
LIHC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.47	6.7	0.34	8.53e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.58	7.36	0.37	1.36e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.97	0.31	5.97e-9	Height;
LIHC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.86	0.3	1.1e-8	Eosinophil percentage of white cells;
LIHC	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg04306507	chr14:55594613	LGALS3	0.32	5.97	0.31	5.81e-9	Protein biomarker;
LIHC	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.17	15.21	0.64	2.92e-40	Blood protein levels;
LIHC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.23e-9	Menopause (age at onset);
LIHC	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.57	-0.5	8.95e-23	Alzheimer's disease;
LIHC	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.75	-0.3	2.03e-8	Metabolite levels;
LIHC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg01629716	chr15:45996671	NA	-0.51	-9.37	-0.45	1.04e-18	Waist circumference;Weight;
LIHC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.74	-10.96	-0.51	3.8e-24	Corneal astigmatism;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs11888559	0.511	rs6736046	chr2:204006242	G/A	cg24605529	chr2:203879461	NBEAL1	0.8	6.1	0.31	2.8e-9	Height;
LIHC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.32	14.12	0.61	5.57e-36	Eosinophil percentage of granulocytes;
LIHC	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg18898632	chr2:242989856	NA	-0.69	-8.75	-0.43	1.01e-16	Obesity-related traits;
LIHC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.24	-0.32	1.26e-9	Morning vs. evening chronotype;
LIHC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.33	6.3	0.32	8.96e-10	Body mass index;
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg12903224	chr12:29470962	FAR2	-0.38	-6.04	-0.31	4.07e-9	QT interval;
LIHC	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg05340658	chr4:99064831	C4orf37	0.71	10.75	0.5	2.03e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.63	8.1	0.4	9.82e-15	Blood metabolite levels;
LIHC	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.31	7.57	0.38	3.48e-13	Gut microbiome composition (winter);
LIHC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.44	6.17	0.32	1.94e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg09182678	chr22:50328711	NA	0.49	6.06	0.31	3.69e-9	Schizophrenia;
LIHC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.75	12.57	0.56	4.94e-30	Mean platelet volume;
LIHC	trans	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg10208301	chr11:6592745	DNHD1	0.45	6.37	0.33	6.09e-10	Coronary artery calcification;
LIHC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.58	8.16	0.4	6.57e-15	Aortic root size;
LIHC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-9.73	-0.47	6.65e-20	Asthma;
LIHC	cis	rs1144333	0.655	rs12405994	chr1:76435420	A/T	cg03433033	chr1:76189801	ACADM	0.54	7.64	0.38	2.18e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.68	10.25	0.48	1.15e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08677398	chr8:58056175	NA	0.4	6.04	0.31	3.94e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-6.24	-0.32	1.28e-9	Arsenic metabolism;
LIHC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg15691649	chr6:25882328	NA	-0.53	-6.96	-0.35	1.79e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg00292662	chr22:38071168	LGALS1	0.4	6.74	0.34	6.93e-11	Fat distribution (HIV);
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.54	-7.42	-0.37	9.08e-13	Menopause (age at onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01485483	chr17:10600905	C17orf48;SCO1	-0.51	-6.14	-0.32	2.34e-9	Systolic blood pressure;
LIHC	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg03934865	chr2:198174659	NA	0.55	8.35	0.41	1.71e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-13.42	-0.59	2.76e-33	Vitiligo;
LIHC	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.9	14.07	0.61	8.42e-36	Obesity-related traits;
LIHC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.81	0.39	6.87e-14	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.26	-0.55	6.75e-29	Alzheimer's disease;
LIHC	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	6.4	0.33	5.14e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24712243	chr11:61310195	SYT7	0.46	6.68	0.34	9.45e-11	Longevity;
LIHC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.81	0.3	1.43e-8	Axial length;
LIHC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-11.96	-0.54	8.84e-28	Colorectal cancer;
LIHC	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg16586182	chr3:47516702	SCAP	-0.47	-8.18	-0.4	5.66e-15	Granulocyte count;Sum neutrophil eosinophil counts;
LIHC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	7.16	0.36	4.86e-12	Lung function (FEV1/FVC);
LIHC	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg06359132	chr10:99160096	RRP12	-0.38	-5.96	-0.31	6.4e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.4	-6.25	-0.32	1.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03517284	chr6:25882590	NA	-0.46	-6.93	-0.35	2.08e-11	Height;
LIHC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-5.74	-0.3	2.08e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.78	11.89	0.54	1.65e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg03543861	chr21:44258195	NA	0.48	7.39	0.37	1.15e-12	Information processing speed;
LIHC	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.47	-0.33	3.42e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.37	6.51	0.33	2.7e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.55	8.88	0.43	3.88e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg26446133	chr18:72167187	CNDP2	-0.49	-6.36	-0.33	6.34e-10	Refractive error;
LIHC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	1.04	19.42	0.72	3.65e-57	Multiple system atrophy;
LIHC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.88	-0.65	6.5e-43	Height;
LIHC	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.62	11.84	0.54	2.52e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg19676328	chr12:49525230	TUBA1B	-0.43	-6.06	-0.31	3.59e-9	Total cholesterol levels;
LIHC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.63	11.06	0.51	1.58e-24	Gestational age at birth (maternal effect);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03041860	chr2:208489911	FAM119A	0.41	6.9	0.35	2.55e-11	Cognitive function;
LIHC	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.78	-0.34	5.34e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17507749	chr15:85114479	UBE2QP1	0.62	7.09	0.36	7.9e-12	Schizophrenia;
LIHC	cis	rs1165668	0.727	rs2722176	chr12:104313943	T/C	cg21863207	chr12:104234989	NT5DC3	0.46	8.01	0.4	1.77e-14	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-7.67	-0.38	1.81e-13	Personality dimensions;
LIHC	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.39	-6.31	-0.32	8.75e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg10402321	chr1:26617780	UBXN11	-0.38	-5.86	-0.3	1.11e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.33	0.52	1.82e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs882732	1.000	rs17091071	chr14:95033708	A/C	cg14866387	chr14:95027382	SERPINA4	-0.45	-6.73	-0.34	7.03e-11	Blood protein levels;
LIHC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.67	-6.39	-0.33	5.37e-10	Breast cancer;
LIHC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-8.13	-0.4	8.08e-15	Tonsillectomy;
LIHC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.12	-0.74	5.95e-60	Height;
LIHC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.51	9.37	0.45	9.75e-19	Mean corpuscular volume;
LIHC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.37	-6.08	-0.31	3.25e-9	Height;
LIHC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.8	13.07	0.58	5.92e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	8.09	0.4	1.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg07133347	chr1:107600762	PRMT6	-0.44	-6.66	-0.34	1.1e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg10360323	chr17:41437877	NA	0.4	6.0	0.31	5.04e-9	Menopause (age at onset);
LIHC	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.43	6.43	0.33	4.2e-10	Night sleep phenotypes;
LIHC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-7.45	-0.37	7.47e-13	Hepatocellular carcinoma;
LIHC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg21466736	chr12:48725269	NA	0.63	8.92	0.43	2.96e-17	Glycated hemoglobin levels;
LIHC	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-7.65	-0.38	2.03e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs918629	0.528	rs2547997	chr5:95254171	G/T	cg10483112	chr5:95245456	ELL2	-0.38	-7.14	-0.36	5.48e-12	IgG glycosylation;
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.38	0.33	5.64e-10	Renal cell carcinoma;
LIHC	cis	rs861318	0.702	rs74122232	chr1:159006423	G/A	cg11003133	chr1:159046391	AIM2	-0.35	-6.7	-0.34	8.71e-11	Obesity-related traits;
LIHC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.13	0.61	5.14e-36	Chronic sinus infection;
LIHC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.82	14.15	0.61	4.03e-36	Chronic sinus infection;
LIHC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.43e-12	Obesity-related traits;
LIHC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.21	-0.36	3.6e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs965469	0.901	rs6139080	chr20:3314506	A/G	cg25506879	chr20:3388711	C20orf194	-0.56	-6.81	-0.35	4.32e-11	IFN-related cytopenia;
LIHC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.49	-7.66	-0.38	1.96e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.31e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10106298	0.846	rs2436936	chr8:103677723	C/A	cg10187029	chr8:103597600	NA	0.47	6.36	0.33	6.56e-10	Schizophrenia;
LIHC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.03	0.55	4.76e-28	Body mass index;
LIHC	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg20302342	chr1:156215951	PAQR6	0.32	6.05	0.31	3.72e-9	Tonsillectomy;
LIHC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.46	7.75	0.39	1.07e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg07424592	chr7:64974309	NA	0.8	9.21	0.45	3.38e-18	Diabetic kidney disease;
LIHC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.8	12.91	0.57	2.53e-31	Colorectal cancer;
LIHC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg15744005	chr10:104629667	AS3MT	-0.36	-6.57	-0.33	1.86e-10	Arsenic metabolism;
LIHC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.46	7.33	0.37	1.66e-12	Height;
LIHC	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.4	-13.76	-0.6	1.3600000000000001e-34	Psoriasis vulgaris;
LIHC	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-10.38	-0.49	4.15e-22	Brugada syndrome;
LIHC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg08824895	chr13:115047677	UPF3A	0.5	7.05	0.36	9.95e-12	Schizophrenia;
LIHC	trans	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.5	-7.35	-0.37	1.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg01864069	chr14:103024347	NA	-0.46	-7.39	-0.37	1.12e-12	Platelet count;
LIHC	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	18.67	0.71	3.82e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12744310	0.887	rs35464028	chr1:41800474	T/G	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.52	8.19	0.41	5.16e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg02990361	chr1:107599529	PRMT6	0.65	11.02	0.51	2.28e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg19302996	chr17:73780495	UNK	-0.46	-6.67	-0.34	1.05e-10	White matter hyperintensity burden;
LIHC	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	1.09	7.82	0.39	6.53e-14	Arsenic metabolism;
LIHC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.11	0.31	2.72e-9	Tonsillectomy;
LIHC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.52	7.54	0.38	4.33e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2637266	0.783	rs846645	chr10:78516000	A/G	cg18941641	chr10:78392320	NA	0.27	5.84	0.3	1.22e-8	Pulmonary function;
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg14515779	chr1:101123966	NA	-0.69	-13.78	-0.6	1.15e-34	Monocyte count;
LIHC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.14	-0.31	2.32e-9	Tonsillectomy;
LIHC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.33	7.08	0.36	8.47e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.93	12.68	0.57	1.9e-30	Blood metabolite levels;
LIHC	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.67	-8.93	-0.43	2.75e-17	Coronary artery disease;
LIHC	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg04004882	chr2:215674386	BARD1	0.53	6.45	0.33	3.83e-10	Neuroblastoma;
LIHC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.22	-0.36	3.33e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg25344623	chr2:136566232	LCT	0.41	8.48	0.42	7.09e-16	Mosquito bite size;
LIHC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg18357526	chr6:26021779	HIST1H4A	0.41	6.26	0.32	1.15e-9	Height;
LIHC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.7e-15	Gut microbiome composition (summer);
LIHC	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg27205649	chr11:78285834	NARS2	0.4	6.12	0.31	2.61e-9	Alzheimer's disease (survival time);
LIHC	trans	rs783540	0.846	rs783539	chr15:83254070	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.06	-0.31	3.51e-9	Schizophrenia;
LIHC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.44	-6.49	-0.33	3.08e-10	Cognitive function;
LIHC	cis	rs526821	0.595	rs517627	chr11:55356489	C/T	cg04317927	chr11:55418816	OR4S2	0.47	8.98	0.44	1.86e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.54	7.31	0.37	1.95e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	0.89	7.01	0.35	1.24e-11	IgG glycosylation;
LIHC	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.45	7.13	0.36	5.92e-12	Cocaine dependence;
LIHC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg20651018	chr11:3035856	CARS	-0.35	-5.94	-0.31	7.09e-9	Longevity;
LIHC	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.06	-0.31	3.56e-9	Metabolite levels;
LIHC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.46	0.33	3.64e-10	Parkinson's disease;
LIHC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.76	-9.49	-0.46	4.06e-19	Systemic lupus erythematosus;
LIHC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.58	8.16	0.4	6.57e-15	Aortic root size;
LIHC	cis	rs1789	0.903	rs4616746	chr4:15673098	A/G	cg24225360	chr4:15471699	CC2D2A	-0.38	-5.91	-0.3	8.24e-9	Blood protein levels;
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.1e-31	Prudent dietary pattern;
LIHC	cis	rs74233809	1.000	rs11191593	chr10:104939215	T/C	cg03493300	chr10:104813866	CNNM2	0.46	6.14	0.32	2.29e-9	Birth weight;
LIHC	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-11.12	-0.52	1.01e-24	Eye color traits;
LIHC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	7.54	0.38	4.13e-13	Monocyte percentage of white cells;
LIHC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.44	5.9	0.3	8.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg22834771	chr12:69754056	YEATS4	-0.4	-6.47	-0.33	3.44e-10	Response to diuretic therapy;
LIHC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.42	-7.39	-0.37	1.12e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs10792665	0.575	rs10792653	chr11:82560312	T/G	cg24227371	chr11:82718527	RAB30	-0.26	-6.27	-0.32	1.1e-9	Obesity-related traits;
LIHC	trans	rs2270927	0.510	rs2913265	chr5:75603886	C/A	cg13563193	chr19:33072644	PDCD5	0.93	8.96	0.44	2.09e-17	Mean corpuscular volume;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.44	-6.65	-0.34	1.15e-10	Body mass index;
LIHC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.41	-6.77	-0.34	5.46e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs61712019	0.679	rs1950161	chr2:77719972	C/T	cg11252801	chr2:77748917	LRRTM4	0.56	7.73	0.39	1.2e-13	Schizophrenia;
LIHC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.98	0.44	1.87e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.85	-15.03	-0.63	1.49e-39	Aortic root size;
LIHC	cis	rs7508	0.511	rs371922	chr8:17900003	T/C	cg01800426	chr8:17659068	MTUS1	-0.44	-6.93	-0.35	2.12e-11	Atrial fibrillation;
LIHC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.8	12.92	0.57	2.29e-31	Fat distribution (HIV);
LIHC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-6.77	-0.34	5.58e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.38	0.49	3.89e-22	Post bronchodilator FEV1;
LIHC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.4	5.89	0.3	9.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	7.89	0.39	4.01e-14	Platelet count;
LIHC	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.42	6.58	0.34	1.82e-10	Response to temozolomide;
LIHC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg25356066	chr3:128598488	ACAD9	0.52	7.34	0.37	1.62e-12	IgG glycosylation;
LIHC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.51	-0.46	3.5e-19	Electroencephalogram traits;
LIHC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	6.82	0.35	4.02e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg17135325	chr3:160939158	NMD3	0.53	7.52	0.38	4.72e-13	Parkinson's disease;
LIHC	cis	rs611744	0.967	rs677330	chr8:109177572	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs249954	0.512	rs703769	chr16:23654509	T/G	cg01460202	chr16:23706506	ERN2	0.35	5.71	0.3	2.42e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.7	-6.3	-0.32	9.29e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs4407350	1.000	rs5765723	chr22:44921554	C/T	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.06	-0.31	3.55e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05673432	chr3:15919505	NA	0.53	6.7	0.34	8.83e-11	Hepatitis;
LIHC	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.84e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg18451016	chr1:38461880	NA	-0.37	-5.83	-0.3	1.31e-8	Coronary artery disease;
LIHC	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.21	5.75	0.3	1.95e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg06598544	chr20:61472147	COL9A3	-0.83	-7.9	-0.39	3.97e-14	Obesity-related traits;
LIHC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.48	9.74	0.47	6.14e-20	Tonsillectomy;
LIHC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.59	9.24	0.45	2.74e-18	Obesity-related traits;
LIHC	cis	rs2637266	0.626	rs2583067	chr10:78555804	A/G	cg18941641	chr10:78392320	NA	0.3	6.46	0.33	3.58e-10	Pulmonary function;
LIHC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.83	7.99	0.4	2.07e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs6594499	0.872	rs7702774	chr5:110460851	G/T	cg04022379	chr5:110408740	TSLP	0.49	8.07	0.4	1.18e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1400745	0.729	rs1741196	chr14:35347020	G/A	cg16230307	chr14:35515116	FAM177A1	0.38	6.1	0.31	2.9e-9	Monocyte count;
LIHC	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg20634798	chr1:152595351	LCE3A	-0.31	-6.03	-0.31	4.26e-9	Psoriasis;
LIHC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.93	17.85	0.69	8.09e-51	Menopause (age at onset);
LIHC	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.54	7.6	0.38	2.78e-13	Recombination rate (females);
LIHC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.55	-6.87	-0.35	3.02e-11	Ileal carcinoids;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.98	-0.31	5.61e-9	Longevity;Endometriosis;
LIHC	cis	rs9309473	0.898	rs10201159	chr2:73858965	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.4	-0.33	5.25e-10	Metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04232541	chr6:144384895	PLAGL1	0.45	6.68	0.34	9.7e-11	Cognitive function;
LIHC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21467203	chr3:49911342	NA	0.44	7.83	0.39	6.17e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg22528358	chr1:107598549	PRMT6	-0.67	-11.08	-0.51	1.4e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs8117834	0.574	rs73076227	chr20:8081168	G/A	cg00593689	chr4:53575888	NA	0.39	6.5	0.33	2.88e-10	Chronic kidney disease;
LIHC	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.31	12.35	0.56	3.28e-29	Uric acid levels;
LIHC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg25344623	chr2:136566232	LCT	0.43	8.46	0.42	8.01e-16	Mosquito bite size;
LIHC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.42	-6.36	-0.33	6.64e-10	Systemic sclerosis;
LIHC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.51	-0.38	5.36e-13	Body mass index;
LIHC	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.47	-6.98	-0.35	1.54e-11	Corneal astigmatism;
LIHC	cis	rs16958440	0.541	rs62095459	chr18:44621382	A/T	cg17192377	chr18:44677553	HDHD2	0.5	6.31	0.32	8.73e-10	Sitting height ratio;
LIHC	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.5	9.68	0.46	9.84e-20	Testicular germ cell tumor;
LIHC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	9.29	0.45	1.82e-18	Body mass index;
LIHC	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.37	-6.34	-0.32	7.11e-10	Lewy body disease;
LIHC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.47	7.64	0.38	2.16e-13	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.55	-8.26	-0.41	3.16e-15	Ulcerative colitis;
LIHC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.8	11.24	0.52	3.72e-25	Body mass index;
LIHC	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg20991723	chr1:152506922	NA	0.53	9.08	0.44	8.95e-18	Hair morphology;
LIHC	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.39	0.33	5.28e-10	Systolic blood pressure;
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.89	-0.35	2.71e-11	Menopause (age at onset);
LIHC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg03037974	chr15:76606532	NA	0.72	13.95	0.6	2.6e-35	Blood metabolite levels;
LIHC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	12.02	0.55	5.2e-28	Body mass index;
LIHC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.48	7.77	0.39	9.34e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.38	-6.21	-0.32	1.56e-9	Monocyte count;
LIHC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.53	-7.55	-0.38	4.11e-13	Body mass index;
LIHC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.62	-0.34	1.42e-10	Alzheimer's disease (late onset);
LIHC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg01629716	chr15:45996671	NA	0.52	9.51	0.46	3.62e-19	Waist circumference;Weight;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg03536881	chr19:49496987	RUVBL2;GYS1	-0.5	-6.07	-0.31	3.39e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-7.46	-0.37	7.36e-13	Heart rate;
LIHC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.58	8.65	0.42	2.02e-16	Aortic root size;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.8	13.55	0.59	8.5e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.16	0.32	2.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.63	9.7	0.46	8.18e-20	Renal cell carcinoma;
LIHC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.23	-0.52	4e-25	Diastolic blood pressure;
LIHC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.84	-0.3	1.25e-8	Personality dimensions;
LIHC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	trans	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg19894588	chr14:64061835	NA	-0.64	-8.79	-0.43	7.65e-17	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2637266	0.905	rs10824428	chr10:78346041	G/A	cg18941641	chr10:78392320	NA	0.29	6.06	0.31	3.52e-9	Pulmonary function;
LIHC	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19671926	chr4:122722719	EXOSC9	0.46	6.76	0.34	6.06e-11	Type 2 diabetes;
LIHC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.66	-12.6	-0.56	3.78e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.15	-0.55	1.74e-28	Alzheimer's disease;
LIHC	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07384357	chr20:62499359	TPD52L2	0.38	6.13	0.31	2.38e-9	Myopia (pathological);
LIHC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.88	0.3	9.85e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4865169	0.811	rs6841086	chr4:57903268	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.5	0.42	5.85e-16	Breast cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18002896	chr8:144465845	RHPN1	0.39	6.07	0.31	3.37e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.35	5.71	0.3	2.43e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs800082	0.734	rs1527236	chr3:144246938	G/A	cg24215973	chr2:240111563	HDAC4	0.44	6.43	0.33	4.33e-10	Smoking behavior;
LIHC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20135002	chr11:47629003	NA	-0.51	-8.59	-0.42	3.11e-16	Subjective well-being;
LIHC	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.41	6.83	0.35	3.79e-11	Lewy body disease;
LIHC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg27478167	chr7:817139	HEATR2	-0.49	-6.73	-0.34	7.37e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.87	-0.63	6.47e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.49	-0.38	6.04e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	7.04	0.36	1.06e-11	Refractive astigmatism;
LIHC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.69	-0.43	1.56e-16	Cognitive function;
LIHC	cis	rs2710642	0.545	rs1406002	chr2:62807091	A/C	cg17519650	chr2:63277830	OTX1	0.41	6.36	0.33	6.57e-10	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.27	-5.91	-0.3	8.31e-9	Pulmonary function;
LIHC	trans	rs7504990	0.722	rs35879011	chr18:50373124	G/A	cg08535148	chr4:26321143	RBPJ	0.56	7.03	0.36	1.12e-11	Gallbladder cancer;
LIHC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg16926213	chr1:1841314	NA	0.32	5.94	0.31	6.98e-9	Body mass index;
LIHC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.12	0.31	2.59e-9	Alzheimer's disease;
LIHC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.57	-8.04	-0.4	1.44e-14	Orofacial clefts;
LIHC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.48	-7.24	-0.36	3.02e-12	Cognitive function;
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.97	0.47	1.02e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg04306507	chr14:55594613	LGALS3	0.32	6.08	0.31	3.13e-9	Protein biomarker;
LIHC	cis	rs96067	0.772	rs6664471	chr1:36606757	A/G	cg24686825	chr1:36642396	MAP7D1	-0.35	-5.87	-0.3	1.06e-8	Corneal structure;
LIHC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg08213375	chr14:104286397	PPP1R13B	0.35	5.73	0.3	2.26e-8	Reticulocyte count;
LIHC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.05	0.31	3.76e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.79	12.39	0.56	2.34e-29	Breast cancer;
LIHC	cis	rs2758596	1.000	rs2241111	chr1:156163718	T/C	cg25208724	chr1:156163844	SLC25A44	0.76	7.59	0.38	2.98e-13	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	7.79	0.39	8.15e-14	Blood protein levels;
LIHC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	8.44	0.42	9.05e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.42	-6.17	-0.32	1.92e-9	IgG glycosylation;
LIHC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg11062466	chr8:58055876	NA	0.4	5.91	0.3	8.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06634786	chr22:41940651	POLR3H	-0.5	-5.85	-0.3	1.16e-8	Vitiligo;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06420487	chr17:61919686	SMARCD2	0.44	5.95	0.31	6.71e-9	Height;
LIHC	cis	rs238295	0.805	rs6053499	chr20:5542546	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.47	-6.53	-0.33	2.43e-10	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.84	-0.54	2.51e-27	Alzheimer's disease;
LIHC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg06640241	chr16:89574553	SPG7	0.82	15.06	0.63	1.08e-39	Multiple myeloma (IgH translocation);
LIHC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	6.04	0.31	3.93e-9	Bipolar disorder;
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	5.84	0.3	1.19e-8	Longevity;
LIHC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.53	-8.16	-0.4	6.29e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs4788570	0.510	rs9931074	chr16:71667680	C/T	cg06353428	chr16:71660113	MARVELD3	1.44	15.19	0.63	3.51e-40	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02037503	chr14:23540729	ACIN1	0.51	7.49	0.38	5.94e-13	Pancreatic cancer;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.57	-10.82	-0.5	1.21e-23	Prudent dietary pattern;
LIHC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.23	-0.36	3.27e-12	Schizophrenia;
LIHC	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.04	0.51	1.98e-24	Coffee consumption (cups per day);
LIHC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.45	-6.47	-0.33	3.4e-10	Aortic root size;
LIHC	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs15676	0.783	rs2417126	chr9:131562457	C/T	cg00228799	chr9:131580591	ENDOG	-0.47	-6.72	-0.34	7.48e-11	Blood metabolite levels;
LIHC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.16	0.44	4.71e-18	Schizophrenia;
LIHC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.37	-6.4	-0.33	4.98e-10	Facial morphology (factor 20);
LIHC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.77	11.85	0.54	2.28e-27	Corneal astigmatism;
LIHC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.57	-8.64	-0.42	2.22e-16	Breast cancer;
LIHC	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg22307029	chr19:49891270	CCDC155	0.56	8.92	0.43	2.92e-17	Multiple sclerosis;
LIHC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2895526	0.765	rs12413453	chr10:12722364	T/C	cg00115178	chr10:12648176	CAMK1D	-0.35	-6.2	-0.32	1.61e-9	Headache;
LIHC	cis	rs10508774	1.000	rs10508774	chr10:32807861	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.03	0.31	4.19e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.61	-7.22	-0.36	3.48e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.0	0.58	1.11e-31	Cognitive test performance;
LIHC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg26441486	chr22:50317300	CRELD2	0.35	6.12	0.31	2.59e-9	Schizophrenia;
LIHC	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-15.51	-0.64	1.93e-41	Exhaled nitric oxide output;
LIHC	cis	rs3812111	0.677	rs1204846	chr6:116522021	C/A	cg08036074	chr6:116424633	NT5DC1	-0.4	-6.46	-0.33	3.52e-10	Age-related macular degeneration;
LIHC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-5.92	-0.3	7.82e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg16586182	chr3:47516702	SCAP	-0.48	-8.63	-0.42	2.31e-16	Colorectal cancer;
LIHC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.71	-9.94	-0.47	1.33e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg08847533	chr14:75593920	NEK9	-0.36	-5.97	-0.31	5.88e-9	Caffeine consumption;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.45	-0.53	6.37e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.72	-7.36	-0.37	1.4e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15344021	chr17:2240169	TSR1;SGSM2	0.44	6.86	0.35	3.15e-11	Cognitive function;
LIHC	trans	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg24036039	chr1:3397125	ARHGEF16	0.4	6.56	0.33	1.99e-10	Schizophrenia;
LIHC	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg01843034	chr6:37503916	NA	-0.44	-7.25	-0.36	2.87e-12	Cognitive performance;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg12311636	chr6:118886798	C6orf204	-0.52	-6.23	-0.32	1.35e-9	Diastolic blood pressure;
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.53	7.02	0.36	1.17e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.17	0.32	1.9e-9	Educational attainment;
LIHC	cis	rs1664789	0.683	rs702636	chr5:53268396	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.46	7.2	0.36	3.98e-12	Waist circumference adjusted for body mass index;
LIHC	cis	rs74544699	1.000	rs78267059	chr4:74798010	G/A	cg02530824	chr4:74847766	PF4	0.66	6.8	0.35	4.61e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.52	8.18	0.4	5.67e-15	Crohn's disease;
LIHC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg07636037	chr3:49044803	WDR6	-0.62	-7.41	-0.37	9.75e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.25	0.32	1.21e-9	Lymphocyte counts;
LIHC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	trans	rs2479768	1.000	rs74041703	chr13:29587083	C/G	cg08641024	chr16:47047688	NA	0.72	6.28	0.32	1.02e-9	Methotrexate phramacokinetics (acute lymphoblastic leukemia);
LIHC	cis	rs3106136	0.814	rs6839224	chr4:95279214	A/C	cg11021082	chr4:95130006	SMARCAD1	0.35	6.08	0.31	3.29e-9	Capecitabine sensitivity;
LIHC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.24	0.61	1.91e-36	Chronic sinus infection;
LIHC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.59	-6.76	-0.34	6.11e-11	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg19623624	chr10:135278901	LOC619207	0.42	6.52	0.33	2.55e-10	Systemic lupus erythematosus;
LIHC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.58	7.6	0.38	2.84e-13	Initial pursuit acceleration;
LIHC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg01629716	chr15:45996671	NA	0.52	9.56	0.46	2.42e-19	Waist circumference;Weight;
LIHC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.73	-10.37	-0.49	4.37e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.4	5.72	0.3	2.37e-8	Schizophrenia;
LIHC	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.48	7.68	0.38	1.7e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.44	0.33	4.01e-10	Prudent dietary pattern;
LIHC	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg23254163	chr1:152506842	NA	0.23	5.88	0.3	9.66e-9	Hair morphology;
LIHC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	7.06	0.36	9.22e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg17385448	chr1:15911702	AGMAT	0.33	5.87	0.3	1.04e-8	Systolic blood pressure;
LIHC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.38	7.0	0.35	1.38e-11	Schizophrenia;
LIHC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.2	-12.68	-0.57	1.9e-30	White matter hyperintensity burden;
LIHC	trans	rs13113518	0.812	rs11133385	chr4:56326652	G/A	cg15358633	chr12:38710606	ALG10B	0.42	6.05	0.31	3.82e-9	Height;
LIHC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	11.28	0.52	2.56e-25	Platelet count;
LIHC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.55	7.28	0.37	2.36e-12	Obesity-related traits;
LIHC	cis	rs738321	0.658	rs5756916	chr22:38507047	G/A	cg25457927	chr22:38595422	NA	-0.33	-7.13	-0.36	5.95e-12	Breast cancer;
LIHC	cis	rs7587476	0.765	rs2121284	chr2:215656260	T/C	cg04530015	chr2:215796436	ABCA12	0.42	7.1	0.36	7.45e-12	Neuroblastoma;
LIHC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.27	5.83	0.3	1.25e-8	Type 2 diabetes;
LIHC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg09222892	chr1:25734099	RHCE	0.48	8.88	0.43	3.86e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg16434002	chr17:42200994	HDAC5	-0.48	-7.16	-0.36	4.87e-12	Total body bone mineral density;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg19517378	chr4:83932058	LIN54	-0.36	-6.33	-0.32	7.53e-10	Oropharynx cancer;
LIHC	cis	rs1144333	0.655	rs76532097	chr1:76320759	G/C	cg10523679	chr1:76189770	ACADM	0.48	6.85	0.35	3.55e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.33	6.04	0.31	4.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.58	-0.46	2.04e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.61	5.73	0.3	2.19e-8	Morning vs. evening chronotype;
LIHC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg03735888	chr19:58951602	ZNF132	0.36	5.95	0.31	6.5e-9	Uric acid clearance;
LIHC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-0.95	-19.73	-0.73	2.22e-58	Height;
LIHC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.11	0.36	6.7e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.21	0.48	1.51e-21	Colorectal cancer;
LIHC	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.7	7.36	0.37	1.36e-12	Systemic lupus erythematosus;
LIHC	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg08000102	chr2:233561755	GIGYF2	-0.45	-6.15	-0.32	2.17e-9	Coronary artery disease;
LIHC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22168489	chr12:122356033	WDR66	0.45	6.46	0.33	3.6e-10	Mean corpuscular volume;
LIHC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg15691649	chr6:25882328	NA	0.46	5.92	0.3	7.84e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01141043	chr14:65007050	HSPA2	-0.52	-6.14	-0.32	2.33e-9	Systolic blood pressure;
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.88	-14.69	-0.62	3.37e-38	Longevity;
LIHC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.51	8.97	0.44	1.94e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs7129220	0.588	rs77092969	chr11:10116298	G/A	cg01453529	chr11:10209919	SBF2	-0.39	-6.93	-0.35	2.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.8	-8.01	-0.4	1.81e-14	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LIHC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.65	0.38	2e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.95	-12.43	-0.56	1.54e-29	Obesity-related traits;
LIHC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	7.08	0.36	8.21e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.38	-6.73	-0.34	7.21e-11	Aortic root size;
LIHC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.35	0.59	5.37e-33	Psoriasis;
LIHC	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	cis	rs11627756	0.958	rs4906238	chr14:103077702	G/A	cg12046867	chr14:103022105	NA	-0.38	-5.88	-0.3	9.97e-9	Mean platelet volume;
LIHC	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.93	0.39	3.1e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg15744005	chr10:104629667	AS3MT	-0.38	-8.42	-0.41	1.04e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.23	-12.9	-0.57	2.61e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-18.94	-0.72	3.09e-55	Schizophrenia;
LIHC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.84	0.3	1.22e-8	Tonsillectomy;
LIHC	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.38	-0.45	9.54e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.14	0.32	2.24e-9	Renal cell carcinoma;
LIHC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.77	0.39	9.57e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.64	-10.17	-0.48	2.12e-21	Dental caries;
LIHC	cis	rs1914816	1.000	rs2456072	chr15:76545844	A/G	cg03037974	chr15:76606532	NA	-0.56	-5.77	-0.3	1.81e-8	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.43	7.1	0.36	7.39e-12	Crohn's disease;
LIHC	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	0.94	19.49	0.73	2.04e-57	Schizophrenia;
LIHC	trans	rs6489882	0.902	rs1981556	chr12:113372961	C/G	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg15705551	chr2:10952987	PDIA6	0.72	10.27	0.49	9.49e-22	Cardiac Troponin-T levels;
LIHC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.4	7.22	0.36	3.4e-12	Schizophrenia;
LIHC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.37	0.33	6.11e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.58	0.42	3.36e-16	Corneal astigmatism;
LIHC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs600806	0.893	rs370088	chr1:109858119	T/C	cg16275483	chr1:110013120	SYPL2	-0.49	-6.11	-0.31	2.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.82	13.39	0.59	3.61e-33	Breast cancer;
LIHC	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg24849736	chr1:201084428	NA	-0.37	-7.22	-0.36	3.41e-12	Permanent tooth development;
LIHC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04476341	chr5:669733	TPPP	-0.36	-8.59	-0.42	3.07e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.64	9.44	0.45	6.17e-19	Monocyte percentage of white cells;
LIHC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.22	0.55	9.47e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.36	5.76	0.3	1.88e-8	Bipolar disorder;
LIHC	cis	rs1144333	0.655	rs76175698	chr1:76454792	C/T	cg10523679	chr1:76189770	ACADM	0.44	5.92	0.31	7.66e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.5	8.32	0.41	2.12e-15	Schizophrenia;
LIHC	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg03934865	chr2:198174659	NA	0.46	6.79	0.34	5.08e-11	Dermatomyositis;
LIHC	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.43	7.12	0.36	6.44e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.66	-0.34	1.06e-10	Mean corpuscular volume;
LIHC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg00106254	chr7:1943704	MAD1L1	0.39	6.09	0.31	3.06e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg23461800	chr14:103021989	NA	-0.5	-7.12	-0.36	6.6e-12	Platelet count;
LIHC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg07713946	chr22:31675144	LIMK2	-0.43	-7.84	-0.39	5.78e-14	Colorectal cancer;
LIHC	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.56	7.79	0.39	8.33e-14	Coronary artery disease;
LIHC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.86	15.63	0.65	6.3e-42	Response to diuretic therapy;
LIHC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.12	-0.44	6.77e-18	Bipolar disorder;
LIHC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg10360323	chr17:41437877	NA	0.45	6.65	0.34	1.17e-10	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16868751	chr10:96162146	TBC1D12	0.4	6.78	0.34	5.14e-11	Cognitive function;
LIHC	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.33	-0.41	1.94e-15	Exhaled nitric oxide output;
LIHC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.98	-20.43	-0.74	3.41e-61	Coronary artery disease;
LIHC	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg14473756	chr11:122847823	NA	-0.37	-6.67	-0.34	1.02e-10	Menarche (age at onset);
LIHC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg12798992	chr6:167411361	FGFR1OP	0.61	10.14	0.48	2.73e-21	Crohn's disease;
LIHC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	16.53	0.67	1.52e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.32	6.16	0.32	2.01e-9	Multiple system atrophy;
LIHC	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg05760424	chr2:242988095	NA	-0.53	-7.14	-0.36	5.58e-12	Obesity-related traits;
LIHC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.91	15.0	0.63	1.91e-39	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.59	-8.19	-0.41	5.14e-15	Sudden cardiac arrest;
LIHC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.81	0.43	6.52e-17	Platelet count;
LIHC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.79	0.34	5.06e-11	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.43	6.92	0.35	2.17e-11	Cognitive function;
LIHC	trans	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04565464	chr8:145669602	NFKBIL2	0.43	7.21	0.36	3.73e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.34	5.75	0.3	1.94e-8	Metabolite levels;
LIHC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg11057378	chr10:81107060	PPIF	0.35	5.77	0.3	1.77e-8	Height;
LIHC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.49	6.09	0.31	3.01e-9	Total body bone mineral density;
LIHC	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.61	10.05	0.48	5.51e-21	Corneal astigmatism;
LIHC	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-8.52	-0.42	5.16e-16	Total cholesterol levels;
LIHC	cis	rs12079745	0.590	rs76692040	chr1:169295689	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-7.15	-0.36	5.28e-12	QT interval;
LIHC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.63	7.46	0.37	7.34e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.46	6.07	0.31	3.47e-9	Obesity (extreme);
LIHC	cis	rs2412488	1.000	rs2090117	chr4:54300591	G/T	cg22241045	chr4:54363911	LNX1	0.45	7.13	0.36	6.01e-12	DNA methylation (variation);
LIHC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.93	0.31	7.49e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.61	6.99	0.35	1.44e-11	Axial length;
LIHC	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.39	-6.92	-0.35	2.28e-11	Schizophrenia;
LIHC	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	19.29	0.72	1.3e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.86	-16.25	-0.66	2.02e-44	Coronary artery disease;
LIHC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg18357645	chr12:58087776	OS9	-0.44	-7.03	-0.36	1.12e-11	Multiple sclerosis;
LIHC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.77	0.34	5.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	6.17	0.32	1.92e-9	Ileal carcinoids;
LIHC	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.39	6.72	0.34	7.63e-11	IgG glycosylation;
LIHC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.32	6.53	0.33	2.33e-10	Renal cell carcinoma;
LIHC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.23	-0.32	1.33e-9	Total body bone mineral density;
LIHC	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.91e-9	Pulmonary function;
LIHC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg25356066	chr3:128598488	ACAD9	0.55	7.7	0.38	1.51e-13	IgG glycosylation;
LIHC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.58	8.22	0.41	4.2e-15	Aortic root size;
LIHC	cis	rs57502260	0.764	rs7105218	chr11:68222461	C/A	cg16797656	chr11:68205561	LRP5	0.59	8.18	0.4	5.52e-15	Total body bone mineral density (age 45-60);
LIHC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.36	9.02	0.44	1.35e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-13.35	-0.59	5.14e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.97	9.91	0.47	1.56e-20	Plasma clusterin levels;
LIHC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.51	-7.46	-0.37	7.38e-13	Psoriasis;
LIHC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.32	-0.32	8.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	7.52	0.38	4.86e-13	Schizophrenia;
LIHC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	8.71	0.43	1.35e-16	Schizophrenia;
LIHC	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.03	-0.36	1.1e-11	Major depressive disorder;
LIHC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.6	-7.68	-0.38	1.69e-13	Obesity-related traits;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg24955400	chr8:30352338	RBPMS	0.54	6.68	0.34	9.97e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg16011800	chr17:1958478	HIC1	-0.52	-7.39	-0.37	1.16e-12	Lymphocyte counts;Red cell distribution width;
LIHC	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.57	-9.17	-0.44	4.63e-18	Corneal astigmatism;
LIHC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18867708	chr6:26865862	GUSBL1	0.54	8.11	0.4	9.31e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02985541	chr2:219472218	PLCD4	-0.38	-6.66	-0.34	1.07e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg07884673	chr3:53033167	SFMBT1	0.9	6.59	0.34	1.65e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs922107	0.713	rs7532966	chr1:89955188	T/C	cg15422784	chr1:90023713	LRRC8B	0.47	7.47	0.37	6.89e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-10.79	-0.5	1.51e-23	Vitiligo;
LIHC	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg16586182	chr3:47516702	SCAP	-0.39	-6.62	-0.34	1.4e-10	Birth weight;
LIHC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.49	-7.52	-0.38	4.81e-13	Longevity;
LIHC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.86	-0.3	1.09e-8	Ulcerative colitis;
LIHC	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.52	8.38	0.41	1.39e-15	Blood protein levels;
LIHC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.64	-0.34	1.21e-10	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg11764359	chr7:65958608	NA	-0.58	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.73	11.28	0.52	2.57e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.55	9.19	0.44	3.95e-18	Cognitive function;
LIHC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.39	-6.37	-0.33	6.08e-10	Menarche (age at onset);
LIHC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg05501817	chr11:14380813	RRAS2	-0.44	-6.21	-0.32	1.54e-9	Sense of smell;
LIHC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.97	17.94	0.7	3.35e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.22	-0.32	1.42e-9	Schizophrenia;
LIHC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.06	-0.4	1.32e-14	Type 2 diabetes;
LIHC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.56	7.51	0.38	5.16e-13	Blood metabolite levels;
LIHC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.48	0.53	4.9e-26	Coronary artery disease;
LIHC	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg25783544	chr11:47291846	MADD	0.43	6.15	0.32	2.22e-9	HDL cholesterol;
LIHC	cis	rs986417	0.540	rs10144415	chr14:61112667	G/C	cg27398547	chr14:60952738	C14orf39	0.66	7.23	0.36	3.14e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg09163369	chr1:210001066	C1orf107	-0.45	-5.8	-0.3	1.53e-8	Orofacial clefts;
LIHC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.44	-7.09	-0.36	7.83e-12	Response to temozolomide;
LIHC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-13.92	-0.6	3.33e-35	Height;
LIHC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.55	9.47	0.46	4.72e-19	Reticulocyte count;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26774971	chr6:158994407	TMEM181	0.43	6.56	0.33	1.97e-10	Immature fraction of reticulocytes;
LIHC	cis	rs8056893	0.686	rs4783558	chr16:68403966	A/G	cg02226672	chr16:68398533	SMPD3	0.45	6.43	0.33	4.37e-10	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs28595532	0.545	rs55699931	chr4:119249835	G/A	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	0.81	13.84	0.6	6.99e-35	Total cholesterol levels;
LIHC	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.43	7.81	0.39	6.96e-14	Schizophrenia;
LIHC	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.94	-0.39	2.95e-14	Capecitabine sensitivity;
LIHC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.52	-8.09	-0.4	1.06e-14	Lymphocyte counts;
LIHC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.44	-0.49	2.4e-22	Chronic sinus infection;
LIHC	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	9.12	0.44	6.52e-18	Brugada syndrome;
LIHC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.42	0.33	4.42e-10	Lung cancer in ever smokers;
LIHC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg07424592	chr7:64974309	NA	0.65	8.24	0.41	3.61e-15	Diabetic kidney disease;
LIHC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.23	13.44	0.59	2.37e-33	White matter hyperintensity burden;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21981481	chr7:127011849	ZNF800	0.28	6.12	0.31	2.5e-9	Cognitive function;
LIHC	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.88	-0.35	2.87e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg11062466	chr8:58055876	NA	0.41	6.11	0.31	2.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.25	-0.37	2.76e-12	Tuberculosis;
LIHC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.86	-0.43	4.39e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.59e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.45	7.28	0.37	2.28e-12	Platelet count;
LIHC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.66	-9.96	-0.47	1.11e-20	Mosquito bite size;
LIHC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg05973401	chr12:123451056	ABCB9	-0.41	-5.72	-0.3	2.35e-8	Neutrophil percentage of white cells;
LIHC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.79	11.5	0.53	4.28e-26	Response to antineoplastic agents;
LIHC	cis	rs6445975	0.667	rs4681672	chr3:58230436	C/T	cg23715586	chr3:58305044	RPP14	-0.35	-5.79	-0.3	1.56e-8	Systemic lupus erythematosus;
LIHC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.66	-9.07	-0.44	9.22e-18	Schizophrenia;
LIHC	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.73	7.18	0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2292096	0.850	rs66893025	chr1:200757200	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-6.1	-0.31	2.84e-9	Epilepsy;
LIHC	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.54	6.71	0.34	8.3e-11	QRS duration;
LIHC	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.8	0.35	4.66e-11	Height;
LIHC	cis	rs6001982	0.541	rs55746155	chr22:41049514	A/G	cg14879645	chr22:41048474	NA	0.4	5.82	0.3	1.35e-8	Breast cancer;
LIHC	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.47	6.7	0.34	8.72e-11	Hepatocellular carcinoma;
LIHC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.71	-13.37	-0.59	4.34e-33	Mean platelet volume;
LIHC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.1	10.04	0.48	5.77e-21	Diabetic retinopathy;
LIHC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.77	-10.66	-0.5	4.12e-23	Systemic lupus erythematosus;
LIHC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.45	5.91	0.3	8.12e-9	Pancreatic cancer;
LIHC	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.46	-7.85	-0.39	5.57e-14	Lung cancer;
LIHC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg12160578	chr15:63334699	TPM1	-0.6	-8.66	-0.42	1.93e-16	Platelet count;
LIHC	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.47	-0.59	1.77e-33	Coffee consumption (cups per day);
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.39	6.09	0.31	3.11e-9	Testicular germ cell tumor;
LIHC	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg12483005	chr1:23474871	LUZP1	0.34	5.76	0.3	1.89e-8	Height;
LIHC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg01864069	chr14:103024347	NA	0.44	6.85	0.35	3.37e-11	Platelet count;
LIHC	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.67	8.61	0.42	2.8e-16	Corneal astigmatism;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.73	-11.05	-0.51	1.74e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.14e-9	Tonsillectomy;
LIHC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.72	-0.34	7.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.63	9.68	0.46	9.9e-20	Height;
LIHC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.02	0.51	2.34e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.36	6.5	0.33	2.91e-10	Aortic root size;
LIHC	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.61e-14	Motion sickness;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	7.33	0.37	1.69e-12	Prudent dietary pattern;
LIHC	cis	rs7944584	0.502	rs10769256	chr11:47378396	C/T	cg20307385	chr11:47447363	PSMC3	0.93	14.83	0.63	8.72e-39	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17507749	chr15:85114479	UBE2QP1	0.63	7.18	0.36	4.38e-12	Schizophrenia;
LIHC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg16586182	chr3:47516702	SCAP	-0.55	-9.99	-0.48	8.46e-21	Colorectal cancer;
LIHC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.19e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.25	-0.37	2.75e-12	Bipolar disorder;
LIHC	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg27398547	chr14:60952738	C14orf39	0.75	8.69	0.43	1.57e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.91	16.81	0.67	1.25e-46	Aortic root size;
LIHC	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg20194872	chr6:41519635	FOXP4	-0.4	-6.36	-0.33	6.37e-10	Prostate cancer;
LIHC	cis	rs10106298	0.846	rs2099408	chr8:103680416	A/C	cg10187029	chr8:103597600	NA	0.43	5.78	0.3	1.69e-8	Schizophrenia;
LIHC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.74e-10	Diabetic kidney disease;
LIHC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-8.05	-0.4	1.42e-14	Parkinson's disease;
LIHC	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg19000871	chr14:103996768	TRMT61A	0.46	7.94	0.39	2.92e-14	Coronary artery disease;
LIHC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.64	9.87	0.47	2.28e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-6.15	-0.32	2.16e-9	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20488757	chr11:16760048	C11orf58	-0.49	-6.11	-0.31	2.71e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	24.58	0.8	1.38e-77	Schizophrenia;
LIHC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.77	11.81	0.54	3.27e-27	Corneal astigmatism;
LIHC	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.95	12.71	0.57	1.45e-30	Breast cancer;
LIHC	cis	rs16828019	0.777	rs12047657	chr1:41461513	G/C	cg03962019	chr1:41807865	NA	0.53	7.01	0.35	1.26e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg18016565	chr1:150552671	MCL1	0.5	9.51	0.46	3.62e-19	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	8.89e-15	Prudent dietary pattern;
LIHC	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.04e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.62	6.96	0.35	1.76e-11	Menarche (age at onset);
LIHC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03264133	chr6:25882463	NA	0.38	5.77	0.3	1.81e-8	Height;
LIHC	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg10820045	chr2:198174542	NA	0.46	7.13	0.36	5.93e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.57	10.86	0.51	8.4e-24	Mean corpuscular volume;
LIHC	cis	rs4450131	0.618	rs3781458	chr10:126343931	C/T	cg20435097	chr10:126320824	FAM53B	-0.61	-11.55	-0.53	2.87e-26	White blood cell count (basophil);
LIHC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.47	0.33	3.48e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.89e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg10756647	chr7:56101905	PSPH	1.11	13.47	0.59	1.75e-33	Diabetic kidney disease;
LIHC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg10932868	chr11:921992	NA	0.36	6.81	0.35	4.31e-11	Alzheimer's disease (late onset);
LIHC	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-9.98	-0.47	9.02e-21	Colorectal cancer;
LIHC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg15448220	chr1:150897856	SETDB1	0.4	6.32	0.32	8.39e-10	Tonsillectomy;
LIHC	trans	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg10208301	chr11:6592745	DNHD1	0.47	6.68	0.34	9.89e-11	Coronary artery calcification;
LIHC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.45	6.47	0.33	3.42e-10	Total body bone mineral density;
LIHC	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.01	0.31	4.87e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.47	7.15	0.36	5.35e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.5	-0.38	5.47e-13	Schizophrenia;
LIHC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg27247782	chr7:158767135	NA	0.28	5.73	0.3	2.2e-8	Facial morphology (factor 20);
LIHC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.35	0.32	6.99e-10	Morning vs. evening chronotype;
LIHC	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.15	0.32	2.21e-9	Schizophrenia;
LIHC	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.4	7.66	0.38	1.95e-13	Height;
LIHC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	5.9	0.3	8.86e-9	Bipolar disorder;
LIHC	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.04e-8	Coronary artery disease;
LIHC	trans	rs561341	0.843	rs879944	chr17:30242803	A/G	cg20587970	chr11:113659929	NA	-0.58	-6.95	-0.35	1.87e-11	Hip circumference adjusted for BMI;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11055926	chr10:111683227	XPNPEP1	0.46	6.29	0.32	9.86e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-7.68	-0.38	1.64e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.12	0.36	6.28e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.39	-6.52	-0.33	2.59e-10	Electroencephalogram traits;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg09992215	chr4:57370492	ARL9	0.39	6.28	0.32	1e-9	Oropharynx cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03710481	chr6:122931605	PKIB	0.5	6.53	0.33	2.41e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg23743573	chr11:89867420	NAALAD2	0.39	5.99	0.31	5.37e-9	White blood cell types;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.71	0.76	2.62e-66	Height;
LIHC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg09009506	chr2:28216851	BRE	-0.3	-6.05	-0.31	3.75e-9	Calcium levels;
LIHC	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg21466736	chr12:48725269	NA	-0.71	-10.95	-0.51	4.12e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg12798992	chr6:167411361	FGFR1OP	0.53	8.25	0.41	3.48e-15	Crohn's disease;
LIHC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.52	-9.29	-0.45	1.82e-18	Lung cancer;
LIHC	cis	rs7614311	0.689	rs73120898	chr3:63828780	G/A	cg22134162	chr3:63841271	THOC7	-0.57	-6.57	-0.33	1.84e-10	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.65	-10.19	-0.48	1.86e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.94	-18.12	-0.7	6.66e-52	Breast cancer;
LIHC	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg04998671	chr14:104000505	TRMT61A	-0.58	-7.6	-0.38	2.93e-13	Coronary artery disease;
LIHC	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.43	6.03	0.31	4.14e-9	Tuberculosis;
LIHC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.76	-0.3	1.88e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs6489882	0.703	rs10850092	chr12:113359703	C/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.54	-9.55	-0.46	2.62e-19	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.43	-0.33	4.27e-10	Type 2 diabetes;
LIHC	cis	rs7116495	1.000	rs2298457	chr11:71734211	T/C	cg10381502	chr11:71823885	C11orf51	-0.54	-5.78	-0.3	1.73e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.53	-0.33	2.31e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.41	5.83	0.3	1.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.35	6.97	0.35	1.65e-11	Renal cell carcinoma;
LIHC	trans	rs11638815	0.581	rs783535	chr15:83250425	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.05	-0.31	3.78e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.92	12.54	0.56	6.11e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.84	-16.51	-0.67	1.83e-45	Testicular germ cell tumor;
LIHC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.47	-6.77	-0.34	5.62e-11	Asthma;
LIHC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.78	12.72	0.57	1.34e-30	Oral cavity cancer;
LIHC	cis	rs17102423	0.806	rs2411994	chr14:65590537	A/G	cg16583315	chr14:65563665	MAX	0.4	8.09	0.4	1.07e-14	Obesity-related traits;
LIHC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.3	6.11	0.31	2.69e-9	Lung cancer;
LIHC	cis	rs2834256	0.847	rs11702148	chr21:35089712	G/T	cg14850771	chr21:34775459	IFNGR2	0.42	6.35	0.32	6.91e-10	Red cell distribution width;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16247931	chr14:102771650	RAGE	-0.41	-6.1	-0.31	2.89e-9	Cognitive function;
LIHC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.45	7.3	0.37	2.01e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	17.19	0.68	3.73e-48	Lung cancer in ever smokers;
LIHC	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.67	11.81	0.54	3.1e-27	Schizophrenia;
LIHC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.6	-0.69	7.78e-50	Body mass index;
LIHC	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-6.57	-0.33	1.84e-10	Ileal carcinoids;
LIHC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-7.86	-0.39	5.01e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.8	-0.3	1.55e-8	Body mass index;
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.5	8.19	0.41	5.12e-15	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.3e-14	Height;
LIHC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.48e-59	Height;
LIHC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs16828019	0.704	rs12024115	chr1:41534357	C/T	cg03962019	chr1:41807865	NA	0.49	7.18	0.36	4.45e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.64	-6.54	-0.33	2.31e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-6.53	-0.33	2.34e-10	Morning vs. evening chronotype;
LIHC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg09165964	chr15:75287851	SCAMP5	-0.61	-7.74	-0.39	1.15e-13	Lung cancer;
LIHC	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	0.37	5.86	0.3	1.12e-8	Coronary artery disease;
LIHC	cis	rs6583826	0.538	rs11187076	chr10:94336963	G/A	cg00519463	chr10:94352821	KIF11	-0.44	-6.27	-0.32	1.11e-9	Type 2 diabetes;
LIHC	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.89	-14.33	-0.61	8.09e-37	Gut microbiota (bacterial taxa);
LIHC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.09	-0.36	7.66e-12	Personality dimensions;
LIHC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.51	-7.43	-0.37	8.97e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg02290350	chr8:58132656	NA	0.48	9.3	0.45	1.78e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.33	5.71	0.3	2.42e-8	Mean corpuscular volume;
LIHC	cis	rs6840360	0.837	rs13138986	chr4:152719310	T/C	cg22705602	chr4:152727874	NA	0.34	7.03	0.36	1.14e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.55	7.12	0.36	6.57e-12	Parkinson's disease;
LIHC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.78	0.47	4.38e-20	Crohn's disease;
LIHC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.31	0.32	8.55e-10	Schizophrenia;
LIHC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.66	0.34	1.12e-10	Renal cell carcinoma;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.56	7.39	0.37	1.1e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg18404041	chr3:52824283	ITIH1	0.44	6.06	0.31	3.53e-9	Schizophrenia;
LIHC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.35	-6.34	-0.32	7.25e-10	Aortic root size;
LIHC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-8.31	-0.41	2.26e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.83	10.94	0.51	4.23e-24	Menopause (age at onset);
LIHC	cis	rs988712	0.705	rs16917204	chr11:27668355	G/C	cg18117895	chr11:27722066	BDNF	0.49	6.85	0.35	3.45e-11	Obesity;
LIHC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.45	-0.33	3.93e-10	Diabetic kidney disease;
LIHC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.27	-7.11	-0.36	6.9e-12	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.84	13.62	0.59	4.63e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.49	0.38	5.79e-13	Prudent dietary pattern;
LIHC	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.47	-6.72	-0.34	7.49e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.64	-0.46	1.35e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21747090	chr2:27597821	SNX17	-0.4	-5.97	-0.31	5.96e-9	Menopause (age at onset);
LIHC	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg03894339	chr8:19674705	INTS10	-0.44	-6.42	-0.33	4.61e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.64	10.32	0.49	6.42e-22	White matter hyperintensity burden;
LIHC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.51	-7.81	-0.39	7.19e-14	Platelet distribution width;
LIHC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.1	0.31	2.94e-9	Rheumatoid arthritis;
LIHC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.62	9.06	0.44	1.04e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg14067834	chr17:29058358	SUZ12P	0.72	7.12	0.36	6.39e-12	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21292957	chr21:34602922	IFNAR2	0.53	7.17	0.36	4.81e-12	Lung function (FEV1/FVC);
LIHC	cis	rs2380220	0.808	rs2716069	chr6:95912976	C/G	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.06	-0.36	9.19e-12	Breast cancer;
LIHC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg18867708	chr6:26865862	GUSBL1	-0.5	-7.69	-0.38	1.59e-13	Schizophrenia;
LIHC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg14092571	chr14:90743983	NA	-0.38	-5.98	-0.31	5.75e-9	Mortality in heart failure;
LIHC	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.58	7.33	0.37	1.66e-12	Corneal astigmatism;
LIHC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.87	0.57	3.53e-31	Colorectal cancer;
LIHC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-9.04	-0.44	1.21e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg10932868	chr11:921992	NA	0.35	6.65	0.34	1.16e-10	Alzheimer's disease (late onset);
LIHC	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs7729447	0.566	rs1421811	chr5:32714270	C/G	cg16267343	chr5:32710456	NPR3	0.45	5.8	0.3	1.53e-8	Blood pressure;
LIHC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.88	0.54	1.73e-27	Cognitive test performance;
LIHC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.28	-0.37	2.34e-12	Breast cancer;
LIHC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08944563	chr10:91174254	IFIT5	0.37	6.03	0.31	4.15e-9	Calcium levels;
LIHC	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.45	-6.5	-0.33	2.91e-10	Asthma;
LIHC	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.36e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs926392	0.799	rs742274	chr20:37680944	T/C	cg16355469	chr20:37678765	NA	0.37	6.0	0.31	5.1e-9	Dialysis-related mortality;
LIHC	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.33	-0.32	7.6e-10	Prevalent atrial fibrillation;
LIHC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.21	5.85	0.3	1.14e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12493885	0.505	rs357489	chr3:153884517	A/T	cg16511985	chr3:153974050	SGEF	0.28	6.1	0.31	2.88e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.4	7.06	0.36	9.53e-12	Obesity;
LIHC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.17	12.88	0.57	3.24e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20297566	chr3:99979976	TBC1D23	0.48	6.47	0.33	3.36e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.62	10.43	0.49	2.75e-22	Diisocyanate-induced asthma;
LIHC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg12042659	chr19:58951599	ZNF132	0.37	6.31	0.32	8.44e-10	Uric acid clearance;
LIHC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.61	7.98	0.4	2.29e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg13271783	chr10:134563150	INPP5A	-0.6	-7.17	-0.36	4.71e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.46	-0.49	2.12e-22	Monocyte percentage of white cells;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20959480	chr12:125599568	AACS	0.37	6.08	0.31	3.25e-9	Longevity;
LIHC	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.37	-6.9	-0.35	2.58e-11	Height;
LIHC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.76	-12.06	-0.55	3.83e-28	Urate levels in obese individuals;
LIHC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg07541023	chr7:19748670	TWISTNB	0.4	6.06	0.31	3.61e-9	Thyroid stimulating hormone;
LIHC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18867708	chr6:26865862	GUSBL1	0.56	8.5	0.42	5.94e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.84	-0.35	3.72e-11	Coronary artery disease;
LIHC	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.48	-9.53	-0.46	3.12e-19	LDL cholesterol levels;
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg20887711	chr4:1340912	KIAA1530	0.8	12.32	0.55	4.23e-29	Longevity;
LIHC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.59	9.87	0.47	2.25e-20	Lung cancer;
LIHC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.3	-0.76	1.1e-64	Height;
LIHC	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-8.1	-0.4	9.48e-15	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.63	0.42	2.3e-16	Motion sickness;
LIHC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg00277334	chr10:82204260	NA	-0.47	-7.07	-0.36	8.92e-12	Post bronchodilator FEV1;
LIHC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg11861562	chr11:117069780	TAGLN	0.45	7.4	0.37	1.07e-12	Blood protein levels;
LIHC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg00864860	chr1:7907996	UTS2	0.6	5.89	0.3	9.05e-9	Inflammatory bowel disease;
LIHC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.74	-14.17	-0.61	3.62e-36	Height;
LIHC	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.52	-12.33	-0.55	3.91e-29	White blood cell count (basophil);
LIHC	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.89	-0.3	9.38e-9	Systemic lupus erythematosus;
LIHC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.72	-0.3	2.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.88	-0.3	9.73e-9	Total body bone mineral density;
LIHC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.43	-7.24	-0.36	2.89e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs783540	0.967	rs17158390	chr15:83293028	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.34	-0.32	7.22e-10	Schizophrenia;
LIHC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	11.3	0.52	2.3e-25	Colorectal cancer;
LIHC	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.61	7.15	0.36	5.16e-12	Exhaled nitric oxide output;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05665937	chr4:1216051	CTBP1	0.39	6.18	0.32	1.83e-9	Obesity-related traits;
LIHC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.48	-9.8	-0.47	3.92e-20	Tonsillectomy;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.15	-0.4	7.14e-15	Lymphocyte counts;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg12962599	chr5:36607024	SLC1A3	0.34	6.24	0.32	1.29e-9	Calcium levels;
LIHC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.69	0.43	1.58e-16	Lung cancer in ever smokers;
LIHC	trans	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg09872104	chr7:134855509	C7orf49	-0.8	-6.38	-0.33	5.59e-10	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs3736485	0.966	rs10775144	chr15:51891134	C/T	cg08986416	chr15:51914746	DMXL2	-0.41	-6.18	-0.32	1.87e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg06565975	chr8:143823917	SLURP1	-0.45	-8.18	-0.4	5.82e-15	Urinary tract infection frequency;
LIHC	cis	rs644148	0.785	rs2140111	chr19:44973019	A/C	cg15540054	chr19:45004280	ZNF180	-0.77	-10.71	-0.5	2.88e-23	Personality dimensions;
LIHC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg12798992	chr6:167411361	FGFR1OP	0.42	6.61	0.34	1.48e-10	Primary biliary cholangitis;
LIHC	cis	rs3849570	0.695	rs9830445	chr3:81508063	T/G	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Waist circumference;Body mass index;
LIHC	cis	rs9649465	0.846	rs13044	chr7:123322716	T/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.07	-0.4	1.19e-14	Migraine;
LIHC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.67	12.08	0.55	3.21e-28	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20621256	chr9:140118465	C9orf169	0.49	7.01	0.35	1.27e-11	Pancreatic cancer;
LIHC	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg10820045	chr2:198174542	NA	-0.5	-7.62	-0.38	2.45e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.83	0.43	5.5e-17	Exhaled nitric oxide levels;
LIHC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.46	-6.97	-0.35	1.61e-11	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23556447	chr6:90529595	MDN1	-0.53	-7.24	-0.36	3.01e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7937890	0.531	rs2597216	chr11:14533916	G/A	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	0.78	10.55	0.5	1.05e-22	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.68	0.53	9.51e-27	Alzheimer's disease;
LIHC	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-0.78	-8.54	-0.42	4.49e-16	Exhaled nitric oxide output;
LIHC	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.88	14.68	0.62	3.68e-38	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05977900	chr3:182512126	ATP11B	0.45	6.34	0.32	7.4e-10	Pancreatic cancer;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.14e-11	Alzheimer's disease;
LIHC	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.43	6.09	0.31	3.11e-9	Tuberculosis;
LIHC	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.07	-0.51	1.46e-24	Morning vs. evening chronotype;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19098793	chr7:1609793	KIAA1908;PSMG3	0.49	6.27	0.32	1.07e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg04013166	chr16:89971882	TCF25	0.47	6.02	0.31	4.48e-9	Skin colour saturation;
LIHC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.3	7.26	0.37	2.63e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg20195005	chr22:42527684	CYP2D6	0.31	5.88	0.3	1e-8	Birth weight;
LIHC	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.45	8.18	0.4	5.6e-15	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg11062466	chr8:58055876	NA	0.4	5.91	0.3	8.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1165668	1.000	rs2583282	chr12:104313579	A/G	cg21863207	chr12:104234989	NT5DC3	0.4	6.4	0.33	5.22e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-5.99	-0.31	5.25e-9	Cognitive function;
LIHC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.75	14.05	0.6	1.05e-35	Height;
LIHC	cis	rs904251	0.523	rs9366935	chr6:37480404	C/T	cg01843034	chr6:37503916	NA	-0.47	-7.99	-0.4	2.12e-14	Cognitive performance;
LIHC	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg12903224	chr12:29470962	FAR2	-0.4	-6.55	-0.33	2.1e-10	QT interval;
LIHC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-6.74	-0.34	6.56e-11	Colorectal cancer;
LIHC	cis	rs2455799	0.927	rs2470514	chr3:15750344	A/C	cg12698662	chr3:15914712	MIR563	-0.41	-5.91	-0.3	8.44e-9	Mean platelet volume;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21235925	chr17:80678270	FN3KRP	0.47	6.35	0.32	6.7e-10	Hip circumference;
LIHC	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.46e-28	Eye color traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17116739	chr16:67063591	CBFB	0.45	6.06	0.31	3.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02396668	chr19:50528878	VRK3;ZNF473	0.48	6.82	0.35	4.23e-11	Pancreatic cancer;
LIHC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.44	-6.32	-0.32	8.03e-10	Tonsillectomy;
LIHC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.55	9.17	0.44	4.38e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg17675199	chr6:35436792	RPL10A	-0.44	-9.16	-0.44	5.05e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16465768	chr2:136287945	R3HDM1;ZRANB3	-0.4	-6.04	-0.31	4.02e-9	Myopia (pathological);
LIHC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.37	5.99	0.31	5.18e-9	Blood metabolite levels;
LIHC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.89	-0.3	9.14e-9	Subjective well-being;
LIHC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.24	-0.36	2.92e-12	IgG glycosylation;
LIHC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.48	-11.36	-0.52	1.33e-25	Urinary metabolites;
LIHC	cis	rs611744	0.967	rs660816	chr8:109178048	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.36	-5.9	-0.3	8.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.64	-8.03	-0.4	1.58e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.5	-6.54	-0.33	2.21e-10	Initial pursuit acceleration;
LIHC	cis	rs10508774	0.850	rs11009020	chr10:32948997	C/G	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.34	6.61	0.34	1.44e-10	Blood protein levels;
LIHC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.6	6.68	0.34	9.57e-11	Axial length;
LIHC	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.28	-13.86	-0.6	5.82e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.48	7.48	0.38	6.17e-13	Methadone dose in opioid dependence;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	5.8	0.3	1.48e-8	Longevity;
LIHC	trans	rs2359714	0.935	rs9661113	chr1:118799439	C/T	cg19861078	chr7:7936962	NA	0.31	6.21	0.32	1.52e-9	Breast size;
LIHC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.35	-5.76	-0.3	1.88e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg13145458	chr22:31556086	RNF185	0.45	6.35	0.32	6.8e-10	Paclitaxel-induced neuropathy;
LIHC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.45	0.42	8.22e-16	Motion sickness;
LIHC	cis	rs16957091	0.909	rs12907826	chr15:43017081	G/A	cg24196017	chr15:43021976	CDAN1	-0.4	-5.8	-0.3	1.53e-8	MGMT methylation in smokers;
LIHC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21016266	chr12:122356598	WDR66	0.43	6.7	0.34	8.35e-11	Mean corpuscular volume;
LIHC	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.19	-0.52	5.62e-25	Eye color traits;
LIHC	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.07e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21545522	chr1:205238299	TMCC2	0.38	7.13	0.36	5.94e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs3789045	0.774	rs12029692	chr1:204532323	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.42	-6.55	-0.33	2.09e-10	Educational attainment (college completion);
LIHC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.59	-0.34	1.67e-10	Longevity;
LIHC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.51	-9.54	-0.46	2.72e-19	Atrioventricular conduction;
LIHC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg08847533	chr14:75593920	NEK9	0.5	7.65	0.38	2.13e-13	IgG glycosylation;
LIHC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg12140854	chr5:148520817	ABLIM3	-0.52	-5.81	-0.3	1.4e-8	Breast cancer;
LIHC	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.52	8.83	0.43	5.45e-17	Schizophrenia;
LIHC	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-12.63	-0.56	2.7e-30	Monocyte count;
LIHC	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	0.73	8.01	0.4	1.79e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.63	12.34	0.56	3.38e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg20140201	chr2:241835670	C2orf54	-0.5	-7.72	-0.39	1.31e-13	Urinary metabolites;
LIHC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.57	11.34	0.52	1.58e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg00280220	chr17:61926910	NA	0.39	5.91	0.3	8.29e-9	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.22	-6.15	-0.32	2.21e-9	Calcium levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14799008	chr19:42947305	CXCL17	0.51	6.59	0.34	1.7e-10	Systolic blood pressure;
LIHC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg26395211	chr5:140044315	WDR55	-0.41	-6.13	-0.31	2.41e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg07706471	chr12:123319906	HIP1R	-0.57	-7.04	-0.36	1.05e-11	Schizophrenia;
LIHC	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	1.07	8.35	0.41	1.77e-15	Arsenic metabolism;
LIHC	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.76	-14.36	-0.61	6.46e-37	Mortality in heart failure;
LIHC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.66	10.16	0.48	2.31e-21	Corneal astigmatism;
LIHC	cis	rs7116495	1.000	rs17161991	chr11:71839960	T/C	cg26138937	chr11:71823887	C11orf51	0.83	8.2	0.41	4.93e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg03146154	chr1:46216737	IPP	0.5	8.54	0.42	4.4e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4407350	1.000	rs12169248	chr22:44920999	G/A	cg26276947	chr22:44892394	LDOC1L	0.34	6.32	0.32	8.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.71	7.16	0.36	4.86e-12	Vitiligo;
LIHC	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.32	7.48e-10	Ulcerative colitis;
LIHC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.7	-9.15	-0.44	5.15e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	8.27	0.41	3.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13343954	0.825	rs12461135	chr19:33534185	A/G	cg27124370	chr19:33622961	WDR88	0.42	5.73	0.3	2.21e-8	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.38e-8	Diabetic kidney disease;
LIHC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.27	-0.41	3.05e-15	Gut microbiome composition (summer);
LIHC	cis	rs1355223	0.902	rs1361645	chr11:34746385	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.43	-0.33	4.18e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Blood protein levels;
LIHC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.26	6.56	0.33	1.93e-10	Rheumatoid arthritis;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg01632497	chr11:8986187	TMEM9B	-0.43	-6.44	-0.33	4.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.58	-0.38	3.22e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs3770081	1.000	rs59947468	chr2:86289436	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.57	8.8	0.43	7.13e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.57	9.15	0.44	5.1e-18	Multiple myeloma (IgH translocation);
LIHC	trans	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg26939375	chr7:64535504	NA	-0.41	-6.38	-0.33	5.83e-10	Aortic root size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18635645	chr1:85667791	SYDE2	0.51	8.54	0.42	4.4e-16	Cognitive function;
LIHC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg05590025	chr7:65112418	INTS4L2	-0.63	-7.05	-0.36	9.75e-12	Diabetic kidney disease;
LIHC	trans	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg10756647	chr7:56101905	PSPH	1.1	13.62	0.59	4.65e-34	Diabetic kidney disease;
LIHC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.74	13.81	0.6	8.87e-35	Iron status biomarkers;
LIHC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.79	-0.34	5.05e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	5.79	0.3	1.62e-8	Height;
LIHC	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.6	0.34	1.61e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.81	6.28	0.32	1.03e-9	Prostate cancer;
LIHC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.65	-0.38	2.11e-13	Total body bone mineral density;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07677032	chr17:61819896	STRADA	0.41	5.88	0.3	9.8e-9	Prudent dietary pattern;
LIHC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.91	-0.47	1.59e-20	Total cholesterol levels;
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.46	0.33	3.51e-10	Renal cell carcinoma;
LIHC	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.64	-9.08	-0.44	8.71e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg21605333	chr4:119757512	SEC24D	0.84	6.89	0.35	2.75e-11	Cannabis dependence symptom count;
LIHC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.36	6.06	0.31	3.58e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-7.43	-0.37	8.6e-13	Personality dimensions;
LIHC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.87	8.14	0.4	7.32e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	0.92	22.48	0.77	2.3e-69	Multiple myeloma;
LIHC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.94	0.7	3.47e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.35e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs17184557	0.871	rs7239855	chr18:67102963	T/A	cg22968167	chr11:4945873	OR51G1	-0.25	-6.13	-0.31	2.48e-9	Osteoporosis-related phenotypes;
LIHC	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg20129853	chr10:51489980	NA	-0.43	-9.44	-0.45	6.14e-19	Prostate-specific antigen levels;
LIHC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg05110241	chr16:68378359	PRMT7	-0.63	-6.99	-0.35	1.45e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.38	-6.14	-0.31	2.33e-9	Menarche (age at onset);
LIHC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.87	12.28	0.55	5.78e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs909002	0.720	rs4949459	chr1:32142354	G/T	cg13919466	chr1:32135498	COL16A1	-0.31	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.82	0.3	1.32e-8	Depression;
LIHC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg15691649	chr6:25882328	NA	-0.53	-7.62	-0.38	2.55e-13	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18502334	chr7:4681577	NA	-0.47	-6.31	-0.32	8.82e-10	Pancreatic cancer;
LIHC	trans	rs17685	0.535	rs6953065	chr7:75601169	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.5	-7.37	-0.37	1.32e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg25344623	chr2:136566232	LCT	0.45	8.95	0.44	2.37e-17	Mosquito bite size;
LIHC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.74	-10.61	-0.5	6.46e-23	Pancreatic cancer;
LIHC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.02	0.31	4.45e-9	Blood metabolite levels;
LIHC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.5	0.33	2.82e-10	Bipolar disorder;
LIHC	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.33	-0.37	1.67e-12	Bipolar disorder;
LIHC	cis	rs2286503	0.839	rs2270108	chr7:22862131	A/C	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.1	-0.36	7.14e-12	Personality dimensions;
LIHC	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.51	0.46	3.63e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg16583315	chr14:65563665	MAX	-0.37	-7.57	-0.38	3.55e-13	Obesity-related traits;
LIHC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.94	18.0	0.7	1.99e-51	Menopause (age at onset);
LIHC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.98	0.57	1.31e-31	Cognitive test performance;
LIHC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg05527609	chr1:210001259	C1orf107	-0.57	-7.59	-0.38	3.09e-13	Red blood cell count;
LIHC	cis	rs1190552	0.894	rs1190546	chr14:102904966	A/G	cg10241871	chr14:102965420	TECPR2	0.47	7.39	0.37	1.14e-12	Blood protein levels;
LIHC	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	6.75	0.34	6.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs3015497	0.789	rs1389652	chr14:51125240	T/C	cg09863266	chr14:51125203	SAV1	-0.43	-6.8	-0.35	4.66e-11	Mean platelet volume;
LIHC	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-7.0	-0.35	1.36e-11	Endometrial cancer;
LIHC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.59	0.46	1.96e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.73	-9.83	-0.47	3.04e-20	Sudden cardiac arrest;
LIHC	cis	rs6723226	0.750	rs762019	chr2:32688601	A/C	cg02381751	chr2:32503542	YIPF4	0.6	8.96	0.44	2.19e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03710119	chr20:44509748	ZSWIM1	0.43	6.27	0.32	1.07e-9	Pancreatic cancer;
LIHC	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.38	-6.47	-0.33	3.42e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.61	8.98	0.44	1.91e-17	Recombination rate (females);
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg00612595	chr21:47717864	NA	-0.35	-5.84	-0.3	1.24e-8	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-7.53	-0.38	4.6e-13	Vitiligo;
LIHC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.52	-8.12	-0.4	8.6e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.88	-12.58	-0.56	4.3e-30	Post bronchodilator FEV1;
LIHC	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.61	-8.73	-0.43	1.11e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1075232	0.522	rs57924788	chr15:31749722	G/A	cg01030201	chr15:31746330	NA	-0.69	-6.02	-0.31	4.46e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs3981351	0.797	rs12414006	chr10:115461485	A/G	cg24846397	chr10:115438155	CASP7	-0.46	-7.13	-0.36	5.86e-12	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-5.9	-0.3	8.73e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.29	-0.32	9.86e-10	Coronary artery disease;
LIHC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	11.82	0.54	2.87e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.67	10.02	0.48	7.12e-21	Mosquito bite size;
LIHC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.49	-0.33	2.99e-10	Mean corpuscular volume;
LIHC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	1.11	12.44	0.56	1.47e-29	White matter hyperintensity burden;
LIHC	cis	rs611744	0.967	rs702802	chr8:109218238	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.74e-17	Dupuytren's disease;
LIHC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg02931644	chr1:25747376	RHCE	-0.33	-7.09	-0.36	7.8e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg04450456	chr4:17643702	FAM184B	0.34	5.73	0.3	2.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg17135325	chr3:160939158	NMD3	0.49	7.32	0.37	1.73e-12	Morning vs. evening chronotype;
LIHC	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.36	-6.85	-0.35	3.44e-11	Growth-regulated protein alpha levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg16993936	chr10:13146903	OPTN	0.39	6.54	0.33	2.19e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg01444801	chr10:135216882	MTG1	-0.63	-9.32	-0.45	1.5e-18	Systemic lupus erythematosus;
LIHC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.35	-8.13	-0.4	7.99e-15	Educational attainment (years of education);
LIHC	cis	rs2526882	0.562	rs12893492	chr14:71506775	T/C	cg15816911	chr14:71606274	NA	0.43	6.92	0.35	2.19e-11	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.58	-6.33	-0.32	7.55e-10	Alzheimer's disease;
LIHC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	5.81	0.3	1.42e-8	Schizophrenia;
LIHC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-10.09	-0.48	4.03e-21	Urinary metabolites;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg06972615	chr5:77081292	NA	0.35	6.28	0.32	1.04e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.47	7.47	0.37	6.79e-13	Multiple sclerosis;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.45	-0.49	2.34e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.93	-12.35	-0.56	3.04e-29	Schizophrenia;
LIHC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.87	-0.47	2.26e-20	Tonsillectomy;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11060661	chr22:24314208	DDT;DDTL	0.6	10.12	0.48	3.12e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg01364799	chr7:75623366	TMEM120A	-0.47	-6.6	-0.34	1.61e-10	Eotaxin levels;
LIHC	cis	rs1789	0.903	rs4453929	chr4:15672173	T/G	cg24225360	chr4:15471699	CC2D2A	-0.38	-5.91	-0.3	8.24e-9	Blood protein levels;
LIHC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg14580859	chr9:123691850	NA	0.36	6.17	0.32	1.97e-9	Rheumatoid arthritis;
LIHC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	12.32	0.55	3.97e-29	Response to antipsychotic treatment;
LIHC	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.12	-0.31	2.62e-9	Diastolic blood pressure;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15773755	chr19:1998801	BTBD2	0.39	6.27	0.32	1.07e-9	Thyroid stimulating hormone;
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	7.09	0.36	7.91e-12	Renal cell carcinoma;
LIHC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.35	-6.39	-0.33	5.29e-10	Aortic root size;
LIHC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.97	-17.64	-0.69	5.52e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs539514	0.718	rs502171	chr13:76320114	T/C	cg04757411	chr13:76259545	LMO7	-0.41	-6.9	-0.35	2.56e-11	Type 1 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15695648	chr17:53828850	PCTP	0.44	6.28	0.32	1.03e-9	Cognitive function;
LIHC	cis	rs7091068	0.536	rs503758	chr10:95406935	C/A	cg20715218	chr10:95462985	C10orf4	-0.54	-8.33	-0.41	2.02e-15	Urinary tract infection frequency;
LIHC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg25894440	chr7:65020034	NA	0.54	6.25	0.32	1.23e-9	Diabetic kidney disease;
LIHC	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-7.93	-0.39	3.17e-14	Electrocardiographic conduction measures;
LIHC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.93	0.31	7.24e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-0.76	-6.96	-0.35	1.69e-11	Coronary artery disease;
LIHC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.97	-0.35	1.64e-11	IgG glycosylation;
LIHC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-5.96	-0.31	6.17e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg24209194	chr3:40518798	ZNF619	0.44	6.24	0.32	1.29e-9	Renal cell carcinoma;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.79	11.85	0.54	2.32e-27	Height;
LIHC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.73	-0.39	1.23e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	9.66	0.46	1.09e-19	Fuchs's corneal dystrophy;
LIHC	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg19413766	chr7:29689036	LOC646762	-0.62	-6.35	-0.32	6.78e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LIHC	trans	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04565464	chr8:145669602	NFKBIL2	0.38	6.25	0.32	1.24e-9	Schizophrenia;
LIHC	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg17691542	chr6:26056736	HIST1H1C	0.45	5.86	0.3	1.09e-8	Iron status biomarkers;
LIHC	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.37	-5.75	-0.3	2e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.59	0.56	4.07e-30	Electrocardiographic conduction measures;
LIHC	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.64	-9.83	-0.47	2.91e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg14593290	chr7:50529359	DDC	-0.4	-6.7	-0.34	8.81e-11	Malaria;
LIHC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg26116260	chr4:7069785	GRPEL1	-0.44	-7.14	-0.36	5.76e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.48	6.83	0.35	4e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7091068	0.754	rs6583903	chr10:95422174	T/C	cg20715218	chr10:95462985	C10orf4	0.56	6.25	0.32	1.23e-9	Urinary tract infection frequency;
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg09260627	chr8:8243751	NA	0.52	6.35	0.32	6.77e-10	Neuroticism;
LIHC	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.65	7.37	0.37	1.26e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs10792665	0.724	rs1320733	chr11:82719810	C/T	cg24227371	chr11:82718527	RAB30	-0.38	-9.3	-0.45	1.69e-18	Obesity-related traits;
LIHC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.5	7.21	0.36	3.67e-12	High light scatter reticulocyte count;
LIHC	cis	rs3812111	0.676	rs7758930	chr6:116503168	C/T	cg08036074	chr6:116424633	NT5DC1	-0.52	-8.71	-0.43	1.33e-16	Age-related macular degeneration;
LIHC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg04315214	chr1:2043799	PRKCZ	0.46	7.27	0.37	2.52e-12	Height;
LIHC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.45	-6.57	-0.33	1.88e-10	Monocyte count;
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.69	9.46	0.46	5.3e-19	Aortic root size;
LIHC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg11839771	chr15:80205821	ST20	-0.28	-5.73	-0.3	2.25e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg23091122	chr1:110024289	SYPL2	-0.46	-6.08	-0.31	3.14e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.45	6.75	0.34	6.33e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.45	7.76	0.39	1.02e-13	Schizophrenia;
LIHC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.74e-11	Dermatomyositis;
LIHC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.66	10.93	0.51	4.64e-24	Response to diuretic therapy;
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg14393609	chr7:65229607	NA	0.44	6.51	0.33	2.61e-10	Calcium levels;
LIHC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.78	12.05	0.55	4.02e-28	Resting heart rate;
LIHC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg08213375	chr14:104286397	PPP1R13B	0.52	9.64	0.46	1.29e-19	Schizophrenia;
LIHC	cis	rs9937943	0.512	rs13335886	chr16:74577161	C/G	cg01733217	chr16:74700730	RFWD3	-0.4	-6.32	-0.32	7.94e-10	Neutrophil percentage of white cells;
LIHC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.49e-10	Alzheimer's disease;
LIHC	cis	rs8083850	0.635	rs1367636	chr18:50860752	A/G	cg24270629	chr18:50823537	DCC	0.53	8.28	0.41	2.73e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05564831	chr3:52568323	NT5DC2	0.34	5.76	0.3	1.87e-8	Bipolar disorder;
LIHC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.5	-0.33	2.9e-10	Diabetic kidney disease;
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11645453	chr3:52864694	ITIH4	0.23	6.17	0.32	1.97e-9	Bipolar disorder;
LIHC	cis	rs10905065	0.735	rs10795347	chr10:5742077	C/G	cg11519256	chr10:5708881	ASB13	-0.46	-6.06	-0.31	3.66e-9	Menopause (age at onset);
LIHC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.86	14.1	0.61	6.35e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.67	-0.34	1.02e-10	Homocysteine levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10289325	chr17:37844171	PGAP3;ERBB2	0.41	6.09	0.31	3.09e-9	Cognitive function;
LIHC	cis	rs74233809	1.000	rs12221064	chr10:104677126	C/T	cg03493300	chr10:104813866	CNNM2	0.46	6.02	0.31	4.57e-9	Birth weight;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.31	-5.77	-0.3	1.74e-8	Aortic root size;
LIHC	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.35	7.92	0.39	3.28e-14	Blood metabolite ratios;
LIHC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg02290350	chr8:58132656	NA	0.29	6.57	0.33	1.86e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.61	0.42	2.62e-16	Lung cancer;
LIHC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg03146154	chr1:46216737	IPP	0.48	8.07	0.4	1.23e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-15.5	-0.64	1.99e-41	Ulcerative colitis;
LIHC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-10.57	-0.5	8.95e-23	Platelet count;
LIHC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.55	6.42	0.33	4.66e-10	Eye color traits;
LIHC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.31	-0.58	7.08e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.6e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg22633049	chr21:46681294	NA	-0.33	-5.84	-0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6782228	0.509	rs4481172	chr3:128372657	C/A	cg16766828	chr3:128327626	NA	-0.4	-6.39	-0.33	5.54e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.66	8.23	0.41	3.92e-15	Gut microbiome composition (summer);
LIHC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.35	-5.81	-0.3	1.45e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs2257205	0.667	rs9909763	chr17:56629640	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.33	2.6e-10	Pancreatic cancer;
LIHC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.64	8.25	0.41	3.43e-15	Motion sickness;
LIHC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.8	16.78	0.67	1.53e-46	Gestational age at birth (maternal effect);
LIHC	cis	rs400736	0.930	rs225119	chr1:8044361	T/C	cg25007680	chr1:8021821	PARK7	0.61	9.79	0.47	4.13e-20	Response to antidepressants and depression;
LIHC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg19635926	chr16:89946313	TCF25	0.54	7.3	0.37	2.02e-12	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	5.97	0.31	6.08e-9	Renal cell carcinoma;
LIHC	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.47e-18	Coffee consumption (cups per day);
LIHC	cis	rs4700695	0.841	rs784276	chr5:65317332	A/T	cg21114390	chr5:65439923	SFRS12	0.49	6.69	0.34	9.15e-11	Facial morphology (factor 19);
LIHC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.4	0.45	7.82e-19	Total body bone mineral density;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-6.75	-0.34	6.17e-11	Lymphocyte counts;
LIHC	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg14146966	chr2:61757674	XPO1	0.46	7.88	0.39	4.49e-14	Tuberculosis;
LIHC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.47	7.75	0.39	1.09e-13	Tuberculosis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03513109	chr11:126138776	SRPR;FOXRED1	0.47	6.66	0.34	1.12e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.32	6.34	0.32	7.13e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.24	-16.14	-0.66	5.64e-44	Diabetic kidney disease;
LIHC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.84	7.52	0.38	4.8e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs4755351	0.553	rs10767991	chr11:33169164	T/C	cg05567920	chr11:33183001	CSTF3	0.43	6.28	0.32	1.04e-9	Lung cancer in ever smokers;
LIHC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.19	-0.45	3.85e-18	Schizophrenia;
LIHC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg16434002	chr17:42200994	HDAC5	-0.51	-7.43	-0.37	8.64e-13	Total body bone mineral density;
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.57	-5.84	-0.3	1.22e-8	Renal cell carcinoma;
LIHC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.92	9.63	0.46	1.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	10.11	0.48	3.3e-21	Electrocardiographic conduction measures;
LIHC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.53	5.74	0.3	2.12e-8	Menopause (age at onset);
LIHC	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.06e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.54	6.21	0.32	1.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8084351	0.577	rs7226390	chr18:50629407	A/C	cg24270629	chr18:50823537	DCC	0.43	6.48	0.33	3.26e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17399234	chr5:110428454	WDR36	0.32	6.46	0.33	3.57e-10	Calcium levels;
LIHC	cis	rs34540877	1.000	rs11667412	chr19:33137748	T/C	cg22980127	chr19:33182716	NUDT19	1.0	6.63	0.34	1.33e-10	Red cell distribution width;
LIHC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.43	9.55	0.46	2.5e-19	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.4	7.75e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.45	-8.25	-0.41	3.5e-15	Tuberculosis;
LIHC	trans	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg09872104	chr7:134855509	C7orf49	-0.78	-6.29	-0.32	9.54e-10	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.52	7.4	0.37	1.05e-12	Asthma;
LIHC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg26026558	chr17:16934655	NA	-0.38	-6.24	-0.32	1.33e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.6	8.84	0.43	5.14e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-8.08	-0.4	1.12e-14	Putamen volume;
LIHC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.3e-16	Motion sickness;
LIHC	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg08824895	chr13:115047677	UPF3A	0.48	6.9	0.35	2.58e-11	Schizophrenia;
LIHC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.37	7.05	0.36	9.79e-12	Asthma (sex interaction);
LIHC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.72	0.5	2.64e-23	Bladder cancer;
LIHC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.48	0.37	6.37e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.7	0.38	1.48e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.23e-27	Motion sickness;
LIHC	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.53	-8.35	-0.41	1.69e-15	Superior crus of antihelix expression;
LIHC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	9.12	0.44	6.71e-18	Platelet count;
LIHC	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg25894440	chr7:65020034	NA	-0.53	-6.04	-0.31	4.05e-9	Diabetic kidney disease;
LIHC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	13.73	0.6	1.8e-34	Multiple sclerosis;
LIHC	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.95e-50	Schizophrenia;
LIHC	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg25124228	chr12:125621409	AACS	-0.44	-7.38	-0.37	1.19e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs72627123	0.867	rs73301475	chr14:74462868	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	8.77	0.43	8.53e-17	Morning vs. evening chronotype;
LIHC	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.19	-0.32	1.73e-9	Tuberculosis;
LIHC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-8.1	-0.4	9.74e-15	Gut microbiome composition (summer);
LIHC	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.87	13.33	0.58	6.06e-33	Gastritis;
LIHC	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.35	24.5	0.8	2.82e-77	Corneal structure;
LIHC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.81	0.3	1.43e-8	Axial length;
LIHC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.37e-12	Bipolar disorder;
LIHC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.39	7.02	0.35	1.2e-11	IgG glycosylation;
LIHC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	0.8	12.02	0.54	5.47e-28	Monocyte percentage of white cells;
LIHC	cis	rs1198430	0.639	rs2297841	chr1:23764149	C/G	cg19827787	chr1:23763612	ASAP3	0.29	6.22	0.32	1.48e-9	Total cholesterol levels;
LIHC	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00495681	chr13:53174319	NA	0.38	6.18	0.32	1.79e-9	Lewy body disease;
LIHC	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.52	8.86	0.43	4.35e-17	Coronary artery disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18649979	chr19:21688263	ZNF429	-0.44	-6.26	-0.32	1.13e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.62	0.34	1.39e-10	Body mass index;
LIHC	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-6.13	-0.31	2.46e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.03	-0.31	4.36e-9	Cognitive function;
LIHC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs4671400	0.516	rs62152277	chr2:61503404	C/T	cg14146966	chr2:61757674	XPO1	-0.37	-5.86	-0.3	1.1e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.65	-10.06	-0.48	4.94e-21	Neutrophil percentage of white cells;
LIHC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg05501817	chr11:14380813	RRAS2	0.44	6.23	0.32	1.35e-9	Sense of smell;
LIHC	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	1.06	8.05	0.4	1.39e-14	Arsenic metabolism;
LIHC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.17	0.52	6.53e-25	Type 2 diabetes;
LIHC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	6.02	0.31	4.62e-9	Mean platelet volume;
LIHC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg20607798	chr8:58055168	NA	0.48	6.66	0.34	1.08e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9921222	0.500	rs12917907	chr16:405866	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.45	7.77	0.39	9.53e-14	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.76	0.39	9.62e-14	Corneal astigmatism;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg19963142	chr11:58345608	ZFP91;LPXN;ZFP91-CNTF	-0.43	-6.14	-0.32	2.34e-9	Neuroblastoma;
LIHC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.53	7.69	0.38	1.58e-13	Type 2 diabetes;
LIHC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.45	-0.42	8.76e-16	Gut microbiome composition (summer);
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.89e-13	Lymphocyte counts;
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.43	5.84	0.3	1.23e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.64e-15	Motion sickness;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12379764	chr21:47803548	PCNT	-0.61	-8.85	-0.43	4.96e-17	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12463550	chr7:65579703	CRCP	0.69	7.22	0.36	3.46e-12	Diabetic kidney disease;
LIHC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.29	0.52	2.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.42	-6.56	-0.33	2.01e-10	Educational attainment;
LIHC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg18944383	chr4:111397179	ENPEP	0.24	6.09	0.31	3.01e-9	Height;
LIHC	cis	rs15676	0.947	rs2293966	chr9:131591832	G/A	cg00228799	chr9:131580591	ENDOG	0.44	6.6	0.34	1.56e-10	Blood metabolite levels;
LIHC	cis	rs1198430	1.000	rs1198439	chr1:23749593	A/T	cg13183780	chr1:23809682	ASAP3	-0.48	-7.22	-0.36	3.3e-12	Total cholesterol levels;
LIHC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.52	-9.32	-0.45	1.45e-18	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.45	-6.3	-0.32	9.04e-10	Initial pursuit acceleration;
LIHC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg25894440	chr7:65020034	NA	-0.53	-6.11	-0.31	2.72e-9	Diabetic kidney disease;
LIHC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.75	-0.43	1.02e-16	Total cholesterol levels;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg10016717	chr17:88246	RPH3AL	0.61	6.6	0.34	1.54e-10	Mean platelet volume;
LIHC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg18887096	chr2:219472410	PLCD4	0.36	6.29	0.32	9.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14266050	chr4:2845671	ADD1	-0.44	-6.09	-0.31	2.97e-9	Bilirubin levels;
LIHC	trans	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg07393940	chr7:158741817	NA	-0.57	-6.95	-0.35	1.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.71	7.06	0.36	9.26e-12	Vitiligo;
LIHC	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.38	13.72	0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg24693881	chr1:107596107	NA	-0.54	-9.46	-0.46	4.95e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27297192	chr10:134578999	INPP5A	0.55	8.1	0.4	9.95e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs7551222	0.752	rs12566957	chr1:204556958	C/T	cg20240347	chr1:204465584	NA	-0.31	-6.34	-0.32	7.1e-10	Schizophrenia;
LIHC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg19645103	chr12:69753606	YEATS4	-0.45	-6.19	-0.32	1.72e-9	Response to diuretic therapy;
LIHC	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg05110241	chr16:68378359	PRMT7	-0.5	-6.0	-0.31	5.05e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7666738	0.539	rs13150465	chr4:99094892	C/T	cg05340658	chr4:99064831	C4orf37	-0.68	-7.58	-0.38	3.24e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs244293	0.965	rs244314	chr17:53214517	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.37	-0.37	1.27e-12	Menarche (age at onset);
LIHC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.99	-0.31	5.17e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-6.01	-0.31	4.76e-9	Life satisfaction;
LIHC	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg03037974	chr15:76606532	NA	-0.51	-8.27	-0.41	3.1e-15	Blood metabolite levels;
LIHC	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg04592579	chr7:75616294	TMEM120A	-0.39	-6.68	-0.34	9.92e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg18121669	chr1:26560928	CCDC21	0.5	8.0	0.4	1.91e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3770081	1.000	rs3770089	chr2:86263815	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-8.75	-0.43	1e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs6442522	0.560	rs2305612	chr3:15518731	C/G	cg16303742	chr3:15540471	COLQ	0.37	5.91	0.3	8.45e-9	Uric acid levels;
LIHC	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-7.52	-0.38	4.81e-13	Brugada syndrome;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.52	6.28	0.32	1.05e-9	Alzheimer's disease;
LIHC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.45	9.93e-19	Bipolar disorder;
LIHC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.84	13.68	0.59	2.79e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10795710	chr1:16693622	C1orf144	0.43	6.74	0.34	6.74e-11	Pancreatic cancer;
LIHC	cis	rs74181299	0.964	rs2540951	chr2:65276736	A/G	cg05010058	chr2:65284262	CEP68	0.4	6.7	0.34	8.6e-11	Pulse pressure;
LIHC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	0.81	6.69	0.34	8.93e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-15.49	-0.64	2.29e-41	Gut microbiome composition (summer);
LIHC	cis	rs6466055	0.748	rs41563	chr7:104852654	G/A	cg04380332	chr7:105027541	SRPK2	-0.34	-6.4	-0.33	5.25e-10	Schizophrenia;
LIHC	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg17085576	chr10:5658249	NA	-0.34	-6.05	-0.31	3.9e-9	Breast cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11412256	chr1:228612818	HIST3H3	-0.37	-6.12	-0.31	2.63e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg00280220	chr17:61926910	NA	0.42	6.64	0.34	1.23e-10	Prudent dietary pattern;
LIHC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-10.46	-0.49	2.04e-22	Total body bone mineral density;
LIHC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg02811702	chr13:24901961	NA	0.26	6.63	0.34	1.3100000000000001e-10	Obesity-related traits;
LIHC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.76	0.34	5.99e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg19635926	chr16:89946313	TCF25	0.52	7.02	0.36	1.17e-11	Skin colour saturation;
LIHC	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg08135965	chr6:41755394	TOMM6	0.46	6.13	0.31	2.41e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.89	15.54	0.64	1.43e-41	Parkinson's disease;
LIHC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	7.49	0.38	5.75e-13	Monocyte percentage of white cells;
LIHC	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.31	5.97	0.31	5.98e-9	DNA methylation (variation);
LIHC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.81	14.27	0.61	1.37e-36	Coronary artery disease;
LIHC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.4	8.67	0.42	1.74e-16	Erythrocyte sedimentation rate;
LIHC	trans	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	6.29e-33	Diabetic kidney disease;
LIHC	cis	rs16828019	0.929	rs35286837	chr1:41682998	T/G	cg20697417	chr1:41786797	NA	0.34	6.51	0.33	2.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.61	0.76	6.3e-66	Prudent dietary pattern;
LIHC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.53	-7.43	-0.37	8.62e-13	Pulse pressure;
LIHC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.7	12.84	0.57	4.54e-31	Lewy body disease;
LIHC	cis	rs4407350	0.870	rs5765715	chr22:44915217	A/G	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.2	-0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg13263691	chr18:77568018	NA	0.25	6.82	0.35	4.08e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.49	-6.58	-0.34	1.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs332507	0.601	rs11711670	chr3:124374215	G/A	cg05980111	chr3:124395277	KALRN	0.32	6.21	0.32	1.57e-9	Plateletcrit;
LIHC	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg12560992	chr17:57184187	TRIM37	0.68	8.74	0.43	1.03e-16	Vitamin D levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.42	6.17	0.32	1.91e-9	Cognitive function;
LIHC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.85	-13.76	-0.6	1.3600000000000001e-34	Post bronchodilator FEV1;
LIHC	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg00792783	chr2:198669748	PLCL1	0.4	5.98	0.31	5.46e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	0.97	12.09	0.55	3.03e-28	Economic and political preferences (immigration/crime);
LIHC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.41	6.3	0.32	8.98e-10	Platelet count;
LIHC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.86	16.28	0.66	1.52e-44	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.49	7.41	0.37	1.01e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg10820262	chr4:111866929	NA	0.39	6.47	0.33	3.44e-10	Electroencephalogram traits;
LIHC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.33	-0.45	1.42e-18	Bipolar disorder;
LIHC	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg02886208	chr11:14281011	SPON1	-0.54	-7.61	-0.38	2.75e-13	Mitochondrial DNA levels;
LIHC	cis	rs9596863	0.898	rs7993276	chr13:54323868	A/G	ch.13.53330881F	chr13:54432880	NA	0.43	5.92	0.3	8.01e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1144333	0.850	rs1144341	chr1:76282659	T/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.63	-0.34	1.29e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.58	0.34	1.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.5	-6.46	-0.33	3.62e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-6.51	-0.33	2.67e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs864643	0.947	rs587054	chr3:39565987	A/G	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	trans	rs877282	0.583	rs11253428	chr10:823233	C/T	cg22713356	chr15:30763199	NA	0.79	6.78	0.34	5.39e-11	Uric acid levels;
LIHC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg21573476	chr21:45109991	RRP1B	-0.54	-10.25	-0.48	1.1e-21	Mean corpuscular volume;
LIHC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.1	-13.13	-0.58	3.71e-32	Vitiligo;
LIHC	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.58	9.35	0.45	1.17e-18	Corneal astigmatism;
LIHC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.75	0.57	9.72e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.1	-10.02	-0.48	6.9299999999999992e-21	Diabetic retinopathy;
LIHC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg16989086	chr20:62203971	PRIC285	0.56	8.2	0.41	4.9e-15	Glioblastoma;
LIHC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg25344623	chr2:136566232	LCT	-0.38	-6.1	-0.31	2.88e-9	Corneal structure;
LIHC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-8.45	-0.42	8.39e-16	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.51	-7.08	-0.36	8.1e-12	Aortic root size;
LIHC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26304930	chr1:119571871	NA	0.35	6.11	0.31	2.78e-9	Cognitive function;
LIHC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.41	-9.34	-0.45	1.23e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02034447	chr16:89574710	SPG7	0.5	7.78	0.39	8.68e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.7	-12.37	-0.56	2.64e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2645424	0.666	rs2272767	chr8:11711059	C/T	cg21281001	chr8:11725306	CTSB	0.53	8.26	0.41	3.14e-15	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
LIHC	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	0.98	6.47	0.33	3.34e-10	Mitochondrial DNA levels;
LIHC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	9.76	0.47	5.17e-20	Prudent dietary pattern;
LIHC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.54	-9.05	-0.44	1.12e-17	Cognitive function;
LIHC	cis	rs360798	0.532	rs360800	chr2:62954326	C/T	cg17519650	chr2:63277830	OTX1	-0.58	-8.79	-0.43	7.5e-17	Coronary artery disease;
LIHC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05665937	chr4:1216051	CTBP1	0.44	5.77	0.3	1.77e-8	Obesity-related traits;
LIHC	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg08992911	chr2:238395768	MLPH	0.5	6.01	0.31	4.86e-9	Prostate cancer;
LIHC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg15902774	chr15:75289873	SCAMP5	0.4	5.95	0.31	6.63e-9	Lung cancer;
LIHC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-9.76	-0.47	5.25e-20	Arsenic metabolism;
LIHC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.74	-8.25	-0.41	3.55e-15	Putamen volume;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	0.8	11.83	0.54	2.6e-27	Menarche (age at onset);
LIHC	cis	rs3812111	0.774	rs568725	chr6:116430803	G/A	cg08036074	chr6:116424633	NT5DC1	0.67	12.09	0.55	2.93e-28	Age-related macular degeneration;
LIHC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg16797656	chr11:68205561	LRP5	0.53	8.31	0.41	2.22e-15	Total body bone mineral density;
LIHC	cis	rs9473924	0.542	rs2857506	chr6:50800308	C/T	cg14470998	chr6:50812995	TFAP2B	0.97	11.7	0.53	8.07e-27	Body mass index;
LIHC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.37	5.88	0.3	9.77e-9	Menopause (age at onset);
LIHC	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.17	-0.52	6.62e-25	Eye color traits;
LIHC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.51	6.32	0.32	8.22e-10	Schizophrenia;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg15382696	chr6:118971807	C6orf204	0.63	6.37	0.33	6.05e-10	Diastolic blood pressure;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12664560	chr15:83621517	HOMER2	0.52	6.2	0.32	1.65e-9	Hepatitis;
LIHC	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.39	-5.82	-0.3	1.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1975974	0.549	rs4889746	chr17:21745187	T/C	cg18423549	chr17:21743878	NA	-0.47	-5.81	-0.3	1.47e-8	Psoriasis;
LIHC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg00656387	chr3:40428638	ENTPD3	0.42	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21467203	chr3:49911342	NA	-0.4	-6.98	-0.35	1.56e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.7	6.88	0.35	2.79e-11	Migraine;Coronary artery disease;
LIHC	cis	rs5753037	0.774	rs140118	chr22:30135806	G/A	cg01021169	chr22:30184971	ASCC2	-0.31	-5.79	-0.3	1.56e-8	Type 1 diabetes;
LIHC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.07	14.18	0.61	3.17e-36	Primary sclerosing cholangitis;
LIHC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.89	-0.35	2.62e-11	HDL cholesterol;
LIHC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.73	-9.88	-0.47	2.06e-20	Asthma;
LIHC	cis	rs9816226	0.591	rs75135487	chr3:185805294	C/G	cg00760338	chr3:185826511	ETV5	-0.71	-5.99	-0.31	5.27e-9	Obesity;Body mass index;
LIHC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.36	-0.49	4.77e-22	Response to antipsychotic treatment;
LIHC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	9.02	0.44	1.37e-17	Menarche (age at onset);
LIHC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.77	-8.68	-0.42	1.66e-16	Cognitive test performance;
LIHC	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg13512537	chr8:22265999	SLC39A14	-0.33	-5.88	-0.3	9.61e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.6	7.29	0.37	2.21e-12	Heart rate;
LIHC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	7.5	0.38	5.66e-13	Glycated hemoglobin levels;
LIHC	cis	rs2073300	1.000	rs6048824	chr20:23457645	C/A	cg12062639	chr20:23401060	NAPB	0.78	9.7	0.46	8.37e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.7	0.34	8.4e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3849570	0.555	rs6548783	chr3:81993621	G/A	cg07356753	chr3:81810745	GBE1	-0.42	-6.57	-0.33	1.91e-10	Waist circumference;Body mass index;
LIHC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.45	-0.37	7.86e-13	Response to antipsychotic treatment;
LIHC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.66	6.61	0.34	1.5e-10	Bipolar disorder;
LIHC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.69	12.1	0.55	2.64e-28	Colorectal cancer;
LIHC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.69e-10	Waist circumference;Weight;
LIHC	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg12463550	chr7:65579703	CRCP	0.7	7.15	0.36	5.32e-12	Diabetic kidney disease;
LIHC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.71	12.36	0.56	2.98e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.0	-0.4	1.97e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.76	10.21	0.48	1.53e-21	Fat distribution (HIV);
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg20090690	chr10:134436459	INPP5A	0.43	5.95	0.31	6.52e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.33	7.64	0.38	2.15e-13	Blood metabolite ratios;
LIHC	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.71	12.05	0.55	4e-28	Platelet distribution width;
LIHC	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.57	11.56	0.53	2.66e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.85	10.2	0.48	1.73e-21	Mean platelet volume;
LIHC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03264133	chr6:25882463	NA	-0.47	-7.24	-0.36	3.06e-12	Height;
LIHC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.27	-0.32	1.11e-9	IgG glycosylation;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg00800038	chr16:89945340	TCF25	-0.61	-9.65	-0.46	1.19e-19	Skin colour saturation;
LIHC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-11.8	-0.54	3.49e-27	Height;
LIHC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.06	0.36	9.34e-12	Diastolic blood pressure;
LIHC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.47	7.37	0.37	1.33e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg03146154	chr1:46216737	IPP	-0.4	-6.55	-0.33	2.11e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.49	6.63	0.34	1.3e-10	Menopause (age at onset);
LIHC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.68	9.3	0.45	1.69e-18	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg13047869	chr3:10149882	C3orf24	0.5	6.43	0.33	4.4e-10	Alzheimer's disease;
LIHC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg15123519	chr2:136567270	LCT	0.37	7.03	0.36	1.14e-11	Mosquito bite size;
LIHC	cis	rs7707921	1.000	rs749402	chr5:81561325	C/T	cg15871215	chr5:81402204	ATG10	-0.59	-5.85	-0.3	1.18e-8	Breast cancer;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.36	6.64	0.34	1.22e-10	Lung cancer;
LIHC	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.48	7.57	0.38	3.41e-13	HDL cholesterol;
LIHC	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg27209729	chr11:64428925	NRXN2	0.38	7.07	0.36	8.58e-12	Body mass index;Urate levels;
LIHC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.59	-9.32	-0.45	1.48e-18	Post bronchodilator FEV1;
LIHC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.57	-7.7	-0.38	1.51e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9596863	0.898	rs9316660	chr13:54353562	T/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.04	0.31	3.93e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.68	7.32	0.37	1.75e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.57	9.37	0.45	1.01e-18	Corneal astigmatism;
LIHC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.63	-0.5	5.24e-23	Coronary artery disease;
LIHC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.59	-0.38	3.13e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg02297831	chr4:17616191	MED28	0.42	6.56	0.33	1.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02767759	chr16:30366751	CD2BP2	0.49	6.64	0.34	1.22e-10	Pancreatic cancer;
LIHC	trans	rs1998584	1.000	rs10961199	chr9:13714854	G/T	cg13665852	chr10:13146898	OPTN	0.41	6.16	0.32	2.02e-9	Survival in microsatellite instability low/stable colorectal cancer;
LIHC	cis	rs7188697	0.809	rs4784956	chr16:58596291	A/C	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg01765077	chr12:122356316	WDR66	0.44	6.64	0.34	1.25e-10	Mean corpuscular volume;
LIHC	trans	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg26939375	chr7:64535504	NA	0.4	6.3	0.32	9.05e-10	Aortic root size;
LIHC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.34	-0.32	7.28e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	7.63	0.38	2.3e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.78	0.3	1.68e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.45	5.77	0.3	1.79e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.71	-11.02	-0.51	2.19e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02290350	chr8:58132656	NA	0.44	9.39	0.45	8.42e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.99	-0.31	5.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.65	6.88	0.35	2.89e-11	Type 2 diabetes;
LIHC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.76	-0.62	1.8e-38	Alzheimer's disease (late onset);
LIHC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg01652190	chr22:50026171	C22orf34	-0.29	-6.61	-0.34	1.52e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.12	-0.36	6.34e-12	Personality dimensions;
LIHC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	6.02e-12	Diabetic kidney disease;
LIHC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.4	-6.9	-0.35	2.48e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.7	0.38	1.48e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.21	-0.36	3.58e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.9	-19.49	-0.73	2.02e-57	Height;
LIHC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.5	0.42	5.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs8084351	0.577	rs9946519	chr18:50631882	T/C	cg24270629	chr18:50823537	DCC	0.43	6.5	0.33	2.82e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.35	-6.04	-0.31	4.05e-9	Menopause (age at onset);
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.56	9.37	0.45	1e-18	Calcium levels;
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg03854865	chr6:26224070	HIST1H3E	0.62	7.11	0.36	6.65e-12	Gout;Renal underexcretion gout;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26541587	chr10:43950885	ZNF487	-0.5	-6.08	-0.31	3.15e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.52	0.49	1.31e-22	Lymphocyte counts;
LIHC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg10932868	chr11:921992	NA	0.38	7.05	0.36	9.7e-12	Alzheimer's disease (late onset);
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg07725925	chr16:89976287	TCF25	0.44	6.03	0.31	4.15e-9	Skin colour saturation;
LIHC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.3	0.45	1.74e-18	Bipolar disorder;
LIHC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.52e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12086130	0.892	rs57331401	chr1:51451372	G/A	cg07174182	chr1:51127561	FAF1	-0.92	-9.87	-0.47	2.14e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.97	20.99	0.75	1.91e-63	Bone mineral density;
LIHC	cis	rs61677309	1.000	rs12576941	chr11:118158002	A/G	cg06090739	chr11:118230722	UBE4A	0.36	6.77	0.34	5.64e-11	Lung cancer in ever smokers;
LIHC	cis	rs2412488	1.000	rs3811782	chr4:54243905	T/C	cg22241045	chr4:54363911	LNX1	-0.46	-7.29	-0.37	2.2e-12	DNA methylation (variation);
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.26	0.32	1.18e-9	Aortic root size;
LIHC	cis	rs2279817	0.863	rs12729433	chr1:18013089	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.44	-5.98	-0.31	5.78e-9	Neuroticism;
LIHC	cis	rs34779708	0.801	rs12255409	chr10:35535425	G/A	cg03585969	chr10:35415529	CREM	0.78	11.47	0.53	5.49e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.38	-6.44	-0.33	4.1e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs12744310	0.887	rs12041352	chr1:41782781	T/G	cg03962019	chr1:41807865	NA	0.39	6.23	0.32	1.38e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.99	0.31	5.4e-9	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27143824	chr4:184580738	C4orf41;RWDD4A	0.45	6.28	0.32	1.02e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs55665837	0.519	rs10832297	chr11:14757737	C/A	cg25251204	chr11:14927456	NA	0.4	5.74	0.3	2.11e-8	Vitamin D levels;
LIHC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.51	7.96	0.4	2.56e-14	Type 2 diabetes;
LIHC	cis	rs7129556	0.520	rs4944164	chr11:77275849	G/A	cg03570279	chr11:77446074	RSF1	-0.35	-6.51	-0.33	2.63e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.88	13.65	0.59	3.7e-34	Skin colour saturation;
LIHC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg03945807	chr20:60948434	NA	0.4	5.77	0.3	1.76e-8	Colorectal cancer;
LIHC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg04310649	chr10:35416472	CREM	-0.43	-5.86	-0.3	1.11e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.99	-16.89	-0.67	5.71e-47	Tonsillectomy;
LIHC	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.23	-6.24	-0.32	1.32e-9	Type 2 diabetes;
LIHC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.1	0.31	2.89e-9	Renal cell carcinoma;
LIHC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-8.75	-0.43	1e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	trans	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg01134436	chr17:81009848	B3GNTL1	0.81	6.59	0.34	1.69e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs77637988	0.533	rs13398791	chr2:48622320	G/C	cg00032884	chr2:48540671	FOXN2	0.37	5.77	0.3	1.77e-8	Joint mobility (Beighton score);
LIHC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-10.08	-0.48	4.21e-21	Arsenic metabolism;
LIHC	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.74	13.39	0.59	3.52e-33	Ewing sarcoma;
LIHC	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.9	-0.3	8.7e-9	Red blood cell traits;
LIHC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg14067834	chr17:29058358	SUZ12P	0.68	6.59	0.34	1.66e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.6	8.33	0.41	1.91e-15	Bladder cancer;
LIHC	cis	rs36051895	0.589	rs10283734	chr9:5217139	A/T	cg02405213	chr9:5042618	JAK2	-0.66	-10.52	-0.49	1.32e-22	Pediatric autoimmune diseases;
LIHC	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.35	5.87	0.3	1.02e-8	Mean platelet volume;
LIHC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.58	0.46	1.99e-19	Bipolar disorder;
LIHC	cis	rs7116495	0.867	rs510925	chr11:71809500	C/T	cg26138937	chr11:71823887	C11orf51	1.09	9.26	0.45	2.35e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.69	-7.3	-0.37	2.09e-12	Post bronchodilator FEV1;
LIHC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	0.94	9.28	0.45	1.95e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs8020095	0.528	rs6573758	chr14:67667906	A/G	cg03487553	chr14:67822707	ATP6V1D	-0.35	-6.12	-0.31	2.52e-9	Depression (quantitative trait);
LIHC	cis	rs922107	0.738	rs12411255	chr1:90036747	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1555399	0.935	rs7144624	chr14:67984109	G/T	cg16224230	chr14:67978224	TMEM229B	-0.25	-5.99	-0.31	5.46e-9	Parkinson's disease;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.75	-13.09	-0.58	5.01e-32	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg00280220	chr17:61926910	NA	0.43	6.75	0.34	6.18e-11	Prudent dietary pattern;
LIHC	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg02290350	chr8:58132656	NA	0.47	9.16	0.44	4.93e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg11946769	chr3:48343235	NME6	-0.48	-6.41	-0.33	4.81e-10	Educational attainment (years of education);
LIHC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.34	8.36	0.41	1.65e-15	Immature fraction of reticulocytes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03262077	chr1:109505986	CLCC1	0.49	6.78	0.34	5.33e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7106204	0.920	rs7946615	chr11:24221036	T/C	ch.11.24196551F	chr11:24239977	NA	0.69	6.96	0.35	1.75e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg25760338	chr6:52860082	GSTA4	-0.42	-6.28	-0.32	1.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.23	10.89	0.51	6.83e-24	Uric acid levels;
LIHC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg12863693	chr15:85201151	NMB	0.48	6.9	0.35	2.49e-11	Schizophrenia;
LIHC	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	0.39	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.48	-7.69	-0.38	1.53e-13	Neurofibrillary tangles;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg21548813	chr6:291882	DUSP22	-0.55	-7.37	-0.37	1.32e-12	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.33	0.52	1.82e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg25566285	chr7:158114605	PTPRN2	0.23	6.22	0.32	1.43e-9	Calcium levels;
LIHC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.12	-12.95	-0.57	1.75e-31	Vitiligo;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg02993280	chr1:107599747	PRMT6	0.64	10.12	0.48	3.04e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs11673344	0.734	rs2551047	chr19:37426076	G/A	cg27390819	chr19:37464633	NA	-0.5	-6.03	-0.31	4.35e-9	Obesity-related traits;
LIHC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg17801930	chr5:56009405	NA	-0.43	-5.71	-0.3	2.41e-8	Type 2 diabetes;
LIHC	cis	rs4908768	0.817	rs11587482	chr1:8743195	T/G	cg25722041	chr1:8623473	RERE	0.43	5.85	0.3	1.16e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg23461800	chr14:103021989	NA	-0.5	-7.12	-0.36	6.6e-12	Platelet count;
LIHC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.01	0.35	1.28e-11	Mean platelet volume;
LIHC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg05044414	chr3:183734942	ABCC5	0.33	5.92	0.3	7.91e-9	Anterior chamber depth;
LIHC	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.26	6.01	0.31	4.69e-9	Obesity-related traits;
LIHC	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-7.2	-0.36	3.77e-12	Vitamin D levels;
LIHC	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.61	-10.37	-0.49	4.49e-22	Pediatric autoimmune diseases;
LIHC	cis	rs78545713	1.000	rs41266821	chr6:26247198	A/G	cg16070018	chr6:26224392	HIST1H3E	0.69	7.32	0.37	1.79e-12	Iron status biomarkers (total iron binding capacity);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12980527	chr5:36875537	NIPBL	-0.41	-6.29	-0.32	9.85e-10	Pancreatic cancer;
LIHC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.59	-7.87	-0.39	4.86e-14	Diastolic blood pressure;
LIHC	cis	rs10888574	1	rs10888574	chr1:150164058	A/G	cg15654264	chr1:150340011	RPRD2	-0.4	-6.02	-0.31	4.48e-9	Pediatric bone mineral content (hip);
LIHC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-5.97	-0.31	5.97e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2282802	0.685	rs67813630	chr5:139623592	C/A	cg26211634	chr5:139558579	C5orf32	0.4	6.14	0.31	2.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.46	8.79	0.43	7.44e-17	Testicular germ cell tumor;
LIHC	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg25182066	chr10:30743637	MAP3K8	-0.49	-8.08	-0.4	1.09e-14	Inflammatory bowel disease;
LIHC	cis	rs2834188	1.000	rs2834190	chr21:34693011	A/T	cg04842828	chr21:34696676	IFNAR1	-0.43	-5.84	-0.3	1.18e-8	Narcolepsy;
LIHC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg06238570	chr21:40685208	BRWD1	0.58	6.98	0.35	1.53e-11	Cognitive function;
LIHC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs12086130	0.892	rs12855	chr1:51440093	C/T	cg07174182	chr1:51127561	FAF1	-0.76	-8.5	-0.42	6.13e-16	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs754466	0.561	rs67332822	chr10:79706118	G/A	cg17075019	chr10:79541650	NA	-0.52	-5.73	-0.3	2.17e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.88	0.3	9.87e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.54	-9.83	-0.47	3.09e-20	Alcohol dependence;
LIHC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.38	0.37	1.2e-12	Morning vs. evening chronotype;
LIHC	cis	rs611744	0.967	rs685690	chr8:109192145	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.58	0.59	6.99e-34	Cognitive test performance;
LIHC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.79	-0.34	4.96e-11	Aortic root size;
LIHC	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.36	6.13	0.31	2.44e-9	Metabolite levels;
LIHC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg18016565	chr1:150552671	MCL1	0.54	10.25	0.48	1.12e-21	Melanoma;
LIHC	cis	rs4908760	0.792	rs6577515	chr1:8714202	G/C	cg20416874	chr1:8611966	RERE	-0.66	-13.58	-0.59	7.04e-34	Vitiligo;
LIHC	trans	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-8.99	-0.44	1.77e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg03037974	chr15:76606532	NA	0.57	9.81	0.47	3.65e-20	Blood metabolite levels;
LIHC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.39	7.82	0.39	6.42e-14	Ewing sarcoma;
LIHC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06050784	chr16:88016603	BANP	0.35	6.43	0.33	4.33e-10	Menopause (age at onset);
LIHC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.8	11.1	0.51	1.18e-24	Skin colour saturation;
LIHC	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.63	-8.49	-0.42	6.49e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8084351	0.560	rs12456646	chr18:50668785	C/T	cg24270629	chr18:50823537	DCC	-0.44	-6.5	-0.33	2.8e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	3.97e-9	Diabetic kidney disease;
LIHC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.53	6.46	0.33	3.67e-10	Alzheimer's disease;
LIHC	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg18963800	chr10:38644991	HSD17B7P2	0.43	6.17	0.32	1.94e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.96	0.31	6.17e-9	Bipolar disorder;
LIHC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.73	-8.02	-0.4	1.65e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.67	9.93	0.47	1.34e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs3106136	0.710	rs6856971	chr4:95296041	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.09	-0.31	3.1e-9	Capecitabine sensitivity;
LIHC	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg05197062	chr11:11642011	GALNTL4	0.46	6.73	0.34	7.11e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.56	10.01	0.48	7.29e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.69	7.01	0.35	1.31e-11	Alzheimer's disease;
LIHC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.54	6.41	0.33	4.82e-10	Alzheimer's disease;
LIHC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.5	-7.47	-0.37	6.86e-13	Obesity-related traits;
LIHC	cis	rs2834188	1.000	rs9982088	chr21:34686841	A/G	cg04842828	chr21:34696676	IFNAR1	0.46	6.16	0.32	2.02e-9	Narcolepsy;
LIHC	cis	rs7903847	0.656	rs61861861	chr10:99143619	C/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.05	-0.31	3.71e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.47	7.43	0.37	8.5e-13	Methadone dose in opioid dependence;
LIHC	cis	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.23	-0.36	3.13e-12	Eotaxin levels;
LIHC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg20487152	chr13:99095054	FARP1	0.45	8.0	0.4	1.98e-14	Neuroticism;
LIHC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.41	-7.2	-0.36	3.78e-12	Platelet distribution width;
LIHC	cis	rs7572733	0.555	rs7590828	chr2:198940251	A/G	cg10820045	chr2:198174542	NA	-0.41	-6.16	-0.32	2.06e-9	Dermatomyositis;
LIHC	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.4	6.21	0.32	1.5e-9	Refractive astigmatism;
LIHC	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.84	-0.35	3.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.5	7.38	0.37	1.19e-12	Total body bone mineral density;
LIHC	cis	rs6722750	0.818	rs13411753	chr2:64394417	A/G	cg22352474	chr2:64371530	PELI1	0.46	6.67	0.34	1.05e-10	Neuroticism;
LIHC	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.57	7.43	0.37	8.67e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27619136	chr4:174291353	SAP30	0.44	6.86	0.35	3.24e-11	Cognitive function;
LIHC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.34	5.82	0.3	1.38e-8	Psoriasis;
LIHC	cis	rs6977660	1.000	rs10260360	chr7:19792824	T/C	cg07541023	chr7:19748670	TWISTNB	0.4	6.19	0.32	1.71e-9	Thyroid stimulating hormone;
LIHC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.26	0.45	2.26e-18	Hemoglobin concentration;
LIHC	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.34	-7.21	-0.36	3.69e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg03859395	chr2:55845619	SMEK2	0.88	15.01	0.63	1.72e-39	Metabolic syndrome;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.55	8.28	0.41	2.76e-15	Longevity;Endometriosis;
LIHC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg06565975	chr8:143823917	SLURP1	-0.41	-7.72	-0.39	1.27e-13	Urinary tract infection frequency;
LIHC	cis	rs12101261	0.536	rs724170	chr14:81457940	G/A	cg06600135	chr14:81408086	NA	0.41	7.27	0.37	2.52e-12	Graves' disease;
LIHC	cis	rs10411936	0.626	rs8113060	chr19:16596795	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.95	0.35	1.81e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.62	-8.45	-0.42	8.66e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2421770	0.530	rs3847622	chr11:35368700	A/G	cg13971030	chr11:35366721	SLC1A2	0.45	7.63	0.38	2.36e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-8.74	-0.43	1.08e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.3	-0.32	9.4e-10	Obesity-related traits;
LIHC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.59	-0.46	1.86e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.6	0.56	3.73e-30	Cognitive test performance;
LIHC	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.4	7.82	0.39	6.82e-14	Coronary artery disease or large artery stroke;
LIHC	trans	rs4714291	0.832	rs9471247	chr6:40105318	A/G	cg02267698	chr19:7991119	CTXN1	-0.4	-6.59	-0.34	1.63e-10	Strep throat;
LIHC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.78	-13.04	-0.58	7.7e-32	Coronary artery disease;
LIHC	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg22705602	chr4:152727874	NA	-0.3	-6.45	-0.33	3.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8020095	0.571	rs8022657	chr14:67390499	C/T	cg03487553	chr14:67822707	ATP6V1D	-0.36	-6.16	-0.32	2.02e-9	Depression (quantitative trait);
LIHC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg20750642	chr13:99100586	FARP1	0.34	6.44	0.33	4.08e-10	Educational attainment (years of education);
LIHC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.25	0.41	3.52e-15	Bladder cancer;
LIHC	cis	rs7619427	0.908	rs9816229	chr3:44080077	T/C	cg24966902	chr3:44043705	NA	0.43	6.19	0.32	1.69e-9	Schizophrenia;
LIHC	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.77	0.34	5.79e-11	Dermatomyositis;
LIHC	cis	rs151997	0.671	rs27907	chr5:50193797	C/G	cg06027927	chr5:50259733	NA	0.44	6.55	0.33	2.12e-10	Callous-unemotional behaviour;
LIHC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.63	9.59	0.46	1.87e-19	Fibroblast growth factor basic levels;
LIHC	trans	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg25214090	chr10:38739885	LOC399744	0.44	6.95	0.35	1.9e-11	Diastolic blood pressure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18679782	chr19:10216839	SNORD105;PPAN-P2RY11;PPAN	-0.53	-6.11	-0.31	2.76e-9	Systolic blood pressure;
LIHC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-9.31	-0.45	1.61e-18	Heart rate;
LIHC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.57e-21	Bladder cancer;
LIHC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.52	-7.79	-0.39	7.98e-14	Total body bone mineral density;
LIHC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	13.87	0.6	5.03e-35	Multiple sclerosis;
LIHC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.88	-18.29	-0.7	1.33e-52	Height;
LIHC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	10.88	0.51	6.99e-24	Alzheimer's disease (late onset);
LIHC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.57	0.33	1.86e-10	Diastolic blood pressure;
LIHC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.88	-11.94	-0.54	1.03e-27	Post bronchodilator FEV1;
LIHC	cis	rs36051895	0.530	rs2093447	chr9:5230374	G/T	cg02405213	chr9:5042618	JAK2	-0.61	-8.95	-0.44	2.35e-17	Pediatric autoimmune diseases;
LIHC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg06565975	chr8:143823917	SLURP1	0.34	6.41	0.33	4.81e-10	Urinary tract infection frequency;
LIHC	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg00012203	chr2:219082015	ARPC2	0.91	15.08	0.63	9.78e-40	Colorectal cancer;
LIHC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.54	5.98	0.31	5.49e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-9.23	-0.45	2.85e-18	Platelet count;
LIHC	cis	rs11971779	0.774	rs7785906	chr7:139122652	T/C	cg07862535	chr7:139043722	LUC7L2	0.6	9.83	0.47	2.9e-20	Diisocyanate-induced asthma;
LIHC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.13	0.58	3.52e-32	Cognitive test performance;
LIHC	cis	rs9443189	1.000	rs1280044	chr6:76522602	A/G	cg01950844	chr6:76311363	SENP6	-0.5	-6.35	-0.32	6.97e-10	Prostate cancer;
LIHC	cis	rs249954	0.512	rs249867	chr16:23668568	G/A	cg09867953	chr16:23706666	ERN2	0.37	6.19	0.32	1.76e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.74	-0.54	5.89e-27	Total cholesterol levels;
LIHC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg27572855	chr1:25598939	RHD	0.41	8.88	0.43	3.87e-17	Plateletcrit;Mean corpuscular volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18017109	chr1:10458942	PGD	0.41	6.15	0.32	2.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12644436	0.534	rs34644026	chr4:88784821	A/G	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.72	-0.3	2.3e-8	Breast cancer;
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.61	0.34	1.45e-10	Renal cell carcinoma;
LIHC	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg03934865	chr2:198174659	NA	0.46	6.58	0.34	1.74e-10	Intracranial aneurysm;
LIHC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	0.94	15.95	0.65	3.43e-43	Testicular germ cell tumor;
LIHC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.6	-8.77	-0.43	8.27e-17	Testicular germ cell tumor;
LIHC	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.22	-5.84	-0.3	1.21e-8	Hepatitis;
LIHC	cis	rs2257205	0.588	rs7214266	chr17:56851920	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.61	-0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg07862535	chr7:139043722	LUC7L2	0.55	9.4	0.45	8.36e-19	Diisocyanate-induced asthma;
LIHC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg10756647	chr7:56101905	PSPH	1.01	11.79	0.54	3.67e-27	Gout;
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.69	9.38	0.45	9.59e-19	Aortic root size;
LIHC	cis	rs722599	0.501	rs10139347	chr14:75390135	T/C	cg11812906	chr14:75593930	NEK9	0.46	7.77	0.39	9e-14	IgG glycosylation;
LIHC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.78	8.98	0.44	1.8e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.13	-0.55	2.01e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.69	0.46	9.08e-20	Alzheimer's disease;
LIHC	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.65	6.88	0.35	2.89e-11	Type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.89	0.39	4.06e-14	Renal cell carcinoma;
LIHC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.23	6.16	0.32	2.04e-9	Calcium levels;
LIHC	cis	rs422249	0.634	rs174610	chr11:61627833	A/G	cg27386326	chr11:61587980	NA	0.36	6.54	0.33	2.19e-10	Trans fatty acid levels;
LIHC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.79	11.35	0.52	1.5e-25	Longevity;
LIHC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.59e-14	Parkinson's disease;
LIHC	cis	rs5753037	0.838	rs28749829	chr22:30219326	C/T	cg01021169	chr22:30184971	ASCC2	-0.34	-6.45	-0.33	3.75e-10	Type 1 diabetes;
LIHC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.31	0.37	1.86e-12	Aortic root size;
LIHC	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.06	-0.36	9.58e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.53	8.07	0.4	1.18e-14	Mean platelet volume;
LIHC	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-7.29	-0.37	2.18e-12	Platelet distribution width;
LIHC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg05941027	chr17:61774174	LIMD2	0.3	6.2	0.32	1.65e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg16989086	chr20:62203971	PRIC285	0.57	8.2	0.41	5.08e-15	Glioblastoma;
LIHC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.78	-0.34	5.41e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	8.27	0.41	2.94e-15	Platelet count;
LIHC	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	7.22	0.36	3.34e-12	Bipolar disorder;
LIHC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg06533319	chr4:3265114	C4orf44	0.32	5.73	0.3	2.26e-8	Parental longevity (mother's age at death);
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg04352962	chr1:209979756	IRF6	0.4	6.22	0.32	1.49e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.4	7.56	0.38	3.69e-13	Testicular germ cell tumor;
LIHC	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.42	0.45	7.02e-19	Bipolar disorder;
LIHC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	1.03	16.92	0.67	4.42e-47	Metabolic syndrome;
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg00656387	chr3:40428638	ENTPD3	0.44	7.16	0.36	4.81e-12	Renal cell carcinoma;
LIHC	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-8.36	-0.41	1.65e-15	Hepatocellular carcinoma;
LIHC	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg24069376	chr3:38537580	EXOG	0.43	7.9	0.39	3.93e-14	Electrocardiographic conduction measures;
LIHC	cis	rs55665837	0.519	rs10832297	chr11:14757737	C/A	cg19336497	chr11:14380999	RRAS2	-0.34	-5.74	-0.3	2.13e-8	Vitamin D levels;
LIHC	cis	rs55702914	0.935	rs17405525	chr2:198214183	C/G	cg10820045	chr2:198174542	NA	-0.38	-5.73	-0.3	2.24e-8	Major depression and alcohol dependence;
LIHC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.58	8.22	0.41	4.2e-15	Aortic root size;
LIHC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg16309518	chr5:176445507	NA	-0.51	-9.11	-0.44	7.04e-18	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg23091122	chr1:110024289	SYPL2	-0.49	-6.49	-0.33	2.97e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.53	6.1	0.31	2.93e-9	Alzheimer's disease;
LIHC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.92	9.63	0.46	1.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.44	0.33	4.12e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.83	-8.64	-0.42	2.25e-16	Macrophage inflammatory protein 1b levels;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg02581963	chr10:102133317	C10orf75	-0.44	-6.77	-0.34	5.7e-11	Morning vs. evening chronotype;
LIHC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg22079354	chr11:130786696	SNX19	0.41	5.82	0.3	1.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.65	-10.51	-0.49	1.47e-22	Blood trace element (Zn levels);
LIHC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg21466736	chr12:48725269	NA	-0.62	-9.15	-0.44	5.19e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.29	0.32	9.87e-10	Lung cancer in ever smokers;
LIHC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.93	-0.35	2.12e-11	Total body bone mineral density;
LIHC	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.22	6.03	0.31	4.25e-9	Calcium levels;
LIHC	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.49	-8.26	-0.41	3.17e-15	Cocaine dependence;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg20908993	chr14:67826378	EIF2S1;ATP6V1D	-0.42	-6.19	-0.32	1.71e-9	Body mass index;
LIHC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.5	-5.71	-0.3	2.42e-8	Pancreatic cancer;
LIHC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.4	0.37	1.06e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18357526	chr6:26021779	HIST1H4A	0.48	7.06	0.36	9.55e-12	Height;
LIHC	cis	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg19680485	chr15:31195859	MTMR15	-0.53	-5.88	-0.3	9.68e-9	Hypertriglyceridemia;
LIHC	cis	rs10916814	1.000	rs7365904	chr1:20904528	G/A	cg24502330	chr1:20914028	CDA	-0.3	-6.1	-0.31	2.8e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.39e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg05425664	chr17:57184151	TRIM37	-0.44	-6.16	-0.32	2e-9	Testicular germ cell tumor;
LIHC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg20569855	chr1:109824440	PSRC1	-0.47	-6.1	-0.31	2.93e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	0.8	6.12	0.31	2.5e-9	IgG glycosylation;
LIHC	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16684958	chr7:75615977	POR	0.39	6.42	0.33	4.61e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.96	-0.51	3.76e-24	Primary sclerosing cholangitis;
LIHC	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.93	7.14	0.36	5.5e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.28	-0.45	2.04e-18	Ulcerative colitis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16528022	chr14:65438707	RAB15	0.46	6.1	0.31	2.87e-9	Hepatitis;
LIHC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.42	-0.33	4.5e-10	Type 2 diabetes;
LIHC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.63	9.88	0.47	2.07e-20	Corneal astigmatism;
LIHC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-0.96	-22.7	-0.78	3.2e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.91	0.3	8.09e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs73186030	1.000	rs55838400	chr3:122032293	T/C	cg13973942	chr17:977984	ABR	0.47	6.06	0.31	3.6e-9	Serum parathyroid hormone levels;
LIHC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.41	-12.24	-0.55	7.93e-29	Hip circumference adjusted for BMI;
LIHC	cis	rs8062405	0.728	rs8056890	chr16:28897452	G/A	cg00204512	chr16:28754710	NA	0.34	6.1	0.31	2.79e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg07134254	chr20:33865797	NA	0.53	6.26	0.32	1.13e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	9.6	0.46	1.7e-19	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	cis	rs6596100	0.538	rs59682592	chr5:132196800	C/T	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	cis	rs9378688	0.654	rs2479004	chr6:2326765	A/G	cg12303981	chr6:2244766	GMDS	-0.45	-6.11	-0.31	2.69e-9	Caudate nucleus volume;
LIHC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg14580859	chr9:123691850	NA	0.39	6.85	0.35	3.54e-11	Rheumatoid arthritis;
LIHC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.16	0.63	4.65e-40	Chronic sinus infection;
LIHC	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.4	-7.4	-0.37	1.04e-12	Height;
LIHC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.52	-6.31	-0.32	8.48e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs7849581	1	rs7849581	chr9:9924724	A/G	cg17933722	chr1:116711077	NA	0.6	6.56	0.33	1.95e-10	Myopia (pathological);
LIHC	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs17106184	1.000	rs72904732	chr1:51342809	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.46	-0.33	3.52e-10	Type 2 diabetes;
LIHC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.47	7.95	0.4	2.71e-14	Mean corpuscular volume;
LIHC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg20933634	chr6:27740509	NA	0.49	6.4	0.33	5.26e-10	Parkinson's disease;
LIHC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.71	8.5	0.42	5.87e-16	Gut microbiome composition (summer);
LIHC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.88	-8.8	-0.43	6.97e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs722599	0.501	rs2286912	chr14:75385437	C/T	cg08847533	chr14:75593920	NEK9	-0.6	-10.25	-0.48	1.16e-21	IgG glycosylation;
LIHC	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.57	-8.68	-0.42	1.64e-16	QRS duration;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08677398	chr8:58056175	NA	0.41	6.47	0.33	3.34e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-9.51	-0.46	3.48e-19	Colorectal cancer;
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg11618577	chr2:27665543	KRTCAP3	-0.44	-5.97	-0.31	5.81e-9	Total body bone mineral density;
LIHC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.71	7.98	0.4	2.23e-14	Iron status biomarkers;
LIHC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.22	6.07	0.31	3.47e-9	Calcium levels;
LIHC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-1.06	-16.0	-0.65	2.14e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.58	9.96	0.47	1.12e-20	Colorectal cancer;
LIHC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.94	17.78	0.69	1.48e-50	Menopause (age at onset);
LIHC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.56	9.23	0.45	2.84e-18	Colorectal cancer;
LIHC	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg03934865	chr2:198174659	NA	0.45	6.51	0.33	2.76e-10	Dermatomyositis;
LIHC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.71	11.37	0.52	1.21e-25	Oral cavity cancer;
LIHC	cis	rs2412488	0.888	rs10028142	chr4:54331867	A/G	cg22241045	chr4:54363911	LNX1	-0.41	-6.65	-0.34	1.15e-10	DNA methylation (variation);
LIHC	cis	rs6448317	0.597	rs3843416	chr4:24903822	T/C	cg21108841	chr4:24914750	CCDC149	0.52	6.39	0.33	5.45e-10	Heschl's gyrus morphology;
LIHC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.44	-6.29	-0.32	9.94e-10	Dental caries;
LIHC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs11779988	0.516	rs426498	chr8:17897158	T/C	cg01800426	chr8:17659068	MTUS1	-0.44	-7.0	-0.35	1.34e-11	Breast cancer;
LIHC	cis	rs507080	0.922	rs478371	chr11:118565336	G/A	cg04173919	chr11:118528438	PHLDB1	0.36	6.63	0.34	1.3e-10	Serum metabolite levels;
LIHC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.81	-0.35	4.44e-11	IgG glycosylation;
LIHC	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.45	-9.01	-0.44	1.51e-17	Immature fraction of reticulocytes;
LIHC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.52	-0.38	5e-13	Platelet distribution width;
LIHC	cis	rs6596100	0.538	rs67504728	chr5:132194045	G/A	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08522065	chr12:46384600	SFRS2IP	-0.44	-6.27	-0.32	1.06e-9	Systolic blood pressure;
LIHC	cis	rs7487075	0.578	rs1492895	chr12:46808755	C/T	cg23829395	chr12:46796953	NA	0.35	6.26	0.32	1.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7635838	0.892	rs4684773	chr3:11418508	C/T	cg00170343	chr3:11313890	ATG7	0.44	7.0	0.35	1.4e-11	HDL cholesterol;
LIHC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.64	-9.12	-0.44	6.56e-18	Blood metabolite levels;
LIHC	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.06	-0.31	3.64e-9	Diastolic blood pressure;
LIHC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.38	-7.49	-0.38	5.95e-13	Urinary metabolites;
LIHC	cis	rs72990858	0.687	rs62418773	chr6:105173120	A/G	cg02098413	chr6:105308735	HACE1	-0.38	-5.75	-0.3	1.97e-8	Sporadic neuroblastoma;
LIHC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	1e-8	Life satisfaction;
LIHC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.59	10.53	0.49	1.23e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.47	6.37	0.33	6.06e-10	Obesity-related traits;
LIHC	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.47	6.14	0.32	2.34e-9	Glioblastoma;Glioma;
LIHC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.55	5.8	0.3	1.48e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.46e-27	Lymphocyte counts;
LIHC	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg11657440	chr19:46296263	DMWD	-0.44	-7.14	-0.36	5.77e-12	Coronary artery disease;
LIHC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.49	-8.89	-0.43	3.55e-17	Longevity;
LIHC	cis	rs11229555	0.645	rs12291551	chr11:58176915	T/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-8.41	-0.41	1.15e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.41	6.52	0.33	2.49e-10	Alzheimer's disease (survival time);
LIHC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.68e-15	Motion sickness;
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02290350	chr8:58132656	NA	0.51	9.6	0.46	1.75e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.54	8.58	0.42	3.3e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-14.7	-0.62	2.98e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.95	11.15	0.52	7.63e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.92	-0.3	7.91e-9	Ulcerative colitis;
LIHC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg23387056	chr11:14280742	SPON1	0.43	5.99	0.31	5.25e-9	Mitochondrial DNA levels;
LIHC	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.6	10.33	0.49	5.86e-22	Height;
LIHC	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg25356066	chr3:128598488	ACAD9	0.55	7.36	0.37	1.4e-12	IgG glycosylation;
LIHC	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg01843034	chr6:37503916	NA	-0.4	-6.58	-0.34	1.8e-10	Cognitive performance;
LIHC	cis	rs6545883	0.825	rs7578139	chr2:61564121	G/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.44	-0.37	7.95e-13	Tuberculosis;
LIHC	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg17507749	chr15:85114479	UBE2QP1	0.7	7.79	0.39	7.88e-14	Schizophrenia;
LIHC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg17771515	chr6:154831774	CNKSR3	0.54	6.02	0.31	4.46e-9	Lipoprotein (a) levels;
LIHC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-10.54	-0.5	1.12e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.61	0.34	1.45e-10	Ileal carcinoids;
LIHC	cis	rs1144333	0.655	rs7418941	chr1:76436020	A/G	cg10523679	chr1:76189770	ACADM	0.46	6.28	0.32	1.05e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg02023728	chr11:77925099	USP35	-0.33	-5.96	-0.31	6.23e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.41	6.09	0.31	3.04e-9	Height;
LIHC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.5	6.26	0.32	1.18e-9	Pancreatic cancer;
LIHC	cis	rs6586163	0.843	rs1926199	chr10:90746660	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.54	-7.82	-0.39	6.64e-14	Chronic lymphocytic leukemia;
LIHC	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.52	8.45	0.42	8.33e-16	Corneal astigmatism;
LIHC	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.08	-0.4	1.1e-14	Vitamin D levels;
LIHC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11645453	chr3:52864694	ITIH4	0.21	5.8	0.3	1.48e-8	Bipolar disorder;
LIHC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.85	0.57	4.31e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.82	9.29	0.45	1.88e-18	Vitiligo;
LIHC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-6.59	-0.34	1.65e-10	Hemoglobin concentration;
LIHC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg03721293	chr16:90014378	DEF8	0.42	7.1	0.36	7.25e-12	Skin colour saturation;
LIHC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.52	-9.69	-0.46	8.84e-20	Hemoglobin concentration;
LIHC	trans	rs3176789	0.671	rs10772128	chr12:9921868	G/A	cg18988856	chr7:99425577	CYP3A43	0.19	6.13	0.31	2.46e-9	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LIHC	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg02359409	chr6:42947317	PEX6	-0.45	-6.66	-0.34	1.11e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11645453	chr3:52864694	ITIH4	0.22	6.04	0.31	3.96e-9	Bipolar disorder;
LIHC	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg22771759	chr13:24902376	NA	0.31	6.44	0.33	3.98e-10	Obesity-related traits;
LIHC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.72	0.39	1.34e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.01	0.44	1.5e-17	IgG glycosylation;
LIHC	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.56	-8.63	-0.42	2.33e-16	Extraversion;
LIHC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-12.02	-0.54	5.34e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	12.1	0.55	2.66e-28	Mean platelet volume;
LIHC	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.15	0.32	2.21e-9	Schizophrenia;
LIHC	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.84	-13.42	-0.59	2.77e-33	Schizophrenia;
LIHC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	6.85	0.35	3.49e-11	Lung cancer in ever smokers;
LIHC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.79	12.54	0.56	5.98e-30	Corneal astigmatism;
LIHC	cis	rs35160687	0.644	rs9309635	chr2:86499402	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.36	-5.91	-0.3	8.09e-9	Night sleep phenotypes;
LIHC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg17980119	chr2:219472607	PLCD4	0.34	5.71	0.3	2.4e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04013166	chr16:89971882	TCF25	0.59	7.84	0.39	5.79e-14	Skin colour saturation;
LIHC	cis	rs422249	0.634	rs174614	chr11:61628915	T/C	cg27386326	chr11:61587980	NA	0.33	5.78	0.3	1.67e-8	Trans fatty acid levels;
LIHC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.77	12.29	0.55	5.32e-29	Colorectal cancer;
LIHC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.6	7.83	0.39	6.06e-14	Parkinson's disease;
LIHC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.47	-6.55	-0.33	2.08e-10	Initial pursuit acceleration;
LIHC	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.73	-0.3	2.2e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.1	11.26	0.52	3.23e-25	Opioid sensitivity;
LIHC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.71	0.3	2.43e-8	Self-reported allergy;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	trans	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.11	-0.36	7.02e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08280861	chr8:58055591	NA	-0.49	-6.2	-0.32	1.59e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg23682824	chr7:23144976	KLHL7	0.43	6.47	0.33	3.41e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-11.63	-0.53	1.48e-26	Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14407075	chr12:50794574	LARP4	0.5	6.61	0.34	1.45e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg16586182	chr3:47516702	SCAP	-0.58	-11.26	-0.52	3.21e-25	Colorectal cancer;
LIHC	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.72	9.52	0.46	3.3e-19	Coronary artery disease;
LIHC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.63	-0.38	2.34e-13	Bipolar disorder;
LIHC	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.36	-5.99	-0.31	5.21e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1000083	0.915	rs1000082	chr5:96533260	A/G	ch.5.96698337R	chr5:96672581	NA	0.87	6.94	0.35	1.96e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-5.76	-0.3	1.83e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05572930	chr6:125404126	RNF217	0.3	6.25	0.32	1.26e-9	Pancreatic cancer;
LIHC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.8	0.39	7.36e-14	Motion sickness;
LIHC	cis	rs1043515	1.000	rs1043515	chr17:36922196	C/T	cg09592244	chr17:37024020	NA	-0.41	-6.68	-0.34	9.49e-11	Height;
LIHC	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.43	-7.24	-0.36	2.99e-12	Coronary artery disease;
LIHC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg11057378	chr10:81107060	PPIF	0.36	6.01	0.31	4.64e-9	Height;
LIHC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.61	-9.06	-0.44	1.02e-17	Parkinson's disease;
LIHC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.96	17.27	0.68	1.68e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.65	-0.46	1.16e-19	Electroencephalogram traits;
LIHC	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.78	-0.47	4.53e-20	Breast cancer;
LIHC	cis	rs963731	0.522	rs1454222	chr2:39215895	C/A	cg04010122	chr2:39346883	SOS1	-0.69	-6.03	-0.31	4.14e-9	Corticobasal degeneration;
LIHC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.77	0.34	5.72e-11	Renal cell carcinoma;
LIHC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.65	-9.17	-0.44	4.59e-18	Body mass index;
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.69	0.57	1.67e-30	Prudent dietary pattern;
LIHC	cis	rs360798	0.512	rs2539978	chr2:63195179	T/C	cg17519650	chr2:63277830	OTX1	0.46	7.12	0.36	6.39e-12	Coronary artery disease;
LIHC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg05941027	chr17:61774174	LIMD2	0.32	6.54	0.33	2.25e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg03929089	chr4:120376271	NA	-0.46	-7.02	-0.35	1.21e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	1.05	15.38	0.64	6.23e-41	Breast cancer;
LIHC	cis	rs7818688	0.697	rs74633235	chr8:95981476	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg04627240	chr19:42746847	GSK3A	-0.42	-6.45	-0.33	3.92e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.67	-0.38	1.81e-13	Ulcerative colitis;
LIHC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.94	-0.31	6.93e-9	Schizophrenia;
LIHC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.37	5.97	0.31	5.97e-9	Blood metabolite levels;
LIHC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.6	-9.49	-0.46	4.02e-19	Multiple sclerosis;
LIHC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01200585	chr1:228362443	C1orf69	0.4	6.08	0.31	3.13e-9	Diastolic blood pressure;
LIHC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-8.36	-0.41	1.57e-15	Schizophrenia;
LIHC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.44	7.35	0.37	1.45e-12	Menarche (age at onset);
LIHC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.28	0.37	2.27e-12	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.44	-5.89	-0.3	9.06e-9	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11555122	chr17:5095235	ZNF594	-0.41	-6.05	-0.31	3.88e-9	Cognitive function;
LIHC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.63	8.43	0.41	9.770000000000001e-16	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg04025307	chr7:1156635	C7orf50	0.46	6.05	0.31	3.75e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs35883536	1.000	rs2282253	chr1:101094383	C/G	cg14515779	chr1:101123966	NA	-0.67	-13.12	-0.58	3.87e-32	Monocyte count;
LIHC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.87	-13.74	-0.6	1.58e-34	Body mass index;
LIHC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.12	0.31	2.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.59	-8.71	-0.43	1.34e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.82	0.35	4.02e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-11.28	-0.52	2.75e-25	Glomerular filtration rate (creatinine);
LIHC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-7.92	-0.39	3.46e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs831571	0.636	rs831565	chr3:64076358	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.53	6.76	0.34	5.93e-11	Type 2 diabetes;
LIHC	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.19e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg21756720	chr8:11724777	CTSB	-0.65	-6.65	-0.34	1.13e-10	Obesity-related traits;
LIHC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	1.05	15.71	0.65	2.87e-42	Breast cancer;
LIHC	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg20991723	chr1:152506922	NA	-0.53	-9.16	-0.44	4.82e-18	Hair morphology;
LIHC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.83	-11.73	-0.54	6.42e-27	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1494373	0.543	rs12410279	chr1:220851520	A/G	cg06786860	chr1:220876396	NA	-0.41	-6.1	-0.31	2.84e-9	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.78	-13.09	-0.58	5.12e-32	Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.49	6.13	0.31	2.48e-9	Alzheimer's disease;
LIHC	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.2	-0.32	1.67e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.64	9.95	0.47	1.18e-20	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.12	-13.54	-0.59	9.53e-34	Vitiligo;
LIHC	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.69	-11.21	-0.52	4.63e-25	Pediatric autoimmune diseases;
LIHC	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.57	-0.42	3.74e-16	Body mass index;
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.28	-0.32	1.02e-9	Schizophrenia;
LIHC	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	0.62	6.78	0.34	5.28e-11	Prostate cancer;
LIHC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.34	-8.82	-0.43	5.92e-17	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.54	6.27	0.32	1.11e-9	Mammographic density (dense area);
LIHC	cis	rs4862307	0.720	rs12650935	chr4:184989565	G/A	cg22054328	chr4:184930219	STOX2	0.35	5.95	0.31	6.78e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.96	-15.77	-0.65	1.67e-42	Body mass index;
LIHC	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.38	-0.33	5.62e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg00292662	chr22:38071168	LGALS1	0.64	8.48	0.42	6.74e-16	Fat distribution (HIV);
LIHC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg26395211	chr5:140044315	WDR55	0.39	5.72	0.3	2.29e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.38	7.54	0.38	4.13e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.54	7.55	0.38	3.98e-13	Pulse pressure;
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.53	8.07	0.4	1.24e-14	Longevity;
LIHC	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg00204748	chr12:29376779	FAR2	0.38	6.72	0.34	7.47e-11	QT interval;
LIHC	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.7	14.28	0.61	1.26e-36	Schizophrenia;
LIHC	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-0.67	-11.1	-0.51	1.14e-24	Pediatric autoimmune diseases;
LIHC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.45	-6.14	-0.32	2.31e-9	Blood pressure (smoking interaction);
LIHC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.13	0.31	2.47e-9	Blood metabolite levels;
LIHC	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg19773385	chr1:10388646	KIF1B	-0.34	-6.03	-0.31	4.33e-9	Hepatocellular carcinoma;
LIHC	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.22	-6.13	-0.31	2.48e-9	Type 2 diabetes;
LIHC	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg07959070	chr22:50026188	C22orf34	-0.3	-7.19	-0.36	4.03e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18804080	chr3:25705791	TOP2B	-0.41	-6.35	-0.32	6.93e-10	Cognitive function;
LIHC	trans	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg01596870	chr19:55963115	NA	-0.59	-6.83	-0.35	3.92e-11	Obesity-related traits;
LIHC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.72	11.57	0.53	2.31e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.02	17.38	0.68	6.31e-49	Testicular germ cell tumor;
LIHC	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg03934865	chr2:198174659	NA	0.42	5.93	0.31	7.6e-9	Dermatomyositis;
LIHC	cis	rs17152411	0.625	rs10901838	chr10:126623542	A/C	cg07906193	chr10:126599966	NA	-0.3	-5.77	-0.3	1.8e-8	Height;
LIHC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.23	-0.32	1.39e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.34	22.33	0.77	8.99e-69	Corneal structure;
LIHC	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.61	-9.77	-0.47	4.66e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs783540	0.934	rs803747	chr15:83258096	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.63	-0.34	1.33e-10	Schizophrenia;
LIHC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.35	-6.25	-0.32	1.2e-9	Aortic root size;
LIHC	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg26395211	chr5:140044315	WDR55	0.39	5.79	0.3	1.61e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4908768	0.906	rs11121182	chr1:8522553	G/T	cg25722041	chr1:8623473	RERE	0.45	6.59	0.34	1.67e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg17135325	chr3:160939158	NMD3	0.42	5.73	0.3	2.21e-8	Parkinson's disease;
LIHC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.36	8.32	0.41	2.16e-15	Crohn's disease;
LIHC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.72	13.24	0.58	1.37e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.51	5.74	0.3	2.11e-8	Primary sclerosing cholangitis;
LIHC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	11.04	0.51	1.93e-24	Type 2 diabetes;
LIHC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg10664184	chr19:17420304	DDA1	0.46	5.88	0.3	9.53e-9	Systemic lupus erythematosus;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01893041	chr5:67583972	PIK3R1	0.44	6.94	0.35	1.96e-11	Cognitive function;
LIHC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.6	7.25	0.37	2.79e-12	Cognitive function;
LIHC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.83	13.71	0.6	2.07e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.59	-8.75	-0.43	9.62e-17	Cognitive ability;
LIHC	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.58	9.59	0.46	1.9e-19	Corneal astigmatism;
LIHC	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.61	-11.1	-0.51	1.2e-24	Breast cancer;
LIHC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.85	12.94	0.57	1.85e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.95	12.37	0.56	2.58e-29	Bladder cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01428361	chr17:48556460	RSAD1	-0.43	-6.22	-0.32	1.47e-9	Cognitive function;
LIHC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	Cognitive function;
LIHC	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.45	-6.13	-0.31	2.42e-9	Total body bone mineral density;
LIHC	cis	rs9549328	0.879	rs12428058	chr13:113636504	G/A	cg08890338	chr13:113700818	MCF2L	-0.34	-5.72	-0.3	2.38e-8	Systolic blood pressure;
LIHC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	1.08	15.0	0.63	1.96e-39	Heart rate;
LIHC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg18121669	chr1:26560928	CCDC21	0.49	8.15	0.4	6.75e-15	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.55	8.25	0.41	3.44e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	11.73	0.54	6.32e-27	Platelet count;
LIHC	cis	rs2540917	0.728	rs243065	chr2:60622064	C/G	cg00543073	chr2:60773386	BCL11A	-0.33	-6.56	-0.33	2.02e-10	Mean corpuscular volume;
LIHC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.45	-7.89	-0.39	4.21e-14	Body mass index;
LIHC	cis	rs6442522	0.606	rs3773459	chr3:15495644	T/C	cg16303742	chr3:15540471	COLQ	0.39	6.3	0.32	9.08e-10	Uric acid levels;
LIHC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07305463	chr2:136567211	LCT	-0.38	-6.02	-0.31	4.47e-9	Corneal structure;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.7	10.02	0.48	6.91e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.39	-5.96	-0.31	6.12e-9	Blood pressure (smoking interaction);
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.11	0.52	1.06e-24	Prudent dietary pattern;
LIHC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.7	-10.03	-0.48	6.22e-21	Lung cancer in ever smokers;
LIHC	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg20194872	chr6:41519635	FOXP4	0.41	6.52	0.33	2.48e-10	Prostate cancer;
LIHC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg16586182	chr3:47516702	SCAP	0.48	8.45	0.42	8.71e-16	Colorectal cancer;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg07725925	chr16:89976287	TCF25	-0.42	-6.07	-0.31	3.37e-9	Skin colour saturation;
LIHC	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.55	5.82	0.3	1.35e-8	IgG glycosylation;
LIHC	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.51	-8.59	-0.42	3.06e-16	Pubertal anthropometrics;
LIHC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg12365402	chr11:9010492	NRIP3	0.23	5.82	0.3	1.33e-8	Hemoglobin concentration;
LIHC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.44	7.04	0.36	1.05e-11	Height;
LIHC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.82	-0.3	1.35e-8	Mean corpuscular volume;
LIHC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.57e-15	Bladder cancer;
LIHC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.51	-7.92	-0.39	3.34e-14	Blood trace element (Zn levels);
LIHC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.82	7.04	0.36	1.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg24579218	chr15:68104479	NA	-0.34	-5.94	-0.31	7.12e-9	Restless legs syndrome;
LIHC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.97	-17.64	-0.69	5.52e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08893839	chr5:154027129	NA	0.49	7.0	0.35	1.37e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg00686598	chr14:53173677	PSMC6	-0.79	-8.73	-0.43	1.17e-16	Alzheimer's disease (late onset);
LIHC	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.53	-5.99	-0.31	5.26e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs17106184	1.000	rs17106184	chr1:50909985	A/G	cg07174182	chr1:51127561	FAF1	0.59	6.77	0.34	5.7e-11	Type 2 diabetes;
LIHC	cis	rs12644436	0.628	rs1540587	chr4:88805810	G/A	cg06891869	chr4:88767617	MEPE	0.43	7.47	0.37	6.87e-13	HIV-1 viral setpoint;
LIHC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.49	7.08	0.36	8.14e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.49	6.62	0.34	1.39e-10	Coronary artery disease;
LIHC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.47	6.29	0.32	9.6e-10	Initial pursuit acceleration;
LIHC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg01629716	chr15:45996671	NA	0.51	9.21	0.45	3.44e-18	Waist circumference;Weight;
LIHC	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-0.7	-7.28	-0.37	2.26e-12	Putamen volume;
LIHC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.39	-0.33	5.51e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2574704	0.961	rs2616557	chr3:11658291	G/A	cg15876825	chr3:11651881	VGLL4	0.5	8.26	0.41	3.17e-15	Body mass index;
LIHC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg03859395	chr2:55845619	SMEK2	0.9	15.77	0.65	1.76e-42	Metabolic syndrome;
LIHC	cis	rs12022452	0.591	rs16827359	chr1:41001438	C/G	cg25568243	chr1:40974465	DEM1	-0.45	-5.93	-0.31	7.24e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg19302996	chr17:73780495	UNK	-0.47	-6.71	-0.34	7.92e-11	White matter hyperintensity burden;
LIHC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.46	-0.33	3.62e-10	Personality dimensions;
LIHC	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.55	9.59	0.46	1.86e-19	Systemic lupus erythematosus;
LIHC	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.78	14.69	0.62	3.25e-38	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.94	17.62	0.69	6.53e-50	Menopause (age at onset);
LIHC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.58	0.5	7.82e-23	Platelet count;
LIHC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.83	-11.78	-0.54	3.97e-27	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.61	-11.04	-0.51	2e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	trans	rs11157436	0.918	rs12437004	chr14:22617415	G/T	cg13567813	chr19:50879636	NR1H2	0.42	6.17	0.32	1.93e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.39e-8	Menopause (age at onset);
LIHC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.45	-0.33	3.78e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs17152411	1.000	rs12571196	chr10:126597749	A/C	cg07906193	chr10:126599966	NA	0.48	7.31	0.37	1.9e-12	Height;
LIHC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.46	7.75	0.39	1.07e-13	Mean corpuscular volume;
LIHC	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.7	-10.72	-0.5	2.59e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.69	9.66	0.46	1.12e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.25	-16.31	-0.66	1.18e-44	Diabetic kidney disease;
LIHC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.47	7.74	0.39	1.11e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg19318889	chr4:1322082	MAEA	0.42	5.77	0.3	1.81e-8	Obesity-related traits;
LIHC	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.48	7.01	0.35	1.26e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.42	6.1	0.31	2.81e-9	Schizophrenia;
LIHC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.47	-7.55	-0.38	4.12e-13	Neurofibrillary tangles;
LIHC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.06e-18	Bipolar disorder;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.48	-8.39	-0.41	1.28e-15	Total body bone mineral density;
LIHC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.09	-0.4	1.03e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg27211696	chr2:191398769	TMEM194B	-0.52	-6.92	-0.35	2.17e-11	Diastolic blood pressure;
LIHC	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg20240347	chr1:204465584	NA	-0.33	-7.0	-0.35	1.36e-11	Schizophrenia;
LIHC	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.69	-7.93	-0.39	3.15e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.76	-9.1	-0.44	7.89e-18	Neuroticism;
LIHC	cis	rs45544231	0.569	rs9302556	chr16:52543645	C/A	cg09051775	chr16:52580266	TOX3	-0.32	-5.77	-0.3	1.77e-8	Restless legs syndrome;
LIHC	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.87	18.25	0.7	1.98e-52	Testicular germ cell tumor;
LIHC	cis	rs116248771	0.549	rs4680461	chr3:158454160	C/G	cg16708174	chr3:158430962	RARRES1	0.7	8.95	0.44	2.38e-17	diarrhoeal disease at age 2;
LIHC	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.33	5.77	0.3	1.76e-8	Mean corpuscular volume;
LIHC	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-6.49	-0.33	2.94e-10	Schizophrenia;
LIHC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg20255370	chr15:40268687	EIF2AK4	-0.6	-8.1	-0.4	9.64e-15	Response to haloperidol in psychosis;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg05064044	chr6:292385	DUSP22	-0.53	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LIHC	cis	rs6141600	0.506	rs2590990	chr20:34671179	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.61	-0.34	1.48e-10	Height;Hip circumference;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.4	-0.41	1.23e-15	Renal cell carcinoma;
LIHC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.43	-6.07	-0.31	3.39e-9	Dental caries;
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.93	0.39	3.13e-14	Renal cell carcinoma;
LIHC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.72	-8.78	-0.43	7.96e-17	Morning vs. evening chronotype;
LIHC	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg12458913	chr13:53173898	NA	0.35	6.01	0.31	4.79e-9	Lewy body disease;
LIHC	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.56	-13.94	-0.6	2.85e-35	White blood cell count (basophil);
LIHC	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.59	9.66	0.46	1.08e-19	Corneal astigmatism;
LIHC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.55	8.18	0.4	5.71e-15	Pulse pressure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11381792	chr21:45432451	TRAPPC10	0.6	7.95	0.39	2.78e-14	Lung function (FEV1/FVC);
LIHC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20570016	chr1:156261298	TMEM79	-0.35	-5.75	-0.3	2.01e-8	Tonsillectomy;
LIHC	trans	rs6489882	0.867	rs4766665	chr12:113363109	T/C	cg10175203	chr3:128143634	NA	0.39	6.38	0.33	5.72e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.15	-0.52	7.67e-25	Eye color traits;
LIHC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.64	11.49	0.53	4.8e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs332507	0.601	rs7618562	chr3:124363001	A/G	cg05980111	chr3:124395277	KALRN	0.31	5.93	0.31	7.3e-9	Plateletcrit;
LIHC	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.47	-0.59	1.77e-33	Coffee consumption (cups per day);
LIHC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	0.83	9.32	0.45	1.51e-18	Vitiligo;
LIHC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg23431851	chr1:46668822	C1orf190;POMGNT1	-0.42	-6.79	-0.34	5.06e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.34	0.32	7.42e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.76	0.3	1.92e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg24036039	chr1:3397125	ARHGEF16	0.39	6.39	0.33	5.58e-10	Schizophrenia;
LIHC	cis	rs4728302	0.869	rs6969899	chr7:133597490	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.47	0.33	3.37e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.39	0.41	1.32e-15	Motion sickness;
LIHC	cis	rs9322817	0.669	rs4079063	chr6:105266118	A/G	cg02098413	chr6:105308735	HACE1	-0.43	-8.05	-0.4	1.34e-14	Thyroid stimulating hormone;
LIHC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-8.21	-0.41	4.61e-15	Gut microbiome composition (summer);
LIHC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	8.53	0.42	4.89e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.17e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs807669	0.770	rs807458	chr22:19220648	G/A	cg26795923	chr22:19165960	SLC25A1	0.81	6.41	0.33	4.7e-10	Metabolite levels;
LIHC	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.46	-6.93	-0.35	2.14e-11	Blood protein levels;
LIHC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg02269571	chr22:50332266	NA	0.61	8.64	0.42	2.24e-16	Schizophrenia;
LIHC	cis	rs1144333	1.000	rs1021464	chr1:76375415	G/A	cg10523679	chr1:76189770	ACADM	0.45	6.52	0.33	2.58e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.73	12.86	0.57	3.67e-31	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs6001982	0.541	rs56203629	chr22:41049685	T/A	cg14879645	chr22:41048474	NA	0.4	5.82	0.3	1.35e-8	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02158565	chr7:150788256	AGAP3	-0.53	-6.91	-0.35	2.44e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.95	0.51	4.18e-24	Morning vs. evening chronotype;
LIHC	cis	rs3740540	0.761	rs34042290	chr10:126286806	G/A	cg20435097	chr10:126320824	FAM53B	0.53	7.78	0.39	8.68e-14	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.71	-10.57	-0.5	8.53e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg17749961	chr2:30669863	LCLAT1	0.44	5.71	0.3	2.45e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.65	0.38	2.02e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg23043544	chr7:2124092	MAD1L1	-0.48	-7.88	-0.39	4.49e-14	Neuroticism;
LIHC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.07	9.61	0.46	1.62e-19	Diabetic retinopathy;
LIHC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.03	-0.31	4.34e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.54	5.81	0.3	1.4e-8	Alzheimer's disease;
LIHC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.61	9.1	0.44	7.85e-18	Recombination rate (females);
LIHC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.42	6.96	0.35	1.72e-11	Red blood cell count;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22037798	chr1:231473786	C1orf124;EXOC8	-0.49	-6.62	-0.34	1.38e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	9.15	0.44	5.39e-18	Body mass index (adult);
LIHC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.78e-8	Parkinson's disease;
LIHC	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.26	0.32	1.15e-9	Mean corpuscular volume;
LIHC	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg08539965	chr1:21396338	EIF4G3	0.32	5.77	0.3	1.81e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg10755058	chr3:40428713	ENTPD3	0.41	6.89	0.35	2.77e-11	Renal cell carcinoma;
LIHC	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.28	-6.11	-0.31	2.65e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs704795	0.702	rs11689803	chr2:27566520	T/A	cg27432699	chr2:27873401	GPN1	-0.65	-6.3	-0.32	9.19e-10	Menopause (age at onset);
LIHC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.49	7.77	0.39	9.03e-14	Methadone dose in opioid dependence;
LIHC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.58	8.42	0.41	1.08e-15	Bone properties (heel);
LIHC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.67	-14.01	-0.6	1.44e-35	Bipolar disorder;
LIHC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.97e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.77	-9.44	-0.45	6.02e-19	Gut microbiome composition (summer);
LIHC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg03037974	chr15:76606532	NA	-0.65	-11.53	-0.53	3.35e-26	Blood metabolite levels;
LIHC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.86e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.24	-0.45	2.67e-18	Schizophrenia;
LIHC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.37	-5.99	-0.31	5.22e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg09045935	chr12:6379348	NA	0.84	6.91	0.35	2.41e-11	Blood metabolite levels;
LIHC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg06238570	chr21:40685208	BRWD1	0.6	7.09	0.36	7.97e-12	Cognitive function;
LIHC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	0.89	20.2	0.74	2.71e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs1494950	1.000	rs7668863	chr4:15088863	G/A	cg12377275	chr4:15005593	CPEB2	-0.84	-7.49	-0.38	5.92e-13	Political ideology;
LIHC	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.26	-6.02	-0.31	4.57e-9	Heart rate;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.35	5.92	0.3	7.8e-9	Height;
LIHC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.79	11.95	0.54	9.51e-28	Monocyte percentage of white cells;
LIHC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.56	8.62	0.42	2.52e-16	Multiple sclerosis;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.07	16.04	0.66	1.47e-43	Cognitive function;
LIHC	cis	rs6539247	0.509	rs2374584	chr12:106445988	C/T	cg20883310	chr12:106464547	NUAK1	0.45	7.26	0.37	2.57e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.44	-6.4	-0.33	5.04e-10	Hepatocellular carcinoma;
LIHC	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.72	0.5	2.59e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs9290065	0.622	rs6797798	chr3:160646598	G/A	cg03342759	chr3:160939853	NMD3	0.6	8.14	0.4	7.31e-15	Kawasaki disease;
LIHC	cis	rs10861342	1.000	rs10861346	chr12:105473245	G/T	cg23923672	chr12:105501055	KIAA1033	0.61	7.38	0.37	1.2e-12	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.43	5.79	0.3	1.6e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.28e-14	Lymphocyte counts;
LIHC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.33	0.41	1.94e-15	Height;
LIHC	trans	rs11157436	0.958	rs3811277	chr14:22658313	C/T	cg13567813	chr19:50879636	NR1H2	0.43	6.14	0.32	2.26e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.54	0.53	3.17e-26	Motion sickness;
LIHC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg14829360	chr17:73884958	NA	-0.37	-6.25	-0.32	1.23e-9	White matter hyperintensity burden;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16919356	chr7:150780878	TMUB1	0.44	6.49	0.33	3.09e-10	Pancreatic cancer;
LIHC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.85	10.57	0.5	9e-23	Bladder cancer;
LIHC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.67	9.96	0.47	1.14e-20	Total body bone mineral density;
LIHC	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.35	7.04	0.36	1.09e-11	Multiple sclerosis;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg05110241	chr16:68378359	PRMT7	-0.51	-5.72	-0.3	2.37e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg16070018	chr6:26224392	HIST1H3E	0.51	6.92	0.35	2.26e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.24	-0.52	3.77e-25	Chronic sinus infection;
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.41	-0.33	4.81e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-0.84	-10.39	-0.49	3.56e-22	Blood pressure (smoking interaction);
LIHC	cis	rs7523273	0.925	rs10863593	chr1:208018074	C/T	cg22525895	chr1:207977042	MIR29B2	0.61	9.3	0.45	1.66e-18	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.49	-15.31	-0.64	1.14e-40	Breast cancer;
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-8.64	-0.42	2.22e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.16	0.48	2.35e-21	Diisocyanate-induced asthma;
LIHC	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg19920283	chr7:105172520	RINT1	0.47	5.97	0.31	5.97e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.81	12.8	0.57	6.53e-31	Longevity;
LIHC	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	0.74	8.61	0.42	2.8e-16	Exhaled nitric oxide output;
LIHC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.4	-0.33	5.06e-10	Schizophrenia;
LIHC	cis	rs258892	0.895	rs266437	chr5:72167441	G/C	cg21869765	chr5:72125136	TNPO1	0.39	5.75	0.3	1.93e-8	Small cell lung carcinoma;
LIHC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg10845886	chr2:3471009	TTC15	-0.44	-7.81	-0.39	6.99e-14	Neurofibrillary tangles;
LIHC	cis	rs11098699	0.769	rs13136692	chr4:124229169	G/A	cg09941581	chr4:124220074	SPATA5	0.33	6.59	0.34	1.68e-10	Mosquito bite size;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.89	0.6	4.43e-35	Primary sclerosing cholangitis;
LIHC	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.92	19.18	0.72	3.65e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.08	10.06	0.48	5.12e-21	Diabetic retinopathy;
LIHC	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg17971929	chr21:40555470	PSMG1	-0.38	-5.72	-0.3	2.29e-8	Menarche (age at onset);
LIHC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.86	9.5	0.46	3.93e-19	Alzheimer's disease;
LIHC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.74	10.01	0.48	7.59e-21	Body mass index;
LIHC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.38	0.59	3.85e-33	Chronic sinus infection;
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-9.78	-0.47	4.42e-20	Skin colour saturation;
LIHC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.08	18.76	0.71	1.68e-54	Testicular germ cell tumor;
LIHC	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-0.68	-11.41	-0.53	8.88e-26	Pediatric autoimmune diseases;
LIHC	cis	rs3780378	0.967	rs10815144	chr9:5010192	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-9.62	-0.46	1.46e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.3	5.84	0.3	1.19e-8	Red blood cell count;
LIHC	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.33	0.41	2.02e-15	Lung cancer in ever smokers;
LIHC	cis	rs75064307	0.834	rs4855562	chr3:108116835	C/T	cg03329597	chr3:108125523	MYH15	0.52	7.09	0.36	7.55e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26084319	chr14:21905280	CHD8	0.56	7.95	0.39	2.66e-14	Pancreatic cancer;
LIHC	cis	rs2834256	0.552	rs7276923	chr21:34868761	A/G	cg14850771	chr21:34775459	IFNGR2	0.47	7.77	0.39	9.31e-14	Red cell distribution width;
LIHC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.46	-9.13	-0.44	5.9e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.22	0.52	4.31e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.16	-0.44	4.85e-18	Schizophrenia;
LIHC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.57	-9.5	-0.46	3.9e-19	Colorectal cancer;
LIHC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.55	-0.53	2.7e-26	Coronary artery disease;
LIHC	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.65	6.73	0.34	6.98e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.51	7.57	0.38	3.55e-13	Type 2 diabetes;
LIHC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-9.01	-0.44	1.48e-17	Colorectal cancer;
LIHC	cis	rs4789452	0.934	rs3987888	chr17:75370274	T/C	cg05865280	chr17:75406074	SEPT9	0.35	7.5	0.38	5.49e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-6.08	-0.31	3.13e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14624505	chr17:4843538	SLC25A11;RNF167	-0.52	-6.09	-0.31	3.08e-9	Systolic blood pressure;
LIHC	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.57	-8.9	-0.43	3.42e-17	Extraversion;
LIHC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.44	-7.5	-0.38	5.51e-13	Mean corpuscular volume;
LIHC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.51	-7.53	-0.38	4.48e-13	Total body bone mineral density;
LIHC	cis	rs151997	0.925	rs27286	chr5:50196324	G/T	cg06027927	chr5:50259733	NA	0.57	7.58	0.38	3.33e-13	Callous-unemotional behaviour;
LIHC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.5e-12	Obesity-related traits;
LIHC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.65	-6.59	-0.34	1.64e-10	Lymphocyte counts;
LIHC	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.6	-8.17	-0.4	6.2e-15	Coronary artery disease;
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.77	0.47	4.84e-20	Lymphocyte counts;
LIHC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg06784218	chr1:46089804	CCDC17	0.37	6.05	0.31	3.74e-9	Platelet count;
LIHC	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.44	-6.54	-0.33	2.19e-10	Facial emotion recognition (sad faces);
LIHC	trans	rs2270927	0.510	rs2972839	chr5:75572943	C/T	cg13563193	chr19:33072644	PDCD5	0.85	8.01	0.4	1.83e-14	Mean corpuscular volume;
LIHC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	7.42	0.37	9.22e-13	Menarche (age at onset);
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg15893493	chr8:124194847	FAM83A	0.81	7.81	0.39	7.07e-14	Urinary uromodulin levels;
LIHC	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.94	-10.34	-0.49	5.3e-22	Platelet distribution width;
LIHC	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg09417038	chr21:47716443	C21orf57	-0.5	-7.69	-0.38	1.62e-13	Testicular germ cell tumor;
LIHC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg15848620	chr12:58087721	OS9	-0.54	-7.31	-0.37	1.9e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg14515779	chr1:101123966	NA	-0.7	-14.08	-0.61	7.92e-36	Monocyte count;
LIHC	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.7	8.95	0.44	2.37e-17	Exhaled nitric oxide output;
LIHC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.25	6.4	0.33	5.19e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.16	-0.32	2.08e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.18	-0.36	4.44e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs8117834	0.574	rs6118062	chr20:8087581	T/C	cg00593689	chr4:53575888	NA	0.38	6.38	0.33	5.83e-10	Chronic kidney disease;
LIHC	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.47	7.48	0.38	6.16e-13	Height;
LIHC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs57590327	0.679	rs62265397	chr3:81543883	A/T	cg07356753	chr3:81810745	GBE1	-0.43	-5.97	-0.31	5.79e-9	Extraversion;
LIHC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.5	0.38	5.69e-13	Mean platelet volume;
LIHC	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.38	6.21	0.32	1.57e-9	Lung cancer;
LIHC	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.39	-5.98	-0.31	5.63e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs965469	0.553	rs6051767	chr20:3324521	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-7.42	-0.37	9.33e-13	IFN-related cytopenia;
LIHC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.73	-6.86	-0.35	3.32e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg12798992	chr6:167411361	FGFR1OP	0.52	8.05	0.4	1.37e-14	Crohn's disease;
LIHC	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.7	-7.69	-0.38	1.63e-13	Exhaled nitric oxide output;
LIHC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	1.05	12.51	0.56	8.16e-30	Cannabis dependence symptom count;
LIHC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.52	-7.59	-0.38	3.07e-13	Platelet count;
LIHC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-9.24	-0.45	2.67e-18	Gut microbiome composition (summer);
LIHC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.5	-7.91	-0.39	3.55e-14	Schizophrenia;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.75	10.54	0.5	1.1e-22	Menarche (age at onset);
LIHC	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.4	6.61	0.34	1.46e-10	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	cis	rs12022452	0.630	rs3795346	chr1:40974425	T/C	cg25568243	chr1:40974465	DEM1	0.45	6.07	0.31	3.37e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg20607798	chr8:58055168	NA	0.47	6.45	0.33	3.79e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	0.91	6.54	0.33	2.26e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.45	0.56	1.39e-29	Menopause (age at onset);
LIHC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-9.89	-0.47	1.87e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg02990361	chr1:107599529	PRMT6	-0.59	-9.53	-0.46	2.99e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.35	-6.68	-0.34	9.61e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.39	6.2	0.32	1.63e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.87	0.57	3.48e-31	Prudent dietary pattern;
LIHC	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.8	9.07	0.44	9.78e-18	Vitiligo;
LIHC	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.57	10.5	0.49	1.59e-22	Lewy body disease;
LIHC	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.52	7.95	0.39	2.75e-14	Corneal astigmatism;
LIHC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	1.04	11.8	0.54	3.42e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.46e-17	Lung cancer in ever smokers;
LIHC	cis	rs600806	0.778	rs2152924	chr1:110011701	G/A	cg16275483	chr1:110013120	SYPL2	-0.49	-6.22	-0.32	1.42e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.25	-7.66	-0.38	1.96e-13	Mean corpuscular volume;
LIHC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.5	-8.61	-0.42	2.69e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.25	0.48	1.1e-21	Resting heart rate;
LIHC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.45	-7.5	-0.38	5.38e-13	Neuroticism;
LIHC	cis	rs8084351	0.577	rs9952089	chr18:50619266	A/G	cg24270629	chr18:50823537	DCC	0.43	6.54	0.33	2.25e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.79	13.85	0.6	5.96e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs8033655	0.963	rs2899446	chr15:50307416	A/G	cg10099229	chr12:6960622	USP5;CDCA3	0.43	6.16	0.32	2.01e-9	Skin pigmentation;
LIHC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg12798992	chr6:167411361	FGFR1OP	0.43	6.45	0.33	3.85e-10	Crohn's disease;
LIHC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.52	7.65	0.38	2e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.54	-8.32	-0.41	2.19e-15	Urinary tract infection frequency;
LIHC	trans	rs4799915	1.000	rs3865392	chr18:34929464	G/T	cg11874882	chr17:31910113	ACCN1	-0.26	-6.08	-0.31	3.14e-9	Response to iloperidone treatment (QT prolongation);
LIHC	cis	rs11971779	0.715	rs6467853	chr7:139127027	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	9.92	0.47	1.46e-20	Diisocyanate-induced asthma;
LIHC	cis	rs7712401	0.791	rs6887101	chr5:122109207	C/T	cg18764291	chr5:122110994	SNX2	-0.36	-6.25	-0.32	1.19e-9	Mean platelet volume;
LIHC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.38	5.76	0.3	1.83e-8	Prostate cancer;
LIHC	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.63	10.2	0.48	1.72e-21	Corneal astigmatism;
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.68	9.83	0.47	2.97e-20	Menarche (age at onset);
LIHC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.31	6.44	0.33	4.13e-10	Bone mineral density;
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.31	-0.37	1.87e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.4	-6.96	-0.35	1.77e-11	Platelet distribution width;
LIHC	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg03868770	chr22:30783737	RNF215	-0.47	-6.14	-0.32	2.3e-9	Tonsillectomy;
LIHC	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.08	-0.31	3.22e-9	Tuberculosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22627950	chr7:44622302	TMED4	0.41	6.27	0.32	1.08e-9	Cognitive function;
LIHC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.37	5.79	0.3	1.57e-8	Menopause (age at onset);
LIHC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.32	-6.33	-0.32	7.83e-10	Colorectal cancer;
LIHC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26734620	chr12:56694298	CS	-0.98	-9.85	-0.47	2.57e-20	Psoriasis vulgaris;
LIHC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16262614	chr3:133464971	TF	-0.37	-7.99	-0.4	2.08e-14	Iron status biomarkers;
LIHC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-6.72	-0.34	7.55e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.99	-0.4	2.13e-14	Lymphocyte counts;
LIHC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.41	6.49	0.33	3.11e-10	Gout;
LIHC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.45	-7.45	-0.37	7.46e-13	Breast cancer;
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg00106254	chr7:1943704	MAD1L1	0.4	6.28	0.32	1.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11112613	0.609	rs4388999	chr12:106047758	G/T	cg03607813	chr12:105948248	NA	0.4	6.27	0.32	1.11e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23296058	chr5:86708877	CCNH	0.46	6.06	0.31	3.6e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	1.03	13.28	0.58	9.93e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.78	-0.34	5.18e-11	Personality dimensions;
LIHC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.6	-7.44	-0.37	8.39e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.4	-6.29	-0.32	9.87e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs77861329	1.000	rs13319566	chr3:52095555	C/G	cg08692210	chr3:52188851	WDR51A	0.84	7.93	0.39	3.05e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs4742903	1.000	rs3739736	chr9:106857908	G/A	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.51	-8.96	-0.44	2.14e-17	Total body bone mineral density;
LIHC	cis	rs10454142	0.700	rs72820427	chr2:48585506	C/T	cg15846641	chr2:48541264	FOXN2	0.48	5.91	0.3	8.49e-9	Sex hormone-binding globulin levels;
LIHC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	6.16	0.32	2.08e-9	Schizophrenia;
LIHC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	7.73	0.39	1.18e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg26395211	chr5:140044315	WDR55	0.41	6.15	0.32	2.17e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.94	17.86	0.69	7.08e-51	Menopause (age at onset);
LIHC	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg19752551	chr11:57585705	CTNND1	-0.5	-6.93	-0.35	2.1e-11	Schizophrenia;
LIHC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00815214	chr21:47717953	NA	-0.36	-5.85	-0.3	1.16e-8	Testicular germ cell tumor;
LIHC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.28	-0.37	2.26e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.36	7.83	0.39	6.24e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg25358565	chr5:93447407	FAM172A	0.92	6.39	0.33	5.58e-10	Diabetic retinopathy;
LIHC	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg00277334	chr10:82204260	NA	-0.54	-6.68	-0.34	9.51e-11	Post bronchodilator FEV1;
LIHC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg23367146	chr19:21773418	NA	0.39	6.22	0.32	1.49e-9	Pain;
LIHC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.4	-7.53	-0.38	4.55e-13	Total body bone mineral density;
LIHC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.51	8.31	0.41	2.32e-15	Corneal astigmatism;
LIHC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.65	-8.06	-0.4	1.32e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7192750	0.586	rs4788584	chr16:71993386	A/T	cg06353428	chr16:71660113	MARVELD3	0.81	9.13	0.44	6.3e-18	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.06	0.4	1.29e-14	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.66	0.65	4.89e-42	Chronic sinus infection;
LIHC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.82	10.54	0.5	1.12e-22	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg03013999	chr17:37608204	MED1	0.36	5.96	0.31	6.44e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.6	7.53	0.38	4.63e-13	Heart rate;
LIHC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.75	11.4	0.52	1.01e-25	Corneal astigmatism;
LIHC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg19752551	chr11:57585705	CTNND1	-0.47	-5.99	-0.31	5.22e-9	Blood protein levels;
LIHC	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.57	6.79	0.34	4.97e-11	Mammographic density (dense area);
LIHC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.93	-0.31	7.33e-9	Arsenic metabolism;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.78	0.43	8.02e-17	Prudent dietary pattern;
LIHC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.61	-8.55	-0.42	4.09e-16	Blood metabolite levels;
LIHC	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.33	0.32	7.76e-10	Response to antipsychotic treatment;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg27088449	chr22:21272634	CRKL	-0.36	-6.06	-0.31	3.54e-9	Body mass index;
LIHC	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.4	7.52	0.38	4.84e-13	Testicular germ cell tumor;
LIHC	cis	rs4700695	1.000	rs4700695	chr5:65411710	G/T	cg21114390	chr5:65439923	SFRS12	-0.47	-5.98	-0.31	5.48e-9	Facial morphology (factor 19);
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg03721293	chr16:90014378	DEF8	0.42	7.0	0.35	1.34e-11	Skin colour saturation;
LIHC	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	9.39e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	8.04e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.45	-0.33	3.86e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00435469	chr11:1495117	HCCA2	-0.44	-6.99	-0.35	1.41e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg24296786	chr1:45957014	TESK2	0.51	7.32	0.37	1.75e-12	High light scatter reticulocyte count;
LIHC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-11.95	-0.54	9.7e-28	Height;
LIHC	cis	rs3015497	0.789	rs3015502	chr14:51108427	T/C	cg09863266	chr14:51125203	SAV1	-0.42	-6.77	-0.34	5.78e-11	Mean platelet volume;
LIHC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg16586182	chr3:47516702	SCAP	-0.47	-8.5	-0.42	6.1e-16	Colorectal cancer;
LIHC	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.64	9.11	0.44	7.11e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.67	-9.83	-0.47	2.95e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs61712019	0.679	rs13025471	chr2:77729571	T/A	cg11252801	chr2:77748917	LRRTM4	0.53	7.2	0.36	3.97e-12	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg07424592	chr7:64974309	NA	0.74	8.56	0.42	3.98e-16	Diabetic kidney disease;
LIHC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10556349	chr10:835070	NA	0.67	5.85	0.3	1.13e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs2997447	0.761	rs79778025	chr1:26449337	A/G	cg19633962	chr1:26362018	EXTL1	-0.67	-6.2	-0.32	1.66e-9	QRS complex (12-leadsum);
LIHC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.26	-0.32	1.16e-9	Morning vs. evening chronotype;
LIHC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.45	7.19	0.36	4.16e-12	Heart rate;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11792649	chr11:68664631	MRPL21	0.47	7.13	0.36	5.94e-12	Longevity;
LIHC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.53	-0.76	1.36e-65	Height;
LIHC	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.91	0.35	2.42e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1419980	0.730	rs1558532	chr12:7735804	G/T	cg10578777	chr12:7781093	NA	-0.4	-5.81	-0.3	1.42e-8	HDL cholesterol levels;
LIHC	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26734620	chr12:56694298	CS	-1.23	-10.54	-0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs17125944	0.686	rs7158114	chr14:53353471	C/G	cg00686598	chr14:53173677	PSMC6	-0.78	-8.8	-0.43	6.93e-17	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg20607798	chr8:58055168	NA	0.45	6.11	0.31	2.7e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.28	0.45	2.02e-18	Corneal astigmatism;
LIHC	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs4671400	0.571	rs4672429	chr2:61495469	G/C	cg14146966	chr2:61757674	XPO1	-0.36	-5.76	-0.3	1.92e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27297192	chr10:134578999	INPP5A	0.54	7.38	0.37	1.21e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg03854865	chr6:26224070	HIST1H3E	0.59	6.47	0.33	3.31e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26897989	chr16:1907736	C16orf73	-0.5	-6.18	-0.32	1.84e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.09	0.36	7.74e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12924588	chr2:68694517	APLF;FBXO48	-0.39	-6.04	-0.31	4.07e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	0.833	rs11032804	chr11:34680598	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.97	-0.31	5.82e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs6586163	1.000	rs1926195	chr10:90753758	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-8.58	-0.42	3.37e-16	Chronic lymphocytic leukemia;
LIHC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.6	-10.89	-0.51	6.72e-24	Alcohol dependence;
LIHC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02290350	chr8:58132656	NA	0.4	8.21	0.41	4.42e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.87	15.99	0.65	2.32e-43	Height;
LIHC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.49	0.38	5.8e-13	Bone mineral density;
LIHC	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	5.99	0.31	5.31e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-11.43	-0.53	7.73e-26	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg00091569	chr3:40428383	ENTPD3	0.4	6.88	0.35	2.82e-11	Renal cell carcinoma;
LIHC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg07451762	chr16:28383216	NA	0.32	6.14	0.31	2.33e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.39	7.9	0.39	3.81e-14	Renal cell carcinoma;
LIHC	cis	rs3791406	0.500	rs11124180	chr2:240031909	C/G	cg14550559	chr2:240039617	HDAC4	-0.67	-8.38	-0.41	1.36e-15	Skin aging (microtopography measurement);
LIHC	cis	rs4919087	0.532	rs61861850	chr10:99073874	C/A	cg25902810	chr10:99078978	FRAT1	-0.6	-7.1	-0.36	7.33e-12	Monocyte count;
LIHC	cis	rs16958440	0.867	rs12386092	chr18:44672058	C/T	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg14593290	chr7:50529359	DDC	0.4	6.7	0.34	8.81e-11	Malaria;
LIHC	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.9	11.19	0.52	5.41e-25	Coronary artery disease;
LIHC	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-0.77	-8.64	-0.42	2.25e-16	Alzheimer's disease (late onset);
LIHC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.73	10.81	0.5	1.27e-23	Corneal astigmatism;
LIHC	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	1.0	12.15	0.55	1.81e-28	Red blood cell traits;
LIHC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg14709524	chr16:89940631	TCF25	0.47	5.85	0.3	1.13e-8	Skin colour saturation;
LIHC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.42	-5.9	-0.3	8.82e-9	Height;
LIHC	cis	rs2569991	0.891	rs361224	chr3:12922313	C/T	cg22481960	chr3:13008800	IQSEC1	-0.38	-6.46	-0.33	3.69e-10	Periodontitis (DPAL);
LIHC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-6.73	-0.34	7.11e-11	Fear of minor pain;
LIHC	cis	rs1198430	0.683	rs534417	chr1:23784965	A/G	cg19827787	chr1:23763612	ASAP3	0.29	6.16	0.32	2e-9	Total cholesterol levels;
LIHC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.34	-6.73	-0.34	7.15e-11	Body mass index;
LIHC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg23533926	chr12:111358616	MYL2	-0.32	-6.12	-0.31	2.61e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.78	10.9	0.51	6.05e-24	Pediatric areal bone mineral density (radius);
LIHC	cis	rs3770081	1.000	rs60649958	chr2:86283000	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.03	0.31	4.36e-9	Facial emotion recognition (sad faces);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11790551	chr10:134593345	INPP5A	-0.39	-6.12	-0.31	2.57e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.47	7.08	0.36	8.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.23	0.64	2.5e-40	Menopause (age at onset);
LIHC	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg03929089	chr4:120376271	NA	0.61	6.45	0.33	3.75e-10	Body mass index;
LIHC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.75	10.73	0.5	2.33e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.36	5.93	0.31	7.32e-9	Height;
LIHC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.82	-0.35	4.1e-11	Menarche (age at onset);
LIHC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.6	10.21	0.48	1.5e-21	Height;
LIHC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.25	0.52	3.36e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.57	8.33	0.41	1.98e-15	Blood metabolite levels;
LIHC	cis	rs787274	1.000	rs4979148	chr9:115553399	C/T	cg13803584	chr9:115635662	SNX30	-0.6	-6.68	-0.34	9.69e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.42	-6.15	-0.32	2.22e-9	Leprosy;
LIHC	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	8.72	0.43	1.23e-16	Eosinophil percentage of white cells;
LIHC	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.02	-0.44	1.33e-17	Capecitabine sensitivity;
LIHC	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.45	7.34	0.37	1.55e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.57	8.08	0.4	1.15e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.53	-7.96	-0.4	2.5e-14	Body mass index;
LIHC	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.45	8.03	0.4	1.54e-14	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.66	0.53	1.1e-26	Motion sickness;
LIHC	cis	rs11673344	0.582	rs114437741	chr19:37446281	G/C	cg27390819	chr19:37464633	NA	-0.53	-6.38	-0.33	5.79e-10	Obesity-related traits;
LIHC	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.51	9.67	0.46	1.02e-19	Testicular germ cell tumor;
LIHC	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg24112000	chr20:60950667	NA	0.43	6.91	0.35	2.41e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-8.49	-0.42	6.23e-16	Corneal structure;
LIHC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg16479474	chr6:28041457	NA	0.47	7.16	0.36	4.85e-12	Parkinson's disease;
LIHC	cis	rs12980942	0.935	rs34075897	chr19:41826598	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.93	0.31	7.49e-9	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.34	6.14	0.32	2.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.63	-9.0	-0.44	1.58e-17	White matter hyperintensity burden;
LIHC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.56	-10.88	-0.51	6.87e-24	Coronary artery disease;
LIHC	cis	rs77637988	0.604	rs7566239	chr2:48598882	G/A	cg15846641	chr2:48541264	FOXN2	0.58	7.96	0.4	2.61e-14	Joint mobility (Beighton score);
LIHC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.83	-16.81	-0.67	1.15e-46	Height;
LIHC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.45	6.03	0.31	4.22e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.46	7.42	0.37	9.07e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.75	7.79	0.39	7.89e-14	Vitiligo;
LIHC	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg08992911	chr2:238395768	MLPH	0.49	5.89	0.3	9.14e-9	Prostate cancer;
LIHC	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Blood protein levels;
LIHC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg05501817	chr11:14380813	RRAS2	-0.45	-6.28	-0.32	1.01e-9	Sense of smell;
LIHC	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.15	-0.36	5.19e-12	Migraine;Coronary artery disease;
LIHC	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.53	-8.31	-0.41	2.26e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.41	6.13	0.31	2.36e-9	Height;
LIHC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.03e-19	Hemoglobin concentration;
LIHC	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	0.65	7.49	0.38	5.75e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs244293	0.862	rs11079146	chr17:53094122	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.47	0.37	6.77e-13	Menarche (age at onset);
LIHC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.64	11.51	0.53	3.76e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs11627756	0.957	rs12434778	chr14:103142135	G/T	cg12046867	chr14:103022105	NA	0.39	5.95	0.31	6.76e-9	Mean platelet volume;
LIHC	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03517284	chr6:25882590	NA	0.48	6.42	0.33	4.5e-10	Blood metabolite levels;
LIHC	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.65	10.56	0.5	9.67e-23	Phospholipid levels (plasma);
LIHC	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg10820045	chr2:198174542	NA	-0.5	-7.71	-0.38	1.43e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.69	12.19	0.55	1.21e-28	Lewy body disease;
LIHC	cis	rs7250872	0.606	rs2289286	chr19:1822668	T/C	cg18850929	chr19:1828978	REXO1	0.4	6.45	0.33	3.88e-10	Bipolar disorder;
LIHC	cis	rs11871801	0.881	rs2071046	chr17:40689613	G/C	cg14558262	chr17:40713999	COASY	-0.51	-6.98	-0.35	1.56e-11	Crohn's disease;
LIHC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg23461800	chr14:103021989	NA	-0.42	-5.87	-0.3	1.03e-8	Platelet count;
LIHC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.63	-11.24	-0.52	3.79e-25	Dental caries;
LIHC	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.26	6.56	0.33	2e-10	Menarche (age at onset);
LIHC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.74	-0.43	1.1e-16	Blood protein levels;
LIHC	cis	rs3736485	0.808	rs55982453	chr15:51951245	C/T	cg08986416	chr15:51914746	DMXL2	-0.43	-6.05	-0.31	3.8e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs151997	1.000	rs152854	chr5:50223206	G/A	cg06027927	chr5:50259733	NA	-0.58	-7.79	-0.39	8.07e-14	Callous-unemotional behaviour;
LIHC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.48e-18	Hemoglobin concentration;
LIHC	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg10756647	chr7:56101905	PSPH	1.01	11.98	0.54	7.24e-28	Diabetic kidney disease;
LIHC	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.27	6.4	0.33	5e-10	Heart rate;
LIHC	cis	rs8083850	0.637	rs2879514	chr18:50846240	T/G	cg24270629	chr18:50823537	DCC	0.53	7.91	0.39	3.71e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07491203	chr7:155089714	INSIG1	0.47	6.29	0.32	9.8e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.53	6.57	0.33	1.88e-10	Menarche (age at onset);
LIHC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg03037974	chr15:76606532	NA	0.76	14.77	0.62	1.62e-38	Blood metabolite levels;
LIHC	cis	rs903552	0.800	rs8026048	chr15:102006353	G/A	cg25677261	chr15:102009856	PCSK6	-0.49	-6.73	-0.34	7.35e-11	Diabetic kidney disease;
LIHC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	12.24	0.55	8.44e-29	Cognitive test performance;
LIHC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.84	-0.51	1.02e-23	Primary sclerosing cholangitis;
LIHC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.6e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	0.96	19.67	0.73	3.65e-58	Schizophrenia;
LIHC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02290350	chr8:58132656	NA	0.4	8.69	0.43	1.48e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.74	14.32	0.61	9.3e-37	Mortality in heart failure;
LIHC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.38	1.4e-13	Glioblastoma;
LIHC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.37	-6.43	-0.33	4.25e-10	IgG glycosylation;
LIHC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg18809830	chr7:99032528	PTCD1	-0.82	-6.37	-0.33	5.95e-10	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07936541	chr2:98206095	ANKRD36B	0.46	7.05	0.36	9.71e-12	Cognitive function;
LIHC	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.69	6.69	0.34	8.95e-11	Migraine;Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg00280220	chr17:61926910	NA	0.4	6.49	0.33	2.94e-10	Prudent dietary pattern;
LIHC	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.55	-0.33	2.16e-10	Hepatocellular carcinoma;
LIHC	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg04865290	chr3:52927548	TMEM110	-0.41	-6.25	-0.32	1.23e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg23517279	chr6:96025343	MANEA	-0.48	-6.37	-0.33	5.97e-10	Electroencephalogram traits;
LIHC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-8.98	-0.44	1.87e-17	Heart rate;
LIHC	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg04511125	chr2:88470314	THNSL2	0.94	10.34	0.49	5.66e-22	Plasma clusterin levels;
LIHC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.55	8.78	0.43	7.98e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.25	0.55	7.23e-29	Eye color traits;
LIHC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.36	6.27	0.32	1.08e-9	Height;
LIHC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	1.01	19.37	0.72	5.94e-57	Breast cancer;
LIHC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.82	0.35	4.16e-11	Diabetic kidney disease;
LIHC	cis	rs7953249	0.791	rs10774579	chr12:121405210	T/C	cg02403541	chr12:121454288	C12orf43	-0.32	-5.74	-0.3	2.06e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.9	15.31	0.64	1.17e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-19.97	-0.73	2.24e-59	Height;
LIHC	trans	rs6489882	0.807	rs1859333	chr12:113370966	T/C	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.75	11.34	0.52	1.56e-25	Corneal astigmatism;
LIHC	cis	rs17428076	0.793	rs3770449	chr2:172692048	C/T	cg13550731	chr2:172543902	DYNC1I2	0.38	6.2	0.32	1.65e-9	Myopia;
LIHC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.86	13.38	0.59	3.95e-33	Vitamin D levels;
LIHC	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-10.32	-0.49	6.61e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.73	-11.01	-0.51	2.42e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.7	0.34	8.36e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.67	13.28	0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02985541	chr2:219472218	PLCD4	0.41	7.0	0.35	1.34e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.39	-6.01	-0.31	4.66e-9	Blood pressure (smoking interaction);
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21747090	chr2:27597821	SNX17	-0.42	-6.33	-0.32	7.49e-10	Total body bone mineral density;
LIHC	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-6.87	-0.35	3.07e-11	Metabolite levels;
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.89	0.3	8.99e-9	Aortic root size;
LIHC	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.51	-6.17	-0.32	1.91e-9	Type 2 diabetes;
LIHC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.73	0.3	2.18e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.73	-11.66	-0.53	1.11e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.86	0.43	4.31e-17	Lung cancer;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.15	-0.48	2.45e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg07133347	chr1:107600762	PRMT6	-0.45	-6.95	-0.35	1.88e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg01677386	chr11:118938358	VPS11	0.45	6.06	0.31	3.62e-9	Coronary artery disease;
LIHC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.46	6.89	0.35	2.73e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.39	0.37	1.15e-12	Vitiligo;
LIHC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.8	0.34	4.81e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.45	-6.49	-0.33	2.94e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19717773	chr7:2847554	GNA12	-0.39	-6.16	-0.32	2.06e-9	Height;
LIHC	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.45	8.18	0.4	5.6e-15	Resting heart rate;
LIHC	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	20.76	0.75	1.6e-62	Colorectal cancer;
LIHC	cis	rs7587476	1.000	rs1542173	chr2:215657560	C/T	cg04530015	chr2:215796436	ABCA12	0.41	6.5	0.33	2.85e-10	Neuroblastoma;
LIHC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg16586182	chr3:47516702	SCAP	-0.5	-9.08	-0.44	9.14e-18	Colorectal cancer;
LIHC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.42	-5.73	-0.3	2.25e-8	Life satisfaction;
LIHC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.5	7.06	0.36	9.17e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg05973401	chr12:123451056	ABCB9	0.43	6.39	0.33	5.58e-10	Platelet count;
LIHC	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.67	0.38	1.81e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg00343986	chr7:65444356	GUSB	0.41	6.24	0.32	1.28e-9	Aortic root size;
LIHC	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.46	-6.04	-0.31	4e-9	Menopause (age at onset);
LIHC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg18887096	chr2:219472410	PLCD4	0.38	6.54	0.33	2.21e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.72	-0.43	1.24e-16	Renal cell carcinoma;
LIHC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	cis	rs2073300	1.000	rs6114137	chr20:23457264	G/A	cg12062639	chr20:23401060	NAPB	0.77	9.63	0.46	1.36e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.66	7.09	0.36	7.76e-12	Blood protein levels;
LIHC	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.97e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.57	-6.34	-0.32	7.32e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.74	14.57	0.62	9.4e-38	Mortality in heart failure;
LIHC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.64	-0.38	2.21e-13	Electroencephalogram traits;
LIHC	trans	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg10208301	chr11:6592745	DNHD1	0.48	6.9	0.35	2.51e-11	Coronary artery calcification;
LIHC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.86	8.15	0.4	6.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5e-9	Prostate cancer;
LIHC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.62	9.83	0.47	3e-20	Corneal astigmatism;
LIHC	cis	rs16828019	0.929	rs11209734	chr1:41698074	C/T	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.84e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.21	-0.55	1.07e-28	Colorectal cancer;
LIHC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg16736954	chr20:23401023	NAPB	0.71	8.28	0.41	2.86e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs74181299	0.620	rs6546123	chr2:65303582	T/C	cg05010058	chr2:65284262	CEP68	-0.38	-6.45	-0.33	3.9e-10	Pulse pressure;
LIHC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02290350	chr8:58132656	NA	0.44	8.57	0.42	3.49e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs16828019	0.852	rs11209545	chr1:41576357	T/G	cg03387723	chr1:41708464	SCMH1	-0.42	-6.93	-0.35	2.07e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-11.45	-0.53	6.55e-26	Morning vs. evening chronotype;
LIHC	cis	rs477692	0.596	rs12247555	chr10:131370520	T/C	cg05714579	chr10:131428358	MGMT	-0.43	-6.86	-0.35	3.33e-11	Response to temozolomide;
LIHC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.73	-0.3	2.16e-8	Life satisfaction;
LIHC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.55	-8.42	-0.41	1.04e-15	White matter hyperintensity burden;
LIHC	cis	rs12286929	0.644	rs4936321	chr11:115041589	C/A	cg04055981	chr11:115044050	NA	0.42	6.95	0.35	1.85e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.38	7.48	0.37	6.47e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.58	8.12	0.4	8.75e-15	Bladder cancer;
LIHC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.54	9.35	0.45	1.21e-18	Mean corpuscular volume;
LIHC	trans	rs1347297	0.526	rs728005	chr2:179251006	C/T	cg14011486	chr1:26737247	LIN28	0.48	6.98	0.35	1.55e-11	Alzheimer disease and age of onset;
LIHC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.76	0.3	1.9e-8	Birth weight;
LIHC	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.95	0.39	2.74e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.43	5.85	0.3	1.14e-8	Life satisfaction;
LIHC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg01657329	chr11:68192670	LRP5	0.48	6.25	0.32	1.25e-9	Total body bone mineral density;
LIHC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.51	6.63	0.34	1.3100000000000001e-10	Initial pursuit acceleration;
LIHC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.61	11.01	0.51	2.47e-24	Total body bone mineral density;
LIHC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.08	0.31	3.18e-9	Electroencephalogram traits;
LIHC	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.55	8.2	0.41	4.9e-15	Multiple sclerosis;
LIHC	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.65	7.73	0.39	1.2e-13	Itch intensity from mosquito bite;
LIHC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.46	6.07	0.31	3.48e-9	Obesity-related traits;
LIHC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg23109721	chr2:106886537	NA	-0.59	-9.63	-0.46	1.45e-19	Facial morphology (factor 23);
LIHC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg07134254	chr20:33865797	NA	0.53	6.26	0.32	1.13e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.58	8.63	0.42	2.29e-16	Prudent dietary pattern;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23978390	chr7:1156363	C7orf50	0.66	10.3	0.49	7.56e-22	Longevity;Endometriosis;
LIHC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18357526	chr6:26021779	HIST1H4A	0.5	7.39	0.37	1.15e-12	Height;
LIHC	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.29	-6.2	-0.32	1.65e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg21724239	chr8:58056113	NA	0.49	6.36	0.33	6.38e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.54	7.06	0.36	9.08e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01413005	chr1:171561022	BAT2L2	0.47	6.13	0.31	2.48e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11630290	0.592	rs12232336	chr15:64153357	T/C	cg12036633	chr15:63758958	NA	0.63	6.7	0.34	8.73e-11	Iris characteristics;
LIHC	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg12253828	chr6:101329408	ASCC3	-0.42	-6.46	-0.33	3.55e-10	Neuroticism;
LIHC	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.27	-0.41	2.97e-15	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg09824255	chr5:140014002	CD14	0.28	5.99	0.31	5.37e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21304211	chr1:112281877	C1orf183	0.45	6.39	0.33	5.41e-10	Lung function (FEV1/FVC);
LIHC	cis	rs3015497	1.000	rs3015495	chr14:51114703	C/T	cg09863266	chr14:51125203	SAV1	-0.39	-6.3	-0.32	9.31e-10	Mean platelet volume;
LIHC	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.17	0.32	1.98e-9	Heart rate;
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	8.44	0.42	8.99e-16	Calcium levels;
LIHC	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	10.62	0.5	5.96e-23	Lung cancer in ever smokers;
LIHC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.92	0.35	2.23e-11	Diabetic kidney disease;
LIHC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.49	7.92	0.39	3.38e-14	Schizophrenia;
LIHC	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.81	-14.35	-0.61	7.14e-37	Height;
LIHC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.15	-28.52	-0.84	2.09e-92	IgG glycosylation;
LIHC	cis	rs10792665	0.724	rs7931613	chr11:82694032	C/T	cg24227371	chr11:82718527	RAB30	-0.38	-9.51	-0.46	3.5e-19	Obesity-related traits;
LIHC	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.5	10.21	0.48	1.49e-21	Endometriosis;
LIHC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.81	-0.35	4.32e-11	Migraine;Coronary artery disease;
LIHC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.38	0.56	2.43e-29	Schizophrenia;
LIHC	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.99	-0.51	2.91e-24	Eye color traits;
LIHC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-6.89	-0.35	2.66e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.54	-13.08	-0.58	5.56e-32	White blood cell count (basophil);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13099106	chr12:120525172	CCDC64	0.53	7.62	0.38	2.45e-13	Pancreatic cancer;
LIHC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.23	-0.32	1.39e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs903552	0.800	rs8026048	chr15:102006353	G/A	cg06707286	chr15:102010195	PCSK6	-0.49	-7.02	-0.35	1.19e-11	Diabetic kidney disease;
LIHC	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.53	-9.25	-0.45	2.42e-18	Gastritis;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.57	10.05	0.48	5.41e-21	Longevity;Endometriosis;
LIHC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.58	9.45	0.46	5.55e-19	Obesity-related traits;
LIHC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.45	-7.03	-0.36	1.16e-11	Cognitive function;
LIHC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.65	6.53	0.33	2.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg26395211	chr5:140044315	WDR55	0.38	5.77	0.3	1.82e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.81	12.15	0.55	1.72e-28	Platelet count;
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg06497051	chr1:156261200	TMEM79	0.38	6.04	0.31	4.07e-9	Tonsillectomy;
LIHC	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.4	0.33	5.15e-10	Lymphocyte counts;
LIHC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg18306943	chr3:40428807	ENTPD3	-0.36	-6.38	-0.33	5.83e-10	Renal cell carcinoma;
LIHC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg04756594	chr16:24857601	SLC5A11	-0.38	-6.27	-0.32	1.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.57	7.81	0.39	6.9e-14	Ulcerative colitis;
LIHC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.72	9.13	0.44	6.05e-18	Body mass index;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.66	-10.12	-0.48	3.1e-21	Renal cell carcinoma;
LIHC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.77	7.44	0.37	7.95e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg15192750	chr16:69999425	NA	0.46	6.89	0.35	2.61e-11	IgE levels;
LIHC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.47	0.33	3.39e-10	Mean platelet volume;
LIHC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.73	13.31	0.58	7.61e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-6.16	-0.32	2.08e-9	Cognitive function;
LIHC	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.34	-5.87	-0.3	1.06e-8	Lewy body disease;
LIHC	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.25	-0.41	3.46e-15	Colorectal cancer;
LIHC	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	11.12	0.52	1.02e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.57	8.98	0.44	1.79e-17	Lymphocyte counts;
LIHC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg06289844	chr6:126071538	HEY2	0.33	5.75	0.3	1.99e-8	Brugada syndrome;
LIHC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.38	6.84	0.35	3.59e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.49	-6.36	-0.33	6.51e-10	Pancreatic cancer;
LIHC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg17372223	chr3:52568218	NT5DC2	0.35	5.87	0.3	1.05e-8	Bipolar disorder;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.51	-7.15	-0.36	5.34e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.45	6.52	0.33	2.47e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg27587257	chr11:1002310	AP2A2	0.42	6.38	0.33	5.9e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7116495	1.000	rs12291678	chr11:71570977	C/G	cg26138937	chr11:71823887	C11orf51	0.7	6.64	0.34	1.25e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-6.65	-0.34	1.16e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.98	22.82	0.78	1.07e-70	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-7.08	-0.36	8.46e-12	Schizophrenia;
LIHC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.76	0.8	2.86e-78	Prudent dietary pattern;
LIHC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg17724175	chr1:150552817	MCL1	0.48	9.63	0.46	1.44e-19	Melanoma;
LIHC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg07713946	chr22:31675144	LIMK2	0.43	7.8	0.39	7.68e-14	Colorectal cancer;
LIHC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-13.17	-0.58	2.54e-32	Vitiligo;
LIHC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11416533	chr1:3773643	KIAA0562;DFFB	-0.51	-6.39	-0.33	5.5e-10	Systolic blood pressure;
LIHC	cis	rs16958440	0.867	rs76922914	chr18:44688454	T/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.23e-16	Sitting height ratio;
LIHC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.98	17.84	0.69	8.98e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.35	5.96	0.31	6.33e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11212737	0.765	rs2624143	chr11:108519363	A/G	cg22776369	chr11:108536276	DDX10	0.38	6.3	0.32	9.38e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg00647820	chr17:40259828	DHX58	0.27	5.88	0.3	9.71e-9	Fibrinogen levels;
LIHC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.42	-6.55	-0.33	2.11e-10	Platelet count;
LIHC	cis	rs9378688	1.000	rs72830182	chr6:2221488	C/T	cg12303981	chr6:2244766	GMDS	-0.5	-6.26	-0.32	1.12e-9	Caudate nucleus volume;
LIHC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-0.96	-22.07	-0.77	1e-67	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.61	8.99	0.44	1.68e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.38	-0.33	5.64e-10	Height;
LIHC	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-0.86	-10.59	-0.5	7.32e-23	Blood pressure (smoking interaction);
LIHC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.55	-7.25	-0.36	2.8e-12	Initial pursuit acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02172222	chr7:2274545	FTSJ2	0.43	6.8	0.35	4.72e-11	Cognitive function;
LIHC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.82	10.11	0.48	3.29e-21	Mean platelet volume;
LIHC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.59	9.93	0.47	1.43e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	7.48	0.37	6.53e-13	Parkinson's disease;
LIHC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	13.49	0.59	1.46e-33	Chronic sinus infection;
LIHC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	17.93	0.7	3.71e-51	Tonsillectomy;
LIHC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.68e-14	Mean platelet volume;
LIHC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.91	16.84	0.67	8.86e-47	Menopause (age at onset);
LIHC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-7.23	-0.36	3.26e-12	Mean platelet volume;
LIHC	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.84	7.23	0.36	3.19e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg02782426	chr3:40428986	ENTPD3	0.33	6.14	0.32	2.24e-9	Renal cell carcinoma;
LIHC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.42	5.88	0.3	9.66e-9	Aortic root size;
LIHC	cis	rs9918079	0.580	rs13120905	chr4:15612288	A/T	cg04067612	chr4:15429572	C1QTNF7	0.28	5.87	0.3	1.03e-8	Obesity-related traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03955296	chr1:157107917	ETV3	-0.49	-6.41	-0.33	4.86e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.01	-0.35	1.27e-11	Type 2 diabetes;
LIHC	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.55	-7.81	-0.39	7.2e-14	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.32	-8.58	-0.42	3.37e-16	Intelligence;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg12311636	chr6:118886798	C6orf204	-0.53	-6.22	-0.32	1.44e-9	Diastolic blood pressure;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg06047700	chr8:9413342	TNKS	-0.58	-6.59	-0.34	1.68e-10	Preeclampsia;
LIHC	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.88	10.86	0.51	8.26e-24	Coronary artery disease;
LIHC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.36	-6.19	-0.32	1.69e-9	Monocyte percentage of white cells;
LIHC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.02	-0.35	1.19e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.55	-6.44	-0.33	3.94e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.15	0.4	7.03e-15	Bladder cancer;
LIHC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.33	-5.79	-0.3	1.63e-8	Schizophrenia;
LIHC	trans	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.46	-0.33	3.65e-10	Educational attainment (years of education);
LIHC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg14067834	chr17:29058358	SUZ12P	0.6	5.94	0.31	6.87e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-6.76	-0.34	6.12e-11	Morning vs. evening chronotype;
LIHC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.48	-0.37	6.43e-13	Uric acid levels;
LIHC	cis	rs12980942	0.935	rs1865051	chr19:41824885	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.09	0.31	2.95e-9	Coronary artery disease;
LIHC	cis	rs7903847	0.656	rs74729163	chr10:99137287	A/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.06	-0.31	3.55e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.61	-7.8	-0.39	7.79e-14	Diastolic blood pressure;
LIHC	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.63	-6.3	-0.32	8.92e-10	Multiple sclerosis;
LIHC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.51	7.31	0.37	1.91e-12	Body mass index;
LIHC	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.64	-6.77	-0.34	5.59e-11	Hair shape;
LIHC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.11	-0.36	6.88e-12	Bipolar disorder;
LIHC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	11.13	0.52	9.14e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.67	-10.89	-0.51	6.46e-24	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg10756647	chr7:56101905	PSPH	1.09	13.52	0.59	1.17e-33	Diabetic kidney disease;
LIHC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	cis	rs2274273	0.653	rs1209087	chr14:55493220	C/T	cg01864836	chr14:55583639	NA	0.35	5.93	0.31	7.48e-9	Protein biomarker;
LIHC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.4	-6.43	-0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04267164	chr19:49402096	TULP2	0.44	6.38	0.33	5.6e-10	Longevity;
LIHC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs1866706	0.796	rs7927865	chr11:12853841	G/A	cg25843174	chr11:12811716	TEAD1	-0.3	-6.18	-0.32	1.82e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.71	0.43	1.33e-16	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.69	11.22	0.52	4.43e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg15691649	chr6:25882328	NA	-0.58	-7.51	-0.38	5.24e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	0.87	11.88	0.54	1.69e-27	Skin colour saturation;
LIHC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg16479474	chr6:28041457	NA	-0.45	-6.35	-0.32	6.94e-10	Depression;
LIHC	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-16.42	-0.66	4.18e-45	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23127064	chr11:842615	TSPAN4;POLR2L	0.38	6.27	0.32	1.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	0.88	5.87	0.3	1.04e-8	Mitochondrial DNA levels;
LIHC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.89	-11.31	-0.52	2.15e-25	Glomerular filtration rate (creatinine);
LIHC	cis	rs16989760	1.000	rs3761430	chr22:31538002	C/T	cg02055988	chr22:31671702	LIMK2	-0.49	-6.53	-0.33	2.41e-10	Age-related hearing impairment;
LIHC	cis	rs6466055	0.604	rs1204078	chr7:104986644	A/T	cg04380332	chr7:105027541	SRPK2	0.37	6.91	0.35	2.32e-11	Schizophrenia;
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.71	10.33	0.49	5.73e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg10864318	chr6:117002220	KPNA5	0.53	6.14	0.32	2.28e-9	Glycated hemoglobin levels;
LIHC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg22787604	chr8:1509810	DLGAP2	0.43	7.66	0.38	1.87e-13	Lung cancer;
LIHC	cis	rs903552	0.800	rs12903584	chr15:101999369	G/A	cg00659931	chr15:102010125	PCSK6	-0.42	-5.75	-0.3	1.94e-8	Diabetic kidney disease;
LIHC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.7	-10.87	-0.51	7.47e-24	Longevity;
LIHC	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg08824895	chr13:115047677	UPF3A	0.49	7.1	0.36	7.08e-12	Schizophrenia;
LIHC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs12980942	0.810	rs3745295	chr19:41785282	T/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.29	0.32	9.54e-10	Coronary artery disease;
LIHC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg09835421	chr16:68378352	PRMT7	-0.49	-5.82	-0.3	1.38e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4407350	0.729	rs9819	chr22:44889386	C/T	cg11695653	chr22:44894386	LDOC1L	0.39	6.68	0.34	9.97e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.46	6.52	0.33	2.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg12903224	chr12:29470962	FAR2	-0.41	-6.67	-0.34	1.01e-10	QT interval;
LIHC	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.31	6.34	0.32	7.38e-10	Joint mobility (Beighton score);
LIHC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02290350	chr8:58132656	NA	0.4	8.45	0.42	8.63e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg02640540	chr1:67518911	SLC35D1	-0.41	-6.4	-0.33	5.19e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg23131131	chr22:24373011	LOC391322	-0.66	-9.64	-0.46	1.29e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.43	7.93	0.39	3.05e-14	Glycated hemoglobin levels;
LIHC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04221910	chr5:616842	CEP72	0.42	7.55	0.38	3.91e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4450131	0.522	rs3781451	chr10:126355477	G/A	cg20435097	chr10:126320824	FAM53B	0.67	12.28	0.55	5.98e-29	White blood cell count (basophil);
LIHC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg03037974	chr15:76606532	NA	0.89	22.87	0.78	6.64e-71	Blood metabolite levels;
LIHC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg07061783	chr6:25882402	NA	-0.44	-6.16	-0.32	2.06e-9	Blood metabolite levels;
LIHC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.43	-6.25	-0.32	1.23e-9	Narcolepsy;
LIHC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.46	6.26	0.32	1.19e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.53	-6.14	-0.32	2.31e-9	Major depressive disorder;
LIHC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.43	6.34	0.32	7.25e-10	Longevity;Endometriosis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09709592	chr16:2580833	AMDHD2;CEMP1	-0.39	-6.38	-0.33	5.73e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.58	-0.46	2.07e-19	Mean platelet volume;
LIHC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.63	10.23	0.48	1.29e-21	Monocyte count;
LIHC	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg14132834	chr19:41945861	ATP5SL	-0.39	-5.72	-0.3	2.39e-8	Height;
LIHC	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.65	-8.44	-0.42	9.29e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.51	5.85	0.3	1.18e-8	IFN-related cytopenia;
LIHC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.44	7.92	0.39	3.47e-14	Prudent dietary pattern;
LIHC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.67	8.89	0.43	3.69e-17	Blood metabolite levels;
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.44	0.33	3.98e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	0.49	6.43	0.33	4.27e-10	Pulse pressure;
LIHC	cis	rs965469	0.779	rs6051710	chr20:3264661	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.63	-0.34	1.33e-10	IFN-related cytopenia;
LIHC	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04530015	chr2:215796436	ABCA12	0.49	9.07	0.44	9.83e-18	Neuroblastoma (high-risk);
LIHC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs35883536	0.875	rs1970227	chr1:101140723	G/A	cg14515779	chr1:101123966	NA	0.66	12.8	0.57	6.44e-31	Monocyte count;
LIHC	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.77	0.47	4.61e-20	Corneal astigmatism;
LIHC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	0.73	11.74	0.54	5.87e-27	Yeast infection;
LIHC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.18	-0.36	4.28e-12	IgG glycosylation;
LIHC	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.63	8.64	0.42	2.25e-16	Lymphocyte counts;Fibrinogen;
LIHC	trans	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	1.01	13.18	0.58	2.34e-32	Red blood cell traits;
LIHC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-1.14	-12.59	-0.56	3.94e-30	White matter hyperintensity burden;
LIHC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg24296786	chr1:45957014	TESK2	0.41	5.94	0.31	7.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	9.47	0.46	4.71e-19	Alzheimer's disease (late onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00850501	chr19:14530371	DDX39	0.5	6.47	0.33	3.32e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.57	0.33	1.83e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.54e-18	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg18306943	chr3:40428807	ENTPD3	0.41	7.0	0.35	1.32e-11	Renal cell carcinoma;
LIHC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.41	0.59	3.07e-33	Airflow obstruction;
LIHC	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.62	6.15	0.32	2.14e-9	Carotid intima media thickness;
LIHC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.52	-0.49	1.29e-22	Chronic sinus infection;
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08219700	chr8:58056026	NA	0.52	6.7	0.34	8.83e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.51	-6.77	-0.34	5.66e-11	Serum thyroid-stimulating hormone levels;
LIHC	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.27e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7534824	0.543	rs1074739	chr1:101362371	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	6.96	0.35	1.73e-11	Refractive astigmatism;
LIHC	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg00012203	chr2:219082015	ARPC2	0.91	15.08	0.63	9.78e-40	Colorectal cancer;
LIHC	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg14345882	chr6:26364793	BTN3A2	0.39	5.79	0.3	1.61e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.67	10.21	0.48	1.56e-21	Body mass index;
LIHC	trans	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg09045935	chr12:6379348	NA	0.84	6.86	0.35	3.33e-11	Blood metabolite levels;
LIHC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.51	-8.68	-0.42	1.69e-16	Type 2 diabetes;
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26338869	chr17:61819248	STRADA	-0.43	-5.87	-0.3	1e-8	Prudent dietary pattern;
LIHC	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg23422044	chr7:1970798	MAD1L1	-0.7	-10.82	-0.51	1.13e-23	Bipolar disorder;
LIHC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	1.21	10.64	0.5	4.8e-23	Obesity-related traits;
LIHC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg00277334	chr10:82204260	NA	0.53	6.49	0.33	2.98e-10	Post bronchodilator FEV1;
LIHC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.76	-11.36	-0.52	1.39e-25	Response to antineoplastic agents;
LIHC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.5	6.84	0.35	3.59e-11	Aortic root size;
LIHC	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.68	0.5	3.74e-23	Hypertriglyceridemia;
LIHC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg17385448	chr1:15911702	AGMAT	0.35	6.21	0.32	1.55e-9	Systolic blood pressure;
LIHC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.5	6.91	0.35	2.43e-11	Schizophrenia;
LIHC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.62	-8.89	-0.43	3.51e-17	Blood pressure (smoking interaction);
LIHC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.57	-0.33	1.92e-10	Mean corpuscular volume;
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg07234388	chr1:156261841	TMEM79	0.52	9.37	0.45	1.04e-18	Tonsillectomy;
LIHC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.38	0.45	9.48e-19	Bipolar disorder;
LIHC	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	0.67	7.41	0.37	1.03e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.47	-7.56	-0.38	3.83e-13	Multiple myeloma;
LIHC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.8	-18.31	-0.7	1.14e-52	Urate levels in lean individuals;
LIHC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.38	5.77	0.3	1.77e-8	Mean corpuscular volume;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03549856	chr1:33593141	NA	-0.41	-6.59	-0.34	1.67e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg04267008	chr7:1944627	MAD1L1	0.44	5.77	0.3	1.76e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.8	-10.24	-0.48	1.23e-21	Type 2 diabetes;
LIHC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.37	-6.17	-0.32	1.98e-9	IgG glycosylation;
LIHC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-6.18	-0.32	1.85e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9381040	0.672	rs6458197	chr6:41144658	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.41	-6.68	-0.34	9.93e-11	Alzheimer's disease (late onset);
LIHC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.59	-9.73	-0.47	6.67e-20	Height;
LIHC	cis	rs2637030	0.559	rs256083	chr5:52893681	G/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-0.66	-10.94	-0.51	4.39e-24	Total body bone mineral density;
LIHC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02290350	chr8:58132656	NA	-0.45	-9.16	-0.44	4.75e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.75	-0.43	1.02e-16	Total cholesterol levels;
LIHC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-8.63	-0.42	2.36e-16	Gut microbiome composition (summer);
LIHC	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg03146154	chr1:46216737	IPP	-0.38	-5.85	-0.3	1.13e-8	High light scatter reticulocyte count;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00069314	chr4:170542039	CLCN3	0.32	6.44	0.33	4.1e-10	Calcium levels;
LIHC	trans	rs6461503	0.644	rs916789	chr7:20572530	A/C	cg01961949	chr17:79791406	FAM195B;DYSFIP1	0.44	6.58	0.34	1.74e-10	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg15902774	chr15:75289873	SCAMP5	0.43	6.56	0.33	2.04e-10	Lung cancer;
LIHC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.31	0.72	1.01e-56	Smoking behavior;
LIHC	trans	rs1464321	0.901	rs7305590	chr12:103658540	T/C	cg15403093	chr12:133312361	ANKLE2	0.38	6.07	0.31	3.49e-9	Body mass index;
LIHC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.41	-6.34	-0.32	7.38e-10	Lung cancer;
LIHC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.54	-9.1	-0.44	7.57e-18	Lewy body disease;
LIHC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.77	11.53	0.53	3.25e-26	Coronary artery disease;
LIHC	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.64	-7.12	-0.36	6.26e-12	Opioid sensitivity;
LIHC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.44	-0.33	4.09e-10	Type 2 diabetes;
LIHC	cis	rs1144333	0.655	rs5745465	chr1:76346832	A/G	cg22875332	chr1:76189707	ACADM	0.39	5.74	0.3	2.13e-8	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.68	-0.34	9.75e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.98	-17.73	-0.69	2.37e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.37	-6.15	-0.32	2.22e-9	Blood metabolite levels;
LIHC	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.43	-7.0	-0.35	1.33e-11	Schizophrenia;
LIHC	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.42	7.11	0.36	6.64e-12	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LIHC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.3	-0.32	9.3e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1816752	0.875	rs3783076	chr13:25064457	C/T	cg22771759	chr13:24902376	NA	0.3	6.18	0.32	1.8e-9	Obesity-related traits;
LIHC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	trans	rs13381277	1.000	rs28380744	chr18:74327655	G/T	cg17352830	chr21:37617589	DOPEY2	-0.54	-6.24	-0.32	1.29e-9	Dental caries;
LIHC	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-8.24	-0.41	3.67e-15	Morning vs. evening chronotype;
LIHC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.74	0.3	2.06e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.75	14.39	0.61	4.87e-37	Crohn's disease;
LIHC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.02	-0.4	1.65e-14	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.75	-10.8	-0.5	1.31e-23	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.38	12.73	0.57	1.14e-30	Uric acid levels;
LIHC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	6.0	0.31	4.97e-9	Height;
LIHC	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs61677309	0.964	rs113145584	chr11:118154798	G/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12600695	chr5:137513806	BRD8;KIF20A	0.46	6.94	0.35	1.98e-11	Cognitive function;
LIHC	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.5	6.56	0.33	2.05e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.31	-0.37	1.89e-12	Personality dimensions;
LIHC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.3e-16	Motion sickness;
LIHC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.7	-9.13	-0.44	6.17e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg19513890	chr22:42538836	CYP2D7P1	0.43	8.34	0.41	1.79e-15	Cognitive function;
LIHC	cis	rs8067354	0.540	rs7221472	chr17:58036737	C/T	cg02344993	chr17:57696989	CLTC	0.65	10.28	0.49	8.95e-22	Hemoglobin concentration;
LIHC	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	6.44	0.33	4.1e-10	Lymphocyte counts;
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.65	-8.23	-0.41	4.09e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8067354	0.958	rs2777889	chr17:57848006	A/G	cg13753209	chr17:57696993	CLTC	0.56	8.42	0.41	1.03e-15	Hemoglobin concentration;
LIHC	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.63	7.82	0.39	6.43e-14	Crohn's disease;
LIHC	cis	rs61440199	0.818	rs57566579	chr3:20180738	T/C	cg00235661	chr3:20228976	SGOL1	-0.42	-5.8	-0.3	1.52e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.58	8.51	0.42	5.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.89	-17.21	-0.68	2.95e-48	Lung cancer in ever smokers;
LIHC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.44	-6.6	-0.34	1.53e-10	Age at first birth;
LIHC	trans	rs36715	1.000	rs251386	chr5:127547298	A/G	cg16011800	chr17:1958478	HIC1	-0.41	-6.06	-0.31	3.56e-9	Breast cancer;
LIHC	cis	rs7487075	0.619	rs2220727	chr12:46805069	G/A	cg23829395	chr12:46796953	NA	0.36	6.29	0.32	9.45e-10	Itch intensity from mosquito bite;
LIHC	cis	rs986417	0.748	rs12436632	chr14:61034416	T/C	cg27398547	chr14:60952738	C14orf39	0.57	7.0	0.35	1.35e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs9378688	1.000	rs2295008	chr6:2230989	G/A	cg12303981	chr6:2244766	GMDS	-0.49	-6.29	-0.32	9.47e-10	Caudate nucleus volume;
LIHC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.72	-11.75	-0.54	5.29e-27	Systemic lupus erythematosus;
LIHC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.73	-0.43	1.12e-16	Heart rate;
LIHC	cis	rs5753037	0.543	rs140119	chr22:30138149	A/T	cg01021169	chr22:30184971	ASCC2	-0.32	-5.98	-0.31	5.69e-9	Type 1 diabetes;
LIHC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.13	0.4	7.83e-15	Bladder cancer;
LIHC	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.29	-0.41	2.67e-15	Exhaled nitric oxide output;
LIHC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.2	-0.41	4.9e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg25019722	chr6:37503610	NA	-0.32	-5.74	-0.3	2.07e-8	Cognitive performance;
LIHC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Body mass index;
LIHC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.7	10.98	0.51	3.2e-24	Corneal astigmatism;
LIHC	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.58	10.12	0.48	3.07e-21	Diisocyanate-induced asthma;
LIHC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.34	-6.15	-0.32	2.15e-9	Sudden cardiac arrest;
LIHC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.79	-0.3	1.61e-8	Pulse pressure;
LIHC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.61	6.88	0.35	2.89e-11	Menarche (age at onset);
LIHC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.66	0.42	1.95e-16	Menarche (age at onset);
LIHC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg21466736	chr12:48725269	NA	-0.63	-9.13	-0.44	6.16e-18	Glycated hemoglobin levels;
LIHC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	7.2	0.36	3.75e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.68	-8.33	-0.41	1.98e-15	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.42	5.84	0.3	1.24e-8	Aortic root size;
LIHC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.56	9.38	0.45	9.64e-19	Cognitive function;
LIHC	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.11	-0.31	2.79e-9	Metabolite levels;
LIHC	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg14930904	chr10:32216787	ARHGAP12	0.35	5.99	0.31	5.46e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.76	-12.1	-0.55	2.78e-28	Breast cancer;
LIHC	cis	rs72627509	0.638	rs12648928	chr4:57902506	C/G	cg26694713	chr4:57773883	REST	0.6	7.5	0.38	5.56e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	12.89	0.57	3e-31	Alzheimer's disease;
LIHC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	trans	rs1864585	0.520	rs73208793	chr8:10680785	T/C	cg26278703	chr11:58910052	FAM111A	0.74	6.71	0.34	8.19e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	7.91	0.39	3.52e-14	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.58e-15	Motion sickness;
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.53	0.38	4.45e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs4790333	0.562	rs2447104	chr17:2257532	C/T	cg02569219	chr17:2266849	SGSM2	0.42	6.28	0.32	1.05e-9	Proinsulin levels;
LIHC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.67	11.0	0.51	2.59e-24	Menopause (age at onset);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg26046968	chr14:57857884	NAA30	-0.43	-6.08	-0.31	3.17e-9	Alopecia areata;
LIHC	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.47	6.44	0.33	4.01e-10	Inflammatory skin disease;
LIHC	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.48	7.35	0.37	1.44e-12	Diastolic blood pressure;
LIHC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-6.63	-0.34	1.3e-10	Type 2 diabetes;
LIHC	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.51	8.95	0.44	2.27e-17	Coronary artery disease;
LIHC	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	16.33	0.66	9.63e-45	Nonalcoholic fatty liver disease;
LIHC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.13	-0.31	2.37e-9	Colorectal cancer;
LIHC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.01	0.4	1.82e-14	Response to antipsychotic treatment;
LIHC	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.93	-12.67	-0.57	2.02e-30	Post bronchodilator FEV1;
LIHC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.5	7.0	0.35	1.37e-11	Asthma;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.43	-7.75	-0.39	1.09e-13	Prudent dietary pattern;
LIHC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.12	24.63	0.8	9.37e-78	Cognitive ability;
LIHC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.48	-7.2	-0.36	3.78e-12	Height;
LIHC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.23	0.45	2.97e-18	IgG glycosylation;
LIHC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.86	0.51	8.19e-24	Personality dimensions;
LIHC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.84	-0.65	9.44e-43	Chronic sinus infection;
LIHC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg19680672	chr10:131412579	MGMT	-0.44	-6.95	-0.35	1.9e-11	Response to temozolomide;
LIHC	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.47	-7.21	-0.36	3.5e-12	Fibroblast growth factor basic levels;
LIHC	cis	rs7250872	0.647	rs2304615	chr19:1826112	A/G	cg18850929	chr19:1828978	REXO1	0.39	6.32	0.32	7.93e-10	Bipolar disorder;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05880217	chr17:79846343	THOC4	0.42	6.29	0.32	9.45e-10	Longevity;
LIHC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.31	-0.37	1.93e-12	Bipolar disorder;
LIHC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.52	-8.53	-0.42	4.94e-16	Multiple sclerosis;
LIHC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.65	-6.42	-0.33	4.47e-10	Migraine;Coronary artery disease;
LIHC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.31	8.2	0.41	4.91e-15	Age-related hearing impairment;
LIHC	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.76	12.36	0.56	3e-29	Body mass index;
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.78	-0.3	1.66e-8	Breast cancer;
LIHC	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg27255678	chr10:102756921	LZTS2	0.52	7.29	0.37	2.22e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-7.59	-0.38	3.02e-13	Exhaled nitric oxide output;
LIHC	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-8.48	-0.42	6.97e-16	Exhaled nitric oxide levels;
LIHC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-1.03	-19.61	-0.73	6.22e-58	Breast cancer;
LIHC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg06565975	chr8:143823917	SLURP1	0.33	6.38	0.33	5.92e-10	Urinary tract infection frequency;
LIHC	cis	rs2191566	0.639	rs7257749	chr19:44548666	G/A	cg20607764	chr19:44506953	ZNF230	-0.37	-6.22	-0.32	1.45e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.87	0.3	1.04e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.41	6.48	0.33	3.16e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.19	0.41	5.16e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.86	0.3	1.1e-8	Bladder cancer;
LIHC	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.49	8.22	0.41	4.23e-15	Schizophrenia;
LIHC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg14393609	chr7:65229607	NA	-0.37	-5.83	-0.3	1.27e-8	Aortic root size;
LIHC	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg17218026	chr1:154582156	ADAR	0.3	5.95	0.31	6.67e-9	Blood protein levels;
LIHC	cis	rs9473924	0.505	rs6908879	chr6:50869856	C/T	cg14470998	chr6:50812995	TFAP2B	0.94	10.91	0.51	5.57e-24	Body mass index;
LIHC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9513627	0.915	rs4324006	chr13:100122545	A/G	cg25919922	chr13:100150906	NA	-0.79	-6.91	-0.35	2.37e-11	Obesity-related traits;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.91	-0.3	8.35e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00587304	chr3:172468157	NA	0.49	7.3	0.37	2.03e-12	Pancreatic cancer;
LIHC	cis	rs918629	0.530	rs3777197	chr5:95237916	T/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.83	-0.35	3.84e-11	IgG glycosylation;
LIHC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.4	8.47	0.42	7.21e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs4853036	0.904	rs12713683	chr2:70156321	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.51	-0.33	2.66e-10	Colorectal or endometrial cancer;
LIHC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.5	7.92	0.39	3.42e-14	Diastolic blood pressure;
LIHC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.3	-5.89	-0.3	9.21e-9	Colorectal cancer;
LIHC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.46	6.74	0.34	6.83e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1144333	0.655	rs114383686	chr1:76325327	C/T	cg10523679	chr1:76189770	ACADM	0.48	6.85	0.35	3.55e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.93	-10.59	-0.5	7.37e-23	Schizophrenia;
LIHC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.82	-0.3	1.38e-8	Body mass index;
LIHC	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.08	-0.51	1.42e-24	Eye color traits;
LIHC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg26139080	chr11:47293733	MADD	-0.5	-8.39	-0.41	1.27e-15	HDL cholesterol;
LIHC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg19682013	chr15:45996608	NA	0.39	6.61	0.34	1.5e-10	Waist circumference;Weight;
LIHC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg12501888	chr15:85177176	SCAND2	-0.49	-7.66	-0.38	1.98e-13	P wave terminal force;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	ch.7.1415213R	chr7:66262805	RABGEF1	0.44	6.64	0.34	1.23e-10	Systolic blood pressure;
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17428076	0.874	rs12619041	chr2:172600716	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.38	-6.16	-0.32	2.1e-9	Myopia;
LIHC	cis	rs425535	0.619	rs13128887	chr4:74821616	G/A	cg02530824	chr4:74847766	PF4	-0.39	-6.26	-0.32	1.13e-9	Blood protein levels;
LIHC	cis	rs11166927	1.000	rs13260415	chr8:140805137	A/C	cg16909799	chr8:140841666	TRAPPC9	0.52	8.25	0.41	3.58e-15	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs12611088	0.602	rs6509092	chr19:44022305	A/T	cg13740135	chr19:44006432	PHLDB3	-0.41	-6.22	-0.32	1.46e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.51	-6.7	-0.34	8.52e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs4356203	0.905	rs7478986	chr11:17131249	T/C	cg15432903	chr11:17409602	KCNJ11	-0.41	-6.24	-0.32	1.31e-9	Schizophrenia;Schizophrenia or bipolar disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08770590	chr10:112064742	SMNDC1	-0.44	-6.29	-0.32	9.87e-10	Cognitive function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25953012	chr14:50052901	RPS29	0.43	6.49	0.33	3.04e-10	Calcium levels;
LIHC	trans	rs4322600	0.929	rs982577	chr14:88290267	C/T	cg16008221	chr8:17823628	PCM1	0.43	6.31	0.32	8.83e-10	Breast cancer;
LIHC	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.29	6.27	0.32	1.11e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.51	8.86	0.43	4.47e-17	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.47	7.63	0.38	2.37e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.41	0.41	1.1e-15	Exhaled nitric oxide output;
LIHC	cis	rs11663156	1.000	rs4940261	chr18:51034552	C/T	cg24270629	chr18:50823537	DCC	-0.47	-6.26	-0.32	1.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.59	-6.15	-0.32	2.15e-9	Vitiligo;
LIHC	cis	rs7937890	0.706	rs7115393	chr11:14268378	T/A	cg02886208	chr11:14281011	SPON1	0.49	6.37	0.33	6.07e-10	Mitochondrial DNA levels;
LIHC	trans	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg25214090	chr10:38739885	LOC399744	-0.4	-6.6	-0.34	1.54e-10	Diastolic blood pressure;
LIHC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	11.04	0.51	1.95e-24	Lung cancer in ever smokers;
LIHC	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.56	9.3	0.45	1.73e-18	Corneal astigmatism;
LIHC	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.79	9.18	0.44	4.09e-18	Exhaled nitric oxide output;
LIHC	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.57	-0.38	3.57e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.54	-7.49	-0.38	5.92e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-8.81	-0.43	6.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg10862848	chr6:42927986	GNMT	-0.24	-5.86	-0.3	1.1e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg10790698	chr19:18539756	SSBP4	-0.35	-7.33	-0.37	1.67e-12	Breast cancer;
LIHC	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.85	0.3	1.12e-8	Bipolar disorder;
LIHC	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.46	-0.46	5.03e-19	Heart rate;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.58	-9.62	-0.46	1.53e-19	Prudent dietary pattern;
LIHC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg02290350	chr8:58132656	NA	0.41	8.72	0.43	1.22e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg25039879	chr17:56429692	SUPT4H1	0.74	8.14	0.4	7.56e-15	Cognitive test performance;
LIHC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.25	-0.36	2.82e-12	Migraine;Coronary artery disease;
LIHC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18252515	chr7:66147081	NA	0.45	6.42	0.33	4.54e-10	Aortic root size;
LIHC	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.78	-0.54	4.01e-27	Coffee consumption (cups per day);
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.4	-5.74	-0.3	2.14e-8	Longevity;
LIHC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg25894440	chr7:65020034	NA	0.55	6.38	0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg05207973	chr5:176823642	SLC34A1	-0.33	-5.77	-0.3	1.8e-8	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.22	0.32	1.49e-9	Iron status biomarkers;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg14990712	chr19:4055085	ZBTB7A	0.42	6.19	0.32	1.72e-9	Alopecia areata;
LIHC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg18016565	chr1:150552671	MCL1	0.5	9.6	0.46	1.71e-19	Melanoma;
LIHC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.94	0.51	4.41e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.47	5.95	0.31	6.6e-9	Obesity (extreme);
LIHC	trans	rs10411161	0.935	rs8107422	chr19:52368775	C/A	cg22319618	chr22:45562946	NUP50	-0.51	-6.84	-0.35	3.76e-11	Breast cancer;
LIHC	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.67	0.38	1.81e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.68	13.61	0.59	5.27e-34	High light scatter reticulocyte count;
LIHC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg24130564	chr14:104152367	KLC1	-0.43	-7.08	-0.36	8.07e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.31	-6.24	-0.32	1.29e-9	Colorectal cancer;
LIHC	cis	rs829883	0.646	rs249836	chr12:98878342	T/C	cg23471612	chr12:98897216	NA	0.31	5.94	0.31	7e-9	Colorectal adenoma (advanced);
LIHC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02711726	chr17:80685570	FN3KRP	-0.49	-9.13	-0.44	6e-18	Glycated hemoglobin levels;
LIHC	cis	rs11605275	1.000	rs11604681	chr11:20031042	G/A	cg14835545	chr11:20032148	NAV2	-0.81	-7.39	-0.37	1.11e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-9.36	-0.45	1.11e-18	Type 2 diabetes;
LIHC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg14067834	chr17:29058358	SUZ12P	0.67	6.52	0.33	2.6e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.35	-6.8	-0.35	4.56e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.56	9.26	0.45	2.28e-18	Colorectal cancer;
LIHC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg20607798	chr8:58055168	NA	0.49	6.19	0.32	1.73e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02475777	chr4:1388615	CRIPAK	0.42	6.22	0.32	1.44e-9	Longevity;
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08280861	chr8:58055591	NA	0.54	5.98	0.31	5.73e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.47e-8	Aortic root size;
LIHC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.55	9.89	0.47	1.82e-20	Alcohol dependence;
LIHC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.41	6.08	0.31	3.29e-9	Lung cancer;
LIHC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.29	-5.8	-0.3	1.48e-8	Body mass index;
LIHC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.49	-5.89	-0.3	9.25e-9	Blood metabolite levels;
LIHC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.8	14.05	0.6	1.02e-35	Coronary artery disease;
LIHC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	1.05	11.67	0.53	1.01e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg16970926	chr12:29381810	FAR2	0.29	6.04	0.31	4.02e-9	QT interval;
LIHC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg09238746	chr17:78121135	EIF4A3	-0.54	-8.26	-0.41	3.19e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LIHC	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.88	-0.47	2.04e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8064024	0.599	rs3185547	chr16:4931100	A/C	cg08329684	chr16:4932620	PPL	0.34	5.85	0.3	1.14e-8	Cancer;
LIHC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.64	12.22	0.55	9.57e-29	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg13409248	chr3:40428643	ENTPD3	0.38	6.2	0.32	1.61e-9	Renal cell carcinoma;
LIHC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.57	6.32	0.32	8.23e-10	Axial length;
LIHC	cis	rs655641	1.000	rs635168	chr11:85771170	T/C	cg09030501	chr11:85779252	PICALM	-0.52	-6.1	-0.31	2.83e-9	Platelet count;
LIHC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.89	10.69	0.5	3.45e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs7119038	0.686	rs55894437	chr11:118607417	C/T	cg19308663	chr11:118741387	NA	0.42	6.43	0.33	4.21e-10	Sjögren's syndrome;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.64	11.24	0.52	3.58e-25	Longevity;Endometriosis;
LIHC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.86	-0.65	7.39e-43	Height;
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg04352962	chr1:209979756	IRF6	0.4	6.18	0.32	1.87e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.48	0.46	4.49e-19	Electroencephalogram traits;
LIHC	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg06935464	chr4:38784597	TLR10	0.41	6.71	0.34	8e-11	Breast cancer;
LIHC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.65	-9.32	-0.45	1.53e-18	IgG glycosylation;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg03721293	chr16:90014378	DEF8	0.37	6.47	0.33	3.49e-10	Skin colour saturation;
LIHC	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	cis	rs2574704	0.886	rs7628261	chr3:11635482	T/G	cg15876825	chr3:11651881	VGLL4	-0.46	-7.39	-0.37	1.15e-12	Body mass index;
LIHC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	6.41	0.33	4.71e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs6058796	1.000	rs6087409	chr20:31257552	A/G	cg02600331	chr11:130417168	NA	0.36	7.75	0.39	1.03e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.73	-0.69	2.35e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-9.3	-0.45	1.74e-18	Dental caries;
LIHC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.21	-0.58	1.83e-32	Type 2 diabetes;
LIHC	cis	rs8058578	0.614	rs2878304	chr16:30878366	C/T	cg02466173	chr16:30829666	NA	0.43	6.55	0.33	2.14e-10	Multiple myeloma;
LIHC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21467203	chr3:49911342	NA	-0.52	-9.03	-0.44	1.29e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg01864069	chr14:103024347	NA	0.35	5.86	0.3	1.11e-8	Platelet count;
LIHC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.96	-0.31	6.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-10.19	-0.48	1.76e-21	Asthma;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.74	0.43	1.08e-16	Lymphocyte counts;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg11878867	chr6:150167359	LRP11	-0.38	-6.36	-0.33	6.51e-10	Lung cancer;
LIHC	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.86	-0.3	1.09e-8	Neuroticism;
LIHC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.64	-6.79	-0.34	4.83e-11	Hair shape;
LIHC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.96	18.58	0.71	9.5e-54	Menopause (age at onset);
LIHC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.57	-13.79	-0.6	1.07e-34	White blood cell count (basophil);
LIHC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg03959625	chr15:84868606	LOC388152	0.42	5.87	0.3	1.05e-8	Schizophrenia;
LIHC	cis	rs11871801	0.918	rs1032070	chr17:40618251	C/T	cg14558262	chr17:40713999	COASY	0.48	6.67	0.34	1.06e-10	Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19518383	chr11:64577818	MEN1	0.49	6.73	0.34	7.07e-11	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00128877	chr1:47070178	MKNK1	0.47	6.91	0.35	2.32e-11	Pancreatic cancer;
LIHC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.45	0.37	7.45e-13	Bone mineral density;
LIHC	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-7.79	-0.39	8.3e-14	Exhaled nitric oxide output;
LIHC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg19318889	chr4:1322082	MAEA	0.46	6.32	0.32	8.33e-10	Obesity-related traits;
LIHC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.4	0.41	1.19e-15	Platelet count;
LIHC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.18	0.36	4.48e-12	Diabetic kidney disease;
LIHC	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.23	-0.32	1.35e-9	Bipolar disorder;
LIHC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.33	-0.76	8.44e-65	Height;
LIHC	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.84	-0.35	3.62e-11	Prevalent atrial fibrillation;
LIHC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.59	8.13	0.4	7.9e-15	Motion sickness;
LIHC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg17750252	chr2:136567154	LCT	0.33	5.77	0.3	1.74e-8	Mosquito bite size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24337644	chr2:234262978	DGKD	0.43	6.26	0.32	1.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.54	9.5	0.46	3.92e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.48	-8.09	-0.4	1.02e-14	Menarche (age at onset);
LIHC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg05527609	chr1:210001259	C1orf107	-0.62	-8.84	-0.43	4.99e-17	Red blood cell count;
LIHC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	1.06	22.36	0.77	6.65e-69	Breast cancer;
LIHC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	8.93	0.43	2.75e-17	Platelet count;
LIHC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg03013999	chr17:37608204	MED1	-0.36	-6.05	-0.31	3.8e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.7	-0.34	8.48e-11	Aortic root size;
LIHC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg04014059	chr22:45813624	RIBC2	-0.49	-5.78	-0.3	1.7e-8	Tonsillectomy;
LIHC	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.49	-0.33	3e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	12.4	0.56	1.98e-29	Monocyte count;
LIHC	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg23791538	chr6:167370224	RNASET2	0.42	6.69	0.34	9.35e-11	Primary biliary cholangitis;
LIHC	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg09795085	chr6:101329169	ASCC3	0.48	6.43	0.33	4.34e-10	Neuroticism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06451949	chr17:48942959	NA	0.42	7.13	0.36	5.87e-12	Cognitive function;
LIHC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg03934865	chr2:198174659	NA	-0.58	-9.21	-0.45	3.48e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs600806	0.665	rs1368988	chr1:110012123	A/T	cg23091122	chr1:110024289	SYPL2	-0.49	-6.72	-0.34	7.49e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.95	0.35	1.89e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg07636037	chr3:49044803	WDR6	-0.81	-8.44	-0.42	9.01e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.64	9.96	0.47	1.13e-20	Corneal astigmatism;
LIHC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.45e-18	Bipolar disorder;
LIHC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg11764359	chr7:65958608	NA	0.59	6.26	0.32	1.18e-9	Diabetic kidney disease;
LIHC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.48	-0.53	5.13e-26	Coronary artery disease;
LIHC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.55	7.74	0.39	1.1e-13	Blood metabolite levels;
LIHC	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.97	-0.4	2.42e-14	Coronary artery disease;
LIHC	cis	rs2073300	1.000	rs6048813	chr20:23448221	G/A	cg12062639	chr20:23401060	NAPB	0.81	9.62	0.46	1.56e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.62	-0.42	2.61e-16	Crohn's disease;
LIHC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.65	10.48	0.49	1.75e-22	Lymphocyte counts;
LIHC	trans	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs6952808	0.743	rs10266703	chr7:1918941	C/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.24	-0.36	2.9e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	11.0	0.51	2.59e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg16586182	chr3:47516702	SCAP	-0.51	-9.25	-0.45	2.51e-18	Colorectal cancer;
LIHC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg17724175	chr1:150552817	MCL1	0.37	7.35	0.37	1.52e-12	Melanoma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04786330	chr12:27091356	C12orf11;FGFR1OP2	0.42	6.18	0.32	1.86e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.64	-10.17	-0.48	2.12e-21	Longevity;
LIHC	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg23091122	chr1:110024289	SYPL2	-0.46	-6.06	-0.31	3.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg11764359	chr7:65958608	NA	0.56	5.96	0.31	6.14e-9	Diabetic kidney disease;
LIHC	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.05e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs965469	1.000	rs6037560	chr20:3323055	T/C	cg25506879	chr20:3388711	C20orf194	-0.59	-7.06	-0.36	9.55e-12	IFN-related cytopenia;
LIHC	trans	rs2797369	0.570	rs2813647	chr6:101582214	G/A	cg04800749	chr22:50320996	CRELD2	0.35	6.1	0.31	2.92e-9	Renal function-related traits (eGRFcrea);
LIHC	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-8.14	-0.4	7.27e-15	Morning vs. evening chronotype;
LIHC	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.54	8.53	0.42	4.82e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.49	7.67	0.38	1.76e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg25344623	chr2:136566232	LCT	-0.38	-6.18	-0.32	1.78e-9	Corneal structure;
LIHC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.37	-6.73	-0.34	7.12e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs6691722	0.503	rs12135404	chr1:24704263	C/T	cg18323236	chr1:24743029	NIPAL3	-0.4	-7.21	-0.36	3.57e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs263063	0.920	rs2240678	chr19:5041178	C/T	cg18473234	chr19:5097819	KDM4B	0.58	7.02	0.35	1.19e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.41	-7.97	-0.4	2.34e-14	Height;
LIHC	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.4	-6.73	-0.34	7.02e-11	Schizophrenia;
LIHC	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.62	8.8	0.43	6.96e-17	Eotaxin levels;
LIHC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.69	-8.6	-0.42	2.87e-16	Gut microbiome composition (summer);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13426544	chr11:65729012	SART1	-0.48	-7.09	-0.36	7.52e-12	Cognitive function;
LIHC	cis	rs11229555	0.645	rs12273638	chr11:58186335	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	13.36	0.59	4.56e-33	Hip circumference adjusted for BMI;
LIHC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.76	0.34	5.99e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs9914544	0.564	rs11868500	chr17:18770254	A/G	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.73	-0.34	7.38e-11	Educational attainment (years of education);
LIHC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-6.03	-0.31	4.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.6	6.01	0.31	4.64e-9	Carotid intima media thickness;
LIHC	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg20991723	chr1:152506922	NA	0.5	8.43	0.41	9.96e-16	Hair morphology;
LIHC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10838687	0.867	rs2633082	chr11:47248050	C/G	cg25783544	chr11:47291846	MADD	-0.5	-6.53	-0.33	2.36e-10	Proinsulin levels;
LIHC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.83	-15.78	-0.65	1.52e-42	Height;
LIHC	cis	rs11212260	0.655	rs75147935	chr11:107289379	G/A	cg25435332	chr11:107328525	CWF19L2	0.8	8.13	0.4	7.75e-15	IgG glycosylation;
LIHC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05195085	chr7:157951403	PTPRN2	0.22	6.46	0.33	3.54e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.72	0.39	1.27e-13	Prudent dietary pattern;
LIHC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-0.68	-7.34	-0.37	1.55e-12	Coronary artery disease;
LIHC	cis	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg03342759	chr3:160939853	NMD3	0.57	7.39	0.37	1.13e-12	Morning vs. evening chronotype;
LIHC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg00204748	chr12:29376779	FAR2	-0.39	-7.52	-0.38	5.02e-13	QT interval;
LIHC	cis	rs12744310	1.000	rs34315814	chr1:41769172	T/C	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg07195577	chr17:27052828	TLCD1	0.43	5.76	0.3	1.85e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.73	-0.39	1.24e-13	QT interval;
LIHC	cis	rs2574704	0.816	rs2443724	chr3:11655351	C/G	cg15876825	chr3:11651881	VGLL4	-0.49	-7.9	-0.39	3.87e-14	Body mass index;
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg13395646	chr4:1353034	KIAA1530	-0.47	-7.78	-0.39	8.83e-14	Obesity-related traits;
LIHC	trans	rs7714584	1.000	rs11951694	chr5:150254338	G/A	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.5	0.42	5.93e-16	Bladder cancer;
LIHC	cis	rs6066825	0.627	rs6012497	chr20:47228591	C/T	cg18078177	chr20:47281410	PREX1	0.48	7.85	0.39	5.23e-14	Colorectal cancer;
LIHC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02886208	chr11:14281011	SPON1	0.61	9.02	0.44	1.39e-17	Mitochondrial DNA levels;
LIHC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.96	-0.47	1.1e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.52	7.99	0.4	2.05e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.49	-8.92	-0.43	2.79e-17	Atrioventricular conduction;
LIHC	trans	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg09045935	chr12:6379348	NA	0.84	6.92	0.35	2.28e-11	Blood metabolite levels;
LIHC	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	9.55	0.46	2.59e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.58	8.04	0.4	1.46e-14	Aortic root size;
LIHC	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.84	0.35	3.68e-11	Height;
LIHC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.36	9.26	0.45	2.27e-18	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21262094	chr8:56986557	SNORD54;RPS20	0.43	6.18	0.32	1.79e-9	Cognitive function;
LIHC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.2	0.45	3.59e-18	Eosinophil percentage of white cells;
LIHC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.57	9.89	0.47	1.96e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.24	6.44	0.33	4.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg05044414	chr3:183734942	ABCC5	0.33	5.99	0.31	5.24e-9	Anterior chamber depth;
LIHC	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.15	0.32	2.11e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.42	6.97	0.35	1.62e-11	Mean corpuscular volume;
LIHC	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.4	-6.16	-0.32	2.03e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.66	-0.5	4.19e-23	Chronic sinus infection;
LIHC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg08847533	chr14:75593920	NEK9	-0.55	-8.37	-0.41	1.55e-15	IgG glycosylation;
LIHC	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.63	5.84	0.3	1.23e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.45	9.1	0.44	7.49e-18	Birth weight;
LIHC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.53	8.12	0.4	8.59e-15	Resting heart rate;
LIHC	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.55	9.64	0.46	1.32e-19	Total cholesterol levels;
LIHC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.68	-9.28	-0.45	1.97e-18	Corneal structure;
LIHC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.11	-0.78	7.6e-72	Height;
LIHC	cis	rs3736485	0.966	rs7173880	chr15:51785433	C/A	cg08986416	chr15:51914746	DMXL2	-0.41	-6.11	-0.31	2.7e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.03e-40	Aortic root size;
LIHC	cis	rs4788570	0.527	rs72791971	chr16:71477297	C/G	cg06353428	chr16:71660113	MARVELD3	-1.18	-10.15	-0.48	2.42e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.43	-8.34	-0.41	1.88e-15	Testicular germ cell tumor;
LIHC	cis	rs965469	1.000	rs1040727	chr20:3264292	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.6	-0.34	1.6e-10	IFN-related cytopenia;
LIHC	trans	rs12753920	0.671	rs4658129	chr1:92577848	C/G	cg15668468	chr10:118892869	VAX1	0.44	6.3	0.32	8.93e-10	Systemic lupus erythematosus;
LIHC	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.47	5.83	0.3	1.31e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.6	12.07	0.55	3.56e-28	Airflow obstruction;
LIHC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.02	-0.44	1.37e-17	Bipolar disorder and schizophrenia;
LIHC	trans	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19862616	chr7:65841803	NCRNA00174	0.61	9.28	0.45	2.02e-18	Eotaxin levels;
LIHC	cis	rs12079745	0.793	rs10919156	chr1:169345054	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-7.12	-0.36	6.54e-12	QT interval;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.13	0.55	2e-28	Prudent dietary pattern;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14191109	chr10:70287438	SLC25A16	-0.4	-6.19	-0.32	1.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15166552	chr3:156273067	SSR3	0.48	6.24	0.32	1.31e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.96	-0.31	6.15e-9	Vitiligo;
LIHC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.93	13.52	0.59	1.12e-33	Primary sclerosing cholangitis;
LIHC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.36	5.85	0.3	1.15e-8	Obesity-related traits;
LIHC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg03037974	chr15:76606532	NA	0.72	13.81	0.6	8.39e-35	Blood metabolite levels;
LIHC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.65	6.45	0.33	3.78e-10	Type 2 diabetes nephropathy;
LIHC	trans	rs4714291	0.832	rs3008839	chr6:40052660	G/A	cg02267698	chr19:7991119	CTXN1	-0.42	-7.13	-0.36	5.92e-12	Strep throat;
LIHC	cis	rs62380364	0.602	rs640177	chr5:88002084	T/A	cg22951263	chr5:87985283	NA	-0.39	-6.89	-0.35	2.7e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7546668	1.000	rs7516435	chr1:15868692	A/G	cg11706911	chr1:15910989	AGMAT	0.43	6.49	0.33	3.09e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.75	8.56	0.42	3.87e-16	Cognitive function;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13852536	chr9:32567045	NDUFB6	0.4	6.07	0.31	3.32e-9	Bilirubin levels;
LIHC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.99	17.27	0.68	1.71e-48	Breast cancer;
LIHC	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg06360820	chr2:242988706	NA	-0.84	-11.71	-0.54	7.1e-27	Obesity-related traits;
LIHC	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.44	-0.33	4.1e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg26195577	chr20:24973756	C20orf3	-1.05	-9.38	-0.45	9.19e-19	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg00656387	chr3:40428638	ENTPD3	0.46	7.79	0.39	7.91e-14	Renal cell carcinoma;
LIHC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg04013166	chr16:89971882	TCF25	0.53	6.67	0.34	1.05e-10	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.47	-8.12	-0.4	8.73e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.51	5.81	0.3	1.42e-8	Alzheimer's disease;
LIHC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg09182678	chr22:50328711	NA	-0.7	-7.85	-0.39	5.58e-14	Schizophrenia;
LIHC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	0.85	11.09	0.51	1.32e-24	Skin colour saturation;
LIHC	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.15e-22	Colorectal cancer;
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.5	7.72	0.39	1.25e-13	Testicular germ cell tumor;
LIHC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.23	18.11	0.7	7.3e-52	Type 1 diabetes nephropathy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10235275	chr10:65225544	JMJD1C;LOC84989	-0.45	-6.44	-0.33	4.08e-10	Pancreatic cancer;
LIHC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.75	-8.57	-0.42	3.65e-16	Vitiligo;
LIHC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02985541	chr2:219472218	PLCD4	0.45	8.49	0.42	6.49e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.29	-16.56	-0.67	1.23e-45	Diabetic kidney disease;
LIHC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.66	-11.39	-0.52	1.08e-25	Crohn's disease;
LIHC	cis	rs918629	0.679	rs57471342	chr5:95272429	A/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.24	-0.32	1.28e-9	IgG glycosylation;
LIHC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.73	6.63	0.34	1.35e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.69	7.04	0.36	1.05e-11	Migraine;Coronary artery disease;
LIHC	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-0.76	-8.83	-0.43	5.67e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.55	-0.33	2.14e-10	Metabolite levels;
LIHC	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg16684958	chr7:75615977	POR	-0.51	-8.52	-0.42	5.27e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17152411	0.895	rs7914206	chr10:126585397	G/A	cg07906193	chr10:126599966	NA	0.42	6.47	0.33	3.4e-10	Height;
LIHC	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg12560992	chr17:57184187	TRIM37	0.69	8.92	0.43	2.78e-17	Vitamin D levels;
LIHC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17554472	chr22:41940697	POLR3H	0.56	6.01	0.31	4.84e-9	Vitiligo;
LIHC	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.34	5.82	0.3	1.39e-8	Mean platelet volume;
LIHC	cis	rs10733682	0.633	rs869500	chr9:129465898	G/A	cg00232160	chr9:129468157	NA	0.37	6.41	0.33	4.89e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14396892	chr9:96623032	NA	-0.32	-6.31	-0.32	8.81e-10	DNA methylation (variation);
LIHC	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.37e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.74	-9.61	-0.46	1.62e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	7.46	0.37	7.05e-13	Total body bone mineral density;
LIHC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.62	9.67	0.46	1.07e-19	Educational attainment;
LIHC	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs75908454	1.000	rs77395702	chr6:169799664	T/C	cg19338460	chr6:170058176	WDR27	-0.58	-5.83	-0.3	1.31e-8	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs11098699	0.821	rs11939262	chr4:124207018	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.38	0.33	5.62e-10	Mosquito bite size;
LIHC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.25	-5.83	-0.3	1.25e-8	Longevity;Endometriosis;
LIHC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.58	0.46	2.05e-19	Tonsillectomy;
LIHC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.61	-8.8	-0.43	7e-17	Testicular germ cell tumor;
LIHC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.68	8.77	0.43	8.6e-17	Fat distribution (HIV);
LIHC	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.51	8.46	0.42	8.07e-16	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.23	0.36	3.09e-12	Lung cancer;
LIHC	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.59	8.89	0.43	3.53e-17	Coronary artery disease;
LIHC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.58	7.83	0.39	6.1e-14	Aortic root size;
LIHC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.77	-11.28	-0.52	2.71e-25	Coronary artery disease;
LIHC	trans	rs6489882	0.703	rs1051042	chr12:113357237	G/C	cg10175203	chr3:128143634	NA	0.39	6.33	0.32	7.64e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.35	9.34	0.45	1.29e-18	Schizophrenia;
LIHC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.25	0.41	3.42e-15	Bladder cancer;
LIHC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	6.21	0.32	1.54e-9	Schizophrenia;
LIHC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.67	-11.89	-0.54	1.67e-27	Iron status biomarkers;
LIHC	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.45	-6.53	-0.33	2.38e-10	Sudden cardiac arrest;
LIHC	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.63	10.22	0.48	1.38e-21	Schizophrenia;
LIHC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.67	-12.11	-0.55	2.54e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-7.08	-0.36	8.35e-12	Neuroticism;
LIHC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg24127593	chr4:1648399	FAM53A	0.42	5.99	0.31	5.18e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17691542	chr6:26056736	HIST1H1C	0.64	7.06	0.36	9.57e-12	Iron status biomarkers;
LIHC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.39	-6.03	-0.31	4.23e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	cis	rs72843506	0.586	rs73980762	chr17:19869426	T/C	cg12065943	chr17:19881925	AKAP10	-0.38	-6.4	-0.33	5.06e-10	Schizophrenia;
LIHC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.63	12.1	0.55	2.64e-28	Mean corpuscular volume;
LIHC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg03859395	chr2:55845619	SMEK2	-0.83	-14.85	-0.63	7.69e-39	Metabolic syndrome;
LIHC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.73	-13.56	-0.59	8.13e-34	Height;
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.02	0.35	1.22e-11	Renal cell carcinoma;
LIHC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.56	7.57	0.38	3.56e-13	Schizophrenia;
LIHC	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.41	5.95	0.31	6.75e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.63	9.87	0.47	2.22e-20	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.96	19.32	0.72	9.56e-57	Height;
LIHC	cis	rs17106184	1.000	rs12095997	chr1:51391845	C/T	cg07174182	chr1:51127561	FAF1	-0.75	-8.33	-0.41	1.95e-15	Type 2 diabetes;
LIHC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-6.15	-0.32	2.22e-9	Immature fraction of reticulocytes;
LIHC	cis	rs858239	0.863	rs466225	chr7:23332403	G/T	cg00469287	chr7:23338798	C7orf30	0.47	6.1	0.31	2.93e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2019216	0.967	rs2342216	chr17:21910379	A/C	cg22648282	chr17:21454238	C17orf51	-0.35	-6.2	-0.32	1.62e-9	Pelvic organ prolapse;
LIHC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.73	0.3	2.21e-8	Morning vs. evening chronotype;
LIHC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.56	0.53	2.52e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.36	-5.71	-0.3	2.41e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03264133	chr6:25882463	NA	-0.45	-6.75	-0.34	6.16e-11	Height;
LIHC	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.38	6.89	0.35	2.62e-11	Obesity;
LIHC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.77	12.85	0.57	4.23e-31	Menarche (age at onset);
LIHC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.58	-11.51	-0.53	3.77e-26	Coronary artery disease;
LIHC	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.94	19.23	0.72	2.29e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg15691649	chr6:25882328	NA	-0.44	-6.98	-0.35	1.58e-11	Height;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.14	-0.32	2.28e-9	Total body bone mineral density;
LIHC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.69	-12.58	-0.56	4.33e-30	Dental caries;
LIHC	cis	rs244293	1.000	rs244296	chr17:53242878	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.26	-0.37	2.66e-12	Menarche (age at onset);
LIHC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	10.13	0.48	2.91e-21	Alzheimer's disease;
LIHC	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00495681	chr13:53174319	NA	-0.39	-6.29	-0.32	9.92e-10	Lewy body disease;
LIHC	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.83	-0.3	1.31e-8	Neuroticism;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.87	0.35	3.05e-11	Renal cell carcinoma;
LIHC	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.35	5.96	0.31	6.36e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	9.0	0.44	1.59e-17	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25654301	chr17:73511699	TSEN54;CASKIN2	0.47	6.27	0.32	1.09e-9	Lung function (FEV1/FVC);
LIHC	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg03934865	chr2:198174659	NA	0.48	6.85	0.35	3.54e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.55	0.56	5.67e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.53	-7.74	-0.39	1.14e-13	Facial morphology (factor 19);
LIHC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.53	-8.21	-0.41	4.64e-15	Total body bone mineral density;
LIHC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02450064	chr17:40260053	DHX58	-0.3	-6.15	-0.32	2.17e-9	Fibrinogen levels;
LIHC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.47	-7.62	-0.38	2.58e-13	Fibrinogen levels;
LIHC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.3	5.87	0.3	1.01e-8	Colorectal cancer;
LIHC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg07061783	chr6:25882402	NA	-0.51	-6.54	-0.33	2.21e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-9.44	-0.45	6.16e-19	Asthma;
LIHC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.83	6.64	0.34	1.26e-10	Body mass index;
LIHC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg18944383	chr4:111397179	ENPEP	0.26	6.41	0.33	4.94e-10	Coronary artery disease;
LIHC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg14580859	chr9:123691850	NA	0.37	6.51	0.33	2.67e-10	Rheumatoid arthritis;
LIHC	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg27124370	chr19:33622961	WDR88	0.47	7.04	0.36	1.03e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg26951091	chr14:76844913	ESRRB	0.59	6.48	0.33	3.28e-10	Putamen volume;
LIHC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.33	2.39e-10	Vitiligo;
LIHC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg10820045	chr2:198174542	NA	-0.55	-9.18	-0.44	4.13e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.82	-10.42	-0.49	2.81e-22	Orofacial clefts;
LIHC	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.61	7.52	0.38	4.92e-13	Coronary artery disease;
LIHC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.5	-7.78	-0.39	8.92e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04476341	chr5:669733	TPPP	0.39	8.78	0.43	7.81e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.46	7.09	0.36	7.93e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.7	-15.47	-0.64	2.8e-41	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09302904	chr17:62340561	TEX2	0.54	7.13	0.36	5.88e-12	Lung function (FEV1/FVC);
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.87	13.67	0.59	2.97e-34	Skin colour saturation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20586607	chr14:50235780	KLHDC2	0.45	6.17	0.32	1.89e-9	Pancreatic cancer;
LIHC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.67	-6.05	-0.31	3.87e-9	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.68	-10.53	-0.49	1.25e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg24163568	chr5:669837	TPPP	0.39	8.14	0.4	7.4e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.42	5.75	0.3	1.98e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.42	6.24	0.32	1.3e-9	Type 2 diabetes;
LIHC	cis	rs4273100	0.526	rs2074280	chr17:18917915	A/G	cg27028682	chr17:19100026	NA	0.52	7.54	0.38	4.18e-13	Schizophrenia;
LIHC	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg18323236	chr1:24743029	NIPAL3	-0.41	-7.83	-0.39	6.18e-14	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.76	-10.4	-0.49	3.39e-22	Alzheimer's disease;
LIHC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.27	-0.45	2.21e-18	Electroencephalogram traits;
LIHC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-9.14	-0.44	5.83e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.61	-0.42	2.75e-16	Exhaled nitric oxide output;
LIHC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg24163568	chr5:669837	TPPP	-0.41	-8.43	-0.41	9.44e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.36	7.06	0.36	9.47e-12	Quantitative traits;
LIHC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.41	0.37	1.02e-12	Tonsillectomy;
LIHC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg05896524	chr21:47604654	C21orf56	0.45	6.86	0.35	3.24e-11	Testicular germ cell tumor;
LIHC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.29	0.66	1.46e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg26441486	chr22:50317300	CRELD2	0.36	6.08	0.31	3.25e-9	Schizophrenia;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.51	0.42	5.55e-16	Motion sickness;
LIHC	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.27	-0.37	2.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.74	11.27	0.52	3e-25	Corneal astigmatism;
LIHC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.5	0.33	2.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3770081	1.000	rs2118521	chr2:86204379	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.04	-0.4	1.49e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs240764	0.645	rs239208	chr6:101139285	G/A	cg12253828	chr6:101329408	ASCC3	0.43	6.48	0.33	3.14e-10	Neuroticism;
LIHC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.72	-11.42	-0.53	8.53e-26	Inflammatory bowel disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04737350	chr12:80170325	PPP1R12A	0.3	6.13	0.31	2.48e-9	Cognitive function;
LIHC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.89	-0.35	2.67e-11	Body mass index;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.49	5.75	0.3	1.97e-8	Bladder cancer;
LIHC	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-6.62	-0.34	1.36e-10	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.42	-5.82	-0.3	1.34e-8	Total body bone mineral density;
LIHC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.35	5.71	0.3	2.43e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.6	-0.34	1.56e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.84	0.39	5.69e-14	Schizophrenia;
LIHC	cis	rs3820500	0.543	rs10923316	chr1:118026778	C/T	cg20383390	chr1:117909022	MAN1A2	0.46	6.03	0.31	4.33e-9	Pneumonia;
LIHC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.49	9.18	0.44	4.06e-18	Hemoglobin concentration;
LIHC	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg18898632	chr2:242989856	NA	-0.67	-8.78	-0.43	7.83e-17	Obesity-related traits;
LIHC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.41	0.33	4.71e-10	Morning vs. evening chronotype;
LIHC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-5.76	-0.3	1.88e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.58	-0.38	3.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs75908454	1.000	rs76673185	chr6:169973675	G/C	cg19338460	chr6:170058176	WDR27	-0.82	-7.41	-0.37	9.95e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg20387954	chr3:183756860	HTR3D	0.28	6.03	0.31	4.37e-9	Anterior chamber depth;
LIHC	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.5	8.02	0.4	1.75e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.46	-0.49	2.18e-22	Chronic sinus infection;
LIHC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.56	7.64	0.38	2.21e-13	Coronary artery disease;
LIHC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.9	0.3	8.52e-9	Life satisfaction;
LIHC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg19680672	chr10:131412579	MGMT	-0.42	-6.58	-0.34	1.75e-10	Response to temozolomide;
LIHC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.67	13.22	0.58	1.57e-32	High light scatter reticulocyte count;
LIHC	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.2	0.32	1.63e-9	Rheumatoid arthritis;
LIHC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.82	-12.49	-0.56	9.48e-30	Obesity-related traits;
LIHC	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg20568497	chr10:133558893	NA	0.41	6.11	0.31	2.7e-9	Survival in rectal cancer;
LIHC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	trans	rs36350	0.624	rs11621415	chr14:72386292	T/C	cg16370061	chr5:179226009	MGAT4B;MIR1229	0.35	6.41	0.33	4.72e-10	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8084351	0.512	rs2068861	chr18:50806973	G/A	cg24270629	chr18:50823537	DCC	-0.51	-7.64	-0.38	2.26e-13	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	trans	rs6866721	0.765	rs62374490	chr5:116214852	G/A	cg07571379	chr11:134631427	NA	-0.29	-6.09	-0.31	3.08e-9	Body mass index;
LIHC	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.43	6.06	0.31	3.57e-9	Tuberculosis;
LIHC	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.58	0.34	1.74e-10	Renal cell carcinoma;
LIHC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg16479474	chr6:28041457	NA	0.46	6.58	0.34	1.79e-10	Depression;
LIHC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg17279839	chr7:150038598	RARRES2	0.5	10.58	0.5	8.39e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.39	7.05	0.36	1e-11	Psoriasis;
LIHC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.68	-7.61	-0.38	2.63e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.42	6.51	0.33	2.63e-10	Resting heart rate;
LIHC	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.3	-5.99	-0.31	5.3300000000000004e-09	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.86	10.8	0.5	1.41e-23	Mean platelet volume;
LIHC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg16586182	chr3:47516702	SCAP	-0.5	-8.93	-0.43	2.66e-17	Colorectal cancer;
LIHC	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.45	6.68	0.34	9.63e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2834188	0.889	rs2040108	chr21:34676158	T/C	cg14352951	chr21:34696688	IFNAR1	0.44	6.11	0.31	2.75e-9	Narcolepsy;
LIHC	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.15	-0.36	5.19e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg11070056	chr1:107600091	PRMT6	-0.72	-12.42	-0.56	1.67e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg18016565	chr1:150552671	MCL1	0.5	9.51	0.46	3.62e-19	Melanoma;
LIHC	trans	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg00845942	chr12:64062724	DPY19L2	-0.55	-6.05	-0.31	3.77e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	6.65	0.34	1.2e-10	IgG glycosylation;
LIHC	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg05262829	chr1:226921576	ITPKB	0.43	8.24	0.41	3.8e-15	Parkinson's disease;
LIHC	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.08	-0.31	3.19e-9	Pancreatic cancer;
LIHC	trans	rs3783890	1.000	rs71419270	chr14:93772500	T/A	cg02802420	chr16:69363236	PDF;COG8	0.32	6.25	0.32	1.24e-9	Body mass index;
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.27	-0.55	6.42e-29	Alzheimer's disease;
LIHC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	2.97e-30	Menopause (age at onset);
LIHC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.78	-0.34	5.16e-11	Obesity-related traits;
LIHC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg07424592	chr7:64974309	NA	0.8	9.43	0.45	6.25e-19	Diabetic kidney disease;
LIHC	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.85	0.3	1.16e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	1.18	14.34	0.61	7.88e-37	Eosinophil percentage of granulocytes;
LIHC	trans	rs3112255	1.000	rs2137674	chr2:101305228	C/A	cg06958034	chr1:23346203	KDM1A	-0.46	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2279817	0.780	rs1124447	chr1:18007598	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.73	-0.39	1.2e-13	Neuroticism;
LIHC	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg01843034	chr6:37503916	NA	-0.47	-8.06	-0.4	1.31e-14	Cognitive performance;
LIHC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.26	6.91	0.35	2.45e-11	Cardiovascular disease risk factors;
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs28735056	0.967	rs56071379	chr18:77647406	G/A	cg20368463	chr18:77673604	PQLC1	-0.36	-6.1	-0.31	2.86e-9	Schizophrenia;
LIHC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.52	0.46	3.16e-19	Hip circumference adjusted for BMI;
LIHC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg27255678	chr10:102756921	LZTS2	0.51	7.31	0.37	1.89e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11212737	0.739	rs2624145	chr11:108520478	A/G	cg22776369	chr11:108536276	DDX10	0.38	6.21	0.32	1.55e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.29	-0.32	9.47e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs903552	1.000	rs8041563	chr15:102005824	G/C	cg19295451	chr15:102010161	PCSK6	-0.46	-6.33	-0.32	7.51e-10	Diabetic kidney disease;
LIHC	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.53	-7.34	-0.37	1.53e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.37	5.71	0.3	2.45e-8	Resting heart rate;
LIHC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.99	0.57	1.21e-31	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.0	-0.31	4.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.94	17.99	0.7	2.25e-51	Menopause (age at onset);
LIHC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.79	11.34	0.52	1.64e-25	Coronary artery disease;
LIHC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.69	9.31	0.45	1.63e-18	Mean platelet volume;
LIHC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.87	-0.47	2.27e-20	Chronic sinus infection;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20347042	chr7:2122685	MAD1L1	0.38	6.05	0.31	3.7e-9	Longevity;
LIHC	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.47	7.64	0.38	2.2e-13	Tuberculosis;
LIHC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.45	-6.64	-0.34	1.23e-10	Diastolic blood pressure;
LIHC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.65	0.38	2.01e-13	Mean platelet volume;
LIHC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.34	7.34e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.49	0.42	6.56e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.43	6.97	0.35	1.61e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.38	-6.39	-0.33	5.41e-10	Educational attainment;
LIHC	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg20368463	chr18:77673604	PQLC1	0.54	6.85	0.35	3.47e-11	Opioid sensitivity;
LIHC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.79	11.3	0.52	2.19e-25	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.45	0.64	3.26e-41	Chronic sinus infection;
LIHC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg15848620	chr12:58087721	OS9	-0.56	-7.67	-0.38	1.85e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.32	-5.92	-0.31	7.69e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs244293	1.000	rs244293	chr17:53230722	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.36	-0.33	6.38e-10	Menarche (age at onset);
LIHC	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.87	-0.35	2.97e-11	Metabolite levels;
LIHC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.34	6.78	0.34	5.26e-11	Renal cell carcinoma;
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	6.68	0.34	9.97e-11	Coronary artery disease;
LIHC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.77	0.69	1.69e-50	Gut microbiome composition (summer);
LIHC	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.61	-8.3	-0.41	2.49e-15	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.82	-0.35	4.26e-11	Blood pressure;
LIHC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg03579045	chr8:11579013	GATA4	0.39	5.75	0.3	2.03e-8	Monocyte count;
LIHC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.44	-6.16	-0.32	2.08e-9	Initial pursuit acceleration;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.01	-0.4	1.84e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.03	-20.26	-0.74	1.58e-60	Exhaled nitric oxide output;
LIHC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg15902774	chr15:75289873	SCAMP5	0.44	6.49	0.33	3.08e-10	Lung cancer;
LIHC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08219700	chr8:58056026	NA	0.5	6.34	0.32	7.14e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1198430	0.759	rs1198438	chr1:23749557	C/G	cg13183780	chr1:23809682	ASAP3	-0.38	-6.68	-0.34	9.44e-11	Total cholesterol levels;
LIHC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg13446199	chr8:143762866	PSCA	-0.2	-5.78	-0.3	1.71e-8	Urinary tract infection frequency;
LIHC	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg03037974	chr15:76606532	NA	0.84	17.63	0.69	6.28e-50	Blood metabolite levels;
LIHC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.55	8.78	0.43	8.02e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.37	6.08	0.31	3.25e-9	Anterior chamber depth;
LIHC	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.84	0.35	3.67e-11	Ileal carcinoids;
LIHC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02290350	chr8:58132656	NA	0.37	7.99	0.4	2.13e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.53	-0.33	2.37e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.63	10.46	0.49	2.05e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.58	11.17	0.52	6.74e-25	Mean corpuscular volume;
LIHC	cis	rs8084351	0.577	rs10502959	chr18:50678732	C/T	cg24270629	chr18:50823537	DCC	-0.44	-6.67	-0.34	1.05e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-0.76	-6.96	-0.35	1.69e-11	Coronary artery disease;
LIHC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.36	-0.37	1.4e-12	Electroencephalogram traits;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10150615	chr22:24372951	LOC391322	-0.57	-8.24	-0.41	3.66e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg20569855	chr1:109824440	PSRC1	0.49	6.32	0.32	7.99e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg19413766	chr7:29689036	LOC646762	-0.62	-6.35	-0.32	6.78e-10	Facial emotion recognition (angry faces);
LIHC	cis	rs13020137	1	rs13020137	chr2:130757304	A/G	cg09663323	chr2:130956255	TUBA3E	0.46	7.05	0.36	1.01e-11	Schizophrenia;
LIHC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.59	0.56	3.89e-30	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.86	-0.3	1.06e-8	Type 2 diabetes;
LIHC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.54	8.04	0.4	1.5e-14	High light scatter reticulocyte count;
LIHC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.65	8.95	0.44	2.27e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.36	-6.54	-0.33	2.31e-10	Immature fraction of reticulocytes;
LIHC	cis	rs74233809	1.000	rs34747231	chr10:104942244	T/G	cg03493300	chr10:104813866	CNNM2	0.45	5.93	0.31	7.42e-9	Birth weight;
LIHC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs11673344	0.750	rs111543213	chr19:37642385	C/A	cg27390819	chr19:37464633	NA	-0.51	-6.23	-0.32	1.35e-9	Obesity-related traits;
LIHC	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-6.49	-0.33	3.04e-10	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.48	0.37	6.36e-13	Aortic root size;
LIHC	cis	rs11603020	0.950	rs28362948	chr11:57369013	A/C	cg19752551	chr11:57585705	CTNND1	-0.54	-6.73	-0.34	7.15e-11	Blood protein levels;
LIHC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21467203	chr3:49911342	NA	-0.6	-10.9	-0.51	6.2e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.71	-13.15	-0.58	3.1e-32	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.43	6.17	0.32	1.89e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg11766577	chr21:47581405	C21orf56	-0.38	-6.01	-0.31	4.86e-9	Testicular germ cell tumor;
LIHC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.34	5.78	0.3	1.65e-8	Schizophrenia;
LIHC	cis	rs847649	0.767	rs11972261	chr7:102641244	T/G	cg18108683	chr7:102477205	FBXL13	0.44	6.6	0.34	1.57e-10	Morning vs. evening chronotype;
LIHC	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.32	7.63	0.38	2.32e-13	Corneal astigmatism;
LIHC	cis	rs2834256	0.886	rs7281625	chr21:35066836	A/C	cg14850771	chr21:34775459	IFNGR2	-0.42	-6.54	-0.33	2.24e-10	Red cell distribution width;
LIHC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.91	15.46	0.64	3.01e-41	Tonsillectomy;
LIHC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.73	-0.3	2.2e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.39	6.59	0.34	1.65e-10	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-1.19	-10.59	-0.5	7.59e-23	Breast cancer;
LIHC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.56	-6.08	-0.31	3.13e-9	Hair shape;
LIHC	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-10.93	-0.51	4.65e-24	Mitochondrial DNA levels;
LIHC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.68	10.93	0.51	4.64e-24	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14877741	chr9:125703099	RABGAP1	0.44	6.34	0.32	7.45e-10	Pancreatic cancer;
LIHC	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.2	-0.32	1.67e-9	Coronary artery disease;
LIHC	cis	rs244293	0.965	rs244303	chr17:53238728	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.2	-0.32	1.6e-9	Menarche (age at onset);
LIHC	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.68	7.0	0.35	1.36e-11	Schizophrenia;
LIHC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.99	19.71	0.73	2.65e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.72	-10.96	-0.51	3.71e-24	Longevity;
LIHC	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma (childhood onset);
LIHC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.48	7.51	0.38	5.23e-13	Methadone dose in opioid dependence;
LIHC	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg10820045	chr2:198174542	NA	0.51	8.09	0.4	1.03e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg26395211	chr5:140044315	WDR55	0.42	6.24	0.32	1.32e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.88	-0.54	1.78e-27	Type 2 diabetes;
LIHC	cis	rs2073300	0.793	rs6048814	chr20:23448411	A/C	cg12062639	chr20:23401060	NAPB	0.81	9.62	0.46	1.56e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg22633049	chr21:46681294	NA	0.37	6.39	0.33	5.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.86	12.17	0.55	1.45e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.47	6.24	0.32	1.32e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.5	-0.38	5.56e-13	Schizophrenia;
LIHC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-9.04	-0.44	1.22e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-8.91	-0.43	3.17e-17	Bipolar disorder;
LIHC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg06598544	chr20:61472147	COL9A3	-0.79	-7.82	-0.39	6.46e-14	Obesity-related traits;
LIHC	cis	rs11031096	0.711	rs10835723	chr11:4207566	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-6.0	-0.31	4.93e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.59	-8.86	-0.43	4.53e-17	Menopause (age at onset);
LIHC	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.66	10.35	0.49	5.05e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs17739167	0.550	rs17739125	chr15:42234424	T/C	cg20935245	chr15:42234343	EHD4	-0.42	-7.82	-0.39	6.41e-14	Monocyte count;
LIHC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.55	-8.17	-0.4	6.15e-15	Age at first birth;
LIHC	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	0.84	13.24	0.58	1.39e-32	Testicular germ cell tumor;
LIHC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.56	10.27	0.49	9.71e-22	Methadone dose in opioid dependence;
LIHC	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg09795085	chr6:101329169	ASCC3	-0.52	-7.25	-0.36	2.82e-12	Neuroticism;
LIHC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg10820045	chr2:198174542	NA	-0.57	-9.48	-0.46	4.3e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs716804	0.703	rs7947666	chr11:10305095	A/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.84	-0.3	1.19e-8	Neuroticism;
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-11.51	-0.53	3.9e-26	Longevity;Endometriosis;
LIHC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10797726	chr6:82957093	IBTK	0.41	6.18	0.32	1.83e-9	Cognitive function;
LIHC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02985541	chr2:219472218	PLCD4	0.43	7.03	0.36	1.15e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.58	-6.45	-0.33	3.82e-10	Vitiligo;
LIHC	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.81	-10.36	-0.49	4.52e-22	Orofacial clefts;
LIHC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.95	-0.31	6.67e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13173722	chr20:60553138	TAF4	0.41	6.18	0.32	1.82e-9	Bilirubin levels;
LIHC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.64	-7.54	-0.38	4.27e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.6	7.61	0.38	2.73e-13	Diastolic blood pressure;
LIHC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.25	-7.75	-0.39	1.08e-13	Motion sickness;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg25084332	chr12:62997409	MIRLET7I;C12orf61	-0.39	-6.35	-0.32	6.8e-10	Eotaxin levels;
LIHC	trans	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg25039879	chr17:56429692	SUPT4H1	0.75	8.44	0.42	8.81e-16	Cognitive test performance;
LIHC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg17724175	chr1:150552817	MCL1	0.47	9.02	0.44	1.38e-17	Melanoma;
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.42	-6.89	-0.35	2.7e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.27	-6.52	-0.33	2.46e-10	Primary biliary cholangitis;
LIHC	trans	rs10411161	0.702	rs10403189	chr19:52400673	A/G	cg22319618	chr22:45562946	NUP50	0.64	8.62	0.42	2.61e-16	Breast cancer;
LIHC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-8.39	-0.41	1.31e-15	Gut microbiome composition (summer);
LIHC	trans	rs4596713	0.508	rs4076287	chr9:71755333	A/G	cg16512924	chr15:28394682	HERC2	0.39	6.12	0.31	2.56e-9	Headache;
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20570016	chr1:156261298	TMEM79	0.38	6.11	0.31	2.75e-9	Tonsillectomy;
LIHC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.69	13.22	0.58	1.6e-32	Sjögren's syndrome;
LIHC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.69	-9.72	-0.47	6.92e-20	Monocyte percentage of white cells;
LIHC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.72	-0.5	2.62e-23	Chronic sinus infection;
LIHC	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.16	-0.36	4.94e-12	Mean platelet volume;
LIHC	cis	rs2607426	1.000	rs2230694	chr19:41263403	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.48	-5.99	-0.31	5.41e-9	Blood protein levels;
LIHC	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.81	-0.3	1.42e-8	Blood pressure;
LIHC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.43	6.55	0.33	2.13e-10	Gut microbiome composition (summer);
LIHC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.52	5.72	0.3	2.33e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.52	-7.24	-0.36	3.08e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg18478394	chr8:109455254	TTC35	0.43	7.59	0.38	3.15e-13	Dupuytren's disease;
LIHC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.2	0.32	1.6e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg07884673	chr3:53033167	SFMBT1	0.9	6.59	0.34	1.65e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs882732	1.000	rs10147337	chr14:95025560	A/T	cg14866387	chr14:95027382	SERPINA4	-0.45	-6.03	-0.31	4.16e-9	Blood protein levels;
LIHC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg07636037	chr3:49044803	WDR6	-0.81	-8.08	-0.4	1.15e-14	Cognitive function;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.06	-0.36	9.31e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15910486	chr5:142783621	NR3C1	0.46	6.15	0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.89	0.6	4.28e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.15	-0.32	2.17e-9	Neuroticism;
LIHC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.52	7.02	0.36	1.17e-11	Ulcerative colitis;
LIHC	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.08	-0.31	3.19e-9	Pancreatic cancer;
LIHC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg19680672	chr10:131412579	MGMT	-0.45	-6.86	-0.35	3.33e-11	Response to temozolomide;
LIHC	cis	rs735860	0.763	rs6458912	chr6:53147965	G/A	cg10236188	chr6:53219634	NA	-0.41	-7.4	-0.37	1.05e-12	Glaucoma;
LIHC	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.62	8.8	0.43	6.96e-17	Eotaxin levels;
LIHC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.26e-34	Aortic root size;
LIHC	trans	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.43	-6.07	-0.31	3.33e-9	Type 2 diabetes;
LIHC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.82	-0.5	1.19e-23	Response to antipsychotic treatment;
LIHC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg25329415	chr6:28076851	NA	0.27	5.81	0.3	1.46e-8	Parkinson's disease;
LIHC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.66	-0.42	1.94e-16	Total cholesterol levels;
LIHC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.6	-0.34	1.55e-10	Menarche (age at onset);
LIHC	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	0.65	6.47	0.33	3.43e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg08888203	chr3:10149979	C3orf24	0.61	6.58	0.34	1.78e-10	Alzheimer's disease;
LIHC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.68	-13.2	-0.58	1.95e-32	Body mass index;
LIHC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.45	-0.37	7.83e-13	Tonsillectomy;
LIHC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg00277334	chr10:82204260	NA	-0.55	-6.91	-0.35	2.43e-11	Post bronchodilator FEV1;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07757386	chr14:102771445	RAGE	0.4	6.06	0.31	3.59e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-7.31	-0.37	1.94e-12	Total body bone mineral density;
LIHC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg03959625	chr15:84868606	LOC388152	0.42	5.79	0.3	1.63e-8	Schizophrenia;
LIHC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg22903471	chr2:27725779	GCKR	-0.41	-6.16	-0.32	2e-9	Blood metabolite levels;
LIHC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.33e-9	Mortality in heart failure;
LIHC	cis	rs61041384	0.661	rs4474478	chr12:123734368	C/T	cg00376283	chr12:123451042	ABCB9	-0.61	-6.45	-0.33	3.89e-10	Schizophrenia;
LIHC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg22079354	chr11:130786696	SNX19	0.43	6.11	0.31	2.76e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.13	0.58	3.53e-32	Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.44	8.19	0.4	5.4e-15	Prudent dietary pattern;
LIHC	cis	rs7715806	0.517	rs34340	chr5:74932099	A/C	cg19683494	chr5:74908142	NA	0.47	6.28	0.32	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-7.74	-0.39	1.16e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.97	-0.4	2.46e-14	Response to antipsychotic treatment;
LIHC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg08125733	chr17:73851984	WBP2	-0.53	-7.97	-0.4	2.34e-14	White matter hyperintensity burden;
LIHC	cis	rs7539409	0.915	rs6576945	chr1:84252882	A/G	cg10977910	chr1:84465055	TTLL7	0.77	6.14	0.32	2.26e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.57	7.62	0.38	2.58e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs787274	1.000	rs787280	chr9:115539085	C/T	cg13803584	chr9:115635662	SNX30	-0.56	-6.35	-0.32	6.91e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.1e-9	Tonsillectomy;
LIHC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.5	7.22	0.36	3.35e-12	High light scatter reticulocyte count;
LIHC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.15	0.32	2.13e-9	Schizophrenia;
LIHC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg19774624	chr17:42201019	HDAC5	-0.42	-5.93	-0.31	7.55e-9	Total body bone mineral density;
LIHC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.54	-8.99	-0.44	1.69e-17	Multiple sclerosis;
LIHC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs8049603	0.947	rs12922614	chr16:23090069	T/A	cg16484020	chr16:23217411	SCNN1G	-0.25	-5.71	-0.3	2.44e-8	Multiple sclerosis;
LIHC	cis	rs11958404	0.517	rs35212858	chr5:157238942	T/C	cg05962755	chr5:157440814	NA	0.67	6.76	0.34	5.96e-11	IgG glycosylation;
LIHC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.31e-18	Bipolar disorder;
LIHC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.36	7.3	0.37	2.02e-12	Colorectal cancer;
LIHC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.97	14.97	0.63	2.61e-39	Metabolic syndrome;
LIHC	cis	rs11644362	1.000	rs12918494	chr16:12988455	C/T	cg06890432	chr16:12997467	SHISA9	-0.4	-6.86	-0.35	3.34e-11	Positive affect;Subjective well-being;
LIHC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.47	-0.33	3.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.51	9.67	0.46	1e-19	Testicular germ cell tumor;
LIHC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.25	-0.52	3.47e-25	Electrocardiographic conduction measures;
LIHC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.42	8.92	0.43	2.79e-17	Coronary artery disease;
LIHC	trans	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.43	-0.37	8.74e-13	Endometrial cancer;
LIHC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	12.26	0.55	6.6e-29	Platelet count;
LIHC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.7	-9.95	-0.47	1.19e-20	Mosquito bite size;
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.43	5.81	0.3	1.4e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg14593290	chr7:50529359	DDC	0.38	6.41	0.33	4.71e-10	Malaria;
LIHC	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.57	10.52	0.49	1.36e-22	Leprosy;
LIHC	cis	rs1144333	1.000	rs17097841	chr1:76462641	T/A	cg10523679	chr1:76189770	ACADM	0.42	5.96	0.31	6.4e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.74	0.34	6.75e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.87	-0.39	4.84e-14	Lung cancer;
LIHC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.67	10.25	0.48	1.14e-21	Height;
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg05856399	chr6:109804852	ZBTB24	0.43	6.19	0.32	1.73e-9	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg22800045	chr5:56110881	MAP3K1	0.56	5.8	0.3	1.47e-8	Type 2 diabetes;
LIHC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.42	0.33	4.49e-10	Schizophrenia;
LIHC	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.83	-0.3	1.29e-8	Tuberculosis;
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.51	6.04	0.31	4.06e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.32	2.29e-9	Ulcerative colitis;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	7.52	0.38	4.86e-13	Schizophrenia;
LIHC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.45	7.51	0.38	5.07e-13	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.62	7.51	0.38	5.29e-13	Cognitive function;
LIHC	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.01e-22	Hypertriglyceridemia;
LIHC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.91	0.35	2.39e-11	Body mass index;
LIHC	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.05e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.61	6.15	0.32	2.22e-9	Carotid intima media thickness;
LIHC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg26441486	chr22:50317300	CRELD2	0.36	6.38	0.33	5.73e-10	Schizophrenia;
LIHC	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.8	15.65	0.65	5.15e-42	Testicular germ cell tumor;
LIHC	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.68	-11.39	-0.52	1.04e-25	Childhood ear infection;
LIHC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg06598544	chr20:61472147	COL9A3	-0.79	-7.77	-0.39	8.98e-14	Obesity-related traits;
LIHC	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	1.04	11.66	0.53	1.09e-26	IgG glycosylation;
LIHC	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.57	9.34	0.45	1.31e-18	Corneal astigmatism;
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.49	6.94	0.35	2.03e-11	Height;
LIHC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.24	-15.97	-0.65	2.67e-43	Diabetic kidney disease;
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.28	-0.41	2.87e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.77	-13.1	-0.58	4.58e-32	Total cholesterol levels;
LIHC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg22212156	chr20:32031449	SNTA1	-0.61	-6.17	-0.32	1.88e-9	Mean platelet volume;
LIHC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg15432903	chr11:17409602	KCNJ11	0.69	10.62	0.5	5.84e-23	Type 2 diabetes;
LIHC	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.96	0.35	1.72e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.53	8.47	0.42	7.52e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.49	7.29	0.37	2.2e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.58	6.16	0.32	2e-9	Vitiligo;
LIHC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.5	0.33	2.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11284414	chr2:232573146	PTMA	-0.44	-6.52	-0.33	2.47e-10	Cognitive function;
LIHC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.26	-0.32	1.16e-9	Colorectal cancer;
LIHC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-8.97	-0.44	2.04e-17	Bipolar disorder;
LIHC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg12046867	chr14:103022105	NA	-0.48	-7.03	-0.36	1.14e-11	Platelet count;
LIHC	cis	rs2731664	0.792	rs2630763	chr5:176901005	T/A	cg23176889	chr5:176863531	GRK6	-0.68	-11.89	-0.54	1.56e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	8.94	0.44	2.51e-17	Total cholesterol levels;
LIHC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.29	16.89	0.67	5.55e-47	Diabetic kidney disease;
LIHC	cis	rs965469	0.779	rs2236121	chr20:3304320	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-5.78	-0.3	1.73e-8	IFN-related cytopenia;
LIHC	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.2	0.32	1.6e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.6	10.48	0.49	1.77e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.15e-41	Mortality in heart failure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21353724	chr7:2303981	SNX8	-0.41	-6.43	-0.33	4.3e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg20991723	chr1:152506922	NA	0.57	10.02	0.48	7.07e-21	Hair morphology;
LIHC	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.42	6.59	0.34	1.63e-10	Mean corpuscular volume;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08292968	chr12:111020671	PPTC7	-0.42	-6.1	-0.31	2.91e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg23587288	chr2:27483067	SLC30A3	-0.32	-6.03	-0.31	4.19e-9	Blood metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19864851	chr10:75503847	SEC24C	0.47	7.3	0.37	2.01e-12	Cognitive function;
LIHC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg25894440	chr7:65020034	NA	-0.57	-6.27	-0.32	1.11e-9	Diabetic kidney disease;
LIHC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg03013999	chr17:37608204	MED1	-0.36	-5.91	-0.3	8.4e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.37	6.86	0.35	3.26e-11	Schizophrenia;
LIHC	cis	rs6442522	0.678	rs12634346	chr3:15500295	C/T	cg16303742	chr3:15540471	COLQ	0.44	7.37	0.37	1.33e-12	Uric acid levels;
LIHC	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.67	-0.34	1.02e-10	Homocysteine levels;
LIHC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.02	-0.51	2.28e-24	Crohn's disease;
LIHC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg21361702	chr7:150065534	REPIN1	0.5	6.8	0.35	4.59e-11	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg21522988	chr12:29376872	FAR2	0.28	6.08	0.31	3.16e-9	QT interval;
LIHC	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.71	11.41	0.53	9e-26	Phospholipid levels (plasma);
LIHC	trans	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg01596870	chr19:55963115	NA	-0.67	-9.61	-0.46	1.58e-19	Obesity-related traits;
LIHC	cis	rs4684776	0.867	rs13062308	chr3:11355139	C/T	cg00170343	chr3:11313890	ATG7	-0.53	-7.32	-0.37	1.8e-12	Small vessel stroke;
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.05	-0.31	3.9e-9	Longevity;
LIHC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	18.18	0.7	3.74e-52	Tonsillectomy;
LIHC	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.54	-0.33	2.24e-10	Prevalent atrial fibrillation;
LIHC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.6	-10.29	-0.49	8.32e-22	Longevity;Endometriosis;
LIHC	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.75	-11.48	-0.53	4.84e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.45	-9.24	-0.45	2.71e-18	Immature fraction of reticulocytes;
LIHC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	9.38	0.45	9.34e-19	Eosinophilic esophagitis;
LIHC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg05760424	chr2:242988095	NA	-0.53	-6.97	-0.35	1.61e-11	Obesity-related traits;
LIHC	trans	rs2352908	1.000	rs2352913	chr14:49453094	T/C	cg01449224	chr4:123073775	NA	-0.47	-6.25	-0.32	1.25e-9	Social communication problems;
LIHC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.55	-7.22	-0.36	3.48e-12	Lung cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19941170	chr5:172067912	NEURL1B	0.5	7.29	0.37	2.14e-12	Lung function (FEV1/FVC);
LIHC	cis	rs8141529	0.600	rs16986825	chr22:29300306	C/T	cg15103426	chr22:29168792	CCDC117	0.45	6.24	0.32	1.27e-9	Lymphocyte counts;
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.73	10.86	0.51	8.42e-24	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	0.99	7.88	0.39	4.4e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs13113518	0.812	rs2035692	chr4:56394968	T/A	cg15358633	chr12:38710606	ALG10B	0.43	6.16	0.32	2.09e-9	Height;
LIHC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.87	-15.09	-0.63	8.7e-40	Aortic root size;
LIHC	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg20016023	chr10:99160130	RRP12	0.4	6.5	0.33	2.78e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10139443	chr6:99963249	USP45	-0.4	-6.32	-0.32	8.08e-10	Pancreatic cancer;
LIHC	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg08345082	chr10:99160200	RRP12	0.39	6.71	0.34	8.19e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg15848620	chr12:58087721	OS9	0.56	7.64	0.38	2.18e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11958404	0.615	rs7727924	chr5:157433736	A/G	cg05962755	chr5:157440814	NA	0.63	8.24	0.41	3.77e-15	IgG glycosylation;
LIHC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg17724175	chr1:150552817	MCL1	-0.44	-9.08	-0.44	9.14e-18	Melanoma;
LIHC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.43	6.14	0.31	2.33e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-11.07	-0.51	1.55e-24	Colorectal cancer;
LIHC	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.97e-9	Pulmonary function;
LIHC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21448741	chr8:58168803	NA	0.39	6.08	0.31	3.26e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.43	-5.89	-0.3	9.14e-9	Neuroticism;
LIHC	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg09795085	chr6:101329169	ASCC3	0.53	7.3	0.37	1.99e-12	Neuroticism;
LIHC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.95	17.13	0.68	6.02e-48	Parkinson's disease;
LIHC	cis	rs1144333	1.000	rs112401426	chr1:76466103	T/A	cg10523679	chr1:76189770	ACADM	0.42	5.97	0.31	6.09e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	1.08	20.69	0.75	2.94e-62	Multiple system atrophy;
LIHC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg22676075	chr6:135203613	NA	0.38	6.22	0.32	1.44e-9	Red blood cell count;
LIHC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg16586182	chr3:47516702	SCAP	0.48	8.48	0.42	6.98e-16	Colorectal cancer;
LIHC	cis	rs79149102	0.737	rs7163332	chr15:75193623	C/T	cg16226627	chr15:75307476	SCAMP5	0.44	6.28	0.32	1.04e-9	Lung cancer;
LIHC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg20607798	chr8:58055168	NA	0.45	6.05	0.31	3.76e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27297192	chr10:134578999	INPP5A	-0.51	-6.96	-0.35	1.74e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.99	-0.4	2.03e-14	Capecitabine sensitivity;
LIHC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg03037974	chr15:76606532	NA	0.74	14.33	0.61	8.31e-37	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21830413	chr10:70884251	VPS26A	-0.42	-6.31	-0.32	8.51e-10	Pancreatic cancer;
LIHC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg06565975	chr8:143823917	SLURP1	0.33	6.47	0.33	3.34e-10	Urinary tract infection frequency;
LIHC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.5e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.27	6.43	0.33	4.34e-10	Heart rate;
LIHC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg23262073	chr20:60523788	NA	-0.28	-5.76	-0.3	1.88e-8	Body mass index;
LIHC	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.57	7.62	0.38	2.49e-13	Age-related disease endophenotypes;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08677398	chr8:58056175	NA	0.41	6.32	0.32	8.32e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9918079	0.542	rs12499412	chr4:15602252	G/C	cg24225360	chr4:15471699	CC2D2A	0.38	6.07	0.31	3.46e-9	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	8.73	0.43	1.15e-16	Platelet count;
LIHC	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	20.32	0.74	9.1e-61	Colorectal cancer;
LIHC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.09	-0.4	1.05e-14	Monocyte percentage of white cells;
LIHC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.84	-0.35	3.58e-11	IgG glycosylation;
LIHC	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.99	7.86	0.39	5.02e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.63	-7.99	-0.4	2.05e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.58	-8.62	-0.42	2.52e-16	Skin colour saturation;
LIHC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg10935138	chr17:73851978	WBP2	0.77	6.61	0.34	1.51e-10	Psoriasis;
LIHC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.87	-0.3	1.02e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.16	0.55	1.6e-28	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg16836995	chr17:43662488	NA	0.71	7.25	0.36	2.72e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg09417038	chr21:47716443	C21orf57	0.54	8.17	0.4	5.84e-15	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.6	-9.3	-0.45	1.68e-18	Renal cell carcinoma;
LIHC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg19302996	chr17:73780495	UNK	-0.5	-6.16	-0.32	2.05e-9	Psoriasis;
LIHC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.78	-0.3	1.71e-8	Schizophrenia;
LIHC	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg24331049	chr13:111365604	ING1	0.8	13.65	0.59	3.75e-34	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.68	0.34	9.69e-11	Diabetic kidney disease;
LIHC	cis	rs34779708	0.766	rs7897088	chr10:35551567	G/T	cg03585969	chr10:35415529	CREM	0.76	10.71	0.5	2.89e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg17644776	chr2:200775616	C2orf69	0.44	6.27	0.32	1.1e-9	Osteoporosis;
LIHC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg14440974	chr22:39074834	NA	0.44	7.18	0.36	4.25e-12	Menopause (age at onset);
LIHC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg15902774	chr15:75289873	SCAMP5	0.4	5.95	0.31	6.63e-9	Lung cancer;
LIHC	cis	rs4788570	0.615	rs9888756	chr16:71740477	G/A	cg06353428	chr16:71660113	MARVELD3	1.37	14.83	0.63	8.96e-39	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-13.87	-0.6	5.19e-35	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26329020	chr12:32909488	YARS2	0.44	6.06	0.31	3.63e-9	Pancreatic cancer;
LIHC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-22.5	-0.77	1.92e-69	Myeloid white cell count;
LIHC	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg07451762	chr16:28383216	NA	0.41	7.12	0.36	6.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.81	-0.39	7.29e-14	Response to antipsychotic treatment;
LIHC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.48	7.52	0.38	4.99e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg10208301	chr11:6592745	DNHD1	0.46	6.6	0.34	1.61e-10	Coronary artery calcification;
LIHC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.18	0.4	5.73e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg05185784	chr16:90016020	DEF8	-0.48	-6.21	-0.32	1.53e-9	Skin colour saturation;
LIHC	cis	rs3770081	1.000	rs3810827	chr2:86334386	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-9.26	-0.45	2.39e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs11018874	0.735	rs4307680	chr11:89900630	A/C	cg05041596	chr11:89867385	NAALAD2	0.43	6.81	0.35	4.43e-11	White blood cell types;
LIHC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	0.83	6.68	0.34	9.65e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs922107	0.675	rs6428548	chr1:89941533	G/A	cg15422784	chr1:90023713	LRRC8B	0.45	7.03	0.36	1.14e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	0.77	8.31	0.41	2.31e-15	Testicular germ cell tumor;
LIHC	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs1400745	0.756	rs799683	chr14:35349236	G/A	cg16230307	chr14:35515116	FAM177A1	0.39	6.21	0.32	1.53e-9	Monocyte count;
LIHC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.58	0.56	4.43e-30	Menopause (age at onset);
LIHC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.66	-8.96	-0.44	2.16e-17	Schizophrenia;
LIHC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	6.28	0.32	1.03e-9	Renal cell carcinoma;
LIHC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.39	5.78	0.3	1.7e-8	Melanoma;
LIHC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.13	0.44	6.17e-18	Cognitive ability;
LIHC	cis	rs11786130	1.000	rs62512837	chr8:129008290	T/G	cg01765152	chr8:129005526	PVT1	-0.3	-6.38	-0.33	5.68e-10	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.93	0.51	4.89e-24	Lung cancer in ever smokers;
LIHC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.97	-0.44	1.96e-17	Skin colour saturation;
LIHC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.96	-0.51	3.7e-24	Hemoglobin concentration;
LIHC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs6722750	0.651	rs12987393	chr2:64421514	C/T	cg22352474	chr2:64371530	PELI1	0.41	5.82	0.3	1.37e-8	Neuroticism;
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.42	0.33	4.5e-10	Renal cell carcinoma;
LIHC	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.63	0.34	1.29e-10	Resting heart rate;
LIHC	cis	rs74233809	1.000	rs12221335	chr10:104769392	T/A	cg03493300	chr10:104813866	CNNM2	0.45	6.06	0.31	3.69e-9	Birth weight;
LIHC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.91	16.84	0.67	8.86e-47	Menopause (age at onset);
LIHC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs238295	0.805	rs6053523	chr20:5571964	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.89	-0.35	2.69e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.39	-6.92	-0.35	2.23e-11	Response to antipsychotic treatment;
LIHC	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg23387056	chr11:14280742	SPON1	-0.44	-5.98	-0.31	5.49e-9	Mitochondrial DNA levels;
LIHC	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg13409248	chr3:40428643	ENTPD3	-0.43	-7.26	-0.37	2.63e-12	Renal cell carcinoma;
LIHC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg03517284	chr6:25882590	NA	-0.44	-6.64	-0.34	1.21e-10	Height;
LIHC	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg19633962	chr1:26362018	EXTL1	-0.7	-6.32	-0.32	8.04e-10	QRS complex (12-leadsum);
LIHC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.74	0.34	6.88e-11	Dupuytren's disease;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg14671364	chr1:107599128	PRMT6	-0.54	-7.93	-0.39	3.08e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs783540	0.967	rs2567635	chr15:83262181	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.66	-0.34	1.09e-10	Schizophrenia;
LIHC	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18509826	chr3:52017385	ACY1	0.46	6.71	0.34	7.89e-11	Calcium levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11815682	chr21:44486381	CBS	0.41	6.06	0.31	3.53e-9	Bilirubin levels;
LIHC	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.5	7.95	0.39	2.75e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13409248	chr3:40428643	ENTPD3	0.49	8.31	0.41	2.24e-15	Renal cell carcinoma;
LIHC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.38	5.98	0.31	5.54e-9	Prostate cancer;
LIHC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.66	-9.42	-0.45	6.79e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	5.77	0.3	1.79e-8	Renal function-related traits (BUN);
LIHC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.7	13.19	0.58	2.05e-32	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg14146966	chr2:61757674	XPO1	0.47	8.2	0.41	4.75e-15	Tuberculosis;
LIHC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.85	0.3	1.17e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg09182678	chr22:50328711	NA	-0.41	-6.08	-0.31	3.15e-9	Schizophrenia;
LIHC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.78	12.51	0.56	8.22e-30	Colorectal cancer;
LIHC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.39	5.89	0.3	9.11e-9	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg00656387	chr3:40428638	ENTPD3	0.49	8.25	0.41	3.48e-15	Renal cell carcinoma;
LIHC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.77	7.44	0.37	7.95e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg09165964	chr15:75287851	SCAMP5	-0.56	-7.56	-0.38	3.74e-13	Lung cancer;
LIHC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.92	17.02	0.68	1.74e-47	Menopause (age at onset);
LIHC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg20129853	chr10:51489980	NA	-0.4	-8.66	-0.42	1.92e-16	Prostate-specific antigen levels;
LIHC	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.56	8.96	0.44	2.2e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs3106136	0.807	rs9997915	chr4:95278027	C/T	cg11021082	chr4:95130006	SMARCAD1	0.38	6.56	0.33	2.02e-10	Capecitabine sensitivity;
LIHC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.64	0.34	1.24e-10	Dupuytren's disease;
LIHC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-6.06	-0.31	3.62e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17228093	chr9:37651075	FRMPD1	0.45	6.68	0.34	9.42e-11	Alopecia areata;
LIHC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.47	-7.32	-0.37	1.76e-12	Blood protein levels;
LIHC	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.68	8.53	0.42	4.89e-16	Corneal astigmatism;
LIHC	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg14515779	chr1:101123966	NA	-0.6	-11.37	-0.52	1.21e-25	Monocyte count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22753607	chr9:37120306	ZCCHC7	0.41	6.36	0.33	6.54e-10	Cognitive function;
LIHC	cis	rs6450176	0.564	rs381024	chr5:53326234	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.75	-13.59	-0.59	6.42e-34	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.46	-6.12	-0.31	2.61e-9	Tourette syndrome;
LIHC	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.68	-0.34	9.52e-11	Exhaled nitric oxide output;
LIHC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.87	-0.3	1.04e-8	Blood metabolite levels;
LIHC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.8	11.61	0.53	1.66e-26	Coronary artery disease;
LIHC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.56	9.9	0.47	1.73e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs12365397	1.000	rs11037360	chr11:43239804	G/A	cg16667275	chr11:43333495	API5	0.44	6.0	0.31	5.15e-9	Migraine;
LIHC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.42	0.41	1.06e-15	Motion sickness;
LIHC	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg26138144	chr22:38071188	LGALS1	0.42	7.88	0.39	4.48e-14	Fat distribution (HIV);
LIHC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.59	8.8	0.43	6.73e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-8.4	-0.41	1.22e-15	Type 2 diabetes;
LIHC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.82	6.88	0.35	2.87e-11	Body mass index;
LIHC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.6	-0.38	2.96e-13	Colorectal cancer;
LIHC	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14154082	chr13:112174009	NA	-0.28	-5.92	-0.3	7.77e-9	Menarche (age at onset);
LIHC	cis	rs644148	0.834	rs2461535	chr19:45000875	C/T	cg15540054	chr19:45004280	ZNF180	-0.71	-10.55	-0.5	1.01e-22	Personality dimensions;
LIHC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	8.04e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.69	10.18	0.48	1.93e-21	Body mass index;
LIHC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.61	0.67	7.88e-46	Smoking behavior;
LIHC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	9.08	0.44	8.77e-18	Motion sickness;
LIHC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-5.96	-0.31	6.21e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg01864069	chr14:103024347	NA	-0.45	-7.12	-0.36	6.24e-12	Platelet count;
LIHC	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg04865290	chr3:52927548	TMEM110	-0.44	-5.8	-0.3	1.5e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.55	8.61	0.42	2.69e-16	Corneal astigmatism;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg00106254	chr7:1943704	MAD1L1	-0.37	-5.86	-0.3	1.09e-8	Schizophrenia;
LIHC	cis	rs17106184	0.536	rs12083078	chr1:51066950	A/T	cg07174182	chr1:51127561	FAF1	0.45	5.85	0.3	1.12e-8	Type 2 diabetes;
LIHC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg27386326	chr11:61587980	NA	0.7	14.64	0.62	5.17e-38	Trans fatty acid levels;
LIHC	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-0.84	-9.92	-0.47	1.47e-20	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.62	8.93	0.43	2.74e-17	Prudent dietary pattern;
LIHC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.54	-0.5	1.14e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg18306943	chr3:40428807	ENTPD3	0.43	7.58	0.38	3.19e-13	Renal cell carcinoma;
LIHC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	1.04	10.68	0.5	3.72e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.53	8.31	0.41	2.29e-15	Anterior chamber depth;
LIHC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.85	13.92	0.6	3.24e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.94	17.57	0.69	1.04e-49	Menopause (age at onset);
LIHC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.37	6.29	0.32	9.86e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07677032	chr17:61819896	STRADA	0.48	6.93	0.35	2.05e-11	Prudent dietary pattern;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14868726	chr18:2571660	METTL4;NDC80	0.4	6.13	0.31	2.49e-9	Metabolic traits;
LIHC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.17	0.32	1.96e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-7.08	-0.36	8.33e-12	Platelet distribution width;
LIHC	cis	rs11673344	0.764	rs826304	chr19:37443583	T/G	cg27390819	chr19:37464633	NA	-0.53	-6.38	-0.33	5.74e-10	Obesity-related traits;
LIHC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.78	10.21	0.48	1.54e-21	Body mass index;
LIHC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.15	0.4	6.78e-15	Motion sickness;
LIHC	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg17135325	chr3:160939158	NMD3	0.51	7.5	0.38	5.44e-13	Morning vs. evening chronotype;
LIHC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.12e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.63	0.46	1.35e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.6	7.54	0.38	4.35e-13	Initial pursuit acceleration;
LIHC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.58	9.27	0.45	2.11e-18	Lymphocyte counts;
LIHC	cis	rs9896052	0.608	rs9797247	chr17:73445814	C/T	cg25649188	chr17:73499917	CASKIN2	0.42	6.62	0.34	1.42e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.34	7.32	0.37	1.8e-12	Ulcerative colitis;
LIHC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24110177	chr3:50126178	RBM5	0.42	6.47	0.33	3.43e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.6	8.85	0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26734620	chr12:56694298	CS	-1.3	-11.32	-0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg14558262	chr17:40713999	COASY	-0.61	-9.48	-0.46	4.24e-19	Crohn's disease;
LIHC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02290350	chr8:58132656	NA	0.47	9.33	0.45	1.38e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.38	6.02	0.31	4.57e-9	Menopause (age at onset);
LIHC	cis	rs507080	0.922	rs558907	chr11:118558455	A/G	cg04173919	chr11:118528438	PHLDB1	0.35	6.59	0.34	1.65e-10	Serum metabolite levels;
LIHC	cis	rs7572733	0.555	rs7420608	chr2:198915930	A/T	cg00792783	chr2:198669748	PLCL1	0.4	5.79	0.3	1.57e-8	Dermatomyositis;
LIHC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.74	0.3	2.07e-8	Height;
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.55	8.06	0.4	1.34e-14	Renal cell carcinoma;
LIHC	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	0.82	7.25	0.36	2.72e-12	Uric acid levels;
LIHC	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-0.79	-11.66	-0.53	1.09e-26	Obesity-related traits;
LIHC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.82	0.3	1.38e-8	Putamen volume;
LIHC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.77	0.39	9.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.5	-6.27	-0.32	1.07e-9	Diisocyanate-induced asthma;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg02993280	chr1:107599747	PRMT6	0.65	10.58	0.5	8.35e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.0	-8.14	-0.4	7.3e-15	Body mass index;
LIHC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.53	6.43	0.33	4.31e-10	Menarche (age at onset);
LIHC	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.66	-10.54	-0.5	1.12e-22	Inflammatory bowel disease;
LIHC	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-6.62	-0.34	1.38e-10	Electroencephalogram traits;
LIHC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg26566283	chr11:622021	MUPCDH	-0.72	-5.93	-0.31	7.41e-9	Body mass index;
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg00809820	chr17:80708513	TBCD;FN3K	0.36	6.2	0.32	1.59e-9	Glycated hemoglobin levels;
LIHC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.82	13.04	0.58	7.63e-32	Breast cancer;
LIHC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.76	-9.29	-0.45	1.81e-18	Systemic lupus erythematosus;
LIHC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.45	-0.46	5.33e-19	Colorectal cancer;
LIHC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.35	6.3	0.32	9.37e-10	Platelet distribution width;
LIHC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	10.35	0.49	4.94e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.32	5.92	0.3	7.87e-9	Aortic root size;
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12016809	chr21:47604291	C21orf56	0.45	6.86	0.35	3.28e-11	Testicular germ cell tumor;
LIHC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg14132834	chr19:41945861	ATP5SL	0.43	6.31	0.32	8.78e-10	Height;
LIHC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	6.1	0.31	2.91e-9	Uric acid clearance;
LIHC	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.19	-0.36	4.04e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg26939375	chr7:64535504	NA	0.41	6.58	0.34	1.8e-10	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10900048	chr4:73935377	COX18	0.47	6.06	0.31	3.62e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16262614	chr3:133464971	TF	0.28	6.23	0.32	1.36e-9	Iron status biomarkers;
LIHC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg19683494	chr5:74908142	NA	-0.54	-7.2	-0.36	3.86e-12	Age-related disease endophenotypes;
LIHC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.57	8.73	0.43	1.11e-16	Uric acid clearance;
LIHC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	10.3	0.49	7.28e-22	Blood protein levels;
LIHC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.5	0.49	1.6e-22	Colorectal cancer;
LIHC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg16586182	chr3:47516702	SCAP	0.4	6.71	0.34	8.29e-11	Birth weight;
LIHC	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.8	9.07	0.44	9.78e-18	Vitiligo;
LIHC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.55	0.42	4.12e-16	Birth weight;
LIHC	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg08992911	chr2:238395768	MLPH	0.63	6.41	0.33	4.69e-10	Prostate cancer;
LIHC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.52	5.93	0.31	7.23e-9	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.06e-19	Renal cell carcinoma;
LIHC	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.5	5.81	0.3	1.45e-8	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LIHC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.75e-8	Parkinson's disease;
LIHC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.42	-5.99	-0.31	5.22e-9	Inflammatory bowel disease;
LIHC	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.92	-0.31	7.64e-9	Red blood cell count;
LIHC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg04025307	chr7:1156635	C7orf50	0.45	6.13	0.31	2.48e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg07424592	chr7:64974309	NA	-0.68	-8.2	-0.41	4.92e-15	Diabetic kidney disease;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg22528358	chr1:107598549	PRMT6	-0.69	-11.54	-0.53	3e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs6594499	0.872	rs2112541	chr5:110449346	T/C	cg04022379	chr5:110408740	TSLP	0.5	8.29	0.41	2.64e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg00204512	chr16:28754710	NA	0.36	6.43	0.33	4.28e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.49	6.84	0.35	3.64e-11	Height;
LIHC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.98	13.3	0.58	7.84e-33	Heart rate;
LIHC	cis	rs1664789	0.836	rs702638	chr5:53268072	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.46	7.23	0.36	3.28e-12	Waist circumference adjusted for body mass index;
LIHC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-6.61	-0.34	1.5e-10	Initial pursuit acceleration;
LIHC	cis	rs9341808	0.556	rs2223875	chr6:81045452	C/T	cg08355045	chr6:80787529	NA	0.33	6.77	0.34	5.6e-11	Sitting height ratio;
LIHC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.57	8.37	0.41	1.54e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.45	-0.37	7.89e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.11	23.43	0.78	4.25e-73	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.36	0.41	1.66e-15	Height;
LIHC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.74	9.84	0.47	2.81e-20	Coronary artery disease;
LIHC	cis	rs7534824	0.625	rs7414132	chr1:101526413	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	7.19	0.36	4.14e-12	Refractive astigmatism;
LIHC	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-7.92	-0.39	3.41e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.39	-11.79	-0.54	3.68e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.25	5.78	0.3	1.7e-8	Gut microbiome composition (winter);
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.19	-0.48	1.77e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs7635838	0.892	rs6792718	chr3:11434380	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.87	0.35	3.04e-11	HDL cholesterol;
LIHC	cis	rs62179067	0.708	rs76035073	chr2:179940750	C/T	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.98	-0.44	1.88e-17	Type 2 diabetes;
LIHC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.69	8.53	0.42	4.92e-16	Mean platelet volume;
LIHC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-24.08	-0.79	1.29e-75	Myeloid white cell count;
LIHC	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.73	-13.53	-0.59	1.1e-33	Mean platelet volume;
LIHC	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-0.69	-7.1	-0.36	7.42e-12	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.45	-5.94	-0.31	6.95e-9	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15563057	chr5:139493612	PURA	0.4	6.33	0.32	7.53e-10	Cognitive function;
LIHC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.94	-0.31	6.88e-9	Morning vs. evening chronotype;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14108327	chr4:890186	GAK	0.39	6.21	0.32	1.55e-9	Bilirubin levels;
LIHC	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-0.91	-10.96	-0.51	3.59e-24	Mitochondrial DNA levels;
LIHC	cis	rs8108269	1.000	rs10421259	chr19:46158860	G/A	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.75	0.69	1.98e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs77637988	0.578	rs11683099	chr2:48611519	A/T	cg00032884	chr2:48540671	FOXN2	0.38	5.88	0.3	9.61e-9	Joint mobility (Beighton score);
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.33	0.32	7.68e-10	Prudent dietary pattern;
LIHC	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.39	0.37	1.15e-12	Airflow obstruction;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03113475	chr19:12833063	TNPO2	0.47	6.27	0.32	1.11e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9918079	0.560	rs10008376	chr4:15623955	A/G	cg21329975	chr4:15471214	CC2D2A	0.39	5.85	0.3	1.13e-8	Obesity-related traits;
LIHC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.22	-10.54	-0.5	1.08e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.76	-0.34	6.07e-11	Total body bone mineral density;
LIHC	cis	rs847649	0.692	rs6969054	chr7:102446569	T/C	cg18108683	chr7:102477205	FBXL13	-0.51	-7.83	-0.39	6.02e-14	Morning vs. evening chronotype;
LIHC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.34	-8.28	-0.41	2.73e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.58	-8.71	-0.43	1.3e-16	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.82	0.35	4.1e-11	Gut microbiome composition (summer);
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.62	11.5	0.53	4.22e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7616330	0.895	rs7615404	chr3:71045288	T/C	cg01511742	chr3:71112437	FOXP1	-0.45	-6.21	-0.32	1.54e-9	QT interval;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg21280719	chr6:42927975	GNMT	-0.36	-7.72	-0.39	1.29e-13	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11777290	chr7:64535486	NA	0.45	6.28	0.32	1.05e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.49	-7.88	-0.39	4.37e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs74233809	1.000	rs943037	chr10:104835919	C/T	cg03493300	chr10:104813866	CNNM2	0.47	6.19	0.32	1.68e-9	Birth weight;
LIHC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg00750074	chr16:89608354	SPG7	0.4	6.23	0.32	1.37e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.58	-8.19	-0.41	5.12e-15	Lymphocyte counts;
LIHC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.8	0.3	1.48e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.78	12.95	0.57	1.68e-31	Phospholipid levels (plasma);
LIHC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.91	0.35	2.42e-11	Breast cancer;
LIHC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-5.8	-0.3	1.55e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.7	11.36	0.52	1.34e-25	Body mass index;
LIHC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.72	10.4	0.49	3.3e-22	Colorectal cancer;
LIHC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.52	8.12	0.4	8.36e-15	Tonsillectomy;
LIHC	cis	rs17639215	0.550	rs9679297	chr2:102914569	T/C	cg09003973	chr2:102972529	NA	0.61	6.09	0.31	3.04e-9	Serum protein levels (sST2);
LIHC	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.55	-8.36	-0.41	1.56e-15	Coronary artery disease;
LIHC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.2	-0.45	3.52e-18	Morning vs. evening chronotype;
LIHC	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.38	6.29	0.32	9.75e-10	Prevalent atrial fibrillation;
LIHC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.23	0.45	2.98e-18	IgG glycosylation;
LIHC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg23485639	chr6:28045615	ZNF165	0.4	6.26	0.32	1.16e-9	Cardiac Troponin-T levels;
LIHC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.26	-0.52	3.07e-25	Diastolic blood pressure;
LIHC	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg15103426	chr22:29168792	CCDC117	0.43	5.81	0.3	1.39e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.08	0.55	3.27e-28	Prudent dietary pattern;
LIHC	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.66	7.18	0.36	4.46e-12	Type 2 diabetes;
LIHC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg18769074	chr3:133464867	TF	0.26	5.9	0.3	8.79e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.68	8.57	0.42	3.53e-16	Corneal astigmatism;
LIHC	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-0.58	-7.62	-0.38	2.59e-13	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-6.0	-0.31	4.96e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg00204512	chr16:28754710	NA	-0.34	-6.29	-0.32	9.64e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs860626	0.583	rs855767	chr10:119316080	C/T	cg10846980	chr10:119306025	EMX2;EMX2OS	-0.52	-7.92	-0.39	3.3e-14	Neuroticism;
LIHC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.54	7.59	0.38	3e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs611744	0.967	rs637626	chr8:109235785	G/T	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-6.83	-0.35	3.84e-11	Alzheimer's disease;
LIHC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.54	0.38	4.15e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-6.46	-0.33	3.5e-10	Red cell distribution width;
LIHC	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.4	-7.12	-0.36	6.46e-12	Crohn's disease;
LIHC	cis	rs8067354	0.574	rs2531898	chr17:58012351	G/C	cg13753209	chr17:57696993	CLTC	0.71	10.58	0.5	7.79e-23	Hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.27e-10	Diabetic kidney disease;
LIHC	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg05425664	chr17:57184151	TRIM37	-0.46	-5.75	-0.3	1.93e-8	Vitamin D levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11504245	chr5:55128562	NA	0.4	6.25	0.32	1.22e-9	Immature fraction of reticulocytes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17695382	chr2:61697821	USP34	0.47	6.17	0.32	1.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.86	0.3	1.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.55	-7.79	-0.39	8.06e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg26939375	chr7:64535504	NA	0.47	7.15	0.36	5.18e-12	Calcium levels;
LIHC	cis	rs600806	0.888	rs652651	chr1:109844532	A/G	cg16275483	chr1:110013120	SYPL2	-0.51	-6.17	-0.32	1.93e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07305463	chr2:136567211	LCT	-0.39	-7.35	-0.37	1.46e-12	Mosquito bite size;
LIHC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.41	6.26	0.32	1.17e-9	Prostate-specific antigen levels;
LIHC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.46	7.21	0.36	3.61e-12	Lymphocyte counts;
LIHC	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg01864836	chr14:55583639	NA	-0.42	-8.24	-0.41	3.64e-15	Protein biomarker;
LIHC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg16479474	chr6:28041457	NA	-0.42	-6.05	-0.31	3.73e-9	Depression;
LIHC	cis	rs116248771	0.690	rs4459938	chr3:158406075	G/A	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.32e-10	diarrhoeal disease at age 2;
LIHC	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg14146966	chr2:61757674	XPO1	0.46	7.8	0.39	7.41e-14	Tuberculosis;
LIHC	cis	rs72627123	0.867	rs78742875	chr14:74457214	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.46	0.42	8.11e-16	Morning vs. evening chronotype;
LIHC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.77	0.39	9.04e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.39	5.84	0.3	1.23e-8	Height;
LIHC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.77	-0.5	1.69e-23	Chronic sinus infection;
LIHC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12501888	chr15:85177176	SCAND2	-0.46	-7.09	-0.36	7.65e-12	P wave terminal force;
LIHC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.27	7.06	0.36	9.08e-12	Cardiovascular disease risk factors;
LIHC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.69	-9.54	-0.46	2.69e-19	Corneal structure;
LIHC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.55	-6.44	-0.33	3.94e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg13753209	chr17:57696993	CLTC	0.73	11.52	0.53	3.71e-26	Hemoglobin concentration;
LIHC	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg22903471	chr2:27725779	GCKR	0.41	6.15	0.32	2.15e-9	Blood metabolite levels;
LIHC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	7.24	0.36	2.99e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg10402321	chr1:26617780	UBXN11	-0.38	-6.06	-0.31	3.63e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-7.91	-0.39	3.61e-14	Neuranatomic and neurocognitive phenotypes;
LIHC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.41	-8.36	-0.41	1.56e-15	Obesity-related traits;
LIHC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.38	-6.01	-0.31	4.65e-9	Lung cancer;
LIHC	trans	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04565464	chr8:145669602	NFKBIL2	0.4	6.69	0.34	9.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.62	-0.38	2.58e-13	Height;
LIHC	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.34	7.65	0.38	2.03e-13	Blood metabolite ratios;
LIHC	cis	rs1823913	1.000	rs4853563	chr2:192119534	G/A	cg12404831	chr2:192114017	MYO1B	-0.33	-6.58	-0.34	1.75e-10	Obesity-related traits;
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg16970926	chr12:29381810	FAR2	0.3	6.14	0.32	2.24e-9	QT interval;
LIHC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-8.91	-0.43	2.99e-17	Vitiligo;
LIHC	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.82	8.6	0.42	3e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.49	0.56	9.68e-30	Schizophrenia;
LIHC	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.67	7.57	0.38	3.45e-13	Schizophrenia;
LIHC	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.74	-0.3	2.06e-8	Crohn's disease;
LIHC	cis	rs699	0.556	rs2478520	chr1:230867197	G/A	cg07502417	chr1:230849801	AGT	0.31	6.56	0.33	1.95e-10	Coronary artery disease;
LIHC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg00409905	chr10:38381863	ZNF37A	0.47	7.74	0.39	1.12e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6977660	1.000	rs6977660	chr7:19805480	C/T	cg07541023	chr7:19748670	TWISTNB	0.39	6.15	0.32	2.14e-9	Thyroid stimulating hormone;
LIHC	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.45	-6.88	-0.35	2.89e-11	Multiple myeloma;
LIHC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-7.73	-0.39	1.25e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.66	12.73	0.57	1.22e-30	High light scatter reticulocyte count;
LIHC	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg15105969	chr2:36825350	FEZ2	0.49	5.85	0.3	1.16e-8	Height;
LIHC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.7	-11.01	-0.51	2.47e-24	Coronary artery disease;
LIHC	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	0.97	24.51	0.8	2.7e-77	Multiple myeloma;
LIHC	cis	rs6708331	0.517	rs6743372	chr2:70352640	G/T	cg01613454	chr2:70366299	NA	0.38	6.14	0.32	2.23e-9	Obesity-related traits;
LIHC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.42	-5.76	-0.3	1.9e-8	Total body bone mineral density;
LIHC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.33	0.32	7.6e-10	Schizophrenia;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg01101903	chr2:240322401	HDAC4	-0.37	-6.35	-0.32	6.95e-10	Neuroblastoma;
LIHC	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.95	-18.12	-0.7	6.36e-52	Schizophrenia;
LIHC	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.87	-0.35	3.05e-11	Pediatric bone mineral density (spine);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20385686	chr1:27024451	ARID1A	0.41	6.64	0.34	1.2e-10	Calcium levels;
LIHC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.17	-0.36	4.71e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.34e-17	Gut microbiome composition (summer);
LIHC	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg17888390	chr10:101282816	NA	-0.3	-5.77	-0.3	1.81e-8	Ulcerative colitis;
LIHC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.08	9.74	0.47	5.89e-20	Diabetic retinopathy;
LIHC	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg19680672	chr10:131412579	MGMT	-0.39	-5.94	-0.31	7.15e-9	Response to temozolomide;
LIHC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.68	6.99	0.35	1.42e-11	Diabetic kidney disease;
LIHC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg05110241	chr16:68378359	PRMT7	-0.56	-6.45	-0.33	3.81e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg17675199	chr6:35436792	RPL10A	0.32	6.27	0.32	1.11e-9	Coronary artery disease;
LIHC	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.52	8.56	0.42	3.76e-16	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs16828019	0.852	rs2268678	chr1:41511053	G/A	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-7.38	-0.37	1.21e-12	Eosinophil percentage of white cells;
LIHC	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs17001868	0.881	rs12484358	chr22:40774660	G/A	cg07138101	chr22:40742427	ADSL	0.59	6.26	0.32	1.18e-9	Mammographic density (dense area);
LIHC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.58	6.72	0.34	7.66e-11	Menarche (age at onset);
LIHC	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.25	0.61	1.74e-36	Multiple sclerosis;
LIHC	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.69	11.97	0.54	8.29e-28	Colorectal cancer;
LIHC	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.73	12.86	0.57	3.9e-31	Eosinophil percentage of white cells;
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.33	0.52	1.76e-25	Height;
LIHC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.93	-17.24	-0.68	2.22e-48	Breast cancer;
LIHC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.48	7.59	0.38	3.02e-13	Systemic lupus erythematosus;
LIHC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	10.91	0.51	5.7e-24	Alzheimer's disease (late onset);
LIHC	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg16586182	chr3:47516702	SCAP	0.51	8.97	0.44	2.04e-17	Colorectal cancer;
LIHC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.5	-8.09	-0.4	1.05e-14	Menarche (age at onset);
LIHC	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg02187348	chr16:89574699	SPG7	0.51	7.82	0.39	6.78e-14	Multiple myeloma (IgH translocation);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08518329	chr2:20101943	TTC32	0.32	6.51	0.33	2.65e-10	Calcium levels;
LIHC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg14440974	chr22:39074834	NA	-0.45	-7.31	-0.37	1.9e-12	Menopause (age at onset);
LIHC	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg05771511	chr15:63340396	TPM1	-0.44	-5.94	-0.31	7.01e-9	Orofacial clefts;
LIHC	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.15	-0.32	2.12e-9	Tuberculosis;
LIHC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg03013999	chr17:37608204	MED1	0.36	6.03	0.31	4.18e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs72653721	1.000	rs2295599	chr6:10961454	C/A	cg13562911	chr6:11044106	ELOVL2	0.49	6.85	0.35	3.48e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.54	0.38	4.37e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg18357645	chr12:58087776	OS9	0.41	5.86	0.3	1.08e-8	Multiple sclerosis;
LIHC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.97	-17.66	-0.69	4.55e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.4	5.81	0.3	1.39e-8	Iron status biomarkers;
LIHC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.19	-0.36	4.03e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6723226	0.806	rs2710606	chr2:32811909	A/G	cg02381751	chr2:32503542	YIPF4	0.75	10.78	0.5	1.57e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.6	9.58	0.46	2.02e-19	Height;
LIHC	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg26138937	chr11:71823887	C11orf51	0.8	7.93	0.39	3.24e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg00677901	chr16:88017247	BANP	0.52	8.02	0.4	1.74e-14	Menopause (age at onset);
LIHC	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.73	-10.14	-0.48	2.67e-21	Dilated cardiomyopathy;
LIHC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.44	6.49	0.33	3.06e-10	Methadone dose in opioid dependence;
LIHC	cis	rs797680	0.822	rs2297707	chr1:93646207	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.87	-0.3	1.03e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.42	-8.03	-0.4	1.63e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs4671400	0.571	rs4672428	chr2:61478497	C/T	cg14146966	chr2:61757674	XPO1	-0.36	-5.71	-0.3	2.44e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.81	-0.3	1.42e-8	Blood pressure;
LIHC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg06766960	chr11:133703094	NA	-0.41	-6.22	-0.32	1.49e-9	Childhood ear infection;
LIHC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.75	0.34	6.28e-11	Renal cell carcinoma;
LIHC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.53	-8.26	-0.41	3.18e-15	High light scatter reticulocyte count;
LIHC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.54	-0.46	2.7e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg14440974	chr22:39074834	NA	-0.44	-7.24	-0.36	2.91e-12	Menopause (age at onset);
LIHC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07305463	chr2:136567211	LCT	0.38	7.46	0.37	7.41e-13	Mosquito bite size;
LIHC	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.56	9.12	0.44	6.51e-18	Breast cancer;
LIHC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.22	5.78	0.3	1.72e-8	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg07424592	chr7:64974309	NA	0.73	8.23	0.41	4.12e-15	Diabetic kidney disease;
LIHC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	1.21	14.35	0.61	7.24e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-20.0	-0.73	1.85e-59	Height;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.37	-0.33	6.2e-10	Total body bone mineral density;
LIHC	cis	rs509477	0.662	rs273343	chr18:32604173	G/C	cg23791764	chr18:32556832	MAPRE2	0.47	6.41	0.33	4.85e-10	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.59	-7.68	-0.38	1.69e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.46	8.49	0.42	6.6e-16	Testicular germ cell tumor;
LIHC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.64	11.24	0.52	3.84e-25	Colorectal cancer;
LIHC	cis	rs986417	0.818	rs965455	chr14:60960314	A/C	cg27398547	chr14:60952738	C14orf39	0.84	9.9	0.47	1.8e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.33	5.97	0.31	6.1e-9	Aortic root size;
LIHC	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg25007680	chr1:8021821	PARK7	0.6	9.5	0.46	3.91e-19	Response to antidepressants and depression;
LIHC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.47	7.86	0.39	5.17e-14	Blood metabolite levels;
LIHC	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.86	-0.3	1.08e-8	Coronary artery disease;
LIHC	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.5	7.83	0.39	6e-14	Alzheimer's disease (survival time);
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.01	15.7	0.65	3.23e-42	Skin colour saturation;
LIHC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.39	0.49	3.75e-22	Dupuytren's disease;
LIHC	cis	rs12079745	0.793	rs11805562	chr1:169292916	A/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-6.98	-0.35	1.51e-11	QT interval;
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.11	-0.31	2.76e-9	Total body bone mineral density;
LIHC	trans	rs783540	0.934	rs10400906	chr15:83297138	A/G	cg18393722	chr15:85113863	UBE2QP1	0.36	6.27	0.32	1.1e-9	Schizophrenia;
LIHC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.78	13.24	0.58	1.39e-32	Psoriasis;
LIHC	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg18867708	chr6:26865862	GUSBL1	-0.5	-7.69	-0.38	1.59e-13	Schizophrenia;
LIHC	cis	rs2997447	0.761	rs17257113	chr1:26449595	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.96	-0.31	6.31e-9	QRS complex (12-leadsum);
LIHC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.52	7.64	0.38	2.21e-13	Prostate cancer;
LIHC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.82	-0.35	4.05e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.65e-12	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05318427	chr2:85199320	KCMF1	0.42	6.74	0.34	6.71e-11	Cognitive function;
LIHC	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-7.02	-0.35	1.21e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.34	7.39	0.37	1.12e-12	Ulcerative colitis;
LIHC	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.29	-6.51	-0.33	2.72e-10	DNA methylation (variation);
LIHC	trans	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.71	6.53	0.33	2.31e-10	Birth weight;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg20090690	chr10:134436459	INPP5A	0.44	5.89	0.3	9.21e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg07061783	chr6:25882402	NA	-0.49	-6.86	-0.35	3.21e-11	Blood metabolite levels;
LIHC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.38	5.87	0.3	1.02e-8	Tuberculosis;
LIHC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	10.14	0.48	2.61e-21	Menarche (age at onset);
LIHC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.74	-0.34	6.95e-11	Schizophrenia;
LIHC	cis	rs8014671	0.519	rs12884918	chr14:70890778	T/C	cg25576086	chr14:70833871	SYNJ2BP	-0.46	-7.14	-0.36	5.58e-12	Prostate cancer;
LIHC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.63	9.45	0.46	5.47e-19	Platelet count;
LIHC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.35	5.96	0.31	6.21e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.68	9.68	0.46	9.56e-20	Diastolic blood pressure;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.51	-7.21	-0.36	3.72e-12	Height;
LIHC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg05110241	chr16:68378359	PRMT7	-0.6	-7.01	-0.35	1.32e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.75	0.47	5.42e-20	Mean platelet volume;
LIHC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-7.07	-0.36	8.53e-12	Schizophrenia;
LIHC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.45	6.1	0.31	2.93e-9	Red cell distribution width;
LIHC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	9.52	0.46	3.13e-19	Multiple sclerosis;
LIHC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.2e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.47	0.42	7.2e-16	Platelet count;
LIHC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.94	0.57	1.83e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.0	23.47	0.79	2.95e-73	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7712401	0.791	rs10071135	chr5:122146978	C/G	cg18764291	chr5:122110994	SNX2	0.35	6.18	0.32	1.86e-9	Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.58	0.34	1.82e-10	Renal cell carcinoma;
LIHC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-6.51	-0.33	2.75e-10	Colorectal cancer;
LIHC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08219700	chr8:58056026	NA	0.52	7.02	0.35	1.21e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.82	-0.3	1.37e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.91	-0.3	8.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.81	11.77	0.54	4.55e-27	Coronary artery disease;
LIHC	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.69	-10.19	-0.48	1.76e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.29	6.82	0.35	4.23e-11	Crohn's disease;
LIHC	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg19683494	chr5:74908142	NA	0.7	7.7	0.38	1.5e-13	Coronary artery disease;
LIHC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02985541	chr2:219472218	PLCD4	0.44	8.33	0.41	2.04e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.46	-7.44	-0.37	8.37e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg20387954	chr3:183756860	HTR3D	0.28	5.98	0.31	5.57e-9	Anterior chamber depth;
LIHC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.71	7.45	0.37	7.63e-13	Diabetic kidney disease;
LIHC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.52	-0.33	2.53e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2292096	0.929	rs6667419	chr1:200756197	G/A	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.21	-0.32	1.52e-9	Epilepsy;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.81	0.39	6.89e-14	Renal cell carcinoma;
LIHC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.45	5.79	0.3	1.63e-8	High light scatter reticulocyte count;
LIHC	cis	rs2108622	0.727	rs3093207	chr19:15988658	T/C	cg13772218	chr19:15982569	NA	0.36	7.35	0.37	1.49e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	7.72	0.39	1.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.73	-0.34	7.3e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg15105060	chr4:7024189	TBC1D14	-0.81	-6.83	-0.35	3.85e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7707921	1.000	rs891159	chr5:81491087	A/G	cg15871215	chr5:81402204	ATG10	-0.61	-6.14	-0.31	2.32e-9	Breast cancer;
LIHC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.12	-0.36	6.26e-12	Body mass index;
LIHC	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.6	11.91	0.54	1.36e-27	Plateletcrit;Platelet count;
LIHC	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg26752003	chr8:145688521	CYHR1	0.61	9.71	0.46	7.77e-20	Age at first birth;
LIHC	cis	rs12744310	0.887	rs12757611	chr1:41808972	C/T	cg03962019	chr1:41807865	NA	0.36	5.79	0.3	1.62e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.65e-12	Breast cancer;
LIHC	cis	rs11098699	0.821	rs11098705	chr4:124229644	C/T	cg09941581	chr4:124220074	SPATA5	0.32	6.45	0.33	3.82e-10	Mosquito bite size;
LIHC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg04025307	chr7:1156635	C7orf50	0.47	6.7	0.34	8.67e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-6.43	-0.33	4.32e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.51	8.23	0.41	4.09e-15	Endometriosis;
LIHC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.65	6.6	0.34	1.54e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.44	0.33	3.97e-10	Height;
LIHC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.56	7.06	0.36	9.42e-12	Initial pursuit acceleration;
LIHC	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg02023728	chr11:77925099	USP35	-0.34	-6.06	-0.31	3.56e-9	Alzheimer's disease (survival time);
LIHC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg16070018	chr6:26224392	HIST1H3E	0.58	6.99	0.35	1.41e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.73	-9.21	-0.45	3.24e-18	Body mass index;
LIHC	cis	rs4919087	0.715	rs946981	chr10:98995076	A/G	cg25902810	chr10:99078978	FRAT1	-0.51	-5.81	-0.3	1.45e-8	Monocyte count;
LIHC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.56	-0.33	2.05e-10	Personality dimensions;
LIHC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.39	6.34	0.32	7.44e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.47	7.33	0.37	1.67e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.58	-11.31	-0.52	2.11e-25	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02602480	chr2:62422689	B3GNT2	0.45	7.17	0.36	4.6e-12	Pancreatic cancer;
LIHC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.49	0.38	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-6.65	-0.34	1.13e-10	Total body bone mineral density;
LIHC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.49	-0.38	5.83e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.67	0.65	4.38e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.49	-8.89	-0.43	3.46e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg00677901	chr16:88017247	BANP	0.52	8.1	0.4	9.58e-15	Menopause (age at onset);
LIHC	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.41	8.45	0.42	8.74e-16	Coronary artery disease;
LIHC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.46	10.36	0.49	4.53e-22	Iron status biomarkers (transferrin levels);
LIHC	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	0.59	6.19	0.32	1.71e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.4	-5.74	-0.3	2.08e-8	Eosinophil percentage of white cells;
LIHC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.61	-10.12	-0.48	3.16e-21	Obesity-related traits;
LIHC	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.39	6.32	0.32	8e-10	Pelvic organ prolapse;
LIHC	trans	rs35995292	0.963	rs7803397	chr7:38905686	C/T	cg06118584	chr16:11770950	SNN	0.32	6.05	0.31	3.86e-9	Subjective well-being (multi-trait analysis);
LIHC	cis	rs11229555	0.645	rs11229436	chr11:58186009	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-10.43	-0.49	2.64e-22	Skin colour saturation;
LIHC	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.48	7.4	0.37	1.05e-12	Longevity;Endometriosis;
LIHC	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	0.92	21.4	0.76	4.51e-65	Multiple myeloma;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.43	7.15	0.36	5.39e-12	Testicular germ cell tumor;
LIHC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	1.05	22.28	0.77	1.42e-68	Breast cancer;
LIHC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	1.06	15.81	0.65	1.17e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg13628971	chr7:2884303	GNA12	0.4	6.32	0.32	8.35e-10	Height;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.71	-10.7	-0.5	3.17e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.85	8.33	0.41	1.95e-15	Inflammatory bowel disease;
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08219700	chr8:58056026	NA	0.5	6.81	0.35	4.4e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.68	-8.4	-0.41	1.25e-15	Gut microbiome composition (summer);
LIHC	cis	rs12980942	0.935	rs11880564	chr19:41831196	C/A	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.81	0.35	4.29e-11	Coronary artery disease;
LIHC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.71	0.6	2.06e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg09222892	chr1:25734099	RHCE	0.48	8.89	0.43	3.55e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.39	-0.33	5.51e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg04958157	chr13:113748321	MCF2L	-0.35	-5.72	-0.3	2.37e-8	Systolic blood pressure;
LIHC	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-8.73	-0.43	1.11e-16	Post bronchodilator FEV1;
LIHC	cis	rs2336384	1.000	rs873457	chr1:12046334	C/G	cg13216073	chr1:12042593	MFN2	0.38	5.72	0.3	2.3e-8	Platelet count;
LIHC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16262614	chr3:133464971	TF	0.29	6.49	0.33	3.1e-10	Iron status biomarkers;
LIHC	cis	rs116248771	0.549	rs9825140	chr3:158435374	C/T	cg16708174	chr3:158430962	RARRES1	0.76	9.78	0.47	4.54e-20	diarrhoeal disease at age 2;
LIHC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg25344623	chr2:136566232	LCT	0.41	8.33	0.41	1.99e-15	Mosquito bite size;
LIHC	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.5	-0.38	5.44e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg18187862	chr3:45730750	SACM1L	-0.51	-6.37	-0.33	6.26e-10	Primary sclerosing cholangitis;
LIHC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.55	-0.82	4.16e-85	Myeloid white cell count;
LIHC	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.27	0.61	1.4e-36	Bipolar disorder;
LIHC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg25039879	chr17:56429692	SUPT4H1	0.43	6.03	0.31	4.37e-9	Cognitive test performance;
LIHC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-7.84	-0.39	5.82e-14	Crohn's disease;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.47	5.82	0.3	1.36e-8	Alzheimer's disease;
LIHC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.59	0.46	1.87e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.33	5.72	0.3	2.37e-8	Mean corpuscular volume;
LIHC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.65	11.09	0.51	1.25e-24	Crohn's disease;
LIHC	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.43	6.69	0.34	9.12e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg12253828	chr6:101329408	ASCC3	0.43	6.81	0.35	4.5e-11	Neuroticism;
LIHC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.57	7.55	0.38	4.1e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg01677386	chr11:118938358	VPS11	0.44	5.85	0.3	1.17e-8	Coronary artery disease;
LIHC	cis	rs12079745	0.793	rs75134881	chr1:169186127	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.65	-6.13	-0.31	2.39e-9	QT interval;
LIHC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.93	14.06	0.61	9.61e-36	Sudden cardiac arrest;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.71	10.51	0.49	1.38e-22	Menarche (age at onset);
LIHC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.48	8.36	0.41	1.56e-15	Height;
LIHC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	1.04	13.79	0.6	1.09e-34	Heart rate;
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg19318889	chr4:1322082	MAEA	0.39	6.35	0.32	6.73e-10	Obesity-related traits;
LIHC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	12.95	0.57	1.72e-31	Lung cancer in ever smokers;
LIHC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.47	-6.94	-0.35	2.03e-11	Response to metformin (IC50);
LIHC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.63	0.42	2.3e-16	Motion sickness;
LIHC	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	8.97	0.44	2.02e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs7635838	0.859	rs6784883	chr3:11444453	G/A	cg00170343	chr3:11313890	ATG7	0.42	6.47	0.33	3.34e-10	HDL cholesterol;
LIHC	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.28	0.49	8.68e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.59	-0.38	2.98e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7575217	0.682	rs4851401	chr2:101700518	T/C	cg23907051	chr2:101730305	TBC1D8	0.25	5.78	0.3	1.66e-8	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.47	7.36	0.37	1.36e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.87	14.54	0.62	1.3e-37	Schizophrenia;
LIHC	cis	rs12744310	1.000	rs12032514	chr1:41760562	G/A	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.54	-8.87	-0.43	4.12e-17	Cognitive function;
LIHC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25951256	chr10:38645740	HSD17B7P2	-0.41	-6.03	-0.31	4.32e-9	Breast cancer;
LIHC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg16070018	chr6:26224392	HIST1H3E	0.57	6.81	0.35	4.47e-11	Gout;Renal underexcretion gout;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18876457	chr1:160071037	NA	0.44	6.6	0.34	1.59e-10	Pancreatic cancer;
LIHC	cis	rs10097731	0.901	rs4398860	chr8:82041753	C/T	cg25230327	chr8:82042993	NA	-0.6	-7.73	-0.39	1.24e-13	Serum total protein level;
LIHC	cis	rs151997	0.537	rs11746939	chr5:50268856	G/A	cg06027927	chr5:50259733	NA	0.52	6.36	0.33	6.5e-10	Callous-unemotional behaviour;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.76	11.85	0.54	2.22e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.67	13.35	0.59	5.28e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02873885	chr7:55000889	NA	0.4	7.52	0.38	4.92e-13	Calcium levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg18240814	chr5:107718300	FBXL17	-0.38	-6.04	-0.31	3.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs911119	0.908	rs8121147	chr20:23601708	T/C	cg16589663	chr20:23618590	CST3	0.74	7.78	0.39	8.48e-14	Chronic kidney disease;
LIHC	cis	rs4147929	1.000	rs4147929	chr19:1063443	A/G	cg05372495	chr19:1063624	ABCA7	-0.44	-6.21	-0.32	1.57e-9	Alzheimer's disease (late onset);
LIHC	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.37	5.87	0.3	1.03e-8	Fear of minor pain;
LIHC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	3.07e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg03146154	chr1:46216737	IPP	-0.39	-6.38	-0.33	5.77e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs16828019	0.777	rs11209363	chr1:41485077	T/C	cg03387723	chr1:41708464	SCMH1	-0.42	-6.7	-0.34	8.55e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4908768	0.906	rs7539382	chr1:8579301	C/T	cg25722041	chr1:8623473	RERE	0.41	5.84	0.3	1.23e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2019216	0.538	rs2341278	chr17:21994959	G/A	cg14296220	chr9:32431791	ACO1	0.39	6.32	0.32	8.24e-10	Pelvic organ prolapse;
LIHC	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	0.66	7.32	0.37	1.81e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.53	7.55	0.38	3.98e-13	Type 2 diabetes;
LIHC	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06420487	chr17:61919686	SMARCD2	0.46	6.26	0.32	1.16e-9	Height;
LIHC	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-8.6	-0.42	2.91e-16	Schizophrenia;
LIHC	cis	rs9649465	1.000	rs2299982	chr7:123356511	A/C	cg03229431	chr7:123269106	ASB15	-0.37	-7.96	-0.4	2.58e-14	Migraine;
LIHC	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-13.27	-0.58	1.09e-32	Morning vs. evening chronotype;
LIHC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.63	10.02	0.48	6.71e-21	Dental caries;
LIHC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.33	0.37	1.63e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	12.78	0.57	7.62e-31	Cognitive test performance;
LIHC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.39	-6.26	-0.32	1.18e-9	Menarche (age at onset);
LIHC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg22633049	chr21:46681294	NA	-0.36	-5.96	-0.31	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	11.68	0.53	9.44e-27	Post bronchodilator FEV1;
LIHC	cis	rs7212590	0.748	rs9904374	chr17:57908096	T/C	cg10252138	chr17:58120427	NA	-0.58	-5.72	-0.3	2.33e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.46	-7.53	-0.38	4.48e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.22	-0.36	3.46e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.61	6.12	0.31	2.55e-9	Carotid intima media thickness;
LIHC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	trans	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg19894588	chr14:64061835	NA	-0.46	-7.35	-0.37	1.52e-12	Fat distribution (HIV);
LIHC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.65	-9.43	-0.45	6.5e-19	Initial pursuit acceleration;
LIHC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.57	-6.42	-0.33	4.68e-10	Breast cancer;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg25631650	chr19:633157	POLRMT	-0.49	-6.06	-0.31	3.5e-9	Facial morphology (factor 20);
LIHC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.47	-7.53	-0.38	4.51e-13	Cognitive function;
LIHC	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.71	0.38	1.35e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs10411936	0.608	rs7259642	chr19:16601926	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.49	6.56	0.33	1.98e-10	White blood cell count;Multiple sclerosis;
LIHC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	0.98	10.61	0.5	6.31e-23	Vitiligo;
LIHC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg12501888	chr15:85177176	SCAND2	-0.48	-7.37	-0.37	1.31e-12	P wave terminal force;
LIHC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-6.29	-0.32	9.94e-10	Hemoglobin concentration;
LIHC	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.06	-0.44	1.01e-17	Capecitabine sensitivity;
LIHC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.49	7.76	0.39	9.95e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.85	-0.3	1.13e-8	Body mass index;
LIHC	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.44	-8.84	-0.43	5.15e-17	LDL cholesterol levels;
LIHC	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	6.02	0.31	4.45e-9	IgG glycosylation;
LIHC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.35	-5.99	-0.31	5.39e-9	IgG glycosylation;
LIHC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.9e-38	Blood metabolite levels;
LIHC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-7.13	-0.36	5.94e-12	Blood protein levels;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02290350	chr8:58132656	NA	0.48	9.89	0.47	1.84e-20	Developmental language disorder (linguistic errors);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15069758	chr1:110198731	GSTM4	0.43	6.25	0.32	1.19e-9	Migraine with aura;
LIHC	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg25356066	chr3:128598488	ACAD9	-0.52	-7.07	-0.36	8.59e-12	IgG glycosylation;
LIHC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.68	0.78	3.75e-70	Chronic sinus infection;
LIHC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.35	6.15	0.32	2.18e-9	Psoriasis;
LIHC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.72	-11.51	-0.53	4.08e-26	Obesity-related traits;
LIHC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg03037974	chr15:76606532	NA	-0.51	-8.19	-0.41	5.17e-15	Blood metabolite levels;
LIHC	trans	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg10756647	chr7:56101905	PSPH	0.88	11.06	0.51	1.69e-24	Diabetic kidney disease;
LIHC	cis	rs3770081	1.000	rs1036554	chr2:86236099	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-9.05	-0.44	1.09e-17	Facial emotion recognition (sad faces);
LIHC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg26338869	chr17:61819248	STRADA	0.53	7.13	0.36	5.96e-12	Height;
LIHC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.53	7.14	0.36	5.79e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.57	9.91	0.47	1.65e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.81	-0.39	7.1e-14	Colorectal cancer;
LIHC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.42	-6.38	-0.33	5.71e-10	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21144462	chr17:42082647	PYY;NAGS	0.46	6.64	0.34	1.23e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.51e-29	Menopause (age at onset);
LIHC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.51	7.28	0.37	2.33e-12	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs2073499	0.935	rs2236939	chr3:50243510	G/T	cg21659725	chr3:3221576	CRBN	0.62	7.0	0.35	1.38e-11	Schizophrenia;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.57	-7.68	-0.38	1.67e-13	Menopause (age at onset);
LIHC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg00677901	chr16:88017247	BANP	0.63	9.54	0.46	2.89e-19	Menopause (age at onset);
LIHC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg12798992	chr6:167411361	FGFR1OP	0.48	7.2	0.36	3.84e-12	Crohn's disease;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.44	0.49	2.47e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1982963	0.951	rs2516592	chr14:52503545	A/G	cg10843707	chr14:52510701	NID2	-0.46	-7.59	-0.38	3.13e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08219700	chr8:58056026	NA	0.52	6.22	0.32	1.43e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.43	7.87	0.39	4.6e-14	Platelet distribution width;
LIHC	cis	rs507080	0.922	rs516153	chr11:118564762	C/A	cg04173919	chr11:118528438	PHLDB1	0.36	6.6	0.34	1.53e-10	Serum metabolite levels;
LIHC	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.43	8.33	0.41	1.98e-15	Testicular germ cell tumor;
LIHC	cis	rs17152411	0.895	rs7086128	chr10:126587373	A/G	cg07906193	chr10:126599966	NA	0.39	6.52	0.33	2.49e-10	Height;
LIHC	cis	rs370915	0.890	rs28610515	chr4:187835260	A/T	cg19519643	chr4:187840862	NA	-0.54	-9.33	-0.45	1.4e-18	Gout;
LIHC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.7	10.96	0.51	3.8e-24	Corneal astigmatism;
LIHC	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg25649188	chr17:73499917	CASKIN2	0.43	6.81	0.35	4.32e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg10932868	chr11:921992	NA	0.36	6.77	0.34	5.46e-11	Alzheimer's disease (late onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12820191	chr3:186524311	RFC4	-0.52	-7.35	-0.37	1.45e-12	Systolic blood pressure;
LIHC	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.76	-0.3	1.84e-8	Pulse pressure;
LIHC	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.58	-8.95	-0.44	2.39e-17	Corneal astigmatism;
LIHC	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-12.25	-0.55	7.47e-29	Pediatric autoimmune diseases;
LIHC	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.51	-7.64	-0.38	2.21e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11102324	chr15:49658865	C15orf33	0.41	6.21	0.32	1.54e-9	Longevity;
LIHC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.6	-7.21	-0.36	3.7e-12	Lung cancer in ever smokers;
LIHC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.1	0.44	7.62e-18	Schizophrenia;
LIHC	cis	rs2439831	0.614	rs2467733	chr15:43693328	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.93	0.51	4.89e-24	Lung cancer in ever smokers;
LIHC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.49	8.31	0.41	2.28e-15	Longevity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03217964	chr16:75182191	ZFP1	0.45	6.63	0.34	1.29e-10	Pancreatic cancer;
LIHC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.24	0.52	3.83e-25	Motion sickness;
LIHC	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.73	-0.34	7.26e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-10.83	-0.51	1.07e-23	Body mass index;
LIHC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.45	6.07	0.31	3.38e-9	Height;
LIHC	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.4	-6.57	-0.33	1.92e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.57	-8.65	-0.42	2.08e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8084351	0.577	rs12970188	chr18:50650350	A/G	cg24270629	chr18:50823537	DCC	-0.43	-6.42	-0.33	4.62e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-1.03	-12.4	-0.56	1.99e-29	Red blood cell traits;
LIHC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	13.34	0.58	5.74e-33	Cognitive test performance;
LIHC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg17135325	chr3:160939158	NMD3	-0.58	-8.72	-0.43	1.25e-16	Parkinson's disease;
LIHC	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.32	0.37	1.76e-12	Lung cancer;
LIHC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.92	0.31	7.63e-9	Schizophrenia;
LIHC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.47	-8.09	-0.4	1.03e-14	Lung cancer;
LIHC	cis	rs244293	1.000	rs244291	chr17:53231137	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.52	-0.33	2.5e-10	Menarche (age at onset);
LIHC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.39	7.17	0.36	4.68e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.8	13.32	0.58	6.79e-33	Psoriasis;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21747090	chr2:27597821	SNX17	-0.4	-5.86	-0.3	1.06e-8	Total body bone mineral density;
LIHC	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.43	6.36	0.33	6.62e-10	Educational attainment;
LIHC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.61	-12.7	-0.57	1.5e-30	Airflow obstruction;
LIHC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.72	-12.76	-0.57	9.47e-31	Multiple sclerosis;
LIHC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.02	0.55	5.22e-28	Prudent dietary pattern;
LIHC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.44	6.17	0.32	1.9e-9	Morning vs. evening chronotype;
LIHC	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.46	-0.37	7.06e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.53	7.18	0.36	4.34e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26768966	chr19:39807167	LRFN1	-0.34	-6.14	-0.32	2.35e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.4	8.66	0.42	1.88e-16	Prostate-specific antigen levels;
LIHC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.52	0.42	5.22e-16	Motion sickness;
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg20090690	chr10:134436459	INPP5A	0.45	5.8	0.3	1.54e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.42	6.78	0.34	5.42e-11	Prostate cancer;
LIHC	cis	rs1892700	0.764	rs12626309	chr21:34888704	A/T	cg14850771	chr21:34775459	IFNGR2	0.44	5.85	0.3	1.17e-8	Educational attainment;
LIHC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21545522	chr1:205238299	TMCC2	0.32	6.14	0.32	2.29e-9	Red blood cell count;
LIHC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.98	0.44	1.79e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.42	5.85	0.3	1.16e-8	Coronary artery disease;
LIHC	cis	rs8081395	0.741	rs180530	chr17:58003594	G/A	cg02344993	chr17:57696989	CLTC	0.35	5.71	0.3	2.44e-8	White blood cell count;
LIHC	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs80282103	0.867	rs7099063	chr10:1078547	C/G	cg20335179	chr10:1068567	C10orf110;IDI2	-0.54	-6.06	-0.31	3.5e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.14	0.44	5.55e-18	IgG glycosylation;
LIHC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.5	9.16	0.44	4.85e-18	Lung cancer;
LIHC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg17927777	chr20:33865990	NA	0.55	6.53	0.33	2.36e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.52	-7.98	-0.4	2.27e-14	P wave terminal force;
LIHC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-14.03	-0.6	1.2e-35	Height;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-8.31	-0.41	2.22e-15	Lymphocyte counts;
LIHC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg26441486	chr22:50317300	CRELD2	0.34	6.07	0.31	3.31e-9	Schizophrenia;
LIHC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg11632617	chr15:75315747	PPCDC	-0.48	-6.75	-0.34	6.34e-11	Blood trace element (Zn levels);
LIHC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg17764715	chr19:33622953	WDR88	0.4	5.72	0.3	2.29e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg09033563	chr22:24373618	LOC391322	-0.42	-5.72	-0.3	2.28e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg15208524	chr1:10270712	KIF1B	-0.37	-5.79	-0.3	1.6e-8	Hepatocellular carcinoma;
LIHC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.77	14.11	0.61	6.22e-36	Blood protein levels;
LIHC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.77	-11.54	-0.53	3.13e-26	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.57	8.71	0.43	1.35e-16	Height;
LIHC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.23	-0.7	2.44e-52	Ulcerative colitis;
LIHC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.12	0.31	2.54e-9	Blood metabolite levels;
LIHC	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.41	8.0	0.4	1.95e-14	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21448741	chr8:58168803	NA	0.31	5.87	0.3	1.02e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.72	-0.3	2.28e-8	Blood metabolite levels;
LIHC	cis	rs611744	0.686	rs424976	chr8:109120820	C/A	cg21045802	chr8:109455806	TTC35	0.5	8.48	0.42	6.86e-16	Dupuytren's disease;
LIHC	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg15208524	chr1:10270712	KIF1B	0.38	5.84	0.3	1.21e-8	Hepatocellular carcinoma;
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.87	13.57	0.59	7.37e-34	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.9	19.52	0.73	1.56e-57	Blood protein levels;
LIHC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.63	10.16	0.48	2.37e-21	Chronic sinus infection;
LIHC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg02290350	chr8:58132656	NA	0.39	7.6	0.38	2.95e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11761441	1.000	rs12718067	chr7:82873	T/C	cg12845006	chr7:82380	NA	0.32	6.07	0.31	3.32e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.65	0.56	2.39e-30	Mean platelet volume;
LIHC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.62	8.82	0.43	5.9e-17	Aortic root size;
LIHC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.23	-0.32	1.39e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg20607798	chr8:58055168	NA	0.49	6.94	0.35	2.02e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.71	-12.18	-0.55	1.33e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.74	-0.54	5.59e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.76	-12.75	-0.57	9.88e-31	Coronary artery disease;
LIHC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.06	0.44	9.94e-18	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.58	-0.5	8.03e-23	Breast cancer;
LIHC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.58	-9.25	-0.45	2.51e-18	Childhood ear infection;
LIHC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.49	-8.18	-0.4	5.78e-15	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11567041	chr10:12391824	CAMK1D	0.47	6.63	0.34	1.32e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6818397	1.000	rs6818397	chr4:3434885	A/C	cg08741688	chr4:3415352	RGS12	0.42	6.53	0.33	2.37e-10	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.94	0.51	4.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18923964	chr14:35451807	SRP54	0.42	6.17	0.32	1.95e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.69	-7.63	-0.38	2.34e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.66	8.42	0.41	1.05e-15	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.5	7.2	0.36	3.82e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs986417	0.901	rs1955694	chr14:61020617	G/T	cg27398547	chr14:60952738	C14orf39	0.58	6.98	0.35	1.57e-11	Gut microbiota (bacterial taxa);
LIHC	trans	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.6	9.02	0.44	1.36e-17	Recombination rate (females);
LIHC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.51	-7.55	-0.38	3.93e-13	Total body bone mineral density;
LIHC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg19635926	chr16:89946313	TCF25	0.45	5.8	0.3	1.53e-8	Skin colour saturation;
LIHC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.34	-0.56	3.41e-29	Primary sclerosing cholangitis;
LIHC	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.79	11.84	0.54	2.36e-27	Response to antineoplastic agents;
LIHC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.53	7.84	0.39	5.8e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.47	6.03	0.31	4.2e-9	Initial pursuit acceleration;
LIHC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.91	0.3	8.07e-9	Schizophrenia;
LIHC	cis	rs72653721	0.667	rs57729033	chr6:11058436	A/T	cg13562911	chr6:11044106	ELOVL2	0.51	7.53	0.38	4.55e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg15282417	chr9:129245246	FAM125B	0.41	6.57	0.33	1.89e-10	Intraocular pressure;
LIHC	cis	rs16828019	0.777	rs16911	chr1:41498021	C/T	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.69	7.29	0.37	2.14e-12	Blood protein levels;
LIHC	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg15208524	chr1:10270712	KIF1B	0.45	6.43	0.33	4.32e-10	Hepatocellular carcinoma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06623259	chr20:25990680	LOC100134868	0.4	6.49	0.33	3.05e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2531992	0.858	rs2230742	chr16:4016676	C/T	cg05927578	chr16:4029543	ADCY9	-0.56	-6.35	-0.32	6.68e-10	Waist circumference;
LIHC	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	23.78	0.79	1.86e-74	Schizophrenia;
LIHC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg04317338	chr11:64019027	PLCB3	0.59	8.03	0.4	1.64e-14	Platelet count;
LIHC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.12	0.36	6.3e-12	Axial length;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22199361	chr20:5081567	C20orf30	-0.48	-6.35	-0.32	6.7e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.46	0.77	2.71e-69	Chronic sinus infection;
LIHC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.61	7.39	0.37	1.1e-12	Eosinophilic esophagitis;
LIHC	cis	rs9921222	0.500	rs12917907	chr16:405866	C/T	cg26913058	chr16:419975	MRPL28	-0.43	-5.76	-0.3	1.89e-8	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.57	-0.42	3.63e-16	Schizophrenia;
LIHC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.6	-10.47	-0.49	1.94e-22	Dental caries;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20552752	chr15:90895281	ZNF774	0.43	6.29	0.32	9.67e-10	Pancreatic cancer;
LIHC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.53	5.86	0.3	1.07e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.4	8.48	0.42	6.71e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.41	-6.41	-0.33	4.94e-10	Schizophrenia;
LIHC	cis	rs3744061	0.505	rs9915915	chr17:74652274	A/G	cg13533061	chr17:74712429	JMJD6	-0.28	-5.72	-0.3	2.39e-8	Retinal arteriolar caliber;
LIHC	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-6.42	-0.33	4.43e-10	Menarche (age at onset);
LIHC	trans	rs6489882	0.807	rs10774677	chr12:113362421	G/A	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.97e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6445975	0.667	rs2037123	chr3:58239193	G/T	cg23715586	chr3:58305044	RPP14	-0.34	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LIHC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.87	14.33	0.61	8.61e-37	Colorectal cancer;
LIHC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.32	-6.0	-0.31	4.95e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.63	10.23	0.48	1.35e-21	Resting heart rate;
LIHC	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.9	-14.83	-0.63	9.11e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	7.68	0.38	1.74e-13	Parkinson's disease;
LIHC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.45	-6.38	-0.33	5.86e-10	Systemic lupus erythematosus;
LIHC	cis	rs7739232	0.920	rs6941645	chr6:53515130	A/G	cg15658676	chr6:53530538	KLHL31	-0.91	-6.63	-0.34	1.3e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1144333	1.000	rs5745343	chr1:76273805	A/G	cg22875332	chr1:76189707	ACADM	-0.41	-6.87	-0.35	3.1e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07305463	chr2:136567211	LCT	0.39	7.49	0.38	6.05e-13	Mosquito bite size;
LIHC	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.22	-0.36	3.3e-12	Metabolite levels;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07424592	chr7:64974309	NA	0.41	6.2	0.32	1.67e-9	Calcium levels;
LIHC	cis	rs17106184	1.000	rs59786222	chr1:51295793	C/T	cg07174182	chr1:51127561	FAF1	-0.61	-6.85	-0.35	3.54e-11	Type 2 diabetes;
LIHC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-0.6	-6.04	-0.31	3.93e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg02290350	chr8:58132656	NA	0.32	7.07	0.36	8.87e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.52	7.52	0.38	4.9e-13	Asthma;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.15	-0.58	3.05e-32	Bipolar disorder and schizophrenia;
LIHC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.04	-12.19	-0.55	1.27e-28	Vitiligo;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.55	9.39	0.45	8.94e-19	Aortic root size;
LIHC	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.72	-0.3	2.32e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg21466736	chr12:48725269	NA	-0.72	-10.97	-0.51	3.37e-24	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs34390795	1	rs34390795	chr12:133112394	CGT/C	cg06183872	chr12:133049993	NA	0.35	5.97	0.31	5.97e-9	Red blood cell count;
LIHC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.45e-8	Alzheimer's disease;
LIHC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	11.88	0.54	1.7e-27	Lung cancer in ever smokers;
LIHC	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.64	11.65	0.53	1.24e-26	Schizophrenia;
LIHC	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg20019720	chr6:154832845	CNKSR3	0.44	6.49	0.33	2.97e-10	Lipoprotein (a) levels;
LIHC	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg14580859	chr9:123691850	NA	-0.38	-6.63	-0.34	1.33e-10	Rheumatoid arthritis;
LIHC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.57	-9.59	-0.46	1.96e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg17764715	chr19:33622953	WDR88	0.41	5.72	0.3	2.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg14593290	chr7:50529359	DDC	0.49	7.86	0.39	5.03e-14	Malaria;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.44	6.48	0.33	3.16e-10	Pancreatic cancer;
LIHC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.76	12.98	0.57	1.3e-31	Aortic root size;
LIHC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg14292368	chr19:18793705	CRTC1	0.41	5.82	0.3	1.38e-8	Menarche (age at onset);
LIHC	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	7.89	0.39	4.22e-14	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18429434	chr2:203499731	FAM117B	-0.47	-6.06	-0.31	3.61e-9	Systolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03120789	chr1:20208808	OTUD3	0.51	7.07	0.36	8.63e-12	Pancreatic cancer;
LIHC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.71	-10.21	-0.48	1.55e-21	Aortic root size;
LIHC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.45	-7.4	-0.37	1.03e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg19338460	chr6:170058176	WDR27	-0.37	-5.76	-0.3	1.9e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg25214090	chr10:38739885	LOC399744	0.43	6.86	0.35	3.18e-11	Diastolic blood pressure;
LIHC	trans	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07305463	chr2:136567211	LCT	0.39	7.54	0.38	4.34e-13	Mosquito bite size;
LIHC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg00656387	chr3:40428638	ENTPD3	0.39	6.43	0.33	4.41e-10	Renal cell carcinoma;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.6	-11.34	-0.52	1.58e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.51	0.49	1.45e-22	Bladder cancer;
LIHC	cis	rs860295	0.812	rs7556519	chr1:155827546	T/C	cg02153340	chr1:155202674	NA	-0.33	-6.08	-0.31	3.28e-9	Body mass index;
LIHC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.75	-8.2	-0.41	5.01e-15	Vitiligo;
LIHC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.43	0.53	7.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.56	7.11	0.36	6.66e-12	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	6.95	0.35	1.87e-11	Breast cancer;
LIHC	cis	rs3736485	0.934	rs8038203	chr15:51870683	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.05e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13559233	chr1:82269258	LPHN2	-0.33	-6.13	-0.31	2.41e-9	Cognitive function;
LIHC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.34e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.85	0.3	1.12e-8	Menopause (age at onset);
LIHC	cis	rs2346268	0.605	rs13310832	chr7:133646213	T/G	cg03336402	chr7:133662267	EXOC4	-0.46	-5.74	-0.3	2.06e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.52	6.52	0.33	2.55e-10	Preschool internalizing problems;
LIHC	cis	rs12022452	0.591	rs4660415	chr1:40978491	C/A	cg25568243	chr1:40974465	DEM1	0.45	6.09	0.31	2.95e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.66	-10.91	-0.51	5.48e-24	Total body bone mineral density;
LIHC	trans	rs72960926	0.744	rs7776273	chr6:74967693	T/C	cg07247405	chr1:2484626	LOC115110	0.53	6.31	0.32	8.75e-10	Metabolite levels (MHPG);
LIHC	cis	rs4908760	0.539	rs7513880	chr1:8839300	G/A	cg20416874	chr1:8611966	RERE	-0.57	-10.22	-0.48	1.47e-21	Vitiligo;
LIHC	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.51	7.86	0.39	5.14e-14	Corneal astigmatism;
LIHC	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.82	-16.32	-0.66	1.11e-44	Longevity;
LIHC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.51	7.28	0.37	2.3e-12	Body mass index;
LIHC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.51e-29	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.82	0.39	6.79e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.72	-10.61	-0.5	6.15e-23	Personality dimensions;
LIHC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	7.11	0.36	6.62e-12	Menopause (age at onset);
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04727924	chr7:799746	HEATR2	-0.63	-8.58	-0.42	3.4e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1110701	0.525	rs11764792	chr7:50496841	C/T	cg18232548	chr7:50535776	DDC	-0.43	-6.28	-0.32	1.05e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs10988449	1.000	rs55700157	chr9:132371965	C/A	cg08482979	chr16:88858277	NA	-0.5	-6.08	-0.31	3.29e-9	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.49	9.47	0.46	4.89e-19	Testicular germ cell tumor;
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.53	5.77	0.3	1.73e-8	Alzheimer's disease;
LIHC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg12798992	chr6:167411361	FGFR1OP	0.6	10.02	0.48	6.67e-21	Crohn's disease;
LIHC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.62	7.46	0.37	7.15e-13	Heart rate;
LIHC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.14	-0.44	5.47e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.75	-13.25	-0.58	1.26e-32	Obesity-related traits;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18128437	chr3:167453397	PDCD10;SERPINI1	0.46	6.57	0.33	1.92e-10	Migraine with aura;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.5	-6.2	-0.32	1.66e-9	Diastolic blood pressure;
LIHC	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	8.33	0.41	1.92e-15	Height;
LIHC	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.71	8.4	0.41	1.24e-15	Exhaled nitric oxide output;
LIHC	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.54	8.47	0.42	7.31e-16	HDL cholesterol;
LIHC	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.98	0.31	5.65e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.64	5.95	0.31	6.51e-9	Inflammatory bowel disease;
LIHC	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.23	-0.52	4.16e-25	Eye color traits;
LIHC	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs67981189	0.574	rs8004452	chr14:71416040	G/A	cg15816911	chr14:71606274	NA	-0.42	-6.6	-0.34	1.59e-10	Schizophrenia;
LIHC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.05	-19.66	-0.73	3.92e-58	Multiple system atrophy;
LIHC	cis	rs9328573	0.967	rs12441141	chr15:100509976	C/A	cg09918751	chr15:100517450	ADAMTS17	-0.49	-7.35	-0.37	1.46e-12	Urate levels in lean individuals;
LIHC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.8	15.24	0.64	2.16e-40	Blood protein levels;
LIHC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-6.02	-0.31	4.45e-9	IgG glycosylation;
LIHC	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-7.87	-0.39	4.72e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.65	-9.76	-0.47	5.19e-20	Obesity-related traits;
LIHC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg16736954	chr20:23401023	NAPB	0.72	8.46	0.42	7.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.22	5.95	0.31	6.65e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.43	6.88	0.35	2.82e-11	Multiple sclerosis;
LIHC	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.4	5.82	0.3	1.33e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.77	-9.45	-0.46	5.46e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs143000161	1	rs143000161	chr2:165710540	A/T	cg03182029	chr2:165697222	COBLL1	0.9	6.87	0.35	2.99e-11	Heschl's gyrus morphology;
LIHC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.63	-0.5	5.35e-23	Aortic root size;
LIHC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.42	6.27	0.32	1.1e-9	Obesity-related traits;
LIHC	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.51	-0.38	5.15e-13	Capecitabine sensitivity;
LIHC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.53	6.89	0.35	2.62e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	0.98	10.31	0.49	7.06e-22	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg00204512	chr16:28754710	NA	0.42	7.09	0.36	7.97e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.26	18.82	0.71	9.63e-55	Type 1 diabetes nephropathy;
LIHC	cis	rs965469	1.000	rs2236118	chr20:3302058	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.81	-0.35	4.29e-11	IFN-related cytopenia;
LIHC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs6684514	0.961	rs11264463	chr1:156242806	A/G	cg16558208	chr1:156270281	VHLL	0.53	10.07	0.48	4.71e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.81	10.3	0.49	7.59e-22	Cognitive function;
LIHC	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg00476317	chr8:12990213	DLC1	0.74	6.72	0.34	7.72e-11	Musician's dystonia;
LIHC	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg01864069	chr14:103024347	NA	-0.57	-9.52	-0.46	3.36e-19	Platelet count;
LIHC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.64	-11.4	-0.52	9.9e-26	Dental caries;
LIHC	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.6	-0.62	7.2e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.45	-7.36	-0.37	1.35e-12	Testicular germ cell tumor;
LIHC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.78	-11.79	-0.54	3.65e-27	Response to antineoplastic agents;
LIHC	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	0.48	6.24	0.32	1.28e-9	Pulse pressure;
LIHC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg16797656	chr11:68205561	LRP5	0.5	7.78	0.39	8.43e-14	Total body bone mineral density;
LIHC	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.97	-0.51	3.35e-24	Response to antipsychotic treatment;
LIHC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.53	8.26	0.41	3.19e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	9.17	0.44	4.47e-18	Platelet count;
LIHC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg06238570	chr21:40685208	BRWD1	0.61	7.43	0.37	9e-13	Cognitive function;
LIHC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.54	10.49	0.49	1.61e-22	Methadone dose in opioid dependence;
LIHC	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg04610667	chr7:75704037	NA	0.34	6.04	0.31	3.96e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg25783544	chr11:47291846	MADD	0.42	6.15	0.32	2.18e-9	HDL cholesterol;
LIHC	cis	rs36051895	0.589	rs7848312	chr9:5237442	T/C	cg02405213	chr9:5042618	JAK2	-0.66	-10.64	-0.5	5.12e-23	Pediatric autoimmune diseases;
LIHC	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.46	-6.27	-0.32	1.09e-9	Initial pursuit acceleration;
LIHC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg05484376	chr2:27715224	FNDC4	0.38	6.3	0.32	9.25e-10	Total body bone mineral density;
LIHC	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.77	-8.36	-0.41	1.63e-15	Alzheimer's disease (late onset);
LIHC	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.4	-5.82	-0.3	1.33e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg02990361	chr1:107599529	PRMT6	0.64	10.65	0.5	4.71e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-21.89	-0.76	4.85e-67	Height;
LIHC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.6	9.99	0.48	8.97e-21	Colorectal cancer;
LIHC	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.3	-6.74	-0.34	6.92e-11	DNA methylation (variation);
LIHC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.39	-5.91	-0.3	8.36e-9	Menarche (age at onset);
LIHC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	7.64	0.38	2.14e-13	Platelet count;
LIHC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg12373951	chr3:133503437	NA	0.54	9.3	0.45	1.73e-18	Iron status biomarkers;
LIHC	cis	rs77861329	1.000	rs171294	chr3:52203599	C/G	cg08692210	chr3:52188851	WDR51A	0.83	7.86	0.39	5.11e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.83	-0.35	3.86e-11	Response to antipsychotic treatment;
LIHC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg22633049	chr21:46681294	NA	-0.35	-6.06	-0.31	3.59e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.91	0.54	1.41e-27	Prudent dietary pattern;
LIHC	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg05697976	chr12:29376483	FAR2	0.29	5.99	0.31	5.43e-9	QT interval;
LIHC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.64	9.62	0.46	1.5e-19	Longevity;
LIHC	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.24	21.06	0.75	1e-63	Corneal structure;
LIHC	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.94	-0.31	7.1e-9	Iron status biomarkers;
LIHC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-6.09	-0.31	2.99e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.47	-7.32	-0.37	1.78e-12	Type 2 diabetes;
LIHC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.32	-7.11	-0.36	6.83e-12	Ulcerative colitis;
LIHC	cis	rs7729447	0.804	rs116090595	chr5:32698148	T/G	cg16267343	chr5:32710456	NPR3	0.47	5.82	0.3	1.35e-8	Blood pressure;
LIHC	trans	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg26939375	chr7:64535504	NA	-0.44	-7.05	-0.36	1.01e-11	Aortic root size;
LIHC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.45	10.22	0.48	1.46e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs922107	0.738	rs12124338	chr1:90053167	A/G	cg15422784	chr1:90023713	LRRC8B	-0.49	-7.78	-0.39	8.58e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg18964960	chr10:1102726	WDR37	0.67	6.11	0.31	2.72e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg03013999	chr17:37608204	MED1	-0.35	-5.9	-0.3	8.64e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	0.8	6.22	0.32	1.46e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12644436	0.628	rs1599720	chr4:88782714	G/A	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21448741	chr8:58168803	NA	0.37	6.66	0.34	1.09e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.36	2.88e-12	Educational attainment;
LIHC	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.45	7.22	0.36	3.43e-12	Height;
LIHC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.65	-10.38	-0.49	4e-22	Lung cancer;
LIHC	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg17623882	chr6:41773611	USP49	-0.44	-5.85	-0.3	1.15e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs7572733	0.555	rs1837495	chr2:198921201	A/G	cg03934865	chr2:198174659	NA	-0.45	-6.48	-0.33	3.15e-10	Dermatomyositis;
LIHC	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02985541	chr2:219472218	PLCD4	-0.43	-6.94	-0.35	1.93e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg17372223	chr3:52568218	NT5DC2	-0.37	-5.73	-0.3	2.18e-8	Bipolar disorder;
LIHC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg13844804	chr7:814759	HEATR2	0.44	5.93	0.31	7.37e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	14.34	0.61	7.3e-37	Primary sclerosing cholangitis;
LIHC	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg26384229	chr12:38710491	ALG10B	0.47	6.37	0.33	6.01e-10	Resting heart rate;
LIHC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	0.59	11.17	0.52	6.81e-25	Fat distribution (HIV);
LIHC	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.88	14.79	0.62	1.35e-38	Schizophrenia;
LIHC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.23	-0.32	1.39e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.92	8.65	0.42	1.96e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.68e-9	Blood metabolite levels;
LIHC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg00750074	chr16:89608354	SPG7	-0.49	-8.02	-0.4	1.74e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg19773385	chr1:10388646	KIF1B	-0.48	-8.15	-0.4	7.07e-15	Hepatocellular carcinoma;
LIHC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg01256987	chr12:42539512	GXYLT1	-0.34	-5.81	-0.3	1.4e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4699052	0.963	rs2061646	chr4:104183894	T/C	cg16532752	chr4:104119610	CENPE	-0.4	-6.33	-0.32	7.56e-10	Testicular germ cell tumor;
LIHC	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.27	6.24	0.32	1.32e-9	Heart rate;
LIHC	cis	rs17286411	0.639	rs12447856	chr16:71790673	A/G	cg06353428	chr16:71660113	MARVELD3	-0.39	-5.83	-0.3	1.25e-8	Blood protein levels;
LIHC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.6	5.91	0.3	8.29e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg11212589	chr17:38028394	ZPBP2	0.38	7.96	0.4	2.59e-14	Self-reported allergy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15613982	chr20:18488017	SEC23B	0.45	6.7	0.34	8.38e-11	Pancreatic cancer;
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.47	6.01	0.31	4.83e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.3	-16.6	-0.67	8.39e-46	Diabetic kidney disease;
LIHC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.56	-0.71	1.09e-53	Height;
LIHC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg04013166	chr16:89971882	TCF25	0.52	6.62	0.34	1.35e-10	Skin colour saturation;
LIHC	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.69	-7.07	-0.36	8.72e-12	Blood protein levels;
LIHC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-7.0	-0.35	1.36e-11	Schizophrenia;
LIHC	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	1.1	13.84	0.6	6.94e-35	Blood protein levels;
LIHC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.59	0.34	1.62e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.41	7.71	0.38	1.39e-13	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.51	0.49	1.4e-22	Alzheimer's disease;
LIHC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.22	0.32	1.41e-9	Rheumatoid arthritis;
LIHC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg05361325	chr10:32636312	EPC1	-0.51	-6.24	-0.32	1.31e-9	Sexual dysfunction (female);
LIHC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	2.01e-11	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14166846	chr1:220268091	IARS2	0.4	6.66	0.34	1.07e-10	Cognitive function;
LIHC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.63	10.65	0.5	4.45e-23	Uric acid clearance;
LIHC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg15691649	chr6:25882328	NA	-0.63	-8.47	-0.42	7.42e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs6058796	1.000	rs6087406	chr20:31241025	G/T	cg02600331	chr11:130417168	NA	0.35	6.26	0.32	1.18e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.45	-0.49	2.22e-22	Platelet count;
LIHC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.36	0.33	6.54e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg17623882	chr6:41773611	USP49	-0.43	-5.74	-0.3	2.09e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.88	0.3	9.5e-9	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.7	0.43	1.41e-16	Prudent dietary pattern;
LIHC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	16.26	0.66	1.93e-44	Platelet count;
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.41	6.34	0.32	7.23e-10	Testicular germ cell tumor;
LIHC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.72	-0.3	2.29e-8	Mortality in heart failure;
LIHC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.09	-0.31	2.97e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.38	5.85	0.3	1.17e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.27	-0.52	2.9e-25	Coronary artery disease;
LIHC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.69	-9.54	-0.46	2.69e-19	Corneal structure;
LIHC	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.38	-0.33	5.65e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.96	0.51	3.7e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.14	-0.32	2.3e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.62	9.26	0.45	2.27e-18	Renal cell carcinoma;
LIHC	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs963731	0.649	rs2123881	chr2:39247742	G/A	cg04010122	chr2:39346883	SOS1	-0.68	-5.84	-0.3	1.19e-8	Corticobasal degeneration;
LIHC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.88	0.39	4.43e-14	Lung cancer;
LIHC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.43	-6.62	-0.34	1.36e-10	Height;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21400344	chr1:25870172	LDLRAP1	-0.51	-6.38	-0.33	5.6e-10	Hepatitis;
LIHC	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	7.67	0.38	1.81e-13	Blood protein levels;
LIHC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.22	-0.45	3.13e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg19645103	chr12:69753606	YEATS4	-0.45	-6.02	-0.31	4.56e-9	Response to diuretic therapy;
LIHC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.19	5.77	0.3	1.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7116495	0.609	rs2276396	chr11:71823905	G/C	cg26138937	chr11:71823887	C11orf51	1.31	10.37	0.49	4.19e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg20636351	chr8:55087400	NA	-0.4	-8.06	-0.4	1.31e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.6	6.03	0.31	4.21e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.85	12.19	0.55	1.26e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.39	-6.23	-0.32	1.37e-9	HDL cholesterol levels;
LIHC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg02290350	chr8:58132656	NA	0.33	7.25	0.36	2.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg00564555	chr16:1970112	NA	0.26	6.08	0.31	3.18e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg06207120	chr15:45996521	NA	0.34	6.62	0.34	1.39e-10	Waist circumference;Weight;
LIHC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg19645103	chr12:69753606	YEATS4	-0.44	-5.77	-0.3	1.76e-8	Response to diuretic therapy;
LIHC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.9	-10.02	-0.48	6.78e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7238033	0.624	rs9946832	chr18:43312790	A/G	cg20610511	chr18:43302872	SLC14A1	0.37	6.24	0.32	1.31e-9	Bladder cancer;
LIHC	trans	rs4714291	0.963	rs4714293	chr6:40009566	T/C	cg02267698	chr19:7991119	CTXN1	0.38	6.15	0.32	2.12e-9	Strep throat;
LIHC	cis	rs3768617	0.868	rs2296299	chr1:183104013	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.52	8.43	0.41	9.75e-16	Fuchs's corneal dystrophy;
LIHC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	0.77	7.12	0.36	6.48e-12	Plateletcrit;
LIHC	cis	rs10838687	0.736	rs7933246	chr11:47262648	G/C	cg25783544	chr11:47291846	MADD	0.46	5.93	0.31	7.57e-9	Proinsulin levels;
LIHC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.46	0.37	7e-13	Schizophrenia;
LIHC	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.41	7.37	0.37	1.26e-12	Response to antipsychotic treatment;
LIHC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.72	-9.99	-0.48	8.35e-21	Colorectal cancer;
LIHC	cis	rs9783347	0.890	rs11024634	chr11:18392074	G/A	cg15585147	chr11:18324498	HPS5	0.42	6.5	0.33	2.78e-10	Pancreatic cancer;
LIHC	cis	rs9921222	0.521	rs9935268	chr16:381562	G/C	cg00101154	chr16:420108	MRPL28	-0.56	-7.89	-0.39	4.15e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7131987	0.675	rs3847678	chr12:29551560	A/C	cg14222432	chr12:29376421	FAR2	-0.3	-5.85	-0.3	1.17e-8	QT interval;
LIHC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg23422044	chr7:1970798	MAD1L1	-0.62	-6.94	-0.35	1.92e-11	Bipolar disorder;
LIHC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-7.18	-0.36	4.28e-12	Coronary artery disease;
LIHC	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-0.84	-9.5	-0.46	3.87e-19	Mitochondrial DNA levels;
LIHC	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg17385448	chr1:15911702	AGMAT	0.37	6.3	0.32	9.39e-10	Systolic blood pressure;
LIHC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.41	-7.06	-0.36	9.22e-12	Schizophrenia;
LIHC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.81	0.35	4.32e-11	Ileal carcinoids;
LIHC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.42	6.06	0.31	3.69e-9	Schizophrenia;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg10360139	chr7:1886902	MAD1L1	-0.43	-6.59	-0.34	1.63e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.35	8.11	0.4	9.08e-15	Crohn's disease;
LIHC	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	0.76	8.46	0.42	8.18e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.47	6.34	0.32	7.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.49	-0.33	3e-10	Height;
LIHC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.85	15.3	0.64	1.23e-40	Aortic root size;
LIHC	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	0.82	11.63	0.53	1.46e-26	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg25894440	chr7:65020034	NA	-0.54	-6.22	-0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.48	0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4517514	0.509	rs11018870	chr11:89871409	T/G	cg05041596	chr11:89867385	NAALAD2	0.42	6.95	0.35	1.88e-11	Trans fatty acid levels;
LIHC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.56	10.16	0.48	2.36e-21	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.52	0.46	3.25e-19	Corneal astigmatism;
LIHC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.58	0.69	1.01e-49	Tonsillectomy;
LIHC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.52	0.53	3.67e-26	Motion sickness;
LIHC	cis	rs9993613	0.934	rs4694493	chr4:73437261	C/T	cg15102770	chr4:73434591	ADAMTS3	0.39	6.26	0.32	1.17e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg01256987	chr12:42539512	GXYLT1	-0.39	-6.56	-0.33	1.97e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.69	-8.69	-0.43	1.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21448741	chr8:58168803	NA	0.31	5.87	0.3	1.02e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.59	5.81	0.3	1.42e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.69	10.67	0.5	3.87e-23	Mosquito bite size;
LIHC	cis	rs546131	0.642	rs34999475	chr11:34829848	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.52	-0.33	2.52e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.9	-14.87	-0.63	6.48e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg26338869	chr17:61819248	STRADA	-0.48	-6.43	-0.33	4.22e-10	Height;
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg21003380	chr1:156261207	TMEM79	0.37	5.98	0.31	5.69e-9	Tonsillectomy;
LIHC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16346588	chr10:242978	ZMYND11	0.38	5.87	0.3	1.02e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.27	-0.37	2.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.73	-12.29	-0.55	5.25e-29	Lewy body disease;
LIHC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.26	6.4	0.33	5.16e-10	Schizophrenia;
LIHC	cis	rs9948	1.000	rs9948	chr2:97500800	C/G	cg01990225	chr2:97406019	LMAN2L	0.58	5.95	0.31	6.59e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18252515	chr7:66147081	NA	0.43	5.88	0.3	9.8e-9	Aortic root size;
LIHC	cis	rs12079745	0.793	rs12067139	chr1:169254507	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-7.4	-0.37	1.04e-12	QT interval;
LIHC	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.39	5.97	0.31	6.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs655641	0.871	rs603615	chr11:85709559	G/A	cg09030501	chr11:85779252	PICALM	-0.53	-6.44	-0.33	4.11e-10	Platelet count;
LIHC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.63	-11.02	-0.51	2.19e-24	Height;
LIHC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.41	-0.33	4.88e-10	Height;
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.29	0.32	9.44e-10	Renal cell carcinoma;
LIHC	cis	rs16912285	0.688	rs10834313	chr11:24348447	G/C	ch.11.24196551F	chr11:24239977	NA	0.67	7.52	0.38	4.96e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01442903	chr1:55181833	TTC4	0.38	6.12	0.31	2.59e-9	Calcium levels;
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.43	5.83	0.3	1.3e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg09035930	chr12:129282057	SLC15A4	-0.5	-6.02	-0.31	4.44e-9	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.34	-0.32	7.27e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.67	-6.59	-0.34	1.71e-10	Multiple sclerosis;
LIHC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.47	0.42	7.46e-16	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22335246	chr12:120763591	PLA2G1B	0.38	6.21	0.32	1.58e-9	Pancreatic cancer;
LIHC	cis	rs7674212	0.541	rs2623064	chr4:104030792	C/A	cg16532752	chr4:104119610	CENPE	-0.44	-6.89	-0.35	2.67e-11	Type 2 diabetes;
LIHC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg22532475	chr10:104410764	TRIM8	0.37	6.39	0.33	5.3e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.58	8.68	0.42	1.7e-16	Coronary artery disease;
LIHC	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg03999872	chr20:62272968	STMN3	-0.46	-6.78	-0.34	5.22e-11	Atopic dermatitis;
LIHC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.65	-0.34	1.18e-10	Height;
LIHC	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg20607764	chr19:44506953	ZNF230	0.39	6.37	0.33	6.01e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.77	-12.84	-0.57	4.68e-31	Tonsillectomy;
LIHC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.59	-7.9	-0.39	3.72e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.9	0.39	3.85e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08168689	chr14:76455272	C14orf179	0.42	6.22	0.32	1.43e-9	Bilirubin levels;
LIHC	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	15.31	0.64	1.18e-40	Lung cancer in ever smokers;
LIHC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg01444801	chr10:135216882	MTG1	-0.63	-9.33	-0.45	1.37e-18	Systemic lupus erythematosus;
LIHC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs600806	0.778	rs518697	chr1:110014778	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.58	-7.38	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg07862535	chr7:139043722	LUC7L2	0.58	10.03	0.48	6.38e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.08	-0.36	8.39e-12	Post bronchodilator FEV1;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20604317	chr20:4129314	SMOX	0.46	6.37	0.33	6.2e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7534824	0.543	rs72734254	chr1:101382039	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.53	0.38	4.55e-13	Refractive astigmatism;
LIHC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.81	0.47	3.45e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.7	10.88	0.51	6.94e-24	Corneal astigmatism;
LIHC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.47	-6.86	-0.35	3.26e-11	Aortic root size;
LIHC	cis	rs9513627	0.915	rs4539436	chr13:100122802	C/G	cg25919922	chr13:100150906	NA	-0.79	-6.95	-0.35	1.86e-11	Obesity-related traits;
LIHC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.96	17.6	0.69	8.27e-50	Breast cancer;
LIHC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-9.94	-0.47	1.28e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg11764359	chr7:65958608	NA	-0.58	-6.03	-0.31	4.27e-9	Diabetic kidney disease;
LIHC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg25356066	chr3:128598488	ACAD9	0.51	7.08	0.36	8.23e-12	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	12.34	0.55	3.57e-29	Prudent dietary pattern;
LIHC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.43	6.44	0.33	4.1e-10	Methadone dose in opioid dependence;
LIHC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.49	-8.6	-0.42	2.91e-16	Height;
LIHC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.69	-0.5	3.28e-23	Hemoglobin concentration;
LIHC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg14580859	chr9:123691850	NA	0.38	6.47	0.33	3.3e-10	Rheumatoid arthritis;
LIHC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.82	-13.06	-0.58	6.88e-32	Colorectal cancer;
LIHC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.33	-7.36	-0.37	1.39e-12	Ulcerative colitis;
LIHC	cis	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg00409905	chr10:38381863	ZNF37A	0.38	5.82	0.3	1.36e-8	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.47	6.84	0.35	3.7e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.97	-0.54	8.07e-28	Alzheimer's disease;
LIHC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg24098013	chr12:12878779	APOLD1	0.56	7.94	0.39	2.89e-14	Lymphocyte counts;
LIHC	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs11671005	0.737	rs11673101	chr19:58995053	G/C	cg25952890	chr19:58913133	NA	0.73	7.45	0.37	7.64e-13	Mean platelet volume;
LIHC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.09	0.44	8.21e-18	Platelet count;
LIHC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.72	-9.55	-0.46	2.67e-19	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07030052	chr1:162531143	UAP1	-0.41	-6.04	-0.31	4.03e-9	Cognitive function;
LIHC	cis	rs7487075	0.780	rs2279559	chr12:46767175	A/C	cg15584813	chr12:47219626	SLC38A4	0.33	5.84	0.3	1.24e-8	Itch intensity from mosquito bite;
LIHC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.02e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.48	7.71	0.38	1.42e-13	HDL cholesterol;
LIHC	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	9.55	0.46	2.59e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.95	14.93	0.63	3.78e-39	Metabolic syndrome;
LIHC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.77	11.85	0.54	2.3e-27	Corneal astigmatism;
LIHC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.42	7.07	0.36	8.66e-12	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg11257324	chr6:150232174	NA	0.37	6.16	0.32	1.99e-9	Lung cancer;
LIHC	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.45	-6.75	-0.34	6.35e-11	Diastolic blood pressure;
LIHC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.68	0.53	9.06e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg13919466	chr1:32135498	COL16A1	-0.34	-6.34	-0.32	7.19e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-7.23	-0.36	3.26e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.69	0.34	9.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.52	8.36	0.41	1.58e-15	Total body bone mineral density;
LIHC	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02985541	chr2:219472218	PLCD4	-0.36	-6.34	-0.32	7.29e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs244293	0.965	rs2628324	chr17:53202977	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.63	-0.38	2.39e-13	Menarche (age at onset);
LIHC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-1.04	-22.88	-0.78	5.95e-71	Height;
LIHC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg25894440	chr7:65020034	NA	-0.51	-5.87	-0.3	1.01e-8	Diabetic kidney disease;
LIHC	trans	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg17675199	chr6:35436792	RPL10A	0.31	6.08	0.31	3.13e-9	Coronary artery disease;
LIHC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.06	-13.4	-0.59	3.34e-33	Corneal structure;
LIHC	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.05	-0.31	3.72e-9	Pancreatic cancer;
LIHC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.69	12.38	0.56	2.55e-29	Colorectal cancer;
LIHC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.47	7.33	0.37	1.64e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12365397	1.000	rs10838072	chr11:43227569	G/A	cg16667275	chr11:43333495	API5	0.44	6.05	0.31	3.91e-9	Migraine;
LIHC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.51	0.42	5.55e-16	Motion sickness;
LIHC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.33	0.32	7.53e-10	Height;
LIHC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.66	6.19	0.32	1.71e-9	Type 2 diabetes nephropathy;
LIHC	cis	rs716804	0.740	rs7938543	chr11:10229851	G/A	cg01453529	chr11:10209919	SBF2	0.3	5.9	0.3	8.58e-9	Neuroticism;
LIHC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.72e-46	Parkinson's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10100767	chr14:105246561	AKT1	0.42	6.25	0.32	1.25e-9	Longevity;
LIHC	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16684958	chr7:75615977	POR	0.51	8.61	0.42	2.78e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.36	0.37	1.39e-12	Monocyte percentage of white cells;
LIHC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.56	-7.62	-0.38	2.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.53	-0.71	1.41e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.04	-0.31	4.12e-9	Resting heart rate;
LIHC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.6	8.03	0.4	1.56e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.67	-8.63	-0.42	2.33e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.49	7.77	0.39	9.5e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	6.51	0.33	2.69e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.96	13.88	0.6	4.81e-35	Primary sclerosing cholangitis;
LIHC	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.61	-0.38	2.7e-13	Homocysteine levels;
LIHC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.47	6.6	0.34	1.59e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098699	0.821	rs7665617	chr4:124201196	C/G	cg09941581	chr4:124220074	SPATA5	0.33	6.61	0.34	1.5e-10	Mosquito bite size;
LIHC	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg20335179	chr10:1068567	C10orf110;IDI2	-0.56	-6.05	-0.31	3.91e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.5	7.88	0.39	4.27e-14	Alzheimer's disease (survival time);
LIHC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.39	-7.57	-0.38	3.56e-13	Diastolic blood pressure;
LIHC	cis	rs4586057	0.514	rs7101301	chr10:92649923	G/A	cg14313238	chr10:92632228	RPP30	0.36	6.04	0.31	4.03e-9	Economic and political preferences (time);
LIHC	cis	rs2834256	0.961	rs9981693	chr21:35042550	A/G	cg14850771	chr21:34775459	IFNGR2	0.39	6.17	0.32	1.98e-9	Red cell distribution width;
LIHC	cis	rs2016586	0.895	rs5750162	chr22:36114551	T/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.39	-0.49	3.62e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.61	-8.22	-0.41	4.13e-15	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg21252483	chr19:49399788	TULP2	-0.45	-7.43	-0.37	8.95e-13	Red cell distribution width;
LIHC	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.85e-11	Dermatomyositis;
LIHC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.49	9.89	0.47	1.92e-20	Tonsillectomy;
LIHC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg14132834	chr19:41945861	ATP5SL	-0.42	-6.18	-0.32	1.83e-9	Height;
LIHC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.68	0.34	9.67e-11	Bipolar disorder;
LIHC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.75	0.47	5.8e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.77	12.25	0.55	7.23e-29	Corneal astigmatism;
LIHC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.47	-7.27	-0.37	2.4e-12	Menarche (age at onset);
LIHC	cis	rs17428076	0.836	rs57775770	chr2:172687731	T/C	cg13550731	chr2:172543902	DYNC1I2	0.38	6.3	0.32	9.4e-10	Myopia;
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg14671364	chr1:107599128	PRMT6	0.52	7.83	0.39	6.25e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11630290	0.592	rs12324668	chr15:64161786	A/T	cg12036633	chr15:63758958	NA	0.61	6.49	0.33	2.94e-10	Iris characteristics;
LIHC	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.63	9.58	0.46	2.01e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg07424592	chr7:64974309	NA	0.8	9.39	0.45	8.41e-19	Diabetic kidney disease;
LIHC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg05501817	chr11:14380813	RRAS2	-0.42	-5.76	-0.3	1.84e-8	Sense of smell;
LIHC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg24296786	chr1:45957014	TESK2	0.41	5.99	0.31	5.42e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	11.19	0.52	5.7e-25	Alzheimer's disease (late onset);
LIHC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.47	6.81	0.35	4.36e-11	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.44	-0.42	9.26e-16	Response to antipsychotic treatment;
LIHC	cis	rs10847980	0.590	rs2292131	chr12:123332354	C/T	cg07706471	chr12:123319906	HIP1R	0.77	8.68	0.42	1.66e-16	Adiponectin levels;
LIHC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.46	6.73	0.34	7.16e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.3	-0.45	1.73e-18	Capecitabine sensitivity;
LIHC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.67	12.13	0.55	2.12e-28	High light scatter reticulocyte count;
LIHC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13374867	chr5:43514950	C5orf34	-0.46	-6.56	-0.33	2e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LIHC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02985541	chr2:219472218	PLCD4	0.46	8.73	0.43	1.18e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.87	15.7	0.65	3.37e-42	Bone mineral density;
LIHC	cis	rs6973256	0.605	rs7794168	chr7:133357606	T/C	cg10665199	chr7:133106180	EXOC4	0.35	5.99	0.31	5.42e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg17675199	chr6:35436792	RPL10A	-0.44	-9.16	-0.44	5.05e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	1.02	12.21	0.55	1.02e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	8.32	0.41	2.13e-15	Blood metabolite levels;
LIHC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg15448220	chr1:150897856	SETDB1	0.42	6.64	0.34	1.23e-10	Tonsillectomy;
LIHC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.52	7.42	0.37	9.08e-13	Uric acid levels;
LIHC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16262614	chr3:133464971	TF	0.28	6.4	0.33	5.03e-10	Iron status biomarkers;
LIHC	trans	rs6531296	0.558	rs9968503	chr4:34266281	T/C	cg03525467	chr1:160098048	ATP1A2	-0.44	-6.25	-0.32	1.23e-9	Thoracic-to-hip circumference ratio;
LIHC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-15.09	-0.63	8.6e-40	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13827970	chr14:55369959	GCH1	0.41	6.08	0.31	3.26e-9	Pancreatic cancer;
LIHC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg11766577	chr21:47581405	C21orf56	-0.4	-6.27	-0.32	1.1e-9	Testicular germ cell tumor;
LIHC	cis	rs1185460	0.565	rs657685	chr11:118912982	G/C	cg23280166	chr11:118938394	VPS11	-0.45	-6.13	-0.31	2.36e-9	Coronary artery disease;
LIHC	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.45	7.61	0.38	2.72e-13	Platelet distribution width;
LIHC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.52	8.04	0.4	1.44e-14	Resting heart rate;
LIHC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.47	-6.96	-0.35	1.76e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs911119	0.818	rs56077567	chr20:23591087	T/C	cg16589663	chr20:23618590	CST3	0.72	7.54	0.38	4.32e-13	Chronic kidney disease;
LIHC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	10.94	0.51	4.38e-24	Response to antipsychotic treatment;
LIHC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.52	-8.8	-0.43	7.1e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.04	0.4	1.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.3e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg14067834	chr17:29058358	SUZ12P	0.68	6.66	0.34	1.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.53	-5.93	-0.31	7.55e-9	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg17796960	chr10:135278976	LOC619207	-0.34	-5.73	-0.3	2.19e-8	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.78	12.57	0.56	4.74e-30	Corneal astigmatism;
LIHC	cis	rs7188697	0.922	rs37036	chr16:58553348	T/C	cg02549819	chr16:58548995	SETD6	-0.49	-7.7	-0.38	1.45e-13	QT interval;
LIHC	cis	rs611744	0.967	rs603889	chr8:109224232	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs17428076	0.874	rs72885529	chr2:172684032	C/T	cg13550731	chr2:172543902	DYNC1I2	0.38	6.21	0.32	1.54e-9	Myopia;
LIHC	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg17764715	chr19:33622953	WDR88	0.51	6.8	0.35	4.57e-11	Bone properties (heel);
LIHC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.54	-0.86	3e-103	Myeloid white cell count;
LIHC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.1	11.26	0.52	3.23e-25	Opioid sensitivity;
LIHC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	9.87	0.47	2.21e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs11098699	0.821	rs11734868	chr4:124211544	A/G	cg09941581	chr4:124220074	SPATA5	0.33	6.61	0.34	1.47e-10	Mosquito bite size;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg23782820	chr8:58130467	NA	-0.33	-5.81	-0.3	1.41e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9918079	0.560	rs6414767	chr4:15655721	A/G	cg21329975	chr4:15471214	CC2D2A	-0.42	-6.33	-0.32	7.71e-10	Obesity-related traits;
LIHC	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.45	-6.61	-0.34	1.5e-10	Menarche (age at onset);
LIHC	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.53	-8.11	-0.4	9.22e-15	Platelet distribution width;
LIHC	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.36	5.97	0.31	5.92e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04371633	chr14:65381025	CHURC1	0.47	7.62	0.38	2.45e-13	Cognitive function;
LIHC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg05941027	chr17:61774174	LIMD2	0.37	7.66	0.38	1.97e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.85	12.2	0.55	1.1e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg14061069	chr19:46274453	DMPK	-0.56	-8.53	-0.42	4.64e-16	Coronary artery disease;
LIHC	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	8.45	0.42	8.36e-16	Total cholesterol levels;
LIHC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.42	-6.75	-0.34	6.36e-11	Mortality in heart failure;
LIHC	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.63	9.57	0.46	2.16e-19	Lymphocyte counts;
LIHC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.6	-9.55	-0.46	2.61e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.47	-7.93	-0.39	3.24e-14	Aortic root size;
LIHC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg19318889	chr4:1322082	MAEA	0.47	6.59	0.34	1.71e-10	Obesity-related traits;
LIHC	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.5	9.51	0.46	3.41e-19	Testicular germ cell tumor;
LIHC	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.53	7.16	0.36	4.87e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.5	8.68	0.43	1.61e-16	Schizophrenia;
LIHC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.13	0.58	3.64e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.76	-9.5	-0.46	3.69e-19	Systemic lupus erythematosus;
LIHC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.53	7.38	0.37	1.22e-12	Height;
LIHC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.29e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.71	-0.34	8.05e-11	Total body bone mineral density;
LIHC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg00750074	chr16:89608354	SPG7	-0.51	-8.13	-0.4	8.18e-15	Multiple myeloma (IgH translocation);
LIHC	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.72	0.43	1.23e-16	Corneal astigmatism;
LIHC	cis	rs6545883	0.860	rs777589	chr2:61425621	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.89	-0.3	9.47e-9	Tuberculosis;
LIHC	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.2	27.54	0.83	8.49e-89	Schizophrenia;
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.09	-0.44	8.37e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.84	-14.71	-0.62	2.74e-38	Nonalcoholic fatty liver disease;
LIHC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg10820045	chr2:198174542	NA	-0.58	-9.71	-0.46	7.47e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.9	0.3	8.95e-9	Menopause (age at onset);
LIHC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-8.32	-0.41	2.11e-15	Gut microbiome composition (summer);
LIHC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.73	7.51	0.38	5.22e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg27247782	chr7:158767135	NA	-0.31	-5.9	-0.3	8.58e-9	Facial morphology (factor 20);
LIHC	cis	rs864643	0.947	rs704962	chr3:39557120	C/T	cg05136238	chr3:39556330	MOBP	-0.29	-5.72	-0.3	2.3e-8	Attention deficit hyperactivity disorder;
LIHC	trans	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg17675199	chr6:35436792	RPL10A	-0.36	-7.1	-0.36	7.35e-12	Coronary artery disease;
LIHC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.34	8.83	0.43	5.49e-17	Schizophrenia;
LIHC	cis	rs244293	0.765	rs7503269	chr17:53019712	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.46	-6.16	-0.32	2.05e-9	Menarche (age at onset);
LIHC	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg25182066	chr10:30743637	MAP3K8	0.69	9.77	0.47	4.87e-20	Itch intensity from mosquito bite;
LIHC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-26.82	-0.82	4.04e-86	Myeloid white cell count;
LIHC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-9.39	-0.45	8.57e-19	Cognitive function;
LIHC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.61	6.51	0.33	2.64e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg09238746	chr17:78121135	EIF4A3	0.55	8.22	0.41	4.33e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LIHC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg12463550	chr7:65579703	CRCP	-0.73	-7.64	-0.38	2.24e-13	Diabetic kidney disease;
LIHC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.59	0.38	3.17e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	9.2	0.45	3.75e-18	Menarche (age at onset);
LIHC	cis	rs8017423	0.845	rs80167706	chr14:90727629	G/C	cg04374321	chr14:90722782	PSMC1	0.78	15.15	0.63	4.85e-40	Mortality in heart failure;
LIHC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg08888203	chr3:10149979	C3orf24	0.52	6.26	0.32	1.14e-9	Alzheimer's disease;
LIHC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.99	23.08	0.78	1.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-8.02	-0.4	1.75e-14	Birth weight;
LIHC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24317988	chr10:33247433	ITGB1	0.43	6.26	0.32	1.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12464559	0.649	rs2030588	chr2:152668750	C/A	cg01189475	chr2:152685088	ARL5A	0.61	7.25	0.36	2.82e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg02466173	chr16:30829666	NA	0.48	7.23	0.36	3.15e-12	Dementia with Lewy bodies;
LIHC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.06e-8	Blood metabolite levels;
LIHC	cis	rs16958440	0.867	rs79078752	chr18:44667462	A/G	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs4891159	0.724	rs690639	chr18:74108957	C/T	cg24786174	chr18:74118243	ZNF516	0.78	13.93	0.6	2.95e-35	Longevity;
LIHC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.08	9.74	0.47	6e-20	Diabetic retinopathy;
LIHC	cis	rs1113500	0.814	rs893983	chr1:108630338	C/T	cg06207961	chr1:108661230	NA	-0.31	-5.84	-0.3	1.19e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.69	0.34	9.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.64	-7.08	-0.36	8.35e-12	Protein C levels;
LIHC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.34	8.56	0.42	4e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg06935464	chr4:38784597	TLR10	-0.39	-6.62	-0.34	1.39e-10	Breast cancer;
LIHC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg18016565	chr1:150552671	MCL1	-0.54	-10.95	-0.51	4.15e-24	Tonsillectomy;
LIHC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.7	10.78	0.5	1.55e-23	Height;
LIHC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.63	-9.02	-0.44	1.38e-17	Response to antineoplastic agents;
LIHC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.78	11.71	0.54	7.24e-27	Dental caries;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.65	-9.77	-0.47	4.87e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-9.41	-0.45	7.39e-19	Alzheimer's disease;
LIHC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.11	0.48	3.29e-21	Colorectal cancer;
LIHC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	8.8	0.43	6.92e-17	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05494465	chr13:74710406	NA	0.42	6.4	0.33	5.15e-10	Lung function (FEV1/FVC);
LIHC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.6	8.81	0.43	6.62e-17	Response to diuretic therapy;
LIHC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.6	0.67	8.6e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.39	0.59	3.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.72	10.24	0.48	1.21e-21	Menarche (age at onset);
LIHC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.82	13.59	0.59	5.98e-34	Psoriasis;
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg20090690	chr10:134436459	INPP5A	0.44	5.71	0.3	2.43e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6977660	1.000	rs10279601	chr7:19822171	G/A	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.63	9.63	0.46	1.44e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.48	6.44	0.33	4.03e-10	Total body bone mineral density;
LIHC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.0	-0.4	1.94e-14	Total cholesterol levels;
LIHC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg17420585	chr12:42539391	GXYLT1	0.35	5.71	0.3	2.39e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg21395723	chr22:39101663	GTPBP1	0.36	6.01	0.31	4.66e-9	Menopause (age at onset);
LIHC	cis	rs17756712	0.570	rs1122256	chr6:611969	A/C	cg14374089	chr6:596013	EXOC2	-0.48	-6.57	-0.33	1.89e-10	Vertical cup-disc ratio;
LIHC	cis	rs8010715	0.816	rs1134340	chr14:24594213	C/T	cg23112188	chr14:24563095	PCK2	-0.29	-5.98	-0.31	5.56e-9	IgG glycosylation;
LIHC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg13837822	chr10:26931731	LOC731789	0.38	7.19	0.36	4.02e-12	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg10587741	chr22:38071170	LGALS1	0.72	12.53	0.56	6.87e-30	Fat distribution (HIV);
LIHC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg16970926	chr12:29381810	FAR2	0.29	5.98	0.31	5.47e-9	QT interval;
LIHC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg03959625	chr15:84868606	LOC388152	0.44	6.3	0.32	8.99e-10	Schizophrenia;
LIHC	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.14	0.48	2.63e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.46	8.7	0.43	1.46e-16	Testicular germ cell tumor;
LIHC	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.99	7.89	0.39	4.09e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.23	0.32	1.41e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.77	-0.34	5.6e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg11189052	chr15:85197271	WDR73	-0.39	-5.86	-0.3	1.08e-8	P wave terminal force;
LIHC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-7.84	-0.39	5.9e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.24	0.41	3.82e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7503168	1.000	rs35237539	chr17:33929582	A/G	cg20932281	chr17:33905541	PEX12	0.54	7.06	0.36	9.38e-12	Plateletcrit;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.41	-5.72	-0.3	2.39e-8	Total body bone mineral density;
LIHC	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.03	-20.04	-0.73	1.2e-59	Exhaled nitric oxide output;
LIHC	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.65	7.37	0.37	1.29e-12	Schizophrenia;
LIHC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	10.44	0.49	2.41e-22	Lung cancer;
LIHC	cis	rs12644436	0.576	rs3857037	chr4:88780468	G/A	cg06891869	chr4:88767617	MEPE	0.43	7.59	0.38	3.12e-13	HIV-1 viral setpoint;
LIHC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.54	8.18	0.4	5.73e-15	Platelet count;
LIHC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.64	9.72	0.47	7.19e-20	Height;
LIHC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.53	0.33	2.32e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.82	9.98	0.47	9.74e-21	Cognitive function;
LIHC	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.21	-5.75	-0.3	2.01e-8	Hepatitis;
LIHC	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs1062177	0.502	rs10463321	chr5:151323905	T/G	cg00977110	chr5:151150581	G3BP1	0.46	5.93	0.31	7.43e-9	Preschool internalizing problems;
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg24209194	chr3:40518798	ZNF619	0.63	9.45	0.46	5.36e-19	Renal cell carcinoma;
LIHC	cis	rs370915	1.000	rs9685837	chr4:187818466	C/T	cg19519643	chr4:187840862	NA	-0.44	-7.19	-0.36	4.14e-12	Gout;
LIHC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.31	0.55	4.45e-29	Electrocardiographic conduction measures;
LIHC	cis	rs9596270	0.772	rs706603	chr13:50855023	A/G	cg17741629	chr13:50024703	SETDB2	-0.53	-5.74	-0.3	2.14e-8	Multiple sclerosis;
LIHC	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg10621924	chr7:39171070	POU6F2	0.41	6.45	0.33	3.86e-10	IgG glycosylation;
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.66	9.92	0.47	1.53e-20	Menarche (age at onset);
LIHC	trans	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg10756647	chr7:56101905	PSPH	1.07	11.64	0.53	1.29e-26	Diabetic kidney disease;
LIHC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.98	0.54	7.77e-28	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25152348	chr22:50946712	NCAPH2;LMF2	0.67	8.82	0.43	5.84e-17	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.29	-0.41	2.54e-15	Response to antipsychotic treatment;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg16132339	chr22:24313637	DDTL;DDT	0.78	15.41	0.64	4.84e-41	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.55	9.05	0.44	1.14e-17	Body mass index;
LIHC	cis	rs3853824	0.965	rs1879145	chr17:54902055	A/G	cg13675837	chr17:54910204	DGKE	0.42	5.96	0.31	6.25e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21016266	chr12:122356598	WDR66	0.54	8.79	0.43	7.46e-17	Mean corpuscular volume;
LIHC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.74	12.33	0.55	3.64e-29	Systemic lupus erythematosus;
LIHC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg17980119	chr2:219472607	PLCD4	0.35	6.05	0.31	3.84e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.91	-0.39	3.71e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.47	6.87	0.35	3.04e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9628987	0.569	rs902355	chr1:8433124	T/C	cg20416874	chr1:8611966	RERE	0.49	5.99	0.31	5.45e-9	Breast cancer;
LIHC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.58	-7.55	-0.38	3.92e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.35	5.73	0.3	2.21e-8	Blood metabolite levels;
LIHC	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-6.21	-0.32	1.51e-9	IFN-related cytopenia;
LIHC	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.49	7.63	0.38	2.42e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.32	-6.9	-0.35	2.5e-11	Weight;
LIHC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.65	13.54	0.59	9.78e-34	Airflow obstruction;
LIHC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-21.71	-0.76	2.59e-66	Height;
LIHC	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.35	-7.56	-0.38	3.76e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.51	-9.54	-0.46	2.72e-19	Atrioventricular conduction;
LIHC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.44	0.33	4.07e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg09572067	chr16:29127029	RRN3P2	0.53	8.44	0.42	9.06e-16	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.25	-16.49	-0.67	2.24e-45	Diabetic kidney disease;
LIHC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.83	14.41	0.61	4e-37	Aortic root size;
LIHC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg23517279	chr6:96025343	MANEA	0.56	5.72	0.3	2.28e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11673344	0.808	rs57916401	chr19:37644051	T/C	cg27390819	chr19:37464633	NA	-0.49	-5.95	-0.31	6.66e-9	Obesity-related traits;
LIHC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.48	-7.98	-0.4	2.2e-14	Response to temozolomide;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.48	-8.51	-0.42	5.38e-16	Paraoxonase activity;
LIHC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.62	-10.02	-0.48	6.72e-21	Menarche (age at onset);
LIHC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs3770081	1.000	rs13390702	chr2:86237935	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.81	-9.0	-0.44	1.58e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.48	8.47	0.42	7.46e-16	Height;
LIHC	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.46	6.06	0.31	3.64e-9	Pursuit maintenance gain;
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg00204748	chr12:29376779	FAR2	0.43	7.89	0.39	4.06e-14	QT interval;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19789021	chr5:95158141	GLRX	0.4	6.12	0.31	2.52e-9	Calcium levels;
LIHC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.84	0.57	4.73e-31	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04530015	chr2:215796436	ABCA12	-0.38	-6.22	-0.32	1.43e-9	Neuroblastoma;
LIHC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg16836995	chr17:43662488	NA	-0.76	-7.8	-0.39	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.51	-9.16	-0.44	4.93e-18	Blood protein levels;
LIHC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.39	-6.07	-0.31	3.33e-9	Glioblastoma;
LIHC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.32	6.78	0.34	5.14e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.55	8.29	0.41	2.6e-15	Height;
LIHC	cis	rs3015497	1.000	rs3015497	chr14:51113398	T/C	cg09863266	chr14:51125203	SAV1	-0.39	-6.4	-0.33	5.05e-10	Mean platelet volume;
LIHC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	6.37	0.33	6.22e-10	Renal cell carcinoma;
LIHC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg03013999	chr17:37608204	MED1	0.35	5.83	0.3	1.31e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.45	-0.33	3.81e-10	Colorectal cancer;
LIHC	cis	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25134081	chr14:64931936	AKAP5	-1.06	-6.87	-0.35	3.1e-11	Cognitive performance;
LIHC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.65	7.82	0.39	6.73e-14	Heart rate;
LIHC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.62	10.22	0.48	1.39e-21	Platelet count;
LIHC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg13393036	chr8:95962371	TP53INP1	0.32	6.14	0.32	2.29e-9	Type 2 diabetes;
LIHC	cis	rs546131	0.642	rs11602886	chr11:34841843	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.71	10.63	0.5	5.35e-23	Aortic root size;
LIHC	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22509189	chr2:225307070	NA	-0.61	-7.44	-0.37	8.3e-13	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.6	10.3	0.49	7.84e-22	Longevity;Endometriosis;
LIHC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg22079354	chr11:130786696	SNX19	0.42	6.02	0.31	4.43e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.14	-0.32	2.25e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.67	-11.28	-0.52	2.65e-25	Crohn's disease;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.57	10.35	0.49	5.24e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg10130564	chr11:117069849	TAGLN	0.34	5.73	0.3	2.25e-8	Blood protein levels;
LIHC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01065977	chr19:18549689	ISYNA1	0.39	5.9	0.3	8.96e-9	Breast cancer;
LIHC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.3	0.61	1.07e-36	Multiple sclerosis;
LIHC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg03037974	chr15:76606532	NA	0.79	16.19	0.66	3.6e-44	Blood metabolite levels;
LIHC	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.88	-0.47	2.04e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.4	7.49	0.38	6.04e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627509	0.638	rs78933653	chr4:57854840	A/G	cg26694713	chr4:57773883	REST	0.65	8.54	0.42	4.32e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.11	-0.51	1.08e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.15	-0.32	2.22e-9	Total body bone mineral density;
LIHC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.44e-19	Bipolar disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24648061	chr7:107114615	COG5;GPR22	0.36	6.59	0.34	1.69e-10	Cognitive function;
LIHC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	8.47	0.42	7.11e-16	IgG glycosylation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02581963	chr10:102133317	C10orf75	0.47	6.42	0.33	4.45e-10	Lung function (FEV1/FVC);
LIHC	cis	rs918629	0.530	rs11739652	chr5:95238582	C/G	cg10483112	chr5:95245456	ELL2	-0.36	-6.55	-0.33	2.08e-10	IgG glycosylation;
LIHC	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.71	-12.44	-0.56	1.47e-29	Refractive error;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23110891	chr1:94344782	DNTTIP2	-0.44	-6.15	-0.32	2.14e-9	Pancreatic cancer;
LIHC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-11.08	-0.51	1.35e-24	Hemoglobin concentration;
LIHC	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.25	6.77	0.34	5.53e-11	Type 2 diabetes;
LIHC	cis	rs8044868	0.566	rs3812984	chr16:72207797	C/T	cg16558253	chr16:72132732	DHX38	-0.38	-6.27	-0.32	1.08e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg06238570	chr21:40685208	BRWD1	0.58	6.85	0.35	3.37e-11	Cognitive function;
LIHC	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.6	-7.85	-0.39	5.41e-14	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.46	7.51	0.38	5.14e-13	Crohn's disease;
LIHC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.74	12.52	0.56	7.42e-30	Blood protein levels;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17152411	0.895	rs7080475	chr10:126585767	A/G	cg07906193	chr10:126599966	NA	0.44	6.96	0.35	1.78e-11	Height;
LIHC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.47	6.77	0.34	5.72e-11	Blood metabolite levels;
LIHC	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.95	-0.35	1.81e-11	Neutrophil percentage of white cells;
LIHC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.5	8.97	0.44	1.99e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg00975115	chr16:30958403	FBXL19	0.45	6.38	0.33	5.84e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.3	7.45	0.37	7.61e-13	Gut microbiome composition (winter);
LIHC	cis	rs34540877	1.000	rs12981834	chr19:33124749	G/A	cg22980127	chr19:33182716	NUDT19	1.01	6.75	0.34	6.37e-11	Red cell distribution width;
LIHC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-8.99	-0.44	1.78e-17	Schizophrenia;
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.69	9.32	0.45	1.45e-18	Aortic root size;
LIHC	cis	rs8081395	0.737	rs4968401	chr17:58040730	T/C	cg02344993	chr17:57696989	CLTC	-0.37	-5.9	-0.3	8.83e-9	White blood cell count;
LIHC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-7.38	-0.37	1.19e-12	P wave terminal force;
LIHC	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	0.39	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.5	6.02	0.31	4.6e-9	Heart rate;
LIHC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.81	0.35	4.44e-11	Lung cancer;
LIHC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.58	8.5	0.42	5.77e-16	Platelet count;
LIHC	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg18898632	chr2:242989856	NA	-0.5	-7.21	-0.36	3.65e-12	Obesity-related traits;
LIHC	trans	rs7721647	0.853	rs10058587	chr5:90872543	G/C	cg11567849	chr6:111751012	REV3L	-0.49	-6.08	-0.31	3.14e-9	Breast cancer;
LIHC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg16070018	chr6:26224392	HIST1H3E	0.57	6.81	0.35	4.47e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.26	-0.32	1.12e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg09904177	chr6:26538194	HMGN4	-0.36	-5.8	-0.3	1.53e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.54	7.22	0.36	3.34e-12	Body mass index;
LIHC	cis	rs10924970	0.649	rs9787250	chr1:235387854	A/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.83	0.3	1.27e-8	Asthma;
LIHC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-7.45	-0.37	7.94e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.48	0.56	1.07e-29	Alzheimer's disease;
LIHC	cis	rs9318086	0.534	rs10507334	chr13:24369787	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.35	-5.84	-0.3	1.18e-8	Myopia (pathological);
LIHC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg25281562	chr12:121454272	C12orf43	0.36	6.23	0.32	1.33e-9	N-glycan levels;
LIHC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg06565975	chr8:143823917	SLURP1	0.34	6.69	0.34	9.21e-11	Urinary tract infection frequency;
LIHC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.41	5.73	0.3	2.15e-8	Tonsillectomy;
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.71	-10.14	-0.48	2.72e-21	Bronchopulmonary dysplasia;
LIHC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.67	7.75	0.39	1.05e-13	Protein C levels;
LIHC	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-6.01	-0.31	4.63e-9	Neuroticism;
LIHC	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg19752551	chr11:57585705	CTNND1	-0.53	-7.48	-0.37	6.33e-13	Schizophrenia;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22887498	chr19:39401301	NA	0.45	6.63	0.34	1.28e-10	Bilirubin levels;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.9	-0.3	8.51e-9	Total body bone mineral density;
LIHC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.56	0.33	1.97e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.79	7.72	0.39	1.27e-13	Putamen volume;
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4407350	0.715	rs3827400	chr22:44890604	T/C	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.23	-0.32	1.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.13	-16.75	-0.67	2.03e-46	Gut microbiome composition (summer);
LIHC	cis	rs74233809	1.000	rs11191551	chr10:104850835	A/G	cg03493300	chr10:104813866	CNNM2	0.46	6.29	0.32	9.93e-10	Birth weight;
LIHC	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.48	5.97	0.31	6.06e-9	Crohn's disease;
LIHC	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.46	-0.42	8.12e-16	Response to antipsychotic treatment;
LIHC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.81	0.65	1.23e-42	Chronic sinus infection;
LIHC	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.65	11.06	0.51	1.66e-24	Uric acid clearance;
LIHC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.53	-8.6	-0.42	3e-16	Fibrinogen levels;
LIHC	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.94	-0.31	6.82e-9	Resting heart rate;
LIHC	cis	rs16828019	0.777	rs67460888	chr1:41469337	T/C	cg03962019	chr1:41807865	NA	0.52	7.06	0.36	9.17e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg11062466	chr8:58055876	NA	0.41	6.02	0.31	4.59e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-8.06	-0.4	1.25e-14	Response to antipsychotic treatment;
LIHC	cis	rs7903847	0.656	rs12412478	chr10:99134923	C/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.06	-0.31	3.55e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.47	6.31	0.32	8.45e-10	Obesity-related traits;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg12419862	chr22:24373484	LOC391322	-0.69	-10.26	-0.49	1.03e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.31	-5.72	-0.3	2.34e-8	Aortic root size;
LIHC	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-12.33	-0.55	3.78e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.66	8.35	0.41	1.71e-15	Initial pursuit acceleration;
LIHC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg19302996	chr17:73780495	UNK	-0.54	-6.71	-0.34	8.24e-11	Psoriasis;
LIHC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg17724175	chr1:150552817	MCL1	0.4	7.54	0.38	4.2e-13	Melanoma;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23017654	chr17:40346486	GHDC	0.41	6.08	0.31	3.19e-9	Migraine with aura;
LIHC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg02640540	chr1:67518911	SLC35D1	0.44	6.83	0.35	3.83e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.7	11.1	0.51	1.21e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg16479474	chr6:28041457	NA	0.39	6.38	0.33	5.78e-10	Parkinson's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01191584	chr2:27594002	SNX17;EIF2B4	0.44	6.18	0.32	1.78e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2579500	0.538	rs17634791	chr2:97328852	C/T	cg26665480	chr2:98280029	ACTR1B	-0.4	-5.92	-0.3	7.78e-9	Eosinophil counts;Eosinophil percentage of white cells;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21157519	chr14:53162301	ERO1L	-0.48	-6.33	-0.32	7.61e-10	Systolic blood pressure;
LIHC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.33e-18	Bipolar disorder;
LIHC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.04	0.31	3.93e-9	Bipolar disorder;
LIHC	cis	rs4517514	0.509	rs11018869	chr11:89865168	A/G	cg05041596	chr11:89867385	NAALAD2	0.41	6.51	0.33	2.63e-10	Trans fatty acid levels;
LIHC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.65	-0.34	1.16e-10	Diabetic kidney disease;
LIHC	cis	rs16958440	0.867	rs74411203	chr18:44677466	G/A	cg17192377	chr18:44677553	HDHD2	0.93	8.68	0.42	1.66e-16	Sitting height ratio;
LIHC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.41	7.97	0.4	2.33e-14	Urinary metabolites;
LIHC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.54	-0.33	2.19e-10	Fear of minor pain;
LIHC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	1.05	21.49	0.76	1.96e-65	Breast cancer;
LIHC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.66	-0.34	1.06e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11548363	chr19:13068138	GADD45GIP1	0.5	6.33	0.32	7.53e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.23e-24	Breast cancer;
LIHC	cis	rs4699052	0.928	rs2126473	chr4:104141533	G/C	cg16532752	chr4:104119610	CENPE	-0.42	-6.71	-0.34	8.25e-11	Testicular germ cell tumor;
LIHC	trans	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.33	-0.32	7.82e-10	Endometrial cancer;
LIHC	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.77	11.42	0.53	8.63e-26	Personality dimensions;
LIHC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.53	0.64	1.5e-41	Chronic sinus infection;
LIHC	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg01864836	chr14:55583639	NA	-0.4	-7.32	-0.37	1.73e-12	Protein biomarker;
LIHC	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.42	-7.24	-0.36	2.98e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.72	13.74	0.6	1.62e-34	Mortality in heart failure;
LIHC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg27478167	chr7:817139	HEATR2	-0.41	-5.85	-0.3	1.13e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.38	-0.37	1.2e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg08126542	chr6:37504118	NA	-0.36	-6.26	-0.32	1.18e-9	Cognitive performance;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01744729	chr13:113474194	ATP11A	0.46	6.82	0.35	4.05e-11	Immature fraction of reticulocytes;
LIHC	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.68	9.73	0.47	6.58e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-5.81	-0.3	1.42e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.48	-7.26	-0.37	2.6e-12	Menarche (age at onset);
LIHC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.07	-0.4	1.19e-14	Morning vs. evening chronotype;
LIHC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-7.21	-0.36	3.67e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.94	14.97	0.63	2.48e-39	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg01864836	chr14:55583639	NA	0.38	6.9	0.35	2.5e-11	Protein biomarker;
LIHC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs12744310	0.887	rs1892419	chr1:41781151	T/C	cg03962019	chr1:41807865	NA	0.39	6.23	0.32	1.36e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg00656387	chr3:40428638	ENTPD3	0.48	7.9	0.39	3.83e-14	Renal cell carcinoma;
LIHC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19524238	chr7:2802976	GNA12	0.38	5.73	0.3	2.18e-8	Height;
LIHC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.22	0.32	1.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.46	-6.35	-0.32	6.84e-10	Other erythrocyte phenotypes;
LIHC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.73	0.39	1.18e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.49	6.2	0.32	1.63e-9	Dilated cardiomyopathy;
LIHC	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.16	-0.32	2.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.51	-7.27	-0.37	2.41e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.48	-10.38	-0.49	3.87e-22	White blood cell count (basophil);
LIHC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.43	5.82	0.3	1.33e-8	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.57	9.79	0.47	4.11e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.76	-0.39	9.97e-14	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg07424592	chr7:64974309	NA	-0.8	-9.25	-0.45	2.42e-18	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11877577	chr6:133135687	RPS12;SNORD101	-0.49	-6.23	-0.32	1.37e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-7.28	-0.37	2.32e-12	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.58	7.83	0.39	6.22e-14	Coronary artery disease;
LIHC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.75	-0.43	9.8e-17	Gut microbiome composition (summer);
LIHC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-8.34	-0.41	1.82e-15	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs911119	0.955	rs7270413	chr20:23593821	C/G	cg16589663	chr20:23618590	CST3	0.69	6.99	0.35	1.49e-11	Chronic kidney disease;
LIHC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.73	-11.1	-0.51	1.15e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.84	-0.51	1.02e-23	Primary sclerosing cholangitis;
LIHC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg15123519	chr2:136567270	LCT	-0.36	-5.77	-0.3	1.76e-8	Corneal structure;
LIHC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg03945807	chr20:60948434	NA	0.38	6.19	0.32	1.7e-9	Colorectal cancer;
LIHC	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.7	-7.17	-0.36	4.59e-12	Putamen volume;
LIHC	cis	rs2997447	0.761	rs61776616	chr1:26455812	C/T	cg19633962	chr1:26362018	EXTL1	-0.67	-6.07	-0.31	3.37e-9	QRS complex (12-leadsum);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06684987	chr19:45567721	SFRS16	0.45	6.25	0.32	1.19e-9	Longevity;
LIHC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg26939375	chr7:64535504	NA	0.45	6.99	0.35	1.48e-11	Aortic root size;
LIHC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.98	0.35	1.56e-11	Lung cancer in ever smokers;
LIHC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.75	12.46	0.56	1.19e-29	Body mass index;
LIHC	cis	rs116248771	0.690	rs73156491	chr3:158416572	A/G	cg16708174	chr3:158430962	RARRES1	0.48	6.34	0.32	7.39e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.39	-0.49	3.56e-22	Platelet count;
LIHC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.63	-8.89	-0.43	3.66e-17	Blood metabolite levels;
LIHC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.81	-11.56	-0.53	2.51e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.5	-7.47	-0.37	6.74e-13	Asthma (sex interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20760063	chr17:41277580	NBR2;BRCA1	-0.57	-7.4	-0.37	1.06e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.25	0.41	3.56e-15	IgG glycosylation;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg21914477	chr6:5067092	NA	0.38	6.6	0.34	1.59e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1865721	1.000	rs72977890	chr18:73198776	C/A	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.16e-13	Intelligence;
LIHC	trans	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg10756647	chr7:56101905	PSPH	-1.07	-13.13	-0.58	3.48e-32	Diabetic kidney disease;
LIHC	cis	rs72627123	0.656	rs4646864	chr14:74526703	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	8.7	0.43	1.38e-16	Morning vs. evening chronotype;
LIHC	cis	rs11031096	0.589	rs935130	chr11:4213530	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-6.25	-0.32	1.2e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs60752752	0.852	rs58127527	chr1:153370085	G/T	cg14901121	chr8:98817630	LAPTM4B	-0.43	-7.17	-0.36	4.6e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.77	9.63	0.46	1.39e-19	Mean platelet volume;
LIHC	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.7	-12.33	-0.55	3.85e-29	Height;
LIHC	cis	rs4908768	0.906	rs6656249	chr1:8581015	A/C	cg20416874	chr1:8611966	RERE	0.56	8.88	0.43	3.9e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg05347473	chr6:146136440	FBXO30	0.37	6.05	0.31	3.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg19680672	chr10:131412579	MGMT	-0.45	-7.07	-0.36	8.69e-12	Response to temozolomide;
LIHC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg19318889	chr4:1322082	MAEA	0.47	6.41	0.33	4.95e-10	Obesity-related traits;
LIHC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.32	0.32	8.01e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.84	0.43	5.1e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg16479474	chr6:28041457	NA	0.43	6.65	0.34	1.15e-10	Parkinson's disease;
LIHC	cis	rs6988985	0.530	rs3819497	chr8:143924052	C/T	cg23373978	chr8:143916136	GML	-0.3	-6.48	-0.33	3.23e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.91	12.64	0.56	2.66e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.35	0.66	8.35e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg25329415	chr6:28076851	NA	0.27	5.74	0.3	2.13e-8	Cardiac Troponin-T levels;
LIHC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg16479474	chr6:28041457	NA	0.38	6.25	0.32	1.19e-9	Parkinson's disease;
LIHC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg12560992	chr17:57184187	TRIM37	0.52	7.21	0.36	3.63e-12	Cognitive test performance;
LIHC	cis	rs7707921	0.881	rs73134739	chr5:81370760	T/C	cg15871215	chr5:81402204	ATG10	-0.61	-5.95	-0.31	6.55e-9	Breast cancer;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg09033563	chr22:24373618	LOC391322	-0.48	-6.79	-0.34	4.9e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2257205	0.667	rs4453568	chr17:56934543	A/G	cg12560992	chr17:57184187	TRIM37	0.67	7.22	0.36	3.29e-12	Pancreatic cancer;
LIHC	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.89	-0.3	9.01e-9	Calcium levels;
LIHC	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.55	-0.38	3.89e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9543976	0.925	rs2876706	chr13:76186305	T/G	cg01531495	chr13:76123901	UCHL3	0.48	5.76	0.3	1.87e-8	Diabetic retinopathy;
LIHC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg14440974	chr22:39074834	NA	-0.35	-5.8	-0.3	1.51e-8	Menopause (age at onset);
LIHC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg14393609	chr7:65229607	NA	0.39	5.83	0.3	1.3e-8	Aortic root size;
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20011983	chr2:74347215	NA	-0.39	-5.74	-0.3	2.12e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg11764359	chr7:65958608	NA	-0.58	-6.11	-0.31	2.67e-9	Diabetic kidney disease;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg25979624	chr1:54954752	NA	0.44	6.54	0.33	2.26e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	11.23	0.52	3.92e-25	Alzheimer's disease (late onset);
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.31	-0.32	8.46e-10	Longevity;
LIHC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.37	7.29	0.37	2.14e-12	Alcohol dependence;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg09847234	chr3:136581777	NCK1	-0.41	-6.12	-0.31	2.53e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs17125944	0.615	rs1886786	chr14:53312189	A/T	cg00686598	chr14:53173677	PSMC6	-0.83	-9.96	-0.47	1.14e-20	Alzheimer's disease (late onset);
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.43	7.85	0.39	5.26e-14	Prudent dietary pattern;
LIHC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.64e-9	Neuroticism;
LIHC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-8.03	-0.4	1.63e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.39	-6.22	-0.32	1.43e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs36051895	0.530	rs4425810	chr9:5222208	A/G	cg02405213	chr9:5042618	JAK2	-0.63	-9.92	-0.47	1.46e-20	Pediatric autoimmune diseases;
LIHC	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.9	8.04	0.4	1.51e-14	White matter integrity;
LIHC	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.07e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg08916839	chr5:415575	AHRR	0.29	6.31	0.32	8.64e-10	Cystic fibrosis severity;
LIHC	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	0.39	6.03	0.31	4.35e-9	Coronary artery disease;
LIHC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.08	0.36	8.34e-12	Height;
LIHC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg24296786	chr1:45957014	TESK2	-0.52	-7.49	-0.38	6.03e-13	Platelet count;
LIHC	cis	rs909341	0.537	rs4809334	chr20:62384972	G/A	cg14758556	chr20:62440591	NA	0.42	6.7	0.34	8.54e-11	Atopic dermatitis;
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.65	10.01	0.48	7.29e-21	Renal cell carcinoma;
LIHC	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-12.45	-0.56	1.35e-29	Chronic sinus infection;
LIHC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.79	0.34	5.01e-11	Morning vs. evening chronotype;
LIHC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.37	5.75	0.3	1.94e-8	Prostate cancer;
LIHC	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.49	-6.57	-0.33	1.87e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.49	6.9	0.35	2.55e-11	High light scatter reticulocyte count;
LIHC	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg18898632	chr2:242989856	NA	-0.46	-6.22	-0.32	1.42e-9	Obesity-related traits;
LIHC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg16479474	chr6:28041457	NA	0.47	7.15	0.36	5.22e-12	Parkinson's disease;
LIHC	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	12.01	0.54	5.59e-28	Post bronchodilator FEV1;
LIHC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.68	11.07	0.51	1.56e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07053964	chr16:624366	PIGQ	-0.46	-6.47	-0.33	3.47e-10	Gut microbiome composition (summer);
LIHC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.6	12.71	0.57	1.45e-30	Fat distribution (HIV);
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg18306943	chr3:40428807	ENTPD3	-0.44	-7.81	-0.39	6.94e-14	Renal cell carcinoma;
LIHC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.44	6.09	0.31	3.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24780086	chr5:14713043	ANKH	0.41	6.34	0.32	7.46e-10	Immature fraction of reticulocytes;
LIHC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs3823572	0.542	rs61286514	chr7:133630693	G/A	cg03336402	chr7:133662267	EXOC4	0.46	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.62	-0.34	1.35e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg05765582	chr2:191677683	NA	0.3	5.77	0.3	1.79e-8	Mean platelet volume;
LIHC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.76	-0.34	5.85e-11	Sudden cardiac arrest;
LIHC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.79	10.34	0.49	5.46e-22	Body mass index;
LIHC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.51	0.33	2.76e-10	Schizophrenia;
LIHC	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.44	6.14	0.32	2.27e-9	Hepatocellular carcinoma;
LIHC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.69	7.29	0.37	2.13e-12	Alzheimer's disease;
LIHC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.31	0.32	8.68e-10	Alzheimer's disease;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg00049323	chr5:472564	LOC25845	0.35	5.75	0.3	1.97e-8	Cystic fibrosis severity;
LIHC	trans	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg10756647	chr7:56101905	PSPH	-1.08	-13.18	-0.58	2.32e-32	Diabetic kidney disease;
LIHC	cis	rs918629	0.530	rs11744881	chr5:95240865	A/T	cg10483112	chr5:95245456	ELL2	0.37	6.85	0.35	3.42e-11	IgG glycosylation;
LIHC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.71	-0.38	1.38e-13	Bipolar disorder;
LIHC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs8067354	0.574	rs1291947	chr17:57996336	G/T	cg13753209	chr17:57696993	CLTC	0.7	10.44	0.49	2.46e-22	Hemoglobin concentration;
LIHC	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg02829992	chr2:10710499	NA	0.39	6.01	0.31	4.74e-9	Prostate cancer;
LIHC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.71	0.43	1.29e-16	Motion sickness;
LIHC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.38	5.89	0.3	9.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.28	-7.05	-0.36	9.75e-12	Cutaneous nevi;
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.31	0.41	2.24e-15	Renal cell carcinoma;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.36	6.12	0.31	2.61e-9	Height;
LIHC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg05527609	chr1:210001259	C1orf107	-0.55	-7.61	-0.38	2.69e-13	Red blood cell count;
LIHC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg20302533	chr7:39170763	POU6F2	0.36	6.6	0.34	1.57e-10	IgG glycosylation;
LIHC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-7.93	-0.39	3.06e-14	Total body bone mineral density;
LIHC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.41	-0.37	1.03e-12	Body mass index;
LIHC	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.61	8.26	0.41	3.33e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs600806	0.683	rs10857789	chr1:110012293	C/T	cg10127483	chr1:110009974	SYPL2	0.5	6.37	0.33	6.23e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	24.69	0.8	5.28e-78	Schizophrenia;
LIHC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02398342	chr17:80708632	TBCD;FN3K	0.39	5.96	0.31	6.12e-9	Glycated hemoglobin levels;
LIHC	cis	rs4684776	0.867	rs1562616	chr3:11374151	C/T	cg00170343	chr3:11313890	ATG7	-0.5	-6.76	-0.34	5.95e-11	Small vessel stroke;
LIHC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg07689907	chr11:61582574	FADS1	0.4	5.78	0.3	1.64e-8	Trans fatty acid levels;
LIHC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg14930904	chr10:32216787	ARHGAP12	0.37	6.48	0.33	3.29e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs4699052	0.963	rs6849319	chr4:104192742	G/C	cg16532752	chr4:104119610	CENPE	-0.4	-6.35	-0.32	6.81e-10	Testicular germ cell tumor;
LIHC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	1.07	12.08	0.55	3.31e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.62	8.71	0.43	1.32e-16	Economic and political preferences (feminism/equality);
LIHC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg24826892	chr11:71159390	DHCR7	0.51	6.69	0.34	8.95e-11	Vitamin D levels;
LIHC	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14154082	chr13:112174009	NA	0.29	6.14	0.32	2.28e-9	Menarche (age at onset);
LIHC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.49	7.76	0.39	9.95e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.86	0.47	2.39e-20	Colorectal cancer;
LIHC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.39	-8.57	-0.42	3.49e-16	Prostate-specific antigen levels;
LIHC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.43	5.71	0.3	2.46e-8	Height;
LIHC	cis	rs11098699	0.848	rs11944380	chr4:124119834	T/C	cg09941581	chr4:124220074	SPATA5	0.3	5.73	0.3	2.15e-8	Mosquito bite size;
LIHC	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg14250997	chr9:106856677	SMC2	-0.35	-5.97	-0.31	6.1e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs67981189	0.593	rs2286311	chr14:71522955	T/C	cg15816911	chr14:71606274	NA	0.42	6.79	0.34	4.98e-11	Schizophrenia;
LIHC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.34	1.58e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-6.0	-0.31	5.09e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-1.09	-15.73	-0.65	2.44e-42	Heart rate;
LIHC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.93	8.51	0.42	5.35e-16	Type 2 diabetes;
LIHC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	0.59	11.22	0.52	4.55e-25	Fat distribution (HIV);
LIHC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg21361702	chr7:150065534	REPIN1	0.44	5.99	0.31	5.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.78	0.3	1.68e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.56	8.67	0.42	1.73e-16	Mood instability;
LIHC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.41	6.08	0.31	3.16e-9	Height;
LIHC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.71	-0.3	2.43e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.35	5.86	0.3	1.11e-8	Height;
LIHC	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.73	11.1	0.51	1.2e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.13	10.32	0.49	6.66e-22	Diabetic retinopathy;
LIHC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.3	-0.45	1.65e-18	Bipolar disorder;
LIHC	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.36	6.0	0.31	5.07e-9	Blood metabolite levels;
LIHC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.66	-0.38	1.87e-13	Personality dimensions;
LIHC	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.43	-6.53	-0.33	2.33e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.27e-9	Menopause (age at onset);
LIHC	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg06640241	chr16:89574553	SPG7	0.5	7.52	0.38	4.98e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.41	6.93	0.35	2.06e-11	Alcohol dependence;
LIHC	cis	rs1198430	0.639	rs2297841	chr1:23764149	C/G	cg13183780	chr1:23809682	ASAP3	-0.38	-6.51	-0.33	2.63e-10	Total cholesterol levels;
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25456515	chr11:125439230	EI24	0.49	6.37	0.33	6.12e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg03013999	chr17:37608204	MED1	-0.35	-5.8	-0.3	1.5e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.4	7.95e-15	Bladder cancer;
LIHC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	8.58	0.42	3.37e-16	HIV-1 control;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01252513	chr12:111758092	CUX2	0.43	6.04	0.31	4.12e-9	Longevity;
LIHC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.56	9.52	0.46	3.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.36	7.4	0.37	1.09e-12	Renal cell carcinoma;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg00800038	chr16:89945340	TCF25	-0.66	-10.35	-0.49	5.25e-22	Skin colour saturation;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	12.25	0.55	7.31e-29	Schizophrenia;
LIHC	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-7.24	-0.36	3.05e-12	Vitamin D levels;
LIHC	cis	rs9309473	0.950	rs7567585	chr2:73751966	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.95	-0.35	1.87e-11	Metabolite levels;
LIHC	cis	rs611744	0.934	rs672408	chr8:109224390	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg07460842	chr6:66804631	NA	-0.53	-6.31	-0.32	8.5e-10	Metabolite levels;
LIHC	cis	rs16912285	0.591	rs12794505	chr11:24364195	A/G	ch.11.24196551F	chr11:24239977	NA	-0.67	-8.14	-0.4	7.44e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs9309473	0.898	rs9807961	chr2:73694043	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.75	-0.34	6.18e-11	Metabolite levels;
LIHC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02985541	chr2:219472218	PLCD4	0.44	8.35	0.41	1.7e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	11.79	0.54	3.8e-27	Colorectal cancer;
LIHC	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.84	10.04	0.48	5.69e-21	Cognitive function;
LIHC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.27	-6.85	-0.35	3.51e-11	Mean corpuscular volume;
LIHC	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg11530693	chr1:120165357	ZNF697	0.47	7.53	0.38	4.59e-13	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.57	11.28	0.52	2.58e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.32	-0.55	4.13e-29	Response to antipsychotic treatment;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05920998	chr6:656504	HUS1B;EXOC2	0.39	6.27	0.32	1.07e-9	Longevity;
LIHC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.76	11.6	0.53	1.88e-26	Corneal astigmatism;
LIHC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg09137382	chr11:130731461	NA	0.42	6.26	0.32	1.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg00012203	chr2:219082015	ARPC2	0.76	10.74	0.5	2.16e-23	Colorectal cancer;
LIHC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.3	-7.01	-0.35	1.3e-11	Menarche (age at onset);
LIHC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.51	9.27	0.45	2.12e-18	Hemoglobin concentration;
LIHC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg14222432	chr12:29376421	FAR2	0.37	7.02	0.35	1.2e-11	QT interval;
LIHC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.49	7.3	0.37	1.99e-12	Mean platelet volume;
LIHC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.59	10.15	0.48	2.57e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg18016565	chr1:150552671	MCL1	0.54	10.13	0.48	2.88e-21	Melanoma;
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.59	6.75	0.34	6.28e-11	Alzheimer's disease;
LIHC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg18357526	chr6:26021779	HIST1H4A	0.52	7.54	0.38	4.18e-13	Blood metabolite levels;
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.8	-9.8	-0.47	3.9e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2274273	0.870	rs10139000	chr14:55849876	G/T	cg01864836	chr14:55583639	NA	-0.38	-6.7	-0.34	8.76e-11	Protein biomarker;
LIHC	trans	rs6938574	0.672	rs6569520	chr6:128365034	C/G	cg01500097	chr6:110011156	AKD1;FIG4	-0.4	-6.71	-0.34	8.07e-11	Menarche (age at onset);
LIHC	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg04362960	chr10:104952993	NT5C2	0.43	5.82	0.3	1.37e-8	Arsenic metabolism;
LIHC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg11657440	chr19:46296263	DMWD	0.68	12.6	0.56	3.72e-30	Coronary artery disease;
LIHC	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.55	-0.38	3.89e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-8.47	-0.42	7.4e-16	Chronic sinus infection;
LIHC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.74	-7.36	-0.37	1.41e-12	Vitiligo;
LIHC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.93	14.06	0.61	9.61e-36	Sudden cardiac arrest;
LIHC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.64	-9.17	-0.44	4.57e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.03	-0.58	8.59e-32	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20390150	chr22:43547555	TSPO	-0.44	-6.56	-0.33	1.94e-10	Cognitive function;
LIHC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	9.52	0.46	3.23e-19	Alzheimer's disease;
LIHC	cis	rs2637266	0.655	rs10824436	chr10:78457848	T/C	cg18941641	chr10:78392320	NA	0.27	5.73	0.3	2.2e-8	Pulmonary function;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg07133347	chr1:107600762	PRMT6	-0.41	-5.75	-0.3	1.96e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9590974	0.796	rs1773128	chr13:47225440	T/A	cg04092803	chr13:47240378	LRCH1	0.29	5.95	0.31	6.47e-9	PR segment;
LIHC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.35	-7.04	-0.36	1.06e-11	Bone mineral density;
LIHC	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg13409248	chr3:40428643	ENTPD3	0.39	6.15	0.32	2.18e-9	Renal cell carcinoma;
LIHC	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg00142150	chr22:38071001	LGALS1	0.44	7.58	0.38	3.38e-13	Fat distribution (HIV);
LIHC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.59	-8.44	-0.42	9.19e-16	Blood metabolite levels;
LIHC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg21361702	chr7:150065534	REPIN1	-0.45	-6.27	-0.32	1.09e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.44	6.27	0.32	1.06e-9	Asthma;
LIHC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg14393609	chr7:65229607	NA	0.37	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Body mass index;
LIHC	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.64	10.76	0.5	1.83e-23	Breast cancer;
LIHC	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-8.29	-0.41	2.6e-15	Extraversion;
LIHC	cis	rs2851682	0.706	rs2072113	chr11:61604967	C/T	cg27386326	chr11:61587980	NA	0.56	8.96	0.44	2.15e-17	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21507487	chr14:71941057	NA	-0.29	-6.39	-0.33	5.45e-10	Calcium levels;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.46e-8	Menopause (age at onset);
LIHC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.4	-5.96	-0.31	6.15e-9	Platelet count;
LIHC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.07	0.4	1.17e-14	Tonsillectomy;
LIHC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.69	12.44	0.56	1.41e-29	Iron status biomarkers;
LIHC	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg25364880	chr3:44379878	C3orf23	0.55	7.49	0.38	5.82e-13	Depressive symptoms;
LIHC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.8	15.25	0.64	2.02e-40	Blood protein levels;
LIHC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.44	-6.97	-0.35	1.63e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02359409	chr6:42947317	PEX6	-0.48	-6.79	-0.34	5.03e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg13903179	chr13:21900392	NA	0.33	5.82	0.3	1.36e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.74	12.12	0.55	2.27e-28	Anterior chamber depth;
LIHC	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg08345082	chr10:99160200	RRP12	-0.39	-6.58	-0.34	1.81e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.38	8.73	0.43	1.11e-16	Blood protein levels;
LIHC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.55	6.27	0.32	1.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.49	6.52	0.33	2.59e-10	Emphysema distribution in smoking;
LIHC	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.25	6.42	0.33	4.58e-10	Type 2 diabetes;
LIHC	cis	rs7246865	0.859	rs16981598	chr19:17204327	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.4	5.9	0.3	8.69e-9	Reticulocyte fraction of red cells;
LIHC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.71	-0.5	2.79e-23	Lung cancer;
LIHC	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6788895	1.000	rs16862858	chr3:150529952	C/T	cg09723797	chr3:150481914	SIAH2	-0.54	-6.44	-0.33	3.94e-10	Breast cancer;
LIHC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg02580895	chr19:2754563	NA	-0.45	-6.41	-0.33	4.94e-10	Total cholesterol levels;
LIHC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.6	8.06	0.4	1.27e-14	Tourette syndrome;
LIHC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.4	7.95e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.32	-6.13	-0.31	2.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	0.948	rs2421550	chr2:73658686	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.05	-0.36	9.96e-12	Metabolite levels;
LIHC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.04	-0.48	5.91e-21	Platelet count;
LIHC	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.62	-9.1	-0.44	7.43e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.68	7.38	0.37	1.22e-12	Exhaled nitric oxide output;
LIHC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.39	0.52	1.08e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs288342	0.797	rs288313	chr2:183649154	C/T	cg02625481	chr2:183667124	NA	-0.29	-6.09	-0.31	2.98e-9	Recurrent major depressive disorder;
LIHC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg16423285	chr20:60520624	NA	-0.53	-8.68	-0.42	1.65e-16	Obesity-related traits;
LIHC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg14930904	chr10:32216787	ARHGAP12	0.38	6.74	0.34	6.74e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs11628318	0.515	rs1190334	chr14:103112591	T/C	cg12046867	chr14:103022105	NA	0.39	5.97	0.31	5.94e-9	Platelet count;
LIHC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.94	-0.35	2.03e-11	Schizophrenia;
LIHC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.95	0.4	2.65e-14	Lung cancer;
LIHC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg24826892	chr11:71159390	DHCR7	0.5	6.42	0.33	4.65e-10	Vitamin D levels;
LIHC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.87	13.11	0.58	4.23e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.29	6.4	0.33	5.23e-10	Pulmonary function;
LIHC	cis	rs1878918	0.967	rs10103022	chr8:32325630	A/G	cg16623836	chr8:32453385	NRG1	0.33	5.73	0.3	2.22e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg07560587	chr16:88016574	BANP	0.38	5.92	0.3	7.95e-9	Menopause (age at onset);
LIHC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg23149560	chr2:74406255	MOBKL1B	0.44	6.18	0.32	1.83e-9	Gestational age at birth (maternal effect);
LIHC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	7.84	0.39	5.67e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg14343924	chr8:8086146	FLJ10661	0.51	6.46	0.33	3.69e-10	Mood instability;
LIHC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg21573476	chr21:45109991	RRP1B	-0.59	-11.13	-0.52	9.11e-25	Mean corpuscular volume;
LIHC	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.68	-10.47	-0.49	1.91e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12249377	0.519	rs11599902	chr10:92598823	A/G	cg14313238	chr10:92632228	RPP30	0.37	6.17	0.32	1.89e-9	White matter microstructure (global fractional anisotropy);
LIHC	trans	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg26939375	chr7:64535504	NA	0.41	6.64	0.34	1.26e-10	Aortic root size;
LIHC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	1.02e-20	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23099349	chr6:26032281	HIST1H3B	0.47	7.11	0.36	6.81e-12	Pancreatic cancer;
LIHC	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.35	0.49	5.26e-22	Platelet count;
LIHC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.42	6.41	0.33	4.94e-10	Heart rate;
LIHC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.36	-0.37	1.35e-12	Bipolar disorder;
LIHC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.87	-0.43	4.18e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg01864069	chr14:103024347	NA	-0.47	-7.45	-0.37	7.91e-13	Platelet count;
LIHC	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg18678763	chr11:4115507	RRM1	-0.43	-6.15	-0.32	2.13e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.08	9.8	0.47	3.72e-20	Diabetic retinopathy;
LIHC	trans	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.8	-12.07	-0.55	3.42e-28	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.53	0.38	4.67e-13	Renal cell carcinoma;
LIHC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7619427	0.908	rs62254360	chr3:44082313	G/A	cg24966902	chr3:44043705	NA	0.43	6.16	0.32	2.08e-9	Schizophrenia;
LIHC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-6.79	-0.34	5e-11	Renal function-related traits (BUN);
LIHC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24110177	chr3:50126178	RBM5	-0.53	-8.22	-0.41	4.25e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-7.77	-0.39	9.01e-14	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08450409	chr12:53342662	KRT18	0.46	6.75	0.34	6.3e-11	Cognitive function;
LIHC	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.21	0.48	1.51e-21	Diisocyanate-induced asthma;
LIHC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.73	-10.61	-0.5	6.22e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg10756647	chr7:56101905	PSPH	1.03	12.52	0.56	7.58e-30	Diabetic kidney disease;
LIHC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.64	9.84	0.47	2.86e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.51	0.46	3.45e-19	Electroencephalogram traits;
LIHC	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.64	9.39	0.45	8.67e-19	Bipolar disorder;
LIHC	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg20991723	chr1:152506922	NA	0.49	8.34	0.41	1.78e-15	Hair morphology;
LIHC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	5.97	0.31	5.8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg23091122	chr1:110024289	SYPL2	-0.49	-6.46	-0.33	3.63e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.13	0.31	2.39e-9	Mean corpuscular volume;
LIHC	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.89	12.45	0.56	1.3e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-0.9	-10.85	-0.51	8.86e-24	Mitochondrial DNA levels;
LIHC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.15	-0.36	5.35e-12	Alcohol dependence;
LIHC	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.86	7.9	0.39	3.83e-14	Body mass index;
LIHC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.62	-7.77	-0.39	9.51e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg15236063	chr3:53919558	SELK	0.43	6.09	0.31	2.98e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.82	0.65	1.12e-42	Chronic sinus infection;
LIHC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg18357645	chr12:58087776	OS9	-0.44	-6.9	-0.35	2.48e-11	Multiple sclerosis;
LIHC	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.22	0.32	1.47e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg13628971	chr7:2884303	GNA12	0.53	7.76	0.39	9.95e-14	Height;
LIHC	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.44	-7.49	-0.38	6.07e-13	Breast cancer;
LIHC	cis	rs17106184	0.786	rs72898974	chr1:50975971	C/T	cg07174182	chr1:51127561	FAF1	-0.7	-7.19	-0.36	4.12e-12	Type 2 diabetes;
LIHC	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-10.63	-0.5	5.51e-23	Alzheimer's disease (late onset);
LIHC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-6.11	-0.31	2.75e-9	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	11.19	0.52	5.77e-25	Chronic sinus infection;
LIHC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg16970926	chr12:29381810	FAR2	0.29	5.97	0.31	5.96e-9	QT interval;
LIHC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.86	0.54	2.09e-27	Platelet count;
LIHC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg04352962	chr1:209979756	IRF6	-0.36	-5.72	-0.3	2.36e-8	Orofacial clefts;
LIHC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	8.86	0.43	4.34e-17	Menarche (age at onset);
LIHC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.52	-18.8	-0.71	1.22e-54	Breast cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg12990219	chr3:17686199	TBC1D5	-0.28	-6.31	-0.32	8.75e-10	Calcium levels;
LIHC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.82	16.87	0.67	6.88e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	7.41	0.37	1.01e-12	Lymphocyte counts;
LIHC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg26149184	chr10:133730230	NA	0.47	7.49	0.38	5.75e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.39	8.33	0.41	1.95e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.51	8.23	0.41	4.06e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.68	0.42	1.65e-16	Corneal astigmatism;
LIHC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg02376097	chr19:46275166	DMPK	-0.44	-6.74	-0.34	6.58e-11	Coronary artery disease;
LIHC	cis	rs611744	0.967	rs602384	chr8:109188185	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	11.77	0.54	4.45e-27	Mean platelet volume;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.03	0.36	1.1e-11	Height;
LIHC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.45	5.77	0.3	1.79e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	6.33	0.32	7.51e-10	Menarche (age at onset);
LIHC	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.34	-0.41	1.81e-15	Exhaled nitric oxide output;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.55	8.48	0.42	6.68e-16	Height;
LIHC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.22	6.07	0.31	3.42e-9	Calcium levels;
LIHC	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.35	-0.41	1.7e-15	Response to antipsychotic treatment;
LIHC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.77	12.52	0.56	7.22e-30	Corneal astigmatism;
LIHC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13647721	chr17:30228624	UTP6	0.8	7.74	0.39	1.17e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.78	6.56	0.33	2.03e-10	Body mass index;
LIHC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19462847	chr11:6633911	TAF10	0.51	7.28	0.37	2.26e-12	Pancreatic cancer;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.69	-10.27	-0.49	9.5e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg24642439	chr20:33292090	TP53INP2	0.66	7.14	0.36	5.8e-12	Protein C levels;
LIHC	cis	rs9611519	0.620	rs9607782	chr22:41587556	T/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.34	-0.37	1.52e-12	Neuroticism;
LIHC	cis	rs1494373	0.509	rs12032280	chr1:220873363	C/T	cg06786860	chr1:220876396	NA	-0.44	-6.34	-0.32	7.46e-10	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg11161837	chr1:110010384	SYPL2	0.45	6.06	0.31	3.51e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg18306943	chr3:40428807	ENTPD3	-0.43	-7.57	-0.38	3.56e-13	Renal cell carcinoma;
LIHC	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.72	11.14	0.52	8.54e-25	Metabolite levels;
LIHC	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.57	6.85	0.35	3.55e-11	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.79	-11.69	-0.53	9e-27	Dental caries;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg05063087	chr10:102133314	C10orf75	0.44	6.26	0.32	1.18e-9	Migraine with aura;
LIHC	cis	rs11212260	0.655	rs79317540	chr11:107285785	T/C	cg25435332	chr11:107328525	CWF19L2	0.8	8.47	0.42	7.45e-16	IgG glycosylation;
LIHC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	9.02	0.44	1.37e-17	Motion sickness;
LIHC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg00901687	chr17:48585270	MYCBPAP	0.45	6.33	0.32	7.63e-10	Visceral fat;
LIHC	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	0.66	7.32	0.37	1.81e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg22951263	chr5:87985283	NA	-0.42	-7.37	-0.37	1.26e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg21385522	chr1:16154831	NA	-0.47	-7.72	-0.39	1.28e-13	Systolic blood pressure;
LIHC	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.56	9.25	0.45	2.52e-18	HDL cholesterol;
LIHC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.57	8.52	0.42	5.28e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.11	-0.4	9.46e-15	Capecitabine sensitivity;
LIHC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	6.07	0.31	3.32e-9	Renal cell carcinoma;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg01339444	chr6:118972232	C6orf204	0.59	5.93	0.31	7.53e-9	Diastolic blood pressure;
LIHC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-8.92	-0.43	2.9e-17	Bipolar disorder;
LIHC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01200585	chr1:228362443	C1orf69	-0.39	-5.85	-0.3	1.17e-8	Diastolic blood pressure;
LIHC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-6.79	-0.34	5.04e-11	Chronic sinus infection;
LIHC	cis	rs16828019	0.852	rs71648535	chr1:41613750	G/A	cg03962019	chr1:41807865	NA	0.53	7.51	0.38	5.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.33	0.41	2.01e-15	Response to antipsychotic treatment;
LIHC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg17371911	chr8:10683139	PINX1;MIR1322	0.5	6.3	0.32	8.9e-10	Neuroticism;
LIHC	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.46	-6.04	-0.31	3.98e-9	Diisocyanate-induced asthma;
LIHC	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.19	-0.45	3.8e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.28	20.79	0.75	1.25e-62	Corneal structure;
LIHC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-6.34	-0.32	7.28e-10	Cognitive test performance;
LIHC	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.53	8.5	0.42	6.13e-16	Blood protein levels;
LIHC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg20140201	chr2:241835670	C2orf54	-0.45	-6.15	-0.32	2.18e-9	Urinary metabolites;
LIHC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.48	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg12365402	chr11:9010492	NRIP3	0.34	8.63	0.42	2.3e-16	Hemoglobin concentration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23260799	chr11:451101	PTDSS2	0.38	6.24	0.32	1.3e-9	Cognitive function;
LIHC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.46	-0.42	8e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs67981189	0.634	rs221900	chr14:71604354	C/T	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.7e-11	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg02782426	chr3:40428986	ENTPD3	-0.32	-5.89	-0.3	9.18e-9	Renal cell carcinoma;
LIHC	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg27417294	chr10:81904244	PLAC9	-0.36	-6.16	-0.32	2.04e-9	Sarcoidosis;
LIHC	cis	rs116248771	0.739	rs7648050	chr3:158377470	G/A	cg16708174	chr3:158430962	RARRES1	0.48	6.38	0.33	5.61e-10	diarrhoeal disease at age 2;
LIHC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.11	-0.36	6.63e-12	IgG glycosylation;
LIHC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg24296786	chr1:45957014	TESK2	-0.39	-5.88	-0.3	9.53e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg11764359	chr7:65958608	NA	0.59	6.14	0.32	2.32e-9	Diabetic kidney disease;
LIHC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.55	-9.13	-0.44	6.31e-18	Blood metabolite levels;
LIHC	cis	rs2526882	0.541	rs2526859	chr14:71412207	C/T	cg15816911	chr14:71606274	NA	-0.43	-6.74	-0.34	6.73e-11	Schizophrenia;
LIHC	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.15	0.48	2.49e-21	Colorectal cancer;
LIHC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.39	5.91	0.3	8.16e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg04691961	chr3:161091175	C3orf57	-0.43	-6.61	-0.34	1.46e-10	Morning vs. evening chronotype;
LIHC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.04	0.31	3.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7095607	0.654	rs7081017	chr10:69954451	A/G	cg18986048	chr10:69913749	MYPN	0.39	5.81	0.3	1.46e-8	Lung function (FVC);
LIHC	cis	rs74233809	1.000	rs77860422	chr10:104748009	G/A	cg03493300	chr10:104813866	CNNM2	0.44	5.76	0.3	1.85e-8	Birth weight;
LIHC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.69	0.34	8.86e-11	Mean corpuscular volume;
LIHC	cis	rs7264396	0.832	rs224416	chr20:34138406	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-6.42	-0.33	4.43e-10	Total cholesterol levels;
LIHC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.71	-0.3	2.42e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg07689907	chr11:61582574	FADS1	0.41	5.94	0.31	6.98e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.43	-6.11	-0.31	2.69e-9	Dental caries;
LIHC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg06046430	chr4:77819534	ANKRD56	0.5	6.18	0.32	1.82e-9	Emphysema distribution in smoking;
LIHC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.53	-7.81	-0.39	7.23e-14	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	8.85	0.43	4.66e-17	Colorectal cancer;
LIHC	cis	rs1789	0.868	rs4631041	chr4:15673395	A/T	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.86	-0.3	1.07e-8	Blood protein levels;
LIHC	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.99	-0.31	5.3300000000000004e-09	Coronary artery disease;
LIHC	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg05044414	chr3:183734942	ABCC5	0.32	5.87	0.3	1.05e-8	Anterior chamber depth;
LIHC	cis	rs600626	0.578	rs10793126	chr11:75453982	C/T	cg24262691	chr11:75473276	NA	-0.4	-5.94	-0.31	6.96e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.59	8.75	0.43	1e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.51	-0.33	2.61e-10	Diabetic kidney disease;
LIHC	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg04592579	chr7:75616294	TMEM120A	0.39	6.73	0.34	7.31e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.1	-0.4	9.71e-15	Chronic sinus infection;
LIHC	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg04374321	chr14:90722782	PSMC1	0.48	6.92	0.35	2.3e-11	Longevity;
LIHC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.68	6.93	0.35	2.16e-11	Bipolar disorder;
LIHC	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg08992911	chr2:238395768	MLPH	0.49	5.95	0.31	6.48e-9	Prostate cancer;
LIHC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg17749961	chr2:30669863	LCLAT1	-0.46	-6.01	-0.31	4.76e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.54	-7.35	-0.37	1.51e-12	Body mass index;
LIHC	cis	rs2933343	0.716	rs9872706	chr3:128567105	A/G	cg25356066	chr3:128598488	ACAD9	-0.53	-6.87	-0.35	3.08e-11	IgG glycosylation;
LIHC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	12.14	0.55	1.94e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10861342	1.000	rs11112371	chr12:105499021	T/C	cg23923672	chr12:105501055	KIAA1033	0.66	7.7	0.38	1.49e-13	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12457740	chr3:56590942	CCDC66	-0.47	-6.74	-0.34	6.6e-11	Pancreatic cancer;
LIHC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.64	-8.06	-0.4	1.3e-14	Gut microbiome composition (summer);
LIHC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.49	-7.58	-0.38	3.17e-13	Heart rate;
LIHC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.35	-5.85	-0.3	1.17e-8	Atrioventricular conduction;
LIHC	trans	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.37	0.33	6.15e-10	Schizophrenia;
LIHC	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.79	12.72	0.57	1.25e-30	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg25894440	chr7:65020034	NA	0.51	5.9	0.3	8.83e-9	Diabetic kidney disease;
LIHC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.31	-0.37	1.89e-12	Schizophrenia;
LIHC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.69	10.52	0.49	1.27e-22	Height;
LIHC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12611088	0.541	rs2599445	chr19:44005025	C/G	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.18	-0.32	1.83e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.22	12.75	0.57	9.9e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.36	-0.37	1.41e-12	Obesity-related traits;
LIHC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.49	8.85	0.43	4.96e-17	Tuberculosis;
LIHC	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.43	-5.75	-0.3	1.95e-8	Dental caries;
LIHC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.63	10.16	0.48	2.24e-21	Obesity-related traits;
LIHC	cis	rs4517514	0.509	rs12417652	chr11:89905239	T/G	cg05041596	chr11:89867385	NAALAD2	0.42	6.77	0.34	5.49e-11	Trans fatty acid levels;
LIHC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.33	-6.28	-0.32	1.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-8.66	-0.42	1.95e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.52	-10.94	-0.51	4.43e-24	Late-onset Alzheimer's disease;
LIHC	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.46	6.96	0.35	1.71e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.69	-9.85	-0.47	2.54e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.28	0.52	2.74e-25	Motion sickness;
LIHC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.53	7.68	0.38	1.7e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	8.03	0.4	1.54e-14	Lymphocyte counts;
LIHC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	trans	rs10761482	0.566	rs4505011	chr10:62200308	T/C	cg17314160	chr12:110399253	GIT2	-0.41	-6.23	-0.32	1.36e-9	Schizophrenia;
LIHC	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg15208524	chr1:10270712	KIF1B	0.45	6.56	0.33	2.04e-10	Hepatocellular carcinoma;
LIHC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.86e-12	Breast cancer;
LIHC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.75	11.22	0.52	4.19e-25	Coronary artery disease;
LIHC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	16.11	0.66	7.33e-44	Platelet count;
LIHC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.67	-8.41	-0.41	1.14e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.67	-11.68	-0.53	9.22e-27	Pediatric autoimmune diseases;
LIHC	cis	rs4407350	1.000	rs4407350	chr22:44922275	G/A	cg26276947	chr22:44892394	LDOC1L	0.35	6.41	0.33	4.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-7.3	-0.37	1.99e-12	Ulcerative colitis;
LIHC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.33	6.52	0.33	2.6e-10	Multiple system atrophy;
LIHC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.58	11.8	0.54	3.52e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg02023728	chr11:77925099	USP35	0.34	6.15	0.32	2.1e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.65	-0.5	4.62e-23	Monocyte percentage of white cells;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.66	-10.02	-0.48	6.77e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.39	-6.33	-0.32	7.5e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.64	10.16	0.48	2.35e-21	Monocyte count;
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.32	-7.21	-0.36	3.72e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.39	5.91	0.3	8.47e-9	Height;
LIHC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.87	-9.75	-0.47	5.67e-20	Vitiligo;
LIHC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg16901082	chr8:26435609	DPYSL2	-0.38	-6.66	-0.34	1.11e-10	Height;
LIHC	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.41e-15	Blood protein levels;
LIHC	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.17	0.32	1.93e-9	Body mass index;
LIHC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.5	7.54	0.38	4.31e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs9858542	0.537	rs73086105	chr3:49356577	A/G	cg07636037	chr3:49044803	WDR6	-0.63	-6.44	-0.33	4.11e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.41	-7.59	-0.38	3.15e-13	Height;
LIHC	cis	rs6546550	0.835	rs3752781	chr2:70124316	T/A	cg02498382	chr2:70120550	SNRNP27	-0.45	-7.54	-0.38	4.36e-13	Prevalent atrial fibrillation;
LIHC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02985541	chr2:219472218	PLCD4	-0.39	-5.94	-0.31	7.04e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.57	-6.78	-0.34	5.27e-11	Major depressive disorder;
LIHC	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.42	6.99	0.35	1.49e-11	Dementia with Lewy bodies;
LIHC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	1.0	11.7	0.53	7.85e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-6.72	-0.34	7.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs13113518	0.812	rs12505880	chr4:56307155	C/A	cg15358633	chr12:38710606	ALG10B	0.43	6.11	0.31	2.78e-9	Height;
LIHC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg14440974	chr22:39074834	NA	-0.38	-5.91	-0.3	8.24e-9	Menopause (age at onset);
LIHC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.16	0.44	4.71e-18	Schizophrenia;
LIHC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.37	6.9	0.35	2.55e-11	Ewing sarcoma;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.57	-8.44	-0.42	9.14e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.52	0.46	3.35e-19	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.43	6.73	0.34	7.26e-11	Testicular germ cell tumor;
LIHC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.62	-6.93	-0.35	2.05e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.47	7.82	0.39	6.71e-14	Lung cancer;
LIHC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.41	0.52	9.23e-26	Menopause (age at onset);
LIHC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-8.29	-0.41	2.57e-15	Monocyte percentage of white cells;
LIHC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08822215	chr16:89438651	ANKRD11	-0.51	-8.06	-0.4	1.33e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20887711	chr4:1340912	KIAA1530	0.47	6.26	0.32	1.17e-9	Obesity-related traits;
LIHC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.79	-13.08	-0.58	5.72e-32	Colorectal cancer;
LIHC	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.64	6.77	0.34	5.66e-11	Type 2 diabetes;
LIHC	cis	rs28830936	0.966	rs11635415	chr15:42133502	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.14	-0.31	2.32e-9	Diastolic blood pressure;
LIHC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg24130564	chr14:104152367	KLC1	-0.55	-8.91	-0.43	3.16e-17	Reticulocyte count;
LIHC	cis	rs903552	0.932	rs2172851	chr15:102012626	C/T	cg19295451	chr15:102010161	PCSK6	-0.53	-7.21	-0.36	3.59e-12	Diabetic kidney disease;
LIHC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.44	0.33	4.16e-10	Rheumatoid arthritis;
LIHC	cis	rs2334880	0.641	rs12325234	chr16:71459628	A/T	cg06353428	chr16:71660113	MARVELD3	-1.06	-9.7	-0.46	8.27e-20	Malaria;
LIHC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.72	-0.3	2.28e-8	Tonsillectomy;
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg05552183	chr6:42928497	GNMT	0.68	10.11	0.48	3.35e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs74181299	0.684	rs12713532	chr2:65356552	G/C	cg05010058	chr2:65284262	CEP68	-0.42	-6.93	-0.35	2.04e-11	Pulse pressure;
LIHC	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.4	8.36	0.41	1.57e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs8056893	0.842	rs3785114	chr16:68372323	C/G	cg02226672	chr16:68398533	SMPD3	0.41	5.78	0.3	1.69e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	trans	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg01596870	chr19:55963115	NA	0.64	8.74	0.43	1.1e-16	Obesity-related traits;
LIHC	cis	rs616147	0.627	rs9871799	chr3:39484320	G/A	cg17944282	chr3:39448217	RPSA	0.42	5.88	0.3	9.61e-9	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.76	8.62	0.42	2.49e-16	Obesity-related traits;
LIHC	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg25952890	chr19:58913133	NA	0.69	7.4	0.37	1.07e-12	Mean platelet volume;
LIHC	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg07541023	chr7:19748670	TWISTNB	-0.37	-5.91	-0.3	8.48e-9	Thyroid stimulating hormone;
LIHC	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.32	7.52	0.38	4.78e-13	Educational attainment (years of education);
LIHC	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.59	-6.14	-0.32	2.31e-9	Inflammatory bowel disease;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.68	0.76	3.28e-66	Prudent dietary pattern;
LIHC	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.52	9.25	0.45	2.53e-18	Systemic lupus erythematosus;
LIHC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.85	8.33	0.41	1.95e-15	Inflammatory bowel disease;
LIHC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs926392	0.965	rs714108	chr20:37687838	G/A	cg16355469	chr20:37678765	NA	0.37	5.9	0.3	8.89e-9	Dialysis-related mortality;
LIHC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg06565975	chr8:143823917	SLURP1	-0.45	-8.19	-0.4	5.37e-15	Urinary tract infection frequency;
LIHC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.23	-0.45	2.95e-18	Heart rate;
LIHC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.96	-0.35	1.78e-11	Diabetic kidney disease;
LIHC	trans	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg10756647	chr7:56101905	PSPH	1.0	11.41	0.53	8.84e-26	Diabetic kidney disease;
LIHC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.33	5.81	0.3	1.4e-8	Anterior chamber depth;
LIHC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.5	-6.65	-0.34	1.19e-10	Narcolepsy;
LIHC	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.15	0.32	2.14e-9	Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.53	5.88	0.3	9.53e-9	Alzheimer's disease;
LIHC	cis	rs3748682	0.861	rs2291297	chr1:38272660	G/A	cg12658694	chr1:38397304	INPP5B	0.44	6.03	0.31	4.2e-9	Hypothyroidism;
LIHC	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	7.92	0.39	3.43e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.54	-7.79	-0.39	7.89e-14	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.27	-6.43	-0.33	4.41e-10	Gut microbiome composition (winter);
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg24693881	chr1:107596107	NA	-0.52	-9.02	-0.44	1.34e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.95	13.47	0.59	1.73e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	7.93	0.39	3.2e-14	IgG glycosylation;
LIHC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.43	-7.14	-0.36	5.47e-12	Blood pressure (smoking interaction);
LIHC	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	6.07	0.31	3.45e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9309473	1.000	rs10189574	chr2:73698518	C/A	cg20560298	chr2:73613845	ALMS1	-0.52	-6.25	-0.32	1.26e-9	Metabolite levels;
LIHC	cis	rs9443189	0.901	rs2038625	chr6:76560968	G/A	cg01950844	chr6:76311363	SENP6	-0.52	-6.76	-0.34	5.8200000000000003e-11	Prostate cancer;
LIHC	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.32	-5.72	-0.3	2.35e-8	Lewy body disease;
LIHC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg15691649	chr6:25882328	NA	-0.51	-7.38	-0.37	1.22e-12	Blood metabolite levels;
LIHC	cis	rs72843506	0.656	rs8073875	chr17:19939059	A/G	cg12065943	chr17:19881925	AKAP10	-0.41	-6.93	-0.35	2.14e-11	Schizophrenia;
LIHC	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-8.01	-0.4	1.84e-14	Migraine;
LIHC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.62	-6.64	-0.34	1.21e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	cis	rs3736485	0.868	rs9744054	chr15:51933163	C/T	cg08986416	chr15:51914746	DMXL2	-0.43	-6.12	-0.31	2.5e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg22777020	chr22:31556080	RNF185	-0.54	-6.14	-0.32	2.23e-9	Colorectal cancer;
LIHC	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg20129853	chr10:51489980	NA	-0.42	-9.1	-0.44	7.71e-18	Prostate-specific antigen levels;
LIHC	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg10820045	chr2:198174542	NA	-0.58	-9.57	-0.46	2.2e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg19936157	chr1:113287238	NA	-0.33	-6.03	-0.31	4.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.94	17.9	0.7	5.08e-51	Menopause (age at onset);
LIHC	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg04610667	chr7:75704037	NA	-0.33	-5.99	-0.31	5.2e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.47	-0.59	1.85e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.53	-8.72	-0.43	1.21e-16	Colorectal cancer;
LIHC	cis	rs11229555	0.598	rs12289876	chr11:58185250	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.57	-8.66	-0.42	1.83e-16	White matter hyperintensity burden;
LIHC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02985541	chr2:219472218	PLCD4	-0.39	-6.06	-0.31	3.65e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.91	-18.26	-0.7	1.76e-52	Homoarginine levels;
LIHC	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.81	0.3	1.44e-8	Educational attainment;
LIHC	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.32	-0.32	8.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg11212589	chr17:38028394	ZPBP2	0.33	6.75	0.34	6.24e-11	Self-reported allergy;
LIHC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.91	-10.46	-0.49	2.07e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.78	-12.19	-0.55	1.27e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02985541	chr2:219472218	PLCD4	0.45	8.41	0.41	1.16e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.54	-10.25	-0.48	1.15e-21	Mean corpuscular volume;
LIHC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.77	0.39	8.99e-14	Bipolar disorder;
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.42	-5.91	-0.3	8.22e-9	Longevity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14490972	chr6:43484812	POLR1C;YIPF3	0.44	6.21	0.32	1.55e-9	Cognitive function;
LIHC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.57	6.25	0.32	1.24e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.75	-14.66	-0.62	4.22e-38	Mortality in heart failure;
LIHC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.35	-6.26	-0.32	1.13e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.34	8.28	0.41	2.79e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	6.3	0.32	9.21e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg25566285	chr7:158114605	PTPRN2	0.23	6.25	0.32	1.23e-9	Calcium levels;
LIHC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.45	6.26	0.32	1.17e-9	Obesity-related traits;
LIHC	cis	rs9921222	0.542	rs9926968	chr16:381561	A/C	cg26913058	chr16:419975	MRPL28	-0.5	-6.85	-0.35	3.37e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg14033944	chr8:11627058	NEIL2	0.59	6.98	0.35	1.57e-11	Neuroticism;
LIHC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.57	9.17	0.44	4.62e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.42	-5.92	-0.3	7.86e-9	Longevity;
LIHC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	12.24	0.55	8.04e-29	Platelet count;
LIHC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.03	-0.44	1.32e-17	Longevity;
LIHC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.03	0.63	1.44e-39	Menopause (age at onset);
LIHC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.85	11.0	0.51	2.59e-24	Heart rate;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.18	-0.44	4.36e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.92	14.64	0.62	5.03e-38	Vitamin D levels;
LIHC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.86	0.8	1.15e-78	Prudent dietary pattern;
LIHC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.24	-0.36	2.92e-12	Bipolar disorder;
LIHC	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg18678763	chr11:4115507	RRM1	-0.44	-6.24	-0.32	1.29e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg17749961	chr2:30669863	LCLAT1	0.47	6.01	0.31	4.8e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.59	-8.16	-0.4	6.65e-15	Pancreatic cancer;
LIHC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.52	7.64	0.38	2.22e-13	Type 2 diabetes;
LIHC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.47	6.06	0.31	3.56e-9	Subjective well-being;
LIHC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg19683494	chr5:74908142	NA	0.69	7.65	0.38	2.07e-13	Coronary artery disease;
LIHC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09331995	chr7:27309021	NA	0.42	6.3	0.32	9.38e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg05343316	chr1:45956843	TESK2	-0.45	-6.6	-0.34	1.57e-10	High light scatter reticulocyte count;
LIHC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.99	-12.87	-0.57	3.42e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.45	7.71	0.38	1.34e-13	Testicular germ cell tumor;
LIHC	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.83	9.69	0.46	9.18e-20	Ulcerative colitis;
LIHC	cis	rs74181299	0.964	rs2540948	chr2:65284623	T/C	cg05010058	chr2:65284262	CEP68	0.41	6.86	0.35	3.18e-11	Pulse pressure;
LIHC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.58	7.61	0.38	2.74e-13	Morning vs. evening chronotype;
LIHC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.45	7.31	0.37	1.86e-12	Height;
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.12	0.31	2.49e-9	Calcium levels;
LIHC	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02353165	chr6:42928485	GNMT	0.6	8.96	0.44	2.21e-17	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.54	6.53	0.33	2.45e-10	IgG glycosylation;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg14222432	chr12:29376421	FAR2	0.38	7.38	0.37	1.2e-12	QT interval;
LIHC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.65	12.08	0.55	3.19e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.33	0.52	1.75e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.45	0.62	2.79e-37	Prudent dietary pattern;
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.28	-0.32	1.05e-9	Calcium levels;
LIHC	trans	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.52	-7.9	-0.39	3.76e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7937890	0.559	rs2597208	chr11:14472329	A/C	cg02886208	chr11:14281011	SPON1	-0.46	-6.44	-0.33	4e-10	Mitochondrial DNA levels;
LIHC	cis	rs332507	0.830	rs4678144	chr3:124404399	C/T	cg05980111	chr3:124395277	KALRN	-0.45	-6.95	-0.35	1.8e-11	Plateletcrit;
LIHC	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.38	6.27	0.32	1.06e-9	Anterior chamber depth;
LIHC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.53	-9.28	-0.45	1.98e-18	White blood cell count;
LIHC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02290350	chr8:58132656	NA	0.47	9.31	0.45	1.6e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs4789452	0.774	rs55727612	chr17:75381723	C/T	cg06761530	chr17:75373219	SEPT9	-0.47	-6.05	-0.31	3.88e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	8.63	0.42	2.31e-16	Height;
LIHC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.4	-6.75	-0.34	6.48e-11	Alcohol dependence;
LIHC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.65	7.82	0.39	6.73e-14	Heart rate;
LIHC	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg17764715	chr19:33622953	WDR88	0.53	7.22	0.36	3.42e-12	Bone properties (heel);
LIHC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02538280	chr7:157956927	PTPRN2	0.36	7.88	0.39	4.55e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LIHC	cis	rs55702914	0.837	rs2195507	chr2:198172336	T/C	cg10820045	chr2:198174542	NA	-0.41	-6.1	-0.31	2.85e-9	Major depression and alcohol dependence;
LIHC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.72	0.54	6.76e-27	Motion sickness;
LIHC	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.5	7.79	0.39	8.35e-14	Alzheimer's disease (survival time);
LIHC	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.51	8.25	0.41	3.56e-15	Blood protein levels;
LIHC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.44	8.08	0.4	1.11e-14	Prudent dietary pattern;
LIHC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.77	12.32	0.55	3.96e-29	Corneal astigmatism;
LIHC	cis	rs922107	0.967	rs6699344	chr1:90023768	G/A	cg15422784	chr1:90023713	LRRC8B	-0.49	-8.01	-0.4	1.84e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs11958404	1.000	rs72816529	chr5:157411454	G/C	cg05962755	chr5:157440814	NA	1.05	11.07	0.51	1.55e-24	IgG glycosylation;
LIHC	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg20140201	chr2:241835670	C2orf54	-0.54	-8.36	-0.41	1.63e-15	Urinary metabolites;
LIHC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.76	0.39	9.63e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs12220238	0.822	rs10824193	chr10:76261759	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.04	0.31	4.05e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg14988396	chr8:25316392	CDCA2;KCTD9	0.52	6.69	0.34	9.09e-11	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-6.59	-0.34	1.63e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.92	-0.3	7.75e-9	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.34	-0.32	7.44e-10	Prevalent atrial fibrillation;
LIHC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.84	15.3	0.64	1.32e-40	Bone mineral density;
LIHC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.48	6.3	0.32	9.16e-10	Lung cancer (smoking interaction);
LIHC	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.68	5.86	0.3	1.08e-8	Body mass index;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.38	5.8	0.3	1.54e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.46	-6.42	-0.33	4.45e-10	Initial pursuit acceleration;
LIHC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-5.95	-0.31	6.57e-9	Cognitive function;
LIHC	cis	rs9367716	0.956	rs7757492	chr6:57120578	T/C	cg03371099	chr6:57305889	PRIM2	0.35	5.74	0.3	2.14e-8	Coronary artery disease;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg18538332	chr22:24372958	LOC391322	-0.65	-9.7	-0.46	8.49e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.5	0.38	5.5e-13	Aortic root size;
LIHC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.52	7.15	0.36	5.17e-12	Body mass index;
LIHC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.86	0.35	3.28e-11	Diabetic kidney disease;
LIHC	cis	rs6442522	0.606	rs3274	chr3:15491756	G/A	cg16303742	chr3:15540471	COLQ	0.39	6.37	0.33	6.05e-10	Uric acid levels;
LIHC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.7	10.48	0.49	1.82e-22	Chronic sinus infection;
LIHC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.67	11.1	0.51	1.22e-24	Menopause (age at onset);
LIHC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	11.11	0.51	1.1e-24	Monocyte percentage of white cells;
LIHC	cis	rs748404	0.556	rs7166467	chr15:43440522	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.36	-5.86	-0.3	1.06e-8	Lung cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24123311	chr19:48675164	NA	0.43	6.45	0.33	3.72e-10	Longevity;
LIHC	cis	rs7523273	0.597	rs11118612	chr1:207979577	T/A	cg22525895	chr1:207977042	MIR29B2	-0.59	-7.12	-0.36	6.45e-12	Schizophrenia;
LIHC	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.51	0.42	5.4e-16	Corneal astigmatism;
LIHC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10503871	0.657	rs6997017	chr8:30341945	A/G	cg26383811	chr8:30366931	RBPMS	0.43	7.46	0.37	7.13e-13	Metabolite levels  (X-11787);
LIHC	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.4	5.85	0.3	1.15e-8	Corneal structure;
LIHC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.38	5.75	0.3	1.97e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1816752	0.875	rs3783076	chr13:25064457	C/T	cg02811702	chr13:24901961	NA	0.25	6.24	0.32	1.28e-9	Obesity-related traits;
LIHC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.73	0.34	6.96e-11	Tonsillectomy;
LIHC	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.59	7.76	0.39	1.01e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg23625390	chr15:77176239	SCAPER	0.35	5.84	0.3	1.19e-8	Blood metabolite levels;
LIHC	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.38	7.11	0.36	6.95e-12	Metabolite levels;
LIHC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.86	10.63	0.5	5.23e-23	Morning vs. evening chronotype;
LIHC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.06	18.53	0.71	1.49e-53	Testicular germ cell tumor;
LIHC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.68	-12.75	-0.57	1.03e-30	Body mass index;
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.77	11.88	0.54	1.75e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs3783890	1.000	rs71429789	chr14:93745184	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.22	0.32	1.44e-9	Body mass index;
LIHC	cis	rs11671005	0.652	rs56225452	chr19:59024646	C/T	cg25952890	chr19:58913133	NA	0.64	6.29	0.32	9.49e-10	Mean platelet volume;
LIHC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6442522	0.772	rs3890477	chr3:15489323	C/G	cg16303742	chr3:15540471	COLQ	0.39	6.19	0.32	1.77e-9	Uric acid levels;
LIHC	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	0.91	11.75	0.54	5.13e-27	Severe influenza A (H1N1) infection;
LIHC	cis	rs12611088	0.600	rs2682578	chr19:44012880	A/G	cg13740135	chr19:44006432	PHLDB3	-0.41	-6.18	-0.32	1.84e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.5	9.51	0.46	3.41e-19	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-13.17	-0.58	2.47e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.61	0.53	1.73e-26	Cognitive test performance;
LIHC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.83	-15.93	-0.65	4.11e-43	Height;
LIHC	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg27205649	chr11:78285834	NARS2	-0.37	-5.82	-0.3	1.38e-8	Testicular germ cell tumor;
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.27	0.37	2.49e-12	Height;
LIHC	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg23461800	chr14:103021989	NA	-0.39	-5.89	-0.3	9.48e-9	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27499259	chr13:28400924	NA	0.41	6.22	0.32	1.49e-9	Cognitive function;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg09033563	chr22:24373618	LOC391322	-0.5	-6.96	-0.35	1.77e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.56	-10.53	-0.49	1.17e-22	Mean corpuscular volume;
LIHC	trans	rs11679072	1.000	rs7592764	chr2:240448167	A/C	cg22966899	chr4:156268508	MAP9	0.6	6.19	0.32	1.7e-9	Blood pressure (smoking interaction);
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.67	-0.42	1.83e-16	Renal cell carcinoma;
LIHC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg10360323	chr17:41437877	NA	0.41	6.09	0.31	3.1e-9	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.6	6.79	0.34	4.83e-11	Alzheimer's disease;
LIHC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-9.35	-0.45	1.13e-18	Bronchopulmonary dysplasia;
LIHC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.93	12.68	0.57	1.9e-30	Blood metabolite levels;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg27309142	chr7:32801485	NA	0.39	6.07	0.31	3.34e-9	Lung function (FEV1);
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg02993280	chr1:107599747	PRMT6	0.69	11.36	0.52	1.36e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.55	-7.98	-0.4	2.18e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.32	0.37	1.74e-12	Monocyte percentage of white cells;
LIHC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.33	-5.84	-0.3	1.19e-8	Headache;
LIHC	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.28	-0.37	2.26e-12	Metabolite levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22068764	chr1:170501645	GORAB	0.49	7.08	0.36	8.37e-12	Cognitive function;
LIHC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.36	-12.15	-0.55	1.72e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.49	0.33	3.07e-10	Mean platelet volume;
LIHC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.45	5.93	0.31	7.39e-9	Parkinson's disease;
LIHC	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.35	6.62	0.34	1.38e-10	Multiple sclerosis;
LIHC	cis	rs2412488	0.893	rs11723755	chr4:54310281	T/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.79	-0.34	5e-11	DNA methylation (variation);
LIHC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.33	-0.58	6.41e-33	Type 2 diabetes;
LIHC	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg04306507	chr14:55594613	LGALS3	0.35	6.57	0.33	1.89e-10	Protein biomarker;
LIHC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.02	-0.31	4.61e-9	Tuberculosis;
LIHC	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.52	-0.42	5.04e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	0.73	12.11	0.55	2.47e-28	Intracerebral hemorrhage;White matter hyperintensity burden;
LIHC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg13395646	chr4:1353034	KIAA1530	-0.86	-12.83	-0.57	4.99e-31	Obesity-related traits;
LIHC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7944735	0.508	rs4147730	chr11:47605427	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-6.16	-0.32	2.01e-9	Intraocular pressure;
LIHC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.55	-0.69	1.28e-49	Height;
LIHC	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.85	-0.54	2.3e-27	Coffee consumption (cups per day);
LIHC	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.61	7.64	0.38	2.26e-13	Crohn's disease;
LIHC	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	0.51	7.78	0.39	8.73e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg18016565	chr1:150552671	MCL1	0.53	9.94	0.47	1.27e-20	Melanoma;
LIHC	cis	rs7520050	0.966	rs6429582	chr1:46321843	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	-0.4	-5.86	-0.3	1.09e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-6.95	-0.35	1.82e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.94	0.8	5.69e-79	Prudent dietary pattern;
LIHC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg14829360	chr17:73884958	NA	-0.52	-7.83	-0.39	5.99e-14	Psoriasis;
LIHC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.54	8.66	0.42	1.96e-16	Colorectal cancer;
LIHC	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26734620	chr12:56694298	CS	1.27	10.9	0.51	6.03e-24	Psoriasis vulgaris;
LIHC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.61	0.56	3.24e-30	Electrocardiographic conduction measures;
LIHC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg06238570	chr21:40685208	BRWD1	0.58	6.91	0.35	2.38e-11	Cognitive function;
LIHC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.6	9.75	0.47	5.69e-20	Platelet count;
LIHC	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.27	-0.37	2.42e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.71	10.1	0.48	3.71e-21	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.74	0.34	6.72e-11	Diabetic kidney disease;
LIHC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	0.62	6.25	0.32	1.22e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.68	-11.24	-0.52	3.82e-25	Menopause (age at onset);
LIHC	trans	rs13113518	0.812	rs7667741	chr4:56410788	T/C	cg15358633	chr12:38710606	ALG10B	0.43	6.12	0.31	2.57e-9	Height;
LIHC	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs903552	1.000	rs11634912	chr15:102005510	A/G	cg06707286	chr15:102010195	PCSK6	-0.44	-6.22	-0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.26	6.07	0.31	3.33e-9	Heart rate;
LIHC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.32	6.33	0.32	7.51e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.35	5.92	0.31	7.71e-9	Height;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.53	7.45	0.37	7.67e-13	Red cell distribution width;
LIHC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg07451762	chr16:28383216	NA	-0.38	-6.79	-0.34	4.97e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04286195	chr16:88099702	BANP	0.56	6.83	0.35	3.99e-11	Lung function (FEV1);
LIHC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.33	7.27	0.37	2.48e-12	Ulcerative colitis;
LIHC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-0.73	-8.25	-0.41	3.56e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08219700	chr8:58056026	NA	0.5	6.33	0.32	7.49e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.84	-0.54	2.51e-27	Alzheimer's disease;
LIHC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.56	7.84	0.39	5.83e-14	Post bronchodilator FEV1;
LIHC	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg20240347	chr1:204465584	NA	-0.34	-7.13	-0.36	5.86e-12	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.72	0.3	2.31e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.49	-0.38	5.88e-13	Uric acid levels;
LIHC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.25	-16.5	-0.67	2.19e-45	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.43	7.54	0.38	4.2e-13	Mean corpuscular volume;
LIHC	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.79	15.25	0.64	2.04e-40	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.84	10.61	0.5	6.35e-23	Cognitive function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18126840	chr2:44689831	C2orf34	-0.28	-6.42	-0.33	4.61e-10	Calcium levels;
LIHC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.67	9.66	0.46	1.08e-19	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08219700	chr8:58056026	NA	-0.44	-5.75	-0.3	2.02e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4878497	0.544	rs3205166	chr9:32459450	G/T	cg14296220	chr9:32431791	ACO1	-0.46	-7.59	-0.38	3.07e-13	Inflammatory skin disease;
LIHC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.2	0.41	4.88e-15	Motion sickness;
LIHC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.57	-8.57	-0.42	3.54e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs35883536	0.647	rs2809795	chr1:101038345	A/G	cg14515779	chr1:101123966	NA	-0.42	-5.89	-0.3	9.19e-9	Monocyte count;
LIHC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	7.28	0.37	2.28e-12	Height;
LIHC	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.48	7.53	0.38	4.61e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs17776563	0.853	rs57761829	chr15:89150488	C/G	cg05013243	chr15:89149849	MIR1179	0.42	6.83	0.35	3.78e-11	Thyroid hormone levels;
LIHC	trans	rs9914544	0.545	rs2386403	chr17:18769600	A/G	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.8	-0.35	4.77e-11	Educational attainment (years of education);
LIHC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.78	12.92	0.57	2.28e-31	Oral cavity cancer;
LIHC	trans	rs10411161	0.702	rs79180893	chr19:52395615	A/G	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs965469	0.779	rs6037528	chr20:3260978	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-6.53	-0.33	2.41e-10	IFN-related cytopenia;
LIHC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.58	-8.96	-0.44	2.21e-17	Metabolic syndrome;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.17	-0.32	1.93e-9	Total body bone mineral density;
LIHC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.75	7.79	0.39	8.35e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg17135325	chr3:160939158	NMD3	0.57	8.45	0.42	8.5e-16	Parkinson's disease;
LIHC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg03859395	chr2:55845619	SMEK2	0.96	16.77	0.67	1.72e-46	Metabolic syndrome;
LIHC	cis	rs7534824	0.625	rs12565777	chr1:101485794	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	6.98	0.35	1.57e-11	Refractive astigmatism;
LIHC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.93	17.15	0.68	5.31e-48	Menopause (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16202803	chr2:240014758	HDAC4	0.51	7.66	0.38	1.96e-13	Longevity;
LIHC	trans	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg26677194	chr12:130822605	PIWIL1	0.49	6.54	0.33	2.29e-10	Menopause (age at onset);
LIHC	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg10820045	chr2:198174542	NA	0.49	7.46	0.37	6.98e-13	Dermatomyositis;
LIHC	cis	rs12220238	0.841	rs11000942	chr10:76025256	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.47	0.33	3.47e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.33	7.27	0.37	2.48e-12	Ulcerative colitis;
LIHC	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-0.84	-9.33	-0.45	1.38e-18	Exhaled nitric oxide output;
LIHC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg13753209	chr17:57696993	CLTC	-0.59	-8.95	-0.44	2.27e-17	Hemoglobin concentration;
LIHC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08280861	chr8:58055591	NA	0.54	6.22	0.32	1.49e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.15	0.4	7.08e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg12698662	chr3:15914712	MIR563	-0.37	-6.68	-0.34	9.79e-11	Mean platelet volume;
LIHC	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg08126542	chr6:37504118	NA	-0.37	-6.27	-0.32	1.09e-9	Cognitive performance;
LIHC	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.74	-0.39	1.13e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.65	-10.89	-0.51	6.75e-24	Pediatric autoimmune diseases;
LIHC	cis	rs288342	0.832	rs288300	chr2:183657279	C/T	cg02625481	chr2:183667124	NA	-0.29	-6.04	-0.31	3.99e-9	Recurrent major depressive disorder;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14733936	chr2:70476139	TIA1	0.42	6.49	0.33	3.05e-10	Calcium levels;
LIHC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.62	9.38	0.45	9.42e-19	Longevity;
LIHC	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-0.77	-8.19	-0.4	5.25e-15	Exhaled nitric oxide output;
LIHC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20135002	chr11:47629003	NA	0.56	9.44	0.45	5.99e-19	Subjective well-being;
LIHC	cis	rs10792665	0.640	rs7947047	chr11:82620556	A/G	cg24227371	chr11:82718527	RAB30	-0.27	-6.13	-0.31	2.41e-9	Obesity-related traits;
LIHC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.16	-0.32	2.05e-9	Alzheimer's disease (late onset);
LIHC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.81	16.67	0.67	4.27e-46	Gestational age at birth (maternal effect);
LIHC	cis	rs2033908	0.620	rs1992334	chr11:12851645	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-7.21	-0.36	3.55e-12	Sitting height ratio;
LIHC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.89	13.42	0.59	2.69e-33	Vitamin D levels;
LIHC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.45	-8.22	-0.41	4.17e-15	Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09896403	chr22:24110173	CHCHD10	0.49	6.16	0.32	2.06e-9	Hepatitis;
LIHC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.41	0.45	7.44e-19	Bipolar disorder;
LIHC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.44	6.94	0.35	2.03e-11	Height;
LIHC	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg23254163	chr1:152506842	NA	0.22	5.81	0.3	1.4e-8	Hair morphology;
LIHC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.5	8.36	0.41	1.58e-15	Obesity-related traits;
LIHC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg00343986	chr7:65444356	GUSB	-0.38	-5.78	-0.3	1.64e-8	Aortic root size;
LIHC	trans	rs6934970	1.000	rs12213231	chr6:113072928	A/G	cg20627988	chr10:133946881	JAKMIP3	0.45	6.23	0.32	1.35e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg21584241	chr15:63341463	TPM1	0.38	5.91	0.3	8.13e-9	Platelet count;
LIHC	cis	rs2540917	0.728	rs243079	chr2:60615028	A/C	cg00543073	chr2:60773386	BCL11A	-0.31	-6.12	-0.31	2.53e-9	Mean corpuscular volume;
LIHC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.52	8.27	0.41	2.96e-15	Total body bone mineral density;
LIHC	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg12560992	chr17:57184187	TRIM37	0.69	8.91	0.43	3.17e-17	Vitamin D levels;
LIHC	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg10935138	chr17:73851978	WBP2	0.46	7.12	0.36	6.6e-12	White matter hyperintensity burden;
LIHC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg16586182	chr3:47516702	SCAP	-0.45	-8.18	-0.4	5.57e-15	Colorectal cancer;
LIHC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.68	-10.35	-0.49	5.21e-22	Testicular germ cell tumor;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.13	0.4	8.12e-15	Height;
LIHC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.42	-7.37	-0.37	1.33e-12	Platelet distribution width;
LIHC	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg02023728	chr11:77925099	USP35	-0.33	-5.84	-0.3	1.2e-8	Alzheimer's disease (survival time);
LIHC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs1144333	1.000	rs17097836	chr1:76462006	T/A	cg03433033	chr1:76189801	ACADM	0.51	7.48	0.38	6.2800000000000005e-13	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.61	6.88	0.35	2.88e-11	Axial length;
LIHC	cis	rs7188697	0.922	rs7199856	chr16:58584772	A/C	cg02549819	chr16:58548995	SETD6	-0.52	-8.16	-0.4	6.7e-15	QT interval;
LIHC	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg18081818	chr7:23246105	NA	-0.41	-5.95	-0.31	6.56e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.45	-9.08	-0.44	9.1e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg13175981	chr1:150552382	MCL1	-0.5	-6.96	-0.35	1.74e-11	Urate levels;
LIHC	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.83	-15.42	-0.64	4.27e-41	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04498913	chr7:1135747	C7orf50	-0.42	-6.62	-0.34	1.37e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.31	-6.14	-0.32	2.29e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9828933	0.626	rs73119018	chr3:63975328	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-9.99	-0.48	8.43e-21	Type 2 diabetes;
LIHC	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.69	8.13	0.4	7.81e-15	Height;
LIHC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.72	-11.26	-0.52	3.05e-25	Inflammatory bowel disease;
LIHC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	6.17	0.32	1.88e-9	Menarche (age at onset);
LIHC	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg23422044	chr7:1970798	MAD1L1	-0.68	-10.5	-0.49	1.59e-22	Bipolar disorder;
LIHC	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.07	-0.51	1.46e-24	Eye color traits;
LIHC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.19	0.32	1.69e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.57	6.07	0.31	3.48e-9	Hip geometry;
LIHC	cis	rs9918079	0.580	rs13120905	chr4:15612288	A/T	cg24225360	chr4:15471699	CC2D2A	0.38	6.07	0.31	3.46e-9	Obesity-related traits;
LIHC	cis	rs4700695	0.764	rs36300	chr5:65348153	C/T	cg21114390	chr5:65439923	SFRS12	0.45	5.75	0.3	2e-8	Facial morphology (factor 19);
LIHC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.49	7.58	0.38	3.28e-13	Platelet count;
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.45	-7.52	-0.38	4.99e-13	Testicular germ cell tumor;
LIHC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg09238746	chr17:78121135	EIF4A3	-0.73	-11.64	-0.53	1.28e-26	Yeast infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06465160	chr1:25071620	CLIC4	0.47	6.56	0.33	1.97e-10	Pancreatic cancer;
LIHC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.09	0.31	2.96e-9	Menopause (age at onset);
LIHC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.44	6.56	0.33	1.94e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg01858014	chr14:56050164	KTN1	-0.63	-6.99	-0.35	1.42e-11	Putamen volume;
LIHC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg08727972	chr1:148025634	NBPF14	-0.4	-6.11	-0.31	2.68e-9	Hip geometry;
LIHC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.52	7.68	0.38	1.69e-13	Height;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12268410	chr8:110346451	ENY2;NUDCD1	-0.43	-6.65	-0.34	1.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.37	-0.33	6.02e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.47	8.27	0.41	3.07e-15	N-glycan levels;
LIHC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.82	-0.63	1.03e-38	Chronic sinus infection;
LIHC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg26939375	chr7:64535504	NA	-0.46	-7.03	-0.36	1.16e-11	Aortic root size;
LIHC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.69	9.74	0.47	5.91e-20	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg04306507	chr14:55594613	LGALS3	0.32	5.97	0.31	5.93e-9	Protein biomarker;
LIHC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg22834771	chr12:69754056	YEATS4	-0.38	-5.83	-0.3	1.27e-8	Response to diuretic therapy;
LIHC	cis	rs4891159	0.584	rs2848958	chr18:74157068	C/T	cg24786174	chr18:74118243	ZNF516	0.81	15.71	0.65	3.06e-42	Longevity;
LIHC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg07424592	chr7:64974309	NA	0.8	9.21	0.45	3.38e-18	Diabetic kidney disease;
LIHC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.71	-7.08	-0.36	8.3e-12	Vitiligo;
LIHC	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.91	-0.3	8.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.59	6.11	0.31	2.65e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs7534824	0.582	rs41312670	chr1:101443431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.38	0.37	1.22e-12	Refractive astigmatism;
LIHC	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-6.4	-0.33	5.12e-10	Schizophrenia;
LIHC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg03934865	chr2:198174659	NA	-0.47	-6.87	-0.35	3.02e-11	Dermatomyositis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13847120	chr17:43224789	HEXIM1	0.43	6.42	0.33	4.48e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12431939	1.000	rs7160729	chr14:51637241	C/T	cg23942311	chr14:51606299	NA	-0.35	-5.84	-0.3	1.21e-8	Cancer;
LIHC	cis	rs6973256	0.568	rs7800126	chr7:133521356	A/C	cg03336402	chr7:133662267	EXOC4	-0.38	-5.83	-0.3	1.25e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg13271783	chr10:134563150	INPP5A	-0.53	-6.52	-0.33	2.6e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.54	0.59	9.52e-34	Lung cancer in ever smokers;
LIHC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.8	12.07	0.55	3.62e-28	Vitamin D levels;
LIHC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.29	-0.32	9.88e-10	Pancreatic cancer;
LIHC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.42	0.41	1.07e-15	Motion sickness;
LIHC	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1000083	0.748	rs3108525	chr5:96625961	A/G	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	12.44	0.56	1.47e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.93	17.53	0.69	1.49e-49	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg22633049	chr21:46681294	NA	-0.37	-6.31	-0.32	8.57e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.99	0.54	6.63e-28	Cognitive test performance;
LIHC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.59	8.8	0.43	6.94e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11628318	0.614	rs4906254	chr14:103209153	C/T	cg12046867	chr14:103022105	NA	-0.42	-6.62	-0.34	1.39e-10	Platelet count;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05195393	chr14:69865263	SLC39A9;ERH	0.34	6.6	0.34	1.55e-10	Calcium levels;
LIHC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.39	7.34	0.37	1.57e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs847649	0.699	rs10242028	chr7:102527785	C/G	cg18108683	chr7:102477205	FBXL13	-0.48	-7.41	-0.37	1.03e-12	Morning vs. evening chronotype;
LIHC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg00612595	chr21:47717864	NA	-0.37	-5.99	-0.31	5.44e-9	Testicular germ cell tumor;
LIHC	cis	rs847851	0.617	rs9394265	chr6:34950274	T/G	cg13137465	chr6:34857473	ANKS1A	0.67	7.45	0.37	7.92e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.55	8.24	0.41	3.7e-15	HIV-1 control;
LIHC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-1.21	-14.69	-0.62	3.13e-38	Eosinophil percentage of granulocytes;
LIHC	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.46	6.33	0.32	7.73e-10	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.71	0.38	1.39e-13	Total body bone mineral density;
LIHC	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg19875535	chr5:140030758	IK	0.37	5.94	0.31	6.91e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.32	-0.37	1.73e-12	Schizophrenia;
LIHC	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.37	7.28	0.37	2.3e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	0.93	7.33	0.37	1.64e-12	IgG glycosylation;
LIHC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.7	8.55	0.42	4.27e-16	Gut microbiome composition (summer);
LIHC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.55	8.78	0.43	8.11e-17	Multiple sclerosis;
LIHC	cis	rs16828019	0.789	rs36084778	chr1:41479538	A/G	cg03962019	chr1:41807865	NA	0.5	7.09	0.36	7.76e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.73	8.14	0.4	7.32e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-9.07	-0.44	9.2e-18	Migraine;
LIHC	cis	rs7200543	1.000	rs16966947	chr16:15141045	T/C	cg07549590	chr16:15018862	NA	-0.32	-5.92	-0.31	7.68e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LIHC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	12.22	0.55	9.81e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.7	10.64	0.5	4.96e-23	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17096262	chr10:29759227	SVIL	0.4	6.15	0.32	2.13e-9	Longevity;
LIHC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.49	-8.75	-0.43	9.86e-17	Colorectal cancer;
LIHC	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.96	0.35	1.71e-11	Blood protein levels;
LIHC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg06611532	chr13:114900021	NA	0.43	7.76	0.39	1.02e-13	Schizophrenia;
LIHC	cis	rs922107	0.738	rs10922665	chr1:90036508	G/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.67	-0.38	1.79e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs4561483	0.583	rs9925010	chr16:11956668	A/G	cg08843971	chr16:11963173	GSPT1	0.39	7.28	0.37	2.36e-12	Testicular germ cell tumor;
LIHC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg03013999	chr17:37608204	MED1	0.35	5.75	0.3	1.94e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.57	9.12	0.44	6.52e-18	Eosinophilic esophagitis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11361691	chr3:57993876	FLNB	0.44	6.17	0.32	1.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01765077	chr12:122356316	WDR66	0.58	7.74	0.39	1.17e-13	Mean corpuscular volume;
LIHC	trans	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.66	9.09	0.44	8.18e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.66	6.76	0.34	5.88e-11	Alzheimer's disease;
LIHC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.49	-6.7	-0.34	8.7e-11	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.62	7.9	0.39	3.77e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.74	-11.31	-0.52	2.01e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg09835421	chr16:68378352	PRMT7	-0.84	-7.91	-0.39	3.63e-14	Magnesium levels;
LIHC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.97	0.54	8.17e-28	Motion sickness;
LIHC	cis	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg17519650	chr2:63277830	OTX1	0.43	6.65	0.34	1.2e-10	LDL cholesterol levels;LDL cholesterol;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00696901	chr1:113933133	MAGI3	-0.48	-6.16	-0.32	2.06e-9	Hepatitis;
LIHC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.73	9.15	0.44	5.37e-18	Body mass index;
LIHC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg02290350	chr8:58132656	NA	0.3	6.85	0.35	3.41e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.55	8.1	0.4	9.62e-15	Diastolic blood pressure;
LIHC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.7	7.6	0.38	2.83e-13	Gut microbiome composition (summer);
LIHC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg16070018	chr6:26224392	HIST1H3E	0.6	7.26	0.37	2.59e-12	Gout;Renal underexcretion gout;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15025054	chr1:212964885	TATDN3;NSL1	0.49	6.69	0.34	8.91e-11	Pancreatic cancer;
LIHC	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	1.09	7.82	0.39	6.73e-14	Arsenic metabolism;
LIHC	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	trans	rs259842	0.800	rs6725456	chr2:180718419	C/T	cg12651014	chr10:32735292	CCDC7	0.44	6.08	0.31	3.2e-9	Blood protein levels;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.0	-0.31	5.01e-9	Diastolic blood pressure;
LIHC	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.56	-8.15	-0.4	7.02e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs3812111	0.641	rs9387383	chr6:116422847	A/G	cg08036074	chr6:116424633	NT5DC1	-0.61	-11.32	-0.52	1.9e-25	Age-related macular degeneration;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.85	-0.35	3.51e-11	Diastolic blood pressure;
LIHC	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.36	-0.33	6.37e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg00750074	chr16:89608354	SPG7	-0.37	-5.75	-0.3	2.01e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-6.28	-0.32	1.03e-9	Subjective well-being;
LIHC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-10.31	-0.49	6.75e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.42	0.33	4.66e-10	Heart rate;
LIHC	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.57	7.32	0.37	1.84e-12	Parkinson's disease;
LIHC	cis	rs2467099	0.786	rs1135889	chr17:73926121	C/A	cg08125733	chr17:73851984	WBP2	0.46	5.8	0.3	1.54e-8	Systolic blood pressure;
LIHC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.44	6.53	0.33	2.32e-10	Obesity-related traits;
LIHC	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.54	-6.06	-0.31	3.64e-9	Coronary artery disease;
LIHC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg13385521	chr17:29058706	SUZ12P	0.75	7.62	0.38	2.44e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.26	-6.78	-0.34	5.43e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.45	-0.37	7.79e-13	Platelet count;
LIHC	cis	rs8081395	0.836	rs1295926	chr17:57909373	A/G	cg13753209	chr17:57696993	CLTC	-0.47	-7.23	-0.36	3.16e-12	White blood cell count;
LIHC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06481639	chr22:41940642	POLR3H	-0.64	-6.55	-0.33	2.08e-10	Vitiligo;
LIHC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg11812906	chr14:75593930	NEK9	-0.42	-6.46	-0.33	3.54e-10	IgG glycosylation;
LIHC	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.66	-0.46	1.12e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg18944383	chr4:111397179	ENPEP	0.35	8.17	0.4	6.09e-15	Coronary artery disease;
LIHC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg17927777	chr20:33865990	NA	0.56	6.56	0.33	2.01e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21467203	chr3:49911342	NA	0.43	7.54	0.38	4.31e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1198430	0.636	rs1009590	chr1:23823798	C/G	cg13183780	chr1:23809682	ASAP3	0.54	7.17	0.36	4.72e-12	Total cholesterol levels;
LIHC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.5	-8.83	-0.43	5.35e-17	Total body bone mineral density;
LIHC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg14393609	chr7:65229607	NA	-0.41	-6.1	-0.31	2.8e-9	Aortic root size;
LIHC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.19	0.45	3.84e-18	Platelet count;
LIHC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.47	7.39	0.37	1.16e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2637030	0.559	rs424955	chr5:52902895	A/G	cg06476337	chr5:52856530	NDUFS4	0.38	6.08	0.31	3.17e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	11.03	0.51	2.04e-24	Colorectal cancer;
LIHC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17507749	chr15:85114479	UBE2QP1	0.64	7.31	0.37	1.92e-12	Schizophrenia;
LIHC	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	0.87	14.3	0.61	1.12e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-17.05	-0.68	1.33e-47	Brugada syndrome;
LIHC	cis	rs7716219	0.751	rs6869221	chr5:54881212	G/T	cg14753740	chr5:54468940	CDC20B;MIR449C	0.42	5.88	0.3	9.69e-9	Height;
LIHC	cis	rs4742903	0.935	rs6479225	chr9:106940330	T/C	cg14250997	chr9:106856677	SMC2	0.35	5.92	0.3	7.73e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg18081818	chr7:23246105	NA	-0.41	-5.92	-0.31	7.69e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	0.79	5.86	0.3	1.08e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.53	-8.47	-0.42	7.32e-16	Superior crus of antihelix expression;
LIHC	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.56	-7.59	-0.38	3.05e-13	Psoriasis vulgaris;
LIHC	cis	rs546131	0.642	rs58210900	chr11:34838047	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs916888	0.821	rs199499	chr17:44865498	C/T	cg13957321	chr17:43675089	NA	0.53	7.14	0.36	5.62e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.75	11.73	0.54	5.96e-27	Corneal astigmatism;
LIHC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.05	24.75	0.8	3.19e-78	IgG glycosylation;
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02359409	chr6:42947317	PEX6	-0.44	-5.94	-0.31	6.85e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	1.01	17.31	0.68	1.16e-48	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.44	7.05	0.36	9.82e-12	Total body bone mineral density;
LIHC	cis	rs8049603	0.524	rs4967967	chr16:23091719	A/T	cg16484020	chr16:23217411	SCNN1G	-0.23	-5.77	-0.3	1.82e-8	Multiple sclerosis;
LIHC	cis	rs7264396	0.561	rs6120993	chr20:34185161	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.85	-0.39	5.29e-14	Total cholesterol levels;
LIHC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg13753209	chr17:57696993	CLTC	0.73	11.52	0.53	3.71e-26	Hemoglobin concentration;
LIHC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-8.66	-0.42	1.95e-16	Crohn's disease;
LIHC	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg26939375	chr7:64535504	NA	0.43	6.82	0.35	4.11e-11	Aortic root size;
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08677398	chr8:58056175	NA	0.4	6.02	0.31	4.51e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.41	7.66	0.38	1.89e-13	Schizophrenia;
LIHC	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.92	-0.3	7.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.0	15.58	0.64	9.86e-42	Skin colour saturation;
LIHC	cis	rs11663156	0.921	rs56054126	chr18:50920599	T/G	cg24270629	chr18:50823537	DCC	-0.48	-6.56	-0.33	2.05e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg19735590	chr5:154026979	NA	-0.48	-5.94	-0.31	6.93e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.35	-6.2	-0.32	1.59e-9	Systemic lupus erythematosus;
LIHC	cis	rs2274273	0.840	rs10136596	chr14:55836773	A/G	cg01864836	chr14:55583639	NA	-0.38	-6.71	-0.34	8.32e-11	Protein biomarker;
LIHC	cis	rs611744	0.901	rs673981	chr8:109191917	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.51	-0.33	2.64e-10	Personality dimensions;
LIHC	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	7.08	0.36	7.98e-12	Neutrophil percentage of white cells;
LIHC	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg02951883	chr7:2050386	MAD1L1	0.54	7.29	0.37	2.21e-12	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg05052194	chr1:2160249	SKI	-0.44	-6.4	-0.33	5.16e-10	Triglycerides;
LIHC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.23e-10	Renal cell carcinoma;
LIHC	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg26536354	chr8:144654954	C8orf73	0.56	6.3	0.32	9.39e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs507080	0.736	rs642224	chr11:118570919	G/A	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg02702477	chr5:179499311	RNF130	0.9	11.96	0.54	9.23e-28	LDL cholesterol;
LIHC	cis	rs17152411	1.000	rs7083298	chr10:126590691	T/C	cg07906193	chr10:126599966	NA	0.46	7.11	0.36	6.9e-12	Height;
LIHC	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg04306507	chr14:55594613	LGALS3	0.34	6.56	0.33	2.05e-10	Protein biomarker;
LIHC	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg27433088	chr4:174089019	GALNT7	-0.37	-7.02	-0.36	1.16e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.44	6.93	0.35	2.07e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg17724175	chr1:150552817	MCL1	-0.38	-7.84	-0.39	5.72e-14	Tonsillectomy;
LIHC	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.83	-0.3	1.32e-8	Systemic lupus erythematosus;
LIHC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.76	0.34	5.96e-11	Morning vs. evening chronotype;
LIHC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	1.0	23.05	0.78	1.35e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.46	-7.11	-0.36	6.9e-12	Longevity;Endometriosis;
LIHC	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg26939375	chr7:64535504	NA	-0.43	-6.25	-0.32	1.21e-9	Aortic root size;
LIHC	cis	rs1975974	1.000	rs17052337	chr17:21710774	A/T	cg18423549	chr17:21743878	NA	-0.45	-5.74	-0.3	2.07e-8	Psoriasis;
LIHC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-1.03	-22.1	-0.77	7.56e-68	Height;
LIHC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.42	-7.71	-0.38	1.4e-13	Electrocardiographic conduction measures;
LIHC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.48	7.74	0.39	1.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.41e-9	Life satisfaction;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.47	0.56	1.09e-29	Prudent dietary pattern;
LIHC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.39	-0.33	5.33e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.59	9.71	0.46	7.58e-20	Corneal astigmatism;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-7.59	-0.38	3.13e-13	Lymphocyte counts;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg03874509	chr1:107600012	PRMT6	-0.74	-11.56	-0.53	2.59e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-9.76	-0.47	5.24e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs7757419	1.000	rs7773901	chr6:34435195	G/A	cg17518776	chr6:34434842	PACSIN1	-0.3	-6.1	-0.31	2.86e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
LIHC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-9.19	-0.45	3.91e-18	Type 2 diabetes;
LIHC	cis	rs4716602	0.596	rs10258969	chr7:156157753	A/G	cg16983916	chr7:156159713	NA	-0.33	-6.06	-0.31	3.62e-9	Anti-saccade response;
LIHC	cis	rs11098699	1.000	rs1031133	chr4:124195336	G/C	cg09941581	chr4:124220074	SPATA5	0.3	5.72	0.3	2.29e-8	Mosquito bite size;
LIHC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.52	6.71	0.34	7.88e-11	Pancreatic cancer;
LIHC	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg16964102	chr10:135390573	NA	0.25	5.8	0.3	1.55e-8	Obesity-related traits;
LIHC	cis	rs12602486	1.000	rs59592125	chr17:42279265	A/G	cg13607699	chr17:42295918	UBTF	-0.79	-6.61	-0.34	1.47e-10	Glycated hemoglobin levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17928916	chr17:80041824	FASN	0.41	6.17	0.32	1.98e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg19635926	chr16:89946313	TCF25	0.55	6.84	0.35	3.57e-11	Skin colour saturation;
LIHC	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.36	-5.99	-0.31	5.4e-9	Schizophrenia;
LIHC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg15017067	chr4:17643749	FAM184B	0.34	5.84	0.3	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-1.01	-10.27	-0.49	9.22e-22	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15008879	chr10:22292810	DNAJC1	0.42	6.13	0.31	2.45e-9	Pancreatic cancer;
LIHC	cis	rs11229555	0.645	rs7929028	chr11:58188258	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.66	-0.38	1.95e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.25	-0.45	2.42e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.43	-6.98	-0.35	1.5e-11	Testicular germ cell tumor;
LIHC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.27	-0.37	2.47e-12	Response to antipsychotic treatment;
LIHC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.37	0.33	6.24e-10	Schizophrenia;
LIHC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.87	0.65	7.12e-43	Breast cancer;
LIHC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-7.2	-0.36	3.83e-12	Obesity (extreme);
LIHC	cis	rs959260	0.858	rs2053156	chr17:73378440	G/T	cg20590849	chr17:73267439	MIF4GD	-0.53	-5.76	-0.3	1.85e-8	Systemic lupus erythematosus;
LIHC	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	8.8	0.43	6.75e-17	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.34	-6.11	-0.31	2.68e-9	Lewy body disease;
LIHC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.95	13.5	0.59	1.39e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.59	9.74	0.47	6.2e-20	Resting heart rate;
LIHC	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	6.44	0.33	3.99e-10	Schizophrenia;
LIHC	cis	rs2625529	0.824	rs4445848	chr15:72354598	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.92	-0.3	7.89e-9	Red blood cell count;
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02290350	chr8:58132656	NA	0.52	11.05	0.51	1.82e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.66	10.86	0.51	8.25e-24	Pulse pressure;
LIHC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.38	7.95	0.39	2.74e-14	Type 2 diabetes;
LIHC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg08528486	chr13:113648767	MCF2L	-0.41	-6.64	-0.34	1.22e-10	Systolic blood pressure;
LIHC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.53e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.45	-6.44	-0.33	4.11e-10	Type 2 diabetes;
LIHC	cis	rs10916814	0.632	rs10799645	chr1:20903784	T/C	cg24502330	chr1:20914028	CDA	-0.32	-6.92	-0.35	2.23e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.67	9.22	0.45	3.08e-18	Menopause (age at onset);
LIHC	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	7.64	0.38	2.18e-13	Height;
LIHC	cis	rs9596863	0.898	rs9568914	chr13:54341107	T/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.1	0.31	2.79e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs244293	0.729	rs2332313	chr17:53018825	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.42	-0.33	4.59e-10	Menarche (age at onset);
LIHC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.03	0.4	1.64e-14	Lung cancer;
LIHC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.8e-9	Alzheimer's disease;
LIHC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.91	16.91	0.67	4.71e-47	Aortic root size;
LIHC	cis	rs3770081	1.000	rs2289237	chr2:86266274	C/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.45	-6.27	-0.32	1.11e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.46	6.08	0.31	3.3e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9888615	0.926	rs12433887	chr14:53322999	G/A	cg00686598	chr14:53173677	PSMC6	-0.5	-6.36	-0.33	6.53e-10	Systolic blood pressure;
LIHC	cis	rs903552	0.935	rs8041582	chr15:102005851	G/A	cg19295451	chr15:102010161	PCSK6	-0.46	-6.33	-0.32	7.51e-10	Diabetic kidney disease;
LIHC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg02487422	chr3:49467188	NICN1	-0.43	-5.72	-0.3	2.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg14146966	chr2:61757674	XPO1	0.47	8.28	0.41	2.83e-15	Tuberculosis;
LIHC	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg07424592	chr7:64974309	NA	0.78	8.92	0.43	2.85e-17	Gout;
LIHC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.23	0.32	1.37e-9	Schizophrenia;
LIHC	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.42	5.73	0.3	2.19e-8	Crohn's disease;
LIHC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg03037974	chr15:76606532	NA	-0.63	-10.8	-0.5	1.38e-23	Blood metabolite levels;
LIHC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.5	8.04	0.4	1.52e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.26	6.87	0.35	3.05e-11	Cardiovascular disease risk factors;
LIHC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-11.92	-0.54	1.24e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg03959625	chr15:84868606	LOC388152	0.42	6.05	0.31	3.84e-9	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.72	-0.3	2.36e-8	Bone mineral density;
LIHC	cis	rs72843506	0.656	rs28567541	chr17:19955102	T/C	cg12065943	chr17:19881925	AKAP10	-0.32	-5.86	-0.3	1.1e-8	Schizophrenia;
LIHC	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.72	-11.53	-0.53	3.33e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.1	0.51	1.16e-24	Menarche (age at onset);
LIHC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.72	12.97	0.57	1.44e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg23254163	chr1:152506842	NA	0.22	5.72	0.3	2.28e-8	Hair morphology;
LIHC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.93	-0.35	2.1e-11	Response to antipsychotic treatment;
LIHC	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg10127483	chr1:110009974	SYPL2	0.48	6.06	0.31	3.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg03934865	chr2:198174659	NA	0.51	7.88	0.39	4.32e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-9.28	-0.45	2.03e-18	Response to antipsychotic treatment;
LIHC	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.66	-10.74	-0.5	2.25e-23	Rheumatoid arthritis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07399355	chr1:155163013	MUC1	0.41	6.65	0.34	1.16e-10	Cognitive function;
LIHC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.73	11.87	0.54	1.91e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs8020095	0.528	rs8004488	chr14:67667402	C/G	cg03487553	chr14:67822707	ATP6V1D	0.35	6.04	0.31	3.92e-9	Depression (quantitative trait);
LIHC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.38	-6.36	-0.33	6.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	8.12e-10	Red blood cell count;
LIHC	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.37	0.45	1.02e-18	Corneal astigmatism;
LIHC	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	9.51	0.46	3.49e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs1866706	0.896	rs10765999	chr11:12859917	C/T	cg25843174	chr11:12811716	TEAD1	-0.31	-6.44	-0.33	4.13e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg26395211	chr5:140044315	WDR55	0.4	5.97	0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.43	6.35	0.32	6.75e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.14	-0.32	2.29e-9	Bipolar disorder;
LIHC	cis	rs8084351	0.577	rs4349221	chr18:50661880	A/G	cg24270629	chr18:50823537	DCC	-0.44	-6.52	-0.33	2.59e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-7.95	-0.39	2.77e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1075232	1.000	rs72722861	chr15:31704288	G/A	cg01030201	chr15:31746330	NA	-0.86	-6.64	-0.34	1.22e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.38	-5.92	-0.3	7.95e-9	Blood pressure (smoking interaction);
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg13511620	chr13:39611918	C13orf23;NHLRC3	0.46	6.16	0.32	2.09e-9	Leprosy;
LIHC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	16.37	0.66	7.03e-45	Smoking behavior;
LIHC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	6.81	0.35	4.49e-11	Menopause (age at onset);
LIHC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.77	-14.71	-0.62	2.61e-38	Mortality in heart failure;
LIHC	cis	rs959260	1.000	rs9900002	chr17:73382018	T/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.8	-0.3	1.51e-8	Systemic lupus erythematosus;
LIHC	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg03806693	chr22:41940476	POLR3H	-0.62	-6.8	-0.35	4.55e-11	Neuroticism;
LIHC	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.66	-12.94	-0.57	1.89e-31	Leprosy;
LIHC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.46	-6.69	-0.34	9.21e-11	Schizophrenia;
LIHC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.68	0.34	9.66e-11	Platelet count;
LIHC	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2e-12	Exhaled nitric oxide output;
LIHC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg04865290	chr3:52927548	TMEM110	-0.51	-5.89	-0.3	9.01e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs55665837	0.701	rs12286408	chr11:14579376	G/A	cg19336497	chr11:14380999	RRAS2	-0.36	-5.94	-0.31	6.82e-9	Vitamin D levels;
LIHC	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	0.97	14.09	0.61	7.13e-36	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.23	-0.32	1.38e-9	Metabolite levels;
LIHC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.39	0.68	5.86e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.51	8.63	0.42	2.33e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01162549	chr5:141367464	RNF14	0.41	6.45	0.33	3.76e-10	Longevity;
LIHC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.29	-0.32	9.94e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.48	7.37	0.37	1.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.47	7.22	0.36	3.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11644362	1.000	rs12934970	chr16:12988077	G/C	cg06890432	chr16:12997467	SHISA9	-0.4	-6.86	-0.35	3.32e-11	Positive affect;Subjective well-being;
LIHC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg18016565	chr1:150552671	MCL1	0.52	9.95	0.47	1.23e-20	Melanoma;
LIHC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg00277334	chr10:82204260	NA	-0.54	-6.75	-0.34	6.5e-11	Post bronchodilator FEV1;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11339965	chr5:93954434	ANKRD32;C5orf36	0.5	6.58	0.34	1.78e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg22079354	chr11:130786696	SNX19	0.41	5.82	0.3	1.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	6.06	0.31	3.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	6.17	0.32	1.96e-9	Coronary artery disease;
LIHC	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.22	13.15	0.58	3.06e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.74	0.57	1.07e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.46	-5.8	-0.3	1.5e-8	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.31	0.64	1.12e-40	Chronic sinus infection;
LIHC	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg14458575	chr2:238380390	NA	0.53	7.21	0.36	3.59e-12	Prostate cancer;
LIHC	cis	rs61712019	0.679	rs11895866	chr2:77716176	A/C	cg11252801	chr2:77748917	LRRTM4	0.56	7.76	0.39	1.01e-13	Schizophrenia;
LIHC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.43	5.87	0.3	1e-8	Life satisfaction;
LIHC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.42	-0.45	6.98e-19	Obesity-related traits;
LIHC	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.39	-6.62	-0.34	1.4e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg25182066	chr10:30743637	MAP3K8	0.45	7.35	0.37	1.46e-12	Inflammatory bowel disease;
LIHC	cis	rs864643	1.000	rs816520	chr3:39569713	C/T	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.54	-0.38	4.37e-13	Bipolar disorder;
LIHC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.28	0.45	2.02e-18	Lung cancer in ever smokers;
LIHC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.64	-8.32	-0.41	2.11e-15	Migraine;
LIHC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.75e-10	Depression;
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.7	-9.97	-0.47	9.87e-21	Bronchopulmonary dysplasia;
LIHC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg10130564	chr11:117069849	TAGLN	0.37	6.19	0.32	1.75e-9	Blood protein levels;
LIHC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.27	6.24	0.32	1.32e-9	Primary biliary cholangitis;
LIHC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg25930673	chr12:123319894	HIP1R	0.85	11.06	0.51	1.6e-24	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.39	7.92	0.39	3.48e-14	Renal cell carcinoma;
LIHC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-6.2	-0.32	1.63e-9	Cognitive test performance;
LIHC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-1.15	-10.21	-0.48	1.54e-21	Breast cancer;
LIHC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg05941027	chr17:61774174	LIMD2	0.34	7.26	0.37	2.7e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.46	6.95	0.35	1.84e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.49	-7.82	-0.39	6.58e-14	Testicular germ cell tumor;
LIHC	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.31	-0.37	1.9e-12	Total body bone mineral density;
LIHC	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.26	6.31	0.32	8.41e-10	Heart rate;
LIHC	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg10820045	chr2:198174542	NA	0.54	8.76	0.43	9e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.76	7.89	0.39	4.24e-14	Chronic kidney disease;
LIHC	cis	rs7264396	0.697	rs6142416	chr20:34174092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.5	8.23	0.41	4.08e-15	Total cholesterol levels;
LIHC	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg14906510	chr12:7781169	NA	-0.47	-6.76	-0.34	5.99e-11	HDL cholesterol levels;
LIHC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.34	-0.55	3.51e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.66	-0.38	1.88e-13	Ulcerative colitis;
LIHC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-8.08	-0.4	1.15e-14	Cognitive function;
LIHC	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.33	6.12	0.31	2.5e-9	Blood pressure (smoking interaction);
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.71	-10.63	-0.5	5.6e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.54	-7.82	-0.39	6.42e-14	Heschl's gyrus morphology;
LIHC	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-0.84	-8.85	-0.43	4.67e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.85	-0.35	3.49e-11	Adiposity;
LIHC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.51	-8.54	-0.42	4.55e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs743757	0.878	rs750510	chr3:50546340	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.38	5.73	0.3	2.22e-8	Diastolic blood pressure;
LIHC	cis	rs6876835	0.511	rs7729233	chr5:6597810	C/T	cg04204831	chr5:6583394	LOC255167	0.42	6.46	0.33	3.67e-10	Visceral fat;
LIHC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.14	0.36	5.5e-12	Lung cancer;
LIHC	cis	rs6545883	0.894	rs778143	chr2:61581890	A/C	cg14146966	chr2:61757674	XPO1	0.42	6.98	0.35	1.53e-11	Tuberculosis;
LIHC	cis	rs2274273	0.967	rs17832359	chr14:55615941	T/C	cg01864836	chr14:55583639	NA	-0.36	-6.14	-0.32	2.27e-9	Protein biomarker;
LIHC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs10847980	0.590	rs12319654	chr12:123327160	C/T	cg22842854	chr12:123319900	HIP1R	0.92	10.44	0.49	2.49e-22	Adiponectin levels;
LIHC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg14779329	chr11:130786720	SNX19	0.39	5.99	0.31	5.36e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg06951627	chr6:26196580	NA	0.53	6.27	0.32	1.07e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	6.96	0.35	1.78e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs7208859	0.673	rs9903862	chr17:29206433	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	7.76	0.39	9.63e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs35883536	1.000	rs11547648	chr1:101106268	G/T	cg14515779	chr1:101123966	NA	-0.67	-13.22	-0.58	1.65e-32	Monocyte count;
LIHC	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg15654264	chr1:150340011	RPRD2	0.49	8.13	0.4	7.9e-15	Migraine;
LIHC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.87	-0.51	7.74e-24	Chronic sinus infection;
LIHC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.41	5.98	0.31	5.47e-9	Height;
LIHC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg19682013	chr15:45996608	NA	0.39	6.63	0.34	1.29e-10	Waist circumference;Weight;
LIHC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg15691649	chr6:25882328	NA	-0.51	-7.43	-0.37	8.62e-13	Blood metabolite levels;
LIHC	cis	rs147538848	1	rs147538848	chr12:31466613	G/A	cg15935736	chr12:31476933	FAM60A;FLJ13224	0.64	5.93	0.31	7.54e-9	Type 2 diabetes;
LIHC	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	10.01	0.48	7.33e-21	Electrocardiographic conduction measures;
LIHC	cis	rs2073300	1.000	rs6114142	chr20:23461082	A/G	cg12062639	chr20:23401060	NAPB	0.79	9.99	0.48	8.63e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg23387056	chr11:14280742	SPON1	0.45	6.24	0.32	1.31e-9	Mitochondrial DNA levels;
LIHC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg10932868	chr11:921992	NA	0.39	7.35	0.37	1.44e-12	Alzheimer's disease (late onset);
LIHC	cis	rs11671005	0.737	rs11671033	chr19:58963669	G/T	cg25952890	chr19:58913133	NA	0.72	7.42	0.37	9.45e-13	Mean platelet volume;
LIHC	cis	rs6586163	0.872	rs1926201	chr10:90746360	G/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.54	-7.82	-0.39	6.61e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.53	8.78	0.43	7.99e-17	Obesity-related traits;
LIHC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.46	7.48	0.37	6.46e-13	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.39	-0.33	5.46e-10	Schizophrenia;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.94	0.31	6.93e-9	Calcium levels;
LIHC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.8	-9.84	-0.47	2.88e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.54	0.33	2.2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs986417	0.901	rs8020084	chr14:61001495	C/T	cg27398547	chr14:60952738	C14orf39	0.79	8.08	0.4	1.09e-14	Gut microbiota (bacterial taxa);
LIHC	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.83	0.43	5.5e-17	Exhaled nitric oxide levels;
LIHC	trans	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg22319618	chr22:45562946	NUP50	-0.59	-8.12	-0.4	8.66e-15	Breast cancer;
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13409248	chr3:40428643	ENTPD3	0.48	7.86	0.39	4.91e-14	Renal cell carcinoma;
LIHC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.97	20.45	0.74	2.68e-61	Height;
LIHC	cis	rs12986413	0.624	rs2238601	chr19:2140374	G/T	cg09261902	chr19:2140048	AP3D1	0.39	6.73	0.34	7.12e-11	Height;
LIHC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg14580859	chr9:123691850	NA	0.37	6.55	0.33	2.11e-10	Rheumatoid arthritis;
LIHC	cis	rs600806	0.889	rs585545	chr1:109841662	A/T	cg23091122	chr1:110024289	SYPL2	-0.46	-5.86	-0.3	1.06e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	6.99	0.35	1.49e-11	Renal cell carcinoma;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.77	-11.38	-0.52	1.13e-25	Menarche (age at onset);
LIHC	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.65	10.12	0.48	3.07e-21	Longevity;Endometriosis;
LIHC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3110496	0.819	rs565977	chr17:27898828	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.45	5.78	0.3	1.7e-8	Height;
LIHC	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-0.81	-11.33	-0.52	1.72e-25	Left atrial antero-posterior diameter;
LIHC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.65	9.55	0.46	2.54e-19	Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.645	rs10769605	chr11:49713723	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.78	0.34	5.32e-11	Height;
LIHC	cis	rs8081395	0.741	rs2645462	chr17:57983559	T/C	cg13753209	chr17:57696993	CLTC	0.38	5.82	0.3	1.33e-8	White blood cell count;
LIHC	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.88	10.03	0.48	6.52e-21	Triglycerides;
LIHC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-10.89	-0.51	6.6e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.83	8.89	0.43	3.5e-17	Vitiligo;
LIHC	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	14.18	0.61	3.16e-36	Coffee consumption (cups per day);
LIHC	trans	rs10511404	1.000	rs6778859	chr3:120517703	G/A	cg09889680	chr22:21922804	UBE2L3	-0.51	-6.51	-0.33	2.65e-10	Tumor necrosis factor alpha levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17317165	chr5:108280702	FER	-0.3	-6.27	-0.32	1.06e-9	Calcium levels;
LIHC	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-13.16	-0.58	2.72e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.88	-17.9	-0.7	4.87e-51	Height;
LIHC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.66	0.38	1.92e-13	IgG glycosylation;
LIHC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.09e-10	Bipolar disorder;
LIHC	cis	rs7187994	0.848	rs16974535	chr16:84783473	G/A	cg07647771	chr16:84786436	USP10	-0.35	-6.91	-0.35	2.44e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.71	-0.34	7.96e-11	Schizophrenia;
LIHC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.86	9.52	0.46	3.2e-19	Cognitive test performance;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg18279126	chr7:2041391	MAD1L1	-0.36	-6.02	-0.31	4.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.41	6.61	0.34	1.52e-10	Schizophrenia;
LIHC	cis	rs2574704	0.781	rs28649408	chr3:11650913	A/T	cg15876825	chr3:11651881	VGLL4	0.45	7.02	0.35	1.2e-11	Body mass index;
LIHC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs17473412	0.677	rs11745493	chr5:122847622	A/G	cg04915494	chr16:2962968	FLYWCH1	-0.46	-6.21	-0.32	1.53e-9	Total body bone mineral density;
LIHC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.44	5.73	0.3	2.18e-8	Schizophrenia;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg15382696	chr6:118971807	C6orf204	0.62	6.45	0.33	3.75e-10	Diastolic blood pressure;
LIHC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.54	-0.46	2.77e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.38	-0.56	2.41e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg05262829	chr1:226921576	ITPKB	0.43	8.28	0.41	2.76e-15	Parkinson's disease;
LIHC	cis	rs9898641	1	rs9898641	chr17:57571033	T/C	cg02344993	chr17:57696989	CLTC	0.45	6.84	0.35	3.63e-11	Interleukin-1-beta levels;
LIHC	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.5	5.82	0.3	1.34e-8	Coronary artery disease;
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg19318889	chr4:1322082	MAEA	0.67	10.46	0.49	2.12e-22	Longevity;
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-8.66	-0.42	1.86e-16	Prudent dietary pattern;
LIHC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.86	-0.39	5.13e-14	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.79	0.3	1.6e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg10756647	chr7:56101905	PSPH	1.06	13.28	0.58	9.29e-33	Diabetic kidney disease;
LIHC	cis	rs7220401	0.515	rs8080772	chr17:28413129	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.08	-0.4	1.13e-14	Coronary artery disease;
LIHC	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg09572067	chr16:29127029	RRN3P2	0.51	8.22	0.41	4.35e-15	Menopause (age at onset);
LIHC	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.37	0.37	1.3e-12	Diastolic blood pressure;
LIHC	trans	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg14791747	chr16:20752902	THUMPD1	0.49	6.7	0.34	8.38e-11	Dental caries;
LIHC	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.49	8.02	0.4	1.7e-14	Corneal astigmatism;
LIHC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	1.04	15.21	0.64	3.01e-40	Breast cancer;
LIHC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.61	11.18	0.52	6.06e-25	Coronary artery disease;
LIHC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.1	0.36	7.27e-12	Aortic root size;
LIHC	cis	rs2073300	1.000	rs6114138	chr20:23457350	G/A	cg12062639	chr20:23401060	NAPB	0.78	9.7	0.46	8.37e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs2380220	0.808	rs2613554	chr6:95916782	C/A	cg15832292	chr6:96025679	MANEA	-0.62	-7.02	-0.35	1.2e-11	Behavioural disinhibition (generation interaction);
LIHC	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	0.96	14.75	0.62	1.96e-38	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.6	0.42	2.93e-16	Motion sickness;
LIHC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg16586182	chr3:47516702	SCAP	0.49	8.87	0.43	4.11e-17	Colorectal cancer;
LIHC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08280861	chr8:58055591	NA	0.49	6.13	0.31	2.38e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg23978390	chr7:1156363	C7orf50	0.5	7.26	0.37	2.62e-12	Longevity;Endometriosis;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.14	-0.36	5.64e-12	Renal cell carcinoma;
LIHC	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.79	-0.34	4.97e-11	Blood pressure;
LIHC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.34	6.78	0.34	5.26e-11	Renal cell carcinoma;
LIHC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-10.62	-0.5	5.79e-23	Alzheimer's disease (late onset);
LIHC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.47	-5.99	-0.31	5.3300000000000004e-09	Breast cancer;
LIHC	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.31	-8.28	-0.41	2.86e-15	Intelligence;
LIHC	cis	rs1144333	0.737	rs1144339	chr1:76280543	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.78	-0.34	5.34e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg25039879	chr17:56429692	SUPT4H1	0.76	8.76	0.43	9.52e-17	Cognitive test performance;
LIHC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.44	-7.47	-0.37	6.58e-13	Dementia with Lewy bodies;
LIHC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.46	-8.01	-0.4	1.76e-14	Alzheimer's disease (late onset);
LIHC	cis	rs116248771	0.739	rs4679831	chr3:158320988	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.08	0.31	3.12e-9	diarrhoeal disease at age 2;
LIHC	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.85	14.35	0.61	7.24e-37	Body mass index;
LIHC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.92	-14.92	-0.63	4.12e-39	Cognitive ability;
LIHC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.15	26.36	0.82	2.29e-84	Cognitive ability;
LIHC	cis	rs861020	0.560	rs649275	chr1:209950681	T/C	cg09163369	chr1:210001066	C1orf107	0.39	5.78	0.3	1.69e-8	Orofacial clefts;
LIHC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg25344623	chr2:136566232	LCT	-0.41	-8.27	-0.41	3.04e-15	Mosquito bite size;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14334965	chr14:100705150	YY1	-0.58	-6.58	-0.34	1.82e-10	Systolic blood pressure;
LIHC	cis	rs72627509	0.638	rs78272732	chr4:57870537	T/A	cg26694713	chr4:57773883	REST	0.66	8.8	0.43	6.82e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6466055	0.739	rs6943183	chr7:104819479	T/C	cg04380332	chr7:105027541	SRPK2	-0.35	-6.61	-0.34	1.47e-10	Schizophrenia;
LIHC	cis	rs12922317	1.000	rs16958792	chr16:12075684	C/A	cg09319797	chr16:12061715	TNFRSF17	0.42	7.28	0.37	2.33e-12	Schizophrenia;
LIHC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg27478167	chr7:817139	HEATR2	-0.51	-6.75	-0.34	6.36e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.74	-0.39	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.18	-0.61	3.33e-36	Alzheimer's disease;
LIHC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.98	-0.35	1.5e-11	Neuroticism;
LIHC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs67981189	0.574	rs2010713	chr14:71368735	T/G	cg15816911	chr14:71606274	NA	-0.41	-6.55	-0.33	2.13e-10	Schizophrenia;
LIHC	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg04450456	chr4:17643702	FAM184B	0.33	5.74	0.3	2.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg17135325	chr3:160939158	NMD3	0.53	7.66	0.38	1.88e-13	Parkinson's disease;
LIHC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-7.05	-0.36	9.92e-12	Diabetic kidney disease;
LIHC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.38	6.88	0.35	2.81e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.18	0.32	1.86e-9	Cognitive ability;
LIHC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.57	0.33	1.92e-10	Rheumatoid arthritis;
LIHC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg24209194	chr3:40518798	ZNF619	0.6	8.65	0.42	2.08e-16	Renal cell carcinoma;
LIHC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.42	-6.56	-0.33	2.03e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg18944383	chr4:111397179	ENPEP	0.29	7.16	0.36	4.84e-12	Height;
LIHC	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.41	5.77	0.3	1.76e-8	Tuberculosis;
LIHC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-9.35	-0.45	1.18e-18	Primary sclerosing cholangitis;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.99	0.54	6.75e-28	Prudent dietary pattern;
LIHC	cis	rs7577696	0.568	rs410469	chr2:32476992	G/T	cg02381751	chr2:32503542	YIPF4	-0.47	-6.61	-0.34	1.46e-10	Inflammatory biomarkers;
LIHC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg14440974	chr22:39074834	NA	-0.38	-5.91	-0.3	8.33e-9	Menopause (age at onset);
LIHC	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg23109721	chr2:106886537	NA	-0.65	-5.98	-0.31	5.59e-9	Facial morphology (factor 23);
LIHC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-8.64	-0.42	2.21e-16	Crohn's disease;
LIHC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	11.83	0.54	2.74e-27	Platelet count;
LIHC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg18944383	chr4:111397179	ENPEP	0.27	7.13	0.36	6.13e-12	Height;
LIHC	cis	rs17106184	1.000	rs1278522	chr1:50895031	T/C	cg07174182	chr1:51127561	FAF1	-0.55	-6.18	-0.32	1.81e-9	Type 2 diabetes;
LIHC	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg08539965	chr1:21396338	EIF4G3	0.34	5.91	0.3	8.14e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.48	-7.47	-0.37	6.85e-13	Bone mineral density (spine);
LIHC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.76	12.82	0.57	5.22e-31	Anterior chamber depth;
LIHC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg18944383	chr4:111397179	ENPEP	0.28	7.09	0.36	7.98e-12	Height;
LIHC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.23	-0.32	1.37e-9	Obesity-related traits;
LIHC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-10.73	-0.5	2.49e-23	Alzheimer's disease (late onset);
LIHC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.14	-0.32	2.23e-9	Vitiligo;
LIHC	cis	rs12101261	0.560	rs1035144	chr14:81445121	C/T	cg06600135	chr14:81408086	NA	0.43	7.72	0.39	1.26e-13	Graves' disease;
LIHC	trans	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg17712092	chr4:129076599	LARP1B	-0.67	-9.78	-0.47	4.34e-20	Eosinophil percentage of white cells;
LIHC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg05425664	chr17:57184151	TRIM37	-0.42	-5.83	-0.3	1.25e-8	Testicular germ cell tumor;
LIHC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.81	-0.3	1.45e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg02811702	chr13:24901961	NA	0.24	5.83	0.3	1.3e-8	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg00280220	chr17:61926910	NA	-0.43	-6.94	-0.35	1.99e-11	Prudent dietary pattern;
LIHC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	12.15	0.55	1.74e-28	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16890600	chr5:98265530	NA	0.48	7.04	0.36	1.08e-11	Cognitive function;
LIHC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.59	-0.34	1.64e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-8.6	-0.42	2.88e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg23978390	chr7:1156363	C7orf50	0.49	7.52	0.38	4.81e-13	Longevity;Endometriosis;
LIHC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.68	12.24	0.55	8.15e-29	Breast cancer;
LIHC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	21.25	0.75	1.83e-64	Body mass index (adult);
LIHC	trans	rs7668874	0.731	rs7691188	chr4:116746338	G/C	cg08917878	chr5:172668965	NA	-0.3	-6.05	-0.31	3.89e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.48	-7.72	-0.39	1.29e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.6e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.23	-0.75	2.11e-64	Height;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.46	7.49	0.38	5.93e-13	Longevity;Endometriosis;
LIHC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.41	7.39	0.37	1.17e-12	Aortic root size;
LIHC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.72	-8.9	-0.43	3.21e-17	Systemic lupus erythematosus;
LIHC	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.4	-6.16	-0.32	2.04e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21747090	chr2:27597821	SNX17	-0.41	-6.02	-0.31	4.53e-9	Total body bone mineral density;
LIHC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs716804	0.740	rs11602090	chr11:10194694	A/G	cg01453529	chr11:10209919	SBF2	-0.29	-5.75	-0.3	1.96e-8	Neuroticism;
LIHC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.86	-15.23	-0.64	2.34e-40	Lung cancer in ever smokers;
LIHC	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	trans	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg26113512	chr3:38035601	VILL	-0.53	-6.09	-0.31	3e-9	Alzheimer's disease;
LIHC	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.34	-7.15	-0.36	5.15e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.42	6.8	0.35	4.66e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.45	5.72	0.3	2.35e-8	Mean platelet volume;
LIHC	cis	rs3780378	1.000	rs7847294	chr9:5097281	A/C	cg02405213	chr9:5042618	JAK2	-0.44	-7.37	-0.37	1.33e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.25	0.32	1.25e-9	Lymphocyte counts;
LIHC	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.24	-0.32	1.29e-9	Coronary artery disease;
LIHC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.68	0.59	2.85e-34	Lung cancer in ever smokers;
LIHC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.3	-16.95	-0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.18	-0.32	1.83e-9	Coronary artery disease;
LIHC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.44	-7.05	-0.36	9.88e-12	Alcohol dependence;
LIHC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02475777	chr4:1388615	CRIPAK	0.41	6.01	0.31	4.79e-9	Longevity;
LIHC	cis	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg18809830	chr7:99032528	PTCD1	-0.8	-6.15	-0.32	2.16e-9	Blood metabolite levels;
LIHC	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg20991723	chr1:152506922	NA	0.41	6.43	0.33	4.37e-10	Hair morphology;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg01699524	chr5:7869638	MTRR;FASTKD3	-0.53	-6.69	-0.34	9.31e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.5	8.07	0.4	1.24e-14	Corneal astigmatism;
LIHC	cis	rs9896052	0.614	rs6501803	chr17:73450225	C/T	cg25649188	chr17:73499917	CASKIN2	0.44	6.57	0.33	1.86e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.48e-9	Resting heart rate;
LIHC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.52	0.49	1.33e-22	Obesity-related traits;
LIHC	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.54	6.21	0.32	1.54e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg16275483	chr1:110013120	SYPL2	-0.5	-6.35	-0.32	6.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.81	0.3	1.44e-8	Resting heart rate;
LIHC	cis	rs611744	0.870	rs638905	chr8:109203406	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs74233809	1.000	rs75970938	chr10:104793648	T/C	cg03493300	chr10:104813866	CNNM2	0.47	6.17	0.32	1.97e-9	Birth weight;
LIHC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.48	11.13	0.52	9.45e-25	Iron status biomarkers (transferrin levels);
LIHC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg23533926	chr12:111358616	MYL2	-0.32	-6.33	-0.32	7.86e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.96	0.6	2.2e-35	Chronic sinus infection;
LIHC	cis	rs6750047	0.719	rs1583171	chr2:38270107	G/A	cg07380506	chr2:38303506	CYP1B1	0.52	6.19	0.32	1.77e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.63	9.72	0.47	7.21e-20	Tonsillectomy;
LIHC	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.52	7.86	0.39	5.12e-14	Verbal declarative memory;
LIHC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.05	0.31	3.8e-9	Morning vs. evening chronotype;
LIHC	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs9596863	1.000	rs9596866	chr13:54459385	A/T	ch.13.53330881F	chr13:54432880	NA	0.46	6.13	0.31	2.48e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.25e-19	Corneal astigmatism;
LIHC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.93	0.31	7.56e-9	Schizophrenia;
LIHC	trans	rs3783890	1.000	rs12896142	chr14:93783443	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.32	0.32	8.12e-10	Body mass index;
LIHC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.35	-0.61	7.13e-37	Alzheimer's disease;
LIHC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.11	-0.44	7.27e-18	Schizophrenia;
LIHC	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.92	0.47	1.54e-20	Coffee consumption (cups per day);
LIHC	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.66	11.41	0.53	9.11e-26	Pediatric autoimmune diseases;
LIHC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg12751644	chr20:60527061	NA	-0.36	-5.94	-0.31	6.96e-9	Body mass index;
LIHC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-5.96	-0.31	6.32e-9	Response to antipsychotic treatment;
LIHC	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.45e-10	Pulmonary function;
LIHC	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	7.81	0.39	6.89e-14	Schizophrenia;
LIHC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.61	-7.55	-0.38	3.91e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg20368463	chr18:77673604	PQLC1	-0.5	-6.01	-0.31	4.8e-9	Opioid sensitivity;
LIHC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-9.41	-0.45	7.35e-19	Initial pursuit acceleration;
LIHC	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.45	-7.14	-0.36	5.57e-12	Multiple sclerosis;
LIHC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.78	15.47	0.64	2.74e-41	Mortality in heart failure;
LIHC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.41e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-5.73	-0.3	2.17e-8	Diastolic blood pressure;
LIHC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.63	9.65	0.46	1.16e-19	Longevity;
LIHC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.27	0.55	6.2e-29	Menopause (age at onset);
LIHC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.88	-0.47	2.07e-20	Total cholesterol levels;
LIHC	cis	rs2412488	0.925	rs1600795	chr4:54221952	T/G	cg22241045	chr4:54363911	LNX1	-0.43	-6.69	-0.34	9.27e-11	DNA methylation (variation);
LIHC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.7	-10.8	-0.5	1.39e-23	Urate levels in obese individuals;
LIHC	cis	rs4728302	0.869	rs6955707	chr7:133612188	G/A	cg10665199	chr7:133106180	EXOC4	0.39	6.72	0.34	7.82e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.66	0.42	1.83e-16	Exhaled nitric oxide output;
LIHC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.38	6.32	0.32	8.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg07393940	chr7:158741817	NA	0.56	6.73	0.34	7.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.53	0.56	6.97e-30	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.39e-8	Blood protein levels;
LIHC	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.87	-16.01	-0.65	1.9e-43	Schizophrenia;
LIHC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg07713946	chr22:31675144	LIMK2	-0.43	-7.8	-0.39	7.68e-14	Colorectal cancer;
LIHC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg23172400	chr8:95962367	TP53INP1	0.38	7.7	0.38	1.45e-13	Type 2 diabetes;
LIHC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.93	15.25	0.64	2.01e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.54	-7.05	-0.36	9.96e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg14146966	chr2:61757674	XPO1	0.48	8.4	0.41	1.21e-15	Tuberculosis;
LIHC	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.91	11.51	0.53	3.89e-26	Coronary artery disease;
LIHC	cis	rs1639906	0.708	rs3779013	chr7:2210844	A/G	cg02951883	chr7:2050386	MAD1L1	-0.55	-7.19	-0.36	4.17e-12	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs983392	0.680	rs56357056	chr11:59986817	A/G	cg17275991	chr19:58003312	ZNF419	0.44	6.23	0.32	1.4e-9	Alzheimer's disease (late onset);
LIHC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.83	-0.35	4e-11	Psoriasis;
LIHC	cis	rs12986413	0.935	rs36065733	chr19:2163771	T/G	cg09261902	chr19:2140048	AP3D1	0.37	6.36	0.33	6.56e-10	Height;
LIHC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.36	-5.72	-0.3	2.39e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.31	-0.37	1.95e-12	Tuberculosis;
LIHC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.39	5.87	0.3	1.04e-8	Red cell distribution width;
LIHC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.6	-7.58	-0.38	3.21e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.51	7.32	0.37	1.76e-12	Body mass index;
LIHC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	8.96	0.44	2.22e-17	Body mass index (adult);
LIHC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.57	9.64	0.46	1.32e-19	Colorectal cancer;
LIHC	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.53	8.01	0.4	1.82e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.16	-0.4	6.4e-15	Glycated hemoglobin levels;
LIHC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11987759	chr7:65425863	GUSB	0.39	6.21	0.32	1.56e-9	Aortic root size;
LIHC	cis	rs7523273	0.565	rs2488248	chr1:207899682	C/T	cg22525895	chr1:207977042	MIR29B2	-0.54	-8.24	-0.41	3.76e-15	Schizophrenia;
LIHC	cis	rs3736594	0.513	rs6751087	chr2:27778016	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.82	0.35	4.26e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg14515779	chr1:101123966	NA	0.56	7.93	0.39	3.15e-14	Monocyte count;
LIHC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.3	0.58	7.79e-33	Cognitive test performance;
LIHC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.15e-9	Mortality in heart failure;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg00280220	chr17:61926910	NA	0.42	6.89	0.35	2.73e-11	Prudent dietary pattern;
LIHC	cis	rs12079745	0.793	rs10800430	chr1:169276782	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	1.94e-11	QT interval;
LIHC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg00990874	chr7:1149470	C7orf50	-0.54	-8.08	-0.4	1.11e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg11062466	chr8:58055876	NA	0.5	6.9	0.35	2.56e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.86	-0.3	1.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.5	0.38	5.41e-13	Menarche (age at onset);
LIHC	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	8.8	0.43	6.71e-17	Schizophrenia;
LIHC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.84	8.01	0.4	1.88e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	0.57	10.01	0.48	7.23e-21	Methadone dose in opioid dependence;
LIHC	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-0.72	-6.88	-0.35	2.92e-11	Putamen volume;
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg08229694	chr2:86422197	IMMT	0.42	6.05	0.31	3.8e-9	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.35	5.72	0.3	2.35e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg18129178	chr5:148520854	ABLIM3	-0.37	-6.16	-0.32	2.09e-9	Breast cancer;
LIHC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.37	5.71	0.3	2.42e-8	Coronary artery disease;
LIHC	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg20240347	chr1:204465584	NA	-0.33	-6.99	-0.35	1.44e-11	Schizophrenia;
LIHC	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.4	-0.41	1.22e-15	Colorectal cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03793131	chr1:43833547	ELOVL1	0.49	6.73	0.34	7.21e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.39	-6.16	-0.32	1.99e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-6.0	-0.31	4.89e-9	Menarche (age at onset);
LIHC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-10.09	-0.48	3.99e-21	Body mass index (adult);
LIHC	cis	rs10463316	0.779	rs6896444	chr5:150777357	T/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.2	-0.32	1.59e-9	Metabolite levels (Pyroglutamine);
LIHC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg18944383	chr4:111397179	ENPEP	-0.28	-6.52	-0.33	2.55e-10	Coronary artery disease;
LIHC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.63	-0.42	2.35e-16	Lymphocyte counts;
LIHC	cis	rs11212260	0.512	rs76580404	chr11:107191013	T/C	cg25435332	chr11:107328525	CWF19L2	0.75	6.87	0.35	3e-11	IgG glycosylation;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.72	-10.94	-0.51	4.23e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg00343986	chr7:65444356	GUSB	-0.39	-5.81	-0.3	1.45e-8	Aortic root size;
LIHC	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg05865280	chr17:75406074	SEPT9	0.62	11.27	0.52	2.89e-25	Airflow obstruction;
LIHC	cis	rs11098699	0.784	rs11098701	chr4:124216461	C/G	cg09941581	chr4:124220074	SPATA5	0.33	6.66	0.34	1.1e-10	Mosquito bite size;
LIHC	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg26811252	chr16:29126840	RRN3P2	0.42	6.88	0.35	2.89e-11	Menopause (age at onset);
LIHC	trans	rs668210	0.793	rs677350	chr11:65761967	G/A	cg17712092	chr4:129076599	LARP1B	0.56	6.1	0.31	2.84e-9	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-13.42	-0.59	2.77e-33	Height;
LIHC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.52	-6.48	-0.33	3.21e-10	Menarche (age at onset);
LIHC	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.3	7.49	0.38	5.79e-13	Gut microbiome composition (winter);
LIHC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg21466736	chr12:48725269	NA	0.33	5.76	0.3	1.9e-8	Plateletcrit;
LIHC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	1.02	19.7	0.73	2.9e-58	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13798302	chr4:100870323	LOC256880;H2AFZ	0.43	6.48	0.33	3.11e-10	Cognitive function;
LIHC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.63	-10.38	-0.49	3.9e-22	Resting heart rate;
LIHC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.09	-0.31	2.99e-9	Obesity-related traits;
LIHC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.48	-7.65	-0.38	2.11e-13	Electroencephalogram traits;
LIHC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.68	0.34	9.43e-11	Bipolar disorder;
LIHC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.75	-9.35	-0.45	1.18e-18	Primary sclerosing cholangitis;
LIHC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02985541	chr2:219472218	PLCD4	-0.44	-7.11	-0.36	6.69e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg14250997	chr9:106856677	SMC2	0.43	7.46	0.37	7.24e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg26939375	chr7:64535504	NA	0.47	7.15	0.36	5.33e-12	Calcium levels;
LIHC	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05731713	chr7:157510257	PTPRN2	0.24	6.45	0.33	3.84e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1775715	0.870	rs11008700	chr10:32236937	A/G	cg14930904	chr10:32216787	ARHGAP12	0.39	6.99	0.35	1.43e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.88	16.85	0.67	8.59e-47	Blood protein levels;
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg14440974	chr22:39074834	NA	0.41	6.46	0.33	3.56e-10	Menopause (age at onset);
LIHC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	5.85	0.3	1.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.1	9.99	0.48	8.93e-21	Diabetic retinopathy;
LIHC	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.17	-0.32	1.95e-9	Pancreatic cancer;
LIHC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	9.07	0.44	9.8e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.65	-7.67	-0.38	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg26939375	chr7:64535504	NA	-0.4	-6.49	-0.33	2.95e-10	Aortic root size;
LIHC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-6.6	-0.34	1.54e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg12365402	chr11:9010492	NRIP3	0.3	7.72	0.39	1.29e-13	Hemoglobin concentration;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.79	12.26	0.55	6.93e-29	Menarche (age at onset);
LIHC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.73	-10.54	-0.5	1.14e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.81	0.35	4.41e-11	Educational attainment;
LIHC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg20302533	chr7:39170763	POU6F2	0.32	6.33	0.32	7.48e-10	IgG glycosylation;
LIHC	cis	rs16958440	1.000	rs2289132	chr18:44602292	G/A	cg17192377	chr18:44677553	HDHD2	0.59	6.52	0.33	2.56e-10	Sitting height ratio;
LIHC	cis	rs77633900	0.881	rs1875883	chr15:76638231	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-5.89	-0.3	9.09e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-14.27	-0.61	1.48e-36	Heart rate;
LIHC	cis	rs918629	0.798	rs3777162	chr5:95293412	G/A	cg10483112	chr5:95245456	ELL2	-0.35	-6.05	-0.31	3.91e-9	IgG glycosylation;
LIHC	cis	rs3736485	0.934	rs12442803	chr15:51898754	C/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.07	-0.31	3.31e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4684776	0.676	rs2067472	chr3:11299190	G/C	cg00170343	chr3:11313890	ATG7	-0.48	-6.47	-0.33	3.31e-10	Small vessel stroke;
LIHC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.45	6.05	0.31	3.8e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.96	-0.35	1.74e-11	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.44	-6.42	-0.33	4.43e-10	Triglycerides;
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.57	6.84	0.35	3.72e-11	Alzheimer's disease;
LIHC	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg22705602	chr4:152727874	NA	-0.31	-6.45	-0.33	3.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.23e-19	Hemoglobin concentration;
LIHC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.92	-17.1	-0.68	8.54e-48	Aortic root size;
LIHC	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.47	8.88	0.43	3.75e-17	Testicular germ cell tumor;
LIHC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.76	0.34	5.91e-11	Rheumatoid arthritis;
LIHC	cis	rs7635838	0.785	rs904475	chr3:11535417	G/A	cg00170343	chr3:11313890	ATG7	0.39	6.07	0.31	3.33e-9	HDL cholesterol;
LIHC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.48	6.93	0.35	2.07e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg19682013	chr15:45996608	NA	0.38	6.52	0.33	2.53e-10	Waist circumference;Weight;
LIHC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.62	-9.83	-0.47	3.06e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg20195005	chr22:42527684	CYP2D6	0.31	5.79	0.3	1.57e-8	Birth weight;
LIHC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.47	-7.01	-0.35	1.29e-11	HDL cholesterol;
LIHC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.43	5.72	0.3	2.27e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2710642	0.849	rs4671450	chr2:62981869	C/A	cg17519650	chr2:63277830	OTX1	-0.54	-8.38	-0.41	1.44e-15	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	11.25	0.52	3.54e-25	Myopia (pathological);
LIHC	cis	rs7116495	1.000	rs596629	chr11:71562576	T/C	cg26138937	chr11:71823887	C11orf51	0.67	6.52	0.33	2.6e-10	Severe influenza A (H1N1) infection;
LIHC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.17	0.44	4.38e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.42	6.68	0.34	9.42e-11	Mean corpuscular volume;
LIHC	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg11204139	chr17:3907470	NA	-0.47	-6.16	-0.32	2.05e-9	Type 2 diabetes;
LIHC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.38	-11.69	-0.53	8.8e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg24004478	chr7:855632	UNC84A	0.49	8.06	0.4	1.3e-14	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.67	0.34	1.01e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22975147	chr17:8021903	ALOXE3	0.39	6.59	0.34	1.7e-10	Cognitive function;
LIHC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg25356066	chr3:128598488	ACAD9	0.53	7.39	0.37	1.14e-12	IgG glycosylation;
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg14709524	chr16:89940631	TCF25	0.59	7.53	0.38	4.51e-13	Skin colour saturation;
LIHC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-10.95	-0.51	4.06e-24	Primary sclerosing cholangitis;
LIHC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.46	0.37	7.18e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	6.77	0.34	5.56e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.87	-0.3	1.02e-8	Pulse pressure;
LIHC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg12373951	chr3:133503437	NA	-0.54	-9.29	-0.45	1.87e-18	Iron status biomarkers;
LIHC	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.51	7.44	0.37	8.48e-13	Height;
LIHC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.49	-6.32	-0.32	8.13e-10	Pancreatic cancer;
LIHC	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.53	-8.33	-0.41	1.96e-15	Endometriosis;
LIHC	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.13	-0.4	7.86e-15	Response to antipsychotic treatment;
LIHC	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.6	9.69	0.46	9.01e-20	Corneal astigmatism;
LIHC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.62	-0.59	4.61e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-8.43	-0.41	1e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs12295403	1.000	rs12789252	chr11:18690389	C/T	cg09887367	chr11:18690185	NA	-0.4	-6.82	-0.35	4.09e-11	Ovarian reserve;
LIHC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.75	-11.68	-0.53	9.53e-27	Body mass index;
LIHC	cis	rs10419226	0.625	rs12980154	chr19:18770119	C/T	cg14292368	chr19:18793705	CRTC1	-0.54	-8.99	-0.44	1.68e-17	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg08125733	chr17:73851984	WBP2	0.51	8.24	0.41	3.84e-15	White matter hyperintensity burden;
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.55	-8.27	-0.41	3.11e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.49	-7.74	-0.39	1.1e-13	Diastolic blood pressure;
LIHC	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg10631902	chr5:14652156	NA	-0.26	-6.47	-0.33	3.37e-10	Hip circumference;Waist circumference;
LIHC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg21724239	chr8:58056113	NA	0.48	6.36	0.33	6.43e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg04585227	chr7:158671570	WDR60	0.42	6.17	0.32	1.89e-9	Alopecia areata;
LIHC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02290350	chr8:58132656	NA	0.45	8.65	0.42	2.09e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg10381502	chr11:71823885	C11orf51	-1.08	-9.2	-0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.08	-0.36	8.34e-12	Heart rate;
LIHC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.55	-7.2	-0.36	3.93e-12	Type 2 diabetes;
LIHC	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.53	-0.42	4.87e-16	Body mass index;
LIHC	cis	rs2421770	0.530	rs4755396	chr11:35370624	G/A	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.6	-0.38	2.86e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-13.58	-0.59	6.9e-34	Total body bone mineral density;
LIHC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.47	15.71	0.65	3.08e-42	Eosinophil percentage of granulocytes;
LIHC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.37	0.59	4.49e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.36	-5.83	-0.3	1.25e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.76	-0.3	1.85e-8	Systemic lupus erythematosus;
LIHC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.48	7.99	0.4	2.14e-14	Schizophrenia;
LIHC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.37	6.9	0.35	2.55e-11	Ewing sarcoma;
LIHC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.81	12.38	0.56	2.51e-29	Corneal astigmatism;
LIHC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.12	-0.4	8.27e-15	Response to antipsychotic treatment;
LIHC	cis	rs3781458	0.803	rs10901793	chr10:126324209	G/A	cg20435097	chr10:126320824	FAM53B	0.73	13.34	0.59	5.56e-33	Male-pattern baldness;
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.49	-0.33	3.03e-10	Total body bone mineral density;
LIHC	cis	rs9980664	1.000	rs9975639	chr21:34736479	C/T	cg04842828	chr21:34696676	IFNAR1	0.47	6.23	0.32	1.39e-9	Cognitive decline (age-related);
LIHC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-7.39	-0.37	1.15e-12	Melanoma;
LIHC	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	6.92	0.35	2.26e-11	Type 2 diabetes;
LIHC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.5	-8.8	-0.43	7.01e-17	Neuroticism;
LIHC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg12374095	chr12:54320830	NA	0.46	7.05	0.36	9.75e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs41271473	0.539	rs763519	chr1:228892855	A/G	cg00850481	chr1:228891306	NA	0.42	6.24	0.32	1.3e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.34	-6.78	-0.34	5.14e-11	Multiple system atrophy;
LIHC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00612595	chr21:47717864	NA	-0.4	-6.57	-0.33	1.9e-10	Testicular germ cell tumor;
LIHC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.66	8.28	0.41	2.87e-15	Mean platelet volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15617699	chr3:38538063	EXOG	0.43	6.16	0.32	2.1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.49	-0.59	1.55e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg00529422	chr1:16285251	ZBTB17	-0.34	-6.54	-0.33	2.19e-10	Systolic blood pressure;
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.5	-7.91	-0.39	3.69e-14	Educational attainment;
LIHC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg03934865	chr2:198174659	NA	-0.55	-8.65	-0.42	2.1e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13394619	0.840	rs11674605	chr2:11722575	A/G	cg07314298	chr2:11723111	GREB1	-0.52	-10.29	-0.49	7.93e-22	Endometriosis;
LIHC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs16828019	0.852	rs71648540	chr1:41722295	G/A	cg03962019	chr1:41807865	NA	0.5	7.19	0.36	4.21e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg11062466	chr8:58055876	NA	0.41	6.26	0.32	1.14e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17152411	0.652	rs10901842	chr10:126635262	C/T	cg07906193	chr10:126599966	NA	0.28	5.74	0.3	2.05e-8	Height;
LIHC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.44	-0.33	4.17e-10	Crohn's disease;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.72	10.22	0.48	1.45e-21	Menarche (age at onset);
LIHC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg02931644	chr1:25747376	RHCE	0.35	7.7	0.38	1.43e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.0	-9.54	-0.46	2.7e-19	Diabetic retinopathy;
LIHC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.63	10.46	0.49	2.2e-22	Crohn's disease;
LIHC	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.13	-0.44	5.97e-18	Exhaled nitric oxide output;
LIHC	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.48	-6.25	-0.32	1.2e-9	Pursuit maintenance gain;
LIHC	trans	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.14	-0.36	5.52e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-7.98	-0.4	2.23e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.47	8.29	0.41	2.69e-15	Pubertal anthropometrics;
LIHC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.61	8.86	0.43	4.31e-17	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg22153463	chr1:85462885	MCOLN2	-0.53	-6.5	-0.33	2.92e-10	Serum sulfate level;
LIHC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.42	6.51	0.33	2.63e-10	Resting heart rate;
LIHC	cis	rs243505	0.762	rs2007404	chr7:148487395	A/G	cg09806900	chr7:148480153	CUL1	0.44	6.62	0.34	1.36e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2073300	1.000	rs6137967	chr20:23447108	A/T	cg12062639	chr20:23401060	NAPB	-0.75	-9.01	-0.44	1.43e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12463550	chr7:65579703	CRCP	0.7	7.19	0.36	4.15e-12	Diabetic kidney disease;
LIHC	cis	rs6432852	0.516	rs12477613	chr2:166717184	G/C	cg15343463	chr2:166634454	GALNT3	0.37	5.97	0.31	5.99e-9	Diabetic kidney disease;
LIHC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg08676812	chr11:65308423	LTBP3	1.05	7.32	0.37	1.84e-12	Height;
LIHC	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.71	10.1	0.48	3.61e-21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.87	11.06	0.51	1.67e-24	Nonalcoholic fatty liver disease;
LIHC	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.67	11.4	0.52	9.8e-26	Superior crus of antihelix expression;
LIHC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.64	0.34	1.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.4	6.35	0.32	6.71e-10	Multiple sclerosis;
LIHC	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.66	-10.09	-0.48	4.02e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.65	11.61	0.53	1.74e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08280861	chr8:58055591	NA	0.51	6.39	0.33	5.56e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	8.55	0.42	4.11e-16	Platelet count;
LIHC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.57	0.53	2.34e-26	Tonsillectomy;
LIHC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.3	-5.76	-0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs886774	0.705	rs10271464	chr7:107579603	A/G	cg27274322	chr4:1357073	KIAA1530	0.35	6.14	0.32	2.33e-9	Ulcerative colitis;
LIHC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.21	19.87	0.73	5.66e-59	Primary sclerosing cholangitis;
LIHC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.27	-0.45	2.12e-18	Bipolar disorder;
LIHC	trans	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg20452738	chr1:226828650	ITPKB	-0.21	-6.08	-0.31	3.21e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.48	-5.77	-0.3	1.78e-8	Parkinson's disease;
LIHC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg08949735	chr16:89699720	DPEP1	-0.46	-6.51	-0.33	2.63e-10	Vitiligo;
LIHC	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.36	0.41	1.64e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs847649	0.692	rs10271184	chr7:102477176	A/G	cg18108683	chr7:102477205	FBXL13	-0.54	-8.61	-0.42	2.71e-16	Morning vs. evening chronotype;
LIHC	cis	rs3780378	0.934	rs10815146	chr9:5015901	T/A	cg02405213	chr9:5042618	JAK2	-0.55	-9.59	-0.46	1.95e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.8	-12.61	-0.56	3.26e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.47	0.42	7.57e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.51	7.52	0.38	4.93e-13	Type 2 diabetes;
LIHC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg19318889	chr4:1322082	MAEA	0.38	5.81	0.3	1.44e-8	Longevity;
LIHC	trans	rs12080794	0.740	rs12726928	chr1:9190254	G/T	cg16853660	chr11:32816211	CCDC73	-0.73	-6.54	-0.33	2.27e-10	Response to antidepressant treatment (citalopram);
LIHC	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.38	6.44	0.33	4.14e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.04	-0.48	5.98e-21	Response to antipsychotic treatment;
LIHC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.91	-0.39	3.57e-14	Total body bone mineral density;
LIHC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.44	7.23	0.36	3.16e-12	Red blood cell count;
LIHC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.55	-9.53	-0.46	3.12e-19	Reticulocyte count;
LIHC	cis	rs986417	0.901	rs1950310	chr14:60988526	T/A	cg27398547	chr14:60952738	C14orf39	0.83	9.55	0.46	2.51e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.42	-6.55	-0.33	2.14e-10	Red blood cell count;
LIHC	cis	rs17001868	0.892	rs12483888	chr22:40801312	A/G	cg07138101	chr22:40742427	ADSL	0.55	5.77	0.3	1.82e-8	Mammographic density (dense area);
LIHC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.38	6.5	0.33	2.83e-10	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg17135325	chr3:160939158	NMD3	0.55	7.64	0.38	2.15e-13	Parkinson's disease;
LIHC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg02081065	chr5:132209139	LEAP2	0.26	5.73	0.3	2.24e-8	Breast cancer;
LIHC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.4	6.65	0.34	1.15e-10	Red blood cell count;
LIHC	trans	rs11088226	0.581	rs2833860	chr21:33882309	G/A	cg09050820	chr6:167586206	TCP10L2	0.49	7.59	0.38	3.08e-13	Gastritis;
LIHC	cis	rs6977660	1.000	rs10249989	chr7:19822296	A/G	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-8.98	-0.44	1.8e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11786130	1.000	rs62512839	chr8:129009401	A/G	cg01765152	chr8:129005526	PVT1	-0.3	-6.33	-0.32	7.77e-10	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.52	8.44	0.42	9.39e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg12698662	chr3:15914712	MIR563	0.4	7.29	0.37	2.15e-12	Mean platelet volume;
LIHC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.43	7.26	0.37	2.56e-12	Mean corpuscular volume;
LIHC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg01069141	chr11:67398826	TBX10;NUDT8	0.36	6.5	0.33	2.78e-10	Mean corpuscular volume;
LIHC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.98	0.51	3.15e-24	Personality dimensions;
LIHC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.42	-0.37	9.43e-13	Breast cancer;
LIHC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.68	10.61	0.5	6.44e-23	Type 2 diabetes;
LIHC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.46	-9.94	-0.47	1.26e-20	Rheumatoid arthritis;
LIHC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.42e-17	Lung cancer in ever smokers;
LIHC	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.74	0.34	6.77e-11	Ileal carcinoids;
LIHC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg07382826	chr16:28625726	SULT1A1	0.5	7.73	0.39	1.19e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1712517	0.838	rs6584543	chr10:104997014	G/A	cg05636881	chr10:105038444	INA	-0.43	-6.94	-0.35	1.99e-11	Migraine;
LIHC	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg17294928	chr15:75287854	SCAMP5	0.46	6.23	0.32	1.35e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05714094	chr11:117102988	RNF214;PCSK7	0.52	7.38	0.37	1.18e-12	Lung function (FEV1/FVC);
LIHC	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg23352942	chr3:46931381	PTH1R	-0.33	-8.84	-0.43	4.97e-17	Birth weight;
LIHC	cis	rs10508774	0.810	rs10508776	chr10:33189027	T/C	cg01819863	chr10:32635814	EPC1	0.64	5.82	0.3	1.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs31251	0.900	rs11953786	chr5:131071440	A/T	cg06307176	chr5:131281290	NA	0.36	5.75	0.3	2.03e-8	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs17428076	0.874	rs62182373	chr2:172685555	C/T	cg13550731	chr2:172543902	DYNC1I2	0.39	6.32	0.32	8.02e-10	Myopia;
LIHC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg21466736	chr12:48725269	NA	-0.33	-5.85	-0.3	1.16e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs7546	0.505	rs760118	chr16:4940994	A/G	cg08329684	chr16:4932620	PPL	-0.42	-7.34	-0.37	1.61e-12	Cancer;
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.36	0.37	1.35e-12	Height;
LIHC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg00612595	chr21:47717864	NA	-0.38	-6.32	-0.32	8.37e-10	Testicular germ cell tumor;
LIHC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.66	-12.99	-0.57	1.21e-31	Schizophrenia;
LIHC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.79	-0.34	5.02e-11	Sudden cardiac arrest;
LIHC	trans	rs10982213	1.000	rs10817607	chr9:117179222	A/G	cg13401823	chr1:204910715	NFASC	0.33	6.06	0.31	3.65e-9	Interleukin-6 levels;
LIHC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.45	0.82	1.05e-84	Cognitive ability;
LIHC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.36	5.89	0.3	9.2e-9	Menopause (age at onset);
LIHC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.69	-12.82	-0.57	5.37e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-11.45	-0.53	6.24e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg15841412	chr13:111365552	ING1	0.49	6.19	0.32	1.75e-9	Coronary artery disease;
LIHC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.5	-8.11	-0.4	9.04e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.81	-0.3	1.45e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs59901009	0.815	rs10500721	chr11:10203610	A/G	cg01453529	chr11:10209919	SBF2	-0.33	-6.58	-0.34	1.78e-10	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs7872515	0.793	rs10820936	chr9:94830974	C/T	cg01248375	chr9:94877805	SPTLC1	-0.53	-7.77	-0.39	9.32e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg20933634	chr6:27740509	NA	0.45	5.95	0.31	6.71e-9	Parkinson's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05680085	chr2:227700568	RHBDD1	-0.49	-6.51	-0.33	2.73e-10	Pancreatic cancer;
LIHC	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.68	-9.28	-0.45	1.97e-18	Corneal structure;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg22528358	chr1:107598549	PRMT6	-0.69	-11.47	-0.53	5.69e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.54	-13.08	-0.58	5.56e-32	White blood cell count (basophil);
LIHC	cis	rs7729447	0.566	rs3828591	chr5:32713108	G/C	cg16267343	chr5:32710456	NPR3	0.5	6.32	0.32	8.34e-10	Blood pressure;
LIHC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg10402321	chr1:26617780	UBXN11	-0.38	-5.8	-0.3	1.48e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.96	16.49	0.67	2.38e-45	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.4	-0.56	2.04e-29	Type 2 diabetes;
LIHC	trans	rs8026198	0.568	rs73403548	chr15:42443298	T/G	cg03976788	chr22:43485480	TTLL1	0.72	6.22	0.32	1.43e-9	Fibrinogen levels;
LIHC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.89	-0.35	2.62e-11	HDL cholesterol;
LIHC	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.54	-6.48	-0.33	3.11e-10	Homocysteine levels;
LIHC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.25	-0.55	7.24e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs611744	0.967	rs702802	chr8:109218238	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.77e-11	Dupuytren's disease;
LIHC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.64	10.67	0.5	4.01e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.72	-13.9	-0.6	3.78e-35	Multiple myeloma;
LIHC	cis	rs17818399	0.501	rs13413254	chr2:46802934	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.36	5.72	0.3	2.37e-8	Height;
LIHC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.49	-6.07	-0.31	3.34e-9	Narcolepsy;
LIHC	cis	rs17106184	1.000	rs10493149	chr1:50970475	A/G	cg07174182	chr1:51127561	FAF1	-0.58	-6.32	-0.32	8.21e-10	Type 2 diabetes;
LIHC	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg01858014	chr14:56050164	KTN1	-0.68	-6.2	-0.32	1.66e-9	Putamen volume;
LIHC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg18478394	chr8:109455254	TTC35	0.4	6.79	0.34	5.1e-11	Dupuytren's disease;
LIHC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs807029	0.533	rs12571302	chr10:102742763	C/A	cg27255678	chr10:102756921	LZTS2	0.52	7.41	0.37	9.92e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.62	-10.07	-0.48	4.62e-21	Corneal astigmatism;
LIHC	cis	rs36051895	0.623	rs11506292	chr9:5257048	C/A	cg02405213	chr9:5042618	JAK2	-0.63	-10.12	-0.48	3.2e-21	Pediatric autoimmune diseases;
LIHC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.49	5.95	0.31	6.61e-9	Schizophrenia;
LIHC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.11	0.31	2.73e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.35	6.79	0.34	5.02e-11	Cancer;
LIHC	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.48	7.68	0.38	1.72e-13	Corneal astigmatism;
LIHC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.36	6.0	0.31	5.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.53	0.33	2.31e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs825937	0.818	rs825938	chr2:4807937	C/G	cg16223976	chr13:33694703	STARD13	0.34	6.14	0.32	2.25e-9	Blood pressure;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.0	-0.31	5.02e-9	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.48	6.87	0.35	3.11e-11	Pancreatic cancer;
LIHC	cis	rs36051895	0.593	rs2094619	chr9:5167712	G/C	cg02405213	chr9:5042618	JAK2	-0.75	-11.74	-0.54	5.74e-27	Pediatric autoimmune diseases;
LIHC	cis	rs7635838	0.819	rs4684781	chr3:11516299	G/A	cg00170343	chr3:11313890	ATG7	0.4	6.04	0.31	4.02e-9	HDL cholesterol;
LIHC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.02	0.51	2.21e-24	Colorectal cancer;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.54	-0.42	4.53e-16	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.51	-0.46	3.39e-19	Blood metabolite levels;
LIHC	cis	rs9649465	1.000	rs627689	chr7:123400543	C/T	cg03229431	chr7:123269106	ASB15	-0.39	-8.39	-0.41	1.25e-15	Migraine;
LIHC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.38	-6.55	-0.33	2.09e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.56	8.23	0.41	4.08e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg11062466	chr8:58055876	NA	0.45	6.12	0.31	2.51e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.616	rs6486011	chr11:49740230	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.81	0.35	4.37e-11	Height;
LIHC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	6.72	0.34	7.75e-11	Height;
LIHC	cis	rs6939532	0.761	rs3799378	chr6:26404374	C/T	cg09904177	chr6:26538194	HMGN4	0.4	6.13	0.31	2.37e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.84	12.56	0.56	5.29e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.58	8.13	0.4	7.77e-15	Aortic root size;
LIHC	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.85	-0.3	1.17e-8	Coronary artery disease;
LIHC	cis	rs600806	0.888	rs444387	chr1:109851127	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.58	-6.81	-0.35	4.51e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.5	-7.68	-0.38	1.73e-13	Menopause (age at onset);
LIHC	cis	rs2073300	1.000	rs6048811	chr20:23446719	G/C	cg12062639	chr20:23401060	NAPB	0.82	9.64	0.46	1.31e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.99	-0.54	7.08e-28	Coffee consumption (cups per day);
LIHC	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	6.61	0.34	1.51e-10	Menarche (age at onset);
LIHC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.83	-0.3	1.31e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.15	-0.48	2.46e-21	Hemoglobin concentration;
LIHC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.65	9.5	0.46	3.88e-19	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg12798992	chr6:167411361	FGFR1OP	-0.54	-8.19	-0.41	5.08e-15	Crohn's disease;
LIHC	cis	rs1434579	0.798	rs12460231	chr19:44954688	A/T	cg15540054	chr19:45004280	ZNF180	0.63	8.65	0.42	2.03e-16	Tuberculosis;
LIHC	cis	rs3818285	1.000	rs3740138	chr10:111630931	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-6.08	-0.31	3.22e-9	Superior crus of antihelix expression;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg04498913	chr7:1135747	C7orf50	0.43	6.9	0.35	2.51e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-6.24	-0.32	1.3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.23	-0.41	4e-15	Exhaled nitric oxide output;
LIHC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.07	-0.63	1.01e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.91	16.8	0.67	1.33e-46	Menopause (age at onset);
LIHC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.5	7.48	0.38	6.19e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21467203	chr3:49911342	NA	-0.48	-8.62	-0.42	2.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.55	6.94	0.35	2.03e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs77633900	0.772	rs79181196	chr15:76656281	G/T	cg21673338	chr15:77095150	SCAPER	-0.53	-6.15	-0.32	2.15e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg07959070	chr22:50026188	C22orf34	-0.33	-8.63	-0.42	2.4e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg15412446	chr2:106886593	NA	-0.72	-6.94	-0.35	1.98e-11	Facial morphology (factor 23);
LIHC	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.41	-6.14	-0.32	2.31e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg20607798	chr8:58055168	NA	0.63	7.79	0.39	7.84e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.51	-8.0	-0.4	1.9e-14	Platelet distribution width;
LIHC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	6.62	0.34	1.35e-10	Pancreatic cancer;
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.61	-0.42	2.69e-16	Obesity-related traits;
LIHC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.94	15.76	0.65	1.93e-42	Tonsillectomy;
LIHC	cis	rs7106204	0.609	rs12785699	chr11:24280489	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	6.38	0.33	5.61e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.37	-6.1	-0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg05983323	chr4:166249203	SC4MOL	-0.4	-6.11	-0.31	2.73e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-8.63	-0.42	2.4e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs7618501	0.570	rs7613875	chr3:49971514	C/A	cg24110177	chr3:50126178	RBM5	-0.48	-7.6	-0.38	2.96e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02002494	chr3:119013045	CDGAP	0.45	6.74	0.34	6.56e-11	Pancreatic cancer;
LIHC	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.37	-6.2	-0.32	1.63e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.7	-0.34	8.47e-11	Lymphocyte counts;
LIHC	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.8	7.0	0.35	1.34e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.09	-0.4	1.03e-14	Type 2 diabetes;
LIHC	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.26	-6.37	-0.33	6.27e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.46	-7.92	-0.39	3.38e-14	Total body bone mineral density;
LIHC	cis	rs8084351	0.577	rs4530205	chr18:50658914	G/A	cg24270629	chr18:50823537	DCC	-0.44	-6.47	-0.33	3.3e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg08345082	chr10:99160200	RRP12	-0.38	-6.25	-0.32	1.23e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg00529422	chr1:16285251	ZBTB17	0.31	6.04	0.31	4.09e-9	Systolic blood pressure;
LIHC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.46	7.4	0.37	1.03e-12	Mean corpuscular volume;
LIHC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg23533926	chr12:111358616	MYL2	-0.32	-6.25	-0.32	1.23e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg10774155	chr7:65338427	VKORC1L1	-0.44	-6.57	-0.33	1.83e-10	Calcium levels;
LIHC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg13844804	chr7:814759	HEATR2	0.44	5.95	0.31	6.62e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.54	0.33	2.18e-10	Bipolar disorder;
LIHC	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.58	7.32	0.37	1.83e-12	Corneal astigmatism;
LIHC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg10820045	chr2:198174542	NA	0.56	9.01	0.44	1.46e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.6	-10.31	-0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg14527280	chr6:3458119	SLC22A23	0.45	6.24	0.32	1.32e-9	Alopecia areata;
LIHC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.43	5.73	0.3	2.26e-8	Obesity-related traits;
LIHC	cis	rs74233809	1.000	rs12221193	chr10:104665267	A/C	cg03493300	chr10:104813866	CNNM2	0.46	6.11	0.31	2.68e-9	Birth weight;
LIHC	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg01652190	chr22:50026171	C22orf34	-0.33	-7.4	-0.37	1.03e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.54	6.27	0.32	1.06e-9	Alzheimer's disease;
LIHC	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-22.18	-0.77	3.7e-68	Myeloid white cell count;
LIHC	cis	rs760762	0.636	rs6129801	chr20:39916437	T/C	cg06424997	chr20:39929561	ZHX3	0.35	5.73	0.3	2.2e-8	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LIHC	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg07382826	chr16:28625726	SULT1A1	0.5	7.69	0.38	1.61e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.86	11.07	0.51	1.46e-24	Coronary artery disease;
LIHC	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.33	-0.41	1.92e-15	HDL cholesterol;
LIHC	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg12046867	chr14:103022105	NA	-0.42	-6.6	-0.34	1.54e-10	Platelet count;
LIHC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg15155738	chr12:121454335	C12orf43	0.47	6.75	0.34	6.46e-11	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.63	-0.38	2.31e-13	Prevalent atrial fibrillation;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22575458	chr10:5667028	NA	0.42	6.49	0.33	2.94e-10	Longevity;
LIHC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-14.83	-0.63	8.92e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg07460842	chr6:66804631	NA	-0.5	-5.96	-0.31	6.42e-9	Metabolite levels;
LIHC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.98	-0.44	1.87e-17	Heart rate;
LIHC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-5.85	-0.3	1.12e-8	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08510077	chr3:113666901	ZDHHC23	0.36	6.09	0.31	2.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7091068	0.754	rs1326224	chr10:95459267	C/T	cg20715218	chr10:95462985	C10orf4	0.62	6.82	0.35	4.07e-11	Urinary tract infection frequency;
LIHC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.56	-0.33	1.96e-10	Height;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02864619	chr17:78933961	RPTOR	0.44	6.74	0.34	6.75e-11	Bilirubin levels;
LIHC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.39	0.45	8.39e-19	IgG glycosylation;
LIHC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.09e-18	Hemoglobin concentration;
LIHC	cis	rs17106184	0.892	rs72902768	chr1:51261965	C/T	cg07174182	chr1:51127561	FAF1	-0.64	-6.96	-0.35	1.75e-11	Type 2 diabetes;
LIHC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.98	0.31	5.74e-9	Menopause (age at onset);
LIHC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07305463	chr2:136567211	LCT	-0.39	-6.04	-0.31	3.94e-9	Corneal structure;
LIHC	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg12858261	chr2:113808755	IL1F8	0.34	5.94	0.31	7.18e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.75	0.47	5.44e-20	Height;
LIHC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.54	-0.5	1.09e-22	Platelet count;
LIHC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.49	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.73	14.04	0.6	1.1e-35	Mortality in heart failure;
LIHC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-8.69	-0.43	1.55e-16	Vitiligo;
LIHC	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.08	-0.4	1.09e-14	Testicular germ cell tumor;
LIHC	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.57	7.28	0.37	2.28e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.78	-0.54	4.01e-27	Coffee consumption (cups per day);
LIHC	cis	rs2637266	0.626	rs1660914	chr10:78525319	T/A	cg18941641	chr10:78392320	NA	0.28	6.05	0.31	3.77e-9	Pulmonary function;
LIHC	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.49	8.97	0.44	1.96e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.52	7.73	0.39	1.23e-13	Menarche (age at onset);
LIHC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.47	-6.64	-0.34	1.23e-10	Other erythrocyte phenotypes;
LIHC	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg22771759	chr13:24902376	NA	0.32	6.49	0.33	3.03e-10	Obesity-related traits;
LIHC	cis	rs713477	0.654	rs61976568	chr14:55906218	A/G	cg13175173	chr14:55914753	NA	-0.31	-6.75	-0.34	6.39e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.73	12.65	0.56	2.27e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs4728302	0.869	rs12707128	chr7:133589796	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.38	0.33	5.64e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.62	9.85	0.47	2.67e-20	Corneal astigmatism;
LIHC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg27478167	chr7:817139	HEATR2	0.4	5.82	0.3	1.37e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.46	8.26	0.41	3.21e-15	Colorectal cancer;
LIHC	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.98	10.83	0.51	1.06e-23	Triglycerides;
LIHC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.59	0.59	6.04e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg13708974	chr9:131466143	PKN3	0.37	5.71	0.3	2.43e-8	Blood metabolite levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg00429477	chr12:6798907	ZNF384	-0.54	-6.5	-0.33	2.87e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.55	-9.11	-0.44	7.26e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.67	-0.5	4.06e-23	Breast cancer;
LIHC	cis	rs1274963	0.601	rs2063634	chr3:39196452	A/G	cg02254461	chr3:39195904	CSRNP1	-0.48	-5.84	-0.3	1.23e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.4	6.4	0.33	5.05e-10	Red blood cell count;
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.4	0.81	1.03e-80	Prudent dietary pattern;
LIHC	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg16797656	chr11:68205561	LRP5	0.45	6.72	0.34	7.41e-11	Total body bone mineral density (age 45-60);
LIHC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.49	-7.59	-0.38	3.01e-13	Asthma (sex interaction);
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg27411370	chr8:25316735	KCTD9;CDCA2	-0.43	-6.05	-0.31	3.77e-9	Monocyte count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00349413	chr17:48171948	PDK2	0.45	7.05	0.36	9.97e-12	Cognitive function;
LIHC	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.79	0.3	1.63e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.32	0.55	4.1e-29	Colorectal cancer;
LIHC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.57	-6.03	-0.31	4.19e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.19	0.55	1.27e-28	Prudent dietary pattern;
LIHC	cis	rs77633900	0.772	rs8031378	chr15:76657874	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-5.95	-0.31	6.72e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-17.46	-0.69	2.88e-49	Height;
LIHC	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.29	0.32	9.57e-10	Diastolic blood pressure;
LIHC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.54	-8.26	-0.41	3.22e-15	Lung cancer;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg16427488	chr8:86132835	C8orf59	-0.43	-6.2	-0.32	1.65e-9	Body mass index;
LIHC	cis	rs2625529	0.938	rs4777464	chr15:72131763	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.86	-0.3	1.12e-8	Red blood cell count;
LIHC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.6	10.11	0.48	3.41e-21	Height;
LIHC	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg09795085	chr6:101329169	ASCC3	0.5	6.8	0.34	4.8e-11	Neuroticism;
LIHC	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg00204512	chr16:28754710	NA	-0.34	-6.12	-0.31	2.61e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.66	13.84	0.6	6.58e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs3762637	0.943	rs9289199	chr3:122277172	G/A	cg24169773	chr3:122142474	KPNA1	-0.45	-9.01	-0.44	1.49e-17	LDL cholesterol levels;
LIHC	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.5	-8.03	-0.4	1.59e-14	Schizophrenia;
LIHC	cis	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.78	-0.34	5.24e-11	Atopic dermatitis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02030672	chr11:45687055	CHST1	0.41	6.31	0.32	8.64e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.36	11.83	0.54	2.74e-27	Uric acid levels;
LIHC	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.96	-10.46	-0.49	2.05e-22	Platelet distribution width;
LIHC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.38	6.13	0.31	2.48e-9	Melanoma;
LIHC	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.65	8.5	0.42	5.81e-16	Body mass index (adult);
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	7.04	0.36	1.04e-11	Renal cell carcinoma;
LIHC	cis	rs1000083	0.704	rs1830366	chr5:96591215	C/T	ch.5.96698337R	chr5:96672581	NA	0.84	6.84	0.35	3.68e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4478037	0.818	rs17522946	chr3:33138777	A/G	cg16652328	chr3:33138982	GLB1;TMPPE	-0.52	-6.68	-0.34	9.44e-11	Major depressive disorder;
LIHC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.16	-0.58	2.7e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg12437481	chr16:420112	MRPL28	-0.63	-8.45	-0.42	8.64e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-6.14	-0.32	2.28e-9	Cognitive function;
LIHC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.28	0.52	2.71e-25	Coronary artery disease;
LIHC	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg18289306	chr13:113640169	MCF2L	0.41	6.58	0.34	1.75e-10	Systolic blood pressure;
LIHC	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	11.77	0.54	4.32e-27	Post bronchodilator FEV1;
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12379764	chr21:47803548	PCNT	-0.59	-8.88	-0.43	3.88e-17	Testicular germ cell tumor;
LIHC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	5.92	0.3	7.78e-9	Cognitive ability;
LIHC	cis	rs9783347	0.857	rs4150561	chr11:18354877	T/C	cg15585147	chr11:18324498	HPS5	0.43	6.73	0.34	6.95e-11	Pancreatic cancer;
LIHC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.33	-0.45	1.41e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs1165668	1.000	rs10778305	chr12:104311974	C/G	cg21863207	chr12:104234989	NT5DC3	0.4	6.39	0.33	5.53e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.56	5.92	0.3	7.86e-9	IgG glycosylation;
LIHC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.44	6.94	0.35	1.97e-11	Melanoma;
LIHC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.22e-34	Aortic root size;
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg00612595	chr21:47717864	NA	-0.4	-6.77	-0.34	5.52e-11	Testicular germ cell tumor;
LIHC	trans	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-8.92	-0.43	2.94e-17	Extraversion;
LIHC	cis	rs7684446	1	rs7684446	chr4:15592864	C/T	cg21123203	chr4:15471301	CC2D2A	0.39	6.54	0.33	2.22e-10	Red blood cell count;
LIHC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.38	-6.23	-0.32	1.39e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.12	0.55	2.27e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg03037974	chr15:76606532	NA	-0.58	-9.93	-0.47	1.4e-20	Blood metabolite levels;
LIHC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.59	-9.04	-0.44	1.21e-17	Platelet count;
LIHC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.87	15.64	0.65	5.61e-42	Dental caries;
LIHC	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.3	6.5	0.33	2.92e-10	Pulmonary function;
LIHC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg20135002	chr11:47629003	NA	-0.52	-9.15	-0.44	5.22e-18	Subjective well-being;
LIHC	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg14593290	chr7:50529359	DDC	0.51	7.9	0.39	3.94e-14	Malaria;
LIHC	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs1144333	1.000	rs12078893	chr1:76370862	T/C	cg03433033	chr1:76189801	ACADM	0.54	8.03	0.4	1.61e-14	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.61	8.56	0.42	3.78e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.7	10.6	0.5	6.79e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.72	11.24	0.52	3.76e-25	Mood instability;
LIHC	trans	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.14e-14	Mean platelet volume;
LIHC	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg03934865	chr2:198174659	NA	0.57	9.09	0.44	8.33e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8016982	0.662	rs1864169	chr14:81670033	G/T	cg01989461	chr14:81687754	GTF2A1	0.52	9.1	0.44	7.41e-18	Schizophrenia;
LIHC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg06565975	chr8:143823917	SLURP1	0.33	6.38	0.33	5.67e-10	Urinary tract infection frequency;
LIHC	cis	rs4728302	0.869	rs10808273	chr7:133597691	G/C	cg10665199	chr7:133106180	EXOC4	0.38	6.64	0.34	1.21e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs903552	0.736	rs11858491	chr15:102007456	C/T	cg25677261	chr15:102009856	PCSK6	0.49	6.87	0.35	3.13e-11	Diabetic kidney disease;
LIHC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.68	8.68	0.42	1.64e-16	Gut microbiome composition (summer);
LIHC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.13	0.55	2.16e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.48	-7.84	-0.39	5.62e-14	Longevity;Endometriosis;
LIHC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	trans	rs10982213	0.514	rs10739411	chr9:117183149	C/T	cg13401823	chr1:204910715	NFASC	-0.32	-6.18	-0.32	1.82e-9	Interleukin-6 levels;
LIHC	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg06191203	chr2:152266755	RIF1	0.58	9.04	0.44	1.16e-17	Lung cancer;
LIHC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.09	0.36	7.74e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.58	8.75	0.43	9.58e-17	Cognitive function;
LIHC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg27286337	chr10:134555280	INPP5A	0.53	6.87	0.35	3.07e-11	Primary sclerosing cholangitis;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	5.79	0.3	1.62e-8	Height;
LIHC	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg24296786	chr1:45957014	TESK2	0.5	7.29	0.37	2.22e-12	High light scatter reticulocyte count;
LIHC	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.57	-8.56	-0.42	3.98e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.14	0.68	5.42e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.31	-6.92	-0.35	2.19e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg12373951	chr3:133503437	NA	0.56	9.51	0.46	3.41e-19	Iron status biomarkers;
LIHC	trans	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg26939375	chr7:64535504	NA	0.42	6.63	0.34	1.32e-10	Aortic root size;
LIHC	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.84	-15.54	-0.64	1.39e-41	Height;
LIHC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg08847533	chr14:75593920	NEK9	0.38	6.42	0.33	4.69e-10	Caffeine consumption;
LIHC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.85	16.19	0.66	3.49e-44	Response to diuretic therapy;
LIHC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18802567	chr5:171433913	FBXW11	0.54	7.19	0.36	4.06e-12	Lung function (FEV1/FVC);
LIHC	cis	rs4908768	0.539	rs11121205	chr1:8658085	G/A	cg20416874	chr1:8611966	RERE	-0.61	-11.1	-0.51	1.22e-24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.46	0.33	3.59e-10	Aortic root size;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.75	7.52	0.38	4.99e-13	Alzheimer's disease;
LIHC	cis	rs80282103	0.618	rs11250264	chr10:1151723	A/C	cg08668510	chr10:1095578	IDI1	0.61	6.03	0.31	4.29e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04967530	chr3:99979613	TBC1D23	0.46	7.2	0.36	3.76e-12	Cognitive function;
LIHC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.29	-0.41	2.7e-15	Longevity;
LIHC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14014604	chr2:175351471	GPR155	-0.45	-6.33	-0.32	7.68e-10	Pancreatic cancer;
LIHC	cis	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg14515779	chr1:101123966	NA	-0.7	-14.1	-0.61	6.72e-36	Monocyte count;
LIHC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02985541	chr2:219472218	PLCD4	0.44	7.26	0.37	2.69e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg04155231	chr12:9217510	LOC144571	0.31	5.94	0.31	7.09e-9	Sjögren's syndrome;
LIHC	cis	rs17152411	0.625	rs4962713	chr10:126654536	A/T	cg07906193	chr10:126599966	NA	-0.31	-6.16	-0.32	2.02e-9	Height;
LIHC	cis	rs12644436	0.526	rs10032322	chr4:88771325	T/G	cg06891869	chr4:88767617	MEPE	-0.49	-7.75	-0.39	1.05e-13	HIV-1 viral setpoint;
LIHC	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.48	7.1	0.36	7.06e-12	Dialysis-related mortality;
LIHC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.46	6.06	0.31	3.54e-9	Height;
LIHC	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.34	0.32	7.41e-10	Systolic blood pressure;
LIHC	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.51	7.72	0.39	1.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg12501888	chr15:85177176	SCAND2	-0.52	-7.69	-0.38	1.54e-13	P wave terminal force;
LIHC	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg20194872	chr6:41519635	FOXP4	0.4	6.33	0.32	7.78e-10	Prostate cancer;
LIHC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg05941027	chr17:61774174	LIMD2	0.33	6.71	0.34	8.24e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.31	20.39	0.74	4.64e-61	IgG glycosylation;
LIHC	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg10127483	chr1:110009974	SYPL2	0.49	6.04	0.31	3.93e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.05	0.31	3.78e-9	Bipolar disorder;
LIHC	trans	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg26939375	chr7:64535504	NA	-0.4	-6.15	-0.32	2.2e-9	Aortic root size;
LIHC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.79	6.82	0.35	4.05e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	19.63	0.73	5.64e-58	Nonalcoholic fatty liver disease;
LIHC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg18404041	chr3:52824283	ITIH1	0.38	5.77	0.3	1.82e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg16797656	chr11:68205561	LRP5	0.51	8.04	0.4	1.47e-14	Total body bone mineral density;
LIHC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.56	7.6	0.38	2.83e-13	Blood metabolite levels;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.68	9.24	0.45	2.77e-18	Aortic root size;
LIHC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.63	-9.32	-0.45	1.49e-18	Renal cell carcinoma;
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02359409	chr6:42947317	PEX6	-0.43	-5.75	-0.3	1.99e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	7.89	0.39	4.23e-14	Motion sickness;
LIHC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg16479474	chr6:28041457	NA	0.39	6.52	0.33	2.57e-10	Cardiac Troponin-T levels;
LIHC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.9	15.98	0.65	2.44e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg07061783	chr6:25882402	NA	-0.44	-6.19	-0.32	1.74e-9	Blood metabolite levels;
LIHC	cis	rs12611088	0.515	rs2599454	chr19:44025201	T/C	cg13740135	chr19:44006432	PHLDB3	-0.41	-6.08	-0.31	3.16e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.39	6.32	0.32	8.29e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.32	-5.82	-0.3	1.33e-8	Calcium levels;
LIHC	trans	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.93	-0.35	2.05e-11	Aortic root size;
LIHC	trans	rs75804782	0.521	rs113497020	chr2:239370813	C/T	cg01134436	chr17:81009848	B3GNTL1	0.87	7.21	0.36	3.66e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.18e-41	Mortality in heart failure;
LIHC	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.96	0.31	6.15e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg06565975	chr8:143823917	SLURP1	-0.37	-6.34	-0.32	7.38e-10	Urinary tract infection frequency;
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.47	7.36	0.37	1.39e-12	Testicular germ cell tumor;
LIHC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.14	-0.36	5.53e-12	Personality dimensions;
LIHC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13126279	chr21:47581558	C21orf56	-0.38	-5.77	-0.3	1.75e-8	Testicular germ cell tumor;
LIHC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg03037974	chr15:76606532	NA	0.58	9.62	0.46	1.55e-19	Blood metabolite levels;
LIHC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.33	-18.17	-0.7	3.94e-52	Diabetic kidney disease;
LIHC	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.56	9.6	0.46	1.72e-19	Mean corpuscular volume;
LIHC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-9.96	-0.47	1.08e-20	Mean corpuscular volume;
LIHC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.36	-7.07	-0.36	8.67e-12	Height;
LIHC	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg10820045	chr2:198174542	NA	-0.48	-7.22	-0.36	3.31e-12	Dermatomyositis;
LIHC	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.92	-0.39	3.43e-14	Response to antipsychotic treatment;
LIHC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.37	0.45	9.9e-19	Melanoma;
LIHC	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.55	7.21	0.36	3.58e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.16	17.97	0.7	2.69e-51	Gut microbiome composition (summer);
LIHC	cis	rs903552	0.932	rs2172851	chr15:102012626	C/T	cg06707286	chr15:102010195	PCSK6	-0.51	-7.21	-0.36	3.7e-12	Diabetic kidney disease;
LIHC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg20140201	chr2:241835670	C2orf54	-0.47	-6.45	-0.33	3.9e-10	Urinary metabolites;
LIHC	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg07959070	chr22:50026188	C22orf34	-0.33	-8.26	-0.41	3.3e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13494334	chr14:75593888	NEK9	0.48	6.64	0.34	1.26e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.63	-0.34	1.3e-10	Response to antipsychotic treatment;
LIHC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg12798992	chr6:167411361	FGFR1OP	0.45	6.75	0.34	6.53e-11	Crohn's disease;
LIHC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.38	9.69	0.46	8.57e-20	Asthma (sex interaction);
LIHC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	7.05	0.36	1.02e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg14515779	chr1:101123966	NA	0.49	6.75	0.34	6.22e-11	Monocyte count;
LIHC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.65	-10.6	-0.5	7.04e-23	Crohn's disease;
LIHC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.5	0.46	3.76e-19	Bipolar disorder;
LIHC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.47	-7.23	-0.36	3.18e-12	Blood protein levels;
LIHC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.5	7.73	0.39	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.39	6.65	0.34	1.19e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.96	-13.24	-0.58	1.38e-32	Cerebrospinal P-tau181p levels;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17687970	chr8:22462467	KIAA1967	-0.42	-6.62	-0.34	1.41e-10	Alopecia areata;
LIHC	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	trans	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg16088116	chr21:44841560	SIK1	-0.42	-6.34	-0.32	7.23e-10	Coronary artery disease;
LIHC	trans	rs2506155	0.566	rs56291819	chr10:33529055	A/C	cg03349118	chr8:59572480	NSMAF	-0.58	-6.11	-0.31	2.75e-9	Migraine;
LIHC	cis	rs526231	0.781	rs2569015	chr5:102608847	A/G	cg05225461	chr5:102596755	C5orf30	0.37	5.75	0.3	1.98e-8	Primary biliary cholangitis;
LIHC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.46	-0.37	7.44e-13	Platelet distribution width;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07791762	chr19:17323290	MYO9B	-0.46	-7.06	-0.36	9.32e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.73	-11.26	-0.52	3.02e-25	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.47	-6.85	-0.35	3.5e-11	Intracranial aneurysm;
LIHC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	1.02	10.5	0.49	1.58e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.52	-0.33	2.59e-10	Metabolite levels;
LIHC	cis	rs3770081	0.793	rs73943946	chr2:86226623	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.44	-0.42	8.84e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg09137382	chr11:130731461	NA	0.42	6.31	0.32	8.44e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.45	6.11	0.31	2.75e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.6	0.46	1.72e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.93	-0.35	2.09e-11	Menarche (age at onset);
LIHC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg23149560	chr2:74406255	MOBKL1B	0.45	6.29	0.32	9.93e-10	Gestational age at birth (maternal effect);
LIHC	cis	rs72829446	0.530	rs8071847	chr17:7407327	A/G	cg02795151	chr17:7402630	POLR2A	0.55	6.39	0.33	5.45e-10	Androgen levels;
LIHC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg07636037	chr3:49044803	WDR6	-0.84	-8.52	-0.42	5.33e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.85	-0.35	3.5e-11	Neuroticism;
LIHC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20335179	chr10:1068567	C10orf110;IDI2	0.42	6.37	0.33	6.06e-10	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.5	8.83	0.43	5.35e-17	Total body bone mineral density;
LIHC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.43	-7.09	-0.36	7.78e-12	IgG glycosylation;
LIHC	cis	rs4450131	0.522	rs3781463	chr10:126337190	C/T	cg20435097	chr10:126320824	FAM53B	0.68	12.5	0.56	9.02e-30	White blood cell count (basophil);
LIHC	cis	rs6545883	0.894	rs778148	chr2:61606866	G/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.39	-0.37	1.1e-12	Tuberculosis;
LIHC	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg17675199	chr6:35436792	RPL10A	0.35	6.55	0.33	2.17e-10	Monocyte count;
LIHC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.41	7.58	0.38	3.2e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.87	0.43	4.09e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.36	6.31	0.32	8.71e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg18016565	chr1:150552671	MCL1	0.55	10.48	0.49	1.73e-22	Melanoma;
LIHC	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.32	7.23	0.36	3.1e-12	Blood metabolite ratios;
LIHC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.61	0.42	2.65e-16	Height;
LIHC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.85	10.78	0.5	1.57e-23	Attention deficit hyperactivity disorder;
LIHC	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.59	-10.44	-0.49	2.56e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.67	11.8	0.54	3.5e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.54	7.6	0.38	2.97e-13	Blood metabolite levels;
LIHC	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.59	-0.38	3.05e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.32	6.74	0.34	6.76e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-7.23	-0.36	3.27e-12	Height;
LIHC	trans	rs4129059	1.000	rs61443257	chr1:214673211	G/A	cg21012737	chr14:105393171	PLD4	-0.36	-6.97	-0.35	1.61e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	6.65	0.34	1.14e-10	Renal cell carcinoma;
LIHC	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.65	9.9	0.47	1.8e-20	Height;
LIHC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.66	12.12	0.55	2.28e-28	Gestational age at birth (maternal effect);
LIHC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg07959070	chr22:50026188	C22orf34	-0.3	-7.7	-0.38	1.44e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.4	-0.33	5.14e-10	Diabetic kidney disease;
LIHC	cis	rs748404	0.601	rs502157	chr15:43528573	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.37	-5.99	-0.31	5.24e-9	Lung cancer;
LIHC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.83	-11.63	-0.53	1.45e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.67	-9.35	-0.45	1.16e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	0.93	11.58	0.53	2.11e-26	Post bronchodilator FEV1;
LIHC	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.79	9.75	0.47	5.53e-20	Schizophrenia;
LIHC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg14651457	chr8:12611650	LONRF1	-0.6	-6.12	-0.31	2.58e-9	Obesity-related traits;
LIHC	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.73	14.03	0.6	1.24e-35	Mortality in heart failure;
LIHC	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.73	10.41	0.49	3.16e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.89	-0.3	9.33e-9	Type 2 diabetes;
LIHC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.5	-9.25	-0.45	2.54e-18	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.59	9.35	0.45	1.15e-18	Uric acid clearance;
LIHC	cis	rs11252926	0.627	rs10751997	chr10:561952	C/T	cg09445902	chr10:555545	DIP2C	-0.41	-6.42	-0.33	4.62e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.52	7.07	0.36	9e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.52	9.23	0.45	3e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg06935464	chr4:38784597	TLR10	0.5	7.76	0.39	1e-13	Breast cancer;
LIHC	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.86	-0.3	1.09e-8	Neuroticism;
LIHC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	11.71	0.53	7.57e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7546668	1.000	rs4646093	chr1:15821400	G/T	cg11706911	chr1:15910989	AGMAT	0.44	6.8	0.35	4.62e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg18016565	chr1:150552671	MCL1	-0.5	-9.44	-0.45	5.92e-19	Tonsillectomy;
LIHC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.23	6.05	0.31	3.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.06	0.55	3.63e-28	Prudent dietary pattern;
LIHC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.28	-6.93	-0.35	2.05e-11	Mean corpuscular volume;
LIHC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.45	6.07	0.31	3.43e-9	Major depressive disorder;
LIHC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.87e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg18306943	chr3:40428807	ENTPD3	0.33	5.87	0.3	1.01e-8	Renal cell carcinoma;
LIHC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.48	-6.52	-0.33	2.5e-10	Initial pursuit acceleration;
LIHC	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg22842854	chr12:123319900	HIP1R	-0.64	-8.28	-0.41	2.76e-15	Schizophrenia;
LIHC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg25356066	chr3:128598488	ACAD9	0.52	7.21	0.36	3.68e-12	IgG glycosylation;
LIHC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	0.84	7.21	0.36	3.73e-12	Cognitive function;
LIHC	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.62	-0.34	1.41e-10	IgG glycosylation;
LIHC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.34	-7.74	-0.39	1.16e-13	Obesity-related traits;
LIHC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg16576597	chr16:28551801	NUPR1	0.36	5.75	0.3	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.48	7.51	0.38	5.3e-13	Height;
LIHC	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	9.65	0.46	1.21e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg18081818	chr7:23246105	NA	-0.4	-6.19	-0.32	1.75e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.98	10.83	0.51	1.06e-23	Triglycerides;
LIHC	cis	rs3106136	0.510	rs28838299	chr4:95215887	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.03	-0.44	1.27e-17	Capecitabine sensitivity;
LIHC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.18	0.48	1.94e-21	Bladder cancer;
LIHC	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	7.84e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	13.66	0.59	3.28e-34	Bipolar disorder;
LIHC	trans	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg17830980	chr10:43048298	ZNF37B	-0.42	-7.65	-0.38	2.11e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.56	9.74	0.47	5.93e-20	Systemic lupus erythematosus;
LIHC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.75	14.41	0.61	4.2e-37	Mortality in heart failure;
LIHC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg04719120	chr6:96025338	MANEA	0.62	6.8	0.35	4.59e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg15948567	chr1:19600454	AKR7L	0.29	5.88	0.3	9.68e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.72	0.65	2.79e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg14393609	chr7:65229607	NA	0.37	5.71	0.3	2.42e-8	Aortic root size;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.8	12.68	0.57	1.85e-30	Longevity;
LIHC	cis	rs6788895	1.000	rs1879420	chr3:150466564	A/G	cg07663535	chr3:150480033	SIAH2	0.55	6.76	0.34	5.97e-11	Breast cancer;
LIHC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.39	-6.15	-0.32	2.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	9.39e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.65	9.87	0.47	2.22e-20	Neutrophil percentage of white cells;
LIHC	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.34e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.43	6.5	0.33	2.83e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg21361702	chr7:150065534	REPIN1	0.46	6.24	0.32	1.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.35	6.68	0.34	9.9e-11	Blood metabolite levels;
LIHC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.56	7.96	0.4	2.56e-14	Lung cancer;
LIHC	cis	rs1198430	0.929	rs1210852	chr1:23753533	T/C	cg13183780	chr1:23809682	ASAP3	-0.53	-7.56	-0.38	3.75e-13	Total cholesterol levels;
LIHC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.59	7.58	0.38	3.25e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7911264	1.000	rs10882100	chr10:94460687	C/G	cg25093409	chr10:94429542	NA	0.34	5.79	0.3	1.64e-8	Inflammatory bowel disease;
LIHC	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	1.09	9.57	0.46	2.29e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.46	-7.52	-0.38	4.91e-13	Alzheimer's disease (late onset);
LIHC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg10820045	chr2:198174542	NA	0.56	8.88	0.43	3.78e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.6	8.92	0.43	2.78e-17	Recombination rate (females);
LIHC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.56	7.14	0.36	5.62e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg05043794	chr9:111880884	C9orf5	-0.23	-5.79	-0.3	1.63e-8	Menarche (age at onset);
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06656553	chr16:89960601	TCF25	0.45	5.85	0.3	1.13e-8	Skin colour saturation;
LIHC	trans	rs8113308	0.810	rs7259622	chr19:52445737	C/T	cg14959425	chr7:20447707	ITGB8	-0.47	-6.1	-0.31	2.87e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs3106136	0.681	rs11097423	chr4:95303161	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs77861329	0.920	rs808787	chr3:52203249	G/A	cg08692210	chr3:52188851	WDR51A	0.83	7.86	0.39	5.11e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.82	7.04	0.36	1.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.49	0.49	1.7e-22	Hypertriglyceridemia;
LIHC	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.33	-6.84	-0.35	3.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg27433088	chr4:174089019	GALNT7	0.39	7.22	0.36	3.35e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg14440974	chr22:39074834	NA	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.71	-0.34	7.92e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg19875535	chr5:140030758	IK	-0.37	-6.02	-0.31	4.48e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	1.04	15.38	0.64	6.07e-41	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.47	7.66	0.38	1.98e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08280861	chr8:58055591	NA	0.5	6.13	0.31	2.38e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.94	-0.44	2.44e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	1.1	18.38	0.7	5.95e-53	IgG glycosylation;
LIHC	cis	rs116975820	0.604	rs80285467	chr12:42564793	T/G	cg01256987	chr12:42539512	GXYLT1	-0.53	-5.81	-0.3	1.46e-8	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.74	-0.3	2.1e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.33	-6.88	-0.35	2.94e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	1.04	14.31	0.61	1.02e-36	Corneal structure;
LIHC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.59	-11.53	-0.53	3.25e-26	Body mass index;
LIHC	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.25	-0.32	1.23e-9	Tuberculosis;
LIHC	cis	rs11696739	0.761	rs2254458	chr20:1551485	C/T	cg15722679	chr20:1638393	SIRPG	-0.41	-7.91	-0.39	3.57e-14	Mean platelet volume;
LIHC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.49	9.06	0.44	1.01e-17	Hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24555065	chr12:6977392	TPI1	0.45	6.41	0.33	4.9e-10	Pancreatic cancer;
LIHC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg20399509	chr21:47717575	C21orf57	0.37	5.84	0.3	1.18e-8	Testicular germ cell tumor;
LIHC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.6	10.49	0.49	1.6400000000000001e-22	Dupuytren's disease;
LIHC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	10.6	0.5	6.72e-23	Coronary artery disease;
LIHC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	9.69	0.46	9.15e-20	Resting heart rate;
LIHC	trans	rs11157436	0.918	rs2178788	chr14:22618870	T/C	cg13567813	chr19:50879636	NR1H2	0.42	6.1	0.31	2.82e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.52	7.77	0.39	9.08e-14	Total body bone mineral density;
LIHC	cis	rs860295	0.812	rs3820594	chr1:155829511	C/T	cg02153340	chr1:155202674	NA	-0.34	-6.24	-0.32	1.3e-9	Body mass index;
LIHC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs611744	0.967	rs650437	chr8:109210927	T/G	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.63	-6.02	-0.31	4.61e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.54	0.38	4.25e-13	Iron status biomarkers;
LIHC	cis	rs58785573	0.570	rs1824652	chr4:38644597	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.5	7.18	0.36	4.41e-12	Lymphocyte percentage of white cells;
LIHC	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.49	-7.61	-0.38	2.72e-13	Pubertal anthropometrics;
LIHC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.54	-7.7	-0.38	1.5e-13	Body mass index;
LIHC	cis	rs9649465	1.000	rs608447	chr7:123395983	A/G	cg03229431	chr7:123269106	ASB15	0.37	7.88	0.39	4.55e-14	Migraine;
LIHC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.46	7.58	0.38	3.23e-13	Response to temozolomide;
LIHC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.8	-12.48	-0.56	1.06e-29	Total body bone mineral density;
LIHC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.9e-9	Body mass index;
LIHC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	7.18	0.36	4.37e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg15832292	chr6:96025679	MANEA	-0.58	-6.48	-0.33	3.22e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.82	-13.04	-0.58	8.12e-32	Colorectal cancer;
LIHC	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.43	7.44	0.37	8.04e-13	Type 2 diabetes;
LIHC	cis	rs249954	0.512	rs249870	chr16:23666178	C/A	cg09867953	chr16:23706666	ERN2	0.37	6.19	0.32	1.76e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-6.02	-0.31	4.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1075232	1.000	rs1075232	chr15:31741216	C/A	cg01030201	chr15:31746330	NA	-0.8	-6.27	-0.32	1.06e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg23091122	chr1:110024289	SYPL2	-0.5	-6.69	-0.34	9.06e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.31e-20	Menopause (age at onset);
LIHC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.74	-0.43	1.08e-16	Total cholesterol levels;
LIHC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.51	-8.06	-0.4	1.25e-14	Fibrinogen levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12620342	chr12:56522011	ESYT1	0.5	6.46	0.33	3.68e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.46	-6.79	-0.34	5.07e-11	Longevity;Endometriosis;
LIHC	cis	rs8081395	0.741	rs1292056	chr17:57959047	C/T	cg13753209	chr17:57696993	CLTC	0.38	5.86	0.3	1.09e-8	White blood cell count;
LIHC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.58	8.38	0.41	1.4e-15	Platelet count;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.45e-10	Prudent dietary pattern;
LIHC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-7.31	-0.37	1.96e-12	Fear of minor pain;
LIHC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.18	0.36	4.47e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg04592579	chr7:75616294	TMEM120A	0.41	7.01	0.35	1.28e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg13409248	chr3:40428643	ENTPD3	-0.39	-6.52	-0.33	2.58e-10	Renal cell carcinoma;
LIHC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.65	6.97	0.35	1.63e-11	Alzheimer's disease;
LIHC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.47	-6.97	-0.35	1.66e-11	Height;
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg12143784	chr7:64541923	NA	0.36	6.3	0.32	9.08e-10	Calcium levels;
LIHC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20135002	chr11:47629003	NA	0.5	8.53	0.42	4.72e-16	Subjective well-being;
LIHC	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.49	6.02	0.31	4.6e-9	Schizophrenia;
LIHC	cis	rs2421770	0.530	rs7945809	chr11:35369253	G/A	cg13971030	chr11:35366721	SLC1A2	-0.44	-7.47	-0.37	6.68e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg13175981	chr1:150552382	MCL1	-0.43	-5.95	-0.31	6.69e-9	Tonsillectomy;
LIHC	cis	rs6442522	0.526	rs2168428	chr3:15529304	A/G	cg16303742	chr3:15540471	COLQ	0.38	6.0	0.31	5.12e-9	Uric acid levels;
LIHC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.58	7.5	0.38	5.57e-13	Morning vs. evening chronotype;
LIHC	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg08345082	chr10:99160200	RRP12	-0.41	-7.13	-0.36	6.01e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg04632378	chr13:21900426	NA	0.37	6.13	0.31	2.48e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.37	0.41	1.55e-15	Platelet count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20259981	chr8:53301664	ST18	-0.42	-6.19	-0.32	1.72e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-7.0	-0.35	1.35e-11	IgG glycosylation;
LIHC	cis	rs7173389	0.530	rs6495064	chr15:73682867	C/T	cg01796676	chr15:73680284	NA	-0.51	-8.29	-0.41	2.64e-15	Resting heart rate;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.71	-11.94	-0.54	1.08e-27	Prudent dietary pattern;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02111705	chr5:43065244	NA	-0.49	-6.28	-0.32	1.01e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs8081395	0.899	rs2645477	chr17:57845624	A/C	cg02344993	chr17:57696989	CLTC	-0.45	-7.21	-0.36	3.7e-12	White blood cell count;
LIHC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg21486233	chr12:29375141	FAR2	0.31	6.25	0.32	1.22e-9	QT interval;
LIHC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.41e-8	Testicular germ cell tumor;
LIHC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	1.18	14.34	0.61	7.88e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12463550	chr7:65579703	CRCP	0.71	7.44	0.37	8.23e-13	Diabetic kidney disease;
LIHC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00802000	chr16:706648	WDR90	-0.39	-6.31	-0.32	8.55e-10	Height;
LIHC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg03146154	chr1:46216737	IPP	0.43	5.8	0.3	1.51e-8	Platelet count;
LIHC	cis	rs911119	0.913	rs4815222	chr20:23576964	A/G	cg16589663	chr20:23618590	CST3	-0.65	-6.82	-0.35	4.1e-11	Chronic kidney disease;
LIHC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23422044	chr7:1970798	MAD1L1	-0.51	-5.81	-0.3	1.41e-8	Neuroticism;
LIHC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.78	0.3	1.68e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2997447	0.761	rs17257120	chr1:26450101	A/G	cg19633962	chr1:26362018	EXTL1	-0.65	-5.96	-0.31	6.31e-9	QRS complex (12-leadsum);
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.31	0.52	2.11e-25	Prudent dietary pattern;
LIHC	cis	rs11603020	0.950	rs78364821	chr11:57370742	C/T	cg19752551	chr11:57585705	CTNND1	-0.47	-5.9	-0.3	8.97e-9	Blood protein levels;
LIHC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.09	-0.4	1.05e-14	Monocyte percentage of white cells;
LIHC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg03037974	chr15:76606532	NA	0.74	14.5	0.62	1.74e-37	Blood metabolite levels;
LIHC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg19680672	chr10:131412579	MGMT	-0.45	-6.86	-0.35	3.33e-11	Response to temozolomide;
LIHC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.72	-0.3	2.27e-8	Subjective well-being;
LIHC	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.27	-0.32	1.1e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17906523	chr1:94883536	ABCD3	0.43	6.07	0.31	3.46e-9	Pancreatic cancer;
LIHC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.19	-0.32	1.73e-9	Breast cancer;
LIHC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.84	-0.51	1.02e-23	Body mass index;
LIHC	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.57	0.33	1.84e-10	Body mass index;
LIHC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.74	9.77	0.47	4.69e-20	Eosinophilic esophagitis;
LIHC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.34	-6.17	-0.32	1.97e-9	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26801646	chr10:76970496	VDAC2	0.51	6.87	0.35	3.1e-11	Lung function (FEV1/FVC);
LIHC	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23491599	chr2:155554688	KCNJ3	-0.43	-6.07	-0.31	3.31e-9	Bilirubin levels;
LIHC	cis	rs12702595	0.552	rs10263069	chr7:7269366	C/T	cg04827551	chr7:7268805	C1GALT1	0.33	6.13	0.31	2.45e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.75	11.76	0.54	4.87e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg03735888	chr19:58951602	ZNF132	0.41	7.14	0.36	5.54e-12	Uric acid clearance;
LIHC	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.25	-6.33	-0.32	7.83e-10	Hepatitis;
LIHC	cis	rs1144333	1.000	rs60144605	chr1:76359699	A/C	cg03433033	chr1:76189801	ACADM	0.55	8.31	0.41	2.21e-15	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.65	-11.02	-0.51	2.23e-24	Crohn's disease;
LIHC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.17	0.32	1.88e-9	Menopause (age at onset);
LIHC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.45	7.37	0.37	1.32e-12	Menarche (age at onset);
LIHC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.51	-8.18	-0.4	5.67e-15	Multiple sclerosis;
LIHC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17507749	chr15:85114479	UBE2QP1	0.76	8.67	0.42	1.79e-16	Schizophrenia;
LIHC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.98	13.29	0.58	8.46e-33	Heart rate;
LIHC	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.21	0.41	4.68e-15	Exhaled nitric oxide output;
LIHC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.73	0.5	2.41e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.5e-10	Asthma;
LIHC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20492807	chr1:225117750	DNAH14	-0.41	-6.11	-0.31	2.75e-9	Immature fraction of reticulocytes;
LIHC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg23682824	chr7:23144976	KLHL7	0.41	6.15	0.32	2.16e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg14146966	chr2:61757674	XPO1	-0.45	-7.71	-0.38	1.42e-13	Tuberculosis;
LIHC	cis	rs6137287	0.668	rs6082329	chr20:21100138	G/T	cg04219410	chr20:21106687	PLK1S1	-0.33	-5.76	-0.3	1.91e-8	Height;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24636629	chr4:40058917	LOC344967;N4BP2	0.42	6.21	0.32	1.56e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.11	-10.34	-0.49	5.5e-22	Breast cancer;
LIHC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-7.92	-0.39	3.32e-14	Menarche (age at onset);
LIHC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	7.72	0.39	1.28e-13	Platelet count;
LIHC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.57	8.0	0.4	2e-14	Bladder cancer;
LIHC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.56	0.53	2.48e-26	Coronary artery disease;
LIHC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.32	-8.16	-0.4	6.27e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs116248771	0.696	rs16847123	chr3:158416137	C/T	cg16708174	chr3:158430962	RARRES1	0.48	6.31	0.32	8.53e-10	diarrhoeal disease at age 2;
LIHC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.8	9.83	0.47	2.96e-20	Morning vs. evening chronotype;
LIHC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12744310	0.887	rs36015391	chr1:41784805	T/G	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.92e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg09990169	chr2:241835740	C2orf54	-0.67	-9.56	-0.46	2.34e-19	Urinary metabolites;
LIHC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.71	-9.79	-0.47	4.09e-20	Asthma;
LIHC	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.26	0.32	1.13e-9	Ulcerative colitis;
LIHC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-6.99	-0.35	1.44e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.21	-0.36	3.73e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7872515	0.651	rs7863564	chr9:94722509	T/C	cg01248375	chr9:94877805	SPTLC1	0.48	6.54	0.33	2.23e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.45	10.24	0.48	1.17e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.6	10.32	0.49	6.21e-22	Height;
LIHC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21211367	chr2:162094118	NA	0.37	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	6.5	0.33	2.76e-10	Schizophrenia;
LIHC	cis	rs787274	0.867	rs1361719	chr9:115535576	A/G	cg13803584	chr9:115635662	SNX30	-0.56	-6.25	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg15902774	chr15:75289873	SCAMP5	0.39	5.96	0.31	6.22e-9	Lung cancer;
LIHC	cis	rs10508774	1.000	rs11009023	chr10:32954752	C/G	cg01819863	chr10:32635814	EPC1	0.64	5.95	0.31	6.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.13	0.55	2.03e-28	Height;
LIHC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.5	0.53	4.13e-26	High light scatter reticulocyte count;
LIHC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.64	-9.18	-0.44	4.09e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg20607798	chr8:58055168	NA	0.46	6.37	0.33	6.2e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1499280	1.000	rs1991004	chr5:52106866	C/T	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.7	11.51	0.53	3.93e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.5	7.84	0.39	5.89e-14	Diastolic blood pressure;
LIHC	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.64	9.67	0.46	1.04e-19	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.91	8.81	0.43	6.36e-17	Inflammatory bowel disease;
LIHC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.34	5.96	0.31	6.31e-9	Aortic root size;
LIHC	cis	rs2526882	0.550	rs10150408	chr14:71563661	G/A	cg15816911	chr14:71606274	NA	0.42	6.73	0.34	7.31e-11	Schizophrenia;
LIHC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.53	-9.41	-0.45	7.59e-19	Diastolic blood pressure;
LIHC	cis	rs858239	0.539	rs10270695	chr7:23188988	C/T	cg23682824	chr7:23144976	KLHL7	-0.42	-6.31	-0.32	8.57e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.74	0.34	6.69e-11	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14138432	chr3:196295511	WDR53;FBXO45	-0.42	-6.19	-0.32	1.71e-9	Pancreatic cancer;
LIHC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.0	-0.31	4.89e-9	Diabetic kidney disease;
LIHC	cis	rs12295403	0.691	rs11607934	chr11:18689168	C/T	cg09887367	chr11:18690185	NA	-0.4	-5.76	-0.3	1.85e-8	Ovarian reserve;
LIHC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-6.5	-0.33	2.88e-10	Axial length;
LIHC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.43	6.01	0.31	4.72e-9	Uric acid clearance;
LIHC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.15	0.4	6.93e-15	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01198024	chr21:33672713	MRAP	-0.5	-8.16	-0.4	6.4e-15	Calcium levels;
LIHC	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.75	11.22	0.52	4.26e-25	Subjective well-being;
LIHC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.21	0.52	4.8e-25	Colorectal cancer;
LIHC	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02985541	chr2:219472218	PLCD4	0.43	7.89	0.39	4.1e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs546131	0.642	rs2956073	chr11:34842883	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.2	0.36	3.82e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg16586182	chr3:47516702	SCAP	-0.45	-8.06	-0.4	1.31e-14	Colorectal cancer;
LIHC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.35	7.42	0.37	9.63e-13	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg12160578	chr15:63334699	TPM1	0.67	8.87	0.43	4.13e-17	Orofacial clefts;
LIHC	trans	rs6897795	1.000	rs72648830	chr5:177608542	C/T	cg19598605	chr2:70056955	GMCL1	-0.59	-7.26	-0.37	2.57e-12	Plateletcrit;
LIHC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.24e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.73	11.5	0.53	4.27e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.68	-9.79	-0.47	4e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.7	13.34	0.59	5.66e-33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg14146966	chr2:61757674	XPO1	0.43	7.27	0.37	2.54e-12	Tuberculosis;
LIHC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg15123519	chr2:136567270	LCT	-0.42	-8.48	-0.42	6.7e-16	Mosquito bite size;
LIHC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10820045	chr2:198174542	NA	-0.59	-9.82	-0.47	3.19e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.47	8.45	0.42	8.36e-16	IgG glycosylation;
LIHC	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.41	5.72	0.3	2.3e-8	Height;
LIHC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.25	-0.36	2.82e-12	Migraine;Coronary artery disease;
LIHC	cis	rs876084	0.505	rs35529075	chr8:121143623	C/G	cg06265175	chr8:121136014	COL14A1	0.42	6.58	0.34	1.82e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg03983715	chr16:68378420	PRMT7	-0.51	-6.23	-0.32	1.38e-9	Schizophrenia;
LIHC	cis	rs12365397	0.775	rs12795606	chr11:43243792	C/T	cg16667275	chr11:43333495	API5	0.41	6.13	0.31	2.36e-9	Migraine;
LIHC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.48	-0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg06882758	chr19:58662330	ZNF329	0.93	7.02	0.36	1.17e-11	Cholesterol, total;
LIHC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg18887096	chr2:219472410	PLCD4	-0.4	-5.96	-0.31	6.33e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.33	-6.03	-0.31	4.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg03264133	chr6:25882463	NA	-0.39	-5.86	-0.3	1.06e-8	Height;
LIHC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.15	0.4	6.78e-15	Motion sickness;
LIHC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg07959070	chr22:50026188	C22orf34	-0.34	-8.39	-0.41	1.25e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg10932868	chr11:921992	NA	0.4	7.58	0.38	3.31e-13	Alzheimer's disease (late onset);
LIHC	cis	rs7106204	0.609	rs12788438	chr11:24284068	G/T	ch.11.24196551F	chr11:24239977	NA	0.67	6.08	0.31	3.21e-9	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.44	-7.75	-0.39	1.04e-13	Aortic root size;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2224391	0.737	rs36117780	chr6:5262233	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-5.96	-0.31	6.36e-9	Height;
LIHC	cis	rs2204008	0.702	rs35409806	chr12:38319500	G/A	cg26384229	chr12:38710491	ALG10B	0.82	9.4	0.45	8.17e-19	Bladder cancer;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-10.12	-0.48	3.1e-21	Renal cell carcinoma;
LIHC	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.48	8.72	0.43	1.26e-16	Testicular germ cell tumor;
LIHC	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-7.65	-0.38	2.02e-13	Systemic lupus erythematosus;
LIHC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg25356066	chr3:128598488	ACAD9	0.55	7.57	0.38	3.47e-13	IgG glycosylation;
LIHC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.86	0.47	2.45e-20	Height;
LIHC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.28	7.01	0.35	1.28e-11	Schizophrenia;
LIHC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.66	-5.94	-0.31	6.85e-9	Menopause (age at onset);
LIHC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.65	8.11	0.4	9.32e-15	Gut microbiome composition (summer);
LIHC	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.59	-9.09	-0.44	7.92e-18	Schizophrenia;
LIHC	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.61	-6.56	-0.33	1.93e-10	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs3736485	0.966	rs4774596	chr15:51910975	C/A	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.56e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-21.71	-0.76	2.59e-66	Height;
LIHC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg20283391	chr11:68216788	NA	0.36	5.79	0.3	1.63e-8	Total body bone mineral density;
LIHC	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.44	8.59	0.42	3.09e-16	Testicular germ cell tumor;
LIHC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.13	0.58	3.61e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.16	0.44	4.82e-18	Cognitive ability;
LIHC	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.74	14.15	0.61	4.29e-36	Mortality in heart failure;
LIHC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	11.45	0.53	6.23e-26	Platelet count;
LIHC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.36	5.76	0.3	1.9e-8	Lewy body disease;
LIHC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.86	0.35	3.28e-11	Body mass index;
LIHC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.76	-12.59	-0.56	3.92e-30	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.59	5.96	0.31	6.44e-9	Breast cancer;
LIHC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.78	9.56	0.46	2.39e-19	Morning vs. evening chronotype;
LIHC	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.95	-0.4	2.67e-14	Response to antipsychotic treatment;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02740969	chr7:139477893	TBXAS1;HIPK2	0.38	6.1	0.31	2.82e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg21522988	chr12:29376872	FAR2	0.25	5.72	0.3	2.28e-8	QT interval;
LIHC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.33	0.52	1.82e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.37	-5.88	-0.3	9.97e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6442522	0.678	rs2345106	chr3:15509028	A/G	cg16303742	chr3:15540471	COLQ	0.47	7.85	0.39	5.45e-14	Uric acid levels;
LIHC	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg15660573	chr17:549704	VPS53	0.51	8.31	0.41	2.23e-15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.62	-8.78	-0.43	8.07e-17	Blood metabolite levels;
LIHC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.91	16.83	0.67	1.04e-46	Aortic root size;
LIHC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.42	-6.66	-0.34	1.08e-10	Schizophrenia;
LIHC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.6	11.33	0.52	1.79e-25	Mean corpuscular volume;
LIHC	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg19308663	chr11:118741387	NA	-0.46	-6.01	-0.31	4.8e-9	Sjögren's syndrome;
LIHC	cis	rs17125944	0.686	rs2357947	chr14:53345378	C/T	cg00686598	chr14:53173677	PSMC6	-0.71	-7.89	-0.39	4.05e-14	Alzheimer's disease (late onset);
LIHC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.59	-9.11	-0.44	7.32e-18	Dental caries;
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs7095607	0.606	rs6480311	chr10:69956848	T/C	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.94e-9	Lung function (FVC);
LIHC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.42	-7.33	-0.37	1.64e-12	Platelet distribution width;
LIHC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.76	-10.08	-0.48	4.37e-21	Systemic lupus erythematosus;
LIHC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.93	17.54	0.69	1.44e-49	Menopause (age at onset);
LIHC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg07424592	chr7:64974309	NA	0.78	9.03	0.44	1.23e-17	Diabetic kidney disease;
LIHC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg03721293	chr16:90014378	DEF8	0.36	5.72	0.3	2.33e-8	Skin colour saturation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23712970	chr14:23540735	ACIN1	0.42	6.11	0.31	2.76e-9	Pancreatic cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27077143	chr5:68666458	TAF9;RAD17	0.38	6.18	0.32	1.87e-9	Calcium levels;
LIHC	cis	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.57	-5.95	-0.31	6.68e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.98	-11.25	-0.52	3.34e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg03934865	chr2:198174659	NA	0.54	8.27	0.41	3.03e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg00343986	chr7:65444356	GUSB	0.39	5.85	0.3	1.14e-8	Aortic root size;
LIHC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.45	6.54	0.33	2.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.3	16.95	0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs9993613	1.000	rs4694504	chr4:73496691	A/G	cg15102770	chr4:73434591	ADAMTS3	0.4	6.28	0.32	1.02e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.51	8.6	0.42	2.85e-16	Schizophrenia;
LIHC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.49e-11	Body mass index;
LIHC	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg08539965	chr1:21396338	EIF4G3	0.34	6.15	0.32	2.22e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg05665937	chr4:1216051	CTBP1	0.44	5.87	0.3	1.04e-8	Obesity-related traits;
LIHC	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.46	7.16	0.36	4.91e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.64	8.43	0.41	9.47e-16	Gut microbiome composition (summer);
LIHC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.36	6.78	0.34	5.36e-11	Mean corpuscular volume;
LIHC	cis	rs5753037	0.803	rs131263	chr22:30133045	C/T	cg01021169	chr22:30184971	ASCC2	-0.32	-5.96	-0.31	6.37e-9	Type 1 diabetes;
LIHC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.69	10.69	0.5	3.38e-23	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06544989	chr22:39130855	UNC84B	0.35	5.91	0.3	8.18e-9	Menopause (age at onset);
LIHC	cis	rs1144333	1.000	rs112401426	chr1:76466103	T/A	cg22875332	chr1:76189707	ACADM	0.4	6.15	0.32	2.16e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.76	14.24	0.61	1.82e-36	Mean platelet volume;
LIHC	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.44	0.49	2.42e-22	Fuchs's corneal dystrophy;
LIHC	trans	rs10761482	0.600	rs72807911	chr10:62228288	T/C	cg17314160	chr12:110399253	GIT2	0.44	6.41	0.33	4.89e-10	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.35	-5.87	-0.3	1.04e-8	Height;
LIHC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.62	10.3	0.49	7.66e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	trans	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.42	0.59	2.9e-33	Diabetic kidney disease;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.43	8.07	0.4	1.25e-14	Prudent dietary pattern;
LIHC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg16434002	chr17:42200994	HDAC5	-0.54	-7.72	-0.39	1.34e-13	Total body bone mineral density;
LIHC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.47	8.29	0.41	2.58e-15	Mean corpuscular volume;
LIHC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.53	-7.55	-0.38	4.11e-13	Body mass index;
LIHC	cis	rs7503168	0.908	rs9911863	chr17:33939899	G/A	cg20932281	chr17:33905541	PEX12	0.56	6.98	0.35	1.54e-11	Plateletcrit;
LIHC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.72	-7.42	-0.37	9.38e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.4	-6.35	-0.32	6.7e-10	Morning vs. evening chronotype;
LIHC	cis	rs4788570	0.667	rs4788557	chr16:71804802	C/T	cg06353428	chr16:71660113	MARVELD3	1.32	14.19	0.61	2.88e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.46	6.13	0.31	2.36e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs778371	0.723	rs4144795	chr2:233562731	C/G	cg08000102	chr2:233561755	GIGYF2	0.76	9.26	0.45	2.34e-18	Schizophrenia;
LIHC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-7.0	-0.35	1.37e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.59	7.29	0.37	2.1e-12	Coronary artery disease;
LIHC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.76	0.47	5.33e-20	Lung cancer;
LIHC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg20607798	chr8:58055168	NA	0.48	5.98	0.31	5.72e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.53	0.64	1.5e-41	Chronic sinus infection;
LIHC	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg02297831	chr4:17616191	MED28	0.47	6.89	0.35	2.66e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg03934865	chr2:198174659	NA	0.46	6.7	0.34	8.48e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.29	-7.16	-0.36	4.95e-12	Migraine;
LIHC	cis	rs11212260	0.655	rs11212243	chr11:107318547	T/C	cg25435332	chr11:107328525	CWF19L2	0.82	8.41	0.41	1.13e-15	IgG glycosylation;
LIHC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg14092571	chr14:90743983	NA	0.39	6.26	0.32	1.13e-9	Mortality in heart failure;
LIHC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.27	7.05	0.36	9.76e-12	Cardiovascular disease risk factors;
LIHC	cis	rs2257205	0.667	rs77326197	chr17:56905618	T/C	cg12560992	chr17:57184187	TRIM37	0.67	7.23	0.36	3.24e-12	Pancreatic cancer;
LIHC	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.27	6.28	0.32	1.03e-9	Heart rate;
LIHC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-8.34	-0.41	1.83e-15	Morning vs. evening chronotype;
LIHC	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	9.49	0.46	4.15e-19	Lewy body disease;
LIHC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.45	7.25	0.37	2.78e-12	Red blood cell count;
LIHC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.9	-0.39	3.89e-14	Type 2 diabetes;
LIHC	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.46	6.86	0.35	3.25e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22045829	chr13:60970476	TDRD3	-0.4	-6.2	-0.32	1.59e-9	Cognitive function;
LIHC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg23533926	chr12:111358616	MYL2	-0.32	-6.12	-0.31	2.61e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.52	9.06	0.44	1.01e-17	Coronary artery disease;
LIHC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.45	6.5	0.33	2.78e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.61	-6.54	-0.33	2.24e-10	Vitiligo;
LIHC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg05564831	chr3:52568323	NT5DC2	-0.36	-5.79	-0.3	1.59e-8	Bipolar disorder;
LIHC	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.94	-12.28	-0.55	5.83e-29	Obesity-related traits;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.32	-0.32	8.17e-10	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20203792	chr4:20701925	PACRGL	0.44	6.43	0.33	4.19e-10	Pancreatic cancer;
LIHC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	12.22	0.55	9.73e-29	Colorectal cancer;
LIHC	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.79	15.22	0.64	2.57e-40	Longevity;
LIHC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg18306943	chr3:40428807	ENTPD3	0.33	5.86	0.3	1.07e-8	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13409248	chr3:40428643	ENTPD3	0.49	8.23	0.41	3.95e-15	Renal cell carcinoma;
LIHC	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.31	-0.37	1.93e-12	Tuberculosis;
LIHC	cis	rs1144333	0.655	rs12402347	chr1:76447986	C/T	cg03433033	chr1:76189801	ACADM	0.54	7.46	0.37	7.27e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.56	-9.11	-0.44	6.87e-18	Colorectal cancer;
LIHC	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	8.26	0.41	3.16e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.8	-9.99	-0.48	8.93e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.62	7.51	0.38	5.29e-13	Cognitive function;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16037096	chr14:20881764	TEP1	-0.55	-6.62	-0.34	1.37e-10	Systolic blood pressure;
LIHC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg22633049	chr21:46681294	NA	-0.36	-6.33	-0.32	7.64e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.17	-0.36	4.75e-12	Personality dimensions;
LIHC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.56	-0.38	3.77e-13	Glioblastoma;
LIHC	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.57	-8.57	-0.42	3.68e-16	Schizophrenia;
LIHC	cis	rs9425766	0.640	rs2295366	chr1:173825692	A/C	cg06124660	chr1:173389066	NA	-0.3	-5.84	-0.3	1.19e-8	Life satisfaction;
LIHC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11229555	0.645	rs7946522	chr11:58197905	G/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg03874509	chr1:107600012	PRMT6	-0.76	-11.93	-0.54	1.18e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.51	9.77	0.47	4.85e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.64	-10.72	-0.5	2.58e-23	Pediatric autoimmune diseases;
LIHC	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.32	7.28	0.37	2.26e-12	Blood metabolite ratios;
LIHC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.94	0.51	4.23e-24	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.13	0.55	2e-28	Prudent dietary pattern;
LIHC	trans	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.97	12.69	0.57	1.64e-30	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg14393609	chr7:65229607	NA	-0.37	-5.81	-0.3	1.4e-8	Aortic root size;
LIHC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.66	0.34	1.11e-10	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.85	13.75	0.6	1.49e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg20090690	chr10:134436459	INPP5A	0.44	5.8	0.3	1.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.71	-6.71	-0.34	8.15e-11	Plateletcrit;
LIHC	cis	rs2239815	0.545	rs5762855	chr22:29246605	A/T	cg15103426	chr22:29168792	CCDC117	0.44	5.87	0.3	1.06e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.61	0.46	1.59e-19	Lymphocyte counts;
LIHC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	6.43	0.33	4.4e-10	Renal cell carcinoma;
LIHC	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.19	-0.36	4.04e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.47	9.84	0.47	2.89e-20	Tonsillectomy;
LIHC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-12.27	-0.55	6.52e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.43	-7.23	-0.36	3.16e-12	Educational attainment;
LIHC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs6594499	0.872	rs13161853	chr5:110446741	C/A	cg04022379	chr5:110408740	TSLP	0.49	8.22	0.41	4.36e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.58	6.51	0.33	2.73e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.45	6.03	0.31	4.22e-9	Height;
LIHC	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.48	-9.53	-0.46	3.12e-19	LDL cholesterol levels;
LIHC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-9.61	-0.46	1.67e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs1144333	0.655	rs1361487	chr1:76430471	A/C	cg10523679	chr1:76189770	ACADM	0.43	5.92	0.3	7.75e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg00228799	chr9:131580591	ENDOG	-0.46	-7.07	-0.36	8.95e-12	Blood metabolite levels;
LIHC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.57	7.88	0.39	4.37e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg26149184	chr10:133730230	NA	-0.46	-7.39	-0.37	1.1e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.36	5.97	0.31	5.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-10.93	-0.51	4.62e-24	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25632853	chr15:73088954	NA	0.36	6.05	0.31	3.77e-9	Triglyceride levels;
LIHC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.35	6.11	0.31	2.71e-9	Total cholesterol levels;
LIHC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.51	0.53	3.81e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-6.73	-0.34	7.36e-11	Schizophrenia;
LIHC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.51	9.05	0.44	1.09e-17	N-glycan levels;
LIHC	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg07541023	chr7:19748670	TWISTNB	0.4	6.08	0.31	3.19e-9	Thyroid stimulating hormone;
LIHC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06481639	chr22:41940642	POLR3H	-0.58	-6.05	-0.31	3.7e-9	Vitiligo;
LIHC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.68	13.0	0.58	1.08e-31	Height;
LIHC	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.35	23.89	0.79	6.73e-75	Corneal structure;
LIHC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.64	-0.46	1.31e-19	Mean platelet volume;
LIHC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.43	-7.95	-0.4	2.67e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.45	-8.0	-0.4	1.92e-14	Calcium levels;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg11070056	chr1:107600091	PRMT6	0.7	12.14	0.55	1.89e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg10756647	chr7:56101905	PSPH	0.62	8.5	0.42	6.09e-16	Corneal structure;
LIHC	cis	rs644148	0.836	rs2571110	chr19:45000712	T/C	cg15540054	chr19:45004280	ZNF180	-0.8	-12.07	-0.55	3.62e-28	Personality dimensions;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.12	-0.36	6.27e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs783540	0.869	rs783521	chr15:83280445	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.14	-0.32	2.27e-9	Schizophrenia;
LIHC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.84	10.51	0.49	1.45e-22	Bladder cancer;
LIHC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.4	6.9	0.35	2.6e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg06664874	chr5:179499304	RNF130	0.58	7.13	0.36	5.93e-12	LDL cholesterol;
LIHC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-13.36	-0.59	4.74e-33	Vitiligo;
LIHC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.32	6.91	0.35	2.31e-11	Ulcerative colitis;
LIHC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.53	-8.57	-0.42	3.64e-16	Fibrinogen levels;
LIHC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.63	-10.05	-0.48	5.42e-21	Dental caries;
LIHC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7224668	0.564	rs7223939	chr17:79241521	A/G	cg08034816	chr17:79219380	SLC38A10	0.39	6.04	0.31	4.01e-9	IgG glycosylation;
LIHC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.55	10.74	0.5	2.16e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg16070018	chr6:26224392	HIST1H3E	0.57	7.05	0.36	9.92e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.73	-0.39	1.18e-13	Total body bone mineral density;
LIHC	cis	rs11822910	0.815	rs11229028	chr11:57193918	G/A	cg00522883	chr11:57194120	SLC43A3	0.67	8.38	0.41	1.36e-15	Platelet distribution width;
LIHC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg26939375	chr7:64535504	NA	0.4	6.31	0.32	8.67e-10	Aortic root size;
LIHC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.36	6.67	0.34	1.04e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.21e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13170468	chr11:10531665	NA	-0.4	-6.13	-0.31	2.49e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	0.56	9.98	0.47	9.72e-21	Methadone dose in opioid dependence;
LIHC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02985541	chr2:219472218	PLCD4	0.45	8.65	0.42	2.09e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.83	0.54	2.7e-27	Colorectal cancer;
LIHC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.45	7.4	0.37	1.09e-12	Response to temozolomide;
LIHC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.68	13.23	0.58	1.46e-32	High light scatter reticulocyte count;
LIHC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.88	0.3	9.88e-9	Electroencephalogram traits;
LIHC	cis	rs2573652	0.657	rs2573668	chr15:100541776	C/T	cg09918751	chr15:100517450	ADAMTS17	0.65	11.54	0.53	3.07e-26	Height;
LIHC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.35	8.75	0.43	1.02e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10411936	1.000	rs873636	chr19:16514771	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.43	5.94	0.31	7.09e-9	White blood cell count;Multiple sclerosis;
LIHC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.78	-11.67	-0.53	1.01e-26	Personality dimensions;
LIHC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	0.67	6.67	0.34	1.03e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-8.4	-0.41	1.18e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg08923669	chr16:420230	MRPL28	-0.45	-5.88	-0.3	9.96e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.38	-6.41	-0.33	4.89e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-1.01	-10.18	-0.48	1.99e-21	Hip circumference adjusted for BMI;
LIHC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	8.9	0.43	3.28e-17	Monocyte count;
LIHC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.74	10.22	0.48	1.4e-21	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.57	0.46	2.21e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.95	17.08	0.68	1.02e-47	Breast cancer;
LIHC	cis	rs6061231	0.958	rs2427304	chr20:60953584	G/A	cg06026331	chr20:60912101	LAMA5	0.44	6.13	0.31	2.43e-9	Colorectal cancer;
LIHC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg04013166	chr16:89971882	TCF25	0.52	6.46	0.33	3.55e-10	Skin colour saturation;
LIHC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.77	9.68	0.46	9.51e-20	Cognitive function;
LIHC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg13409248	chr3:40428643	ENTPD3	0.5	8.37	0.41	1.47e-15	Renal cell carcinoma;
LIHC	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.81	0.54	3.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.14	0.44	5.62e-18	Mean platelet volume;
LIHC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.54	-7.64	-0.38	2.18e-13	Menarche (age at onset);
LIHC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.48	7.01	0.35	1.31e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.47	7.95	0.4	2.68e-14	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg16088116	chr21:44841560	SIK1	-0.41	-6.39	-0.33	5.52e-10	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.52	-0.38	4.82e-13	Initial pursuit acceleration;
LIHC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.92	-0.35	2.2e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg22951263	chr5:87985283	NA	-0.39	-6.79	-0.34	5.1e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.74	0.39	1.11e-13	Renal cell carcinoma;
LIHC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.58	6.89	0.35	2.62e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg00656387	chr3:40428638	ENTPD3	0.49	8.25	0.41	3.48e-15	Renal cell carcinoma;
LIHC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.79	-12.45	-0.56	1.3e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7212590	0.581	rs57812342	chr17:57827154	A/G	cg10252138	chr17:58120427	NA	-0.65	-6.31	-0.32	8.87e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.74	13.76	0.6	1.41e-34	Prudent dietary pattern;
LIHC	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg12698662	chr3:15914712	MIR563	-0.36	-6.71	-0.34	7.91e-11	Mean platelet volume;
LIHC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.08	-0.48	4.45e-21	Response to antipsychotic treatment;
LIHC	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.06	0.55	3.76e-28	Eye color traits;
LIHC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.42	-8.43	-0.41	9.83e-16	Obesity-related traits;
LIHC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-7.95	-0.4	2.7e-14	Obesity-related traits;
LIHC	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.72	-10.06	-0.48	4.91e-21	Tonsillectomy;
LIHC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	0.95	6.71	0.34	8.03e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.86	-0.35	3.16e-11	Cognitive test performance;
LIHC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.9	-0.47	1.73e-20	Response to antipsychotic treatment;
LIHC	cis	rs12644436	0.671	rs13107310	chr4:88787350	G/T	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	cis	rs526821	0.553	rs510095	chr11:55289154	T/C	cg04317927	chr11:55418816	OR4S2	0.47	8.96	0.44	2.11e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg03037974	chr15:76606532	NA	0.72	13.99	0.6	1.74e-35	Blood metabolite levels;
LIHC	trans	rs11039100	1.000	rs12362071	chr11:5828450	T/C	cg11650987	chr12:10280440	CLEC7A	0.4	6.05	0.31	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg03934865	chr2:198174659	NA	0.46	6.59	0.34	1.63e-10	Dermatomyositis;
LIHC	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg01843034	chr6:37503916	NA	-0.39	-6.53	-0.33	2.36e-10	Cognitive performance;
LIHC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.25	0.55	7.54e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.22e-26	Motion sickness;
LIHC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.4	-0.33	4.97e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-12.28	-0.55	5.86e-29	Platelet distribution width;
LIHC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.41	-7.46	-0.37	7.27e-13	Hepatocellular carcinoma;
LIHC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.73	13.82	0.6	7.8e-35	Mortality in heart failure;
LIHC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg00529422	chr1:16285251	ZBTB17	0.35	6.8	0.34	4.8e-11	Systolic blood pressure;
LIHC	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-8.24	-0.41	3.64e-15	Obesity-related traits;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg26634121	chr16:88897219	GALNS	0.43	6.72	0.34	7.84e-11	Longevity;
LIHC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg25039879	chr17:56429692	SUPT4H1	0.74	8.37	0.41	1.49e-15	Cognitive test performance;
LIHC	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.43	9.16	0.44	4.81e-18	Migraine;
LIHC	cis	rs7577696	0.524	rs805831	chr2:32484228	C/G	cg02381751	chr2:32503542	YIPF4	0.45	6.2	0.32	1.66e-9	Inflammatory biomarkers;
LIHC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.67	13.33	0.58	6.32e-33	High light scatter reticulocyte count;
LIHC	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg12698662	chr3:15914712	MIR563	-0.41	-7.55	-0.38	3.91e-13	Mean platelet volume;
LIHC	cis	rs9980664	1.000	rs9978569	chr21:34737271	C/T	cg04842828	chr21:34696676	IFNAR1	0.46	6.15	0.32	2.21e-9	Cognitive decline (age-related);
LIHC	cis	rs4604732	0.603	rs10925051	chr1:247641834	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.24	5.9	0.3	8.94e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	trans	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg04373760	chr16:53404718	NA	0.6	7.55	0.38	4.11e-13	Hypertriglyceridemia;
LIHC	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg21466736	chr12:48725269	NA	0.61	9.33	0.45	1.38e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.02	9.21	0.45	3.38e-18	Diabetic retinopathy;
LIHC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.36	5.92	0.3	7.83e-9	Blood metabolite levels;
LIHC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.23	6.09	0.31	3e-9	Calcium levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07148452	chr15:90176987	KIF7	-0.44	-6.45	-0.33	3.74e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg01028140	chr2:1542097	TPO	-0.46	-5.71	-0.3	2.41e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.62	-10.93	-0.51	4.72e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.6	-0.46	1.78e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs11673344	0.764	rs524802	chr19:37446947	G/A	cg27390819	chr19:37464633	NA	-0.53	-6.38	-0.33	5.79e-10	Obesity-related traits;
LIHC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.59	-6.38	-0.33	5.91e-10	Vitiligo;
LIHC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.41	-7.11	-0.36	7.01e-12	Type 2 diabetes;
LIHC	trans	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17712092	chr4:129076599	LARP1B	-0.78	-11.95	-0.54	9.65e-28	Eosinophil percentage of white cells;
LIHC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	8.86	0.43	4.6e-17	Hemoglobin concentration;
LIHC	cis	rs74181299	0.533	rs6722972	chr2:65374596	A/T	cg05010058	chr2:65284262	CEP68	-0.36	-5.8	-0.3	1.53e-8	Pulse pressure;
LIHC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.84	12.73	0.57	1.2e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	0.56	8.15	0.4	6.75e-15	Prudent dietary pattern;
LIHC	cis	rs12980942	0.872	rs7248164	chr19:41807700	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.26	0.32	1.13e-9	Coronary artery disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08330117	chr8:90770456	RIPK2	0.47	7.36	0.37	1.4e-12	Cognitive function;
LIHC	cis	rs11673344	0.704	rs540451	chr19:37435521	C/T	cg27390819	chr19:37464633	NA	-0.49	-5.84	-0.3	1.23e-8	Obesity-related traits;
LIHC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.53	-0.49	1.19e-22	Hemoglobin concentration;
LIHC	cis	rs2279817	0.863	rs12742364	chr1:18013430	T/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-8.38	-0.41	1.42e-15	Neuroticism;
LIHC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-6.26	-0.32	1.13e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg21518248	chr2:162101506	NA	0.4	5.89	0.3	9.46e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg13319975	chr6:146136371	FBXO30	-0.37	-6.11	-0.31	2.77e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg22771759	chr13:24902376	NA	0.32	6.59	0.34	1.71e-10	Obesity-related traits;
LIHC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.48	-7.0	-0.35	1.37e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.76	-11.07	-0.51	1.56e-24	Obesity-related traits;
LIHC	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.49	6.42	0.33	4.53e-10	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.69	9.92	0.47	1.47e-20	Lymphocyte counts;
LIHC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.63	7.55	0.38	4.02e-13	Initial pursuit acceleration;
LIHC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg20651018	chr11:3035856	CARS	0.37	6.4	0.33	5.13e-10	Longevity;
LIHC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.76	-12.02	-0.55	5.27e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.52	-0.42	5.17e-16	Total cholesterol levels;
LIHC	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg02811702	chr13:24901961	NA	0.24	6.01	0.31	4.75e-9	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07866137	chr8:67579786	VCPIP1	0.5	7.21	0.36	3.69e-12	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg07424592	chr7:64974309	NA	0.79	9.39	0.45	8.48e-19	Diabetic kidney disease;
LIHC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.54	-0.33	2.22e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs1461503	0.934	rs930982	chr11:122834378	C/T	cg25161029	chr11:122845972	NA	0.41	6.85	0.35	3.44e-11	Menarche (age at onset);
LIHC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.71	-8.35	-0.41	1.68e-15	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.73	12.86	0.57	3.67e-31	Eosinophil percentage of white cells;
LIHC	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg23682824	chr7:23144976	KLHL7	0.39	5.93	0.31	7.42e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg24693881	chr1:107596107	NA	-0.55	-9.72	-0.47	6.99e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22674798	chr1:3096360	PRDM16	0.26	6.36	0.33	6.31e-10	Migraine;
LIHC	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.6	6.36	0.33	6.38e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg11062466	chr8:58055876	NA	0.41	5.8	0.3	1.5e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17106184	1.000	rs72904749	chr1:51367420	C/T	cg07174182	chr1:51127561	FAF1	-0.75	-8.1	-0.4	1.01e-14	Type 2 diabetes;
LIHC	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00482020	chr16:25026850	ARHGAP17	0.39	6.1	0.31	2.89e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17106184	1.000	rs72902789	chr1:51293606	G/C	cg07174182	chr1:51127561	FAF1	-0.6	-6.39	-0.33	5.43e-10	Type 2 diabetes;
LIHC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.32	0.45	1.52e-18	Bipolar disorder;
LIHC	cis	rs7818688	0.697	rs57890591	chr8:95983130	G/A	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.46	6.83	0.35	3.78e-11	Asthma (sex interaction);
LIHC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.26	6.15	0.32	2.14e-9	Heart rate;
LIHC	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg18473234	chr19:5097819	KDM4B	-0.56	-6.76	-0.34	5.94e-11	Monocyte percentage of white cells;
LIHC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.58	-10.19	-0.48	1.84e-21	Platelet distribution width;
LIHC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.53	9.18	0.44	4.13e-18	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg22153463	chr1:85462885	MCOLN2	0.5	5.89	0.3	9.03e-9	Serum sulfate level;
LIHC	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	9.23	0.45	2.88e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21467203	chr3:49911342	NA	0.42	7.39	0.37	1.11e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.76	0.3	1.83e-8	Menopause (age at onset);
LIHC	cis	rs2108622	0.727	rs62106158	chr19:15980492	T/G	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg26921586	chr4:493489	ZNF721;PIGG	-0.56	-6.27	-0.32	1.1e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.1	0.36	7.35e-12	Morning vs. evening chronotype;
LIHC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg26138937	chr11:71823887	C11orf51	1.32	10.9	0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.53	8.42	0.41	1.07e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15166898	chr19:59008294	NA	-0.46	-6.29	-0.32	9.79e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg00601450	chr5:74908170	NA	0.59	7.18	0.36	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.55	-0.33	2.08e-10	Response to antipsychotic treatment;
LIHC	cis	rs1789	0.786	rs6414768	chr4:15695363	A/G	cg21123203	chr4:15471301	CC2D2A	-0.44	-6.86	-0.35	3.28e-11	Blood protein levels;
LIHC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.27	0.41	3e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg23978390	chr7:1156363	C7orf50	0.41	5.78	0.3	1.65e-8	Longevity;Endometriosis;
LIHC	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg04865290	chr3:52927548	TMEM110	-0.51	-5.91	-0.3	8.05e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.39	7.8	0.39	7.72e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.76	0.43	9.13e-17	Height;
LIHC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	ch.11.42038R	chr11:967971	AP2A2	0.54	9.72	0.47	6.88e-20	Alzheimer's disease (late onset);
LIHC	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.5	8.03	0.4	1.63e-14	Tuberculosis;
LIHC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.31	-5.8	-0.3	1.52e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6442522	0.678	rs12494919	chr3:15498272	G/A	cg16303742	chr3:15540471	COLQ	0.44	7.54	0.38	4.15e-13	Uric acid levels;
LIHC	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.62	-10.3	-0.49	7.5e-22	Waist circumference;Body mass index;
LIHC	cis	rs1198430	0.562	rs7546989	chr1:23789698	C/G	cg13183780	chr1:23809682	ASAP3	-0.34	-6.08	-0.31	3.29e-9	Total cholesterol levels;
LIHC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg21361702	chr7:150065534	REPIN1	0.46	6.35	0.32	6.92e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.56	9.15	0.44	5.24e-18	Lymphocyte counts;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10765909	chr12:53715428	AAAS	0.39	6.46	0.33	3.55e-10	Calcium levels;
LIHC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.42	-0.37	9.63e-13	Psoriasis;
LIHC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.47	16.88	0.67	6.43e-47	Eosinophil percentage of granulocytes;
LIHC	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.82	16.39	0.66	5.92e-45	Longevity;
LIHC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.14	-0.36	5.8e-12	Migraine;Coronary artery disease;
LIHC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.54	9.33	0.45	1.4e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs7534824	0.543	rs61780300	chr1:101403601	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	7.49	0.38	6.07e-13	Refractive astigmatism;
LIHC	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	7.4	0.37	1.06e-12	Adiposity;
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.39	0.8	7.99e-77	Prudent dietary pattern;
LIHC	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.38	-6.0	-0.31	5.02e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17545146	chr20:62289982	RTEL1	-0.53	-6.1	-0.31	2.9e-9	Systolic blood pressure;
LIHC	cis	rs77633900	0.614	rs2469241	chr15:76873908	A/G	cg21673338	chr15:77095150	SCAPER	-0.48	-7.11	-0.36	6.97e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.99	-0.35	1.41e-11	Adiposity;
LIHC	cis	rs1355223	0.902	rs1258468	chr11:34729731	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.32	-0.32	8.28e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg24220031	chr2:73402428	NA	-0.28	-6.08	-0.31	3.24e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2257205	0.667	rs7213035	chr17:56857281	A/G	cg12560992	chr17:57184187	TRIM37	0.68	7.44	0.37	8.24e-13	Pancreatic cancer;
LIHC	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-16.02	-0.65	1.72e-43	Coronary artery disease;
LIHC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08219700	chr8:58056026	NA	0.42	5.78	0.3	1.73e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.55	0.53	2.76e-26	Platelet count;
LIHC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.79	13.09	0.58	5.05e-32	Breast cancer;
LIHC	cis	rs9322817	0.691	rs6929746	chr6:105167548	G/C	cg02098413	chr6:105308735	HACE1	-0.4	-7.49	-0.38	5.82e-13	Thyroid stimulating hormone;
LIHC	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.72	-0.47	7.19e-20	Ulcerative colitis;
LIHC	cis	rs61041384	0.661	rs74240769	chr12:123688228	C/A	cg00376283	chr12:123451042	ABCB9	-0.55	-6.14	-0.32	2.28e-9	Schizophrenia;
LIHC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.47	6.31	0.32	8.75e-10	Mean platelet volume;
LIHC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	10.08	0.48	4.18e-21	Cognitive test performance;
LIHC	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg23583168	chr7:148888333	NA	-0.67	-8.89	-0.43	3.69e-17	Sum basophil neutrophil counts;Neutrophil count;
LIHC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.64	0.34	1.2e-10	Lung cancer;
LIHC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.31	0.66	1.17e-44	Smoking behavior;
LIHC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-8.92	-0.43	2.87e-17	Heart rate;
LIHC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.37	6.75	0.34	6.3e-11	Electrocardiographic conduction measures;
LIHC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.83	-0.43	5.69e-17	Type 2 diabetes;
LIHC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg13446199	chr8:143762866	PSCA	-0.2	-5.8	-0.3	1.48e-8	Urinary tract infection frequency;
LIHC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.56	9.49	0.46	4.12e-19	Colorectal cancer;
LIHC	cis	rs2710642	0.586	rs62180020	chr2:62819915	C/G	cg17519650	chr2:63277830	OTX1	0.44	6.92	0.35	2.25e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-0.65	-6.97	-0.35	1.59e-11	Post bronchodilator FEV1;
LIHC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.13	9.96	0.47	1.1e-20	Alzheimer's disease;
LIHC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-10.49	-0.49	1.7e-22	Platelet count;
LIHC	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.45	7.39	0.37	1.14e-12	Corneal astigmatism;
LIHC	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.55	-8.75	-0.43	9.65e-17	Morning vs. evening chronotype;
LIHC	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.76	-0.43	9.39e-17	Colorectal cancer;
LIHC	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.77	9.8	0.47	3.73e-20	Response to hepatitis C treatment;
LIHC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21467203	chr3:49911342	NA	-0.41	-7.17	-0.36	4.75e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.47	-7.88	-0.39	4.51e-14	Testicular germ cell tumor;
LIHC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.96	17.77	0.69	1.61e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.09	0.31	2.96e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.73	-8.95	-0.44	2.37e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.4	6.15	0.32	2.22e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs711245	0.748	rs2276671	chr2:36771701	C/A	cg09467607	chr2:36825704	FEZ2	0.47	6.87	0.35	2.98e-11	Height;
LIHC	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.42	12.22	0.55	9.43e-29	Uric acid levels;
LIHC	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.03	-0.4	1.55e-14	Alzheimer's disease;
LIHC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.54	-0.33	2.23e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.4	-0.41	1.24e-15	Vitamin D levels;
LIHC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.75	12.29	0.55	5.11e-29	Colorectal cancer;
LIHC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg22676075	chr6:135203613	NA	0.41	6.57	0.33	1.87e-10	Red blood cell count;
LIHC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg06363034	chr20:62225388	GMEB2	-0.44	-7.52	-0.38	4.72e-13	Glioblastoma;
LIHC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.89	12.6	0.56	3.55e-30	Blood metabolite levels;
LIHC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg24163568	chr5:669837	TPPP	-0.41	-8.58	-0.42	3.48e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.58	-10.54	-0.5	1.15e-22	Mean corpuscular volume;
LIHC	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg21467203	chr3:49911342	NA	-0.44	-5.9	-0.3	8.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.36	-8.01	-0.4	1.78e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1866706	1.000	rs11022517	chr11:12884855	G/A	cg25843174	chr11:12811716	TEAD1	0.3	6.31	0.32	8.6e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.58	-0.38	3.21e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs11674184	0.564	rs746579	chr2:11744694	C/T	cg07314298	chr2:11723111	GREB1	-0.44	-7.0	-0.35	1.35e-11	Endometriosis;
LIHC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg05941027	chr17:61774174	LIMD2	0.3	5.97	0.31	5.91e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.87	-0.3	1.01e-8	Multiple myeloma (IgH translocation);
LIHC	trans	rs1034394	0.775	rs5999351	chr22:34818610	A/T	cg02641517	chr3:54169983	CACNA2D3	-0.24	-6.1	-0.31	2.93e-9	Major depressive disorder;
LIHC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.14e-9	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.91	0.57	2.45e-31	Prudent dietary pattern;
LIHC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.49	9.33	0.45	1.34e-18	Atrioventricular conduction;
LIHC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.59	6.9	0.35	2.48e-11	Cognitive function;
LIHC	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.6	-8.62	-0.42	2.45e-16	Obesity-related traits;
LIHC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.52	9.66	0.46	1.12e-19	Hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.88	-12.36	-0.56	3.02e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs4938303	0.633	rs567209	chr11:116534828	C/T	cg13436940	chr11:116064295	NA	0.42	5.72	0.3	2.37e-8	Triglycerides;
LIHC	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.48	7.01	0.35	1.26e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2273156	0.636	rs12892552	chr14:35505414	A/G	cg16230307	chr14:35515116	FAM177A1	-0.42	-6.06	-0.31	3.67e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.55	6.48	0.33	3.24e-10	Breast cancer;
LIHC	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.67	9.36	0.45	1.09e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg00656387	chr3:40428638	ENTPD3	0.38	5.98	0.31	5.69e-9	Renal cell carcinoma;
LIHC	cis	rs9896052	0.514	rs11656576	chr17:73447658	T/C	cg25649188	chr17:73499917	CASKIN2	0.47	7.03	0.36	1.11e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.38	5.79	0.3	1.6e-8	Resting heart rate;
LIHC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs965469	0.947	rs965468	chr20:3381443	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.67	-0.34	1.01e-10	IFN-related cytopenia;
LIHC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg16479474	chr6:28041457	NA	0.45	6.34	0.32	7.43e-10	Depression;
LIHC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.67	-9.09	-0.44	7.97e-18	Schizophrenia;
LIHC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.67	-9.62	-0.46	1.54e-19	Initial pursuit acceleration;
LIHC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.75	0.3	1.99e-8	Bladder cancer;
LIHC	cis	rs61041384	0.661	rs74240781	chr12:123792701	T/C	cg00376283	chr12:123451042	ABCB9	-0.62	-6.58	-0.34	1.8e-10	Schizophrenia;
LIHC	cis	rs7192380	0.624	rs11075730	chr16:69650522	C/T	cg15192750	chr16:69999425	NA	0.37	5.78	0.3	1.69e-8	Sjögren's syndrome;
LIHC	cis	rs10792665	0.575	rs7101888	chr11:82559984	T/C	cg24227371	chr11:82718527	RAB30	-0.27	-6.56	-0.33	2e-10	Obesity-related traits;
LIHC	cis	rs2108622	0.727	rs12611242	chr19:15978564	G/A	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.87e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	1.02	21.64	0.76	5.09e-66	Height;
LIHC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.63	-0.42	2.31e-16	Colorectal cancer;
LIHC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.46	6.31	0.32	8.79e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg04865290	chr3:52927548	TMEM110	-0.53	-6.14	-0.31	2.33e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.41	6.63	0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17507749	chr15:85114479	UBE2QP1	0.68	7.72	0.39	1.31e-13	Schizophrenia;
LIHC	cis	rs67981189	0.613	rs4366661	chr14:71452316	A/T	cg15816911	chr14:71606274	NA	-0.41	-6.81	-0.35	4.4e-11	Schizophrenia;
LIHC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.53	-8.31	-0.41	2.27e-15	Lymphocyte counts;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg01696603	chr6:125623444	HDDC2	0.57	6.24	0.32	1.3e-9	Mean platelet volume;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	5.96	0.31	6.29e-9	Aortic root size;
LIHC	cis	rs55702914	0.625	rs787989	chr2:198200123	G/A	cg03934865	chr2:198174659	NA	-0.41	-5.96	-0.31	6.44e-9	Major depression and alcohol dependence;
LIHC	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	8.45	0.42	8.61e-16	LDL cholesterol;
LIHC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.48	7.67	0.38	1.75e-13	Total body bone mineral density;
LIHC	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg10820045	chr2:198174542	NA	0.47	7.03	0.36	1.12e-11	Intracranial aneurysm;
LIHC	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.77	-10.77	-0.5	1.73e-23	Ear protrusion;
LIHC	cis	rs62573167	0.547	rs17063622	chr9:80037320	A/G	cg14445849	chr9:79791814	VPS13A;LOC100286938	0.36	6.01	0.31	4.75e-9	Reticulocyte count;
LIHC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.44	0.45	6.18e-19	Hemoglobin concentration;
LIHC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg22834771	chr12:69754056	YEATS4	-0.37	-5.96	-0.31	6.23e-9	Blood protein levels;
LIHC	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.17e-8	Pulmonary function;
LIHC	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg23942311	chr14:51606299	NA	0.35	7.29	0.37	2.17e-12	Cancer;
LIHC	cis	rs10792665	0.575	rs10792654	chr11:82560445	T/G	cg24227371	chr11:82718527	RAB30	-0.26	-6.07	-0.31	3.46e-9	Obesity-related traits;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.94	-0.35	2.02e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.1	0.4	9.76e-15	Height;
LIHC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.99	0.31	5.43e-9	Electroencephalogram traits;
LIHC	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.08	-0.4	1.09e-14	Response to antipsychotic treatment;
LIHC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.3	5.86	0.3	1.06e-8	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10820045	chr2:198174542	NA	-0.61	-10.32	-0.49	6.7e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg25019722	chr6:37503610	NA	-0.33	-5.89	-0.3	9.46e-9	Cognitive performance;
LIHC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7572733	0.576	rs4850441	chr2:198913413	A/G	cg00792783	chr2:198669748	PLCL1	-0.42	-5.93	-0.31	7.4e-9	Dermatomyositis;
LIHC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.62	-8.81	-0.43	6.39e-17	Aortic root size;
LIHC	cis	rs17106184	1.000	rs12075991	chr1:51252618	A/G	cg07174182	chr1:51127561	FAF1	-0.71	-8.19	-0.41	5.08e-15	Type 2 diabetes;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19748516	chr19:18684528	UBA52	0.44	6.09	0.31	3.12e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.26	-0.41	3.28e-15	Colorectal cancer;
LIHC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.63	-8.48	-0.42	6.94e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.42	6.82	0.35	4.09e-11	Red blood cell count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08132132	chr8:82644559	CHMP4C	0.39	6.29	0.32	9.89e-10	Cognitive function;
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg19318889	chr4:1322082	MAEA	0.52	8.77	0.43	8.86e-17	Obesity-related traits;
LIHC	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.24	0.32	1.26e-9	Body mass index;
LIHC	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.42	-6.53	-0.33	2.37e-10	Metabolite levels;
LIHC	cis	rs6782228	0.606	rs2811488	chr3:128336517	C/T	cg16766828	chr3:128327626	NA	-0.39	-6.19	-0.32	1.69e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs8064024	0.650	rs12926178	chr16:4905915	C/T	cg08329684	chr16:4932620	PPL	-0.34	-5.83	-0.3	1.26e-8	Cancer;
LIHC	cis	rs9309473	1.000	rs2901438	chr2:73665656	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.93	-0.35	2.16e-11	Metabolite levels;
LIHC	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg15654264	chr1:150340011	RPRD2	0.52	8.91	0.43	3.19e-17	Migraine;
LIHC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg18912006	chr12:123335444	HIP1R	-0.64	-7.67	-0.38	1.78e-13	Schizophrenia;
LIHC	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	0.75	9.4	0.45	8.12e-19	Corneal structure;
LIHC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	8.38	0.41	1.38e-15	Diastolic blood pressure;
LIHC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg04083430	chr16:4736063	MGRN1	-0.44	-5.84	-0.3	1.19e-8	Schizophrenia;
LIHC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.41	8.23	0.41	3.9e-15	Cardiovascular disease risk factors;
LIHC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.56	6.67	0.34	1.02e-10	QRS duration;
LIHC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	1.01	19.32	0.72	9.73e-57	Breast cancer;
LIHC	cis	rs1419980	0.643	rs7296689	chr12:7779241	G/A	cg10578777	chr12:7781093	NA	-0.4	-5.83	-0.3	1.26e-8	HDL cholesterol levels;
LIHC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.17	0.55	1.54e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7911264	1.000	rs7911264	chr10:94436851	C/T	cg25506282	chr10:94462361	NA	-0.43	-7.39	-0.37	1.16e-12	Inflammatory bowel disease;
LIHC	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.38	6.89	0.35	2.62e-11	Obesity;
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg00280220	chr17:61926910	NA	0.41	6.46	0.33	3.61e-10	Prudent dietary pattern;
LIHC	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.86	17.99	0.7	2.19e-51	Testicular germ cell tumor;
LIHC	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.45	8.28	0.41	2.77e-15	Testicular germ cell tumor;
LIHC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.51	-7.64	-0.38	2.23e-13	Metabolic syndrome;
LIHC	cis	rs4684776	0.935	rs13059407	chr3:11377345	G/C	cg00170343	chr3:11313890	ATG7	-0.49	-6.72	-0.34	7.43e-11	Small vessel stroke;
LIHC	cis	rs2599510	0.748	rs6718214	chr2:32550485	T/C	cg02381751	chr2:32503542	YIPF4	-0.51	-6.95	-0.35	1.9e-11	Interleukin-18 levels;
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.93	12.65	0.56	2.45e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg22705602	chr4:152727874	NA	0.29	6.08	0.31	3.18e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.12	-0.31	2.53e-9	Vitiligo;
LIHC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.65	7.98	0.4	2.17e-14	Heart rate;
LIHC	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.01	-0.31	4.81e-9	Blood metabolite levels;
LIHC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.67	-8.24	-0.41	3.73e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg08888203	chr3:10149979	C3orf24	0.62	6.74	0.34	6.91e-11	Alzheimer's disease;
LIHC	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.78	14.41	0.61	3.99e-37	Longevity;
LIHC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	9.34	0.45	1.31e-18	Hip circumference adjusted for BMI;
LIHC	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs7624766	0.508	rs9831287	chr3:160579248	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-5.83	-0.3	1.27e-8	Response to methotrexate in rheumatoid arthritis;
LIHC	cis	rs74544699	1.000	rs79981249	chr4:74784164	T/C	cg02530824	chr4:74847766	PF4	0.66	6.82	0.35	4.2e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.9	11.48	0.53	5.09e-26	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.19e-9	Bipolar disorder;
LIHC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.38	6.15	0.32	2.21e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs4908768	0.906	rs12568293	chr1:8540912	C/T	cg25722041	chr1:8623473	RERE	-0.4	-5.95	-0.31	6.65e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00152838	chr16:24741724	TNRC6A	-0.53	-6.38	-0.33	5.63e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.55	-8.25	-0.41	3.39e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg02702477	chr5:179499311	RNF130	0.75	10.44	0.49	2.46e-22	LDL cholesterol;
LIHC	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg16586182	chr3:47516702	SCAP	-0.54	-9.77	-0.47	4.79e-20	Colorectal cancer;
LIHC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg12903224	chr12:29470962	FAR2	-0.41	-6.46	-0.33	3.54e-10	QT interval;
LIHC	cis	rs1664789	0.901	rs702635	chr5:53270188	G/T	ch.5.1024479R	chr5:53302184	ARL15	0.47	7.44	0.37	8.32e-13	Waist circumference adjusted for body mass index;
LIHC	cis	rs3736594	0.513	rs6704596	chr2:27796927	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.76	0.34	6.12e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.43	-7.61	-0.38	2.67e-13	Paraoxonase activity;
LIHC	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg21252483	chr19:49399788	TULP2	-0.98	-10.91	-0.51	5.59e-24	Red cell distribution width;
LIHC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.36	5.83	0.3	1.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.44	7.69	0.38	1.53e-13	Schizophrenia;
LIHC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg15841412	chr13:111365552	ING1	-0.5	-6.37	-0.33	6.24e-10	Coronary artery disease;
LIHC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.72	-9.14	-0.44	5.77e-18	Gut microbiome composition (summer);
LIHC	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.69	9.33	0.45	1.4e-18	Morning vs. evening chronotype;
LIHC	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg09795085	chr6:101329169	ASCC3	-0.39	-5.71	-0.3	2.41e-8	Neuroticism;
LIHC	cis	rs12744310	1.000	rs12031169	chr1:41768251	A/G	cg03962019	chr1:41807865	NA	0.4	6.49	0.33	3.01e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01538066	chr19:57946466	ZNF749	-0.52	-6.18	-0.32	1.85e-9	Systolic blood pressure;
LIHC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.63	9.73	0.47	6.73e-20	Renal cell carcinoma;
LIHC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg14393609	chr7:65229607	NA	-0.35	-5.71	-0.3	2.4e-8	Aortic root size;
LIHC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.24	6.62	0.34	1.39e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.98	0.31	5.65e-9	Educational attainment;
LIHC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.47	0.56	1.09e-29	Prudent dietary pattern;
LIHC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg08417687	chr6:108582627	SNX3	-0.56	-6.13	-0.31	2.41e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.46	-7.26	-0.37	2.58e-12	Type 2 diabetes;
LIHC	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.02	-0.44	1.33e-17	Type 2 diabetes;
LIHC	cis	rs6952808	0.743	rs10266703	chr7:1918941	C/A	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.74	-0.34	6.73e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.75	13.24	0.58	1.32e-32	Prudent dietary pattern;
LIHC	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.45	-7.08	-0.36	8.12e-12	Type 2 diabetes;
LIHC	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg14515779	chr1:101123966	NA	0.64	11.96	0.54	8.49e-28	Monocyte count;
LIHC	cis	rs11229555	0.645	rs12801475	chr11:58189034	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.7	-8.26	-0.41	3.21e-15	Vitiligo;
LIHC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.57	9.32	0.45	1.48e-18	Longevity;Endometriosis;
LIHC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.8	0.57	6.26e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.42	0.41	1.06e-15	Motion sickness;
LIHC	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.7	-11.43	-0.53	7.42e-26	White matter hyperintensity burden;
LIHC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.38	-6.05	-0.31	3.86e-9	Mortality in heart failure;
LIHC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.01	0.35	1.3e-11	Height;
LIHC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.79	-0.47	3.97e-20	Gut microbiome composition (summer);
LIHC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.5	-7.99	-0.4	2.07e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.54	8.63	0.42	2.31e-16	Neurofibrillary tangles;
LIHC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.46	-0.37	7.18e-13	Body mass index;
LIHC	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.66	10.07	0.48	4.8e-21	Body mass index;
LIHC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.47	-7.91	-0.39	3.56e-14	Bipolar disorder;
LIHC	cis	rs713477	0.692	rs8019270	chr14:55907172	C/G	cg13175173	chr14:55914753	NA	-0.31	-6.72	-0.34	7.76e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.11	-0.31	2.73e-9	Obesity-related traits;
LIHC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.67	0.57	1.93e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.84	-0.57	4.5e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7944735	0.508	rs4752786	chr11:47628536	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-6.32	-0.32	7.94e-10	Intraocular pressure;
LIHC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.99	17.94	0.7	3.45e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.79	13.97	0.6	2.14e-35	Body mass index;
LIHC	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-8.73	-0.43	1.14e-16	Obesity-related traits;
LIHC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.86	-0.35	3.33e-11	Bladder cancer;
LIHC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.4	0.33	5.21e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.53	-7.43	-0.37	9.02e-13	Body mass index;
LIHC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs713477	0.618	rs6573033	chr14:55919060	C/G	cg13175173	chr14:55914753	NA	-0.3	-6.76	-0.34	6.11e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6088813	1.000	rs4911494	chr20:33971914	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-5.83	-0.3	1.25e-8	Height;
LIHC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.65	-0.34	1.14e-10	Diabetic kidney disease;
LIHC	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.48	-5.85	-0.3	1.15e-8	Vitiligo;
LIHC	trans	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	11.65	0.53	1.25e-26	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	13.33	0.58	6.23e-33	Alzheimer's disease;
LIHC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.52	-7.41	-0.37	9.96e-13	Longevity;Endometriosis;
LIHC	cis	rs970821	0.900	rs2008198	chr8:124754567	T/C	cg00283535	chr8:124749564	ANXA13	0.37	6.05	0.31	3.78e-9	Breast cancer;
LIHC	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg12698662	chr3:15914712	MIR563	-0.36	-6.63	-0.34	1.34e-10	Mean platelet volume;
LIHC	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	6.8	0.35	4.65e-11	Response to antipsychotic treatment;
LIHC	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.46	6.95	0.35	1.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.87	-16.87	-0.67	6.67e-47	Coronary artery disease;
LIHC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.52	7.18	0.36	4.4e-12	Monobrow;
LIHC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.46	-0.42	8.15e-16	Total body bone mineral density;
LIHC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg16989086	chr20:62203971	PRIC285	0.57	8.25	0.41	3.51e-15	Glioblastoma;
LIHC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg21734168	chr11:67353974	GSTP1	-0.28	-6.88	-0.35	2.94e-11	Mean corpuscular volume;
LIHC	cis	rs6466055	0.777	rs2299308	chr7:104825819	A/C	cg04380332	chr7:105027541	SRPK2	-0.34	-6.42	-0.33	4.59e-10	Schizophrenia;
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.73	14.3	0.61	1.09e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.44	6.33	0.32	7.52e-10	Aortic root size;
LIHC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.5	-8.36	-0.41	1.55e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs17106184	0.818	rs112095647	chr1:51237302	C/G	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.16e-10	Type 2 diabetes;
LIHC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.11	0.4	9.33e-15	Menarche (age at onset);
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.53	-7.78	-0.39	8.63e-14	Height;
LIHC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg17294928	chr15:75287854	SCAMP5	-0.51	-6.56	-0.33	2.03e-10	Lung cancer;
LIHC	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.55	0.33	2.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7529073	0.545	rs340884	chr1:214145389	T/C	cg24083324	chr1:214162604	PROX1	0.49	7.47	0.37	6.79e-13	Schizophrenia;
LIHC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.41	5.89	0.3	9.04e-9	Blood protein levels;
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg03854865	chr6:26224070	HIST1H3E	0.63	7.23	0.36	3.28e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.61	10.66	0.5	4.39e-23	Coronary artery disease;
LIHC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg09445902	chr10:555545	DIP2C	-0.39	-6.33	-0.32	7.73e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg03959625	chr15:84868606	LOC388152	0.45	6.21	0.32	1.55e-9	Schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01154392	chr12:48167362	SLC48A1	0.59	7.16	0.36	5.02e-12	Hepatitis;
LIHC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.01	0.44	1.48e-17	Schizophrenia;
LIHC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.64	-9.94	-0.47	1.28e-20	Glaucoma (primary open-angle);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06665941	chr21:34602869	IFNAR2	0.46	7.28	0.37	2.32e-12	Pancreatic cancer;
LIHC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.37	7.85	0.39	5.49e-14	Obesity (extreme);
LIHC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20135002	chr11:47629003	NA	-0.56	-9.52	-0.46	3.18e-19	Subjective well-being;
LIHC	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.9	9.62	0.46	1.5e-19	LDL cholesterol;
LIHC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.45	-7.6	-0.38	2.94e-13	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg00343986	chr7:65444356	GUSB	0.39	5.77	0.3	1.76e-8	Aortic root size;
LIHC	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg00934597	chr7:893267	UNC84A	-0.5	-6.25	-0.32	1.22e-9	Perceived unattractiveness to mosquitoes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22159483	chr17:1588198	PRPF8	0.44	6.94	0.35	1.93e-11	Cognitive function;
LIHC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10556349	chr10:835070	NA	0.67	5.85	0.3	1.13e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.87	0.3	1.03e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.15	0.4	6.89e-15	Height;
LIHC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg09244754	chr6:122792965	PKIB;SERINC1	-0.4	-6.21	-0.32	1.51e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg07424592	chr7:64974309	NA	-0.82	-9.4	-0.45	7.95e-19	Diabetic kidney disease;
LIHC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg03859395	chr2:55845619	SMEK2	-0.54	-9.18	-0.44	4.24e-18	Metabolic syndrome;
LIHC	cis	rs75908454	1.000	rs79325961	chr6:169934196	T/C	cg19338460	chr6:170058176	WDR27	-0.83	-7.75	-0.39	1.04e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.51	-8.19	-0.41	5.18e-15	Body mass index;
LIHC	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.58	10.81	0.5	1.31e-23	Lewy body disease;
LIHC	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg26384229	chr12:38710491	ALG10B	0.56	7.15	0.36	5.39e-12	Morning vs. evening chronotype;
LIHC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.45	9.1	0.44	7.45e-18	Birth weight;
LIHC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.75	0.34	6.42e-11	Obesity-related traits;
LIHC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.37	6.14	0.32	2.28e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	20.47	0.74	2.34e-61	Height;
LIHC	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg08469215	chr1:156261351	TMEM79	0.37	5.89	0.3	9.37e-9	Tonsillectomy;
LIHC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-7.43	-0.37	9e-13	Platelet distribution width;
LIHC	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	0.99	11.88	0.54	1.71e-27	Red blood cell traits;
LIHC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	6.25	0.32	1.19e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.65	12.47	0.56	1.16e-29	Menopause (age at onset);
LIHC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	0.79	6.68	0.34	9.53e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs10276381	0.579	rs9648026	chr7:28161983	A/G	cg23620719	chr7:28220237	JAZF1	-0.59	-6.67	-0.34	1e-10	Crohn's disease;
LIHC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.92	0.3	7.9e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs860295	1.000	rs708611	chr1:155743310	A/C	cg02153340	chr1:155202674	NA	0.31	5.86	0.3	1.09e-8	Body mass index;
LIHC	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg10820045	chr2:198174542	NA	-0.47	-6.97	-0.35	1.6e-11	Intracranial aneurysm;
LIHC	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.49	-7.17	-0.36	4.53e-12	Obesity (extreme);
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.53	-7.32	-0.37	1.75e-12	Menopause (age at onset);
LIHC	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.46	5.92	0.3	7.99e-9	Dialysis-related mortality;
LIHC	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.51	9.62	0.46	1.5700000000000001e-19	Testicular germ cell tumor;
LIHC	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.37e-8	Lewy body disease;
LIHC	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.38	-0.37	1.18e-12	Protein biomarker;
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg14393609	chr7:65229607	NA	-0.44	-6.55	-0.33	2.06e-10	Aortic root size;
LIHC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.43	-6.29	-0.32	9.77e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.66	8.37	0.41	1.54e-15	Corneal astigmatism;
LIHC	cis	rs16828019	0.929	rs35813191	chr1:41742800	T/C	cg20697417	chr1:41786797	NA	0.35	6.61	0.34	1.45e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.41	-7.43	-0.37	8.83e-13	Height;
LIHC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.72	9.25	0.45	2.55e-18	Eosinophilic esophagitis;
LIHC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.53	-0.38	4.56e-13	Bipolar disorder;
LIHC	cis	rs2282032	0.527	rs8004573	chr14:90765743	C/T	cg04374321	chr14:90722782	PSMC1	0.49	7.07	0.36	8.56e-12	Longevity;
LIHC	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg22951263	chr5:87985283	NA	-0.4	-7.09	-0.36	7.67e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	trans	rs2352908	0.786	rs68126816	chr14:49445734	C/A	cg16568472	chr20:3190600	ITPA	-0.46	-6.17	-0.32	1.94e-9	Social communication problems;
LIHC	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg21775007	chr8:11205619	TDH	-0.43	-6.35	-0.32	7e-10	Mood instability;
LIHC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.78	7.57	0.38	3.48e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.35	-5.86	-0.3	1.12e-8	Menopause (age at onset);
LIHC	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	0.67	8.55	0.42	4.05e-16	Corneal structure;
LIHC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.67	0.38	1.81e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	cis	rs911119	0.955	rs8121405	chr20:23605226	G/A	cg16589663	chr20:23618590	CST3	0.76	8.04	0.4	1.44e-14	Chronic kidney disease;
LIHC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.9	-14.83	-0.63	9.37e-39	Cognitive ability;
LIHC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.34	-6.33	-0.32	7.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02632643	chr19:8370165	CD320	0.43	6.09	0.31	3.07e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg12698349	chr2:225449008	CUL3	0.45	5.97	0.31	5.9e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg20607798	chr8:58055168	NA	0.46	6.43	0.33	4.2e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-9.34	-0.45	1.23e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8084351	0.577	rs7506783	chr18:50625519	A/G	cg24270629	chr18:50823537	DCC	0.42	6.43	0.33	4.18e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.33	7.61	0.38	2.73e-13	Blood metabolite ratios;
LIHC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.56	6.23	0.32	1.4e-9	Axial length;
LIHC	cis	rs4728302	0.869	rs10224683	chr7:133590937	A/G	cg10665199	chr7:133106180	EXOC4	-0.35	-6.02	-0.31	4.44e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.36	6.06	0.31	3.58e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.37	6.13	0.31	2.41e-9	Monobrow;
LIHC	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.42	7.47	0.37	6.86e-13	Testicular germ cell tumor;
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg21877656	chr19:58662188	ZNF329	1.07	8.34	0.41	1.83e-15	Cholesterol, total;
LIHC	cis	rs1866706	0.896	rs4757957	chr11:12881398	C/G	cg25843174	chr11:12811716	TEAD1	-0.29	-6.08	-0.31	3.29e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg10820045	chr2:198174542	NA	-0.56	-9.25	-0.45	2.44e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	17.35	0.68	8.06e-49	Nonalcoholic fatty liver disease;
LIHC	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.34	5.74	0.3	2.07e-8	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27619136	chr4:174291353	SAP30	0.52	7.41	0.37	9.88e-13	Pancreatic cancer;
LIHC	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.39	6.09	0.31	3.11e-9	Alzheimer's disease (survival time);
LIHC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg23205692	chr1:25664452	TMEM50A	0.39	6.22	0.32	1.45e-9	Plateletcrit;Mean corpuscular volume;
LIHC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.63	8.13	0.4	8.07e-15	Morning vs. evening chronotype;
LIHC	cis	rs1000083	0.915	rs9314193	chr5:96577154	A/G	ch.5.96698337R	chr5:96672581	NA	0.84	6.81	0.35	4.37e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.79	-9.84	-0.47	2.7e-20	Type 2 diabetes;
LIHC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.61	-8.78	-0.43	7.77e-17	Aortic root size;
LIHC	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.68	8.53	0.42	4.89e-16	Corneal astigmatism;
LIHC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.58	8.19	0.4	5.43e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg04359351	chr2:3481828	TTC15	0.28	5.91	0.3	8.31e-9	Neurofibrillary tangles;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06397381	chr3:12943820	IQSEC1	0.42	6.06	0.31	3.53e-9	Longevity;
LIHC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.49	-10.21	-0.48	1.6e-21	Tonsillectomy;
LIHC	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.47	7.7	0.38	1.52e-13	Corneal astigmatism;
LIHC	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.87	0.35	3.01e-11	Heart rate;
LIHC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.57	9.44	0.45	6.09e-19	Type 2 diabetes;
LIHC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21467203	chr3:49911342	NA	0.54	9.86	0.47	2.38e-20	Body mass index;
LIHC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.6	-0.34	1.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21171335	chr12:122356390	WDR66	0.48	7.94	0.39	2.85e-14	Mean corpuscular volume;
LIHC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.86	-10.66	-0.5	4.22e-23	Cognitive function;
LIHC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21467203	chr3:49911342	NA	0.39	6.63	0.34	1.28e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg14456004	chr13:21872349	NA	-1.26	-13.34	-0.58	5.91e-33	White matter hyperintensity burden;
LIHC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.53e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.48	7.53	0.38	4.65e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.91	13.9	0.6	3.76e-35	Sudden cardiac arrest;
LIHC	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.68	9.78	0.47	4.41e-20	Eosinophil percentage of granulocytes;
LIHC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	10.58	0.5	7.76e-23	Hemoglobin concentration;
LIHC	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-19.0	-0.72	1.79e-55	Schizophrenia;
LIHC	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-10.43	-0.49	2.69e-22	Asthma;
LIHC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.65	0.56	2.41e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg16434002	chr17:42200994	HDAC5	0.45	5.77	0.3	1.73e-8	Total body bone mineral density;
LIHC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg18357526	chr6:26021779	HIST1H4A	0.52	7.33	0.37	1.71e-12	Blood metabolite levels;
LIHC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.31	0.52	2.11e-25	Lung cancer in ever smokers;
LIHC	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.95	10.87	0.51	7.78e-24	Neuroticism;
LIHC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.67	-0.5	3.98e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	1.02	19.59	0.73	8.04e-58	Breast cancer;
LIHC	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.38	-6.06	-0.31	3.58e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.77	-13.58	-0.59	6.95e-34	Height;
LIHC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.9	19.46	0.72	2.57e-57	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg00656387	chr3:40428638	ENTPD3	0.5	8.29	0.41	2.68e-15	Renal cell carcinoma;
LIHC	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.79	11.27	0.52	2.85e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.33	-0.49	6.14e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg17135325	chr3:160939158	NMD3	0.54	7.62	0.38	2.49e-13	Parkinson's disease;
LIHC	cis	rs16958440	0.581	rs56395942	chr18:44672299	G/T	cg17192377	chr18:44677553	HDHD2	0.51	6.33	0.32	7.85e-10	Sitting height ratio;
LIHC	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4722404	0.502	rs13234017	chr7:3110587	C/A	cg19214707	chr7:3157722	NA	-0.34	-5.85	-0.3	1.13e-8	Atopic dermatitis;
LIHC	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19902697	chr11:76494208	TSKU	0.46	6.37	0.33	6.11e-10	Lung function (FEV1/FVC);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14131272	chr14:39583276	SIP1	-0.45	-6.76	-0.34	6.12e-11	Hepatitis;
LIHC	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.74	13.11	0.58	4.39e-32	Eosinophil percentage of white cells;
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12516959	chr21:47718080	NA	0.36	5.94	0.31	7.17e-9	Testicular germ cell tumor;
LIHC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.38	0.37	1.24e-12	Morning vs. evening chronotype;
LIHC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.27	0.45	2.13e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg05044414	chr3:183734942	ABCC5	0.35	6.17	0.32	1.97e-9	Anterior chamber depth;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11310629	chr13:45991975	SLC25A30	0.43	6.24	0.32	1.27e-9	Pancreatic cancer;
LIHC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	8.02	0.4	1.73e-14	Lymphocyte counts;
LIHC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.72	0.39	1.27e-13	Bipolar disorder;
LIHC	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.73	-6.62	-0.34	1.42e-10	Blood protein levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19949018	chr17:2275913	SGSM2	-0.41	-6.28	-0.32	1.01e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.46	-7.35	-0.37	1.44e-12	Prostate cancer;
LIHC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	9.71	0.46	7.65e-20	Mean platelet volume;
LIHC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg00529422	chr1:16285251	ZBTB17	-0.32	-5.93	-0.31	7.31e-9	Systolic blood pressure;
LIHC	cis	rs546131	0.642	rs12793173	chr11:34834204	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.34	1.66e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-8.93	-0.43	2.76e-17	Crohn's disease;
LIHC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1982963	1.000	rs2029975	chr14:52506070	C/T	cg10843707	chr14:52510701	NID2	-0.44	-7.7	-0.38	1.51e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg03037974	chr15:76606532	NA	-0.6	-9.88	-0.47	2.11e-20	Blood metabolite levels;
LIHC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.3	-0.37	2.1e-12	Response to antipsychotic treatment;
LIHC	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg24879335	chr3:133465180	TF	0.44	6.99	0.35	1.49e-11	Iron status biomarkers (transferrin levels);
LIHC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.76	-17.64	-0.69	5.3e-50	Brugada syndrome;
LIHC	cis	rs4728302	0.869	rs13228262	chr7:133598288	A/G	cg10665199	chr7:133106180	EXOC4	0.38	6.64	0.34	1.21e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	1.06	14.27	0.61	1.46e-36	Heart rate;
LIHC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.86	7.78	0.39	8.5e-14	Type 2 diabetes;
LIHC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg17980119	chr2:219472607	PLCD4	0.34	5.88	0.3	9.92e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.71	-8.65	-0.42	2.05e-16	Gut microbiome composition (summer);
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-7.12	-0.36	6.33e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg02811702	chr13:24901961	NA	0.25	6.25	0.32	1.24e-9	Obesity-related traits;
LIHC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.69	9.96	0.47	1.09e-20	IgG glycosylation;
LIHC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.64	9.8	0.47	3.74e-20	Prostate cancer;
LIHC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.07	16.04	0.66	1.47e-43	Cognitive function;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.72	-0.43	1.26e-16	Gut microbiome composition (summer);
LIHC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg25801113	chr15:45476975	SHF	0.37	6.4	0.33	5.06e-10	Uric acid levels;
LIHC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.62	-10.16	-0.48	2.37e-21	Obesity-related traits;
LIHC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg23625390	chr15:77176239	SCAPER	-0.35	-5.79	-0.3	1.63e-8	Blood metabolite levels;
LIHC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg20946044	chr11:1010712	AP2A2	-0.33	-5.87	-0.3	1.04e-8	Alzheimer's disease (late onset);
LIHC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.45	0.33	3.75e-10	Menopause (age at onset);
LIHC	cis	rs4742903	0.967	rs2122577	chr9:106866703	C/T	cg14250997	chr9:106856677	SMC2	0.42	7.31	0.37	1.9e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.76	-12.29	-0.55	5.2e-29	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.45	0.33	3.81e-10	Height;
LIHC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs875971	0.929	rs778712	chr7:65849978	C/T	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.84	-0.3	1.24e-8	Biliary atresia;
LIHC	cis	rs12220238	0.554	rs10824192	chr10:76251573	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.39	0.33	5.51e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.02	0.31	4.61e-9	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	1.02	10.44	0.49	2.55e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg26939375	chr7:64535504	NA	-0.47	-7.16	-0.36	4.97e-12	Aortic root size;
LIHC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.4	6.39	0.33	5.53e-10	Menopause (age at onset);
LIHC	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.59	-9.07	-0.44	9.36e-18	QRS duration;
LIHC	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.6	0.59	5.86e-34	Coffee consumption (cups per day);
LIHC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.66	9.61	0.46	1.62e-19	Schizophrenia;
LIHC	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.49	-8.17	-0.4	6.18e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg16576597	chr16:28551801	NUPR1	0.42	6.16	0.32	2.1e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.11e-27	IgG glycosylation;
LIHC	cis	rs12464559	0.826	rs78092271	chr2:152649909	G/C	cg01189475	chr2:152685088	ARL5A	-0.69	-6.55	-0.33	2.06e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.74e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	14.17	0.61	3.6e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	7.51	0.38	5.34e-13	Diastolic blood pressure;
LIHC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.47	8.57	0.42	3.7e-16	Colorectal cancer;
LIHC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.34	-8.7	-0.43	1.38e-16	Hemoglobin concentration;
LIHC	cis	rs61863818	0.521	rs7923907	chr10:99143499	C/T	cg06359132	chr10:99160096	RRP12	0.35	5.78	0.3	1.65e-8	Monocyte percentage of white cells;
LIHC	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.28	-6.53	-0.33	2.37e-10	Educational attainment (years of education);
LIHC	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.51	-7.93	-0.39	3.05e-14	Extraversion;
LIHC	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg16346588	chr10:242978	ZMYND11	-0.49	-5.79	-0.3	1.61e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.44	-8.22	-0.41	4.36e-15	Schizophrenia;
LIHC	cis	rs400736	0.859	rs379920	chr1:8028865	G/C	cg25007680	chr1:8021821	PARK7	0.61	9.79	0.47	4.16e-20	Response to antidepressants and depression;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01809819	chr1:31192165	MATN1	0.38	6.32	0.32	8.17e-10	Cognitive function;
LIHC	cis	rs11053548	0.602	rs11053554	chr12:10175667	G/A	cg04314261	chr12:10163030	CLEC12B	0.39	6.16	0.32	1.99e-9	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.24	0.41	3.62e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.78	12.75	0.57	1.02e-30	Breast cancer;
LIHC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.3	-5.73	-0.3	2.15e-8	Mean corpuscular volume;
LIHC	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg11812906	chr14:75593930	NEK9	0.42	6.47	0.33	3.47e-10	IgG glycosylation;
LIHC	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg23533926	chr12:111358616	MYL2	0.31	6.05	0.31	3.88e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7616330	0.836	rs6780338	chr3:71029408	C/T	cg01511742	chr3:71112437	FOXP1	0.41	5.83	0.3	1.29e-8	QT interval;
LIHC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-8.98	-0.44	1.85e-17	Menarche (age at onset);
LIHC	trans	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg17675199	chr6:35436792	RPL10A	-0.32	-6.34	-0.32	7.25e-10	Coronary artery disease;
LIHC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.46	6.81	0.35	4.41e-11	Aortic root size;
LIHC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.79	-0.73	1.21e-58	Height;
LIHC	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.89	-0.3	9.25e-9	Dental caries;
LIHC	cis	rs6449957	0.832	rs7715780	chr5:67453288	A/G	cg23036683	chr5:67512108	NA	0.41	5.85	0.3	1.13e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-0.89	-9.83	-0.47	3.11e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.47	9.51	0.46	3.53e-19	Immature fraction of reticulocytes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20982606	chr12:109535391	UNG	-0.51	-7.66	-0.38	1.89e-13	Cognitive function;
LIHC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.85	-16.45	-0.66	3.43e-45	Coronary artery disease;
LIHC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.42	-5.93	-0.31	7.22e-9	Aortic root size;
LIHC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.59	-0.34	1.7e-10	Mean corpuscular volume;
LIHC	cis	rs11229555	0.645	rs11229428	chr11:58180382	C/T	cg15696309	chr11:58395628	NA	-0.66	-7.75	-0.39	1.06e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs539514	0.690	rs607095	chr13:76316165	A/T	cg04757411	chr13:76259545	LMO7	-0.47	-8.18	-0.4	5.52e-15	Type 1 diabetes;
LIHC	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.75	6.01	0.31	4.86e-9	Blood protein levels;
LIHC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg06207120	chr15:45996521	NA	0.34	6.62	0.34	1.39e-10	Waist circumference;Weight;
LIHC	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg00977110	chr5:151150581	G3BP1	0.56	7.11	0.36	6.8e-12	Preschool internalizing problems;
LIHC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs9325144	0.647	rs12427164	chr12:38868777	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.55	-0.38	4.12e-13	Morning vs. evening chronotype;
LIHC	cis	rs9543976	0.920	rs9543972	chr13:76121675	T/C	cg01531495	chr13:76123901	UCHL3	0.52	6.14	0.31	2.32e-9	Diabetic retinopathy;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.71	0.38	1.35e-13	Prudent dietary pattern;
LIHC	trans	rs11088226	0.581	rs2016103	chr21:33878030	G/A	cg09050820	chr6:167586206	TCP10L2	0.5	7.83	0.39	6.22e-14	Gastritis;
LIHC	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.9	0.35	2.53e-11	Bipolar disorder;
LIHC	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.52	-6.11	-0.31	2.79e-9	Ulcerative colitis;
LIHC	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.84	-0.3	1.2e-8	IFN-related cytopenia;
LIHC	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg00277334	chr10:82204260	NA	0.43	6.33	0.32	7.86e-10	Post bronchodilator FEV1;
LIHC	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.44	-0.33	3.98e-10	HDL cholesterol;
LIHC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.39	6.31	0.32	8.81e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg13152130	chr6:118910203	C6orf204	-0.65	-7.34	-0.37	1.61e-12	Diastolic blood pressure;
LIHC	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.63	-12.12	-0.55	2.26e-28	Neurofibrillary tangles;
LIHC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.84	13.99	0.6	1.74e-35	Breast cancer;
LIHC	trans	rs3783890	0.943	rs11628518	chr14:93746667	C/T	cg02802420	chr16:69363236	PDF;COG8	0.32	6.22	0.32	1.44e-9	Body mass index;
LIHC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.6	11.23	0.52	4.14e-25	Systemic lupus erythematosus;
LIHC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-0.48	-5.89	-0.3	9.04e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg03037974	chr15:76606532	NA	0.73	14.44	0.62	3.04e-37	Blood metabolite levels;
LIHC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.46	6.09	0.31	3.08e-9	Parkinson's disease;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.12	-0.31	2.52e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.47	8.38	0.41	1.4e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg26967526	chr14:35346199	BAZ1A	-0.36	-5.71	-0.3	2.43e-8	Psoriasis;
LIHC	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.54	7.97	0.4	2.43e-14	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.01	-0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	0.67	7.41	0.37	1.03e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.67	0.5	4.02e-23	Alzheimer's disease;
LIHC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg21466736	chr12:48725269	NA	-0.7	-10.78	-0.5	1.59e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg07884673	chr3:53033167	SFMBT1	0.95	6.86	0.35	3.21e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg04865290	chr3:52927548	TMEM110	-0.44	-6.35	-0.32	6.71e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg07424592	chr7:64974309	NA	0.78	7.27	0.37	2.44e-12	Gout;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg00593699	chr11:472782	PTDSS2	0.61	6.42	0.33	4.52e-10	Mean platelet volume;
LIHC	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.43	-5.73	-0.3	2.16e-8	Coronary artery calcification;
LIHC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.47	-8.24	-0.41	3.65e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02160872	chr5:212506	CCDC127	0.48	6.19	0.32	1.72e-9	Hepatitis;
LIHC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.47	7.73	0.39	1.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.5	0.46	3.78e-19	Morning vs. evening chronotype;
LIHC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-8.3	-0.41	2.52e-15	Bipolar disorder;
LIHC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg21231739	chr4:1642635	FAM53A	0.36	5.76	0.3	1.89e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.38	7.83	0.39	6.11e-14	Optic cup area;
LIHC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg17135325	chr3:160939158	NMD3	0.57	8.13	0.4	7.9e-15	Parkinson's disease;
LIHC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg27432699	chr2:27873401	GPN1	-0.43	-6.03	-0.31	4.25e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.15e-11	Body mass index;
LIHC	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg05636881	chr10:105038444	INA	-0.4	-6.3	-0.32	8.95e-10	Migraine;
LIHC	cis	rs6586163	1.000	rs6586163	chr10:90752018	A/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-8.24	-0.41	3.65e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.75	0.39	1.09e-13	Systemic lupus erythematosus;
LIHC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	trans	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.27	0.32	1.1e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-7.36	-0.37	1.4e-12	Height;
LIHC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg22633049	chr21:46681294	NA	-0.37	-6.43	-0.33	4.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.61	7.25	0.36	2.84e-12	Cognitive function;
LIHC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.08	0.4	1.12e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.42	5.99	0.31	5.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.65	-11.57	-0.53	2.47e-26	Coronary artery disease;
LIHC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-6.07	-0.31	3.45e-9	Fear of minor pain;
LIHC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-1.02	-19.85	-0.73	7.14e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs7945718	0.621	rs11022465	chr11:12686139	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-7.51	-0.38	5.18e-13	Educational attainment (years of education);
LIHC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03878208	chr11:72483293	STARD10	0.63	5.76	0.3	1.83e-8	Type 2 diabetes;
LIHC	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg02811702	chr13:24901961	NA	0.25	6.17	0.32	1.96e-9	Obesity-related traits;
LIHC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.85	13.91	0.6	3.46e-35	Colorectal cancer;
LIHC	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg03999872	chr20:62272968	STMN3	0.42	6.25	0.32	1.25e-9	Atopic dermatitis;
LIHC	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg22356347	chr1:167427500	CD247	-0.34	-5.81	-0.3	1.45e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.45	0.33	3.76e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.48	7.36	0.37	1.37e-12	Parkinson's disease;
LIHC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.47	6.59	0.34	1.62e-10	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg06565975	chr8:143823917	SLURP1	-0.38	-6.51	-0.33	2.66e-10	Urinary tract infection frequency;
LIHC	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.41	7.62	0.38	2.52e-13	Capecitabine sensitivity;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	5.75	0.3	2.02e-8	Longevity;
LIHC	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.55	-9.55	-0.46	2.56e-19	Obesity-related traits;
LIHC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.0	-0.35	1.37e-11	Alcohol dependence;
LIHC	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg24579218	chr15:68104479	NA	-0.34	-5.77	-0.3	1.81e-8	Restless legs syndrome;
LIHC	cis	rs7619427	0.544	rs9809968	chr3:44042297	A/T	cg24966902	chr3:44043705	NA	0.53	8.19	0.41	5.14e-15	Schizophrenia;
LIHC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.17	0.32	1.96e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.53	0.33	2.37e-10	Schizophrenia;
LIHC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg11057378	chr10:81107060	PPIF	0.36	5.76	0.3	1.89e-8	Height;
LIHC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.46	5.96	0.31	6.3e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.04	-0.31	4.06e-9	Total body bone mineral density;
LIHC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.4	6.46	0.33	3.65e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg20636351	chr8:55087400	NA	-0.35	-7.27	-0.37	2.47e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.92	13.39	0.59	3.72e-33	Primary sclerosing cholangitis;
LIHC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-0.62	-9.69	-0.46	9.19e-20	Yeast infection;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg01799338	chr1:36348937	EIF2C1	-0.41	-6.51	-0.33	2.71e-10	Triglycerides;
LIHC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.3	-0.41	2.45e-15	Schizophrenia;
LIHC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg22777020	chr22:31556080	RNF185	0.56	6.4	0.33	4.98e-10	Colorectal cancer;
LIHC	trans	rs6600671	1.000	rs12145080	chr1:121185531	C/T	cg09829573	chr1:144692074	NBPF9	0.43	7.78	0.39	8.39e-14	Hip geometry;
LIHC	cis	rs74544699	1.000	rs529312	chr4:74767982	A/T	cg02530824	chr4:74847766	PF4	0.61	6.34	0.32	7.16e-10	Growth-regulated protein alpha levels;
LIHC	trans	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg09045935	chr12:6379348	NA	0.83	6.85	0.35	3.36e-11	Blood metabolite levels;
LIHC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.49	7.35	0.37	1.48e-12	Total body bone mineral density;
LIHC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.56	-9.77	-0.47	4.72e-20	Age at first birth;
LIHC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	6.19	0.32	1.71e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.81	-11.23	-0.52	4e-25	Schizophrenia;
LIHC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg07061783	chr6:25882402	NA	-0.44	-6.16	-0.32	2.06e-9	Blood metabolite levels;
LIHC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg14092571	chr14:90743983	NA	0.38	6.03	0.31	4.36e-9	Mortality in heart failure;
LIHC	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26734620	chr12:56694298	CS	-1.26	-11.0	-0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.3	-0.55	4.7e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00510787	chr6:151772946	C6orf211;RMND1	0.43	6.18	0.32	1.78e-9	Cognitive function;
LIHC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg07560587	chr16:88016574	BANP	0.35	5.82	0.3	1.39e-8	Menopause (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12944146	chr22:50725609	PLXNB2	0.44	6.8	0.35	4.77e-11	Longevity;
LIHC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.47	-0.33	3.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.28	-5.82	-0.3	1.33e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17152411	1.000	rs61873277	chr10:126619331	C/A	cg07906193	chr10:126599966	NA	0.47	7.36	0.37	1.34e-12	Height;
LIHC	cis	rs9596863	0.898	rs9591534	chr13:54363861	C/G	ch.13.53330881F	chr13:54432880	NA	0.42	5.77	0.3	1.75e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs6691722	0.503	rs6656485	chr1:24707685	A/G	cg18323236	chr1:24743029	NIPAL3	0.41	7.37	0.37	1.29e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.84e-10	Diabetic kidney disease;
LIHC	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg00204512	chr16:28754710	NA	-0.38	-6.3	-0.32	9.25e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.88	-18.83	-0.71	8.98e-55	Height;
LIHC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.73	-11.35	-0.52	1.54e-25	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg05501817	chr11:14380813	RRAS2	-0.42	-5.73	-0.3	2.16e-8	Sense of smell;
LIHC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.26	6.34	0.32	7.27e-10	Primary biliary cholangitis;
LIHC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.19	0.48	1.8e-21	Morning vs. evening chronotype;
LIHC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.76	13.96	0.6	2.26e-35	Neutrophil count;
LIHC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.63	-0.56	2.81e-30	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	24.53	0.8	2.3e-77	Chronic sinus infection;
LIHC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.88	-11.02	-0.51	2.31e-24	Mean platelet volume;
LIHC	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg11812906	chr14:75593930	NEK9	0.43	6.45	0.33	3.75e-10	IgG glycosylation;
LIHC	cis	rs12980942	0.591	rs1946613	chr19:41767785	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.58	7.04	0.36	1.03e-11	Coronary artery disease;
LIHC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.37	-6.74	-0.34	6.67e-11	Aortic root size;
LIHC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-6.58	-0.34	1.77e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg17724175	chr1:150552817	MCL1	0.43	8.21	0.41	4.48e-15	Melanoma;
LIHC	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs7188697	0.922	rs9926577	chr16:58613431	C/T	cg02549819	chr16:58548995	SETD6	0.48	7.62	0.38	2.52e-13	QT interval;
LIHC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	0.84	11.74	0.54	5.79e-27	Skin colour saturation;
LIHC	cis	rs4450131	0.900	rs11245333	chr10:126383088	C/A	cg20435097	chr10:126320824	FAM53B	0.52	9.26	0.45	2.24e-18	White blood cell count (basophil);
LIHC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.97	-0.35	1.63e-11	Bipolar disorder;
LIHC	trans	rs78049276	0.736	rs73855810	chr4:148383424	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-7.62	-0.38	2.46e-13	Pulse pressure;
LIHC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.61	-8.83	-0.43	5.48e-17	Aortic root size;
LIHC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.87	-15.19	-0.63	3.51e-40	Aortic root size;
LIHC	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg20636351	chr8:55087400	NA	-0.35	-7.27	-0.37	2.47e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.63	8.86	0.43	4.44e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.56	-0.38	3.76e-13	Calcium levels;
LIHC	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.63	6.65	0.34	1.19e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-7.06	-0.36	9.56e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.5	5.96	0.31	6.28e-9	Total body bone mineral density;
LIHC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.58	-0.38	3.34e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.49e-10	Alzheimer's disease;
LIHC	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg15595755	chr5:1867978	NA	0.4	8.11	0.4	8.87e-15	Cardiovascular disease risk factors;
LIHC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.49	7.17	0.36	4.77e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7188697	0.922	rs246196	chr16:58574253	T/C	cg02549819	chr16:58548995	SETD6	-0.45	-7.18	-0.36	4.43e-12	QT interval;
LIHC	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.36	-5.98	-0.31	5.68e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.47	5.95	0.31	6.6e-9	Obesity (extreme);
LIHC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.3	-0.45	1.65e-18	Bipolar disorder;
LIHC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.7	11.6	0.53	1.82e-26	Oral cavity cancer;
LIHC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.47	-0.37	6.94e-13	Tonsillectomy;
LIHC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-7.8	-0.39	7.67e-14	Vitiligo;
LIHC	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.31	-0.37	1.96e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.32	-16.27	-0.66	1.7e-44	Diabetic kidney disease;
LIHC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg14250997	chr9:106856677	SMC2	0.43	7.55	0.38	3.9e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.64	-9.16	-0.44	5.03e-18	White matter hyperintensity burden;
LIHC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.37	6.83	0.35	4.01e-11	Ewing sarcoma;
LIHC	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg03037974	chr15:76606532	NA	0.72	13.91	0.6	3.6e-35	Blood metabolite levels;
LIHC	cis	rs2933343	1.000	rs876756	chr3:128627623	G/A	cg25356066	chr3:128598488	ACAD9	0.53	7.0	0.35	1.39e-11	IgG glycosylation;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.48	7.47	0.37	6.96e-13	Testicular germ cell tumor;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	10.9	0.51	5.85e-24	Prudent dietary pattern;
LIHC	cis	rs2574704	0.851	rs2574719	chr3:11660688	G/A	cg15876825	chr3:11651881	VGLL4	0.49	7.9	0.39	3.85e-14	Body mass index;
LIHC	cis	rs918629	0.716	rs3756703	chr5:95276063	G/A	cg10483112	chr5:95245456	ELL2	-0.35	-5.9	-0.3	8.71e-9	IgG glycosylation;
LIHC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.58	-11.49	-0.53	4.63e-26	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.52	9.68	0.46	9.7e-20	Testicular germ cell tumor;
LIHC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.72	-0.3	2.37e-8	Colorectal cancer;
LIHC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06481639	chr22:41940642	POLR3H	0.66	6.95	0.35	1.9e-11	Vitiligo;
LIHC	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg10756647	chr7:56101905	PSPH	-0.98	-11.62	-0.53	1.57e-26	Gout;
LIHC	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.55	-8.81	-0.43	6.49e-17	Colorectal cancer;
LIHC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.37	-0.59	4.35e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.32	5.99	0.31	5.26e-9	Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08007990	chr2:231276624	NA	0.45	6.4	0.33	5.16e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.74	-10.71	-0.5	2.79e-23	Coronary artery disease;
LIHC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg07424592	chr7:64974309	NA	0.8	9.08	0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs4728302	0.869	rs7792905	chr7:133595602	G/T	cg10665199	chr7:133106180	EXOC4	0.37	6.54	0.33	2.24e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7039377	0.554	rs7873962	chr9:38673606	T/G	cg14625731	chr9:38672608	NA	-0.47	-7.57	-0.38	3.55e-13	Obesity-related traits;
LIHC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.58	-6.29	-0.32	9.81e-10	Vitiligo;
LIHC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg11406765	chr11:980039	AP2A2	-0.35	-5.78	-0.3	1.69e-8	Alzheimer's disease (late onset);
LIHC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg10587741	chr22:38071170	LGALS1	0.43	7.65	0.38	2.1e-13	Fat distribution (HIV);
LIHC	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.55	6.75	0.34	6.34e-11	QRS duration;
LIHC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.5	0.46	3.78e-19	Bipolar disorder;
LIHC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.59	0.53	2.02e-26	Tonsillectomy;
LIHC	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg02795151	chr17:7402630	POLR2A	0.54	5.87	0.3	1.01e-8	Androgen levels;
LIHC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.43	-6.12	-0.31	2.53e-9	Menarche (age at onset);
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg07234388	chr1:156261841	TMEM79	0.52	9.28	0.45	2.01e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.43	-6.31	-0.32	8.51e-10	Blood protein levels;
LIHC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg19635926	chr16:89946313	TCF25	0.49	6.24	0.32	1.28e-9	Skin colour saturation;
LIHC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.78	-0.39	8.65e-14	Ulcerative colitis;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10150615	chr22:24372951	LOC391322	-0.47	-6.29	-0.32	9.65e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.76	0.34	5.98e-11	Diabetic kidney disease;
LIHC	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.36	-0.33	6.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg11070056	chr1:107600091	PRMT6	-0.71	-12.16	-0.55	1.64e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.67	0.34	1.01e-10	Mean platelet volume;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg01339444	chr6:118972232	C6orf204	0.59	5.93	0.31	7.53e-9	Diastolic blood pressure;
LIHC	cis	rs909341	0.537	rs6011098	chr20:62398935	C/T	cg14758556	chr20:62440591	NA	-0.46	-7.24	-0.36	2.95e-12	Atopic dermatitis;
LIHC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.18e-31	Sense of smell;
LIHC	cis	rs11212260	0.573	rs71488249	chr11:107162752	A/G	cg25435332	chr11:107328525	CWF19L2	0.65	6.23	0.32	1.38e-9	IgG glycosylation;
LIHC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg07959070	chr22:50026188	C22orf34	-0.31	-7.9	-0.39	3.93e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.71	-0.38	1.38e-13	Monocyte percentage of white cells;
LIHC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2016586	0.929	rs5999960	chr22:36105267	T/A	cg26342177	chr22:36113512	APOL5	-0.38	-6.22	-0.32	1.41e-9	Body mass index;
LIHC	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.87	-0.35	3.1e-11	Prevalent atrial fibrillation;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25920645	chr2:176047472	ATP5G3	-0.32	-6.53	-0.33	2.45e-10	Calcium levels;
LIHC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.53	-0.49	1.24e-22	Chronic sinus infection;
LIHC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.3	5.71	0.3	2.44e-8	Multiple system atrophy;
LIHC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg21466736	chr12:48725269	NA	-0.65	-9.8	-0.47	3.87e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs3736485	0.966	rs28376817	chr15:51889280	A/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.73	-0.3	2.2e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.02	16.61	0.67	7.62e-46	Orofacial clefts;
LIHC	trans	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.46	-7.28	-0.37	2.25e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg10820045	chr2:198174542	NA	0.48	7.27	0.37	2.45e-12	Dermatomyositis;
LIHC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.7	7.91	0.39	3.57e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-8.96	-0.44	2.11e-17	Blood metabolite levels;
LIHC	cis	rs600806	0.850	rs4970846	chr1:109946095	A/C	cg16275483	chr1:110013120	SYPL2	-0.46	-5.72	-0.3	2.38e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.85	12.94	0.57	1.93e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg24203234	chr3:128598194	ACAD9	0.45	6.33	0.32	7.77e-10	IgG glycosylation;
LIHC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.9	8.19	0.41	5.11e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs11039100	0.850	rs12796660	chr11:5843681	T/C	cg11650987	chr12:10280440	CLEC7A	0.4	6.11	0.31	2.69e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg05084668	chr3:125655381	ALG1L	-0.42	-6.72	-0.34	7.77e-11	Blood pressure (smoking interaction);
LIHC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.61	7.98	0.4	2.27e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.04e-32	Psoriasis;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	9.37e-15	Prudent dietary pattern;
LIHC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-5.95	-0.31	6.46e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg26138937	chr11:71823887	C11orf51	1.31	10.34	0.49	5.49e-22	Severe influenza A (H1N1) infection;
LIHC	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-7.79	-0.39	8.37e-14	Exhaled nitric oxide output;
LIHC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.41	7.9	0.39	3.83e-14	Testicular germ cell tumor;
LIHC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	0.72	8.17	0.4	6.16e-15	Hip circumference adjusted for BMI;
LIHC	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	1.29	11.19	0.52	5.54e-25	Uric acid levels;
LIHC	trans	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.47	-6.25	-0.32	1.22e-9	Mean corpuscular volume;
LIHC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg20946044	chr11:1010712	AP2A2	-0.33	-5.78	-0.3	1.68e-8	Alzheimer's disease (late onset);
LIHC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.04	-0.31	4.01e-9	Vitiligo;
LIHC	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.82	-0.35	4.2e-11	HDL cholesterol;
LIHC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-6.99	-0.35	1.45e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.86	12.54	0.56	5.89e-30	Menarche (age at onset);
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.34	0.45	1.27e-18	Lymphocyte counts;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09372778	chr14:24702290	GMPR2;NEDD8	0.41	6.47	0.33	3.39e-10	Cognitive function;
LIHC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.34	13.9	0.6	3.84e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs10792665	0.902	rs7930571	chr11:82651948	G/A	cg24227371	chr11:82718527	RAB30	-0.3	-7.04	-0.36	1.09e-11	Obesity-related traits;
LIHC	cis	rs11671005	0.735	rs11667723	chr19:58927489	A/G	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs10847980	0.590	rs75794148	chr12:123287329	C/G	cg18912006	chr12:123335444	HIP1R	0.73	7.15	0.36	5.33e-12	Adiponectin levels;
LIHC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg12560992	chr17:57184187	TRIM37	-0.55	-7.69	-0.38	1.5700000000000001e-13	Cognitive test performance;
LIHC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.78	12.12	0.55	2.23e-28	Resting heart rate;
LIHC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-11.6	-0.53	1.86e-26	Pediatric autoimmune diseases;
LIHC	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.96	-8.77	-0.43	8.81e-17	White matter integrity;
LIHC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.87	-12.52	-0.56	7.56e-30	Diastolic blood pressure;
LIHC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.39	6.26	0.32	1.13e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.47	-7.67	-0.38	1.86e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.74	10.89	0.51	6.82e-24	Corneal astigmatism;
LIHC	cis	rs55882075	0.634	rs11249657	chr5:179111637	G/C	cg14593053	chr5:179126677	CANX	0.37	6.29	0.32	9.93e-10	Monocyte percentage of white cells;
LIHC	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.53	-7.6	-0.38	2.92e-13	Obesity-related traits;
LIHC	cis	rs2708977	0.867	rs12717782	chr2:97254116	G/A	cg01950434	chr2:97203154	ARID5A	0.49	6.24	0.32	1.27e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.32	0.41	2.16e-15	Birth weight;
LIHC	cis	rs67981189	0.513	rs2526856	chr14:71412717	A/G	cg15816911	chr14:71606274	NA	0.43	6.8	0.35	4.6e-11	Schizophrenia;
LIHC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs10213084	1.000	rs13120781	chr4:147480413	T/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.52	6.23	0.32	1.37e-9	Heart rate;
LIHC	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.02	-0.31	4.61e-9	Diastolic blood pressure;
LIHC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.95	15.13	0.63	5.74e-40	Metabolic syndrome;
LIHC	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.48	8.53	0.42	4.96e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.49	-0.42	6.56e-16	Obesity-related traits;
LIHC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.84	13.52	0.59	1.14e-33	Colorectal cancer;
LIHC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.56	8.5	0.42	5.79e-16	Resting heart rate;
LIHC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.64	0.38	2.22e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg20487152	chr13:99095054	FARP1	-0.4	-6.78	-0.34	5.41e-11	Longevity;
LIHC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.82	0.35	4.02e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.75	-10.79	-0.5	1.54e-23	Mosquito bite size;
LIHC	cis	rs6442522	1.000	rs6778562	chr3:15482775	C/G	cg16303742	chr3:15540471	COLQ	0.45	7.46	0.37	7.36e-13	Uric acid levels;
LIHC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.61	7.68	0.38	1.65e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.87	17.8	0.69	1.21e-50	Testicular germ cell tumor;
LIHC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.88e-9	Body mass index;
LIHC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.22	0.32	1.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	0.86	9.46	0.46	5.31e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7635838	0.573	rs73019547	chr3:11493323	A/C	cg00170343	chr3:11313890	ATG7	0.41	6.37	0.33	6.22e-10	HDL cholesterol;
LIHC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.97	9.8	0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs7116495	0.881	rs475759	chr11:71578992	C/T	cg26138937	chr11:71823887	C11orf51	0.67	6.6	0.34	1.58e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs8056893	0.714	rs1465470	chr16:68397909	A/G	cg02226672	chr16:68398533	SMPD3	0.43	6.06	0.31	3.58e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00185336	chr7:73153699	ABHD11	0.42	6.03	0.31	4.14e-9	Pancreatic cancer;
LIHC	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.94	-0.44	2.54e-17	Atrioventricular conduction;
LIHC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg21231739	chr4:1642635	FAM53A	0.37	5.86	0.3	1.07e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg10820045	chr2:198174542	NA	-0.62	-10.56	-0.5	9.39e-23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.49	7.84	0.39	5.64e-14	HDL cholesterol;
LIHC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg13409248	chr3:40428643	ENTPD3	0.41	6.41	0.33	4.84e-10	Renal cell carcinoma;
LIHC	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	7.0	0.35	1.32e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs11638815	0.520	rs4779032	chr15:83245326	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.6	-0.34	1.54e-10	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LIHC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-6.74	-0.34	6.79e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg05084668	chr3:125655381	ALG1L	-0.41	-6.37	-0.33	6.13e-10	Blood pressure (smoking interaction);
LIHC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.44	-0.59	2.32e-33	Alzheimer's disease;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.55	8.62	0.42	2.45e-16	Longevity;Endometriosis;
LIHC	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.42	7.71	0.38	1.37e-13	Schizophrenia;
LIHC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-7.14	-0.36	5.58e-12	Platelet count;
LIHC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg10820045	chr2:198174542	NA	-0.56	-9.22	-0.45	3.01e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.51	0.53	3.83e-26	Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.57	-7.94	-0.39	3.02e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.44	8.0	0.4	1.94e-14	Prudent dietary pattern;
LIHC	cis	rs3770081	1.000	rs6759489	chr2:86176032	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.74	0.3	2.06e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.33	-6.5	-0.33	2.8e-10	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg16822855	chr3:40428330	ENTPD3	0.31	5.77	0.3	1.8e-8	Renal cell carcinoma;
LIHC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs10216189	0.785	rs10807949	chr7:5528375	C/T	cg05318486	chr7:5553423	FBXL18	0.42	5.85	0.3	1.16e-8	Relative hand skill in reading disability;
LIHC	cis	rs72627123	0.867	rs118113209	chr14:74432158	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.48	0.42	6.78e-16	Morning vs. evening chronotype;
LIHC	cis	rs546131	0.642	rs12278295	chr11:34846254	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.47	-0.33	3.33e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.7	0.57	1.57e-30	Total body bone mineral density;
LIHC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg01864069	chr14:103024347	NA	-0.55	-9.19	-0.44	3.96e-18	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01029676	chr3:122785968	PDIA5	-0.49	-6.73	-0.34	7.05e-11	Pancreatic cancer;
LIHC	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.47	6.92	0.35	2.21e-11	Nonalcoholic fatty liver disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02447287	chr2:238707023	RBM44	-0.41	-6.45	-0.33	3.82e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.73	10.95	0.51	3.91e-24	Corneal astigmatism;
LIHC	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.35	-0.32	6.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg22771759	chr13:24902376	NA	0.33	6.65	0.34	1.14e-10	Obesity-related traits;
LIHC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.18	-19.07	-0.72	9.98e-56	Urate levels;
LIHC	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg00274965	chr21:34405681	NA	0.35	6.27	0.32	1.11e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.63	11.71	0.53	7.6e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs12915189	1.000	rs7180053	chr15:91114735	T/G	cg26821196	chr15:91095069	CRTC3	0.33	5.93	0.31	7.43e-9	Information processing speed;
LIHC	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs1030877	0.824	rs2576738	chr2:105891644	C/A	cg02079111	chr2:105885981	TGFBRAP1	0.66	11.55	0.53	2.78e-26	Obesity-related traits;
LIHC	cis	rs743757	1.000	rs762897	chr3:50428766	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.46	6.95	0.35	1.85e-11	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27433451	chr1:51443332	NA	-0.51	-7.27	-0.37	2.51e-12	Pancreatic cancer;
LIHC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg22842854	chr12:123319900	HIP1R	-0.65	-8.57	-0.42	3.5e-16	Schizophrenia;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg19687152	chr14:102968497	TECPR2	0.45	6.68	0.34	9.8e-11	Electroencephalogram traits;
LIHC	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.44	6.82	0.35	4.08e-11	Coenzyme Q10 levels;
LIHC	cis	rs9915021	0.623	rs12452797	chr17:33890976	C/G	cg20932281	chr17:33905541	PEX12	0.62	7.69	0.38	1.55e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs12431939	1.000	rs11850391	chr14:51639759	A/G	cg23942311	chr14:51606299	NA	-0.35	-5.92	-0.31	7.66e-9	Cancer;
LIHC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	6.49	0.33	2.99e-10	Renal function-related traits (BUN);
LIHC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.53	8.08	0.4	1.1e-14	Resting heart rate;
LIHC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.71	-10.73	-0.5	2.4e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg07884673	chr3:53033167	SFMBT1	0.93	6.67	0.34	1.05e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg08992911	chr2:238395768	MLPH	0.51	6.23	0.32	1.39e-9	Prostate cancer;
LIHC	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	trans	rs1814175	0.615	rs7113020	chr11:49746540	C/T	cg03929089	chr4:120376271	NA	-0.86	-17.01	-0.68	1.92e-47	Height;
LIHC	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.56	-9.11	-0.44	6.87e-18	Colorectal cancer;
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg21522988	chr12:29376872	FAR2	0.3	6.86	0.35	3.28e-11	QT interval;
LIHC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.29	0.52	2.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg16479474	chr6:28041457	NA	0.46	6.58	0.34	1.79e-10	Depression;
LIHC	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg11812906	chr14:75593930	NEK9	0.41	6.32	0.32	8.3e-10	Platelet count;
LIHC	cis	rs17094222	0.812	rs11190658	chr10:102443374	C/T	cg26540559	chr10:102447443	NA	0.32	5.9	0.3	8.91e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12101261	1.000	rs4903961	chr14:81462649	C/G	cg06600135	chr14:81408086	NA	0.37	6.33	0.32	7.5e-10	Graves' disease;
LIHC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.57	7.31	0.37	1.87e-12	Parkinson's disease;
LIHC	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.68	11.2	0.52	5.36e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02972257	chr16:68554789	NA	0.59	6.37	0.33	6.14e-10	Plateletcrit;
LIHC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22442454	chr1:209979470	IRF6	0.4	6.08	0.31	3.28e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.18	0.61	3.24e-36	Bipolar disorder;
LIHC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.71	-11.63	-0.53	1.48e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.24	0.36	3.03e-12	Aortic root size;
LIHC	trans	rs56292044	0.706	rs10104949	chr8:138775701	A/G	cg05886954	chr16:3631570	BTBD12	-0.31	-6.1	-0.31	2.82e-9	Post bronchodilator FEV1/FVC ratio in COPD;
LIHC	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg03934865	chr2:198174659	NA	0.54	8.15	0.4	6.71e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.36	-0.49	4.61e-22	Hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.07	-0.55	3.6e-28	Alzheimer's disease;
LIHC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.79	-0.43	7.56e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs963731	0.649	rs12620071	chr2:39345873	G/A	cg04010122	chr2:39346883	SOS1	0.68	5.88	0.3	9.58e-9	Corticobasal degeneration;
LIHC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.34	6.03	0.31	4.27e-9	Headache;
LIHC	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.63	-8.86	-0.43	4.45e-17	Blood metabolite levels;
LIHC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.7	-9.6	-0.46	1.75e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.21e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.34	-5.83	-0.3	1.29e-8	IgG glycosylation;
LIHC	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.01	-19.65	-0.73	4.33e-58	Exhaled nitric oxide output;
LIHC	cis	rs4965272	0.830	rs11631633	chr15:100560186	C/A	cg09918751	chr15:100517450	ADAMTS17	-0.43	-5.91	-0.3	8.33e-9	Gastroesophageal reflux disease;
LIHC	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07080220	chr10:102295463	HIF1AN	-0.41	-5.8	-0.3	1.48e-8	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.42	8.54	0.42	4.51e-16	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.08	0.44	9.16e-18	Platelet count;
LIHC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.06	-0.31	3.55e-9	Tonsillectomy;
LIHC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg01765077	chr12:122356316	WDR66	0.42	6.29	0.32	9.64e-10	Mean corpuscular volume;
LIHC	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-6.63	-0.34	1.34e-10	Mosquito bite size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15688767	chr3:125093330	ZNF148	0.46	7.35	0.37	1.43e-12	Cognitive function;
LIHC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg11861562	chr11:117069780	TAGLN	0.37	5.98	0.31	5.56e-9	Blood protein levels;
LIHC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.36	9.34	0.45	1.29e-18	Schizophrenia;
LIHC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.61e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.24	-0.41	3.72e-15	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.49	6.51	0.33	2.72e-10	Vitiligo;
LIHC	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02985541	chr2:219472218	PLCD4	-0.42	-7.65	-0.38	2.07e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.9	0.35	2.6e-11	Gut microbiome composition (summer);
LIHC	cis	rs11229555	0.645	rs12802960	chr11:58174775	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.59	9.48	0.46	4.25e-19	Corneal astigmatism;
LIHC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.47	6.16	0.32	2.09e-9	Parkinson's disease;
LIHC	cis	rs2191566	1.000	rs2356549	chr19:44511202	A/T	cg20607764	chr19:44506953	ZNF230	-0.45	-7.38	-0.37	1.22e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.73	-0.34	7.14e-11	Response to antipsychotic treatment;
LIHC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg24296786	chr1:45957014	TESK2	-0.41	-5.75	-0.3	2.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.39	6.24	0.32	1.29e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.72	-10.98	-0.51	3.13e-24	Aortic root size;
LIHC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.76	11.48	0.53	5.12e-26	Corneal astigmatism;
LIHC	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.29	-0.32	9.71e-10	Aortic root size;
LIHC	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg11657440	chr19:46296263	DMWD	-0.54	-8.28	-0.41	2.75e-15	Coronary artery disease;
LIHC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.26	-0.45	2.36e-18	Body mass index;
LIHC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.08	-0.44	8.66e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.4	6.21	0.32	1.58e-9	Iron status biomarkers;
LIHC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.79	-7.4	-0.37	1.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.34	0.32	7.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg20295408	chr7:1910781	MAD1L1	0.44	6.51	0.33	2.75e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-11.62	-0.53	1.55e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.4	6.47	0.33	3.38e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.54	-7.5	-0.38	5.51e-13	Colorectal cancer;
LIHC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg23461800	chr14:103021989	NA	-0.43	-6.12	-0.31	2.62e-9	Platelet count;
LIHC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.48	-7.06	-0.36	9.13e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs12086130	0.892	rs6694036	chr1:51452068	T/A	cg07174182	chr1:51127561	FAF1	-0.92	-9.87	-0.47	2.14e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg18016565	chr1:150552671	MCL1	-0.5	-10.31	-0.49	6.78e-22	Tonsillectomy;
LIHC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.7	10.37	0.49	4.49e-22	Mosquito bite size;
LIHC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.11	-0.44	7.27e-18	Schizophrenia;
LIHC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.62	0.34	1.43e-10	Platelet count;
LIHC	trans	rs6934970	1.000	rs4945480	chr6:113120853	A/G	cg05569086	chr8:143859399	LYNX1	-0.55	-6.04	-0.31	3.93e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-6.22	-0.32	1.45e-9	Ulcerative colitis;
LIHC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.53	8.67	0.42	1.75e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.4	-5.92	-0.3	7.97e-9	Systemic sclerosis;
LIHC	cis	rs11673344	0.864	rs703530	chr19:37500918	G/A	cg27390819	chr19:37464633	NA	-0.52	-6.38	-0.33	5.73e-10	Obesity-related traits;
LIHC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.62	10.8	0.5	1.4e-23	Colorectal cancer;
LIHC	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg27433088	chr4:174089019	GALNT7	0.41	7.01	0.35	1.25e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs7188697	0.922	rs1981961	chr16:58597291	A/T	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	0.84	13.57	0.59	7.09e-34	Left atrial antero-posterior diameter;
LIHC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg04025307	chr7:1156635	C7orf50	0.55	7.3	0.37	1.97e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.48	-0.42	7.08e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	8.12e-10	Red blood cell count;
LIHC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.07	15.39	0.64	5.41e-41	Cognitive function;
LIHC	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.46	-0.37	7.07e-13	QT interval;
LIHC	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg03805757	chr16:71968109	PKD1L3	-0.68	-7.8	-0.39	7.8e-14	Post bronchodilator FEV1;
LIHC	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.59	10.92	0.51	5.04e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	trans	rs2211698	1.000	rs4384872	chr21:35837113	A/G	cg18044562	chr7:50468399	IKZF1	0.51	7.42	0.37	9.41e-13	Cancer;
LIHC	cis	rs2279817	0.818	rs34036216	chr1:17986046	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.22	-0.36	3.45e-12	Neuroticism;
LIHC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg01864069	chr14:103024347	NA	-0.57	-9.52	-0.46	3.36e-19	Platelet count;
LIHC	cis	rs17125944	0.615	rs2025633	chr14:53317340	C/T	cg00686598	chr14:53173677	PSMC6	-0.84	-9.96	-0.47	1.07e-20	Alzheimer's disease (late onset);
LIHC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg18225595	chr11:63971243	STIP1	0.63	8.03	0.4	1.54e-14	Mean platelet volume;
LIHC	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.97	8.5	0.42	6.05e-16	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4759375	0.510	rs12367421	chr12:123783691	T/A	cg00376283	chr12:123451042	ABCB9	-0.49	-6.31	-0.32	8.53e-10	HDL cholesterol;
LIHC	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.54	-13.08	-0.58	5.78e-32	White blood cell count (basophil);
LIHC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.99	21.35	0.76	6.81e-65	Bone mineral density;
LIHC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg07713946	chr22:31675144	LIMK2	-0.43	-7.78	-0.39	8.78e-14	Colorectal cancer;
LIHC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.6	9.74	0.47	5.95e-20	Body mass index;
LIHC	cis	rs2997447	0.723	rs2802338	chr1:26475257	G/A	cg19633962	chr1:26362018	EXTL1	-0.55	-6.43	-0.33	4.22e-10	QRS complex (12-leadsum);
LIHC	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg23533926	chr12:111358616	MYL2	-0.36	-6.86	-0.35	3.18e-11	Extrinsic epigenetic age acceleration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02763798	chr12:58335209	XRCC6BP1	0.47	6.33	0.32	7.61e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.48	7.85	0.39	5.51e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10420951	0.617	rs7246328	chr19:18619057	T/C	cg10790698	chr19:18539756	SSBP4	-0.42	-5.93	-0.31	7.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-7.7	-0.38	1.51e-13	Electroencephalogram traits;
LIHC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.84	-14.47	-0.62	2.29e-37	Dental caries;
LIHC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.75e-22	Hemoglobin concentration;
LIHC	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.55	-6.97	-0.35	1.59e-11	QRS complex (12-leadsum);
LIHC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.7	-10.52	-0.49	1.32e-22	Platelet count;
LIHC	cis	rs3853824	0.965	rs6503764	chr17:54880082	T/C	cg13675837	chr17:54910204	DGKE	0.39	5.88	0.3	9.79e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.11	0.31	2.71e-9	Schizophrenia;
LIHC	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07421368	chr2:67624930	ETAA1	0.5	7.58	0.38	3.33e-13	Cognitive function;
LIHC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg03013999	chr17:37608204	MED1	-0.36	-6.01	-0.31	4.76e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07161888	chr16:53537348	AKTIP	0.43	6.16	0.32	2.07e-9	Lung function (FEV1/FVC);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12390003	chr1:160068671	IGSF8	0.48	6.68	0.34	9.89e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.69	11.16	0.52	7.11e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	0.77	6.2	0.32	1.65e-9	Blood protein levels;
LIHC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.72	0.34	7.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs882732	1.000	rs10142033	chr14:95041623	A/T	cg14866387	chr14:95027382	SERPINA4	-0.48	-6.45	-0.33	3.82e-10	Blood protein levels;
LIHC	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.52	7.16	0.36	4.96e-12	Mean corpuscular volume;
LIHC	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.46	5.92	0.31	7.67e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs288342	0.832	rs288305	chr2:183652328	C/T	cg02625481	chr2:183667124	NA	-0.29	-5.96	-0.31	6.2e-9	Recurrent major depressive disorder;
LIHC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	8.43	0.41	9.98e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.57	6.94	0.35	1.94e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.41	7.52	0.38	4.9e-13	Essential tremor;
LIHC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.55	-0.42	4.1e-16	Type 2 diabetes;
LIHC	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.85	-0.39	5.38e-14	Coronary artery disease;
LIHC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.75	7.57	0.38	3.48e-13	Vitiligo;
LIHC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.93	0.31	7.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.42	0.33	4.64e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.0	-22.44	-0.77	3.43e-69	Height;
LIHC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.95	17.64	0.69	5.55e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.81	-9.64	-0.46	1.34e-19	Alzheimer's disease (late onset);
LIHC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg01256987	chr12:42539512	GXYLT1	-0.35	-5.74	-0.3	2.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.35	0.52	1.52e-25	Platelet count;
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21448741	chr8:58168803	NA	0.33	6.01	0.31	4.72e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg05535760	chr7:792225	HEATR2	-0.49	-6.83	-0.35	3.9e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg14132834	chr19:41945861	ATP5SL	-0.41	-6.05	-0.31	3.82e-9	Height;
LIHC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.48	9.37	0.45	1.01e-18	Blood protein levels;
LIHC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.58	0.42	3.46e-16	Initial pursuit acceleration;
LIHC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.81	0.39	7.09e-14	Alzheimer's disease;
LIHC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17507749	chr15:85114479	UBE2QP1	0.62	7.05	0.36	1.02e-11	Schizophrenia;
LIHC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.94	20.29	0.74	1.24e-60	Blood protein levels;
LIHC	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg27205649	chr11:78285834	NARS2	0.4	5.95	0.31	6.76e-9	Alzheimer's disease (survival time);
LIHC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	1.03	20.62	0.74	5.72e-62	Breast cancer;
LIHC	trans	rs7504990	0.754	rs1030592	chr18:50374721	T/C	cg08535148	chr4:26321143	RBPJ	0.58	7.31	0.37	1.92e-12	Gallbladder cancer;
LIHC	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.51	9.49	0.46	4.22e-19	Testicular germ cell tumor;
LIHC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20135002	chr11:47629003	NA	-0.58	-10.01	-0.48	7.32e-21	Subjective well-being;
LIHC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg04374321	chr14:90722782	PSMC1	0.44	6.46	0.33	3.62e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs12744310	0.887	rs6660265	chr1:41818676	C/T	cg03962019	chr1:41807865	NA	-0.39	-6.25	-0.32	1.23e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg02782426	chr3:40428986	ENTPD3	-0.32	-6.12	-0.31	2.61e-9	Renal cell carcinoma;
LIHC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.25	-0.52	3.46e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.78	12.68	0.57	1.87e-30	Longevity;
LIHC	cis	rs600806	0.714	rs2781552	chr1:110025881	A/G	cg02415029	chr1:110025642	ATXN7L2	0.46	6.05	0.31	3.75e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26567012	chr5:151202148	GLRA1	-0.42	-6.51	-0.33	2.66e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1355223	0.902	rs1453387	chr11:34707898	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.3	-0.32	9.3e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg05110241	chr16:68378359	PRMT7	-0.63	-7.06	-0.36	9.6e-12	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7078219	0.505	rs10883372	chr10:101292483	T/A	cg06854084	chr10:101292507	NKX2-3	-0.34	-6.22	-0.32	1.44e-9	Dental caries;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13370280	chr6:137539688	IFNGR1	0.52	7.62	0.38	2.44e-13	Pancreatic cancer;
LIHC	cis	rs4780401	0.933	rs4780395	chr16:11809940	A/G	cg01061890	chr16:11836724	TXNDC11	-0.4	-5.75	-0.3	2.03e-8	Rheumatoid arthritis;
LIHC	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.49	6.1	0.31	2.87e-9	Interleukin-17 levels;
LIHC	cis	rs7945718	0.905	rs6486032	chr11:12723693	G/A	cg25843174	chr11:12811716	TEAD1	0.33	7.34	0.37	1.62e-12	Educational attainment (years of education);
LIHC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01587390	chr19:10221818	PPAN-P2RY11;P2RY11;PPAN	-0.39	-6.04	-0.31	4.08e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.54	-0.33	2.24e-10	Prevalent atrial fibrillation;
LIHC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.97	17.43	0.69	3.72e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.03	-0.31	4.33e-9	Colorectal cancer;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.43	7.73	0.39	1.24e-13	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.95	-0.51	4.13e-24	Hemoglobin concentration;
LIHC	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.01	21.22	0.75	2.26e-64	Schizophrenia;
LIHC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.66	8.27	0.41	3.06e-15	Mean platelet volume;
LIHC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.75	-8.07	-0.4	1.22e-14	Putamen volume;
LIHC	cis	rs629922	0.642	rs615119	chr11:114072224	T/C	cg01914181	chr11:114070210	ZBTB16	0.54	7.52	0.38	4.72e-13	Paneth cell defects in Crohn's disease;
LIHC	cis	rs3816183	1.000	rs920390	chr2:43019144	A/G	cg17246140	chr2:43020264	HAAO	0.39	5.82	0.3	1.33e-8	Hypospadias;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19502700	chr4:113558183	LARP7;C4orf21	0.48	7.36	0.37	1.41e-12	Calcium levels;
LIHC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20135002	chr11:47629003	NA	-0.58	-10.09	-0.48	3.95e-21	Subjective well-being;
LIHC	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg19683494	chr5:74908142	NA	0.7	7.74	0.39	1.14e-13	Coronary artery disease;
LIHC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.85	-12.16	-0.55	1.6e-28	Diastolic blood pressure;
LIHC	cis	rs12286929	0.606	rs11823428	chr11:115071222	C/A	cg04055981	chr11:115044050	NA	0.51	7.94	0.39	2.84e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.51	8.25	0.41	3.48e-15	Corneal astigmatism;
LIHC	cis	rs7165170	0.678	rs12592070	chr15:91197016	C/A	cg26821196	chr15:91095069	CRTC3	-0.37	-6.9	-0.35	2.54e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs422249	0.615	rs174612	chr11:61628266	C/G	cg27386326	chr11:61587980	NA	0.38	6.97	0.35	1.62e-11	Trans fatty acid levels;
LIHC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.47	6.24	0.32	1.32e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	12.74	0.57	1.0500000000000001e-30	Schizophrenia;
LIHC	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.7	14.5	0.62	1.81e-37	Schizophrenia;
LIHC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.18	0.32	1.87e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05025164	chr4:1340916	KIAA1530	0.74	11.05	0.51	1.76e-24	Longevity;
LIHC	cis	rs7581030	0.874	rs4852772	chr2:71443645	A/G	cg07678644	chr2:71558969	ZNF638	0.46	6.49	0.33	2.99e-10	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg21724239	chr8:58056113	NA	0.48	6.4	0.33	5.2400000000000005e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg22676075	chr6:135203613	NA	0.39	6.38	0.33	5.82e-10	Red blood cell count;
LIHC	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21467203	chr3:49911342	NA	-0.43	-7.28	-0.37	2.3e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.49	-7.08	-0.36	8.23e-12	Body mass index;
LIHC	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11227645	chr1:224544764	CNIH4	0.43	6.36	0.33	6.57e-10	Lung function (FEV1/FVC);
LIHC	trans	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.81e-11	Aortic root size;
LIHC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.53e-9	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.36	6.09	0.31	2.96e-9	Height;
LIHC	cis	rs12980942	0.872	rs7256416	chr19:41787931	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.29	0.32	9.54e-10	Coronary artery disease;
LIHC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg05000987	chr1:87379871	SEP15;HS2ST1	-0.39	-6.17	-0.32	1.96e-9	Oropharynx cancer;
LIHC	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-6.53	-0.33	2.38e-10	Total body bone mineral density (age 45-60);
LIHC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.59	-0.46	1.93e-19	Bipolar disorder;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.57	8.92	0.43	2.78e-17	Longevity;Endometriosis;
LIHC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.27	-7.11	-0.36	6.9e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs80282103	0.618	rs11818314	chr10:1148157	G/C	cg08668510	chr10:1095578	IDI1	0.62	6.07	0.31	3.45e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.83	0.43	5.6e-17	Lung cancer in ever smokers;
LIHC	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.29	0.32	9.59e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs249954	0.512	rs7588	chr16:23681165	G/A	cg01460202	chr16:23706506	ERN2	0.35	5.77	0.3	1.76e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg03146154	chr1:46216737	IPP	-0.37	-6.18	-0.32	1.87e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg09035930	chr12:129282057	SLC15A4	-0.47	-5.75	-0.3	1.93e-8	Systemic lupus erythematosus;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13985271	chr9:97140681	HIATL1	0.46	6.37	0.33	6.04e-10	Pancreatic cancer;
LIHC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-6.4	-0.33	5.02e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg07424592	chr7:64974309	NA	0.75	8.5	0.42	5.89e-16	Diabetic kidney disease;
LIHC	cis	rs919433	0.714	rs2333855	chr2:198200213	T/G	cg10820045	chr2:198174542	NA	-0.56	-9.1	-0.44	7.5e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6466055	0.777	rs10277120	chr7:104834417	A/T	cg04380332	chr7:105027541	SRPK2	0.34	6.49	0.33	3.02e-10	Schizophrenia;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11102324	chr15:49658865	C15orf33	0.4	6.04	0.31	4.04e-9	Bilirubin levels;
LIHC	cis	rs77637988	0.578	rs12328506	chr2:48623184	C/T	cg15846641	chr2:48541264	FOXN2	0.54	7.14	0.36	5.48e-12	Joint mobility (Beighton score);
LIHC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.48	-7.48	-0.37	6.34e-13	Diastolic blood pressure;
LIHC	cis	rs807029	0.577	rs701834	chr10:102761801	C/T	cg17130504	chr10:102756923	LZTS2	0.54	7.18	0.36	4.29e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg07451762	chr16:28383216	NA	0.32	5.96	0.31	6.31e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	11.02	0.51	2.2e-24	HIV-1 control;
LIHC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.47	-7.85	-0.39	5.33e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs12980942	0.872	rs12985339	chr19:41801756	A/T	cg25627403	chr19:41769009	HNRNPUL1	-0.54	-6.67	-0.34	1.02e-10	Coronary artery disease;
LIHC	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg14758556	chr20:62440591	NA	0.42	6.61	0.34	1.51e-10	Atopic dermatitis;
LIHC	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.69	-0.34	9e-11	Total cholesterol levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02711976	chr1:36023590	NCDN;KIAA0319L	0.51	6.65	0.34	1.17e-10	Lung function (FEV1/FVC);
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.55	9.4	0.45	7.97e-19	Aortic root size;
LIHC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg19635926	chr16:89946313	TCF25	0.48	6.17	0.32	1.97e-9	Skin colour saturation;
LIHC	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-7.26	-0.37	2.56e-12	Mortality in heart failure;
LIHC	trans	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg14791747	chr16:20752902	THUMPD1	-0.48	-6.74	-0.34	6.59e-11	Dental caries;
LIHC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	0.82	6.42	0.33	4.69e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-0.84	-12.85	-0.57	4.07e-31	Obesity-related traits;
LIHC	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.51	6.23	0.32	1.38e-9	Menarche (age at onset);
LIHC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.46	-7.22	-0.36	3.44e-12	Height;
LIHC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg15841412	chr13:111365552	ING1	-0.5	-6.3	-0.32	9.41e-10	Coronary artery disease;
LIHC	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.46	-6.78	-0.34	5.43e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.14	0.32	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.55	-8.77	-0.43	8.47e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.41	0.52	9.26e-26	Coronary artery disease;
LIHC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg06096015	chr1:231504339	EGLN1	0.47	8.57	0.42	3.57e-16	Hemoglobin concentration;
LIHC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.44	-6.67	-0.34	1.03e-10	Height;
LIHC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.49	8.61	0.42	2.69e-16	Height;
LIHC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.3	-6.35	-0.32	6.69e-10	Blood metabolite levels;
LIHC	cis	rs4671400	0.571	rs28480287	chr2:61489289	G/C	cg14146966	chr2:61757674	XPO1	-0.36	-5.74	-0.3	2.1e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.87	15.75	0.65	2.09e-42	Body mass index;
LIHC	cis	rs829883	0.604	rs249841	chr12:98871743	A/G	cg23471612	chr12:98897216	NA	0.3	5.84	0.3	1.21e-8	Colorectal adenoma (advanced);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13888710	chr4:39699558	UBE2K	-0.48	-6.9	-0.35	2.56e-11	Immature fraction of reticulocytes;
LIHC	cis	rs7911264	1.000	rs10882100	chr10:94460687	C/G	cg25506282	chr10:94462361	NA	0.42	7.29	0.37	2.22e-12	Inflammatory bowel disease;
LIHC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.91	-0.35	2.35e-11	Diabetic kidney disease;
LIHC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.34	-0.32	7.13e-10	Height;
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08219700	chr8:58056026	NA	0.52	7.12	0.36	6.34e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.4	6.77	0.34	5.69e-11	Menopause (age at onset);
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.76	11.26	0.52	3.09e-25	Menarche (age at onset);
LIHC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	12.05	0.55	3.99e-28	High light scatter reticulocyte count;
LIHC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.73	10.6	0.5	7e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.76	-0.3	1.9e-8	Coronary artery disease;
LIHC	cis	rs3761218	0.866	rs579111	chr20:3763872	T/C	cg25011176	chr20:3776985	CDC25B	-0.45	-5.89	-0.3	9.12e-9	Bipolar disorder;
LIHC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.79	6.39	0.33	5.48e-10	Body mass index;
LIHC	cis	rs249954	0.512	rs42873	chr16:23694732	C/G	cg09867953	chr16:23706666	ERN2	0.34	5.86	0.3	1.11e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.38	5.83	0.3	1.26e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.93	-12.27	-0.55	6.56e-29	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	13.08	0.58	5.81e-32	Prudent dietary pattern;
LIHC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg21361702	chr7:150065534	REPIN1	0.46	6.24	0.32	1.3e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg00280220	chr17:61926910	NA	0.41	6.72	0.34	7.41e-11	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07387570	chr22:46663686	TTC38	0.41	6.75	0.34	6.29e-11	Cognitive function;
LIHC	cis	rs611744	0.805	rs396149	chr8:109108740	A/C	cg21045802	chr8:109455806	TTC35	0.49	8.43	0.41	9.51e-16	Dupuytren's disease;
LIHC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg25039879	chr17:56429692	SUPT4H1	0.79	8.95	0.44	2.32e-17	Cognitive test performance;
LIHC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.58	9.88	0.47	2.04e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.88	12.2	0.55	1.13e-28	Blood metabolite levels;
LIHC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.56e-8	Bladder cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01194468	chr9:33264774	SUGT1P1;CHMP5;BAG1	0.43	6.05	0.31	3.75e-9	Pancreatic cancer;
LIHC	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg26138144	chr22:38071188	LGALS1	0.72	10.53	0.49	1.17e-22	Fat distribution (HIV);
LIHC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.46e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.26	6.04	0.31	3.96e-9	Heart rate;
LIHC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.13	0.36	5.88e-12	Self-reported allergy;
LIHC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-9.04	-0.44	1.21e-17	Crohn's disease;
LIHC	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.86	-0.3	1.09e-8	Resting heart rate;
LIHC	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.81	-0.3	1.44e-8	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg11764359	chr7:65958608	NA	0.6	6.34	0.32	7.29e-10	Diabetic kidney disease;
LIHC	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg08126542	chr6:37504118	NA	-0.37	-6.3	-0.32	9.37e-10	Cognitive performance;
LIHC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	1.03	15.41	0.64	4.8e-41	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05744073	chr17:1953268	MIR132	0.45	6.72	0.34	7.54e-11	Pancreatic cancer;
LIHC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	9.49	0.46	4.07e-19	IgG glycosylation;
LIHC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.31	6.49	0.33	3e-10	Blood metabolite levels;
LIHC	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-10.59	-0.5	7.16e-23	Hypertriglyceridemia;
LIHC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24229701	chr12:130821962	PIWIL1	0.44	6.73	0.34	7.1e-11	Menopause (age at onset);
LIHC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg19302996	chr17:73780495	UNK	-0.6	-9.51	-0.46	3.52e-19	White matter hyperintensity burden;
LIHC	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.83	0.3	1.27e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20925434	chr21:35014276	ITSN1;CRYZL1	-0.52	-6.18	-0.32	1.84e-9	Systolic blood pressure;
LIHC	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg27205649	chr11:78285834	NARS2	0.4	6.26	0.32	1.17e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg18252515	chr7:66147081	NA	-0.71	-9.63	-0.46	1.37e-19	Corneal structure;
LIHC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.4	6.0	0.31	4.97e-9	Height;
LIHC	cis	rs12644436	0.560	rs10013459	chr4:88781743	A/G	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg00091569	chr3:40428383	ENTPD3	0.38	6.38	0.33	5.64e-10	Renal cell carcinoma;
LIHC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.51	8.5	0.42	6e-16	Obesity-related traits;
LIHC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.12	0.68	6.77e-48	Gut microbiome composition (summer);
LIHC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.31	0.41	2.3e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22535057	chr3:9542104	LHFPL4	0.47	6.61	0.34	1.51e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.6	11.02	0.51	2.25e-24	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23243902	chr11:117049849	SIDT2	0.53	7.26	0.37	2.55e-12	Lung function (FEV1/FVC);
LIHC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.8	-0.39	7.55e-14	Type 2 diabetes;
LIHC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-14.46	-0.62	2.67e-37	Chronic sinus infection;
LIHC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.59	0.42	3.08e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	11.75	0.54	5.28e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.4e-8	Heart rate;
LIHC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg19645103	chr12:69753606	YEATS4	-0.4	-5.92	-0.3	7.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg07393940	chr7:158741817	NA	0.54	6.25	0.32	1.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.67	9.17	0.44	4.49e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.47	6.7	0.34	8.53e-11	Asthma;
LIHC	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	0.88	14.57	0.62	1e-37	Left atrial antero-posterior diameter;
LIHC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg21724239	chr8:58056113	NA	0.49	6.46	0.33	3.61e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.63	7.87	0.39	4.72e-14	Crohn's disease;
LIHC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.67	11.12	0.52	9.84e-25	Childhood ear infection;
LIHC	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.51	-6.51	-0.33	2.68e-10	Schizophrenia;
LIHC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.78	0.34	5.43e-11	Aortic root size;
LIHC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.31	-6.77	-0.34	5.72e-11	Longevity;
LIHC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg01753270	chr2:239240285	TRAF3IP1	-0.43	-8.1	-0.4	9.89e-15	Multiple system atrophy;
LIHC	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.28	6.18	0.32	1.79e-9	Pulmonary function;
LIHC	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	7.63	0.38	2.3e-13	Body mass index;
LIHC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.38e-11	Aortic root size;
LIHC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg20735989	chr4:730612	PCGF3	-0.66	-8.72	-0.43	1.26e-16	White blood cell count;
LIHC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.57	0.38	3.4e-13	Lymphocyte counts;
LIHC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.63	9.57	0.46	2.29e-19	Height;
LIHC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.57	-9.24	-0.45	2.63e-18	Colorectal cancer;
LIHC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.2	-0.36	3.77e-12	Height;
LIHC	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg03934865	chr2:198174659	NA	0.47	6.74	0.34	6.87e-11	Dermatomyositis;
LIHC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.86	-0.3	1.07e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-11.13	-0.52	9.45e-25	Ulcerative colitis;
LIHC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	10.58	0.5	7.85e-23	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.32	6.37	0.33	6.09e-10	Renal cell carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24549639	chr12:69201477	MDM2	0.45	6.37	0.33	6.14e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.17	14.97	0.63	2.61e-39	Diabetic kidney disease;
LIHC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-6.77	-0.34	5.61e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-10.39	-0.49	3.57e-22	Chronic sinus infection;
LIHC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg05665937	chr4:1216051	CTBP1	0.44	5.87	0.3	1.04e-8	Obesity-related traits;
LIHC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.61	7.69	0.38	1.53e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.5	0.38	5.37e-13	Electroencephalogram traits;
LIHC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg11783602	chr8:55087084	NA	-0.29	-5.73	-0.3	2.24e-8	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg00280220	chr17:61926910	NA	0.42	6.83	0.35	3.82e-11	Prudent dietary pattern;
LIHC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.34	-5.98	-0.31	5.53e-9	IgG glycosylation;
LIHC	cis	rs8067354	0.789	rs1292068	chr17:57929319	T/C	cg02344993	chr17:57696989	CLTC	0.54	8.68	0.42	1.67e-16	Hemoglobin concentration;
LIHC	cis	rs7729447	0.813	rs10941022	chr5:32691416	C/T	cg16267343	chr5:32710456	NPR3	0.46	5.73	0.3	2.19e-8	Blood pressure;
LIHC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg20607798	chr8:58055168	NA	0.46	6.3	0.32	9.07e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-0.8	-10.95	-0.51	3.97e-24	Monocyte percentage of white cells;
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.26	-6.31	-0.32	8.41e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25029360	chr8:141646502	EIF2C2	-0.53	-6.66	-0.34	1.12e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-7.02	-0.35	1.23e-11	Hepatocellular carcinoma;
LIHC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.59	0.62	8.17e-38	Prudent dietary pattern;
LIHC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.93	-0.31	7.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.35	0.41	1.66e-15	Platelet count;
LIHC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.15	-0.32	2.21e-9	Ulcerative colitis;
LIHC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-8.22	-0.41	4.25e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg18180155	chr22:45809454	SMC1B;RIBC2	0.54	6.01	0.31	4.87e-9	Tonsillectomy;
LIHC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg05973401	chr12:123451056	ABCB9	0.42	6.38	0.33	5.89e-10	Platelet count;
LIHC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.94	-0.31	7.07e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg00601450	chr5:74908170	NA	0.47	6.56	0.33	2.03e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-13.08	-0.58	5.37e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	0.74	8.26	0.41	3.24e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	0.94	17.62	0.69	6.38e-50	Breast cancer;
LIHC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	9.78	0.47	4.54e-20	Total body bone mineral density;
LIHC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.42	5.74	0.3	2.07e-8	Life satisfaction;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02916409	chr16:2510063	C16orf59	0.45	6.35	0.32	6.92e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.84	0.39	5.64e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.92	10.26	0.49	1.01e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.46	6.25	0.32	1.23e-9	Pulse pressure;
LIHC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.04	0.31	3.94e-9	Morning vs. evening chronotype;
LIHC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.54	7.49	0.38	5.95e-13	Lung disease severity in cystic fibrosis;
LIHC	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg00012203	chr2:219082015	ARPC2	-0.46	-5.93	-0.31	7.4e-9	Ulcerative colitis;
LIHC	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.94	10.62	0.5	5.85e-23	Breast cancer;
LIHC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.96	-0.31	6.35e-9	Menarche (age at onset);
LIHC	cis	rs6504950	0.800	rs17745183	chr17:53013595	G/T	cg10237252	chr17:52977213	TOM1L1	-0.35	-6.16	-0.32	2.03e-9	Breast cancer;
LIHC	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.45	7.02	0.35	1.19e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16346588	chr10:242978	ZMYND11	0.39	5.97	0.31	5.99e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.67	-9.16	-0.44	4.99e-18	Morning vs. evening chronotype;
LIHC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.33	-7.06	-0.36	9.29e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	7.84	0.39	5.89e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg26338869	chr17:61819248	STRADA	0.52	6.98	0.35	1.54e-11	Height;
LIHC	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.47	7.04	0.36	1.08e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.68	-0.46	9.65e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.54	-0.46	2.86e-19	Blood metabolite levels;
LIHC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	8.7	0.43	1.39e-16	Lymphocyte counts;
LIHC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg20933634	chr6:27740509	NA	0.46	6.07	0.31	3.32e-9	Parkinson's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07832834	chr1:2457954	PANK4	0.52	6.59	0.34	1.68e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.64	-10.74	-0.5	2.22e-23	Colorectal cancer;
LIHC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg09855544	chr8:135498122	ZFAT	0.38	6.13	0.31	2.44e-9	Educational attainment;
LIHC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg24296786	chr1:45957014	TESK2	-0.52	-7.6	-0.38	2.87e-13	Platelet count;
LIHC	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg00792783	chr2:198669748	PLCL1	0.45	6.52	0.33	2.57e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.52	7.12	0.36	6.28e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg14067834	chr17:29058358	SUZ12P	0.69	6.69	0.34	9.41e-11	Body mass index;
LIHC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.99	0.35	1.48e-11	Bipolar disorder;
LIHC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.48	-0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.16	-0.32	2.09e-9	Metabolite levels;
LIHC	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	0.71	7.5	0.38	5.5e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.88	11.43	0.53	7.95e-26	Cognitive function;
LIHC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg06466757	chr4:1255808	NA	0.35	5.93	0.31	7.24e-9	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08862778	chr1:11322643	MTOR	0.47	7.01	0.35	1.28e-11	Pancreatic cancer;
LIHC	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-14.36	-0.61	6.1e-37	Mortality in heart failure;
LIHC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.48	-0.38	6.16e-13	Chronic sinus infection;
LIHC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg24826892	chr11:71159390	DHCR7	0.47	6.1	0.31	2.81e-9	Vitamin D levels;
LIHC	cis	rs6442522	0.772	rs3846127	chr3:15491527	G/C	cg16303742	chr3:15540471	COLQ	0.44	7.12	0.36	6.47e-12	Uric acid levels;
LIHC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.77	0.3	1.75e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.75	-7.71	-0.38	1.35e-13	Vitiligo;
LIHC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.86	0.3	1.11e-8	Platelet count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21983178	chr1:45120676	TMEM53	-0.41	-6.24	-0.32	1.29e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg00204512	chr16:28754710	NA	0.4	6.89	0.35	2.68e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg15902774	chr15:75289873	SCAMP5	0.45	6.78	0.34	5.29e-11	Lung cancer;
LIHC	cis	rs17152411	1.000	rs7077936	chr10:126650065	C/T	cg07906193	chr10:126599966	NA	0.48	7.85	0.39	5.28e-14	Height;
LIHC	cis	rs3789045	0.729	rs12039968	chr1:204490674	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.43	-6.62	-0.34	1.4e-10	Educational attainment (college completion);
LIHC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.58	-0.34	1.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg24209194	chr3:40518798	ZNF619	0.49	7.37	0.37	1.32e-12	Renal cell carcinoma;
LIHC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.69	-13.53	-0.59	1.03e-33	Body mass index;
LIHC	cis	rs75908454	1.000	rs75669960	chr6:169939060	A/G	cg19338460	chr6:170058176	WDR27	-0.8	-7.48	-0.37	6.38e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.86	0.35	3.21e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs611744	0.967	rs650401	chr8:109196854	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.83	14.78	0.62	1.42e-38	Aortic root size;
LIHC	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.53	7.93	0.39	3.04e-14	Body mass index;
LIHC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.96	17.34	0.68	8.84e-49	Breast cancer;
LIHC	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.38	-13.21	-0.58	1.83e-32	Psoriasis vulgaris;
LIHC	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.2	-6.34	-0.32	7.2e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.37	-6.37	-0.33	6.1e-10	Menopause (age at onset);
LIHC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.86	-0.35	3.33e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.72	-0.3	2.31e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05203659	chr16:12009378	GSPT1	0.48	6.09	0.31	3.03e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-11.25	-0.52	3.37e-25	Glycated hemoglobin levels;
LIHC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.09	12.73	0.57	1.19e-30	Vitiligo;
LIHC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.68	-8.4	-0.41	1.25e-15	Gut microbiome composition (summer);
LIHC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg26149184	chr10:133730230	NA	-0.4	-6.16	-0.32	2.08e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs903552	0.932	rs1587108	chr15:102006825	G/A	cg06707286	chr15:102010195	PCSK6	-0.47	-6.64	-0.34	1.21e-10	Diabetic kidney disease;
LIHC	cis	rs6783573	0.524	rs11130097	chr3:46620614	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.29	-5.74	-0.3	2.14e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-6.18	-0.32	1.83e-9	Morning vs. evening chronotype;
LIHC	cis	rs17125944	0.686	rs912861	chr14:53333290	C/G	cg00686598	chr14:53173677	PSMC6	-0.75	-8.62	-0.42	2.62e-16	Alzheimer's disease (late onset);
LIHC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.73	-10.47	-0.49	1.93e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.44	7.5	0.38	5.72e-13	Educational attainment;
LIHC	trans	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.72	0.34	7.7e-11	Mean corpuscular volume;
LIHC	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	0.77	9.96	0.47	1.11e-20	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08511015	chr19:11515999	RGL3	-0.37	-6.43	-0.33	4.31e-10	Calcium levels;
LIHC	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.19	-0.32	1.7e-9	Response to antipsychotic treatment;
LIHC	cis	rs1144333	0.850	rs1146651	chr1:76273594	C/A	cg10523679	chr1:76189770	ACADM	-0.46	-6.73	-0.34	7.26e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	15.08	0.63	9.22e-40	Platelet count;
LIHC	cis	rs3736485	0.873	rs12441759	chr15:51755033	C/A	cg08986416	chr15:51914746	DMXL2	-0.39	-5.81	-0.3	1.4e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	6.37	0.33	5.99e-10	Platelet distribution width;
LIHC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg04013166	chr16:89971882	TCF25	0.53	6.67	0.34	1.04e-10	Skin colour saturation;
LIHC	cis	rs3770081	1.000	rs1561328	chr2:86272758	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-9.32	-0.45	1.46e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.43	-8.03	-0.4	1.61e-14	Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.54e-79	Prudent dietary pattern;
LIHC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.57	10.29	0.49	8.26e-22	Mean corpuscular volume;
LIHC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04013166	chr16:89971882	TCF25	0.46	5.73	0.3	2.2e-8	Skin colour saturation;
LIHC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.56	9.35	0.45	1.21e-18	Colorectal cancer;
LIHC	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.1	9.16	0.44	5.02e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-6.36	-0.33	6.63e-10	Electroencephalogram traits;
LIHC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.8	0.3	1.55e-8	Menopause (age at onset);
LIHC	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.64	8.81	0.43	6.33e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.81	14.37	0.61	5.58e-37	Coronary artery disease;
LIHC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg10381502	chr11:71823885	C11orf51	1.08	9.2	0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg19645103	chr12:69753606	YEATS4	-0.45	-5.98	-0.31	5.74e-9	Response to diuretic therapy;
LIHC	cis	rs2723064	0.543	rs2080385	chr2:65292762	G/T	cg05010058	chr2:65284262	CEP68	0.36	5.84	0.3	1.19e-8	Atrial fibrillation;
LIHC	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.34	-0.32	7.25e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.84	-9.3	-0.45	1.71e-18	Vitiligo;
LIHC	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg20283391	chr11:68216788	NA	-0.48	-5.91	-0.3	8.35e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.68	-9.78	-0.47	4.46e-20	Initial pursuit acceleration;
LIHC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-10.89	-0.51	6.64e-24	Monocyte percentage of white cells;
LIHC	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease;
LIHC	trans	rs8113308	0.810	rs11881650	chr19:52450139	A/C	cg14959425	chr7:20447707	ITGB8	0.47	6.11	0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg16989086	chr20:62203971	PRIC285	0.53	7.6	0.38	2.84e-13	Glioblastoma;
LIHC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.36	5.98	0.31	5.73e-9	Monocyte count;
LIHC	cis	rs7674212	0.512	rs2720462	chr4:104056210	T/G	cg16532752	chr4:104119610	CENPE	-0.43	-6.68	-0.34	9.82e-11	Type 2 diabetes;
LIHC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.34	-0.32	7.09e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.51	9.77	0.47	4.85e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	6.14	0.32	2.24e-9	Schizophrenia;
LIHC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.58	0.34	1.76e-10	Bipolar disorder;
LIHC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	10.99	0.51	2.83e-24	Menarche (age at onset);
LIHC	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.57	-8.57	-0.42	3.55e-16	Blood protein levels;
LIHC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.51	-0.49	1.38e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.65	9.85	0.47	2.57e-20	Height;
LIHC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.52	8.28	0.41	2.9e-15	Height;
LIHC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	12.25	0.55	7.55e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.42	-0.49	2.81e-22	Chronic sinus infection;
LIHC	cis	rs3770081	0.793	rs60719866	chr2:86284378	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.96	-11.41	-0.53	9.09e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.91	-0.35	2.37e-11	Axial length;
LIHC	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.36	7.04	0.36	1.04e-11	Multiple sclerosis;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21747090	chr2:27597821	SNX17	-0.4	-5.86	-0.3	1.06e-8	Total body bone mineral density;
LIHC	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg02023728	chr11:77925099	USP35	0.33	5.96	0.31	6.39e-9	Alzheimer's disease (survival time);
LIHC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2352908	1.000	rs1890724	chr14:49442749	A/T	cg16568472	chr20:3190600	ITPA	-0.44	-6.04	-0.31	3.95e-9	Social communication problems;
LIHC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-6.0	-0.31	5.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.49	8.11	0.4	9.31e-15	Mean corpuscular volume;
LIHC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.8	-18.23	-0.7	2.41e-52	Urate levels in lean individuals;
LIHC	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg03645007	chr3:50255295	SLC38A3	0.53	7.09	0.36	7.83e-12	Schizophrenia;
LIHC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.34	7.24	0.36	2.99e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.82	-12.75	-0.57	1.02e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs2637030	0.559	rs187659	chr5:52916018	G/A	cg06476337	chr5:52856530	NDUFS4	0.43	6.81	0.35	4.3e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs1434579	0.865	rs12978546	chr19:44945947	C/A	cg15540054	chr19:45004280	ZNF180	0.57	7.9	0.39	3.88e-14	Tuberculosis;
LIHC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg14709524	chr16:89940631	TCF25	0.47	5.79	0.3	1.58e-8	Skin colour saturation;
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.49e-32	Colorectal cancer;
LIHC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg08253296	chr5:74907592	NA	-0.51	-6.52	-0.33	2.49e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.7	-9.09	-0.44	7.94e-18	Body mass index;
LIHC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.78	13.52	0.59	1.17e-33	Aortic root size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06989074	chr11:68133177	LRP5	-0.4	-6.67	-0.34	1.01e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.78	8.99	0.44	1.67e-17	Exhaled nitric oxide levels;
LIHC	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.6	12.01	0.54	5.6e-28	Plateletcrit;Platelet count;
LIHC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg17385448	chr1:15911702	AGMAT	0.34	5.98	0.31	5.77e-9	Systolic blood pressure;
LIHC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.37	-0.59	4.35e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg18944383	chr4:111397179	ENPEP	0.25	6.34	0.32	7.08e-10	Coronary artery disease;
LIHC	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.37	-8.43	-0.41	9.81e-16	Congenital heart disease (maternal effect);
LIHC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.47	-0.33	3.39e-10	Response to antipsychotic treatment;
LIHC	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-8.85	-0.43	4.79e-17	Corneal astigmatism;
LIHC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.66	-10.88	-0.51	6.89e-24	Childhood ear infection;
LIHC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg19508488	chr2:152266495	RIF1	0.5	7.15	0.36	5.24e-12	Squamous cell lung carcinoma;
LIHC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.89	-0.54	1.56e-27	Chronic sinus infection;
LIHC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg18478394	chr8:109455254	TTC35	0.41	7.01	0.35	1.28e-11	Dupuytren's disease;
LIHC	trans	rs6934970	1.000	rs12196496	chr6:113021779	T/A	cg20627988	chr10:133946881	JAKMIP3	0.49	6.36	0.33	6.55e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.52	7.28	0.37	2.38e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26734620	chr12:56694298	CS	1.23	10.54	0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.51	6.03	0.31	4.36e-9	Alzheimer's disease;
LIHC	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg13945301	chr2:157190182	NR4A2	0.38	6.13	0.31	2.4e-9	Hippocampal sclerosis of aging;
LIHC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg20651018	chr11:3035856	CARS	-0.34	-5.75	-0.3	2.03e-8	Longevity;
LIHC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg00656387	chr3:40428638	ENTPD3	-0.42	-6.86	-0.35	3.15e-11	Renal cell carcinoma;
LIHC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.6	-7.78	-0.39	8.66e-14	Lung cancer;
LIHC	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.57	8.97	0.44	2.03e-17	Corneal astigmatism;
LIHC	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.49	9.45	0.46	5.4e-19	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.37	6.02	0.31	4.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg16070018	chr6:26224392	HIST1H3E	0.6	7.43	0.37	8.88e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.64	-9.32	-0.45	1.46e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-6.4	-0.33	5.19e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg25364880	chr3:44379878	C3orf23	0.47	6.68	0.34	9.7e-11	Depressive symptoms;
LIHC	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.0	-0.35	1.36e-11	Homocysteine levels;
LIHC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	0.92	17.13	0.68	6.07e-48	Bone mineral density;
LIHC	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.9	-0.3	8.64e-9	Diisocyanate-induced asthma;
LIHC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg12560992	chr17:57184187	TRIM37	0.73	10.84	0.51	9.51e-24	Cognitive test performance;
LIHC	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.66	8.27	0.41	3.09e-15	Corneal astigmatism;
LIHC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.63	8.95	0.44	2.25e-17	Testicular germ cell tumor;
LIHC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.38	-5.92	-0.3	7.91e-9	Blood pressure (smoking interaction);
LIHC	cis	rs4407350	0.967	rs4501045	chr22:44922321	G/A	cg26276947	chr22:44892394	LDOC1L	0.35	6.35	0.32	6.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.6	7.39	0.37	1.1e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.68	10.0	0.48	7.98e-21	Testicular germ cell tumor;
LIHC	cis	rs1555399	0.901	rs7140470	chr14:67983559	T/C	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.95	-0.31	6.51e-9	Parkinson's disease;
LIHC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13647721	chr17:30228624	UTP6	0.63	6.24	0.32	1.28e-9	Hip circumference adjusted for BMI;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg07897659	chr22:50316901	CRELD2	-0.49	-6.28	-0.32	1.01e-9	Alcohol dependence;
LIHC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg05343316	chr1:45956843	TESK2	0.45	6.6	0.34	1.58e-10	High light scatter reticulocyte count;
LIHC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg15208524	chr1:10270712	KIF1B	0.4	6.02	0.31	4.4e-9	Hepatocellular carcinoma;
LIHC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.31	6.36	0.32	6.65e-10	Blood metabolite levels;
LIHC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg09182678	chr22:50328711	NA	0.47	6.0	0.31	5.14e-9	Schizophrenia;
LIHC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg01134436	chr17:81009848	B3GNTL1	0.82	6.89	0.35	2.67e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs55665837	0.701	rs2007361	chr11:14662722	A/G	cg00085434	chr11:14927489	NA	0.42	5.81	0.3	1.47e-8	Vitamin D levels;
LIHC	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.49	8.12	0.4	8.43e-15	Schizophrenia;
LIHC	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-7.24	-0.36	3.05e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg21466736	chr12:48725269	NA	-0.72	-11.01	-0.51	2.49e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.77	6.64	0.34	1.25e-10	Type 2 diabetes;
LIHC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.58	9.41	0.45	7.61e-19	Lymphocyte counts;
LIHC	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg16275483	chr1:110013120	SYPL2	-0.5	-6.29	-0.32	9.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.18	-0.32	1.79e-9	Lung function (FVC);Lung function (FEV1);
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg25029360	chr8:141646502	EIF2C2	-0.48	-7.14	-0.36	5.71e-12	Body mass index;
LIHC	cis	rs6973256	0.583	rs2042000	chr7:133322697	T/C	cg10665199	chr7:133106180	EXOC4	0.34	5.77	0.3	1.76e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs61332075	0.500	rs55917008	chr2:239380244	C/A	cg01134436	chr17:81009848	B3GNTL1	0.87	7.24	0.36	2.94e-12	Lung function (FEV1/FVC);
LIHC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg13607699	chr17:42295918	UBTF	-0.44	-6.93	-0.35	2.08e-11	Total body bone mineral density;
LIHC	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.01	-0.35	1.28e-11	Prevalent atrial fibrillation;
LIHC	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-7.84	-0.39	5.66e-14	Obesity-related traits;
LIHC	trans	rs13325613	0.915	rs71327040	chr3:46263208	G/T	cg26337592	chr1:153642686	ILF2	0.68	6.2	0.32	1.66e-9	Monocyte count;
LIHC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg03934865	chr2:198174659	NA	-0.57	-9.07	-0.44	9.59e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.31	6.01	0.31	4.81e-9	Tonsillectomy;
LIHC	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.51	-6.05	-0.31	3.91e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs7714584	1.000	rs10053750	chr5:150270051	A/G	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.45	8.13	0.4	7.75e-15	Prudent dietary pattern;
LIHC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-9.1	-0.44	7.89e-18	Total cholesterol levels;
LIHC	cis	rs9649465	0.967	rs3779261	chr7:123315174	A/G	cg03229431	chr7:123269106	ASB15	-0.36	-7.57	-0.38	3.53e-13	Migraine;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.61	0.5	6.52e-23	Lymphocyte counts;
LIHC	cis	rs6973256	0.569	rs9649595	chr7:133385921	G/C	cg03336402	chr7:133662267	EXOC4	-0.38	-5.82	-0.3	1.35e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.78	0.39	8.73e-14	Educational attainment (years of education);
LIHC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.03	0.31	4.3e-9	Educational attainment;
LIHC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg08132940	chr7:1081526	C7orf50	-0.77	-6.47	-0.33	3.47e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.66	-8.9	-0.43	3.25e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.71	-11.0	-0.51	2.72e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.1	7.88	0.39	4.53e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02985541	chr2:219472218	PLCD4	0.45	8.58	0.42	3.34e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.59	-8.12	-0.4	8.29e-15	Vitamin D levels;
LIHC	cis	rs611744	0.967	rs630492	chr8:109215368	C/T	cg21045802	chr8:109455806	TTC35	-0.49	-8.63	-0.42	2.38e-16	Dupuytren's disease;
LIHC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.74	0.43	1.08e-16	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04479987	chr5:180649488	TRIM41	0.51	6.94	0.35	1.93e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.6	-0.5	6.94e-23	Coronary artery disease;
LIHC	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	6.67	0.34	1.01e-10	Blood protein levels;
LIHC	cis	rs2282802	0.685	rs7717576	chr5:139623591	G/A	cg26211634	chr5:139558579	C5orf32	0.4	6.14	0.31	2.33e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	cis	rs2257205	0.667	rs74961279	chr17:56904991	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-6.46	-0.33	3.5e-10	Pancreatic cancer;
LIHC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.17	-0.52	6.66e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.61	10.43	0.49	2.63e-22	Diastolic blood pressure;
LIHC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	0.97	14.03	0.6	1.24e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	7.43	0.37	8.73e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-5.97	-0.31	6.03e-9	Total body bone mineral density;
LIHC	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-8.02	-0.4	1.73e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.44	6.47	0.33	3.46e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.39	-0.33	5.54e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.79	-0.34	5.05e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.67	9.88	0.47	2.04e-20	Schizophrenia;
LIHC	trans	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg25214090	chr10:38739885	LOC399744	0.42	7.02	0.35	1.18e-11	Diastolic blood pressure;
LIHC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.58	8.74	0.43	1.09e-16	Response to diuretic therapy;
LIHC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.62	6.14	0.32	2.27e-9	Carotid intima media thickness;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg21881364	chr11:72438004	ARAP1	0.4	6.06	0.31	3.69e-9	Longevity;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg10840064	chr1:42800299	FOXJ3	0.45	6.07	0.31	3.33e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg20315796	chr2:16690541	NA	-0.26	-6.06	-0.31	3.55e-9	Neurofibrillary tangles;
LIHC	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg08345082	chr10:99160200	RRP12	-0.4	-6.91	-0.35	2.39e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs860295	0.702	rs475550	chr1:155652081	A/T	cg02153340	chr1:155202674	NA	-0.35	-6.51	-0.33	2.71e-10	Body mass index;
LIHC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	11.54	0.53	3.02e-26	Personality dimensions;
LIHC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.54	7.16	0.36	5.12e-12	Body mass index;
LIHC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-13.75	-0.6	1.53e-34	Body mass index;
LIHC	trans	rs2352908	0.729	rs2352911	chr14:49445212	A/G	cg01449224	chr4:123073775	NA	0.46	6.04	0.31	4.1e-9	Social communication problems;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19015611	chr2:71126446	VAX2	0.38	6.03	0.31	4.17e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.7	-11.93	-0.54	1.18e-27	Monocyte count;
LIHC	cis	rs7258015	1.000	rs3176766	chr19:10449778	G/A	cg13981319	chr19:10446556	ICAM3	0.42	6.61	0.34	1.5e-10	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs903552	0.736	rs2132196	chr15:102007089	A/G	cg00659931	chr15:102010125	PCSK6	-0.5	-6.89	-0.35	2.76e-11	Diabetic kidney disease;
LIHC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.36	-0.33	6.6e-10	Total cholesterol levels;
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.5	7.75	0.39	1.03e-13	Testicular germ cell tumor;
LIHC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.38	-5.97	-0.31	5.93e-9	Glioblastoma;
LIHC	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.85	-13.5	-0.59	1.35e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg07382826	chr16:28625726	SULT1A1	0.48	7.48	0.37	6.43e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12463550	chr7:65579703	CRCP	0.68	7.01	0.35	1.27e-11	Diabetic kidney disease;
LIHC	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.7	-12.51	-0.56	7.78e-30	Intelligence (multi-trait analysis);
LIHC	trans	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg07474051	chr12:120942642	COQ5	0.35	6.33	0.32	7.53e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.31	5.74e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	12.87	0.57	3.56e-31	Cognitive test performance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02048317	chr17:80004967	NA	0.42	6.54	0.33	2.25e-10	Pancreatic cancer;
LIHC	cis	rs80282103	0.867	rs7099063	chr10:1078547	C/G	cg18964960	chr10:1102726	WDR37	0.66	6.36	0.33	6.47e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.87	0.35	3.04e-11	Bipolar disorder;
LIHC	trans	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg02365086	chr1:27701171	FCN3	0.26	6.23	0.32	1.39e-9	Testicular germ cell tumor;
LIHC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.46	0.33	3.59e-10	Bipolar disorder;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18867321	chr14:73493951	ZFYVE1	-0.54	-6.09	-0.31	2.97e-9	Lung function (FEV1);
LIHC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.14	0.4	7.3e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.65	0.38	2.03e-13	Triglyceride levels;
LIHC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12516959	chr21:47718080	NA	-0.38	-5.89	-0.3	9.48e-9	Testicular germ cell tumor;
LIHC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.53	-8.28	-0.41	2.78e-15	Platelet count;
LIHC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg03037974	chr15:76606532	NA	0.72	13.8	0.6	9.72e-35	Blood metabolite levels;
LIHC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.48	-18.2	-0.7	3.22e-52	Breast cancer;
LIHC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg24296786	chr1:45957014	TESK2	0.52	7.7	0.38	1.53e-13	Platelet count;
LIHC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg03013999	chr17:37608204	MED1	0.35	5.73	0.3	2.17e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.51	9.07	0.44	9.37e-18	Total body bone mineral density;
LIHC	cis	rs526821	0.595	rs624478	chr11:55340778	C/G	cg04317927	chr11:55418816	OR4S2	0.47	9.0	0.44	1.6e-17	Pediatric bone mineral density (spine);
LIHC	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.35	0.32	6.86e-10	Mean corpuscular volume;
LIHC	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg01674679	chr13:27998804	GTF3A	-0.46	-6.86	-0.35	3.16e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.34	-18.69	-0.71	3.43e-54	Gout;
LIHC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg18887096	chr2:219472410	PLCD4	0.37	6.5	0.33	2.92e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.67	-0.34	1.06e-10	Metabolite levels;
LIHC	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.65	10.35	0.49	4.94e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.74	-14.17	-0.61	3.62e-36	Height;
LIHC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.66	11.69	0.53	8.65e-27	High light scatter reticulocyte count;
LIHC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.99	19.75	0.73	1.74e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.41	6.74	0.34	6.89e-11	Menopause (age at onset);
LIHC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.71	-9.68	-0.46	9.94e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg27366882	chr3:133540807	NA	-0.43	-7.27	-0.37	2.43e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.86	0.43	4.31e-17	Lung cancer;
LIHC	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.86	17.95	0.7	3.1e-51	Height;
LIHC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg25039879	chr17:56429692	SUPT4H1	-0.8	-9.03	-0.44	1.29e-17	Cognitive test performance;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.53	7.75	0.39	1.08e-13	Lymphocyte counts;
LIHC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg23533926	chr12:111358616	MYL2	0.34	6.7	0.34	8.44e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.94	-0.31	7.04e-9	Coronary artery disease;
LIHC	cis	rs2071426	0.959	rs1592037	chr10:96792328	A/G	cg09036531	chr10:96991505	NA	0.53	6.21	0.32	1.5e-9	Blood metabolite levels;
LIHC	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.59	9.9	0.47	1.7e-20	Dupuytren's disease;
LIHC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.7	12.61	0.56	3.26e-30	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.5	-9.16	-0.44	4.77e-18	Schizophrenia;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg02636461	chr16:69148474	HAS3	0.62	6.46	0.33	3.56e-10	Mean platelet volume;
LIHC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.03	-0.36	1.15e-11	IgG glycosylation;
LIHC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.28	-0.32	1.05e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.64	11.62	0.53	1.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.45	8.29	0.41	2.54e-15	Platelet distribution width;
LIHC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.27	0.41	2.94e-15	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.91	0.54	1.31e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.53	-7.14	-0.36	5.77e-12	Coronary artery disease;
LIHC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg19752551	chr11:57585705	CTNND1	0.41	5.85	0.3	1.15e-8	Schizophrenia;
LIHC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	trans	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg09045935	chr12:6379348	NA	-0.68	-6.03	-0.31	4.17e-9	Blood metabolite levels;
LIHC	cis	rs4788570	0.615	rs6499531	chr16:71731485	T/C	cg06353428	chr16:71660113	MARVELD3	1.32	13.45	0.59	2.06e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.55	-8.98	-0.44	1.89e-17	Longevity;Endometriosis;
LIHC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg19513890	chr22:42538836	CYP2D7P1	0.43	8.39	0.41	1.3e-15	Cognitive function;
LIHC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.41	6.41	0.33	4.97e-10	Resting heart rate;
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.14	-0.36	5.71e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.64	10.2	0.48	1.61e-21	Dental caries;
LIHC	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.74	11.57	0.53	2.4e-26	Intelligence (multi-trait analysis);
LIHC	trans	rs11989868	0.609	rs17320272	chr8:14541970	A/G	cg02565878	chr1:111295745	NA	-0.45	-6.06	-0.31	3.63e-9	Obesity-related traits;
LIHC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.52	0.64	1.69e-41	Chronic sinus infection;
LIHC	cis	rs7250872	0.606	rs1078229	chr19:1826383	A/C	cg18850929	chr19:1828978	REXO1	0.39	6.34	0.32	7.27e-10	Bipolar disorder;
LIHC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-1.02	-18.43	-0.71	3.5e-53	Tonsillectomy;
LIHC	cis	rs10744422	0.800	rs6489240	chr12:123275030	T/C	cg18912006	chr12:123335444	HIP1R	-0.54	-6.24	-0.32	1.27e-9	Schizophrenia;
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.0	-0.31	4.95e-9	Longevity;Endometriosis;
LIHC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.61	12.78	0.57	7.77e-31	Breast size;
LIHC	trans	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg08566640	chr11:64091735	NA	-0.69	-6.5	-0.33	2.77e-10	Androgen levels;
LIHC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00004055	chr16:66586745	CKLF	0.48	6.48	0.33	3.29e-10	Pancreatic cancer;
LIHC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.6e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11663156	1.000	rs67318347	chr18:50915178	A/G	cg24270629	chr18:50823537	DCC	-0.49	-6.64	-0.34	1.21e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.81	16.82	0.67	1.1e-46	Gestational age at birth (maternal effect);
LIHC	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Colorectal cancer;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg03585969	chr10:35415529	CREM	0.76	11.02	0.51	2.18e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7487075	0.619	rs10748448	chr12:46803338	C/T	cg23829395	chr12:46796953	NA	0.36	6.43	0.33	4.34e-10	Itch intensity from mosquito bite;
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.28	0.32	1.02e-9	Prudent dietary pattern;
LIHC	cis	rs2070433	0.851	rs1029231	chr21:47931653	A/G	cg12379764	chr21:47803548	PCNT	0.6	8.79	0.43	7.23e-17	Lymphocyte counts;
LIHC	cis	rs539514	0.690	rs2761398	chr13:76316933	C/A	cg04757411	chr13:76259545	LMO7	-0.46	-8.13	-0.4	7.86e-15	Type 1 diabetes;
LIHC	trans	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg16724585	chr3:197361211	NA	-0.46	-6.39	-0.33	5.35e-10	Pancreatic cancer;
LIHC	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg08847533	chr14:75593920	NEK9	-0.36	-6.13	-0.31	2.39e-9	Caffeine consumption;
LIHC	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.76	12.09	0.55	2.83e-28	Eye color traits;
LIHC	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.68	7.36	0.37	1.37e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs2000813	0.857	rs11082763	chr18:47100285	G/T	cg01564661	chr14:105942636	CRIP2	0.34	6.12	0.31	2.64e-9	Coronary artery disease;
LIHC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.02	-0.4	1.66e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.5	-8.44	-0.41	9.44e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs113252371	1	rs113252371	chr16:30476517	C/T	cg17640201	chr16:30407289	ZNF48	-0.63	-6.06	-0.31	3.58e-9	Number of common colds;
LIHC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg24203234	chr3:128598194	ACAD9	0.46	6.47	0.33	3.43e-10	IgG glycosylation;
LIHC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.4	7.71	0.38	1.38e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.29	14.02	0.6	1.4e-35	White matter hyperintensity burden;
LIHC	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	1.12	14.83	0.63	9.49e-39	Blood protein levels;
LIHC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.68	11.46	0.53	5.83e-26	Menopause (age at onset);
LIHC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.66	-9.65	-0.46	1.19e-19	Testicular germ cell tumor;
LIHC	cis	rs867186	0.614	rs75401510	chr20:33434423	C/G	cg08999081	chr20:33150536	PIGU	0.63	5.88	0.3	9.63e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11733071	chr1:886543	NOC2L	-0.47	-6.06	-0.31	3.63e-9	Alcohol dependence;
LIHC	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.23	-0.45	2.89e-18	Exhaled nitric oxide output;
LIHC	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.9	-0.35	2.48e-11	Metabolite levels;
LIHC	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.29	0.45	1.82e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25683012	chr12:57030113	BAZ2A	0.37	6.5	0.33	2.79e-10	Cognitive function;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23001456	chr17:2615074	KIAA0664	-0.45	-6.18	-0.32	1.85e-9	Systolic blood pressure;
LIHC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.57	7.95	0.4	2.67e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.49	7.23	0.36	3.24e-12	Type 2 diabetes;
LIHC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.54	-7.08	-0.36	8.23e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg10755058	chr3:40428713	ENTPD3	-0.4	-6.92	-0.35	2.2e-11	Renal cell carcinoma;
LIHC	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.53	-10.31	-0.49	7.21e-22	Multiple myeloma;
LIHC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg14393609	chr7:65229607	NA	-0.43	-6.39	-0.33	5.36e-10	Aortic root size;
LIHC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg22834771	chr12:69754056	YEATS4	0.48	8.05	0.4	1.34e-14	Blood protein levels;
LIHC	cis	rs988712	0.550	rs988748	chr11:27724745	C/G	cg18117895	chr11:27722066	BDNF	-0.5	-6.91	-0.35	2.37e-11	Obesity;
LIHC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg04511125	chr2:88470314	THNSL2	-0.41	-6.26	-0.32	1.13e-9	Response to metformin (IC50);
LIHC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.42	-7.08	-0.36	8.14e-12	Schizophrenia;
LIHC	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.61	10.35	0.49	5.15e-22	HDL cholesterol;
LIHC	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-8.77	-0.43	8.27e-17	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.62	0.34	1.39e-10	Renal cell carcinoma;
LIHC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg14930904	chr10:32216787	ARHGAP12	0.38	6.76	0.34	5.84e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg27491609	chr17:62779607	LOC146880	0.43	6.24	0.32	1.31e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.22e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.34e-15	Chronic sinus infection;
LIHC	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.43	-5.96	-0.31	6.23e-9	Systolic blood pressure;
LIHC	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-7.13	-0.36	5.99e-12	Parkinson's disease;
LIHC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.95	17.65	0.69	4.96e-50	Menopause (age at onset);
LIHC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	1.06	14.27	0.61	1.46e-36	Heart rate;
LIHC	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.26	-17.34	-0.68	8.8e-49	Ulcerative colitis;
LIHC	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.56	8.66	0.42	1.86e-16	Extraversion;
LIHC	cis	rs12101261	0.580	rs3783949	chr14:81448382	A/C	cg06600135	chr14:81408086	NA	0.4	7.4	0.37	1.06e-12	Graves' disease;
LIHC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg22834771	chr12:69754056	YEATS4	-0.48	-8.11	-0.4	9.46e-15	Blood protein levels;
LIHC	trans	rs71435601	0.943	rs67332771	chr2:21312210	C/T	cg01780092	chr15:83380063	AP3B2	0.61	6.14	0.32	2.25e-9	Cholesterol, total;
LIHC	cis	rs7619427	1.000	rs7631201	chr3:44069531	A/C	cg24966902	chr3:44043705	NA	0.56	7.76	0.39	9.6e-14	Schizophrenia;
LIHC	cis	rs6504950	0.720	rs12602751	chr17:52994174	C/A	cg10237252	chr17:52977213	TOM1L1	-0.36	-6.32	-0.32	8.02e-10	Breast cancer;
LIHC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.26	0.45	2.39e-18	Hemoglobin concentration;
LIHC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Electroencephalogram traits;
LIHC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.71	0.38	1.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.3	0.32	8.99e-10	Ulcerative colitis;
LIHC	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.77	0.54	4.41e-27	Coffee consumption (cups per day);
LIHC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.65	0.42	2.06e-16	Initial pursuit acceleration;
LIHC	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.23	-0.41	3.97e-15	Exhaled nitric oxide output;
LIHC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.45	6.95	0.35	1.91e-11	Longevity;
LIHC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.47	6.87	0.35	3.04e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	5.84	0.3	1.2e-8	Tonsillectomy;
LIHC	cis	rs7238033	0.663	rs11660575	chr18:43320438	A/G	cg20610511	chr18:43302872	SLC14A1	0.37	6.23	0.32	1.37e-9	Bladder cancer;
LIHC	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.56	8.88	0.43	3.77e-17	Eosinophilic esophagitis;
LIHC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.89	-16.5	-0.67	2.04e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.35	6.12	0.31	2.61e-9	Schizophrenia;
LIHC	trans	rs2496022	0.669	rs2451484	chr10:106596282	A/T	cg23224828	chr19:52511591	ZNF615	0.57	6.33	0.32	7.87e-10	Depressive symptoms;Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg19636519	chr7:99541626	NA	0.3	5.72	0.3	2.32e-8	Coronary artery disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08168689	chr14:76455272	C14orf179	0.44	6.56	0.33	1.93e-10	Longevity;
LIHC	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg01444801	chr10:135216882	MTG1	-0.53	-8.65	-0.42	1.97e-16	Systemic lupus erythematosus;
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.05	-0.44	1.12e-17	Schizophrenia;
LIHC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg18944383	chr4:111397179	ENPEP	-0.26	-6.35	-0.32	6.77e-10	Coronary artery disease;
LIHC	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07998070	chr1:206785660	LGTN	0.46	6.16	0.32	2.01e-9	Lung function (FEV1/FVC);
LIHC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.42	8.07	0.4	1.23e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.26	-0.45	2.28e-18	Bipolar disorder;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07192240	chr11:3829780	PGAP2	0.39	6.2	0.32	1.6e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.68	11.96	0.54	8.87e-28	High light scatter reticulocyte count;
LIHC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13390975	chr5:34915890	BRIX1;RAD1	-0.46	-6.49	-0.33	2.98e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.71	-12.43	-0.56	1.64e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13409248	chr3:40428643	ENTPD3	-0.48	-8.37	-0.41	1.52e-15	Renal cell carcinoma;
LIHC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.24	5.96	0.31	6.31e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Paclitaxel-induced neuropathy;
LIHC	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg14515779	chr1:101123966	NA	-0.59	-11.3	-0.52	2.24e-25	Monocyte count;
LIHC	cis	rs2242420	0.920	rs16825734	chr1:21956199	C/A	cg18150885	chr1:21978612	RAP1GAP	-0.48	-5.74	-0.3	2.13e-8	Hematological and biochemical traits;
LIHC	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg24220031	chr2:73402428	NA	-0.27	-5.87	-0.3	1.04e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg05484376	chr2:27715224	FNDC4	0.37	6.08	0.31	3.13e-9	Total body bone mineral density;
LIHC	cis	rs12220238	0.822	rs2395087	chr10:76082637	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg13175173	chr14:55914753	NA	-0.35	-8.13	-0.4	7.98e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-0.78	-9.39	-0.45	8.39e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg22771759	chr13:24902376	NA	0.31	6.44	0.33	4.06e-10	Obesity-related traits;
LIHC	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg10932868	chr11:921992	NA	0.36	6.61	0.34	1.52e-10	Alzheimer's disease (late onset);
LIHC	cis	rs3736485	0.966	rs4774595	chr15:51893161	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.25	-0.32	1.21e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6686842	0.601	rs213736	chr1:41623679	G/A	cg08462924	chr1:41848221	NA	0.32	5.83	0.3	1.31e-8	Height;
LIHC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg23625390	chr15:77176239	SCAPER	0.36	5.87	0.3	1.04e-8	Blood metabolite levels;
LIHC	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.97	0.35	1.61e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1712517	0.771	rs11191672	chr10:105138961	C/T	cg05636881	chr10:105038444	INA	0.48	7.47	0.37	6.6e-13	Migraine;
LIHC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.32	7.4	0.37	1.06e-12	Crohn's disease;
LIHC	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg08992911	chr2:238395768	MLPH	0.49	5.95	0.31	6.48e-9	Prostate cancer;
LIHC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.92	-18.79	-0.71	1.28e-54	Height;
LIHC	cis	rs7534824	0.543	rs17408457	chr1:101385693	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.41	0.37	9.75e-13	Refractive astigmatism;
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.86	12.47	0.56	1.11e-29	Menarche (age at onset);
LIHC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-9.64	-0.46	1.29e-19	Mean corpuscular volume;
LIHC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.68	-9.9	-0.47	1.81e-20	Mosquito bite size;
LIHC	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg14092571	chr14:90743983	NA	-0.37	-5.82	-0.3	1.37e-8	Mortality in heart failure;
LIHC	cis	rs588177	0.919	rs2244625	chr11:64026144	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.46	-6.83	-0.35	3.83e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.68	9.54	0.46	2.86e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.37	-0.33	5.93e-10	Crohn's disease;
LIHC	cis	rs4759375	1.000	rs10773005	chr12:123790007	A/G	cg00376283	chr12:123451042	ABCB9	-0.49	-6.25	-0.32	1.25e-9	HDL cholesterol;
LIHC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.0	0.4	1.99e-14	Motion sickness;
LIHC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.78	0.43	7.86e-17	Cognitive test performance;
LIHC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.82	-0.43	5.8e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.37	-8.48	-0.42	7.03e-16	Educational attainment (years of education);
LIHC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.33	-7.15	-0.36	5.32e-12	Multiple sclerosis;
LIHC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.67	-6.49	-0.33	2.97e-10	Urate levels in lean individuals;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.65	-11.29	-0.52	2.49e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg11645453	chr3:52864694	ITIH4	0.23	5.99	0.31	5.41e-9	Bipolar disorder;
LIHC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.13	-0.31	2.37e-9	Colorectal cancer;
LIHC	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07080220	chr10:102295463	HIF1AN	0.45	6.15	0.32	2.12e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.24	-15.85	-0.65	7.92e-43	Diabetic kidney disease;
LIHC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg15155738	chr12:121454335	C12orf43	0.47	6.81	0.35	4.38e-11	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.71	8.57	0.42	3.56e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06530960	chr19:49140787	SEC1;DBP	0.58	8.91	0.43	3.18e-17	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg03037974	chr15:76606532	NA	0.9	19.49	0.73	2.01e-57	Blood metabolite levels;
LIHC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11645453	chr3:52864694	ITIH4	0.21	5.71	0.3	2.41e-8	Bipolar disorder;
LIHC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.66	-9.52	-0.46	3.25e-19	Initial pursuit acceleration;
LIHC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.55	-8.38	-0.41	1.35e-15	Multiple sclerosis;
LIHC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.53	7.61	0.38	2.76e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.29	-0.45	1.89e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.48	0.56	1.07e-29	Alzheimer's disease;
LIHC	cis	rs10454142	0.731	rs11680719	chr2:48657843	G/A	cg15846641	chr2:48541264	FOXN2	0.47	6.29	0.32	9.97e-10	Sex hormone-binding globulin levels;
LIHC	trans	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-8.53	-0.42	4.81e-16	Obesity-related traits;
LIHC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.8	0.3	1.48e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.57	-7.21	-0.36	3.6e-12	Blood pressure (smoking interaction);
LIHC	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04530015	chr2:215796436	ABCA12	0.46	7.81	0.39	6.87e-14	Neuroblastoma;
LIHC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.36	3.49e-12	Protein C levels;
LIHC	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.6	-0.38	2.93e-13	Post bronchodilator FEV1;
LIHC	cis	rs62458065	1.000	rs10231294	chr7:32465357	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.65	-7.37	-0.37	1.3e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg19636519	chr7:99541626	NA	-0.3	-5.86	-0.3	1.1e-8	Coronary artery disease;
LIHC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-8.8	-0.43	7.01e-17	Vitiligo;
LIHC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.85	14.27	0.61	1.37e-36	Aortic root size;
LIHC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.8	0.34	4.81e-11	Heart rate;
LIHC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	0.92	8.77	0.43	8.28e-17	Alzheimer's disease;
LIHC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.43	-6.16	-0.32	2.02e-9	Height;
LIHC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	3.97e-9	Diabetic kidney disease;
LIHC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.67	6.05	0.31	3.71e-9	Body mass index;
LIHC	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-9.53	-0.46	2.96e-19	Colorectal cancer;
LIHC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg25329415	chr6:28076851	NA	0.27	5.73	0.3	2.18e-8	Cardiac Troponin-T levels;
LIHC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.75	11.88	0.54	1.71e-27	Corneal astigmatism;
LIHC	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.58	-8.66	-0.42	1.92e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	0.91	15.0	0.63	1.96e-39	Testicular germ cell tumor;
LIHC	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.86	17.78	0.69	1.46e-50	Testicular germ cell tumor;
LIHC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.87	0.35	2.98e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.15e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15527401	chr19:59071099	UBE2M;LOC100131691	0.43	6.08	0.31	3.19e-9	Pancreatic cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13898548	chr5:176924827	PDLIM7	0.49	6.19	0.32	1.71e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.49	5.72	0.3	2.37e-8	Plateletcrit;Platelet count;
LIHC	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-0.82	-8.86	-0.43	4.39e-17	Blood pressure (smoking interaction);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20399842	chr2:21346738	NA	0.33	6.09	0.31	3.08e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-17.6	-0.69	7.85e-50	Body mass index;
LIHC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg21724239	chr8:58056113	NA	0.47	6.27	0.32	1.09e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.4	7.12	0.36	6.22e-12	Obesity;
LIHC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	trans	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg17675199	chr6:35436792	RPL10A	0.38	7.83	0.39	6.17e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.53	-0.33	2.41e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.43	-6.7	-0.34	8.46e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs943466	1.000	rs61394483	chr6:33751945	G/A	cg25922239	chr6:33757077	LEMD2	-0.47	-5.78	-0.3	1.66e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.5	-8.33	-0.41	2e-15	Menarche (age at onset);
LIHC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg21573476	chr21:45109991	RRP1B	0.58	10.89	0.51	6.3e-24	Mean corpuscular volume;
LIHC	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg05110241	chr16:68378359	PRMT7	-0.5	-5.95	-0.31	6.56e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.35	6.36	0.33	6.34e-10	Aortic root size;
LIHC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	6.04	0.31	3.94e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.16	-0.58	2.7e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.56	9.33	0.45	1.42e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17849194	chr4:71553882	UTP3	-0.45	-6.34	-0.32	7.34e-10	Pancreatic cancer;
LIHC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.47	7.51	0.38	5.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02290350	chr8:58132656	NA	0.5	10.78	0.5	1.58e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	0.98	7.84	0.39	5.9e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.8	-13.03	-0.58	8.36e-32	Colorectal cancer;
LIHC	cis	rs12079745	0.793	rs12561922	chr1:169265794	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-7.09	-0.36	7.5e-12	QT interval;
LIHC	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.71	11.08	0.51	1.35e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.57	10.01	0.48	7.37e-21	Mean corpuscular volume;
LIHC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg11764359	chr7:65958608	NA	0.57	5.82	0.3	1.39e-8	Diabetic kidney disease;
LIHC	cis	rs3106136	0.843	rs6840479	chr4:95275842	A/G	cg11021082	chr4:95130006	SMARCAD1	0.41	6.97	0.35	1.67e-11	Capecitabine sensitivity;
LIHC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14067834	chr17:29058358	SUZ12P	0.61	6.32	0.32	8.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04374321	chr14:90722782	PSMC1	0.71	13.43	0.59	2.6e-33	Mortality in heart failure;
LIHC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg16226627	chr15:75307476	SCAMP5	0.49	8.67	0.42	1.8e-16	Lung cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08536481	chr12:123459152	ABCB9;OGFOD2	-0.44	-6.28	-0.32	1e-9	Systolic blood pressure;
LIHC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.22	-5.95	-0.31	6.65e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.42	-6.7	-0.34	8.43e-11	Neutrophil percentage of white cells;
LIHC	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	6.06	0.31	3.52e-9	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.39	6.34	0.32	7.29e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.44	5.81	0.3	1.44e-8	Obesity-related traits;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.74e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-10.22	-0.48	1.44e-21	Platelet count;
LIHC	cis	rs12464559	0.522	rs1916301	chr2:152640498	G/A	cg01189475	chr2:152685088	ARL5A	0.66	8.24	0.41	3.62e-15	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.5	6.13	0.31	2.37e-9	Resting heart rate;
LIHC	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.31	6.69	0.34	9.31e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.73	0.57	1.18e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17152411	1.000	rs1065301	chr10:126616038	A/G	cg07906193	chr10:126599966	NA	0.47	7.33	0.37	1.66e-12	Height;
LIHC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.44	7.73	0.39	1.18e-13	Tuberculosis;
LIHC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.48	-7.78	-0.39	8.7e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs911119	0.837	rs2208289	chr20:23579526	A/G	cg16589663	chr20:23618590	CST3	-0.65	-7.06	-0.36	9.21e-12	Chronic kidney disease;
LIHC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.83	-14.16	-0.61	3.9e-36	Body mass index (adult);
LIHC	cis	rs4517514	0.509	rs2156434	chr11:89896417	A/G	cg05041596	chr11:89867385	NAALAD2	0.42	6.71	0.34	7.96e-11	Trans fatty acid levels;
LIHC	cis	rs4684776	0.867	rs1470612	chr3:11336966	C/T	cg00170343	chr3:11313890	ATG7	-0.49	-6.87	-0.35	3.06e-11	Small vessel stroke;
LIHC	cis	rs3106136	0.678	rs6857185	chr4:95296089	C/T	cg11021082	chr4:95130006	SMARCAD1	0.35	6.06	0.31	3.64e-9	Capecitabine sensitivity;
LIHC	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.65	-7.0	-0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg10381502	chr11:71823885	C11orf51	-1.08	-9.2	-0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg10360139	chr7:1886902	MAD1L1	-0.38	-6.0	-0.31	5.12e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.49	-8.91	-0.43	3e-17	Atrioventricular conduction;
LIHC	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.58	-11.56	-0.53	2.66e-26	Myopia (pathological);
LIHC	trans	rs10411161	1.000	rs10414104	chr19:52368132	G/A	cg22319618	chr22:45562946	NUP50	-0.51	-6.83	-0.35	4.01e-11	Breast cancer;
LIHC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.87	12.06	0.55	3.78e-28	Blood metabolite levels;
LIHC	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	1.08	8.7	0.43	1.4e-16	Cannabis dependence symptom count;
LIHC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg03854865	chr6:26224070	HIST1H3E	0.59	6.49	0.33	3.04e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.81	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.57	8.82	0.43	5.76e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.22	-0.55	9.39e-29	Colorectal cancer;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.41	-5.79	-0.3	1.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.53	8.73	0.43	1.16e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg27205649	chr11:78285834	NARS2	0.39	5.95	0.31	6.52e-9	Alzheimer's disease (survival time);
LIHC	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.49	7.3	0.37	2.09e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg15208524	chr1:10270712	KIF1B	0.44	6.38	0.33	5.61e-10	Hepatocellular carcinoma;
LIHC	trans	rs6580110	0.793	rs9324792	chr5:154078564	A/G	cg02272667	chr7:1922866	MAD1L1	0.27	6.07	0.31	3.43e-9	Facial morphology (factor 9, facial height related to vertical position of nasion);
LIHC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.8	12.66	0.56	2.11e-30	Breast cancer;
LIHC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.98	0.54	7.42e-28	High light scatter reticulocyte count;
LIHC	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg11642891	chr2:3452563	TTC15	-0.45	-7.2	-0.36	3.8e-12	Obesity-related traits;
LIHC	cis	rs986417	0.688	rs1950317	chr14:61022789	T/G	cg27398547	chr14:60952738	C14orf39	0.6	7.42	0.37	9.36e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.06	-0.31	3.57e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.35	-5.72	-0.3	2.34e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2076346	1.000	rs2076346	chr1:24083649	A/G	cg15997130	chr1:24165203	NA	0.34	5.89	0.3	9.27e-9	Inflammatory skin disease;
LIHC	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.05	-0.31	3.72e-9	Blood metabolite levels;
LIHC	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg10820045	chr2:198174542	NA	0.56	9.0	0.44	1.6e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.49	-8.36	-0.41	1.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg14067834	chr17:29058358	SUZ12P	0.6	6.35	0.32	6.72e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.79	-11.95	-0.54	9.9e-28	Total body bone mineral density;
LIHC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.56	6.19	0.32	1.71e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg10820045	chr2:198174542	NA	0.43	6.5	0.33	2.92e-10	Intracranial aneurysm;
LIHC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	0.82	11.12	0.52	1.01e-24	Skin colour saturation;
LIHC	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.48	6.96	0.35	1.8e-11	Atrial fibrillation;
LIHC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.37	-8.42	-0.41	1.04e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.14	10.33	0.49	6.1e-22	Diabetic retinopathy;
LIHC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg20991723	chr1:152506922	NA	0.59	10.51	0.49	1.41e-22	Hair morphology;
LIHC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.45	8.6	0.42	3e-16	Schizophrenia;
LIHC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.76	-11.52	-0.53	3.54e-26	Corneal astigmatism;
LIHC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg14440974	chr22:39074834	NA	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.49	-9.29	-0.45	1.84e-18	Testicular germ cell tumor;
LIHC	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.94	0.51	4.28e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg12863693	chr15:85201151	NMB	0.41	5.93	0.31	7.37e-9	Schizophrenia;
LIHC	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-10.6	-0.5	6.89e-23	Bipolar disorder;
LIHC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.78	-12.55	-0.56	5.47e-30	Post bronchodilator FEV1;
LIHC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg06664874	chr5:179499304	RNF130	-0.58	-7.13	-0.36	5.93e-12	LDL cholesterol;
LIHC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg16506815	chr2:162101123	NA	0.47	7.74	0.39	1.17e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20859525	chr6:80714300	TTK	0.5	7.7	0.38	1.5e-13	Cognitive function;
LIHC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.02	0.58	9.58e-32	Cognitive test performance;
LIHC	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg06359132	chr10:99160096	RRP12	-0.42	-6.43	-0.33	4.29e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.85	-0.35	3.36e-11	Pediatric bone mineral density (spine);
LIHC	trans	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg10756647	chr7:56101905	PSPH	1.07	13.42	0.59	2.9e-33	Diabetic kidney disease;
LIHC	cis	rs6435862	0.517	rs6757091	chr2:215672793	G/C	cg04004882	chr2:215674386	BARD1	-0.58	-8.74	-0.43	1.06e-16	Neuroblastoma (high-risk);
LIHC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.67	0.59	3.13e-34	Lung cancer in ever smokers;
LIHC	cis	rs4407350	0.870	rs1894461	chr22:44911287	C/T	cg26276947	chr22:44892394	LDOC1L	0.34	6.56	0.33	1.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.43	-0.37	8.87e-13	Psoriasis;
LIHC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.38	0.59	4.02e-33	Psoriasis;
LIHC	trans	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.32	6.06	0.31	3.56e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg20435097	chr10:126320824	FAM53B	0.35	5.93	0.31	7.57e-9	Asthma;
LIHC	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg21452805	chr1:244014465	NA	0.42	5.72	0.3	2.35e-8	RR interval (heart rate);
LIHC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.23	-0.41	3.98e-15	Type 2 diabetes;
LIHC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.45	6.24	0.32	1.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	7.74e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.51	-0.33	2.69e-10	Testicular germ cell tumor;
LIHC	cis	rs2834188	1.000	rs2834187	chr21:34687410	A/G	cg04842828	chr21:34696676	IFNAR1	0.45	6.0	0.31	5.04e-9	Narcolepsy;
LIHC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.2	-0.32	1.67e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.47	-7.68	-0.38	1.64e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.26	-0.37	2.64e-12	IgG glycosylation;
LIHC	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-8.38	-0.41	1.37e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.44	6.78	0.34	5.33e-11	Cognitive test performance;
LIHC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.94	20.44	0.74	3.16e-61	Blood protein levels;
LIHC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.42	-6.66	-0.34	1.1e-10	Iron status biomarkers;
LIHC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.12	-0.31	2.49e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.11	0.36	6.63e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7534824	0.625	rs61780281	chr1:101324152	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	6.39	0.33	5.28e-10	Refractive astigmatism;
LIHC	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg25364880	chr3:44379878	C3orf23	0.58	8.14	0.4	7.5e-15	Depressive symptoms;
LIHC	trans	rs12960119	0.536	rs7342985	chr18:23722582	A/G	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.25	0.66	2.16e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs17106184	1.000	rs72904725	chr1:51334488	C/T	cg07174182	chr1:51127561	FAF1	-0.62	-6.55	-0.33	2.17e-10	Type 2 diabetes;
LIHC	trans	rs12620999	0.941	rs58678188	chr2:237971036	C/A	cg15676719	chr1:167598521	RCSD1	0.34	6.13	0.31	2.36e-9	Systemic lupus erythematosus;
LIHC	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.39	6.51	0.33	2.75e-10	Lewy body disease;
LIHC	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.24	-6.4	-0.33	5.26e-10	Menarche (age at onset);
LIHC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.2e-56	Breast cancer;
LIHC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg13409248	chr3:40428643	ENTPD3	0.38	5.82	0.3	1.35e-8	Renal cell carcinoma;
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg14222432	chr12:29376421	FAR2	0.37	7.17	0.36	4.76e-12	QT interval;
LIHC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.33	-0.41	1.95e-15	Vitamin D levels;
LIHC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.75	-0.3	2.03e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.86	10.31	0.49	7.16e-22	Cognitive function;
LIHC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.95	16.88	0.67	6.01e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.53	-10.19	-0.48	1.76e-21	Asthma;
LIHC	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-6.9	-0.35	2.51e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.82	-0.35	4.15e-11	Coronary artery disease;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.39	6.17	0.32	1.96e-9	Testicular germ cell tumor;
LIHC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.64e-16	Motion sickness;
LIHC	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg08992911	chr2:238395768	MLPH	0.49	5.95	0.31	6.48e-9	Prostate cancer;
LIHC	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.27	-0.45	2.08e-18	Testicular germ cell tumor;
LIHC	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg02733842	chr7:1102375	C7orf50	-0.68	-7.14	-0.36	5.82e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.83	15.24	0.64	2.18e-40	Monocyte count;
LIHC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.75	14.54	0.62	1.23e-37	Mortality in heart failure;
LIHC	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-8.31	-0.41	2.36e-15	Morning vs. evening chronotype;
LIHC	cis	rs1555322	0.530	rs2425049	chr20:33874720	C/T	cg08210727	chr20:33865349	NA	0.49	5.72	0.3	2.36e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.51	-7.17	-0.36	4.52e-12	Menopause (age at onset);
LIHC	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.33	0.45	1.36e-18	Coffee consumption (cups per day);
LIHC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg00677901	chr16:88017247	BANP	0.51	7.92	0.39	3.26e-14	Menopause (age at onset);
LIHC	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg03934865	chr2:198174659	NA	-0.46	-6.53	-0.33	2.44e-10	Dermatomyositis;
LIHC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.57	6.76	0.34	6.09e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.46	6.62	0.34	1.35e-10	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg11453546	chr21:43990049	SLC37A1	0.42	6.04	0.31	4.13e-9	Electroencephalogram traits;
LIHC	cis	rs1494950	1.000	rs10084853	chr4:14973469	C/T	cg12377275	chr4:15005593	CPEB2	-0.78	-6.69	-0.34	9e-11	Political ideology;
LIHC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg06207120	chr15:45996521	NA	0.34	6.64	0.34	1.27e-10	Waist circumference;Weight;
LIHC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg07959070	chr22:50026188	C22orf34	-0.32	-8.48	-0.42	6.96e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4649203	0.954	rs10794648	chr1:24518206	C/T	cg01960748	chr1:24522592	NA	0.44	6.95	0.35	1.81e-11	Psoriasis;
LIHC	cis	rs1712517	0.904	rs4918007	chr10:105107470	G/A	cg05636881	chr10:105038444	INA	-0.43	-6.59	-0.34	1.67e-10	Migraine;
LIHC	cis	rs7487075	0.554	rs7960819	chr12:46628782	T/C	cg15584813	chr12:47219626	SLC38A4	0.31	5.72	0.3	2.32e-8	Itch intensity from mosquito bite;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.39	-7.8	-0.39	7.81e-14	Renal cell carcinoma;
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg12311636	chr6:118886798	C6orf204	-0.54	-6.26	-0.32	1.15e-9	Diastolic blood pressure;
LIHC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg15208524	chr1:10270712	KIF1B	0.4	6.08	0.31	3.22e-9	Hepatocellular carcinoma;
LIHC	cis	rs10861342	1.000	rs7305712	chr12:105519188	A/T	cg23923672	chr12:105501055	KIAA1033	-0.58	-7.71	-0.38	1.34e-13	IgG glycosylation;
LIHC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg18912006	chr12:123335444	HIP1R	-0.64	-7.67	-0.38	1.78e-13	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.12	0.4	8.4e-15	Height;
LIHC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.67	0.5	3.8e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.73	-10.34	-0.49	5.46e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg00656387	chr3:40428638	ENTPD3	0.42	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg05941027	chr17:61774174	LIMD2	0.33	6.73	0.34	7.37e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.23	-0.32	1.38e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07318088	chr6:90539243	CASP8AP2	0.41	6.41	0.33	4.81e-10	Cognitive function;
LIHC	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg09695851	chr17:3907499	NA	0.59	6.8	0.35	4.58e-11	Type 2 diabetes;
LIHC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.83	14.41	0.61	4e-37	Aortic root size;
LIHC	cis	rs10792665	0.934	rs11233382	chr11:82657221	G/T	cg24227371	chr11:82718527	RAB30	0.3	7.03	0.36	1.13e-11	Obesity-related traits;
LIHC	cis	rs7520050	0.933	rs12565042	chr1:46299110	C/A	cg03146154	chr1:46216737	IPP	-0.37	-5.98	-0.31	5.62e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.28	0.32	1.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	8.72	0.43	1.25e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.39	-6.05	-0.31	3.73e-9	Response to temozolomide;
LIHC	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.43	-5.89	-0.3	9.01e-9	Coronary artery calcification;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg12630522	chr1:45956424	TESK2	-0.42	-6.04	-0.31	3.99e-9	Eotaxin levels;
LIHC	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.34	22.96	0.78	3.03e-71	Corneal structure;
LIHC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.37	6.01	0.31	4.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.68	11.43	0.53	7.35e-26	Mean platelet volume;
LIHC	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.51e-11	Type 2 diabetes;
LIHC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg12798992	chr6:167411361	FGFR1OP	0.43	6.75	0.34	6.52e-11	Primary biliary cholangitis;
LIHC	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.41	-0.41	1.15e-15	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18776992	chr19:48113764	GLTSCR1	0.45	6.49	0.33	3.07e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg14930904	chr10:32216787	ARHGAP12	0.37	6.47	0.33	3.35e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-1.06	-13.42	-0.59	2.72e-33	Intelligence (multi-trait analysis);
LIHC	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.25	-13.18	-0.58	2.36e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg24879335	chr3:133465180	TF	-0.27	-6.0	-0.31	5.05e-9	Iron status biomarkers;
LIHC	cis	rs8084351	0.568	rs6508190	chr18:50575723	A/G	cg24270629	chr18:50823537	DCC	0.39	5.95	0.31	6.79e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.37	-0.41	1.51e-15	Schizophrenia;
LIHC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-8.94	-0.44	2.53e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg13957321	chr17:43675089	NA	0.5	7.69	0.38	1.62e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.28	0.55	5.73e-29	Electrocardiographic conduction measures;
LIHC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg00677901	chr16:88017247	BANP	0.52	8.03	0.4	1.58e-14	Menopause (age at onset);
LIHC	cis	rs6060717	0.610	rs1891154	chr20:34617129	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.91	-0.39	3.49e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs10411936	0.692	rs10413787	chr19:16594967	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.95	0.35	1.81e-11	White blood cell count;Multiple sclerosis;
LIHC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.24	-0.52	3.61e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.12	14.3	0.61	1.05e-36	Body mass index;
LIHC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.42	6.98	0.35	1.51e-11	Mean corpuscular volume;
LIHC	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg00977110	chr5:151150581	G3BP1	0.56	7.11	0.36	6.8e-12	Preschool internalizing problems;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg26338869	chr17:61819248	STRADA	0.56	8.1	0.4	9.86e-15	Prudent dietary pattern;
LIHC	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-0.79	-11.66	-0.53	1.09e-26	Obesity-related traits;
LIHC	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg12483005	chr1:23474871	LUZP1	0.46	7.01	0.35	1.31e-11	Height;
LIHC	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg19773385	chr1:10388646	KIF1B	-0.47	-8.1	-0.4	9.72e-15	Hepatocellular carcinoma;
LIHC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	8.18	0.4	5.73e-15	Platelet count;
LIHC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.62	9.04	0.44	1.18e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.08	-0.31	3.15e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.29	-0.41	2.53e-15	Vitamin D levels;
LIHC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.31	-5.83	-0.3	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg11212589	chr17:38028394	ZPBP2	0.34	6.8	0.35	4.59e-11	Self-reported allergy;
LIHC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.43e-16	Motion sickness;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.48	-7.05	-0.36	1.01e-11	Cognitive function;
LIHC	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	8.36	0.41	1.62e-15	Height;
LIHC	cis	rs4908760	0.965	rs1884352	chr1:8537289	G/A	cg20416874	chr1:8611966	RERE	-0.67	-14.22	-0.61	2.28e-36	Vitiligo;
LIHC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.59	10.37	0.49	4.22e-22	Dupuytren's disease;
LIHC	cis	rs9326778	0.520	rs10077438	chr5:108827962	C/A	cg17395555	chr5:108820864	NA	-0.36	-6.13	-0.31	2.48e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg05197062	chr11:11642011	GALNTL4	0.45	6.61	0.34	1.48e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.56	-7.36	-0.37	1.38e-12	Initial pursuit acceleration;
LIHC	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	ch.11.1111744F	chr11:58378857	ZFP91;ZFP91-CNTF	0.33	6.13	0.31	2.49e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LIHC	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.71	9.12	0.44	6.34e-18	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07415654	chr3:15797850	ANKRD28	-0.47	-6.07	-0.31	3.44e-9	Hepatitis;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg27050550	chr7:44613552	DDX56	-0.48	-6.28	-0.32	1.01e-9	Lung function (FEV1);
LIHC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.55	9.79	0.47	4.08e-20	Alzheimer's disease (late onset);
LIHC	cis	rs11955398	0.716	rs2061250	chr5:59917678	C/A	cg02684056	chr5:59996105	DEPDC1B	0.41	6.09	0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.66	-9.78	-0.47	4.28e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.42	-5.74	-0.3	2.06e-8	Life satisfaction;
LIHC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.48	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.41	6.12	0.31	2.58e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.27	5.72	0.3	2.35e-8	Pulmonary function;
LIHC	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-7.2	-0.36	3.96e-12	Response to antipsychotic treatment;
LIHC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.61	-10.14	-0.48	2.78e-21	Platelet count;
LIHC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.74	5.85	0.3	1.14e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.52	-6.96	-0.35	1.79e-11	Menopause (age at onset);
LIHC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.15	0.58	3.08e-32	Colorectal cancer;
LIHC	cis	rs963731	0.649	rs4670272	chr2:39260468	A/C	cg04010122	chr2:39346883	SOS1	-0.68	-6.11	-0.31	2.73e-9	Corticobasal degeneration;
LIHC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.15	0.55	1.79e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.49	-7.28	-0.37	2.37e-12	Coronary artery disease;
LIHC	cis	rs2412488	1.000	rs17082782	chr4:54306440	A/T	cg22241045	chr4:54363911	LNX1	-0.46	-7.29	-0.37	2.23e-12	DNA methylation (variation);
LIHC	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg01843034	chr6:37503916	NA	-0.38	-6.13	-0.31	2.39e-9	Cognitive performance;
LIHC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.09	-0.4	1.08e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.62	-8.23	-0.41	3.99e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.93	14.8	0.62	1.14e-38	Breast cancer;
LIHC	cis	rs2758596	1.000	rs2241111	chr1:156163718	T/C	cg24450063	chr1:156163899	SLC25A44	1.0	9.95	0.47	1.23e-20	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.43	7.15	0.36	5.21e-12	Red blood cell count;
LIHC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	7.86	0.39	5.11e-14	HDL cholesterol;
LIHC	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg26138937	chr11:71823887	C11orf51	1.32	10.9	0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg03146154	chr1:46216737	IPP	-0.37	-6.21	-0.32	1.57e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.69	11.35	0.52	1.49e-25	Age at first birth;
LIHC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-6.25	-0.32	1.2e-9	Resting heart rate;
LIHC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.38	-0.86	1.02e-102	Myeloid white cell count;
LIHC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.45	8.81	0.43	6.38e-17	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.26	-0.37	2.61e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs5753037	0.543	rs131268	chr22:30147938	C/G	cg01021169	chr22:30184971	ASCC2	-0.31	-5.87	-0.3	1.02e-8	Type 1 diabetes;
LIHC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg23205692	chr1:25664452	TMEM50A	0.39	6.18	0.32	1.83e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg06363034	chr20:62225388	GMEB2	-0.42	-7.29	-0.37	2.15e-12	Glioblastoma;
LIHC	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.44	6.49	0.33	2.95e-10	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2274273	0.661	rs8019978	chr14:55557284	A/G	cg01864836	chr14:55583639	NA	0.36	6.7	0.34	8.39e-11	Protein biomarker;
LIHC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	6.75	0.34	6.51e-11	Mean corpuscular hemoglobin;
LIHC	trans	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.47	8.43	0.41	9.62e-16	Colorectal cancer;
LIHC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg19743168	chr1:23544995	NA	0.35	5.79	0.3	1.62e-8	Height;
LIHC	cis	rs1419980	0.643	rs12228661	chr12:7745882	C/G	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs12744310	0.887	rs12047272	chr1:41801943	G/A	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.91	16.81	0.67	1.25e-46	Aortic root size;
LIHC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.11	0.4	9.42e-15	Morning vs. evening chronotype;
LIHC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03193865	chr8:145510099	BOP1	-0.41	-6.28	-0.32	1.01e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.5	0.56	8.64e-30	Alzheimer's disease;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg27411370	chr8:25316735	KCTD9;CDCA2	-0.54	-6.28	-0.32	1.04e-9	Obesity-related traits;
LIHC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02985541	chr2:219472218	PLCD4	0.46	8.61	0.42	2.77e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.04	-9.5	-0.46	3.86e-19	Diabetic retinopathy;
LIHC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg19920283	chr7:105172520	RINT1	0.66	5.94	0.31	6.91e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.65	-9.59	-0.46	1.84e-19	Monocyte count;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07677032	chr17:61819896	STRADA	0.41	6.07	0.31	3.32e-9	Prudent dietary pattern;
LIHC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.15	0.55	1.69e-28	Height;
LIHC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.61	-11.58	-0.53	2.16e-26	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg26831259	chr4:1366826	KIAA1530	0.35	5.75	0.3	1.99e-8	Obesity-related traits;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.44	-6.87	-0.35	3.07e-11	Blood protein levels;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.64	12.18	0.55	1.37e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.36	-8.11	-0.4	9.32e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2143950	0.607	rs58770366	chr14:35528023	A/G	cg16230307	chr14:35515116	FAM177A1	-0.39	-6.35	-0.32	6.69e-10	Atopic dermatitis;
LIHC	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.32	-8.58	-0.42	3.37e-16	Intelligence;
LIHC	trans	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg19894588	chr14:64061835	NA	-0.61	-7.84	-0.39	5.74e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01839850	chr22:38240395	ANKRD54;MIR658	0.41	6.87	0.35	3.11e-11	Cognitive function;
LIHC	cis	rs61677309	0.597	rs112590920	chr11:118143586	G/A	cg06090739	chr11:118230722	UBE4A	0.32	6.03	0.31	4.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.58	-7.54	-0.38	4.19e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg23485639	chr6:28045615	ZNF165	0.39	6.05	0.31	3.78e-9	Cardiac Troponin-T levels;
LIHC	cis	rs4759375	1.000	rs7312145	chr12:123825339	A/G	cg00376283	chr12:123451042	ABCB9	0.5	6.37	0.33	6.18e-10	HDL cholesterol;
LIHC	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg10820045	chr2:198174542	NA	0.51	7.99	0.4	2.06e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.49	8.12	0.4	8.43e-15	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.38	-0.33	5.59e-10	Morning vs. evening chronotype;
LIHC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18357526	chr6:26021779	HIST1H4A	0.44	6.4	0.33	5.18e-10	Height;
LIHC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.48	0.46	4.3e-19	Tonsillectomy;
LIHC	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-7.35	-0.37	1.44e-12	Vitamin D levels;
LIHC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.41e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	0.93	11.43	0.53	7.91e-26	Post bronchodilator FEV1;
LIHC	cis	rs7617773	0.823	rs9839447	chr3:48194667	T/C	cg11946769	chr3:48343235	NME6	-0.65	-8.3	-0.41	2.51e-15	Coronary artery disease;
LIHC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.55	0.33	2.08e-10	Lung cancer;
LIHC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.8	-0.39	7.74e-14	Total body bone mineral density;
LIHC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.74	-9.62	-0.46	1.53e-19	Asthma;
LIHC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.46	7.53	0.38	4.68e-13	Age at first birth;
LIHC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.95	17.19	0.68	3.62e-48	Parkinson's disease;
LIHC	cis	rs797680	0.856	rs797681	chr1:93717746	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	0.34	5.96	0.31	6.39e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs4773330	1.000	rs3809341	chr13:111805412	G/A	cg26911804	chr13:111806221	ARHGEF7	0.6	5.88	0.3	9.6e-9	Bilirubin levels;
LIHC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.25	0.32	1.22e-9	Schizophrenia;
LIHC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg12751644	chr20:60527061	NA	-0.37	-6.24	-0.32	1.28e-9	Body mass index;
LIHC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.77	-11.23	-0.52	3.96e-25	Longevity;
LIHC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.5	8.25	0.41	3.45e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg20818283	chr2:191399100	TMEM194B	0.47	6.32	0.32	8.34e-10	Pulse pressure;
LIHC	cis	rs2380220	0.808	rs2380224	chr6:95895553	C/T	cg04719120	chr6:96025338	MANEA	-0.56	-6.01	-0.31	4.64e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	8.95	0.44	2.35e-17	Schizophrenia;
LIHC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg21466736	chr12:48725269	NA	0.62	9.0	0.44	1.57e-17	Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.9	-0.39	3.77e-14	Capecitabine sensitivity;
LIHC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.93	-0.31	7.39e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2016586	0.929	rs8136429	chr22:36111828	C/G	cg26342177	chr22:36113512	APOL5	-0.38	-6.3	-0.32	9.32e-10	Body mass index;
LIHC	cis	rs7523273	0.565	rs2104303	chr1:207886684	C/T	cg22525895	chr1:207977042	MIR29B2	-0.52	-7.75	-0.39	1.09e-13	Schizophrenia;
LIHC	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg04610667	chr7:75704037	NA	0.33	5.94	0.31	7.16e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg14580859	chr9:123691850	NA	0.36	6.01	0.31	4.83e-9	Rheumatoid arthritis;
LIHC	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.8	-12.52	-0.56	7.6e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs2016586	0.647	rs5999943	chr22:36092836	C/G	cg26342177	chr22:36113512	APOL5	-0.36	-5.92	-0.31	7.7e-9	Body mass index;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-7.57	-0.38	3.57e-13	Prudent dietary pattern;
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09256448	chr16:638327	NA	0.38	6.25	0.32	1.25e-9	Height;
LIHC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.72	10.98	0.51	3.13e-24	Aortic root size;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg18934136	chr17:55927456	MRPS23	-0.45	-6.2	-0.32	1.65e-9	Alopecia areata;
LIHC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	13.05	0.58	7.11e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg26939375	chr7:64535504	NA	0.44	7.48	0.37	6.5e-13	Calcium levels;
LIHC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg16586182	chr3:47516702	SCAP	-0.52	-9.48	-0.46	4.55e-19	Colorectal cancer;
LIHC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.63	12.73	0.57	1.19e-30	Airflow obstruction;
LIHC	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.45	7.26	0.37	2.55e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9921222	0.597	rs3848369	chr16:415078	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	7.35	0.37	1.44e-12	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs7537660	1.000	rs7522811	chr1:248005213	C/G	cg07583490	chr19:15375374	BRD4	0.65	6.11	0.31	2.66e-9	Platelet distribution width;
LIHC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.53	-6.44	-0.33	4.07e-10	Menarche (age at onset);
LIHC	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.32	-6.2	-0.32	1.6e-9	Sitting height ratio;
LIHC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.31	0.66	1.25e-44	Parkinson's disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22691340	chr12:62997631	C12orf61	0.4	6.05	0.31	3.74e-9	Calcium levels;
LIHC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	12.47	0.56	1.1e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23590525	chr1:1469787	ATAD3A	0.36	6.05	0.31	3.91e-9	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.4	0.33	5.16e-10	Renal cell carcinoma;
LIHC	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	7.32	0.37	1.8e-12	Colorectal cancer;
LIHC	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.71	-11.78	-0.54	3.95e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg26924012	chr15:45694286	SPATA5L1	0.41	6.25	0.32	1.22e-9	Uric acid levels;
LIHC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.09	-0.31	3.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2997447	0.846	rs72886619	chr1:26452604	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.96	-0.31	6.43e-9	QRS complex (12-leadsum);
LIHC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs9921222	0.597	rs3848369	chr16:415078	C/T	cg26913058	chr16:419975	MRPL28	-0.62	-9.36	-0.45	1.1e-18	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.53	0.56	6.44e-30	Mean platelet volume;
LIHC	cis	rs7100689	0.615	rs10788639	chr10:82233225	C/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.54	0.38	4.14e-13	Post bronchodilator FEV1;
LIHC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.08	0.36	8.16e-12	Height;
LIHC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.91	-12.3	-0.55	4.8e-29	Heart rate;
LIHC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.65	-9.37	-0.45	1.05e-18	Obesity-related traits;
LIHC	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg02023728	chr11:77925099	USP35	-0.34	-6.01	-0.31	4.72e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.67	-14.07	-0.61	8.23e-36	Brugada syndrome;
LIHC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg04013166	chr16:89971882	TCF25	0.51	6.45	0.33	3.75e-10	Skin colour saturation;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04575144	chr19:4067379	ZBTB7A	0.4	6.08	0.31	3.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg12826209	chr6:26865740	GUSBL1	0.49	6.22	0.32	1.47e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.65	-0.34	1.14e-10	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-8.01	-0.4	1.77e-14	Fibrinogen levels;
LIHC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg23806715	chr17:73775811	H3F3B	0.53	7.19	0.36	3.98e-12	Psoriasis;
LIHC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg21734168	chr11:67353974	GSTP1	-0.26	-6.5	-0.33	2.91e-10	Mean corpuscular volume;
LIHC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.43	-6.45	-0.33	3.93e-10	Type 2 diabetes;
LIHC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg23262073	chr20:60523788	NA	-0.29	-6.15	-0.32	2.15e-9	Body mass index;
LIHC	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg01652190	chr22:50026171	C22orf34	-0.34	-7.62	-0.38	2.46e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.11e-13	Lung cancer;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-5.82	-0.3	1.33e-8	Longevity;
LIHC	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg27205649	chr11:78285834	NARS2	-0.38	-5.78	-0.3	1.68e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.85	-13.98	-0.6	2.01e-35	Post bronchodilator FEV1;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg22920498	chr9:19103109	HAUS6	-0.37	-6.12	-0.31	2.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg02426739	chr12:132285352	NA	0.36	5.78	0.3	1.72e-8	Migraine;
LIHC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.83	0.51	1.03e-23	Alzheimer's disease (late onset);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08123528	chr3:72438132	RYBP	-0.29	-6.7	-0.34	8.38e-11	Calcium levels;
LIHC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.62	10.33	0.49	5.98e-22	Menopause (age at onset);
LIHC	cis	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg14515779	chr1:101123966	NA	-0.61	-10.39	-0.49	3.8e-22	Monocyte count;
LIHC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg07234388	chr1:156261841	TMEM79	0.5	8.92	0.43	2.97e-17	Tonsillectomy;
LIHC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.37	5.98	0.31	5.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-8.86	-0.43	4.39e-17	Blood pressure (smoking interaction);
LIHC	cis	rs8083850	0.635	rs2195722	chr18:50861536	G/T	cg24270629	chr18:50823537	DCC	-0.56	-8.62	-0.42	2.62e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.77	-0.43	8.46e-17	Cognitive function;
LIHC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.58	8.53	0.42	4.98e-16	Platelet count;
LIHC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg16576597	chr16:28551801	NUPR1	0.37	5.83	0.3	1.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.31	0.32	8.81e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg14593290	chr7:50529359	DDC	0.63	9.81	0.47	3.41e-20	Malaria;
LIHC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg04310649	chr10:35416472	CREM	-0.43	-5.8	-0.3	1.5e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.68	-6.06	-0.31	3.5e-9	Bipolar disorder;
LIHC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg06951627	chr6:26196580	NA	0.46	5.92	0.3	7.96e-9	Gout;Renal underexcretion gout;
LIHC	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.1	-0.44	7.85e-18	Colorectal cancer;
LIHC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg23461800	chr14:103021989	NA	-0.48	-6.87	-0.35	3.13e-11	Platelet count;
LIHC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.57	7.87	0.39	4.65e-14	Neuroblastoma;
LIHC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg10932868	chr11:921992	NA	0.31	5.8	0.3	1.52e-8	Alzheimer's disease (late onset);
LIHC	trans	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-8.73	-0.43	1.14e-16	Obesity-related traits;
LIHC	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg24069376	chr3:38537580	EXOG	0.41	7.52	0.38	4.73e-13	Electrocardiographic conduction measures;
LIHC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.4	6.2	0.32	1.64e-9	Schizophrenia;
LIHC	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg14593290	chr7:50529359	DDC	0.63	9.96	0.47	1.09e-20	Malaria;
LIHC	cis	rs963731	0.579	rs11692687	chr2:39265428	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-6.11	-0.31	2.73e-9	Corticobasal degeneration;
LIHC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-10.62	-0.5	6.09e-23	Morning vs. evening chronotype;
LIHC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.53	-7.5	-0.38	5.65e-13	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg13535736	chr9:111863775	C9orf5	-0.38	-5.84	-0.3	1.19e-8	Menarche (age at onset);
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-11.5	-0.53	4.13e-26	Longevity;Endometriosis;
LIHC	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.44	7.23	0.36	3.14e-12	Menopause (age at onset);
LIHC	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-10.86	-0.51	8.38e-24	Alzheimer's disease;
LIHC	cis	rs16944613	0.510	rs8035793	chr15:91150084	C/T	cg26821196	chr15:91095069	CRTC3	0.32	5.99	0.31	5.42e-9	Colorectal cancer;
LIHC	cis	rs2637266	0.756	rs7079818	chr10:78469935	T/A	cg18941641	chr10:78392320	NA	0.28	5.97	0.31	5.82e-9	Pulmonary function;
LIHC	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.43	7.35	0.37	1.47e-12	Endometriosis;
LIHC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18075073	chr11:210610	RIC8A	0.41	6.37	0.33	6.22e-10	Pancreatic cancer;
LIHC	cis	rs10411936	0.720	rs2885706	chr19:16582937	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	6.41	0.33	4.78e-10	White blood cell count;Multiple sclerosis;
LIHC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs9918079	0.560	rs4557256	chr4:15626647	A/C	cg21123203	chr4:15471301	CC2D2A	-0.46	-7.32	-0.37	1.79e-12	Obesity-related traits;
LIHC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.7	7.85	0.39	5.45e-14	Migraine;Coronary artery disease;
LIHC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.4	0.37	1.09e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg15534755	chr11:117069859	TAGLN	0.36	6.18	0.32	1.78e-9	Blood protein levels;
LIHC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	6.49	0.33	2.94e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.53	8.24	0.41	3.76e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs3823572	0.542	rs2971961	chr7:133639737	G/A	cg03336402	chr7:133662267	EXOC4	0.47	5.81	0.3	1.42e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg11783602	chr8:55087084	NA	-0.3	-5.99	-0.31	5.24e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs35160687	0.509	rs35723061	chr2:86549088	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.36	5.77	0.3	1.8e-8	Night sleep phenotypes;
LIHC	cis	rs11195062	0.766	rs7922679	chr10:112014428	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.83	-0.3	1.28e-8	Multiple myeloma;
LIHC	cis	rs471756	0.523	rs575307	chr9:219774	G/A	cg14500300	chr9:211689	NA	0.25	5.81	0.3	1.45e-8	Mean platelet volume;
LIHC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.38	-0.33	5.63e-10	Blood metabolite levels;
LIHC	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.29	-0.32	9.78e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	8.93	0.43	2.72e-17	Lung cancer in ever smokers;
LIHC	cis	rs1355223	0.902	rs286862	chr11:34718779	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.45	6.28	0.32	1.01e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20566420	chr12:122327043	PSMD9	0.52	7.34	0.37	1.58e-12	Pancreatic cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08134342	chr12:122239035	LOC338799	-0.39	-6.05	-0.31	3.87e-9	Cognitive function;
LIHC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg17764715	chr19:33622953	WDR88	0.45	6.51	0.33	2.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg10932868	chr11:921992	NA	0.35	6.42	0.33	4.54e-10	Alzheimer's disease (late onset);
LIHC	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.76	-11.11	-0.51	1.1e-24	Morning vs. evening chronotype;
LIHC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg09238746	chr17:78121135	EIF4A3	-0.48	-7.2	-0.36	3.8e-12	Yeast infection;
LIHC	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	1.08	8.7	0.43	1.4e-16	Cannabis dependence symptom count;
LIHC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg08847533	chr14:75593920	NEK9	-0.51	-7.94	-0.39	2.93e-14	IgG glycosylation;
LIHC	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.58	9.28	0.45	1.95e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.49	-6.57	-0.33	1.82e-10	Heschl's gyrus morphology;
LIHC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	25.87	0.81	1.63e-82	Cognitive ability;
LIHC	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.55	0.33	2.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.67	-12.39	-0.56	2.33e-29	Height;
LIHC	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.22	0.32	1.49e-9	Mean corpuscular volume;
LIHC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.23	-10.79	-0.5	1.51e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg18478394	chr8:109455254	TTC35	0.36	6.02	0.31	4.56e-9	Dupuytren's disease;
LIHC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg18944383	chr4:111397179	ENPEP	0.35	8.07	0.4	1.23e-14	Coronary artery disease;
LIHC	cis	rs11888559	0.655	rs9288334	chr2:204022020	G/A	cg24605529	chr2:203879461	NBEAL1	0.78	5.9	0.3	8.76e-9	Height;
LIHC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.56e-16	Primary biliary cholangitis;
LIHC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.45	8.57	0.42	3.58e-16	Tuberculosis;
LIHC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-9.28	-0.45	2e-18	Colorectal cancer;
LIHC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.57	-0.5	8.95e-23	Hemoglobin concentration;
LIHC	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg04306507	chr14:55594613	LGALS3	0.32	5.95	0.31	6.71e-9	Protein biomarker;
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.42	8.51	0.42	5.4e-16	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11013164	chr5:43483764	C5orf28	-0.44	-6.19	-0.32	1.69e-9	Pancreatic cancer;
LIHC	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg16736954	chr20:23401023	NAPB	0.53	5.85	0.3	1.16e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	8.08	0.4	1.11e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.68	10.33	0.49	5.88e-22	Diisocyanate-induced asthma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23051664	chr8:23020966	TNFRSF10D	-0.49	-6.06	-0.31	3.59e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.37	5.94	0.31	7.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	12.06	0.55	3.86e-28	Height;
LIHC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg23625390	chr15:77176239	SCAPER	0.34	5.81	0.3	1.4e-8	Blood metabolite levels;
LIHC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.44	7.61	0.38	2.7e-13	Bipolar disorder;
LIHC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.68	10.02	0.48	7e-21	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.62	0.42	2.56e-16	Menarche (age at onset);
LIHC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.68	10.24	0.48	1.22e-21	Mosquito bite size;
LIHC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.69	-11.23	-0.52	3.87e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.48	-8.65	-0.42	2.1e-16	Colorectal cancer;
LIHC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.63	12.81	0.57	5.75e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.03	0.4	1.64e-14	Lung cancer;
LIHC	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.51	-7.17	-0.36	4.61e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22650146	chr1:221915355	DUSP10	0.47	6.51	0.33	2.65e-10	Pancreatic cancer;
LIHC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.01	-0.31	4.81e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.06	-0.31	3.69e-9	Total body bone mineral density;
LIHC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.82	0.35	4.27e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.96e-38	Blood metabolite levels;
LIHC	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.74	11.39	0.52	1.05e-25	Vitamin D levels;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg13647721	chr17:30228624	UTP6	0.71	7.26	0.37	2.71e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg16586182	chr3:47516702	SCAP	-0.58	-11.08	-0.51	1.43e-24	Colorectal cancer;
LIHC	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.54	9.51	0.46	3.46e-19	Systemic lupus erythematosus;
LIHC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	6.59	0.34	1.67e-10	Renal cell carcinoma;
LIHC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.67	9.95	0.47	1.22e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.55	-0.33	2.1e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.32	-5.94	-0.31	6.96e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	6.47	0.33	3.45e-10	Schizophrenia;
LIHC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.2	0.32	1.61e-9	Bladder cancer;
LIHC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg01411142	chr8:19674711	INTS10	-0.48	-7.51	-0.38	5.35e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-8.98	-0.44	1.87e-17	Body mass index;
LIHC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06544989	chr22:39130855	UNC84B	0.35	5.77	0.3	1.78e-8	Menopause (age at onset);
LIHC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.43	6.1	0.31	2.86e-9	Colorectal cancer;
LIHC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.36	5.89	0.3	9.03e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-6.52	-0.33	2.57e-10	Lung cancer in ever smokers;
LIHC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.84	0.54	2.48e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.66	11.67	0.53	1.02e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.69	-0.34	8.96e-11	Alzheimer's disease (late onset);
LIHC	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-17.94	-0.7	3.3e-51	Height;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg07133347	chr1:107600762	PRMT6	-0.45	-6.73	-0.34	7.25e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.45	-0.33	3.8e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg06096015	chr1:231504339	EGLN1	0.5	9.46	0.46	5.31e-19	Hemoglobin concentration;
LIHC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.76	12.65	0.56	2.34e-30	Fat distribution (HIV);
LIHC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.56	-9.53	-0.46	2.99e-19	Alcohol dependence;
LIHC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.31	0.52	2.03e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	5.1e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.48	-5.98	-0.31	5.47e-9	Diastolic blood pressure;
LIHC	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.56	6.8	0.35	4.63e-11	Coronary artery disease;
LIHC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg17724175	chr1:150552817	MCL1	0.41	8.05	0.4	1.34e-14	Melanoma;
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27297192	chr10:134578999	INPP5A	0.54	7.75	0.39	1.07e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.54	7.58	0.38	3.18e-13	Lymphocyte counts;
LIHC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg16576597	chr16:28551801	NUPR1	0.37	5.83	0.3	1.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16684958	chr7:75615977	POR	-0.5	-8.44	-0.42	9.36e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12467847	1.000	rs4387792	chr2:113691288	T/C	cg12858261	chr2:113808755	IL1F8	-0.35	-5.88	-0.3	9.83e-9	Response to amphetamines;
LIHC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18252515	chr7:66147081	NA	-0.43	-5.93	-0.31	7.31e-9	Aortic root size;
LIHC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-5.93	-0.31	7.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2122469	0.655	rs17603982	chr8:20581401	G/C	cg20211604	chr17:11632341	DNAH9	0.52	6.43	0.33	4.34e-10	Serum tamsulosin hydrochloride concentration;
LIHC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08280861	chr8:58055591	NA	0.55	6.28	0.32	1.05e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.35	6.28	0.32	1.01e-9	Calcium levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12032228	chr14:64854572	MTHFD1	-0.4	-6.06	-0.31	3.62e-9	Cognitive function;
LIHC	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	11.1	0.51	1.2e-24	Diisocyanate-induced asthma;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25468541	chr7:5014008	RNF216L	0.53	6.37	0.33	6.22e-10	Hepatitis;
LIHC	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.68	-11.87	-0.54	1.96e-27	Pediatric autoimmune diseases;
LIHC	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg05714579	chr10:131428358	MGMT	0.41	6.63	0.34	1.3100000000000001e-10	Response to temozolomide;
LIHC	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg22771759	chr13:24902376	NA	0.32	6.66	0.34	1.12e-10	Obesity-related traits;
LIHC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.48	8.68	0.42	1.62e-16	Colorectal cancer;
LIHC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.19	0.41	5.17e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.64	-0.42	2.19e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs918629	0.567	rs6885567	chr5:95258754	T/G	cg10483112	chr5:95245456	ELL2	-0.38	-7.17	-0.36	4.76e-12	IgG glycosylation;
LIHC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.93	17.06	0.68	1.15e-47	Breast cancer;
LIHC	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.48	6.5	0.33	2.91e-10	Bipolar disorder;
LIHC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.85	14.99	0.63	2.13e-39	Bone mineral density;
LIHC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27189623	chr16:705930	WDR90	0.42	6.96	0.35	1.74e-11	Height;
LIHC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg03037974	chr15:76606532	NA	0.74	14.31	0.61	1e-36	Blood metabolite levels;
LIHC	cis	rs4671400	0.602	rs2694623	chr2:61553466	C/T	cg14146966	chr2:61757674	XPO1	-0.38	-5.94	-0.31	7.06e-9	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg25894440	chr7:65020034	NA	-0.55	-6.33	-0.32	7.79e-10	Diabetic kidney disease;
LIHC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.1	-0.31	2.87e-9	Bipolar disorder;
LIHC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4920343	0.645	rs851115	chr1:19070229	T/A	cg19637330	chr1:19110922	NA	0.32	5.89	0.3	9.24e-9	Knee osteoarthritis;
LIHC	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.4	-7.65	-0.38	2.09e-13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.13	-0.44	6.09e-18	Capecitabine sensitivity;
LIHC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.37	5.91	0.3	8.06e-9	Menopause (age at onset);
LIHC	cis	rs9473924	0.505	rs9296644	chr6:50828247	G/A	cg14470998	chr6:50812995	TFAP2B	0.86	9.78	0.47	4.3e-20	Body mass index;
LIHC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	trans	rs35740288	0.621	rs12916001	chr15:86245269	G/A	cg20536716	chr7:119913368	KCND2	0.4	6.17	0.32	1.9e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg04013166	chr16:89971882	TCF25	0.61	7.97	0.4	2.38e-14	Skin colour saturation;
LIHC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	8.09	0.4	1.05e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.45	7.77	0.39	9.55e-14	Prevalent atrial fibrillation;
LIHC	trans	rs13381277	1.000	rs9959410	chr18:74329953	G/A	cg17352830	chr21:37617589	DOPEY2	-0.55	-6.4	-0.33	5e-10	Dental caries;
LIHC	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06634786	chr22:41940651	POLR3H	0.56	6.16	0.32	2e-9	Vitiligo;
LIHC	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.5	8.15	0.4	7.13e-15	Corneal astigmatism;
LIHC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-17.23	-0.68	2.46e-48	Chronic sinus infection;
LIHC	cis	rs7238033	0.624	rs7233769	chr18:43306681	A/G	cg20610511	chr18:43302872	SLC14A1	0.4	6.59	0.34	1.69e-10	Bladder cancer;
LIHC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.55	-0.38	3.87e-13	Chronic sinus infection;
LIHC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg13628971	chr7:2884303	GNA12	0.39	5.79	0.3	1.63e-8	Height;
LIHC	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.11	-0.31	2.73e-9	Total body bone mineral density;
LIHC	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg11657440	chr19:46296263	DMWD	-0.53	-8.19	-0.4	5.43e-15	Coronary artery disease;
LIHC	cis	rs425535	0.619	rs4694655	chr4:74806082	C/T	cg02530824	chr4:74847766	PF4	-0.39	-6.02	-0.31	4.48e-9	Blood protein levels;
LIHC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.43	7.55	0.38	3.92e-13	Aortic root size;
LIHC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg26395211	chr5:140044315	WDR55	0.42	6.23	0.32	1.35e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.39	6.31	0.32	8.56e-10	Mean corpuscular volume;
LIHC	cis	rs79387448	0.655	rs77763678	chr2:102916749	G/A	cg09003973	chr2:102972529	NA	1.2	9.65	0.46	1.2e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.06	0.36	9.42e-12	Diabetic kidney disease;
LIHC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.62	6.62	0.34	1.38e-10	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.39	0.37	1.14e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.9	8.74	0.43	1.04e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.9	0.3	8.88e-9	Bipolar disorder;
LIHC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.46	7.21	0.36	3.52e-12	HDL cholesterol levels;
LIHC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.45	-6.22	-0.32	1.41e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	5.74	0.3	2.14e-8	Protein C levels;
LIHC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.47	-0.37	6.75e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg11062466	chr8:58055876	NA	0.4	5.84	0.3	1.21e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07573366	chr7:32802765	NA	0.31	7.47	0.37	6.95e-13	Bilirubin levels;
LIHC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg00318621	chr2:106887213	NA	-0.58	-5.78	-0.3	1.73e-8	Facial morphology (factor 23);
LIHC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.23	-0.32	1.34e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg14906510	chr12:7781169	NA	0.48	7.3	0.37	1.97e-12	HDL cholesterol levels;
LIHC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.76	12.72	0.57	1.34e-30	Menarche (age at onset);
LIHC	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.53	8.29	0.41	2.56e-15	Waist circumference;Body mass index;
LIHC	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.74	7.62	0.38	2.51e-13	Bipolar disorder;
LIHC	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.64	10.3	0.49	7.46e-22	Schizophrenia;
LIHC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.46	-7.6	-0.38	2.85e-13	Alzheimer's disease (late onset);
LIHC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.82	-0.35	4.18e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.45	6.88	0.35	2.86e-11	Height;
LIHC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.68	-10.84	-0.51	9.9899999999999993e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs1355223	0.902	rs7121272	chr11:34752562	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.56	-0.33	2e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.79	12.47	0.56	1.1e-29	Breast cancer;
LIHC	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg02527881	chr3:46936655	PTH1R	-0.54	-11.92	-0.54	1.2e-27	Birth weight;
LIHC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18252515	chr7:66147081	NA	0.43	5.73	0.3	2.2e-8	Aortic root size;
LIHC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.79	8.82	0.43	6.02e-17	Vitiligo;
LIHC	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	ch.11.42038R	chr11:967971	AP2A2	0.6	11.25	0.52	3.48e-25	Alzheimer's disease (late onset);
LIHC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.79	-0.54	3.69e-27	Type 2 diabetes;
LIHC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg20435097	chr10:126320824	FAM53B	-0.41	-6.0	-0.31	4.96e-9	Cocaine dependence;
LIHC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11987759	chr7:65425863	GUSB	0.38	6.14	0.31	2.32e-9	Aortic root size;
LIHC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.49	9.89	0.47	1.92e-20	Tonsillectomy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21509040	chr20:61814830	NA	0.37	6.13	0.31	2.36e-9	Cognitive function;
LIHC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.5	-7.35	-0.37	1.44e-12	Obesity-related traits;
LIHC	cis	rs1198430	0.639	rs1767147	chr1:23770516	A/G	cg19827787	chr1:23763612	ASAP3	0.28	6.09	0.31	2.99e-9	Total cholesterol levels;
LIHC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg09069446	chr16:4462122	CORO7	-0.35	-5.71	-0.3	2.45e-8	Schizophrenia;
LIHC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.44	-7.17	-0.36	4.57e-12	Menarche (age at onset);
LIHC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg24069376	chr3:38537580	EXOG	-0.4	-7.32	-0.37	1.78e-12	Electrocardiographic conduction measures;
LIHC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.71	0.38	1.35e-13	Prudent dietary pattern;
LIHC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.46	0.33	3.5e-10	Blood metabolite levels;
LIHC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09835421	chr16:68378352	PRMT7	-0.52	-5.98	-0.31	5.58e-9	Schizophrenia;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.75	11.07	0.51	1.51e-24	Menarche (age at onset);
LIHC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.53	-8.69	-0.43	1.55e-16	Blood metabolite levels;
LIHC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.49	8.95	0.44	2.37e-17	Mean corpuscular volume;
LIHC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	0.75	6.93	0.35	2.08e-11	Plateletcrit;
LIHC	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.63	-12.77	-0.57	8.58e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs4950322	0.553	rs12093870	chr1:146852536	A/C	cg25205988	chr1:146714368	CHD1L	-0.41	-5.95	-0.31	6.75e-9	Protein quantitative trait loci;
LIHC	cis	rs7534824	0.625	rs61780286	chr1:101359898	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.97	0.35	1.6e-11	Refractive astigmatism;
LIHC	cis	rs6977660	0.941	rs5017192	chr7:19820114	C/T	cg07541023	chr7:19748670	TWISTNB	0.36	5.74	0.3	2.1e-8	Thyroid stimulating hormone;
LIHC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.34	-6.32	-0.32	7.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	7e-29	Eye color traits;
LIHC	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg07541023	chr7:19748670	TWISTNB	-0.38	-6.05	-0.31	3.77e-9	Thyroid stimulating hormone;
LIHC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.8	12.66	0.56	2.11e-30	Breast cancer;
LIHC	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg13919466	chr1:32135498	COL16A1	-0.34	-6.33	-0.32	7.68e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.56	8.6	0.42	2.91e-16	Menopause (age at onset);
LIHC	cis	rs10508774	0.810	rs1402185	chr10:32778152	G/A	cg01819863	chr10:32635814	EPC1	0.61	5.8	0.3	1.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2257205	0.667	rs7221142	chr17:56758786	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.47	-0.33	3.49e-10	Pancreatic cancer;
LIHC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.43	6.83	0.35	3.86e-11	Melanoma;
LIHC	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.45	-6.69	-0.34	9.34e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.64	7.9	0.39	3.86e-14	Heart rate;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.61	-0.34	1.49e-10	Total body bone mineral density;
LIHC	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.28	-11.31	-0.52	2.13e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs244293	0.965	rs2214980	chr17:53207061	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.45	-0.37	7.67e-13	Menarche (age at onset);
LIHC	cis	rs9612	0.718	rs346536	chr19:44251470	A/T	cg08581076	chr19:44259116	C19orf61	0.59	7.77	0.39	9.53e-14	Exhaled nitric oxide output;
LIHC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg20435097	chr10:126320824	FAM53B	-0.41	-5.98	-0.31	5.77e-9	Cocaine dependence;
LIHC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.61	11.02	0.51	2.19e-24	Total body bone mineral density;
LIHC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.4	8.56	0.42	3.81e-16	Blood metabolite levels;
LIHC	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.63	-9.94	-0.47	1.23e-20	Lung cancer;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	0.58	9.22	0.45	3.14e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.75	-0.3	1.97e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.19	-0.4	5.22e-15	Morning vs. evening chronotype;
LIHC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.39	-6.9	-0.35	2.52e-11	Height;
LIHC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-7.29	-0.37	2.18e-12	Total body bone mineral density;
LIHC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.5	0.38	5.48e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs921968	1.000	rs56191141	chr2:219272145	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-5.95	-0.31	6.78e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.37	-0.33	5.98e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.49	-6.96	-0.35	1.75e-11	Body mass index;
LIHC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.38	6.12	0.31	2.62e-9	Type 2 diabetes;
LIHC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg18270830	chr10:32634957	EPC1	0.54	6.61	0.34	1.46e-10	Sexual dysfunction (female);
LIHC	trans	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg01134436	chr17:81009848	B3GNTL1	0.81	6.82	0.35	4.06e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.52	7.62	0.38	2.5e-13	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg11764359	chr7:65958608	NA	-0.58	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.76	-0.39	9.71e-14	Ulcerative colitis;
LIHC	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.71	-0.34	7.92e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.53	0.33	2.43e-10	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00142735	chr15:64454827	PPIB	0.44	6.34	0.32	7.16e-10	Pancreatic cancer;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg20971159	chr15:74703254	SEMA7A	0.39	6.32	0.32	8.22e-10	Alopecia areata;
LIHC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-1.03	-19.89	-0.73	4.87e-59	Breast cancer;
LIHC	cis	rs4450131	0.522	rs11245323	chr10:126344624	C/T	cg20435097	chr10:126320824	FAM53B	0.67	12.2	0.55	1.12e-28	White blood cell count (basophil);
LIHC	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg22153463	chr1:85462885	MCOLN2	-0.54	-6.89	-0.35	2.72e-11	Serum sulfate level;
LIHC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.6	-10.31	-0.49	6.83e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.48	0.46	4.54e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.92	-17.0	-0.68	2.02e-47	Menopause (age at onset);
LIHC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.28	0.41	2.77e-15	Morning vs. evening chronotype;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02793854	chr16:67867809	CENPT	-0.53	-6.11	-0.31	2.72e-9	Systolic blood pressure;
LIHC	trans	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg19894588	chr14:64061835	NA	-0.66	-9.1	-0.44	7.89e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.57	-0.42	3.68e-16	Total cholesterol levels;
LIHC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.08	-11.42	-0.53	8.04e-26	Vitiligo;
LIHC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.38	7.48	0.37	6.45e-13	Urinary metabolites;
LIHC	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg08847533	chr14:75593920	NEK9	0.51	7.69	0.38	1.58e-13	IgG glycosylation;
LIHC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.81	6.01	0.31	4.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	5.83	0.3	1.27e-8	Schizophrenia;
LIHC	cis	rs16958440	0.867	rs3809966	chr18:44677627	C/T	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.51	-7.35	-0.37	1.47e-12	Body mass index;
LIHC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg07451762	chr16:28383216	NA	-0.38	-6.55	-0.33	2.16e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4407350	0.870	rs5764877	chr22:44915530	T/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.51	0.33	2.69e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12368702	chr16:53165711	CHD9	0.48	6.73	0.34	7.31e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.33	0.32	7.63e-10	Renal cell carcinoma;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg12903224	chr12:29470962	FAR2	-0.37	-5.94	-0.31	6.91e-9	QT interval;
LIHC	cis	rs5995875	0.524	rs7284506	chr22:41057977	C/T	cg14879645	chr22:41048474	NA	0.4	5.72	0.3	2.3e-8	Breast size;
LIHC	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.42	7.24	0.36	3.06e-12	Monocyte percentage of white cells;
LIHC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.45	-7.48	-0.38	6.25e-13	Fibrinogen levels;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.74e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs116248771	0.690	rs73156492	chr3:158416799	G/C	cg16708174	chr3:158430962	RARRES1	0.48	6.34	0.32	7.39e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.38	6.89	0.35	2.62e-11	Obesity;
LIHC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.48	6.72	0.34	7.41e-11	Response to diuretic therapy;
LIHC	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.37	6.11	0.31	2.73e-9	Lung cancer;
LIHC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.45	5.89	0.3	9.42e-9	High light scatter reticulocyte count;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17370785	chr4:2252266	MXD4	0.41	6.04	0.31	4.02e-9	Longevity;
LIHC	trans	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.5	0.33	2.88e-10	Endometrial cancer;
LIHC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	7.49	0.38	5.81e-13	Alzheimer's disease;
LIHC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg16736954	chr20:23401023	NAPB	0.71	8.3	0.41	2.48e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.21	0.32	1.55e-9	Ileal carcinoids;
LIHC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.48	0.56	1.05e-29	Cognitive test performance;
LIHC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24229701	chr12:130821962	PIWIL1	0.42	6.12	0.31	2.57e-9	Menopause (age at onset);
LIHC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.86	0.43	4.45e-17	Cognitive ability;
LIHC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.82	0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.71	0.3	2.42e-8	Rheumatoid arthritis;
LIHC	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.62	-8.42	-0.41	1.05e-15	Ulcerative colitis;
LIHC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.5	0.33	2.77e-10	Renal cell carcinoma;
LIHC	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.11	23.99	0.79	2.76e-75	Schizophrenia;
LIHC	cis	rs7575217	0.767	rs796064	chr2:101729682	G/A	cg23907051	chr2:101730305	TBC1D8	-0.28	-6.46	-0.33	3.67e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg12863693	chr15:85201151	NMB	-0.4	-5.77	-0.3	1.76e-8	Schizophrenia;
LIHC	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.86	12.79	0.57	6.99e-31	Body mass index;
LIHC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.97	20.63	0.74	5.12e-62	Bone mineral density;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04953579	chr7:151216578	RHEB	0.48	6.61	0.34	1.45e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21467203	chr3:49911342	NA	0.43	7.67	0.38	1.82e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.73	14.06	0.61	9.37e-36	Mortality in heart failure;
LIHC	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg14515779	chr1:101123966	NA	-0.59	-11.08	-0.51	1.33e-24	Monocyte count;
LIHC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg08773314	chr2:239334832	ASB1	0.31	5.79	0.3	1.63e-8	Multiple system atrophy;
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.87	13.06	0.58	6.89e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg04517722	chr19:17905589	B3GNT3	0.46	6.93	0.35	2.16e-11	Tumor biomarkers;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg18580296	chr7:15726411	MEOX2	-0.39	-6.57	-0.33	1.89e-10	Body mass index;
LIHC	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.45	7.24	0.36	2.95e-12	Corneal astigmatism;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg02782426	chr3:40428986	ENTPD3	0.33	6.1	0.31	2.87e-9	Renal cell carcinoma;
LIHC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.75	7.6	0.38	2.9e-13	Schizophrenia;
LIHC	trans	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.56	-6.8	-0.35	4.55e-11	Breast cancer;
LIHC	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.69	0.46	9.07e-20	Corneal astigmatism;
LIHC	cis	rs6066825	0.644	rs6019380	chr20:47318845	A/G	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.59e-12	Colorectal cancer;
LIHC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg05484376	chr2:27715224	FNDC4	0.4	6.69	0.34	9.08e-11	Total body bone mineral density;
LIHC	cis	rs10792665	0.671	rs3862772	chr11:82671930	C/G	cg24227371	chr11:82718527	RAB30	-0.3	-6.62	-0.34	1.38e-10	Obesity-related traits;
LIHC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg08888203	chr3:10149979	C3orf24	0.52	6.26	0.32	1.14e-9	Alzheimer's disease;
LIHC	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg03263716	chr11:64435066	NRXN2	0.34	7.31	0.37	1.95e-12	Body mass index;Urate levels;
LIHC	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09525523	chr12:16064153	DERA	-0.47	-6.74	-0.34	6.73e-11	Pancreatic cancer;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.6	9.32	0.45	1.51e-18	Height;
LIHC	cis	rs8103278	0.701	rs116959973	chr19:46252333	A/T	cg02376097	chr19:46275166	DMPK	-0.45	-6.67	-0.34	1.04e-10	Coronary artery disease;
LIHC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-10.02	-0.48	6.9e-21	Electrocardiographic conduction measures;
LIHC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12463550	chr7:65579703	CRCP	0.59	5.93	0.31	7.32e-9	Diabetic kidney disease;
LIHC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.6	0.46	1.76e-19	Bipolar disorder;
LIHC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.56	-0.33	2.01e-10	Mean corpuscular volume;
LIHC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.38	0.37	1.2e-12	Morning vs. evening chronotype;
LIHC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg10790698	chr19:18539756	SSBP4	-0.37	-7.74	-0.39	1.16e-13	Breast cancer;
LIHC	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.74	11.47	0.53	5.53e-26	Metabolite levels;
LIHC	cis	rs7116495	1.000	rs2460254	chr11:71570110	A/G	cg26138937	chr11:71823887	C11orf51	0.73	7.0	0.35	1.34e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17708016	chr12:54321992	NA	0.43	7.64	0.38	2.26e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21467203	chr3:49911342	NA	-0.4	-6.88	-0.35	2.9100000000000002e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.76	6.97	0.35	1.6e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.02	-0.35	1.2e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg13699009	chr12:122356056	WDR66	0.49	7.81	0.39	7.04e-14	Mean corpuscular volume;
LIHC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.36	5.95	0.31	6.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.08	0.31	3.13e-9	Protein biomarker;
LIHC	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg06640241	chr16:89574553	SPG7	0.65	10.79	0.5	1.45e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs13006863	0.509	rs1667605	chr2:74374884	G/A	cg23149560	chr2:74406255	MOBKL1B	-0.39	-5.84	-0.3	1.22e-8	Post-traumatic stress disorder (asjusted for relatedness);Immune reponse to smallpox (secreted TNF-alpha);
LIHC	cis	rs55882075	0.967	rs62404346	chr5:179141391	A/C	cg14593053	chr5:179126677	CANX	0.39	7.26	0.37	2.62e-12	Monocyte percentage of white cells;
LIHC	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg12698662	chr3:15914712	MIR563	-0.39	-7.13	-0.36	5.91e-12	Mean platelet volume;
LIHC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.46	-7.48	-0.37	6.49e-13	Birth weight;
LIHC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.78	-18.01	-0.7	1.85e-51	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.46	6.13	0.31	2.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.7	7.28	0.37	2.38e-12	Vitiligo;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.67	9.78	0.47	4.51e-20	Lymphocyte counts;
LIHC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.34	5.79	0.3	1.56e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.84	10.13	0.48	2.89e-21	Mean platelet volume;
LIHC	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg20697417	chr1:41786797	NA	0.32	6.06	0.31	3.52e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg02023728	chr11:77925099	USP35	-0.33	-5.84	-0.3	1.2e-8	Alzheimer's disease (survival time);
LIHC	trans	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg25214090	chr10:38739885	LOC399744	0.37	6.08	0.31	3.14e-9	Diastolic blood pressure;
LIHC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.39	-6.51	-0.33	2.73e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.38	-13.24	-0.58	1.4e-32	Psoriasis vulgaris;
LIHC	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg08126542	chr6:37504118	NA	-0.35	-5.74	-0.3	2.05e-8	Cognitive performance;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.66	0.53	1.13e-26	Height;
LIHC	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.48	8.69	0.43	1.5e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.19	0.32	1.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.06	0.4	1.32e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.65	0.42	2.09e-16	Height;
LIHC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02450064	chr17:40260053	DHX58	-0.3	-6.12	-0.31	2.53e-9	Fibrinogen levels;
LIHC	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.28	-0.37	2.26e-12	Mean platelet volume;
LIHC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.39	-6.91	-0.35	2.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.95	-0.31	6.52e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.83	11.9	0.54	1.49e-27	Pediatric areal bone mineral density (radius);
LIHC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-8.25	-0.41	3.46e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg01864836	chr14:55583639	NA	-0.37	-6.29	-0.32	9.82e-10	Protein biomarker;
LIHC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.72	0.39	1.29e-13	Lymphocyte counts;
LIHC	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.63	-0.42	2.41e-16	Brugada syndrome;
LIHC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.56	-9.45	-0.45	5.65e-19	Blood metabolite levels;
LIHC	cis	rs999943	1.000	rs999943	chr6:33624733	A/G	cg14003231	chr6:33640908	ITPR3	0.37	7.64	0.38	2.16e-13	Obesity (extreme);
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-6.04	-0.31	4.13e-9	Longevity;
LIHC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg17135325	chr3:160939158	NMD3	0.47	7.11	0.36	6.79e-12	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg06453172	chr10:134556979	INPP5A	-0.66	-9.26	-0.45	2.31e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.39	-5.78	-0.3	1.73e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg11062466	chr8:58055876	NA	0.51	7.61	0.38	2.72e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.89	-18.29	-0.7	1.34e-52	Height;
LIHC	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	5.05e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg24849736	chr1:201084428	NA	-0.33	-5.93	-0.31	7.22e-9	Permanent tooth development;
LIHC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.42	0.41	1.06e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13647721	chr17:30228624	UTP6	0.78	7.34	0.37	1.57e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.88	-0.3	9.96e-9	Personality dimensions;
LIHC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03701779	chr10:74927978	FAM149B1;ECD	-0.49	-6.33	-0.32	7.71e-10	Hepatitis;
LIHC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	8.65	0.42	2.06e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.37	-6.48	-0.33	3.29e-10	Asthma;
LIHC	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	6.35	0.32	6.85e-10	Iron status biomarkers;
LIHC	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg18912006	chr12:123335444	HIP1R	-0.6	-7.25	-0.36	2.85e-12	Schizophrenia;
LIHC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	11.47	0.53	5.53e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg10755058	chr3:40428713	ENTPD3	0.42	7.14	0.36	5.82e-12	Renal cell carcinoma;
LIHC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	8.46	0.42	7.83e-16	HIV-1 control;
LIHC	trans	rs11039100	1.000	rs12366070	chr11:5828394	C/T	cg11650987	chr12:10280440	CLEC7A	0.4	6.05	0.31	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg15841412	chr13:111365552	ING1	0.51	6.5	0.33	2.86e-10	Coronary artery disease;
LIHC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	16.32	0.66	1.13e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.18	0.32	1.86e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg04592579	chr7:75616294	TMEM120A	-0.35	-6.05	-0.31	3.79e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	10.47	0.49	1.95e-22	Total body bone mineral density;
LIHC	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.34	6.77	0.34	5.73e-11	Testicular germ cell tumor;
LIHC	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.18	-0.4	5.53e-15	Colorectal cancer;
LIHC	cis	rs12079745	0.590	rs7544446	chr1:169256524	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-7.4	-0.37	1.04e-12	QT interval;
LIHC	cis	rs1419980	0.730	rs2004838	chr12:7780920	C/T	cg10578777	chr12:7781093	NA	-0.4	-5.83	-0.3	1.26e-8	HDL cholesterol levels;
LIHC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.78	11.65	0.53	1.25e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.38	6.52	0.33	2.54e-10	Schizophrenia;
LIHC	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04004882	chr2:215674386	BARD1	0.5	6.05	0.31	3.85e-9	Neuroblastoma;
LIHC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.45	0.49	2.38e-22	Lymphocyte percentage of white cells;
LIHC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.77	11.87	0.54	1.94e-27	Corneal astigmatism;
LIHC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.64	-0.62	5.13e-38	Alzheimer's disease (late onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.41	-6.29	-0.32	9.78e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.74	-10.41	-0.49	3.17e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.81	-6.83	-0.35	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg16589663	chr20:23618590	CST3	0.74	7.51	0.38	5.16e-13	Chronic kidney disease;
LIHC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg02297831	chr4:17616191	MED28	0.48	7.41	0.37	1.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.81	-12.42	-0.56	1.73e-29	Total body bone mineral density;
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg24693881	chr1:107596107	NA	0.5	8.49	0.42	6.42e-16	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.55	6.14	0.32	2.28e-9	Axial length;
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.45	7.2	0.36	3.87e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs6783573	0.965	rs7650998	chr3:46607255	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	0.34	5.73	0.3	2.25e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg13409248	chr3:40428643	ENTPD3	-0.51	-8.62	-0.42	2.46e-16	Renal cell carcinoma;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03990998	chr4:15006727	CPEB2	-0.43	-6.06	-0.31	3.5e-9	Immature fraction of reticulocytes;
LIHC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.63	-5.82	-0.3	1.36e-8	Red cell distribution width;
LIHC	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg27205649	chr11:78285834	NARS2	-0.41	-6.02	-0.31	4.44e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg10381502	chr11:71823885	C11orf51	1.08	9.2	0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg16479474	chr6:28041457	NA	0.43	6.65	0.34	1.15e-10	Parkinson's disease;
LIHC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.32	7.34	0.37	1.61e-12	Crohn's disease;
LIHC	cis	rs1982963	0.627	rs61971552	chr14:52481524	G/T	cg10843707	chr14:52510701	NID2	0.38	6.0	0.31	5.05e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.93	-0.39	3.16e-14	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.53	-7.46	-0.37	7.31e-13	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.58	7.69	0.38	1.63e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg26338869	chr17:61819248	STRADA	0.49	6.54	0.33	2.19e-10	Height;
LIHC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.77	12.02	0.55	5.13e-28	Corneal astigmatism;
LIHC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.46	6.12	0.31	2.52e-9	Emphysema distribution in smoking;
LIHC	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg09752223	chr19:15281200	NOTCH3	-0.35	-6.18	-0.32	1.82e-9	Pulse pressure;
LIHC	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.46	8.09	0.4	1.07e-14	Inhibitory control;
LIHC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.44	6.55	0.33	2.15e-10	Platelet count;
LIHC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg17294928	chr15:75287854	SCAMP5	-0.47	-6.09	-0.31	3.08e-9	Lung cancer;
LIHC	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.58	7.38	0.37	1.18e-12	Corneal astigmatism;
LIHC	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.74	-11.49	-0.53	4.78e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18264753	chr6:138188625	TNFAIP3	0.44	6.27	0.32	1.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.33	0.72	8.32e-57	Smoking behavior;
LIHC	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg21573476	chr21:45109991	RRP1B	0.47	7.93	0.39	3.15e-14	Mean corpuscular volume;
LIHC	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.7	0.43	1.42e-16	Schizophrenia;
LIHC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.41	-6.91	-0.35	2.41e-11	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg12798992	chr6:167411361	FGFR1OP	0.42	6.38	0.33	5.71e-10	Primary biliary cholangitis;
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.43	6.04	0.31	4.08e-9	Longevity;Endometriosis;
LIHC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg06598544	chr20:61472147	COL9A3	-0.79	-7.73	-0.39	1.25e-13	Obesity-related traits;
LIHC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.72	8.74	0.43	1.04e-16	Heart rate;
LIHC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.91	-16.9	-0.67	5.28e-47	Aortic root size;
LIHC	trans	rs3783890	0.887	rs2295702	chr14:93813988	G/A	cg02802420	chr16:69363236	PDF;COG8	0.33	6.29	0.32	9.92e-10	Body mass index;
LIHC	cis	rs4575098	0.681	rs11579514	chr1:161143312	A/G	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.36	6.74	0.34	6.62e-11	Monocyte percentage of white cells;
LIHC	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.53	9.36	0.45	1.07e-18	Breast cancer;
LIHC	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.75	11.32	0.52	1.92e-25	Obesity-related traits;
LIHC	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	0.86	7.22	0.36	3.31e-12	Uric acid levels;
LIHC	cis	rs2286503	0.839	rs2270107	chr7:22862183	G/A	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.48	8.52	0.42	5.34e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.9	12.2	0.55	1.12e-28	Blood metabolite levels;
LIHC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.91	16.91	0.67	4.71e-47	Aortic root size;
LIHC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2251381	0.640	rs2183568	chr21:30484782	A/T	cg08807101	chr21:30365312	RNF160	-0.73	-10.02	-0.48	7.12e-21	Selective IgA deficiency;
LIHC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg03945807	chr20:60948434	NA	0.38	6.08	0.31	3.13e-9	Colorectal cancer;
LIHC	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-8.98	-0.44	1.84e-17	Exhaled nitric oxide output;
LIHC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.32	-6.8	-0.35	4.65e-11	Longevity;
LIHC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.54	-9.8	-0.47	3.7799999999999997e-20	Diastolic blood pressure;
LIHC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg01864069	chr14:103024347	NA	-0.58	-9.32	-0.45	1.47e-18	Platelet count;
LIHC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.47	8.93	0.43	2.64e-17	Atrioventricular conduction;
LIHC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.04	0.31	3.93e-9	Bipolar disorder;
LIHC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg11642891	chr2:3452563	TTC15	-0.39	-6.22	-0.32	1.48e-9	Obesity-related traits;
LIHC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg27386326	chr11:61587980	NA	0.42	6.17	0.32	1.93e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs864643	1.000	rs536454	chr3:39550318	A/G	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.74	11.05	0.51	1.83e-24	Corneal astigmatism;
LIHC	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-6.49	-0.33	3.04e-10	Metabolite levels;
LIHC	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg11812906	chr14:75593930	NEK9	-0.71	-13.35	-0.59	5.36e-33	Height;
LIHC	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.41	-7.3	-0.37	2e-12	Crohn's disease;
LIHC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.53	-9.31	-0.45	1.55e-18	Coronary artery disease;
LIHC	cis	rs11630290	0.667	rs6494441	chr15:64166877	A/G	cg12036633	chr15:63758958	NA	0.57	5.96	0.31	6.35e-9	Iris characteristics;
LIHC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg10820045	chr2:198174542	NA	-0.59	-10.13	-0.48	2.93e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.22	-5.91	-0.3	8.16e-9	Rheumatoid arthritis;
LIHC	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.13	0.31	2.38e-9	Protein biomarker;
LIHC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.38	6.07	0.31	3.36e-9	Menopause (age at onset);
LIHC	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.56	7.13	0.36	5.85e-12	Breast cancer;
LIHC	cis	rs6695567	0.934	rs6692772	chr1:53629190	G/A	cg20326410	chr1:53600821	SLC1A7	0.3	6.32	0.32	8.26e-10	Systemic lupus erythematosus;
LIHC	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	trans	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg19894588	chr14:64061835	NA	-0.59	-8.01	-0.4	1.82e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs28830936	0.966	rs2303516	chr15:42128568	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.85	-0.3	1.16e-8	Diastolic blood pressure;
LIHC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg02580895	chr19:2754563	NA	-0.46	-6.81	-0.35	4.34e-11	Total cholesterol levels;
LIHC	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.91	0.39	3.5e-14	Refractive astigmatism;
LIHC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.58	-8.61	-0.42	2.7e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.43	-6.52	-0.33	2.51e-10	Asthma (sex interaction);
LIHC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg16989086	chr20:62203971	PRIC285	0.57	8.2	0.41	5.08e-15	Glioblastoma;
LIHC	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg15654264	chr1:150340011	RPRD2	0.51	8.34	0.41	1.89e-15	Migraine;
LIHC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.74	12.08	0.55	3.32e-28	Oral cavity cancer;
LIHC	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.57	0.46	2.14e-19	Corneal astigmatism;
LIHC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.34	8.83	0.43	5.49e-17	Schizophrenia;
LIHC	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.54	-0.42	4.37e-16	Gut microbiome composition (summer);
LIHC	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.01	-0.51	2.46e-24	Coffee consumption (cups per day);
LIHC	cis	rs16828019	0.852	rs3904243	chr1:41574852	T/G	cg20697417	chr1:41786797	NA	0.32	6.12	0.31	2.52e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg14393609	chr7:65229607	NA	-0.38	-6.03	-0.31	4.36e-9	Aortic root size;
LIHC	cis	rs1559088	0.512	rs60197880	chr19:33562695	C/A	cg27124370	chr19:33622961	WDR88	0.44	5.83	0.3	1.29e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.93	-12.67	-0.57	2.02e-30	Post bronchodilator FEV1;
LIHC	trans	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg10756647	chr7:56101905	PSPH	1.11	13.27	0.58	1.06e-32	Diabetic kidney disease;
LIHC	trans	rs4714291	1.000	rs1100098	chr6:40026044	A/G	cg02267698	chr19:7991119	CTXN1	0.39	6.08	0.31	3.2e-9	Strep throat;
LIHC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.48	6.62	0.34	1.39e-10	Height;
LIHC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs1403694	1.000	rs1624230	chr3:186438935	A/C	cg12454167	chr3:186435060	KNG1	-0.27	-6.66	-0.34	1.12e-10	Blood protein levels;
LIHC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02985541	chr2:219472218	PLCD4	0.47	8.94	0.44	2.53e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1983891	1.000	rs913074	chr6:41538545	T/C	cg15051332	chr6:41514432	FOXP4	0.42	5.71	0.3	2.44e-8	Prostate cancer;
LIHC	trans	rs35333254	0.588	rs1501172	chr4:14438109	G/T	cg20299935	chr17:21795943	NA	-0.53	-6.22	-0.32	1.46e-9	Age-related hearing impairment;
LIHC	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.9	9.12	0.44	6.47e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs2629751	0.512	rs2723845	chr12:104446721	T/C	cg14987745	chr12:104360022	TDG	-0.69	-6.85	-0.35	3.51e-11	Hepatitis C induced liver fibrosis;
LIHC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.57	9.82	0.47	3.37e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10216189	1.000	rs7799970	chr7:5527714	G/C	cg05318486	chr7:5553423	FBXL18	-0.56	-8.26	-0.41	3.27e-15	Relative hand skill in reading disability;
LIHC	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.01e-22	Hypertriglyceridemia;
LIHC	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.7	-11.07	-0.51	1.48e-24	Blood pressure (smoking interaction);
LIHC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.42	-9.55	-0.46	2.49e-19	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	1.12	14.83	0.63	9.49e-39	Blood protein levels;
LIHC	cis	rs13161895	1.000	rs4700853	chr5:179473328	G/A	cg02702477	chr5:179499311	RNF130	0.8	11.17	0.52	6.67e-25	LDL cholesterol;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.55	-9.71	-0.46	7.63e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7945718	0.591	rs4489724	chr11:12684166	G/T	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.12	0.36	6.48e-12	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.34	6.78	0.34	5.26e-11	Renal cell carcinoma;
LIHC	trans	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg17830980	chr10:43048298	ZNF37B	0.42	7.91	0.39	3.5e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.53	8.26	0.41	3.23e-15	White matter hyperintensity burden;
LIHC	cis	rs11671005	0.656	rs11671092	chr19:59009109	T/C	cg25952890	chr19:58913133	NA	0.68	6.45	0.33	3.82e-10	Mean platelet volume;
LIHC	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.34	-6.65	-0.34	1.13e-10	DNA methylation (variation);
LIHC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	9.3	0.45	1.66e-18	Response to antipsychotic treatment;
LIHC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.63	-9.81	-0.47	3.39e-20	Corneal structure;
LIHC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.79	-11.91	-0.54	1.38e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.47	11.04	0.51	1.95e-24	Iron status biomarkers (transferrin levels);
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.13	0.55	2e-28	Prudent dietary pattern;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.54	-9.85	-0.47	2.65e-20	Paraoxonase activity;
LIHC	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.48	8.75	0.43	1e-16	Testicular germ cell tumor;
LIHC	trans	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.45	-6.36	-0.33	6.4e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.27	-13.88	-0.6	4.83e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.89e-13	Lymphocyte counts;
LIHC	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.26	-13.03	-0.58	9e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.53	8.07	0.4	1.18e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	1.02	7.42	0.37	9.45e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs12079745	0.590	rs3766088	chr1:169268692	A/T	cg09363564	chr1:169337483	NME7;BLZF1	0.7	6.51	0.33	2.61e-10	QT interval;
LIHC	cis	rs56146971	0.763	rs55950330	chr14:91872978	C/T	cg16433844	chr14:91963127	SMEK1	-0.5	-5.77	-0.3	1.74e-8	Alzheimer disease and age of onset;
LIHC	cis	rs61677309	1.000	rs1074457	chr11:118156117	A/T	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.08	-0.36	8.42e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.69	8.85	0.43	4.91e-17	Exhaled nitric oxide output;
LIHC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg01864069	chr14:103024347	NA	-0.46	-7.35	-0.37	1.5e-12	Platelet count;
LIHC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg25894440	chr7:65020034	NA	0.51	5.9	0.3	8.83e-9	Diabetic kidney disease;
LIHC	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.52	7.59	0.38	3.1400000000000003e-13	Schizophrenia;
LIHC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20135002	chr11:47629003	NA	-0.58	-10.1	-0.48	3.59e-21	Subjective well-being;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.51	-7.01	-0.35	1.31e-11	Menopause (age at onset);
LIHC	trans	rs13301469	0.831	rs12685989	chr9:3909039	C/T	cg10281478	chr7:95402528	DYNC1I1	-0.39	-6.16	-0.32	2.08e-9	Schizophrenia;
LIHC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg19680672	chr10:131412579	MGMT	-0.44	-6.85	-0.35	3.35e-11	Response to temozolomide;
LIHC	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.6	6.05	0.31	3.89e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-6.42	-0.33	4.55e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.93	-0.31	7.29e-9	Menarche (age at onset);
LIHC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.72	-10.17	-0.48	2.08e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs5753037	0.702	rs131301	chr22:30185889	A/T	cg01021169	chr22:30184971	ASCC2	-0.36	-6.93	-0.35	2.1e-11	Type 1 diabetes;
LIHC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.83	-0.35	3.85e-11	Schizophrenia;
LIHC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.56	9.16	0.44	4.94e-18	Body mass index;
LIHC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.9	0.3	8.79e-9	Bipolar disorder;
LIHC	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	5.86	0.3	1.1e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2412488	0.927	rs56998298	chr4:54248698	A/G	cg22241045	chr4:54363911	LNX1	-0.4	-6.48	-0.33	3.15e-10	DNA methylation (variation);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01059432	chr1:45279684	BTBD19	0.43	6.24	0.32	1.26e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.29	-0.32	9.88e-10	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg20607798	chr8:58055168	NA	0.5	6.12	0.31	2.55e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2292096	0.925	rs4554747	chr1:200698597	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-6.02	-0.31	4.41e-9	Epilepsy;
LIHC	cis	rs7258015	1.000	rs10408916	chr19:10447770	T/G	cg13981319	chr19:10446556	ICAM3	0.46	7.21	0.36	3.68e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.48	-5.98	-0.31	5.47e-9	Diastolic blood pressure;
LIHC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.79	-0.3	1.56e-8	Life satisfaction;
LIHC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.22	0.55	9.48e-29	Alzheimer's disease;
LIHC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg08847533	chr14:75593920	NEK9	-0.54	-8.58	-0.42	3.41e-16	IgG glycosylation;
LIHC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg00529422	chr1:16285251	ZBTB17	-0.34	-6.64	-0.34	1.25e-10	Systolic blood pressure;
LIHC	cis	rs57244997	0.725	rs73028496	chr6:162422243	A/G	cg17173639	chr6:162384350	PARK2	-0.53	-6.86	-0.35	3.26e-11	Mosquito bite size;
LIHC	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-8.77	-0.43	8.38e-17	Obesity-related traits;
LIHC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.91	0.3	8.47e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.09	-0.31	2.96e-9	Bipolar disorder;
LIHC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg21522988	chr12:29376872	FAR2	-0.28	-6.35	-0.32	6.82e-10	QT interval;
LIHC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg17420585	chr12:42539391	GXYLT1	-0.34	-5.72	-0.3	2.35e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.53	8.8	0.43	6.98e-17	Obesity-related traits;
LIHC	trans	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.34	-0.32	7.19e-10	Dental caries;
LIHC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.51	5.91	0.3	8.06e-9	Metabolite levels;
LIHC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.64	-7.9	-0.39	3.93e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.14	-26.59	-0.82	3.05e-85	Cognitive ability;
LIHC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.79	-0.5	1.5e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg23587288	chr2:27483067	SLC30A3	-0.32	-5.91	-0.3	8.32e-9	Blood metabolite levels;
LIHC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.73	0.43	1.14e-16	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09656405	chr15:69745057	RPLP1	0.46	6.93	0.35	2.09e-11	Pancreatic cancer;
LIHC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	7.79	0.39	7.86e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.66	-9.6	-0.46	1.74e-19	Coronary artery disease;
LIHC	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg00012203	chr2:219082015	ARPC2	0.76	10.74	0.5	2.16e-23	Colorectal cancer;
LIHC	cis	rs10411936	0.720	rs4808513	chr19:16580498	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	6.41	0.33	4.7e-10	White blood cell count;Multiple sclerosis;
LIHC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.16	-0.58	2.7e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.36	5.94	0.31	7.07e-9	Cystic fibrosis severity;
LIHC	cis	rs2637030	0.559	rs7728496	chr5:52867330	G/T	cg06476337	chr5:52856530	NDUFS4	-0.39	-6.26	-0.32	1.12e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg20933634	chr6:27740509	NA	0.45	5.94	0.31	6.83e-9	Parkinson's disease;
LIHC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.49	0.33	3.08e-10	Menarche (age at onset);
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg27432699	chr2:27873401	GPN1	-0.54	-7.84	-0.39	5.98e-14	Total body bone mineral density;
LIHC	trans	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg19676328	chr12:49525230	TUBA1B	-0.37	-6.08	-0.31	3.23e-9	Total cholesterol levels;
LIHC	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg06781209	chr11:61594997	FADS2	-0.72	-6.38	-0.33	5.92e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.13	0.52	9.01e-25	Coronary artery disease;
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg05527609	chr1:210001259	C1orf107	0.43	6.37	0.33	6e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.71	-0.38	1.35e-13	Type 2 diabetes;
LIHC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.37	6.02	0.31	4.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11243680	chr12:31881778	AMN1	-0.53	-6.61	-0.34	1.51e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.45	6.64	0.34	1.2e-10	Schizophrenia;
LIHC	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.32	9.63e-10	Axial length;
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.0	15.26	0.64	1.86e-40	Skin colour saturation;
LIHC	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg12940439	chr1:67600707	NA	0.38	6.84	0.35	3.65e-11	Psoriasis;
LIHC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg16586182	chr3:47516702	SCAP	-0.49	-8.91	-0.43	3.15e-17	Colorectal cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14929913	chr10:1147979	WDR37	0.41	6.04	0.31	3.96e-9	Longevity;
LIHC	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg22961513	chr11:14280813	SPON1	-0.39	-5.73	-0.3	2.22e-8	Mitochondrial DNA levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24419099	chr11:47270565	NR1H3;ACP2	0.46	7.04	0.36	1.09e-11	Cognitive function;
LIHC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg12046867	chr14:103022105	NA	-0.48	-6.84	-0.35	3.7e-11	Platelet count;
LIHC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.59	9.05	0.44	1.12e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg14773178	chr5:1868261	NA	0.27	7.05	0.36	1e-11	Cardiovascular disease risk factors;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19569686	chr19:1555141	MEX3D	0.44	6.25	0.32	1.21e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg05973401	chr12:123451056	ABCB9	0.41	6.02	0.31	4.4e-9	Platelet count;
LIHC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	7.36	0.37	1.41e-12	Menopause (age at onset);
LIHC	cis	rs2607426	0.681	rs2545760	chr19:41299824	G/A	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.51	-5.73	-0.3	2.15e-8	Blood protein levels;
LIHC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.06	-0.31	3.54e-9	Type 2 diabetes;
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26076054	chr5:421317	AHRR	0.27	5.99	0.31	5.35e-9	Cystic fibrosis severity;
LIHC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs2292096	1.000	rs72746858	chr1:200783153	T/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-5.92	-0.3	7.95e-9	Epilepsy;
LIHC	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.64	-0.38	2.22e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.86	-0.47	2.44e-20	Gut microbiome composition (summer);
LIHC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	15.21	0.64	2.77e-40	Platelet count;
LIHC	cis	rs11628318	0.515	rs7142819	chr14:103133385	A/G	cg12046867	chr14:103022105	NA	0.39	6.04	0.31	4.06e-9	Platelet count;
LIHC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.67	7.25	0.36	2.83e-12	Gut microbiome composition (summer);
LIHC	cis	rs34375054	0.752	rs35505608	chr12:125662252	G/T	cg25124228	chr12:125621409	AACS	-0.41	-6.67	-0.34	1.06e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs712039	0.652	rs67879888	chr17:35795312	A/G	cg16670864	chr17:35848621	DUSP14	0.34	5.91	0.3	8.19e-9	Tuberculosis;
LIHC	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.33	-12.81	-0.57	5.98e-31	Psoriasis vulgaris;
LIHC	cis	rs922107	0.967	rs6428556	chr1:90019581	C/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.77	-0.39	9.19e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg01843034	chr6:37503916	NA	-0.41	-6.4	-0.33	5.17e-10	Cognitive performance;
LIHC	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.68	0.5	3.74e-23	Colorectal cancer;
LIHC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.69	13.69	0.59	2.57e-34	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.68	8.74	0.43	1.03e-16	Initial pursuit acceleration;
LIHC	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg04317338	chr11:64019027	PLCB3	0.84	8.09	0.4	1.06e-14	Mean platelet volume;
LIHC	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.56	-10.12	-0.48	3.05e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02985541	chr2:219472218	PLCD4	0.44	7.26	0.37	2.69e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2421770	0.530	rs11033084	chr11:35367408	T/G	cg13971030	chr11:35366721	SLC1A2	-0.44	-7.44	-0.37	8.06e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.5	-7.49	-0.38	5.74e-13	Total body bone mineral density;
LIHC	trans	rs6073597	0.967	rs6124676	chr20:43647261	G/A	cg14213297	chr9:130870109	SLC25A25	-0.35	-6.22	-0.32	1.49e-9	Positive affect;
LIHC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs7937890	0.559	rs2575831	chr11:14486194	A/T	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.63	-12.14	-0.55	1.97e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.02	-0.31	4.5e-9	Mood instability;
LIHC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.04	0.4	1.5e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.63	10.44	0.49	2.55e-22	Alcohol dependence;
LIHC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.26	-16.85	-0.67	8.29e-47	Diabetic kidney disease;
LIHC	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg13482628	chr17:19912719	NA	0.4	6.68	0.34	9.93e-11	Schizophrenia;
LIHC	cis	rs8084351	0.501	rs11876419	chr18:50627202	G/C	cg24270629	chr18:50823537	DCC	0.42	6.43	0.33	4.18e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.62	-9.65	-0.46	1.18e-19	Smoking behavior;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg10081115	chr2:190686883	PMS1	0.45	6.13	0.31	2.43e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9649465	0.967	rs10487806	chr7:123314446	C/T	cg03229431	chr7:123269106	ASB15	0.37	8.04	0.4	1.52e-14	Migraine;
LIHC	cis	rs655641	1.000	rs2509608	chr11:85779297	T/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.01	-0.31	4.83e-9	Platelet count;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.76	0.5	1.88e-23	Lymphocyte counts;
LIHC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.38	5.97	0.31	5.92e-9	Menopause (age at onset);
LIHC	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.77	-0.34	5.48e-11	Metabolite levels;
LIHC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg20607798	chr8:58055168	NA	0.65	7.65	0.38	2.05e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1075232	1.000	rs67634762	chr15:31748055	G/T	cg01030201	chr15:31746330	NA	-0.86	-6.79	-0.34	5e-11	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.49	7.88	0.39	4.27e-14	Corneal astigmatism;
LIHC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.63	-10.37	-0.49	4.28e-22	Bipolar disorder;
LIHC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.58	-10.65	-0.5	4.57e-23	Itch intensity from mosquito bite;
LIHC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.6	8.88	0.43	3.98e-17	Height;
LIHC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.43e-16	Motion sickness;
LIHC	cis	rs7572733	0.555	rs1837495	chr2:198921201	A/G	cg10820045	chr2:198174542	NA	-0.41	-6.2	-0.32	1.65e-9	Dermatomyositis;
LIHC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9628987	0.569	rs3753275	chr1:8425900	T/C	cg20416874	chr1:8611966	RERE	0.5	6.05	0.31	3.71e-9	Breast cancer;
LIHC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.35	0.59	5.37e-33	Psoriasis;
LIHC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.31	-0.32	8.83e-10	Ulcerative colitis;
LIHC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.56	-0.38	3.7e-13	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07282944	chr12:48499338	SENP1;PFKM	0.5	7.09	0.36	7.76e-12	Pancreatic cancer;
LIHC	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.38	12.73	0.57	1.14e-30	Uric acid levels;
LIHC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.55	-0.46	2.51e-19	Total cholesterol levels;
LIHC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.35	6.45	0.33	3.83e-10	Aortic root size;
LIHC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-1.12	-11.66	-0.53	1.15e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs13113518	0.783	rs6843722	chr4:56331332	A/C	cg15358633	chr12:38710606	ALG10B	0.42	6.05	0.31	3.82e-9	Height;
LIHC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.4	5.97	0.31	6.01e-9	Gout;
LIHC	trans	rs494453	0.583	rs559981	chr1:112219338	C/T	cg13908074	chr2:149259371	MBD5	0.4	6.44	0.33	3.96e-10	Osteoporosis-related phenotypes;
LIHC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.15e-11	Height;
LIHC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg03037974	chr15:76606532	NA	0.74	14.5	0.62	1.85e-37	Blood metabolite levels;
LIHC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25833597	chr17:30823145	MYO1D	-0.55	-7.43	-0.37	8.96e-13	Schizophrenia;
LIHC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.71	-13.64	-0.59	4.1e-34	Body mass index;
LIHC	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	6.11	0.31	2.7e-9	Blood protein levels;
LIHC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg04517722	chr19:17905589	B3GNT3	0.46	7.07	0.36	8.85e-12	Tumor biomarkers;
LIHC	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.82	-0.3	1.34e-8	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7546668	1.000	rs12741552	chr1:15853276	T/C	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.44	6.21	0.32	1.51e-9	Asthma;
LIHC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.95	-0.51	4e-24	Hemoglobin concentration;
LIHC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.78	-8.56	-0.42	3.9e-16	Vitiligo;
LIHC	cis	rs4759375	1.000	rs12317103	chr12:123802814	T/C	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.06e-34	Gastritis;
LIHC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.59	-7.98	-0.4	2.3e-14	Sudden cardiac arrest;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19379625	chr4:71859087	DCK	0.42	6.31	0.32	8.6e-10	Pancreatic cancer;
LIHC	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.65	6.88	0.35	2.89e-11	Type 2 diabetes;
LIHC	cis	rs903552	0.736	rs2412008	chr15:102006841	C/T	cg00659931	chr15:102010125	PCSK6	-0.51	-6.84	-0.35	3.75e-11	Diabetic kidney disease;
LIHC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.89	18.51	0.71	1.68e-53	IgG glycosylation;
LIHC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg12365402	chr11:9010492	NRIP3	-0.3	-7.72	-0.39	1.27e-13	Hemoglobin concentration;
LIHC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.84	10.61	0.5	6.44e-23	Cognitive function;
LIHC	cis	rs7129220	0.660	rs61878632	chr11:10136032	A/C	cg01453529	chr11:10209919	SBF2	-0.39	-7.02	-0.35	1.22e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.56	10.93	0.51	4.67e-24	Coronary artery disease;
LIHC	cis	rs9902453	0.654	rs3794809	chr17:28531258	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.85	0.43	4.91e-17	Coffee consumption (cups per day);
LIHC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.03	0.44	1.29e-17	Bipolar disorder;
LIHC	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg14515779	chr1:101123966	NA	-0.59	-11.19	-0.52	5.38e-25	Monocyte count;
LIHC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.45	6.22	0.32	1.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.33	0.41	2.02e-15	Lung cancer in ever smokers;
LIHC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.54	7.55	0.38	3.92e-13	Pulse pressure;
LIHC	cis	rs797680	0.856	rs2031226	chr1:93786764	G/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.04	-0.31	3.95e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-8.37	-0.41	1.52e-15	Lymphocyte counts;
LIHC	trans	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg19894588	chr14:64061835	NA	-0.69	-10.03	-0.48	6.37e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs9590974	0.663	rs842408	chr13:47228097	T/A	cg04092803	chr13:47240378	LRCH1	0.26	5.74	0.3	2.14e-8	PR segment;
LIHC	cis	rs832187	0.666	rs2241823	chr3:63965093	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.47	-6.51	-0.33	2.73e-10	Schizophrenia;
LIHC	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.72	8.06	0.4	1.31e-14	Dental caries;
LIHC	cis	rs965469	1.000	rs6037556	chr20:3317890	G/C	cg25506879	chr20:3388711	C20orf194	-0.58	-7.06	-0.36	9.15e-12	IFN-related cytopenia;
LIHC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg21395723	chr22:39101663	GTPBP1	0.37	5.72	0.3	2.3e-8	Menopause (age at onset);
LIHC	cis	rs10847980	0.590	rs78462864	chr12:123365867	C/T	cg18912006	chr12:123335444	HIP1R	0.76	7.12	0.36	6.42e-12	Adiponectin levels;
LIHC	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.5	-9.97	-0.47	1.04e-20	Late-onset Alzheimer's disease;
LIHC	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.88	17.17	0.68	4.41e-48	Eosinophil percentage of white cells;
LIHC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.52	9.46	0.46	5.22e-19	Total body bone mineral density;
LIHC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg00601450	chr5:74908170	NA	-0.74	-9.64	-0.46	1.27e-19	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.45	6.29	0.32	9.72e-10	Obesity-related traits;
LIHC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.9	-0.3	8.61e-9	Ulcerative colitis;
LIHC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.65	11.75	0.54	5.2e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs77633900	0.772	rs2957607	chr15:76686527	A/G	cg21673338	chr15:77095150	SCAPER	0.53	5.92	0.3	7.98e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.56	8.15	0.4	6.96e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg03929089	chr4:120376271	NA	-0.4	-6.09	-0.31	3.02e-9	HDL cholesterol;
LIHC	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.49	6.86	0.35	3.3e-11	Obesity-related traits;
LIHC	cis	rs9473924	0.505	rs28360639	chr6:50783501	G/A	cg14470998	chr6:50812995	TFAP2B	0.98	10.74	0.5	2.24e-23	Body mass index;
LIHC	cis	rs10838687	0.736	rs7120158	chr11:47265194	G/C	cg25783544	chr11:47291846	MADD	0.46	5.89	0.3	9.29e-9	Proinsulin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16872847	chr19:39893195	NA	0.44	6.17	0.32	1.9e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.47e-18	Bipolar disorder;
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.53	-7.58	-0.38	3.37e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02359409	chr6:42947317	PEX6	-0.48	-6.83	-0.35	3.93e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9649465	1.000	rs2109723	chr7:123325339	A/G	cg03229431	chr7:123269106	ASB15	-0.38	-8.18	-0.4	5.61e-15	Migraine;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15378686	chr17:62492736	POLG2	0.47	6.23	0.32	1.38e-9	Pancreatic cancer;
LIHC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.48	-8.03	-0.4	1.58e-14	Lung cancer;
LIHC	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.77	8.22	0.41	4.14e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg03959625	chr15:84868606	LOC388152	0.42	5.87	0.3	1.05e-8	Schizophrenia;
LIHC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.74	10.86	0.51	8.1e-24	Corneal astigmatism;
LIHC	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg01864836	chr14:55583639	NA	-0.41	-7.45	-0.37	7.75e-13	Protein biomarker;
LIHC	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	9.55	0.46	2.59e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.21	6.52	0.33	2.47e-10	Motion sickness;
LIHC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	0.98	9.39	0.45	8.92e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-7.02	-0.35	1.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg24101359	chr6:42928495	GNMT	0.45	5.72	0.3	2.31e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.49	0.38	6e-13	Schizophrenia;
LIHC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.7	-11.19	-0.52	5.59e-25	Lung cancer in ever smokers;
LIHC	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.71	-0.3	2.41e-8	Resting heart rate;
LIHC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg25894440	chr7:65020034	NA	-0.51	-5.83	-0.3	1.26e-8	Diabetic kidney disease;
LIHC	cis	rs4908760	0.827	rs6692693	chr1:8707116	T/G	cg20416874	chr1:8611966	RERE	-0.64	-13.11	-0.58	4.36e-32	Vitiligo;
LIHC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg22842854	chr12:123319900	HIP1R	-0.64	-8.31	-0.41	2.28e-15	Schizophrenia;
LIHC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.55	8.84	0.43	5.25e-17	Bipolar disorder;
LIHC	cis	rs1165668	1.000	rs1165670	chr12:104318406	G/A	cg21863207	chr12:104234989	NT5DC3	0.4	6.36	0.33	6.43e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg25665528	chr16:2260870	C16orf79	-0.35	-6.02	-0.31	4.43e-9	Height;
LIHC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.38	6.01	0.31	4.86e-9	Menopause (age at onset);
LIHC	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.41	7.85	0.39	5.35e-14	Coronary artery disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15094104	chr5:133406808	NA	0.35	6.11	0.31	2.74e-9	Cognitive function;
LIHC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg25039879	chr17:56429692	SUPT4H1	0.74	8.14	0.4	7.56e-15	Cognitive test performance;
LIHC	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.42	-7.27	-0.37	2.49e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs9993613	1.000	rs28627296	chr4:73487092	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.37	-5.77	-0.3	1.79e-8	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg00343986	chr7:65444356	GUSB	-0.38	-5.71	-0.3	2.45e-8	Aortic root size;
LIHC	trans	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg23598604	chr1:99732472	LPPR4	-0.3	-6.23	-0.32	1.37e-9	Multiple myeloma;
LIHC	cis	rs3736485	0.966	rs8040080	chr15:51904459	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.97	-0.35	1.64e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.34	-6.23	-0.32	1.36e-9	Red blood cell count;
LIHC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21467203	chr3:49911342	NA	0.44	7.76	0.39	1.01e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7818688	0.697	rs3802192	chr8:95987471	C/T	cg16049864	chr8:95962084	TP53INP1	0.59	6.42	0.33	4.5e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.44	6.77	0.34	5.56e-11	Alzheimer's disease (survival time);
LIHC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.88	10.72	0.5	2.63e-23	Mean platelet volume;
LIHC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg03034668	chr16:1723424	CRAMP1L	-0.36	-6.41	-0.33	4.89e-10	Coronary artery disease;
LIHC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.52	-9.07	-0.44	9.52e-18	Height;
LIHC	trans	rs6901152	0.525	rs4896651	chr6:143691393	A/G	cg25622597	chr3:49449489	RHOA;TCTA	-0.43	-6.59	-0.34	1.65e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.53	8.58	0.42	3.26e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg20194872	chr6:41519635	FOXP4	0.4	6.48	0.33	3.16e-10	Prostate cancer;
LIHC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.74	13.42	0.59	2.89e-33	Ewing sarcoma;
LIHC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-19.17	-0.72	3.84e-56	Coronary artery disease;
LIHC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg21361702	chr7:150065534	REPIN1	0.47	6.58	0.34	1.77e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg16822855	chr3:40428330	ENTPD3	0.34	6.23	0.32	1.34e-9	Renal cell carcinoma;
LIHC	trans	rs9641123	0.639	rs2677095	chr7:93251234	C/T	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-6.05	-0.31	3.78e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.31	-7.31	-0.37	1.86e-12	Corneal astigmatism;
LIHC	cis	rs860295	0.676	rs2666826	chr1:155658085	T/C	cg02153340	chr1:155202674	NA	-0.33	-6.1	-0.31	2.87e-9	Body mass index;
LIHC	cis	rs9543976	0.800	rs4885318	chr13:76151537	G/A	cg01531495	chr13:76123901	UCHL3	0.51	6.15	0.32	2.2e-9	Diabetic retinopathy;
LIHC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.61	-0.42	2.81e-16	Gut microbiome composition (summer);
LIHC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg04727924	chr7:799746	HEATR2	-0.63	-8.63	-0.42	2.42e-16	Cerebrospinal P-tau181p levels;
LIHC	trans	rs7874142	0.714	rs10776907	chr9:137692739	T/G	cg18109838	chr5:88185987	MEF2C	-0.36	-6.94	-0.35	2.01e-11	Longevity;
LIHC	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.99	-0.35	1.46e-11	Neutrophil percentage of white cells;
LIHC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.83	-16.32	-0.66	1.14e-44	Coronary artery disease;
LIHC	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	10.71	0.5	2.92e-23	Platelet count;
LIHC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.92	12.9	0.57	2.77e-31	Primary sclerosing cholangitis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg02760007	chr6:43139670	SRF	-0.44	-6.39	-0.33	5.35e-10	Systolic blood pressure;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.4	7.93	0.39	3.04e-14	Renal cell carcinoma;
LIHC	cis	rs11212260	0.655	rs74862732	chr11:107173483	T/G	cg25435332	chr11:107328525	CWF19L2	0.74	6.86	0.35	3.29e-11	IgG glycosylation;
LIHC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04727924	chr7:799746	HEATR2	-0.62	-8.52	-0.42	5.15e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.67	-14.14	-0.61	4.54e-36	Sense of smell;
LIHC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.81	0.5	1.27e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg10664184	chr19:17420304	DDA1	0.45	5.78	0.3	1.69e-8	Systemic lupus erythematosus;
LIHC	cis	rs11671005	0.735	rs3088284	chr19:58929427	G/A	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg00142150	chr22:38071001	LGALS1	0.7	11.28	0.52	2.75e-25	Fat distribution (HIV);
LIHC	cis	rs77633900	0.772	rs2469554	chr15:76642700	G/C	cg21673338	chr15:77095150	SCAPER	-0.53	-5.89	-0.3	9.09e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.74	0.3	2.08e-8	Coronary artery disease;
LIHC	cis	rs8010715	0.816	rs6573565	chr14:24594733	A/G	cg23112188	chr14:24563095	PCK2	0.28	5.78	0.3	1.69e-8	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.91	0.35	2.34e-11	Gut microbiome composition (summer);
LIHC	trans	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.6	0.34	1.61e-10	Coronary artery calcification;
LIHC	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg05623727	chr3:50126028	RBM5	0.35	5.88	0.3	9.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.43	7.89	0.39	4.07e-14	Schizophrenia;
LIHC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.61	10.15	0.48	2.49e-21	Platelet count;
LIHC	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	0.4	6.22	0.32	1.43e-9	Coronary artery disease;
LIHC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.55	9.13	0.44	6.21e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs965469	0.779	rs6037516	chr20:3233142	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-6.24	-0.32	1.3e-9	IFN-related cytopenia;
LIHC	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg00280220	chr17:61926910	NA	0.38	6.37	0.33	6.22e-10	Prudent dietary pattern;
LIHC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-6.64	-0.34	1.23e-10	Height;
LIHC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.46	-6.89	-0.35	2.69e-11	Coronary artery disease;
LIHC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.93	-0.43	2.59e-17	Total cholesterol levels;
LIHC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.34	0.58	5.79e-33	Cognitive test performance;
LIHC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.48	9.03	0.44	1.3e-17	Atrioventricular conduction;
LIHC	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg05425664	chr17:57184151	TRIM37	-0.47	-5.85	-0.3	1.18e-8	Vitamin D levels;
LIHC	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg02702477	chr5:179499311	RNF130	0.74	10.22	0.48	1.4e-21	LDL cholesterol;
LIHC	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.09e-27	Obesity-related traits;
LIHC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12501888	chr15:85177176	SCAND2	-0.49	-7.48	-0.38	6.14e-13	P wave terminal force;
LIHC	trans	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.75	-0.34	6.31e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.31	0.49	7.15e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.53	-7.64	-0.38	2.15e-13	Corneal structure;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-7.92	-0.39	3.38e-14	Total body bone mineral density;
LIHC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-11.77	-0.54	4.61e-27	Total cholesterol levels;
LIHC	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-6.28	-0.32	1.05e-9	Coronary artery disease;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.73	-12.03	-0.55	4.8e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg00792783	chr2:198669748	PLCL1	0.42	5.94	0.31	7.19e-9	Dermatomyositis;
LIHC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.62	6.18	0.32	1.78e-9	Hip geometry;
LIHC	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.41	0.33	4.86e-10	Ileal carcinoids;
LIHC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.26	-17.06	-0.68	1.18e-47	Diabetic kidney disease;
LIHC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg10628098	chr11:65292300	SCYL1	-0.38	-5.95	-0.31	6.47e-9	Bone mineral density;
LIHC	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.58	-8.7	-0.43	1.44e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.23	0.41	4.04e-15	Schizophrenia;
LIHC	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.43	6.04	0.31	4.01e-9	Longevity;Endometriosis;
LIHC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.64	6.83	0.35	3.97e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-8.95	-0.44	2.34e-17	Morning vs. evening chronotype;
LIHC	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg15282417	chr9:129245246	FAM125B	0.4	6.34	0.32	7.13e-10	Intraocular pressure;
LIHC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.61	-8.55	-0.42	4.09e-16	Blood metabolite levels;
LIHC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.5	0.42	5.79e-16	Birth weight;
LIHC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.63	11.51	0.53	4e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.65	13.83	0.6	7.52e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	10.12	0.48	3.21e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg21747090	chr2:27597821	SNX17	-0.43	-6.38	-0.33	5.6e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.11	10.2	0.48	1.72e-21	Diabetic retinopathy;
LIHC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02985541	chr2:219472218	PLCD4	-0.41	-6.65	-0.34	1.13e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg17279839	chr7:150038598	RARRES2	0.51	10.71	0.5	2.84e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.79	0.39	8.12e-14	Prudent dietary pattern;
LIHC	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg19680672	chr10:131412579	MGMT	-0.38	-5.71	-0.3	2.43e-8	Response to temozolomide;
LIHC	cis	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.56e-11	Atopic dermatitis;
LIHC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.57	9.8	0.47	3.69e-20	Colorectal cancer;
LIHC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	7.34	0.37	1.54e-12	Total body bone mineral density;
LIHC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg12292205	chr6:26970375	C6orf41	0.42	7.1	0.36	7.41e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.3e-16	Motion sickness;
LIHC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg14709524	chr16:89940631	TCF25	0.47	5.79	0.3	1.58e-8	Skin colour saturation;
LIHC	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.58	8.58	0.42	3.3e-16	Height;
LIHC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg05941027	chr17:61774174	LIMD2	0.38	7.98	0.4	2.31e-14	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.31	-0.45	1.63e-18	Type 2 diabetes;
LIHC	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg04455712	chr21:45112962	RRP1B	0.44	7.34	0.37	1.58e-12	Mean corpuscular volume;
LIHC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-6.36	-0.33	6.35e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs7707921	0.881	rs324910	chr5:81400264	A/C	cg15871215	chr5:81402204	ATG10	-0.63	-6.26	-0.32	1.12e-9	Breast cancer;
LIHC	cis	rs2580764	0.566	rs2968827	chr2:55297629	C/G	cg09592903	chr2:55203963	RTN4	0.62	11.46	0.53	5.95e-26	Mean platelet volume;
LIHC	cis	rs16828019	0.929	rs12037037	chr1:41698256	C/T	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.84e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	9.22	0.45	3.11e-18	Height;
LIHC	cis	rs6445975	0.715	rs3773006	chr3:58269539	C/T	cg23715586	chr3:58305044	RPP14	-0.38	-6.34	-0.32	7.22e-10	Systemic lupus erythematosus;
LIHC	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg09572067	chr16:29127029	RRN3P2	-0.56	-8.94	-0.44	2.52e-17	Menopause (age at onset);
LIHC	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.56	-8.64	-0.42	2.26e-16	Smoking behavior;
LIHC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.41	0.45	7.69e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.57	-8.93	-0.43	2.7e-17	Crohn's disease;
LIHC	cis	rs807029	0.533	rs735137	chr10:102735835	C/G	cg27255678	chr10:102756921	LZTS2	0.52	7.37	0.37	1.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs10202249	0.587	rs75553848	chr2:154068889	C/T	cg26927150	chr5:137523911	CDC23	0.39	6.04	0.31	4.03e-9	Conotruncal heart defects (inherited effects);
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21747090	chr2:27597821	SNX17	-0.39	-5.77	-0.3	1.79e-8	Total body bone mineral density;
LIHC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.93	0.31	7.39e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs526821	0.595	rs485555	chr11:55323570	A/G	cg15704280	chr7:45808275	SEPT13	0.51	7.72	0.39	1.32e-13	Pediatric bone mineral density (spine);
LIHC	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.59	7.7	0.38	1.46e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs6945071	0.590	rs17322566	chr7:26108984	C/T	cg16105687	chr19:22805801	NA	0.56	6.27	0.32	1.08e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	1.02	19.7	0.73	2.9e-58	Breast cancer;
LIHC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg14709524	chr16:89940631	TCF25	0.47	5.74	0.3	2.05e-8	Skin colour saturation;
LIHC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.16	-0.52	6.99e-25	Hemoglobin concentration;
LIHC	cis	rs12980942	0.872	rs7257583	chr19:41788117	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.3	0.32	9.22e-10	Coronary artery disease;
LIHC	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.19	-12.33	-0.55	3.78e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06634786	chr22:41940651	POLR3H	-0.54	-6.2	-0.32	1.61e-9	Neuroticism;
LIHC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.03e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.78	-0.39	8.73e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12960505	0.506	rs2134296	chr18:50999730	G/A	cg24270629	chr18:50823537	DCC	-0.48	-6.7	-0.34	8.65e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.85	16.34	0.66	9.49e-45	Multiple myeloma (IgH translocation);
LIHC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg18912006	chr12:123335444	HIP1R	-0.6	-7.27	-0.37	2.39e-12	Schizophrenia;
LIHC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs7220401	0.521	rs2278217	chr17:27904617	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	7.31	0.37	1.86e-12	Coronary artery disease;
LIHC	cis	rs12744310	1.000	rs7553908	chr1:41768241	G/T	cg03962019	chr1:41807865	NA	0.4	6.49	0.33	3.01e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-7.53	-0.38	4.48e-13	Initial pursuit acceleration;
LIHC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.36	9.05	0.44	1.06e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.59	8.84	0.43	5.05e-17	Platelet count;
LIHC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.63	-0.38	2.34e-13	Bipolar disorder;
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.69	10.52	0.49	1.28e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg04727924	chr7:799746	HEATR2	-0.58	-7.91	-0.39	3.67e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	9.39	0.45	8.92e-19	Multiple sclerosis;
LIHC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.54	-0.33	2.28e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7238033	0.624	rs4316845	chr18:43309135	G/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.64	11.61	0.53	1.67e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg16724585	chr3:197361211	NA	-0.47	-6.25	-0.32	1.21e-9	Pancreatic cancer;
LIHC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg14078730	chr11:63896557	MACROD1	-0.37	-5.82	-0.3	1.34e-8	Mean platelet volume;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02290350	chr8:58132656	NA	0.5	10.51	0.49	1.39e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.55	8.44	0.42	8.87e-16	Longevity;Endometriosis;
LIHC	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.34e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg00277334	chr10:82204260	NA	-0.49	-5.99	-0.31	5.29e-9	Post bronchodilator FEV1;
LIHC	cis	rs61440199	0.818	rs73818816	chr3:20148316	C/G	cg00235661	chr3:20228976	SGOL1	-0.4	-5.73	-0.3	2.25e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.73	-0.3	2.21e-8	Monocyte percentage of white cells;
LIHC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg08694578	chr2:241835147	C2orf54	-0.49	-6.76	-0.34	5.92e-11	Urinary metabolites;
LIHC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-10.74	-0.5	2.21e-23	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13190986	chr12:133263482	PXMP2;POLE	-0.57	-7.88	-0.39	4.42e-14	Pancreatic cancer;
LIHC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.59	8.37	0.41	1.46e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.71	-8.75	-0.43	1.02e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.08	9.8	0.47	3.72e-20	Diabetic retinopathy;
LIHC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.44	6.1	0.31	2.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.51	7.2	0.36	3.97e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg07541023	chr7:19748670	TWISTNB	0.42	6.28	0.32	1.03e-9	Thyroid stimulating hormone;
LIHC	cis	rs12079745	0.793	rs10919110	chr1:169214293	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.75	-6.99	-0.35	1.44e-11	QT interval;
LIHC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-9.97	-0.47	1.01e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg13393036	chr8:95962371	TP53INP1	-0.3	-6.02	-0.31	4.42e-9	Type 2 diabetes;
LIHC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	10.62	0.5	5.7e-23	Platelet count;
LIHC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.39	5.96	0.31	6.29e-9	Height;
LIHC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.18	0.4	5.61e-15	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11645453	chr3:52864694	ITIH4	-0.22	-5.71	-0.3	2.46e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9596863	1.000	rs9596860	chr13:54431215	G/A	ch.13.53330881F	chr13:54432880	NA	0.46	6.2	0.32	1.66e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.65	-9.85	-0.47	2.68e-20	Subjective well-being;
LIHC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg12373951	chr3:133503437	NA	0.5	8.26	0.41	3.34e-15	Iron status biomarkers;
LIHC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-13.3	-0.58	7.92e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10861342	0.892	rs77497436	chr12:105636896	C/G	cg23923672	chr12:105501055	KIAA1033	0.62	6.99	0.35	1.49e-11	IgG glycosylation;
LIHC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.29	0.32	9.8e-10	Tonsillectomy;
LIHC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.79	0.47	4.2e-20	Morning vs. evening chronotype;
LIHC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.78e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-8.08	-0.4	1.12e-14	Exhaled nitric oxide output;
LIHC	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.03	-0.31	4.14e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.8	9.75	0.47	5.54e-20	Cognitive function;
LIHC	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.23e-11	Prudent dietary pattern;
LIHC	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.31	5.86	0.3	1.08e-8	Red blood cell count;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-8.34	-0.41	1.89e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-0.85	-9.33	-0.45	1.41e-18	Magnesium levels;
LIHC	trans	rs6489882	0.867	rs7305035	chr12:113365803	T/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg17135325	chr3:160939158	NMD3	0.55	7.76	0.39	1.01e-13	Parkinson's disease;
LIHC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.95	11.14	0.52	8.8e-25	Triglycerides;
LIHC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.38	-8.93	-0.43	2.6e-17	Type 2 diabetes;
LIHC	cis	rs6738485	0.561	rs7590731	chr2:106810233	C/A	cg15412446	chr2:106886593	NA	0.39	6.02	0.31	4.62e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13446153	chr8:41435704	AGPAT6	-0.39	-6.08	-0.31	3.19e-9	Pancreatic cancer;
LIHC	cis	rs9443189	0.813	rs3798439	chr6:76566734	T/G	cg01950844	chr6:76311363	SENP6	-0.53	-6.79	-0.34	4.88e-11	Prostate cancer;
LIHC	cis	rs7129220	0.557	rs61878580	chr11:10080572	G/A	cg01453529	chr11:10209919	SBF2	-0.4	-7.0	-0.35	1.37e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25654301	chr17:73511699	TSEN54;CASKIN2	-0.42	-6.44	-0.33	4.09e-10	Cognitive function;
LIHC	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.35	7.97	0.4	2.43e-14	Educational attainment (years of education);
LIHC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.75	11.34	0.52	1.56e-25	Corneal astigmatism;
LIHC	cis	rs7635838	0.892	rs66974661	chr3:11482729	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.73	0.34	7.15e-11	HDL cholesterol;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.76	11.72	0.54	6.98e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.08	-0.36	8.36e-12	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27333517	chr8:92083018	OTUD6B	0.42	6.33	0.32	7.7e-10	Cognitive function;
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05590025	chr7:65112418	INTS4L2	0.45	6.75	0.34	6.33e-11	Calcium levels;
LIHC	cis	rs80282103	0.618	rs11819230	chr10:1128812	A/G	cg08668510	chr10:1095578	IDI1	0.68	6.62	0.34	1.41e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22828804	chr20:3140466	UBOX5;FASTKD5	-0.38	-6.06	-0.31	3.53e-9	Cognitive function;
LIHC	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.62	-6.13	-0.31	2.47e-9	Multiple sclerosis;
LIHC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-5.85	-0.3	1.14e-8	Aortic root size;
LIHC	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.47	-0.37	6.89e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs8117834	0.574	rs73076232	chr20:8081611	C/A	cg00593689	chr4:53575888	NA	0.37	6.28	0.32	1.02e-9	Chronic kidney disease;
LIHC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.39	6.35	0.32	6.71e-10	Red blood cell count;
LIHC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.94	16.81	0.67	1.18e-46	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.95	-0.31	6.7e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.81	0.39	7.06e-14	Lymphocyte counts;
LIHC	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg27205649	chr11:78285834	NARS2	-0.37	-5.86	-0.3	1.11e-8	Alzheimer's disease (survival time);
LIHC	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.96	-0.35	1.75e-11	Personality dimensions;
LIHC	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.53	7.16	0.36	4.87e-12	Proinsulin levels;
LIHC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.44	-6.74	-0.34	6.81e-11	Height;
LIHC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	1.02e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	trans	rs11264799	0.598	rs79853736	chr1:157732091	A/C	cg08109850	chr2:219773886	NA	-0.42	-6.05	-0.31	3.9e-9	IgA nephropathy;
LIHC	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.76	9.4	0.45	7.94e-19	Blood protein levels;
LIHC	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.92	-0.31	7.64e-9	Response to antipsychotic treatment;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03647581	chr2:242660564	ING5	-0.42	-6.04	-0.31	4.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.9	14.1	0.61	6.38e-36	Metabolic syndrome;
LIHC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg21747090	chr2:27597821	SNX17	-0.4	-5.82	-0.3	1.34e-8	Total body bone mineral density;
LIHC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.6	10.03	0.48	6.19e-21	Blood protein levels;
LIHC	cis	rs17021463	0.676	rs11097421	chr4:95302915	T/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.08	0.36	8.49e-12	Testicular germ cell tumor;
LIHC	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.71	-0.34	8.07e-11	Blood pressure;
LIHC	cis	rs7091068	0.522	rs10882322	chr10:95483273	C/G	cg20715218	chr10:95462985	C10orf4	0.52	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LIHC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg13647721	chr17:30228624	UTP6	0.8	7.65	0.38	2.07e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.47	7.09	0.36	7.77e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.8	8.53	0.42	4.83e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1983891	1.000	rs9381080	chr6:41527698	G/C	cg20194872	chr6:41519635	FOXP4	0.43	6.81	0.35	4.32e-11	Prostate cancer;
LIHC	cis	rs11871801	0.918	rs2006141	chr17:40679718	C/T	cg14558262	chr17:40713999	COASY	-0.52	-7.15	-0.36	5.23e-12	Crohn's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06522697	chr10:121356224	TIAL1	0.4	6.09	0.31	2.99e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs300890	0.520	rs713140	chr4:144317867	A/G	cg21939631	chr18:11821960	GNAL	-0.36	-6.27	-0.32	1.09e-9	Nasopharyngeal carcinoma;
LIHC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.68	-10.84	-0.51	9.9899999999999993e-24	Intelligence (multi-trait analysis);
LIHC	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.45	6.34	0.32	7.26e-10	Smoking behavior;
LIHC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs2073300	1.000	rs6132620	chr20:23436654	A/G	cg12062639	chr20:23401060	NAPB	0.79	9.65	0.46	1.19e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.78	-14.79	-0.62	1.31e-38	Mortality in heart failure;
LIHC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg17279839	chr7:150038598	RARRES2	0.49	10.08	0.48	4.39e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	5.72	0.3	2.27e-8	Educational attainment;
LIHC	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-5.78	-0.3	1.71e-8	Total body bone mineral density (age 45-60);
LIHC	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.94	10.72	0.5	2.65e-23	Neuroticism;
LIHC	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg02811702	chr13:24901961	NA	0.25	6.42	0.33	4.48e-10	Obesity-related traits;
LIHC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg07061783	chr6:25882402	NA	-0.47	-5.78	-0.3	1.71e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	1.000	rs75399471	chr1:76339092	A/T	cg10523679	chr1:76189770	ACADM	0.45	6.01	0.31	4.88e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.45	7.02	0.36	1.17e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-6.89	-0.35	2.66e-11	IgG glycosylation;
LIHC	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.52	-10.83	-0.51	1.06e-23	Late-onset Alzheimer's disease;
LIHC	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg16070123	chr10:51489643	NA	0.37	5.9	0.3	8.68e-9	Prostate-specific antigen levels;
LIHC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg21649660	chr6:10995125	ELOVL2	-0.33	-6.23	-0.32	1.41e-9	Pain;
LIHC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.5	-6.34	-0.32	7.07e-10	Menarche (age at onset);
LIHC	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg11946769	chr3:48343235	NME6	-0.47	-6.22	-0.32	1.45e-9	Educational attainment (years of education);
LIHC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.03	-7.25	-0.36	2.89e-12	Body mass index;
LIHC	cis	rs8081395	0.801	rs2645479	chr17:57920532	A/G	cg02344993	chr17:57696989	CLTC	0.46	7.61	0.38	2.69e-13	White blood cell count;
LIHC	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.84	-0.3	1.23e-8	Resting heart rate;
LIHC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	1.06	22.62	0.77	6.65e-70	Breast cancer;
LIHC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.74	13.51	0.59	1.27e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.74	0.3	2.07e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg23043544	chr7:2124092	MAD1L1	-0.51	-8.22	-0.41	4.2e-15	Neuroticism;
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg10217327	chr6:118973057	C6orf204	0.64	6.22	0.32	1.48e-9	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05886006	chr1:161359784	NA	0.49	7.49	0.38	5.75e-13	Pancreatic cancer;
LIHC	cis	rs11671005	0.779	rs3794971	chr19:58985866	T/C	cg25952890	chr19:58913133	NA	0.72	7.38	0.37	1.17e-12	Mean platelet volume;
LIHC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.4	5.86	0.3	1.11e-8	Menarche (age at onset);
LIHC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.46	5.84	0.3	1.18e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2803122	0.502	rs1329731	chr9:19234908	C/T	cg13469590	chr9:19229767	NA	-0.37	-6.4	-0.33	5.05e-10	Pulse pressure;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01868382	chr3:182698721	DCUN1D1	0.4	6.17	0.32	1.91e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs6467710	0.744	rs28653652	chr7:137204683	A/T	cg04467748	chr15:79760772	KIAA1024	0.44	6.47	0.33	3.32e-10	AIDS progression;
LIHC	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg26138937	chr11:71823887	C11orf51	-1.31	-10.43	-0.49	2.7e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs5753037	0.702	rs140143	chr22:30173109	G/T	cg01021169	chr22:30184971	ASCC2	-0.35	-6.59	-0.34	1.69e-10	Type 1 diabetes;
LIHC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.54	-6.66	-0.34	1.09e-10	Menarche (age at onset);
LIHC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	7.12	0.36	6.56e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg10381502	chr11:71823885	C11orf51	-1.06	-9.3	-0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.47	6.23	0.32	1.41e-9	Pancreatic cancer;
LIHC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.47	-6.82	-0.35	4.17e-11	Corneal structure;
LIHC	cis	rs7487075	0.619	rs10880973	chr12:46853209	C/A	cg23829395	chr12:46796953	NA	0.33	5.82	0.3	1.33e-8	Itch intensity from mosquito bite;
LIHC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg26441486	chr22:50317300	CRELD2	0.35	6.33	0.32	7.65e-10	Schizophrenia;
LIHC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg10402321	chr1:26617780	UBXN11	-0.38	-5.8	-0.3	1.48e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs6448317	1.000	rs13105803	chr4:24940002	A/G	cg21108841	chr4:24914750	CCDC149	-0.47	-6.0	-0.31	5e-9	Heschl's gyrus morphology;
LIHC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.36	-0.37	1.39e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg02297831	chr4:17616191	MED28	0.43	6.83	0.35	3.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8062405	0.558	rs151228	chr16:28563026	A/G	cg00204512	chr16:28754710	NA	0.3	6.0	0.31	5.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.49	8.08	0.4	1.16e-14	Corneal astigmatism;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg23601095	chr6:26197514	HIST1H3D	0.55	5.83	0.3	1.27e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.42	7.48	0.37	6.3e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	5.99	0.31	5.39e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-1.03	-20.55	-0.74	1.15e-61	Breast cancer;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs35892873	0.959	rs9877710	chr3:126091223	A/G	cg15490784	chr3:126061950	KLF15	0.45	6.51	0.33	2.68e-10	Male-pattern baldness;
LIHC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.89	-8.94	-0.44	2.52e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.91	-11.35	-0.52	1.44e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02985541	chr2:219472218	PLCD4	0.36	6.31	0.32	8.61e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	16.08	0.66	1.01e-43	Electrocardiographic conduction measures;
LIHC	cis	rs818427	0.964	rs351767	chr5:112200098	A/G	cg07820702	chr5:112228657	REEP5	0.36	5.75	0.3	1.95e-8	Total body bone mineral density;
LIHC	cis	rs12980942	1.000	rs1865053	chr19:41814412	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.18	0.32	1.81e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.66	-7.61	-0.38	2.62e-13	Putamen volume;
LIHC	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.83	7.29	0.37	2.12e-12	Uric acid levels;
LIHC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.51	5.84	0.3	1.23e-8	Alzheimer's disease;
LIHC	cis	rs2073300	1.000	rs6036422	chr20:23456962	A/T	cg12062639	chr20:23401060	NAPB	0.77	9.63	0.46	1.36e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	10.88	0.51	7.15e-24	Myopia (pathological);
LIHC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.46	-6.01	-0.31	4.77e-9	Pancreatic cancer;
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg03721293	chr16:90014378	DEF8	0.42	7.0	0.35	1.33e-11	Skin colour saturation;
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg26338869	chr17:61819248	STRADA	0.53	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg10774155	chr7:65338427	VKORC1L1	0.44	6.49	0.33	3.05e-10	Calcium levels;
LIHC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.66	11.79	0.54	3.69e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs920590	1.000	rs920590	chr8:19651161	A/G	cg03894339	chr8:19674705	INTS10	0.42	6.25	0.32	1.22e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.35	0.8	1.14e-76	Prudent dietary pattern;
LIHC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.81	0.3	1.42e-8	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	7.51	0.38	5.27e-13	Renal cell carcinoma;
LIHC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.36	-6.45	-0.33	3.85e-10	Platelet distribution width;
LIHC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.87	0.43	4.28e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2380220	0.808	rs2613553	chr6:95916704	A/G	cg04719120	chr6:96025338	MANEA	-0.58	-6.24	-0.32	1.33e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.71	10.07	0.48	4.8e-21	Lymphocyte counts;
LIHC	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.45	-0.37	7.71e-13	Urate levels in overweight individuals;
LIHC	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.49	7.73	0.39	1.19e-13	HDL cholesterol;
LIHC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.8	-12.42	-0.56	1.75e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.44	7.21	0.36	3.56e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.46	6.02	0.31	4.61e-9	Primary sclerosing cholangitis;
LIHC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.52	-0.46	3.21e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs7487075	0.606	rs4768714	chr12:46814245	T/A	cg23829395	chr12:46796953	NA	0.35	6.26	0.32	1.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-0.96	-22.01	-0.77	1.75e-67	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16828019	0.929	rs35286837	chr1:41682998	T/G	cg03387723	chr1:41708464	SCMH1	-0.44	-7.23	-0.36	3.16e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg17372223	chr3:52568218	NT5DC2	0.36	5.97	0.31	5.98e-9	Bipolar disorder;
LIHC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.46	8.12	0.4	8.52e-15	N-glycan levels;
LIHC	cis	rs12960505	0.506	rs1910132	chr18:51000262	C/T	cg24270629	chr18:50823537	DCC	-0.43	-6.07	-0.31	3.34e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.6	9.92	0.47	1.47e-20	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.84	8.15	0.4	7.08e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	1.02	12.88	0.57	3.34e-31	Iron status biomarkers;
LIHC	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06636551	chr8:101224915	SPAG1	-0.47	-8.38	-0.41	1.35e-15	Atrioventricular conduction;
LIHC	cis	rs10426930	0.738	rs2620815	chr19:5051840	C/G	cg18473234	chr19:5097819	KDM4B	-0.49	-6.22	-0.32	1.45e-9	Monocyte percentage of white cells;
LIHC	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.66	13.29	0.58	9.02e-33	Leprosy;
LIHC	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.42	5.74	0.3	2.1e-8	Tuberculosis;
LIHC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.35	6.53	0.33	2.44e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.42	7.19	0.36	4.22e-12	Perceived unattractiveness to mosquitoes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11792281	chr17:26443366	NLK	-0.41	-6.12	-0.31	2.6e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.41	0.45	7.27e-19	IgG glycosylation;
LIHC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.16	0.52	7.26e-25	Personality dimensions;
LIHC	cis	rs847649	0.699	rs7794668	chr7:102510416	C/T	cg18108683	chr7:102477205	FBXL13	0.49	7.61	0.38	2.67e-13	Morning vs. evening chronotype;
LIHC	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs918629	0.530	rs13361837	chr5:95250478	T/G	cg10483112	chr5:95245456	ELL2	-0.39	-7.18	-0.36	4.42e-12	IgG glycosylation;
LIHC	cis	rs7119038	0.865	rs7951740	chr11:118740418	G/C	cg19308663	chr11:118741387	NA	-0.46	-6.04	-0.31	4.1e-9	Sjögren's syndrome;
LIHC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.79	0.3	1.6e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg12046867	chr14:103022105	NA	0.43	6.69	0.34	9.34e-11	Platelet count;
LIHC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.98	16.85	0.67	7.96e-47	Breast cancer;
LIHC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.59	-7.43	-0.37	9.04e-13	Longevity;
LIHC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg20991723	chr1:152506922	NA	0.59	10.62	0.5	5.87e-23	Hair morphology;
LIHC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.39	-5.87	-0.3	1.03e-8	P wave terminal force;
LIHC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.12	0.4	8.29e-15	Morning vs. evening chronotype;
LIHC	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs926937	0.843	rs5752577	chr22:27930781	A/G	cg19819135	chr1:70710422	SFRS11	-0.78	-6.12	-0.31	2.51e-9	Age-related cataracts;
LIHC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.61	8.86	0.43	4.39e-17	Emphysema distribution in smoking;
LIHC	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.65	0.34	1.16e-10	Mean corpuscular volume;
LIHC	cis	rs72843506	0.586	rs75836592	chr17:19838352	A/C	cg12065943	chr17:19881925	AKAP10	-0.39	-6.53	-0.33	2.32e-10	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08079518	chr17:73775869	H3F3B	0.49	7.1	0.36	7.13e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.53	-0.49	1.22e-22	Eye color traits;
LIHC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.16	0.4	6.26e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.1	0.4	9.89e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg08499158	chr17:42289980	UBTF	-0.5	-8.55	-0.42	4.12e-16	Total body bone mineral density;
LIHC	cis	rs2071426	0.652	rs11188127	chr10:96761891	A/G	cg09036531	chr10:96991505	NA	-0.51	-6.06	-0.31	3.62e-9	Blood metabolite levels;
LIHC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.99	17.46	0.69	2.81e-49	Tonsillectomy;
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg16970926	chr12:29381810	FAR2	0.31	6.58	0.34	1.79e-10	QT interval;
LIHC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.39	-0.49	3.83e-22	Platelet count;
LIHC	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg22705602	chr4:152727874	NA	0.28	5.78	0.3	1.65e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09695851	chr17:3907499	NA	0.59	7.82	0.39	6.68e-14	Type 2 diabetes;
LIHC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	7.96	0.4	2.53e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs77633900	0.772	rs283796	chr15:76774105	G/A	cg21673338	chr15:77095150	SCAPER	-0.52	-5.82	-0.3	1.33e-8	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg16586182	chr3:47516702	SCAP	0.57	10.5	0.49	1.53e-22	Colorectal cancer;
LIHC	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.83	11.05	0.51	1.8e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-8.67	-0.42	1.75e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.72	0.43	1.25e-16	Corneal astigmatism;
LIHC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	8.7	0.43	1.45e-16	Platelet count;
LIHC	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.29	6.09	0.31	3.1e-9	Pulmonary function;
LIHC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.64	-0.59	4.13e-34	Aortic root size;
LIHC	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.61	-8.14	-0.4	7.42e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.42	-0.41	1.04e-15	Lymphocyte counts;
LIHC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.51	6.61	0.34	1.5e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.92	-0.31	7.68e-9	Life satisfaction;
LIHC	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	7.0	0.35	1.33e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.31	-0.37	1.95e-12	Bipolar disorder;
LIHC	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16684958	chr7:75615977	POR	-0.5	-8.45	-0.42	8.7e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg05484376	chr2:27715224	FNDC4	0.39	6.65	0.34	1.14e-10	Total body bone mineral density;
LIHC	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs918629	0.761	rs3777165	chr5:95291425	A/G	cg10483112	chr5:95245456	ELL2	0.36	6.18	0.32	1.85e-9	IgG glycosylation;
LIHC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.65	9.16	0.44	5.03e-18	Schizophrenia;
LIHC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	7.18	0.36	4.41e-12	Coronary artery disease;
LIHC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.57	9.89	0.47	1.96e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.66	-10.62	-0.5	5.95e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.51	7.14	0.36	5.65e-12	Morning vs. evening chronotype;
LIHC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.85	-0.43	4.75e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9828933	0.832	rs3774723	chr3:63962339	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.75	-9.64	-0.46	1.32e-19	Type 2 diabetes;
LIHC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg25894440	chr7:65020034	NA	0.53	6.15	0.32	2.16e-9	Diabetic kidney disease;
LIHC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02290350	chr8:58132656	NA	0.37	8.07	0.4	1.22e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.5	-0.38	5.59e-13	Capecitabine sensitivity;
LIHC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.42	6.76	0.34	6.04e-11	Height;
LIHC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.49	-7.61	-0.38	2.64e-13	Breast size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15731816	chr14:75230414	YLPM1	0.39	6.39	0.33	5.5e-10	Pancreatic cancer;
LIHC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.19	-0.52	5.65e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.63	-9.37	-0.45	1.04e-18	Menarche (age at onset);
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.69	-0.34	9.07e-11	Total body bone mineral density;
LIHC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.66	0.42	1.89e-16	Motion sickness;
LIHC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg21522988	chr12:29376872	FAR2	0.26	5.83	0.3	1.29e-8	QT interval;
LIHC	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.76	-6.57	-0.33	1.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.22	-0.58	1.56e-32	Primary sclerosing cholangitis;
LIHC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.55	-8.64	-0.42	2.2e-16	Blood pressure (smoking interaction);
LIHC	trans	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.48	0.33	3.19e-10	Schizophrenia;
LIHC	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.46	0.46	5.21e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg05197062	chr11:11642011	GALNTL4	-0.42	-6.11	-0.31	2.73e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.02	0.31	4.5e-9	Renal cell carcinoma;
LIHC	cis	rs1494950	1.000	rs77326179	chr4:15024940	A/G	cg12377275	chr4:15005593	CPEB2	-0.85	-7.41	-0.37	9.71e-13	Political ideology;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-7.13	-0.36	6e-12	Total body bone mineral density;
LIHC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.53	7.46	0.37	7.18e-13	Prostate cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03332314	chr8:146278003	C8orf33	0.5	6.49	0.33	3.01e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.53	0.33	2.44e-10	Total body bone mineral density;
LIHC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg14092571	chr14:90743983	NA	-0.39	-6.21	-0.32	1.5e-9	Mortality in heart failure;
LIHC	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.67	10.48	0.49	1.76e-22	Obesity-related traits;
LIHC	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.14	-0.4	7.54e-15	Exhaled nitric oxide output;
LIHC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.8	0.5	1.4e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	1.02	16.69	0.67	3.68e-46	Diastolic blood pressure;Systolic blood pressure;
LIHC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs10411936	0.692	rs62118141	chr19:16602808	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.5	6.73	0.34	7.31e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg18306943	chr3:40428807	ENTPD3	-0.37	-6.5	-0.33	2.83e-10	Renal cell carcinoma;
LIHC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	0.97	9.55	0.46	2.5e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg13047869	chr3:10149882	C3orf24	0.5	6.43	0.33	4.4e-10	Alzheimer's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25236837	chr7:65959120	NA	-0.47	-6.21	-0.32	1.57e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.98	-0.35	1.51e-11	Electroencephalogram traits;
LIHC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.52	6.77	0.34	5.67e-11	Initial pursuit acceleration;
LIHC	cis	rs11786130	0.901	rs4733817	chr8:129005584	G/A	cg01765152	chr8:129005526	PVT1	-0.29	-6.28	-0.32	1.03e-9	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg22079354	chr11:130786696	SNX19	0.41	6.02	0.31	4.39e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21314978	chr2:96191015	NA	0.43	6.32	0.32	8.01e-10	Immature fraction of reticulocytes;
LIHC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.47	0.33	3.39e-10	Mean platelet volume;
LIHC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.9	-19.03	-0.72	1.35e-55	IgG glycosylation;
LIHC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.42	6.92	0.35	2.31e-11	Monocyte count;
LIHC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.33	5.92	0.31	7.7e-9	Aortic root size;
LIHC	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.57	-8.32	-0.41	2.14e-15	Body mass index;
LIHC	cis	rs11605275	1.000	rs11605704	chr11:20032096	A/G	cg14835545	chr11:20032148	NAV2	0.8	7.41	0.37	1.02e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg23625390	chr15:77176239	SCAPER	0.42	6.98	0.35	1.54e-11	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	0.58	8.58	0.42	3.28e-16	Prudent dietary pattern;
LIHC	cis	rs28489187	0.706	rs3087894	chr1:85787118	G/C	cg16011679	chr1:85725395	C1orf52	0.48	6.14	0.31	2.35e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	11.35	0.52	1.54e-25	Coronary artery disease;
LIHC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.32	-0.41	2.16e-15	Body mass index;
LIHC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg25281562	chr12:121454272	C12orf43	0.36	6.17	0.32	1.91e-9	N-glycan levels;
LIHC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	12.46	0.56	1.21e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.81	0.35	4.49e-11	Dupuytren's disease;
LIHC	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16684958	chr7:75615977	POR	-0.49	-8.3	-0.41	2.38e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.55	6.9	0.35	2.5e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.53	-8.64	-0.42	2.17e-16	Body mass index;
LIHC	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.55	0.46	2.51e-19	Corneal astigmatism;
LIHC	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	8.18	0.4	5.59e-15	Diastolic blood pressure;
LIHC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7432375	0.901	rs35874192	chr3:136470004	G/C	cg21827317	chr3:136751795	NA	-0.44	-5.75	-0.3	2.01e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.42	5.83	0.3	1.27e-8	Tonsillectomy;
LIHC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.53	6.34	0.32	7.3e-10	Morning vs. evening chronotype;
LIHC	cis	rs1075232	0.826	rs4779556	chr15:32173245	T/C	cg01030201	chr15:31746330	NA	0.78	6.22	0.32	1.42e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	9.04	0.44	1.16e-17	Motion sickness;
LIHC	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg02569219	chr17:2266849	SGSM2	0.42	6.41	0.33	4.97e-10	Proinsulin levels;
LIHC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21211367	chr2:162094118	NA	0.37	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-8.53	-0.42	4.85e-16	Lymphocyte counts;
LIHC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg03647239	chr10:116582469	FAM160B1	0.46	6.77	0.34	5.47e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg03959625	chr15:84868606	LOC388152	-0.48	-6.96	-0.35	1.71e-11	Schizophrenia;
LIHC	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.7	-10.57	-0.5	8.56e-23	Schizophrenia (inflammation and infection response interaction);
LIHC	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.85	0.47	2.67e-20	Corneal astigmatism;
LIHC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.89	-18.22	-0.7	2.49e-52	Height;
LIHC	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg12698662	chr3:15914712	MIR563	-0.39	-7.44	-0.37	8.16e-13	Mean platelet volume;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.73	-12.02	-0.54	5.37e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.86	-0.35	3.22e-11	Fear of minor pain;
LIHC	trans	rs4907240	0.883	rs11678174	chr2:97249103	T/C	cg26665480	chr2:98280029	ACTR1B	-0.41	-6.17	-0.32	1.88e-9	Event-related brain oscillations;
LIHC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.68	11.96	0.54	8.87e-28	High light scatter reticulocyte count;
LIHC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.57	-10.23	-0.48	1.3e-21	Platelet distribution width;
LIHC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.14e-9	Tonsillectomy;
LIHC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-9.58	-0.46	2.07e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.68	9.93	0.47	1.36e-20	Testicular germ cell tumor;
LIHC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-7.25	-0.36	2.84e-12	Schizophrenia;
LIHC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.53e-9	Childhood ear infection;
LIHC	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.75	-0.3	1.94e-8	Blood pressure;
LIHC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.59	6.71	0.34	8.15e-11	Neutrophil percentage of white cells;
LIHC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.57	7.87	0.39	4.59e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.55	-8.23	-0.41	3.96e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-6.69	-0.34	8.99e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.08	0.58	5.63e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-7.73	-0.39	1.17e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.42	6.48	0.33	3.25e-10	Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.44	0.33	4.01e-10	Prudent dietary pattern;
LIHC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.44	7.22	0.36	3.5e-12	Red blood cell count;
LIHC	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.55	-6.17	-0.32	1.96e-9	Ulcerative colitis;
LIHC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	8.12	0.4	8.8e-15	Nonalcoholic fatty liver disease;
LIHC	cis	rs6066825	0.644	rs2143563	chr20:47320211	A/G	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.59e-12	Colorectal cancer;
LIHC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-7.17	-0.36	4.71e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.6	7.9	0.39	3.93e-14	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs66569888	0.633	rs11124085	chr2:106758629	A/G	cg16099169	chr2:106886729	NA	-0.63	-6.76	-0.34	6.1e-11	Facial morphology (factor 23);
LIHC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.62	-10.1	-0.48	3.74e-21	Platelet count;
LIHC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.8	11.63	0.53	1.47e-26	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-0.94	-21.27	-0.75	1.48e-64	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.83	-13.26	-0.58	1.11e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg03037974	chr15:76606532	NA	-0.56	-9.16	-0.44	4.87e-18	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg15192750	chr16:69999425	NA	0.41	6.27	0.32	1.07e-9	IgE levels;
LIHC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.83	13.53	0.59	1.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.76	11.64	0.53	1.3e-26	Corneal astigmatism;
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04013166	chr16:89971882	TCF25	-0.56	-7.41	-0.37	9.73e-13	Skin colour saturation;
LIHC	cis	rs9328573	1.000	rs12903084	chr15:100510081	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.46	-6.79	-0.34	4.91e-11	Urate levels in lean individuals;
LIHC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.33	0.32	7.86e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.77	-0.5	1.69e-23	Chronic sinus infection;
LIHC	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.41	6.31	0.32	8.89e-10	Neuroticism;
LIHC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.83	-0.3	1.26e-8	Fibrinogen levels;
LIHC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	1.03	11.41	0.53	9.08e-26	Triglycerides;
LIHC	cis	rs2302190	0.882	rs7216856	chr17:56472295	C/T	cg05425664	chr17:57184151	TRIM37	-0.48	-5.94	-0.31	7.16e-9	Vitamin D levels;
LIHC	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14396892	chr9:96623032	NA	-0.33	-6.3	-0.32	9.35e-10	DNA methylation (variation);
LIHC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	1.05	13.8	0.6	9.26e-35	Red blood cell traits;
LIHC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3018712	0.532	rs2513281	chr11:68417094	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-5.79	-0.3	1.56e-8	Total body bone mineral density;
LIHC	cis	rs12702595	0.509	rs2108784	chr7:7266745	A/G	cg04827551	chr7:7268805	C1GALT1	-0.33	-6.15	-0.32	2.13e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-7.94	-0.39	3.03e-14	Lymphocyte counts;
LIHC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.5	7.86	0.39	5.12e-14	Pulse pressure;
LIHC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg14132834	chr19:41945861	ATP5SL	-0.45	-6.67	-0.34	1.06e-10	Height;
LIHC	cis	rs2061333	1.000	rs2061333	chr19:44614208	A/G	cg18700516	chr19:44507157	ZNF230	0.36	5.94	0.31	7.06e-9	Alzheimer's disease;
LIHC	cis	rs7619427	0.507	rs9311347	chr3:44011358	A/G	cg24966902	chr3:44043705	NA	-0.42	-6.53	-0.33	2.37e-10	Schizophrenia;
LIHC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg05941027	chr17:61774174	LIMD2	0.34	7.25	0.36	2.87e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg25039879	chr17:56429692	SUPT4H1	0.79	8.97	0.44	1.98e-17	Cognitive test performance;
LIHC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.57	-8.47	-0.42	7.53e-16	Height;
LIHC	cis	rs539514	0.690	rs1092601	chr13:76309746	C/T	cg04757411	chr13:76259545	LMO7	-0.44	-7.85	-0.39	5.28e-14	Type 1 diabetes;
LIHC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.65	-10.37	-0.49	4.18e-22	Metabolic syndrome;
LIHC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.09	0.4	1.02e-14	Lymphocyte counts;
LIHC	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.61	-10.39	-0.49	3.72e-22	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs35160687	0.644	rs17738058	chr2:86513203	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	5.85	0.3	1.18e-8	Night sleep phenotypes;
LIHC	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.51	7.98	0.4	2.21e-14	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937890	0.505	rs4403769	chr11:14450176	C/T	cg02886208	chr11:14281011	SPON1	-0.48	-6.76	-0.34	5.83e-11	Mitochondrial DNA levels;
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg00656387	chr3:40428638	ENTPD3	0.44	7.38	0.37	1.24e-12	Renal cell carcinoma;
LIHC	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg05340658	chr4:99064831	C4orf37	0.7	10.67	0.5	3.88e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg06627628	chr2:24431161	ITSN2	-0.64	-7.43	-0.37	8.75e-13	Lymphocyte counts;
LIHC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.81	13.13	0.58	3.65e-32	Cognitive test performance;
LIHC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.1	10.14	0.48	2.65e-21	Diabetic retinopathy;
LIHC	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-6.7	-0.34	8.65e-11	Endometrial cancer;
LIHC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs611744	0.806	rs374810	chr8:109096029	G/A	cg21045802	chr8:109455806	TTC35	0.52	9.0	0.44	1.55e-17	Dupuytren's disease;
LIHC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.63	11.52	0.53	3.73e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.49	-0.33	2.94e-10	Total body bone mineral density;
LIHC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg03983715	chr16:68378420	PRMT7	-0.53	-6.16	-0.32	1.99e-9	Magnesium levels;
LIHC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	1.01	19.45	0.72	2.8e-57	Breast cancer;
LIHC	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg08992911	chr2:238395768	MLPH	0.59	6.17	0.32	1.96e-9	Prostate cancer;
LIHC	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg26441486	chr22:50317300	CRELD2	0.34	5.91	0.3	8.35e-9	Schizophrenia;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.01	-0.4	1.84e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg16586182	chr3:47516702	SCAP	-0.5	-9.13	-0.44	6.17e-18	Colorectal cancer;
LIHC	cis	rs2574704	0.886	rs3856797	chr3:11630613	C/A	cg15876825	chr3:11651881	VGLL4	-0.48	-7.77	-0.39	9.17e-14	Body mass index;
LIHC	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.85	10.94	0.51	4.39e-24	Coronary artery disease;
LIHC	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.49	-0.33	2.97e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.46	0.33	3.52e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs800082	1.000	rs6440259	chr3:144286614	C/T	cg24215973	chr2:240111563	HDAC4	0.42	6.25	0.32	1.2e-9	Smoking behavior;
LIHC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg06289844	chr6:126071538	HEY2	0.33	5.74	0.3	2.13e-8	Brugada syndrome;
LIHC	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.35	0.45	1.18e-18	Morning vs. evening chronotype;
LIHC	cis	rs3812111	0.615	rs9488860	chr6:116495717	G/T	cg08036074	chr6:116424633	NT5DC1	-0.53	-8.8	-0.43	6.79e-17	Age-related macular degeneration;
LIHC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.4	6.54	0.33	2.26e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.69	11.66	0.53	1.08e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg03785755	chr6:26196794	NA	0.53	5.76	0.3	1.89e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg09594475	chr20:60884601	LAMA5	-0.53	-6.28	-0.32	1.03e-9	Colorectal cancer;
LIHC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.39	0.52	1.05e-25	Cognitive test performance;
LIHC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.89	-0.3	9.37e-9	Systemic lupus erythematosus;
LIHC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg03854865	chr6:26224070	HIST1H3E	0.63	6.97	0.35	1.59e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	0.95	9.89	0.47	1.96e-20	Vitiligo;
LIHC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-10.49	-0.49	1.69e-22	Vitiligo;
LIHC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-15.37	-0.64	6.6e-41	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.71	-0.54	7.04e-27	Total cholesterol levels;
LIHC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg15691649	chr6:25882328	NA	-0.53	-7.62	-0.38	2.55e-13	Blood metabolite levels;
LIHC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.41	5.87	0.3	1.05e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.45	-0.42	8.41e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg24209194	chr3:40518798	ZNF619	0.46	6.61	0.34	1.5e-10	Renal cell carcinoma;
LIHC	cis	rs9328573	1.000	rs8037666	chr15:100512079	C/T	cg09918751	chr15:100517450	ADAMTS17	0.5	7.93	0.39	3.07e-14	Urate levels in lean individuals;
LIHC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.44	6.96	0.35	1.72e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs11212260	0.573	rs12808887	chr11:107161907	C/T	cg25435332	chr11:107328525	CWF19L2	0.64	6.06	0.31	3.66e-9	IgG glycosylation;
LIHC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.38	-5.78	-0.3	1.67e-8	Schizophrenia;
LIHC	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.34	7.25	0.36	2.84e-12	Ulcerative colitis;
LIHC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.08	9.8	0.47	3.72e-20	Diabetic retinopathy;
LIHC	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg24579218	chr15:68104479	NA	-0.34	-5.73	-0.3	2.18e-8	Restless legs syndrome;
LIHC	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.34e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.78	12.75	0.57	9.63e-31	Anterior chamber depth;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.82	-0.3	1.36e-8	Subjective well-being;
LIHC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.2	-0.41	4.94e-15	Body mass index;
LIHC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.8	-14.14	-0.61	4.59e-36	Coronary artery disease;
LIHC	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.24	-0.45	2.77e-18	Ulcerative colitis;
LIHC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg06096015	chr1:231504339	EGLN1	0.47	8.57	0.42	3.57e-16	Hemoglobin concentration;
LIHC	trans	rs59551326	0.920	rs2829722	chr21:26760879	T/C	cg09399716	chr2:46890238	NA	-0.58	-6.31	-0.32	8.54e-10	Alcohol dependence;
LIHC	cis	rs11955398	0.716	rs10939860	chr5:59999360	C/T	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.54	-6.66	-0.34	1.09e-10	Menarche (age at onset);
LIHC	trans	rs7874142	0.616	rs3811158	chr9:137690877	A/G	cg18109838	chr5:88185987	MEF2C	-0.36	-7.12	-0.36	6.48e-12	Longevity;
LIHC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.33	-6.47	-0.33	3.38e-10	Colorectal cancer;
LIHC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.43	-9.24	-0.45	2.7e-18	Rheumatoid arthritis;
LIHC	cis	rs8192917	0.832	rs10873219	chr14:25101706	A/C	cg03875678	chr14:25103546	GZMB	-0.39	-6.48	-0.33	3.24e-10	Vitiligo;
LIHC	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-8.79	-0.43	7.39e-17	Type 1 diabetes;
LIHC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.48	-7.08	-0.36	8.46e-12	Coronary artery disease;
LIHC	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.75	-10.47	-0.49	1.89e-22	Response to hepatitis C treatment;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25187967	chr11:77024606	NA	0.42	6.08	0.31	3.18e-9	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.6e-18	Bipolar disorder;
LIHC	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.51e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.43	6.49	0.33	3.08e-10	Post bronchodilator FEV1;
LIHC	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.8	11.26	0.52	3.07e-25	Body mass index;
LIHC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.92	10.83	0.51	1.06e-23	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8017423	0.845	rs114583024	chr14:90727628	T/C	cg04374321	chr14:90722782	PSMC1	0.78	15.15	0.63	4.85e-40	Mortality in heart failure;
LIHC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08677398	chr8:58056175	NA	0.41	6.38	0.33	5.63e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.52	9.63	0.46	1.39e-19	Testicular germ cell tumor;
LIHC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.36	-5.9	-0.3	8.88e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg22633049	chr21:46681294	NA	-0.35	-6.3	-0.32	9.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	1.04	10.68	0.5	3.59e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.63e-13	Bone mineral density;
LIHC	cis	rs76533333	0.564	rs74344057	chr13:113420293	G/A	cg08557188	chr13:113420371	ATP11A	-0.8	-6.03	-0.31	4.23e-9	Red cell distribution width;
LIHC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.2	0.55	1.19e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.1	-0.4	9.51e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.93	-0.35	2.16e-11	Adiposity;
LIHC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.67	12.15	0.55	1.74e-28	Menopause (age at onset);
LIHC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.59	-0.38	3.09e-13	Glioblastoma;
LIHC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg10932868	chr11:921992	NA	0.39	7.31	0.37	1.89e-12	Alzheimer's disease (late onset);
LIHC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.55	-6.64	-0.34	1.25e-10	Breast cancer;
LIHC	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg24203234	chr3:128598194	ACAD9	-0.43	-5.91	-0.3	8.2e-9	IgG glycosylation;
LIHC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg06207120	chr15:45996521	NA	0.33	6.43	0.33	4.24e-10	Waist circumference;Weight;
LIHC	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.32	-0.32	7.99e-10	Coronary artery disease;
LIHC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	trans	rs6866721	0.791	rs7704624	chr5:116217105	A/T	cg07571379	chr11:134631427	NA	0.29	6.08	0.31	3.17e-9	Body mass index;
LIHC	cis	rs6137287	0.668	rs6082331	chr20:21108350	A/G	cg04219410	chr20:21106687	PLK1S1	0.33	5.78	0.3	1.64e-8	Height;
LIHC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.07	-0.31	3.35e-9	Bladder cancer;
LIHC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg25344623	chr2:136566232	LCT	0.4	8.18	0.4	5.76e-15	Mosquito bite size;
LIHC	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.59	-7.06	-0.36	9.25e-12	Blood metabolite levels;
LIHC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg19635926	chr16:89946313	TCF25	0.51	6.41	0.33	4.89e-10	Skin colour saturation;
LIHC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-7.51	-0.38	5.06e-13	Longevity;
LIHC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	7.36	0.37	1.4e-12	Alzheimer's disease;
LIHC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05771511	chr15:63340396	TPM1	0.46	6.87	0.35	3.02e-11	Platelet count;
LIHC	cis	rs6545883	0.894	rs778158	chr2:61555421	A/G	cg15711740	chr2:61764176	XPO1	0.42	5.76	0.3	1.84e-8	Tuberculosis;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21745873	chr7:4794773	FOXK1	0.41	6.12	0.31	2.6e-9	Bilirubin levels;
LIHC	trans	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg17675199	chr6:35436792	RPL10A	-0.44	-8.99	-0.44	1.76e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.46	0.46	5.15e-19	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.8	-12.07	-0.55	3.42e-28	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.58	-7.6	-0.38	2.92e-13	Initial pursuit acceleration;
LIHC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.48	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.46	6.5	0.33	2.91e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.35	5.88	0.3	9.9e-9	Type 2 diabetes;
LIHC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.61	-9.81	-0.47	3.56e-20	Crohn's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10334222	chr21:43430726	ZNF295	-0.5	-6.33	-0.32	7.59e-10	Systolic blood pressure;
LIHC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.49	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.22	-0.32	1.49e-9	Diastolic blood pressure;
LIHC	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.83	-12.68	-0.57	1.77e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-6.55	-0.33	2.07e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.52	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg15208524	chr1:10270712	KIF1B	0.45	6.64	0.34	1.2e-10	Hepatocellular carcinoma;
LIHC	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.22	-5.88	-0.3	9.86e-9	Hepatitis;
LIHC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.66	12.84	0.57	4.6e-31	Rheumatoid arthritis;
LIHC	cis	rs3770081	1.000	rs3770082	chr2:86280922	T/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.45	6.24	0.32	1.28e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07305463	chr2:136567211	LCT	-0.38	-5.81	-0.3	1.42e-8	Corneal structure;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.9	-0.35	2.48e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.49	7.16	0.36	5.01e-12	Prostate cancer;
LIHC	cis	rs655641	1.000	rs2155051	chr11:85713565	A/C	cg09030501	chr11:85779252	PICALM	-0.5	-6.09	-0.31	3.01e-9	Platelet count;
LIHC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.79	-0.5	1.51e-23	Mean corpuscular volume;
LIHC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.38	6.07	0.31	3.38e-9	Menopause (age at onset);
LIHC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg21395723	chr22:39101663	GTPBP1	0.37	6.28	0.32	1.06e-9	Menopause (age at onset);
LIHC	cis	rs11112613	0.653	rs2374533	chr12:106047891	A/G	cg03607813	chr12:105948248	NA	0.4	6.27	0.32	1.11e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg20283391	chr11:68216788	NA	-0.37	-5.87	-0.3	1.04e-8	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.4	-8.53	-0.42	4.7e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.13	-0.31	2.37e-9	Total body bone mineral density;
LIHC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.5	9.19	0.45	3.85e-18	Colorectal cancer;
LIHC	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.6	-6.41	-0.33	4.84e-10	Lung cancer;Squamous cell lung carcinoma;
LIHC	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.08	9.42	0.45	6.98e-19	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.39	-5.77	-0.3	1.81e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs832187	0.813	rs704370	chr3:63868250	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.48	6.82	0.35	4.07e-11	Schizophrenia;
LIHC	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg04610667	chr7:75704037	NA	-0.35	-6.31	-0.32	8.43e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.69	11.77	0.54	4.42e-27	Crohn's disease;
LIHC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.87	-0.3	1.03e-8	Prostate cancer;
LIHC	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg10820045	chr2:198174542	NA	0.48	7.55	0.38	4.04e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg16011800	chr17:1958478	HIC1	-0.53	-7.46	-0.37	7.15e-13	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg25204440	chr1:209979598	IRF6	-0.4	-5.93	-0.31	7.59e-9	Monobrow;
LIHC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-6.72	-0.34	7.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.82e-9	Ulcerative colitis;
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg18279126	chr7:2041391	MAD1L1	0.37	6.01	0.31	4.88e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.58	0.46	1.99e-19	Melanoma;
LIHC	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs12101261	0.556	rs2300516	chr14:81446908	A/G	cg06600135	chr14:81408086	NA	0.42	7.65	0.38	2.03e-13	Graves' disease;
LIHC	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg09795085	chr6:101329169	ASCC3	-0.53	-7.33	-0.37	1.65e-12	Neuroticism;
LIHC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg13628971	chr7:2884303	GNA12	0.37	5.73	0.3	2.26e-8	Height;
LIHC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.85	0.51	8.91e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.76	10.14	0.48	2.75e-21	Coronary artery disease;
LIHC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.36	0.33	6.49e-10	Obesity-related traits;
LIHC	cis	rs1419980	0.730	rs11054880	chr12:7772069	A/G	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg13409248	chr3:40428643	ENTPD3	-0.42	-7.08	-0.36	8.36e-12	Renal cell carcinoma;
LIHC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.79	11.3	0.52	2.31e-25	Cerebrospinal P-tau181p levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08616681	chr16:718778	RHOT2	0.42	6.07	0.31	3.43e-9	Pancreatic cancer;
LIHC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg22532475	chr10:104410764	TRIM8	0.36	6.34	0.32	7.18e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.7	11.18	0.52	6.05e-25	Neutrophil percentage of white cells;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg22705602	chr4:152727874	NA	0.33	6.96	0.35	1.75e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.06	0.36	9.23e-12	Hemoglobin concentration;
LIHC	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.54	7.91	0.39	3.63e-14	Blood protein levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg09192333	chr22:38142150	TRIOBP	-0.49	-6.1	-0.31	2.88e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg15595755	chr5:1867978	NA	0.33	6.12	0.31	2.58e-9	Cardiovascular disease risk factors;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.9	0.43	3.32e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg23791538	chr6:167370224	RNASET2	0.43	6.93	0.35	2.06e-11	Primary biliary cholangitis;
LIHC	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.33	8.26	0.41	3.33e-15	Gut microbiome composition (winter);
LIHC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg17279839	chr7:150038598	RARRES2	0.49	10.02	0.48	6.78e-21	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.51	7.75	0.39	1.08e-13	Corneal astigmatism;
LIHC	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg20578329	chr17:80767326	TBCD	-0.66	-6.66	-0.34	1.07e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.59	8.8	0.43	6.97e-17	Recombination rate (females);
LIHC	cis	rs903552	0.800	rs28470883	chr15:102000824	G/A	cg06707286	chr15:102010195	PCSK6	-0.44	-6.06	-0.31	3.54e-9	Diabetic kidney disease;
LIHC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.16	-0.32	2.1e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.34	22.76	0.78	1.85e-70	Corneal structure;
LIHC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.54	9.54	0.46	2.7e-19	Systemic lupus erythematosus;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08535411	chr7:151826219	NA	-0.46	-6.41	-0.33	4.78e-10	Lung function (FEV1/FVC);
LIHC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13395646	chr4:1353034	KIAA1530	0.64	9.07	0.44	9.45e-18	Obesity-related traits;
LIHC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg14067834	chr17:29058358	SUZ12P	0.62	6.38	0.33	5.64e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.38	5.98	0.31	5.68e-9	Migraine;
LIHC	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	12.04	0.55	4.45e-28	Eye color traits;
LIHC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.39	-7.08	-0.36	8.25e-12	Asthma;
LIHC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.63	-11.98	-0.54	7.74e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	1.01	11.64	0.53	1.36e-26	Red blood cell traits;
LIHC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg17724175	chr1:150552817	MCL1	-0.38	-7.65	-0.38	2.01e-13	Tonsillectomy;
LIHC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17554472	chr22:41940697	POLR3H	0.56	6.01	0.31	4.84e-9	Vitiligo;
LIHC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	5.91	0.3	8.36e-9	Resting heart rate;
LIHC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	13.95	0.6	2.42e-35	Cognitive test performance;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07991241	chr10:33269695	NA	0.4	6.79	0.34	4.95e-11	Cognitive function;
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg00800038	chr16:89945340	TCF25	-0.69	-10.65	-0.5	4.77e-23	Skin colour saturation;
LIHC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.79	-0.43	7.56e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-12.21	-0.55	1.04e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg07061783	chr6:25882402	NA	-0.47	-6.48	-0.33	3.29e-10	Blood metabolite levels;
LIHC	trans	rs75804782	0.641	rs59499060	chr2:239341411	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	6.97	0.35	1.59e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.58	-9.0	-0.44	1.59e-17	Breast size;
LIHC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.41	-7.98	-0.4	2.3e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs2292096	1.000	rs115714635	chr1:200786230	A/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-5.74	-0.3	2.06e-8	Epilepsy;
LIHC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.05	-0.31	3.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg19680672	chr10:131412579	MGMT	0.44	6.8	0.34	4.78e-11	Response to temozolomide;
LIHC	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.82	-0.35	4.04e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	1.03	13.28	0.58	9.93e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg07308232	chr7:1071921	C7orf50	-0.43	-6.64	-0.34	1.2e-10	Longevity;Endometriosis;
LIHC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg06640241	chr16:89574553	SPG7	0.65	10.55	0.5	1.04e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.85	-0.43	4.74e-17	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.23	-15.83	-0.65	9.88e-43	Diabetic kidney disease;
LIHC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg03859395	chr2:55845619	SMEK2	0.93	16.45	0.66	3.33e-45	Metabolic syndrome;
LIHC	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg15192750	chr16:69999425	NA	0.45	6.78	0.34	5.35e-11	IgE levels;
LIHC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.24	0.52	3.81e-25	Coronary artery disease;
LIHC	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06108461	chr20:60628389	TAF4	-0.52	-6.81	-0.35	4.29e-11	Body mass index;
LIHC	cis	rs3814244	0.515	rs3015002	chr12:68404633	A/C	cg15249341	chr12:68405565	NA	0.34	7.12	0.36	6.21e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.46	-0.46	5.21e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.67	13.31	0.58	7.33e-33	Leprosy;
LIHC	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.58	7.79	0.39	8.18e-14	Economic and political preferences (feminism/equality);
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.48	7.22	0.36	3.33e-12	Testicular germ cell tumor;
LIHC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg12046867	chr14:103022105	NA	-0.57	-8.43	-0.41	9.98e-16	Platelet count;
LIHC	trans	rs4322600	0.929	rs12885815	chr14:88286403	T/G	cg16008221	chr8:17823628	PCM1	-0.4	-6.1	-0.31	2.87e-9	Breast cancer;
LIHC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.69	-0.5	3.28e-23	Chronic sinus infection;
LIHC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.8e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.33	-18.17	-0.7	3.94e-52	Diabetic kidney disease;
LIHC	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.39	8.02	0.4	1.69e-14	Cardiovascular disease risk factors;
LIHC	cis	rs17106184	1.000	rs3789577	chr1:50954128	A/G	cg07174182	chr1:51127561	FAF1	0.66	7.45	0.37	7.92e-13	Type 2 diabetes;
LIHC	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg02376097	chr19:46275166	DMPK	-0.44	-6.82	-0.35	4.18e-11	Coronary artery disease;
LIHC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg03929089	chr4:120376271	NA	-0.45	-6.72	-0.34	7.46e-11	HDL cholesterol;
LIHC	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16684958	chr7:75615977	POR	0.52	8.65	0.42	2.08e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.48	7.85	0.39	5.36e-14	Diastolic blood pressure;
LIHC	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.62	8.97	0.44	2.01e-17	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.45	6.24	0.32	1.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.53	7.96	0.4	2.5e-14	Iron status biomarkers;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.05	-0.31	3.78e-9	Total body bone mineral density;
LIHC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.03	-0.31	4.34e-9	Total body bone mineral density;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg26338869	chr17:61819248	STRADA	0.53	7.17	0.36	4.67e-12	Height;
LIHC	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.54	0.46	2.84e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.23	-0.32	1.4e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21467203	chr3:49911342	NA	-0.61	-11.02	-0.51	2.35e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg11789530	chr4:8429930	ACOX3	-0.57	-7.98	-0.4	2.23e-14	Response to antineoplastic agents;
LIHC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg18404041	chr3:52824283	ITIH1	0.42	5.78	0.3	1.65e-8	Schizophrenia;
LIHC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs2758596	0.826	rs2758606	chr1:156201920	G/A	cg25208724	chr1:156163844	SLC25A44	0.75	7.83	0.39	6.12e-14	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs3823572	0.586	rs2971969	chr7:133656264	G/T	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.46	-6.08	-0.31	3.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.97	-0.57	1.45e-31	Primary sclerosing cholangitis;
LIHC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.34	-0.68	8.85e-49	Height;
LIHC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	8.25	0.41	3.56e-15	Testicular germ cell tumor;
LIHC	cis	rs11098699	0.800	rs302543	chr4:124205662	G/C	cg09941581	chr4:124220074	SPATA5	0.31	5.73	0.3	2.26e-8	Mosquito bite size;
LIHC	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg00564555	chr16:1970112	NA	-0.28	-5.84	-0.3	1.2e-8	Blood metabolite levels;
LIHC	trans	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg10756647	chr7:56101905	PSPH	-1.01	-12.51	-0.56	7.98e-30	Diabetic kidney disease;
LIHC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	1.01	19.71	0.73	2.59e-58	Breast cancer;
LIHC	cis	rs2336384	1.000	rs4846085	chr1:12050634	T/C	cg13216073	chr1:12042593	MFN2	0.38	5.73	0.3	2.2e-8	Platelet count;
LIHC	cis	rs7546668	0.744	rs1800615	chr1:15832281	C/T	cg11706911	chr1:15910989	AGMAT	0.44	6.89	0.35	2.76e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg13263691	chr18:77568018	NA	-0.23	-6.03	-0.31	4.23e-9	Schizophrenia;
LIHC	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg26138937	chr11:71823887	C11orf51	-1.28	-10.45	-0.49	2.31e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27654529	chr19:35418345	ZNF30	0.45	6.93	0.35	2.16e-11	Pancreatic cancer;
LIHC	cis	rs11125080	0.588	rs896211	chr2:46746682	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.64	-6.29	-0.32	9.45e-10	Anti-saccade response;Anti-saccade error rate in psychotic disorders;
LIHC	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.33	-5.93	-0.31	7.5e-9	Lewy body disease;
LIHC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg07713946	chr22:31675144	LIMK2	0.43	7.71	0.38	1.36e-13	Colorectal cancer;
LIHC	trans	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg10756647	chr7:56101905	PSPH	1.11	13.6	0.59	5.63e-34	Diabetic kidney disease;
LIHC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.53	7.08	0.36	8.07e-12	Morning vs. evening chronotype;
LIHC	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.45	0.49	2.25e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs3812111	0.774	rs534932	chr6:116425605	C/T	cg08036074	chr6:116424633	NT5DC1	-0.64	-11.3	-0.52	2.31e-25	Age-related macular degeneration;
LIHC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.66	0.38	1.9e-13	Schizophrenia;
LIHC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.25	5.81	0.3	1.39e-8	Childhood ear infection;
LIHC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.36	8.32	0.41	2.16e-15	Crohn's disease;
LIHC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.91	-16.09	-0.66	8.97e-44	Oral cavity cancer;
LIHC	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg18357526	chr6:26021779	HIST1H4A	0.41	6.2	0.32	1.62e-9	Height;
LIHC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.7	-10.63	-0.5	5.29e-23	Obesity-related traits;
LIHC	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg09911534	chr15:67153556	NA	-0.49	-6.0	-0.31	4.92e-9	Lung cancer (smoking interaction);
LIHC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.52	8.47	0.42	7.48e-16	Lung cancer;
LIHC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.77	9.87	0.47	2.18e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.04	0.31	4.05e-9	Personality dimensions;
LIHC	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.47	7.88	0.39	4.4e-14	Endometrial cancer;
LIHC	cis	rs6061231	0.916	rs58488796	chr20:60949050	G/C	cg03945807	chr20:60948434	NA	0.44	6.87	0.35	3.08e-11	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.57	0.33	1.85e-10	Renal cell carcinoma;
LIHC	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.45	-8.96	-0.44	2.12e-17	LDL cholesterol levels;
LIHC	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg04267008	chr7:1944627	MAD1L1	0.43	5.74	0.3	2.08e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.3	-0.55	4.7e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.58	8.89	0.43	3.51e-17	Noise-induced hearing loss;
LIHC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.32	-0.45	1.43e-18	Obesity (extreme);
LIHC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.72	10.74	0.5	2.22e-23	Body mass index;
LIHC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-11.11	-0.51	1.12e-24	Platelet count;
LIHC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.64	8.06	0.4	1.31e-14	Morning vs. evening chronotype;
LIHC	cis	rs6545883	0.525	rs2049747	chr2:61364154	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.89	0.3	9.23e-9	Tuberculosis;
LIHC	trans	rs2209875	0.921	rs752827	chr9:91799117	T/C	cg26057616	chr1:222234397	NA	0.38	6.36	0.33	6.46e-10	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24963443	chr5:180673122	NA	0.42	6.34	0.32	7.17e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg08469215	chr1:156261351	TMEM79	0.35	6.22	0.32	1.46e-9	Tonsillectomy;
LIHC	trans	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.47	-7.03	-0.36	1.13e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg13919466	chr1:32135498	COL16A1	-0.34	-6.5	-0.33	2.83e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2625529	0.824	rs7172309	chr15:72384483	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.87	-0.3	1.05e-8	Red blood cell count;
LIHC	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.63	6.65	0.34	1.19e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.68	0.59	2.85e-34	Lung cancer in ever smokers;
LIHC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg05501817	chr11:14380813	RRAS2	-0.44	-6.2	-0.32	1.67e-9	Sense of smell;
LIHC	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.5e-10	Asthma;
LIHC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.97	-0.31	5.98e-9	Life satisfaction;
LIHC	cis	rs244293	0.929	rs244371	chr17:53185225	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.48	7.52	0.38	4.96e-13	Breast cancer;
LIHC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.56	8.93	0.43	2.75e-17	Bipolar disorder;
LIHC	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg20634798	chr1:152595351	LCE3A	0.3	6.02	0.31	4.49e-9	Psoriasis;
LIHC	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-7.8	-0.39	7.82e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.33	-0.37	1.69e-12	Response to antipsychotic treatment;
LIHC	cis	rs10861342	0.892	rs77479670	chr12:105516631	C/T	cg23923672	chr12:105501055	KIAA1033	0.66	7.75	0.39	1.08e-13	IgG glycosylation;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg24693881	chr1:107596107	NA	-0.52	-9.28	-0.45	2.02e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.4	7.22	0.36	3.29e-12	QT interval;
LIHC	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.35	12.61	0.56	3.43e-30	Uric acid levels;
LIHC	cis	rs7523273	0.565	rs1998538	chr1:207886487	C/T	cg22525895	chr1:207977042	MIR29B2	-0.52	-7.72	-0.39	1.33e-13	Schizophrenia;
LIHC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	0.84	11.48	0.53	5.17e-26	Skin colour saturation;
LIHC	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.68	-11.67	-0.53	9.93e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.85	15.18	0.63	3.92e-40	Dental caries;
LIHC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.74	9.77	0.47	4.79e-20	Coronary artery disease;
LIHC	cis	rs6442522	0.737	rs905640	chr3:15495840	A/G	cg16303742	chr3:15540471	COLQ	0.37	6.21	0.32	1.51e-9	Uric acid levels;
LIHC	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	0.71	8.29	0.41	2.64e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.59	-8.23	-0.41	3.92e-15	Platelet count;
LIHC	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.31	0.32	8.89e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7937890	0.559	rs2575829	chr11:14485021	C/T	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.6	10.03	0.48	6.14e-21	HDL cholesterol;
LIHC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.92	10.9	0.51	6.06e-24	Platelet count;
LIHC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg18121669	chr1:26560928	CCDC21	0.48	7.67	0.38	1.77e-13	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00801568	chr15:66649150	TIPIN	0.43	6.56	0.33	1.99e-10	Calcium levels;
LIHC	cis	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg27432699	chr2:27873401	GPN1	0.46	6.84	0.35	3.7e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.54	10.47	0.49	1.88e-22	Mean corpuscular volume;
LIHC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg11861562	chr11:117069780	TAGLN	0.37	5.96	0.31	6.22e-9	Blood protein levels;
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.32	-0.45	1.5e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.56	-0.42	4.01e-16	Type 2 diabetes;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-6.76	-0.34	6.03e-11	Lymphocyte counts;
LIHC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg06742321	chr12:123595122	PITPNM2	0.31	5.85	0.3	1.14e-8	Platelet count;
LIHC	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.61	10.35	0.49	4.91e-22	Pediatric autoimmune diseases;
LIHC	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.47	-7.07	-0.36	8.68e-12	Dermatomyositis;
LIHC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.42	-0.37	9.1e-13	Response to antipsychotic treatment;
LIHC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.16	0.44	4.87e-18	Bipolar disorder;
LIHC	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23348161	chr2:240964931	NDUFA10	0.48	6.13	0.31	2.46e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4388979	0.595	rs11067292	chr12:109487822	G/A	cg03220751	chr12:109490328	USP30	0.6	9.38	0.45	9.36e-19	Plateletcrit;Platelet count;
LIHC	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.22	-6.79	-0.34	5.12e-11	Mean corpuscular volume;
LIHC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.38	6.02	0.31	4.6e-9	Colorectal cancer;
LIHC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06002616	chr8:101225028	SPAG1	-0.34	-5.81	-0.3	1.43e-8	Atrioventricular conduction;
LIHC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.3	-5.8	-0.3	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.43	-6.52	-0.33	2.51e-10	Asthma (sex interaction);
LIHC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg22961513	chr11:14280813	SPON1	0.48	7.52	0.38	4.81e-13	Mitochondrial DNA levels;
LIHC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.06	-0.48	5.1e-21	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.93e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.56	-0.33	2.01e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.48	7.56	0.38	3.7e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.76	-10.96	-0.51	3.61e-24	Pancreatic cancer;
LIHC	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	15.73	0.65	2.44e-42	Lung cancer in ever smokers;
LIHC	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg10587741	chr22:38071170	LGALS1	0.68	9.51	0.46	3.59e-19	Fat distribution (HIV);
LIHC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.44	7.32	0.37	1.75e-12	Bipolar disorder;
LIHC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg24209194	chr3:40518798	ZNF619	0.47	7.01	0.35	1.3e-11	Renal cell carcinoma;
LIHC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.41	-6.62	-0.34	1.38e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.5	-0.46	3.7e-19	Bipolar disorder;
LIHC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.45	-6.69	-0.34	9.28e-11	Asthma (sex interaction);
LIHC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.43	-0.33	4.27e-10	Type 2 diabetes;
LIHC	cis	rs2637266	0.714	rs4475870	chr10:78450724	T/A	cg18941641	chr10:78392320	NA	0.27	5.93	0.31	7.46e-9	Pulmonary function;
LIHC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs7238033	0.581	rs7229753	chr18:43312460	A/G	cg20610511	chr18:43302872	SLC14A1	0.38	6.33	0.32	7.48e-10	Bladder cancer;
LIHC	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.83	-10.21	-0.48	1.5e-21	Type 2 diabetes;
LIHC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	1.01	19.25	0.72	1.82e-56	Breast cancer;
LIHC	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-7.2	-0.36	3.85e-12	Mortality in heart failure;
LIHC	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.76	14.39	0.61	4.79e-37	Mortality in heart failure;
LIHC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.39	7.63	0.38	2.43e-13	Type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg00656387	chr3:40428638	ENTPD3	0.5	8.4	0.41	1.19e-15	Renal cell carcinoma;
LIHC	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg14222432	chr12:29376421	FAR2	-0.36	-7.04	-0.36	1.09e-11	QT interval;
LIHC	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg01364799	chr7:75623366	TMEM120A	-0.41	-6.12	-0.31	2.5e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.6	0.67	8.33e-46	Smoking behavior;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20743544	chr7:32982957	RP9P	0.4	6.08	0.31	3.14e-9	Cognitive function;
LIHC	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26734620	chr12:56694298	CS	1.23	10.54	0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16684958	chr7:75615977	POR	0.51	8.56	0.42	3.74e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.66	-9.83	-0.47	3.1e-20	Subjective well-being;
LIHC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17554472	chr22:41940697	POLR3H	-0.56	-6.08	-0.31	3.16e-9	Vitiligo;
LIHC	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.54	7.22	0.36	3.29e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.48	7.37	0.37	1.33e-12	Triglyceride levels;
LIHC	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06108461	chr20:60628389	TAF4	-0.51	-6.79	-0.34	4.87e-11	Body mass index;
LIHC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg22834771	chr12:69754056	YEATS4	-0.39	-5.91	-0.3	8.46e-9	Response to diuretic therapy;
LIHC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	1.01	16.7	0.67	3.3e-46	Diastolic blood pressure;Systolic blood pressure;
LIHC	trans	rs1814175	0.564	rs12416819	chr11:49755567	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.81	0.35	4.37e-11	Height;
LIHC	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.35	-6.99	-0.35	1.44e-11	DNA methylation (variation);
LIHC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.58	8.12	0.4	8.7e-15	Aortic root size;
LIHC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.5	7.65	0.38	2.03e-13	Longevity;Endometriosis;
LIHC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.45	7.12	0.36	6.52e-12	HDL cholesterol levels;
LIHC	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg13919466	chr1:32135498	COL16A1	-0.32	-6.16	-0.32	1.99e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg16394018	chr11:14927549	NA	0.4	5.72	0.3	2.27e-8	Vitamin D levels;
LIHC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg16736954	chr20:23401023	NAPB	0.7	8.15	0.4	6.87e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.27	-0.32	1.1e-9	Total body bone mineral density;
LIHC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.41	6.31	0.32	8.62e-10	Educational attainment;
LIHC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.4	-8.48	-0.42	6.68e-16	Obesity-related traits;
LIHC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.77	0.6	1.2e-34	Lung cancer in ever smokers;
LIHC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg15691649	chr6:25882328	NA	-0.53	-7.76	-0.39	1.01e-13	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.36	0.8	1.03e-76	Prudent dietary pattern;
LIHC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-7.17	-0.36	4.76e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg14784868	chr12:69753453	YEATS4	0.51	7.12	0.36	6.25e-12	Response to diuretic therapy;
LIHC	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.37	-6.58	-0.34	1.74e-10	Response to antipsychotic treatment;
LIHC	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg13713052	chr3:122102218	FAM162A;CCDC58	0.38	6.15	0.32	2.15e-9	Hippocampal sclerosis of aging;
LIHC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-9.19	-0.45	3.79e-18	Parkinson's disease;
LIHC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.14	-0.32	2.29e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.92	6.89	0.35	2.76e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg21724239	chr8:58056113	NA	0.46	6.02	0.31	4.47e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13500430	chr11:2965905	NAP1L4	0.41	6.13	0.31	2.36e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.74	10.9	0.51	6.12e-24	Corneal astigmatism;
LIHC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg09137382	chr11:130731461	NA	0.38	5.8	0.3	1.49e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2637266	0.714	rs6480835	chr10:78446863	T/C	cg18941641	chr10:78392320	NA	0.27	5.93	0.31	7.46e-9	Pulmonary function;
LIHC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-5.71	-0.3	2.4e-8	Schizophrenia;
LIHC	trans	rs6934970	1.000	rs12212976	chr6:113109747	C/T	cg19071452	chr2:152146944	NMI	-0.57	-6.19	-0.32	1.77e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.65	10.44	0.49	2.51e-22	Multiple myeloma (IgH translocation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06613666	chr12:46123163	ARID2;LOC400027	0.5	7.08	0.36	8.3e-12	Pancreatic cancer;
LIHC	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg08992911	chr2:238395768	MLPH	0.67	6.98	0.35	1.58e-11	Prostate cancer;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08989290	chr16:615782	NHLRC4	0.33	6.46	0.33	3.69e-10	Height;
LIHC	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg14593290	chr7:50529359	DDC	-0.61	-10.0	-0.48	7.79e-21	Malaria;
LIHC	cis	rs965469	0.947	rs965470	chr20:3381588	C/G	cg25506879	chr20:3388711	C20orf194	-0.56	-6.75	-0.34	6.38e-11	IFN-related cytopenia;
LIHC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.82	-0.35	4.24e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.46	7.64	0.38	2.24e-13	Platelet distribution width;
LIHC	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.45	-6.98	-0.35	1.55e-11	Type 2 diabetes;
LIHC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-6.93	-0.35	2.1e-11	Bipolar disorder;
LIHC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.8	11.88	0.54	1.7e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.79	0.3	1.56e-8	Height;
LIHC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.57	6.34	0.32	7.3e-10	Axial length;
LIHC	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.77	11.75	0.54	5.12e-27	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.68	5.89	0.3	9.32e-9	Blood protein levels;
LIHC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.62	9.48	0.46	4.3e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg06359132	chr10:99160096	RRP12	0.4	6.32	0.32	8.22e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.2	-0.32	1.6e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.75	-0.34	6.3e-11	Morning vs. evening chronotype;
LIHC	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24110177	chr3:50126178	RBM5	-0.45	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs660498	0.516	rs620664	chr10:27746471	C/T	cg07529754	chr2:50575098	NRXN1	0.4	6.25	0.32	1.21e-9	Asthma (childhood onset);
LIHC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg04013166	chr16:89971882	TCF25	0.5	6.13	0.31	2.39e-9	Skin colour saturation;
LIHC	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg13753209	chr17:57696993	CLTC	0.56	8.59	0.42	3.15e-16	Hemoglobin concentration;
LIHC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.6	9.4	0.45	8.36e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs11671005	0.693	rs11084542	chr19:58932099	T/A	cg25952890	chr19:58913133	NA	0.67	7.2	0.36	3.89e-12	Mean platelet volume;
LIHC	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.38e-12	Cognitive performance;
LIHC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.45	6.07	0.31	3.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.1	0.48	3.78e-21	Schizophrenia;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Life satisfaction;
LIHC	cis	rs57590327	0.679	rs17019030	chr3:81552062	C/T	cg07356753	chr3:81810745	GBE1	-0.45	-6.17	-0.32	1.9e-9	Extraversion;
LIHC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02244288	chr16:89573955	SPG7	-0.3	-5.8	-0.3	1.49e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-8.37	-0.41	1.53e-15	Longevity;Endometriosis;
LIHC	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg20636351	chr8:55087400	NA	-0.34	-7.09	-0.36	7.97e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7116495	1.000	rs520025	chr11:71562832	C/G	cg26138937	chr11:71823887	C11orf51	0.7	6.74	0.34	6.73e-11	Severe influenza A (H1N1) infection;
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg21298408	chr8:18027853	NAT1	0.28	6.28	0.32	1.04e-9	Neuroticism;
LIHC	cis	rs7945718	0.621	rs11022464	chr11:12685477	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.54	8.15	0.4	6.95e-15	Longevity;Endometriosis;
LIHC	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-0.67	-6.87	-0.35	3.04e-11	Coronary artery disease;
LIHC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.44	0.33	3.95e-10	Rheumatoid arthritis;
LIHC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs7116495	1.000	rs548127	chr11:71575294	C/G	cg26138937	chr11:71823887	C11orf51	-0.73	-7.23	-0.36	3.15e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.55	8.88	0.43	3.95e-17	Tonometry;
LIHC	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg23260525	chr10:116636907	FAM160B1	0.36	6.84	0.35	3.7e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1144333	0.655	rs12405994	chr1:76435420	A/T	cg22875332	chr1:76189707	ACADM	0.41	6.1	0.31	2.89e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg26138144	chr22:38071188	LGALS1	0.76	14.14	0.61	4.78e-36	Fat distribution (HIV);
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2574704	0.886	rs13078952	chr3:11630963	T/A	cg15876825	chr3:11651881	VGLL4	-0.47	-7.68	-0.38	1.66e-13	Body mass index;
LIHC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.84	0.35	3.77e-11	Lung cancer in ever smokers;
LIHC	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg21231739	chr4:1642635	FAM53A	-0.37	-5.94	-0.31	7e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.64	10.46	0.49	2.15e-22	Resting heart rate;
LIHC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg16226627	chr15:75307476	SCAMP5	0.54	9.74	0.47	5.98e-20	Lung cancer;
LIHC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.53	-8.28	-0.41	2.78e-15	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.45	0.42	8.36e-16	Motion sickness;
LIHC	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg19680672	chr10:131412579	MGMT	0.39	5.78	0.3	1.68e-8	Response to temozolomide;
LIHC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	11.04	0.51	1.93e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2257205	0.667	rs7342862	chr17:56816561	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.64	-0.34	1.21e-10	Pancreatic cancer;
LIHC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.58	7.81	0.39	6.88e-14	Blood metabolite levels;
LIHC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg14580859	chr9:123691850	NA	0.38	6.55	0.33	2.16e-10	Rheumatoid arthritis;
LIHC	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.71	-12.43	-0.56	1.56e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg13047869	chr3:10149882	C3orf24	0.5	6.08	0.31	3.23e-9	Alzheimer's disease;
LIHC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.82	-0.35	4.19e-11	Aortic root size;
LIHC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.18	0.52	5.97e-25	Motion sickness;
LIHC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.73	-7.68	-0.38	1.7e-13	Bipolar disorder;
LIHC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	10.44	0.49	2.4e-22	Lymphocyte percentage of white cells;
LIHC	cis	rs7106204	1.000	rs4622259	chr11:24215789	A/G	ch.11.24196551F	chr11:24239977	NA	0.68	6.83	0.35	3.89e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	cis	rs10924970	0.805	rs12030234	chr1:235517557	T/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.79	0.3	1.58e-8	Asthma;
LIHC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.12	0.52	1e-24	Personality dimensions;
LIHC	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.47	7.44	0.37	8.27e-13	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14751398	chr6:20402153	E2F3	0.47	6.68	0.34	9.97e-11	Pancreatic cancer;
LIHC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.36	6.92	0.35	2.24e-11	Multiple system atrophy;
LIHC	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.5	-8.24	-0.41	3.6e-15	Blood metabolite levels;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.58	-8.01	-0.4	1.8e-14	Menopause (age at onset);
LIHC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.49	0.53	4.8e-26	Tonsillectomy;
LIHC	trans	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg24637308	chr11:6592297	DNHD1	0.44	6.18	0.32	1.78e-9	Coronary artery calcification;
LIHC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.43	5.91	0.3	8.43e-9	Major depressive disorder;
LIHC	cis	rs11673344	0.832	rs8104296	chr19:37516536	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.24	-0.32	1.26e-9	Obesity-related traits;
LIHC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.68	8.84	0.43	5.02e-17	Calcium levels;
LIHC	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.71	10.94	0.51	4.47e-24	Monocyte count;
LIHC	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.82	-0.3	1.35e-8	Educational attainment (years of education);
LIHC	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg16684958	chr7:75615977	POR	0.49	8.07	0.4	1.17e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.0	-0.31	5.03e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.47	-6.75	-0.34	6.52e-11	Other erythrocyte phenotypes;
LIHC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.15	0.36	5.31e-12	Self-reported allergy;
LIHC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	7.0	0.35	1.37e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.58	8.74	0.43	1.06e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.44	6.79	0.34	4.83e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.28	-6.94	-0.35	1.96e-11	Primary biliary cholangitis;
LIHC	cis	rs2257205	0.667	rs7214805	chr17:56931895	C/G	cg05425664	chr17:57184151	TRIM37	-0.61	-6.67	-0.34	1.05e-10	Pancreatic cancer;
LIHC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	0.85	7.43	0.37	8.5e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.72	11.19	0.52	5.63e-25	Corneal astigmatism;
LIHC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.46	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.34	7.4	0.37	1.09e-12	Ulcerative colitis;
LIHC	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.46	-6.95	-0.35	1.81e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg26939375	chr7:64535504	NA	0.41	6.44	0.33	4.13e-10	Aortic root size;
LIHC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.6	8.1	0.4	9.87e-15	Coronary artery disease;
LIHC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	8.91	0.43	3.19e-17	Menarche (age at onset);
LIHC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-9.72	-0.47	7.03e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.16	-0.36	5.06e-12	Personality dimensions;
LIHC	cis	rs35160687	0.623	rs11127021	chr2:86474919	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	6.31	0.32	8.7e-10	Night sleep phenotypes;
LIHC	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	0.67	8.57	0.42	3.67e-16	Corneal structure;
LIHC	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.65	-10.07	-0.48	4.81e-21	Corneal structure;
LIHC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg03934865	chr2:198174659	NA	-0.61	-9.95	-0.47	1.16e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.16	0.4	6.43e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.85	-0.43	4.93e-17	Type 2 diabetes;
LIHC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.74	-9.1	-0.44	7.65e-18	Systemic lupus erythematosus;
LIHC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.81	-0.43	6.21e-17	Obesity-related traits;
LIHC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.97	0.35	1.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.57	-10.09	-0.48	3.85e-21	Platelet distribution width;
LIHC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.86	-0.3	1.1e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg17675199	chr6:35436792	RPL10A	0.34	6.68	0.34	9.43e-11	Coronary artery disease;
LIHC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.55	-0.46	2.56e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.41	6.31	0.32	8.62e-10	Educational attainment;
LIHC	cis	rs12369635	1.000	rs11060121	chr12:129564206	C/T	cg01909103	chr12:129572610	TMEM132D	-0.61	-6.12	-0.31	2.51e-9	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.57	-9.35	-0.45	1.16e-18	Type 2 diabetes;
LIHC	cis	rs9596863	1.000	rs7328970	chr13:54424225	G/C	ch.13.53330881F	chr13:54432880	NA	-0.43	-6.0	-0.31	5.16e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg18279126	chr7:2041391	MAD1L1	0.38	6.45	0.33	3.84e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	6.89	0.35	2.77e-11	Renal cell carcinoma;
LIHC	cis	rs7914558	0.646	rs10883796	chr10:104655315	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-7.38	-0.37	1.22e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs67981189	0.572	rs7156009	chr14:71515431	G/A	cg15816911	chr14:71606274	NA	0.42	6.85	0.35	3.4e-11	Schizophrenia;
LIHC	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.08	-0.36	8.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs546131	0.642	rs12794294	chr11:34827518	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.35	-0.32	6.82e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.58	-10.04	-0.48	5.67e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.28	7.02	0.36	1.17e-11	Schizophrenia;
LIHC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg12798992	chr6:167411361	FGFR1OP	-0.5	-8.05	-0.4	1.36e-14	Crohn's disease;
LIHC	cis	rs79387448	0.745	rs75644281	chr2:103151316	A/T	cg09003973	chr2:102972529	NA	0.85	7.47	0.37	6.82e-13	Gut microbiota (bacterial taxa);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25356086	chr21:33764900	C21orf119;URB1	0.45	6.45	0.33	3.76e-10	Pancreatic cancer;
LIHC	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2270927	0.510	rs2358712	chr5:75580687	A/G	cg13563193	chr19:33072644	PDCD5	0.97	9.17	0.44	4.59e-18	Mean corpuscular volume;
LIHC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg10664184	chr19:17420304	DDA1	0.46	5.86	0.3	1.07e-8	Systemic lupus erythematosus;
LIHC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.85	-0.3	1.13e-8	Mean corpuscular volume;
LIHC	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg03934865	chr2:198174659	NA	0.43	6.1	0.31	2.89e-9	Dermatomyositis;
LIHC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.61	-0.65	7.33e-42	Headache;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03843852	chr15:55611099	PIGB	-0.44	-6.67	-0.34	1.01e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17426592	chr5:6712363	NA	0.44	6.68	0.34	9.69e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-6.32	-0.32	8.19e-10	Blood metabolite levels;
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.52	5.88	0.3	9.99e-9	Alzheimer's disease;
LIHC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.68	-0.34	9.89e-11	Mean corpuscular volume;
LIHC	cis	rs7945718	0.781	rs11022513	chr11:12840986	C/T	cg25843174	chr11:12811716	TEAD1	-0.27	-6.31	-0.32	8.61e-10	Educational attainment (years of education);
LIHC	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg23461800	chr14:103021989	NA	-0.39	-5.94	-0.31	7.2e-9	Platelet count;
LIHC	cis	rs16828019	0.852	rs71648536	chr1:41632008	T/A	cg03387723	chr1:41708464	SCMH1	-0.42	-6.98	-0.35	1.59e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.44	-6.7	-0.34	8.61e-11	Height;
LIHC	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.98	0.31	5.56e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.0	-0.35	1.37e-11	Blood pressure;
LIHC	cis	rs17433710	0.516	rs10737487	chr1:162667331	G/A	cg01063088	chr1:162760584	HSD17B7	0.44	6.32	0.32	8.32e-10	Dupuytren's disease;
LIHC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg06466757	chr4:1255808	NA	0.34	5.79	0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.2	-0.48	1.67e-21	Ear protrusion;
LIHC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.61	-0.59	5.27e-34	Coffee consumption (cups per day);
LIHC	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.41	0.41	1.16e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg19894588	chr14:64061835	NA	-0.47	-7.44	-0.37	8.1e-13	Fat distribution (HIV);
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.64	-9.28	-0.45	1.99e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.39	-6.3	-0.32	9.22e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.36	6.49	0.33	2.93e-10	Mean corpuscular volume;
LIHC	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg15123519	chr2:136567270	LCT	-0.38	-5.99	-0.31	5.29e-9	Corneal structure;
LIHC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.57	-0.53	2.42e-26	Platelet distribution width;
LIHC	cis	rs2834256	1.000	rs2834259	chr21:35133091	C/T	cg14850771	chr21:34775459	IFNGR2	0.38	5.78	0.3	1.66e-8	Red cell distribution width;
LIHC	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg25179470	chr10:102756915	LZTS2	0.45	6.36	0.32	6.65e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4407350	0.870	rs5765716	chr22:44915251	T/C	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.2	-0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.53	7.64	0.38	2.19e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.5	9.14	0.44	5.69e-18	Hemoglobin concentration;
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06656553	chr16:89960601	TCF25	-0.48	-5.98	-0.31	5.65e-9	Skin colour saturation;
LIHC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg09182678	chr22:50328711	NA	-0.44	-6.32	-0.32	8.36e-10	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.18	-0.4	5.58e-15	Lymphocyte counts;
LIHC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg22079354	chr11:130786696	SNX19	0.41	5.82	0.3	1.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.4	-6.13	-0.31	2.44e-9	Educational attainment;
LIHC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.59	-10.92	-0.51	5.31e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.14	-0.4	7.19e-15	Morning vs. evening chronotype;
LIHC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg03476357	chr21:30257390	N6AMT1	-0.49	-6.69	-0.34	9.28e-11	Cognitive test performance;
LIHC	cis	rs6009527	0.711	rs8141990	chr22:49570455	T/G	cg12746016	chr22:49560550	NA	0.26	6.14	0.32	2.27e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg23933399	chr1:1462973	ATAD3A	0.41	6.62	0.34	1.43e-10	Immature fraction of reticulocytes;
LIHC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.75	-10.68	-0.5	3.56e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-7.03	-0.36	1.14e-11	HDL cholesterol;
LIHC	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg04610667	chr7:75704037	NA	0.35	6.2	0.32	1.61e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg06466757	chr4:1255808	NA	0.35	5.93	0.31	7.24e-9	Obesity-related traits;
LIHC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.64	-0.34	1.21e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	23.89	0.79	7.09e-75	Prudent dietary pattern;
LIHC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.35	8.63	0.42	2.4e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.45	-7.27	-0.37	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.67	0.42	1.82e-16	Menarche (age at onset);
LIHC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg00800038	chr16:89945340	TCF25	-0.63	-9.45	-0.45	5.73e-19	Skin colour saturation;
LIHC	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.34	-5.78	-0.3	1.65e-8	Mean platelet volume;
LIHC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.79	12.14	0.55	1.86e-28	Total body bone mineral density;
LIHC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-6.75	-0.34	6.39e-11	Colorectal cancer;
LIHC	cis	rs8108269	0.868	rs10422601	chr19:46159414	G/C	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.47	-8.09	-0.4	1.07e-14	Refractive error;
LIHC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.16	18.07	0.7	1.04e-51	Gut microbiome composition (summer);
LIHC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.47	0.33	3.46e-10	Rheumatoid arthritis;
LIHC	cis	rs116248771	0.739	rs73156437	chr3:158359284	T/C	cg16708174	chr3:158430962	RARRES1	0.49	6.43	0.33	4.26e-10	diarrhoeal disease at age 2;
LIHC	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.1400000000000002e-19	Corneal astigmatism;
LIHC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.4	6.47	0.33	3.48e-10	Red blood cell count;
LIHC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg13409248	chr3:40428643	ENTPD3	-0.4	-6.64	-0.34	1.23e-10	Renal cell carcinoma;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.68	0.57	1.87e-30	Prudent dietary pattern;
LIHC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.85	-0.43	4.65e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-7.63	-0.38	2.38e-13	Testicular germ cell tumor;
LIHC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.55	-8.97	-0.44	1.98e-17	Obesity-related traits;
LIHC	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.55	8.55	0.42	4.08e-16	White matter hyperintensity burden;
LIHC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-8.3	-0.41	2.5e-15	Alzheimer's disease;
LIHC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.8	7.66	0.38	1.99e-13	Diabetic retinopathy;
LIHC	cis	rs2710642	0.693	rs10168771	chr2:62903187	G/A	cg17519650	chr2:63277830	OTX1	0.53	7.6	0.38	2.96e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.62	-6.56	-0.33	1.96e-10	Hair shape;
LIHC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.13	0.66	6.33e-44	Electrocardiographic conduction measures;
LIHC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg21573476	chr21:45109991	RRP1B	-0.53	-10.07	-0.48	4.56e-21	Mean corpuscular volume;
LIHC	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg20991723	chr1:152506922	NA	0.44	6.75	0.34	6.36e-11	Hair morphology;
LIHC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.7	-0.57	1.55e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg13271783	chr10:134563150	INPP5A	-0.54	-6.8	-0.34	4.77e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.53	0.33	2.39e-10	Lung cancer in ever smokers;
LIHC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.86	-0.3	1.07e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.78	0.34	5.42e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.1	-0.31	2.9e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg01652190	chr22:50026171	C22orf34	-0.29	-6.3	-0.32	9.2e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.58	7.92	0.39	3.33e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg12253828	chr6:101329408	ASCC3	-0.4	-6.28	-0.32	1.03e-9	Neuroticism;
LIHC	cis	rs2412488	1.000	rs6554100	chr4:54240108	C/T	cg22241045	chr4:54363911	LNX1	-0.45	-7.1	-0.36	7.36e-12	DNA methylation (variation);
LIHC	cis	rs7712401	0.755	rs1545697	chr5:122102277	T/C	cg18764291	chr5:122110994	SNX2	0.36	6.12	0.31	2.56e-9	Mean platelet volume;
LIHC	cis	rs17428076	0.874	rs17581361	chr2:172682612	T/G	cg13550731	chr2:172543902	DYNC1I2	0.38	6.21	0.32	1.55e-9	Myopia;
LIHC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.42	-8.57	-0.42	3.6e-16	Obesity-related traits;
LIHC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.14	10.04	0.48	6e-21	Type 2 diabetes;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	7.04	0.36	1.04e-11	Height;
LIHC	cis	rs11098699	0.821	rs1562063	chr4:124204110	G/A	cg09941581	chr4:124220074	SPATA5	0.32	6.38	0.33	5.62e-10	Mosquito bite size;
LIHC	cis	rs11958404	1.000	rs11958404	chr5:157410278	A/T	cg05962755	chr5:157440814	NA	0.88	10.05	0.48	5.43e-21	IgG glycosylation;
LIHC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	12.68	0.57	1.83e-30	Alzheimer's disease;
LIHC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.78	12.78	0.57	7.81e-31	Fat distribution (HIV);
LIHC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.4	6.18	0.32	1.8e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.04e-32	Psoriasis;
LIHC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg10018233	chr7:150070692	REPIN1	0.5	8.19	0.4	5.27e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.08e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-7.44	-0.37	7.98e-13	P wave terminal force;
LIHC	trans	rs3783890	1.000	rs17129006	chr14:93788891	A/G	cg02802420	chr16:69363236	PDF;COG8	0.32	6.32	0.32	8.12e-10	Body mass index;
LIHC	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.55	10.16	0.48	2.32e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg20569855	chr1:109824440	PSRC1	0.5	6.53	0.33	2.42e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg02297831	chr4:17616191	MED28	0.43	6.95	0.35	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.64	11.58	0.53	2.23e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	9.82	0.47	3.35e-20	Post bronchodilator FEV1;
LIHC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-6.77	-0.34	5.64e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-9.12	-0.44	6.57e-18	Tonsillectomy;
LIHC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.44	0.53	7.19e-26	Platelet count;
LIHC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg03854865	chr6:26224070	HIST1H3E	0.62	6.86	0.35	3.24e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.65	-9.28	-0.45	2.02e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.72	10.34	0.49	5.45e-22	Diastolic blood pressure;
LIHC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.79	-0.34	4.99e-11	Aortic root size;
LIHC	cis	rs9596863	0.898	rs9568898	chr13:54317030	G/T	ch.13.53330881F	chr13:54432880	NA	0.42	5.76	0.3	1.85e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.56	-6.18	-0.32	1.79e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg24130564	chr14:104152367	KLC1	-0.38	-5.97	-0.31	6.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg00343986	chr7:65444356	GUSB	-0.4	-5.99	-0.31	5.21e-9	Aortic root size;
LIHC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.67e-21	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.42	0.59	2.91e-33	Diabetic kidney disease;
LIHC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.56	0.53	2.56e-26	Coronary artery disease;
LIHC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.37	5.96	0.31	6.42e-9	Menopause (age at onset);
LIHC	cis	rs6066825	0.590	rs729663	chr20:47304306	C/T	cg18078177	chr20:47281410	PREX1	-0.47	-8.18	-0.4	5.51e-15	Colorectal cancer;
LIHC	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.78	-0.3	1.67e-8	Diastolic blood pressure;
LIHC	cis	rs832187	0.776	rs854622	chr3:63862842	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.48	-7.05	-0.36	9.91e-12	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.69	7.22	0.36	3.4e-12	Alzheimer's disease;
LIHC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.34	6.09	0.31	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-0.59	-10.72	-0.5	2.7e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.25	0.41	3.49e-15	Response to antipsychotic treatment;
LIHC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.75	11.19	0.52	5.45e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg12501888	chr15:85177176	SCAND2	-0.5	-7.65	-0.38	2.13e-13	P wave terminal force;
LIHC	cis	rs16828019	0.777	rs12748235	chr1:41466221	G/A	cg03387723	chr1:41708464	SCMH1	-0.45	-6.66	-0.34	1.07e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.5	-6.5	-0.33	2.81e-10	Pancreatic cancer;
LIHC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg02297831	chr4:17616191	MED28	0.49	7.57	0.38	3.54e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4763879	0.739	rs12582584	chr12:9824138	T/G	cg26689682	chr12:9723402	NA	-0.36	-5.88	-0.3	9.53e-9	Type 1 diabetes;
LIHC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg07560587	chr16:88016574	BANP	-0.36	-5.8	-0.3	1.48e-8	Menopause (age at onset);
LIHC	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.91	-18.54	-0.71	1.34e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg07424592	chr7:64974309	NA	0.83	9.7	0.46	7.94e-20	Diabetic kidney disease;
LIHC	cis	rs2257205	0.667	rs6503879	chr17:56888183	T/A	cg05425664	chr17:57184151	TRIM37	-0.6	-6.61	-0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.17	-0.36	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.58	8.35	0.41	1.7e-15	Osteoporosis;
LIHC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg12601576	chr4:906860	GAK	-0.61	-5.73	-0.3	2.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg26939375	chr7:64535504	NA	-0.46	-7.03	-0.36	1.16e-11	Aortic root size;
LIHC	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg03146154	chr1:46216737	IPP	-0.37	-6.18	-0.32	1.8e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg26939375	chr7:64535504	NA	-0.41	-6.55	-0.33	2.11e-10	Aortic root size;
LIHC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.86	0.35	3.29e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg15605315	chr1:45957053	TESK2	-0.44	-5.71	-0.3	2.43e-8	Platelet count;
LIHC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.38	-0.86	1.02e-102	Myeloid white cell count;
LIHC	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.45	6.79	0.34	5.04e-11	Night sleep phenotypes;
LIHC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.12	0.31	2.59e-9	Menopause (age at onset);
LIHC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg12064134	chr16:90016061	DEF8	-0.44	-5.79	-0.3	1.61e-8	Skin colour saturation;
LIHC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.61	0.53	1.76e-26	Colorectal cancer;
LIHC	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.21	13.52	0.59	1.13e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs4714291	0.926	rs847771	chr6:40048586	T/C	cg02267698	chr19:7991119	CTXN1	0.39	6.23	0.32	1.4e-9	Strep throat;
LIHC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.88	-16.77	-0.67	1.77e-46	Coronary artery disease;
LIHC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.18	-0.48	1.89e-21	Longevity;Endometriosis;
LIHC	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.5	9.62	0.46	1.52e-19	Testicular germ cell tumor;
LIHC	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg20129853	chr10:51489980	NA	-0.4	-8.62	-0.42	2.56e-16	Prostate-specific antigen levels;
LIHC	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.6	8.37	0.41	1.45e-15	Eotaxin levels;
LIHC	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg10820045	chr2:198174542	NA	-0.46	-6.89	-0.35	2.66e-11	Intracranial aneurysm;
LIHC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg20295408	chr7:1910781	MAD1L1	0.39	5.74	0.3	2.07e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.32	-6.68	-0.34	9.58e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.59	-7.97	-0.4	2.32e-14	Tourette syndrome;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.76	-0.34	6.07e-11	Menopause (age at onset);
LIHC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg21361702	chr7:150065534	REPIN1	0.46	6.4	0.33	5.1e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.08	-0.4	1.11e-14	Type 2 diabetes;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.51	-0.38	5.16e-13	Lymphocyte counts;
LIHC	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.69	-0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	1.03	10.49	0.49	1.71e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.84	12.17	0.55	1.49e-28	Menarche (age at onset);
LIHC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.57	-7.36	-0.37	1.38e-12	Post bronchodilator FEV1;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg16822855	chr3:40428330	ENTPD3	-0.33	-6.23	-0.32	1.36e-9	Renal cell carcinoma;
LIHC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1144333	0.655	rs1417402	chr1:76437196	C/T	cg03433033	chr1:76189801	ACADM	0.55	7.57	0.38	3.42e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg12903224	chr12:29470962	FAR2	-0.41	-6.51	-0.33	2.68e-10	QT interval;
LIHC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.54	7.88	0.39	4.38e-14	Initial pursuit acceleration;
LIHC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg06012730	chr15:75315579	PPCDC	0.34	6.38	0.33	5.61e-10	Blood trace element (Zn levels);
LIHC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg16558253	chr16:72132732	DHX38	-0.51	-8.13	-0.4	8.1e-15	Fibrinogen levels;
LIHC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.41	5.85	0.3	1.13e-8	Longevity;Endometriosis;
LIHC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.75	-7.35	-0.37	1.46e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.62	-10.82	-0.51	1.14e-23	Inflammatory bowel disease;
LIHC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.4	7.13	0.36	6.02e-12	Aortic root size;
LIHC	cis	rs1185460	0.565	rs10892325	chr11:118912702	T/C	cg23280166	chr11:118938394	VPS11	-0.43	-5.88	-0.3	9.62e-9	Coronary artery disease;
LIHC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.9	14.26	0.61	1.52e-36	Vitamin D levels;
LIHC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-8.39	-0.41	1.28e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-0.74	-8.34	-0.41	1.87e-15	Exhaled nitric oxide output;
LIHC	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14577476	chr17:49337432	MBTD1;UTP18	-0.45	-6.72	-0.34	7.8e-11	Cognitive function;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.75	0.62	1.85e-38	Prudent dietary pattern;
LIHC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.2	-0.41	4.82e-15	Chronic sinus infection;
LIHC	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg00204512	chr16:28754710	NA	-0.37	-6.44	-0.33	4.15e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.49	8.02	0.4	1.73e-14	Blood protein levels;
LIHC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.6	-0.56	3.54e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27297192	chr10:134578999	INPP5A	0.53	7.42	0.37	9.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg25801113	chr15:45476975	SHF	0.38	6.51	0.33	2.69e-10	Uric acid levels;
LIHC	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.59	7.43	0.37	8.73e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.72	0.34	7.55e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	16.85	0.67	8.05e-47	Lung cancer in ever smokers;
LIHC	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-0.95	-12.04	-0.55	4.32e-28	Obesity-related traits;
LIHC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.45	-6.79	-0.34	4.9e-11	Height;
LIHC	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	6.59	0.34	1.66e-10	Mean corpuscular hemoglobin;
LIHC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg07541023	chr7:19748670	TWISTNB	0.36	5.73	0.3	2.19e-8	Thyroid stimulating hormone;
LIHC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.37	0.52	1.3e-25	Alzheimer's disease;
LIHC	trans	rs2073499	0.935	rs2624836	chr3:50208868	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-6.53	-0.33	2.41e-10	Schizophrenia;
LIHC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.7	-9.9	-0.47	1.7e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.93	17.2	0.68	3.13e-48	Menopause (age at onset);
LIHC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.23	0.36	3.16e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs748404	0.556	rs574856	chr15:43460834	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.37	-5.91	-0.3	8.46e-9	Lung cancer;
LIHC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-6.07	-0.31	3.39e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg00792783	chr2:198669748	PLCL1	0.46	6.86	0.35	3.19e-11	Dermatomyositis;
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.04	-0.31	4.12e-9	Total body bone mineral density;
LIHC	cis	rs16958440	0.867	rs80106524	chr18:44676639	G/A	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.44	-6.47	-0.33	3.37e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.58	8.48	0.42	7e-16	Emphysema distribution in smoking;
LIHC	trans	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.74	-0.3	2.14e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg06565975	chr8:143823917	SLURP1	-0.3	-5.74	-0.3	2.1e-8	Urinary tract infection frequency;
LIHC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.57	8.72	0.43	1.26e-16	Uric acid clearance;
LIHC	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.54	-0.38	4.27e-13	Metabolite levels;
LIHC	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.47	7.49	0.38	5.87e-13	HDL cholesterol;
LIHC	cis	rs6788895	1.000	rs16862842	chr3:150484844	A/G	cg09723797	chr3:150481914	SIAH2	0.8	10.9	0.51	5.87e-24	Breast cancer;
LIHC	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.43	6.81	0.35	4.29e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.16	-0.32	2.08e-9	Prevalent atrial fibrillation;
LIHC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12516959	chr21:47718080	NA	-0.37	-6.02	-0.31	4.5e-9	Testicular germ cell tumor;
LIHC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.11	-11.31	-0.52	2.16e-25	Type 1 diabetes nephropathy;
LIHC	cis	rs12808519	0.688	rs35759009	chr11:69583722	A/G	cg19831575	chr11:69590090	FGF4	0.5	7.01	0.35	1.26e-11	Urate levels in overweight individuals;
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06873352	chr17:61820015	STRADA	-0.47	-7.02	-0.35	1.19e-11	Height;
LIHC	trans	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.81	0.6	8.58e-35	Bipolar disorder;
LIHC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.3	-0.37	2e-12	Heart rate;
LIHC	cis	rs151997	0.830	rs27282	chr5:50198970	G/A	cg06027927	chr5:50259733	NA	0.44	6.55	0.33	2.12e-10	Callous-unemotional behaviour;
LIHC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.42	7.44	0.37	8.45e-13	Schizophrenia;
LIHC	cis	rs3789045	0.560	rs3747634	chr1:204411063	C/T	cg17419461	chr1:204415978	PIK3C2B	0.52	8.04	0.4	1.48e-14	Educational attainment (college completion);
LIHC	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.78	8.98	0.44	1.88e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs244293	1.000	rs244286	chr17:53232594	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-7.02	-0.35	1.22e-11	Menarche (age at onset);
LIHC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.64	10.12	0.48	3.23e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.11	-0.4	8.87e-15	Crohn's disease;
LIHC	cis	rs16944613	0.510	rs11636571	chr15:91143857	A/G	cg26821196	chr15:91095069	CRTC3	0.32	5.99	0.31	5.4e-9	Colorectal cancer;
LIHC	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg27205649	chr11:78285834	NARS2	0.42	6.3	0.32	8.98e-10	Alzheimer's disease (survival time);
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.59	-8.99	-0.44	1.77e-17	Testicular germ cell tumor;
LIHC	trans	rs2681424	1.000	rs4974394	chr3:121756249	A/G	cg03946530	chr15:65596423	NA	-0.48	-6.22	-0.32	1.46e-9	Multiple sclerosis;
LIHC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	6.32	0.32	8.03e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1982963	1.000	rs904061	chr14:52504624	T/C	cg10843707	chr14:52510701	NID2	-0.44	-7.58	-0.38	3.3e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	0.94	15.84	0.65	9.26e-43	Testicular germ cell tumor;
LIHC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.37	12.19	0.55	1.23e-28	Uric acid levels;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg16103275	chr6:290800	DUSP22	0.5	6.55	0.33	2.16e-10	Menopause (age at onset);
LIHC	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.34	-7.89	-0.39	4.14e-14	Educational attainment (years of education);
LIHC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg15051332	chr6:41514432	FOXP4	0.42	5.76	0.3	1.83e-8	Prostate cancer;
LIHC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.54	-0.33	2.19e-10	Fear of minor pain;
LIHC	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.75	0.39	1.09e-13	Systemic lupus erythematosus;
LIHC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.68	10.9	0.51	5.88e-24	Platelet count;
LIHC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.56	7.36	0.37	1.36e-12	Vitiligo;
LIHC	cis	rs10864907	0.553	rs7578034	chr2:113718077	C/T	cg12858261	chr2:113808755	IL1F8	0.35	5.99	0.31	5.38e-9	Pulmonary function;
LIHC	cis	rs4742903	0.935	rs1580014	chr9:106933625	A/C	cg14250997	chr9:106856677	SMC2	0.35	5.91	0.3	8.19e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.92	14.6	0.62	7.04e-38	Vitamin D levels;
LIHC	cis	rs9473924	0.505	rs34793301	chr6:50859462	G/T	cg14470998	chr6:50812995	TFAP2B	1.02	9.21	0.45	3.31e-18	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25733915	chr17:40829168	PLEKHH3	0.44	6.93	0.35	2.11e-11	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06966887	chr5:443603	EXOC3;C5orf55	0.46	6.68	0.34	9.49e-11	Pancreatic cancer;
LIHC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	6.05	0.31	3.86e-9	Uric acid clearance;
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.26	0.32	1.18e-9	Calcium levels;
LIHC	trans	rs7569426	0.676	rs2098566	chr2:34405818	A/G	cg05775492	chr16:86258717	NA	0.24	6.45	0.33	3.83e-10	Subjective well-being;
LIHC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-9.4	-0.45	8.36e-19	Parkinson's disease;
LIHC	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.48	6.09	0.31	2.98e-9	Panic disorder;
LIHC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.46	7.09	0.36	7.91e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.65	11.33	0.52	1.83e-25	Superior crus of antihelix expression;
LIHC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.86	-0.3	1.06e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg04998671	chr14:104000505	TRMT61A	-0.59	-7.83	-0.39	6.16e-14	Coronary artery disease;
LIHC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.35	-0.37	1.43e-12	Response to antipsychotic treatment;
LIHC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	10.11	0.48	3.46e-21	Menarche (age at onset);
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.84	12.64	0.56	2.54e-30	Migraine;
LIHC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.83	-0.3	1.26e-8	Breast cancer;
LIHC	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.33	-7.54	-0.38	4.2e-13	Breast cancer;
LIHC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.84	0.3	1.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.47	-5.77	-0.3	1.76e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	0.55	7.2	0.36	3.87e-12	Pulse pressure;
LIHC	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.39	5.77	0.3	1.75e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs10213084	0.920	rs56271575	chr4:147498323	A/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.47	6.12	0.31	2.63e-9	Heart rate;
LIHC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.54	-7.72	-0.39	1.28e-13	Longevity;
LIHC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg12310025	chr6:25882481	NA	-0.52	-6.75	-0.34	6.45e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.9	0.57	2.79e-31	Prudent dietary pattern;
LIHC	cis	rs12980942	1.000	rs2241720	chr19:41829309	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.81	0.35	4.29e-11	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.3e-14	Height;
LIHC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg02290350	chr8:58132656	NA	0.53	9.48	0.46	4.32e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg08132940	chr7:1081526	C7orf50	-0.71	-6.21	-0.32	1.52e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.74	-0.43	1.08e-16	Hemoglobin concentration;
LIHC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg19645103	chr12:69753606	YEATS4	-0.4	-5.96	-0.31	6.15e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.46	-6.07	-0.31	3.49e-9	Subjective well-being;
LIHC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.84e-10	Diabetic kidney disease;
LIHC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg13957321	chr17:43675089	NA	0.5	7.88	0.39	4.56e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12463550	chr7:65579703	CRCP	0.71	7.44	0.37	8.23e-13	Diabetic kidney disease;
LIHC	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	0.93	12.82	0.57	5.52e-31	Mitochondrial DNA levels;
LIHC	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.95	-0.31	6.74e-9	Diisocyanate-induced asthma;
LIHC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.41	8.86	0.43	4.43e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.85	0.3	1.14e-8	Calcium levels;
LIHC	cis	rs965469	1.000	rs2236106	chr20:3278410	A/C	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.6	-10.01	-0.48	7.29e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg10424330	chr16:71894309	ZNF821;ATXN1L	0.41	6.22	0.32	1.47e-9	Immature fraction of reticulocytes;
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.61	10.64	0.5	4.85e-23	Height;
LIHC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	1.0	23.05	0.78	1.35e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.5	6.55	0.33	2.11e-10	Mean corpuscular volume;
LIHC	cis	rs6782228	0.585	rs2811492	chr3:128356279	A/G	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg21361702	chr7:150065534	REPIN1	0.44	5.99	0.31	5.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-0.5	-7.88	-0.39	4.35e-14	Atopic dermatitis;
LIHC	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.35	6.22	0.32	1.45e-9	Mean platelet volume;
LIHC	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.91	13.79	0.6	1.02e-34	Obesity-related traits;
LIHC	cis	rs611744	0.967	rs598477	chr8:109187874	G/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.54	-7.73	-0.39	1.22e-13	Uric acid levels;
LIHC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-1.01	-19.13	-0.72	5.63e-56	Breast cancer;
LIHC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg07636037	chr3:49044803	WDR6	-0.84	-8.52	-0.42	5.33e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.43	-6.51	-0.33	2.67e-10	Educational attainment;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08219700	chr8:58056026	NA	0.52	7.14	0.36	5.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.39	6.16	0.32	2.01e-9	Menopause (age at onset);
LIHC	cis	rs3106136	0.649	rs28463907	chr4:95302595	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg05361325	chr10:32636312	EPC1	-0.5	-6.18	-0.32	1.87e-9	Sexual dysfunction (female);
LIHC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.35	-0.37	1.49e-12	Platelet count;
LIHC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	9.06	0.44	9.93e-18	IgG glycosylation;
LIHC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg00219956	chr16:30794205	ZNF629	0.42	6.05	0.31	3.84e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg09855544	chr8:135498122	ZFAT	-0.49	-8.3	-0.41	2.41e-15	Hypertension (SNP x SNP interaction);
LIHC	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-6.49	-0.33	2.99e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.14	-21.79	-0.76	1.28e-66	Triglycerides;
LIHC	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	9.03	0.44	1.26e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.75	8.57	0.42	3.54e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.88	0.3	9.88e-9	Electroencephalogram traits;
LIHC	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.26	-0.32	1.12e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg08989290	chr16:615782	NHLRC4	0.31	5.99	0.31	5.42e-9	Height;
LIHC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.52	6.05	0.31	3.8e-9	Alzheimer's disease;
LIHC	trans	rs783540	0.869	rs783533	chr15:83250186	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.42	-0.33	4.57e-10	Schizophrenia;
LIHC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.19	-0.36	3.98e-12	Body mass index;
LIHC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.6	6.91	0.35	2.34e-11	Menarche (age at onset);
LIHC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.55	0.69	1.29e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	trans	rs11165623	0.582	rs10875023	chr1:97012386	T/C	cg10631902	chr5:14652156	NA	-0.25	-6.22	-0.32	1.43e-9	Hip circumference;Waist circumference;
LIHC	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	0.72	8.41	0.41	1.11e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.7	10.35	0.49	5.21e-22	Prostate cancer;
LIHC	cis	rs4788570	0.697	rs6499540	chr16:71822250	A/C	cg06353428	chr16:71660113	MARVELD3	1.33	14.27	0.61	1.38e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.48e-9	Cognitive performance;
LIHC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.38	6.43	0.33	4.18e-10	Uric acid levels;
LIHC	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.91	-0.47	1.62e-20	Total cholesterol levels;
LIHC	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg09795085	chr6:101329169	ASCC3	-0.52	-7.15	-0.36	5.31e-12	Neuroticism;
LIHC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.59	-7.07	-0.36	8.73e-12	Blood metabolite levels;
LIHC	cis	rs12922040	1.000	rs2075516	chr16:15869525	C/T	cg08214245	chr16:15829296	MYH11	0.31	6.07	0.31	3.37e-9	Serum uric acid levels in response to allopurinol in gout;
LIHC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	13.34	0.58	5.74e-33	Cognitive test performance;
LIHC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.68	-9.24	-0.45	2.64e-18	Aortic root size;
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg03874509	chr1:107600012	PRMT6	0.7	10.95	0.51	4.01e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12379764	chr21:47803548	PCNT	0.54	8.12	0.4	8.75e-15	Testicular germ cell tumor;
LIHC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs2637266	1.000	rs2395385	chr10:78341125	G/A	cg18941641	chr10:78392320	NA	0.3	6.41	0.33	4.93e-10	Pulmonary function;
LIHC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.81	13.77	0.6	1.3e-34	Chronic sinus infection;
LIHC	cis	rs4684776	0.676	rs35975472	chr3:11292653	T/G	cg00170343	chr3:11313890	ATG7	-0.48	-6.49	-0.33	3.08e-10	Small vessel stroke;
LIHC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.41	-0.59	3.06e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.8	12.53	0.56	6.95e-30	Multiple system atrophy;
LIHC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.24	5.77	0.3	1.75e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	trans	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg27088830	chr6:166401018	C6orf176;LOC441177	-0.45	-6.28	-0.32	1.02e-9	Response to hepatitis C treatment;
LIHC	trans	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg04702396	chr17:15466718	FAM18B2	0.46	6.95	0.35	1.82e-11	Educational attainment (years of education);
LIHC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.58	-5.87	-0.3	1e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.24	-0.32	1.29e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.55	7.53	0.38	4.43e-13	Blood metabolite levels;
LIHC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.63	-12.34	-0.56	3.43e-29	Sense of smell;
LIHC	cis	rs244293	0.965	rs244362	chr17:53188917	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.26e-13	Menarche (age at onset);
LIHC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-10.74	-0.5	2.25e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	11.56	0.53	2.48e-26	Schizophrenia;
LIHC	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg14675211	chr2:100938903	LONRF2	0.54	8.13	0.4	8.09e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.27	0.32	1.1e-9	Obesity-related traits;
LIHC	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.4	-8.41	-0.41	1.13e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.67	9.58	0.46	2.13e-19	Multiple sclerosis;
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12379764	chr21:47803548	PCNT	-0.58	-8.37	-0.41	1.54e-15	Testicular germ cell tumor;
LIHC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.39	-6.76	-0.34	5.97e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02034447	chr16:89574710	SPG7	0.45	7.06	0.36	9.24e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.78	0.54	4.13e-27	Prudent dietary pattern;
LIHC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg14440974	chr22:39074834	NA	-0.44	-7.0	-0.35	1.36e-11	Menopause (age at onset);
LIHC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.74	13.64	0.59	3.84e-34	Height;
LIHC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.57	-10.2	-0.48	1.68e-21	Platelet distribution width;
LIHC	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg22903471	chr2:27725779	GCKR	-0.31	-5.84	-0.3	1.2e-8	Total body bone mineral density;
LIHC	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg25952890	chr19:58913133	NA	0.71	7.73	0.39	1.18e-13	Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.63	9.66	0.46	1.09e-19	Renal cell carcinoma;
LIHC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg25344623	chr2:136566232	LCT	0.33	6.23	0.32	1.41e-9	Mosquito bite size;
LIHC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.4	7.49	0.38	6.05e-13	Schizophrenia;
LIHC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg12365402	chr11:9010492	NRIP3	0.29	7.72	0.39	1.3e-13	Hemoglobin concentration;
LIHC	cis	rs7523273	0.925	rs12132780	chr1:207999605	C/T	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.59	-0.5	7.74e-23	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02084834	chr2:201983708	CFLAR	0.44	6.52	0.33	2.53e-10	Pancreatic cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg09148975	chr1:38274245	C1orf122;YRDC	-0.53	-6.14	-0.32	2.26e-9	Systolic blood pressure;
LIHC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.8	-0.75	1.1e-62	Height;
LIHC	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.14	0.32	2.26e-9	Schizophrenia;
LIHC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.32	7.4	0.37	1.08e-12	Crohn's disease;
LIHC	cis	rs588177	0.613	rs3782101	chr11:64131280	A/G	cg18375707	chr11:64034959	PLCB3	-0.36	-5.82	-0.3	1.37e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-9.04	-0.44	1.18e-17	Blood metabolite levels;
LIHC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.5	6.26	0.32	1.16e-9	Alzheimer's disease;
LIHC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.52	0.38	4.84e-13	Schizophrenia;
LIHC	trans	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16471864	chr4:38666270	KLF3;FLJ13197	0.45	6.64	0.34	1.22e-10	Type 2 diabetes;
LIHC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg26149184	chr10:133730230	NA	0.47	7.44	0.37	7.99e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.59	8.53	0.42	4.83e-16	Coronary artery disease;
LIHC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg14067834	chr17:29058358	SUZ12P	0.65	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.84e-22	Hemoglobin concentration;
LIHC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.41	5.84	0.3	1.19e-8	Cognitive ability;
LIHC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.77	0.54	4.4e-27	Motion sickness;
LIHC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.47	7.07	0.36	8.54e-12	Diastolic blood pressure;
LIHC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-6.65	-0.34	1.13e-10	IgG glycosylation;
LIHC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.72	-8.85	-0.43	4.84e-17	Gut microbiome composition (summer);
LIHC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-9.68	-0.46	9.68e-20	Mean corpuscular volume;
LIHC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg19016816	chr7:1267987	NA	0.27	5.79	0.3	1.55e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.12	-0.44	6.77e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02290350	chr8:58132656	NA	0.4	8.21	0.41	4.42e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	trans	rs12753920	0.703	rs2391116	chr1:92622569	A/G	cg15668468	chr10:118892869	VAX1	0.42	6.12	0.31	2.58e-9	Systemic lupus erythematosus;
LIHC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.16	-0.52	7.22e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06656553	chr16:89960601	TCF25	0.44	6.01	0.31	4.81e-9	Skin colour saturation;
LIHC	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.42	6.28	0.32	1.05e-9	Menopause (age at onset);
LIHC	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	0.99	15.05	0.63	1.21e-39	Corneal structure;
LIHC	cis	rs3790645	1.000	rs444482	chr1:26890648	C/G	cg17456097	chr1:26900765	RPS6KA1	0.4	5.84	0.3	1.2e-8	Glucose homeostasis traits;
LIHC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.38	-6.14	-0.31	2.35e-9	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg00656387	chr3:40428638	ENTPD3	0.5	8.29	0.41	2.68e-15	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04722168	chr1:26324647	PAFAH2	0.46	6.56	0.33	1.95e-10	Pancreatic cancer;
LIHC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.41	7.96	0.4	2.55e-14	Cardiovascular disease risk factors;
LIHC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.54	9.24	0.45	2.67e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg08125733	chr17:73851984	WBP2	0.51	8.19	0.41	5.19e-15	White matter hyperintensity burden;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.63	0.46	1.44e-19	Height;
LIHC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20135002	chr11:47629003	NA	-0.51	-8.75	-0.43	9.91e-17	Subjective well-being;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23183521	chr12:57146030	PRIM1	0.49	6.67	0.34	1.04e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.57	11.64	0.53	1.29e-26	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2540917	0.765	rs2244030	chr2:60612238	A/G	cg00543073	chr2:60773386	BCL11A	-0.32	-6.33	-0.32	7.64e-10	Mean corpuscular volume;
LIHC	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16684958	chr7:75615977	POR	0.4	6.57	0.33	1.87e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg26138937	chr11:71823887	C11orf51	-1.34	-10.79	-0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs10924970	0.805	rs2789363	chr1:235519034	A/T	cg26050004	chr1:235667680	B3GALNT2	0.42	6.19	0.32	1.68e-9	Asthma;
LIHC	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg15352829	chr14:105391018	PLD4	-0.44	-8.91	-0.43	3.08e-17	Rheumatoid arthritis;
LIHC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.78	-0.43	7.71e-17	Bipolar disorder and schizophrenia;
LIHC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.7	0.34	8.5e-11	Axial length;
LIHC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.57	9.28	0.45	1.92e-18	Lymphocyte counts;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg14250997	chr9:106856677	SMC2	0.42	7.44	0.37	8.21e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.02	0.6	1.31e-35	Prudent dietary pattern;
LIHC	trans	rs2288327	0.673	rs35504893	chr2:179421294	C/T	cg14011486	chr1:26737247	LIN28	0.53	7.37	0.37	1.29e-12	Atrial fibrillation;
LIHC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.06	15.48	0.64	2.49e-41	Cognitive function;
LIHC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Tonsillectomy;
LIHC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.44	6.53	0.33	2.34e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.36	5.93	0.31	7.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg11764359	chr7:65958608	NA	-0.58	-5.98	-0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg05890377	chr2:74357713	NA	0.62	12.63	0.56	2.76e-30	Gestational age at birth (maternal effect);
LIHC	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	0.67	6.69	0.34	8.97e-11	Lung disease severity in cystic fibrosis;
LIHC	trans	rs11760633	0.607	rs7777233	chr7:1831671	C/T	cg00395210	chr12:48592465	NA	0.35	6.11	0.31	2.79e-9	Coronary artery disease;
LIHC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-1.01	-10.2	-0.48	1.62e-21	Breast cancer;
LIHC	cis	rs249954	0.512	rs42873	chr16:23694732	C/G	cg05131483	chr16:23706242	ERN2	0.35	5.82	0.3	1.38e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg22903471	chr2:27725779	GCKR	0.34	5.8	0.3	1.53e-8	Oral cavity cancer;
LIHC	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.44	7.32	0.37	1.75e-12	Corneal astigmatism;
LIHC	cis	rs12744310	0.887	rs12040046	chr1:41797583	C/T	cg03962019	chr1:41807865	NA	-0.36	-5.87	-0.3	1.02e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.71	10.72	0.5	2.6e-23	Aortic root size;
LIHC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg20818283	chr2:191399100	TMEM194B	-0.44	-6.04	-0.31	4e-9	Pulse pressure;
LIHC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.78	-0.57	7.66e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs965469	1.000	rs2281494	chr20:3235494	A/G	cg25506879	chr20:3388711	C20orf194	-0.56	-6.95	-0.35	1.82e-11	IFN-related cytopenia;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg00960700	chr17:80709150	TBCD	0.36	5.98	0.31	5.64e-9	Glycated hemoglobin levels;
LIHC	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg20697417	chr1:41786797	NA	0.31	5.93	0.31	7.37e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs963731	0.649	rs378698	chr2:39316301	T/C	cg04010122	chr2:39346883	SOS1	-0.68	-6.03	-0.31	4.15e-9	Corticobasal degeneration;
LIHC	cis	rs7872515	0.824	rs7858659	chr9:94822146	A/C	cg01248375	chr9:94877805	SPTLC1	0.51	6.89	0.35	2.77e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22509189	chr2:225307070	NA	-0.51	-7.49	-0.38	6.06e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg12863693	chr15:85201151	NMB	0.49	7.03	0.36	1.13e-11	Schizophrenia;
LIHC	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.06	0.55	3.76e-28	Eye color traits;
LIHC	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg22771759	chr13:24902376	NA	0.32	6.49	0.33	3.03e-10	Obesity-related traits;
LIHC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg24296786	chr1:45957014	TESK2	-0.48	-7.13	-0.36	6.05e-12	Platelet count;
LIHC	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.74	-7.53	-0.38	4.59e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17467752	chr17:38218738	THRA	-0.51	-8.67	-0.42	1.71e-16	Myeloid white cell count;
LIHC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-8.47	-0.42	7.33e-16	Schizophrenia;
LIHC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.9	0.6	4.07e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.72	0.39	1.28e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10838687	0.736	rs2279238	chr11:47282024	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.95	-0.31	6.57e-9	Proinsulin levels;
LIHC	cis	rs11671005	0.610	rs3816329	chr19:59058693	G/A	cg25952890	chr19:58913133	NA	0.66	6.71	0.34	7.94e-11	Mean platelet volume;
LIHC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.67	-0.5	3.81e-23	Coronary artery disease;
LIHC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	9.47	0.46	4.84e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg09835421	chr16:68378352	PRMT7	-0.63	-7.18	-0.36	4.35e-12	Magnesium levels;
LIHC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.6	10.23	0.48	1.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.86	10.84	0.51	9.63e-24	Cognitive function;
LIHC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	14.13	0.61	5.07e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.41	-6.18	-0.32	1.85e-9	Height;
LIHC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.51	9.21	0.45	3.45e-18	Atrioventricular conduction;
LIHC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.45	6.05	0.31	3.72e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg12046867	chr14:103022105	NA	-0.42	-6.65	-0.34	1.15e-10	Platelet count;
LIHC	cis	rs7578199	0.752	rs746675	chr2:242193706	T/A	cg19372975	chr2:242212901	HDLBP	-0.6	-5.83	-0.3	1.26e-8	Chronic lymphocytic leukemia;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07537819	chr6:156886127	NA	0.39	6.23	0.32	1.4e-9	Bilirubin levels;
LIHC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.66	-9.89	-0.47	1.88e-20	Testicular germ cell tumor;
LIHC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg12365402	chr11:9010492	NRIP3	-0.29	-7.81	-0.39	7.25e-14	Hemoglobin concentration;
LIHC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg24209194	chr3:40518798	ZNF619	0.42	5.97	0.31	6.06e-9	Renal cell carcinoma;
LIHC	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg27205649	chr11:78285834	NARS2	-0.37	-5.78	-0.3	1.68e-8	Alzheimer's disease (survival time);
LIHC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.83	-11.63	-0.53	1.45e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs67981189	0.593	rs2810109	chr14:71419892	A/T	cg15816911	chr14:71606274	NA	-0.42	-6.75	-0.34	6.4e-11	Schizophrenia;
LIHC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.64	-9.18	-0.44	4.09e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.63	11.68	0.53	9.66e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	0.85	7.04	0.36	1.09e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.67	-10.25	-0.48	1.15e-21	Neutrophil percentage of white cells;
LIHC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	9.08	0.44	8.54e-18	Lung cancer in ever smokers;
LIHC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.53	6.94	0.35	2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.4	-8.48	-0.42	6.68e-16	Obesity-related traits;
LIHC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg17980119	chr2:219472607	PLCD4	0.36	6.14	0.31	2.34e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.55	8.3	0.41	2.36e-15	Longevity;
LIHC	cis	rs1198430	0.925	rs1767148	chr1:23765472	A/G	cg13183780	chr1:23809682	ASAP3	-0.54	-7.73	-0.39	1.2e-13	Total cholesterol levels;
LIHC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.47	0.33	3.37e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15044954	chr7:89874365	C7orf63	0.41	6.26	0.32	1.18e-9	Cognitive function;
LIHC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg03934865	chr2:198174659	NA	-0.59	-9.5	-0.46	3.88e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.58	8.32	0.41	2.18e-15	Osteoporosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14275779	chr17:40830236	PLEKHH3	0.41	6.77	0.34	5.55e-11	Cognitive function;
LIHC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	8.29	0.41	2.68e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10792665	0.898	rs4511296	chr11:82678953	A/C	cg24227371	chr11:82718527	RAB30	-0.31	-7.15	-0.36	5.21e-12	Obesity-related traits;
LIHC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg04310649	chr10:35416472	CREM	0.43	5.82	0.3	1.37e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.51	-7.68	-0.38	1.66e-13	Cognitive function;
LIHC	cis	rs2292096	0.925	rs72746845	chr1:200711624	C/A	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-5.98	-0.31	5.56e-9	Epilepsy;
LIHC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.6	8.83	0.43	5.59e-17	Recombination rate (females);
LIHC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg12903224	chr12:29470962	FAR2	0.43	7.04	0.36	1.06e-11	QT interval;
LIHC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg04013166	chr16:89971882	TCF25	0.49	6.07	0.31	3.31e-9	Skin colour saturation;
LIHC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	12.13	0.55	2.05e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg23556447	chr6:90529595	MDN1	-0.52	-6.14	-0.32	2.35e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.43	5.85	0.3	1.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg02503808	chr4:7069936	GRPEL1	0.41	6.42	0.33	4.68e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7.19e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg03037974	chr15:76606532	NA	0.74	14.44	0.62	3.1e-37	Blood metabolite levels;
LIHC	cis	rs77637988	0.631	rs7587385	chr2:48600691	T/G	cg15846641	chr2:48541264	FOXN2	0.59	8.0	0.4	1.97e-14	Joint mobility (Beighton score);
LIHC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.92	-0.39	3.34e-14	Schizophrenia;
LIHC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg09835421	chr16:68378352	PRMT7	-0.5	-5.92	-0.3	7.91e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-6.99	-0.35	1.48e-11	IgG glycosylation;
LIHC	cis	rs8084351	0.577	rs12457189	chr18:50665754	T/C	cg24270629	chr18:50823537	DCC	-0.43	-6.39	-0.33	5.46e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9649465	1.000	rs7805759	chr7:123318696	C/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.18	-0.4	5.61e-15	Migraine;
LIHC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	9.81	0.47	3.52e-20	Alzheimer's disease (late onset);
LIHC	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.8	14.45	0.62	2.92e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.14e-8	Blood protein levels;
LIHC	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.51	0.53	4.02e-26	Motion sickness;
LIHC	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.73	-13.35	-0.59	5.3e-33	Longevity;
LIHC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs57590327	0.503	rs9880844	chr3:81507217	C/T	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Extraversion;
LIHC	cis	rs1975974	0.511	rs113941161	chr17:21741346	T/C	cg18423549	chr17:21743878	NA	-0.46	-5.73	-0.3	2.25e-8	Psoriasis;
LIHC	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.12	10.24	0.48	1.19e-21	Diabetic retinopathy;
LIHC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.38	8.6	0.42	2.85e-16	Crohn's disease;
LIHC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.5	0.53	4.36e-26	Tonsillectomy;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.37	-6.25	-0.32	1.22e-9	Height;
LIHC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.36	-6.08	-0.31	3.23e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.5	-6.49	-0.33	2.96e-10	Breast cancer;
LIHC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.08	15.66	0.65	4.6e-42	Cognitive function;
LIHC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.85	-0.51	8.78e-24	Response to antipsychotic treatment;
LIHC	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.14	-0.32	2.31e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15664640	chr17:80829946	TBCD	0.57	5.92	0.3	7.79e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg01557791	chr16:72042693	DHODH	-0.39	-6.54	-0.33	2.28e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.92	0.57	2.17e-31	Prudent dietary pattern;
LIHC	cis	rs11577318	0.579	rs12131370	chr1:26698430	G/A	cg18121669	chr1:26560928	CCDC21	-0.48	-7.15	-0.36	5.44e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9948	0.786	rs55674661	chr2:97473929	A/G	cg01990225	chr2:97406019	LMAN2L	-0.53	-5.99	-0.31	5.46e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs61041384	0.661	rs75338281	chr12:123507484	G/A	cg25930673	chr12:123319894	HIP1R	0.64	5.86	0.3	1.11e-8	Schizophrenia;
LIHC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.5	-8.63	-0.42	2.34e-16	White blood cell count;
LIHC	cis	rs12744310	1.000	rs72665698	chr1:41775589	T/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7575217	0.643	rs2309996	chr2:101735838	T/G	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.06	-0.31	3.52e-9	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.92	0.31	7.62e-9	Educational attainment;
LIHC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.18	-0.44	4.28e-18	Bipolar disorder;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg02546883	chr6:157721111	C6orf35	0.38	6.16	0.32	2.09e-9	Body mass index;
LIHC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.57	-10.96	-0.51	3.6e-24	Coronary artery disease;
LIHC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.91	0.39	3.53e-14	Lung cancer;
LIHC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	7.54	0.38	4.13e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg18944383	chr4:111397179	ENPEP	-0.32	-7.07	-0.36	8.91e-12	Coronary artery disease;
LIHC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg15832292	chr6:96025679	MANEA	0.69	8.54	0.42	4.57e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs77633900	0.772	rs157775	chr15:76755641	A/G	cg21673338	chr15:77095150	SCAPER	-0.52	-5.93	-0.31	7.45e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.46	-7.28	-0.37	2.27e-12	Alcohol dependence;
LIHC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.47	6.99	0.35	1.42e-11	Multiple sclerosis;
LIHC	cis	rs4794202	0.534	rs8078688	chr17:45919869	T/C	cg10638573	chr17:45915098	SCRN2	0.57	6.22	0.32	1.43e-9	Alzheimer's disease (cognitive decline);
LIHC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg23485639	chr6:28045615	ZNF165	-0.44	-5.82	-0.3	1.34e-8	Parkinson's disease;
LIHC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.31	14.02	0.6	1.33e-35	White matter hyperintensity burden;
LIHC	cis	rs288342	0.832	rs288309	chr2:183651433	C/T	cg02625481	chr2:183667124	NA	-0.29	-5.95	-0.31	6.48e-9	Recurrent major depressive disorder;
LIHC	cis	rs1865721	0.755	rs3813081	chr18:73185096	A/G	cg26385618	chr18:73139727	C18orf62	-0.27	-7.14	-0.36	5.69e-12	Intelligence;
LIHC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.83	-11.73	-0.54	6.42e-27	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.39	5.91	0.3	8.47e-9	Prostate cancer;
LIHC	cis	rs55702914	0.809	rs2914982	chr2:198202793	G/C	cg10820045	chr2:198174542	NA	-0.41	-5.91	-0.3	8.36e-9	Major depression and alcohol dependence;
LIHC	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.64	-10.71	-0.5	2.9e-23	Waist circumference;Body mass index;
LIHC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.61	-0.79	8.2e-74	Height;
LIHC	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.69	10.65	0.5	4.45e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.28	-0.7	1.53e-52	Exhaled nitric oxide levels;
LIHC	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.72	-0.43	1.26e-16	Hepatocellular carcinoma;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg18538332	chr22:24372958	LOC391322	0.57	7.56	0.38	3.73e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg09574498	chr17:48944758	NA	0.41	6.2	0.32	1.61e-9	Alopecia areata;
LIHC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg19680672	chr10:131412579	MGMT	-0.44	-6.78	-0.34	5.39e-11	Response to temozolomide;
LIHC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg14440974	chr22:39074834	NA	-0.46	-7.37	-0.37	1.27e-12	Menopause (age at onset);
LIHC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	1.03	18.22	0.7	2.47e-52	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.4	8.01	0.4	1.83e-14	Renal cell carcinoma;
LIHC	cis	rs244293	0.965	rs244313	chr17:53214332	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.37	-0.37	1.27e-12	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12463550	chr7:65579703	CRCP	-0.68	-7.09	-0.36	7.77e-12	Diabetic kidney disease;
LIHC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.69	7.17	0.36	4.61e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.55	9.62	0.46	1.54e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.49	8.24	0.41	3.68e-15	Schizophrenia;
LIHC	cis	rs2292096	1.000	rs12736176	chr1:200801028	T/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-6.07	-0.31	3.33e-9	Epilepsy;
LIHC	cis	rs4908768	1.000	rs12122666	chr1:8741438	A/C	cg20416874	chr1:8611966	RERE	-0.52	-7.64	-0.38	2.24e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg18323236	chr1:24743029	NIPAL3	0.41	7.49	0.38	5.82e-13	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.32	-6.11	-0.31	2.71e-9	Systemic lupus erythematosus;
LIHC	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.6e-12	Corneal astigmatism;
LIHC	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.16	-0.52	6.99e-25	Platelet distribution width;
LIHC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.44	-7.65	-0.38	2e-13	Alzheimer's disease (late onset);
LIHC	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.93	0.31	7.28e-9	Educational attainment;
LIHC	trans	rs1814175	0.530	rs11040482	chr11:49727068	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-20.66	-0.75	4.12e-62	Height;
LIHC	cis	rs6141600	0.540	rs761312	chr20:34687809	A/G	cg03520225	chr20:34742782	EPB41L1	0.47	5.72	0.3	2.28e-8	Height;Hip circumference;
LIHC	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.57	-7.45	-0.37	7.53e-13	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LIHC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.39	-6.66	-0.34	1.09e-10	Type 2 diabetes;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.7	11.93	0.54	1.15e-27	Prudent dietary pattern;
LIHC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02034447	chr16:89574710	SPG7	0.47	7.35	0.37	1.47e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs15676	0.947	rs3115874	chr9:131579338	G/C	cg13708974	chr9:131466143	PKN3	0.38	5.81	0.3	1.43e-8	Blood metabolite levels;
LIHC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.59	-8.49	-0.42	6.55e-16	Coronary artery disease;
LIHC	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.16	-0.44	4.71e-18	Colorectal cancer;
LIHC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	7.82	0.39	6.67e-14	Protein C levels;
LIHC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.66	12.65	0.56	2.44e-30	Rheumatoid arthritis;
LIHC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.82	-8.3	-0.41	2.47e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs4774899	0.597	rs538382	chr15:56998703	C/A	cg26554170	chr1:227968812	SNAP47	0.36	6.04	0.31	4.01e-9	Urinary tract infection frequency;
LIHC	cis	rs8084351	0.577	rs3922754	chr18:50609302	T/C	cg24270629	chr18:50823537	DCC	0.46	6.93	0.35	2.16e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	31.58	0.86	2.1e-103	IgG glycosylation;
LIHC	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.51	-6.48	-0.33	3.11e-10	Hip circumference adjusted for BMI;
LIHC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-23.92	-0.79	5.38e-75	Height;
LIHC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.75	13.59	0.59	6.12e-34	Platelet count;
LIHC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.46	-7.33	-0.37	1.68e-12	Morning vs. evening chronotype;
LIHC	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg00012203	chr2:219082015	ARPC2	-0.52	-7.05	-0.36	1.01e-11	Ulcerative colitis;
LIHC	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14396892	chr9:96623032	NA	-0.32	-6.21	-0.32	1.53e-9	DNA methylation (variation);
LIHC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg23485639	chr6:28045615	ZNF165	0.38	6.04	0.31	4.02e-9	Cardiac Troponin-T levels;
LIHC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	8.92	0.43	2.8e-17	Menarche (age at onset);
LIHC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.59	6.86	0.35	3.17e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs988712	0.587	rs117567901	chr11:27706040	T/C	cg18117895	chr11:27722066	BDNF	0.51	7.16	0.36	4.97e-12	Obesity;
LIHC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.9	-18.69	-0.71	3.18e-54	Height;
LIHC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.49	-0.38	6.06e-13	Uric acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24515799	chr6:149867235	PPIL4	-0.44	-6.06	-0.31	3.64e-9	Pancreatic cancer;
LIHC	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg03934865	chr2:198174659	NA	-0.58	-9.26	-0.45	2.24e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6066825	0.605	rs761274	chr20:47315362	T/C	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.51e-12	Colorectal cancer;
LIHC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg14024328	chr4:719362	PCGF3	-0.46	-6.73	-0.34	6.98e-11	White blood cell count;
LIHC	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.35	7.9	0.39	3.84e-14	Educational attainment (years of education);
LIHC	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	0.81	9.21	0.45	3.34e-18	Exhaled nitric oxide output;
LIHC	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.37	-6.92	-0.35	2.2e-11	Height;
LIHC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.58	-0.38	3.3e-13	Urate levels in overweight individuals;
LIHC	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.09	-0.31	3.04e-9	Gout;
LIHC	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg00576331	chr11:65640516	EFEMP2	-0.41	-5.92	-0.3	8.04e-9	DNA methylation (variation);
LIHC	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.83	-11.41	-0.53	9.06e-26	Obesity-related traits;
LIHC	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.69	11.14	0.52	8.27e-25	Diisocyanate-induced asthma;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11987759	chr7:65425863	GUSB	0.38	6.07	0.31	3.43e-9	Aortic root size;
LIHC	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg00204512	chr16:28754710	NA	0.42	7.12	0.36	6.45e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.79	0.34	4.91e-11	Type 2 diabetes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09862616	chr5:122736738	CEP120	0.45	6.51	0.33	2.69e-10	Longevity;
LIHC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.73	-10.33	-0.49	5.82e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg20697417	chr1:41786797	NA	0.31	5.88	0.3	9.66e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11630290	0.736	rs7183958	chr15:64155534	C/G	cg12036633	chr15:63758958	NA	-0.65	-5.96	-0.31	6.38e-9	Iris characteristics;
LIHC	cis	rs12638540	0.543	rs13433871	chr3:32559673	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.94	8.04	0.4	1.45e-14	Mortality in heart failure;
LIHC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-7.29	-0.37	2.16e-12	Personality dimensions;
LIHC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.63	10.5	0.49	1.57e-22	Platelet count;
LIHC	trans	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg19694781	chr19:47549865	TMEM160	0.63	6.63	0.34	1.32e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs11031096	0.655	rs11031252	chr11:4211165	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-6.11	-0.31	2.66e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.49	-7.26	-0.37	2.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	7.77	0.39	9.54e-14	Iron status biomarkers;
LIHC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	1.01	14.83	0.63	9.44e-39	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.53	7.2	0.36	3.91e-12	Morning vs. evening chronotype;
LIHC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.48	7.86	0.39	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18030105	chr11:3396237	ZNF195	0.43	6.25	0.32	1.23e-9	Pancreatic cancer;
LIHC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	trans	rs17586843	0.528	rs1821010	chr4:116834041	A/G	cg25881869	chr10:114609298	LOC143188	0.43	6.57	0.33	1.89e-10	Age-related macular degeneration;
LIHC	cis	rs12079745	0.793	rs12097260	chr1:169317195	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-7.08	-0.36	8.09e-12	QT interval;
LIHC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg14440974	chr22:39074834	NA	0.35	5.9	0.3	8.63e-9	Menopause (age at onset);
LIHC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg07636037	chr3:49044803	WDR6	-0.81	-7.87	-0.39	4.82e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.74	-0.5	2.21e-23	Total cholesterol levels;
LIHC	cis	rs12079745	0.590	rs12061080	chr1:169332848	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	1.95e-11	QT interval;
LIHC	cis	rs16912285	0.584	rs7131124	chr11:24249455	A/G	ch.11.24196551F	chr11:24239977	NA	0.79	10.77	0.5	1.71e-23	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg04756594	chr16:24857601	SLC5A11	0.46	7.08	0.36	8.22e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.74	-8.85	-0.43	4.87e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs11014306	1.000	rs1409306	chr10:25205965	C/G	cg17214381	chr4:188916668	ZFP42	-0.55	-6.24	-0.32	1.29e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.37	-5.71	-0.3	2.44e-8	Obesity-related traits;
LIHC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.01	11.75	0.54	5.02e-27	White matter hyperintensity burden;
LIHC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.78	-0.5	1.66e-23	Coronary artery disease;
LIHC	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg22764044	chr5:178986830	RUFY1	-0.4	-5.88	-0.3	9.73e-9	Lung cancer;
LIHC	cis	rs2637266	0.756	rs846607	chr10:78561254	A/T	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.96e-9	Pulmonary function;
LIHC	cis	rs782590	0.687	rs62165255	chr2:55932585	G/A	cg03859395	chr2:55845619	SMEK2	0.8	13.43	0.59	2.56e-33	Metabolic syndrome;
LIHC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.57	-0.33	1.9e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.62	-0.34	1.36e-10	Bladder cancer;
LIHC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg05941027	chr17:61774174	LIMD2	0.35	7.35	0.37	1.48e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.5	0.53	4.16e-26	Height;
LIHC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg18478394	chr8:109455254	TTC35	0.42	7.21	0.36	3.61e-12	Dupuytren's disease;
LIHC	cis	rs61712019	0.563	rs35286009	chr2:77730722	C/G	cg11252801	chr2:77748917	LRRTM4	0.45	6.17	0.32	1.98e-9	Schizophrenia;
LIHC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.72	9.38	0.45	9.41e-19	Dilated cardiomyopathy;
LIHC	cis	rs249954	0.512	rs703769	chr16:23654509	T/G	cg09867953	chr16:23706666	ERN2	0.38	6.39	0.33	5.36e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.97	-0.4	2.44e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.6	-10.79	-0.5	1.42e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs611744	0.837	rs438191	chr8:109124222	A/G	cg21045802	chr8:109455806	TTC35	0.5	8.48	0.42	7e-16	Dupuytren's disease;
LIHC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.02e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Parkinson's disease;
LIHC	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg27255678	chr10:102756921	LZTS2	0.52	7.29	0.37	2.22e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-11.07	-0.51	1.5e-24	Platelet count;
LIHC	cis	rs807029	0.533	rs2295716	chr10:102744214	T/C	cg17130504	chr10:102756923	LZTS2	0.56	7.8	0.39	7.35e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.32	0.58	6.55e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.22	-0.32	1.44e-9	Alzheimer's disease (late onset);
LIHC	cis	rs244293	0.831	rs11079149	chr17:53095046	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.51	0.38	5.12e-13	Menarche (age at onset);
LIHC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.8	0.78	1.28e-70	Prudent dietary pattern;
LIHC	cis	rs7520050	0.933	rs6666743	chr1:46311275	C/T	cg03146154	chr1:46216737	IPP	-0.37	-5.92	-0.3	8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7508	0.509	rs441764	chr8:17903157	A/G	cg01800426	chr8:17659068	MTUS1	-0.41	-6.66	-0.34	1.08e-10	Atrial fibrillation;
LIHC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg01256987	chr12:42539512	GXYLT1	-0.38	-6.3	-0.32	9.16e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg12863693	chr15:85201151	NMB	0.44	6.34	0.32	7.18e-10	Schizophrenia;
LIHC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.89	0.43	3.61e-17	Lymphocyte percentage of white cells;
LIHC	trans	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg26939375	chr7:64535504	NA	0.43	6.96	0.35	1.72e-11	Aortic root size;
LIHC	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg20737812	chr15:86336631	KLHL25	-0.42	-5.83	-0.3	1.27e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.44	6.28	0.32	1.06e-9	Aortic root size;
LIHC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.42	7.63	0.38	2.34e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg07541023	chr7:19748670	TWISTNB	0.49	7.32	0.37	1.74e-12	Thyroid stimulating hormone;
LIHC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.74	-0.3	2.06e-8	Type 2 diabetes;
LIHC	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.26	-0.32	1.12e-9	Coronary artery disease;
LIHC	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg00083206	chr6:110721305	DDO	-0.33	-6.6	-0.34	1.57e-10	Platelet distribution width;
LIHC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.61	7.16	0.36	4.89e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-11.56	-0.53	2.55e-26	Colorectal cancer;
LIHC	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.47	8.98	0.44	1.88e-17	Testicular germ cell tumor;
LIHC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.26	6.98	0.35	1.56e-11	Cardiovascular disease risk factors;
LIHC	cis	rs611744	0.901	rs639746	chr8:109234825	T/C	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.35	1.23e-11	Diabetic kidney disease;
LIHC	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.85	-0.35	3.46e-11	Adiposity;
LIHC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.47	7.9	0.39	3.73e-14	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16582978	chr5:170814878	NPM1	0.42	6.03	0.31	4.16e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.63	9.45	0.46	5.47e-19	Platelet count;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.48	0.38	6.27e-13	Aortic root size;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00480142	chr12:96046743	NA	0.43	6.53	0.33	2.39e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.8	-12.43	-0.56	1.56e-29	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg13409248	chr3:40428643	ENTPD3	-0.48	-8.37	-0.41	1.52e-15	Renal cell carcinoma;
LIHC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg07424592	chr7:64974309	NA	-0.82	-9.43	-0.45	6.33e-19	Diabetic kidney disease;
LIHC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.55	-8.3	-0.41	2.4e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.4	-5.81	-0.3	1.44e-8	Narcolepsy;
LIHC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg04315214	chr1:2043799	PRKCZ	0.46	7.35	0.37	1.5e-12	Height;
LIHC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.81	9.5	0.46	3.89e-19	Bladder cancer;
LIHC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg21724239	chr8:58056113	NA	0.49	6.36	0.33	6.38e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg20932281	chr17:33905541	PEX12	0.42	5.81	0.3	1.44e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.72	9.19	0.45	3.85e-18	Gut microbiome composition (summer);
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05277466	chr16:88082055	BANP	0.47	6.38	0.33	5.81e-10	Myopia (pathological);
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-21.07	-0.75	9.58e-64	Prudent dietary pattern;
LIHC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-6.47	-0.33	3.38e-10	Height;
LIHC	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.71	-7.1	-0.36	7.45e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs231513	0.954	rs231505	chr17:41970268	A/T	cg26893861	chr17:41843967	DUSP3	0.62	5.81	0.3	1.47e-8	Cognitive function;
LIHC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.3	-16.7	-0.67	3.38e-46	Diabetic kidney disease;
LIHC	cis	rs600806	0.821	rs4970840	chr1:109873367	A/G	cg23091122	chr1:110024289	SYPL2	-0.45	-5.93	-0.31	7.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg00612595	chr21:47717864	NA	-0.35	-5.76	-0.3	1.9e-8	Testicular germ cell tumor;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.74e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg05185784	chr16:90016020	DEF8	-0.48	-6.39	-0.33	5.56e-10	Skin colour saturation;
LIHC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.09	20.8	0.75	1.08e-62	Multiple system atrophy;
LIHC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	10.03	0.48	6.29e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.94	0.44	2.57e-17	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.28	0.45	2.01e-18	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	0.6	8.75	0.43	9.91e-17	Prudent dietary pattern;
LIHC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.58	-7.8	-0.39	7.55e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.55	-8.18	-0.4	5.58e-15	Body mass index;
LIHC	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.49	-0.33	3.08e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg26939375	chr7:64535504	NA	0.41	6.62	0.34	1.42e-10	Aortic root size;
LIHC	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.52	-6.41	-0.33	4.93e-10	Ileal carcinoids;
LIHC	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	8.91	0.43	2.98e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg09182678	chr22:50328711	NA	-0.39	-5.82	-0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.34	6.48	0.33	3.21e-10	Multiple system atrophy;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.51	8.25	0.41	3.55e-15	Testicular germ cell tumor;
LIHC	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg01843034	chr6:37503916	NA	0.51	8.22	0.41	4.13e-15	Cognitive performance;
LIHC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.79	11.76	0.54	4.78e-27	Coronary artery disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12232852	chr3:69129018	UBA3	0.47	7.21	0.36	3.67e-12	Cognitive function;
LIHC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg17764715	chr19:33622953	WDR88	0.45	6.5	0.33	2.78e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg04727924	chr7:799746	HEATR2	0.53	6.79	0.34	5.09e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6782228	0.606	rs1127030	chr3:128338953	T/C	cg16766828	chr3:128327626	NA	-0.41	-6.46	-0.33	3.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.56	6.91	0.35	2.38e-11	Heart rate;
LIHC	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.46	7.61	0.38	2.62e-13	Crohn's disease;
LIHC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.54	-8.56	-0.42	3.78e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg06935464	chr4:38784597	TLR10	0.49	7.56	0.38	3.65e-13	Breast cancer;
LIHC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs860295	0.580	rs6672284	chr1:155277963	C/T	cg02153340	chr1:155202674	NA	-0.37	-6.58	-0.34	1.73e-10	Body mass index;
LIHC	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.54	-8.0	-0.4	1.91e-14	Age at first birth;
LIHC	cis	rs12365397	0.748	rs11037372	chr11:43254162	C/A	cg16667275	chr11:43333495	API5	0.42	6.31	0.32	8.67e-10	Migraine;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.39	7.94	0.39	2.93e-14	Renal cell carcinoma;
LIHC	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.41	-8.66	-0.42	1.95e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.63	11.27	0.52	2.99e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.51	-0.38	5.11e-13	Mean platelet volume;
LIHC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg10790698	chr19:18539756	SSBP4	-0.35	-7.41	-0.37	9.66e-13	Breast cancer;
LIHC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.8	9.01	0.44	1.46e-17	Vitiligo;
LIHC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs11586313	0.507	rs3856026	chr1:152869763	T/C	cg07796016	chr1:152779584	LCE1C	-0.36	-5.83	-0.3	1.26e-8	Vitamin D levels;
LIHC	cis	rs7481584	0.717	rs3759025	chr11:3017377	G/A	cg25174290	chr11:3078921	CARS	-0.4	-5.88	-0.3	9.68e-9	Calcium levels;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.69	-10.96	-0.51	3.73e-24	Skin colour saturation;
LIHC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.67	-14.14	-0.61	4.54e-36	Sense of smell;
LIHC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.08	-0.48	4.34e-21	Tonsillectomy;
LIHC	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg10820045	chr2:198174542	NA	0.5	7.98	0.4	2.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.24	0.45	2.6e-18	Bipolar disorder;
LIHC	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	6.24	0.32	1.33e-9	Ileal carcinoids;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.6	0.56	3.7e-30	Prudent dietary pattern;
LIHC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.63	-12.08	-0.55	3.25e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7961581	0.719	rs1798071	chr12:71599401	C/A	cg05756094	chr12:71608604	NA	0.41	6.71	0.34	7.99e-11	Type 2 diabetes;
LIHC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg25356066	chr3:128598488	ACAD9	0.55	7.66	0.38	1.9e-13	IgG glycosylation;
LIHC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.43	-7.14	-0.36	5.47e-12	Blood pressure (smoking interaction);
LIHC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	6.09	0.31	2.99e-9	Schizophrenia;
LIHC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	0.82	6.76	0.34	5.85e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02985541	chr2:219472218	PLCD4	-0.42	-6.86	-0.35	3.33e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.91	0.35	2.44e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.31	6.89	0.35	2.63e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LIHC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.08	14.26	0.61	1.61e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.52	8.34	0.41	1.89e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.68	10.3	0.49	7.28e-22	Menarche (age at onset);
LIHC	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.58	9.15	0.44	5.35e-18	Height;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12609600	chr11:1595974	HCCA2;LOC338651	0.38	6.98	0.35	1.54e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	8.67	0.42	1.81e-16	Blood protein levels;
LIHC	cis	rs11718455	0.585	rs11710802	chr3:43930155	T/G	cg08738300	chr3:44038990	NA	0.36	6.11	0.31	2.65e-9	Coronary artery disease;
LIHC	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg00012203	chr2:219082015	ARPC2	-0.52	-7.02	-0.35	1.19e-11	Ulcerative colitis;
LIHC	cis	rs7546	0.504	rs2015319	chr16:4936280	C/G	cg08329684	chr16:4932620	PPL	-0.43	-7.6	-0.38	2.92e-13	Cancer;
LIHC	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.91	0.35	2.36e-11	Bipolar disorder;
LIHC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	0.84	13.52	0.59	1.11e-33	Left atrial antero-posterior diameter;
LIHC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.08	19.18	0.72	3.56e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.07	-0.31	3.48e-9	Colorectal cancer;
LIHC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.35	-6.12	-0.31	2.63e-9	Aortic root size;
LIHC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.99	0.4	2.09e-14	Motion sickness;
LIHC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.69	13.69	0.59	2.57e-34	Coronary artery disease;
LIHC	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	20.12	0.74	5.76e-60	Exhaled nitric oxide output;
LIHC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg22079354	chr11:130786696	SNX19	0.48	7.23	0.36	3.15e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.89	-9.02	-0.44	1.35e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.13	-0.61	5.04e-36	Alzheimer's disease;
LIHC	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.59	-0.53	1.95e-26	Coffee consumption (cups per day);
LIHC	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.75	0.47	5.75e-20	Morning vs. evening chronotype;
LIHC	cis	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.74	-0.3	2.13e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg19318889	chr4:1322082	MAEA	-0.46	-6.41	-0.33	4.7e-10	Obesity-related traits;
LIHC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg14024328	chr4:719362	PCGF3	-0.48	-7.14	-0.36	5.61e-12	White blood cell count;
LIHC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.95	0.31	6.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02881034	chr2:86426836	MRPL35	0.34	6.41	0.33	4.76e-10	Calcium levels;
LIHC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.93	15.25	0.64	2.01e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.58	8.22	0.41	4.39e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg23202291	chr11:1979235	NA	-0.42	-6.05	-0.31	3.91e-9	DNA methylation (variation);
LIHC	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg04218760	chr10:45406644	TMEM72	-0.19	-5.76	-0.3	1.88e-8	Mean corpuscular volume;
LIHC	cis	rs3853824	0.930	rs11079260	chr17:54908599	G/T	cg13675837	chr17:54910204	DGKE	0.42	5.91	0.3	8.42e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.33	-6.56	-0.33	2.05e-10	Aortic root size;
LIHC	trans	rs783540	0.746	rs7165125	chr15:83297936	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.13	-0.31	2.37e-9	Schizophrenia;
LIHC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.15e-16	Motion sickness;
LIHC	cis	rs8053891	0.756	rs28629271	chr16:72003732	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.7	-0.34	8.73e-11	Coronary artery disease;
LIHC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg15832292	chr6:96025679	MANEA	-0.72	-9.0	-0.44	1.64e-17	Behavioural disinhibition (generation interaction);
LIHC	cis	rs1322512	1.000	rs2758816	chr6:152968338	A/T	cg03415253	chr6:152958462	SYNE1	-0.33	-5.97	-0.31	6.06e-9	Tonometry;
LIHC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.42	-0.59	2.81e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.51	7.86	0.39	5.11e-14	Systemic lupus erythematosus;
LIHC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.37	5.9	0.3	8.52e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.38	-5.97	-0.31	5.97e-9	Morning vs. evening chronotype;
LIHC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg15448220	chr1:150897856	SETDB1	-0.43	-6.35	-0.32	6.71e-10	Blood protein levels;
LIHC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.59	-11.54	-0.53	3.12e-26	Coronary artery disease;
LIHC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-1.01	-19.62	-0.73	5.91e-58	Breast cancer;
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.39	7.92	0.39	3.48e-14	Renal cell carcinoma;
LIHC	trans	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg10756647	chr7:56101905	PSPH	1.06	12.81	0.57	5.83e-31	Diabetic kidney disease;
LIHC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.7	0.34	8.66e-11	Lung cancer;
LIHC	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03517284	chr6:25882590	NA	0.48	6.41	0.33	4.85e-10	Blood metabolite levels;
LIHC	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.74	10.66	0.5	4.27e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg07424592	chr7:64974309	NA	0.84	9.54	0.46	2.71e-19	Diabetic kidney disease;
LIHC	cis	rs9783347	1.000	rs4150622	chr11:18365710	A/G	cg15585147	chr11:18324498	HPS5	0.43	6.64	0.34	1.21e-10	Pancreatic cancer;
LIHC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg01320579	chr17:75405842	SEPT9	-0.5	-7.15	-0.36	5.44e-12	Airflow obstruction;
LIHC	trans	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg07541023	chr7:19748670	TWISTNB	0.42	6.13	0.31	2.42e-9	Thyroid stimulating hormone;
LIHC	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg23254163	chr1:152506842	NA	0.23	5.94	0.31	6.86e-9	Hair morphology;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.59	8.72	0.43	1.19e-16	Prudent dietary pattern;
LIHC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-6.23	-0.32	1.37e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg08888203	chr3:10149979	C3orf24	0.56	6.43	0.33	4.31e-10	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12427896	chr2:111880694	BCL2L11	0.39	6.55	0.33	2.17e-10	Cognitive function;
LIHC	trans	rs1484948	0.560	rs4261271	chr11:41943080	C/T	cg09339301	chr6:163836245	QKI	0.56	6.09	0.31	3.06e-9	RR interval (heart rate);
LIHC	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.4	-6.57	-0.33	1.92e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05742294	chr8:124169368	NA	0.46	6.61	0.34	1.43e-10	Cognitive function;
LIHC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.67	11.55	0.53	2.84e-26	Colorectal cancer;
LIHC	cis	rs909002	0.830	rs1356803	chr1:32131163	C/G	cg13919466	chr1:32135498	COL16A1	-0.34	-6.31	-0.32	8.71e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg03031660	chr17:73257791	MRPS7;GGA3	-0.41	-6.38	-0.33	5.71e-10	Body mass index;
LIHC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.65	-9.32	-0.45	1.47e-18	Blood metabolite levels;
LIHC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.55	7.26	0.37	2.67e-12	Initial pursuit acceleration;
LIHC	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12079745	0.623	rs2901092	chr1:169456393	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-7.3	-0.37	2.08e-12	QT interval;
LIHC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.42	6.8	0.35	4.66e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.62	6.92	0.35	2.26e-11	Schizophrenia;
LIHC	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.75	6.25	0.32	1.2e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	6.85	0.35	3.35e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.74	0.39	1.12e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.52	-6.98	-0.35	1.52e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.55	0.53	2.78e-26	Platelet count;
LIHC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg03037974	chr15:76606532	NA	0.77	15.22	0.64	2.7e-40	Blood metabolite levels;
LIHC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	1.06	15.95	0.65	3.23e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.19	-6.01	-0.31	4.65e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.36	-5.95	-0.31	6.72e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21467203	chr3:49911342	NA	0.52	9.46	0.46	5.1e-19	Body mass index;
LIHC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.53	-6.18	-0.32	1.87e-9	Corneal curvature;
LIHC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.7	11.65	0.53	1.25e-26	Mean platelet volume;
LIHC	cis	rs11229555	0.645	rs61889554	chr11:58424081	C/A	cg15696309	chr11:58395628	NA	-0.64	-6.21	-0.32	1.56e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg19302996	chr17:73780495	UNK	-0.47	-6.69	-0.34	9.14e-11	White matter hyperintensity burden;
LIHC	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg17410650	chr12:54324560	NA	-0.4	-7.22	-0.36	3.4e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg14593290	chr7:50529359	DDC	-0.48	-7.85	-0.39	5.28e-14	Malaria;
LIHC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.53	-7.4	-0.37	1.04e-12	Body mass index;
LIHC	cis	rs4908768	0.501	rs6577488	chr1:8534529	T/C	cg20416874	chr1:8611966	RERE	-0.69	-14.74	-0.62	2.15e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-6.85	-0.35	3.49e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg24296786	chr1:45957014	TESK2	-0.4	-5.88	-0.3	9.95e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.43	-7.09	-0.36	7.56e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs74544699	1.000	rs4082827	chr4:74831180	A/C	cg15398841	chr4:74847761	PF4	-0.56	-5.85	-0.3	1.12e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.42	8.03	0.4	1.54e-14	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-6.04	-0.31	3.96e-9	Calcium levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13445258	chr3:128369860	RPN1	0.4	6.52	0.33	2.57e-10	Cognitive function;
LIHC	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.55	9.58	0.46	2.01e-19	Menopause (age at onset);
LIHC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.67	-9.97	-0.47	9.98e-21	Mosquito bite size;
LIHC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg05941027	chr17:61774174	LIMD2	0.37	7.44	0.37	8.41e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.8e-52	Breast cancer;
LIHC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.69	-10.97	-0.51	3.38e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	15.58	0.64	9.78e-42	Lung cancer in ever smokers;
LIHC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg06466757	chr4:1255808	NA	0.34	5.82	0.3	1.32e-8	Obesity-related traits;
LIHC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.35	7.74	0.39	1.15e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg04025307	chr7:1156635	C7orf50	0.47	5.86	0.3	1.12e-8	Bronchopulmonary dysplasia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23211358	chr19:17378293	C19orf62	-0.52	-6.23	-0.32	1.35e-9	Systolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04691540	chr1:179198414	ABL2	0.42	6.97	0.35	1.65e-11	Pancreatic cancer;
LIHC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.68	10.24	0.48	1.19e-21	Height;
LIHC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg00750074	chr16:89608354	SPG7	-0.49	-7.92	-0.39	3.27e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.3e-9	Aortic root size;
LIHC	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.77	-12.3	-0.55	4.73e-29	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.39	6.12	0.31	2.54e-9	Height;
LIHC	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg10820045	chr2:198174542	NA	0.45	6.85	0.35	3.5e-11	Dermatomyositis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08128228	chr1:167191360	POU2F1	0.53	6.85	0.35	3.48e-11	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg18769074	chr3:133464867	TF	0.26	5.89	0.3	9.45e-9	Iron status biomarkers (transferrin levels);
LIHC	trans	rs975809	0.966	rs11004607	chr10:56622686	G/T	cg05965430	chr12:49962171	MCRS1	0.42	6.1	0.31	2.8e-9	Carotid intima media thickness;
LIHC	cis	rs2257205	0.667	rs1018051	chr17:56909926	A/G	cg12560992	chr17:57184187	TRIM37	0.63	7.0	0.35	1.32e-11	Pancreatic cancer;
LIHC	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.49	-9.27	-0.45	2.09e-18	Endometriosis;
LIHC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg14440974	chr22:39074834	NA	-0.42	-6.68	-0.34	9.85e-11	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23676114	chr9:33264786	SUGT1P1;CHMP5;BAG1	0.48	6.87	0.35	3.1e-11	Pancreatic cancer;
LIHC	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22509189	chr2:225307070	NA	-0.44	-5.75	-0.3	2e-8	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.45	0.37	7.93e-13	Neuroticism;
LIHC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg10088519	chr17:8066240	VAMP2	-0.38	-6.06	-0.31	3.51e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
LIHC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.77	-12.07	-0.55	3.52e-28	Breast cancer;
LIHC	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.04	-0.31	3.92e-9	Blood pressure;
LIHC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg15691649	chr6:25882328	NA	-0.64	-8.51	-0.42	5.68e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg20607798	chr8:58055168	NA	0.64	7.7	0.38	1.51e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-23.79	-0.79	1.71e-74	Myeloid white cell count;
LIHC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	8.5	0.42	5.94e-16	Lung cancer;
LIHC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.39	6.25	0.32	1.24e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.86	0.43	4.49e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-6.47	-0.33	3.31e-10	Initial pursuit acceleration;
LIHC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.69	10.28	0.49	8.63e-22	Dental caries;
LIHC	cis	rs7326068	0.524	rs2497484	chr13:21199265	C/T	cg27234864	chr13:21295941	IL17D	-0.37	-5.91	-0.3	8.25e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.62	-8.52	-0.42	5.26e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg13271783	chr10:134563150	INPP5A	-0.59	-7.08	-0.36	8.16e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg14793835	chr3:28283034	CMC1	0.42	6.06	0.31	3.51e-9	Cannabis use (initiation);
LIHC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.84	0.3	1.22e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.94	0.31	7.19e-9	Menopause (age at onset);
LIHC	cis	rs10508774	0.810	rs11008965	chr10:32824451	G/T	cg01819863	chr10:32635814	EPC1	0.6	5.76	0.3	1.88e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg00280220	chr17:61926910	NA	0.43	6.79	0.34	4.99e-11	Prudent dietary pattern;
LIHC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.38	6.58	0.34	1.73e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-9.0	-0.44	1.57e-17	Electroencephalogram traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07650554	chr16:30457408	SEPHS2	0.44	6.46	0.33	3.68e-10	Pancreatic cancer;
LIHC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.43	5.89	0.3	9.29e-9	Osteoporosis;
LIHC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.54	8.41	0.41	1.12e-15	Vitiligo;
LIHC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.86	0.35	3.28e-11	Diabetic kidney disease;
LIHC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.71	13.23	0.58	1.48e-32	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.44	7.28	0.37	2.26e-12	Corneal astigmatism;
LIHC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.48	-7.48	-0.37	6.43e-13	Coronary artery disease;
LIHC	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg19773385	chr1:10388646	KIF1B	-0.48	-8.41	-0.41	1.16e-15	Hepatocellular carcinoma;
LIHC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.37	-6.53	-0.33	2.41e-10	Aortic root size;
LIHC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.65	6.43	0.33	4.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg05973401	chr12:123451056	ABCB9	0.43	5.94	0.31	7.13e-9	Neutrophil percentage of white cells;
LIHC	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg10820045	chr2:198174542	NA	0.53	8.49	0.42	6.29e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.97	22.07	0.77	9.37e-68	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.48	-5.89	-0.3	9.04e-9	Parkinson's disease;
LIHC	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg26138937	chr11:71823887	C11orf51	-1.31	-10.34	-0.49	5.49e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.83	0.39	6.36e-14	Lymphocyte counts;
LIHC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.6	-9.18	-0.44	4.2e-18	Height;
LIHC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg19682013	chr15:45996608	NA	0.41	7.25	0.37	2.78e-12	Waist circumference;Weight;
LIHC	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg12698662	chr3:15914712	MIR563	-0.39	-7.2	-0.36	3.84e-12	Mean platelet volume;
LIHC	trans	rs73186030	0.920	rs55784797	chr3:122054635	C/T	cg13973942	chr17:977984	ABR	0.47	6.06	0.31	3.54e-9	Serum parathyroid hormone levels;
LIHC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	7.12	0.36	6.32e-12	Body mass index;
LIHC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg07645718	chr20:61493192	TCFL5	0.7	6.02	0.31	4.52e-9	Obesity-related traits;
LIHC	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.49	7.7	0.38	1.43e-13	Diastolic blood pressure;
LIHC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	0.74	7.69	0.38	1.5700000000000001e-13	Testicular germ cell tumor;
LIHC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg18016565	chr1:150552671	MCL1	0.52	9.77	0.47	4.63e-20	Melanoma;
LIHC	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg06664874	chr5:179499304	RNF130	0.7	7.67	0.38	1.83e-13	LDL cholesterol;
LIHC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg03037974	chr15:76606532	NA	-0.6	-10.1	-0.48	3.62e-21	Blood metabolite levels;
LIHC	cis	rs5753037	0.809	rs2074707	chr22:30210356	G/A	cg01021169	chr22:30184971	ASCC2	-0.36	-6.83	-0.35	3.97e-11	Type 1 diabetes;
LIHC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg25356066	chr3:128598488	ACAD9	0.55	7.67	0.38	1.82e-13	IgG glycosylation;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22887498	chr19:39401301	NA	0.46	6.21	0.32	1.53e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-7.52	-0.38	4.99e-13	Cognitive function;
LIHC	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg02403541	chr12:121454288	C12orf43	-0.37	-6.34	-0.32	7.23e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.58	9.54	0.46	2.7e-19	Resting heart rate;
LIHC	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.0	-0.35	1.37e-11	Blood pressure;
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.36	6.04	0.31	4.13e-9	Height;
LIHC	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs72829446	0.530	rs4796430	chr17:7401903	A/G	cg02795151	chr17:7402630	POLR2A	0.55	6.26	0.32	1.16e-9	Androgen levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16515820	chr3:114866447	ZBTB20	0.41	6.49	0.33	3.05e-10	Cognitive function;
LIHC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg13175981	chr1:150552382	MCL1	-0.44	-6.06	-0.31	3.55e-9	Tonsillectomy;
LIHC	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.86	8.76	0.43	9.07e-17	Uric acid levels;
LIHC	cis	rs3736485	0.934	rs8036821	chr15:51861646	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.73	12.04	0.55	4.55e-28	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs509477	0.718	rs273358	chr18:32596784	C/T	cg23791764	chr18:32556832	MAPRE2	0.43	5.96	0.31	6.28e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs709400	0.628	rs10150072	chr14:103977605	C/T	cg26031613	chr14:104095156	KLC1	0.72	9.14	0.44	5.86e-18	Body mass index;
LIHC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg25894440	chr7:65020034	NA	-0.53	-6.11	-0.31	2.72e-9	Diabetic kidney disease;
LIHC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.07e-40	Aortic root size;
LIHC	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg15192750	chr16:69999425	NA	0.46	6.89	0.35	2.71e-11	IgE levels;
LIHC	cis	rs903552	0.736	rs9806369	chr15:102008430	A/C	cg06707286	chr15:102010195	PCSK6	-0.55	-7.91	-0.39	3.69e-14	Diabetic kidney disease;
LIHC	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.42	0.41	1.02e-15	Exhaled nitric oxide output;
LIHC	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg20283391	chr11:68216788	NA	-0.48	-5.9	-0.3	8.91e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.06e-19	Renal cell carcinoma;
LIHC	cis	rs4979906	1.000	rs7098023	chr10:79449665	A/C	cg07817648	chr10:79422355	NA	-0.29	-6.32	-0.32	8.17e-10	Mortality in heart failure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08949621	chr15:42265044	EHD4	0.48	6.41	0.33	4.82e-10	Lung function (FEV1/FVC);
LIHC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.32	-6.71	-0.34	8.3e-11	Longevity;
LIHC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.26	-0.52	3.12e-25	Chronic sinus infection;
LIHC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.08	0.58	5.63e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.92	-16.02	-0.65	1.72e-43	Tonsillectomy;
LIHC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	12.4	0.56	2.14e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.66	0.38	1.89e-13	Prudent dietary pattern;
LIHC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.36	0.49	4.68e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.49	7.73	0.39	1.19e-13	HDL cholesterol;
LIHC	trans	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg26939375	chr7:64535504	NA	0.43	6.94	0.35	2.02e-11	Aortic root size;
LIHC	cis	rs11628318	0.563	rs1190344	chr14:103097912	A/G	cg12046867	chr14:103022105	NA	-0.43	-6.69	-0.34	9.31e-11	Platelet count;
LIHC	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg16479474	chr6:28041457	NA	0.46	6.58	0.34	1.78e-10	Depression;
LIHC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.59	8.56	0.42	3.94e-16	Platelet count;
LIHC	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.62	-10.69	-0.5	3.22e-23	Schizophrenia;
LIHC	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.99	-0.35	1.43e-11	Blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20286844	chr1:204485360	MDM4	0.5	6.92	0.35	2.21e-11	Pancreatic cancer;
LIHC	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg22153463	chr1:85462885	MCOLN2	0.51	6.04	0.31	4.12e-9	Serum sulfate level;
LIHC	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.33	-0.41	1.94e-15	Exhaled nitric oxide output;
LIHC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.32	-0.41	2.16e-15	Heart rate;
LIHC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.11	-0.36	6.7e-12	Menopause (age at onset);
LIHC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.79	12.47	0.56	1.1e-29	Breast cancer;
LIHC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.93	-17.78	-0.69	1.56e-50	Height;
LIHC	cis	rs2257205	0.667	rs6503881	chr17:56911251	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-6.51	-0.33	2.72e-10	Pancreatic cancer;
LIHC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg14393609	chr7:65229607	NA	0.37	5.84	0.3	1.22e-8	Aortic root size;
LIHC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.08	0.36	8.05e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg14779329	chr11:130786720	SNX19	0.39	5.84	0.3	1.22e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg27386326	chr11:61587980	NA	0.47	6.8	0.35	4.71e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs3736485	0.652	rs2054166	chr15:51974910	A/T	cg08986416	chr15:51914746	DMXL2	-0.43	-6.27	-0.32	1.1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.77	12.78	0.57	7.9e-31	Tonsillectomy;
LIHC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.37	-0.59	4.35e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.88	0.35	2.95e-11	Renal cell carcinoma;
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg00204748	chr12:29376779	FAR2	0.43	8.05	0.4	1.43e-14	QT interval;
LIHC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.07	25.45	0.81	6.59e-81	IgG glycosylation;
LIHC	cis	rs1865721	1.000	rs1865721	chr18:73192446	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.95	-0.31	6.71e-9	Biliary atresia;
LIHC	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.52	-12.18	-0.55	1.35e-28	White blood cell count (basophil);
LIHC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.79	-0.3	1.64e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12463550	chr7:65579703	CRCP	0.68	7.14	0.36	5.69e-12	Diabetic kidney disease;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.34	5.81	0.3	1.42e-8	Lung cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25880573	chr1:24073129	TCEB3	-0.36	-6.37	-0.33	5.93e-10	Pancreatic cancer;
LIHC	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.84	0.3	1.19e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.28	0.52	2.62e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg06935464	chr4:38784597	TLR10	0.46	7.19	0.36	4.1e-12	Breast cancer;
LIHC	cis	rs75908454	1.000	rs75908454	chr6:169970623	T/C	cg19338460	chr6:170058176	WDR27	-0.62	-6.01	-0.31	4.63e-9	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs57244997	0.725	rs73785320	chr6:162439590	A/C	cg17173639	chr6:162384350	PARK2	-0.51	-6.68	-0.34	9.43e-11	Mosquito bite size;
LIHC	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Migraine;
LIHC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg13271783	chr10:134563150	INPP5A	-0.52	-6.75	-0.34	6.38e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.06	-0.31	3.64e-9	Diastolic blood pressure;
LIHC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.36	0.37	1.34e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.47	-0.33	3.35e-10	Bipolar disorder;
LIHC	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg19773385	chr1:10388646	KIF1B	-0.52	-8.58	-0.42	3.31e-16	Hepatocellular carcinoma;
LIHC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.68	10.05	0.48	5.41e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	trans	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.8	-15.07	-0.63	9.94e-40	Multiple myeloma (IgH translocation);
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg14709524	chr16:89940631	TCF25	0.59	7.63	0.38	2.43e-13	Skin colour saturation;
LIHC	cis	rs11233413	0.559	rs11233391	chr11:82683038	A/C	cg24227371	chr11:82718527	RAB30	-0.33	-7.35	-0.37	1.44e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs903552	1.000	rs8027380	chr15:102005810	T/C	cg19295451	chr15:102010161	PCSK6	-0.46	-6.33	-0.32	7.51e-10	Diabetic kidney disease;
LIHC	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.67	7.22	0.36	3.48e-12	Type 2 diabetes;
LIHC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.93	-0.47	1.36e-20	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22509189	chr2:225307070	NA	0.56	7.19	0.36	4.07e-12	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs400736	0.526	rs10864329	chr1:8164460	G/A	cg25007680	chr1:8021821	PARK7	-0.48	-7.22	-0.36	3.31e-12	Response to antidepressants and depression;
LIHC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.43	6.49	0.33	3.09e-10	Personality dimensions;
LIHC	cis	rs2421770	0.530	rs7930134	chr11:35367017	A/C	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.59	-0.38	3.02e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16266895	chr12:101674004	UTP20	0.44	6.3	0.32	9.28e-10	Pancreatic cancer;
LIHC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.37	-6.53	-0.33	2.38e-10	Tuberculosis;
LIHC	cis	rs244293	0.760	rs4794547	chr17:53011172	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-7.31	-0.37	1.9e-12	Menarche (age at onset);
LIHC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg23262073	chr20:60523788	NA	-0.29	-5.94	-0.31	6.89e-9	Body mass index;
LIHC	cis	rs12915845	0.545	rs17197019	chr15:89079672	C/T	cg05013243	chr15:89149849	MIR1179	0.37	6.74	0.34	6.56e-11	Menarche (age at onset);
LIHC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-8.54	-0.42	4.58e-16	Gut microbiome composition (summer);
LIHC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.9	18.89	0.71	5.17e-55	Height;
LIHC	cis	rs1983891	0.874	rs2395779	chr6:41511950	C/T	cg20194872	chr6:41519635	FOXP4	0.42	6.86	0.35	3.23e-11	Prostate cancer;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17360233	chr16:10479841	NA	0.42	6.35	0.32	6.89e-10	Alopecia areata;
LIHC	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.61	-7.58	-0.38	3.21e-13	Crohn's disease;
LIHC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.47	9.0	0.44	1.63e-17	Schizophrenia;
LIHC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.43	-6.53	-0.33	2.32e-10	Height;
LIHC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg24130564	chr14:104152367	KLC1	-0.35	-5.74	-0.3	2.07e-8	Schizophrenia;
LIHC	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.21	-0.32	1.52e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs57590327	0.503	rs9874464	chr3:81505488	C/G	cg07356753	chr3:81810745	GBE1	-0.47	-7.02	-0.35	1.2e-11	Extraversion;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20612964	chr1:1668511	SLC35E2	0.43	6.73	0.34	7.27e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	6e-11	Prudent dietary pattern;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.64	-0.34	1.2e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg03959625	chr15:84868606	LOC388152	0.46	6.65	0.34	1.14e-10	Schizophrenia;
LIHC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg18906360	chr14:60633047	DHRS7	0.51	6.26	0.32	1.13e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs77861329	1.000	rs183029	chr3:52209884	A/G	cg08692210	chr3:52188851	WDR51A	0.79	7.52	0.38	4.79e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg01806965	chr8:144378397	ZNF696	0.42	6.53	0.33	2.42e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.82	0.39	6.66e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.83	-0.39	6.23e-14	Schizophrenia;
LIHC	cis	rs8081395	0.801	rs2665404	chr17:57875396	A/G	cg13753209	chr17:57696993	CLTC	0.45	6.99	0.35	1.48e-11	White blood cell count;
LIHC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.42	-6.48	-0.33	3.21e-10	Morning vs. evening chronotype;
LIHC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.94	15.56	0.64	1.17e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.82	-0.35	4.26e-11	Personality dimensions;
LIHC	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.16	0.48	2.33e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7119038	0.818	rs1048024	chr11:118618776	A/T	cg19308663	chr11:118741387	NA	0.43	5.79	0.3	1.56e-8	Sjögren's syndrome;
LIHC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg17479956	chr11:44115929	EXT2	0.46	5.81	0.3	1.45e-8	IgA nephropathy;
LIHC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	8.7	0.43	1.39e-16	Lymphocyte counts;
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.73	10.37	0.49	4.46e-22	Menarche (age at onset);
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.98	-0.4	2.21e-14	Lymphocyte counts;
LIHC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.09	9.99	0.48	8.38e-21	Uric acid levels;
LIHC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.95	14.75	0.62	1.81e-38	Metabolic syndrome;
LIHC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13126279	chr21:47581558	C21orf56	-0.44	-6.9	-0.35	2.46e-11	Testicular germ cell tumor;
LIHC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.38	6.25	0.32	1.19e-9	Tuberculosis;
LIHC	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14154082	chr13:112174009	NA	0.29	6.14	0.32	2.28e-9	Menarche (age at onset);
LIHC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg05555928	chr11:63887634	MACROD1	0.52	6.75	0.34	6.22e-11	Mean platelet volume;
LIHC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg14580859	chr9:123691850	NA	0.38	6.68	0.34	9.57e-11	Rheumatoid arthritis;
LIHC	cis	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg01231543	chr16:68741748	NA	0.37	5.88	0.3	9.91e-9	Colorectal cancer;
LIHC	cis	rs4788570	0.566	rs1804984	chr16:71481520	T/A	cg06353428	chr16:71660113	MARVELD3	-1.13	-10.2	-0.48	1.67e-21	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.45	6.41	0.33	4.71e-10	Morning vs. evening chronotype;
LIHC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.83	-14.81	-0.63	1.06e-38	Coronary artery disease;
LIHC	cis	rs2712381	0.797	rs62270806	chr3:128376269	C/T	cg16766828	chr3:128327626	NA	-0.41	-6.46	-0.33	3.51e-10	Monocyte count;
LIHC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.03	-0.44	1.29e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg06238570	chr21:40685208	BRWD1	0.56	6.59	0.34	1.71e-10	Cognitive function;
LIHC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.67	0.5	3.91e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.7	-9.77	-0.47	4.94e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.35	0.52	1.51e-25	Menarche (age at onset);
LIHC	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.22	-0.32	1.42e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs3743266	0.507	rs9630426	chr15:60739053	C/T	cg22293140	chr15:60689852	ANXA2	-0.62	-6.01	-0.31	4.69e-9	Menarche (age at onset);
LIHC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.65	-9.66	-0.46	1.13e-19	Coronary artery disease;
LIHC	trans	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	6.79	0.34	4.97e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs75804782	0.521	rs72982590	chr2:239451826	T/C	cg01134436	chr17:81009848	B3GNTL1	0.74	6.27	0.32	1.11e-9	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.16	-0.36	5.09e-12	Psoriasis;
LIHC	cis	rs57590327	0.679	rs35381070	chr3:81590374	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-6.44	-0.33	4e-10	Extraversion;
LIHC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08392591	chr16:89556376	ANKRD11	-0.39	-5.84	-0.3	1.24e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg24101359	chr6:42928495	GNMT	0.46	6.25	0.32	1.19e-9	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-0.8	-6.71	-0.34	8.11e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11125080	0.735	rs7609080	chr2:46733783	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.56	6.39	0.33	5.33e-10	Anti-saccade response;Anti-saccade error rate in psychotic disorders;
LIHC	cis	rs10193935	0.901	rs1439231	chr2:42542884	G/A	cg27598129	chr2:42591480	NA	-0.71	-11.2	-0.52	5.04e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg12698662	chr3:15914712	MIR563	0.37	6.83	0.35	3.78e-11	Mean platelet volume;
LIHC	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.45	5.92	0.3	7.91e-9	Obesity (extreme);
LIHC	trans	rs4714291	0.722	rs9296320	chr6:40118298	C/G	cg02267698	chr19:7991119	CTXN1	0.36	6.1	0.31	2.85e-9	Strep throat;
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.97	0.44	2.02e-17	Height;
LIHC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg22834771	chr12:69754056	YEATS4	-0.5	-8.44	-0.41	9.43e-16	Blood protein levels;
LIHC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-7.39	-0.37	1.14e-12	Cognitive function;
LIHC	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg17074339	chr11:11642133	GALNTL4	0.44	6.77	0.34	5.71e-11	Telomere length;
LIHC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	7.17	0.36	4.75e-12	Menopause (age at onset);
LIHC	cis	rs807029	0.758	rs807025	chr10:102764821	C/T	cg17130504	chr10:102756923	LZTS2	0.43	5.77	0.3	1.8e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.87	-0.3	1.01e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg15051332	chr6:41514432	FOXP4	0.42	5.83	0.3	1.31e-8	Prostate cancer;
LIHC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.51	0.38	5.34e-13	Aortic root size;
LIHC	trans	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg02228481	chr6:31165922	HCG27	-0.46	-6.09	-0.31	3e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LIHC	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.6	10.11	0.48	3.28e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-6.41	-0.33	4.73e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.52	-0.38	4.72e-13	Height;
LIHC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.53	8.25	0.41	3.4e-15	Crohn's disease;
LIHC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.95	-12.64	-0.56	2.48e-30	Schizophrenia;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg13390998	chr8:145670370	NFKBIL2	-0.4	-6.05	-0.31	3.89e-9	Body mass index;
LIHC	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.31	-6.88	-0.35	2.9e-11	Cutaneous nevi;
LIHC	cis	rs6882046	0.513	rs639725	chr5:88001969	A/G	cg22951263	chr5:87985283	NA	-0.39	-6.89	-0.35	2.7e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.67	11.77	0.54	4.38e-27	Platelet distribution width;
LIHC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.67	9.61	0.46	1.67e-19	Cognitive function;
LIHC	trans	rs72632736	1.000	rs72632731	chr1:4445471	C/T	cg21153040	chr19:13985688	MIR181D	-0.45	-6.07	-0.31	3.3e-9	Systemic juvenile idiopathic arthritis;
LIHC	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.42	6.75	0.34	6.42e-11	Morning vs. evening chronotype;
LIHC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg17077180	chr1:38461687	NA	-0.4	-6.44	-0.33	4.02e-10	Coronary artery disease;
LIHC	cis	rs74544699	1.000	rs116433096	chr4:74775629	C/T	cg02530824	chr4:74847766	PF4	0.54	6.1	0.31	2.81e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.28	0.52	2.74e-25	Motion sickness;
LIHC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg14092571	chr14:90743983	NA	0.39	6.31	0.32	8.75e-10	Mortality in heart failure;
LIHC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.94	0.44	2.46e-17	Lung cancer in ever smokers;
LIHC	cis	rs4722404	0.502	rs13223548	chr7:3110446	T/C	cg19214707	chr7:3157722	NA	-0.34	-5.85	-0.3	1.13e-8	Atopic dermatitis;
LIHC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg12310025	chr6:25882481	NA	-0.38	-5.73	-0.3	2.26e-8	Height;
LIHC	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.7	-7.17	-0.36	4.59e-12	Putamen volume;
LIHC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.39	6.41	0.33	4.69e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.36	0.37	1.34e-12	Mean platelet volume;
LIHC	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg03934865	chr2:198174659	NA	0.53	8.19	0.41	5.14e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg10932868	chr11:921992	NA	0.4	7.54	0.38	4.38e-13	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.52	7.54	0.38	4.33e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.6	0.53	1.82e-26	Motion sickness;
LIHC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	6.26	0.32	1.17e-9	Lymphocyte counts;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.84	12.17	0.55	1.49e-28	Menarche (age at onset);
LIHC	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.5	8.18	0.4	5.7e-15	Corneal astigmatism;
LIHC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.94	17.56	0.69	1.12e-49	Menopause (age at onset);
LIHC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.36	-8.05	-0.4	1.4e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-6.55	-0.33	2.08e-10	Schizophrenia;
LIHC	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.11	-0.36	6.81e-12	Body mass index;
LIHC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	11.19	0.52	5.77e-25	Chronic sinus infection;
LIHC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.67	-7.05	-0.36	1e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.34	0.32	7.17e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.66	-10.85	-0.51	9.38e-24	Colorectal cancer;
LIHC	cis	rs3015497	0.752	rs6572682	chr14:51144800	A/T	cg09863266	chr14:51125203	SAV1	-0.39	-6.27	-0.32	1.07e-9	Mean platelet volume;
LIHC	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02251663	chr11:14281053	SPON1	0.48	6.47	0.33	3.36e-10	Mitochondrial DNA levels;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg00204748	chr12:29376779	FAR2	0.45	8.58	0.42	3.35e-16	QT interval;
LIHC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04530015	chr2:215796436	ABCA12	-0.39	-6.39	-0.33	5.58e-10	Neuroblastoma;
LIHC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.91	-0.3	8.11e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.24e-13	Electroencephalogram traits;
LIHC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.34	6.94	0.35	1.97e-11	Renal cell carcinoma;
LIHC	trans	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg01596870	chr19:55963115	NA	-0.62	-7.38	-0.37	1.23e-12	Obesity-related traits;
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.95	13.48	0.59	1.68e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.19	0.32	1.74e-9	Ulcerative colitis;
LIHC	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs10503871	0.625	rs4292648	chr8:30324803	C/T	cg26383811	chr8:30366931	RBPMS	0.45	7.82	0.39	6.51e-14	Metabolite levels  (X-11787);
LIHC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.87	0.35	3.1e-11	Diabetic kidney disease;
LIHC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg03037974	chr15:76606532	NA	0.88	22.28	0.77	1.42e-68	Blood metabolite levels;
LIHC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.8	-14.44	-0.62	3.07e-37	Refractive error;
LIHC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg21573476	chr21:45109991	RRP1B	-0.48	-8.32	-0.41	2.08e-15	Mean corpuscular volume;
LIHC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.44	-6.63	-0.34	1.3100000000000001e-10	Adiposity;
LIHC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.36	6.07	0.31	3.48e-9	Blood metabolite levels;
LIHC	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.35	-0.32	6.83e-10	Prevalent atrial fibrillation;
LIHC	cis	rs3823572	0.564	rs10272509	chr7:133636302	A/G	cg03336402	chr7:133662267	EXOC4	0.47	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.84	0.35	3.73e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.18	-19.12	-0.72	5.96e-56	Urate levels;
LIHC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.47	6.72	0.34	7.41e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.6	-10.05	-0.48	5.49e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.61	10.12	0.48	3.13e-21	Body mass index;
LIHC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-9.1	-0.44	7.36e-18	Dental caries;
LIHC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.64	0.53	1.3e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.27	6.31	0.32	8.71e-10	Heart rate;
LIHC	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg21605333	chr4:119757512	SEC24D	1.03	7.8	0.39	7.67e-14	Cannabis dependence symptom count;
LIHC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.89	-0.3	9.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.28	0.49	9.09e-22	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08280861	chr8:58055591	NA	0.49	6.11	0.31	2.69e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.44	-0.45	5.92e-19	Schizophrenia;
LIHC	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.34	-0.32	7.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-1.11	-12.94	-0.57	1.82e-31	Eosinophil percentage of granulocytes;
LIHC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.4	-8.11	-0.4	9.08e-15	Urinary metabolites;
LIHC	cis	rs12731740	0.908	rs12568382	chr1:207966393	C/T	cg22525895	chr1:207977042	MIR29B2	-0.49	-5.74	-0.3	2.14e-8	Biomedical quantitative traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11599998	chr3:160283537	KPNA4	0.45	6.42	0.33	4.68e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.642	rs11189167	chr10:99125722	A/G	cg06359132	chr10:99160096	RRP12	-0.39	-5.72	-0.3	2.38e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.39	-5.96	-0.31	6.14e-9	HDL cholesterol;
LIHC	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.04	21.1	0.75	7.19e-64	Schizophrenia;
LIHC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.4	0.49	3.53e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg06026331	chr20:60912101	LAMA5	-0.55	-6.74	-0.34	6.76e-11	Colorectal cancer;
LIHC	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.4	7.67	0.38	1.8e-13	Height;
LIHC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.42	-6.88	-0.35	2.85e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7707921	0.881	rs111907176	chr5:81312399	A/G	cg15871215	chr5:81402204	ATG10	-0.64	-6.34	-0.32	7.41e-10	Breast cancer;
LIHC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.69	11.22	0.52	4.43e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	0.89	19.43	0.72	3.6e-57	Night sleep phenotypes;
LIHC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg20607798	chr8:58055168	NA	0.49	6.21	0.32	1.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.71	10.9	0.51	6.09e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18866267	chr4:3310044	NA	0.41	6.29	0.32	9.91e-10	Bilirubin levels;
LIHC	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.65	-0.42	2.1e-16	Colorectal cancer;
LIHC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg06714761	chr1:201096289	NA	0.35	5.93	0.31	7.23e-9	Permanent tooth development;
LIHC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.0	-0.68	2.14e-47	Systemic lupus erythematosus;
LIHC	cis	rs11112613	0.609	rs4991814	chr12:106046709	G/A	cg03607813	chr12:105948248	NA	0.4	6.27	0.32	1.11e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.34	-0.37	1.55e-12	Hemoglobin concentration;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.31	-0.32	8.8e-10	Longevity;Endometriosis;
LIHC	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.6	6.32	0.32	8.05e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.4	6.15	0.32	2.22e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-11.17	-0.52	6.66e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.56	-6.26	-0.32	1.15e-9	Ulcerative colitis;
LIHC	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	6.99	0.35	1.45e-11	Schizophrenia;
LIHC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.25	-0.36	2.86e-12	Personality dimensions;
LIHC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.05	-0.31	3.87e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg21734168	chr11:67353974	GSTP1	-0.27	-6.68	-0.34	9.94e-11	Mean corpuscular volume;
LIHC	trans	rs3760776	0.522	rs78060698	chr19:5832773	G/A	cg16574191	chr19:14063234	PODNL1;DCAF15	-0.83	-6.49	-0.33	2.94e-10	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
LIHC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	7.01	0.35	1.26e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.94	0.51	4.35e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.55	-13.29	-0.58	8.94e-33	White blood cell count (basophil);
LIHC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.44	0.53	7.27e-26	Motion sickness;
LIHC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.91	18.55	0.71	1.17e-53	Bone mineral density;
LIHC	cis	rs2191566	0.960	rs12232810	chr19:44525122	A/G	cg20607764	chr19:44506953	ZNF230	-0.41	-6.7	-0.34	8.85e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg06611532	chr13:114900021	NA	0.4	7.31	0.37	1.93e-12	Schizophrenia;
LIHC	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.55	-8.83	-0.43	5.71e-17	Body mass index;
LIHC	cis	rs8084351	0.539	rs11874659	chr18:50588260	T/C	cg24270629	chr18:50823537	DCC	0.45	6.95	0.35	1.86e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.79	0.3	1.61e-8	Bipolar disorder;
LIHC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg05834625	chr6:170176447	C6orf70	0.42	6.25	0.32	1.2e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg02466173	chr16:30829666	NA	-0.43	-6.32	-0.32	8.25e-10	Diastolic blood pressure;
LIHC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.94	15.14	0.63	5.24e-40	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.49	-8.92	-0.43	2.79e-17	Atrioventricular conduction;
LIHC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00958927	chr1:175162553	KIAA0040	0.39	6.41	0.33	4.89e-10	Alcohol dependence;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25764190	chr19:44037015	ZNF575	0.38	6.08	0.31	3.29e-9	Cognitive function;
LIHC	cis	rs8027181	0.839	rs7176223	chr15:73077742	T/G	cg25632853	chr15:73088954	NA	0.4	6.59	0.34	1.63e-10	Triglyceride levels;
LIHC	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.78	-0.34	5.15e-11	Neuroticism;
LIHC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.83	9.9	0.47	1.78e-20	Cognitive function;
LIHC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.71	-9.87	-0.47	2.27e-20	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.74	-0.43	1.09e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.38	6.18	0.32	1.82e-9	Menopause (age at onset);
LIHC	cis	rs12922317	0.964	rs8043644	chr16:12077124	G/T	cg09319797	chr16:12061715	TNFRSF17	0.4	7.09	0.36	7.68e-12	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.66	8.23	0.41	3.92e-15	Gut microbiome composition (summer);
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.15	-0.32	2.15e-9	Total body bone mineral density;
LIHC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg03517284	chr6:25882590	NA	-0.44	-6.65	-0.34	1.17e-10	Height;
LIHC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.45	0.64	3.26e-41	Chronic sinus infection;
LIHC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17428076	0.793	rs12622772	chr2:172625737	T/C	cg13550731	chr2:172543902	DYNC1I2	0.39	6.3	0.32	9.23e-10	Myopia;
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg18279126	chr7:2041391	MAD1L1	0.36	5.89	0.3	9.28e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs4290604	0.748	rs10754942	chr2:238075187	T/C	cg15676719	chr1:167598521	RCSD1	-0.46	-6.19	-0.32	1.77e-9	Asthma;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03383661	chr6:42714115	TBCC	0.45	6.59	0.34	1.71e-10	Longevity;
LIHC	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.96	10.52	0.49	1.28e-22	IgG glycosylation;
LIHC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.22	-0.36	3.39e-12	Body mass index;
LIHC	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.52	-0.38	4.85e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg25364880	chr3:44379878	C3orf23	0.44	6.22	0.32	1.47e-9	Depressive symptoms;
LIHC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.39	-0.33	5.58e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.36	0.45	1.13e-18	Bipolar disorder;
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02359409	chr6:42947317	PEX6	-0.48	-6.78	-0.34	5.4e-11	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg18898632	chr2:242989856	NA	-0.72	-8.92	-0.43	2.84e-17	Obesity-related traits;
LIHC	cis	rs116248771	0.739	rs4680455	chr3:158384883	C/A	cg16708174	chr3:158430962	RARRES1	0.48	6.4	0.33	5.08e-10	diarrhoeal disease at age 2;
LIHC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.71	-6.42	-0.33	4.53e-10	Hip circumference adjusted for BMI;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14803350	chr5:159545855	PWWP2A	-0.32	-6.06	-0.31	3.69e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs17756712	0.666	rs9378442	chr6:633631	T/G	cg14374089	chr6:596013	EXOC2	0.4	5.71	0.3	2.42e-8	Vertical cup-disc ratio;
LIHC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.32	5.97	0.31	5.94e-9	HDL cholesterol;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg06143244	chr16:22435202	RRN3P3	-0.38	-6.12	-0.31	2.61e-9	Calcium levels;
LIHC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.66	-8.21	-0.41	4.48e-15	Gut microbiome composition (summer);
LIHC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.72	10.11	0.48	3.49e-21	Multiple sclerosis;
LIHC	trans	rs3783890	1.000	rs12894309	chr14:93783067	A/T	cg02802420	chr16:69363236	PDF;COG8	0.31	6.06	0.31	3.53e-9	Body mass index;
LIHC	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg07636037	chr3:49044803	WDR6	-0.55	-6.19	-0.32	1.77e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.36	-5.84	-0.3	1.2e-8	Body mass index;
LIHC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.14	0.36	5.47e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.67	12.06	0.55	3.72e-28	Lewy body disease;
LIHC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-9.83	-0.47	3.08e-20	Obesity-related traits;
LIHC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.29	0.55	5.1e-29	Cognitive test performance;
LIHC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.33	-0.32	7.62e-10	Menopause (age at onset);
LIHC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.51	8.33	0.41	1.96e-15	Obesity-related traits;
LIHC	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.83	8.63	0.42	2.35e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	8.47	0.42	7.11e-16	IgG glycosylation;
LIHC	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.09	-0.31	3.12e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-5.97	-0.31	5.87e-9	Longevity;
LIHC	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.19	-0.4	5.28e-15	Body mass index;
LIHC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg17980119	chr2:219472607	PLCD4	-0.34	-5.75	-0.3	2e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17639215	0.550	rs4851003	chr2:102909277	T/C	cg09003973	chr2:102972529	NA	0.59	5.84	0.3	1.21e-8	Serum protein levels (sST2);
LIHC	cis	rs12472274	0.617	rs7568705	chr2:239081808	C/T	cg17459225	chr2:239074497	NA	0.66	10.63	0.5	5.39e-23	Phospholipid levels (plasma);
LIHC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	13.97	0.6	2.07e-35	Chronic sinus infection;
LIHC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg17279839	chr7:150038598	RARRES2	0.47	9.87	0.47	2.21e-20	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg01864069	chr14:103024347	NA	0.45	6.98	0.35	1.51e-11	Platelet count;
LIHC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.64	-0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.6	-8.67	-0.42	1.8e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg15784997	chr19:3196307	NCLN	0.4	6.13	0.31	2.49e-9	Bilirubin levels;
LIHC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.65	12.52	0.56	7.48e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.01	0.48	7.51e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg02426739	chr12:132285352	NA	0.35	5.87	0.3	1.01e-8	Migraine;
LIHC	cis	rs903552	1.000	rs12904206	chr15:102006294	C/T	cg00659931	chr15:102010125	PCSK6	-0.45	-6.11	-0.31	2.79e-9	Diabetic kidney disease;
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22442454	chr1:209979470	IRF6	0.39	5.84	0.3	1.21e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.6	-0.38	2.89e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg20991723	chr1:152506922	NA	0.49	8.32	0.41	2.12e-15	Hair morphology;
LIHC	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.46	6.61	0.34	1.48e-10	Pulse pressure;
LIHC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.42	6.36	0.33	6.54e-10	Neuroticism;
LIHC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.46	-0.46	5.02e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.09	22.73	0.78	2.47e-70	Myeloid white cell count;
LIHC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.87	-17.99	-0.7	2.11e-51	Height;
LIHC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg17279839	chr7:150038598	RARRES2	0.48	10.04	0.48	5.91e-21	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26326168	chr12:133405726	GOLGA3	0.49	6.57	0.33	1.86e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.47	6.0	0.31	4.97e-9	Alzheimer's disease;
LIHC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg13957321	chr17:43675089	NA	0.5	7.97	0.4	2.39e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.58	11.69	0.53	8.52e-27	Glycated hemoglobin levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08808811	chr3:184079573	CLCN2	-0.44	-6.7	-0.34	8.72e-11	Systolic blood pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24865406	chr1:230203041	GALNT2	0.39	6.11	0.31	2.67e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	19.63	0.73	5.64e-58	Nonalcoholic fatty liver disease;
LIHC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.52	-9.49	-0.46	3.99e-19	Asthma;
LIHC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg06238570	chr21:40685208	BRWD1	0.57	6.51	0.33	2.65e-10	Cognitive function;
LIHC	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.76	11.44	0.53	6.77e-26	Subjective well-being;
LIHC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.9	-15.61	-0.64	7.66e-42	Colorectal cancer;
LIHC	cis	rs4908768	0.911	rs12121933	chr1:8777081	A/T	cg20416874	chr1:8611966	RERE	0.53	8.09	0.4	1.06e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00081347	chr17:78188837	SGSH	0.47	6.35	0.32	6.81e-10	Hepatitis;
LIHC	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg09795085	chr6:101329169	ASCC3	0.53	7.48	0.37	6.49e-13	Neuroticism;
LIHC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.36	6.48	0.33	3.21e-10	Aortic root size;
LIHC	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.48	7.11	0.36	7.02e-12	Dermatomyositis;
LIHC	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	18.21	0.7	2.91e-52	Colorectal cancer;
LIHC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.18	-0.48	2e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2279817	0.863	rs6679957	chr1:18011361	T/G	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-7.48	-0.37	6.38e-13	Neuroticism;
LIHC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.31	-6.53	-0.33	2.32e-10	Platelet distribution width;
LIHC	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.68	11.27	0.52	2.96e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs67981189	0.593	rs221924	chr14:71580778	G/A	cg15816911	chr14:71606274	NA	-0.43	-6.78	-0.34	5.26e-11	Schizophrenia;
LIHC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg14132834	chr19:41945861	ATP5SL	0.45	6.59	0.34	1.67e-10	Height;
LIHC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21467203	chr3:49911342	NA	0.44	7.76	0.39	1.01e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs3015497	0.789	rs3015498	chr14:51112824	T/C	cg09863266	chr14:51125203	SAV1	-0.43	-7.0	-0.35	1.37e-11	Mean platelet volume;
LIHC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21467203	chr3:49911342	NA	0.42	7.47	0.37	6.73e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.91	16.81	0.67	1.25e-46	Menopause (age at onset);
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	0.51	5.77	0.3	1.77e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.08	-0.36	8.23e-12	Schizophrenia;
LIHC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-9.8	-0.47	3.94e-20	Schizophrenia;
LIHC	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.71	-11.34	-0.52	1.59e-25	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.81	0.3	1.46e-8	Bipolar disorder;
LIHC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.43	6.0	0.31	5.06e-9	Height;
LIHC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.47e-27	Lymphocyte counts;
LIHC	cis	rs904251	0.523	rs9366935	chr6:37480404	C/T	cg08126542	chr6:37504118	NA	-0.37	-6.33	-0.32	7.78e-10	Cognitive performance;
LIHC	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.77	10.5	0.49	1.54e-22	Pediatric areal bone mineral density (radius);
LIHC	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-6.33	-0.32	7.68e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.57	-8.9	-0.43	3.44e-17	Dental caries;
LIHC	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg05697976	chr12:29376483	FAR2	0.29	6.0	0.31	4.96e-9	QT interval;
LIHC	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg10820045	chr2:198174542	NA	0.48	7.23	0.36	3.2e-12	Dermatomyositis;
LIHC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.39	6.65	0.34	1.14e-10	Methadone dose in opioid dependence;
LIHC	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg26139080	chr11:47293733	MADD	-0.51	-8.65	-0.42	2.02e-16	HDL cholesterol;
LIHC	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg20991723	chr1:152506922	NA	0.57	9.99	0.48	8.48e-21	Hair morphology;
LIHC	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.22	-0.41	4.13e-15	Schizophrenia;
LIHC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.29	-0.52	2.52e-25	Primary sclerosing cholangitis;
LIHC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.75	-0.39	1.03e-13	Response to antipsychotic treatment;
LIHC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.78	12.74	0.57	1.12e-30	Oral cavity cancer;
LIHC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg17135325	chr3:160939158	NMD3	0.54	7.27	0.37	2.54e-12	Parkinson's disease;
LIHC	trans	rs2211698	0.881	rs75650525	chr21:35830233	C/G	cg18044562	chr7:50468399	IKZF1	0.52	7.57	0.38	3.46e-13	Cancer;
LIHC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.03e-19	Hemoglobin concentration;
LIHC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	11.06	0.51	1.62e-24	Lung cancer in ever smokers;
LIHC	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg27205649	chr11:78285834	NARS2	-0.38	-5.72	-0.3	2.29e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.54	5.8	0.3	1.47e-8	Vitiligo;
LIHC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.66	-13.3	-0.58	7.83e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.4	5.83	0.3	1.26e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.59	-8.7	-0.43	1.4e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs16912285	0.688	rs7128680	chr11:24338796	C/T	ch.11.24196551F	chr11:24239977	NA	0.72	8.27	0.41	3.09e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg23091122	chr1:110024289	SYPL2	-0.45	-6.0	-0.31	4.98e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.63	-8.94	-0.44	2.56e-17	Blood metabolite levels;
LIHC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs244293	0.931	rs244351	chr17:53195566	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.51	-0.38	5.37e-13	Menarche (age at onset);
LIHC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.62	9.31	0.45	1.55e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.25	-0.32	1.23e-9	Metabolite levels;
LIHC	trans	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg26939375	chr7:64535504	NA	0.41	6.52	0.33	2.47e-10	Aortic root size;
LIHC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17554472	chr22:41940697	POLR3H	0.55	6.23	0.32	1.37e-9	Vitiligo;
LIHC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg05003411	chr4:15428768	C1QTNF7	0.32	5.93	0.31	7.38e-9	Obesity-related traits;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.34	0.61	7.33e-37	Prudent dietary pattern;
LIHC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.78	-0.34	5.21e-11	Height;
LIHC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17507749	chr15:85114479	UBE2QP1	0.6	6.72	0.34	7.82e-11	Schizophrenia;
LIHC	cis	rs72627509	0.638	rs1608165	chr4:57894717	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.58	-8.49	-0.42	6.53e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg17385448	chr1:15911702	AGMAT	0.37	6.27	0.32	1.08e-9	Systolic blood pressure;
LIHC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg04756594	chr16:24857601	SLC5A11	0.46	7.16	0.36	4.92e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.84	12.75	0.57	9.71e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.56e-13	Alzheimer's disease (late onset);
LIHC	cis	rs12611088	0.541	rs2682579	chr19:44012609	T/C	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.27	-0.32	1.12e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs11673344	0.797	rs3745768	chr19:37488809	A/G	cg27390819	chr19:37464633	NA	-0.5	-6.05	-0.31	3.82e-9	Obesity-related traits;
LIHC	cis	rs4788570	0.584	rs11862723	chr16:71704222	T/C	cg06353428	chr16:71660113	MARVELD3	1.39	14.48	0.62	2.14e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.56	-8.57	-0.42	3.71e-16	Menarche (age at onset);
LIHC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.58	-8.45	-0.42	8.7e-16	Response to diuretic therapy;
LIHC	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	5.09e-12	Corneal astigmatism;
LIHC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg24296786	chr1:45957014	TESK2	0.4	5.76	0.3	1.88e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.95	-19.26	-0.72	1.68e-56	Schizophrenia;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.6	-8.53	-0.42	4.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.52	-0.33	2.5e-10	Height;
LIHC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg05697976	chr12:29376483	FAR2	-0.29	-6.01	-0.31	4.62e-9	QT interval;
LIHC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.5	-7.44	-0.37	8.48e-13	HDL cholesterol;
LIHC	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.96	0.35	1.7e-11	Bipolar disorder;
LIHC	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.48	0.33	3.26e-10	Ulcerative colitis;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.32	-7.23	-0.36	3.17e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.59	-9.11	-0.44	6.98e-18	Menopause (age at onset);
LIHC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.54	7.84	0.39	5.6e-14	Initial pursuit acceleration;
LIHC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.34e-17	Gut microbiome composition (summer);
LIHC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.04	16.21	0.66	2.92e-44	Breast cancer;
LIHC	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.63	7.35	0.37	1.47e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.59	-0.5	7.44e-23	Hemoglobin concentration;
LIHC	cis	rs6732160	0.549	rs6744529	chr2:73480869	A/G	cg24220031	chr2:73402428	NA	-0.27	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg25839482	chr15:75931953	IMP3	0.39	5.72	0.3	2.36e-8	Height;
LIHC	cis	rs7715806	0.500	rs77544433	chr5:75001025	C/A	cg19683494	chr5:74908142	NA	0.56	6.67	0.34	1.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.76	11.04	0.51	1.85e-24	Menarche (age at onset);
LIHC	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg08126542	chr6:37504118	NA	-0.37	-6.04	-0.31	3.99e-9	Cognitive performance;
LIHC	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg18867708	chr6:26865862	GUSBL1	-0.51	-7.74	-0.39	1.12e-13	Schizophrenia;
LIHC	cis	rs6442522	0.733	rs4143273	chr3:15501808	C/T	cg16303742	chr3:15540471	COLQ	-0.45	-7.52	-0.38	4.71e-13	Uric acid levels;
LIHC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg03665457	chr10:38645376	HSD17B7P2	0.4	5.95	0.31	6.46e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7487075	0.930	rs4076248	chr12:46833605	C/T	cg11331445	chr12:47219877	SLC38A4	0.28	5.97	0.31	5.93e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.25	0.52	3.29e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg27478167	chr7:817139	HEATR2	-0.4	-5.77	-0.3	1.74e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4908768	0.871	rs11121221	chr1:8767529	A/G	cg25722041	chr1:8623473	RERE	0.39	5.74	0.3	2.04e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14477263	chr1:1168550	SDF4;B3GALT6	0.43	6.37	0.33	6.18e-10	Longevity;
LIHC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg12292205	chr6:26970375	C6orf41	0.35	5.85	0.3	1.14e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02668984	chr17:48172022	PDK2	0.48	7.43	0.37	8.66e-13	Pancreatic cancer;
LIHC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.81	-13.0	-0.58	1.14e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg12798992	chr6:167411361	FGFR1OP	0.59	9.73	0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs9513627	1.000	rs7322368	chr13:100213990	T/C	cg25919922	chr13:100150906	NA	0.76	6.67	0.34	1.02e-10	Obesity-related traits;
LIHC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.63	11.35	0.52	1.44e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	6.79	0.34	4.98e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08280861	chr8:58055591	NA	0.56	6.26	0.32	1.19e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.21	-0.48	1.55e-21	Blood metabolite levels;
LIHC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg09990169	chr2:241835740	C2orf54	-0.65	-10.32	-0.49	6.65e-22	Urinary metabolites;
LIHC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	cis	rs74544699	1.000	rs79981249	chr4:74784164	T/C	cg16072462	chr4:74847758	PF4	0.6	6.14	0.32	2.27e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs611744	0.967	rs639059	chr8:109236119	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.81	0.43	6.6e-17	Dupuytren's disease;
LIHC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.79	0.39	7.8500000000000006e-14	Schizophrenia;
LIHC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg07382826	chr16:28625726	SULT1A1	0.51	7.92	0.39	3.44e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.55	-9.23	-0.45	2.92e-18	Cocaine dependence;
LIHC	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.92	0.39	3.41e-14	Lung cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20236831	chr1:1259679	GLTPD1;CPSF3L	-0.55	-6.42	-0.33	4.47e-10	Systolic blood pressure;
LIHC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.58	-9.27	-0.45	2.17e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs244293	0.899	rs244355	chr17:53194085	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.47	-0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-8.79	-0.43	7.39e-17	Vitiligo;
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg02869306	chr7:64672164	INTS4L1	-0.28	-6.07	-0.31	3.4e-9	Calcium levels;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg13409248	chr3:40428643	ENTPD3	-0.51	-8.62	-0.42	2.46e-16	Renal cell carcinoma;
LIHC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.56	6.79	0.34	4.99e-11	Cognitive function;
LIHC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.19	-0.44	3.99e-18	Bipolar disorder;
LIHC	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.07	-19.71	-0.73	2.65e-58	Triglycerides;
LIHC	trans	rs76648483	0.568	rs1987102	chr15:80265888	T/C	cg11476254	chr16:89159666	ACSF3	-0.5	-6.43	-0.33	4.37e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04633058	chr17:48474099	LRRC59	0.41	6.66	0.34	1.07e-10	Cognitive function;
LIHC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.71	12.33	0.55	3.62e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg17279839	chr7:150038598	RARRES2	0.39	7.58	0.38	3.24e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	0.74	8.43	0.41	9.88e-16	Exhaled nitric oxide output;
LIHC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.15	0.32	2.18e-9	Schizophrenia;
LIHC	cis	rs58235267	0.564	rs360808	chr2:62927475	T/C	cg17519650	chr2:63277830	OTX1	-0.61	-9.93	-0.47	1.38e-20	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.26	0.49	1.06e-21	Diabetic retinopathy;
LIHC	cis	rs4917300	0.586	rs1352949	chr8:143096253	G/C	cg25363559	chr8:143086065	NA	-0.27	-8.22	-0.41	4.42e-15	Amyotrophic lateral sclerosis;
LIHC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.93	0.39	3.23e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.54	8.19	0.4	5.43e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.77	-0.34	5.5e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.52	-0.62	1.44e-37	Alzheimer's disease;
LIHC	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.36	5.72	0.3	2.29e-8	Prostate cancer;
LIHC	cis	rs7520050	0.902	rs1355642	chr1:46598903	A/G	cg03146154	chr1:46216737	IPP	-0.35	-5.84	-0.3	1.21e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg21486233	chr12:29375141	FAR2	0.31	6.22	0.32	1.46e-9	QT interval;
LIHC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.65	-8.13	-0.4	8.08e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs16958440	0.867	rs12326457	chr18:44678425	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs273218	1.000	rs156437	chr5:53376454	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.62	10.07	0.48	4.8e-21	Migraine;
LIHC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.63	10.63	0.5	5.4e-23	Platelet distribution width;
LIHC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.35	-6.05	-0.31	3.89e-9	Body mass index;
LIHC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg10664184	chr19:17420304	DDA1	0.45	5.74	0.3	2.12e-8	Systemic lupus erythematosus;
LIHC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg21724239	chr8:58056113	NA	0.49	6.5	0.33	2.77e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.79	0.3	1.63e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg24634471	chr8:143751801	JRK	-0.41	-5.98	-0.31	5.52e-9	Urinary tract infection frequency;
LIHC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.43	6.05	0.31	3.77e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.42	-6.27	-0.32	1.07e-9	Iron status biomarkers;
LIHC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.47	6.04	0.31	4.11e-9	Initial pursuit acceleration;
LIHC	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-7.18	-0.36	4.46e-12	Putamen volume;
LIHC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.91	0.35	2.44e-11	Aortic root size;
LIHC	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.76	-0.34	5.87e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.44	7.77	0.39	9.04e-14	Coronary artery disease;
LIHC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg00656387	chr3:40428638	ENTPD3	0.38	5.96	0.31	6.37e-9	Renal cell carcinoma;
LIHC	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.51	-0.38	5.07e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg09165964	chr15:75287851	SCAMP5	0.48	6.48	0.33	3.28e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg04374321	chr14:90722782	PSMC1	0.47	6.5	0.33	2.85e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs963731	0.579	rs2373497	chr2:39288098	C/T	cg04010122	chr2:39346883	SOS1	-0.57	-5.79	-0.3	1.63e-8	Corticobasal degeneration;
LIHC	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.58	0.5	7.92e-23	Hypertriglyceridemia;
LIHC	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.72	12.51	0.56	8.06e-30	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.52	-6.62	-0.34	1.41e-10	Ileal carcinoids;
LIHC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.43	6.02	0.31	4.55e-9	Breast cancer;
LIHC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.26	6.28	0.32	1.05e-9	Childhood ear infection;
LIHC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-8.56	-0.42	3.77e-16	Gut microbiome composition (summer);
LIHC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs75908454	1.000	rs76123929	chr6:169829086	G/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.77	-0.39	9.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.8	-0.35	4.65e-11	Coronary artery disease;
LIHC	cis	rs4908768	0.906	rs10492965	chr1:8598127	G/A	cg20416874	chr1:8611966	RERE	0.58	9.1	0.44	7.41e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.53	-7.72	-0.39	1.29e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.65	10.13	0.48	2.86e-21	Monocyte count;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-6.99	-0.35	1.4e-11	Ulcerative colitis;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.37	-8.05	-0.4	1.36e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.43	6.21	0.32	1.57e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.35	7.63	0.38	2.31e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.42	-7.35	-0.37	1.46e-12	Platelet distribution width;
LIHC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.2	0.45	3.6e-18	Lung cancer in ever smokers;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.93	0.63	3.67e-39	Prudent dietary pattern;
LIHC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	6.07	0.31	3.37e-9	Schizophrenia;
LIHC	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.96	16.77	0.67	1.82e-46	Subjective well-being;
LIHC	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg20636351	chr8:55087400	NA	-0.34	-7.13	-0.36	6.09e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.36	-6.58	-0.34	1.73e-10	Aortic root size;
LIHC	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	0.37	5.76	0.3	1.87e-8	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.69	0.34	9.33e-11	Bipolar disorder;
LIHC	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.77	-0.34	5.74e-11	Total cholesterol levels;
LIHC	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-13.11	-0.58	4.34e-32	Pediatric autoimmune diseases;
LIHC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.67	-10.04	-0.48	6.02e-21	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg03585969	chr10:35415529	CREM	0.76	10.96	0.51	3.65e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7771547	0.589	rs6941918	chr6:36514721	T/G	cg07856975	chr6:36356162	ETV7	0.38	6.25	0.32	1.22e-9	Platelet distribution width;
LIHC	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.55	-8.37	-0.41	1.5e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg01557791	chr16:72042693	DHODH	-0.41	-6.88	-0.35	2.88e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg20887711	chr4:1340912	KIAA1530	0.59	9.16	0.44	4.76e-18	Obesity-related traits;
LIHC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.7	-9.96	-0.47	1.08e-20	Bronchopulmonary dysplasia;
LIHC	trans	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg08566640	chr11:64091735	NA	-0.75	-6.92	-0.35	2.25e-11	Androgen levels;
LIHC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.04	0.31	4.04e-9	Rheumatoid arthritis;
LIHC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs7534824	0.625	rs72736234	chr1:101526098	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.74	6.93	0.35	2.06e-11	Refractive astigmatism;
LIHC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.65e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-18.61	-0.71	6.58e-54	Height;
LIHC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg17980119	chr2:219472607	PLCD4	0.34	5.81	0.3	1.43e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs74544699	1.000	rs116254820	chr4:74804444	G/A	cg16072462	chr4:74847758	PF4	0.57	5.86	0.3	1.11e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.66	-9.37	-0.45	1.01e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.87	0.3	1.04e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.31	-6.21	-0.32	1.58e-9	DNA methylation (variation);
LIHC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	8.04	0.4	1.44e-14	LDL cholesterol;
LIHC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.36	-5.77	-0.3	1.76e-8	Menopause (age at onset);
LIHC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.45	7.04	0.36	1.09e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg20991723	chr1:152506922	NA	0.6	10.87	0.51	7.75e-24	Hair morphology;
LIHC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.79	12.86	0.57	3.74e-31	Fat distribution (HIV);
LIHC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.94	9.63	0.46	1.39e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.57	-8.36	-0.41	1.61e-15	Blood metabolite levels;
LIHC	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.2	-0.36	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs911119	0.913	rs3004145	chr20:23582876	C/G	cg16589663	chr20:23618590	CST3	-0.67	-7.23	-0.36	3.23e-12	Chronic kidney disease;
LIHC	trans	rs2228638	1.000	rs12415845	chr10:33472820	T/A	cg17012154	chr7:2275030	FTSJ2	0.63	6.06	0.31	3.51e-9	Tetralogy of Fallot;
LIHC	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.52	-8.46	-0.42	7.64e-16	Blood protein levels;
LIHC	cis	rs74233809	1.000	rs78821730	chr10:104684544	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.02	0.31	4.57e-9	Birth weight;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.18	0.44	4.23e-18	Lung cancer in ever smokers;
LIHC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.41	-6.54	-0.33	2.22e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.12	16.62	0.67	6.91e-46	Sexual dysfunction (female);
LIHC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.02	14.54	0.62	1.3e-37	Cognitive function;
LIHC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg05343316	chr1:45956843	TESK2	-0.42	-6.19	-0.32	1.69e-9	High light scatter reticulocyte count;
LIHC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg16822855	chr3:40428330	ENTPD3	0.32	5.87	0.3	1.03e-8	Renal cell carcinoma;
LIHC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg17771515	chr6:154831774	CNKSR3	0.59	6.53	0.33	2.36e-10	Lipoprotein (a) levels;
LIHC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.85	-0.43	4.65e-17	Monocyte count;
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.42	-6.69	-0.34	8.95e-11	Schizophrenia;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27189623	chr16:705930	WDR90	0.44	7.49	0.38	6.02e-13	Height;
LIHC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.42	-6.26	-0.32	1.13e-9	Calcium levels;
LIHC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.73	-16.51	-0.67	1.98e-45	Brugada syndrome;
LIHC	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.42e-9	Prostate cancer;
LIHC	cis	rs1030268	0.962	rs12707122	chr7:133517309	A/C	cg03336402	chr7:133662267	EXOC4	-0.46	-6.32	-0.32	7.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.41	-7.05	-0.36	9.67e-12	Schizophrenia;
LIHC	trans	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg11693508	chr17:37793320	STARD3	0.75	7.41	0.37	9.91e-13	Neuroticism;
LIHC	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.42	7.16	0.36	5.05e-12	Crohn's disease;
LIHC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.4	6.88	0.35	2.84e-11	Diastolic blood pressure;
LIHC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-10.57	-0.5	8.95e-23	Platelet count;
LIHC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.79	0.39	8.3e-14	Morning vs. evening chronotype;
LIHC	cis	rs939574	0.512	rs908197	chr2:220144410	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.6	7.16	0.36	4.95e-12	Platelet distribution width;
LIHC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.52	-0.38	5.01e-13	Body mass index;
LIHC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg18016565	chr1:150552671	MCL1	0.5	9.51	0.46	3.62e-19	Melanoma;
LIHC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.66	-9.37	-0.45	1.01e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg20634798	chr1:152595351	LCE3A	-0.31	-6.07	-0.31	3.46e-9	Psoriasis;
LIHC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.97e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.32	-0.32	8.31e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	0.96	16.18	0.66	4.17e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg13628971	chr7:2884303	GNA12	0.42	6.57	0.33	1.93e-10	Height;
LIHC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.52	9.14	0.44	5.56e-18	N-glycan levels;
LIHC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.59	-8.25	-0.41	3.5e-15	Menarche (age at onset);
LIHC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18252515	chr7:66147081	NA	-0.41	-5.76	-0.3	1.86e-8	Aortic root size;
LIHC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.88	-0.3	9.64e-9	Schizophrenia;
LIHC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.46	7.16	0.36	5.09e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.55	7.16	0.36	5e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	0.95	22.19	0.77	3.15e-68	Multiple myeloma;
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.01	-0.35	1.32e-11	Obesity-related traits;
LIHC	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.27	-0.32	1.08e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.75	-0.5	2.07e-23	Total cholesterol levels;
LIHC	cis	rs5753037	0.809	rs17711377	chr22:30212986	C/T	cg01021169	chr22:30184971	ASCC2	-0.35	-6.59	-0.34	1.65e-10	Type 1 diabetes;
LIHC	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.55	8.35	0.41	1.74e-15	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg15902774	chr15:75289873	SCAMP5	0.34	5.96	0.31	6.31e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.83	-13.95	-0.6	2.63e-35	Aortic root size;
LIHC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.45	8.28	0.41	2.83e-15	Platelet distribution width;
LIHC	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg12501888	chr15:85177176	SCAND2	-0.51	-7.9	-0.39	3.88e-14	P wave terminal force;
LIHC	cis	rs36051895	0.623	rs17426903	chr9:5203292	A/C	cg02405213	chr9:5042618	JAK2	-0.62	-9.82	-0.47	3.14e-20	Pediatric autoimmune diseases;
LIHC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg09222892	chr1:25734099	RHCE	-0.45	-8.22	-0.41	4.25e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	cis	rs2637030	0.559	rs2636991	chr5:52943067	T/G	cg06476337	chr5:52856530	NDUFS4	0.43	6.82	0.35	4.25e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs1914816	1.000	rs2456075	chr15:76555986	C/T	cg03037974	chr15:76606532	NA	-0.61	-6.36	-0.33	6.48e-10	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.38	6.69	0.34	9.02e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	0.93	11.04	0.51	1.9e-24	Mitochondrial DNA levels;
LIHC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.35	-5.77	-0.3	1.78e-8	Systemic lupus erythematosus;
LIHC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.42	-0.33	4.48e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.67	0.42	1.75e-16	Lung cancer;
LIHC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg20607798	chr8:58055168	NA	0.5	5.91	0.3	8.11e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.51	7.29	0.37	2.18e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg24826892	chr11:71159390	DHCR7	0.5	6.43	0.33	4.31e-10	Vitamin D levels;
LIHC	cis	rs244293	0.931	rs244349	chr17:53196169	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg12751644	chr20:60527061	NA	-0.37	-6.04	-0.31	3.94e-9	Body mass index;
LIHC	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg10820045	chr2:198174542	NA	0.55	8.96	0.44	2.12e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.66	11.66	0.53	1.09e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.37	-5.77	-0.3	1.82e-8	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01358551	chr19:47353761	AP2S1	0.45	6.57	0.33	1.88e-10	Cognitive function;
LIHC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.52	-7.8	-0.39	7.74e-14	Total body bone mineral density;
LIHC	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.34	7.78	0.39	8.45e-14	Blood metabolite ratios;
LIHC	cis	rs9378688	0.654	rs2450307	chr6:2324639	A/G	cg12303981	chr6:2244766	GMDS	-0.43	-6.08	-0.31	3.21e-9	Caudate nucleus volume;
LIHC	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.32	6.05	0.31	3.77e-9	Red blood cell count;
LIHC	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.25	0.36	2.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.41	4.57e-15	Morning vs. evening chronotype;
LIHC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.39	-0.71	5.32e-53	Height;
LIHC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	9.25	0.45	2.56e-18	Hip circumference adjusted for BMI;
LIHC	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02985541	chr2:219472218	PLCD4	-0.36	-6.36	-0.33	6.34e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-1.01	-17.63	-0.69	6.12e-50	Monocyte percentage of white cells;
LIHC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg05590025	chr7:65112418	INTS4L2	0.62	6.79	0.34	4.9e-11	Diabetic kidney disease;
LIHC	trans	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg19894588	chr14:64061835	NA	0.7	10.05	0.48	5.4e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.78	9.96	0.47	1.06e-20	Cognitive function;
LIHC	cis	rs17125944	0.686	rs1952090	chr14:53342992	A/G	cg00686598	chr14:53173677	PSMC6	-0.7	-7.73	-0.39	1.24e-13	Alzheimer's disease (late onset);
LIHC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.61	11.3	0.52	2.28e-25	Alzheimer's disease (late onset);
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.3	-0.32	9.17e-10	Longevity;Endometriosis;
LIHC	cis	rs3736485	0.868	rs2124592	chr15:51922979	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.55	-0.33	2.05e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.5	-0.38	5.69e-13	Tonsillectomy;
LIHC	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg04357082	chr16:980022	LMF1	0.47	8.22	0.41	4.16e-15	Non-glioblastoma glioma;Glioblastoma;Glioma;
LIHC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.33	7.12	0.36	6.2e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	0.82	16.35	0.66	8.67e-45	Longevity;
LIHC	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-8.79	-0.43	7.25e-17	Obesity-related traits;
LIHC	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.35	-8.9	-0.43	3.4e-17	Hip circumference;Waist circumference;
LIHC	cis	rs903552	1.000	rs12904206	chr15:102006294	C/T	cg25677261	chr15:102009856	PCSK6	-0.44	-5.95	-0.31	6.77e-9	Diabetic kidney disease;
LIHC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.79	6.64	0.34	1.22e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg13409248	chr3:40428643	ENTPD3	-0.51	-8.62	-0.42	2.46e-16	Renal cell carcinoma;
LIHC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-10.91	-0.51	5.63e-24	Colorectal cancer;
LIHC	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	0.77	8.53	0.42	4.73e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-7.14	-0.36	5.49e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.72	12.25	0.55	7.76e-29	Menopause (age at onset);
LIHC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.44	5.86	0.3	1.06e-8	Blood metabolite levels;
LIHC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.24	-7.49	-0.38	5.76e-13	Mean corpuscular volume;
LIHC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17467752	chr17:38218738	THRA	-0.45	-7.39	-0.37	1.14e-12	Myeloid white cell count;
LIHC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.9	0.35	2.48e-11	Height;
LIHC	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.86	-0.35	3.22e-11	Metabolite levels;
LIHC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.8	-12.51	-0.56	7.63e-30	Breast cancer;
LIHC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.79	11.26	0.52	3.25e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.41	0.33	4.92e-10	Lung cancer in ever smokers;
LIHC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.48	5.73	0.3	2.18e-8	Schizophrenia;
LIHC	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.63	8.04	0.4	1.47e-14	Neuroticism;
LIHC	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.47	-0.37	6.61e-13	Response to antipsychotic treatment;
LIHC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.47	-5.87	-0.3	1.02e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.18e-31	Sense of smell;
LIHC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.52	6.48	0.33	3.19e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.67	10.59	0.5	7.4e-23	Monocyte count;
LIHC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.38	-8.1	-0.4	9.63e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.58	-0.38	3.27e-13	Total body bone mineral density;
LIHC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-0.84	-10.47	-0.49	1.94e-22	Blood pressure (smoking interaction);
LIHC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.48	-7.7	-0.38	1.44e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6442522	0.678	rs3732722	chr3:15507761	G/A	cg16303742	chr3:15540471	COLQ	0.45	7.61	0.38	2.72e-13	Uric acid levels;
LIHC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.25	7.43	0.37	8.78e-13	Calcium levels;
LIHC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.3	0.61	1.07e-36	Multiple sclerosis;
LIHC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-8.81	-0.43	6.41e-17	Schizophrenia;
LIHC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.47	8.4	0.41	1.17e-15	IgG glycosylation;
LIHC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.48	-8.11	-0.4	9.34e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg09035930	chr12:129282057	SLC15A4	-0.49	-6.08	-0.31	3.21e-9	Systemic lupus erythematosus;
LIHC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.82	12.26	0.55	6.73e-29	Motion sickness;
LIHC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.6	0.67	8.6e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.61	7.03	0.36	1.09e-11	Menarche (age at onset);
LIHC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.16	-0.52	6.98e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.54	-13.23	-0.58	1.53e-32	White blood cell count (basophil);
LIHC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg26441486	chr22:50317300	CRELD2	0.35	5.87	0.3	1.02e-8	Schizophrenia;
LIHC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.84	13.94	0.6	2.78e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.74	-12.05	-0.55	4.28e-28	Body mass index;
LIHC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.86	-0.3	1.06e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.49	-8.87	-0.43	4.05e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	0.56	7.27	0.37	2.46e-12	Opioid sensitivity;
LIHC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	8.16	0.4	6.58e-15	Platelet count;
LIHC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02249930	chr10:70166207	RUFY2	-0.54	-6.8	-0.35	4.57e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.75	-0.3	2.03e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	cis	rs4788570	0.615	rs10852502	chr16:71652072	C/A	cg06353428	chr16:71660113	MARVELD3	1.4	13.76	0.6	1.39e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.87	-0.3	1.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.48	-6.79	-0.34	5.04e-11	Lymphocyte counts;
LIHC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.7	7.8	0.39	7.48e-14	Testicular germ cell tumor;
LIHC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.25	-0.45	2.55e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.35	8.18	0.4	5.67e-15	Crohn's disease;
LIHC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	8.97	0.44	1.94e-17	Mean platelet volume;
LIHC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-1.04	-17.76	-0.69	1.89e-50	Monocyte percentage of white cells;
LIHC	cis	rs12286929	0.679	rs11606814	chr11:115042513	G/T	cg04055981	chr11:115044050	NA	0.4	6.7	0.34	8.6e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.82	-0.3	1.38e-8	Body mass index;
LIHC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.32	7.27	0.37	2.53e-12	Crohn's disease;
LIHC	cis	rs507080	1.000	rs659969	chr11:118549803	C/T	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.93	0.31	7.49e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	0.89	8.57	0.42	3.56e-16	Alzheimer's disease;
LIHC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.77	-0.34	5.49e-11	Psoriasis;
LIHC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg07451762	chr16:28383216	NA	0.39	6.91	0.35	2.38e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.54	8.46	0.42	8e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1215050	0.904	rs260898	chr4:98706492	C/G	cg05340658	chr4:99064831	C4orf37	-0.45	-5.77	-0.3	1.77e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.04	19.88	0.73	5.56e-59	Cognitive ability;
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg19635926	chr16:89946313	TCF25	0.51	7.13	0.36	5.91e-12	Skin colour saturation;
LIHC	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg01864069	chr14:103024347	NA	0.39	6.38	0.33	5.69e-10	Platelet count;
LIHC	cis	rs16828019	0.929	rs12029321	chr1:41682530	G/C	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.84e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.76	-10.66	-0.5	4.28e-23	Diastolic blood pressure;
LIHC	trans	rs7714584	1.000	rs10061105	chr5:150255185	C/G	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.27	-16.34	-0.66	9.2e-45	Diabetic kidney disease;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg18635645	chr1:85667791	SYDE2	-0.41	-6.16	-0.32	2.03e-9	Urinary tract infection frequency;
LIHC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.24	0.41	3.7e-15	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg05973401	chr12:123451056	ABCB9	0.45	6.21	0.32	1.56e-9	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg24579218	chr15:68104479	NA	-0.34	-5.83	-0.3	1.27e-8	Restless legs syndrome;
LIHC	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	0.98	12.36	0.56	2.84e-29	Economic and political preferences (immigration/crime);
LIHC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.68	0.34	9.97e-11	Platelet count;
LIHC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.67	6.87	0.35	3.01e-11	Bipolar disorder;
LIHC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.43	8.29	0.41	2.54e-15	Tuberculosis;
LIHC	cis	rs7937890	0.505	rs4403769	chr11:14450176	C/T	cg22961513	chr11:14280813	SPON1	-0.4	-6.0	-0.31	4.91e-9	Mitochondrial DNA levels;
LIHC	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/A	cg07817648	chr10:79422355	NA	-0.32	-6.85	-0.35	3.47e-11	Mortality in heart failure;
LIHC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-22.99	-0.78	2.18e-71	Height;
LIHC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11673344	0.704	rs517110	chr19:37422394	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.07	-0.31	3.38e-9	Obesity-related traits;
LIHC	cis	rs7635838	0.859	rs7632040	chr3:11427455	A/G	cg00170343	chr3:11313890	ATG7	0.45	7.16	0.36	5.09e-12	HDL cholesterol;
LIHC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.88	0.43	3.76e-17	Motion sickness;
LIHC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg17980119	chr2:219472607	PLCD4	0.36	6.25	0.32	1.25e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.41	7.54	0.38	4.37e-13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.26	-0.52	3.07e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.58	9.98	0.47	9.4e-21	Alcohol dependence;
LIHC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg23091122	chr1:110024289	SYPL2	-0.5	-6.85	-0.35	3.38e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.65	6.46	0.33	3.51e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	7.68	0.38	1.74e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	9.61	0.46	1.59e-19	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg23091122	chr1:110024289	SYPL2	-0.45	-5.96	-0.31	6.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg17135325	chr3:160939158	NMD3	0.47	7.11	0.36	6.97e-12	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg20607798	chr8:58055168	NA	0.61	7.51	0.38	5.2e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.8	9.02	0.44	1.43e-17	Vitiligo;
LIHC	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg02702477	chr5:179499311	RNF130	0.89	12.04	0.55	4.51e-28	LDL cholesterol;
LIHC	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.45	6.92	0.35	2.23e-11	Triglyceride levels;
LIHC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.07	0.31	3.36e-9	Menopause (age at onset);
LIHC	cis	rs1144333	0.655	rs76416835	chr1:76341511	G/T	cg03433033	chr1:76189801	ACADM	0.54	7.45	0.37	7.82e-13	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs3821902	0.547	rs56237630	chr3:64049375	C/A	cg22906524	chr22:19960525	ARVCF	-0.49	-6.04	-0.31	3.94e-9	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24926775	chr1:151584391	SNX27	0.43	7.01	0.35	1.3e-11	Cognitive function;
LIHC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg08923669	chr16:420230	MRPL28	-0.47	-6.18	-0.32	1.81e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7238033	0.602	rs10460034	chr18:43311399	C/T	cg20610511	chr18:43302872	SLC14A1	0.38	6.34	0.32	7.44e-10	Bladder cancer;
LIHC	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.43	-0.37	8.62e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.48	-7.82	-0.39	6.5e-14	Menarche (age at onset);
LIHC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.41	0.53	8.76e-26	Alzheimer's disease (late onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00221035	chr7:7222342	C1GALT1	-0.49	-6.27	-0.32	1.08e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.3	-6.3	-0.32	9.18e-10	Platelet distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06594919	chr10:102827590	NA	0.48	6.94	0.35	2.02e-11	Pancreatic cancer;
LIHC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.64	-10.47	-0.49	1.94e-22	Alcohol dependence;
LIHC	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.99	-0.31	5.38e-9	Schizophrenia;
LIHC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.82	9.05	0.44	1.13e-17	Vitiligo;
LIHC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg07382826	chr16:28625726	SULT1A1	0.5	8.03	0.4	1.55e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-9.24	-0.45	2.71e-18	Schizophrenia;
LIHC	cis	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg01864836	chr14:55583639	NA	-0.38	-6.51	-0.33	2.74e-10	Protein biomarker;
LIHC	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.49	0.49	1.69e-22	Colorectal cancer;
LIHC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.43	6.83	0.35	3.94e-11	Schizophrenia;
LIHC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.58	0.56	4.44e-30	Cognitive test performance;
LIHC	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg26138937	chr11:71823887	C11orf51	1.32	10.9	0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs4924935	0.781	rs2472694	chr17:18848498	A/G	cg26378065	chr17:18585709	ZNF286B	0.53	5.88	0.3	9.67e-9	Pancreatic cancer;
LIHC	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.72	-10.44	-0.49	2.54e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.33	0.32	7.63e-10	Renal cell carcinoma;
LIHC	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg00647820	chr17:40259828	DHX58	-0.27	-5.71	-0.3	2.46e-8	Fibrinogen levels;
LIHC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	7.53	0.38	4.5e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.21	-0.32	1.56e-9	Body mass index;
LIHC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg11406765	chr11:980039	AP2A2	-0.34	-5.71	-0.3	2.46e-8	Alzheimer's disease (late onset);
LIHC	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg23517279	chr6:96025343	MANEA	-0.61	-6.08	-0.31	3.23e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.78	-9.06	-0.44	1.06e-17	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.63	7.96	0.4	2.64e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.66	9.23	0.45	2.8e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.73	0.62	2.16e-38	Myeloid white cell count;
LIHC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.86	11.26	0.52	3.21e-25	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08677398	chr8:58056175	NA	0.39	6.06	0.31	3.68e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs7219021	1.000	rs57185954	chr17:46844961	T/C	cg14968300	chr8:23585186	NA	-0.35	-6.44	-0.33	3.97e-10	Schizophrenia or bipolar disorder;
LIHC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg06640241	chr16:89574553	SPG7	0.64	10.15	0.48	2.43e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	8.35	0.41	1.74e-15	Mean platelet volume;
LIHC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.61	9.85	0.47	2.59e-20	Obesity-related traits;
LIHC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.68	-0.34	9.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.71	-0.38	1.36e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1494950	0.661	rs55952030	chr4:14987310	T/C	cg12377275	chr4:15005593	CPEB2	-0.79	-6.68	-0.34	9.49e-11	Political ideology;
LIHC	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.52	-5.79	-0.3	1.61e-8	Blood protein levels;
LIHC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.03	0.51	2.09e-24	Colorectal cancer;
LIHC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.65	0.42	2.02e-16	Motion sickness;
LIHC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.52	8.85	0.43	4.83e-17	Coronary artery disease;
LIHC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg07061783	chr6:25882402	NA	0.43	6.24	0.32	1.31e-9	Blood metabolite levels;
LIHC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.71	12.04	0.55	4.57e-28	Menopause (age at onset);
LIHC	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.44	-7.44	-0.37	8.32e-13	Pelvic organ prolapse;
LIHC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg10402321	chr1:26617780	UBXN11	-0.37	-5.8	-0.3	1.53e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg00091569	chr3:40428383	ENTPD3	-0.38	-6.24	-0.32	1.26e-9	Renal cell carcinoma;
LIHC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.38	6.63	0.34	1.3e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.63	8.01	0.4	1.76e-14	Morning vs. evening chronotype;
LIHC	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.44	-6.08	-0.31	3.26e-9	Systolic blood pressure;
LIHC	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	18.23	0.7	2.29e-52	Colorectal cancer;
LIHC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs15676	0.783	rs11515530	chr9:131576367	C/T	cg00228799	chr9:131580591	ENDOG	-0.47	-6.84	-0.35	3.56e-11	Blood metabolite levels;
LIHC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.43	-8.02	-0.4	1.75e-14	Neurofibrillary tangles;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.86	0.76	6.43e-67	Prudent dietary pattern;
LIHC	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.68	11.27	0.52	2.96e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.42	-6.57	-0.33	1.88e-10	Dental caries;
LIHC	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg19413766	chr7:29689036	LOC646762	0.58	6.08	0.31	3.19e-9	Facial emotion recognition;Facial emotion recognition (sad faces);
LIHC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.08	-0.36	8.34e-12	Monocyte percentage of white cells;
LIHC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18357526	chr6:26021779	HIST1H4A	0.46	6.83	0.35	3.79e-11	Height;
LIHC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.6	10.67	0.5	3.87e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.98	22.84	0.78	9.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.5	6.9	0.35	2.54e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.44	7.57	0.38	3.54e-13	Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg02702477	chr5:179499311	RNF130	-0.74	-10.27	-0.49	9.85e-22	LDL cholesterol;
LIHC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.94	-0.31	6.94e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.25	-18.52	-0.71	1.55e-53	Ulcerative colitis;
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	10.2	0.48	1.71e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.56	9.17	0.44	4.69e-18	Longevity;Endometriosis;
LIHC	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.54	0.38	4.21e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg12798992	chr6:167411361	FGFR1OP	0.53	8.23	0.41	3.96e-15	Crohn's disease;
LIHC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.73	-10.47	-0.49	1.93e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.61	-12.04	-0.55	4.38e-28	Plateletcrit;Platelet count;
LIHC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	8.88	0.43	3.82e-17	Body mass index (adult);
LIHC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.26	-16.43	-0.66	3.87e-45	Diabetic kidney disease;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.47	0.56	1.09e-29	Prudent dietary pattern;
LIHC	cis	rs5995875	0.524	rs73171017	chr22:41060853	A/T	cg14879645	chr22:41048474	NA	0.4	5.82	0.3	1.35e-8	Breast size;
LIHC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.55	-8.8	-0.43	6.88e-17	Menarche (age at onset);
LIHC	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.39	6.1	0.31	2.91e-9	Platelet count;
LIHC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.77	0.43	8.47e-17	Motion sickness;
LIHC	cis	rs2637266	0.655	rs861744	chr10:78519132	T/G	cg18941641	chr10:78392320	NA	0.28	6.05	0.31	3.76e-9	Pulmonary function;
LIHC	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.73	-11.29	-0.52	2.5e-25	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08355568	chr6:7108248	RREB1	-0.44	-6.16	-0.32	2.07e-9	Bilirubin levels;
LIHC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.45	6.35	0.32	6.81e-10	Height;
LIHC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.57	9.96	0.47	1.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.06	-0.36	9.19e-12	Breast cancer;
LIHC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg07061783	chr6:25882402	NA	-0.46	-6.49	-0.33	3.02e-10	Blood metabolite levels;
LIHC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.64	-0.53	1.33e-26	Coronary artery disease;
LIHC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.34e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1419980	0.730	rs11054899	chr12:7774445	C/T	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.75	-9.25	-0.45	2.44e-18	Systemic lupus erythematosus;
LIHC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.89	-0.35	2.64e-11	Personality dimensions;
LIHC	cis	rs16958440	0.541	rs11876448	chr18:44644530	G/A	cg17192377	chr18:44677553	HDHD2	0.49	6.2	0.32	1.62e-9	Sitting height ratio;
LIHC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.8	12.63	0.56	2.75e-30	Blood metabolite levels;
LIHC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.87	-0.39	4.59e-14	Body mass index;
LIHC	cis	rs7084416	0.517	rs75453629	chr10:82010658	C/T	cg01528321	chr10:82214614	TSPAN14	-0.53	-7.0	-0.35	1.33e-11	Post bronchodilator FEV1;
LIHC	cis	rs797680	0.856	rs693737	chr1:93724924	G/A	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.72	0.54	6.76e-27	Motion sickness;
LIHC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.18	0.52	6.23e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.86	-0.3	1.07e-8	Systolic blood pressure;
LIHC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.35	6.49	0.33	3.02e-10	Aortic root size;
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg22528358	chr1:107598549	PRMT6	0.71	11.67	0.53	1.07e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.83	0.39	6.12e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00290607	chr11:67383545	NA	0.38	5.77	0.3	1.74e-8	Mean corpuscular volume;
LIHC	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02985541	chr2:219472218	PLCD4	-0.39	-6.52	-0.33	2.58e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg07061783	chr6:25882402	NA	0.47	6.03	0.31	4.26e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.92	15.43	0.64	3.78e-41	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08334199	chr2:178128998	NFE2L2	-0.51	-6.11	-0.31	2.78e-9	Systolic blood pressure;
LIHC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.57	9.74	0.47	6.17e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg07382826	chr16:28625726	SULT1A1	0.48	7.54	0.38	4.35e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.88	0.3	9.81e-9	Blood metabolite levels;
LIHC	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.73	10.99	0.51	2.8e-24	Subjective well-being;
LIHC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.65	9.9	0.47	1.74e-20	Body mass index;
LIHC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.44	6.34	0.32	7.33e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.73	6.63	0.34	1.35e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.4	6.36	0.33	6.58e-10	Red blood cell count;
LIHC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.56	-7.97	-0.4	2.43e-14	Coronary artery disease;
LIHC	cis	rs2257205	0.667	rs6503874	chr17:56780459	C/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.56	-0.33	2e-10	Pancreatic cancer;
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg05185784	chr16:90016020	DEF8	-0.44	-5.96	-0.31	6.27e-9	Skin colour saturation;
LIHC	cis	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg03342759	chr3:160939853	NMD3	0.56	7.29	0.37	2.19e-12	Morning vs. evening chronotype;
LIHC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.43	-9.23	-0.45	2.83e-18	Rheumatoid arthritis;
LIHC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.77	7.58	0.38	3.18e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-6.74	-0.34	6.58e-11	Cognitive function;
LIHC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.09e-8	Bipolar disorder;
LIHC	cis	rs918629	0.567	rs13361341	chr5:95250273	A/T	cg10483112	chr5:95245456	ELL2	-0.38	-7.04	-0.36	1.08e-11	IgG glycosylation;
LIHC	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg24849736	chr1:201084428	NA	-0.33	-5.77	-0.3	1.73e-8	Permanent tooth development;
LIHC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.08	-0.31	3.16e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11212260	0.655	rs2276271	chr11:107328544	C/T	cg25435332	chr11:107328525	CWF19L2	0.8	8.44	0.42	8.85e-16	IgG glycosylation;
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg05697976	chr12:29376483	FAR2	-0.31	-6.27	-0.32	1.07e-9	QT interval;
LIHC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.31	-5.83	-0.3	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098699	0.821	rs13120866	chr4:124199293	A/G	cg09941581	chr4:124220074	SPATA5	0.31	6.2	0.32	1.6e-9	Mosquito bite size;
LIHC	cis	rs3736485	0.966	rs12443007	chr15:51892192	G/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.73	-0.3	2.22e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11673344	0.503	rs1667370	chr19:37490220	A/T	cg27390819	chr19:37464633	NA	-0.47	-6.12	-0.31	2.6e-9	Obesity-related traits;
LIHC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-9.64	-0.46	1.26e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.67	-9.95	-0.47	1.16e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.98	22.81	0.78	1.15e-70	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg09033563	chr22:24373618	LOC391322	0.43	5.86	0.3	1.07e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg26939375	chr7:64535504	NA	0.43	7.21	0.36	3.56e-12	Calcium levels;
LIHC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	1.19	13.99	0.6	1.82e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg13647721	chr17:30228624	UTP6	0.73	8.08	0.4	1.13e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs11229555	0.645	rs12805062	chr11:58214584	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.63	-0.38	2.37e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs3783890	1.000	rs12881444	chr14:93784302	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.32	0.32	8.12e-10	Body mass index;
LIHC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.66	11.69	0.53	8.68e-27	Total body bone mineral density;
LIHC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.92	-0.31	7.68e-9	Life satisfaction;
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg07234388	chr1:156261841	TMEM79	0.52	9.39	0.45	8.5e-19	Tonsillectomy;
LIHC	cis	rs34779708	0.832	rs12764283	chr10:35530460	G/A	cg03585969	chr10:35415529	CREM	0.86	12.57	0.56	4.89e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg24296786	chr1:45957014	TESK2	-0.4	-5.92	-0.31	7.63e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.76	0.34	5.87e-11	Primary biliary cholangitis;
LIHC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.96	0.35	1.71e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg12160578	chr15:63334699	TPM1	0.67	8.87	0.43	4.13e-17	Orofacial clefts;
LIHC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.41	-6.99	-0.35	1.48e-11	Aortic root size;
LIHC	cis	rs3815308	0.530	rs2269880	chr19:2195611	T/C	cg09261902	chr19:2140048	AP3D1	0.37	6.29	0.32	9.63e-10	Breast cancer;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.51	0.53	4.06e-26	Colorectal cancer;
LIHC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.6	0.42	2.85e-16	Schizophrenia;
LIHC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.27	-7.01	-0.35	1.29e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	0.92	9.44	0.45	5.9e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg05760424	chr2:242988095	NA	-0.51	-6.79	-0.34	4.88e-11	Obesity-related traits;
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08280861	chr8:58055591	NA	0.51	6.39	0.33	5.56e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg17135325	chr3:160939158	NMD3	0.53	7.38	0.37	1.25e-12	Parkinson's disease;
LIHC	cis	rs655641	1.000	rs1996108	chr11:85728030	T/C	cg09030501	chr11:85779252	PICALM	-0.51	-6.21	-0.32	1.56e-9	Platelet count;
LIHC	trans	rs1422110	0.513	rs987280	chr5:85448604	C/T	cg01787110	chr1:109008453	NBPF6	-0.3	-7.48	-0.37	6.45e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.67	12.05	0.55	3.99e-28	High light scatter reticulocyte count;
LIHC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg12798992	chr6:167411361	FGFR1OP	0.53	8.45	0.42	8.47e-16	Crohn's disease;
LIHC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.99	-0.31	5.24e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.55	8.06	0.4	1.28e-14	Diastolic blood pressure;
LIHC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.82	7.41	0.37	1.01e-12	Lymphocyte counts;
LIHC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg12798992	chr6:167411361	FGFR1OP	0.48	7.37	0.37	1.32e-12	Crohn's disease;
LIHC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.35	5.75	0.3	1.96e-8	Platelet distribution width;
LIHC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.04	-0.55	4.49e-28	Type 2 diabetes;
LIHC	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.56	8.1	0.4	1e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.8	0.43	6.75e-17	Monocyte count;
LIHC	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.97	0.35	1.66e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	0.4	6.14	0.32	2.34e-9	Cognitive function;
LIHC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.48	5.79	0.3	1.58e-8	Bladder cancer;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.44	7.27	0.37	2.42e-12	Testicular germ cell tumor;
LIHC	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.46	6.4	0.33	5.08e-10	Diastolic blood pressure;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.47	6.58	0.34	1.78e-10	Menopause (age at onset);
LIHC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg07424592	chr7:64974309	NA	0.74	8.57	0.42	3.67e-16	Diabetic kidney disease;
LIHC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.07e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs8113308	1.000	rs8104737	chr19:52441697	T/G	cg14959425	chr7:20447707	ITGB8	-0.48	-6.47	-0.33	3.34e-10	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.0	0.35	1.34e-11	Aortic root size;
LIHC	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg21584241	chr15:63341463	TPM1	0.44	6.33	0.32	7.58e-10	Orofacial clefts;
LIHC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.39	6.09	0.31	3.12e-9	Resting heart rate;
LIHC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.83	0.3	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7923837	0.687	rs2185756	chr10:94430497	A/C	cg25506282	chr10:94462361	NA	0.39	6.9	0.35	2.54e-11	Body mass index;Multiple sclerosis;
LIHC	cis	rs7238033	0.624	rs9304322	chr18:43308198	G/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg05043794	chr9:111880884	C9orf5	-0.27	-6.44	-0.33	4.06e-10	Menarche (age at onset);
LIHC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg15123519	chr2:136567270	LCT	-0.4	-8.1	-0.4	9.92e-15	Mosquito bite size;
LIHC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.3	-0.32	9.34e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.92	13.82	0.6	8.34e-35	Primary sclerosing cholangitis;
LIHC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.35	-6.52	-0.33	2.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.7	0.46	8.04e-20	Electroencephalogram traits;
LIHC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg18944383	chr4:111397179	ENPEP	0.35	8.04	0.4	1.48e-14	Coronary artery disease;
LIHC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-8.54	-0.42	4.57e-16	Vitiligo;
LIHC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.29	-0.37	2.11e-12	Heart rate;
LIHC	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.39	5.93	0.31	7.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.61	-9.77	-0.47	4.66e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	1.02	13.21	0.58	1.75e-32	Severe influenza A (H1N1) infection;
LIHC	cis	rs4407350	0.967	rs5765731	chr22:44922759	C/T	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.0	-0.31	5.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg20016023	chr10:99160130	RRP12	-0.43	-7.0	-0.35	1.35e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg16576597	chr16:28551801	NUPR1	0.37	6.1	0.31	2.86e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs459482	1.000	rs461981	chr21:42794081	T/C	cg14166395	chr21:42792516	MX1	0.69	9.99	0.48	8.77e-21	IgG glycosylation;
LIHC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-6.41	-0.33	4.93e-10	Renal function-related traits (BUN);
LIHC	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.49	-9.44	-0.45	5.8e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.44	-8.15	-0.4	6.71e-15	IgG glycosylation;
LIHC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.41	-6.09	-0.31	3e-9	Height;
LIHC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg03689076	chr20:33865952	NA	-0.58	-6.7	-0.34	8.38e-11	Attention deficit hyperactivity disorder;
LIHC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.92	14.27	0.61	1.49e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.13	0.48	2.94e-21	Colorectal cancer;
LIHC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.49	-7.46	-0.37	7.19e-13	Crohn's disease;
LIHC	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.36	7.12	0.36	6.29e-12	Blood protein levels;
LIHC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.42	-0.37	9.36e-13	Bipolar disorder;
LIHC	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.48	8.11	0.4	9.4e-15	Schizophrenia;
LIHC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.57	6.41	0.33	4.81e-10	Vitiligo;
LIHC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg17279839	chr7:150038598	RARRES2	-0.4	-8.04	-0.4	1.5e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.97	8.2	0.41	4.91e-15	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-22.7	-0.78	3.18e-70	Height;
LIHC	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12826209	chr6:26865740	GUSBL1	0.57	5.84	0.3	1.2e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg02269571	chr22:50332266	NA	-1.03	-10.49	-0.49	1.68e-22	Mean platelet volume;
LIHC	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg05110241	chr16:68378359	PRMT7	-0.61	-6.92	-0.35	2.23e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg25039879	chr17:56429692	SUPT4H1	0.86	9.69	0.46	9e-20	Cognitive test performance;
LIHC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.85	-0.65	8.31e-43	Chronic sinus infection;
LIHC	cis	rs12644436	0.671	rs4693189	chr4:88787249	T/C	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.53	-6.57	-0.33	1.92e-10	Iron status biomarkers;
LIHC	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.77	-0.5	1.69e-23	Chronic sinus infection;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04282497	chr4:82350883	RASGEF1B	0.42	6.56	0.33	1.95e-10	Immature fraction of reticulocytes;
LIHC	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.44	0.33	4.09e-10	Mean corpuscular volume;
LIHC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-8.9	-0.43	3.27e-17	Atrioventricular conduction;
LIHC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.24	-0.36	2.92e-12	Vitiligo;
LIHC	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg18081818	chr7:23246105	NA	-0.39	-5.75	-0.3	1.95e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.4	-7.99	-0.4	2.11e-14	Cognitive function;
LIHC	cis	rs6545883	0.860	rs4671399	chr2:61458518	C/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.2	-0.36	3.95e-12	Tuberculosis;
LIHC	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	trans	rs7120489	0.708	rs3812759	chr11:12443958	T/C	cg08537300	chr5:179058959	NA	0.57	6.21	0.32	1.55e-9	Mortality in heart failure;
LIHC	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.36	6.18	0.32	1.82e-9	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.21e-8	Menopause (age at onset);
LIHC	cis	rs4728302	0.869	rs889825	chr7:133596227	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.54	0.33	2.24e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.55	8.83	0.43	5.63e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.61	-0.34	1.49e-10	Total body bone mineral density;
LIHC	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg13395646	chr4:1353034	KIAA1530	-0.75	-10.69	-0.5	3.4e-23	Obesity-related traits;
LIHC	cis	rs1789	0.839	rs9997068	chr4:15650990	T/C	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.85	-0.3	1.16e-8	Blood protein levels;
LIHC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.42	0.37	9.49e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.13	0.31	2.43e-9	Coronary artery disease;
LIHC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-21.75	-0.76	1.77e-66	Height;
LIHC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-8.41	-0.41	1.12e-15	Parkinson's disease;
LIHC	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.33	-6.03	-0.31	4.26e-9	IgG glycosylation;
LIHC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-6.58	-0.34	1.74e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg20240347	chr1:204465584	NA	-0.29	-5.93	-0.31	7.56e-9	Schizophrenia;
LIHC	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg03237606	chr10:63212265	TMEM26	0.29	6.29	0.32	9.89e-10	Night sleep phenotypes;
LIHC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.37	6.3	0.32	9.14e-10	Type 2 diabetes;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg13996397	chr19:1420048	DAZAP1	0.42	7.08	0.36	8.34e-12	Calcium levels;
LIHC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.53	-0.49	1.17e-22	Alzheimer's disease;
LIHC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.12	0.68	6.77e-48	Gut microbiome composition (summer);
LIHC	cis	rs4908760	0.539	rs6690928	chr1:8859491	G/C	cg20416874	chr1:8611966	RERE	-0.57	-10.28	-0.49	8.98e-22	Vitiligo;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02287918	chr21:30396957	USP16	-0.48	-7.36	-0.37	1.4e-12	Cognitive function;
LIHC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.4	-0.33	5.09e-10	Subjective well-being;
LIHC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg14132834	chr19:41945861	ATP5SL	-0.39	-5.77	-0.3	1.78e-8	Height;
LIHC	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg21231739	chr4:1642635	FAM53A	-0.38	-6.1	-0.31	2.82e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.52	7.57	0.38	3.48e-13	Corneal astigmatism;
LIHC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	1.11	13.75	0.6	1.53e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.41	6.61	0.34	1.48e-10	Mean corpuscular volume;
LIHC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.68	-8.33	-0.41	1.97e-15	Gut microbiome composition (summer);
LIHC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.99	9.66	0.46	1.12e-19	Eosinophil percentage of granulocytes;
LIHC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.06	7.47	0.37	6.75e-13	Cognitive function;
LIHC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.34	-0.58	5.73e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9649465	0.967	rs13239184	chr7:123314618	G/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.08	-0.4	1.09e-14	Migraine;
LIHC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg09990169	chr2:241835740	C2orf54	-0.66	-9.15	-0.44	5.22e-18	Urinary metabolites;
LIHC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.43	-7.78	-0.39	8.65e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg10790698	chr19:18539756	SSBP4	-0.37	-7.49	-0.38	5.79e-13	Breast cancer;
LIHC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.8	-0.43	6.82e-17	Gut microbiome composition (summer);
LIHC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.71	-0.38	1.38e-13	Type 2 diabetes;
LIHC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg24203234	chr3:128598194	ACAD9	0.45	6.32	0.32	8.18e-10	IgG glycosylation;
LIHC	cis	rs72627509	0.629	rs1277313	chr4:57903948	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	7.33	0.37	1.65e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	9.16	0.44	4.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.74	-0.5	2.19e-23	Alzheimer's disease;
LIHC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.57	9.75	0.47	5.52e-20	Vitiligo;
LIHC	trans	rs8117834	0.574	rs6086336	chr20:8088710	C/T	cg00593689	chr4:53575888	NA	0.38	6.38	0.33	5.83e-10	Chronic kidney disease;
LIHC	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.47	-0.37	6.61e-13	Response to antipsychotic treatment;
LIHC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg09222892	chr1:25734099	RHCE	-0.48	-8.89	-0.43	3.55e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.33	-7.23	-0.36	3.22e-12	Ulcerative colitis;
LIHC	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19671926	chr4:122722719	EXOSC9	0.57	8.71	0.43	1.31e-16	Type 2 diabetes;
LIHC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs7520050	0.966	rs6429582	chr1:46321843	C/T	cg03146154	chr1:46216737	IPP	0.36	5.88	0.3	9.63e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.54	8.38	0.41	1.38e-15	Dental caries;
LIHC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.73	0.54	6.22e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg23422044	chr7:1970798	MAD1L1	-0.56	-8.76	-0.43	8.91e-17	Neuroticism;
LIHC	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	19.02	0.72	1.56e-55	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17776563	0.959	rs11857151	chr15:89112877	C/G	cg05013243	chr15:89149849	MIR1179	0.45	7.57	0.38	3.55e-13	Thyroid hormone levels;
LIHC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg16102536	chr7:156981717	UBE3C	0.36	6.11	0.31	2.72e-9	Body mass index;
LIHC	cis	rs2274273	0.840	rs28493647	chr14:55824463	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.62	-0.34	1.36e-10	Protein biomarker;
LIHC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.7	8.33	0.41	1.98e-15	Dental caries;
LIHC	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg08462924	chr1:41848221	NA	0.35	5.94	0.31	6.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg08135965	chr6:41755394	TOMM6	0.43	5.84	0.3	1.2e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.32	6.22	0.32	1.43e-9	Type 2 diabetes;
LIHC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.32	5.72	0.3	2.35e-8	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.77	-0.69	1.69e-50	Gut microbiome composition (summer);
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-6.77	-0.34	5.6e-11	Lymphocyte counts;
LIHC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.45	5.8	0.3	1.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	1.05	15.45	0.64	3.09e-41	Intelligence (multi-trait analysis);
LIHC	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg01864836	chr14:55583639	NA	-0.36	-6.59	-0.34	1.64e-10	Protein biomarker;
LIHC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs2273156	1.000	rs7145608	chr14:35463497	G/T	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.03	16.27	0.66	1.75e-44	Breast cancer;
LIHC	cis	rs17106184	0.892	rs57254915	chr1:51139001	G/T	cg07174182	chr1:51127561	FAF1	-0.76	-8.12	-0.4	8.47e-15	Type 2 diabetes;
LIHC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.39	7.14	0.36	5.72e-12	Psoriasis;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02926110	chr15:72411069	MYO9A;SENP8	-0.41	-6.12	-0.31	2.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.7e-10	Uric acid levels;
LIHC	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.54e-12	Corneal astigmatism;
LIHC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.61	0.46	1.69e-19	Electroencephalogram traits;
LIHC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.37	-6.73	-0.34	7.14e-11	Aortic root size;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.34	0.37	1.58e-12	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.4	8.25	0.41	3.44e-15	Renal cell carcinoma;
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg14393609	chr7:65229607	NA	0.44	6.55	0.33	2.08e-10	Calcium levels;
LIHC	cis	rs3748682	0.731	rs9729719	chr1:38298207	G/A	cg12658694	chr1:38397304	INPP5B	0.42	5.72	0.3	2.29e-8	Hypothyroidism;
LIHC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg20283391	chr11:68216788	NA	0.38	6.05	0.31	3.85e-9	Total body bone mineral density;
LIHC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.44	6.41	0.33	4.83e-10	Methadone dose in opioid dependence;
LIHC	cis	rs4891159	0.790	rs7237974	chr18:74108860	A/G	cg24786174	chr18:74118243	ZNF516	-0.78	-13.83	-0.6	7.18e-35	Longevity;
LIHC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.29	0.52	2.51e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.53	7.48	0.38	6.23e-13	Schizophrenia;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-7.14	-0.36	5.48e-12	Lymphocyte counts;
LIHC	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs11031096	0.655	rs10835734	chr11:4211832	A/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.92	-0.3	7.73e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.62	6.2	0.32	1.62e-9	Carotid intima media thickness;
LIHC	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.44	-7.21	-0.36	3.65e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg09835421	chr16:68378352	PRMT7	-0.83	-10.03	-0.48	6.35e-21	Schizophrenia;
LIHC	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.58	-7.33	-0.37	1.72e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10924970	0.649	rs1933247	chr1:235432767	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.73	0.3	2.15e-8	Asthma;
LIHC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.56	-0.5	9.29e-23	Schizophrenia;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg14393609	chr7:65229607	NA	0.44	6.54	0.33	2.18e-10	Aortic root size;
LIHC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.61	-8.38	-0.41	1.39e-15	Vitiligo;
LIHC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs7572733	0.555	rs7420608	chr2:198915930	A/T	cg10820045	chr2:198174542	NA	0.41	6.2	0.32	1.67e-9	Dermatomyositis;
LIHC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg23205692	chr1:25664452	TMEM50A	0.38	6.11	0.31	2.65e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.58	10.0	0.48	7.94e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	7.6	0.38	2.93e-13	Tonsillectomy;
LIHC	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-6.16	-0.32	2.01e-9	Tuberculosis;
LIHC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg16989086	chr20:62203971	PRIC285	0.51	7.31	0.37	1.86e-12	Glioblastoma;
LIHC	trans	rs465757	1.000	rs465757	chr20:15580283	A/G	cg12283520	chr1:27989987	NA	-0.45	-6.31	-0.32	8.7e-10	Interleukin-10 levels;
LIHC	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.76	11.15	0.52	7.94e-25	Obesity-related traits;
LIHC	cis	rs9993613	0.935	rs11942991	chr4:73524203	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.38	-5.74	-0.3	2.05e-8	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1355223	0.902	rs836466	chr11:34737366	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.42	-7.28	-0.37	2.35e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.07e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25887850	chr20:44509743	ZSWIM1	0.43	6.53	0.33	2.36e-10	Cognitive function;
LIHC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs16828019	0.704	rs34486565	chr1:41522510	C/T	cg20697417	chr1:41786797	NA	0.31	5.82	0.3	1.35e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.38	6.15	0.32	2.21e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg03959625	chr15:84868606	LOC388152	0.43	5.84	0.3	1.22e-8	Schizophrenia;
LIHC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg00074818	chr8:8560427	CLDN23	0.37	6.15	0.32	2.21e-9	Obesity-related traits;
LIHC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.5e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.37	-0.33	5.95e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.23	-12.78	-0.57	7.71e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.59	8.85	0.43	4.78e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.48	6.7	0.34	8.45e-11	Schizophrenia;
LIHC	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.59	9.12	0.44	6.48e-18	Platelet distribution width;
LIHC	cis	rs7129220	0.588	rs61878631	chr11:10134832	C/T	cg01453529	chr11:10209919	SBF2	-0.38	-6.8	-0.35	4.72e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.54	10.86	0.51	8.57e-24	Myopia (pathological);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23018242	chr22:31608245	LIMK2	-0.43	-6.35	-0.32	6.81e-10	Cognitive function;
LIHC	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.93	-0.39	3.1e-14	Capecitabine sensitivity;
LIHC	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.6	8.67	0.42	1.77e-16	Facial morphology (factor 19);
LIHC	cis	rs74233809	1.000	rs79993475	chr10:104901031	A/G	cg03493300	chr10:104813866	CNNM2	0.47	6.26	0.32	1.13e-9	Birth weight;
LIHC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg23625390	chr15:77176239	SCAPER	0.35	6.04	0.31	4.02e-9	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.29	17.25	0.68	2.03e-48	Diabetic kidney disease;
LIHC	cis	rs6466055	0.739	rs10953474	chr7:104923005	A/G	cg04380332	chr7:105027541	SRPK2	0.37	6.86	0.35	3.2e-11	Schizophrenia;
LIHC	cis	rs10420951	0.617	rs79888481	chr19:18569957	G/A	cg10790698	chr19:18539756	SSBP4	-0.42	-5.93	-0.31	7.23e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.46	-7.24	-0.36	2.94e-12	Cognitive function;
LIHC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	13.96	0.6	2.37e-35	Lung cancer in ever smokers;
LIHC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.79	12.59	0.56	4.04e-30	Breast cancer;
LIHC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg01629716	chr15:45996671	NA	0.52	9.49	0.46	4.11e-19	Waist circumference;Weight;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27614445	chr3:179041226	ZNF639	0.58	7.55	0.38	4.03e-13	Lung function (FEV1/FVC);
LIHC	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	0.96	15.99	0.65	2.39e-43	Triglycerides;
LIHC	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.78	-0.54	4.04e-27	Coffee consumption (cups per day);
LIHC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.44	5.71	0.3	2.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.32	-0.37	1.79e-12	Mean platelet volume;
LIHC	cis	rs12980942	0.810	rs12974323	chr19:41807071	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.18	0.32	1.8e-9	Coronary artery disease;
LIHC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	10.94	0.51	4.43e-24	Cognitive test performance;
LIHC	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18357526	chr6:26021779	HIST1H4A	0.56	8.22	0.41	4.23e-15	Schizophrenia;
LIHC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.5	5.81	0.3	1.45e-8	Alzheimer's disease;
LIHC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.43	7.4	0.37	1.06e-12	Aortic root size;
LIHC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.34	7.42	0.37	9.5e-13	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs2421770	0.504	rs4756213	chr11:35363566	T/C	cg13971030	chr11:35366721	SLC1A2	-0.43	-7.29	-0.37	2.11e-12	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-8.97	-0.44	1.93e-17	Total body bone mineral density;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.69	9.38	0.45	9.59e-19	Calcium levels;
LIHC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.7	-12.25	-0.55	7.23e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs116248771	0.549	rs1548013	chr3:158431070	C/T	cg16708174	chr3:158430962	RARRES1	0.76	9.78	0.47	4.54e-20	diarrhoeal disease at age 2;
LIHC	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg02702477	chr5:179499311	RNF130	0.75	10.33	0.49	5.85e-22	LDL cholesterol;
LIHC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.65	0.42	2.06e-16	Initial pursuit acceleration;
LIHC	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.4	-5.96	-0.31	6.35e-9	Red blood cell traits;
LIHC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg14393609	chr7:65229607	NA	-0.43	-6.47	-0.33	3.47e-10	Cotinine glucuronidation;
LIHC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.82	-12.82	-0.57	5.62e-31	Total body bone mineral density;
LIHC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.38	-0.37	1.23e-12	Platelet count;
LIHC	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg25039879	chr17:56429692	SUPT4H1	0.53	7.35	0.37	1.44e-12	Cognitive test performance;
LIHC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg20607798	chr8:58055168	NA	0.53	6.63	0.34	1.27e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.51	-7.86	-0.39	5.14e-14	P wave terminal force;
LIHC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.94	14.44	0.62	3.01e-37	Breast cancer;
LIHC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.34	6.09	0.31	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg18306943	chr3:40428807	ENTPD3	-0.44	-7.81	-0.39	6.94e-14	Renal cell carcinoma;
LIHC	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.54	9.53	0.46	2.96e-19	Breast cancer;
LIHC	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-0.42	-6.67	-0.34	1.01e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-9.22	-0.45	3.01e-18	Parkinson's disease;
LIHC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.26	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg00792783	chr2:198669748	PLCL1	0.42	5.99	0.31	5.44e-9	Dermatomyositis;
LIHC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.83	13.64	0.59	4.07e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.16	0.32	2.02e-9	Rheumatoid arthritis;
LIHC	cis	rs1789	0.903	rs4453929	chr4:15672173	T/G	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.02	-0.35	1.23e-11	Blood protein levels;
LIHC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg07713946	chr22:31675144	LIMK2	-0.41	-7.4	-0.37	1.04e-12	Colorectal cancer;
LIHC	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg10127483	chr1:110009974	SYPL2	0.46	5.95	0.31	6.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.59	6.56	0.33	2.02e-10	Putamen volume;
LIHC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.04	0.31	4.13e-9	Tonsillectomy;
LIHC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.65	10.48	0.49	1.82e-22	Type 2 diabetes;
LIHC	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.22	-5.88	-0.3	9.86e-9	Hepatitis;
LIHC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.98	0.54	7.32e-28	High light scatter reticulocyte count;
LIHC	cis	rs4845459	0.967	rs9633406	chr1:152591446	C/G	cg20634798	chr1:152595351	LCE3A	-0.31	-5.92	-0.3	7.88e-9	Psoriasis;
LIHC	cis	rs4908768	0.871	rs7553298	chr1:8770883	A/G	cg25722041	chr1:8623473	RERE	0.42	6.2	0.32	1.63e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-12.28	-0.55	5.86e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.53	0.59	1.08e-33	Electrocardiographic conduction measures;
LIHC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.59	5.72	0.3	2.3e-8	Plasma clusterin levels;
LIHC	cis	rs1198430	1.000	rs1198431	chr1:23755716	C/T	cg19827787	chr1:23763612	ASAP3	-0.36	-6.43	-0.33	4.31e-10	Total cholesterol levels;
LIHC	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg21605333	chr4:119757512	SEC24D	0.8	6.82	0.35	4.23e-11	Cannabis dependence symptom count;
LIHC	cis	rs12611088	0.600	rs2682553	chr19:44004566	A/G	cg13740135	chr19:44006432	PHLDB3	-0.43	-6.29	-0.32	9.78e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.58	7.69	0.38	1.5700000000000001e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.51	-8.11	-0.4	9.28e-15	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LIHC	cis	rs2834188	0.924	rs2409487	chr21:34684958	C/T	cg14352951	chr21:34696688	IFNAR1	0.46	6.39	0.33	5.42e-10	Narcolepsy;
LIHC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.51	6.48	0.33	3.25e-10	Menarche (age at onset);
LIHC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.53	-0.33	2.39e-10	Morning vs. evening chronotype;
LIHC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.44	7.38	0.37	1.19e-12	Mean corpuscular volume;
LIHC	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.05	0.31	3.8e-9	Educational attainment;
LIHC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.8	-0.39	7.69e-14	Crohn's disease;
LIHC	cis	rs2120019	1.000	rs34655806	chr15:75362586	T/C	cg17294928	chr15:75287854	SCAMP5	-0.5	-7.55	-0.38	4.07e-13	Blood trace element (Zn levels);
LIHC	cis	rs9378688	0.654	rs2505662	chr6:2326185	T/C	cg12303981	chr6:2244766	GMDS	-0.45	-6.06	-0.31	3.59e-9	Caudate nucleus volume;
LIHC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	9.06	0.44	1.01e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.65	-9.72	-0.47	7.17e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.51	-7.23	-0.36	3.25e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.61	6.88	0.35	2.89e-11	Menarche (age at onset);
LIHC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-8.28	-0.41	2.89e-15	Ulcerative colitis;
LIHC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	7.58	0.38	3.34e-13	Parkinson's disease;
LIHC	cis	rs61440199	0.818	rs11917197	chr3:20181393	C/T	cg00235661	chr3:20228976	SGOL1	-0.42	-5.77	-0.3	1.74e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.59	-8.65	-0.42	2.01e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.44	8.25	0.41	3.56e-15	Schizophrenia;
LIHC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg06565975	chr8:143823917	SLURP1	0.33	6.16	0.32	2.07e-9	Urinary tract infection frequency;
LIHC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.8	5.94	0.31	6.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.36	0.45	1.07e-18	Bipolar disorder;
LIHC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	1.13	8.79	0.43	7.28e-17	Arsenic metabolism;
LIHC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg03859395	chr2:55845619	SMEK2	0.88	14.91	0.63	4.44e-39	Metabolic syndrome;
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06656553	chr16:89960601	TCF25	-0.48	-5.93	-0.31	7.6e-9	Skin colour saturation;
LIHC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	7.01	0.35	1.28e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.49	6.16	0.32	2.03e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.53	-6.29	-0.32	9.93e-10	Hair shape;
LIHC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.35	-5.99	-0.31	5.39e-9	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12868349	chr11:71639594	RNF121;LOC100133315	0.47	6.37	0.33	6.1e-10	Pancreatic cancer;
LIHC	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg10587741	chr22:38071170	LGALS1	0.44	7.93	0.39	3.22e-14	Fat distribution (HIV);
LIHC	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.36	-8.25	-0.41	3.45e-15	Congenital heart disease (maternal effect);
LIHC	trans	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg07393940	chr7:158741817	NA	-0.57	-6.94	-0.35	1.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11671005	0.779	rs35631681	chr19:58999840	C/T	cg25952890	chr19:58913133	NA	0.73	7.57	0.38	3.39e-13	Mean platelet volume;
LIHC	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.22e-9	Lewy body disease;
LIHC	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg23422044	chr7:1970798	MAD1L1	-0.46	-7.05	-0.36	9.83e-12	Neuroticism;
LIHC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.47	6.7	0.34	8.35e-11	Eosinophil percentage of white cells;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.89	-0.3	9.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.92	17.07	0.68	1.09e-47	Menopause (age at onset);
LIHC	cis	rs8032158	1.000	rs8032158	chr15:56194877	T/C	cg24530489	chr15:56299380	NA	0.43	6.01	0.31	4.81e-9	Keloid;
LIHC	cis	rs655641	1.000	rs592297	chr11:85725937	C/T	cg09030501	chr11:85779252	PICALM	-0.52	-6.14	-0.32	2.26e-9	Platelet count;
LIHC	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg14473756	chr11:122847823	NA	-0.37	-6.65	-0.34	1.18e-10	Menarche (age at onset);
LIHC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	8.66	0.42	1.93e-16	Platelet count;
LIHC	cis	rs7116495	0.881	rs1783959	chr11:71595981	T/C	cg26138937	chr11:71823887	C11orf51	0.7	7.07	0.36	8.59e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.58	10.27	0.49	9.39e-22	Dupuytren's disease;
LIHC	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.69	11.17	0.52	6.72e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21537245	chr1:20960434	PINK1	-0.57	-6.76	-0.34	5.9e-11	Systolic blood pressure;
LIHC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-9.84	-0.47	2.83e-20	Mean corpuscular volume;
LIHC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.66	-9.7	-0.46	8.22e-20	Testicular germ cell tumor;
LIHC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg25182066	chr10:30743637	MAP3K8	0.5	7.96	0.4	2.53e-14	Inflammatory bowel disease;
LIHC	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.83	16.02	0.65	1.79e-43	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.62	-8.17	-0.4	5.86e-15	Motion sickness;
LIHC	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.7	11.58	0.53	2.26e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg11212589	chr17:38028394	ZPBP2	0.29	6.1	0.31	2.89e-9	Self-reported allergy;
LIHC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-8.28	-0.41	2.86e-15	Menarche (age at onset);
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.88	0.3	9.84e-9	Aortic root size;
LIHC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.64	10.51	0.49	1.4e-22	Blood protein levels;
LIHC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.63	11.52	0.53	3.73e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10947003	chr16:67218230	KIAA0895L	0.47	6.95	0.35	1.85e-11	Cognitive function;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04816434	chr15:22945077	CYFIP1	0.41	6.06	0.31	3.51e-9	Longevity;
LIHC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.78	0.54	4.09e-27	Motion sickness;
LIHC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.34	-0.41	1.81e-15	Schizophrenia;
LIHC	cis	rs965469	0.779	rs6051761	chr20:3321568	A/G	cg25506879	chr20:3388711	C20orf194	0.51	6.22	0.32	1.45e-9	IFN-related cytopenia;
LIHC	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg26138937	chr11:71823887	C11orf51	1.32	10.9	0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	trans	rs3783890	1.000	rs12587394	chr14:93754437	A/G	cg02802420	chr16:69363236	PDF;COG8	0.32	6.24	0.32	1.29e-9	Body mass index;
LIHC	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.46	8.33	0.41	2.04e-15	Platelet distribution width;
LIHC	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	0.65	7.25	0.37	2.77e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg01864069	chr14:103024347	NA	0.45	6.98	0.35	1.51e-11	Platelet count;
LIHC	cis	rs12744310	0.887	rs12728217	chr1:41798269	C/T	cg03962019	chr1:41807865	NA	0.38	6.18	0.32	1.78e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg00117651	chr22:45809523	SMC1B;RIBC2	0.52	5.9	0.3	8.69e-9	Tonsillectomy;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg21003380	chr1:156261207	TMEM79	0.37	5.96	0.31	6.12e-9	Tonsillectomy;
LIHC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.72	-10.61	-0.5	6.57e-23	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.03	-23.61	-0.79	8.66e-74	IgG glycosylation;
LIHC	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.17e-8	Pulmonary function;
LIHC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg24879335	chr3:133465180	TF	0.31	6.97	0.35	1.69e-11	Iron status biomarkers (transferrin levels);
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg18306943	chr3:40428807	ENTPD3	0.43	7.58	0.38	3.19e-13	Renal cell carcinoma;
LIHC	trans	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg23598604	chr1:99732472	LPPR4	-0.31	-6.47	-0.33	3.38e-10	Multiple myeloma;
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.24	-5.81	-0.3	1.4e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-11.34	-0.52	1.68e-25	Hemoglobin concentration;
LIHC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.25	-16.9	-0.67	5.3e-47	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16614638	chr11:34073070	CAPRIN1	0.51	7.06	0.36	9.21e-12	Lung function (FEV1/FVC);
LIHC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg24130564	chr14:104152367	KLC1	-0.54	-9.07	-0.44	9.8e-18	Reticulocyte count;
LIHC	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-8.55	-0.42	4.18e-16	Waist circumference;Body mass index;
LIHC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.46	6.19	0.32	1.74e-9	Height;
LIHC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.78	15.24	0.64	2.26e-40	Mortality in heart failure;
LIHC	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14169450	chr9:139327907	INPP5E	0.35	5.72	0.3	2.3e-8	Monocyte percentage of white cells;
LIHC	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.32	-0.32	8.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.33	0.41	1.91e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.49	-6.38	-0.33	5.68e-10	Emphysema distribution in smoking;
LIHC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.17	-0.32	1.91e-9	Total body bone mineral density;
LIHC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg15026243	chr5:465330	EXOC3	0.5	6.24	0.32	1.27e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14109799	chr14:31495427	AP4S1;STRN3	-0.44	-6.1	-0.31	2.89e-9	Pancreatic cancer;
LIHC	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg04592579	chr7:75616294	TMEM120A	0.41	7.02	0.35	1.22e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9326778	0.520	rs17673070	chr5:108833361	C/G	cg17395555	chr5:108820864	NA	-0.35	-5.93	-0.31	7.22e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-11.09	-0.51	1.27e-24	Mean corpuscular volume;
LIHC	cis	rs6087771	0.504	rs6087786	chr20:30451844	C/T	cg13852791	chr20:30311386	BCL2L1	0.6	6.04	0.31	3.93e-9	Subcortical brain region volumes;Putamen volume;
LIHC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.77	15.19	0.63	3.32e-40	Mortality in heart failure;
LIHC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.47	-7.05	-0.36	9.66e-12	Asthma (sex interaction);
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg00815214	chr21:47717953	NA	-0.36	-6.12	-0.31	2.57e-9	Testicular germ cell tumor;
LIHC	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.32	-6.26	-0.32	1.15e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg10756647	chr7:56101905	PSPH	-1.03	-12.6	-0.56	3.61e-30	Diabetic kidney disease;
LIHC	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.9e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg01320579	chr17:75405842	SEPT9	0.54	7.72	0.39	1.26e-13	Airflow obstruction;
LIHC	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.33	-0.32	7.73e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.71	8.08	0.4	1.1e-14	Testicular germ cell tumor;
LIHC	cis	rs1144333	1.000	rs1586936	chr1:76366877	T/C	cg22875332	chr1:76189707	ACADM	0.4	6.27	0.32	1.06e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.44	-6.67	-0.34	1e-10	Cognitive function;
LIHC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg02344993	chr17:57696989	CLTC	0.72	12.37	0.56	2.76e-29	Obesity-related traits;
LIHC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.72	-9.63	-0.46	1.44e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg18081818	chr7:23246105	NA	-0.41	-5.86	-0.3	1.06e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.59	0.46	1.9e-19	Lymphocyte counts;
LIHC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.45	-6.41	-0.33	4.93e-10	Height;
LIHC	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.44	-7.89	-0.39	4.26e-14	Inhibitory control;
LIHC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.5	0.53	4.42e-26	Motion sickness;
LIHC	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs9888615	0.646	rs11624016	chr14:53384280	T/A	cg00686598	chr14:53173677	PSMC6	-0.46	-6.17	-0.32	1.95e-9	Systolic blood pressure;
LIHC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.74	10.83	0.51	1.08e-23	Breast cancer;
LIHC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.55	-9.17	-0.44	4.62e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.64	-7.82	-0.39	6.66e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.66	9.06	0.44	1.02e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg03934865	chr2:198174659	NA	-0.48	-6.93	-0.35	2.16e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.89	-10.69	-0.5	3.2e-23	Primary sclerosing cholangitis;
LIHC	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.23	-0.32	1.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.66	9.85	0.47	2.55e-20	Menarche (age at onset);
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.77	0.62	1.56e-38	Prudent dietary pattern;
LIHC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.98	17.36	0.68	7.68e-49	Monocyte percentage of white cells;
LIHC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	ch.11.42038R	chr11:967971	AP2A2	0.53	9.4	0.45	8.28e-19	Alzheimer's disease (late onset);
LIHC	cis	rs11663156	0.804	rs10515959	chr18:50893222	A/C	cg24270629	chr18:50823537	DCC	0.52	7.1	0.36	7.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs965469	0.895	rs6051840	chr20:3391483	C/T	cg25506879	chr20:3388711	C20orf194	0.56	6.57	0.33	1.84e-10	IFN-related cytopenia;
LIHC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.82	0.39	6.75e-14	Mean platelet volume;
LIHC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.39	6.19	0.32	1.74e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg14146966	chr2:61757674	XPO1	0.44	7.3	0.37	2.08e-12	Tuberculosis;
LIHC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.68	-7.16	-0.36	4.83e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.27	-0.32	1.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.31	-7.38	-0.37	1.25e-12	Crohn's disease;
LIHC	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/A	cg03649353	chr15:75614953	NA	0.43	6.49	0.33	3.06e-10	Sudden cardiac arrest;
LIHC	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	0.66	6.73	0.34	7.37e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.19	-0.52	5.55e-25	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02290350	chr8:58132656	NA	0.49	10.02	0.48	6.91e-21	Developmental language disorder (linguistic errors);
LIHC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.55	-8.51	-0.42	5.59e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.51	-7.7	-0.38	1.48e-13	Coronary artery disease;
LIHC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.37	6.23	0.32	1.4e-9	Monobrow;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.47	-7.51	-0.38	5.09e-13	Testicular germ cell tumor;
LIHC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.55e-9	Vitamin D levels;
LIHC	cis	rs4903214	0.848	rs34692843	chr14:74707535	T/C	cg11132536	chr14:74711944	VSX2	-0.26	-5.75	-0.3	1.96e-8	Inflammatory bowel disease;
LIHC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg14092571	chr14:90743983	NA	0.4	6.29	0.32	9.48e-10	Mortality in heart failure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14416316	chr13:111145583	COL4A2	-0.42	-6.71	-0.34	8.19e-11	Lung function (FEV1/FVC);
LIHC	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg10820045	chr2:198174542	NA	0.49	7.49	0.38	5.81e-13	Intracranial aneurysm;
LIHC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.91	0.35	2.41e-11	Renal cell carcinoma;
LIHC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.45	-7.89	-0.39	4.09e-14	Aortic root size;
LIHC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.25	-0.36	2.81e-12	Response to antipsychotic treatment;
LIHC	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.12	-0.31	2.55e-9	Ulcerative colitis;
LIHC	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg05697976	chr12:29376483	FAR2	0.28	5.72	0.3	2.32e-8	QT interval;
LIHC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs655641	1.000	rs622220	chr11:85725621	C/T	cg09030501	chr11:85779252	PICALM	-0.49	-6.01	-0.31	4.73e-9	Platelet count;
LIHC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.53	-7.48	-0.38	6.23e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7106204	0.609	rs12804374	chr11:24338016	A/G	ch.11.24196551F	chr11:24239977	NA	0.66	5.78	0.3	1.71e-8	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg17830980	chr10:43048298	ZNF37B	-0.43	-7.72	-0.39	1.28e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.83	-0.35	3.86e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.53	8.63	0.42	2.42e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10792665	0.512	rs7926170	chr11:82583957	A/G	cg24227371	chr11:82718527	RAB30	-0.28	-6.69	-0.34	9.32e-11	Obesity-related traits;
LIHC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.95	0.65	3.35e-43	Electrocardiographic conduction measures;
LIHC	cis	rs655641	0.954	rs634719	chr11:85771065	T/C	cg09030501	chr11:85779252	PICALM	-0.49	-5.96	-0.31	6.21e-9	Platelet count;
LIHC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg16822855	chr3:40428330	ENTPD3	0.31	5.77	0.3	1.8e-8	Renal cell carcinoma;
LIHC	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.97	7.08	0.36	8.01e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.36	5.76	0.3	1.89e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.56	-10.31	-0.49	7.02e-22	Systemic lupus erythematosus;
LIHC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	10.02	0.48	6.73e-21	Menarche (age at onset);
LIHC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.64	-9.76	-0.47	5.33e-20	Schizophrenia;
LIHC	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.34e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.3	-0.32	9.3e-10	Lung cancer;
LIHC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.64	-9.53	-0.46	2.93e-19	Cognitive ability;
LIHC	cis	rs4407350	0.837	rs4823328	chr22:44908999	C/T	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.06	-0.31	3.69e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.62	-9.47	-0.46	4.89e-19	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs9303280	0.901	rs7216558	chr17:38070071	C/T	cg11212589	chr17:38028394	ZPBP2	-0.33	-6.69	-0.34	9.17e-11	Self-reported allergy;
LIHC	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22857025	chr5:266934	NA	-1.5	-16.06	-0.66	1.21e-43	Breast cancer;
LIHC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.34	6.15	0.32	2.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25937148	chr3:43147320	C3orf39	-0.45	-6.67	-0.34	1.04e-10	Cognitive function;
LIHC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.48	-0.49	1.83e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.56	9.44	0.45	5.79e-19	Aortic root size;
LIHC	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.78	-11.37	-0.52	1.25e-25	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.77	-10.11	-0.48	3.44e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs4788815	0.513	rs7204967	chr16:71804287	A/G	cg06353428	chr16:71660113	MARVELD3	1.29	13.45	0.59	2.15e-33	Metabolite levels;
LIHC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.32	6.16	0.32	2.02e-9	Body mass index;
LIHC	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.98	-0.4	2.26e-14	Coronary artery disease;
LIHC	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-7.12	-0.36	6.38e-12	Vitamin D levels;
LIHC	cis	rs7523273	0.565	rs12733108	chr1:207887210	C/T	cg22525895	chr1:207977042	MIR29B2	0.52	7.77	0.39	9.54e-14	Schizophrenia;
LIHC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.52	-8.06	-0.4	1.27e-14	Lymphocyte counts;
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.5	-0.33	2.91e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.5	5.73	0.3	2.2e-8	Weight;
LIHC	trans	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg17830980	chr10:43048298	ZNF37B	0.4	7.07	0.36	8.8e-12	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.93	-19.71	-0.73	2.57e-58	Bone mineral density;
LIHC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21448741	chr8:58168803	NA	0.34	6.13	0.31	2.42e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg06533319	chr4:3265114	C4orf44	0.31	5.85	0.3	1.17e-8	Mean platelet volume;
LIHC	cis	rs10861342	0.892	rs9634185	chr12:105624825	C/T	cg23923672	chr12:105501055	KIAA1033	0.67	7.66	0.38	1.87e-13	IgG glycosylation;
LIHC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	0.77	6.32	0.32	8.14e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg16586182	chr3:47516702	SCAP	0.6	11.71	0.54	7.09e-27	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg13047869	chr3:10149882	C3orf24	0.5	6.08	0.31	3.23e-9	Alzheimer's disease;
LIHC	cis	rs12086130	0.892	rs3176468	chr1:51438881	T/C	cg07174182	chr1:51127561	FAF1	-0.75	-8.2	-0.41	4.86e-15	Hip circumference adjusted for BMI;Hip circumference;
LIHC	trans	rs4714291	0.963	rs1304602	chr6:40013471	T/G	cg02267698	chr19:7991119	CTXN1	0.39	6.39	0.33	5.47e-10	Strep throat;
LIHC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.94	13.93	0.6	2.97e-35	Primary sclerosing cholangitis;
LIHC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.97	-20.3	-0.74	1.15e-60	IgG glycosylation;
LIHC	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg00792783	chr2:198669748	PLCL1	-0.43	-6.28	-0.32	1.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.75	11.45	0.53	6.54e-26	Corneal astigmatism;
LIHC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.59	7.56	0.38	3.77e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg16586182	chr3:47516702	SCAP	-0.55	-9.99	-0.48	8.46e-21	Colorectal cancer;
LIHC	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.56	10.03	0.48	6.55e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.56	10.03	0.48	6.55e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.56	-9.26	-0.45	2.3e-18	Colorectal cancer;
LIHC	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg12193833	chr17:30244370	NA	-0.51	-5.94	-0.31	6.92e-9	Hip circumference adjusted for BMI;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26705765	chr19:10252866	DNMT1	0.47	6.11	0.31	2.67e-9	Hepatitis;
LIHC	cis	rs74544699	1.000	rs76595330	chr4:74801272	T/G	cg16072462	chr4:74847758	PF4	0.6	6.12	0.31	2.62e-9	Growth-regulated protein alpha levels;
LIHC	trans	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.62e-9	Coronary artery disease;
LIHC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.28	6.62	0.34	1.38e-10	Primary biliary cholangitis;
LIHC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.33	-7.06	-0.36	9.29e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-9.65	-0.46	1.19e-19	Response to antipsychotic treatment;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg14222432	chr12:29376421	FAR2	0.36	6.87	0.35	3.12e-11	QT interval;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13319278	chr19:633649	POLRMT	0.43	6.12	0.31	2.61e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	cis	rs67981189	0.593	rs9806042	chr14:71530993	G/C	cg15816911	chr14:71606274	NA	0.43	6.93	0.35	2.12e-11	Schizophrenia;
LIHC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.9	0.43	3.24e-17	Menarche (age at onset);
LIHC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.56	9.46	0.46	5.21e-19	Calcium levels;
LIHC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.69	7.07	0.36	8.52e-12	Alzheimer's disease;
LIHC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.96	0.57	1.59e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.52	7.53	0.38	4.55e-13	Response to diuretic therapy;
LIHC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.93	17.07	0.68	1.12e-47	Parkinson's disease;
LIHC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg03721293	chr16:90014378	DEF8	0.42	6.9	0.35	2.47e-11	Skin colour saturation;
LIHC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.85	9.43	0.45	6.49e-19	Vitiligo;
LIHC	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.61	-0.38	2.69e-13	Prevalent atrial fibrillation;
LIHC	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-18.11	-0.7	6.85e-52	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg02527881	chr3:46936655	PTH1R	-0.32	-6.14	-0.32	2.3e-9	Colorectal cancer;
LIHC	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-14.37	-0.61	5.58e-37	Schizophrenia;
LIHC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg18944383	chr4:111397179	ENPEP	0.28	6.52	0.33	2.56e-10	Coronary artery disease;
LIHC	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.32	-6.61	-0.34	1.48e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2380220	0.751	rs117986000	chr6:95923454	A/C	cg15832292	chr6:96025679	MANEA	-0.62	-6.79	-0.34	5.11e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	1.05	19.18	0.72	3.44e-56	Multiple system atrophy;
LIHC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26734620	chr12:56694298	CS	1.0	10.11	0.48	3.46e-21	Psoriasis vulgaris;
LIHC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg03013999	chr17:37608204	MED1	-0.36	-6.04	-0.31	4e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs6596140	0.620	rs10515463	chr5:133032214	C/T	cg19518232	chr4:120222109	C4orf3	-0.46	-6.45	-0.33	3.87e-10	Hypertension;
LIHC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.52	7.68	0.38	1.67e-13	Mean platelet volume;
LIHC	cis	rs16944613	0.541	rs4288973	chr15:91093676	G/A	cg26821196	chr15:91095069	CRTC3	0.46	7.98	0.4	2.23e-14	Colorectal cancer;
LIHC	trans	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.15	0.32	2.13e-9	Ulcerative colitis;
LIHC	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.66	11.68	0.53	9.79e-27	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg11764359	chr7:65958608	NA	0.56	5.99	0.31	5.28e-9	Diabetic kidney disease;
LIHC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18909525	chr9:132403873	ASB6	0.41	6.26	0.32	1.18e-9	Cognitive function;
LIHC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	1.04	13.79	0.6	1.09e-34	Heart rate;
LIHC	cis	rs2607426	0.681	rs8109099	chr19:41282509	T/A	cg20631044	chr19:41255890	C19orf54;SNRPA	0.54	6.26	0.32	1.15e-9	Blood protein levels;
LIHC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.47	-6.58	-0.34	1.75e-10	Breast cancer;
LIHC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-6.73	-0.34	7.26e-11	Educational attainment;
LIHC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg24209194	chr3:40518798	ZNF619	0.4	5.73	0.3	2.2e-8	Renal cell carcinoma;
LIHC	cis	rs16858210	0.607	rs57874587	chr3:183584749	C/T	cg25686905	chr3:183603175	PARL	-0.48	-8.56	-0.42	3.82e-16	Menopause (age at onset);
LIHC	cis	rs1434579	0.652	rs7249536	chr19:44938980	G/A	cg15540054	chr19:45004280	ZNF180	0.65	9.83	0.47	3.04e-20	Tuberculosis;
LIHC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.41	-8.44	-0.42	9e-16	Renal cell carcinoma;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26390924	chr15:50613702	GABPB1	0.38	6.08	0.31	3.18e-9	Hepatitis;
LIHC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.7	-10.8	-0.5	1.39e-23	Urate levels in obese individuals;
LIHC	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.43	6.11	0.31	2.71e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg23254163	chr1:152506842	NA	0.22	5.8	0.3	1.48e-8	Hair morphology;
LIHC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.34	8.82	0.43	6.1e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs655641	1.000	rs592314	chr11:85673124	A/G	cg09030501	chr11:85779252	PICALM	-0.5	-6.05	-0.31	3.75e-9	Platelet count;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg17385448	chr1:15911702	AGMAT	0.35	6.11	0.31	2.64e-9	Systolic blood pressure;
LIHC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.52	6.73	0.34	6.97e-11	Initial pursuit acceleration;
LIHC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.23	0.61	1.96e-36	Chronic sinus infection;
LIHC	cis	rs4650994	0.571	rs6700047	chr1:178508742	G/A	cg05350800	chr1:178550844	NA	-0.3	-6.47	-0.33	3.41e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.21	-0.45	3.25e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs3018712	0.532	rs4930587	chr11:68415135	T/C	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.12e-8	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.06e-19	Renal cell carcinoma;
LIHC	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg06766960	chr11:133703094	NA	-0.41	-6.14	-0.32	2.31e-9	Childhood ear infection;
LIHC	cis	rs9871864	0.734	rs4405944	chr3:20367764	C/A	cg00235661	chr3:20228976	SGOL1	0.3	5.76	0.3	1.85e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.57	7.5	0.38	5.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.16	0.48	2.36e-21	Colorectal cancer;
LIHC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.37	-6.01	-0.31	4.67e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.52	7.97	0.4	2.43e-14	Cognitive function;
LIHC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	8.23	0.41	3.86e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	0.96	18.16	0.7	4.49e-52	Ewing sarcoma;
LIHC	trans	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg26939375	chr7:64535504	NA	0.4	6.34	0.32	7.06e-10	Aortic root size;
LIHC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.79	-13.56	-0.59	7.88e-34	Lung cancer in ever smokers;
LIHC	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.62	-9.77	-0.47	4.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.74	6.91	0.35	2.41e-11	Plasma clusterin levels;
LIHC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg21395723	chr22:39101663	GTPBP1	0.35	5.98	0.31	5.67e-9	Menopause (age at onset);
LIHC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.86	-0.35	3.24e-11	Body mass index;
LIHC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.76	-0.3	1.87e-8	Inflammatory bowel disease;
LIHC	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.52	7.69	0.38	1.58e-13	Extraversion;
LIHC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-21.39	-0.76	4.76e-65	Myeloid white cell count;
LIHC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.56	-8.38	-0.41	1.39e-15	Metabolic syndrome;
LIHC	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg02269571	chr22:50332266	NA	0.69	7.94	0.39	2.89e-14	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.45	6.3	0.32	9.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12493885	0.818	rs61791541	chr3:153758155	G/T	cg10247383	chr3:153839028	SGEF	0.64	5.95	0.31	6.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.48	-5.77	-0.3	1.76e-8	Blood metabolite levels;
LIHC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.59	11.99	0.54	7.09e-28	Glycated hemoglobin levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02127607	chr17:61920694	SMARCD2	-0.4	-6.12	-0.31	2.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07305463	chr2:136567211	LCT	-0.39	-6.04	-0.31	3.94e-9	Corneal structure;
LIHC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.15e-10	Diabetic kidney disease;
LIHC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.81	-0.35	4.48e-11	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.54	6.11	0.31	2.79e-9	Primary sclerosing cholangitis;
LIHC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.31	0.52	2.11e-25	Lung cancer in ever smokers;
LIHC	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg07817648	chr10:79422355	NA	0.29	6.19	0.32	1.73e-9	Mortality in heart failure;
LIHC	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.81	-8.63	-0.42	2.29e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-6.94	-0.35	1.98e-11	Schizophrenia;
LIHC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg18478394	chr8:109455254	TTC35	0.44	7.61	0.38	2.77e-13	Dupuytren's disease;
LIHC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.85	-0.39	5.44e-14	Total body bone mineral density;
LIHC	cis	rs16870629	0.567	rs35661060	chr5:1060379	G/A	cg18655438	chr5:1077845	SLC12A7	0.36	5.83	0.3	1.26e-8	QT interval;
LIHC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.27e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-7.96	-0.4	2.58e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.81	10.49	0.49	1.62e-22	Bladder cancer;
LIHC	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.42	6.27	0.32	1.08e-9	Diastolic blood pressure;
LIHC	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	0.78	8.24	0.41	3.82e-15	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.6	-9.7	-0.46	8.48e-20	Pediatric autoimmune diseases;
LIHC	cis	rs6750047	0.771	rs1056837	chr2:38298150	A/G	cg07380506	chr2:38303506	CYP1B1	0.59	7.63	0.38	2.43e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg07424592	chr7:64974309	NA	-0.8	-9.08	-0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.46	-5.92	-0.3	7.85e-9	Dental caries;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.66	9.86	0.47	2.45e-20	Menarche (age at onset);
LIHC	cis	rs16854884	0.632	rs59287916	chr3:143638337	G/A	cg06585982	chr3:143692056	C3orf58	0.61	8.48	0.42	7.1e-16	Economic and political preferences (feminism/equality);
LIHC	cis	rs4668356	0.773	rs11883894	chr2:172034974	G/C	cg13882835	chr2:172017928	TLK1	0.43	5.88	0.3	9.85e-9	Cognitive performance;
LIHC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.75	-8.91	-0.43	3.07e-17	Morning vs. evening chronotype;
LIHC	cis	rs1144333	0.655	rs946164	chr1:76383286	A/T	cg10523679	chr1:76189770	ACADM	0.46	6.14	0.31	2.34e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg18306943	chr3:40428807	ENTPD3	0.34	6.06	0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg05941027	chr17:61774174	LIMD2	0.31	6.0	0.31	5.14e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.42	-0.37	9.58e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-9.34	-0.45	1.23e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs79040073	0.911	rs17393193	chr15:49332079	T/C	cg04482760	chr15:49339272	SECISBP2L	-0.47	-5.8	-0.3	1.49e-8	Lung cancer in ever smokers;
LIHC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg03060546	chr3:49711283	APEH	0.38	5.72	0.3	2.38e-8	Menarche (age at onset);
LIHC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.58	8.22	0.41	4.13e-15	Lymphocyte counts;
LIHC	cis	rs6782228	0.675	rs9813845	chr3:128399623	G/C	cg16766828	chr3:128327626	NA	-0.43	-6.61	-0.34	1.44e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.25	-13.3	-0.58	8.06e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.76	-7.77	-0.39	9.23e-14	Vitiligo;
LIHC	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.58	9.97	0.47	1.01e-20	Dupuytren's disease;
LIHC	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg14930904	chr10:32216787	ARHGAP12	0.38	6.76	0.34	5.84e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.35	5.81	0.3	1.44e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg05484376	chr2:27715224	FNDC4	0.37	6.29	0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg22834771	chr12:69754056	YEATS4	-0.37	-5.96	-0.31	6.19e-9	Blood protein levels;
LIHC	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.75	10.59	0.5	7.73e-23	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg02782426	chr3:40428986	ENTPD3	0.33	6.07	0.31	3.34e-9	Renal cell carcinoma;
LIHC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11645453	chr3:52864694	ITIH4	0.22	6.04	0.31	4.06e-9	Bipolar disorder;
LIHC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.31	0.32	8.71e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-1.02	-10.11	-0.48	3.29e-21	Breast cancer;
LIHC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.47	-8.19	-0.4	5.34e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.58e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs10508774	1.000	rs117817425	chr10:32879194	C/A	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.36	-5.78	-0.3	1.7e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.32e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg11070056	chr1:107600091	PRMT6	-0.72	-12.38	-0.56	2.53e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12986413	1.000	rs4807208	chr19:2170205	A/C	cg09261902	chr19:2140048	AP3D1	0.37	6.27	0.32	1.1e-9	Height;
LIHC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.66	12.03	0.55	4.94e-28	High light scatter reticulocyte count;
LIHC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg15017067	chr4:17643749	FAM184B	0.34	5.83	0.3	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4919087	0.705	rs701812	chr10:98975413	A/G	cg25902810	chr10:99078978	FRAT1	-0.54	-6.25	-0.32	1.22e-9	Monocyte count;
LIHC	cis	rs1198430	0.925	rs7534474	chr1:23773851	A/G	cg19827787	chr1:23763612	ASAP3	0.36	6.38	0.33	5.7e-10	Total cholesterol levels;
LIHC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg16970926	chr12:29381810	FAR2	0.29	6.1	0.31	2.81e-9	QT interval;
LIHC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.45	-7.73	-0.39	1.19e-13	Schizophrenia;
LIHC	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg13628971	chr7:2884303	GNA12	0.43	7.5	0.38	5.59e-13	Height;
LIHC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.64	6.21	0.32	1.56e-9	Plasma clusterin levels;
LIHC	cis	rs8084351	0.577	rs4534924	chr18:50642112	G/A	cg24270629	chr18:50823537	DCC	0.43	6.36	0.33	6.37e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs4908760	0.795	rs6693009	chr1:8743710	A/G	cg20416874	chr1:8611966	RERE	-0.61	-11.53	-0.53	3.29e-26	Vitiligo;
LIHC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg22676075	chr6:135203613	NA	0.38	6.34	0.32	7.1e-10	Red blood cell count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10494282	chr1:44440945	ATP6V0B	0.47	6.82	0.35	4.02e-11	Lung function (FEV1/FVC);
LIHC	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.56	8.22	0.41	4.29e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-6.87	-0.35	3.07e-11	Metabolite levels;
LIHC	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.81	-0.3	1.44e-8	Systolic blood pressure;
LIHC	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.43	8.06	0.4	1.31e-14	Height;
LIHC	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.45	0.33	3.84e-10	Resting heart rate;
LIHC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.87	-0.3	1.02e-8	Personality dimensions;
LIHC	cis	rs17001868	1.000	rs73167022	chr22:40797256	A/T	cg07138101	chr22:40742427	ADSL	0.58	6.31	0.32	8.78e-10	Mammographic density (dense area);
LIHC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs7953249	0.791	rs1920792	chr12:121404584	T/C	cg02403541	chr12:121454288	C12orf43	-0.34	-5.93	-0.31	7.27e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.34	0.37	1.54e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.66	10.91	0.51	5.38e-24	Pulse pressure;
LIHC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-1.03	-12.74	-0.57	1.11e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.39	6.23	0.32	1.4e-9	Height;
LIHC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.58	-11.44	-0.53	6.85e-26	Coronary artery disease;
LIHC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.38	-6.88	-0.35	2.9100000000000002e-11	Schizophrenia;
LIHC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.6	-0.34	1.56e-10	Putamen volume;
LIHC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.83	10.02	0.48	7.1e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-0.99	-10.44	-0.49	2.57e-22	Vitiligo;
LIHC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	0.6	6.05	0.31	3.75e-9	Obesity-related traits;
LIHC	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	0.77	8.43	0.41	1.01e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.36	-6.4	-0.33	5.1e-10	Immature fraction of reticulocytes;
LIHC	cis	rs3770081	1.000	rs17026854	chr2:86280496	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.45	6.24	0.32	1.28e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.67	-0.38	1.81e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.09	-0.4	1.03e-14	Extrinsic epigenetic age acceleration;
LIHC	cis	rs970821	0.966	rs4549748	chr8:124743332	G/A	cg00283535	chr8:124749564	ANXA13	0.36	6.09	0.31	3e-9	Breast cancer;
LIHC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.4	-0.41	1.21e-15	Total cholesterol levels;
LIHC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2e-12	Exhaled nitric oxide output;
LIHC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.56	-6.61	-0.34	1.45e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.54	-6.68	-0.34	9.5e-11	Menarche (age at onset);
LIHC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.94	17.54	0.69	1.39e-49	Menopause (age at onset);
LIHC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.54	9.33	0.45	1.38e-18	Dental caries;
LIHC	cis	rs2257205	0.667	rs9889631	chr17:56630359	G/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.09	0.36	7.92e-12	Self-reported allergy;
LIHC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.9	16.59	0.67	9.5e-46	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg09417038	chr21:47716443	C21orf57	0.52	7.94	0.39	2.93e-14	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg02023728	chr11:77925099	USP35	-0.34	-5.97	-0.31	6.07e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.85	14.77	0.62	1.57e-38	Headache;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07479988	chr2:39103277	MORN2;DHX57	-0.41	-6.15	-0.32	2.15e-9	Triglycerides;
LIHC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.76	13.96	0.6	2.22e-35	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13783546	chr17:76671452	CYTH1	0.42	6.3	0.32	9.41e-10	Longevity;
LIHC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.4	6.43	0.33	4.25e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.88	13.43	0.59	2.55e-33	Myeloid white cell count;
LIHC	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	0.63	6.17	0.32	1.91e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.49	7.27	0.37	2.5e-12	Total body bone mineral density;
LIHC	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.43	-7.08	-0.36	8.34e-12	Corneal astigmatism;
LIHC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	1.01	16.7	0.67	3.3e-46	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.43	6.13	0.31	2.38e-9	Colorectal cancer;
LIHC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg03959625	chr15:84868606	LOC388152	-0.43	-6.11	-0.31	2.69e-9	Schizophrenia;
LIHC	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.46	-6.98	-0.35	1.51e-11	Red blood cell count;
LIHC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg00750074	chr16:89608354	SPG7	-0.5	-7.9	-0.39	3.74e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	1.08	7.54	0.38	4.15e-13	Arsenic metabolism;
LIHC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.61e-12	Bipolar disorder;
LIHC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	8.54	0.42	4.53e-16	Diastolic blood pressure;
LIHC	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.47	0.62	2.26e-37	Bipolar disorder;
LIHC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg05564831	chr3:52568323	NT5DC2	0.38	6.18	0.32	1.83e-9	Bipolar disorder;
LIHC	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg09904177	chr6:26538194	HMGN4	-0.37	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg06046430	chr4:77819534	ANKRD56	0.5	6.53	0.33	2.34e-10	Emphysema distribution in smoking;
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00960700	chr17:80709150	TBCD	-0.37	-6.13	-0.31	2.42e-9	Glycated hemoglobin levels;
LIHC	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg03258749	chr1:151040405	MLLT11	-0.46	-7.19	-0.36	4.15e-12	Childhood ear infection;
LIHC	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg00792783	chr2:198669748	PLCL1	0.45	6.56	0.33	2.04e-10	Dermatomyositis;
LIHC	cis	rs2191566	0.881	rs1996408	chr19:44532732	G/A	cg20607764	chr19:44506953	ZNF230	-0.44	-7.18	-0.36	4.51e-12	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.57	6.37	0.33	6.02e-10	Axial length;
LIHC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.71	11.25	0.52	3.46e-25	Corneal astigmatism;
LIHC	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg07817648	chr10:79422355	NA	-0.28	-5.89	-0.3	9.15e-9	Bone mineral density;
LIHC	cis	rs611744	0.967	rs598477	chr8:109187874	G/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs12644436	0.526	rs9998083	chr4:88771391	A/C	cg06891869	chr4:88767617	MEPE	-0.49	-7.75	-0.39	1.05e-13	HIV-1 viral setpoint;
LIHC	cis	rs6445975	0.575	rs7614726	chr3:58243289	C/T	cg23715586	chr3:58305044	RPP14	-0.34	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LIHC	cis	rs1144333	0.655	rs12401729	chr1:76336586	T/G	cg22875332	chr1:76189707	ACADM	0.44	6.44	0.33	4.14e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	6.29e-33	Diabetic kidney disease;
LIHC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03264133	chr6:25882463	NA	-0.52	-6.72	-0.34	7.69e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.05	-0.31	3.7e-9	Aortic root size;
LIHC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.46	-0.69	2.95e-49	Gut microbiome composition (summer);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26820233	chr16:838206	RPUSD1;CHTF18	-0.45	-6.24	-0.32	1.32e-9	Migraine with aura;
LIHC	cis	rs700651	0.789	rs10190226	chr2:198901564	A/G	cg00792783	chr2:198669748	PLCL1	-0.43	-6.21	-0.32	1.55e-9	Intracranial aneurysm;
LIHC	cis	rs11760633	0.672	rs11763500	chr7:1826385	T/A	cg23422044	chr7:1970798	MAD1L1	-0.37	-5.71	-0.3	2.41e-8	Coronary artery disease;
LIHC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-8.54	-0.42	4.54e-16	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.97	22.6	0.77	7.56e-70	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	0.53	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.37	12.03	0.55	4.86e-28	Uric acid levels;
LIHC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-21.06	-0.75	1.02e-63	Height;
LIHC	cis	rs3736594	0.527	rs62141279	chr2:27771415	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.7	0.34	8.52e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	7.93	0.39	3.18e-14	Parkinson's disease;
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.51	-8.17	-0.4	6.21e-15	Longevity;Endometriosis;
LIHC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.79	-14.57	-0.62	9.28e-38	Crohn's disease;
LIHC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.64	-12.27	-0.55	6.52e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	0.93	22.33	0.77	9.16e-69	Multiple myeloma;
LIHC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.29	-0.68	1.4e-48	Body mass index;
LIHC	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.66	7.38	0.37	1.19e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.59	8.21	0.41	4.58e-15	Aortic root size;
LIHC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg09417038	chr21:47716443	C21orf57	-0.5	-7.29	-0.37	2.12e-12	Testicular germ cell tumor;
LIHC	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg02023728	chr11:77925099	USP35	0.33	5.89	0.3	9.28e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.87	14.69	0.62	3.31e-38	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-6.12	-0.31	2.58e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.12	-0.31	2.6e-9	Tonsillectomy;
LIHC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.68	12.49	0.56	9.47e-30	Dental caries;
LIHC	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.43	7.22	0.36	3.46e-12	Crohn's disease;
LIHC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	6.83	0.35	3.81e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg20607798	chr8:58055168	NA	0.46	6.62	0.34	1.42e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.22	0.32	1.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2997447	0.739	rs60141220	chr1:26395741	G/A	cg19633962	chr1:26362018	EXTL1	-0.5	-5.82	-0.3	1.38e-8	QRS complex (12-leadsum);
LIHC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.44	-0.33	4.17e-10	Crohn's disease;
LIHC	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.41	6.59	0.34	1.62e-10	Migraine;
LIHC	cis	rs8067354	0.527	rs1292039	chr17:57974913	A/T	cg13753209	chr17:57696993	CLTC	0.71	10.6	0.5	6.68e-23	Hemoglobin concentration;
LIHC	cis	rs2882877	0.661	rs35623329	chr2:190443445	T/C	cg10752008	chr2:190445175	SLC40A1	0.54	6.25	0.32	1.19e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.81	8.95	0.44	2.25e-17	Initial pursuit acceleration;
LIHC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.32	-5.85	-0.3	1.14e-8	Diastolic blood pressure;
LIHC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	8.84	0.43	5.08e-17	IgG glycosylation;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.8	15.72	0.65	2.69e-42	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg04166393	chr7:2884313	GNA12	0.37	6.08	0.31	3.23e-9	Height;
LIHC	cis	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-7.18	-0.36	4.42e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.2	0.32	1.67e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.51	7.65	0.38	2.07e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02034447	chr16:89574710	SPG7	0.49	7.52	0.38	4.88e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21448741	chr8:58168803	NA	0.34	6.37	0.33	5.94e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02985541	chr2:219472218	PLCD4	-0.42	-6.84	-0.35	3.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.05	0.31	3.77e-9	Rheumatoid arthritis;
LIHC	cis	rs4853036	0.951	rs61422548	chr2:70110249	G/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.31	-0.32	8.61e-10	Colorectal or endometrial cancer;
LIHC	cis	rs67981189	0.593	rs221919	chr14:71588229	A/G	cg15816911	chr14:71606274	NA	-0.44	-7.03	-0.36	1.16e-11	Schizophrenia;
LIHC	cis	rs10792665	0.631	rs10736758	chr11:82635214	C/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.07	-0.31	3.33e-9	Obesity-related traits;
LIHC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.05e-17	Bipolar disorder;
LIHC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg05555928	chr11:63887634	MACROD1	0.55	7.47	0.37	6.77e-13	Mean platelet volume;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.7	0.38	1.51e-13	Height;
LIHC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15228606	chr17:1812096	NA	0.41	6.03	0.31	4.17e-9	Pancreatic cancer;
LIHC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	7.08	0.36	8.02e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17760058	chr19:2321626	LSM7	0.41	6.18	0.32	1.85e-9	Immature fraction of reticulocytes;
LIHC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg18306943	chr3:40428807	ENTPD3	0.33	5.84	0.3	1.21e-8	Renal cell carcinoma;
LIHC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg20487152	chr13:99095054	FARP1	-0.4	-6.73	-0.34	7.33e-11	Longevity;
LIHC	cis	rs7726558	0.543	rs76930980	chr5:118839793	G/A	cg05185946	chr5:118791606	HSD17B4	-0.3	-6.0	-0.31	5.05e-9	QT interval (sulfonylurea treatment interaction);
LIHC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21467203	chr3:49911342	NA	-0.4	-6.93	-0.35	2.16e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg25039879	chr17:56429692	SUPT4H1	-0.52	-6.47	-0.33	3.37e-10	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-6.52	-0.33	2.57e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg27124370	chr19:33622961	WDR88	0.47	7.04	0.36	1.09e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-8.72	-0.43	1.2e-16	Body mass index;
LIHC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.52	8.07	0.4	1.17e-14	Tonsillectomy;
LIHC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	5.98	0.31	5.59e-9	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg08890338	chr13:113700818	MCF2L	-0.35	-5.81	-0.3	1.41e-8	Systolic blood pressure;
LIHC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg03934865	chr2:198174659	NA	0.55	8.81	0.43	6.28e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.99	0.6	1.73e-35	Coffee consumption (cups per day);
LIHC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.6	6.7	0.34	8.82e-11	Axial length;
LIHC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.72	12.46	0.56	1.26e-29	Aortic root size;
LIHC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg00101154	chr16:420108	MRPL28	-0.57	-7.69	-0.38	1.62e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.75	11.85	0.54	2.2e-27	Corneal astigmatism;
LIHC	cis	rs3753275	0.690	rs6577500	chr1:8614571	G/C	cg20416874	chr1:8611966	RERE	-0.49	-6.21	-0.32	1.54e-9	Educational attainment;
LIHC	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.45	6.48	0.33	3.11e-10	Asthma;
LIHC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.1	0.4	9.91e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.99	-0.35	1.48e-11	IgG glycosylation;
LIHC	cis	rs8016982	0.559	rs10133562	chr14:81732758	C/T	cg01989461	chr14:81687754	GTF2A1	-0.47	-7.87	-0.39	4.69e-14	Schizophrenia;
LIHC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.69	-0.34	8.87e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02290350	chr8:58132656	NA	0.4	8.26	0.41	3.23e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02985541	chr2:219472218	PLCD4	0.43	7.99	0.4	2.14e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.86	0.8	1.15e-78	Prudent dietary pattern;
LIHC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.71	0.43	1.33e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg09990169	chr2:241835740	C2orf54	0.65	9.17	0.44	4.48e-18	Urinary metabolites;
LIHC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.55e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.39	6.67	0.34	1.01e-10	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.45	0.42	8.22e-16	Platelet count;
LIHC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.77	0.3	1.8e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg11783602	chr8:55087084	NA	0.31	6.06	0.31	3.68e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg01843034	chr6:37503916	NA	-0.5	-7.99	-0.4	2.02e-14	Cognitive performance;
LIHC	cis	rs12079745	0.623	rs115415855	chr1:169322993	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-6.96	-0.35	1.77e-11	QT interval;
LIHC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.04	0.36	1.09e-11	Height;
LIHC	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.28	0.41	2.83e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg27205649	chr11:78285834	NARS2	0.39	5.93	0.31	7.41e-9	Alzheimer's disease (survival time);
LIHC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.96	11.96	0.54	8.6e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.48	7.92	0.39	3.25e-14	Diastolic blood pressure;
LIHC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	11.28	0.52	2.61e-25	Coronary artery disease;
LIHC	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg10820045	chr2:198174542	NA	0.52	8.21	0.41	4.61e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg03037974	chr15:76606532	NA	-0.59	-10.21	-0.48	1.54e-21	Blood metabolite levels;
LIHC	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	0.92	21.87	0.76	5.98e-67	Multiple myeloma;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.07e-31	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12463550	chr7:65579703	CRCP	0.69	7.19	0.36	4.02e-12	Diabetic kidney disease;
LIHC	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.54	7.64	0.38	2.2e-13	Post bronchodilator FEV1;
LIHC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.51	6.98	0.35	1.56e-11	Aortic root size;
LIHC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.58	-9.86	-0.47	2.38e-20	Colorectal cancer;
LIHC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.81	12.74	0.57	1.12e-30	Height;
LIHC	cis	rs785830	0.717	rs542669	chr9:224367	G/C	cg14500300	chr9:211689	NA	0.3	6.9	0.35	2.61e-11	Platelet distribution width;
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg19635926	chr16:89946313	TCF25	0.52	6.87	0.35	3.06e-11	Skin colour saturation;
LIHC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.8	13.41	0.59	3.01e-33	Psoriasis;
LIHC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.43	6.12	0.31	2.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	1.14	8.85	0.43	4.77e-17	Arsenic metabolism;
LIHC	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.43	-7.1	-0.36	7.37e-12	Pelvic organ prolapse;
LIHC	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg10381502	chr11:71823885	C11orf51	-1.06	-9.3	-0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs2933343	1.000	rs1680790	chr3:128625853	G/T	cg25356066	chr3:128598488	ACAD9	0.53	7.0	0.35	1.39e-11	IgG glycosylation;
LIHC	cis	rs2380220	0.808	rs2716074	chr6:95907662	T/C	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-7.01	-0.35	1.24e-11	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs6578985	0.769	rs4929957	chr11:2128309	C/T	cg20230732	chr3:128721448	CCDC48	0.37	6.18	0.32	1.85e-9	Femoral neck bone geometry and menarche (age at onset);
LIHC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04400940	chr3:150329548	SELT	0.42	6.05	0.31	3.75e-9	Pancreatic cancer;
LIHC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.77	12.97	0.57	1.42e-31	Menarche (age at onset);
LIHC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.67	7.93	0.39	3.14e-14	Chronic sinus infection;
LIHC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.43	-7.37	-0.37	1.31e-12	Aortic root size;
LIHC	cis	rs12594515	0.548	rs55932467	chr15:45997124	C/T	cg01629716	chr15:45996671	NA	0.53	5.84	0.3	1.24e-8	Waist circumference;Weight;
LIHC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.75	10.66	0.5	4.25e-23	Coronary artery disease;
LIHC	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg20240347	chr1:204465584	NA	-0.36	-7.56	-0.38	3.85e-13	Schizophrenia;
LIHC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.59	-11.55	-0.53	2.92e-26	Coronary artery disease;
LIHC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09015484	chr9:96929106	NA	0.4	6.65	0.34	1.15e-10	Cognitive function;
LIHC	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.23	-6.12	-0.31	2.6e-9	Obesity-related traits;
LIHC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.58	0.56	4.43e-30	Menopause (age at onset);
LIHC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.15	0.55	1.8e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg14671364	chr1:107599128	PRMT6	-0.52	-7.59	-0.38	3.1e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7116495	1.000	rs2845857	chr11:71715215	C/G	cg26138937	chr11:71823887	C11orf51	-0.77	-7.74	-0.39	1.14e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	12.86	0.57	3.97e-31	Schizophrenia;
LIHC	cis	rs138249	0.902	rs138240	chr22:50564181	A/C	cg24864161	chr22:50528282	MOV10L1	-0.36	-5.93	-0.31	7.37e-9	Gestational age at birth in labor-initiated deliveries (child effect);
LIHC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.75	12.68	0.57	1.77e-30	Aortic root size;
LIHC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.68	-12.68	-0.57	1.9e-30	Refractive error;
LIHC	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.96	-0.31	6.13e-9	Systemic lupus erythematosus;
LIHC	cis	rs716804	0.740	rs10743131	chr11:10266856	C/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.12e-8	Neuroticism;
LIHC	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23485639	chr6:28045615	ZNF165	-0.45	-5.97	-0.31	6.01e-9	Depression;
LIHC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.61	0.34	1.46e-10	Bipolar disorder;
LIHC	cis	rs8027181	0.839	rs7176223	chr15:73077742	T/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.58	0.38	3.33e-13	Triglyceride levels;
LIHC	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.3	5.95	0.31	6.49e-9	Sitting height ratio;
LIHC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.32	0.37	1.82e-12	Diabetic kidney disease;
LIHC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-9.2	-0.45	3.57e-18	Chronic sinus infection;
LIHC	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.44	6.55	0.33	2.06e-10	Menopause (age at onset);
LIHC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs6545883	0.894	rs7602859	chr2:61458206	A/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.12	-0.36	6.22e-12	Tuberculosis;
LIHC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20135002	chr11:47629003	NA	-0.52	-8.8	-0.43	6.76e-17	Subjective well-being;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15910486	chr5:142783621	NR3C1	-0.55	-6.18	-0.32	1.8e-9	Systolic blood pressure;
LIHC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	1.07	12.08	0.55	3.31e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.47	6.0	0.31	5.15e-9	Alzheimer's disease;
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.72	-0.43	1.24e-16	Renal cell carcinoma;
LIHC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg11839771	chr15:80205821	ST20	-0.32	-6.72	-0.34	7.5e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.77	11.61	0.53	1.65e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.83	-0.39	6.39e-14	Type 2 diabetes;
LIHC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.13	0.4	8.09e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg18944383	chr4:111397179	ENPEP	0.27	6.96	0.35	1.78e-11	Height;
LIHC	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.79	6.54	0.33	2.25e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.41	6.21	0.32	1.51e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs9326778	0.520	rs62375284	chr5:108842127	A/T	cg17395555	chr5:108820864	NA	-0.37	-6.35	-0.32	6.96e-10	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.85	14.96	0.63	2.83e-39	Body mass index (adult);
LIHC	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg18964960	chr10:1102726	WDR37	0.67	6.37	0.33	5.99e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg17980119	chr2:219472607	PLCD4	0.35	6.05	0.31	3.84e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs15676	0.947	rs3115874	chr9:131579338	G/C	cg00228799	chr9:131580591	ENDOG	0.46	7.01	0.35	1.26e-11	Blood metabolite levels;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14828511	chr1:107599125	PRMT6	-0.43	-6.06	-0.31	3.68e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.1	-0.4	9.63e-15	Response to antipsychotic treatment;
LIHC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	1.06	13.61	0.59	5.41e-34	Dilated cardiomyopathy;
LIHC	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg08539965	chr1:21396338	EIF4G3	0.34	5.93	0.31	7.29e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-7.61	-0.38	2.65e-13	Electroencephalogram traits;
LIHC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma (childhood onset);
LIHC	cis	rs2257205	0.667	rs9899893	chr17:56754597	T/C	cg12560992	chr17:57184187	TRIM37	0.71	7.79	0.39	8.05e-14	Pancreatic cancer;
LIHC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.0	0.4	1.99e-14	Tonsillectomy;
LIHC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg18270830	chr10:32634957	EPC1	0.52	6.29	0.32	9.59e-10	Sexual dysfunction (female);
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	9.27e-15	Prudent dietary pattern;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.6	8.81	0.43	6.54e-17	Prudent dietary pattern;
LIHC	cis	rs4908768	0.871	rs7553298	chr1:8770883	A/G	cg20416874	chr1:8611966	RERE	0.54	8.59	0.42	3.11e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27138727	chr3:107150777	NA	0.42	6.3	0.32	9.35e-10	Cognitive function;
LIHC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.15	-13.36	-0.59	4.64e-33	White matter hyperintensity burden;
LIHC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.43	-7.23	-0.36	3.18e-12	Prostate cancer;
LIHC	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	1.08	8.7	0.43	1.4e-16	Cannabis dependence symptom count;
LIHC	cis	rs9322817	0.691	rs2499658	chr6:105291412	A/G	cg02098413	chr6:105308735	HACE1	0.45	8.39	0.41	1.31e-15	Thyroid stimulating hormone;
LIHC	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.62	-9.66	-0.46	1.12e-19	Pediatric autoimmune diseases;
LIHC	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.39	6.31	0.32	8.87e-10	Menopause (age at onset);
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.6	8.96	0.44	2.14e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.85	0.39	5.53e-14	Prudent dietary pattern;
LIHC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.63	9.84	0.47	2.89e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.5	-9.06	-0.44	1.02e-17	Atrioventricular conduction;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg21976603	chr20:61516759	DIDO1	0.46	6.64	0.34	1.25e-10	Longevity;
LIHC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg02344993	chr17:57696989	CLTC	0.72	12.37	0.56	2.76e-29	Hemoglobin concentration;
LIHC	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.62	-9.74	-0.47	5.83e-20	Schizophrenia;
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02034447	chr16:89574710	SPG7	-0.42	-6.38	-0.33	5.63e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.46	-6.95	-0.35	1.88e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg00977110	chr5:151150581	G3BP1	0.49	6.27	0.32	1.11e-9	Preschool internalizing problems;
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.45	-7.41	-0.37	9.98e-13	Testicular germ cell tumor;
LIHC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.01	0.54	5.93e-28	Alzheimer's disease;
LIHC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.36	0.41	1.6e-15	Platelet count;
LIHC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.43	6.59	0.34	1.65e-10	Red cell distribution width;
LIHC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg16102536	chr7:156981717	UBE3C	0.35	5.85	0.3	1.17e-8	Body mass index;
LIHC	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.47	7.33	0.37	1.63e-12	Diastolic blood pressure;
LIHC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.31	-0.37	1.84e-12	Response to antipsychotic treatment;
LIHC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	1.07	14.38	0.61	5.24e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.61	8.81	0.43	6.51e-17	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs10733682	0.659	rs3906146	chr9:129463613	C/T	cg00232160	chr9:129468157	NA	0.35	6.1	0.31	2.92e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.73	0.34	7.1e-11	Renal cell carcinoma;
LIHC	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.72	-9.05	-0.44	1.09e-17	Type 2 diabetes;
LIHC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-7.0	-0.35	1.34e-11	Hepatocellular carcinoma;
LIHC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg07061783	chr6:25882402	NA	-0.43	-6.07	-0.31	3.41e-9	Blood metabolite levels;
LIHC	cis	rs7546668	1.000	rs4661640	chr1:15854882	T/G	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.05e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.75	0.43	9.98e-17	Schizophrenia;
LIHC	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.27	7.27	0.37	2.43e-12	Type 2 diabetes;
LIHC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.04	-0.48	5.98e-21	Response to antipsychotic treatment;
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.89	0.78	5.76e-71	Height;
LIHC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg09222892	chr1:25734099	RHCE	-0.45	-8.14	-0.4	7.61e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.55	6.87	0.35	2.98e-11	Systemic lupus erythematosus;
LIHC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-12.02	-0.54	5.36e-28	Platelet distribution width;
LIHC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.32	-0.32	8.15e-10	Renal cell carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17450446	chr1:160002111	PIGM	0.5	6.47	0.33	3.37e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.38	-6.75	-0.34	6.32e-11	Asthma;
LIHC	trans	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg17675199	chr6:35436792	RPL10A	0.38	7.71	0.38	1.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.18	-0.4	5.45e-15	Capecitabine sensitivity;
LIHC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.13	25.87	0.81	1.63e-82	Cognitive ability;
LIHC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.56	-6.09	-0.31	3.09e-9	Menarche (age at onset);
LIHC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.48e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2290416	0.710	rs61005957	chr8:144669512	T/G	cg26536354	chr8:144654954	C8orf73	0.54	6.17	0.32	1.94e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.57	11.56	0.53	2.61e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-6.2	-0.32	1.67e-9	Morning vs. evening chronotype;
LIHC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.48	7.28	0.37	2.31e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs45567533	0.790	rs7427574	chr3:38684835	C/G	cg14758556	chr20:62440591	NA	0.4	6.28	0.32	1.01e-9	PR interval;
LIHC	cis	rs13161895	1.000	rs27012	chr5:179402211	A/C	cg02702477	chr5:179499311	RNF130	0.71	9.94	0.47	1.28e-20	LDL cholesterol;
LIHC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21448741	chr8:58168803	NA	0.35	6.51	0.33	2.69e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.37	-7.9	-0.39	3.89e-14	Erythrocyte sedimentation rate;
LIHC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.71	7.3	0.37	2e-12	Bipolar disorder;
LIHC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs57502260	0.704	rs72936570	chr11:68307139	A/G	cg20283391	chr11:68216788	NA	-0.51	-5.96	-0.31	6.27e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	0.55	10.39	0.49	3.56e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs611744	0.967	rs686251	chr8:109198907	C/A	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	6.02e-17	Dupuytren's disease;
LIHC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.47	-8.32	-0.41	2.05e-15	IgG glycosylation;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.55	-7.9	-0.39	3.92e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12602486	1.000	rs60684277	chr17:42281307	G/A	cg08193365	chr17:42277699	NA	0.97	6.64	0.34	1.23e-10	Glycated hemoglobin levels;
LIHC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.83	14.89	0.63	5.27e-39	Menopause (age at onset);
LIHC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.82	7.48	0.38	6.26e-13	IgG glycosylation;
LIHC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.62	11.47	0.53	5.54e-26	Gestational age at birth (maternal effect);
LIHC	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-0.72	-6.37	-0.33	6.2e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs2412488	0.893	rs36011216	chr4:54350726	T/A	cg22241045	chr4:54363911	LNX1	-0.43	-6.96	-0.35	1.7e-11	DNA methylation (variation);
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.99	-0.31	5.28e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.49	-6.87	-0.35	3.14e-11	Body mass index;
LIHC	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	6.76	0.34	6.02e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.8	0.3	1.55e-8	Melanoma;
LIHC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg00990874	chr7:1149470	C7orf50	-0.64	-9.01	-0.44	1.5e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.55	8.74	0.43	1.07e-16	Granulocyte count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg24296786	chr1:45957014	TESK2	0.41	5.76	0.3	1.85e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.7	-0.34	8.61e-11	Bipolar disorder;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	20.87	0.75	5.93e-63	Prudent dietary pattern;
LIHC	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.4	-5.71	-0.3	2.42e-8	Longevity;
LIHC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.9	-0.3	8.56e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.49	9.3	0.45	1.68e-18	Testicular germ cell tumor;
LIHC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	0.84	11.24	0.52	3.56e-25	Skin colour saturation;
LIHC	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg14473756	chr11:122847823	NA	-0.37	-6.65	-0.34	1.18e-10	Menarche (age at onset);
LIHC	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.44	-7.47	-0.37	6.97e-13	Migraine - clinic-based;
LIHC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.36	-5.78	-0.3	1.7e-8	Mood instability;
LIHC	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg25356066	chr3:128598488	ACAD9	0.52	6.84	0.35	3.62e-11	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14604386	chr6:119670882	MAN1A1	-0.43	-6.51	-0.33	2.7e-10	Cognitive function;
LIHC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-15.02	-0.63	1.64e-39	Alzheimer's disease (late onset);
LIHC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg00142150	chr22:38071001	LGALS1	0.71	11.5	0.53	4.34e-26	Fat distribution (HIV);
LIHC	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.42	-8.56	-0.42	3.9e-16	Testicular germ cell tumor;
LIHC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-8.96	-0.44	2.22e-17	Schizophrenia;
LIHC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.86	-0.3	1.09e-8	Colorectal cancer;
LIHC	cis	rs3736485	0.934	rs882385	chr15:51882369	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.48	8.5	0.42	6e-16	IgG glycosylation;
LIHC	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg25344623	chr2:136566232	LCT	-0.37	-5.99	-0.31	5.2e-9	Corneal structure;
LIHC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	4.12e-15	Schizophrenia;
LIHC	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg16970926	chr12:29381810	FAR2	0.32	6.8	0.34	4.75e-11	QT interval;
LIHC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg10578777	chr12:7781093	NA	0.47	8.23	0.41	3.87e-15	HDL cholesterol levels;
LIHC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.55	6.0	0.31	4.95e-9	Alzheimer's disease;
LIHC	cis	rs7095607	0.606	rs7095774	chr10:69957554	C/T	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.94e-9	Lung function (FVC);
LIHC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.92	14.31	0.61	9.88e-37	Glomerular filtration rate (creatinine);
LIHC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg12863693	chr15:85201151	NMB	0.5	7.22	0.36	3.42e-12	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-11.64	-0.53	1.36e-26	Coronary artery disease;
LIHC	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg23091122	chr1:110024289	SYPL2	-0.52	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.52	7.47	0.37	6.66e-13	Initial pursuit acceleration;
LIHC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg03859395	chr2:55845619	SMEK2	0.77	12.77	0.57	8.65e-31	Metabolic syndrome;
LIHC	cis	rs6466055	0.639	rs11760317	chr7:104711711	T/C	cg04380332	chr7:105027541	SRPK2	-0.33	-6.27	-0.32	1.11e-9	Schizophrenia;
LIHC	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-7.69	-0.38	1.56e-13	Exhaled nitric oxide output;
LIHC	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	7.95	0.4	2.67e-14	HIV-1 control;
LIHC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-8.65	-0.42	2.07e-16	Gut microbiome composition (summer);
LIHC	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.77	-0.34	5.56e-11	Prevalent atrial fibrillation;
LIHC	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.1	-0.31	2.91e-9	Total body bone mineral density;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.78	-0.34	5.41e-11	Longevity;Endometriosis;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.5	-0.38	5.37e-13	Lymphocyte counts;
LIHC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.35	-0.45	1.2e-18	Bipolar disorder;
LIHC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.78	-10.2	-0.48	1.68e-21	Systemic lupus erythematosus;
LIHC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.45	6.41	0.33	4.71e-10	Coronary artery disease;
LIHC	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	0.73	8.29	0.41	2.61e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.51	6.09	0.31	3.11e-9	Interleukin-17 levels;
LIHC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg10402321	chr1:26617780	UBXN11	-0.38	-5.8	-0.3	1.48e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.85	0.3	1.12e-8	Bipolar disorder;
LIHC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.72	9.71	0.46	7.44e-20	Heart rate;
LIHC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.74	9.03	0.44	1.26e-17	Gut microbiome composition (summer);
LIHC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.42	8.03	0.4	1.54e-14	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.54	9.41	0.45	7.45e-19	Monocyte count;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.39	0.8	7.99e-77	Prudent dietary pattern;
LIHC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.51	7.12	0.36	6.59e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg23978390	chr7:1156363	C7orf50	0.52	7.77	0.39	9.45e-14	Longevity;Endometriosis;
LIHC	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg19636519	chr7:99541626	NA	0.31	6.22	0.32	1.47e-9	Coronary artery disease;
LIHC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-7.89	-0.39	4.18e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs747782	0.702	rs17790804	chr11:47447202	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.76	-0.3	1.84e-8	Intraocular pressure;
LIHC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.56	-14.83	-0.63	9.18e-39	Alzheimer's disease (late onset);
LIHC	cis	rs8083850	0.635	rs1897261	chr18:50851974	A/G	cg24270629	chr18:50823537	DCC	0.53	7.97	0.4	2.39e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.0	-0.44	1.54e-17	Type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12738264	chr7:148725795	PDIA4	0.34	6.06	0.31	3.6e-9	Cognitive function;
LIHC	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg27386326	chr11:61587980	NA	0.7	14.82	0.63	9.56e-39	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.52	6.25	0.32	1.22e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.74	12.15	0.55	1.71e-28	Anterior chamber depth;
LIHC	cis	rs61041384	0.661	rs7967118	chr12:123571503	C/G	cg00376283	chr12:123451042	ABCB9	-0.6	-5.72	-0.3	2.27e-8	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg25356066	chr3:128598488	ACAD9	0.56	7.28	0.37	2.31e-12	IgG glycosylation;
LIHC	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.37	-7.1	-0.36	7.47e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-20.19	-0.74	3.18e-60	Exhaled nitric oxide output;
LIHC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.49	7.1	0.36	7.39e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.49	6.66	0.34	1.1e-10	Glioblastoma;Glioma;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14967899	chr8:26434689	DPYSL2	-0.44	-6.28	-0.32	1.02e-9	Triglycerides;
LIHC	cis	rs9918079	0.560	rs6414767	chr4:15655721	A/G	cg16509355	chr4:15471240	CC2D2A	-0.47	-7.21	-0.36	3.51e-12	Obesity-related traits;
LIHC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg19645103	chr12:69753606	YEATS4	-0.46	-6.28	-0.32	1.04e-9	Response to diuretic therapy;
LIHC	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg18081818	chr7:23246105	NA	-0.46	-7.03	-0.36	1.13e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7119038	0.580	rs7123726	chr11:118694547	T/C	cg19308663	chr11:118741387	NA	0.4	6.14	0.32	2.27e-9	Sjögren's syndrome;
LIHC	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	0.9	10.56	0.5	9.71e-23	Breast cancer;
LIHC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02969873	chr4:1330999	MAEA	-0.42	-6.54	-0.33	2.2e-10	Longevity;
LIHC	cis	rs611744	0.967	rs645070	chr8:109216345	A/C	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.74e-17	Dupuytren's disease;
LIHC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.16	0.44	4.84e-18	Bipolar disorder;
LIHC	cis	rs2637266	0.783	rs58247832	chr10:78471383	C/A	cg18941641	chr10:78392320	NA	0.27	5.86	0.3	1.11e-8	Pulmonary function;
LIHC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-9.76	-0.47	5e-20	Asthma;
LIHC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.53	0.64	1.5e-41	Chronic sinus infection;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03009463	chr7:17980271	SNX13	-0.52	-6.06	-0.31	3.53e-9	Systolic blood pressure;
LIHC	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg01320579	chr17:75405842	SEPT9	0.54	7.09	0.36	7.62e-12	Airflow obstruction;
LIHC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.14	0.52	8.37e-25	Menarche (age at onset);
LIHC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.98	-0.31	5.54e-9	Life satisfaction;
LIHC	cis	rs365132	0.934	rs183686	chr5:176494102	A/G	cg16309518	chr5:176445507	NA	-0.57	-10.7	-0.5	3.06e-23	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs11630290	0.592	rs11634436	chr15:64158394	T/G	cg12036633	chr15:63758958	NA	0.61	6.55	0.33	2.08e-10	Iris characteristics;
LIHC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg27523141	chr10:43048294	ZNF37B	-0.37	-6.36	-0.33	6.37e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg25281562	chr12:121454272	C12orf43	0.36	6.27	0.32	1.06e-9	N-glycan levels;
LIHC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.55	-6.07	-0.31	3.49e-9	Menarche (age at onset);
LIHC	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.33	6.36	0.33	6.42e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	7.0	0.35	1.39e-11	Systolic blood pressure;
LIHC	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg03934865	chr2:198174659	NA	-0.57	-9.01	-0.44	1.51e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.54	-0.38	4.25e-13	Aortic root size;
LIHC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.76	-18.09	-0.7	8.59e-52	Brugada syndrome;
LIHC	cis	rs72772090	0.908	rs72772091	chr5:96040122	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-6.53	-0.33	2.37e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.76	-0.39	9.64e-14	Capecitabine sensitivity;
LIHC	cis	rs12079745	1.000	rs74967728	chr1:169202731	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-7.09	-0.36	7.82e-12	QT interval;
LIHC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.81	0.43	6.41e-17	Cognitive test performance;
LIHC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.49	-7.41	-0.37	1e-12	Menarche (age at onset);
LIHC	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.39	-9.36	-0.45	1.06e-18	Cutaneous nevi;
LIHC	cis	rs16958440	1.000	rs16958440	chr18:44632884	C/G	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg24884572	chr19:58661833	ZNF329	0.96	7.48	0.37	6.44e-13	Cholesterol, total;
LIHC	cis	rs4407350	0.721	rs105248	chr22:44891399	C/G	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.54	-0.33	2.23e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.47	-0.59	1.77e-33	Coffee consumption (cups per day);
LIHC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg06742321	chr12:123595122	PITPNM2	0.31	5.84	0.3	1.25e-8	Platelet count;
LIHC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.25	-0.32	1.2e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg00656387	chr3:40428638	ENTPD3	0.44	7.45	0.37	7.71e-13	Renal cell carcinoma;
LIHC	cis	rs986417	0.818	rs2092722	chr14:61062890	T/A	cg27398547	chr14:60952738	C14orf39	0.49	5.88	0.3	9.67e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.78	-12.09	-0.55	3.05e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg00204748	chr12:29376779	FAR2	0.44	8.53	0.42	4.83e-16	QT interval;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14077301	chr14:58766370	ARID4A	0.47	6.37	0.33	6.18e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg03859395	chr2:55845619	SMEK2	0.72	11.75	0.54	5.37e-27	Metabolic syndrome;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12357364	chr17:1557144	PRPF8	0.44	6.19	0.32	1.7e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14257396	chr1:107603778	NA	0.35	5.72	0.3	2.33e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs16828019	0.852	rs12406620	chr1:41512664	A/T	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-8.6	-0.42	2.88e-16	Primary biliary cholangitis;
LIHC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg03854865	chr6:26224070	HIST1H3E	-0.7	-7.74	-0.39	1.16e-13	Gout;Renal underexcretion gout;
LIHC	cis	rs4780401	0.933	rs1579258	chr16:11824903	C/G	cg01061890	chr16:11836724	TXNDC11	-0.4	-5.87	-0.3	1.05e-8	Rheumatoid arthritis;
LIHC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.89	18.09	0.7	8.88e-52	Height;
LIHC	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg04218760	chr10:45406644	TMEM72	-0.21	-6.27	-0.32	1.06e-9	Mean corpuscular volume;
LIHC	cis	rs2710642	0.525	rs1601673	chr2:62842559	G/C	cg17519650	chr2:63277830	OTX1	0.46	7.29	0.37	2.19e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12016809	chr21:47604291	C21orf56	0.45	6.59	0.34	1.63e-10	Testicular germ cell tumor;
LIHC	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-9.33	-0.45	1.32e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	7.79	0.39	8.16e-14	Height;
LIHC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg18446336	chr7:2847575	GNA12	0.35	6.94	0.35	1.95e-11	Loneliness (linear analysis);
LIHC	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.39	6.64	0.34	1.2e-10	Menopause (age at onset);
LIHC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.43	5.73	0.3	2.22e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg25214090	chr10:38739885	LOC399744	0.4	6.8	0.35	4.74e-11	Diastolic blood pressure;
LIHC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs539514	0.501	rs8000656	chr13:76400640	A/G	cg04757411	chr13:76259545	LMO7	0.38	5.99	0.31	5.29e-9	Type 1 diabetes;
LIHC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg07959070	chr22:50026188	C22orf34	-0.33	-8.01	-0.4	1.88e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.56	-6.64	-0.34	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.48	-7.38	-0.37	1.22e-12	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs6114141	chr20:23460620	T/G	cg12062639	chr20:23401060	NAPB	0.79	9.93	0.47	1.36e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg22134162	chr3:63841271	THOC7	-0.53	-5.85	-0.3	1.15e-8	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg16586182	chr3:47516702	SCAP	0.47	8.14	0.4	7.42e-15	Colorectal cancer;
LIHC	cis	rs12286929	0.583	rs10458966	chr11:115102758	T/C	cg04055981	chr11:115044050	NA	0.38	5.83	0.3	1.32e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.82	-0.3	1.34e-8	Tuberculosis;
LIHC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.78	-0.43	8.05e-17	Body mass index (adult);
LIHC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.52	-8.59	-0.42	3.15e-16	Blood metabolite levels;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.74e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.97	13.1	0.58	4.65e-32	Heart rate;
LIHC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-10.74	-0.5	2.17e-23	Colorectal cancer;
LIHC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.53	-7.56	-0.38	3.83e-13	Body mass index;
LIHC	cis	rs3736485	0.903	rs9944241	chr15:51898058	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs7714584	1.000	rs2345001	chr5:150266518	G/T	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.53	6.87	0.35	3.01e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-6.35	-0.32	6.82e-10	Osteoporosis;
LIHC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.04	-0.48	5.98e-21	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.31	0.41	2.3e-15	Motion sickness;
LIHC	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg02811702	chr13:24901961	NA	0.23	5.76	0.3	1.89e-8	Obesity-related traits;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.98	-0.31	5.5e-9	Total body bone mineral density;
LIHC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	1.03	20.74	0.75	1.91e-62	Breast cancer;
LIHC	cis	rs847649	0.548	rs10953380	chr7:102747149	C/G	cg18108683	chr7:102477205	FBXL13	0.41	6.32	0.32	8.13e-10	Morning vs. evening chronotype;
LIHC	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	0.96	13.84	0.6	6.82e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.47	7.9	0.39	3.95e-14	Mean corpuscular volume;
LIHC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.41	-6.65	-0.34	1.14e-10	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26294578	chr17:79319535	NA	0.42	6.12	0.31	2.54e-9	Pancreatic cancer;
LIHC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.55	9.76	0.47	5.21e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-8.78	-0.43	7.96e-17	Morning vs. evening chronotype;
LIHC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs600626	0.529	rs59913369	chr11:75473265	A/G	cg24262691	chr11:75473276	NA	0.44	6.49	0.33	2.94e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21467203	chr3:49911342	NA	0.52	9.5	0.46	3.72e-19	Body mass index;
LIHC	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.72	8.1	0.4	9.78e-15	Height;
LIHC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg23978390	chr7:1156363	C7orf50	0.43	6.52	0.33	2.59e-10	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.86	-0.35	3.3e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.1	0.36	7.27e-12	Aortic root size;
LIHC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-9.72	-0.47	7.19e-20	Inflammatory bowel disease;
LIHC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg08807892	chr2:162101083	NA	0.36	5.83	0.3	1.28e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs17106184	1.000	rs72902726	chr1:51223500	T/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs7534824	0.625	rs61780331	chr1:101480610	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	6.74	0.34	6.76e-11	Refractive astigmatism;
LIHC	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.62	6.14	0.32	2.27e-9	Carotid intima media thickness;
LIHC	cis	rs2607426	0.681	rs2233153	chr19:41281106	G/C	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-6.02	-0.31	4.59e-9	Blood protein levels;
LIHC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg00086871	chr4:6988644	TBC1D14	0.89	6.27	0.32	1.07e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.35	8.76	0.43	8.91e-17	Asthma (sex interaction);
LIHC	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.91	0.3	8.09e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2286503	0.780	rs2286506	chr7:22854815	T/C	cg11367502	chr7:22862612	TOMM7	0.47	8.14	0.4	7.59e-15	Fibrinogen;
LIHC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg10360323	chr17:41437877	NA	0.42	6.12	0.31	2.53e-9	Menopause (age at onset);
LIHC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.7	0.38	1.51e-13	IgG glycosylation;
LIHC	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg03934865	chr2:198174659	NA	0.51	7.55	0.38	3.92e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs611744	0.967	rs650401	chr8:109196854	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.61	9.18	0.44	4.16e-18	Menopause (age at onset);
LIHC	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.18	-0.48	1.9e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.62	-0.38	2.57e-13	Prevalent atrial fibrillation;
LIHC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.51	-9.56	-0.46	2.42e-19	Atrioventricular conduction;
LIHC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.18	0.36	4.25e-12	Protein C levels;
LIHC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.4	6.36	0.33	6.63e-10	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23409613	chr14:53196849	STYX	-0.35	-6.16	-0.32	2.08e-9	Pancreatic cancer;
LIHC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg04719120	chr6:96025338	MANEA	0.66	5.93	0.31	7.49e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.43	-6.91	-0.35	2.35e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg14061069	chr19:46274453	DMPK	-0.58	-9.27	-0.45	2.1e-18	Coronary artery disease;
LIHC	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.7	-0.38	1.5e-13	Response to antipsychotic treatment;
LIHC	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.55	-6.71	-0.34	8.3e-11	Bipolar disorder;
LIHC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.44	-0.33	4.05e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.11	-0.31	2.73e-9	Mean corpuscular volume;
LIHC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.67	12.89	0.57	2.87e-31	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.96	0.35	1.73e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs36051895	0.502	rs10975003	chr9:5213687	T/C	cg02405213	chr9:5042618	JAK2	-0.61	-10.1	-0.48	3.53e-21	Pediatric autoimmune diseases;
LIHC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	6.7	0.34	8.64e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.46	6.01	0.31	4.8e-9	Pulmonary function decline;
LIHC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.19	-0.41	5.14e-15	Type 2 diabetes;
LIHC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.46	-0.42	7.96e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.55	-8.44	-0.42	9.24e-16	Blood protein levels;
LIHC	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	7.12	0.36	6.22e-12	Lung cancer in ever smokers;
LIHC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.74	-8.03	-0.4	1.61e-14	Putamen volume;
LIHC	cis	rs67981189	0.593	rs116016	chr14:71577480	G/A	cg15816911	chr14:71606274	NA	-0.42	-6.74	-0.34	6.65e-11	Schizophrenia;
LIHC	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg10820045	chr2:198174542	NA	0.43	6.51	0.33	2.64e-10	Intracranial aneurysm;
LIHC	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.64	6.68	0.34	9.96e-11	Type 2 diabetes;
LIHC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	12.21	0.55	1.05e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.95	14.18	0.61	3.07e-36	Coronary artery disease;
LIHC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.57	8.06	0.4	1.32e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.32	-5.8	-0.3	1.5e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.12	0.31	2.61e-9	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.57	-6.94	-0.35	1.99e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.14e-38	Intelligence (multi-trait analysis);
LIHC	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.89	15.25	0.64	1.96e-40	Gastritis;
LIHC	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.56	6.52	0.33	2.55e-10	Mammographic density (dense area);
LIHC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.25	-0.32	1.23e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.57	7.0	0.35	1.39e-11	QRS duration;
LIHC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.87	-0.63	6.47e-39	Alzheimer's disease (late onset);
LIHC	cis	rs3780378	0.875	rs7861599	chr9:5067298	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.14	-0.44	5.58e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.67	10.56	0.5	9.29e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg17385448	chr1:15911702	AGMAT	0.4	6.44	0.33	4.15e-10	Systolic blood pressure;
LIHC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.52	8.3	0.41	2.43e-15	Total body bone mineral density;
LIHC	cis	rs918629	0.761	rs17085333	chr5:95280848	A/T	cg10483112	chr5:95245456	ELL2	0.36	6.07	0.31	3.41e-9	IgG glycosylation;
LIHC	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg08847533	chr14:75593920	NEK9	-0.35	-5.92	-0.3	7.87e-9	Caffeine consumption;
LIHC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.08	-0.55	3.12e-28	Type 2 diabetes;
LIHC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.25	-0.37	2.75e-12	Schizophrenia;
LIHC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.04	0.31	3.98e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.94	0.35	1.98e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.54	7.89	0.39	4.03e-14	Longevity;Endometriosis;
LIHC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.4	6.43	0.33	4.27e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-7.62	-0.38	2.58e-13	Fibrinogen levels;
LIHC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.26	-6.13	-0.31	2.47e-9	Subjective well-being;
LIHC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg00204512	chr16:28754710	NA	0.34	6.95	0.35	1.86e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.76	7.78	0.39	8.47e-14	Cannabis dependence symptom count;
LIHC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.62	-9.43	-0.45	6.37e-19	Aortic root size;
LIHC	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	6.02	0.31	4.49e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.45	7.8	0.39	7.6e-14	Mean corpuscular volume;
LIHC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12016809	chr21:47604291	C21orf56	0.43	6.27	0.32	1.11e-9	Testicular germ cell tumor;
LIHC	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.64	-0.34	1.22e-10	Metabolite levels;
LIHC	cis	rs7212590	0.581	rs8081710	chr17:57838040	G/A	cg10252138	chr17:58120427	NA	-0.59	-5.88	-0.3	9.59e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.4e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16517634	chr2:8977876	KIDINS220	-0.46	-6.56	-0.33	1.97e-10	Pancreatic cancer;
LIHC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg22834771	chr12:69754056	YEATS4	0.45	7.92	0.39	3.3e-14	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.64	-0.42	2.21e-16	Lymphocyte counts;
LIHC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg14779329	chr11:130786720	SNX19	0.4	6.03	0.31	4.22e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs2681424	1.000	rs12488766	chr3:121757789	C/G	cg03946530	chr15:65596423	NA	0.47	6.04	0.31	4.04e-9	Multiple sclerosis;
LIHC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.87	-0.51	7.47e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs4934494	0.768	rs12571268	chr10:91458587	T/C	cg19698084	chr10:91461284	KIF20B	-0.49	-6.47	-0.33	3.39e-10	Red blood cell count;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg03874509	chr1:107600012	PRMT6	-0.78	-12.44	-0.56	1.4e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.75	-0.39	1.03e-13	Type 2 diabetes;
LIHC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.14e-9	Tonsillectomy;
LIHC	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.51	7.77	0.39	9.43e-14	Schizophrenia;
LIHC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg09695851	chr17:3907499	NA	0.61	7.15	0.36	5.42e-12	Type 2 diabetes;
LIHC	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg27205649	chr11:78285834	NARS2	-0.4	-6.38	-0.33	5.92e-10	Alzheimer's disease (survival time);
LIHC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.21	0.36	3.54e-12	Bipolar disorder;
LIHC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.49	5.84	0.3	1.2e-8	Total body bone mineral density;
LIHC	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.54	0.62	1.3e-37	Bipolar disorder;
LIHC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.46	7.19	0.36	4.18e-12	Breast cancer;
LIHC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.9	0.35	2.49e-11	Diabetic kidney disease;
LIHC	cis	rs61440199	0.818	rs79027229	chr3:20180363	T/C	cg00235661	chr3:20228976	SGOL1	-0.42	-5.79	-0.3	1.58e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	trans	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg04702396	chr17:15466718	FAM18B2	0.43	6.47	0.33	3.3e-10	Educational attainment (years of education);
LIHC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.69	0.34	9.33e-11	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.46	-7.2	-0.36	3.87e-12	Longevity;Endometriosis;
LIHC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.5e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs4742903	0.935	rs4743692	chr9:106931890	A/G	cg14250997	chr9:106856677	SMC2	0.36	6.05	0.31	3.91e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.1	-0.7	7.56e-52	Tonsillectomy;
LIHC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.06	15.14	0.63	5.6e-40	Cognitive function;
LIHC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.85	0.3	1.17e-8	Menopause (age at onset);
LIHC	cis	rs986417	0.901	rs12883305	chr14:61006690	A/G	cg27398547	chr14:60952738	C14orf39	0.83	9.47	0.46	4.66e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs11678584	0.502	rs17011982	chr2:32726313	A/G	cg02381751	chr2:32503542	YIPF4	0.61	6.06	0.31	3.52e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg06766960	chr11:133703094	NA	-0.44	-6.81	-0.35	4.52e-11	Childhood ear infection;
LIHC	cis	rs1494950	1.000	rs16891297	chr4:15034472	A/G	cg12377275	chr4:15005593	CPEB2	-0.85	-7.5	-0.38	5.68e-13	Political ideology;
LIHC	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	6.87	0.35	2.96e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg03989125	chr22:38214979	NA	0.43	5.79	0.3	1.61e-8	Glioblastoma;Glioma;
LIHC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.61	-8.77	-0.43	8.53e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.54	0.42	4.46e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg17802220	chr15:77601643	NA	-0.4	-6.07	-0.31	3.48e-9	Risky sexual behaviors (alcohol dependence interaction);
LIHC	trans	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg01596870	chr19:55963115	NA	-0.64	-8.49	-0.42	6.49e-16	Obesity-related traits;
LIHC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.95	-19.87	-0.73	5.74e-59	Birth weight;
LIHC	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.51	8.44	0.42	9.03e-16	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.45	6.38	0.33	5.89e-10	Asthma;
LIHC	cis	rs4903214	0.895	rs7161419	chr14:74695757	A/G	cg11132536	chr14:74711944	VSX2	-0.25	-6.04	-0.31	3.94e-9	Inflammatory bowel disease;
LIHC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.6e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.5	8.87	0.43	4e-17	Colorectal cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27318635	chr16:3781749	CREBBP	0.41	6.19	0.32	1.71e-9	Longevity;
LIHC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.46	5.72	0.3	2.36e-8	Coronary artery calcification;
LIHC	trans	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.46	-0.33	3.65e-10	Educational attainment (years of education);
LIHC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.77	-12.05	-0.55	4.28e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1144333	1.000	rs75399471	chr1:76339092	A/T	cg03433033	chr1:76189801	ACADM	0.54	7.44	0.37	8.34e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10431058	0.930	rs7948142	chr11:107478703	T/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.4	6.48	0.33	3.28e-10	Common traits (Other);
LIHC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.61	8.33	0.41	2.05e-15	Ulcerative colitis;
LIHC	cis	rs2425143	1.000	rs12481228	chr20:34218673	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-5.89	-0.3	9.47e-9	Blood protein levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20518154	chr20:39318705	MAFB	0.47	6.31	0.32	8.54e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16247931	chr14:102771650	RAGE	-0.46	-6.16	-0.32	2.09e-9	Pancreatic cancer;
LIHC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.14e-25	Corneal astigmatism;
LIHC	cis	rs611744	0.967	rs612265	chr8:109188650	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.37e-17	Dupuytren's disease;
LIHC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.21	-0.32	1.54e-9	Total body bone mineral density;
LIHC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg00800038	chr16:89945340	TCF25	-0.62	-9.31	-0.45	1.63e-18	Skin colour saturation;
LIHC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.49	-9.11	-0.44	7.2e-18	Body mass index;
LIHC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg14580859	chr9:123691850	NA	0.39	6.85	0.35	3.45e-11	Rheumatoid arthritis;
LIHC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.79	11.9	0.54	1.44e-27	Dental caries;
LIHC	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg03989125	chr22:38214979	NA	-0.44	-6.16	-0.32	2.06e-9	Glioblastoma;Glioma;
LIHC	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg12641515	chr19:46296257	DMWD	0.46	6.94	0.35	2e-11	Coronary artery disease;
LIHC	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg11005552	chr10:105648138	OBFC1	0.38	6.1	0.31	2.85e-9	Coronary artery disease;
LIHC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.13	-0.4	7.91e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.87	0.35	3.09e-11	Bipolar disorder;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-9.75	-0.47	5.72e-20	Skin colour saturation;
LIHC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	1.15	9.07	0.44	9.6e-18	Arsenic metabolism;
LIHC	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.65	6.68	0.34	9.53e-11	Blood pressure;
LIHC	cis	rs507080	0.733	rs4486664	chr11:118569067	A/C	cg04173919	chr11:118528438	PHLDB1	0.34	6.27	0.32	1.09e-9	Serum metabolite levels;
LIHC	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.5	-7.42	-0.37	9.25e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs4407350	1.000	rs4373013	chr22:44922248	C/T	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.05	-0.31	3.8e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.4	6.62	0.34	1.39e-10	Red blood cell count;
LIHC	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.26	6.26	0.32	1.12e-9	Schizophrenia;
LIHC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.51	-0.49	1.42e-22	Menarche (age at onset);
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.57	-0.38	3.46e-13	Schizophrenia;
LIHC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.46	-6.65	-0.34	1.17e-10	Corneal structure;
LIHC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.77	0.5	1.73e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.49	8.35	0.41	1.76e-15	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg25214090	chr10:38739885	LOC399744	0.4	6.64	0.34	1.25e-10	Diastolic blood pressure;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.67	-12.44	-0.56	1.46e-29	Paraoxonase activity;
LIHC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg15017067	chr4:17643749	FAM184B	0.34	5.79	0.3	1.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9326778	0.520	rs55796690	chr5:108842398	G/T	cg17395555	chr5:108820864	NA	-0.37	-6.34	-0.32	7.42e-10	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs332507	0.601	rs3772775	chr3:124369360	C/G	cg05980111	chr3:124395277	KALRN	-0.31	-5.98	-0.31	5.65e-9	Plateletcrit;
LIHC	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.39	5.91	0.3	8.37e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.75	0.54	5.27e-27	Eye color traits;
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.03	-0.31	4.3e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs151997	0.925	rs27624	chr5:50167662	C/T	cg06027927	chr5:50259733	NA	0.58	7.48	0.37	6.51e-13	Callous-unemotional behaviour;
LIHC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg19635926	chr16:89946313	TCF25	0.48	6.2	0.32	1.65e-9	Skin colour saturation;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09543727	chr4:120550218	PDE5A	0.45	6.27	0.32	1.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1322512	0.883	rs2758814	chr6:152966367	C/T	cg03415253	chr6:152958462	SYNE1	-0.33	-6.21	-0.32	1.5e-9	Tonometry;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.82	-0.35	4.15e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4788570	0.616	rs11075901	chr16:71790812	A/C	cg06353428	chr16:71660113	MARVELD3	1.36	14.03	0.6	1.21e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg10578777	chr12:7781093	NA	-0.48	-7.81	-0.39	7.16e-14	HDL cholesterol levels;
LIHC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.73	-13.69	-0.59	2.61e-34	Height;
LIHC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6750047	0.566	rs1157184	chr2:38285774	C/G	cg07380506	chr2:38303506	CYP1B1	0.65	8.43	0.41	9.69e-16	Cutaneous malignant melanoma;Melanoma;
LIHC	trans	rs6489882	0.867	rs6489876	chr12:113368055	G/A	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg20607798	chr8:58055168	NA	0.49	6.11	0.31	2.75e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.84	11.3	0.52	2.29e-25	Type 2 diabetes;
LIHC	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.04e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.53	-0.38	4.45e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.12	0.55	2.31e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.5	-6.7	-0.34	8.68e-11	Serum thyroid-stimulating hormone levels;
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	10.48	0.49	1.81e-22	Prudent dietary pattern;
LIHC	cis	rs4788570	0.578	rs8062188	chr16:71729825	T/C	cg06353428	chr16:71660113	MARVELD3	1.35	13.8	0.6	1e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.53	-6.78	-0.34	5.15e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.92	0.57	2.17e-31	Prudent dietary pattern;
LIHC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg24163568	chr5:669837	TPPP	-0.41	-8.6	-0.42	2.98e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.67	0.42	1.71e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg22532475	chr10:104410764	TRIM8	0.36	6.34	0.32	7.18e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7188697	0.883	rs4485352	chr16:58601410	A/G	cg02549819	chr16:58548995	SETD6	0.48	7.62	0.38	2.52e-13	QT interval;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02408009	chr15:28422194	HERC2	-0.42	-6.33	-0.32	7.67e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.59	6.86	0.35	3.17e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	6.85	0.35	3.54e-11	Type 2 diabetes;
LIHC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	6.04	0.31	3.93e-9	Bipolar disorder;
LIHC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	0.67	8.59	0.42	3.21e-16	Corneal structure;
LIHC	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg03934865	chr2:198174659	NA	0.48	6.87	0.35	3.09e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.36	6.09	0.31	2.96e-9	Height;
LIHC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.78	11.75	0.54	5.36e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3812111	0.525	rs3749893	chr6:116571695	A/G	cg08036074	chr6:116424633	NT5DC1	-0.44	-7.1	-0.36	7.07e-12	Age-related macular degeneration;
LIHC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.47	6.63	0.34	1.29e-10	High light scatter reticulocyte count;
LIHC	cis	rs7818688	0.697	rs74553842	chr8:95984392	C/T	cg16049864	chr8:95962084	TP53INP1	0.6	6.55	0.33	2.08e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7395581	1.000	rs830085	chr11:47251199	G/A	cg26139080	chr11:47293733	MADD	0.49	8.19	0.4	5.25e-15	HDL cholesterol;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00873521	chr9:95056130	IARS;SNORA84	0.45	6.54	0.33	2.21e-10	Pancreatic cancer;
LIHC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg06634786	chr22:41940651	POLR3H	-0.52	-6.12	-0.31	2.62e-9	Vitiligo;
LIHC	cis	rs8067354	0.540	rs72840315	chr17:58018142	G/C	cg02344993	chr17:57696989	CLTC	0.65	10.18	0.48	2.01e-21	Hemoglobin concentration;
LIHC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg19513890	chr22:42538836	CYP2D7P1	0.41	8.29	0.41	2.65e-15	Cognitive function;
LIHC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	0.6	11.17	0.52	6.72e-25	Fat distribution (HIV);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00370926	chr17:7835519	TRAPPC1;CNTROB	0.45	6.27	0.32	1.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-10.77	-0.5	1.73e-23	Crohn's disease;
LIHC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.33	-6.02	-0.31	4.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg14146966	chr2:61757674	XPO1	0.47	8.11	0.4	9.17e-15	Tuberculosis;
LIHC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg12798992	chr6:167411361	FGFR1OP	0.5	8.17	0.4	5.95e-15	Primary biliary cholangitis;
LIHC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.68	-0.5	3.47e-23	Breast cancer;
LIHC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.57	-7.8	-0.39	7.65e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.84	-0.3	1.23e-8	Resting heart rate;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg16797656	chr11:68205561	LRP5	0.49	7.71	0.38	1.39e-13	Total body bone mineral density;
LIHC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.82	0.47	3.16e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.71	11.25	0.52	3.29e-25	Corneal astigmatism;
LIHC	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14396892	chr9:96623032	NA	-0.33	-6.31	-0.32	8.63e-10	DNA methylation (variation);
LIHC	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.49	-0.38	5.9e-13	Capecitabine sensitivity;
LIHC	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.48	6.85	0.35	3.41e-11	Lung cancer;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.79e-14	Prudent dietary pattern;
LIHC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.87	12.93	0.57	2.15e-31	Vitamin D levels;
LIHC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.73	-11.46	-0.53	6.2e-26	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.67	-9.94	-0.47	1.29e-20	Monocyte count;
LIHC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.83	-0.3	1.25e-8	Blood metabolite levels;
LIHC	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.51	8.24	0.41	3.6e-15	Schizophrenia;
LIHC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg18016565	chr1:150552671	MCL1	-0.5	-10.32	-0.49	6.68e-22	Tonsillectomy;
LIHC	trans	rs2363709	1.000	rs2363713	chr3:67422600	G/A	cg25028035	chr6:42016671	CCND3	-0.84	-6.07	-0.31	3.44e-9	IgE levels;
LIHC	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.49	-5.99	-0.31	5.41e-9	Mammographic density (dense area);
LIHC	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.42	6.86	0.35	3.17e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs11212260	0.573	rs34582397	chr11:107161242	A/G	cg25435332	chr11:107328525	CWF19L2	0.65	6.23	0.32	1.38e-9	IgG glycosylation;
LIHC	cis	rs11212260	0.655	rs12225955	chr11:107289846	G/A	cg25435332	chr11:107328525	CWF19L2	0.8	8.13	0.4	7.75e-15	IgG glycosylation;
LIHC	cis	rs1198430	0.925	rs7534474	chr1:23773851	A/G	cg13183780	chr1:23809682	ASAP3	-0.53	-7.61	-0.38	2.68e-13	Total cholesterol levels;
LIHC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg09182678	chr22:50328711	NA	-0.69	-7.62	-0.38	2.47e-13	Schizophrenia;
LIHC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg15893493	chr8:124194847	FAM83A	0.88	8.18	0.4	5.81e-15	Urinary uromodulin levels;
LIHC	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.71	0.34	8.24e-11	Bipolar disorder;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22622886	chr1:9189641	GPR157	0.42	6.05	0.31	3.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12744310	0.945	rs72665691	chr1:41775245	T/A	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.62	-7.9	-0.39	3.77e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.9	-16.01	-0.65	1.92e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13448814	chr8:114447055	CSMD3	-0.42	-6.04	-0.31	4.07e-9	Myopia (pathological);
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.32	5.84	0.3	1.19e-8	Menarche (age at onset);
LIHC	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-9.79	-0.47	4e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs7523273	0.565	rs2796232	chr1:207900368	T/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-8.18	-0.4	5.47e-15	Schizophrenia;
LIHC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.78	-0.3	1.64e-8	Personality dimensions;
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.83	13.97	0.6	2.14e-35	Height;
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg18306943	chr3:40428807	ENTPD3	0.43	7.58	0.38	3.19e-13	Renal cell carcinoma;
LIHC	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg12365402	chr11:9010492	NRIP3	0.29	7.38	0.37	1.2e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg10217327	chr6:118973057	C6orf204	0.7	7.26	0.37	2.67e-12	Diastolic blood pressure;
LIHC	cis	rs1982963	0.951	rs56834750	chr14:52509483	T/C	cg10843707	chr14:52510701	NID2	-0.47	-8.59	-0.42	3.21e-16	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.44	6.91	0.35	2.35e-11	Melanoma;
LIHC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19671926	chr4:122722719	EXOSC9	0.52	8.0	0.4	1.95e-14	Type 2 diabetes;
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	10.48	0.49	1.73e-22	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.11	16.42	0.66	4.34e-45	Sexual dysfunction (female);
LIHC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.87	13.18	0.58	2.31e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.61	-6.82	-0.35	4.12e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs3781458	0.842	rs897300	chr10:126320902	A/G	cg20435097	chr10:126320824	FAM53B	0.72	14.32	0.61	9.36e-37	Male-pattern baldness;
LIHC	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	11.84	0.54	2.43e-27	Post bronchodilator FEV1;
LIHC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.68	0.34	9.44e-11	Rheumatoid arthritis;
LIHC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.61	-9.25	-0.45	2.54e-18	Corneal astigmatism;
LIHC	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg24838063	chr12:130822603	PIWIL1	0.66	9.47	0.46	4.81e-19	Menopause (age at onset);
LIHC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.63	0.56	2.93e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs12744310	0.887	rs34152153	chr1:41801408	T/C	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.42	7.52	0.38	4.84e-13	Mean corpuscular volume;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg14671364	chr1:107599128	PRMT6	-0.5	-7.37	-0.37	1.27e-12	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05947499	chr12:113704091	TPCN1	0.42	6.49	0.33	3e-10	Bilirubin levels;
LIHC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg08694578	chr2:241835147	C2orf54	-0.48	-6.62	-0.34	1.39e-10	Urinary metabolites;
LIHC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg03959625	chr15:84868606	LOC388152	0.49	6.15	0.32	2.12e-9	Schizophrenia;
LIHC	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg07451762	chr16:28383216	NA	0.32	5.98	0.31	5.58e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.4	6.3	0.32	9.04e-10	Resting heart rate;
LIHC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.6	-10.83	-0.51	1.09e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.33	-8.51	-0.42	5.73e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.37	-6.38	-0.33	5.85e-10	Alzheimer's disease;
LIHC	cis	rs4919087	0.651	rs12240590	chr10:99072066	C/G	cg25902810	chr10:99078978	FRAT1	-0.6	-7.23	-0.36	3.16e-12	Monocyte count;
LIHC	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg12858261	chr2:113808755	IL1F8	0.34	5.94	0.31	7.18e-9	Pulmonary function;
LIHC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.04	-0.55	4.63e-28	Type 2 diabetes;
LIHC	cis	rs2274273	1.000	rs4644	chr14:55604935	C/A	cg01864836	chr14:55583639	NA	-0.36	-6.15	-0.32	2.14e-9	Protein biomarker;
LIHC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.59e-14	Parkinson's disease;
LIHC	cis	rs3740540	0.530	rs10794163	chr10:126291398	A/G	cg04949429	chr10:126290192	LHPP	0.44	7.2	0.36	3.97e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.43	6.64	0.34	1.2e-10	Glioblastoma;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg09535738	chr8:17500436	PDGFRL	0.51	6.07	0.31	3.42e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.32	-0.49	6.61e-22	Breast cancer;
LIHC	cis	rs67981189	0.593	rs10140225	chr14:71491121	T/C	cg15816911	chr14:71606274	NA	0.4	6.4	0.33	5.1e-10	Schizophrenia;
LIHC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg16434002	chr17:42200994	HDAC5	-0.53	-7.58	-0.38	3.29e-13	Total body bone mineral density;
LIHC	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.47	-0.46	4.59e-19	Colorectal cancer;
LIHC	trans	rs13113518	0.812	rs12501746	chr4:56303605	C/T	cg15358633	chr12:38710606	ALG10B	0.44	6.29	0.32	9.6e-10	Height;
LIHC	cis	rs4845459	0.967	rs4845450	chr1:152591200	T/C	cg20634798	chr1:152595351	LCE3A	-0.32	-6.2	-0.32	1.63e-9	Psoriasis;
LIHC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.59	-10.89	-0.51	6.77e-24	Menopause (age at onset);
LIHC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.6	11.04	0.51	1.89e-24	Total body bone mineral density;
LIHC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.51	0.56	7.88e-30	Alzheimer's disease;
LIHC	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg15871215	chr5:81402204	ATG10	-0.68	-8.21	-0.41	4.7e-15	Breast cancer;
LIHC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg06207120	chr15:45996521	NA	0.32	6.02	0.31	4.55e-9	Waist circumference;Weight;
LIHC	cis	rs6449957	0.801	rs921792	chr5:67465803	C/T	cg23036683	chr5:67512108	NA	0.45	6.57	0.33	1.85e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg24849736	chr1:201084428	NA	-0.33	-5.77	-0.3	1.73e-8	Permanent tooth development;
LIHC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg15605315	chr1:45957053	TESK2	-0.44	-5.71	-0.3	2.43e-8	Platelet count;
LIHC	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02985541	chr2:219472218	PLCD4	0.41	7.38	0.37	1.2e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4742903	0.935	rs10991165	chr9:106973498	A/G	cg14250997	chr9:106856677	SMC2	-0.35	-5.87	-0.3	1.05e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.5	-0.33	2.85e-10	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	trans	rs9531686	0.935	rs4635230	chr13:85546607	A/C	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.3	0.32	9.31e-10	Anorexia nervosa;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg17512779	chr8:17104072	CNOT7;VPS37A	-0.44	-6.21	-0.32	1.52e-9	Monocyte count;
LIHC	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.43	7.09	0.36	7.52e-12	Corneal astigmatism;
LIHC	trans	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg25214090	chr10:38739885	LOC399744	-0.39	-6.24	-0.32	1.27e-9	Diastolic blood pressure;
LIHC	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.31	-0.32	8.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.57	0.46	2.25e-19	Height;
LIHC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.56	9.46	0.46	5.02e-19	Colorectal cancer;
LIHC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.49	-7.64	-0.38	2.18e-13	Bone mineral density (spine);
LIHC	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16576597	chr16:28551801	NUPR1	0.48	7.31	0.37	1.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg21466736	chr12:48725269	NA	-0.34	-5.96	-0.31	6.2e-9	Plateletcrit;
LIHC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg11062466	chr8:58055876	NA	0.39	5.74	0.3	2.05e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg00277334	chr10:82204260	NA	-0.56	-6.94	-0.35	2.02e-11	Post bronchodilator FEV1;
LIHC	cis	rs6504950	0.800	rs72829484	chr17:53009280	G/T	cg10237252	chr17:52977213	TOM1L1	-0.35	-6.15	-0.32	2.15e-9	Breast cancer;
LIHC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.68	-13.38	-0.59	4.07e-33	Blood protein levels;
LIHC	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.33	8.46	0.42	7.96e-16	Gut microbiome composition (winter);
LIHC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.91	-16.18	-0.66	3.92e-44	Monocyte percentage of white cells;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.85	-0.3	1.16e-8	Total body bone mineral density;
LIHC	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg16060761	chr17:80687452	NA	-0.46	-6.93	-0.35	2.13e-11	Glycated hemoglobin levels;
LIHC	trans	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg21659725	chr3:3221576	CRBN	0.62	6.04	0.31	3.98e-9	Schizophrenia;
LIHC	trans	rs1814175	0.588	rs7481648	chr11:49754910	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.81	0.35	4.37e-11	Height;
LIHC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg05044414	chr3:183734942	ABCC5	0.33	5.81	0.3	1.43e-8	Anterior chamber depth;
LIHC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-5.89	-0.3	9.26e-9	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.86	12.48	0.56	1.07e-29	Psoriasis;
LIHC	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.42	-8.39	-0.41	1.29e-15	Testicular germ cell tumor;
LIHC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.79	-11.84	-0.54	2.52e-27	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.36	-11.75	-0.54	5.3e-27	Hip circumference adjusted for BMI;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06240896	chr7:100136768	AGFG2	0.47	6.5	0.33	2.84e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.76	-10.41	-0.49	3.22e-22	Blood pressure (smoking interaction);
LIHC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19500275	chr17:80737654	TBCD	0.4	5.77	0.3	1.77e-8	Glycated hemoglobin levels;
LIHC	cis	rs4700695	1.000	rs111339	chr5:65420347	T/A	cg21114390	chr5:65439923	SFRS12	-0.52	-7.03	-0.36	1.14e-11	Facial morphology (factor 19);
LIHC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg24296786	chr1:45957014	TESK2	0.41	5.94	0.31	7.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.46	-7.39	-0.37	1.11e-12	Type 2 diabetes;
LIHC	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.45	-6.66	-0.34	1.06e-10	P wave terminal force;
LIHC	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.87	6.74	0.34	6.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.02	0.31	4.59e-9	Morning vs. evening chronotype;
LIHC	cis	rs8084351	0.539	rs9947827	chr18:50622997	G/A	cg24270629	chr18:50823537	DCC	0.43	6.48	0.33	3.2e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06050784	chr16:88016603	BANP	0.45	8.01	0.4	1.76e-14	Menopause (age at onset);
LIHC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11645453	chr3:52864694	ITIH4	0.22	5.85	0.3	1.14e-8	Bipolar disorder;
LIHC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	9.05	0.44	1.1e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.88	-15.33	-0.64	9.23e-41	Colorectal cancer;
LIHC	cis	rs6977660	1.000	rs6955510	chr7:19821333	G/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03263168	chr2:158732716	ACVR1	0.46	6.54	0.33	2.2e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.96	18.34	0.7	8.49e-53	Ewing sarcoma;
LIHC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.79	6.96	0.35	1.77e-11	Type 2 diabetes;
LIHC	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	11.06	0.51	1.69e-24	Platelet count;
LIHC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.38	5.8	0.3	1.54e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-7.66	-0.38	1.9e-13	Hepatocellular carcinoma;
LIHC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-6.25	-0.32	1.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.34	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg27205649	chr11:78285834	NARS2	-0.37	-5.79	-0.3	1.63e-8	Alzheimer's disease (survival time);
LIHC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.93	17.08	0.68	9.97e-48	Breast cancer;
LIHC	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.44	8.51	0.42	5.6e-16	Coronary artery disease;
LIHC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.82	-13.45	-0.59	2.22e-33	Colorectal cancer;
LIHC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.93	17.45	0.69	3.28e-49	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06874399	chr5:79704109	ZFYVE16	0.45	6.09	0.31	3.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs3814231	0.531	rs17090904	chr10:115476138	C/T	cg24846397	chr10:115438155	CASP7	-0.41	-6.83	-0.35	3.83e-11	Vitiligo;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.44	7.9	0.39	3.86e-14	Prudent dietary pattern;
LIHC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.66	-8.87	-0.43	3.99e-17	Coronary artery disease;
LIHC	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.48	6.02	0.31	4.48e-9	Plateletcrit;
LIHC	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.63	-0.38	2.31e-13	Prevalent atrial fibrillation;
LIHC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	14.65	0.62	4.81e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg12798992	chr6:167411361	FGFR1OP	0.49	7.27	0.37	2.49e-12	Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11769966	chr7:140396384	LOC100134713;NDUFB2	0.45	6.16	0.32	2.02e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12980942	0.810	rs35812313	chr19:41789178	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.58	7.06	0.36	9.13e-12	Coronary artery disease;
LIHC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.78	12.88	0.57	3.2e-31	Anterior chamber depth;
LIHC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.51	1.09e-24	Crohn's disease;
LIHC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.34	-6.17	-0.32	1.97e-9	Aortic root size;
LIHC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	15.36	0.64	7.3400000000000005e-41	Body mass index (adult);
LIHC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.51	0.33	2.68e-10	Bipolar disorder;
LIHC	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg20991723	chr1:152506922	NA	0.47	8.23	0.41	3.94e-15	Hair morphology;
LIHC	cis	rs3917254	0.509	rs13035227	chr2:102763837	T/C	cg22835712	chr2:102737379	NA	-0.5	-5.75	-0.3	1.94e-8	Blood protein levels;
LIHC	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.76	-8.55	-0.42	4.3e-16	Exhaled nitric oxide output;
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg19318889	chr4:1322082	MAEA	0.52	8.57	0.42	3.62e-16	Obesity-related traits;
LIHC	cis	rs9420	0.528	rs7102271	chr11:57396825	G/T	cg19752551	chr11:57585705	CTNND1	-0.45	-5.81	-0.3	1.4e-8	Schizophrenia;
LIHC	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg17507749	chr15:85114479	UBE2QP1	0.7	6.67	0.34	1.01e-10	Schizophrenia;
LIHC	trans	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	6.36	0.33	6.41e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-8.24	-0.41	3.82e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.82	0.69	1.01e-50	Smoking behavior;
LIHC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.62	10.31	0.49	6.98e-22	Platelet count;
LIHC	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.53	-8.08	-0.4	1.14e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	1.04	18.81	0.71	1.09e-54	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.65	10.42	0.49	2.84e-22	Lymphocyte counts;
LIHC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg11764359	chr7:65958608	NA	0.65	6.35	0.32	6.86e-10	Diabetic kidney disease;
LIHC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.56	7.17	0.36	4.76e-12	Parkinson's disease;
LIHC	cis	rs4742903	0.935	rs10820616	chr9:106945991	G/A	cg14250997	chr9:106856677	SMC2	0.36	5.94	0.31	7.02e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.98	0.35	1.51e-11	Axial length;
LIHC	cis	rs13161895	0.646	rs75894617	chr5:179499854	G/C	cg06664874	chr5:179499304	RNF130	0.69	7.35	0.37	1.47e-12	LDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04865659	chr15:90771840	SEMA4B	-0.45	-6.16	-0.32	2.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg10360323	chr17:41437877	NA	0.4	5.98	0.31	5.76e-9	Menopause (age at onset);
LIHC	cis	rs7780883	0.821	rs7789836	chr7:77060365	A/T	cg12876866	chr7:77025528	PION	-0.48	-5.82	-0.3	1.38e-8	Cervical cancer;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.65	-9.71	-0.46	7.46e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg18306943	chr3:40428807	ENTPD3	0.35	5.86	0.3	1.07e-8	Renal cell carcinoma;
LIHC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg03517284	chr6:25882590	NA	-0.38	-5.76	-0.3	1.83e-8	Height;
LIHC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg00343986	chr7:65444356	GUSB	-0.4	-5.98	-0.31	5.5e-9	Aortic root size;
LIHC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.94	15.71	0.65	2.93e-42	Cognitive ability;
LIHC	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.23	-6.44	-0.33	4.03e-10	Type 2 diabetes;
LIHC	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg27147174	chr7:100797783	AP1S1	-0.48	-7.12	-0.36	6.42e-12	Life satisfaction;
LIHC	cis	rs7192750	0.562	rs9889011	chr16:71987816	T/A	cg06353428	chr16:71660113	MARVELD3	0.77	8.89	0.43	3.46e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.15	0.52	7.79e-25	Colorectal cancer;
LIHC	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg11189052	chr15:85197271	WDR73	-0.4	-5.96	-0.31	6.45e-9	P wave terminal force;
LIHC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg20129853	chr10:51489980	NA	-0.39	-8.51	-0.42	5.5e-16	Prostate-specific antigen levels;
LIHC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.6	8.85	0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.18	-0.36	4.32e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.25e-19	Corneal astigmatism;
LIHC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	12.17	0.55	1.45e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7937890	0.559	rs10766184	chr11:14542577	A/G	cg02886208	chr11:14281011	SPON1	-0.44	-6.18	-0.32	1.82e-9	Mitochondrial DNA levels;
LIHC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg17764715	chr19:33622953	WDR88	0.53	7.06	0.36	9.43e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg12046867	chr14:103022105	NA	0.53	7.53	0.38	4.54e-13	Platelet count;
LIHC	trans	rs2096176	0.530	rs36024300	chr10:26303585	G/T	cg01396774	chr2:218299024	DIRC3	-0.31	-6.2	-0.32	1.58e-9	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.52	7.72	0.39	1.33e-13	Renal cell carcinoma;
LIHC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.69	11.69	0.53	8.71e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-15.08	-0.63	9.48e-40	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.7	-8.61	-0.42	2.69e-16	Mean platelet volume;
LIHC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-9.56	-0.46	2.48e-19	Arsenic metabolism;
LIHC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.45	-6.97	-0.35	1.61e-11	Blood metabolite levels;
LIHC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg12863693	chr15:85201151	NMB	0.41	5.83	0.3	1.31e-8	Schizophrenia;
LIHC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.42	0.33	4.54e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.3	0.37	2e-12	Parkinson's disease;
LIHC	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.43	-0.45	6.24e-19	Alzheimer's disease;
LIHC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	1.02e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs3812111	0.706	rs4946140	chr6:116477278	C/T	cg08036074	chr6:116424633	NT5DC1	-0.49	-8.33	-0.41	1.94e-15	Age-related macular degeneration;
LIHC	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.49	9.33	0.45	1.35e-18	Testicular germ cell tumor;
LIHC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.76	-8.33	-0.41	2.05e-15	Exhaled nitric oxide output;
LIHC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg03989125	chr22:38214979	NA	-0.44	-6.08	-0.31	3.23e-9	Glioblastoma;Glioma;
LIHC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.36	5.83	0.3	1.3e-8	Hematocrit;
LIHC	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg18192155	chr21:44258298	NA	0.44	6.22	0.32	1.42e-9	Information processing speed;
LIHC	cis	rs1403694	1.000	rs1656911	chr3:186439373	T/C	cg12454167	chr3:186435060	KNG1	0.29	7.09	0.36	7.92e-12	Blood protein levels;
LIHC	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg17927777	chr20:33865990	NA	0.52	6.27	0.32	1.08e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.94	-0.31	7.1e-9	Iron status biomarkers;
LIHC	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.45	-8.96	-0.44	2.12e-17	LDL cholesterol levels;
LIHC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.37	-0.56	2.56e-29	Alzheimer's disease;
LIHC	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	20.87	0.75	5.76e-63	Colorectal cancer;
LIHC	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-15.1	-0.63	7.57e-40	Body mass index;
LIHC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.14	0.4	7.46e-15	Response to antipsychotic treatment;
LIHC	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.59	7.48	0.38	6.22e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.35	0.41	1.75e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs9503598	0.502	rs17309827	chr6:3433318	A/C	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.82	-0.3	1.34e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.04	-0.48	5.96e-21	Platelet count;
LIHC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg10755058	chr3:40428713	ENTPD3	0.35	5.75	0.3	1.95e-8	Renal cell carcinoma;
LIHC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-7.72	-0.39	1.3e-13	Electrocardiographic conduction measures;
LIHC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.54	8.92	0.43	2.9e-17	Longevity;Endometriosis;
LIHC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-6.7	-0.34	8.78e-11	Schizophrenia;
LIHC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.63e-24	Primary sclerosing cholangitis;
LIHC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04530015	chr2:215796436	ABCA12	-0.39	-6.39	-0.33	5.58e-10	Neuroblastoma;
LIHC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg13647721	chr17:30228624	UTP6	0.69	6.72	0.34	7.39e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg22705602	chr4:152727874	NA	0.31	6.53	0.33	2.35e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs783540	0.900	rs783525	chr15:83284629	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.18	-0.32	1.87e-9	Schizophrenia;
LIHC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.57	-0.33	1.89e-10	Neuroticism;
LIHC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.66	8.3	0.41	2.5e-15	Mean platelet volume;
LIHC	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.66	-10.16	-0.48	2.21e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.55	8.85	0.43	4.83e-17	Body mass index;
LIHC	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg20607764	chr19:44506953	ZNF230	0.44	7.1	0.36	7.45e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg02640540	chr1:67518911	SLC35D1	0.44	6.01	0.31	4.67e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs9948	1.000	rs1320146	chr2:97507727	T/C	cg01990225	chr2:97406019	LMAN2L	-0.59	-6.04	-0.31	4.02e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.57	10.01	0.48	7.43e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.66	-9.25	-0.45	2.41e-18	Mean platelet volume;
LIHC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02359409	chr6:42947317	PEX6	-0.46	-6.09	-0.31	2.96e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg18306943	chr3:40428807	ENTPD3	0.35	6.09	0.31	3.1e-9	Renal cell carcinoma;
LIHC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	10.07	0.48	4.6e-21	Schizophrenia;
LIHC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg07959070	chr22:50026188	C22orf34	-0.3	-7.22	-0.36	3.33e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.92	0.3	7.85e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12744310	0.887	rs12026404	chr1:41801912	C/A	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.46	-6.24	-0.32	1.33e-9	Menopause (age at onset);
LIHC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00152838	chr16:24741724	TNRC6A	-0.53	-6.4	-0.33	4.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg08668510	chr10:1095578	IDI1	0.65	6.67	0.34	1.06e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.73	0.34	7.01e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02155528	chr15:90808716	NGRN	-0.44	-6.11	-0.31	2.67e-9	Migraine with aura;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg05223897	chr7:65842437	NCRNA00174	-0.36	-6.14	-0.32	2.35e-9	Migraine with aura;
LIHC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.82	0.39	6.72e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.46	8.5	0.42	6.04e-16	Gestational age at birth (maternal effect);
LIHC	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.49	7.73	0.39	1.25e-13	Diastolic blood pressure;
LIHC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.42	-0.37	9.26e-13	Psoriasis;
LIHC	trans	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg10756647	chr7:56101905	PSPH	1.08	13.21	0.58	1.84e-32	Diabetic kidney disease;
LIHC	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.53	7.54	0.38	4.36e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg14709524	chr16:89940631	TCF25	0.51	6.39	0.33	5.36e-10	Skin colour saturation;
LIHC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.72	-0.43	1.26e-16	Gut microbiome composition (summer);
LIHC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01765077	chr12:122356316	WDR66	0.54	8.42	0.41	1.06e-15	Mean corpuscular volume;
LIHC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.83	-0.3	1.29e-8	Colorectal cancer;
LIHC	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.54	7.06	0.36	9.48e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.51	6.28	0.32	1e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg17340655	chr8:38088874	DDHD2	-0.36	-6.06	-0.31	3.59e-9	Eotaxin levels;
LIHC	cis	rs2953174	0.529	rs3997219	chr2:241541619	T/C	cg07929629	chr2:241523174	NA	0.54	6.73	0.34	7.11e-11	Bipolar disorder;
LIHC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.4	-0.33	5.21e-10	Alzheimer's disease (late onset);
LIHC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg07636037	chr3:49044803	WDR6	-0.69	-7.47	-0.37	6.81e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.36	0.37	1.39e-12	Bipolar disorder;
LIHC	cis	rs4561483	0.551	rs1126889	chr16:12061910	C/G	cg08843971	chr16:11963173	GSPT1	-0.3	-6.11	-0.31	2.74e-9	Testicular germ cell tumor;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.26	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg06664874	chr5:179499304	RNF130	0.62	7.62	0.38	2.56e-13	LDL cholesterol;
LIHC	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.5	7.95	0.4	2.7e-14	Blood protein levels;
LIHC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	-0.53	-10.15	-0.48	2.55e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.76	-0.6	1.41e-34	Coffee consumption (cups per day);
LIHC	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.52	8.71	0.43	1.32e-16	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.44	0.53	6.8e-26	Alzheimer's disease (late onset);
LIHC	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.43	-8.85	-0.43	4.82e-17	Ulcerative colitis;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15573783	chr19:45927056	ERCC1	0.46	6.76	0.34	6.01e-11	Calcium levels;
LIHC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.31	5.74	0.3	2.14e-8	Diastolic blood pressure;
LIHC	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg07884673	chr3:53033167	SFMBT1	0.93	6.67	0.34	1.05e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.86	-0.3	1.09e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg03859395	chr2:55845619	SMEK2	-0.48	-7.47	-0.37	6.58e-13	Metabolic syndrome;
LIHC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.64	-8.21	-0.41	4.74e-15	Gut microbiome composition (summer);
LIHC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.44	7.87	0.39	4.84e-14	Platelet distribution width;
LIHC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.8	-18.05	-0.7	1.24e-51	Urate levels in lean individuals;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.42	0.33	4.5e-10	Renal cell carcinoma;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.54e-79	Prudent dietary pattern;
LIHC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.17	-0.36	4.69e-12	Response to antipsychotic treatment;
LIHC	trans	rs10411161	0.702	rs75647161	chr19:52398984	T/C	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	11.94	0.54	1.06e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-0.86	-9.39	-0.45	8.54e-19	Exhaled nitric oxide output;
LIHC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg08499158	chr17:42289980	UBTF	-0.48	-7.83	-0.39	6.36e-14	Total body bone mineral density;
LIHC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg26138144	chr22:38071188	LGALS1	0.76	14.22	0.61	2.25e-36	Fat distribution (HIV);
LIHC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.98	0.31	5.68e-9	Height;
LIHC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.98	0.51	3.15e-24	Personality dimensions;
LIHC	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.54	5.81	0.3	1.45e-8	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	9.15e-15	Prudent dietary pattern;
LIHC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg26695010	chr11:65641043	EFEMP2	0.44	6.02	0.31	4.44e-9	Eosinophil percentage of white cells;
LIHC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.68	12.58	0.56	4.34e-30	Coronary artery disease;
LIHC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.6	-8.72	-0.43	1.2e-16	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.52	0.53	3.63e-26	Alzheimer's disease;
LIHC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.43	7.16	0.36	4.85e-12	Red blood cell count;
LIHC	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.8	-14.62	-0.62	5.86e-38	Longevity;
LIHC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.39	6.21	0.32	1.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg17456097	chr1:26900765	RPS6KA1	0.43	6.2	0.32	1.64e-9	Glucose homeostasis traits;
LIHC	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg10381502	chr11:71823885	C11orf51	1.06	9.3	0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.75	0.3	1.97e-8	Morning vs. evening chronotype;
LIHC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.47	7.4	0.37	1.1e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg21724239	chr8:58056113	NA	0.45	6.01	0.31	4.68e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg13271783	chr10:134563150	INPP5A	-0.57	-6.8	-0.35	4.6e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-0.96	-22.18	-0.77	3.68e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.6	-11.64	-0.53	1.31e-26	Body mass index;
LIHC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.97	0.51	3.31e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.92	10.57	0.5	8.6e-23	IgG glycosylation;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg12432846	chr1:85741899	BCL10	-0.47	-6.51	-0.33	2.73e-10	Electroencephalogram traits;
LIHC	cis	rs10894308	0.543	rs7106928	chr11:130809259	T/G	cg12179176	chr11:130786555	SNX19	0.68	9.66	0.46	1.08e-19	Schizophrenia;
LIHC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-9.41	-0.45	7.51e-19	Prudent dietary pattern;
LIHC	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.29	0.32	9.96e-10	Rheumatoid arthritis;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg09143319	chr8:144997224	PLEC1	0.45	6.58	0.34	1.72e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-8.18	-0.4	5.75e-15	Hepatocellular carcinoma;
LIHC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg03037974	chr15:76606532	NA	0.74	14.68	0.62	3.61e-38	Blood metabolite levels;
LIHC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.9	10.77	0.5	1.76e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.46	-6.76	-0.34	6.13e-11	Diastolic blood pressure;
LIHC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.59	-8.34	-0.41	1.83e-15	Initial pursuit acceleration;
LIHC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.72	0.3	2.28e-8	Parkinson's disease;
LIHC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.64	-8.72	-0.43	1.22e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg22903471	chr2:27725779	GCKR	-0.43	-6.06	-0.31	3.54e-9	Blood metabolite levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg23640757	chr6:7889014	TXNDC5	0.37	6.24	0.32	1.3e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.71	-0.46	7.79e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.58	-8.61	-0.42	2.7e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23485639	chr6:28045615	ZNF165	0.44	5.74	0.3	2.08e-8	Depression;
LIHC	cis	rs16828019	0.704	rs4996176	chr1:41488168	G/T	cg03387723	chr1:41708464	SCMH1	-0.4	-6.27	-0.32	1.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.38	-0.37	1.2e-12	Bipolar disorder;
LIHC	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.96	-14.75	-0.62	1.93e-38	Mean platelet volume;
LIHC	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg15595755	chr5:1867978	NA	0.34	6.27	0.32	1.08e-9	Cardiovascular disease risk factors;
LIHC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.2	0.61	2.58e-36	Chronic sinus infection;
LIHC	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.18	-0.4	5.45e-15	Capecitabine sensitivity;
LIHC	cis	rs244293	0.831	rs12450607	chr17:53127255	C/G	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.45	0.37	7.89e-13	Menarche (age at onset);
LIHC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.03	0.31	4.21e-9	Educational attainment;
LIHC	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.11	0.48	3.31e-21	Hypertriglyceridemia;
LIHC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs7119038	0.818	rs73003215	chr11:118649512	G/A	cg19308663	chr11:118741387	NA	0.4	6.19	0.32	1.72e-9	Sjögren's syndrome;
LIHC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg21995068	chr20:25989032	LOC100134868	-0.51	-7.64	-0.38	2.25e-13	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.58	0.34	1.74e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg00792783	chr2:198669748	PLCL1	-0.45	-6.49	-0.33	3.1e-10	Intracranial aneurysm;
LIHC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-7.73	-0.39	1.2e-13	Neuroticism;
LIHC	cis	rs7617773	0.851	rs13068288	chr3:48331751	A/T	cg11946769	chr3:48343235	NME6	0.86	10.96	0.51	3.74e-24	Coronary artery disease;
LIHC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.71	9.3	0.45	1.76e-18	Gut microbiome composition (summer);
LIHC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	9.38	0.45	9.36e-19	Eosinophilic esophagitis;
LIHC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	0.99	13.54	0.59	1.01e-33	Cognitive function;
LIHC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.81	-12.44	-0.56	1.43e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-8.04	-0.4	1.47e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.82e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg08992911	chr2:238395768	MLPH	0.56	6.21	0.32	1.51e-9	Prostate cancer;
LIHC	cis	rs10792665	1.000	rs4944419	chr11:82646964	A/G	cg24227371	chr11:82718527	RAB30	0.31	6.95	0.35	1.9e-11	Obesity-related traits;
LIHC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.23	-7.31	-0.37	1.96e-12	Mean corpuscular volume;
LIHC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.26e-11	Ileal carcinoids;
LIHC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.64	11.01	0.51	2.46e-24	Colorectal cancer;
LIHC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.65	-7.48	-0.38	6.21e-13	Lymphocyte counts;
LIHC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.73	-9.61	-0.46	1.67e-19	Asthma;
LIHC	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-7.91	-0.39	3.51e-14	Homocysteine levels;
LIHC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.82	-8.77	-0.43	8.72e-17	Vitiligo;
LIHC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.56	0.53	2.65e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1881396	0.947	rs77350364	chr2:27866139	A/G	cg27432699	chr2:27873401	GPN1	0.51	7.87	0.39	4.73e-14	Nonalcoholic fatty liver disease;
LIHC	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.56	8.27	0.41	2.93e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg14828511	chr1:107599125	PRMT6	0.43	6.14	0.32	2.31e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.35	-6.52	-0.33	2.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs7116495	1.000	rs4945435	chr11:71759219	C/T	cg26138937	chr11:71823887	C11orf51	-0.76	-7.53	-0.38	4.68e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.63	11.06	0.51	1.62e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.88	-0.39	4.43e-14	Blood trace element (Zn levels);
LIHC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	8.78	0.43	8.03e-17	Coronary artery disease;
LIHC	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.17e-8	Pulmonary function;
LIHC	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg19683494	chr5:74908142	NA	-0.62	-8.8	-0.43	6.78e-17	Age-related disease endophenotypes;
LIHC	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	trans	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg15676719	chr1:167598521	RCSD1	-0.37	-6.51	-0.33	2.67e-10	Systemic lupus erythematosus;
LIHC	trans	rs2579103	0.767	rs2247166	chr12:90661266	C/T	cg00091569	chr3:40428383	ENTPD3	0.37	6.07	0.31	3.42e-9	Body mass index;
LIHC	cis	rs4517514	0.509	rs11018894	chr11:89904238	C/A	cg05041596	chr11:89867385	NAALAD2	0.42	6.77	0.34	5.49e-11	Trans fatty acid levels;
LIHC	cis	rs11671005	0.736	rs11668201	chr19:59003632	A/T	cg25952890	chr19:58913133	NA	0.61	6.3	0.32	9.37e-10	Mean platelet volume;
LIHC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.41	-12.24	-0.55	7.93e-29	Hip circumference adjusted for BMI;
LIHC	cis	rs3736485	0.844	rs8041197	chr15:51865877	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.31	-0.32	8.45e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.75	-12.11	-0.55	2.51e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.33	-0.32	7.86e-10	Height;
LIHC	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-6.04	-0.31	3.98e-9	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.61	8.84	0.43	5.28e-17	Prudent dietary pattern;
LIHC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.35	6.8	0.35	4.73e-11	HDL cholesterol levels;
LIHC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	8.73	0.43	1.15e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7129220	0.588	rs7129047	chr11:10143942	C/A	cg01453529	chr11:10209919	SBF2	-0.38	-6.71	-0.34	8.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.63	6.98	0.35	1.54e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-8.23	-0.41	3.95e-15	Menarche (age at onset);
LIHC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	11.22	0.52	4.54e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.46	-9.15	-0.44	5.13e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.07	0.31	3.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.58	10.3	0.49	7.48e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.18	0.32	1.87e-9	Rheumatoid arthritis;
LIHC	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	0.86	14.74	0.62	2.01e-38	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg11062466	chr8:58055876	NA	0.43	6.26	0.32	1.16e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.79	-0.34	4.84e-11	Self-reported allergy;
LIHC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.48	-0.33	3.15e-10	Type 2 diabetes;
LIHC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.63e-13	Bone mineral density;
LIHC	cis	rs7474896	1.000	rs61858629	chr10:38014770	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-6.29	-0.32	9.83e-10	Obesity (extreme);
LIHC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.52	7.83	0.39	6.05e-14	Obesity-related traits;
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.43	6.5	0.33	2.8e-10	Longevity;
LIHC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-1.0	-11.73	-0.54	6.22e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg26338869	chr17:61819248	STRADA	0.53	7.16	0.36	5.11e-12	Height;
LIHC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-1.02	-19.48	-0.73	2.17e-57	Breast cancer;
LIHC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-6.16	-0.32	2.06e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.08	13.09	0.58	4.97e-32	Vitiligo;
LIHC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg08847533	chr14:75593920	NEK9	-0.38	-6.42	-0.33	4.53e-10	Caffeine consumption;
LIHC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.54e-9	Aortic root size;
LIHC	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.19	25.49	0.81	4.62e-81	Schizophrenia;
LIHC	cis	rs12474201	0.569	rs13411633	chr2:46932666	A/G	cg06386533	chr2:46925753	SOCS5	0.5	5.99	0.31	5.32e-9	Height;
LIHC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.32	7.36	0.37	1.34e-12	Crohn's disease;
LIHC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg09182678	chr22:50328711	NA	-0.38	-5.86	-0.3	1.09e-8	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18450294	chr17:423235	VPS53	-0.42	-6.26	-0.32	1.18e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4407350	0.870	rs5764873	chr22:44908153	G/A	cg26276947	chr22:44892394	LDOC1L	0.35	6.79	0.34	4.92e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg18478394	chr8:109455254	TTC35	0.42	7.21	0.36	3.52e-12	Dupuytren's disease;
LIHC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.7	8.62	0.42	2.58e-16	Gut microbiome composition (summer);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21496518	chr3:15374154	SH3BP5	-0.44	-6.31	-0.32	8.77e-10	Hepatitis;
LIHC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.41	6.44	0.33	4.12e-10	Neutrophil percentage of white cells;
LIHC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.11	-0.61	6.26e-36	Alzheimer's disease;
LIHC	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.78	-11.1	-0.51	1.21e-24	Pediatric areal bone mineral density (radius);
LIHC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg20283391	chr11:68216788	NA	-0.38	-6.04	-0.31	4.12e-9	Total body bone mineral density;
LIHC	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.62	-7.9	-0.39	3.83e-14	Macular telangiectasia type 2;
LIHC	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.11	0.4	8.92e-15	Corneal astigmatism;
LIHC	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.91e-12	Growth-regulated protein alpha levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10964577	chr17:15160725	PMP22	0.46	6.31	0.32	8.65e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.58	10.36	0.49	4.62e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg20607798	chr8:58055168	NA	0.59	6.85	0.35	3.44e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.47	8.57	0.42	3.7e-16	Colorectal cancer;
LIHC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.44	-7.15	-0.36	5.36e-12	Menarche (age at onset);
LIHC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	14.6	0.62	7e-38	Lymphocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	trans	rs783540	0.867	rs11855735	chr15:83296545	A/T	cg18393722	chr15:85113863	UBE2QP1	0.36	6.17	0.32	1.88e-9	Schizophrenia;
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.55	9.36	0.45	1.07e-18	Calcium levels;
LIHC	cis	rs17106184	0.582	rs60848584	chr1:51010143	C/T	cg07174182	chr1:51127561	FAF1	-0.68	-7.06	-0.36	9.61e-12	Type 2 diabetes;
LIHC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-7.83	-0.39	6.27e-14	Initial pursuit acceleration;
LIHC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.67	10.92	0.51	5.2e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13047869	chr3:10149882	C3orf24	0.43	5.92	0.31	7.68e-9	Alzheimer's disease;
LIHC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.4	6.33	0.32	7.76e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.87	10.96	0.51	3.84e-24	Mean platelet volume;
LIHC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg04359351	chr2:3481828	TTC15	0.28	5.95	0.31	6.72e-9	Neurofibrillary tangles;
LIHC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg19338460	chr6:170058176	WDR27	-0.37	-5.76	-0.3	1.9e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs56146971	0.703	rs79190905	chr14:91848149	C/T	cg16433844	chr14:91963127	SMEK1	-0.56	-5.83	-0.3	1.25e-8	Alzheimer disease and age of onset;
LIHC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.63	-7.85	-0.39	5.38e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.56	10.32	0.49	6.24e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.72	0.3	2.3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05665937	chr4:1216051	CTBP1	0.44	5.79	0.3	1.62e-8	Obesity-related traits;
LIHC	cis	rs11991744	0.681	rs7387855	chr8:124665211	C/T	cg22342100	chr8:124666123	KLHL38	-0.39	-6.03	-0.31	4.37e-9	Electrocardiographic traits;
LIHC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.25	5.9	0.3	8.52e-9	Childhood ear infection;
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg00612595	chr21:47717864	NA	-0.38	-6.18	-0.32	1.87e-9	Testicular germ cell tumor;
LIHC	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg27433088	chr4:174089019	GALNT7	0.36	6.21	0.32	1.55e-9	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.53	8.11	0.4	8.97e-15	HDL cholesterol;
LIHC	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.29	0.32	9.72e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3820500	0.543	rs1290549	chr1:118051748	C/G	cg20383390	chr1:117909022	MAN1A2	-0.47	-6.01	-0.31	4.66e-9	Pneumonia;
LIHC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.45	7.39	0.37	1.13e-12	Height;
LIHC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.57	0.33	1.92e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.6	7.76	0.39	9.8e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18594562	chr20:57797677	ZNF831	0.48	6.38	0.33	5.69e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg00049323	chr5:472564	LOC25845	0.35	5.82	0.3	1.39e-8	Cystic fibrosis severity;
LIHC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.58	-8.6	-0.42	2.86e-16	Cerebrospinal P-tau181p levels;
LIHC	trans	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg10756647	chr7:56101905	PSPH	1.11	13.56	0.59	7.83e-34	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.22	0.45	3.03e-18	Hemoglobin concentration;
LIHC	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.26	-0.32	1.18e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs61542988	0.797	rs4329182	chr7:22882621	C/T	cg11367502	chr7:22862612	TOMM7	0.56	9.74	0.47	6.1e-20	Fibrinogen levels;
LIHC	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg27386326	chr11:61587980	NA	-0.69	-14.55	-0.62	1.17e-37	Trans fatty acid levels;
LIHC	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.08	0.51	1.4e-24	Coffee consumption (cups per day);
LIHC	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.5	-7.82	-0.39	6.65e-14	Schizophrenia;
LIHC	cis	rs867186	0.614	rs117065834	chr20:33426568	G/A	cg08999081	chr20:33150536	PIGU	0.63	5.94	0.31	6.97e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg00710249	chr16:2144849	PKD1	0.38	6.1	0.31	2.91e-9	Eotaxin levels;
LIHC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.54	8.58	0.42	3.38e-16	Height;
LIHC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.86	-14.95	-0.63	2.94e-39	Height;
LIHC	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg26138937	chr11:71823887	C11orf51	1.32	10.32	0.49	6.52e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.95	-0.4	2.69e-14	Migraine;Coronary artery disease;
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.56	9.33	0.45	1.34e-18	Aortic root size;
LIHC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.51	-0.46	3.55e-19	Gut microbiome composition (summer);
LIHC	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.8	-0.3	1.5e-8	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.49	-7.82	-0.39	6.78e-14	Dental caries;
LIHC	trans	rs7504990	0.708	rs35002729	chr18:50379832	C/T	cg08535148	chr4:26321143	RBPJ	0.56	6.9	0.35	2.5e-11	Gallbladder cancer;
LIHC	cis	rs12086130	0.892	rs72906818	chr1:51470403	T/G	cg07174182	chr1:51127561	FAF1	-0.82	-8.83	-0.43	5.69e-17	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.69	7.1	0.36	7.14e-12	Alzheimer's disease;
LIHC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.33	-0.49	5.89e-22	Coronary artery disease;
LIHC	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-8.73	-0.43	1.14e-16	Obesity-related traits;
LIHC	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.88	-10.29	-0.49	7.92e-22	Alzheimer's disease (late onset);
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg06951627	chr6:26196580	NA	0.53	6.34	0.32	7.09e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.29	0.52	2.45e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg03263716	chr11:64435066	NRXN2	0.34	7.23	0.36	3.1e-12	Body mass index;Urate levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22874627	chr3:31575329	STT3B	0.48	6.75	0.34	6.51e-11	Pancreatic cancer;
LIHC	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.45	6.29	0.32	9.54e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg01652190	chr22:50026171	C22orf34	-0.35	-7.69	-0.38	1.59e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg10664184	chr19:17420304	DDA1	0.46	5.88	0.3	9.65e-9	Systemic lupus erythematosus;
LIHC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.49	6.37	0.33	6.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-0.84	-9.5	-0.46	3.87e-19	Mitochondrial DNA levels;
LIHC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg10978503	chr1:24200527	CNR2	0.37	8.73	0.43	1.16e-16	Immature fraction of reticulocytes;
LIHC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	1.05	15.68	0.65	4e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg04374321	chr14:90722782	PSMC1	-0.48	-7.06	-0.36	9.55e-12	Mortality in heart failure;
LIHC	cis	rs61041384	0.661	rs74917517	chr12:123688805	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-6.14	-0.32	2.28e-9	Schizophrenia;
LIHC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.03	-0.31	4.35e-9	Arsenic metabolism;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.61e-14	Prudent dietary pattern;
LIHC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg11406765	chr11:980039	AP2A2	-0.35	-5.78	-0.3	1.69e-8	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.7	0.62	2.96e-38	Chronic sinus infection;
LIHC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.85	-11.31	-0.52	2.1e-25	Chronic sinus infection;
LIHC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.06	-0.36	9.19e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs244293	0.965	rs2628318	chr17:53210312	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.59	-10.11	-0.48	3.33e-21	Dupuytren's disease;
LIHC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg18357526	chr6:26021779	HIST1H4A	0.57	7.77	0.39	8.99e-14	Blood metabolite levels;
LIHC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg20283391	chr11:68216788	NA	-0.38	-6.1	-0.31	2.83e-9	Total body bone mineral density;
LIHC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.45e-18	Gut microbiome composition (summer);
LIHC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.5	7.34	0.37	1.59e-12	Obesity-related traits;
LIHC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.3	6.99	0.35	1.45e-11	Primary biliary cholangitis;
LIHC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.78	-10.1	-0.48	3.66e-21	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.51	-0.33	2.71e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7116495	0.786	rs10736784	chr11:71718911	T/A	cg26138937	chr11:71823887	C11orf51	-0.81	-8.15	-0.4	6.86e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg13395646	chr4:1353034	KIAA1530	-0.61	-9.06	-0.44	1.06e-17	Obesity-related traits;
LIHC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.4	-6.0	-0.31	5.11e-9	Heart rate;
LIHC	cis	rs1256061	0.624	rs944046	chr14:64700299	G/A	cg23250157	chr14:64679961	SYNE2	0.4	5.9	0.3	8.74e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.74	-8.25	-0.41	3.55e-15	Putamen volume;
LIHC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg25356066	chr3:128598488	ACAD9	0.55	7.66	0.38	1.9e-13	IgG glycosylation;
LIHC	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.6	-8.02	-0.4	1.66e-14	Economic and political preferences (feminism/equality);
LIHC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.61	-7.11	-0.36	6.99e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	6.57	0.33	1.86e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-13.22	-0.58	1.69e-32	Vitiligo;
LIHC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg25039879	chr17:56429692	SUPT4H1	0.75	8.37	0.41	1.55e-15	Cognitive test performance;
LIHC	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.61	-9.77	-0.47	4.81e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.32	-6.88	-0.35	2.86e-11	Longevity;
LIHC	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg16275483	chr1:110013120	SYPL2	-0.52	-6.54	-0.33	2.19e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.79	9.9	0.47	1.7e-20	Cognitive function;
LIHC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg07706471	chr12:123319906	HIP1R	-0.57	-7.55	-0.38	4.03e-13	Schizophrenia;
LIHC	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21023284	chr11:6624872	ILK;RRP8	-0.43	-6.22	-0.32	1.44e-9	Cognitive function;
LIHC	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	0.83	6.51	0.33	2.74e-10	LDL cholesterol;
LIHC	cis	rs10861342	1.000	rs11112359	chr12:105471661	C/A	cg23923672	chr12:105501055	KIAA1033	0.67	7.86	0.39	5.11e-14	IgG glycosylation;
LIHC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.63	0.5	5.3e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.19	0.36	4.12e-12	Diabetic kidney disease;
LIHC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.93	-14.85	-0.63	7.4e-39	Chronic sinus infection;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07089783	chr10:31607955	ZEB1;LOC220930	0.49	6.42	0.33	4.56e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.7	10.66	0.5	4.21e-23	Gastritis;
LIHC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.45	-0.37	7.83e-13	Tonsillectomy;
LIHC	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg20469991	chr17:27169893	C17orf63	-0.62	-6.48	-0.33	3.27e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.6	8.88	0.43	3.89e-17	Height;
LIHC	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.36	-0.37	1.35e-12	Bipolar disorder;
LIHC	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.44	6.38	0.33	5.61e-10	Hepatocellular carcinoma;
LIHC	cis	rs28493229	0.786	rs3745213	chr19:41248009	C/T	cg21869046	chr19:41225005	ITPKC	0.47	6.08	0.31	3.18e-9	Kawasaki disease;
LIHC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.53	-7.8	-0.39	7.78e-14	Total body bone mineral density;
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.49	-7.64	-0.38	2.18e-13	Testicular germ cell tumor;
LIHC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg12046867	chr14:103022105	NA	0.48	6.95	0.35	1.89e-11	Platelet count;
LIHC	cis	rs7635838	0.892	rs9870881	chr3:11447082	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.41	0.33	4.92e-10	HDL cholesterol;
LIHC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.29	-17.47	-0.69	2.78e-49	Diabetic kidney disease;
LIHC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.45	6.73	0.34	7.11e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	0.96	14.01	0.6	1.46e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.84	-11.36	-0.52	1.34e-25	Menopause (age at onset);
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.9	-0.35	2.57e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.58	8.51	0.42	5.55e-16	Recombination rate (females);
LIHC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg21466736	chr12:48725269	NA	0.33	5.95	0.31	6.81e-9	Plateletcrit;
LIHC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.66	7.91	0.39	3.52e-14	Iron status biomarkers;
LIHC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.4	0.45	8.31e-19	Bipolar disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17246714	chr3:55519186	WNT5A	0.49	6.67	0.34	1.05e-10	Lung function (FEV1/FVC);
LIHC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.44	5.81	0.3	1.44e-8	Obesity-related traits;
LIHC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.47	6.97	0.35	1.63e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg04865290	chr3:52927548	TMEM110	-0.57	-6.37	-0.33	6.22e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.05e-11	Alzheimer's disease;
LIHC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.86	-0.3	1.07e-8	Joint mobility (Beighton score);
LIHC	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.1	-0.31	2.91e-9	Tuberculosis;
LIHC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.79	0.47	4.2e-20	Morning vs. evening chronotype;
LIHC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.85	13.94	0.6	2.63e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.67	9.87	0.47	2.18e-20	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.76	10.14	0.48	2.76e-21	Schizophrenia;
LIHC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg03934865	chr2:198174659	NA	0.57	8.76	0.43	9.31e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs875971	0.545	rs801199	chr7:66025273	A/G	cg26939375	chr7:64535504	NA	-0.39	-6.2	-0.32	1.66e-9	Aortic root size;
LIHC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.37	-6.19	-0.32	1.7e-9	Blood metabolite levels;
LIHC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg10932868	chr11:921992	NA	0.36	6.61	0.34	1.52e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.18	26.67	0.82	1.47e-85	Schizophrenia;
LIHC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.47	-8.54	-0.42	4.6e-16	Colorectal cancer;
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.6	-0.38	2.85e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg13844804	chr7:814759	HEATR2	0.43	5.78	0.3	1.71e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.59	0.38	2.99e-13	Electroencephalogram traits;
LIHC	trans	rs10411161	0.702	rs17835311	chr19:52386781	A/C	cg22319618	chr22:45562946	NUP50	-0.62	-8.5	-0.42	6.04e-16	Breast cancer;
LIHC	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg23254163	chr1:152506842	NA	0.23	5.89	0.3	9.35e-9	Plantar warts;
LIHC	trans	rs6934970	0.929	rs12194950	chr6:113095306	G/C	cg09308777	chr6:169852575	NA	0.62	6.16	0.32	2.08e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9649465	0.967	rs768680	chr7:123364127	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-8.01	-0.4	1.82e-14	Migraine;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	10.7	0.5	3.14e-23	Lymphocyte counts;
LIHC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07305463	chr2:136567211	LCT	0.38	7.25	0.36	2.83e-12	Mosquito bite size;
LIHC	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.4	-6.01	-0.31	4.68e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.27	0.32	1.11e-9	Rheumatoid arthritis;
LIHC	cis	rs2710642	0.611	rs10172216	chr2:62869546	C/G	cg17519650	chr2:63277830	OTX1	0.52	7.52	0.38	4.73e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg11123440	chr8:11619852	NA	0.37	6.53	0.33	2.33e-10	Myopia (pathological);
LIHC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.71	-10.94	-0.51	4.45e-24	Corneal astigmatism;
LIHC	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg27170947	chr2:26402098	FAM59B	0.62	6.48	0.33	3.19e-10	Gut microbiome composition (summer);
LIHC	cis	rs2637266	0.655	rs846584	chr10:78495419	G/A	cg18941641	chr10:78392320	NA	0.28	6.09	0.31	3.12e-9	Pulmonary function;
LIHC	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg00792783	chr2:198669748	PLCL1	-0.43	-6.27	-0.32	1.09e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.41	-5.95	-0.31	6.48e-9	Narcolepsy;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg12176815	chr19:1979540	CSNK1G2	0.38	6.14	0.32	2.23e-9	Bipolar disorder;
LIHC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.18e-41	Mortality in heart failure;
LIHC	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.55	8.31	0.41	2.24e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.07	18.28	0.7	1.45e-52	Testicular germ cell tumor;
LIHC	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.78	-0.5	1.59e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.22	13.08	0.58	5.37e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.68	12.28	0.55	5.75e-29	Longevity;
LIHC	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.35	-0.32	6.98e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00794227	chr1:28696966	PHACTR4	0.44	6.33	0.32	7.76e-10	Lung function (FEV1/FVC);
LIHC	cis	rs61041384	0.661	rs7967118	chr12:123571503	C/G	cg25930673	chr12:123319894	HIP1R	0.64	5.82	0.3	1.33e-8	Schizophrenia;
LIHC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.91	15.22	0.64	2.61e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.43	7.17	0.36	4.55e-12	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg17675199	chr6:35436792	RPL10A	0.43	8.89	0.43	3.45e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.56	9.58	0.46	1.99e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.0	-0.7	1.99e-51	Height;
LIHC	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-12.19	-0.55	1.28e-28	Coffee consumption (cups per day);
LIHC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17554472	chr22:41940697	POLR3H	-0.56	-6.11	-0.31	2.77e-9	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04787407	chr4:99916511	METAP1	0.43	6.38	0.33	5.83e-10	Pancreatic cancer;
LIHC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.8	-11.23	-0.52	4.14e-25	IgG glycosylation;
LIHC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.43	-5.77	-0.3	1.74e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	12.24	0.55	8.44e-29	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.6	-8.6	-0.42	2.86e-16	Motion sickness;
LIHC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	0.94	17.03	0.68	1.55e-47	Coronary artery disease;
LIHC	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.85	0.35	3.49e-11	Systolic blood pressure;
LIHC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.67	9.77	0.47	4.62e-20	Lymphocyte counts;
LIHC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.96	-12.14	-0.55	1.87e-28	HIV-1 control;
LIHC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	5.97	0.31	5.8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.57	7.02	0.35	1.22e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.67	-7.29	-0.37	2.1e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-9.01	-0.44	1.46e-17	Blood metabolite levels;
LIHC	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	0.91	22.92	0.78	4.37e-71	Multiple myeloma;
LIHC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02187348	chr16:89574699	SPG7	0.53	7.87	0.39	4.62e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.4	6.47	0.33	3.45e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05949034	chr4:83295361	HNRNPD	-0.58	-7.11	-0.36	6.85e-12	Systolic blood pressure;
LIHC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg03146154	chr1:46216737	IPP	-0.46	-7.75	-0.39	1.09e-13	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	6.47	0.33	3.48e-10	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	7.68	0.38	1.74e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg16822855	chr3:40428330	ENTPD3	0.32	5.89	0.3	9.28e-9	Renal cell carcinoma;
LIHC	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-8.19	-0.41	5.14e-15	Hepatocellular carcinoma;
LIHC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26734620	chr12:56694298	CS	-1.02	-10.33	-0.49	5.91e-22	Psoriasis vulgaris;
LIHC	trans	rs2352908	1.000	rs6572530	chr14:49446168	C/T	cg16568472	chr20:3190600	ITPA	-0.45	-6.13	-0.31	2.41e-9	Social communication problems;
LIHC	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg27386326	chr11:61587980	NA	0.71	15.37	0.64	6.9e-41	Trans fatty acid levels;
LIHC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.59	-0.5	7.31e-23	Chronic sinus infection;
LIHC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg03037974	chr15:76606532	NA	-0.58	-9.57	-0.46	2.14e-19	Blood metabolite levels;
LIHC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.97	-0.47	1e-20	Response to antipsychotic treatment;
LIHC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.33	-8.23	-0.41	4.08e-15	Longevity;Endometriosis;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.52	-6.79	-0.34	5.03e-11	Menopause (age at onset);
LIHC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-7.15	-0.36	5.35e-12	Monocyte percentage of white cells;
LIHC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.62	12.91	0.57	2.47e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.9	10.53	0.49	1.23e-22	Prostate cancer;
LIHC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	cis	rs7312774	0.618	rs726943	chr12:107331647	A/G	cg16260113	chr12:107380972	MTERFD3	0.84	11.09	0.51	1.28e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs249954	0.512	rs703769	chr16:23654509	T/G	cg05131483	chr16:23706242	ERN2	0.37	5.94	0.31	7.05e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs1814175	0.588	rs4076322	chr11:49745094	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	1.94e-11	Height;
LIHC	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	8.56	0.42	3.8e-16	Eosinophil percentage of white cells;
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.81	-0.5	1.3e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.67	9.82	0.47	3.33e-20	Testicular germ cell tumor;
LIHC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.38	6.04	0.31	4.09e-9	Menopause (age at onset);
LIHC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.67	10.22	0.48	1.45e-21	Response to diuretic therapy;
LIHC	cis	rs2569991	0.891	rs361224	chr3:12922313	C/T	cg07263372	chr3:12940286	IQSEC1	-0.34	-5.75	-0.3	2.03e-8	Periodontitis (DPAL);
LIHC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.32	5.78	0.3	1.65e-8	Pancreatic cancer;
LIHC	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.83	14.96	0.63	2.72e-39	Monocyte count;
LIHC	trans	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg10756647	chr7:56101905	PSPH	1.11	13.27	0.58	1.06e-32	Diabetic kidney disease;
LIHC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg09417038	chr21:47716443	C21orf57	0.55	8.37	0.41	1.45e-15	Testicular germ cell tumor;
LIHC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.8e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg23262073	chr20:60523788	NA	-0.29	-5.94	-0.31	6.89e-9	Body mass index;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01171360	chr6:293285	DUSP22	-0.47	-6.82	-0.35	4.08e-11	Menopause (age at onset);
LIHC	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.63	-0.42	2.28e-16	Waist circumference;Body mass index;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.64	9.67	0.46	1.06e-19	Renal cell carcinoma;
LIHC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.83	-0.47	2.99e-20	Schizophrenia;
LIHC	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.53	-8.92	-0.43	2.95e-17	Height;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11673344	0.864	rs7256213	chr19:37511491	T/C	cg27390819	chr19:37464633	NA	-0.51	-6.21	-0.32	1.57e-9	Obesity-related traits;
LIHC	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.42	8.19	0.41	5.14e-15	Testicular germ cell tumor;
LIHC	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-8.16	-0.4	6.51e-15	Body mass index;
LIHC	trans	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21659725	chr3:3221576	CRBN	0.68	10.57	0.5	8.75e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.42	-7.34	-0.37	1.6e-12	Platelet distribution width;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg27417846	chr2:88927289	EIF2AK3	-0.39	-6.06	-0.31	3.63e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg04306507	chr14:55594613	LGALS3	0.33	6.37	0.33	6.21e-10	Protein biomarker;
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.77	-13.32	-0.58	6.54e-33	Bipolar disorder and schizophrenia;
LIHC	cis	rs4834770	1.000	rs1397613	chr4:120242929	G/T	cg09307838	chr4:120376055	NA	0.43	6.5	0.33	2.87e-10	Blood protein levels;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.7	-11.47	-0.53	5.26e-26	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2710642	0.611	rs1843779	chr2:62866762	T/C	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.79	6.82	0.35	4.05e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.39	5.72	0.3	2.35e-8	Life satisfaction;
LIHC	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	trans	rs916888	0.821	rs199499	chr17:44865498	C/T	cg22968622	chr17:43663579	NA	1.24	11.45	0.53	6.4e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12493885	0.725	rs4680113	chr3:153727337	C/T	cg10247383	chr3:153839028	SGEF	0.65	5.97	0.31	5.93e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	17.9	0.7	4.78e-51	Smoking behavior;
LIHC	cis	rs918629	0.563	rs3777188	chr5:95254502	A/G	cg10483112	chr5:95245456	ELL2	-0.35	-6.48	-0.33	3.12e-10	IgG glycosylation;
LIHC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg12863693	chr15:85201151	NMB	0.44	6.02	0.31	4.62e-9	Schizophrenia;
LIHC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.77	-0.3	1.82e-8	Alzheimer's disease (late onset);
LIHC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.6	-0.59	5.55e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.5	-0.42	5.91e-16	Vitamin D levels;
LIHC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.47	6.31	0.32	8.77e-10	Major depressive disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24631450	chr2:234262952	DGKD	0.45	6.22	0.32	1.47e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.54	-6.65	-0.34	1.18e-10	Menarche (age at onset);
LIHC	cis	rs6442522	0.809	rs12494163	chr3:15423834	A/G	cg16303742	chr3:15540471	COLQ	0.37	6.04	0.31	4.09e-9	Uric acid levels;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.42	-5.82	-0.3	1.34e-8	Total body bone mineral density;
LIHC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.57	-9.67	-0.46	1.07e-19	Bipolar disorder;
LIHC	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.4	6.32	0.32	8.31e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.22	-0.32	1.49e-9	Diastolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04844971	chr15:50979486	TRPM7	0.48	7.71	0.38	1.38e-13	Cognitive function;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14992232	chr1:20811153	CAMK2N1	0.41	6.08	0.31	3.18e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01809819	chr1:31192165	MATN1	0.45	6.86	0.35	3.19e-11	Pancreatic cancer;
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12516959	chr21:47718080	NA	-0.36	-5.8	-0.3	1.48e-8	Testicular germ cell tumor;
LIHC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.68	-11.27	-0.52	2.86e-25	Inflammatory bowel disease;
LIHC	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.81	-0.3	1.41e-8	Arsenic metabolism;
LIHC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02980000	chr4:1222292	CTBP1	-0.55	-7.9	-0.39	3.77e-14	Obesity-related traits;
LIHC	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.71	-6.47	-0.33	3.42e-10	Obesity;Body mass index;
LIHC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg22961513	chr11:14280813	SPON1	-0.46	-7.24	-0.36	3e-12	Mitochondrial DNA levels;
LIHC	cis	rs7534824	0.625	rs6686202	chr1:101493078	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.73	7.28	0.37	2.36e-12	Refractive astigmatism;
LIHC	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14396892	chr9:96623032	NA	-0.31	-6.14	-0.32	2.23e-9	DNA methylation (variation);
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg24693881	chr1:107596107	NA	-0.54	-9.39	-0.45	8.42e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg02290350	chr8:58132656	NA	0.39	7.6	0.38	2.95e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.32	6.17	0.32	1.9e-9	Cancer;
LIHC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.48	7.47	0.37	6.75e-13	Systemic lupus erythematosus;
LIHC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.45	0.33	3.82e-10	Schizophrenia;
LIHC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.03e-32	Psoriasis;
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.43	5.89	0.3	9.26e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.13	-0.31	2.48e-9	Total body bone mineral density;
LIHC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.48	6.23	0.32	1.4e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.33	-7.25	-0.36	2.82e-12	Ulcerative colitis;
LIHC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.41	-6.3	-0.32	9.11e-10	HDL cholesterol;
LIHC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.75e-10	Uric acid levels;
LIHC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.48	9.63	0.46	1.44e-19	Tonsillectomy;
LIHC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	6.16	0.32	2.06e-9	Bipolar disorder;
LIHC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.37	-5.71	-0.3	2.44e-8	Lung cancer;
LIHC	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.86	0.43	4.37e-17	Exhaled nitric oxide levels;
LIHC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.39	0.33	5.3e-10	Cognitive test performance;
LIHC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.95	-12.64	-0.56	2.48e-30	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24084363	chr13:45992551	SLC25A30	0.42	6.05	0.31	3.84e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18850918	chr19:18633063	ELL	0.4	6.03	0.31	4.14e-9	Cognitive function;
LIHC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg20140201	chr2:241835670	C2orf54	-0.47	-6.47	-0.33	3.31e-10	Urinary metabolites;
LIHC	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg00601450	chr5:74908170	NA	0.48	6.47	0.33	3.31e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.66	0.5	4.1000000000000003e-23	Colorectal cancer;
LIHC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg11204139	chr17:3907470	NA	0.59	6.89	0.35	2.72e-11	Type 2 diabetes;
LIHC	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.73	-8.31	-0.41	2.21e-15	Lymphocyte percentage of white cells;
LIHC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.88	-0.3	9.64e-9	Subjective well-being;
LIHC	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg20129853	chr10:51489980	NA	0.4	8.57	0.42	3.7e-16	Prostate-specific antigen levels;
LIHC	cis	rs4716602	0.596	rs4490714	chr7:156162510	C/A	cg16983916	chr7:156159713	NA	-0.34	-5.95	-0.31	6.58e-9	Anti-saccade response;
LIHC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg21573476	chr21:45109991	RRP1B	-0.54	-10.29	-0.49	8.03e-22	Mean corpuscular volume;
LIHC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	0.82	9.3	0.45	1.69e-18	Opioid sensitivity;
LIHC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.06	-13.52	-0.59	1.14e-33	Primary sclerosing cholangitis;
LIHC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg04719120	chr6:96025338	MANEA	0.49	6.06	0.31	3.63e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.4	5.89	0.3	9.18e-9	Longevity;
LIHC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.51	-7.9	-0.39	3.74e-14	Crohn's disease;
LIHC	cis	rs8067354	0.574	rs7219089	chr17:58032865	C/T	cg02344993	chr17:57696989	CLTC	0.65	10.28	0.49	8.95e-22	Hemoglobin concentration;
LIHC	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.49	-0.33	3.05e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg21123203	chr4:15471301	CC2D2A	0.47	7.57	0.38	3.41e-13	Obesity-related traits;
LIHC	cis	rs9596863	1.000	rs7995218	chr13:54427874	C/G	ch.13.53330881F	chr13:54432880	NA	0.45	5.88	0.3	9.55e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.57	-6.35	-0.32	6.83e-10	Axial length;
LIHC	cis	rs1355223	0.902	rs1539251	chr11:34742772	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.94	13.39	0.59	3.54e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.2	15.24	0.64	2.21e-40	Alzheimer's disease (late onset);
LIHC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.52	7.09	0.36	7.61e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.65	-9.79	-0.47	4.25e-20	Parkinson's disease;
LIHC	cis	rs11958404	0.517	rs35714701	chr5:157302862	T/C	cg05962755	chr5:157440814	NA	0.76	7.35	0.37	1.51e-12	IgG glycosylation;
LIHC	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-8.03	-0.4	1.58e-14	Hepatocellular carcinoma;
LIHC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.83	-12.64	-0.56	2.6e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs59698941	0.825	rs4705974	chr5:132198942	C/T	cg02081065	chr5:132209139	LEAP2	0.27	6.11	0.31	2.69e-9	Apolipoprotein A-IV levels;
LIHC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.85	8.06	0.4	1.32e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	6.89	0.35	2.62e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7503168	1.000	rs7503168	chr17:33885904	A/G	cg20932281	chr17:33905541	PEX12	0.57	7.34	0.37	1.6e-12	Plateletcrit;
LIHC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.32	-8.06	-0.4	1.32e-14	Gut microbiome composition (winter);
LIHC	cis	rs4742903	0.935	rs1450681	chr9:106932435	A/G	cg14250997	chr9:106856677	SMC2	0.35	5.93	0.31	7.38e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.54	5.8	0.3	1.48e-8	Menopause (age at onset);
LIHC	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.56	-13.8	-0.6	9.24e-35	White blood cell count (basophil);
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.65	9.88	0.47	1.98e-20	Menarche (age at onset);
LIHC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg19682013	chr15:45996608	NA	0.4	6.9	0.35	2.58e-11	Waist circumference;Weight;
LIHC	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.73	0.3	2.16e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4908768	0.539	rs1381928	chr1:8690933	G/A	cg20416874	chr1:8611966	RERE	-0.64	-12.53	-0.56	6.67e-30	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.44	8.19	0.4	5.24e-15	Prudent dietary pattern;
LIHC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg22676075	chr6:135203613	NA	0.39	6.33	0.32	7.87e-10	Red blood cell count;
LIHC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	8.92	0.43	2.83e-17	Menarche (age at onset);
LIHC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.49	-6.96	-0.35	1.7e-11	Height;
LIHC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.95	0.31	6.67e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	8.67	0.42	1.78e-16	Total cholesterol levels;
LIHC	cis	rs11229555	0.645	rs12800531	chr11:58180099	C/T	cg15696309	chr11:58395628	NA	-0.66	-7.76	-0.39	1.02e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.56	8.5	0.42	5.79e-16	Resting heart rate;
LIHC	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg02038173	chr21:34852701	TMEM50B	0.48	6.06	0.31	3.66e-9	Morning vs. evening chronotype;
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg20090690	chr10:134436459	INPP5A	0.42	5.89	0.3	9.36e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.66	9.34	0.45	1.28e-18	Schizophrenia;
LIHC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.45	6.19	0.32	1.69e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg16070018	chr6:26224392	HIST1H3E	0.56	6.67	0.34	1.06e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.63	-10.35	-0.49	5.09e-22	Crohn's disease;
LIHC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg14067834	chr17:29058358	SUZ12P	0.68	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	11.26	0.52	3.14e-25	Myopia (pathological);
LIHC	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg08992911	chr2:238395768	MLPH	0.54	6.03	0.31	4.14e-9	Prostate cancer;
LIHC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.96	22.23	0.77	2.2e-68	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7684446	1	rs7684446	chr4:15592864	C/T	cg21329975	chr4:15471214	CC2D2A	0.37	5.96	0.31	6.35e-9	Red blood cell count;
LIHC	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.54	-0.33	2.31e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.967	rs610452	chr8:109188263	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.67	-9.86	-0.47	2.44e-20	Coronary artery disease;
LIHC	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.51	8.68	0.42	1.69e-16	Blood metabolite levels;
LIHC	cis	rs7106204	0.686	rs12803558	chr11:24288205	C/A	ch.11.24196551F	chr11:24239977	NA	0.69	6.42	0.33	4.64e-10	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg19752551	chr11:57585705	CTNND1	0.51	7.25	0.37	2.72e-12	Schizophrenia;
LIHC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.63	8.15	0.4	6.95e-15	Morning vs. evening chronotype;
LIHC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.55	-6.65	-0.34	1.17e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.37	-7.02	-0.36	1.17e-11	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.91	15.63	0.65	5.94e-42	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.6	0.34	1.56e-10	Sudden cardiac arrest;
LIHC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.54	7.19	0.36	3.98e-12	Body mass index;
LIHC	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.38	-7.59	-0.38	3.09e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs7487075	0.619	rs10880970	chr12:46830420	A/G	cg23829395	chr12:46796953	NA	0.34	6.05	0.31	3.81e-9	Itch intensity from mosquito bite;
LIHC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-7.83	-0.39	6.27e-14	Initial pursuit acceleration;
LIHC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.59	10.31	0.49	6.87e-22	Mean corpuscular volume;
LIHC	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg08738300	chr3:44038990	NA	0.36	6.27	0.32	1.08e-9	Coronary artery disease;
LIHC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg20384732	chr3:195601375	TNK2	0.36	5.73	0.3	2.21e-8	Pancreatic cancer;
LIHC	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg12560992	chr17:57184187	TRIM37	0.71	9.19	0.45	3.87e-18	Vitamin D levels;
LIHC	cis	rs7116495	0.881	rs7128974	chr11:71677032	C/G	cg26138937	chr11:71823887	C11orf51	0.83	8.19	0.41	5.11e-15	Severe influenza A (H1N1) infection;
LIHC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.91	16.8	0.67	1.33e-46	Menopause (age at onset);
LIHC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.37	-0.37	1.28e-12	Aortic root size;
LIHC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg22633049	chr21:46681294	NA	-0.42	-7.56	-0.38	3.85e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18712231	chr3:57903821	SLMAP	-0.29	-6.76	-0.34	5.88e-11	Calcium levels;
LIHC	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.48	8.02	0.4	1.66e-14	Blood metabolite levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11490961	chr3:123418713	MYLK	0.39	6.53	0.33	2.38e-10	Bilirubin levels;
LIHC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.79	0.54	3.82e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	7.52	0.38	4.97e-13	Systemic lupus erythematosus;
LIHC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg02527881	chr3:46936655	PTH1R	0.31	6.08	0.31	3.23e-9	Colorectal cancer;
LIHC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-13.35	-0.59	5.14e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg04610667	chr7:75704037	NA	-0.35	-6.21	-0.32	1.54e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.31	4.25e-9	Heart rate;
LIHC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.55	-8.3	-0.41	2.36e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3106136	0.843	rs4282187	chr4:95273145	T/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.27	0.37	2.44e-12	Capecitabine sensitivity;
LIHC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.46	-0.37	7.4e-13	Height;
LIHC	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.54	10.33	0.49	5.84e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.71	-0.3	2.41e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.34e-9	Aortic root size;
LIHC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.22	0.36	3.35e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	trans	rs4342066	0.736	rs35374336	chr3:28371399	T/G	cg11103623	chr3:57235255	HESX1	-0.37	-6.04	-0.31	4.03e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.45	6.18	0.32	1.85e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2274273	0.840	rs10150760	chr14:55821548	C/T	cg01864836	chr14:55583639	NA	0.38	6.67	0.34	1.05e-10	Protein biomarker;
LIHC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.84	7.52	0.38	4.8e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	7.31	0.37	1.87e-12	Personality dimensions;
LIHC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.46	6.48	0.33	3.17e-10	Schizophrenia;
LIHC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.1e-8	Blood metabolite levels;
LIHC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.41	7.48	0.37	6.42e-13	Electrocardiographic conduction measures;
LIHC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.44	-7.77	-0.39	9.28e-14	Alzheimer's disease (late onset);
LIHC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.52	0.49	1.28e-22	Total body bone mineral density;
LIHC	cis	rs17125944	0.686	rs12884504	chr14:53360494	G/A	cg00686598	chr14:53173677	PSMC6	-0.8	-8.91	-0.43	3.18e-17	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.69	10.98	0.51	3.03e-24	Response to diuretic therapy;
LIHC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.55	-0.33	2.05e-10	Total body bone mineral density;
LIHC	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	8.76	0.43	9.08e-17	Height;
LIHC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg00204512	chr16:28754710	NA	0.41	7.18	0.36	4.49e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg25251204	chr11:14927456	NA	0.42	6.0	0.31	5.12e-9	Vitamin D levels;
LIHC	cis	rs2274273	1.000	rs67805055	chr14:55587552	C/T	cg01864836	chr14:55583639	NA	-0.36	-6.1	-0.31	2.79e-9	Protein biomarker;
LIHC	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.59	-0.42	3.07e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.9	-0.3	8.7e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs3118233	1	rs3118233	chr16:68733646	G/C	cg01231543	chr16:68741748	NA	0.37	5.85	0.3	1.15e-8	Red cell distribution width;
LIHC	cis	rs2607426	0.681	rs79361456	chr19:41240363	A/C	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.52	-6.18	-0.32	1.78e-9	Blood protein levels;
LIHC	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.33	8.22	0.41	4.28e-15	Schizophrenia;
LIHC	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.28	0.49	8.73e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.54	-6.88	-0.35	2.9100000000000002e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2637030	0.559	rs256095	chr5:52972669	C/T	cg06476337	chr5:52856530	NDUFS4	-0.4	-6.56	-0.33	1.98e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg05110241	chr16:68378359	PRMT7	-0.48	-5.83	-0.3	1.27e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.61	-9.47	-0.46	4.93e-19	Lung cancer;
LIHC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	12.01	0.54	5.93e-28	Electrocardiographic conduction measures;
LIHC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.46	6.48	0.33	3.29e-10	HDL cholesterol;HDL cholesterol levels;
LIHC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.73	-13.5	-0.59	1.32e-33	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01181084	chr8:43059863	NA	-0.43	-6.22	-0.32	1.47e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.48	-0.37	6.4e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07550334	chr14:75518271	MLH3	0.46	6.11	0.31	2.67e-9	Lung function (FEV1/FVC);
LIHC	cis	rs12220238	0.841	rs11001001	chr10:76097678	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.27	0.32	1.07e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.79	12.07	0.55	3.43e-28	Total body bone mineral density;
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02359409	chr6:42947317	PEX6	-0.47	-6.67	-0.34	1.03e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.43	-7.37	-0.37	1.31e-12	Aortic root size;
LIHC	cis	rs965469	0.696	rs6037570	chr20:3334292	C/A	cg25506879	chr20:3388711	C20orf194	-0.55	-6.44	-0.33	3.99e-10	IFN-related cytopenia;
LIHC	cis	rs77633900	0.772	rs284898	chr15:76750695	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-6.01	-0.31	4.72e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.55	10.57	0.5	8.74e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg18964960	chr10:1102726	WDR37	-0.51	-6.59	-0.34	1.62e-10	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg12437481	chr16:420112	MRPL28	-0.62	-8.34	-0.41	1.83e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.92	-0.65	4.52e-43	Chronic sinus infection;
LIHC	cis	rs16944613	0.541	rs6496690	chr15:91097401	T/C	cg26821196	chr15:91095069	CRTC3	0.47	8.04	0.4	1.47e-14	Colorectal cancer;
LIHC	cis	rs6442522	1.000	rs11918807	chr3:15446277	C/T	cg16303742	chr3:15540471	COLQ	0.41	6.94	0.35	1.93e-11	Uric acid levels;
LIHC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.14	-0.32	2.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.58	0.34	1.76e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.4	-5.78	-0.3	1.72e-8	Red blood cell traits;
LIHC	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.02	-0.31	4.48e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.97	-0.31	5.89e-9	Fear of minor pain;
LIHC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg00071026	chr13:113650936	MCF2L	-0.38	-5.93	-0.31	7.3e-9	Systolic blood pressure;
LIHC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.69	12.44	0.56	1.41e-29	Iron status biomarkers;
LIHC	cis	rs1144333	0.655	rs4949682	chr1:76443196	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.17	-0.32	1.93e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12980942	0.872	rs3752705	chr19:41798111	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.3	0.32	9.22e-10	Coronary artery disease;
LIHC	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg20991723	chr1:152506922	NA	0.5	8.45	0.42	8.79e-16	Hair morphology;
LIHC	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.49	-8.05	-0.4	1.42e-14	Blood metabolite levels;
LIHC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.72	8.47	0.42	7.35e-16	Dental caries;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02664216	chr12:19592651	AEBP2	0.42	6.54	0.33	2.18e-10	Cognitive function;
LIHC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.71	0.3	2.43e-8	Lung function (FEV1/FVC);
LIHC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.53	9.26	0.45	2.4e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg02070205	chr10:30722105	MAP3K8	-0.43	-5.77	-0.3	1.75e-8	Inflammatory bowel disease;
LIHC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.52	-7.69	-0.38	1.62e-13	Facial morphology (factor 19);
LIHC	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg20933634	chr6:27740509	NA	0.46	6.04	0.31	4.06e-9	Parkinson's disease;
LIHC	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.64	-10.56	-0.5	9.85e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.48	0.53	4.87e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12463550	chr7:65579703	CRCP	0.67	7.18	0.36	4.48e-12	Diabetic kidney disease;
LIHC	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.87	0.35	3.06e-11	Diastolic blood pressure;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg00958676	chr8:9911641	MSRA	-0.62	-6.39	-0.33	5.49e-10	Obesity-related traits;
LIHC	trans	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg01596870	chr19:55963115	NA	-0.63	-8.16	-0.4	6.49e-15	Obesity-related traits;
LIHC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.53	8.55	0.42	4.03e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg20636351	chr8:55087400	NA	-0.34	-7.1	-0.36	7.46e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.34	6.63	0.34	1.32e-10	Renal cell carcinoma;
LIHC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.23	6.13	0.31	2.39e-9	Calcium levels;
LIHC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.85	-0.35	3.46e-11	Morning vs. evening chronotype;
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.73	10.37	0.49	4.46e-22	Menarche (age at onset);
LIHC	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.7	11.62	0.53	1.51e-26	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs1914816	0.887	rs2460155	chr15:76478925	C/T	cg03037974	chr15:76606532	NA	-0.6	-5.96	-0.31	6.25e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.47	6.78	0.34	5.15e-11	Longevity;Endometriosis;
LIHC	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg04865290	chr3:52927548	TMEM110	-0.42	-6.34	-0.32	7.28e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg25894440	chr7:65020034	NA	-0.52	-6.12	-0.31	2.54e-9	Diabetic kidney disease;
LIHC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg18867708	chr6:26865862	GUSBL1	-0.52	-7.96	-0.4	2.57e-14	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21448741	chr8:58168803	NA	0.35	6.09	0.31	3.02e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.66	11.67	0.53	9.94e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.44	-6.23	-0.32	1.36e-9	Systemic sclerosis;
LIHC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.51	8.28	0.41	2.74e-15	Height;
LIHC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs6669384	0.723	rs4844395	chr1:208037967	A/G	cg22525895	chr1:207977042	MIR29B2	0.56	6.23	0.32	1.34e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	cis	rs17106184	1.000	rs72898961	chr1:50966976	G/A	cg07174182	chr1:51127561	FAF1	-0.64	-6.75	-0.34	6.45e-11	Type 2 diabetes;
LIHC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-6.14	-0.32	2.25e-9	Body mass index;
LIHC	cis	rs36051895	0.623	rs2181115	chr9:5263058	G/A	cg02405213	chr9:5042618	JAK2	-0.64	-10.23	-0.48	1.31e-21	Pediatric autoimmune diseases;
LIHC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.31	-10.19	-0.48	1.83e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.4	0.37	1.06e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs16858210	0.874	rs35717944	chr3:183607361	C/A	cg25686905	chr3:183603175	PARL	-0.5	-9.32	-0.45	1.45e-18	Menopause (age at onset);
LIHC	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.4	-6.68	-0.34	9.54e-11	Endometrial cancer;
LIHC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.86	-13.81	-0.6	8.62e-35	Schizophrenia;
LIHC	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.7	9.85	0.47	2.5e-20	Lymphocyte counts;
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08219700	chr8:58056026	NA	0.52	6.29	0.32	9.5e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.22	-0.32	1.49e-9	Diastolic blood pressure;
LIHC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	12.18	0.55	1.31e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.4	-5.79	-0.3	1.6e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.86	15.56	0.64	1.14e-41	Body mass index;
LIHC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.58	11.25	0.52	3.55e-25	Coronary artery disease;
LIHC	cis	rs61677309	1.000	rs56346212	chr11:118172342	T/A	cg06090739	chr11:118230722	UBE4A	0.34	6.32	0.32	7.96e-10	Lung cancer in ever smokers;
LIHC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg01200585	chr1:228362443	C1orf69	0.49	6.24	0.32	1.26e-9	Diastolic blood pressure;
LIHC	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	0.67	7.42	0.37	9.41e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs12744310	1.000	rs34027267	chr1:41756677	T/C	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.82e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg20016023	chr10:99160130	RRP12	-0.41	-6.48	-0.33	3.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.69	9.98	0.47	9.63e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.1	0.44	7.65e-18	Coffee consumption (cups per day);
LIHC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.64	-8.21	-0.41	4.74e-15	Gut microbiome composition (summer);
LIHC	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	8.63	0.42	2.39e-16	Diastolic blood pressure;
LIHC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg27478167	chr7:817139	HEATR2	-0.51	-6.81	-0.35	4.52e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.45	7.81	0.39	7.32e-14	Total body bone mineral density;
LIHC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.89	-19.76	-0.73	1.55e-58	Height;
LIHC	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.39	0.33	5.27e-10	Ileal carcinoids;
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg01646665	chr1:156251436	TMEM79;SMG5	0.3	5.8	0.3	1.5e-8	Tonsillectomy;
LIHC	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg02580895	chr19:2754563	NA	-0.41	-6.04	-0.31	3.96e-9	Total cholesterol levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27010136	chr7:1131122	GPER;C7orf50	-0.39	-6.22	-0.32	1.48e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.55	-8.46	-0.42	8.04e-16	Blood protein levels;
LIHC	cis	rs7212590	0.655	rs8070039	chr17:57973585	G/C	cg10252138	chr17:58120427	NA	-0.62	-6.64	-0.34	1.23e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.41	6.25	0.32	1.21e-9	Educational attainment;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20278634	chr1:36274212	EIF2C4	0.45	6.58	0.34	1.82e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.73	7.18	0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.83	9.95	0.47	1.23e-20	Cognitive function;
LIHC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg03037974	chr15:76606532	NA	0.76	14.68	0.62	3.63e-38	Blood metabolite levels;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg19635926	chr16:89946313	TCF25	-0.5	-7.23	-0.36	3.28e-12	Skin colour saturation;
LIHC	cis	rs1029738	0.615	rs717624	chr7:22894487	T/C	cg22407942	chr7:22894828	SNORD93	-0.34	-6.39	-0.33	5.42e-10	Fibrinogen levels;
LIHC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.94	0.31	7.12e-9	Bipolar disorder;
LIHC	cis	rs7818688	0.697	rs78802294	chr8:95977974	G/A	cg16049864	chr8:95962084	TP53INP1	0.62	6.77	0.34	5.73e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg11070056	chr1:107600091	PRMT6	0.63	10.95	0.51	3.98e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	9.18	0.44	4.05e-18	Lung cancer in ever smokers;
LIHC	trans	rs3112255	0.967	rs2015067	chr2:101305478	T/C	cg06958034	chr1:23346203	KDM1A	-0.45	-6.05	-0.31	3.77e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs1864585	0.505	rs73208792	chr8:10680471	C/T	cg20373634	chr10:103911536	NOLC1	-0.46	-6.1	-0.31	2.92e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.1	-0.36	7.1e-12	Diabetic kidney disease;
LIHC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg14411527	chr7:55640598	VOPP1	0.49	6.26	0.32	1.19e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.15e-11	Body mass index;
LIHC	trans	rs9641123	0.639	rs7341502	chr7:93229453	C/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.46	-0.33	3.6e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.73	-12.28	-0.55	5.6e-29	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.58	9.37	0.45	1.04e-18	Childhood ear infection;
LIHC	trans	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg02580895	chr19:2754563	NA	0.47	7.04	0.36	1.09e-11	Total cholesterol levels;
LIHC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.39	-0.49	3.59e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.89e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg14593290	chr7:50529359	DDC	0.62	9.79	0.47	4.21e-20	Malaria;
LIHC	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	0.92	18.16	0.7	4.43e-52	Schizophrenia;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg18279126	chr7:2041391	MAD1L1	0.37	6.11	0.31	2.66e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-9.53	-0.46	3.08e-19	Mean corpuscular volume;
LIHC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	0.86	7.54	0.38	4.2e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.68	0.38	1.65e-13	Prudent dietary pattern;
LIHC	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.47	0.42	7.42e-16	Coffee consumption (cups per day);
LIHC	cis	rs4690686	0.808	rs6553945	chr4:177270965	T/C	cg17059388	chr4:177262070	NA	0.35	6.55	0.33	2.12e-10	Essential tremor;
LIHC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg00204512	chr16:28754710	NA	0.41	7.16	0.36	4.9e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.59	-0.5	7.31e-23	Chronic sinus infection;
LIHC	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.42	-7.67	-0.38	1.81e-13	Testicular germ cell tumor;
LIHC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.53	8.01	0.4	1.8e-14	Uric acid clearance;
LIHC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.54	-0.62	1.29e-37	Electrocardiographic conduction measures;
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.8	-9.8	-0.47	3.9e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	14.25	0.61	1.74e-36	Multiple sclerosis;
LIHC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.48	7.85	0.39	5.51e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3015497	0.616	rs4901044	chr14:51090295	A/G	cg09863266	chr14:51125203	SAV1	-0.39	-6.18	-0.32	1.85e-9	Mean platelet volume;
LIHC	cis	rs3015497	0.763	rs2934689	chr14:51118327	A/C	cg09863266	chr14:51125203	SAV1	-0.43	-6.84	-0.35	3.61e-11	Mean platelet volume;
LIHC	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09597638	chr17:3907349	NA	-0.5	-7.67	-0.38	1.85e-13	Type 2 diabetes;
LIHC	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.86	-0.39	5.04e-14	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.18	0.32	1.81e-9	Alzheimer's disease;
LIHC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.97	17.94	0.7	3.35e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg06951627	chr6:26196580	NA	-0.53	-5.92	-0.3	7.75e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.52	9.07	0.44	9.26e-18	Coronary artery disease;
LIHC	cis	rs74233809	0.901	rs7098825	chr10:104628234	T/C	cg03493300	chr10:104813866	CNNM2	0.43	5.77	0.3	1.79e-8	Birth weight;
LIHC	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg23461800	chr14:103021989	NA	0.38	5.74	0.3	2.06e-8	Platelet count;
LIHC	trans	rs10152207	1.000	rs12595513	chr15:38150151	C/T	cg04477917	chr16:71660055	MARVELD3	0.6	6.19	0.32	1.74e-9	Survival in rectal cancer;
LIHC	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.75	9.32	0.45	1.43e-18	Blood protein levels;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.66	11.66	0.53	1.1e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs7534824	0.543	rs1074739	chr1:101362371	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	7.33	0.37	1.69e-12	Refractive astigmatism;
LIHC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.4	6.45	0.33	3.86e-10	Red blood cell count;
LIHC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.83	13.48	0.59	1.59e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs7714584	1.000	rs3906527	chr5:150266392	T/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18357526	chr6:26021779	HIST1H4A	0.48	6.97	0.35	1.64e-11	Height;
LIHC	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.74	0.47	6.17e-20	Tonsillectomy;
LIHC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.51	-18.3	-0.7	1.23e-52	Breast cancer;
LIHC	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01765077	chr12:122356316	WDR66	0.56	7.44	0.37	7.97e-13	Mean corpuscular volume;
LIHC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.02	-10.36	-0.49	4.51e-22	Platelet count;
LIHC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.56	7.52	0.38	4.81e-13	Emphysema distribution in smoking;
LIHC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.4	0.52	9.54e-26	Colorectal cancer;
LIHC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.06	-0.31	3.59e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs903552	0.932	rs9806551	chr15:102008206	C/T	cg00659931	chr15:102010125	PCSK6	-0.5	-6.88	-0.35	2.84e-11	Diabetic kidney disease;
LIHC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.54	9.14	0.44	5.49e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg25364880	chr3:44379878	C3orf23	-0.51	-7.22	-0.36	3.42e-12	Depressive symptoms;
LIHC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.45	7.76	0.39	1.02e-13	Schizophrenia;
LIHC	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.09	0.48	4.09e-21	Colorectal cancer;
LIHC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.82	0.35	4.17e-11	Height;
LIHC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.91	-0.3	8.11e-9	Cognitive function;
LIHC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg05941027	chr17:61774174	LIMD2	0.3	6.34	0.32	7.31e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.67	9.62	0.46	1.56e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.76	0.34	5.96e-11	Aortic root size;
LIHC	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.6	8.5	0.42	5.85e-16	Lymphocyte counts;
LIHC	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.43	-6.75	-0.34	6.46e-11	Response to antidepressants and depression;
LIHC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	8.3	0.41	2.49e-15	Diastolic blood pressure;
LIHC	cis	rs72627509	0.638	rs78933653	chr4:57854840	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.64	-9.21	-0.45	3.27e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1029738	0.500	rs13227008	chr7:22883708	C/T	cg11367502	chr7:22862612	TOMM7	-0.35	-5.82	-0.3	1.33e-8	Fibrinogen levels;
LIHC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.85	10.14	0.48	2.66e-21	Cognitive function;
LIHC	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.93	-0.31	7.46e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.38	-5.83	-0.3	1.31e-8	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.43	-0.41	1e-15	Lymphocyte counts;
LIHC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.49	8.67	0.42	1.73e-16	Colorectal cancer;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg03874509	chr1:107600012	PRMT6	0.72	11.72	0.54	6.52e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg14393609	chr7:65229607	NA	-0.39	-5.73	-0.3	2.26e-8	Calcium levels;
LIHC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05665937	chr4:1216051	CTBP1	0.46	6.09	0.31	3.11e-9	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.7	0.53	7.79e-27	Alzheimer's disease;
LIHC	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.31	-22.74	-0.78	2.29e-70	Corneal structure;
LIHC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.73	6.32	0.32	8.17e-10	Mean corpuscular hemoglobin;
LIHC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg22676075	chr6:135203613	NA	0.4	6.56	0.33	1.96e-10	Red blood cell count;
LIHC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	6.89	0.35	2.73e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs365132	0.875	rs353477	chr5:176418927	C/T	cg16309518	chr5:176445507	NA	-0.53	-9.96	-0.47	1.06e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.21e-16	Motion sickness;
LIHC	cis	rs11229555	0.645	rs11229549	chr11:58395914	T/C	cg15696309	chr11:58395628	NA	-0.69	-6.37	-0.33	6.13e-10	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.73	-11.29	-0.52	2.5e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.56	-8.25	-0.41	3.56e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.51	-6.1	-0.31	2.89e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.42	7.08	0.36	8.23e-12	Platelet distribution width;
LIHC	cis	rs10916814	1.000	rs72649163	chr1:20900592	G/C	cg24502330	chr1:20914028	CDA	-0.28	-5.86	-0.3	1.1e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.82	13.84	0.6	6.45e-35	Monocyte count;
LIHC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg03970086	chr16:88974840	CBFA2T3	0.35	6.75	0.34	6.25e-11	Social autistic-like traits;
LIHC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.57	0.53	2.46e-26	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.41	6.09	0.31	3.06e-9	Pancreatic cancer;
LIHC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.54	7.13	0.36	5.97e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.47	7.08	0.36	8.21e-12	P wave terminal force;
LIHC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	1.0	9.98	0.47	9.59e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4332037	0.588	rs61409925	chr7:1971226	G/A	cg23422044	chr7:1970798	MAD1L1	-0.66	-7.24	-0.36	2.9e-12	Bipolar disorder;
LIHC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-5.76	-0.3	1.91e-8	Body mass index;
LIHC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.66	-0.34	1.13e-10	Hepatocellular carcinoma;
LIHC	cis	rs8020095	0.528	rs73279056	chr14:67701536	T/G	cg03487553	chr14:67822707	ATP6V1D	-0.35	-6.07	-0.31	3.32e-9	Depression (quantitative trait);
LIHC	cis	rs1494950	1.000	rs7675235	chr4:15063390	A/T	cg12377275	chr4:15005593	CPEB2	-0.87	-7.42	-0.37	9.28e-13	Political ideology;
LIHC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.22	-0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.78	-0.3	1.65e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg22777020	chr22:31556080	RNF185	-0.55	-6.35	-0.32	6.77e-10	Colorectal cancer;
LIHC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-7.37	-0.37	1.29e-12	Total body bone mineral density;
LIHC	cis	rs3770081	1.000	rs60981340	chr2:86177046	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.82	-0.43	6.02e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.81	8.82	0.43	5.9e-17	Initial pursuit acceleration;
LIHC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.74	-10.12	-0.48	3.14e-21	Sudden cardiac arrest;
LIHC	trans	rs4596713	0.538	rs7865373	chr9:71765105	T/C	cg16512924	chr15:28394682	HERC2	0.4	6.41	0.33	4.8e-10	Headache;
LIHC	cis	rs3812111	0.676	rs9488845	chr6:116452658	C/A	cg08036074	chr6:116424633	NT5DC1	-0.5	-8.51	-0.42	5.47e-16	Age-related macular degeneration;
LIHC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.19	-0.4	5.41e-15	Morning vs. evening chronotype;
LIHC	trans	rs60752752	0.852	rs6702735	chr1:153370917	C/T	cg14901121	chr8:98817630	LAPTM4B	-0.43	-7.09	-0.36	7.9e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05665937	chr4:1216051	CTBP1	0.39	6.2	0.32	1.59e-9	Obesity-related traits;
LIHC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6442522	0.533	rs2100545	chr3:15521619	C/T	cg16303742	chr3:15540471	COLQ	0.37	6.0	0.31	4.94e-9	Uric acid levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02287918	chr21:30396957	USP16	0.62	8.56	0.42	3.86e-16	Lung function (FEV1/FVC);
LIHC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.38	6.19	0.32	1.71e-9	Monocyte count;
LIHC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	8.86	0.43	4.29e-17	IgG glycosylation;
LIHC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.81	15.03	0.63	1.54e-39	Blood protein levels;
LIHC	cis	rs1419980	0.730	rs11054890	chr12:7773096	T/C	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs831571	0.668	rs34723451	chr3:64081836	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.5	-5.86	-0.3	1.08e-8	Type 2 diabetes;
LIHC	trans	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg17675199	chr6:35436792	RPL10A	0.35	6.78	0.34	5.2e-11	Coronary artery disease;
LIHC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.74	0.3	2.07e-8	Height;
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.39	7.92	0.39	3.4e-14	Renal cell carcinoma;
LIHC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.49	-6.13	-0.31	2.37e-9	Pancreatic cancer;
LIHC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17507749	chr15:85114479	UBE2QP1	0.78	8.96	0.44	2.12e-17	Schizophrenia;
LIHC	cis	rs11630290	0.640	rs1811744	chr15:64167428	T/C	cg12036633	chr15:63758958	NA	0.57	5.96	0.31	6.42e-9	Iris characteristics;
LIHC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.14	-0.32	2.29e-9	Aortic root size;
LIHC	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg12437481	chr16:420112	MRPL28	-0.46	-6.16	-0.32	2.07e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-0.99	-22.13	-0.77	5.79e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg00800038	chr16:89945340	TCF25	-0.6	-8.5	-0.42	5.92e-16	Skin colour saturation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13648088	chr10:124768538	ACADSB;IKZF5	0.59	7.73	0.39	1.2e-13	Lung function (FEV1/FVC);
LIHC	cis	rs12477438	0.539	rs13394175	chr2:99590713	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-9.55	-0.46	2.5e-19	Chronic sinus infection;
LIHC	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	cg04338863	chr8:33670619	NA	0.31	5.74	0.3	2.14e-8	Body mass index;
LIHC	cis	rs28830936	0.934	rs28401754	chr15:42116903	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-5.97	-0.31	5.9e-9	Diastolic blood pressure;
LIHC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.64	-10.38	-0.49	4.02e-22	Longevity;
LIHC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.61	-10.12	-0.48	3.11e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.75	11.81	0.54	3.25e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.43	0.45	6.45e-19	Corneal astigmatism;
LIHC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.63	0.38	2.39e-13	Bipolar disorder;
LIHC	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg20194872	chr6:41519635	FOXP4	0.42	6.74	0.34	6.66e-11	Prostate cancer;
LIHC	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg24225360	chr4:15471699	CC2D2A	0.4	6.46	0.33	3.56e-10	Obesity-related traits;
LIHC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg12863693	chr15:85201151	NMB	0.44	6.14	0.32	2.24e-9	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.35	14.76	0.62	1.75e-38	Eosinophil percentage of granulocytes;
LIHC	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.34	-6.06	-0.31	3.56e-9	Lewy body disease;
LIHC	cis	rs8108269	0.956	rs10420680	chr19:46158828	A/G	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.37	-6.1	-0.31	2.86e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg00204512	chr16:28754710	NA	-0.37	-6.5	-0.33	2.89e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs943466	1.000	rs6933568	chr6:33751261	G/A	cg25922239	chr6:33757077	LEMD2	-0.48	-5.81	-0.3	1.45e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg27205649	chr11:78285834	NARS2	0.39	5.87	0.3	1.04e-8	Alzheimer's disease (survival time);
LIHC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.43	-9.22	-0.45	3.04e-18	Rheumatoid arthritis;
LIHC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.15	-0.4	6.97e-15	Body mass index;
LIHC	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.38	-7.57	-0.38	3.42e-13	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.8	9.02	0.44	1.43e-17	Vitiligo;
LIHC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.5	-0.56	8.97e-30	Vitiligo;
LIHC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.51	-7.11	-0.36	6.66e-12	Menarche (age at onset);
LIHC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.5e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19623624	chr10:135278901	LOC619207	-0.45	-6.98	-0.35	1.53e-11	Systemic lupus erythematosus;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.42	-0.33	4.65e-10	Longevity;Endometriosis;
LIHC	cis	rs2108225	0.714	rs10953548	chr7:107436232	G/A	cg18560240	chr7:107437656	SLC26A3	-0.51	-8.04	-0.4	1.46e-14	Ulcerative colitis;
LIHC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.21	-6.67	-0.34	1.03e-10	Mean corpuscular volume;
LIHC	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.35	-7.78	-0.39	8.79e-14	Breast cancer;
LIHC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg04310649	chr10:35416472	CREM	-0.44	-5.94	-0.31	7.05e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1023500	1.000	rs9620001	chr22:42330229	T/C	cg04733989	chr22:42467013	NAGA	-0.53	-6.18	-0.32	1.84e-9	Schizophrenia;
LIHC	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.85	-0.3	1.15e-8	Breast cancer;
LIHC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg17279839	chr7:150038598	RARRES2	0.48	8.99	0.44	1.77e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.42	0.41	1.05e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg10560079	chr2:191398806	TMEM194B	-0.42	-6.08	-0.31	3.28e-9	Mean platelet volume;
LIHC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.59	-10.46	-0.49	2.08e-22	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg10756647	chr7:56101905	PSPH	-1.04	-12.56	-0.56	5.34e-30	Diabetic kidney disease;
LIHC	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.93	0.31	7.36e-9	Mean corpuscular volume;
LIHC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg03983715	chr16:68378420	PRMT7	-0.48	-5.81	-0.3	1.47e-8	Schizophrenia;
LIHC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	10.75	0.5	2.13e-23	Colorectal cancer;
LIHC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.52	8.36	0.41	1.55e-15	Schizophrenia;
LIHC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg02931644	chr1:25747376	RHCE	0.35	7.6	0.38	2.88e-13	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg27433088	chr4:174089019	GALNT7	-0.4	-6.87	-0.35	2.98e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.6	11.19	0.52	5.57e-25	Airflow obstruction;
LIHC	cis	rs9871864	0.868	rs9820730	chr3:20348723	A/G	cg00235661	chr3:20228976	SGOL1	-0.31	-5.87	-0.3	1.06e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg01557791	chr16:72042693	DHODH	-0.45	-7.52	-0.38	4.95e-13	Fibrinogen levels;
LIHC	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg03263716	chr11:64435066	NRXN2	0.35	7.61	0.38	2.72e-13	Body mass index;Urate levels;
LIHC	trans	rs10761482	0.564	rs10733765	chr10:62237399	T/C	cg17314160	chr12:110399253	GIT2	-0.42	-6.21	-0.32	1.56e-9	Schizophrenia;
LIHC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.48	-8.24	-0.41	3.61e-15	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26820641	chr20:30326728	TPX2	0.43	6.24	0.32	1.31e-9	Cognitive function;
LIHC	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg25344623	chr2:136566232	LCT	0.36	5.86	0.3	1.06e-8	Corneal structure;
LIHC	cis	rs2274273	0.745	rs8005399	chr14:55542845	A/G	cg01864836	chr14:55583639	NA	-0.37	-6.34	-0.32	7.3e-10	Protein biomarker;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02667081	chr16:71880439	ATXN1L	0.39	6.05	0.31	3.74e-9	Cognitive function;
LIHC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.61	-9.03	-0.44	1.29e-17	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-11.3	-0.52	2.25e-25	Hemoglobin concentration;
LIHC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.56	8.65	0.42	2.1e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.62	-8.91	-0.43	3.13e-17	Blood metabolite levels;
LIHC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.39	-6.04	-0.31	4.02e-9	Menarche (age at onset);
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.41	5.75	0.3	1.95e-8	Glycated hemoglobin levels;
LIHC	cis	rs7945718	0.621	rs10831894	chr11:12680733	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.87	0.39	4.59e-14	Educational attainment (years of education);
LIHC	cis	rs36051895	0.589	rs6476945	chr9:5191793	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-11.64	-0.53	1.32e-26	Pediatric autoimmune diseases;
LIHC	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.44	-7.67	-0.38	1.77e-13	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-11.4	-0.52	9.58e-26	Personality dimensions;
LIHC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.92	0.47	1.51e-20	Height;
LIHC	cis	rs861318	0.646	rs2518555	chr1:159012535	A/G	cg11003133	chr1:159046391	AIM2	0.34	6.77	0.34	5.5e-11	Obesity-related traits;
LIHC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.3	0.32	9.35e-10	Schizophrenia;
LIHC	cis	rs3812111	0.647	rs1546943	chr6:116501503	G/A	cg08036074	chr6:116424633	NT5DC1	-0.54	-9.09	-0.44	8.47e-18	Age-related macular degeneration;
LIHC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.91	16.91	0.67	4.8e-47	Menopause (age at onset);
LIHC	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.09	-0.51	1.25e-24	Morning vs. evening chronotype;
LIHC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.46	-7.83	-0.39	6.03e-14	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06443542	chr10:100206752	HPS1	-0.41	-6.41	-0.33	4.78e-10	Pancreatic cancer;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.56	-7.58	-0.38	3.23e-13	Menopause (age at onset);
LIHC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.56	7.2	0.36	3.96e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg08822215	chr16:89438651	ANKRD11	-0.4	-6.3	-0.32	9.31e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	7.76	0.39	1.02e-13	Platelet count;
LIHC	cis	rs35883536	1.000	rs12724990	chr1:101137030	G/A	cg14515779	chr1:101123966	NA	-0.7	-14.03	-0.6	1.21e-35	Monocyte count;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg26149108	chr5:65275261	ERBB2IP	-0.39	-7.35	-0.37	1.48e-12	Calcium levels;
LIHC	cis	rs7395581	0.775	rs2269434	chr11:47360412	T/C	cg25783544	chr11:47291846	MADD	0.41	5.92	0.3	7.85e-9	HDL cholesterol;
LIHC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg19680672	chr10:131412579	MGMT	0.43	6.69	0.34	9.13e-11	Response to temozolomide;
LIHC	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.79	9.18	0.44	4.09e-18	Exhaled nitric oxide output;
LIHC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg19318889	chr4:1322082	MAEA	0.46	6.49	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.48e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	3.09e-9	Mortality in heart failure;
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.43	6.31	0.32	8.4e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.39	-6.21	-0.32	1.55e-9	Hypospadias;
LIHC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.58	11.02	0.51	2.21e-24	Schizophrenia;
LIHC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.45	-12.12	-0.55	2.26e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.65	-6.4	-0.33	5.26e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg16797656	chr11:68205561	LRP5	0.51	8.04	0.4	1.47e-14	Total body bone mineral density;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.34	5.77	0.3	1.82e-8	Height;
LIHC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.79	-0.34	4.84e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.9	-0.35	2.54e-11	Bipolar disorder;
LIHC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.64	-7.37	-0.37	1.32e-12	Lymphocyte counts;
LIHC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.83	-9.87	-0.47	2.22e-20	Bone mineral density;
LIHC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.22	0.41	4.32e-15	Motion sickness;
LIHC	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.51	7.07	0.36	8.75e-12	Dialysis-related mortality;
LIHC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs10792665	0.575	rs10736757	chr11:82560858	A/G	cg24227371	chr11:82718527	RAB30	-0.26	-6.24	-0.32	1.28e-9	Obesity-related traits;
LIHC	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs1494950	1.000	rs7661362	chr4:15077742	T/A	cg12377275	chr4:15005593	CPEB2	-0.88	-7.56	-0.38	3.77e-13	Political ideology;
LIHC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.61	-9.85	-0.47	2.65e-20	Height;
LIHC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.72	-0.3	2.34e-8	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07867325	chr3:73159953	NA	-0.3	-6.07	-0.31	3.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.39	5.77	0.3	1.74e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs59072263	0.850	rs55916403	chr7:8144051	T/A	cg21324884	chr3:64801329	MIR548A2	0.74	6.12	0.31	2.53e-9	Intraocular pressure;
LIHC	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs244293	0.760	rs12945393	chr17:53045243	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.45	-0.33	3.89e-10	Menarche (age at onset);
LIHC	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.34	-7.01	-0.35	1.27e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg22528358	chr1:107598549	PRMT6	-0.65	-10.64	-0.5	4.93e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.42	-7.35	-0.37	1.46e-12	Platelet distribution width;
LIHC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.74	0.47	6.17e-20	Tonsillectomy;
LIHC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.01	0.31	4.66e-9	Resting heart rate;
LIHC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.64	10.21	0.48	1.51e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.3	6.94	0.35	1.99e-11	DNA methylation (variation);
LIHC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.14	0.44	5.63e-18	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg14515779	chr1:101123966	NA	-0.45	-6.38	-0.33	5.67e-10	Monocyte count;
LIHC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.83	-14.24	-0.61	1.88e-36	Multiple sclerosis;
LIHC	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg00012203	chr2:219082015	ARPC2	-0.47	-6.1	-0.31	2.81e-9	Ulcerative colitis;
LIHC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.96	-9.61	-0.46	1.6e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.09	0.31	2.97e-9	Renal cell carcinoma;
LIHC	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg09795085	chr6:101329169	ASCC3	0.51	7.12	0.36	6.46e-12	Neuroticism;
LIHC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.09	-0.36	7.59e-12	Mean corpuscular volume;
LIHC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg18887096	chr2:219472410	PLCD4	-0.39	-6.69	-0.34	9.17e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	6.87	0.35	2.96e-11	Migraine;Coronary artery disease;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg03395511	chr6:291903	DUSP22	-0.48	-6.3	-0.32	8.94e-10	Menopause (age at onset);
LIHC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.85	0.3	1.13e-8	Body mass index;
LIHC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg12365402	chr11:9010492	NRIP3	0.27	6.78	0.34	5.16e-11	Hemoglobin concentration;
LIHC	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg17456097	chr1:26900765	RPS6KA1	-0.4	-5.85	-0.3	1.13e-8	Glucose homeostasis traits;
LIHC	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.4	-5.82	-0.3	1.33e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	0.97	13.74	0.6	1.66e-34	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.96	17.37	0.68	6.51e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.54	-8.29	-0.41	2.56e-15	Coronary artery disease;
LIHC	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.78	13.07	0.58	6.31e-32	Coronary artery disease;
LIHC	cis	rs4788570	0.697	rs9930015	chr16:71801092	C/G	cg06353428	chr16:71660113	MARVELD3	1.22	13.1	0.58	4.55e-32	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.74	0.39	1.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11888559	0.655	rs12615537	chr2:204005715	T/A	cg24605529	chr2:203879461	NBEAL1	0.78	5.92	0.31	7.62e-9	Height;
LIHC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.48	8.71	0.43	1.34e-16	Hemoglobin concentration;
LIHC	cis	rs7116495	1.000	rs658661	chr11:71559269	T/G	cg26138937	chr11:71823887	C11orf51	0.67	6.43	0.33	4.3e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs10508774	1.000	rs35949115	chr10:33054173	G/A	cg01819863	chr10:32635814	EPC1	0.63	5.78	0.3	1.68e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.3	6.5	0.33	2.92e-10	Pulmonary function;
LIHC	trans	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg26939375	chr7:64535504	NA	0.41	6.48	0.33	3.18e-10	Aortic root size;
LIHC	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.29	-0.41	2.55e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg00199846	chr13:37393246	RFXAP	0.45	6.16	0.32	2e-9	Leprosy;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.57	1.31e-31	Prudent dietary pattern;
LIHC	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	0.73	8.41	0.41	1.1e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.41	0.33	4.79e-10	Renal cell carcinoma;
LIHC	trans	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg01596870	chr19:55963115	NA	-0.6	-7.01	-0.35	1.25e-11	Obesity-related traits;
LIHC	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg12373951	chr3:133503437	NA	-0.48	-6.8	-0.35	4.65e-11	Alcohol consumption (transferrin glycosylation);
LIHC	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.48	6.51	0.33	2.69e-10	Glioblastoma;Glioma;
LIHC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-7.34	-0.37	1.59e-12	Melanoma;
LIHC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.37	0.52	1.3e-25	Menarche (age at onset);
LIHC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.44	6.36	0.33	6.28e-10	Breast cancer;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg00280220	chr17:61926910	NA	0.42	6.89	0.35	2.73e-11	Prudent dietary pattern;
LIHC	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25632853	chr15:73088954	NA	0.36	6.02	0.31	4.47e-9	Triglyceride levels;
LIHC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-8.32	-0.41	2.17e-15	Chronic sinus infection;
LIHC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.75e-22	Hemoglobin concentration;
LIHC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.94	-0.47	1.23e-20	Total cholesterol levels;
LIHC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.82	13.38	0.59	3.95e-33	Colorectal cancer;
LIHC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.52	-7.33	-0.37	1.63e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg13919466	chr1:32135498	COL16A1	-0.31	-6.17	-0.32	1.92e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.04	9.51	0.46	3.49e-19	Diabetic retinopathy;
LIHC	cis	rs922107	0.967	rs1885746	chr1:90015719	A/C	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.71	-0.38	1.4e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7872515	0.775	rs7024583	chr9:94824750	C/T	cg01248375	chr9:94877805	SPTLC1	0.53	7.55	0.38	4.1e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.06	0.4	1.27e-14	Response to antipsychotic treatment;
LIHC	cis	rs4788570	0.615	rs1058750	chr16:71679057	C/T	cg06353428	chr16:71660113	MARVELD3	1.45	15.6	0.64	8.48e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg17085576	chr10:5658249	NA	-0.35	-6.2	-0.32	1.66e-9	Breast cancer;
LIHC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-1.0	-8.17	-0.4	6.1e-15	Arsenic metabolism;
LIHC	cis	rs1144333	1.000	rs12082448	chr1:76353225	C/T	cg10523679	chr1:76189770	ACADM	0.47	6.73	0.34	7.29e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2997447	0.637	rs2000403	chr1:26410161	A/G	cg19633962	chr1:26362018	EXTL1	-0.7	-6.4	-0.33	5.06e-10	QRS complex (12-leadsum);
LIHC	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	19.32	0.72	9.83e-57	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.13	-0.31	2.49e-9	Total body bone mineral density;
LIHC	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.22	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.88	-14.15	-0.61	4.17e-36	Prudent dietary pattern;
LIHC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.68	-10.64	-0.5	4.94e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.59	0.42	3.17e-16	Response to antipsychotic treatment;
LIHC	cis	rs10792665	0.844	rs10751084	chr11:82682918	C/G	cg24227371	chr11:82718527	RAB30	-0.32	-7.58	-0.38	3.31e-13	Obesity-related traits;
LIHC	cis	rs11603020	0.950	rs28362951	chr11:57372526	A/G	cg19752551	chr11:57585705	CTNND1	-0.46	-5.88	-0.3	9.93e-9	Blood protein levels;
LIHC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.37	7.16	0.36	5e-12	Multiple system atrophy;
LIHC	trans	rs17473412	0.677	rs7703751	chr5:122831981	A/T	cg04915494	chr16:2962968	FLYWCH1	-0.47	-6.2	-0.32	1.66e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08280861	chr8:58055591	NA	0.51	6.38	0.33	5.8e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.81	-0.39	6.91e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs1144333	0.655	rs76175698	chr1:76454792	C/T	cg22875332	chr1:76189707	ACADM	0.4	5.93	0.31	7.52e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.94	10.37	0.49	4.19e-22	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01074676	chr14:60601069	C14orf135	-0.33	-6.24	-0.32	1.29e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.36	-0.33	6.61e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg15282417	chr9:129245246	FAM125B	0.42	6.96	0.35	1.71e-11	Intraocular pressure;
LIHC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.31	-0.74	9.9e-61	Height;
LIHC	trans	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg01596870	chr19:55963115	NA	-0.63	-8.42	-0.41	1.08e-15	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.11	-0.36	6.93e-12	Diabetic kidney disease;
LIHC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg15103426	chr22:29168792	CCDC117	-0.56	-8.88	-0.43	3.96e-17	Lymphocyte counts;
LIHC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.39	-5.91	-0.3	8.46e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg16586182	chr3:47516702	SCAP	-0.43	-7.47	-0.37	6.74e-13	Colorectal cancer;
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs546131	0.642	rs523246	chr11:34845011	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.46	0.46	5.25e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4700695	0.841	rs251306	chr5:65252453	C/T	cg21114390	chr5:65439923	SFRS12	0.44	5.77	0.3	1.8e-8	Facial morphology (factor 19);
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg03785755	chr6:26196794	NA	0.51	5.97	0.31	5.8e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg04310649	chr10:35416472	CREM	-0.45	-6.08	-0.31	3.17e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg18305652	chr10:134549665	INPP5A	-0.39	-6.45	-0.33	3.79e-10	Migraine;
LIHC	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.48	6.41	0.33	4.9e-10	Glioblastoma;Glioma;
LIHC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.64	-0.38	2.14e-13	Total cholesterol levels;
LIHC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.33	0.41	2.01e-15	Response to antipsychotic treatment;
LIHC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg07671805	chr5:74907694	NA	-0.52	-6.16	-0.32	2.02e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02985541	chr2:219472218	PLCD4	-0.39	-6.61	-0.34	1.46e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03685910	chr17:39844834	EIF1	0.36	6.03	0.31	4.17e-9	Cognitive function;
LIHC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.52	6.02	0.31	4.48e-9	Cerebrospinal P-tau181p levels;
LIHC	trans	rs6489882	0.867	rs4766676	chr12:113365581	A/G	cg10175203	chr3:128143634	NA	-0.39	-6.22	-0.32	1.44e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.28	-5.96	-0.31	6.11e-9	Pulmonary function;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.34	0.32	7.32e-10	Total body bone mineral density;
LIHC	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.39	-5.74	-0.3	2.04e-8	Ulcerative colitis;
LIHC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg14440974	chr22:39074834	NA	0.37	6.24	0.32	1.29e-9	Menopause (age at onset);
LIHC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.44	0.33	3.97e-10	Height;
LIHC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.52	6.81	0.35	4.3e-11	Myopia;
LIHC	cis	rs716804	0.740	rs4442543	chr11:10306774	C/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.84	-0.3	1.25e-8	Neuroticism;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24182963	chr17:48350615	TMEM92	-0.48	-6.13	-0.31	2.49e-9	Systolic blood pressure;
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg16970926	chr12:29381810	FAR2	0.29	6.1	0.31	2.81e-9	QT interval;
LIHC	cis	rs8192917	0.623	rs2273843	chr14:25103409	T/C	cg08766149	chr14:25103301	GZMB	0.33	5.95	0.31	6.69e-9	Vitiligo;
LIHC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	8.04e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.59	-8.53	-0.42	4.87e-16	Body mass index;
LIHC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.89	-18.35	-0.7	7.62e-53	Height;
LIHC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.3	0.45	1.65e-18	Melanoma;
LIHC	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.31	-0.37	1.86e-12	Protein biomarker;
LIHC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.43	6.07	0.31	3.49e-9	Alzheimer's disease;
LIHC	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	6.82	0.35	4.09e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.14	-10.75	-0.5	1.99e-23	Breast cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08398855	chr16:89283970	ZNF778	-0.5	-6.06	-0.31	3.64e-9	Systolic blood pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21426974	chr4:140005758	ELF2	0.44	6.45	0.33	3.74e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	0.95	9.63	0.46	1.39e-19	Cannabis dependence symptom count;
LIHC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	0.98	10.31	0.49	7.06e-22	Vitiligo;
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.4	-5.82	-0.3	1.33e-8	Longevity;
LIHC	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.73	-0.3	2.24e-8	Coronary artery disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24335600	chr1:241682994	FH	0.44	6.3	0.32	9.26e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9513627	0.915	rs73556179	chr13:100122009	G/A	cg25919922	chr13:100150906	NA	-0.8	-7.07	-0.36	8.77e-12	Obesity-related traits;
LIHC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.76	-13.64	-0.59	3.94e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs3812111	0.676	rs6915372	chr6:116475557	T/G	cg08036074	chr6:116424633	NT5DC1	-0.49	-8.27	-0.41	3.05e-15	Age-related macular degeneration;
LIHC	cis	rs151997	0.671	rs27281	chr5:50200764	C/T	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.64	-5.78	-0.3	1.66e-8	Menopause (age at onset);
LIHC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.69	12.44	0.56	1.41e-29	Iron status biomarkers;
LIHC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.52	7.07	0.36	8.54e-12	Morning vs. evening chronotype;
LIHC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.35	-6.07	-0.31	3.43e-9	IgG glycosylation;
LIHC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.69	0.69	3.56e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1639906	0.895	rs78469080	chr7:2200729	G/A	cg02951883	chr7:2050386	MAD1L1	0.57	7.68	0.38	1.73e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11603020	0.904	rs4926	chr11:57381989	G/A	cg19752551	chr11:57585705	CTNND1	-0.46	-5.98	-0.31	5.62e-9	Blood protein levels;
LIHC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.64	0.53	1.27e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.96	-0.31	6.24e-9	Menarche (age at onset);
LIHC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg18357645	chr12:58087776	OS9	-0.42	-6.3	-0.32	9.23e-10	Multiple sclerosis;
LIHC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg15848620	chr12:58087721	OS9	-0.55	-7.52	-0.38	4.99e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.52	9.46	0.46	5.04e-19	Systemic lupus erythematosus;
LIHC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.02	0.36	1.17e-11	Osteoporosis;
LIHC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.3	-17.72	-0.69	2.68e-50	Diabetic kidney disease;
LIHC	trans	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	Androgen levels;
LIHC	cis	rs7716219	0.751	rs4865956	chr5:54882505	T/A	cg14753740	chr5:54468940	CDC20B;MIR449C	0.46	6.25	0.32	1.2e-9	Height;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.69	0.8	5.21e-78	Prudent dietary pattern;
LIHC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg15691649	chr6:25882328	NA	-0.58	-7.48	-0.37	6.53e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-5.96	-0.31	6.36e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11980791	chr9:131084797	COQ4;TRUB2	-0.51	-6.32	-0.32	7.93e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6728642	0.519	rs7589232	chr2:97566148	C/T	cg26665480	chr2:98280029	ACTR1B	-0.52	-5.81	-0.3	1.45e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.43	6.72	0.34	7.81e-11	Neurofibrillary tangles;
LIHC	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.36	-5.97	-0.31	5.97e-9	Mean arterial pressure;
LIHC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.22	0.52	4.26e-25	Platelet count;
LIHC	trans	rs8113308	0.810	rs8104121	chr19:52443063	C/T	cg14959425	chr7:20447707	ITGB8	-0.48	-6.15	-0.32	2.22e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.15	0.32	2.12e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.08	-0.44	8.97e-18	Testicular germ cell tumor;
LIHC	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-9.04	-0.44	1.2e-17	Response to antipsychotic treatment;
LIHC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.52	8.34	0.41	1.89e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.5	-7.29	-0.37	2.16e-12	Obesity (extreme);
LIHC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.67	-8.82	-0.43	6.07e-17	Motion sickness;
LIHC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.53	8.2	0.41	4.87e-15	Lymphocyte counts;
LIHC	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg25072359	chr17:41440525	NA	0.4	6.28	0.32	1.04e-9	Menopause (age at onset);
LIHC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg05110241	chr16:68378359	PRMT7	-0.56	-6.45	-0.33	3.85e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.2	0.55	1.19e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	cis	rs75920871	0.557	rs11216275	chr11:116975704	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-5.93	-0.31	7.4e-9	Subjective well-being;
LIHC	cis	rs2257205	0.667	rs16943147	chr17:56720752	C/A	cg12560992	chr17:57184187	TRIM37	0.7	7.73	0.39	1.22e-13	Pancreatic cancer;
LIHC	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.38	6.44	0.33	4.14e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.64	7.99	0.4	2.03e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-0.9	-10.85	-0.51	8.86e-24	Mitochondrial DNA levels;
LIHC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.48	-0.33	3.13e-10	Type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26189035	chr5:180661257	TRIM41	-0.37	-6.4	-0.33	5.09e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.4	-6.15	-0.32	2.18e-9	Breast cancer;
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg03517284	chr6:25882590	NA	-0.44	-6.67	-0.34	1.04e-10	Height;
LIHC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs546131	0.559	rs12803664	chr11:34851929	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.51	-0.33	2.63e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs11671005	0.735	rs3764532	chr19:58929222	G/A	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.55	9.93	0.47	1.41e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.87	-17.46	-0.69	3.02e-49	Height;
LIHC	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.39	7.37	0.37	1.33e-12	Height;
LIHC	cis	rs7534824	0.625	rs6676834	chr1:101463788	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.74	7.06	0.36	9.28e-12	Refractive astigmatism;
LIHC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.29	0.32	9.51e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.51e-27	Corneal astigmatism;
LIHC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.75	11.31	0.52	2.12e-25	Menarche (age at onset);
LIHC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.7	-0.34	8.71e-11	Height;
LIHC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg13446199	chr8:143762866	PSCA	-0.2	-5.93	-0.31	7.44e-9	Urinary tract infection frequency;
LIHC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.95	-0.31	6.67e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.84	-0.35	3.61e-11	Metabolite levels;
LIHC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg15902774	chr15:75289873	SCAMP5	0.4	6.0	0.31	4.97e-9	Lung cancer;
LIHC	cis	rs965469	1.000	rs6051762	chr20:3321590	T/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.67	-0.34	1e-10	IFN-related cytopenia;
LIHC	cis	rs1789	0.872	rs4333182	chr4:15684712	G/A	cg16509355	chr4:15471240	CC2D2A	-0.45	-6.73	-0.34	7.04e-11	Blood protein levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06350524	chr2:169747178	SPC25	0.51	6.77	0.34	5.56e-11	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.44	7.91	0.39	3.7e-14	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg13409248	chr3:40428643	ENTPD3	0.41	6.91	0.35	2.41e-11	Renal cell carcinoma;
LIHC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-9.5	-0.46	3.87e-19	Schizophrenia;
LIHC	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg00376283	chr12:123451042	ABCB9	0.55	8.78	0.43	7.97e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs561341	0.843	rs56389115	chr17:30237308	T/C	cg13647721	chr17:30228624	UTP6	0.72	7.19	0.36	4e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg21522988	chr12:29376872	FAR2	-0.26	-5.76	-0.3	1.85e-8	QT interval;
LIHC	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	6.91	0.35	2.42e-11	Height;
LIHC	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11212260	0.655	rs11212213	chr11:107286421	A/G	cg25435332	chr11:107328525	CWF19L2	0.8	8.47	0.42	7.45e-16	IgG glycosylation;
LIHC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.7	0.38	1.45e-13	Diastolic blood pressure;
LIHC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-11.03	-0.51	2.02e-24	Type 2 diabetes;
LIHC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	1.03	12.62	0.56	3.16e-30	Vitiligo;
LIHC	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.32	-6.03	-0.31	4.26e-9	Body mass index;
LIHC	cis	rs6960043	0.584	rs992823	chr7:15041187	C/T	cg19272540	chr7:15055459	NA	0.24	6.53	0.33	2.41e-10	Type 2 diabetes;
LIHC	cis	rs10097731	0.901	rs7823749	chr8:82047828	C/A	cg25230327	chr8:82042993	NA	-0.58	-7.77	-0.39	9.18e-14	Serum total protein level;
LIHC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.23	-19.07	-0.72	9.59e-56	Ulcerative colitis;
LIHC	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg23254163	chr1:152506842	NA	0.23	5.83	0.3	1.28e-8	Hair morphology;
LIHC	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg11783602	chr8:55087084	NA	-0.31	-6.18	-0.32	1.84e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg14393609	chr7:65229607	NA	-0.37	-5.83	-0.3	1.27e-8	Aortic root size;
LIHC	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.47	-9.18	-0.44	4.16e-18	LDL cholesterol levels;
LIHC	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg27417294	chr10:81904244	PLAC9	-0.36	-6.18	-0.32	1.78e-9	Sarcoidosis;
LIHC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	14.38	0.61	5.17e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs7914558	0.621	rs10786722	chr10:104660068	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.2	-0.36	3.87e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.63	6.62	0.34	1.4e-10	Type 2 diabetes;
LIHC	cis	rs34540877	0.590	rs78187313	chr19:33141734	C/T	cg22980127	chr19:33182716	NUDT19	0.89	6.22	0.32	1.43e-9	Red cell distribution width;
LIHC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg18306943	chr3:40428807	ENTPD3	-0.4	-7.21	-0.36	3.61e-12	Renal cell carcinoma;
LIHC	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg27286337	chr10:134555280	INPP5A	-1.01	-18.45	-0.71	3.13e-53	Migraine;
LIHC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg15744005	chr10:104629667	AS3MT	0.4	8.59	0.42	3.15e-16	Waist circumference;Hip circumference;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.71	0.34	8.26e-11	Renal cell carcinoma;
LIHC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.24	0.32	1.31e-9	Menarche (age at onset);
LIHC	cis	rs4934494	0.634	rs12762448	chr10:91390240	A/C	cg19698084	chr10:91461284	KIF20B	-0.46	-6.19	-0.32	1.74e-9	Red blood cell count;
LIHC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.66	10.66	0.5	4.41e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.53	7.87	0.39	4.72e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21582582	chr3:182698605	DCUN1D1	0.54	6.99	0.35	1.41e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg16070018	chr6:26224392	HIST1H3E	0.56	6.67	0.34	1.06e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg05185784	chr16:90016020	DEF8	-0.44	-5.71	-0.3	2.4e-8	Skin colour saturation;
LIHC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.35	6.02	0.31	4.39e-9	Educational attainment;
LIHC	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg09572067	chr16:29127029	RRN3P2	0.52	8.31	0.41	2.35e-15	Menopause (age at onset);
LIHC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.15e-9	Mortality in heart failure;
LIHC	cis	rs7487075	0.619	rs4768725	chr12:46848478	T/C	cg23829395	chr12:46796953	NA	0.35	6.15	0.32	2.11e-9	Itch intensity from mosquito bite;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17608500	chr1:154955711	FLAD1	0.42	6.98	0.35	1.56e-11	Cognitive function;
LIHC	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.41	6.6	0.34	1.6e-10	Mean corpuscular volume;
LIHC	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg17623882	chr6:41773611	USP49	-0.42	-5.84	-0.3	1.24e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.49	-0.33	3.04e-10	Longevity;Endometriosis;
LIHC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-5.83	-0.3	1.28e-8	Heart rate;
LIHC	cis	rs7919006	1.000	rs7919006	chr10:76808760	C/T	cg01390419	chr10:76803856	DUPD1	0.49	7.33	0.37	1.68e-12	Weight;
LIHC	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02985541	chr2:219472218	PLCD4	-0.36	-6.34	-0.32	7.39e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.48	7.3	0.37	2.02e-12	HDL cholesterol;
LIHC	cis	rs12986413	0.935	rs12980417	chr19:2184166	G/A	cg09261902	chr19:2140048	AP3D1	0.4	6.72	0.34	7.53e-11	Height;
LIHC	cis	rs10426930	0.675	rs2613772	chr19:5075787	T/C	cg18473234	chr19:5097819	KDM4B	-0.57	-7.33	-0.37	1.72e-12	Monocyte percentage of white cells;
LIHC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.77	6.78	0.34	5.28e-11	Type 2 diabetes;
LIHC	cis	rs9918079	0.560	rs7685083	chr4:15610771	G/A	cg21329975	chr4:15471214	CC2D2A	0.41	6.18	0.32	1.84e-9	Obesity-related traits;
LIHC	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.57	-0.38	3.46e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg06854084	chr10:101292507	NKX2-3	-0.35	-6.46	-0.33	3.64e-10	Dental caries;
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.32	6.2	0.32	1.65e-9	Tonsillectomy;
LIHC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.79	13.86	0.6	5.39e-35	Coronary artery disease;
LIHC	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.84	-0.3	1.18e-8	Neuroticism;
LIHC	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09356193	chr14:105816327	PACS2	0.5	7.47	0.37	6.81e-13	Longevity;
LIHC	cis	rs965469	0.947	rs6139087	chr20:3329062	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.74	8.77	0.43	8.84e-17	Neuroticism;
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.18	-0.32	1.79e-9	Aortic root size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00975115	chr16:30958403	FBXL19	-0.43	-6.19	-0.32	1.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.12	-0.4	8.5e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.24	0.32	1.28e-9	Heart rate;
LIHC	trans	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg16088116	chr21:44841560	SIK1	-0.42	-6.52	-0.33	2.59e-10	Coronary artery disease;
LIHC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.94	-0.63	3.43e-39	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	9.9	0.47	1.76e-20	Chronic sinus infection;
LIHC	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg08126542	chr6:37504118	NA	-0.36	-6.2	-0.32	1.58e-9	Cognitive performance;
LIHC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.6	6.64	0.34	1.22e-10	Vitiligo;
LIHC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.7	12.96	0.57	1.54e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-7.18	-0.36	4.39e-12	Eosinophil percentage of white cells;
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02290350	chr8:58132656	NA	0.49	10.4	0.49	3.47e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Total cholesterol levels;
LIHC	cis	rs7116495	1.000	rs3793938	chr11:71823133	G/A	cg26138937	chr11:71823887	C11orf51	0.81	7.98	0.4	2.23e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.6	8.99	0.44	1.67e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.4	-6.12	-0.31	2.5e-9	Menarche (age at onset);
LIHC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.58	6.28	0.32	1.04e-9	Systemic lupus erythematosus;
LIHC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-9.31	-0.45	1.64e-18	Bipolar disorder;
LIHC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.45	-0.59	2.13e-33	Vitiligo;
LIHC	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg05973401	chr12:123451056	ABCB9	0.41	6.11	0.31	2.72e-9	Height;Educational attainment;Head circumference (infant);
LIHC	trans	rs10411161	0.748	rs17835306	chr19:52385266	G/A	cg22319618	chr22:45562946	NUP50	-0.6	-7.1	-0.36	7.48e-12	Breast cancer;
LIHC	trans	rs800082	1.000	rs1007564	chr3:144311843	C/T	cg24215973	chr2:240111563	HDAC4	-0.42	-6.1	-0.31	2.92e-9	Smoking behavior;
LIHC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.69	-9.9	-0.47	1.69e-20	Corneal structure;
LIHC	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	1.03	10.03	0.48	6.42e-21	Mean corpuscular volume;
LIHC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.32	0.58	6.77e-33	Vitiligo;
LIHC	cis	rs244293	1.000	rs244299	chr17:53240266	A/C	cg19360675	chr17:53046073	COX11;STXBP4	0.44	6.22	0.32	1.45e-9	Menarche (age at onset);
LIHC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg14024328	chr4:719362	PCGF3	-0.47	-7.07	-0.36	8.66e-12	White blood cell count;
LIHC	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg23690444	chr14:81902736	NA	-0.44	-6.21	-0.32	1.53e-9	Night sleep phenotypes;
LIHC	cis	rs57590327	0.504	rs4856348	chr3:81502923	T/G	cg07356753	chr3:81810745	GBE1	0.45	6.57	0.33	1.83e-10	Extraversion;
LIHC	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.22	6.02	0.31	4.4e-9	Calcium levels;
LIHC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.38	0.33	5.62e-10	Glycated hemoglobin levels;
LIHC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg11062466	chr8:58055876	NA	0.4	5.82	0.3	1.35e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.5	8.18	0.4	5.68e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	0.87	14.21	0.61	2.47e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs9543976	1.000	rs8192762	chr13:76176680	A/T	cg01531495	chr13:76123901	UCHL3	0.49	5.84	0.3	1.23e-8	Diabetic retinopathy;
LIHC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.81	-0.35	4.48e-11	Gut microbiome composition (summer);
LIHC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.1	0.44	7.68e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs5756813	0.715	rs5756825	chr22:38199950	T/C	cg19894588	chr14:64061835	NA	0.81	14.18	0.61	3.3e-36	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.62	-8.87	-0.43	4.06e-17	White matter hyperintensity burden;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03698702	chr19:36236336	PSENEN;U2AF1L4	0.47	6.52	0.33	2.48e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.36	-5.97	-0.31	5.95e-9	IgG glycosylation;
LIHC	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg15841412	chr13:111365552	ING1	0.5	6.17	0.32	1.9e-9	Coronary artery disease;
LIHC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.34	-6.83	-0.35	3.89e-11	Body mass index;
LIHC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-11.05	-0.51	1.77e-24	Mean corpuscular volume;
LIHC	cis	rs7129220	0.588	rs61878628	chr11:10128872	T/G	cg01453529	chr11:10209919	SBF2	-0.39	-6.8	-0.35	4.7e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.96	0.31	6.15e-9	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs13098911	0.540	rs2171531	chr3:45981171	C/T	cg21656520	chr2:210867290	RPE	0.85	6.08	0.31	3.26e-9	Celiac disease;
LIHC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21467203	chr3:49911342	NA	0.5	9.13	0.44	6.05e-18	Body mass index;
LIHC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg05535760	chr7:792225	HEATR2	-0.46	-6.34	-0.32	7.3e-10	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs7116495	0.881	rs7930142	chr11:71737016	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-8.04	-0.4	1.43e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.74	-0.3	2.04e-8	Colorectal cancer;
LIHC	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.59	9.76	0.47	5.12e-20	Gait speed in old age;
LIHC	cis	rs9888615	0.646	rs11157934	chr14:53365816	A/G	cg00686598	chr14:53173677	PSMC6	-0.47	-6.36	-0.33	6.33e-10	Systolic blood pressure;
LIHC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.6	-0.38	2.91e-13	Schizophrenia;
LIHC	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.75	8.4	0.41	1.19e-15	Exhaled nitric oxide levels;
LIHC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.43	-6.86	-0.35	3.27e-11	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.62	0.38	2.44e-13	Prudent dietary pattern;
LIHC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.61	7.03	0.36	1.09e-11	Menarche (age at onset);
LIHC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.44	0.37	8.16e-13	Endometrial cancer;
LIHC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.14	11.67	0.53	1e-26	Opioid sensitivity;
LIHC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.36	-6.5	-0.33	2.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.57	9.74	0.47	5.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11645453	chr3:52864694	ITIH4	-0.22	-6.16	-0.32	1.99e-9	Bipolar disorder;
LIHC	cis	rs12477438	0.539	rs62156558	chr2:99553104	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-12.36	-0.56	2.79e-29	Chronic sinus infection;
LIHC	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg00042356	chr1:8021962	PARK7	0.9	9.08	0.44	8.51e-18	Inflammatory bowel disease;
LIHC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.74	-0.3	2.1e-8	Uric acid levels;
LIHC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.83	-0.39	6.02e-14	Type 2 diabetes;
LIHC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	1.01	18.36	0.7	6.84e-53	Tonsillectomy;
LIHC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg13047869	chr3:10149882	C3orf24	0.49	6.39	0.33	5.37e-10	Alzheimer's disease;
LIHC	cis	rs72627123	0.867	rs77321049	chr14:74455219	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.46	0.42	8.11e-16	Morning vs. evening chronotype;
LIHC	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.03	-0.44	1.32e-17	Coronary heart disease;
LIHC	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.27	0.32	1.07e-9	Response to antipsychotic treatment;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg05484376	chr2:27715224	FNDC4	0.36	6.16	0.32	2.07e-9	Total body bone mineral density;
LIHC	cis	rs4650994	0.593	rs7552110	chr1:178542154	A/T	cg05350800	chr1:178550844	NA	-0.35	-7.64	-0.38	2.26e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03627896	chr16:30934334	NCRNA00095	0.47	6.72	0.34	7.49e-11	Cognitive function;
LIHC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg08824895	chr13:115047677	UPF3A	0.49	7.11	0.36	7.01e-12	Schizophrenia;
LIHC	cis	rs600806	0.888	rs12046539	chr1:109875415	C/T	cg16275483	chr1:110013120	SYPL2	-0.49	-6.11	-0.31	2.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs151997	0.671	rs152926	chr5:50201787	G/A	cg06027927	chr5:50259733	NA	-0.45	-6.64	-0.34	1.25e-10	Callous-unemotional behaviour;
LIHC	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg15704280	chr7:45808275	SEPT13	0.62	6.4	0.33	5.11e-10	Axial length;
LIHC	cis	rs807029	0.533	rs2295716	chr10:102744214	T/C	cg27255678	chr10:102756921	LZTS2	0.52	7.31	0.37	1.85e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	6.15	0.32	2.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.4	8.09	0.4	1.05e-14	Renal cell carcinoma;
LIHC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	13.56	0.59	8.18e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.33	7.38	0.37	1.19e-12	Ulcerative colitis;
LIHC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.06	0.36	9.37e-12	Response to antipsychotic treatment;
LIHC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.26	-0.49	1.02e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg08888203	chr3:10149979	C3orf24	0.55	6.36	0.33	6.56e-10	Alzheimer's disease;
LIHC	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.35	-0.32	6.71e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg14791747	chr16:20752902	THUMPD1	0.48	6.61	0.34	1.44e-10	Dental caries;
LIHC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg15832292	chr6:96025679	MANEA	0.59	7.82	0.39	6.63e-14	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg12903224	chr12:29470962	FAR2	-0.4	-6.39	-0.33	5.49e-10	QT interval;
LIHC	trans	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg10208301	chr11:6592745	DNHD1	0.47	6.68	0.34	9.96e-11	Coronary artery calcification;
LIHC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg17771515	chr6:154831774	CNKSR3	0.58	6.14	0.32	2.25e-9	Lipoprotein (a) levels;
LIHC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.92	0.47	1.54e-20	Platelet count;
LIHC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.77	-0.3	1.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-6.97	-0.35	1.67e-11	Hepatocellular carcinoma;
LIHC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg24130564	chr14:104152367	KLC1	-0.56	-9.2	-0.45	3.52e-18	Reticulocyte count;
LIHC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16024904	chr19:17905718	B3GNT3	0.42	6.05	0.31	3.79e-9	Tumor biomarkers;
LIHC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-7.08	-0.36	8.04e-12	Morning vs. evening chronotype;
LIHC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.09	0.55	2.84e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg24441899	chr7:4244372	SDK1	-0.29	-6.07	-0.31	3.44e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LIHC	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.67	0.38	1.8e-13	Corneal astigmatism;
LIHC	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.69	-0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.35	-5.72	-0.3	2.32e-8	IgG glycosylation;
LIHC	cis	rs332507	0.830	rs12631364	chr3:124405042	A/T	cg05980111	chr3:124395277	KALRN	0.45	6.91	0.35	2.34e-11	Plateletcrit;
LIHC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-8.04	-0.4	1.46e-14	Crohn's disease;
LIHC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.27	0.61	1.46e-36	Multiple sclerosis;
LIHC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg03945807	chr20:60948434	NA	0.39	6.49	0.33	3.07e-10	Colorectal cancer;
LIHC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.94	0.51	4.32e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.72	-6.15	-0.32	2.14e-9	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.2	0.36	3.76e-12	Monocyte percentage of white cells;
LIHC	trans	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg23598604	chr1:99732472	LPPR4	-0.3	-6.06	-0.31	3.5e-9	Multiple myeloma;
LIHC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.39	6.5	0.33	2.9e-10	Reticulocyte count;High light scatter reticulocyte count;
LIHC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.48	7.31	0.37	1.94e-12	Height;
LIHC	trans	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg01134436	chr17:81009848	B3GNTL1	0.8	6.95	0.35	1.89e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.55	7.29	0.37	2.14e-12	Emphysema distribution in smoking;
LIHC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg12863693	chr15:85201151	NMB	0.43	6.13	0.31	2.36e-9	Schizophrenia;
LIHC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.01	0.58	1.08e-31	Cognitive test performance;
LIHC	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.63	11.79	0.54	3.78e-27	Schizophrenia;
LIHC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.39	-6.01	-0.31	4.72e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.47	-7.45	-0.37	7.78e-13	Cognitive function;
LIHC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.43	-6.1	-0.31	2.86e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.9	0.43	3.43e-17	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.86	0.3	1.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9322817	0.691	rs4299867	chr6:105325383	G/C	cg02098413	chr6:105308735	HACE1	0.41	7.7	0.38	1.49e-13	Thyroid stimulating hormone;
LIHC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.76	0.34	5.9e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg02836325	chr17:76403955	PGS1	0.33	6.55	0.33	2.09e-10	HDL cholesterol levels;
LIHC	cis	rs400736	0.729	rs9434949	chr1:8006083	C/G	cg25007680	chr1:8021821	PARK7	-0.48	-7.57	-0.38	3.44e-13	Response to antidepressants and depression;
LIHC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.71	9.07	0.44	9.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	6.92	0.35	2.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.8	0.35	4.69e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.54	-7.4	-0.37	1.07e-12	Body mass index;
LIHC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.35	-5.72	-0.3	2.36e-8	Menopause (age at onset);
LIHC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.21	0.41	4.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-10.81	-0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-6.0	-0.31	5.09e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs1853665	0.580	rs4242283	chr6:150273406	C/G	cg16301758	chr6:150275521	NA	0.4	6.15	0.32	2.18e-9	Radiation response;
LIHC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.34	-6.43	-0.33	4.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	6.04e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg26395211	chr5:140044315	WDR55	-0.41	-6.09	-0.31	3.04e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.23	0.41	3.92e-15	Mean corpuscular volume;
LIHC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.46	0.59	1.91e-33	Lung cancer in ever smokers;
LIHC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.02	0.48	6.82e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg07148914	chr20:33460835	GGT7	-0.57	-8.68	-0.43	1.6e-16	Height;
LIHC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.8	9.86	0.47	2.41e-20	Cognitive function;
LIHC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.62	8.39	0.41	1.28e-15	Behavioural disinhibition (generation interaction);
LIHC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg10820045	chr2:198174542	NA	0.53	8.7	0.43	1.44e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.51	6.24	0.32	1.3e-9	Bone mineral density (hip);Bone mineral density (spine);
LIHC	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	trans	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg25482853	chr8:67687455	SGK3	0.62	6.77	0.34	5.53e-11	Obesity-related traits;
LIHC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg06565975	chr8:143823917	SLURP1	0.33	6.14	0.32	2.24e-9	Urinary tract infection frequency;
LIHC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.86	-0.35	3.29e-11	Diabetic kidney disease;
LIHC	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.66	7.4	0.37	1.08e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs10106298	0.846	rs1550005	chr8:103681662	C/G	cg10187029	chr8:103597600	NA	0.46	6.17	0.32	1.9e-9	Schizophrenia;
LIHC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.52	8.56	0.42	3.83e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.44	7.22	0.36	3.4e-12	Mean corpuscular volume;
LIHC	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.42	-5.74	-0.3	2.05e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.02	0.44	1.37e-17	Response to antipsychotic treatment;
LIHC	cis	rs8103278	0.740	rs72626215	chr19:46294136	G/A	cg14061069	chr19:46274453	DMPK	-0.47	-6.76	-0.34	6.08e-11	Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-11.01	-0.51	2.51e-24	Alzheimer's disease;
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg16358155	chr3:195490169	MUC4	0.45	6.84	0.35	3.76e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.64	9.41	0.45	7.22e-19	Monocyte count;
LIHC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg24296786	chr1:45957014	TESK2	0.42	5.99	0.31	5.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6750047	0.625	rs336036	chr2:38261143	C/T	cg07380506	chr2:38303506	CYP1B1	-0.55	-6.93	-0.35	2.09e-11	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg24069376	chr3:38537580	EXOG	-0.39	-7.04	-0.36	1.09e-11	Electrocardiographic conduction measures;
LIHC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.37	8.83	0.43	5.34e-17	Immature fraction of reticulocytes;
LIHC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.61	-8.46	-0.42	8.09e-16	Migraine;
LIHC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg06781209	chr11:61594997	FADS2	-0.69	-6.44	-0.33	4.1e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.63	0.38	2.33e-13	Mean platelet volume;
LIHC	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.64	12.8	0.57	6.22e-31	Schizophrenia;
LIHC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg15832292	chr6:96025679	MANEA	0.63	6.98	0.35	1.58e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7258015	0.865	rs7250656	chr19:10448566	A/G	cg13981319	chr19:10446556	ICAM3	0.46	7.21	0.36	3.68e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs2421770	0.530	rs4756218	chr11:35370113	G/A	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.59	-0.38	3.02e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg18266620	chr1:110882148	RBM15	-0.39	-6.03	-0.31	4.18e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	1.02	21.29	0.75	1.19e-64	Height;
LIHC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.99	16.06	0.66	1.2e-43	Metabolic syndrome;
LIHC	cis	rs6442522	0.526	rs909354	chr3:15520244	C/T	cg16303742	chr3:15540471	COLQ	0.36	5.88	0.3	9.93e-9	Uric acid levels;
LIHC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.77	0.34	5.75e-11	Subjective well-being;
LIHC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.5	-0.33	2.91e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg22842854	chr12:123319900	HIP1R	-0.74	-9.7	-0.46	8.23e-20	Schizophrenia;
LIHC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-15.13	-0.63	6.18e-40	Headache;
LIHC	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg27211696	chr2:191398769	TMEM194B	-0.44	-5.83	-0.3	1.3e-8	Diastolic blood pressure;
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.65	9.23	0.45	2.89e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg11693508	chr17:37793320	STARD3	-0.68	-7.39	-0.37	1.12e-12	Bipolar disorder;
LIHC	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.45	0.33	3.82e-10	Mean corpuscular volume;
LIHC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	0.6	6.13	0.31	2.43e-9	Obesity-related traits;
LIHC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.21	-0.36	3.58e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg18887096	chr2:219472410	PLCD4	0.36	6.39	0.33	5.46e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7619427	1.000	rs7610078	chr3:44074018	C/T	cg24966902	chr3:44043705	NA	0.52	7.61	0.38	2.63e-13	Schizophrenia;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14531310	chr9:34401237	C9orf25	0.38	6.11	0.31	2.79e-9	Bilirubin levels;
LIHC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg05110241	chr16:68378359	PRMT7	-0.87	-9.82	-0.47	3.27e-20	Schizophrenia;
LIHC	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	0.72	7.97	0.4	2.39e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs74181299	0.570	rs10197530	chr2:65355604	T/A	cg05010058	chr2:65284262	CEP68	-0.41	-6.74	-0.34	6.94e-11	Pulse pressure;
LIHC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.74	10.99	0.51	2.94e-24	Corneal astigmatism;
LIHC	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.88	-19.19	-0.72	3.14e-56	Height;
LIHC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.56	5.95	0.31	6.77e-9	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.63	9.62	0.46	1.51e-19	Renal cell carcinoma;
LIHC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.31	-5.73	-0.3	2.18e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.74	-10.79	-0.5	1.52e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.64	-0.38	2.18e-13	Body mass index;
LIHC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21467203	chr3:49911342	NA	-0.51	-9.37	-0.45	1.02e-18	Body mass index;
LIHC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.66	6.35	0.32	6.89e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02290350	chr8:58132656	NA	0.5	8.99	0.44	1.74e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	12.11	0.55	2.49e-28	Platelet count;
LIHC	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.5	7.6	0.38	2.92e-13	Corneal astigmatism;
LIHC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.54	-6.42	-0.33	4.61e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.47	7.97	0.4	2.37e-14	Obesity-related traits;
LIHC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.51	5.8	0.3	1.51e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg04306507	chr14:55594613	LGALS3	0.32	5.96	0.31	6.19e-9	Protein biomarker;
LIHC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.74	-0.3	2.12e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11673344	0.765	rs826296	chr19:37438286	A/G	cg27390819	chr19:37464633	NA	-0.52	-6.22	-0.32	1.42e-9	Obesity-related traits;
LIHC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.98	-0.44	1.91e-17	Blood metabolite levels;
LIHC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.47	7.66	0.38	1.88e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11603020	0.950	rs11229066	chr11:57374871	C/G	cg19752551	chr11:57585705	CTNND1	-0.46	-5.9	-0.3	8.98e-9	Blood protein levels;
LIHC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.54	-9.67	-0.46	1.07e-19	Mean corpuscular volume;
LIHC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg12373951	chr3:133503437	NA	0.53	8.8	0.43	6.65e-17	Ankle injury;
LIHC	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg19336497	chr11:14380999	RRAS2	-0.36	-6.12	-0.31	2.54e-9	Mitochondrial DNA levels;
LIHC	cis	rs2637266	0.597	rs2583065	chr10:78555915	A/G	cg18941641	chr10:78392320	NA	0.3	6.46	0.33	3.58e-10	Pulmonary function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11212172	chr10:53459438	PRKG1;CSTF2T	0.45	7.13	0.36	6.17e-12	Cognitive function;
LIHC	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.29	-8.22	-0.41	4.24e-15	Intelligence;
LIHC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.75	-11.65	-0.53	1.23e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.98	0.4	2.24e-14	Corneal astigmatism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02804564	chr10:112679224	NCRNA00081;SHOC2	0.44	7.15	0.36	5.44e-12	Cognitive function;
LIHC	cis	rs2334880	0.678	rs12918320	chr16:71463602	A/G	cg06353428	chr16:71660113	MARVELD3	-0.97	-9.46	-0.46	5.06e-19	Malaria;
LIHC	cis	rs611744	0.967	rs688746	chr8:109225725	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-7.24	-0.36	3.03e-12	Post bronchodilator FEV1;
LIHC	cis	rs2191566	0.821	rs62119173	chr19:44518073	G/A	cg18700516	chr19:44507157	ZNF230	-0.35	-5.86	-0.3	1.11e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.66	-13.7	-0.6	2.43e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs3820500	1.000	rs3820500	chr1:118013322	A/G	cg20383390	chr1:117909022	MAN1A2	-0.44	-5.87	-0.3	1.01e-8	Pneumonia;
LIHC	cis	rs963731	0.649	rs297140	chr2:39319121	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-5.95	-0.31	6.6e-9	Corticobasal degeneration;
LIHC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.06	0.4	1.29e-14	Motion sickness;
LIHC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.51	6.88	0.35	2.79e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11955398	0.529	rs62373032	chr5:59956159	G/C	cg02684056	chr5:59996105	DEPDC1B	0.39	5.81	0.3	1.44e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg09417038	chr21:47716443	C21orf57	0.52	7.94	0.39	2.93e-14	Testicular germ cell tumor;
LIHC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	1.15	9.07	0.44	9.6e-18	Arsenic metabolism;
LIHC	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.66	-5.72	-0.3	2.34e-8	Inflammatory biomarkers;
LIHC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.46	-6.29	-0.32	9.58e-10	Blood pressure (smoking interaction);
LIHC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.0	0.51	2.64e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.08e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Coronary artery disease;
LIHC	cis	rs7523273	0.526	rs1204706	chr1:208021060	G/T	cg22525895	chr1:207977042	MIR29B2	-0.59	-9.1	-0.44	7.76e-18	Schizophrenia;
LIHC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.87	-12.24	-0.55	8.17e-29	Diastolic blood pressure;
LIHC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.9	-18.33	-0.7	9.41e-53	Height;
LIHC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg20487152	chr13:99095054	FARP1	0.38	6.23	0.32	1.37e-9	Longevity;
LIHC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02985541	chr2:219472218	PLCD4	-0.38	-5.91	-0.3	8.4e-9	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.51	6.89	0.35	2.68e-11	Emphysema distribution in smoking;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27576415	chr15:41709087	RTF1	0.41	6.42	0.33	4.59e-10	Cognitive function;
LIHC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg13444538	chr7:158905317	VIPR2	-0.32	-5.95	-0.31	6.65e-9	Facial morphology (factor 20);
LIHC	cis	rs244293	1.000	rs244292	chr17:53230734	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.33	-0.37	1.65e-12	Menarche (age at onset);
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.61	9.45	0.46	5.37e-19	Height;
LIHC	trans	rs11985561	1.000	rs11985561	chr8:3452262	A/C	cg21587066	chr13:37004940	CCNA1	0.5	6.55	0.33	2.14e-10	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LIHC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.67	-9.66	-0.46	1.11e-19	Initial pursuit acceleration;
LIHC	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.38	5.85	0.3	1.17e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	5.88	0.3	9.78e-9	Schizophrenia;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg07772128	chr15:75095447	CSK	-0.48	-6.43	-0.33	4.26e-10	Glycated hemoglobin levels;
LIHC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	11.46	0.53	5.76e-26	Platelet count;
LIHC	cis	rs10242455	0.571	rs11972210	chr7:99206943	A/C	cg18809830	chr7:99032528	PTCD1	-0.78	-6.21	-0.32	1.53e-9	Blood metabolite levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07729303	chr15:22940817	CYFIP1	0.42	6.98	0.35	1.58e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-0.85	-9.19	-0.45	3.91e-18	Exhaled nitric oxide output;
LIHC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.66	11.76	0.54	4.95e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.55	-9.01	-0.44	1.53e-17	Cognitive function;
LIHC	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.61	-9.07	-0.44	9.29e-18	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LIHC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg18944383	chr4:111397179	ENPEP	0.32	7.21	0.36	3.69e-12	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18502334	chr7:4681577	NA	0.51	6.65	0.34	1.16e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg11441379	chr12:63026424	NA	0.61	6.22	0.32	1.45e-9	IgG glycosylation;
LIHC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	0.92	15.83	0.65	9.93e-43	Testicular germ cell tumor;
LIHC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-13.28	-0.58	1e-32	Ulcerative colitis;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg01399255	chr7:100271274	GNB2	-0.45	-6.62	-0.34	1.36e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.35	0.66	8.35e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.29	-0.41	2.7e-15	Response to antipsychotic treatment;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.96	-0.35	1.79e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.42	6.64	0.34	1.23e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg21361702	chr7:150065534	REPIN1	0.48	6.54	0.33	2.26e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.4	6.03	0.31	4.22e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg07959070	chr22:50026188	C22orf34	-0.26	-6.68	-0.34	9.87e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	12.76	0.57	8.76e-31	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.44	6.21	0.32	1.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs74233809	1.000	rs10509759	chr10:104689665	A/T	cg03493300	chr10:104813866	CNNM2	0.47	6.15	0.32	2.16e-9	Birth weight;
LIHC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.52	-6.52	-0.33	2.51e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.53	-8.87	-0.43	4.05e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg10763598	chr19:19431466	KIAA0892;SF4	0.58	6.49	0.33	3.01e-10	Tonsillectomy;
LIHC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.16	0.44	4.71e-18	Schizophrenia;
LIHC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.41	5.87	0.3	1.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.87	-0.3	1.01e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.93	-0.31	7.29e-9	Calcium levels;
LIHC	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.77	-0.3	1.82e-8	Biliary atresia;
LIHC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-10.31	-0.49	6.79e-22	Asthma;
LIHC	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.19	-0.36	4.23e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg15848620	chr12:58087721	OS9	0.5	6.38	0.33	5.68e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	4.09e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.99	10.76	0.5	1.9e-23	Triglycerides;
LIHC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.8	-7.85	-0.39	5.25e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.26	0.37	2.61e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.65	-0.38	2e-13	Schizophrenia;
LIHC	cis	rs74181299	0.712	rs2241160	chr2:65291546	A/G	cg05010058	chr2:65284262	CEP68	0.36	6.38	0.33	5.72e-10	Pulse pressure;
LIHC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.66	-6.54	-0.33	2.23e-10	Vitiligo;
LIHC	cis	rs11958404	0.546	rs7727054	chr5:157442692	G/A	cg05962755	chr5:157440814	NA	0.63	8.24	0.41	3.77e-15	IgG glycosylation;
LIHC	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.94	17.56	0.69	1.21e-49	Menopause (age at onset);
LIHC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs7116495	1.000	rs656640	chr11:71781710	T/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-6.23	-0.32	1.37e-9	Longevity;
LIHC	trans	rs78049276	0.568	rs10305839	chr4:148400413	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.47	-0.37	6.61e-13	Pulse pressure;
LIHC	cis	rs4268898	0.828	rs2702121	chr2:24610392	C/A	cg06627628	chr2:24431161	ITSN2	0.55	7.57	0.38	3.5e-13	Asthma;
LIHC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.35	6.41	0.33	4.78e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg25801113	chr15:45476975	SHF	0.38	6.55	0.33	2.1e-10	Uric acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15254786	chr2:207630414	MDH1B;FASTKD2	0.43	6.19	0.32	1.76e-9	Pancreatic cancer;
LIHC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.47	-7.48	-0.37	6.31e-13	Height;
LIHC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.67	11.04	0.51	1.99e-24	Type 2 diabetes;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg00626518	chr5:10441665	ROPN1L	-0.42	-6.04	-0.31	4.03e-9	Eotaxin levels;
LIHC	trans	rs10411161	0.752	rs9973239	chr19:52406779	C/T	cg22319618	chr22:45562946	NUP50	-0.5	-6.55	-0.33	2.13e-10	Breast cancer;
LIHC	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg12560992	chr17:57184187	TRIM37	0.68	8.8	0.43	7e-17	Vitamin D levels;
LIHC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.52	-7.86	-0.39	5.06e-14	Response to diuretic therapy;
LIHC	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg07856975	chr6:36356162	ETV7	0.35	5.78	0.3	1.69e-8	Platelet distribution width;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13619988	chr14:58894515	KIAA0586;TIMM9	0.51	7.46	0.37	7.3e-13	Cognitive function;
LIHC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.48	-6.28	-0.32	1.03e-9	Subjective well-being;
LIHC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg23461800	chr14:103021989	NA	-0.43	-5.88	-0.3	9.57e-9	Platelet count;
LIHC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.96	0.44	2.2e-17	Lung cancer in ever smokers;
LIHC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.79	11.65	0.53	1.22e-26	Metabolic syndrome;
LIHC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.56	8.12	0.4	8.67e-15	Renal cell carcinoma;
LIHC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.98	12.81	0.57	5.69e-31	Breast cancer;
LIHC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.82	-13.79	-0.6	1.02e-34	Aortic root size;
LIHC	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.37	7.24	0.36	3.02e-12	Growth-regulated protein alpha levels;
LIHC	trans	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.52	-7.9	-0.39	3.79e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.58	0.53	2.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09133192	chr4:89205337	PPM1K	0.47	6.34	0.32	7.23e-10	Pancreatic cancer;
LIHC	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.35	-8.13	-0.4	8e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg07133347	chr1:107600762	PRMT6	-0.45	-6.73	-0.34	6.96e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.84	0.3	1.19e-8	Self-reported allergy;
LIHC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.66	0.59	3.37e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.93	17.76	0.69	1.75e-50	Menopause (age at onset);
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08219700	chr8:58056026	NA	0.55	6.72	0.34	7.75e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.34	-8.4	-0.41	1.21e-15	Longevity;Endometriosis;
LIHC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.74	-0.3	2.06e-8	Uric acid levels;
LIHC	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg03934865	chr2:198174659	NA	-0.46	-6.63	-0.34	1.32e-10	Intracranial aneurysm;
LIHC	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg07884673	chr3:53033167	SFMBT1	0.76	6.02	0.31	4.5e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.69	-8.69	-0.43	1.55e-16	Gut microbiome composition (summer);
LIHC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.33	6.06	0.31	3.5e-9	HDL cholesterol;
LIHC	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg06026331	chr20:60912101	LAMA5	-0.45	-7.43	-0.37	8.9e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg09165964	chr15:75287851	SCAMP5	-0.42	-5.87	-0.3	1.01e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.46	-6.99	-0.35	1.47e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs10916814	0.589	rs7416238	chr1:20897240	A/G	cg24502330	chr1:20914028	CDA	-0.31	-6.76	-0.34	6.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.6	9.5	0.46	3.88e-19	Obesity-related traits;
LIHC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	9.75	0.47	5.54e-20	Chronic sinus infection;
LIHC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.53	-7.15	-0.36	5.44e-12	Blood metabolite levels;
LIHC	cis	rs4407350	0.715	rs3827400	chr22:44890604	T/C	cg26276947	chr22:44892394	LDOC1L	0.33	6.19	0.32	1.69e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg25364880	chr3:44379878	C3orf23	0.5	7.19	0.36	4.22e-12	Depressive symptoms;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg05052194	chr1:2160249	SKI	0.43	6.18	0.32	1.85e-9	Migraine with aura;
LIHC	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg19735590	chr5:154026979	NA	0.47	5.73	0.3	2.22e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.33	6.6	0.34	1.53e-10	Multiple sclerosis;
LIHC	cis	rs1511802	0.501	rs7661323	chr4:187115996	T/G	cg24794857	chr4:187113578	CYP4V2	0.37	5.88	0.3	9.86e-9	Blood protein levels;
LIHC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11987759	chr7:65425863	GUSB	0.38	6.06	0.31	3.61e-9	Calcium levels;
LIHC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.95	11.11	0.51	1.12e-24	Triglycerides;
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.58	6.82	0.35	4.03e-11	Alzheimer's disease;
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.67	10.06	0.48	4.98e-21	Menarche (age at onset);
LIHC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.62	9.08	0.44	8.69e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	15.86	0.65	7.41e-43	Smoking behavior;
LIHC	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg21174375	chr14:64681225	SYNE2	-0.39	-6.09	-0.31	3.09e-9	Atrial fibrillation;
LIHC	cis	rs12644436	0.615	rs4416441	chr4:88776233	A/G	cg06891869	chr4:88767617	MEPE	0.43	7.64	0.38	2.2e-13	HIV-1 viral setpoint;
LIHC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.41	1.56e-15	Bladder cancer;
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02290350	chr8:58132656	NA	0.48	9.52	0.46	3.28e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.63	0.46	1.44e-19	Melanoma;
LIHC	cis	rs887797	0.538	rs6504444	chr17:64579751	A/G	cg27019712	chr17:64599478	PRKCA	-0.39	-6.71	-0.34	8.12e-11	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.54	8.45	0.42	8.75e-16	Waist circumference;Body mass index;
LIHC	cis	rs36051895	0.623	rs7035456	chr9:5261440	G/A	cg02405213	chr9:5042618	JAK2	-0.57	-9.29	-0.45	1.91e-18	Pediatric autoimmune diseases;
LIHC	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.52	-8.67	-0.42	1.75e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19500275	chr17:80737654	TBCD	0.41	5.76	0.3	1.86e-8	Glycated hemoglobin levels;
LIHC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.93	14.46	0.62	2.67e-37	Vitamin D levels;
LIHC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	0.92	16.54	0.67	1.44e-45	Parkinson's disease;
LIHC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.92	0.3	7.89e-9	Electroencephalogram traits;
LIHC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.41	-6.22	-0.32	1.42e-9	Obesity-related traits;
LIHC	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg14593290	chr7:50529359	DDC	0.4	6.65	0.34	1.18e-10	Malaria;
LIHC	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.6	-0.62	7.2e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19671926	chr4:122722719	EXOSC9	0.55	8.49	0.42	6.41e-16	Type 2 diabetes;
LIHC	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.51	7.28	0.37	2.38e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.15	0.32	2.12e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.32	-6.43	-0.33	4.29e-10	DNA methylation (variation);
LIHC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.74	9.22	0.45	3.14e-18	Cognitive function;
LIHC	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.39	-8.51	-0.42	5.36e-16	Obesity-related traits;
LIHC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.47	6.74	0.34	6.8e-11	Diastolic blood pressure;
LIHC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.65	-9.86	-0.47	2.36e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs847649	0.961	rs10250490	chr7:102537277	A/G	cg18108683	chr7:102477205	FBXL13	-0.48	-7.09	-0.36	7.8e-12	Morning vs. evening chronotype;
LIHC	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.65	10.76	0.5	1.96e-23	Pediatric autoimmune diseases;
LIHC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg12798992	chr6:167411361	FGFR1OP	-0.48	-7.76	-0.39	1.02e-13	Crohn's disease;
LIHC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg05590025	chr7:65112418	INTS4L2	0.61	6.78	0.34	5.22e-11	Diabetic kidney disease;
LIHC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.58	10.31	0.49	6.89e-22	Dupuytren's disease;
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-8.49	-0.42	6.37e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.33	-5.73	-0.3	2.2e-8	Lymphocyte counts;
LIHC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg11812906	chr14:75593930	NEK9	-0.46	-7.28	-0.37	2.32e-12	IgG glycosylation;
LIHC	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.39	6.71	0.34	8.13e-11	Lewy body disease;
LIHC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.42	-8.3	-0.41	2.43e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs2257205	0.667	rs78253932	chr17:56804101	C/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.67	-0.34	1e-10	Pancreatic cancer;
LIHC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg02931644	chr1:25747376	RHCE	-0.37	-8.22	-0.41	4.26e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.68	-0.53	9.29e-27	Chronic sinus infection;
LIHC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-7.45	-0.37	7.48e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9326778	0.520	rs60417058	chr5:108842205	G/A	cg17395555	chr5:108820864	NA	-0.37	-6.41	-0.33	4.88e-10	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.19	6.05	0.31	3.87e-9	Cutaneous nevi;
LIHC	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-7.16	-0.36	5.11e-12	Schizophrenia;
LIHC	cis	rs6583826	0.538	rs11187076	chr10:94336963	G/A	cg25506282	chr10:94462361	NA	0.37	6.38	0.33	5.64e-10	Type 2 diabetes;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08585897	chr16:75680535	KARS;TERF2IP	0.48	6.68	0.34	9.66e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02290350	chr8:58132656	NA	0.4	8.56	0.42	4.01e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.35	0.52	1.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.52	0.53	3.75e-26	Colorectal cancer;
LIHC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg06565975	chr8:143823917	SLURP1	0.33	6.28	0.32	1.01e-9	Urinary tract infection frequency;
LIHC	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	10.67	0.5	3.88e-23	Myopia (pathological);
LIHC	cis	rs2834256	0.527	rs9983905	chr21:34866858	C/T	cg14850771	chr21:34775459	IFNGR2	0.47	7.77	0.39	9.31e-14	Red cell distribution width;
LIHC	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg20240347	chr1:204465584	NA	-0.34	-7.13	-0.36	5.86e-12	Schizophrenia;
LIHC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.6	6.62	0.34	1.36e-10	Alzheimer's disease;
LIHC	trans	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg01134436	chr17:81009848	B3GNTL1	0.86	7.21	0.36	3.6e-12	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg13395646	chr4:1353034	KIAA1530	-0.65	-8.8	-0.43	7.08e-17	Longevity;
LIHC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.31	-0.37	1.88e-12	Lymphocyte counts;
LIHC	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.62	-0.38	2.56e-13	Capecitabine sensitivity;
LIHC	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.25	-0.32	1.22e-9	Metabolite levels;
LIHC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21467203	chr3:49911342	NA	-0.41	-7.07	-0.36	9e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.53	8.7	0.43	1.41e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7818688	0.653	rs11775475	chr8:95905489	T/G	cg16049864	chr8:95962084	TP53INP1	0.56	5.76	0.3	1.88e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg26139080	chr11:47293733	MADD	0.51	8.51	0.42	5.72e-16	HDL cholesterol;
LIHC	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.32	-0.37	1.83e-12	Urate levels in overweight individuals;
LIHC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.35	8.22	0.41	4.17e-15	Crohn's disease;
LIHC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs965469	1.000	rs6051672	chr20:3224819	C/T	cg25506879	chr20:3388711	C20orf194	-0.59	-6.8	-0.35	4.69e-11	IFN-related cytopenia;
LIHC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-14.67	-0.62	3.78e-38	Chronic sinus infection;
LIHC	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.34	-6.45	-0.33	3.83e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	7.02	0.36	1.17e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg21573476	chr21:45109991	RRP1B	-0.51	-9.63	-0.46	1.44e-19	Mean corpuscular volume;
LIHC	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-10.56	-0.5	9.78e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.64	-9.71	-0.46	7.59e-20	Longevity;
LIHC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21448741	chr8:58168803	NA	0.36	5.91	0.3	8.43e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21467203	chr3:49911342	NA	0.52	9.35	0.45	1.18e-18	Body mass index;
LIHC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg03859395	chr2:55845619	SMEK2	0.9	15.68	0.65	3.88e-42	Metabolic syndrome;
LIHC	cis	rs4788570	0.566	rs72795867	chr16:71484465	A/G	cg06353428	chr16:71660113	MARVELD3	-1.12	-10.11	-0.48	3.28e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	trans	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg26939375	chr7:64535504	NA	-0.42	-6.77	-0.34	5.53e-11	Aortic root size;
LIHC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.09	0.31	2.96e-9	Menopause (age at onset);
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.3	0.37	1.98e-12	Height;
LIHC	cis	rs4908768	0.520	rs11121224	chr1:8773515	A/G	cg20416874	chr1:8611966	RERE	-0.63	-11.43	-0.53	7.67e-26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.09	0.36	7.73e-12	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13128305	chr8:95961759	TP53INP1	-0.41	-6.22	-0.32	1.41e-9	Pancreatic cancer;
LIHC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.75	13.53	0.59	1.05e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11673344	0.734	rs1644638	chr19:37461415	C/A	cg27390819	chr19:37464633	NA	-0.53	-6.29	-0.32	9.74e-10	Obesity-related traits;
LIHC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg14222432	chr12:29376421	FAR2	0.36	7.2	0.36	3.95e-12	QT interval;
LIHC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.04e-32	Psoriasis;
LIHC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.72	-10.41	-0.49	3.17e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.44	-7.15	-0.36	5.21e-12	Homoarginine levels;
LIHC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.12	-0.36	6.25e-12	Heart rate;
LIHC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.07	-12.24	-0.55	7.79e-29	Vitiligo;
LIHC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.24	-0.41	3.72e-15	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.64	-9.25	-0.45	2.55e-18	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10624105	chr20:48729304	UBE2V1;TMEM189-UBE2V1	0.46	6.81	0.35	4.48e-11	Pancreatic cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08676730	chr17:53828263	PCTP	-0.5	-6.04	-0.31	4.02e-9	Systolic blood pressure;
LIHC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.34	6.72	0.34	7.68e-11	Coronary artery disease;
LIHC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.84	-0.43	5.21e-17	Blood metabolite levels;
LIHC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.69	7.29	0.37	2.18e-12	Alzheimer's disease;
LIHC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg16736954	chr20:23401023	NAPB	-0.7	-8.31	-0.41	2.21e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs11014306	1.000	rs7084900	chr10:25201585	G/A	cg17214381	chr4:188916668	ZFP42	-0.55	-6.24	-0.32	1.29e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.6	10.06	0.48	4.97e-21	Height;
LIHC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.8	0.3	1.54e-8	Menopause (age at onset);
LIHC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.71e-15	Body mass index;
LIHC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.7	8.73	0.43	1.16e-16	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.69	-0.38	1.56e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	7.45	0.37	7.65e-13	Lung cancer in ever smokers;
LIHC	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-0.87	-9.38	-0.45	9.07e-19	Exhaled nitric oxide output;
LIHC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.66	-10.33	-0.49	6.06e-22	Response to diuretic therapy;
LIHC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.46	6.59	0.34	1.65e-10	Longevity;
LIHC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg03013999	chr17:37608204	MED1	-0.36	-5.91	-0.3	8.49e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.48	-7.26	-0.37	2.67e-12	Height;
LIHC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.69	13.29	0.58	8.71e-33	Systemic lupus erythematosus;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14134019	chr9:90140250	DAPK1	0.41	6.53	0.33	2.32e-10	Bilirubin levels;
LIHC	cis	rs6977660	1.000	rs6959591	chr7:19821824	A/G	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs9378688	0.546	rs9405548	chr6:2208409	G/A	cg12303981	chr6:2244766	GMDS	-0.46	-6.19	-0.32	1.68e-9	Caudate nucleus volume;
LIHC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs9918079	0.560	rs10008376	chr4:15623955	A/G	cg21123203	chr4:15471301	CC2D2A	0.43	6.95	0.35	1.83e-11	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25219047	chr19:3500813	DOHH	0.43	6.44	0.33	4.08e-10	Pancreatic cancer;
LIHC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	9.11	0.44	6.83e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.91	16.39	0.66	5.92e-45	Parkinson's disease;
LIHC	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg25356066	chr3:128598488	ACAD9	0.54	7.21	0.36	3.57e-12	IgG glycosylation;
LIHC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.65	11.2	0.52	5.34e-25	Menopause (age at onset);
LIHC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	12.13	0.55	2.13e-28	Cognitive test performance;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg04013166	chr16:89971882	TCF25	0.55	7.23	0.36	3.16e-12	Skin colour saturation;
LIHC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.16	-0.32	2.06e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.54e-18	Bipolar disorder;
LIHC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.89	0.43	3.52e-17	Alzheimer's disease;
LIHC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.46	6.16	0.32	2.01e-9	Tourette syndrome;
LIHC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg20607798	chr8:58055168	NA	0.49	6.13	0.31	2.37e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-6.61	-0.34	1.47e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg19635926	chr16:89946313	TCF25	-0.52	-7.08	-0.36	8.23e-12	Skin colour saturation;
LIHC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg03037974	chr15:76606532	NA	0.74	14.42	0.62	3.55e-37	Blood metabolite levels;
LIHC	cis	rs526821	0.789	rs10896993	chr11:55303410	A/G	cg04317927	chr11:55418816	OR4S2	0.42	8.21	0.41	4.54e-15	Pediatric bone mineral density (spine);
LIHC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg10932868	chr11:921992	NA	0.38	7.32	0.37	1.83e-12	Alzheimer's disease (late onset);
LIHC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.23	-0.41	3.91e-15	Alzheimer's disease;
LIHC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.81	-11.89	-0.54	1.57e-27	Response to antineoplastic agents;
LIHC	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg25182066	chr10:30743637	MAP3K8	-0.48	-7.93	-0.39	3.23e-14	Inflammatory bowel disease;
LIHC	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.82	-0.35	4.26e-11	Blood pressure;
LIHC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.97	-0.47	9.8e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	1.22	9.96	0.47	1.14e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.8	12.79	0.57	7e-31	Chronic lymphocytic leukemia;
LIHC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.24	6.09	0.31	3.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.64	-9.06	-0.44	9.89e-18	Blood metabolite levels;
LIHC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.48	-7.82	-0.39	6.61e-14	Cognitive function;
LIHC	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.75	-0.3	2.01e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs526231	0.819	rs35801	chr5:102608213	G/T	cg05225461	chr5:102596755	C5orf30	0.37	5.75	0.3	1.98e-8	Primary biliary cholangitis;
LIHC	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.85	10.05	0.48	5.4e-21	Breast cancer;
LIHC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.35	4.56e-11	Diabetic kidney disease;
LIHC	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.34	20.4	0.74	4.42e-61	Corneal structure;
LIHC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.53	6.03	0.31	4.28e-9	Alzheimer's disease;
LIHC	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.48	-7.28	-0.37	2.34e-12	Blood protein levels;
LIHC	cis	rs12474201	0.832	rs35722922	chr2:47002226	A/G	cg06386533	chr2:46925753	SOCS5	0.6	6.43	0.33	4.25e-10	Height;
LIHC	cis	rs3820500	0.543	rs1290553	chr1:118056073	G/T	cg20383390	chr1:117909022	MAN1A2	-0.45	-5.8	-0.3	1.48e-8	Pneumonia;
LIHC	cis	rs4908768	0.906	rs10492965	chr1:8598127	G/A	cg25722041	chr1:8623473	RERE	0.42	6.01	0.31	4.7e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.79	-12.22	-0.55	9.41e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.53	9.18	0.44	4.13e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg25952890	chr19:58913133	NA	0.74	7.42	0.37	9.22e-13	Mean platelet volume;
LIHC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.67	12.46	0.56	1.26e-29	Longevity;
LIHC	trans	rs8030605	0.778	rs72740579	chr15:56640038	C/T	cg01710580	chr16:598674	SOLH	-0.66	-6.09	-0.31	3.08e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.55	9.0	0.44	1.6e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.82	-0.47	3.36e-20	Ulcerative colitis;
LIHC	cis	rs797680	0.856	rs4240966	chr1:93774812	C/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.67e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.13	0.4	7.92e-15	Electrocardiographic conduction measures;
LIHC	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.31	7.1	0.36	7.07e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg04359351	chr2:3481828	TTC15	0.28	5.94	0.31	7.04e-9	Neurofibrillary tangles;
LIHC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.38	-0.33	5.82e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs12980942	0.872	rs12327659	chr19:41796472	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.3	0.32	9.42e-10	Coronary artery disease;
LIHC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.92	0.47	1.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.59	-0.53	2.02e-26	Coffee consumption (cups per day);
LIHC	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg17218026	chr1:154582156	ADAR	0.31	6.07	0.31	3.3e-9	Blood protein levels;
LIHC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg04691961	chr3:161091175	C3orf57	0.41	6.48	0.33	3.12e-10	Morning vs. evening chronotype;
LIHC	cis	rs11955398	0.501	rs4235480	chr5:60032371	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.4	-5.71	-0.3	2.46e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.64	10.83	0.51	1.07e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.39	6.27	0.32	1.11e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.67	7.04	0.36	1.04e-11	Alzheimer's disease;
LIHC	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.52	-10.65	-0.5	4.47e-23	Late-onset Alzheimer's disease;
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.18	-0.48	2.02e-21	Type 2 diabetes;
LIHC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.79	-7.68	-0.38	1.74e-13	Diabetic retinopathy;
LIHC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.61	11.18	0.52	6.06e-25	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01500945	chr16:51185672	SALL1	0.45	6.8	0.35	4.72e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-9.14	-0.44	5.81e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4903214	0.895	rs10142706	chr14:74717304	A/G	cg11132536	chr14:74711944	VSX2	-0.24	-5.96	-0.31	6.29e-9	Inflammatory bowel disease;
LIHC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.82	-15.69	-0.65	3.74e-42	Coronary artery disease;
LIHC	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg04998671	chr14:104000505	TRMT61A	0.46	6.28	0.32	1.05e-9	Coronary artery disease;
LIHC	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.58	-0.34	1.72e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.45e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.48	0.53	5.19e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35883536	1.000	rs17403905	chr1:101107358	T/C	cg14515779	chr1:101123966	NA	-0.67	-13.22	-0.58	1.65e-32	Monocyte count;
LIHC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg22676075	chr6:135203613	NA	0.39	6.38	0.33	5.82e-10	Red blood cell count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24274347	chr12:132497611	EP400	-0.4	-6.1	-0.31	2.81e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg05564831	chr3:52568323	NT5DC2	0.37	5.93	0.31	7.25e-9	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01123250	chr2:210673545	UNC80	0.34	6.47	0.33	3.33e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.51	9.79	0.47	4.25e-20	Testicular germ cell tumor;
LIHC	cis	rs6466055	0.720	rs1204056	chr7:104957761	G/A	cg04380332	chr7:105027541	SRPK2	0.37	6.84	0.35	3.76e-11	Schizophrenia;
LIHC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	10.94	0.51	4.24e-24	Platelet count;
LIHC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.46	5.99	0.31	5.45e-9	Pancreatic cancer;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.33	5.9	0.3	8.69e-9	Calcium levels;
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg20090690	chr10:134436459	INPP5A	0.44	5.77	0.3	1.76e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.6	-9.12	-0.44	6.69e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	1.97e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7153648	1.000	rs7153648	chr14:61122526	C/G	cg27398547	chr14:60952738	C14orf39	0.63	7.05	0.36	1.02e-11	Prostate cancer;
LIHC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.57	9.86	0.47	2.46e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.42	5.8	0.3	1.5e-8	Mean platelet volume;
LIHC	trans	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg02759110	chr4:141489859	UCP1	-0.48	-6.37	-0.33	6.14e-10	Parkinson's disease;
LIHC	cis	rs16944613	0.588	rs6496698	chr15:91135558	A/G	cg26821196	chr15:91095069	CRTC3	0.43	7.27	0.37	2.5e-12	Colorectal cancer;
LIHC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.76	11.49	0.53	4.66e-26	Corneal astigmatism;
LIHC	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg03934865	chr2:198174659	NA	-0.59	-9.35	-0.45	1.19e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.43	8.3	0.41	2.37e-15	Height;
LIHC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg16479474	chr6:28041457	NA	0.38	6.3	0.32	9.1e-10	Cardiac Troponin-T levels;
LIHC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-9.73	-0.47	6.39e-20	Electroencephalogram traits;
LIHC	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.54	-8.25	-0.41	3.47e-15	Extraversion;
LIHC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.21	19.96	0.73	2.46e-59	Primary sclerosing cholangitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02585790	chr2:232329254	NCL	0.56	7.12	0.36	6.35e-12	Lung function (FEV1/FVC);
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22442454	chr1:209979470	IRF6	0.4	6.17	0.32	1.94e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.5	7.95	0.4	2.7e-14	Blood protein levels;
LIHC	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.82	7.64	0.38	2.28e-13	LDL cholesterol;
LIHC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg06466757	chr4:1255808	NA	-0.35	-5.9	-0.3	8.82e-9	Obesity-related traits;
LIHC	cis	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg23923672	chr12:105501055	KIAA1033	0.69	8.03	0.4	1.63e-14	IgG glycosylation;
LIHC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg14092571	chr14:90743983	NA	-0.37	-5.8	-0.3	1.53e-8	Mortality in heart failure;
LIHC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.85	12.81	0.57	6.11e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg16339924	chr4:17578868	LAP3	0.46	6.32	0.32	8.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg13628971	chr7:2884303	GNA12	0.42	6.52	0.33	2.55e-10	Height;
LIHC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.37	-5.93	-0.31	7.28e-9	Bipolar disorder;
LIHC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.8	-0.54	3.42e-27	Bipolar disorder and schizophrenia;
LIHC	cis	rs7546668	1.000	rs12759296	chr1:15881237	T/G	cg11706911	chr1:15910989	AGMAT	0.43	6.39	0.33	5.41e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.71	7.98	0.4	2.23e-14	Iron status biomarkers;
LIHC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	8.54	0.42	4.38e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.25	-0.32	1.21e-9	Morning vs. evening chronotype;
LIHC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.55	8.84	0.43	5.19e-17	Height;
LIHC	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.32	6.46	0.33	3.59e-10	DNA methylation (variation);
LIHC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.99	17.64	0.69	5.54e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.52	7.3	0.37	2.05e-12	Morning vs. evening chronotype;
LIHC	cis	rs6088813	1.000	rs6088825	chr20:33995972	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-5.88	-0.3	9.69e-9	Height;
LIHC	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.46	-6.7	-0.34	8.55e-11	Obesity-related traits;
LIHC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06026331	chr20:60912101	LAMA5	0.4	5.96	0.31	6.23e-9	Colorectal cancer;
LIHC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.04	-22.1	-0.77	7.08e-68	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.26e-27	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23115158	chr6:80341412	SH3BGRL2	0.46	6.12	0.31	2.58e-9	Lung function (FEV1/FVC);
LIHC	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.56	8.86	0.43	4.48e-17	Corneal astigmatism;
LIHC	trans	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21659725	chr3:3221576	CRBN	0.57	8.19	0.4	5.34e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	6.36	0.33	6.29e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6960043	0.818	rs1974619	chr7:15065300	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.74	-0.34	6.6e-11	Type 2 diabetes;
LIHC	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.51	-0.62	1.72e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	14.26	0.61	1.52e-36	Chronic sinus infection;
LIHC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.82	13.01	0.58	1e-31	Glomerular filtration rate (creatinine);
LIHC	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	6.27e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.78	-0.3	1.69e-8	Resting heart rate;
LIHC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.56	8.72	0.43	1.27e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg11441379	chr12:63026424	NA	0.6	6.15	0.32	2.12e-9	IgG glycosylation;
LIHC	cis	rs3770081	1.000	rs60649958	chr2:86283000	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.69	-0.43	1.57e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	9.15	0.44	5.21e-18	Initial pursuit acceleration;
LIHC	cis	rs2518564	0.507	rs866484	chr1:158986477	C/G	cg11003133	chr1:159046391	AIM2	0.26	5.8	0.3	1.52e-8	White blood cell count;
LIHC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	8.71	0.43	1.35e-16	Platelet count;
LIHC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg21486233	chr12:29375141	FAR2	0.3	5.82	0.3	1.36e-8	QT interval;
LIHC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.9	18.61	0.71	7.12e-54	Blood protein levels;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.69	11.35	0.52	1.45e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.85	-14.65	-0.62	4.54e-38	Oral cavity cancer;
LIHC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg12863693	chr15:85201151	NMB	0.46	6.66	0.34	1.11e-10	Schizophrenia;
LIHC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.75	-0.34	6.28e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.46	-6.17	-0.32	1.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	7.24	0.36	2.98e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.14	24.31	0.8	1.58e-76	Schizophrenia;
LIHC	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg25566285	chr7:158114605	PTPRN2	0.23	6.15	0.32	2.14e-9	Calcium levels;
LIHC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.8	-12.84	-0.57	4.63e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Blood metabolite levels;
LIHC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.05	9.44	0.45	6.16e-19	Diabetic retinopathy;
LIHC	cis	rs6693567	0.874	rs698915	chr1:150388318	C/T	cg15654264	chr1:150340011	RPRD2	-0.42	-6.17	-0.32	1.96e-9	Migraine;
LIHC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.44	-7.13	-0.36	5.89e-12	Total body bone mineral density;
LIHC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18867708	chr6:26865862	GUSBL1	0.54	8.2	0.41	4.83e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.75	11.05	0.51	1.83e-24	Corneal astigmatism;
LIHC	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.26	0.49	1.06e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.58	8.48	0.42	6.77e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.41	0.45	7.27e-19	IgG glycosylation;
LIHC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs61041384	0.661	rs74240781	chr12:123792701	T/C	cg07919128	chr17:18022025	MYO15A	0.75	7.54	0.38	4.13e-13	Schizophrenia;
LIHC	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg21724239	chr8:58056113	NA	0.46	6.06	0.31	3.55e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.47	0.37	6.95e-13	IgG glycosylation;
LIHC	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-9.36	-0.45	1.07e-18	Platelet distribution width;
LIHC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.39	14.54	0.62	1.26e-37	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg01843034	chr6:37503916	NA	-0.4	-6.54	-0.33	2.22e-10	Cognitive performance;
LIHC	cis	rs7937890	0.587	rs11023204	chr11:14411223	C/A	cg02251663	chr11:14281053	SPON1	-0.43	-5.79	-0.3	1.57e-8	Mitochondrial DNA levels;
LIHC	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.93	-0.35	2.14e-11	Neuroticism;
LIHC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.2	0.41	4.78e-15	Lymphocyte counts;
LIHC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.51	-8.33	-0.41	1.92e-15	White matter hyperintensity burden;
LIHC	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg05590025	chr7:65112418	INTS4L2	0.53	6.24	0.32	1.3e-9	Diabetic kidney disease;
LIHC	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.85	0.3	1.13e-8	Tuberculosis;
LIHC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.43	5.89	0.3	9.07e-9	Life satisfaction;
LIHC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.93	11.99	0.54	6.8e-28	Coronary artery disease;
LIHC	cis	rs7700895	0.737	rs3777184	chr5:95262044	G/C	cg10483112	chr5:95245456	ELL2	-0.38	-6.9	-0.35	2.59e-11	IgG glycosylation;
LIHC	cis	rs1982963	0.950	rs61973203	chr14:52510567	A/G	cg10843707	chr14:52510701	NID2	0.46	8.36	0.41	1.55e-15	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg18306943	chr3:40428807	ENTPD3	0.33	5.72	0.3	2.29e-8	Renal cell carcinoma;
LIHC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg18016565	chr1:150552671	MCL1	-0.51	-9.99	-0.48	8.84e-21	Tonsillectomy;
LIHC	trans	rs7714584	1.000	rs11167520	chr5:150265639	T/C	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg12297030	chr17:43662878	NA	-0.63	-6.23	-0.32	1.38e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-10.37	-0.49	4.36e-22	Schizophrenia;
LIHC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.55	9.05	0.44	1.08e-17	Total body bone mineral density;
LIHC	cis	rs847649	0.731	rs1829957	chr7:102687010	T/A	cg18108683	chr7:102477205	FBXL13	0.4	6.08	0.31	3.26e-9	Morning vs. evening chronotype;
LIHC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.5	-6.14	-0.32	2.23e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.51	-8.18	-0.4	5.81e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.29	-0.32	9.45e-10	Aortic root size;
LIHC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.76	-8.37	-0.41	1.53e-15	Vitiligo;
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.54	5.87	0.3	1.05e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.52	-0.33	2.57e-10	Testicular germ cell tumor;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05368115	chr19:901123	C19orf22	0.45	6.22	0.32	1.44e-9	Bilirubin levels;
LIHC	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.79	-0.34	5.12e-11	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.93	-17.51	-0.69	1.81e-49	Coronary artery disease;
LIHC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.18	-0.36	4.49e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13441983	chr11:10327014	ADM	0.44	6.74	0.34	6.77e-11	Pancreatic cancer;
LIHC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg21017887	chr14:105400489	NA	0.67	12.5	0.56	8.74e-30	Rheumatoid arthritis;
LIHC	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.73	-11.86	-0.54	2e-27	Obesity-related traits;
LIHC	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.42	-6.04	-0.31	4.11e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.91	10.34	0.49	5.39e-22	Triglycerides;
LIHC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.49	6.35	0.32	6.96e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.37	8.52	0.42	5.09e-16	Educational attainment (years of education);
LIHC	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg12698662	chr3:15914712	MIR563	-0.36	-6.57	-0.33	1.87e-10	Mean platelet volume;
LIHC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs7432375	0.901	rs7618518	chr3:136370092	C/T	cg21827317	chr3:136751795	NA	-0.44	-5.85	-0.3	1.14e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.4	-6.45	-0.33	3.71e-10	Menarche (age at onset);
LIHC	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02829992	chr2:10710499	NA	0.38	5.95	0.31	6.59e-9	Prostate cancer;
LIHC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg06497051	chr1:156261200	TMEM79	0.34	5.9	0.3	8.84e-9	Tonsillectomy;
LIHC	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg06533319	chr4:3265114	C4orf44	0.31	5.72	0.3	2.27e-8	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.6	-8.58	-0.42	3.33e-16	Motion sickness;
LIHC	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg11204139	chr17:3907470	NA	0.63	8.26	0.41	3.19e-15	Type 2 diabetes;
LIHC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.25	0.48	1.15e-21	Cognitive test performance;
LIHC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.89	-0.35	2.65e-11	IgG glycosylation;
LIHC	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-0.8	-8.66	-0.42	1.95e-16	Exhaled nitric oxide output;
LIHC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.52	7.63	0.38	2.37e-13	Glycated hemoglobin levels;
LIHC	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.42e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	0.95	6.93	0.35	2.12e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg22842854	chr12:123319900	HIP1R	-0.67	-8.73	-0.43	1.18e-16	Schizophrenia;
LIHC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24110177	chr3:50126178	RBM5	-0.42	-6.66	-0.34	1.06e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg27433088	chr4:174089019	GALNT7	0.38	6.93	0.35	2.07e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.81	0.43	6.54e-17	Prudent dietary pattern;
LIHC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.83	-13.94	-0.6	2.66e-35	Aortic root size;
LIHC	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg02702477	chr5:179499311	RNF130	-0.75	-10.29	-0.49	7.91e-22	LDL cholesterol;
LIHC	cis	rs2901460	0.509	rs6721488	chr2:62071562	A/T	cg02183531	chr2:62113199	CCT4	-0.42	-6.2	-0.32	1.61e-9	Mean corpuscular volume;
LIHC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.54	-8.81	-0.43	6.31e-17	Cognitive function;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.94	-0.6	2.78e-35	Alzheimer's disease;
LIHC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs6489882	0.703	rs1131476	chr12:113357209	G/A	cg10175203	chr3:128143634	NA	0.39	6.33	0.32	7.64e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.41	-6.34	-0.32	7.48e-10	Metabolite levels;
LIHC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.78	-15.56	-0.64	1.18e-41	Height;
LIHC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs12286929	0.610	rs11606838	chr11:115042859	C/A	cg04055981	chr11:115044050	NA	0.39	6.66	0.34	1.13e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.32	7.18	0.36	4.41e-12	Blood metabolite ratios;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	13.19	0.58	2.05e-32	Chronic sinus infection;
LIHC	cis	rs903552	0.800	rs8026048	chr15:102006353	G/A	cg19295451	chr15:102010161	PCSK6	-0.5	-6.94	-0.35	1.94e-11	Diabetic kidney disease;
LIHC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.39	6.49	0.33	3.02e-10	Tuberculosis;
LIHC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.72	-0.43	1.26e-16	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.73	8.5	0.42	5.84e-16	Schizophrenia;
LIHC	cis	rs611744	0.967	rs594405	chr8:109193607	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.36	5.84	0.3	1.22e-8	Schizophrenia;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13012494	chr21:47604986	C21orf56	0.39	5.9	0.3	8.83e-9	Testicular germ cell tumor;
LIHC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg16479474	chr6:28041457	NA	0.43	6.07	0.31	3.36e-9	Depression;
LIHC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21467203	chr3:49911342	NA	-0.44	-7.79	-0.39	7.94e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.850	rs4970846	chr1:109946095	A/C	cg23091122	chr1:110024289	SYPL2	-0.44	-5.88	-0.3	9.61e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.32	-0.37	1.83e-12	Reticulocyte count;
LIHC	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.63	9.32	0.45	1.52e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.42	6.68	0.34	9.99e-11	Mean corpuscular volume;
LIHC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg02376097	chr19:46275166	DMPK	-0.46	-6.97	-0.35	1.68e-11	Coronary artery disease;
LIHC	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.68	-12.22	-0.55	9.28e-29	Pediatric autoimmune diseases;
LIHC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg10935138	chr17:73851978	WBP2	0.66	8.83	0.43	5.48e-17	Psoriasis;
LIHC	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.62	-11.7	-0.53	8.08e-27	Neurofibrillary tangles;
LIHC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg00529422	chr1:16285251	ZBTB17	-0.34	-6.56	-0.33	1.94e-10	Systolic blood pressure;
LIHC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg15691649	chr6:25882328	NA	-0.55	-7.93	-0.39	3.14e-14	Blood metabolite levels;
LIHC	trans	rs12125971	1.000	rs11185012	chr1:107461522	T/A	cg08941669	chr1:7778234	CAMTA1	0.57	6.09	0.31	3e-9	Intelligence;
LIHC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.84	7.51	0.38	5.07e-13	Eosinophil percentage of granulocytes;
LIHC	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.58	7.05	0.36	1.03e-11	Breast cancer;
LIHC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.99	15.93	0.65	4.11e-43	Nonalcoholic fatty liver disease;
LIHC	cis	rs2273156	1.000	rs2273158	chr14:35465784	A/T	cg16230307	chr14:35515116	FAM177A1	0.42	6.23	0.32	1.35e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7116495	1.000	rs6592455	chr11:71689541	C/T	cg26138937	chr11:71823887	C11orf51	0.88	8.83	0.43	5.49e-17	Severe influenza A (H1N1) infection;
LIHC	trans	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg24637308	chr11:6592297	DNHD1	0.44	6.17	0.32	1.98e-9	Coronary artery calcification;
LIHC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.46	-7.93	-0.39	3.1e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.7	8.33	0.41	2.04e-15	Dental caries;
LIHC	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.37	0.33	6.18e-10	Mean corpuscular volume;
LIHC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg27478167	chr7:817139	HEATR2	-0.52	-6.94	-0.35	1.93e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4906332	0.782	rs7161305	chr14:104002234	G/A	cg04998671	chr14:104000505	TRMT61A	-0.57	-7.14	-0.36	5.48e-12	Coronary artery disease;
LIHC	cis	rs116248771	0.739	rs2082158	chr3:158359791	G/C	cg16708174	chr3:158430962	RARRES1	0.48	6.42	0.33	4.46e-10	diarrhoeal disease at age 2;
LIHC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.61	-9.99	-0.48	8.77e-21	Post bronchodilator FEV1;
LIHC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-5.95	-0.31	6.72e-9	Vitiligo;
LIHC	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg24112000	chr20:60950667	NA	-0.59	-8.59	-0.42	3.03e-16	Colorectal cancer;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg12311636	chr6:118886798	C6orf204	-0.53	-6.22	-0.32	1.44e-9	Diastolic blood pressure;
LIHC	cis	rs16828019	0.777	rs2300658	chr1:41505022	G/A	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	10.93	0.51	4.75e-24	Lung cancer in ever smokers;
LIHC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.42	-5.75	-0.3	1.99e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.72	-10.34	-0.49	5.67e-22	Longevity;
LIHC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.67	-0.42	1.7e-16	Gut microbiome composition (summer);
LIHC	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	6.79	0.34	4.98e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.51	-9.54	-0.46	2.8e-19	Mean corpuscular volume;
LIHC	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.65	9.51	0.46	3.56e-19	Monocyte count;
LIHC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	9.63	0.46	1.4e-19	Platelet count;
LIHC	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.42	-6.94	-0.35	1.98e-11	Schizophrenia;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg02464098	chr8:26240309	BNIP3L	-0.54	-6.18	-0.32	1.87e-9	Preeclampsia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03972606	chr2:234750062	HJURP	0.45	6.22	0.32	1.46e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.46	8.02	0.4	1.72e-14	IgG glycosylation;
LIHC	cis	rs9649465	1.000	rs12537287	chr7:123364747	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.15e-15	Migraine;
LIHC	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.76	-8.38	-0.41	1.42e-15	Exhaled nitric oxide output;
LIHC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.29	-16.5	-0.67	2e-45	Diabetic kidney disease;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.66	-10.56	-0.5	9.36e-23	Skin colour saturation;
LIHC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.79	-11.81	-0.54	3.22e-27	Motion sickness;
LIHC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	7.09	0.36	7.56e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.02	-0.44	1.33e-17	Capecitabine sensitivity;
LIHC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.48	-6.38	-0.33	5.84e-10	Blood trace element (Zn levels);
LIHC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.51	8.46	0.42	7.66e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.78	-8.65	-0.42	1.99e-16	Exhaled nitric oxide output;
LIHC	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg05527609	chr1:210001259	C1orf107	-0.56	-7.72	-0.39	1.29e-13	Red blood cell count;
LIHC	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg01864836	chr14:55583639	NA	-0.38	-7.02	-0.35	1.22e-11	Protein biomarker;
LIHC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.68	10.77	0.5	1.77e-23	Platelet count;
LIHC	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.67	-14.11	-0.61	5.91e-36	Sense of smell;
LIHC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.65	0.53	1.18e-26	Cognitive ability;
LIHC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg05697976	chr12:29376483	FAR2	0.3	6.04	0.31	4.07e-9	QT interval;
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.06	0.31	3.63e-9	HDL cholesterol;
LIHC	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.71	-7.51	-0.38	5.15e-13	Body mass index;
LIHC	cis	rs4930561	0.714	rs7126326	chr11:67947275	T/G	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.76	-0.3	1.87e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-11.94	-0.54	1.03e-27	Alzheimer's disease;
LIHC	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg12062639	chr20:23401060	NAPB	0.83	9.78	0.47	4.3e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.64e-11	Aortic root size;
LIHC	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.45	-6.87	-0.35	3.11e-11	Ulcerative colitis;
LIHC	cis	rs6448317	1.000	rs11938296	chr4:24938861	A/G	cg21108841	chr4:24914750	CCDC149	-0.47	-6.0	-0.31	5e-9	Heschl's gyrus morphology;
LIHC	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.08	-0.4	1.12e-14	Exhaled nitric oxide output;
LIHC	cis	rs4561483	0.603	rs7202065	chr16:11951045	C/T	cg08843971	chr16:11963173	GSPT1	0.37	6.74	0.34	6.6e-11	Testicular germ cell tumor;
LIHC	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	cis	rs16828019	0.929	rs12029321	chr1:41682530	G/C	cg20697417	chr1:41786797	NA	0.34	6.51	0.33	2.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.72	-10.99	-0.51	2.92e-24	Migraine;Coronary artery disease;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg03874509	chr1:107600012	PRMT6	0.69	10.03	0.48	6.39e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.34	-6.35	-0.32	6.75e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.88	16.86	0.67	7.47e-47	Blood protein levels;
LIHC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.39	-5.87	-0.3	1.02e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs5753037	0.629	rs140138	chr22:30164628	T/G	cg01021169	chr22:30184971	ASCC2	-0.32	-5.84	-0.3	1.24e-8	Type 1 diabetes;
LIHC	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.57	-7.72	-0.39	1.29e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.67	-6.39	-0.33	5.41e-10	Bipolar disorder;
LIHC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.5	10.58	0.5	7.8e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.66	-10.84	-0.51	9.9899999999999993e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.93	-0.35	2.09e-11	Response to antipsychotic treatment;
LIHC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-9.61	-0.46	1.58e-19	Response to antipsychotic treatment;
LIHC	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.71	7.24	0.36	2.93e-12	Schizophrenia;
LIHC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.89e-11	Rheumatoid arthritis;
LIHC	trans	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg15704280	chr7:45808275	SEPT13	-0.54	-8.37	-0.41	1.5e-15	Pediatric bone mineral density (spine);
LIHC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.2	0.45	3.6e-18	Bipolar disorder;
LIHC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg18202521	chr1:19600702	AKR7L	-0.37	-6.33	-0.32	7.77e-10	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.56	-8.83	-0.43	5.37e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.77	-0.3	1.75e-8	Axial length;
LIHC	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.98	-0.31	5.61e-9	Crohn's disease;
LIHC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.75	-12.96	-0.57	1.64e-31	Coronary artery disease;
LIHC	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.81	-0.35	4.27e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	Cognitive function;
LIHC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.6e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.38	6.01	0.31	4.72e-9	Menopause (age at onset);
LIHC	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.36	5.72	0.3	2.29e-8	Height;
LIHC	cis	rs3770081	0.590	rs60785155	chr2:86452798	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.71	-7.51	-0.38	5.31e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.62	11.24	0.52	3.65e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.42	6.45	0.33	3.87e-10	Prostate cancer;
LIHC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.8	10.91	0.51	5.64e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-8.33	-0.41	1.94e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.54	7.87	0.39	4.76e-14	Longevity;
LIHC	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.59	9.36	0.45	1.08e-18	Corneal astigmatism;
LIHC	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg02023728	chr11:77925099	USP35	0.34	6.03	0.31	4.14e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg14067834	chr17:29058358	SUZ12P	-0.62	-5.99	-0.31	5.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.31	5.92	0.3	7.87e-9	Sitting height ratio;
LIHC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.77	9.25	0.45	2.44e-18	Cognitive function;
LIHC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.96	-18.04	-0.7	1.31e-51	Breast cancer;
LIHC	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	7.67	0.38	1.81e-13	Blood protein levels;
LIHC	cis	rs2273156	1.000	rs8018114	chr14:35470019	T/C	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.75	-0.5	2e-23	Platelet count;
LIHC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg02640540	chr1:67518911	SLC35D1	-0.48	-6.52	-0.33	2.57e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs11229555	0.645	rs7929868	chr11:58209418	C/T	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	11.24	0.52	3.65e-25	Chronic sinus infection;
LIHC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg18478394	chr8:109455254	TTC35	0.4	6.95	0.35	1.85e-11	Dupuytren's disease;
LIHC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg03146154	chr1:46216737	IPP	0.48	8.08	0.4	1.12e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-9.46	-0.46	5.3e-19	Type 2 diabetes;
LIHC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.49	0.38	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25237692	chr15:64752785	NA	0.4	6.16	0.32	2.1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.42	0.33	4.45e-10	Schizophrenia;
LIHC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg03647239	chr10:116582469	FAM160B1	0.46	6.67	0.34	1.05e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.33	6.51	0.33	2.76e-10	Cancer;
LIHC	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.71	-0.34	8.24e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.26	0.37	2.71e-12	Lung cancer in ever smokers;
LIHC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.95	0.57	1.78e-31	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.67	-0.34	1.04e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg05255149	chr17:80675120	FN3KRP	0.45	6.51	0.33	2.71e-10	Glycated hemoglobin levels;
LIHC	cis	rs965469	0.619	rs6037565	chr20:3330308	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg08126542	chr6:37504118	NA	-0.38	-5.89	-0.3	9.16e-9	Cognitive performance;
LIHC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.64	-7.06	-0.36	9.24e-12	Vitiligo;
LIHC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-18.88	-0.71	5.42e-55	Height;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08514994	chr20:47805136	STAU1	-0.44	-6.1	-0.31	2.91e-9	Migraine with aura;
LIHC	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.2	-0.36	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.75	11.81	0.54	3.06e-27	Corneal astigmatism;
LIHC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg14092571	chr14:90743983	NA	-0.37	-5.76	-0.3	1.9e-8	Mortality in heart failure;
LIHC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.69	-0.43	1.58e-16	Gut microbiome composition (summer);
LIHC	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg25364880	chr3:44379878	C3orf23	0.53	7.1	0.36	7.12e-12	Depressive symptoms;
LIHC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.95	-0.39	2.73e-14	Schizophrenia;
LIHC	cis	rs860295	0.812	rs2297775	chr1:155735012	C/T	cg02153340	chr1:155202674	NA	0.34	6.4	0.33	5.04e-10	Body mass index;
LIHC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.32	6.2	0.32	1.63e-9	Tonsillectomy;
LIHC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.56	-7.98	-0.4	2.19e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg08539965	chr1:21396338	EIF4G3	0.34	6.15	0.32	2.22e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.74	-8.83	-0.43	5.39e-17	Morning vs. evening chronotype;
LIHC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.13	0.4	8.12e-15	Morning vs. evening chronotype;
LIHC	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg12062639	chr20:23401060	NAPB	0.85	10.27	0.49	9.9700000000000009e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.47	7.49	0.38	5.74e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.4	-6.23	-0.32	1.4e-9	Educational attainment;
LIHC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.91	-16.91	-0.67	4.78e-47	Aortic root size;
LIHC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.44	7.14	0.36	5.57e-12	Red blood cell count;
LIHC	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.47	-6.48	-0.33	3.26e-10	Smoking behavior;
LIHC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.34	-0.37	1.62e-12	Hemoglobin concentration;
LIHC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg17135325	chr3:160939158	NMD3	0.54	7.68	0.38	1.71e-13	Parkinson's disease;
LIHC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.59	6.78	0.34	5.41e-11	Menarche (age at onset);
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg14828511	chr1:107599125	PRMT6	-0.42	-6.01	-0.31	4.79e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.85	0.3	1.17e-8	Neutrophil percentage of white cells;
LIHC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg02931644	chr1:25747376	RHCE	0.36	7.79	0.39	7.95e-14	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs243505	0.660	rs10274701	chr7:148552456	C/T	cg09806900	chr7:148480153	CUL1	0.43	6.17	0.32	1.92e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.57	-0.5	8.68e-23	Mean corpuscular volume;
LIHC	cis	rs2033908	0.620	rs10765996	chr11:12853043	A/G	cg25843174	chr11:12811716	TEAD1	-0.32	-7.21	-0.36	3.71e-12	Sitting height ratio;
LIHC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg13047869	chr3:10149882	C3orf24	0.51	6.63	0.34	1.29e-10	Alzheimer's disease;
LIHC	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg00601450	chr5:74908170	NA	0.59	7.18	0.36	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-11.15	-0.52	7.63e-25	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.15	-0.32	2.22e-9	Total body bone mineral density;
LIHC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.66	10.21	0.48	1.59e-21	Corneal astigmatism;
LIHC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	1.13	18.64	0.71	5.42e-54	IgG glycosylation;
LIHC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.56	8.84	0.43	5.07e-17	Corneal astigmatism;
LIHC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.43	7.12	0.36	6.24e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg16479474	chr6:28041457	NA	0.45	6.45	0.33	3.72e-10	Depression;
LIHC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg03037974	chr15:76606532	NA	0.71	13.86	0.6	5.53e-35	Blood metabolite levels;
LIHC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.7	9.09	0.44	8.25e-18	Gut microbiome composition (summer);
LIHC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg07090678	chr1:91966139	CDC7	0.51	7.01	0.35	1.29e-11	Breast cancer;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02290350	chr8:58132656	NA	0.5	10.64	0.5	5.15e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg23352942	chr3:46931381	PTH1R	-0.27	-6.75	-0.34	6.26e-11	Birth weight;
LIHC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	6.27	0.32	1.11e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.4	-6.27	-0.32	1.09e-9	Iron status biomarkers;
LIHC	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.39	-5.76	-0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.74	9.78	0.47	4.6e-20	Coronary artery disease;
LIHC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.67	6.76	0.34	5.87e-11	Vitiligo;
LIHC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg03732007	chr1:2071316	PRKCZ	0.35	6.08	0.31	3.21e-9	Height;
LIHC	cis	rs7017697	0.793	rs7018235	chr8:19682698	C/T	cg03894339	chr8:19674705	INTS10	0.39	5.74	0.3	2.09e-8	Breast cancer;
LIHC	cis	rs151997	0.671	rs3991902	chr5:50203749	A/T	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14331148	chr19:47551893	TMEM160	-0.48	-6.39	-0.33	5.35e-10	Pancreatic cancer;
LIHC	cis	rs546131	0.642	rs512013	chr11:34842225	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.2	0.36	3.82e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.65	-0.46	1.16e-19	Electroencephalogram traits;
LIHC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.68	-10.1	-0.48	3.64e-21	Testicular germ cell tumor;
LIHC	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	0.83	9.44	0.45	5.83e-19	Opioid sensitivity;
LIHC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	1.03	13.51	0.59	1.26e-33	Red blood cell traits;
LIHC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.06	-0.31	3.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.54	7.91	0.39	3.53e-14	Heschl's gyrus morphology;
LIHC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.94	-0.51	4.54e-24	Hemoglobin concentration;
LIHC	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.44	6.43	0.33	4.33e-10	Bipolar disorder;
LIHC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	9.51	0.46	3.45e-19	Multiple sclerosis;
LIHC	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.56	8.36	0.41	1.57e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.83	8.89	0.43	3.5e-17	Vitiligo;
LIHC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg08847533	chr14:75593920	NEK9	-0.37	-6.05	-0.31	3.78e-9	Caffeine consumption;
LIHC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-8.36	-0.41	1.57e-15	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.7	8.52	0.42	4.99e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs747782	0.646	rs17198158	chr11:47477849	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-6.35	-0.32	6.99e-10	Intraocular pressure;
LIHC	cis	rs16828019	0.929	rs2363805	chr1:41719434	G/T	cg03387723	chr1:41708464	SCMH1	-0.44	-7.21	-0.36	3.66e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg01864836	chr14:55583639	NA	-0.44	-8.71	-0.43	1.28e-16	Protein biomarker;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06253862	chr6:160201362	SNORA20;TCP1	0.41	6.24	0.32	1.3e-9	Longevity;
LIHC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-7.64	-0.38	2.2e-13	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg18016565	chr1:150552671	MCL1	0.51	9.67	0.46	1.03e-19	Melanoma;
LIHC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.68	8.84	0.43	5.21e-17	Gut microbiome composition (summer);
LIHC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs1000083	0.666	rs1609327	chr5:96633109	G/A	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	6.74	0.34	6.68e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg03854865	chr6:26224070	HIST1H3E	0.59	6.43	0.33	4.36e-10	Gout;Renal underexcretion gout;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08365438	chr10:21683093	NA	0.42	6.04	0.31	4.02e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.75e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg07706471	chr12:123319906	HIP1R	-0.62	-8.26	-0.41	3.29e-15	Schizophrenia;
LIHC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.23e-19	Hemoglobin concentration;
LIHC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.42	5.75	0.3	1.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.57e-22	Fuchs's corneal dystrophy;
LIHC	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	19.24	0.72	2.06e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg14146966	chr2:61757674	XPO1	-0.42	-7.16	-0.36	4.83e-12	Tuberculosis;
LIHC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-9.47	-0.46	4.73e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15357518	chr19:36120356	RBM42	0.51	8.07	0.4	1.25e-14	Pancreatic cancer;
LIHC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	8.0	0.4	1.88e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.14	-0.36	5.64e-12	Renal cell carcinoma;
LIHC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.42	5.81	0.3	1.44e-8	Height;
LIHC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.53	7.75	0.39	1.07e-13	Type 2 diabetes;
LIHC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.46	-7.38	-0.37	1.21e-12	Vitiligo;
LIHC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.38	-6.05	-0.31	3.87e-9	Glioblastoma;
LIHC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.55	-7.21	-0.36	3.58e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.65	10.37	0.49	4.24e-22	Longevity;
LIHC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.42	-6.59	-0.34	1.69e-10	Dental caries;
LIHC	cis	rs6723226	0.842	rs1901355	chr2:32835664	A/G	cg02381751	chr2:32503542	YIPF4	-0.71	-10.33	-0.49	5.77e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg24209194	chr3:40518798	ZNF619	0.42	5.94	0.31	7.2e-9	Renal cell carcinoma;
LIHC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.45	-0.42	8.62e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-9.21	-0.45	3.31e-18	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.46	-11.99	-0.54	6.92e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg02290350	chr8:58132656	NA	0.31	7.15	0.36	5.41e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	20.94	0.75	3.08e-63	Height;
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.95	-0.31	6.52e-9	Total body bone mineral density;
LIHC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Total cholesterol levels;
LIHC	cis	rs1144333	1.000	rs12082448	chr1:76353225	C/T	cg22875332	chr1:76189707	ACADM	0.42	6.54	0.33	2.3e-10	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15209934	chr19:52800385	ZNF480	0.45	6.11	0.31	2.66e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg23517279	chr6:96025343	MANEA	0.55	6.32	0.32	8.37e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-7.29	-0.37	2.12e-12	Ulcerative colitis;
LIHC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.53	5.99	0.31	5.32e-9	Alzheimer's disease;
LIHC	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg20607764	chr19:44506953	ZNF230	0.45	7.31	0.37	1.86e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg20991723	chr1:152506922	NA	0.53	8.94	0.44	2.47e-17	Hair morphology;
LIHC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.97	19.28	0.72	1.44e-56	Breast cancer;
LIHC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.3	-5.75	-0.3	1.97e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg25364880	chr3:44379878	C3orf23	0.57	7.8	0.39	7.71e-14	Depressive symptoms;
LIHC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg16836995	chr17:43662488	NA	-0.75	-7.68	-0.38	1.67e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg20991723	chr1:152506922	NA	0.54	9.07	0.44	9.25e-18	Hair morphology;
LIHC	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09497769	chr2:24248384	NA	0.45	6.34	0.32	7.17e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.92	-0.54	1.22e-27	Coffee consumption (cups per day);
LIHC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-5.73	-0.3	2.26e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.4	-8.11	-0.4	9.08e-15	Urinary metabolites;
LIHC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07305463	chr2:136567211	LCT	-0.38	-5.82	-0.3	1.38e-8	Corneal structure;
LIHC	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.39	6.85	0.35	3.35e-11	Monocyte percentage of white cells;
LIHC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.36	2.88e-12	Educational attainment;
LIHC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.23	-0.36	3.08e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-6.09	-0.31	2.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.65	0.5	4.76e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs2274273	0.624	rs11848456	chr14:55755392	A/G	cg01864836	chr14:55583639	NA	-0.36	-5.95	-0.31	6.6e-9	Protein biomarker;
LIHC	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.44	11.86	0.54	2.03e-27	Uric acid levels;
LIHC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.16e-9	Tonsillectomy;
LIHC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.77	-12.67	-0.57	1.94e-30	Breast cancer;
LIHC	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.77	-9.64	-0.46	1.26e-19	Type 2 diabetes;
LIHC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg05555928	chr11:63887634	MACROD1	0.48	6.23	0.32	1.34e-9	Mean platelet volume;
LIHC	cis	rs9921222	0.692	rs11860497	chr16:405416	A/G	cg26913058	chr16:419975	MRPL28	-0.51	-7.88	-0.39	4.41e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.79	-0.39	8.19e-14	QT interval;
LIHC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.84	0.43	5.15e-17	Cognitive test performance;
LIHC	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.35	-8.16	-0.4	6.31e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs965469	1.000	rs6051722	chr20:3274435	A/G	cg25506879	chr20:3388711	C20orf194	-0.6	-7.17	-0.36	4.77e-12	IFN-related cytopenia;
LIHC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg16479474	chr6:28041457	NA	0.39	6.68	0.34	9.59e-11	Cardiac Troponin-T levels;
LIHC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.48	-6.22	-0.32	1.46e-9	Pancreatic cancer;
LIHC	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.38	-6.75	-0.34	6.32e-11	Asthma;
LIHC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs72843506	0.656	rs57040439	chr17:19939835	C/G	cg12065943	chr17:19881925	AKAP10	-0.41	-6.93	-0.35	2.14e-11	Schizophrenia;
LIHC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.93	-12.38	-0.56	2.45e-29	Schizophrenia;
LIHC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg13628971	chr7:2884303	GNA12	0.43	6.76	0.34	6.07e-11	Height;
LIHC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg14440974	chr22:39074834	NA	-0.46	-7.37	-0.37	1.29e-12	Menopause (age at onset);
LIHC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.45	6.56	0.33	1.97e-10	Aortic root size;
LIHC	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg26395211	chr5:140044315	WDR55	0.4	5.89	0.3	9.1e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs6934970	1.000	rs62413975	chr6:113059510	T/G	cg09308777	chr6:169852575	NA	0.58	6.06	0.31	3.67e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.81	10.43	0.49	2.66e-22	Morning vs. evening chronotype;
LIHC	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.49	8.14	0.4	7.64e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.52	7.09	0.36	7.61e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.2	0.36	3.93e-12	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.52	0.53	3.63e-26	Alzheimer's disease;
LIHC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg25356066	chr3:128598488	ACAD9	0.53	7.47	0.37	6.95e-13	IgG glycosylation;
LIHC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg19635926	chr16:89946313	TCF25	0.46	5.99	0.31	5.24e-9	Skin colour saturation;
LIHC	trans	rs975809	0.966	rs11004607	chr10:56622686	G/T	cg15219393	chr5:149109878	PPARGC1B	-0.43	-6.06	-0.31	3.59e-9	Carotid intima media thickness;
LIHC	cis	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg26384229	chr12:38710491	ALG10B	0.77	8.97	0.44	2.06e-17	Bladder cancer;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06420487	chr17:61919686	SMARCD2	-0.43	-5.88	-0.3	9.92e-9	Height;
LIHC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.79	11.3	0.52	2.19e-25	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg25039879	chr17:56429692	SUPT4H1	0.75	8.68	0.42	1.66e-16	Cognitive test performance;
LIHC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	13.85	0.6	6.2e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.49	-0.33	3.04e-10	Total body bone mineral density;
LIHC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.45	6.12	0.31	2.61e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg12140854	chr5:148520817	ABLIM3	0.52	6.1	0.31	2.85e-9	Breast cancer;
LIHC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.74e-10	Diabetic kidney disease;
LIHC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg19338460	chr6:170058176	WDR27	-0.38	-5.8	-0.3	1.47e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.52	7.2	0.36	3.78e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.54	7.15	0.36	5.38e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.56	7.19	0.36	4.06e-12	Parkinson's disease;
LIHC	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg09855544	chr8:135498122	ZFAT	0.45	7.75	0.39	1.07e-13	Hypertension (SNP x SNP interaction);
LIHC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.59	-0.38	3.17e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs2637266	0.783	rs846647	chr10:78515508	C/G	cg18941641	chr10:78392320	NA	0.27	5.84	0.3	1.22e-8	Pulmonary function;
LIHC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.59	0.38	3.12e-13	Bladder cancer;
LIHC	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg15841412	chr13:111365552	ING1	-0.5	-6.06	-0.31	3.6e-9	Coronary artery disease;
LIHC	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.48	-6.39	-0.33	5.53e-10	Obesity-related traits;
LIHC	cis	rs10792665	0.735	rs10898064	chr11:82675897	A/G	cg24227371	chr11:82718527	RAB30	-0.31	-7.51	-0.38	5.14e-13	Obesity-related traits;
LIHC	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.61	-8.55	-0.42	4.23e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	0.91	13.29	0.58	9.07e-33	Post bronchodilator FEV1;
LIHC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg19680672	chr10:131412579	MGMT	-0.45	-6.96	-0.35	1.74e-11	Response to temozolomide;
LIHC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-10.31	-0.49	6.75e-22	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.45	6.37	0.33	6.22e-10	Asthma;
LIHC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	8.09	0.4	1.08e-14	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg05484376	chr2:27715224	FNDC4	0.36	6.09	0.31	3.04e-9	Total body bone mineral density;
LIHC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.98	-0.31	5.7e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-1.02	-19.52	-0.73	1.47e-57	Breast cancer;
LIHC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.32	-6.57	-0.33	1.91e-10	Blood metabolite levels;
LIHC	cis	rs9649465	1.000	rs10228367	chr7:123370903	C/T	cg03229431	chr7:123269106	ASB15	-0.37	-7.99	-0.4	2.03e-14	Migraine;
LIHC	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg11212589	chr17:38028394	ZPBP2	0.32	6.17	0.32	1.93e-9	Self-reported allergy;
LIHC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-0.73	-8.32	-0.41	2.12e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg02466173	chr16:30829666	NA	-0.44	-6.46	-0.33	3.59e-10	Multiple myeloma;
LIHC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.51	-8.22	-0.41	4.22e-15	Obesity-related traits;
LIHC	cis	rs10454142	0.961	rs10454143	chr2:48646400	G/T	cg15846641	chr2:48541264	FOXN2	0.45	5.96	0.31	6.15e-9	Sex hormone-binding globulin levels;
LIHC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.51	-0.79	2.04e-73	Height;
LIHC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg02290350	chr8:58132656	NA	0.41	8.36	0.41	1.65e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg19894588	chr14:64061835	NA	-0.66	-9.1	-0.44	7.48e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.86	-13.59	-0.59	6.08e-34	Skin colour saturation;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.66e-17	Prudent dietary pattern;
LIHC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.16	0.36	4.85e-12	Morning vs. evening chronotype;
LIHC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.34	-0.55	3.51e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.9	0.3	8.83e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.33	0.41	1.98e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.01	-0.35	1.27e-11	Response to antipsychotic treatment;
LIHC	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-6.42	-0.33	4.57e-10	Axial length;
LIHC	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg26138937	chr11:71823887	C11orf51	-1.32	-10.43	-0.49	2.71e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.17	-0.36	4.52e-12	Psoriasis;
LIHC	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.61	7.0	0.35	1.32e-11	Systolic blood pressure;
LIHC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg25894440	chr7:65020034	NA	-0.52	-5.89	-0.3	9.49e-9	Diabetic kidney disease;
LIHC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.71	-7.26	-0.37	2.59e-12	Putamen volume;
LIHC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.05	0.58	7.17e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg11062466	chr8:58055876	NA	0.5	6.18	0.32	1.82e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.49	-7.32	-0.37	1.77e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.11	-0.36	6.78e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.5	7.81	0.39	7.29e-14	Alzheimer's disease (survival time);
LIHC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	1.02	12.86	0.57	3.71e-31	Iron status biomarkers;
LIHC	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.51	7.38	0.37	1.2e-12	Asthma;
LIHC	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	0.68	8.71	0.43	1.31e-16	Corneal structure;
LIHC	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg08694578	chr2:241835147	C2orf54	-0.63	-10.15	-0.48	2.48e-21	Urinary metabolites;
LIHC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.5	-0.33	2.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg05697976	chr12:29376483	FAR2	0.3	6.05	0.31	3.9e-9	QT interval;
LIHC	trans	rs4596713	0.508	rs7467352	chr9:71766081	G/A	cg16512924	chr15:28394682	HERC2	0.4	6.41	0.33	4.8e-10	Headache;
LIHC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.67	-9.74	-0.47	5.91e-20	Birth weight;
LIHC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-7.94	-0.39	2.84e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg10381502	chr11:71823885	C11orf51	-0.94	-7.88	-0.39	4.44e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.86	6.23	0.32	1.39e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg09417038	chr21:47716443	C21orf57	-0.48	-7.22	-0.36	3.41e-12	Testicular germ cell tumor;
LIHC	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.8	-0.39	7.43e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.79	13.97	0.6	2.12e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-6.21	-0.32	1.52e-9	Schizophrenia;
LIHC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.05	-0.36	9.75e-12	IgG glycosylation;
LIHC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-7.36	-0.37	1.38e-12	Morning vs. evening chronotype;
LIHC	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg22356347	chr1:167427500	CD247	-0.34	-6.19	-0.32	1.68e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	cis	rs7116495	1.000	rs7103210	chr11:71648966	G/C	cg26138937	chr11:71823887	C11orf51	-0.7	-6.99	-0.35	1.45e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.84	-0.35	3.66e-11	Metabolite levels;
LIHC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.53	9.38	0.45	9.28e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.11	0.44	6.89e-18	Cognitive ability;
LIHC	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg08992911	chr2:238395768	MLPH	0.54	5.98	0.31	5.71e-9	Prostate cancer;
LIHC	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.46	6.96	0.35	1.71e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg18944383	chr4:111397179	ENPEP	0.27	7.01	0.35	1.28e-11	Height;
LIHC	trans	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.2e-10	Aortic root size;
LIHC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.68	-11.52	-0.53	3.56e-26	Platelet distribution width;
LIHC	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg20045696	chr14:77926864	AHSA1	0.77	6.21	0.32	1.55e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LIHC	cis	rs1866706	0.865	rs61878772	chr11:12873769	C/G	cg25843174	chr11:12811716	TEAD1	-0.29	-6.07	-0.31	3.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.65	-7.48	-0.38	6.21e-13	Lymphocyte counts;
LIHC	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.7	-7.73	-0.39	1.22e-13	Exhaled nitric oxide output;
LIHC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.27	-0.7	1.61e-52	Height;
LIHC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg12373951	chr3:133503437	NA	0.51	8.37	0.41	1.53e-15	Iron status biomarkers;
LIHC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.31	-0.32	8.65e-10	Systemic lupus erythematosus;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18755078	chr14:31028811	G2E3	0.36	6.08	0.31	3.17e-9	Cognitive function;
LIHC	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.24	-6.54	-0.33	2.21e-10	Type 2 diabetes;
LIHC	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.79	11.28	0.52	2.77e-25	Pediatric areal bone mineral density (radius);
LIHC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg12798992	chr6:167411361	FGFR1OP	0.45	6.72	0.34	7.81e-11	Crohn's disease;
LIHC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.47	-6.06	-0.31	3.69e-9	Pancreatic cancer;
LIHC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.12	0.4	8.57e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg25403416	chr19:30193069	C19orf12	0.32	6.11	0.31	2.69e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.72	10.68	0.5	3.75e-23	Subjective well-being;
LIHC	trans	rs7448169	1.000	rs7705032	chr5:99147433	C/G	cg11015893	chr7:135433540	FAM180A	0.25	6.14	0.32	2.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17424134	chr2:27616206	FTHL3;PPM1G	-0.42	-6.25	-0.32	1.26e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.43	5.9	0.3	8.69e-9	Height;
LIHC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg17801930	chr5:56009405	NA	-0.59	-6.9	-0.35	2.59e-11	Type 2 diabetes;
LIHC	cis	rs17286411	0.750	rs4788561	chr16:71878255	G/A	cg03805757	chr16:71968109	PKD1L3	0.44	6.24	0.32	1.26e-9	Blood protein levels;
LIHC	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.35	7.88	0.39	4.41e-14	Educational attainment (years of education);
LIHC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.49	-0.53	4.52e-26	Type 2 diabetes;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg24947258	chr10:43904864	HNRNPF	-0.51	-6.06	-0.31	3.53e-9	Facial morphology (factor 20);
LIHC	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.37	-0.33	6.11e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.88	-0.39	4.53e-14	Neuroticism;
LIHC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17507749	chr15:85114479	UBE2QP1	0.62	7.09	0.36	7.9e-12	Schizophrenia;
LIHC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.65	11.71	0.54	7.1e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.89	0.3	9.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg25363559	chr8:143086065	NA	-0.28	-8.34	-0.41	1.8e-15	Amyotrophic lateral sclerosis;
LIHC	trans	rs783540	1.000	rs1267657	chr15:83215251	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.46	-0.37	6.98e-13	Schizophrenia;
LIHC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.65	8.69	0.43	1.53e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18035571	chr5:176580675	NSD1	-0.28	-6.51	-0.33	2.63e-10	Calcium levels;
LIHC	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.56	-8.53	-0.42	4.73e-16	White matter hyperintensity burden;
LIHC	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg12085619	chr1:248636455	OR2T3	0.33	6.29	0.32	9.77e-10	Common traits (Other);
LIHC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.75	-0.39	1.05e-13	Total body bone mineral density;
LIHC	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.26	6.18	0.32	1.8e-9	Obesity-related traits;
LIHC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg07959070	chr22:50026188	C22orf34	-0.28	-6.92	-0.35	2.29e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.74	-0.3	2.07e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2637030	0.515	rs381374	chr5:52927813	A/G	cg06476337	chr5:52856530	NDUFS4	0.43	6.83	0.35	3.88e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.32	6.25	0.32	1.23e-9	Cancer;
LIHC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17554472	chr22:41940697	POLR3H	0.56	6.01	0.31	4.84e-9	Vitiligo;
LIHC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.81	-0.47	3.63e-20	Response to antipsychotic treatment;
LIHC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.44	0.42	8.89e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg04511125	chr2:88470314	THNSL2	0.9	8.95	0.44	2.25e-17	Plasma clusterin levels;
LIHC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	7.47	0.37	6.92e-13	Migraine;Coronary artery disease;
LIHC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.27	-0.32	1.11e-9	IgG glycosylation;
LIHC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.65	0.34	1.13e-10	Educational attainment;
LIHC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.18	-0.36	4.25e-12	Vitiligo;
LIHC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg05941027	chr17:61774174	LIMD2	0.34	6.9	0.35	2.47e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6066825	0.546	rs2598	chr20:47241618	A/G	cg18078177	chr20:47281410	PREX1	0.47	7.76	0.39	9.74e-14	Colorectal cancer;
LIHC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.77	6.32	0.32	8.14e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.72	10.69	0.5	3.41e-23	Corneal astigmatism;
LIHC	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.43	0.33	4.34e-10	Heart rate;
LIHC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.66	10.86	0.51	8.12e-24	Monocyte percentage of white cells;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg23601095	chr6:26197514	HIST1H3D	0.55	5.83	0.3	1.27e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.32	-7.77	-0.39	9.44e-14	Longevity;Endometriosis;
LIHC	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	9.71	0.46	7.5e-20	Response to antipsychotic treatment;
LIHC	trans	rs4710654	0.516	rs6914109	chr6:68509394	A/G	cg00011122	chr16:11439027	C16orf75	-0.4	-6.05	-0.31	3.78e-9	Response to amphetamines;
LIHC	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.6	-8.71	-0.43	1.35e-16	Lymphocyte counts;
LIHC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.86	0.3	1.09e-8	Blood metabolite levels;
LIHC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.53	-7.7	-0.38	1.51e-13	Total body bone mineral density;
LIHC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.32	0.32	8.29e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs807029	0.577	rs3740488	chr10:102754033	A/T	cg27255678	chr10:102756921	LZTS2	0.51	7.28	0.37	2.37e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg13533061	chr17:74712429	JMJD6	-0.32	-5.74	-0.3	2.04e-8	Retinal arteriolar caliber;
LIHC	trans	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg23598604	chr1:99732472	LPPR4	-0.29	-6.21	-0.32	1.5e-9	Multiple myeloma;
LIHC	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.6	8.94	0.44	2.57e-17	Recombination rate (females);
LIHC	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.51	-5.78	-0.3	1.71e-8	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.7	14.06	0.61	9.79e-36	Schizophrenia;
LIHC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-22.08	-0.77	8.55e-68	Coronary artery disease;
LIHC	trans	rs867371	1.000	rs881308	chr15:82475797	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.75	-0.34	6.31e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.75	9.28	0.45	1.99e-18	Body mass index;
LIHC	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.51	7.77	0.39	9.47e-14	Corneal astigmatism;
LIHC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.7	-12.65	-0.56	2.45e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.8	-0.3	1.51e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.44	0.33	4.01e-10	Prudent dietary pattern;
LIHC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.35	5.78	0.3	1.72e-8	Obesity-related traits;
LIHC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.69	-0.38	1.53e-13	Ulcerative colitis;
LIHC	cis	rs4788815	0.691	rs4788808	chr16:71615613	A/G	cg06353428	chr16:71660113	MARVELD3	-0.43	-6.61	-0.34	1.49e-10	Metabolite levels;
LIHC	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.62	-6.44	-0.33	4.04e-10	Bipolar disorder;
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.53	7.55	0.38	3.96e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4908768	0.906	rs12117910	chr1:8556953	A/C	cg20416874	chr1:8611966	RERE	0.57	8.8	0.43	6.93e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs61990749	0.511	rs10146144	chr14:78325300	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.5	7.9	0.39	3.95e-14	Fibroblast growth factor basic levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06862150	chr5:151150984	G3BP1	0.44	6.07	0.31	3.42e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.5	-6.26	-0.32	1.12e-9	Diastolic blood pressure;
LIHC	cis	rs12079745	0.793	rs113298876	chr1:169280579	C/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	1.94e-11	QT interval;
LIHC	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	0.75	6.33	0.32	7.78e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.42e-9	Prostate cancer;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs28530618	0.603	rs13043743	chr20:31257083	C/T	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.84	-0.3	1.2e-8	Birth weight;
LIHC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.46	8.97	0.44	2.03e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.87e-10	Asthma;
LIHC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.46	7.6	0.38	2.88e-13	Alcohol dependence;
LIHC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.08	-10.13	-0.48	2.9e-21	Diabetic retinopathy;
LIHC	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.76	0.34	5.8e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.32	-5.91	-0.3	8.39e-9	Aortic root size;
LIHC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.74e-14	Mean platelet volume;
LIHC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.37	7.39	0.37	1.1e-12	Immature fraction of reticulocytes;
LIHC	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	13.68	0.59	2.69e-34	Coffee consumption (cups per day);
LIHC	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg26031613	chr14:104095156	KLC1	0.99	12.53	0.56	6.56e-30	Body mass index;
LIHC	cis	rs4407350	0.933	rs5765732	chr22:44922761	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	6.33	0.32	7.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	7.0	0.35	1.33e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg27205649	chr11:78285834	NARS2	0.4	6.0	0.31	5.1e-9	Alzheimer's disease (survival time);
LIHC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.31	-5.71	-0.3	2.44e-8	Body mass index;
LIHC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.84	8.43	0.41	1e-15	Body mass index;
LIHC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.3	-16.9	-0.67	5.23e-47	Diabetic kidney disease;
LIHC	cis	rs8084351	0.577	rs35840237	chr18:50607475	T/A	cg24270629	chr18:50823537	DCC	0.44	6.59	0.34	1.69e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs12980942	1.000	rs7257310	chr19:41827120	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.95	0.31	6.73e-9	Coronary artery disease;
LIHC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	0.85	11.71	0.53	7.62e-27	Skin colour saturation;
LIHC	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	1.05	7.58	0.38	3.32e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.04	-0.31	4.08e-9	Total body bone mineral density;
LIHC	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.5	-7.17	-0.36	4.6e-12	Urate levels in overweight individuals;
LIHC	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.93	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.2	-0.36	3.84e-12	Type 2 diabetes;
LIHC	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.55	-8.63	-0.42	2.27e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg00792783	chr2:198669748	PLCL1	-0.43	-6.24	-0.32	1.27e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.5	16.55	0.67	1.29e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg19752551	chr11:57585705	CTNND1	-0.46	-5.98	-0.31	5.62e-9	Schizophrenia;
LIHC	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.8	13.99	0.6	1.81e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	8.27	0.41	3.06e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.15	16.2	0.66	3.44e-44	Corneal structure;
LIHC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.38	7.88	0.39	4.51e-14	Immature fraction of reticulocytes;
LIHC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-12.94	-0.57	1.87e-31	Primary sclerosing cholangitis;
LIHC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.43	-0.45	6.54e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg19920283	chr7:105172520	RINT1	0.48	6.13	0.31	2.49e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.16e-13	Vitiligo;
LIHC	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.85	10.78	0.5	1.66e-23	HIV-1 control;
LIHC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.57	7.67	0.38	1.76e-13	Blood metabolite levels;
LIHC	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-14.42	-0.61	3.6e-37	Schizophrenia;
LIHC	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.95	0.35	1.83e-11	Exhaled nitric oxide output;
LIHC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.53e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.85	-0.39	5.35e-14	Intelligence;
LIHC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg11062466	chr8:58055876	NA	0.4	5.87	0.3	1.03e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08219700	chr8:58056026	NA	0.55	6.74	0.34	6.72e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.72	7.02	0.36	1.16e-11	Breast cancer;
LIHC	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg02811702	chr13:24901961	NA	0.23	5.76	0.3	1.89e-8	Obesity-related traits;
LIHC	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg00977110	chr5:151150581	G3BP1	0.55	6.98	0.35	1.56e-11	Preschool internalizing problems;
LIHC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.44	-8.04	-0.4	1.45e-14	Body mass index;
LIHC	trans	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg10756647	chr7:56101905	PSPH	1.08	13.33	0.58	6.29e-33	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.37	-6.78	-0.34	5.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2637030	0.559	rs376566	chr5:53005420	G/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.69	0.34	8.96e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.84e-19	Waist circumference;Weight;
LIHC	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.04e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg21522988	chr12:29376872	FAR2	0.28	6.41	0.33	4.84e-10	QT interval;
LIHC	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.59	5.94	0.31	7.19e-9	Carotid intima media thickness;
LIHC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.67	12.09	0.55	2.96e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.92	-0.39	3.27e-14	Response to antipsychotic treatment;
LIHC	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.01	0.31	4.66e-9	Resting heart rate;
LIHC	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-8.43	-0.41	9.52e-16	Exhaled nitric oxide output;
LIHC	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.39	-0.37	1.17e-12	Lymphocyte counts;
LIHC	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	5.86	0.3	1.09e-8	Iron status biomarkers;
LIHC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.71	9.39	0.45	8.96e-19	Gut microbiome composition (summer);
LIHC	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg25356066	chr3:128598488	ACAD9	0.54	7.21	0.36	3.73e-12	IgG glycosylation;
LIHC	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs4919087	0.748	rs701819	chr10:98986316	C/A	cg25902810	chr10:99078978	FRAT1	-0.56	-6.49	-0.33	3.07e-10	Monocyte count;
LIHC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg06935464	chr4:38784597	TLR10	0.48	7.38	0.37	1.23e-12	Breast cancer;
LIHC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg00280220	chr17:61926910	NA	0.43	7.06	0.36	9.37e-12	Prudent dietary pattern;
LIHC	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.69	6.4	0.33	5.03e-10	Lymphocyte counts;
LIHC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg14067834	chr17:29058358	SUZ12P	-0.62	-6.47	-0.33	3.45e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11955398	0.665	rs11948543	chr5:59918937	T/C	cg02684056	chr5:59996105	DEPDC1B	0.41	6.09	0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.33	-0.37	1.71e-12	Tuberculosis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07810114	chr1:12018622	PLOD1	0.54	8.2	0.41	4.8e-15	Longevity;
LIHC	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.76	-0.3	1.85e-8	Prostate cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06329143	chr18:48556512	SMAD4	-0.49	-6.43	-0.33	4.18e-10	Systolic blood pressure;
LIHC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg17385448	chr1:15911702	AGMAT	0.35	6.15	0.32	2.21e-9	Systolic blood pressure;
LIHC	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	7.18	0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.48	-7.73	-0.39	1.18e-13	Neurofibrillary tangles;
LIHC	cis	rs918629	0.530	rs3777203	chr5:95234377	C/T	cg10483112	chr5:95245456	ELL2	-0.36	-6.59	-0.34	1.67e-10	IgG glycosylation;
LIHC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.43	6.22	0.32	1.45e-9	Longevity;Endometriosis;
LIHC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	12.12	0.55	2.25e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.56	0.59	8.25e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs12086130	0.892	rs3176466	chr1:51438365	A/G	cg07174182	chr1:51127561	FAF1	0.72	8.34	0.41	1.84e-15	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs6960043	1.000	rs6972516	chr7:15051789	G/T	cg19272540	chr7:15055459	NA	-0.22	-6.26	-0.32	1.12e-9	Type 2 diabetes;
LIHC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	0.81	6.72	0.34	7.8e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.41	-6.73	-0.34	7.22e-11	Dementia with Lewy bodies;
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.73	13.65	0.59	3.58e-34	Prudent dietary pattern;
LIHC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.73	-11.26	-0.52	3.02e-25	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg05044414	chr3:183734942	ABCC5	0.33	5.88	0.3	9.51e-9	Anterior chamber depth;
LIHC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.82	7.72	0.39	1.3e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg11946769	chr3:48343235	NME6	-0.47	-6.24	-0.32	1.27e-9	Educational attainment (years of education);
LIHC	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.08	-0.31	3.2e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.42	8.46	0.42	7.64e-16	Renal cell carcinoma;
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.21	-0.45	3.26e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.53	-6.36	-0.33	6.6e-10	Schizophrenia;
LIHC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.5	6.23	0.32	1.37e-9	Schizophrenia;
LIHC	cis	rs16958440	1.000	rs62096464	chr18:44629207	T/A	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.49	7.57	0.38	3.47e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	cis	rs12980942	1.000	rs6957	chr19:41830606	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.97	0.31	6.08e-9	Coronary artery disease;
LIHC	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg10587741	chr22:38071170	LGALS1	0.68	9.4	0.45	8.19e-19	Fat distribution (HIV);
LIHC	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	0.99	15.16	0.63	4.38e-40	Corneal structure;
LIHC	cis	rs7523273	1.000	rs12123251	chr1:207992546	G/A	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.45	-0.49	2.26e-22	Schizophrenia;
LIHC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08280861	chr8:58055591	NA	0.52	6.04	0.31	3.92e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg25039879	chr17:56429692	SUPT4H1	0.84	9.58	0.46	1.99e-19	Cognitive test performance;
LIHC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg05044414	chr3:183734942	ABCC5	0.34	5.87	0.3	1.04e-8	Anterior chamber depth;
LIHC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.98	-0.51	3.16e-24	Hemoglobin concentration;
LIHC	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg27205649	chr11:78285834	NARS2	0.39	6.15	0.32	2.14e-9	Alzheimer's disease (survival time);
LIHC	trans	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg14393609	chr7:65229607	NA	0.38	5.87	0.3	1.02e-8	Aortic root size;
LIHC	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg12160578	chr15:63334699	TPM1	0.69	9.02	0.44	1.34e-17	Orofacial clefts;
LIHC	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.28	-6.39	-0.33	5.35e-10	Educational attainment (years of education);
LIHC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.6	0.59	5.67e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg07424592	chr7:64974309	NA	0.83	9.56	0.46	2.47e-19	Diabetic kidney disease;
LIHC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.64	-10.74	-0.5	2.3e-23	Pediatric autoimmune diseases;
LIHC	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16684958	chr7:75615977	POR	0.51	8.59	0.42	3.18e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg18306943	chr3:40428807	ENTPD3	-0.36	-6.45	-0.33	3.87e-10	Renal cell carcinoma;
LIHC	cis	rs8081395	0.741	rs180532	chr17:58003297	A/G	cg02344993	chr17:57696989	CLTC	0.35	5.71	0.3	2.44e-8	White blood cell count;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg05484376	chr2:27715224	FNDC4	0.38	6.46	0.33	3.57e-10	Total body bone mineral density;
LIHC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.75	-11.33	-0.52	1.8e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.75	-0.34	6.36e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.75	9.68	0.46	9.64e-20	Body mass index;
LIHC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.84	0.35	3.55e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.59	11.62	0.53	1.59e-26	Coronary artery disease;
LIHC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.5	0.56	9.04e-30	Prudent dietary pattern;
LIHC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.53	-8.48	-0.42	6.68e-16	Coronary artery disease;
LIHC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg16586182	chr3:47516702	SCAP	0.6	11.55	0.53	2.77e-26	Colorectal cancer;
LIHC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	9.59	0.46	1.91e-19	Lung cancer in ever smokers;
LIHC	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg25566285	chr7:158114605	PTPRN2	0.23	6.15	0.32	2.11e-9	Calcium levels;
LIHC	cis	rs7075426	0.669	rs4934211	chr10:88203735	C/T	cg07322936	chr10:88137208	NA	0.49	6.36	0.33	6.63e-10	Migraine without aura;
LIHC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg09835421	chr16:68378352	PRMT7	-0.52	-5.98	-0.31	5.58e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.24	0.55	7.83e-29	Cognitive test performance;
LIHC	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.62	-6.96	-0.35	1.72e-11	Bipolar disorder;
LIHC	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.61	-9.61	-0.46	1.67e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.49	-7.26	-0.37	2.63e-12	Blood trace element (Zn levels);
LIHC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.83	-0.3	1.25e-8	Body mass index;
LIHC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	12.24	0.55	8.44e-29	Mean platelet volume;
LIHC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.6	7.86	0.39	4.91e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.92	0.51	5.31e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.53	8.66	0.42	1.91e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg17764715	chr19:33622953	WDR88	0.47	6.84	0.35	3.62e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.59	-11.71	-0.53	7.4e-27	Urate levels in overweight individuals;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13886124	chr9:130186480	ZNF79	0.48	6.43	0.33	4.42e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	7.02	0.35	1.21e-11	Obesity-related traits;
LIHC	cis	rs12464559	0.649	rs4664066	chr2:152632406	T/C	cg01189475	chr2:152685088	ARL5A	0.63	7.43	0.37	8.56e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg14067834	chr17:29058358	SUZ12P	0.71	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg25024717	chr12:54324583	NA	-0.32	-6.3	-0.32	8.9e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.47	-9.72	-0.47	6.84e-20	Breast cancer;
LIHC	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.64	9.38	0.45	9.2e-19	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.15	0.36	5.23e-12	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg20284218	chr11:62648405	SLC3A2	-0.54	-6.72	-0.34	7.76e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg10096929	chr1:156261403	TMEM79	0.4	6.63	0.34	1.28e-10	Tonsillectomy;
LIHC	cis	rs2997447	0.846	rs61775427	chr1:26408768	G/A	cg19633962	chr1:26362018	EXTL1	-0.69	-6.32	-0.32	8.04e-10	QRS complex (12-leadsum);
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg00049323	chr5:472564	LOC25845	0.35	5.85	0.3	1.14e-8	Cystic fibrosis severity;
LIHC	trans	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg17712092	chr4:129076599	LARP1B	-0.7	-10.23	-0.48	1.32e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14705778	chr4:174254825	HMGB2	0.38	6.21	0.32	1.57e-9	Migraine with aura;
LIHC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs2274273	1.000	rs67098772	chr14:55595242	G/A	cg01864836	chr14:55583639	NA	-0.36	-6.15	-0.32	2.14e-9	Protein biomarker;
LIHC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs2274273	0.901	rs10140801	chr14:55730404	C/T	cg01864836	chr14:55583639	NA	-0.4	-7.31	-0.37	1.95e-12	Protein biomarker;
LIHC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.55	7.84	0.39	5.64e-14	Asthma;
LIHC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.14	-0.32	2.24e-9	Vitiligo;
LIHC	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg03146154	chr1:46216737	IPP	-0.4	-6.54	-0.33	2.27e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.14	0.31	2.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	1.05	9.89	0.47	1.83e-20	Obesity-related traits;
LIHC	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg00071026	chr13:113650936	MCF2L	-0.38	-5.93	-0.31	7.3e-9	Systolic blood pressure;
LIHC	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.21	0.32	1.55e-9	Ileal carcinoids;
LIHC	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.53	-7.44	-0.37	8.18e-13	Body mass index;
LIHC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06002616	chr8:101225028	SPAG1	0.36	6.25	0.32	1.24e-9	Atrioventricular conduction;
LIHC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.62	0.53	1.6e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.48	0.56	1.05e-29	Prudent dietary pattern;
LIHC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Urate levels;
LIHC	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-5.78	-0.3	1.65e-8	Neuroticism;
LIHC	trans	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.96	0.35	1.78e-11	Corneal astigmatism;
LIHC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.31	-0.32	8.61e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.51	9.2	0.45	3.53e-18	Height;
LIHC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.53	7.71	0.38	1.35e-13	Obesity-related traits;
LIHC	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	7.88	0.39	4.41e-14	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg18016565	chr1:150552671	MCL1	-0.49	-9.54	-0.46	2.81e-19	Tonsillectomy;
LIHC	cis	rs7897654	0.571	rs7920697	chr10:104633337	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-7.54	-0.38	4.23e-13	Schizophrenia;
LIHC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06544989	chr22:39130855	UNC84B	0.35	5.74	0.3	2.11e-8	Menopause (age at onset);
LIHC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.69	12.43	0.56	1.61e-29	Iron status biomarkers;
LIHC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.03	0.36	1.14e-11	Heart rate;
LIHC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.44	17.03	0.68	1.51e-47	Breast cancer;
LIHC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-7.21	-0.36	3.56e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs6665290	1.000	rs6665290	chr1:227201106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-26.8	-0.82	5e-86	Myeloid white cell count;
LIHC	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.02	-0.31	4.51e-9	Resting heart rate;
LIHC	cis	rs937213	0.573	rs3816900	chr15:40302243	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.36	-6.05	-0.31	3.75e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.52	9.04	0.44	1.19e-17	Coronary artery disease;
LIHC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.47	6.62	0.34	1.36e-10	Morning vs. evening chronotype;
LIHC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg21782813	chr7:2030301	MAD1L1	0.47	8.1	0.4	9.64e-15	Bipolar disorder and schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21619287	chr16:3767727	TRAP1	-0.5	-6.62	-0.34	1.39e-10	Systolic blood pressure;
LIHC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	0.96	18.34	0.7	8.49e-53	Ewing sarcoma;
LIHC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.42	-9.55	-0.46	2.51e-19	Arsenic metabolism;
LIHC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.32	6.55	0.33	2.1e-10	Immature fraction of reticulocytes;
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	9.32e-15	Prudent dietary pattern;
LIHC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-9.98	-0.47	9.32e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.59e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg15103426	chr22:29168792	CCDC117	0.43	5.81	0.3	1.45e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg00292662	chr22:38071168	LGALS1	0.63	10.04	0.48	6.04e-21	Fat distribution (HIV);
LIHC	cis	rs10792665	0.541	rs1318423	chr11:82615502	T/C	cg24227371	chr11:82718527	RAB30	-0.28	-6.54	-0.33	2.25e-10	Obesity-related traits;
LIHC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.46	-7.43	-0.37	9.04e-13	Cognitive function;
LIHC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02985541	chr2:219472218	PLCD4	0.44	8.5	0.42	5.86e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.38	0.52	1.13e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.84	0.39	5.68e-14	Renal cell carcinoma;
LIHC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.7	-9.6	-0.46	1.78e-19	Corneal structure;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg26338869	chr17:61819248	STRADA	0.5	6.5	0.33	2.87e-10	Height;
LIHC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.82	0.43	5.99e-17	Eosinophil percentage of white cells;
LIHC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.55	0.33	2.07e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.81	-0.3	1.47e-8	Red blood cell count;
LIHC	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.64	10.73	0.5	2.47e-23	Coronary artery disease;
LIHC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-8.33	-0.41	2e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs61677309	1.000	rs55789743	chr11:118171949	C/A	cg06090739	chr11:118230722	UBE4A	0.34	6.32	0.32	8.33e-10	Lung cancer in ever smokers;
LIHC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.5	0.42	5.96e-16	Motion sickness;
LIHC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.3	-16.6	-0.67	8.39e-46	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.42	0.53	8.07e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17327406	chr4:6303265	WFS1	-0.41	-6.19	-0.32	1.76e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7523273	0.565	rs2796234	chr1:207900695	T/A	cg22525895	chr1:207977042	MIR29B2	-0.54	-8.24	-0.41	3.61e-15	Schizophrenia;
LIHC	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.27	-0.37	2.46e-12	Mean platelet volume;
LIHC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-10.66	-0.5	4.14e-23	Asthma;
LIHC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	12.59	0.56	4e-30	Platelet count;
LIHC	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg00601450	chr5:74908170	NA	0.55	6.38	0.33	5.82e-10	Coronary artery disease;
LIHC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.72	11.54	0.53	3.16e-26	Oral cavity cancer;
LIHC	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.12	0.36	6.4e-12	Height;
LIHC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.32	-5.77	-0.3	1.75e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.47	-6.16	-0.32	2e-9	Vitiligo;
LIHC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.37	-6.05	-0.31	3.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs11673344	0.704	rs1644711	chr19:37417322	C/G	cg27390819	chr19:37464633	NA	-0.48	-5.82	-0.3	1.35e-8	Obesity-related traits;
LIHC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.48	-6.8	-0.34	4.79e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs6449957	0.639	rs831227	chr5:67517646	A/C	cg23036683	chr5:67512108	NA	0.51	7.62	0.38	2.5e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-12.04	-0.55	4.54e-28	Alzheimer's disease (late onset);
LIHC	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-8.58	-0.42	3.33e-16	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-19.73	-0.73	2.22e-58	Height;
LIHC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg12661370	chr5:149340060	SLC26A2	0.54	6.5	0.33	2.9e-10	HIV-1 control;
LIHC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.86	15.61	0.64	7.81e-42	Bone mineral density;
LIHC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	9.23	0.45	2.86e-18	Aortic root size;
LIHC	cis	rs911119	0.913	rs6048929	chr20:23588855	T/C	cg16589663	chr20:23618590	CST3	0.71	7.5	0.38	5.61e-13	Chronic kidney disease;
LIHC	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.55	8.98	0.44	1.9e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9473924	0.505	rs7753025	chr6:50858352	A/C	cg14470998	chr6:50812995	TFAP2B	0.94	10.91	0.51	5.57e-24	Body mass index;
LIHC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.26	0.37	2.66e-12	Mood instability;
LIHC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.65	10.31	0.49	6.92e-22	Obesity-related traits;
LIHC	cis	rs3110496	1.000	rs3110496	chr17:27917771	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.96	0.35	1.8e-11	Height;
LIHC	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg18289306	chr13:113640169	MCF2L	0.42	6.65	0.34	1.13e-10	Systolic blood pressure;
LIHC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	1.03	17.37	0.68	7.07e-49	Obesity-related traits;
LIHC	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg07234388	chr1:156261841	TMEM79	0.51	8.77	0.43	8.74e-17	Tonsillectomy;
LIHC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.66	13.02	0.58	9.38e-32	Schizophrenia;
LIHC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg16506815	chr2:162101123	NA	-0.46	-7.49	-0.38	5.74e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs963731	0.579	rs2168042	chr2:39273536	C/T	cg04010122	chr2:39346883	SOS1	-0.7	-6.48	-0.33	3.22e-10	Corticobasal degeneration;
LIHC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.21	0.32	1.51e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.53	-6.52	-0.33	2.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg16275483	chr1:110013120	SYPL2	-0.49	-6.22	-0.32	1.45e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.37	0.59	4.48e-33	Hip circumference adjusted for BMI;
LIHC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.38	5.9	0.3	8.74e-9	Lung cancer;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.53	-7.64	-0.38	2.22e-13	Menopause (age at onset);
LIHC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	9.23	0.45	2.91e-18	Monocyte percentage of white cells;
LIHC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.57	9.26	0.45	2.37e-18	Lymphocyte counts;
LIHC	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16684958	chr7:75615977	POR	0.52	8.59	0.42	3.22e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.79	-0.3	1.61e-8	Pulse pressure;
LIHC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-6.52	-0.33	2.52e-10	Height;
LIHC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.9e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.12	0.58	4.05e-32	Cognitive test performance;
LIHC	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.82	-12.26	-0.55	6.88e-29	Obesity-related traits;
LIHC	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.86	-0.3	1.09e-8	Calcium levels;
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.51	-7.44	-0.37	8.47e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs16958440	1.000	rs16958432	chr18:44631773	G/A	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.61e-11	Sitting height ratio;
LIHC	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.69	6.69	0.34	8.95e-11	Migraine;Coronary artery disease;
LIHC	cis	rs12500138	0.572	rs56681900	chr4:166180240	A/G	cg25064052	chr4:166216151	KLHL2	-0.65	-6.01	-0.31	4.63e-9	Cognitive function;
LIHC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.36	0.33	6.5e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.73	7.53	0.38	4.48e-13	Bipolar disorder;
LIHC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.91	-0.35	2.37e-11	Neuroticism;
LIHC	cis	rs7129220	0.512	rs11042666	chr11:10227393	A/T	cg01453529	chr11:10209919	SBF2	-0.41	-7.64	-0.38	2.2e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16715692	chr19:1104863	GPX4	-0.39	-6.12	-0.31	2.54e-9	Pancreatic cancer;
LIHC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.6	8.06	0.4	1.28e-14	Neutrophil percentage of white cells;
LIHC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-9.33	-0.45	1.32e-18	Prudent dietary pattern;
LIHC	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.91	-0.3	8.15e-9	Coronary artery disease;
LIHC	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.91	-15.92	-0.65	4.35e-43	Schizophrenia;
LIHC	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs75908454	1.000	rs75999861	chr6:169827317	T/C	cg19338460	chr6:170058176	WDR27	-0.87	-7.81	-0.39	7.2e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg15208524	chr1:10270712	KIF1B	0.38	5.85	0.3	1.18e-8	Hepatocellular carcinoma;
LIHC	cis	rs1144333	1.000	rs1586936	chr1:76366877	T/C	cg10523679	chr1:76189770	ACADM	0.46	6.55	0.33	2.13e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.41	-6.84	-0.35	3.6e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.49	-7.61	-0.38	2.62e-13	Breast size;
LIHC	cis	rs3753275	0.690	rs6697997	chr1:8609111	A/G	cg20416874	chr1:8611966	RERE	-0.5	-6.48	-0.33	3.18e-10	Educational attainment;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01091156	chr16:87991122	BANP	0.42	6.39	0.33	5.38e-10	Longevity;
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.75	-12.39	-0.56	2.2e-29	Longevity;
LIHC	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.44	6.56	0.33	1.97e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.65	7.76	0.39	9.58e-14	QRS complex (12-leadsum);
LIHC	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.84	16.2	0.66	3.25e-44	Nonalcoholic fatty liver disease;
LIHC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.34	7.54	0.38	4.23e-13	Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg03894339	chr8:19674705	INTS10	0.41	5.83	0.3	1.26e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.83	-0.3	1.26e-8	Breast cancer;
LIHC	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.51	-7.95	-0.39	2.73e-14	Verbal declarative memory;
LIHC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.56e-13	Prudent dietary pattern;
LIHC	cis	rs1059312	0.669	rs11059917	chr12:129287925	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-11.98	-0.54	7.16e-28	Systemic lupus erythematosus;
LIHC	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.4	5.73	0.3	2.18e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.86	8.17	0.4	6.14e-15	Vitiligo;
LIHC	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.58	0.34	1.75e-10	Dermatomyositis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18281101	chr1:157015843	ARHGEF11	0.45	6.31	0.32	8.44e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.51	-7.35	-0.37	1.52e-12	Lymphocyte counts;
LIHC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11645453	chr3:52864694	ITIH4	0.22	5.95	0.31	6.75e-9	Bipolar disorder;
LIHC	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.5	-7.91	-0.39	3.65e-14	Blood metabolite levels;
LIHC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg13257436	chr8:145726034	PPP1R16A	0.36	6.38	0.33	5.62e-10	Age at first birth;
LIHC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.36	0.37	1.35e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.72	5.83	0.3	1.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.64	9.18	0.44	4.33e-18	Lymphocyte counts;
LIHC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.8	11.9	0.54	1.48e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.73	-8.92	-0.43	2.81e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.49	7.58	0.38	3.19e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-9.61	-0.46	1.67e-19	Asthma;
LIHC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.92	18.75	0.71	1.84e-54	Bone mineral density;
LIHC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.52	-7.42	-0.37	9.14e-13	Body mass index;
LIHC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.61	-0.34	1.48e-10	Height;
LIHC	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.72	-13.47	-0.59	1.86e-33	Mean platelet volume;
LIHC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.42	7.21	0.36	3.53e-12	Tuberculosis;
LIHC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.35	-5.73	-0.3	2.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg04691961	chr3:161091175	C3orf57	-0.41	-6.43	-0.33	4.24e-10	Morning vs. evening chronotype;
LIHC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.39	5.93	0.31	7.46e-9	Educational attainment;
LIHC	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg15902774	chr15:75289873	SCAMP5	0.33	5.95	0.31	6.73e-9	Systemic lupus erythematosus;
LIHC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.0	-0.44	1.57e-17	Longevity;
LIHC	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.85	0.35	3.36e-11	Mean corpuscular volume;
LIHC	cis	rs72843506	0.656	rs111249650	chr17:19911830	A/T	cg12065943	chr17:19881925	AKAP10	-0.41	-7.0	-0.35	1.35e-11	Schizophrenia;
LIHC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.68	13.52	0.59	1.12e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2599510	1.000	rs2599510	chr2:32826002	A/G	cg02381751	chr2:32503542	YIPF4	0.52	6.98	0.35	1.5e-11	Interleukin-18 levels;
LIHC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.31	-7.92	-0.39	3.44e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.47	7.81	0.39	7.03e-14	Tuberculosis;
LIHC	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg07884673	chr3:53033167	SFMBT1	0.92	6.74	0.34	6.85e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg26788993	chr3:159706828	IL12A	-0.41	-6.14	-0.32	2.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.48	6.74	0.34	6.84e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg09033563	chr22:24373618	LOC391322	-0.47	-6.5	-0.33	2.88e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.49	8.17	0.4	5.9e-15	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25338623	chr11:67250427	AIP	0.45	6.06	0.31	3.5e-9	Pancreatic cancer;
LIHC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.82	0.65	1.12e-42	Chronic sinus infection;
LIHC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-10.57	-0.5	8.53e-23	Primary sclerosing cholangitis;
LIHC	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg14146966	chr2:61757674	XPO1	0.48	8.47	0.42	7.3e-16	Tuberculosis;
LIHC	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-0.81	-12.2	-0.55	1.11e-28	Obesity-related traits;
LIHC	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.52	8.91	0.43	3.02e-17	Coronary artery disease;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg03721293	chr16:90014378	DEF8	0.43	7.01	0.35	1.25e-11	Skin colour saturation;
LIHC	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg05163923	chr11:71159392	DHCR7	-0.59	-7.26	-0.37	2.69e-12	Vitamin D levels;
LIHC	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg01028140	chr2:1542097	TPO	-0.45	-7.23	-0.36	3.09e-12	IgG glycosylation;
LIHC	trans	rs10213084	1.000	rs28755940	chr4:147480048	A/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.52	6.23	0.32	1.37e-9	Heart rate;
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.63	9.79	0.47	4.19e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.41	6.25	0.32	1.21e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.75	-8.67	-0.42	1.79e-16	Morning vs. evening chronotype;
LIHC	cis	rs2741335	0.876	rs2741338	chr8:27335734	C/T	cg07150473	chr8:27338183	CHRNA2	0.46	6.42	0.33	4.42e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.56	-8.26	-0.41	3.21e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.6	10.56	0.5	9.19e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.38	-6.44	-0.33	4.1e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.78	11.05	0.51	1.81e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	0.95	17.52	0.69	1.67e-49	Menopause (age at onset);
LIHC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.93	16.74	0.67	2.27e-46	Parkinson's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01479911	chr17:7145805	GABARAP	-0.56	-6.4	-0.33	5.04e-10	Systolic blood pressure;
LIHC	cis	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg01231543	chr16:68741748	NA	-0.38	-5.8	-0.3	1.55e-8	Colorectal cancer;
LIHC	cis	rs11031096	0.563	rs12281849	chr11:4224832	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-6.45	-0.33	3.91e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6586163	0.527	rs12775501	chr10:90750909	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.79	12.72	0.57	1.33e-30	Chronic lymphocytic leukemia;
LIHC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	9.25	0.45	2.58e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.23	-0.45	2.97e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg02770688	chr6:168491649	NA	0.31	5.89	0.3	9.39e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LIHC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg18016565	chr1:150552671	MCL1	-0.54	-11.08	-0.51	1.43e-24	Tonsillectomy;
LIHC	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg16275483	chr1:110013120	SYPL2	-0.48	-5.96	-0.31	6.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	8.7	0.43	1.39e-16	Lymphocyte counts;
LIHC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.81	10.44	0.49	2.52e-22	Cognitive function;
LIHC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.34	7.59	0.38	3.13e-13	Crohn's disease;
LIHC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.68	-11.78	-0.54	3.92e-27	Height;
LIHC	cis	rs1144333	1.000	rs17097863	chr1:76468787	T/G	cg22875332	chr1:76189707	ACADM	0.39	6.1	0.31	2.9e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs11031096	0.711	rs12270809	chr11:4206537	G/A	cg18678763	chr11:4115507	RRM1	-0.39	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.3	-0.37	1.97e-12	Platelet count;
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6467136	0.540	rs56216302	chr7:127180679	G/A	cg25922125	chr7:127225783	GCC1	-0.45	-5.84	-0.3	1.25e-8	Type 2 diabetes;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19498110	chr22:17590091	IL17RA	-0.44	-7.42	-0.37	9.38e-13	Calcium levels;
LIHC	cis	rs8192917	1.000	rs2273844	chr14:25103414	G/A	cg03875678	chr14:25103546	GZMB	0.4	7.08	0.36	8.45e-12	Vitiligo;
LIHC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.16	-0.4	6.3e-15	Glycated hemoglobin levels;
LIHC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.27	-16.34	-0.66	9.2e-45	Diabetic kidney disease;
LIHC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.51	0.33	2.74e-10	Schizophrenia;
LIHC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.19	-0.36	4.17e-12	Body mass index;
LIHC	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.73	-11.26	-0.52	3.12e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2642442	0.962	rs2807834	chr1:220970593	A/C	cg04704887	chr1:220970030	MOSC1	-0.45	-6.1	-0.31	2.84e-9	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.91	0.3	8.11e-9	Alzheimer's disease;
LIHC	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.91	11.33	0.52	1.81e-25	Coronary artery disease;
LIHC	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg18898632	chr2:242989856	NA	-0.38	-5.73	-0.3	2.25e-8	Obesity-related traits;
LIHC	trans	rs2270221	0.767	rs12701153	chr7:31906164	G/T	cg06873401	chr5:77792105	LHFPL2	0.49	6.05	0.31	3.72e-9	Endometriosis;
LIHC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.64	10.69	0.5	3.21e-23	Type 2 diabetes;
LIHC	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.79	15.27	0.64	1.7e-40	Testicular germ cell tumor;
LIHC	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.46	6.15	0.32	2.17e-9	Obesity (extreme);
LIHC	trans	rs11088226	0.581	rs2833862	chr21:33884390	A/G	cg09050820	chr6:167586206	TCP10L2	0.47	7.26	0.37	2.6e-12	Gastritis;
LIHC	trans	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg10756647	chr7:56101905	PSPH	1.06	13.29	0.58	8.51e-33	Diabetic kidney disease;
LIHC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.67	10.91	0.51	5.54e-24	Type 2 diabetes;
LIHC	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg05163923	chr11:71159392	DHCR7	-0.59	-7.23	-0.36	3.18e-12	Vitamin D levels;
LIHC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.55	-7.58	-0.38	3.26e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.58	-8.73	-0.43	1.18e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10256972	0.640	rs10271082	chr7:1081562	G/C	cg04025307	chr7:1156635	C7orf50	0.4	6.32	0.32	8.31e-10	Longevity;Endometriosis;
LIHC	cis	rs10949834	0.618	rs810551	chr7:73492093	C/G	cg07137043	chr7:73588983	EIF4H	-0.51	-6.04	-0.31	3.99e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs9596863	1.000	rs1458268	chr13:54405594	C/T	ch.13.53330881F	chr13:54432880	NA	-0.43	-6.06	-0.31	3.61e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	1.03	12.62	0.56	3.16e-30	Vitiligo;
LIHC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	6.03	0.31	4.31e-9	Schizophrenia;
LIHC	cis	rs2834188	0.669	rs1467845	chr21:34666376	A/G	cg14352951	chr21:34696688	IFNAR1	0.42	6.02	0.31	4.62e-9	Narcolepsy;
LIHC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.93	0.31	7.29e-9	Electroencephalogram traits;
LIHC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.53	7.75	0.39	1.07e-13	Type 2 diabetes;
LIHC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.57	-0.38	3.53e-13	Body mass index;
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.18	-0.36	4.44e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.88	-10.38	-0.49	4.11e-22	Alzheimer's disease (late onset);
LIHC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg18912006	chr12:123335444	HIP1R	0.58	7.11	0.36	6.8e-12	Schizophrenia;
LIHC	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-12.5	-0.56	8.42e-30	Response to antipsychotic treatment;
LIHC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.68	0.78	3.75e-70	Chronic sinus infection;
LIHC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.67	10.75	0.5	2.04e-23	Corneal astigmatism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23797839	chr10:60094994	UBE2D1	0.5	6.96	0.35	1.76e-11	Lung function (FEV1/FVC);
LIHC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	14.34	0.61	7.33e-37	Menopause (age at onset);
LIHC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.48	-17.71	-0.69	2.89e-50	Breast cancer;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg00656387	chr3:40428638	ENTPD3	0.5	8.29	0.41	2.68e-15	Renal cell carcinoma;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg18279126	chr7:2041391	MAD1L1	0.38	6.39	0.33	5.37e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg20604317	chr20:4129314	SMOX	0.44	6.56	0.33	2.05e-10	Migraine with aura;
LIHC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg15017067	chr4:17643749	FAM184B	0.33	5.78	0.3	1.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg18898632	chr2:242989856	NA	-0.51	-7.27	-0.37	2.48e-12	Obesity-related traits;
LIHC	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg15704280	chr7:45808275	SEPT13	0.63	6.57	0.33	1.86e-10	Axial length;
LIHC	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.83	8.48	0.42	6.99e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.47	5.86	0.3	1.12e-8	Alzheimer's disease;
LIHC	trans	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.36	0.33	6.63e-10	Ulcerative colitis;
LIHC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.08	9.74	0.47	5.89e-20	Diabetic retinopathy;
LIHC	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.42	7.02	0.36	1.18e-11	Lewy body disease;
LIHC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-5.94	-0.31	7.05e-9	Blood metabolite levels;
LIHC	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	4.01e-23	Hypertriglyceridemia;
LIHC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.41	-6.38	-0.33	5.63e-10	Blood pressure (smoking interaction);
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-6.24	-0.32	1.31e-9	Bipolar disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24113505	chr7:92861286	CCDC132	0.44	6.45	0.33	3.93e-10	Cognitive function;
LIHC	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.18	-0.32	1.85e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs4700695	0.925	rs796728	chr5:65382500	C/T	cg21114390	chr5:65439923	SFRS12	-0.46	-6.11	-0.31	2.76e-9	Facial morphology (factor 19);
LIHC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.35	-0.37	1.5e-12	Mean platelet volume;
LIHC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.81	-0.73	1e-58	Height;
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg14671364	chr1:107599128	PRMT6	0.53	7.92	0.39	3.28e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.65	10.36	0.49	4.83e-22	Schizophrenia;
LIHC	cis	rs6466055	0.748	rs6962856	chr7:104953466	A/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.13	-0.36	5.85e-12	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08677755	chr19:7604888	PNPLA6	0.46	6.45	0.33	3.79e-10	Pancreatic cancer;
LIHC	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.09e-22	Hypertriglyceridemia;
LIHC	cis	rs8016947	0.583	rs7140505	chr14:35830213	C/G	cg03549618	chr14:35838977	NA	0.44	6.98	0.35	1.54e-11	Psoriasis;
LIHC	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	6.93	0.35	2.06e-11	Exhaled nitric oxide output;
LIHC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg26395211	chr5:140044315	WDR55	-0.41	-6.04	-0.31	4.1e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.4	-6.57	-0.33	1.92e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.74	-7.1	-0.36	7.45e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.92e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg17675199	chr6:35436792	RPL10A	-0.45	-9.34	-0.45	1.24e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.15	-0.36	5.44e-12	Height;
LIHC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.47	6.71	0.34	8.23e-11	Schizophrenia;
LIHC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.19	-25.41	-0.81	8.99e-81	Myeloid white cell count;
LIHC	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg03934865	chr2:198174659	NA	0.43	6.19	0.32	1.74e-9	Intracranial aneurysm;
LIHC	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg00864860	chr1:7907996	UTS2	0.57	5.72	0.3	2.39e-8	Inflammatory bowel disease;
LIHC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.5	7.08	0.36	8.02e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17554472	chr22:41940697	POLR3H	0.55	6.33	0.32	7.79e-10	Vitiligo;
LIHC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.59	-9.93	-0.47	1.39e-20	Height;
LIHC	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.86	-0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs6061231	0.958	rs2427305	chr20:60953749	G/C	cg24112000	chr20:60950667	NA	-0.6	-8.34	-0.41	1.78e-15	Colorectal cancer;
LIHC	trans	rs2352908	0.786	rs2000013	chr14:49442395	C/T	cg16568472	chr20:3190600	ITPA	-0.44	-6.04	-0.31	4.05e-9	Social communication problems;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14476630	chr11:72437731	ARAP1	0.43	6.07	0.31	3.44e-9	Hip circumference;
LIHC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.53	-9.28	-0.45	1.98e-18	White blood cell count;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg03785755	chr6:26196794	NA	0.51	5.97	0.31	5.8e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.6	-7.44	-0.37	8.31e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg18944383	chr4:111397179	ENPEP	0.25	6.2	0.32	1.6e-9	Coronary artery disease;
LIHC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.03	0.51	2.09e-24	Personality dimensions;
LIHC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	6.59	0.34	1.68e-10	Height;
LIHC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg01788221	chr16:89496183	ANKRD11	-0.41	-6.33	-0.32	7.89e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs939574	0.586	rs3731892	chr2:220136351	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.85	5.72	0.3	2.33e-8	Platelet distribution width;
LIHC	trans	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.19	0.32	1.7e-9	Coronary artery calcification;
LIHC	cis	rs655641	1.000	rs618679	chr11:85671702	A/C	cg09030501	chr11:85779252	PICALM	-0.49	-5.78	-0.3	1.68e-8	Platelet count;
LIHC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.86	-0.3	1.06e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.1	-0.7	7.56e-52	Tonsillectomy;
LIHC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg23625390	chr15:77176239	SCAPER	0.35	5.84	0.3	1.19e-8	Blood metabolite levels;
LIHC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.76	12.89	0.57	2.9e-31	Anterior chamber depth;
LIHC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.69	-6.41	-0.33	4.77e-10	Breast cancer;
LIHC	cis	rs74181299	0.750	rs13421845	chr2:65336033	G/A	cg05010058	chr2:65284262	CEP68	-0.39	-6.63	-0.34	1.33e-10	Pulse pressure;
LIHC	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg02023728	chr11:77925099	USP35	0.35	6.29	0.32	9.61e-10	Alzheimer's disease (survival time);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16780771	chr16:81643766	CMIP	-0.43	-6.07	-0.31	3.33e-9	Systolic blood pressure;
LIHC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg24130564	chr14:104152367	KLC1	-0.54	-8.65	-0.42	2e-16	Reticulocyte count;
LIHC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.93	15.35	0.64	7.91e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2607426	0.681	rs2254326	chr19:41255889	G/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.56	-6.63	-0.34	1.29e-10	Blood protein levels;
LIHC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.33	7.42	0.37	9.44e-13	Ulcerative colitis;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg14709524	chr16:89940631	TCF25	0.53	7.17	0.36	4.75e-12	Skin colour saturation;
LIHC	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.91	-0.3	8.15e-9	Coronary artery disease;
LIHC	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.7	-7.27	-0.37	2.42e-12	Putamen volume;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.48	-8.39	-0.41	1.27e-15	Total body bone mineral density;
LIHC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.67	11.63	0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.78	0.34	5.45e-11	Renal cell carcinoma;
LIHC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.6	11.22	0.52	4.42e-25	Systemic lupus erythematosus;
LIHC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	11.36	0.52	1.33e-25	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.19	-0.36	4.23e-12	Personality dimensions;
LIHC	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs903552	0.866	rs11247296	chr15:102007919	T/C	cg16179521	chr15:102009894	PCSK6	-0.42	-5.76	-0.3	1.91e-8	Diabetic kidney disease;
LIHC	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-0.81	-9.54	-0.46	2.73e-19	Alzheimer's disease (late onset);
LIHC	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.85	-13.54	-0.59	9.49e-34	Schizophrenia;
LIHC	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.68	-0.5	3.72e-23	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg00656387	chr3:40428638	ENTPD3	0.5	8.29	0.41	2.68e-15	Renal cell carcinoma;
LIHC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.45	-0.62	2.75e-37	Headache;
LIHC	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.59	6.88	0.35	2.84e-11	Bipolar disorder;
LIHC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg12751644	chr20:60527061	NA	-0.36	-5.9	-0.3	8.53e-9	Body mass index;
LIHC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.44	-6.87	-0.35	3.04e-11	Schizophrenia;
LIHC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.34	7.4	0.37	1.09e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	2.97e-9	Mortality in heart failure;
LIHC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.58	-7.63	-0.38	2.32e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	6.24	0.32	1.3e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11645453	chr3:52864694	ITIH4	0.21	5.76	0.3	1.85e-8	Bipolar disorder;
LIHC	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.63	-0.38	2.36e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg12463550	chr7:65579703	CRCP	0.73	7.64	0.38	2.26e-13	Diabetic kidney disease;
LIHC	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.6	11.85	0.54	2.27e-27	Plateletcrit;Platelet count;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.39	-6.08	-0.31	3.15e-9	Tuberculosis;
LIHC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.41	-7.37	-0.37	1.33e-12	Colorectal cancer;
LIHC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.39	5.95	0.31	6.53e-9	Lipoprotein (a) levels;
LIHC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	7.08	0.36	8.34e-12	Breast cancer;
LIHC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	1.23	11.01	0.51	2.37e-24	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.55	-6.09	-0.31	3.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11229555	0.645	rs4594017	chr11:58194788	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2250417	0.935	rs10891343	chr11:112080384	T/C	cg07267984	chr11:112037134	TEX12	-0.41	-6.31	-0.32	8.7e-10	Inflammatory biomarkers;Protein quantitative trait loci;
LIHC	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg14061069	chr19:46274453	DMPK	-0.55	-8.58	-0.42	3.39e-16	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg26338869	chr17:61819248	STRADA	0.52	6.97	0.35	1.61e-11	Height;
LIHC	cis	rs6088813	1.000	rs6088815	chr20:33976474	G/C	cg14752227	chr20:34000481	UQCC	-0.4	-5.72	-0.3	2.39e-8	Height;
LIHC	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.96	-0.35	1.74e-11	Schizophrenia;
LIHC	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.25	-0.32	1.21e-9	Response to antipsychotic treatment;
LIHC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.34	-0.37	1.6e-12	Body mass index;
LIHC	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.91	0.35	2.36e-11	Systolic blood pressure;
LIHC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.6	-10.31	-0.49	6.83e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.73	0.65	2.41e-42	Chronic sinus infection;
LIHC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.56	-7.59	-0.38	3.09e-13	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05492810	chr11:78129288	GAB2	0.43	6.09	0.31	3.01e-9	Lung function (FEV1/FVC);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg25005279	chr10:135113451	TUBGCP2	0.38	6.2	0.32	1.66e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.95	-0.57	1.7e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.48	6.3	0.32	9.42e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg19645103	chr12:69753606	YEATS4	-0.45	-6.05	-0.31	3.7e-9	Response to diuretic therapy;
LIHC	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.48	7.25	0.36	2.86e-12	Diastolic blood pressure;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg00656387	chr3:40428638	ENTPD3	0.5	8.52	0.42	5.28e-16	Renal cell carcinoma;
LIHC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg03013999	chr17:37608204	MED1	-0.35	-5.81	-0.3	1.4e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-13.22	-0.58	1.58e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.51	8.23	0.41	4.08e-15	Schizophrenia;
LIHC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg15448220	chr1:150897856	SETDB1	-0.42	-6.41	-0.33	4.83e-10	Urate levels;
LIHC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01200585	chr1:228362443	C1orf69	-0.4	-5.85	-0.3	1.16e-8	Diastolic blood pressure;
LIHC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg05941027	chr17:61774174	LIMD2	0.34	6.47	0.33	3.39e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.42	-8.43	-0.41	9.770000000000001e-16	Obesity-related traits;
LIHC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg06289844	chr6:126071538	HEY2	-0.36	-6.27	-0.32	1.07e-9	Brugada syndrome;
LIHC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.36	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	5.79	0.3	1.57e-8	Renal cell carcinoma;
LIHC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.58	-0.5	7.82e-23	Total cholesterol levels;
LIHC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.81	0.39	6.87e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.48	-7.74	-0.39	1.15e-13	Electroencephalogram traits;
LIHC	cis	rs244293	1.000	rs2628314	chr17:53235182	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-6.1	-0.31	2.82e-9	Menarche (age at onset);
LIHC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.07	25.0	0.8	3.33e-79	IgG glycosylation;
LIHC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	8.64	0.42	2.16e-16	Schizophrenia;
LIHC	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.64	9.6	0.46	1.83e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg26531700	chr6:26746687	NA	-0.34	-5.77	-0.3	1.77e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	0.655	rs1361487	chr1:76430471	A/C	cg03433033	chr1:76189801	ACADM	0.52	7.33	0.37	1.72e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.88	0.39	4.53e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3015497	0.789	rs2356457	chr14:51116863	C/T	cg09863266	chr14:51125203	SAV1	-0.43	-7.04	-0.36	1.08e-11	Mean platelet volume;
LIHC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg04317338	chr11:64019027	PLCB3	0.86	8.31	0.41	2.26e-15	Mean platelet volume;
LIHC	cis	rs8053891	0.756	rs9928413	chr16:72001110	C/T	cg01557791	chr16:72042693	DHODH	-0.44	-6.24	-0.32	1.27e-9	Coronary artery disease;
LIHC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg11764359	chr7:65958608	NA	0.58	6.06	0.31	3.57e-9	Diabetic kidney disease;
LIHC	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Hypertriglyceridemia;
LIHC	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9367125	0.816	rs9357384	chr6:41997926	A/G	cg12151296	chr6:42013349	CCND3	0.41	5.98	0.31	5.6e-9	Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs11958404	1.000	rs72816527	chr5:157409633	C/T	cg05962755	chr5:157440814	NA	1.05	11.42	0.53	8.24e-26	IgG glycosylation;
LIHC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08392591	chr16:89556376	ANKRD11	0.39	5.91	0.3	8.29e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.35	0.41	1.71e-15	Platelet count;
LIHC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg19635926	chr16:89946313	TCF25	0.44	5.78	0.3	1.66e-8	Skin colour saturation;
LIHC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.76	-0.47	5.26e-20	Colorectal cancer;
LIHC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg06096015	chr1:231504339	EGLN1	-0.5	-9.42	-0.45	7.08e-19	Hemoglobin concentration;
LIHC	trans	rs7668874	0.779	rs961954	chr4:116814751	T/A	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.89	-8.94	-0.44	2.52e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.48	0.56	1.05e-29	Colorectal cancer;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.77	9.67	0.46	1.01e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.37	-14.09	-0.61	7.21e-36	Gout;
LIHC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.36	-0.33	6.53e-10	Type 2 diabetes;
LIHC	trans	rs13113518	0.812	rs13116035	chr4:56427385	G/A	cg15358633	chr12:38710606	ALG10B	0.44	6.27	0.32	1.07e-9	Height;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg01676552	chr8:146156633	ZNF16	0.4	6.13	0.31	2.46e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg05941027	chr17:61774174	LIMD2	0.35	7.29	0.37	2.18e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.32	6.0	0.31	5.14e-9	Body mass index;
LIHC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.58	-0.38	3.29e-13	Tonsillectomy;
LIHC	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg27089200	chr19:41531976	NA	0.37	6.35	0.32	6.72e-10	DDT metabolite (p,p'-DDE levels);
LIHC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.82	8.99	0.44	1.71e-17	Vitiligo;
LIHC	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.26	7.0	0.35	1.34e-11	Type 2 diabetes;
LIHC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg23205692	chr1:25664452	TMEM50A	0.39	6.34	0.32	7.48e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.13	-0.31	2.47e-9	Total body bone mineral density;
LIHC	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg17372223	chr3:52568218	NT5DC2	0.38	5.84	0.3	1.21e-8	Bipolar disorder;
LIHC	cis	rs7937890	0.559	rs2597187	chr11:14517019	C/G	cg02886208	chr11:14281011	SPON1	-0.43	-6.09	-0.31	3.04e-9	Mitochondrial DNA levels;
LIHC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.53	6.11	0.31	2.72e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.53	-10.87	-0.51	7.65e-24	Late-onset Alzheimer's disease;
LIHC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.46	0.82	9.25e-85	Cognitive ability;
LIHC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.39	6.2	0.32	1.58e-9	Menopause (age at onset);
LIHC	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.02	0.31	4.43e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs249954	0.512	rs249870	chr16:23666178	C/A	cg05131483	chr16:23706242	ERN2	0.38	6.3	0.32	8.91e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	7.91	0.39	3.52e-14	Height;
LIHC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-1.1	-17.57	-0.69	1.08e-49	Urate levels;
LIHC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21467203	chr3:49911342	NA	-0.44	-7.91	-0.39	3.57e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.49	0.46	4.04e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg21466736	chr12:48725269	NA	-0.71	-10.87	-0.51	7.92e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg19635926	chr16:89946313	TCF25	0.54	7.33	0.37	1.65e-12	Skin colour saturation;
LIHC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-7.34	-0.37	1.61e-12	Response to bleomycin (chromatid breaks);
LIHC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.83	-15.82	-0.65	1.12e-42	Height;
LIHC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.54	6.99	0.35	1.48e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs35892873	0.959	rs756182	chr3:126093885	C/T	cg15490784	chr3:126061950	KLF15	0.42	5.95	0.31	6.51e-9	Male-pattern baldness;
LIHC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.46	6.68	0.34	9.83e-11	Monobrow;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25396690	chr2:7006004	CMPK2	-0.55	-6.88	-0.35	2.88e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.95	-0.35	1.88e-11	IgG glycosylation;
LIHC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.43	6.43	0.33	4.37e-10	Methadone dose in opioid dependence;
LIHC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.69	7.91	0.39	3.57e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.17	9.34	0.45	1.3e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs911119	0.913	rs1158167	chr20:23578189	G/A	cg16589663	chr20:23618590	CST3	-0.69	-7.29	-0.37	2.21e-12	Chronic kidney disease;
LIHC	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg25208724	chr1:156163844	SLC25A44	0.9	15.13	0.63	6.16e-40	Testicular germ cell tumor;
LIHC	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs712039	0.583	rs853223	chr17:35791149	T/C	cg16670864	chr17:35848621	DUSP14	0.33	5.71	0.3	2.4e-8	Tuberculosis;
LIHC	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.63	-9.78	-0.47	4.29e-20	Uric acid clearance;
LIHC	cis	rs12808519	0.605	rs3893155	chr11:69597881	T/C	cg19831575	chr11:69590090	FGF4	0.51	6.88	0.35	2.82e-11	Urate levels in overweight individuals;
LIHC	cis	rs611744	0.967	rs662714	chr8:109221659	C/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.32e-16	Dupuytren's disease;
LIHC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.64	-10.4	-0.49	3.41e-22	Alcohol dependence;
LIHC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.99	16.22	0.66	2.8e-44	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	15.3	0.64	1.28e-40	Prudent dietary pattern;
LIHC	cis	rs11605275	1.000	rs78091560	chr11:20032279	G/A	cg14835545	chr11:20032148	NAV2	-0.8	-7.38	-0.37	1.18e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20303232	chr11:114270563	C11orf71;RBM7	0.46	6.64	0.34	1.27e-10	Cognitive function;
LIHC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.33	0.37	1.64e-12	Morning vs. evening chronotype;
LIHC	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg13395646	chr4:1353034	KIAA1530	0.42	6.57	0.33	1.83e-10	Obesity-related traits;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg00147976	chr12:53846229	PCBP2	0.4	6.16	0.32	2.04e-9	Migraine with aura;
LIHC	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg02811702	chr13:24901961	NA	0.24	6.01	0.31	4.69e-9	Obesity-related traits;
LIHC	trans	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg21372672	chr17:16614065	CCDC144A	-0.26	-6.41	-0.33	4.84e-10	Educational attainment (years of education);
LIHC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.35	-6.32	-0.32	7.96e-10	Aortic root size;
LIHC	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-7.65	-0.38	2.07e-13	Extraversion;
LIHC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23324888	chr5:111093475	C5orf13	-0.45	-6.08	-0.31	3.15e-9	Systolic blood pressure;
LIHC	cis	rs2286885	1.000	rs10760438	chr9:129245334	C/A	cg15282417	chr9:129245246	FAM125B	0.4	6.45	0.33	3.77e-10	Intraocular pressure;
LIHC	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs9648428	1.000	rs9648428	chr7:36211749	C/T	cg14708893	chr7:36124863	NA	-0.51	-6.08	-0.31	3.13e-9	Obesity-related traits;
LIHC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.44	6.01	0.31	4.75e-9	Iron status biomarkers;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10883266	chr13:100741297	PCCA	-0.45	-6.39	-0.33	5.49e-10	Systolic blood pressure;
LIHC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg22563815	chr15:78856949	CHRNA5	0.35	6.19	0.32	1.77e-9	Sudden cardiac arrest;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25437947	chr8:17941982	ASAH1	-0.54	-6.18	-0.32	1.83e-9	Systolic blood pressure;
LIHC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.28	-6.88	-0.35	2.84e-11	Primary biliary cholangitis;
LIHC	cis	rs16828019	0.852	rs12759023	chr1:41603978	T/C	cg03387723	chr1:41708464	SCMH1	-0.45	-7.22	-0.36	3.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	0.5	7.48	0.37	6.37e-13	Methadone dose in opioid dependence;
LIHC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Parkinson's disease;
LIHC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	10.54	0.5	1.15e-22	Lung cancer in ever smokers;
LIHC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	ch.11.42038R	chr11:967971	AP2A2	0.55	9.85	0.47	2.58e-20	Alzheimer's disease (late onset);
LIHC	cis	rs74181299	0.533	rs6751786	chr2:65374595	G/T	cg05010058	chr2:65284262	CEP68	-0.36	-5.8	-0.3	1.53e-8	Pulse pressure;
LIHC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.26	-0.32	1.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg20295408	chr7:1910781	MAD1L1	0.41	6.13	0.31	2.38e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.58	-0.38	3.33e-13	Type 2 diabetes;
LIHC	cis	rs7707921	0.723	rs226203	chr5:81570394	G/A	cg15871215	chr5:81402204	ATG10	0.65	7.63	0.38	2.31e-13	Breast cancer;
LIHC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.61	-0.46	1.69e-19	Blood metabolite levels;
LIHC	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.4	5.74	0.3	2.12e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.44	8.19	0.4	5.24e-15	Prudent dietary pattern;
LIHC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-9.53	-0.46	3.01e-19	Hemoglobin concentration;
LIHC	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg01652190	chr22:50026171	C22orf34	-0.33	-7.3	-0.37	1.98e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs3743102	0.519	rs76496098	chr15:83229141	T/C	cg01542190	chr22:50604728	NA	-0.51	-6.56	-0.33	2.01e-10	Colorectal adenoma (advanced);
LIHC	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.15	12.58	0.56	4.39e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.59	-8.88	-0.43	3.85e-17	Schizophrenia;
LIHC	cis	rs11955398	0.625	rs6874072	chr5:59987682	C/G	cg02684056	chr5:59996105	DEPDC1B	0.44	6.23	0.32	1.36e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs16958440	1.000	rs16952848	chr18:44597829	A/G	cg17192377	chr18:44677553	HDHD2	0.57	6.11	0.31	2.68e-9	Sitting height ratio;
LIHC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.25	-0.45	2.55e-18	Bipolar disorder;
LIHC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.53	-8.82	-0.43	5.86e-17	Blood metabolite levels;
LIHC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg19645103	chr12:69753606	YEATS4	-0.52	-7.83	-0.39	6.3e-14	Response to diuretic therapy;
LIHC	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg15208524	chr1:10270712	KIF1B	0.45	6.6	0.34	1.55e-10	Hepatocellular carcinoma;
LIHC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.02	-0.31	4.58e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg03983715	chr16:68378420	PRMT7	-0.53	-6.16	-0.32	1.99e-9	Schizophrenia;
LIHC	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05508062	chr3:62110348	ID2B;PTPRG	0.44	6.34	0.32	7.12e-10	Pancreatic cancer;
LIHC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.22e-34	Aortic root size;
LIHC	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.39	-9.52	-0.46	3.28e-19	Cutaneous nevi;
LIHC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.47	-7.66	-0.38	1.94e-13	Blood protein levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07294177	chr3:160283371	KPNA4	-0.53	-6.5	-0.33	2.79e-10	Systolic blood pressure;
LIHC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg09137382	chr11:130731461	NA	0.42	6.26	0.32	1.18e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.96	-0.44	2.07e-17	Bipolar disorder and schizophrenia;
LIHC	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.57	9.27	0.45	2.21e-18	Corneal astigmatism;
LIHC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.44	-7.58	-0.38	3.27e-13	Lung cancer;
LIHC	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg09795085	chr6:101329169	ASCC3	0.5	7.05	0.36	1.02e-11	Neuroticism;
LIHC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.37	7.27	0.37	2.51e-12	Alcohol dependence;
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.4	8.24	0.41	3.63e-15	Renal cell carcinoma;
LIHC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21467203	chr3:49911342	NA	0.44	7.76	0.39	1.01e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	11.71	0.54	7.11e-27	Prudent dietary pattern;
LIHC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.9	-13.96	-0.6	2.3e-35	Body mass index;
LIHC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.52	-8.58	-0.42	3.44e-16	Cognitive function;
LIHC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.65	0.34	1.13e-10	Educational attainment;
LIHC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.87	10.35	0.49	4.91e-22	Cognitive function;
LIHC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.74	-10.57	-0.5	8.59e-23	Pancreatic cancer;
LIHC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.4	6.68	0.34	9.83e-11	Blood metabolite levels;
LIHC	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19676328	chr12:49525230	TUBA1B	-0.37	-6.13	-0.31	2.39e-9	Total cholesterol levels;
LIHC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.8e-12	Waist circumference;Weight;
LIHC	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.0	-0.35	1.39e-11	Metabolite levels;
LIHC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.61	9.11	0.44	7.27e-18	Gout;
LIHC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21448741	chr8:58168803	NA	0.35	6.55	0.33	2.1e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.78	-0.67	1.55e-46	Ulcerative colitis;
LIHC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-6.95	-0.35	1.85e-11	Osteoporosis;
LIHC	cis	rs831571	1.000	rs831571	chr3:64048297	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.52	6.49	0.33	2.94e-10	Type 2 diabetes;
LIHC	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.24	-0.32	1.27e-9	Tuberculosis;
LIHC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg25039879	chr17:56429692	SUPT4H1	0.77	8.74	0.43	1.05e-16	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg06207120	chr15:45996521	NA	0.33	6.44	0.33	4.12e-10	Waist circumference;Weight;
LIHC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg15605315	chr1:45957053	TESK2	0.48	6.72	0.34	7.49e-11	High light scatter reticulocyte count;
LIHC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.14	-21.7	-0.76	2.95e-66	Triglycerides;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.11	0.55	2.37e-28	Prudent dietary pattern;
LIHC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.65e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.34	6.97	0.35	1.64e-11	Renal cell carcinoma;
LIHC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.55	-0.38	4.1e-13	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.68	-0.5	3.48e-23	Alzheimer's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09655191	chr17:73915849	FBF1	0.44	6.84	0.35	3.63e-11	Longevity;
LIHC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg05564831	chr3:52568323	NT5DC2	0.38	6.05	0.31	3.78e-9	Bipolar disorder;
LIHC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg17796960	chr10:135278976	LOC619207	-0.35	-5.79	-0.3	1.61e-8	Systemic lupus erythematosus;
LIHC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-8.19	-0.41	5.1e-15	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06341202	chr17:78010343	CCDC40;TBC1D16	0.45	6.19	0.32	1.71e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.78e-13	Bone mineral density;
LIHC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg17420585	chr12:42539391	GXYLT1	-0.39	-6.33	-0.32	7.92e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2257205	0.667	rs8081074	chr17:56836596	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-6.61	-0.34	1.5e-10	Pancreatic cancer;
LIHC	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.4	-5.95	-0.31	6.49e-9	Lung cancer;
LIHC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg19683494	chr5:74908142	NA	-0.82	-10.49	-0.49	1.62e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4650994	0.593	rs16853043	chr1:178545926	A/G	cg05350800	chr1:178550844	NA	-0.34	-7.26	-0.37	2.56e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06734816	chr6:116422381	NT5DC1	0.45	6.13	0.31	2.39e-9	Pancreatic cancer;
LIHC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg16586182	chr3:47516702	SCAP	-0.43	-7.51	-0.38	5.16e-13	Colorectal cancer;
LIHC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.48	5.94	0.31	6.98e-9	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.38	0.45	9.63e-19	Bipolar disorder;
LIHC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.28	-0.32	1e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.53	-0.33	2.4e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.48	7.74	0.39	1.1e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.47	-8.98	-0.44	1.89e-17	Abdominal aortic aneurysm;
LIHC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.82	-0.35	4.05e-11	Response to antipsychotic treatment;
LIHC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg06808227	chr14:105710500	BRF1	-0.54	-7.09	-0.36	7.57e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.06	0.44	1.05e-17	Schizophrenia;
LIHC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	10.89	0.51	6.6e-24	Coffee consumption (cups per day);
LIHC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.83	-9.2	-0.45	3.56e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs1419980	0.730	rs115594156	chr12:7751337	A/G	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.47	-7.65	-0.38	2.02e-13	Blood metabolite levels;
LIHC	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.59	-6.61	-0.34	1.5e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg01864836	chr14:55583639	NA	-0.41	-7.61	-0.38	2.65e-13	Protein biomarker;
LIHC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	0.95	16.87	0.67	7.2e-47	IgG glycosylation;
LIHC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.82	-7.39	-0.37	1.17e-12	Type 2 diabetes;
LIHC	trans	rs6489882	0.966	rs6489880	chr12:113380271	C/T	cg10175203	chr3:128143634	NA	0.39	6.23	0.32	1.37e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs13161895	0.702	rs73810942	chr5:179499267	C/A	cg02702477	chr5:179499311	RNF130	1.0	12.72	0.57	1.27e-30	LDL cholesterol;
LIHC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.43	8.2	0.41	4.79e-15	Schizophrenia;
LIHC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.85	15.59	0.64	8.92e-42	Multiple myeloma (IgH translocation);
LIHC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg19318889	chr4:1322082	MAEA	0.41	5.73	0.3	2.17e-8	Obesity-related traits;
LIHC	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	0.74	8.61	0.42	2.8e-16	Exhaled nitric oxide output;
LIHC	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.2	0.52	5.05e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.75	0.57	9.72e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17286411	0.750	rs4788568	chr16:71913025	C/T	cg03805757	chr16:71968109	PKD1L3	0.41	5.85	0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg13919466	chr1:32135498	COL16A1	-0.36	-6.66	-0.34	1.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg26395211	chr5:140044315	WDR55	0.39	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9513627	1.000	rs3928271	chr13:100186958	G/A	cg25919922	chr13:100150906	NA	0.76	6.88	0.35	2.85e-11	Obesity-related traits;
LIHC	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.2	28.8	0.84	1.89e-93	Schizophrenia;
LIHC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.63	11.4	0.52	9.93e-26	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18230796	chr4:3294592	NA	-0.56	-6.3	-0.32	9.39e-10	Systolic blood pressure;
LIHC	cis	rs2060793	0.506	rs10741658	chr11:14924736	T/C	cg00085434	chr11:14927489	NA	0.43	6.17	0.32	1.95e-9	Vitamin D levels;
LIHC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg13047869	chr3:10149882	C3orf24	0.5	6.11	0.31	2.71e-9	Alzheimer's disease;
LIHC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.69	10.45	0.49	2.36e-22	Neutrophil percentage of white cells;
LIHC	cis	rs922107	0.934	rs12118131	chr1:90041187	T/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.77	-0.39	9.52e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	19.44	0.72	3.22e-57	Smoking behavior;
LIHC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg04359351	chr2:3481828	TTC15	0.28	5.94	0.31	7.04e-9	Neurofibrillary tangles;
LIHC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg16586182	chr3:47516702	SCAP	0.39	6.68	0.34	9.73e-11	Birth weight;
LIHC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-9.26	-0.45	2.38e-18	Schizophrenia;
LIHC	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.86	13.44	0.59	2.26e-33	Schizophrenia;
LIHC	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.8	-0.39	7.72e-14	Response to antipsychotic treatment;
LIHC	cis	rs9918079	0.560	rs7662032	chr4:15635414	C/G	cg16509355	chr4:15471240	CC2D2A	-0.45	-7.08	-0.36	8.31e-12	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.61	-6.74	-0.34	6.6e-11	Alzheimer's disease;
LIHC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg21466736	chr12:48725269	NA	0.6	8.26	0.41	3.26e-15	Glycated hemoglobin levels;
LIHC	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg27129171	chr3:47204927	SETD2	0.49	7.71	0.38	1.42e-13	Birth weight;
LIHC	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	0.65	6.51	0.33	2.69e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.44	6.12	0.31	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10540	0.915	rs35333170	chr11:526478	A/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.1	-0.36	7.26e-12	Body mass index;
LIHC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-11.6	-0.53	1.8e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg19635926	chr16:89946313	TCF25	0.52	6.57	0.33	1.88e-10	Skin colour saturation;
LIHC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.49	6.24	0.32	1.3e-9	Initial pursuit acceleration;
LIHC	cis	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg01864836	chr14:55583639	NA	-0.38	-6.49	-0.33	3e-10	Protein biomarker;
LIHC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.41	-7.34	-0.37	1.59e-12	Hepatocellular carcinoma;
LIHC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.49	7.27	0.37	2.48e-12	Asthma (sex interaction);
LIHC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.44	-6.32	-0.32	8.28e-10	Morning vs. evening chronotype;
LIHC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.81	12.86	0.57	3.98e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15072735	chr9:72375102	PTAR1	0.42	6.62	0.34	1.38e-10	Cognitive function;
LIHC	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	15.16	0.63	4.42e-40	Exhaled nitric oxide output;
LIHC	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.25	0.32	1.22e-9	Heart rate;
LIHC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg16102536	chr7:156981717	UBE3C	0.37	6.16	0.32	2.05e-9	Body mass index;
LIHC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg03874509	chr1:107600012	PRMT6	-0.73	-11.5	-0.53	4.4e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg05973401	chr12:123451056	ABCB9	0.45	6.21	0.32	1.56e-9	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.42	8.87	0.43	4e-17	Coronary artery disease;
LIHC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.32	-6.59	-0.34	1.7e-10	Blood metabolite levels;
LIHC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.76	11.77	0.54	4.28e-27	Longevity;
LIHC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.85	0.54	2.23e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-1.03	-19.56	-0.73	1.04e-57	Breast cancer;
LIHC	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.04	0.36	1.04e-11	Exhaled nitric oxide output;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg24689585	chr15:22957012	CYFIP1	0.41	6.34	0.32	7.34e-10	Alopecia areata;
LIHC	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg04610667	chr7:75704037	NA	0.35	6.24	0.32	1.27e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	0.97	12.34	0.56	3.48e-29	Severe influenza A (H1N1) infection;
LIHC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.68	8.42	0.41	1.04e-15	Mean platelet volume;
LIHC	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.84e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg21395723	chr22:39101663	GTPBP1	0.43	7.42	0.37	9.23e-13	Menopause (age at onset);
LIHC	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.43	-6.18	-0.32	1.87e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.91e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.51	7.25	0.36	2.88e-12	Menopause (age at onset);
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg02993280	chr1:107599747	PRMT6	-0.63	-9.83	-0.47	2.96e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.96	0.4	2.57e-14	Tonsillectomy;
LIHC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.26	-0.41	3.27e-15	Chronic sinus infection;
LIHC	cis	rs611744	0.967	rs631031	chr8:109190032	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg06609049	chr19:2785107	THOP1	0.61	9.64	0.46	1.33e-19	Total cholesterol levels;
LIHC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.47	6.85	0.35	3.45e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg19635926	chr16:89946313	TCF25	0.54	7.38	0.37	1.25e-12	Skin colour saturation;
LIHC	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.79	0.57	6.95e-31	Airflow obstruction;
LIHC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-14.17	-0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.54	0.42	4.46e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg20195005	chr22:42527684	CYP2D6	0.3	5.72	0.3	2.36e-8	Birth weight;
LIHC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.46	-6.41	-0.33	4.94e-10	Initial pursuit acceleration;
LIHC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04317338	chr11:64019027	PLCB3	0.49	6.69	0.34	9.11e-11	Platelet count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01320780	chr8:22298453	PPP3CC	0.45	6.51	0.33	2.67e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2710642	0.611	rs1534420	chr2:62884053	C/T	cg17519650	chr2:63277830	OTX1	-0.46	-6.67	-0.34	1.01e-10	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.09	0.75	7.41e-64	Height;
LIHC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg02079420	chr8:82753780	SNX16	0.34	6.06	0.31	3.63e-9	Diastolic blood pressure;
LIHC	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg26138937	chr11:71823887	C11orf51	-0.81	-7.95	-0.39	2.8e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.88	0.43	3.76e-17	Motion sickness;
LIHC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.6	0.46	1.71e-19	Asthma (sex interaction);
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg15382696	chr6:118971807	C6orf204	0.62	6.27	0.32	1.06e-9	Diastolic blood pressure;
LIHC	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg27255678	chr10:102756921	LZTS2	0.52	7.29	0.37	2.22e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.63	12.84	0.57	4.74e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.88	-14.83	-0.63	8.91e-39	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.49	0.56	9.45e-30	Prudent dietary pattern;
LIHC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg03543861	chr21:44258195	NA	0.49	7.66	0.38	1.96e-13	Information processing speed;
LIHC	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	7.37	0.37	1.31e-12	Adiposity;
LIHC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.01e-19	Height;
LIHC	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg02376097	chr19:46275166	DMPK	-0.46	-7.02	-0.35	1.19e-11	Coronary artery disease;
LIHC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.52	-0.53	3.47e-26	Chronic sinus infection;
LIHC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.4	5.86	0.3	1.11e-8	Menarche (age at onset);
LIHC	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.37	-0.33	5.93e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	7.12	0.36	6.32e-12	Body mass index;
LIHC	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.76	10.98	0.51	3.13e-24	Response to hepatitis C treatment;
LIHC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.32	-6.51	-0.33	2.71e-10	Body mass index;
LIHC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-5.99	-0.31	5.17e-9	Vitiligo;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.86	0.8	1.15e-78	Prudent dietary pattern;
LIHC	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.6	8.94	0.44	2.57e-17	Recombination rate (females);
LIHC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.73	-14.34	-0.61	7.85e-37	Mortality in heart failure;
LIHC	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	6.35	0.32	6.85e-10	Iron status biomarkers;
LIHC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.75	-0.5	2e-23	Platelet count;
LIHC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg15848620	chr12:58087721	OS9	0.51	6.59	0.34	1.71e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.49	8.53	0.42	4.65e-16	Bone mineral density (spine);
LIHC	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.6	10.26	0.49	9.98e-22	HDL cholesterol;
LIHC	cis	rs8044995	0.568	rs112086775	chr16:68310917	A/C	cg05110241	chr16:68378359	PRMT7	-0.71	-7.72	-0.39	1.28e-13	Schizophrenia;
LIHC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg02931644	chr1:25747376	RHCE	-0.34	-7.42	-0.37	9.5e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.67	-0.34	1.02e-10	Homocysteine levels;
LIHC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	7.63	0.38	2.29e-13	Mean platelet volume;
LIHC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.41	6.71	0.34	7.85e-11	Red blood cell count;
LIHC	cis	rs77633900	0.772	rs283799	chr15:76752834	A/C	cg21673338	chr15:77095150	SCAPER	-0.52	-6.11	-0.31	2.78e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs6429082	0.509	rs6699315	chr1:235525253	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.45	-6.72	-0.34	7.46e-11	Adiposity;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.07	-0.31	3.43e-9	Total body bone mineral density;
LIHC	cis	rs4834770	1.000	rs4336213	chr4:120236469	G/T	cg09307838	chr4:120376055	NA	0.41	6.14	0.32	2.27e-9	Blood protein levels;
LIHC	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.6	10.07	0.48	4.8e-21	HDL cholesterol;
LIHC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg24296786	chr1:45957014	TESK2	-0.56	-8.03	-0.4	1.64e-14	Platelet count;
LIHC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-8.52	-0.42	5.12e-16	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs2096176	0.632	rs12572400	chr10:26312475	G/A	cg01396774	chr2:218299024	DIRC3	-0.31	-6.08	-0.31	3.26e-9	Obesity-related traits;
LIHC	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	1.06	8.55	0.42	4.25e-16	Cannabis dependence symptom count;
LIHC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.9	0.54	1.44e-27	Motion sickness;
LIHC	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.66	9.93	0.47	1.33e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.62	-10.88	-0.51	7.12e-24	Neuroticism;
LIHC	trans	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.21	-0.41	4.62e-15	Obesity-related traits;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01171360	chr6:293285	DUSP22	-0.45	-6.48	-0.33	3.19e-10	Menopause (age at onset);
LIHC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.66	9.69	0.46	9.09e-20	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.34	0.55	3.52e-29	Alzheimer's disease;
LIHC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1853665	0.580	rs6557200	chr6:150272532	C/T	cg16301758	chr6:150275521	NA	0.41	6.19	0.32	1.75e-9	Radiation response;
LIHC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.44	0.33	4.09e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	7.12	0.36	6.27e-12	Obesity-related traits;
LIHC	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.79	0.5	1.46e-23	Fuchs's corneal dystrophy;
LIHC	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-12.48	-0.56	1.02e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.65	13.82	0.6	8.15e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.5	7.13	0.36	5.91e-12	Glycated hemoglobin levels;
LIHC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	1.02	10.14	0.48	2.72e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4294134	0.935	rs3110823	chr7:135357476	A/C	cg20392616	chr7:135392013	SLC13A4	0.39	6.55	0.33	2.12e-10	Paget's disease;
LIHC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.79	0.5	1.48e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.14	0.4	7.59e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg19680672	chr10:131412579	MGMT	-0.4	-6.04	-0.31	4e-9	Response to temozolomide;
LIHC	cis	rs74181299	0.648	rs6730986	chr2:65353549	C/T	cg05010058	chr2:65284262	CEP68	-0.41	-6.67	-0.34	1.06e-10	Pulse pressure;
LIHC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.5	7.6	0.38	2.81e-13	Resting heart rate;
LIHC	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.48	5.71	0.3	2.42e-8	Bladder cancer;
LIHC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	0.67	6.67	0.34	1.03e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg00800038	chr16:89945340	TCF25	-0.62	-8.84	-0.43	5.24e-17	Skin colour saturation;
LIHC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.57	0.33	1.87e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.29	0.49	8.51e-22	Platelet count;
LIHC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-11.13	-0.52	8.93e-25	Chronic sinus infection;
LIHC	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg09462578	chr12:12878428	APOLD1	0.46	7.23	0.36	3.27e-12	Pulse pressure;
LIHC	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg08800856	chr11:64428347	NRXN2	0.4	6.29	0.32	9.75e-10	Body mass index;Urate levels;
LIHC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.07	15.83	0.65	9.81e-43	Cognitive function;
LIHC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18867708	chr6:26865862	GUSBL1	0.56	8.47	0.42	7.16e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.47	6.89	0.35	2.67e-11	Aortic root size;
LIHC	cis	rs5753037	0.838	rs140145	chr22:30178305	C/T	cg01021169	chr22:30184971	ASCC2	-0.34	-6.35	-0.32	6.84e-10	Type 1 diabetes;
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.51	-9.02	-0.44	1.4e-17	Total body bone mineral density;
LIHC	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg23533926	chr12:111358616	MYL2	-0.33	-6.33	-0.32	7.73e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.58	-8.56	-0.42	3.86e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.39	-6.45	-0.33	3.93e-10	Non-substance related behavioral disinhibition;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.45	8.13	0.4	7.75e-15	Prudent dietary pattern;
LIHC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.64	-11.73	-0.54	6.08e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.68	0.5	3.74e-23	Hypertriglyceridemia;
LIHC	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.9	-14.83	-0.63	9.11e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-8.84	-0.43	5.07e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.3	-6.88	-0.35	2.89e-11	Crohn's disease;
LIHC	cis	rs3015497	0.967	rs3015483	chr14:51137474	C/G	cg09863266	chr14:51125203	SAV1	-0.41	-6.62	-0.34	1.38e-10	Mean platelet volume;
LIHC	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.53	9.27	0.45	2.21e-18	Total cholesterol levels;
LIHC	trans	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg21659725	chr3:3221576	CRBN	0.64	6.43	0.33	4.35e-10	Schizophrenia;
LIHC	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.57	-0.33	1.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.63	12.69	0.57	1.62e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg06664874	chr5:179499304	RNF130	0.58	7.22	0.36	3.48e-12	LDL cholesterol;
LIHC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.44	-6.67	-0.34	1.03e-10	Lung cancer;
LIHC	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.67	6.8	0.35	4.56e-11	Lymphocyte counts;
LIHC	cis	rs864643	1.000	rs689352	chr3:39550766	T/A	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.68	9.02	0.44	1.34e-17	Psoriasis;
LIHC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg05973401	chr12:123451056	ABCB9	0.41	6.33	0.32	7.53e-10	Platelet count;
LIHC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	1.03	11.96	0.54	9.22e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.89	-16.92	-0.68	4.31e-47	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02290350	chr8:58132656	NA	0.5	10.96	0.51	3.66e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.55	7.07	0.36	8.98e-12	Parkinson's disease;
LIHC	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.9	-15.84	-0.65	9.08e-43	Migraine;
LIHC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.06	-0.31	3.54e-9	Type 2 diabetes;
LIHC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.55	8.96	0.44	2.2e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs988712	0.705	rs4244531	chr11:27657250	A/G	cg18117895	chr11:27722066	BDNF	0.45	6.11	0.31	2.71e-9	Obesity;
LIHC	cis	rs10056811	0.538	rs2035191	chr5:74413713	T/C	cg00601450	chr5:74908170	NA	0.45	5.86	0.3	1.07e-8	Coronary artery disease;
LIHC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg00612595	chr21:47717864	NA	-0.35	-5.86	-0.3	1.12e-8	Testicular germ cell tumor;
LIHC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.51	-8.7	-0.43	1.38e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg10411590	chr13:21900810	NA	0.46	7.63	0.38	2.3e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.41	7.36	0.37	1.41e-12	Electrocardiographic conduction measures;
LIHC	trans	rs9531686	1.000	rs9546995	chr13:85547170	A/G	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.3	0.32	9.31e-10	Anorexia nervosa;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18574395	chr18:9102960	NDUFV2	0.47	6.42	0.33	4.5e-10	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.92	-0.31	7.72e-9	Diabetic kidney disease;
LIHC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.64	-10.4	-0.49	3.34e-22	Platelet count;
LIHC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-8.87	-0.43	4.15e-17	Schizophrenia;
LIHC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24110177	chr3:50126178	RBM5	0.42	6.49	0.33	3.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.47	-8.57	-0.42	3.7e-16	Colorectal cancer;
LIHC	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.45	6.41	0.33	4.73e-10	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg15208524	chr1:10270712	KIF1B	0.38	5.85	0.3	1.18e-8	Hepatocellular carcinoma;
LIHC	cis	rs7238033	0.624	rs7234310	chr18:43306793	G/A	cg20610511	chr18:43302872	SLC14A1	0.4	6.65	0.34	1.13e-10	Bladder cancer;
LIHC	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.61	6.06	0.31	3.51e-9	Carotid intima media thickness;
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg26338869	chr17:61819248	STRADA	0.52	6.95	0.35	1.83e-11	Height;
LIHC	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-7.58	-0.38	3.23e-13	Educational attainment (years of education);
LIHC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg05555928	chr11:63887634	MACROD1	0.55	7.42	0.37	9.28e-13	Mean platelet volume;
LIHC	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg17859187	chr1:168147929	TIPRL	0.52	6.8	0.34	4.77e-11	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.45	5.76	0.3	1.85e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.31	7.13	0.36	6.13e-12	Blood metabolite ratios;
LIHC	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-0.81	-9.45	-0.46	5.43e-19	Exhaled nitric oxide output;
LIHC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.75	11.1	0.51	1.19e-24	Coronary artery disease;
LIHC	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.36	3.49e-12	Protein C levels;
LIHC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-5.81	-0.3	1.41e-8	Colorectal cancer;
LIHC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg03859395	chr2:55845619	SMEK2	0.7	11.22	0.52	4.45e-25	Metabolic syndrome;
LIHC	cis	rs6977660	1.000	rs5017191	chr7:19820158	C/A	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.51	7.48	0.37	6.39e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.63	9.36	0.45	1.08e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.48	7.1	0.36	7.32e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18252515	chr7:66147081	NA	0.43	5.98	0.31	5.63e-9	Aortic root size;
LIHC	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs7116495	0.618	rs669835	chr11:71566075	T/C	cg26138937	chr11:71823887	C11orf51	0.65	6.31	0.32	8.62e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.89	-18.03	-0.7	1.44e-51	Height;
LIHC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.51	7.14	0.36	5.65e-12	Morning vs. evening chronotype;
LIHC	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.62	10.12	0.48	3.02e-21	Recombination rate (males);
LIHC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.81	10.49	0.49	1.62e-22	Bladder cancer;
LIHC	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg10820045	chr2:198174542	NA	0.43	6.51	0.33	2.64e-10	Intracranial aneurysm;
LIHC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.52	-6.84	-0.35	3.71e-11	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-28.19	-0.84	3.3e-91	Myeloid white cell count;
LIHC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-11.93	-0.54	1.17e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.12	-0.36	6.23e-12	Blood metabolite levels;
LIHC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg09323728	chr8:95962352	TP53INP1	0.3	5.83	0.3	1.27e-8	Type 2 diabetes;
LIHC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg25039879	chr17:56429692	SUPT4H1	0.76	8.2	0.41	4.97e-15	Cognitive test performance;
LIHC	cis	rs858239	1.000	rs199351	chr7:23300049	A/C	cg00469287	chr7:23338798	C7orf30	0.42	5.86	0.3	1.08e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.44	-6.32	-0.32	8.35e-10	Schizophrenia;
LIHC	cis	rs3770081	0.590	rs12623761	chr2:86505712	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.68	-6.91	-0.35	2.45e-11	Facial emotion recognition (sad faces);
LIHC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.5	6.56	0.33	2.05e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.72	0.39	1.26e-13	Prudent dietary pattern;
LIHC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.65	-11.32	-0.52	1.9e-25	Coronary artery disease;
LIHC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	0.97	10.4	0.49	3.29e-22	Vitiligo;
LIHC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.32	-5.91	-0.3	8.49e-9	Aortic root size;
LIHC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-0.94	-8.78	-0.43	8.18e-17	Diabetic retinopathy;
LIHC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.6	9.54	0.46	2.71e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-5.9	-0.3	8.64e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.15	-0.44	5.23e-18	Ulcerative colitis;
LIHC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.46	-6.1	-0.31	2.93e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	8.77	0.43	8.36e-17	Post bronchodilator FEV1;
LIHC	cis	rs7129556	0.539	rs1945747	chr11:77277387	A/T	cg03570279	chr11:77446074	RSF1	-0.35	-6.51	-0.33	2.63e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-8.58	-0.42	3.48e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg18357645	chr12:58087776	OS9	-0.44	-6.9	-0.35	2.48e-11	Multiple sclerosis;
LIHC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.55	8.71	0.43	1.35e-16	Red cell distribution width;
LIHC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg07884673	chr3:53033167	SFMBT1	0.9	6.59	0.34	1.65e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21448741	chr8:58168803	NA	-0.35	-6.45	-0.33	3.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg25214090	chr10:38739885	LOC399744	0.39	6.51	0.33	2.75e-10	Diastolic blood pressure;
LIHC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg09417038	chr21:47716443	C21orf57	-0.49	-7.21	-0.36	3.56e-12	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg00204748	chr12:29376779	FAR2	0.38	6.99	0.35	1.44e-11	QT interval;
LIHC	trans	rs2486152	0.786	rs61867311	chr10:108544720	T/C	cg09955886	chr10:7603804	ITIH5	0.54	6.03	0.31	4.15e-9	Metabolite levels (Pyroglutamine);
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg26010095	chr1:52522216	TXNDC12;BTF3L4	0.45	6.12	0.31	2.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.82	15.21	0.64	2.95e-40	Multiple myeloma (IgH translocation);
LIHC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	9.43	0.45	6.46e-19	Longevity;
LIHC	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	1.04	14.34	0.61	7.85e-37	Mosquito bite size;
LIHC	cis	rs735860	0.763	rs1346603	chr6:53149262	C/T	cg10236188	chr6:53219634	NA	0.4	7.26	0.37	2.68e-12	Glaucoma;
LIHC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.9e-38	Blood metabolite levels;
LIHC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-0.84	-9.25	-0.45	2.56e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	5.76	0.3	1.89e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs2270927	0.510	rs6453214	chr5:75584423	A/G	cg13563193	chr19:33072644	PDCD5	0.97	9.13	0.44	5.94e-18	Mean corpuscular volume;
LIHC	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.39	-6.55	-0.33	2.18e-10	Menopause (age at onset);
LIHC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg16226627	chr15:75307476	SCAMP5	0.54	9.01	0.44	1.47e-17	Blood trace element (Zn levels);
LIHC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg22633049	chr21:46681294	NA	-0.37	-6.29	-0.32	9.79e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25733915	chr17:40829168	PLEKHH3	0.48	6.94	0.35	1.92e-11	Pancreatic cancer;
LIHC	cis	rs6708331	0.517	rs12617812	chr2:70359471	A/G	cg01613454	chr2:70366299	NA	0.38	6.11	0.31	2.75e-9	Obesity-related traits;
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.76	-0.39	9.71e-14	Lymphocyte counts;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17412405	chr5:114880687	FEM1C	0.47	6.41	0.33	4.95e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.31	-7.08	-0.36	8.44e-12	Cutaneous nevi;
LIHC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.26	6.29	0.32	9.74e-10	Crohn's disease;
LIHC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.53	-10.19	-0.48	1.76e-21	Asthma;
LIHC	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-7.23	-0.36	3.23e-12	Breast cancer;
LIHC	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg23533926	chr12:111358616	MYL2	-0.32	-6.35	-0.32	6.79e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9783347	1.000	rs2061164	chr11:18329006	T/C	cg15585147	chr11:18324498	HPS5	0.44	6.81	0.35	4.35e-11	Pancreatic cancer;
LIHC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-0.84	-10.67	-0.5	3.77e-23	Blood pressure (smoking interaction);
LIHC	trans	rs1464321	0.901	rs7302493	chr12:103652558	T/G	cg15403093	chr12:133312361	ANKLE2	0.38	6.05	0.31	3.78e-9	Body mass index;
LIHC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	5.84	0.3	1.24e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg22705602	chr4:152727874	NA	-0.3	-6.32	-0.32	8.21e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08893839	chr5:154027129	NA	0.49	6.97	0.35	1.59e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.5	-5.94	-0.31	6.94e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7116495	1.000	rs4945426	chr11:71748146	A/C	cg26138937	chr11:71823887	C11orf51	0.78	7.59	0.38	3.12e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs611744	0.967	rs702801	chr8:109211802	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs9896052	0.614	rs11077791	chr17:73474629	T/G	cg25649188	chr17:73499917	CASKIN2	0.43	6.52	0.33	2.55e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.8e-30	Menopause (age at onset);
LIHC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.31	0.37	1.85e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.24	-15.89	-0.65	5.57e-43	Diabetic kidney disease;
LIHC	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.6	-0.34	1.56e-10	Putamen volume;
LIHC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg02290350	chr8:58132656	NA	0.32	7.17	0.36	4.73e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9810089	0.814	rs2688600	chr3:136252596	C/A	cg21827317	chr3:136751795	NA	0.45	6.03	0.31	4.34e-9	Gestational age at birth (child effect);
LIHC	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.49	7.71	0.38	1.42e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.45e-11	Height;
LIHC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.7	0.34	8.58e-11	Lung cancer in ever smokers;
LIHC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.76	12.64	0.56	2.48e-30	Menarche (age at onset);
LIHC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.44	-7.39	-0.37	1.16e-12	IgG glycosylation;
LIHC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg08999081	chr20:33150536	PIGU	-0.34	-5.75	-0.3	1.98e-8	Height;
LIHC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg04944784	chr2:26401820	FAM59B	-0.56	-7.18	-0.36	4.5e-12	Gut microbiome composition (summer);
LIHC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.63	10.84	0.51	9.98e-24	Colorectal cancer;
LIHC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.44	6.2	0.32	1.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.79	-15.13	-0.63	5.84e-40	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-1.02	-19.78	-0.73	1.29e-58	Breast cancer;
LIHC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.6	10.0	0.48	8.02e-21	Resting heart rate;
LIHC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.33	-0.49	5.76e-22	Blood metabolite levels;
LIHC	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.24	0.61	1.84e-36	Myeloid white cell count;
LIHC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs15676	0.783	rs7044955	chr9:131567152	C/T	cg00228799	chr9:131580591	ENDOG	-0.47	-6.7	-0.34	8.42e-11	Blood metabolite levels;
LIHC	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg00576331	chr11:65640516	EFEMP2	-0.41	-5.9	-0.3	8.79e-9	DNA methylation (variation);
LIHC	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-7.77	-0.39	9.35e-14	Homocysteine levels;
LIHC	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.3	6.63	0.34	1.32e-10	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.51	7.95	0.39	2.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.54	5.77	0.3	1.76e-8	Menopause (age at onset);
LIHC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.69	9.38	0.45	9.18e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.33	-6.23	-0.32	1.35e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.51	9.4	0.45	8.37e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg12798992	chr6:167411361	FGFR1OP	0.43	6.54	0.33	2.28e-10	Primary biliary cholangitis;
LIHC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg18887096	chr2:219472410	PLCD4	-0.39	-5.96	-0.31	6.25e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27297192	chr10:134578999	INPP5A	0.55	8.03	0.4	1.63e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.61	-9.75	-0.47	5.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg17135325	chr3:160939158	NMD3	0.47	7.11	0.36	6.79e-12	Morning vs. evening chronotype;
LIHC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.88	-0.35	2.87e-11	IgG glycosylation;
LIHC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.79	-14.36	-0.61	6.53e-37	Obesity-related traits;
LIHC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08793459	chr17:57784647	PTRH2;TMEM49	0.43	6.33	0.32	7.48e-10	Cognitive function;
LIHC	cis	rs8083850	0.731	rs8084830	chr18:50835809	T/C	cg24270629	chr18:50823537	DCC	-0.53	-8.12	-0.4	8.29e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-8.46	-0.42	7.67e-16	Cognitive function;
LIHC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.02	0.31	4.48e-9	Eosinophil percentage of white cells;
LIHC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.36	5.94	0.31	6.91e-9	Electroencephalogram traits;
LIHC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.6e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.45	-5.85	-0.3	1.16e-8	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01334186	chr1:151372572	PSMB4	0.44	7.71	0.38	1.36e-13	Cognitive function;
LIHC	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg03585969	chr10:35415529	CREM	0.76	11.02	0.51	2.18e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.51	-0.33	2.61e-10	Diabetic kidney disease;
LIHC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	1.05	14.04	0.6	1.14e-35	Body mass index;
LIHC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.16	0.44	4.71e-18	Schizophrenia;
LIHC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg27494647	chr7:150038898	RARRES2	0.34	6.33	0.32	7.59e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.75	10.87	0.51	7.89e-24	Corneal astigmatism;
LIHC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg26531700	chr6:26746687	NA	0.34	5.76	0.3	1.86e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.51	0.42	5.74e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.68	-0.43	1.59e-16	Total cholesterol levels;
LIHC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	cis	rs6788895	1.000	rs41372346	chr3:150489116	C/G	cg07663535	chr3:150480033	SIAH2	0.57	7.17	0.36	4.53e-12	Breast cancer;
LIHC	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg14515779	chr1:101123966	NA	0.46	6.58	0.34	1.73e-10	Monocyte count;
LIHC	cis	rs10878977	0.565	rs56810029	chr12:69809869	C/T	cg17330252	chr12:69809627	NA	0.38	5.97	0.31	6.01e-9	Colorectal cancer;
LIHC	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg09085632	chr11:111637200	PPP2R1B	0.73	8.4	0.41	1.23e-15	Primary sclerosing cholangitis;
LIHC	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg00977110	chr5:151150581	G3BP1	0.55	7.05	0.36	1.01e-11	Preschool internalizing problems;
LIHC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.51	7.16	0.36	5.03e-12	Red cell distribution width;
LIHC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.08	-0.4	1.09e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs4934494	0.727	rs12783845	chr10:91482629	A/T	cg19698084	chr10:91461284	KIF20B	-0.47	-6.35	-0.32	6.84e-10	Red blood cell count;
LIHC	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.35	6.14	0.32	2.28e-9	Colorectal cancer;
LIHC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.5	-7.73	-0.39	1.21e-13	Schizophrenia;
LIHC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.63	9.52	0.46	3.19e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.32	6.92	0.35	2.22e-11	Ulcerative colitis;
LIHC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg05110241	chr16:68378359	PRMT7	-0.61	-6.77	-0.34	5.71e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs273218	1.000	rs168861	chr5:53377310	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.65	10.32	0.49	6.48e-22	Migraine;
LIHC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.51	7.38	0.37	1.21e-12	Chronic sinus infection;
LIHC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg23625390	chr15:77176239	SCAPER	0.36	5.79	0.3	1.59e-8	Blood metabolite levels;
LIHC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg03934865	chr2:198174659	NA	-0.57	-9.01	-0.44	1.5e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.48	7.23	0.36	3.19e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.35	7.45	0.37	7.8e-13	Bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06612452	chr1:20960677	PINK1	0.5	7.21	0.36	3.58e-12	Pancreatic cancer;
LIHC	cis	rs12744310	0.887	rs12724690	chr1:41800257	T/C	cg03387723	chr1:41708464	SCMH1	-0.32	-5.82	-0.3	1.37e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.45	-6.91	-0.35	2.44e-11	Glycated hemoglobin levels;
LIHC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg08302003	chr7:100435192	NA	-0.39	-6.32	-0.32	8.02e-10	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.52	9.96	0.47	1.13e-20	Testicular germ cell tumor;
LIHC	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.53	-0.46	2.99e-19	Total cholesterol levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11865413	chr10:72969054	NA	0.44	6.25	0.32	1.25e-9	Pancreatic cancer;
LIHC	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.81	-0.39	7.15e-14	Coronary artery disease;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg18279126	chr7:2041391	MAD1L1	0.38	6.42	0.33	4.59e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg14690197	chr8:22456421	C8orf58	-0.4	-6.42	-0.33	4.46e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs4908760	0.864	rs12136766	chr1:8663821	C/T	cg20416874	chr1:8611966	RERE	-0.61	-12.45	-0.56	1.39e-29	Vitiligo;
LIHC	cis	rs1986734	0.576	rs2068062	chr4:77417214	A/C	cg24201034	chr4:77507246	SHROOM3	-0.37	-5.86	-0.3	1.07e-8	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg03146154	chr1:46216737	IPP	0.37	6.1	0.31	2.87e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.56e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.66	-9.97	-0.47	1.01e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg21573476	chr21:45109991	RRP1B	-0.51	-9.66	-0.46	1.15e-19	Mean corpuscular volume;
LIHC	cis	rs77861329	1.000	rs9868101	chr3:52138377	T/C	cg08692210	chr3:52188851	WDR51A	0.84	8.05	0.4	1.41e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.44	-0.42	9.27e-16	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25804072	chr2:10829725	NOL10	0.5	7.04	0.36	1.09e-11	Pancreatic cancer;
LIHC	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.28	5.88	0.3	9.74e-9	Pulmonary function;
LIHC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.75	-13.55	-0.59	9.23e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-7.06	-0.36	9.53e-12	Electroencephalogram traits;
LIHC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.02	-0.44	1.33e-17	Capecitabine sensitivity;
LIHC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg16226627	chr15:75307476	SCAMP5	0.55	9.55	0.46	2.53e-19	Lung cancer;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.59	8.92	0.43	2.93e-17	Height;
LIHC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.33	0.37	1.67e-12	Electroencephalogram traits;
LIHC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.41	5.77	0.3	1.79e-8	Longevity;Endometriosis;
LIHC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.13	0.31	2.47e-9	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs6934970	0.929	rs62413974	chr6:113058301	G/T	cg09308777	chr6:169852575	NA	0.58	6.06	0.31	3.67e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs16958440	0.867	rs28587821	chr18:44687906	G/A	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.74	-0.47	6.16e-20	Schizophrenia;
LIHC	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	0.52	9.57	0.46	2.2e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg23461800	chr14:103021989	NA	-0.41	-5.8	-0.3	1.5e-8	Platelet count;
LIHC	trans	rs3783890	0.943	rs76446292	chr14:93775028	A/C	cg02802420	chr16:69363236	PDF;COG8	0.34	6.08	0.31	3.24e-9	Body mass index;
LIHC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.52	6.87	0.35	3.02e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.83	-13.84	-0.6	6.59e-35	Aortic root size;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.44	8.08	0.4	1.15e-14	Prudent dietary pattern;
LIHC	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.85	-0.39	5.38e-14	Coronary artery disease;
LIHC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	7.15	0.36	5.34e-12	Personality dimensions;
LIHC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.75	-0.69	2e-50	Gut microbiome composition (summer);
LIHC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg00990874	chr7:1149470	C7orf50	-0.37	-6.02	-0.31	4.49e-9	Longevity;Endometriosis;
LIHC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.42	-9.55	-0.46	2.61e-19	Arsenic metabolism;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg21548464	chr13:50707937	NA	0.45	6.7	0.34	8.58e-11	Longevity;
LIHC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.8	13.18	0.58	2.26e-32	Breast cancer;
LIHC	trans	rs12614435	0.512	rs36113194	chr2:179490785	C/T	cg14011486	chr1:26737247	LIN28	0.46	6.66	0.34	1.1e-10	Atrial fibrillation;
LIHC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg14779329	chr11:130786720	SNX19	0.42	6.36	0.33	6.33e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.44	-6.17	-0.32	1.96e-9	Rheumatoid arthritis;
LIHC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.58	-0.38	3.24e-13	Morning vs. evening chronotype;
LIHC	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12205742	chr18:68097929	NA	0.43	6.09	0.31	3.01e-9	Hepatitis;
LIHC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.93	18.27	0.7	1.56e-52	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	0.84	11.07	0.51	1.52e-24	Skin colour saturation;
LIHC	cis	rs61440199	0.892	rs73818810	chr3:20143380	C/T	cg00235661	chr3:20228976	SGOL1	-0.41	-5.84	-0.3	1.23e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.19	-0.36	4.01e-12	Monocyte percentage of white cells;
LIHC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	10.99	0.51	2.89e-24	Alzheimer's disease (late onset);
LIHC	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.46	8.73	0.43	1.15e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.5	-9.2	-0.45	3.62e-18	Asthma;
LIHC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.34	-6.32	-0.32	7.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.8	-9.11	-0.44	7.24e-18	Exhaled nitric oxide output;
LIHC	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.41	5.83	0.3	1.27e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg13441142	chr10:134499734	INPP5A	0.46	6.06	0.31	3.52e-9	Primary sclerosing cholangitis;
LIHC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg24130564	chr14:104152367	KLC1	-0.35	-5.76	-0.3	1.91e-8	Schizophrenia;
LIHC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.72	7.31	0.37	1.94e-12	Vitiligo;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02290350	chr8:58132656	NA	0.5	9.72	0.47	7.22e-20	Developmental language disorder (linguistic errors);
LIHC	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg23218760	chr8:16884364	EFHA2	0.48	6.06	0.31	3.52e-9	Myopia (pathological);
LIHC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg14393609	chr7:65229607	NA	0.36	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00166722	chr3:10149974	C3orf24	0.51	5.92	0.3	7.85e-9	Alzheimer's disease;
LIHC	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg25182066	chr10:30743637	MAP3K8	0.47	7.59	0.38	3.02e-13	Inflammatory bowel disease;
LIHC	trans	rs10795130	0.568	rs6601800	chr10:4130066	C/T	cg20550677	chr22:43506316	BIK	-0.5	-6.09	-0.31	3.07e-9	Sex hormone-binding globulin levels;
LIHC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg12903224	chr12:29470962	FAR2	0.4	6.4	0.33	5.25e-10	QT interval;
LIHC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.17	0.36	4.76e-12	Parkinson's disease;
LIHC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.61	-0.34	1.5e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg24110177	chr3:50126178	RBM5	-0.43	-6.62	-0.34	1.38e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.53	5.82	0.3	1.37e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3849570	0.514	rs4389498	chr3:82015395	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-6.54	-0.33	2.28e-10	Waist circumference;Body mass index;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-7.37	-0.37	1.28e-12	Prudent dietary pattern;
LIHC	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg19773385	chr1:10388646	KIF1B	-0.48	-8.21	-0.41	4.66e-15	Hepatocellular carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05792022	chr13:41239732	FOXO1	0.47	6.49	0.33	3.02e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.05	-16.0	-0.65	2.14e-43	Cognitive function;
LIHC	trans	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.92	0.43	2.81e-17	Cognitive test performance;
LIHC	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.56	8.27	0.41	2.98e-15	Itch intensity from mosquito bite;
LIHC	cis	rs4722404	0.643	rs4722443	chr7:3156031	T/C	cg19214707	chr7:3157722	NA	0.36	6.57	0.33	1.86e-10	Atopic dermatitis;
LIHC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg26149184	chr10:133730230	NA	0.48	7.55	0.38	4.05e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg01843034	chr6:37503916	NA	-0.46	-7.8	-0.39	7.63e-14	Cognitive performance;
LIHC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	ch.11.42038R	chr11:967971	AP2A2	0.55	9.9	0.47	1.81e-20	Alzheimer's disease (late onset);
LIHC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.61	6.88	0.35	2.89e-11	Menarche (age at onset);
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.48	6.81	0.35	4.45e-11	Longevity;Endometriosis;
LIHC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.79	11.27	0.52	2.85e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21467203	chr3:49911342	NA	0.52	9.52	0.46	3.25e-19	Body mass index;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs911119	1.000	rs2016161	chr20:23621174	G/T	cg16589663	chr20:23618590	CST3	-0.78	-8.44	-0.42	9.09e-16	Chronic kidney disease;
LIHC	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.72	-10.2	-0.48	1.72e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.67	-0.42	1.75e-16	Asthma;
LIHC	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.65	0.38	2.08e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs7534824	0.582	rs41312670	chr1:101443431	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	7.29	0.37	2.23e-12	Refractive astigmatism;
LIHC	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.8	-0.5	1.36e-23	Schizophrenia;
LIHC	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.58	-7.88	-0.39	4.46e-14	Waist circumference;Body mass index;
LIHC	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.62	10.05	0.48	5.46e-21	Corneal astigmatism;
LIHC	cis	rs2710642	0.611	rs2204655	chr2:62883786	C/T	cg17519650	chr2:63277830	OTX1	0.52	7.52	0.38	4.73e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.46	-8.33	-0.41	2.04e-15	Paraoxonase activity;
LIHC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.15	-0.36	5.17e-12	Personality dimensions;
LIHC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.65	13.41	0.59	3.07e-33	Airflow obstruction;
LIHC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.07	15.42	0.64	4.13e-41	Cognitive function;
LIHC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.38	5.98	0.31	5.55e-9	Menopause (age at onset);
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.9	-0.35	2.55e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg07971674	chr14:23388846	RBM23	0.41	5.96	0.31	6.23e-9	Cognitive ability (multi-trait analysis);
LIHC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.89	-18.22	-0.7	2.49e-52	Height;
LIHC	cis	rs17433710	0.516	rs6691289	chr1:162644912	G/A	cg01063088	chr1:162760584	HSD17B7	0.44	6.09	0.31	3.11e-9	Dupuytren's disease;
LIHC	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	0.81	5.81	0.3	1.4e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg21724239	chr8:58056113	NA	0.49	6.45	0.33	3.86e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg10756647	chr7:56101905	PSPH	-1.08	-13.21	-0.58	1.83e-32	Diabetic kidney disease;
LIHC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	6.98	0.35	1.58e-11	Height;
LIHC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.38	1.4e-13	Glioblastoma;
LIHC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.78	0.43	8.18e-17	Motion sickness;
LIHC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.92	0.39	3.38e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs10213084	0.920	rs6835151	chr4:147529209	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.47	6.76	0.34	5.98e-11	Heart rate;
LIHC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg12863693	chr15:85201151	NMB	0.44	6.12	0.31	2.56e-9	Schizophrenia;
LIHC	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.44	0.37	8.16e-13	Endometrial cancer;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.35	-5.81	-0.3	1.44e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.94	0.57	1.88e-31	Prudent dietary pattern;
LIHC	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.3	-0.32	8.94e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.72	-8.86	-0.43	4.33e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs74181299	0.525	rs4671119	chr2:65362211	C/G	cg05010058	chr2:65284262	CEP68	-0.36	-5.72	-0.3	2.36e-8	Pulse pressure;
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.59	-0.46	1.88e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-11.81	-0.54	3.08e-27	Colorectal cancer;
LIHC	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.43	6.12	0.31	2.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg20435097	chr10:126320824	FAM53B	-0.42	-6.25	-0.32	1.21e-9	Cocaine dependence;
LIHC	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.53	8.57	0.42	3.58e-16	Dialysis-related mortality;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg20090690	chr10:134436459	INPP5A	0.46	5.86	0.3	1.12e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.76	-0.3	1.84e-8	Total body bone mineral density;
LIHC	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.88	0.47	2.03e-20	Coffee consumption (cups per day);
LIHC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.59	10.42	0.49	2.88e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22509189	chr2:225307070	NA	-0.55	-6.81	-0.35	4.28e-11	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.97	13.44	0.59	2.33e-33	Cerebrospinal P-tau181p levels;
LIHC	trans	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg01596870	chr19:55963115	NA	-0.62	-6.91	-0.35	2.37e-11	Obesity-related traits;
LIHC	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.25	-13.43	-0.59	2.45e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs507080	0.769	rs11603616	chr11:118496066	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	5.79	0.3	1.58e-8	Serum metabolite levels;
LIHC	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	14.23	0.61	1.99e-36	Coffee consumption (cups per day);
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg09417038	chr21:47716443	C21orf57	-0.59	-9.07	-0.44	9.17e-18	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.78	-0.3	1.65e-8	Body mass index;
LIHC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	6.35	0.32	6.93e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.15e-10	Putamen volume;
LIHC	cis	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg16684958	chr7:75615977	POR	0.41	6.23	0.32	1.37e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.81	10.43	0.49	2.66e-22	Morning vs. evening chronotype;
LIHC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00152838	chr16:24741724	TNRC6A	-0.48	-6.34	-0.32	7.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.5	6.11	0.31	2.74e-9	Schizophrenia;
LIHC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02290350	chr8:58132656	NA	0.5	8.99	0.44	1.74e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.2	0.32	1.58e-9	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.75	-11.49	-0.53	4.54e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.61	-11.0	-0.51	2.6e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	-0.47	-6.53	-0.33	2.38e-10	Mean platelet volume;
LIHC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg02702477	chr5:179499311	RNF130	-0.75	-10.29	-0.49	7.91e-22	LDL cholesterol;
LIHC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg12863693	chr15:85201151	NMB	0.44	6.34	0.32	7.18e-10	Schizophrenia;
LIHC	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg05197062	chr11:11642011	GALNTL4	0.45	6.61	0.34	1.48e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-9.23	-0.45	2.94e-18	Blood metabolite levels;
LIHC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.56	-7.77	-0.39	9.32e-14	Type 2 diabetes;
LIHC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.29	-0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.55e-9	Childhood ear infection;
LIHC	cis	rs919433	0.726	rs11904247	chr2:198238424	T/G	cg10820045	chr2:198174542	NA	0.55	8.73	0.43	1.13e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.65	-12.09	-0.55	3.04e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg24169773	chr3:122142474	KPNA1	-0.45	-8.79	-0.43	7.44e-17	LDL cholesterol levels;
LIHC	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.9	-0.39	3.77e-14	Capecitabine sensitivity;
LIHC	cis	rs903552	0.800	rs12903584	chr15:101999369	G/A	cg06707286	chr15:102010195	PCSK6	-0.42	-6.02	-0.31	4.4e-9	Diabetic kidney disease;
LIHC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.73	-8.31	-0.41	2.22e-15	Neuroticism;
LIHC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg04727924	chr7:799746	HEATR2	0.41	6.27	0.32	1.07e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg00280220	chr17:61926910	NA	0.42	6.79	0.34	4.88e-11	Prudent dietary pattern;
LIHC	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.49	-7.59	-0.38	3.02e-13	Blood pressure (smoking interaction);
LIHC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg24296786	chr1:45957014	TESK2	-0.49	-6.38	-0.33	5.64e-10	Platelet count;
LIHC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.96	17.6	0.69	8.27e-50	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00292435	chr9:91925643	CKS2	0.46	6.51	0.33	2.6e-10	Pancreatic cancer;
LIHC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20930618	chr1:151162157	VPS72	0.39	6.05	0.31	3.82e-9	Pancreatic cancer;
LIHC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg27121462	chr16:89883253	FANCA	0.42	6.44	0.33	3.93e-10	Vitiligo;
LIHC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs4755351	0.553	rs11032165	chr11:33164117	A/G	cg05567920	chr11:33183001	CSTF3	0.42	6.21	0.32	1.56e-9	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01839850	chr22:38240395	ANKRD54;MIR658	0.48	7.4	0.37	1.04e-12	Pancreatic cancer;
LIHC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.45	-9.12	-0.44	6.8e-18	Birth weight;
LIHC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-10.05	-0.48	5.34e-21	Lung cancer in ever smokers;
LIHC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.9	9.36	0.45	1.12e-18	Mean corpuscular hemoglobin;
LIHC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.05	-0.4	1.35e-14	Monocyte percentage of white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16800975	chr8:17434541	PDGFRL	0.44	6.58	0.34	1.79e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg20636351	chr8:55087400	NA	-0.36	-7.31	-0.37	1.87e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg24296786	chr1:45957014	TESK2	0.4	5.74	0.3	2.04e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg10978503	chr1:24200527	CNR2	-0.38	-8.97	-0.44	2.02e-17	Immature fraction of reticulocytes;
LIHC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	6.02	0.31	4.5e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.55	11.16	0.52	7.14e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.42	-6.1	-0.31	2.87e-9	Blood protein levels;
LIHC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.03e-32	Psoriasis;
LIHC	trans	rs10213084	1.000	rs13113553	chr4:147494348	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.65	8.98	0.44	1.81e-17	Coronary artery disease;
LIHC	trans	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg18335740	chr13:41363409	SLC25A15	0.38	6.6	0.34	1.57e-10	Lewy body disease;
LIHC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-9.22	-0.45	3.07e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg19683494	chr5:74908142	NA	0.58	7.71	0.38	1.4e-13	Age-related disease endophenotypes;
LIHC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.85	8.12	0.4	8.32e-15	Lymphocyte counts;
LIHC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-11.88	-0.54	1.72e-27	Coronary artery disease;
LIHC	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.39	6.02	0.31	4.39e-9	Neutrophil percentage of white cells;
LIHC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.37	-6.1	-0.31	2.86e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.43	-0.56	1.53e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.74	12.98	0.57	1.38e-31	Eosinophil percentage of white cells;
LIHC	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.46	-7.48	-0.38	6.21e-13	Menarche (age at onset);
LIHC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20135002	chr11:47629003	NA	-0.53	-9.01	-0.44	1.47e-17	Subjective well-being;
LIHC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg23149560	chr2:74406255	MOBKL1B	0.44	6.18	0.32	1.86e-9	Gestational age at birth (maternal effect);
LIHC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.48	-6.75	-0.34	6.39e-11	Menarche (age at onset);
LIHC	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.16	0.44	5.06e-18	Schizophrenia;
LIHC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.43	6.11	0.31	2.71e-9	Aortic root size;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.66	10.7	0.5	3e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.55	-10.54	-0.5	1.12e-22	Mean corpuscular volume;
LIHC	cis	rs35160687	0.623	rs11127019	chr2:86467618	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.4	6.45	0.33	3.91e-10	Night sleep phenotypes;
LIHC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.22e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10489202	0.954	rs11586522	chr1:168091031	G/T	cg17859187	chr1:168147929	TIPRL	0.52	6.96	0.35	1.7e-11	Schizophrenia;
LIHC	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg15105060	chr4:7024189	TBC1D14	-0.72	-6.04	-0.31	3.96e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2019960	0.679	rs2648846	chr8:129179990	A/G	cg15331705	chr8:129180010	NA	-0.38	-6.98	-0.35	1.55e-11	Hodgkin's lymphoma;Multiple sclerosis;
LIHC	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.63	11.39	0.52	1.08e-25	Schizophrenia;
LIHC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg06714761	chr1:201096289	NA	0.35	5.97	0.31	5.82e-9	Permanent tooth development;
LIHC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.8	-0.67	1.3e-46	Systemic lupus erythematosus;
LIHC	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg04865290	chr3:52927548	TMEM110	-0.51	-5.9	-0.3	8.82e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.76	0.34	5.96e-11	Red blood cell count;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	8.71	0.43	1.29e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs1355223	0.867	rs1377495	chr11:34682962	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.91	0.3	8.18e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7872515	0.887	rs10992234	chr9:94877836	A/G	cg01248375	chr9:94877805	SPTLC1	0.54	8.16	0.4	6.26e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	10.52	0.49	1.29e-22	Colorectal cancer;
LIHC	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11645453	chr3:52864694	ITIH4	0.22	5.75	0.3	1.98e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9443189	0.950	rs6938349	chr6:76484280	A/T	cg01950844	chr6:76311363	SENP6	0.48	5.77	0.3	1.8e-8	Prostate cancer;
LIHC	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.89	-0.3	9.25e-9	Personality dimensions;
LIHC	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.33	-6.57	-0.33	1.86e-10	DNA methylation (variation);
LIHC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.65	-8.93	-0.43	2.76e-17	Aortic root size;
LIHC	cis	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs273218	1.000	rs156380	chr5:53378450	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.64	9.96	0.47	1.07e-20	Migraine;
LIHC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	cis	rs17095355	1.000	rs7921609	chr10:111691599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.17	-0.32	1.9e-9	Biliary atresia;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.66	-0.38	1.97e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs6466055	0.720	rs1121194	chr7:104981133	T/C	cg04380332	chr7:105027541	SRPK2	0.35	6.62	0.34	1.38e-10	Schizophrenia;
LIHC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-8.24	-0.41	3.75e-15	Menarche (age at onset);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24866320	chr6:158703163	NA	-0.25	-6.21	-0.32	1.56e-9	Calcium levels;
LIHC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.73	0.3	2.21e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.39	-6.09	-0.31	2.99e-9	Uric acid levels;
LIHC	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg16586182	chr3:47516702	SCAP	-0.46	-7.8	-0.39	7.62e-14	Colorectal cancer;
LIHC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.53	-6.44	-0.33	4.07e-10	Menarche (age at onset);
LIHC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.98	-0.44	1.8e-17	Blood metabolite levels;
LIHC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.58	8.84	0.43	5.32e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.52	-6.45	-0.33	3.73e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.3e-9	Coronary artery disease;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg10134156	chr14:77732494	MIR1260;NGB	-0.38	-6.27	-0.32	1.08e-9	Mild influenza (H1N1) infection;
LIHC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg15902774	chr15:75289873	SCAMP5	0.45	6.52	0.33	2.49e-10	Lung cancer;
LIHC	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-10.26	-0.48	1.08e-21	Colorectal cancer;
LIHC	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg01864069	chr14:103024347	NA	0.36	5.94	0.31	7.16e-9	Platelet count;
LIHC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.31	-7.0	-0.35	1.36e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg22961513	chr11:14280813	SPON1	-0.44	-6.6	-0.34	1.54e-10	Mitochondrial DNA levels;
LIHC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.5	7.3	0.37	2.01e-12	Obesity-related traits;
LIHC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.39	7.04	0.36	1.04e-11	Psoriasis;
LIHC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21467203	chr3:49911342	NA	0.5	9.2	0.45	3.71e-18	Body mass index;
LIHC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.52	-9.26	-0.45	2.36e-18	Blood protein levels;
LIHC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26764764	chr17:79077412	BAIAP2	-0.39	-6.42	-0.33	4.49e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5995875	0.556	rs73171007	chr22:41049101	A/G	cg14879645	chr22:41048474	NA	0.4	5.82	0.3	1.35e-8	Breast size;
LIHC	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.42	6.48	0.33	3.14e-10	Brain structure;
LIHC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.29	6.86	0.35	3.3e-11	Primary biliary cholangitis;
LIHC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.5	6.72	0.34	7.79e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12402495	chr1:154192844	C1orf43;UBAP2L	0.43	6.75	0.34	6.29e-11	Cognitive function;
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.72	0.39	1.27e-13	Prudent dietary pattern;
LIHC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-7.07	-0.36	8.54e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.65	12.51	0.56	7.71e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.4	-6.9	-0.35	2.52e-11	Type 2 diabetes;
LIHC	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.79	8.93	0.43	2.68e-17	Bipolar disorder;
LIHC	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.52	8.31	0.41	2.27e-15	Blood protein levels;
LIHC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.58	9.62	0.46	1.5700000000000001e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	14.65	0.62	4.81e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.9	0.3	8.86e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg02951883	chr7:2050386	MAD1L1	-0.64	-9.98	-0.47	9.65e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.98	9.98	0.47	9.25e-21	Plasma clusterin levels;
LIHC	cis	rs2834188	1.000	rs1018742	chr21:34686381	A/G	cg04842828	chr21:34696676	IFNAR1	0.44	5.98	0.31	5.73e-9	Narcolepsy;
LIHC	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg06627628	chr2:24431161	ITSN2	-0.63	-7.2	-0.36	3.96e-12	Lymphocyte counts;
LIHC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg09222892	chr1:25734099	RHCE	0.48	8.89	0.43	3.55e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.47	0.49	1.98e-22	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10838687	0.800	rs10838686	chr11:47311367	G/T	cg26139080	chr11:47293733	MADD	-0.41	-5.77	-0.3	1.73e-8	Proinsulin levels;
LIHC	trans	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg23605328	chr1:201951606	RNPEP	0.39	6.2	0.32	1.66e-9	Monocyte percentage of white cells;
LIHC	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.48	5.79	0.3	1.61e-8	Pancreatic cancer;
LIHC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg10130564	chr11:117069849	TAGLN	-0.37	-6.21	-0.32	1.51e-9	Blood protein levels;
LIHC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	10.0	0.48	8.23e-21	Lung cancer;
LIHC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg08499158	chr17:42289980	UBTF	-0.49	-7.99	-0.4	2.15e-14	Total body bone mineral density;
LIHC	cis	rs6988636	0.536	rs16898043	chr8:124155886	A/G	cg15893493	chr8:124194847	FAM83A	0.81	7.25	0.37	2.74e-12	Urinary uromodulin levels;
LIHC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.5	6.0	0.31	5.01e-9	Total body bone mineral density;
LIHC	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg14515779	chr1:101123966	NA	0.43	6.09	0.31	3.05e-9	Monocyte count;
LIHC	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.66	-10.17	-0.48	2.2e-21	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.37	6.15	0.32	2.21e-9	Educational attainment;
LIHC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg22633049	chr21:46681294	NA	-0.36	-6.15	-0.32	2.1e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.73	0.34	7.11e-11	Lung cancer in ever smokers;
LIHC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg13319975	chr6:146136371	FBXO30	0.34	5.72	0.3	2.29e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09918751	chr15:100517450	ADAMTS17	0.73	12.2	0.55	1.18e-28	Height;
LIHC	cis	rs611744	0.934	rs673356	chr8:109185159	A/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.21	-0.32	1.54e-9	Schizophrenia;
LIHC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.15	0.36	5.31e-12	Parkinson's disease;
LIHC	trans	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg10756647	chr7:56101905	PSPH	1.1	13.4	0.59	3.2e-33	Diabetic kidney disease;
LIHC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.52	-7.34	-0.37	1.58e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	7.5	0.38	5.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4919087	0.532	rs7068063	chr10:99083968	C/T	cg25902810	chr10:99078978	FRAT1	-0.59	-6.88	-0.35	2.82e-11	Monocyte count;
LIHC	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.68	-7.81	-0.39	7.06e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6669384	0.774	rs4844622	chr1:208034329	C/T	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.96	-0.31	6.45e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20007465	chr7:1068125	C7orf50	0.44	6.06	0.31	3.53e-9	Triglycerides;
LIHC	cis	rs7095607	0.560	rs10997955	chr10:69914664	C/T	cg18986048	chr10:69913749	MYPN	0.41	6.04	0.31	3.95e-9	Lung function (FVC);
LIHC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	8.09	0.4	1.09e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.53	-0.49	1.17e-22	Alzheimer's disease;
LIHC	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg25011176	chr20:3776985	CDC25B	0.46	6.48	0.33	3.21e-10	Bipolar disorder;
LIHC	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.37	-0.37	1.32e-12	Obesity-related traits;
LIHC	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.76	-14.0	-0.6	1.64e-35	Mean platelet volume;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.06	-0.31	3.58e-9	Bronchopulmonary dysplasia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25750404	chr12:6579648	VAMP1	0.45	6.2	0.32	1.63e-9	Pancreatic cancer;
LIHC	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.61	10.38	0.49	4.09e-22	HDL cholesterol;
LIHC	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg03934865	chr2:198174659	NA	-0.57	-9.1	-0.44	7.61e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg17306686	chr7:157230923	NA	-0.28	-5.79	-0.3	1.58e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs754466	0.706	rs7099526	chr10:79657705	C/G	cg17075019	chr10:79541650	NA	-0.66	-9.37	-0.45	1.03e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12980942	0.748	rs67511749	chr19:41825158	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.47	5.88	0.3	9.65e-9	Coronary artery disease;
LIHC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.45	10.13	0.48	2.79e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-7.84	-0.39	5.88e-14	Alzheimer's disease;
LIHC	cis	rs9513627	0.920	rs16956607	chr13:100120220	A/G	cg25919922	chr13:100150906	NA	-0.78	-7.02	-0.35	1.19e-11	Obesity-related traits;
LIHC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10802521	chr3:52805072	NEK4	-0.5	-6.99	-0.35	1.43e-11	Systolic blood pressure;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18513200	chr4:13629548	BOD1L	0.43	6.13	0.31	2.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg08888203	chr3:10149979	C3orf24	0.51	6.21	0.32	1.56e-9	Alzheimer's disease;
LIHC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.24	-7.35	-0.37	1.47e-12	Mean corpuscular volume;
LIHC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.09e-9	Major depressive disorder;
LIHC	cis	rs1018836	0.828	rs4140679	chr8:91584269	A/C	cg16814680	chr8:91681699	NA	-0.57	-8.98	-0.44	1.83e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.67	8.85	0.43	4.92e-17	Schizophrenia;
LIHC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.47	-6.82	-0.35	4.17e-11	Corneal structure;
LIHC	cis	rs2421770	0.504	rs7943314	chr11:35363823	A/G	cg13971030	chr11:35366721	SLC1A2	-0.43	-7.31	-0.37	1.93e-12	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg22705602	chr4:152727874	NA	-0.28	-6.0	-0.31	4.9e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.45	-6.24	-0.32	1.31e-9	Longevity;
LIHC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.7	-9.74	-0.47	6.04e-20	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24769499	chr2:120189242	TMEM37	-0.58	-6.89	-0.35	2.74e-11	Systolic blood pressure;
LIHC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.56	-8.41	-0.41	1.15e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.23	-17.07	-0.68	1.13e-47	Ulcerative colitis;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg14593290	chr7:50529359	DDC	-0.61	-10.0	-0.48	7.91e-21	Malaria;
LIHC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.42	-6.94	-0.35	2.03e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2274273	1.000	rs7493394	chr14:55617755	A/T	cg01864836	chr14:55583639	NA	-0.36	-6.12	-0.31	2.62e-9	Protein biomarker;
LIHC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.5	-5.79	-0.3	1.63e-8	Pancreatic cancer;
LIHC	cis	rs611744	0.967	rs627604	chr8:109189819	C/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.46	0.42	8.11e-16	Motion sickness;
LIHC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.39	-5.74	-0.3	2.06e-8	Narcolepsy;
LIHC	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.4	-6.24	-0.32	1.31e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.33	0.41	1.97e-15	Lymphocyte counts;
LIHC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg25576086	chr14:70833871	SYNJ2BP	-0.56	-10.54	-0.5	1.15e-22	Prostate cancer;
LIHC	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	trans	rs10411161	0.808	rs892040	chr19:52396645	A/G	cg22319618	chr22:45562946	NUP50	-0.65	-7.43	-0.37	9.01e-13	Breast cancer;
LIHC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg23625390	chr15:77176239	SCAPER	0.35	5.73	0.3	2.19e-8	Blood metabolite levels;
LIHC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.63	-9.99	-0.48	8.83e-21	Sudden cardiac arrest;
LIHC	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.58	-8.8	-0.43	6.86e-17	Prostate cancer;
LIHC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg13126279	chr21:47581558	C21orf56	-0.37	-5.84	-0.3	1.18e-8	Testicular germ cell tumor;
LIHC	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.02	-0.44	1.33e-17	Capecitabine sensitivity;
LIHC	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.55	-8.44	-0.42	9.24e-16	Blood protein levels;
LIHC	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.84	-15.91	-0.65	4.87e-43	Height;
LIHC	cis	rs9309473	1.000	rs3738848	chr2:73761881	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.95	-0.35	1.87e-11	Metabolite levels;
LIHC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.81	16.24	0.66	2.37e-44	Gestational age at birth (maternal effect);
LIHC	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	7.17e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.5	-7.46	-0.37	7.07e-13	Longevity;
LIHC	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.24	-6.63	-0.34	1.34e-10	Type 2 diabetes;
LIHC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.49	7.23	0.36	3.19e-12	Obesity-related traits;
LIHC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.36	5.76	0.3	1.88e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2073300	1.000	rs6132631	chr20:23461848	T/C	cg12062639	chr20:23401060	NAPB	0.78	9.74	0.47	6.27e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	13.78	0.6	1.2e-34	Primary sclerosing cholangitis;
LIHC	cis	rs9918079	0.560	rs4557256	chr4:15626647	A/C	cg21329975	chr4:15471214	CC2D2A	-0.42	-6.29	-0.32	9.48e-10	Obesity-related traits;
LIHC	cis	rs600806	0.665	rs1368988	chr1:110012123	A/T	cg10127483	chr1:110009974	SYPL2	0.5	6.44	0.33	4.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg27572855	chr1:25598939	RHD	0.43	9.55	0.46	2.65e-19	Erythrocyte sedimentation rate;
LIHC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.58e-15	Motion sickness;
LIHC	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-8.71	-0.43	1.3e-16	Vitamin D levels;
LIHC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg27147174	chr7:100797783	AP1S1	-0.47	-6.72	-0.34	7.49e-11	Life satisfaction;
LIHC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.51	8.32	0.41	2.06e-15	Schizophrenia;
LIHC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.73	14.29	0.61	1.18e-36	Mortality in heart failure;
LIHC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.42	12.94	0.57	1.88e-31	Uric acid levels;
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06558623	chr16:89946397	TCF25	0.86	13.32	0.58	7.01e-33	Skin colour saturation;
LIHC	cis	rs79419269	0.673	rs2792432	chr7:150927763	T/C	cg01623806	chr7:150929509	CHPF2	-0.55	-5.77	-0.3	1.73e-8	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.74	7.34	0.37	1.53e-12	Facial morphology (factor 23);
LIHC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	12.82	0.57	5.26e-31	Menopause (age at onset);
LIHC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.77	-0.57	8.47e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg03146154	chr1:46216737	IPP	-0.36	-6.01	-0.31	4.78e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.73	14.29	0.61	1.21e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.54	7.18	0.36	4.29e-12	Vitiligo;
LIHC	cis	rs7546668	1.000	rs12124078	chr1:15869899	A/G	cg11706911	chr1:15910989	AGMAT	0.43	6.48	0.33	3.11e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.5	-6.35	-0.32	6.85e-10	Schizophrenia;
LIHC	cis	rs7677751	1.000	rs73252946	chr4:55125992	G/A	cg17187183	chr4:55093834	PDGFRA	0.66	7.73	0.39	1.19e-13	Corneal astigmatism;
LIHC	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.74	0.5	2.15e-23	Colorectal cancer;
LIHC	cis	rs12594515	0.694	rs2068295	chr15:45985546	T/C	cg19682013	chr15:45996608	NA	0.39	6.77	0.34	5.62e-11	Waist circumference;Weight;
LIHC	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg12698662	chr3:15914712	MIR563	-0.36	-6.57	-0.33	1.87e-10	Mean platelet volume;
LIHC	trans	rs6489882	0.703	rs10774673	chr12:113361158	C/T	cg10175203	chr3:128143634	NA	0.4	6.49	0.33	3.02e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.45	7.0	0.35	1.4e-11	Prostate cancer;
LIHC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg06565975	chr8:143823917	SLURP1	0.33	6.38	0.33	5.92e-10	Urinary tract infection frequency;
LIHC	cis	rs1198430	1.000	rs1198430	chr1:23755513	C/T	cg13183780	chr1:23809682	ASAP3	0.48	7.33	0.37	1.62e-12	Total cholesterol levels;
LIHC	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs875971	0.545	rs316305	chr7:65617971	G/A	cg26939375	chr7:64535504	NA	-0.41	-6.47	-0.33	3.36e-10	Aortic root size;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg00800038	chr16:89945340	TCF25	0.6	10.06	0.48	4.9e-21	Skin colour saturation;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.79	11.75	0.54	5.18e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.12	0.31	2.54e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.84	0.35	3.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12500138	1.000	rs59157290	chr4:166214959	C/T	cg25064052	chr4:166216151	KLHL2	-0.62	-5.86	-0.3	1.12e-8	Cognitive function;
LIHC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10861342	0.892	rs3829297	chr12:105592823	G/C	cg23923672	chr12:105501055	KIAA1033	0.62	7.36	0.37	1.34e-12	IgG glycosylation;
LIHC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.38	6.65	0.34	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.93	-0.54	1.16e-27	Urate levels in overweight individuals;
LIHC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.41e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.7	-0.34	8.76e-11	Diabetic kidney disease;
LIHC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.63	-12.45	-0.56	1.37e-29	Urate levels in overweight individuals;
LIHC	cis	rs526231	0.819	rs2569016	chr5:102603132	A/G	cg05225461	chr5:102596755	C5orf30	0.38	5.89	0.3	9.25e-9	Primary biliary cholangitis;
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.61	8.78	0.43	8.21e-17	Menarche (age at onset);
LIHC	cis	rs922107	0.738	rs12733491	chr1:90039033	C/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.53	-0.38	4.6e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.42	-6.07	-0.31	3.44e-9	Morning vs. evening chronotype;
LIHC	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg08345082	chr10:99160200	RRP12	-0.39	-6.65	-0.34	1.14e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10197940	0.810	rs4664045	chr2:152267072	T/G	cg19508488	chr2:152266495	RIF1	0.71	11.55	0.53	2.83e-26	Lung cancer;
LIHC	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.03	-0.4	1.57e-14	Exhaled nitric oxide output;
LIHC	cis	rs77633900	0.772	rs157760	chr15:76800260	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-6.09	-0.31	3.11e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.67	-10.4	-0.49	3.32e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.33	-7.87	-0.39	4.88e-14	Longevity;Endometriosis;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-8.68	-0.42	1.67e-16	Lymphocyte counts;
LIHC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	10.05	0.48	5.4e-21	Lung cancer;
LIHC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-8.12	-0.4	8.67e-15	Tonsillectomy;
LIHC	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-8.82	-0.43	5.94e-17	Schizophrenia;
LIHC	cis	rs8081395	0.804	rs2777884	chr17:57830426	G/A	cg13753209	chr17:57696993	CLTC	-0.48	-7.3	-0.37	2.08e-12	White blood cell count;
LIHC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg11839771	chr15:80205821	ST20	-0.32	-6.92	-0.35	2.21e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.56	0.38	3.77e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg00977110	chr5:151150581	G3BP1	-0.56	-7.11	-0.36	6.89e-12	Preschool internalizing problems;
LIHC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.95	-13.05	-0.58	7.5e-32	Cognitive test performance;
LIHC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg04359351	chr2:3481828	TTC15	0.28	5.92	0.3	7.84e-9	Neurofibrillary tangles;
LIHC	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.61	-0.42	2.75e-16	Exhaled nitric oxide output;
LIHC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.74	12.49	0.56	9.32e-30	Blood protein levels;
LIHC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.36	5.95	0.31	6.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.48	-0.33	3.22e-10	Endometrial cancer;
LIHC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.61	-6.99	-0.35	1.43e-11	Menarche (age at onset);
LIHC	cis	rs2710642	0.544	rs10204410	chr2:62829979	G/T	cg17519650	chr2:63277830	OTX1	0.43	6.8	0.35	4.61e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs713477	0.692	rs56280202	chr14:55911201	C/T	cg13175173	chr14:55914753	NA	-0.31	-6.71	-0.34	8.09e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.48	6.35	0.32	6.91e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22509189	chr2:225307070	NA	-0.51	-6.63	-0.34	1.29e-10	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.07	-0.31	3.36e-9	Mean corpuscular volume;
LIHC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20135002	chr11:47629003	NA	-0.52	-8.78	-0.43	8.22e-17	Subjective well-being;
LIHC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs7534824	0.625	rs17525507	chr1:101430504	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	6.98	0.35	1.58e-11	Refractive astigmatism;
LIHC	trans	rs7374732	0.692	rs6800955	chr3:23139179	C/T	cg27575106	chr3:119396361	COX17	0.4	6.48	0.33	3.12e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.93	-0.35	2.11e-11	IgG glycosylation;
LIHC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.78	13.24	0.58	1.39e-32	Psoriasis;
LIHC	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.74	-11.02	-0.51	2.34e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs12752401	0.764	rs72725348	chr1:103024349	G/A	cg03332897	chr19:740442	PALM	0.55	6.73	0.34	7.27e-11	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	4.92e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg24663255	chr8:146228920	ZNF252;C8orf77	-0.42	-6.41	-0.33	4.81e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg04155231	chr12:9217510	LOC144571	0.31	5.97	0.31	5.89e-9	Sjögren's syndrome;
LIHC	cis	rs10838687	0.736	rs2242261	chr11:47266808	T/G	cg26139080	chr11:47293733	MADD	-0.42	-5.89	-0.3	8.99e-9	Proinsulin levels;
LIHC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.18	-0.7	3.85e-52	Tonsillectomy;
LIHC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.71	12.11	0.55	2.51e-28	Menopause (age at onset);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24664570	chr2:159825143	TANC1	0.46	6.9	0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg12798992	chr6:167411361	FGFR1OP	0.55	9.21	0.45	3.32e-18	Crohn's disease;
LIHC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.84	-14.07	-0.61	8.63e-36	Body mass index;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.6	8.8	0.43	6.68e-17	Prudent dietary pattern;
LIHC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.6	-8.77	-0.43	8.36e-17	Testicular germ cell tumor;
LIHC	trans	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg08566640	chr11:64091735	NA	-0.69	-6.54	-0.33	2.2e-10	Androgen levels;
LIHC	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.28	6.49	0.33	2.97e-10	Educational attainment (years of education);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg13145437	chr2:85582358	ELMOD3;RETSAT	0.43	6.15	0.32	2.12e-9	Alopecia areata;
LIHC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.46	0.33	3.52e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg23485639	chr6:28045615	ZNF165	0.39	5.94	0.31	7.13e-9	Parkinson's disease;
LIHC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.53	-7.58	-0.38	3.27e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.34	-5.86	-0.3	1.1e-8	Parkinson's disease;
LIHC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.36	-6.54	-0.33	2.2e-10	Aortic root size;
LIHC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.38	-5.82	-0.3	1.37e-8	Dental caries;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg05760424	chr2:242988095	NA	-0.51	-6.91	-0.35	2.4e-11	Obesity-related traits;
LIHC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.57	-8.74	-0.43	1.08e-16	Longevity;
LIHC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.87	-0.47	2.27e-20	Chronic sinus infection;
LIHC	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.8	14.8	0.62	1.19e-38	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.52	6.52	0.33	2.59e-10	Total body bone mineral density;
LIHC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.97	0.35	1.59e-11	Breast cancer;
LIHC	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.39	-6.66	-0.34	1.1e-10	Breast cancer;
LIHC	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.5	8.31	0.41	2.26e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.44	0.66	3.67e-45	Smoking behavior;
LIHC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.48	0.42	6.79e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.47	8.98	0.44	1.82e-17	Schizophrenia;
LIHC	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg06102954	chr21:42741788	MX2	0.38	6.53	0.33	2.33e-10	Melanoma;
LIHC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg21395723	chr22:39101663	GTPBP1	0.37	5.71	0.3	2.44e-8	Menopause (age at onset);
LIHC	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-11.21	-0.52	4.87e-25	Coronary artery disease;
LIHC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg21329975	chr4:15471214	CC2D2A	-0.44	-6.78	-0.34	5.2e-11	Obesity-related traits;
LIHC	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg03146154	chr1:46216737	IPP	0.38	6.19	0.32	1.75e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.24	-6.53	-0.33	2.41e-10	Type 2 diabetes;
LIHC	cis	rs546131	0.642	rs12293044	chr11:34851049	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.52	-0.33	2.53e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.51	-9.01	-0.44	1.44e-17	Longevity;
LIHC	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.56	-6.21	-0.32	1.57e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.21e-26	Motion sickness;
LIHC	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg27386326	chr11:61587980	NA	0.66	13.87	0.6	5.18e-35	Trans fatty acid levels;
LIHC	cis	rs243505	0.668	rs2072406	chr7:148483760	G/A	cg09806900	chr7:148480153	CUL1	0.45	6.7	0.34	8.62e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.99	-14.61	-0.62	6.69e-38	Breast cancer;
LIHC	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.63	9.45	0.46	5.47e-19	Platelet count;
LIHC	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg10820045	chr2:198174542	NA	0.54	8.7	0.43	1.42e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs74233809	1.000	rs11191479	chr10:104723620	T/C	cg03493300	chr10:104813866	CNNM2	0.45	5.99	0.31	5.43e-9	Birth weight;
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04498913	chr7:1135747	C7orf50	0.44	7.0	0.35	1.34e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25087434	chr10:11797550	ECHDC3	-0.4	-6.34	-0.32	7.1e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg07645718	chr20:61493192	TCFL5	0.79	6.45	0.33	3.85e-10	Obesity-related traits;
LIHC	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg14779329	chr11:130786720	SNX19	0.4	6.18	0.32	1.83e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.3	0.37	2.02e-12	Diabetic kidney disease;
LIHC	cis	rs7618501	0.570	rs7613875	chr3:49971514	C/A	cg21467203	chr3:49911342	NA	-0.43	-7.62	-0.38	2.44e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-10.84	-0.51	9.9899999999999993e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.86	15.08	0.63	9.44e-40	Headache;
LIHC	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.35	0.49	5.1e-22	Colorectal cancer;
LIHC	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg18898632	chr2:242989856	NA	-0.47	-6.44	-0.33	4e-10	Obesity-related traits;
LIHC	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.48	8.64	0.42	2.16e-16	Colorectal cancer;
LIHC	cis	rs77633900	0.772	rs284905	chr15:76743345	C/T	cg21673338	chr15:77095150	SCAPER	-0.51	-5.95	-0.31	6.51e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg16586182	chr3:47516702	SCAP	-0.38	-6.52	-0.33	2.59e-10	Birth weight;
LIHC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.51	8.09	0.4	1.03e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.74	-0.34	6.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.21	0.52	4.79e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg17294928	chr15:75287854	SCAMP5	0.47	6.56	0.33	2e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg17279839	chr7:150038598	RARRES2	0.4	7.9	0.39	3.97e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.4	6.67	0.34	1e-10	Menopause (age at onset);
LIHC	trans	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg04702396	chr17:15466718	FAM18B2	0.45	7.06	0.36	9.45e-12	Educational attainment (years of education);
LIHC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.44	6.94	0.35	1.93e-11	HDL cholesterol levels;
LIHC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.75	-0.3	1.96e-8	Uric acid levels;
LIHC	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.38	6.28	0.32	1.02e-9	Lung cancer;
LIHC	cis	rs6435862	0.500	rs6756902	chr2:215672827	C/T	cg04530015	chr2:215796436	ABCA12	0.49	9.01	0.44	1.46e-17	Neuroblastoma (high-risk);
LIHC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.4	5.99	0.31	5.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11958404	0.615	rs7717235	chr5:157447772	C/G	cg05962755	chr5:157440814	NA	0.61	7.98	0.4	2.23e-14	IgG glycosylation;
LIHC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg13844804	chr7:814759	HEATR2	0.44	5.95	0.31	6.72e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg03037974	chr15:76606532	NA	-0.59	-10.08	-0.48	4.4e-21	Blood metabolite levels;
LIHC	trans	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg17712092	chr4:129076599	LARP1B	0.6	7.51	0.38	5.35e-13	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg16586182	chr3:47516702	SCAP	0.58	10.66	0.5	4.27e-23	Colorectal cancer;
LIHC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg24169773	chr3:122142474	KPNA1	-0.45	-9.0	-0.44	1.59e-17	LDL cholesterol levels;
LIHC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.67	-8.26	-0.41	3.13e-15	Gut microbiome composition (summer);
LIHC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg03854865	chr6:26224070	HIST1H3E	0.56	6.35	0.32	6.74e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg20607798	chr8:58055168	NA	0.64	7.7	0.38	1.51e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg10130564	chr11:117069849	TAGLN	0.35	5.83	0.3	1.28e-8	Blood protein levels;
LIHC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.21	-0.36	3.63e-12	Response to antipsychotic treatment;
LIHC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.32	-5.95	-0.31	6.64e-9	Body mass index;
LIHC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.45	-7.07	-0.36	8.84e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs507080	0.922	rs533646	chr11:118566746	C/G	cg04173919	chr11:118528438	PHLDB1	0.36	6.62	0.34	1.43e-10	Serum metabolite levels;
LIHC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.26	0.37	2.71e-12	Lung cancer in ever smokers;
LIHC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.92	0.3	7.74e-9	Menopause (age at onset);
LIHC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.0	-0.6	1.58e-35	Systemic lupus erythematosus;
LIHC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.5	0.77	1.86e-69	Chronic sinus infection;
LIHC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	7.43	0.37	9.02e-13	Platelet count;
LIHC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	14.11	0.61	5.76e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.84	-12.24	-0.55	8.31e-29	Diastolic blood pressure;
LIHC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg25039879	chr17:56429692	SUPT4H1	0.42	5.82	0.3	1.36e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16684958	chr7:75615977	POR	0.52	8.66	0.42	1.84e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.81e-16	Melanoma;
LIHC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg17980119	chr2:219472607	PLCD4	0.35	6.12	0.31	2.56e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.72	-0.39	1.3e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg03934865	chr2:198174659	NA	0.54	8.27	0.41	2.96e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2363709	1.000	rs2363713	chr3:67422600	G/A	cg13681781	chr9:139102396	QSOX2	0.83	6.35	0.32	6.79e-10	IgE levels;
LIHC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg10360323	chr17:41437877	NA	0.4	5.93	0.31	7.22e-9	Menopause (age at onset);
LIHC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg07636037	chr3:49044803	WDR6	-0.81	-8.29	-0.41	2.55e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6815814	0.731	rs66735315	chr4:38774180	G/T	cg06935464	chr4:38784597	TLR10	0.38	5.96	0.31	6.18e-9	Breast cancer;
LIHC	cis	rs7729447	0.566	rs3828589	chr5:32713327	T/C	cg16267343	chr5:32710456	NPR3	0.48	6.1	0.31	2.9e-9	Blood pressure;
LIHC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg05555928	chr11:63887634	MACROD1	0.51	6.64	0.34	1.24e-10	Mean platelet volume;
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.87	-15.07	-0.63	1.04e-39	Height;
LIHC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10792665	0.502	rs11233367	chr11:82610041	T/A	cg24227371	chr11:82718527	RAB30	-0.27	-6.2	-0.32	1.61e-9	Obesity-related traits;
LIHC	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg09795085	chr6:101329169	ASCC3	-0.53	-7.4	-0.37	1.03e-12	Neuroticism;
LIHC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg22676075	chr6:135203613	NA	0.38	6.14	0.31	2.33e-9	Red blood cell count;
LIHC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.9	10.79	0.5	1.52e-23	Primary sclerosing cholangitis;
LIHC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.62	-11.42	-0.53	8.1e-26	Height;
LIHC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.72	13.44	0.59	2.32e-33	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.46	0.46	5.03e-19	Hemoglobin concentration;
LIHC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.28	-17.31	-0.68	1.18e-48	Diabetic kidney disease;
LIHC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11031096	0.679	rs12292515	chr11:4206385	T/G	cg18678763	chr11:4115507	RRM1	-0.4	-5.86	-0.3	1.08e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.39	7.26	0.37	2.59e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg21734168	chr11:67353974	GSTP1	-0.27	-6.76	-0.34	6.08e-11	Mean corpuscular volume;
LIHC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.34	-8.67	-0.42	1.74e-16	Hip circumference;Waist circumference;
LIHC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-0.84	-9.02	-0.44	1.36e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs4788570	0.584	rs979790	chr16:71665985	A/T	cg06353428	chr16:71660113	MARVELD3	-1.28	-10.98	-0.51	3.07e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.65	7.72	0.39	1.28e-13	Heart rate;
LIHC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.57	9.62	0.46	1.47e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-7.65	-0.38	2.02e-13	Cognitive function;
LIHC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.04	0.31	3.94e-9	Bipolar disorder;
LIHC	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	7.71	0.38	1.41e-13	HDL cholesterol;
LIHC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.67	6.22	0.32	1.41e-9	Schizophrenia;
LIHC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.63	-12.44	-0.56	1.47e-29	Schizophrenia;
LIHC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.57	-8.16	-0.4	6.64e-15	Menarche (age at onset);
LIHC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.56	0.53	2.64e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.66	9.6	0.46	1.7e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg09003973	chr2:102972529	NA	0.86	6.26	0.32	1.17e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.36	7.07	0.36	8.65e-12	HDL cholesterol levels;
LIHC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.38	-5.89	-0.3	9.28e-9	Alcohol dependence;
LIHC	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.44	-8.84	-0.43	5.15e-17	LDL cholesterol levels;
LIHC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-13.52	-0.59	1.11e-33	Headache;
LIHC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.48	-7.26	-0.37	2.57e-12	Multiple sclerosis;
LIHC	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg13647721	chr17:30228624	UTP6	0.69	6.82	0.35	4.21e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	1.02	11.92	0.54	1.28e-27	Red blood cell traits;
LIHC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.09	-8.16	-0.4	6.35e-15	Body mass index;
LIHC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.07	15.83	0.65	9.81e-43	Cognitive function;
LIHC	trans	rs8099121	0.585	rs76565763	chr18:4986099	A/G	cg15792134	chr6:169051418	SMOC2	0.36	6.13	0.31	2.41e-9	Schizophrenia;
LIHC	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.82	-0.3	1.33e-8	Metabolite levels;
LIHC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg13319975	chr6:146136371	FBXO30	0.53	7.66	0.38	1.88e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	11.36	0.52	1.39e-25	Cognitive test performance;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21747090	chr2:27597821	SNX17	-0.42	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18642567	chr14:21755798	RPGRIP1	0.36	6.65	0.34	1.19e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.77	-13.39	-0.59	3.52e-33	Aortic root size;
LIHC	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg14146966	chr2:61757674	XPO1	0.46	8.02	0.4	1.67e-14	Tuberculosis;
LIHC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	7.19	0.36	3.99e-12	Menopause (age at onset);
LIHC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.48	-7.18	-0.36	4.41e-12	Psoriasis;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.58	-8.53	-0.42	4.84e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-6.47	-0.33	3.31e-10	Height;
LIHC	cis	rs11955398	0.716	rs12515025	chr5:59999437	G/A	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9378688	0.654	rs13217030	chr6:2248675	C/T	cg12303981	chr6:2244766	GMDS	-0.43	-5.77	-0.3	1.79e-8	Caudate nucleus volume;
LIHC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.86	12.54	0.56	6.38e-30	Diastolic blood pressure;
LIHC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.48	6.35	0.32	6.91e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17428076	0.836	rs3770455	chr2:172667895	C/T	cg13550731	chr2:172543902	DYNC1I2	0.37	6.06	0.31	3.54e-9	Myopia;
LIHC	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.8	-0.3	1.49e-8	Educational attainment (years of education);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06253862	chr6:160201362	SNORA20;TCP1	0.5	7.18	0.36	4.32e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg18887096	chr2:219472410	PLCD4	0.38	6.54	0.33	2.21e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.45	6.12	0.31	2.5e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg16586182	chr3:47516702	SCAP	-0.55	-9.99	-0.48	8.46e-21	Colorectal cancer;
LIHC	cis	rs10838687	0.736	rs2306353	chr11:47256708	C/T	cg25783544	chr11:47291846	MADD	0.46	5.77	0.3	1.73e-8	Proinsulin levels;
LIHC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.34	5.78	0.3	1.69e-8	Atrioventricular conduction;
LIHC	cis	rs10785877	0.717	rs7848602	chr9:137120763	T/C	cg21243944	chr9:137118148	NA	-0.44	-6.1	-0.31	2.87e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs10790268	1	rs10790268	chr11:118729391	A/G	cg19308663	chr11:118741387	NA	-0.46	-6.01	-0.31	4.8e-9	Rheumatoid arthritis;
LIHC	cis	rs10426930	0.752	rs56249413	chr19:5036730	G/A	cg18473234	chr19:5097819	KDM4B	0.58	6.56	0.33	2e-10	Monocyte percentage of white cells;
LIHC	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.54	6.4	0.33	5.03e-10	Mammographic density (dense area);
LIHC	cis	rs943466	0.614	rs4713677	chr6:33731225	C/G	cg25922239	chr6:33757077	LEMD2	-0.46	-7.67	-0.38	1.85e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg23682824	chr7:23144976	KLHL7	0.45	6.78	0.34	5.44e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05439608	chr7:156761192	NOM1	0.41	6.46	0.33	3.58e-10	Immature fraction of reticulocytes;
LIHC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.73	8.59	0.42	3.13e-16	Cognitive function;
LIHC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.2	0.41	4.78e-15	Lymphocyte counts;
LIHC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg24112000	chr20:60950667	NA	-0.59	-8.73	-0.43	1.14e-16	Colorectal cancer;
LIHC	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.61	-6.85	-0.35	3.55e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.39	0.52	1.05e-25	Cognitive test performance;
LIHC	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.28	5.86	0.3	1.11e-8	Pulmonary function;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg11070056	chr1:107600091	PRMT6	0.61	10.44	0.49	2.54e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg07817648	chr10:79422355	NA	-0.3	-6.19	-0.32	1.71e-9	Mortality in heart failure;
LIHC	trans	rs1432089	0.773	rs114562833	chr4:171784712	A/G	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.25	-5.84	-0.3	1.24e-8	Subjective well-being;
LIHC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-7.25	-0.36	2.81e-12	Monocyte percentage of white cells;
LIHC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.57	8.58	0.42	3.41e-16	HIV-1 control;
LIHC	cis	rs2637266	0.905	rs1907313	chr10:78338072	A/G	cg18941641	chr10:78392320	NA	0.28	5.92	0.3	7.79e-9	Pulmonary function;
LIHC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02985541	chr2:219472218	PLCD4	0.45	8.81	0.43	6.32e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-9.67	-0.46	1.05e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.07	0.36	8.54e-12	Morning vs. evening chronotype;
LIHC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.56	-7.6	-0.38	2.9e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg14758556	chr20:62440591	NA	0.42	6.7	0.34	8.54e-11	Atopic dermatitis;
LIHC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.07	-10.11	-0.48	3.28e-21	Hip circumference adjusted for BMI;
LIHC	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.58	7.15	0.36	5.43e-12	Breast cancer;
LIHC	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.15	-0.36	5.3e-12	Hepatocellular carcinoma;
LIHC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.44	6.37	0.33	5.99e-10	Platelet count;
LIHC	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.36	-6.04	-0.31	3.97e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	trans	rs60752752	0.852	rs3014880	chr1:153344374	C/G	cg14901121	chr8:98817630	LAPTM4B	-0.45	-6.65	-0.34	1.18e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.36	5.78	0.3	1.7e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg08539965	chr1:21396338	EIF4G3	0.34	6.15	0.32	2.22e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.52	7.56	0.38	3.77e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	1.02	10.26	0.48	1.08e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg09033563	chr22:24373618	LOC391322	-0.46	-6.51	-0.33	2.68e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.8	-0.3	1.48e-8	Red blood cell count;
LIHC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.8	12.26	0.55	6.83e-29	Corneal astigmatism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12830327	chr11:85339628	TMEM126B;DLG2	0.5	6.88	0.35	2.94e-11	Lung function (FEV1/FVC);
LIHC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	10.81	0.5	1.23e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs10792665	0.610	rs5006165	chr11:82557662	C/A	cg24227371	chr11:82718527	RAB30	-0.25	-5.81	-0.3	1.41e-8	Obesity-related traits;
LIHC	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08051602	chr17:1394674	MYO1C	-0.53	-6.36	-0.33	6.53e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05788437	chr3:197476880	FYTTD1;KIAA0226	0.65	8.74	0.43	1.09e-16	Lung function (FEV1/FVC);
LIHC	cis	rs526821	0.595	rs629948	chr11:55356448	G/A	cg04317927	chr11:55418816	OR4S2	0.47	8.98	0.44	1.86e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.04e-11	Alzheimer's disease;
LIHC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.41	0.41	1.1e-15	Resting heart rate;
LIHC	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg25588787	chr5:154027256	NA	0.38	5.73	0.3	2.17e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-5.83	-0.3	1.26e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg19302996	chr17:73780495	UNK	-0.47	-6.69	-0.34	9.23e-11	White matter hyperintensity burden;
LIHC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.83	13.74	0.6	1.67e-34	Breast cancer;
LIHC	cis	rs4148883	0.513	rs1154402	chr4:100009596	C/G	cg12011299	chr4:100065546	ADH4	0.33	6.46	0.33	3.69e-10	Alcohol dependence;
LIHC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg12365402	chr11:9010492	NRIP3	-0.32	-8.43	-0.41	9.61e-16	Hemoglobin concentration;
LIHC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg21724239	chr8:58056113	NA	0.42	5.71	0.3	2.39e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.92	-0.3	7.85e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	9.7	0.46	8.02e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs4407350	0.649	rs5764897	chr22:44930087	A/G	cg26276947	chr22:44892394	LDOC1L	0.34	5.86	0.3	1.08e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-1.01	-20.44	-0.74	3.16e-61	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg05896524	chr21:47604654	C21orf56	0.44	6.64	0.34	1.25e-10	Testicular germ cell tumor;
LIHC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.33	-8.32	-0.41	2.05e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg18016565	chr1:150552671	MCL1	0.5	9.51	0.46	3.62e-19	Tonsillectomy;
LIHC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02290350	chr8:58132656	NA	0.5	9.52	0.46	3.18e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg15448220	chr1:150897856	SETDB1	0.38	5.87	0.3	1.05e-8	Urate levels;
LIHC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-6.14	-0.32	2.24e-9	Colorectal cancer;
LIHC	cis	rs3762637	0.941	rs9810996	chr3:122074387	G/A	cg24169773	chr3:122142474	KPNA1	-0.49	-9.52	-0.46	3.18e-19	LDL cholesterol levels;
LIHC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg10820045	chr2:198174542	NA	0.56	8.87	0.43	3.99e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21933743	chr11:65367160	MAP3K11	0.41	6.87	0.35	2.99e-11	Pancreatic cancer;
LIHC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg03859395	chr2:55845619	SMEK2	0.91	15.47	0.64	2.62e-41	Metabolic syndrome;
LIHC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	9.15	0.44	5.43e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	6.46	0.33	3.66e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.35	6.43	0.33	4.22e-10	Platelet distribution width;
LIHC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-9.47	-0.46	4.75e-19	Asthma;
LIHC	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	0.72	8.17	0.4	6.16e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg00601450	chr5:74908170	NA	0.58	7.08	0.36	8.42e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.62	0.42	2.48e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.43	-6.02	-0.31	4.49e-9	QT interval;
LIHC	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg03934865	chr2:198174659	NA	-0.48	-6.97	-0.35	1.68e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.39	6.06	0.31	3.54e-9	Testicular germ cell tumor;
LIHC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.32	-8.08	-0.4	1.15e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg02290350	chr8:58132656	NA	0.41	8.7	0.43	1.43e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.48	-18.17	-0.7	4.09e-52	Breast cancer;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.56	9.46	0.46	5.21e-19	Calcium levels;
LIHC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.27	-6.07	-0.31	3.43e-9	Type 2 diabetes;
LIHC	cis	rs1000083	0.666	rs727316	chr5:96625157	A/C	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.8	-7.71	-0.38	1.41e-13	Diabetic retinopathy;
LIHC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg20933634	chr6:27740509	NA	0.45	6.01	0.31	4.67e-9	Parkinson's disease;
LIHC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.58	-0.38	3.36e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.51	5.86	0.3	1.08e-8	Alzheimer's disease;
LIHC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.98	-0.31	5.5e-9	Headache;
LIHC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.08	0.36	8.01e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15140822	chr8:33423979	RNF122	0.46	6.31	0.32	8.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	16.26	0.66	1.88e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.42	0.41	1.03e-15	Brugada syndrome;
LIHC	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.59	11.79	0.54	3.71e-27	Plateletcrit;Platelet count;
LIHC	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	cis	rs1000083	0.748	rs2113015	chr5:96619623	T/G	ch.5.96698337R	chr5:96672581	NA	0.96	7.3	0.37	2.09e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs4742903	0.935	rs10739885	chr9:106912892	G/A	cg14250997	chr9:106856677	SMC2	0.37	6.4	0.33	5.27e-10	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6815814	0.731	rs28532329	chr4:38771368	C/T	cg06935464	chr4:38784597	TLR10	0.38	5.96	0.31	6.18e-9	Breast cancer;
LIHC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg15832292	chr6:96025679	MANEA	0.67	8.61	0.42	2.67e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.5	-0.46	3.75e-19	Obesity-related traits;
LIHC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg25024717	chr12:54324583	NA	-0.38	-7.79	-0.39	8.17e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg05501817	chr11:14380813	RRAS2	-0.45	-6.3	-0.32	9.24e-10	Sense of smell;
LIHC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg09417038	chr21:47716443	C21orf57	-0.5	-7.36	-0.37	1.35e-12	Testicular germ cell tumor;
LIHC	cis	rs6546886	0.536	rs828868	chr2:74324504	A/G	cg19729930	chr2:74357872	NA	0.32	5.94	0.31	7.21e-9	Dialysis-related mortality;
LIHC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.59	6.94	0.35	1.92e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.88	-0.3	9.92e-9	Cognitive ability (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00329943	chr16:72127485	TXNL4B;DHX38	0.45	6.79	0.34	4.98e-11	Calcium levels;
LIHC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg16989086	chr20:62203971	PRIC285	0.57	8.12	0.4	8.31e-15	Glioblastoma;
LIHC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-15.0	-0.63	1.97e-39	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg25894440	chr7:65020034	NA	-0.52	-6.07	-0.31	3.44e-9	Diabetic kidney disease;
LIHC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg15448220	chr1:150897856	SETDB1	0.43	6.68	0.34	9.91e-11	Tonsillectomy;
LIHC	trans	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.92e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1434579	0.897	rs12977016	chr19:44942756	G/A	cg15540054	chr19:45004280	ZNF180	0.57	7.8	0.39	7.39e-14	Tuberculosis;
LIHC	cis	rs6815814	0.731	rs4504265	chr4:38773865	G/T	cg06935464	chr4:38784597	TLR10	0.38	5.96	0.31	6.18e-9	Breast cancer;
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.6	7.22	0.36	3.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.58	10.19	0.48	1.79e-21	Schizophrenia;
LIHC	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.54e-12	Corneal astigmatism;
LIHC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg09835421	chr16:68378352	PRMT7	-0.52	-5.98	-0.31	5.58e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.1e-34	Gastritis;
LIHC	cis	rs4788570	0.578	rs9934789	chr16:71662467	A/G	cg06353428	chr16:71660113	MARVELD3	1.4	13.97	0.6	2.15e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.41	-6.33	-0.32	7.48e-10	Cognitive function;
LIHC	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg14515779	chr1:101123966	NA	0.43	5.92	0.3	7.9e-9	Monocyte count;
LIHC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	9.99	0.48	8.36e-21	Platelet count;
LIHC	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg20991723	chr1:152506922	NA	0.59	10.48	0.49	1.85e-22	Hair morphology;
LIHC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.4e-11	Diabetic kidney disease;
LIHC	trans	rs12752401	0.764	rs72725348	chr1:103024349	G/A	cg24921808	chr19:740313	PALM	0.56	6.74	0.34	6.71e-11	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.57	-8.5	-0.42	5.99e-16	White matter hyperintensity burden;
LIHC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg20607798	chr8:58055168	NA	0.49	6.19	0.32	1.74e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.48	9.74	0.47	6.17e-20	Tonsillectomy;
LIHC	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.66	5.99	0.31	5.18e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg24296786	chr1:45957014	TESK2	0.49	7.37	0.37	1.26e-12	Platelet count;
LIHC	cis	rs1030268	0.859	rs11763958	chr7:133417163	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.36	-0.33	6.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.75	-0.39	1.06e-13	Obesity-related traits;
LIHC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg10978503	chr1:24200527	CNR2	0.38	9.1	0.44	7.34e-18	Immature fraction of reticulocytes;
LIHC	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.2	-0.36	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg21522988	chr12:29376872	FAR2	0.3	6.86	0.35	3.28e-11	QT interval;
LIHC	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg10820045	chr2:198174542	NA	-0.57	-9.61	-0.46	1.67e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg09417038	chr21:47716443	C21orf57	-0.58	-8.99	-0.44	1.71e-17	Testicular germ cell tumor;
LIHC	cis	rs1669338	0.588	rs4684375	chr3:3170966	T/C	cg16797762	chr3:3221439	CRBN	-0.98	-8.39	-0.41	1.27e-15	White matter integrity;
LIHC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.58	10.55	0.5	9.88e-23	Diastolic blood pressure;
LIHC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg14440974	chr22:39074834	NA	-0.45	-7.21	-0.36	3.67e-12	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg25894440	chr7:65020034	NA	-0.53	-6.04	-0.31	4.05e-9	Diabetic kidney disease;
LIHC	cis	rs55665837	0.701	rs1522633	chr11:14645238	A/T	cg19336497	chr11:14380999	RRAS2	-0.36	-6.07	-0.31	3.37e-9	Vitamin D levels;
LIHC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-5.81	-0.3	1.45e-8	Aortic root size;
LIHC	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.57	-6.4	-0.33	5.14e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs7619427	0.544	rs9821661	chr3:44031551	G/A	cg24966902	chr3:44043705	NA	0.53	8.23	0.41	4.07e-15	Schizophrenia;
LIHC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.95	-0.39	2.84e-14	Body mass index;
LIHC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.59	0.56	3.89e-30	Colorectal cancer;
LIHC	trans	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.57	-0.33	1.87e-10	Type 2 diabetes;
LIHC	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.85	0.39	5.54e-14	Educational attainment (years of education);
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.75	0.39	1.07e-13	Lymphocyte counts;
LIHC	cis	rs922107	0.967	rs6428555	chr1:90010388	A/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.83	-0.39	6.16e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.41	6.7	0.34	8.8e-11	Blood pressure (smoking interaction);
LIHC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.56	-0.53	2.52e-26	Coronary artery disease;
LIHC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.25	-0.45	2.4e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.94	17.57	0.69	1.01e-49	Menopause (age at onset);
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	7.11	0.36	7.02e-12	Height;
LIHC	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.44	-5.95	-0.31	6.77e-9	Height;
LIHC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg21724239	chr8:58056113	NA	0.49	6.42	0.33	4.65e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-9.69	-0.46	8.82e-20	Asthma;
LIHC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.85	-0.3	1.14e-8	IgG glycosylation;
LIHC	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.48	-8.39	-0.41	1.27e-15	Total body bone mineral density;
LIHC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.3	7.1	0.36	7.4e-12	Menarche (age at onset);
LIHC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.2	-0.45	3.62e-18	Obesity-related traits;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16436489	chr17:80757606	TBCD	0.44	6.75	0.34	6.23e-11	Longevity;
LIHC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.67	0.53	1.02e-26	Alzheimer's disease;
LIHC	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.82	12.62	0.56	3.13e-30	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg17764715	chr19:33622953	WDR88	0.41	5.75	0.3	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.95	-0.31	6.49e-9	Systemic lupus erythematosus;
LIHC	cis	rs7487075	0.619	rs7485580	chr12:46830374	A/C	cg23829395	chr12:46796953	NA	0.34	6.05	0.31	3.81e-9	Itch intensity from mosquito bite;
LIHC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.49	-12.54	-0.56	6.15e-30	Hip circumference adjusted for BMI;
LIHC	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg03934865	chr2:198174659	NA	0.48	6.87	0.35	3.09e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11212260	0.655	rs11212245	chr11:107319942	G/A	cg25435332	chr11:107328525	CWF19L2	0.82	8.41	0.41	1.13e-15	IgG glycosylation;
LIHC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.71	-13.07	-0.58	6.26e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	8.87	0.43	4.22e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.89	0.3	9.25e-9	Bipolar disorder;
LIHC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.41	7.61	0.38	2.77e-13	Testicular germ cell tumor;
LIHC	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.32	-7.53	-0.38	4.7e-13	Hip circumference;Waist circumference;
LIHC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg07424592	chr7:64974309	NA	-0.8	-9.26	-0.45	2.4e-18	Diabetic kidney disease;
LIHC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	6.66	0.34	1.1e-10	Hemoglobin concentration;
LIHC	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-10.93	-0.51	4.85e-24	Colorectal cancer;
LIHC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.04	-24.22	-0.79	3.42e-76	IgG glycosylation;
LIHC	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg14132834	chr19:41945861	ATP5SL	0.43	6.24	0.32	1.32e-9	Height;
LIHC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.52	8.46	0.42	7.96e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.89	0.3	9.14e-9	Platelet count;
LIHC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	12.26	0.55	7.08e-29	Schizophrenia;
LIHC	cis	rs922107	0.967	rs12752582	chr1:90019713	G/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.77	-0.39	9.19e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-11.65	-0.53	1.23e-26	Eye color traits;
LIHC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.64	8.14	0.4	7.45e-15	Gut microbiome composition (summer);
LIHC	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.77	0.69	1.69e-50	Gut microbiome composition (summer);
LIHC	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.38	-6.16	-0.32	2.06e-9	IgG glycosylation;
LIHC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.63	-7.92	-0.39	3.31e-14	Diastolic blood pressure;
LIHC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg05484376	chr2:27715224	FNDC4	0.38	6.44	0.33	4.06e-10	Menopause (age at onset);
LIHC	trans	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.88	-0.35	2.83e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg13770153	chr20:60521292	NA	-0.34	-6.72	-0.34	7.41e-11	Body mass index;
LIHC	cis	rs6586163	0.872	rs7914490	chr10:90747447	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.54	-7.82	-0.39	6.64e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.71	13.4	0.59	3.48e-33	Mean platelet volume;
LIHC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.9	-0.3	8.64e-9	Diisocyanate-induced asthma;
LIHC	trans	rs9914544	0.545	rs8066636	chr17:18761109	G/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Educational attainment (years of education);
LIHC	cis	rs77637988	0.578	rs6718068	chr2:48604978	C/T	cg15846641	chr2:48541264	FOXN2	0.57	7.69	0.38	1.6e-13	Joint mobility (Beighton score);
LIHC	cis	rs1914816	0.793	rs4636879	chr15:76630303	T/C	cg03037974	chr15:76606532	NA	0.5	5.78	0.3	1.66e-8	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.45	7.09	0.36	7.55e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg05110241	chr16:68378359	PRMT7	-0.58	-6.83	-0.35	3.97e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg02491457	chr7:128862824	NA	0.46	7.23	0.36	3.09e-12	White matter hyperintensity burden;
LIHC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.85	-10.96	-0.51	3.82e-24	Chronic sinus infection;
LIHC	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg24044564	chr13:99115944	STK24	0.39	5.79	0.3	1.58e-8	Obesity-related traits;
LIHC	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-7.26	-0.37	2.64e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg19773385	chr1:10388646	KIF1B	-0.47	-8.1	-0.4	9.87e-15	Hepatocellular carcinoma;
LIHC	cis	rs146817970	1	rs146817970	chr5:81512947	TA/T	cg15871215	chr5:81402204	ATG10	-0.6	-5.9	-0.3	8.6e-9	Breast cancer;
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.72	12.51	0.56	8.03e-30	Prudent dietary pattern;
LIHC	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg25364880	chr3:44379878	C3orf23	0.55	7.44	0.37	7.99e-13	Depressive symptoms;
LIHC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg21466736	chr12:48725269	NA	0.63	9.14	0.44	5.64e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs6750047	0.546	rs10192788	chr2:38272672	C/T	cg07380506	chr2:38303506	CYP1B1	0.61	7.89	0.39	4.19e-14	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.83	-0.3	1.29e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg14092571	chr14:90743983	NA	0.41	5.73	0.3	2.25e-8	Mortality in heart failure;
LIHC	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.48	9.05	0.44	1.12e-17	Testicular germ cell tumor;
LIHC	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.55	6.27	0.32	1.07e-9	Ulcerative colitis;
LIHC	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.63	10.43	0.49	2.67e-22	Glycated hemoglobin levels;
LIHC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.38	-6.25	-0.32	1.23e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.14	0.31	2.35e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg25019722	chr6:37503610	NA	-0.37	-6.33	-0.32	7.75e-10	Cognitive performance;
LIHC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.45	7.68	0.38	1.69e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7707921	0.881	rs17243791	chr5:81322547	A/G	cg15871215	chr5:81402204	ATG10	-0.64	-6.37	-0.33	5.99e-10	Breast cancer;
LIHC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg14779329	chr11:130786720	SNX19	0.42	6.34	0.32	7.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.73	-0.34	7.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.25	0.37	2.79e-12	Response to antipsychotic treatment;
LIHC	cis	rs4908768	0.906	rs751790	chr1:8529141	C/T	cg20416874	chr1:8611966	RERE	-0.54	-7.38	-0.37	1.22e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.4	6.32	0.32	8.03e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Coronary artery disease;
LIHC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21467203	chr3:49911342	NA	-0.45	-8.11	-0.4	9.32e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.76	-9.53	-0.46	2.92e-19	Mean platelet volume;
LIHC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.49	7.82	0.39	6.7e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.66	9.69	0.46	9.09e-20	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.47	7.76	0.39	9.96e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21448741	chr8:58168803	NA	0.36	6.62	0.34	1.38e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg02189925	chr1:205091232	RBBP5	-0.42	-6.27	-0.32	1.11e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.87	11.23	0.52	3.88e-25	Coronary artery disease;
LIHC	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg10241871	chr14:102965420	TECPR2	0.44	6.66	0.34	1.08e-10	Plateletcrit;
LIHC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.69	12.44	0.56	1.41e-29	Iron status biomarkers;
LIHC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg06804625	chr1:109812012	CELSR2	-0.38	-5.77	-0.3	1.81e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs3764618	1.000	rs16981031	chr19:49497453	A/C	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.71	-5.81	-0.3	1.41e-8	Follicule stimulating hormone;
LIHC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.81	12.02	0.55	5.2e-28	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.73	10.28	0.49	8.78e-22	Menarche (age at onset);
LIHC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.78	-0.34	5.41e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17507749	chr15:85114479	UBE2QP1	0.62	7.05	0.36	1.02e-11	Schizophrenia;
LIHC	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.31	5.77	0.3	1.82e-8	Body mass index;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06357940	chr3:58416685	PDHB	0.33	6.09	0.31	3.02e-9	Longevity;
LIHC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.79e-14	Parkinson's disease;
LIHC	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.57	10.94	0.51	4.3e-24	Coronary artery disease;
LIHC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg21734168	chr11:67353974	GSTP1	-0.28	-6.78	-0.34	5.17e-11	Mean corpuscular volume;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10593459	chr1:44447478	B4GALT2	0.46	7.0	0.35	1.39e-11	Longevity;
LIHC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6024905	0.722	rs2275954	chr20:36962667	C/T	cg07053727	chr20:36965646	BPI	-0.49	-8.56	-0.42	3.85e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.47	7.93	0.39	3.22e-14	Response to temozolomide;
LIHC	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg04306507	chr14:55594613	LGALS3	0.32	5.98	0.31	5.52e-9	Protein biomarker;
LIHC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.79	-10.09	-0.48	4e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.59	8.98	0.44	1.81e-17	Tumor biomarkers;
LIHC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.45	-6.91	-0.35	2.33e-11	Height;
LIHC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.38	5.82	0.3	1.39e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.47	-0.62	2.31e-37	Longevity;
LIHC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.45	-7.59	-0.38	3e-13	Educational attainment;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg07133347	chr1:107600762	PRMT6	-0.42	-6.24	-0.32	1.26e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg23461800	chr14:103021989	NA	-0.54	-7.51	-0.38	5.19e-13	Platelet count;
LIHC	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.84	-0.3	1.19e-8	Coronary artery disease;
LIHC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.92	-0.35	2.25e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-9.73	-0.47	6.71e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.85	17.39	0.68	5.72e-49	Longevity;
LIHC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	16.59	0.67	8.93e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6449957	0.832	rs960383	chr5:67450986	A/G	cg23036683	chr5:67512108	NA	0.43	6.14	0.31	2.34e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg18306943	chr3:40428807	ENTPD3	0.34	5.92	0.3	7.9e-9	Renal cell carcinoma;
LIHC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg12863693	chr15:85201151	NMB	0.44	6.26	0.32	1.13e-9	Schizophrenia;
LIHC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02290350	chr8:58132656	NA	0.41	8.59	0.42	3.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.48	0.42	6.75e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21496518	chr3:15374154	SH3BP5	0.38	6.21	0.32	1.57e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg16736954	chr20:23401023	NAPB	0.71	8.21	0.41	4.5e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8084351	0.599	rs12967822	chr18:50676348	C/G	cg24270629	chr18:50823537	DCC	-0.45	-6.66	-0.34	1.1e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26734620	chr12:56694298	CS	-0.93	-9.37	-0.45	1.05e-18	Psoriasis vulgaris;
LIHC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.44	-7.17	-0.36	4.57e-12	Menarche (age at onset);
LIHC	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.41	-6.79	-0.34	4.88e-11	Facial morphology (factor 20);
LIHC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs965469	1.000	rs6051790	chr20:3342994	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.57	-0.33	1.89e-10	IFN-related cytopenia;
LIHC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.37	0.52	1.28e-25	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.01e-30	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg07424592	chr7:64974309	NA	0.74	8.34	0.41	1.84e-15	Diabetic kidney disease;
LIHC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.57	-8.69	-0.43	1.52e-16	Corneal astigmatism;
LIHC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.44	5.94	0.31	6.83e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.67	-11.27	-0.52	2.79e-25	Childhood ear infection;
LIHC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg16822855	chr3:40428330	ENTPD3	0.32	5.89	0.3	9.15e-9	Renal cell carcinoma;
LIHC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.0	0.4	1.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.05	-0.4	1.43e-14	Type 2 diabetes;
LIHC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.3	8.53e-9	Obesity (extreme);
LIHC	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.78	-12.92	-0.57	2.33e-31	Coronary artery disease;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.97	0.35	1.65e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-6.04	-0.31	4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3746446	0.678	rs6120777	chr20:33560172	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	7.06	0.36	9.42e-12	Congenital left-sided heart lesions;
LIHC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg25179470	chr10:102756915	LZTS2	0.44	6.16	0.32	2.03e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.75	-8.52	-0.42	5.3e-16	Height;
LIHC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.66e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.58	9.27	0.45	2.11e-18	Lymphocyte counts;
LIHC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg01320579	chr17:75405842	SEPT9	0.53	7.56	0.38	3.74e-13	Airflow obstruction;
LIHC	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.47	8.92	0.43	2.88e-17	Testicular germ cell tumor;
LIHC	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.42	8.22	0.41	4.19e-15	Testicular germ cell tumor;
LIHC	cis	rs75908454	1.000	rs78348261	chr6:169831423	C/T	cg19338460	chr6:170058176	WDR27	-0.86	-7.77	-0.39	9.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg01557791	chr16:72042693	DHODH	0.4	6.7	0.34	8.61e-11	Fibrinogen levels;
LIHC	cis	rs17776563	0.887	rs12148467	chr15:89128870	G/A	cg05013243	chr15:89149849	MIR1179	0.41	6.79	0.34	4.84e-11	Thyroid hormone levels;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg16060761	chr17:80687452	NA	-0.48	-7.26	-0.37	2.6e-12	Glycated hemoglobin levels;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.73	0.34	7.35e-11	Renal cell carcinoma;
LIHC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg24955955	chr5:415729	AHRR	0.58	10.93	0.51	4.92e-24	Fat distribution (HIV);
LIHC	trans	rs10411161	0.721	rs1433082	chr19:52390726	A/C	cg22319618	chr22:45562946	NUP50	0.56	7.84	0.39	5.66e-14	Breast cancer;
LIHC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.73	9.24	0.45	2.62e-18	Body mass index;
LIHC	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.41	-6.62	-0.34	1.43e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.63	11.07	0.51	1.56e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.44	-7.63	-0.38	2.3e-13	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg07424592	chr7:64974309	NA	0.81	9.45	0.45	5.58e-19	Diabetic kidney disease;
LIHC	cis	rs7078219	0.505	rs7077040	chr10:101281014	C/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.19	-0.32	1.77e-9	Dental caries;
LIHC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg13047869	chr3:10149882	C3orf24	0.49	6.0	0.31	4.96e-9	Alzheimer's disease;
LIHC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.42	7.46	0.37	7.09e-13	IgG glycosylation;
LIHC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.52	7.72	0.39	1.32e-13	Height;
LIHC	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.76	-0.3	1.85e-8	Subjective well-being;
LIHC	cis	rs77633900	0.772	rs2460161	chr15:76640430	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-5.89	-0.3	9.09e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.38e-12	Bipolar disorder;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.32	-5.72	-0.3	2.38e-8	Lymphocyte counts;
LIHC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg05110241	chr16:68378359	PRMT7	-0.92	-10.44	-0.49	2.49e-22	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09782746	chr12:132553998	EP400	0.41	6.09	0.31	3.11e-9	Pancreatic cancer;
LIHC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.06	-0.36	9.46e-12	Monocyte percentage of white cells;
LIHC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg05941027	chr17:61774174	LIMD2	0.38	7.73	0.39	1.24e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.35	-6.3	-0.32	8.97e-10	IgG glycosylation;
LIHC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.44	-7.16	-0.36	4.97e-12	Menarche (age at onset);
LIHC	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.47	-7.35	-0.37	1.44e-12	Superior crus of antihelix expression;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22827060	chr13:30424359	UBL3	-0.44	-6.21	-0.32	1.54e-9	Pancreatic cancer;
LIHC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg03037974	chr15:76606532	NA	-0.6	-10.01	-0.48	7.34e-21	Blood metabolite levels;
LIHC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	6.75	0.34	6.3e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg19635926	chr16:89946313	TCF25	0.51	7.1	0.36	7.25e-12	Skin colour saturation;
LIHC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02711726	chr17:80685570	FN3KRP	-0.43	-7.83	-0.39	6.24e-14	Glycated hemoglobin levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16797244	chr6:12013002	HIVEP1	0.4	6.21	0.32	1.51e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.0	0.6	1.63e-35	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.8	15.1	0.63	8.15e-40	IgG glycosylation;
LIHC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.68	-13.32	-0.58	6.69e-33	Total body bone mineral density;
LIHC	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.48	7.1	0.36	7.37e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7739232	0.920	rs77374381	chr6:53530662	A/G	cg00536792	chr6:53530503	KLHL31	-0.96	-6.93	-0.35	2.11e-11	Hip circumference adjusted for BMI;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.15.91235825F	chr15:93434821	NA	-0.34	-6.22	-0.32	1.44e-9	Cognitive function;
LIHC	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.59	6.32	0.32	8.24e-10	Schizophrenia;
LIHC	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.73	-11.18	-0.52	6.11e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.14	-0.44	5.47e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs981946	0.544	rs12204759	chr6:3352636	G/A	cg18842474	chr6:3356384	SLC22A23	0.36	5.73	0.3	2.23e-8	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
LIHC	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.96	-0.31	6.22e-9	Tuberculosis;
LIHC	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg20636351	chr8:55087400	NA	-0.38	-7.73	-0.39	1.2e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4700695	0.764	rs251593	chr5:65313889	G/A	cg21114390	chr5:65439923	SFRS12	0.45	5.8	0.3	1.48e-8	Facial morphology (factor 19);
LIHC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.52	9.02	0.44	1.36e-17	Alcohol dependence;
LIHC	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-0.9	-10.9	-0.51	5.93e-24	Mitochondrial DNA levels;
LIHC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.42	6.82	0.35	4.14e-11	Red blood cell count;
LIHC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.36	6.95	0.35	1.85e-11	HDL cholesterol levels;
LIHC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg26441486	chr22:50317300	CRELD2	0.37	6.35	0.32	7.05e-10	Schizophrenia;
LIHC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-7.86	-0.39	5.01e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.46	5.78	0.3	1.64e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13487185	chr1:29213677	EPB41	-0.44	-6.08	-0.31	3.2e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.72	0.39	1.32e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.94	-0.39	2.85e-14	Body mass index;
LIHC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.33	-7.78	-0.39	8.49e-14	Longevity;Endometriosis;
LIHC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg27147174	chr7:100797783	AP1S1	0.45	6.44	0.33	4.01e-10	Life satisfaction;
LIHC	cis	rs4908768	0.906	rs7539382	chr1:8579301	C/T	cg20416874	chr1:8611966	RERE	0.56	8.65	0.42	1.99e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg20991723	chr1:152506922	NA	0.53	8.76	0.43	9.49e-17	Hair morphology;
LIHC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.36	8.55	0.42	4.08e-16	Immature fraction of reticulocytes;
LIHC	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.6	11.85	0.54	2.27e-27	Plateletcrit;Platelet count;
LIHC	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.49	0.59	1.44e-33	Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.7	0.6	2.43e-34	Prudent dietary pattern;
LIHC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.94	17.82	0.69	1.05e-50	Menopause (age at onset);
LIHC	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.61	8.38	0.41	1.39e-15	Sudden cardiac arrest;
LIHC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.97	0.31	6.09e-9	Mean platelet volume;
LIHC	cis	rs600806	0.888	rs638542	chr1:109845252	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.56	-6.59	-0.34	1.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.51	7.96	0.4	2.49e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg19894588	chr14:64061835	NA	-0.61	-7.78	-0.39	8.85e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.55	7.25	0.36	2.82e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.29	17.34	0.68	9.06e-49	Diabetic kidney disease;
LIHC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg16576597	chr16:28551801	NUPR1	0.37	6.1	0.31	2.86e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs35150201	0.529	rs7806221	chr7:135318779	T/C	cg23117316	chr7:135346802	PL-5283	-0.36	-6.43	-0.33	4.32e-10	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LIHC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg02290350	chr8:58132656	NA	0.29	6.84	0.35	3.75e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7106204	0.514	rs2083753	chr11:24255896	A/G	ch.11.24196551F	chr11:24239977	NA	0.83	12.03	0.55	5.01e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg23743573	chr11:89867420	NAALAD2	0.38	6.01	0.31	4.78e-9	White blood cell types;
LIHC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg17724175	chr1:150552817	MCL1	0.41	7.88	0.39	4.53e-14	Melanoma;
LIHC	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.79	-14.9	-0.63	4.73e-39	Longevity;
LIHC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.8	-6.45	-0.33	3.93e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	trans	rs6467710	0.590	rs834441	chr7:137258446	T/C	cg04467748	chr15:79760772	KIAA1024	0.42	7.1	0.36	7.42e-12	AIDS progression;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06420487	chr17:61919686	SMARCD2	0.42	5.76	0.3	1.88e-8	Height;
LIHC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg08499158	chr17:42289980	UBTF	0.52	8.77	0.43	8.74e-17	Total body bone mineral density;
LIHC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg19645103	chr12:69753606	YEATS4	-0.4	-5.92	-0.3	7.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.74	13.22	0.58	1.66e-32	Prudent dietary pattern;
LIHC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.59	0.34	1.71e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs847649	1.000	rs1100046	chr7:102549295	T/A	cg18108683	chr7:102477205	FBXL13	-0.49	-7.43	-0.37	8.6e-13	Morning vs. evening chronotype;
LIHC	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.94	-0.31	7.1e-9	Metabolite levels;
LIHC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.37	-5.82	-0.3	1.36e-8	Bipolar disorder;
LIHC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.83	-0.51	1.06e-23	Hemoglobin concentration;
LIHC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.94	-22.16	-0.77	4.43e-68	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-12.49	-0.56	9.37e-30	Alzheimer's disease (late onset);
LIHC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.33	7.38	0.37	1.23e-12	Ulcerative colitis;
LIHC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.04	-0.36	1.08e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg18944383	chr4:111397179	ENPEP	0.32	7.57	0.38	3.55e-13	Coronary artery disease;
LIHC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.17	12.88	0.57	3.18e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23043544	chr7:2124092	MAD1L1	-0.38	-5.99	-0.31	5.21e-9	Bipolar disorder;
LIHC	cis	rs17428076	0.874	rs12614709	chr2:172680872	C/G	cg13550731	chr2:172543902	DYNC1I2	0.38	6.23	0.32	1.4e-9	Myopia;
LIHC	cis	rs7224685	0.569	rs12942513	chr17:4016721	C/A	cg11204139	chr17:3907470	NA	0.57	6.51	0.33	2.71e-10	Type 2 diabetes;
LIHC	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.48	7.25	0.37	2.74e-12	Diastolic blood pressure;
LIHC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg23461800	chr14:103021989	NA	-0.47	-6.65	-0.34	1.15e-10	Platelet count;
LIHC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02290350	chr8:58132656	NA	0.47	9.27	0.45	2.1e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.7	-10.73	-0.5	2.42e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg03517284	chr6:25882590	NA	-0.38	-5.72	-0.3	2.27e-8	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05654049	chr3:23852499	UBE2E1	-0.47	-6.72	-0.34	7.59e-11	Cognitive function;
LIHC	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.51	-9.36	-0.45	1.09e-18	Schizophrenia;
LIHC	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.77	-9.64	-0.46	1.26e-19	Type 2 diabetes;
LIHC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.67	10.4	0.49	3.48e-22	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.02	-0.44	1.42e-17	Bipolar disorder;
LIHC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.77	-9.44	-0.45	6.02e-19	Gut microbiome composition (summer);
LIHC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-14.14	-0.61	4.49e-36	Ulcerative colitis;
LIHC	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs13113518	1.000	rs13132420	chr4:56392813	A/G	cg15358633	chr12:38710606	ALG10B	-0.42	-6.11	-0.31	2.73e-9	Height;
LIHC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.61	-9.64	-0.46	1.34e-19	Obesity-related traits;
LIHC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg20933634	chr6:27740509	NA	0.49	6.26	0.32	1.18e-9	Parkinson's disease;
LIHC	cis	rs963731	0.649	rs2888585	chr2:39246683	C/T	cg04010122	chr2:39346883	SOS1	-0.7	-6.08	-0.31	3.14e-9	Corticobasal degeneration;
LIHC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.53	7.99	0.4	2.04e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs471756	0.554	rs2484967	chr9:221874	C/T	cg14500300	chr9:211689	NA	0.25	5.91	0.3	8.32e-9	Mean platelet volume;
LIHC	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.3	5.72	0.3	2.3e-8	Red blood cell count;
LIHC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs6977660	0.941	rs5017197	chr7:19819967	T/A	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.35	-8.62	-0.42	2.47e-16	Cutaneous nevi;
LIHC	trans	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.52	0.49	1.28e-22	Total body bone mineral density;
LIHC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-6.32	-0.32	8.2e-10	Cognitive test performance;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg11766577	chr21:47581405	C21orf56	-0.44	-7.09	-0.36	7.81e-12	Testicular germ cell tumor;
LIHC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.47	6.85	0.35	3.43e-11	Aortic root size;
LIHC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.9	-0.43	3.31e-17	Atrioventricular conduction;
LIHC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg16989086	chr20:62203971	PRIC285	0.53	7.62	0.38	2.47e-13	Glioblastoma;
LIHC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.94	-0.54	1.07e-27	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.5	0.53	4.42e-26	Motion sickness;
LIHC	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg16583315	chr14:65563665	MAX	-0.4	-8.17	-0.4	6.11e-15	Obesity-related traits;
LIHC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.22	-5.74	-0.3	2.09e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.85	15.57	0.64	1.05e-41	Multiple myeloma (IgH translocation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08541880	chr3:137833983	DZIP1L	-0.44	-6.45	-0.33	3.89e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.46	8.09	0.4	1.04e-14	IgG glycosylation;
LIHC	cis	rs1008898	0.793	rs10257835	chr7:7234587	A/C	cg19603390	chr7:7222222	C1GALT1	-0.47	-6.36	-0.33	6.62e-10	Coronary artery disease;
LIHC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.49	-7.61	-0.38	2.62e-13	Breast size;
LIHC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.26	-0.32	1.13e-9	Arsenic metabolism;
LIHC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	0.82	5.83	0.3	1.31e-8	Height;
LIHC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.61	6.99	0.35	1.44e-11	Axial length;
LIHC	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg09238746	chr17:78121135	EIF4A3	-0.64	-10.51	-0.49	1.45e-22	Yeast infection;
LIHC	trans	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04565464	chr8:145669602	NFKBIL2	0.42	7.0	0.35	1.33e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg20607798	chr8:58055168	NA	0.69	7.73	0.39	1.25e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.86	12.99	0.57	1.26e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.71	-0.46	7.52e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.91	8.21	0.41	4.74e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.09	0.44	8.21e-18	Platelet count;
LIHC	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.77	11.69	0.53	8.4e-27	Corneal astigmatism;
LIHC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.29	-0.41	2.58e-15	Gut microbiome composition (summer);
LIHC	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.67	6.99	0.35	1.48e-11	Homocysteine levels;
LIHC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.98	16.61	0.67	7.54e-46	Cognitive ability;
LIHC	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg26138937	chr11:71823887	C11orf51	-1.34	-10.79	-0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg13175981	chr1:150552382	MCL1	-0.43	-6.19	-0.32	1.72e-9	Tonsillectomy;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10150615	chr22:24372951	LOC391322	0.43	6.3	0.32	8.92e-10	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.54	5.81	0.3	1.4e-8	Alzheimer's disease;
LIHC	cis	rs3818285	1.000	rs3818285	chr10:111635212	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-6.02	-0.31	4.44e-9	Superior crus of antihelix expression;
LIHC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.41	6.31	0.32	8.62e-10	Educational attainment;
LIHC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-8.89	-0.43	3.58e-17	Schizophrenia;
LIHC	cis	rs903552	1.000	rs12915569	chr15:102001883	G/A	cg06707286	chr15:102010195	PCSK6	-0.42	-5.97	-0.31	6.1e-9	Diabetic kidney disease;
LIHC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.15	-0.52	8.04e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.61	9.95	0.47	1.16e-20	Resting heart rate;
LIHC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs4700695	0.841	rs27569	chr5:65373419	C/T	cg21114390	chr5:65439923	SFRS12	-0.5	-6.83	-0.35	3.91e-11	Facial morphology (factor 19);
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18110333	chr6:292329	DUSP22	-0.53	-6.9	-0.35	2.51e-11	Menopause (age at onset);
LIHC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg00750074	chr16:89608354	SPG7	-0.38	-5.79	-0.3	1.59e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.91	0.35	2.34e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2108622	0.727	rs77780918	chr19:15982707	T/C	cg13772218	chr19:15982569	NA	0.37	7.78	0.39	8.7e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs6934970	1.000	rs12198343	chr6:113057679	T/C	cg09308777	chr6:169852575	NA	0.58	6.06	0.31	3.67e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.77	0.43	8.84e-17	Prudent dietary pattern;
LIHC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.48	-7.85	-0.39	5.32e-14	Menarche (age at onset);
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.63	0.62	5.37e-38	Prudent dietary pattern;
LIHC	cis	rs4919087	0.590	rs78376466	chr10:99034835	G/A	cg25902810	chr10:99078978	FRAT1	-0.61	-6.72	-0.34	7.57e-11	Monocyte count;
LIHC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.78	0.34	5.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.63	0.38	2.39e-13	Bipolar disorder;
LIHC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	7.94	0.39	2.93e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00986762	chr1:36107072	PSMB2	0.4	6.25	0.32	1.2e-9	Metabolic traits;
LIHC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg06212747	chr3:49208901	KLHDC8B	0.47	6.12	0.31	2.51e-9	Resting heart rate;
LIHC	trans	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.5	0.33	2.88e-10	Endometrial cancer;
LIHC	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.86	19.94	0.73	3e-59	Gestational age at birth (maternal effect);
LIHC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.96	-0.35	1.75e-11	Personality dimensions;
LIHC	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.6	-8.77	-0.43	8.27e-17	Testicular germ cell tumor;
LIHC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	0.81	6.21	0.32	1.5e-9	Plateletcrit;
LIHC	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs735860	0.763	rs1429146	chr6:53130285	C/T	cg10236188	chr6:53219634	NA	-0.42	-7.73	-0.39	1.19e-13	Glaucoma;
LIHC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.0	15.51	0.64	1.82e-41	Breast cancer;
LIHC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg24296786	chr1:45957014	TESK2	0.4	5.88	0.3	9.86e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.25	0.52	3.32e-25	Coronary artery disease;
LIHC	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.54	6.07	0.31	3.34e-9	Height;
LIHC	cis	rs8081395	0.741	rs180532	chr17:58003297	A/G	cg13753209	chr17:57696993	CLTC	0.39	5.95	0.31	6.59e-9	White blood cell count;
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg20090690	chr10:134436459	INPP5A	0.42	5.72	0.3	2.27e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9596837	0.514	rs7320587	chr13:54201004	G/T	ch.13.53330881F	chr13:54432880	NA	0.36	6.46	0.33	3.61e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25198656	chr7:5013641	RNF216L	-0.37	-6.08	-0.31	3.18e-9	Pancreatic cancer;
LIHC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.63	0.34	1.27e-10	Bipolar disorder;
LIHC	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06360820	chr2:242988706	NA	-0.8	-11.89	-0.54	1.58e-27	Obesity-related traits;
LIHC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg14779329	chr11:130786720	SNX19	0.4	6.03	0.31	4.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg17888390	chr10:101282816	NA	-0.29	-5.71	-0.3	2.44e-8	Dental caries;
LIHC	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.77	11.13	0.52	9.13e-25	Obesity-related traits;
LIHC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.33	5.84	0.3	1.22e-8	Pancreatic cancer;
LIHC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg07451762	chr16:28383216	NA	0.33	6.15	0.32	2.12e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.63	-0.42	2.41e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs17106184	1.000	rs2095864	chr1:51299597	A/G	cg07174182	chr1:51127561	FAF1	0.58	6.43	0.33	4.18e-10	Type 2 diabetes;
LIHC	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	1.04	14.38	0.61	5.16e-37	Mosquito bite size;
LIHC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.21	-20.29	-0.74	1.16e-60	Primary sclerosing cholangitis;
LIHC	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.54	-0.38	4.19e-13	QT interval;
LIHC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.43	-6.45	-0.33	3.92e-10	Systemic sclerosis;
LIHC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg22079354	chr11:130786696	SNX19	0.43	5.92	0.3	7.82e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-8.31	-0.41	2.3e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.58	8.26	0.41	3.31e-15	HIV-1 control;
LIHC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg06026331	chr20:60912101	LAMA5	0.41	5.98	0.31	5.65e-9	Colorectal cancer;
LIHC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.83	13.53	0.59	1.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4671400	0.543	rs2290324	chr2:61448776	A/C	cg14146966	chr2:61757674	XPO1	-0.37	-5.78	-0.3	1.66e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg24391279	chr8:1708526	NA	0.37	6.56	0.33	1.94e-10	Systolic blood pressure;
LIHC	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg00012203	chr2:219082015	ARPC2	0.91	15.08	0.63	9.78e-40	Colorectal cancer;
LIHC	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	10.58	0.5	8.35e-23	HIV-1 control;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03601098	chr7:127228532	ARF5	-0.48	-6.56	-0.33	2.02e-10	Systolic blood pressure;
LIHC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-8.9	-0.43	3.35e-17	Chronic sinus infection;
LIHC	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg14146966	chr2:61757674	XPO1	0.46	7.91	0.39	3.54e-14	Tuberculosis;
LIHC	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.17	-9.72	-0.47	7.12e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs72772090	0.710	rs56122780	chr5:96059895	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.2	-0.36	3.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.89	0.43	3.61e-17	Menarche (age at onset);
LIHC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	1.18	14.34	0.61	7.88e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.78	-0.34	5.27e-11	Coronary artery disease;
LIHC	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	5.79	0.3	1.57e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.45	0.49	2.26e-22	Coffee consumption (cups per day);
LIHC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.65	-8.23	-0.41	4.09e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.72	0.3	2.34e-8	Superior frontal gyrus grey matter volume;
LIHC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.71	11.57	0.53	2.29e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02034447	chr16:89574710	SPG7	0.5	7.57	0.38	3.53e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs2540917	0.765	rs243078	chr2:60615303	A/G	cg00543073	chr2:60773386	BCL11A	-0.32	-6.31	-0.32	8.48e-10	Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02983885	chr19:42772892	NA	0.48	6.64	0.34	1.26e-10	Pancreatic cancer;
LIHC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.66	11.82	0.54	3e-27	High light scatter reticulocyte count;
LIHC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg15103426	chr22:29168792	CCDC117	-0.56	-8.87	-0.43	4.19e-17	Lymphocyte counts;
LIHC	cis	rs7635838	0.859	rs6779840	chr3:11425423	A/G	cg00170343	chr3:11313890	ATG7	0.45	7.11	0.36	6.61e-12	HDL cholesterol;
LIHC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.94	-0.39	2.91e-14	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs8067354	0.872	rs2645483	chr17:57848184	T/G	cg02344993	chr17:57696989	CLTC	0.53	8.46	0.42	7.98e-16	Hemoglobin concentration;
LIHC	cis	rs2242420	0.920	rs12090311	chr1:21960194	G/T	cg18150885	chr1:21978612	RAP1GAP	-0.48	-5.86	-0.3	1.09e-8	Hematological and biochemical traits;
LIHC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.48	6.26	0.32	1.15e-9	Parkinson's disease;
LIHC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.04	0.55	4.52e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24707616	chr17:16342815	NCRNA00188;SNORD49B;SNORD49A	0.46	6.47	0.33	3.31e-10	Pancreatic cancer;
LIHC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg12463550	chr7:65579703	CRCP	0.73	7.15	0.36	5.34e-12	Diabetic kidney disease;
LIHC	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.43	6.45	0.33	3.91e-10	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs3015497	0.603	rs3015455	chr14:51062162	G/A	cg15834202	chr5:58865918	PDE4D	0.44	6.07	0.31	3.39e-9	Mean platelet volume;
LIHC	cis	rs11229555	0.574	rs66573492	chr11:58183797	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-7.91	-0.39	3.5e-14	Gut microbiome composition (summer);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01272081	chr9:32551527	TOPORS	0.46	6.62	0.34	1.41e-10	Cognitive function;
LIHC	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg09035930	chr12:129282057	SLC15A4	-0.49	-5.86	-0.3	1.12e-8	Systemic lupus erythematosus;
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.75	11.78	0.54	3.99e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-6.49	-0.33	3.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.39	7.79	0.39	8.31e-14	Renal cell carcinoma;
LIHC	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.46	-0.33	3.51e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.06	0.55	3.63e-28	Prudent dietary pattern;
LIHC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.46	-7.23	-0.36	3.1e-12	Multiple myeloma;
LIHC	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.19	-0.32	1.68e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs77637988	0.578	rs11689645	chr2:48608559	G/C	cg00032884	chr2:48540671	FOXN2	0.38	5.84	0.3	1.19e-8	Joint mobility (Beighton score);
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-0.63	-9.15	-0.44	5.24e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs507080	0.883	rs693306	chr11:118558333	A/G	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg16032384	chr1:17766173	RCC2	-0.39	-6.08	-0.31	3.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.57	-8.15	-0.4	6.83e-15	Body mass index;
LIHC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.9	-18.4	-0.71	4.84e-53	Height;
LIHC	cis	rs6938574	0.672	rs6569520	chr6:128365034	C/G	cg11798873	chr6:128799726	PTPRK	-0.47	-6.08	-0.31	3.18e-9	Menarche (age at onset);
LIHC	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.0	0.4	1.9e-14	Lung cancer;
LIHC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-11.29	-0.52	2.46e-25	Mean corpuscular volume;
LIHC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.45	-8.45	-0.42	8.69e-16	Platelet distribution width;
LIHC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.58e-32	Colorectal cancer;
LIHC	cis	rs10508774	1.000	rs72782237	chr10:32936671	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08805160	chr11:8704501	RPL27A;SNORA3	0.49	6.38	0.33	5.63e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.56	-8.79	-0.43	7.45e-17	Menarche (age at onset);
LIHC	cis	rs244293	0.931	rs244354	chr17:53194142	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.2e-13	Menarche (age at onset);
LIHC	cis	rs2412488	1.000	rs3765158	chr4:54327584	A/G	cg22241045	chr4:54363911	LNX1	-0.45	-7.07	-0.36	8.51e-12	DNA methylation (variation);
LIHC	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.71	-8.73	-0.43	1.11e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.42	6.77	0.34	5.57e-11	Red blood cell count;
LIHC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.85	-16.42	-0.66	4.29e-45	Coronary artery disease;
LIHC	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg22373622	chr1:1489544	SSU72	-0.55	-7.06	-0.36	9.38e-12	Alcohol dependence;
LIHC	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.51	7.27	0.37	2.47e-12	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.68	0.34	9.59e-11	Mean corpuscular volume;
LIHC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.79	9.27	0.45	2.08e-18	Cognitive test performance;
LIHC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.4	-6.2	-0.32	1.66e-9	Educational attainment;
LIHC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg20435097	chr10:126320824	FAM53B	0.43	6.29	0.32	9.91e-10	Cocaine dependence;
LIHC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.59	5.98	0.31	5.71e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.2e-10	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02539911	chr17:58677246	PPM1D	0.43	6.11	0.31	2.76e-9	Pancreatic cancer;
LIHC	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg09182678	chr22:50328711	NA	0.49	6.13	0.31	2.4e-9	Schizophrenia;
LIHC	cis	rs4788570	0.609	rs72795869	chr16:71485515	C/T	cg06353428	chr16:71660113	MARVELD3	-1.11	-10.1	-0.48	3.73e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.84	-0.43	5.01e-17	Gut microbiome composition (summer);
LIHC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.85	0.51	9.4e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.19	-0.36	4.09e-12	Monocyte percentage of white cells;
LIHC	cis	rs3736485	0.903	rs11070863	chr15:51904590	A/C	cg08986416	chr15:51914746	DMXL2	-0.42	-5.87	-0.3	1.05e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9473924	0.542	rs35546156	chr6:50829785	C/T	cg14470998	chr6:50812995	TFAP2B	0.96	10.84	0.51	9.97e-24	Body mass index;
LIHC	cis	rs2176862	1.000	rs115595413	chr3:46612022	G/A	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.34	-0.32	7.42e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	8.74	0.43	1.08e-16	Body mass index (adult);
LIHC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg12863693	chr15:85201151	NMB	0.42	5.8	0.3	1.5e-8	Schizophrenia;
LIHC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.42	6.34	0.32	7.17e-10	Gout;
LIHC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg02187348	chr16:89574699	SPG7	0.44	6.03	0.31	4.16e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.71	-0.43	1.28e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	11.05	0.51	1.79e-24	Prudent dietary pattern;
LIHC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	13.3	0.58	8.29e-33	Mean platelet volume;
LIHC	trans	rs10242455	0.850	rs57367781	chr7:99116819	G/A	cg09045935	chr12:6379348	NA	0.84	6.92	0.35	2.28e-11	Blood metabolite levels;
LIHC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.5	6.0	0.31	5.13e-9	Menarche (age at onset);
LIHC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.38	-6.86	-0.35	3.32e-11	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.49e-79	Prudent dietary pattern;
LIHC	cis	rs10416265	0.528	rs17884930	chr19:33595390	A/G	cg27124370	chr19:33622961	WDR88	0.49	6.87	0.35	3e-11	Bone properties (heel);
LIHC	cis	rs9810089	0.814	rs73226190	chr3:136213310	T/C	cg21827317	chr3:136751795	NA	0.46	6.19	0.32	1.74e-9	Gestational age at birth (child effect);
LIHC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.71	14.77	0.62	1.55e-38	Schizophrenia;
LIHC	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.76	-10.69	-0.5	3.24e-23	Ear protrusion;
LIHC	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.49	6.66	0.34	1.11e-10	Panic disorder;
LIHC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.82	14.64	0.62	4.93e-38	Coronary artery disease;
LIHC	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.76	14.28	0.61	1.29e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg27170947	chr2:26402098	FAM59B	-0.71	-8.69	-0.43	1.54e-16	Gut microbiome composition (summer);
LIHC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.18	0.32	1.81e-9	Platelet count;
LIHC	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-8.08	-0.4	1.1e-14	Putamen volume;
LIHC	cis	rs4700695	0.841	rs152933	chr5:65359530	A/G	cg21114390	chr5:65439923	SFRS12	-0.46	-5.93	-0.31	7.4e-9	Facial morphology (factor 19);
LIHC	cis	rs13394619	0.533	rs12615856	chr2:11746177	C/T	cg07314298	chr2:11723111	GREB1	0.36	6.07	0.31	3.4e-9	Endometriosis;
LIHC	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg25332918	chr7:158766061	NA	-0.39	-6.01	-0.31	4.8e-9	Facial morphology (factor 20);
LIHC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	21.25	0.75	1.75e-64	Chronic sinus infection;
LIHC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.8	17.63	0.69	5.84e-50	Gestational age at birth (maternal effect);
LIHC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.35	-6.65	-0.34	1.18e-10	Cognitive function;
LIHC	cis	rs74181299	0.653	rs2723091	chr2:65302017	C/T	cg05010058	chr2:65284262	CEP68	0.39	6.46	0.33	3.55e-10	Pulse pressure;
LIHC	cis	rs2334880	0.678	rs66778248	chr16:71451424	A/G	cg06353428	chr16:71660113	MARVELD3	-0.89	-8.37	-0.41	1.52e-15	Malaria;
LIHC	cis	rs12744310	0.887	rs28399806	chr1:41784971	C/T	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.92e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11673344	0.864	rs2562595	chr19:37514866	A/T	cg27390819	chr19:37464633	NA	-0.52	-6.38	-0.33	5.73e-10	Obesity-related traits;
LIHC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.31	-0.37	1.89e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg16583315	chr14:65563665	MAX	-0.37	-7.12	-0.36	6.39e-12	Obesity-related traits;
LIHC	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.69	-0.43	1.49e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.68	7.11	0.36	6.86e-12	Alzheimer's disease;
LIHC	cis	rs67981189	0.513	rs221893	chr14:71611414	G/A	cg15816911	chr14:71606274	NA	-0.45	-7.16	-0.36	4.99e-12	Schizophrenia;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	20.47	0.74	2.34e-61	Height;
LIHC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.45	7.16	0.36	5.1e-12	Height;
LIHC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.48	-18.29	-0.7	1.38e-52	Breast cancer;
LIHC	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.75	-12.45	-0.56	1.37e-29	Longevity;
LIHC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.46	7.21	0.36	3.52e-12	HDL cholesterol levels;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg18306943	chr3:40428807	ENTPD3	0.43	7.6	0.38	2.94e-13	Renal cell carcinoma;
LIHC	cis	rs7095607	0.630	rs7069569	chr10:69955140	T/A	cg18986048	chr10:69913749	MYPN	0.39	5.81	0.3	1.46e-8	Lung function (FVC);
LIHC	cis	rs2412488	0.927	rs12649718	chr4:54259862	C/T	cg22241045	chr4:54363911	LNX1	-0.41	-6.62	-0.34	1.36e-10	DNA methylation (variation);
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.25	-0.32	1.25e-9	Total body bone mineral density;
LIHC	cis	rs4908768	0.501	rs1922983	chr1:8531326	A/G	cg20416874	chr1:8611966	RERE	-0.67	-14.35	-0.61	7.27e-37	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg15654264	chr1:150340011	RPRD2	0.49	8.18	0.4	5.54e-15	Migraine;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25542733	chr7:73256925	WBSCR27	0.45	6.24	0.32	1.33e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1144333	0.522	rs1144338	chr1:76279908	T/C	cg22875332	chr1:76189707	ACADM	-0.36	-6.03	-0.31	4.37e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg00677901	chr16:88017247	BANP	0.53	8.14	0.4	7.67e-15	Menopause (age at onset);
LIHC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.73	-0.34	7.07e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	6.69	0.34	8.97e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24229701	chr12:130821962	PIWIL1	0.44	6.82	0.35	4.19e-11	Menopause (age at onset);
LIHC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.42	-9.79	-0.47	4.01e-20	Type 2 diabetes;
LIHC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.64	7.62	0.38	2.59e-13	Heart rate;
LIHC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.71	10.49	0.49	1.66e-22	Height;
LIHC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.08e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.47	-7.12	-0.36	6.23e-12	Height;
LIHC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.44	-5.75	-0.3	2.01e-8	Colorectal cancer;
LIHC	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	7.88	0.39	4.55e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	9.19	0.44	4.03e-18	Lung cancer in ever smokers;
LIHC	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.29	-7.13	-0.36	6.09e-12	Gut microbiome composition (winter);
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg05603623	chr19:8008081	TIMM44	-0.56	-6.19	-0.32	1.7e-9	Bronchial neuroendocrine tumor;
LIHC	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg10820045	chr2:198174542	NA	-0.51	-7.82	-0.39	6.65e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	0.99	7.18	0.36	4.46e-12	Diabetic retinopathy;
LIHC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg26531700	chr6:26746687	NA	0.39	6.49	0.33	3.05e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2224391	0.704	rs17139985	chr6:5261603	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.42	-6.28	-0.32	1.02e-9	Height;
LIHC	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.39	-6.96	-0.35	1.77e-11	Blood protein levels;
LIHC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.45	6.03	0.31	4.2e-9	Parkinson's disease;
LIHC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.45	5.99	0.31	5.41e-9	Parkinson's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11699593	chr8:22102731	POLR3D;MIR320A	0.44	6.05	0.31	3.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.28	-0.45	1.96e-18	Alzheimer's disease;
LIHC	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg20560298	chr2:73613845	ALMS1	0.35	5.73	0.3	2.22e-8	Metabolite levels;
LIHC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg18306943	chr3:40428807	ENTPD3	0.34	5.73	0.3	2.16e-8	Renal cell carcinoma;
LIHC	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.42	-5.85	-0.3	1.15e-8	Rheumatoid arthritis;
LIHC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.41	6.22	0.32	1.48e-9	Schizophrenia;
LIHC	cis	rs2412488	0.893	rs11133276	chr4:54369040	G/A	cg22241045	chr4:54363911	LNX1	-0.39	-6.25	-0.32	1.2e-9	DNA methylation (variation);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11733266	chr13:99096847	FARP1	0.41	6.06	0.31	3.64e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.81	-0.43	6.54e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.44	6.44	0.33	4.17e-10	Crohn's disease;
LIHC	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.45	0.33	3.88e-10	Body mass index;
LIHC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.01	0.44	1.49e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.51	-8.31	-0.41	2.23e-15	Lung cancer;
LIHC	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.35	-6.2	-0.32	1.62e-9	Lewy body disease;
LIHC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg27490568	chr2:178487706	NA	0.7	9.3	0.45	1.76e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.39	5.88	0.3	1e-8	Lung cancer;
LIHC	cis	rs2108622	0.727	rs12610967	chr19:15977929	C/A	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.87e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21506059	chr17:65242309	HELZ	-0.39	-6.06	-0.31	3.68e-9	Pancreatic cancer;
LIHC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.89	13.79	0.6	1.05e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.73	11.15	0.52	7.68e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.38	6.41	0.33	4.87e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2274273	1.000	rs2075603	chr14:55609955	C/A	cg01864836	chr14:55583639	NA	-0.36	-6.15	-0.32	2.14e-9	Protein biomarker;
LIHC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.17	0.66	4.52e-44	Smoking behavior;
LIHC	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.49	7.38	0.37	1.18e-12	Thyroid stimulating hormone;
LIHC	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.59	-8.9	-0.43	3.42e-17	White matter hyperintensity burden;
LIHC	cis	rs9908158	1	rs9908158	chr17:33890083	T/C	cg20932281	chr17:33905541	PEX12	0.42	5.77	0.3	1.78e-8	Platelet count;Platelet distribution width;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg15219393	chr5:149109878	PPARGC1B	0.6	7.85	0.39	5.45e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10659575	chr11:102188233	BIRC3	0.49	7.22	0.36	3.46e-12	Pancreatic cancer;
LIHC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	0.98	10.53	0.49	1.23e-22	Vitiligo;
LIHC	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg00977110	chr5:151150581	G3BP1	0.49	6.25	0.32	1.22e-9	Preschool internalizing problems;
LIHC	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.61	-0.34	1.46e-10	Body mass index;
LIHC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg01411142	chr8:19674711	INTS10	0.5	7.6	0.38	2.79e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg00656387	chr3:40428638	ENTPD3	-0.44	-7.49	-0.38	6.11e-13	Renal cell carcinoma;
LIHC	trans	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg17675199	chr6:35436792	RPL10A	-0.42	-8.54	-0.42	4.58e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.08	-0.36	8.34e-12	Heart rate;
LIHC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.81	-0.75	9.66e-63	Height;
LIHC	trans	rs9914544	0.545	rs34417974	chr17:18773636	T/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.54	-0.33	2.19e-10	Educational attainment (years of education);
LIHC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.6	-11.32	-0.52	1.94e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg11861562	chr11:117069780	TAGLN	0.47	7.76	0.39	9.76e-14	Blood protein levels;
LIHC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.68	9.19	0.44	3.98e-18	Mean platelet volume;
LIHC	cis	rs3018712	0.532	rs57813595	chr11:68402606	C/G	cg16797656	chr11:68205561	LRP5	0.5	6.22	0.32	1.45e-9	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg24209194	chr3:40518798	ZNF619	0.44	6.28	0.32	1.05e-9	Renal cell carcinoma;
LIHC	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.57	6.65	0.34	1.17e-10	Ulcerative colitis;
LIHC	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-8.7	-0.43	1.46e-16	Blood protein levels;
LIHC	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-11.85	-0.54	2.3e-27	Platelet distribution width;
LIHC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg16576597	chr16:28551801	NUPR1	0.36	5.72	0.3	2.32e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.8	13.53	0.59	1.09e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.31	-6.53	-0.33	2.32e-10	Platelet distribution width;
LIHC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	15.52	0.64	1.62e-41	Platelet count;
LIHC	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.4	8.8	0.43	7.12e-17	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.92	9.28	0.45	2.02e-18	Mean corpuscular hemoglobin;
LIHC	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg08847533	chr14:75593920	NEK9	0.54	8.24	0.41	3.59e-15	IgG glycosylation;
LIHC	cis	rs16828019	0.929	rs4131949	chr1:41738637	C/T	cg20697417	chr1:41786797	NA	0.35	6.59	0.34	1.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.76e-9	Menopause (age at onset);
LIHC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.45	5.82	0.3	1.33e-8	Mean platelet volume;
LIHC	cis	rs600806	0.778	rs4970761	chr1:109995398	C/T	cg16275483	chr1:110013120	SYPL2	-0.47	-5.83	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.9	-19.8	-0.73	1.09e-58	Height;
LIHC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.9	11.93	0.54	1.14e-27	Heart rate;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09997638	chr19:17530742	FAM125A	0.62	8.18	0.4	5.59e-15	Lung function (FEV1/FVC);
LIHC	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.53	7.15	0.36	5.23e-12	Fat distribution (HIV);
LIHC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.83	8.96	0.44	2.12e-17	Vitiligo;
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.25	-0.32	1.22e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg13535736	chr9:111863775	C9orf5	-0.37	-5.75	-0.3	1.95e-8	Menarche (age at onset);
LIHC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.66	9.79	0.47	4.16e-20	Menopause (age at onset);
LIHC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.93	-0.31	7.42e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9814567	0.752	rs13064209	chr3:134335993	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	9.1	0.44	7.53e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.48	-10.24	-0.48	1.19e-21	White blood cell count (basophil);
LIHC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.15	0.66	5.24e-44	Lymphocyte percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13457890	chr11:804976	LRDD	0.43	6.42	0.33	4.64e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.77	0.39	9.31e-14	Lymphocyte counts;
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg01652190	chr22:50026171	C22orf34	-0.35	-7.75	-0.39	1.03e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg26395211	chr5:140044315	WDR55	0.39	5.73	0.3	2.17e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg19645103	chr12:69753606	YEATS4	-0.44	-5.9	-0.3	8.78e-9	Response to diuretic therapy;
LIHC	cis	rs2380220	0.872	rs67846436	chr6:95951521	G/T	cg15832292	chr6:96025679	MANEA	-0.6	-6.63	-0.34	1.3e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.33	-0.32	7.83e-10	Colorectal cancer;
LIHC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.46	-11.99	-0.54	6.92e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg07424592	chr7:64974309	NA	0.65	8.17	0.4	6.03e-15	Diabetic kidney disease;
LIHC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-0.97	-22.14	-0.77	5.02e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg02023728	chr11:77925099	USP35	-0.33	-5.8	-0.3	1.55e-8	Alzheimer's disease (survival time);
LIHC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.73	-11.07	-0.51	1.5e-24	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-6.36	-0.33	6.41e-10	Monocyte count;
LIHC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.46	6.83	0.35	3.78e-11	Asthma (sex interaction);
LIHC	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg13919466	chr1:32135498	COL16A1	-0.3	-5.96	-0.31	6.35e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.41	-8.42	-0.41	1.02e-15	Renal cell carcinoma;
LIHC	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.92	-0.39	3.35e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.63	-10.94	-0.51	4.5e-24	Diisocyanate-induced asthma;
LIHC	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.68	7.23	0.36	3.16e-12	Exhaled nitric oxide output;
LIHC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.94	0.51	4.23e-24	Monocyte percentage of white cells;
LIHC	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27286337	chr10:134555280	INPP5A	0.89	12.44	0.56	1.44e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.28	-0.32	1.04e-9	Ulcerative colitis;
LIHC	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.45	8.02	0.4	1.73e-14	Coronary artery disease;
LIHC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.77	-11.2	-0.52	5.3e-25	Diastolic blood pressure;
LIHC	trans	rs1509701	0.773	rs61834561	chr1:239198199	T/G	cg02310027	chr17:77704741	ENPP7	0.42	6.36	0.33	6.59e-10	Shingles;
LIHC	cis	rs8192917	1.000	rs2273844	chr14:25103414	G/A	cg08766149	chr14:25103301	GZMB	0.33	7.58	0.38	3.18e-13	Vitiligo;
LIHC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.93	-17.24	-0.68	2.31e-48	Coronary artery disease;
LIHC	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.52	8.28	0.41	2.89e-15	Blood protein levels;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/T	cg23422044	chr7:1970798	MAD1L1	-0.73	-6.3	-0.32	9.12e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs10411161	0.702	rs17778790	chr19:52399559	C/T	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.8	17.61	0.69	7.36e-50	Gestational age at birth (maternal effect);
LIHC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.58	6.44	0.33	4.09e-10	Neutrophil percentage of white cells;
LIHC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg11764359	chr7:65958608	NA	0.54	6.26	0.32	1.17e-9	Diabetic kidney disease;
LIHC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-11.54	-0.53	2.94e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.43	6.96	0.35	1.74e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.55	-10.09	-0.48	3.98e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.56	-0.33	2.01e-10	Renal cell carcinoma;
LIHC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.85	10.16	0.48	2.26e-21	Cognitive function;
LIHC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.46	-7.6	-0.38	2.86e-13	Mean corpuscular volume;
LIHC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.07	0.36	8.84e-12	Bipolar disorder;
LIHC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	1.11	13.81	0.6	9.05e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg12903224	chr12:29470962	FAR2	-0.42	-6.81	-0.35	4.31e-11	QT interval;
LIHC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.03	-18.01	-0.7	1.74e-51	Body mass index;
LIHC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.32	0.32	7.96e-10	Height;
LIHC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.1	-0.31	2.86e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.26	-5.83	-0.3	1.27e-8	Gut microbiome composition (winter);
LIHC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.57	9.62	0.46	1.49e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.37	0.49	4.22e-22	Dupuytren's disease;
LIHC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12501888	chr15:85177176	SCAND2	-0.5	-7.68	-0.38	1.69e-13	P wave terminal force;
LIHC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.51	-7.21	-0.36	3.58e-12	Red cell distribution width;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05330977	chr17:18154724	FLII	-0.42	-6.28	-0.32	1.01e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	0.85	11.71	0.53	7.62e-27	Skin colour saturation;
LIHC	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg03263716	chr11:64435066	NRXN2	0.33	7.02	0.36	1.17e-11	Body mass index;Urate levels;
LIHC	cis	rs10847980	0.623	rs7955367	chr12:123828792	G/A	cg00376283	chr12:123451042	ABCB9	0.62	6.53	0.33	2.41e-10	Adiponectin levels;
LIHC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.58	7.23	0.36	3.14e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.86	0.3	1.11e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.51	-7.83	-0.39	6.34e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.62	9.34	0.45	1.28e-18	Longevity;
LIHC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.58	-9.77	-0.47	4.81e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg13919466	chr1:32135498	COL16A1	0.34	6.47	0.33	3.48e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.11e-35	White blood cell count (basophil);
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg10774155	chr7:65338427	VKORC1L1	0.45	6.61	0.34	1.43e-10	Calcium levels;
LIHC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	9.89	0.47	1.9e-20	Resting heart rate;
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.49	-7.86	-0.39	5.16e-14	Longevity;Endometriosis;
LIHC	cis	rs7897654	0.571	rs12771681	chr10:104635620	T/C	cg15744005	chr10:104629667	AS3MT	-0.38	-7.68	-0.38	1.66e-13	Schizophrenia;
LIHC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.49	8.17	0.4	5.93e-15	Response to temozolomide;
LIHC	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	0.66	6.56	0.33	1.97e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.57	8.37	0.41	1.49e-15	Platelet count;
LIHC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.44	-7.65	-0.38	2e-13	Alzheimer's disease (late onset);
LIHC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.8	-12.56	-0.56	5.02e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.49	7.14	0.36	5.5e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.63	0.56	2.74e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.57	-8.96	-0.44	2.14e-17	Dental caries;
LIHC	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07080220	chr10:102295463	HIF1AN	0.44	6.02	0.31	4.49e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.5	-10.7	-0.5	3.17e-23	Birth weight;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg18306943	chr3:40428807	ENTPD3	0.43	7.52	0.38	4.92e-13	Renal cell carcinoma;
LIHC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	7.81	0.39	7.1e-14	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	6.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.5	6.56	0.33	2.05e-10	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.23	-0.41	3.96e-15	Obesity-related traits;
LIHC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-6.9	-0.35	2.49e-11	Total body bone mineral density;
LIHC	trans	rs10737562	0.870	rs1928492	chr1:189583522	T/A	cg21603006	chr19:1428919	DAZAP1	-0.35	-6.1	-0.31	2.9e-9	Systemic lupus erythematosus;
LIHC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.12	0.4	8.83e-15	Motion sickness;
LIHC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg25801113	chr15:45476975	SHF	0.37	6.25	0.32	1.25e-9	Uric acid levels;
LIHC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.21	-0.32	1.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.48	-0.38	6.2800000000000005e-13	Platelet distribution width;
LIHC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	cis	rs238295	0.805	rs6116855	chr20:5555317	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.53	-7.13	-0.36	5.98e-12	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-7.93	-0.39	3.24e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.5	8.32	0.41	2.16e-15	Obesity-related traits;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.01	15.53	0.64	1.55e-41	Skin colour saturation;
LIHC	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg14930904	chr10:32216787	ARHGAP12	0.35	6.1	0.31	2.81e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs36022378	0.504	rs4688688	chr3:50042690	C/G	cg24110177	chr3:50126178	RBM5	0.47	6.23	0.32	1.35e-9	Diastolic blood pressure;
LIHC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.47	6.96	0.35	1.76e-11	Multiple sclerosis;
LIHC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.58	8.23	0.41	4.11e-15	Response to diuretic therapy;
LIHC	cis	rs2257205	0.667	rs8071942	chr17:56778271	T/C	cg12560992	chr17:57184187	TRIM37	0.72	7.97	0.4	2.33e-14	Pancreatic cancer;
LIHC	cis	rs965469	0.947	rs7274193	chr20:3329750	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.59e-11	IFN-related cytopenia;
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.53	6.95	0.35	1.88e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03122602	chr16:89799836	ZNF276	0.41	6.2	0.32	1.65e-9	Longevity;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	11.28	0.52	2.6e-25	Prudent dietary pattern;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.69	0.62	3.3e-38	Prudent dietary pattern;
LIHC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	8.8	0.43	6.95e-17	Lung cancer in ever smokers;
LIHC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.77	-15.45	-0.64	3.1e-41	Mortality in heart failure;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg11328140	chr12:108079443	PWP1	-0.4	-6.06	-0.31	3.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13571388	chr1:26947729	NA	0.45	6.17	0.32	1.96e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs332507	0.601	rs4677938	chr3:124374259	G/A	cg05980111	chr3:124395277	KALRN	0.32	6.21	0.32	1.57e-9	Plateletcrit;
LIHC	cis	rs2637266	1.000	rs12413656	chr10:78379666	A/C	cg18941641	chr10:78392320	NA	0.3	6.53	0.33	2.43e-10	Pulmonary function;
LIHC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.06e-9	Tonsillectomy;
LIHC	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.68	0.38	1.71e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg07817648	chr10:79422355	NA	-0.3	-6.4	-0.33	5.15e-10	Mortality in heart failure;
LIHC	cis	rs1816752	0.819	rs4770665	chr13:24988948	G/A	cg22771759	chr13:24902376	NA	0.3	6.02	0.31	4.43e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg12863693	chr15:85201151	NMB	0.49	7.09	0.36	7.55e-12	Schizophrenia;
LIHC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.6	-0.34	1.57e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.51e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg09572067	chr16:29127029	RRN3P2	0.51	8.06	0.4	1.3e-14	Menopause (age at onset);
LIHC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg10715820	chr1:17235063	NA	0.64	7.13	0.36	5.84e-12	Mean platelet volume;
LIHC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg11161837	chr1:110010384	SYPL2	0.44	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.49	-9.45	-0.46	5.63e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.42	-8.79	-0.43	7.26e-17	Ulcerative colitis;
LIHC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00152838	chr16:24741724	TNRC6A	-0.51	-5.99	-0.31	5.22e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.45	6.28	0.32	1.02e-9	Height;
LIHC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.17	0.44	4.45e-18	Schizophrenia;
LIHC	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg22705602	chr4:152727874	NA	-0.29	-6.31	-0.32	8.61e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.63	7.32	0.37	1.8e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.62	-0.38	2.57e-13	Aortic root size;
LIHC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.87	-0.3	1.06e-8	Pulse pressure;
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.42	-6.83	-0.35	3.92e-11	Cleft lip with or without cleft palate;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.87	0.35	3.05e-11	Renal cell carcinoma;
LIHC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.46	6.71	0.34	8.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.48	-6.23	-0.32	1.4e-9	Vitiligo;
LIHC	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg05552183	chr6:42928497	GNMT	0.49	7.06	0.36	9.43e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.77	-0.34	5.6e-11	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03732293	chr1:179335087	C1orf125	0.41	6.11	0.31	2.67e-9	Cognitive function;
LIHC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.59	9.31	0.45	1.55e-18	Lymphocyte counts;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.65	0.34	1.16e-10	Obesity-related traits;
LIHC	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.4	7.21	0.36	3.58e-12	Refractive astigmatism;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.92	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.54	9.68	0.46	9.93e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs10792665	0.611	rs10898053	chr11:82610033	T/A	cg24227371	chr11:82718527	RAB30	-0.26	-5.95	-0.31	6.73e-9	Obesity-related traits;
LIHC	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1789	0.903	rs6850422	chr4:15682437	C/T	cg21123203	chr4:15471301	CC2D2A	-0.43	-6.74	-0.34	6.86e-11	Blood protein levels;
LIHC	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.58	-9.68	-0.46	9.5e-20	Mononucleosis;
LIHC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.55	8.95	0.44	2.25e-17	Bipolar disorder;
LIHC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.44	5.74	0.3	2.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs798766	0.903	rs811316	chr4:1689377	T/C	cg21231739	chr4:1642635	FAM53A	-0.38	-5.76	-0.3	1.91e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.15e-11	Prudent dietary pattern;
LIHC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21467203	chr3:49911342	NA	0.43	7.65	0.38	2.09e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.33	-8.3	-0.41	2.51e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg21466736	chr12:48725269	NA	-0.7	-10.65	-0.5	4.47e-23	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	trans	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg01596870	chr19:55963115	NA	-0.65	-9.1	-0.44	7.62e-18	Obesity-related traits;
LIHC	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.33	6.37	0.33	5.98e-10	Sitting height ratio;
LIHC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg20607798	chr8:58055168	NA	0.49	6.0	0.31	5.08e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg04162153	chr10:124029871	BTBD16	0.43	5.86	0.3	1.11e-8	Total body bone mineral density;
LIHC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.28	-6.93	-0.35	2.09e-11	Longevity;Endometriosis;
LIHC	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.28	6.13	0.31	2.45e-9	Pulmonary function;
LIHC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.31	0.32	8.81e-10	Schizophrenia;
LIHC	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.82	-0.3	1.36e-8	Menarche (age at onset);
LIHC	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.45	6.14	0.32	2.28e-9	Pulmonary function decline;
LIHC	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.78	-8.65	-0.42	1.99e-16	Exhaled nitric oxide output;
LIHC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.23	6.54	0.33	2.29e-10	Type 2 diabetes;
LIHC	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg08539965	chr1:21396338	EIF4G3	0.35	6.07	0.31	3.43e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.75	0.3	1.98e-8	Electroencephalogram traits;
LIHC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.65	-10.62	-0.5	6.03e-23	Obesity-related traits;
LIHC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	8.14	0.4	7.23e-15	Tonsillectomy;
LIHC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg15123519	chr2:136567270	LCT	0.45	9.33	0.45	1.33e-18	Mosquito bite size;
LIHC	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.7	-11.53	-0.53	3.33e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-10.4	-0.49	3.51e-22	Coronary artery disease;
LIHC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-19.81	-0.73	1e-58	Height;
LIHC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-5.78	-0.3	1.65e-8	Vitiligo;
LIHC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.4	6.7	0.34	8.55e-11	Alcohol dependence;
LIHC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.91	17.07	0.68	1.13e-47	Menopause (age at onset);
LIHC	trans	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	7.22	0.36	3.37e-12	Chronotype;
LIHC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg06845991	chr7:90032834	CLDN12	-0.43	-6.62	-0.34	1.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.27	0.49	9.23e-22	Hypertriglyceridemia;
LIHC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.23e-16	Schizophrenia;
LIHC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.51	7.6	0.38	2.96e-13	Height;
LIHC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.26	-0.37	2.63e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs611744	0.901	rs599357	chr8:109194160	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.5	6.46	0.33	3.5e-10	Initial pursuit acceleration;
LIHC	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.57	9.05	0.44	1.13e-17	Corneal astigmatism;
LIHC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.85	-0.39	5.44e-14	Total body bone mineral density;
LIHC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.51	0.46	3.49e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg24296786	chr1:45957014	TESK2	0.42	6.02	0.31	4.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.87	-0.51	7.74e-24	Chronic sinus infection;
LIHC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	1.03	10.19	0.48	1.77e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.29	0.37	2.11e-12	HDL cholesterol levels;
LIHC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg17796960	chr10:135278976	LOC619207	-0.35	-5.74	-0.3	2.1e-8	Systemic lupus erythematosus;
LIHC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-8.54	-0.42	4.57e-16	Vitiligo;
LIHC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg16797656	chr11:68205561	LRP5	0.52	8.25	0.41	3.4e-15	Total body bone mineral density;
LIHC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08822215	chr16:89438651	ANKRD11	-0.46	-7.19	-0.36	4.04e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.81	9.04	0.44	1.2e-17	Cognitive test performance;
LIHC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.43	-0.37	8.83e-13	Platelet distribution width;
LIHC	cis	rs9378688	0.654	rs6596879	chr6:2364847	T/C	cg12303981	chr6:2244766	GMDS	0.48	6.37	0.33	5.97e-10	Caudate nucleus volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17308151	chr11:8703888	RPL27A	0.46	6.14	0.32	2.25e-9	Pancreatic cancer;
LIHC	cis	rs12744310	0.887	rs16828071	chr1:41783603	G/A	cg03962019	chr1:41807865	NA	0.4	6.37	0.33	6.06e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs611744	0.967	rs684904	chr8:109199417	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs713477	1.000	rs713477	chr14:55904426	C/A	cg13175173	chr14:55914753	NA	-0.31	-7.11	-0.36	6.98e-12	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg10774155	chr7:65338427	VKORC1L1	-0.43	-6.38	-0.33	5.63e-10	Calcium levels;
LIHC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.41	5.78	0.3	1.67e-8	Blood protein levels;
LIHC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.32	7.24	0.36	3.01e-12	Crohn's disease;
LIHC	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	6.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg19680672	chr10:131412579	MGMT	-0.45	-6.85	-0.35	3.39e-11	Response to temozolomide;
LIHC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-7.8	-0.39	7.76e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.6	6.34	0.32	7.17e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg20991723	chr1:152506922	NA	-0.53	-8.96	-0.44	2.21e-17	Hair morphology;
LIHC	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg18367735	chr17:79674897	NA	0.69	7.7	0.38	1.44e-13	Dental caries;
LIHC	cis	rs2741335	0.876	rs2741336	chr8:27337606	C/T	cg07150473	chr8:27338183	CHRNA2	-0.42	-6.03	-0.31	4.16e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.93	0.35	2.12e-11	Height;
LIHC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-10.15	-0.48	2.43e-21	Platelet count;
LIHC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg13409248	chr3:40428643	ENTPD3	0.42	7.14	0.36	5.71e-12	Renal cell carcinoma;
LIHC	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.02	0.54	5.41e-28	Eye color traits;
LIHC	cis	rs7187994	0.732	rs3764281	chr16:84767152	A/G	cg07647771	chr16:84786436	USP10	-0.33	-5.84	-0.3	1.2e-8	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.7	11.05	0.51	1.72e-24	Corneal astigmatism;
LIHC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.41	0.53	8.67e-26	Tonsillectomy;
LIHC	cis	rs4450131	0.898	rs3824805	chr10:126320721	C/T	cg20435097	chr10:126320824	FAM53B	-0.53	-9.53	-0.46	3.09e-19	White blood cell count (basophil);
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.67	10.76	0.5	1.83e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs9513627	0.915	rs9582298	chr13:100118707	T/C	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs3814244	0.528	rs2906854	chr12:68387346	G/A	cg15249341	chr12:68405565	NA	0.33	6.78	0.34	5.29e-11	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.89	15.58	0.64	1.02e-41	Colorectal cancer;
LIHC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.56	8.59	0.42	3.24e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs903552	1.000	rs4965872	chr15:102004002	C/T	cg19295451	chr15:102010161	PCSK6	-0.46	-6.31	-0.32	8.81e-10	Diabetic kidney disease;
LIHC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.73	-9.93	-0.47	1.34e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9341808	0.500	rs2223873	chr6:81048288	A/G	cg08355045	chr6:80787529	NA	0.34	6.96	0.35	1.75e-11	Sitting height ratio;
LIHC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg19635926	chr16:89946313	TCF25	0.54	6.74	0.34	6.74e-11	Skin colour saturation;
LIHC	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	10.8	0.5	1.39e-23	Eye color traits;
LIHC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	7.19	0.36	4.01e-12	Longevity;
LIHC	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg26138937	chr11:71823887	C11orf51	0.81	7.98	0.4	2.22e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs986417	0.748	rs2179971	chr14:61055466	T/C	cg27398547	chr14:60952738	C14orf39	0.49	5.9	0.3	8.74e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg24324837	chr19:49891574	CCDC155	0.39	5.87	0.3	1.05e-8	Multiple sclerosis;
LIHC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.69	9.87	0.47	2.25e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg03013999	chr17:37608204	MED1	0.36	5.97	0.31	5.97e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.65	6.79	0.34	4.98e-11	Type 2 diabetes;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09758671	chr8:99058522	RPL30	-0.5	-6.18	-0.32	1.86e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.42	0.33	4.6e-10	Morning vs. evening chronotype;
LIHC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.34	-5.98	-0.31	5.72e-9	IgG glycosylation;
LIHC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.64	0.42	2.17e-16	Total body bone mineral density;
LIHC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.41	5.76	0.3	1.84e-8	Breast cancer;
LIHC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.66	8.41	0.41	1.12e-15	Initial pursuit acceleration;
LIHC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	6.54	0.33	2.22e-10	Height;
LIHC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.34	5.83	0.3	1.3e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.6	11.76	0.54	5e-27	Plateletcrit;Platelet count;
LIHC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg18016565	chr1:150552671	MCL1	0.5	9.51	0.46	3.62e-19	Melanoma;
LIHC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.83	-0.3	1.3e-8	Arsenic metabolism;
LIHC	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg01666796	chr15:70364327	TLE3	-0.59	-7.66	-0.38	1.94e-13	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg22633049	chr21:46681294	NA	-0.36	-6.36	-0.33	6.34e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2851682	1.000	rs2845573	chr11:61601908	C/T	cg27386326	chr11:61587980	NA	-0.59	-8.81	-0.43	6.2e-17	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.52	8.32	0.41	2.19e-15	Lung cancer;
LIHC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg22961513	chr11:14280813	SPON1	-0.44	-6.91	-0.35	2.4e-11	Mitochondrial DNA levels;
LIHC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.49	6.89	0.35	2.64e-11	High light scatter reticulocyte count;
LIHC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.62	-0.34	1.42e-10	Height;
LIHC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.08	0.58	5.63e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs238295	0.843	rs238288	chr20:5591903	T/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.58	-7.75	-0.39	1.08e-13	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg03387723	chr1:41708464	SCMH1	-0.4	-6.53	-0.33	2.36e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.24	0.45	2.73e-18	Response to antipsychotic treatment;
LIHC	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg17074339	chr11:11642133	GALNTL4	0.47	7.32	0.37	1.83e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.65	9.0	0.44	1.54e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.53	-8.59	-0.42	3.03e-16	Mortality in heart failure;
LIHC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg07424592	chr7:64974309	NA	0.82	9.58	0.46	2.09e-19	Diabetic kidney disease;
LIHC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.42	-0.45	6.74e-19	Gut microbiome composition (summer);
LIHC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.56	0.38	3.68e-13	Bipolar disorder;
LIHC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg27386326	chr11:61587980	NA	0.7	14.85	0.63	7.91e-39	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.87	0.39	4.83e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg16926213	chr1:1841314	NA	0.33	6.03	0.31	4.23e-9	Body mass index;
LIHC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.85	0.43	4.66e-17	Menarche (age at onset);
LIHC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.47	7.49	0.38	6.12e-13	Multiple sclerosis;
LIHC	cis	rs2884670	1.000	rs2884670	chr12:4675218	C/T	cg14576962	chr12:4671597	NA	-0.37	-5.94	-0.31	6.83e-9	Allergic rhinitis;
LIHC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg17135325	chr3:160939158	NMD3	0.42	6.09	0.31	3.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02985541	chr2:219472218	PLCD4	0.42	6.94	0.35	1.94e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg14393609	chr7:65229607	NA	-0.35	-5.78	-0.3	1.72e-8	Aortic root size;
LIHC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.62	-7.76	-0.39	9.6e-14	Diastolic blood pressure;
LIHC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.51	7.23	0.36	3.12e-12	Body mass index;
LIHC	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg00977110	chr5:151150581	G3BP1	-0.56	-6.98	-0.35	1.58e-11	Preschool internalizing problems;
LIHC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.36	6.15	0.32	2.11e-9	Height;
LIHC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.95e-9	Menopause (age at onset);
LIHC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.42	-6.11	-0.31	2.65e-9	Inflammatory bowel disease;
LIHC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.56	7.05	0.36	9.69e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-10.67	-0.5	3.83e-23	Breast cancer;
LIHC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.87	11.2	0.52	5.12e-25	Coronary artery disease;
LIHC	cis	rs860626	0.645	rs242963	chr10:119311371	G/C	cg10846980	chr10:119306025	EMX2;EMX2OS	-0.54	-8.1	-0.4	1e-14	Neuroticism;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.87	0.57	3.48e-31	Prudent dietary pattern;
LIHC	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg03934865	chr2:198174659	NA	0.43	6.09	0.31	3.01e-9	Dermatomyositis;
LIHC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.19	0.32	1.71e-9	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg03037974	chr15:76606532	NA	-0.6	-9.99	-0.48	8.76e-21	Blood metabolite levels;
LIHC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-11.97	-0.54	8.31e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-23.54	-0.79	1.53e-73	Prudent dietary pattern;
LIHC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	5.87	0.3	1.02e-8	Resting heart rate;
LIHC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-7.99	-0.4	2.16e-14	Schizophrenia;
LIHC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg14132834	chr19:41945861	ATP5SL	0.44	6.49	0.33	3.05e-10	Height;
LIHC	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.68	10.63	0.5	5.51e-23	Monocyte count;
LIHC	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.62	6.93	0.35	2.15e-11	Alzheimer's disease;
LIHC	cis	rs61990749	0.571	rs4448861	chr14:78307735	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.51	7.84	0.39	5.75e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.73	-0.47	6.67e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.97	-0.35	1.64e-11	Endometrial cancer;
LIHC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.43	6.0	0.31	5.06e-9	Height;
LIHC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.48	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.29	6.34	0.32	7.36e-10	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.13	-0.31	2.37e-9	Colorectal cancer;
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23647884	chr3:120315025	NDUFB4	-0.48	-6.7	-0.34	8.73e-11	Pancreatic cancer;
LIHC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.61	7.5	0.38	5.64e-13	Heart rate;
LIHC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.68	-9.81	-0.47	3.45e-20	Schizophrenia;
LIHC	cis	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg01864836	chr14:55583639	NA	-0.36	-6.08	-0.31	3.15e-9	Protein biomarker;
LIHC	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg08992911	chr2:238395768	MLPH	0.55	6.42	0.33	4.5e-10	Prostate cancer;
LIHC	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg14473756	chr11:122847823	NA	-0.32	-5.75	-0.3	1.98e-8	Menarche (age at onset);
LIHC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02290350	chr8:58132656	NA	0.4	8.54	0.42	4.47e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	4.01e-23	Hypertriglyceridemia;
LIHC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-1.14	-8.66	-0.42	1.86e-16	Body mass index;
LIHC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.22	0.45	3.2e-18	Platelet count;
LIHC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.87	-13.34	-0.59	5.45e-33	Lymphocyte percentage of white cells;
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15854934	chr14:55518152	MAPK1IP1L	0.42	6.17	0.32	1.91e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg23149560	chr2:74406255	MOBKL1B	0.4	5.75	0.3	2.01e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.82	0.43	5.8e-17	Motion sickness;
LIHC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg21531657	chr3:10005747	TMEM111	0.39	5.96	0.31	6.15e-9	Alzheimer's disease;
LIHC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.43	-0.41	9.71e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.83	11.29	0.52	2.48e-25	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.69	-7.16	-0.36	5.04e-12	Alzheimer's disease;
LIHC	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg01652190	chr22:50026171	C22orf34	-0.33	-7.48	-0.38	6.26e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg05425664	chr17:57184151	TRIM37	-0.45	-5.82	-0.3	1.37e-8	Vitamin D levels;
LIHC	cis	rs16854884	0.739	rs1898265	chr3:143776096	A/G	cg06585982	chr3:143692056	C3orf58	-0.52	-6.54	-0.33	2.23e-10	Economic and political preferences (feminism/equality);
LIHC	cis	rs655641	0.863	rs7951988	chr11:85714288	T/C	cg09030501	chr11:85779252	PICALM	-0.49	-5.85	-0.3	1.14e-8	Platelet count;
LIHC	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.82	0.35	4.25e-11	Ileal carcinoids;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06098346	chr12:48499667	PFKM;SENP1	-0.5	-6.68	-0.34	9.87e-11	Pancreatic cancer;
LIHC	cis	rs151997	0.777	rs3846499	chr5:50254200	G/A	cg06027927	chr5:50259733	NA	0.62	8.46	0.42	8.06e-16	Callous-unemotional behaviour;
LIHC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg03146154	chr1:46216737	IPP	-0.41	-6.67	-0.34	1.01e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.38	-5.92	-0.31	7.7e-9	Lung cancer;
LIHC	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.63	5.84	0.3	1.23e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.48	6.35	0.32	6.73e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11673344	0.864	rs2562587	chr19:37510259	C/T	cg27390819	chr19:37464633	NA	-0.49	-5.95	-0.31	6.78e-9	Obesity-related traits;
LIHC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.49	-8.3	-0.41	2.5e-15	Response to temozolomide;
LIHC	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg27205649	chr11:78285834	NARS2	0.39	5.92	0.3	7.82e-9	Alzheimer's disease (survival time);
LIHC	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg17385448	chr1:15911702	AGMAT	0.4	6.7	0.34	8.78e-11	Systolic blood pressure;
LIHC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.22	-0.36	3.41e-12	Bipolar disorder;
LIHC	cis	rs4684776	0.676	rs1809049	chr3:11302884	C/T	cg00170343	chr3:11313890	ATG7	-0.47	-6.61	-0.34	1.47e-10	Small vessel stroke;
LIHC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.88	16.67	0.67	4.28e-46	Multiple myeloma (IgH translocation);
LIHC	cis	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg09021430	chr5:549028	NA	-0.46	-8.03	-0.4	1.61e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2120019	1.000	rs34655806	chr15:75362586	T/C	cg11632617	chr15:75315747	PPCDC	-0.45	-6.35	-0.32	6.86e-10	Blood trace element (Zn levels);
LIHC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.36e-16	Motion sickness;
LIHC	trans	rs2847476	0.690	rs7929497	chr11:114192132	C/G	cg16823064	chr1:19206559	ALDH4A1	-0.34	-6.3	-0.32	9.1e-10	Volumetric brain MRI;
LIHC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg00656387	chr3:40428638	ENTPD3	0.42	6.95	0.35	1.81e-11	Renal cell carcinoma;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.49e-17	Prudent dietary pattern;
LIHC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg10932868	chr11:921992	NA	0.34	6.43	0.33	4.32e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.3	-5.72	-0.3	2.27e-8	Prostate cancer;
LIHC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.31	0.32	8.84e-10	Ulcerative colitis;
LIHC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg25344623	chr2:136566232	LCT	0.42	8.65	0.42	2.08e-16	Mosquito bite size;
LIHC	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.51	-0.33	2.73e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11229555	0.645	rs12295551	chr11:58188983	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16490440	chr1:144620428	NBPF9	0.42	6.14	0.32	2.29e-9	Longevity;
LIHC	trans	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg17675199	chr6:35436792	RPL10A	0.34	6.47	0.33	3.32e-10	Coronary artery disease;
LIHC	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg15282417	chr9:129245246	FAM125B	0.4	6.34	0.32	7.13e-10	Intraocular pressure;
LIHC	cis	rs4450131	0.522	rs6597851	chr10:126413773	A/C	cg20435097	chr10:126320824	FAM53B	-0.63	-11.4	-0.52	9.7e-26	White blood cell count (basophil);
LIHC	cis	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg01737554	chr17:33866071	SLFN12L	-0.39	-8.05	-0.4	1.35e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs1355223	0.902	rs2226113	chr11:34746289	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg05484376	chr2:27715224	FNDC4	0.39	6.82	0.35	4.03e-11	Total body bone mineral density;
LIHC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.33	-0.32	7.82e-10	Endometrial cancer;
LIHC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-7.96	-0.4	2.5e-14	Colorectal cancer;
LIHC	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-7.44	-0.37	8.34e-13	Hepatocellular carcinoma;
LIHC	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.6	-8.2	-0.41	4.85e-15	Waist circumference;Body mass index;
LIHC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.82	-0.35	4.04e-11	Height;
LIHC	trans	rs743793	0.818	rs9607019	chr22:33580562	C/T	cg20274824	chr1:36638199	MAP7D1	0.46	6.42	0.33	4.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs4845459	0.967	rs4112788	chr1:152551276	A/G	cg20634798	chr1:152595351	LCE3A	-0.31	-5.94	-0.31	6.97e-9	Psoriasis;
LIHC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.47	7.61	0.38	2.61e-13	Caffeine consumption;
LIHC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.04e-16	Motion sickness;
LIHC	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg21252483	chr19:49399788	TULP2	-0.61	-9.47	-0.46	4.65e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg12798992	chr6:167411361	FGFR1OP	0.42	6.51	0.33	2.69e-10	Primary biliary cholangitis;
LIHC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21467203	chr3:49911342	NA	-0.43	-7.74	-0.39	1.17e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.28	-6.66	-0.34	1.11e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg04727924	chr7:799746	HEATR2	0.6	8.19	0.4	5.25e-15	Cerebrospinal P-tau181p levels;
LIHC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg17385448	chr1:15911702	AGMAT	0.33	5.8	0.3	1.53e-8	Systolic blood pressure;
LIHC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.94	17.62	0.69	6.39e-50	Menopause (age at onset);
LIHC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.18	0.32	1.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.9	-0.3	8.84e-9	Coronary artery disease;
LIHC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	12.41	0.56	1.92e-29	Response to bleomycin (chromatid breaks);
LIHC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.71	-0.71	2.82e-54	Height;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.25	-0.32	1.24e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10792665	0.934	rs2105644	chr11:82656623	A/G	cg24227371	chr11:82718527	RAB30	-0.29	-6.77	-0.34	5.78e-11	Obesity-related traits;
LIHC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg19743168	chr1:23544995	NA	0.36	6.0	0.31	4.94e-9	Height;
LIHC	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg04306507	chr14:55594613	LGALS3	0.32	5.98	0.31	5.52e-9	Protein biomarker;
LIHC	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg04374321	chr14:90722782	PSMC1	0.48	6.98	0.35	1.53e-11	Longevity;
LIHC	trans	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-9.02	-0.44	1.33e-17	Total body bone mineral density;
LIHC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.7	-6.71	-0.34	8.24e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.42	-6.9	-0.35	2.6e-11	Schizophrenia;
LIHC	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.66	-7.98	-0.4	2.23e-14	Homocysteine levels;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.52	-6.7	-0.34	8.5e-11	Menopause (age at onset);
LIHC	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.55	8.29	0.41	2.61e-15	Body mass index;
LIHC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.47	6.45	0.33	3.73e-10	Blood metabolite levels;
LIHC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.72	11.35	0.52	1.43e-25	Hemoglobin concentration;Hematocrit;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg20300707	chr1:1162156	SDF4	0.62	6.39	0.33	5.53e-10	Mean platelet volume;
LIHC	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.46	-5.93	-0.31	7.53e-9	Sjögren's syndrome;
LIHC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.44	7.18	0.36	4.36e-12	Educational attainment;
LIHC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-12.22	-0.55	9.8e-29	Body mass index;
LIHC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.36	-7.12	-0.36	6.6e-12	Testicular germ cell tumor;
LIHC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.7	0.43	1.39e-16	Cognitive test performance;
LIHC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg26395211	chr5:140044315	WDR55	0.4	5.86	0.3	1.11e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7534824	0.625	rs7545402	chr1:101321076	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	6.73	0.34	7.09e-11	Refractive astigmatism;
LIHC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.05	-17.39	-0.69	5.55e-49	Dilated cardiomyopathy;
LIHC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.83e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs4819388	0.789	rs4568033	chr21:45649778	A/G	cg17383793	chr5:52405638	MOCS2	0.4	6.29	0.32	9.67e-10	Celiac disease;
LIHC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.29	7.6	0.38	2.86e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.9	-0.3	8.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-7.34	-0.37	1.61e-12	Personality dimensions;
LIHC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.72	-0.3	2.38e-8	Breast cancer;
LIHC	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.39	8.18	0.4	5.8e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.9	11.57	0.53	2.38e-26	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-5.75	-0.3	1.94e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	9.63	0.46	1.4e-19	Coronary artery disease;
LIHC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg21466736	chr12:48725269	NA	0.63	9.14	0.44	5.64e-18	Glycated hemoglobin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00513467	chr9:21335551	KLHL9	0.43	6.25	0.32	1.25e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.5	9.38	0.45	9.31e-19	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.29	-0.45	1.82e-18	Diabetic kidney disease;
LIHC	trans	rs743793	0.818	rs137387	chr22:33581050	G/A	cg20274824	chr1:36638199	MAP7D1	0.46	6.42	0.33	4.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg14558262	chr17:40713999	COASY	0.62	9.47	0.46	4.78e-19	Crohn's disease;
LIHC	cis	rs17106184	1.000	rs3789587	chr1:51266474	C/T	cg07174182	chr1:51127561	FAF1	-0.63	-7.44	-0.37	8.28e-13	Type 2 diabetes;
LIHC	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg02811702	chr13:24901961	NA	0.24	5.83	0.3	1.29e-8	Obesity-related traits;
LIHC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.82	-13.72	-0.6	1.97e-34	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.29	0.55	5.25e-29	Schizophrenia;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23298160	chr5:137514800	BRD8;KIF20A	0.38	6.59	0.34	1.63e-10	Calcium levels;
LIHC	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.52	-8.67	-0.42	1.78e-16	Fibroblast growth factor basic levels;
LIHC	cis	rs1983891	1.000	rs4714483	chr6:41528214	G/A	cg20194872	chr6:41519635	FOXP4	0.43	6.84	0.35	3.74e-11	Prostate cancer;
LIHC	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.73	-10.59	-0.5	7.16e-23	Coronary artery disease;
LIHC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg13647721	chr17:30228624	UTP6	0.73	6.47	0.33	3.41e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg06766960	chr11:133703094	NA	-0.45	-6.89	-0.35	2.67e-11	Childhood ear infection;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15792688	chr4:124693	ZNF718	0.42	6.13	0.31	2.39e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03189756	chr1:241803820	OPN3	0.4	6.09	0.31	2.98e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.77	14.16	0.61	3.92e-36	Testicular germ cell tumor;
LIHC	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.5	7.44	0.37	8e-13	Lymphocyte counts;
LIHC	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.56	8.5	0.42	5.79e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.82	7.72	0.39	1.28e-13	LDL cholesterol;
LIHC	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.58	-6.76	-0.34	5.91e-11	Bipolar disorder;
LIHC	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.89	-0.3	9.45e-9	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-13.59	-0.59	6.35e-34	Prudent dietary pattern;
LIHC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02985541	chr2:219472218	PLCD4	0.41	6.72	0.34	7.42e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	trans	rs2681424	0.897	rs62269211	chr3:121760639	T/C	cg03946530	chr15:65596423	NA	-0.48	-6.2	-0.32	1.67e-9	Multiple sclerosis;
LIHC	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.75	-8.21	-0.41	4.63e-15	QRS complex (12-leadsum);
LIHC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.84	6.87	0.35	2.96e-11	Breast cancer;
LIHC	cis	rs6545883	0.794	rs12053388	chr2:61532320	G/A	cg14146966	chr2:61757674	XPO1	-0.44	-7.28	-0.37	2.3e-12	Tuberculosis;
LIHC	cis	rs7703744	0.747	rs6896553	chr5:118678700	G/T	cg10911160	chr5:118691794	TNFAIP8	-0.5	-5.94	-0.31	6.86e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10411936	0.712	rs10414751	chr19:16591695	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	6.81	0.35	4.36e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs903552	0.800	rs6598479	chr15:102005913	A/C	cg00659931	chr15:102010125	PCSK6	-0.49	-6.51	-0.33	2.66e-10	Diabetic kidney disease;
LIHC	cis	rs3106136	0.649	rs4699410	chr4:95299486	T/G	cg11021082	chr4:95130006	SMARCAD1	0.36	6.13	0.31	2.43e-9	Capecitabine sensitivity;
LIHC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.02	0.44	1.38e-17	Platelet count;
LIHC	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.06	-0.31	3.63e-9	Resting heart rate;
LIHC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.62	9.84	0.47	2.77e-20	Corneal astigmatism;
LIHC	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.22	0.66	2.74e-44	Electrocardiographic conduction measures;
LIHC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.68	-0.42	1.61e-16	Gut microbiome composition (summer);
LIHC	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs507080	0.733	rs657769	chr11:118571316	C/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg05185784	chr16:90016020	DEF8	-0.47	-6.08	-0.31	3.18e-9	Skin colour saturation;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04860157	chr6:36842651	PPIL1	-0.44	-6.42	-0.33	4.55e-10	Triglycerides;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23715700	chr19:16188274	TPM4	0.38	6.26	0.32	1.12e-9	Cognitive function;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg14666006	chr8:27629879	CCDC25	-0.58	-6.41	-0.33	4.88e-10	Preeclampsia;
LIHC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.59	9.48	0.46	4.42e-19	Lymphocyte counts;
LIHC	cis	rs911119	0.955	rs2067488	chr20:23594331	T/G	cg16589663	chr20:23618590	CST3	0.72	7.6	0.38	2.88e-13	Chronic kidney disease;
LIHC	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.73	12.35	0.56	3.06e-29	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.04	0.36	1.04e-11	Exhaled nitric oxide output;
LIHC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.36	-9.38	-0.45	9.7e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.09	-0.31	2.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs244293	0.795	rs11079150	chr17:53095061	G/C	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.45	0.37	7.84e-13	Menarche (age at onset);
LIHC	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg16275483	chr1:110013120	SYPL2	-0.5	-6.22	-0.32	1.44e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.87	16.16	0.66	4.6e-44	Dental caries;
LIHC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.39	6.17	0.32	1.97e-9	Menopause (age at onset);
LIHC	cis	rs2412488	0.927	rs7655975	chr4:54286484	A/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.87	-0.35	3.02e-11	DNA methylation (variation);
LIHC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.26	6.24	0.32	1.28e-9	Heart rate;
LIHC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.68e-15	Motion sickness;
LIHC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	10.71	0.5	2.77e-23	Monocyte percentage of white cells;
LIHC	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.46	6.61	0.34	1.48e-10	Pulse pressure;
LIHC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg24296786	chr1:45957014	TESK2	-0.39	-5.88	-0.3	9.77e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.91	0.39	3.62e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.22	0.52	4.27e-25	Coronary artery disease;
LIHC	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.62	8.59	0.42	3.04e-16	Neuroticism;
LIHC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.8	0.35	4.56e-11	Gut microbiome composition (summer);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25506325	chr7:2093962	MAD1L1	0.45	6.81	0.35	4.46e-11	Bilirubin levels;
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.77	11.46	0.53	6.06e-26	Menarche (age at onset);
LIHC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.64	-10.38	-0.49	3.97e-22	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg07117364	chr1:16154769	NA	-0.39	-6.84	-0.35	3.56e-11	Dilated cardiomyopathy;
LIHC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.34	-0.32	7.28e-10	Diabetic kidney disease;
LIHC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.91	16.7	0.67	3.44e-46	Menopause (age at onset);
LIHC	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.54	-11.39	-0.52	1.03e-25	Late-onset Alzheimer's disease;
LIHC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.38	-7.11	-0.36	7.01e-12	Height;
LIHC	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.01e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg01339444	chr6:118972232	C6orf204	0.59	5.82	0.3	1.32e-8	Diastolic blood pressure;
LIHC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-9.14	-0.44	5.52e-18	Height;
LIHC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.48	0.42	6.71e-16	Lung cancer;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.12	-0.4	8.7e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.46	6.18	0.32	1.82e-9	Major depressive disorder;
LIHC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.42	-7.08	-0.36	8.48e-12	Mean corpuscular volume;
LIHC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.75	-0.43	1.02e-16	Total cholesterol levels;
LIHC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.6	0.34	1.57e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.65	-7.01	-0.35	1.25e-11	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg25124228	chr12:125621409	AACS	-0.43	-6.86	-0.35	3.28e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs238295	0.805	rs6076852	chr20:5544502	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	0.52	7.01	0.35	1.28e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-6.23	-0.32	1.38e-9	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.61	-12.03	-0.55	4.93e-28	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.68	8.49	0.42	6.36e-16	Corneal astigmatism;
LIHC	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.69	7.88	0.39	4.56e-14	Height;
LIHC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg14930904	chr10:32216787	ARHGAP12	0.38	6.83	0.35	3.99e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	13.31	0.58	7.52e-33	Chronic sinus infection;
LIHC	cis	rs8067354	0.574	rs2526354	chr17:57976658	A/G	cg13753209	chr17:57696993	CLTC	0.69	10.11	0.48	3.49e-21	Hemoglobin concentration;
LIHC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.58	-0.5	8.0700000000000006e-23	Response to antipsychotic treatment;
LIHC	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.0	-0.54	6.29e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16684958	chr7:75615977	POR	-0.51	-8.54	-0.42	4.4e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.74	0.34	6.57e-11	Cognitive ability;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs911119	0.955	rs8115417	chr20:23605223	T/A	cg16589663	chr20:23618590	CST3	0.76	8.04	0.4	1.44e-14	Chronic kidney disease;
LIHC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.71	-8.06	-0.4	1.3e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17554472	chr22:41940697	POLR3H	-0.53	-5.82	-0.3	1.35e-8	Vitiligo;
LIHC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg26874164	chr19:58962979	ZNF324B	0.59	9.02	0.44	1.33e-17	Uric acid clearance;
LIHC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.09	13.26	0.58	1.12e-32	Primary sclerosing cholangitis;
LIHC	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg15595755	chr5:1867978	NA	0.34	6.25	0.32	1.2e-9	Cardiovascular disease risk factors;
LIHC	cis	rs847649	0.804	rs4729866	chr7:102685561	A/C	cg18108683	chr7:102477205	FBXL13	0.45	6.88	0.35	2.85e-11	Morning vs. evening chronotype;
LIHC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	0.93	9.48	0.46	4.33e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.6	7.43	0.37	8.82e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-8.62	-0.42	2.61e-16	Chronic sinus infection;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09403165	chr15:90118814	C15orf42	0.42	6.23	0.32	1.34e-9	Lung function (FEV1/FVC);
LIHC	cis	rs16858210	0.874	rs73177525	chr3:183570286	G/C	cg25686905	chr3:183603175	PARL	-0.5	-9.38	-0.45	9.47e-19	Menopause (age at onset);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21410120	chr7:540775	PDGFA	0.39	6.28	0.32	1.03e-9	Immature fraction of reticulocytes;
LIHC	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	6.59	0.34	1.71e-10	Lymphocyte counts;
LIHC	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.07	-0.31	3.37e-9	Alzheimer's disease (late onset);
LIHC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.11	-0.31	2.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.8	-9.95	-0.47	1.18e-20	Mean platelet volume;
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.51	5.86	0.3	1.08e-8	Alzheimer's disease;
LIHC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	12.98	0.57	1.38e-31	Cognitive test performance;
LIHC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg07541023	chr7:19748670	TWISTNB	0.48	7.03	0.36	1.13e-11	Thyroid stimulating hormone;
LIHC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg04865290	chr3:52927548	TMEM110	-0.51	-5.89	-0.3	9.01e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg09752223	chr19:15281200	NOTCH3	-0.36	-6.29	-0.32	9.6e-10	Pulse pressure;
LIHC	cis	rs7810240	1.000	rs56333034	chr7:150093330	G/A	cg10018233	chr7:150070692	REPIN1	-0.4	-6.19	-0.32	1.77e-9	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LIHC	cis	rs4730268	1.000	rs4730268	chr7:107443386	C/T	cg18560240	chr7:107437656	SLC26A3	-0.49	-5.85	-0.3	1.17e-8	IgG glycosylation;
LIHC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.73	0.34	7.11e-11	Lung cancer in ever smokers;
LIHC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-6.0	-0.31	4.89e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs955333	0.543	rs6557365	chr6:154924457	A/G	cg01304710	chr4:3766151	NA	0.26	6.16	0.32	2e-9	Diabetic kidney disease;
LIHC	cis	rs860295	0.756	rs7546258	chr1:155698645	T/A	cg02153340	chr1:155202674	NA	-0.35	-6.35	-0.32	6.94e-10	Body mass index;
LIHC	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg20991723	chr1:152506922	NA	0.54	9.0	0.44	1.57e-17	Hair morphology;
LIHC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.56	9.52	0.46	3.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg13271783	chr10:134563150	INPP5A	-0.56	-6.5	-0.33	2.79e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg14222432	chr12:29376421	FAR2	0.35	6.77	0.34	5.62e-11	QT interval;
LIHC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	7.63	0.38	2.42e-13	Lymphocyte counts;
LIHC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6967414	0.786	rs6953825	chr7:6755624	A/C	cg00387323	chr7:6746715	ZNF12	0.68	7.19	0.36	4.16e-12	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs9560113	0.573	rs9560130	chr13:112229460	G/A	cg10483660	chr13:112241077	NA	0.24	6.01	0.31	4.67e-9	Menarche (age at onset);
LIHC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.79	0.34	5.01e-11	Morning vs. evening chronotype;
LIHC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg10932868	chr11:921992	NA	0.39	7.3	0.37	2.09e-12	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.9	-0.35	2.55e-11	Aortic root size;
LIHC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.79	14.84	0.63	8.41e-39	Multiple myeloma (IgH translocation);
LIHC	cis	rs2074193	0.951	rs215345	chr12:47733033	C/T	cg02516419	chr12:47771422	NA	-0.42	-5.82	-0.3	1.38e-8	Migraine with aura;
LIHC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg08923669	chr16:420230	MRPL28	-0.43	-5.9	-0.3	8.9e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.9	8.69	0.43	1.54e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-9.09	-0.44	8.15e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.22e-26	Motion sickness;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07677032	chr17:61819896	STRADA	0.45	6.55	0.33	2.14e-10	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00815214	chr21:47717953	NA	0.36	5.81	0.3	1.45e-8	Testicular germ cell tumor;
LIHC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.91	16.72	0.67	2.64e-46	Menopause (age at onset);
LIHC	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.82	-0.3	1.32e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.4	-6.68	-0.34	9.72e-11	Red blood cell count;
LIHC	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	1.0	11.81	0.54	3.17e-27	Red blood cell traits;
LIHC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.44	7.0	0.35	1.32e-11	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg17175376	chr5:145562478	LARS	-0.4	-6.15	-0.32	2.17e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.02	0.4	1.69e-14	Menarche (age at onset);
LIHC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.52	8.5	0.42	5.89e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05360402	chr5:110848191	STARD4	0.38	6.24	0.32	1.28e-9	Cognitive function;
LIHC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.64	12.12	0.55	2.24e-28	Schizophrenia;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg14671364	chr1:107599128	PRMT6	0.53	7.93	0.39	3.05e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.64	7.39	0.37	1.14e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.99	-10.54	-0.5	1.11e-22	Vitiligo;
LIHC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg14779329	chr11:130786720	SNX19	0.41	6.24	0.32	1.26e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs988712	0.705	rs10767654	chr11:27640223	T/G	cg18117895	chr11:27722066	BDNF	-0.44	-5.85	-0.3	1.14e-8	Obesity;
LIHC	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.36	-8.56	-0.42	3.75e-16	Cutaneous nevi;
LIHC	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	7.63	0.38	2.32e-13	Platelet count;
LIHC	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg18192155	chr21:44258298	NA	0.44	7.01	0.35	1.27e-11	Information processing speed;
LIHC	cis	rs2839627	0.561	rs9977774	chr21:44342476	G/C	cg18192155	chr21:44258298	NA	0.42	5.77	0.3	1.8e-8	Information processing speed;
LIHC	cis	rs4684776	0.867	rs921226	chr3:11324794	A/G	cg00170343	chr3:11313890	ATG7	0.48	6.68	0.34	9.54e-11	Small vessel stroke;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg23260799	chr11:451101	PTDSS2	-0.41	-6.16	-0.32	1.99e-9	Urinary tract infection frequency;
LIHC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.67	13.45	0.59	2.07e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.65	-0.42	2.01e-16	Schizophrenia;
LIHC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.43	-7.08	-0.36	8.17e-12	Blood pressure (smoking interaction);
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.21	-0.36	3.69e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.3	-7.06	-0.36	9.11e-12	Menarche (age at onset);
LIHC	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.84	-0.39	5.64e-14	Breast cancer;
LIHC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg14393609	chr7:65229607	NA	0.39	5.76	0.3	1.92e-8	Aortic root size;
LIHC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.63	9.62	0.46	1.51e-19	Renal cell carcinoma;
LIHC	cis	rs17213078	0.602	rs4851926	chr2:106742660	A/G	cg15412446	chr2:106886593	NA	0.39	5.72	0.3	2.32e-8	Facial morphology (factor 23);
LIHC	trans	rs2540949	0.538	rs2540970	chr2:65255099	C/T	cg02773337	chr10:3171970	PFKP	-0.36	-6.28	-0.32	1.01e-9	Atrial fibrillation;
LIHC	trans	rs2681424	1.000	rs12495209	chr3:121757803	A/C	cg03946530	chr15:65596423	NA	-0.48	-6.14	-0.32	2.35e-9	Multiple sclerosis;
LIHC	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.47	6.29	0.32	9.64e-10	Cognitive test performance;
LIHC	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg21559469	chr19:19431446	KIAA0892;SF4	0.62	7.29	0.37	2.22e-12	Tonsillectomy;
LIHC	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg03934865	chr2:198174659	NA	0.47	7.02	0.35	1.2e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.59	-11.89	-0.54	1.55e-27	Coronary artery disease;
LIHC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.56	7.82	0.39	6.52e-14	Morning vs. evening chronotype;
LIHC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.61	9.03	0.44	1.31e-17	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06109949	chr2:178937838	PDE11A	0.47	7.34	0.37	1.56e-12	Pancreatic cancer;
LIHC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.38	7.64	0.38	2.27e-13	Type 2 diabetes;
LIHC	trans	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.47	6.72	0.34	7.41e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.95	-0.31	6.67e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.85	-0.3	1.16e-8	Total body bone mineral density;
LIHC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.52	11.05	0.51	1.75e-24	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg23461800	chr14:103021989	NA	0.45	6.31	0.32	8.6e-10	Platelet count;
LIHC	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.72	-11.37	-0.52	1.31e-25	White matter hyperintensity burden;
LIHC	cis	rs9993613	0.935	rs6844500	chr4:73442681	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.39	-6.19	-0.32	1.69e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.25	-5.79	-0.3	1.61e-8	Heart rate;
LIHC	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.2	10.14	0.48	2.69e-21	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.16	-0.32	2.04e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	0.63	7.72	0.39	1.28e-13	Corneal structure;
LIHC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.67	7.08	0.36	7.98e-12	Diabetic kidney disease;
LIHC	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.4	6.19	0.32	1.76e-9	Neutrophil percentage of white cells;
LIHC	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg03945807	chr20:60948434	NA	-0.38	-6.9	-0.35	2.52e-11	Colorectal cancer;
LIHC	cis	rs12464559	0.522	rs7583148	chr2:152620986	C/T	cg01189475	chr2:152685088	ARL5A	0.65	7.99	0.4	2.02e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7116495	0.786	rs678193	chr11:71770273	A/C	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.42	-6.94	-0.35	1.92e-11	Bipolar disorder;
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	6.93	0.35	2.11e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.59	8.88	0.43	3.78e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg18016565	chr1:150552671	MCL1	0.49	9.35	0.45	1.17e-18	Melanoma;
LIHC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.41	-0.53	8.75e-26	Chronic sinus infection;
LIHC	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.57	-10.21	-0.48	1.54e-21	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.6	-0.38	2.83e-13	Body mass index;
LIHC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.13	-0.48	2.99e-21	Schizophrenia;
LIHC	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.62	-9.65	-0.46	1.25e-19	Schizophrenia;
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-7.74	-0.39	1.1e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.76	-0.62	1.8e-38	Alzheimer's disease (late onset);
LIHC	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg26695010	chr11:65641043	EFEMP2	0.44	6.04	0.31	4e-9	Eosinophil percentage of white cells;
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.66	-9.77	-0.47	4.71e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg14779329	chr11:130786720	SNX19	0.42	6.39	0.33	5.31e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Psoriasis vulgaris;
LIHC	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg26939375	chr7:64535504	NA	-0.4	-5.89	-0.3	9.09e-9	Calcium levels;
LIHC	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.26	11.29	0.52	2.46e-25	Uric acid levels;
LIHC	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg15123519	chr2:136567270	LCT	-0.38	-6.06	-0.31	3.64e-9	Corneal structure;
LIHC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.67	7.02	0.35	1.24e-11	Schizophrenia;
LIHC	cis	rs11630290	0.639	rs925248	chr15:64167543	G/A	cg12036633	chr15:63758958	NA	0.57	5.96	0.31	6.42e-9	Iris characteristics;
LIHC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	6.97	0.35	1.6e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs7721647	0.810	rs6864520	chr5:90799016	A/G	cg10859192	chr12:54071672	ATP5G2	-0.41	-6.07	-0.31	3.43e-9	Breast cancer;
LIHC	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs244293	0.760	rs8069447	chr17:53008873	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.44	-0.37	8e-13	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.83	0.54	2.74e-27	Motion sickness;
LIHC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.88	-0.65	6.5e-43	Height;
LIHC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.67	13.28	0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg24110177	chr3:50126178	RBM5	-0.51	-7.88	-0.39	4.27e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.73	-13.87	-0.6	5.32e-35	Mortality in heart failure;
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.47	-7.68	-0.38	1.68e-13	Testicular germ cell tumor;
LIHC	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.6	7.63	0.38	2.37e-13	Crohn's disease;
LIHC	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.86	-0.3	1.06e-8	Tuberculosis;
LIHC	cis	rs2257205	0.667	rs8075108	chr17:56657248	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.86	0.39	5.22e-14	Pancreatic cancer;
LIHC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.63	10.74	0.5	2.24e-23	Uric acid clearance;
LIHC	trans	rs4714291	0.832	rs6936016	chr6:40097013	A/G	cg02267698	chr19:7991119	CTXN1	-0.4	-6.75	-0.34	6.34e-11	Strep throat;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21433329	chr20:49574938	DPM1;MOCS3	-0.42	-6.15	-0.32	2.13e-9	Pancreatic cancer;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.65	9.36	0.45	1.1e-18	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	8.76	0.43	9.08e-17	Height;
LIHC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.66	-13.08	-0.58	5.4e-32	Urate levels;
LIHC	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.68	-0.38	1.67e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.9e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.4e-8	Heart rate;
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg01339444	chr6:118972232	C6orf204	0.59	5.82	0.3	1.32e-8	Diastolic blood pressure;
LIHC	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg07424592	chr7:64974309	NA	0.78	8.94	0.44	2.44e-17	Diabetic kidney disease;
LIHC	trans	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs6973256	0.569	rs13246174	chr7:133395004	C/T	cg10665199	chr7:133106180	EXOC4	0.35	6.03	0.31	4.27e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.8	13.08	0.58	5.67e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06446895	chr17:79829189	ARHGDIA	0.58	7.54	0.38	4.24e-13	Lung function (FEV1/FVC);
LIHC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.6	0.46	1.71e-19	Asthma (sex interaction);
LIHC	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg08528486	chr13:113648767	MCF2L	-0.39	-6.35	-0.32	6.69e-10	Systolic blood pressure;
LIHC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.36	5.86	0.3	1.1e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.06	13.37	0.59	4.41e-33	Economic and political preferences (immigration/crime);
LIHC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.25	-7.77	-0.39	9.52e-14	Motion sickness;
LIHC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.15	0.4	6.9e-15	Menarche (age at onset);
LIHC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.7	-0.38	1.44e-13	Monocyte percentage of white cells;
LIHC	cis	rs926392	0.965	rs6129168	chr20:37689360	T/C	cg16355469	chr20:37678765	NA	0.36	5.77	0.3	1.76e-8	Dialysis-related mortality;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.32	7.23	0.36	3.19e-12	Blood metabolite ratios;
LIHC	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.57	7.39	0.37	1.11e-12	Parkinson's disease;
LIHC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.46	4.67e-19	Bipolar disorder;
LIHC	cis	rs9513627	0.920	rs7320057	chr13:100155586	G/A	cg25919922	chr13:100150906	NA	0.78	7.14	0.36	5.66e-12	Obesity-related traits;
LIHC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	12.03	0.55	4.99e-28	Menopause (age at onset);
LIHC	cis	rs2292096	0.929	rs16847224	chr1:200764858	G/A	cg11814564	chr1:200748674	CAMSAP1L1	-0.46	-6.16	-0.32	2.03e-9	Epilepsy;
LIHC	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.45	7.22	0.36	3.41e-12	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.91	0.51	5.7e-24	Alzheimer's disease (late onset);
LIHC	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg01858014	chr14:56050164	KTN1	-0.62	-5.89	-0.3	9.46e-9	Putamen volume;
LIHC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.47e-18	Bipolar disorder;
LIHC	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.8	-0.3	1.53e-8	Blood metabolite levels;
LIHC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.81	-12.39	-0.56	2.33e-29	Corneal astigmatism;
LIHC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.79	15.87	0.65	6.9e-43	Colorectal cancer;
LIHC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.65	10.24	0.48	1.21e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs1355223	0.902	rs865070	chr11:34742497	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.43	-0.33	4.18e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.5	-7.51	-0.38	5.23e-13	Gut microbiome composition (summer);
LIHC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.3	0.37	2.04e-12	Body mass index;
LIHC	cis	rs7487075	0.780	rs10785624	chr12:46766787	C/T	cg11331445	chr12:47219877	SLC38A4	0.29	5.93	0.31	7.49e-9	Itch intensity from mosquito bite;
LIHC	cis	rs11190604	0.943	rs59481707	chr10:102317603	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	6.42	0.33	4.54e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.84	-14.07	-0.61	8.7e-36	Body mass index;
LIHC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.75	8.35	0.41	1.71e-15	Height;
LIHC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg03037974	chr15:76606532	NA	-0.6	-10.01	-0.48	7.38e-21	Blood metabolite levels;
LIHC	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.84	-0.3	1.24e-8	Systolic blood pressure;
LIHC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.21	0.36	3.53e-12	Vitiligo;
LIHC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg21466736	chr12:48725269	NA	-0.35	-6.07	-0.31	3.38e-9	Plateletcrit;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17462381	chr3:132441365	NCRNA00119;NPHP3	-0.47	-6.21	-0.32	1.55e-9	Bilirubin levels;
LIHC	trans	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.16e-10	Aortic root size;
LIHC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20135002	chr11:47629003	NA	-0.52	-8.88	-0.43	3.73e-17	Subjective well-being;
LIHC	cis	rs2257205	0.667	rs9909635	chr17:56752159	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.79	0.39	8.05e-14	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.55	0.33	2.15e-10	Renal cell carcinoma;
LIHC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.36	-0.64	7.55e-41	Chronic sinus infection;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg10252516	chr19:56671462	ZNF444	0.44	6.51	0.33	2.76e-10	Bilirubin levels;
LIHC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.89	-8.94	-0.44	2.52e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10426930	0.607	rs2613768	chr19:5074637	G/A	cg18473234	chr19:5097819	KDM4B	-0.62	-7.49	-0.38	6.07e-13	Monocyte percentage of white cells;
LIHC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-7.01	-0.35	1.28e-11	Lung cancer in ever smokers;
LIHC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.52	-9.23	-0.45	2.82e-18	Blood protein levels;
LIHC	cis	rs2777491	0.872	rs11267024	chr15:41576241	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-7.24	-0.36	3.03e-12	Ulcerative colitis;
LIHC	cis	rs17106184	0.579	rs12074850	chr1:51248316	A/G	cg07174182	chr1:51127561	FAF1	-0.6	-7.03	-0.36	1.1e-11	Type 2 diabetes;
LIHC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.43	-0.33	4.2e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.64	-9.78	-0.47	4.5e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.44	8.44	0.42	8.87e-16	Testicular germ cell tumor;
LIHC	cis	rs35883536	1.000	rs1577504	chr1:101123913	A/T	cg14515779	chr1:101123966	NA	-0.69	-13.94	-0.6	2.76e-35	Monocyte count;
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.68	9.31	0.45	1.58e-18	Calcium levels;
LIHC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.78	-0.3	1.64e-8	Inflammatory bowel disease;
LIHC	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.84	7.32	0.37	1.82e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.71	10.66	0.5	4.29e-23	Corneal astigmatism;
LIHC	cis	rs10792665	0.512	rs7104905	chr11:82610139	A/G	cg24227371	chr11:82718527	RAB30	-0.28	-6.59	-0.34	1.69e-10	Obesity-related traits;
LIHC	cis	rs2016586	0.802	rs5755925	chr22:36114994	A/G	cg26342177	chr22:36113512	APOL5	-0.38	-6.49	-0.33	3.01e-10	Body mass index;
LIHC	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.28	-6.52	-0.33	2.45e-10	Hip circumference;Waist circumference;
LIHC	cis	rs11628318	0.515	rs10144272	chr14:103086289	T/G	cg12046867	chr14:103022105	NA	-0.37	-5.72	-0.3	2.28e-8	Platelet count;
LIHC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22168489	chr12:122356033	WDR66	0.46	6.53	0.33	2.33e-10	Mean corpuscular volume;
LIHC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.41	-6.18	-0.32	1.79e-9	Menarche (age at onset);
LIHC	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.34	-6.66	-0.34	1.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg06565975	chr8:143823917	SLURP1	-0.31	-5.86	-0.3	1.06e-8	Urinary tract infection frequency;
LIHC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.63	9.98	0.47	9.42e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.9e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12016809	chr21:47604291	C21orf56	-0.42	-5.99	-0.31	5.22e-9	Testicular germ cell tumor;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg25405998	chr7:65216604	CCT6P1	0.44	6.53	0.33	2.41e-10	Calcium levels;
LIHC	cis	rs11958404	0.860	rs11135023	chr5:157420082	G/T	cg05962755	chr5:157440814	NA	0.83	10.79	0.5	1.44e-23	IgG glycosylation;
LIHC	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.51	7.62	0.38	2.59e-13	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.65	10.44	0.49	2.49e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.82	-14.73	-0.62	2.28e-38	Height;
LIHC	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.57	-0.33	1.93e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	10.18	0.48	2.02e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.19	-0.32	1.76e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.73	-0.39	1.2e-13	Bipolar disorder;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14257396	chr1:107603778	NA	-0.35	-5.76	-0.3	1.9e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg14146966	chr2:61757674	XPO1	0.48	8.3	0.41	2.47e-15	Tuberculosis;
LIHC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.86	0.35	3.28e-11	Diabetic kidney disease;
LIHC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.79	12.26	0.55	7.09e-29	Dental caries;
LIHC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.83	0.3	1.27e-8	Hepatocellular carcinoma;
LIHC	cis	rs965469	1.000	rs2236122	chr20:3305240	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.63	-0.34	1.3e-10	IFN-related cytopenia;
LIHC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.77	-14.69	-0.62	3.22e-38	Mortality in heart failure;
LIHC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02290350	chr8:58132656	NA	0.45	8.65	0.42	2.09e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg00800038	chr16:89945340	TCF25	-0.67	-10.47	-0.49	1.92e-22	Skin colour saturation;
LIHC	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-6.09	-0.31	3.11e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs116975820	0.648	rs11181363	chr12:42566282	T/C	cg01256987	chr12:42539512	GXYLT1	-0.55	-6.06	-0.31	3.56e-9	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.46	6.22	0.32	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.71	10.31	0.49	7.24e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.51	6.49	0.33	3.08e-10	Menarche (age at onset);
LIHC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.66	9.43	0.45	6.59e-19	Bronchopulmonary dysplasia;
LIHC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.22	0.32	1.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9378688	1.000	rs56196406	chr6:2219565	T/C	cg12303981	chr6:2244766	GMDS	-0.5	-6.31	-0.32	8.61e-10	Caudate nucleus volume;
LIHC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.45	8.27	0.41	3.11e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg18912006	chr12:123335444	HIP1R	-0.64	-7.67	-0.38	1.78e-13	Schizophrenia;
LIHC	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.73	-0.3	2.25e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.82	11.44	0.53	7.07e-26	Menarche (age at onset);
LIHC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.47	0.46	4.81e-19	Electroencephalogram traits;
LIHC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.55	-8.52	-0.42	5.18e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.37	-6.3	-0.32	9.4e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.33	-7.25	-0.36	2.82e-12	Ulcerative colitis;
LIHC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.02	-0.4	1.74e-14	Type 2 diabetes;
LIHC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg26939375	chr7:64535504	NA	-0.47	-7.11	-0.36	6.97e-12	Aortic root size;
LIHC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	0.9	16.31	0.66	1.26e-44	Bone mineral density;
LIHC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.24	-0.41	3.72e-15	Gut microbiome composition (summer);
LIHC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.57	-8.64	-0.42	2.18e-16	Multiple sclerosis;
LIHC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg15848620	chr12:58087721	OS9	0.5	6.43	0.33	4.2e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.41	-6.62	-0.34	1.42e-10	Dementia with Lewy bodies;
LIHC	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg16583315	chr14:65563665	MAX	-0.36	-6.83	-0.35	3.84e-11	Obesity-related traits;
LIHC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.34	-8.75	-0.43	9.93e-17	Schizophrenia;
LIHC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg00677901	chr16:88017247	BANP	0.52	7.87	0.39	4.62e-14	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.94	17.99	0.7	2.25e-51	Menopause (age at onset);
LIHC	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.91	18.79	0.71	1.31e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	0.98	13.75	0.6	1.46e-34	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03041730	chr4:903314	GAK	0.47	6.75	0.34	6.35e-11	Longevity;
LIHC	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.31	-0.37	1.89e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg18898632	chr2:242989856	NA	-0.69	-8.68	-0.42	1.63e-16	Obesity-related traits;
LIHC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.42e-14	Morning vs. evening chronotype;
LIHC	cis	rs10849893	0.538	rs7961855	chr12:121829943	C/T	cg01154721	chr12:121881891	KDM2B	-0.4	-6.52	-0.33	2.57e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs11779988	0.545	rs427168	chr8:17784829	G/A	cg01800426	chr8:17659068	MTUS1	-0.42	-5.92	-0.3	7.96e-9	Breast cancer;
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg23782820	chr8:58130467	NA	0.33	5.95	0.31	6.66e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.18e-41	Mortality in heart failure;
LIHC	cis	rs10845606	0.505	rs10845604	chr12:12832734	A/G	cg09462578	chr12:12878428	APOLD1	0.44	6.66	0.34	1.08e-10	Systemic lupus erythematosus;
LIHC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.46	7.52	0.38	4.84e-13	Multiple sclerosis;
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs12744310	1.000	rs35812095	chr1:41766074	T/C	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.6e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg16226627	chr15:75307476	SCAMP5	0.52	9.34	0.45	1.29e-18	Lung cancer;
LIHC	cis	rs11688816	0.904	rs360791	chr2:62917256	G/A	cg17519650	chr2:63277830	OTX1	-0.47	-7.2	-0.36	3.88e-12	Body mass index;
LIHC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg24296786	chr1:45957014	TESK2	-0.51	-7.52	-0.38	4.86e-13	Platelet count;
LIHC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.48	6.83	0.35	3.83e-11	Schizophrenia;
LIHC	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.51	6.32	0.32	8.05e-10	Total body bone mineral density;
LIHC	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.45	-8.92	-0.43	2.94e-17	LDL cholesterol levels;
LIHC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.85	-0.35	3.48e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg01134436	chr17:81009848	B3GNTL1	0.86	7.22	0.36	3.31e-12	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.15	29.4	0.85	1.23e-95	IgG glycosylation;
LIHC	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.5	0.38	5.46e-13	Schizophrenia;
LIHC	cis	rs1198430	0.562	rs10799795	chr1:23773998	C/A	cg13183780	chr1:23809682	ASAP3	-0.34	-6.02	-0.31	4.61e-9	Total cholesterol levels;
LIHC	cis	rs7729447	0.776	rs58529247	chr5:32693889	C/T	cg16267343	chr5:32710456	NPR3	0.47	5.78	0.3	1.71e-8	Blood pressure;
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.57	7.54	0.38	4.37e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11605275	1.000	rs11605275	chr11:20031865	C/T	cg14835545	chr11:20032148	NAV2	-0.81	-7.38	-0.37	1.18e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.47	6.29	0.32	9.64e-10	Cognitive test performance;
LIHC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.36	-0.49	4.83e-22	Total cholesterol levels;
LIHC	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg01843034	chr6:37503916	NA	-0.47	-8.12	-0.4	8.59e-15	Cognitive performance;
LIHC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.38	-6.41	-0.33	4.94e-10	White matter hyperintensity burden;
LIHC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.59	-6.98	-0.35	1.51e-11	Cognitive function;
LIHC	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.67	11.93	0.54	1.11e-27	High light scatter reticulocyte count;
LIHC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.42	-7.89	-0.39	4.15e-14	Temperament;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg25124228	chr12:125621409	AACS	-0.43	-6.67	-0.34	1.05e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.42e-23	Mean corpuscular volume;
LIHC	cis	rs1555399	0.935	rs7144333	chr14:67984105	C/T	cg16224230	chr14:67978224	TMEM229B	-0.25	-5.95	-0.31	6.81e-9	Parkinson's disease;
LIHC	cis	rs9322817	0.691	rs56075147	chr6:105337494	T/A	cg02098413	chr6:105308735	HACE1	0.39	7.48	0.38	6.25e-13	Thyroid stimulating hormone;
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.77	-0.3	1.78e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-6.96	-0.35	1.71e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.46	5.83	0.3	1.32e-8	RR interval (heart rate);
LIHC	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.57	8.02	0.4	1.73e-14	Aortic root size;
LIHC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.78e-10	Menarche (age at onset);
LIHC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.79	11.94	0.54	1.09e-27	Dental caries;
LIHC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg02290350	chr8:58132656	NA	0.39	8.4	0.41	1.23e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	6.09	0.31	2.95e-9	Renal cell carcinoma;
LIHC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-11.72	-0.54	7.03e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.45	-0.53	6.66e-26	Total cholesterol levels;
LIHC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.48	7.81	0.39	7.22e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.62	-10.45	-0.49	2.21e-22	Recombination rate (males);
LIHC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.37	0.56	2.77e-29	Menopause (age at onset);
LIHC	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.6	0.38	2.96e-13	Exhaled nitric oxide output;
LIHC	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.15	16.19	0.66	3.6e-44	Corneal structure;
LIHC	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-7.13	-0.36	5.88e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.58	6.72	0.34	7.66e-11	Menarche (age at onset);
LIHC	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	1.05	14.54	0.62	1.3e-37	Corneal structure;
LIHC	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg26138937	chr11:71823887	C11orf51	0.83	8.25	0.41	3.52e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.52	6.55	0.33	2.14e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-13.93	-0.6	2.98e-35	Prudent dietary pattern;
LIHC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11645453	chr3:52864694	ITIH4	0.22	5.9	0.3	8.59e-9	Bipolar disorder;
LIHC	trans	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg07393940	chr7:158741817	NA	0.54	6.25	0.32	1.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg19000871	chr14:103996768	TRMT61A	0.44	7.39	0.37	1.13e-12	Coronary artery disease;
LIHC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.46	-6.76	-0.34	5.84e-11	Corneal structure;
LIHC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	10.15	0.48	2.56e-21	Personality dimensions;
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.66	-0.42	1.85e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg04709771	chr16:646395	RAB40C	0.45	8.27	0.41	3.01e-15	Height;
LIHC	cis	rs3823572	0.542	rs2346267	chr7:133639554	T/C	cg03336402	chr7:133662267	EXOC4	0.46	5.75	0.3	2e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13492289	chr10:51027379	PARG	0.42	6.5	0.33	2.91e-10	Longevity;
LIHC	cis	rs546131	0.642	rs12272777	chr11:34850902	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.55	-0.33	2.17e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02450064	chr17:40260053	DHX58	-0.3	-6.15	-0.32	2.17e-9	Fibrinogen levels;
LIHC	cis	rs937213	0.573	rs12592831	chr15:40302441	G/A	cg20255370	chr15:40268687	EIF2AK4	-0.37	-6.17	-0.32	1.88e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.03	-0.4	1.59e-14	Exhaled nitric oxide output;
LIHC	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.09	0.48	4.09e-21	Colorectal cancer;
LIHC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	1.02	13.17	0.58	2.63e-32	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.68	11.56	0.53	2.64e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.55	5.8	0.3	1.48e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg27398547	chr14:60952738	C14orf39	-0.59	-6.2	-0.32	1.66e-9	Gut microbiota (bacterial taxa);
LIHC	trans	rs2159537	0.526	rs12940578	chr17:12366311	C/T	cg20708305	chr3:9744919	CPNE9	0.39	6.07	0.31	3.44e-9	Systolic blood pressure change trajectories;
LIHC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.86	-0.35	3.24e-11	IgG glycosylation;
LIHC	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg08992911	chr2:238395768	MLPH	0.48	5.93	0.31	7.32e-9	Prostate cancer;
LIHC	cis	rs11031096	0.711	rs10835694	chr11:4178757	G/C	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.53	6.13	0.31	2.43e-9	Axial length;
LIHC	cis	rs27434	0.607	rs695965	chr5:96148366	C/T	cg16492584	chr5:96139282	ERAP1	-0.33	-6.13	-0.31	2.41e-9	Ankylosing spondylitis;
LIHC	cis	rs57502260	0.704	rs12286536	chr11:68290234	C/G	cg16797656	chr11:68205561	LRP5	0.46	5.81	0.3	1.45e-8	Total body bone mineral density (age 45-60);
LIHC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.57	-10.96	-0.51	3.6e-24	Coronary artery disease;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.71	13.07	0.58	6.06e-32	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.72	11.27	0.52	2.89e-25	Corneal astigmatism;
LIHC	cis	rs2236918	0.710	rs851781	chr1:242034868	C/T	cg17736920	chr1:242011382	EXO1	0.41	6.07	0.31	3.48e-9	Menopause (age at onset);
LIHC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg01987224	chr1:201084466	NA	-0.32	-5.98	-0.31	5.76e-9	Permanent tooth development;
LIHC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.4	-6.44	-0.33	4.11e-10	Bipolar disorder;
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-7.89	-0.39	4.08e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.79	9.02	0.44	1.39e-17	Bipolar disorder;
LIHC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	14.71	0.62	2.82e-38	Menopause (age at onset);
LIHC	trans	rs6489882	0.703	rs10850093	chr12:113360468	C/T	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg18538332	chr22:24372958	LOC391322	-0.58	-8.01	-0.4	1.86e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg05941027	chr17:61774174	LIMD2	0.35	7.39	0.37	1.13e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.49	-6.45	-0.33	3.89e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19671926	chr4:122722719	EXOSC9	0.56	8.63	0.42	2.3e-16	Type 2 diabetes;
LIHC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.6	6.48	0.33	3.17e-10	Vitiligo;
LIHC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-6.96	-0.35	1.78e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26076054	chr5:421317	AHRR	-0.27	-6.05	-0.31	3.81e-9	Cystic fibrosis severity;
LIHC	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.37	7.09	0.36	7.9e-12	Testicular germ cell tumor;
LIHC	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.35	8.97	0.44	2.02e-17	Asthma (sex interaction);
LIHC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.68	10.37	0.49	4.2e-22	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.49	0.49	1.61e-22	Lymphocyte counts;
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	10.18	0.48	1.92e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.62	-13.36	-0.59	4.76e-33	Schizophrenia;
LIHC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21467203	chr3:49911342	NA	-0.51	-8.85	-0.43	4.63e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.4	6.25	0.32	1.26e-9	Resting heart rate;
LIHC	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.8	0.35	4.65e-11	Systolic blood pressure;
LIHC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.38	0.45	9.63e-19	Bipolar disorder;
LIHC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.32	-0.32	8.4e-10	Colorectal cancer;
LIHC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17691542	chr6:26056736	HIST1H1C	0.44	6.24	0.32	1.27e-9	Height;
LIHC	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg08539965	chr1:21396338	EIF4G3	0.32	5.75	0.3	1.94e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	5.98	0.31	5.71e-9	Coronary artery disease;
LIHC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.35	-5.76	-0.3	1.88e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.51	0.33	2.6200000000000003e-10	Systolic blood pressure;
LIHC	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.55	8.02	0.4	1.69e-14	Left atrial antero-posterior diameter;
LIHC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg22633049	chr21:46681294	NA	-0.35	-5.97	-0.31	5.8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.65	0.42	2.04e-16	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg22633049	chr21:46681294	NA	-0.34	-6.01	-0.31	4.68e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs75908454	1.000	rs16887979	chr6:169801808	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.52	-0.38	4.91e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.4	7.67	0.38	1.84e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs13161895	1.000	rs27012	chr5:179402211	A/C	cg06664874	chr5:179499304	RNF130	0.55	6.84	0.35	3.66e-11	LDL cholesterol;
LIHC	cis	rs114532231	0.661	rs34339158	chr2:86498574	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.68	-6.91	-0.35	2.45e-11	Asymmetrical dimethylarginine levels;
LIHC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg03732007	chr1:2071316	PRKCZ	0.35	6.05	0.31	3.78e-9	Height;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.65	9.71	0.46	7.5599999999999994e-20	Menarche (age at onset);
LIHC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.25	-11.87	-0.54	1.92e-27	Uric acid levels;
LIHC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.55	0.64	1.25e-41	Chronic sinus infection;
LIHC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.85	15.2	0.64	3.07e-40	Aortic root size;
LIHC	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.51	9.77	0.47	4.85e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.89	0.3	9.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs882732	1.000	rs7159121	chr14:95040935	G/T	cg14866387	chr14:95027382	SERPINA4	-0.48	-6.45	-0.33	3.82e-10	Blood protein levels;
LIHC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.44	6.97	0.35	1.64e-11	Melanoma;
LIHC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.74	-0.3	2.14e-8	Menopause (age at onset);
LIHC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.25	0.32	1.2e-9	Glycated hemoglobin levels;
LIHC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	6.83	0.35	3.88e-11	Menopause (age at onset);
LIHC	cis	rs2286503	0.839	rs2270103	chr7:22862722	C/T	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	cis	rs7577696	0.524	rs12991444	chr2:32265125	G/T	cg02381751	chr2:32503542	YIPF4	-0.43	-6.05	-0.31	3.73e-9	Inflammatory biomarkers;
LIHC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.52	-15.89	-0.65	5.89e-43	Breast cancer;
LIHC	cis	rs3736485	0.966	rs2124876	chr15:51906162	T/C	cg08986416	chr15:51914746	DMXL2	-0.41	-6.11	-0.31	2.69e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs360798	0.512	rs360801	chr2:62955387	C/T	cg17519650	chr2:63277830	OTX1	0.53	8.13	0.4	7.83e-15	Coronary artery disease;
LIHC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.64	-7.43	-0.37	8.83e-13	Neutrophil percentage of white cells;
LIHC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.38e-13	Heart rate;
LIHC	cis	rs10792665	0.640	rs3763814	chr11:82612842	C/G	cg24227371	chr11:82718527	RAB30	-0.27	-6.24	-0.32	1.28e-9	Obesity-related traits;
LIHC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.62	-0.5	5.69e-23	Hemoglobin concentration;
LIHC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs6596100	0.500	rs35534543	chr5:132160057	C/T	cg02081065	chr5:132209139	LEAP2	0.28	5.77	0.3	1.81e-8	Breast cancer;
LIHC	cis	rs7614311	0.689	rs56329572	chr3:63846672	G/A	cg22134162	chr3:63841271	THOC7	-0.56	-6.38	-0.33	5.62e-10	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg26338869	chr17:61819248	STRADA	0.54	7.22	0.36	3.37e-12	Height;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05091115	chr10:65280959	REEP3	-0.44	-6.32	-0.32	7.95e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg06026331	chr20:60912101	LAMA5	-0.5	-8.56	-0.42	3.89e-16	Colorectal cancer;
LIHC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.58	-7.93	-0.39	3.04e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.91	0.67	4.81e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	0.97	18.73	0.71	2.23e-54	Platelet distribution width;
LIHC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg17750252	chr2:136567154	LCT	0.33	5.77	0.3	1.81e-8	Mosquito bite size;
LIHC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.46	-0.33	3.6e-10	Alzheimer's disease (late onset);
LIHC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.47	-6.76	-0.34	5.8200000000000003e-11	Corneal structure;
LIHC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.9	0.3	8.68e-9	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08576880	chr16:1359158	UBE2I	-0.46	-6.52	-0.33	2.53e-10	Pancreatic cancer;
LIHC	cis	rs1866706	1.000	rs4757953	chr11:12874513	C/T	cg25843174	chr11:12811716	TEAD1	0.31	6.64	0.34	1.25e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.27	-0.32	1.07e-9	Vitamin D levels;
LIHC	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.23	-0.32	1.39e-9	Response to antipsychotic treatment;
LIHC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.76	-11.64	-0.53	1.27e-26	Anterior chamber depth;
LIHC	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-5.88	-0.3	9.5e-9	Schizophrenia;
LIHC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.67	13.14	0.58	3.35e-32	Body mass index;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-7.5	-0.38	5.6e-13	Prudent dietary pattern;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.87	0.8	1.08e-78	Prudent dietary pattern;
LIHC	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg10820045	chr2:198174542	NA	0.54	8.7	0.43	1.47e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.64	-9.08	-0.44	8.7e-18	Blood metabolite levels;
LIHC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.58	-0.53	2.12e-26	Chronic sinus infection;
LIHC	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.06	19.05	0.72	1.18e-55	Triglycerides;
LIHC	cis	rs847851	0.617	rs3807051	chr6:34922439	T/C	cg13137465	chr6:34857473	ANKS1A	0.67	7.34	0.37	1.6e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2710642	0.564	rs6752597	chr2:62823444	T/C	cg17519650	chr2:63277830	OTX1	0.46	7.23	0.36	3.24e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.48	6.36	0.33	6.43e-10	Major depressive disorder;
LIHC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.73	-14.0	-0.6	1.63e-35	Mortality in heart failure;
LIHC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg05425664	chr17:57184151	TRIM37	0.52	7.46	0.37	7.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.33e-18	Bipolar disorder;
LIHC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg02290350	chr8:58132656	NA	0.32	6.91	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.55	8.5	0.42	5.96e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.06e-10	Renal cell carcinoma;
LIHC	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.29	6.33	0.32	7.54e-10	Pulmonary function;
LIHC	cis	rs1144333	0.655	rs1144337	chr1:76278877	A/G	cg22875332	chr1:76189707	ACADM	-0.41	-6.7	-0.34	8.62e-11	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25789201	chr7:72395803	POM121	0.48	7.37	0.37	1.31e-12	Cognitive function;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg19575813	chr18:46476937	SMAD7	-0.4	-6.09	-0.31	2.97e-9	Alopecia areata;
LIHC	cis	rs4650994	0.593	rs12568310	chr1:178514622	C/T	cg05350800	chr1:178550844	NA	-0.35	-7.47	-0.37	6.85e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.33	7.77	0.39	9.1e-14	Educational attainment (years of education);
LIHC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02450064	chr17:40260053	DHX58	-0.29	-6.03	-0.31	4.3e-9	Fibrinogen levels;
LIHC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.6	7.48	0.38	6.18e-13	Heart rate;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2138798	0.560	rs11899838	chr2:63478136	C/T	cg17519650	chr2:63277830	OTX1	0.48	5.99	0.31	5.38e-9	Obesity-related traits;
LIHC	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.48	-8.1	-0.4	9.68e-15	Longevity;
LIHC	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27458888	chr15:25684578	UBE3A	0.39	6.38	0.33	5.67e-10	Cognitive function;
LIHC	cis	rs12644436	0.965	rs10024946	chr4:88790584	A/G	cg06891869	chr4:88767617	MEPE	0.31	5.72	0.3	2.28e-8	HIV-1 viral setpoint;
LIHC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg12798992	chr6:167411361	FGFR1OP	0.43	6.62	0.34	1.39e-10	Primary biliary cholangitis;
LIHC	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.56	-6.45	-0.33	3.84e-10	Primary sclerosing cholangitis;
LIHC	cis	rs2274273	0.804	rs28428911	chr14:55843596	G/T	cg01864836	chr14:55583639	NA	-0.38	-6.69	-0.34	9.03e-11	Protein biomarker;
LIHC	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg12698662	chr3:15914712	MIR563	-0.38	-6.99	-0.35	1.47e-11	Mean platelet volume;
LIHC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.89	0.3	9e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg02290350	chr8:58132656	NA	0.35	8.24	0.41	3.84e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	0.91	12.6	0.56	3.57e-30	Mitochondrial DNA levels;
LIHC	cis	rs10508774	0.925	rs56391924	chr10:32745248	A/C	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.72e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.49	-6.67	-0.34	1.05e-10	Cognitive ability;
LIHC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg01652190	chr22:50026171	C22orf34	-0.32	-7.31	-0.37	1.93e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.83	12.75	0.57	1.01e-30	Motion sickness;
LIHC	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.08	-0.4	1.1e-14	Vitamin D levels;
LIHC	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg03543861	chr21:44258195	NA	0.53	8.66	0.42	1.9e-16	Information processing speed;
LIHC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.45	-7.58	-0.38	3.19e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.76	7.03	0.36	1.15e-11	Plasma clusterin levels;
LIHC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg25281562	chr12:121454272	C12orf43	0.36	6.15	0.32	2.16e-9	N-glycan levels;
LIHC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.61	-10.45	-0.49	2.26e-22	Height;
LIHC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	9.02	0.44	1.37e-17	Motion sickness;
LIHC	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg14222432	chr12:29376421	FAR2	0.33	6.26	0.32	1.13e-9	QT interval;
LIHC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13395646	chr4:1353034	KIAA1530	0.63	9.11	0.44	7.15e-18	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg13047869	chr3:10149882	C3orf24	0.51	5.88	0.3	9.55e-9	Alzheimer's disease;
LIHC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	9.04	0.44	1.18e-17	Initial pursuit acceleration;
LIHC	trans	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg10756647	chr7:56101905	PSPH	-1.04	-12.61	-0.56	3.42e-30	Diabetic kidney disease;
LIHC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Body mass index;
LIHC	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.69	11.98	0.54	7.23e-28	Colorectal cancer;
LIHC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.58	9.54	0.46	2.83e-19	Colorectal cancer;
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.23	-0.41	3.85e-15	Total body bone mineral density;
LIHC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.86	-0.43	4.49e-17	Bipolar disorder;
LIHC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.45	6.5	0.33	2.83e-10	Aortic root size;
LIHC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	1.04	20.83	0.75	8.28e-63	Breast cancer;
LIHC	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.24	0.32	1.31e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.91	-18.61	-0.71	6.98e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10744422	1.000	rs2343108	chr12:123331301	C/T	cg22842854	chr12:123319900	HIP1R	-0.74	-9.79	-0.47	4.11e-20	Schizophrenia;
LIHC	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.56	-8.91	-0.43	3.11e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg24296786	chr1:45957014	TESK2	-0.52	-8.01	-0.4	1.77e-14	High light scatter reticulocyte count;
LIHC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.79	14.03	0.6	1.24e-35	Obesity-related traits;
LIHC	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.55	-10.17	-0.48	2.08e-21	Urate levels in overweight individuals;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18222961	chr2:48009935	MSH6	0.42	6.06	0.31	3.54e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs9641123	0.639	rs2214872	chr7:93250631	C/T	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs74544699	0.826	rs74499711	chr4:74842764	G/A	cg15398841	chr4:74847761	PF4	0.54	6.08	0.31	3.29e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg21466736	chr12:48725269	NA	0.34	5.96	0.31	6.37e-9	Plateletcrit;
LIHC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	8.02	0.4	1.73e-14	Electrocardiographic conduction measures;
LIHC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.65	8.42	0.41	1.05e-15	Initial pursuit acceleration;
LIHC	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.83	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.31	-0.41	2.26e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.77	-0.34	5.55e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs3736485	0.934	rs4775952	chr15:51869056	T/C	cg08986416	chr15:51914746	DMXL2	-0.41	-6.06	-0.31	3.5e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.51	7.2	0.36	3.75e-12	Obesity-related traits;
LIHC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg05361325	chr10:32636312	EPC1	-0.52	-6.41	-0.33	4.77e-10	Sexual dysfunction (female);
LIHC	cis	rs7129220	0.512	rs58652557	chr11:10121925	C/G	cg01453529	chr11:10209919	SBF2	-0.39	-6.9	-0.35	2.47e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.36e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs75908454	1.000	rs79558633	chr6:169819490	C/T	cg19338460	chr6:170058176	WDR27	-0.85	-7.44	-0.37	8.17e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.29	0.32	9.98e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg12575136	chr18:32820987	ZNF397	0.48	7.12	0.36	6.25e-12	White blood cell count;
LIHC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.73	9.37	0.45	1.03e-18	Gut microbiome composition (summer);
LIHC	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.03	-0.36	1.11e-11	Pediatric bone mineral density (spine);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00776160	chr1:149815087	HIST2H2AA3;HIST2H2AA4	0.41	6.65	0.34	1.18e-10	Cognitive function;
LIHC	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.35	8.55	0.42	4.32e-16	Cutaneous nevi;
LIHC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.79	10.26	0.49	1.02e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.42	-7.35	-0.37	1.45e-12	Mean corpuscular volume;
LIHC	cis	rs7639513	0.520	rs79141906	chr3:12711977	A/C	cg23032965	chr3:12705835	RAF1	0.6	6.61	0.34	1.51e-10	Itch intensity from mosquito bite;
LIHC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.46	0.33	3.61e-10	Initial pursuit acceleration;
LIHC	cis	rs1986734	0.560	rs4859683	chr4:77419073	C/T	cg24201034	chr4:77507246	SHROOM3	-0.38	-6.12	-0.31	2.62e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.37e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg18944383	chr4:111397179	ENPEP	0.25	6.32	0.32	7.95e-10	Height;
LIHC	trans	rs4596713	0.538	rs4421408	chr9:71760884	G/T	cg16512924	chr15:28394682	HERC2	0.39	6.27	0.32	1.07e-9	Headache;
LIHC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.09	0.4	1.03e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-6.6	-0.34	1.61e-10	Fibrinogen levels;
LIHC	cis	rs28830936	0.934	rs3959569	chr15:42115747	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.86	-0.3	1.09e-8	Diastolic blood pressure;
LIHC	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.63	7.84	0.39	5.87e-14	Blood metabolite levels;
LIHC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	1.05	15.47	0.64	2.58e-41	Breast cancer;
LIHC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.34	0.58	5.79e-33	Cognitive test performance;
LIHC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg18769074	chr3:133464867	TF	0.27	6.1	0.31	2.9e-9	Iron status biomarkers;
LIHC	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.34	0.52	1.64e-25	Motion sickness;
LIHC	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg14930904	chr10:32216787	ARHGAP12	0.37	6.48	0.33	3.2e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.55	7.13	0.36	6.01e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs611744	0.967	rs662591	chr8:109211358	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg25952890	chr19:58913133	NA	0.7	7.64	0.38	2.23e-13	Mean platelet volume;
LIHC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg13301601	chr7:774633	HEATR2	-0.4	-5.71	-0.3	2.44e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.57	-8.77	-0.43	8.66e-17	Red cell distribution width;
LIHC	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg19920283	chr7:105172520	RINT1	0.48	6.13	0.31	2.49e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.46	8.51	0.42	5.51e-16	Hand grip strength;
LIHC	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.86	9.63	0.46	1.43e-19	Ulcerative colitis;
LIHC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.89e-27	Motion sickness;
LIHC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg08694578	chr2:241835147	C2orf54	0.48	6.6	0.34	1.57e-10	Urinary metabolites;
LIHC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.11	-0.48	3.3e-21	Response to antipsychotic treatment;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.78	0.47	4.28e-20	Lymphocyte counts;
LIHC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.69	-11.23	-0.52	3.92e-25	Prostate cancer;
LIHC	cis	rs74233809	1.000	rs74233809	chr10:104913940	T/C	cg03493300	chr10:104813866	CNNM2	0.46	6.04	0.31	3.94e-9	Birth weight;
LIHC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg07061783	chr6:25882402	NA	0.42	5.73	0.3	2.15e-8	Blood metabolite levels;
LIHC	cis	rs2257205	0.667	rs6503876	chr17:56814988	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-6.66	-0.34	1.08e-10	Pancreatic cancer;
LIHC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.67	9.95	0.47	1.22e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.53	-10.94	-0.51	4.33e-24	Late-onset Alzheimer's disease;
LIHC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg14067834	chr17:29058358	SUZ12P	0.67	6.54	0.33	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg02290350	chr8:58132656	NA	0.31	6.73	0.34	7.15e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.33	5.98	0.31	5.68e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.38	-0.33	5.85e-10	Longevity;Endometriosis;
LIHC	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.24	-0.32	1.26e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.92	-0.39	3.31e-14	Asthma;
LIHC	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-0.53	-5.86	-0.3	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs807029	0.533	rs722435	chr10:102745062	G/T	cg17130504	chr10:102756923	LZTS2	0.56	7.8	0.39	7.35e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.5	-8.64	-0.42	2.13e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs10411161	0.702	rs7251929	chr19:52389258	C/T	cg22319618	chr22:45562946	NUP50	-0.62	-8.57	-0.42	3.59e-16	Breast cancer;
LIHC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	1.14	13.62	0.59	4.65e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.44	-8.19	-0.4	5.26e-15	Hemoglobin concentration;
LIHC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg11764359	chr7:65958608	NA	-0.58	-5.98	-0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs922107	0.713	rs1380416	chr1:89949213	A/G	cg15422784	chr1:90023713	LRRC8B	0.41	6.43	0.33	4.3e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.52	-9.23	-0.45	2.82e-18	Blood protein levels;
LIHC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05025164	chr4:1340916	KIAA1530	-0.4	-5.96	-0.31	6.35e-9	Obesity-related traits;
LIHC	trans	rs1459104	0.673	rs7118132	chr11:55126517	C/T	cg03929089	chr4:120376271	NA	0.51	6.98	0.35	1.5e-11	Body mass index;
LIHC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.3	5.77	0.3	1.81e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.59	8.36	0.41	1.58e-15	Monocyte count;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.44	-8.16	-0.4	6.52e-15	Prudent dietary pattern;
LIHC	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.45	-6.01	-0.31	4.86e-9	IgE levels;
LIHC	cis	rs2607426	0.681	rs1531063	chr19:41225319	C/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.5	-5.97	-0.31	6.06e-9	Blood protein levels;
LIHC	cis	rs3736485	0.932	rs8037167	chr15:51918126	G/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.8	-0.35	4.61e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs459482	0.534	rs458255	chr21:42801128	G/A	cg14166395	chr21:42792516	MX1	0.51	7.03	0.36	1.16e-11	IgG glycosylation;
LIHC	cis	rs3744061	0.557	rs9889862	chr17:74647976	A/G	cg13533061	chr17:74712429	JMJD6	-0.3	-6.17	-0.32	1.88e-9	Retinal arteriolar caliber;
LIHC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.61	-7.36	-0.37	1.4e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg15269541	chr15:43626905	ADAL	-0.3	-5.88	-0.3	9.9e-9	Lung cancer in ever smokers;
LIHC	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.85	11.72	0.54	6.66e-27	Menopause (age at onset);
LIHC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg09222892	chr1:25734099	RHCE	-0.47	-8.83	-0.43	5.58e-17	Erythrocyte sedimentation rate;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10983056	chr13:113344077	ATP11A	0.47	6.66	0.34	1.07e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.65	8.24	0.41	3.74e-15	Prostate cancer;
LIHC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.38	7.78	0.39	8.76e-14	Immature fraction of reticulocytes;
LIHC	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.59	9.36	0.45	1.08e-18	Corneal astigmatism;
LIHC	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.15	0.32	2.16e-9	Coronary artery calcification;
LIHC	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	5.91	0.3	8.44e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7187994	0.836	rs16974519	chr16:84782750	A/C	cg07647771	chr16:84786436	USP10	-0.34	-6.7	-0.34	8.38e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06656553	chr16:89960601	TCF25	-0.43	-5.74	-0.3	2.05e-8	Skin colour saturation;
LIHC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.38	6.33	0.32	7.67e-10	Red blood cell count;
LIHC	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.84	0.6	6.95e-35	Bipolar disorder;
LIHC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.54	0.33	2.21e-10	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.91	-0.39	3.62e-14	Response to antipsychotic treatment;
LIHC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.63	10.29	0.49	8.39e-22	Multiple myeloma (IgH translocation);
LIHC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.7	10.98	0.51	3.09e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs4407350	0.967	rs5765731	chr22:44922759	C/T	cg26276947	chr22:44892394	LDOC1L	0.33	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.77	-15.14	-0.63	5.41e-40	Height;
LIHC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.74	-0.34	6.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.84	0.3	1.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs17021463	0.615	rs4626213	chr4:95297241	G/A	cg11021082	chr4:95130006	SMARCAD1	0.43	7.18	0.36	4.27e-12	Testicular germ cell tumor;
LIHC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.74	-0.3	2.1e-8	Body mass index;
LIHC	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.78	13.44	0.59	2.44e-33	Aortic root size;
LIHC	cis	rs4450131	0.522	rs3781460	chr10:126342919	A/G	cg20435097	chr10:126320824	FAM53B	-0.67	-12.26	-0.55	6.68e-29	White blood cell count (basophil);
LIHC	cis	rs2834188	1.000	rs2252930	chr21:34704201	C/G	cg14352951	chr21:34696688	IFNAR1	-0.51	-6.73	-0.34	7.03e-11	Narcolepsy;
LIHC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.74	-11.48	-0.53	4.86e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg09835421	chr16:68378352	PRMT7	-0.47	-5.77	-0.3	1.75e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.82	-0.39	6.44e-14	Response to antipsychotic treatment;
LIHC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg03854865	chr6:26224070	HIST1H3E	0.62	7.01	0.35	1.3e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.65	0.38	2.03e-13	Height;
LIHC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.49	-7.11	-0.36	6.83e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.36	-0.41	1.57e-15	Gut microbiome composition (summer);
LIHC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.75	11.3	0.52	2.24e-25	Coronary artery disease;
LIHC	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg04455712	chr21:45112962	RRP1B	0.39	6.54	0.33	2.22e-10	Mean corpuscular volume;
LIHC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.62	11.44	0.53	7.14e-26	Coronary artery disease;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.2	-0.32	1.65e-9	Total body bone mineral density;
LIHC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-9.95	-0.47	1.17e-20	Obesity-related traits;
LIHC	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg15352829	chr14:105391018	PLD4	-0.44	-9.24	-0.45	2.61e-18	Systemic lupus erythematosus;
LIHC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg14709524	chr16:89940631	TCF25	0.47	5.85	0.3	1.13e-8	Skin colour saturation;
LIHC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21467203	chr3:49911342	NA	-0.51	-8.96	-0.44	2.09e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.86	-11.24	-0.52	3.86e-25	Schizophrenia;
LIHC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg04824913	chr4:887549	GAK	0.61	7.68	0.38	1.71e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs5769707	0.777	rs8141219	chr22:50044546	A/G	cg01652190	chr22:50026171	C22orf34	-0.35	-7.98	-0.4	2.3e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.02	0.35	1.23e-11	Exhaled nitric oxide output;
LIHC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.41	-6.38	-0.33	5.63e-10	Blood pressure (smoking interaction);
LIHC	cis	rs4285214	0.715	rs10079692	chr5:124025450	A/G	cg15082166	chr5:124005151	ZNF608	-0.41	-5.92	-0.31	7.68e-9	Survival in pancreatic cancer;
LIHC	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.41	7.99	0.4	2.11e-14	Plateletcrit;Platelet count;
LIHC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.6	10.91	0.51	5.64e-24	Total body bone mineral density;
LIHC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.37	-0.56	2.66e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.56	7.39	0.37	1.1e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.44	7.81	0.39	6.84e-14	Aortic root size;
LIHC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.26	-17.06	-0.68	1.18e-47	Diabetic kidney disease;
LIHC	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.3	-6.67	-0.34	1.04e-10	DNA methylation (variation);
LIHC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	11.72	0.54	6.56e-27	Cognitive test performance;
LIHC	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg02297831	chr4:17616191	MED28	0.49	7.53	0.38	4.66e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.79	11.77	0.54	4.32e-27	Coronary artery disease;
LIHC	cis	rs4908768	0.906	rs12401496	chr1:8600401	C/T	cg25722041	chr1:8623473	RERE	0.42	5.91	0.3	8.17e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3736485	0.932	rs11633395	chr15:51917957	G/T	cg08986416	chr15:51914746	DMXL2	-0.47	-7.03	-0.36	1.16e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14471096	chr4:185570637	CCDC111;CASP3	0.43	6.12	0.31	2.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.67	12.77	0.57	8.09e-31	Menopause (age at onset);
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13126279	chr21:47581558	C21orf56	-0.4	-6.11	-0.31	2.72e-9	Testicular germ cell tumor;
LIHC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18252515	chr7:66147081	NA	0.42	6.03	0.31	4.17e-9	Aortic root size;
LIHC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.03e-14	Motion sickness;
LIHC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.78	-0.67	1.55e-46	Ulcerative colitis;
LIHC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg21724239	chr8:58056113	NA	0.49	6.53	0.33	2.43e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg17385448	chr1:15911702	AGMAT	0.38	6.66	0.34	1.12e-10	Systolic blood pressure;
LIHC	trans	rs13202860	1.000	rs34281235	chr6:87188343	C/T	cg27326224	chr7:950474	ADAP1	-0.57	-6.32	-0.32	8.05e-10	Sexual dysfunction (female);
LIHC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.6	9.0	0.44	1.61e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.65	-12.0	-0.54	6.23e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs2286503	0.780	rs981792	chr7:22861639	C/A	cg11367502	chr7:22862612	TOMM7	0.45	7.51	0.38	5.08e-13	Fibrinogen;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17808901	chr3:39093368	WDR48	0.49	6.78	0.34	5.36e-11	Pancreatic cancer;
LIHC	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.74	-0.3	2.1e-8	Osteoarthritis;
LIHC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.38	-6.33	-0.32	7.86e-10	Educational attainment;
LIHC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.55	-0.33	2.15e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-7.25	-0.36	2.89e-12	Hepatocellular carcinoma;
LIHC	cis	rs2978263	0.689	rs16877110	chr8:30368430	G/T	cg05780722	chr8:30327988	RBPMS	-0.35	-6.77	-0.34	5.59e-11	Cognitive performance;
LIHC	cis	rs9596863	0.950	rs1379827	chr13:54395414	A/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.08e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.38	7.48	0.37	6.47e-13	Growth-regulated protein alpha levels;
LIHC	trans	rs12753920	0.703	rs1601021	chr1:92621413	A/G	cg15668468	chr10:118892869	VAX1	0.43	6.15	0.32	2.19e-9	Systemic lupus erythematosus;
LIHC	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-7.42	-0.37	9.42e-13	Metabolite levels;
LIHC	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16346588	chr10:242978	ZMYND11	0.39	6.04	0.31	3.96e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.38	6.12	0.31	2.63e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg20607798	chr8:58055168	NA	0.46	6.26	0.32	1.18e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg14709524	chr16:89940631	TCF25	0.47	5.85	0.3	1.13e-8	Skin colour saturation;
LIHC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00152838	chr16:24741724	TNRC6A	-0.53	-6.51	-0.33	2.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.76	13.03	0.58	8.94e-32	Mean platelet volume;
LIHC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg14067834	chr17:29058358	SUZ12P	0.71	6.99	0.35	1.49e-11	Body mass index;
LIHC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.48	-6.95	-0.35	1.86e-11	Menarche (age at onset);
LIHC	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.49	-0.38	6.04e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.19	-0.4	5.23e-15	Longevity;
LIHC	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg08911820	chr1:110026001	ATXN7L2	0.61	7.73	0.39	1.2e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.69	0.5	3.4e-23	Colorectal cancer;
LIHC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.44	6.97	0.35	1.64e-11	Melanoma;
LIHC	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg01145232	chr6:150245071	RAET1G	-0.37	-7.26	-0.37	2.62e-12	Lung cancer;
LIHC	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.49	8.1	0.4	9.75e-15	Schizophrenia;
LIHC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.43	0.33	4.19e-10	Cognitive test performance;
LIHC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.64	9.01	0.44	1.52e-17	Colorectal cancer;
LIHC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.43	6.62	0.34	1.4e-10	Neuroticism;
LIHC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.77	12.44	0.56	1.41e-29	Night sleep phenotypes;
LIHC	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.61	-8.05	-0.4	1.43e-14	Coronary artery disease;
LIHC	cis	rs4800452	0.826	rs28625207	chr18:20746672	A/G	cg26136497	chr18:20735537	CABLES1	-0.44	-5.72	-0.3	2.29e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.62	-10.18	-0.48	1.93e-21	Obesity-related traits;
LIHC	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs62179067	0.708	rs11903793	chr2:179934583	C/G	cg27622325	chr2:179545785	TTN	0.58	5.77	0.3	1.82e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.76	13.94	0.6	2.82e-35	Platelet count;
LIHC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg08847533	chr14:75593920	NEK9	0.51	7.88	0.39	4.49e-14	Neuroticism (multi-trait analysis);
LIHC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	7.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg17724175	chr1:150552817	MCL1	-0.42	-8.74	-0.43	1.04e-16	Melanoma;
LIHC	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.33	-0.32	7.65e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg02931644	chr1:25747376	RHCE	0.36	7.89	0.39	4.2e-14	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg10755058	chr3:40428713	ENTPD3	0.35	5.75	0.3	1.95e-8	Renal cell carcinoma;
LIHC	cis	rs1494950	1.000	rs79999663	chr4:14974623	T/G	cg12377275	chr4:15005593	CPEB2	-0.78	-6.57	-0.33	1.83e-10	Political ideology;
LIHC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg20607798	chr8:58055168	NA	0.46	6.3	0.32	9.07e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs965469	0.671	rs6139076	chr20:3305210	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg21724239	chr8:58056113	NA	0.46	6.14	0.32	2.25e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-12.91	-0.57	2.54e-31	Dental caries;
LIHC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20135002	chr11:47629003	NA	-0.53	-9.25	-0.45	2.54e-18	Subjective well-being;
LIHC	cis	rs2933343	1.000	rs789237	chr3:128636961	A/C	cg25356066	chr3:128598488	ACAD9	0.52	6.95	0.35	1.86e-11	IgG glycosylation;
LIHC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.13	-0.36	6e-12	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.61	-12.03	-0.55	4.8e-28	Prudent dietary pattern;
LIHC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg21522988	chr12:29376872	FAR2	0.28	6.42	0.33	4.61e-10	QT interval;
LIHC	trans	rs11157436	0.874	rs35951144	chr14:22617926	G/C	cg13567813	chr19:50879636	NR1H2	0.45	6.6	0.34	1.57e-10	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-7.54	-0.38	4.39e-13	Lymphocyte counts;
LIHC	cis	rs507080	0.922	rs471227	chr11:118564601	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.57	0.33	1.89e-10	Serum metabolite levels;
LIHC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.49	6.67	0.34	1.04e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.42	0.37	9.14e-13	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07318050	chr1:233086124	C1orf57	0.47	7.39	0.37	1.17e-12	Pancreatic cancer;
LIHC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.6	8.37	0.41	1.52e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs16958440	0.581	rs11082564	chr18:44659149	C/G	cg17192377	chr18:44677553	HDHD2	0.51	6.36	0.33	6.31e-10	Sitting height ratio;
LIHC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.87	-0.35	2.96e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.52	8.85	0.43	4.69e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	1.02	19.65	0.73	4.62e-58	Breast cancer;
LIHC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.4	5.79	0.3	1.61e-8	Lipoprotein (a) levels;
LIHC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.62	-8.13	-0.4	7.77e-15	Obesity-related traits;
LIHC	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg20129853	chr10:51489980	NA	-0.41	-8.96	-0.44	2.14e-17	Prostate-specific antigen levels;
LIHC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg18016565	chr1:150552671	MCL1	0.5	9.59	0.46	1.87e-19	Melanoma;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10860527	chr2:109403091	CCDC138	-0.59	-6.91	-0.35	2.39e-11	Systolic blood pressure;
LIHC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11645453	chr3:52864694	ITIH4	0.21	5.71	0.3	2.43e-8	Bipolar disorder;
LIHC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.61	-11.06	-0.51	1.69e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.26	18.82	0.71	9.63e-55	Type 1 diabetes nephropathy;
LIHC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.44	7.97	0.4	2.31e-14	Platelet distribution width;
LIHC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.21	-0.32	1.52e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.59	7.83	0.39	6.21e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.61	-9.97	-0.47	1.02e-20	Alcohol dependence;
LIHC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.88	15.14	0.63	5.21e-40	Parkinson's disease;
LIHC	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.57	-9.17	-0.44	4.49e-18	HDL cholesterol;
LIHC	cis	rs10744422	1.000	rs2061101	chr12:123348925	C/A	cg22842854	chr12:123319900	HIP1R	-0.64	-7.64	-0.38	2.24e-13	Schizophrenia;
LIHC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-7.31	-0.37	1.96e-12	Fear of minor pain;
LIHC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.39	6.9	0.35	2.55e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.37	-6.08	-0.31	3.14e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg14828511	chr1:107599125	PRMT6	0.42	6.07	0.31	3.32e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.5	-9.34	-0.45	1.31e-18	Hemoglobin concentration;
LIHC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.59	5.8	0.3	1.53e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg19645103	chr12:69753606	YEATS4	-0.4	-5.89	-0.3	9.05e-9	Blood protein levels;
LIHC	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	10.32	0.49	6.7e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.77	-6.44	-0.33	4.06e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07159469	chr16:89355005	ANKRD11	-0.4	-6.13	-0.31	2.41e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	9.06	0.44	1.06e-17	IgG glycosylation;
LIHC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.13	-13.08	-0.58	5.75e-32	White matter hyperintensity burden;
LIHC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.63	12.53	0.56	6.42e-30	Sjögren's syndrome;
LIHC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.5	8.85	0.43	4.7e-17	Total body bone mineral density;
LIHC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.34	0.32	7.21e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg04373760	chr16:53404718	NA	0.61	7.97	0.4	2.38e-14	Hypertriglyceridemia;
LIHC	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.24	-6.14	-0.32	2.27e-9	Hepatitis;
LIHC	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.66	-0.38	1.96e-13	Schizophrenia;
LIHC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.68	10.14	0.48	2.6e-21	Coronary artery disease;
LIHC	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.46	-8.7	-0.43	1.42e-16	Testicular germ cell tumor;
LIHC	cis	rs4684776	0.867	rs1499119	chr3:11333291	G/T	cg00170343	chr3:11313890	ATG7	-0.53	-7.34	-0.37	1.53e-12	Small vessel stroke;
LIHC	trans	rs1414896	0.692	rs3767316	chr1:95705053	C/T	cg24483554	chr1:179544584	NPHS2	-0.25	-6.13	-0.31	2.41e-9	Non-alcoholic fatty liver disease histology (AST);
LIHC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	7.93	0.39	3.19e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.84	13.25	0.58	1.21e-32	Gastritis;
LIHC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	1.0	18.4	0.71	4.69e-53	Monocyte percentage of white cells;
LIHC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	1.02	19.53	0.73	1.36e-57	Breast cancer;
LIHC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.55	8.96	0.44	2.07e-17	Uric acid clearance;
LIHC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg21466736	chr12:48725269	NA	0.33	5.74	0.3	2.04e-8	Plateletcrit;
LIHC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg14092571	chr14:90743983	NA	-0.41	-6.53	-0.33	2.34e-10	Mortality in heart failure;
LIHC	cis	rs3820500	0.585	rs1289960	chr1:117926118	C/T	cg20383390	chr1:117909022	MAN1A2	0.44	5.74	0.3	2.11e-8	Pneumonia;
LIHC	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.69	0.34	9.14e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg16070123	chr10:51489643	NA	0.37	5.9	0.3	8.68e-9	Prostate-specific antigen levels;
LIHC	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs2710642	0.525	rs1601673	chr2:62842559	G/C	cg23713900	chr18:615496	CLUL1	-0.24	-6.23	-0.32	1.4e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs8081395	0.801	rs2665405	chr17:57875292	G/A	cg02344993	chr17:57696989	CLTC	-0.44	-7.19	-0.36	3.99e-12	White blood cell count;
LIHC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	trans	rs2352908	1.000	rs12897476	chr14:49453299	G/T	cg16568472	chr20:3190600	ITPA	-0.45	-6.12	-0.31	2.55e-9	Social communication problems;
LIHC	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.66	-13.88	-0.6	4.79e-35	Bipolar disorder;
LIHC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.49	6.49	0.33	2.95e-10	Major depressive disorder;
LIHC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.45	7.44	0.37	8.06e-13	Aortic root size;
LIHC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.72	0.54	6.76e-27	Motion sickness;
LIHC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.72	-11.73	-0.54	6.15e-27	Body mass index;
LIHC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.57	8.88	0.43	3.93e-17	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8103278	0.701	rs116959973	chr19:46252333	A/T	cg14061069	chr19:46274453	DMPK	-0.49	-7.15	-0.36	5.22e-12	Coronary artery disease;
LIHC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.93	-0.54	1.16e-27	Urate levels in overweight individuals;
LIHC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg20341384	chr10:131568735	NA	-0.41	-6.27	-0.32	1.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.76	-11.04	-0.51	1.87e-24	Longevity;
LIHC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.51	7.96	0.4	2.49e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14047548	chr9:136199066	SURF6	0.44	7.0	0.35	1.36e-11	Longevity;
LIHC	cis	rs1789	0.903	rs4470622	chr4:15674175	T/G	cg21329975	chr4:15471214	CC2D2A	-0.4	-5.87	-0.3	1.06e-8	Blood protein levels;
LIHC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.37	6.75	0.34	6.39e-11	Aortic root size;
LIHC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-7.07	-0.36	8.6e-12	Body mass index;
LIHC	cis	rs611744	0.905	rs677031	chr8:109152068	G/A	cg21045802	chr8:109455806	TTC35	0.48	8.12	0.4	8.4e-15	Dupuytren's disease;
LIHC	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.36	-0.37	1.42e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.57	7.58	0.38	3.22e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.77	11.16	0.52	7.08e-25	Response to hepatitis C treatment;
LIHC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.44	0.66	3.6e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.83	-13.0	-0.58	1.14e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.72	14.5	0.62	1.76e-37	Menopause (age at onset);
LIHC	cis	rs7091068	0.721	rs618951	chr10:95404967	A/G	cg20715218	chr10:95462985	C10orf4	-0.6	-6.87	-0.35	3.04e-11	Urinary tract infection frequency;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.56	9.53	0.46	3.07e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.36	7.05	0.36	1.02e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.63	-10.63	-0.5	5.61e-23	Crohn's disease;
LIHC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.42	-9.08	-0.44	9.13e-18	Rheumatoid arthritis;
LIHC	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.61	-8.62	-0.42	2.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.78	13.24	0.58	1.39e-32	Psoriasis;
LIHC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.52	7.66	0.38	1.96e-13	Type 2 diabetes;
LIHC	cis	rs507080	0.922	rs519848	chr11:118552715	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	5.99	0.31	5.4e-9	Serum metabolite levels;
LIHC	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg20991723	chr1:152506922	NA	0.57	10.02	0.48	7.07e-21	Hair morphology;
LIHC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.36	0.45	1.11e-18	Bipolar disorder;
LIHC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.54	-9.23	-0.45	2.8e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg12365402	chr11:9010492	NRIP3	0.31	8.04	0.4	1.5e-14	Hemoglobin concentration;
LIHC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg04592579	chr7:75616294	TMEM120A	-0.39	-6.73	-0.34	7.3e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.67	-0.34	1.03e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.36	-0.33	6.28e-10	Personality dimensions;
LIHC	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	0.8	8.98	0.44	1.83e-17	Exhaled nitric oxide output;
LIHC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.72	9.24	0.45	2.74e-18	Gut microbiome composition (summer);
LIHC	cis	rs8081395	0.801	rs12938273	chr17:57901652	G/A	cg02344993	chr17:57696989	CLTC	-0.46	-7.57	-0.38	3.41e-13	White blood cell count;
LIHC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-6.49	-0.33	2.93e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.08	14.15	0.61	4.1e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4407350	0.901	rs5765717	chr22:44917646	G/T	cg26276947	chr22:44892394	LDOC1L	0.34	6.4	0.33	4.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	0.74	8.46	0.42	7.95e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.56	9.89	0.47	1.84e-20	Alcohol dependence;
LIHC	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.52	8.41	0.41	1.14e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.68	8.52	0.42	5.13e-16	Corneal astigmatism;
LIHC	cis	rs7107174	0.901	rs7937277	chr11:78114977	C/G	cg02023728	chr11:77925099	USP35	0.35	6.24	0.32	1.28e-9	Testicular germ cell tumor;
LIHC	cis	rs2851682	0.706	rs2524299	chr11:61604782	A/T	cg27386326	chr11:61587980	NA	0.57	9.23	0.45	2.89e-18	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg03934865	chr2:198174659	NA	0.56	8.81	0.43	6.23e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.1e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.67	-9.84	-0.47	2.69e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4790333	0.529	rs3101409	chr17:2258147	C/T	cg02569219	chr17:2266849	SGSM2	0.42	6.41	0.33	4.77e-10	Proinsulin levels;
LIHC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-10.07	-0.48	4.6e-21	Asthma;
LIHC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.18	0.32	1.77e-9	Renal cell carcinoma;
LIHC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.57	0.59	7.69e-34	Lung cancer in ever smokers;
LIHC	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg16589663	chr20:23618590	CST3	0.77	7.89	0.39	4.17e-14	Chronic kidney disease;
LIHC	trans	rs7668874	0.821	rs1898879	chr4:116808018	G/A	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.56	8.34	0.41	1.87e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.27	7.23	0.36	3.19e-12	Cardiovascular disease risk factors;
LIHC	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04530015	chr2:215796436	ABCA12	0.48	8.98	0.44	1.85e-17	Neuroblastoma (high-risk);
LIHC	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-9.99	-0.48	8.82e-21	Eye color traits;
LIHC	cis	rs17286411	0.750	rs12444594	chr16:71941912	A/T	cg06353428	chr16:71660113	MARVELD3	0.55	6.68	0.34	9.6e-11	Blood protein levels;
LIHC	cis	rs4676482	0.796	rs4676609	chr3:39214256	C/T	cg02254461	chr3:39195904	CSRNP1	0.63	6.92	0.35	2.17e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4700695	0.841	rs251300	chr5:65299715	C/G	cg21114390	chr5:65439923	SFRS12	-0.44	-5.76	-0.3	1.9e-8	Facial morphology (factor 19);
LIHC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.62	-9.66	-0.46	1.13e-19	Lung cancer;
LIHC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg20283391	chr11:68216788	NA	-0.37	-5.95	-0.31	6.65e-9	Total body bone mineral density;
LIHC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.44	0.33	4.13e-10	Lung cancer;
LIHC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg13409248	chr3:40428643	ENTPD3	-0.42	-6.73	-0.34	7.27e-11	Renal cell carcinoma;
LIHC	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.63	12.7	0.57	1.59e-30	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07704136	chr3:110790533	PVRL3	0.42	6.12	0.31	2.55e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg26031613	chr14:104095156	KLC1	-0.4	-5.72	-0.3	2.31e-8	Coronary artery disease;
LIHC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.55	9.89	0.47	1.82e-20	Alcohol dependence;
LIHC	cis	rs9503598	0.605	rs9968900	chr6:3457687	C/T	cg00476032	chr6:3446245	SLC22A23	0.41	7.86	0.39	5.11e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	1.0	19.05	0.72	1.18e-55	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07881982	chr3:156878112	CCNL1	0.49	6.71	0.34	8.04e-11	Pancreatic cancer;
LIHC	cis	rs8053891	0.673	rs10492824	chr16:72018771	A/C	cg01557791	chr16:72042693	DHODH	-0.5	-7.34	-0.37	1.53e-12	Coronary artery disease;
LIHC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21545522	chr1:205238299	TMCC2	0.36	6.86	0.35	3.19e-11	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.54	9.25	0.45	2.44e-18	Mean corpuscular volume;
LIHC	cis	rs4575098	0.626	rs11265557	chr1:161106354	T/G	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.4	7.4	0.37	1.03e-12	Monocyte percentage of white cells;
LIHC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.88	10.83	0.51	1.1e-23	Bladder cancer;
LIHC	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.18	30.61	0.86	5.36e-100	IgG glycosylation;
LIHC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-6.74	-0.34	6.89e-11	Total body bone mineral density;
LIHC	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.24	-6.0	-0.31	5.08e-9	Gut microbiome composition (winter);
LIHC	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.25	-0.32	1.23e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg16479474	chr6:28041457	NA	0.39	6.51	0.33	2.68e-10	Cardiac Troponin-T levels;
LIHC	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.46	8.51	0.42	5.45e-16	Testicular germ cell tumor;
LIHC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg11764359	chr7:65958608	NA	0.49	6.56	0.33	2.02e-10	Corneal structure;
LIHC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg03034668	chr16:1723424	CRAMP1L	-0.4	-7.08	-0.36	8.25e-12	Coronary artery disease;
LIHC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.74	-9.76	-0.47	5.22e-20	Schizophrenia;
LIHC	cis	rs526231	0.963	rs12187443	chr5:102660400	T/C	cg05225461	chr5:102596755	C5orf30	0.37	5.74	0.3	2.13e-8	Primary biliary cholangitis;
LIHC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.49	8.52	0.42	5.29e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.95	17.94	0.7	3.4e-51	Menopause (age at onset);
LIHC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.92	13.72	0.6	1.9e-34	Sudden cardiac arrest;
LIHC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.7	-10.61	-0.5	6.46e-23	Neutrophil percentage of white cells;
LIHC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.37	-6.33	-0.32	7.92e-10	Menopause (age at onset);
LIHC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg13114125	chr14:105738426	BRF1	-0.71	-9.56	-0.46	2.33e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11955398	0.716	rs12514253	chr5:59998301	G/A	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.82	0.47	3.16e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.28	21.06	0.75	1.03e-63	Corneal structure;
LIHC	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.69	0.38	1.62e-13	Fuchs's corneal dystrophy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03771185	chr4:775700	NA	0.43	6.27	0.32	1.11e-9	Pancreatic cancer;
LIHC	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg19539972	chr4:7069911	GRPEL1	-0.69	-7.44	-0.37	8.36e-13	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.47	-6.22	-0.32	1.43e-9	Monocyte count;
LIHC	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.84	0.63	8.46e-39	Prudent dietary pattern;
LIHC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.65	0.42	2e-16	Cognitive test performance;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.56	0.62	1.09e-37	Prudent dietary pattern;
LIHC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.34	0.55	3.52e-29	Alzheimer's disease;
LIHC	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg00204748	chr12:29376779	FAR2	-0.38	-7.08	-0.36	8.41e-12	QT interval;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.71	12.16	0.55	1.68e-28	Prudent dietary pattern;
LIHC	cis	rs9942416	0.533	rs12109251	chr5:75024240	C/A	cg19683494	chr5:74908142	NA	0.58	6.25	0.32	1.2e-9	Age-related disease endophenotypes;
LIHC	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-6.69	-0.34	9.07e-11	Neuroticism;
LIHC	cis	rs11958404	0.929	rs72816508	chr5:157356031	G/T	cg05962755	chr5:157440814	NA	1.0	9.55	0.46	2.51e-19	IgG glycosylation;
LIHC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.03	15.13	0.63	6.21e-40	Cognitive function;
LIHC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.06	0.48	4.9e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg21951975	chr1:209979733	IRF6	0.45	7.3	0.37	2.05e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.78	12.57	0.56	4.77e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs7614311	0.731	rs6445387	chr3:63962678	C/G	cg22134162	chr3:63841271	THOC7	-0.5	-6.19	-0.32	1.73e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.81	-8.97	-0.44	2.05e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.66	-9.9	-0.47	1.76e-20	Response to diuretic therapy;
LIHC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	1.16	12.42	0.56	1.67e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg06026331	chr20:60912101	LAMA5	-0.5	-8.25	-0.41	3.41e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.72	-8.09	-0.4	1.07e-14	Neuroticism;
LIHC	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.87	-0.35	3.1e-11	Bipolar disorder;
LIHC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Blood protein levels;
LIHC	cis	rs6504950	0.720	rs9910653	chr17:52992268	C/T	cg10237252	chr17:52977213	TOM1L1	-0.36	-6.21	-0.32	1.57e-9	Breast cancer;
LIHC	cis	rs2033908	0.620	rs10765993	chr11:12849185	C/G	cg25843174	chr11:12811716	TEAD1	-0.32	-7.45	-0.37	7.71e-13	Sitting height ratio;
LIHC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	10.97	0.51	3.37e-24	Type 2 diabetes;
LIHC	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg14146966	chr2:61757674	XPO1	0.41	6.77	0.34	5.6e-11	Tuberculosis;
LIHC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.54	-10.07	-0.48	4.6e-21	Asthma;
LIHC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.56	9.49	0.46	4.12e-19	Colorectal cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg11223184	chr2:198033295	ANKRD44	-0.36	-6.19	-0.32	1.69e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	1.07	12.48	0.56	9.98e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21467203	chr3:49911342	NA	-0.4	-6.93	-0.35	2.11e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg03037974	chr15:76606532	NA	0.8	16.45	0.66	3.21e-45	Blood metabolite levels;
LIHC	trans	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg02990361	chr1:107599529	PRMT6	0.59	9.04	0.44	1.17e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7487075	0.578	rs11183486	chr12:46837704	A/C	cg23829395	chr12:46796953	NA	0.35	6.19	0.32	1.76e-9	Itch intensity from mosquito bite;
LIHC	trans	rs913351	0.826	rs633858	chr9:129725493	A/G	cg13692105	chr9:138592489	SOHLH1	0.39	6.07	0.31	3.36e-9	Lewy body disease;
LIHC	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7487075	0.780	rs10785624	chr12:46766787	C/T	cg15584813	chr12:47219626	SLC38A4	0.33	5.84	0.3	1.24e-8	Itch intensity from mosquito bite;
LIHC	cis	rs986417	1.000	rs10130255	chr14:60944435	C/T	cg27398547	chr14:60952738	C14orf39	0.81	9.28	0.45	1.97e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	cis	rs244293	1.000	rs244295	chr17:53242899	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.26	-0.37	2.66e-12	Menarche (age at onset);
LIHC	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	0.85	10.96	0.51	3.74e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09311052	chr1:154531418	UBE2Q1	0.43	6.68	0.34	9.53e-11	Pancreatic cancer;
LIHC	trans	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg01596870	chr19:55963115	NA	-0.65	-9.38	-0.45	9.71e-19	Obesity-related traits;
LIHC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.93	-10.59	-0.5	7.37e-23	Magnesium levels;
LIHC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.53	6.87	0.35	3.01e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.46	8.28	0.41	2.79e-15	Prudent dietary pattern;
LIHC	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg10820045	chr2:198174542	NA	0.45	6.82	0.35	4.18e-11	Dermatomyositis;
LIHC	cis	rs6446731	0.734	rs9996868	chr4:3275484	C/T	cg06533319	chr4:3265114	C4orf44	-0.34	-6.35	-0.32	6.93e-10	Mean platelet volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16139199	chr18:19180362	ESCO1	0.43	6.53	0.33	2.43e-10	Pancreatic cancer;
LIHC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.69	10.02	0.48	7.08e-21	Monocyte percentage of white cells;
LIHC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.51	-8.82	-0.43	5.86e-17	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.44	0.64	3.48e-41	Chronic sinus infection;
LIHC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.21e-10	Obesity-related traits;
LIHC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.62	11.17	0.52	6.85e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.79	10.43	0.49	2.69e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs3762637	0.943	rs7629285	chr3:122265739	A/G	cg24169773	chr3:122142474	KPNA1	0.41	8.38	0.41	1.38e-15	LDL cholesterol levels;
LIHC	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.78	-0.3	1.71e-8	Red blood cell count;
LIHC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18252515	chr7:66147081	NA	0.42	6.03	0.31	4.17e-9	Aortic root size;
LIHC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.0	-0.4	1.94e-14	Monocyte percentage of white cells;
LIHC	cis	rs10916814	0.546	rs10799643	chr1:20903181	G/C	cg24502330	chr1:20914028	CDA	-0.3	-6.62	-0.34	1.38e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	0.48	6.24	0.32	1.28e-9	Pulse pressure;
LIHC	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg16486109	chr11:613632	IRF7	0.58	6.17	0.32	1.89e-9	Systemic lupus erythematosus;
LIHC	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.27e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4407350	0.721	rs3827402	chr22:44890651	T/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.43	0.33	4.31e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs116248771	0.739	rs73156496	chr3:158421162	T/C	cg16708174	chr3:158430962	RARRES1	0.46	6.31	0.32	8.56e-10	diarrhoeal disease at age 2;
LIHC	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.35	-7.55	-0.38	3.91e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.3	6.41	0.33	4.95e-10	Pulmonary function;
LIHC	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg08847533	chr14:75593920	NEK9	0.54	8.24	0.41	3.59e-15	IgG glycosylation;
LIHC	trans	rs11165623	0.564	rs11165658	chr1:96985670	A/G	cg10631902	chr5:14652156	NA	-0.3	-6.92	-0.35	2.24e-11	Hip circumference;Waist circumference;
LIHC	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.36	-7.74	-0.39	1.12e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.35	6.45	0.33	3.86e-10	Aortic root size;
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg26338869	chr17:61819248	STRADA	0.52	6.94	0.35	1.98e-11	Height;
LIHC	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.81	7.09	0.36	7.59e-12	Gut microbiota (bacterial taxa);
LIHC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs17106184	1.000	rs2175794	chr1:51333179	A/T	cg07174182	chr1:51127561	FAF1	-0.62	-6.5	-0.33	2.91e-10	Type 2 diabetes;
LIHC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.54	-0.46	2.84e-19	Obesity-related traits;
LIHC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.37	-0.33	6.06e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.2	-0.32	1.63e-9	Colorectal cancer;
LIHC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.53	7.43	0.37	8.65e-13	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21211866	chr9:35111727	KIAA1539	0.48	8.06	0.4	1.32e-14	Cognitive function;
LIHC	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.09e-27	Obesity-related traits;
LIHC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.43	7.94	0.39	2.86e-14	Schizophrenia;
LIHC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.43	6.43	0.33	4.22e-10	Schizophrenia;
LIHC	cis	rs507080	0.961	rs34413584	chr11:118545782	G/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.07	0.31	3.35e-9	Serum metabolite levels;
LIHC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.38	-6.74	-0.34	6.73e-11	Aortic root size;
LIHC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.35	1.25e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.77	-11.92	-0.54	1.27e-27	Corneal astigmatism;
LIHC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.68	9.33	0.45	1.39e-18	Mean platelet volume;
LIHC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg16586182	chr3:47516702	SCAP	0.49	8.69	0.43	1.52e-16	Colorectal cancer;
LIHC	cis	rs2412488	0.927	rs6833766	chr4:54312706	A/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.79	-0.34	4.97e-11	DNA methylation (variation);
LIHC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg26677194	chr12:130822605	PIWIL1	0.49	6.44	0.33	4.03e-10	Menopause (age at onset);
LIHC	trans	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg10756647	chr7:56101905	PSPH	1.08	11.93	0.54	1.13e-27	Diabetic kidney disease;
LIHC	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.93	-18.32	-0.7	1.02e-52	Height;
LIHC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.11	-0.4	8.86e-15	Morning vs. evening chronotype;
LIHC	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.41	6.05	0.31	3.89e-9	Height;
LIHC	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.96	0.31	6.39e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg23509745	chr3:184045221	EIF4G1	0.53	8.36	0.41	1.62e-15	Longevity;
LIHC	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.71	-10.96	-0.51	3.83e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00587304	chr3:172468157	NA	0.37	6.28	0.32	1.01e-9	Metabolic traits;
LIHC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.04	17.14	0.68	5.85e-48	Testicular germ cell tumor;
LIHC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg09137382	chr11:130731461	NA	0.4	5.99	0.31	5.19e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg03037974	chr15:76606532	NA	0.76	14.72	0.62	2.43e-38	Blood metabolite levels;
LIHC	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg15192750	chr16:69999425	NA	0.49	7.41	0.37	1.03e-12	IgE levels;
LIHC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.66	6.78	0.34	5.22e-11	Migraine;Coronary artery disease;
LIHC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.47	7.31	0.37	1.89e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.59	-8.74	-0.43	1.09e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.66	-11.66	-0.53	1.12e-26	Pediatric autoimmune diseases;
LIHC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.64	-0.38	2.25e-13	Total body bone mineral density;
LIHC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.15	-0.48	2.39e-21	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg23782820	chr8:58130467	NA	0.33	5.98	0.31	5.72e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17400366	chr19:10420311	ZGLP1	0.42	6.46	0.33	3.54e-10	Alopecia areata;
LIHC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg24209194	chr3:40518798	ZNF619	0.46	6.84	0.35	3.57e-11	Renal cell carcinoma;
LIHC	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.79	12.23	0.55	9.12e-29	Multiple system atrophy;
LIHC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-6.83	-0.35	3.99e-11	Ileal carcinoids;
LIHC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.8	-0.39	7.55e-14	Type 2 diabetes;
LIHC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.37	8.0	0.4	2e-14	Type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.94	0.31	6.94e-9	Alzheimer's disease;
LIHC	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.52	-6.33	-0.32	7.62e-10	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.55	5.94	0.31	6.87e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.68	9.97	0.47	9.92e-21	Testicular germ cell tumor;
LIHC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.51	5.72	0.3	2.32e-8	Primary sclerosing cholangitis;
LIHC	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg14146966	chr2:61757674	XPO1	0.49	8.81	0.43	6.32e-17	Tuberculosis;
LIHC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.56	9.89	0.47	1.84e-20	Alcohol dependence;
LIHC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-6.07	-0.31	3.43e-9	Type 2 diabetes;
LIHC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.01	15.75	0.65	2.03e-42	Breast cancer;
LIHC	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg05425664	chr17:57184151	TRIM37	0.51	6.89	0.35	2.61e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg01655898	chr14:21439243	NA	-0.39	-6.28	-0.32	1.02e-9	Eotaxin levels;
LIHC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-6.33	-0.32	7.83e-10	Colorectal cancer;
LIHC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.4	6.63	0.34	1.29e-10	Red blood cell count;
LIHC	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg12560992	chr17:57184187	TRIM37	0.69	8.81	0.43	6.18e-17	Vitamin D levels;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.41	5.77	0.3	1.79e-8	Longevity;Endometriosis;
LIHC	trans	rs783540	0.843	rs28374463	chr15:83299364	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.77	-0.34	5.62e-11	Schizophrenia;
LIHC	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg09904177	chr6:26538194	HMGN4	-0.35	-5.87	-0.3	1.01e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7729447	0.566	rs3792765	chr5:32713836	A/G	cg16267343	chr5:32710456	NPR3	0.48	6.1	0.31	2.9e-9	Blood pressure;
LIHC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg02023728	chr11:77925099	USP35	0.34	6.11	0.31	2.67e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2019216	0.934	rs7405575	chr17:21936954	T/C	cg22648282	chr17:21454238	C17orf51	-0.34	-5.71	-0.3	2.44e-8	Pelvic organ prolapse;
LIHC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.65	11.76	0.54	4.66e-27	Gestational age at birth (maternal effect);
LIHC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.32	0.32	8.18e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	22.52	0.77	1.55e-69	Prudent dietary pattern;
LIHC	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg04374321	chr14:90722782	PSMC1	0.47	6.5	0.33	2.85e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg15123519	chr2:136567270	LCT	-0.38	-6.09	-0.31	3.03e-9	Corneal structure;
LIHC	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.73	-11.49	-0.53	4.78e-26	White matter hyperintensity burden;
LIHC	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.34	-5.82	-0.3	1.32e-8	Coronary artery disease;
LIHC	cis	rs11628318	0.515	rs12433517	chr14:103126912	T/G	cg12046867	chr14:103022105	NA	0.39	5.92	0.3	7.82e-9	Platelet count;
LIHC	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.04	-0.31	3.92e-9	Blood pressure;
LIHC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.82	0.65	1.12e-42	Chronic sinus infection;
LIHC	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.56	9.24	0.45	2.72e-18	Corneal astigmatism;
LIHC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	7.54	0.38	4.2e-13	Personality dimensions;
LIHC	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.83	0.43	5.71e-17	Exhaled nitric oxide levels;
LIHC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.97	-0.31	6.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.5	7.63	0.38	2.43e-13	Obesity-related traits;
LIHC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg14092571	chr14:90743983	NA	-0.37	-5.8	-0.3	1.53e-8	Mortality in heart failure;
LIHC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.87	11.32	0.52	1.96e-25	Coronary artery disease;
LIHC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	0.69	7.78	0.39	8.61e-14	Coronary artery disease;
LIHC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.55	-9.23	-0.45	2.94e-18	Blood metabolite levels;
LIHC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.41	-7.34	-0.37	1.58e-12	Aortic root size;
LIHC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.4	-0.59	3.26e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01123282	chr2:157189755	NR4A2	-0.4	-6.07	-0.31	3.48e-9	Pancreatic cancer;
LIHC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg10756647	chr7:56101905	PSPH	0.46	6.93	0.35	2.1e-11	Aortic root size;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05412136	chr9:36191352	CLTA	0.38	6.2	0.32	1.64e-9	Cognitive function;
LIHC	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.69	7.88	0.39	4.45e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.56	-7.86	-0.39	5.16e-14	Total body bone mineral density;
LIHC	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.2	-0.48	1.71e-21	Waist circumference;Body mass index;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.08	-0.31	3.3e-9	Menopause (age at onset);
LIHC	cis	rs2933343	0.716	rs9867404	chr3:128566138	A/G	cg25356066	chr3:128598488	ACAD9	-0.52	-6.82	-0.35	4.11e-11	IgG glycosylation;
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.6	8.75	0.43	1.02e-16	Menarche (age at onset);
LIHC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	6.03	0.31	4.36e-9	Putamen volume;
LIHC	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.59	9.4	0.45	8.36e-19	Corneal astigmatism;
LIHC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.39	0.33	5.46e-10	Hemoglobin concentration;
LIHC	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.4	-7.52	-0.38	4.77e-13	Height;
LIHC	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.4	-5.97	-0.31	6.04e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-0.65	-10.99	-0.51	3.01e-24	Pediatric autoimmune diseases;
LIHC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.46	8.2	0.41	4.79e-15	IgG glycosylation;
LIHC	cis	rs861318	0.640	rs3768514	chr1:159010309	A/G	cg11003133	chr1:159046391	AIM2	-0.35	-6.66	-0.34	1.07e-10	Obesity-related traits;
LIHC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05025164	chr4:1340916	KIAA1530	0.74	11.09	0.51	1.24e-24	Longevity;
LIHC	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16684958	chr7:75615977	POR	0.51	8.49	0.42	6.51e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg16586182	chr3:47516702	SCAP	0.61	11.96	0.54	8.96e-28	Colorectal cancer;
LIHC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-7.47	-0.37	6.83e-13	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04628465	chr16:85015467	ZDHHC7	-0.43	-6.28	-0.32	1.04e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8027181	0.682	rs890354	chr15:73100924	C/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.43	6.73	0.34	7.07e-11	Triglyceride levels;
LIHC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.62	-8.68	-0.42	1.69e-16	Lung cancer in ever smokers;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.46	-0.37	7.27e-13	Height;
LIHC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.8	9.65	0.46	1.16e-19	Cognitive function;
LIHC	cis	rs4908768	0.906	rs12122851	chr1:8634290	A/G	cg20416874	chr1:8611966	RERE	-0.57	-9.2	-0.45	3.63e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.66	12.86	0.57	3.7e-31	Rheumatoid arthritis;
LIHC	cis	rs4407350	1.000	rs5765724	chr22:44921575	G/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.32	0.32	8.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.77e-9	Prudent dietary pattern;
LIHC	cis	rs72627123	0.656	rs17096208	chr14:74555269	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	8.36	0.41	1.65e-15	Morning vs. evening chronotype;
LIHC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.22	6.07	0.31	3.42e-9	Calcium levels;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.46	-8.33	-0.41	2.04e-15	Late-onset Alzheimer's disease;
LIHC	trans	rs1814175	0.616	rs10839349	chr11:49753748	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.39	-0.74	4.73e-61	Height;
LIHC	cis	rs7619427	0.544	rs9872382	chr3:44021964	C/A	cg24966902	chr3:44043705	NA	0.52	7.98	0.4	2.25e-14	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09379601	chr19:12992224	DNASE2	0.45	6.7	0.34	8.83e-11	Pancreatic cancer;
LIHC	trans	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg01596870	chr19:55963115	NA	-0.65	-9.51	-0.46	3.63e-19	Obesity-related traits;
LIHC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.62	6.15	0.32	2.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-8.9	-0.43	3.41e-17	Blood protein levels;
LIHC	cis	rs988712	0.622	rs10767664	chr11:27725986	T/A	cg18117895	chr11:27722066	BDNF	-0.49	-6.85	-0.35	3.39e-11	Obesity;
LIHC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs11112613	0.609	rs7966960	chr12:106032152	G/A	cg03607813	chr12:105948248	NA	0.42	6.59	0.34	1.64e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.08	-11.22	-0.52	4.43e-25	Type 1 diabetes nephropathy;
LIHC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg01086810	chr6:28234912	ZNF187	0.65	5.72	0.3	2.28e-8	Depression;
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.64	11.59	0.53	2.03e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2574704	0.851	rs2574720	chr3:11660412	A/C	cg15876825	chr3:11651881	VGLL4	0.45	7.08	0.36	8.46e-12	Body mass index;
LIHC	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.36	-6.23	-0.32	1.4e-9	Menopause (age at onset);
LIHC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16346588	chr10:242978	ZMYND11	-0.39	-6.08	-0.31	3.13e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	1.04	12.38	0.56	2.36e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.47	-0.37	6.61e-13	Response to antipsychotic treatment;
LIHC	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg02023728	chr11:77925099	USP35	0.33	6.01	0.31	4.82e-9	Alzheimer's disease (survival time);
LIHC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	6.07	0.31	3.32e-9	Longevity;
LIHC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.73	12.63	0.56	2.82e-30	Menopause (age at onset);
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs7212590	0.748	rs7220187	chr17:57897609	C/T	cg10252138	chr17:58120427	NA	-0.62	-6.11	-0.31	2.78e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.54	8.16	0.4	6.57e-15	HDL cholesterol;
LIHC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.41	0.56	1.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05061393	chr2:220043337	FAM134A	-0.45	-6.8	-0.35	4.77e-11	Cognitive function;
LIHC	cis	rs903552	0.736	rs2412008	chr15:102006841	C/T	cg19295451	chr15:102010161	PCSK6	-0.54	-7.53	-0.38	4.68e-13	Diabetic kidney disease;
LIHC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.78	-0.3	1.65e-8	Body mass index;
LIHC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-8.18	-0.4	5.48e-15	Urinary metabolites;
LIHC	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg12903224	chr12:29470962	FAR2	-0.4	-6.21	-0.32	1.51e-9	QT interval;
LIHC	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.66	-10.34	-0.49	5.69e-22	Cognitive test performance;
LIHC	cis	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg08516792	chr17:33866067	SLFN12L	-0.38	-6.98	-0.35	1.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg17712092	chr4:129076599	LARP1B	0.74	12.74	0.57	1.11e-30	Eosinophil percentage of white cells;
LIHC	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg23091122	chr1:110024289	SYPL2	-0.5	-6.38	-0.33	5.72e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-9.88	-0.47	2.01e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3736485	0.966	rs11070859	chr15:51890802	C/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.66e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.91	14.5	0.62	1.76e-37	Vitamin D levels;
LIHC	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.83	16.99	0.68	2.23e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg20607798	chr8:58055168	NA	0.5	6.29	0.32	9.8e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.72	-12.89	-0.57	2.99e-31	Height;
LIHC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.86	12.98	0.57	1.3e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.52	-0.33	2.59e-10	Metabolite levels;
LIHC	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.53	6.86	0.35	3.24e-11	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05573182	chr20:39318437	MAFB	0.4	6.48	0.33	3.16e-10	Cognitive function;
LIHC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.66	11.49	0.53	4.72e-26	Menopause (age at onset);
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.64	-8.36	-0.41	1.64e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.58	5.91	0.3	8.17e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs11229555	0.645	rs11229427	chr11:58180275	A/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.87	-0.3	1.03e-8	Tonsillectomy;
LIHC	cis	rs11671005	0.568	rs73068325	chr19:59079096	C/T	cg25952890	chr19:58913133	NA	0.68	6.88	0.35	2.81e-11	Mean platelet volume;
LIHC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.99	0.6	1.73e-35	Coffee consumption (cups per day);
LIHC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.45	5.71	0.3	2.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.8	12.39	0.56	2.21e-29	Resting heart rate;
LIHC	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.5	7.24	0.36	3.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg00035636	chr13:21900591	NA	0.4	6.8	0.35	4.57e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.44	7.8	0.39	7.35e-14	Tuberculosis;
LIHC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.49	8.02	0.4	1.73e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.16	0.32	2.02e-9	Mean corpuscular volume;
LIHC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg00204512	chr16:28754710	NA	0.35	6.4	0.33	4.98e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg20932281	chr17:33905541	PEX12	0.42	5.87	0.3	1.01e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.51	7.95	0.39	2.82e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.51	-0.33	2.65e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-6.04	-0.31	4.11e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.83	-0.3	1.25e-8	Blood metabolite levels;
LIHC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.58	8.59	0.42	3.04e-16	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.35	-0.32	6.67e-10	Longevity;
LIHC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg26395211	chr5:140044315	WDR55	0.4	5.97	0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.91e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.53	-8.87	-0.43	4.05e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13409248	chr3:40428643	ENTPD3	0.5	8.31	0.41	2.27e-15	Renal cell carcinoma;
LIHC	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-9.03	-0.44	1.27e-17	Atrioventricular conduction;
LIHC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.62	6.44	0.33	4.13e-10	Axial length;
LIHC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg25039879	chr17:56429692	SUPT4H1	0.78	8.84	0.43	5.22e-17	Cognitive test performance;
LIHC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.58e-15	Motion sickness;
LIHC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-7.81	-0.39	7.23e-14	Cognitive function;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg24613906	chr8:27452753	NA	-0.28	-6.08	-0.31	3.22e-9	Monocyte count;
LIHC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.7	-10.37	-0.49	4.24e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg03647239	chr10:116582469	FAM160B1	0.47	6.79	0.34	4.83e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg26138937	chr11:71823887	C11orf51	1.32	10.9	0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.57	-6.98	-0.35	1.5e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.96	17.4	0.69	5.04e-49	Intelligence (multi-trait analysis);
LIHC	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.66	-10.04	-0.48	6.03e-21	Pulse pressure;
LIHC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg01444801	chr10:135216882	MTG1	-0.63	-9.35	-0.45	1.2e-18	Systemic lupus erythematosus;
LIHC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg17927777	chr20:33865990	NA	0.55	6.39	0.33	5.5e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg01256987	chr12:42539512	GXYLT1	-0.43	-7.12	-0.36	6.2e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.23	-6.2	-0.32	1.62e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04925841	chr12:24715491	SOX5	0.44	6.07	0.31	3.48e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.45	6.31	0.32	8.45e-10	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.01	-0.35	1.28e-11	Reticulocyte count;
LIHC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg20140201	chr2:241835670	C2orf54	-0.54	-8.37	-0.41	1.49e-15	Urinary metabolites;
LIHC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.71	-0.57	1.37e-30	Vitiligo;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11645453	chr3:52864694	ITIH4	0.21	5.72	0.3	2.33e-8	Electroencephalogram traits;
LIHC	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.42	0.45	6.81e-19	Intelligence (multi-trait analysis);
LIHC	trans	rs9641123	0.578	rs2528540	chr7:93252839	C/G	cg09745688	chr16:2908918	PRSS22	-0.37	-6.45	-0.33	3.79e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.49	8.02	0.4	1.7e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.49	0.49	1.67e-22	Bladder cancer;
LIHC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.41	6.0	0.31	4.92e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.1	0.36	7.36e-12	Self-reported allergy;
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.56	8.65	0.42	2.11e-16	Longevity;Endometriosis;
LIHC	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.84	-14.68	-0.62	3.45e-38	Aortic root size;
LIHC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.07	0.4	1.19e-14	Schizophrenia;
LIHC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.62	-10.86	-0.51	8.51e-24	Neuroticism;
LIHC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.41	0.33	4.7e-10	Response to antipsychotic treatment;
LIHC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.29	7.18	0.36	4.26e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9948	0.881	rs7580942	chr2:97468276	C/G	cg01990225	chr2:97406019	LMAN2L	-0.57	-5.83	-0.3	1.31e-8	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.76	-0.3	1.84e-8	Total body bone mineral density;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01328164	chr9:35814704	HINT2	-0.41	-6.18	-0.32	1.87e-9	Calcium levels;
LIHC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg07645718	chr20:61493192	TCFL5	0.79	6.45	0.33	3.85e-10	Obesity-related traits;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.48	-6.54	-0.33	2.27e-10	Menopause (age at onset);
LIHC	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.56	9.23	0.45	2.95e-18	Corneal astigmatism;
LIHC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg15848620	chr12:58087721	OS9	-0.55	-7.43	-0.37	8.96e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.02e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.34	-6.95	-0.35	1.83e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.46	8.06	0.4	1.31e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20135002	chr11:47629003	NA	-0.54	-9.11	-0.44	6.97e-18	Subjective well-being;
LIHC	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.77	11.6	0.53	1.8e-26	Intelligence (multi-trait analysis);
LIHC	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.25e-19	Corneal astigmatism;
LIHC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg20195005	chr22:42527684	CYP2D6	0.3	5.74	0.3	2.04e-8	Birth weight;
LIHC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.56	8.05	0.4	1.43e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.73	11.89	0.54	1.58e-27	Anterior chamber depth;
LIHC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	1.18	14.34	0.61	7.88e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.61	8.21	0.41	4.59e-15	Bladder cancer;
LIHC	cis	rs3770081	1.000	rs12622009	chr2:86248325	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-9.1	-0.44	7.41e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.42	-0.37	9.26e-13	Psoriasis;
LIHC	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.23	-15.51	-0.64	1.89e-41	Diabetic kidney disease;
LIHC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.81	0.3	1.42e-8	Menopause (age at onset);
LIHC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg25356066	chr3:128598488	ACAD9	0.55	7.66	0.38	1.9e-13	IgG glycosylation;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	9.97	0.47	9.89e-21	Lymphocyte counts;
LIHC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Parkinson's disease;
LIHC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	10.8	0.5	1.32e-23	Alzheimer's disease (late onset);
LIHC	cis	rs7810240	1.000	rs1010614	chr7:150083805	T/C	cg10018233	chr7:150070692	REPIN1	-0.41	-6.47	-0.33	3.43e-10	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LIHC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg02269571	chr22:50332266	NA	-0.66	-8.9	-0.43	3.32e-17	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg00280220	chr17:61926910	NA	0.42	6.77	0.34	5.73e-11	Prudent dietary pattern;
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.51	6.04	0.31	4.06e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.79	12.47	0.56	1.1e-29	Breast cancer;
LIHC	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-10.87	-0.51	7.6e-24	Alzheimer's disease;
LIHC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.46	1.94e-19	Bipolar disorder;
LIHC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.94	-14.19	-0.61	3.02e-36	Sudden cardiac arrest;
LIHC	cis	rs735860	0.726	rs209500	chr6:53188137	A/C	cg10236188	chr6:53219634	NA	-0.4	-7.41	-0.37	1e-12	Glaucoma;
LIHC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg15848620	chr12:58087721	OS9	-0.56	-7.6	-0.38	2.84e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.5	7.65	0.38	2.11e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.46	-6.42	-0.33	4.45e-10	Primary sclerosing cholangitis;
LIHC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.38	-5.81	-0.3	1.46e-8	Cognitive function;
LIHC	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-0.59	-8.22	-0.41	4.37e-15	Obesity-related traits;
LIHC	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.56	-8.91	-0.43	3.11e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.47	-7.61	-0.38	2.7e-13	Fibrinogen levels;
LIHC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg13395646	chr4:1353034	KIAA1530	0.41	6.4	0.33	5.23e-10	Obesity-related traits;
LIHC	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg25182066	chr10:30743637	MAP3K8	-0.68	-10.88	-0.51	7.11e-24	Itch intensity from mosquito bite;
LIHC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	9.78	0.47	4.55e-20	Total body bone mineral density;
LIHC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.74	12.52	0.56	7.42e-30	Blood protein levels;
LIHC	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.5	-0.38	5.49e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.44	6.83	0.35	4.01e-11	Schizophrenia;
LIHC	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.37	-5.89	-0.3	9.1e-9	Dupuytren's disease;
LIHC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.22	5.96	0.31	6.38e-9	Calcium levels;
LIHC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg11062466	chr8:58055876	NA	0.42	6.29	0.32	9.84e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg00280220	chr17:61926910	NA	0.4	6.58	0.34	1.81e-10	Prudent dietary pattern;
LIHC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.58	-10.13	-0.48	3.01e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	20.88	0.75	5.2e-63	Smoking behavior;
LIHC	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg01364799	chr7:75623366	TMEM120A	0.54	8.4	0.41	1.2e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.78	6.96	0.35	1.72e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LIHC	cis	rs2273156	1.000	rs7141293	chr14:35462910	T/A	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.07	-0.31	3.45e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg23625390	chr15:77176239	SCAPER	0.36	5.87	0.3	1.04e-8	Blood metabolite levels;
LIHC	cis	rs77669868	0.568	rs3825045	chr11:114073200	C/T	cg01914181	chr11:114070210	ZBTB16	0.49	5.78	0.3	1.65e-8	Monocyte percentage of white cells;
LIHC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg06096015	chr1:231504339	EGLN1	0.48	9.12	0.44	6.77e-18	Hemoglobin concentration;
LIHC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.86	-0.35	3.23e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.71	0.5	2.77e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg03146154	chr1:46216737	IPP	-0.38	-5.84	-0.3	1.23e-8	High light scatter reticulocyte count;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg01238044	chr22:24384105	GSTT1	0.49	6.27	0.32	1.06e-9	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs2380220	0.872	rs66723559	chr6:95956338	T/C	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.52e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg16586182	chr3:47516702	SCAP	0.58	10.56	0.5	9.27e-23	Colorectal cancer;
LIHC	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.16	0.32	2.04e-9	Diastolic blood pressure;
LIHC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	12.24	0.55	8.34e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.34	-6.04	-0.31	4.07e-9	Lewy body disease;
LIHC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.34	-8.22	-0.41	4.23e-15	Longevity;Endometriosis;
LIHC	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg18898632	chr2:242989856	NA	-0.56	-7.56	-0.38	3.7e-13	Obesity-related traits;
LIHC	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.9	0.35	2.55e-11	Morning vs. evening chronotype;
LIHC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-16.21	-0.66	3.15e-44	Coronary artery disease;
LIHC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.71e-10	Waist circumference;Weight;
LIHC	cis	rs7149337	1.000	rs7149337	chr14:51709017	G/T	cg23942311	chr14:51606299	NA	0.35	6.71	0.34	7.97e-11	Cancer;
LIHC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.57	-8.75	-0.43	1e-16	Corneal astigmatism;
LIHC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.8	0.65	1.35e-42	Chronic sinus infection;
LIHC	trans	rs7120489	0.643	rs12276659	chr11:12447289	T/C	cg08537300	chr5:179058959	NA	0.57	6.18	0.32	1.84e-9	Mortality in heart failure;
LIHC	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.5	-9.66	-0.46	1.11e-19	LDL cholesterol levels;
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.43	-5.81	-0.3	1.4e-8	Total body bone mineral density;
LIHC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg17750252	chr2:136567154	LCT	-0.36	-6.48	-0.33	3.16e-10	Mosquito bite size;
LIHC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.1	-0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs611744	0.967	rs635624	chr8:109197799	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.79	0.43	7.57e-17	Dupuytren's disease;
LIHC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-14.65	-0.62	4.82e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg04261877	chr17:18218829	SMCR8;TOP3A	0.42	6.27	0.32	1.12e-9	Multiple sclerosis;
LIHC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.4	0.33	5.14e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg01864836	chr14:55583639	NA	-0.4	-7.61	-0.38	2.61e-13	Protein biomarker;
LIHC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.55e-9	Vitamin D levels;
LIHC	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.21	-0.48	1.54e-21	Eye color traits;
LIHC	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg01843034	chr6:37503916	NA	-0.39	-6.21	-0.32	1.51e-9	Cognitive performance;
LIHC	cis	rs9783347	1.000	rs4150612	chr11:18364358	G/T	cg15585147	chr11:18324498	HPS5	0.38	6.15	0.32	2.17e-9	Pancreatic cancer;
LIHC	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg10820045	chr2:198174542	NA	0.55	8.95	0.44	2.22e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.17	29.81	0.85	4.05e-97	IgG glycosylation;
LIHC	cis	rs6750047	0.609	rs2121259	chr2:38269475	T/C	cg07380506	chr2:38303506	CYP1B1	0.58	7.32	0.37	1.79e-12	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg06533319	chr4:3265114	C4orf44	0.35	6.44	0.33	4.11e-10	Parental longevity (mother's age at death);
LIHC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.45	7.18	0.36	4.51e-12	Total body bone mineral density;
LIHC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg11764359	chr7:65958608	NA	-0.57	-6.07	-0.31	3.45e-9	Diabetic kidney disease;
LIHC	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.77	11.58	0.53	2.15e-26	Subjective well-being;
LIHC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.66	-0.38	1.88e-13	Ulcerative colitis;
LIHC	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-6.92	-0.35	2.18e-11	Post bronchodilator FEV1;
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg07384165	chr1:10488281	NA	-0.32	-5.76	-0.3	1.85e-8	Prostate cancer;
LIHC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.86	14.87	0.63	6.41e-39	Headache;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17482927	chr17:63133259	RGS9	0.49	6.98	0.35	1.57e-11	Pancreatic cancer;
LIHC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg08029281	chr1:67600428	NA	0.37	6.21	0.32	1.54e-9	Psoriasis;
LIHC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg15123519	chr2:136567270	LCT	0.44	8.45	0.42	8.73e-16	Mosquito bite size;
LIHC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.48	-7.73	-0.39	1.21e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-0.8	-8.97	-0.44	2.05e-17	Schizophrenia;
LIHC	trans	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.46	-0.33	3.65e-10	Educational attainment (years of education);
LIHC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.68	9.93	0.47	1.38e-20	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07677032	chr17:61819896	STRADA	0.43	6.14	0.32	2.23e-9	Prudent dietary pattern;
LIHC	cis	rs922107	0.738	rs4658280	chr1:90022971	G/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.83	-0.39	6.2e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.63	-8.58	-0.42	3.28e-16	Coronary artery disease;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.58	-8.31	-0.41	2.23e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	9.64	0.46	1.3e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.5	9.39	0.45	9e-19	Type 2 diabetes;
LIHC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.5	7.71	0.38	1.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.68	-10.66	-0.5	4.19e-23	Skin colour saturation;
LIHC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg23205692	chr1:25664452	TMEM50A	-0.39	-6.34	-0.32	7.28e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.45	7.64	0.38	2.16e-13	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg10756647	chr7:56101905	PSPH	1.1	13.62	0.59	4.65e-34	Diabetic kidney disease;
LIHC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.64	11.01	0.51	2.46e-24	Colorectal cancer;
LIHC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-8.29	-0.41	2.71e-15	Menarche (age at onset);
LIHC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.85	0.35	3.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg21231739	chr4:1642635	FAM53A	-0.37	-5.89	-0.3	9.23e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs539514	0.612	rs1830760	chr13:76296625	G/A	cg04757411	chr13:76259545	LMO7	-0.46	-7.76	-0.39	9.65e-14	Type 1 diabetes;
LIHC	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.43	-6.98	-0.35	1.53e-11	Migraine;
LIHC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg03647239	chr10:116582469	FAM160B1	0.47	6.88	0.35	2.95e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs6717918	0.517	rs2633262	chr2:233130584	T/C	cg19760917	chr1:2411643	PLCH2	-0.4	-6.24	-0.32	1.29e-9	Height;
LIHC	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.57	0.38	3.53e-13	Refractive astigmatism;
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.37	-0.33	6.01e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs16828019	0.704	rs12031277	chr1:41491801	A/G	cg03962019	chr1:41807865	NA	0.5	7.0	0.35	1.38e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg14558262	chr17:40713999	COASY	0.63	9.76	0.47	5.2e-20	Crohn's disease;
LIHC	cis	rs3770081	1.000	rs74733602	chr2:86303442	T/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-8.69	-0.43	1.49e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.1	-0.31	2.86e-9	Longevity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03558299	chr20:47662597	CSE1L	0.49	6.95	0.35	1.84e-11	Pancreatic cancer;
LIHC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg20607798	chr8:58055168	NA	0.69	7.73	0.39	1.25e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg04373760	chr16:53404718	NA	0.55	6.4	0.33	5.11e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12173535	chr19:54694174	MBOAT7;TSEN34	0.39	6.2	0.32	1.61e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.69e-11	IgG glycosylation;
LIHC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.46	0.46	4.99e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.0	-0.31	5.01e-9	Diastolic blood pressure;
LIHC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.38	-0.49	4e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.32	6.03	0.31	4.32e-9	Tonsillectomy;
LIHC	cis	rs12249377	0.519	rs7906960	chr10:92586205	A/G	cg14313238	chr10:92632228	RPP30	0.38	6.37	0.33	5.94e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.48e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.48	-5.92	-0.3	7.98e-9	Serum sulfate level;
LIHC	cis	rs2820292	1.000	rs1032524	chr1:201790826	C/T	cg11586189	chr1:201857591	SHISA4	-0.41	-6.18	-0.32	1.81e-9	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.22	0.52	4.19e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.61	9.85	0.47	2.57e-20	Corneal astigmatism;
LIHC	trans	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.39	0.33	5.55e-10	Ulcerative colitis;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg02993280	chr1:107599747	PRMT6	-0.7	-11.34	-0.52	1.56e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.08	0.31	3.25e-9	Protein biomarker;
LIHC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-5.85	-0.3	1.15e-8	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.74	-14.52	-0.62	1.53e-37	Height;
LIHC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg17085576	chr10:5658249	NA	-0.33	-6.25	-0.32	1.22e-9	Breast cancer;
LIHC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.65	8.36	0.41	1.64e-15	Gut microbiome composition (summer);
LIHC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-0.76	-11.79	-0.54	3.72e-27	Platelet distribution width;
LIHC	trans	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg18335740	chr13:41363409	SLC25A15	-0.38	-6.61	-0.34	1.49e-10	Lewy body disease;
LIHC	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.5	8.4	0.41	1.17e-15	Schizophrenia;
LIHC	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.28	6.67	0.34	1.02e-10	Gut microbiome composition (winter);
LIHC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.63	0.56	2.73e-30	Alzheimer's disease;
LIHC	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg18081818	chr7:23246105	NA	-0.46	-7.06	-0.36	9.47e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.4	-8.03	-0.4	1.54e-14	Renal cell carcinoma;
LIHC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.63	9.34	0.45	1.3e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.56	-8.45	-0.42	8.7e-16	Height;
LIHC	cis	rs7633770	0.735	rs12491294	chr3:46688498	G/T	cg11219411	chr3:46661640	NA	-0.43	-7.49	-0.38	6.02e-13	Coronary artery disease;
LIHC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg00677901	chr16:88017247	BANP	0.51	7.85	0.39	5.52e-14	Menopause (age at onset);
LIHC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg12798992	chr6:167411361	FGFR1OP	0.43	6.6	0.34	1.53e-10	Primary biliary cholangitis;
LIHC	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.38	0.33	5.76e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.59	9.79	0.47	4.21e-20	White matter hyperintensity burden;
LIHC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	15.6	0.64	8.17e-42	Tonsillectomy;
LIHC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.68	0.34	9.67e-11	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg11764359	chr7:65958608	NA	0.57	5.82	0.3	1.39e-8	Diabetic kidney disease;
LIHC	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg06212747	chr3:49208901	KLHDC8B	0.45	5.79	0.3	1.6e-8	Resting heart rate;
LIHC	cis	rs8067354	0.574	rs2526354	chr17:57976658	A/G	cg02344993	chr17:57696989	CLTC	0.66	10.37	0.49	4.25e-22	Hemoglobin concentration;
LIHC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg05043794	chr9:111880884	C9orf5	-0.28	-6.7	-0.34	8.43e-11	Menarche (age at onset);
LIHC	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.46	-7.39	-0.37	1.11e-12	Type 2 diabetes;
LIHC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.42e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.77	13.14	0.58	3.37e-32	Body mass index;
LIHC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	cis	rs7903847	0.612	rs9887994	chr10:99159815	T/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.09	-0.31	3.1e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg15290081	chr7:76254647	POMZP3;LOC100133091	0.46	7.06	0.36	9.06e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.29	-0.49	8.14e-22	Response to antipsychotic treatment;
LIHC	cis	rs6445975	0.688	rs2271633	chr3:58260073	A/G	cg23715586	chr3:58305044	RPP14	-0.34	-5.87	-0.3	1.03e-8	Systemic lupus erythematosus;
LIHC	cis	rs7635838	0.892	rs7644968	chr3:11489493	C/T	cg00170343	chr3:11313890	ATG7	0.43	6.7	0.34	8.7e-11	HDL cholesterol;
LIHC	cis	rs12220238	0.841	rs11000993	chr10:76084111	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.27	0.32	1.07e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.53	-8.87	-0.43	4.05e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs17152411	0.895	rs61872121	chr10:126586795	T/C	cg07906193	chr10:126599966	NA	0.44	6.89	0.35	2.74e-11	Height;
LIHC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.48	-7.73	-0.39	1.22e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.16	-0.32	1.99e-9	Aortic root size;
LIHC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-0.85	-9.52	-0.46	3.26e-19	Schizophrenia;
LIHC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-8.7	-0.43	1.4e-16	Body mass index (adult);
LIHC	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg14132834	chr19:41945861	ATP5SL	0.43	6.24	0.32	1.32e-9	Height;
LIHC	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.83	-15.4	-0.64	5.18e-41	Monocyte count;
LIHC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.6	-9.8	-0.47	3.84e-20	Post bronchodilator FEV1;
LIHC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.79	8.77	0.43	8.37e-17	Iron status biomarkers;
LIHC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.72	-0.3	2.33e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.35	6.8	0.34	4.8e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.69	-9.36	-0.45	1.08e-18	Corneal structure;
LIHC	trans	rs800082	0.934	rs1007566	chr3:144311752	G/A	cg24215973	chr2:240111563	HDAC4	-0.42	-6.1	-0.31	2.92e-9	Smoking behavior;
LIHC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.83	-13.26	-0.58	1.16e-32	Colorectal cancer;
LIHC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	7.05	0.36	1.02e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01765077	chr12:122356316	WDR66	-0.53	-8.3	-0.41	2.5e-15	Mean corpuscular volume;
LIHC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.65	-5.89	-0.3	9.4e-9	Menopause (age at onset);
LIHC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.52	-7.46	-0.37	7.14e-13	Psoriasis;
LIHC	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg07862535	chr7:139043722	LUC7L2	-0.57	-9.88	-0.47	2.04e-20	Diisocyanate-induced asthma;
LIHC	cis	rs9372498	0.505	rs1690654	chr6:118654172	A/G	cg01339444	chr6:118972232	C6orf204	0.71	6.24	0.32	1.26e-9	Diastolic blood pressure;
LIHC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.19	0.32	1.76e-9	Schizophrenia;
LIHC	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg15867164	chr4:3464754	DOK7	-0.42	-7.17	-0.36	4.6e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.44	0.53	6.89e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.74	-0.3	2.12e-8	Tonsillectomy;
LIHC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-8.55	-0.42	4.22e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg00204512	chr16:28754710	NA	0.41	7.11	0.36	6.83e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg24826892	chr11:71159390	DHCR7	0.45	5.77	0.3	1.8e-8	Vitamin D levels;
LIHC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.54	-8.53	-0.42	4.93e-16	Coronary artery disease;
LIHC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.54	-0.33	2.28e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg14593290	chr7:50529359	DDC	-0.61	-9.94	-0.47	1.31e-20	Malaria;
LIHC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.61	7.88	0.39	4.36e-14	Motion sickness;
LIHC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.39	-6.08	-0.31	3.18e-9	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.74	0.43	1.06e-16	Exhaled nitric oxide levels;
LIHC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.59	-11.55	-0.53	2.89e-26	Asthma;
LIHC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.53	6.34	0.32	7.3e-10	Morning vs. evening chronotype;
LIHC	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	8.43	0.41	9.6e-16	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	8.91	0.43	3.18e-17	Initial pursuit acceleration;
LIHC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.55	0.38	3.95e-13	Tonsillectomy;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg16970926	chr12:29381810	FAR2	0.31	6.6	0.34	1.61e-10	QT interval;
LIHC	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.56	9.78	0.47	4.52e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg20607798	chr8:58055168	NA	0.46	6.15	0.32	2.11e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.34	5.92	0.3	8e-9	Mean corpuscular volume;
LIHC	cis	rs288342	0.829	rs288243	chr2:183661310	C/G	cg02625481	chr2:183667124	NA	-0.28	-5.86	-0.3	1.11e-8	Recurrent major depressive disorder;
LIHC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.61	-10.08	-0.48	4.31e-21	Smoking initiation;
LIHC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.65	12.1	0.55	2.64e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.22	6.37	0.33	5.98e-10	Monocyte percentage of white cells;Monocyte count;
LIHC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.38	-0.37	1.2e-12	Breast cancer;
LIHC	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.31	2.7e-9	Mean corpuscular volume;
LIHC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg18887096	chr2:219472410	PLCD4	0.38	6.72	0.34	7.81e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.68	9.94	0.47	1.3e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.04	0.31	4.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg20991723	chr1:152506922	NA	0.53	9.23	0.45	2.89e-18	Hair morphology;
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08219700	chr8:58056026	NA	0.58	7.02	0.35	1.19e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg03037974	chr15:76606532	NA	0.72	13.82	0.6	8.32e-35	Blood metabolite levels;
LIHC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.54	7.13	0.36	6.18e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05794813	chr7:1057827	C7orf50	-0.27	-6.1	-0.31	2.87e-9	Calcium levels;
LIHC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	7.9	0.39	3.84e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-12.01	-0.54	5.83e-28	Type 2 diabetes;
LIHC	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.89	0.35	2.7e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.6	8.64	0.42	2.14e-16	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.34	-6.78	-0.34	5.36e-11	Renal cell carcinoma;
LIHC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg02297831	chr4:17616191	MED28	0.42	5.82	0.3	1.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.69	-11.91	-0.54	1.37e-27	Height;
LIHC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.66	6.97	0.35	1.65e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.25	0.41	3.42e-15	Bladder cancer;
LIHC	trans	rs4356975	0.522	rs7679184	chr4:69965930	C/G	cg18043070	chr17:72199725	RPL38	-0.42	-6.42	-0.33	4.45e-10	Obesity-related traits;
LIHC	trans	rs6934970	1.000	rs6934970	chr6:113124301	A/G	cg02462569	chr6:150064036	NUP43	0.44	6.04	0.31	4.09e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs507080	0.922	rs546890	chr11:118557198	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	cis	rs807029	0.533	rs735137	chr10:102735835	C/G	cg17130504	chr10:102756923	LZTS2	0.56	7.88	0.39	4.34e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.78	-0.5	1.55e-23	Inflammatory bowel disease;
LIHC	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23598886	chr18:12777645	NA	0.48	6.48	0.33	3.27e-10	Inflammatory skin disease;
LIHC	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.4	-6.36	-0.33	6.46e-10	Inhibitory control;
LIHC	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.37	2.22e-12	Migraine;Coronary artery disease;
LIHC	cis	rs244293	0.965	rs244339	chr17:53200114	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg17417191	chr1:218458683	RRP15	-0.48	-6.23	-0.32	1.35e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07677032	chr17:61819896	STRADA	0.44	6.44	0.33	4.01e-10	Prudent dietary pattern;
LIHC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.57	-9.45	-0.45	5.69e-19	Colorectal cancer;
LIHC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.43	-6.52	-0.33	2.51e-10	Asthma (sex interaction);
LIHC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.46	8.89	0.43	3.49e-17	Schizophrenia;
LIHC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.9	16.44	0.66	3.72e-45	Aortic root size;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.43	1.61e-16	Prudent dietary pattern;
LIHC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.42	-6.5	-0.33	2.83e-10	Iron status biomarkers;
LIHC	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.31	-6.67	-0.34	1.04e-10	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg09222892	chr1:25734099	RHCE	-0.44	-7.88	-0.39	4.35e-14	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	5.87e-9	Menopause (age at onset);
LIHC	cis	rs12079745	1.000	rs11810815	chr1:169329790	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-7.06	-0.36	9.27e-12	QT interval;
LIHC	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.47	-0.49	1.97e-22	Rheumatoid arthritis;
LIHC	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.47	-6.06	-0.31	3.67e-9	Breast cancer;
LIHC	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg17830980	chr10:43048298	ZNF37B	0.42	7.94	0.39	3.02e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg18081818	chr7:23246105	NA	-0.47	-7.16	-0.36	5.03e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg22496339	chr2:162101262	NA	-0.51	-6.8	-0.35	4.66e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg01753270	chr2:239240285	TRAF3IP1	0.32	6.19	0.32	1.71e-9	Multiple system atrophy;
LIHC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.45	-6.14	-0.32	2.23e-9	Longevity;
LIHC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.33	0.55	3.6e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.23	-0.41	3.95e-15	Exhaled nitric oxide output;
LIHC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-10.33	-0.49	6.14e-22	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg02419362	chr12:121203948	SPPL3	-0.34	-5.91	-0.3	8.51e-9	Mean corpuscular volume;
LIHC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.48	0.46	4.5e-19	Morning vs. evening chronotype;
LIHC	cis	rs4742903	0.935	rs7026246	chr9:106955686	A/C	cg14250997	chr9:106856677	SMC2	0.36	6.07	0.31	3.36e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15636057	chr19:36119798	RBM42	0.44	6.28	0.32	1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.44	-6.44	-0.33	4.11e-10	Narcolepsy;
LIHC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.72	-10.18	-0.48	1.95e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.48	-9.49	-0.46	4.19e-19	LDL cholesterol levels;
LIHC	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.38	7.96	0.4	2.58e-14	Sitting height ratio;
LIHC	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.47e-9	Cognitive performance;
LIHC	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.44	-6.65	-0.34	1.17e-10	Fibroblast growth factor basic levels;
LIHC	cis	rs965469	1.000	rs6051737	chr20:3296992	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.62	-10.68	-0.5	3.61e-23	Uric acid clearance;
LIHC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg27490568	chr2:178487706	NA	0.72	9.46	0.46	5.29e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16600020	chr8:30210405	NA	-0.29	-6.28	-0.32	1e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.8	-10.9	-0.51	6.16e-24	Response to hepatitis C treatment;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.75	13.7	0.6	2.43e-34	Prudent dietary pattern;
LIHC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg22903471	chr2:27725779	GCKR	-0.44	-7.56	-0.38	3.68e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.47	6.94	0.35	1.93e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg10381502	chr11:71823885	C11orf51	1.06	9.3	0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06116397	chr18:32820960	ZNF397	0.45	6.37	0.33	6.03e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.53	-8.01	-0.4	1.82e-14	Response to antidepressants and depression;
LIHC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.39	-6.44	-0.33	4.01e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.76	11.62	0.53	1.63e-26	Mosquito bite size;
LIHC	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.85	-0.35	3.36e-11	Mean corpuscular volume;
LIHC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-14.82	-0.63	1.03e-38	Chronic sinus infection;
LIHC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg26441486	chr22:50317300	CRELD2	0.4	6.7	0.34	8.43e-11	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.98	0.44	1.78e-17	Platelet count;
LIHC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.36	-5.81	-0.3	1.45e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.28	5.77	0.3	1.82e-8	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.96e-38	Blood metabolite levels;
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.36	6.22	0.32	1.41e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg16226627	chr15:75307476	SCAMP5	0.54	9.88	0.47	2.04e-20	Lung cancer;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.71	-0.71	2.82e-54	Height;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01172114	chr10:5979283	FBXO18	0.41	6.05	0.31	3.76e-9	Bilirubin levels;
LIHC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.13	0.4	7.99e-15	Tonsillectomy;
LIHC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg00204748	chr12:29376779	FAR2	0.4	7.43	0.37	8.63e-13	QT interval;
LIHC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.18	-0.4	5.8e-15	Schizophrenia;
LIHC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.66	-0.38	1.95e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2573652	0.722	rs11636084	chr15:100543394	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.69	-11.97	-0.54	8.3e-28	Height;
LIHC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.74	12.09	0.55	2.85e-28	Body mass index;
LIHC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.16	-0.32	2.06e-9	Aortic root size;
LIHC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	9.24	0.45	2.79e-18	Lung cancer in ever smokers;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg01809437	chr16:84695622	KLHL36	0.43	6.71	0.34	7.89e-11	Bipolar disorder;
LIHC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	9.3	0.45	1.65e-18	Platelet count;
LIHC	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.29	-6.2	-0.32	1.65e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.52	7.57	0.38	3.51e-13	Obesity-related traits;
LIHC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.54	8.84	0.43	5.31e-17	Mean corpuscular volume;
LIHC	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02985541	chr2:219472218	PLCD4	-0.42	-6.59	-0.34	1.66e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg06565975	chr8:143823917	SLURP1	-0.39	-6.44	-0.33	4.01e-10	Urinary tract infection frequency;
LIHC	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg27417294	chr10:81904244	PLAC9	-0.36	-6.16	-0.32	2.04e-9	Sarcoidosis;
LIHC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.73	0.3	2.21e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg10820045	chr2:198174542	NA	0.44	6.48	0.33	3.27e-10	Intracranial aneurysm;
LIHC	cis	rs6066825	0.644	rs6125442	chr20:47331210	C/G	cg18078177	chr20:47281410	PREX1	0.41	6.66	0.34	1.09e-10	Colorectal cancer;
LIHC	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.45	-7.05	-0.36	1.01e-11	Aortic root size;
LIHC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.48	6.48	0.33	3.12e-10	Monobrow;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg16103275	chr6:290800	DUSP22	0.5	6.64	0.34	1.21e-10	Menopause (age at onset);
LIHC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg07061783	chr6:25882402	NA	-0.49	-6.93	-0.35	2.06e-11	Blood metabolite levels;
LIHC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.58e-15	Motion sickness;
LIHC	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg02466173	chr16:30829666	NA	0.48	7.23	0.36	3.15e-12	Dementia with Lewy bodies;
LIHC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg15123519	chr2:136567270	LCT	0.45	9.45	0.45	5.65e-19	Mosquito bite size;
LIHC	cis	rs2191566	0.845	rs7258517	chr19:44535999	G/T	cg20607764	chr19:44506953	ZNF230	-0.42	-6.81	-0.35	4.5e-11	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.18	12.9	0.57	2.59e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.4	6.52	0.33	2.6e-10	Mean corpuscular volume;
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg13152130	chr6:118910203	C6orf204	-0.61	-6.58	-0.34	1.81e-10	Diastolic blood pressure;
LIHC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg22676075	chr6:135203613	NA	0.38	6.24	0.32	1.32e-9	Red blood cell count;
LIHC	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.44	7.25	0.37	2.79e-12	Dementia with Lewy bodies;
LIHC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.6	11.2	0.52	5.04e-25	Systemic lupus erythematosus;
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.89	13.27	0.58	1.09e-32	Menarche (age at onset);
LIHC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.36	-0.37	1.39e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.45	-6.91	-0.35	2.43e-11	Diastolic blood pressure;
LIHC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	9.53	0.46	2.9e-19	Fat distribution (HIV);
LIHC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	7.44	0.37	8.21e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs918629	0.599	rs4563648	chr5:95265556	G/A	cg10483112	chr5:95245456	ELL2	-0.39	-7.05	-0.36	9.91e-12	IgG glycosylation;
LIHC	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg21174375	chr14:64681225	SYNE2	0.41	6.62	0.34	1.42e-10	Atrial fibrillation;
LIHC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19671926	chr4:122722719	EXOSC9	0.53	8.4	0.41	1.22e-15	Type 2 diabetes;
LIHC	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg06238570	chr21:40685208	BRWD1	-0.37	-5.84	-0.3	1.24e-8	Menarche (age at onset);
LIHC	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg05262829	chr1:226921576	ITPKB	0.4	8.25	0.41	3.49e-15	Parkinson's disease;
LIHC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.4	0.37	1.07e-12	Diastolic blood pressure;
LIHC	cis	rs2574704	0.962	rs11709778	chr3:11652034	C/T	cg15876825	chr3:11651881	VGLL4	-0.5	-8.2	-0.41	4.88e-15	Body mass index;
LIHC	cis	rs6867032	0.917	rs4975719	chr5:2010162	C/T	cg26168224	chr5:2018326	NA	0.24	5.89	0.3	9.02e-9	Gut microbiome composition (winter);
LIHC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.17	0.52	6.66e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.9	-0.35	2.49e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.57	6.14	0.31	2.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	0.92	22.83	0.78	9.57e-71	Multiple myeloma;
LIHC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg19680672	chr10:131412579	MGMT	-0.42	-6.42	-0.33	4.45e-10	Response to temozolomide;
LIHC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.18	-0.63	3.71e-40	Coronary artery disease;
LIHC	cis	rs7095607	0.630	rs10998012	chr10:69958690	A/G	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.66e-9	Lung function (FVC);
LIHC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.59	-10.17	-0.48	2.07e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.35	6.0	0.31	5.09e-9	Hemoglobin concentration;
LIHC	trans	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.07	-0.31	3.39e-9	Coronary artery disease;
LIHC	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.68	-0.53	9.33e-27	Coffee consumption (cups per day);
LIHC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg25356066	chr3:128598488	ACAD9	0.55	7.67	0.38	1.82e-13	IgG glycosylation;
LIHC	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.8	0.35	4.7e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7707921	0.881	rs1428940	chr5:81447995	A/G	cg15871215	chr5:81402204	ATG10	-0.63	-6.25	-0.32	1.26e-9	Breast cancer;
LIHC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.49	-6.17	-0.32	1.97e-9	Pancreatic cancer;
LIHC	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.49	6.08	0.31	3.23e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.88	15.8	0.65	1.25e-42	Aortic root size;
LIHC	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.4	7.25	0.36	2.83e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg01843034	chr6:37503916	NA	-0.46	-7.24	-0.36	3.01e-12	Cognitive performance;
LIHC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02450064	chr17:40260053	DHX58	-0.28	-5.75	-0.3	1.95e-8	Fibrinogen levels;
LIHC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.4	-10.54	-0.5	1.08e-22	Asthma (sex interaction);
LIHC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.64	-0.34	1.25e-10	Height;
LIHC	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg18289306	chr13:113640169	MCF2L	0.41	6.58	0.34	1.75e-10	Systolic blood pressure;
LIHC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06481639	chr22:41940642	POLR3H	0.66	6.95	0.35	1.9e-11	Vitiligo;
LIHC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.55	10.04	0.48	5.92e-21	Lewy body disease;
LIHC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg16479474	chr6:28041457	NA	0.46	6.76	0.34	5.91e-11	Depression;
LIHC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg16797656	chr11:68205561	LRP5	0.5	7.82	0.39	6.67e-14	Total body bone mineral density;
LIHC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.36	6.09	0.31	3.06e-9	Schizophrenia;
LIHC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12744310	0.943	rs35972058	chr1:41769146	G/A	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.68	8.49	0.42	6.36e-16	Corneal astigmatism;
LIHC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg06212747	chr3:49208901	KLHDC8B	0.47	6.12	0.31	2.51e-9	Resting heart rate;
LIHC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.22	-6.23	-0.32	1.35e-9	Type 2 diabetes;
LIHC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs10847980	0.623	rs7955367	chr12:123828792	G/A	cg07919128	chr17:18022025	MYO15A	-0.75	-7.58	-0.38	3.33e-13	Adiponectin levels;
LIHC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.86	-16.26	-0.66	1.94e-44	Coronary artery disease;
LIHC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.68	6.42	0.33	4.65e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.42	7.15	0.36	5.45e-12	Mean corpuscular volume;
LIHC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-9.58	-0.46	2.11e-19	Response to antipsychotic treatment;
LIHC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg15848620	chr12:58087721	OS9	-0.55	-7.47	-0.37	6.68e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.58	7.85	0.39	5.26e-14	Bone mineral density (spine);
LIHC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02985541	chr2:219472218	PLCD4	0.44	8.13	0.4	7.89e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.68	-7.32	-0.37	1.79e-12	Neuroticism;
LIHC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg12317470	chr15:67143691	NA	0.58	5.94	0.31	7.01e-9	Lung cancer (smoking interaction);
LIHC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.37	-6.61	-0.34	1.45e-10	Aortic root size;
LIHC	trans	rs6489882	0.703	rs2057778	chr12:113350796	A/C	cg10175203	chr3:128143634	NA	-0.38	-6.28	-0.32	1.03e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-11.47	-0.53	5.42e-26	Platelet distribution width;
LIHC	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.8	-0.35	4.63e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg22509189	chr2:225307070	NA	-0.45	-5.75	-0.3	2.02e-8	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg00800038	chr16:89945340	TCF25	-0.64	-9.34	-0.45	1.31e-18	Skin colour saturation;
LIHC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	0.83	14.57	0.62	9.76e-38	Bone mineral density;
LIHC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.63	8.73	0.43	1.14e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg18306943	chr3:40428807	ENTPD3	0.44	7.6	0.38	2.84e-13	Renal cell carcinoma;
LIHC	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.64	-10.28	-0.49	9.19e-22	Rheumatoid arthritis;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.53	-7.36	-0.37	1.42e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.37	6.68	0.34	9.57e-11	Aortic root size;
LIHC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	6.02e-12	Diabetic kidney disease;
LIHC	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	0.77	7.61	0.38	2.65e-13	Arsenic metabolism;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg03479204	chr13:114193155	TMCO3	-0.42	-6.69	-0.34	9.25e-11	Pain;
LIHC	cis	rs965469	0.857	rs1922990	chr20:3252348	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-6.46	-0.33	3.58e-10	IFN-related cytopenia;
LIHC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.66	-5.8	-0.3	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7572733	0.555	rs11889006	chr2:198928647	A/G	cg10820045	chr2:198174542	NA	0.42	6.33	0.32	7.54e-10	Dermatomyositis;
LIHC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.34	0.32	7.45e-10	Tonsillectomy;
LIHC	cis	rs4742903	0.875	rs4543600	chr9:106939884	A/G	cg14250997	chr9:106856677	SMC2	0.35	5.92	0.3	7.8e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg03859395	chr2:55845619	SMEK2	-0.48	-7.93	-0.39	3.11e-14	Metabolic syndrome;
LIHC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg15848620	chr12:58087721	OS9	-0.53	-7.14	-0.36	5.69e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.12	0.36	6.23e-12	Diabetic kidney disease;
LIHC	cis	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg14515779	chr1:101123966	NA	-0.69	-13.89	-0.6	4.36e-35	Monocyte count;
LIHC	cis	rs716804	0.598	rs10840381	chr11:10297957	A/C	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.11e-8	Neuroticism;
LIHC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.79	10.11	0.48	3.45e-21	HIV-1 control;
LIHC	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-17.66	-0.69	4.41e-50	Schizophrenia;
LIHC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.46	6.28	0.32	1.01e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.74	10.55	0.5	1.04e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg24826892	chr11:71159390	DHCR7	0.48	6.15	0.32	2.21e-9	Vitamin D levels;
LIHC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.51	7.08	0.36	8.1e-12	Aortic root size;
LIHC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.84	-0.47	2.74e-20	Response to antipsychotic treatment;
LIHC	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg27386326	chr11:61587980	NA	0.67	13.45	0.59	2.07e-33	Red cell distribution width;Mean platelet volume;
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.57	-5.84	-0.3	1.22e-8	Diastolic blood pressure;
LIHC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.72	13.13	0.58	3.64e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7106204	0.514	rs12293105	chr11:24256048	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	12.17	0.55	1.5e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4934494	0.813	rs12775783	chr10:91406251	G/A	cg19698084	chr10:91461284	KIF20B	-0.5	-6.53	-0.33	2.45e-10	Red blood cell count;
LIHC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.9	-0.43	3.31e-17	Atrioventricular conduction;
LIHC	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg03441853	chr15:73075003	ADPGK	0.29	5.99	0.31	5.23e-9	Triglyceride levels;
LIHC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg23485639	chr6:28045615	ZNF165	0.38	6.0	0.31	5.1e-9	Cardiac Troponin-T levels;
LIHC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.63	0.42	2.28e-16	Height;
LIHC	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.8	-14.47	-0.62	2.43e-37	Height;
LIHC	cis	rs4407350	0.655	rs135623	chr22:44890672	C/T	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.17	-0.32	1.94e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.45	-5.74	-0.3	2.09e-8	Obesity (extreme);
LIHC	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg25952890	chr19:58913133	NA	0.7	7.64	0.38	2.23e-13	Mean platelet volume;
LIHC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02475777	chr4:1388615	CRIPAK	0.4	6.48	0.33	3.3e-10	Obesity-related traits;
LIHC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.76	0.39	9.59e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24583131	chr6:18265189	DEK	0.44	6.17	0.32	1.91e-9	Pancreatic cancer;
LIHC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.47	0.46	4.6e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	0.99	18.17	0.7	3.94e-52	Monocyte percentage of white cells;
LIHC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.47	-7.78	-0.39	8.51e-14	Platelet distribution width;
LIHC	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.72	-11.12	-0.52	9.97e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg25251204	chr11:14927456	NA	0.41	5.87	0.3	1.03e-8	Vitamin D levels;
LIHC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.91	-0.3	8.06e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-8.01	-0.4	1.84e-14	Urinary tract infection frequency;
LIHC	cis	rs807029	0.533	rs735137	chr10:102735835	C/G	cg25179470	chr10:102756915	LZTS2	0.46	6.46	0.33	3.51e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.61	-0.42	2.81e-16	Colorectal cancer;
LIHC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.65	9.87	0.47	2.22e-20	Neutrophil percentage of white cells;
LIHC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.23	-5.71	-0.3	2.44e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	0.97	24.93	0.8	6.49e-79	Multiple myeloma;
LIHC	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.47	-8.42	-0.41	1.09e-15	Blood pressure;
LIHC	cis	rs939574	0.512	rs55908154	chr2:220145960	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.59	7.08	0.36	8.04e-12	Platelet distribution width;
LIHC	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.59	-0.53	2.07e-26	Coffee consumption (cups per day);
LIHC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.72	-0.3	2.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.43	6.92	0.35	2.2e-11	Red blood cell count;
LIHC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-9.74	-0.47	6.02e-20	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16031872	chr3:142297641	ATR	0.47	6.25	0.32	1.22e-9	Lung function (FEV1/FVC);
LIHC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.33	5.74	0.3	2.11e-8	Parkinson's disease;
LIHC	cis	rs922107	0.935	rs1077539	chr1:90013144	T/G	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.66	-0.38	1.87e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.53	6.89	0.35	2.76e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.57	-8.48	-0.42	6.79e-16	White matter hyperintensity burden;
LIHC	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.41	-0.33	4.73e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17106184	1.000	rs72898944	chr1:50958027	C/A	cg07174182	chr1:51127561	FAF1	-0.59	-6.64	-0.34	1.23e-10	Type 2 diabetes;
LIHC	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg00647820	chr17:40259828	DHX58	-0.29	-5.77	-0.3	1.79e-8	Fibrinogen levels;
LIHC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg27490568	chr2:178487706	NA	0.38	6.05	0.31	3.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.72	8.53	0.42	4.73e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02290350	chr8:58132656	NA	0.5	10.54	0.5	1.11e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg23461800	chr14:103021989	NA	0.46	6.34	0.32	7.13e-10	Platelet count;
LIHC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.98	11.98	0.54	7.58e-28	Eosinophil percentage of granulocytes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00001245	chr3:15106710	MRPS25	0.51	6.55	0.33	2.15e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.49	7.03	0.36	1.13e-11	Schizophrenia;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21131796	chr12:124829443	NCOR2	0.43	6.28	0.32	1.02e-9	Bilirubin levels;
LIHC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.44	6.56	0.33	2e-10	Asthma (sex interaction);
LIHC	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.41	-8.68	-0.42	1.66e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.34	0.32	7.42e-10	Height;
LIHC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.45	5.93	0.31	7.39e-9	Parkinson's disease;
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.78	0.34	5.32e-11	Renal cell carcinoma;
LIHC	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-6.24	-0.32	1.31e-9	Coronary artery disease;
LIHC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg25281562	chr12:121454272	C12orf43	0.33	5.73	0.3	2.24e-8	N-glycan levels;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg19806062	chr19:11319688	DOCK6	0.47	7.16	0.36	4.98e-12	Alopecia areata;
LIHC	cis	rs911119	0.955	rs67997662	chr20:23592864	G/A	cg16589663	chr20:23618590	CST3	0.72	7.59	0.38	3.09e-13	Chronic kidney disease;
LIHC	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.72	10.68	0.5	3.75e-23	Subjective well-being;
LIHC	cis	rs12464559	0.649	rs11896217	chr2:152591189	G/A	cg01189475	chr2:152685088	ARL5A	0.67	7.83	0.39	6.03e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs526821	0.595	rs551665	chr11:55343268	G/A	cg04317927	chr11:55418816	OR4S2	0.47	8.98	0.44	1.87e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.31e-20	Menopause (age at onset);
LIHC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.41	0.37	9.68e-13	Renal cell carcinoma;
LIHC	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg03934865	chr2:198174659	NA	0.53	8.06	0.4	1.26e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-7.84	-0.39	5.63e-14	Crohn's disease;
LIHC	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.51	-6.0	-0.31	4.97e-9	Body mass index;
LIHC	cis	rs7188861	1.000	rs7188861	chr16:11454650	C/A	cg01510278	chr16:11456238	NA	0.5	6.07	0.31	3.37e-9	HDL cholesterol;
LIHC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.01	0.54	5.93e-28	Alzheimer's disease;
LIHC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.67	0.38	1.85e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7945718	0.621	rs7939509	chr11:12688130	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.69	0.5	3.27e-23	Alzheimer's disease;
LIHC	cis	rs2108622	0.668	rs62106153	chr19:15978507	C/T	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.87e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs2236267	0.564	rs8007372	chr14:88629117	C/T	cg02175263	chr14:88627849	NA	0.37	6.82	0.35	4.14e-11	Food antigen IgG levels;
LIHC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.53	9.24	0.45	2.59e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.78	-13.54	-0.59	9.39e-34	Tonsillectomy;
LIHC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.86	13.38	0.59	3.95e-33	Vitamin D levels;
LIHC	cis	rs15676	0.783	rs10988119	chr9:131564585	T/C	cg00228799	chr9:131580591	ENDOG	-0.48	-6.8	-0.34	4.79e-11	Blood metabolite levels;
LIHC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.57	6.81	0.35	4.35e-11	Alzheimer's disease;
LIHC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11702148	0.552	rs11701506	chr21:34904352	T/A	cg14850771	chr21:34775459	IFNGR2	0.46	7.52	0.38	4.81e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21448741	chr8:58168803	NA	0.37	6.69	0.34	9.39e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.78	13.62	0.59	4.71e-34	Aortic root size;
LIHC	trans	rs783540	0.900	rs12916980	chr15:83306447	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.17	-0.32	1.9e-9	Schizophrenia;
LIHC	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.66	-0.42	1.92e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.37	-6.88	-0.35	2.84e-11	Height;
LIHC	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.37	-5.81	-0.3	1.41e-8	Lewy body disease;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg26939375	chr7:64535504	NA	0.47	8.25	0.41	3.36e-15	Calcium levels;
LIHC	cis	rs6088590	0.610	rs6088461	chr20:32905161	G/T	cg24642439	chr20:33292090	TP53INP2	0.61	7.52	0.38	4.99e-13	Coronary artery disease;
LIHC	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.53	-8.11	-0.4	8.91e-15	Extraversion;
LIHC	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg02487422	chr3:49467188	NICN1	-0.49	-6.34	-0.32	7.39e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9503598	0.517	rs11242860	chr6:3463536	A/C	cg00476032	chr6:3446245	SLC22A23	0.42	7.94	0.39	2.91e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.07	-0.51	1.46e-24	Morning vs. evening chronotype;
LIHC	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.14	-0.4	7.54e-15	Exhaled nitric oxide output;
LIHC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg02290350	chr8:58132656	NA	0.32	7.05	0.36	9.69e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg22676075	chr6:135203613	NA	0.41	6.54	0.33	2.19e-10	Red blood cell count;
LIHC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-7.41	-0.37	1.03e-12	Morning vs. evening chronotype;
LIHC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	11.56	0.53	2.61e-26	Lung cancer in ever smokers;
LIHC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.89	-0.3	9.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.65	-10.97	-0.51	3.54e-24	Pediatric autoimmune diseases;
LIHC	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.53	-8.18	-0.4	5.65e-15	Extraversion;
LIHC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.57	9.9	0.47	1.78e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.87	-15.19	-0.63	3.51e-40	Aortic root size;
LIHC	cis	rs8049603	1.000	rs35260685	chr16:23088062	C/A	cg16484020	chr16:23217411	SCNN1G	-0.25	-5.71	-0.3	2.44e-8	Multiple sclerosis;
LIHC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg18016565	chr1:150552671	MCL1	0.51	9.67	0.46	1.03e-19	Melanoma;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.57	6.84	0.35	3.72e-11	Alzheimer's disease;
LIHC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.21	-5.75	-0.3	1.93e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.73	-11.45	-0.53	6.72e-26	Fibrinogen levels;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.72	0.47	6.89e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.07	-0.51	1.46e-24	Morning vs. evening chronotype;
LIHC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.35	8.97	0.44	2.05e-17	Schizophrenia;
LIHC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02228675	chr17:40259724	DHX58	0.25	5.72	0.3	2.3e-8	Fibrinogen levels;
LIHC	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1789	0.903	rs4453929	chr4:15672173	T/G	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.86	-0.3	1.07e-8	Blood protein levels;
LIHC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.57	8.98	0.44	1.84e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.49e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.36	-5.99	-0.31	5.28e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg11395062	chr17:14139857	CDRT15	0.53	9.52	0.46	3.17e-19	Temperament;
LIHC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.61	10.49	0.49	1.6e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg16479474	chr6:28041457	NA	0.39	6.68	0.34	9.98e-11	Cardiac Troponin-T levels;
LIHC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.59	-8.34	-0.41	1.9e-15	Neuroblastoma;
LIHC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.45	5.94	0.31	6.98e-9	Tourette syndrome;
LIHC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	6.54	0.33	2.22e-10	Height;
LIHC	cis	rs9783347	1.000	rs1140047	chr11:18327684	G/T	cg15585147	chr11:18324498	HPS5	0.44	6.81	0.35	4.35e-11	Pancreatic cancer;
LIHC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg08847533	chr14:75593920	NEK9	-0.37	-6.05	-0.31	3.78e-9	Caffeine consumption;
LIHC	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg16586182	chr3:47516702	SCAP	-0.38	-6.22	-0.32	1.48e-9	Birth weight;
LIHC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-6.8	-0.35	4.66e-11	Longevity;Endometriosis;
LIHC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.29	6.89	0.35	2.62e-11	Menarche (age at onset);
LIHC	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14396892	chr9:96623032	NA	-0.31	-6.1	-0.31	2.81e-9	DNA methylation (variation);
LIHC	cis	rs7187994	0.895	rs7184644	chr16:84786460	C/A	cg07647771	chr16:84786436	USP10	-0.33	-6.36	-0.33	6.37e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.82	0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.64	9.07	0.44	9.29e-18	Economic and political preferences (feminism/equality);
LIHC	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg03146154	chr1:46216737	IPP	-0.41	-6.87	-0.35	3.09e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg03934865	chr2:198174659	NA	-0.47	-6.96	-0.35	1.79e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg23091122	chr1:110024289	SYPL2	-0.47	-6.18	-0.32	1.84e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.28	6.93	0.35	2.09e-11	Migraine;
LIHC	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.57	-7.19	-0.36	4.22e-12	Blood pressure (smoking interaction);
LIHC	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	6.96	0.35	1.73e-11	Blood protein levels;
LIHC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg16479474	chr6:28041457	NA	0.38	6.44	0.33	4.05e-10	Cardiac Troponin-T levels;
LIHC	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-7.5	-0.38	5.62e-13	Hepatocellular carcinoma;
LIHC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.64	0.56	2.6e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-7.1	-0.36	7.42e-12	Monocyte percentage of white cells;
LIHC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg14558114	chr2:88469736	THNSL2	-0.37	-5.77	-0.3	1.76e-8	Response to metformin (IC50);
LIHC	cis	rs332507	0.830	rs2242425	chr3:124398644	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.07	0.36	8.83e-12	Plateletcrit;
LIHC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.48	-7.86	-0.39	4.91e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.967	rs686630	chr8:109233239	G/C	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.45	6.06	0.31	3.65e-9	Parkinson's disease;
LIHC	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg16006841	chr5:176797999	RGS14	0.7	8.45	0.42	8.57e-16	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg16262614	chr3:133464971	TF	0.43	6.82	0.35	4.04e-11	Iron status biomarkers (transferrin levels);
LIHC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg01198024	chr21:33672713	MRAP	-0.42	-6.1	-0.31	2.88e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	10.72	0.5	2.54e-23	Personality dimensions;
LIHC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.44	5.94	0.31	6.83e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.45	5.93	0.31	7.39e-9	Parkinson's disease;
LIHC	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.4	6.25	0.32	1.2e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-11.52	-0.53	3.72e-26	Longevity;Endometriosis;
LIHC	cis	rs7116495	0.786	rs10736782	chr11:71654012	A/G	cg26138937	chr11:71823887	C11orf51	-0.67	-6.83	-0.35	3.88e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.46	6.89	0.35	2.65e-11	Night sleep phenotypes;
LIHC	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.57	-10.09	-0.48	3.86e-21	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.53	-6.43	-0.33	4.38e-10	Diastolic blood pressure;
LIHC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg03037974	chr15:76606532	NA	0.75	14.71	0.62	2.68e-38	Blood metabolite levels;
LIHC	cis	rs4908768	0.906	rs28422051	chr1:8618337	T/C	cg25722041	chr1:8623473	RERE	0.43	6.06	0.31	3.55e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.71	-12.28	-0.55	6.01e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.96	0.31	6.13e-9	Renal cell carcinoma;
LIHC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg19318889	chr4:1322082	MAEA	0.47	6.51	0.33	2.69e-10	Obesity-related traits;
LIHC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.75e-10	Depression;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg27432699	chr2:27873401	GPN1	-0.54	-7.82	-0.39	6.44e-14	Total body bone mineral density;
LIHC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21467203	chr3:49911342	NA	-0.42	-7.51	-0.38	5.13e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.41	5.81	0.3	1.43e-8	Height;
LIHC	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.33	-0.32	7.67e-10	Metabolite levels;
LIHC	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.72	11.74	0.54	5.55e-27	Oral cavity cancer;
LIHC	cis	rs16828019	0.852	rs12759050	chr1:41664204	T/A	cg03387723	chr1:41708464	SCMH1	-0.44	-7.13	-0.36	6.14e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9649465	1.000	rs2109725	chr7:123325459	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.02e-15	Migraine;
LIHC	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg18887096	chr2:219472410	PLCD4	-0.38	-6.41	-0.33	4.95e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1144333	1.000	rs78223982	chr1:76465203	T/C	cg22875332	chr1:76189707	ACADM	0.4	6.15	0.32	2.16e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.58	8.95	0.44	2.34e-17	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-6.91	-0.35	2.43e-11	Type 2 diabetes;
LIHC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.41	6.39	0.33	5.42e-10	Melanoma;
LIHC	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg18898632	chr2:242989856	NA	-0.46	-6.3	-0.32	9.04e-10	Obesity-related traits;
LIHC	trans	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	8.89	0.43	3.5e-17	Colorectal cancer;
LIHC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.55	7.06	0.36	9.12e-12	Morning vs. evening chronotype;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.17	-0.32	1.95e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.55	-8.35	-0.41	1.66e-15	Schizophrenia;
LIHC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.66	10.1	0.48	3.58e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.74	13.96	0.6	2.27e-35	Crohn's disease;
LIHC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg16226627	chr15:75307476	SCAMP5	0.49	8.62	0.42	2.57e-16	Lung cancer;
LIHC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.63	8.13	0.4	8.07e-15	Morning vs. evening chronotype;
LIHC	trans	rs759244	0.676	rs1005416	chr4:25060151	G/C	cg18314424	chr4:184718605	NA	0.32	6.14	0.32	2.32e-9	Interleukin-2 receptor antagonist levels;
LIHC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.44	5.82	0.3	1.35e-8	Subjective well-being;
LIHC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	0.59	11.21	0.52	4.69e-25	Fat distribution (HIV);
LIHC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.89	0.3	9.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.59	-9.14	-0.44	5.66e-18	Pediatric autoimmune diseases;
LIHC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.92	17.05	0.68	1.3e-47	Menopause (age at onset);
LIHC	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg01843034	chr6:37503916	NA	-0.48	-8.21	-0.41	4.45e-15	Cognitive performance;
LIHC	cis	rs61041384	0.661	rs74240770	chr12:123691742	T/G	cg00376283	chr12:123451042	ABCB9	-0.54	-5.9	-0.3	8.66e-9	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs7116495	0.737	rs2460252	chr11:71567504	T/C	cg26138937	chr11:71823887	C11orf51	0.69	6.64	0.34	1.23e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.6	8.92	0.43	2.94e-17	Recombination rate (females);
LIHC	cis	rs939574	0.660	rs6716253	chr2:220127016	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.94	6.39	0.33	5.43e-10	Platelet distribution width;
LIHC	trans	rs859980	0.514	rs9386402	chr6:104519786	C/T	cg15957524	chr2:233415782	TIGD1;EIF4E2	0.46	6.54	0.33	2.19e-10	Tourette's syndrome or obsessive-compulsive disorder;
LIHC	cis	rs79149102	1.000	rs78940327	chr15:75152480	G/A	cg16226627	chr15:75307476	SCAMP5	0.44	5.93	0.31	7.41e-9	Lung cancer;
LIHC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg25039879	chr17:56429692	SUPT4H1	0.77	8.57	0.42	3.73e-16	Cognitive test performance;
LIHC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.59	8.15	0.4	6.79e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06258179	chr7:92463261	CDK6	-0.46	-6.32	-0.32	8.06e-10	Pancreatic cancer;
LIHC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.7	-10.49	-0.49	1.67e-22	Obesity-related traits;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05926266	chr13:39612065	C13orf23;NHLRC3	0.42	6.04	0.31	4.02e-9	Hepatitis;
LIHC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14067834	chr17:29058358	SUZ12P	0.62	6.45	0.33	3.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.88	0.3	9.88e-9	Electroencephalogram traits;
LIHC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	12.22	0.55	9.59e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg04592579	chr7:75616294	TMEM120A	0.41	7.01	0.35	1.28e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs8113308	0.810	rs16983256	chr19:52449481	G/A	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg27386326	chr11:61587980	NA	0.7	15.04	0.63	1.32e-39	Trans fatty acid levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17128461	chr4:186125334	KIAA1430	0.44	6.29	0.32	9.98e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.52	-6.28	-0.32	1.05e-9	Schizophrenia;
LIHC	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.76	-0.3	1.85e-8	Blood protein levels;
LIHC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.67	-11.63	-0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs965469	0.901	rs7270135	chr20:3247922	T/C	cg25506879	chr20:3388711	C20orf194	-0.58	-6.76	-0.34	5.89e-11	IFN-related cytopenia;
LIHC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.53	7.94	0.39	2.93e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.94	-17.6	-0.69	7.7e-50	Menopause (age at onset);
LIHC	cis	rs7129220	0.588	rs7931957	chr11:10094304	G/A	cg01453529	chr11:10209919	SBF2	-0.39	-6.91	-0.35	2.43e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12445461	chr9:6681608	NA	0.46	7.1	0.36	7.39e-12	Cognitive function;
LIHC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg12292205	chr6:26970375	C6orf41	-0.34	-5.89	-0.3	9.06e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg17834443	chr8:19674713	INTS10	0.42	6.57	0.33	1.88e-10	Breast cancer;
LIHC	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg26139080	chr11:47293733	MADD	-0.5	-8.33	-0.41	2.01e-15	HDL cholesterol;
LIHC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.41	8.96	0.44	2.08e-17	Rheumatoid arthritis;
LIHC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.59	-8.17	-0.4	6.22e-15	Response to antineoplastic agents;
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.28	0.32	1.03e-9	Total body bone mineral density;
LIHC	cis	rs11673344	0.832	rs76781063	chr19:37526942	T/C	cg27390819	chr19:37464633	NA	-0.51	-6.16	-0.32	2.02e-9	Obesity-related traits;
LIHC	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Intracranial aneurysm;
LIHC	trans	rs800082	1.000	rs1405599	chr3:144328759	T/C	cg24215973	chr2:240111563	HDAC4	-0.5	-7.44	-0.37	8.47e-13	Smoking behavior;
LIHC	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.41	0.33	4.9e-10	Ileal carcinoids;
LIHC	cis	rs1864585	0.806	rs17778223	chr8:10729692	A/T	cg11557530	chr8:9911760	MSRA	-0.5	-6.03	-0.31	4.18e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg23043544	chr7:2124092	MAD1L1	-0.43	-6.51	-0.33	2.6e-10	Bipolar disorder;
LIHC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.66	-8.74	-0.43	1.05e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10056811	0.538	rs2035191	chr5:74413713	T/C	cg02573091	chr5:74908125	NA	0.52	6.47	0.33	3.31e-10	Coronary artery disease;
LIHC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg00750074	chr16:89608354	SPG7	-0.38	-5.76	-0.3	1.89e-8	Multiple myeloma (IgH translocation);
LIHC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.88	-18.26	-0.7	1.79e-52	Height;
LIHC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg17750252	chr2:136567154	LCT	0.32	5.88	0.3	9.69e-9	Mosquito bite size;
LIHC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.37	6.06	0.31	3.53e-9	Mood instability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23249942	chr5:109027037	MAN2A1	0.44	6.83	0.35	3.98e-11	Pancreatic cancer;
LIHC	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.65e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.38	6.11	0.31	2.65e-9	Menopause (age at onset);
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07424592	chr7:64974309	NA	-0.45	-6.88	-0.35	2.8e-11	Calcium levels;
LIHC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.39	-6.85	-0.35	3.53e-11	Aortic root size;
LIHC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg12560992	chr17:57184187	TRIM37	0.44	6.29	0.32	9.63e-10	Cognitive test performance;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.74	12.66	0.56	2.2e-30	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg00829961	chr8:25909326	NA	-0.45	-6.14	-0.32	2.33e-9	Preeclampsia;
LIHC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	0.73	13.31	0.58	7.69e-33	Lewy body disease;
LIHC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg18850127	chr7:39170497	POU6F2	0.41	7.31	0.37	1.93e-12	IgG glycosylation;
LIHC	cis	rs716804	0.765	rs4366477	chr11:10306881	A/G	cg01453529	chr11:10209919	SBF2	-0.29	-5.87	-0.3	1.01e-8	Neuroticism;
LIHC	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-7.45	-0.37	7.63e-13	Metabolite levels;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.65	9.69	0.46	8.92e-20	Menarche (age at onset);
LIHC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg11861562	chr11:117069780	TAGLN	0.41	6.76	0.34	5.86e-11	Blood protein levels;
LIHC	cis	rs12602486	1.000	rs59592125	chr17:42279265	A/G	cg08193365	chr17:42277699	NA	1.0	6.8	0.34	4.75e-11	Glycated hemoglobin levels;
LIHC	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.67	13.23	0.58	1.48e-32	Leprosy;
LIHC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg03934865	chr2:198174659	NA	0.46	6.58	0.34	1.74e-10	Dermatomyositis;
LIHC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8081395	0.836	rs2063353	chr17:57889192	T/G	cg13753209	chr17:57696993	CLTC	-0.48	-7.37	-0.37	1.3e-12	White blood cell count;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg00280220	chr17:61926910	NA	-0.42	-6.82	-0.35	4.03e-11	Prudent dietary pattern;
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.56	-0.56	4.99e-30	Bipolar disorder and schizophrenia;
LIHC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.44	6.93	0.35	2.16e-11	Mortality in heart failure;
LIHC	cis	rs965469	1.000	rs6139064	chr20:3277050	G/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.58	-7.55	-0.38	4.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17152411	0.947	rs17152408	chr10:126649007	C/T	cg07906193	chr10:126599966	NA	0.43	7.25	0.37	2.74e-12	Height;
LIHC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.42	6.86	0.35	3.16e-11	Red blood cell count;
LIHC	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.56	-10.22	-0.48	1.46e-21	Urate levels in overweight individuals;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.85	-0.35	3.51e-11	Diastolic blood pressure;
LIHC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.62	-0.38	2.48e-13	Initial pursuit acceleration;
LIHC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg15848620	chr12:58087721	OS9	-0.59	-8.1	-0.4	9.68e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg08135965	chr6:41755394	TOMM6	0.46	6.13	0.31	2.41e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.51	8.94	0.44	2.43e-17	Coronary artery disease;
LIHC	trans	rs1624005	1.000	rs1756329	chr14:43379366	C/A	cg11960719	chr5:1510684	LPCAT1	-0.35	-6.21	-0.32	1.54e-9	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LIHC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg26566898	chr11:117069891	TAGLN	0.48	7.61	0.38	2.68e-13	Blood protein levels;
LIHC	trans	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.21	-0.41	4.62e-15	Obesity-related traits;
LIHC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg05697976	chr12:29376483	FAR2	0.33	6.86	0.35	3.29e-11	QT interval;
LIHC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-9.02	-0.44	1.4e-17	Vitiligo;
LIHC	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg06359132	chr10:99160096	RRP12	-0.39	-5.98	-0.31	5.5e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.86	-0.3	1.09e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg14941975	chr14:105892536	MTA1	0.41	6.23	0.32	1.34e-9	Alopecia areata;
LIHC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg22676075	chr6:135203613	NA	0.38	6.17	0.32	1.88e-9	Red blood cell count;
LIHC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.4	-6.5	-0.33	2.92e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.4	-6.07	-0.31	3.48e-9	Multiple myeloma;
LIHC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.41	-6.91	-0.35	2.39e-11	Platelet distribution width;
LIHC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg11812906	chr14:75593930	NEK9	-0.45	-7.22	-0.36	3.36e-12	IgG glycosylation;
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg12311636	chr6:118886798	C6orf204	-0.55	-6.29	-0.32	9.78e-10	Diastolic blood pressure;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg04525508	chr3:124774877	HEG1	-0.45	-6.14	-0.32	2.3e-9	Alopecia areata;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09260951	chr22:39096513	JOSD1	-0.39	-6.04	-0.31	4.07e-9	Pancreatic cancer;
LIHC	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg19636519	chr7:99541626	NA	0.31	6.01	0.31	4.67e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.7	-0.34	8.47e-11	Lymphocyte counts;
LIHC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.55	7.45	0.37	7.63e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02290350	chr8:58132656	NA	0.48	8.74	0.43	1.04e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.88	11.05	0.51	1.82e-24	Coronary artery disease;
LIHC	cis	rs2120019	1.000	rs34655806	chr15:75362586	T/C	cg09165964	chr15:75287851	SCAMP5	-0.59	-9.25	-0.45	2.48e-18	Blood trace element (Zn levels);
LIHC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg22676075	chr6:135203613	NA	0.4	6.51	0.33	2.73e-10	Red blood cell count;
LIHC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.81	-14.81	-0.63	1.05e-38	Height;
LIHC	trans	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.89e-11	Aortic root size;
LIHC	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.45	-6.19	-0.32	1.69e-9	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg03945807	chr20:60948434	NA	-0.36	-6.62	-0.34	1.37e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.4	8.66	0.42	1.87e-16	Prostate-specific antigen levels;
LIHC	cis	rs787274	1.000	rs1891403	chr9:115527183	C/T	cg13803584	chr9:115635662	SNX30	-0.56	-6.27	-0.32	1.11e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.09	0.51	1.25e-24	Body mass index;
LIHC	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.58	14.33	0.61	8.13e-37	White blood cell count (basophil);
LIHC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.53	12.28	0.55	5.55e-29	Skin aging (microtopography measurement);
LIHC	cis	rs11955398	0.716	rs1870014	chr5:60000470	T/C	cg02684056	chr5:59996105	DEPDC1B	0.4	5.89	0.3	9.26e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.63	7.87	0.39	4.71e-14	Gut microbiome composition (summer);
LIHC	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.94	-14.23	-0.61	1.97e-36	Corneal structure;
LIHC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.51	-7.31	-0.37	1.88e-12	Breast cancer;
LIHC	cis	rs965469	1.000	rs6051736	chr20:3296898	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.83	-0.35	3.86e-11	IFN-related cytopenia;
LIHC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.67	9.4	0.45	8.26e-19	Schizophrenia;
LIHC	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16684958	chr7:75615977	POR	0.51	8.61	0.42	2.78e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg24955955	chr5:415729	AHRR	0.5	9.51	0.46	3.38e-19	Fat distribution (HIV);
LIHC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.41	-7.37	-0.37	1.27e-12	Aortic root size;
LIHC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg02836325	chr17:76403955	PGS1	0.34	6.67	0.34	1.04e-10	HDL cholesterol levels;
LIHC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.15	30.51	0.86	1.26e-99	Myeloid white cell count;
LIHC	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.67	0.38	1.83e-13	Educational attainment (years of education);
LIHC	cis	rs672413	0.620	rs663646	chr5:78285778	G/A	cg26802063	chr5:78281964	ARSB	-0.39	-6.31	-0.32	8.74e-10	Blood and toenail selenium levels;Blood protein levels;
LIHC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19904058	chr10:135279010	LOC619207	-0.35	-5.77	-0.3	1.77e-8	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.67	13.37	0.59	4.22e-33	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs919433	0.714	rs2333855	chr2:198200213	T/G	cg03934865	chr2:198174659	NA	-0.54	-8.48	-0.42	7.04e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs2504916	0.830	rs2504934	chr6:160781666	A/G	cg18126027	chr6:160773436	SLC22A3	0.38	5.76	0.3	1.87e-8	Response to hepatitis C treatment;
LIHC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1669338	0.510	rs3804788	chr3:3169466	C/A	cg16797762	chr3:3221439	CRBN	-0.98	-8.3	-0.41	2.4e-15	White matter integrity;
LIHC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.41	-6.09	-0.31	3.11e-9	Platelet count;
LIHC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.21e-11	Cognitive function;
LIHC	trans	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg26939375	chr7:64535504	NA	-0.43	-7.33	-0.37	1.64e-12	Aortic root size;
LIHC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.21	-0.36	3.71e-12	Personality dimensions;
LIHC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.71	-9.3	-0.45	1.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.52e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26897989	chr16:1907736	C16orf73	-0.47	-5.89	-0.3	9.03e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.67	12.02	0.55	5.26e-28	Menopause (age at onset);
LIHC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg20697417	chr1:41786797	NA	0.31	5.86	0.3	1.09e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-11.29	-0.52	2.38e-25	Total cholesterol levels;
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.52	8.07	0.4	1.19e-14	Longevity;Endometriosis;
LIHC	cis	rs7715806	0.500	rs3797581	chr5:75002895	G/T	cg00601450	chr5:74908170	NA	0.49	6.24	0.32	1.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.65	10.73	0.5	2.43e-23	Alcohol dependence;
LIHC	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg26149184	chr10:133730230	NA	0.47	7.4	0.37	1.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg25182066	chr10:30743637	MAP3K8	-0.49	-7.98	-0.4	2.19e-14	Inflammatory bowel disease;
LIHC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.94	12.82	0.57	5.48e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.83	-8.77	-0.43	8.65e-17	Pancreatic cancer;
LIHC	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.32	6.8	0.34	4.79e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.42	-13.82	-0.6	8e-35	Psoriasis vulgaris;
LIHC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21448741	chr8:58168803	NA	0.3	5.74	0.3	2.04e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05397629	chr11:3848986	RHOG	0.4	6.21	0.32	1.51e-9	Pancreatic cancer;
LIHC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg25114630	chr15:101792522	CHSY1	0.56	7.12	0.36	6.56e-12	Corneal structure;
LIHC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg00277334	chr10:82204260	NA	-0.55	-6.91	-0.35	2.43e-11	Post bronchodilator FEV1;
LIHC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg03543861	chr21:44258195	NA	0.53	8.63	0.42	2.32e-16	Information processing speed;
LIHC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.48e-11	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.41	7.35	0.37	1.43e-12	Aortic root size;
LIHC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.9	12.01	0.54	5.87e-28	Heart rate;
LIHC	cis	rs7619427	0.507	rs7616472	chr3:44016039	G/A	cg24966902	chr3:44043705	NA	0.46	6.99	0.35	1.46e-11	Schizophrenia;
LIHC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg05697976	chr12:29376483	FAR2	0.29	5.79	0.3	1.58e-8	QT interval;
LIHC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.51	0.42	5.59e-16	Lung cancer in ever smokers;
LIHC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.96	0.44	2.2e-17	Lung cancer in ever smokers;
LIHC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.68	11.53	0.53	3.39e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.94	0.39	2.97e-14	Renal cell carcinoma;
LIHC	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.68	8.53	0.42	4.89e-16	Corneal astigmatism;
LIHC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.51	8.23	0.41	4.08e-15	Schizophrenia;
LIHC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.76	-0.3	1.86e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.85	7.21	0.36	3.56e-12	Uric acid levels;
LIHC	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg08528486	chr13:113648767	MCF2L	-0.39	-6.38	-0.33	5.82e-10	Systolic blood pressure;
LIHC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg06064525	chr11:970664	AP2A2	-0.47	-11.7	-0.53	8.17e-27	Alzheimer's disease (late onset);
LIHC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg05044414	chr3:183734942	ABCC5	0.35	6.07	0.31	3.4e-9	Anterior chamber depth;
LIHC	cis	rs9322817	0.607	rs7772567	chr6:105155782	C/A	cg02098413	chr6:105308735	HACE1	-0.41	-7.76	-0.39	1e-13	Thyroid stimulating hormone;
LIHC	cis	rs7534824	0.625	rs12569251	chr1:101372040	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	6.52	0.33	2.57e-10	Refractive astigmatism;
LIHC	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.33	-5.93	-0.31	7.54e-9	Lewy body disease;
LIHC	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.7	8.93	0.43	2.7e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg10241871	chr14:102965420	TECPR2	-0.48	-7.53	-0.38	4.65e-13	Blood protein levels;
LIHC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.95	-0.39	2.74e-14	Total body bone mineral density;
LIHC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.01	-14.97	-0.63	2.57e-39	Ulcerative colitis;
LIHC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.59	10.79	0.5	1.54e-23	Mean corpuscular volume;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Menopause (age at onset);
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg03874509	chr1:107600012	PRMT6	0.75	12.0	0.54	6.56e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg24209194	chr3:40518798	ZNF619	0.56	8.16	0.4	6.31e-15	Renal cell carcinoma;
LIHC	trans	rs9531686	0.935	rs9547000	chr13:85549213	C/G	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.25	0.32	1.19e-9	Anorexia nervosa;
LIHC	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg11783602	chr8:55087084	NA	-0.3	-6.02	-0.31	4.55e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs17102423	0.896	rs8004805	chr14:65579720	T/C	cg11161011	chr14:65562177	MAX	-0.5	-7.0	-0.35	1.33e-11	Obesity-related traits;
LIHC	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg25930673	chr12:123319894	HIP1R	1.03	11.42	0.53	8.16e-26	Adiponectin levels;
LIHC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg17980119	chr2:219472607	PLCD4	0.33	5.72	0.3	2.3e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg02376097	chr19:46275166	DMPK	-0.48	-7.5	-0.38	5.4e-13	Coronary artery disease;
LIHC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.64	10.54	0.5	1.14e-22	Platelet count;
LIHC	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.56	8.71	0.43	1.28e-16	Corneal astigmatism;
LIHC	cis	rs7523273	0.565	rs2761422	chr1:207893266	A/T	cg22525895	chr1:207977042	MIR29B2	0.44	7.09	0.36	7.68e-12	Schizophrenia;
LIHC	cis	rs2412488	1.000	rs6834934	chr4:54242085	T/C	cg22241045	chr4:54363911	LNX1	-0.46	-7.29	-0.37	2.2e-12	DNA methylation (variation);
LIHC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg10546459	chr2:36825355	FEZ2	0.51	6.31	0.32	8.89e-10	Height;
LIHC	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg18657303	chr4:1051139	NA	0.36	5.73	0.3	2.26e-8	Recombination rate (females);
LIHC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.54	8.63	0.42	2.32e-16	Colorectal cancer;
LIHC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.61	7.91	0.39	3.67e-14	Obesity-related traits;
LIHC	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs2073300	0.826	rs6048809	chr20:23443788	C/T	cg12062639	chr20:23401060	NAPB	0.85	10.21	0.48	1.55e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.45	-6.85	-0.35	3.4e-11	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25979624	chr1:54954752	NA	0.4	6.28	0.32	1e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs882732	1.000	rs10139629	chr14:95035277	C/T	cg14866387	chr14:95027382	SERPINA4	-0.45	-6.48	-0.33	3.14e-10	Blood protein levels;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg02990361	chr1:107599529	PRMT6	0.64	10.65	0.5	4.71e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg10208301	chr11:6592745	DNHD1	0.47	6.27	0.32	1.11e-9	Coronary artery calcification;
LIHC	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-9.98	-0.47	9.38e-21	Platelet count;
LIHC	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.5	-6.35	-0.32	6.85e-10	Schizophrenia;
LIHC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg20933634	chr6:27740509	NA	0.46	6.15	0.32	2.22e-9	Parkinson's disease;
LIHC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.62	-10.52	-0.49	1.28e-22	Alcohol dependence;
LIHC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.86	0.57	3.97e-31	Schizophrenia;
LIHC	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.4	-7.08	-0.36	8.03e-12	Glaucoma;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00570391	chr7:815417	HEATR2	0.43	6.37	0.33	5.99e-10	Longevity;
LIHC	cis	rs3736485	0.934	rs28410165	chr15:51875019	C/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-8.76	-0.43	9.14e-17	Platelet distribution width;
LIHC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.46	-7.97	-0.4	2.32e-14	Height;
LIHC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.24	0.41	3.66e-15	Platelet count;
LIHC	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.52	7.22	0.36	3.47e-12	Menopause (age at onset);
LIHC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.55	7.03	0.36	1.16e-11	Initial pursuit acceleration;
LIHC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.18	0.32	1.82e-9	Morning vs. evening chronotype;
LIHC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg14473756	chr11:122847823	NA	-0.37	-6.67	-0.34	1.02e-10	Menarche (age at onset);
LIHC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg22676075	chr6:135203613	NA	0.38	6.25	0.32	1.25e-9	Red blood cell count;
LIHC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.39	6.3	0.32	8.96e-10	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.84	-6.24	-0.32	1.29e-9	Mosquito bite size;
LIHC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.45	7.4	0.37	1.04e-12	Breast cancer;
LIHC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-11.33	-0.52	1.69e-25	Hemoglobin concentration;
LIHC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.43	5.92	0.3	7.79e-9	Alzheimer's disease;
LIHC	cis	rs7712401	0.755	rs3213794	chr5:122161638	A/C	cg18764291	chr5:122110994	SNX2	0.35	5.98	0.31	5.77e-9	Mean platelet volume;
LIHC	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.82	8.66	0.42	1.86e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.97	-0.44	2.04e-17	Bipolar disorder;
LIHC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.49	-7.57	-0.38	3.4e-13	P wave terminal force;
LIHC	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	1.32	20.54	0.74	1.16e-61	IgG glycosylation;
LIHC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.99	-0.31	5.42e-9	Aortic root size;
LIHC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg17306686	chr7:157230923	NA	0.43	9.51	0.46	3.6e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg18016565	chr1:150552671	MCL1	0.54	10.13	0.48	2.88e-21	Melanoma;
LIHC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.52	7.47	0.37	6.66e-13	Initial pursuit acceleration;
LIHC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-6.53	-0.33	2.35e-10	High light scatter reticulocyte count;
LIHC	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	1.0	19.76	0.73	1.6e-58	Platelet distribution width;
LIHC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.46	-7.47	-0.37	6.73e-13	Menarche (age at onset);
LIHC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg07090678	chr1:91966139	CDC7	0.5	6.76	0.34	5.81e-11	Breast cancer;
LIHC	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.72	13.7	0.6	2.35e-34	Mortality in heart failure;
LIHC	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.62	8.95	0.44	2.29e-17	Monocyte count;
LIHC	trans	rs10213084	1.000	rs10213045	chr4:147500975	T/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.45	10.18	0.48	1.97e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	9.37	0.45	1.04e-18	Platelet count;
LIHC	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-8.16	-0.4	6.51e-15	Body mass index;
LIHC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.2	-0.45	3.69e-18	Bipolar disorder;
LIHC	cis	rs1664789	0.715	rs697111	chr5:53261330	G/A	ch.5.1024479R	chr5:53302184	ARL15	0.44	6.59	0.34	1.71e-10	Waist circumference adjusted for body mass index;
LIHC	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.58	-8.38	-0.41	1.37e-15	Facial morphology (factor 19);
LIHC	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg02886208	chr11:14281011	SPON1	-0.57	-8.46	-0.42	8.07e-16	Mitochondrial DNA levels;
LIHC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg06064525	chr11:970664	AP2A2	-0.44	-10.73	-0.5	2.49e-23	Alzheimer's disease (late onset);
LIHC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-12.14	-0.55	1.97e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.82	-12.26	-0.55	6.88e-29	Obesity-related traits;
LIHC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.7	-0.34	8.8e-11	Alcohol dependence;
LIHC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.29	-0.37	2.21e-12	Response to antipsychotic treatment;
LIHC	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs3849570	0.695	rs62265411	chr3:81573660	T/C	cg07356753	chr3:81810745	GBE1	-0.53	-8.03	-0.4	1.6e-14	Waist circumference;Body mass index;
LIHC	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.88	-0.3	9.5e-9	Response to antipsychotic treatment;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.23	0.55	9.15e-29	Prudent dietary pattern;
LIHC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	26.03	0.82	4.07e-83	Cognitive ability;
LIHC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27297192	chr10:134578999	INPP5A	-0.51	-7.88	-0.39	4.29e-14	Migraine;
LIHC	cis	rs7818688	0.697	rs2904889	chr8:95940598	T/G	cg16049864	chr8:95962084	TP53INP1	0.54	6.1	0.31	2.95e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.58	-6.66	-0.34	1.07e-10	Lung cancer in ever smokers;
LIHC	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.5	-7.54	-0.38	4.16e-13	Triglyceride levels;
LIHC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	1.07	12.12	0.55	2.31e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.52	-6.02	-0.31	4.48e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.75	0.34	6.52e-11	Obesity-related traits;
LIHC	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg25251204	chr11:14927456	NA	0.41	5.86	0.3	1.06e-8	Vitamin D levels;
LIHC	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg19508488	chr2:152266495	RIF1	-0.46	-6.48	-0.33	3.25e-10	Lung cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03052632	chr12:57634626	NDUFA4L2	0.44	7.51	0.38	5.19e-13	Pancreatic cancer;
LIHC	trans	rs4714291	0.802	rs3008833	chr6:39986303	G/A	cg02267698	chr19:7991119	CTXN1	-0.38	-6.46	-0.33	3.66e-10	Strep throat;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.48	-5.98	-0.31	5.47e-9	Diastolic blood pressure;
LIHC	cis	rs13343954	0.825	rs2216595	chr19:33533292	C/T	cg27124370	chr19:33622961	WDR88	0.42	5.73	0.3	2.18e-8	Colorectal cancer;
LIHC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.39	5.71	0.3	2.41e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.42	-5.98	-0.31	5.72e-9	Height;
LIHC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs9341808	0.559	rs7762895	chr6:81061431	C/T	cg08355045	chr6:80787529	NA	0.34	6.86	0.35	3.22e-11	Sitting height ratio;
LIHC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.31	0.32	8.75e-10	Tonsillectomy;
LIHC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.61	9.76	0.47	5.11e-20	Red cell distribution width;
LIHC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.4	6.54	0.33	2.18e-10	Erythrocyte sedimentation rate;
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21448741	chr8:58168803	NA	0.33	5.86	0.3	1.11e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9783347	1.000	rs4150641	chr11:18370739	C/A	cg15585147	chr11:18324498	HPS5	0.42	6.7	0.34	8.6e-11	Pancreatic cancer;
LIHC	cis	rs4605213	0.686	rs9896627	chr17:49328705	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.44	-5.81	-0.3	1.41e-8	Height;
LIHC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg17385448	chr1:15911702	AGMAT	0.35	6.11	0.31	2.64e-9	Systolic blood pressure;
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg14671364	chr1:107599128	PRMT6	0.53	7.93	0.39	3.05e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg20818283	chr2:191399100	TMEM194B	0.46	6.19	0.32	1.75e-9	Pulse pressure;
LIHC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.75	-0.34	6.16e-11	Hepatocellular carcinoma;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.88	0.57	3.12e-31	Prudent dietary pattern;
LIHC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.48	-5.9	-0.3	8.64e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.58	8.88	0.43	3.97e-17	Longevity;
LIHC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.51	-6.96	-0.35	1.76e-11	Aortic root size;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	9.32e-15	Prudent dietary pattern;
LIHC	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-5.74	-0.3	2.09e-8	Response to antipsychotic treatment;
LIHC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.4	0.33	5.18e-10	Rheumatoid arthritis;
LIHC	cis	rs4759375	1.000	rs10773006	chr12:123790051	T/C	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg21466736	chr12:48725269	NA	-0.71	-10.96	-0.51	3.57e-24	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	trans	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg26939375	chr7:64535504	NA	0.4	6.41	0.33	4.92e-10	Aortic root size;
LIHC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg04155231	chr12:9217510	LOC144571	0.31	6.02	0.31	4.58e-9	Sjögren's syndrome;
LIHC	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-19.31	-0.72	1.02e-56	Schizophrenia;
LIHC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.88	13.23	0.58	1.56e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6429082	0.509	rs2803845	chr1:235520228	C/G	cg26050004	chr1:235667680	B3GALNT2	0.43	6.38	0.33	5.76e-10	Adiposity;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20237291	chr3:113233670	CCDC52	0.4	6.59	0.34	1.66e-10	Calcium levels;
LIHC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.67	-10.39	-0.49	3.72e-22	Height;
LIHC	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg10241871	chr14:102965420	TECPR2	-0.49	-7.74	-0.39	1.11e-13	Blood protein levels;
LIHC	cis	rs2737618	0.722	rs2737676	chr1:200086839	T/C	cg21825944	chr1:200113062	NR5A2	-0.41	-6.59	-0.34	1.62e-10	Uric acid levels;
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg10755058	chr3:40428713	ENTPD3	0.42	7.14	0.36	5.82e-12	Renal cell carcinoma;
LIHC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.77	-0.3	1.76e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3790844	0.876	rs3790847	chr1:200006217	G/T	cg13229857	chr1:200006247	NR5A2	0.43	7.03	0.36	1.16e-11	Pancreatic cancer;
LIHC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.55	9.37	0.45	9.95e-19	Dupuytren's disease;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg06329022	chr17:26926511	SPAG5	0.38	6.13	0.31	2.35e-9	Morning vs. evening chronotype;
LIHC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg02297831	chr4:17616191	MED28	-0.45	-7.18	-0.36	4.51e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07080220	chr10:102295463	HIF1AN	0.57	7.23	0.36	3.09e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.1	-0.4	9.71e-15	Chronic sinus infection;
LIHC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	1.0	16.23	0.66	2.48e-44	Tonsillectomy;
LIHC	cis	rs16828019	0.929	rs10524	chr1:41726473	T/C	cg03962019	chr1:41807865	NA	0.49	7.12	0.36	6.54e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20720553	chr15:101792477	CHSY1	0.48	6.35	0.32	6.76e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2224391	0.822	rs36055504	chr6:5262230	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-5.96	-0.31	6.36e-9	Height;
LIHC	cis	rs9322817	0.691	rs9391244	chr6:105257690	G/A	cg02098413	chr6:105308735	HACE1	-0.43	-8.06	-0.4	1.28e-14	Thyroid stimulating hormone;
LIHC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.13	0.52	9.42e-25	Personality dimensions;
LIHC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.63	10.31	0.49	7.24e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.32	0.58	6.47e-33	Cognitive test performance;
LIHC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.3	-7.9	-0.39	3.91e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.5	8.93	0.43	2.73e-17	Height;
LIHC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg01320579	chr17:75405842	SEPT9	0.52	7.44	0.37	8.37e-13	Airflow obstruction;
LIHC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.49	-6.87	-0.35	3.03e-11	Body mass index;
LIHC	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.05	-0.31	3.85e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.53	-6.02	-0.31	4.53e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg02290350	chr8:58132656	NA	0.4	8.38	0.41	1.4e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09299307	chr5:86709023	CCNH	0.45	6.28	0.32	1.01e-9	Pancreatic cancer;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.57	-8.19	-0.4	5.42e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.35	-7.16	-0.36	5.02e-12	Colorectal cancer;
LIHC	trans	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.37	-6.04	-0.31	4.08e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7523273	0.586	rs2761425	chr1:207894033	C/T	cg22525895	chr1:207977042	MIR29B2	-0.52	-8.0	-0.4	1.97e-14	Schizophrenia;
LIHC	cis	rs2569991	0.636	rs9211	chr3:12939546	A/G	cg22481960	chr3:13008800	IQSEC1	0.44	7.84	0.39	5.63e-14	Periodontitis (DPAL);
LIHC	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.54	5.93	0.31	7.59e-9	IgG glycosylation;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg03721293	chr16:90014378	DEF8	0.39	6.62	0.34	1.38e-10	Skin colour saturation;
LIHC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.36e-11	Red blood cell count;
LIHC	cis	rs17106184	1.000	rs72904713	chr1:51312992	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.5	6.4	0.33	5.12e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02985541	chr2:219472218	PLCD4	0.43	6.95	0.35	1.84e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.46	-6.06	-0.31	3.57e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6429082	0.509	rs7516807	chr1:235523555	G/T	cg26050004	chr1:235667680	B3GALNT2	0.42	6.38	0.33	5.72e-10	Adiposity;
LIHC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.98	0.4	2.19e-14	Motion sickness;
LIHC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.95	16.84	0.67	9.18e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.02	-0.31	4.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.62	0.34	1.4e-10	Lung cancer in ever smokers;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03885098	chr1:207991780	LOC148696	0.5	6.15	0.32	2.21e-9	Hip circumference;
LIHC	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-16.49	-0.67	2.23e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg14675211	chr2:100938903	LONRF2	-0.51	-7.54	-0.38	4.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.51	7.56	0.38	3.65e-13	Total body bone mineral density;
LIHC	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.6	-12.35	-0.56	3.1e-29	Plateletcrit;Platelet count;
LIHC	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg08916839	chr5:415575	AHRR	0.47	9.87	0.47	2.21e-20	Fat distribution (HIV);
LIHC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.49	-7.87	-0.39	4.68e-14	Diastolic blood pressure;
LIHC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg25344623	chr2:136566232	LCT	-0.36	-5.74	-0.3	2.03e-8	Corneal structure;
LIHC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.38	-0.66	6.33e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-8.81	-0.43	6.51e-17	Total body bone mineral density;
LIHC	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.42	-7.23	-0.36	3.2e-12	Breast cancer;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13495025	chr9:130230056	LRSAM1	0.49	6.07	0.31	3.34e-9	Lung function (FEV1);
LIHC	cis	rs12220238	0.915	rs11000948	chr10:76031721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.61	-6.03	-0.31	4.3e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.29	-5.74	-0.3	2.11e-8	Prostate cancer;
LIHC	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.49	-0.33	2.99e-10	Ulcerative colitis;
LIHC	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	8.76	0.43	9.08e-17	Height;
LIHC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.51	6.26	0.32	1.17e-9	Alzheimer's disease;
LIHC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg01518246	chr11:63870912	FLRT1;MACROD1	0.51	7.49	0.38	5.97e-13	Mean platelet volume;
LIHC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.74	0.47	6.17e-20	Tonsillectomy;
LIHC	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg04610667	chr7:75704037	NA	-0.35	-6.21	-0.32	1.54e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.47	0.37	6.71e-13	IgG glycosylation;
LIHC	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg13318129	chr22:45737514	FAM118A	0.49	6.51	0.33	2.75e-10	Tonsillectomy;
LIHC	trans	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg10756647	chr7:56101905	PSPH	-1.05	-12.59	-0.56	3.99e-30	Diabetic kidney disease;
LIHC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg16479474	chr6:28041457	NA	0.38	6.32	0.32	8.32e-10	Parkinson's disease;
LIHC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.87	0.35	2.95e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.69	7.91	0.39	3.57e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg03013999	chr17:37608204	MED1	0.34	5.77	0.3	1.78e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs6489882	0.703	rs10850095	chr12:113360575	T/C	cg10175203	chr3:128143634	NA	0.39	6.22	0.32	1.47e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21284376	chr1:72748601	NEGR1	-0.37	-6.08	-0.31	3.22e-9	Pancreatic cancer;
LIHC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg18016565	chr1:150552671	MCL1	0.56	10.24	0.48	1.19e-21	Melanoma;
LIHC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.39	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LIHC	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.3	-5.89	-0.3	9.21e-9	Colorectal cancer;
LIHC	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg06627628	chr2:24431161	ITSN2	0.66	7.77	0.39	9.34e-14	Lymphocyte counts;
LIHC	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.56	9.79	0.47	4.16e-20	Systemic lupus erythematosus;
LIHC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg24634471	chr8:143751801	JRK	-0.44	-6.05	-0.31	3.74e-9	Urinary tract infection frequency;
LIHC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.59	8.9	0.43	3.3e-17	Tumor biomarkers;
LIHC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.37	5.81	0.3	1.47e-8	Lewy body disease;
LIHC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-6.07	-0.31	3.3e-9	Initial pursuit acceleration;
LIHC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.66	10.54	0.5	1.11e-22	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.48	7.7	0.38	1.44e-13	Blood pressure (smoking interaction);
LIHC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.34	-0.58	5.73e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01505148	chr19:56170617	U2AF2	0.45	6.76	0.34	6.15e-11	Longevity;
LIHC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs4908768	0.520	rs11121216	chr1:8738944	A/G	cg20416874	chr1:8611966	RERE	-0.6	-11.79	-0.54	3.85e-27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.65	-0.38	2.05e-13	Chronic sinus infection;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01696603	chr6:125623444	HDDC2	0.4	6.07	0.31	3.48e-9	Bilirubin levels;
LIHC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20135002	chr11:47629003	NA	-0.54	-9.17	-0.44	4.61e-18	Subjective well-being;
LIHC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg00656387	chr3:40428638	ENTPD3	0.43	6.9	0.35	2.59e-11	Renal cell carcinoma;
LIHC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.28	-18.54	-0.71	1.29e-53	Gout;
LIHC	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.37	-6.12	-0.31	2.56e-9	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.42	-6.45	-0.33	3.76e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.54	-9.85	-0.47	2.49e-20	Total body bone mineral density;
LIHC	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg26138937	chr11:71823887	C11orf51	-1.31	-10.34	-0.49	5.49e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg14092571	chr14:90743983	NA	-0.38	-6.1	-0.31	2.89e-9	Mortality in heart failure;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.0	-0.31	5.01e-9	Diastolic blood pressure;
LIHC	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.43	6.27	0.32	1.06e-9	Menopause (age at onset);
LIHC	cis	rs2412488	0.927	rs10001201	chr4:54269096	G/A	cg22241045	chr4:54363911	LNX1	-0.41	-6.71	-0.34	8.15e-11	DNA methylation (variation);
LIHC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs3770081	1.000	rs3770090	chr2:86263288	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-9.3	-0.45	1.76e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs7633770	0.664	rs34000414	chr3:46689958	G/A	cg11219411	chr3:46661640	NA	-0.35	-5.79	-0.3	1.56e-8	Coronary artery disease;
LIHC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg14067834	chr17:29058358	SUZ12P	0.67	6.54	0.33	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs10861342	1.000	rs7968711	chr12:105447921	G/A	cg23923672	chr12:105501055	KIAA1033	0.68	7.87	0.39	4.7e-14	IgG glycosylation;
LIHC	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg03934865	chr2:198174659	NA	0.45	6.49	0.33	2.93e-10	Dermatomyositis;
LIHC	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.52	6.14	0.32	2.25e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-6.99	-0.35	1.41e-11	Diabetic kidney disease;
LIHC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg14780466	chr2:20870812	GDF7	-0.42	-8.58	-0.42	3.43e-16	Abdominal aortic aneurysm;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25116269	chr2:55509523	PRDXDD1P	-0.48	-6.92	-0.35	2.2e-11	Cognitive function;
LIHC	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.65	-7.0	-0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg02290350	chr8:58132656	NA	0.32	6.93	0.35	2.1e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.39	0.41	1.28e-15	Lung cancer;
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21448741	chr8:58168803	NA	0.35	5.76	0.3	1.88e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg18944383	chr4:111397179	ENPEP	0.26	6.67	0.34	1.05e-10	Height;
LIHC	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg19752551	chr11:57585705	CTNND1	-0.53	-7.41	-0.37	9.81e-13	Schizophrenia;
LIHC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.88	11.96	0.54	8.49e-28	Post bronchodilator FEV1;
LIHC	trans	rs6600671	0.966	rs6600664	chr1:121222436	G/A	cg09829573	chr1:144692074	NBPF9	-0.39	-6.94	-0.35	1.92e-11	Hip geometry;
LIHC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.69	10.02	0.48	6.78e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.94	15.79	0.65	1.38e-42	Cognitive ability;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.68	-9.26	-0.45	2.34e-18	Aortic root size;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg02993280	chr1:107599747	PRMT6	-0.69	-11.17	-0.52	6.48e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.83	0.35	3.93e-11	Height;
LIHC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.5	-7.52	-0.38	4.97e-13	Multiple sclerosis;
LIHC	cis	rs7961581	0.957	rs1353361	chr12:71608199	C/A	cg05756094	chr12:71608604	NA	0.37	5.86	0.3	1.08e-8	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.56	10.32	0.49	6.24e-22	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23307218	chr19:11616766	ECSIT;ZNF653	-0.47	-6.73	-0.34	7.36e-11	Pancreatic cancer;
LIHC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg03934865	chr2:198174659	NA	0.53	8.31	0.41	2.21e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg22676075	chr6:135203613	NA	0.41	6.62	0.34	1.36e-10	Red blood cell count;
LIHC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.39	0.37	1.15e-12	Obesity-related traits;
LIHC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.31	-0.32	8.85e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	6.28	0.32	1.02e-9	Blood protein levels;
LIHC	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14396892	chr9:96623032	NA	-0.31	-6.14	-0.32	2.23e-9	DNA methylation (variation);
LIHC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.57	9.12	0.44	6.69e-18	Birth weight;
LIHC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.87	10.81	0.5	1.21e-23	Bladder cancer;
LIHC	cis	rs807029	0.577	rs750866	chr10:102761458	A/G	cg25179470	chr10:102756915	LZTS2	0.42	5.73	0.3	2.22e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00742472	chr14:31889912	NA	-0.38	-6.67	-0.34	1.03e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.45	-0.42	8.54e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21668880	chr6:34759629	UHRF1BP1	0.46	6.36	0.33	6.5e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.6	8.07	0.4	1.17e-14	Blood metabolite levels;
LIHC	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.28	6.43	0.33	4.26e-10	Weight;
LIHC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.51	6.48	0.33	3.25e-10	Menarche (age at onset);
LIHC	cis	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg17371580	chr8:9182401	NA	-0.36	-5.8	-0.3	1.52e-8	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	6.29	0.32	9.8e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.43	-7.24	-0.36	2.89e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.43	-0.33	4.33e-10	Total body bone mineral density;
LIHC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.1	0.4	1.01e-14	Alzheimer's disease;
LIHC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-14.43	-0.62	3.3e-37	Systemic lupus erythematosus;
LIHC	cis	rs249954	0.512	rs171617	chr16:23694774	A/T	cg05131483	chr16:23706242	ERN2	0.37	6.04	0.31	3.95e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg23205692	chr1:25664452	TMEM50A	0.37	5.88	0.3	9.89e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.34	6.66	0.34	1.07e-10	Renal cell carcinoma;
LIHC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.34	-0.58	5.73e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.98	-0.31	5.61e-9	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.78	0.34	5.29e-11	Renal cell carcinoma;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12379764	chr21:47803548	PCNT	-0.59	-8.55	-0.42	4.24e-16	Testicular germ cell tumor;
LIHC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.67	11.37	0.52	1.29e-25	Lymphocyte counts;
LIHC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.29	0.55	5.1e-29	Cognitive test performance;
LIHC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg11634705	chr7:873449	UNC84A	0.39	5.92	0.31	7.63e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg11062466	chr8:58055876	NA	0.48	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.42	-5.82	-0.3	1.32e-8	Longevity;Endometriosis;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.69	0.57	1.65e-30	Prudent dietary pattern;
LIHC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.51	-8.35	-0.41	1.75e-15	Cognitive function;
LIHC	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.19	-0.36	4.13e-12	Response to antipsychotic treatment;
LIHC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-10.7	-0.5	3.08e-23	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.75	0.54	5.45e-27	Motion sickness;
LIHC	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.89	-0.3	9.45e-9	Blood protein levels;
LIHC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.75	7.95	0.39	2.76e-14	Vitiligo;
LIHC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg11764359	chr7:65958608	NA	-0.58	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.86	0.57	3.86e-31	Alzheimer's disease;
LIHC	trans	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg19894588	chr14:64061835	NA	-0.44	-6.88	-0.35	2.92e-11	Fat distribution (HIV);
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.75	0.62	1.8e-38	Prudent dietary pattern;
LIHC	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.48	-8.03	-0.4	1.61e-14	Blood metabolite levels;
LIHC	cis	rs6466055	0.777	rs10281886	chr7:104835888	T/C	cg04380332	chr7:105027541	SRPK2	-0.35	-6.6	-0.34	1.52e-10	Schizophrenia;
LIHC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00149659	chr3:10157352	C3orf10	0.54	5.93	0.31	7.37e-9	Alzheimer's disease;
LIHC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.25e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-6.53	-0.33	2.41e-10	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.23	0.81	4.46e-80	Prudent dietary pattern;
LIHC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.3	-5.76	-0.3	1.86e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg16586182	chr3:47516702	SCAP	-0.5	-9.13	-0.44	6.03e-18	Colorectal cancer;
LIHC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg24826892	chr11:71159390	DHCR7	0.47	6.12	0.31	2.52e-9	Vitamin D levels;
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-5.95	-0.31	6.63e-9	Longevity;Endometriosis;
LIHC	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.3	-6.33	-0.32	7.73e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	6.44	0.33	3.98e-10	Renal cell carcinoma;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-7.03	-0.36	1.14e-11	Vitiligo;
LIHC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.67	8.8	0.43	7.12e-17	Aortic root size;
LIHC	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg00908766	chr1:109817496	CELSR2	-0.48	-8.34	-0.41	1.83e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg27490568	chr2:178487706	NA	0.71	7.48	0.38	6.24e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.37	6.21	0.32	1.56e-9	Blood metabolite levels;
LIHC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.7	-7.8	-0.39	7.58e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.41	-0.37	1.01e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.615	rs11495518	chr12:38060505	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.5	0.42	5.94e-16	Bladder cancer;
LIHC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1401454	1.000	rs1519125	chr11:16244588	G/C	cg10927848	chr11:16298618	SOX6	-0.33	-6.12	-0.31	2.53e-9	Blood pressure;
LIHC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg11783602	chr8:55087084	NA	-0.31	-6.16	-0.32	2.02e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.46	6.89	0.35	2.69e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.77	11.95	0.54	9.51e-28	Corneal astigmatism;
LIHC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.84	-0.43	5.01e-17	Gut microbiome composition (summer);
LIHC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.55	-8.43	-0.41	9.94e-16	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs244293	0.965	rs244301	chr17:53239140	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.19	-0.36	4.2e-12	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13034943	chr12:132379564	ULK1	-0.42	-6.37	-0.33	6.01e-10	Pancreatic cancer;
LIHC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.25	-0.45	2.55e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.33	0.49	6.2e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg16479474	chr6:28041457	NA	0.45	6.34	0.32	7.43e-10	Depression;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12566780	chr7:92157604	PEX1;C7orf64	0.41	6.11	0.31	2.65e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.76	-13.77	-0.6	1.22e-34	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.16	0.32	2.03e-9	Schizophrenia;
LIHC	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg08126542	chr6:37504118	NA	-0.36	-6.16	-0.32	2.03e-9	Cognitive performance;
LIHC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.56	6.42	0.33	4.53e-10	Primary sclerosing cholangitis;
LIHC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-9.3	-0.45	1.72e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.45	-6.52	-0.33	2.55e-10	Other erythrocyte phenotypes;
LIHC	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.73	11.4	0.52	9.96e-26	Metabolite levels;
LIHC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.7	-11.45	-0.53	6.49e-26	Hip circumference adjusted for BMI;
LIHC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.91	0.35	2.34e-11	Gut microbiome composition (summer);
LIHC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.23	-0.41	3.99e-15	Schizophrenia;
LIHC	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.45	-0.42	8.55e-16	Schizophrenia;
LIHC	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg12863693	chr15:85201151	NMB	0.42	5.71	0.3	2.44e-8	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.59	7.56	0.38	3.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg03013999	chr17:37608204	MED1	0.35	5.78	0.3	1.71e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.69	10.62	0.5	5.94e-23	Corneal astigmatism;
LIHC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg12560992	chr17:57184187	TRIM37	-0.7	-10.49	-0.49	1.65e-22	Cognitive test performance;
LIHC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12379764	chr21:47803548	PCNT	-0.57	-8.35	-0.41	1.67e-15	Testicular germ cell tumor;
LIHC	cis	rs7395581	0.959	rs59663860	chr11:47276350	G/C	cg26139080	chr11:47293733	MADD	-0.5	-8.53	-0.42	4.94e-16	HDL cholesterol;
LIHC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.3	-5.76	-0.3	1.85e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.42e-11	Dermatomyositis;
LIHC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg01200585	chr1:228362443	C1orf69	-0.4	-5.92	-0.31	7.63e-9	Diastolic blood pressure;
LIHC	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.44	-0.33	3.98e-10	Metabolite levels;
LIHC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg14393609	chr7:65229607	NA	-0.42	-6.12	-0.31	2.55e-9	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05281506	chr4:72052869	SLC4A4	0.48	6.95	0.35	1.88e-11	Pancreatic cancer;
LIHC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	6.13	0.31	2.36e-9	Multiple sclerosis;
LIHC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.84	-0.3	1.22e-8	Inflammatory bowel disease;
LIHC	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg12698662	chr3:15914712	MIR563	-0.37	-6.72	-0.34	7.42e-11	Mean platelet volume;
LIHC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.98	0.51	3.17e-24	Personality dimensions;
LIHC	trans	rs2797369	0.570	rs1928070	chr6:101583773	G/T	cg04800749	chr22:50320996	CRELD2	0.35	6.05	0.31	3.76e-9	Renal function-related traits (eGRFcrea);
LIHC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.45	7.12	0.36	6.46e-12	HDL cholesterol levels;
LIHC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.4	6.36	0.33	6.58e-10	Red blood cell count;
LIHC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.64	7.43	0.37	8.57e-13	Lymphocyte counts;
LIHC	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg03999872	chr20:62272968	STMN3	-0.46	-6.78	-0.34	5.22e-11	Atopic dermatitis;
LIHC	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg25783544	chr11:47291846	MADD	0.42	6.17	0.32	1.95e-9	HDL cholesterol;
LIHC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.33	6.9	0.35	2.57e-11	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.88	0.39	4.43e-14	Motion sickness;
LIHC	cis	rs6504950	0.695	rs9904377	chr17:52985982	C/T	cg10237252	chr17:52977213	TOM1L1	-0.42	-7.53	-0.38	4.44e-13	Breast cancer;
LIHC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.42	6.28	0.32	1.01e-9	Neuroticism;
LIHC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.63	9.35	0.45	1.17e-18	Lung cancer;
LIHC	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.53	6.38	0.33	5.61e-10	Metabolite levels;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06420487	chr17:61919686	SMARCD2	0.42	5.81	0.3	1.41e-8	Height;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07308232	chr7:1071921	C7orf50	-0.4	-6.5	-0.33	2.79e-10	Longevity;Endometriosis;
LIHC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.66	-10.85	-0.51	9.17e-24	Monocyte percentage of white cells;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25622317	chr11:1002295	AP2A2	0.43	6.21	0.32	1.5e-9	Longevity;
LIHC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.95	-0.31	6.72e-9	Morning vs. evening chronotype;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg06476606	chr10:91061728	IFIT2	0.48	6.98	0.35	1.56e-11	Morning vs. evening chronotype;
LIHC	cis	rs8020095	0.528	rs73282769	chr14:67780267	A/G	cg03487553	chr14:67822707	ATP6V1D	-0.34	-5.84	-0.3	1.24e-8	Depression (quantitative trait);
LIHC	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg25566285	chr7:158114605	PTPRN2	0.22	6.07	0.31	3.35e-9	Calcium levels;
LIHC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.98	11.7	0.53	7.98e-27	Vitiligo;
LIHC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.65	0.5	4.53e-23	Bladder cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26541027	chr1:110163313	AMPD2	0.51	6.99	0.35	1.49e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg16479474	chr6:28041457	NA	0.39	6.46	0.33	3.58e-10	Parkinson's disease;
LIHC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.47	0.49	1.98e-22	Vitiligo;
LIHC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-1.03	-10.58	-0.5	8.03e-23	Breast cancer;
LIHC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-7.57	-0.38	3.6e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4759375	0.915	rs7954704	chr12:123811371	G/A	cg00376283	chr12:123451042	ABCB9	0.5	6.37	0.33	6.18e-10	HDL cholesterol;
LIHC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	6.62	0.34	1.36e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.1	-0.31	2.84e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.76	-10.84	-0.51	9.66e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.49	7.61	0.38	2.67e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.45	-6.27	-0.32	1.11e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-15.02	-0.63	1.63e-39	Alzheimer's disease (late onset);
LIHC	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.33	-6.17	-0.32	1.98e-9	Response to antipsychotic treatment;
LIHC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-7.24	-0.36	3e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.38	-6.07	-0.31	3.39e-9	Multiple myeloma;
LIHC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.53	-6.49	-0.33	3.03e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-6.11	-0.31	2.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg24296786	chr1:45957014	TESK2	-0.49	-7.31	-0.37	1.96e-12	Platelet count;
LIHC	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.88	-0.39	4.35e-14	Coronary artery disease;
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg10096929	chr1:156261403	TMEM79	0.4	6.73	0.34	7.35e-11	Tonsillectomy;
LIHC	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-7.26	-0.37	2.56e-12	Mortality in heart failure;
LIHC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.88	9.84	0.47	2.72e-20	Primary sclerosing cholangitis;
LIHC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-8.19	-0.41	5.1e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20583945	chr8:144636462	GSDMD	0.6	8.7	0.43	1.42e-16	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-0.78	-8.72	-0.43	1.25e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs16828019	0.852	rs35992757	chr1:41652862	C/T	cg20697417	chr1:41786797	NA	0.35	6.65	0.34	1.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs903552	0.935	rs12907726	chr15:102003626	C/G	cg06707286	chr15:102010195	PCSK6	-0.44	-6.33	-0.32	7.48e-10	Diabetic kidney disease;
LIHC	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.04	16.14	0.66	5.73e-44	Corneal structure;
LIHC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-15.25	-0.64	2.01e-40	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg13409248	chr3:40428643	ENTPD3	0.41	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg00292662	chr22:38071168	LGALS1	0.63	9.9	0.47	1.69e-20	Fat distribution (HIV);
LIHC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.52	-0.56	7.42e-30	Alzheimer's disease;
LIHC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	2.04e-10	Personality dimensions;
LIHC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.52	-7.1	-0.36	7.24e-12	Aortic root size;
LIHC	cis	rs7729447	0.776	rs17540155	chr5:32694033	C/T	cg16267343	chr5:32710456	NPR3	0.48	5.86	0.3	1.09e-8	Blood pressure;
LIHC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg10018233	chr7:150070692	REPIN1	0.5	8.19	0.4	5.27e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg18279126	chr7:2041391	MAD1L1	0.36	5.99	0.31	5.22e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.65	9.04	0.44	1.22e-17	Body mass index;
LIHC	cis	rs7577696	0.554	rs3769605	chr2:32322456	A/G	cg02381751	chr2:32503542	YIPF4	-0.47	-6.53	-0.33	2.35e-10	Inflammatory biomarkers;
LIHC	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.77	6.81	0.35	4.28e-11	Uric acid levels;
LIHC	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.59	5.97	0.31	6.06e-9	Hip geometry;
LIHC	cis	rs244293	0.965	rs244312	chr17:53213197	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.37	-0.37	1.27e-12	Menarche (age at onset);
LIHC	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg17074339	chr11:11642133	GALNTL4	0.4	6.06	0.31	3.65e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.48	-0.42	6.93e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg08462924	chr1:41848221	NA	-0.39	-6.45	-0.33	3.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.4	7.18	0.36	4.4e-12	Psoriasis;
LIHC	cis	rs1144333	0.510	rs1146652	chr1:76273708	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.01	-0.31	4.66e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.45	-7.05	-0.36	1.01e-11	Cognitive function;
LIHC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg25281562	chr12:121454272	C12orf43	0.33	5.74	0.3	2.08e-8	N-glycan levels;
LIHC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.86	10.58	0.5	8.25e-23	Schizophrenia;
LIHC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.51	-0.38	5.29e-13	Breast cancer;
LIHC	cis	rs6466055	0.748	rs1204080	chr7:104988848	A/G	cg04380332	chr7:105027541	SRPK2	0.37	6.91	0.35	2.32e-11	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.59	10.65	0.5	4.73e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.48	7.93	0.39	3.11e-14	Age at first birth;
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-6.63	-0.34	1.28e-10	Longevity;Endometriosis;
LIHC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.43	-9.16	-0.44	4.97e-18	Rheumatoid arthritis;
LIHC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21467203	chr3:49911342	NA	0.44	7.87	0.39	4.61e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.44	5.99	0.31	5.44e-9	Initial pursuit acceleration;
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.23	6.12	0.31	2.58e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.66	11.16	0.52	7.31e-25	Obesity-related traits;
LIHC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-10.1	-0.48	3.74e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.35	-0.32	6.75e-10	Schizophrenia;
LIHC	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg20016023	chr10:99160130	RRP12	-0.41	-6.34	-0.32	7.3e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.9	0.3	8.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs332507	0.789	rs13064861	chr3:124352236	A/G	cg05980111	chr3:124395277	KALRN	0.38	6.15	0.32	2.13e-9	Plateletcrit;
LIHC	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.78	-0.34	5.42e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.51	8.96	0.44	2.13e-17	Mean corpuscular volume;
LIHC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg25356066	chr3:128598488	ACAD9	0.52	7.15	0.36	5.21e-12	IgG glycosylation;
LIHC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.84	14.85	0.63	7.54e-39	Aortic root size;
LIHC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.95	17.37	0.68	6.45e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg14004847	chr7:1930337	MAD1L1	0.45	6.71	0.34	8.03e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.86	-0.35	3.17e-11	Personality dimensions;
LIHC	trans	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg18335740	chr13:41363409	SLC25A15	0.37	6.3	0.32	9.27e-10	Lewy body disease;
LIHC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.5	0.53	4.16e-26	Height;
LIHC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg15848620	chr12:58087721	OS9	0.49	6.16	0.32	2e-9	Multiple sclerosis;
LIHC	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.21	-0.32	1.5e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	7.14	0.36	5.5e-12	Bone mineral density;
LIHC	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg06359132	chr10:99160096	RRP12	-0.36	-5.94	-0.31	6.95e-9	Monocyte percentage of white cells;
LIHC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg15208524	chr1:10270712	KIF1B	0.39	5.99	0.31	5.17e-9	Hepatocellular carcinoma;
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.39	7.8	0.39	7.76e-14	Renal cell carcinoma;
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.65	-9.67	-0.46	1.02e-19	Longevity;
LIHC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.73	7.56	0.38	3.68e-13	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21866054	chr4:103748674	UBE2D3	0.46	7.03	0.36	1.14e-11	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.76	6.82	0.35	4.02e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.89e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-7.01	-0.35	1.28e-11	Body mass index;
LIHC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.16	0.32	2.03e-9	Renal cell carcinoma;
LIHC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg05564831	chr3:52568323	NT5DC2	0.39	6.29	0.32	9.51e-10	Bipolar disorder;
LIHC	cis	rs911119	1.000	rs1010117	chr20:23608421	G/C	cg16589663	chr20:23618590	CST3	0.74	7.76	0.39	1.01e-13	Chronic kidney disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21250466	chr4:854474	GAK	0.49	6.56	0.33	2.01e-10	Hepatitis;
LIHC	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.66	0.5	4.09e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-18.14	-0.7	5.18e-52	Schizophrenia;
LIHC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-12.31	-0.55	4.52e-29	Chronic sinus infection;
LIHC	cis	rs2834188	1.000	rs2409488	chr21:34688914	A/C	cg14352951	chr21:34696688	IFNAR1	0.47	6.49	0.33	2.95e-10	Narcolepsy;
LIHC	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.88	-0.39	4.27e-14	Capecitabine sensitivity;
LIHC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.76	8.73	0.43	1.13e-16	Vitiligo;
LIHC	cis	rs903552	1.000	rs12906575	chr15:102003617	G/A	cg19295451	chr15:102010161	PCSK6	-0.44	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs2637266	0.599	rs2395425	chr10:78461920	C/T	cg18941641	chr10:78392320	NA	0.27	5.73	0.3	2.2e-8	Pulmonary function;
LIHC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.15	-0.58	2.94e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26734620	chr12:56694298	CS	1.23	10.54	0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs903552	0.736	rs2132196	chr15:102007089	A/G	cg25677261	chr15:102009856	PCSK6	-0.51	-7.0	-0.35	1.36e-11	Diabetic kidney disease;
LIHC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.44	6.61	0.34	1.48e-10	Height;
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.61	6.92	0.35	2.29e-11	Alzheimer's disease;
LIHC	cis	rs7116495	0.786	rs4479013	chr11:71673732	C/G	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	6.97	0.35	1.65e-11	Self-reported allergy;
LIHC	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.72	-16.2	-0.66	3.33e-44	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg21605333	chr4:119757512	SEC24D	0.86	7.22	0.36	3.48e-12	Cannabis dependence symptom count;
LIHC	cis	rs35892873	0.959	rs9845572	chr3:126092217	C/T	cg15490784	chr3:126061950	KLF15	0.45	6.68	0.34	9.7e-11	Male-pattern baldness;
LIHC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	trans	rs1814175	0.645	rs10769605	chr11:49713723	A/G	cg03929089	chr4:120376271	NA	-0.86	-16.65	-0.67	5.35e-46	Height;
LIHC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.45	-0.37	7.47e-13	HDL cholesterol;
LIHC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.08	-0.31	3.14e-9	Obesity-related traits;
LIHC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.27	-0.37	2.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg10932868	chr11:921992	NA	0.36	6.72	0.34	7.52e-11	Alzheimer's disease (late onset);
LIHC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.64	8.23	0.41	4.04e-15	Motion sickness;
LIHC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.35	-7.09	-0.36	7.73e-12	Body mass index;
LIHC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg10664184	chr19:17420304	DDA1	0.46	5.87	0.3	1.03e-8	Systemic lupus erythematosus;
LIHC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.33	0.55	3.79e-29	Cognitive test performance;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00929392	chr1:19283191	IFFO2	-0.47	-6.47	-0.33	3.44e-10	Longevity;
LIHC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-6.66	-0.34	1.1e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg00750074	chr16:89608354	SPG7	-0.38	-5.75	-0.3	1.93e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.4	0.33	5.12e-10	Breast cancer;
LIHC	cis	rs1043515	0.935	rs2338115	chr17:36929578	C/T	cg20826740	chr17:37024042	NA	0.36	5.79	0.3	1.56e-8	Height;
LIHC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.42	5.8	0.3	1.51e-8	Life satisfaction;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.88	13.68	0.59	2.77e-34	Skin colour saturation;
LIHC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg14067834	chr17:29058358	SUZ12P	0.6	6.24	0.32	1.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg18306943	chr3:40428807	ENTPD3	0.34	5.76	0.3	1.88e-8	Renal cell carcinoma;
LIHC	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.61	10.02	0.48	7.11e-21	Corneal astigmatism;
LIHC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.6	9.37	0.45	1.03e-18	Mean corpuscular volume;
LIHC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.53	-0.38	4.65e-13	Psoriasis;
LIHC	cis	rs7395581	0.775	rs2269434	chr11:47360412	T/C	cg26139080	chr11:47293733	MADD	-0.49	-8.26	-0.41	3.31e-15	HDL cholesterol;
LIHC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg07451762	chr16:28383216	NA	0.34	6.47	0.33	3.31e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7635838	0.892	rs9838141	chr3:11488639	C/T	cg00170343	chr3:11313890	ATG7	0.43	6.7	0.34	8.63e-11	HDL cholesterol;
LIHC	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.71	9.13	0.44	5.89e-18	Type 2 diabetes;
LIHC	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.65	6.57	0.33	1.86e-10	Lymphocyte counts;
LIHC	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.87	11.2	0.52	5e-25	Coronary artery disease;
LIHC	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.86	-13.79	-0.6	1.05e-34	Colorectal cancer;
LIHC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.65	13.64	0.59	3.82e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	0.655	rs76735776	chr1:76455211	A/G	cg03433033	chr1:76189801	ACADM	0.54	7.51	0.38	5.03e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.88	-15.37	-0.64	6.43e-41	Aortic root size;
LIHC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.91	0.35	2.31e-11	Bipolar disorder;
LIHC	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.41	6.11	0.31	2.68e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9464760	0.527	rs9476757	chr6:15157289	A/G	cg15799072	chr6:15248335	JARID2	0.6	5.9	0.3	8.63e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.21	-0.64	2.78e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-9.47	-0.46	4.6e-19	Blood metabolite levels;
LIHC	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg25457927	chr22:38595422	NA	-0.31	-6.92	-0.35	2.27e-11	Breast cancer;
LIHC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.52	-0.49	1.34e-22	Hemoglobin concentration;
LIHC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.26	-0.32	1.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg16586182	chr3:47516702	SCAP	0.47	8.18	0.4	5.46e-15	Colorectal cancer;
LIHC	cis	rs965469	1.000	rs6051779	chr20:3333449	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.28	17.42	0.69	4.2e-49	Diabetic kidney disease;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg05771511	chr15:63340396	TPM1	-0.44	-5.94	-0.31	7.01e-9	Orofacial clefts;
LIHC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.88	11.0	0.51	2.73e-24	Mean platelet volume;
LIHC	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg16275483	chr1:110013120	SYPL2	-0.49	-6.15	-0.32	2.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.73	-9.24	-0.45	2.78e-18	Gut microbiome composition (summer);
LIHC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.65	-0.38	2.11e-13	Bipolar disorder;
LIHC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	0.99	10.62	0.5	5.84e-23	Cannabis dependence symptom count;
LIHC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg18016565	chr1:150552671	MCL1	-0.48	-9.33	-0.45	1.33e-18	Tonsillectomy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02685901	chr6:43597772	MAD2L1BP;GTPBP2	0.44	7.25	0.36	2.8e-12	Cognitive function;
LIHC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.76	12.98	0.57	1.34e-31	Anterior chamber depth;
LIHC	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.83	-0.3	1.28e-8	Resting heart rate;
LIHC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.67	10.09	0.48	4.04e-21	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08204369	chr17:73150733	HN1	0.49	7.52	0.38	4.73e-13	Pancreatic cancer;
LIHC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-10.76	-0.5	1.86e-23	Cognitive function;
LIHC	cis	rs17106184	1.000	rs72902772	chr1:51265368	C/T	cg07174182	chr1:51127561	FAF1	-0.65	-6.99	-0.35	1.46e-11	Type 2 diabetes;
LIHC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-7.51	-0.38	5.17e-13	Cognitive test performance;
LIHC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.62	10.32	0.49	6.23e-22	Mean platelet volume;
LIHC	cis	rs6539247	0.542	rs880298	chr12:106443134	C/T	cg20883310	chr12:106464547	NUAK1	0.43	6.96	0.35	1.7e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.54e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg22787604	chr8:1509810	DLGAP2	-0.33	-5.73	-0.3	2.22e-8	Lung cancer;
LIHC	cis	rs17094222	0.812	rs17113328	chr10:102435953	T/G	cg26540559	chr10:102447443	NA	0.32	6.15	0.32	2.17e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg06664874	chr5:179499304	RNF130	0.7	7.62	0.38	2.55e-13	LDL cholesterol;
LIHC	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.32	-8.71	-0.43	1.35e-16	Intelligence;
LIHC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11645453	chr3:52864694	ITIH4	0.21	5.83	0.3	1.26e-8	Bipolar disorder;
LIHC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.55e-73	Height;
LIHC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.69	0.73	3.11e-58	Smoking behavior;
LIHC	cis	rs2286503	0.780	rs929464	chr7:22874770	T/C	cg11367502	chr7:22862612	TOMM7	0.48	8.42	0.41	1.04e-15	Fibrinogen;
LIHC	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg01145232	chr6:150245071	RAET1G	-0.34	-6.94	-0.35	1.94e-11	Lung cancer;
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.42	7.06	0.36	9.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.53	10.11	0.48	3.39e-21	Testicular germ cell tumor;
LIHC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg01864069	chr14:103024347	NA	-0.46	-7.35	-0.37	1.5e-12	Platelet count;
LIHC	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.32	6.75	0.34	6.43e-11	Ulcerative colitis;
LIHC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg15848620	chr12:58087721	OS9	-0.58	-8.02	-0.4	1.65e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.53	-6.38	-0.33	5.77e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	18.46	0.71	2.67e-53	Tonsillectomy;
LIHC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.89	19.47	0.72	2.46e-57	Blood protein levels;
LIHC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9915021	0.623	rs9899927	chr17:33949083	T/G	cg20932281	chr17:33905541	PEX12	0.61	7.52	0.38	4.73e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg10381502	chr11:71823885	C11orf51	0.56	5.84	0.3	1.18e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs9513627	0.665	rs79036236	chr13:100116405	C/T	cg25919922	chr13:100150906	NA	-0.76	-6.41	-0.33	4.7e-10	Obesity-related traits;
LIHC	cis	rs116248771	0.739	rs73156478	chr3:158398716	C/T	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.32e-10	diarrhoeal disease at age 2;
LIHC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg27170947	chr2:26402098	FAM59B	0.67	8.3	0.41	2.47e-15	Gut microbiome composition (summer);
LIHC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	6.12	0.31	2.57e-9	Parkinson's disease;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg14709524	chr16:89940631	TCF25	0.53	6.44	0.33	4.03e-10	Skin colour saturation;
LIHC	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-9.16	-0.44	4.8e-18	Colorectal cancer;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-6.34	-0.32	7.34e-10	Longevity;Endometriosis;
LIHC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.64	8.78	0.43	7.87e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.41e-8	Menopause (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg19478983	chr7:120590592	ING3	-0.44	-6.81	-0.35	4.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg14784868	chr12:69753453	YEATS4	0.51	6.94	0.35	2e-11	Response to diuretic therapy;
LIHC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.66	-9.44	-0.45	5.76e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.4	6.07	0.31	3.45e-9	Educational attainment;
LIHC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.99	18.78	0.71	1.38e-54	Monocyte percentage of white cells;
LIHC	cis	rs10508774	0.810	rs11008979	chr10:32860267	A/G	cg01819863	chr10:32635814	EPC1	0.61	5.83	0.3	1.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-0.74	-12.12	-0.55	2.34e-28	Platelet distribution width;
LIHC	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-6.11	-0.31	2.65e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-7.95	-0.39	2.82e-14	Obesity-related traits;
LIHC	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.99e-50	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	5.93	0.31	7.55e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.43	-6.27	-0.32	1.06e-9	Cognitive function;
LIHC	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg09597638	chr17:3907349	NA	0.55	6.69	0.34	9.08e-11	Type 2 diabetes;
LIHC	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.39	5.9	0.3	8.9e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9309473	1.000	rs10187416	chr2:73713741	T/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.66	-0.34	1.12e-10	Metabolite levels;
LIHC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-7.24	-0.36	2.91e-12	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25739137	chr3:183851986	EIF2B5	-0.44	-6.65	-0.34	1.14e-10	Pancreatic cancer;
LIHC	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.46	-7.08	-0.36	8.29e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.94	0.39	2.88e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs7937890	0.587	rs11023204	chr11:14411223	C/A	cg22961513	chr11:14280813	SPON1	-0.44	-6.63	-0.34	1.32e-10	Mitochondrial DNA levels;
LIHC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	8.49	0.42	6.45e-16	Blood metabolite levels;
LIHC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.1	0.4	9.64e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.09	-0.36	7.78e-12	Body mass index;
LIHC	cis	rs7818688	0.697	rs78088250	chr8:95972718	G/A	cg16049864	chr8:95962084	TP53INP1	0.57	6.33	0.32	7.64e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg16586182	chr3:47516702	SCAP	-0.48	-8.46	-0.42	7.82e-16	Colorectal cancer;
LIHC	cis	rs611744	0.967	rs702805	chr8:109235929	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	24.31	0.8	1.54e-76	Chronic sinus infection;
LIHC	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.55	7.71	0.38	1.37e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg00656387	chr3:40428638	ENTPD3	0.42	6.59	0.34	1.67e-10	Renal cell carcinoma;
LIHC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.81	7.14	0.36	5.64e-12	Arsenic metabolism;
LIHC	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.4	6.2	0.32	1.64e-9	Inflammatory skin disease;
LIHC	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.33	5.77	0.3	1.73e-8	Mean corpuscular volume;
LIHC	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.21	0.55	1.02e-28	Eye color traits;
LIHC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.58	-8.33	-0.41	1.92e-15	Emphysema distribution in smoking;
LIHC	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg25930673	chr12:123319894	HIP1R	-1.0	-11.02	-0.51	2.32e-24	Adiponectin levels;
LIHC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.54	8.36	0.41	1.63e-15	Glycated hemoglobin levels;
LIHC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.9	14.94	0.63	3.46e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs5753037	0.543	rs131284	chr22:30157589	T/C	cg01021169	chr22:30184971	ASCC2	-0.33	-6.29	-0.32	9.81e-10	Type 1 diabetes;
LIHC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.96	9.81	0.47	3.41e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.74	0.39	1.14e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg07061783	chr6:25882402	NA	-0.43	-6.05	-0.31	3.77e-9	Blood metabolite levels;
LIHC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.2	0.61	2.65e-36	Chronic sinus infection;
LIHC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.51	-0.33	2.68e-10	Type 2 diabetes;
LIHC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.41	-6.97	-0.35	1.65e-11	Aortic root size;
LIHC	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.6	9.93	0.47	1.4e-20	HDL cholesterol;
LIHC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.8	9.79	0.47	3.96e-20	Mean platelet volume;
LIHC	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg04592579	chr7:75616294	TMEM120A	-0.35	-6.01	-0.31	4.79e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg23649088	chr2:200775458	C2orf69	-0.49	-6.85	-0.35	3.53e-11	QT interval;
LIHC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02985541	chr2:219472218	PLCD4	-0.42	-6.72	-0.34	7.85e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.82	-0.35	4.25e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12963312	chr6:52441723	TRAM2	0.43	6.3	0.32	9.28e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06634786	chr22:41940651	POLR3H	-0.57	-6.8	-0.35	4.67e-11	Neuroticism;
LIHC	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.75	-11.39	-0.52	1.11e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	0.76	10.02	0.48	6.77e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.55	9.67	0.46	1.05e-19	Total cholesterol levels;
LIHC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg04155231	chr12:9217510	LOC144571	-0.31	-6.01	-0.31	4.78e-9	Sjögren's syndrome;
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.86	-18.03	-0.7	1.47e-51	Height;
LIHC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.66	10.14	0.48	2.7e-21	Height;
LIHC	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg08800856	chr11:64428347	NRXN2	0.39	6.11	0.31	2.65e-9	Body mass index;Urate levels;
LIHC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21467203	chr3:49911342	NA	-0.6	-10.96	-0.51	3.81e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs7238033	0.641	rs8086499	chr18:43321412	A/G	cg20610511	chr18:43302872	SLC14A1	0.35	5.82	0.3	1.37e-8	Bladder cancer;
LIHC	cis	rs716804	0.729	rs10840382	chr11:10298050	C/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.11e-8	Neuroticism;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02520519	chr3:4345006	SETMAR	-0.51	-6.81	-0.35	4.29e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg04865290	chr3:52927548	TMEM110	-0.45	-6.11	-0.31	2.65e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.54	-6.87	-0.35	3.06e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg05197062	chr11:11642011	GALNTL4	0.42	6.08	0.31	3.17e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-6.92	-0.35	2.29e-11	Blood protein levels;
LIHC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.48	5.75	0.3	1.96e-8	Bladder cancer;
LIHC	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.43	0.53	7.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.34	6.07	0.31	3.35e-9	Aortic root size;
LIHC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.34	-0.45	1.3e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.21	-0.32	1.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg05484376	chr2:27715224	FNDC4	0.37	6.41	0.33	4.8e-10	Total body bone mineral density;
LIHC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.56	-11.46	-0.53	6.04e-26	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.44	-8.16	-0.4	6.42e-15	Prudent dietary pattern;
LIHC	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.98	-0.35	1.54e-11	Prevalent atrial fibrillation;
LIHC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.52	8.5	0.42	5.89e-16	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg10756647	chr7:56101905	PSPH	1.15	13.19	0.58	2.04e-32	Diabetic kidney disease;
LIHC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-8.64	-0.42	2.18e-16	Primary biliary cholangitis;
LIHC	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.55	8.98	0.44	1.91e-17	Breast cancer;
LIHC	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	1.13	10.28	0.49	8.88e-22	Type 2 diabetes;
LIHC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg18944383	chr4:111397179	ENPEP	0.25	6.15	0.32	2.15e-9	Coronary artery disease;
LIHC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.15	0.36	5.42e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.42	-0.49	2.98e-22	Schizophrenia;
LIHC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.33	-0.32	7.81e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.56	10.14	0.48	2.61e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11645453	chr3:52864694	ITIH4	0.23	5.8	0.3	1.5e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7651039	0.641	rs2455827	chr3:15662906	C/G	cg16303742	chr3:15540471	COLQ	0.54	9.54	0.46	2.74e-19	Coronary heart disease;
LIHC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.41	6.57	0.33	1.89e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs8027181	0.804	rs7178130	chr15:72978202	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.5	-7.79	-0.39	8.37e-14	Triglyceride levels;
LIHC	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg09003973	chr2:102972529	NA	0.89	7.63	0.38	2.33e-13	Gut microbiota (bacterial taxa);
LIHC	trans	rs6897795	0.680	rs10074768	chr5:177610700	A/G	cg19598605	chr2:70056955	GMCL1	-0.6	-7.65	-0.38	2.05e-13	Plateletcrit;
LIHC	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.63	8.27	0.41	3.06e-15	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.39	6.04	0.31	3.92e-9	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg23485639	chr6:28045615	ZNF165	0.39	6.0	0.31	5.11e-9	Parkinson's disease;
LIHC	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg21329975	chr4:15471214	CC2D2A	0.43	6.47	0.33	3.44e-10	Obesity-related traits;
LIHC	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.38	6.38	0.33	5.68e-10	Menopause (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06438056	chr1:33502433	AK2	-0.49	-6.93	-0.35	2.06e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.82	8.92	0.43	2.96e-17	Vitiligo;
LIHC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	0.47	8.4	0.41	1.23e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.74	12.16	0.55	1.65e-28	Mean platelet volume;
LIHC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-8.24	-0.41	3.78e-15	Chronic sinus infection;
LIHC	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.34	-5.93	-0.31	7.46e-9	Lewy body disease;
LIHC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.85	-0.3	1.15e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg25363559	chr8:143086065	NA	0.25	7.84	0.39	5.95e-14	Amyotrophic lateral sclerosis;
LIHC	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-0.68	-11.62	-0.53	1.54e-26	Pediatric autoimmune diseases;
LIHC	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.25	6.93	0.35	2.08e-11	Type 2 diabetes;
LIHC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.67	-12.11	-0.55	2.54e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	0.55	10.36	0.49	4.85e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.74	14.71	0.62	2.82e-38	Menopause (age at onset);
LIHC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-6.43	-0.33	4.2e-10	Schizophrenia;
LIHC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg18944383	chr4:111397179	ENPEP	0.26	6.37	0.33	6.14e-10	Coronary artery disease;
LIHC	cis	rs6662572	0.806	rs11211133	chr1:45991079	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	5.93	0.31	7.33e-9	Blood protein levels;
LIHC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.76	-10.08	-0.48	4.45e-21	Schizophrenia;
LIHC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.81	8.88	0.43	3.93e-17	Initial pursuit acceleration;
LIHC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.08	-10.08	-0.48	4.39e-21	Hip circumference adjusted for BMI;
LIHC	trans	rs1920116	0.744	rs9833035	chr3:169553498	G/T	cg00669760	chr2:44735195	C2orf34	0.38	6.11	0.31	2.79e-9	Glioma (high-grade);
LIHC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	1.06	14.27	0.61	1.48e-36	Body mass index;
LIHC	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.36	-6.87	-0.35	3.1e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7188861	1.000	rs889648	chr16:11455816	G/C	cg01510278	chr16:11456238	NA	0.48	5.71	0.3	2.44e-8	HDL cholesterol;
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.44	0.37	8.23e-13	Renal cell carcinoma;
LIHC	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg04592579	chr7:75616294	TMEM120A	-0.39	-6.83	-0.35	3.98e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.76	6.26	0.32	1.17e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg08392591	chr16:89556376	ANKRD11	0.4	6.02	0.31	4.55e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.54	-8.34	-0.41	1.88e-15	High light scatter reticulocyte count;
LIHC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07305463	chr2:136567211	LCT	-0.33	-6.13	-0.31	2.41e-9	Mosquito bite size;
LIHC	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.49	-6.31	-0.32	8.8e-10	Coronary artery calcification;
LIHC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22168489	chr12:122356033	WDR66	0.46	6.43	0.33	4.3e-10	Mean corpuscular volume;
LIHC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.78	11.86	0.54	2.11e-27	Total body bone mineral density;
LIHC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.77	0.39	8.97e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.31	-8.01	-0.4	1.85e-14	Intelligence;
LIHC	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.56	-13.68	-0.59	2.88e-34	White blood cell count (basophil);
LIHC	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.58	-0.34	1.75e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	1.0	9.71	0.46	7.65e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	0.59	8.7	0.43	1.42e-16	Prudent dietary pattern;
LIHC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.3	0.32	9.39e-10	Tonsillectomy;
LIHC	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.46	6.03	0.31	4.31e-9	Neuroticism;
LIHC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.44	5.8	0.3	1.54e-8	Height;
LIHC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.83	-0.3	1.28e-8	Heart rate;
LIHC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.48	0.53	5.1e-26	Alzheimer's disease;
LIHC	cis	rs903552	1.000	rs12904206	chr15:102006294	C/T	cg19295451	chr15:102010161	PCSK6	-0.44	-6.12	-0.31	2.6e-9	Diabetic kidney disease;
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg21003380	chr1:156261207	TMEM79	0.37	5.92	0.31	7.71e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs11958404	0.517	rs17679725	chr5:157221489	A/G	cg05962755	chr5:157440814	NA	0.67	6.76	0.34	5.96e-11	IgG glycosylation;
LIHC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.29	-0.52	2.47e-25	Primary sclerosing cholangitis;
LIHC	cis	rs12980942	0.872	rs12974420	chr19:41798660	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.58	7.08	0.36	8.42e-12	Coronary artery disease;
LIHC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	0.69	6.44	0.33	3.97e-10	Inflammatory bowel disease;
LIHC	cis	rs6442522	0.678	rs3773452	chr3:15509954	C/A	cg16303742	chr3:15540471	COLQ	0.47	7.85	0.39	5.45e-14	Uric acid levels;
LIHC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.74	13.56	0.59	8.11e-34	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.56	7.1	0.36	7.43e-12	Large artery stroke;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10660865	chr9:128024595	GAPVD1	0.46	6.65	0.34	1.16e-10	Morning vs. evening chronotype;
LIHC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.42	6.78	0.34	5.45e-11	Iron status biomarkers;
LIHC	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.82	-0.43	5.91e-17	Brugada syndrome;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.53	8.1	0.4	9.82e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9628987	0.612	rs6684863	chr1:8426236	G/A	cg20416874	chr1:8611966	RERE	0.49	5.96	0.31	6.22e-9	Breast cancer;
LIHC	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg07541023	chr7:19748670	TWISTNB	0.4	5.88	0.3	9.55e-9	Thyroid stimulating hormone;
LIHC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg16970926	chr12:29381810	FAR2	0.29	5.91	0.3	8.14e-9	QT interval;
LIHC	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.67	-0.42	1.83e-16	Colorectal cancer;
LIHC	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.73	10.52	0.49	1.34e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.23	5.72	0.3	2.31e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg19645103	chr12:69753606	YEATS4	-0.44	-5.97	-0.31	5.96e-9	Response to diuretic therapy;
LIHC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.44	0.37	8.37e-13	Airflow obstruction;
LIHC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg21361702	chr7:150065534	REPIN1	-0.45	-6.32	-0.32	8.35e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.89	11.16	0.52	7.38e-25	Coronary artery disease;
LIHC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.65	6.97	0.35	1.63e-11	Alzheimer's disease;
LIHC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.77	11.95	0.54	9.51e-28	Corneal astigmatism;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg20295408	chr7:1910781	MAD1L1	0.47	6.95	0.35	1.89e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.48	-11.61	-0.53	1.74e-26	Diastolic blood pressure;
LIHC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.79	13.36	0.59	4.59e-33	Colorectal cancer;
LIHC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.52	0.49	1.35e-22	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg12365402	chr11:9010492	NRIP3	0.3	7.88	0.39	4.54e-14	Hemoglobin concentration;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.46	-7.92	-0.39	3.38e-14	Total body bone mineral density;
LIHC	cis	rs9420	0.528	rs73480556	chr11:57400462	G/C	cg19752551	chr11:57585705	CTNND1	-0.46	-5.88	-0.3	9.75e-9	Schizophrenia;
LIHC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.48	7.85	0.39	5.47e-14	Obesity-related traits;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.64	-9.07	-0.44	9.61e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35160687	0.623	rs11689971	chr2:86474471	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	6.31	0.32	8.7e-10	Night sleep phenotypes;
LIHC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.68	9.38	0.45	9.41e-19	Mean platelet volume;
LIHC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.82	0.47	3.32e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23651808	chr4:8200974	SH3TC1	0.47	6.16	0.32	2.1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.56	-8.51	-0.42	5.67e-16	Height;
LIHC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.53	8.33	0.41	1.92e-15	Lymphocyte counts;
LIHC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.68	-10.74	-0.5	2.2e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg18850929	chr19:1828978	REXO1	0.39	6.39	0.33	5.51e-10	Bipolar disorder;
LIHC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg20607798	chr8:58055168	NA	0.41	5.98	0.31	5.63e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1256061	0.603	rs1152579	chr14:64695087	A/G	cg23250157	chr14:64679961	SYNE2	0.43	6.29	0.32	9.9e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.95	0.65	3.35e-43	Electrocardiographic conduction measures;
LIHC	cis	rs35883536	0.967	rs4908091	chr1:101138171	G/A	cg14515779	chr1:101123966	NA	-0.67	-13.3	-0.58	8.12e-33	Monocyte count;
LIHC	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.72	-12.96	-0.57	1.62e-31	Longevity;
LIHC	cis	rs2273669	0.588	rs111353760	chr6:109306493	T/G	cg05315195	chr6:109294784	ARMC2	-0.52	-5.76	-0.3	1.88e-8	Prostate cancer;
LIHC	trans	rs72960926	0.744	rs952120	chr6:74917250	T/G	cg07247405	chr1:2484626	LOC115110	0.52	6.19	0.32	1.75e-9	Metabolite levels (MHPG);
LIHC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.35	5.8	0.3	1.52e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.66	6.35	0.32	6.89e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.37	0.41	1.49e-15	Birth weight;
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.64	-9.14	-0.44	5.8e-18	Lymphocyte counts;
LIHC	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.6	7.82	0.39	6.51e-14	Economic and political preferences (feminism/equality);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01999652	chr6:28220110	ZKSCAN4	0.52	7.27	0.37	2.48e-12	Pancreatic cancer;
LIHC	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg02344993	chr17:57696989	CLTC	0.53	8.5	0.42	6.08e-16	Hemoglobin concentration;
LIHC	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	0.71	11.81	0.54	3.09e-27	Testicular germ cell tumor;
LIHC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.69	8.8	0.43	6.79e-17	Initial pursuit acceleration;
LIHC	cis	rs9596863	1.000	rs9596855	chr13:54407032	G/A	ch.13.53330881F	chr13:54432880	NA	0.44	5.98	0.31	5.48e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.8	12.54	0.56	6.13e-30	Mosquito bite size;
LIHC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg01788221	chr16:89496183	ANKRD11	0.39	6.14	0.32	2.31e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.52	-7.25	-0.37	2.78e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.65	11.23	0.52	3.92e-25	Longevity;Endometriosis;
LIHC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.55	6.54	0.33	2.27e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12516959	chr21:47718080	NA	-0.36	-5.8	-0.3	1.51e-8	Testicular germ cell tumor;
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg09417038	chr21:47716443	C21orf57	-0.49	-7.48	-0.37	6.46e-13	Testicular germ cell tumor;
LIHC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.38	5.85	0.3	1.13e-8	Prostate cancer;
LIHC	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.56	8.27	0.41	3.07e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.41	6.77	0.34	5.52e-11	Brain structure;
LIHC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	-0.29	-5.74	-0.3	2.14e-8	Coronary artery disease;
LIHC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.57	8.3	0.41	2.49e-15	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs17021463	0.643	rs6841656	chr4:95300532	A/G	cg11021082	chr4:95130006	SMARCAD1	0.42	7.08	0.36	8.2e-12	Testicular germ cell tumor;
LIHC	cis	rs79149102	0.850	rs78646589	chr15:75170580	C/T	cg16226627	chr15:75307476	SCAMP5	0.45	6.31	0.32	8.67e-10	Lung cancer;
LIHC	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.61	-9.83	-0.47	2.93e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.67	-11.15	-0.52	7.7e-25	Childhood ear infection;
LIHC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.85	7.17	0.36	4.77e-12	Body mass index;
LIHC	trans	rs7120489	0.541	rs11022352	chr11:12444804	T/C	cg08537300	chr5:179058959	NA	0.58	6.28	0.32	1.03e-9	Mortality in heart failure;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg00280220	chr17:61926910	NA	0.42	6.5	0.33	2.82e-10	Prudent dietary pattern;
LIHC	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-7.22	-0.36	3.46e-12	Obesity-related traits;
LIHC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg07451762	chr16:28383216	NA	0.39	6.93	0.35	2.05e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.13	0.48	3.01e-21	Schizophrenia;
LIHC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.82	-0.35	4.21e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.29	-6.07	-0.31	3.48e-9	Blood metabolite levels;
LIHC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-8.86	-0.43	4.3e-17	Total body bone mineral density;
LIHC	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.67	0.34	1.04e-10	Type 2 diabetes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20864579	chr11:76813988	OMP;CAPN5	0.42	6.17	0.32	1.98e-9	Longevity;
LIHC	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.78	-11.82	-0.54	2.82e-27	Mosquito bite size;
LIHC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.91	0.6	3.63e-35	Primary sclerosing cholangitis;
LIHC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.66	9.78	0.47	4.5e-20	Menopause (age at onset);
LIHC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.9	0.3	8.56e-9	Birth weight;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.67	-9.61	-0.46	1.69e-19	Menopause (age at onset);
LIHC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	9.15	0.44	5.2e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg22528358	chr1:107598549	PRMT6	-0.69	-11.54	-0.53	3e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.76	11.8	0.54	3.51e-27	Corneal astigmatism;
LIHC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.53	0.33	2.32e-10	Bipolar disorder;
LIHC	cis	rs4853525	0.522	rs6434412	chr2:191585275	A/G	cg05765582	chr2:191677683	NA	0.3	5.79	0.3	1.63e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.17	-0.32	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.62	-0.42	2.47e-16	Type 2 diabetes;
LIHC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg06917634	chr15:78832804	PSMA4	0.5	6.31	0.32	8.62e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.65	0.38	2.01e-13	Prudent dietary pattern;
LIHC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg15704280	chr7:45808275	SEPT13	-0.45	-6.81	-0.35	4.36e-11	HDL cholesterol;
LIHC	cis	rs8083850	0.698	rs4940251	chr18:50833082	A/C	cg24270629	chr18:50823537	DCC	-0.54	-8.36	-0.41	1.61e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.54e-79	Prudent dietary pattern;
LIHC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg22676075	chr6:135203613	NA	0.41	6.59	0.34	1.66e-10	Red blood cell count;
LIHC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.32	7.15	0.36	5.36e-12	Crohn's disease;
LIHC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg14779329	chr11:130786720	SNX19	0.4	6.15	0.32	2.11e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.6	-0.34	1.53e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg05973401	chr12:123451056	ABCB9	-0.4	-6.19	-0.32	1.73e-9	Platelet count;
LIHC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.79	-14.71	-0.62	2.74e-38	Refractive error;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.54	7.72	0.39	1.29e-13	Lymphocyte counts;
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.69	-0.43	1.48e-16	Gut microbiome composition (summer);
LIHC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.74	-0.3	2.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08219700	chr8:58056026	NA	0.54	7.21	0.36	3.64e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10508774	1.000	rs12251052	chr10:32746625	T/C	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg18944383	chr4:111397179	ENPEP	-0.31	-6.93	-0.35	2.04e-11	Coronary artery disease;
LIHC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.65	11.49	0.53	4.61e-26	High light scatter reticulocyte count;
LIHC	trans	rs7142002	1.000	rs12588314	chr14:102363857	G/A	cg18984499	chr17:8286166	RPL26	0.65	6.19	0.32	1.77e-9	Autism;
LIHC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg16586182	chr3:47516702	SCAP	-0.58	-11.29	-0.52	2.44e-25	Colorectal cancer;
LIHC	cis	rs3764618	1.000	rs3764619	chr19:49497277	G/A	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.71	-5.81	-0.3	1.41e-8	Follicule stimulating hormone;
LIHC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.6	0.42	2.93e-16	Motion sickness;
LIHC	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg08800856	chr11:64428347	NRXN2	0.39	6.12	0.31	2.52e-9	Body mass index;Urate levels;
LIHC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg20135002	chr11:47629003	NA	-0.53	-9.22	-0.45	3.08e-18	Subjective well-being;
LIHC	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.43	6.49	0.33	2.93e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.61	0.42	2.78e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs4908768	0.501	rs1024197	chr1:8537058	C/G	cg20416874	chr1:8611966	RERE	-0.66	-13.83	-0.6	7.4e-35	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.88	0.51	7.29e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg14289826	chr9:140003911	NA	0.35	5.84	0.3	1.23e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1e-57	Breast cancer;
LIHC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.71	10.55	0.5	1.04e-22	Aortic root size;
LIHC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.31	-7.15	-0.36	5.34e-12	Menarche (age at onset);
LIHC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.78	12.12	0.55	2.34e-28	Resting heart rate;
LIHC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.79	12.8	0.57	6.41e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	7.97	0.4	2.47e-14	Diastolic blood pressure;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg23601095	chr6:26197514	HIST1H3D	0.55	5.83	0.3	1.27e-8	Gout;Renal underexcretion gout;
LIHC	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.32	-0.41	2.07e-15	Exhaled nitric oxide output;
LIHC	trans	rs2073499	0.935	rs2526400	chr3:50186948	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.35	-0.37	1.43e-12	Schizophrenia;
LIHC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg25024717	chr12:54324583	NA	-0.38	-8.01	-0.4	1.79e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.63	-6.74	-0.34	6.64e-11	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg27205649	chr11:78285834	NARS2	-0.39	-6.0	-0.31	4.89e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.44	6.79	0.34	4.88e-11	Methadone dose in opioid dependence;
LIHC	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.41	-0.33	4.83e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	0.67	12.72	0.57	1.31e-30	Rheumatoid arthritis;
LIHC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg23517279	chr6:96025343	MANEA	0.55	6.41	0.33	4.8e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11212260	0.655	rs11212222	chr11:107293442	A/G	cg25435332	chr11:107328525	CWF19L2	0.79	8.09	0.4	1.08e-14	IgG glycosylation;
LIHC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg26395211	chr5:140044315	WDR55	0.4	5.89	0.3	9.36e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg26149184	chr10:133730230	NA	0.48	7.57	0.38	3.46e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21448741	chr8:58168803	NA	0.36	5.91	0.3	8.43e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.37	6.11	0.31	2.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.84	-0.3	1.2e-8	Biliary atresia;
LIHC	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	13.15	0.58	2.91e-32	Nonalcoholic fatty liver disease;
LIHC	cis	rs16958440	1.000	rs62096478	chr18:44662409	A/G	cg17192377	chr18:44677553	HDHD2	0.6	6.71	0.34	8.24e-11	Sitting height ratio;
LIHC	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.55	8.18	0.4	5.66e-15	Diastolic blood pressure;
LIHC	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg07150772	chr14:90864620	CALM1	-0.41	-5.83	-0.3	1.29e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.69	-8.11	-0.4	8.87e-15	Morning vs. evening chronotype;
LIHC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs12936587	0.536	rs8075153	chr17:17622666	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-6.85	-0.35	3.35e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LIHC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.75	11.85	0.54	2.2e-27	Corneal astigmatism;
LIHC	cis	rs7635838	0.892	rs6442252	chr3:11451416	T/C	cg00170343	chr3:11313890	ATG7	0.42	6.57	0.33	1.83e-10	HDL cholesterol;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg24693881	chr1:107596107	NA	0.52	9.02	0.44	1.39e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.39	6.04	0.31	3.95e-9	Resting heart rate;
LIHC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.47	-6.61	-0.34	1.47e-10	Breast cancer;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg22528358	chr1:107598549	PRMT6	0.72	11.91	0.54	1.33e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.52	8.42	0.41	1.06e-15	Corneal astigmatism;
LIHC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.16	-0.32	2.01e-9	Blood metabolite levels;
LIHC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.09	10.02	0.48	6.77e-21	Diabetic retinopathy;
LIHC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.43	-0.74	3.49e-61	Height;
LIHC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	9.41	0.45	7.71e-19	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	1.03	18.23	0.7	2.34e-52	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.74	0.34	6.56e-11	Ileal carcinoids;
LIHC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg08847533	chr14:75593920	NEK9	-0.38	-6.42	-0.33	4.53e-10	Caffeine consumption;
LIHC	cis	rs600806	0.676	rs2781553	chr1:110026989	G/T	cg11161837	chr1:110010384	SYPL2	-0.43	-5.78	-0.3	1.65e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs2096176	0.632	rs1915478	chr10:26330218	T/G	cg01396774	chr2:218299024	DIRC3	-0.31	-6.12	-0.31	2.51e-9	Obesity-related traits;
LIHC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.65	-12.49	-0.56	9.64e-30	Schizophrenia;
LIHC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.67	10.53	0.49	1.2e-22	Platelet count;
LIHC	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.72	-13.47	-0.59	1.86e-33	Mean platelet volume;
LIHC	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg14146966	chr2:61757674	XPO1	0.4	6.68	0.34	9.77e-11	Tuberculosis;
LIHC	cis	rs8049040	0.644	rs16973000	chr16:71493165	T/C	cg06353428	chr16:71660113	MARVELD3	-0.76	-7.39	-0.37	1.12e-12	Blood protein levels;
LIHC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.68	0.38	1.65e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.42	-5.82	-0.3	1.34e-8	Total body bone mineral density;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg05185784	chr16:90016020	DEF8	-0.47	-6.1	-0.31	2.87e-9	Skin colour saturation;
LIHC	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg07706471	chr12:123319906	HIP1R	-0.6	-7.94	-0.39	2.86e-14	Schizophrenia;
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg00750074	chr16:89608354	SPG7	0.43	6.82	0.35	4.15e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg12798992	chr6:167411361	FGFR1OP	0.43	6.65	0.34	1.18e-10	Primary biliary cholangitis;
LIHC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-6.85	-0.35	3.39e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.28	0.41	2.88e-15	Response to antipsychotic treatment;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg11070056	chr1:107600091	PRMT6	-0.7	-12.0	-0.54	6.27e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.76	-0.3	1.88e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.16	0.32	2.04e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.49	10.45	0.49	2.33e-22	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs288342	0.832	rs288307	chr2:183652094	C/T	cg02625481	chr2:183667124	NA	-0.29	-6.17	-0.32	1.96e-9	Recurrent major depressive disorder;
LIHC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.53	7.53	0.38	4.49e-13	Prostate cancer;
LIHC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg05590025	chr7:65112418	INTS4L2	-0.59	-6.58	-0.34	1.81e-10	Diabetic kidney disease;
LIHC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg14709524	chr16:89940631	TCF25	0.48	5.89	0.3	9.25e-9	Skin colour saturation;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg15383120	chr6:291909	DUSP22	-0.47	-6.07	-0.31	3.35e-9	Menopause (age at onset);
LIHC	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.3	0.32	8.94e-10	Ulcerative colitis;
LIHC	cis	rs903552	1.000	rs12908079	chr15:102003820	C/A	cg06707286	chr15:102010195	PCSK6	-0.44	-6.48	-0.33	3.2e-10	Diabetic kidney disease;
LIHC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18110333	chr6:292329	DUSP22	-0.48	-6.57	-0.33	1.82e-10	Menopause (age at onset);
LIHC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	7.54	0.38	4.32e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.32	-0.52	1.88e-25	Total cholesterol levels;
LIHC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.92	-0.35	2.21e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs11030122	0.673	rs11030639	chr11:4039056	A/G	cg18678763	chr11:4115507	RRM1	-0.54	-8.14	-0.4	7.53e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.73	0.65	2.42e-42	Lymphocyte percentage of white cells;
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.75	11.81	0.54	3.2e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.63	-0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.52	8.33	0.41	1.98e-15	Diastolic blood pressure;
LIHC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.47	-7.66	-0.38	1.98e-13	Fibrinogen levels;
LIHC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.93	0.65	3.83e-43	White blood cell count;
LIHC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-5.94	-0.31	7.05e-9	Blood metabolite levels;
LIHC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs861318	0.702	rs74359395	chr1:159027003	A/G	cg11003133	chr1:159046391	AIM2	-0.36	-7.02	-0.35	1.21e-11	Obesity-related traits;
LIHC	cis	rs12464559	0.571	rs6741567	chr2:152578014	T/C	cg01189475	chr2:152685088	ARL5A	0.67	7.88	0.39	4.55e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.63	10.89	0.51	6.46e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.42	-0.33	4.63e-10	Testicular germ cell tumor;
LIHC	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	0.66	7.26	0.37	2.57e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.56	0.59	8.23e-34	Coffee consumption (cups per day);
LIHC	cis	rs2637030	0.559	rs256108	chr5:52874253	C/T	cg06476337	chr5:52856530	NDUFS4	0.42	6.64	0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg15711740	chr2:61764176	XPO1	0.42	5.71	0.3	2.41e-8	Tuberculosis;
LIHC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.49	0.33	3.06e-10	Morning vs. evening chronotype;
LIHC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.81	16.04	0.66	1.42e-43	Gestational age at birth (maternal effect);
LIHC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.46	-8.38	-0.41	1.36e-15	Glycated hemoglobin levels;
LIHC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	7.33	0.37	1.66e-12	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07424155	chr7:116503126	CAPZA2	-0.52	-7.16	-0.36	4.98e-12	Pancreatic cancer;
LIHC	cis	rs4908768	0.906	rs12405049	chr1:8626117	C/T	cg25722041	chr1:8623473	RERE	0.43	6.12	0.31	2.5e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.54	7.19	0.36	3.98e-12	Body mass index;
LIHC	cis	rs11955398	0.625	rs11739209	chr5:59959767	T/C	cg02684056	chr5:59996105	DEPDC1B	0.44	6.09	0.31	3e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.72	-0.3	2.33e-8	Body mass index;
LIHC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg18225595	chr11:63971243	STIP1	0.64	6.55	0.33	2.15e-10	Mean platelet volume;
LIHC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.82	0.3	1.39e-8	Eosinophil percentage of white cells;
LIHC	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.6	-7.25	-0.36	2.86e-12	Migraine;Coronary artery disease;
LIHC	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.6	9.73	0.47	6.29e-20	Corneal astigmatism;
LIHC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12016809	chr21:47604291	C21orf56	0.41	5.97	0.31	6.06e-9	Testicular germ cell tumor;
LIHC	cis	rs9596863	0.898	rs7328420	chr13:54320465	G/A	ch.13.53330881F	chr13:54432880	NA	0.44	5.99	0.31	5.36e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs17001868	0.892	rs117667045	chr22:40736961	C/T	cg07138101	chr22:40742427	ADSL	0.58	6.05	0.31	3.71e-9	Mammographic density (dense area);
LIHC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.74	-8.03	-0.4	1.61e-14	Putamen volume;
LIHC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.66	0.56	2.23e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg04727924	chr7:799746	HEATR2	-0.62	-8.14	-0.4	7.42e-15	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.59	12.37	0.56	2.56e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.35	5.72	0.3	2.35e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.7	0.53	7.98e-27	Motion sickness;
LIHC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.51	-7.4	-0.37	1.07e-12	Breast size;
LIHC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.69	12.35	0.56	3.22e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	0.83	14.8	0.62	1.15e-38	Exhaled nitric oxide output;
LIHC	cis	rs3106136	0.681	rs11097420	chr4:95301035	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.84	-0.3	1.24e-8	Capecitabine sensitivity;
LIHC	cis	rs11605275	0.818	rs35645523	chr11:20046171	G/A	cg14835545	chr11:20032148	NAV2	-0.6	-5.8	-0.3	1.48e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg27203090	chr3:33138513	GLB1;TMPPE	-0.56	-7.42	-0.37	9.36e-13	Major depressive disorder;
LIHC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.76	8.62	0.42	2.57e-16	Cognitive test performance;
LIHC	trans	rs2681424	0.966	rs1962532	chr3:121751531	C/T	cg03946530	chr15:65596423	NA	0.5	6.43	0.33	4.27e-10	Multiple sclerosis;
LIHC	cis	rs1892700	0.730	rs2834231	chr21:34892359	A/C	cg14850771	chr21:34775459	IFNGR2	-0.45	-6.06	-0.31	3.54e-9	Educational attainment;
LIHC	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.4	-13.81	-0.6	8.69e-35	Psoriasis vulgaris;
LIHC	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.52	8.27	0.41	3.08e-15	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-7.09	-0.36	7.81e-12	Height;
LIHC	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.53	9.98	0.48	9.08e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.43	-6.98	-0.35	1.55e-11	Schizophrenia;
LIHC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.94	0.31	7.16e-9	Rheumatoid arthritis;
LIHC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.51	6.45	0.33	3.74e-10	Menarche (age at onset);
LIHC	trans	rs10411161	0.748	rs78410648	chr19:52399401	G/A	cg22319618	chr22:45562946	NUP50	-0.65	-7.43	-0.37	8.54e-13	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25411849	chr6:89855994	PM20D2	-0.4	-6.25	-0.32	1.19e-9	Pancreatic cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27233612	chr3:25824257	NGLY1	0.39	6.12	0.31	2.52e-9	Pancreatic cancer;
LIHC	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.43	-0.33	4.18e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.5	-6.1	-0.31	2.9e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.62	10.36	0.49	4.56e-22	Recombination rate (males);
LIHC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.71	6.28	0.32	1.03e-9	Cognitive function;
LIHC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.51	0.46	3.54e-19	Schizophrenia;
LIHC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.52	-9.27	-0.45	2.09e-18	Blood protein levels;
LIHC	cis	rs2108622	0.527	rs67617968	chr19:15977565	A/G	cg13772218	chr19:15982569	NA	0.35	7.56	0.38	3.72e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03129853	chr11:93862749	PANX1	-0.55	-6.49	-0.33	2.93e-10	Lung function (FEV1);
LIHC	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.04	-0.4	1.45e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs4728302	0.869	rs6943986	chr7:133616965	G/A	cg10665199	chr7:133106180	EXOC4	0.38	6.48	0.33	3.24e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs3812111	0.866	rs9488837	chr6:116435957	G/A	cg08036074	chr6:116424633	NT5DC1	-0.65	-11.18	-0.52	5.86e-25	Age-related macular degeneration;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.45	8.32	0.41	2.12e-15	Prudent dietary pattern;
LIHC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg18357645	chr12:58087776	OS9	-0.43	-6.07	-0.31	3.39e-9	Multiple sclerosis;
LIHC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.35	-6.52	-0.33	2.46e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg11764359	chr7:65958608	NA	0.59	6.26	0.32	1.18e-9	Diabetic kidney disease;
LIHC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06002616	chr8:101225028	SPAG1	0.34	5.94	0.31	6.98e-9	Atrioventricular conduction;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04471375	chr16:58752165	GOT2	-0.37	-6.08	-0.31	3.25e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.94	15.5	0.64	1.98e-41	Metabolic syndrome;
LIHC	cis	rs4699052	0.963	rs11097801	chr4:104150323	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-6.63	-0.34	1.28e-10	Testicular germ cell tumor;
LIHC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18357526	chr6:26021779	HIST1H4A	0.52	7.67	0.38	1.83e-13	Height;
LIHC	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.43	-5.87	-0.3	1.01e-8	Parkinson's disease;
LIHC	cis	rs74181299	0.571	rs71424153	chr2:65280894	G/C	cg05010058	chr2:65284262	CEP68	0.37	5.94	0.31	7.05e-9	Pulse pressure;
LIHC	cis	rs4742903	0.904	rs12380062	chr9:106941903	A/G	cg14250997	chr9:106856677	SMC2	0.35	5.92	0.3	7.73e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg01364799	chr7:75623366	TMEM120A	-0.41	-6.12	-0.31	2.5e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs8083850	0.572	rs7235888	chr18:50879701	A/T	cg24270629	chr18:50823537	DCC	-0.57	-8.65	-0.42	2.06e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg14580859	chr9:123691850	NA	0.38	6.7	0.34	8.79e-11	Rheumatoid arthritis;
LIHC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.89	-12.58	-0.56	4.34e-30	Diastolic blood pressure;
LIHC	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg00977110	chr5:151150581	G3BP1	-0.57	-7.21	-0.36	3.73e-12	Preschool internalizing problems;
LIHC	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg15871215	chr5:81402204	ATG10	-0.59	-8.19	-0.4	5.35e-15	Breast cancer;
LIHC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.78	0.34	5.4e-11	Menopause (age at onset);
LIHC	cis	rs507080	0.769	rs483283	chr11:118506402	T/C	cg04173919	chr11:118528438	PHLDB1	0.31	5.72	0.3	2.34e-8	Serum metabolite levels;
LIHC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.47	0.49	1.98e-22	Vitiligo;
LIHC	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.05	0.31	3.84e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.37	5.96	0.31	6.29e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.51	8.29	0.41	2.61e-15	Corneal astigmatism;
LIHC	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.51	5.83	0.3	1.26e-8	Retinal vascular caliber;
LIHC	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg16586182	chr3:47516702	SCAP	0.51	9.01	0.44	1.45e-17	Colorectal cancer;
LIHC	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.9	-0.35	2.5e-11	Bipolar disorder;
LIHC	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg14930904	chr10:32216787	ARHGAP12	0.38	6.77	0.34	5.61e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg02640540	chr1:67518911	SLC35D1	0.41	6.49	0.33	3.1e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.95	-0.31	6.7e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.49	-8.7	-0.43	1.38e-16	Colorectal cancer;
LIHC	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg10820045	chr2:198174542	NA	0.5	7.86	0.39	4.89e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.55	-6.49	-0.33	2.94e-10	Blood protein levels;
LIHC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.24e-9	Coronary artery disease;
LIHC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg00647820	chr17:40259828	DHX58	-0.28	-5.91	-0.3	8.35e-9	Fibrinogen levels;
LIHC	cis	rs12928939	0.774	rs7205340	chr16:71645670	A/T	cg03805757	chr16:71968109	PKD1L3	0.51	6.33	0.32	7.53e-10	Post bronchodilator FEV1;
LIHC	cis	rs11622475	0.677	rs12889842	chr14:104344947	G/T	cg12183467	chr14:104352244	NA	-0.49	-7.19	-0.36	4.12e-12	Bipolar disorder;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10073129	chr8:67974421	COPS5	0.39	6.14	0.32	2.3e-9	Calcium levels;
LIHC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.45	-7.86	-0.39	5.06e-14	HDL cholesterol levels;
LIHC	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.83	-0.35	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.51	7.48	0.38	6.14e-13	Thyroid stimulating hormone;
LIHC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg10736770	chr19:49115456	FAM83E	-0.41	-6.95	-0.35	1.87e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg24849736	chr1:201084428	NA	0.39	7.96	0.4	2.62e-14	Permanent tooth development;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04588562	chr17:46756094	NA	0.46	6.58	0.34	1.73e-10	Pancreatic cancer;
LIHC	cis	rs2191566	0.664	rs4803669	chr19:44539962	C/A	cg20607764	chr19:44506953	ZNF230	-0.36	-5.98	-0.31	5.63e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.09	20.85	0.75	6.7e-63	Multiple system atrophy;
LIHC	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.41	6.27	0.32	1.06e-9	HDL cholesterol;
LIHC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	11.75	0.54	5.35e-27	Coronary artery disease;
LIHC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	6.09	0.31	3.09e-9	Height;
LIHC	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-9.33	-0.45	1.4e-18	Colorectal cancer;
LIHC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg13393036	chr8:95962371	TP53INP1	0.33	7.95	0.4	2.67e-14	Alzheimer's disease (late onset);
LIHC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.74	12.11	0.55	2.47e-28	Body mass index;
LIHC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.36	-8.27	-0.41	2.99e-15	Educational attainment (years of education);
LIHC	cis	rs4650994	0.571	rs6676507	chr1:178508743	C/G	cg05350800	chr1:178550844	NA	-0.3	-6.47	-0.33	3.41e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18786515	chr8:10207915	MSRA	0.45	6.2	0.32	1.61e-9	Longevity;
LIHC	cis	rs6466055	0.669	rs6950620	chr7:104770386	A/G	cg04380332	chr7:105027541	SRPK2	0.32	6.63	0.34	1.3e-10	Schizophrenia;
LIHC	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.54	-0.38	4.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-0.63	-9.19	-0.44	3.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05318427	chr2:85199320	KCMF1	0.48	6.92	0.35	2.28e-11	Pancreatic cancer;
LIHC	cis	rs7945718	0.591	rs10831892	chr11:12676272	T/A	cg25843174	chr11:12811716	TEAD1	0.33	7.71	0.38	1.42e-13	Educational attainment (years of education);
LIHC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.76	7.78	0.39	8.57e-14	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1198430	0.683	rs1198440	chr1:23780861	C/A	cg19827787	chr1:23763612	ASAP3	0.28	5.99	0.31	5.29e-9	Total cholesterol levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09590193	chr11:105947389	KBTBD3;AASDHPPT	0.42	6.24	0.32	1.27e-9	Cognitive function;
LIHC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.28	0.41	2.77e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.58	-0.5	8.39e-23	Alzheimer's disease;
LIHC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg10402321	chr1:26617780	UBXN11	-0.37	-5.78	-0.3	1.65e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.75	-11.24	-0.52	3.6e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs6973256	0.543	rs13243553	chr7:133506955	A/G	cg03336402	chr7:133662267	EXOC4	0.4	6.15	0.32	2.14e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9918079	0.560	rs12651550	chr4:15641018	G/C	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.86	-0.3	1.09e-8	Obesity-related traits;
LIHC	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.67	-11.75	-0.54	5.35e-27	Pediatric autoimmune diseases;
LIHC	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.5	7.82	0.39	6.79e-14	Alzheimer's disease (survival time);
LIHC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.26	6.5	0.33	2.91e-10	Cutaneous nevi;
LIHC	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg27433088	chr4:174089019	GALNT7	0.41	7.01	0.35	1.25e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg14067834	chr17:29058358	SUZ12P	-0.67	-6.74	-0.34	6.63e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg15848620	chr12:58087721	OS9	-0.55	-7.52	-0.38	4.99e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs240764	0.817	rs240110	chr6:101059629	T/C	cg09795085	chr6:101329169	ASCC3	0.52	7.23	0.36	3.15e-12	Neuroticism;
LIHC	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg10127483	chr1:110009974	SYPL2	0.47	5.98	0.31	5.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.45	-0.33	3.74e-10	Height;
LIHC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.56	7.14	0.36	5.62e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg05484376	chr2:27715224	FNDC4	0.39	6.64	0.34	1.26e-10	Total body bone mineral density;
LIHC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.51	7.9	0.39	3.81e-14	Blood protein levels;
LIHC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg12826209	chr6:26865740	GUSBL1	0.49	6.0	0.31	5.07e-9	Small cell lung carcinoma;
LIHC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg14580859	chr9:123691850	NA	0.37	6.53	0.33	2.42e-10	Rheumatoid arthritis;
LIHC	cis	rs11696739	0.513	rs34600126	chr20:1597433	G/T	cg15722679	chr20:1638393	SIRPG	0.54	9.88	0.47	2.01e-20	Mean platelet volume;
LIHC	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.63	0.34	1.3100000000000001e-10	Mean corpuscular volume;
LIHC	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.47	7.01	0.35	1.31e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs3770081	1.000	rs735737	chr2:86177101	G/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.39	5.83	0.3	1.27e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg11764359	chr7:65958608	NA	0.65	6.36	0.33	6.62e-10	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.27	16.64	0.67	5.64e-46	Diabetic kidney disease;
LIHC	cis	rs7945071	0.507	rs11213397	chr11:110296813	A/G	cg04157658	chr11:110243994	NA	0.34	6.23	0.32	1.4e-9	Cognitive function;
LIHC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	8.88	0.43	3.86e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14154082	chr13:112174009	NA	0.29	6.14	0.32	2.28e-9	Menarche (age at onset);
LIHC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg08499158	chr17:42289980	UBTF	-0.48	-7.81	-0.39	7.16e-14	Total body bone mineral density;
LIHC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20307385	chr11:47447363	PSMC3	0.45	5.87	0.3	1.05e-8	Subjective well-being;
LIHC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg16586182	chr3:47516702	SCAP	-0.58	-11.26	-0.52	3.21e-25	Colorectal cancer;
LIHC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.65	10.02	0.48	7.06e-21	Prostate cancer;
LIHC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.47	0.46	4.88e-19	Platelet count;
LIHC	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.67	7.13	0.36	6.11e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9326778	0.520	rs6882181	chr5:108823545	G/A	cg17395555	chr5:108820864	NA	-0.37	-6.24	-0.32	1.27e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LIHC	trans	rs9531686	0.967	rs9531685	chr13:85549282	A/G	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.25	0.32	1.19e-9	Anorexia nervosa;
LIHC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg03146154	chr1:46216737	IPP	-0.5	-8.52	-0.42	5.21e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.54	-0.38	4.37e-13	Metabolite levels;
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12016809	chr21:47604291	C21orf56	0.4	5.86	0.3	1.07e-8	Testicular germ cell tumor;
LIHC	cis	rs8081395	0.801	rs2777895	chr17:57879610	A/G	cg02344993	chr17:57696989	CLTC	-0.44	-7.28	-0.37	2.31e-12	White blood cell count;
LIHC	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.59	-9.31	-0.45	1.62e-18	Retinal vascular caliber;
LIHC	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg15123519	chr2:136567270	LCT	0.44	8.77	0.43	8.42e-17	Mosquito bite size;
LIHC	cis	rs244293	0.894	rs244372	chr17:53185212	G/C	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg14515779	chr1:101123966	NA	0.46	6.56	0.33	2.04e-10	Monocyte count;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg22100476	chr1:43638037	WDR65;EBNA1BP2	-0.43	-6.27	-0.32	1.06e-9	Bipolar disorder;
LIHC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg10932868	chr11:921992	NA	0.36	6.77	0.34	5.46e-11	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.597	rs11771318	chr7:66062480	G/T	cg18876405	chr7:65276391	NA	-0.43	-6.6	-0.34	1.55e-10	Aortic root size;
LIHC	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.74	10.61	0.5	6.28e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17930852	chr1:45957182	TESK2	0.45	6.61	0.34	1.48e-10	Pancreatic cancer;
LIHC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.61	-0.34	1.45e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.72	12.91	0.57	2.49e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg06359132	chr10:99160096	RRP12	-0.38	-5.96	-0.31	6.4e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.24	-0.55	7.9e-29	Primary sclerosing cholangitis;
LIHC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.11	-0.31	2.75e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.53	8.08	0.4	1.1e-14	Resting heart rate;
LIHC	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13647721	chr17:30228624	UTP6	0.71	7.37	0.37	1.29e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.3	0.45	1.74e-18	Bipolar disorder;
LIHC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.43	-0.37	8.68e-13	Breast cancer;
LIHC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.65	10.29	0.49	8.29e-22	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.56	8.42	0.41	1.04e-15	Height;
LIHC	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.29	-0.32	9.79e-10	Diastolic blood pressure;
LIHC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg02487422	chr3:49467188	NICN1	-0.44	-5.79	-0.3	1.63e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs3106136	0.778	rs1593554	chr4:95278501	C/T	cg11021082	chr4:95130006	SMARCAD1	0.38	6.48	0.33	3.16e-10	Capecitabine sensitivity;
LIHC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.9	15.24	0.64	2.16e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	0.99	6.88	0.35	2.8e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.51	5.8	0.3	1.55e-8	Primary sclerosing cholangitis;
LIHC	cis	rs16828019	0.852	rs12742803	chr1:41648131	G/A	cg03962019	chr1:41807865	NA	0.53	7.53	0.38	4.66e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25749165	chr10:75634242	CAMK2G	0.41	6.44	0.33	3.94e-10	Calcium levels;
LIHC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	6.28	0.32	1.04e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23043544	chr7:2124092	MAD1L1	-0.41	-6.61	-0.34	1.49e-10	Neuroticism;
LIHC	cis	rs244293	0.760	rs1990673	chr17:53050025	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-7.21	-0.36	3.52e-12	Menarche (age at onset);
LIHC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.62	5.75	0.3	2e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-12.55	-0.56	5.67e-30	Alzheimer's disease (late onset);
LIHC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.57	-7.51	-0.38	5.04e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.51	-8.54	-0.42	4.49e-16	Pubertal anthropometrics;
LIHC	cis	rs4728302	0.869	rs2042456	chr7:133580447	G/A	cg10665199	chr7:133106180	EXOC4	0.36	6.26	0.32	1.13e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.62	9.47	0.46	4.77e-19	Longevity;
LIHC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg20140201	chr2:241835670	C2orf54	-0.47	-6.4	-0.33	5.18e-10	Urinary metabolites;
LIHC	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.58	9.18	0.44	4.22e-18	Corneal astigmatism;
LIHC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.3	-0.37	2e-12	Response to antipsychotic treatment;
LIHC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.25	-0.32	1.24e-9	Total body bone mineral density;
LIHC	cis	rs16944613	0.510	rs4932350	chr15:91143438	A/G	cg26821196	chr15:91095069	CRTC3	0.33	6.22	0.32	1.44e-9	Colorectal cancer;
LIHC	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.37	7.61	0.38	2.65e-13	Sitting height ratio;
LIHC	cis	rs1975974	1.000	rs7224508	chr17:21722352	T/A	cg18423549	chr17:21743878	NA	-0.46	-6.08	-0.31	3.28e-9	Psoriasis;
LIHC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.85	-15.29	-0.64	1.41e-40	Menopause (age at onset);
LIHC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.04	17.13	0.68	6.37e-48	Nonalcoholic fatty liver disease;
LIHC	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg21100191	chr22:23484243	RTDR1	0.88	15.68	0.65	4.01e-42	Bone mineral density;
LIHC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.22	-0.41	4.22e-15	Gut microbiome composition (summer);
LIHC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.79	-0.3	1.56e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.57	7.81	0.39	7.31e-14	Eotaxin levels;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg01339444	chr6:118972232	C6orf204	0.59	5.93	0.31	7.53e-9	Diastolic blood pressure;
LIHC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.78	0.54	4.11e-27	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.37	0.41	1.45e-15	Eotaxin levels;
LIHC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.19e-9	Bipolar disorder;
LIHC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg12661370	chr5:149340060	SLC26A2	0.49	6.03	0.31	4.27e-9	HIV-1 control;
LIHC	cis	rs3790645	1.000	rs369385	chr1:26893229	C/T	cg23229016	chr1:26872525	RPS6KA1	0.23	5.75	0.3	1.95e-8	Glucose homeostasis traits;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg20760063	chr17:41277580	NBR2;BRCA1	-0.42	-6.48	-0.33	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	cis	rs77861329	0.925	rs72964042	chr3:52088485	A/C	cg08692210	chr3:52188851	WDR51A	0.84	7.61	0.38	2.76e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.53	9.98	0.48	9.08e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.37	0.41	1.55e-15	Platelet count;
LIHC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.2e-13	Heart rate;
LIHC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg07451762	chr16:28383216	NA	0.41	7.29	0.37	2.1e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs611744	0.967	rs612265	chr8:109188650	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.64e-11	Dupuytren's disease;
LIHC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg03013999	chr17:37608204	MED1	0.36	6.1	0.31	2.85e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg20283391	chr11:68216788	NA	-0.39	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg05110241	chr16:68378359	PRMT7	-0.92	-10.27	-0.49	9.39e-22	Schizophrenia;
LIHC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	19.02	0.72	1.49e-55	Nonalcoholic fatty liver disease;
LIHC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.01	0.4	1.82e-14	Tonsillectomy;
LIHC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg15902774	chr15:75289873	SCAMP5	0.45	6.8	0.35	4.58e-11	Lung cancer;
LIHC	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.46	5.92	0.3	7.9e-9	Obesity (extreme);
LIHC	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg07689907	chr11:61582574	FADS1	0.41	5.96	0.31	6.2e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.53	8.39	0.41	1.29e-15	Glycated hemoglobin levels;
LIHC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.2	-0.48	1.64e-21	Blood metabolite levels;
LIHC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.48	8.58	0.42	3.43e-16	Colorectal cancer;
LIHC	cis	rs2292864	0.764	rs1969269	chr17:45335537	C/A	cg18085866	chr17:45331354	ITGB3	-0.62	-6.79	-0.34	4.89e-11	Left atrial antero-posterior diameter;
LIHC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.71	10.74	0.5	2.3e-23	Aortic root size;
LIHC	trans	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg10208301	chr11:6592745	DNHD1	0.47	6.73	0.34	7.31e-11	Coronary artery calcification;
LIHC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg01320579	chr17:75405842	SEPT9	0.5	6.52	0.33	2.53e-10	Airflow obstruction;
LIHC	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.46	6.73	0.34	7.19e-11	Dermatomyositis;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.43	7.22	0.36	3.34e-12	Breast cancer;
LIHC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg19318889	chr4:1322082	MAEA	0.46	6.49	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.78	10.09	0.48	3.97e-21	Body mass index;
LIHC	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.78	9.85	0.47	2.62e-20	Blood protein levels;
LIHC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.41	-7.95	-0.39	2.72e-14	Coronary artery disease;
LIHC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06002616	chr8:101225028	SPAG1	-0.35	-5.91	-0.3	8.14e-9	Atrioventricular conduction;
LIHC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg16262614	chr3:133464971	TF	0.32	7.01	0.35	1.3e-11	Iron status biomarkers (transferrin levels);
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.89	-0.35	2.66e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.62	11.58	0.53	2.19e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.65	11.6	0.53	1.83e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.51	6.28	0.32	1e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.41	6.59	0.34	1.62e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02972257	chr16:68554789	NA	0.59	6.35	0.32	6.99e-10	Ulcerative colitis;
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg09094615	chr8:17779997	PCM1	0.47	6.33	0.32	7.81e-10	Neuroticism;
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.54	-6.32	-0.32	8.33e-10	Alzheimer's disease;
LIHC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.72	-9.99	-0.48	8.79e-21	Pancreatic cancer;
LIHC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.77	-0.34	5.58e-11	Aortic root size;
LIHC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.76	-0.34	5.99e-11	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.38	-0.33	5.85e-10	Response to antipsychotic treatment;
LIHC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.28	0.58	9.81e-33	Cognitive test performance;
LIHC	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.51	6.91	0.35	2.44e-11	Pulse pressure;
LIHC	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg09508736	chr19:41385865	CYP2A7	-0.45	-7.59	-0.38	2.97e-13	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LIHC	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.68	0.5	3.67e-23	Hypertriglyceridemia;
LIHC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	0.71	11.84	0.54	2.5e-27	Testicular germ cell tumor;
LIHC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.08	9.74	0.47	5.89e-20	Diabetic retinopathy;
LIHC	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.15	-0.32	2.19e-9	Ulcerative colitis;
LIHC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.74	11.99	0.54	6.58e-28	Body mass index;
LIHC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.81	6.71	0.34	8.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.5	5.85	0.3	1.14e-8	Bladder cancer;
LIHC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg15691649	chr6:25882328	NA	-0.54	-7.75	-0.39	1.07e-13	Blood metabolite levels;
LIHC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.67	7.78	0.39	8.77e-14	Protein C levels;
LIHC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.13	-0.31	2.4e-9	Mean corpuscular volume;
LIHC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.61	8.73	0.43	1.12e-16	Aortic root size;
LIHC	cis	rs28489187	0.706	rs2268667	chr1:85793746	A/G	cg16011679	chr1:85725395	C1orf52	-0.46	-5.94	-0.31	7.01e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.42	-6.21	-0.32	1.54e-9	Calcium levels;
LIHC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-11.15	-0.52	7.67e-25	Platelet count;
LIHC	trans	rs7714584	1.000	rs114244137	chr5:150264753	C/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.41	-0.33	4.72e-10	Menarche (age at onset);
LIHC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.92	17.05	0.68	1.3e-47	Menopause (age at onset);
LIHC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.82	11.52	0.53	3.71e-26	Skin colour saturation;
LIHC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-7.93	-0.39	3.19e-14	Lymphocyte counts;
LIHC	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg20240347	chr1:204465584	NA	-0.33	-6.73	-0.34	7.01e-11	Schizophrenia;
LIHC	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.41	-6.23	-0.32	1.35e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.76	12.95	0.57	1.69e-31	Menarche (age at onset);
LIHC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg14067834	chr17:29058358	SUZ12P	0.68	6.79	0.34	5.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.73	13.14	0.58	3.29e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.01e-9	Systolic blood pressure;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02290350	chr8:58132656	NA	0.49	10.45	0.49	2.26e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20135002	chr11:47629003	NA	-0.57	-10.03	-0.48	6.14e-21	Subjective well-being;
LIHC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.25	-0.32	1.22e-9	Bipolar disorder;
LIHC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.26	-5.92	-0.3	7.79e-9	Longevity;Endometriosis;
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg13903179	chr13:21900392	NA	0.37	6.32	0.32	8.25e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg12798992	chr6:167411361	FGFR1OP	0.49	7.54	0.38	4.33e-13	Crohn's disease;
LIHC	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg04998671	chr14:104000505	TRMT61A	0.43	6.11	0.31	2.77e-9	Coronary artery disease;
LIHC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	6.79	0.34	4.91e-11	Breast cancer;
LIHC	cis	rs11711311	0.712	rs4682139	chr3:113331859	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.36	-6.3	-0.32	9.1e-10	IgG glycosylation;
LIHC	cis	rs9309473	0.948	rs7566385	chr2:73756817	G/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.95	-0.35	1.87e-11	Metabolite levels;
LIHC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg18016565	chr1:150552671	MCL1	0.53	10.02	0.48	6.73e-21	Melanoma;
LIHC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.79	9.79	0.47	4.2e-20	Morning vs. evening chronotype;
LIHC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg20387954	chr3:183756860	HTR3D	0.27	5.85	0.3	1.13e-8	Anterior chamber depth;
LIHC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.53	-0.46	3.11e-19	Coronary artery disease;
LIHC	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.4	7.56	0.38	3.82e-13	Height;
LIHC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.45	-8.73	-0.43	1.14e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7129220	0.588	rs61878585	chr11:10101987	C/T	cg01453529	chr11:10209919	SBF2	-0.39	-6.97	-0.35	1.62e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg23461800	chr14:103021989	NA	0.4	6.12	0.31	2.54e-9	Platelet count;
LIHC	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg18016565	chr1:150552671	MCL1	-0.5	-10.32	-0.49	6.68e-22	Tonsillectomy;
LIHC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.44	6.61	0.34	1.51e-10	Post bronchodilator FEV1;
LIHC	trans	rs2073499	0.935	rs57842657	chr3:50227787	T/A	cg21659725	chr3:3221576	CRBN	0.6	6.64	0.34	1.24e-10	Schizophrenia;
LIHC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.4	6.41	0.33	4.74e-10	Red blood cell count;
LIHC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.49	8.09	0.4	1.06e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg06640241	chr16:89574553	SPG7	0.66	10.62	0.5	5.89e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg03854865	chr6:26224070	HIST1H3E	0.71	7.81	0.39	7.07e-14	Gout;Renal underexcretion gout;
LIHC	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.79	-12.87	-0.57	3.65e-31	Morning vs. evening chronotype;
LIHC	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg18121669	chr1:26560928	CCDC21	-0.49	-7.24	-0.36	3.02e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-6.88	-0.35	2.83e-11	Alzheimer's disease (survival time);
LIHC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.75	0.34	6.21e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.45	-6.88	-0.35	2.9100000000000002e-11	Cognitive function;
LIHC	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.14	-0.32	2.27e-9	Neuroticism;
LIHC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg14393609	chr7:65229607	NA	-0.35	-5.77	-0.3	1.76e-8	Aortic root size;
LIHC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-7.59	-0.38	3.1e-13	Morning vs. evening chronotype;
LIHC	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.67	6.78	0.34	5.26e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.65	0.34	1.14e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13198984	chr17:80129470	CCDC57	-0.33	-5.83	-0.3	1.26e-8	Life satisfaction;
LIHC	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.76	11.7	0.53	7.91e-27	Eye color traits;
LIHC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-0.86	-10.74	-0.5	2.22e-23	Blood pressure (smoking interaction);
LIHC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg17750252	chr2:136567154	LCT	0.33	5.76	0.3	1.87e-8	Mosquito bite size;
LIHC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	7.99	0.4	2.12e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.47	5.86	0.3	1.12e-8	Alzheimer's disease;
LIHC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17554472	chr22:41940697	POLR3H	-0.53	-5.86	-0.3	1.08e-8	Vitiligo;
LIHC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.52	-0.53	3.72e-26	Coronary artery disease;
LIHC	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg16583315	chr14:65563665	MAX	-0.4	-8.17	-0.4	5.92e-15	Obesity-related traits;
LIHC	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.53	-10.87	-0.51	7.81e-24	Late-onset Alzheimer's disease;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.78	0.5	1.63e-23	Lymphocyte counts;
LIHC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	1.0	8.02	0.4	1.66e-14	Arsenic metabolism;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05834845	chr3:195489306	MUC4	-0.64	-9.69	-0.46	9.09e-20	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.47	-6.56	-0.33	2.04e-10	Breast cancer;
LIHC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.64	8.69	0.43	1.5e-16	Neutrophil percentage of white cells;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.04	-0.31	4.08e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.0	0.54	6.16e-28	Motion sickness;
LIHC	cis	rs507080	0.961	rs520543	chr11:118538157	G/A	cg04173919	chr11:118528438	PHLDB1	0.33	6.2	0.32	1.67e-9	Serum metabolite levels;
LIHC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg27478167	chr7:817139	HEATR2	-0.41	-5.82	-0.3	1.38e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs864643	0.891	rs661366	chr3:39561348	G/T	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg02376097	chr19:46275166	DMPK	-0.45	-6.92	-0.35	2.23e-11	Coronary artery disease;
LIHC	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg19773385	chr1:10388646	KIF1B	-0.38	-6.71	-0.34	8.26e-11	Hepatocellular carcinoma;
LIHC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.34	6.97	0.35	1.64e-11	Renal cell carcinoma;
LIHC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg13628971	chr7:2884303	GNA12	0.38	6.06	0.31	3.6e-9	Height;
LIHC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	Monocyte percentage of white cells;
LIHC	cis	rs4742903	0.584	rs10217250	chr9:106911633	A/T	cg14250997	chr9:106856677	SMC2	0.38	6.71	0.34	7.95e-11	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-7.48	-0.37	6.37e-13	Obesity-related traits;
LIHC	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg05353290	chr17:79219831	SLC38A10	0.39	5.93	0.31	7.42e-9	Frontotemporal dementia;
LIHC	cis	rs3015497	0.789	rs7147956	chr14:51142605	G/A	cg09863266	chr14:51125203	SAV1	-0.39	-6.21	-0.32	1.52e-9	Mean platelet volume;
LIHC	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	0.54	7.08	0.36	8.26e-12	Pulse pressure;
LIHC	cis	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg21605333	chr4:119757512	SEC24D	0.97	8.11	0.4	9.41e-15	Cannabis dependence symptom count;
LIHC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-11.92	-0.54	1.24e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs986417	1.000	rs1272688	chr14:60920718	T/C	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs2384207	0.789	rs7137793	chr12:113658124	T/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.51	6.19	0.32	1.71e-9	Response to fenofibrate (adiponectin levels);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27438756	chr1:74663921	TNNI3K;FPGT;LRRIQ3	-0.55	-7.8	-0.39	7.78e-14	Pancreatic cancer;
LIHC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	19.01	0.72	1.71e-55	Testicular germ cell tumor;
LIHC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.72	0.57	1.32e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.16	-0.36	5.12e-12	Reticulocyte count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26794364	chr3:9691143	MTMR14	0.44	6.45	0.33	3.77e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.44	-7.49	-0.38	5.83e-13	Lung cancer;
LIHC	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.27	-0.32	1.07e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.73	-0.3	2.17e-8	Response to amphetamines;
LIHC	trans	rs920065	0.713	rs13323468	chr3:5934638	G/T	cg25753567	chr19:1420366	DAZAP1	-0.58	-6.16	-0.32	2.08e-9	Excessive daytime sleepiness;
LIHC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg21609526	chr1:3105151	PRDM16	-0.3	-6.67	-0.34	1.04e-10	Migraine;
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	cis	rs797680	0.856	rs6685271	chr1:93634590	C/A	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.03	-0.31	4.16e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg18964960	chr10:1102726	WDR37	0.67	6.29	0.32	9.47e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs797680	0.856	rs637646	chr1:93716383	A/C	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.89	0.3	9.29e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg05896524	chr21:47604654	C21orf56	0.45	6.78	0.34	5.34e-11	Testicular germ cell tumor;
LIHC	cis	rs10792665	0.649	rs948182	chr11:82746231	C/T	cg24227371	chr11:82718527	RAB30	-0.39	-9.27	-0.45	2.16e-18	Obesity-related traits;
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26240231	chr7:1148101	C7orf50	-0.39	-5.94	-0.31	6.84e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg02344993	chr17:57696989	CLTC	0.7	11.84	0.54	2.48e-27	Hemoglobin concentration;
LIHC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.49	-6.86	-0.35	3.26e-11	Prostate cancer;
LIHC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.07	0.4	1.22e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.49	-8.26	-0.41	3.17e-15	Cocaine dependence;
LIHC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.81	0.39	6.87e-14	Schizophrenia;
LIHC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.59	-0.38	3.05e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-8.87	-0.43	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg07541023	chr7:19748670	TWISTNB	0.42	6.13	0.31	2.42e-9	Thyroid stimulating hormone;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.51	-7.11	-0.36	6.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20135002	chr11:47629003	NA	-0.56	-9.24	-0.45	2.72e-18	Subjective well-being;
LIHC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg07061783	chr6:25882402	NA	-0.46	-6.41	-0.33	4.91e-10	Blood metabolite levels;
LIHC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-6.81	-0.35	4.38e-11	Type 2 diabetes;
LIHC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.39	-5.77	-0.3	1.81e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.38	-6.05	-0.31	3.87e-9	Glioblastoma;
LIHC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.51	-9.06	-0.44	1.01e-17	Total body bone mineral density;
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.72	-9.07	-0.44	9.56e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg21361702	chr7:150065534	REPIN1	0.54	7.51	0.38	5.12e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.49	0.33	2.93e-10	Ileal carcinoids;
LIHC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	11.52	0.53	3.75e-26	Cognitive test performance;
LIHC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.47	8.17	0.4	6.14e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.45	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs16958440	0.867	rs78854354	chr18:44666924	C/G	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg10820045	chr2:198174542	NA	-0.47	-7.2	-0.36	3.92e-12	Dermatomyositis;
LIHC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.23	0.32	1.34e-9	Schizophrenia;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00815214	chr21:47717953	NA	0.36	5.86	0.3	1.07e-8	Testicular germ cell tumor;
LIHC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.85	13.13	0.58	3.7e-32	Multiple sclerosis;
LIHC	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg19773385	chr1:10388646	KIF1B	-0.41	-7.45	-0.37	7.79e-13	Hepatocellular carcinoma;
LIHC	trans	rs1144333	0.655	rs58722308	chr1:76423525	A/G	cg10154597	chr10:134910271	GPR123	0.31	6.11	0.31	2.69e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11800820	0.555	rs12565947	chr1:246650225	T/C	cg16700716	chr1:246684329	NA	-0.43	-7.58	-0.38	3.2e-13	Obesity-related traits;
LIHC	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.81	-0.39	6.99e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.22	-6.12	-0.31	2.57e-9	Type 2 diabetes;
LIHC	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg21231739	chr4:1642635	FAM53A	-0.38	-5.98	-0.31	5.67e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.05	-9.67	-0.46	1.03e-19	Diabetic retinopathy;
LIHC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02251663	chr11:14281053	SPON1	0.45	6.2	0.32	1.59e-9	Mitochondrial DNA levels;
LIHC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.79	13.36	0.59	4.81e-33	Parkinson's disease;
LIHC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.58	0.34	1.79e-10	Bipolar disorder;
LIHC	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.66	0.46	1.08e-19	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.71	10.58	0.5	8.11e-23	Aortic root size;
LIHC	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-5.84	-0.3	1.19e-8	Blood metabolite levels;
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.63	10.1	0.48	3.77e-21	Longevity;
LIHC	cis	rs2766692	1.000	rs2766690	chr14:100682154	A/G	cg14866419	chr14:100704911	YY1	-0.44	-5.99	-0.31	5.38e-9	Electroencephalographic traits in alcoholism;
LIHC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	17.13	0.68	6.05e-48	Lung cancer in ever smokers;
LIHC	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.65	0.46	1.18e-19	Morning vs. evening chronotype;
LIHC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.96e-11	Rheumatoid arthritis;
LIHC	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.99	-0.31	5.35e-9	Tuberculosis;
LIHC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.95	14.93	0.63	3.78e-39	Metabolic syndrome;
LIHC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg03959625	chr15:84868606	LOC388152	0.43	6.0	0.31	5.03e-9	Schizophrenia;
LIHC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.26	-0.41	3.31e-15	Chronic sinus infection;
LIHC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.45	-7.4	-0.37	1.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02184643	chr11:10879647	ZBED5	-0.48	-6.23	-0.32	1.34e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.71	-0.71	2.82e-54	Height;
LIHC	cis	rs12931792	0.682	rs12373113	chr16:30187513	C/T	cg17640201	chr16:30407289	ZNF48	0.39	6.45	0.33	3.84e-10	Tonsillectomy;
LIHC	cis	rs6782228	0.585	rs2712392	chr3:128424257	G/A	cg16766828	chr3:128327626	NA	-0.36	-5.79	-0.3	1.55e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs12249377	0.519	rs66650915	chr10:92592468	T/C	cg14313238	chr10:92632228	RPP30	0.38	6.37	0.33	5.94e-10	White matter microstructure (global fractional anisotropy);
LIHC	trans	rs7922314	0.764	rs12220702	chr10:64628704	G/A	cg06816054	chr8:27695695	PBK	0.56	6.14	0.32	2.24e-9	Cutaneous psoriasis;
LIHC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08677398	chr8:58056175	NA	0.4	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.9	15.72	0.65	2.67e-42	Parkinson's disease;
LIHC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.55	0.38	3.99e-13	Electroencephalogram traits;
LIHC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.72	-13.22	-0.58	1.56e-32	Mortality in heart failure;
LIHC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.49	-8.59	-0.42	3.08e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg17724175	chr1:150552817	MCL1	-0.36	-6.82	-0.35	4.1e-11	Tonsillectomy;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.92	-0.3	7.93e-9	Aortic root size;
LIHC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19723775	chr5:179050963	HNRNPH1	0.42	6.54	0.33	2.25e-10	Lung cancer;
LIHC	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.59	8.67	0.42	1.71e-16	Recombination rate (females);
LIHC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.43	0.37	8.68e-13	Aortic root size;
LIHC	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.61	9.95	0.47	1.21e-20	Schizophrenia;
LIHC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg02993280	chr1:107599747	PRMT6	0.59	9.32	0.45	1.46e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.58	8.64	0.42	2.17e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.43	6.02	0.31	4.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2122469	0.655	rs17603934	chr8:20576344	A/G	cg23188819	chr8:21947203	FAM160B2	-0.57	-6.04	-0.31	3.93e-9	Serum tamsulosin hydrochloride concentration;
LIHC	trans	rs1814175	0.588	rs4076322	chr11:49745094	G/A	cg03929089	chr4:120376271	NA	-0.86	-16.84	-0.67	9.09e-47	Height;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.15	-0.32	2.2e-9	Total body bone mineral density;
LIHC	cis	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg03213289	chr20:61660250	NA	0.53	9.18	0.44	4.2e-18	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.62	-9.63	-0.46	1.4e-19	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.58	10.07	0.48	4.65e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1555399	1.000	rs1555398	chr14:67984373	C/G	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.81	-0.3	1.46e-8	Parkinson's disease;
LIHC	cis	rs986417	0.748	rs10133403	chr14:60945298	C/T	cg27398547	chr14:60952738	C14orf39	0.81	9.39	0.45	8.69e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs11212260	0.655	rs11212198	chr11:107263130	T/C	cg25435332	chr11:107328525	CWF19L2	0.8	8.44	0.42	9.23e-16	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15392845	chr14:73360933	DPF3	0.42	6.36	0.33	6.28e-10	Cognitive function;
LIHC	cis	rs7551222	0.749	rs11240761	chr1:204566700	C/A	cg20240347	chr1:204465584	NA	-0.3	-6.2	-0.32	1.59e-9	Schizophrenia;
LIHC	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.4	8.55	0.42	4.13e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.49	8.49	0.42	6.2e-16	Methadone dose in opioid dependence;
LIHC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.55	11.39	0.52	1.05e-25	Urate levels;
LIHC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.41	6.22	0.32	1.47e-9	Educational attainment;
LIHC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	16.14	0.66	5.71e-44	Lung cancer in ever smokers;
LIHC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.65	-7.54	-0.38	4.39e-13	Neuroticism;
LIHC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg10587741	chr22:38071170	LGALS1	0.68	11.72	0.54	6.64e-27	Fat distribution (HIV);
LIHC	cis	rs11031096	0.655	rs35898891	chr11:4211112	G/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.87	-0.3	1.05e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.95	-0.31	6.49e-9	Systemic lupus erythematosus;
LIHC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-8.08	-0.4	1.09e-14	Longevity;
LIHC	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-10.88	-0.51	6.98e-24	Brugada syndrome;
LIHC	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.77	12.68	0.57	1.88e-30	Anterior chamber depth;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07194495	chr7:148958859	ZNF783	0.4	7.0	0.35	1.38e-11	Cognitive function;
LIHC	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg10381502	chr11:71823885	C11orf51	-1.0	-8.62	-0.42	2.6e-16	Severe influenza A (H1N1) infection;
LIHC	trans	rs4714291	0.792	rs9471241	chr6:40080211	C/T	cg02267698	chr19:7991119	CTXN1	-0.41	-6.91	-0.35	2.42e-11	Strep throat;
LIHC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.04	-0.31	3.92e-9	Blood pressure;
LIHC	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.6	8.19	0.41	5.18e-15	Breast cancer;
LIHC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg03647239	chr10:116582469	FAM160B1	0.46	6.64	0.34	1.21e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.8	-10.65	-0.5	4.69e-23	Blood pressure (smoking interaction);
LIHC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.7	-9.69	-0.46	8.81e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04751069	chr16:89787483	ZNF276;C16orf7	0.51	6.2	0.32	1.6e-9	Hepatitis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23679085	chr3:183892773	AP2M1	0.45	6.69	0.34	9.35e-11	Pancreatic cancer;
LIHC	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.48	8.81	0.43	6.4e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.03	-0.51	2.07e-24	Response to antipsychotic treatment;
LIHC	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.5	7.94	0.39	2.96e-14	Corneal astigmatism;
LIHC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.35	-9.28	-0.45	2.03e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.95	-12.12	-0.55	2.25e-28	Body mass index;
LIHC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.45	7.79	0.39	8.14e-14	Mean corpuscular volume;
LIHC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.6	-8.45	-0.42	8.31e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22854549	chr19:5904785	VMAC;NDUFA11	0.53	7.01	0.35	1.25e-11	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg21724239	chr8:58056113	NA	0.48	6.29	0.32	9.98e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.99	-0.31	5.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.59	-8.02	-0.4	1.65e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.4	-5.87	-0.3	1.05e-8	Multiple sclerosis;
LIHC	cis	rs611744	0.967	rs2212704	chr8:109198415	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs2279817	0.818	rs71644062	chr1:17980530	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.11	-0.36	6.68e-12	Neuroticism;
LIHC	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg01444801	chr10:135216882	MTG1	0.66	9.88	0.47	2.12e-20	Systemic lupus erythematosus;
LIHC	cis	rs9896850	0.513	rs10445407	chr17:79261809	A/C	cg08034816	chr17:79219380	SLC38A10	-0.37	-6.23	-0.32	1.36e-9	Frontotemporal dementia;
LIHC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg18887096	chr2:219472410	PLCD4	0.36	6.33	0.32	7.86e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.5	7.83	0.39	6.24e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.38	0.59	4.07e-33	Diabetic kidney disease;
LIHC	cis	rs1185460	0.565	rs2276060	chr11:118919132	G/A	cg23280166	chr11:118938394	VPS11	-0.43	-5.81	-0.3	1.44e-8	Coronary artery disease;
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.4	7.83	0.39	6.01e-14	Renal cell carcinoma;
LIHC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.55	8.66	0.42	1.94e-16	Menarche (age at onset);
LIHC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.43	-6.13	-0.31	2.4e-9	Height;
LIHC	cis	rs62458065	1.000	rs10275978	chr7:32466719	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.65	-7.43	-0.37	8.69e-13	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.08	0.4	1.09e-14	Bladder cancer;
LIHC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	0.92	16.29	0.66	1.43e-44	Parkinson's disease;
LIHC	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs2279817	0.735	rs71644063	chr1:17987274	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.22	-0.36	3.45e-12	Neuroticism;
LIHC	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.56	-9.06	-0.44	1.06e-17	Colorectal cancer;
LIHC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.51	-8.13	-0.4	8.13e-15	Diastolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02037503	chr14:23540729	ACIN1	0.41	6.38	0.33	5.85e-10	Cognitive function;
LIHC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.39	-5.97	-0.31	5.98e-9	Blood pressure (smoking interaction);
LIHC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.19	-0.32	1.69e-9	Type 2 diabetes;
LIHC	cis	rs7188697	0.922	rs1549607	chr16:58583975	A/G	cg02549819	chr16:58548995	SETD6	0.48	7.59	0.38	3.16e-13	QT interval;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg14536467	chr19:17412305	ABHD8	0.36	6.2	0.32	1.67e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg21231739	chr4:1642635	FAM53A	-0.38	-6.0	-0.31	4.9e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg03785755	chr6:26196794	NA	0.5	5.88	0.3	9.89e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg02290350	chr8:58132656	NA	0.39	8.4	0.41	1.19e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.54e-9	Alzheimer's disease;
LIHC	cis	rs61677309	1.000	rs12576947	chr11:118158055	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.43	-10.27	-0.49	9.53e-22	Type 2 diabetes;
LIHC	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.44	-8.27	-0.41	2.98e-15	Vitamin D levels;
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.73	10.28	0.49	8.78e-22	Menarche (age at onset);
LIHC	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.64	10.24	0.48	1.24e-21	Obesity-related traits;
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.71	10.17	0.48	2.1e-21	Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.4	0.8	7.17e-77	Prudent dietary pattern;
LIHC	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-6.03	-0.31	4.26e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02290350	chr8:58132656	NA	0.47	8.77	0.43	8.27e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.49	0.33	2.93e-10	Heart rate;
LIHC	trans	rs2211698	1.000	rs58861465	chr21:35827067	C/T	cg18044562	chr7:50468399	IKZF1	0.5	7.2	0.36	3.82e-12	Cancer;
LIHC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.96	-0.35	1.71e-11	Response to antipsychotic treatment;
LIHC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.81	10.06	0.48	5.15e-21	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00920043	chr1:11333412	UBIAD1	0.39	6.43	0.33	4.2e-10	Cognitive function;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg14671364	chr1:107599128	PRMT6	0.42	5.9	0.3	8.68e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.5	6.28	0.32	1.04e-9	Migraine;Coronary artery disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04305134	chr10:75173374	ANXA7	-0.48	-6.58	-0.34	1.78e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-11.33	-0.52	1.73e-25	Platelet count;
LIHC	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.93	-0.31	7.52e-9	Bipolar disorder;
LIHC	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.95	10.52	0.49	1.35e-22	Neuroticism;
LIHC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg00292662	chr22:38071168	LGALS1	0.38	6.45	0.33	3.71e-10	Fat distribution (HIV);
LIHC	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.42e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6584283	0.846	rs11190135	chr10:101286848	A/G	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.86	-0.3	1.06e-8	Ulcerative colitis;
LIHC	cis	rs1499280	1.000	rs2059202	chr5:52097183	A/G	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.37	-6.17	-0.32	1.9e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06056004	chr5:44809616	MRPS30	0.45	6.48	0.33	3.25e-10	Pancreatic cancer;
LIHC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.48	-6.57	-0.33	1.88e-10	Osteoporosis;
LIHC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.69	-9.14	-0.44	5.69e-18	Mean platelet volume;
LIHC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.61	-0.46	1.65e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.66	11.31	0.52	2.01e-25	Menopause (age at onset);
LIHC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg00601450	chr5:74908170	NA	0.48	6.88	0.35	2.85e-11	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.09	0.79	1.13e-75	Prudent dietary pattern;
LIHC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02290350	chr8:58132656	NA	0.42	8.88	0.43	3.83e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg16088116	chr21:44841560	SIK1	-0.41	-6.29	-0.32	9.47e-10	Coronary artery disease;
LIHC	trans	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg10756647	chr7:56101905	PSPH	-1.04	-12.49	-0.56	9.63e-30	Diabetic kidney disease;
LIHC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg25356066	chr3:128598488	ACAD9	0.56	7.77	0.39	8.97e-14	IgG glycosylation;
LIHC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.99e-10	Personality dimensions;
LIHC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg27490568	chr2:178487706	NA	0.72	9.4	0.45	8.25e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.62	8.7	0.43	1.37e-16	Skin colour saturation;
LIHC	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.38	8.77	0.43	8.72e-17	Blood protein levels;
LIHC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.44	-6.74	-0.34	6.89e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.77	-0.3	1.8e-8	Crohn's disease;
LIHC	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.62	-8.3	-0.41	2.37e-15	Major depressive disorder;
LIHC	cis	rs1198430	0.925	rs1207124	chr1:23760408	A/G	cg19827787	chr1:23763612	ASAP3	0.35	6.45	0.33	3.73e-10	Total cholesterol levels;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.81	12.62	0.56	3.05e-30	Longevity;
LIHC	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.55	8.41	0.41	1.12e-15	Height;
LIHC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.81	8.68	0.43	1.61e-16	Vitiligo;
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg21486233	chr12:29375141	FAR2	0.32	6.34	0.32	7.08e-10	QT interval;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.56	0.62	1.09e-37	Prudent dietary pattern;
LIHC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.03	-0.36	1.12e-11	Obesity-related traits;
LIHC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-23.53	-0.79	1.77e-73	Height;
LIHC	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.2	-0.48	1.67e-21	Ear protrusion;
LIHC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.74	-10.47	-0.49	1.94e-22	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.56	-0.33	2e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg10820045	chr2:198174542	NA	-0.54	-8.63	-0.42	2.41e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.77	0.43	8.85e-17	Bipolar disorder;
LIHC	cis	rs72627509	0.638	rs1608165	chr4:57894717	G/C	cg26694713	chr4:57773883	REST	0.65	9.02	0.44	1.39e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.74	-9.6	-0.46	1.77e-19	Bone mineral density;
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg05697976	chr12:29376483	FAR2	0.35	7.13	0.36	6.01e-12	QT interval;
LIHC	cis	rs12079745	0.793	rs60011235	chr1:169254727	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-7.4	-0.37	1.04e-12	QT interval;
LIHC	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.69	10.21	0.48	1.54e-21	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.33	-5.89	-0.3	9.16e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	10.66	0.5	4.33e-23	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	0.94	15.98	0.65	2.44e-43	Testicular germ cell tumor;
LIHC	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.45	-7.64	-0.38	2.16e-13	Prevalent atrial fibrillation;
LIHC	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg20991723	chr1:152506922	NA	0.58	10.26	0.49	1.06e-21	Hair morphology;
LIHC	trans	rs6934970	1.000	rs10457251	chr6:113060793	C/T	cg09308777	chr6:169852575	NA	0.58	6.06	0.31	3.67e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.78	-9.49	-0.46	4.23e-19	Mean platelet volume;
LIHC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.42	-0.37	9.26e-13	Psoriasis;
LIHC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.83	-15.82	-0.65	1.04e-42	Height;
LIHC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.12	0.31	2.54e-9	Blood metabolite levels;
LIHC	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.29	-7.2	-0.36	3.78e-12	Colorectal cancer;
LIHC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.0	-0.31	4.89e-9	Menarche (age at onset);
LIHC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	21.86	0.76	6.53e-67	Body mass index (adult);
LIHC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.98	-0.44	1.88e-17	Type 2 diabetes;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg13152130	chr6:118910203	C6orf204	-0.65	-7.34	-0.37	1.61e-12	Diastolic blood pressure;
LIHC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.68	12.18	0.55	1.36e-28	Lewy body disease;
LIHC	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-18.97	-0.72	2.54e-55	Height;
LIHC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-7.42	-0.37	9.28e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs8084351	0.577	rs10469018	chr18:50628199	T/G	cg24270629	chr18:50823537	DCC	0.43	6.48	0.33	3.26e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.61	8.97	0.44	1.94e-17	Recombination rate (females);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19848599	chr5:131658161	SLC22A4	-0.42	-6.3	-0.32	9.11e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	15.15	0.63	4.92e-40	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.52	7.83	0.39	6.37e-14	Lymphocyte counts;
LIHC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.71	-0.38	1.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12810548	chr4:53579237	SNORA26;KIAA0114	0.47	6.63	0.34	1.3100000000000001e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-8.42	-0.41	1.04e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.35	-7.57	-0.38	3.59e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.48	8.59	0.42	3.22e-16	Colorectal cancer;
LIHC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg13385521	chr17:29058706	SUZ12P	-0.58	-5.82	-0.3	1.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4853036	0.904	rs62152020	chr2:70147664	C/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.25	-0.32	1.23e-9	Colorectal or endometrial cancer;
LIHC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	5.86	0.3	1.08e-8	Tonsillectomy;
LIHC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.33	6.1	0.31	2.95e-9	Height;
LIHC	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.73	-13.04	-0.58	7.77e-32	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.64	7.32	0.37	1.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.55	0.42	4.13e-16	Initial pursuit acceleration;
LIHC	trans	rs6011368	0.749	rs4809418	chr20:62915231	G/A	cg13869341	chr1:15865	WASH5P	-0.42	-7.14	-0.36	5.8e-12	Clozapine-induced cytotoxicity;
LIHC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.54	8.5	0.42	6.04e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg16145915	chr7:1198662	ZFAND2A	0.35	7.12	0.36	6.4e-12	Bronchopulmonary dysplasia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09288320	chr2:210994670	C2orf67	0.28	6.35	0.32	6.79e-10	Cognitive function;
LIHC	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.34	0.32	7.41e-10	Systolic blood pressure;
LIHC	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.18	0.48	1.88e-21	Diisocyanate-induced asthma;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18905668	chr11:18388147	GTF2H1	0.35	6.39	0.33	5.5e-10	Bilirubin levels;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs918629	0.567	rs1057964	chr5:95235627	T/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.94	-0.35	2.03e-11	IgG glycosylation;
LIHC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.44	-6.74	-0.34	6.69e-11	Longevity;Endometriosis;
LIHC	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	11.35	0.52	1.54e-25	Coronary artery disease;
LIHC	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	6.53	0.33	2.36e-10	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.73	12.86	0.57	3.9e-31	Eosinophil percentage of white cells;
LIHC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg09323728	chr8:95962352	TP53INP1	0.3	5.99	0.31	5.36e-9	Type 2 diabetes;
LIHC	cis	rs939574	1.000	rs939574	chr2:220118531	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.94	-10.18	-0.48	1.94e-21	Platelet distribution width;
LIHC	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg02811702	chr13:24901961	NA	0.25	6.42	0.33	4.69e-10	Obesity-related traits;
LIHC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.52	0.42	5.28e-16	Birth weight;
LIHC	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.61	-0.59	5.31e-34	Coffee consumption (cups per day);
LIHC	cis	rs6442522	0.606	rs3846128	chr3:15492150	C/T	cg16303742	chr3:15540471	COLQ	0.39	6.37	0.33	6.05e-10	Uric acid levels;
LIHC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg12658694	chr1:38397304	INPP5B	0.42	6.1	0.31	2.94e-9	Coronary artery disease;
LIHC	cis	rs6977660	0.941	rs6953957	chr7:19820560	A/G	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.45	6.34	0.32	7.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	13.33	0.58	6.13e-33	Lung cancer in ever smokers;
LIHC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.65	10.84	0.51	1.01e-23	Response to diuretic therapy;
LIHC	cis	rs988712	0.622	rs2030323	chr11:27728539	A/C	cg18117895	chr11:27722066	BDNF	-0.49	-6.85	-0.35	3.39e-11	Obesity;
LIHC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.29	16.87	0.67	7.21e-47	Diabetic kidney disease;
LIHC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.33	-0.76	8.44e-65	Height;
LIHC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.38	5.83	0.3	1.28e-8	Menarche (age at onset);
LIHC	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg11367502	chr7:22862612	TOMM7	0.57	9.29	0.45	1.84e-18	Fibrinogen levels;
LIHC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.3	6.82	0.35	4.05e-11	Blood metabolite ratios;
LIHC	cis	rs611744	0.967	rs651814	chr8:109196571	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.86	14.76	0.62	1.65e-38	Longevity;
LIHC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04221910	chr5:616842	CEP72	-0.4	-7.53	-0.38	4.48e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg03146154	chr1:46216737	IPP	-0.38	-6.2	-0.32	1.59e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg18357645	chr12:58087776	OS9	-0.44	-6.77	-0.34	5.59e-11	Multiple sclerosis;
LIHC	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.91	-0.39	3.49e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.45	8.32	0.41	2.12e-15	Prudent dietary pattern;
LIHC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.9	-0.35	2.6e-11	Gut microbiome composition (summer);
LIHC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.48	-0.46	4.42e-19	Total cholesterol levels;
LIHC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.04	-0.48	5.96e-21	Platelet count;
LIHC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg02070205	chr10:30722105	MAP3K8	-0.44	-5.93	-0.31	7.37e-9	Inflammatory bowel disease;
LIHC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.58	-11.33	-0.52	1.73e-25	Coronary artery disease;
LIHC	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.53	8.61	0.42	2.65e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg08499158	chr17:42289980	UBTF	-0.41	-6.63	-0.34	1.32e-10	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.45	0.33	3.92e-10	Body mass index;
LIHC	cis	rs611744	0.967	rs673015	chr8:109191669	C/T	cg21045802	chr8:109455806	TTC35	0.54	9.35	0.45	1.15e-18	Dupuytren's disease;
LIHC	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.6	-10.23	-0.48	1.3e-21	Colorectal cancer;
LIHC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.81	0.54	3.03e-27	Cognitive test performance;
LIHC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.45	7.64	0.38	2.23e-13	Response to temozolomide;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16472210	chr3:81810621	GBE1	-0.43	-6.44	-0.33	3.95e-10	Pancreatic cancer;
LIHC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.58	7.92	0.39	3.33e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs2997447	0.846	rs3008420	chr1:26401403	C/T	cg19633962	chr1:26362018	EXTL1	-0.53	-6.0	-0.31	5.11e-9	QRS complex (12-leadsum);
LIHC	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg05590025	chr7:65112418	INTS4L2	0.62	6.79	0.34	4.9e-11	Diabetic kidney disease;
LIHC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-10.1	-0.48	3.73e-21	Electrocardiographic conduction measures;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16458507	chr12:113376293	OAS3	-0.46	-7.07	-0.36	9.02e-12	Pancreatic cancer;
LIHC	cis	rs7116495	0.737	rs693648	chr11:71570446	G/A	cg26138937	chr11:71823887	C11orf51	0.69	6.62	0.34	1.4e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.1	-0.48	3.72e-21	Response to antipsychotic treatment;
LIHC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.99	0.4	2.1e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.83	-0.3	1.25e-8	Total body bone mineral density;
LIHC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.68	-9.78	-0.47	4.41e-20	Mosquito bite size;
LIHC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	6.33	0.32	7.88e-10	Lung function (FEV1/FVC);
LIHC	trans	rs10411161	1.000	rs8108477	chr19:52364902	C/T	cg22319618	chr22:45562946	NUP50	-0.53	-7.16	-0.36	4.92e-12	Breast cancer;
LIHC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.38	-6.24	-0.32	1.31e-9	Monocyte count;
LIHC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.55	-7.47	-0.37	6.88e-13	Type 2 diabetes;
LIHC	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.35	-6.33	-0.32	7.7e-10	Blood pressure (smoking interaction);
LIHC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.73	0.5	2.43e-23	Smoking initiation;
LIHC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-10.21	-0.48	1.57e-21	Asthma;
LIHC	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.79	8.92	0.43	2.84e-17	Exhaled nitric oxide levels;
LIHC	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg03934865	chr2:198174659	NA	-0.45	-6.44	-0.33	4.06e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10503871	0.545	rs13253760	chr8:30503792	C/T	cg26383811	chr8:30366931	RBPMS	-0.4	-6.37	-0.33	6.13e-10	Metabolite levels  (X-11787);
LIHC	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg18192155	chr21:44258298	NA	0.45	7.12	0.36	6.5e-12	Information processing speed;
LIHC	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.63	9.87	0.47	2.26e-20	Response to antidepressants and depression;
LIHC	cis	rs507080	0.883	rs656575	chr11:118549908	T/G	cg04173919	chr11:118528438	PHLDB1	0.31	5.85	0.3	1.12e-8	Serum metabolite levels;
LIHC	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	7.52	0.38	4.87e-13	LDL cholesterol;
LIHC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.36	5.95	0.31	6.57e-9	Electroencephalogram traits;
LIHC	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.22	-5.88	-0.3	9.86e-9	Hepatitis;
LIHC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.35	6.03	0.31	4.19e-9	Parkinson's disease;
LIHC	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.93	0.31	7.28e-9	Educational attainment;
LIHC	cis	rs970821	0.900	rs10097319	chr8:124755313	C/T	cg00283535	chr8:124749564	ANXA13	0.37	6.04	0.31	4.02e-9	Breast cancer;
LIHC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg01652190	chr22:50026171	C22orf34	-0.34	-7.64	-0.38	2.2e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	7.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.65	-11.43	-0.53	7.72e-26	Height;
LIHC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.49	7.06	0.36	9.53e-12	Asthma;
LIHC	cis	rs263063	0.764	rs12979556	chr19:5076856	G/A	cg18473234	chr19:5097819	KDM4B	0.56	6.99	0.35	1.47e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.6	-10.34	-0.49	5.34e-22	Crohn's disease;
LIHC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.32	-6.51	-0.33	2.71e-10	Alcohol dependence;
LIHC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg26072250	chr5:443457	EXOC3;C5orf55	0.61	8.47	0.42	7.51e-16	Fat distribution (HIV);
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg12903224	chr12:29470962	FAR2	-0.42	-6.81	-0.35	4.43e-11	QT interval;
LIHC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.87	0.3	1.05e-8	Tonsillectomy;
LIHC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-7.61	-0.38	2.62e-13	Platelet count;
LIHC	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.43	6.0	0.31	5e-9	Tuberculosis;
LIHC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg03188948	chr7:1209495	NA	0.86	6.07	0.31	3.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.2	0.32	1.66e-9	Cognitive ability;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	10.28	0.49	8.94e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg03721293	chr16:90014378	DEF8	0.43	7.27	0.37	2.53e-12	Skin colour saturation;
LIHC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg07308232	chr7:1071921	C7orf50	-0.39	-6.1	-0.31	2.82e-9	Longevity;Endometriosis;
LIHC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg07117364	chr1:16154769	NA	-0.4	-5.88	-0.3	9.97e-9	Dilated cardiomyopathy;
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.73	-9.53	-0.46	2.98e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.52	-6.77	-0.34	5.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg17724175	chr1:150552817	MCL1	0.38	7.59	0.38	3.03e-13	Tonsillectomy;
LIHC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.38	5.93	0.31	7.25e-9	Lung cancer;
LIHC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.52	7.47	0.37	6.66e-13	Initial pursuit acceleration;
LIHC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.46	-5.99	-0.31	5.18e-9	Total body bone mineral density;
LIHC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.63	13.1	0.58	4.69e-32	Breast size;
LIHC	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.37	-6.51	-0.33	2.66e-10	IgG glycosylation;
LIHC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-1.04	-17.59	-0.69	8.92e-50	Monocyte percentage of white cells;
LIHC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.62	0.34	1.4e-10	Bipolar disorder;
LIHC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.72	-11.25	-0.52	3.46e-25	Longevity;
LIHC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.22e-11	Aortic root size;
LIHC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.48	-7.26	-0.37	2.66e-12	Cognitive function;
LIHC	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.45	-6.07	-0.31	3.34e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.51	8.27	0.41	3e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.07	11.23	0.52	4.09e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	10.59	0.5	7.32e-23	Alzheimer's disease (late onset);
LIHC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.99e-10	Personality dimensions;
LIHC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	11.38	0.52	1.15e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.43	-7.56	-0.38	3.72e-13	Aortic root size;
LIHC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg24879335	chr3:133465180	TF	0.28	6.36	0.33	6.58e-10	Iron status biomarkers;
LIHC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg02640540	chr1:67518911	SLC35D1	0.45	6.12	0.31	2.51e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs1075232	1.000	rs34959140	chr15:31725223	G/A	cg01030201	chr15:31746330	NA	-0.86	-6.64	-0.34	1.22e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.3	0.37	2.01e-12	Lung cancer;
LIHC	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.31	6.68	0.34	9.91e-11	Pulmonary function;
LIHC	cis	rs6733011	0.644	rs6719634	chr2:99460614	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.09	-0.31	2.96e-9	Bipolar disorder;
LIHC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.42	6.67	0.34	1.02e-10	Red blood cell count;
LIHC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.37	-5.97	-0.31	5.81e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.1	-0.58	4.87e-32	Type 2 diabetes;
LIHC	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	8.05	0.4	1.41e-14	Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.59	0.56	4.01e-30	Prudent dietary pattern;
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg18306943	chr3:40428807	ENTPD3	0.39	6.71	0.34	8.13e-11	Renal cell carcinoma;
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07021052	chr2:20871279	NA	-0.39	-7.0	-0.35	1.39e-11	Abdominal aortic aneurysm;
LIHC	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-9.93	-0.47	1.38e-20	Pediatric autoimmune diseases;
LIHC	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10420951	0.573	rs76184771	chr19:18567189	A/G	cg10790698	chr19:18539756	SSBP4	-0.43	-6.05	-0.31	3.87e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17817474	chr15:90809403	NGRN	0.43	6.75	0.34	6.39e-11	Cognitive function;
LIHC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg22676075	chr6:135203613	NA	0.37	6.14	0.32	2.3e-9	Red blood cell count;
LIHC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.48	0.67	2.53e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.42	-6.75	-0.34	6.26e-11	Blood pressure (smoking interaction);
LIHC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.44	6.02	0.31	4.57e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.08	-15.22	-0.64	2.63e-40	Corneal structure;
LIHC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.63	9.65	0.46	1.17e-19	Corneal astigmatism;
LIHC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg06238570	chr21:40685208	BRWD1	-0.38	-6.16	-0.32	2.03e-9	Menarche (age at onset);
LIHC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.52	6.26	0.32	1.15e-9	Breast cancer;
LIHC	cis	rs7075426	0.524	rs12779025	chr10:88188716	T/A	cg07322936	chr10:88137208	NA	0.49	6.01	0.31	4.71e-9	Migraine without aura;
LIHC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.81	-0.43	6.38e-17	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg02297831	chr4:17616191	MED28	0.42	6.7	0.34	8.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg23024448	chr19:51222118	NA	-0.59	-6.04	-0.31	4.1e-9	Mean platelet volume;
LIHC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	0.67	6.66	0.34	1.09e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.04	-0.48	5.98e-21	Response to antipsychotic treatment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10578084	chr7:1288010	NA	0.43	6.51	0.33	2.63e-10	Lung function (FEV1/FVC);
LIHC	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg03934865	chr2:198174659	NA	0.47	6.99	0.35	1.42e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg19773385	chr1:10388646	KIF1B	-0.41	-7.33	-0.37	1.67e-12	Hepatocellular carcinoma;
LIHC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg24296786	chr1:45957014	TESK2	-0.49	-6.38	-0.33	5.64e-10	Platelet count;
LIHC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.69	11.05	0.51	1.78e-24	Prostate cancer;
LIHC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.32	6.96	0.35	1.77e-11	Ulcerative colitis;
LIHC	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg04990556	chr1:26633338	UBXN11	-0.56	-8.97	-0.44	2.06e-17	Obesity-related traits;
LIHC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg06627628	chr2:24431161	ITSN2	-0.44	-5.89	-0.3	9.14e-9	Quantitative traits;
LIHC	cis	rs965469	1.000	rs6051745	chr20:3307243	T/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.83	-0.35	3.86e-11	IFN-related cytopenia;
LIHC	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.68	-0.34	9.54e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.36	6.06	0.31	3.62e-9	Height;
LIHC	cis	rs611744	0.901	rs639746	chr8:109234825	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.02	-0.51	2.28e-24	Chronic sinus infection;
LIHC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.34	-7.38	-0.37	1.22e-12	Multiple sclerosis;
LIHC	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.49	-0.42	6.28e-16	Lymphocyte counts;
LIHC	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.34	5.76	0.3	1.91e-8	Mean corpuscular volume;
LIHC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg23149560	chr2:74406255	MOBKL1B	0.41	5.83	0.3	1.29e-8	Gestational age at birth (maternal effect);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17187048	chr2:122407283	CLASP1	0.51	7.14	0.36	5.58e-12	Pancreatic cancer;
LIHC	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs12744310	1.000	rs12041533	chr1:41768271	C/T	cg03962019	chr1:41807865	NA	0.4	6.44	0.33	4.14e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.41e-15	Bladder cancer;
LIHC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.23	-0.36	3.27e-12	Schizophrenia;
LIHC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-5.79	-0.3	1.56e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	trans	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg23598604	chr1:99732472	LPPR4	-0.3	-6.39	-0.33	5.5e-10	Multiple myeloma;
LIHC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.62	-9.43	-0.45	6.42e-19	Aortic root size;
LIHC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.46	-7.03	-0.36	1.15e-11	Height;
LIHC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.68	-10.85	-0.51	9.32e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3789045	0.685	rs12036042	chr1:204469314	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.4	-6.05	-0.31	3.86e-9	Educational attainment (college completion);
LIHC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg02297831	chr4:17616191	MED28	0.43	6.8	0.35	4.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-19.81	-0.73	1.07e-58	Height;
LIHC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.84	0.3	1.21e-8	Bipolar disorder;
LIHC	cis	rs882732	1.000	rs10133253	chr14:95033681	A/G	cg14866387	chr14:95027382	SERPINA4	-0.45	-6.73	-0.34	7.03e-11	Blood protein levels;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.46	-6.97	-0.35	1.64e-11	Total body bone mineral density;
LIHC	cis	rs7923837	0.650	rs10882098	chr10:94444793	C/T	cg25506282	chr10:94462361	NA	0.41	7.22	0.36	3.44e-12	Body mass index;Multiple sclerosis;
LIHC	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg03146154	chr1:46216737	IPP	-0.39	-6.51	-0.33	2.69e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.68	-10.36	-0.49	4.7e-22	Aortic root size;
LIHC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg08694578	chr2:241835147	C2orf54	-0.51	-7.16	-0.36	4.88e-12	Urinary metabolites;
LIHC	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.35	-0.32	6.83e-10	Prevalent atrial fibrillation;
LIHC	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.49	-6.44	-0.33	4.07e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-0.78	-6.04	-0.31	3.92e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.83	13.33	0.58	6.38e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.76	-0.34	6.07e-11	Total body bone mineral density;
LIHC	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.89	15.82	0.65	1.09e-42	Eotaxin levels;
LIHC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00958927	chr1:175162553	KIAA0040	-0.39	-6.46	-0.33	3.61e-10	Alcohol dependence;
LIHC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.86	16.11	0.66	7.9e-44	Blood protein levels;
LIHC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.55e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg25329296	chr4:113486062	C4orf21	0.41	6.19	0.32	1.68e-9	Alopecia areata;
LIHC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.51e-16	Platelet count;
LIHC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.68	11.1	0.51	1.2e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.43	7.4	0.37	1.06e-12	Aortic root size;
LIHC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.53	-0.53	3.33e-26	Coronary artery disease;
LIHC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.46	6.95	0.35	1.91e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.57	9.23	0.45	2.81e-18	Longevity;Endometriosis;
LIHC	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.4	-6.57	-0.33	1.92e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.63	9.49	0.46	4.11e-19	Platelet count;
LIHC	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.35	-6.65	-0.34	1.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg10820045	chr2:198174542	NA	0.56	8.88	0.43	3.78e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.45	6.38	0.33	5.88e-10	Longevity;Endometriosis;
LIHC	cis	rs12744310	1.000	rs34073585	chr1:41777199	T/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs17106184	1.000	rs72904718	chr1:51315456	T/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	trans	rs72960926	0.744	rs55764691	chr6:74924388	T/C	cg07247405	chr1:2484626	LOC115110	0.56	6.62	0.34	1.36e-10	Metabolite levels (MHPG);
LIHC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg07424592	chr7:64974309	NA	0.82	9.43	0.45	6.33e-19	Diabetic kidney disease;
LIHC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.41	6.96	0.35	1.76e-11	Alcohol dependence;
LIHC	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-7.27	-0.37	2.54e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.5	-9.19	-0.45	3.85e-18	Plateletcrit;Platelet count;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.85	0.3	1.18e-8	Longevity;
LIHC	cis	rs12477438	0.539	rs62156558	chr2:99553104	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-8.43	-0.41	9.8e-16	Chronic sinus infection;
LIHC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	6.88	0.35	2.95e-11	Electroencephalogram traits;
LIHC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.9	0.3	8.82e-9	Mean platelet volume;
LIHC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.5	7.8	0.39	7.36e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg13409248	chr3:40428643	ENTPD3	0.39	6.36	0.33	6.45e-10	Renal cell carcinoma;
LIHC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.63	-10.25	-0.48	1.16e-21	Obesity-related traits;
LIHC	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.06	-0.31	3.57e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21890592	chr7:5013639	RNF216L	-0.54	-6.47	-0.33	3.43e-10	Systolic blood pressure;
LIHC	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg20487152	chr13:99095054	FARP1	-0.38	-6.16	-0.32	2.01e-9	Longevity;
LIHC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.58	-8.59	-0.42	3.21e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg19894588	chr14:64061835	NA	-0.45	-7.12	-0.36	6.3e-12	Fat distribution (HIV);
LIHC	cis	rs11871801	1.000	rs78594996	chr17:40570109	A/G	cg14558262	chr17:40713999	COASY	0.46	5.74	0.3	2.04e-8	Crohn's disease;
LIHC	cis	rs787274	1.000	rs7859381	chr9:115546649	C/T	cg13803584	chr9:115635662	SNX30	-0.59	-6.33	-0.32	7.74e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-5.83	-0.3	1.29e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.85	-11.96	-0.54	9.18e-28	Obesity-related traits;
LIHC	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.59	-0.42	3.21e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs2579103	0.767	rs1347845	chr12:90663011	A/G	cg00091569	chr3:40428383	ENTPD3	0.39	6.17	0.32	1.89e-9	Body mass index;
LIHC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg25281562	chr12:121454272	C12orf43	0.38	6.44	0.33	4.1e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.45	-7.74	-0.39	1.1e-13	Prevalent atrial fibrillation;
LIHC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg00800038	chr16:89945340	TCF25	-0.63	-9.48	-0.46	4.32e-19	Skin colour saturation;
LIHC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.33	5.82	0.3	1.35e-8	Body mass index;
LIHC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.5	-0.38	5.73e-13	Uric acid levels;
LIHC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.16	0.48	2.21e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.5	-8.96	-0.44	2.17e-17	Height;
LIHC	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	ch.11.42038R	chr11:967971	AP2A2	0.53	9.72	0.47	7.06e-20	Alzheimer's disease (late onset);
LIHC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.52	-9.35	-0.45	1.15e-18	Lung cancer;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23396286	chr10:99258505	UBTD1;MMS19	0.4	6.45	0.33	3.77e-10	Cognitive function;
LIHC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.61	0.42	2.66e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.6	5.77	0.3	1.81e-8	Vitiligo;
LIHC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.77	-9.2	-0.45	3.63e-18	Neuroticism;
LIHC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg26395211	chr5:140044315	WDR55	0.41	6.01	0.31	4.69e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg03466237	chr11:1298256	TOLLIP	0.44	6.73	0.34	7.19e-11	Alopecia areata;
LIHC	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg10096929	chr1:156261403	TMEM79	0.37	6.03	0.31	4.36e-9	Tonsillectomy;
LIHC	cis	rs238295	0.805	rs6053527	chr20:5582457	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-6.91	-0.35	2.44e-11	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.68	-0.43	1.59e-16	Total cholesterol levels;
LIHC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.56	-8.6	-0.42	2.82e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg17691542	chr6:26056736	HIST1H1C	0.43	5.91	0.3	8.33e-9	Blood metabolite levels;
LIHC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.83	0.54	2.66e-27	Cognitive test performance;
LIHC	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg23461800	chr14:103021989	NA	0.41	6.14	0.32	2.24e-9	Platelet count;
LIHC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.3	16.83	0.67	1.01e-46	Diabetic kidney disease;
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg20887711	chr4:1340912	KIAA1530	0.5	7.86	0.39	5.08e-14	Obesity-related traits;
LIHC	trans	rs6489882	0.836	rs10850099	chr12:113364504	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6.02e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.99	-0.31	5.31e-9	Headache;
LIHC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg17771515	chr6:154831774	CNKSR3	0.54	6.14	0.32	2.25e-9	Lipoprotein (a) levels;
LIHC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.66	9.71	0.46	7.89e-20	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19584341	chr11:506908	RNH1	-0.45	-6.78	-0.34	5.42e-11	Pancreatic cancer;
LIHC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.57	10.09	0.48	4.04e-21	Alcohol dependence;
LIHC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.64	8.61	0.42	2.65e-16	Asthma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg09310383	chr3:37218128	LRRFIP2	-0.51	-6.34	-0.32	7.46e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg03859395	chr2:55845619	SMEK2	-0.86	-14.66	-0.62	4.25e-38	Metabolic syndrome;
LIHC	cis	rs600626	0.636	rs11236515	chr11:75451411	A/G	cg24262691	chr11:75473276	NA	0.4	5.88	0.3	9.5e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.51	-0.33	2.72e-10	Mood instability;
LIHC	cis	rs6808694	0.568	rs17006711	chr3:20228005	C/T	cg00235661	chr3:20228976	SGOL1	0.38	6.67	0.34	1.02e-10	Ischemic stroke;
LIHC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.27	-7.48	-0.38	6.16e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9290065	0.585	rs716779	chr3:160645428	G/A	cg03342759	chr3:160939853	NMD3	0.6	8.14	0.4	7.31e-15	Kawasaki disease;
LIHC	trans	rs75804782	0.521	rs72993065	chr2:239409001	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	6.91	0.35	2.39e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs7142002	1.000	rs7145940	chr14:102361134	G/A	cg18984499	chr17:8286166	RPL26	0.65	6.14	0.32	2.3e-9	Autism;
LIHC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.65	7.82	0.39	6.73e-14	Heart rate;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4742903	1.000	rs4742906	chr9:106857078	A/G	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs1814175	0.571	rs12294066	chr11:49738287	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	1.94e-11	Height;
LIHC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.53	0.42	4.8e-16	Initial pursuit acceleration;
LIHC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	9.02	0.44	1.39e-17	Cognitive test performance;
LIHC	trans	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg03959625	chr15:84868606	LOC388152	0.47	6.76	0.34	6.14e-11	Schizophrenia;
LIHC	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	8.3	0.41	2.48e-15	Height;
LIHC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-10.81	-0.5	1.26e-23	Platelet count;
LIHC	cis	rs988712	0.622	rs4922793	chr11:27729505	A/G	cg18117895	chr11:27722066	BDNF	0.5	6.92	0.35	2.2e-11	Obesity;
LIHC	cis	rs600806	0.778	rs4970761	chr1:109995398	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.61	-0.38	2.77e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2070433	0.756	rs9637220	chr21:47887436	T/C	cg12379764	chr21:47803548	PCNT	0.61	8.84	0.43	5.2e-17	Lymphocyte counts;
LIHC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.71	0.3	2.42e-8	Tonsillectomy;
LIHC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs74544699	1.000	rs7666671	chr4:74807007	G/A	cg02530824	chr4:74847766	PF4	0.62	6.45	0.33	3.77e-10	Growth-regulated protein alpha levels;
LIHC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.65	-9.91	-0.47	1.57e-20	Height;
LIHC	cis	rs712039	0.652	rs853222	chr17:35790022	G/T	cg16670864	chr17:35848621	DUSP14	0.34	5.73	0.3	2.16e-8	Tuberculosis;
LIHC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.58	0.38	3.39e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.43	-5.91	-0.3	8.47e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.72	-10.77	-0.5	1.73e-23	Aortic root size;
LIHC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.46	6.19	0.32	1.76e-9	Major depressive disorder;
LIHC	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.59	7.79	0.39	7.91e-14	Platelet count;
LIHC	cis	rs6545883	0.894	rs2463102	chr2:61571295	G/C	cg15711740	chr2:61764176	XPO1	0.43	5.88	0.3	9.65e-9	Tuberculosis;
LIHC	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.71	0.5	2.76e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.6	-9.11	-0.44	7.08e-18	QRS duration;
LIHC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.96	12.69	0.57	1.68e-30	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs10411161	0.702	rs8113768	chr19:52383938	C/T	cg22319618	chr22:45562946	NUP50	-0.6	-8.17	-0.4	6.12e-15	Breast cancer;
LIHC	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.42	6.31	0.32	8.83e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.89	0.3	9.31e-9	Tonsillectomy;
LIHC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.7	-8.42	-0.41	1.07e-15	Morning vs. evening chronotype;
LIHC	cis	rs6596100	0.538	rs4705972	chr5:132179237	T/A	cg02081065	chr5:132209139	LEAP2	0.3	6.38	0.33	5.75e-10	Breast cancer;
LIHC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.28	7.45	0.37	7.61e-13	Skin aging (microtopography measurement);
LIHC	cis	rs611744	0.967	rs684093	chr8:109199355	G/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.85	-0.35	3.44e-11	Total cholesterol levels;
LIHC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg23109721	chr2:106886537	NA	-0.65	-6.29	-0.32	9.47e-10	Facial morphology (factor 23);
LIHC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20135002	chr11:47629003	NA	-0.53	-9.09	-0.44	8.16e-18	Subjective well-being;
LIHC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.42	-6.79	-0.34	5.06e-11	Melanoma;
LIHC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.65	8.02	0.4	1.64e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.78	0.3	1.64e-8	Morning vs. evening chronotype;
LIHC	cis	rs2257205	0.667	rs8080281	chr17:56938558	A/G	cg12560992	chr17:57184187	TRIM37	-0.66	-7.18	-0.36	4.32e-12	Pancreatic cancer;
LIHC	cis	rs12611088	0.600	rs2355994	chr19:44005107	T/C	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.16	-0.32	2.03e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.58	-6.8	-0.34	4.8e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.94	-13.55	-0.59	8.86e-34	Blood metabolite levels;
LIHC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.42e-11	Height;
LIHC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	0.77	7.45	0.37	7.5e-13	Midgestational circulating levels of PBDEs (fetal genetic effect);
LIHC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.19	-0.4	5.24e-15	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.5	6.06	0.31	3.53e-9	Alzheimer's disease;
LIHC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02985541	chr2:219472218	PLCD4	0.41	7.56	0.38	3.86e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.63	0.5	5.57e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg01864069	chr14:103024347	NA	-0.58	-9.5	-0.46	3.83e-19	Platelet count;
LIHC	cis	rs9322817	1.000	rs6900902	chr6:105235757	A/G	cg02098413	chr6:105308735	HACE1	-0.37	-6.01	-0.31	4.87e-9	Thyroid stimulating hormone;
LIHC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg18944383	chr4:111397179	ENPEP	0.26	6.34	0.32	7.06e-10	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.18	0.32	1.83e-9	Bipolar disorder;
LIHC	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.75	-11.92	-0.54	1.27e-27	Pediatric autoimmune diseases;
LIHC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg03859395	chr2:55845619	SMEK2	-0.56	-9.32	-0.45	1.49e-18	Metabolic syndrome;
LIHC	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.31	-0.32	8.85e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.48	-5.95	-0.31	6.52e-9	Alzheimer's disease;
LIHC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.46	-9.13	-0.44	5.9e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7707921	0.881	rs112355050	chr5:81386035	C/T	cg15871215	chr5:81402204	ATG10	-0.61	-5.95	-0.31	6.55e-9	Breast cancer;
LIHC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.5	-7.48	-0.37	6.53e-13	Asthma (sex interaction);
LIHC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.8	-0.43	6.72e-17	Type 2 diabetes;
LIHC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg15691649	chr6:25882328	NA	0.52	7.73	0.39	1.24e-13	Blood metabolite levels;
LIHC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.55	-9.5	-0.46	3.67e-19	Reticulocyte count;
LIHC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg24826892	chr11:71159390	DHCR7	0.56	7.13	0.36	5.91e-12	Vitamin D levels;
LIHC	cis	rs7712401	0.791	rs6595409	chr5:122113756	G/A	cg18764291	chr5:122110994	SNX2	0.35	5.94	0.31	7.13e-9	Mean platelet volume;
LIHC	cis	rs7078219	0.505	rs10883367	chr10:101287990	A/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.17	-0.32	1.97e-9	Dental caries;
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg01028140	chr2:1542097	TPO	-0.41	-6.53	-0.33	2.36e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg04592579	chr7:75616294	TMEM120A	0.4	7.0	0.35	1.32e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.5e-16	Platelet count;
LIHC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.9	0.51	5.81e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.48	-7.29	-0.37	2.11e-12	Diastolic blood pressure;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg00280220	chr17:61926910	NA	0.4	6.46	0.33	3.69e-10	Prudent dietary pattern;
LIHC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.67	13.2	0.58	2e-32	High light scatter reticulocyte count;
LIHC	cis	rs333960	0.597	rs333962	chr1:110440117	C/T	cg09167608	chr1:110449308	NA	0.42	5.88	0.3	9.59e-9	Obesity-related traits;
LIHC	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	0.63	8.11	0.4	9.21e-15	Corneal structure;
LIHC	cis	rs2422052	0.639	rs1433531	chr2:118646201	A/C	cg22545206	chr2:118617499	NA	0.36	6.08	0.31	3.19e-9	Mosquito bite size;
LIHC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg05084668	chr3:125655381	ALG1L	-0.39	-6.0	-0.31	5.01e-9	Blood pressure (smoking interaction);
LIHC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.3	-0.45	1.65e-18	Bipolar disorder;
LIHC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.42	6.3	0.32	9.14e-10	Schizophrenia;
LIHC	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.47	6.95	0.35	1.9e-11	Dermatomyositis;
LIHC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.76	-8.05	-0.4	1.34e-14	Vitiligo;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07677032	chr17:61819896	STRADA	0.43	5.98	0.31	5.56e-9	Prudent dietary pattern;
LIHC	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.6	8.8	0.43	7.07e-17	Retinal vascular caliber;
LIHC	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19671926	chr4:122722719	EXOSC9	0.47	6.96	0.35	1.78e-11	Type 2 diabetes;
LIHC	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg23495837	chr4:3480318	DOK7	-0.37	-6.75	-0.34	6.25e-11	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.77e-28	Motion sickness;
LIHC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	13.43	0.59	2.61e-33	Lung cancer in ever smokers;
LIHC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	4.76e-74	Height;
LIHC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.26	0.41	3.32e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs2637030	0.559	rs923609	chr5:52912249	G/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.35	0.32	7.02e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg04610667	chr7:75704037	NA	-0.33	-6.0	-0.31	5.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.57	5.92	0.3	8.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4699052	0.963	rs7679365	chr4:104212980	G/C	cg16532752	chr4:104119610	CENPE	-0.39	-6.29	-0.32	9.82e-10	Testicular germ cell tumor;
LIHC	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg02886208	chr11:14281011	SPON1	-0.5	-7.14	-0.36	5.66e-12	Mitochondrial DNA levels;
LIHC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.44	-6.44	-0.33	4.11e-10	Narcolepsy;
LIHC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	11.57	0.53	2.37e-26	Platelet count;
LIHC	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.69	8.87	0.43	4.09e-17	Exhaled nitric oxide output;
LIHC	cis	rs7633770	0.664	rs11130101	chr3:46685895	T/A	cg11219411	chr3:46661640	NA	-0.35	-5.78	-0.3	1.66e-8	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.75	-11.5	-0.53	4.41e-26	Response to antineoplastic agents;
LIHC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.58	8.66	0.42	1.91e-16	Cognitive function;
LIHC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.41	-7.22	-0.36	3.49e-12	Platelet distribution width;
LIHC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-23.35	-0.78	8.99e-73	Height;
LIHC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	1.01	19.45	0.72	2.9e-57	Breast cancer;
LIHC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg17724175	chr1:150552817	MCL1	-0.36	-7.62	-0.38	2.51e-13	Tonsillectomy;
LIHC	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg10820045	chr2:198174542	NA	0.47	7.44	0.37	7.99e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00365505	chr7:150066001	REPIN1	-0.47	-7.17	-0.36	4.74e-12	Cognitive function;
LIHC	cis	rs832187	0.593	rs3774713	chr3:63917692	G/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.45	-6.27	-0.32	1.06e-9	Schizophrenia;
LIHC	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg12046867	chr14:103022105	NA	0.43	6.62	0.34	1.36e-10	Platelet count;
LIHC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.82	12.26	0.55	6.73e-29	Motion sickness;
LIHC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7208859	0.673	rs57432042	chr17:29241038	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	7.06	0.36	9.39e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg26149184	chr10:133730230	NA	0.49	7.59	0.38	3.13e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg12863693	chr15:85201151	NMB	0.43	6.09	0.31	3.07e-9	Schizophrenia;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.68	11.04	0.51	1.93e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.49	0.46	3.93e-19	Corneal astigmatism;
LIHC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.71	10.58	0.5	8.25e-23	Coronary artery disease;
LIHC	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Blood protein levels;
LIHC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg06627628	chr2:24431161	ITSN2	-0.65	-7.6	-0.38	2.84e-13	Lymphocyte counts;
LIHC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg04865290	chr3:52927548	TMEM110	-0.51	-5.73	-0.3	2.2e-8	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.72	-11.65	-0.53	1.21e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.88	-18.1	-0.7	8.06e-52	Height;
LIHC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.26	0.37	2.59e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.78	12.51	0.56	8.22e-30	Colorectal cancer;
LIHC	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg00792783	chr2:198669748	PLCL1	0.45	6.6	0.34	1.52e-10	Dermatomyositis;
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg24884572	chr19:58661833	ZNF329	0.98	7.8	0.39	7.58e-14	Cholesterol, total;
LIHC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.61	-10.04	-0.48	5.84e-21	Post bronchodilator FEV1;
LIHC	cis	rs11663156	0.804	rs4940255	chr18:50907179	C/A	cg24270629	chr18:50823537	DCC	-0.56	-7.88	-0.39	4.36e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.6	-9.3	-0.45	1.68e-18	Renal cell carcinoma;
LIHC	cis	rs4789452	0.655	rs2001613	chr17:75383679	C/T	cg06761530	chr17:75373219	SEPT9	-0.47	-6.12	-0.31	2.62e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs10949834	0.838	rs1091811	chr7:73491212	A/G	cg07137043	chr7:73588983	EIF4H	0.56	6.05	0.31	3.8e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs2274273	0.840	rs17674463	chr14:55824863	A/T	cg01864836	chr14:55583639	NA	-0.37	-6.62	-0.34	1.36e-10	Protein biomarker;
LIHC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg20735989	chr4:730612	PCGF3	-0.67	-8.72	-0.43	1.19e-16	White blood cell count;
LIHC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg20568497	chr10:133558893	NA	0.42	6.55	0.33	2.09e-10	Survival in rectal cancer;
LIHC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.95	-0.35	1.87e-11	Mean corpuscular volume;
LIHC	trans	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg24133106	chr7:129690864	ZC3HC1	-0.49	-6.1	-0.31	2.85e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LIHC	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.73	-13.47	-0.59	1.87e-33	Mean platelet volume;
LIHC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.9	-0.3	8.56e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.47	6.52	0.33	2.53e-10	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg12698662	chr3:15914712	MIR563	-0.36	-6.57	-0.33	1.87e-10	Mean platelet volume;
LIHC	cis	rs9633740	0.685	rs4934284	chr10:82277297	C/G	cg01528321	chr10:82214614	TSPAN14	-0.85	-6.99	-0.35	1.41e-11	Post bronchodilator FEV1;
LIHC	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg27205649	chr11:78285834	NARS2	0.43	6.49	0.33	3.01e-10	Alzheimer's disease (survival time);
LIHC	trans	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg16011800	chr17:1958478	HIC1	0.5	7.06	0.36	9.16e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.49	-0.38	6.08e-13	Chronic sinus infection;
LIHC	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg25364880	chr3:44379878	C3orf23	0.6	8.46	0.42	8.16e-16	Depressive symptoms;
LIHC	trans	rs783540	0.934	rs1594511	chr15:83307063	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.63	-0.34	1.32e-10	Schizophrenia;
LIHC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.54	-8.0	-0.4	1.91e-14	Age at first birth;
LIHC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.41	-6.32	-0.32	8.35e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.6	10.39	0.49	3.67e-22	Diisocyanate-induced asthma;
LIHC	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.4	6.74	0.34	6.73e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3736485	0.934	rs17609693	chr15:51868000	T/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.02e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-6.72	-0.34	7.68e-11	Reticulocyte count;
LIHC	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.97	7.08	0.36	8.01e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.89	-0.3	9.27e-9	Cognitive function;
LIHC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg23387056	chr11:14280742	SPON1	-0.42	-5.87	-0.3	1.05e-8	Mitochondrial DNA levels;
LIHC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.09	-0.36	7.81e-12	Vitiligo;
LIHC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg23461800	chr14:103021989	NA	-0.47	-6.65	-0.34	1.13e-10	Platelet count;
LIHC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	10.94	0.51	4.19e-24	Platelet count;
LIHC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.88	0.3	9.64e-9	Tonsillectomy;
LIHC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.57	5.79	0.3	1.62e-8	Schizophrenia;
LIHC	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.04	-0.36	1.09e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.66	12.63	0.56	2.77e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.86	0.35	3.3e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7487075	0.619	rs7134289	chr12:46838336	G/A	cg23829395	chr12:46796953	NA	0.34	6.05	0.31	3.81e-9	Itch intensity from mosquito bite;
LIHC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.68	-9.98	-0.47	9.55e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25951256	chr10:38645740	HSD17B7P2	-0.39	-5.78	-0.3	1.69e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg24004478	chr7:855632	UNC84A	0.48	7.95	0.39	2.84e-14	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs7712401	0.720	rs12109791	chr5:122146831	C/T	cg18764291	chr5:122110994	SNX2	0.36	6.09	0.31	2.99e-9	Mean platelet volume;
LIHC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.51	7.93	0.39	3.2e-14	Pulse pressure;
LIHC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.82	0.39	6.63e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.37	-0.37	1.27e-12	Protein biomarker;
LIHC	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.14	-10.1	-0.48	3.66e-21	Schizophrenia;
LIHC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.91	0.35	2.33e-11	Height;
LIHC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.64	-12.53	-0.56	6.8e-30	Rheumatoid arthritis;
LIHC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.86	-0.3	1.12e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.53	5.78	0.3	1.68e-8	Menopause (age at onset);
LIHC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.86	13.39	0.59	3.5e-33	IgG glycosylation;
LIHC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg00656387	chr3:40428638	ENTPD3	0.44	7.46	0.37	7.03e-13	Renal cell carcinoma;
LIHC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg15691649	chr6:25882328	NA	-0.63	-8.11	-0.4	8.88e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-22.14	-0.77	5.02e-68	Myeloid white cell count;
LIHC	cis	rs74181299	0.890	rs2723062	chr2:65280220	G/A	cg05010058	chr2:65284262	CEP68	0.41	6.91	0.35	2.31e-11	Pulse pressure;
LIHC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	trans	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.37	-0.33	6.01e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.61	0.53	1.65e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2292096	1.000	rs16847183	chr1:200731955	A/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.12	-0.31	2.57e-9	Epilepsy;
LIHC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg02269571	chr22:50332266	NA	-0.74	-8.91	-0.43	3.1e-17	Schizophrenia;
LIHC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	9.2	0.45	3.64e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg12863693	chr15:85201151	NMB	0.44	6.34	0.32	7.18e-10	Schizophrenia;
LIHC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.33	5.91	0.3	8.5e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.57	7.5	0.38	5.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.79	-7.65	-0.38	2.1e-13	Diabetic retinopathy;
LIHC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.69	-10.69	-0.5	3.4e-23	Longevity;
LIHC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.42	-8.44	-0.42	9.17e-16	Obesity-related traits;
LIHC	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg03934865	chr2:198174659	NA	0.46	6.79	0.34	5.08e-11	Dermatomyositis;
LIHC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.35	8.82	0.43	6.11e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg01256987	chr12:42539512	GXYLT1	0.34	5.79	0.3	1.63e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.85	13.75	0.6	1.49e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.33	-0.45	1.36e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.72	8.97	0.44	1.96e-17	Blood protein levels;
LIHC	cis	rs2010672	0.500	rs4932351	chr15:91143720	C/G	cg26821196	chr15:91095069	CRTC3	0.32	5.99	0.31	5.4e-9	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LIHC	cis	rs9328573	1.000	rs9920482	chr15:100510477	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.49	-7.55	-0.38	3.93e-13	Urate levels in lean individuals;
LIHC	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg14784868	chr12:69753453	YEATS4	0.61	5.76	0.3	1.89e-8	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg27203090	chr3:33138513	GLB1;TMPPE	0.57	7.08	0.36	8.28e-12	Major depressive disorder;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg18944383	chr4:111397179	ENPEP	0.27	7.06	0.36	9.16e-12	Height;
LIHC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.01	-21.15	-0.75	4.3e-64	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.26	-0.49	1.01e-21	Coronary artery disease;
LIHC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	1.02e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.22	6.02	0.31	4.4e-9	Calcium levels;
LIHC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg07423050	chr13:99094983	FARP1	-0.33	-5.85	-0.3	1.13e-8	Educational attainment (years of education);
LIHC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.93	-0.31	7.27e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg21573476	chr21:45109991	RRP1B	-0.6	-11.29	-0.52	2.54e-25	Mean corpuscular volume;
LIHC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.27	-0.37	2.39e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	8.84	0.43	5.3e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg14343924	chr8:8086146	FLJ10661	0.47	5.92	0.31	7.66e-9	Neuroticism;
LIHC	cis	rs694739	0.894	rs12421615	chr11:64021605	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.73	9.12	0.44	6.47e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.45	6.62	0.34	1.41e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg22079354	chr11:130786696	SNX19	0.43	6.11	0.31	2.76e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05665937	chr4:1216051	CTBP1	-0.45	-5.98	-0.31	5.62e-9	Obesity-related traits;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.59	-9.61	-0.46	1.64e-19	Prudent dietary pattern;
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg13271783	chr10:134563150	INPP5A	-0.57	-7.2	-0.36	3.87e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.5	-6.87	-0.35	3.09e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs4755351	0.527	rs12420035	chr11:33111487	A/G	cg05567920	chr11:33183001	CSTF3	0.42	6.07	0.31	3.44e-9	Lung cancer in ever smokers;
LIHC	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg19752551	chr11:57585705	CTNND1	-0.51	-7.14	-0.36	5.64e-12	Schizophrenia;
LIHC	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.23	-0.32	1.33e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.63	10.8	0.5	1.37e-23	Diisocyanate-induced asthma;
LIHC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.25	0.52	3.29e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	6.77	0.34	5.56e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs61677309	1.000	rs3782040	chr11:118176097	A/G	cg06090739	chr11:118230722	UBE4A	0.34	6.16	0.32	2e-9	Lung cancer in ever smokers;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg09984469	chr2:72372162	CYP26B1	-0.51	-6.11	-0.31	2.76e-9	Systolic blood pressure;
LIHC	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	trans	rs7668874	0.738	rs7683194	chr4:116813821	T/C	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.1	-0.51	1.19e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.95	17.59	0.69	8.51e-50	Menopause (age at onset);
LIHC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	0.53	7.11	0.36	6.93e-12	Pulse pressure;
LIHC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.73	11.5	0.53	4.27e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg25182066	chr10:30743637	MAP3K8	-0.49	-7.98	-0.4	2.19e-14	Inflammatory bowel disease;
LIHC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20135002	chr11:47629003	NA	-0.58	-10.06	-0.48	4.98e-21	Subjective well-being;
LIHC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg00204512	chr16:28754710	NA	0.41	7.16	0.36	4.9e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.98	-0.35	1.5e-11	Vitiligo;
LIHC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.4	6.43	0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.42	5.87	0.3	1.01e-8	QT interval;
LIHC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.15	0.44	5.12e-18	Gut microbiome composition (summer);
LIHC	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.4	-0.41	1.24e-15	Exhaled nitric oxide output;
LIHC	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-10.54	-0.5	1.1e-22	Morning vs. evening chronotype;
LIHC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.61	-8.57	-0.42	3.71e-16	Motion sickness;
LIHC	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.53	8.95	0.44	2.23e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	trans	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg26939375	chr7:64535504	NA	0.4	6.29	0.32	9.67e-10	Aortic root size;
LIHC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg10411590	chr13:21900810	NA	0.41	6.93	0.35	2.05e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.49	8.7	0.43	1.42e-16	Reticulocyte fraction of red cells;
LIHC	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.52	8.93	0.43	2.74e-17	Coronary heart disease;
LIHC	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg02733842	chr7:1102375	C7orf50	-0.69	-7.49	-0.38	5.79e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.42	0.33	4.62e-10	Mean platelet volume;
LIHC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.49	0.42	6.51e-16	Platelet count;
LIHC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg16479474	chr6:28041457	NA	0.5	5.88	0.3	9.81e-9	Depression;
LIHC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.48	-6.83	-0.35	3.85e-11	Uric acid levels;
LIHC	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.4	8.76	0.43	9.09e-17	Gait variability;
LIHC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.86	14.97	0.63	2.6e-39	Parkinson's disease;
LIHC	cis	rs2836974	0.545	rs2776311	chr21:40716885	A/G	cg11890956	chr21:40555474	PSMG1	0.55	8.04	0.4	1.53e-14	Cognitive function;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.32	0.41	2.06e-15	Height;
LIHC	cis	rs1008375	0.897	rs4334752	chr4:17615430	C/T	cg16339924	chr4:17578868	LAP3	0.44	6.0	0.31	5.14e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs74233809	1.000	rs11191560	chr10:104869038	A/G	cg03493300	chr10:104813866	CNNM2	0.45	5.99	0.31	5.3e-9	Birth weight;
LIHC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06634786	chr22:41940651	POLR3H	0.55	6.05	0.31	3.87e-9	Vitiligo;
LIHC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.77	11.93	0.54	1.14e-27	Corneal astigmatism;
LIHC	cis	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg17459225	chr2:239074497	NA	0.37	5.9	0.3	8.9e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg18016565	chr1:150552671	MCL1	0.56	10.28	0.49	9.16e-22	Melanoma;
LIHC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.25	-7.65	-0.38	2.03e-13	Mean corpuscular volume;
LIHC	trans	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg18187862	chr3:45730750	SACM1L	0.57	6.65	0.34	1.17e-10	Primary sclerosing cholangitis;
LIHC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	16.01	0.65	1.96e-43	Chronic sinus infection;
LIHC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	6.43	0.33	4.18e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.04	0.51	1.88e-24	Hip circumference adjusted for BMI;
LIHC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.76	-11.63	-0.53	1.41e-26	Longevity;
LIHC	cis	rs8084351	0.599	rs4940245	chr18:50694137	A/G	cg24270629	chr18:50823537	DCC	-0.47	-6.96	-0.35	1.72e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.93	-0.35	2.07e-11	Metabolite levels;
LIHC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.88	-0.3	9.54e-9	Mean corpuscular volume;
LIHC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.02	21.83	0.76	8.48e-67	Height;
LIHC	cis	rs12744310	1.000	rs34008156	chr1:41773182	G/T	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.88	0.39	4.4e-14	Renal cell carcinoma;
LIHC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg03037974	chr15:76606532	NA	-0.73	-14.24	-0.61	1.89e-36	Blood metabolite levels;
LIHC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.97	17.78	0.69	1.45e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.46e-15	Facial morphology (factor 19);
LIHC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg10702113	chr3:196664466	NCBP2	0.36	6.08	0.31	3.14e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.68	8.76	0.43	9.26e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.645	rs240152	chr6:101067489	G/C	cg09795085	chr6:101329169	ASCC3	0.44	6.38	0.33	5.77e-10	Neuroticism;
LIHC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.4	7.8	0.39	7.48e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.13	-0.31	2.49e-9	Schizophrenia;
LIHC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-7.02	-0.35	1.23e-11	Total body bone mineral density;
LIHC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.66	-10.93	-0.51	4.66e-24	Childhood ear infection;
LIHC	cis	rs1075232	1.000	rs72722829	chr15:31639114	G/A	cg01030201	chr15:31746330	NA	-0.78	-6.0	-0.31	5.07e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.51	-0.33	2.69e-10	Type 2 diabetes;
LIHC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.63	-0.46	1.42e-19	Mean platelet volume;
LIHC	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.61	-0.38	2.61e-13	QT interval;
LIHC	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.71	-0.3	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg03244087	chr7:25164935	CYCS	-0.38	-6.07	-0.31	3.48e-9	Eotaxin levels;
LIHC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg14440974	chr22:39074834	NA	-0.45	-7.17	-0.36	4.73e-12	Menopause (age at onset);
LIHC	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-14.53	-0.62	1.41e-37	Schizophrenia;
LIHC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.48	5.92	0.3	7.95e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg08345082	chr10:99160200	RRP12	-0.4	-6.91	-0.35	2.39e-11	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs61332075	0.501	rs55706928	chr2:239445806	T/C	cg01134436	chr17:81009848	B3GNTL1	0.75	6.32	0.32	8.37e-10	Lung function (FEV1/FVC);
LIHC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg02580895	chr19:2754563	NA	-0.47	-6.91	-0.35	2.35e-11	Total cholesterol levels;
LIHC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.53	6.46	0.33	3.67e-10	Alzheimer's disease;
LIHC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.41	0.37	9.86e-13	Bone mineral density;
LIHC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.37	7.04	0.36	1.09e-11	Blood metabolite levels;
LIHC	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-0.71	-7.27	-0.37	2.4e-12	Putamen volume;
LIHC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.55	8.43	0.41	9.93e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg16586182	chr3:47516702	SCAP	0.55	10.06	0.48	5.16e-21	Colorectal cancer;
LIHC	cis	rs16828019	0.852	rs10489520	chr1:41511755	C/A	cg03962019	chr1:41807865	NA	0.49	7.03	0.36	1.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs244293	0.730	rs12945579	chr17:53022714	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.03	-0.31	4.32e-9	Menarche (age at onset);
LIHC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg21466736	chr12:48725269	NA	-0.71	-10.97	-0.51	3.49e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg14222432	chr12:29376421	FAR2	0.38	7.2	0.36	3.97e-12	QT interval;
LIHC	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-0.78	-8.54	-0.42	4.49e-16	Exhaled nitric oxide output;
LIHC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.15	0.66	5.24e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.49	-8.64	-0.42	2.22e-16	Monocyte count;
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg00656387	chr3:40428638	ENTPD3	0.51	8.38	0.41	1.36e-15	Renal cell carcinoma;
LIHC	cis	rs12079745	0.623	rs2275300	chr1:169337515	G/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	2.01e-11	QT interval;
LIHC	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg10820045	chr2:198174542	NA	-0.49	-7.61	-0.38	2.64e-13	Dermatomyositis;
LIHC	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.7	-10.23	-0.48	1.32e-21	Eosinophil percentage of white cells;
LIHC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.32	8.2	0.41	4.87e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.45	7.4	0.37	1.09e-12	Response to temozolomide;
LIHC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.84	-14.67	-0.62	3.85e-38	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02985541	chr2:219472218	PLCD4	-0.42	-6.83	-0.35	3.99e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg17074339	chr11:11642133	GALNTL4	0.4	6.1	0.31	2.92e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg00091569	chr3:40428383	ENTPD3	-0.37	-6.28	-0.32	1.01e-9	Renal cell carcinoma;
LIHC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.42	6.72	0.34	7.61e-11	Melanoma;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.46	0.37	7.18e-13	Renal cell carcinoma;
LIHC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.81e-14	Motion sickness;
LIHC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.11	-0.31	2.78e-9	Total body bone mineral density;
LIHC	trans	rs10078397	0.518	rs6594295	chr5:107601618	C/G	cg14380426	chr14:74418789	COQ6	-0.49	-6.07	-0.31	3.4e-9	Neuroticism;
LIHC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.59	-9.98	-0.48	9.15e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.39	-0.33	5.52e-10	Longevity;
LIHC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.67	-9.34	-0.45	1.23e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7095607	0.560	rs7095238	chr10:69913203	T/C	cg18986048	chr10:69913749	MYPN	0.41	6.07	0.31	3.47e-9	Lung function (FVC);
LIHC	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.35	-5.74	-0.3	2.13e-8	Hypospadias;
LIHC	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.98	-0.4	2.29e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.8	-0.47	3.82e-20	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg06766960	chr11:133703094	NA	-0.66	-11.14	-0.52	8.18e-25	Childhood ear infection;
LIHC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	7.02	0.36	1.17e-11	Pulse pressure;
LIHC	cis	rs4919087	0.532	rs56189004	chr10:99086632	A/G	cg25902810	chr10:99078978	FRAT1	-0.62	-7.82	-0.39	6.8e-14	Monocyte count;
LIHC	cis	rs600806	0.854	rs3768496	chr1:109866569	T/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.25	-0.36	2.8e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	6.68	0.34	9.56e-11	Renal cell carcinoma;
LIHC	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.93	-10.26	-0.49	1.01e-21	Ulcerative colitis;
LIHC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.81	-0.35	4.46e-11	Diabetic kidney disease;
LIHC	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg11212589	chr17:38028394	ZPBP2	-0.34	-6.88	-0.35	2.79e-11	Self-reported allergy;
LIHC	cis	rs970821	0.667	rs2385508	chr8:124744682	C/A	cg00283535	chr8:124749564	ANXA13	0.42	7.7	0.38	1.46e-13	Breast cancer;
LIHC	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.4	5.8	0.3	1.54e-8	Life satisfaction;
LIHC	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.44	6.14	0.32	2.27e-9	Hepatocellular carcinoma;
LIHC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.54	5.88	0.3	9.97e-9	Menarche (age at onset);
LIHC	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.68	11.18	0.52	6.33e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.85	-12.73	-0.57	1.18e-30	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02290350	chr8:58132656	NA	0.5	9.94	0.47	1.23e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	8.71	0.43	1.33e-16	Morning vs. evening chronotype;
LIHC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.6	-9.53	-0.46	2.92e-19	Platelet count;
LIHC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-8.11	-0.4	9.08e-15	Urinary metabolites;
LIHC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	8.23	0.41	4.08e-15	Platelet count;
LIHC	cis	rs9888615	1.000	rs12881375	chr14:53371980	C/A	cg00686598	chr14:53173677	PSMC6	-0.51	-6.43	-0.33	4.26e-10	Systolic blood pressure;
LIHC	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.62	-6.0	-0.31	4.96e-9	Breast cancer;
LIHC	trans	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg17675199	chr6:35436792	RPL10A	-0.31	-6.22	-0.32	1.46e-9	Coronary artery disease;
LIHC	cis	rs9596863	1.000	rs9568939	chr13:54411497	A/C	ch.13.53330881F	chr13:54432880	NA	0.44	5.98	0.31	5.48e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs2359714	0.905	rs7515420	chr1:118823147	A/G	cg10221014	chr12:47618577	FAM113B	-0.37	-6.04	-0.31	3.99e-9	Breast size;
LIHC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg21518248	chr2:162101506	NA	0.42	6.21	0.32	1.56e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12079745	0.793	rs12058325	chr1:169264037	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-6.94	-0.35	2.01e-11	QT interval;
LIHC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16990120	chr1:149871080	BOLA1	0.39	6.04	0.31	4.04e-9	Pancreatic cancer;
LIHC	cis	rs10845606	0.505	rs7299416	chr12:12831568	C/T	cg09462578	chr12:12878428	APOLD1	0.42	6.53	0.33	2.45e-10	Systemic lupus erythematosus;
LIHC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.54	8.11	0.4	9.19e-15	Longevity;
LIHC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.73	12.29	0.55	5.15e-29	Systemic lupus erythematosus;
LIHC	cis	rs9814567	0.752	rs4456908	chr3:134340353	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-8.91	-0.43	3.07e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.73	-0.34	7.2e-11	Arsenic metabolism;
LIHC	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg19752551	chr11:57585705	CTNND1	0.46	6.38	0.33	5.8e-10	Schizophrenia;
LIHC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg05527609	chr1:210001259	C1orf107	0.58	7.77	0.39	9.22e-14	Red blood cell count;
LIHC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.39	6.04	0.31	3.95e-9	Resting heart rate;
LIHC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00958927	chr1:175162553	KIAA0040	-0.38	-6.21	-0.32	1.52e-9	Alcohol dependence;
LIHC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03573702	chr19:44669354	ZNF226	0.46	6.93	0.35	2.05e-11	Pancreatic cancer;
LIHC	cis	rs2637266	0.756	rs2583064	chr10:78557708	A/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.96e-9	Pulmonary function;
LIHC	cis	rs507080	0.961	rs4457789	chr11:118539170	G/T	cg04173919	chr11:118528438	PHLDB1	0.33	6.2	0.32	1.64e-9	Serum metabolite levels;
LIHC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.95	0.65	3.45e-43	Electrocardiographic conduction measures;
LIHC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.6	12.21	0.55	1.01e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.57	9.95	0.47	1.17e-20	Methadone dose in opioid dependence;
LIHC	cis	rs9513627	0.915	rs73556177	chr13:100121840	G/A	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.0	-0.31	4.89e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg03970086	chr16:88974840	CBFA2T3	0.31	5.96	0.31	6.26e-9	Social autistic-like traits;
LIHC	trans	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg17675199	chr6:35436792	RPL10A	0.32	6.41	0.33	4.87e-10	Coronary artery disease;
LIHC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.88	0.39	4.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.49	-8.61	-0.42	2.72e-16	Longevity;
LIHC	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.44	5.95	0.31	6.53e-9	QT interval;
LIHC	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.01	17.79	0.69	1.34e-50	Subjective well-being;
LIHC	cis	rs6442522	0.560	rs3816526	chr3:15516910	T/C	cg16303742	chr3:15540471	COLQ	0.36	5.91	0.3	8.12e-9	Uric acid levels;
LIHC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.27	-0.45	2.13e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs72653721	1.000	rs72653721	chr6:10971886	C/T	cg13562911	chr6:11044106	ELOVL2	0.5	7.02	0.35	1.2e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	0.97	8.25	0.41	3.56e-15	Lymphocyte counts;
LIHC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.52	-9.99	-0.48	8.87e-21	Prudent dietary pattern;
LIHC	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.54	-0.69	1.36e-49	Schizophrenia;
LIHC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs11761441	0.669	rs13241486	chr7:79536	G/C	cg19711949	chr7:80907	NA	0.33	6.68	0.34	9.99e-11	Alzheimer's disease in APOE e4- carriers;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg17290526	chr17:61600384	KCNH6	-0.42	-6.08	-0.31	3.14e-9	Alopecia areata;
LIHC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.2	-0.41	4.92e-15	Schizophrenia;
LIHC	trans	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg26939375	chr7:64535504	NA	-0.43	-6.97	-0.35	1.65e-11	Aortic root size;
LIHC	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg27386326	chr11:61587980	NA	0.72	15.56	0.64	1.18e-41	Trans fatty acid levels;
LIHC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02290350	chr8:58132656	NA	0.42	8.81	0.43	6.51e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.54	10.17	0.48	2.17e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.15e-11	Body mass index;
LIHC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg22676075	chr6:135203613	NA	0.38	6.29	0.32	9.78e-10	Red blood cell count;
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.23e-9	Blood pressure;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17470061	chr1:33336618	FNDC5	-0.41	-6.05	-0.31	3.79e-9	Calcium levels;
LIHC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.39	6.3	0.32	9.09e-10	Anterior chamber depth;
LIHC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.19	-15.09	-0.63	8.25e-40	Alzheimer's disease (late onset);
LIHC	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	0.66	6.55	0.33	2.15e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.82	-0.47	3.18e-20	Morning vs. evening chronotype;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06420487	chr17:61919686	SMARCD2	0.45	6.22	0.32	1.43e-9	Height;
LIHC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-7.76	-0.39	9.79e-14	Crohn's disease;
LIHC	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.88	-0.39	4.34e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.42	6.18	0.32	1.8e-9	Neuroticism;
LIHC	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.55	6.78	0.34	5.21e-11	Coronary artery disease;
LIHC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.41	-6.18	-0.32	1.79e-9	Menarche (age at onset);
LIHC	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg07817648	chr10:79422355	NA	-0.3	-6.29	-0.32	9.56e-10	Mortality in heart failure;
LIHC	trans	rs7219021	1.000	rs72831853	chr17:46842575	A/T	cg14968300	chr8:23585186	NA	-0.35	-6.44	-0.33	4.1e-10	Schizophrenia or bipolar disorder;
LIHC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.62	7.37	0.37	1.31e-12	Testicular germ cell tumor;
LIHC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.27	-7.1	-0.36	7.05e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.79	0.34	5e-11	Rheumatoid arthritis;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.16	-0.32	2.09e-9	Longevity;
LIHC	cis	rs2766692	0.956	rs35696661	chr14:100742355	G/C	cg14866419	chr14:100704911	YY1	0.44	5.95	0.31	6.67e-9	Electroencephalographic traits in alcoholism;
LIHC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.8	-10.39	-0.49	3.82e-22	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs17818399	0.749	rs35625984	chr2:46805908	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.18	0.36	4.38e-12	Height;
LIHC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs911119	0.954	rs2405367	chr20:23622880	A/G	cg16589663	chr20:23618590	CST3	-0.73	-7.49	-0.38	5.76e-13	Chronic kidney disease;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.33	-12.81	-0.57	5.98e-31	Psoriasis vulgaris;
LIHC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg04709771	chr16:646395	RAB40C	0.45	8.37	0.41	1.44e-15	Height;
LIHC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.11	0.51	1.12e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.58	6.46	0.33	3.59e-10	Eosinophil percentage of granulocytes;
LIHC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.62	-12.58	-0.56	4.45e-30	Plateletcrit;Platelet count;
LIHC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.43	-6.55	-0.33	2.12e-10	Height;
LIHC	cis	rs10861342	1.000	rs11112396	chr12:105568359	T/G	cg23923672	chr12:105501055	KIAA1033	0.69	8.59	0.42	3.19e-16	IgG glycosylation;
LIHC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.56	-7.83	-0.39	6.1e-14	Menopause (age at onset);
LIHC	cis	rs1499280	1.000	rs7711599	chr5:52098755	A/G	cg21153758	chr5:52083992	ITGA1;PELO	-0.65	-5.95	-0.31	6.74e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	trans	rs2096176	0.530	rs7911700	chr10:26286367	G/A	cg01396774	chr2:218299024	DIRC3	-0.31	-6.12	-0.31	2.55e-9	Obesity-related traits;
LIHC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.7	12.44	0.56	1.42e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.74	0.54	5.73e-27	Cognitive ability;
LIHC	trans	rs72960926	0.744	rs72954354	chr6:74949552	C/G	cg07247405	chr1:2484626	LOC115110	0.53	6.41	0.33	4.83e-10	Metabolite levels (MHPG);
LIHC	cis	rs7251806	1	rs7251806	chr19:16499569	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.66	7.81	0.39	6.9e-14	Lymphocyte counts;
LIHC	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.57	7.41	0.37	1.01e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs11958404	0.615	rs10044900	chr5:157451580	C/T	cg05962755	chr5:157440814	NA	-0.58	-7.81	-0.39	7.01e-14	IgG glycosylation;
LIHC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.37	-0.37	1.33e-12	Diabetic kidney disease;
LIHC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.09	20.9	0.75	4.37e-63	Multiple system atrophy;
LIHC	cis	rs712039	0.652	rs7226252	chr17:35794912	C/G	cg16670864	chr17:35848621	DUSP14	0.34	5.91	0.3	8.19e-9	Tuberculosis;
LIHC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.58	-10.07	-0.48	4.71e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg27432699	chr2:27873401	GPN1	-0.55	-8.13	-0.4	7.8e-15	Total body bone mineral density;
LIHC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.7	-11.3	-0.52	2.19e-25	Lung cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17608500	chr1:154955711	FLAD1	0.49	7.39	0.37	1.13e-12	Pancreatic cancer;
LIHC	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg10381502	chr11:71823885	C11orf51	-1.0	-8.62	-0.42	2.6e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11645453	chr3:52864694	ITIH4	0.22	5.83	0.3	1.29e-8	Bipolar disorder;
LIHC	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.83	8.63	0.42	2.35e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.48	6.98	0.35	1.57e-11	Dermatomyositis;
LIHC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	10.3	0.49	7.37e-22	Alzheimer's disease;
LIHC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.78	0.3	1.67e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg25039879	chr17:56429692	SUPT4H1	0.76	8.76	0.43	9.27e-17	Cognitive test performance;
LIHC	trans	rs9836270	1.000	rs9836270	chr3:131916996	G/T	cg10702113	chr3:196664466	NCBP2	-0.37	-6.11	-0.31	2.68e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs8081395	0.804	rs2777884	chr17:57830426	G/A	cg02344993	chr17:57696989	CLTC	-0.45	-7.29	-0.37	2.22e-12	White blood cell count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12633356	chr12:51318640	METTL7A	0.4	6.62	0.34	1.37e-10	Cognitive function;
LIHC	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.55	0.53	2.89e-26	Alzheimer's disease;
LIHC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.39	7.41	0.37	1.01e-12	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.43	-0.53	7.8e-26	Response to antipsychotic treatment;
LIHC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.66	-13.1	-0.58	4.72e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02985541	chr2:219472218	PLCD4	0.45	8.35	0.41	1.69e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.85	0.51	9.34e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs12915189	1.000	rs4352026	chr15:91116163	A/C	cg26821196	chr15:91095069	CRTC3	0.33	5.97	0.31	5.98e-9	Information processing speed;
LIHC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	9.74	0.47	6.22e-20	Personality dimensions;
LIHC	trans	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg21841682	chr14:69445844	ACTN1	0.45	6.1	0.31	2.94e-9	Extraversion;
LIHC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.63	-10.39	-0.49	3.8e-22	Colorectal cancer;
LIHC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg24203234	chr3:128598194	ACAD9	0.45	6.29	0.32	9.77e-10	IgG glycosylation;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.59	-0.38	3.11e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09844907	chr16:15489619	MPV17L	-0.48	-7.08	-0.36	8.47e-12	Cognitive function;
LIHC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.28	0.55	5.92e-29	Prudent dietary pattern;
LIHC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.92	-0.43	2.87e-17	Heart rate;
LIHC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.34	-5.97	-0.31	6.05e-9	IgG glycosylation;
LIHC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg12365402	chr11:9010492	NRIP3	0.29	7.54	0.38	4.21e-13	Hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18732869	chr19:6739680	TRIP10	-0.44	-6.81	-0.35	4.34e-11	Pancreatic cancer;
LIHC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.08	-20.65	-0.74	4.56e-62	IgG glycosylation;
LIHC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	7.75	0.39	1.09e-13	Platelet count;
LIHC	cis	rs2279817	0.863	rs13375581	chr1:18016491	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-8.05	-0.4	1.36e-14	Neuroticism;
LIHC	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.64	10.43	0.49	2.66e-22	Recombination rate (males);
LIHC	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg22138327	chr13:27999177	GTF3A	0.76	6.26	0.32	1.17e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg02573091	chr5:74908125	NA	-0.55	-6.71	-0.34	8.03e-11	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-5.91	-0.3	8.31e-9	Neuroticism;
LIHC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.67	-9.97	-0.47	9.98e-21	Mosquito bite size;
LIHC	cis	rs2274273	0.623	rs1187881	chr14:55489197	G/A	cg01864836	chr14:55583639	NA	0.34	5.74	0.3	2.07e-8	Protein biomarker;
LIHC	cis	rs17286411	0.777	rs4788569	chr16:71914785	A/G	cg06353428	chr16:71660113	MARVELD3	0.56	7.06	0.36	9.2e-12	Blood protein levels;
LIHC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.69	5.79	0.3	1.62e-8	Cognitive function;
LIHC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.65	12.6	0.56	3.54e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.07	16.04	0.66	1.47e-43	Cognitive function;
LIHC	cis	rs1163251	0.623	rs493427	chr1:120207482	A/T	cg19096424	chr1:120255104	PHGDH	-0.52	-6.49	-0.33	2.95e-10	Blood metabolite levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03627896	chr16:30934334	NCRNA00095	-0.5	-6.08	-0.31	3.14e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01688141	chr8:23539808	NKX3-1	0.47	6.5	0.33	2.82e-10	Pancreatic cancer;
LIHC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	7.29	0.37	2.13e-12	Total body bone mineral density;
LIHC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg05084668	chr3:125655381	ALG1L	-0.34	-6.13	-0.31	2.39e-9	Blood pressure (smoking interaction);
LIHC	cis	rs17079247	1.000	rs17079247	chr13:85665879	C/T	ch.13.84760847R	chr13:85862846	NA	-0.51	-6.66	-0.34	1.08e-10	Bipolar disorder (mania);
LIHC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.4	6.44	0.33	4e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg03146154	chr1:46216737	IPP	-0.41	-6.78	-0.34	5.34e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs61041384	0.661	rs4148858	chr12:123540022	G/A	cg00376283	chr12:123451042	ABCB9	-0.6	-5.72	-0.3	2.37e-8	Schizophrenia;
LIHC	cis	rs1461503	0.934	rs7115679	chr11:122831963	A/G	cg25161029	chr11:122845972	NA	0.41	6.7	0.34	8.41e-11	Menarche (age at onset);
LIHC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.07	0.36	8.6e-12	Hemoglobin concentration;
LIHC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg14393609	chr7:65229607	NA	-0.37	-5.88	-0.3	9.55e-9	Aortic root size;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.6	8.85	0.43	4.66e-17	Menarche (age at onset);
LIHC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.38	-6.08	-0.31	3.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg12317470	chr15:67143691	NA	0.58	5.94	0.31	7.01e-9	Lung cancer (smoking interaction);
LIHC	cis	rs7619427	0.908	rs7639253	chr3:44076205	C/T	cg24966902	chr3:44043705	NA	0.5	7.05	0.36	9.76e-12	Schizophrenia;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.16	-0.32	2.05e-9	Total body bone mineral density;
LIHC	cis	rs507080	0.769	rs571001	chr11:118500173	C/T	cg04173919	chr11:118528438	PHLDB1	0.32	5.86	0.3	1.11e-8	Serum metabolite levels;
LIHC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg11764359	chr7:65958608	NA	0.57	5.87	0.3	1.06e-8	Diabetic kidney disease;
LIHC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-6.38	-0.33	5.6e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.8	-0.3	1.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg16070123	chr10:51489643	NA	-0.38	-5.96	-0.31	6.16e-9	Prostate-specific antigen levels;
LIHC	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.05	0.44	1.07e-17	Coffee consumption (cups per day);
LIHC	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg04865290	chr3:52927548	TMEM110	-0.41	-6.03	-0.31	4.15e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.29	20.62	0.74	5.6e-62	Corneal structure;
LIHC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.86	-0.43	4.32e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg12863693	chr15:85201151	NMB	0.45	6.29	0.32	9.9e-10	Schizophrenia;
LIHC	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-0.91	-10.65	-0.5	4.46e-23	Vitiligo;
LIHC	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	6.59	0.34	1.71e-10	Lymphocyte counts;
LIHC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.57	-6.31	-0.32	8.54e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs4322600	0.963	rs34332718	chr14:88287016	C/A	cg16008221	chr8:17823628	PCM1	-0.42	-6.23	-0.32	1.36e-9	Breast cancer;
LIHC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.89	10.61	0.5	6.2e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.79	0.3	1.63e-8	Bipolar disorder;
LIHC	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.54e-12	Corneal astigmatism;
LIHC	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg07952391	chr2:88470173	THNSL2	0.76	7.81	0.39	6.93e-14	Plasma clusterin levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11829380	chr17:5323521	RPAIN;NUP88	-0.46	-6.18	-0.32	1.83e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.59	0.5	7.57e-23	Bladder cancer;
LIHC	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.77	8.87	0.43	4.24e-17	Neuroticism;
LIHC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-8.65	-0.42	1.97e-16	Schizophrenia;
LIHC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.37	-0.45	1.05e-18	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.49	7.22	0.36	3.4e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.52	8.08	0.4	1.15e-14	Tonsillectomy;
LIHC	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	8.21	0.41	4.68e-15	Response to antipsychotic treatment;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-8.01	-0.4	1.84e-14	Lymphocyte counts;
LIHC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.63	9.98	0.47	9.57e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs2257205	0.667	rs11653526	chr17:56761417	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-6.79	-0.34	5.06e-11	Pancreatic cancer;
LIHC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.39	-0.37	1.12e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg09182678	chr22:50328711	NA	-0.46	-6.68	-0.34	9.66e-11	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.21	0.61	2.47e-36	Chronic sinus infection;
LIHC	cis	rs600806	0.778	rs11101962	chr1:110014187	A/T	cg23091122	chr1:110024289	SYPL2	-0.44	-6.09	-0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs9649465	1.000	rs13230338	chr7:123373622	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.25e-15	Migraine;
LIHC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg14930904	chr10:32216787	ARHGAP12	0.4	7.02	0.35	1.21e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7187994	0.895	rs12933276	chr16:84770867	C/T	cg07647771	chr16:84786436	USP10	-0.33	-6.02	-0.31	4.44e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.76	0.3	1.88e-8	Vitiligo;
LIHC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.19	-0.32	1.73e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.65	-8.91	-0.43	2.99e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2506155	0.525	rs56242597	chr10:33528271	T/C	cg03349118	chr8:59572480	NSMAF	-0.6	-6.35	-0.32	6.96e-10	Migraine;
LIHC	cis	rs10423674	0.526	rs11085241	chr19:18828546	G/A	cg16673477	chr19:18812017	CRTC1	-0.41	-6.5	-0.33	2.82e-10	Menarche (age at onset);
LIHC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.66	-9.89	-0.47	1.92e-20	Coronary artery disease;
LIHC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg15691649	chr6:25882328	NA	-0.42	-6.7	-0.34	8.62e-11	Height;
LIHC	cis	rs595982	0.702	rs623520	chr19:49369943	A/G	cg21252483	chr19:49399788	TULP2	-0.46	-7.61	-0.38	2.71e-13	Red cell distribution width;
LIHC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.48	-8.26	-0.41	3.14e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.45	6.59	0.34	1.62e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.86	0.39	4.98e-14	Schizophrenia;
LIHC	cis	rs34540877	1.000	rs11666270	chr19:33146471	A/G	cg22980127	chr19:33182716	NUDT19	-0.86	-5.96	-0.31	6.39e-9	Red cell distribution width;
LIHC	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.49	-7.2	-0.36	3.93e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	1.0	11.72	0.54	6.83e-27	Red blood cell traits;
LIHC	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.72	-13.06	-0.58	6.65e-32	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.26	-7.01	-0.35	1.26e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1144333	0.655	rs12401729	chr1:76336586	T/G	cg10523679	chr1:76189770	ACADM	0.45	6.01	0.31	4.88e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs9531686	1.000	rs7319821	chr13:85548207	G/A	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.29	0.32	9.79e-10	Anorexia nervosa;
LIHC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.55	-9.29	-0.45	1.88e-18	Cognitive function;
LIHC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.46	-9.13	-0.44	5.9e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.67	-0.46	1.04e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg14393609	chr7:65229607	NA	0.44	6.56	0.33	2.04e-10	Aortic root size;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02254876	chr3:42922351	NA	-0.49	-6.27	-0.32	1.11e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.48	0.37	6.42e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs9918079	0.542	rs1789	chr4:15664535	G/A	cg21123203	chr4:15471301	CC2D2A	-0.45	-7.19	-0.36	4.13e-12	Obesity-related traits;
LIHC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.45	-7.29	-0.37	2.18e-12	Cognitive function;
LIHC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-8.19	-0.4	5.34e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.58	-0.38	3.36e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.55	6.45	0.33	3.89e-10	Mammographic density (dense area);
LIHC	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg14709524	chr16:89940631	TCF25	0.59	7.64	0.38	2.24e-13	Skin colour saturation;
LIHC	cis	rs887797	0.557	rs8080721	chr17:64585357	C/T	cg27019712	chr17:64599478	PRKCA	-0.39	-6.84	-0.35	3.61e-11	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs12986413	0.651	rs2238612	chr19:2149694	C/T	cg09261902	chr19:2140048	AP3D1	-0.42	-6.98	-0.35	1.54e-11	Height;
LIHC	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	0.79	8.68	0.43	1.59e-16	Mitochondrial DNA levels;
LIHC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.62	-0.42	2.57e-16	Heart rate;
LIHC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg10845886	chr2:3471009	TTC15	-0.44	-8.32	-0.41	2.09e-15	Neurofibrillary tangles;
LIHC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.54	0.53	2.93e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs370915	1.000	rs370915	chr4:187818256	C/G	cg19519643	chr4:187840862	NA	-0.39	-6.63	-0.34	1.29e-10	Gout;
LIHC	cis	rs17106184	1.000	rs58791125	chr1:51342856	G/A	cg07174182	chr1:51127561	FAF1	-0.61	-6.84	-0.35	3.57e-11	Type 2 diabetes;
LIHC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.86	-0.3	1.06e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7635838	0.892	rs9852530	chr3:11466469	C/T	cg00170343	chr3:11313890	ATG7	0.43	6.77	0.34	5.46e-11	HDL cholesterol;
LIHC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.56	8.46	0.42	7.75e-16	Resting heart rate;
LIHC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.17	0.55	1.54e-28	Motion sickness;
LIHC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-5.97	-0.31	5.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.32	6.2	0.32	1.65e-9	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg25894440	chr7:65020034	NA	0.55	6.21	0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.18	0.44	4.06e-18	Hemoglobin concentration;
LIHC	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-0.79	-9.02	-0.44	1.36e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	6.99	0.35	1.42e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.4	-5.84	-0.3	1.21e-8	Iron status biomarkers;
LIHC	trans	rs12643302	0.634	rs6553566	chr4:172373998	G/C	cg18857951	chr14:94395516	FAM181A	0.22	6.22	0.32	1.49e-9	Facial morphology (factor 3, length of philtrum);
LIHC	cis	rs903552	1.000	rs12903048	chr15:102006325	G/T	cg06707286	chr15:102010195	PCSK6	-0.44	-6.26	-0.32	1.13e-9	Diabetic kidney disease;
LIHC	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.59	9.55	0.46	2.59e-19	Corneal astigmatism;
LIHC	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg19680672	chr10:131412579	MGMT	-0.43	-6.41	-0.33	4.97e-10	Response to temozolomide;
LIHC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.51	-7.37	-0.37	1.31e-12	Breast size;
LIHC	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg26138937	chr11:71823887	C11orf51	-1.34	-10.79	-0.5	1.53e-23	Severe influenza A (H1N1) infection;
LIHC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.59	-9.34	-0.45	1.27e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg20240347	chr1:204465584	NA	-0.35	-7.48	-0.37	6.51e-13	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06425136	chr16:31040922	NA	-0.38	-6.54	-0.33	2.22e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-8.18	-0.4	5.75e-15	Hepatocellular carcinoma;
LIHC	cis	rs965469	1.000	rs6037554	chr20:3315613	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-7.06	-0.36	9.15e-12	IFN-related cytopenia;
LIHC	cis	rs4450131	0.522	rs3781453	chr10:126348761	T/C	cg20435097	chr10:126320824	FAM53B	0.67	12.35	0.56	3.21e-29	White blood cell count (basophil);
LIHC	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg10820045	chr2:198174542	NA	0.47	7.01	0.35	1.27e-11	Dermatomyositis;
LIHC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg09904177	chr6:26538194	HMGN4	-0.53	-5.72	-0.3	2.37e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06441946	chr5:145583671	RBM27	0.48	6.68	0.34	9.44e-11	Pancreatic cancer;
LIHC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.58	8.65	0.42	1.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19626725	chr5:178986131	RUFY1	-0.38	-5.85	-0.3	1.16e-8	Lung cancer;
LIHC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.6	-10.76	-0.5	1.95e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27022615	chr11:70049105	FADD	0.44	6.34	0.32	7.26e-10	Pancreatic cancer;
LIHC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.26	6.48	0.33	3.12e-10	Cutaneous nevi;
LIHC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.0	0.31	4.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.59	-0.34	1.67e-10	Blood metabolite levels;
LIHC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.65	12.48	0.56	1e-29	High light scatter reticulocyte count;
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.43	0.33	4.31e-10	Prudent dietary pattern;
LIHC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.49	8.2	0.41	4.8e-15	Longevity;Endometriosis;
LIHC	cis	rs7503168	1.000	rs16971227	chr17:33949222	G/A	cg20932281	chr17:33905541	PEX12	0.54	7.01	0.35	1.24e-11	Plateletcrit;
LIHC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.59	8.43	0.41	9.64e-16	Aortic root size;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12467960	chr11:68201194	LRP5	0.42	6.17	0.32	1.94e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.87e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.38	5.79	0.3	1.59e-8	Eosinophil percentage of white cells;
LIHC	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07080220	chr10:102295463	HIF1AN	0.44	6.02	0.31	4.49e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-6.91	-0.35	2.38e-11	Prostate cancer;
LIHC	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg26441486	chr22:50317300	CRELD2	0.36	6.47	0.33	3.32e-10	Schizophrenia;
LIHC	cis	rs6066825	0.644	rs4810864	chr20:47319142	G/C	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.59e-12	Colorectal cancer;
LIHC	cis	rs72627509	0.680	rs3733309	chr4:57857188	A/G	cg26694713	chr4:57773883	REST	0.66	8.72	0.43	1.19e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg00656387	chr3:40428638	ENTPD3	0.42	6.95	0.35	1.81e-11	Renal cell carcinoma;
LIHC	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.25	5.97	0.31	5.97e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	10.61	0.5	6.32e-23	Body mass index (adult);
LIHC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.64	11.2	0.52	5.02e-25	Platelet distribution width;
LIHC	cis	rs4700695	0.841	rs27132	chr5:65288791	A/G	cg21114390	chr5:65439923	SFRS12	0.44	5.74	0.3	2.11e-8	Facial morphology (factor 19);
LIHC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg12458913	chr13:53173898	NA	0.5	8.04	0.4	1.5e-14	Lewy body disease;
LIHC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg27432699	chr2:27873401	GPN1	-0.53	-7.58	-0.38	3.33e-13	Total body bone mineral density;
LIHC	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.4	-5.92	-0.3	7.77e-9	Smoking behavior;
LIHC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-7.22	-0.36	3.32e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.17	-13.06	-0.58	6.87e-32	White matter hyperintensity burden;
LIHC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-7.49	-0.38	5.97e-13	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.59	-7.14	-0.36	5.7e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.46	7.01	0.35	1.31e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.43	0.53	7.85e-26	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.06	0.36	9.33e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg25801113	chr15:45476975	SHF	0.38	6.55	0.33	2.1e-10	Uric acid levels;
LIHC	cis	rs7395581	0.918	rs326214	chr11:47298360	G/A	cg25783544	chr11:47291846	MADD	-0.4	-5.87	-0.3	1.04e-8	HDL cholesterol;
LIHC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.88	0.35	2.86e-11	Red blood cell count;
LIHC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg14393609	chr7:65229607	NA	0.44	6.48	0.33	3.28e-10	Aortic root size;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01516881	chr6:292596	DUSP22	-0.5	-6.37	-0.33	6.27e-10	Menopause (age at onset);
LIHC	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.73	11.2	0.52	5.32e-25	Metabolite levels;
LIHC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg18944383	chr4:111397179	ENPEP	-0.38	-8.9	-0.43	3.31e-17	Height;
LIHC	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg19773385	chr1:10388646	KIF1B	-0.46	-7.13	-0.36	6.02e-12	Hepatocellular carcinoma;
LIHC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	10.47	0.49	1.92e-22	Alzheimer's disease;
LIHC	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg13395646	chr4:1353034	KIAA1530	0.41	6.49	0.33	2.97e-10	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.66	10.66	0.5	4.18e-23	Menopause (age at onset);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19712745	chr6:131275789	EPB41L2	-0.27	-6.31	-0.32	8.52e-10	Calcium levels;
LIHC	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.32	7.23	0.36	3.19e-12	Blood metabolite ratios;
LIHC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg03945807	chr20:60948434	NA	-0.46	-6.19	-0.32	1.76e-9	Colorectal cancer;
LIHC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.3	0.37	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03523744	chr5:108746281	PJA2	0.42	6.49	0.33	3.08e-10	Pancreatic cancer;
LIHC	cis	rs7937890	0.559	rs4369365	chr11:14444515	C/G	cg22961513	chr11:14280813	SPON1	-0.43	-6.38	-0.33	5.89e-10	Mitochondrial DNA levels;
LIHC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.39	-6.63	-0.34	1.35e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.54e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg00277334	chr10:82204260	NA	-0.53	-6.47	-0.33	3.37e-10	Post bronchodilator FEV1;
LIHC	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-6.87	-0.35	3.07e-11	Metabolite levels;
LIHC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.86	0.43	4.49e-17	Cognitive ability;
LIHC	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.33	-0.37	1.67e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.51	-7.3	-0.37	2.1e-12	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.8	0.43	6.83e-17	Asthma (sex interaction);
LIHC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-6.57	-0.33	1.9e-10	Hemoglobin concentration;
LIHC	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg27386326	chr11:61587980	NA	0.69	14.74	0.62	1.99e-38	Trans fatty acid levels;
LIHC	cis	rs611744	0.868	rs612722	chr8:109194850	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.55	-8.39	-0.41	1.26e-15	Systemic sclerosis;
LIHC	cis	rs10508774	1.000	rs12243271	chr10:32746639	G/C	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.2e-10	Renal cell carcinoma;
LIHC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.41	6.41	0.33	4.75e-10	Multiple sclerosis;
LIHC	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg07424592	chr7:64974309	NA	0.78	8.92	0.43	2.84e-17	Gout;
LIHC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg20129853	chr10:51489980	NA	0.41	8.96	0.44	2.11e-17	Prostate-specific antigen levels;
LIHC	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg17757837	chr7:157058334	UBE3C	-0.57	-5.89	-0.3	9.45e-9	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg25894440	chr7:65020034	NA	-0.49	-5.73	-0.3	2.23e-8	Diabetic kidney disease;
LIHC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.95e-11	Aortic root size;
LIHC	cis	rs7116495	1.000	rs674735	chr11:71560580	A/G	cg26138937	chr11:71823887	C11orf51	0.67	6.43	0.33	4.3e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.33	7.23	0.36	3.22e-12	Ulcerative colitis;
LIHC	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg18192155	chr21:44258298	NA	0.38	5.72	0.3	2.29e-8	Information processing speed;
LIHC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.63	8.95	0.44	2.34e-17	Initial pursuit acceleration;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg00656387	chr3:40428638	ENTPD3	-0.47	-8.32	-0.41	2.16e-15	Renal cell carcinoma;
LIHC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.22	0.36	3.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.69	9.8	0.47	3.66e-20	IgG glycosylation;
LIHC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.26	0.61	1.54e-36	Chronic sinus infection;
LIHC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.47	-7.05	-0.36	9.86e-12	Cognitive function;
LIHC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.58	8.44	0.42	9.01e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.45	-7.41	-0.37	9.95e-13	Obesity-related traits;
LIHC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-6.6	-0.34	1.57e-10	Initial pursuit acceleration;
LIHC	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.11	-0.44	6.87e-18	Colorectal cancer;
LIHC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.75	0.43	1.01e-16	Menarche (age at onset);
LIHC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.6	0.34	1.57e-10	Bipolar disorder;
LIHC	cis	rs72781680	0.566	rs6713979	chr2:23899876	A/G	cg08917208	chr2:24149416	ATAD2B	0.62	6.13	0.31	2.41e-9	Lymphocyte counts;
LIHC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	6.37	0.33	6.07e-10	Mean corpuscular hemoglobin;
LIHC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	1.01	19.67	0.73	3.61e-58	Breast cancer;
LIHC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07305463	chr2:136567211	LCT	-0.38	-5.84	-0.3	1.2e-8	Corneal structure;
LIHC	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.66	10.41	0.49	3.11e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1881396	0.947	rs10173720	chr2:27855397	A/T	cg27432699	chr2:27873401	GPN1	-0.49	-7.54	-0.38	4.38e-13	Nonalcoholic fatty liver disease;
LIHC	cis	rs16828019	0.852	rs12729586	chr1:41522377	C/A	cg20697417	chr1:41786797	NA	0.31	5.82	0.3	1.35e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg15902774	chr15:75289873	SCAMP5	0.33	5.86	0.3	1.06e-8	Systemic lupus erythematosus;
LIHC	cis	rs17152411	1.000	rs11245423	chr10:126588435	C/A	cg07906193	chr10:126599966	NA	0.42	6.61	0.34	1.48e-10	Height;
LIHC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg23205692	chr1:25664452	TMEM50A	0.37	5.75	0.3	1.94e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg01200585	chr1:228362443	C1orf69	0.5	6.32	0.32	8.19e-10	Diastolic blood pressure;
LIHC	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.33	-0.37	1.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.45	6.56	0.33	1.99e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21467203	chr3:49911342	NA	-0.45	-8.05	-0.4	1.37e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.93	0.39	3.07e-14	Tonsillectomy;
LIHC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.46	7.62	0.38	2.6e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg03854865	chr6:26224070	HIST1H3E	0.65	7.72	0.39	1.33e-13	Gout;Renal underexcretion gout;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg03395511	chr6:291903	DUSP22	-0.51	-6.7	-0.34	8.71e-11	Menopause (age at onset);
LIHC	trans	rs11088226	0.692	rs2833863	chr21:33886986	A/G	cg09050820	chr6:167586206	TCP10L2	0.46	6.88	0.35	2.79e-11	Gastritis;
LIHC	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.61	0.5	6.21e-23	Hypertriglyceridemia;
LIHC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.52	-0.38	4.91e-13	Psoriasis;
LIHC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.3	16.95	0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs7903847	1.000	rs7903847	chr10:99154982	T/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.12	-0.31	2.5e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg03517284	chr6:25882590	NA	-0.38	-5.76	-0.3	1.83e-8	Height;
LIHC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17554472	chr22:41940697	POLR3H	0.56	5.99	0.31	5.18e-9	Vitiligo;
LIHC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.6	0.42	2.93e-16	Motion sickness;
LIHC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg25281562	chr12:121454272	C12orf43	0.47	8.0	0.4	2.01e-14	N-glycan levels;
LIHC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.42	5.99	0.31	5.45e-9	Breast cancer;
LIHC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg10018233	chr7:150070692	REPIN1	0.56	8.61	0.42	2.75e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.46	6.83	0.35	3.89e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg20933634	chr6:27740509	NA	0.47	6.31	0.32	8.82e-10	Parkinson's disease;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.46	-6.85	-0.35	3.44e-11	Menopause (age at onset);
LIHC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08280861	chr8:58055591	NA	0.54	6.13	0.31	2.45e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.44	0.53	7.17e-26	Coronary artery disease;
LIHC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.39	6.22	0.32	1.42e-9	Red blood cell count;
LIHC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg24879335	chr3:133465180	TF	0.31	6.98	0.35	1.56e-11	Iron status biomarkers;
LIHC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.42	6.1	0.31	2.82e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.69	-8.39	-0.41	1.25e-15	Morning vs. evening chronotype;
LIHC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg22079354	chr11:130786696	SNX19	0.41	5.82	0.3	1.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	10.06	0.48	5.19e-21	Hip circumference adjusted for BMI;
LIHC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.28	-0.45	2e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg14671364	chr1:107599128	PRMT6	-0.47	-6.93	-0.35	2.04e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg03387723	chr1:41708464	SCMH1	-0.41	-6.76	-0.34	5.83e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg09003973	chr2:102972529	NA	0.81	7.04	0.36	1.04e-11	Gut microbiota (bacterial taxa);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15072735	chr9:72375102	PTAR1	0.47	6.79	0.34	5.02e-11	Pancreatic cancer;
LIHC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.7	-9.62	-0.46	1.53e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs17152411	0.895	rs7084646	chr10:126585738	T/C	cg07906193	chr10:126599966	NA	0.44	6.9	0.35	2.5e-11	Height;
LIHC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.34	0.45	1.31e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.02	-19.4	-0.72	4.36e-57	Exhaled nitric oxide output;
LIHC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-13.53	-0.59	1.04e-33	Vitiligo;
LIHC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-13.15	-0.58	2.95e-32	Sense of smell;
LIHC	cis	rs11673344	0.704	rs1644710	chr19:37417062	A/G	cg27390819	chr19:37464633	NA	-0.5	-6.01	-0.31	4.69e-9	Obesity-related traits;
LIHC	cis	rs7793919	0.628	rs4720402	chr7:4780961	T/G	cg09789173	chr7:4769017	FOXK1	0.73	10.52	0.49	1.28e-22	Mosquito bite size;
LIHC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.82	-0.63	1.04e-38	Alzheimer's disease (late onset);
LIHC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.83	0.54	2.58e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.86	11.85	0.54	2.32e-27	Blood metabolite levels;
LIHC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg16558253	chr16:72132732	DHX38	0.38	6.19	0.32	1.71e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.85	-0.35	3.41e-11	Diabetic kidney disease;
LIHC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.11	-0.31	2.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04238871	chr10:126431886	FAM53B	0.39	6.4	0.33	4.99e-10	Cognitive function;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03861428	chr1:17380702	SDHB	0.44	6.42	0.33	4.58e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.55	8.41	0.41	1.16e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	8.33	0.41	1.92e-15	Height;
LIHC	cis	rs1461503	0.512	rs4259833	chr11:122809205	G/A	cg25161029	chr11:122845972	NA	0.34	6.07	0.31	3.4e-9	Menarche (age at onset);
LIHC	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.65	-10.48	-0.49	1.83e-22	Pediatric autoimmune diseases;
LIHC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.67	11.31	0.52	2.06e-25	Lymphocyte counts;
LIHC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.33	7.41	0.37	9.82e-13	Inflammatory bowel disease;Ulcerative colitis;
LIHC	trans	rs78049276	0.736	rs17612742	chr4:148414651	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.54	6.57	0.33	1.92e-10	Pulse pressure;
LIHC	cis	rs6450176	0.909	rs11742688	chr5:53291081	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs4919087	0.715	rs2484880	chr10:98998355	T/C	cg25902810	chr10:99078978	FRAT1	-0.51	-5.91	-0.3	8.29e-9	Monocyte count;
LIHC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.35	-6.14	-0.32	2.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs12744310	1.000	rs35318047	chr1:41755166	C/T	cg03962019	chr1:41807865	NA	0.38	6.19	0.32	1.73e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs15676	0.783	rs2280843	chr9:131585069	A/G	cg00228799	chr9:131580591	ENDOG	0.48	6.99	0.35	1.44e-11	Blood metabolite levels;
LIHC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.31	5.75	0.3	1.99e-8	Diastolic blood pressure;
LIHC	cis	rs10426930	0.607	rs858423	chr19:5048374	T/C	cg18473234	chr19:5097819	KDM4B	-0.58	-6.88	-0.35	2.94e-11	Monocyte percentage of white cells;
LIHC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.25	0.45	2.45e-18	Eosinophil percentage of white cells;
LIHC	cis	rs9612	0.718	rs346535	chr19:44251425	C/T	cg08581076	chr19:44259116	C19orf61	0.59	7.77	0.39	9.53e-14	Exhaled nitric oxide output;
LIHC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg07895657	chr22:50616420	PANX2	-0.38	-6.85	-0.35	3.35e-11	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.97	0.8	4.54e-79	Prudent dietary pattern;
LIHC	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.79	13.09	0.58	5.05e-32	Breast cancer;
LIHC	cis	rs1555399	0.967	rs11627207	chr14:67985000	G/T	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.72	-0.3	2.37e-8	Parkinson's disease;
LIHC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.43	-0.33	4.27e-10	Type 2 diabetes;
LIHC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg26874164	chr19:58962979	ZNF324B	0.59	8.96	0.44	2.09e-17	Uric acid clearance;
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.76	13.37	0.59	4.41e-33	Bipolar disorder and schizophrenia;
LIHC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	11.32	0.52	1.93e-25	Electrocardiographic conduction measures;
LIHC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg20487152	chr13:99095054	FARP1	-0.35	-5.76	-0.3	1.9e-8	Longevity;
LIHC	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.77	11.13	0.52	9.25e-25	Response to hepatitis C treatment;
LIHC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.56	6.62	0.34	1.4e-10	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	0.67	6.65	0.34	1.14e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	15.52	0.64	1.67e-41	Exhaled nitric oxide output;
LIHC	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.28	6.62	0.34	1.38e-10	Gut microbiome composition (winter);
LIHC	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.66	-0.34	1.06e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23422044	chr7:1970798	MAD1L1	-0.51	-7.99	-0.4	2.07e-14	Neuroticism;
LIHC	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.14	0.36	5.67e-12	Breast cancer;
LIHC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.44	6.67	0.34	1.05e-10	Post bronchodilator FEV1;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.77	-0.3	1.73e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.52	0.38	5.02e-13	Mean platelet volume;
LIHC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.76	0.3	1.84e-8	Menopause (age at onset);
LIHC	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.2	0.55	1.12e-28	Eye color traits;
LIHC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.49	0.49	1.69e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.13	-0.63	6.08e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-7.02	-0.35	1.22e-11	Morning vs. evening chronotype;
LIHC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.95	-0.31	6.56e-9	Headache;
LIHC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.91	-0.51	5.6e-24	Hemoglobin concentration;
LIHC	cis	rs600806	0.778	rs2152924	chr1:110011701	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.24	-0.32	1.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.48	-5.87	-0.3	1.04e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.28	-0.37	2.34e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs648044	0.520	rs500629	chr11:114045560	G/T	cg01914181	chr11:114070210	ZBTB16	0.49	7.22	0.36	3.3e-12	Non-glioblastoma glioma;
LIHC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.26	-0.45	2.34e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.9	-0.39	3.86e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18598152	chr14:24020957	NA	0.41	6.1	0.31	2.93e-9	Pancreatic cancer;
LIHC	cis	rs600806	0.778	rs10494040	chr1:110015732	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.58	-7.38	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg19160353	chr10:3827878	KLF6	-0.43	-6.09	-0.31	3.06e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.53	6.57	0.33	1.88e-10	Menarche (age at onset);
LIHC	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.48	-6.34	-0.32	7.09e-10	Interleukin-17 levels;
LIHC	trans	rs10411161	0.938	rs17778649	chr19:52381616	C/T	cg22319618	chr22:45562946	NUP50	-0.53	-7.23	-0.36	3.19e-12	Breast cancer;
LIHC	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.63	-0.5	5.35e-23	Eye color traits;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg22054328	chr4:184930219	STOX2	0.34	5.81	0.3	1.46e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	trans	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg17675199	chr6:35436792	RPL10A	0.31	6.22	0.32	1.49e-9	Coronary artery disease;
LIHC	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	0.87	14.04	0.6	1.14e-35	Left atrial antero-posterior diameter;
LIHC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.92	0.51	5.04e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.29	-0.37	2.18e-12	Monocyte percentage of white cells;
LIHC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.97	15.36	0.64	7.3e-41	Metabolic syndrome;
LIHC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg11764359	chr7:65958608	NA	-0.56	-5.87	-0.3	1.03e-8	Diabetic kidney disease;
LIHC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.57	-7.73	-0.39	1.21e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.32	6.45	0.33	3.76e-10	QRS complex (12-leadsum);
LIHC	cis	rs4788570	0.537	rs12149254	chr16:71458851	G/A	cg06353428	chr16:71660113	MARVELD3	-0.92	-8.43	-0.41	9.69e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	11.01	0.51	2.43e-24	Myopia (pathological);
LIHC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.65	-10.83	-0.51	1.04e-23	Monocyte percentage of white cells;
LIHC	cis	rs12101261	0.536	rs2371463	chr14:81457788	G/A	cg06600135	chr14:81408086	NA	0.41	7.2	0.36	3.88e-12	Graves' disease;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	23.27	0.78	1.78e-72	Prudent dietary pattern;
LIHC	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg12454167	chr3:186435060	KNG1	0.33	7.74	0.39	1.11e-13	Blood protein levels;
LIHC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.52	0.53	3.62e-26	Coronary artery disease;
LIHC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg02931644	chr1:25747376	RHCE	-0.37	-8.22	-0.41	4.26e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg23978390	chr7:1156363	C7orf50	0.54	8.06	0.4	1.32e-14	Longevity;Endometriosis;
LIHC	cis	rs709400	0.588	rs61996718	chr14:104048834	G/A	cg26031613	chr14:104095156	KLC1	1.03	10.38	0.49	4.11e-22	Body mass index;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg14709524	chr16:89940631	TCF25	0.48	6.4	0.33	5.23e-10	Skin colour saturation;
LIHC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.39	6.59	0.34	1.65e-10	Schizophrenia;
LIHC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg12458913	chr13:53173898	NA	0.49	7.68	0.38	1.7e-13	Lewy body disease;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg11766577	chr21:47581405	C21orf56	-0.37	-5.86	-0.3	1.1e-8	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg15192750	chr16:69999425	NA	0.47	7.11	0.36	6.86e-12	IgE levels;
LIHC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.67	7.18	0.36	4.27e-12	Triglycerides;
LIHC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.39	6.05	0.31	3.75e-9	Menopause (age at onset);
LIHC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg19680672	chr10:131412579	MGMT	0.42	6.4	0.33	5.22e-10	Response to temozolomide;
LIHC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.26	-0.32	1.16e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12463550	chr7:65579703	CRCP	0.61	6.65	0.34	1.18e-10	Gout;
LIHC	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg08824895	chr13:115047677	UPF3A	0.5	7.23	0.36	3.16e-12	Schizophrenia;
LIHC	cis	rs807029	0.577	rs11190787	chr10:102758625	G/T	cg17130504	chr10:102756923	LZTS2	0.55	7.59	0.38	3.15e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.7	11.37	0.52	1.29e-25	Parkinson's disease;
LIHC	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg20697417	chr1:41786797	NA	0.35	6.59	0.34	1.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19671926	chr4:122722719	EXOSC9	0.45	6.72	0.34	7.7e-11	Type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.52	-0.33	2.52e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	1.01	16.18	0.66	4.1e-44	Body mass index;
LIHC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.4	7.58	0.38	3.39e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs939574	1.000	rs6712442	chr2:220117333	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.94	-10.18	-0.48	1.94e-21	Platelet distribution width;
LIHC	cis	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17459225	chr2:239074497	NA	0.36	5.81	0.3	1.47e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.33	7.43	0.37	8.91e-13	Ulcerative colitis;
LIHC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.59	5.78	0.3	1.71e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.59	9.46	0.46	4.95e-19	Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.3	-0.37	2.02e-12	Body mass index;
LIHC	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.4	-0.33	5.1e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg14132834	chr19:41945861	ATP5SL	-0.39	-5.8	-0.3	1.51e-8	Height;
LIHC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.41	7.48	0.37	6.38e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.72	0.3	2.37e-8	Platelet count;
LIHC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	1.04	13.56	0.59	7.96e-34	Red blood cell traits;
LIHC	cis	rs9378688	0.654	rs2505663	chr6:2325931	A/G	cg12303981	chr6:2244766	GMDS	-0.43	-6.08	-0.31	3.21e-9	Caudate nucleus volume;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12517452	chr5:52084045	ITGA1;PELO	-0.4	-6.26	-0.32	1.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.41	6.91	0.35	2.33e-11	Neuroticism;
LIHC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-8.85	-0.43	4.67e-17	Vitiligo;
LIHC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	7.06	0.36	9.18e-12	Monocyte percentage of white cells;
LIHC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.88	-0.39	4.28e-14	Type 2 diabetes;
LIHC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.91	-0.35	2.4e-11	Morning vs. evening chronotype;
LIHC	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.69	0.34	9.01e-11	Ileal carcinoids;
LIHC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.6	-0.34	1.55e-10	Menarche (age at onset);
LIHC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.39	-6.31	-0.32	8.5e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.84	0.3	1.24e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.83	14.84	0.63	8.54e-39	Coronary artery disease;
LIHC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.98	-0.31	5.54e-9	Life satisfaction;
LIHC	cis	rs4919087	0.748	rs11189131	chr10:99085835	G/A	cg25902810	chr10:99078978	FRAT1	-0.6	-7.81	-0.39	6.9e-14	Monocyte count;
LIHC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg06238570	chr21:40685208	BRWD1	-0.59	-7.09	-0.36	7.51e-12	Cognitive function;
LIHC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.43	6.01	0.31	4.66e-9	Life satisfaction;
LIHC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.5	8.54	0.42	4.58e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg26149184	chr10:133730230	NA	0.5	7.83	0.39	6.05e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.48	6.36	0.33	6.58e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08161947	chr12:19592900	AEBP2	-0.55	-6.88	-0.35	2.86e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs8192917	0.895	rs2236338	chr14:25100282	A/G	cg08766149	chr14:25103301	GZMB	0.31	7.36	0.37	1.38e-12	Vitiligo;
LIHC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.75	11.9	0.54	1.51e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.85	-11.31	-0.52	2.1e-25	Chronic sinus infection;
LIHC	cis	rs6586163	0.872	rs1926197	chr10:90748626	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.55	-7.95	-0.39	2.72e-14	Chronic lymphocytic leukemia;
LIHC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.16	0.44	4.94e-18	Longevity;Endometriosis;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.16	-0.32	2.09e-9	Longevity;
LIHC	cis	rs2758596	1.000	rs2842875	chr1:156161794	T/C	cg25208724	chr1:156163844	SLC25A44	0.75	7.57	0.38	3.5e-13	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.56	10.25	0.48	1.1e-21	Methadone dose in opioid dependence;
LIHC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg23625390	chr15:77176239	SCAPER	0.35	5.72	0.3	2.39e-8	Blood metabolite levels;
LIHC	cis	rs7106204	0.514	rs12291514	chr11:24360203	T/C	ch.11.24196551F	chr11:24239977	NA	0.71	8.61	0.42	2.75e-16	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.77	12.34	0.56	3.42e-29	Corneal astigmatism;
LIHC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.6	-8.57	-0.42	3.56e-16	Blood metabolite levels;
LIHC	cis	rs9309473	1.000	rs10496191	chr2:73673798	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.83	-0.35	3.84e-11	Metabolite levels;
LIHC	trans	rs6489882	0.966	rs7311182	chr12:113379123	T/C	cg10175203	chr3:128143634	NA	0.39	6.29	0.32	9.47e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.59	6.53	0.33	2.43e-10	Bipolar disorder;
LIHC	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg07862535	chr7:139043722	LUC7L2	0.58	9.91	0.47	1.66e-20	Diisocyanate-induced asthma;
LIHC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.1	0.55	2.67e-28	Body mass index;
LIHC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.94	17.72	0.69	2.62e-50	Menopause (age at onset);
LIHC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.83	-0.57	4.97e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg20607798	chr8:58055168	NA	0.49	5.91	0.3	8.09e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs507080	0.922	rs592280	chr11:118553218	T/C	cg04173919	chr11:118528438	PHLDB1	0.32	6.05	0.31	3.87e-9	Serum metabolite levels;
LIHC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.47	-5.85	-0.3	1.14e-8	Breast cancer;
LIHC	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg09592903	chr2:55203963	RTN4	0.63	11.59	0.53	2.04e-26	Mean platelet volume;
LIHC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	11.42	0.53	8.05e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.69	8.05	0.4	1.38e-14	Behavioural disinhibition (generation interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08651674	chr6:7108441	RREB1	0.45	6.21	0.32	1.54e-9	Pancreatic cancer;
LIHC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.74	12.42	0.56	1.7e-29	Aortic root size;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg23990641	chr6:118823964	C6orf204;BRD7P3	0.49	5.94	0.31	7.12e-9	Diastolic blood pressure;
LIHC	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	0.71	7.97	0.4	2.43e-14	Coronary artery disease;
LIHC	cis	rs2257205	0.667	rs28380401	chr17:56755613	T/G	cg12560992	chr17:57184187	TRIM37	0.73	7.79	0.39	8.34e-14	Pancreatic cancer;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg11070056	chr1:107600091	PRMT6	0.67	11.32	0.52	1.95e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-9.13	-0.44	6.31e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	9.82	0.47	3.32e-20	Mean platelet volume;
LIHC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.8	8.45	0.42	8.66e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7598759	0.527	rs4973417	chr2:232349636	G/T	cg19187155	chr2:232395269	NMUR1	0.57	8.29	0.41	2.58e-15	Noise-induced hearing loss;
LIHC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.3	7.83	0.39	6.02e-14	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	trans	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	6.08	0.31	3.14e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.62	-9.43	-0.45	6.37e-19	Aortic root size;
LIHC	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg16736954	chr20:23401023	NAPB	-0.54	-6.0	-0.31	5.13e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	0.98	10.67	0.5	4.01e-23	Vitiligo;
LIHC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.54	-8.12	-0.4	8.78e-15	Metabolic syndrome;
LIHC	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-14.53	-0.62	1.42e-37	Mortality in heart failure;
LIHC	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.63	12.47	0.56	1.1e-29	Airflow obstruction;
LIHC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.52	-6.51	-0.33	2.7e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26059219	chr3:4508837	SUMF1	0.39	6.3	0.32	8.93e-10	Cognitive function;
LIHC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	7.98	0.4	2.31e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23043544	chr7:2124092	MAD1L1	-0.41	-6.6	-0.34	1.56e-10	Neuroticism;
LIHC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.33	5.88	0.3	9.53e-9	Prostate cancer;
LIHC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	9.3	0.45	1.69e-18	Platelet count;
LIHC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	1.0	19.76	0.73	1.63e-58	Breast cancer;
LIHC	cis	rs2016586	0.894	rs5755917	chr22:36099749	C/G	cg26342177	chr22:36113512	APOL5	-0.4	-6.54	-0.33	2.26e-10	Body mass index;
LIHC	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	1.02	12.43	0.56	1.56e-29	Red blood cell traits;
LIHC	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.67	-9.07	-0.44	9.33e-18	Morning vs. evening chronotype;
LIHC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.26	0.32	1.13e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.58	8.66	0.42	1.86e-16	HDL cholesterol;
LIHC	cis	rs7914558	0.646	rs7897654	chr10:104662458	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-6.74	-0.34	6.8e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07305463	chr2:136567211	LCT	-0.38	-5.85	-0.3	1.18e-8	Corneal structure;
LIHC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.65	8.24	0.41	3.81e-15	Mean platelet volume;
LIHC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19623624	chr10:135278901	LOC619207	-0.44	-6.86	-0.35	3.18e-11	Systemic lupus erythematosus;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19816107	chr7:33101939	NT5C3	-0.51	-6.53	-0.33	2.37e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-6.73	-0.34	7.26e-11	Body mass index;
LIHC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg13175981	chr1:150552382	MCL1	-0.44	-6.06	-0.31	3.55e-9	Tonsillectomy;
LIHC	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	1.1	9.73	0.47	6.4e-20	Gut microbiota (bacterial taxa);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18551892	chr11:86667149	FZD4	-0.42	-6.59	-0.34	1.64e-10	Pancreatic cancer;
LIHC	trans	rs2744203	1.000	rs72610885	chr6:104644680	A/C	cg27088726	chr16:83171155	CDH13	-0.46	-6.08	-0.31	3.14e-9	IgG glycosylation;
LIHC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.45	-0.49	2.23e-22	Chronic sinus infection;
LIHC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-18.17	-0.7	4.24e-52	Height;
LIHC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.85	12.19	0.55	1.26e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs12702595	0.505	rs7811763	chr7:7266601	T/C	cg04827551	chr7:7268805	C1GALT1	0.32	5.99	0.31	5.29e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg18548523	chr11:67260961	PITPNM1	0.42	6.78	0.34	5.33e-11	Bipolar disorder;
LIHC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.37	-6.56	-0.33	1.96e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-15.34	-0.64	8.95e-41	Longevity;
LIHC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.19	-0.32	1.75e-9	Height;
LIHC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.62	10.89	0.51	6.44e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg14593290	chr7:50529359	DDC	0.42	6.91	0.35	2.34e-11	Malaria;
LIHC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg03934865	chr2:198174659	NA	-0.61	-9.93	-0.47	1.44e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07355551	chr20:2489285	ZNF343	0.38	6.04	0.31	4e-9	Cognitive function;
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg08687515	chr19:58661962	ZNF329	0.98	7.56	0.38	3.82e-13	Cholesterol, total;
LIHC	cis	rs11031096	0.655	rs12275560	chr11:4211564	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.97	-0.31	6e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.46	-6.75	-0.34	6.3e-11	Dermatomyositis;
LIHC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg11812906	chr14:75593930	NEK9	-0.44	-7.08	-0.36	8.15e-12	IgG glycosylation;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02079963	chr6:160512064	IGF2R	0.41	6.13	0.31	2.41e-9	Bilirubin levels;
LIHC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg00106254	chr7:1943704	MAD1L1	0.42	6.92	0.35	2.19e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10838687	0.673	rs59567949	chr11:47300155	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.86	-0.3	1.08e-8	Proinsulin levels;
LIHC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.37	-0.49	4.39e-22	Blood metabolite levels;
LIHC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.67	-11.57	-0.53	2.42e-26	Platelet distribution width;
LIHC	cis	rs7106204	0.513	rs7131144	chr11:24249486	A/G	ch.11.24196551F	chr11:24239977	NA	0.73	9.02	0.44	1.37e-17	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04389422	chr12:24715564	SOX5	0.43	6.91	0.35	2.39e-11	Cognitive function;
LIHC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.46	-0.37	7.38e-13	Platelet distribution width;
LIHC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.44	6.08	0.31	3.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.84	0.3	1.21e-8	Longevity;
LIHC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.79	13.33	0.58	6.25e-33	Colorectal cancer;
LIHC	trans	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg10756647	chr7:56101905	PSPH	-1.11	-13.6	-0.59	5.46e-34	Diabetic kidney disease;
LIHC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.5	9.39	0.45	8.97e-19	Hemoglobin concentration;
LIHC	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.41	7.33	0.37	1.69e-12	Testicular germ cell tumor;
LIHC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	1.07	14.89	0.63	5.24e-39	Heart rate;
LIHC	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.4	5.98	0.31	5.65e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.07	0.48	4.48e-21	Diabetic retinopathy;
LIHC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	6.91	0.35	2.44e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.64	7.37	0.37	1.26e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-11.1	-0.51	1.17e-24	Chronic sinus infection;
LIHC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.71	-0.3	2.45e-8	Subjective well-being;
LIHC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg00750074	chr16:89608354	SPG7	-0.37	-5.87	-0.3	1.02e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.36	-6.01	-0.31	4.64e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	0.78	5.96	0.31	6.3e-9	IgG glycosylation;
LIHC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21545522	chr1:205238299	TMCC2	0.31	5.86	0.3	1.11e-8	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg15902774	chr15:75289873	SCAMP5	0.33	6.0	0.31	4.93e-9	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-7.39	-0.37	1.17e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.85	-0.3	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	6.95	0.35	1.89e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.76	9.31	0.45	1.64e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.35	5.76	0.3	1.93e-8	Electroencephalogram traits;
LIHC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.51	7.15	0.36	5.29e-12	Menopause (age at onset);
LIHC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.84	12.75	0.57	9.56e-31	IgG glycosylation;
LIHC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg22676075	chr6:135203613	NA	0.38	6.13	0.31	2.39e-9	Red blood cell count;
LIHC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-6.85	-0.35	3.49e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.78	0.3	1.69e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.8	0.34	4.81e-11	Ileal carcinoids;
LIHC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.36	-6.01	-0.31	4.77e-9	Educational attainment;
LIHC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.81	-14.7	-0.62	2.98e-38	Refractive error;
LIHC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg14146966	chr2:61757674	XPO1	-0.45	-7.9	-0.39	3.73e-14	Tuberculosis;
LIHC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.91	-18.47	-0.71	2.61e-53	Height;
LIHC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.68	11.11	0.52	1.06e-24	Platelet count;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20723414	chr7:157207071	DNAJB6	0.44	6.22	0.32	1.44e-9	Bilirubin levels;
LIHC	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.49	9.32	0.45	1.51e-18	Endometriosis;
LIHC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.01	13.32	0.58	6.5e-33	HIV-1 control;
LIHC	cis	rs17286411	0.787	rs1834036	chr16:71972060	G/A	cg03805757	chr16:71968109	PKD1L3	0.45	6.47	0.33	3.39e-10	Blood protein levels;
LIHC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-1.06	-12.29	-0.55	5.36e-29	Vitiligo;
LIHC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg07959070	chr22:50026188	C22orf34	-0.32	-8.22	-0.41	4.36e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.33	6.32	0.32	8.2e-10	Tonsillectomy;
LIHC	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	0.47	6.17	0.32	1.88e-9	Pulmonary function decline;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.43	-0.37	8.66e-13	Lymphocyte counts;
LIHC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.57	8.63	0.42	2.31e-16	Height;
LIHC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg03037974	chr15:76606532	NA	-0.59	-10.05	-0.48	5.29e-21	Blood metabolite levels;
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg13271783	chr10:134563150	INPP5A	-0.57	-7.29	-0.37	2.16e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs3858145	0.588	rs76854765	chr10:70037456	C/T	cg04882175	chr6:131122610	NA	-0.48	-6.05	-0.31	3.7e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg08822215	chr16:89438651	ANKRD11	-0.5	-7.94	-0.39	2.97e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs7236492	0.683	rs59828426	chr18:77204397	T/C	cg15644404	chr18:77186268	NFATC1	-0.39	-5.83	-0.3	1.29e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg06664874	chr5:179499304	RNF130	0.58	7.08	0.36	8.06e-12	LDL cholesterol;
LIHC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg12641515	chr19:46296257	DMWD	0.45	6.85	0.35	3.37e-11	Coronary artery disease;
LIHC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-7.84	-0.39	5.73e-14	Lymphocyte counts;
LIHC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.28	0.32	1e-9	Rheumatoid arthritis;
LIHC	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.37	6.37	0.33	6.17e-10	IgG glycosylation;
LIHC	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.36	0.33	6.41e-10	Platelet distribution width;
LIHC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.33	6.24	0.32	1.26e-9	Total body bone mineral density;
LIHC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	17.36	0.68	7.38e-49	Lung cancer in ever smokers;
LIHC	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-11.2	-0.52	5.37e-25	Morning vs. evening chronotype;
LIHC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.47	9.56	0.46	2.35e-19	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg10755058	chr3:40428713	ENTPD3	0.41	6.89	0.35	2.77e-11	Renal cell carcinoma;
LIHC	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.46	-7.26	-0.37	2.55e-12	Type 2 diabetes;
LIHC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.44	6.98	0.35	1.53e-11	Mortality in heart failure;
LIHC	cis	rs7937890	0.599	rs2597204	chr11:14481017	C/T	cg22961513	chr11:14280813	SPON1	-0.4	-5.74	-0.3	2.14e-8	Mitochondrial DNA levels;
LIHC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.58	-7.63	-0.38	2.32e-13	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.8	12.07	0.55	3.62e-28	Vitamin D levels;
LIHC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg16226627	chr15:75307476	SCAMP5	0.54	8.93	0.43	2.59e-17	Lung cancer;
LIHC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.19	-0.41	5.13e-15	Alzheimer's disease;
LIHC	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.68	10.69	0.5	3.45e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg17675199	chr6:35436792	RPL10A	0.31	6.39	0.33	5.56e-10	Coronary artery disease;
LIHC	cis	rs36051895	0.632	rs111573904	chr9:5169804	A/T	cg02405213	chr9:5042618	JAK2	-0.62	-9.08	-0.44	9.14e-18	Pediatric autoimmune diseases;
LIHC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg16226627	chr15:75307476	SCAMP5	0.36	6.95	0.35	1.81e-11	Blood trace element (Zn levels);
LIHC	trans	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg13309027	chr11:47870224	NUP160	-0.45	-6.63	-0.34	1.35e-10	Gait speed in old age;
LIHC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.69	-7.88	-0.39	4.48e-14	Iron status biomarkers;
LIHC	cis	rs963731	0.579	rs2060987	chr2:39282079	A/G	cg04010122	chr2:39346883	SOS1	-0.66	-6.08	-0.31	3.3e-9	Corticobasal degeneration;
LIHC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.41	-0.33	4.72e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.23	0.32	1.34e-9	Personality dimensions;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03222257	chr8:38034392	LSM1;BAG4	-0.55	-6.42	-0.33	4.46e-10	Systolic blood pressure;
LIHC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.15	-0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	trans	rs9377619	0.541	rs9404533	chr6:104770074	C/T	cg13683534	chr9:139221076	GPSM1;LOC26102	0.34	6.29	0.32	9.61e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.62	8.19	0.41	5.17e-15	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02306730	chr19:39109456	MAP4K1;EIF3K	-0.43	-6.17	-0.32	1.89e-9	Pancreatic cancer;
LIHC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04025307	chr7:1156635	C7orf50	0.53	6.9	0.35	2.57e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.31	-6.94	-0.35	2.02e-11	Menarche (age at onset);
LIHC	cis	rs11673344	0.832	rs8101407	chr19:37515346	A/T	cg27390819	chr19:37464633	NA	-0.52	-6.38	-0.33	5.73e-10	Obesity-related traits;
LIHC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.38	7.89	0.39	4.2e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg12863693	chr15:85201151	NMB	0.44	6.27	0.32	1.11e-9	Schizophrenia;
LIHC	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg13679303	chr9:96623674	NA	-0.3	-6.62	-0.34	1.37e-10	DNA methylation (variation);
LIHC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07305463	chr2:136567211	LCT	-0.37	-7.14	-0.36	5.78e-12	Mosquito bite size;
LIHC	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.62	0.34	1.4e-10	Mammographic density (dense area);
LIHC	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg25182066	chr10:30743637	MAP3K8	0.43	6.93	0.35	2.06e-11	Inflammatory bowel disease;
LIHC	cis	rs8108269	0.911	rs10415769	chr19:46158643	G/T	cg13320842	chr19:46175254	GIPR	0.41	7.7	0.38	1.5e-13	Type 2 diabetes;
LIHC	cis	rs981946	0.928	rs13193394	chr6:3369046	C/T	cg18842474	chr6:3356384	SLC22A23	0.36	5.72	0.3	2.34e-8	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
LIHC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.66	6.21	0.32	1.55e-9	Body mass index;
LIHC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17554472	chr22:41940697	POLR3H	0.56	6.06	0.31	3.53e-9	Vitiligo;
LIHC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.6	12.71	0.57	1.45e-30	Fat distribution (HIV);
LIHC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.56	-0.46	2.45e-19	Schizophrenia;
LIHC	cis	rs4699052	0.963	rs2085978	chr4:104193614	A/G	cg16532752	chr4:104119610	CENPE	-0.39	-6.07	-0.31	3.34e-9	Testicular germ cell tumor;
LIHC	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.18	0.44	4.1e-18	Coffee consumption (cups per day);
LIHC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Blood protein levels;
LIHC	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.45	7.57	0.38	3.4e-13	Mean corpuscular volume;
LIHC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.48	7.62	0.38	2.46e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg19318889	chr4:1322082	MAEA	0.41	5.91	0.3	8.37e-9	Obesity-related traits;
LIHC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg07451762	chr16:28383216	NA	0.36	6.66	0.34	1.07e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg13271783	chr10:134563150	INPP5A	-0.58	-7.24	-0.36	3.01e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2412488	0.850	rs11133266	chr4:54234371	G/T	cg22241045	chr4:54363911	LNX1	-0.42	-6.4	-0.33	5.2e-10	DNA methylation (variation);
LIHC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.37	-5.86	-0.3	1.07e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8083850	0.698	rs12956187	chr18:50869695	A/G	cg24270629	chr18:50823537	DCC	0.52	7.87	0.39	4.7e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs72843506	0.586	rs16960554	chr17:19869798	A/G	cg12065943	chr17:19881925	AKAP10	-0.39	-6.58	-0.34	1.78e-10	Schizophrenia;
LIHC	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.73	-0.3	2.21e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21068152	chr12:120740453	SIRT4	0.46	7.19	0.36	4.04e-12	Cognitive function;
LIHC	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.47	7.03	0.36	1.1e-11	Schizophrenia;
LIHC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg10820045	chr2:198174542	NA	0.56	8.88	0.43	3.78e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	17.36	0.68	7.38e-49	Lung cancer in ever smokers;
LIHC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.66	8.24	0.41	3.72e-15	Gut microbiome composition (summer);
LIHC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.2	0.32	1.58e-9	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6717918	0.672	rs2853359	chr2:233118874	C/G	ch.2.233013039R	chr2:233304795	NA	0.59	6.17	0.32	1.91e-9	Height;
LIHC	cis	rs6545883	0.894	rs2593633	chr2:61571513	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.38	-0.37	1.21e-12	Tuberculosis;
LIHC	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.6	-12.14	-0.55	1.85e-28	Plateletcrit;Platelet count;
LIHC	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg20991723	chr1:152506922	NA	0.55	9.44	0.45	6.15e-19	Hair morphology;
LIHC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.33	-6.16	-0.32	2.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.5	9.51	0.46	3.41e-19	Testicular germ cell tumor;
LIHC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.62	-7.31	-0.37	1.88e-12	Lymphocyte counts;
LIHC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.6	7.16	0.36	4.89e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs116248771	0.739	rs73156415	chr3:158342695	C/A	cg16708174	chr3:158430962	RARRES1	0.48	6.41	0.33	4.83e-10	diarrhoeal disease at age 2;
LIHC	trans	rs2270221	0.723	rs11763013	chr7:31909596	C/T	cg06873401	chr5:77792105	LHFPL2	0.49	6.05	0.31	3.72e-9	Endometriosis;
LIHC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg26566283	chr11:622021	MUPCDH	-0.81	-6.14	-0.31	2.35e-9	Body mass index;
LIHC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.43	-6.28	-0.32	1.01e-9	Crohn's disease;
LIHC	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg20999565	chr14:68265668	ZFYVE26	-0.34	-6.07	-0.31	3.45e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg02023728	chr11:77925099	USP35	0.34	6.11	0.31	2.67e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.38	-6.36	-0.33	6.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.31	7.55	0.38	4e-13	Breast cancer;Mosquito bite size;
LIHC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.27	-16.34	-0.66	9.2e-45	Diabetic kidney disease;
LIHC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.51	-8.52	-0.42	5.07e-16	Obesity-related traits;
LIHC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18357526	chr6:26021779	HIST1H4A	0.46	6.78	0.34	5.36e-11	Height;
LIHC	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.57	0.42	3.6e-16	Corneal astigmatism;
LIHC	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.73	13.95	0.6	2.44e-35	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.57	9.44	0.45	6.19e-19	Corneal astigmatism;
LIHC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.37	-6.35	-0.32	6.92e-10	Alzheimer's disease (late onset);
LIHC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.97	16.13	0.66	6.11e-44	Subjective well-being;
LIHC	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.55	-8.91	-0.43	3.04e-17	Corneal astigmatism;
LIHC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.64	8.22	0.41	4.21e-15	Motion sickness;
LIHC	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.65	7.85	0.39	5.27e-14	Itch intensity from mosquito bite;
LIHC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.92	0.3	7.85e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.5	9.62	0.46	1.56e-19	Testicular germ cell tumor;
LIHC	cis	rs7520050	0.872	rs1707308	chr1:46604315	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.44	6.78	0.34	5.28e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg17859187	chr1:168147929	TIPRL	0.51	6.53	0.33	2.33e-10	Schizophrenia;
LIHC	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.32	1.55e-9	Ulcerative colitis;
LIHC	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.41	-0.33	4.83e-10	Ulcerative colitis;
LIHC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.56	7.74	0.39	1.17e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-14.91	-0.63	4.53e-39	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg02290350	chr8:58132656	NA	0.31	7.18	0.36	4.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg03342759	chr3:160939853	NMD3	0.53	7.04	0.36	1.07e-11	Kawasaki disease;
LIHC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.58	10.23	0.48	1.32e-21	Dupuytren's disease;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.9	-0.3	8.51e-9	Total body bone mineral density;
LIHC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.45	-7.68	-0.38	1.67e-13	Brugada syndrome;
LIHC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.5	-8.57	-0.42	3.74e-16	White blood cell count;
LIHC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.77	12.28	0.55	5.89e-29	Colorectal cancer;
LIHC	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg04492858	chr10:133558786	NA	0.47	7.16	0.36	4.98e-12	Survival in rectal cancer;
LIHC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-9.94	-0.47	1.32e-20	Chronic sinus infection;
LIHC	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.29	6.26	0.32	1.14e-9	Pulmonary function;
LIHC	cis	rs7707921	0.752	rs2406909	chr5:81276087	T/C	cg15871215	chr5:81402204	ATG10	0.66	7.16	0.36	5.09e-12	Breast cancer;
LIHC	trans	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg19894588	chr14:64061835	NA	0.61	8.55	0.42	4.12e-16	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-10.96	-0.51	3.76e-24	Lung cancer;
LIHC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.38	-11.72	-0.54	6.87e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.38	0.45	9.45e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.47	-7.89	-0.39	4.1e-14	Response to temozolomide;
LIHC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	6.34	0.32	7.4e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs67981189	0.634	rs221898	chr14:71605516	A/G	cg15816911	chr14:71606274	NA	0.42	6.75	0.34	6.23e-11	Schizophrenia;
LIHC	cis	rs903552	0.673	rs4965878	chr15:102009589	C/T	cg19295451	chr15:102010161	PCSK6	-0.55	-7.63	-0.38	2.34e-13	Diabetic kidney disease;
LIHC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.4	-6.15	-0.32	2.12e-9	Menarche (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04882175	chr6:131122610	NA	0.54	6.81	0.35	4.33e-11	Hepatitis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05016131	chr16:29606629	NA	-0.53	-6.32	-0.32	8.08e-10	Systolic blood pressure;
LIHC	trans	rs654384	0.898	rs13242365	chr7:4175025	G/T	cg26675336	chr15:86133334	AKAP13	0.3	6.16	0.32	2.08e-9	Positive affect;
LIHC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.38	5.97	0.31	6.05e-9	Menopause (age at onset);
LIHC	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	6.81	0.35	4.29e-11	Type 2 diabetes;
LIHC	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.41	6.62	0.34	1.39e-10	Menopause (age at onset);
LIHC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg00809820	chr17:80708513	TBCD;FN3K	0.35	6.03	0.31	4.31e-9	Glycated hemoglobin levels;
LIHC	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.48	7.4	0.37	1.08e-12	Alzheimer's disease (survival time);
LIHC	cis	rs6442522	0.643	rs7620149	chr3:15500896	A/G	cg16303742	chr3:15540471	COLQ	-0.42	-7.05	-0.36	9.81e-12	Uric acid levels;
LIHC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg05343316	chr1:45956843	TESK2	0.46	6.89	0.35	2.73e-11	High light scatter reticulocyte count;
LIHC	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.52	0.42	5.1e-16	Exhaled nitric oxide output;
LIHC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg12903224	chr12:29470962	FAR2	-0.42	-6.81	-0.35	4.31e-11	QT interval;
LIHC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.7	-0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg13446199	chr8:143762866	PSCA	-0.2	-5.85	-0.3	1.12e-8	Urinary tract infection frequency;
LIHC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	11.22	0.52	4.3e-25	Alzheimer's disease (late onset);
LIHC	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.43	-8.54	-0.42	4.39e-16	Testicular germ cell tumor;
LIHC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.36	5.98	0.31	5.76e-9	Monocyte count;
LIHC	cis	rs28829049	0.536	rs2073105	chr1:19549864	T/C	cg13387374	chr1:19411106	UBR4	0.39	5.76	0.3	1.9e-8	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg18867708	chr6:26865862	GUSBL1	0.52	8.1	0.4	9.8e-15	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg10756647	chr7:56101905	PSPH	1.09	13.36	0.59	4.74e-33	Diabetic kidney disease;
LIHC	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.4	-6.01	-0.31	4.84e-9	Systemic sclerosis;
LIHC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.5	-9.02	-0.44	1.33e-17	Height;
LIHC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg10360323	chr17:41437877	NA	0.4	5.98	0.31	5.76e-9	Menopause (age at onset);
LIHC	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.28	7.06	0.36	9.32e-12	Schizophrenia;
LIHC	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.53	7.24	0.36	3.07e-12	Coronary artery disease;
LIHC	cis	rs8032158	1.000	rs8029247	chr15:56273446	C/T	cg24530489	chr15:56299380	NA	-0.42	-5.94	-0.31	7.21e-9	Keloid;
LIHC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg16736954	chr20:23401023	NAPB	0.7	8.14	0.4	7.4e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.38	6.15	0.32	2.21e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.75	-11.49	-0.53	4.64e-26	Corneal astigmatism;
LIHC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.47	8.05	0.4	1.41e-14	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.67	0.38	1.8e-13	Prudent dietary pattern;
LIHC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.37	2.41e-12	Bipolar disorder;
LIHC	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	0.93	7.29	0.37	2.21e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.66	-10.74	-0.5	2.3e-23	Lung cancer;
LIHC	trans	rs980000	1.000	rs980000	chr15:60900963	C/T	cg19429466	chr4:87515395	PTPN13	-0.79	-6.08	-0.31	3.18e-9	Menarche (age at onset);
LIHC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.82	-11.46	-0.53	5.93e-26	Schizophrenia;
LIHC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.66	-10.75	-0.5	2.02e-23	Lung cancer;
LIHC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.67	10.74	0.5	2.24e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12463550	chr7:65579703	CRCP	0.67	7.03	0.36	1.15e-11	Diabetic kidney disease;
LIHC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg09145019	chr1:17972199	ARHGEF10L	0.56	6.23	0.32	1.37e-9	Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.57	0.62	9.41e-38	Prudent dietary pattern;
LIHC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.45	-0.42	8.7e-16	Total cholesterol levels;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.68	-10.39	-0.49	3.8e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.52	-10.38	-0.49	4.01e-22	Diastolic blood pressure;
LIHC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	0.67	6.67	0.34	1.03e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg26138937	chr11:71823887	C11orf51	-1.32	-10.43	-0.49	2.71e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs3733606	0.503	rs11731274	chr4:6891455	T/G	cg05012661	chr4:6891264	NA	0.39	6.26	0.32	1.12e-9	Platelet count;
LIHC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2637030	0.559	rs372135	chr5:52944948	T/C	cg06476337	chr5:52856530	NDUFS4	0.43	6.82	0.35	4.25e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.38	12.35	0.56	3.16e-29	Uric acid levels;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.44	5.98	0.31	5.71e-9	Total body bone mineral density;
LIHC	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.64	7.1	0.36	7.25e-12	Iron status biomarkers;
LIHC	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.93	0.31	7.36e-9	Mean corpuscular volume;
LIHC	cis	rs1198430	0.639	rs16860685	chr1:23766644	A/G	cg13183780	chr1:23809682	ASAP3	-0.37	-6.47	-0.33	3.31e-10	Total cholesterol levels;
LIHC	cis	rs2274273	0.870	rs11625001	chr14:55758160	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.55	-0.33	2.15e-10	Protein biomarker;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15231902	chr12:56618064	OBFC2B	0.44	6.3	0.32	9.14e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	1.04	10.68	0.5	3.61e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.81	-0.39	7.19e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7192380	0.651	rs920191	chr16:69689120	G/A	cg15192750	chr16:69999425	NA	0.36	5.72	0.3	2.28e-8	Sjögren's syndrome;
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.53	-0.38	4.58e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.17	0.32	1.98e-9	Prudent dietary pattern;
LIHC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	7.68	0.38	1.64e-13	Aortic root size;
LIHC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.5	9.21	0.45	3.3e-18	Hemoglobin concentration;
LIHC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-8.87	-0.43	4.24e-17	Vitiligo;
LIHC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-17.87	-0.69	6.79e-51	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21321768	chr18:19176371	ESCO1	0.28	6.06	0.31	3.64e-9	Cognitive function;
LIHC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.24	9.74	0.47	6.14e-20	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.72	0.6	1.95e-34	Prudent dietary pattern;
LIHC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.84	10.02	0.48	6.79e-21	Cognitive function;
LIHC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	0.88	5.96	0.31	6.31e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg00977110	chr5:151150581	G3BP1	0.54	6.9	0.35	2.52e-11	Preschool internalizing problems;
LIHC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.08	0.31	3.15e-9	Schizophrenia;
LIHC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-12.76	-0.57	9.25e-31	Sense of smell;
LIHC	cis	rs7000551	0.700	rs2469761	chr8:22367274	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	7.37	0.37	1.3e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.45	6.79	0.34	5.04e-11	Night sleep phenotypes;
LIHC	cis	rs2637266	1.000	rs34483246	chr10:78342790	G/A	cg18941641	chr10:78392320	NA	0.3	6.41	0.33	4.93e-10	Pulmonary function;
LIHC	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.67	13.31	0.58	7.42e-33	Leprosy;
LIHC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.52	-7.79	-0.39	7.98e-14	Total body bone mineral density;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.44	8.07	0.4	1.23e-14	Prudent dietary pattern;
LIHC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02985541	chr2:219472218	PLCD4	-0.47	-8.79	-0.43	7.21e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	0.77	6.0	0.31	4.9e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16434002	chr17:42200994	HDAC5	0.54	7.82	0.39	6.67e-14	Total body bone mineral density;
LIHC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg21724239	chr8:58056113	NA	0.44	5.93	0.31	7.47e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	8.01	0.4	1.85e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-6.75	-0.34	6.41e-11	Body mass index;
LIHC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg01903971	chr7:100434983	NA	-0.39	-6.35	-0.32	6.79e-10	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg25039879	chr17:56429692	SUPT4H1	0.77	8.77	0.43	8.65e-17	Cognitive test performance;
LIHC	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.61	9.4	0.45	8.23e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.59	6.39	0.33	5.54e-10	Vitiligo;
LIHC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	9.22	0.45	3.12e-18	Lung cancer in ever smokers;
LIHC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02290350	chr8:58132656	NA	0.42	9.08	0.44	8.67e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs9326778	0.520	rs11956367	chr5:108818903	G/A	cg17395555	chr5:108820864	NA	-0.34	-5.86	-0.3	1.11e-8	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	0.6	11.31	0.52	2.02e-25	Fat distribution (HIV);
LIHC	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.9	-16.3	-0.66	1.33e-44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.77	0.6	1.2e-34	Lung cancer in ever smokers;
LIHC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.67	0.53	1.03e-26	Motion sickness;
LIHC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	8.49	0.42	6.45e-16	Blood metabolite levels;
LIHC	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.73	12.54	0.56	6.38e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07277818	chr5:137774639	REEP2	0.41	6.06	0.31	3.51e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.45e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-14.15	-0.61	4.37e-36	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.46	-0.33	3.65e-10	Educational attainment (years of education);
LIHC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg14779329	chr11:130786720	SNX19	0.39	5.95	0.31	6.72e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.68	0.34	9.49e-11	Electroencephalogram traits;
LIHC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.83	9.16	0.44	4.85e-18	Vitiligo;
LIHC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.27e-12	Bipolar disorder;
LIHC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg01557791	chr16:72042693	DHODH	-0.42	-6.97	-0.35	1.63e-11	Fibrinogen levels;
LIHC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.58	11.5	0.53	4.36e-26	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.45	-8.26	-0.41	3.19e-15	Prudent dietary pattern;
LIHC	cis	rs16958440	0.867	rs12326465	chr18:44678645	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	trans	rs2071426	0.959	rs11572139	chr10:96808886	A/G	cg04948438	chr10:99301906	UBTD1	-0.36	-6.12	-0.31	2.52e-9	Blood metabolite levels;
LIHC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.64	-0.42	2.17e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg08843971	chr16:11963173	GSPT1	0.41	7.06	0.36	9.31e-12	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg11764359	chr7:65958608	NA	0.58	6.02	0.31	4.5e-9	Diabetic kidney disease;
LIHC	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg11812906	chr14:75593930	NEK9	0.43	6.51	0.33	2.63e-10	IgG glycosylation;
LIHC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.64	-9.73	-0.47	6.37e-20	Renal cell carcinoma;
LIHC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg05343316	chr1:45956843	TESK2	-0.43	-6.4	-0.33	5.08e-10	High light scatter reticulocyte count;
LIHC	trans	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19862616	chr7:65841803	NCRNA00174	0.64	9.98	0.47	9.69e-21	Eotaxin levels;
LIHC	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.48	-11.73	-0.54	6.14e-27	Diastolic blood pressure;
LIHC	cis	rs10426930	0.738	rs2613757	chr19:5062405	T/C	cg18473234	chr19:5097819	KDM4B	-0.43	-5.73	-0.3	2.26e-8	Monocyte percentage of white cells;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg10266188	chr1:32645867	TXLNA	-0.41	-6.06	-0.31	3.59e-9	Bipolar disorder;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12394426	chr11:64009745	FKBP2	-0.41	-6.34	-0.32	7.28e-10	Triglycerides;
LIHC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg16586182	chr3:47516702	SCAP	-0.51	-9.17	-0.44	4.43e-18	Colorectal cancer;
LIHC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg14440974	chr22:39074834	NA	-0.35	-5.89	-0.3	9.1e-9	Menopause (age at onset);
LIHC	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg14593290	chr7:50529359	DDC	0.49	7.86	0.39	5.03e-14	Malaria;
LIHC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg12160578	chr15:63334699	TPM1	-0.6	-8.6	-0.42	2.96e-16	Platelet count;
LIHC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	6.87	0.35	3.06e-11	Mood instability;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.58	8.88	0.43	3.75e-17	Prudent dietary pattern;
LIHC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.35	6.35	0.32	6.71e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16163324	chr1:46712932	RAD54L	0.44	6.37	0.33	6.09e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg20607798	chr8:58055168	NA	0.71	8.55	0.42	4.1e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07021052	chr2:20871279	NA	-0.41	-7.42	-0.37	9.48e-13	Abdominal aortic aneurysm;
LIHC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.52e-16	Motion sickness;
LIHC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.42	6.86	0.35	3.16e-11	Red blood cell count;
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg01652190	chr22:50026171	C22orf34	-0.35	-7.7	-0.38	1.48e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.48e-59	Height;
LIHC	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.48	-7.16	-0.36	5e-12	Neuroticism;
LIHC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.78	12.51	0.56	8.22e-30	Colorectal cancer;
LIHC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg18016565	chr1:150552671	MCL1	0.5	9.52	0.46	3.37e-19	Melanoma;
LIHC	cis	rs2257205	0.667	rs7208872	chr17:56777649	A/G	cg12560992	chr17:57184187	TRIM37	0.72	7.93	0.39	3.17e-14	Pancreatic cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01958230	chr17:40428024	STAT5B	-0.53	-6.12	-0.31	2.61e-9	Systolic blood pressure;
LIHC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.69	10.4	0.49	3.53e-22	Aortic root size;
LIHC	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-6.38	-0.33	5.79e-10	Axial length;
LIHC	cis	rs10916814	0.588	rs10799640	chr1:20896411	T/C	cg24502330	chr1:20914028	CDA	-0.31	-6.76	-0.34	6.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.46	-8.26	-0.41	3.13e-15	Colorectal cancer;
LIHC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.63	10.64	0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.67	10.25	0.48	1.15e-21	Corneal astigmatism;
LIHC	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.67	-10.15	-0.48	2.38e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6691722	0.503	rs7546875	chr1:24703667	T/C	cg18323236	chr1:24743029	NIPAL3	0.38	7.08	0.36	8.34e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.37	-0.33	5.95e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg18120998	chr12:113376286	OAS3	-0.43	-6.12	-0.31	2.54e-9	Alopecia areata;
LIHC	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg01674679	chr13:27998804	GTF3A	-0.49	-7.61	-0.38	2.73e-13	Weight;
LIHC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.52	-6.69	-0.34	9.34e-11	Pancreatic cancer;
LIHC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.89	8.16	0.4	6.36e-15	Menarche (age at onset);
LIHC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	8.07	0.4	1.17e-14	Immature fraction of reticulocytes;
LIHC	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.44e-28	Eye color traits;
LIHC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.24e-12	Renal cell carcinoma;
LIHC	trans	rs4704846	0.660	rs246878	chr5:156556674	C/T	cg02632742	chr2:60187357	NA	-0.6	-6.05	-0.31	3.83e-9	Blood protein levels;
LIHC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.79	14.76	0.62	1.74e-38	Graves' disease;
LIHC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.69	-0.76	3.18e-66	Height;
LIHC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.69	-13.57	-0.59	7.32e-34	Body mass index;
LIHC	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg25952890	chr19:58913133	NA	0.7	7.64	0.38	2.23e-13	Mean platelet volume;
LIHC	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.45	-7.16	-0.36	4.98e-12	IgG glycosylation;
LIHC	cis	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05901451	chr6:126070800	HEY2	0.47	8.34	0.41	1.82e-15	Endometrial cancer;
LIHC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.12	-0.31	2.59e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg16583315	chr14:65563665	MAX	-0.4	-8.17	-0.4	6.07e-15	Obesity-related traits;
LIHC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.5	-8.17	-0.4	6.06e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.68	6.94	0.35	1.98e-11	Alzheimer's disease;
LIHC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg15105060	chr4:7024189	TBC1D14	-0.68	-6.1	-0.31	2.88e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.49	6.53	0.33	2.37e-10	Major depressive disorder;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11987759	chr7:65425863	GUSB	0.38	6.0	0.31	5.09e-9	Aortic root size;
LIHC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg10820045	chr2:198174542	NA	0.55	9.25	0.45	2.43e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11212260	0.655	rs11212237	chr11:107310213	T/A	cg25435332	chr11:107328525	CWF19L2	0.84	8.08	0.4	1.15e-14	IgG glycosylation;
LIHC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04221910	chr5:616842	CEP72	-0.41	-7.42	-0.37	9.5e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.07	22.78	0.78	1.5e-70	Schizophrenia;
LIHC	cis	rs2274273	0.837	rs8008119	chr14:55831228	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.65	-0.34	1.13e-10	Protein biomarker;
LIHC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.95	12.62	0.56	3.2e-30	Heart rate;
LIHC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.15	0.32	2.19e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs507080	0.769	rs645637	chr11:118505090	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	5.87	0.3	1.06e-8	Serum metabolite levels;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.03	0.8	2.65e-79	Prudent dietary pattern;
LIHC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.65	11.78	0.54	4.06e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7095607	0.579	rs6480308	chr10:69952953	T/C	cg18986048	chr10:69913749	MYPN	0.38	5.73	0.3	2.25e-8	Lung function (FVC);
LIHC	cis	rs13424612	1.000	rs13424612	chr2:240900121	C/T	cg01812947	chr2:240904978	NDUFA10	0.37	5.73	0.3	2.21e-8	Odorant perception (isobutyraldehyde);
LIHC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.72	9.53	0.46	2.91e-19	Eosinophilic esophagitis;
LIHC	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02985541	chr2:219472218	PLCD4	-0.36	-6.34	-0.32	7.39e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg06804625	chr1:109812012	CELSR2	-0.4	-5.78	-0.3	1.71e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	16.26	0.66	1.87e-44	Smoking behavior;
LIHC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg06935464	chr4:38784597	TLR10	0.46	7.19	0.36	4.1e-12	Breast cancer;
LIHC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.8	12.5	0.56	8.57e-30	Resting heart rate;
LIHC	trans	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-7.36	-0.37	1.41e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.52	8.08	0.4	1.13e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs10106298	0.846	rs2436940	chr8:103678521	A/C	cg10187029	chr8:103597600	NA	0.47	6.42	0.33	4.55e-10	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	8.24	0.41	3.79e-15	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08280861	chr8:58055591	NA	0.54	6.28	0.32	1.05e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.36	-0.33	6.6e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.61	8.81	0.43	6.51e-17	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg26395211	chr5:140044315	WDR55	0.4	5.87	0.3	1.05e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1551570	0.766	rs55752217	chr19:10218434	C/T	cg16327482	chr19:10226339	EIF3G	0.48	8.37	0.41	1.53e-15	Narcolepsy;
LIHC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.52	-9.69	-0.46	8.64e-20	Mean corpuscular volume;
LIHC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.41	-6.57	-0.33	1.93e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg01134436	chr17:81009848	B3GNTL1	-0.74	-6.76	-0.34	5.94e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg14257396	chr1:107603778	NA	-0.37	-6.17	-0.32	1.98e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.46	6.22	0.32	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg00750074	chr16:89608354	SPG7	-0.41	-6.22	-0.32	1.48e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.46	6.66	0.34	1.12e-10	Schizophrenia;
LIHC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.6	0.34	1.61e-10	Hemoglobin concentration;
LIHC	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-7.76	-0.39	9.73e-14	Exhaled nitric oxide output;
LIHC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22442454	chr1:209979470	IRF6	0.39	5.92	0.3	7.76e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.86	0.39	5.04e-14	Mood instability;
LIHC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg14930904	chr10:32216787	ARHGAP12	0.37	6.54	0.33	2.26e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.52	8.72	0.43	1.24e-16	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.96	0.31	6.14e-9	Birth weight;
LIHC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.5	7.71	0.38	1.38e-13	Breast cancer;
LIHC	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg14250997	chr9:106856677	SMC2	-0.42	-7.48	-0.38	6.23e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.33	-6.68	-0.34	9.68e-11	Platelet distribution width;
LIHC	cis	rs1866706	1.000	rs1866704	chr11:12866938	T/C	cg25843174	chr11:12811716	TEAD1	-0.33	-6.95	-0.35	1.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.26	6.69	0.34	9.18e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.48	7.33	0.37	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.29	-6.4	-0.33	5.17e-10	DNA methylation (variation);
LIHC	cis	rs8192917	1.000	rs6573911	chr14:25100933	A/G	cg08766149	chr14:25103301	GZMB	-0.35	-8.13	-0.4	8.11e-15	Vitiligo;
LIHC	cis	rs4908768	0.501	rs910581	chr1:8529524	T/C	cg20416874	chr1:8611966	RERE	-0.66	-13.71	-0.6	2.11e-34	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00774050	chr4:73935472	COX18	-0.46	-6.32	-0.32	8.26e-10	Pancreatic cancer;
LIHC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.6	10.28	0.49	9.16e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.65	-11.39	-0.52	1.09e-25	Height;
LIHC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.17	0.4	6.16e-15	Heart rate;
LIHC	cis	rs6024905	0.595	rs2022499	chr20:36966531	G/T	cg07053727	chr20:36965646	BPI	0.59	10.94	0.51	4.28e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg10018233	chr7:150070692	REPIN1	0.43	6.52	0.33	2.56e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg13047869	chr3:10149882	C3orf24	0.52	5.92	0.3	7.9e-9	Alzheimer's disease;
LIHC	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg04610667	chr7:75704037	NA	-0.34	-6.21	-0.32	1.55e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24371536	chr6:79943342	HMGN3	0.46	6.16	0.32	2.03e-9	Pancreatic cancer;
LIHC	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.77	13.03	0.58	8.91e-32	Coronary artery disease;
LIHC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.62	0.42	2.58e-16	Menarche (age at onset);
LIHC	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.72	11.31	0.52	2.07e-25	Phospholipid levels (plasma);
LIHC	trans	rs3758911	0.796	rs59525924	chr11:107210012	C/T	cg21068293	chr15:74496576	STRA6	0.26	6.27	0.32	1.08e-9	Coronary artery disease;
LIHC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.23	6.48	0.33	3.16e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg24846343	chr22:24311635	DDTL	-0.63	-10.7	-0.5	3e-23	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.69	-12.82	-0.57	5.58e-31	Height;
LIHC	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.7	-7.58	-0.38	3.24e-13	Exhaled nitric oxide output;
LIHC	trans	rs4714291	0.832	rs9471244	chr6:40092331	A/G	cg02267698	chr19:7991119	CTXN1	0.4	6.85	0.35	3.53e-11	Strep throat;
LIHC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.43	-6.81	-0.35	4.53e-11	Menarche (age at onset);
LIHC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.39	6.39	0.33	5.42e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg13535736	chr9:111863775	C9orf5	0.42	6.39	0.33	5.28e-10	Menarche (age at onset);
LIHC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.59	7.79	0.39	8.37e-14	Body mass index;
LIHC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.74	12.98	0.57	1.37e-31	Platelet count;
LIHC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg18944383	chr4:111397179	ENPEP	-0.28	-6.49	-0.33	3.02e-10	Coronary artery disease;
LIHC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg05082376	chr22:42548792	NA	-0.4	-5.76	-0.3	1.84e-8	Schizophrenia;
LIHC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.33	-0.49	6.13e-22	Total cholesterol levels;
LIHC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg15192750	chr16:69999425	NA	0.46	7.04	0.36	1.09e-11	IgE levels;
LIHC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.07	-0.31	3.46e-9	Total body bone mineral density;
LIHC	trans	rs8113308	0.810	rs8108525	chr19:52444136	G/T	cg14959425	chr7:20447707	ITGB8	-0.48	-6.15	-0.32	2.22e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs15676	0.947	rs2280842	chr9:131585808	C/G	cg00228799	chr9:131580591	ENDOG	0.47	7.15	0.36	5.46e-12	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.36	7.4	0.37	1.09e-12	Renal cell carcinoma;
LIHC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg01864069	chr14:103024347	NA	-0.48	-7.48	-0.37	6.48e-13	Platelet count;
LIHC	cis	rs888194	0.738	rs7956536	chr12:109980516	A/G	cg05360138	chr12:110035743	NA	-0.4	-5.75	-0.3	2.03e-8	Neuroticism;
LIHC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3015497	0.586	rs12587842	chr14:51092562	A/G	cg09863266	chr14:51125203	SAV1	-0.39	-6.17	-0.32	1.88e-9	Mean platelet volume;
LIHC	cis	rs11229555	0.645	rs34350060	chr11:58184902	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8067354	0.507	rs72840511	chr17:57806011	G/T	cg13753209	chr17:57696993	CLTC	0.77	12.29	0.55	5.3e-29	Hemoglobin concentration;
LIHC	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.45	6.85	0.35	3.49e-11	Diastolic blood pressure;
LIHC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.85	-12.4	-0.56	1.99e-29	Post bronchodilator FEV1;
LIHC	cis	rs3814244	0.515	rs2906856	chr12:68390201	T/C	cg15249341	chr12:68405565	NA	0.34	7.07	0.36	8.6e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21467203	chr3:49911342	NA	-0.52	-9.56	-0.46	2.44e-19	Body mass index;
LIHC	cis	rs7267979	0.528	rs6076366	chr20:25564626	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.44	-6.02	-0.31	4.47e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg21531657	chr3:10005747	TMEM111	-0.39	-5.87	-0.3	1.03e-8	Alzheimer's disease;
LIHC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12016809	chr21:47604291	C21orf56	0.42	6.21	0.32	1.5e-9	Testicular germ cell tumor;
LIHC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-7.7	-0.38	1.48e-13	Chronic sinus infection;
LIHC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.55	8.86	0.43	4.42e-17	Cognitive function;
LIHC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.45	7.61	0.38	2.68e-13	Mean corpuscular volume;
LIHC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs7192750	0.538	rs11075911	chr16:71988505	T/C	cg06353428	chr16:71660113	MARVELD3	0.78	9.05	0.44	1.1e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.69	11.0	0.51	2.63e-24	Prostate cancer;
LIHC	cis	rs3981351	0.797	rs34394259	chr10:115441082	A/G	cg24846397	chr10:115438155	CASP7	-0.45	-6.98	-0.35	1.58e-11	Obesity-related traits;
LIHC	cis	rs12464559	0.579	rs1523181	chr2:152679462	T/C	cg01189475	chr2:152685088	ARL5A	0.64	7.54	0.38	4.29e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.47	0.46	4.59e-19	Electroencephalogram traits;
LIHC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg17980119	chr2:219472607	PLCD4	0.34	5.88	0.3	9.92e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.29	-0.45	1.85e-18	Ulcerative colitis;
LIHC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg02836325	chr17:76403955	PGS1	0.34	6.71	0.34	8.09e-11	HDL cholesterol;
LIHC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.48	8.48	0.42	6.83e-16	Mean corpuscular volume;
LIHC	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.39	-7.18	-0.36	4.37e-12	Height;
LIHC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg00990874	chr7:1149470	C7orf50	-0.53	-7.86	-0.39	4.96e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs2834188	1.000	rs2843994	chr21:34706870	G/A	cg14352951	chr21:34696688	IFNAR1	0.51	6.72	0.34	7.54e-11	Narcolepsy;
LIHC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.02e-16	Height;
LIHC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.3	-5.74	-0.3	2.03e-8	Body mass index;
LIHC	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-6.78	-0.34	5.24e-11	Post bronchodilator FEV1;
LIHC	cis	rs4917300	0.626	rs1388796	chr8:143096437	A/G	cg25363559	chr8:143086065	NA	-0.27	-8.25	-0.41	3.55e-15	Amyotrophic lateral sclerosis;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.33	2.99e-10	Alzheimer's disease;
LIHC	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg03934865	chr2:198174659	NA	-0.57	-9.09	-0.44	8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.6	7.27	0.37	2.54e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.05	0.44	1.12e-17	Schizophrenia;
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.45	7.12	0.36	6.27e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19671926	chr4:122722719	EXOSC9	0.53	8.11	0.4	9.07e-15	Type 2 diabetes;
LIHC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.33	6.3	0.32	8.96e-10	Body mass index;
LIHC	trans	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg10756647	chr7:56101905	PSPH	1.08	13.28	0.58	9.41e-33	Diabetic kidney disease;
LIHC	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25632853	chr15:73088954	NA	0.36	5.99	0.31	5.27e-9	Triglyceride levels;
LIHC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04476341	chr5:669733	TPPP	0.38	8.69	0.43	1.55e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-11.34	-0.52	1.66e-25	Height;
LIHC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.43	5.84	0.3	1.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.57	7.8	0.39	7.43e-14	Blood metabolite levels;
LIHC	cis	rs459482	0.576	rs461448	chr21:42800923	C/A	cg14166395	chr21:42792516	MX1	0.44	6.13	0.31	2.45e-9	IgG glycosylation;
LIHC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.66	-7.84	-0.39	5.8e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06558623	chr16:89946397	TCF25	0.84	12.35	0.56	3.22e-29	Skin colour saturation;
LIHC	cis	rs7911264	0.628	rs6583833	chr10:94409800	C/T	cg00519463	chr10:94352821	KIF11	-0.46	-6.44	-0.33	3.99e-10	Inflammatory bowel disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25976004	chr4:56815073	CEP135	-0.5	-6.48	-0.33	3.29e-10	Systolic blood pressure;
LIHC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg05973401	chr12:123451056	ABCB9	-0.42	-6.42	-0.33	4.61e-10	Neutrophil percentage of white cells;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.86	-0.39	4.96e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.08	-0.51	1.43e-24	Eye color traits;
LIHC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	cis	rs34245846	0.704	rs11264280	chr1:154862952	C/T	cg24250549	chr1:154909240	PMVK	-0.68	-9.08	-0.44	8.6e-18	Atrial fibrillation;
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg14828511	chr1:107599125	PRMT6	0.4	5.72	0.3	2.35e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.37e-8	Lewy body disease;
LIHC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.48	8.74	0.43	1.05e-16	IgG glycosylation;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg21941105	chr19:10491405	TYK2	-0.47	-6.64	-0.34	1.24e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.85	0.3	1.14e-8	Tonsillectomy;
LIHC	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.43	7.68	0.38	1.64e-13	Testicular germ cell tumor;
LIHC	cis	rs611744	0.967	rs639059	chr8:109236119	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.67	0.34	1.04e-10	Dupuytren's disease;
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.74	0.39	1.11e-13	Platelet count;
LIHC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.56	-9.5	-0.46	3.68e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.56	8.62	0.42	2.52e-16	Multiple sclerosis;
LIHC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg08888203	chr3:10149979	C3orf24	0.56	6.48	0.33	3.23e-10	Alzheimer's disease;
LIHC	cis	rs7945718	0.870	rs10831903	chr11:12758660	C/T	cg25843174	chr11:12811716	TEAD1	0.35	7.93	0.39	3.24e-14	Educational attainment (years of education);
LIHC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.44	-7.2	-0.36	3.94e-12	Fibrinogen levels;
LIHC	trans	rs12780046	0.656	rs1539396	chr10:100824035	C/G	cg05980083	chr9:112191166	PTPN3	-0.5	-6.53	-0.33	2.38e-10	Non-glioblastoma glioma;
LIHC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.6	7.26	0.37	2.58e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg22676075	chr6:135203613	NA	0.38	6.24	0.32	1.26e-9	Red blood cell count;
LIHC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.81	17.55	0.69	1.22e-49	Gestational age at birth (maternal effect);
LIHC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.57	0.33	1.91e-10	Bipolar disorder;
LIHC	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.46	8.81	0.43	6.43e-17	Testicular germ cell tumor;
LIHC	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.73	8.07	0.4	1.21e-14	Putamen volume;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.5	-7.58	-0.38	3.17e-13	Menopause (age at onset);
LIHC	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.78	-10.25	-0.48	1.13e-21	Body mass index;
LIHC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.42	-8.39	-0.41	1.26e-15	Obesity-related traits;
LIHC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg03959625	chr15:84868606	LOC388152	0.45	6.1	0.31	2.82e-9	Schizophrenia;
LIHC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.66	-0.46	1.13e-19	Bipolar disorder;
LIHC	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.72	-8.61	-0.42	2.64e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg10932868	chr11:921992	NA	0.4	7.54	0.38	4.38e-13	Alzheimer's disease (late onset);
LIHC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.4	-0.49	3.54e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.0	-0.35	1.39e-11	Vitiligo;
LIHC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	12.1	0.55	2.66e-28	Mean platelet volume;
LIHC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.44	-6.13	-0.31	2.43e-9	Longevity;
LIHC	trans	rs11165623	0.602	rs942904	chr1:97025708	C/T	cg10631902	chr5:14652156	NA	-0.25	-6.17	-0.32	1.89e-9	Hip circumference;Waist circumference;
LIHC	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.53	0.33	2.37e-10	Response to antipsychotic treatment;
LIHC	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg26597838	chr10:835615	NA	0.67	6.03	0.31	4.23e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg21522988	chr12:29376872	FAR2	0.29	6.42	0.33	4.68e-10	QT interval;
LIHC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.08e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs1347297	0.526	rs890579	chr2:179263287	C/T	cg14011486	chr1:26737247	LIN28	0.49	7.67	0.38	1.81e-13	Alzheimer disease and age of onset;
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg26338869	chr17:61819248	STRADA	0.52	6.91	0.35	2.31e-11	Height;
LIHC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08219700	chr8:58056026	NA	0.5	6.81	0.35	4.4e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.76	-9.18	-0.44	4.28e-18	Psoriasis vulgaris;
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg12903224	chr12:29470962	FAR2	0.39	6.36	0.33	6.41e-10	QT interval;
LIHC	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.51	9.54	0.46	2.81e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	0.85	11.06	0.51	1.61e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-7.0	-0.35	1.35e-11	Chronic sinus infection;
LIHC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.69	12.39	0.56	2.18e-29	Colorectal cancer;
LIHC	cis	rs611744	0.967	rs536860	chr8:109230722	A/C	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.55	9.14	0.44	5.47e-18	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs539514	0.664	rs634729	chr13:76307981	C/T	cg04757411	chr13:76259545	LMO7	-0.43	-7.34	-0.37	1.57e-12	Type 1 diabetes;
LIHC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.68	-10.66	-0.5	4.24e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09048334	chr6:37012640	NA	0.49	6.07	0.31	3.34e-9	Lung function (FEV1);
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg17385448	chr1:15911702	AGMAT	0.38	6.34	0.32	7.41e-10	Systolic blood pressure;
LIHC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.2	0.52	5.37e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.77	-0.43	8.52e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.86	14.37	0.61	6.07e-37	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.87	10.43	0.49	2.62e-22	Cognitive function;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	7.47	0.37	6.88e-13	Osteoporosis;
LIHC	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.36	-0.33	6.52e-10	Schizophrenia;
LIHC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg13385521	chr17:29058706	SUZ12P	0.84	8.15	0.4	7.08e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.41	6.2	0.32	1.6e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg14515779	chr1:101123966	NA	-0.43	-6.11	-0.31	2.67e-9	Monocyte count;
LIHC	cis	rs4423214	0.550	rs4944885	chr11:71114075	C/T	cg05163923	chr11:71159392	DHCR7	0.74	11.39	0.52	1.02e-25	Vitamin D levels;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.63	0.38	2.37e-13	Prudent dietary pattern;
LIHC	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.37	-6.11	-0.31	2.75e-9	Bipolar disorder;
LIHC	trans	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg14791747	chr16:20752902	THUMPD1	0.45	6.4	0.33	5.07e-10	Dental caries;
LIHC	cis	rs7587476	0.906	rs2734674	chr2:215658895	A/G	cg04004882	chr2:215674386	BARD1	-0.52	-6.96	-0.35	1.74e-11	Neuroblastoma;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.44	8.04	0.4	1.47e-14	Prudent dietary pattern;
LIHC	cis	rs2637030	0.559	rs2637027	chr5:52980471	G/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.66	0.34	1.1e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-6.64	-0.34	1.23e-10	Monocyte percentage of white cells;
LIHC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.6	7.29	0.37	2.21e-12	Heart rate;
LIHC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg12751644	chr20:60527061	NA	-0.38	-6.41	-0.33	4.81e-10	Body mass index;
LIHC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-8.19	-0.41	5.15e-15	Schizophrenia;
LIHC	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg22771759	chr13:24902376	NA	0.33	6.75	0.34	6.39e-11	Obesity-related traits;
LIHC	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	1.01e-12	Mean platelet volume;
LIHC	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg08126542	chr6:37504118	NA	-0.35	-5.91	-0.3	8.4e-9	Cognitive performance;
LIHC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.36	5.71	0.3	2.44e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.49	0.33	2.95e-10	Height;
LIHC	trans	rs3783890	1.000	rs34625843	chr14:93793329	C/T	cg02802420	chr16:69363236	PDF;COG8	0.32	6.32	0.32	8.12e-10	Body mass index;
LIHC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg06742321	chr12:123595122	PITPNM2	0.31	5.85	0.3	1.14e-8	Platelet count;
LIHC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.54	-6.44	-0.33	4.01e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg25344623	chr2:136566232	LCT	0.33	6.31	0.32	8.42e-10	Mosquito bite size;
LIHC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.7	0.38	1.46e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.8	8.9	0.43	3.22e-17	Vitiligo;
LIHC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg03146154	chr1:46216737	IPP	-0.4	-6.55	-0.33	2.11e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg10096929	chr1:156261403	TMEM79	0.41	6.77	0.34	5.47e-11	Tonsillectomy;
LIHC	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg20991723	chr1:152506922	NA	0.56	9.9	0.47	1.69e-20	Hair morphology;
LIHC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.22	-0.55	9.39e-29	Colorectal cancer;
LIHC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.44	0.53	7.1e-26	Coronary artery disease;
LIHC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg14393609	chr7:65229607	NA	-0.43	-6.36	-0.33	6.33e-10	Aortic root size;
LIHC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.74	12.15	0.55	1.69e-28	Mean platelet volume;
LIHC	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg16589663	chr20:23618590	CST3	0.76	7.87	0.39	4.59e-14	Chronic kidney disease;
LIHC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.67	-10.2	-0.48	1.6e-21	Total body bone mineral density;
LIHC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22509189	chr2:225307070	NA	-0.64	-7.69	-0.38	1.5700000000000001e-13	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs75908454	1.000	rs75367524	chr6:169922592	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.45	-0.37	7.84e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08161947	chr12:19592900	AEBP2	-0.53	-7.75	-0.39	1.04e-13	Bilirubin levels;
LIHC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg14440974	chr22:39074834	NA	-0.44	-7.16	-0.36	4.96e-12	Menopause (age at onset);
LIHC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.24	0.45	2.73e-18	Bipolar disorder;
LIHC	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-0.76	-8.76	-0.43	9.24e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs858239	0.539	rs4295546	chr7:23191021	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.38	0.33	5.6e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.71	-10.32	-0.49	6.67e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.47	7.2	0.36	3.81e-12	Diastolic blood pressure;
LIHC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.57	-9.04	-0.44	1.19e-17	Systemic sclerosis;
LIHC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg21361702	chr7:150065534	REPIN1	0.45	6.1	0.31	2.85e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.18	-0.4	5.45e-15	Capecitabine sensitivity;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11527367	chr1:144612646	C1orf152	0.39	6.12	0.31	2.56e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs963731	0.649	rs10779924	chr2:39208057	G/T	cg04010122	chr2:39346883	SOS1	-0.66	-5.8	-0.3	1.52e-8	Corticobasal degeneration;
LIHC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg03037974	chr15:76606532	NA	-0.61	-10.28	-0.49	8.86e-22	Blood metabolite levels;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.55	-7.86	-0.39	5.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.74	-13.36	-0.59	4.7e-33	Longevity;
LIHC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg19682013	chr15:45996608	NA	0.39	6.67	0.34	1.01e-10	Waist circumference;Weight;
LIHC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.03	14.59	0.62	7.75e-38	Cognitive function;
LIHC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg24130564	chr14:104152367	KLC1	-0.34	-5.74	-0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.89	13.85	0.6	6.12e-35	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.38	-0.33	5.86e-10	Total body bone mineral density;
LIHC	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.13	-0.48	2.91e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Obesity-related traits;
LIHC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	6.51	0.33	2.63e-10	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.33	0.45	1.42e-18	Platelet count;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.31	0.32	8.57e-10	Prudent dietary pattern;
LIHC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.64	6.52	0.33	2.59e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.49	-7.64	-0.38	2.18e-13	Bone mineral density (spine);
LIHC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.78	-12.2	-0.55	1.13e-28	Dental caries;
LIHC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-9.2	-0.45	3.57e-18	Skin colour saturation;
LIHC	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.34	20.98	0.75	2.15e-63	Corneal structure;
LIHC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.83	10.81	0.5	1.27e-23	Schizophrenia;
LIHC	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs5167	0.506	rs11669173	chr19:45492559	G/A	cg09555818	chr19:45449301	APOC2	-0.22	-6.36	-0.33	6.47e-10	Blood protein levels;
LIHC	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg20991723	chr1:152506922	NA	-0.58	-10.08	-0.48	4.16e-21	Hair morphology;
LIHC	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.2	-0.45	3.51e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.48	7.74	0.39	1.17e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.6	-7.41	-0.37	1e-12	Mosquito bite size;
LIHC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg12798992	chr6:167411361	FGFR1OP	-0.61	-9.78	-0.47	4.55e-20	Crohn's disease;
LIHC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-12.95	-0.57	1.81e-31	Response to antipsychotic treatment;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	0.59	8.47	0.42	7.56e-16	Prudent dietary pattern;
LIHC	cis	rs965469	0.779	rs6051820	chr20:3365301	A/G	cg25506879	chr20:3388711	C20orf194	-0.52	-6.32	-0.32	8.17e-10	IFN-related cytopenia;
LIHC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.13	-0.31	2.39e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg10174797	chr19:8464628	RAB11B	0.44	6.07	0.31	3.31e-9	HDL cholesterol;
LIHC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.32	-5.94	-0.31	7.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.18e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.55	-8.33	-0.41	1.96e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.67	0.38	1.86e-13	Educational attainment (years of education);
LIHC	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg26138937	chr11:71823887	C11orf51	1.31	10.34	0.49	5.49e-22	Severe influenza A (H1N1) infection;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02562419	chr6:159049626	TMEM181	0.44	6.24	0.32	1.32e-9	Bilirubin levels;
LIHC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.75	-12.91	-0.57	2.44e-31	Aortic root size;
LIHC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	0.91	21.23	0.75	2.15e-64	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.04	-0.36	1.06e-11	Body mass index;
LIHC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.44	-7.47	-0.37	6.73e-13	Dementia with Lewy bodies;
LIHC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	8.16	0.4	6.67e-15	Lung cancer in ever smokers;
LIHC	cis	rs2637030	0.559	rs1559266	chr5:52851931	C/T	cg06476337	chr5:52856530	NDUFS4	0.43	6.7	0.34	8.59e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04784014	chr7:5521290	FBXL18	0.46	6.73	0.34	7.35e-11	Pancreatic cancer;
LIHC	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-9.79	-0.47	4.18e-20	Facial emotion recognition (sad faces);
LIHC	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.46	-6.82	-0.35	4.27e-11	Coffee consumption (cups per day);
LIHC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.41	0.33	4.84e-10	Renal cell carcinoma;
LIHC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.25	-0.55	7.24e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg07713946	chr22:31675144	LIMK2	-0.44	-7.91	-0.39	3.52e-14	Colorectal cancer;
LIHC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.28	-0.32	1.06e-9	Obesity-related traits;
LIHC	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.2	0.48	1.73e-21	Alzheimer's disease (late onset);
LIHC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg23625390	chr15:77176239	SCAPER	0.34	6.0	0.31	5.02e-9	Blood metabolite levels;
LIHC	cis	rs2412488	0.893	rs6848887	chr4:54279292	A/G	cg22241045	chr4:54363911	LNX1	-0.41	-6.71	-0.34	8.15e-11	DNA methylation (variation);
LIHC	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.43	6.16	0.32	2.06e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.87	19.19	0.72	3.09e-56	Ulcerative colitis;
LIHC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-11.15	-0.52	7.49e-25	Coronary artery disease;
LIHC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.66	0.42	1.91e-16	Motion sickness;
LIHC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg18887096	chr2:219472410	PLCD4	0.34	5.78	0.3	1.68e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1866706	1.000	rs1866706	chr11:12867214	T/C	cg25843174	chr11:12811716	TEAD1	-0.33	-6.95	-0.35	1.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4934494	0.768	rs1926139	chr10:91513152	A/G	cg19698084	chr10:91461284	KIF20B	-0.44	-5.88	-0.3	9.5e-9	Red blood cell count;
LIHC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.76	12.76	0.57	8.85e-31	Menarche (age at onset);
LIHC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.26e-9	Menopause (age at onset);
LIHC	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg05896524	chr21:47604654	C21orf56	0.46	6.97	0.35	1.61e-11	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16406212	chr2:24163862	UBXN2A	0.38	6.12	0.31	2.6e-9	Pancreatic cancer;
LIHC	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.38	5.87	0.3	1.06e-8	Alzheimer's disease (survival time);
LIHC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.49	6.31	0.32	8.72e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg20129853	chr10:51489980	NA	0.42	9.21	0.45	3.39e-18	Prostate-specific antigen levels;
LIHC	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg17623882	chr6:41773611	USP49	-0.43	-5.78	-0.3	1.68e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.53	-0.49	1.22e-22	Eye color traits;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21747090	chr2:27597821	SNX17	-0.46	-7.0	-0.35	1.37e-11	Total body bone mineral density;
LIHC	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg09597638	chr17:3907349	NA	0.54	6.49	0.33	3.07e-10	Type 2 diabetes;
LIHC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.92	-0.65	4.52e-43	Chronic sinus infection;
LIHC	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.9	0.47	1.78e-20	Corneal astigmatism;
LIHC	cis	rs17152411	1.000	rs7083336	chr10:126590771	T/C	cg07906193	chr10:126599966	NA	0.46	7.11	0.36	6.9e-12	Height;
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.27	-6.48	-0.33	3.2e-10	Plasma homocysteine levels (post-methionine load test);
LIHC	trans	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-7.72	-0.39	1.29e-13	Pulse pressure;
LIHC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.74	-0.3	2.07e-8	Personality dimensions;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10463451	chr21:37432625	SETD4	0.58	7.51	0.38	5.12e-13	Lung function (FEV1/FVC);
LIHC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.38	-5.95	-0.31	6.79e-9	Testicular germ cell tumor;
LIHC	trans	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg10756647	chr7:56101905	PSPH	-1.07	-13.13	-0.58	3.48e-32	Diabetic kidney disease;
LIHC	cis	rs17102884	0.600	rs9671386	chr14:75151047	G/A	cg08847533	chr14:75593920	NEK9	0.44	6.55	0.33	2.13e-10	Neuroticism;
LIHC	cis	rs7187994	0.848	rs16974527	chr16:84782822	C/T	cg07647771	chr16:84786436	USP10	-0.33	-6.47	-0.33	3.47e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg05110241	chr16:68378359	PRMT7	-0.54	-6.51	-0.33	2.67e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.36	7.6	0.38	2.95e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.52	8.84	0.43	5.2e-17	Coronary artery disease;
LIHC	cis	rs72781680	0.566	rs6714016	chr2:23899948	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	6.18	0.32	1.85e-9	Lymphocyte counts;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04130928	chr5:176449623	ZNF346	-0.52	-6.63	-0.34	1.29e-10	Systolic blood pressure;
LIHC	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.88	14.7	0.62	2.92e-38	Schizophrenia;
LIHC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-6.99	-0.35	1.49e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs727809	0.927	rs4958336	chr5:152582060	A/T	cg21580998	chr1:227751410	ZNF678	-0.48	-6.09	-0.31	3.02e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.52	-7.96	-0.4	2.61e-14	Menarche (age at onset);
LIHC	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg06611532	chr13:114900021	NA	0.41	7.4	0.37	1.04e-12	Schizophrenia;
LIHC	cis	rs1639906	0.895	rs6972752	chr7:2196551	G/A	cg02951883	chr7:2050386	MAD1L1	0.58	7.79	0.39	8.3e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.81	12.72	0.57	1.32e-30	Height;
LIHC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.05	-0.4	1.41e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.5	-7.75	-0.39	1.04e-13	Blood protein levels;
LIHC	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.68	0.53	9.52e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.57	-8.93	-0.44	2.59e-17	Crohn's disease;
LIHC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.35	0.77	7.7e-69	Chronic sinus infection;
LIHC	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-7.41	-0.37	9.84e-13	Vitamin D levels;
LIHC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.7	9.26	0.45	2.3e-18	Gut microbiome composition (summer);
LIHC	trans	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17183009	chr3:120277827	NA	0.52	6.13	0.31	2.45e-9	Corneal astigmatism;
LIHC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-11.29	-0.52	2.54e-25	Primary sclerosing cholangitis;
LIHC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05665937	chr4:1216051	CTBP1	0.45	6.08	0.31	3.23e-9	Obesity-related traits;
LIHC	cis	rs77633900	0.772	rs2469224	chr15:76651327	T/G	cg21673338	chr15:77095150	SCAPER	-0.53	-6.15	-0.32	2.15e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg19318889	chr4:1322082	MAEA	0.46	6.49	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.65	0.38	2e-13	Prudent dietary pattern;
LIHC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg11070056	chr1:107600091	PRMT6	-0.71	-12.16	-0.55	1.64e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs16912285	0.688	rs7128427	chr11:24338598	C/T	ch.11.24196551F	chr11:24239977	NA	0.72	8.27	0.41	3.09e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg02344993	chr17:57696989	CLTC	0.71	11.85	0.54	2.25e-27	Hemoglobin concentration;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.61	-5.93	-0.31	7.54e-9	Urate levels in lean individuals;
LIHC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.66	-6.47	-0.33	3.34e-10	Vitiligo;
LIHC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.51	-7.8	-0.39	7.61e-14	Systemic lupus erythematosus;
LIHC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.46	-6.39	-0.33	5.57e-10	Tuberculosis;
LIHC	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg10756647	chr7:56101905	PSPH	1.01	11.98	0.54	7.24e-28	Diabetic kidney disease;
LIHC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.66	-8.86	-0.43	4.53e-17	Aortic root size;
LIHC	trans	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.65	0.34	1.16e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	13.91	0.6	3.46e-35	Lung cancer in ever smokers;
LIHC	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.23	12.68	0.57	1.86e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg22705602	chr4:152727874	NA	0.31	6.33	0.32	7.53e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg12062639	chr20:23401060	NAPB	0.8	9.83	0.47	3.06e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.34	-6.15	-0.32	2.16e-9	Aortic root size;
LIHC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.32	6.22	0.32	1.43e-9	Type 2 diabetes;
LIHC	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg02527881	chr3:46936655	PTH1R	-0.5	-10.55	-0.5	1.02e-22	Birth weight;
LIHC	cis	rs1144333	0.655	rs1146602	chr1:76239309	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.85	-0.3	1.16e-8	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12611088	0.634	rs2682566	chr19:44024942	G/T	cg13740135	chr19:44006432	PHLDB3	-0.42	-6.09	-0.31	3.04e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.66	10.4	0.49	3.51e-22	Corneal astigmatism;
LIHC	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg08392591	chr16:89556376	ANKRD11	0.44	6.77	0.34	5.78e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.59	-0.46	1.88e-19	Total cholesterol levels;
LIHC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.98	-17.72	-0.69	2.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08280861	chr8:58055591	NA	0.54	6.29	0.32	9.97e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.84	8.41	0.41	1.14e-15	Mean platelet volume;
LIHC	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg17385448	chr1:15911702	AGMAT	0.38	6.34	0.32	7.41e-10	Systolic blood pressure;
LIHC	trans	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.38	0.56	2.46e-29	Menopause (age at onset);
LIHC	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03576123	chr11:487126	PTDSS2	-1.06	-7.04	-0.36	1.09e-11	Body mass index;
LIHC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.59	-8.08	-0.4	1.16e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12374732	chr8:103251909	RRM2B	0.46	6.42	0.33	4.65e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg07451762	chr16:28383216	NA	0.32	6.09	0.31	3.1e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.3	7.05	0.36	1.01e-11	Blood protein levels;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.56	8.45	0.42	8.62e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-26.16	-0.82	1.28e-83	Myeloid white cell count;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-7.77	-0.39	9.34e-14	Lymphocyte counts;
LIHC	cis	rs7716219	0.672	rs10940473	chr5:54873285	C/T	cg14753740	chr5:54468940	CDC20B;MIR449C	0.51	7.19	0.36	4.18e-12	Height;
LIHC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg25344623	chr2:136566232	LCT	-0.37	-5.91	-0.3	8.3e-9	Corneal structure;
LIHC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06226973	chr2:179315633	PRKRA;MIR548N;DFNB59	0.43	6.27	0.32	1.1e-9	Brain volume in infants (cerebrospinal fluid);
LIHC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-6.86	-0.35	3.27e-11	Morning vs. evening chronotype;
LIHC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	9.01	0.44	1.53e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.43	0.62	3.54e-37	Prudent dietary pattern;
LIHC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.98	18.38	0.7	5.65e-53	Menopause (age at onset);
LIHC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.13	0.31	2.4e-9	Alzheimer's disease;
LIHC	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.42e-11	Intracranial aneurysm;
LIHC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.67	10.01	0.48	7.42e-21	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6782228	0.606	rs1697	chr3:128356852	C/T	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.32	-0.32	8.08e-10	Metabolite levels;
LIHC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.68	10.28	0.49	9.12e-22	Aortic root size;
LIHC	cis	rs61041384	0.661	rs3759111	chr12:123687774	A/G	cg00376283	chr12:123451042	ABCB9	0.58	6.43	0.33	4.2e-10	Schizophrenia;
LIHC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg22961513	chr11:14280813	SPON1	0.48	7.31	0.37	1.9e-12	Mitochondrial DNA levels;
LIHC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg02527881	chr3:46936655	PTH1R	0.32	6.4	0.33	5.18e-10	Colorectal cancer;
LIHC	cis	rs9918079	0.560	rs10008975	chr4:15624571	C/T	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.85	-0.3	1.14e-8	Obesity-related traits;
LIHC	trans	rs8117834	0.574	rs6086331	chr20:8083296	G/A	cg00593689	chr4:53575888	NA	0.38	6.5	0.33	2.77e-10	Chronic kidney disease;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.6	7.4	0.37	1.09e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg08949735	chr16:89699720	DPEP1	0.41	8.2	0.41	4.91e-15	Vitiligo;
LIHC	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.36	7.52	0.38	4.8e-13	Sitting height ratio;
LIHC	cis	rs7106204	0.514	rs7935857	chr11:24252420	C/T	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.57	-9.44	-0.45	5.85e-19	Colorectal cancer;
LIHC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.03e-8	Tonsillectomy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15106226	chr19:11878036	ZNF441	-0.54	-6.09	-0.31	2.99e-9	Systolic blood pressure;
LIHC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25463822	chr1:193028375	TROVE2;UCHL5	-0.55	-6.63	-0.34	1.29e-10	Systolic blood pressure;
LIHC	cis	rs243505	0.762	rs734002	chr7:148505788	A/G	cg09806900	chr7:148480153	CUL1	0.43	6.43	0.33	4.3e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1000083	0.599	rs7734922	chr5:96745629	G/T	ch.5.96698337R	chr5:96672581	NA	0.74	6.26	0.32	1.13e-9	Cisplatin-induced ototoxicity;
LIHC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.52	8.99	0.44	1.72e-17	Type 2 diabetes;
LIHC	cis	rs13126513	0.708	rs2172138	chr4:100489785	G/C	cg05468953	chr4:100565104	NA	0.32	6.06	0.31	3.64e-9	Metabolite levels (MHPG);
LIHC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.42	6.35	0.32	6.89e-10	Post bronchodilator FEV1;
LIHC	cis	rs4478037	0.822	rs9817393	chr3:33117069	A/G	cg27203090	chr3:33138513	GLB1;TMPPE	-0.58	-7.42	-0.37	9.39e-13	Major depressive disorder;
LIHC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.77	-0.34	5.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.23	-0.36	3.14e-12	Response to antipsychotic treatment;
LIHC	cis	rs7578199	0.744	rs7590080	chr2:242205466	C/T	cg19372975	chr2:242212901	HDLBP	-0.61	-5.84	-0.3	1.2e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.37	-6.17	-0.32	1.96e-9	Monobrow;
LIHC	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	1.03	9.14	0.44	5.57e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.71	-11.27	-0.52	2.84e-25	White matter hyperintensity burden;
LIHC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.46	7.86	0.39	5.1e-14	Mean corpuscular volume;
LIHC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.38	-11.71	-0.53	7.6e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg12863693	chr15:85201151	NMB	0.44	6.16	0.32	2.01e-9	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10744422	0.748	rs1671688	chr12:123255733	A/T	cg18912006	chr12:123335444	HIP1R	-0.52	-6.13	-0.31	2.41e-9	Schizophrenia;
LIHC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.33	7.06	0.36	9.29e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-25.41	-0.81	8.99e-81	Myeloid white cell count;
LIHC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-11.09	-0.51	1.29e-24	Chronic sinus infection;
LIHC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.15	-0.4	7.09e-15	Chronic sinus infection;
LIHC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.42	-7.35	-0.37	1.46e-12	Platelet distribution width;
LIHC	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.74	-0.3	2.11e-8	Alcohol dependence;
LIHC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	1.02	19.69	0.73	3.16e-58	Breast cancer;
LIHC	cis	rs72653721	0.793	rs4713100	chr6:10968216	T/C	cg13562911	chr6:11044106	ELOVL2	0.48	6.83	0.35	3.96e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs895636	0.848	rs4953156	chr2:45189763	G/A	cg16198908	chr2:45192207	NA	0.39	5.94	0.31	6.97e-9	Metabolite levels;Fasting plasma glucose;
LIHC	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.51	0.53	4.03e-26	Coffee consumption (cups per day);
LIHC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg11952622	chr19:58962976	ZNF324B	0.47	7.13	0.36	5.94e-12	Uric acid clearance;
LIHC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg22633049	chr21:46681294	NA	-0.36	-6.3	-0.32	9.33e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	6.27	0.32	1.09e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs16958440	1.000	rs62096476	chr18:44658621	T/C	cg17192377	chr18:44677553	HDHD2	0.6	6.71	0.34	8.24e-11	Sitting height ratio;
LIHC	cis	rs1034435	1.000	rs9680744	chr22:48889547	C/G	cg05992904	chr22:48892994	FAM19A5	-0.46	-9.09	-0.44	8.24e-18	Late-onset Alzheimer's disease;
LIHC	cis	rs7116495	0.609	rs7924834	chr11:71644333	C/T	cg26138937	chr11:71823887	C11orf51	1.09	9.77	0.47	4.79e-20	Severe influenza A (H1N1) infection;
LIHC	trans	rs412658	0.776	rs12460025	chr19:22318230	A/G	cg05197062	chr11:11642011	GALNTL4	-0.46	-6.4	-0.33	5e-10	Telomere length;
LIHC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.45	-6.65	-0.34	1.13e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs507080	0.961	rs4938523	chr11:118548838	G/T	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-1.19	-10.59	-0.5	7.59e-23	Breast cancer;
LIHC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.74	-0.3	2.1e-8	Coronary artery disease;
LIHC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.47	-6.12	-0.31	2.61e-9	Pancreatic cancer;
LIHC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.65	8.47	0.42	7.58e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.51	-6.88	-0.35	2.81e-11	Type 2 diabetes;
LIHC	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25632853	chr15:73088954	NA	0.37	6.17	0.32	1.95e-9	Triglyceride levels;
LIHC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.45	-7.24	-0.36	3.07e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg20607798	chr8:58055168	NA	0.48	5.98	0.31	5.72e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.86	15.12	0.63	6.25e-40	Headache;
LIHC	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.57	-0.5	8.95e-23	Alzheimer's disease;
LIHC	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg16309518	chr5:176445507	NA	-0.52	-9.6	-0.46	1.78e-19	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.39	-6.64	-0.34	1.25e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs9326778	0.520	rs11957948	chr5:108850012	G/T	cg17395555	chr5:108820864	NA	-0.36	-6.2	-0.32	1.67e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.93	-0.31	7.43e-9	Life satisfaction;
LIHC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg18016565	chr1:150552671	MCL1	0.5	9.91	0.47	1.67e-20	Melanoma;
LIHC	cis	rs12530845	0.887	rs59400686	chr7:135360029	A/G	cg23117316	chr7:135346802	PL-5283	-0.37	-5.75	-0.3	1.98e-8	Red blood cell traits;
LIHC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg02290350	chr8:58132656	NA	-0.32	-7.41	-0.37	9.98e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26897989	chr16:1907736	C16orf73	-0.47	-5.89	-0.3	9.03e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.51	7.18	0.36	4.45e-12	Waist circumference;
LIHC	trans	rs2270927	0.510	rs246813	chr5:75599605	G/T	cg13563193	chr19:33072644	PDCD5	1.0	9.95	0.47	1.14e-20	Mean corpuscular volume;
LIHC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.41	-6.68	-0.34	9.76e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.42	5.85	0.3	1.13e-8	Tuberculosis;
LIHC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	1.0	11.04	0.51	1.94e-24	Triglycerides;
LIHC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.29	-0.37	2.13e-12	Monocyte percentage of white cells;
LIHC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg24112000	chr20:60950667	NA	-0.61	-9.86	-0.47	2.42e-20	Colorectal cancer;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.62	6.93	0.35	2.15e-11	Alzheimer's disease;
LIHC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.71	0.3	2.43e-8	Lung function (FEV1/FVC);
LIHC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg15208524	chr1:10270712	KIF1B	0.41	6.37	0.33	6.22e-10	Hepatocellular carcinoma;
LIHC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg23758822	chr17:41437982	NA	0.97	17.99	0.7	2.07e-51	Menopause (age at onset);
LIHC	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg22771759	chr13:24902376	NA	0.32	6.79	0.34	4.99e-11	Obesity-related traits;
LIHC	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.32	-5.99	-0.31	5.36e-9	Red blood cell count;
LIHC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.5	-0.49	1.54e-22	Total cholesterol levels;
LIHC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	11.36	0.52	1.36e-25	Platelet count;
LIHC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06636551	chr8:101224915	SPAG1	0.49	9.27	0.45	2.12e-18	Atrioventricular conduction;
LIHC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.14	-0.55	1.84e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg13919466	chr1:32135498	COL16A1	-0.33	-6.28	-0.32	1.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.35	0.49	4.9e-22	Bladder cancer;
LIHC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg01256987	chr12:42539512	GXYLT1	-0.44	-7.19	-0.36	4.15e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11605275	1.000	rs78687006	chr11:20032176	G/A	cg14835545	chr11:20032148	NAV2	-0.8	-7.38	-0.37	1.18e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.19	-0.36	4.1e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.92e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.48	-0.62	2.09e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs4788570	0.615	rs7188675	chr16:71680002	C/T	cg06353428	chr16:71660113	MARVELD3	1.45	15.6	0.64	8.48e-42	Intelligence (multi-trait analysis);
LIHC	trans	rs668210	0.793	rs534201	chr11:65776728	A/T	cg17712092	chr4:129076599	LARP1B	0.59	6.27	0.32	1.08e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-11.57	-0.53	2.28e-26	Platelet distribution width;
LIHC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg07451762	chr16:28383216	NA	0.39	7.01	0.35	1.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.3	-0.41	2.47e-15	Bladder cancer;
LIHC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.65	-10.51	-0.49	1.47e-22	Blood trace element (Zn levels);
LIHC	cis	rs7937890	0.504	rs2575822	chr11:14519851	C/A	cg02886208	chr11:14281011	SPON1	-0.43	-6.12	-0.31	2.56e-9	Mitochondrial DNA levels;
LIHC	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs6728642	0.519	rs59131346	chr2:97566768	C/T	cg26665480	chr2:98280029	ACTR1B	-0.6	-6.51	-0.33	2.75e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.07e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.96	-0.31	6.44e-9	Coronary artery disease;
LIHC	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg05110241	chr16:68378359	PRMT7	-0.52	-6.11	-0.31	2.77e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	7.94	0.39	2.98e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	1.06	14.08	0.61	7.59e-36	Body mass index;
LIHC	cis	rs428668	0.681	rs192193	chr5:150692590	A/G	cg11125805	chr5:150678162	SLC36A3	0.4	8.1	0.4	1.01e-14	Skin aging (microtopography measurement);
LIHC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg16586182	chr3:47516702	SCAP	0.6	11.82	0.54	2.88e-27	Colorectal cancer;
LIHC	cis	rs6088813	1.000	rs6087702	chr20:33995945	T/A	cg14752227	chr20:34000481	UQCC	-0.4	-5.75	-0.3	1.99e-8	Height;
LIHC	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.84	-12.56	-0.56	5.15e-30	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs151997	0.962	rs27476	chr5:50178160	A/T	cg06027927	chr5:50259733	NA	-0.56	-7.5	-0.38	5.52e-13	Callous-unemotional behaviour;
LIHC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.7	-12.65	-0.56	2.45e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.62	-0.34	1.42e-10	Alzheimer's disease (late onset);
LIHC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg01788221	chr16:89496183	ANKRD11	-0.43	-6.66	-0.34	1.09e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg17724175	chr1:150552817	MCL1	0.39	7.67	0.38	1.75e-13	Melanoma;
LIHC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.01	0.4	1.79e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.7	-6.72	-0.34	7.41e-11	Red cell distribution width;
LIHC	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.63	10.22	0.48	1.38e-21	Schizophrenia;
LIHC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.54	5.77	0.3	1.76e-8	Menopause (age at onset);
LIHC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.78	0.57	7.96e-31	Mean platelet volume;
LIHC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.26	-0.55	6.69e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.34	0.32	7.45e-10	Tonsillectomy;
LIHC	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	8.5	0.42	5.93e-16	Colorectal cancer;
LIHC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.45	6.5	0.33	2.78e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.69	-0.34	9.07e-11	Neuroticism;
LIHC	trans	rs800082	0.734	rs1726538	chr3:144248888	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.45	0.33	3.73e-10	Smoking behavior;
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.37	-7.56	-0.38	3.86e-13	Renal cell carcinoma;
LIHC	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.47	-6.17	-0.32	1.97e-9	Psoriasis;
LIHC	cis	rs2073300	1.000	rs112057098	chr20:23448901	C/T	cg12062639	chr20:23401060	NAPB	0.81	9.62	0.46	1.56e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-0.47	-6.16	-0.32	2.07e-9	Opioid sensitivity;
LIHC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg03959625	chr15:84868606	LOC388152	-0.45	-6.53	-0.33	2.4e-10	Schizophrenia;
LIHC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg19645103	chr12:69753606	YEATS4	-0.43	-5.82	-0.3	1.39e-8	Response to diuretic therapy;
LIHC	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg10381502	chr11:71823885	C11orf51	0.91	8.04	0.4	1.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.83	7.19	0.36	3.98e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.05e-13	Uric acid levels;
LIHC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.42	6.29	0.32	9.74e-10	Educational attainment;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.76	0.8	2.86e-78	Prudent dietary pattern;
LIHC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.26	22.35	0.77	7.48e-69	Primary sclerosing cholangitis;
LIHC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.64	11.1	0.51	1.21e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.64	8.57	0.42	3.62e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	6.21	0.32	1.56e-9	Height;
LIHC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.68	-10.95	-0.51	4.02e-24	Lung cancer;
LIHC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.61	9.14	0.44	5.69e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.52	9.85	0.47	2.66e-20	Coronary artery disease;
LIHC	cis	rs4919087	0.620	rs793515	chr10:98988469	A/C	cg25902810	chr10:99078978	FRAT1	-0.56	-6.29	-0.32	9.75e-10	Monocyte count;
LIHC	cis	rs8067354	0.574	rs9789060	chr17:58018570	A/G	cg13753209	chr17:57696993	CLTC	0.71	10.58	0.5	7.79e-23	Hemoglobin concentration;
LIHC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg14440974	chr22:39074834	NA	-0.35	-6.02	-0.31	4.46e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.49	5.82	0.3	1.39e-8	Alzheimer's disease;
LIHC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.68	13.4	0.59	3.38e-33	High light scatter reticulocyte count;
LIHC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.46	-6.76	-0.34	5.84e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.16	12.47	0.56	1.09e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.35	7.62	0.38	2.52e-13	Type 2 diabetes;
LIHC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.62	10.68	0.5	3.62e-23	Colorectal cancer;
LIHC	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.45	6.73	0.34	7.1e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	0.91	6.66	0.34	1.09e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.66e-9	Mortality in heart failure;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23888375	chr2:203776317	ALS2CR8;WDR12	-0.35	-6.13	-0.31	2.39e-9	Bilirubin levels;
LIHC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.52	7.39	0.37	1.13e-12	Post bronchodilator FEV1;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.48	0.38	6.21e-13	Prudent dietary pattern;
LIHC	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.56	7.87	0.39	4.72e-14	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	7.82	0.39	6.53e-14	Motion sickness;
LIHC	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.45	6.69	0.34	9.09e-11	Atrial fibrillation;
LIHC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.32	-15.69	-0.65	3.57e-42	Diabetic kidney disease;
LIHC	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.74	-11.45	-0.53	6.21e-26	Metabolite levels;
LIHC	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg22705602	chr4:152727874	NA	-0.36	-7.52	-0.38	4.76e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.31	-7.56	-0.38	3.82e-13	Corneal astigmatism;
LIHC	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.65	-11.3	-0.52	2.29e-25	Pediatric autoimmune diseases;
LIHC	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg20240347	chr1:204465584	NA	-0.35	-7.51	-0.38	5.23e-13	Schizophrenia;
LIHC	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.63	6.87	0.35	2.99e-11	Alzheimer's disease;
LIHC	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg21605333	chr4:119757512	SEC24D	0.79	6.71	0.34	8.15e-11	Cannabis dependence symptom count;
LIHC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.13	0.36	6.18e-12	Axial length;
LIHC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.75	12.66	0.56	2.2e-30	Mean platelet volume;
LIHC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.94	20.42	0.74	3.62e-61	Blood protein levels;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.63	0.5	5.22e-23	Lymphocyte counts;
LIHC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.51	-7.6	-0.38	2.86e-13	Total body bone mineral density;
LIHC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	0.96	18.1	0.7	7.59e-52	Ewing sarcoma;
LIHC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.74	-14.5	-0.62	1.87e-37	Height;
LIHC	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23598886	chr18:12777645	NA	-0.43	-5.77	-0.3	1.81e-8	Inflammatory skin disease;
LIHC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	5.73	0.3	2.19e-8	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9309473	0.898	rs6546861	chr2:73849861	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.65	-0.34	1.13e-10	Metabolite levels;
LIHC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs8192917	0.832	rs10873219	chr14:25101706	A/C	cg08766149	chr14:25103301	GZMB	-0.33	-7.11	-0.36	6.68e-12	Vitiligo;
LIHC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg13409248	chr3:40428643	ENTPD3	-0.41	-7.01	-0.35	1.3e-11	Renal cell carcinoma;
LIHC	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg26031613	chr14:104095156	KLC1	1.15	15.1	0.63	8.1e-40	Body mass index;
LIHC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.76	-0.39	1.02e-13	Gut microbiome composition (summer);
LIHC	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.6	-7.9	-0.39	3.79e-14	Vitamin D levels;
LIHC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg24130564	chr14:104152367	KLC1	-0.36	-6.12	-0.31	2.61e-9	Schizophrenia;
LIHC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.66	-0.42	1.92e-16	Heart rate;
LIHC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.98	-0.35	1.53e-11	Mood instability;
LIHC	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	0.54	10.14	0.48	2.7e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9993613	1.000	rs4694502	chr4:73496157	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.38	-5.83	-0.3	1.3e-8	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-8.05	-0.4	1.35e-14	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg03037974	chr15:76606532	NA	-0.47	-7.23	-0.36	3.17e-12	Blood metabolite levels;
LIHC	cis	rs4764487	0.735	rs3181301	chr12:6345784	G/T	cg08284733	chr12:6341482	CD9	0.35	6.01	0.31	4.69e-9	Mean platelet volume;
LIHC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.32	0.45	1.51e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.45	6.72	0.34	7.72e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.95	17.65	0.69	4.96e-50	Menopause (age at onset);
LIHC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg16070123	chr10:51489643	NA	-0.37	-5.89	-0.3	9.03e-9	Prostate-specific antigen levels;
LIHC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.79	-12.07	-0.55	3.59e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-8.86	-0.43	4.32e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg13482628	chr17:19912719	NA	0.49	7.98	0.4	2.24e-14	Schizophrenia;
LIHC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-12.27	-0.55	6.3e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.52	-7.55	-0.38	4.04e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.93	0.31	7.39e-9	Tonsillectomy;
LIHC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.44	7.19	0.36	4.16e-12	Methadone dose in opioid dependence;
LIHC	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.67	-7.91	-0.39	3.62e-14	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.1e-31	Prudent dietary pattern;
LIHC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.87	-8.27	-0.41	3.09e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-10.62	-0.5	5.68e-23	Coronary artery disease;
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg00705908	chr8:17942569	ASAH1	0.46	6.35	0.32	6.91e-10	Neuroticism;
LIHC	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.88	9.25	0.45	2.45e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.43	-6.44	-0.33	4.03e-10	Gut microbiome composition (summer);
LIHC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.36	-7.88	-0.39	4.27e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-0.72	-11.21	-0.52	4.9e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg22974920	chr21:40686053	BRWD1	-0.4	-5.78	-0.3	1.66e-8	Cognitive function;
LIHC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.46	6.43	0.33	4.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg17279839	chr7:150038598	RARRES2	0.49	10.02	0.48	6.78e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	0.89	6.49	0.33	3.1e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.97	12.61	0.56	3.25e-30	HIV-1 control;
LIHC	cis	rs55665837	0.523	rs10832301	chr11:14788964	G/A	cg25251204	chr11:14927456	NA	0.41	5.79	0.3	1.56e-8	Vitamin D levels;
LIHC	trans	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg01596870	chr19:55963115	NA	-0.64	-8.49	-0.42	6.49e-16	Obesity-related traits;
LIHC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.42	-5.81	-0.3	1.42e-8	Longevity;
LIHC	cis	rs7937890	0.559	rs2575836	chr11:14497864	T/G	cg02886208	chr11:14281011	SPON1	-0.44	-6.15	-0.32	2.17e-9	Mitochondrial DNA levels;
LIHC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	0.99	13.74	0.6	1.57e-34	Body mass index;
LIHC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	6.6	0.34	1.61e-10	Bipolar disorder;
LIHC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.98	0.54	7.42e-28	High light scatter reticulocyte count;
LIHC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.18	-0.36	4.36e-12	Alcohol dependence;
LIHC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.72	-12.53	-0.56	6.93e-30	Colorectal cancer;
LIHC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.67	14.0	0.6	1.66e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs55665837	0.701	rs11023265	chr11:14616038	C/T	cg16394018	chr11:14927549	NA	0.41	5.85	0.3	1.12e-8	Vitamin D levels;
LIHC	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	trans	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-6.38	-0.33	5.67e-10	Mosquito bite size;
LIHC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.56	-8.79	-0.43	7.45e-17	Menarche (age at onset);
LIHC	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-6.0	-0.31	5.03e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	1.11	13.81	0.6	9.05e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.29	0.37	2.18e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg21466736	chr12:48725269	NA	-0.71	-10.74	-0.5	2.25e-23	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.23	-16.1	-0.66	8.28e-44	Diabetic kidney disease;
LIHC	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.47	-0.33	3.39e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.28	-21.05	-0.75	1.06e-63	Corneal structure;
LIHC	cis	rs4934494	0.768	rs2094214	chr10:91409381	G/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.5	-0.33	2.91e-10	Red blood cell count;
LIHC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24229701	chr12:130821962	PIWIL1	0.43	6.29	0.32	9.44e-10	Menopause (age at onset);
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.97	-0.35	1.59e-11	Total body bone mineral density;
LIHC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.44	6.81	0.35	4.5e-11	Methadone dose in opioid dependence;
LIHC	trans	rs11088226	0.758	rs2833864	chr21:33888393	A/C	cg09050820	chr6:167586206	TCP10L2	0.49	6.64	0.34	1.23e-10	Gastritis;
LIHC	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.31	-8.53	-0.42	4.8e-16	Intelligence;
LIHC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs16828019	0.852	rs12044539	chr1:41661732	A/C	cg03962019	chr1:41807865	NA	0.52	7.6	0.38	2.92e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs492146	0.740	rs1032418	chr6:52834957	A/T	cg24393602	chr6:52860404	GSTA4	0.43	6.21	0.32	1.57e-9	Epilepsy (remission after treatment);
LIHC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7715806	0.517	rs253392	chr5:74928883	G/T	cg19683494	chr5:74908142	NA	-0.54	-6.98	-0.35	1.58e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9896052	0.608	rs61264861	chr17:73459278	T/C	cg25649188	chr17:73499917	CASKIN2	0.43	6.65	0.34	1.17e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg18306943	chr3:40428807	ENTPD3	0.35	5.92	0.31	7.71e-9	Renal cell carcinoma;
LIHC	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg11441379	chr12:63026424	NA	0.6	6.18	0.32	1.87e-9	IgG glycosylation;
LIHC	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg16589663	chr20:23618590	CST3	0.75	7.66	0.38	1.98e-13	Chronic kidney disease;
LIHC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	0.66	9.39	0.45	8.9e-19	Monocyte percentage of white cells;
LIHC	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	5.95	0.31	6.55e-9	Asthma;
LIHC	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-6.62	-0.34	1.4e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg01843034	chr6:37503916	NA	-0.39	-6.37	-0.33	6.15e-10	Cognitive performance;
LIHC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.99	-0.63	2.07e-39	Longevity;
LIHC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-16.52	-0.67	1.7e-45	Gut microbiome composition (summer);
LIHC	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.38	5.92	0.3	7.74e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7635838	0.892	rs9874535	chr3:11463730	A/G	cg00170343	chr3:11313890	ATG7	0.45	7.01	0.35	1.3e-11	HDL cholesterol;
LIHC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg16586182	chr3:47516702	SCAP	-0.58	-10.97	-0.51	3.34e-24	Colorectal cancer;
LIHC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.38	-5.85	-0.3	1.12e-8	Cognitive function;
LIHC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.71	-0.38	1.41e-13	Ulcerative colitis;
LIHC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.27e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.54	8.08	0.4	1.11e-14	Platelet count;
LIHC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.54	8.71	0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.77	14.24	0.61	1.85e-36	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.96e-11	Rheumatoid arthritis;
LIHC	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.68	-0.34	9.45e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Life satisfaction;
LIHC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.57	-8.3	-0.41	2.51e-15	Motion sickness;
LIHC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-6.51	-0.33	2.6e-10	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.37	5.95	0.31	6.7e-9	Menopause (age at onset);
LIHC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.42	7.12	0.36	6.33e-12	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	15.91	0.65	4.81e-43	Smoking behavior;
LIHC	cis	rs36051895	0.593	rs12682970	chr9:5168137	C/T	cg02405213	chr9:5042618	JAK2	-0.68	-10.36	-0.49	4.58e-22	Pediatric autoimmune diseases;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.63	-9.6	-0.46	1.82e-19	Renal cell carcinoma;
LIHC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.9	-0.3	8.85e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.36	-8.05	-0.4	1.39e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.39	7.63	0.38	2.34e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.46	6.02	0.31	4.43e-9	Obesity (extreme);
LIHC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-8.33	-0.41	2.02e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10861342	1.000	rs11112397	chr12:105568381	T/C	cg23923672	chr12:105501055	KIAA1033	0.69	8.59	0.42	3.19e-16	IgG glycosylation;
LIHC	cis	rs4759375	0.915	rs11503021	chr12:123844558	C/T	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.57e-10	HDL cholesterol;
LIHC	cis	rs4788570	0.513	rs2113223	chr16:71607915	A/G	cg06353428	chr16:71660113	MARVELD3	-1.25	-11.09	-0.51	1.25e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg03037974	chr15:76606532	NA	-0.59	-9.92	-0.47	1.49e-20	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-7.77	-0.39	9.19e-14	Alzheimer's disease;
LIHC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.46	-6.52	-0.33	2.54e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.71	-11.37	-0.52	1.24e-25	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00049502	chr12:112280971	C12orf47;MAPKAPK5	0.41	6.11	0.31	2.74e-9	Pancreatic cancer;
LIHC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	0.9	8.64	0.42	2.21e-16	Alzheimer's disease;
LIHC	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg05760424	chr2:242988095	NA	-0.51	-6.79	-0.34	4.97e-11	Obesity-related traits;
LIHC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.61	11.19	0.52	5.72e-25	Chronic sinus infection;
LIHC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4716602	0.586	rs13224457	chr7:156161005	G/T	cg16983916	chr7:156159713	NA	-0.32	-5.72	-0.3	2.39e-8	Anti-saccade response;
LIHC	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.16	0.48	2.37e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	1.02	18.24	0.7	2.09e-52	Tonsillectomy;
LIHC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg00318621	chr2:106887213	NA	-0.58	-5.92	-0.3	7.75e-9	Facial morphology (factor 23);
LIHC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.3	0.61	1.07e-36	Multiple sclerosis;
LIHC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.82	0.3	1.39e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9392556	0.600	rs611500	chr6:4126763	C/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.24	5.76	0.3	1.84e-8	Blood metabolite levels;
LIHC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.68	9.97	0.47	9.8e-21	Monocyte percentage of white cells;
LIHC	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.58	-0.56	4.43e-30	Response to antipsychotic treatment;
LIHC	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.88e-13	Mean platelet volume;
LIHC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	1.1	13.54	0.59	9.53e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.35	9.12	0.44	6.64e-18	Schizophrenia;
LIHC	cis	rs8053891	0.625	rs12921355	chr16:72014687	T/A	cg01557791	chr16:72042693	DHODH	-0.51	-7.41	-0.37	9.99e-13	Coronary artery disease;
LIHC	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-12.22	-0.55	9.4e-29	Eye color traits;
LIHC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	5.72	0.3	2.29e-8	Schizophrenia;
LIHC	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg00601450	chr5:74908170	NA	0.58	7.1	0.36	7.09e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9322817	1.000	rs9322817	chr6:105232233	A/C	cg02098413	chr6:105308735	HACE1	-0.37	-6.06	-0.31	3.67e-9	Thyroid stimulating hormone;
LIHC	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.93	-11.99	-0.54	6.86e-28	Breast cancer;
LIHC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	0.96	18.34	0.7	8.49e-53	Ewing sarcoma;
LIHC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	6.6	0.34	1.61e-10	Renal cell carcinoma;
LIHC	cis	rs8049040	0.967	rs7203200	chr16:71465613	T/G	cg06353428	chr16:71660113	MARVELD3	-0.56	-5.88	-0.3	9.8e-9	Blood protein levels;
LIHC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.61	8.99	0.44	1.72e-17	Recombination rate (females);
LIHC	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg23533926	chr12:111358616	MYL2	0.31	6.05	0.31	3.88e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg08847533	chr14:75593920	NEK9	0.53	8.17	0.4	6.15e-15	IgG glycosylation;
LIHC	cis	rs6596100	0.538	rs55976357	chr5:132194565	C/A	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.79	-0.39	7.87e-14	Neuroticism;
LIHC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.24	0.32	1.29e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.62	-8.97	-0.44	2.02e-17	Menopause (age at onset);
LIHC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.33	-0.58	6.15e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	10.83	0.51	1.03e-23	Alzheimer's disease (late onset);
LIHC	cis	rs10870270	0.564	rs45519634	chr10:133782616	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.61	-5.92	-0.31	7.67e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg17724175	chr1:150552817	MCL1	0.43	8.68	0.42	1.61e-16	Melanoma;
LIHC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.81	-12.55	-0.56	5.48e-30	Psoriasis;
LIHC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg11812906	chr14:75593930	NEK9	-0.45	-7.0	-0.35	1.33e-11	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03480535	chr4:87856849	AFF1	0.47	7.56	0.38	3.62e-13	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26398791	chr1:38455867	SF3A3	0.42	6.14	0.32	2.28e-9	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12346351	chr4:152330392	FAM160A1	0.49	7.34	0.37	1.59e-12	Pancreatic cancer;
LIHC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.65	-9.14	-0.44	5.74e-18	Body mass index;
LIHC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	6.53	0.33	2.32e-10	Height;
LIHC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.67	11.13	0.52	9.19e-25	Type 2 diabetes;
LIHC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg07117364	chr1:16154769	NA	-0.39	-7.05	-0.36	1.02e-11	Dilated cardiomyopathy;
LIHC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.44	-7.17	-0.36	4.57e-12	Menarche (age at onset);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg23416307	chr4:858299	GAK	0.62	6.31	0.32	8.86e-10	Mean platelet volume;
LIHC	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.73	10.56	0.5	9.66e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.64	-9.17	-0.44	4.48e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	7.67	0.38	1.78e-13	Parkinson's disease;
LIHC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.77	0.47	4.61e-20	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.22	-0.36	3.36e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg26939375	chr7:64535504	NA	0.46	6.79	0.34	5.01e-11	Calcium levels;
LIHC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg20607798	chr8:58055168	NA	0.49	6.3	0.32	9.41e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.72	-12.99	-0.57	1.23e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.04	-0.4	1.43e-14	Glycated hemoglobin levels;
LIHC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.43	-6.42	-0.33	4.48e-10	Cognitive function;
LIHC	cis	rs6545883	0.825	rs7578139	chr2:61564121	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.79	0.3	1.56e-8	Tuberculosis;
LIHC	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.63	11.33	0.52	1.78e-25	Breast cancer;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.34	7.11	0.36	6.99e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.63	-0.46	1.41e-19	Bipolar disorder and schizophrenia;
LIHC	trans	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	cis	rs12022452	0.591	rs6672398	chr1:41002177	A/T	cg25568243	chr1:40974465	DEM1	0.43	5.87	0.3	1.02e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg14515779	chr1:101123966	NA	0.49	6.84	0.35	3.64e-11	Monocyte count;
LIHC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.47	0.33	3.31e-10	Schizophrenia;
LIHC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04498913	chr7:1135747	C7orf50	0.45	7.1	0.36	7.45e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg03859395	chr2:55845619	SMEK2	0.86	15.43	0.64	4.04e-41	Metabolic syndrome;
LIHC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.15	-0.32	2.21e-9	Ulcerative colitis;
LIHC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg24296786	chr1:45957014	TESK2	0.4	5.76	0.3	1.87e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.4	-6.23	-0.32	1.36e-9	Educational attainment;
LIHC	trans	rs8113308	0.810	rs11879040	chr19:52450109	A/C	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.26	13.03	0.58	8.73e-32	Eosinophil percentage of granulocytes;
LIHC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.06	0.31	3.62e-9	Menopause (age at onset);
LIHC	cis	rs5753037	0.653	rs131286	chr22:30158351	C/T	cg01021169	chr22:30184971	ASCC2	-0.31	-5.72	-0.3	2.31e-8	Type 1 diabetes;
LIHC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg06742321	chr12:123595122	PITPNM2	-0.32	-6.06	-0.31	3.69e-9	Platelet count;
LIHC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.56	-9.5	-0.46	3.64e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.44e-28	Height;
LIHC	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.82e-11	Breast cancer;
LIHC	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.29e-24	Breast cancer;
LIHC	cis	rs918629	0.567	rs1423268	chr5:95256974	T/C	cg10483112	chr5:95245456	ELL2	-0.38	-7.13	-0.36	5.83e-12	IgG glycosylation;
LIHC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.04	0.31	4.04e-9	Rheumatoid arthritis;
LIHC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.89	15.95	0.65	3.36e-43	Parkinson's disease;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.65	0.62	4.57e-38	Prudent dietary pattern;
LIHC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.54	-6.94	-0.35	1.92e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs17106184	1.000	rs17106219	chr1:50935031	C/T	cg07174182	chr1:51127561	FAF1	-0.56	-6.55	-0.33	2.08e-10	Type 2 diabetes;
LIHC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg25598624	chr8:12235727	FAM66A	0.3	6.11	0.31	2.77e-9	Myopia (pathological);
LIHC	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg00601450	chr5:74908170	NA	0.58	7.1	0.36	7.09e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.5	-8.73	-0.43	1.13e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.7	10.87	0.51	7.44e-24	Corneal astigmatism;
LIHC	cis	rs2257205	0.667	rs9904996	chr17:56711707	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.45	10.02	0.48	6.77e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg18887096	chr2:219472410	PLCD4	0.4	7.12	0.36	6.42e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	6.8	0.35	4.61e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.45	-0.37	7.5e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.68	10.37	0.49	4.2e-22	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg08888203	chr3:10149979	C3orf24	0.44	5.79	0.3	1.57e-8	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg11062466	chr8:58055876	NA	0.49	7.98	0.4	2.21e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-5.71	-0.3	2.45e-8	Aortic root size;
LIHC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	8.04	0.4	1.52e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.91	16.38	0.66	6.2e-45	Parkinson's disease;
LIHC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg03037974	chr15:76606532	NA	0.66	11.78	0.54	4.1e-27	Blood metabolite levels;
LIHC	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	27.36	0.83	3.84e-88	Schizophrenia;
LIHC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.54	-9.08	-0.44	8.92e-18	Colorectal cancer;
LIHC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.51	-6.81	-0.35	4.4e-11	Body mass index;
LIHC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg12365402	chr11:9010492	NRIP3	-0.25	-6.35	-0.32	7.05e-10	Hemoglobin concentration;
LIHC	cis	rs2010672	0.500	rs4261511	chr15:91151276	C/G	cg26821196	chr15:91095069	CRTC3	0.36	6.49	0.33	3.02e-10	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LIHC	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	9.45	0.46	5.39e-19	Schizophrenia;
LIHC	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.54	8.41	0.41	1.09e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.42	6.55	0.33	2.16e-10	Prostate cancer;
LIHC	cis	rs7712401	0.791	rs3822367	chr5:122146272	A/G	cg18764291	chr5:122110994	SNX2	-0.36	-6.2	-0.32	1.66e-9	Mean platelet volume;
LIHC	cis	rs3809566	0.710	rs4075583	chr15:63340227	C/T	cg12160578	chr15:63334699	TPM1	-0.44	-6.36	-0.33	6.45e-10	Platelet count;
LIHC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.66	-6.29	-0.32	9.9e-10	Breast cancer;
LIHC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.63	-8.94	-0.44	2.56e-17	Blood metabolite levels;
LIHC	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg09904177	chr6:26538194	HMGN4	-0.37	-5.83	-0.3	1.31e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10426930	0.816	rs8101347	chr19:5044620	C/T	cg18473234	chr19:5097819	KDM4B	0.54	6.79	0.34	4.86e-11	Monocyte percentage of white cells;
LIHC	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.69	10.58	0.5	8e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4919087	0.715	rs13439	chr10:99006083	C/T	cg25902810	chr10:99078978	FRAT1	-0.5	-5.72	-0.3	2.35e-8	Monocyte count;
LIHC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.64	0.42	2.24e-16	Motion sickness;
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.87	0.8	1.07e-78	Prudent dietary pattern;
LIHC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.58	-9.8	-0.47	3.94e-20	Colorectal cancer;
LIHC	cis	rs12286929	0.639	rs4938181	chr11:115041163	A/G	cg04055981	chr11:115044050	NA	0.41	6.71	0.34	7.87e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25220896	chr1:11004296	NA	0.42	6.98	0.35	1.53e-11	Cognitive function;
LIHC	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02829992	chr2:10710499	NA	0.39	6.01	0.31	4.68e-9	Prostate cancer;
LIHC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.54	-9.84	-0.47	2.7e-20	Glomerular filtration rate (creatinine);
LIHC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg07706471	chr12:123319906	HIP1R	-0.56	-7.0	-0.35	1.39e-11	Schizophrenia;
LIHC	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.45	-5.97	-0.31	6.06e-9	Psoriasis;
LIHC	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Osteoarthritis;
LIHC	cis	rs1144333	0.655	rs76532097	chr1:76320759	G/C	cg22875332	chr1:76189707	ACADM	0.44	6.83	0.35	3.94e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-8.15	-0.4	7.18e-15	Ulcerative colitis;
LIHC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-7.48	-0.37	6.39e-13	Cognitive function;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.32	0.32	8.12e-10	Prudent dietary pattern;
LIHC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.38	0.33	5.92e-10	Lung cancer in ever smokers;
LIHC	cis	rs34779708	0.766	rs7913451	chr10:35551525	T/C	cg03585969	chr10:35415529	CREM	0.76	10.71	0.5	2.89e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg02290350	chr8:58132656	NA	0.32	7.17	0.36	4.56e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg00990874	chr7:1149470	C7orf50	-0.63	-9.15	-0.44	5.26e-18	Bronchopulmonary dysplasia;
LIHC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.07	25.0	0.8	3.33e-79	IgG glycosylation;
LIHC	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg10756647	chr7:56101905	PSPH	1.02	12.11	0.55	2.53e-28	Diabetic kidney disease;
LIHC	cis	rs67981189	0.613	rs221892	chr14:71611606	C/A	cg15816911	chr14:71606274	NA	-0.42	-6.73	-0.34	7.34e-11	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.83	0.35	3.82e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.75	12.72	0.57	1.25e-30	Aortic root size;
LIHC	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.65	12.25	0.55	7.42e-29	Itch intensity from mosquito bite;
LIHC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	6.34	0.32	7.37e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.45	-5.95	-0.31	6.58e-9	Type 1 diabetes;
LIHC	cis	rs922107	0.713	rs12129433	chr1:90059575	G/T	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.74	-0.39	1.11e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.76	12.98	0.57	1.28e-31	Aortic root size;
LIHC	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg05714579	chr10:131428358	MGMT	0.48	7.96	0.4	2.53e-14	Response to temozolomide;
LIHC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.32	-5.87	-0.3	1.05e-8	Aortic root size;
LIHC	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04004882	chr2:215674386	BARD1	0.56	7.65	0.38	2.13e-13	Neuroblastoma;
LIHC	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.44	-6.17	-0.32	1.98e-9	Mean corpuscular volume;
LIHC	trans	rs983392	0.805	rs2123314	chr11:59966295	C/T	cg17275991	chr19:58003312	ZNF419	-0.47	-6.15	-0.32	2.14e-9	Alzheimer's disease (late onset);
LIHC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg16576597	chr16:28551801	NUPR1	0.37	6.1	0.31	2.86e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.86	-0.3	1.07e-8	Systolic blood pressure;
LIHC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.47	-7.66	-0.38	1.96e-13	Cognitive function;
LIHC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.61	8.46	0.42	7.99e-16	Platelet count;
LIHC	cis	rs832187	0.629	rs59971314	chr3:63914618	G/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-7.16	-0.36	5.1e-12	Schizophrenia;
LIHC	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg16275483	chr1:110013120	SYPL2	-0.47	-5.83	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.51	9.06	0.44	1.04e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.64	11.39	0.52	1.09e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.6	8.56	0.42	3.76e-16	Emphysema distribution in smoking;
LIHC	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.35	-8.08	-0.4	1.1e-14	Congenital heart disease (maternal effect);
LIHC	cis	rs10508774	0.759	rs12414205	chr10:32740040	A/G	cg01819863	chr10:32635814	EPC1	0.61	5.81	0.3	1.45e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	cg04338863	chr8:33670619	NA	0.31	5.8	0.3	1.53e-8	Body mass index;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.83	0.57	4.79e-31	Prudent dietary pattern;
LIHC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg15103426	chr22:29168792	CCDC117	0.67	11.21	0.52	4.86e-25	Lymphocyte counts;
LIHC	cis	rs1712517	0.904	rs7905968	chr10:105135319	C/T	cg05636881	chr10:105038444	INA	0.45	6.94	0.35	2.01e-11	Migraine;
LIHC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-8.17	-0.4	5.89e-15	Parkinson's disease;
LIHC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.02	0.51	2.25e-24	Alzheimer's disease;
LIHC	cis	rs988712	0.705	rs11030104	chr11:27684517	C/T	cg18117895	chr11:27722066	BDNF	-0.54	-7.5	-0.38	5.57e-13	Obesity;
LIHC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.37	-6.52	-0.33	2.5e-10	Schizophrenia;
LIHC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.29	7.18	0.36	4.26e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs860295	1.000	rs6427286	chr1:155723297	T/C	cg02153340	chr1:155202674	NA	-0.32	-5.91	-0.3	8.29e-9	Body mass index;
LIHC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.79	13.45	0.59	2.14e-33	Aortic root size;
LIHC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.51	7.93	0.39	3.2e-14	Pulse pressure;
LIHC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.49	-5.91	-0.3	8.33e-9	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.84	11.29	0.52	2.53e-25	Blood metabolite levels;
LIHC	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.39	5.82	0.3	1.37e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg18081818	chr7:23246105	NA	0.42	6.27	0.32	1.1e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.13	13.08	0.58	5.61e-32	Vitiligo;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.45	8.32	0.41	2.12e-15	Prudent dietary pattern;
LIHC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg25894440	chr7:65020034	NA	-0.55	-6.31	-0.32	8.7e-10	Diabetic kidney disease;
LIHC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.24	0.45	2.62e-18	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.27	-0.32	1.11e-9	Bipolar disorder;
LIHC	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.57	7.83	0.39	6.29e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.42	7.01	0.35	1.25e-11	Platelet distribution width;
LIHC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.59	-6.86	-0.35	3.28e-11	Menarche (age at onset);
LIHC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.86	0.43	4.4e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg18944383	chr4:111397179	ENPEP	0.25	6.12	0.31	2.5e-9	Height;
LIHC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	7.92	0.39	3.26e-14	Mean platelet volume;
LIHC	cis	rs61712019	0.837	rs12329048	chr2:77706281	C/G	cg11252801	chr2:77748917	LRRTM4	0.54	7.41	0.37	1.03e-12	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.4	0.33	5.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs13325613	0.915	rs35613615	chr3:46265243	T/C	cg26337592	chr1:153642686	ILF2	0.68	6.2	0.32	1.66e-9	Monocyte count;
LIHC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.56	6.37	0.33	6.04e-10	Alzheimer's disease;
LIHC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.06	0.31	3.6e-9	Menopause (age at onset);
LIHC	cis	rs244293	0.831	rs12453699	chr17:53171846	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.45	0.37	7.54e-13	Menarche (age at onset);
LIHC	trans	rs60752752	0.852	rs73018470	chr1:153369532	G/A	cg14901121	chr8:98817630	LAPTM4B	-0.43	-7.17	-0.36	4.6e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.05	0.31	3.91e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.62e-13	Alzheimer's disease;
LIHC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg03037974	chr15:76606532	NA	0.8	16.47	0.67	2.75e-45	Blood metabolite levels;
LIHC	cis	rs611744	0.967	rs677842	chr8:109212468	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.95	11.15	0.52	7.63e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.86	12.89	0.57	2.82e-31	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.33	-5.97	-0.31	5.93e-9	Lewy body disease;
LIHC	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg26695010	chr11:65641043	EFEMP2	0.44	6.17	0.32	1.91e-9	Eosinophil percentage of white cells;
LIHC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.79	0.3	1.58e-8	Bladder cancer;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.72	12.75	0.57	1.04e-30	Prudent dietary pattern;
LIHC	trans	rs12752401	0.717	rs34542611	chr1:103028047	C/T	cg03332897	chr19:740442	PALM	0.46	6.04	0.31	3.94e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.72	-0.43	1.26e-16	Atrioventricular conduction;
LIHC	cis	rs6586163	0.934	rs7897395	chr10:90754607	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-8.36	-0.41	1.64e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21448741	chr8:58168803	NA	0.35	6.52	0.33	2.58e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg03342759	chr3:160939853	NMD3	0.57	7.49	0.38	5.91e-13	Morning vs. evening chronotype;
LIHC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.42	0.59	2.73e-33	Colorectal cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24264674	chr11:8285509	LMO1	0.4	6.25	0.32	1.25e-9	Calcium levels;
LIHC	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-5.97	-0.31	5.79e-9	Bladder cancer;
LIHC	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg00792783	chr2:198669748	PLCL1	0.41	5.93	0.31	7.58e-9	Dermatomyositis;
LIHC	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg26220594	chr1:19110978	NA	-0.36	-6.15	-0.32	2.18e-9	Drug-induced liver injury (nitrofurantoin);
LIHC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.35e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.64	10.02	0.48	6.75e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.69	-9.49	-0.46	3.98e-19	Corneal structure;
LIHC	cis	rs6432852	0.516	rs2304002	chr2:166714095	G/A	cg15343463	chr2:166634454	GALNT3	0.38	6.09	0.31	2.98e-9	Diabetic kidney disease;
LIHC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg14222432	chr12:29376421	FAR2	0.36	6.96	0.35	1.7e-11	QT interval;
LIHC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-9.11	-0.44	7.02e-18	Colorectal cancer;
LIHC	trans	rs72960926	0.744	rs3898077	chr6:74959122	G/A	cg07247405	chr1:2484626	LOC115110	0.54	6.46	0.33	3.61e-10	Metabolite levels (MHPG);
LIHC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg12064134	chr16:90016061	DEF8	-0.43	-5.82	-0.3	1.34e-8	Skin colour saturation;
LIHC	cis	rs1564271	0.704	rs1780191	chr10:26994412	T/C	cg13837822	chr10:26931731	LOC731789	0.35	6.27	0.32	1.09e-9	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.72	11.99	0.54	6.73e-28	Mean platelet volume;
LIHC	cis	rs425535	0.619	rs10033521	chr4:74829332	C/A	cg02530824	chr4:74847766	PF4	-0.37	-5.95	-0.31	6.57e-9	Blood protein levels;
LIHC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.34	-0.59	5.58e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.65	-10.18	-0.48	1.88e-21	Corneal astigmatism;
LIHC	cis	rs10916814	0.632	rs10916817	chr1:20897294	C/T	cg24502330	chr1:20914028	CDA	-0.31	-6.76	-0.34	6.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.57	-9.63	-0.46	1.37e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22857025	chr5:266934	NA	-1.41	-14.94	-0.63	3.26e-39	Breast cancer;
LIHC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.96	0.31	6.39e-9	Heart rate;
LIHC	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.44	-8.7	-0.43	1.39e-16	Type 1 diabetes;
LIHC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-0.96	-21.95	-0.76	2.89e-67	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg16586182	chr3:47516702	SCAP	-0.58	-11.26	-0.52	3.21e-25	Colorectal cancer;
LIHC	trans	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg08566640	chr11:64091735	NA	-0.69	-6.54	-0.33	2.2e-10	Androgen levels;
LIHC	cis	rs17428076	0.874	rs17581347	chr2:172682601	T/C	cg13550731	chr2:172543902	DYNC1I2	0.38	6.21	0.32	1.55e-9	Myopia;
LIHC	cis	rs1034435	1.000	rs6007867	chr22:48889170	T/G	cg05992904	chr22:48892994	FAM19A5	-0.46	-9.09	-0.44	8.32e-18	Late-onset Alzheimer's disease;
LIHC	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.87	16.31	0.66	1.24e-44	Body mass index;
LIHC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	0.85	7.04	0.36	1.09e-11	Cognitive function;
LIHC	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.62	11.38	0.52	1.14e-25	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.42	0.41	1.06e-15	Motion sickness;
LIHC	cis	rs2019960	0.759	rs2720697	chr8:129173118	C/G	cg15331705	chr8:129180010	NA	-0.36	-6.63	-0.34	1.34e-10	Hodgkin's lymphoma;Multiple sclerosis;
LIHC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg00149659	chr3:10157352	C3orf10	0.69	7.06	0.36	9.46e-12	Alzheimer's disease;
LIHC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg19302996	chr17:73780495	UNK	-0.51	-6.11	-0.31	2.64e-9	Psoriasis;
LIHC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg02931644	chr1:25747376	RHCE	0.35	7.7	0.38	1.46e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs12744310	0.887	rs12724690	chr1:41800257	T/C	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.53	-7.83	-0.39	6.13e-14	Height;
LIHC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg04166393	chr7:2884313	GNA12	0.45	6.03	0.31	4.29e-9	Height;
LIHC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.38	0.37	1.22e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.65	-6.81	-0.35	4.28e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.16	-0.4	6.4e-15	Glycated hemoglobin levels;
LIHC	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.4	-7.35	-0.37	1.45e-12	Hepatocellular carcinoma;
LIHC	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.81	0.57	5.84e-31	Colorectal cancer;
LIHC	cis	rs61677309	0.638	rs4245180	chr11:118144512	G/A	cg06090739	chr11:118230722	UBE4A	0.32	6.03	0.31	4.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg18016565	chr1:150552671	MCL1	0.39	6.11	0.31	2.78e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg03013999	chr17:37608204	MED1	-0.35	-5.98	-0.31	5.66e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg14092571	chr14:90743983	NA	0.44	6.83	0.35	3.91e-11	Mortality in heart failure;
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg00656387	chr3:40428638	ENTPD3	0.49	8.34	0.41	1.84e-15	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.4	6.39	0.33	5.4e-10	Cognitive function;
LIHC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.79	-0.34	5.05e-11	IgG glycosylation;
LIHC	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.55	-7.73	-0.39	1.19e-13	Blood pressure (smoking interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12594348	chr12:51477468	CSRNP2	0.47	6.34	0.32	7.42e-10	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.39	6.06	0.31	3.53e-9	Lung cancer;
LIHC	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg22138327	chr13:27999177	GTF3A	0.76	6.24	0.32	1.26e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	9.99	0.48	8.36e-21	Platelet count;
LIHC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.58	0.34	1.78e-10	Bipolar disorder;
LIHC	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg25011176	chr20:3776985	CDC25B	-0.48	-6.67	-0.34	1.01e-10	Bipolar disorder;
LIHC	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.55	-0.33	2.1e-10	Body mass index;
LIHC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.87	-17.73	-0.69	2.38e-50	Height;
LIHC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg01200585	chr1:228362443	C1orf69	0.49	6.29	0.32	9.72e-10	Diastolic blood pressure;
LIHC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.91	0.39	3.69e-14	Obesity-related traits;
LIHC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.98	-0.31	5.65e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs252716	1	rs252716	chr5:110425063	G/C	cg04022379	chr5:110408740	TSLP	-0.48	-7.64	-0.38	2.19e-13	Eosinophilic esophagitis;
LIHC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.24	0.58	1.38e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.49	-0.33	2.96e-10	Menopause (age at onset);
LIHC	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.38	-7.46	-0.37	7.27e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.68	9.48	0.46	4.27e-19	Selective IgA deficiency;
LIHC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.46	6.75	0.34	6.33e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.2	-0.32	1.66e-9	Alzheimer's disease (late onset);
LIHC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg19318889	chr4:1322082	MAEA	-0.47	-7.79	-0.39	8.06e-14	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9473924	0.580	rs60100577	chr6:50816134	C/T	cg14470998	chr6:50812995	TFAP2B	0.93	10.62	0.5	6.08e-23	Body mass index;
LIHC	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.44	6.72	0.34	7.73e-11	Neutrophil percentage of white cells;
LIHC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	10.47	0.49	1.93e-22	Hemoglobin concentration;
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg04352962	chr1:209979756	IRF6	0.38	5.78	0.3	1.71e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs243505	0.762	rs3779036	chr7:148488507	C/T	cg09806900	chr7:148480153	CUL1	0.45	6.7	0.34	8.77e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.09	0.36	7.83e-12	IgG glycosylation;
LIHC	cis	rs911119	0.955	rs1555355	chr20:23594580	T/C	cg16589663	chr20:23618590	CST3	0.72	7.54	0.38	4.32e-13	Chronic kidney disease;
LIHC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.64	-9.15	-0.44	5.31e-18	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07145255	chr5:59995354	DEPDC1B	0.47	6.95	0.35	1.82e-11	Pancreatic cancer;
LIHC	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.63	9.58	0.46	2.14e-19	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.85	12.84	0.57	4.67e-31	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.2	-0.32	1.6e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.47	7.17	0.36	4.66e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.74	-0.3	2.07e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19623624	chr10:135278901	LOC619207	-0.45	-7.11	-0.36	6.77e-12	Systemic lupus erythematosus;
LIHC	trans	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.11	-0.36	6.84e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.31	0.37	1.95e-12	Vitiligo;
LIHC	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.89	-0.3	9.45e-9	Blood protein levels;
LIHC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.29	-6.62	-0.34	1.42e-10	Migraine;
LIHC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.81	15.47	0.64	2.8e-41	Blood protein levels;
LIHC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.66	13.67	0.59	3.1e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.83	-0.39	6.39e-14	Pediatric bone mineral density (spine);
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg21850448	chr4:88023169	AFF1	0.28	6.04	0.31	3.94e-9	Oropharynx cancer;
LIHC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg13753209	chr17:57696993	CLTC	-0.59	-8.85	-0.43	4.64e-17	Hemoglobin concentration;
LIHC	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.82	-9.66	-0.46	1.15e-19	Alzheimer's disease (late onset);
LIHC	trans	rs3783890	1.000	rs1503960	chr14:93778741	T/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.26	0.32	1.14e-9	Body mass index;
LIHC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.75	-0.39	1.09e-13	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg24955955	chr5:415729	AHRR	0.48	9.33	0.45	1.41e-18	Fat distribution (HIV);
LIHC	trans	rs10411161	0.810	rs17778711	chr19:52385300	A/G	cg22319618	chr22:45562946	NUP50	-0.61	-7.41	-0.37	9.93e-13	Breast cancer;
LIHC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-7.15	-0.36	5.15e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.37	0.77	6.21e-69	Chronic sinus infection;
LIHC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.38	-5.78	-0.3	1.71e-8	P wave terminal force;
LIHC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg20417195	chr1:21767127	NBPF3	0.39	6.03	0.31	4.22e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7700895	0.729	rs3777182	chr5:95263752	T/A	cg10483112	chr5:95245456	ELL2	-0.38	-6.63	-0.34	1.33e-10	IgG glycosylation;
LIHC	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02985541	chr2:219472218	PLCD4	-0.38	-6.43	-0.33	4.32e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.11	0.31	2.7e-9	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10372485	chr13:111294754	CARS2	-0.41	-6.31	-0.32	8.8e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs939574	0.722	rs55951006	chr2:220132151	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.93	6.28	0.32	1e-9	Platelet distribution width;
LIHC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.33	-0.32	7.5e-10	Obesity-related traits;
LIHC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.15	-0.32	2.22e-9	Total body bone mineral density;
LIHC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg11212589	chr17:38028394	ZPBP2	-0.31	-6.13	-0.31	2.44e-9	Self-reported allergy;
LIHC	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	10.0	0.48	7.88e-21	Hypertriglyceridemia;
LIHC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.35	-0.45	1.22e-18	Hemoglobin concentration;
LIHC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.45	6.18	0.32	1.87e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg14067834	chr17:29058358	SUZ12P	0.69	7.14	0.36	5.51e-12	Body mass index;
LIHC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	21.1	0.75	6.92e-64	Chronic sinus infection;
LIHC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.55	0.33	2.11e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.41	12.37	0.56	2.77e-29	Uric acid levels;
LIHC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg00934597	chr7:893267	UNC84A	0.48	5.79	0.3	1.57e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.5	-7.89	-0.39	4.18e-14	Educational attainment;
LIHC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.61	-8.99	-0.44	1.73e-17	Recombination rate (females);
LIHC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.57	8.12	0.4	8.68e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.73	11.46	0.53	5.94e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06656553	chr16:89960601	TCF25	-0.44	-5.94	-0.31	6.94e-9	Skin colour saturation;
LIHC	cis	rs4788570	0.667	rs9929840	chr16:71800942	C/T	cg06353428	chr16:71660113	MARVELD3	-1.28	-12.62	-0.56	2.95e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.94	-12.25	-0.55	7.33e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.66	9.92	0.47	1.53e-20	Menarche (age at onset);
LIHC	cis	rs2607426	0.681	rs10420685	chr19:41235120	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.52	-6.2	-0.32	1.67e-9	Blood protein levels;
LIHC	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.57	8.36	0.41	1.6e-15	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.49	7.04	0.36	1.07e-11	High light scatter reticulocyte count;
LIHC	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.62	-12.58	-0.56	4.45e-30	Plateletcrit;Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02056921	chr1:901892	PLEKHN1	0.41	6.21	0.32	1.56e-9	Pancreatic cancer;
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.61	7.19	0.36	4.19e-12	Alzheimer's disease;
LIHC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	cis	rs10792665	0.724	rs7940718	chr11:82696885	C/G	cg24227371	chr11:82718527	RAB30	-0.38	-9.44	-0.45	5.95e-19	Obesity-related traits;
LIHC	cis	rs10861342	1.000	rs7136344	chr12:105528268	A/G	cg23923672	chr12:105501055	KIAA1033	0.68	8.46	0.42	7.85e-16	IgG glycosylation;
LIHC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.58	-8.62	-0.42	2.57e-16	Heart rate;
LIHC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.38	-5.81	-0.3	1.43e-8	Height;
LIHC	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-15.0	-0.63	1.94e-39	Body mass index;
LIHC	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg22705602	chr4:152727874	NA	-0.29	-6.05	-0.31	3.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.54	-11.02	-0.51	2.3e-24	Tonsillectomy;
LIHC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.76	11.04	0.51	1.85e-24	Menarche (age at onset);
LIHC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.5	7.3	0.37	2.01e-12	Obesity-related traits;
LIHC	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.85	12.01	0.54	5.59e-28	Post bronchodilator FEV1;
LIHC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-5.78	-0.3	1.72e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.57	0.53	2.35e-26	Motion sickness;
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg06497051	chr1:156261200	TMEM79	0.38	6.05	0.31	3.83e-9	Tonsillectomy;
LIHC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.6	-0.34	1.58e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-24.08	-0.79	1.29e-75	Myeloid white cell count;
LIHC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg12798992	chr6:167411361	FGFR1OP	0.48	7.32	0.37	1.77e-12	Crohn's disease;
LIHC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.53	-6.45	-0.33	3.93e-10	Alzheimer's disease;
LIHC	cis	rs6691722	0.503	rs6667695	chr1:24707669	G/A	cg18323236	chr1:24743029	NIPAL3	0.41	7.41	0.37	9.79e-13	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13047869	chr3:10149882	C3orf24	0.41	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02034447	chr16:89574710	SPG7	0.49	7.37	0.37	1.29e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs3736485	0.966	rs12372948	chr15:51894311	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-6.09	-0.31	2.95e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.71	10.55	0.5	1.01e-22	Subjective well-being;
LIHC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	12.68	0.57	1.81e-30	Mean platelet volume;
LIHC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.66	8.23	0.41	3.92e-15	Gut microbiome composition (summer);
LIHC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.5	6.23	0.32	1.38e-9	Menarche (age at onset);
LIHC	cis	rs3106136	0.678	rs1529339	chr4:95297283	T/A	cg11021082	chr4:95130006	SMARCAD1	0.36	6.14	0.32	2.27e-9	Capecitabine sensitivity;
LIHC	cis	rs507080	0.771	rs523715	chr11:118574188	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	6.02	0.31	4.44e-9	Serum metabolite levels;
LIHC	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg02297831	chr4:17616191	MED28	0.45	6.96	0.35	1.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.45	6.78	0.34	5.22e-11	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg22771759	chr13:24902376	NA	0.32	6.8	0.35	4.62e-11	Obesity-related traits;
LIHC	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.36	-7.29	-0.37	2.18e-12	Renal cell carcinoma;
LIHC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg20291162	chr17:40259547	DHX58	-0.4	-6.36	-0.33	6.38e-10	Fibrinogen levels;
LIHC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg20651018	chr11:3035856	CARS	-0.35	-5.99	-0.31	5.34e-9	Longevity;
LIHC	trans	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg07393940	chr7:158741817	NA	-0.58	-6.83	-0.35	3.81e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg17135325	chr3:160939158	NMD3	0.47	7.11	0.36	6.79e-12	Morning vs. evening chronotype;
LIHC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.62	10.8	0.5	1.4e-23	Colorectal cancer;
LIHC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.54	8.27	0.41	3.02e-15	Menarche (age at onset);
LIHC	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.89	0.43	3.58e-17	Corneal astigmatism;
LIHC	cis	rs4920343	0.710	rs638256	chr1:19091182	C/A	cg19637330	chr1:19110922	NA	0.35	6.42	0.33	4.45e-10	Knee osteoarthritis;
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.67	-0.34	1e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09587826	chr20:62204140	PRIC285	0.47	6.73	0.34	7.14e-11	Hepatitis;
LIHC	cis	rs7551222	0.614	rs4951385	chr1:204454165	C/T	cg20240347	chr1:204465584	NA	-0.32	-6.7	-0.34	8.57e-11	Schizophrenia;
LIHC	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.43	6.57	0.33	1.82e-10	Neutrophil percentage of white cells;
LIHC	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.48	-7.05	-0.36	1.02e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17776563	0.887	rs11638658	chr15:89124610	C/G	cg05013243	chr15:89149849	MIR1179	-0.4	-6.6	-0.34	1.6e-10	Thyroid hormone levels;
LIHC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.36	-5.74	-0.3	2.13e-8	Bipolar disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15248989	chr19:14682900	NDUFB7	0.52	7.02	0.35	1.17e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	9.86	0.47	2.3e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.68	0.53	9.06e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23359048	chr12:2921757	ITFG2	0.5	6.63	0.34	1.29e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-7.32	-0.37	1.84e-12	Monocyte percentage of white cells;
LIHC	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.64	-10.69	-0.5	3.32e-23	Pediatric autoimmune diseases;
LIHC	trans	rs1432089	0.773	rs1030614	chr4:171786339	C/T	cg02328223	chr3:127541927	MGLL	-0.42	-6.09	-0.31	3.07e-9	Endometriosis;
LIHC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.38	6.01	0.31	4.72e-9	Menopause (age at onset);
LIHC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg05110241	chr16:68378359	PRMT7	-0.6	-7.01	-0.35	1.32e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.63	9.38	0.45	9.53e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.34	-0.37	1.57e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	0.99	10.62	0.5	5.84e-23	Vitiligo;
LIHC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.56	0.42	3.89e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg05941027	chr17:61774174	LIMD2	0.32	6.74	0.34	6.7e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.33	-0.37	1.63e-12	Obesity (extreme);
LIHC	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	11.69	0.53	8.66e-27	Schizophrenia;
LIHC	cis	rs16837677	0.649	rs16837622	chr1:156695504	C/T	cg19377421	chr1:156697041	ISG20L2;C1orf66	-0.63	-7.46	-0.37	7e-13	Sjögren's syndrome;
LIHC	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.5	-0.38	5.71e-13	Mean platelet volume;
LIHC	cis	rs12980942	1.000	rs7245398	chr19:41810644	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.21	0.32	1.56e-9	Coronary artery disease;
LIHC	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-8.38	-0.41	1.39e-15	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.46	7.34	0.37	1.57e-12	Platelet count;
LIHC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.22	-0.45	3.13e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.64	0.34	1.24e-10	Sudden cardiac arrest;
LIHC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.22	-0.32	1.47e-9	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.88	0.43	3.76e-17	Motion sickness;
LIHC	cis	rs11761441	1.000	rs11761441	chr7:82377	G/A	cg12845006	chr7:82380	NA	0.32	6.07	0.31	3.34e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.55	-6.57	-0.33	1.88e-10	Opioid sensitivity;
LIHC	trans	rs2744203	1.000	rs72610890	chr6:104657337	A/T	cg27088726	chr16:83171155	CDH13	-0.45	-6.07	-0.31	3.35e-9	IgG glycosylation;
LIHC	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg00277334	chr10:82204260	NA	-0.55	-6.91	-0.35	2.43e-11	Post bronchodilator FEV1;
LIHC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.66	-9.61	-0.46	1.62e-19	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.97	0.35	1.68e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg00750074	chr16:89608354	SPG7	-0.52	-8.49	-0.42	6.33e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.25	-0.32	1.19e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6728642	0.561	rs58984980	chr2:97570759	T/A	cg26665480	chr2:98280029	ACTR1B	-0.57	-5.79	-0.3	1.57e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.82	-0.5	1.18e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.31	-0.37	1.88e-12	IgG glycosylation;
LIHC	cis	rs832187	0.629	rs7624403	chr3:63970077	G/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.45	-6.41	-0.33	4.74e-10	Schizophrenia;
LIHC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.93	0.31	7.24e-9	Educational attainment;
LIHC	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.89	-0.39	4.24e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	11.07	0.51	1.51e-24	Cognitive test performance;
LIHC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7106204	0.748	rs2403891	chr11:24213130	C/T	ch.11.24196551F	chr11:24239977	NA	0.76	10.16	0.48	2.29e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs8023580	1.000	rs4984511	chr15:96704443	C/T	cg01739960	chr15:96715164	NA	0.37	5.93	0.31	7.43e-9	Sex hormone-binding globulin levels;
LIHC	cis	rs990171	0.506	rs6543107	chr2:102750730	A/T	cg22835712	chr2:102737379	NA	0.57	8.76	0.43	9.21e-17	Lymphocyte counts;
LIHC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg08499158	chr17:42289980	UBTF	0.48	7.71	0.38	1.34e-13	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.92	-0.35	2.28e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	14.36	0.61	6.24e-37	Menopause (age at onset);
LIHC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	2.02e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.85	12.53	0.56	6.46e-30	Psoriasis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01216607	chr7:100860773	ZNHIT1;PLOD3	0.43	6.32	0.32	8.14e-10	Lung function (FEV1/FVC);
LIHC	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg01843034	chr6:37503916	NA	-0.4	-6.46	-0.33	3.57e-10	Cognitive performance;
LIHC	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg15105060	chr4:7024189	TBC1D14	-0.78	-6.26	-0.32	1.15e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.7	-10.28	-0.49	9.02e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.14e-11	Alzheimer's disease;
LIHC	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg16736954	chr20:23401023	NAPB	0.53	5.84	0.3	1.22e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.5	9.47	0.46	4.85e-19	Testicular germ cell tumor;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23521253	chr10:126653589	ZRANB1	-0.28	-6.4	-0.33	5.19e-10	Calcium levels;
LIHC	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.61	9.99	0.48	8.49e-21	Corneal astigmatism;
LIHC	cis	rs11018874	0.808	rs71471032	chr11:89888921	A/T	cg05041596	chr11:89867385	NAALAD2	0.42	6.73	0.34	7.15e-11	White blood cell types;
LIHC	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.67	-6.3	-0.32	9.17e-10	Bipolar disorder;
LIHC	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.78	-0.3	1.71e-8	Response to amphetamines;
LIHC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.28	-6.48	-0.33	3.15e-10	Menarche (age at onset);
LIHC	cis	rs7187994	0.848	rs60566983	chr16:84774799	A/G	cg07647771	chr16:84786436	USP10	-0.33	-6.27	-0.32	1.06e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.88	0.39	4.37e-14	Bladder cancer;
LIHC	cis	rs876084	0.505	rs9297614	chr8:121105444	C/T	cg06265175	chr8:121136014	COL14A1	0.49	7.93	0.39	3.09e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg08135965	chr6:41755394	TOMM6	0.43	5.75	0.3	2.01e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.62	7.33	0.37	1.64e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.38	7.14	0.36	5.58e-12	Total body bone mineral density;
LIHC	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	1.02	13.78	0.6	1.1e-34	Corneal structure;
LIHC	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg20283391	chr11:68216788	NA	-0.51	-6.08	-0.31	3.28e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.61	-5.95	-0.31	6.78e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg17859187	chr1:168147929	TIPRL	0.6	7.6	0.38	2.94e-13	Schizophrenia;
LIHC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.55	9.93	0.47	1.41e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg24642844	chr7:1081250	C7orf50	-0.74	-6.32	-0.32	8.23e-10	Longevity;Endometriosis;
LIHC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg21724239	chr8:58056113	NA	0.46	6.08	0.31	3.23e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg17712092	chr4:129076599	LARP1B	0.54	6.56	0.33	1.94e-10	Glomerular filtration rate (creatinine);Chronic kidney disease;
LIHC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.52	-7.85	-0.39	5.44e-14	Total body bone mineral density;
LIHC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.58	-11.42	-0.53	8.16e-26	Coronary artery disease;
LIHC	cis	rs2710642	0.583	rs7421841	chr2:62880765	G/A	cg17519650	chr2:63277830	OTX1	0.5	7.26	0.37	2.63e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg22705602	chr4:152727874	NA	-0.29	-6.29	-0.32	9.49e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.35	6.8	0.35	4.73e-11	HDL cholesterol levels;
LIHC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.81	0.39	6.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.03	-0.4	1.63e-14	Total cholesterol levels;
LIHC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.66	8.91	0.43	2.98e-17	Corneal structure;
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.54	5.9	0.3	8.94e-9	Alzheimer's disease;
LIHC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.33	-0.76	8.44e-65	Height;
LIHC	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.74	11.8	0.54	3.56e-27	Chronic lymphocytic leukemia;
LIHC	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	trans	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg07393940	chr7:158741817	NA	0.56	6.73	0.34	7.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-8.76	-0.43	8.91e-17	Neuroticism;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-12.07	-0.55	3.34e-28	Bipolar disorder and schizophrenia;
LIHC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.35	6.19	0.32	1.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	9.24	0.45	2.64e-18	Platelet count;
LIHC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg15691649	chr6:25882328	NA	-0.97	-12.43	-0.56	1.65e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs7961581	0.576	rs1798076	chr12:71589671	A/G	cg05756094	chr12:71608604	NA	-0.35	-5.85	-0.3	1.15e-8	Type 2 diabetes;
LIHC	cis	rs2274273	0.870	rs59629906	chr14:55781189	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.55	-0.33	2.17e-10	Protein biomarker;
LIHC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.22	0.45	3.2e-18	Platelet count;
LIHC	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg24130564	chr14:104152367	KLC1	-0.44	-7.04	-0.36	1.07e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg15691649	chr6:25882328	NA	-0.97	-12.64	-0.56	2.6e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg12219531	chr12:120966889	COQ5	0.49	8.16	0.4	6.53e-15	High light scatter reticulocyte count;
LIHC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg14393609	chr7:65229607	NA	0.37	5.78	0.3	1.71e-8	Aortic root size;
LIHC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	10.46	0.49	2.14e-22	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.95	0.35	1.83e-11	Height;
LIHC	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.39	-0.37	1.14e-12	Metabolite levels;
LIHC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	ch.11.42038R	chr11:967971	AP2A2	0.58	10.63	0.5	5.59e-23	Alzheimer's disease (late onset);
LIHC	cis	rs10768122	0.642	rs3847619	chr11:35360747	C/T	cg13971030	chr11:35366721	SLC1A2	-0.35	-5.76	-0.3	1.9e-8	Vitiligo;
LIHC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.67	9.11	0.44	7.27e-18	Sudden cardiac arrest;
LIHC	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.76	-8.34	-0.41	1.89e-15	Exhaled nitric oxide output;
LIHC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.1	0.31	2.87e-9	Renal cell carcinoma;
LIHC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg00529422	chr1:16285251	ZBTB17	-0.34	-6.43	-0.33	4.37e-10	Systolic blood pressure;
LIHC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg02297831	chr4:17616191	MED28	0.49	7.61	0.38	2.63e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.41	-0.49	3.04e-22	Platelet count;
LIHC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg08847533	chr14:75593920	NEK9	0.5	7.65	0.38	2.05e-13	IgG glycosylation;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg10932868	chr11:921992	NA	0.36	6.77	0.34	5.46e-11	Alzheimer's disease (late onset);
LIHC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.49	-7.34	-0.37	1.53e-12	Height;
LIHC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.8	-0.35	4.59e-11	Schizophrenia;
LIHC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.56	7.23	0.36	3.26e-12	Parkinson's disease;
LIHC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.4	-6.75	-0.34	6.24e-11	Monocyte count;
LIHC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.73	7.41	0.37	1.02e-12	Platelet count;
LIHC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.94	0.51	4.23e-24	Monocyte percentage of white cells;
LIHC	cis	rs17106184	1.000	rs77701130	chr1:51232628	G/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.69	11.5	0.53	4.32e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg17675199	chr6:35436792	RPL10A	-0.43	-8.59	-0.42	3.03e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7523273	0.526	rs3849274	chr1:208021557	T/A	cg22525895	chr1:207977042	MIR29B2	-0.61	-9.3	-0.45	1.7e-18	Schizophrenia;
LIHC	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.25	0.41	3.48e-15	Corneal astigmatism;
LIHC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.55	0.64	1.28e-41	Electrocardiographic conduction measures;
LIHC	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.92	-0.47	1.46e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg26441486	chr22:50317300	CRELD2	-0.35	-6.32	-0.32	7.96e-10	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04297576	chr16:85588660	NA	-0.48	-6.15	-0.32	2.15e-9	Systolic blood pressure;
LIHC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg19318889	chr4:1322082	MAEA	0.46	6.49	0.33	3.11e-10	Obesity-related traits;
LIHC	trans	rs3112255	0.967	rs1606552	chr2:101304053	T/G	cg06958034	chr1:23346203	KDM1A	-0.46	-6.06	-0.31	3.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6066825	0.532	rs6012506	chr20:47285637	A/G	cg18078177	chr20:47281410	PREX1	0.45	7.5	0.38	5.57e-13	Colorectal cancer;
LIHC	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg22771759	chr13:24902376	NA	0.31	6.36	0.33	6.62e-10	Obesity-related traits;
LIHC	cis	rs9625935	0.536	rs9608819	chr22:30260809	A/C	cg01021169	chr22:30184971	ASCC2	0.37	6.3	0.32	8.93e-10	Tonsillectomy;
LIHC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.92	-17.1	-0.68	8.54e-48	Aortic root size;
LIHC	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg18898632	chr2:242989856	NA	-0.47	-6.48	-0.33	3.26e-10	Obesity-related traits;
LIHC	trans	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17183009	chr3:120277827	NA	0.52	6.11	0.31	2.73e-9	Corneal astigmatism;
LIHC	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.51	-7.44	-0.37	8.48e-13	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs965469	0.762	rs6515783	chr20:3245006	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-6.24	-0.32	1.3e-9	IFN-related cytopenia;
LIHC	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	0.84	13.34	0.58	5.86e-33	Testicular germ cell tumor;
LIHC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.69	-10.15	-0.48	2.49e-21	Coronary artery disease;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg06267636	chr1:156308293	CCT3;C1orf182	-0.43	-6.36	-0.33	6.62e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.75	11.33	0.52	1.79e-25	Corneal astigmatism;
LIHC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.87	8.53	0.42	4.82e-16	Mean platelet volume;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.43	-6.14	-0.32	2.24e-9	Longevity;
LIHC	cis	rs151997	0.925	rs27570	chr5:50191974	G/A	cg06027927	chr5:50259733	NA	0.57	7.7	0.38	1.53e-13	Callous-unemotional behaviour;
LIHC	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.39	6.03	0.31	4.29e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.26e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.64	10.65	0.5	4.42e-23	Recombination rate (males);
LIHC	cis	rs6750047	0.719	rs336035	chr2:38261467	A/G	cg07380506	chr2:38303506	CYP1B1	-0.49	-5.94	-0.31	6.93e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg02640540	chr1:67518911	SLC35D1	0.41	6.42	0.33	4.48e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg07148914	chr20:33460835	GGT7	-0.5	-7.14	-0.36	5.64e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs798766	0.909	rs744658	chr4:1755074	C/T	cg21231739	chr4:1642635	FAM53A	-0.37	-6.0	-0.31	5.04e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs4700695	1.000	rs153389	chr5:65422729	C/T	cg21114390	chr5:65439923	SFRS12	-0.52	-7.08	-0.36	8.22e-12	Facial morphology (factor 19);
LIHC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg05555928	chr11:63887634	MACROD1	0.51	6.6	0.34	1.59e-10	Mean platelet volume;
LIHC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09068447	chr15:34502498	C15orf29	0.45	6.68	0.34	9.45e-11	Pancreatic cancer;
LIHC	cis	rs4700695	0.764	rs251278	chr5:65381826	G/A	cg21114390	chr5:65439923	SFRS12	-0.5	-6.89	-0.35	2.67e-11	Facial morphology (factor 19);
LIHC	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg18192155	chr21:44258298	NA	0.4	6.12	0.31	2.61e-9	Information processing speed;
LIHC	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg25783544	chr11:47291846	MADD	0.43	6.27	0.32	1.1e-9	HDL cholesterol;
LIHC	trans	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.48	-0.33	3.19e-10	Dental caries;
LIHC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.44	7.76	0.39	9.9e-14	Tuberculosis;
LIHC	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.74	0.39	1.1e-13	Corneal astigmatism;
LIHC	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.35	-8.13	-0.4	7.98e-15	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs13113518	0.729	rs13120134	chr4:56281320	A/G	cg15358633	chr12:38710606	ALG10B	0.43	6.05	0.31	3.76e-9	Height;
LIHC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg18016565	chr1:150552671	MCL1	0.49	9.28	0.45	1.95e-18	Melanoma;
LIHC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.84	-0.43	5.27e-17	Gut microbiome composition (summer);
LIHC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-10.16	-0.48	2.21e-21	Urate levels in overweight individuals;
LIHC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-1.11	-8.28	-0.41	2.82e-15	Body mass index;
LIHC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.2	-6.18	-0.32	1.82e-9	Motion sickness;
LIHC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.57	6.48	0.33	3.26e-10	Body mass index;
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-5.78	-0.3	1.69e-8	Menarche (age at onset);
LIHC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.41	1.35e-15	Morning vs. evening chronotype;
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.5	-8.54	-0.42	4.44e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.75	11.39	0.52	1.1e-25	Corneal astigmatism;
LIHC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.95	-0.39	2.74e-14	Body mass index;
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-7.63	-0.38	2.29e-13	Obesity-related traits;
LIHC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.66e-9	Mortality in heart failure;
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.68	10.21	0.48	1.55e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.91	18.75	0.71	1.96e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg16070018	chr6:26224392	HIST1H3E	0.65	7.79	0.39	7.91e-14	Gout;Renal underexcretion gout;
LIHC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.5	0.42	5.86e-16	Motion sickness;
LIHC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.43	-0.49	2.72e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.39	-5.91	-0.3	8.3e-9	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.75	-11.86	-0.54	2.13e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs988712	0.705	rs1829469	chr11:27730556	A/G	cg18117895	chr11:27722066	BDNF	0.51	7.07	0.36	8.55e-12	Obesity;
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.41	-0.41	1.13e-15	Calcium levels;
LIHC	cis	rs9896052	0.580	rs6501809	chr17:73467274	C/T	cg25649188	chr17:73499917	CASKIN2	0.5	7.43	0.37	8.98e-13	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.86	13.68	0.59	2.69e-34	Longevity;
LIHC	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.69	7.0	0.35	1.4e-11	Alzheimer's disease;
LIHC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.77	-0.39	9.21e-14	Glioblastoma;
LIHC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg18016565	chr1:150552671	MCL1	-0.56	-11.02	-0.51	2.32e-24	Tonsillectomy;
LIHC	cis	rs1866706	0.896	rs2083440	chr11:12865839	C/T	cg25843174	chr11:12811716	TEAD1	-0.3	-6.26	-0.32	1.12e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.78	12.16	0.55	1.58e-28	Acylcarnitine levels;
LIHC	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.35	0.41	1.78e-15	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg23682824	chr7:23144976	KLHL7	0.4	6.02	0.31	4.4e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.52	-7.45	-0.37	7.49e-13	Response to antineoplastic agents;
LIHC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.36	-0.33	6.64e-10	Longevity;Endometriosis;
LIHC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg06207120	chr15:45996521	NA	0.31	5.83	0.3	1.27e-8	Waist circumference;Weight;
LIHC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.34	-6.28	-0.32	1.02e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09970552	chr11:57520334	BTBD18	0.49	6.65	0.34	1.18e-10	Hepatitis;
LIHC	cis	rs2108622	0.727	rs55954696	chr19:15981805	A/G	cg13772218	chr19:15982569	NA	0.37	7.83	0.39	6.2e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.04e-24	Crohn's disease;
LIHC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.69	0.5	3.44e-23	Lymphocyte percentage of white cells;
LIHC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-1.01	-10.33	-0.49	5.92e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.12	13.03	0.58	8.92e-32	Vitiligo;
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23978390	chr7:1156363	C7orf50	0.66	10.34	0.49	5.55e-22	Longevity;Endometriosis;
LIHC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.4	-6.25	-0.32	1.19e-9	Melanoma;
LIHC	cis	rs1075232	0.826	rs60333545	chr15:31807319	G/C	cg01030201	chr15:31746330	NA	-0.85	-6.66	-0.34	1.08e-10	Survival in colorectal cancer (non-distant metastatic);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.14.1056569F	chr14:73577815	RBM25	-0.32	-6.53	-0.33	2.35e-10	Cognitive function;
LIHC	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.76	0.34	5.98e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs74181299	0.855	rs2723066	chr2:65279321	T/G	cg05010058	chr2:65284262	CEP68	0.41	6.86	0.35	3.18e-11	Pulse pressure;
LIHC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg05941027	chr17:61774174	LIMD2	0.37	7.78	0.39	8.47e-14	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg06784218	chr1:46089804	CCDC17	-0.37	-6.53	-0.33	2.39e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.41	5.97	0.31	6e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.35	0.41	1.67e-15	Lung cancer in ever smokers;
LIHC	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg20607798	chr8:58055168	NA	0.46	6.3	0.32	9.07e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.15	-0.36	5.15e-12	Body mass index;
LIHC	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.57	-7.51	-0.38	5.04e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.45	-6.98	-0.35	1.53e-11	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs16912059	0.590	rs7128158	chr11:24273521	A/T	ch.11.24196551F	chr11:24239977	NA	-0.73	-6.05	-0.31	3.87e-9	Thrombin-antithrombin complex levels in ischemic stroke;
LIHC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.21	-0.36	3.58e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07308232	chr7:1071921	C7orf50	-0.46	-7.25	-0.36	2.82e-12	Longevity;Endometriosis;
LIHC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.49	7.61	0.38	2.65e-13	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.06	0.55	3.69e-28	Prudent dietary pattern;
LIHC	cis	rs1190552	0.747	rs9324048	chr14:102881323	T/G	cg10241871	chr14:102965420	TECPR2	0.4	6.05	0.31	3.72e-9	Blood protein levels;
LIHC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.03	0.31	4.17e-9	Tonsillectomy;
LIHC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-10.51	-0.49	1.47e-22	Breast cancer;
LIHC	cis	rs2279817	0.863	rs6672069	chr1:18013835	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-8.38	-0.41	1.42e-15	Neuroticism;
LIHC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	9.55	0.46	2.58e-19	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25954914	chr2:54785183	SPTBN1	-0.42	-6.15	-0.32	2.16e-9	Pancreatic cancer;
LIHC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.52	9.46	0.46	5.04e-19	Systemic lupus erythematosus;
LIHC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.29	-0.32	9.98e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.4	7.53	0.38	4.49e-13	Schizophrenia;
LIHC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.99	-0.31	5.26e-9	Heart rate;
LIHC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.6	-12.21	-0.55	1.02e-28	Coronary artery disease;
LIHC	cis	rs965469	0.779	rs2236109	chr20:3286439	C/A	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.55	-7.93	-0.39	3.23e-14	Coronary artery disease;
LIHC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	10.99	0.51	3.01e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg07796016	chr1:152779584	LCE1C	-0.46	-7.13	-0.36	6.08e-12	Vitamin D levels;
LIHC	cis	rs2637030	0.586	rs1030228	chr5:52842569	A/G	cg06476337	chr5:52856530	NDUFS4	0.38	6.22	0.32	1.43e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.2	-0.32	1.61e-9	Mean corpuscular volume;
LIHC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	10.3	0.49	7.82e-22	Menopause (age at onset);
LIHC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.4	7.56	0.38	3.67e-13	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.56	0.62	1.09e-37	Prudent dietary pattern;
LIHC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.75	11.95	0.54	1e-27	Obesity-related traits;
LIHC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.74	16.13	0.66	6.35e-44	Urate levels in lean individuals;
LIHC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.45	6.06	0.31	3.66e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	10.91	0.51	5.47e-24	Monocyte percentage of white cells;
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg14709524	chr16:89940631	TCF25	0.51	6.44	0.33	4.1e-10	Skin colour saturation;
LIHC	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.33	6.74	0.34	6.62e-11	Multiple sclerosis;
LIHC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.8	-12.28	-0.55	5.67e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21659725	chr3:3221576	CRBN	0.72	11.09	0.51	1.24e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg08135965	chr6:41755394	TOMM6	-0.45	-6.01	-0.31	4.75e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.09	0.55	2.92e-28	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg11764359	chr7:65958608	NA	0.56	5.96	0.31	6.14e-9	Diabetic kidney disease;
LIHC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.75	-0.3	2.03e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.65	-5.79	-0.3	1.59e-8	Platelet count;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.68	11.48	0.53	4.92e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	1.01	19.44	0.72	3.05e-57	Breast cancer;
LIHC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.44	7.48	0.37	6.45e-13	Mean corpuscular volume;
LIHC	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg26139080	chr11:47293733	MADD	-0.5	-8.45	-0.42	8.46e-16	HDL cholesterol;
LIHC	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg00085434	chr11:14927489	NA	0.41	5.86	0.3	1.06e-8	Vitamin D levels;
LIHC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.09	-0.44	8.01e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs911119	1.000	rs6515375	chr20:23610841	G/A	cg16589663	chr20:23618590	CST3	0.74	7.5	0.38	5.58e-13	Chronic kidney disease;
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.62	9.02	0.44	1.42e-17	Menarche (age at onset);
LIHC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.67	-8.58	-0.42	3.37e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05788437	chr3:197476880	FYTTD1;KIAA0226	-0.52	-7.82	-0.39	6.46e-14	Cognitive function;
LIHC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.77	12.34	0.56	3.42e-29	Corneal astigmatism;
LIHC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.88	-16.98	-0.68	2.43e-47	Height;
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.49	-0.53	4.61e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.6	-9.18	-0.44	4.15e-18	Serum sulfate level;
LIHC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.24	-0.55	7.9e-29	Primary sclerosing cholangitis;
LIHC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg00204512	chr16:28754710	NA	-0.38	-6.65	-0.34	1.13e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg15744005	chr10:104629667	AS3MT	-0.35	-6.42	-0.33	4.59e-10	Arsenic metabolism;
LIHC	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.95	-0.31	6.49e-9	Bipolar disorder;
LIHC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg17385448	chr1:15911702	AGMAT	0.35	6.15	0.32	2.21e-9	Systolic blood pressure;
LIHC	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.67	-7.44	-0.37	7.95e-13	Exhaled nitric oxide output;
LIHC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.79	-0.34	4.92e-11	Gut microbiome composition (summer);
LIHC	cis	rs2997447	0.761	rs61776596	chr1:26454968	T/C	cg19633962	chr1:26362018	EXTL1	-0.65	-5.76	-0.3	1.87e-8	QRS complex (12-leadsum);
LIHC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.42	6.76	0.34	6.07e-11	Red blood cell count;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.71	13.06	0.58	6.6e-32	Prudent dietary pattern;
LIHC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.48	6.23	0.32	1.4e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1712517	0.740	rs11191663	chr10:105118462	C/T	cg05636881	chr10:105038444	INA	0.49	7.54	0.38	4.16e-13	Migraine;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg05185784	chr16:90016020	DEF8	0.44	6.15	0.32	2.22e-9	Skin colour saturation;
LIHC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg16011800	chr17:1958478	HIC1	-0.46	-6.54	-0.33	2.29e-10	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg03645007	chr3:50255295	SLC38A3	0.56	6.56	0.33	1.99e-10	Schizophrenia;
LIHC	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.21	-0.32	1.51e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.45	-7.86	-0.39	5.1e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs9948	1.000	rs13419073	chr2:97507554	G/C	cg01990225	chr2:97406019	LMAN2L	-0.59	-5.99	-0.31	5.19e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01813165	chr2:202646406	ALS2	0.5	7.25	0.36	2.75e-12	Pancreatic cancer;
LIHC	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.26	-6.45	-0.33	3.71e-10	Mean corpuscular volume;
LIHC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.63	7.65	0.38	2.09e-13	Iron status biomarkers;
LIHC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.53	8.66	0.42	1.91e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg08847533	chr14:75593920	NEK9	-0.39	-6.63	-0.34	1.29e-10	Caffeine consumption;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07283595	chr17:5372003	DHX33	0.51	7.11	0.36	6.76e-12	Lung function (FEV1/FVC);
LIHC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg00656387	chr3:40428638	ENTPD3	0.39	6.07	0.31	3.37e-9	Renal cell carcinoma;
LIHC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.76	12.99	0.57	1.2e-31	Aortic root size;
LIHC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg03945807	chr20:60948434	NA	-0.36	-6.47	-0.33	3.37e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2292096	0.789	rs36041093	chr1:200696648	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-6.03	-0.31	4.24e-9	Epilepsy;
LIHC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-15.49	-0.64	2.2e-41	Headache;
LIHC	cis	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg21507958	chr17:78818871	RPTOR	0.4	5.8	0.3	1.53e-8	Electroencephalogram traits;
LIHC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg12374095	chr12:54320830	NA	0.39	5.76	0.3	1.83e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.4	-0.56	1.98e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	8.24	0.41	3.81e-15	Coronary artery disease;
LIHC	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg20607798	chr8:58055168	NA	0.46	6.71	0.34	7.96e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg12160578	chr15:63334699	TPM1	0.63	8.97	0.44	1.97e-17	Platelet count;
LIHC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.64	-10.05	-0.48	5.35e-21	Lung cancer;
LIHC	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.56	6.69	0.34	8.98e-11	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.39	7.8	0.39	7.39e-14	Renal cell carcinoma;
LIHC	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.69	11.3	0.52	2.25e-25	Intelligence (multi-trait analysis);
LIHC	trans	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg17074339	chr11:11642133	GALNTL4	-0.42	-6.16	-0.32	2.08e-9	Telomere length;
LIHC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.64	9.08	0.44	8.77e-18	Motion sickness;
LIHC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.78	11.0	0.51	2.6e-24	Blood metabolite levels;
LIHC	cis	rs882732	1.000	rs5510	chr14:95033356	A/G	cg14866387	chr14:95027382	SERPINA4	0.46	6.96	0.35	1.72e-11	Blood protein levels;
LIHC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.57	8.53	0.42	4.94e-16	Total body bone mineral density;
LIHC	cis	rs116248771	0.739	rs12633687	chr3:158338168	G/T	cg16708174	chr3:158430962	RARRES1	0.47	6.18	0.32	1.8e-9	diarrhoeal disease at age 2;
LIHC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.64	0.53	1.27e-26	Cognitive test performance;
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	5.99	0.31	5.24e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.42	-0.33	4.47e-10	Body mass index;
LIHC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.49	6.34	0.32	7.47e-10	Breast cancer;
LIHC	cis	rs74233809	1.000	rs3740390	chr10:104638480	C/T	cg03493300	chr10:104813866	CNNM2	0.46	6.08	0.31	3.27e-9	Birth weight;
LIHC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.56	7.38	0.37	1.21e-12	Body mass index;
LIHC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg06046430	chr4:77819534	ANKRD56	0.48	6.41	0.33	4.97e-10	Emphysema distribution in smoking;
LIHC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.24	-0.32	1.26e-9	Metabolite levels;
LIHC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.75	-0.34	6.37e-11	Psoriasis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03952484	chr1:149899818	SF3B4	0.36	6.05	0.31	3.7e-9	Cognitive function;
LIHC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.45	0.56	1.34e-29	Cognitive test performance;
LIHC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.89	0.35	2.75e-11	Axial length;
LIHC	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07080220	chr10:102295463	HIF1AN	-0.44	-6.26	-0.32	1.18e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg10127483	chr1:110009974	SYPL2	0.48	6.06	0.31	3.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.63	0.38	2.41e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.67	6.4	0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.48	7.34	0.37	1.53e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	8.29	0.41	2.56e-15	Chronic sinus infection;
LIHC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.81	-18.3	-0.7	1.2e-52	Urate levels in lean individuals;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.14	0.55	1.86e-28	Prudent dietary pattern;
LIHC	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg00204512	chr16:28754710	NA	-0.38	-6.29	-0.32	9.96e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	7.66	0.38	1.92e-13	Mean platelet volume;
LIHC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.85	-0.3	1.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.55	-8.24	-0.41	3.6e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.78	9.03	0.44	1.31e-17	Exhaled nitric oxide output;
LIHC	cis	rs7116495	0.881	rs6592451	chr11:71674937	G/A	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02290350	chr8:58132656	NA	0.45	8.41	0.41	1.1e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.43	5.95	0.31	6.46e-9	QT interval;
LIHC	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.69	10.54	0.5	1.14e-22	Height;
LIHC	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.45	-6.45	-0.33	3.8e-10	Blood protein levels;
LIHC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-7.85	-0.39	5.51e-14	Cognitive function;
LIHC	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	7.02	0.35	1.21e-11	Response to bleomycin (chromatid breaks);
LIHC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.71	-6.78	-0.34	5.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.44	0.37	8.16e-13	Endometrial cancer;
LIHC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.54	-8.27	-0.41	3.1e-15	Inflammatory bowel disease;
LIHC	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.23	-5.84	-0.3	1.2e-8	Hepatitis;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg02447779	chr16:31505062	C16orf58	-0.39	-6.19	-0.32	1.75e-9	Bipolar disorder;
LIHC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.45e-10	Colorectal cancer;
LIHC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.47	-7.77	-0.39	9.16e-14	Menarche (age at onset);
LIHC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.51	0.53	3.97e-26	Motion sickness;
LIHC	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.12e-9	Coronary artery disease;
LIHC	trans	rs12780046	0.656	rs7085445	chr10:100858581	C/T	cg05980083	chr9:112191166	PTPN3	-0.46	-6.09	-0.31	2.95e-9	Non-glioblastoma glioma;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.37	0.37	1.3e-12	Renal cell carcinoma;
LIHC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.69	-7.07	-0.36	8.51e-12	Vitiligo;
LIHC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.56	7.79	0.39	8.17e-14	Morning vs. evening chronotype;
LIHC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg16479474	chr6:28041457	NA	0.38	6.29	0.32	9.81e-10	Parkinson's disease;
LIHC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.58	-0.34	1.72e-10	Mean corpuscular volume;
LIHC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg09835421	chr16:68378352	PRMT7	-0.49	-5.77	-0.3	1.8e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-10.28	-0.49	8.89e-22	Dental caries;
LIHC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg14067834	chr17:29058358	SUZ12P	0.71	7.01	0.35	1.26e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.72	8.74	0.43	1.04e-16	Heart rate;
LIHC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg16479474	chr6:28041457	NA	0.46	6.46	0.33	3.5e-10	Depression;
LIHC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.74	-9.55	-0.46	2.67e-19	Systemic lupus erythematosus;
LIHC	cis	rs9322817	0.691	rs4460239	chr6:105325562	C/T	cg02098413	chr6:105308735	HACE1	0.41	7.59	0.38	3.02e-13	Thyroid stimulating hormone;
LIHC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.51	8.03	0.4	1.54e-14	Tonsillectomy;
LIHC	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.88	0.57	3.23e-31	Colorectal cancer;
LIHC	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.81	-0.39	7.29e-14	Response to antipsychotic treatment;
LIHC	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg02023728	chr11:77925099	USP35	0.33	5.89	0.3	9.28e-9	Alzheimer's disease (survival time);
LIHC	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-0.81	-12.36	-0.56	3.02e-29	Obesity-related traits;
LIHC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.73	-14.52	-0.62	1.47e-37	Height;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17271960	chr1:1550779	MIB2	0.52	6.26	0.32	1.17e-9	Hepatitis;
LIHC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.54	-0.42	4.32e-16	Type 2 diabetes;
LIHC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg10932868	chr11:921992	NA	0.31	5.8	0.3	1.52e-8	Alzheimer's disease (late onset);
LIHC	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-7.37	-0.37	1.27e-12	Metabolite levels;
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.71	-8.81	-0.43	6.37e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1198430	0.925	rs2510072	chr1:23769674	A/G	cg19827787	chr1:23763612	ASAP3	0.35	6.02	0.31	4.39e-9	Total cholesterol levels;
LIHC	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.85	17.39	0.68	5.72e-49	Longevity;
LIHC	cis	rs72653721	0.730	rs12664138	chr6:11039799	T/C	cg13562911	chr6:11044106	ELOVL2	0.53	7.59	0.38	3.16e-13	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.74	0.5	2.26e-23	Coffee consumption (cups per day);
LIHC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.76	-13.02	-0.58	9.81e-32	Platelet distribution width;
LIHC	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.05	0.44	1.08e-17	Response to antipsychotic treatment;
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.03	-0.36	1.12e-11	Renal cell carcinoma;
LIHC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.59e-14	Motion sickness;
LIHC	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.14	0.32	2.24e-9	Protein biomarker;
LIHC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg24203234	chr3:128598194	ACAD9	0.45	6.22	0.32	1.47e-9	IgG glycosylation;
LIHC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.76	-11.3	-0.52	2.34e-25	Coronary artery disease;
LIHC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.83	-0.51	1.11e-23	Mean corpuscular volume;
LIHC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.69	10.76	0.5	1.95e-23	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.96	-0.4	2.5e-14	Exhaled nitric oxide output;
LIHC	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.81	11.39	0.52	1.08e-25	Body mass index;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs61712019	1.000	rs61712019	chr2:77704889	C/T	cg11252801	chr2:77748917	LRRTM4	0.51	7.77	0.39	9.52e-14	Schizophrenia;
LIHC	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.59	6.34	0.32	7.22e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.68	0.46	9.54e-20	Platelet count;
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg26939375	chr7:64535504	NA	0.48	7.22	0.36	3.46e-12	Aortic root size;
LIHC	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3770081	1.000	rs77621359	chr2:86330353	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-9.26	-0.45	2.39e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.68	-0.5	3.74e-23	Coronary artery disease;
LIHC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.51	-7.8	-0.39	7.62e-14	Menarche (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg24141198	chr1:115259970	CSDE1;NRAS	0.47	6.79	0.34	5.08e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.73	-12.81	-0.57	5.85e-31	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.4	6.48	0.33	3.25e-10	Red blood cell count;
LIHC	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-6.49	-0.33	3.1e-10	Breast cancer;
LIHC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.64	-8.82	-0.43	6.16e-17	Aortic root size;
LIHC	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.44	8.88	0.43	3.74e-17	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.56e-13	Prudent dietary pattern;
LIHC	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg15902774	chr15:75289873	SCAMP5	-0.33	-6.0	-0.31	5e-9	Systemic lupus erythematosus;
LIHC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-9.0	-0.44	1.58e-17	Body mass index;
LIHC	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	0.55	7.3	0.37	2.02e-12	Pulse pressure;
LIHC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	0.97	19.98	0.73	2.12e-59	IgG glycosylation;
LIHC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg01444801	chr10:135216882	MTG1	-0.63	-9.32	-0.45	1.5e-18	Systemic lupus erythematosus;
LIHC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	11.96	0.54	8.87e-28	High light scatter reticulocyte count;
LIHC	cis	rs9503598	0.502	rs6937621	chr6:3430128	G/A	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.84	-0.3	1.2e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg02344993	chr17:57696989	CLTC	0.72	12.37	0.56	2.76e-29	Hemoglobin concentration;
LIHC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-7.84	-0.39	5.82e-14	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17183009	chr3:120277827	NA	0.52	6.23	0.32	1.38e-9	Corneal astigmatism;
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg02782426	chr3:40428986	ENTPD3	-0.32	-6.06	-0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg23091122	chr1:110024289	SYPL2	-0.45	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	0.98	13.79	0.6	1.1e-34	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs9513627	1.000	rs73556172	chr13:100121684	A/G	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-9.27	-0.45	2.1e-18	Schizophrenia;
LIHC	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.53	0.49	1.24e-22	Colorectal cancer;
LIHC	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.43	-8.51	-0.42	5.4e-16	Testicular germ cell tumor;
LIHC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.03	-0.4	1.58e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg24069376	chr3:38537580	EXOG	0.43	8.04	0.4	1.48e-14	Electrocardiographic conduction measures;
LIHC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.73	-0.3	2.2e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.56	0.46	2.37e-19	Mean platelet volume;
LIHC	cis	rs17106184	0.892	rs72900926	chr1:51101616	C/G	cg07174182	chr1:51127561	FAF1	-0.65	-7.04	-0.36	1.03e-11	Type 2 diabetes;
LIHC	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.58	6.75	0.34	6.29e-11	Multiple myeloma (IgH translocation);
LIHC	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.39	11.65	0.53	1.2e-26	Uric acid levels;
LIHC	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.42	12.22	0.55	9.43e-29	Uric acid levels;
LIHC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.79	0.34	4.88e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	9.0	0.44	1.64e-17	Post bronchodilator FEV1;
LIHC	cis	rs6782228	0.606	rs4857919	chr3:128407495	C/T	cg16766828	chr3:128327626	NA	-0.38	-6.07	-0.31	3.46e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.25	0.32	1.21e-9	Mean corpuscular hemoglobin;
LIHC	cis	rs7619427	0.643	rs6800613	chr3:44098325	T/C	cg24966902	chr3:44043705	NA	0.51	6.75	0.34	6.47e-11	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04073608	chr11:65268100	MALAT1	-0.51	-6.38	-0.33	5.63e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	trans	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.77e-11	Aortic root size;
LIHC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.25	-0.55	7.24e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08980237	chr3:156534860	NA	-0.48	-6.17	-0.32	1.96e-9	Systolic blood pressure;
LIHC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-8.94	-0.44	2.56e-17	Gut microbiome composition (summer);
LIHC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-8.24	-0.41	3.78e-15	Chronic sinus infection;
LIHC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.13	-0.36	5.99e-12	Personality dimensions;
LIHC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.65	-9.01	-0.44	1.47e-17	Menarche (age at onset);
LIHC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	0.93	16.95	0.68	3.21e-47	Parkinson's disease;
LIHC	cis	rs2380220	0.808	rs2613547	chr6:95910311	C/T	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.68	-9.61	-0.46	1.7e-19	Menarche (age at onset);
LIHC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs668210	0.793	rs506873	chr11:65767215	A/C	cg17712092	chr4:129076599	LARP1B	-0.58	-6.2	-0.32	1.67e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9517320	0.967	rs9517337	chr13:99181647	A/C	cg07423050	chr13:99094983	FARP1	0.36	5.92	0.31	7.65e-9	Longevity;
LIHC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg20932281	chr17:33905541	PEX12	-0.53	-6.14	-0.32	2.29e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	0.92	15.86	0.65	7.73e-43	Testicular germ cell tumor;
LIHC	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	0.59	8.22	0.41	4.19e-15	Post bronchodilator FEV1;
LIHC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21171335	chr12:122356390	WDR66	0.47	7.76	0.39	9.78e-14	Mean corpuscular volume;
LIHC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.62	8.89	0.43	3.61e-17	Blood metabolite levels;
LIHC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.6	7.98	0.4	2.23e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.71	13.02	0.58	9.36e-32	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs6058796	0.892	rs6141780	chr20:31262423	C/G	cg02600331	chr11:130417168	NA	-0.36	-7.85	-0.39	5.51e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg04727924	chr7:799746	HEATR2	0.46	6.81	0.35	4.35e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.44	-7.5	-0.38	5.51e-13	Lung cancer;
LIHC	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18030105	chr11:3396237	ZNF195	-0.46	-6.92	-0.35	2.21e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	0.87	6.48	0.33	3.28e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-7.88	-0.39	4.3e-14	Neuranatomic and neurocognitive phenotypes;
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.22	-0.32	1.45e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02290350	chr8:58132656	NA	0.51	10.88	0.51	7.37e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.42	-7.05	-0.36	9.65e-12	Squamous cell lung carcinoma;
LIHC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg21466736	chr12:48725269	NA	0.33	5.92	0.3	7.87e-9	Plateletcrit;
LIHC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.85	0.3	1.12e-8	Menopause (age at onset);
LIHC	cis	rs1113500	0.814	rs12039712	chr1:108641199	A/G	cg06207961	chr1:108661230	NA	0.32	6.07	0.31	3.38e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg16479474	chr6:28041457	NA	0.37	6.18	0.32	1.78e-9	Cardiac Troponin-T levels;
LIHC	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.52	7.58	0.38	3.3e-13	Obesity-related traits;
LIHC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17554472	chr22:41940697	POLR3H	0.54	5.9	0.3	8.82e-9	Vitiligo;
LIHC	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02985541	chr2:219472218	PLCD4	0.37	6.51	0.33	2.75e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.28	-0.61	1.32e-36	Alzheimer's disease;
LIHC	cis	rs6445975	0.715	rs6769100	chr3:58259999	C/T	cg23715586	chr3:58305044	RPP14	0.34	5.82	0.3	1.39e-8	Systemic lupus erythematosus;
LIHC	cis	rs1982963	1.000	rs3742536	chr14:52507429	C/T	cg10843707	chr14:52510701	NID2	0.45	8.26	0.41	3.27e-15	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.77	12.92	0.57	2.32e-31	Oral cavity cancer;
LIHC	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.61	-0.59	5.31e-34	Coffee consumption (cups per day);
LIHC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.94	-0.35	1.96e-11	Acylcarnitine levels;
LIHC	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	5.93	0.31	7.52e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs288342	0.832	rs288303	chr2:183655230	G/T	cg02625481	chr2:183667124	NA	-0.29	-5.96	-0.31	6.25e-9	Recurrent major depressive disorder;
LIHC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs11382616	1	rs11382616	chr14:103081465	G/GC	cg12046867	chr14:103022105	NA	-0.38	-5.79	-0.3	1.59e-8	Plateletcrit;Platelet count;
LIHC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-7.31	-0.37	1.88e-12	Height;
LIHC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg25344623	chr2:136566232	LCT	0.42	8.59	0.42	3.11e-16	Mosquito bite size;
LIHC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.52	7.15	0.36	5.24e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.31	0.32	8.67e-10	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3106136	0.814	rs6532482	chr4:95277414	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.37	-6.41	-0.33	4.73e-10	Capecitabine sensitivity;
LIHC	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.45	6.68	0.34	9.63e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg03013999	chr17:37608204	MED1	0.35	5.75	0.3	1.94e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	13.28	0.58	9.25e-33	Bipolar disorder;
LIHC	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.42	-5.93	-0.31	7.25e-9	Smoking behavior;
LIHC	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg05368731	chr17:41323189	NBR1	0.7	11.55	0.53	2.72e-26	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg22633049	chr21:46681294	NA	-0.36	-6.11	-0.31	2.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.73	11.03	0.51	2.09e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.54	7.88	0.39	4.5e-14	Diastolic blood pressure;
LIHC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg09462578	chr12:12878428	APOLD1	-0.74	-10.02	-0.48	6.64e-21	Systemic lupus erythematosus;
LIHC	cis	rs77633900	0.772	rs494268	chr15:76815713	T/C	cg21673338	chr15:77095150	SCAPER	-0.53	-5.92	-0.3	7.98e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.97	0.31	5.94e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.58	8.84	0.43	5.22e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.58	10.12	0.48	3.07e-21	Diisocyanate-induced asthma;
LIHC	cis	rs17106184	0.892	rs72900998	chr1:51205760	T/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.85	-0.35	3.47e-11	Type 2 diabetes;
LIHC	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14154082	chr13:112174009	NA	0.3	6.26	0.32	1.16e-9	Menarche (age at onset);
LIHC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.75	0.65	2e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.11	-0.31	2.64e-9	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25262866	chr7:16686311	BZW2;ANKMY2	0.41	6.35	0.32	6.69e-10	Cognitive function;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.52	-9.03	-0.44	1.29e-17	Total body bone mineral density;
LIHC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.51	6.63	0.34	1.3100000000000001e-10	Initial pursuit acceleration;
LIHC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.0	-0.6	1.66e-35	Alzheimer's disease;
LIHC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.69	11.62	0.53	1.5e-26	Menopause (age at onset);
LIHC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.5	0.33	2.79e-10	Heart rate;
LIHC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.84	8.3	0.41	2.5e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.56	10.01	0.48	7.54e-21	Mean corpuscular volume;
LIHC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.5	6.57	0.33	1.91e-10	Height;
LIHC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02034447	chr16:89574710	SPG7	0.45	6.81	0.35	4.5e-11	Multiple myeloma (IgH translocation);
LIHC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.15	0.4	6.95e-15	Morning vs. evening chronotype;
LIHC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-20.5	-0.74	1.72e-61	Coronary artery disease;
LIHC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.41	6.09	0.31	3.04e-9	Height;
LIHC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.39	-0.37	1.14e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.57	9.16	0.44	4.83e-18	Eosinophilic esophagitis;
LIHC	trans	rs41997	1.000	rs41997	chr7:117991895	A/G	cg09887251	chr4:1024735	NA	-0.34	-6.05	-0.31	3.72e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.41	6.96	0.35	1.76e-11	Mean corpuscular volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21584983	chr19:11640070	ECSIT	0.46	6.76	0.34	6.09e-11	Pancreatic cancer;
LIHC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg03037974	chr15:76606532	NA	-0.71	-13.88	-0.6	4.72e-35	Blood metabolite levels;
LIHC	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.47	6.15	0.32	2.22e-9	Glioblastoma;Glioma;
LIHC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.25	-0.52	3.37e-25	Crohn's disease;
LIHC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-11.04	-0.51	1.96e-24	Platelet count;
LIHC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.92e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg00280220	chr17:61926910	NA	0.42	6.79	0.34	4.88e-11	Prudent dietary pattern;
LIHC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg17796960	chr10:135278976	LOC619207	-0.34	-5.8	-0.3	1.53e-8	Systemic lupus erythematosus;
LIHC	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.7	11.46	0.53	5.82e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg12297030	chr17:43662878	NA	-0.65	-6.27	-0.32	1.11e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	1.01	13.63	0.59	4.25e-34	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.72	-0.43	1.24e-16	Total cholesterol levels;
LIHC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	0.67	6.66	0.34	1.09e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.3	-6.88	-0.35	2.81e-11	Breast cancer;
LIHC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.54	9.33	0.45	1.38e-18	Dental caries;
LIHC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg26913058	chr16:419975	MRPL28	-0.47	-5.92	-0.3	7.88e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.65	-11.02	-0.51	2.23e-24	Crohn's disease;
LIHC	cis	rs867186	0.614	rs75076672	chr20:33451713	C/T	cg08999081	chr20:33150536	PIGU	0.64	5.79	0.3	1.61e-8	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg21605333	chr4:119757512	SEC24D	1.07	8.66	0.42	1.91e-16	Cannabis dependence symptom count;
LIHC	trans	rs2270927	0.510	rs246814	chr5:75599208	C/T	cg13563193	chr19:33072644	PDCD5	1.0	9.5	0.46	3.86e-19	Mean corpuscular volume;
LIHC	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.95	-0.54	9.66e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.61	-0.5	6.24e-23	Breast cancer;
LIHC	cis	rs17106184	1.000	rs12088617	chr1:51347213	G/T	cg07174182	chr1:51127561	FAF1	0.59	6.48	0.33	3.16e-10	Type 2 diabetes;
LIHC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.11	-0.36	6.91e-12	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.44	7.11	0.36	7.01e-12	Diastolic blood pressure;
LIHC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg02070205	chr10:30722105	MAP3K8	-0.43	-5.82	-0.3	1.35e-8	Inflammatory bowel disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03147627	chr4:83956202	COPS4	0.44	6.85	0.35	3.38e-11	Cognitive function;
LIHC	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg08992911	chr2:238395768	MLPH	0.51	5.98	0.31	5.5e-9	Prostate cancer;
LIHC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.59	-8.59	-0.42	3.1e-16	Testicular germ cell tumor;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.45	7.18	0.36	4.28e-12	Testicular germ cell tumor;
LIHC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-0.9	-10.85	-0.51	8.86e-24	Mitochondrial DNA levels;
LIHC	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg08126542	chr6:37504118	NA	-0.38	-6.08	-0.31	3.15e-9	Cognitive performance;
LIHC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg16797656	chr11:68205561	LRP5	0.52	8.25	0.41	3.44e-15	Total body bone mineral density;
LIHC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.68	10.17	0.48	2.16e-21	Plasma homocysteine levels (post-methionine load test);
LIHC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg11764359	chr7:65958608	NA	0.59	6.01	0.31	4.75e-9	Diabetic kidney disease;
LIHC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	0.83	7.02	0.36	1.18e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg01364799	chr7:75623366	TMEM120A	0.5	7.65	0.38	2.04e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.5	6.02	0.31	4.43e-9	Menarche (age at onset);
LIHC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.98	-0.68	2.44e-47	Gut microbiome composition (summer);
LIHC	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.44	-8.84	-0.43	5.15e-17	LDL cholesterol levels;
LIHC	cis	rs7212590	0.748	rs7213697	chr17:57903041	G/C	cg10252138	chr17:58120427	NA	-0.62	-6.11	-0.31	2.78e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.78	12.23	0.55	9.18e-29	Longevity;
LIHC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.49	5.85	0.3	1.13e-8	Total body bone mineral density;
LIHC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.44	6.59	0.34	1.62e-10	Testicular germ cell tumor;
LIHC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-6.62	-0.34	1.37e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs10456809	0.808	rs6918261	chr6:17815431	A/G	cg24822696	chr6:125283245	STL	-0.38	-6.22	-0.32	1.43e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg16970926	chr12:29381810	FAR2	0.31	6.59	0.34	1.7e-10	QT interval;
LIHC	trans	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg17675199	chr6:35436792	RPL10A	-0.41	-8.5	-0.42	5.82e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg07424592	chr7:64974309	NA	0.82	9.56	0.46	2.36e-19	Diabetic kidney disease;
LIHC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg07117364	chr1:16154769	NA	-0.38	-6.8	-0.35	4.61e-11	Dilated cardiomyopathy;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.72	-11.91	-0.54	1.32e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.64	-9.05	-0.44	1.09e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs55665837	0.540	rs3206554	chr11:14797945	A/T	cg00085434	chr11:14927489	NA	0.4	5.78	0.3	1.65e-8	Vitamin D levels;
LIHC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.77	0.34	5.75e-11	Monocyte percentage of white cells;
LIHC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.11	-0.36	7.03e-12	Bipolar disorder;
LIHC	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.62	9.87	0.47	2.16e-20	Anterior chamber depth;
LIHC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.13	0.48	2.88e-21	Melanoma;
LIHC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-8.92	-0.43	2.85e-17	Gut microbiome composition (summer);
LIHC	cis	rs3736485	0.966	rs2414111	chr15:51901357	A/G	cg08986416	chr15:51914746	DMXL2	0.41	6.12	0.31	2.59e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.77	0.3	1.76e-8	Self-reported allergy;
LIHC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-14.8	-0.62	1.23e-38	Refractive error;
LIHC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.37	6.35	0.32	7.05e-10	Height;
LIHC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg08132940	chr7:1081526	C7orf50	-0.63	-6.05	-0.31	3.74e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.55	-0.42	4.1e-16	Type 2 diabetes;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.68	11.35	0.52	1.53e-25	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.79	-0.34	4.89e-11	Personality dimensions;
LIHC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.36	-5.98	-0.31	5.61e-9	Educational attainment;
LIHC	cis	rs249954	0.512	rs249856	chr16:23658976	G/A	cg05131483	chr16:23706242	ERN2	0.36	5.85	0.3	1.14e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.82	-0.3	1.36e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg00800038	chr16:89945340	TCF25	-0.61	-8.89	-0.43	3.56e-17	Skin colour saturation;
LIHC	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.4	6.17	0.32	1.93e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.53	8.23	0.41	3.93e-15	Longevity;Endometriosis;
LIHC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.48	-7.12	-0.36	6.34e-12	Cognitive function;
LIHC	trans	rs78049276	0.651	rs59415853	chr4:148378225	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.66	-8.27	-0.41	2.92e-15	Pulse pressure;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg19819135	chr1:70710422	SFRS11	0.4	6.46	0.33	3.64e-10	Longevity;
LIHC	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.46	-6.86	-0.35	3.32e-11	Diastolic blood pressure;
LIHC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.68	-0.42	1.69e-16	Skin colour saturation;
LIHC	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.59	0.5	7.57e-23	Colorectal cancer;
LIHC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.4	6.36	0.33	6.46e-10	Menopause (age at onset);
LIHC	cis	rs9378688	0.654	rs2505660	chr6:2326441	A/G	cg12303981	chr6:2244766	GMDS	-0.43	-6.08	-0.31	3.21e-9	Caudate nucleus volume;
LIHC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.47	-7.86	-0.39	4.88e-14	Vitiligo;
LIHC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.35	5.76	0.3	1.9e-8	Colorectal cancer;
LIHC	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.68	-0.34	9.56e-11	Blood pressure;
LIHC	cis	rs4407350	0.837	rs4823326	chr22:44908678	C/T	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.15	-0.32	2.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2705520	0.744	rs1814052	chr3:112231907	C/T	cg09473763	chr3:112282684	SLC35A5	-0.74	-8.93	-0.43	2.61e-17	Asthma (childhood onset);
LIHC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.75	11.08	0.51	1.43e-24	Corneal astigmatism;
LIHC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-6.05	-0.31	3.76e-9	Mean corpuscular volume;
LIHC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg22834771	chr12:69754056	YEATS4	-0.41	-6.08	-0.31	3.27e-9	Response to diuretic therapy;
LIHC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg07308232	chr7:1071921	C7orf50	-0.39	-5.98	-0.31	5.55e-9	Longevity;Endometriosis;
LIHC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	7.0	0.35	1.35e-11	Menopause (age at onset);
LIHC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	8.79	0.43	7.58e-17	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs10792665	0.606	rs1939133	chr11:82602895	C/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.1	-0.31	2.94e-9	Obesity-related traits;
LIHC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.26	-6.36	-0.33	6.6e-10	Cutaneous nevi;
LIHC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.86	-15.61	-0.65	7.28e-42	Bone mineral density;
LIHC	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.58	10.93	0.51	4.58e-24	Leprosy;
LIHC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.62	7.58	0.38	3.3e-13	Cognitive function;
LIHC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.79	10.32	0.49	6.46e-22	Body mass index;
LIHC	cis	rs10131894	0.575	rs1860935	chr14:75432464	G/A	cg08847533	chr14:75593920	NEK9	0.8	14.99	0.63	2.2e-39	Coronary artery disease;
LIHC	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg20302342	chr1:156215951	PAQR6	0.32	6.03	0.31	4.22e-9	Tonsillectomy;
LIHC	cis	rs2279817	0.731	rs11203435	chr1:18010233	T/A	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-5.86	-0.3	1.09e-8	Neuroticism;
LIHC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg06046430	chr4:77819534	ANKRD56	0.5	6.53	0.33	2.34e-10	Emphysema distribution in smoking;
LIHC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.51	8.0	0.4	1.89e-14	Lymphocyte counts;
LIHC	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs244293	0.801	rs11655949	chr17:53169883	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.59	0.38	3.01e-13	Menarche (age at onset);
LIHC	cis	rs9513627	0.920	rs73556201	chr13:100128753	C/G	cg25919922	chr13:100150906	NA	-0.77	-6.89	-0.35	2.74e-11	Obesity-related traits;
LIHC	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg18478394	chr8:109455254	TTC35	0.41	6.73	0.34	7.31e-11	Dupuytren's disease;
LIHC	cis	rs546131	0.642	rs61881107	chr11:34848020	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.53	-0.33	2.4e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.75	-12.75	-0.57	1.03e-30	Aortic root size;
LIHC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.64	13.12	0.58	4.06e-32	Airflow obstruction;
LIHC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.35	-5.76	-0.3	1.89e-8	IgG glycosylation;
LIHC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Bone mineral density;
LIHC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg13844804	chr7:814759	HEATR2	0.44	5.88	0.3	9.97e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.34	-5.72	-0.3	2.3e-8	Bipolar disorder;
LIHC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg13647721	chr17:30228624	UTP6	-0.78	-6.61	-0.34	1.5e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg12560992	chr17:57184187	TRIM37	0.68	8.8	0.43	7e-17	Vitamin D levels;
LIHC	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.45	-6.75	-0.34	6.18e-11	Primary biliary cholangitis;
LIHC	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.86	-9.37	-0.45	1.01e-18	QRS complex (12-leadsum);
LIHC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.84	14.02	0.6	1.29e-35	Breast cancer;
LIHC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.59	9.83	0.47	3.09e-20	Alcohol dependence;
LIHC	cis	rs988712	0.537	rs10742179	chr11:27650524	A/G	cg18117895	chr11:27722066	BDNF	-0.46	-6.57	-0.33	1.88e-10	Obesity;
LIHC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg14779329	chr11:130786720	SNX19	0.42	6.34	0.32	7.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.94	-12.3	-0.55	4.98e-29	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06808467	chr18:5237767	LOC339290;C18orf18	0.59	7.79	0.39	8.17e-14	Lung function (FEV1/FVC);
LIHC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.38	-5.92	-0.31	7.64e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.71	-8.44	-0.42	8.82e-16	Vitiligo;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.68	-10.09	-0.48	4e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg03989125	chr22:38214979	NA	-0.44	-6.14	-0.32	2.25e-9	Glioblastoma;Glioma;
LIHC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.25	0.32	1.19e-9	Urate levels;
LIHC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.58	9.54	0.46	2.83e-19	Colorectal cancer;
LIHC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg20607798	chr8:58055168	NA	0.68	7.75	0.39	1.04e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7095607	0.560	rs2101484	chr10:69927711	T/C	cg18986048	chr10:69913749	MYPN	0.48	7.2	0.36	3.76e-12	Lung function (FVC);
LIHC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.91	0.35	2.35e-11	Height;
LIHC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.5	-5.82	-0.3	1.37e-8	Alzheimer's disease;
LIHC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.45	5.89	0.3	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24504843	chr4:56896641	CEP135	-0.44	-6.61	-0.34	1.51e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.99	0.44	1.76e-17	Height;
LIHC	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg01864836	chr14:55583639	NA	-0.44	-8.27	-0.41	3.04e-15	Protein biomarker;
LIHC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-9.41	-0.45	7.59e-19	Parkinson's disease;
LIHC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.41	5.74	0.3	2.09e-8	Iron status biomarkers;
LIHC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-6.27	-0.32	1.09e-9	Initial pursuit acceleration;
LIHC	cis	rs11630290	0.736	rs7174738	chr15:64144813	A/T	cg12036633	chr15:63758958	NA	-0.56	-5.75	-0.3	2e-8	Iris characteristics;
LIHC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.45	-6.74	-0.34	6.88e-11	Cognitive function;
LIHC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.66e-9	Mortality in heart failure;
LIHC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.38	5.75	0.3	1.96e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.83	-0.3	1.3e-8	Height;
LIHC	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.63	10.44	0.49	2.46e-22	Waist circumference;Body mass index;
LIHC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.34	7.78	0.39	8.88e-14	Blood metabolite ratios;
LIHC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.79	-0.5	1.53e-23	Monocyte count;
LIHC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.88	14.31	0.61	1.02e-36	Colorectal cancer;
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg19016816	chr7:1267987	NA	-0.26	-5.74	-0.3	2.03e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.63	-9.42	-0.45	7.01e-19	Multiple myeloma (IgH translocation);
LIHC	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.34	-6.16	-0.32	2.09e-9	IgG glycosylation;
LIHC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.47	6.06	0.31	3.62e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-7.21	-0.36	3.67e-12	Renal cell carcinoma;
LIHC	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg02415029	chr1:110025642	ATXN7L2	-0.46	-5.78	-0.3	1.65e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.967	rs591792	chr8:109200446	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.62	7.19	0.36	4.22e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg03037974	chr15:76606532	NA	0.89	22.97	0.78	2.62e-71	Blood metabolite levels;
LIHC	trans	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.46	-0.33	3.65e-10	Educational attainment (years of education);
LIHC	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-0.82	-11.87	-0.54	1.94e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg13152130	chr6:118910203	C6orf204	-0.65	-7.47	-0.37	6.87e-13	Diastolic blood pressure;
LIHC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.45	6.31	0.32	8.47e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02985541	chr2:219472218	PLCD4	-0.38	-6.59	-0.34	1.67e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg22153463	chr1:85462885	MCOLN2	0.53	6.22	0.32	1.43e-9	Serum sulfate level;
LIHC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	7.81	0.39	6.96e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.69	11.88	0.54	1.68e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.18	0.4	5.47e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.66	10.59	0.5	7.23e-23	White matter hyperintensity burden;
LIHC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.58	8.44	0.42	9.01e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.99	-0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.87	0.39	4.64e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-0.84	-10.53	-0.49	1.2e-22	Blood pressure (smoking interaction);
LIHC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.28	-0.32	1.02e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.38	-0.41	1.37e-15	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27590859	chr20:54967608	AURKA;CSTF1	0.43	6.1	0.31	2.87e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg07645718	chr20:61493192	TCFL5	0.68	5.87	0.3	1.01e-8	Obesity-related traits;
LIHC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg04727924	chr7:799746	HEATR2	-0.62	-8.41	-0.41	1.1e-15	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.38	-5.82	-0.3	1.32e-8	Height;
LIHC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.88	-12.9	-0.57	2.81e-31	Sudden cardiac arrest;
LIHC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.69	12.0	0.54	6.31e-28	Lewy body disease;
LIHC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.52	8.34	0.41	1.82e-15	Total body bone mineral density;
LIHC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg19680672	chr10:131412579	MGMT	0.43	6.53	0.33	2.38e-10	Response to temozolomide;
LIHC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.9	-0.3	8.87e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7587476	0.505	rs777323	chr2:215738485	A/G	cg04004882	chr2:215674386	BARD1	-0.51	-7.06	-0.36	9.41e-12	Neuroblastoma;
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.94	-0.6	2.78e-35	Alzheimer's disease;
LIHC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.51	8.05	0.4	1.42e-14	Testicular germ cell tumor;
LIHC	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.64	-0.34	1.24e-10	Ulcerative colitis;
LIHC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.57	-0.38	3.61e-13	Obesity-related traits;
LIHC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.89	11.69	0.53	8.84e-27	Cerebrospinal P-tau181p levels;
LIHC	cis	rs600806	0.778	rs2152924	chr1:110011701	G/A	cg23091122	chr1:110024289	SYPL2	-0.5	-6.78	-0.34	5.27e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg19338460	chr6:170058176	WDR27	-0.38	-5.9	-0.3	8.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.67	6.4	0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.09	0.4	1.05e-14	Bladder cancer;
LIHC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.8	10.13	0.48	2.81e-21	HIV-1 control;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677032	chr17:61819896	STRADA	-0.43	-6.34	-0.32	7.28e-10	Prudent dietary pattern;
LIHC	cis	rs28595532	0.545	rs13132957	chr4:119250841	G/C	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.64	6.53	0.33	2.42e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.56	-6.4	-0.33	5.27e-10	Ulcerative colitis;
LIHC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg24209194	chr3:40518798	ZNF619	0.46	6.84	0.35	3.57e-11	Renal cell carcinoma;
LIHC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.87	-9.75	-0.47	5.67e-20	Vitiligo;
LIHC	cis	rs8192917	0.887	rs2236337	chr14:25100247	T/C	cg08766149	chr14:25103301	GZMB	0.31	7.33	0.37	1.69e-12	Vitiligo;
LIHC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-8.22	-0.41	4.22e-15	Gut microbiome composition (summer);
LIHC	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg00800038	chr16:89945340	TCF25	-0.64	-9.57	-0.46	2.29e-19	Skin colour saturation;
LIHC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	8.12	0.4	8.32e-15	Lymphocyte counts;
LIHC	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.62	-0.34	1.37e-10	Homocysteine levels;
LIHC	cis	rs903552	0.800	rs1587107	chr15:102006485	T/C	cg19295451	chr15:102010161	PCSK6	-0.52	-7.08	-0.36	8.29e-12	Diabetic kidney disease;
LIHC	trans	rs875971	1.000	rs709597	chr7:65825983	A/G	cg10756647	chr7:56101905	PSPH	-0.43	-6.27	-0.32	1.07e-9	Aortic root size;
LIHC	cis	rs700651	0.789	rs10190226	chr2:198901564	A/G	cg03934865	chr2:198174659	NA	-0.45	-6.37	-0.33	6.09e-10	Intracranial aneurysm;
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	7.71	0.38	1.4e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg20651018	chr11:3035856	CARS	-0.35	-5.87	-0.3	1.04e-8	Longevity;
LIHC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg05941027	chr17:61774174	LIMD2	-0.36	-7.38	-0.37	1.23e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.2	0.45	3.71e-18	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs7534824	0.543	rs61780299	chr1:101403471	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.44	0.37	8.3e-13	Refractive astigmatism;
LIHC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.35	0.32	7.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-11.69	-0.53	8.49e-27	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.94	0.31	6.87e-9	Electroencephalogram traits;
LIHC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.51	8.23	0.41	4.08e-15	Schizophrenia;
LIHC	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg12798992	chr6:167411361	FGFR1OP	0.6	10.0	0.48	8.15e-21	Crohn's disease;
LIHC	trans	rs4146653	0.608	rs1901639	chr10:4763871	A/T	cg25345178	chr8:72459908	NA	0.32	6.05	0.31	3.75e-9	Major depressive disorder;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.2.2322915R	chr2:111420003	BUB1	-0.4	-6.68	-0.34	9.5e-11	Hepatitis;
LIHC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.26	-6.06	-0.31	3.5e-9	Subjective well-being;
LIHC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.9	-0.39	3.75e-14	Type 2 diabetes;
LIHC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.89	-0.3	9.39e-9	Pulse pressure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15965583	chr1:150601949	ENSA	0.41	6.61	0.34	1.47e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01423368	chr11:76155379	C11orf30	0.44	6.14	0.32	2.32e-9	Pancreatic cancer;
LIHC	cis	rs4919087	0.590	rs701821	chr10:99038562	G/A	cg25902810	chr10:99078978	FRAT1	-0.6	-6.68	-0.34	9.41e-11	Monocyte count;
LIHC	cis	rs12922317	0.927	rs12923439	chr16:12073958	C/T	cg09319797	chr16:12061715	TNFRSF17	0.41	7.29	0.37	2.2e-12	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.58	-0.34	1.79e-10	Gut microbiome composition (summer);
LIHC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-8.08	-0.4	1.14e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg05527609	chr1:210001259	C1orf107	-0.55	-7.65	-0.38	2.09e-13	Red blood cell count;
LIHC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.46	0.46	5.22e-19	Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg14393609	chr7:65229607	NA	-0.39	-6.21	-0.32	1.5e-9	Calcium levels;
LIHC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg03037974	chr15:76606532	NA	-0.58	-9.89	-0.47	1.93e-20	Blood metabolite levels;
LIHC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.45	8.62	0.42	2.55e-16	Tuberculosis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08522707	chr7:140714747	MRPS33	-0.57	-6.55	-0.33	2.12e-10	Systolic blood pressure;
LIHC	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-5.95	-0.31	6.69e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.56	8.39	0.41	1.3e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs9914544	0.545	rs9914914	chr17:18787780	G/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.57	-0.33	1.82e-10	Educational attainment (years of education);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16674323	chr3:42846108	HIGD1A	0.5	6.34	0.32	7.1e-10	Hepatitis;
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	1.15	9.07	0.44	9.6e-18	Arsenic metabolism;
LIHC	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	0.8	6.78	0.34	5.13e-11	Cannabis dependence symptom count;
LIHC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.11	0.31	2.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-11.99	-0.54	7.02e-28	Prudent dietary pattern;
LIHC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.96	0.4	2.61e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.46	-0.33	3.51e-10	Metabolite levels;
LIHC	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.35	-7.47	-0.37	6.9e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg06363034	chr20:62225388	GMEB2	-0.44	-7.52	-0.38	4.94e-13	Glioblastoma;
LIHC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	6.19	0.32	1.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.51	7.49	0.38	5.87e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.0	-0.44	1.55e-17	Obesity-related traits;
LIHC	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.55	-0.38	4.03e-13	QT interval;
LIHC	cis	rs3770081	1.000	rs75109362	chr2:86289889	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.84	-8.59	-0.42	3.03e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.9	0.54	1.54e-27	Cognitive test performance;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg26338869	chr17:61819248	STRADA	0.53	7.03	0.36	1.15e-11	Height;
LIHC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg17724175	chr1:150552817	MCL1	-0.37	-7.45	-0.37	7.54e-13	Tonsillectomy;
LIHC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.14	-0.44	5.47e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg10820045	chr2:198174542	NA	0.45	7.12	0.36	6.57e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg23043544	chr7:2124092	MAD1L1	-0.4	-6.52	-0.33	2.49e-10	Neuroticism;
LIHC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.18	0.48	1.95e-21	Cognitive test performance;
LIHC	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.66	7.9	0.39	3.78e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-8.16	-0.4	6.61e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.45	5.81	0.3	1.47e-8	RR interval (heart rate);
LIHC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.06	0.55	3.84e-28	Body mass index;
LIHC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.56	-10.75	-0.5	2e-23	Body mass index;
LIHC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.87	0.3	1.04e-8	Blood metabolite levels;
LIHC	cis	rs6466055	0.666	rs4730081	chr7:105006850	C/T	cg04380332	chr7:105027541	SRPK2	-0.37	-6.9	-0.35	2.52e-11	Schizophrenia;
LIHC	cis	rs7487075	0.930	rs4076248	chr12:46833605	C/T	cg22049899	chr12:47219821	SLC38A4	0.34	5.99	0.31	5.44e-9	Itch intensity from mosquito bite;
LIHC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.84	-9.3	-0.45	1.71e-18	Vitiligo;
LIHC	cis	rs11628318	0.515	rs8009257	chr14:103155594	A/G	cg12046867	chr14:103022105	NA	0.4	6.04	0.31	4.06e-9	Platelet count;
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.44e-28	Height;
LIHC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	6.74	0.34	6.68e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg14440974	chr22:39074834	NA	-0.36	-6.04	-0.31	4.07e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-6.11	-0.31	2.69e-9	Colorectal cancer;
LIHC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.48	7.56	0.38	3.66e-13	Methadone dose in opioid dependence;
LIHC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.97	19.09	0.72	8.38e-56	Intelligence (multi-trait analysis);
LIHC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.7	10.55	0.5	1e-22	Response to diuretic therapy;
LIHC	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.53	-7.44	-0.37	8.12e-13	Obesity-related traits;
LIHC	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	6.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	7.01	0.35	1.31e-11	Blood protein levels;
LIHC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.57	-9.7	-0.46	8.38e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg09222892	chr1:25734099	RHCE	0.48	9.06	0.44	1.02e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.06	-0.4	1.25e-14	Migraine;
LIHC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg06565975	chr8:143823917	SLURP1	-0.41	-7.72	-0.39	1.27e-13	Urinary tract infection frequency;
LIHC	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.58	-8.82	-0.43	5.82e-17	White matter hyperintensity burden;
LIHC	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.32	-0.37	1.79e-12	QT interval;
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.02	-0.35	1.22e-11	Testicular germ cell tumor;
LIHC	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.56	-8.57	-0.42	3.68e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.57	10.37	0.49	4.33e-22	Diastolic blood pressure;
LIHC	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.69	-11.8	-0.54	3.34e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs304172	0.793	rs304170	chr3:62780639	A/G	cg19950079	chr6:79788502	PHIP	0.87	6.25	0.32	1.25e-9	IgG glycosylation;
LIHC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg02290350	chr8:58132656	NA	0.41	8.72	0.43	1.25e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11822910	0.724	rs60961847	chr11:57184224	G/A	cg00522883	chr11:57194120	SLC43A3	0.72	8.48	0.42	6.95e-16	Platelet distribution width;
LIHC	cis	rs1355223	0.902	rs10501134	chr11:34749137	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.46	-0.33	3.61e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.38	-6.06	-0.31	3.65e-9	Menarche (age at onset);
LIHC	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.78e-10	Menarche (age at onset);
LIHC	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.3	5.73	0.3	2.19e-8	Asthma;
LIHC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.23	18.11	0.7	7.3e-52	Type 1 diabetes nephropathy;
LIHC	cis	rs1789	0.903	rs4616746	chr4:15673098	A/G	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.86	-0.3	1.07e-8	Blood protein levels;
LIHC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.63	9.84	0.47	2.82e-20	Corneal astigmatism;
LIHC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.33	6.29	0.32	9.9e-10	Body mass index;
LIHC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	8.24	0.41	3.62e-15	Platelet count;
LIHC	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.56	-6.5	-0.33	2.87e-10	Metabolite levels;
LIHC	cis	rs400736	0.729	rs1546846	chr1:8004259	C/T	cg25007680	chr1:8021821	PARK7	-0.46	-7.29	-0.37	2.13e-12	Response to antidepressants and depression;
LIHC	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.32	-6.11	-0.31	2.71e-9	Systemic lupus erythematosus;
LIHC	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.53	0.33	2.33e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.93	-0.31	7.58e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.06	0.4	1.29e-14	Motion sickness;
LIHC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg02297831	chr4:17616191	MED28	0.42	6.65	0.34	1.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2073300	1.000	rs6114139	chr20:23458390	T/G	cg12062639	chr20:23401060	NAPB	0.78	9.87	0.47	2.16e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.77	-0.43	8.77e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-9.43	-0.45	6.57e-19	Parkinson's disease;
LIHC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.59	7.44	0.37	8.05e-13	Post bronchodilator FEV1;
LIHC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.75	11.44	0.53	6.88e-26	Corneal astigmatism;
LIHC	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	22.42	0.77	3.87e-69	Colorectal cancer;
LIHC	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg20991723	chr1:152506922	NA	0.59	10.46	0.49	2.16e-22	Hair morphology;
LIHC	cis	rs1775715	1.000	rs1775715	chr10:32309005	A/G	cg14930904	chr10:32216787	ARHGAP12	-0.41	-7.39	-0.37	1.13e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg10756647	chr7:56101905	PSPH	1.06	13.26	0.58	1.11e-32	Diabetic kidney disease;
LIHC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-13.49	-0.59	1.53e-33	Chronic sinus infection;
LIHC	cis	rs6066825	0.644	rs6019393	chr20:47334435	G/C	cg18078177	chr20:47281410	PREX1	0.41	6.67	0.34	1.05e-10	Colorectal cancer;
LIHC	cis	rs539514	0.627	rs9530463	chr13:76293772	C/T	cg04757411	chr13:76259545	LMO7	-0.44	-7.42	-0.37	9.61e-13	Type 1 diabetes;
LIHC	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24705708	chr2:74329833	TET3	0.5	6.22	0.32	1.47e-9	Lung function (FEV1);
LIHC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.35e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.33	0.37	1.64e-12	Corneal astigmatism;
LIHC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.47	7.39	0.37	1.17e-12	Longevity;
LIHC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.66	-11.04	-0.51	1.86e-24	Bipolar disorder;
LIHC	trans	rs2830585	0.700	rs73187830	chr21:28369613	G/A	cg00844328	chr13:33002010	N4BP2L1	0.5	6.05	0.31	3.88e-9	Blood protein levels;
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.69	9.94	0.47	1.24e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg24209194	chr3:40518798	ZNF619	0.46	6.86	0.35	3.32e-11	Renal cell carcinoma;
LIHC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.33	6.0	0.31	5.06e-9	Aortic root size;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.54e-28	Height;
LIHC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg11937346	chr2:201936362	NDUFB3;FAM126B	0.33	6.15	0.32	2.11e-9	Calcium levels;
LIHC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg16736954	chr20:23401023	NAPB	0.7	8.18	0.4	5.66e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg21003380	chr1:156261207	TMEM79	0.38	6.11	0.31	2.72e-9	Tonsillectomy;
LIHC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	5.72	0.3	2.38e-8	Resting heart rate;
LIHC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.76	13.15	0.58	2.89e-32	Mean platelet volume;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg05970768	chr5:171682616	UBTD2	0.38	6.05	0.31	3.88e-9	Alopecia areata;
LIHC	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	19.89	0.73	4.77e-59	Colorectal cancer;
LIHC	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.48	-10.3	-0.49	7.81e-22	White blood cell count (basophil);
LIHC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg01320579	chr17:75405842	SEPT9	0.52	7.44	0.37	8.37e-13	Airflow obstruction;
LIHC	cis	rs36051895	0.623	rs10283473	chr9:5244708	C/A	cg02405213	chr9:5042618	JAK2	-0.63	-10.06	-0.48	5.15e-21	Pediatric autoimmune diseases;
LIHC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.85	-0.43	4.64e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg15123519	chr2:136567270	LCT	0.34	5.83	0.3	1.29e-8	Corneal structure;
LIHC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg19680672	chr10:131412579	MGMT	-0.45	-7.07	-0.36	8.6e-12	Response to temozolomide;
LIHC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23485639	chr6:28045615	ZNF165	0.43	5.75	0.3	1.93e-8	Depression;
LIHC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.63	10.88	0.51	6.85e-24	Longevity;Endometriosis;
LIHC	cis	rs10426930	1.000	rs10426930	chr19:5038917	G/A	cg18473234	chr19:5097819	KDM4B	0.52	6.44	0.33	4.12e-10	Monocyte percentage of white cells;
LIHC	cis	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg07636037	chr3:49044803	WDR6	-0.53	-6.39	-0.33	5.39e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.05	19.8	0.73	1.11e-58	Multiple system atrophy;
LIHC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.77	-11.86	-0.54	2.01e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg00334542	chr7:100209784	MOSPD3	-0.74	-7.8	-0.39	7.63e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs4596713	0.507	rs2275428	chr9:71792582	A/T	cg16512924	chr15:28394682	HERC2	0.38	6.17	0.32	1.97e-9	Headache;
LIHC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.44	-7.38	-0.37	1.19e-12	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg12798992	chr6:167411361	FGFR1OP	0.6	9.97	0.47	1.01e-20	Crohn's disease;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg20102877	chr2:27665638	KRTCAP3	-0.43	-6.03	-0.31	4.32e-9	Total body bone mineral density;
LIHC	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.42	8.16	0.4	6.39e-15	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.42	0.41	1.09e-15	Schizophrenia;
LIHC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.47	8.45	0.42	8.36e-16	IgG glycosylation;
LIHC	cis	rs2292096	1.000	rs2275194	chr1:200821924	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.44	-5.97	-0.31	5.88e-9	Epilepsy;
LIHC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg00321850	chr1:175162397	KIAA0040	-0.38	-5.86	-0.3	1.08e-8	Alcohol dependence;
LIHC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.76	0.47	5.24e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg01557791	chr16:72042693	DHODH	-0.4	-6.71	-0.34	7.93e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.44	-7.03	-0.36	1.11e-11	Multiple sclerosis;
LIHC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.0	0.31	5.05e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.8	0.43	7.08e-17	Platelet count;
LIHC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.64	11.67	0.53	1.06e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.64	-10.46	-0.49	2.12e-22	Bipolar disorder;
LIHC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.06e-26	Chronic sinus infection;
LIHC	cis	rs1823913	0.599	rs13001899	chr2:192150168	C/T	cg12404831	chr2:192114017	MYO1B	0.28	5.72	0.3	2.39e-8	Obesity-related traits;
LIHC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.0	-0.35	1.39e-11	Vitiligo;
LIHC	cis	rs903552	0.736	rs11858491	chr15:102007456	C/T	cg00659931	chr15:102010125	PCSK6	0.5	6.97	0.35	1.63e-11	Diabetic kidney disease;
LIHC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21467203	chr3:49911342	NA	-0.41	-7.07	-0.36	9e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg08668510	chr10:1095578	IDI1	0.71	7.12	0.36	6.24e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-6.42	-0.33	4.49e-10	Dental caries;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21887597	chr15:83419354	NA	0.44	6.37	0.33	6.09e-10	Pancreatic cancer;
LIHC	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg07451762	chr16:28383216	NA	0.33	6.74	0.34	6.7e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.92	-16.4	-0.66	5.47e-45	Colorectal cancer;
LIHC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg04155231	chr12:9217510	LOC144571	0.32	6.11	0.31	2.75e-9	Sjögren's syndrome;
LIHC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-6.0	-0.31	5.02e-9	Cognitive function;
LIHC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.5	8.34	0.41	1.82e-15	Longevity;Endometriosis;
LIHC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.99	-0.4	2.05e-14	Monocyte percentage of white cells;
LIHC	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	0.55	8.56	0.42	3.82e-16	Atopic dermatitis;
LIHC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.89	-0.39	4.18e-14	Monocyte percentage of white cells;
LIHC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg17830980	chr10:43048298	ZNF37B	0.46	9.18	0.44	4.31e-18	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.68	-9.91	-0.47	1.68e-20	Mosquito bite size;
LIHC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.61	-6.6	-0.34	1.58e-10	Vitiligo;
LIHC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg05590025	chr7:65112418	INTS4L2	-0.66	-7.2	-0.36	3.94e-12	Diabetic kidney disease;
LIHC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.62	11.86	0.54	2e-27	Bone mineral density;
LIHC	cis	rs4407350	0.837	rs4823328	chr22:44908999	C/T	cg26276947	chr22:44892394	LDOC1L	0.34	6.56	0.33	1.99e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.3	-0.68	1.29e-48	Gut microbiome composition (summer);
LIHC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.64	7.22	0.36	3.36e-12	Alzheimer's disease;
LIHC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.08	25.4	0.81	1.05e-80	IgG glycosylation;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20570016	chr1:156261298	TMEM79	0.37	6.01	0.31	4.75e-9	Tonsillectomy;
LIHC	cis	rs2412488	0.888	rs6554104	chr4:54276662	A/T	cg22241045	chr4:54363911	LNX1	-0.41	-6.71	-0.34	8.15e-11	DNA methylation (variation);
LIHC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.74	-9.76	-0.47	5.22e-20	Schizophrenia;
LIHC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-8.47	-0.42	7.14e-16	Gut microbiome composition (summer);
LIHC	cis	rs12997796	0.556	rs12477737	chr2:86930966	G/T	cg25203885	chr2:87302643	LOC285074	-0.63	-5.99	-0.31	5.24e-9	Schizophrenia;
LIHC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg07636037	chr3:49044803	WDR6	-0.87	-7.21	-0.36	3.61e-12	Cognitive function;
LIHC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg25039879	chr17:56429692	SUPT4H1	0.74	8.28	0.41	2.76e-15	Cognitive test performance;
LIHC	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26714650	chr12:56694279	CS	-1.35	-12.74	-0.57	1.09e-30	Psoriasis vulgaris;
LIHC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.54	-10.98	-0.51	3.13e-24	Tonsillectomy;
LIHC	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.42	-6.29	-0.32	9.43e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg27094323	chr7:1216898	NA	-0.4	-5.78	-0.3	1.7e-8	Longevity;Endometriosis;
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg02782426	chr3:40428986	ENTPD3	0.33	6.0	0.31	4.91e-9	Renal cell carcinoma;
LIHC	cis	rs3015497	0.789	rs2934688	chr14:51112360	G/A	cg09863266	chr14:51125203	SAV1	-0.44	-7.06	-0.36	9.54e-12	Mean platelet volume;
LIHC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.02	-0.35	1.22e-11	Diabetic kidney disease;
LIHC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.99	-0.35	1.4e-11	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.38	-6.13	-0.31	2.49e-9	Menopause (age at onset);
LIHC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.25	-15.27	-0.64	1.6e-40	Psoriasis vulgaris;
LIHC	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg02811702	chr13:24901961	NA	0.24	5.99	0.31	5.26e-9	Obesity-related traits;
LIHC	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.25	19.61	0.73	6.4e-58	Corneal structure;
LIHC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2257205	0.667	rs8076021	chr17:56694646	T/G	cg12560992	chr17:57184187	TRIM37	0.71	7.86	0.39	5.22e-14	Pancreatic cancer;
LIHC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg18357526	chr6:26021779	HIST1H4A	0.42	6.27	0.32	1.07e-9	Height;
LIHC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-7.79	-0.39	8.2e-14	Electroencephalogram traits;
LIHC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.71	11.37	0.52	1.21e-25	Oral cavity cancer;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.97	0.6	2.11e-35	Coffee consumption (cups per day);
LIHC	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.49	7.15	0.36	5.38e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.58	8.87	0.43	4.06e-17	Uric acid clearance;
LIHC	cis	rs8053891	0.664	rs34972708	chr16:72008225	A/G	cg01557791	chr16:72042693	DHODH	-0.51	-7.44	-0.37	8.46e-13	Coronary artery disease;
LIHC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.76	0.3	1.92e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.31	-5.71	-0.3	2.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.96	0.57	1.63e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.47	7.63	0.38	2.32e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg13395646	chr4:1353034	KIAA1530	-0.38	-5.73	-0.3	2.18e-8	Longevity;
LIHC	cis	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg08564027	chr20:61660810	NA	0.37	6.71	0.34	8.08e-11	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.66	-10.51	-0.49	1.41e-22	Rheumatoid arthritis;
LIHC	cis	rs400736	0.729	rs2493216	chr1:8008366	C/A	cg25007680	chr1:8021821	PARK7	-0.47	-7.34	-0.37	1.53e-12	Response to antidepressants and depression;
LIHC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.87	14.3	0.61	1.07e-36	Multiple sclerosis;
LIHC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.68	0.38	1.65e-13	Corneal astigmatism;
LIHC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	6.46	0.33	3.51e-10	Obesity-related traits;
LIHC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.73	-7.97	-0.4	2.4e-14	Vitiligo;
LIHC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.5	6.57	0.33	1.88e-10	Major depressive disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09809285	chr5:188949	PLEKHG4B	0.45	6.04	0.31	3.92e-9	Lung function (FEV1/FVC);
LIHC	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.33	6.94	0.35	1.97e-11	Ulcerative colitis;
LIHC	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.04	0.36	1.04e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.46	-6.56	-0.33	1.94e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03228054	chr9:19049082	RRAGA	0.44	6.59	0.34	1.62e-10	Cognitive function;
LIHC	cis	rs6977660	1.000	rs13231036	chr7:19806141	G/A	cg07541023	chr7:19748670	TWISTNB	0.39	6.16	0.32	2.01e-9	Thyroid stimulating hormone;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09872104	chr7:134855509	C7orf49	-0.41	-6.17	-0.32	1.89e-9	Immature fraction of reticulocytes;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.63	9.18	0.44	4.2e-18	Menarche (age at onset);
LIHC	cis	rs4141404	0.701	rs5753483	chr22:31549581	A/G	cg07713946	chr22:31675144	LIMK2	-0.34	-5.79	-0.3	1.58e-8	Paclitaxel-induced neuropathy;
LIHC	cis	rs1789	0.786	rs6414768	chr4:15695363	A/G	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.77	-0.3	1.75e-8	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.16e-21	Chronic sinus infection;
LIHC	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	5.95	0.31	6.55e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.53	-9.44	-0.45	6.06e-19	Coronary artery disease;
LIHC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.79	-0.3	1.61e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.4	-6.43	-0.33	4.41e-10	Migraine;
LIHC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.07	-0.4	1.2e-14	Monocyte percentage of white cells;
LIHC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.55	8.59	0.42	3.08e-16	Longevity;Endometriosis;
LIHC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	0.97	10.43	0.49	2.59e-22	Vitiligo;
LIHC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs546131	0.642	rs10836315	chr11:34853346	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.53	6.45	0.33	3.83e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg20933634	chr6:27740509	NA	0.46	6.16	0.32	2.07e-9	Parkinson's disease;
LIHC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02886208	chr11:14281011	SPON1	0.58	8.52	0.42	5.24e-16	Mitochondrial DNA levels;
LIHC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.46	-6.95	-0.35	1.9e-11	Height;
LIHC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg19680672	chr10:131412579	MGMT	-0.45	-6.86	-0.35	3.33e-11	Response to temozolomide;
LIHC	cis	rs11673344	0.704	rs551717	chr19:37427879	A/G	cg27390819	chr19:37464633	NA	-0.5	-6.01	-0.31	4.88e-9	Obesity-related traits;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg00280220	chr17:61926910	NA	0.39	6.16	0.32	2.01e-9	Prudent dietary pattern;
LIHC	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.46	-6.66	-0.34	1.07e-10	Mortality in heart failure;
LIHC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg15691649	chr6:25882328	NA	-0.56	-7.12	-0.36	6.42e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs8084351	0.599	rs4940242	chr18:50687196	G/A	cg24270629	chr18:50823537	DCC	-0.44	-6.57	-0.33	1.82e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.9	-0.39	3.79e-14	Vitamin D levels;
LIHC	cis	rs1419980	0.730	rs57677315	chr12:7746232	C/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs2279817	0.863	rs12753636	chr1:18013602	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-8.38	-0.41	1.42e-15	Neuroticism;
LIHC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.55	0.42	4.29e-16	Lung cancer in ever smokers;
LIHC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.87	-0.47	2.26e-20	Tonsillectomy;
LIHC	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.68	0.46	9.74e-20	Morning vs. evening chronotype;
LIHC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.23	-6.22	-0.32	1.46e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg03645007	chr3:50255295	SLC38A3	0.45	6.75	0.34	6.35e-11	Schizophrenia;
LIHC	cis	rs4865169	0.560	rs1277311	chr4:57902761	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.38	-5.84	-0.3	1.23e-8	Breast cancer;
LIHC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.59	7.14	0.36	5.69e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26148815	chr2:113379707	NA	0.37	6.13	0.31	2.46e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.53	6.49	0.33	3.04e-10	QRS duration;
LIHC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg16070123	chr10:51489643	NA	0.38	6.03	0.31	4.15e-9	Prostate-specific antigen levels;
LIHC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.86	-17.21	-0.68	2.94e-48	Height;
LIHC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.62	10.24	0.48	1.25e-21	Platelet count;
LIHC	trans	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg25214090	chr10:38739885	LOC399744	-0.39	-6.37	-0.33	6.04e-10	Diastolic blood pressure;
LIHC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg00142150	chr22:38071001	LGALS1	0.7	11.49	0.53	4.61e-26	Fat distribution (HIV);
LIHC	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.4	5.88	0.3	9.88e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.9	-0.35	2.58e-11	Schizophrenia;
LIHC	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg24296786	chr1:45957014	TESK2	0.5	7.18	0.36	4.44e-12	High light scatter reticulocyte count;
LIHC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.58	-8.75	-0.43	9.77e-17	Height;
LIHC	cis	rs6722750	0.846	rs34923691	chr2:64395183	C/T	cg22352474	chr2:64371530	PELI1	0.46	6.67	0.34	1.04e-10	Neuroticism;
LIHC	cis	rs10792665	0.545	rs7925212	chr11:82561984	G/A	cg24227371	chr11:82718527	RAB30	-0.27	-6.45	-0.33	3.83e-10	Obesity-related traits;
LIHC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	9.3e-10	Aortic root size;
LIHC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	0.93	11.93	0.54	1.1e-27	Economic and political preferences (immigration/crime);
LIHC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.87	-0.54	1.91e-27	Response to antipsychotic treatment;
LIHC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-6.67	-0.34	1.04e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1914816	0.941	rs2460151	chr15:76487507	G/C	cg03037974	chr15:76606532	NA	-0.6	-6.17	-0.32	1.88e-9	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg06238570	chr21:40685208	BRWD1	0.56	6.79	0.34	4.99e-11	Cognitive function;
LIHC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.64	-0.34	1.21e-10	Blood metabolite levels;
LIHC	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.43	8.38	0.41	1.38e-15	Testicular germ cell tumor;
LIHC	cis	rs4407350	1.000	rs12169248	chr22:44920999	G/A	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.11	-0.31	2.64e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.95	15.28	0.64	1.47e-40	Vitamin D levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18145393	chr4:520203	PIGG	0.42	6.18	0.32	1.85e-9	Longevity;
LIHC	trans	rs7395555	1.000	rs34116051	chr11:80061735	G/A	cg06295071	chr21:33766731	URB1	-0.43	-6.29	-0.32	9.51e-10	Response to antipsychotic treatment;
LIHC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.72	-9.56	-0.46	2.37e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs2257205	0.667	rs16943186	chr17:56801848	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.67	-0.34	1e-10	Pancreatic cancer;
LIHC	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.42	-6.02	-0.31	4.4e-9	Blood protein levels;
LIHC	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.38	6.19	0.32	1.73e-9	Mean corpuscular volume;
LIHC	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	11.24	0.52	3.74e-25	Myopia (pathological);
LIHC	cis	rs249954	0.512	rs703767	chr16:23661639	G/C	cg09867953	chr16:23706666	ERN2	0.37	6.38	0.33	5.74e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1144333	0.579	rs35591768	chr1:76308257	C/T	cg22875332	chr1:76189707	ACADM	0.38	6.34	0.32	7.3e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.53	0.42	4.71e-16	Menarche (age at onset);
LIHC	cis	rs6449957	0.639	rs40419	chr5:67515602	T/C	cg23036683	chr5:67512108	NA	0.52	7.67	0.38	1.82e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.59	-11.92	-0.54	1.29e-27	Coronary artery disease;
LIHC	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.18	-0.32	1.86e-9	Coronary artery disease;
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.51	-0.38	5.22e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.51	0.46	3.53e-19	Morning vs. evening chronotype;
LIHC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.57	-9.5	-0.46	3.65e-19	Cognitive function;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg14671364	chr1:107599128	PRMT6	-0.51	-7.53	-0.38	4.59e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs249954	0.512	rs26767	chr16:23698457	A/C	cg05131483	chr16:23706242	ERN2	0.37	6.15	0.32	2.16e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.52	-8.09	-0.4	1.04e-14	Coronary artery disease;
LIHC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs6088813	1.000	rs6141549	chr20:33974051	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-5.83	-0.3	1.25e-8	Height;
LIHC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.58	-0.5	8.06e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs425535	0.619	rs1435521	chr4:74807928	A/G	cg02530824	chr4:74847766	PF4	-0.38	-5.88	-0.3	9.94e-9	Blood protein levels;
LIHC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.75	11.9	0.54	1.51e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	11.46	0.53	5.76e-26	Platelet count;
LIHC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.54	-7.99	-0.4	2.05e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.04	0.4	1.46e-14	Height;
LIHC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.67	0.67	4.38e-46	Smoking behavior;
LIHC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.68	9.37	0.45	9.82e-19	Mean platelet volume;
LIHC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.27	0.45	2.09e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.53	-0.38	4.51e-13	Response to antipsychotic treatment;
LIHC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.58	8.94	0.44	2.52e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01200585	chr1:228362443	C1orf69	-0.4	-5.85	-0.3	1.16e-8	Diastolic blood pressure;
LIHC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg24296786	chr1:45957014	TESK2	0.4	5.73	0.3	2.23e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.68	-9.17	-0.44	4.4e-18	Sudden cardiac arrest;
LIHC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.73	0.34	7.2e-11	Bipolar disorder;
LIHC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.52	8.25	0.41	3.51e-15	Platelet count;
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg10096929	chr1:156261403	TMEM79	0.41	6.83	0.35	3.92e-11	Tonsillectomy;
LIHC	cis	rs332507	0.830	rs11715641	chr3:124423675	G/A	cg05980111	chr3:124395277	KALRN	0.42	6.44	0.33	3.95e-10	Plateletcrit;
LIHC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.77	-0.34	5.52e-11	Mean corpuscular volume;
LIHC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17708016	chr12:54321992	NA	0.4	7.1	0.36	7.47e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	trans	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.46	-7.28	-0.37	2.33e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-6.93	-0.35	2.1e-11	Reticulocyte count;
LIHC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.44	-7.93	-0.39	3.13e-14	Prudent dietary pattern;
LIHC	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	0.97	22.67	0.77	4.25e-70	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09835421	chr16:68378352	PRMT7	-0.48	-5.82	-0.3	1.36e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg14558114	chr2:88469736	THNSL2	0.59	5.79	0.3	1.64e-8	Plasma clusterin levels;
LIHC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.58	5.74	0.3	2.04e-8	Neutrophil percentage of white cells;
LIHC	cis	rs858239	0.601	rs6461702	chr7:23249273	C/G	cg18081818	chr7:23246105	NA	-0.41	-5.97	-0.31	5.96e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg04317338	chr11:64019027	PLCB3	0.49	6.71	0.34	8.3e-11	Platelet count;
LIHC	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg04865290	chr3:52927548	TMEM110	-0.44	-6.51	-0.33	2.61e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg12062639	chr20:23401060	NAPB	0.83	9.78	0.47	4.3e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg10360323	chr17:41437877	NA	0.39	5.79	0.3	1.55e-8	Menopause (age at onset);
LIHC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg05941027	chr17:61774174	LIMD2	0.3	5.97	0.31	5.91e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.67	-0.5	3.86e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.5	-8.17	-0.4	5.97e-15	Cognitive function;
LIHC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02359409	chr6:42947317	PEX6	-0.48	-6.79	-0.34	4.85e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.13	-0.58	3.68e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9473924	0.505	rs7746581	chr6:50853479	T/C	cg14470998	chr6:50812995	TFAP2B	0.95	10.98	0.51	3.11e-24	Body mass index;
LIHC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.51	6.59	0.34	1.63e-10	Orofacial clefts;
LIHC	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	6.13	0.31	2.48e-9	Response to antipsychotic treatment;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08137080	chr1:16482430	EPHA2	-0.45	-6.04	-0.31	4.13e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	0.94	13.54	0.59	1.01e-33	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.35	5.76	0.3	1.89e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.61	11.63	0.53	1.39e-26	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs918629	0.761	rs57243277	chr5:95288165	G/A	cg10483112	chr5:95245456	ELL2	-0.37	-6.22	-0.32	1.42e-9	IgG glycosylation;
LIHC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg23806715	chr17:73775811	H3F3B	0.53	7.26	0.37	2.62e-12	Psoriasis;
LIHC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg01081584	chr15:40268610	EIF2AK4	-0.61	-8.35	-0.41	1.68e-15	Response to haloperidol in psychosis;
LIHC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.06	8.42	0.41	1.06e-15	Body mass index;
LIHC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.95	-0.31	6.7e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.43	7.15	0.36	5.39e-12	Testicular germ cell tumor;
LIHC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.57	9.74	0.47	5.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.84	-15.97	-0.65	2.85e-43	Coronary artery disease;
LIHC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg10932868	chr11:921992	NA	0.4	7.69	0.38	1.55e-13	Alzheimer's disease (late onset);
LIHC	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.72	-16.2	-0.66	3.33e-44	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs7523273	0.568	rs61821293	chr1:208007277	T/G	cg22525895	chr1:207977042	MIR29B2	-0.58	-6.48	-0.33	3.23e-10	Schizophrenia;
LIHC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.87	14.96	0.63	2.78e-39	Parkinson's disease;
LIHC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.74	13.0	0.58	1.15e-31	Platelet count;
LIHC	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.93	-15.76	-0.65	1.87e-42	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.7	7.21	0.36	3.69e-12	Alzheimer's disease;
LIHC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg13628971	chr7:2884303	GNA12	0.42	6.57	0.33	1.93e-10	Height;
LIHC	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg14930904	chr10:32216787	ARHGAP12	0.33	5.82	0.3	1.39e-8	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.35	-0.32	6.8e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.57	0.46	2.2e-19	Electroencephalogram traits;
LIHC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.37	-7.23	-0.36	3.14e-12	Multiple system atrophy;
LIHC	cis	rs600806	0.888	rs638542	chr1:109845252	G/A	cg23091122	chr1:110024289	SYPL2	-0.46	-5.94	-0.31	7.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11683229	0.704	rs35589581	chr2:63107944	T/C	cg17519650	chr2:63277830	OTX1	-0.52	-5.73	-0.3	2.15e-8	Protein quantitative trait loci;
LIHC	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.83	9.53	0.46	3.06e-19	Mitochondrial DNA levels;
LIHC	cis	rs12022452	0.591	rs11208356	chr1:41006931	A/G	cg25568243	chr1:40974465	DEM1	0.45	5.89	0.3	9.26e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.25	-0.45	2.45e-18	Capecitabine sensitivity;
LIHC	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.51	7.38	0.37	1.19e-12	Schizophrenia;
LIHC	cis	rs6750047	0.932	rs11124631	chr2:38274908	A/G	cg07380506	chr2:38303506	CYP1B1	-0.53	-6.56	-0.33	2e-10	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.93	-0.35	2.15e-11	Total body bone mineral density;
LIHC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.72	-11.76	-0.54	4.98e-27	Body mass index;
LIHC	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.27	6.3	0.32	9.42e-10	Heart rate;
LIHC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	10.07	0.48	4.63e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21448741	chr8:58168803	NA	0.32	5.99	0.31	5.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.55	-9.95	-0.47	1.17e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg08528486	chr13:113648767	MCF2L	-0.39	-6.36	-0.33	6.59e-10	Systolic blood pressure;
LIHC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.94	17.9	0.7	5.08e-51	Menopause (age at onset);
LIHC	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.56	0.38	3.62e-13	Mean platelet volume;
LIHC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.33	-0.32	7.67e-10	Metabolite levels;
LIHC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.53	-7.68	-0.38	1.64e-13	Prostate cancer;
LIHC	cis	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg01864836	chr14:55583639	NA	0.36	6.07	0.31	3.46e-9	Protein biomarker;
LIHC	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.57	-8.21	-0.41	4.51e-15	Body mass index;
LIHC	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.35	-0.32	6.9e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9649465	1.000	rs3958047	chr7:123327936	G/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.13	-0.4	8.02e-15	Migraine;
LIHC	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.67	8.4	0.41	1.2e-15	Corneal astigmatism;
LIHC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.4	5.79	0.3	1.64e-8	Aortic root size;
LIHC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.51	7.18	0.36	4.41e-12	Coronary artery disease;
LIHC	cis	rs10744422	0.800	rs2649902	chr12:123243687	G/A	cg07706471	chr12:123319906	HIP1R	-0.57	-7.36	-0.37	1.36e-12	Schizophrenia;
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.74	-0.3	2.07e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs7267979	0.565	rs13040726	chr20:25559881	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.44	-6.02	-0.31	4.47e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg26939375	chr7:64535504	NA	0.42	6.77	0.34	5.53e-11	Aortic root size;
LIHC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.39	6.07	0.31	3.41e-9	Multiple sclerosis;
LIHC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.69	-6.56	-0.33	2.03e-10	Schizophrenia;
LIHC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22442454	chr1:209979470	IRF6	0.38	5.8	0.3	1.49e-8	Cleft lip with or without cleft palate;
LIHC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.54e-19	Morning vs. evening chronotype;
LIHC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.58	-8.56	-0.42	3.97e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg12373951	chr3:133503437	NA	-0.51	-7.64	-0.38	2.24e-13	Iron status biomarkers (transferrin levels);
LIHC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.79	-12.08	-0.55	3.15e-28	Mosquito bite size;
LIHC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg25364880	chr3:44379878	C3orf23	0.58	7.97	0.4	2.36e-14	Depressive symptoms;
LIHC	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	10.83	0.51	1.07e-23	Post bronchodilator FEV1;
LIHC	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	13.8	0.6	9.39e-35	Coffee consumption (cups per day);
LIHC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11212260	0.512	rs7121072	chr11:107174439	C/A	cg25435332	chr11:107328525	CWF19L2	0.74	6.86	0.35	3.29e-11	IgG glycosylation;
LIHC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-0.81	-11.29	-0.52	2.55e-25	Urate levels;
LIHC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-9.3	-0.45	1.68e-18	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.53	7.55	0.38	3.99e-13	Chronic sinus infection;
LIHC	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg09592903	chr2:55203963	RTN4	0.69	12.84	0.57	4.61e-31	Mean platelet volume;
LIHC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg07959070	chr22:50026188	C22orf34	-0.33	-8.37	-0.41	1.53e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.78	-0.39	8.4e-14	QT interval;
LIHC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.53	-7.98	-0.4	2.31e-14	Huntington's disease progression;
LIHC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.16e-13	Vitiligo;
LIHC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg17980119	chr2:219472607	PLCD4	0.35	6.02	0.31	4.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.79	13.15	0.58	3.06e-32	Breast cancer;
LIHC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-6.11	-0.31	2.68e-9	Dental caries;
LIHC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg11212589	chr17:38028394	ZPBP2	0.35	7.08	0.36	8.3e-12	Self-reported allergy;
LIHC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.54	-10.29	-0.49	8.35e-22	Mean corpuscular volume;
LIHC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.66	9.38	0.45	9.74e-19	Menopause (age at onset);
LIHC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.64	0.56	2.6e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.56	10.86	0.51	8.12e-24	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg12463550	chr7:65579703	CRCP	-0.64	-6.7	-0.34	8.82e-11	Diabetic kidney disease;
LIHC	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.94	-10.36	-0.49	4.72e-22	Response to radiotherapy in cancer (late toxicity);
LIHC	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg27523141	chr10:43048294	ZNF37B	-0.38	-6.5	-0.33	2.83e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg17980119	chr2:219472607	PLCD4	0.33	5.75	0.3	1.93e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06420487	chr17:61919686	SMARCD2	0.46	6.3	0.32	9.34e-10	Height;
LIHC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.87	10.02	0.48	6.8e-21	Eosinophil percentage of granulocytes;
LIHC	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.74	11.57	0.53	2.4e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.9	19.5	0.73	1.79e-57	Blood protein levels;
LIHC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.14	-0.48	2.62e-21	Longevity;Endometriosis;
LIHC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg15848620	chr12:58087721	OS9	-0.54	-7.29	-0.37	2.1e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7432375	0.901	rs4038587	chr3:136381368	A/C	cg21827317	chr3:136751795	NA	-0.44	-5.82	-0.3	1.37e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.68	-10.2	-0.48	1.66e-21	Mosquito bite size;
LIHC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1669338	0.588	rs62228634	chr3:3184985	A/G	cg16797762	chr3:3221439	CRBN	-0.81	-7.35	-0.37	1.49e-12	White matter integrity;
LIHC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	7.41	0.37	1.01e-12	Lymphocyte counts;
LIHC	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg07541023	chr7:19748670	TWISTNB	0.44	6.47	0.33	3.4e-10	Thyroid stimulating hormone;
LIHC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.41	5.71	0.3	2.46e-8	Iron status biomarkers;
LIHC	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.56	-8.79	-0.43	7.24e-17	Corneal astigmatism;
LIHC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.65	7.35	0.37	1.45e-12	Neutrophil percentage of white cells;
LIHC	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg16797656	chr11:68205561	LRP5	0.48	6.07	0.31	3.36e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.98	10.72	0.5	2.58e-23	Triglycerides;
LIHC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.78	-0.34	5.22e-11	Bipolar disorder;
LIHC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.46	0.56	1.21e-29	Cognitive test performance;
LIHC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.11	0.51	1.12e-24	Personality dimensions;
LIHC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.5	-6.56	-0.33	2.01e-10	Breast cancer;
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.41	7.79	0.39	8.14e-14	Testicular germ cell tumor;
LIHC	cis	rs2444240	0.935	rs4936509	chr11:120041444	C/T	cg04390734	chr11:120039366	NA	0.32	6.17	0.32	1.95e-9	Corneal curvature;
LIHC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	1.02	19.62	0.73	5.89e-58	Breast cancer;
LIHC	cis	rs10838687	0.800	rs7928073	chr11:47361857	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.77	-0.3	1.78e-8	Proinsulin levels;
LIHC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.16	-0.36	5.11e-12	Diabetic kidney disease;
LIHC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.37	-6.72	-0.34	7.54e-11	Aortic root size;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.36	0.33	6.38e-10	Renal cell carcinoma;
LIHC	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	13.99	0.6	1.78e-35	Coffee consumption (cups per day);
LIHC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.49e-11	Height;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-7.01	-0.35	1.26e-11	Bipolar disorder and schizophrenia;
LIHC	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg21051086	chr3:73046214	PPP4R2	0.37	6.09	0.31	3.08e-9	Pancreatic cancer;
LIHC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	10.47	0.49	1.96e-22	Hemoglobin concentration;
LIHC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.84	16.94	0.68	3.62e-47	Height;
LIHC	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.63	9.86	0.47	2.3e-20	Pediatric autoimmune diseases;
LIHC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-8.05	-0.4	1.38e-14	Total body bone mineral density;
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.46	8.12	0.4	8.76e-15	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.52	-5.79	-0.3	1.6e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	1.06	14.86	0.63	6.89e-39	Heart rate;
LIHC	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.59	-9.26	-0.45	2.35e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg20291162	chr17:40259547	DHX58	-0.4	-6.26	-0.32	1.12e-9	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.75	-12.49	-0.56	9.68e-30	Prudent dietary pattern;
LIHC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	7.98	0.4	2.27e-14	Coronary artery disease;
LIHC	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	10.16	0.48	2.37e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-0.96	-9.1	-0.44	7.36e-18	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LIHC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18867708	chr6:26865862	GUSBL1	-0.56	-8.55	-0.42	4.13e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	9.74	0.47	6.02e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs66569888	0.607	rs11687271	chr2:106727456	G/A	cg16099169	chr2:106886729	NA	-0.63	-6.82	-0.35	4.18e-11	Facial morphology (factor 23);
LIHC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.58	-8.47	-0.42	7.36e-16	Glaucoma (primary open-angle);
LIHC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	15.13	0.63	6.04e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg06359132	chr10:99160096	RRP12	-0.4	-6.15	-0.32	2.19e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.46	7.65	0.38	2.08e-13	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.24	-16.0	-0.65	2.11e-43	Diabetic kidney disease;
LIHC	trans	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg24036039	chr1:3397125	ARHGEF16	0.37	6.19	0.32	1.71e-9	Schizophrenia;
LIHC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.55e-73	Height;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg24707616	chr17:16342815	NCRNA00188;SNORD49B;SNORD49A	-0.5	-6.35	-0.32	6.79e-10	Facial morphology (factor 20);
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg09033563	chr22:24373618	LOC391322	-0.43	-5.94	-0.31	6.87e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg07424592	chr7:64974309	NA	0.82	9.52	0.46	3.35e-19	Diabetic kidney disease;
LIHC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.61	10.76	0.5	1.96e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.48	-6.22	-0.32	1.42e-9	Subjective well-being;
LIHC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.9	8.69	0.43	1.54e-16	Eosinophil percentage of granulocytes;
LIHC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.88	13.18	0.58	2.35e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.56	12.13	0.55	2.15e-28	Obesity-related traits;
LIHC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.73	-0.34	7.32e-11	Colorectal cancer;
LIHC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.61	-9.27	-0.45	2.1e-18	Aortic root size;
LIHC	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg05425664	chr17:57184151	TRIM37	-0.47	-5.89	-0.3	9.43e-9	Vitamin D levels;
LIHC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.62	-9.37	-0.45	1.02e-18	Height;
LIHC	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.92	11.74	0.54	5.67e-27	Coronary artery disease;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.15	0.32	2.12e-9	Prudent dietary pattern;
LIHC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.63	7.99	0.4	2.06e-14	Morning vs. evening chronotype;
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.34	5.98	0.31	5.68e-9	Calcium levels;
LIHC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg25894440	chr7:65020034	NA	-0.56	-6.48	-0.33	3.21e-10	Diabetic kidney disease;
LIHC	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4716602	0.596	rs12386634	chr7:156158373	G/A	cg16983916	chr7:156159713	NA	-0.32	-5.87	-0.3	1.03e-8	Anti-saccade response;
LIHC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-15.43	-0.64	3.99e-41	Headache;
LIHC	cis	rs10508774	0.810	rs12244832	chr10:32872120	C/T	cg01819863	chr10:32635814	EPC1	0.61	5.83	0.3	1.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg03934865	chr2:198174659	NA	0.54	8.27	0.41	3.03e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.84	10.51	0.49	1.45e-22	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg12373951	chr3:133503437	NA	-0.49	-6.87	-0.35	2.98e-11	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.05	0.4	1.35e-14	Platelet count;
LIHC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.46	-9.26	-0.45	2.3e-18	Birth weight;
LIHC	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg10845886	chr2:3471009	TTC15	-0.36	-6.35	-0.32	6.82e-10	Neurofibrillary tangles;
LIHC	cis	rs12602486	1.000	rs16940540	chr17:42229702	C/A	cg08193365	chr17:42277699	NA	1.05	7.39	0.37	1.16e-12	Glycated hemoglobin levels;
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg20090690	chr10:134436459	INPP5A	0.44	5.8	0.3	1.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.07	0.51	1.47e-24	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.5	5.98	0.31	5.48e-9	Alzheimer's disease;
LIHC	trans	rs13405020	0.578	rs2198439	chr2:138218082	A/C	cg10008445	chr10:105630969	NA	-0.37	-6.09	-0.31	2.99e-9	Non-small cell lung cancer;
LIHC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg26441486	chr22:50317300	CRELD2	0.37	6.08	0.31	3.19e-9	Schizophrenia;
LIHC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.19	-0.36	4.24e-12	Schizophrenia;
LIHC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.46	6.39	0.33	5.32e-10	Initial pursuit acceleration;
LIHC	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg20887711	chr4:1340912	KIAA1530	-0.47	-7.2	-0.36	3.85e-12	Obesity-related traits;
LIHC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.8	-9.8	-0.47	3.9e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg00564555	chr16:1970112	NA	0.26	5.92	0.3	8.04e-9	Insulin-like growth factors;
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10499694	0.735	rs2044859	chr7:50612562	A/G	cg14593290	chr7:50529359	DDC	0.41	7.06	0.36	9.52e-12	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20977600	chr12:106751964	POLR3B	-0.44	-6.09	-0.31	3.05e-9	Pancreatic cancer;
LIHC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	12.29	0.55	5.46e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	6.58	0.34	1.78e-10	Schizophrenia;
LIHC	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	0.91	6.91	0.35	2.38e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.97	22.6	0.77	7.56e-70	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg23091122	chr1:110024289	SYPL2	-0.46	-6.06	-0.31	3.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.03	0.4	1.63e-14	Menarche (age at onset);
LIHC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	12.68	0.57	1.81e-30	Alzheimer's disease;
LIHC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.56	-16.35	-0.66	8.71e-45	Breast cancer;
LIHC	trans	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg10208301	chr11:6592745	DNHD1	0.49	6.57	0.33	1.89e-10	Coronary artery calcification;
LIHC	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.58	0.5	7.9399999999999994e-23	LDL cholesterol;
LIHC	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg00250761	chr1:31883323	NA	-0.27	-6.13	-0.31	2.46e-9	Alcohol dependence;
LIHC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.43e-23	Personality dimensions;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17200204	chr3:43732323	ABHD5	0.48	6.56	0.33	1.96e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.95	0.31	6.69e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg10820045	chr2:198174542	NA	0.56	8.88	0.43	3.78e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13647721	chr17:30228624	UTP6	0.68	6.85	0.35	3.52e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.97	0.47	1.04e-20	Lymphocyte counts;
LIHC	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg03934865	chr2:198174659	NA	0.51	7.82	0.39	6.55e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-8.3	-0.41	2.36e-15	Body mass index (adult);
LIHC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	1.05	21.05	0.75	1.13e-63	Breast cancer;
LIHC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Total cholesterol levels;
LIHC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.55	0.38	4.11e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.5	-6.71	-0.34	8.03e-11	Facial morphology (factor 19);
LIHC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-5.98	-0.31	5.52e-9	Menarche (age at onset);
LIHC	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg18867708	chr6:26865862	GUSBL1	0.55	8.3	0.41	2.37e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.52	-7.71	-0.38	1.37e-13	Total body bone mineral density;
LIHC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	8.93	0.43	2.62e-17	Platelet count;
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27305525	chr1:154955752	FLAD1	0.34	6.12	0.31	2.52e-9	Metabolic traits;
LIHC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.8	-9.99	-0.48	8.79e-21	Cognitive function;
LIHC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg13319975	chr6:146136371	FBXO30	-0.36	-6.06	-0.31	3.63e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.71	-8.73	-0.43	1.11e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.78	-0.3	1.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	14.0	0.6	1.67e-35	Coffee consumption (cups per day);
LIHC	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.31	0.41	2.32e-15	Corneal astigmatism;
LIHC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.07	-0.36	8.6e-12	Vitiligo;
LIHC	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-0.79	-9.02	-0.44	1.36e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.48	-7.49	-0.38	5.94e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18357526	chr6:26021779	HIST1H4A	0.41	6.14	0.32	2.31e-9	Height;
LIHC	cis	rs4930103	0.564	rs1618613	chr11:1969888	G/A	cg23202291	chr11:1979235	NA	-0.52	-6.63	-0.34	1.29e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.29	6.23	0.32	1.38e-9	Pulmonary function;
LIHC	cis	rs7258015	0.909	rs3176769	chr19:10447034	A/G	cg13981319	chr19:10446556	ICAM3	0.46	7.21	0.36	3.68e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.56	-0.5	9.46e-23	Hemoglobin concentration;
LIHC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg03934865	chr2:198174659	NA	0.54	8.6	0.42	2.86e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	6.53	0.33	2.35e-10	Bipolar disorder;
LIHC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.67	10.88	0.51	7.04e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.36	-6.25	-0.32	1.2e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg22563815	chr15:78856949	CHRNA5	0.35	6.21	0.32	1.5e-9	Sudden cardiac arrest;
LIHC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.87	18.9	0.71	4.62e-55	Height;
LIHC	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.33	-0.32	7.73e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05582585	chr5:150138399	DCTN4	0.42	6.37	0.33	6.27e-10	Calcium levels;
LIHC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.88	0.39	4.45e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.47	-6.34	-0.32	7.39e-10	Body mass index;
LIHC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02985541	chr2:219472218	PLCD4	0.43	7.83	0.39	6.23e-14	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22387939	chr2:71175719	ATP6V1B1	0.44	6.33	0.32	7.57e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg03146154	chr1:46216737	IPP	-0.37	-6.16	-0.32	1.99e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.22	-13.29	-0.58	8.49e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26794364	chr3:9691143	MTMR14	-0.48	-6.23	-0.32	1.36e-9	Hepatitis;
LIHC	cis	rs9871864	0.645	rs9856107	chr3:20353124	C/T	cg00235661	chr3:20228976	SGOL1	-0.33	-6.41	-0.33	4.91e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.39	5.72	0.3	2.28e-8	Monocyte count;
LIHC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.45	6.56	0.33	1.97e-10	Aortic root size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24930797	chr15:66083595	DENND4A	0.42	6.37	0.33	6.12e-10	Cognitive function;
LIHC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.77	11.96	0.54	8.81e-28	Corneal astigmatism;
LIHC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.62	-9.7	-0.46	8.01e-20	Childhood ear infection;
LIHC	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-9.47	-0.46	4.8e-19	Colorectal cancer;
LIHC	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.29	-0.37	2.19e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.34	0.41	1.9e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.32	6.0	0.31	5.14e-9	Body mass index;
LIHC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg24296786	chr1:45957014	TESK2	0.5	7.45	0.37	7.81e-13	Platelet count;
LIHC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	14.58	0.62	9.14e-38	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10190329	chr10:126605450	NA	-0.45	-6.62	-0.34	1.43e-10	Cognitive function;
LIHC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.01	0.48	7.45e-21	Schizophrenia;
LIHC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	7.4	0.37	1.07e-12	Diastolic blood pressure;
LIHC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.59	6.51	0.33	2.63e-10	Vitiligo;
LIHC	cis	rs6066825	0.666	rs6019374	chr20:47303812	A/G	cg18078177	chr20:47281410	PREX1	0.44	7.16	0.36	5.04e-12	Colorectal cancer;
LIHC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg06634786	chr22:41940651	POLR3H	-0.51	-5.91	-0.3	8.17e-9	Vitiligo;
LIHC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg08694578	chr2:241835147	C2orf54	-0.51	-7.16	-0.36	4.88e-12	Urinary metabolites;
LIHC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.49	0.33	2.93e-10	Heart rate;
LIHC	cis	rs897984	0.568	rs11862962	chr16:30909706	C/G	cg02466173	chr16:30829666	NA	-0.43	-6.25	-0.32	1.23e-9	Dementia with Lewy bodies;
LIHC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg12798992	chr6:167411361	FGFR1OP	0.46	7.19	0.36	4.2e-12	Crohn's disease;
LIHC	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.34	-7.74	-0.39	1.16e-13	Congenital heart disease (maternal effect);
LIHC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg19645103	chr12:69753606	YEATS4	-0.45	-6.05	-0.31	3.7e-9	Response to diuretic therapy;
LIHC	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.71	-11.23	-0.52	3.89e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.67	-0.42	1.83e-16	Renal cell carcinoma;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00239003	chr19:45458398	CLPTM1	-0.49	-6.04	-0.31	4.1e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.57	0.53	2.35e-26	Motion sickness;
LIHC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.36	-6.6	-0.34	1.59e-10	Diastolic blood pressure;
LIHC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.05	17.32	0.68	1.08e-48	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.8	0.54	3.56e-27	Motion sickness;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02290350	chr8:58132656	NA	0.48	9.55	0.46	2.59e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.74	14.16	0.61	3.7e-36	Mortality in heart failure;
LIHC	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	1.17	9.75	0.47	5.68e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.64	12.26	0.55	6.84e-29	High light scatter reticulocyte count;
LIHC	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg11161837	chr1:110010384	SYPL2	0.42	5.71	0.3	2.41e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.33	5.92	0.31	7.67e-9	Osteoporosis;
LIHC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.5	-8.88	-0.43	3.94e-17	Total body bone mineral density;
LIHC	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg06917634	chr15:78832804	PSMA4	0.63	8.28	0.41	2.83e-15	Sudden cardiac arrest;
LIHC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg03934865	chr2:198174659	NA	0.46	6.61	0.34	1.44e-10	Dermatomyositis;
LIHC	cis	rs75908454	1.000	rs79670745	chr6:169954036	A/G	cg19338460	chr6:170058176	WDR27	-0.82	-7.66	-0.38	1.91e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg09222892	chr1:25734099	RHCE	-0.47	-8.66	-0.42	1.85e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg09137382	chr11:130731461	NA	0.42	6.52	0.33	2.47e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.39	-5.72	-0.3	2.3e-8	Ulcerative colitis;
LIHC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.22	-6.02	-0.31	4.49e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs713477	0.967	rs8020152	chr14:55907025	T/A	cg13175173	chr14:55914753	NA	-0.34	-7.86	-0.39	4.97e-14	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg21279826	chr15:52358353	MAPK6	0.37	6.16	0.32	2.06e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02985541	chr2:219472218	PLCD4	-0.4	-6.4	-0.33	5.17e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12744310	0.887	rs12047875	chr1:41785176	C/T	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.92e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.08	0.4	1.1e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.32	0.37	1.77e-12	Endometrial cancer;
LIHC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg22834771	chr12:69754056	YEATS4	-0.44	-7.47	-0.37	6.94e-13	Blood protein levels;
LIHC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.45	6.85	0.35	3.47e-11	Educational attainment;
LIHC	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.64	-10.55	-0.5	1.07e-22	Waist circumference;Body mass index;
LIHC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.37	6.85	0.35	3.52e-11	Height;
LIHC	cis	rs1775715	0.614	rs806808	chr10:32381186	T/C	cg14930904	chr10:32216787	ARHGAP12	-0.38	-6.48	-0.33	3.25e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg17385448	chr1:15911702	AGMAT	0.41	6.8	0.35	4.65e-11	Systolic blood pressure;
LIHC	cis	rs12984174	0.877	rs408484	chr19:18139771	C/T	cg21649277	chr19:18117794	ARRDC2	0.67	6.2	0.32	1.59e-9	Pulmonary function in asthmatics;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05951308	chr12:72080128	TMEM19	-0.49	-6.48	-0.33	3.2e-10	Systolic blood pressure;
LIHC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.02	-23.78	-0.79	1.79e-74	Height;
LIHC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.6	8.07	0.4	1.22e-14	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg05590025	chr7:65112418	INTS4L2	-0.66	-7.2	-0.36	3.94e-12	Diabetic kidney disease;
LIHC	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.55	-8.55	-0.42	4.23e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs4575098	0.681	rs10908824	chr1:161111931	A/G	cg08545169	chr1:161169143	NDUFS2;ADAMTS4	0.43	7.78	0.39	8.77e-14	Monocyte percentage of white cells;
LIHC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg00277334	chr10:82204260	NA	-0.5	-6.21	-0.32	1.49e-9	Post bronchodilator FEV1;
LIHC	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg23387056	chr11:14280742	SPON1	-0.42	-5.8	-0.3	1.48e-8	Mitochondrial DNA levels;
LIHC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.93	-0.31	7.44e-9	Type 2 diabetes;
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.84	0.43	5.01e-17	Height;
LIHC	cis	rs10847980	0.590	rs77970074	chr12:123292186	T/G	cg18912006	chr12:123335444	HIP1R	0.73	7.17	0.36	4.65e-12	Adiponectin levels;
LIHC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.38	-11.71	-0.53	7.6e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.7	-0.38	1.49e-13	Electroencephalogram traits;
LIHC	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg20560298	chr2:73613845	ALMS1	0.36	5.78	0.3	1.72e-8	Metabolite levels;
LIHC	cis	rs4684776	0.867	rs2305686	chr3:11350553	C/T	cg00170343	chr3:11313890	ATG7	-0.53	-7.28	-0.37	2.31e-12	Small vessel stroke;
LIHC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg03013999	chr17:37608204	MED1	0.35	5.78	0.3	1.71e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.52	7.79	0.39	7.89e-14	Red blood cell count;
LIHC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.33	-0.41	2.03e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg27386326	chr11:61587980	NA	0.72	15.86	0.65	7.59e-43	Trans fatty acid levels;
LIHC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.59	7.41	0.37	9.85e-13	Body mass index;
LIHC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.98	0.54	7.4e-28	Colorectal cancer;
LIHC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.54	-8.06	-0.4	1.25e-14	Ulcerative colitis;
LIHC	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.64	-11.51	-0.53	3.92e-26	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs10762653	0.541	rs11001300	chr10:76884960	C/T	cg27380788	chr16:4526765	HMOX2	0.48	6.24	0.32	1.26e-9	Pneumonia;
LIHC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.79	7.52	0.38	4.77e-13	Plasma clusterin levels;
LIHC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg23205692	chr1:25664452	TMEM50A	0.4	6.53	0.33	2.35e-10	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs28595532	0.545	rs72677057	chr4:119264162	A/T	cg21605333	chr4:119757512	SEC24D	0.79	6.67	0.34	1.02e-10	Cannabis dependence symptom count;
LIHC	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.81	11.44	0.53	6.82e-26	Body mass index;
LIHC	cis	rs4903214	0.895	rs7157482	chr14:74712696	C/T	cg11132536	chr14:74711944	VSX2	-0.24	-6.14	-0.32	2.29e-9	Inflammatory bowel disease;
LIHC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.43	0.56	1.65e-29	Menopause (age at onset);
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.49	6.57	0.33	1.89e-10	Menopause (age at onset);
LIHC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.35	5.85	0.3	1.16e-8	Monocyte count;
LIHC	trans	rs111706465	1	rs111706465	chr2:239452382	A/C	cg01134436	chr17:81009848	B3GNTL1	0.74	6.36	0.33	6.55e-10	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.63	11.12	0.52	1.01e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.71	-8.42	-0.41	1.08e-15	Morning vs. evening chronotype;
LIHC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg02269571	chr22:50332266	NA	-0.64	-8.68	-0.42	1.68e-16	Schizophrenia;
LIHC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.6	9.08	0.44	8.72e-18	Alzheimer's disease;
LIHC	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg11161837	chr1:110010384	SYPL2	0.46	6.3	0.32	9.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.65	12.61	0.56	3.24e-30	High light scatter reticulocyte count;
LIHC	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg04374321	chr14:90722782	PSMC1	0.47	6.53	0.33	2.34e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg18898632	chr2:242989856	NA	-0.47	-6.48	-0.33	3.25e-10	Obesity-related traits;
LIHC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.67	10.93	0.51	4.82e-24	Menopause (age at onset);
LIHC	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.32	7.26	0.37	2.64e-12	Blood metabolite ratios;
LIHC	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.98	0.35	1.52e-11	Exhaled nitric oxide output;
LIHC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.93	17.41	0.69	4.79e-49	Menopause (age at onset);
LIHC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	3.97e-29	Corneal astigmatism;
LIHC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.47	7.74	0.39	1.11e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.44	-7.85	-0.39	5.3e-14	Aortic root size;
LIHC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.61	-9.99	-0.48	8.77e-21	Post bronchodilator FEV1;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.04e-14	Height;
LIHC	cis	rs4908768	0.906	rs11121207	chr1:8681848	C/A	cg20416874	chr1:8611966	RERE	0.54	7.66	0.38	1.91e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg02640540	chr1:67518911	SLC35D1	-0.41	-6.39	-0.33	5.49e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.82	-0.3	1.33e-8	Systemic lupus erythematosus;
LIHC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-8.21	-0.41	4.43e-15	Body mass index;
LIHC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18252515	chr7:66147081	NA	0.42	6.03	0.31	4.37e-9	Aortic root size;
LIHC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg19682013	chr15:45996608	NA	0.39	6.57	0.33	1.92e-10	Waist circumference;Weight;
LIHC	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.6	-9.21	-0.45	3.38e-18	Eotaxin levels;
LIHC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg02640540	chr1:67518911	SLC35D1	0.41	6.44	0.33	4.02e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.59	-11.23	-0.52	4.11e-25	Body mass index;
LIHC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg16070018	chr6:26224392	HIST1H3E	0.57	6.83	0.35	3.8e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.66	12.76	0.57	9.24e-31	Rheumatoid arthritis;
LIHC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.6	8.96	0.44	2.14e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.86	15.21	0.64	2.77e-40	Headache;
LIHC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.83	11.26	0.52	3.21e-25	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26155979	chr10:105110866	PCGF6	-0.44	-6.44	-0.33	4.08e-10	Pancreatic cancer;
LIHC	cis	rs9425766	0.640	rs16846439	chr1:173824038	T/G	cg06124660	chr1:173389066	NA	-0.33	-6.4	-0.33	5.25e-10	Life satisfaction;
LIHC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.44	-7.95	-0.39	2.76e-14	Glycated hemoglobin levels;
LIHC	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.22	5.97	0.31	6.05e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg11812906	chr14:75593930	NEK9	0.4	6.07	0.31	3.33e-9	IgG glycosylation;
LIHC	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	1.02	20.69	0.75	3.04e-62	Height;
LIHC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.48	7.43	0.37	8.5e-13	Systemic lupus erythematosus;
LIHC	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.39	-6.49	-0.33	3.03e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.66	9.67	0.46	1.03e-19	Lymphocyte counts;
LIHC	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	5.85	0.3	1.18e-8	Schizophrenia;
LIHC	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.72	0.34	7.39e-11	Height;
LIHC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg08499158	chr17:42289980	UBTF	-0.48	-7.69	-0.38	1.63e-13	Total body bone mineral density;
LIHC	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.46	8.57	0.42	3.54e-16	Testicular germ cell tumor;
LIHC	cis	rs2257205	0.667	rs6503879	chr17:56888183	T/A	cg12560992	chr17:57184187	TRIM37	0.68	7.44	0.37	8.24e-13	Pancreatic cancer;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg26939375	chr7:64535504	NA	-0.47	-7.23	-0.36	3.24e-12	Aortic root size;
LIHC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.46	7.05	0.36	9.79e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.63	-9.19	-0.45	3.79e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg20090690	chr10:134436459	INPP5A	0.45	5.87	0.3	1.02e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-8.25	-0.41	3.54e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.33	8.09	0.4	1.07e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg18473234	chr19:5097819	KDM4B	-0.57	-6.86	-0.35	3.15e-11	Monocyte percentage of white cells;
LIHC	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.84	-0.3	1.24e-8	Systolic blood pressure;
LIHC	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-0.83	-8.7	-0.43	1.44e-16	Blood pressure (smoking interaction);
LIHC	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs174601	0.721	rs174530	chr11:61546592	A/G	cg27386326	chr11:61587980	NA	0.69	14.41	0.61	3.89e-37	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.83	18.15	0.7	4.75e-52	Colorectal cancer;
LIHC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg07451762	chr16:28383216	NA	0.33	6.13	0.31	2.44e-9	Tonsillectomy;Mean corpuscular volume;
LIHC	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg03387723	chr1:41708464	SCMH1	-0.44	-7.13	-0.36	6.14e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.4	6.42	0.33	4.43e-10	Menopause (age at onset);
LIHC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.61	0.53	1.65e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7224314	1.000	rs62084077	chr17:65386837	G/A	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.92	-0.3	7.84e-9	Diisocyanate-induced asthma;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.88	-0.3	9.77e-9	Menopause (age at onset);
LIHC	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.5	6.62	0.34	1.39e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.38	9.8	0.47	3.79e-20	Asthma (sex interaction);
LIHC	cis	rs2073300	1.000	rs6036423	chr20:23459810	A/C	cg12062639	chr20:23401060	NAPB	0.78	9.87	0.47	2.16e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.51	-8.32	-0.41	2.07e-15	Corneal astigmatism;
LIHC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.57e-21	Bladder cancer;
LIHC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	1.02	10.23	0.48	1.29e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05665937	chr4:1216051	CTBP1	0.46	6.05	0.31	3.78e-9	Obesity-related traits;
LIHC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg11212589	chr17:38028394	ZPBP2	0.35	7.18	0.36	4.31e-12	Self-reported allergy;
LIHC	cis	rs7961581	0.748	rs7314537	chr12:71620125	A/G	cg05756094	chr12:71608604	NA	0.38	6.01	0.31	4.82e-9	Type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05051957	chr8:141522459	CHRAC1	0.44	6.32	0.32	8.05e-10	Pancreatic cancer;
LIHC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.73	11.99	0.54	6.75e-28	Colorectal cancer;
LIHC	cis	rs2637266	0.655	rs7902535	chr10:78460889	C/T	cg18941641	chr10:78392320	NA	0.28	6.04	0.31	4.09e-9	Pulmonary function;
LIHC	cis	rs509477	1.000	rs11660848	chr18:32574010	T/C	cg23791764	chr18:32556832	MAPRE2	-0.52	-7.33	-0.37	1.63e-12	Cerebrospinal fluid AB1-42 levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09578018	chr15:60883649	RORA	0.49	7.73	0.39	1.2e-13	Cognitive function;
LIHC	cis	rs12744310	0.943	rs34862272	chr1:41768653	A/C	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs903552	1.000	rs4965386	chr15:102003207	G/A	cg06707286	chr15:102010195	PCSK6	-0.45	-6.42	-0.33	4.43e-10	Diabetic kidney disease;
LIHC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.39	5.8	0.3	1.55e-8	Melanoma;
LIHC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.44	-0.33	4.17e-10	Crohn's disease;
LIHC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.38	6.28	0.32	1e-9	Height;
LIHC	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.61	7.49	0.38	6.11e-13	Exhaled nitric oxide output;
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02359409	chr6:42947317	PEX6	-0.47	-6.63	-0.34	1.28e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.75	-0.39	1.02e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg05484376	chr2:27715224	FNDC4	0.37	6.33	0.32	7.68e-10	Total body bone mineral density;
LIHC	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.29	-0.41	2.67e-15	Exhaled nitric oxide output;
LIHC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg11072887	chr6:37322624	RNF8	-0.59	-6.76	-0.34	5.8e-11	Kashin-Beck disease;
LIHC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.48	-8.15	-0.4	6.74e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.52	-6.6	-0.34	1.55e-10	Type 2 diabetes;
LIHC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.0	14.18	0.61	3.28e-36	Cognitive function;
LIHC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg24296786	chr1:45957014	TESK2	-0.49	-7.29	-0.37	2.15e-12	Platelet count;
LIHC	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.73	-0.6	1.82e-34	Coffee consumption (cups per day);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg26521561	chr2:198283608	SF3B1	-0.25	-6.07	-0.31	3.49e-9	Calcium levels;
LIHC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg06096015	chr1:231504339	EGLN1	0.5	9.3	0.45	1.73e-18	Hemoglobin concentration;
LIHC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.96	-0.31	6.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03634708	chr10:32345420	KIF5B	-0.43	-6.13	-0.31	2.47e-9	Pancreatic cancer;
LIHC	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.9	0.35	2.48e-11	Bipolar disorder;
LIHC	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg23730037	chr7:158596552	ESYT2	-0.71	-5.79	-0.3	1.64e-8	Hippocampal volume;
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg14709524	chr16:89940631	TCF25	0.5	6.38	0.33	5.66e-10	Skin colour saturation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26770187	chr3:14693171	C3orf19	0.45	7.34	0.37	1.6e-12	Cognitive function;
LIHC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	24.75	0.8	3.3e-78	Chronic sinus infection;
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06481639	chr22:41940642	POLR3H	-0.67	-6.74	-0.34	6.54e-11	Vitiligo;
LIHC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.68	11.3	0.52	2.29e-25	Menopause (age at onset);
LIHC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.38	6.12	0.31	2.53e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.47	7.45	0.37	7.62e-13	Gout;
LIHC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.49	6.95	0.35	1.86e-11	Longevity;Endometriosis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25372841	chr8:145675454	CYHR1	-0.4	-6.25	-0.32	1.24e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-5.96	-0.31	6.14e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02985541	chr2:219472218	PLCD4	0.41	6.66	0.34	1.1e-10	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.92	0.31	7.68e-9	Electroencephalogram traits;
LIHC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg14393609	chr7:65229607	NA	0.37	5.81	0.3	1.4e-8	Aortic root size;
LIHC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.81	-8.83	-0.43	5.65e-17	Vitiligo;
LIHC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.59	-8.36	-0.41	1.65e-15	Blood metabolite levels;
LIHC	cis	rs1892700	0.821	rs62227705	chr21:34919593	A/C	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.95e-8	Educational attainment;
LIHC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg03934865	chr2:198174659	NA	-0.61	-9.92	-0.47	1.49e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.41	-0.33	4.76e-10	Hepatocellular carcinoma;
LIHC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.74	-0.39	1.11e-13	QT interval;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.8	-11.85	-0.54	2.23e-27	Motion sickness;
LIHC	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.35	8.07	0.4	1.21e-14	Educational attainment (years of education);
LIHC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg05697976	chr12:29376483	FAR2	0.33	6.76	0.34	6.05e-11	QT interval;
LIHC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.32	5.98	0.31	5.73e-9	Renal cell carcinoma;
LIHC	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg21584241	chr15:63341463	TPM1	0.44	6.35	0.32	6.75e-10	Orofacial clefts;
LIHC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.97	0.54	8.17e-28	Motion sickness;
LIHC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg21395723	chr22:39101663	GTPBP1	-0.38	-6.14	-0.32	2.28e-9	Menopause (age at onset);
LIHC	cis	rs6449957	0.741	rs6882730	chr5:67464205	C/T	cg23036683	chr5:67512108	NA	0.44	6.25	0.32	1.22e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg20636351	chr8:55087400	NA	-0.4	-8.07	-0.4	1.22e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg16558253	chr16:72132732	DHX38	-0.4	-6.89	-0.35	2.68e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.6	-8.61	-0.42	2.71e-16	Blood metabolite levels;
LIHC	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.58	10.88	0.51	7.03e-24	Leprosy;
LIHC	cis	rs11663156	0.804	rs34563569	chr18:50900013	C/T	cg24270629	chr18:50823537	DCC	0.47	6.48	0.33	3.19e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.9	14.43	0.62	3.47e-37	Metabolic syndrome;
LIHC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.46	9.36	0.45	1.12e-18	Tonsillectomy;
LIHC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg12458913	chr13:53173898	NA	0.48	7.87	0.39	4.62e-14	Lewy body disease;
LIHC	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg20016023	chr10:99160130	RRP12	-0.43	-7.0	-0.35	1.35e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.81	0.35	4.44e-11	Bipolar disorder;
LIHC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg16574807	chr4:6945745	TBC1D14	0.54	6.2	0.32	1.65e-9	Mean platelet volume;
LIHC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.28	0.41	2.72e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg16652328	chr3:33138982	GLB1;TMPPE	0.53	6.74	0.34	6.87e-11	Major depressive disorder;
LIHC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg11764359	chr7:65958608	NA	-0.57	-5.93	-0.31	7.25e-9	Diabetic kidney disease;
LIHC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.94	0.35	1.95e-11	Morning vs. evening chronotype;
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.88	13.54	0.59	9.29e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.34e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.1	-0.31	2.85e-9	Breast cancer;
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07677032	chr17:61819896	STRADA	0.43	6.18	0.32	1.79e-9	Prudent dietary pattern;
LIHC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg04958157	chr13:113748321	MCF2L	-0.35	-5.72	-0.3	2.37e-8	Systolic blood pressure;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.7	13.69	0.6	2.45e-34	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.59	8.72	0.43	1.24e-16	Prudent dietary pattern;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.55	0.53	2.84e-26	Prudent dietary pattern;
LIHC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg05535760	chr7:792225	HEATR2	-0.48	-6.63	-0.34	1.33e-10	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.48	8.07	0.4	1.18e-14	Response to temozolomide;
LIHC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.57	-8.03	-0.4	1.6e-14	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.76	12.98	0.57	1.3e-31	Aortic root size;
LIHC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.29	-6.79	-0.34	5e-11	Menarche (age at onset);
LIHC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.47	-7.09	-0.36	7.77e-12	Height;
LIHC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.4	-6.45	-0.33	3.76e-10	Blood pressure (smoking interaction);
LIHC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.52	0.33	2.5e-10	Bipolar disorder;
LIHC	cis	rs4759375	1.000	rs4759377	chr12:123796849	C/T	cg00376283	chr12:123451042	ABCB9	-0.5	-6.4	-0.33	5.02e-10	HDL cholesterol;
LIHC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.12	-0.44	6.77e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11098699	0.821	rs7665722	chr4:124201501	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.46	0.33	3.58e-10	Mosquito bite size;
LIHC	cis	rs17152411	0.744	rs10901835	chr10:126589712	G/T	cg07906193	chr10:126599966	NA	-0.3	-5.87	-0.3	1.04e-8	Height;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.05	-0.31	3.71e-9	Diastolic blood pressure;
LIHC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-6.38	-0.33	5.67e-10	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19524238	chr7:2802976	GNA12	-0.38	-5.9	-0.3	8.69e-9	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14514174	chr9:99181512	ZNF367	0.5	6.45	0.33	3.72e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.29	6.22	0.32	1.43e-9	Pulmonary function;
LIHC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.64	6.43	0.33	4.22e-10	Bipolar disorder;
LIHC	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.65	0.38	2.12e-13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LIHC	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.61	-8.89	-0.43	3.66e-17	Blood protein levels;
LIHC	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.59	-9.85	-0.47	2.5e-20	Fibroblast growth factor basic levels;
LIHC	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.65	9.93	0.47	1.39e-20	White matter hyperintensity burden;
LIHC	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.74	11.02	0.51	2.29e-24	Subjective well-being;
LIHC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.29	6.75	0.34	6.23e-11	Primary biliary cholangitis;
LIHC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-9.78	-0.47	4.48e-20	Colorectal cancer;
LIHC	cis	rs35160687	0.644	rs4832274	chr2:86529084	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	5.92	0.3	7.97e-9	Night sleep phenotypes;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23674352	chr6:100016770	CCNC	-0.4	-6.07	-0.31	3.48e-9	Cognitive function;
LIHC	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.35	-6.66	-0.34	1.11e-10	Coronary artery disease or large artery stroke;
LIHC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.04	0.31	3.94e-9	Morning vs. evening chronotype;
LIHC	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.59	6.83	0.35	3.85e-11	Bipolar disorder;
LIHC	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.41	5.99	0.31	5.24e-9	Eosinophil percentage of white cells;
LIHC	cis	rs10744422	0.800	rs2649902	chr12:123243687	G/A	cg22842854	chr12:123319900	HIP1R	-0.64	-8.07	-0.4	1.24e-14	Schizophrenia;
LIHC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.59	8.81	0.43	6.19e-17	Obesity-related traits;
LIHC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.18	0.44	4.12e-18	Hemoglobin concentration;
LIHC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.47	-7.12	-0.36	6.58e-12	Height;
LIHC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg13647721	chr17:30228624	UTP6	-0.74	-6.9	-0.35	2.57e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg00656387	chr3:40428638	ENTPD3	-0.39	-6.35	-0.32	7.02e-10	Renal cell carcinoma;
LIHC	cis	rs4853036	0.597	rs1048165	chr2:70131964	A/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.28	-0.32	1.02e-9	Colorectal or endometrial cancer;
LIHC	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.63	-6.79	-0.34	4.99e-11	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-21.06	-0.75	1.04e-63	Exhaled nitric oxide output;
LIHC	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg16576597	chr16:28551801	NUPR1	0.38	6.16	0.32	2.1e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	1.1	8.81	0.43	6.58e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs6448317	1.000	rs7698504	chr4:24939386	A/T	cg21108841	chr4:24914750	CCDC149	-0.47	-6.0	-0.31	5e-9	Heschl's gyrus morphology;
LIHC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.59	8.46	0.42	8.12e-16	Blood metabolite levels;
LIHC	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.53	0.53	3.21e-26	Motion sickness;
LIHC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.52	7.3	0.37	2.09e-12	Height;
LIHC	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.29	6.42	0.33	4.55e-10	Pulmonary function;
LIHC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-5.95	-0.31	6.46e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.02	-0.35	1.21e-11	Body mass index;
LIHC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.62	-10.15	-0.48	2.47e-21	Obesity-related traits;
LIHC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.49	-0.33	2.94e-10	Schizophrenia;
LIHC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs757110	0.690	rs35271178	chr11:17411020	C/T	cg15432903	chr11:17409602	KCNJ11	0.59	9.04	0.44	1.14e-17	Type 2 diabetes;
LIHC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.57	-6.04	-0.31	4.06e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.3	0.41	2.4e-15	Eotaxin levels;
LIHC	cis	rs526231	0.819	rs568999	chr5:102601358	G/C	cg05225461	chr5:102596755	C5orf30	0.38	5.89	0.3	9.25e-9	Primary biliary cholangitis;
LIHC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.74	0.3	2.09e-8	Bipolar disorder;
LIHC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.51	6.53	0.33	2.43e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg00656387	chr3:40428638	ENTPD3	-0.4	-6.53	-0.33	2.35e-10	Renal cell carcinoma;
LIHC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.45	-6.9	-0.35	2.54e-11	Glycated hemoglobin levels;
LIHC	cis	rs847649	1.000	rs28856331	chr7:102543763	T/G	cg18108683	chr7:102477205	FBXL13	-0.49	-7.43	-0.37	8.6e-13	Morning vs. evening chronotype;
LIHC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	0.83	11.58	0.53	2.18e-26	Skin colour saturation;
LIHC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg12798992	chr6:167411361	FGFR1OP	0.51	8.3	0.41	2.5e-15	Primary biliary cholangitis;
LIHC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.24e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg15383120	chr6:291909	DUSP22	-0.47	-6.15	-0.32	2.15e-9	Menopause (age at onset);
LIHC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg01028140	chr2:1542097	TPO	-0.47	-5.84	-0.3	1.23e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.36	-6.47	-0.33	3.32e-10	Breast cancer;
LIHC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.87	-9.75	-0.47	5.67e-20	Vitiligo;
LIHC	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg14515779	chr1:101123966	NA	0.5	6.9	0.35	2.56e-11	Monocyte count;
LIHC	cis	rs1892700	0.764	rs62227703	chr21:34906317	A/G	cg14850771	chr21:34775459	IFNGR2	-0.45	-5.91	-0.3	8.47e-9	Educational attainment;
LIHC	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.57	-8.93	-0.43	2.64e-17	Extraversion;
LIHC	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.37e-8	Lewy body disease;
LIHC	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg12698662	chr3:15914712	MIR563	-0.35	-6.5	-0.33	2.83e-10	Mean platelet volume;
LIHC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-7.96	-0.4	2.63e-14	Alzheimer's disease;
LIHC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-11.11	-0.51	1.13e-24	Coronary artery disease;
LIHC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	0.92	6.1	0.31	2.93e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.96	-0.35	1.77e-11	Metabolite levels;
LIHC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.64	11.59	0.53	2.03e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.37	8.41	0.41	1.1e-15	Educational attainment (years of education);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg06998038	chr14:65209844	PLEKHG3	0.44	6.45	0.33	3.79e-10	Longevity;
LIHC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.2e-22	Cognitive function;
LIHC	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.46	-6.75	-0.34	6.3e-11	Dermatomyositis;
LIHC	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.27	6.5	0.33	2.84e-10	Heart rate;
LIHC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-8.22	-0.41	4.33e-15	Body mass index (adult);
LIHC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg03146154	chr1:46216737	IPP	-0.48	-8.01	-0.4	1.83e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg16586182	chr3:47516702	SCAP	-0.4	-6.81	-0.35	4.37e-11	Birth weight;
LIHC	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg26395211	chr5:140044315	WDR55	0.38	5.73	0.3	2.2e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg24879335	chr3:133465180	TF	0.29	6.55	0.33	2.05e-10	Iron status biomarkers;
LIHC	cis	rs240764	0.746	rs240156	chr6:101063149	C/G	cg09795085	chr6:101329169	ASCC3	0.5	6.78	0.34	5.17e-11	Neuroticism;
LIHC	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg03037974	chr15:76606532	NA	-0.6	-9.88	-0.47	2.04e-20	Blood metabolite levels;
LIHC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25072359	chr17:41440525	NA	0.4	6.29	0.32	9.63e-10	Menopause (age at onset);
LIHC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Morning vs. evening chronotype;
LIHC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.41	-6.66	-0.34	1.08e-10	Menarche (age at onset);
LIHC	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg12483005	chr1:23474871	LUZP1	0.42	6.34	0.32	7.36e-10	Height;
LIHC	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.9	-0.39	3.81e-14	Coronary artery disease;
LIHC	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.55	0.33	2.11e-10	Response to antipsychotic treatment;
LIHC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg03037974	chr15:76606532	NA	-0.64	-11.17	-0.52	6.59e-25	Blood metabolite levels;
LIHC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.51	7.52	0.38	4.93e-13	Type 2 diabetes;
LIHC	cis	rs12815613	0.539	rs7300883	chr12:121459440	C/G	cg02403541	chr12:121454288	C12orf43	-0.43	-6.44	-0.33	4.15e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg21724239	chr8:58056113	NA	0.44	5.94	0.31	7.09e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.64	11.48	0.53	4.88e-26	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs5756813	0.668	rs6000881	chr22:38154544	G/A	cg19894588	chr14:64061835	NA	0.44	6.39	0.33	5.31e-10	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7119038	0.865	rs4936443	chr11:118740864	C/T	cg19308663	chr11:118741387	NA	-0.48	-6.29	-0.32	9.76e-10	Sjögren's syndrome;
LIHC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.94	17.6	0.69	7.76e-50	Breast cancer;
LIHC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg03959625	chr15:84868606	LOC388152	0.39	5.82	0.3	1.38e-8	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04571369	chr19:19749068	GMIP	0.4	6.15	0.32	2.15e-9	Pancreatic cancer;
LIHC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg14930904	chr10:32216787	ARHGAP12	0.4	7.02	0.35	1.21e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.32	0.32	8.27e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17854409	0.764	rs12625513	chr20:61475661	G/A	cg07645718	chr20:61493192	TCFL5	0.82	6.1	0.31	2.8e-9	Obesity-related traits;
LIHC	trans	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg26939375	chr7:64535504	NA	0.42	6.82	0.35	4.26e-11	Aortic root size;
LIHC	cis	rs7818688	0.697	rs74861094	chr8:95981385	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.69	0.34	9.39e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07682378	chr3:150128910	TSC22D2	0.39	6.28	0.32	1.05e-9	Cognitive function;
LIHC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.8	-0.43	6.79e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs11168351	0.927	rs11168342	chr12:48383797	G/T	cg21466736	chr12:48725269	NA	-0.57	-7.85	-0.39	5.57e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Obesity-related traits;
LIHC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.42	5.83	0.3	1.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.34	13.9	0.6	3.84e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12927203	chr7:56032122	GBAS	-0.5	-7.17	-0.36	4.73e-12	Pancreatic cancer;
LIHC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg23849483	chr19:15224544	SYDE1	-0.5	-6.04	-0.31	3.94e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.27	0.41	3e-15	Motion sickness;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23674352	chr6:100016770	CCNC	-0.5	-6.99	-0.35	1.46e-11	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.83	-0.35	3.91e-11	Diabetic kidney disease;
LIHC	cis	rs10503871	0.761	rs6997010	chr8:30365489	T/A	cg26383811	chr8:30366931	RBPMS	0.42	7.46	0.37	7.27e-13	Metabolite levels  (X-11787);
LIHC	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.69	11.39	0.52	1.02e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.75	12.66	0.56	2.14e-30	Aortic root size;
LIHC	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg01364799	chr7:75623366	TMEM120A	0.4	6.09	0.31	3.12e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg00656387	chr3:40428638	ENTPD3	0.38	5.95	0.31	6.7e-9	Renal cell carcinoma;
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.76	11.82	0.54	2.82e-27	Longevity;
LIHC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	7.07	0.36	8.98e-12	Parkinson's disease;
LIHC	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg14345882	chr6:26364793	BTN3A2	0.34	5.74	0.3	2.04e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs11673344	0.868	rs1047333	chr19:37642165	G/A	cg27390819	chr19:37464633	NA	-0.53	-6.3	-0.32	8.94e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.46	-7.24	-0.36	3.06e-12	Schizophrenia;
LIHC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg05555928	chr11:63887634	MACROD1	0.46	6.02	0.31	4.41e-9	Mean platelet volume;
LIHC	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	1.0	11.73	0.54	6.22e-27	IgG glycosylation;
LIHC	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.34	-8.5	-0.42	5.84e-16	Hip circumference;Waist circumference;
LIHC	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	18.64	0.71	5.42e-54	Colorectal cancer;
LIHC	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.46	6.2	0.32	1.64e-9	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg16836995	chr17:43662488	NA	-0.76	-7.82	-0.39	6.7e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00852675	chr7:150105086	LOC728743	0.41	6.31	0.32	8.4e-10	Bilirubin levels;
LIHC	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.46	8.69	0.43	1.58e-16	Testicular germ cell tumor;
LIHC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.02	0.51	2.26e-24	Personality dimensions;
LIHC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.09	-0.31	3.12e-9	Total body bone mineral density;
LIHC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.25	-5.89	-0.3	9.48e-9	Subjective well-being;
LIHC	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.48	6.99	0.35	1.43e-11	Dialysis-related mortality;
LIHC	cis	rs17750015	0.733	rs12454362	chr18:54396186	G/A	cg18434998	chr18:54306185	TXNL1	-0.48	-6.64	-0.34	1.2e-10	Depression and alcohol dependence;
LIHC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.66	0.65	4.89e-42	Chronic sinus infection;
LIHC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.88	10.35	0.49	5.19e-22	Eosinophil percentage of granulocytes;
LIHC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.38	6.02	0.31	4.56e-9	Menopause (age at onset);
LIHC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	7.43	0.37	9.02e-13	Platelet count;
LIHC	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg17425144	chr1:10567563	PEX14	0.52	10.11	0.48	3.46e-21	Prostate cancer;
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12379764	chr21:47803548	PCNT	0.54	8.09	0.4	1.02e-14	Testicular germ cell tumor;
LIHC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.79	0.3	1.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs36051895	0.589	rs10122037	chr9:5192874	A/G	cg02405213	chr9:5042618	JAK2	0.68	11.49	0.53	4.61e-26	Pediatric autoimmune diseases;
LIHC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg08213375	chr14:104286397	PPP1R13B	0.49	9.3	0.45	1.68e-18	Schizophrenia;
LIHC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg06466757	chr4:1255808	NA	0.34	5.75	0.3	1.96e-8	Obesity-related traits;
LIHC	trans	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.89	0.3	9.25e-9	Bipolar disorder;
LIHC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.42	7.15	0.36	5.3e-12	IgG glycosylation;
LIHC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.49	0.33	2.93e-10	Heart rate;
LIHC	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.48	9.02	0.44	1.4e-17	Testicular germ cell tumor;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.43	5.95	0.31	6.57e-9	Longevity;Endometriosis;
LIHC	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.26	-6.05	-0.31	3.79e-9	Gut microbiome composition (winter);
LIHC	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg21281001	chr8:11725306	CTSB	-0.48	-7.4	-0.37	1.04e-12	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
LIHC	cis	rs2257205	0.667	rs7211439	chr17:56847832	A/T	cg12560992	chr17:57184187	TRIM37	0.68	7.44	0.37	8.24e-13	Pancreatic cancer;
LIHC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.34	0.32	7.24e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	7.15	0.36	5.14e-12	Protein C levels;
LIHC	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.92	6.47	0.33	3.39e-10	Platelet distribution width;
LIHC	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.17	9.23	0.45	2.83e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs992157	0.764	rs2382827	chr2:219184387	G/A	cg00012203	chr2:219082015	ARPC2	0.75	10.52	0.49	1.33e-22	Colorectal cancer;
LIHC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.52	8.88	0.43	3.94e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.53	-8.23	-0.41	4e-15	P wave terminal force;
LIHC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.66	-12.59	-0.56	4e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.16	-0.55	1.65e-28	Colorectal cancer;
LIHC	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg09572067	chr16:29127029	RRN3P2	0.47	7.55	0.38	4.01e-13	Menopause (age at onset);
LIHC	trans	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg26939375	chr7:64535504	NA	0.43	6.9	0.35	2.56e-11	Aortic root size;
LIHC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.36	-0.49	4.56e-22	Schizophrenia;
LIHC	cis	rs2019216	0.872	rs6565384	chr17:21897456	T/C	cg22648282	chr17:21454238	C17orf51	-0.34	-5.82	-0.3	1.33e-8	Pelvic organ prolapse;
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs12986413	0.624	rs2108825	chr19:2136515	T/C	cg09261902	chr19:2140048	AP3D1	0.4	6.83	0.35	3.92e-11	Height;
LIHC	cis	rs3753275	0.690	rs2399144	chr1:8539269	C/A	cg20416874	chr1:8611966	RERE	-0.47	-5.73	-0.3	2.25e-8	Educational attainment;
LIHC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.67	12.36	0.56	2.97e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.37	-0.45	1.01e-18	Schizophrenia;
LIHC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg04065206	chr12:109973212	UBE3B	-0.58	-6.58	-0.34	1.73e-10	Neuroticism;
LIHC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.63	0.38	2.42e-13	Lymphocyte counts;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg16512924	chr15:28394682	HERC2	0.37	6.26	0.32	1.13e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.46	-6.43	-0.33	4.26e-10	Diastolic blood pressure;
LIHC	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.43	6.3	0.32	9.15e-10	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10198271	chr20:55966838	RBM38	0.5	6.43	0.33	4.37e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg15691649	chr6:25882328	NA	-0.53	-7.68	-0.38	1.67e-13	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg11764359	chr7:65958608	NA	-0.59	-6.17	-0.32	1.94e-9	Diabetic kidney disease;
LIHC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.15	-0.32	2.21e-9	Ulcerative colitis;
LIHC	cis	rs3823572	0.526	rs2971966	chr7:133642559	A/G	cg03336402	chr7:133662267	EXOC4	-0.46	-5.72	-0.3	2.3e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg21466736	chr12:48725269	NA	0.63	8.99	0.44	1.69e-17	Glycated hemoglobin levels;
LIHC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.36	7.54	0.38	4.18e-13	Cancer;
LIHC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.39	6.01	0.31	4.81e-9	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.53	6.43	0.33	4.35e-10	Alzheimer's disease;
LIHC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.96	-13.14	-0.58	3.26e-32	Heart rate;
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.28	-0.32	1.05e-9	Calcium levels;
LIHC	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.86	0.43	4.39e-17	Exhaled nitric oxide output;
LIHC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg16586182	chr3:47516702	SCAP	0.61	11.58	0.53	2.11e-26	Colorectal cancer;
LIHC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	8.61	0.42	2.8e-16	Mean corpuscular hemoglobin;
LIHC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.59	10.06	0.48	4.97e-21	Mean corpuscular volume;
LIHC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-8.65	-0.42	1.97e-16	Schizophrenia;
LIHC	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.56	11.19	0.52	5.64e-25	Schizophrenia;
LIHC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-7.89	-0.39	4.14e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs17152411	1.000	rs17152377	chr10:126592852	T/G	cg07906193	chr10:126599966	NA	0.46	7.14	0.36	5.71e-12	Height;
LIHC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg04013166	chr16:89971882	TCF25	0.49	6.08	0.31	3.24e-9	Skin colour saturation;
LIHC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.03	-0.36	1.1e-11	IgG glycosylation;
LIHC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.43	5.73	0.3	2.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-11.43	-0.53	7.89e-26	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21467203	chr3:49911342	NA	-0.41	-7.07	-0.36	9e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.7	7.13	0.36	5.91e-12	Bipolar disorder;
LIHC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.87	-9.81	-0.47	3.64e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.83e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.17	0.4	5.97e-15	Response to antipsychotic treatment;
LIHC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg25364880	chr3:44379878	C3orf23	0.55	7.54	0.38	4.19e-13	Depressive symptoms;
LIHC	cis	rs2637266	0.783	rs2583070	chr10:78518555	C/T	cg18941641	chr10:78392320	NA	0.27	5.84	0.3	1.22e-8	Pulmonary function;
LIHC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	15.56	0.64	1.13e-41	Nonalcoholic fatty liver disease;
LIHC	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.41	6.23	0.32	1.39e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs45544231	0.569	rs9933556	chr16:52548302	C/T	cg09051775	chr16:52580266	TOX3	-0.32	-5.77	-0.3	1.81e-8	Restless legs syndrome;
LIHC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.45	-9.11	-0.44	7.33e-18	Birth weight;
LIHC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.46	7.33	0.37	1.66e-12	Height;
LIHC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	0.53	5.99	0.31	5.29e-9	Alzheimer's disease;
LIHC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16684958	chr7:75615977	POR	-0.39	-6.58	-0.34	1.78e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4517514	0.509	rs11018875	chr11:89876356	T/C	cg05041596	chr11:89867385	NAALAD2	0.41	6.51	0.33	2.63e-10	Trans fatty acid levels;
LIHC	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.45	6.74	0.34	6.66e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg22834771	chr12:69754056	YEATS4	-0.47	-8.04	-0.4	1.53e-14	Blood protein levels;
LIHC	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	13.18	0.58	2.34e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9378688	0.654	rs2505657	chr6:2331510	T/C	cg12303981	chr6:2244766	GMDS	-0.45	-6.06	-0.31	3.69e-9	Caudate nucleus volume;
LIHC	cis	rs67981189	0.574	rs2810118	chr14:71388575	A/G	cg15816911	chr14:71606274	NA	-0.4	-6.34	-0.32	7.09e-10	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.61	8.79	0.43	7.16e-17	Menopause (age at onset);
LIHC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.35	-7.02	-0.36	1.17e-11	Colorectal cancer;
LIHC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.55	10.24	0.48	1.19e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg22842854	chr12:123319900	HIP1R	-0.61	-7.5	-0.38	5.44e-13	Schizophrenia;
LIHC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.32	7.36	0.37	1.42e-12	Crohn's disease;
LIHC	cis	rs11252926	0.650	rs11252902	chr10:562796	G/T	cg09445902	chr10:555545	DIP2C	-0.39	-6.21	-0.32	1.49e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20011983	chr2:74347215	NA	-0.41	-6.18	-0.32	1.77e-9	Gestational age at birth (maternal effect);
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.45	0.37	7.47e-13	Renal cell carcinoma;
LIHC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-1.19	-10.49	-0.49	1.66e-22	Breast cancer;
LIHC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.52	0.33	2.48e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg24955406	chr1:100503596	HIAT1	0.6	5.99	0.31	5.44e-9	Carotid intima media thickness;
LIHC	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.64	-0.34	1.24e-10	Eosinophil percentage of white cells;
LIHC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.2e-10	Renal cell carcinoma;
LIHC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.23	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.59	8.08	0.4	1.11e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-17.46	-0.69	2.95e-49	Gut microbiome composition (summer);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24063092	chr5:65018104	NLN;SGTB	0.46	6.51	0.33	2.74e-10	Lung function (FEV1/FVC);
LIHC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	10.15	0.48	2.43e-21	Lung cancer;
LIHC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs2637266	0.626	rs846617	chr10:78546881	A/G	cg18941641	chr10:78392320	NA	0.29	6.25	0.32	1.24e-9	Pulmonary function;
LIHC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs238295	0.766	rs6038204	chr20:5549071	T/A	cg24001556	chr20:5591874	RP5-1022P6.2	-0.53	-7.19	-0.36	4.16e-12	Occipital cortical area (total cortical area interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27449836	chr1:179846920	TOR1AIP2	-0.48	-6.73	-0.34	7.3e-11	Pancreatic cancer;
LIHC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg03037974	chr15:76606532	NA	-0.62	-10.45	-0.49	2.24e-22	Blood metabolite levels;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-7.32	-0.37	1.77e-12	Longevity;Endometriosis;
LIHC	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.55	7.73	0.39	1.21e-13	Blood protein levels;
LIHC	cis	rs1355223	0.902	rs2185700	chr11:34724204	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.37	-0.33	5.97e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-6.36	-0.33	6.59e-10	Renal cell carcinoma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11442381	chr3:52312806	WDR82	0.51	6.49	0.33	2.99e-10	Lung function (FEV1/FVC);
LIHC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.86	0.43	4.51e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.65	8.74	0.43	1.08e-16	Mean platelet volume;
LIHC	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg03342759	chr3:160939853	NMD3	-0.58	-8.0	-0.4	1.98e-14	Morning vs. evening chronotype;
LIHC	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg01666796	chr15:70364327	TLE3	-0.6	-7.57	-0.38	3.55e-13	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs78545713	1.000	rs114970164	chr6:26241993	G/C	cg16070018	chr6:26224392	HIST1H3E	0.68	7.25	0.37	2.75e-12	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.05	-0.55	4.04e-28	Colorectal cancer;
LIHC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.32	6.03	0.31	4.26e-9	Body mass index;
LIHC	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg09454613	chr16:77233327	SYCE1L;MON1B	-0.37	-5.83	-0.3	1.31e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	0.84	11.74	0.54	5.79e-27	Skin colour saturation;
LIHC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg04709771	chr16:646395	RAB40C	0.46	8.19	0.41	5.1e-15	Height;
LIHC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-5.78	-0.3	1.69e-8	Electroencephalogram traits;
LIHC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.7e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg06565975	chr8:143823917	SLURP1	0.34	6.57	0.33	1.84e-10	Urinary tract infection frequency;
LIHC	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.45	6.89	0.35	2.71e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg13446199	chr8:143762866	PSCA	-0.2	-5.78	-0.3	1.71e-8	Urinary tract infection frequency;
LIHC	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.71	10.98	0.51	3.07e-24	Metabolite levels;
LIHC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.52	7.55	0.38	4.04e-13	Type 2 diabetes;
LIHC	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg27433088	chr4:174089019	GALNT7	0.39	7.18	0.36	4.26e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg04498913	chr7:1135747	C7orf50	0.38	6.06	0.31	3.52e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	8.59	0.42	3.06e-16	Height;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.16	0.55	1.61e-28	Prudent dietary pattern;
LIHC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.39	0.68	5.86e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg05697976	chr12:29376483	FAR2	0.28	5.76	0.3	1.83e-8	QT interval;
LIHC	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.31	6.82	0.35	4.02e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.75	-10.69	-0.5	3.33e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.92	0.6	3.4000000000000003e-35	Glomerular filtration rate (creatinine);
LIHC	cis	rs4388979	0.595	rs9668456	chr12:109493428	C/T	cg03220751	chr12:109490328	USP30	0.6	9.41	0.45	7.4e-19	Plateletcrit;Platelet count;
LIHC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.61	-10.36	-0.49	4.6e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg26138144	chr22:38071188	LGALS1	0.41	7.42	0.37	9.25e-13	Fat distribution (HIV);
LIHC	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	8.91	0.43	3.18e-17	Exhaled nitric oxide levels;
LIHC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.24	-15.85	-0.65	7.92e-43	Diabetic kidney disease;
LIHC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg18944383	chr4:111397179	ENPEP	0.25	6.25	0.32	1.22e-9	Coronary artery disease;
LIHC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.42	6.0	0.31	4.97e-9	Blood protein levels;
LIHC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.4	-6.74	-0.34	6.75e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.36	6.03	0.31	4.26e-9	Height;
LIHC	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.26	6.23	0.32	1.39e-9	Heart rate;
LIHC	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	14.53	0.62	1.34e-37	Schizophrenia;
LIHC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12516959	chr21:47718080	NA	0.4	6.42	0.33	4.59e-10	Testicular germ cell tumor;
LIHC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.71	13.03	0.58	8.72e-32	Myeloid white cell count;
LIHC	trans	rs7693389	0.925	rs4376200	chr4:58463119	T/G	cg13593275	chr9:128777788	NA	0.56	6.11	0.31	2.75e-9	Diisocyanate-induced asthma;
LIHC	cis	rs12744310	0.887	rs12045979	chr1:41809477	A/G	cg03962019	chr1:41807865	NA	0.4	6.32	0.32	8e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg07148914	chr20:33460835	GGT7	-0.5	-7.1	-0.36	7.36e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.93	-0.47	1.36e-20	Obesity-related traits;
LIHC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg27523141	chr10:43048294	ZNF37B	0.39	6.74	0.34	6.92e-11	Extrinsic epigenetic age acceleration;
LIHC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.72	-11.93	-0.54	1.14e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs12079745	0.793	rs10919098	chr1:169189422	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.65	-6.13	-0.31	2.39e-9	QT interval;
LIHC	cis	rs79419269	0.673	rs2792430	chr7:150926360	A/G	cg01623806	chr7:150929509	CHPF2	-0.56	-5.87	-0.3	1.03e-8	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.71	7.31	0.37	1.95e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.38	-8.78	-0.43	8e-17	Cutaneous nevi;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg09417038	chr21:47716443	C21orf57	-0.46	-7.05	-0.36	1.01e-11	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg12798992	chr6:167411361	FGFR1OP	-0.61	-9.81	-0.47	3.56e-20	Crohn's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17451422	chr2:61293253	KIAA1841	-0.52	-6.05	-0.31	3.75e-9	Systolic blood pressure;
LIHC	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.41	-0.41	1.15e-15	Blood protein levels;
LIHC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.46	6.32	0.32	8.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.63	9.02	0.44	1.4e-17	Monocyte count;
LIHC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.47	0.53	5.43e-26	Hip circumference adjusted for BMI;
LIHC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.62	0.53	1.61e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.6	8.42	0.41	1.02e-15	Platelet count;
LIHC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.72	-0.39	1.27e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg07090678	chr1:91966139	CDC7	0.48	6.44	0.33	4.03e-10	Breast cancer;
LIHC	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.47	-7.24	-0.36	2.97e-12	Pubertal anthropometrics;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.62	-8.64	-0.42	2.18e-16	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18247177	chr17:7745472	KDM6B	0.44	6.3	0.32	9.13e-10	Pancreatic cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg23800573	chr21:45114399	RRP1B	0.44	6.97	0.35	1.67e-11	Immature fraction of reticulocytes;
LIHC	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg20240347	chr1:204465584	NA	-0.36	-7.61	-0.38	2.75e-13	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19853194	chr18:9913725	VAPA	0.47	7.57	0.38	3.45e-13	Pancreatic cancer;
LIHC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.39	-5.95	-0.31	6.81e-9	Menarche (age at onset);
LIHC	cis	rs6746896	0.959	rs2271893	chr2:97405440	G/A	cg26665480	chr2:98280029	ACTR1B	0.44	5.73	0.3	2.16e-8	Bipolar disorder;
LIHC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	5.86	0.3	1.08e-8	Schizophrenia;
LIHC	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.46	-9.33	-0.45	1.4e-18	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.36	5.76	0.3	1.89e-8	Menopause (age at onset);
LIHC	cis	rs5769765	0.773	rs9616751	chr22:50222236	T/G	cg09182678	chr22:50328711	NA	-0.46	-5.93	-0.31	7.32e-9	Schizophrenia;
LIHC	cis	rs10733682	0.659	rs13292976	chr9:129467340	C/T	cg00232160	chr9:129468157	NA	0.38	6.59	0.34	1.68e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg19318889	chr4:1322082	MAEA	0.43	5.95	0.31	6.65e-9	Obesity-related traits;
LIHC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.77	-0.43	8.43e-17	Monocyte count;
LIHC	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.72	11.27	0.52	2.97e-25	Phospholipid levels (plasma);
LIHC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.37	-0.56	2.66e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.38	5.76	0.3	1.92e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg15208524	chr1:10270712	KIF1B	0.44	6.37	0.33	6e-10	Hepatocellular carcinoma;
LIHC	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.44	8.49	0.42	6.59e-16	Testicular germ cell tumor;
LIHC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	6.2	0.32	1.66e-9	Resting heart rate;
LIHC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg00656387	chr3:40428638	ENTPD3	0.48	7.93	0.39	3.13e-14	Renal cell carcinoma;
LIHC	cis	rs10792665	0.934	rs10898060	chr11:82660037	A/G	cg24227371	chr11:82718527	RAB30	-0.31	-7.24	-0.36	2.97e-12	Obesity-related traits;
LIHC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.62	-9.26	-0.45	2.31e-18	Parkinson's disease;
LIHC	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.61	-0.38	2.77e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.52	7.45	0.37	7.84e-13	Glycated hemoglobin levels;
LIHC	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.82	-0.3	1.33e-8	Systemic lupus erythematosus;
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg01444801	chr10:135216882	MTG1	-0.64	-9.56	-0.46	2.41e-19	Systemic lupus erythematosus;
LIHC	cis	rs12493885	0.769	rs61791508	chr3:153750816	A/G	cg10247383	chr3:153839028	SGEF	0.61	5.77	0.3	1.8e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.65	-0.38	2.03e-13	Morning vs. evening chronotype;
LIHC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.52	-9.19	-0.44	3.98e-18	Total body bone mineral density;
LIHC	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg06804625	chr1:109812012	CELSR2	-0.4	-5.73	-0.3	2.21e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs1669338	0.588	rs6788122	chr3:3171897	T/C	cg16797762	chr3:3221439	CRBN	-0.79	-7.15	-0.36	5.26e-12	White matter integrity;
LIHC	cis	rs2455799	0.573	rs2455793	chr3:15743844	A/G	cg12698662	chr3:15914712	MIR563	-0.35	-6.36	-0.33	6.42e-10	Mean platelet volume;
LIHC	trans	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg10756647	chr7:56101905	PSPH	-0.47	-6.89	-0.35	2.66e-11	Calcium levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03315687	chr19:40932206	SERTAD1	0.38	6.15	0.32	2.13e-9	Cognitive function;
LIHC	cis	rs62458065	1.000	rs1450868	chr7:32463666	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.65	-7.42	-0.37	9.08e-13	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.64	6.89	0.35	2.73e-11	Type 2 diabetes;
LIHC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.56	-9.21	-0.45	3.48e-18	Colorectal cancer;
LIHC	cis	rs17106184	0.892	rs11205766	chr1:51191935	T/A	cg07174182	chr1:51127561	FAF1	-0.64	-7.32	-0.37	1.77e-12	Type 2 diabetes;
LIHC	cis	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.68	-0.34	9.84e-11	Colorectal or endometrial cancer;
LIHC	cis	rs57920188	0.568	rs12137595	chr1:4094068	C/T	cg20703997	chr1:4087676	NA	0.67	6.49	0.33	2.95e-10	Interleukin-17 levels;
LIHC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.39	6.36	0.33	6.45e-10	Facial morphology (factor 20);
LIHC	trans	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg17675199	chr6:35436792	RPL10A	-0.44	-9.12	-0.44	6.8e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg03146154	chr1:46216737	IPP	-0.37	-6.16	-0.32	1.99e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-8.5	-0.42	6.15e-16	Chronic sinus infection;
LIHC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg15691649	chr6:25882328	NA	-0.63	-8.0	-0.4	1.96e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.5	7.83	0.39	6.02e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg07706471	chr12:123319906	HIP1R	-0.61	-8.02	-0.4	1.68e-14	Schizophrenia;
LIHC	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-7.31	-0.37	1.93e-12	Crohn's disease;
LIHC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-0.91	-15.94	-0.65	3.5e-43	Testicular germ cell tumor;
LIHC	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg20568497	chr10:133558893	NA	0.4	6.12	0.31	2.59e-9	Survival in rectal cancer;
LIHC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg19318889	chr4:1322082	MAEA	0.47	6.59	0.34	1.68e-10	Obesity-related traits;
LIHC	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg22951263	chr5:87985283	NA	-0.39	-6.73	-0.34	7.35e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.44	0.66	3.67e-45	Smoking behavior;
LIHC	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.76	0.39	9.98e-14	Triglyceride levels;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-6.82	-0.35	4.05e-11	Longevity;Endometriosis;
LIHC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.32	-5.73	-0.3	2.21e-8	Migraine;Coronary artery disease;
LIHC	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg15704280	chr7:45808275	SEPT13	0.62	6.45	0.33	3.86e-10	Axial length;
LIHC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.74	9.18	0.44	4.31e-18	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.75	-12.58	-0.56	4.3e-30	Aortic root size;
LIHC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11987759	chr7:65425863	GUSB	0.39	6.21	0.32	1.56e-9	Aortic root size;
LIHC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.48	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.46	7.49	0.38	5.86e-13	Response to temozolomide;
LIHC	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.24	-0.32	1.3e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.88	-0.43	3.84e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	25.6	0.81	1.67e-81	Prudent dietary pattern;
LIHC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-11.29	-0.52	2.41e-25	Cognitive ability;
LIHC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg19635926	chr16:89946313	TCF25	0.51	6.41	0.33	4.89e-10	Skin colour saturation;
LIHC	cis	rs922107	0.738	rs2390762	chr1:90052626	A/G	cg15422784	chr1:90023713	LRRC8B	-0.5	-7.99	-0.4	2.06e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.42	7.41	0.37	9.7e-13	Testicular germ cell tumor;
LIHC	cis	rs2084898	0.891	rs501021	chr11:120000872	T/C	cg13907859	chr11:120009124	TRIM29	-0.53	-6.57	-0.33	1.86e-10	Stroke (pediatric);
LIHC	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.7	8.95	0.44	2.37e-17	Exhaled nitric oxide output;
LIHC	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs10861342	1.000	rs10861350	chr12:105484913	G/A	cg23923672	chr12:105501055	KIAA1033	0.64	7.47	0.37	6.71e-13	IgG glycosylation;
LIHC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.73	-9.82	-0.47	3.16e-20	Asthma;
LIHC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs365132	0.870	rs2454949	chr5:176466011	G/A	cg16309518	chr5:176445507	NA	-0.58	-11.2	-0.52	5.06e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.96	-0.4	2.51e-14	Response to antipsychotic treatment;
LIHC	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.82	0.35	4.15e-11	Educational attainment;
LIHC	cis	rs34375054	0.573	rs12823172	chr12:125646283	C/G	cg25124228	chr12:125621409	AACS	-0.43	-6.72	-0.34	7.74e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-5.78	-0.3	1.73e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12016809	chr21:47604291	C21orf56	0.48	7.17	0.36	4.63e-12	Testicular germ cell tumor;
LIHC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg17724175	chr1:150552817	MCL1	0.39	7.63	0.38	2.29e-13	Melanoma;
LIHC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg22777020	chr22:31556080	RNF185	-0.55	-6.29	-0.32	9.49e-10	Colorectal cancer;
LIHC	cis	rs831571	0.550	rs153734	chr3:64078009	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.5	-6.61	-0.34	1.44e-10	Type 2 diabetes;
LIHC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-0.78	-9.68	-0.46	9.23e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-0.76	-8.35	-0.41	1.75e-15	Exhaled nitric oxide output;
LIHC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.64	12.06	0.55	3.72e-28	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg23091122	chr1:110024289	SYPL2	-0.48	-6.46	-0.33	3.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-23.05	-0.78	1.27e-71	Height;
LIHC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.76	-12.65	-0.56	2.48e-30	Breast cancer;
LIHC	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-9.28	-0.45	1.99e-18	Response to antipsychotic treatment;
LIHC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08011328	chr6:41889049	MED20;BYSL	0.46	6.63	0.34	1.34e-10	Pancreatic cancer;
LIHC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.58	0.38	3.34e-13	Bipolar disorder;
LIHC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.7	0.34	8.36e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.58	-7.79	-0.39	8.24e-14	Diastolic blood pressure;
LIHC	cis	rs2637266	1.000	rs11001829	chr10:78343387	A/T	cg18941641	chr10:78392320	NA	0.3	6.41	0.33	4.93e-10	Pulmonary function;
LIHC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.68	-12.6	-0.56	3.74e-30	Refractive error;
LIHC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21747090	chr2:27597821	SNX17	-0.47	-7.04	-0.36	1.05e-11	Total body bone mineral density;
LIHC	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.06	-0.31	3.57e-9	Blood pressure;
LIHC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.3	-0.58	7.93e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs1704198	1.000	rs861229	chr1:213898329	C/T	cg02442787	chr4:139230014	NA	0.4	6.14	0.32	2.32e-9	Obesity;
LIHC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.79	-11.72	-0.54	6.73e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.91e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.26	12.96	0.57	1.55e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.12	0.31	2.55e-9	Mean corpuscular volume;
LIHC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.5	-8.86	-0.43	4.55e-17	Neuroticism;
LIHC	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.9	-14.88	-0.63	5.71e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.47	7.07	0.36	8.95e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs847649	0.692	rs10257317	chr7:102447056	T/C	cg18108683	chr7:102477205	FBXL13	-0.51	-7.83	-0.39	6.02e-14	Morning vs. evening chronotype;
LIHC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.39	-0.45	8.43e-19	Mean platelet volume;
LIHC	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.77	10.54	0.5	1.12e-22	Left atrial antero-posterior diameter;
LIHC	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.93	0.35	2.04e-11	Bipolar disorder;
LIHC	cis	rs10508774	1.000	rs12413262	chr10:32910504	G/C	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.35	6.46	0.33	3.65e-10	Aortic root size;
LIHC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.95	0.39	2.83e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg20194872	chr6:41519635	FOXP4	0.4	6.48	0.33	3.16e-10	Prostate cancer;
LIHC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.48	0.37	6.3e-13	Bone mineral density;
LIHC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	12.31	0.55	4.43e-29	Motion sickness;
LIHC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.7	-13.23	-0.58	1.44e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.78e-10	Obesity-related traits;
LIHC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg12046867	chr14:103022105	NA	0.48	6.88	0.35	2.85e-11	Platelet count;
LIHC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.53	-0.62	1.34e-37	Alzheimer's disease (late onset);
LIHC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-11.04	-0.51	2e-24	Platelet count;
LIHC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg20607798	chr8:58055168	NA	0.47	6.75	0.34	6.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.45	6.3	0.32	9.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.32	8.75e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13409248	chr3:40428643	ENTPD3	0.48	7.86	0.39	4.91e-14	Renal cell carcinoma;
LIHC	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	ch.11.42038R	chr11:967971	AP2A2	0.53	9.57	0.46	2.17e-19	Alzheimer's disease (late onset);
LIHC	cis	rs4716602	0.596	rs10949585	chr7:156165258	A/C	cg16983916	chr7:156159713	NA	-0.33	-5.8	-0.3	1.48e-8	Anti-saccade response;
LIHC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.51	8.38	0.41	1.38e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg02829992	chr2:10710499	NA	-0.38	-6.05	-0.31	3.75e-9	Prostate cancer;
LIHC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.61	-10.07	-0.48	4.66e-21	Post bronchodilator FEV1;
LIHC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.21	0.36	3.64e-12	Monocyte percentage of white cells;
LIHC	cis	rs67981189	0.593	rs8007425	chr14:71508200	A/G	cg15816911	chr14:71606274	NA	0.43	6.96	0.35	1.76e-11	Schizophrenia;
LIHC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.68	12.15	0.55	1.69e-28	Lewy body disease;
LIHC	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg20697417	chr1:41786797	NA	0.31	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.68	8.76	0.43	8.95e-17	Exhaled nitric oxide output;
LIHC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg18769074	chr3:133464867	TF	0.27	6.03	0.31	4.26e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.5	-8.02	-0.4	1.72e-14	Fibrinogen levels;
LIHC	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.5	7.03	0.36	1.1e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg06787764	chr1:46668870	C1orf190;POMGNT1	-0.49	-7.38	-0.37	1.2e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.65	-12.49	-0.56	9.64e-30	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16606324	chr3:10149918	C3orf24	0.49	5.71	0.3	2.45e-8	Alzheimer's disease;
LIHC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.82	-0.57	5.2e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg10820045	chr2:198174542	NA	0.54	8.65	0.42	2.1e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg22705602	chr4:152727874	NA	-0.29	-6.06	-0.31	3.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg03013999	chr17:37608204	MED1	0.35	5.8	0.3	1.49e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.61	-0.42	2.68e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.74	-0.3	2.04e-8	Colorectal cancer;
LIHC	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.33	0.41	1.96e-15	Schizophrenia;
LIHC	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	15.39	0.64	5.38e-41	Lung cancer in ever smokers;
LIHC	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg24069376	chr3:38537580	EXOG	0.43	7.9	0.39	3.93e-14	Electrocardiographic conduction measures;
LIHC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.67	10.53	0.49	1.25e-22	Prostate cancer;
LIHC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	0.96	10.03	0.48	6.58e-21	Vitiligo;
LIHC	cis	rs611744	0.967	rs686265	chr8:109199763	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	trans	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg26951091	chr14:76844913	ESRRB	0.55	6.09	0.31	2.97e-9	Putamen volume;
LIHC	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.36	-8.18	-0.4	5.66e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.38	-5.72	-0.3	2.36e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.54	8.39	0.41	1.28e-15	Multiple sclerosis;
LIHC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg04374321	chr14:90722782	PSMC1	0.7	13.12	0.58	3.83e-32	Mortality in heart failure;
LIHC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2412488	0.893	rs17082893	chr4:54353275	C/T	cg22241045	chr4:54363911	LNX1	-0.41	-6.72	-0.34	7.68e-11	DNA methylation (variation);
LIHC	trans	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.59	-0.34	1.68e-10	Educational attainment (years of education);
LIHC	trans	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.66	-0.34	1.1e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18779695	chr6:36164024	BRPF3	0.41	6.37	0.33	6.24e-10	Cognitive function;
LIHC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg12046867	chr14:103022105	NA	0.56	8.44	0.42	8.99e-16	Platelet count;
LIHC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.85	-14.08	-0.61	7.52e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	7.91	0.39	3.58e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21467203	chr3:49911342	NA	-0.52	-9.67	-0.46	1.07e-19	Body mass index;
LIHC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.45	-6.14	-0.32	2.31e-9	Blood pressure (smoking interaction);
LIHC	cis	rs7520050	0.872	rs1707308	chr1:46604315	G/A	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.38	5.87	0.3	1.04e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.59	-10.14	-0.48	2.72e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	8.33	0.41	1.92e-15	Height;
LIHC	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-7.04	-0.36	1.08e-11	Metabolite levels;
LIHC	cis	rs10861342	1.000	rs10861353	chr12:105515290	T/C	cg23923672	chr12:105501055	KIAA1033	0.66	7.75	0.39	1.08e-13	IgG glycosylation;
LIHC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.92	14.64	0.62	5.03e-38	Vitamin D levels;
LIHC	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg00204748	chr12:29376779	FAR2	0.34	6.43	0.33	4.3e-10	QT interval;
LIHC	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.7	7.74	0.39	1.11e-13	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.57	0.53	2.35e-26	Motion sickness;
LIHC	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.51	8.94	0.44	2.43e-17	Coronary artery disease;
LIHC	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	0.87	5.97	0.31	6.1e-9	Mitochondrial DNA levels;
LIHC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.53	-7.47	-0.37	6.91e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs860626	0.536	rs4751627	chr10:119312103	C/T	cg10846980	chr10:119306025	EMX2;EMX2OS	-0.53	-8.12	-0.4	8.79e-15	Neuroticism;
LIHC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.73	-0.3	2.16e-8	Life satisfaction;
LIHC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg13319975	chr6:146136371	FBXO30	0.35	5.86	0.3	1.06e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.11e-13	Lung cancer;
LIHC	cis	rs7799006	0.723	rs33922585	chr7:2285178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.38	-5.78	-0.3	1.64e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs11673344	0.704	rs571340	chr19:37424883	C/T	cg27390819	chr19:37464633	NA	-0.51	-6.14	-0.31	2.34e-9	Obesity-related traits;
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.1	0.31	2.87e-9	Renal cell carcinoma;
LIHC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.73	-11.28	-0.52	2.76e-25	Corneal astigmatism;
LIHC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.71	11.7	0.53	8.02e-27	Lymphocyte percentage of white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg21468385	chr11:120207433	ARHGEF12	0.43	6.36	0.33	6.43e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10454142	0.700	rs11690845	chr2:48584826	A/G	cg15846641	chr2:48541264	FOXN2	-0.46	-5.75	-0.3	1.98e-8	Sex hormone-binding globulin levels;
LIHC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg24296786	chr1:45957014	TESK2	-0.41	-6.06	-0.31	3.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg15704280	chr7:45808275	SEPT13	-0.45	-6.72	-0.34	7.45e-11	HDL cholesterol;
LIHC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.72	-8.4	-0.41	1.18e-15	Neuroticism;
LIHC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	1.01	19.32	0.72	9.73e-57	Breast cancer;
LIHC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.7	9.84	0.47	2.77e-20	Selective IgA deficiency;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.84	0.3	1.23e-8	Calcium levels;
LIHC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-10.65	-0.5	4.76e-23	Colorectal cancer;
LIHC	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.88	13.71	0.6	2.1e-34	Gastritis;
LIHC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.47	-7.5	-0.38	5.42e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.43	8.47	0.42	7.24e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.84	12.68	0.57	1.82e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg17182837	chr8:41585554	ANK1	-0.23	-5.85	-0.3	1.13e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.75	0.34	6.52e-11	Height;
LIHC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.88	8.49	0.42	6.42e-16	Plasma clusterin levels;
LIHC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg11764359	chr7:65958608	NA	0.58	5.98	0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs12249377	0.519	rs10881838	chr10:92590233	A/G	cg14313238	chr10:92632228	RPP30	0.38	6.37	0.33	5.94e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs10861342	1.000	rs10778370	chr12:105603139	T/C	cg23923672	chr12:105501055	KIAA1033	0.66	7.7	0.38	1.46e-13	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.7	0.43	1.42e-16	Prudent dietary pattern;
LIHC	cis	rs16837677	0.826	rs3795737	chr1:156697056	A/G	cg19377421	chr1:156697041	ISG20L2;C1orf66	0.65	7.73	0.39	1.19e-13	Sjögren's syndrome;
LIHC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg21526220	chr14:64108088	WDR89	-0.43	-6.24	-0.32	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.69	-12.98	-0.57	1.37e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.39	-5.77	-0.3	1.81e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.45	0.42	8.28e-16	Lymphocyte counts;
LIHC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.68	-9.71	-0.47	7.32e-20	Intelligence (multi-trait analysis);
LIHC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.53	6.8	0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.7	-13.15	-0.58	2.95e-32	Height;
LIHC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	6.78	0.34	5.38e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-6.47	-0.33	3.34e-10	Blood pressure (smoking interaction);
LIHC	trans	rs1805008	0.561	rs8046635	chr16:90123493	C/T	cg17139369	chr19:8478169	MARCH2	0.56	6.18	0.32	1.83e-9	Skin colour saturation;
LIHC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.86	11.98	0.54	7.63e-28	Post bronchodilator FEV1;
LIHC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg06565975	chr8:143823917	SLURP1	-0.45	-8.35	-0.41	1.76e-15	Urinary tract infection frequency;
LIHC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.45	6.29	0.32	9.45e-10	Obesity-related traits;
LIHC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg15448220	chr1:150897856	SETDB1	0.43	6.59	0.34	1.69e-10	Blood protein levels;
LIHC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.33	-6.19	-0.32	1.71e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg02290350	chr8:58132656	NA	0.3	6.85	0.35	3.41e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.79	12.25	0.55	7.55e-29	Menarche (age at onset);
LIHC	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.57	6.61	0.34	1.5e-10	Eye color traits;
LIHC	cis	rs1144333	0.510	rs1250882	chr1:76287314	C/A	cg22875332	chr1:76189707	ACADM	-0.43	-6.51	-0.33	2.67e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.87	-0.3	1.02e-8	Schizophrenia;
LIHC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.56	-0.5	9.76e-23	Total cholesterol levels;
LIHC	cis	rs3791556	0.501	rs3791533	chr2:240100616	G/A	cg03281426	chr2:240109471	HDAC4	0.38	6.18	0.32	1.84e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.84	13.73	0.6	1.78e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.6	7.32	0.37	1.79e-12	Corneal structure;
LIHC	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.16	-0.4	6.51e-15	Body mass index;
LIHC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.65	0.46	1.18e-19	Menarche (age at onset);
LIHC	cis	rs420259	0.727	rs249871	chr16:23664503	C/T	cg05131483	chr16:23706242	ERN2	0.34	5.8	0.3	1.47e-8	Bipolar disorder;
LIHC	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.65	7.16	0.36	4.86e-12	Lymphocyte percentage of white cells;
LIHC	cis	rs151997	0.508	rs9292165	chr5:50272619	T/C	cg06027927	chr5:50259733	NA	0.54	6.6	0.34	1.61e-10	Callous-unemotional behaviour;
LIHC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.33	0.41	1.99e-15	Platelet count;
LIHC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.53	7.86	0.39	5e-14	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg18306943	chr3:40428807	ENTPD3	0.34	6.06	0.31	3.55e-9	Renal cell carcinoma;
LIHC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg12798992	chr6:167411361	FGFR1OP	0.44	6.65	0.34	1.13e-10	Primary biliary cholangitis;
LIHC	trans	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg17675199	chr6:35436792	RPL10A	0.34	6.68	0.34	9.71e-11	Coronary artery disease;
LIHC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.69	11.19	0.52	5.62e-25	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.4	0.59	3.42e-33	Diabetic kidney disease;
LIHC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.74	13.42	0.59	2.89e-33	Ewing sarcoma;
LIHC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs2637266	0.967	rs2395407	chr10:78380573	T/A	cg18941641	chr10:78392320	NA	0.3	6.53	0.33	2.43e-10	Pulmonary function;
LIHC	cis	rs67981189	0.634	rs221891	chr14:71611627	C/T	cg15816911	chr14:71606274	NA	-0.42	-6.73	-0.34	7.34e-11	Schizophrenia;
LIHC	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.7	0.43	1.42e-16	Motion sickness;
LIHC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.94	17.78	0.69	1.48e-50	Menopause (age at onset);
LIHC	cis	rs4934494	0.768	rs1409357	chr10:91429476	G/A	cg19698084	chr10:91461284	KIF20B	-0.49	-6.45	-0.33	3.76e-10	Red blood cell count;
LIHC	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	0.94	17.92	0.7	3.96e-51	Schizophrenia;
LIHC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg07636037	chr3:49044803	WDR6	-0.66	-6.17	-0.32	1.95e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.62	-7.77	-0.39	9.51e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20135002	chr11:47629003	NA	-0.51	-8.59	-0.42	3.11e-16	Subjective well-being;
LIHC	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.33	-5.93	-0.31	7.54e-9	Lewy body disease;
LIHC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.91	13.84	0.6	6.78e-35	Sudden cardiac arrest;
LIHC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.41	6.44	0.33	4.1e-10	Obesity-related traits;
LIHC	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.91	12.07	0.55	3.48e-28	Macular telangiectasia type 2;
LIHC	cis	rs965469	1.000	rs77763497	chr20:3250007	A/G	cg25506879	chr20:3388711	C20orf194	-0.58	-6.94	-0.35	1.99e-11	IFN-related cytopenia;
LIHC	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	9.25	0.45	2.56e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.65	0.38	2.08e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.17	0.48	2.04e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.45	-6.98	-0.35	1.52e-11	Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26823989	chr1:87380673	SEP15;HS2ST1	0.42	6.32	0.32	8.22e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.53	5.77	0.3	1.73e-8	Alzheimer's disease;
LIHC	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.92	-0.35	2.17e-11	Metabolite levels;
LIHC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05944369	chr4:174255616	HMGB2	0.41	6.06	0.31	3.68e-9	Electrocardiographic conduction measures;
LIHC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.4	-0.33	5.01e-10	Monocyte percentage of white cells;
LIHC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.77	11.65	0.53	1.17e-26	Subjective well-being;
LIHC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.54	7.48	0.37	6.36e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-11.92	-0.54	1.22e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.56	9.41	0.45	7.31e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.94	20.34	0.74	7.61e-61	Blood protein levels;
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg02990361	chr1:107599529	PRMT6	-0.61	-9.78	-0.47	4.42e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg03037974	chr15:76606532	NA	0.71	13.73	0.6	1.72e-34	Blood metabolite levels;
LIHC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	7.6	0.38	2.81e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	10.49	0.49	1.65e-22	Hemoglobin concentration;
LIHC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.6	5.85	0.3	1.15e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.7	-10.52	-0.49	1.3e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg18887096	chr2:219472410	PLCD4	0.37	6.45	0.33	3.92e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	0.86	14.74	0.62	2.01e-38	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.57	-9.52	-0.46	3.36e-19	Height;
LIHC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.46	-6.28	-0.32	1.03e-9	Longevity;
LIHC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.68	11.86	0.54	2.1e-27	Menopause (age at onset);
LIHC	trans	rs903027	0.752	rs11774171	chr8:62477247	C/T	cg11014794	chr10:93999688	CPEB3	0.4	6.13	0.31	2.42e-9	Whole-brain volume;
LIHC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.8	-0.39	7.55e-14	Type 2 diabetes;
LIHC	cis	rs72627123	0.749	rs10149956	chr14:74649106	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.88	-8.37	-0.41	1.53e-15	Morning vs. evening chronotype;
LIHC	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.94	-17.68	-0.69	3.78e-50	Schizophrenia;
LIHC	cis	rs12286929	0.644	rs7942036	chr11:115078356	G/C	cg04055981	chr11:115044050	NA	0.54	8.76	0.43	9.05e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-13.75	-0.6	1.53e-34	Body mass index;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.23	-7.24	-0.36	2.92e-12	Mean corpuscular volume;
LIHC	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg16322792	chr1:120165303	ZNF697	0.46	8.45	0.42	8.77e-16	Systemic lupus erythematosus;
LIHC	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg20129853	chr10:51489980	NA	-0.42	-9.18	-0.44	4.36e-18	Prostate-specific antigen levels;
LIHC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-9.37	-0.45	9.81e-19	Mean corpuscular volume;
LIHC	cis	rs17106184	1.000	rs60788683	chr1:51262653	A/C	cg07174182	chr1:51127561	FAF1	-0.64	-7.04	-0.36	1.03e-11	Type 2 diabetes;
LIHC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.74	7.41	0.37	9.67e-13	Platelet count;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17504306	chr11:2951538	PHLDA2	0.43	6.45	0.33	3.75e-10	Calcium levels;
LIHC	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.18	-0.4	5.45e-15	Capecitabine sensitivity;
LIHC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.31	0.66	1.25e-44	Parkinson's disease;
LIHC	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.41	6.2	0.32	1.63e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.04	0.31	3.98e-9	Blood metabolite levels;
LIHC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.76	0.3	1.89e-8	Vitiligo;
LIHC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.68	10.52	0.49	1.3e-22	Height;
LIHC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg13753209	chr17:57696993	CLTC	0.76	12.16	0.55	1.65e-28	Hemoglobin concentration;
LIHC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg17980119	chr2:219472607	PLCD4	0.35	5.91	0.3	8.24e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-9.44	-0.45	6.15e-19	Ulcerative colitis;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg07133347	chr1:107600762	PRMT6	-0.4	-5.8	-0.3	1.54e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.69	13.69	0.59	2.57e-34	Coronary artery disease;
LIHC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.33	-0.49	6.14e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg05185784	chr16:90016020	DEF8	-0.45	-5.88	-0.3	9.64e-9	Skin colour saturation;
LIHC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.98	-0.31	5.74e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9918079	0.560	rs7685083	chr4:15610771	G/A	cg21123203	chr4:15471301	CC2D2A	0.45	7.24	0.36	3.06e-12	Obesity-related traits;
LIHC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.73	15.59	0.64	8.61e-42	Itch intensity from mosquito bite;
LIHC	cis	rs12986413	0.781	rs2864419	chr19:2183175	A/C	cg09261902	chr19:2140048	AP3D1	-0.38	-6.54	-0.33	2.29e-10	Height;
LIHC	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.34	-6.68	-0.34	9.71e-11	DNA methylation (variation);
LIHC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg01518246	chr11:63870912	FLRT1;MACROD1	0.47	6.54	0.33	2.27e-10	Mean platelet volume;
LIHC	cis	rs16828019	0.777	rs3738369	chr1:41486408	G/A	cg03962019	chr1:41807865	NA	0.49	6.85	0.35	3.43e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg16309518	chr5:176445507	NA	-0.52	-10.0	-0.48	7.92e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.47	-5.77	-0.3	1.76e-8	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.51	0.33	2.66e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27297192	chr10:134578999	INPP5A	0.51	8.08	0.4	1.14e-14	Migraine;
LIHC	cis	rs10949834	0.824	rs2285025	chr7:73529976	T/C	cg07137043	chr7:73588983	EIF4H	-0.6	-6.01	-0.31	4.74e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	6.01	0.31	4.68e-9	Multiple sclerosis;
LIHC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg15691649	chr6:25882328	NA	-0.5	-7.44	-0.37	8.05e-13	Blood metabolite levels;
LIHC	cis	rs10845606	0.505	rs2417221	chr12:12829914	C/T	cg04607235	chr12:12878440	APOLD1	0.44	6.35	0.32	6.71e-10	Systemic lupus erythematosus;
LIHC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg00656387	chr3:40428638	ENTPD3	0.38	6.08	0.31	3.29e-9	Renal cell carcinoma;
LIHC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.15	0.36	5.31e-12	Self-reported allergy;
LIHC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg18192155	chr21:44258298	NA	0.45	7.11	0.36	6.69e-12	Information processing speed;
LIHC	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg10820045	chr2:198174542	NA	0.44	6.79	0.34	5.06e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4917833	1.000	rs4917833	chr10:100217808	A/G	cg19043522	chr10:100227446	HPSE2	-0.4	-5.82	-0.3	1.39e-8	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.53	-7.91	-0.39	3.53e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02985541	chr2:219472218	PLCD4	0.45	8.6	0.42	2.98e-16	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg17042098	chr1:61519631	NA	0.49	6.59	0.34	1.69e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg03517284	chr6:25882590	NA	0.42	6.33	0.32	7.76e-10	Blood metabolite levels;
LIHC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	5.92	0.31	7.67e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs57590327	0.504	rs4856349	chr3:81502928	C/T	cg07356753	chr3:81810745	GBE1	0.45	6.57	0.33	1.83e-10	Extraversion;
LIHC	cis	rs1712517	0.873	rs1163086	chr10:105039579	A/G	cg05636881	chr10:105038444	INA	0.41	6.41	0.33	4.85e-10	Migraine;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg07928289	chr15:42783210	NA	-0.44	-6.2	-0.32	1.63e-9	Alopecia areata;
LIHC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.54	-8.67	-0.42	1.75e-16	Height;
LIHC	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.42	-6.26	-0.32	1.16e-9	Coronary artery disease;
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.57	8.57	0.42	3.65e-16	Testicular germ cell tumor;
LIHC	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.45	7.32	0.37	1.84e-12	Corneal astigmatism;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01246421	chr22:18632905	USP18	-0.48	-6.14	-0.32	2.24e-9	Systolic blood pressure;
LIHC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.71	10.42	0.49	2.8e-22	Aortic root size;
LIHC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.71	7.64	0.38	2.21e-13	Bipolar disorder;
LIHC	cis	rs903552	0.800	rs1587107	chr15:102006485	T/C	cg06707286	chr15:102010195	PCSK6	-0.49	-6.86	-0.35	3.34e-11	Diabetic kidney disease;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg05185784	chr16:90016020	DEF8	0.44	6.13	0.31	2.44e-9	Skin colour saturation;
LIHC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.75e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.92	14.68	0.62	3.48e-38	Tonsillectomy;
LIHC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.41	-6.72	-0.34	7.74e-11	Dementia with Lewy bodies;
LIHC	cis	rs4728302	0.869	rs10156088	chr7:133592544	G/A	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg14793835	chr3:28283034	CMC1	0.45	6.21	0.32	1.56e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs801193	0.773	rs801207	chr7:66020590	T/C	cg26939375	chr7:64535504	NA	-0.44	-7.46	-0.37	7.43e-13	Aortic root size;
LIHC	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg04610667	chr7:75704037	NA	-0.36	-6.41	-0.33	4.96e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs72627123	0.867	rs78496651	chr14:74480070	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.2	0.45	3.67e-18	Morning vs. evening chronotype;
LIHC	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.74	-0.3	2.1e-8	Coronary artery disease;
LIHC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.63	-0.53	1.47e-26	Coronary artery disease;
LIHC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg18270830	chr10:32634957	EPC1	0.54	6.59	0.34	1.68e-10	Sexual dysfunction (female);
LIHC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.74	9.66	0.46	1.11e-19	Coronary artery disease;
LIHC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.71	-7.81	-0.39	6.85e-14	Neuroticism;
LIHC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.08	20.6	0.74	6.86e-62	Multiple system atrophy;
LIHC	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.24	-0.32	1.31e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.21	-0.36	3.61e-12	Metabolite levels (Pyroglutamine);
LIHC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.16	0.36	5.01e-12	Height;
LIHC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.71	0.34	7.97e-11	Bipolar disorder;
LIHC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.65	-12.29	-0.55	5.17e-29	Systemic lupus erythematosus;
LIHC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11987759	chr7:65425863	GUSB	-0.38	-6.02	-0.31	4.48e-9	Aortic root size;
LIHC	trans	rs7120489	0.786	rs12281138	chr11:12453702	G/A	cg08537300	chr5:179058959	NA	0.56	6.04	0.31	3.95e-9	Mortality in heart failure;
LIHC	cis	rs4920343	0.698	rs851121	chr1:19087765	C/T	cg26220594	chr1:19110978	NA	0.28	5.72	0.3	2.38e-8	Knee osteoarthritis;
LIHC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.71	-10.09	-0.48	3.85e-21	Pancreatic cancer;
LIHC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-10.57	-0.5	8.53e-23	Primary sclerosing cholangitis;
LIHC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.57	-6.03	-0.31	4.36e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.73	0.43	1.17e-16	Motion sickness;
LIHC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.38	0.64	5.93e-41	Chronic sinus infection;
LIHC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg26441486	chr22:50317300	CRELD2	0.36	6.38	0.33	5.73e-10	Schizophrenia;
LIHC	cis	rs6967414	0.685	rs6944332	chr7:6758018	G/A	cg00387323	chr7:6746715	ZNF12	0.67	7.47	0.37	6.56e-13	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.44	-6.07	-0.31	3.4e-9	Inflammatory biomarkers;
LIHC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg03959625	chr15:84868606	LOC388152	0.45	6.32	0.32	8.1e-10	Schizophrenia;
LIHC	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.54	-6.92	-0.35	2.17e-11	Prostate cancer;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13409248	chr3:40428643	ENTPD3	0.49	8.27	0.41	3.08e-15	Renal cell carcinoma;
LIHC	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.93	0.54	1.12e-27	Eye color traits;
LIHC	cis	rs6466055	0.720	rs2040914	chr7:104972174	A/G	cg04380332	chr7:105027541	SRPK2	0.35	6.74	0.34	6.76e-11	Schizophrenia;
LIHC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.47	-7.37	-0.37	1.29e-12	Multiple myeloma;
LIHC	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.46	0.46	5.13e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.44	-6.06	-0.31	3.69e-9	Menopause (age at onset);
LIHC	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.23e-24	Breast cancer;
LIHC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.24	-7.49	-0.38	6.04e-13	Mean corpuscular volume;
LIHC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg00204512	chr16:28754710	NA	0.35	6.42	0.33	4.63e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg24069376	chr3:38537580	EXOG	-0.38	-7.04	-0.36	1.06e-11	Electrocardiographic conduction measures;
LIHC	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg12253828	chr6:101329408	ASCC3	-0.41	-6.28	-0.32	1.04e-9	Neuroticism;
LIHC	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.38	5.85	0.3	1.17e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6750047	0.585	rs336033	chr2:38263808	A/G	cg07380506	chr2:38303506	CYP1B1	-0.59	-7.47	-0.37	6.71e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.21	0.48	1.53e-21	Diabetic retinopathy;
LIHC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21467203	chr3:49911342	NA	-0.44	-7.91	-0.39	3.57e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.03	15.83	0.65	1e-42	Breast cancer;
LIHC	cis	rs72627509	0.680	rs79641006	chr4:57847443	T/G	cg26694713	chr4:57773883	REST	0.65	8.69	0.43	1.53e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg05791018	chr13:19965014	NA	-0.28	-6.16	-0.32	2e-9	Schizophrenia;
LIHC	trans	rs3783890	1.000	rs12892710	chr14:93746091	A/C	cg02802420	chr16:69363236	PDF;COG8	0.32	6.22	0.32	1.44e-9	Body mass index;
LIHC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.64	-0.46	1.35e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.71	-0.57	1.46e-30	Alzheimer's disease;
LIHC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	13.0	0.58	1.15e-31	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg07424592	chr7:64974309	NA	0.77	8.99	0.44	1.74e-17	Diabetic kidney disease;
LIHC	cis	rs6466055	0.669	rs2003506	chr7:104761741	A/G	cg04380332	chr7:105027541	SRPK2	-0.3	-6.04	-0.31	4.02e-9	Schizophrenia;
LIHC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.75	0.47	5.46e-20	Mean platelet volume;
LIHC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.83e-10	Aortic root size;
LIHC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg04013166	chr16:89971882	TCF25	0.52	6.46	0.33	3.55e-10	Skin colour saturation;
LIHC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg06046430	chr4:77819534	ANKRD56	0.49	6.48	0.33	3.18e-10	Emphysema distribution in smoking;
LIHC	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.47	-0.33	3.42e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg24209194	chr3:40518798	ZNF619	0.45	6.46	0.33	3.69e-10	Renal cell carcinoma;
LIHC	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.77	-15.04	-0.63	1.39e-39	Longevity;
LIHC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.82	-0.3	1.36e-8	Morning vs. evening chronotype;
LIHC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg03989125	chr22:38214979	NA	-0.44	-6.03	-0.31	4.34e-9	Glioblastoma;Glioma;
LIHC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.45	6.62	0.34	1.4e-10	Osteoporosis;
LIHC	cis	rs2274273	0.624	rs10146637	chr14:55744810	G/A	cg01864836	chr14:55583639	NA	-0.35	-5.8	-0.3	1.48e-8	Protein biomarker;
LIHC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.63	-10.32	-0.49	6.61e-22	Bipolar disorder;
LIHC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.73	7.47	0.37	6.92e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.65	-8.84	-0.43	5.19e-17	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17582391	chr3:119814100	GSK3B	0.48	6.61	0.34	1.46e-10	Lung function (FEV1/FVC);
LIHC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.63	-0.67	6.46e-46	Lymphocyte percentage of white cells;
LIHC	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.49	8.22	0.41	4.28e-15	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	1.17	13.75	0.6	1.47e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.48	7.54	0.38	4.28e-13	Systemic lupus erythematosus;
LIHC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	0.99	10.63	0.5	5.22e-23	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.43	-6.99	-0.35	1.46e-11	Menarche (age at onset);
LIHC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.65	6.57	0.33	1.86e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.52	8.19	0.41	5.16e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	12.58	0.56	4.44e-30	Cognitive test performance;
LIHC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.75	0.39	1.05e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg23598604	chr1:99732472	LPPR4	0.3	6.34	0.32	7.28e-10	Multiple myeloma;
LIHC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.47	-6.82	-0.35	4.17e-11	Corneal structure;
LIHC	cis	rs4517514	0.509	rs10830417	chr11:89871940	A/G	cg05041596	chr11:89867385	NAALAD2	0.4	6.4	0.33	5.17e-10	Trans fatty acid levels;
LIHC	cis	rs55665837	0.665	rs11023273	chr11:14630819	G/A	cg16394018	chr11:14927549	NA	0.41	5.84	0.3	1.2e-8	Vitamin D levels;
LIHC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.5	7.35	0.37	1.52e-12	Type 2 diabetes;
LIHC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-8.46	-0.42	7.76e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16684958	chr7:75615977	POR	0.49	8.29	0.41	2.54e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg08888203	chr3:10149979	C3orf24	0.62	6.74	0.34	6.91e-11	Alzheimer's disease;
LIHC	cis	rs3736485	0.966	rs11070852	chr15:51782294	G/T	cg08986416	chr15:51914746	DMXL2	-0.39	-5.75	-0.3	1.95e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs861318	0.702	rs3737522	chr1:159021445	A/G	cg11003133	chr1:159046391	AIM2	-0.3	-5.77	-0.3	1.74e-8	Obesity-related traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg00760200	chr1:115053833	TRIM33	-0.47	-6.21	-0.32	1.54e-9	Systolic blood pressure;
LIHC	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.45	7.32	0.37	1.78e-12	Corneal astigmatism;
LIHC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21467203	chr3:49911342	NA	-0.34	-5.79	-0.3	1.59e-8	Menarche (age at onset);
LIHC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	11.11	0.52	1.04e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12016809	chr21:47604291	C21orf56	0.48	7.47	0.37	6.92e-13	Testicular germ cell tumor;
LIHC	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.63	5.82	0.3	1.35e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg23485639	chr6:28045615	ZNF165	0.39	5.94	0.31	7.13e-9	Parkinson's disease;
LIHC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.63	-10.31	-0.49	6.79e-22	Obesity-related traits;
LIHC	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg17182837	chr8:41585554	ANK1	-0.22	-5.78	-0.3	1.64e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.03	16.08	0.66	9.97e-44	Breast cancer;
LIHC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.9	0.47	1.7e-20	Platelet count;
LIHC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.78	-0.34	5.39e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18713687	chr3:195489789	MUC4	0.67	10.06	0.48	5.04e-21	Lung disease severity in cystic fibrosis;
LIHC	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-8.98	-0.44	1.9e-17	Schizophrenia;
LIHC	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.94	-0.31	6.82e-9	Resting heart rate;
LIHC	cis	rs797680	0.856	rs602204	chr1:93727579	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.77	0.3	1.78e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.52	-8.84	-0.43	5.26e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.38	12.35	0.56	3.16e-29	Uric acid levels;
LIHC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.38	6.13	0.31	2.43e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.71	10.55	0.5	1.04e-22	Aortic root size;
LIHC	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg23587288	chr2:27483067	SLC30A3	-0.31	-5.73	-0.3	2.22e-8	Blood metabolite levels;
LIHC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.62	7.65	0.38	2e-13	Diastolic blood pressure;
LIHC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.09	-0.31	2.96e-9	Cognitive function;
LIHC	cis	rs77637988	0.553	rs10169629	chr2:48625044	G/T	cg00032884	chr2:48540671	FOXN2	0.37	5.79	0.3	1.59e-8	Joint mobility (Beighton score);
LIHC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg23533926	chr12:111358616	MYL2	0.33	6.42	0.33	4.66e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.39	-5.95	-0.31	6.8e-9	Menarche (age at onset);
LIHC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.42	5.95	0.31	6.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.47	-7.69	-0.38	1.59e-13	Type 2 diabetes and other traits;Type 2 diabetes;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03359468	chr8:26240463	BNIP3L	0.44	6.15	0.32	2.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.27	-6.3	-0.32	8.93e-10	Subjective well-being;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00095276	chr5:1068111	SLC12A7	0.52	7.81	0.39	7.14e-14	Cognitive function;
LIHC	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	0.93	12.07	0.55	3.51e-28	Post bronchodilator FEV1;
LIHC	cis	rs10792665	0.934	rs10792668	chr11:82679581	A/C	cg24227371	chr11:82718527	RAB30	-0.31	-7.18	-0.36	4.32e-12	Obesity-related traits;
LIHC	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.82	-0.3	1.39e-8	Resting heart rate;
LIHC	cis	rs13343954	0.825	rs7254716	chr19:33532128	T/C	cg27124370	chr19:33622961	WDR88	0.42	5.73	0.3	2.21e-8	Colorectal cancer;
LIHC	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.47	-0.37	6.73e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.49	-8.11	-0.4	8.91e-15	Platelet distribution width;
LIHC	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.29	6.05	0.31	3.81e-9	Pulmonary function;
LIHC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.6	9.47	0.46	4.75e-19	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	trans	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg17675199	chr6:35436792	RPL10A	-0.44	-9.21	-0.45	3.25e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02551910	chr10:12110991	DHTKD1	0.48	6.54	0.33	2.26e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg06627628	chr2:24431161	ITSN2	-0.43	-5.73	-0.3	2.21e-8	Quantitative traits;
LIHC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.43	5.76	0.3	1.85e-8	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20573562	chr11:18034664	SERGEF	0.49	6.09	0.31	2.98e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.47	8.5	0.42	6.07e-16	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.65	-9.49	-0.46	4.03e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.72	-13.3	-0.58	7.78e-33	Height;
LIHC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20135002	chr11:47629003	NA	0.54	9.0	0.44	1.58e-17	Subjective well-being;
LIHC	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.57	-8.42	-0.41	1.01e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10861342	0.892	rs12322134	chr12:105646804	G/C	cg23923672	chr12:105501055	KIAA1033	0.67	7.74	0.39	1.12e-13	IgG glycosylation;
LIHC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.59e-14	Platelet count;
LIHC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.57	8.08	0.4	1.15e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.72	11.61	0.53	1.73e-26	Oral cavity cancer;
LIHC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.49	-0.38	5.95e-13	Platelet distribution width;
LIHC	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.57	9.0	0.44	1.63e-17	Height;
LIHC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.72	10.26	0.49	1.02e-21	Menarche (age at onset);
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.81	9.67	0.46	1.06e-19	Cognitive function;
LIHC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg27478167	chr7:817139	HEATR2	-0.42	-5.97	-0.31	5.91e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg15902774	chr15:75289873	SCAMP5	0.41	5.82	0.3	1.34e-8	Lung cancer;
LIHC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.37	5.83	0.3	1.31e-8	Resting heart rate;
LIHC	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.79	-0.3	1.61e-8	Red blood cell count;
LIHC	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.76	8.99	0.44	1.68e-17	Migraine;
LIHC	trans	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg07393940	chr7:158741817	NA	-0.57	-6.76	-0.34	5.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.65	0.42	1.97e-16	Lymphocyte counts;
LIHC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.72	-0.43	1.23e-16	Colorectal cancer;
LIHC	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-6.37	-0.33	6.27e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.06	0.44	1e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-8.12	-0.4	8.51e-15	Vitamin D levels;
LIHC	cis	rs4878497	0.646	rs10813816	chr9:32437249	C/T	cg14296220	chr9:32431791	ACO1	-0.56	-9.83	-0.47	2.96e-20	Inflammatory skin disease;
LIHC	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.73	11.31	0.52	2.15e-25	Oral cavity cancer;
LIHC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.31	-7.89	-0.39	4.18e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.34	5.86	0.3	1.12e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs74544699	1.000	rs353028	chr4:74777223	C/T	cg02530824	chr4:74847766	PF4	0.52	6.0	0.31	5.17e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs965469	1.000	rs6051827	chr20:3372007	C/T	cg25506879	chr20:3388711	C20orf194	-0.56	-6.7	-0.34	8.49e-11	IFN-related cytopenia;
LIHC	trans	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg14791747	chr16:20752902	THUMPD1	0.46	6.24	0.32	1.26e-9	Dental caries;
LIHC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.85	-14.29	-0.61	1.21e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.42	-6.84	-0.35	3.65e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg21361702	chr7:150065534	REPIN1	0.46	6.4	0.33	5.01e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.55	-0.38	3.92e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.77	11.65	0.53	1.17e-26	Subjective well-being;
LIHC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.56	0.33	2.01e-10	Rheumatoid arthritis;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg24693881	chr1:107596107	NA	-0.57	-10.04	-0.48	6.09e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg11706911	chr1:15910989	AGMAT	0.47	7.46	0.37	7.32e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.36	-0.33	6.6e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6722750	0.506	rs12612392	chr2:64373635	G/A	cg22352474	chr2:64371530	PELI1	0.57	8.02	0.4	1.72e-14	Neuroticism;
LIHC	cis	rs6596100	0.538	rs10491280	chr5:132196383	G/T	cg02081065	chr5:132209139	LEAP2	-0.26	-5.88	-0.3	9.86e-9	Breast cancer;
LIHC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.07	-0.36	8.73e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg18867708	chr6:26865862	GUSBL1	0.53	8.11	0.4	8.86e-15	Schizophrenia;
LIHC	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.47	7.93	0.39	3.13e-14	Urate levels in overweight individuals;
LIHC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.41	6.0	0.31	5.06e-9	Height;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.29	-0.32	9.61e-10	Total body bone mineral density;
LIHC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.71	-0.79	3.38e-74	Height;
LIHC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg18912006	chr12:123335444	HIP1R	-0.63	-7.64	-0.38	2.14e-13	Schizophrenia;
LIHC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.45	7.66	0.38	1.99e-13	Mean corpuscular volume;
LIHC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-9.22	-0.45	3.12e-18	Type 2 diabetes;
LIHC	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.44	-7.18	-0.36	4.26e-12	Corneal astigmatism;
LIHC	cis	rs4407350	0.748	rs131170	chr22:44901601	C/A	cg26276947	chr22:44892394	LDOC1L	0.34	6.61	0.34	1.49e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05290708	chr7:140372864	ADCK2	-0.47	-6.08	-0.31	3.23e-9	Thyroid stimulating hormone;
LIHC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.57	9.63	0.46	1.4e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.74	10.81	0.5	1.3e-23	Platelet count;
LIHC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.56	9.35	0.45	1.21e-18	Colorectal cancer;
LIHC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	0.95	9.91	0.47	1.67e-20	Vitiligo;
LIHC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02290350	chr8:58132656	NA	0.4	8.26	0.41	3.23e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg06359132	chr10:99160096	RRP12	-0.39	-6.22	-0.32	1.47e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.06	18.4	0.71	4.79e-53	Mitochondrial DNA levels;
LIHC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-8.03	-0.4	1.59e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.52	5.72	0.3	2.27e-8	Body mass index;
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.47	7.95	0.39	2.73e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg25364880	chr3:44379878	C3orf23	0.44	6.11	0.31	2.79e-9	Depressive symptoms;
LIHC	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg21252483	chr19:49399788	TULP2	-0.45	-7.4	-0.37	1.03e-12	Red cell distribution width;
LIHC	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.57	8.5	0.42	5.96e-16	HDL cholesterol;
LIHC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg03146154	chr1:46216737	IPP	-0.37	-6.16	-0.32	1.99e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.33	-6.44	-0.33	4.15e-10	Body mass index;
LIHC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.98	0.54	7.4e-28	Colorectal cancer;
LIHC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.42	5.93	0.31	7.29e-9	Stearic acid (18:0) levels;
LIHC	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.53	9.11	0.44	7.07e-18	Systemic lupus erythematosus;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg06391762	chr17:46908391	CALCOCO2	-0.4	-6.24	-0.32	1.33e-9	Alopecia areata;
LIHC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.58	-0.38	3.18e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg27129171	chr3:47204927	SETD2	0.48	7.67	0.38	1.79e-13	Birth weight;
LIHC	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg05207973	chr5:176823642	SLC34A1	0.34	5.77	0.3	1.8e-8	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.42	6.29	0.32	9.54e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.13	0.55	2.03e-28	Height;
LIHC	cis	rs546131	0.642	rs61881097	chr11:34821598	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-6.2	-0.32	1.6e-9	Lung disease severity in cystic fibrosis;
LIHC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.43	6.29	0.32	9.78e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	11.04	0.51	1.88e-24	Type 2 diabetes;
LIHC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.46	6.71	0.34	8.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.49	-5.73	-0.3	2.19e-8	Alzheimer's disease;
LIHC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.75	0.57	9.72e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.68	8.61	0.42	2.73e-16	Initial pursuit acceleration;
LIHC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.41	6.15	0.32	2.11e-9	Eosinophil percentage of white cells;
LIHC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	25.87	0.81	1.63e-82	Cognitive ability;
LIHC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.89	8.44	0.42	9.23e-16	Eosinophil percentage of granulocytes;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg26861219	chr6:157472057	ARID1B	0.36	6.09	0.31	3.05e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.8	-8.88	-0.43	3.88e-17	Obesity-related traits;
LIHC	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.95	0.31	6.57e-9	Morning vs. evening chronotype;
LIHC	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.54	6.75	0.34	6.45e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.31	6.49	0.33	2.95e-10	QRS complex (12-leadsum);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16982658	chr22:20104937	RANBP1;TRMT2A	0.4	6.05	0.31	3.76e-9	Hepatitis;
LIHC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.39	8.11	0.4	9.38e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg05043794	chr9:111880884	C9orf5	0.28	7.01	0.35	1.3e-11	Menarche (age at onset);
LIHC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg03859395	chr2:55845619	SMEK2	0.79	13.39	0.59	3.71e-33	Metabolic syndrome;
LIHC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-1.09	-14.09	-0.61	7.1e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	0.78	6.47	0.33	3.38e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg26802063	chr5:78281964	ARSB	0.5	7.55	0.38	3.89e-13	Blood and toenail selenium levels;Blood trace element (Se levels);
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.53	-7.11	-0.36	7.01e-12	Menopause (age at onset);
LIHC	cis	rs6024905	0.551	rs2425364	chr20:36969340	G/T	cg07053727	chr20:36965646	BPI	0.57	10.64	0.5	4.92e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs2412488	0.925	rs6852884	chr4:54236559	G/A	cg22241045	chr4:54363911	LNX1	-0.44	-6.84	-0.35	3.71e-11	DNA methylation (variation);
LIHC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.6	7.39	0.37	1.1e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.12	-0.4	8.43e-15	Type 2 diabetes;
LIHC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.76	-0.43	9.08e-17	Total cholesterol levels;
LIHC	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.66	-11.16	-0.52	7.45e-25	Monocyte count;
LIHC	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.79	8.16	0.4	6.68e-15	Schizophrenia;
LIHC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.43	-6.82	-0.35	4.05e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	0.94	9.16	0.44	4.77e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs7116495	1.000	rs2511116	chr11:71802160	G/A	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.61	-11.32	-0.52	1.89e-25	Neurofibrillary tangles;
LIHC	cis	rs6793245	0.960	rs7373779	chr3:38593943	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-6.76	-0.34	5.88e-11	QT interval;
LIHC	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.53	-0.33	2.38e-10	Type 2 diabetes;
LIHC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-9.71	-0.46	7.44e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg13263691	chr18:77568018	NA	0.24	6.33	0.32	7.82e-10	Schizophrenia;
LIHC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.41	-6.25	-0.32	1.2e-9	Height;
LIHC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.47	-8.72	-0.43	1.24e-16	Body mass index;
LIHC	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.46e-15	Facial morphology (factor 19);
LIHC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.36	7.44	0.37	8.17e-13	Bone mineral density;
LIHC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg11062466	chr8:58055876	NA	0.39	5.73	0.3	2.23e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs847649	0.692	rs6949391	chr7:102446863	C/T	cg18108683	chr7:102477205	FBXL13	-0.51	-7.83	-0.39	6.02e-14	Morning vs. evening chronotype;
LIHC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.33	7.27	0.37	2.48e-12	Ulcerative colitis;
LIHC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.68	12.11	0.55	2.47e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.59	11.46	0.53	6.04e-26	Coronary artery disease;
LIHC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.45	5.82	0.3	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.58	9.03	0.44	1.24e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.63	-16.72	-0.67	2.82e-46	Breast cancer;
LIHC	cis	rs75064307	0.834	rs4588370	chr3:108114050	G/A	cg03329597	chr3:108125523	MYH15	0.51	6.88	0.35	2.94e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.41	-6.17	-0.32	1.91e-9	Iron status biomarkers;
LIHC	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg01652190	chr22:50026171	C22orf34	-0.34	-7.61	-0.38	2.7e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.35	5.81	0.3	1.44e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.87	11.2	0.52	5.12e-25	Coronary artery disease;
LIHC	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.52	-0.38	4.98e-13	Protein biomarker;
LIHC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.68	9.31	0.45	1.57e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6066825	0.555	rs6019378	chr20:47309716	C/T	cg18078177	chr20:47281410	PREX1	0.41	6.88	0.35	2.84e-11	Colorectal cancer;
LIHC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.66	11.38	0.52	1.19e-25	Colorectal cancer;
LIHC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.06	15.48	0.64	2.51e-41	Cognitive function;
LIHC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	cis	rs7523273	0.565	rs2985104	chr1:207892012	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-7.94	-0.39	3e-14	Schizophrenia;
LIHC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg01652190	chr22:50026171	C22orf34	-0.29	-6.85	-0.35	3.44e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	0.88	6.01	0.31	4.81e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.47	-7.59	-0.38	2.99e-13	Menarche (age at onset);
LIHC	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.52	8.21	0.41	4.57e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-1.08	-16.93	-0.68	3.93e-47	Urate levels;
LIHC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.38	-0.33	5.85e-10	Response to antipsychotic treatment;
LIHC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-6.75	-0.34	6.37e-11	Chronic sinus infection;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg00656387	chr3:40428638	ENTPD3	0.49	8.28	0.41	2.86e-15	Renal cell carcinoma;
LIHC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21467203	chr3:49911342	NA	0.51	9.19	0.44	3.98e-18	Body mass index;
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.15	-0.32	2.19e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg07959070	chr22:50026188	C22orf34	-0.34	-8.68	-0.42	1.61e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.13	0.31	2.48e-9	Prudent dietary pattern;
LIHC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg24209194	chr3:40518798	ZNF619	0.46	6.56	0.33	1.95e-10	Renal cell carcinoma;
LIHC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg11861562	chr11:117069780	TAGLN	0.48	8.03	0.4	1.56e-14	Blood protein levels;
LIHC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg19635926	chr16:89946313	TCF25	0.52	7.0	0.35	1.35e-11	Skin colour saturation;
LIHC	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.5	0.46	3.84e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.47	6.62	0.34	1.36e-10	Morning vs. evening chronotype;
LIHC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.66	11.68	0.53	9.17e-27	Total body bone mineral density;
LIHC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs1144333	0.655	rs79322031	chr1:76391978	C/T	cg03433033	chr1:76189801	ACADM	0.54	7.58	0.38	3.31e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs11229555	0.574	rs11229454	chr11:58203682	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg16275483	chr1:110013120	SYPL2	-0.52	-6.3	-0.32	9.12e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg14222432	chr12:29376421	FAR2	0.35	6.53	0.33	2.4e-10	QT interval;
LIHC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.13	-0.36	5.84e-12	Personality dimensions;
LIHC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.05e-17	Bipolar disorder;
LIHC	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.65	7.02	0.35	1.21e-11	Type 2 diabetes;
LIHC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.55	7.16	0.36	4.85e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.5	6.94	0.35	1.99e-11	Aortic root size;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg06123940	chr18:29597493	RNF125	0.43	6.13	0.31	2.44e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg18016565	chr1:150552671	MCL1	-0.5	-10.14	-0.48	2.62e-21	Lymphocyte counts;
LIHC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.45	7.45	0.37	7.66e-13	Testicular germ cell tumor;
LIHC	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.52	9.85	0.47	2.68e-20	Testicular germ cell tumor;
LIHC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg17764715	chr19:33622953	WDR88	0.41	5.79	0.3	1.61e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.67e-12	Bipolar disorder;
LIHC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.9	-13.9	-0.6	3.85e-35	Body mass index;
LIHC	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.37	5.87	0.3	1.01e-8	Height;
LIHC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.3	-6.8	-0.35	4.71e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.91	14.41	0.61	3.92e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10637722	1	rs10637722	chr13:61742144	A/ACT	cg09384787	chr13:61988802	PCDH20	-0.33	-5.89	-0.3	9.37e-9	beta-nerve growth factor levels;
LIHC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-6.12	-0.31	2.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.38	5.75	0.3	1.98e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.61	11.76	0.54	4.78e-27	Leprosy;
LIHC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.84	0.3	1.22e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg25114630	chr15:101792522	CHSY1	0.58	7.21	0.36	3.63e-12	Corneal structure;
LIHC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.55	0.46	2.57e-19	Melanoma;
LIHC	trans	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.19	0.32	1.71e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg05361325	chr10:32636312	EPC1	-0.49	-6.0	-0.31	4.96e-9	Sexual dysfunction (female);
LIHC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05590025	chr7:65112418	INTS4L2	-0.45	-6.97	-0.35	1.67e-11	Calcium levels;
LIHC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.64	10.8	0.5	1.37e-23	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.58	10.82	0.5	1.17e-23	Leprosy;
LIHC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.84	0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg07424592	chr7:64974309	NA	0.8	8.97	0.44	1.98e-17	Diabetic kidney disease;
LIHC	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg19676328	chr12:49525230	TUBA1B	-0.38	-6.25	-0.32	1.25e-9	Total cholesterol levels;
LIHC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.77	-10.19	-0.48	1.76e-21	Schizophrenia;
LIHC	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	6.19	0.32	1.68e-9	Smoking behavior;
LIHC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.71	11.58	0.53	2.16e-26	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.81	9.89	0.47	1.82e-20	Morning vs. evening chronotype;
LIHC	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-7.49	-0.38	5.79e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg04450456	chr4:17643702	FAM184B	0.34	5.72	0.3	2.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs479844	1.000	rs479844	chr11:65551957	A/G	cg17712092	chr4:129076599	LARP1B	-0.48	-6.78	-0.34	5.36e-11	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
LIHC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.34	5.96	0.31	6.16e-9	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.46	6.33	0.32	7.88e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.45	-0.33	3.81e-10	Colorectal cancer;
LIHC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.15	-0.32	2.22e-9	Neuroticism;
LIHC	cis	rs2412488	0.927	rs4864760	chr4:54283313	A/G	cg22241045	chr4:54363911	LNX1	0.4	6.6	0.34	1.57e-10	DNA methylation (variation);
LIHC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.49	6.26	0.32	1.16e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.78	-0.3	1.67e-8	Menarche (age at onset);
LIHC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg18306943	chr3:40428807	ENTPD3	0.36	6.1	0.31	2.84e-9	Renal cell carcinoma;
LIHC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.41	-0.37	1.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.93	-17.25	-0.68	2.02e-48	Menopause (age at onset);
LIHC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.87	-0.39	4.86e-14	Monocyte percentage of white cells;
LIHC	trans	rs72960926	0.744	rs55792900	chr6:74924010	C/A	cg07247405	chr1:2484626	LOC115110	0.55	6.58	0.34	1.75e-10	Metabolite levels (MHPG);
LIHC	cis	rs67981189	0.593	rs221906	chr14:71597393	C/G	cg15816911	chr14:71606274	NA	0.39	6.28	0.32	1.02e-9	Schizophrenia;
LIHC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.69	0.43	1.58e-16	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	7.14	0.36	5.71e-12	Renal cell carcinoma;
LIHC	cis	rs10792665	0.611	rs2170010	chr11:82640826	C/T	cg24227371	chr11:82718527	RAB30	0.27	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02985541	chr2:219472218	PLCD4	0.44	7.32	0.37	1.74e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg12698662	chr3:15914712	MIR563	-0.34	-6.41	-0.33	4.94e-10	Mean platelet volume;
LIHC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.62	8.11	0.4	8.95e-15	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.58	8.04	0.4	1.49e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-9.81	-0.47	3.4e-20	Body mass index;
LIHC	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.47	7.42	0.37	9.49e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.79	-13.46	-0.59	1.92e-33	Age at first birth;
LIHC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.29	-6.81	-0.35	4.31e-11	Hip circumference;Waist circumference;
LIHC	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg23091122	chr1:110024289	SYPL2	-0.48	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs72843506	1.000	rs10459969	chr17:19935901	T/C	cg12065943	chr17:19881925	AKAP10	-0.35	-6.33	-0.32	7.88e-10	Schizophrenia;
LIHC	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.52	7.35	0.37	1.5e-12	Fibroblast growth factor basic levels;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-7.35	-0.37	1.5e-12	Total body bone mineral density;
LIHC	cis	rs11822910	1.000	rs2439448	chr11:57199211	T/C	cg00522883	chr11:57194120	SLC43A3	0.68	9.0	0.44	1.63e-17	Platelet distribution width;
LIHC	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.47	-0.33	3.31e-10	Metabolite levels;
LIHC	cis	rs10861342	0.892	rs11112418	chr12:105630463	A/G	cg23923672	chr12:105501055	KIAA1033	0.61	6.87	0.35	2.97e-11	IgG glycosylation;
LIHC	cis	rs4407350	0.870	rs131172	chr22:44902759	A/G	cg11695653	chr22:44894386	LDOC1L	-0.33	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	1.000	rs117372845	chr11:71568849	C/T	cg26138937	chr11:71823887	C11orf51	0.69	6.6	0.34	1.58e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg22705602	chr4:152727874	NA	-0.3	-6.46	-0.33	3.5e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg08213375	chr14:104286397	PPP1R13B	0.51	9.66	0.46	1.12e-19	Schizophrenia;
LIHC	cis	rs2274273	0.588	rs7145727	chr14:55847573	G/A	cg01864836	chr14:55583639	NA	-0.41	-7.46	-0.37	7.09e-13	Protein biomarker;
LIHC	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16684958	chr7:75615977	POR	0.52	8.77	0.43	8.8e-17	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.32	0.49	6.33e-22	Post bronchodilator FEV1;
LIHC	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.72	-7.4	-0.37	1.03e-12	Blood protein levels;
LIHC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.4	6.39	0.33	5.36e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg23461800	chr14:103021989	NA	0.38	5.73	0.3	2.2e-8	Platelet count;
LIHC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03116466	chr7:2116512	MAD1L1	-0.37	-6.44	-0.33	4.1e-10	Calcium levels;
LIHC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-1.07	-10.67	-0.5	3.83e-23	Breast cancer;
LIHC	trans	rs75804782	0.521	rs56227677	chr2:239449867	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	6.28	0.32	1.03e-9	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.57	-0.42	3.74e-16	Body mass index;
LIHC	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.66	0.65	4.59e-42	Electrocardiographic conduction measures;
LIHC	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg22777020	chr22:31556080	RNF185	-0.54	-6.23	-0.32	1.37e-9	Colorectal cancer;
LIHC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.72	-14.28	-0.61	1.27e-36	Body mass index;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg20626144	chr17:157107	RPH3AL	0.4	6.09	0.31	3.1e-9	Electroencephalogram traits;
LIHC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.06	0.36	9.32e-12	Nonalcoholic fatty liver disease;
LIHC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.09	0.36	7.75e-12	Diabetic kidney disease;
LIHC	cis	rs4834770	1.000	rs10034579	chr4:120244029	A/C	cg09307838	chr4:120376055	NA	0.44	6.56	0.33	2.04e-10	Blood protein levels;
LIHC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.14	-0.44	5.47e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.65	13.78	0.6	1.14e-34	Intelligence (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25008156	chr6:170893875	PDCD2	-0.48	-6.04	-0.31	4.02e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.71	0.47	7.38e-20	Lung cancer;
LIHC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg14393609	chr7:65229607	NA	-0.35	-5.75	-0.3	2.01e-8	Aortic root size;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.44	8.14	0.4	7.19e-15	Prudent dietary pattern;
LIHC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.8	-0.5	1.33e-23	Lung cancer;
LIHC	cis	rs151997	0.720	rs152096	chr5:50213850	A/G	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.65	8.74	0.43	1.05e-16	Mean platelet volume;
LIHC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.45	0.42	8.7e-16	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07050772	chr17:48423262	XYLT2	-0.42	-6.64	-0.34	1.23e-10	Pancreatic cancer;
LIHC	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-7.19	-0.36	4.2e-12	Exhaled nitric oxide output;
LIHC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.13	-0.48	2.99e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg14393609	chr7:65229607	NA	0.37	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.24	0.32	1.32e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg25024717	chr12:54324583	NA	-0.31	-6.16	-0.32	2.06e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg15841412	chr13:111365552	ING1	-0.49	-6.05	-0.31	3.78e-9	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg11764359	chr7:65958608	NA	0.57	5.95	0.31	6.62e-9	Diabetic kidney disease;
LIHC	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs243505	0.762	rs10225300	chr7:148502007	G/C	cg09806900	chr7:148480153	CUL1	0.44	6.52	0.33	2.48e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.73	-11.97	-0.54	7.84e-28	Body mass index;
LIHC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.47	6.44	0.33	4.11e-10	Obesity-related traits;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-7.39	-0.37	1.16e-12	Lung cancer;
LIHC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.82	12.89	0.57	2.86e-31	Breast cancer;
LIHC	cis	rs1816752	0.837	rs9318530	chr13:24998557	A/G	cg22771759	chr13:24902376	NA	-0.29	-5.87	-0.3	1.05e-8	Obesity-related traits;
LIHC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.51	-6.95	-0.35	1.91e-11	Aortic root size;
LIHC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.52	9.03	0.44	1.26e-17	Alcohol dependence;
LIHC	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.3	-5.78	-0.3	1.73e-8	Red blood cell count;
LIHC	trans	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg09045935	chr12:6379348	NA	0.83	6.85	0.35	3.36e-11	Blood metabolite levels;
LIHC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.67	9.96	0.47	1.11e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg07451762	chr16:28383216	NA	0.33	6.18	0.32	1.78e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.57	9.76	0.47	4.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14839808	chr12:28343774	NA	0.44	6.15	0.32	2.19e-9	Lung function (FEV1/FVC);
LIHC	cis	rs28493229	0.737	rs2288450	chr19:41209177	C/T	cg21869046	chr19:41225005	ITPKC	0.5	6.22	0.32	1.43e-9	Kawasaki disease;
LIHC	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg16309518	chr5:176445507	NA	-0.58	-11.56	-0.53	2.68e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg05110241	chr16:68378359	PRMT7	-0.6	-6.77	-0.34	5.6e-11	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.79	13.92	0.6	3.27e-35	Coronary artery disease;
LIHC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg03037974	chr15:76606532	NA	0.8	16.51	0.67	1.94e-45	Blood metabolite levels;
LIHC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-6.76	-0.34	6.08e-11	Vitiligo;
LIHC	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.56	-8.26	-0.41	3.15e-15	Menarche (age at onset);
LIHC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.9	18.69	0.71	3.15e-54	Height;
LIHC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-7.73	-0.39	1.19e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-5.72	-0.3	2.34e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.52	0.33	2.57e-10	Bipolar disorder;
LIHC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	10.52	0.49	1.3e-22	Type 2 diabetes;
LIHC	trans	rs6489882	0.902	rs3759376	chr12:113373563	A/G	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg00071026	chr13:113650936	MCF2L	-0.39	-5.92	-0.31	7.67e-9	Systolic blood pressure;
LIHC	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg12698662	chr3:15914712	MIR563	-0.39	-7.33	-0.37	1.71e-12	Mean platelet volume;
LIHC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.55	-7.68	-0.38	1.73e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-8.94	-0.44	2.45e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.59	7.48	0.38	6.2800000000000005e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.49	7.36	0.37	1.36e-12	Height;
LIHC	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg25952890	chr19:58913133	NA	0.67	7.14	0.36	5.76e-12	Mean platelet volume;
LIHC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.94	0.51	4.21e-24	Personality dimensions;
LIHC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg17723122	chr1:205641542	SLC45A3	0.38	5.75	0.3	1.99e-8	Menarche (age at onset);
LIHC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.52	-0.69	1.72e-49	Gut microbiome composition (summer);
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg10096929	chr1:156261403	TMEM79	0.41	6.77	0.34	5.47e-11	Tonsillectomy;
LIHC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.73	0.39	1.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	9.39e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.4	0.56	2.05e-29	Menopause (age at onset);
LIHC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.46	8.24	0.41	3.81e-15	IgG glycosylation;
LIHC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.5	0.53	4.36e-26	Tonsillectomy;
LIHC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg03013999	chr17:37608204	MED1	0.36	6.13	0.31	2.47e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.77	9.68	0.46	9.51e-20	Cognitive function;
LIHC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg08469215	chr1:156261351	TMEM79	0.37	5.9	0.3	8.6e-9	Tonsillectomy;
LIHC	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg05197062	chr11:11642011	GALNTL4	0.42	6.05	0.31	3.77e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.86	13.05	0.58	7.33e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg14719990	chr4:57843890	C4orf14;POLR2B	0.41	5.75	0.3	2.03e-8	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.41	6.19	0.32	1.74e-9	Height;
LIHC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg19645103	chr12:69753606	YEATS4	-0.4	-5.92	-0.3	7.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg14440974	chr22:39074834	NA	-0.45	-7.3	-0.37	2.09e-12	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.86	0.3	1.08e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.54	-7.36	-0.37	1.41e-12	Body mass index;
LIHC	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.87	0.3	1.04e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.35	5.78	0.3	1.66e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.43	6.11	0.31	2.71e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg02269571	chr22:50332266	NA	-0.61	-8.72	-0.43	1.23e-16	Schizophrenia;
LIHC	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs12986413	0.846	rs12609327	chr19:2183000	A/C	cg09261902	chr19:2140048	AP3D1	0.39	6.55	0.33	2.06e-10	Height;
LIHC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg14773178	chr5:1868261	NA	0.26	6.68	0.34	9.8e-11	Cardiovascular disease risk factors;
LIHC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00802000	chr16:706648	WDR90	-0.38	-6.2	-0.32	1.62e-9	Height;
LIHC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg00800038	chr16:89945340	TCF25	-0.59	-8.21	-0.41	4.6e-15	Skin colour saturation;
LIHC	cis	rs12464559	0.649	rs12693116	chr2:152623917	A/G	cg01189475	chr2:152685088	ARL5A	0.64	7.55	0.38	3.92e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02251663	chr11:14281053	SPON1	0.44	6.12	0.31	2.57e-9	Mitochondrial DNA levels;
LIHC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.57	7.31	0.37	1.85e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.36	8.0	0.4	1.9e-14	Blood metabolite ratios;
LIHC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-7.05	-0.36	1.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.69	0.43	1.5e-16	Lung cancer in ever smokers;
LIHC	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.63	9.32	0.45	1.52e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs332507	0.789	rs11928787	chr3:124408149	C/T	cg05980111	chr3:124395277	KALRN	0.45	6.88	0.35	2.92e-11	Plateletcrit;
LIHC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.62	0.56	3.14e-30	Schizophrenia;
LIHC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.55	-0.33	2.13e-10	Diabetic kidney disease;
LIHC	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg08687137	chr11:62389499	B3GAT3	-0.44	-6.05	-0.31	3.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7212590	0.529	rs60283440	chr17:57994248	T/C	cg10252138	chr17:58120427	NA	-0.62	-6.61	-0.34	1.45e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	6.93	0.35	2.08e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.39	6.49	0.33	3.07e-10	Red blood cell count;
LIHC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg07636037	chr3:49044803	WDR6	0.53	6.38	0.33	5.75e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	6.36	0.33	6.46e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.48	7.91	0.39	3.49e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.77	11.92	0.54	1.29e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.69	-10.67	-0.5	4.02e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-8.44	-0.42	9.2e-16	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00258694	chr4:56815070	CEP135	-0.45	-6.28	-0.32	1.02e-9	Pancreatic cancer;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.46	-6.61	-0.34	1.51e-10	Lymphocyte counts;
LIHC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.63	8.76	0.43	9.5e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	7.89	0.39	3.99e-14	Platelet count;
LIHC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	6.54	0.33	2.24e-10	Aortic root size;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.18	0.52	5.97e-25	Motion sickness;
LIHC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg22496339	chr2:162101262	NA	-0.54	-7.33	-0.37	1.65e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg15123519	chr2:136567270	LCT	-0.36	-5.81	-0.3	1.45e-8	Corneal structure;
LIHC	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	0.77	9.25	0.45	2.58e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg11783602	chr8:55087084	NA	-0.31	-6.04	-0.31	4e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	11.34	0.52	1.68e-25	Cognitive test performance;
LIHC	cis	rs611744	0.967	rs628843	chr8:109196115	C/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.56	8.92	0.43	2.86e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17246404	chr3:65365162	MAGI1	0.38	6.19	0.32	1.71e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.58	7.7	0.38	1.46e-13	Aortic root size;
LIHC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg01557791	chr16:72042693	DHODH	-0.43	-7.11	-0.36	6.79e-12	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.81	0.39	7.2e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-9.66	-0.46	1.07e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.52	6.22	0.32	1.43e-9	Menarche (age at onset);
LIHC	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.39	-8.32	-0.41	2.19e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7503168	1.000	rs9894057	chr17:33889923	G/A	cg20932281	chr17:33905541	PEX12	0.58	7.34	0.37	1.61e-12	Plateletcrit;
LIHC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.55	0.33	2.09e-10	Lymphocyte counts;
LIHC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.56	-10.51	-0.49	1.47e-22	Asthma;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22997252	chr11:11643842	GALNTL4	0.49	6.39	0.33	5.47e-10	Lung function (FEV1/FVC);
LIHC	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.4	8.8	0.43	7.12e-17	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg15848620	chr12:58087721	OS9	-0.58	-8.01	-0.4	1.77e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6750047	0.649	rs4670231	chr2:38267836	T/G	cg07380506	chr2:38303506	CYP1B1	0.5	5.88	0.3	9.77e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg10932868	chr11:921992	NA	0.4	7.62	0.38	2.53e-13	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.89	16.21	0.66	3.09e-44	Menopause (age at onset);
LIHC	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.67	-0.42	1.73e-16	Blood metabolite levels;
LIHC	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.79	12.39	0.56	2.31e-29	Breast cancer;
LIHC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-7.51	-0.38	5.32e-13	Longevity;Endometriosis;
LIHC	cis	rs1185460	0.547	rs667584	chr11:118911544	C/T	cg23280166	chr11:118938394	VPS11	-0.45	-6.13	-0.31	2.36e-9	Coronary artery disease;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.5	0.56	9.04e-30	Prudent dietary pattern;
LIHC	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.45	6.15	0.32	2.13e-9	QT interval;
LIHC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-9.29	-0.45	1.79e-18	Gut microbiome composition (summer);
LIHC	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-27.37	-0.83	3.73e-88	Myeloid white cell count;
LIHC	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.82	8.47	0.42	7.44e-16	Blood protein levels;
LIHC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg21559469	chr19:19431446	KIAA0892;SF4	0.49	5.85	0.3	1.12e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.83	10.66	0.5	4.38e-23	Gut microbiome composition (summer);
LIHC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.79	10.16	0.48	2.24e-21	Bladder cancer;
LIHC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.46	-6.16	-0.32	2.01e-9	Major depressive disorder;
LIHC	cis	rs17152411	0.652	rs4962412	chr10:126654643	C/G	cg07906193	chr10:126599966	NA	-0.31	-6.16	-0.32	2.02e-9	Height;
LIHC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.68	-11.04	-0.51	1.92e-24	Mean platelet volume;
LIHC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg10360323	chr17:41437877	NA	0.41	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs7546668	1.000	rs4646100	chr1:15820041	C/T	cg11706911	chr1:15910989	AGMAT	0.46	7.05	0.36	1.01e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.63	0.34	1.3e-10	Rheumatoid arthritis;
LIHC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.86	-0.35	3.23e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7116495	1.000	rs2298456	chr11:71730715	A/T	cg26138937	chr11:71823887	C11orf51	0.8	8.21	0.41	4.64e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.51	5.77	0.3	1.77e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14676711	chr18:48405181	ME2	-0.43	-6.18	-0.32	1.79e-9	Calcium levels;
LIHC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.49	-8.25	-0.41	3.39e-15	Menarche (age at onset);
LIHC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg00225070	chr15:80189496	MTHFS	0.46	7.46	0.37	7.09e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.02	19.65	0.73	4.3e-58	Exhaled nitric oxide output;
LIHC	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.69	14.0	0.6	1.64e-35	Schizophrenia;
LIHC	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg00529422	chr1:16285251	ZBTB17	-0.35	-6.86	-0.35	3.22e-11	Systolic blood pressure;
LIHC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.8	0.39	7.81e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.83	-0.3	1.27e-8	Body mass index;
LIHC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.78	9.5	0.46	3.88e-19	Morning vs. evening chronotype;
LIHC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.68	0.57	1.87e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	0.98	15.35	0.64	8.11e-41	Corneal structure;
LIHC	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.47	6.98	0.35	1.56e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.15	-0.36	5.32e-12	Monocyte percentage of white cells;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.46	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.38	-0.52	1.12e-25	Bipolar disorder and schizophrenia;
LIHC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.42	-0.49	2.92e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.29	-0.45	1.85e-18	Bipolar disorder;
LIHC	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.85	13.42	0.59	2.73e-33	Gastritis;
LIHC	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.32	-6.21	-0.32	1.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.07	-0.31	3.39e-9	Total body bone mineral density;
LIHC	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg16586182	chr3:47516702	SCAP	0.52	9.17	0.44	4.62e-18	Colorectal cancer;
LIHC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs74233809	1.000	rs11191558	chr10:104864678	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.7	9.66	0.46	1.08e-19	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.5	6.01	0.31	4.85e-9	Schizophrenia;
LIHC	trans	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg26939375	chr7:64535504	NA	0.41	6.51	0.33	2.74e-10	Aortic root size;
LIHC	cis	rs546131	0.642	rs1594426	chr11:34833459	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.34	1.66e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.46	7.32	0.37	1.8e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.73	-11.46	-0.53	6.2e-26	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.83	8.75	0.43	9.79e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.48	7.8	0.39	7.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07258852	chr11:94227583	ANKRD49;MRE11A	-0.39	-6.21	-0.32	1.55e-9	Cognitive function;
LIHC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.94	16.47	0.67	2.75e-45	Parkinson's disease;
LIHC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.63	-0.53	1.39e-26	Platelet distribution width;
LIHC	trans	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg16088116	chr21:44841560	SIK1	-0.42	-6.51	-0.33	2.73e-10	Coronary artery disease;
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg23978390	chr7:1156363	C7orf50	0.5	7.28	0.37	2.3e-12	Longevity;Endometriosis;
LIHC	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.64	9.75	0.47	5.46e-20	Renal cell carcinoma;
LIHC	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-7.22	-0.36	3.39e-12	Schizophrenia;
LIHC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg24130564	chr14:104152367	KLC1	-0.35	-5.83	-0.3	1.31e-8	Schizophrenia;
LIHC	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.48	7.82	0.39	6.42e-14	Schizophrenia;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg09033563	chr22:24373618	LOC391322	-0.44	-6.01	-0.31	4.68e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9443189	0.526	rs9359124	chr6:76200514	G/A	cg01950844	chr6:76311363	SENP6	0.89	10.14	0.48	2.69e-21	Prostate cancer;
LIHC	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.57	-9.15	-0.44	5.41e-18	Corneal astigmatism;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14027857	chr1:208136797	NA	0.64	8.04	0.4	1.53e-14	Hepatitis;
LIHC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.73	-0.47	6.61e-20	Coronary artery disease;
LIHC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.1e-9	Tonsillectomy;
LIHC	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg01320579	chr17:75405842	SEPT9	0.55	7.31	0.37	1.96e-12	Airflow obstruction;
LIHC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.62	-8.41	-0.41	1.1e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14510374	chr3:50365322	TUSC2	0.5	6.41	0.33	4.94e-10	Lung function (FEV1/FVC);
LIHC	trans	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg19894588	chr14:64061835	NA	-0.61	-7.84	-0.39	5.74e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7187994	0.895	rs12598223	chr16:84783873	A/G	cg07647771	chr16:84786436	USP10	-0.33	-6.66	-0.34	1.12e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.95	0.31	6.65e-9	Obesity-related traits;
LIHC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg09417038	chr21:47716443	C21orf57	-0.55	-8.31	-0.41	2.33e-15	Testicular germ cell tumor;
LIHC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg21518248	chr2:162101506	NA	-0.39	-5.87	-0.3	1.05e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2073499	0.935	rs2526400	chr3:50186948	A/G	cg24110177	chr3:50126178	RBM5	0.52	6.04	0.31	3.98e-9	Schizophrenia;
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.21	-0.32	1.56e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.26	-0.32	1.14e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs10924970	0.601	rs2803847	chr1:235503611	C/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.72e-8	Asthma;
LIHC	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.91	10.22	0.48	1.37e-21	IgG glycosylation;
LIHC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs12406019	0.510	rs2025614	chr1:78618151	G/A	cg20826526	chr3:156266748	SSR3	-0.64	-10.8	-0.5	1.37e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg07451762	chr16:28383216	NA	-0.34	-6.54	-0.33	2.19e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-8.6	-0.42	2.9e-16	Morning vs. evening chronotype;
LIHC	cis	rs16858210	0.520	rs34190894	chr3:183550412	A/T	cg25686905	chr3:183603175	PARL	-0.45	-7.33	-0.37	1.69e-12	Menopause (age at onset);
LIHC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg23283495	chr1:209979779	IRF6	0.34	5.75	0.3	1.95e-8	Monobrow;
LIHC	cis	rs6750047	0.771	rs2855658	chr2:38296890	T/C	cg07380506	chr2:38303506	CYP1B1	0.6	7.72	0.39	1.27e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.77	-0.3	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-9.11	-0.44	7.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10508774	1.000	rs72795556	chr10:32868840	C/G	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.66	-0.34	1.11e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.43	7.48	0.37	6.44e-13	Aortic root size;
LIHC	cis	rs2302190	0.882	rs7221464	chr17:56552353	A/T	cg12560992	chr17:57184187	TRIM37	0.71	8.91	0.43	3.09e-17	Vitamin D levels;
LIHC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.48e-8	Breast cancer;
LIHC	cis	rs9494145	0.680	rs4895441	chr6:135426573	C/T	cg22676075	chr6:135203613	NA	-0.42	-6.05	-0.31	3.83e-9	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LIHC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.59	7.8	0.39	7.7e-14	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.07	-0.36	8.56e-12	IgG glycosylation;
LIHC	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.42	0.45	6.81e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.72	11.61	0.53	1.73e-26	Oral cavity cancer;
LIHC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.66	-12.31	-0.55	4.29e-29	Systemic lupus erythematosus;
LIHC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg18478394	chr8:109455254	TTC35	0.41	7.2	0.36	3.95e-12	Dupuytren's disease;
LIHC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	7.43	0.37	8.88e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.67	-0.38	1.81e-13	Morning vs. evening chronotype;
LIHC	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg16006841	chr5:176797999	RGS14	0.62	6.0	0.31	5.09e-9	Urate levels in lean individuals;
LIHC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.61	0.46	1.6e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg09795085	chr6:101329169	ASCC3	0.51	7.14	0.36	5.7e-12	Neuroticism;
LIHC	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	0.68	8.69	0.43	1.55e-16	Corneal structure;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.41	-0.33	4.78e-10	Total body bone mineral density;
LIHC	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.35	5.89	0.3	9.06e-9	Cognitive performance;
LIHC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg15208524	chr1:10270712	KIF1B	0.41	6.03	0.31	4.19e-9	Hepatocellular carcinoma;
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg14393609	chr7:65229607	NA	-0.39	-6.63	-0.34	1.28e-10	Calcium levels;
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.33	0.37	1.71e-12	Renal cell carcinoma;
LIHC	cis	rs7188697	0.848	rs40187	chr16:58556566	T/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.27	-0.37	2.47e-12	QT interval;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04180460	chr3:41240962	CTNNB1	0.37	6.12	0.31	2.5e-9	Cognitive function;
LIHC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.88	14.01	0.6	1.47e-35	Metabolic syndrome;
LIHC	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.41	0.49	3.07e-22	Colorectal cancer;
LIHC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg09033563	chr22:24373618	LOC391322	-0.47	-6.48	-0.33	3.27e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-8.36	-0.41	1.57e-15	Schizophrenia;
LIHC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.54	-9.0	-0.44	1.62e-17	Longevity;Endometriosis;
LIHC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg27211696	chr2:191398769	TMEM194B	-0.61	-8.17	-0.4	6.17e-15	Diastolic blood pressure;
LIHC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.64	-11.61	-0.53	1.76e-26	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg11225849	chr1:211500348	TRAF5	-0.46	-6.61	-0.34	1.51e-10	Alopecia areata;
LIHC	cis	rs6752107	0.901	rs10206299	chr2:234146271	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	7.81	0.39	7.01e-14	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7223966	0.584	rs76957877	chr17:61621330	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	5.83	0.3	1.25e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs151997	1.000	rs152803	chr5:50212120	C/T	cg06027927	chr5:50259733	NA	0.58	7.86	0.39	5.18e-14	Callous-unemotional behaviour;
LIHC	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-8.63	-0.42	2.31e-16	Schizophrenia;
LIHC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-7.05	-0.36	9.71e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.75	0.5	2.1e-23	Bladder cancer;
LIHC	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.61	6.48	0.33	3.19e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg12143784	chr7:64541923	NA	0.37	6.42	0.33	4.55e-10	Calcium levels;
LIHC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.79	0.54	3.68e-27	Motion sickness;
LIHC	cis	rs12220238	0.915	rs11001014	chr10:76128832	A/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.63	-6.12	-0.31	2.55e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs244293	0.831	rs2111097	chr17:53090474	A/C	cg19360675	chr17:53046073	COX11;STXBP4	0.51	7.64	0.38	2.27e-13	Menarche (age at onset);
LIHC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg20129853	chr10:51489980	NA	-0.4	-8.66	-0.42	1.92e-16	Prostate-specific antigen levels;
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.05	-0.36	9.78e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.47	0.53	5.46e-26	Alzheimer's disease (late onset);
LIHC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.48	7.86	0.39	4.97e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.72	0.47	7.13e-20	Tonsillectomy;
LIHC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	6.41	0.33	4.95e-10	Initial pursuit acceleration;
LIHC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg12798992	chr6:167411361	FGFR1OP	0.48	7.18	0.36	4.3e-12	Crohn's disease;
LIHC	cis	rs8067354	0.574	rs1292033	chr17:57990597	A/T	cg13753209	chr17:57696993	CLTC	0.7	10.48	0.49	1.74e-22	Hemoglobin concentration;
LIHC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg10018233	chr7:150070692	REPIN1	0.5	8.5	0.42	6.03e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg04004882	chr2:215674386	BARD1	-0.51	-6.28	-0.32	1.03e-9	Neuroblastoma;
LIHC	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.52	-6.08	-0.31	3.26e-9	Ulcerative colitis;
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.45	-6.41	-0.33	4.85e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.92	16.51	0.67	1.87e-45	Menopause (age at onset);
LIHC	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.7	-13.68	-0.59	2.91e-34	Survival in pancreatic cancer;
LIHC	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg24296786	chr1:45957014	TESK2	0.52	8.03	0.4	1.62e-14	High light scatter reticulocyte count;
LIHC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.62	-0.42	2.5e-16	Primary biliary cholangitis;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.94	19.79	0.73	1.18e-58	Height;
LIHC	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.66	10.52	0.49	1.33e-22	Obesity-related traits;
LIHC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.87	0.3	1.05e-8	Tonsillectomy;
LIHC	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.72	8.07	0.4	1.17e-14	Height;
LIHC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.47	-0.53	5.57e-26	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg07424592	chr7:64974309	NA	0.81	9.2	0.45	3.52e-18	Diabetic kidney disease;
LIHC	cis	rs9503598	0.502	rs4518545	chr6:3433890	T/A	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.8	-0.3	1.52e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs11644362	1.000	rs35972357	chr16:12987664	C/T	cg06890432	chr16:12997467	SHISA9	-0.4	-6.77	-0.34	5.6e-11	Positive affect;Subjective well-being;
LIHC	cis	rs8084351	0.539	rs9947905	chr18:50623076	G/A	cg24270629	chr18:50823537	DCC	0.43	6.48	0.33	3.2e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06438056	chr1:33502433	AK2	0.46	7.11	0.36	7.01e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.56	-8.56	-0.42	3.99e-16	Multiple sclerosis;
LIHC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.82	-0.57	5.53e-31	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg04592579	chr7:75616294	TMEM120A	0.38	6.58	0.34	1.73e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.59	7.35	0.37	1.51e-12	Exhaled nitric oxide output;
LIHC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.76	-11.16	-0.52	7.14e-25	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2274273	0.905	rs8007620	chr14:55586587	T/C	cg01864836	chr14:55583639	NA	-0.39	-7.19	-0.36	4.22e-12	Protein biomarker;
LIHC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.94	0.39	2.95e-14	Lung cancer;
LIHC	cis	rs12744310	1.000	rs12034357	chr1:41768229	G/A	cg03962019	chr1:41807865	NA	0.4	6.49	0.33	3.01e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.96	-0.35	1.75e-11	IgG glycosylation;
LIHC	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-7.27	-0.37	2.46e-12	Mortality in heart failure;
LIHC	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg16275483	chr1:110013120	SYPL2	-0.49	-6.18	-0.32	1.8e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.38	6.27	0.32	1.07e-9	Height;
LIHC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	0.88	15.98	0.65	2.42e-43	Testicular germ cell tumor;
LIHC	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16684958	chr7:75615977	POR	-0.5	-8.47	-0.42	7.27e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg03934865	chr2:198174659	NA	0.53	8.29	0.41	2.61e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.93	-12.21	-0.55	1.04e-28	Cognitive test performance;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09747232	chr8:103827049	NA	0.4	6.17	0.32	1.96e-9	Cognitive function;
LIHC	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs2336384	1.000	rs7551874	chr1:12048130	A/G	cg13216073	chr1:12042593	MFN2	0.38	5.73	0.3	2.2e-8	Platelet count;
LIHC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.72	-12.18	-0.55	1.33e-28	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LIHC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.57	9.8	0.47	3.68e-20	Colorectal cancer;
LIHC	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.4	5.98	0.31	5.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.47	-0.73	2.3e-57	Height;
LIHC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.94	20.33	0.74	8.36e-61	Blood protein levels;
LIHC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.22	-0.45	3.18e-18	Hemoglobin concentration;
LIHC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.25	0.52	3.44e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg15670579	chr15:102264312	TARSL2	-0.5	-7.36	-0.37	1.41e-12	Immature fraction of reticulocytes;
LIHC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-7.15	-0.36	5.22e-12	Fibrinogen levels;
LIHC	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25632853	chr15:73088954	NA	0.38	6.41	0.33	4.89e-10	Triglyceride levels;
LIHC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg07424592	chr7:64974309	NA	-0.8	-9.08	-0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg20435097	chr10:126320824	FAM53B	-0.42	-6.16	-0.32	2.02e-9	Cocaine dependence;
LIHC	trans	rs6934970	1.000	rs62413982	chr6:113102637	A/G	cg09308777	chr6:169852575	NA	0.6	6.26	0.32	1.13e-9	Bipolar disorder (body mass index interaction);
LIHC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.4	-0.78	5.64e-73	Height;
LIHC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.46e-9	Renal cell carcinoma;
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.76	-0.39	9.66e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg11812906	chr14:75593930	NEK9	-0.4	-6.28	-0.32	1.01e-9	IgG glycosylation;
LIHC	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.33	0.49	5.94e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.57	8.31	0.41	2.24e-15	Emphysema distribution in smoking;
LIHC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.58	9.42	0.45	7.06e-19	Lymphocyte counts;
LIHC	cis	rs1494950	1.000	rs2604547	chr4:15089689	A/C	cg12377275	chr4:15005593	CPEB2	-0.79	-7.1	-0.36	7.17e-12	Political ideology;
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.55	-0.33	2.17e-10	Total body bone mineral density;
LIHC	cis	rs716804	0.765	rs10743133	chr11:10307879	A/G	cg01453529	chr11:10209919	SBF2	-0.29	-5.78	-0.3	1.64e-8	Neuroticism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03582286	chr4:71571171	RUFY3	0.41	6.17	0.32	1.92e-9	Lung function (FEV1/FVC);
LIHC	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs13161895	1.000	rs13161895	chr5:179471201	C/T	cg02702477	chr5:179499311	RNF130	0.8	11.17	0.52	6.67e-25	LDL cholesterol;
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08219700	chr8:58056026	NA	0.53	7.04	0.36	1.06e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.49	7.73	0.39	1.22e-13	Mood instability;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	11.15	0.52	7.52e-25	Calcium levels;
LIHC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	8.26	0.41	3.21e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg17980119	chr2:219472607	PLCD4	0.37	6.27	0.32	1.1e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.5	7.32	0.37	1.82e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02251663	chr11:14281053	SPON1	-0.47	-6.47	-0.33	3.42e-10	Mitochondrial DNA levels;
LIHC	cis	rs288342	0.832	rs288311	chr2:183649700	C/T	cg02625481	chr2:183667124	NA	-0.29	-5.95	-0.31	6.48e-9	Recurrent major depressive disorder;
LIHC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.45	-0.49	2.26e-22	Chronic sinus infection;
LIHC	cis	rs4759375	0.915	rs11057273	chr12:123814466	T/C	cg00376283	chr12:123451042	ABCB9	0.5	6.48	0.33	3.2e-10	HDL cholesterol;
LIHC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.78	-13.61	-0.59	5.2e-34	Aortic root size;
LIHC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.85	8.33	0.41	1.95e-15	Inflammatory bowel disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06660842	chr3:93733689	ARL13B;STX19	0.31	6.11	0.31	2.65e-9	Hepatitis;
LIHC	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.87e-10	Asthma;
LIHC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.91	-16.72	-0.67	2.77e-46	Aortic root size;
LIHC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-8.16	-0.4	6.6e-15	Menarche (age at onset);
LIHC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.94	17.44	0.69	3.65e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs117851058	0.590	rs2607412	chr19:41268243	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.47	-5.74	-0.3	2.04e-8	Post bronchodilator FEV1;
LIHC	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg13444538	chr7:158905317	VIPR2	-0.31	-5.8	-0.3	1.48e-8	Facial morphology (factor 20);
LIHC	cis	rs747782	0.582	rs4752843	chr11:47531884	T/G	cg20307385	chr11:47447363	PSMC3	-0.54	-6.16	-0.32	2.09e-9	Intraocular pressure;
LIHC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg22079354	chr11:130786696	SNX19	0.4	5.72	0.3	2.27e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.44	6.33	0.32	7.55e-10	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.26	0.32	1.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.59e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.38	5.91	0.3	8.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.96	11.5	0.53	4.44e-26	Eosinophil percentage of granulocytes;
LIHC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.48	0.37	6.53e-13	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.42	-0.33	4.57e-10	Diabetic kidney disease;
LIHC	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg02290350	chr8:58132656	NA	0.39	8.4	0.41	1.19e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-7.08	-0.36	8.37e-12	Hemoglobin concentration;
LIHC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.21	-0.36	3.63e-12	Response to antipsychotic treatment;
LIHC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13198984	chr17:80129470	CCDC57	-0.33	-5.83	-0.3	1.26e-8	Life satisfaction;
LIHC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.34	-6.09	-0.31	3.08e-9	Height;
LIHC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg16479474	chr6:28041457	NA	0.39	6.36	0.33	6.35e-10	Parkinson's disease;
LIHC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.61	-8.54	-0.42	4.58e-16	Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.28	0.55	5.92e-29	Prudent dietary pattern;
LIHC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.73	0.34	7.26e-11	Rheumatoid arthritis;
LIHC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg19318889	chr4:1322082	MAEA	-0.46	-6.47	-0.33	3.33e-10	Obesity-related traits;
LIHC	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.16	-0.32	2.09e-9	Resting heart rate;
LIHC	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.52	-7.48	-0.38	6.2800000000000005e-13	Schizophrenia;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg12371169	chr4:99182555	RAP1GDS1	-0.43	-6.21	-0.32	1.57e-9	Neuroblastoma;
LIHC	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.48	6.95	0.35	1.81e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg18912006	chr12:123335444	HIP1R	-0.58	-7.03	-0.36	1.12e-11	Schizophrenia;
LIHC	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.8	12.12	0.55	2.24e-28	Subjective well-being;
LIHC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.13	-0.36	6.01e-12	Blood metabolite levels;
LIHC	cis	rs16854884	0.683	rs920968	chr3:143770698	C/G	cg06585982	chr3:143692056	C3orf58	0.45	6.37	0.33	6.17e-10	Economic and political preferences (feminism/equality);
LIHC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.42	-0.37	9.26e-13	Psoriasis;
LIHC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.64	8.11	0.4	9.3e-15	Bronchopulmonary dysplasia;
LIHC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03377073	chr7:157980803	PTPRN2	0.34	6.95	0.35	1.81e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg00280220	chr17:61926910	NA	0.42	6.79	0.34	4.88e-11	Prudent dietary pattern;
LIHC	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.33	5.76	0.3	1.91e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.34e-8	Thyroid stimulating hormone;
LIHC	cis	rs7188697	0.922	rs6499962	chr16:58610750	A/C	cg02549819	chr16:58548995	SETD6	0.49	7.64	0.38	2.25e-13	QT interval;
LIHC	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg03999872	chr20:62272968	STMN3	0.41	6.08	0.31	3.29e-9	Prostate cancer;
LIHC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.74	-12.37	-0.56	2.77e-29	Systemic lupus erythematosus;
LIHC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	0.9	20.85	0.75	6.94e-63	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.75	13.68	0.59	2.85e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2637266	1.000	rs2637264	chr10:78322794	A/C	cg18941641	chr10:78392320	NA	0.29	6.12	0.31	2.55e-9	Pulmonary function;
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02290350	chr8:58132656	NA	0.5	10.64	0.5	5.15e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs1712517	0.740	rs11191643	chr10:105057561	C/G	cg05636881	chr10:105038444	INA	0.5	7.86	0.39	5.01e-14	Migraine;
LIHC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg14092571	chr14:90743983	NA	0.44	6.9	0.35	2.46e-11	Mortality in heart failure;
LIHC	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	16.26	0.66	1.85e-44	Electrocardiographic conduction measures;
LIHC	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.69	-0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	8.27	0.41	2.94e-15	Platelet count;
LIHC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-7.19	-0.36	4.01e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.39	6.43	0.33	4.22e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.41	-5.85	-0.3	1.13e-8	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24504288	chr15:56996376	ZNF280D	0.28	6.21	0.32	1.52e-9	Cognitive function;
LIHC	trans	rs6112176	0.679	rs6075446	chr20:18955126	A/G	cg11266874	chr3:93699352	ARL13B	-0.76	-6.12	-0.31	2.57e-9	Alcoholic chronic pancreatitis;
LIHC	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg10820045	chr2:198174542	NA	0.52	8.29	0.41	2.69e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.49	-0.38	6e-13	Mean platelet volume;
LIHC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.26	0.37	2.59e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs611744	0.967	rs2212704	chr8:109198415	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.55	10.78	0.5	1.65e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.39	7.55	0.38	4.07e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.54	-12.93	-0.57	2.05e-31	White blood cell count (basophil);
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06420487	chr17:61919686	SMARCD2	0.45	6.13	0.31	2.45e-9	Height;
LIHC	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	0.51	9.26	0.45	2.31e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	5.83	0.3	1.27e-8	Schizophrenia;
LIHC	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.91	10.22	0.48	1.37e-21	IgG glycosylation;
LIHC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg02297831	chr4:17616191	MED28	0.47	7.43	0.37	8.6e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2279817	0.863	rs3766311	chr1:17978186	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-7.23	-0.36	3.23e-12	Neuroticism;
LIHC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.76	0.54	4.85e-27	Motion sickness;
LIHC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.44	7.24	0.36	3.05e-12	Menarche (age at onset);
LIHC	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg11879182	chr18:77439856	CTDP1	0.83	13.38	0.59	4.01e-33	Monocyte count;
LIHC	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.51	8.29	0.41	2.61e-15	Corneal astigmatism;
LIHC	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.4	-6.45	-0.33	3.81e-10	Lewy body disease;
LIHC	cis	rs11603020	0.950	rs11229063	chr11:57369730	G/A	cg19752551	chr11:57585705	CTNND1	-0.46	-5.82	-0.3	1.35e-8	Blood protein levels;
LIHC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.37	5.91	0.3	8.06e-9	Menopause (age at onset);
LIHC	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.57	-6.8	-0.35	4.57e-11	Mammographic density (dense area);
LIHC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-9.41	-0.45	7.4e-19	Crohn's disease;
LIHC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg14829360	chr17:73884958	NA	-0.51	-7.71	-0.38	1.37e-13	Psoriasis;
LIHC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.25	-15.27	-0.64	1.6e-40	Psoriasis vulgaris;
LIHC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.86	-0.3	1.06e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg18016565	chr1:150552671	MCL1	0.56	10.71	0.5	2.81e-23	Melanoma;
LIHC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.49	6.22	0.32	1.42e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs6732160	0.631	rs7557285	chr2:73442812	G/A	cg24220031	chr2:73402428	NA	-0.28	-6.01	-0.31	4.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.74	7.41	0.37	9.71e-13	Platelet count;
LIHC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.59	10.05	0.48	5.26e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.62	10.27	0.49	9.5e-22	Height;
LIHC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7619427	0.822	rs62254362	chr3:44083403	C/A	cg24966902	chr3:44043705	NA	0.45	5.92	0.3	7.82e-9	Schizophrenia;
LIHC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.57	9.59	0.46	1.94e-19	Colorectal cancer;
LIHC	cis	rs526231	0.853	rs2288786	chr5:102600754	C/T	cg05225461	chr5:102596755	C5orf30	0.4	6.3	0.32	8.96e-10	Primary biliary cholangitis;
LIHC	cis	rs3823572	0.542	rs62470446	chr7:133631002	C/T	cg03336402	chr7:133662267	EXOC4	0.48	5.93	0.31	7.34e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.46	-5.84	-0.3	1.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.51	-10.69	-0.5	3.44e-23	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.37	5.83	0.3	1.29e-8	Resting heart rate;
LIHC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg22676075	chr6:135203613	NA	0.41	6.64	0.34	1.25e-10	Red blood cell count;
LIHC	cis	rs61677309	1.000	rs12577820	chr11:118164233	C/T	cg06090739	chr11:118230722	UBE4A	0.35	6.58	0.34	1.82e-10	Lung cancer in ever smokers;
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg18306943	chr3:40428807	ENTPD3	0.41	7.34	0.37	1.58e-12	Renal cell carcinoma;
LIHC	cis	rs3762637	0.882	rs9818537	chr3:122086457	G/T	cg24169773	chr3:122142474	KPNA1	-0.48	-9.3	-0.45	1.66e-18	LDL cholesterol levels;
LIHC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.39	6.14	0.31	2.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.68	10.27	0.49	9.37e-22	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg09021430	chr5:549028	NA	-0.45	-7.97	-0.4	2.36e-14	Lung disease severity in cystic fibrosis;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg09026481	chr5:74633022	HMGCR	-0.5	-6.11	-0.31	2.74e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	7.04	0.36	1.03e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.72	-10.12	-0.48	3.25e-21	Pancreatic cancer;
LIHC	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg13798912	chr7:905769	UNC84A	-0.54	-6.62	-0.34	1.37e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg22771759	chr13:24902376	NA	0.31	6.29	0.32	9.98e-10	Obesity-related traits;
LIHC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg07451762	chr16:28383216	NA	0.33	6.13	0.31	2.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.02	-0.31	4.43e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.65	-9.85	-0.47	2.68e-20	Subjective well-being;
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.49	-5.83	-0.3	1.29e-8	Alzheimer's disease;
LIHC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.65	13.83	0.6	7.52e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.01	0.58	1.07e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.34	0.32	7.41e-10	Systolic blood pressure;
LIHC	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.71	-0.3	2.45e-8	Bipolar disorder;
LIHC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.68	10.06	0.48	4.89e-21	Coronary artery disease;
LIHC	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.4	7.37	0.37	1.33e-12	Testicular germ cell tumor;
LIHC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.57	11.03	0.51	2.04e-24	Coronary artery disease;
LIHC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.88	9.85	0.47	2.52e-20	Triglycerides;
LIHC	trans	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg23598604	chr1:99732472	LPPR4	-0.29	-6.21	-0.32	1.5e-9	Multiple myeloma;
LIHC	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.54	-8.4	-0.41	1.19e-15	Coronary artery disease;
LIHC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg24203234	chr3:128598194	ACAD9	0.45	6.3	0.32	9.19e-10	IgG glycosylation;
LIHC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.5	-7.64	-0.38	2.17e-13	Corneal astigmatism;
LIHC	trans	rs916888	0.821	rs199499	chr17:44865498	C/T	cg07870213	chr5:140052090	DND1	0.94	7.93	0.39	3.08e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.56	9.44	0.45	6.07e-19	Pelvic organ prolapse;
LIHC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.47	7.96	0.4	2.53e-14	Mean corpuscular volume;
LIHC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.49	-7.82	-0.39	6.58e-14	Testicular germ cell tumor;
LIHC	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg09835421	chr16:68378352	PRMT7	-0.48	-5.9	-0.3	8.74e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.51	6.67	0.34	1.02e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.53	-0.33	2.42e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00593699	chr11:472782	PTDSS2	0.45	6.71	0.34	7.86e-11	Bilirubin levels;
LIHC	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.43	-7.06	-0.36	9.23e-12	Schizophrenia;
LIHC	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.71	11.53	0.53	3.24e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21467203	chr3:49911342	NA	-0.44	-7.59	-0.38	3.08e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-12.48	-0.56	1.02e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs10423674	0.526	rs757317	chr19:18819984	C/T	cg14292368	chr19:18793705	CRTC1	-0.42	-5.83	-0.3	1.27e-8	Menarche (age at onset);
LIHC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.77	15.19	0.63	3.32e-40	Mortality in heart failure;
LIHC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.77	11.76	0.54	4.89e-27	Subjective well-being;
LIHC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.57	6.12	0.31	2.6e-9	Facial morphology (factor 23);
LIHC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.96	-12.76	-0.57	9.14e-31	Schizophrenia;
LIHC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.8	-7.7	-0.38	1.47e-13	Diabetic retinopathy;
LIHC	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.75	11.26	0.52	3.03e-25	Subjective well-being;
LIHC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.46	-7.24	-0.36	3.03e-12	Type 2 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg09897639	chr1:178063342	RASAL2;LOC100302401	0.46	6.67	0.34	1.04e-10	Lung function (FEV1/FVC);
LIHC	trans	rs10761482	0.600	rs1572843	chr10:62226980	C/T	cg17314160	chr12:110399253	GIT2	-0.41	-6.11	-0.31	2.66e-9	Schizophrenia;
LIHC	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	1.08	8.7	0.43	1.4e-16	Cannabis dependence symptom count;
LIHC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg09779027	chr19:7224513	INSR	0.29	6.55	0.33	2.12e-10	Hypothyroidism;
LIHC	cis	rs2932538	0.702	rs7519368	chr1:113150644	T/A	cg22162597	chr1:113214053	CAPZA1	0.66	8.86	0.43	4.52e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07866137	chr8:67579786	VCPIP1	0.48	7.83	0.39	6e-14	Cognitive function;
LIHC	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.53	9.15	0.44	5.45e-18	Breast cancer;
LIHC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg24203234	chr3:128598194	ACAD9	0.44	6.18	0.32	1.78e-9	IgG glycosylation;
LIHC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.32	-8.21	-0.41	4.44e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.84	0.63	8.42e-39	Prudent dietary pattern;
LIHC	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.29	6.23	0.32	1.36e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.06	9.65	0.46	1.25e-19	Diabetic retinopathy;
LIHC	cis	rs2286503	0.839	rs2240726	chr7:22853135	C/T	cg11367502	chr7:22862612	TOMM7	0.43	7.16	0.36	4.96e-12	Fibrinogen;
LIHC	cis	rs7944735	0.508	rs111228939	chr11:47456067	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.85	-0.3	1.16e-8	Intraocular pressure;
LIHC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.19	-0.32	1.74e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.49	7.14	0.36	5.5e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-1.03	-19.95	-0.73	2.89e-59	Breast cancer;
LIHC	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg07884673	chr3:53033167	SFMBT1	0.91	6.6	0.34	1.58e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg00792783	chr2:198669748	PLCL1	-0.4	-5.89	-0.3	9.13e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.58	-7.83	-0.39	6.1e-14	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.8	-0.35	4.7e-11	Height;
LIHC	cis	rs6728642	0.519	rs4260285	chr2:97570081	A/G	cg26665480	chr2:98280029	ACTR1B	-0.6	-6.51	-0.33	2.75e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.38	-0.49	3.99e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg15871215	chr5:81402204	ATG10	0.68	8.17	0.4	6.13e-15	Breast cancer;
LIHC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg06969265	chr17:73775802	H3F3B	0.47	5.89	0.3	9.23e-9	Psoriasis;
LIHC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.81	0.5	1.3e-23	Personality dimensions;
LIHC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.27	0.37	2.45e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.75	17.37	0.68	6.74e-49	Brugada syndrome;
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg04352962	chr1:209979756	IRF6	-0.37	-5.75	-0.3	2.01e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg12046867	chr14:103022105	NA	-0.5	-7.1	-0.36	7.46e-12	Platelet count;
LIHC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.54	-10.31	-0.49	6.9e-22	Coronary artery disease;
LIHC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.01	-21.18	-0.75	3.43e-64	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg24879335	chr3:133465180	TF	0.28	6.28	0.32	1e-9	Iron status biomarkers;
LIHC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg11764359	chr7:65958608	NA	0.59	6.2	0.32	1.65e-9	Diabetic kidney disease;
LIHC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.92	8.3	0.41	2.43e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	11.4	0.52	9.42e-26	Multiple sclerosis;
LIHC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.55	7.24	0.36	2.96e-12	Body mass index;
LIHC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.34	-0.52	1.56e-25	Electrocardiographic conduction measures;
LIHC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.88	0.39	4.45e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16007711	chr8:22857750	RHOBTB2	-0.41	-6.16	-0.32	2.05e-9	Triglycerides;
LIHC	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.65	-0.34	1.13e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.36	5.89	0.3	9.26e-9	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs546131	0.642	rs512013	chr11:34842225	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.65	9.31	0.45	1.64e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs370915	0.542	rs28440880	chr4:187793213	T/G	cg12892747	chr4:187813459	NA	-0.37	-5.74	-0.3	2.07e-8	Gout;
LIHC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg02573091	chr5:74908125	NA	-0.58	-6.83	-0.35	3.9e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.12	12.95	0.57	1.74e-31	Vitiligo;
LIHC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg20651018	chr11:3035856	CARS	-0.34	-5.81	-0.3	1.45e-8	Longevity;
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	5.89	0.3	9.12e-9	Height;
LIHC	cis	rs943466	1.000	rs4711346	chr6:33730996	C/G	cg25922239	chr6:33757077	LEMD2	-0.5	-6.3	-0.32	9.24e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.91	16.39	0.66	5.92e-45	Parkinson's disease;
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg26939375	chr7:64535504	NA	0.47	7.19	0.36	4.13e-12	Calcium levels;
LIHC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17507749	chr15:85114479	UBE2QP1	0.76	8.75	0.43	9.72e-17	Schizophrenia;
LIHC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.76	0.39	1.01e-13	Lymphocyte counts;
LIHC	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs62005083	0.867	rs45569432	chr14:74666225	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.64	5.83	0.3	1.29e-8	Mean corpuscular volume;
LIHC	cis	rs61677309	1.000	rs7480736	chr11:118172364	A/G	cg06090739	chr11:118230722	UBE4A	0.34	6.41	0.33	4.92e-10	Lung cancer in ever smokers;
LIHC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.8	11.98	0.54	7.48e-28	Height;
LIHC	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.12	-0.31	2.51e-9	Blood pressure;
LIHC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.23	-0.36	3.18e-12	Personality dimensions;
LIHC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.66	-0.34	1.09e-10	Response to antipsychotic treatment;
LIHC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.38	0.59	3.85e-33	Chronic sinus infection;
LIHC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.75	-11.78	-0.54	4.12e-27	Tonsillectomy;
LIHC	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg27386326	chr11:61587980	NA	0.69	14.45	0.62	2.72e-37	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.48	5.88	0.3	9.58e-9	Bronchopulmonary dysplasia;
LIHC	trans	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.88	0.51	7.41e-24	Motion sickness;
LIHC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.41	-6.44	-0.33	4.15e-10	Multiple myeloma;
LIHC	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg20991723	chr1:152506922	NA	0.58	10.07	0.48	4.79e-21	Hair morphology;
LIHC	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.75	0.3	1.97e-8	Morning vs. evening chronotype;
LIHC	trans	rs2096176	0.632	rs17813720	chr10:26318795	G/A	cg01396774	chr2:218299024	DIRC3	-0.31	-6.05	-0.31	3.76e-9	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg12863693	chr15:85201151	NMB	0.45	6.41	0.33	4.96e-10	Schizophrenia;
LIHC	cis	rs6564851	0.545	rs4889285	chr16:81252258	C/T	cg00908271	chr16:81254010	PKD1L2	-0.35	-7.42	-0.37	9.12e-13	Carotenoid and tocopherol levels;
LIHC	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.11e-27	IgG glycosylation;
LIHC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.4	8.7	0.43	1.47e-16	Erythrocyte sedimentation rate;
LIHC	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.13	0.31	2.43e-9	Prudent dietary pattern;
LIHC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg21395723	chr22:39101663	GTPBP1	0.41	6.88	0.35	2.8e-11	Menopause (age at onset);
LIHC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.85	-0.47	2.62e-20	Crohn's disease;
LIHC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.51	-7.37	-0.37	1.29e-12	Total body bone mineral density;
LIHC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.61	-7.4	-0.37	1.04e-12	Mean platelet volume;
LIHC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.58	8.78	0.43	8.21e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.81	6.96	0.35	1.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.98	20.42	0.74	3.78e-61	Height;
LIHC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	1.01	19.32	0.72	9.73e-57	Breast cancer;
LIHC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg12798992	chr6:167411361	FGFR1OP	0.62	10.3	0.49	7.73e-22	Crohn's disease;
LIHC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.67	10.9	0.51	6.13e-24	Inflammatory bowel disease;
LIHC	cis	rs7095607	0.704	rs1900013	chr10:69953929	A/G	cg18986048	chr10:69913749	MYPN	0.43	6.53	0.33	2.36e-10	Lung function (FVC);
LIHC	trans	rs7448080	0.702	rs950392	chr5:123340716	A/G	cg23779626	chr6:33864747	NA	-0.59	-6.06	-0.31	3.62e-9	Alcohol dependence (age at onset);
LIHC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.72	6.92	0.35	2.27e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	7.93	0.39	3.14e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	17.36	0.68	7.38e-49	Lung cancer in ever smokers;
LIHC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg19680672	chr10:131412579	MGMT	-0.44	-6.73	-0.34	7.38e-11	Response to temozolomide;
LIHC	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg05084668	chr3:125655381	ALG1L	-0.59	-6.17	-0.32	1.98e-9	Blood pressure (smoking interaction);
LIHC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.45	-0.33	3.81e-10	Colorectal cancer;
LIHC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg12365402	chr11:9010492	NRIP3	-0.27	-7.06	-0.36	9.37e-12	Hemoglobin concentration;
LIHC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.44	-5.83	-0.3	1.27e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.06	-0.36	9.55e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-7.71	-0.38	1.39e-13	Gut microbiome composition (summer);
LIHC	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.58	-8.33	-0.41	2.02e-15	Neuroblastoma;
LIHC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg25801113	chr15:45476975	SHF	0.38	6.39	0.33	5.42e-10	Uric acid levels;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg00280220	chr17:61926910	NA	0.44	7.16	0.36	4.98e-12	Prudent dietary pattern;
LIHC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg18357645	chr12:58087776	OS9	-0.44	-6.89	-0.35	2.65e-11	Multiple sclerosis;
LIHC	cis	rs7474896	0.832	rs12570943	chr10:38022469	T/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.97	-0.31	5.83e-9	Obesity (extreme);
LIHC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.53	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.21	0.52	4.58e-25	Platelet count;
LIHC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.56	7.92	0.39	3.44e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.57	0.46	2.16e-19	Height;
LIHC	cis	rs970821	0.667	rs10956146	chr8:124749704	T/G	cg00283535	chr8:124749564	ANXA13	-0.44	-7.93	-0.39	3.16e-14	Breast cancer;
LIHC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.84	-0.35	3.69e-11	Menarche (age at onset);
LIHC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.8	-12.28	-0.55	5.73e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.14	-0.36	5.59e-12	Total body bone mineral density;
LIHC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.71	0.46	7.55e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9580312	0.706	rs9510016	chr13:22754512	G/A	cg15352224	chr3:10157326	C3orf10	-0.45	-6.45	-0.33	3.85e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.76	-0.3	1.9e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.11	23.84	0.79	1.03e-74	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.99	-0.31	5.36e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.48	0.56	1.06e-29	Prudent dietary pattern;
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.69	0.53	8.7e-27	Height;
LIHC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-8.28	-0.41	2.75e-15	Gut microbiome composition (summer);
LIHC	cis	rs1866706	1.000	rs1866705	chr11:12867171	T/C	cg25843174	chr11:12811716	TEAD1	-0.33	-6.92	-0.35	2.27e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs17102884	0.506	rs10873274	chr14:75407372	G/T	cg08847533	chr14:75593920	NEK9	-0.63	-10.94	-0.51	4.46e-24	Neuroticism;
LIHC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg13175981	chr1:150552382	MCL1	-0.43	-5.9	-0.3	8.64e-9	Melanoma;
LIHC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.34	-10.9	-0.51	5.97e-24	Obesity-related traits;
LIHC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.09	0.36	7.92e-12	Self-reported allergy;
LIHC	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg15282417	chr9:129245246	FAM125B	0.38	6.4	0.33	5.26e-10	Intraocular pressure;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.56	8.45	0.42	8.24e-16	Longevity;
LIHC	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg15893493	chr8:124194847	FAM83A	0.89	8.3	0.41	2.48e-15	Urinary uromodulin levels;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.46	-6.33	-0.32	7.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg08847533	chr14:75593920	NEK9	0.54	8.35	0.41	1.67e-15	IgG glycosylation;
LIHC	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg00792783	chr2:198669748	PLCL1	-0.47	-7.01	-0.35	1.26e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.52	8.95	0.44	2.29e-17	Alcohol dependence;
LIHC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.97	-17.33	-0.68	9.8e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.4	6.35	0.32	6.81e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.96	17.37	0.68	6.51e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-14.09	-0.61	7.01e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6753473	1.000	rs6753473	chr2:26526419	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.86	6.1	0.31	2.87e-9	Non-small cell lung cancer;
LIHC	cis	rs1494950	1.000	rs73797791	chr4:15051734	C/A	cg12377275	chr4:15005593	CPEB2	-0.85	-7.78	-0.39	8.87e-14	Political ideology;
LIHC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.94	-0.35	2e-11	IgG glycosylation;
LIHC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.82	0.35	4.14e-11	Renal cell carcinoma;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg27484876	chr20:33872021	EIF6	-0.46	-6.65	-0.34	1.2e-10	Eotaxin levels;
LIHC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.71	-0.43	1.28e-16	Primary biliary cholangitis;
LIHC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-10.27	-0.49	9.53e-22	Type 2 diabetes;
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.36	5.81	0.3	1.4e-8	Height;
LIHC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.15	-0.32	2.2e-9	Mean corpuscular volume;
LIHC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.56	15.05	0.63	1.25e-39	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.44	7.72	0.39	1.3e-13	Aortic root size;
LIHC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg02269571	chr22:50332266	NA	0.66	8.9	0.43	3.44e-17	Schizophrenia;
LIHC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.4	5.79	0.3	1.56e-8	Lipoprotein (a) levels;
LIHC	cis	rs16828019	0.929	rs4131949	chr1:41738637	C/T	cg03387723	chr1:41708464	SCMH1	-0.44	-7.13	-0.36	5.89e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg10820045	chr2:198174542	NA	0.46	6.9	0.35	2.59e-11	Dermatomyositis;
LIHC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-6.3	-0.32	8.94e-10	Body mass index;
LIHC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg27211696	chr2:191398769	TMEM194B	-0.49	-6.45	-0.33	3.85e-10	Diastolic blood pressure;
LIHC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.87	-0.35	2.98e-11	IgG glycosylation;
LIHC	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.76	12.59	0.56	3.95e-30	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	0.94	23.04	0.78	1.42e-71	Multiple myeloma;
LIHC	cis	rs75908454	1.000	rs77129004	chr6:169822879	G/A	cg19338460	chr6:170058176	WDR27	-0.86	-7.47	-0.37	6.6e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs807029	0.758	rs807025	chr10:102764821	C/T	cg27255678	chr10:102756921	LZTS2	0.42	5.77	0.3	1.8e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7534824	0.625	rs61780287	chr1:101382744	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	6.9	0.35	2.48e-11	Refractive astigmatism;
LIHC	trans	rs8012283	0.656	rs10148502	chr14:51261957	A/G	cg07338119	chr7:157211683	NA	0.66	6.09	0.31	3.02e-9	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	1.07	12.82	0.57	5.57e-31	Vitiligo;
LIHC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.34	0.52	1.64e-25	Motion sickness;
LIHC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg12903224	chr12:29470962	FAR2	0.41	6.37	0.33	6.13e-10	QT interval;
LIHC	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.52	7.69	0.38	1.63e-13	Schizophrenia;
LIHC	cis	rs7923837	0.651	rs11187107	chr10:94391697	G/A	cg25506282	chr10:94462361	NA	0.34	5.76	0.3	1.85e-8	Body mass index;Multiple sclerosis;
LIHC	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.04	0.51	1.9e-24	Coffee consumption (cups per day);
LIHC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24110177	chr3:50126178	RBM5	-0.45	-7.05	-0.36	1.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.41	5.88	0.3	1e-8	Height;
LIHC	cis	rs903552	0.932	rs11858490	chr15:102007443	G/T	cg19295451	chr15:102010161	PCSK6	0.49	6.98	0.35	1.58e-11	Diabetic kidney disease;
LIHC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.97	-0.31	6.01e-9	Calcium levels;
LIHC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.64	-7.18	-0.36	4.31e-12	Diabetic kidney disease;
LIHC	trans	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg21372672	chr17:16614065	CCDC144A	-0.33	-7.86	-0.39	4.93e-14	Educational attainment (years of education);
LIHC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-9.29	-0.45	1.79e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg01231543	chr16:68741748	NA	0.4	6.09	0.31	3.08e-9	Colorectal cancer;
LIHC	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg01652190	chr22:50026171	C22orf34	-0.35	-7.74	-0.39	1.1e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.57	0.38	3.42e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.21	-0.36	3.53e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg23172400	chr8:95962367	TP53INP1	0.3	6.81	0.35	4.41e-11	Alzheimer's disease (late onset);
LIHC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.64	-9.51	-0.46	3.63e-19	Systemic lupus erythematosus;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.73	13.44	0.59	2.27e-33	Prudent dietary pattern;
LIHC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.6	-8.8	-0.43	6.86e-17	Body mass index;
LIHC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.28	-7.21	-0.36	3.61e-12	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.3	-0.32	9.26e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6088813	1.000	rs6088813	chr20:33975181	C/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.83	-0.3	1.25e-8	Height;
LIHC	trans	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg16011800	chr17:1958478	HIC1	-0.53	-7.49	-0.38	6.1e-13	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg03342759	chr3:160939853	NMD3	-0.74	-9.18	-0.44	4.34e-18	Morning vs. evening chronotype;
LIHC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25833597	chr17:30823145	MYO1D	0.36	6.03	0.31	4.18e-9	Schizophrenia;
LIHC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-7.48	-0.37	6.46e-13	Vitiligo;
LIHC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.42	-5.84	-0.3	1.23e-8	Colorectal cancer;
LIHC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.87	-8.69	-0.43	1.54e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.71	-10.95	-0.51	3.86e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.86	12.99	0.57	1.26e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.48	-6.79	-0.34	5.01e-11	Lymphocyte counts;
LIHC	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs77861329	0.920	rs9846049	chr3:52120214	A/G	cg08692210	chr3:52188851	WDR51A	0.85	8.42	0.41	1.05e-15	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.98	-18.25	-0.7	2.02e-52	Breast cancer;
LIHC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.73	-0.34	7.29e-11	Bladder cancer;
LIHC	cis	rs2901460	0.509	rs12470090	chr2:62094367	T/C	cg02183531	chr2:62113199	CCT4	-0.4	-5.88	-0.3	1e-8	Mean corpuscular volume;
LIHC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg05110241	chr16:68378359	PRMT7	-0.6	-6.94	-0.35	2.02e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.53	9.21	0.45	3.29e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.03	-18.03	-0.7	1.5e-51	Body mass index;
LIHC	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.45	-7.01	-0.35	1.25e-11	Type 2 diabetes;
LIHC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg16586182	chr3:47516702	SCAP	-0.53	-9.5	-0.46	3.72e-19	Colorectal cancer;
LIHC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.34e-11	Aortic root size;
LIHC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.26	-0.37	2.71e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	0.77	8.77	0.43	8.38e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs7188697	0.921	rs12445577	chr16:58587164	T/C	cg02549819	chr16:58548995	SETD6	0.48	7.59	0.38	3.16e-13	QT interval;
LIHC	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg25208724	chr1:156163844	SLC25A44	0.89	14.29	0.61	1.15e-36	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.35	-8.9	-0.43	3.4e-17	Hip circumference;Waist circumference;
LIHC	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12922317	0.964	rs8061496	chr16:12076752	A/G	cg09319797	chr16:12061715	TNFRSF17	0.41	7.16	0.36	5.07e-12	Schizophrenia;
LIHC	cis	rs1144333	0.655	rs946164	chr1:76383286	A/T	cg22875332	chr1:76189707	ACADM	0.41	6.16	0.32	2.05e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg02811702	chr13:24901961	NA	0.24	6.01	0.31	4.84e-9	Obesity-related traits;
LIHC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.11	0.52	1.07e-24	Coronary artery disease;
LIHC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.95	17.96	0.7	2.95e-51	Menopause (age at onset);
LIHC	cis	rs713477	1.000	rs2185036	chr14:55907710	A/G	cg13175173	chr14:55914753	NA	-0.35	-8.13	-0.4	7.79e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	0.7	6.17	0.32	1.96e-9	Blood protein levels;
LIHC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	19.4	0.72	4.5e-57	Nonalcoholic fatty liver disease;
LIHC	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.59	-0.34	1.66e-10	Neuroticism;
LIHC	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.13	0.31	2.42e-9	Mean corpuscular volume;
LIHC	cis	rs860295	1.000	rs6427287	chr1:155723420	T/C	cg02153340	chr1:155202674	NA	-0.32	-5.91	-0.3	8.24e-9	Body mass index;
LIHC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg23791538	chr6:167370224	RNASET2	-0.51	-7.81	-0.39	6.86e-14	Crohn's disease;
LIHC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-8.96	-0.44	2.09e-17	Vitiligo;
LIHC	cis	rs7192750	0.586	rs11075908	chr16:71928850	C/T	cg06353428	chr16:71660113	MARVELD3	-0.8	-9.13	-0.44	5.89e-18	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.74	-10.25	-0.48	1.13e-21	Monocyte percentage of white cells;
LIHC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.54	-7.61	-0.38	2.66e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LIHC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.41	6.25	0.32	1.21e-9	Educational attainment;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21653586	chr11:10530636	NA	0.43	6.1	0.31	2.88e-9	Immature fraction of reticulocytes;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg08726195	chr7:77427851	PHTF2;TMEM60	-0.55	-6.18	-0.32	1.85e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.79	12.2	0.55	1.19e-28	Dental caries;
LIHC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.49	-5.89	-0.3	9.23e-9	Parkinson's disease;
LIHC	cis	rs2380220	0.810	rs877096	chr6:95937046	A/G	cg15832292	chr6:96025679	MANEA	-0.6	-6.73	-0.34	7.25e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs860295	0.650	rs28662267	chr1:155680449	T/C	cg02153340	chr1:155202674	NA	-0.35	-6.42	-0.33	4.57e-10	Body mass index;
LIHC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.71	10.3	0.49	7.86e-22	Selective IgA deficiency;
LIHC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-6.44	-0.33	4.05e-10	Electroencephalogram traits;
LIHC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	5.75	0.3	1.99e-8	IgG glycosylation;
LIHC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.99	0.35	1.49e-11	Alzheimer's disease;
LIHC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.33	-5.91	-0.3	8.34e-9	Schizophrenia;
LIHC	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	0.85	11.13	0.52	9.19e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg07959070	chr22:50026188	C22orf34	-0.33	-8.5	-0.42	5.96e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-10.88	-0.51	7.04e-24	Myopia (pathological);
LIHC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg03959625	chr15:84868606	LOC388152	0.44	6.12	0.31	2.64e-9	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12463550	chr7:65579703	CRCP	0.68	7.14	0.36	5.69e-12	Diabetic kidney disease;
LIHC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.52	-18.96	-0.72	2.61e-55	Breast cancer;
LIHC	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg16070018	chr6:26224392	HIST1H3E	0.53	6.31	0.32	8.62e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg21395723	chr22:39101663	GTPBP1	0.37	6.28	0.32	1.06e-9	Menopause (age at onset);
LIHC	cis	rs4700695	0.764	rs10066817	chr5:65319853	A/G	cg21114390	chr5:65439923	SFRS12	0.45	5.87	0.3	1.05e-8	Facial morphology (factor 19);
LIHC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg15103426	chr22:29168792	CCDC117	0.51	7.84	0.39	5.71e-14	Lymphocyte counts;
LIHC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.53	7.3	0.37	2.02e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.59	-6.33	-0.32	7.7e-10	Lung cancer;Squamous cell lung carcinoma;
LIHC	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.53	8.29	0.41	2.55e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.6	-8.51	-0.42	5.36e-16	Blood metabolite levels;
LIHC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.61	-7.37	-0.37	1.3e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-0.79	-8.85	-0.43	4.67e-17	Exhaled nitric oxide output;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25983288	chr5:137681122	FAM53C	0.43	6.52	0.33	2.6e-10	Immature fraction of reticulocytes;
LIHC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-9.1	-0.44	7.85e-18	Total body bone mineral density;
LIHC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.53	7.1	0.36	7.34e-12	Dialysis-related mortality;
LIHC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	trans	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	6.65	0.34	1.13e-10	Breast cancer;
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.67	7.58	0.38	3.32e-13	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.55	0.56	5.46e-30	Alzheimer's disease;
LIHC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.41	6.32	0.32	8.18e-10	Resting heart rate;
LIHC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.58	10.29	0.49	8.01e-22	Mean corpuscular volume;
LIHC	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.51	8.27	0.41	3.06e-15	Corneal astigmatism;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26853048	chr5:132387620	HSPA4	-0.4	-6.06	-0.31	3.63e-9	Systolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05635121	chr17:7154132	C17orf81;DULLARD	0.49	7.45	0.37	7.86e-13	Cognitive function;
LIHC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.58	-0.34	1.76e-10	Gut microbiome composition (summer);
LIHC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	9.4	0.45	8.28e-19	Tonsillectomy;
LIHC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.97	0.51	3.3e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.58	6.72	0.34	7.66e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.36	2.88e-12	Educational attainment;
LIHC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.01	15.91	0.65	4.71e-43	Breast cancer;
LIHC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.53	0.42	4.92e-16	Motion sickness;
LIHC	cis	rs4853036	0.903	rs13021969	chr2:70117602	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.82	-0.35	4.21e-11	Colorectal or endometrial cancer;
LIHC	trans	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg17675199	chr6:35436792	RPL10A	0.46	9.69	0.46	8.54e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-10.28	-0.49	8.9e-22	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg06135574	chr16:1550622	TELO2	0.38	6.17	0.32	1.96e-9	Tonsillectomy;
LIHC	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.55	-8.44	-0.42	8.96e-16	Coronary artery disease;
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.91	-0.35	2.4e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.6	-0.34	1.55e-10	Total body bone mineral density;
LIHC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.63	-0.38	2.35e-13	Monocyte percentage of white cells;
LIHC	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-9.25	-0.45	2.45e-18	Schizophrenia;
LIHC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.54	-0.33	2.24e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.48	-5.86	-0.3	1.09e-8	Parkinson's disease;
LIHC	cis	rs10849605	0.867	rs10849602	chr12:1062479	A/G	cg22937753	chr12:1022477	RAD52	-0.37	-7.02	-0.36	1.18e-11	Lung cancer;
LIHC	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.6	6.28	0.32	1.02e-9	Carotid intima media thickness;
LIHC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.72	-11.01	-0.51	2.56e-24	Aortic root size;
LIHC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.51	7.9	0.39	3.78e-14	Systemic lupus erythematosus;
LIHC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.25	0.32	1.22e-9	Melanoma;
LIHC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.41	5.73	0.3	2.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	1.04	10.68	0.5	3.72e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg25214090	chr10:38739885	LOC399744	0.4	6.73	0.34	6.99e-11	Diastolic blood pressure;
LIHC	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg14784868	chr12:69753453	YEATS4	0.51	6.94	0.35	2e-11	Response to diuretic therapy;
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.0	15.61	0.65	7.51e-42	Skin colour saturation;
LIHC	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg15711740	chr2:61764176	XPO1	0.41	5.73	0.3	2.24e-8	Tuberculosis;
LIHC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.79	13.72	0.6	2.01e-34	Parkinson's disease;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.78e-9	Menopause (age at onset);
LIHC	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	6.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg09795085	chr6:101329169	ASCC3	-0.52	-7.14	-0.36	5.5e-12	Neuroticism;
LIHC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16262614	chr3:133464971	TF	0.28	6.12	0.31	2.6e-9	Iron status biomarkers;
LIHC	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.35	7.14	0.36	5.67e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg16070018	chr6:26224392	HIST1H3E	-0.54	-6.58	-0.34	1.76e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg01843034	chr6:37503916	NA	-0.46	-7.97	-0.4	2.41e-14	Cognitive performance;
LIHC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.39	6.47	0.33	3.33e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13078911	chr2:44393479	NA	0.36	6.13	0.31	2.46e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.57e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.41	8.25	0.41	3.45e-15	Renal cell carcinoma;
LIHC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-9.34	-0.45	1.27e-18	Bipolar disorder;
LIHC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg00656387	chr3:40428638	ENTPD3	0.38	5.94	0.31	6.88e-9	Renal cell carcinoma;
LIHC	trans	rs783540	0.846	rs783534	chr15:83250243	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.19	-0.32	1.71e-9	Schizophrenia;
LIHC	cis	rs763512	0.504	rs1051838	chr17:35870833	G/A	cg16670864	chr17:35848621	DUSP14	0.35	5.75	0.3	1.96e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	1.09	7.68	0.38	1.71e-13	Height;
LIHC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.61	9.17	0.44	4.39e-18	Platelet count;
LIHC	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	cis	rs3814113	0.546	rs7868157	chr9:16851977	C/A	cg13173848	chr9:16870893	BNC2	0.64	7.07	0.36	8.97e-12	Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;
LIHC	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.21e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.58	0.56	4.25e-30	Platelet count;
LIHC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.3	-16.66	-0.67	4.63e-46	Diabetic kidney disease;
LIHC	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg02023728	chr11:77925099	USP35	-0.34	-6.01	-0.31	4.72e-9	Alzheimer's disease (survival time);
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.84	0.3	1.22e-8	Aortic root size;
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.21	-0.45	3.26e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	7.1	0.36	7.41e-12	Pulse pressure;
LIHC	cis	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg01864836	chr14:55583639	NA	-0.38	-6.48	-0.33	3.18e-10	Protein biomarker;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11060661	chr22:24314208	DDT;DDTL	-0.56	-8.99	-0.44	1.69e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.92	-0.35	2.17e-11	Metabolite levels;
LIHC	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg09445902	chr10:555545	DIP2C	-0.38	-6.15	-0.32	2.11e-9	Psychosis in Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07830086	chr19:18107778	KCNN1	0.47	6.13	0.31	2.41e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.72	-0.43	1.2e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg26139080	chr11:47293733	MADD	-0.5	-8.44	-0.42	8.85e-16	HDL cholesterol;
LIHC	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.75	-0.39	1.04e-13	Coronary artery disease;
LIHC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg17750252	chr2:136567154	LCT	0.34	6.24	0.32	1.27e-9	Mosquito bite size;
LIHC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.42	-6.79	-0.34	5.01e-11	Schizophrenia;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg00280220	chr17:61926910	NA	0.41	6.5	0.33	2.79e-10	Prudent dietary pattern;
LIHC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.89	10.97	0.51	3.51e-24	Coronary artery disease;
LIHC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.83	-0.35	3.94e-11	Response to antipsychotic treatment;
LIHC	trans	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg10208301	chr11:6592745	DNHD1	0.46	6.08	0.31	3.28e-9	Coronary artery calcification;
LIHC	cis	rs4728302	0.838	rs6974143	chr7:133603550	G/A	cg10665199	chr7:133106180	EXOC4	0.39	6.82	0.35	4.1e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.34	-6.21	-0.32	1.5e-9	Platelet distribution width;
LIHC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.79	-7.67	-0.38	1.77e-13	Diabetic retinopathy;
LIHC	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	0.78	6.8	0.35	4.56e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg19743168	chr1:23544995	NA	0.34	5.72	0.3	2.33e-8	Height;
LIHC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06002616	chr8:101225028	SPAG1	-0.36	-6.01	-0.31	4.72e-9	Atrioventricular conduction;
LIHC	trans	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.72	13.91	0.6	3.57e-35	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21467203	chr3:49911342	NA	0.44	7.79	0.39	7.94e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.5	-7.36	-0.37	1.41e-12	Multiple sclerosis;
LIHC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg16423285	chr20:60520624	NA	-0.53	-8.83	-0.43	5.49e-17	Obesity-related traits;
LIHC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.53	-9.81	-0.47	3.56e-20	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg12463550	chr7:65579703	CRCP	0.71	7.26	0.37	2.63e-12	Diabetic kidney disease;
LIHC	cis	rs6782228	0.606	rs6807019	chr3:128405934	G/A	cg16766828	chr3:128327626	NA	-0.39	-6.2	-0.32	1.63e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg19800026	chr5:14492945	TRIO	0.41	6.42	0.33	4.58e-10	Longevity;
LIHC	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.35	-0.32	6.92e-10	Hepatocellular carcinoma;
LIHC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.57	0.5	9e-23	Bladder cancer;
LIHC	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.54	-0.42	4.44e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.44	5.8	0.3	1.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.58	8.61	0.42	2.7e-16	Height;
LIHC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.11e-9	Height;
LIHC	cis	rs6442522	0.809	rs2290537	chr3:15455717	A/G	cg16303742	chr3:15540471	COLQ	0.37	5.91	0.3	8.44e-9	Uric acid levels;
LIHC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg15208524	chr1:10270712	KIF1B	0.39	5.99	0.31	5.17e-9	Hepatocellular carcinoma;
LIHC	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg12501888	chr15:85177176	SCAND2	-0.5	-7.76	-0.39	9.75e-14	P wave terminal force;
LIHC	cis	rs2997447	0.706	rs2783712	chr1:26429344	A/C	cg19633962	chr1:26362018	EXTL1	-0.52	-5.91	-0.3	8.31e-9	QRS complex (12-leadsum);
LIHC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.92	0.3	7.89e-9	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.67	11.43	0.53	7.61e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.41	-0.49	3.17e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.39	-6.91	-0.35	2.45e-11	Aortic root size;
LIHC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.37	-0.49	4.37e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.61	-0.38	2.69e-13	Platelet count;
LIHC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12463550	chr7:65579703	CRCP	0.68	7.26	0.37	2.63e-12	Diabetic kidney disease;
LIHC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.4	-6.43	-0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-7.82	-0.39	6.53e-14	Cognitive function;
LIHC	cis	rs3762637	0.941	rs9289192	chr3:122076115	C/G	cg24169773	chr3:122142474	KPNA1	-0.49	-9.63	-0.46	1.42e-19	LDL cholesterol levels;
LIHC	trans	rs1362756	0.958	rs8053277	chr16:51469726	T/C	cg06577604	chr3:184279443	EPHB3	0.47	6.08	0.31	3.21e-9	Optic disc parameters;Optic disc area;
LIHC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	12.46	0.56	1.21e-29	Platelet count;
LIHC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg15534755	chr11:117069859	TAGLN	0.36	6.07	0.31	3.45e-9	Blood protein levels;
LIHC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	1.03	20.26	0.74	1.61e-60	Breast cancer;
LIHC	trans	rs4714291	0.802	rs2983143	chr6:40044850	G/T	cg02267698	chr19:7991119	CTXN1	-0.41	-6.87	-0.35	3.08e-11	Strep throat;
LIHC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg21100191	chr22:23484243	RTDR1	0.94	17.8	0.69	1.3e-50	Bone mineral density;
LIHC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	8.49	0.42	6.5e-16	Alzheimer's disease;
LIHC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg06026331	chr20:60912101	LAMA5	0.49	6.5	0.33	2.83e-10	Colorectal cancer;
LIHC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.45	-5.98	-0.31	5.75e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.92	16.56	0.67	1.24e-45	Parkinson's disease;
LIHC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.34	-0.32	7.1e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.45	-6.69	-0.34	9.17e-11	Diastolic blood pressure;
LIHC	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.16	0.32	2.03e-9	Schizophrenia;
LIHC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.9	-9.3	-0.45	1.7e-18	Facial morphology (factor 23);
LIHC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.87	-12.51	-0.56	7.67e-30	Blood metabolite levels;
LIHC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.67	-11.56	-0.53	2.49e-26	Crohn's disease;
LIHC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.8	9.13	0.44	6.23e-18	Cognitive function;
LIHC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg03037974	chr15:76606532	NA	0.88	22.78	0.78	1.53e-70	Blood metabolite levels;
LIHC	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.17	-0.32	1.91e-9	Schizophrenia;
LIHC	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.35	7.91	0.39	3.53e-14	Educational attainment (years of education);
LIHC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg02290350	chr8:58132656	NA	0.45	9.06	0.44	9.93e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.3	6.36	0.33	6.6e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg08847533	chr14:75593920	NEK9	0.54	8.22	0.41	4.24e-15	IgG glycosylation;
LIHC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	cis	rs56146971	0.670	rs12590074	chr14:91867390	T/G	cg16433844	chr14:91963127	SMEK1	-0.51	-6.06	-0.31	3.58e-9	Alzheimer disease and age of onset;
LIHC	cis	rs3823572	0.564	rs2971962	chr7:133639770	G/A	cg03336402	chr7:133662267	EXOC4	0.48	5.74	0.3	2.07e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	11.45	0.53	6.59e-26	Platelet count;
LIHC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.9	0.6	4.02e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.6	9.32	0.45	1.51e-18	Height;
LIHC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.34	-6.52	-0.33	2.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	trans	rs73186030	1.000	rs73186044	chr3:122028476	G/T	cg13973942	chr17:977984	ABR	0.47	6.06	0.31	3.6e-9	Serum parathyroid hormone levels;
LIHC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.86	12.22	0.55	9.54e-29	Menarche (age at onset);
LIHC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg07424592	chr7:64974309	NA	0.78	9.03	0.44	1.23e-17	Diabetic kidney disease;
LIHC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.96	-0.31	6.38e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2744203	1.000	rs72610883	chr6:104640613	A/G	cg27088726	chr16:83171155	CDH13	-0.46	-6.08	-0.31	3.14e-9	IgG glycosylation;
LIHC	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.51	8.18	0.4	5.49e-15	Diastolic blood pressure;
LIHC	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg16275483	chr1:110013120	SYPL2	-0.49	-6.04	-0.31	4.11e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.34	-5.98	-0.31	5.75e-9	Asthma;
LIHC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.61	9.23	0.45	2.86e-18	Longevity;
LIHC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs9948	0.500	rs62152903	chr2:97570377	T/C	cg26665480	chr2:98280029	ACTR1B	-0.57	-5.79	-0.3	1.57e-8	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.77	0.3	1.77e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.01	0.35	1.26e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.51	9.74	0.47	6.19e-20	Testicular germ cell tumor;
LIHC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.64	0.34	1.24e-10	Obesity-related traits;
LIHC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.45	7.18	0.36	4.37e-12	Lipoprotein (a) levels;
LIHC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg02733842	chr7:1102375	C7orf50	-0.65	-7.12	-0.36	6.34e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.43	-6.68	-0.34	9.56e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.95	-12.12	-0.55	2.25e-28	Body mass index;
LIHC	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	6.97e-29	Eye color traits;
LIHC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.22	0.32	1.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.53	-7.86	-0.39	5.21e-14	Total body bone mineral density;
LIHC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.56	-0.5	9.46e-23	Chronic sinus infection;
LIHC	cis	rs151997	0.962	rs27271	chr5:50183369	A/G	cg06027927	chr5:50259733	NA	0.56	7.66	0.38	1.9e-13	Callous-unemotional behaviour;
LIHC	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg07423050	chr13:99094983	FARP1	0.37	6.19	0.32	1.71e-9	Longevity;
LIHC	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.42	-7.35	-0.37	1.51e-12	Male sexual orientation;
LIHC	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.86	9.43	0.45	6.48e-19	LDL cholesterol;
LIHC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.74	-10.38	-0.49	4.13e-22	Dental caries;
LIHC	cis	rs7537052	0.669	rs475591	chr1:36642420	T/C	cg24686825	chr1:36642396	MAP7D1	-0.7	-11.51	-0.53	3.92e-26	Schizophrenia;
LIHC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.11	0.58	4.33e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.49	7.17	0.36	4.7e-12	Prostate cancer;
LIHC	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg03962019	chr1:41807865	NA	0.49	7.13	0.36	6.13e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.04	0.51	1.95e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	7.65	0.38	2.01e-13	Mean platelet volume;
LIHC	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.94	0.31	7.19e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs2637030	0.515	rs1532163	chr5:52856716	A/G	cg06476337	chr5:52856530	NDUFS4	0.43	6.76	0.34	6.13e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	trans	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg01596870	chr19:55963115	NA	-0.67	-9.63	-0.46	1.36e-19	Obesity-related traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08266417	chr2:201450575	AOX1	-0.53	-6.46	-0.33	3.69e-10	Systolic blood pressure;
LIHC	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10861342	1.000	rs1345095	chr12:105471577	C/T	cg23923672	chr12:105501055	KIAA1033	0.69	8.02	0.4	1.68e-14	IgG glycosylation;
LIHC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg00977110	chr5:151150581	G3BP1	0.56	7.12	0.36	6.6e-12	Preschool internalizing problems;
LIHC	cis	rs16854884	0.683	rs10935505	chr3:143777966	T/C	cg06585982	chr3:143692056	C3orf58	0.48	6.76	0.34	6.15e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.9	10.74	0.5	2.17e-23	Prostate cancer;
LIHC	trans	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg24036039	chr1:3397125	ARHGEF16	-0.42	-7.15	-0.36	5.3e-12	Schizophrenia;
LIHC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg23517279	chr6:96025343	MANEA	0.57	5.78	0.3	1.7e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.38	-6.73	-0.34	7.21e-11	Aortic root size;
LIHC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg04083430	chr16:4736063	MGRN1	-0.42	-5.79	-0.3	1.59e-8	Schizophrenia;
LIHC	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg15893493	chr8:124194847	FAM83A	0.89	8.31	0.41	2.26e-15	Urinary uromodulin levels;
LIHC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.21	0.32	1.57e-9	Educational attainment;
LIHC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.63	-0.42	2.4e-16	Type 2 diabetes;
LIHC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.67	10.04	0.48	5.65e-21	Mosquito bite size;
LIHC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.5	-7.25	-0.36	2.88e-12	Uric acid levels;
LIHC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.48	0.33	3.29e-10	Bipolar disorder;
LIHC	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.83	8.62	0.42	2.57e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.33	-8.6	-0.42	2.84e-16	Schizophrenia;
LIHC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.0	-23.99	-0.79	2.76e-75	Prudent dietary pattern;
LIHC	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.75	11.68	0.53	9.81e-27	Corneal astigmatism;
LIHC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.83	-0.43	5.44e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7729447	0.813	rs4867470	chr5:32692536	C/A	cg16267343	chr5:32710456	NPR3	0.47	5.78	0.3	1.69e-8	Blood pressure;
LIHC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.63	10.46	0.49	2.12e-22	Multiple myeloma (IgH translocation);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21905229	chr20:32031732	SNTA1	-0.54	-6.31	-0.32	8.59e-10	Systolic blood pressure;
LIHC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg10130564	chr11:117069849	TAGLN	0.37	6.17	0.32	1.96e-9	Blood protein levels;
LIHC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.59	6.94	0.35	1.92e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg22676075	chr6:135203613	NA	0.38	6.14	0.31	2.33e-9	Red blood cell count;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg07264154	chr3:142546513	PCOLCE2	0.52	6.22	0.32	1.46e-9	Mean platelet volume;
LIHC	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.99e-50	Schizophrenia;
LIHC	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.41	6.77	0.34	5.55e-11	Lewy body disease;
LIHC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.95	-0.7	3.2e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg03959625	chr15:84868606	LOC388152	0.46	6.51	0.33	2.67e-10	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.74	12.38	0.56	2.36e-29	Platelet distribution width;
LIHC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	8.31	0.41	2.25e-15	Multiple sclerosis;
LIHC	cis	rs12935418	0.672	rs1453327	chr16:81048564	A/C	cg08265926	chr16:81039227	CENPN;C16orf61	-0.33	-5.78	-0.3	1.66e-8	Mean corpuscular volume;
LIHC	cis	rs2637266	0.905	rs4357630	chr10:78382883	T/G	cg18941641	chr10:78392320	NA	0.29	6.16	0.32	2.01e-9	Pulmonary function;
LIHC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02290350	chr8:58132656	NA	0.47	9.27	0.45	2.1e-18	Developmental language disorder (linguistic errors);
LIHC	trans	rs7714584	1.000	rs7734928	chr5:150256613	G/A	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-7.39	-0.37	1.11e-12	Cognitive function;
LIHC	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4684776	0.867	rs13058769	chr3:11342305	A/G	cg00170343	chr3:11313890	ATG7	-0.53	-7.28	-0.37	2.31e-12	Small vessel stroke;
LIHC	cis	rs2412488	1.000	rs931182	chr4:54243230	T/C	cg22241045	chr4:54363911	LNX1	-0.46	-7.29	-0.37	2.19e-12	DNA methylation (variation);
LIHC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.33	5.84	0.3	1.23e-8	Platelet distribution width;
LIHC	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg10157359	chr2:10953004	PDIA6	-0.52	-7.07	-0.36	8.74e-12	Cardiac Troponin-T levels;
LIHC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.86	15.42	0.64	4.39e-41	Headache;
LIHC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.12	0.61	5.45e-36	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.69	-9.55	-0.46	2.65e-19	Multiple sclerosis;
LIHC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.59	-0.38	3.13e-13	NT-proBNP levels in acute coronary syndrome;
LIHC	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg16099169	chr2:106886729	NA	0.43	6.53	0.33	2.36e-10	Facial morphology (factor 23);
LIHC	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg17425144	chr1:10567563	PEX14	0.52	10.11	0.48	3.5e-21	Prostate cancer;
LIHC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.57	11.12	0.52	1.03e-24	Coronary artery disease;
LIHC	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-6.36	-0.33	6.41e-10	Monocyte count;
LIHC	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg10381502	chr11:71823885	C11orf51	-1.02	-8.51	-0.42	5.38e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	3.15e-30	Menopause (age at onset);
LIHC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg15704280	chr7:45808275	SEPT13	-0.45	-6.81	-0.35	4.36e-11	HDL cholesterol;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.88	0.39	4.49e-14	Prudent dietary pattern;
LIHC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.46	6.19	0.32	1.76e-9	Major depressive disorder;
LIHC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.39	-7.11	-0.36	6.72e-12	Electrocardiographic conduction measures;
LIHC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.57	9.86	0.47	2.47e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.61	-11.4	-0.52	9.82e-26	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17106184	1.000	rs72902778	chr1:51276715	A/G	cg07174182	chr1:51127561	FAF1	-0.65	-6.99	-0.35	1.46e-11	Type 2 diabetes;
LIHC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg15105060	chr4:7024189	TBC1D14	-0.7	-6.31	-0.32	8.73e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11987759	chr7:65425863	GUSB	-0.39	-6.09	-0.31	3.1e-9	Aortic root size;
LIHC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg18016565	chr1:150552671	MCL1	0.52	9.57	0.46	2.2e-19	Melanoma;
LIHC	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-0.8	-6.21	-0.32	1.53e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.88	-12.24	-0.55	8.15e-29	Urate levels;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg02869306	chr7:64672164	INTS4L1	-0.3	-6.42	-0.33	4.47e-10	Calcium levels;
LIHC	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg12310025	chr6:25882481	NA	-0.42	-6.32	-0.32	8.09e-10	Height;
LIHC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.95	-18.2	-0.7	3.08e-52	Breast cancer;
LIHC	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg19683494	chr5:74908142	NA	0.68	8.91	0.43	3.09e-17	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.45	5.73	0.3	2.25e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02985541	chr2:219472218	PLCD4	0.47	8.94	0.44	2.53e-17	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg26888861	chr11:62521812	ZBTB3	-0.48	-7.99	-0.4	2.07e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.29	0.55	5.3e-29	Prudent dietary pattern;
LIHC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.44	7.09	0.36	7.67e-12	Total body bone mineral density;
LIHC	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.65	0.38	2.08e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.24	6.02	0.31	4.61e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.73	-0.3	2.16e-8	Arsenic metabolism;
LIHC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.5	0.33	2.79e-10	Heart rate;
LIHC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.82	9.65	0.46	1.19e-19	Vitiligo;
LIHC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg17294928	chr15:75287854	SCAMP5	-0.52	-6.67	-0.34	1.06e-10	Lung cancer;
LIHC	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-7.22	-0.36	3.46e-12	Obesity-related traits;
LIHC	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.07	0.31	3.41e-9	Morning vs. evening chronotype;
LIHC	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.29	0.32	9.53e-10	Schizophrenia;
LIHC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg13753209	chr17:57696993	CLTC	0.59	9.03	0.44	1.28e-17	Hemoglobin concentration;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07677032	chr17:61819896	STRADA	0.41	5.76	0.3	1.84e-8	Prudent dietary pattern;
LIHC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.45	5.85	0.3	1.14e-8	Major depressive disorder;
LIHC	cis	rs17286411	0.750	rs35619990	chr16:71949266	C/T	cg06353428	chr16:71660113	MARVELD3	0.55	6.87	0.35	3.06e-11	Blood protein levels;
LIHC	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg06533319	chr4:3265114	C4orf44	0.33	6.5	0.33	2.91e-10	Parental longevity (mother's age at death);
LIHC	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.51	-7.74	-0.39	1.12e-13	Menarche (age at onset);
LIHC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.48	-6.16	-0.32	2.08e-9	Pancreatic cancer;
LIHC	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.2	-0.36	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7326068	0.524	rs7998500	chr13:21159000	A/G	cg27499820	chr13:21296301	IL17D	0.37	5.9	0.3	8.93e-9	Schizophrenia, bipolar disorder and depression (combined);
LIHC	cis	rs7116495	1.000	rs515358	chr11:71562302	G/C	cg26138937	chr11:71823887	C11orf51	0.65	6.27	0.32	1.11e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.32	-7.62	-0.38	2.45e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.77	-13.13	-0.58	3.65e-32	Body mass index;
LIHC	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.71	-0.34	8.07e-11	Blood pressure;
LIHC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.68	0.59	2.85e-34	Lung cancer in ever smokers;
LIHC	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg08345082	chr10:99160200	RRP12	-0.4	-6.76	-0.34	5.81e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.58	-9.09	-0.44	8.35e-18	Menarche (age at onset);
LIHC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.65	9.62	0.46	1.5700000000000001e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-7.32	-0.37	1.81e-12	Post bronchodilator FEV1;
LIHC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.72	-9.63	-0.46	1.44e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26734620	chr12:56694298	CS	1.21	10.14	0.48	2.67e-21	Psoriasis vulgaris;
LIHC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg03859395	chr2:55845619	SMEK2	0.93	16.59	0.67	9.1e-46	Metabolic syndrome;
LIHC	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.91	-12.47	-0.56	1.08e-29	Obesity-related traits;
LIHC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.57	-0.33	1.92e-10	Alzheimer's disease (late onset);
LIHC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.66	-10.75	-0.5	2e-23	Childhood ear infection;
LIHC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.85	-15.28	-0.64	1.5e-40	Bipolar disorder and schizophrenia;
LIHC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.6	-8.51	-0.42	5.64e-16	Blood metabolite levels;
LIHC	cis	rs1892700	0.764	rs8971	chr21:34883618	T/C	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27297192	chr10:134578999	INPP5A	0.56	7.73	0.39	1.19e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.93	-7.04	-0.36	1.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg14166365	chr9:126165469	DENND1A;MIR601	-0.36	-6.2	-0.32	1.66e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.57	8.28	0.41	2.81e-15	Mean corpuscular volume;
LIHC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	22.61	0.77	7.14e-70	Body mass index (adult);
LIHC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.58	-8.2	-0.41	4.96e-15	Response to antineoplastic agents;
LIHC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.62	-5.99	-0.31	5.26e-9	Urate levels in lean individuals;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.73	10.33	0.49	6.15e-22	Menarche (age at onset);
LIHC	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.52	7.93	0.39	3.24e-14	Corneal astigmatism;
LIHC	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.59	9.42	0.45	6.98e-19	HDL cholesterol;
LIHC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.38	-5.74	-0.3	2.06e-8	Longevity;Endometriosis;
LIHC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.79	9.68	0.46	9.64e-20	Morning vs. evening chronotype;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01181084	chr8:43059863	NA	0.47	6.74	0.34	6.78e-11	Longevity;
LIHC	cis	rs11671005	0.652	rs11670864	chr19:59030580	G/T	cg25952890	chr19:58913133	NA	0.62	6.19	0.32	1.69e-9	Mean platelet volume;
LIHC	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.58	-8.21	-0.41	4.71e-15	Obesity-related traits;
LIHC	cis	rs7503807	0.651	rs901065	chr17:78599655	G/T	cg09596252	chr17:78655493	RPTOR	0.36	6.1	0.31	2.82e-9	Obesity;
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21747090	chr2:27597821	SNX17	-0.41	-6.1	-0.31	2.94e-9	Total body bone mineral density;
LIHC	cis	rs12602486	1.000	rs78673779	chr17:42217936	G/A	cg13607699	chr17:42295918	UBTF	-0.72	-6.27	-0.32	1.12e-9	Glycated hemoglobin levels;
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.56	8.11	0.4	9.34e-15	Renal cell carcinoma;
LIHC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.68	10.03	0.48	6.31e-21	Monocyte percentage of white cells;
LIHC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	1.03	10.46	0.49	2.09e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg00576331	chr11:65640516	EFEMP2	-0.41	-5.92	-0.3	8.04e-9	DNA methylation (variation);
LIHC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg15848620	chr12:58087721	OS9	-0.58	-7.97	-0.4	2.37e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.08	-0.36	8.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg10587741	chr22:38071170	LGALS1	0.44	7.95	0.39	2.72e-14	Fat distribution (HIV);
LIHC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-0.33	-8.48	-0.42	7.1e-16	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15356674	chr10:79471309	NA	0.41	6.05	0.31	3.77e-9	Pancreatic cancer;
LIHC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.38	7.2	0.36	3.94e-12	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg25894440	chr7:65020034	NA	-0.52	-5.79	-0.3	1.6e-8	Diabetic kidney disease;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.58	9.71	0.47	7.38e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.54	0.46	2.78e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.91	-13.68	-0.59	2.89e-34	Obesity-related traits;
LIHC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-8.72	-0.43	1.24e-16	Platelet distribution width;
LIHC	trans	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg19894588	chr14:64061835	NA	-0.47	-7.44	-0.37	8.1e-13	Fat distribution (HIV);
LIHC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.65	10.55	0.5	1.03e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.86	-0.35	3.29e-11	Diabetic kidney disease;
LIHC	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.42	7.45	0.37	7.54e-13	Dementia with Lewy bodies;
LIHC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg03859395	chr2:55845619	SMEK2	0.93	16.56	0.67	1.2e-45	Metabolic syndrome;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03811519	chr9:134001305	NUP214	0.42	6.14	0.32	2.32e-9	Pancreatic cancer;
LIHC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.56	-0.38	3.67e-13	IgG glycosylation;
LIHC	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.24	0.41	3.62e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.58	10.13	0.48	2.96e-21	Mean corpuscular volume;
LIHC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.83	-8.95	-0.44	2.36e-17	Vitiligo;
LIHC	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg20129853	chr10:51489980	NA	0.4	8.57	0.42	3.7e-16	Prostate-specific antigen levels;
LIHC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.05	-11.66	-0.53	1.15e-26	Vitiligo;
LIHC	cis	rs7116495	1.000	rs609181	chr11:71569672	T/C	cg26138937	chr11:71823887	C11orf51	0.68	6.64	0.34	1.24e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07305463	chr2:136567211	LCT	-0.38	-5.88	-0.3	9.67e-9	Corneal structure;
LIHC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.32	-7.11	-0.36	6.83e-12	Ulcerative colitis;
LIHC	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg15192750	chr16:69999425	NA	0.44	6.65	0.34	1.14e-10	IgE levels;
LIHC	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	24.79	0.8	2.18e-78	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	7.97	0.4	2.37e-14	Motion sickness;
LIHC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-7.38	-0.37	1.25e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2467099	0.735	rs55793071	chr17:73909948	C/T	cg08125733	chr17:73851984	WBP2	0.45	5.72	0.3	2.31e-8	Systolic blood pressure;
LIHC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.17	0.55	1.54e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-0.97	-22.11	-0.77	6.56e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.52	-7.91	-0.39	3.67e-14	Attention deficit hyperactivity disorder;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.91	-15.1	-0.63	8.06e-40	Longevity;
LIHC	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-0.81	-8.38	-0.41	1.35e-15	Blood pressure (smoking interaction);
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg14393609	chr7:65229607	NA	0.42	7.11	0.36	6.92e-12	Calcium levels;
LIHC	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	0.87	14.21	0.61	2.47e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.55	-0.42	4.21e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.43	6.48	0.33	3.2e-10	Weight;
LIHC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08219700	chr8:58056026	NA	0.51	6.44	0.33	4.08e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg10217327	chr6:118973057	C6orf204	-0.62	-7.01	-0.35	1.29e-11	Diastolic blood pressure;
LIHC	cis	rs3770081	1.000	rs2012798	chr2:86182756	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.74	-7.41	-0.37	1.01e-12	Facial emotion recognition (sad faces);
LIHC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg03959625	chr15:84868606	LOC388152	0.44	6.3	0.32	8.99e-10	Schizophrenia;
LIHC	cis	rs3770081	1.000	rs12624126	chr2:86342366	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.45	5.76	0.3	1.88e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg03934865	chr2:198174659	NA	-0.6	-9.65	-0.46	1.16e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.6	-9.3	-0.45	1.73e-18	Coronary artery disease;
LIHC	cis	rs2574704	0.781	rs2574722	chr3:11659877	T/C	cg15876825	chr3:11651881	VGLL4	0.49	7.9	0.39	3.94e-14	Body mass index;
LIHC	cis	rs6445797	0.632	rs2004199	chr3:56645866	A/G	cg13792233	chr3:56591045	CCDC66	-0.39	-5.77	-0.3	1.81e-8	Gastritis;
LIHC	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.62	7.71	0.38	1.35e-13	Itch intensity from mosquito bite;
LIHC	cis	rs9948	1.000	rs12172	chr2:97500852	C/G	cg01990225	chr2:97406019	LMAN2L	-0.65	-6.05	-0.31	3.75e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1144333	1.000	rs12410724	chr1:76459134	A/G	cg10523679	chr1:76189770	ACADM	0.42	5.97	0.31	6.05e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.06	-0.31	3.57e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4700695	0.925	rs12657113	chr5:65396959	A/C	cg21114390	chr5:65439923	SFRS12	-0.5	-6.92	-0.35	2.24e-11	Facial morphology (factor 19);
LIHC	cis	rs2933343	0.951	rs789220	chr3:128592135	A/G	cg25356066	chr3:128598488	ACAD9	-0.53	-7.01	-0.35	1.25e-11	IgG glycosylation;
LIHC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.39	-0.33	5.47e-10	Colorectal cancer;
LIHC	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.7	-14.33	-0.61	8.4e-37	Schizophrenia;
LIHC	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.4	5.93	0.31	7.41e-9	Schizophrenia;
LIHC	cis	rs28530618	0.603	rs11167173	chr20:31241612	A/T	cg13636640	chr20:31349939	DNMT3B	-0.43	-6.13	-0.31	2.38e-9	Birth weight;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.57	7.41	0.37	9.92e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.61	7.5	0.38	5.64e-13	Heart rate;
LIHC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.92	13.82	0.6	8.34e-35	Primary sclerosing cholangitis;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07161888	chr16:53537348	AKTIP	-0.4	-6.08	-0.31	3.19e-9	Triglycerides;
LIHC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg00204748	chr12:29376779	FAR2	0.41	7.6	0.38	2.81e-13	QT interval;
LIHC	trans	rs4815879	0.509	rs4815883	chr20:6040283	C/T	cg23629183	chr3:97691400	MINA	-0.63	-6.65	-0.34	1.18e-10	Preeclampsia;
LIHC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-13.02	-0.58	9.18e-32	Height;
LIHC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-9.71	-0.47	7.35e-20	Longevity;Endometriosis;
LIHC	cis	rs8044995	0.636	rs12596500	chr16:68299771	G/A	cg09835421	chr16:68378352	PRMT7	-0.57	-5.92	-0.3	7.89e-9	Schizophrenia;
LIHC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg14222432	chr12:29376421	FAR2	0.36	6.97	0.35	1.64e-11	QT interval;
LIHC	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.36	6.59	0.34	1.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.08	-0.4	1.12e-14	Exhaled nitric oxide output;
LIHC	cis	rs9871864	0.868	rs62243505	chr3:20345616	T/C	cg00235661	chr3:20228976	SGOL1	-0.3	-5.75	-0.3	1.96e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.94	-0.44	2.52e-17	Skin colour saturation;
LIHC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.41	6.76	0.34	6.09e-11	IgG glycosylation;
LIHC	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.78	8.88	0.43	3.91e-17	Exhaled nitric oxide levels;
LIHC	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.26	6.09	0.31	3.08e-9	Total body bone mineral density;
LIHC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg25024717	chr12:54324583	NA	-0.38	-8.12	-0.4	8.31e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.96	-17.18	-0.68	4.1e-48	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25852545	chr3:113775465	KIAA1407;QTRTD1	-0.44	-6.15	-0.32	2.2e-9	Pancreatic cancer;
LIHC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	7.45	0.37	7.45e-13	Bone mineral density;
LIHC	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg19894588	chr14:64061835	NA	-0.59	-8.01	-0.4	1.82e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg03647239	chr10:116582469	FAM160B1	0.46	6.58	0.34	1.77e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4407350	0.721	rs131156	chr22:44891370	T/C	cg26276947	chr22:44892394	LDOC1L	0.31	6.01	0.31	4.71e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.13	-0.36	6.16e-12	Response to antipsychotic treatment;
LIHC	cis	rs1165668	1.000	rs1866071	chr12:104310638	T/C	cg21863207	chr12:104234989	NT5DC3	0.4	6.39	0.33	5.27e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs7116495	0.609	rs501308	chr11:71581325	C/G	cg10381502	chr11:71823885	C11orf51	0.96	8.13	0.4	7.71e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs11255291	0.668	rs4749169	chr10:7737661	G/C	cg00997801	chr10:7671259	ITIH5	0.37	6.01	0.31	4.87e-9	Ovarian reserve;
LIHC	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	6.21	0.32	1.54e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs7551222	0.646	rs6594015	chr1:204461622	C/T	cg20240347	chr1:204465584	NA	-0.33	-6.86	-0.35	3.25e-11	Schizophrenia;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg15920131	chr12:57601886	LRP1	0.4	6.71	0.34	8.15e-11	Alopecia areata;
LIHC	cis	rs77633900	0.772	rs157761	chr15:76796078	C/A	cg21673338	chr15:77095150	SCAPER	-0.51	-5.84	-0.3	1.21e-8	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.83	0.39	6.04e-14	Height;
LIHC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.39	-6.66	-0.34	1.07e-10	Facial morphology (factor 20);
LIHC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.49	-9.04	-0.44	1.22e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.71	-15.18	-0.63	3.67e-40	Itch intensity from mosquito bite;
LIHC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.44	-7.35	-0.37	1.46e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.91	0.39	3.69e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.39	-0.61	4.81e-37	Headache;
LIHC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg15704280	chr7:45808275	SEPT13	0.6	7.45	0.37	7.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.09	0.51	1.23e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.38	6.91	0.35	2.43e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.26	7.1	0.36	7.33e-12	Cardiovascular disease risk factors;
LIHC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg13319975	chr6:146136371	FBXO30	0.36	5.76	0.3	1.9e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg27255678	chr10:102756921	LZTS2	0.52	7.41	0.37	9.92e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	7.08	0.36	8.34e-12	Breast cancer;
LIHC	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.62	8.97	0.44	1.99e-17	Monocyte count;
LIHC	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg26072250	chr5:443457	EXOC3;C5orf55	0.54	7.15	0.36	5.29e-12	Fat distribution (HIV);
LIHC	cis	rs72638986	1.000	rs6474359	chr8:41549194	A/G	cg22352078	chr8:41424982	NA	-0.36	-5.83	-0.3	1.27e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg05185784	chr16:90016020	DEF8	-0.45	-5.91	-0.3	8.49e-9	Skin colour saturation;
LIHC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.6	10.46	0.49	2.11e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.85	0.3	1.18e-8	Electroencephalogram traits;
LIHC	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.85	13.53	0.59	1.05e-33	Gastritis;
LIHC	trans	rs6489882	0.902	rs4767040	chr12:113374017	C/G	cg10175203	chr3:128143634	NA	0.38	6.17	0.32	1.96e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.17	0.32	1.92e-9	Mean corpuscular volume;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06010356	chr16:74847234	NA	0.42	6.09	0.31	3.11e-9	Lung function (FEV1/FVC);
LIHC	cis	rs244293	0.929	rs181728	chr17:53185803	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	10.08	0.48	4.14e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.57	7.81	0.39	6.92e-14	Neuroblastoma;
LIHC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.76	9.3	0.45	1.66e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg00280220	chr17:61926910	NA	0.44	7.07	0.36	8.7e-12	Prudent dietary pattern;
LIHC	cis	rs2191566	0.960	rs8105571	chr19:44510341	C/T	cg18700516	chr19:44507157	ZNF230	-0.35	-5.79	-0.3	1.62e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.58	-9.67	-0.46	9.95e-20	Menopause (age at onset);
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.71	10.31	0.49	7.13e-22	Menarche (age at onset);
LIHC	trans	rs2359714	0.935	rs1344010	chr1:118802310	A/G	cg19861078	chr7:7936962	NA	-0.31	-6.18	-0.32	1.8e-9	Breast size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25951580	chr19:58962937	ZNF324B	-0.48	-6.32	-0.32	8.29e-10	Pancreatic cancer;
LIHC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-7.01	-0.35	1.32e-11	Aortic root size;
LIHC	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.56	9.12	0.44	6.71e-18	Eosinophilic esophagitis;
LIHC	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg25019722	chr6:37503610	NA	0.37	6.35	0.32	6.94e-10	Cognitive performance;
LIHC	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.49	-7.03	-0.36	1.1e-11	Schizophrenia;
LIHC	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	5.01e-12	Corneal astigmatism;
LIHC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-7.17	-0.36	4.76e-12	Chronic sinus infection;
LIHC	cis	rs7106204	0.514	rs12282611	chr11:24271352	A/C	ch.11.24196551F	chr11:24239977	NA	0.73	8.86	0.43	4.29e-17	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.97	17.74	0.69	2.19e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24229701	chr12:130821962	PIWIL1	0.43	6.24	0.32	1.27e-9	Menopause (age at onset);
LIHC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.84	0.3	1.19e-8	Self-reported allergy;
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.53	6.15	0.32	2.11e-9	Alzheimer's disease;
LIHC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg04234412	chr22:24373322	LOC391322	-0.71	-10.58	-0.5	8.19e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.39	6.36	0.33	6.6e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2286503	0.839	rs2240728	chr7:22852499	C/T	cg11367502	chr7:22862612	TOMM7	0.43	7.16	0.36	4.96e-12	Fibrinogen;
LIHC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.57	-0.46	2.24e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.85	0.35	3.35e-11	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.57	7.5	0.38	5.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.25	-17.87	-0.69	6.28e-51	Ulcerative colitis;
LIHC	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg14930904	chr10:32216787	ARHGAP12	-0.39	-7.03	-0.36	1.12e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg16070018	chr6:26224392	HIST1H3E	0.57	6.81	0.35	4.47e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs4407350	0.756	rs3827401	chr22:44890618	A/G	cg11695653	chr22:44894386	LDOC1L	-0.38	-6.45	-0.33	3.84e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg06050784	chr16:88016603	BANP	0.38	6.97	0.35	1.67e-11	Menopause (age at onset);
LIHC	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.67	-0.34	1.05e-10	Bipolar disorder;
LIHC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg04610667	chr7:75704037	NA	-0.34	-6.08	-0.31	3.13e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17528700	chr6:99968879	NA	-0.47	-6.59	-0.34	1.7e-10	Pancreatic cancer;
LIHC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.25	-5.79	-0.3	1.55e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg09795085	chr6:101329169	ASCC3	-0.52	-7.15	-0.36	5.42e-12	Neuroticism;
LIHC	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.35	-0.32	6.66e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.21e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.41	-5.75	-0.3	1.94e-8	Schizophrenia;
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.65	9.82	0.47	3.35e-20	Menarche (age at onset);
LIHC	trans	rs9914544	0.545	rs12600851	chr17:18767518	T/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.56	-0.33	2.02e-10	Educational attainment (years of education);
LIHC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.38	-6.05	-0.31	3.87e-9	Glioblastoma;
LIHC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg23352942	chr3:46931381	PTH1R	-0.25	-6.12	-0.31	2.57e-9	Birth weight;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.15	-0.32	2.18e-9	Total body bone mineral density;
LIHC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.32	0.37	1.81e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.5	0.53	4.26e-26	Prudent dietary pattern;
LIHC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.75	11.59	0.53	1.95e-26	Corneal astigmatism;
LIHC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.82	14.46	0.62	2.56e-37	Coronary artery disease;
LIHC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg06050784	chr16:88016603	BANP	0.38	6.66	0.34	1.09e-10	Menopause (age at onset);
LIHC	cis	rs6977660	1.000	rs7779902	chr7:19803491	G/A	cg07541023	chr7:19748670	TWISTNB	0.39	6.18	0.32	1.82e-9	Thyroid stimulating hormone;
LIHC	cis	rs2851682	1.000	rs2845574	chr11:61601872	C/T	cg27386326	chr11:61587980	NA	0.59	8.8	0.43	7e-17	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.7	-9.36	-0.45	1.08e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.66	-9.21	-0.45	3.36e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-6.05	-0.31	3.91e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.63	0.5	5.27e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.83	0.39	6e-14	Prudent dietary pattern;
LIHC	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.19	0.48	1.79e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs11868206	1	rs11868206	chr17:33959247	G/A	cg20932281	chr17:33905541	PEX12	0.57	7.4	0.37	1.08e-12	Mean platelet volume;
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.29	0.41	2.61e-15	Corneal astigmatism;
LIHC	trans	rs926340	0.777	rs5753284	chr22:31116394	A/G	cg09032630	chr6:27831956	HIST1H2AL	0.35	6.48	0.33	3.13e-10	Colorectal cancer;
LIHC	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.0	0.6	1.59e-35	Bipolar disorder;
LIHC	cis	rs818427	0.896	rs818429	chr5:112220534	T/C	cg07820702	chr5:112228657	REEP5	-0.39	-6.14	-0.32	2.23e-9	Total body bone mineral density;
LIHC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.43	-6.86	-0.35	3.22e-11	Schizophrenia;
LIHC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02985541	chr2:219472218	PLCD4	-0.44	-7.18	-0.36	4.25e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.19	-0.36	3.98e-12	Body mass index;
LIHC	cis	rs4450131	1.000	rs10901799	chr10:126348274	A/G	cg20435097	chr10:126320824	FAM53B	-0.5	-9.16	-0.44	4.73e-18	White blood cell count (basophil);
LIHC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-12.2	-0.55	1.16e-28	Breast cancer;
LIHC	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.41	6.18	0.32	1.82e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.65	11.72	0.54	6.98e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2108622	0.727	rs76984410	chr19:15982700	C/T	cg13772218	chr19:15982569	NA	0.37	7.78	0.39	8.7e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg08539965	chr1:21396338	EIF4G3	-0.32	-5.73	-0.3	2.26e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.52	-7.75	-0.39	1.05e-13	Total body bone mineral density;
LIHC	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-6.23	-0.32	1.4e-9	Eosinophil percentage of white cells;
LIHC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg27478167	chr7:817139	HEATR2	-0.51	-6.81	-0.35	4.4e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	0.95	14.57	0.62	9.88e-38	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27658640	chr17:4843839	RNF167;SLC25A11	0.43	6.82	0.35	4.24e-11	Cognitive function;
LIHC	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.09e-10	Metabolite levels;
LIHC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24229701	chr12:130821962	PIWIL1	0.43	6.63	0.34	1.35e-10	Menopause (age at onset);
LIHC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.33	0.32	7.6e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.72	11.04	0.51	1.9e-24	Aortic root size;
LIHC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.65	-9.16	-0.44	4.84e-18	Psoriasis;
LIHC	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg09695851	chr17:3907499	NA	0.62	7.16	0.36	5.04e-12	Type 2 diabetes;
LIHC	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.5	9.52	0.46	3.35e-19	Testicular germ cell tumor;
LIHC	cis	rs67981189	0.593	rs2240531	chr14:71553606	A/G	cg15816911	chr14:71606274	NA	0.44	6.99	0.35	1.45e-11	Schizophrenia;
LIHC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.96	17.17	0.68	4.27e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg25344623	chr2:136566232	LCT	0.35	5.73	0.3	2.19e-8	Corneal structure;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04219446	chr17:73629082	RECQL5;LOC643008	-0.43	-6.13	-0.31	2.47e-9	Triglycerides;
LIHC	cis	rs9993613	1.000	rs9993613	chr4:73476014	T/G	cg15102770	chr4:73434591	ADAMTS3	-0.37	-5.75	-0.3	2.01e-8	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg19635926	chr16:89946313	TCF25	0.54	6.9	0.35	2.49e-11	Skin colour saturation;
LIHC	trans	rs11724903	0.935	rs7698341	chr4:183211749	G/A	cg16239906	chr20:35724590	RBL1	-0.66	-6.22	-0.32	1.46e-9	Smoking initiation;
LIHC	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs10861342	1.000	rs10861358	chr12:105559563	G/A	cg23923672	chr12:105501055	KIAA1033	0.57	7.43	0.37	8.65e-13	IgG glycosylation;
LIHC	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.74	-0.3	2.1e-8	Coronary artery disease;
LIHC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.79	-0.34	5.08e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.44	6.09	0.31	3.04e-9	Mean platelet volume;
LIHC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.47	7.64	0.38	2.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.56	9.87	0.47	2.2e-20	Alcohol dependence;
LIHC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.58	9.58	0.46	2.05e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1198872	0.503	rs1627163	chr2:10954844	A/G	cg15705551	chr2:10952987	PDIA6	0.47	6.49	0.33	3.1e-10	Cardiac Troponin-T levels;
LIHC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg12903224	chr12:29470962	FAR2	-0.38	-6.01	-0.31	4.86e-9	QT interval;
LIHC	cis	rs644148	0.872	rs2686780	chr19:44974126	G/C	cg15540054	chr19:45004280	ZNF180	-0.77	-10.71	-0.5	2.88e-23	Personality dimensions;
LIHC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.79	-15.85	-0.65	8.51e-43	Refractive error;
LIHC	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.3	-0.32	9.25e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg13395646	chr4:1353034	KIAA1530	0.42	6.71	0.34	7.99e-11	Obesity-related traits;
LIHC	cis	rs9596863	0.898	rs9568911	chr13:54338082	A/G	ch.13.53330881F	chr13:54432880	NA	0.44	6.1	0.31	2.92e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.5	10.59	0.5	7.42e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg14393609	chr7:65229607	NA	0.43	6.26	0.32	1.14e-9	Aortic root size;
LIHC	cis	rs17286411	0.669	rs4788814	chr16:71634604	A/T	cg06353428	chr16:71660113	MARVELD3	-0.41	-6.01	-0.31	4.8e-9	Blood protein levels;
LIHC	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.35	-0.32	6.92e-10	Hepatocellular carcinoma;
LIHC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.49	-7.02	-0.36	1.18e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg05614176	chr13:113242512	TUBGCP3	-0.46	-6.14	-0.32	2.33e-9	Alcohol dependence;
LIHC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.49	-0.33	3.09e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.91	0.39	3.71e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.79	-0.43	7.38e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.78	-0.5	1.56e-23	Inflammatory bowel disease;
LIHC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg07424592	chr7:64974309	NA	0.78	9.0	0.44	1.64e-17	Diabetic kidney disease;
LIHC	cis	rs876084	0.505	rs7827219	chr8:121130164	G/A	cg06265175	chr8:121136014	COL14A1	0.42	6.68	0.34	9.71e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg11161837	chr1:110010384	SYPL2	0.45	6.28	0.32	1.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.69	12.44	0.56	1.41e-29	Iron status biomarkers;
LIHC	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.96	14.3	0.61	1.08e-36	Primary sclerosing cholangitis;
LIHC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.89	-0.51	6.8e-24	Mean corpuscular volume;
LIHC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	11.1	0.51	1.14e-24	Monocyte percentage of white cells;
LIHC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.89	-17.95	-0.7	3.03e-51	Height;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg16684958	chr7:75615977	POR	0.49	8.35	0.41	1.76e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.85	13.77	0.6	1.22e-34	Glomerular filtration rate (creatinine);
LIHC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-12.65	-0.56	2.47e-30	Coronary artery disease;
LIHC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.66	10.36	0.49	4.77e-22	Lymphocyte counts;
LIHC	trans	rs12752401	0.867	rs34777937	chr1:103036317	C/A	cg24921808	chr19:740313	PALM	0.49	6.42	0.33	4.6e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.88	0.3	9.95e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6088813	1.000	rs6060401	chr20:34005214	C/T	cg14752227	chr20:34000481	UQCC	-0.4	-5.8	-0.3	1.54e-8	Height;
LIHC	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.44	6.19	0.32	1.76e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.38	-6.38	-0.33	5.63e-10	IgG glycosylation;
LIHC	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.02	0.35	1.22e-11	Bipolar disorder;
LIHC	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.97	-0.35	1.67e-11	Hepatocellular carcinoma;
LIHC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.7	-0.38	1.44e-13	Aortic root size;
LIHC	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	5.05e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg14515779	chr1:101123966	NA	0.5	6.9	0.35	2.49e-11	Monocyte count;
LIHC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.47	-7.44	-0.37	7.96e-13	Diastolic blood pressure;
LIHC	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.32	6.05	0.31	3.81e-9	Mean corpuscular volume;
LIHC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.44	6.74	0.34	6.63e-11	Melanoma;
LIHC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.41	-6.52	-0.33	2.47e-10	Glomerular filtration rate (creatinine);
LIHC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs10426930	0.816	rs858414	chr19:5055196	T/C	cg18473234	chr19:5097819	KDM4B	-0.54	-6.87	-0.35	3.14e-11	Monocyte percentage of white cells;
LIHC	cis	rs3823572	0.542	rs28654576	chr7:133624445	A/G	cg03336402	chr7:133662267	EXOC4	0.51	6.4	0.33	5.2400000000000005e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.93	17.45	0.69	3.28e-49	Menopause (age at onset);
LIHC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9980664	1.000	rs2834204	chr21:34737098	T/C	cg04842828	chr21:34696676	IFNAR1	0.46	6.15	0.32	2.12e-9	Cognitive decline (age-related);
LIHC	cis	rs7187994	0.848	rs12933308	chr16:84770973	A/G	cg07647771	chr16:84786436	USP10	-0.34	-6.3	-0.32	9.21e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg14473756	chr11:122847823	NA	-0.35	-6.22	-0.32	1.42e-9	Menarche (age at onset);
LIHC	cis	rs10508774	0.925	rs11008947	chr10:32765415	G/A	cg01819863	chr10:32635814	EPC1	0.65	6.08	0.31	3.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1401454	1.000	rs2351958	chr11:16248020	C/A	cg02656851	chr11:16430247	SOX6	-0.33	-6.27	-0.32	1.08e-9	Blood pressure;
LIHC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.48	5.78	0.3	1.71e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.67	-0.42	1.73e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.09	20.65	0.74	4.29e-62	Multiple system atrophy;
LIHC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.42	5.82	0.3	1.36e-8	Initial pursuit acceleration;
LIHC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg22903471	chr2:27725779	GCKR	-0.41	-6.16	-0.32	2e-9	Blood metabolite levels;
LIHC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.8	12.87	0.57	3.46e-31	Colorectal cancer;
LIHC	cis	rs10861342	0.786	rs11112386	chr12:105538758	A/G	cg23923672	chr12:105501055	KIAA1033	0.64	7.66	0.38	1.98e-13	IgG glycosylation;
LIHC	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg22951263	chr5:87985283	NA	-0.36	-6.28	-0.32	1.05e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg08694578	chr2:241835147	C2orf54	-0.51	-6.91	-0.35	2.31e-11	Urinary metabolites;
LIHC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.66	-6.29	-0.32	9.9e-10	Breast cancer;
LIHC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.5	-6.29	-0.32	9.94e-10	Pancreatic cancer;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.67	-0.34	1.05e-10	Total body bone mineral density;
LIHC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.24	0.32	1.28e-9	Glycated hemoglobin levels;
LIHC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.37	-0.33	6.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-7.25	-0.37	2.72e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg26138937	chr11:71823887	C11orf51	-1.32	-10.9	-0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.8	-0.3	1.48e-8	Red blood cell count;
LIHC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.8	0.34	4.82e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.51	-7.02	-0.35	1.21e-11	QT interval;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg00280220	chr17:61926910	NA	0.42	6.79	0.34	4.88e-11	Prudent dietary pattern;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13462232	chr20:17551166	DSTN	0.49	6.16	0.32	2.09e-9	Hepatitis;
LIHC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg11764359	chr7:65958608	NA	0.58	5.98	0.31	5.58e-9	Diabetic kidney disease;
LIHC	cis	rs2274273	0.623	rs1187877	chr14:55495161	T/C	cg01864836	chr14:55583639	NA	0.36	6.07	0.31	3.31e-9	Protein biomarker;
LIHC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-5.89	-0.3	9.07e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs11958404	0.932	rs72816547	chr5:157417820	G/T	cg05962755	chr5:157440814	NA	1.05	11.06	0.51	1.64e-24	IgG glycosylation;
LIHC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.3	-0.32	9.14e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.74	14.16	0.61	3.76e-36	Mortality in heart failure;
LIHC	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.92	10.56	0.5	9.87e-23	IgG glycosylation;
LIHC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3736485	0.934	rs4775956	chr15:51882638	G/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01941274	chr14:50234650	KLHDC2	0.44	6.52	0.33	2.53e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.61	10.48	0.49	1.84e-22	Colorectal cancer;
LIHC	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.63	-8.97	-0.44	1.92e-17	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg10756647	chr7:56101905	PSPH	0.63	8.62	0.42	2.51e-16	Corneal structure;
LIHC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.98	-0.54	7.53e-28	Response to antipsychotic treatment;
LIHC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.97	-15.09	-0.63	8.46e-40	Urate levels;
LIHC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.51	-6.12	-0.31	2.59e-9	Blood metabolite levels;
LIHC	trans	rs2744203	1.000	rs57058824	chr6:104649911	C/T	cg27088726	chr16:83171155	CDH13	-0.46	-6.08	-0.31	3.14e-9	IgG glycosylation;
LIHC	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.3	7.27	0.37	2.43e-12	Corneal astigmatism;
LIHC	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	15.1	0.63	8.08e-40	Monocyte count;
LIHC	cis	rs16828019	0.777	rs3738369	chr1:41486408	G/A	cg03387723	chr1:41708464	SCMH1	-0.39	-6.16	-0.32	2.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.78	13.21	0.58	1.77e-32	Menarche (age at onset);
LIHC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg13628971	chr7:2884303	GNA12	-0.38	-6.01	-0.31	4.72e-9	Height;
LIHC	cis	rs2292096	0.636	rs6427859	chr1:200780153	C/A	cg11814564	chr1:200748674	CAMSAP1L1	-0.54	-10.37	-0.49	4.26e-22	Epilepsy;
LIHC	cis	rs240110	0.548	rs12190574	chr6:101173842	T/G	cg09795085	chr6:101329169	ASCC3	-0.49	-6.65	-0.34	1.13e-10	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22583711	chr7:154795321	PAXIP1;LOC202781	-0.39	-6.68	-0.34	9.85e-11	Pancreatic cancer;
LIHC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07305463	chr2:136567211	LCT	-0.38	-6.02	-0.31	4.47e-9	Corneal structure;
LIHC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.38	5.96	0.31	6.14e-9	Menopause (age at onset);
LIHC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.11	-0.31	2.68e-9	Menarche (age at onset);
LIHC	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg13409248	chr3:40428643	ENTPD3	0.45	7.28	0.37	2.25e-12	Renal cell carcinoma;
LIHC	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg25019722	chr6:37503610	NA	-0.32	-5.74	-0.3	2.09e-8	Cognitive performance;
LIHC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg15902774	chr15:75289873	SCAMP5	0.41	6.04	0.31	4.13e-9	Lung cancer;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg12311636	chr6:118886798	C6orf204	-0.55	-6.29	-0.32	9.78e-10	Diastolic blood pressure;
LIHC	cis	rs9630089	0.521	rs4917761	chr10:98967236	C/T	cg25902810	chr10:99078978	FRAT1	0.42	5.86	0.3	1.09e-8	Neutrophil percentage of white cells;
LIHC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.04	-0.31	4.11e-9	Colorectal cancer;
LIHC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg20435097	chr10:126320824	FAM53B	0.34	5.93	0.31	7.58e-9	Asthma;
LIHC	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg02023728	chr11:77925099	USP35	-0.36	-6.21	-0.32	1.53e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg21518248	chr2:162101506	NA	0.42	6.28	0.32	1.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9326778	0.520	rs4957818	chr5:108828856	C/G	cg17395555	chr5:108820864	NA	-0.36	-6.13	-0.31	2.48e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.38	5.75	0.3	2.02e-8	Height;
LIHC	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg18898632	chr2:242989856	NA	-0.72	-8.77	-0.43	8.53e-17	Obesity-related traits;
LIHC	trans	rs13113518	0.812	rs6849474	chr4:56318462	G/A	cg15358633	chr12:38710606	ALG10B	0.44	6.23	0.32	1.33e-9	Height;
LIHC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.23	-5.94	-0.31	7.17e-9	Schizophrenia;
LIHC	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.35	-8.14	-0.4	7.56e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23043544	chr7:2124092	MAD1L1	-0.39	-6.33	-0.32	7.91e-10	Neuroticism;
LIHC	cis	rs714027	0.534	rs140124	chr22:30143693	G/C	cg01021169	chr22:30184971	ASCC2	-0.31	-5.79	-0.3	1.59e-8	Lymphocyte counts;
LIHC	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.4	-6.02	-0.31	4.41e-9	Reticulocyte fraction of red cells;
LIHC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.98	19.58	0.73	8.45e-58	Birth weight;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27304813	chr3:120068385	LRRC58	0.47	6.99	0.35	1.41e-11	Pancreatic cancer;
LIHC	trans	rs72829446	0.530	rs8075007	chr17:7374507	A/T	cg08566640	chr11:64091735	NA	-0.74	-6.67	-0.34	1.02e-10	Androgen levels;
LIHC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19346786	chr7:2764209	NA	-0.46	-6.98	-0.35	1.58e-11	Height;
LIHC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.67	9.95	0.47	1.15e-20	Coronary artery disease;
LIHC	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.45	-6.72	-0.34	7.45e-11	Pulse pressure;
LIHC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg26441486	chr22:50317300	CRELD2	0.35	6.29	0.32	9.46e-10	Schizophrenia;
LIHC	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.3	0.37	1.99e-12	Blood protein levels;
LIHC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-0.74	-8.29	-0.41	2.64e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.47e-14	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs2388896	0.836	rs1243418	chr10:8966800	A/C	cg02781394	chr13:30880900	KATNAL1	-0.49	-6.7	-0.34	8.64e-11	Tetralogy of Fallot;
LIHC	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg07706471	chr12:123319906	HIP1R	0.55	7.36	0.37	1.42e-12	Schizophrenia;
LIHC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.52	8.08	0.4	1.16e-14	Tonsillectomy;
LIHC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg20607798	chr8:58055168	NA	0.46	5.81	0.3	1.44e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.77	-0.5	1.75e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs644148	0.676	rs2571114	chr19:44997579	A/G	cg15540054	chr19:45004280	ZNF180	-0.4	-6.0	-0.31	5.08e-9	Personality dimensions;
LIHC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.65	7.85	0.39	5.27e-14	Itch intensity from mosquito bite;
LIHC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs4907240	0.961	rs66727130	chr2:97324991	G/C	cg26665480	chr2:98280029	ACTR1B	-0.4	-5.95	-0.31	6.82e-9	Event-related brain oscillations;
LIHC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg00204748	chr12:29376779	FAR2	0.44	8.48	0.42	7.11e-16	QT interval;
LIHC	cis	rs7903847	0.620	rs10882907	chr10:99125788	C/G	cg08345082	chr10:99160200	RRP12	0.35	5.83	0.3	1.27e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21467203	chr3:49911342	NA	0.42	7.6	0.38	2.84e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg14146966	chr2:61757674	XPO1	0.48	8.47	0.42	7.3e-16	Tuberculosis;
LIHC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.38	5.95	0.31	6.52e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.48	-7.63	-0.38	2.31e-13	Cognitive function;
LIHC	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.46	8.81	0.43	6.43e-17	Testicular germ cell tumor;
LIHC	cis	rs79149102	0.737	rs74450883	chr15:75193432	A/G	cg16226627	chr15:75307476	SCAMP5	0.44	6.23	0.32	1.35e-9	Lung cancer;
LIHC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.89	11.91	0.54	1.38e-27	Heart rate;
LIHC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.39	5.78	0.3	1.73e-8	Vitiligo;
LIHC	cis	rs1789	0.868	rs4631041	chr4:15673395	A/T	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.02	-0.35	1.23e-11	Blood protein levels;
LIHC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	0.92	17.14	0.68	5.72e-48	Bone mineral density;
LIHC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs4908760	0.792	rs4908505	chr1:8728864	G/A	cg20416874	chr1:8611966	RERE	-0.66	-13.75	-0.6	1.52e-34	Vitiligo;
LIHC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.79	-14.12	-0.61	5.27e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.7	8.25	0.41	3.4e-15	Behavioural disinhibition (generation interaction);
LIHC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.29	-0.32	9.9e-10	Breast cancer;
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.7	-8.68	-0.43	1.59e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.48	-18.17	-0.7	4.09e-52	Breast cancer;
LIHC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	9.41	0.45	7.22e-19	Mood instability;
LIHC	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.44	7.03	0.36	1.15e-11	Alcohol dependence;
LIHC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg18912006	chr12:123335444	HIP1R	-0.64	-7.67	-0.38	1.78e-13	Schizophrenia;
LIHC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg12903224	chr12:29470962	FAR2	-0.41	-6.45	-0.33	3.89e-10	QT interval;
LIHC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-8.24	-0.41	3.62e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs74544699	1.000	rs76595330	chr4:74801272	T/G	cg02530824	chr4:74847766	PF4	0.65	6.72	0.34	7.77e-11	Growth-regulated protein alpha levels;
LIHC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.7	-12.17	-0.55	1.5e-28	Total body bone mineral density;
LIHC	cis	rs2108622	0.727	rs7253684	chr19:15981126	C/T	cg13772218	chr19:15982569	NA	0.37	7.83	0.39	6.2e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg05044414	chr3:183734942	ABCC5	0.33	5.88	0.3	9.51e-9	Anterior chamber depth;
LIHC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg00277334	chr10:82204260	NA	-0.55	-6.86	-0.35	3.31e-11	Post bronchodilator FEV1;
LIHC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.58	6.4	0.33	5.01e-10	Gut microbiome composition (summer);
LIHC	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.54	7.38	0.37	1.24e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-10.18	-0.48	1.88e-21	Tonsillectomy;
LIHC	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.55	9.19	0.44	3.94e-18	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-7.32	-0.37	1.75e-12	Testicular germ cell tumor;
LIHC	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.78	0.39	8.8e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs2257205	0.667	rs6503874	chr17:56780459	C/G	cg12560992	chr17:57184187	TRIM37	0.72	7.97	0.4	2.33e-14	Pancreatic cancer;
LIHC	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.86e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.62	-0.5	6.08e-23	Total cholesterol levels;
LIHC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg01629716	chr15:45996671	NA	0.51	9.08	0.44	8.99e-18	Waist circumference;Weight;
LIHC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	18.35	0.7	7.4e-53	Tonsillectomy;
LIHC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.55	7.12	0.36	6.57e-12	Parkinson's disease;
LIHC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.52	-6.69	-0.34	9.34e-11	Pancreatic cancer;
LIHC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.25	-0.32	1.23e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02985541	chr2:219472218	PLCD4	-0.43	-8.09	-0.4	1.05e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.74	7.15	0.36	5.14e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg08135965	chr6:41755394	TOMM6	0.43	5.72	0.3	2.38e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.56	10.31	0.49	7e-22	Lewy body disease;
LIHC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.51	9.79	0.47	4.25e-20	Testicular germ cell tumor;
LIHC	cis	rs4450131	0.522	rs34209544	chr10:126350452	G/C	cg20435097	chr10:126320824	FAM53B	0.66	11.98	0.54	7.24e-28	White blood cell count (basophil);
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.57	-7.69	-0.38	1.59e-13	Menopause (age at onset);
LIHC	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.7	-15.3	-0.64	1.32e-40	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.6	10.31	0.49	6.97e-22	Diisocyanate-induced asthma;
LIHC	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg17623882	chr6:41773611	USP49	-0.43	-5.85	-0.3	1.13e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.6	9.31	0.45	1.59e-18	Height;
LIHC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.66	10.21	0.48	1.51e-21	Schizophrenia;
LIHC	cis	rs959260	1.000	rs7216423	chr17:73365671	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.83	-0.3	1.25e-8	Systemic lupus erythematosus;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-7.07	-0.36	8.55e-12	Total body bone mineral density;
LIHC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.68	-0.38	1.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2380220	0.872	rs115871915	chr6:95934180	T/C	cg15832292	chr6:96025679	MANEA	-0.6	-6.73	-0.34	7.25e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	1.03	7.76	0.39	9.66e-14	Cannabis dependence symptom count;
LIHC	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.39	7.16	0.36	4.85e-12	Monocyte count;
LIHC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.7	-0.53	8.18e-27	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00938859	chr5:1591904	SDHAP3	0.57	7.07	0.36	8.57e-12	Breast cancer;
LIHC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.65	-12.41	-0.56	1.87e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.61	0.65	7.19e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.3	0.37	2.06e-12	HDL cholesterol levels;
LIHC	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.08	-0.31	3.17e-9	Tuberculosis;
LIHC	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg20019720	chr6:154832845	CNKSR3	0.44	6.48	0.33	3.14e-10	Lipoprotein (a) levels;
LIHC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg03959625	chr15:84868606	LOC388152	0.44	6.11	0.31	2.64e-9	Schizophrenia;
LIHC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.38e-11	Aortic root size;
LIHC	cis	rs12744310	1.000	rs12756822	chr1:41777327	A/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg23091122	chr1:110024289	SYPL2	-0.48	-6.42	-0.33	4.54e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.41	-0.37	9.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2607426	0.681	rs2607418	chr19:41257396	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	0.56	6.68	0.34	9.47e-11	Blood protein levels;
LIHC	cis	rs7116495	1.000	rs59339387	chr11:71558232	A/G	cg26138937	chr11:71823887	C11orf51	0.65	6.02	0.31	4.41e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs55665837	0.701	rs11023265	chr11:14616038	C/T	cg00085434	chr11:14927489	NA	0.43	6.05	0.31	3.74e-9	Vitamin D levels;
LIHC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.51	8.2	0.41	4.77e-15	Schizophrenia;
LIHC	cis	rs7116495	1.000	rs542752	chr11:71810644	T/A	cg26138937	chr11:71823887	C11orf51	0.82	8.2	0.41	4.99e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.08	0.31	3.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.55	-7.27	-0.37	2.47e-12	Menopause (age at onset);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06679777	chr13:30881210	KATNAL1	-0.45	-6.16	-0.32	2e-9	Bilirubin levels;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13981034	chr14:21860709	SNORD9;CHD8	0.44	6.33	0.32	7.57e-10	Migraine with aura;
LIHC	cis	rs700651	0.789	rs10190226	chr2:198901564	A/G	cg10820045	chr2:198174542	NA	-0.42	-6.17	-0.32	1.95e-9	Intracranial aneurysm;
LIHC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.64	6.18	0.32	1.86e-9	Breast cancer;
LIHC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs7937890	0.559	rs2597206	chr11:14477538	A/C	cg02886208	chr11:14281011	SPON1	-0.46	-6.58	-0.34	1.75e-10	Mitochondrial DNA levels;
LIHC	trans	rs2797369	0.766	rs2629978	chr6:101684574	A/G	cg18702971	chr22:29920546	THOC5	0.58	6.15	0.32	2.2e-9	Renal function-related traits (eGRFcrea);
LIHC	trans	rs17184557	0.914	rs77202769	chr18:67108558	T/C	cg22968167	chr11:4945873	OR51G1	-0.24	-6.06	-0.31	3.69e-9	Osteoporosis-related phenotypes;
LIHC	cis	rs6500637	0.631	rs12921187	chr16:4943019	T/G	cg08329684	chr16:4932620	PPL	-0.42	-7.32	-0.37	1.83e-12	Cancer;
LIHC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.46	-0.37	7.18e-13	Platelet distribution width;
LIHC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.63	-8.9	-0.43	3.25e-17	Blood metabolite levels;
LIHC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	8.89e-15	Prudent dietary pattern;
LIHC	cis	rs4742903	0.935	rs1507507	chr9:106949429	A/G	cg14250997	chr9:106856677	SMC2	0.35	5.92	0.3	7.9e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07551314	chr1:26190155	PAQR7	0.41	6.04	0.31	4.08e-9	Longevity;
LIHC	cis	rs1000083	1.000	rs1000083	chr5:96533469	A/G	ch.5.96698337R	chr5:96672581	NA	0.87	7.04	0.36	1.07e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	0.94	6.69	0.34	9.22e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7534824	0.625	rs10493939	chr1:101378026	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	6.55	0.33	2.15e-10	Refractive astigmatism;
LIHC	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg23625390	chr15:77176239	SCAPER	0.35	5.75	0.3	1.98e-8	Blood metabolite levels;
LIHC	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg20636351	chr8:55087400	NA	-0.36	-7.33	-0.37	1.66e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-8.9	-0.43	3.44e-17	Dental caries;
LIHC	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.43	-0.33	4.2e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.49	-7.3	-0.37	2.05e-12	Multiple sclerosis;
LIHC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.51	8.54	0.42	4.38e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.57	6.79	0.34	4.97e-11	Economic and political preferences (immigration/crime);
LIHC	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg16103275	chr6:290800	DUSP22	0.51	6.95	0.35	1.84e-11	Menopause (age at onset);
LIHC	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.11	-0.31	2.79e-9	Metabolite levels;
LIHC	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.66	10.01	0.48	7.56e-21	Breast cancer;
LIHC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.07	-10.03	-0.48	6.2e-21	Hip circumference adjusted for BMI;
LIHC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg14580349	chr1:25664531	TMEM50A	0.39	6.05	0.31	3.86e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.53	9.28	0.45	2.02e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.55	10.18	0.48	1.98e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	trans	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.53	-0.33	2.42e-10	Dental caries;
LIHC	cis	rs1144333	0.655	rs3765682	chr1:76333172	T/C	cg10523679	chr1:76189770	ACADM	0.45	6.01	0.31	4.88e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.33	-0.49	5.77e-22	Chronic sinus infection;
LIHC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.49	5.82	0.3	1.39e-8	Alzheimer's disease;
LIHC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.36	-6.14	-0.32	2.23e-9	Headache;
LIHC	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.5	-0.33	2.92e-10	IgG glycosylation;
LIHC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg20651018	chr11:3035856	CARS	-0.38	-6.26	-0.32	1.14e-9	Longevity;
LIHC	cis	rs4759375	0.920	rs28786830	chr12:123860472	C/G	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.57e-10	HDL cholesterol;
LIHC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.54	-9.21	-0.45	3.35e-18	Blood metabolite levels;
LIHC	cis	rs74233809	1.000	rs35125602	chr10:104656039	G/A	cg03493300	chr10:104813866	CNNM2	0.45	5.92	0.3	7.89e-9	Birth weight;
LIHC	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg03387723	chr1:41708464	SCMH1	-0.42	-6.82	-0.35	4.06e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.5	-8.12	-0.4	8.79e-15	Testicular germ cell tumor;
LIHC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.42	5.92	0.3	8.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.37	6.09	0.31	3.05e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg02869306	chr7:64672164	INTS4L1	-0.29	-6.38	-0.33	5.87e-10	Calcium levels;
LIHC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.18	-0.55	1.37e-28	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.66	10.79	0.5	1.49e-23	Schizophrenia;
LIHC	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.46	8.51	0.42	5.64e-16	Testicular germ cell tumor;
LIHC	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.69	8.49	0.42	6.56e-16	IgG glycosylation;
LIHC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.62	-0.53	1.59e-26	Alzheimer's disease;
LIHC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg18944383	chr4:111397179	ENPEP	0.25	6.08	0.31	3.14e-9	Coronary artery disease;
LIHC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	6.37	0.33	6.22e-10	Ileal carcinoids;
LIHC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.64	8.64	0.42	2.23e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02290350	chr8:58132656	NA	0.38	8.28	0.41	2.75e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	12.28	0.55	5.66e-29	Prudent dietary pattern;
LIHC	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	5.82	0.3	1.37e-8	Height;
LIHC	cis	rs2569991	0.588	rs62240725	chr3:12929360	A/G	cg22481960	chr3:13008800	IQSEC1	0.43	7.46	0.37	7.14e-13	Periodontitis (DPAL);
LIHC	cis	rs1198430	0.599	rs946269	chr1:23769359	T/C	cg13183780	chr1:23809682	ASAP3	-0.38	-6.56	-0.33	1.98e-10	Total cholesterol levels;
LIHC	cis	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.63	-6.09	-0.31	3.02e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg14283194	chr7:91763737	CYP51A1	-0.42	-6.22	-0.32	1.43e-9	Body mass index;
LIHC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.63	-8.89	-0.43	3.66e-17	Blood metabolite levels;
LIHC	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.43	7.33	0.37	1.64e-12	Prevalent atrial fibrillation;
LIHC	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.67	-0.34	1.02e-10	Bipolar disorder;
LIHC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.61	-10.86	-0.51	8.37e-24	Diastolic blood pressure;
LIHC	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg05197062	chr11:11642011	GALNTL4	0.42	6.08	0.31	3.17e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.56	7.92	0.39	3.27e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs4714291	0.802	rs7759622	chr6:40114735	C/T	cg02267698	chr19:7991119	CTXN1	-0.39	-6.56	-0.33	2.04e-10	Strep throat;
LIHC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.5	7.53	0.38	4.44e-13	Resting heart rate;
LIHC	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	0.87	10.38	0.49	3.89e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.87	-9.86	-0.47	2.36e-20	Red cell distribution width;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13409248	chr3:40428643	ENTPD3	0.48	7.86	0.39	4.91e-14	Renal cell carcinoma;
LIHC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.6	6.82	0.35	4.14e-11	Alzheimer's disease;
LIHC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg25356066	chr3:128598488	ACAD9	0.54	7.47	0.37	6.64e-13	IgG glycosylation;
LIHC	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.04	-0.36	1.05e-11	Bipolar disorder;
LIHC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	15.59	0.64	9.01e-42	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg16822855	chr3:40428330	ENTPD3	0.32	5.72	0.3	2.27e-8	Renal cell carcinoma;
LIHC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg24296786	chr1:45957014	TESK2	-0.51	-7.63	-0.38	2.29e-13	Platelet count;
LIHC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.43	8.87	0.43	4.24e-17	Height;
LIHC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.67	-10.79	-0.5	1.46e-23	Monocyte percentage of white cells;
LIHC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.44	-6.77	-0.34	5.62e-11	Height;
LIHC	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.38	6.41	0.33	4.76e-10	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-6.43	-0.33	4.29e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23797200	chr17:40174494	NKIRAS2	0.42	6.46	0.33	3.69e-10	Cognitive function;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.43	6.4	0.33	5.14e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.39	6.31	0.32	8.47e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.39e-18	Subjective well-being;
LIHC	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.45	5.96	0.31	6.23e-9	Pulmonary function decline;
LIHC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.97	17.97	0.7	2.53e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.66	-9.33	-0.45	1.36e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.53	-7.15	-0.36	5.37e-12	Motion sickness;
LIHC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.38	-0.33	5.85e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.7	-0.34	8.35e-11	Height;
LIHC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.42	-6.47	-0.33	3.3e-10	Height;
LIHC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.51	-9.38	-0.45	9.7e-19	Asthma;
LIHC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.41	-6.95	-0.35	1.86e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg05941027	chr17:61774174	LIMD2	0.32	6.61	0.34	1.44e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	6.71	0.34	8.05e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9899728	0.764	rs9660	chr17:73038746	A/G	cg27626185	chr17:73056755	KCTD2	-0.61	-10.95	-0.51	4.14e-24	Alzheimer's disease or small vessel stroke;
LIHC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg04359351	chr2:3481828	TTC15	0.3	5.97	0.31	5.98e-9	Neurofibrillary tangles;
LIHC	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-13.8	-0.6	9.43e-35	Height;
LIHC	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg27129171	chr3:47204927	SETD2	0.49	7.66	0.38	1.98e-13	Birth weight;
LIHC	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-11.61	-0.53	1.72e-26	Pediatric autoimmune diseases;
LIHC	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.48	-0.33	3.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.44	-5.73	-0.3	2.2e-8	Left atrial antero-posterior diameter;
LIHC	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.28	0.45	2e-18	Response to antipsychotic treatment;
LIHC	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.79	0.3	1.63e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg12798992	chr6:167411361	FGFR1OP	0.49	7.47	0.37	6.63e-13	Crohn's disease;
LIHC	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.85	13.24	0.58	1.39e-32	Multiple system atrophy;
LIHC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-7.33	-0.37	1.67e-12	Hepatocellular carcinoma;
LIHC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg16226627	chr15:75307476	SCAMP5	0.51	8.55	0.42	4.14e-16	Lung cancer;
LIHC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.62	8.45	0.42	8.23e-16	Neutrophil percentage of white cells;
LIHC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.57	8.44	0.42	9.23e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.84	-9.08	-0.44	8.66e-18	QRS complex (12-leadsum);
LIHC	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.65	-6.99	-0.35	1.44e-11	Exhaled nitric oxide output;
LIHC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-8.81	-0.43	6.53e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	trans	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg09045935	chr12:6379348	NA	0.83	6.86	0.35	3.19e-11	Blood metabolite levels;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	9.32	0.45	1.43e-18	Height;
LIHC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.84	-0.51	9.68e-24	Monocyte percentage of white cells;
LIHC	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.56	-8.06	-0.4	1.34e-14	Neuroticism;
LIHC	cis	rs17106184	1.000	rs59029934	chr1:50992756	C/T	cg07174182	chr1:51127561	FAF1	-0.7	-7.11	-0.36	6.97e-12	Type 2 diabetes;
LIHC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21467203	chr3:49911342	NA	0.5	9.13	0.44	6.05e-18	Body mass index;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.59	-0.34	1.62e-10	Renal cell carcinoma;
LIHC	trans	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-7.05	-0.36	9.78e-12	Obesity (extreme);
LIHC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.52	8.12	0.4	8.27e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4407350	1.000	rs4386428	chr22:44922359	T/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.08	-0.31	3.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.69	-10.0	-0.48	8.1e-21	Mosquito bite size;
LIHC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.42	-0.37	9.26e-13	Psoriasis;
LIHC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.97	11.63	0.53	1.38e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	8.08	0.4	1.15e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg12751644	chr20:60527061	NA	-0.35	-5.88	-0.3	9.88e-9	Body mass index;
LIHC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.62	10.48	0.49	1.79e-22	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25022925	chr5:126112600	LMNB1	0.47	6.51	0.33	2.66e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.26	-6.28	-0.32	1e-9	Primary biliary cholangitis;
LIHC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.45	-8.75	-0.43	9.7e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	9.45	0.46	5.4e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg01028140	chr2:1542097	TPO	-0.42	-6.63	-0.34	1.28e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.52	6.61	0.34	1.52e-10	Menarche (age at onset);
LIHC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg17135325	chr3:160939158	NMD3	0.52	7.49	0.38	6.11e-13	Parkinson's disease;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	0.54	6.28	0.32	1.02e-9	Alzheimer's disease;
LIHC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.86	7.95	0.39	2.75e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.83	0.3	1.27e-8	Electroencephalogram traits;
LIHC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg18887096	chr2:219472410	PLCD4	0.36	6.15	0.32	2.12e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg12798992	chr6:167411361	FGFR1OP	-0.45	-7.28	-0.37	2.28e-12	Crohn's disease;
LIHC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.81	0.3	1.43e-8	Bipolar disorder;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03133777	chr2:170361364	BBS5	0.43	6.41	0.33	4.89e-10	Hepatitis;
LIHC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.14	-0.52	8.36e-25	Coronary artery disease;
LIHC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.5	8.71	0.43	1.35e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	12.35	0.56	3.15e-29	Post bronchodilator FEV1;
LIHC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.8	0.47	3.77e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.31	6.52	0.33	2.46e-10	Blood metabolite levels;
LIHC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.5	-8.16	-0.4	6.58e-15	Fibrinogen levels;
LIHC	cis	rs7106204	0.800	rs6484026	chr11:24214633	G/A	ch.11.24196551F	chr11:24239977	NA	0.77	10.47	0.49	1.94e-22	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg17724175	chr1:150552817	MCL1	-0.37	-7.3	-0.37	2e-12	Tonsillectomy;
LIHC	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.78	-8.72	-0.43	1.19e-16	Alzheimer's disease (late onset);
LIHC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-19.42	-0.72	3.67e-57	Height;
LIHC	cis	rs1144333	0.655	rs77244403	chr1:76304872	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.41	0.37	9.69e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3857067	1.000	rs3846292	chr4:95027717	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.35	-0.37	1.43e-12	QT interval;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23470272	chr19:14640395	TECR;MIR639	-0.46	-6.44	-0.33	3.98e-10	Pancreatic cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14592024	chr15:48624386	DUT	0.48	6.06	0.31	3.51e-9	Lung function (FEV1/FVC);
LIHC	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.93	-10.58	-0.5	8.34e-23	Platelet distribution width;
LIHC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.55	-8.33	-0.41	2e-15	Height;
LIHC	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs9322817	0.902	rs963949	chr6:105174273	A/G	cg02098413	chr6:105308735	HACE1	-0.38	-6.09	-0.31	3.03e-9	Thyroid stimulating hormone;
LIHC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.57	-9.38	-0.45	9.26e-19	Cognitive function;
LIHC	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg08126542	chr6:37504118	NA	-0.36	-6.18	-0.32	1.86e-9	Cognitive performance;
LIHC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.07	16.73	0.67	2.44e-46	Breast cancer;
LIHC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.51	8.88	0.43	3.88e-17	Total body bone mineral density;
LIHC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.11	13.28	0.58	1e-32	Gut microbiome composition (summer);
LIHC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.36	7.39	0.37	1.14e-12	Renal cell carcinoma;
LIHC	cis	rs918629	0.798	rs3777170	chr5:95284340	T/C	cg10483112	chr5:95245456	ELL2	-0.36	-6.25	-0.32	1.24e-9	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.57	0.56	4.75e-30	Cognitive test performance;
LIHC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.29	-7.65	-0.38	2.13e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.38	-0.49	4e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg21734168	chr11:67353974	GSTP1	-0.27	-6.76	-0.34	6.08e-11	Mean corpuscular volume;
LIHC	cis	rs7551222	0.646	rs1398148	chr1:204458328	C/G	cg20240347	chr1:204465584	NA	-0.32	-6.69	-0.34	9e-11	Schizophrenia;
LIHC	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-0.72	-6.88	-0.35	2.92e-11	Putamen volume;
LIHC	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.7	-10.73	-0.5	2.38e-23	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07920148	chr11:33397821	NA	-0.4	-6.06	-0.31	3.54e-9	Pancreatic cancer;
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	20.47	0.74	2.35e-61	Height;
LIHC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg02290350	chr8:58132656	NA	0.41	8.54	0.42	4.46e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-7.29	-0.37	2.23e-12	Hepatocellular carcinoma;
LIHC	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.41e-9	Prostate cancer;
LIHC	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.85e-11	Dermatomyositis;
LIHC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.64	-11.6	-0.53	1.84e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72627123	0.531	rs79328555	chr14:74588572	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.87	8.43	0.41	1.01e-15	Morning vs. evening chronotype;
LIHC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.27	-6.03	-0.31	4.25e-9	Type 2 diabetes;
LIHC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.16	-0.36	4.93e-12	Personality dimensions;
LIHC	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-5.85	-0.3	1.13e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.4	-6.19	-0.32	1.7e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg22138327	chr13:27999177	GTF3A	0.76	6.26	0.32	1.17e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.29	-0.37	2.22e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs903552	0.935	rs4965387	chr15:102003209	G/A	cg25677261	chr15:102009856	PCSK6	-0.45	-6.23	-0.32	1.35e-9	Diabetic kidney disease;
LIHC	cis	rs9649465	1.000	rs13225220	chr7:123371026	C/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.25e-15	Migraine;
LIHC	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.62	-0.42	2.56e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs35955747	0.934	rs131200	chr22:31703272	T/C	cg22777020	chr22:31556080	RNF185	0.51	5.87	0.3	1.01e-8	Neutrophil count;Sum basophil neutrophil counts;
LIHC	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.53	-7.89	-0.39	4.26e-14	Body mass index;
LIHC	cis	rs422249	0.727	rs174606	chr11:61626973	G/T	cg27386326	chr11:61587980	NA	0.37	6.83	0.35	3.87e-11	Trans fatty acid levels;
LIHC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg05868516	chr6:26286170	HIST1H4H	0.45	6.98	0.35	1.57e-11	Educational attainment;
LIHC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.0	0.58	1.11e-31	Prudent dietary pattern;
LIHC	cis	rs1475718	0.526	rs10785875	chr9:137122570	C/T	cg21243944	chr9:137118148	NA	-0.42	-5.92	-0.3	7.86e-9	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.89	7.23	0.36	3.19e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg18016565	chr1:150552671	MCL1	0.52	9.86	0.47	2.31e-20	Melanoma;
LIHC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.88	-0.39	4.52e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.22	-0.41	4.37e-15	Vitamin D levels;
LIHC	cis	rs4561483	0.582	rs3850997	chr16:12043512	G/T	cg08843971	chr16:11963173	GSPT1	-0.31	-6.35	-0.32	6.95e-10	Testicular germ cell tumor;
LIHC	cis	rs7707921	0.667	rs111549985	chr5:81268070	C/G	cg15871215	chr5:81402204	ATG10	-0.61	-5.84	-0.3	1.2e-8	Breast cancer;
LIHC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.31	6.83	0.35	3.91e-11	Ulcerative colitis;
LIHC	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.71	-11.02	-0.51	2.18e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.62	0.53	1.55e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg18289306	chr13:113640169	MCF2L	0.41	6.37	0.33	6.11e-10	Systolic blood pressure;
LIHC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.59	8.83	0.43	5.49e-17	Height;
LIHC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg14132834	chr19:41945861	ATP5SL	0.42	6.34	0.32	7.3e-10	Height;
LIHC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.87	-0.3	1.02e-8	Personality dimensions;
LIHC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.48	7.26	0.37	2.58e-12	Glycated hemoglobin levels;
LIHC	cis	rs903552	1.000	rs12908406	chr15:102004046	C/T	cg25677261	chr15:102009856	PCSK6	-0.48	-6.53	-0.33	2.44e-10	Diabetic kidney disease;
LIHC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg14906510	chr12:7781169	NA	0.48	7.45	0.37	7.73e-13	HDL cholesterol levels;
LIHC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg23485639	chr6:28045615	ZNF165	0.38	5.96	0.31	6.31e-9	Cardiac Troponin-T levels;
LIHC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	9.9	0.47	1.76e-20	Chronic sinus infection;
LIHC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-12.47	-0.56	1.15e-29	Vitiligo;
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.53	-8.22	-0.41	4.34e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.5	7.99	0.4	2.03e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.61	-5.92	-0.3	7.95e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.57	8.94	0.44	2.45e-17	Colorectal cancer;
LIHC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.71	-12.24	-0.55	8.01e-29	Refractive error;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.48	0.37	6.51e-13	Prudent dietary pattern;
LIHC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.87	-13.44	-0.59	2.43e-33	Vitamin D levels;
LIHC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20135002	chr11:47629003	NA	0.5	8.43	0.41	9.57e-16	Subjective well-being;
LIHC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.59	8.87	0.43	4.15e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08219700	chr8:58056026	NA	0.46	5.8	0.3	1.48e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.4	6.1	0.31	2.89e-9	Lipoprotein (a) levels;
LIHC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1e-57	Breast cancer;
LIHC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.41	-8.13	-0.4	7.71e-15	Urinary metabolites;
LIHC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	10.51	0.49	1.42e-22	Lung cancer;
LIHC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.52	0.42	5.06e-16	Schizophrenia;
LIHC	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.73	-7.35	-0.37	1.45e-12	Triglycerides;
LIHC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.37	7.03	0.36	1.13e-11	Multiple system atrophy;
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg24209194	chr3:40518798	ZNF619	-0.59	-8.73	-0.43	1.12e-16	Renal cell carcinoma;
LIHC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg05941027	chr17:61774174	LIMD2	0.33	6.19	0.32	1.68e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg12798992	chr6:167411361	FGFR1OP	-0.59	-9.83	-0.47	3.11e-20	Crohn's disease;
LIHC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	9.71	0.46	7.5599999999999994e-20	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs3814244	0.528	rs7962511	chr12:68396634	C/G	cg15249341	chr12:68405565	NA	-0.33	-6.35	-0.32	6.73e-10	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-8.61	-0.42	2.79e-16	Lung cancer in ever smokers;
LIHC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg24163568	chr5:669837	TPPP	0.39	8.2	0.41	5.01e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2412488	0.893	rs6840343	chr4:54359680	C/T	cg22241045	chr4:54363911	LNX1	0.4	6.54	0.33	2.24e-10	DNA methylation (variation);
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg11070056	chr1:107600091	PRMT6	-0.63	-10.46	-0.49	2.05e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.7	-11.64	-0.53	1.3e-26	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg18016565	chr1:150552671	MCL1	0.52	9.74	0.47	6.21e-20	Melanoma;
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg14828511	chr1:107599125	PRMT6	0.42	6.07	0.31	3.32e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-6.57	-0.33	1.87e-10	Mosquito bite size;
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.71	13.12	0.58	3.78e-32	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.34	-0.55	3.55e-29	Vitiligo;
LIHC	cis	rs8067545	0.750	rs1421174	chr17:19950190	G/T	cg13482628	chr17:19912719	NA	0.5	8.23	0.41	3.93e-15	Schizophrenia;
LIHC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.91	11.36	0.52	1.36e-25	Coronary artery disease;
LIHC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg09695851	chr17:3907499	NA	0.6	6.91	0.35	2.33e-11	Type 2 diabetes;
LIHC	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.72	-0.5	2.65e-23	Eye color traits;
LIHC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg06951627	chr6:26196580	NA	0.53	5.94	0.31	7.2e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.4	0.37	1.05e-12	Prudent dietary pattern;
LIHC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.84	12.66	0.56	2.25e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.52	-8.6	-0.42	2.94e-16	Cognitive function;
LIHC	trans	rs13067260	1.000	rs16835220	chr3:123960246	C/T	cg16386950	chr1:201616077	NAV1	0.52	6.33	0.32	7.5e-10	PR interval in Tripanosoma cruzi seropositivity;
LIHC	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.57	9.36	0.45	1.13e-18	Corneal astigmatism;
LIHC	cis	rs12220238	0.915	rs11001027	chr10:76152655	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.76	0.3	1.85e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs539514	0.690	rs34545980	chr13:76309637	C/A	cg04757411	chr13:76259545	LMO7	-0.44	-7.89	-0.39	4.13e-14	Type 1 diabetes;
LIHC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-8.04	-0.4	1.5e-14	Blood metabolite levels;
LIHC	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.8	10.49	0.49	1.67e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.57	-8.46	-0.42	8.06e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.59	8.79	0.43	7.18e-17	Recombination rate (females);
LIHC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-1.03	-14.31	-0.61	9.75e-37	Breast cancer;
LIHC	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.4	5.78	0.3	1.73e-8	Life satisfaction;
LIHC	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.64	8.82	0.43	5.9e-17	Coronary artery disease;
LIHC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.42	0.33	4.42e-10	Lung cancer in ever smokers;
LIHC	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg16576597	chr16:28551801	NUPR1	-0.36	-6.02	-0.31	4.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg22633049	chr21:46681294	NA	-0.38	-6.5	-0.33	2.79e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.52	8.0	0.4	1.91e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.86	14.92	0.63	4.06e-39	Headache;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.45	-0.33	3.81e-10	Colorectal cancer;
LIHC	trans	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg01596870	chr19:55963115	NA	-0.67	-9.66	-0.46	1.09e-19	Obesity-related traits;
LIHC	cis	rs4663866	1.000	rs13033501	chr2:239181860	G/A	cg16914508	chr2:239161102	PER2	0.8	5.9	0.3	8.86e-9	Irritable bowel syndrome;
LIHC	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.47	6.44	0.33	4.01e-10	Inflammatory skin disease;
LIHC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.29	6.93	0.35	2.04e-11	Primary biliary cholangitis;
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg16586182	chr3:47516702	SCAP	-0.44	-7.73	-0.39	1.17e-13	Colorectal cancer;
LIHC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.59	0.38	3.02e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.2	0.32	1.63e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.73	-10.87	-0.51	7.92e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.89	0.3	9.48e-9	Aortic root size;
LIHC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.57	6.76	0.34	5.85e-11	Alzheimer's disease;
LIHC	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.39	6.42	0.33	4.58e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs3820500	0.543	rs34368125	chr1:118026538	C/A	cg20383390	chr1:117909022	MAN1A2	-0.47	-6.03	-0.31	4.32e-9	Pneumonia;
LIHC	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.54	-8.64	-0.42	2.16e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	0.97	8.04	0.4	1.44e-14	Lymphocyte counts;
LIHC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.49	-9.73	-0.47	6.48e-20	Tonsillectomy;
LIHC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	0.78	12.43	0.56	1.61e-29	Total cholesterol levels;
LIHC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg11057378	chr10:81107060	PPIF	0.37	6.01	0.31	4.75e-9	Height;
LIHC	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.74	10.66	0.5	4.27e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-0.63	-7.29	-0.37	2.19e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-10.85	-0.51	8.78e-24	Platelet count;
LIHC	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.54	-0.33	2.29e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.48	-7.49	-0.38	5.84e-13	Blood protein levels;
LIHC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg12160578	chr15:63334699	TPM1	0.6	8.63	0.42	2.4e-16	Platelet count;
LIHC	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.48	9.15	0.44	5.44e-18	Testicular germ cell tumor;
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.59	-8.59	-0.42	3.1e-16	Lymphocyte counts;
LIHC	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.81	0.54	3.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.6	-11.76	-0.54	4.99e-27	Urate levels in overweight individuals;
LIHC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.51	-8.54	-0.42	4.46e-16	Blood metabolite levels;
LIHC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	15.51	0.64	1.79e-41	Tonsillectomy;
LIHC	cis	rs13223928	0.658	rs67519056	chr7:3157176	G/C	cg19214707	chr7:3157722	NA	-0.45	-8.46	-0.42	7.99e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-7.33	-0.37	1.65e-12	Hepatocellular carcinoma;
LIHC	trans	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg12575136	chr18:32820987	ZNF397	0.48	7.04	0.36	1.06e-11	White blood cell count;
LIHC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.53	-7.28	-0.37	2.32e-12	Body mass index;
LIHC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg18964960	chr10:1102726	WDR37	0.66	5.9	0.3	8.54e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.86	0.3	1.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.47	7.09	0.36	7.77e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.26	-0.37	2.69e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	5.97	0.31	5.82e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.36	2.88e-12	Educational attainment;
LIHC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs61677309	1.000	rs12576100	chr11:118158281	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.76	10.9	0.51	6.19e-24	Coronary artery disease;
LIHC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.69	-0.34	9.36e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.81	12.06	0.55	3.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg08213375	chr14:104286397	PPP1R13B	0.5	8.43	0.41	9.97e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.53	-0.76	1.36e-65	Height;
LIHC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	8.44	0.42	9.17e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.58	8.71	0.43	1.36e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.87	-8.64	-0.42	2.2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg14393609	chr7:65229607	NA	0.38	5.91	0.3	8.22e-9	Aortic root size;
LIHC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.82	-0.35	4.19e-11	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	16.24	0.66	2.26e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.52	7.68	0.38	1.71e-13	Corneal astigmatism;
LIHC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.7	-0.43	1.38e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg20651018	chr11:3035856	CARS	-0.36	-6.25	-0.32	1.22e-9	Longevity;
LIHC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.7	-0.5	3.09e-23	Total cholesterol levels;
LIHC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.41	6.25	0.32	1.21e-9	Educational attainment;
LIHC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg24585782	chr17:78113791	EIF4A3	-0.44	-5.85	-0.3	1.12e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04578738	chr17:34136331	TAF15	0.42	6.11	0.31	2.64e-9	Pancreatic cancer;
LIHC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	7.48	0.38	6.24e-13	Schizophrenia;
LIHC	cis	rs10508774	1.000	rs10160127	chr10:32953719	T/C	cg01819863	chr10:32635814	EPC1	0.61	5.72	0.3	2.33e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.48	6.01	0.31	4.66e-9	Economic and political preferences (feminism/equality);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11446345	chr19:17445677	ANO8	0.38	6.07	0.31	3.32e-9	Metabolic traits;
LIHC	cis	rs10508774	0.810	rs56102114	chr10:32748855	C/T	cg01819863	chr10:32635814	EPC1	0.61	5.81	0.3	1.45e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg07661805	chr8:143867942	LY6D	-0.32	-6.86	-0.35	3.16e-11	Urinary tract infection frequency;
LIHC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.46	-0.59	1.92e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.91	-0.3	8.06e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.34	-5.9	-0.3	8.75e-9	IgG glycosylation;
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.0	0.4	1.99e-14	Tonsillectomy;
LIHC	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg17294928	chr15:75287854	SCAMP5	0.47	6.64	0.34	1.25e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs4650994	0.593	rs12033086	chr1:178540925	C/T	cg05350800	chr1:178550844	NA	-0.35	-7.7	-0.38	1.49e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg25344623	chr2:136566232	LCT	0.4	8.07	0.4	1.2e-14	Mosquito bite size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02973843	chr8:42268727	NA	-0.44	-6.41	-0.33	4.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6504950	0.800	rs12952253	chr17:53005716	A/G	cg10237252	chr17:52977213	TOM1L1	-0.35	-6.15	-0.32	2.15e-9	Breast cancer;
LIHC	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.26	-6.04	-0.31	4.05e-9	Alcohol dependence;
LIHC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.55	7.32	0.37	1.77e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	0.82	6.42	0.33	4.69e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03346523	chr11:32951061	QSER1	-0.3	-6.8	-0.35	4.62e-11	Calcium levels;
LIHC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.53	0.64	1.5e-41	Chronic sinus infection;
LIHC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.6	8.19	0.4	5.21e-15	Bladder cancer;
LIHC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.16	-0.36	4.89e-12	Migraine;Coronary artery disease;
LIHC	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.49	7.55	0.38	4.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.94	-0.31	6.95e-9	Mood instability;
LIHC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.55	6.89	0.35	2.76e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	1.19	13.58	0.59	7.02e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.7	10.46	0.49	2.17e-22	Prostate cancer;
LIHC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	7.06	0.36	9.42e-12	Response to bleomycin (chromatid breaks);
LIHC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	12.29	0.55	5.46e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.43	5.95	0.31	6.57e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	11.49	0.53	4.74e-26	Platelet count;
LIHC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg12374095	chr12:54320830	NA	0.4	5.74	0.3	2.1e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.48	0.37	6.42e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.95	14.44	0.62	3.05e-37	Skin colour saturation;
LIHC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.72	-7.59	-0.38	3.13e-13	Vitiligo;
LIHC	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	0.88	14.61	0.62	6.47e-38	Left atrial antero-posterior diameter;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09273779	chr9:35605990	TESK1	0.48	7.41	0.37	1.02e-12	Pancreatic cancer;
LIHC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.63	9.63	0.46	1.46e-19	Tonsillectomy;
LIHC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.65	-11.54	-0.53	2.94e-26	Iron status biomarkers;
LIHC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.71	0.54	7.16e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.19	-0.36	4.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.4	0.37	1.08e-12	Electroencephalogram traits;
LIHC	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-7.6	-0.38	2.95e-13	Exhaled nitric oxide output;
LIHC	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.89	13.34	0.59	5.63e-33	Vitamin D levels;
LIHC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	6.26	0.32	1.14e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.06	0.55	3.76e-28	Eye color traits;
LIHC	cis	rs12986413	1.000	rs12982593	chr19:2175891	C/A	cg09261902	chr19:2140048	AP3D1	0.37	6.38	0.33	5.85e-10	Height;
LIHC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.68	-11.21	-0.52	4.89e-25	Colorectal cancer;
LIHC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.57	-8.5	-0.42	5.75e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.22	-0.32	1.48e-9	Mean corpuscular volume;
LIHC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.8	9.2	0.45	3.64e-18	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg26338869	chr17:61819248	STRADA	0.5	6.66	0.34	1.1e-10	Height;
LIHC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.74	6.08	0.31	3.21e-9	Breast cancer;
LIHC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11708118	chr12:6862968	MLF2	0.51	6.54	0.33	2.2e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.9	16.48	0.67	2.42e-45	Menopause (age at onset);
LIHC	cis	rs7116495	1.000	rs4944242	chr11:71667141	G/T	cg26138937	chr11:71823887	C11orf51	-0.81	-7.96	-0.4	2.64e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.61	-11.04	-0.51	1.96e-24	Breast cancer;
LIHC	cis	rs61677309	0.929	rs58983315	chr11:118167759	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.44	0.33	4.14e-10	Lung cancer in ever smokers;
LIHC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.79	11.65	0.53	1.22e-26	Metabolic syndrome;
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg08200770	chr17:80723486	TBCD	-0.35	-5.81	-0.3	1.42e-8	Glycated hemoglobin levels;
LIHC	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.57	6.44	0.33	3.99e-10	White matter hyperintensity burden;
LIHC	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg25182066	chr10:30743637	MAP3K8	0.56	8.8	0.43	6.96e-17	Inflammatory bowel disease;
LIHC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.55	-8.28	-0.41	2.73e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg05343316	chr1:45956843	TESK2	-0.42	-6.19	-0.32	1.71e-9	High light scatter reticulocyte count;
LIHC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.51	6.85	0.35	3.53e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16684958	chr7:75615977	POR	0.51	8.53	0.42	4.98e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-9.65	-0.46	1.17e-19	Asthma;
LIHC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.26	-0.37	2.61e-12	Bipolar disorder;
LIHC	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.76	-8.55	-0.42	4.17e-16	Exhaled nitric oxide output;
LIHC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	0.89	16.04	0.66	1.5e-43	Bone mineral density;
LIHC	cis	rs6450176	0.633	rs617777	chr5:53330440	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.76	-13.72	-0.6	1.87e-34	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.7	0.57	1.59e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12986413	0.624	rs2159213	chr19:2136102	T/C	cg09261902	chr19:2140048	AP3D1	0.4	6.89	0.35	2.75e-11	Height;
LIHC	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg16070018	chr6:26224392	HIST1H3E	0.62	6.9	0.35	2.5e-11	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.7	-9.69	-0.46	8.55e-20	Cotinine glucuronidation;
LIHC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	0.96	18.01	0.7	1.72e-51	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.07	0.44	9.79e-18	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.35	-6.96	-0.35	1.8e-11	Body mass index;
LIHC	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.64	-10.66	-0.5	4.28e-23	Waist circumference;Body mass index;
LIHC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.5	8.36	0.41	1.56e-15	Obesity-related traits;
LIHC	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg09835421	chr16:68378352	PRMT7	-0.56	-5.89	-0.3	9.22e-9	Schizophrenia;
LIHC	cis	rs6708331	0.517	rs9989836	chr2:70342727	G/A	cg01613454	chr2:70366299	NA	0.38	6.15	0.32	2.18e-9	Obesity-related traits;
LIHC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.43	-0.59	2.61e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.49	7.25	0.36	2.83e-12	Intracranial aneurysm;
LIHC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.6	-0.5	6.95e-23	Total cholesterol levels;
LIHC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.94	-17.93	-0.7	3.9e-51	Menopause (age at onset);
LIHC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08822215	chr16:89438651	ANKRD11	-0.45	-7.15	-0.36	5.41e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs67981189	0.593	rs9323557	chr14:71470840	C/T	cg15816911	chr14:71606274	NA	-0.45	-6.28	-0.32	1.02e-9	Schizophrenia;
LIHC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.4	6.51	0.33	2.6200000000000003e-10	Red blood cell count;
LIHC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg05555928	chr11:63887634	MACROD1	0.51	6.58	0.34	1.81e-10	Mean platelet volume;
LIHC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg01864069	chr14:103024347	NA	-0.58	-9.55	-0.46	2.53e-19	Platelet count;
LIHC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.91	15.17	0.63	4.07e-40	Multiple system atrophy;
LIHC	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.29	6.43	0.33	4.41e-10	Weight;
LIHC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.36	5.82	0.3	1.37e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg03146154	chr1:46216737	IPP	-0.38	-6.13	-0.31	2.47e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.95	8.99	0.44	1.67e-17	Neuroticism;
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.95	0.57	1.78e-31	Prudent dietary pattern;
LIHC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.56	0.56	4.96e-30	Total body bone mineral density;
LIHC	cis	rs10792665	0.649	rs10792671	chr11:82728209	A/C	cg24227371	chr11:82718527	RAB30	-0.37	-9.31	-0.45	1.61e-18	Obesity-related traits;
LIHC	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25632853	chr15:73088954	NA	0.37	6.25	0.32	1.19e-9	Triglyceride levels;
LIHC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.75	11.43	0.53	7.53e-26	Corneal astigmatism;
LIHC	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.22	6.0	0.31	5.1e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg27166718	chr6:118880109	PLN;C6orf204	-0.54	-6.33	-0.32	7.71e-10	Diastolic blood pressure;
LIHC	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.67	0.34	1.03e-10	Blood protein levels;
LIHC	cis	rs1000083	0.915	rs2643573	chr5:96609704	C/T	ch.5.96698337R	chr5:96672581	NA	0.93	7.47	0.37	6.63e-13	Cisplatin-induced ototoxicity;
LIHC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.9e-9	Mortality in heart failure;
LIHC	cis	rs7116495	1.000	rs12293885	chr11:71816092	T/A	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.42	-5.86	-0.3	1.08e-8	Longevity;
LIHC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg22834771	chr12:69754056	YEATS4	-0.39	-6.0	-0.31	4.9e-9	Response to diuretic therapy;
LIHC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20135002	chr11:47629003	NA	-0.57	-9.6	-0.46	1.8e-19	Subjective well-being;
LIHC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.34	6.09	0.31	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.52	5.94	0.31	7.02e-9	Metabolite levels;
LIHC	cis	rs11233413	1.000	rs4944425	chr11:82776861	C/A	cg24227371	chr11:82718527	RAB30	-0.36	-7.83	-0.39	6.19e-14	Economic and political preferences (feminism/equality);
LIHC	cis	rs2607426	1.000	rs2607426	chr19:41274713	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.48	-6.12	-0.31	2.56e-9	Blood protein levels;
LIHC	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.66	-0.34	1.11e-10	IgG glycosylation;
LIHC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg00292662	chr22:38071168	LGALS1	-0.64	-10.27	-0.49	9.46e-22	Fat distribution (HIV);
LIHC	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.32	8.12	0.4	8.61e-15	Hip circumference;Waist circumference;
LIHC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	0.76	8.22	0.41	4.36e-15	Testicular germ cell tumor;
LIHC	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.5	-6.35	-0.32	6.8e-10	Blood pressure (smoking interaction);
LIHC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.14	0.68	5.42e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg03037974	chr15:76606532	NA	-0.74	-14.6	-0.62	7.12e-38	Blood metabolite levels;
LIHC	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.16	-0.32	2e-9	Coronary artery disease;
LIHC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.56	10.94	0.51	4.4e-24	Coronary artery disease;
LIHC	cis	rs4742903	0.967	rs10820601	chr9:106861281	G/A	cg14250997	chr9:106856677	SMC2	0.42	7.42	0.37	9.36e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	8.49	0.42	6.32e-16	Schizophrenia;
LIHC	cis	rs17428076	0.881	rs17581439	chr2:172737267	T/C	cg13550731	chr2:172543902	DYNC1I2	0.38	6.14	0.32	2.24e-9	Myopia;
LIHC	trans	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg08270573	chr4:147443996	SLC10A7	-0.68	-6.09	-0.31	3.03e-9	LDL cholesterol;
LIHC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg24203234	chr3:128598194	ACAD9	0.44	6.13	0.31	2.42e-9	IgG glycosylation;
LIHC	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.33	-0.32	7.73e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs965469	0.779	rs1884563	chr20:3335540	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-6.41	-0.33	4.8e-10	IFN-related cytopenia;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.01	0.58	9.97e-32	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13897145	chr3:113557582	GRAMD1C	0.41	6.2	0.32	1.61e-9	Cognitive function;
LIHC	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.84	-11.75	-0.54	5.1e-27	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.44	-6.2	-0.32	1.62e-9	Tuberculosis;
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.69	0.34	8.89e-11	Renal cell carcinoma;
LIHC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg03517284	chr6:25882590	NA	-0.4	-6.05	-0.31	3.73e-9	Height;
LIHC	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg14930904	chr10:32216787	ARHGAP12	0.38	6.8	0.35	4.57e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.52	0.53	3.51e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08772111	chr2:240002329	HDAC4	-0.38	-6.42	-0.33	4.55e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.41	6.04	0.31	3.99e-9	Menopause (age at onset);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07962309	chr12:42628089	YAF2	-0.25	-6.21	-0.32	1.5e-9	Calcium levels;
LIHC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs16858210	0.648	rs57604063	chr3:183578689	A/T	cg25686905	chr3:183603175	PARL	-0.48	-8.56	-0.42	3.82e-16	Menopause (age at onset);
LIHC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.38	-6.02	-0.31	4.59e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.02	-0.35	1.23e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg22834771	chr12:69754056	YEATS4	-0.48	-8.26	-0.41	3.33e-15	Blood protein levels;
LIHC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.52	-7.81	-0.39	6.88e-14	Response to diuretic therapy;
LIHC	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.95	-0.35	1.86e-11	Breast cancer;
LIHC	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.81	0.35	4.41e-11	Dermatomyositis;
LIHC	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	0.56	7.34	0.37	1.61e-12	Pulse pressure;
LIHC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.27	5.85	0.3	1.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.39	6.71	0.34	8.13e-11	Lewy body disease;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs9914544	0.545	rs4393623	chr17:18775900	A/G	cg21372672	chr17:16614065	CCDC144A	-0.25	-6.06	-0.31	3.6e-9	Educational attainment (years of education);
LIHC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.81	0.3	1.45e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg15664640	chr17:80829946	TBCD	0.39	6.14	0.32	2.3e-9	Glycated hemoglobin levels;
LIHC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	3.97e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7106204	0.668	rs7951530	chr11:24246904	T/C	ch.11.24196551F	chr11:24239977	NA	0.82	11.64	0.53	1.36e-26	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-22.08	-0.77	8.55e-68	Coronary artery disease;
LIHC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.16e-23	Bladder cancer;
LIHC	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.28	5.85	0.3	1.17e-8	Pulmonary function;
LIHC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg03945807	chr20:60948434	NA	0.4	6.44	0.33	3.95e-10	Colorectal cancer;
LIHC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-10.79	-0.5	1.5e-23	Asthma;
LIHC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.45	7.33	0.37	1.69e-12	Response to temozolomide;
LIHC	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.44	7.11	0.36	6.76e-12	Migraine;
LIHC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.42	5.88	0.3	9.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.99	0.48	9e-21	Lung cancer;
LIHC	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg03970086	chr16:88974840	CBFA2T3	0.35	7.01	0.35	1.32e-11	Social autistic-like traits;
LIHC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-14.45	-0.62	2.82e-37	Alzheimer's disease (late onset);
LIHC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.33	-5.88	-0.3	1e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs7756236	0.521	rs6907437	chr6:36625021	A/G	cg08179530	chr6:36648295	CDKN1A	0.42	6.34	0.32	7.29e-10	QRS duration;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.97	-0.35	1.59e-11	Total body bone mineral density;
LIHC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.09e-10	Bipolar disorder;
LIHC	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.22	-5.81	-0.3	1.43e-8	Obesity-related traits;
LIHC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.32	-0.32	8.11e-10	Blood metabolite levels;
LIHC	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.42	7.69	0.38	1.5700000000000001e-13	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.33	0.64	9.22e-41	Chronic sinus infection;
LIHC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21467203	chr3:49911342	NA	-0.43	-7.78	-0.39	8.93e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.85	0.3	1.13e-8	Self-reported allergy;
LIHC	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg12698662	chr3:15914712	MIR563	-0.39	-7.36	-0.37	1.4e-12	Mean platelet volume;
LIHC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.28	-7.15	-0.36	5.35e-12	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.4e-11	Diabetic kidney disease;
LIHC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.86	-0.43	4.32e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg20636351	chr8:55087400	NA	-0.34	-7.09	-0.36	7.97e-12	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg16724585	chr3:197361211	NA	-0.47	-6.6	-0.34	1.57e-10	Pancreatic cancer;
LIHC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.12	21.68	0.76	3.39e-66	Myeloid white cell count;
LIHC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg19680672	chr10:131412579	MGMT	-0.41	-6.37	-0.33	6e-10	Response to temozolomide;
LIHC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.63	-0.46	1.43e-19	Response to antipsychotic treatment;
LIHC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.6	8.29	0.41	2.67e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.43	9.67	0.46	1.07e-19	Erythrocyte sedimentation rate;
LIHC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.36	6.44	0.33	3.94e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7572733	0.555	rs7420608	chr2:198915930	A/T	cg03934865	chr2:198174659	NA	0.45	6.53	0.33	2.35e-10	Dermatomyositis;
LIHC	cis	rs710865	0.541	rs12567768	chr1:19568603	T/A	cg13387374	chr1:19411106	UBR4	0.42	6.53	0.33	2.31e-10	Brain structure;
LIHC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24110177	chr3:50126178	RBM5	0.43	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs151997	0.962	rs28676922	chr5:50247221	C/T	cg06027927	chr5:50259733	NA	0.6	7.87	0.39	4.86e-14	Callous-unemotional behaviour;
LIHC	cis	rs4878497	0.542	rs10813815	chr9:32436683	G/C	cg14296220	chr9:32431791	ACO1	0.6	10.11	0.48	3.38e-21	Inflammatory skin disease;
LIHC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.66	5.98	0.31	5.58e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.12	0.31	2.56e-9	Cognitive ability;
LIHC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.38	6.65	0.34	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	9.92	0.47	1.54e-20	Mean platelet volume;
LIHC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.47	-7.01	-0.35	1.29e-11	HDL cholesterol;
LIHC	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.42	0.41	1.05e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.83	-0.35	3.95e-11	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12463550	chr7:65579703	CRCP	0.66	6.98	0.35	1.54e-11	Diabetic kidney disease;
LIHC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.39	6.2	0.32	1.59e-9	Alzheimer's disease;
LIHC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-7.16	-0.36	4.87e-12	Height;
LIHC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.38	-8.61	-0.42	2.8e-16	Type 2 diabetes;
LIHC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.45	-8.73	-0.43	1.14e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.46e-8	Menopause (age at onset);
LIHC	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.13	0.31	2.37e-9	Ulcerative colitis;
LIHC	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.31	-0.52	2.13e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs2279817	0.908	rs12137775	chr1:18018927	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.63	7.96	0.4	2.57e-14	Neuroticism;
LIHC	trans	rs6489882	0.703	rs10850096	chr12:113360786	T/C	cg10175203	chr3:128143634	NA	0.4	6.43	0.33	4.19e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs3770081	1.000	rs73943920	chr2:86186195	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.75	-7.67	-0.38	1.8e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg17279839	chr7:150038598	RARRES2	0.37	7.26	0.37	2.63e-12	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg01596870	chr19:55963115	NA	-0.64	-8.52	-0.42	5.27e-16	Obesity-related traits;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11354472	chr22:17589511	IL17RA	0.42	6.43	0.33	4.39e-10	Immature fraction of reticulocytes;
LIHC	trans	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg10756647	chr7:56101905	PSPH	1.06	13.19	0.58	2.2e-32	Diabetic kidney disease;
LIHC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.91	-0.57	2.43e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-7.32	-0.37	1.74e-12	Height;
LIHC	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg11204139	chr17:3907470	NA	0.67	11.3	0.52	2.3e-25	Type 2 diabetes;
LIHC	cis	rs1494950	1.000	rs7442191	chr4:15023295	G/A	cg12377275	chr4:15005593	CPEB2	0.84	7.35	0.37	1.46e-12	Political ideology;
LIHC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.6	10.6	0.5	6.66e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.59	-0.53	1.95e-26	Coffee consumption (cups per day);
LIHC	cis	rs780096	0.967	rs1260333	chr2:27748624	A/G	cg22903471	chr2:27725779	GCKR	-0.31	-5.88	-0.3	9.91e-9	Total body bone mineral density;
LIHC	cis	rs28595532	0.545	rs17516526	chr4:119259199	C/G	cg21605333	chr4:119757512	SEC24D	0.79	6.65	0.34	1.19e-10	Cannabis dependence symptom count;
LIHC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.76	-10.95	-0.51	3.99e-24	Response to antineoplastic agents;
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.33	2.99e-10	Alzheimer's disease;
LIHC	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg14593290	chr7:50529359	DDC	0.35	5.76	0.3	1.88e-8	Malaria;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11339840	chr1:203596058	ATP2B4	0.43	6.4	0.33	5.12e-10	Pancreatic cancer;
LIHC	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-5.86	-0.3	1.07e-8	Blood protein levels;
LIHC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.37	0.66	6.68e-45	Smoking behavior;
LIHC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	2.97e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.93	7.04	0.36	1.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.46	6.64	0.34	1.22e-10	Longevity;
LIHC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18252515	chr7:66147081	NA	0.42	5.88	0.3	9.6e-9	Aortic root size;
LIHC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.7	-10.75	-0.5	2.08e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.41	0.33	4.8e-10	Total body bone mineral density;
LIHC	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.76	-11.88	-0.54	1.68e-27	Colorectal cancer;
LIHC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	8.87	0.43	4.24e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.12	0.31	2.64e-9	Renal cell carcinoma;
LIHC	cis	rs10147008	1	rs10147008	chr14:59990474	G/A	cg13540075	chr14:59894425	NA	0.42	6.97	0.35	1.6e-11	Tonsillectomy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24594383	chr20:62564955	DNAJC5	-0.45	-6.91	-0.35	2.43e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg14024328	chr4:719362	PCGF3	-0.47	-6.96	-0.35	1.78e-11	White blood cell count;
LIHC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg03037974	chr15:76606532	NA	-0.65	-11.48	-0.53	4.96e-26	Blood metabolite levels;
LIHC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.22	0.41	4.39e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.65	-10.92	-0.51	5.15e-24	Childhood ear infection;
LIHC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.5	-6.14	-0.32	2.24e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	1.04	15.14	0.63	5.49e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-8.4	-0.41	1.24e-15	Extraversion;
LIHC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.53	-8.16	-0.4	6.29e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.77	0.62	1.56e-38	Prudent dietary pattern;
LIHC	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.53	6.92	0.35	2.2e-11	Eotaxin levels;
LIHC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.65	10.03	0.48	6.22e-21	Schizophrenia;
LIHC	cis	rs7129220	0.588	rs61878634	chr11:10140114	A/T	cg01453529	chr11:10209919	SBF2	-0.37	-6.69	-0.34	9.33e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.44	-6.35	-0.32	6.91e-10	Blood protein levels;
LIHC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.85	-14.22	-0.61	2.25e-36	Post bronchodilator FEV1;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02684603	chr4:89445054	PIGY	0.44	6.39	0.33	5.33e-10	Lung function (FEV1/FVC);
LIHC	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.42	0.45	6.81e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	1.18	12.71	0.57	1.35e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg09835421	chr16:68378352	PRMT7	-0.86	-9.0	-0.44	1.6e-17	Schizophrenia;
LIHC	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	1.13	8.8	0.43	6.86e-17	Arsenic metabolism;
LIHC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg14343924	chr8:8086146	FLJ10661	0.49	5.99	0.31	5.31e-9	Parkinson's disease;
LIHC	cis	rs864643	1.000	rs1513214	chr3:39560265	T/A	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-7.73	-0.39	1.23e-13	Body mass index (adult);
LIHC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.66	-11.39	-0.52	1.08e-25	Crohn's disease;
LIHC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.83e-10	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23018242	chr22:31608245	LIMK2	0.54	7.01	0.35	1.25e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.6	8.96	0.44	2.09e-17	Recombination rate (females);
LIHC	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs6750047	0.719	rs4670232	chr2:38272033	C/G	cg07380506	chr2:38303506	CYP1B1	0.5	5.94	0.31	7.01e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Osteoarthritis;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg20607798	chr8:58055168	NA	0.64	8.21	0.41	4.61e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs12744310	1.000	rs55892603	chr1:41773994	T/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7091068	0.616	rs10748611	chr10:95482761	A/C	cg20715218	chr10:95462985	C10orf4	0.54	5.82	0.3	1.32e-8	Urinary tract infection frequency;
LIHC	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.23	-0.36	3.12e-12	Urate levels in overweight individuals;
LIHC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.78	-9.66	-0.46	1.15e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg14092571	chr14:90743983	NA	-0.38	-6.04	-0.31	4.01e-9	Mortality in heart failure;
LIHC	cis	rs62179067	0.786	rs11891599	chr2:179940326	G/A	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-7.02	-0.35	1.22e-11	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.9	0.3	8.58e-9	Bladder cancer;
LIHC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-1.01	-19.28	-0.72	1.37e-56	Breast cancer;
LIHC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.27	6.35	0.32	6.84e-10	Childhood ear infection;
LIHC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.28	-7.19	-0.36	3.98e-12	Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12232852	chr3:69129018	UBA3	0.49	6.85	0.35	3.36e-11	Pancreatic cancer;
LIHC	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.86	18.02	0.7	1.7e-51	Testicular germ cell tumor;
LIHC	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg25783544	chr11:47291846	MADD	0.41	5.95	0.31	6.8e-9	HDL cholesterol;
LIHC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.8	-0.39	7.68e-14	Colorectal cancer;
LIHC	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.15e-10	Putamen volume;
LIHC	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg02023728	chr11:77925099	USP35	-0.38	-6.58	-0.34	1.74e-10	Alzheimer's disease (survival time);
LIHC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.71e-15	Body mass index;
LIHC	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.47	-7.53	-0.38	4.47e-13	Aortic root size;
LIHC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.06e-10	Renal cell carcinoma;
LIHC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.68e-11	Blood pressure;
LIHC	cis	rs6450176	0.909	rs67721004	chr5:53290571	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.51	6.94	0.35	1.96e-11	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.46	6.63	0.34	1.32e-10	Platelet count;
LIHC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.71	11.26	0.52	3.14e-25	Corneal astigmatism;
LIHC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg11812906	chr14:75593930	NEK9	-0.43	-6.99	-0.35	1.47e-11	IgG glycosylation;
LIHC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.03	16.24	0.66	2.33e-44	Breast cancer;
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg05527609	chr1:210001259	C1orf107	0.45	6.54	0.33	2.21e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.67	0.42	1.73e-16	Platelet count;
LIHC	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.76	-11.28	-0.52	2.63e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg12560992	chr17:57184187	TRIM37	-0.52	-7.37	-0.37	1.33e-12	Cognitive test performance;
LIHC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.35	7.33	0.37	1.7e-12	Cancer;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg14709524	chr16:89940631	TCF25	0.59	7.54	0.38	4.25e-13	Skin colour saturation;
LIHC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.43	-0.49	2.61e-22	Hemoglobin concentration;
LIHC	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg20607798	chr8:58055168	NA	0.59	6.85	0.35	3.44e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2000813	0.789	rs12970066	chr18:47107152	C/G	cg01564661	chr14:105942636	CRIP2	0.34	6.08	0.31	3.29e-9	Coronary artery disease;
LIHC	cis	rs4450131	0.522	rs11245325	chr10:126348061	C/T	cg20435097	chr10:126320824	FAM53B	0.67	12.2	0.55	1.12e-28	White blood cell count (basophil);
LIHC	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.85	-7.28	-0.37	2.24e-12	Uric acid levels;
LIHC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.98	0.54	7.16e-28	Motion sickness;
LIHC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.35	-6.87	-0.35	3.11e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs10744422	0.800	rs1696320	chr12:123269814	A/G	cg22842854	chr12:123319900	HIP1R	-0.64	-8.09	-0.4	1.07e-14	Schizophrenia;
LIHC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg13409248	chr3:40428643	ENTPD3	0.41	6.5	0.33	2.91e-10	Renal cell carcinoma;
LIHC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg16070123	chr10:51489643	NA	0.37	5.9	0.3	8.68e-9	Prostate-specific antigen levels;
LIHC	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.57	-0.38	3.52e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.86	0.54	2.09e-27	Platelet count;
LIHC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02290350	chr8:58132656	NA	0.4	8.44	0.42	9.38e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	trans	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.3	0.32	9.04e-10	Mean corpuscular volume;
LIHC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	12.65	0.56	2.31e-30	Cognitive test performance;
LIHC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.27	-7.13	-0.36	5.85e-12	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.07	9.34	0.45	1.3e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-1.01	-19.21	-0.72	2.67e-56	Breast cancer;
LIHC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg01320579	chr17:75405842	SEPT9	0.52	8.91	0.43	3.04e-17	Airflow obstruction;
LIHC	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.42	-7.12	-0.36	6.49e-12	Coronary artery disease;
LIHC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-11.3	-0.52	2.27e-25	Hemoglobin concentration;
LIHC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.58	9.75	0.47	5.74e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.84	0.54	2.41e-27	Prudent dietary pattern;
LIHC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.87	0.43	4e-17	Mean corpuscular volume;
LIHC	cis	rs10916814	0.610	rs10799641	chr1:20897250	G/A	cg24502330	chr1:20914028	CDA	-0.31	-6.76	-0.34	6.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.3	-6.72	-0.34	7.82e-11	DNA methylation (variation);
LIHC	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.47	6.07	0.31	3.48e-9	Panic disorder;
LIHC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.54	8.79	0.43	7.3e-17	Body mass index;
LIHC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.49	8.05	0.4	1.38e-14	Longevity;Endometriosis;
LIHC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-9.61	-0.46	1.65e-19	Bipolar disorder;
LIHC	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg00576331	chr11:65640516	EFEMP2	0.42	6.09	0.31	3.05e-9	DNA methylation (variation);
LIHC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-6.97	-0.35	1.65e-11	Reticulocyte count;
LIHC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg18944383	chr4:111397179	ENPEP	0.25	6.32	0.32	7.95e-10	Height;
LIHC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.85	11.0	0.51	2.59e-24	Heart rate;
LIHC	cis	rs6429082	0.509	rs12027995	chr1:235517607	C/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.79	0.3	1.58e-8	Adiposity;
LIHC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg00656387	chr3:40428638	ENTPD3	0.38	5.9	0.3	8.91e-9	Renal cell carcinoma;
LIHC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg02980000	chr4:1222292	CTBP1	-0.54	-7.51	-0.38	5.16e-13	Obesity-related traits;
LIHC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.56	0.42	3.8e-16	Birth weight;
LIHC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.41	-5.83	-0.3	1.31e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg18944383	chr4:111397179	ENPEP	0.35	8.19	0.4	5.35e-15	Coronary artery disease;
LIHC	cis	rs6429082	0.905	rs12405889	chr1:235597252	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.4	-6.28	-0.32	1.03e-9	Adiposity;
LIHC	cis	rs11673344	0.704	rs1726719	chr19:37418032	T/C	cg27390819	chr19:37464633	NA	-0.48	-5.82	-0.3	1.35e-8	Obesity-related traits;
LIHC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg23517279	chr6:96025343	MANEA	0.54	5.98	0.31	5.71e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.91	16.91	0.67	4.67e-47	Aortic root size;
LIHC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04221910	chr5:616842	CEP72	-0.4	-7.04	-0.36	1.08e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.63	-10.25	-0.48	1.16e-21	Proinsulin levels;
LIHC	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04530015	chr2:215796436	ABCA12	0.45	7.55	0.38	4.06e-13	Neuroblastoma;
LIHC	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg20487152	chr13:99095054	FARP1	-0.38	-6.09	-0.31	2.98e-9	Longevity;
LIHC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.46	9.05	0.44	1.14e-17	Schizophrenia;
LIHC	cis	rs10256972	0.640	rs10271082	chr7:1081562	G/C	cg07308232	chr7:1071921	C7orf50	-0.41	-6.49	-0.33	2.97e-10	Longevity;Endometriosis;
LIHC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.34	-7.16	-0.36	4.97e-12	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg07451762	chr16:28383216	NA	-0.33	-6.03	-0.31	4.22e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.67	10.96	0.51	3.8e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.85	0.35	3.43e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12016809	chr21:47604291	C21orf56	-0.45	-6.77	-0.34	5.71e-11	Testicular germ cell tumor;
LIHC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.47	6.78	0.34	5.13e-11	Ulcerative colitis;
LIHC	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.34	-5.98	-0.31	5.75e-9	Asthma;
LIHC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.06e-9	Tonsillectomy;
LIHC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.46	8.17	0.4	6.12e-15	Prudent dietary pattern;
LIHC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-6.61	-0.34	1.48e-10	Vitiligo;
LIHC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-9.19	-0.44	4.01e-18	Body mass index;
LIHC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	8.78	0.43	8.17e-17	Coronary artery disease;
LIHC	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg15704280	chr7:45808275	SEPT13	0.59	6.05	0.31	3.74e-9	Axial length;
LIHC	cis	rs6442522	0.898	rs2219251	chr3:15429168	G/A	cg16303742	chr3:15540471	COLQ	0.41	6.94	0.35	1.92e-11	Uric acid levels;
LIHC	cis	rs8016982	0.662	rs8014406	chr14:81657760	A/C	cg01989461	chr14:81687754	GTF2A1	0.54	9.58	0.46	2.14e-19	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.07	-0.44	9.29e-18	Gut microbiome composition (summer);
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg26939375	chr7:64535504	NA	0.47	8.29	0.41	2.59e-15	Calcium levels;
LIHC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs595982	0.661	rs657008	chr19:49373632	A/G	cg21252483	chr19:49399788	TULP2	-0.46	-7.57	-0.38	3.59e-13	Red cell distribution width;
LIHC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	21.06	0.75	1.02e-63	Chronic sinus infection;
LIHC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg24209194	chr3:40518798	ZNF619	0.42	5.97	0.31	6.06e-9	Renal cell carcinoma;
LIHC	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg15208524	chr1:10270712	KIF1B	0.46	6.65	0.34	1.15e-10	Hepatocellular carcinoma;
LIHC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg20291162	chr17:40259547	DHX58	-0.39	-5.94	-0.31	6.99e-9	Fibrinogen levels;
LIHC	cis	rs7707921	0.881	rs73136777	chr5:81434479	T/A	cg15871215	chr5:81402204	ATG10	-0.61	-5.9	-0.3	8.67e-9	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15421363	chr5:131826865	IRF1	0.41	6.49	0.33	2.94e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg06359132	chr10:99160096	RRP12	0.38	5.96	0.31	6.36e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.45	-7.12	-0.36	6.53e-12	Retinal vascular caliber;
LIHC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.56	0.56	5.19e-30	Menopause (age at onset);
LIHC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-11.47	-0.53	5.66e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.88	0.57	3.23e-31	Colorectal cancer;
LIHC	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	9.59	0.46	1.87e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	0.9	16.17	0.66	4.42e-44	Bone mineral density;
LIHC	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.66	0.38	1.9e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.52	9.58	0.46	2.1e-19	Hemoglobin concentration;
LIHC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	11.99	0.54	6.85e-28	Response to antipsychotic treatment;
LIHC	cis	rs7707921	1.000	rs2407064	chr5:81457358	C/A	cg15871215	chr5:81402204	ATG10	0.6	5.89	0.3	9.03e-9	Breast cancer;
LIHC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	0.69	7.52	0.38	4.91e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs943466	0.614	rs4711345	chr6:33730954	G/A	cg25922239	chr6:33757077	LEMD2	-0.45	-7.24	-0.36	3.07e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.12.1981639F	chr12:100732545	SCYL2	-0.28	-6.05	-0.31	3.87e-9	Cognitive function;
LIHC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.56	9.53	0.46	2.96e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.52	-6.86	-0.35	3.29e-11	Vitiligo;
LIHC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.94	22.36	0.77	6.84e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-9.26	-0.45	2.31e-18	Parkinson's disease;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg00280220	chr17:61926910	NA	-0.42	-6.71	-0.34	8.13e-11	Prudent dietary pattern;
LIHC	cis	rs8083850	0.731	rs56291455	chr18:50830973	C/A	cg24270629	chr18:50823537	DCC	-0.55	-8.62	-0.42	2.6e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26804004	chr15:77155428	SCAPER	0.27	6.22	0.32	1.48e-9	Cognitive function;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.5	8.55	0.42	4.06e-16	Response to temozolomide;
LIHC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.66	10.67	0.5	3.84e-23	Colorectal cancer;
LIHC	cis	rs10242455	0.557	rs57830676	chr7:99281363	C/T	cg18809830	chr7:99032528	PTCD1	-0.83	-6.62	-0.34	1.42e-10	Blood metabolite levels;
LIHC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17554472	chr22:41940697	POLR3H	0.56	5.99	0.31	5.18e-9	Vitiligo;
LIHC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-7.13	-0.36	6.01e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.71	0.38	1.35e-13	Prudent dietary pattern;
LIHC	trans	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg12575136	chr18:32820987	ZNF397	0.47	7.01	0.35	1.28e-11	White blood cell count;
LIHC	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.49	6.72	0.34	7.67e-11	Red cell distribution width;
LIHC	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.41	-6.92	-0.35	2.23e-11	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg02415029	chr1:110025642	ATXN7L2	-0.48	-5.98	-0.31	5.73e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-7.54	-0.38	4.21e-13	Vitiligo;
LIHC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.07	-11.37	-0.52	1.22e-25	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.79	-7.68	-0.38	1.74e-13	Diabetic retinopathy;
LIHC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Bone mineral density;
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LIHC	cis	rs72627123	0.656	rs17096949	chr14:74602360	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.84	7.81	0.39	7.1e-14	Morning vs. evening chronotype;
LIHC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-0.69	-7.87	-0.39	4.66e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.63	9.58	0.46	2.04e-19	Monocyte percentage of white cells;
LIHC	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg03934865	chr2:198174659	NA	-0.62	-10.02	-0.48	7.06e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22509189	chr2:225307070	NA	-0.52	-6.97	-0.35	1.64e-11	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.62	9.73	0.47	6.5e-20	Tonsillectomy;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg13239297	chr3:50192725	SEMA3F	-0.41	-6.68	-0.34	9.92e-11	Calcium levels;
LIHC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.63e-13	Bone mineral density;
LIHC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.02	-0.36	1.17e-11	Schizophrenia;
LIHC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg03013999	chr17:37608204	MED1	0.36	5.91	0.3	8.43e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.76	0.34	5.88e-11	Personality dimensions;
LIHC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.09e-8	Bipolar disorder;
LIHC	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg22842854	chr12:123319900	HIP1R	-0.63	-7.66	-0.38	1.87e-13	Schizophrenia;
LIHC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.73	-0.3	2.26e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.38	5.78	0.3	1.71e-8	Lung cancer;
LIHC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.44	5.99	0.31	5.45e-9	Major depressive disorder;
LIHC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.48	0.42	6.99e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.82	9.06	0.44	1.02e-17	Vitiligo;
LIHC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02985541	chr2:219472218	PLCD4	0.44	8.35	0.41	1.7e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg07148914	chr20:33460835	GGT7	0.53	5.93	0.31	7.54e-9	Protein C levels;
LIHC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.41	-6.01	-0.31	4.82e-9	Height;
LIHC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.56	-8.6	-0.42	2.82e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg04359351	chr2:3481828	TTC15	0.29	5.97	0.31	5.94e-9	Neurofibrillary tangles;
LIHC	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg13047869	chr3:10149882	C3orf24	0.51	5.89	0.3	9e-9	Alzheimer's disease;
LIHC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.59	-0.56	4.11e-30	Alzheimer's disease;
LIHC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.69e-19	Waist circumference;Weight;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26376749	chr17:30677620	ZNF207	0.41	6.16	0.32	2.08e-9	Cognitive function;
LIHC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.38	-6.43	-0.33	4.37e-10	IgG glycosylation;
LIHC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.32	-8.36	-0.41	1.55e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.38	6.09	0.31	2.98e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.48	7.01	0.35	1.32e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg04162153	chr10:124029871	BTBD16	0.42	5.82	0.3	1.33e-8	Total body bone mineral density;
LIHC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg14067834	chr17:29058358	SUZ12P	0.64	6.57	0.33	1.83e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg07424592	chr7:64974309	NA	0.82	9.23	0.45	2.79e-18	Diabetic kidney disease;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg25281562	chr12:121454272	C12orf43	0.33	5.78	0.3	1.67e-8	N-glycan levels;
LIHC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.93	0.47	1.33e-20	Alzheimer's disease;
LIHC	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.32	6.09	0.31	3.07e-9	Red blood cell count;
LIHC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg12374095	chr12:54320830	NA	0.4	5.81	0.3	1.42e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg01864836	chr14:55583639	NA	-0.41	-7.96	-0.4	2.5e-14	Protein biomarker;
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.03	-0.44	1.27e-17	Bipolar disorder and schizophrenia;
LIHC	trans	rs1814175	0.616	rs10839341	chr11:49742615	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.37	-0.74	5.91e-61	Height;
LIHC	cis	rs2334880	0.836	rs9934715	chr16:71757387	C/G	cg06353428	chr16:71660113	MARVELD3	1.41	15.53	0.64	1.56e-41	Malaria;
LIHC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07080220	chr10:102295463	HIF1AN	0.56	8.01	0.4	1.85e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg22528358	chr1:107598549	PRMT6	-0.66	-10.63	-0.5	5.44e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9309473	1.000	rs6724782	chr2:73679990	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.83	-0.35	3.84e-11	Metabolite levels;
LIHC	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.66	6.65	0.34	1.15e-10	Schizophrenia;
LIHC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.4	6.36	0.33	6.4e-10	Homoarginine levels;
LIHC	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.47	6.8	0.35	4.73e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.78	13.62	0.59	4.71e-34	Aortic root size;
LIHC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.46	-6.96	-0.35	1.73e-11	P wave terminal force;
LIHC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.48	-8.44	-0.42	9.22e-16	Longevity;
LIHC	cis	rs55893317	0.505	rs56850765	chr11:10050776	C/G	cg01453529	chr11:10209919	SBF2	-0.35	-6.35	-0.32	6.72e-10	Red blood cell count;
LIHC	cis	rs797680	0.856	rs6688230	chr1:93641124	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.88	-0.3	9.71e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg01249735	chr7:156742241	NOM1	-0.43	-6.43	-0.33	4.29e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.13	0.44	5.9e-18	IgG glycosylation;
LIHC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.97	0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.25	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.53	0.38	4.66e-13	Mean platelet volume;
LIHC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2997447	0.846	rs2997445	chr1:26390154	C/T	cg19633962	chr1:26362018	EXTL1	-0.54	-6.07	-0.31	3.31e-9	QRS complex (12-leadsum);
LIHC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg01200585	chr1:228362443	C1orf69	0.42	6.44	0.33	4.08e-10	Diastolic blood pressure;
LIHC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.5	-0.49	1.5e-22	Chronic sinus infection;
LIHC	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.41	-0.49	3.13e-22	Waist circumference;Body mass index;
LIHC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.48	-7.01	-0.35	1.25e-11	Longevity;Endometriosis;
LIHC	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.78	10.38	0.49	4e-22	Post bronchodilator FEV1;
LIHC	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.94	-0.39	2.98e-14	Coronary artery disease;
LIHC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.56	-6.64	-0.34	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.14	-0.48	2.69e-21	Response to antipsychotic treatment;
LIHC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.38	7.78	0.39	8.76e-14	Immature fraction of reticulocytes;
LIHC	trans	rs6489882	0.703	rs6489864	chr12:113360025	A/G	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs3770081	1.000	rs73947314	chr2:86273116	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.45	6.19	0.32	1.71e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.73	11.2	0.52	5.32e-25	Metabolite levels;
LIHC	cis	rs6450176	0.633	rs25858	chr5:53339518	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-13.38	-0.59	3.86e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.47	-8.4	-0.41	1.2e-15	Longevity;
LIHC	cis	rs9309473	0.528	rs7573275	chr2:73552542	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs7639513	0.545	rs9874557	chr3:12720967	A/G	cg23032965	chr3:12705835	RAF1	0.58	6.35	0.32	6.93e-10	Itch intensity from mosquito bite;
LIHC	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-6.04	-0.31	4.06e-9	Total body bone mineral density;
LIHC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg03645007	chr3:50255295	SLC38A3	0.51	6.3	0.32	9.06e-10	Schizophrenia;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.69	-11.14	-0.52	8.14e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9918079	0.560	rs4557256	chr4:15626647	A/C	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.14	-0.31	2.34e-9	Obesity-related traits;
LIHC	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg27205649	chr11:78285834	NARS2	0.41	6.18	0.32	1.79e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.72	-0.47	7.08e-20	Electroencephalogram traits;
LIHC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.59	-0.34	1.67e-10	Blood metabolite levels;
LIHC	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg25649188	chr17:73499917	CASKIN2	0.43	6.63	0.34	1.33e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.43	6.06	0.31	3.57e-9	Aortic root size;
LIHC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05665937	chr4:1216051	CTBP1	0.46	6.4	0.33	5.08e-10	Obesity-related traits;
LIHC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.57	8.38	0.41	1.39e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg24391279	chr8:1708526	NA	-0.35	-5.89	-0.3	9.11e-9	Systolic blood pressure;
LIHC	cis	rs72653721	0.793	rs4713102	chr6:10968671	A/G	cg13562911	chr6:11044106	ELOVL2	0.47	6.65	0.34	1.16e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg02702477	chr5:179499311	RNF130	-0.74	-10.27	-0.49	9.85e-22	LDL cholesterol;
LIHC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.16	0.79	6.11e-76	Prudent dietary pattern;
LIHC	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg26395211	chr5:140044315	WDR55	-0.44	-6.5	-0.33	2.85e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.47	-0.42	7.3e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.63	-0.42	2.41e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.53	8.59	0.42	3.06e-16	Birth weight;
LIHC	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	7.08	0.36	8.34e-12	Bipolar disorder;
LIHC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.59	10.21	0.48	1.49e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.44	5.73	0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg25686905	chr3:183603175	PARL	-0.47	-7.59	-0.38	3.06e-13	Menopause (age at onset);
LIHC	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.76	-0.3	1.88e-8	Red blood cell count;
LIHC	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.66	-5.72	-0.3	2.35e-8	Inflammatory biomarkers;
LIHC	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg12454167	chr3:186435060	KNG1	0.32	7.68	0.38	1.73e-13	Adiponectin levels;
LIHC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04025307	chr7:1156635	C7orf50	0.56	7.49	0.38	5.76e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Bone mineral density;
LIHC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	9.98	0.47	9.6e-21	Alzheimer's disease;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg12064134	chr16:90016061	DEF8	-0.46	-6.16	-0.32	2.08e-9	Skin colour saturation;
LIHC	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.76	0.3	1.88e-8	Educational attainment;
LIHC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.28	-6.4	-0.33	5.1e-10	Migraine;
LIHC	trans	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg00571809	chr1:3397113	ARHGEF16	0.37	6.16	0.32	2.06e-9	Schizophrenia;
LIHC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.63	5.77	0.3	1.75e-8	Menopause (age at onset);
LIHC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.62	-8.62	-0.42	2.57e-16	Body mass index;
LIHC	cis	rs4453791	0.932	rs4315640	chr3:38923700	G/A	cg02254461	chr3:39195904	CSRNP1	0.66	5.89	0.3	9.44e-9	Social communication problems;
LIHC	cis	rs7903847	0.612	rs9887994	chr10:99159815	T/G	cg06359132	chr10:99160096	RRP12	-0.4	-5.88	-0.3	9.93e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.13	-0.36	6.2e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06434972	chr7:44122219	POLM	0.43	6.22	0.32	1.43e-9	Pancreatic cancer;
LIHC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg07061783	chr6:25882402	NA	-0.54	-6.8	-0.35	4.6e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	6.87	0.35	2.98e-11	Height;
LIHC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg06466757	chr4:1255808	NA	0.34	5.77	0.3	1.76e-8	Obesity-related traits;
LIHC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.57	6.35	0.32	6.75e-10	Axial length;
LIHC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.48	7.58	0.38	3.18e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.45	6.37	0.33	6.19e-10	Diastolic blood pressure;
LIHC	cis	rs10411936	0.712	rs8103486	chr19:16603107	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.54	7.17	0.36	4.65e-12	White blood cell count;Multiple sclerosis;
LIHC	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.2	-6.38	-0.33	5.6e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-7.57	-0.38	3.56e-13	Cognitive function;
LIHC	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-0.84	-9.92	-0.47	1.47e-20	Alzheimer's disease (late onset);
LIHC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.47	7.92	0.39	3.32e-14	Response to temozolomide;
LIHC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.13	-0.36	5.87e-12	Personality dimensions;
LIHC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.39	-0.45	8.66e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.41	6.07	0.31	3.43e-9	Menopause (age at onset);
LIHC	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.8	0.35	4.72e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	9.14	0.44	5.87e-18	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.94	22.01	0.77	1.64e-67	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg01674679	chr13:27998804	GTF3A	-0.44	-6.41	-0.33	4.76e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.46	5.75	0.3	2.01e-8	Blood protein levels;
LIHC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.47	-6.94	-0.35	2e-11	Response to metformin (IC50);
LIHC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.0	0.4	1.91e-14	Height;
LIHC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg18357526	chr6:26021779	HIST1H4A	0.4	5.95	0.31	6.78e-9	Height;
LIHC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.44	7.6	0.38	2.95e-13	Schizophrenia;
LIHC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.52	8.08	0.4	1.16e-14	Tonsillectomy;
LIHC	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg20295408	chr7:1910781	MAD1L1	-0.53	-7.64	-0.38	2.18e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg15605315	chr1:45957053	TESK2	-0.44	-5.76	-0.3	1.91e-8	Platelet count;
LIHC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.37	6.53	0.33	2.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs4728302	0.574	rs7804463	chr7:133447651	T/C	cg10665199	chr7:133106180	EXOC4	0.35	5.99	0.31	5.18e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.02	0.31	4.47e-9	Blood metabolite levels;
LIHC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.53	-7.1	-0.36	7.4e-12	Vitiligo;
LIHC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg12863693	chr15:85201151	NMB	0.45	6.13	0.31	2.45e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.41	-6.57	-0.33	1.92e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg08539965	chr1:21396338	EIF4G3	0.32	5.71	0.3	2.44e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.51	9.03	0.44	1.3e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.6	8.29	0.41	2.57e-15	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-7.02	-0.35	1.23e-11	Hepatocellular carcinoma;
LIHC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.39	8.03	0.4	1.54e-14	Type 2 diabetes;
LIHC	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg19413766	chr7:29689036	LOC646762	-0.61	-6.28	-0.32	1e-9	Facial emotion recognition;Facial emotion recognition (sad faces);
LIHC	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.26	6.75	0.34	6.51e-11	Type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	11.73	0.54	6.26e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.61	-6.96	-0.35	1.76e-11	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs8067354	0.574	rs2526353	chr17:57988607	G/T	cg02344993	chr17:57696989	CLTC	0.67	10.55	0.5	1.06e-22	Hemoglobin concentration;
LIHC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg05347473	chr6:146136440	FBXO30	0.35	5.72	0.3	2.27e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-9.77	-0.47	4.95e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03878208	chr11:72483293	STARD10	0.62	5.84	0.3	1.21e-8	Type 2 diabetes;
LIHC	cis	rs5167	0.506	rs11669173	chr19:45492559	G/A	cg13119609	chr19:45449297	APOC2	-0.23	-6.66	-0.34	1.09e-10	Blood protein levels;
LIHC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.31	-6.39	-0.33	5.53e-10	Blood metabolite levels;
LIHC	cis	rs965469	1.000	rs6051723	chr20:3278512	C/A	cg25506879	chr20:3388711	C20orf194	-0.6	-6.91	-0.35	2.43e-11	IFN-related cytopenia;
LIHC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.38	-0.33	5.86e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg08200770	chr17:80723486	TBCD	-0.35	-5.83	-0.3	1.28e-8	Glycated hemoglobin levels;
LIHC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg03959625	chr15:84868606	LOC388152	0.47	6.66	0.34	1.07e-10	Schizophrenia;
LIHC	cis	rs57244997	0.725	rs11964513	chr6:162414779	C/T	cg17173639	chr6:162384350	PARK2	-0.53	-6.96	-0.35	1.71e-11	Mosquito bite size;
LIHC	cis	rs11628318	0.515	rs2093259	chr14:103145646	T/A	cg12046867	chr14:103022105	NA	0.4	5.98	0.31	5.76e-9	Platelet count;
LIHC	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	6.49	0.33	3e-10	Bipolar disorder;
LIHC	trans	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg05926928	chr17:57297772	GDPD1	0.64	6.74	0.34	6.76e-11	Opioid sensitivity;
LIHC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs539514	0.587	rs7320216	chr13:76332689	A/G	cg04757411	chr13:76259545	LMO7	-0.4	-6.71	-0.34	8.23e-11	Type 1 diabetes;
LIHC	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.17	-13.21	-0.58	1.84e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.9e-10	Menarche (age at onset);
LIHC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg16586182	chr3:47516702	SCAP	-0.58	-11.28	-0.52	2.6e-25	Colorectal cancer;
LIHC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.48	8.41	0.41	1.13e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.49	5.93	0.31	7.58e-9	Menarche (age at onset);
LIHC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg13974409	chr11:65292307	SCYL1	-0.38	-6.06	-0.31	3.69e-9	Bone mineral density;
LIHC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg07884673	chr3:53033167	SFMBT1	0.94	6.91	0.35	2.38e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18252515	chr7:66147081	NA	0.46	6.54	0.33	2.18e-10	Aortic root size;
LIHC	trans	rs1432089	0.773	rs72700805	chr4:171784005	T/C	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.31	-5.75	-0.3	1.98e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.15e-41	Mortality in heart failure;
LIHC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.69	0.34	9.33e-11	Bipolar disorder;
LIHC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.76	0.39	9.94e-14	Response to antipsychotic treatment;
LIHC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.35	6.04	0.31	4.08e-9	Body mass index;
LIHC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.48	-0.37	6.33e-13	Schizophrenia;
LIHC	cis	rs12744310	1.000	rs68132196	chr1:41770620	C/A	cg03962019	chr1:41807865	NA	0.41	6.53	0.33	2.44e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	10.12	0.48	3.06e-21	Menarche (age at onset);
LIHC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.74	-10.48	-0.49	1.83e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.18	0.32	1.86e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-6.78	-0.34	5.23e-11	Alzheimer's disease;
LIHC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-10.43	-0.49	2.72e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg11657440	chr19:46296263	DMWD	-0.54	-8.47	-0.42	7.27e-16	Coronary artery disease;
LIHC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	6.02	0.31	4.48e-9	Obesity-related traits;
LIHC	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.42e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.32	5.75	0.3	1.96e-8	Alopecia areata;
LIHC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg12046867	chr14:103022105	NA	0.5	7.24	0.36	3.01e-12	Platelet count;
LIHC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg12798992	chr6:167411361	FGFR1OP	0.62	10.42	0.49	2.99e-22	Crohn's disease;
LIHC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.6	8.98	0.44	1.83e-17	Recombination rate (females);
LIHC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.57	9.9	0.47	1.78e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2422052	1.000	rs2422052	chr2:118651764	G/C	cg22545206	chr2:118617499	NA	0.36	6.11	0.31	2.76e-9	Mosquito bite size;
LIHC	cis	rs2074193	0.826	rs215349	chr12:47734467	A/T	cg02516419	chr12:47771422	NA	0.42	6.61	0.34	1.49e-10	Migraine with aura;
LIHC	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg02344993	chr17:57696989	CLTC	0.56	9.19	0.44	4.04e-18	Hemoglobin concentration;
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.66	9.65	0.46	1.17e-19	Menarche (age at onset);
LIHC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg15448220	chr1:150897856	SETDB1	0.43	6.77	0.34	5.77e-11	Tonsillectomy;
LIHC	trans	rs11037575	0.966	rs2863002	chr11:43714768	C/T	cg11141497	chr11:6633666	TAF10	-0.41	-6.07	-0.31	3.37e-9	Neuroblastoma;
LIHC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg03037974	chr15:76606532	NA	-0.84	-20.52	-0.74	1.44e-61	Blood metabolite levels;
LIHC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-11.07	-0.51	1.51e-24	Mean corpuscular volume;
LIHC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.64	-0.46	1.28e-19	Initial pursuit acceleration;
LIHC	cis	rs11031096	0.683	rs10835729	chr11:4210847	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.97	-0.31	6e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	0.81	6.82	0.35	4.16e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.19	0.36	4.14e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627123	0.656	rs75646425	chr14:74529433	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	5.78	0.3	1.69e-8	Morning vs. evening chronotype;
LIHC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	0.6	11.32	0.52	1.94e-25	Fat distribution (HIV);
LIHC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.45	-6.48	-0.33	3.11e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg00452199	chr11:44088257	ACCS	-0.53	-6.77	-0.34	5.64e-11	IgA nephropathy;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-8.7	-0.43	1.47e-16	Total body bone mineral density;
LIHC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg11953164	chr1:23521307	HTR1D	0.29	5.78	0.3	1.68e-8	Height;
LIHC	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.75	-9.46	-0.46	5.05e-19	Blood protein levels;
LIHC	cis	rs3736485	0.903	rs4545756	chr15:51877790	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.59	10.34	0.49	5.45e-22	Dupuytren's disease;
LIHC	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.17	-0.48	2.14e-21	Alzheimer's disease;
LIHC	cis	rs7429990	0.901	rs7374482	chr3:48168390	A/G	cg11946769	chr3:48343235	NME6	-0.47	-6.24	-0.32	1.28e-9	Educational attainment (years of education);
LIHC	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg20220242	chr21:30392188	RWDD2B	0.48	6.59	0.34	1.68e-10	Cognitive test performance;
LIHC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.1	0.36	7.26e-12	Axial length;
LIHC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.46	6.13	0.31	2.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.9	0.3	8.68e-9	Tonsillectomy;
LIHC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg05044414	chr3:183734942	ABCC5	-0.36	-6.01	-0.31	4.65e-9	Anterior chamber depth;
LIHC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	5.91	0.3	8.46e-9	Bipolar disorder;
LIHC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.41	-0.37	1.03e-12	Body mass index;
LIHC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg05941027	chr17:61774174	LIMD2	0.35	7.43	0.37	8.8e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18931685	chr19:45505298	RELB	0.43	6.12	0.31	2.62e-9	Pancreatic cancer;
LIHC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg23205692	chr1:25664452	TMEM50A	-0.37	-5.97	-0.31	6.1e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg17764715	chr19:33622953	WDR88	0.41	5.79	0.3	1.61e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.39	5.86	0.3	1.06e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7818688	0.697	rs11781397	chr8:95974506	G/T	cg16049864	chr8:95962084	TP53INP1	0.62	6.78	0.34	5.18e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.66	12.95	0.57	1.74e-31	Schizophrenia;
LIHC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.82	-0.3	1.38e-8	Body mass index;
LIHC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.65	-9.77	-0.47	4.92e-20	Subjective well-being;
LIHC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs2637266	0.935	rs2583058	chr10:78396018	T/A	cg18941641	chr10:78392320	NA	0.29	6.36	0.33	6.43e-10	Pulmonary function;
LIHC	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg27205649	chr11:78285834	NARS2	-0.38	-5.88	-0.3	9.86e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.83	-0.3	1.29e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6061231	0.654	rs2427322	chr20:60979370	T/C	cg24112000	chr20:60950667	NA	-0.55	-8.53	-0.42	4.75e-16	Colorectal cancer;
LIHC	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.56	-9.8	-0.47	3.81e-20	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg19680672	chr10:131412579	MGMT	0.43	6.6	0.34	1.56e-10	Response to temozolomide;
LIHC	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg02023728	chr11:77925099	USP35	0.34	6.02	0.31	4.41e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.71	13.04	0.58	7.81e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	6.17	0.32	1.96e-9	Coronary artery disease;
LIHC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.71	12.97	0.57	1.46e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.51	-6.39	-0.33	5.41e-10	Pancreatic cancer;
LIHC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.01	-0.31	4.86e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7619427	0.544	rs9866639	chr3:43990450	G/A	cg24966902	chr3:44043705	NA	0.44	6.67	0.34	1.03e-10	Schizophrenia;
LIHC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.5	7.53	0.38	4.44e-13	Resting heart rate;
LIHC	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.43	-5.8	-0.3	1.53e-8	Menopause (age at onset);
LIHC	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.3	-5.72	-0.3	2.38e-8	Red blood cell count;
LIHC	cis	rs7715806	0.500	rs3797581	chr5:75002895	G/T	cg19683494	chr5:74908142	NA	0.56	6.67	0.34	1.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg06012730	chr15:75315579	PPCDC	-0.32	-6.14	-0.32	2.25e-9	Blood trace element (Zn levels);
LIHC	cis	rs8056893	0.714	rs1530643	chr16:68396092	T/C	cg02226672	chr16:68398533	SMPD3	0.42	5.98	0.31	5.77e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg01324507	chr7:1177794	C7orf50	0.51	6.66	0.34	1.07e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg14146966	chr2:61757674	XPO1	0.46	8.07	0.4	1.18e-14	Tuberculosis;
LIHC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.45	7.79	0.39	8.08e-14	Schizophrenia;
LIHC	cis	rs4700695	0.925	rs10069614	chr5:65396530	A/C	cg21114390	chr5:65439923	SFRS12	-0.44	-5.89	-0.3	9.12e-9	Facial morphology (factor 19);
LIHC	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg12179176	chr11:130786555	SNX19	0.55	7.93	0.39	3.19e-14	Schizophrenia;
LIHC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg03013999	chr17:37608204	MED1	-0.35	-5.77	-0.3	1.77e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	0.9	9.24	0.45	2.74e-18	Type 2 diabetes nephropathy;
LIHC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-0.64	-7.41	-0.37	9.95e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.62	9.16	0.44	5e-18	Cognitive function;
LIHC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.36	-0.37	1.39e-12	HDL cholesterol;
LIHC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.31	0.52	2.11e-25	Lung cancer in ever smokers;
LIHC	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.42	-6.51	-0.33	2.61e-10	Metabolite levels;
LIHC	cis	rs2380220	0.808	rs2380224	chr6:95895553	C/T	cg15832292	chr6:96025679	MANEA	-0.63	-7.24	-0.36	2.96e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.44	6.81	0.35	4.29e-11	Schizophrenia;
LIHC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-1.07	-16.57	-0.67	1.09e-45	Uric acid levels;
LIHC	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.43	-7.27	-0.37	2.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.88	0.39	4.37e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6429082	0.509	rs35446932	chr1:235523480	C/T	cg26050004	chr1:235667680	B3GALNT2	0.43	6.43	0.33	4.32e-10	Adiposity;
LIHC	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg25930673	chr12:123319894	HIP1R	1.04	11.55	0.53	2.78e-26	Adiponectin levels;
LIHC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-10.24	-0.48	1.19e-21	Colorectal cancer;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.8	-0.3	1.55e-8	Total body bone mineral density;
LIHC	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg14515779	chr1:101123966	NA	0.55	7.81	0.39	7.03e-14	Monocyte count;
LIHC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs9378688	1.000	rs12661136	chr6:2227239	C/A	cg12303981	chr6:2244766	GMDS	-0.49	-6.22	-0.32	1.48e-9	Caudate nucleus volume;
LIHC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg05941027	chr17:61774174	LIMD2	0.34	6.92	0.35	2.2e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg02573091	chr5:74908125	NA	-0.6	-7.1	-0.36	7.22e-12	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg17428748	chr7:158741438	NA	-0.37	-6.68	-0.34	9.73e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.71	-12.45	-0.56	1.31e-29	Refractive error;
LIHC	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	9.7e-13	Putamen volume;
LIHC	cis	rs7961581	0.748	rs1072672	chr12:71597470	A/C	cg05756094	chr12:71608604	NA	0.41	6.62	0.34	1.36e-10	Type 2 diabetes;
LIHC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.58	8.36	0.41	1.56e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.45	7.42	0.37	9.57e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.7	-6.94	-0.35	1.97e-11	Vitiligo;
LIHC	cis	rs1434579	0.966	rs12151338	chr19:44933947	G/A	cg15540054	chr19:45004280	ZNF180	0.58	7.82	0.39	6.58e-14	Tuberculosis;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	6.99	0.35	1.49e-11	Renal cell carcinoma;
LIHC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.05e-11	Ileal carcinoids;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	0.45	6.91	0.35	2.38e-11	Pancreatic cancer;
LIHC	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.75	0.34	6.2e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.53	-8.99	-0.44	1.73e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.33	2.33e-10	Vitiligo;
LIHC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.08	-0.31	3.15e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-7.95	-0.4	2.66e-14	Response to antipsychotic treatment;
LIHC	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.66	6.81	0.35	4.27e-11	Bipolar disorder;
LIHC	cis	rs244293	0.965	rs2529505	chr17:53206808	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg10820045	chr2:198174542	NA	0.48	7.4	0.37	1.09e-12	Dermatomyositis;
LIHC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.25	-0.32	1.23e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.11	0.58	4.22e-32	Alzheimer's disease;
LIHC	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg25363559	chr8:143086065	NA	-0.28	-8.43	-0.41	9.45e-16	Amyotrophic lateral sclerosis;
LIHC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.2e-13	Electroencephalogram traits;
LIHC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.33	-6.94	-0.35	2.02e-11	Bone mineral density;
LIHC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.59	-8.43	-0.41	9.93e-16	Blood metabolite levels;
LIHC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg03959625	chr15:84868606	LOC388152	-0.44	-6.47	-0.33	3.31e-10	Schizophrenia;
LIHC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.63	10.29	0.49	8.51e-22	Platelet count;
LIHC	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg07424592	chr7:64974309	NA	0.82	9.53	0.46	2.98e-19	Diabetic kidney disease;
LIHC	cis	rs72627123	0.656	rs11159064	chr14:74614743	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.84	-7.95	-0.39	2.79e-14	Morning vs. evening chronotype;
LIHC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg12798992	chr6:167411361	FGFR1OP	0.45	6.99	0.35	1.46e-11	Crohn's disease;
LIHC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.52	-0.33	2.5e-10	Height;
LIHC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.54	7.8	0.39	7.56e-14	Height;
LIHC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg14593290	chr7:50529359	DDC	-0.53	-8.94	-0.44	2.55e-17	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg02023728	chr11:77925099	USP35	-0.33	-5.94	-0.31	6.92e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.38e-17	Recombination rate (females);
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.44	8.13	0.4	7.79e-15	Prudent dietary pattern;
LIHC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg04013166	chr16:89971882	TCF25	0.53	6.67	0.34	1.04e-10	Skin colour saturation;
LIHC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.06	18.21	0.7	2.78e-52	Testicular germ cell tumor;
LIHC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.45	-0.33	3.8e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1144333	1.000	rs112401426	chr1:76466103	T/A	cg03433033	chr1:76189801	ACADM	0.51	7.5	0.38	5.47e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.33	-0.41	2.02e-15	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs12752401	1.000	rs67551785	chr1:102978472	T/C	cg17681729	chr19:740608	PALM	0.46	6.49	0.33	2.99e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs3099143	0.803	rs28618274	chr15:77220243	C/T	cg21673338	chr15:77095150	SCAPER	-0.49	-7.06	-0.36	9.46e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13409248	chr3:40428643	ENTPD3	0.48	7.83	0.39	6.01e-14	Renal cell carcinoma;
LIHC	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.41	0.33	4.91e-10	HDL cholesterol;
LIHC	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg10756647	chr7:56101905	PSPH	-0.45	-6.34	-0.32	7.36e-10	Aortic root size;
LIHC	trans	rs6600671	1.000	rs11249351	chr1:121171942	G/A	cg09829573	chr1:144692074	NBPF9	-0.45	-8.23	-0.41	4.12e-15	Hip geometry;
LIHC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.67	10.34	0.49	5.7e-22	Corneal astigmatism;
LIHC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-8.0	-0.4	1.95e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02985541	chr2:219472218	PLCD4	0.47	8.81	0.43	6.64e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs797680	0.856	rs2031225	chr1:93786714	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	0.35	6.24	0.32	1.32e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.72	10.66	0.5	4.1000000000000003e-23	Corneal astigmatism;
LIHC	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg10127483	chr1:110009974	SYPL2	0.48	6.06	0.31	3.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg22705602	chr4:152727874	NA	-0.31	-6.53	-0.33	2.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg24693881	chr1:107596107	NA	-0.54	-9.63	-0.46	1.38e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4660306	0.744	rs11211115	chr1:45926438	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	6.73	0.34	7.06e-11	Homocysteine levels;
LIHC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-9.02	-0.44	1.39e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.41	-6.5	-0.33	2.92e-10	Morning vs. evening chronotype;
LIHC	cis	rs9596863	0.898	rs35863857	chr13:54372546	A/G	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.1e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.7	0.34	8.71e-11	Bipolar disorder;
LIHC	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.45	-7.41	-0.37	9.79e-13	Schizophrenia;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.68	-10.24	-0.48	1.24e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.45	-7.74	-0.39	1.11e-13	Uric acid levels;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg14671364	chr1:107599128	PRMT6	0.46	6.62	0.34	1.38e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.57	11.15	0.52	7.58e-25	Coronary artery disease;
LIHC	cis	rs7212590	0.655	rs8072050	chr17:58010972	G/A	cg10252138	chr17:58120427	NA	-0.58	-5.87	-0.3	1.01e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg26695010	chr11:65641043	EFEMP2	0.46	6.48	0.33	3.29e-10	Eosinophil percentage of white cells;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08280861	chr8:58055591	NA	0.51	6.39	0.33	5.56e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg20129853	chr10:51489980	NA	-0.43	-9.35	-0.45	1.15e-18	Prostate-specific antigen levels;
LIHC	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.47	-7.04	-0.36	1.06e-11	Adiposity;
LIHC	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg00071026	chr13:113650936	MCF2L	-0.37	-5.87	-0.3	1.02e-8	Systolic blood pressure;
LIHC	cis	rs7432375	0.901	rs4521165	chr3:136369710	T/C	cg21827317	chr3:136751795	NA	-0.44	-5.85	-0.3	1.14e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.55	-11.04	-0.51	1.96e-24	Tonsillectomy;
LIHC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.43	6.78	0.34	5.3e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.49	-9.1	-0.44	7.79e-18	Atrioventricular conduction;
LIHC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.68	-6.29	-0.32	9.66e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	1.04	13.43	0.59	2.67e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.33	6.05	0.31	3.83e-9	Aortic root size;
LIHC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.16	0.36	4.89e-12	Self-reported allergy;
LIHC	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg26395211	chr5:140044315	WDR55	-0.44	-6.56	-0.33	2.03e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.3	-7.08	-0.36	8.21e-12	Rheumatoid arthritis;
LIHC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	9.92	0.47	1.48e-20	Personality dimensions;
LIHC	cis	rs10769945	0.538	rs739906	chr11:1980568	T/C	cg23202291	chr11:1979235	NA	-0.47	-7.04	-0.36	1.07e-11	DNA methylation (variation);
LIHC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.77	12.8	0.57	6.22e-31	Psoriasis;
LIHC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.57	8.24	0.41	3.74e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07498874	chr1:110577829	FAM40A	-0.42	-6.14	-0.32	2.32e-9	Pancreatic cancer;
LIHC	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg27205649	chr11:78285834	NARS2	0.4	6.05	0.31	3.89e-9	Alzheimer's disease (survival time);
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	11.74	0.54	5.67e-27	Prudent dietary pattern;
LIHC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg13628971	chr7:2884303	GNA12	0.48	8.42	0.41	1.06e-15	Height;
LIHC	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg03934865	chr2:198174659	NA	-0.57	-9.1	-0.44	7.61e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs67981189	0.634	rs2526875	chr14:71378360	G/C	cg15816911	chr14:71606274	NA	-0.39	-6.11	-0.31	2.67e-9	Schizophrenia;
LIHC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02290350	chr8:58132656	NA	0.47	9.31	0.45	1.6e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	6.94	0.35	2.01e-11	Blood protein levels;
LIHC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03517284	chr6:25882590	NA	-0.48	-7.35	-0.37	1.48e-12	Height;
LIHC	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.67	-0.34	1.02e-10	Homocysteine levels;
LIHC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.34	-0.32	7.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg18944383	chr4:111397179	ENPEP	0.25	6.25	0.32	1.23e-9	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-9.22	-0.45	3.1e-18	Initial pursuit acceleration;
LIHC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.49	6.26	0.32	1.16e-9	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19455953	chr2:207630073	FASTKD2;MDH1B	0.4	6.47	0.33	3.43e-10	Pancreatic cancer;
LIHC	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg27523141	chr10:43048294	ZNF37B	0.37	6.51	0.33	2.74e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.15	0.32	2.15e-9	Lymphocyte counts;
LIHC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg03854865	chr6:26224070	HIST1H3E	0.64	7.12	0.36	6.24e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22509189	chr2:225307070	NA	-0.55	-6.81	-0.35	4.28e-11	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.41	-5.72	-0.3	2.33e-8	Atrial fibrillation;
LIHC	cis	rs11673344	0.730	rs1644641	chr19:37462139	A/G	cg27390819	chr19:37464633	NA	-0.53	-6.35	-0.32	6.69e-10	Obesity-related traits;
LIHC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg03037974	chr15:76606532	NA	-0.73	-14.36	-0.61	6.49e-37	Blood metabolite levels;
LIHC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.53	9.09	0.44	7.99e-18	Blood metabolite levels;
LIHC	trans	rs9513675	0.816	rs7994234	chr13:100493620	A/C	cg27600510	chr10:36137546	NA	0.22	6.08	0.31	3.24e-9	Obesity-related traits;
LIHC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.51	7.48	0.37	6.32e-13	HIV-1 control;
LIHC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	0.83	7.04	0.36	1.05e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	0.75	8.1	0.4	9.98e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs16828019	0.850	rs12027691	chr1:41462032	C/T	cg03962019	chr1:41807865	NA	0.53	7.01	0.35	1.26e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.77	0.34	5.63e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.74	9.77	0.47	4.69e-20	Eosinophilic esophagitis;
LIHC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.86	-0.39	4.94e-14	Schizophrenia;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.59	8.61	0.42	2.79e-16	Menarche (age at onset);
LIHC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	7.12	0.36	6.32e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg03785755	chr6:26196794	NA	-0.52	-5.72	-0.3	2.38e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11645453	chr3:52864694	ITIH4	-0.22	-5.79	-0.3	1.59e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.84	-12.53	-0.56	6.84e-30	IgG glycosylation;
LIHC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.84	13.46	0.59	1.96e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.41	0.56	1.96e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg07959070	chr22:50026188	C22orf34	0.3	7.77	0.39	9.07e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg11212589	chr17:38028394	ZPBP2	-0.36	-7.39	-0.37	1.11e-12	Self-reported allergy;
LIHC	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.01	0.31	4.62e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg06533319	chr4:3265114	C4orf44	-0.34	-6.53	-0.33	2.33e-10	Parental longevity (mother's age at death);
LIHC	trans	rs8117834	0.511	rs1079778	chr20:8084107	A/T	cg00593689	chr4:53575888	NA	0.38	6.5	0.33	2.77e-10	Chronic kidney disease;
LIHC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.79	-12.15	-0.55	1.83e-28	Total body bone mineral density;
LIHC	trans	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.45	-6.44	-0.33	4.11e-10	Type 2 diabetes;
LIHC	cis	rs12079745	0.590	rs76722603	chr1:169321442	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-7.08	-0.36	8.09e-12	QT interval;
LIHC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.56	-11.22	-0.52	4.28e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.32	6.59	0.34	1.67e-10	QRS complex (12-leadsum);
LIHC	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.57	9.86	0.47	2.31e-20	Dupuytren's disease;
LIHC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.07	0.55	3.38e-28	Motion sickness;
LIHC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg19006947	chr11:64034861	PLCB3	-0.46	-7.21	-0.36	3.51e-12	Body mass index;
LIHC	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg12698662	chr3:15914712	MIR563	0.36	6.81	0.35	4.5e-11	Mean platelet volume;
LIHC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.72	9.21	0.45	3.25e-18	Cognitive function;
LIHC	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-20.18	-0.74	3.41e-60	Exhaled nitric oxide output;
LIHC	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg18478394	chr8:109455254	TTC35	0.4	6.8	0.35	4.75e-11	Dupuytren's disease;
LIHC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-8.47	-0.42	7.15e-16	Gut microbiome composition (summer);
LIHC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg00343986	chr7:65444356	GUSB	-0.39	-5.81	-0.3	1.45e-8	Aortic root size;
LIHC	cis	rs9326778	0.520	rs4635977	chr5:108840166	A/T	cg17395555	chr5:108820864	NA	0.35	5.91	0.3	8.2e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	trans	rs875971	1.000	rs778694	chr7:65871558	A/G	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg07424592	chr7:64974309	NA	0.79	9.07	0.44	9.53e-18	Diabetic kidney disease;
LIHC	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg19683494	chr5:74908142	NA	0.7	7.73	0.39	1.21e-13	Coronary artery disease;
LIHC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg12310025	chr6:25882481	NA	0.41	6.13	0.31	2.44e-9	Blood metabolite levels;
LIHC	cis	rs8064024	0.650	rs3813749	chr16:4919127	T/C	cg08329684	chr16:4932620	PPL	0.35	5.97	0.31	6.02e-9	Cancer;
LIHC	cis	rs922107	0.738	rs12739453	chr1:90040287	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12145289	chr11:65385911	PCNXL3	-0.39	-6.27	-0.32	1.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Parkinson's disease;
LIHC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg23206463	chr5:561769	NA	-0.5	-8.16	-0.4	6.51e-15	Obesity-related traits;
LIHC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.44	5.74	0.3	2.09e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.52	0.38	4.82e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg18081818	chr7:23246105	NA	-0.42	-6.01	-0.31	4.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg15704280	chr7:45808275	SEPT13	0.6	6.12	0.31	2.53e-9	Axial length;
LIHC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.58	0.53	2.13e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg12903224	chr12:29470962	FAR2	-0.39	-5.99	-0.31	5.39e-9	QT interval;
LIHC	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.59	8.65	0.42	2.05e-16	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05136179	chr3:52740483	GLT8D1;SPCS1	0.47	6.21	0.32	1.58e-9	Lung function (FEV1/FVC);
LIHC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.83	0.39	6.13e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg20135002	chr11:47629003	NA	-0.56	-9.77	-0.47	4.76e-20	Subjective well-being;
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.48	0.37	6.3e-13	Renal cell carcinoma;
LIHC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.18	-0.4	5.53e-15	Total cholesterol levels;
LIHC	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.56	-13.94	-0.6	2.85e-35	White blood cell count (basophil);
LIHC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.44	7.08	0.36	8.3e-12	Melanoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10354764	chr16:3285464	ZNF200	0.4	6.47	0.33	3.31e-10	Cognitive function;
LIHC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.32	7.07	0.36	8.7e-12	Ulcerative colitis;
LIHC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-7.72	-0.39	1.28e-13	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.49	8.22	0.41	4.28e-15	Schizophrenia;
LIHC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs965469	1.000	rs6037533	chr20:3268817	T/C	cg25506879	chr20:3388711	C20orf194	-0.58	-7.06	-0.36	9.15e-12	IFN-related cytopenia;
LIHC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	1.16	14.03	0.6	1.18e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-6.22	-0.32	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg10241871	chr14:102965420	TECPR2	-0.48	-7.53	-0.38	4.65e-13	Blood protein levels;
LIHC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.57	0.46	2.18e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg05560165	chr5:133450315	TCF7	0.36	6.5	0.33	2.78e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg24130564	chr14:104152367	KLC1	0.36	5.72	0.3	2.35e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg07689907	chr11:61582574	FADS1	0.39	5.77	0.3	1.77e-8	LDL cholesterol;
LIHC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.5	7.5	0.38	5.48e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.39	6.9	0.35	2.54e-11	Height;
LIHC	cis	rs1144333	0.655	rs17097681	chr1:76376926	C/T	cg10523679	chr1:76189770	ACADM	0.44	5.88	0.3	9.62e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	0.84	9.86	0.47	2.44e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-6.79	-0.34	4.91e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12379764	chr21:47803548	PCNT	0.54	8.0	0.4	1.96e-14	Testicular germ cell tumor;
LIHC	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.73	8.53	0.42	4.78e-16	Dental caries;
LIHC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.53	-7.7	-0.38	1.51e-13	Obesity-related traits;
LIHC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg13607699	chr17:42295918	UBTF	0.77	15.73	0.65	2.48e-42	Total body bone mineral density;
LIHC	cis	rs9921222	0.542	rs9926968	chr16:381561	A/C	cg08923669	chr16:420230	MRPL28	-0.43	-5.73	-0.3	2.17e-8	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	7.0	0.35	1.34e-11	Personality dimensions;
LIHC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	1.03	20.57	0.74	8.9e-62	Breast cancer;
LIHC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.3	-16.6	-0.67	8.39e-46	Diabetic kidney disease;
LIHC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.82	7.11	0.36	6.78e-12	Arsenic metabolism;
LIHC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg21531657	chr3:10005747	TMEM111	0.39	5.76	0.3	1.86e-8	Alzheimer's disease;
LIHC	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.57	9.72	0.47	7.13e-20	Colorectal cancer;
LIHC	cis	rs8020095	0.528	rs28521373	chr14:67738075	T/C	cg03487553	chr14:67822707	ATP6V1D	-0.33	-5.71	-0.3	2.42e-8	Depression (quantitative trait);
LIHC	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg16797656	chr11:68205561	LRP5	0.47	7.93	0.39	3.17e-14	Total body bone mineral density;
LIHC	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	0.97	14.97	0.63	2.64e-39	Corneal structure;
LIHC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.54	7.59	0.38	3.09e-13	Pulse pressure;
LIHC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.16	-0.36	4.99e-12	Body mass index;
LIHC	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.46	0.42	8.18e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg23791764	chr18:32556832	MAPRE2	-0.51	-7.38	-0.37	1.21e-12	Cerebrospinal fluid AB1-42 levels;
LIHC	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg09572067	chr16:29127029	RRN3P2	0.53	8.07	0.4	1.23e-14	Menopause (age at onset);
LIHC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg00677901	chr16:88017247	BANP	0.51	7.77	0.39	9.22e-14	Menopause (age at onset);
LIHC	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.65	-0.42	2.02e-16	Schizophrenia;
LIHC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.51	-6.78	-0.34	5.16e-11	Narcolepsy;
LIHC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.44	7.78	0.39	8.74e-14	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18342900	chr16:46865048	C16orf87	0.46	6.59	0.34	1.66e-10	Pancreatic cancer;
LIHC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.55	0.56	5.46e-30	Alzheimer's disease;
LIHC	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.55	-8.5	-0.42	5.84e-16	White matter hyperintensity burden;
LIHC	cis	rs77861329	1.000	rs9815010	chr3:52196548	C/T	cg08692210	chr3:52188851	WDR51A	0.81	7.64	0.38	2.2e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.37	-6.7	-0.34	8.75e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13557139	chr1:156630023	NA	0.44	6.13	0.31	2.39e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs986417	0.901	rs10151423	chr14:60996667	A/G	cg27398547	chr14:60952738	C14orf39	0.81	9.34	0.45	1.25e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.65	12.74	0.57	1.0500000000000001e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.45	-7.32	-0.37	1.8e-12	Homoarginine levels;
LIHC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20135002	chr11:47629003	NA	0.5	8.4	0.41	1.17e-15	Subjective well-being;
LIHC	cis	rs1144333	1.000	rs5745343	chr1:76273805	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.56	-0.33	2.02e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.35	-6.19	-0.32	1.68e-9	Lewy body disease;
LIHC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.43	-6.98	-0.35	1.58e-11	Blood pressure (smoking interaction);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg22671938	chr6:21596462	SOX4	-0.44	-6.15	-0.32	2.21e-9	Migraine with aura;
LIHC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.47	-7.59	-0.38	3.15e-13	Menarche (age at onset);
LIHC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.2	0.41	4.77e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	10.01	0.48	7.45e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.41	6.07	0.31	3.42e-9	Schizophrenia;
LIHC	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.46	0.33	3.6e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13409248	chr3:40428643	ENTPD3	0.5	8.35	0.41	1.66e-15	Renal cell carcinoma;
LIHC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.92	0.3	7.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.57	-9.11	-0.44	7.26e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08957018	chr22:42487540	NDUFA6	0.39	6.17	0.32	1.93e-9	Cognitive function;
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.35	0.32	6.82e-10	Prudent dietary pattern;
LIHC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.86	-17.2	-0.68	3.23e-48	Height;
LIHC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg26441486	chr22:50317300	CRELD2	0.4	6.76	0.34	5.91e-11	Schizophrenia;
LIHC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg10820045	chr2:198174542	NA	-0.61	-10.36	-0.49	4.73e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs963731	0.649	rs77498284	chr2:39349726	C/A	cg04010122	chr2:39346883	SOS1	0.69	6.08	0.31	3.14e-9	Corticobasal degeneration;
LIHC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg17135325	chr3:160939158	NMD3	0.42	5.95	0.31	6.55e-9	Morning vs. evening chronotype;
LIHC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.49	-6.98	-0.35	1.55e-11	High light scatter reticulocyte count;
LIHC	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.5	7.83	0.39	6.34e-14	Alzheimer's disease (survival time);
LIHC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.44	6.26	0.32	1.15e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg27478167	chr7:817139	HEATR2	-0.53	-7.09	-0.36	7.51e-12	Cerebrospinal P-tau181p levels;
LIHC	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-0.98	-10.28	-0.49	8.63e-22	Mean corpuscular volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22152050	chr18:60987904	BCL2	0.45	6.18	0.32	1.83e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.65	-9.86	-0.47	2.38e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.6	8.87	0.43	4.17e-17	Breast cancer;
LIHC	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg12042659	chr19:58951599	ZNF132	0.37	6.04	0.31	4.06e-9	Uric acid clearance;
LIHC	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.75	0.34	6.52e-11	Bipolar disorder;
LIHC	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg13047869	chr3:10149882	C3orf24	0.49	6.43	0.33	4.26e-10	Alzheimer's disease;
LIHC	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.09	-0.55	2.9e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs28830936	0.966	rs3743024	chr15:42118971	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-5.97	-0.31	5.9e-9	Diastolic blood pressure;
LIHC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.89	-0.3	9.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.9	-0.35	2.6e-11	Gut microbiome composition (summer);
LIHC	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg08345082	chr10:99160200	RRP12	-0.4	-6.8	-0.35	4.57e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2997447	0.846	rs3008414	chr1:26404747	G/A	cg19633962	chr1:26362018	EXTL1	-0.62	-5.72	-0.3	2.29e-8	QRS complex (12-leadsum);
LIHC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg09779027	chr19:7224513	INSR	0.29	6.64	0.34	1.23e-10	Hypothyroidism;
LIHC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.53	7.7	0.38	1.51e-13	Height;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23144123	chr6:147828073	NA	0.37	6.16	0.32	2.04e-9	Migraine with aura;
LIHC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.86	13.05	0.58	7.33e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.97	-0.35	1.63e-11	Hepatocellular carcinoma;
LIHC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	2.97e-11	Renal cell carcinoma;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.81	12.92	0.57	2.26e-31	Longevity;
LIHC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.14	0.31	2.33e-9	Iron status biomarkers;
LIHC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.51	8.82	0.43	6.01e-17	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.94	17.56	0.69	1.21e-49	Menopause (age at onset);
LIHC	cis	rs1434579	0.652	rs2356889	chr19:44936245	A/G	cg15540054	chr19:45004280	ZNF180	0.65	9.83	0.47	3.04e-20	Tuberculosis;
LIHC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.42	6.35	0.32	6.89e-10	Post bronchodilator FEV1;
LIHC	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.62e-10	Coronary artery calcification;
LIHC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	7.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg07382826	chr16:28625726	SULT1A1	0.49	7.65	0.38	2.01e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg10820045	chr2:198174542	NA	0.46	6.9	0.35	2.59e-11	Dermatomyositis;
LIHC	cis	rs11233413	1.000	rs4944422	chr11:82715482	T/C	cg24227371	chr11:82718527	RAB30	-0.33	-7.17	-0.36	4.74e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.32	7.05	0.36	1.01e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26913058	chr16:419975	MRPL28	-0.42	-5.83	-0.3	1.27e-8	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.07	0.31	3.47e-9	Tonsillectomy;
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg24209194	chr3:40518798	ZNF619	0.56	8.15	0.4	6.98e-15	Renal cell carcinoma;
LIHC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.32e-9	Lung cancer in ever smokers;
LIHC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.75	-0.3	2e-8	Type 2 diabetes;
LIHC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.51	-7.58	-0.38	3.27e-13	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.14	0.32	2.25e-9	Diastolic blood pressure;
LIHC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.09	-0.36	7.87e-12	Bipolar disorder;
LIHC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.71	-0.5	2.89e-23	Breast cancer;
LIHC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.62	-11.84	-0.54	2.46e-27	Bone mineral density;
LIHC	cis	rs74233809	1.000	rs11191543	chr10:104824387	G/A	cg03493300	chr10:104813866	CNNM2	0.48	6.36	0.33	6.41e-10	Birth weight;
LIHC	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.38	6.77	0.34	5.52e-11	Capecitabine sensitivity;
LIHC	cis	rs4728302	0.838	rs6954700	chr7:133588739	G/A	cg10665199	chr7:133106180	EXOC4	0.36	6.31	0.32	8.4e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg09021898	chr2:174075476	ZAK	0.31	6.44	0.33	3.96e-10	Calcium levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16451430	chr20:42940032	FITM2	0.44	6.14	0.32	2.35e-9	Lung function (FEV1/FVC);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21452443	chr17:43138359	NMT1;DCAKD	-0.5	-6.23	-0.32	1.4e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02290350	chr8:58132656	NA	0.49	10.48	0.49	1.81e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg17279839	chr7:150038598	RARRES2	0.51	10.71	0.5	2.84e-23	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23182539	chr10:121355708	TIAL1	0.39	6.33	0.32	7.91e-10	Cognitive function;
LIHC	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg06598544	chr20:61472147	COL9A3	-0.88	-7.83	-0.39	6.11e-14	Obesity-related traits;
LIHC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.88	0.39	4.27e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.28	-6.06	-0.31	3.57e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16684958	chr7:75615977	POR	0.5	8.39	0.41	1.27e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.79	-11.16	-0.52	7.03e-25	Obesity-related traits;
LIHC	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg00977110	chr5:151150581	G3BP1	-0.57	-7.12	-0.36	6.25e-12	Preschool internalizing problems;
LIHC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg05973401	chr12:123451056	ABCB9	0.43	5.94	0.31	7.13e-9	Schizophrenia;
LIHC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.32	-7.21	-0.36	3.56e-12	Menarche (age at onset);
LIHC	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg26695010	chr11:65641043	EFEMP2	0.43	5.98	0.31	5.66e-9	Eosinophil percentage of white cells;
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.73	10.24	0.48	1.21e-21	Menarche (age at onset);
LIHC	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07424592	chr7:64974309	NA	-0.44	-6.63	-0.34	1.28e-10	Calcium levels;
LIHC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg10820045	chr2:198174542	NA	-0.58	-9.85	-0.47	2.55e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.55	-0.42	4.13e-16	Migraine;
LIHC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.16	-0.36	5.06e-12	Bipolar disorder;
LIHC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.51	-6.5	-0.33	2.77e-10	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs61041384	0.661	rs4148858	chr12:123540022	G/A	cg25930673	chr12:123319894	HIP1R	0.64	5.83	0.3	1.31e-8	Schizophrenia;
LIHC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg03735888	chr19:58951602	ZNF132	0.36	5.95	0.31	6.5e-9	Uric acid clearance;
LIHC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.42	6.0	0.31	5.15e-9	Osteoporosis;
LIHC	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.29	6.44	0.33	4.17e-10	Pulmonary function;
LIHC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.52	-0.46	3.19e-19	Response to antipsychotic treatment;
LIHC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg09238746	chr17:78121135	EIF4A3	-0.48	-7.21	-0.36	3.56e-12	Yeast infection;
LIHC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.58	9.41	0.45	7.54e-19	Lymphocyte counts;
LIHC	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg01557791	chr16:72042693	DHODH	-0.42	-6.17	-0.32	1.91e-9	Coronary artery disease;
LIHC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.53	7.13	0.36	5.83e-12	Coronary artery disease;
LIHC	cis	rs1712517	0.904	rs6584547	chr10:105065409	C/T	cg05636881	chr10:105038444	INA	0.45	6.96	0.35	1.72e-11	Migraine;
LIHC	cis	rs9596863	0.898	rs8000371	chr13:54344502	A/G	ch.13.53330881F	chr13:54432880	NA	0.44	5.88	0.3	9.89e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.21	-19.58	-0.73	8.44e-58	Primary sclerosing cholangitis;
LIHC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4684776	0.867	rs13081232	chr3:11342271	T/G	cg00170343	chr3:11313890	ATG7	-0.53	-7.28	-0.37	2.31e-12	Small vessel stroke;
LIHC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg04756594	chr16:24857601	SLC5A11	-0.47	-7.36	-0.37	1.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-11.94	-0.54	1.04e-27	Vitiligo;
LIHC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.41	5.78	0.3	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.15	0.32	2.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.81	0.3	1.43e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.63	7.33	0.37	1.62e-12	Body mass index;
LIHC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	1.05	15.6	0.64	8.26e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg21573476	chr21:45109991	RRP1B	0.5	9.65	0.46	1.19e-19	Mean corpuscular volume;
LIHC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.52	-8.99	-0.44	1.71e-17	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.65	7.0	0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-11.46	-0.53	5.77e-26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.21e-9	Urinary tract infection frequency;
LIHC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg16558253	chr16:72132732	DHX38	-0.42	-5.74	-0.3	2.06e-8	Fibrinogen levels;
LIHC	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-7.85	-0.39	5.35e-14	Menopause (age at onset);
LIHC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg06238570	chr21:40685208	BRWD1	0.57	6.91	0.35	2.37e-11	Cognitive function;
LIHC	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg20607798	chr8:58055168	NA	0.45	5.98	0.31	5.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.36	-0.37	1.37e-12	Body mass index;
LIHC	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-0.82	-6.38	-0.33	5.89e-10	Blood metabolite levels;
LIHC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.85	0.35	3.49e-11	Lung cancer;
LIHC	cis	rs918629	0.761	rs3777173	chr5:95281353	C/T	cg10483112	chr5:95245456	ELL2	-0.38	-6.37	-0.33	6.26e-10	IgG glycosylation;
LIHC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg18944383	chr4:111397179	ENPEP	-0.34	-7.97	-0.4	2.41e-14	Coronary artery disease;
LIHC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg00860370	chr1:104068121	RNPC3	0.42	6.41	0.33	4.92e-10	Total body bone mineral density;
LIHC	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-7.24	-0.36	2.93e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs2274273	1.000	rs10140857	chr14:55619611	G/C	cg01864836	chr14:55583639	NA	-0.35	-5.82	-0.3	1.36e-8	Protein biomarker;
LIHC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.36	-0.37	1.39e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg00934597	chr7:893267	UNC84A	0.48	5.79	0.3	1.57e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.45	-6.04	-0.31	4.02e-9	Inflammatory skin disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06656027	chr12:50016493	PRPF40B	0.44	6.26	0.32	1.16e-9	Pancreatic cancer;
LIHC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg14222432	chr12:29376421	FAR2	0.37	7.04	0.36	1.05e-11	QT interval;
LIHC	cis	rs611744	0.934	rs672591	chr8:109192453	T/A	cg21045802	chr8:109455806	TTC35	0.51	8.68	0.42	1.63e-16	Dupuytren's disease;
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg21294424	chr19:58662284	ZNF329	0.91	6.98	0.35	1.52e-11	Cholesterol, total;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.5	-7.27	-0.37	2.45e-12	Body mass index;
LIHC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.67	10.69	0.5	3.22e-23	Monocyte count;
LIHC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.99	-0.4	2.15e-14	Total body bone mineral density;
LIHC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.7	-8.45	-0.42	8.24e-16	Morning vs. evening chronotype;
LIHC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.66	13.04	0.58	7.61e-32	High light scatter reticulocyte count;
LIHC	cis	rs12744310	1.000	rs12032215	chr1:41769334	A/G	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg16479474	chr6:28041457	NA	0.46	6.52	0.33	2.53e-10	Depression;
LIHC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.78	-0.34	5.21e-11	Height;
LIHC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	9.91	0.47	1.58e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.28	6.89	0.35	2.69e-11	Primary biliary cholangitis;
LIHC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-8.45	-0.42	8.33e-16	Body mass index (adult);
LIHC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.85	12.2	0.55	1.11e-28	Post bronchodilator FEV1;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg23374814	chr5:72292757	FCHO2	0.61	6.33	0.32	7.77e-10	Mean platelet volume;
LIHC	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.34	-0.59	5.58e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.51	-0.33	2.72e-10	Blood trace element (Zn levels);
LIHC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	9.38	0.45	9.36e-19	Eosinophilic esophagitis;
LIHC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.82	9.36	0.45	1.1e-18	Vitiligo;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.62	-9.88	-0.47	2e-20	Prudent dietary pattern;
LIHC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg02640540	chr1:67518911	SLC35D1	0.41	6.42	0.33	4.48e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.43	5.9	0.3	8.52e-9	Life satisfaction;
LIHC	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13647721	chr17:30228624	UTP6	0.71	7.37	0.37	1.29e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.74e-10	Diabetic kidney disease;
LIHC	cis	rs7961581	0.748	rs6581994	chr12:71620269	T/A	cg05756094	chr12:71608604	NA	0.38	6.01	0.31	4.78e-9	Type 2 diabetes;
LIHC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02985541	chr2:219472218	PLCD4	0.44	8.09	0.4	1.08e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04612198	chr11:61880024	NA	0.44	6.07	0.31	3.32e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.69	-0.38	1.58e-13	Calcium levels;
LIHC	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.51	7.76	0.39	9.62e-14	Corneal astigmatism;
LIHC	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.43	-6.97	-0.35	1.68e-11	Lewy body disease;
LIHC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.43e-12	Obesity-related traits;
LIHC	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg01843034	chr6:37503916	NA	-0.39	-6.44	-0.33	4.15e-10	Cognitive performance;
LIHC	trans	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.23	0.32	1.34e-9	Coronary artery calcification;
LIHC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.72	13.24	0.58	1.37e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg14222432	chr12:29376421	FAR2	0.37	6.71	0.34	7.99e-11	QT interval;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.02	-23.9	-0.79	6.29e-75	Prudent dietary pattern;
LIHC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.53	6.8	0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg16586182	chr3:47516702	SCAP	-0.43	-7.51	-0.38	5.35e-13	Colorectal cancer;
LIHC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg27478167	chr7:817139	HEATR2	-0.53	-6.94	-0.35	1.93e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg05110241	chr16:68378359	PRMT7	-0.6	-6.94	-0.35	2.02e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.4	8.47	0.42	7.21e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.56	8.46	0.42	8.16e-16	Coronary artery disease;
LIHC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.72	10.9	0.51	6.07e-24	Breast cancer;
LIHC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07305463	chr2:136567211	LCT	-0.4	-7.61	-0.38	2.74e-13	Mosquito bite size;
LIHC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.43	6.78	0.34	5.45e-11	Height;
LIHC	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg20991723	chr1:152506922	NA	0.48	8.36	0.41	1.65e-15	Hair morphology;
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg13126279	chr21:47581558	C21orf56	-0.39	-6.05	-0.31	3.75e-9	Testicular germ cell tumor;
LIHC	cis	rs933688	0.509	rs7731341	chr5:90524105	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.37	-5.83	-0.3	1.27e-8	Smoking behavior;
LIHC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.21	0.41	4.55e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02290350	chr8:58132656	NA	0.47	8.61	0.42	2.81e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.82	17.09	0.68	9.37e-48	Gestational age at birth (maternal effect);
LIHC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.51	-18.48	-0.71	2.28e-53	Breast cancer;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg15848620	chr12:58087721	OS9	-0.58	-7.96	-0.4	2.5e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-6.0	-0.31	4.95e-9	Longevity;
LIHC	cis	rs9649465	0.807	rs11770249	chr7:123286412	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.18e-15	Migraine;
LIHC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.6	9.93	0.47	1.4e-20	Obesity-related traits;
LIHC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.22	-0.32	1.45e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg05425664	chr17:57184151	TRIM37	-0.46	-5.81	-0.3	1.4e-8	Vitamin D levels;
LIHC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.11	0.55	2.47e-28	Body mass index;
LIHC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.39	5.95	0.31	6.66e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.56	-6.64	-0.34	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg16479474	chr6:28041457	NA	0.38	6.24	0.32	1.29e-9	Parkinson's disease;
LIHC	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg14930904	chr10:32216787	ARHGAP12	0.34	6.03	0.31	4.17e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9467160	0.520	rs793671	chr6:24438662	C/T	cg20631270	chr6:24437470	GPLD1	-0.41	-6.09	-0.31	2.96e-9	Liver enzyme levels;
LIHC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.4	0.33	5.12e-10	Breast cancer;
LIHC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg07424592	chr7:64974309	NA	-0.8	-9.32	-0.45	1.44e-18	Diabetic kidney disease;
LIHC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg23791538	chr6:167370224	RNASET2	-0.47	-7.04	-0.36	1.05e-11	Crohn's disease;
LIHC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.22	11.53	0.53	3.24e-26	Plateletcrit;
LIHC	cis	rs3106136	0.618	rs6853674	chr4:95309190	T/C	cg11021082	chr4:95130006	SMARCAD1	0.35	5.85	0.3	1.13e-8	Capecitabine sensitivity;
LIHC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg15848620	chr12:58087721	OS9	-0.55	-7.43	-0.37	8.96e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.71	0.76	2.66e-66	Height;
LIHC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg05590025	chr7:65112418	INTS4L2	0.58	6.43	0.33	4.21e-10	Diabetic kidney disease;
LIHC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg00677901	chr16:88017247	BANP	0.53	7.82	0.39	6.76e-14	Menopause (age at onset);
LIHC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.67	-10.12	-0.48	3.1e-21	Parkinson's disease;
LIHC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.42	-6.41	-0.33	4.81e-10	Testicular germ cell tumor;
LIHC	cis	rs1144333	1.000	rs5745354	chr1:76275178	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-8.1	-0.4	9.77e-15	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	8.19	0.41	5.15e-15	Schizophrenia;
LIHC	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg04374321	chr14:90722782	PSMC1	0.74	14.02	0.6	1.37e-35	Mortality in heart failure;
LIHC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.43	7.38	0.37	1.24e-12	Aortic root size;
LIHC	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	0.91	11.62	0.53	1.51e-26	Blood protein levels;
LIHC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.99	-11.96	-0.54	8.71e-28	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.42	5.81	0.3	1.4e-8	Response to bleomycin (chromatid breaks);
LIHC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.71	-0.34	7.98e-11	Personality dimensions;
LIHC	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.67	-10.44	-0.49	2.49e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4865169	0.560	rs1277311	chr4:57902761	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	9.65	0.46	1.24e-19	Breast cancer;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs12744310	1.000	rs35529558	chr1:41767022	A/G	cg03962019	chr1:41807865	NA	0.38	6.22	0.32	1.46e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.44	6.33	0.32	7.52e-10	Aortic root size;
LIHC	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.45	7.27	0.37	2.49e-12	Corneal astigmatism;
LIHC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg03929089	chr4:120376271	NA	-0.41	-6.09	-0.31	3e-9	HDL cholesterol;
LIHC	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.0	-0.31	5.07e-9	Tuberculosis;
LIHC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg14784868	chr12:69753453	YEATS4	0.51	7.14	0.36	5.79e-12	Response to diuretic therapy;
LIHC	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.09e-10	Metabolite levels;
LIHC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg17927777	chr20:33865990	NA	0.54	6.35	0.32	6.72e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg18887096	chr2:219472410	PLCD4	-0.39	-6.88	-0.35	2.84e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.74	-7.49	-0.38	6.03e-13	Vitiligo;
LIHC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.79	9.81	0.47	3.6e-20	Body mass index;
LIHC	trans	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg17830980	chr10:43048298	ZNF37B	0.42	7.97	0.4	2.42e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs8062405	0.540	rs151226	chr16:28549823	A/C	cg00204512	chr16:28754710	NA	0.29	5.85	0.3	1.17e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	7.28	0.37	2.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg07234388	chr1:156261841	TMEM79	0.5	8.91	0.43	3e-17	Tonsillectomy;
LIHC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg15448220	chr1:150897856	SETDB1	-0.39	-6.05	-0.31	3.85e-9	Tonsillectomy;
LIHC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.56	-0.33	1.95e-10	Type 2 diabetes;
LIHC	cis	rs12744310	0.887	rs35592291	chr1:41791271	G/A	cg03962019	chr1:41807865	NA	0.38	6.09	0.31	2.99e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.44	5.71	0.3	2.41e-8	Coronary artery disease;
LIHC	cis	rs1144333	0.655	rs7418941	chr1:76436020	A/G	cg03433033	chr1:76189801	ACADM	0.55	7.82	0.39	6.64e-14	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.9	-18.13	-0.7	5.87e-52	Height;
LIHC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	1.09	12.3	0.55	5.01e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.45	0.42	8.7e-16	Lung cancer in ever smokers;
LIHC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.42	6.28	0.32	1.05e-9	Gout;
LIHC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs2455826	0.520	rs2455835	chr3:15754247	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-5.83	-0.3	1.29e-8	Inflammatory skin disease;
LIHC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.74	14.17	0.61	3.49e-36	Mortality in heart failure;
LIHC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.54	-9.08	-0.44	8.94e-18	Height;
LIHC	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.46	8.12	0.4	8.41e-15	Schizophrenia;
LIHC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.71	13.13	0.58	3.47e-32	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00628130	chr8:95908808	CCNE2	0.54	6.78	0.34	5.44e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.0	-0.31	5.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17952549	chr19:58983050	ZNF324	0.44	6.27	0.32	1.11e-9	Immature fraction of reticulocytes;
LIHC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.8	12.81	0.57	6.15e-31	Multiple sclerosis;
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.56	6.98	0.35	1.5e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	19.38	0.72	5.7e-57	Nonalcoholic fatty liver disease;
LIHC	cis	rs2834256	0.961	rs2251854	chr21:35056247	A/G	cg14850771	chr21:34775459	IFNGR2	0.39	6.1	0.31	2.85e-9	Red cell distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05889321	chr10:97416837	ALDH18A1	0.47	6.89	0.35	2.68e-11	Pancreatic cancer;
LIHC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.65	12.82	0.57	5.39e-31	Menopause (age at onset);
LIHC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg02269571	chr22:50332266	NA	0.61	8.63	0.42	2.37e-16	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.26e-51	Menopause (age at onset);
LIHC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.34	-0.45	1.29e-18	Bipolar disorder;
LIHC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.74	12.55	0.56	5.46e-30	Aortic root size;
LIHC	cis	rs67981189	0.593	rs7144986	chr14:71473431	C/T	cg15816911	chr14:71606274	NA	0.39	6.21	0.32	1.54e-9	Schizophrenia;
LIHC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.54	7.59	0.38	3e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.35	-7.43	-0.37	8.48e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18252515	chr7:66147081	NA	0.45	6.4	0.33	5.18e-10	Aortic root size;
LIHC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.58	-8.09	-0.4	1.03e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	8.63	0.42	2.33e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20307385	chr11:47447363	PSMC3	-0.45	-5.84	-0.3	1.21e-8	Subjective well-being;
LIHC	trans	rs2363709	1.000	rs2363714	chr3:67421846	C/G	cg13681781	chr9:139102396	QSOX2	-0.81	-6.33	-0.32	7.66e-10	IgE levels;
LIHC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.9	0.39	3.92e-14	Triglyceride levels;
LIHC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.6	-0.34	1.61e-10	Fibrinogen levels;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.53	-7.38	-0.37	1.24e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17507749	chr15:85114479	UBE2QP1	0.75	8.88	0.43	3.72e-17	Schizophrenia;
LIHC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.84	0.39	5.61e-14	Schizophrenia;
LIHC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg12798992	chr6:167411361	FGFR1OP	0.49	7.21	0.36	3.58e-12	Crohn's disease;
LIHC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.97	13.1	0.58	4.65e-32	Heart rate;
LIHC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.66	8.19	0.4	5.24e-15	Mean platelet volume;
LIHC	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.63	-12.17	-0.55	1.54e-28	Neurofibrillary tangles;
LIHC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.52	-0.38	4.91e-13	Psoriasis;
LIHC	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg13395646	chr4:1353034	KIAA1530	0.42	6.57	0.33	1.83e-10	Obesity-related traits;
LIHC	trans	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg26939375	chr7:64535504	NA	0.4	6.27	0.32	1.06e-9	Aortic root size;
LIHC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.36	-6.08	-0.31	3.12e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3736485	0.966	rs11070855	chr15:51850283	C/T	cg08986416	chr15:51914746	DMXL2	-0.41	-6.07	-0.31	3.49e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.55	8.65	0.42	2e-16	Height;
LIHC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.89	-15.04	-0.63	1.38e-39	Chronic sinus infection;
LIHC	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.32	7.75	0.39	1.05e-13	Weight;
LIHC	trans	rs9641123	0.639	rs2528536	chr7:93245923	G/A	cg09745688	chr16:2908918	PRSS22	-0.36	-6.34	-0.32	7.07e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.36	0.33	6.52e-10	Schizophrenia;
LIHC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-10.74	-0.5	2.25e-23	Lung cancer in ever smokers;
LIHC	trans	rs7668874	0.731	rs9784551	chr4:116743086	C/T	cg08917878	chr5:172668965	NA	-0.31	-6.15	-0.32	2.12e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26897989	chr16:1907736	C16orf73	-0.49	-6.14	-0.32	2.25e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-8.97	-0.44	1.99e-17	Chronic sinus infection;
LIHC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17554472	chr22:41940697	POLR3H	0.54	5.8	0.3	1.48e-8	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.67	-11.05	-0.51	1.77e-24	Inflammatory bowel disease;
LIHC	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.4	5.77	0.3	1.75e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	1.01	16.7	0.67	3.3e-46	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.57	9.05	0.44	1.08e-17	HDL cholesterol;
LIHC	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.26	0.37	2.63e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg18944383	chr4:111397179	ENPEP	0.26	6.29	0.32	9.97e-10	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13495574	chr1:173793781	CENPL;DARS2	0.41	6.15	0.32	2.14e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.13	-0.31	2.41e-9	Alzheimer's disease (late onset);
LIHC	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.45	-0.37	7.93e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.35	6.38	0.33	5.9e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.88	-13.22	-0.58	1.69e-32	Sudden cardiac arrest;
LIHC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.16	-0.44	4.85e-18	Schizophrenia;
LIHC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.89	-16.42	-0.66	4.39e-45	Lung cancer in ever smokers;
LIHC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.25	-5.76	-0.3	1.92e-8	Subjective well-being;
LIHC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.76	-12.73	-0.57	1.14e-30	Aortic root size;
LIHC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-11.09	-0.51	1.23e-24	Chronic sinus infection;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00570391	chr7:815417	HEATR2	0.43	6.39	0.33	5.47e-10	Bilirubin levels;
LIHC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg00647820	chr17:40259828	DHX58	-0.28	-5.91	-0.3	8.35e-9	Fibrinogen levels;
LIHC	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg14132834	chr19:41945861	ATP5SL	0.45	6.61	0.34	1.5e-10	Height;
LIHC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12516959	chr21:47718080	NA	0.4	6.53	0.33	2.39e-10	Testicular germ cell tumor;
LIHC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.43	6.47	0.33	3.33e-10	Mean platelet volume;
LIHC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg12365402	chr11:9010492	NRIP3	0.32	8.35	0.41	1.71e-15	Tonsillectomy;
LIHC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.74	-8.03	-0.4	1.61e-14	Putamen volume;
LIHC	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.01	-0.35	1.28e-11	Inflammatory bowel disease;
LIHC	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.78	-8.19	-0.4	5.25e-15	Putamen volume;
LIHC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg09177884	chr7:1199841	ZFAND2A	0.5	5.9	0.3	8.74e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs17428076	0.836	rs12053046	chr2:172673399	A/G	cg13550731	chr2:172543902	DYNC1I2	0.39	6.36	0.33	6.51e-10	Myopia;
LIHC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-14.45	-0.62	2.76e-37	Height;
LIHC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.36	0.37	1.42e-12	Lymphocyte counts;
LIHC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg12661370	chr5:149340060	SLC26A2	0.5	6.06	0.31	3.58e-9	HIV-1 control;
LIHC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01200585	chr1:228362443	C1orf69	-0.39	-5.85	-0.3	1.17e-8	Diastolic blood pressure;
LIHC	trans	rs28735056	0.584	rs11664834	chr18:77644876	G/T	cg05926928	chr17:57297772	GDPD1	0.69	8.66	0.42	1.83e-16	Schizophrenia;
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg00091569	chr3:40428383	ENTPD3	0.36	6.0	0.31	4.92e-9	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.85	0.35	3.4e-11	Renal cell carcinoma;
LIHC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg12863693	chr15:85201151	NMB	0.41	5.77	0.3	1.77e-8	Schizophrenia;
LIHC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg27490568	chr2:178487706	NA	0.7	9.37	0.45	1.04e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.57	-6.5	-0.33	2.77e-10	Opioid sensitivity;
LIHC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.89	-0.51	6.7e-24	Platelet count;
LIHC	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	5.93	0.31	7.53e-9	Parkinson's disease;
LIHC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.77	8.73	0.43	1.16e-16	LDL cholesterol;
LIHC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg10820045	chr2:198174542	NA	-0.48	-7.4	-0.37	1.04e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg25124228	chr12:125621409	AACS	-0.47	-8.02	-0.4	1.69e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7116495	1.000	rs635701	chr11:71554921	A/G	cg26138937	chr11:71823887	C11orf51	0.64	5.88	0.3	9.52e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.34	8.83	0.43	5.49e-17	Schizophrenia;
LIHC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg12863693	chr15:85201151	NMB	0.44	6.31	0.32	8.81e-10	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg20016023	chr10:99160130	RRP12	-0.43	-7.06	-0.36	9.6e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-15.1	-0.63	7.88e-40	Height;
LIHC	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.09	-0.31	3.04e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3018712	0.532	rs7116363	chr11:68412798	G/A	cg16797656	chr11:68205561	LRP5	-0.46	-6.04	-0.31	4.09e-9	Total body bone mineral density;
LIHC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg15269541	chr15:43626905	ADAL	-0.3	-5.88	-0.3	9.76e-9	Lung cancer in ever smokers;
LIHC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg03959625	chr15:84868606	LOC388152	0.43	5.9	0.3	8.86e-9	Schizophrenia;
LIHC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs4908760	0.759	rs6577514	chr1:8712743	T/G	cg20416874	chr1:8611966	RERE	-0.63	-12.8	-0.57	6.2e-31	Vitiligo;
LIHC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.67	9.4	0.45	7.91e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.4	-6.29	-0.32	9.82e-10	Dementia with Lewy bodies;
LIHC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg22676075	chr6:135203613	NA	0.39	6.37	0.33	6.26e-10	Red blood cell count;
LIHC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4788570	0.585	rs7499576	chr16:71789553	T/G	cg06353428	chr16:71660113	MARVELD3	1.38	14.61	0.62	6.57e-38	Intelligence (multi-trait analysis);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24093715	chr4:47983620	CNGA1	0.33	6.12	0.31	2.49e-9	Hepatitis;
LIHC	cis	rs918629	0.530	rs9314162	chr5:95252594	C/A	cg10483112	chr5:95245456	ELL2	-0.38	-7.0	-0.35	1.37e-11	IgG glycosylation;
LIHC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-7.58	-0.38	3.22e-13	Cognitive function;
LIHC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Obesity-related traits;
LIHC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.96	17.24	0.68	2.29e-48	Breast cancer;
LIHC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.26	-6.47	-0.33	3.42e-10	Mean corpuscular volume;
LIHC	cis	rs61677309	0.558	rs4245179	chr11:118144445	A/G	cg06090739	chr11:118230722	UBE4A	0.32	6.03	0.31	4.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.57	-0.5	8.92e-23	Chronic sinus infection;
LIHC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.36	-6.28	-0.32	1.05e-9	HIV-1 susceptibility;
LIHC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.87	-0.3	1.05e-8	Vitiligo;
LIHC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg12798992	chr6:167411361	FGFR1OP	0.59	9.73	0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.59	-8.59	-0.42	3.24e-16	Menarche (age at onset);
LIHC	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.29	-12.34	-0.55	3.55e-29	Psoriasis vulgaris;
LIHC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.59e-9	Life satisfaction;
LIHC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-1.02	-13.53	-0.59	1.1e-33	Intelligence (multi-trait analysis);
LIHC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.37	-6.23	-0.32	1.34e-9	Educational attainment;
LIHC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg20487152	chr13:99095054	FARP1	-0.38	-6.21	-0.32	1.5e-9	Longevity;
LIHC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.14	11.65	0.53	1.23e-26	Opioid sensitivity;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg07002622	chr6:118822466	C6orf204;BRD7P3	-0.57	-6.22	-0.32	1.49e-9	Diastolic blood pressure;
LIHC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.96	0.31	6.14e-9	Birth weight;
LIHC	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.45	0.37	7.93e-13	Neuroticism;
LIHC	trans	rs950169	0.649	rs12901010	chr15:84699034	G/A	cg24036039	chr1:3397125	ARHGEF16	0.39	6.21	0.32	1.57e-9	Schizophrenia;
LIHC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	11.25	0.52	3.29e-25	Lung cancer in ever smokers;
LIHC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.65	-9.27	-0.45	2.15e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg05110241	chr16:68378359	PRMT7	-0.63	-6.85	-0.35	3.34e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-5.74	-0.3	2.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.55	6.46	0.33	3.62e-10	Mammographic density (dense area);
LIHC	cis	rs10857712	0.521	rs10857714	chr10:135235370	C/A	cg01444801	chr10:135216882	MTG1	-0.52	-8.46	-0.42	7.93e-16	Systemic lupus erythematosus;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22772771	chr6:159420466	RSPH3	0.48	6.96	0.35	1.77e-11	Cognitive function;
LIHC	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.03	0.31	4.28e-9	Morning vs. evening chronotype;
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg07341007	chr3:195489909	MUC4	0.45	8.0	0.4	1.96e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.73	-0.3	2.19e-8	Neuroticism;
LIHC	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg06835404	chr16:988973	LMF1	0.43	7.95	0.39	2.74e-14	Non-glioblastoma glioma;Glioblastoma;Glioma;
LIHC	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.31	-0.32	8.85e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.49	7.38	0.37	1.18e-12	Mortality in heart failure;
LIHC	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.01	0.35	1.27e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.68	7.32	0.37	1.8e-12	Exhaled nitric oxide output;
LIHC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.47	7.14	0.36	5.54e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg18898632	chr2:242989856	NA	-0.57	-7.68	-0.38	1.66e-13	Obesity-related traits;
LIHC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.56	-9.09	-0.44	8.38e-18	Obesity-related traits;
LIHC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.21	-0.41	4.71e-15	Vitamin D levels;
LIHC	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.53	-7.12	-0.36	6.52e-12	Coronary artery disease;
LIHC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	0.74	13.05	0.58	7.03e-32	Testicular germ cell tumor;
LIHC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg08499158	chr17:42289980	UBTF	0.54	9.6	0.46	1.78e-19	Total body bone mineral density;
LIHC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.83	0.39	6.12e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs831571	1.000	rs17069791	chr3:64052279	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.58	-6.34	-0.32	7.18e-10	Type 2 diabetes;
LIHC	cis	rs7534824	0.625	rs61780288	chr1:101389945	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	6.9	0.35	2.61e-11	Refractive astigmatism;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg14709524	chr16:89940631	TCF25	0.54	7.17	0.36	4.57e-12	Skin colour saturation;
LIHC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.47	8.18	0.4	5.69e-15	IgG glycosylation;
LIHC	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.22	-12.51	-0.56	7.75e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-20.64	-0.74	4.98e-62	Coronary artery disease;
LIHC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.43	0.41	1.01e-15	Lung cancer in ever smokers;
LIHC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.87	14.35	0.61	6.76e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg06238570	chr21:40685208	BRWD1	-0.55	-6.73	-0.34	7.16e-11	Cognitive function;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11060661	chr22:24314208	DDT;DDTL	-0.57	-10.02	-0.48	6.65e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg21486233	chr12:29375141	FAR2	0.3	5.96	0.31	6.42e-9	QT interval;
LIHC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.71	-0.34	7.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.39	-0.37	1.12e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	-0.61	-8.95	-0.44	2.25e-17	Prudent dietary pattern;
LIHC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.54	-0.38	4.16e-13	Bipolar disorder;
LIHC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.46	8.19	0.4	5.38e-15	IgG glycosylation;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.42	0.56	1.71e-29	Prudent dietary pattern;
LIHC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.38	6.12	0.31	2.63e-9	Menopause (age at onset);
LIHC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg23791538	chr6:167370224	RNASET2	0.45	7.52	0.38	5.03e-13	Crohn's disease;
LIHC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.88	0.54	1.75e-27	Alzheimer's disease;
LIHC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.28	0.41	2.77e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22601191	chr20:60968625	CABLES2	0.45	5.81	0.3	1.4e-8	Colorectal cancer;
LIHC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.67	11.39	0.52	1.08e-25	Coronary artery disease;
LIHC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.22	5.72	0.3	2.36e-8	Calcium levels;
LIHC	trans	rs9350100	0.806	rs9477970	chr6:19082663	T/A	cg18972584	chr15:25476056	SNORD115-15;SNORD115-21;SNORD115-33;SNORD115-34	0.32	6.09	0.31	3.05e-9	Age at voice drop;
LIHC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.85	10.81	0.5	1.31e-23	Cognitive function;
LIHC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.45	0.33	3.91e-10	Alzheimer's disease;
LIHC	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg19743168	chr1:23544995	NA	0.38	7.1	0.36	7.17e-12	Height;
LIHC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.61	-11.58	-0.53	2.16e-26	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.22	0.32	1.47e-9	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10974104	chr11:119076790	CBL	-0.42	-6.28	-0.32	1.01e-9	Pancreatic cancer;
LIHC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.98	-17.73	-0.69	2.34e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.4	-9.11	-0.44	6.87e-18	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-8.76	-0.43	9.2e-17	Neuroticism;
LIHC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.51	-7.25	-0.36	2.88e-12	Red cell distribution width;
LIHC	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg08917208	chr2:24149416	ATAD2B	0.86	7.79	0.39	7.84e-14	Lymphocyte counts;
LIHC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.67	-10.84	-0.51	9.69e-24	Schizophrenia;
LIHC	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg18306943	chr3:40428807	ENTPD3	0.39	6.44	0.33	4.02e-10	Renal cell carcinoma;
LIHC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.73	-0.3	2.15e-8	Uric acid levels;
LIHC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.91	-0.3	8.49e-9	Systemic lupus erythematosus;
LIHC	cis	rs2334880	0.678	rs12919092	chr16:71446490	T/C	cg06353428	chr16:71660113	MARVELD3	-0.88	-8.03	-0.4	1.62e-14	Malaria;
LIHC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.85	0.35	3.49e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.74	11.17	0.52	6.34e-25	Vitamin D levels;
LIHC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.41	6.31	0.32	8.62e-10	Educational attainment;
LIHC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.85	0.3	1.16e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.64	-8.72	-0.43	1.22e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.44	8.08	0.4	1.11e-14	Prudent dietary pattern;
LIHC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.18	0.36	4.32e-12	Height;
LIHC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.68	-0.42	1.68e-16	Gut microbiome composition (summer);
LIHC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.37	-0.52	1.23e-25	Primary sclerosing cholangitis;
LIHC	cis	rs7635838	0.892	rs12163566	chr3:11483096	T/A	cg00170343	chr3:11313890	ATG7	0.42	6.61	0.34	1.45e-10	HDL cholesterol;
LIHC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	8.23	0.41	3.95e-15	Cognitive ability;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25506325	chr7:2093962	MAD1L1	-0.41	-6.24	-0.32	1.32e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.13	0.55	2e-28	Prudent dietary pattern;
LIHC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.51	6.1	0.31	2.89e-9	Menarche (age at onset);
LIHC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-6.33	-0.32	7.61e-10	Dental caries;
LIHC	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg00647820	chr17:40259828	DHX58	-0.29	-6.16	-0.32	2.08e-9	Fibrinogen levels;
LIHC	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg26395211	chr5:140044315	WDR55	0.38	5.74	0.3	2.08e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.15	-0.32	2.22e-9	Aortic root size;
LIHC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg04310649	chr10:35416472	CREM	-0.42	-5.78	-0.3	1.65e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg06466757	chr4:1255808	NA	0.34	5.75	0.3	2e-8	Obesity-related traits;
LIHC	cis	rs9628987	0.500	rs12079653	chr1:8430594	C/A	cg20416874	chr1:8611966	RERE	0.5	5.82	0.3	1.33e-8	Breast cancer;
LIHC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.53	5.84	0.3	1.23e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.41	5.84	0.3	1.19e-8	Cognitive ability;
LIHC	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.01	-0.4	1.84e-14	Response to antipsychotic treatment;
LIHC	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.15	-0.32	2.11e-9	Ulcerative colitis;
LIHC	trans	rs7714584	1.000	rs2344180	chr5:150267357	T/A	cg20675040	chr8:143813288	C8orf55	0.33	6.07	0.31	3.46e-9	Crohn's disease;
LIHC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.71	11.25	0.52	3.29e-25	Corneal astigmatism;
LIHC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg14067834	chr17:29058358	SUZ12P	0.65	6.78	0.34	5.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08677398	chr8:58056175	NA	-0.41	-6.31	-0.32	8.8e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.65	0.42	1.97e-16	Lymphocyte counts;
LIHC	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.54	-9.53	-0.46	3.04e-19	Systemic lupus erythematosus;
LIHC	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.79	15.33	0.64	9.8e-41	Testicular germ cell tumor;
LIHC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.61	-0.34	1.45e-10	Height;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	9.41	0.45	7.5e-19	Lymphocyte counts;
LIHC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.73	0.3	2.16e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.53	9.36	0.45	1.07e-18	Breast cancer;
LIHC	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.36	-6.27	-0.32	1.11e-9	Endometriosis;
LIHC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg03689076	chr20:33865952	NA	0.54	6.37	0.33	6.12e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.81	-0.3	1.46e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs61677309	0.964	rs55798741	chr11:118154114	G/T	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.68	12.4	0.56	2.1e-29	Schizophrenia;
LIHC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg04610667	chr7:75704037	NA	-0.34	-6.17	-0.32	1.91e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.65	6.58	0.34	1.75e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.98e-10	Personality dimensions;
LIHC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.51	7.96	0.4	2.56e-14	Type 2 diabetes;
LIHC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.28	-17.02	-0.68	1.74e-47	Diabetic kidney disease;
LIHC	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg15192750	chr16:69999425	NA	-0.45	-6.73	-0.34	7.09e-11	IgE levels;
LIHC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.53	-0.33	2.32e-10	Renal cell carcinoma;
LIHC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.45	-6.0	-0.31	5.02e-9	Lung cancer (smoking interaction);
LIHC	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.36	5.97	0.31	5.83e-9	Homoarginine levels;
LIHC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.42	-9.49	-0.46	4.1e-19	Arsenic metabolism;
LIHC	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	0.6	10.34	0.49	5.38e-22	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg21531657	chr3:10005747	TMEM111	0.39	5.76	0.3	1.92e-8	Alzheimer's disease;
LIHC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg27572855	chr1:25598939	RHD	0.43	9.66	0.46	1.11e-19	Erythrocyte sedimentation rate;
LIHC	cis	rs1000083	0.666	rs2697598	chr5:96633928	C/T	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs7923837	0.713	rs10882099	chr10:94460650	T/C	cg25506282	chr10:94462361	NA	0.38	6.76	0.34	6.14e-11	Body mass index;Multiple sclerosis;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1789	0.903	rs6850422	chr4:15682437	C/T	cg16509355	chr4:15471240	CC2D2A	-0.46	-6.94	-0.35	1.99e-11	Blood protein levels;
LIHC	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg10820045	chr2:198174542	NA	0.41	6.03	0.31	4.23e-9	Dermatomyositis;
LIHC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.94	0.39	2.89e-14	Morning vs. evening chronotype;
LIHC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-8.39	-0.41	1.29e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.83	0.39	6.05e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs4714291	0.963	rs847759	chr6:40024483	G/A	cg02267698	chr19:7991119	CTXN1	0.39	6.21	0.32	1.56e-9	Strep throat;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08280861	chr8:58055591	NA	0.51	6.39	0.33	5.56e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg16684958	chr7:75615977	POR	0.52	8.57	0.42	3.5e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg10755058	chr3:40428713	ENTPD3	0.41	6.92	0.35	2.29e-11	Renal cell carcinoma;
LIHC	cis	rs332507	0.830	rs3772787	chr3:124395368	G/C	cg05980111	chr3:124395277	KALRN	0.45	6.72	0.34	7.51e-11	Plateletcrit;
LIHC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.66	0.34	1.08e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.33	0.32	7.89e-10	Response to antipsychotic treatment;
LIHC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.36e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10792665	0.512	rs7928466	chr11:82596733	T/G	cg24227371	chr11:82718527	RAB30	-0.28	-6.59	-0.34	1.68e-10	Obesity-related traits;
LIHC	trans	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg05791018	chr13:19965014	NA	-0.3	-6.57	-0.33	1.86e-10	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.46	-0.37	7.34e-13	Response to antipsychotic treatment;
LIHC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.6	0.46	1.76e-19	Bipolar disorder;
LIHC	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.53	-8.08	-0.4	1.14e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg19752551	chr11:57585705	CTNND1	-0.46	-6.37	-0.33	6.21e-10	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.47	-12.07	-0.55	3.44e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg13047869	chr3:10149882	C3orf24	0.5	6.12	0.31	2.62e-9	Alzheimer's disease;
LIHC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.6	10.67	0.5	3.87e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.09	0.31	2.96e-9	Prudent dietary pattern;
LIHC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.96	-0.44	2.07e-17	Heart rate;
LIHC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.91	-16.95	-0.68	3.19e-47	Aortic root size;
LIHC	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.77	-14.18	-0.61	3.16e-36	Longevity;
LIHC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.44	-6.71	-0.34	8.23e-11	Height;
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.23	-0.32	1.38e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04721582	chr2:178257292	LOC100130691;AGPS	0.45	6.25	0.32	1.19e-9	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05320259	chr20:25370897	ABHD12	0.44	6.54	0.33	2.25e-10	Pancreatic cancer;
LIHC	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20887711	chr4:1340912	KIAA1530	0.78	12.0	0.54	6.26e-28	Longevity;
LIHC	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg26939375	chr7:64535504	NA	0.43	6.83	0.35	3.81e-11	Aortic root size;
LIHC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg14580859	chr9:123691850	NA	-0.37	-6.55	-0.33	2.14e-10	Rheumatoid arthritis;
LIHC	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.91	0.3	8.09e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs943466	1.000	rs943462	chr6:33769578	G/A	cg25922239	chr6:33757077	LEMD2	-0.5	-6.41	-0.33	4.91e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.42	-6.13	-0.31	2.42e-9	Cognitive ability;
LIHC	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg01864836	chr14:55583639	NA	-0.37	-6.68	-0.34	9.57e-11	Protein biomarker;
LIHC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.39	-0.45	8.43e-19	Mean platelet volume;
LIHC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.85	0.47	2.57e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs3812111	0.774	rs564980	chr6:116424653	C/T	cg08036074	chr6:116424633	NT5DC1	0.66	12.08	0.55	3.11e-28	Age-related macular degeneration;
LIHC	cis	rs2280630	0.505	rs2249736	chr3:39195462	G/T	cg02254461	chr3:39195904	CSRNP1	-0.32	-5.89	-0.3	9.24e-9	Verbal declarative memory;
LIHC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.4	0.45	8.18e-19	Platelet count;
LIHC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.09	0.4	1.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.56	5.92	0.3	7.86e-9	IgG glycosylation;
LIHC	cis	rs787274	1.000	rs787274	chr9:115550363	A/C	cg13803584	chr9:115635662	SNX30	-0.59	-6.39	-0.33	5.54e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg14930904	chr10:32216787	ARHGAP12	0.35	5.99	0.31	5.46e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.9	13.21	0.58	1.73e-32	Sudden cardiac arrest;
LIHC	cis	rs17428076	0.831	rs55957712	chr2:172587956	C/T	cg13550731	chr2:172543902	DYNC1I2	0.38	6.21	0.32	1.54e-9	Myopia;
LIHC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.58	7.45	0.37	7.88e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs10065203	0.527	rs152177	chr5:14354270	G/A	cg26595256	chr5:14380529	TRIO	-0.43	-6.46	-0.33	3.55e-10	Paclitaxel-induced neuropathy;
LIHC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	12.39	0.56	2.21e-29	Alzheimer's disease;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13580526	chr8:37553077	ZNF703	-0.45	-6.24	-0.32	1.32e-9	Bilirubin levels;
LIHC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.85	-12.9	-0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	6.09	0.31	2.99e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.64	-9.3	-0.45	1.7e-18	Skin colour saturation;
LIHC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg16736954	chr20:23401023	NAPB	0.72	8.46	0.42	7.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs12744310	0.887	rs2363810	chr1:41783873	C/T	cg03962019	chr1:41807865	NA	0.38	6.12	0.31	2.59e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.47	7.72	0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg25930673	chr12:123319894	HIP1R	-0.81	-9.36	-0.45	1.08e-18	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.45	7.36	0.37	1.36e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.33	5.97	0.31	6.1e-9	Aortic root size;
LIHC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.42	6.12	0.31	2.58e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05523500	chr3:73046033	PPP4R2	0.35	6.11	0.31	2.74e-9	Electrocardiographic conduction measures;
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs911119	0.908	rs6048950	chr20:23603252	A/G	cg16589663	chr20:23618590	CST3	0.75	7.89	0.39	4.1e-14	Chronic kidney disease;
LIHC	cis	rs11958404	0.517	rs17680818	chr5:157248548	T/A	cg05962755	chr5:157440814	NA	0.67	6.76	0.34	5.96e-11	IgG glycosylation;
LIHC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.94	14.48	0.62	2.22e-37	Skin colour saturation;
LIHC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.9	-0.63	4.72e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.19	0.36	4.19e-12	Axial length;
LIHC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.05	-0.31	3.85e-9	Mean corpuscular volume;
LIHC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.13	-0.31	2.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg05272587	chr13:111038400	COL4A2	-0.36	-7.5	-0.38	5.7e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.61	0.38	2.72e-13	Prudent dietary pattern;
LIHC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.5	6.2	0.32	1.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.35	-7.61	-0.38	2.64e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.89	-17.53	-0.69	1.56e-49	Height;
LIHC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.43e-11	Height;
LIHC	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	0.87	5.97	0.31	6.1e-9	Mitochondrial DNA levels;
LIHC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg16576597	chr16:28551801	NUPR1	0.37	5.83	0.3	1.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.44	0.45	5.75e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.26	-5.95	-0.31	6.67e-9	Menarche (age at onset);
LIHC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	6.87	0.35	3.13e-11	Bone mineral density;
LIHC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.41	6.5	0.33	2.9e-10	Red blood cell count;
LIHC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.62	9.15	0.44	5.21e-18	Alzheimer's disease;
LIHC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.43	-8.22	-0.41	4.4e-15	Neurofibrillary tangles;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20831041	chr11:464554	PTDSS2	0.44	6.67	0.34	1.06e-10	Bilirubin levels;
LIHC	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.73	-10.96	-0.51	3.67e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.32	-8.25	-0.41	3.55e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs243505	0.732	rs10255478	chr7:148501985	C/G	cg09806900	chr7:148480153	CUL1	0.44	6.52	0.33	2.48e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg03264133	chr6:25882463	NA	0.41	6.02	0.31	4.51e-9	Blood metabolite levels;
LIHC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.43	8.11	0.4	8.99e-15	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.63	9.32	0.45	1.52e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.66	10.9	0.51	6.27e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.46	-7.9	-0.39	3.82e-14	Lung cancer;
LIHC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.87	-0.51	7.74e-24	Chronic sinus infection;
LIHC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg06199346	chr11:14280333	SPON1	0.34	5.76	0.3	1.85e-8	Mitochondrial DNA levels;
LIHC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.04	0.31	4.02e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg07061783	chr6:25882402	NA	-0.5	-6.41	-0.33	4.71e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.3	-6.73	-0.34	7.39e-11	DNA methylation (variation);
LIHC	cis	rs7635838	0.892	rs9310384	chr3:11491980	A/G	cg00170343	chr3:11313890	ATG7	0.42	6.7	0.34	8.68e-11	HDL cholesterol;
LIHC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.31	-6.14	-0.32	2.24e-9	Colorectal cancer;
LIHC	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.38	-0.45	9.54e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Coronary artery disease;
LIHC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	11.2	0.52	4.97e-25	Type 2 diabetes;
LIHC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.52	0.49	1.28e-22	Total body bone mineral density;
LIHC	cis	rs1400745	0.718	rs799681	chr14:35350579	A/G	cg05294307	chr14:35346193	BAZ1A	-0.45	-7.45	-0.37	7.57e-13	Monocyte count;
LIHC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg03959625	chr15:84868606	LOC388152	0.46	6.65	0.34	1.14e-10	Schizophrenia;
LIHC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.54	7.85	0.39	5.47e-14	Type 2 diabetes;
LIHC	trans	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg17675199	chr6:35436792	RPL10A	-0.44	-9.19	-0.45	3.88e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.62	0.59	4.65e-34	Diabetic kidney disease;
LIHC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.7	-13.03	-0.58	8.42e-32	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00958927	chr1:175162553	KIAA0040	0.39	6.75	0.34	6.39e-11	Alcohol dependence;
LIHC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.49	9.07	0.44	9.82e-18	Hemoglobin concentration;
LIHC	cis	rs3780378	1.000	rs3780378	chr9:5112288	C/T	cg02405213	chr9:5042618	JAK2	-0.43	-7.54	-0.38	4.15e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg07862535	chr7:139043722	LUC7L2	-0.58	-10.06	-0.48	5.01e-21	Diisocyanate-induced asthma;
LIHC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.41	7.06	0.36	9.05e-12	Aortic root size;
LIHC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.49	7.76	0.39	9.79e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg04013166	chr16:89971882	TCF25	0.5	6.13	0.31	2.39e-9	Skin colour saturation;
LIHC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.67	10.26	0.49	1e-21	Height;
LIHC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10150615	chr22:24372951	LOC391322	-0.63	-9.39	-0.45	8.72e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.08	-0.31	3.28e-9	Colorectal cancer;
LIHC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.8	0.3	1.53e-8	Bladder cancer;
LIHC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.15	0.44	5.14e-18	Bipolar disorder;
LIHC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.54	9.77	0.47	4.95e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7116495	1.000	rs73543633	chr11:71828844	T/C	cg26138937	chr11:71823887	C11orf51	0.82	8.33	0.41	2.03e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7944735	0.568	rs59631865	chr11:47501619	T/G	cg20307385	chr11:47447363	PSMC3	-0.56	-6.36	-0.33	6.34e-10	Intraocular pressure;
LIHC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.5	-7.26	-0.37	2.6e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.33	0.52	1.77e-25	Alzheimer's disease (late onset);
LIHC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.27	-7.13	-0.36	6.08e-12	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.27	0.41	3.06e-15	Corneal astigmatism;
LIHC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	6.69	0.34	9.09e-11	Osteoporosis;
LIHC	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.64	-7.36	-0.37	1.38e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.69	12.26	0.55	6.81e-29	Iron status biomarkers;
LIHC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.59	0.59	6.27e-34	Lung cancer in ever smokers;
LIHC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.86	-0.3	1.07e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.42	7.29	0.37	2.17e-12	Aortic root size;
LIHC	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.91e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04530015	chr2:215796436	ABCA12	0.39	6.34	0.32	7.23e-10	Neuroblastoma;
LIHC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.06	0.31	3.57e-9	HDL cholesterol;
LIHC	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.38	-0.45	9.54e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.71	10.58	0.5	8.11e-23	Aortic root size;
LIHC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.57	6.4	0.33	5.1e-10	Eosinophil percentage of granulocytes;
LIHC	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.21	-0.32	1.5e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs57502260	0.915	rs7106320	chr11:68210118	C/T	cg16797656	chr11:68205561	LRP5	0.62	8.35	0.41	1.75e-15	Total body bone mineral density (age 45-60);
LIHC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	7.15	0.36	5.41e-12	Protein C levels;
LIHC	cis	rs9921222	0.692	rs11860497	chr16:405416	A/G	cg00101154	chr16:420108	MRPL28	-0.47	-7.24	-0.36	2.93e-12	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-8.1	-0.4	9.53e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.89	-14.18	-0.61	3.26e-36	Metabolic syndrome;
LIHC	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg26139080	chr11:47293733	MADD	-0.5	-8.45	-0.42	8.46e-16	HDL cholesterol;
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.68	9.31	0.45	1.58e-18	Calcium levels;
LIHC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.46	-7.08	-0.36	8.21e-12	Height;
LIHC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.55	6.84	0.35	3.77e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-5.79	-0.3	1.57e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.0	-17.47	-0.69	2.63e-49	Body mass index;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs11676348	0.935	rs4674248	chr2:218960131	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-7.18	-0.36	4.33e-12	Ulcerative colitis;
LIHC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.79	0.39	8.18e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08280861	chr8:58055591	NA	0.49	6.11	0.31	2.69e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg11161837	chr1:110010384	SYPL2	0.46	6.18	0.32	1.81e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg14593290	chr7:50529359	DDC	0.4	6.65	0.34	1.15e-10	Malaria;
LIHC	cis	rs922107	0.713	rs2031119	chr1:90042745	C/T	cg15422784	chr1:90023713	LRRC8B	-0.46	-7.54	-0.38	4.16e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg19635926	chr16:89946313	TCF25	0.49	6.38	0.33	5.81e-10	Skin colour saturation;
LIHC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.57	9.02	0.44	1.4e-17	Longevity;
LIHC	cis	rs12980942	0.935	rs16958996	chr19:41825138	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.48	5.99	0.31	5.29e-9	Coronary artery disease;
LIHC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.57	9.3	0.45	1.74e-18	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.27	-0.45	2.17e-18	Diabetic kidney disease;
LIHC	cis	rs4788570	0.686	rs9937511	chr16:71815913	C/T	cg06353428	chr16:71660113	MARVELD3	1.3	13.62	0.59	4.58e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg11161837	chr1:110010384	SYPL2	0.44	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1144333	0.655	rs3765682	chr1:76333172	T/C	cg22875332	chr1:76189707	ACADM	0.44	6.44	0.33	4.14e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12022452	0.591	rs11208315	chr1:40985402	G/C	cg25568243	chr1:40974465	DEM1	0.46	6.17	0.32	1.91e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.6	8.79	0.43	7.43e-17	Menarche (age at onset);
LIHC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.52	7.32	0.37	1.84e-12	Lung cancer;
LIHC	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.52	-8.5	-0.42	5.81e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs77633900	0.772	rs283802	chr15:76791270	C/T	cg21673338	chr15:77095150	SCAPER	-0.51	-5.84	-0.3	1.21e-8	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.43	7.1	0.36	7.32e-12	Response to temozolomide;
LIHC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg21665744	chr7:39171113	POU6F2	0.31	5.78	0.3	1.7e-8	IgG glycosylation;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07308232	chr7:1071921	C7orf50	-0.36	-5.81	-0.3	1.43e-8	Longevity;Endometriosis;
LIHC	cis	rs3736485	0.966	rs4775959	chr15:51891636	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.66e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg11011602	chr9:136215029	SNORD24;MED22;RPL7A	-0.44	-6.86	-0.35	3.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg07862535	chr7:139043722	LUC7L2	0.61	10.49	0.49	1.66e-22	Diisocyanate-induced asthma;
LIHC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	7.71	0.38	1.42e-13	Response to antipsychotic treatment;
LIHC	cis	rs2204008	0.720	rs10880697	chr12:38594529	G/C	cg26384229	chr12:38710491	ALG10B	0.87	10.03	0.48	6.16e-21	Bladder cancer;
LIHC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.03e-11	Ileal carcinoids;
LIHC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.68	10.02	0.48	7e-21	Testicular germ cell tumor;
LIHC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.4	-6.04	-0.31	4.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.68	-12.43	-0.56	1.61e-29	Pediatric autoimmune diseases;
LIHC	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.6	9.45	0.46	5.52e-19	White matter hyperintensity burden;
LIHC	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.91	13.85	0.6	6.07e-35	Obesity-related traits;
LIHC	cis	rs1434579	0.966	rs1062093	chr19:44931995	C/G	cg15540054	chr19:45004280	ZNF180	0.58	7.98	0.4	2.25e-14	Tuberculosis;
LIHC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg16346588	chr10:242978	ZMYND11	-0.47	-5.82	-0.3	1.35e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.62	-7.66	-0.38	2e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00462763	chr11:64949223	CAPN1	0.45	6.22	0.32	1.45e-9	Lung function (FEV1/FVC);
LIHC	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg15676719	chr1:167598521	RCSD1	-0.37	-6.65	-0.34	1.18e-10	Systemic lupus erythematosus;
LIHC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.28	22.06	0.77	1.09e-67	Corneal structure;
LIHC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.36	0.33	6.34e-10	Response to antipsychotic treatment;
LIHC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-6.86	-0.35	3.23e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.71	-12.61	-0.56	3.32e-30	Prudent dietary pattern;
LIHC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg10360323	chr17:41437877	NA	0.41	6.1	0.31	2.81e-9	Menopause (age at onset);
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.65	-9.89	-0.47	1.94e-20	Testicular germ cell tumor;
LIHC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg14440974	chr22:39074834	NA	-0.36	-5.97	-0.31	5.9e-9	Menopause (age at onset);
LIHC	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	1.04	11.66	0.53	1.09e-26	IgG glycosylation;
LIHC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.49	5.96	0.31	6.29e-9	Schizophrenia;
LIHC	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.86	-13.85	-0.6	6.32e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.33	6.21	0.32	1.5e-9	Renal cell carcinoma;
LIHC	trans	rs2270927	0.510	rs2972840	chr5:75572956	G/A	cg13563193	chr19:33072644	PDCD5	0.84	8.0	0.4	1.89e-14	Mean corpuscular volume;
LIHC	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.37	-0.45	1.02e-18	Bipolar disorder;
LIHC	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.04	0.51	1.98e-24	Coffee consumption (cups per day);
LIHC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.59	-8.17	-0.4	6.22e-15	Response to antineoplastic agents;
LIHC	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg14515779	chr1:101123966	NA	0.63	11.26	0.52	3.12e-25	Monocyte count;
LIHC	cis	rs7914558	0.646	rs7100709	chr10:104649729	A/C	cg15744005	chr10:104629667	AS3MT	-0.36	-7.58	-0.38	3.35e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.65e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.6	9.97	0.47	9.89e-21	Resting heart rate;
LIHC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.73	-0.34	7.3e-11	Schizophrenia;
LIHC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg13393036	chr8:95962371	TP53INP1	0.31	5.97	0.31	5.81e-9	Type 2 diabetes;
LIHC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.4	6.36	0.33	6.58e-10	Red blood cell count;
LIHC	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg24838063	chr12:130822603	PIWIL1	0.66	9.47	0.46	4.81e-19	Menopause (age at onset);
LIHC	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg06353428	chr16:71660113	MARVELD3	0.61	6.69	0.34	9.08e-11	Blood protein levels;
LIHC	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.3	-6.06	-0.31	3.55e-9	Schizophrenia;
LIHC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.79	13.25	0.58	1.22e-32	Colorectal cancer;
LIHC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	10.44	0.49	2.42e-22	Platelet count;
LIHC	cis	rs1144333	1.000	rs1021464	chr1:76375415	G/A	cg22875332	chr1:76189707	ACADM	0.4	6.27	0.32	1.07e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg09835421	chr16:68378352	PRMT7	-0.8	-9.67	-0.46	1.03e-19	Schizophrenia;
LIHC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.76	-11.22	-0.52	4.49e-25	Lung cancer in ever smokers;
LIHC	cis	rs2412488	1.000	rs2271554	chr4:54252222	C/G	cg22241045	chr4:54363911	LNX1	-0.46	-7.29	-0.37	2.2e-12	DNA methylation (variation);
LIHC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.46	6.27	0.32	1.09e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21448741	chr8:58168803	NA	0.37	6.69	0.34	9.34e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19371097	chr1:17735001	RCC2	0.42	6.18	0.32	1.79e-9	Pancreatic cancer;
LIHC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.14	0.52	8.53e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.34	-7.17	-0.36	4.61e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.85	-0.43	4.95e-17	Menarche (age at onset);
LIHC	cis	rs10768122	0.642	rs11033079	chr11:35362050	G/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-5.91	-0.3	8.45e-9	Vitiligo;
LIHC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-7.59	-0.38	3.13e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs9914544	0.545	rs12937933	chr17:18770283	C/G	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.73	-0.34	7.38e-11	Educational attainment (years of education);
LIHC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.49	6.3	0.32	9.41e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg21366198	chr4:185655624	MLF1IP	0.62	10.16	0.48	2.23e-21	Kawasaki disease;
LIHC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg18944383	chr4:111397179	ENPEP	0.28	6.52	0.33	2.56e-10	Coronary artery disease;
LIHC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.27	0.52	2.87e-25	Melanoma;
LIHC	trans	rs11157436	0.918	rs12433895	chr14:22622510	A/G	cg13567813	chr19:50879636	NR1H2	0.42	6.05	0.31	3.84e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.85	0.39	5.44e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.1	0.31	2.93e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg03934865	chr2:198174659	NA	0.54	8.22	0.41	4.19e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-7.67	-0.38	1.82e-13	Response to antipsychotic treatment;
LIHC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.61	5.85	0.3	1.16e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg11766577	chr21:47581405	C21orf56	-0.37	-5.86	-0.3	1.1e-8	Testicular germ cell tumor;
LIHC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.79	13.26	0.58	1.1e-32	Psoriasis;
LIHC	cis	rs8084351	0.501	rs28629395	chr18:50604504	G/A	cg24270629	chr18:50823537	DCC	0.46	7.05	0.36	9.72e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.38	6.89	0.35	2.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.75	10.06	0.48	5e-21	Alzheimer's disease;
LIHC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg23262073	chr20:60523788	NA	-0.28	-5.86	-0.3	1.09e-8	Body mass index;
LIHC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	4.98e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.28	5.88	0.3	9.74e-9	Pulmonary function;
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.64	-9.15	-0.44	5.16e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.53	-8.36	-0.41	1.61e-15	Superior crus of antihelix expression;
LIHC	cis	rs3814244	0.528	rs2860609	chr12:68390995	A/G	cg15249341	chr12:68405565	NA	0.34	6.87	0.35	2.97e-11	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.32	-7.23	-0.36	3.28e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.14	0.36	5.48e-12	Bipolar disorder;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.64	-9.94	-0.47	1.26e-20	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03952484	chr1:149899818	SF3B4	0.51	8.05	0.4	1.34e-14	Pancreatic cancer;
LIHC	cis	rs611744	0.967	rs859788	chr8:109227570	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04413644	chr1:9242184	NA	0.44	6.3	0.32	9.03e-10	Lung function (FEV1/FVC);
LIHC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.69	-0.46	8.58e-20	Bipolar disorder;
LIHC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.36	5.95	0.31	6.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.86	0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.36	-0.37	1.42e-12	Mean platelet volume;
LIHC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02985541	chr2:219472218	PLCD4	0.46	8.93	0.43	2.66e-17	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.44	-8.57	-0.42	3.49e-16	Testicular germ cell tumor;
LIHC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.97	15.52	0.64	1.64e-41	Nonalcoholic fatty liver disease;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg10755058	chr3:40428713	ENTPD3	0.41	6.99	0.35	1.47e-11	Renal cell carcinoma;
LIHC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11588001	chr19:29704240	UQCRFS1	0.41	6.53	0.33	2.4e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.68	9.31	0.45	1.54e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2033732	0.706	rs7839360	chr8:85069719	G/T	cg05716166	chr8:85095498	RALYL	0.38	6.03	0.31	4.24e-9	Body mass index;
LIHC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.05	0.6	1.02e-35	Chronic sinus infection;
LIHC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg05185784	chr16:90016020	DEF8	-0.46	-5.95	-0.31	6.75e-9	Skin colour saturation;
LIHC	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.38	-6.45	-0.33	3.89e-10	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20279895	chr14:31091012	SCFD1	-0.32	-6.46	-0.33	3.7e-10	Cognitive function;
LIHC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg05564831	chr3:52568323	NT5DC2	0.37	5.83	0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.88	0.39	4.53e-14	Prudent dietary pattern;
LIHC	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.6	9.75	0.47	5.57e-20	Corneal astigmatism;
LIHC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.5	8.27	0.41	3.03e-15	Obesity-related traits;
LIHC	cis	rs9534463	0.667	rs7999058	chr13:47216812	C/G	cg04092803	chr13:47240378	LRCH1	-0.27	-5.98	-0.31	5.56e-9	Platelet distribution width;
LIHC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.5e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.45	6.43	0.33	4.42e-10	Longevity;Endometriosis;
LIHC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg16070123	chr10:51489643	NA	-0.38	-5.97	-0.31	6.05e-9	Prostate-specific antigen levels;
LIHC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg10935138	chr17:73851978	WBP2	-0.48	-6.97	-0.35	1.65e-11	White matter hyperintensity burden;
LIHC	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.25	0.32	1.25e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4908768	0.871	rs4908775	chr1:8794410	G/A	cg20416874	chr1:8611966	RERE	0.49	7.0	0.35	1.35e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg03859395	chr2:55845619	SMEK2	0.78	13.22	0.58	1.57e-32	Metabolic syndrome;
LIHC	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.62	8.73	0.43	1.15e-16	Neuroticism;
LIHC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.76	10.22	0.48	1.4e-21	Coronary artery disease;
LIHC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.53	7.67	0.38	1.76e-13	Response to diuretic therapy;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.06	0.36	9.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.47	-7.21	-0.36	3.65e-12	Blood protein levels;
LIHC	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.55	7.21	0.36	3.58e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg03934865	chr2:198174659	NA	0.47	6.9	0.35	2.47e-11	Intracranial aneurysm;
LIHC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.96	0.31	6.36e-9	Blood metabolite levels;
LIHC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.47	-7.33	-0.37	1.63e-12	Blood metabolite levels;
LIHC	trans	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg17675199	chr6:35436792	RPL10A	0.31	6.1	0.31	2.85e-9	Coronary artery disease;
LIHC	cis	rs10426930	0.844	rs58250802	chr19:5034575	C/T	cg18473234	chr19:5097819	KDM4B	0.54	6.61	0.34	1.5e-10	Monocyte percentage of white cells;
LIHC	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.73	7.55	0.38	4.04e-13	Bipolar disorder;
LIHC	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg21584241	chr15:63341463	TPM1	-0.42	-6.31	-0.32	8.84e-10	Orofacial clefts;
LIHC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.45	5.8	0.3	1.5e-8	Mean platelet volume;
LIHC	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.55	6.97	0.35	1.69e-11	Eye color traits;
LIHC	cis	rs17152411	0.843	rs7904691	chr10:126582927	G/T	cg07906193	chr10:126599966	NA	0.43	6.84	0.35	3.73e-11	Height;
LIHC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg00318621	chr2:106887213	NA	-0.58	-5.96	-0.31	6.17e-9	Facial morphology (factor 23);
LIHC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.83	12.3	0.55	5.05e-29	IgG glycosylation;
LIHC	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.75	11.4	0.52	9.85e-26	Eye color traits;
LIHC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.52	6.55	0.33	2.09e-10	Pancreatic cancer;
LIHC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.46	-0.33	3.53e-10	Gut microbiome composition (summer);
LIHC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.36	-6.58	-0.34	1.74e-10	Aortic root size;
LIHC	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-7.75	-0.39	1.03e-13	Obesity-related traits;
LIHC	trans	rs783540	0.967	rs783527	chr15:83285847	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.7	-0.34	8.41e-11	Schizophrenia;
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg05484376	chr2:27715224	FNDC4	0.37	6.41	0.33	4.8e-10	Total body bone mineral density;
LIHC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.73	0.39	1.22e-13	Cognitive function;
LIHC	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.54	-8.46	-0.42	7.9e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg07172676	chr8:144997714	PLEC1	0.44	6.46	0.33	3.57e-10	Alopecia areata;
LIHC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.83e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg16822855	chr3:40428330	ENTPD3	0.32	5.76	0.3	1.85e-8	Renal cell carcinoma;
LIHC	cis	rs11888559	0.655	rs10932007	chr2:204005409	T/A	cg24605529	chr2:203879461	NBEAL1	0.77	5.85	0.3	1.16e-8	Height;
LIHC	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg08345082	chr10:99160200	RRP12	-0.37	-6.26	-0.32	1.13e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg19635926	chr16:89946313	TCF25	0.57	7.54	0.38	4.19e-13	Skin colour saturation;
LIHC	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	trans	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg26939375	chr7:64535504	NA	-0.43	-7.01	-0.35	1.28e-11	Aortic root size;
LIHC	cis	rs9649465	1.000	rs3779260	chr7:123348315	A/G	cg03229431	chr7:123269106	ASB15	0.37	8.01	0.4	1.88e-14	Migraine;
LIHC	cis	rs1419980	0.730	rs11054877	chr12:7771545	A/G	cg10578777	chr12:7781093	NA	-0.39	-5.84	-0.3	1.23e-8	HDL cholesterol levels;
LIHC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.48	-7.01	-0.35	1.29e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg18081818	chr7:23246105	NA	0.46	6.93	0.35	2.16e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.77	0.34	5.68e-11	Breast cancer;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-18.19	-0.7	3.42e-52	Height;
LIHC	cis	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg20368463	chr18:77673604	PQLC1	-0.36	-6.2	-0.32	1.67e-9	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13409248	chr3:40428643	ENTPD3	0.41	6.77	0.34	5.65e-11	Renal cell carcinoma;
LIHC	cis	rs12980942	0.630	rs7257825	chr19:41788344	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.29	0.32	9.54e-10	Coronary artery disease;
LIHC	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.04	21.5	0.76	1.83e-65	Schizophrenia;
LIHC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.02e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg00204748	chr12:29376779	FAR2	0.44	8.32	0.41	2.08e-15	QT interval;
LIHC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.5	-6.7	-0.34	8.68e-11	Initial pursuit acceleration;
LIHC	cis	rs1823913	0.927	rs35530564	chr2:192112050	T/G	cg12404831	chr2:192114017	MYO1B	0.32	6.45	0.33	3.82e-10	Obesity-related traits;
LIHC	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.49	8.13	0.4	8.18e-15	Corneal astigmatism;
LIHC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.04	0.44	1.15e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg18357526	chr6:26021779	HIST1H4A	0.41	6.2	0.32	1.62e-9	Height;
LIHC	cis	rs2191566	1.000	rs384544	chr19:44505255	A/T	cg20607764	chr19:44506953	ZNF230	0.43	6.79	0.34	4.84e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.74	-7.13	-0.36	6.12e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.74	-11.6	-0.53	1.92e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg11161837	chr1:110010384	SYPL2	0.46	6.43	0.33	4.41e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.72	-10.75	-0.5	2e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.52	6.69	0.34	9.06e-11	Alzheimer's disease;
LIHC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg11062466	chr8:58055876	NA	0.39	5.73	0.3	2.23e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg24112000	chr20:60950667	NA	-0.43	-5.72	-0.3	2.37e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg27205649	chr11:78285834	NARS2	-0.4	-6.31	-0.32	8.54e-10	Alzheimer's disease (survival time);
LIHC	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg05110241	chr16:68378359	PRMT7	-0.9	-8.2	-0.41	4.89e-15	Magnesium levels;
LIHC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07305463	chr2:136567211	LCT	0.36	6.53	0.33	2.31e-10	Mosquito bite size;
LIHC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg08499158	chr17:42289980	UBTF	-0.5	-8.13	-0.4	7.94e-15	Total body bone mineral density;
LIHC	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.46	-6.56	-0.33	1.97e-10	Life satisfaction;
LIHC	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	trans	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg26939375	chr7:64535504	NA	0.4	6.34	0.32	7.06e-10	Aortic root size;
LIHC	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg03962019	chr1:41807865	NA	0.51	7.43	0.37	8.87e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.93	-0.44	2.57e-17	Type 2 diabetes;
LIHC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-9.42	-0.45	7.14e-19	Mean corpuscular volume;
LIHC	cis	rs1789	0.786	rs6449161	chr4:15692954	A/G	cg21329975	chr4:15471214	CC2D2A	-0.41	-5.97	-0.31	5.94e-9	Blood protein levels;
LIHC	cis	rs611744	0.967	rs628340	chr8:109189425	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs9914544	0.583	rs11078422	chr17:18804413	C/T	cg21372672	chr17:16614065	CCDC144A	-0.25	-6.2	-0.32	1.62e-9	Educational attainment (years of education);
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.26	-0.55	6.75e-29	Alzheimer's disease;
LIHC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.56	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LIHC	trans	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg21659725	chr3:3221576	CRBN	0.66	6.47	0.33	3.34e-10	Schizophrenia;
LIHC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.63	0.34	1.3e-10	Blood metabolite levels;
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.18	0.32	1.77e-9	Renal cell carcinoma;
LIHC	trans	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.93	0.35	2.15e-11	Diastolic blood pressure;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.85e-9	Total body bone mineral density;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.63	-9.6	-0.46	1.82e-19	Renal cell carcinoma;
LIHC	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg26811252	chr16:29126840	RRN3P2	0.42	6.91	0.35	2.42e-11	Menopause (age at onset);
LIHC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg07713946	chr22:31675144	LIMK2	-0.42	-7.41	-0.37	9.8e-13	Colorectal cancer;
LIHC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.41	5.73	0.3	2.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13409248	chr3:40428643	ENTPD3	0.5	8.38	0.41	1.36e-15	Renal cell carcinoma;
LIHC	cis	rs6516091	0.706	rs62199230	chr20:6050124	G/C	cg25325723	chr20:6104886	FERMT1	-0.71	-5.88	-0.3	9.8e-9	Abdominal aortic aneurysm;
LIHC	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.37	5.87	0.3	1.01e-8	Height;
LIHC	cis	rs3748682	0.861	rs72661832	chr1:38260733	C/T	cg12658694	chr1:38397304	INPP5B	0.43	5.9	0.3	8.66e-9	Hypothyroidism;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.51	-7.27	-0.37	2.51e-12	Menopause (age at onset);
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg11070056	chr1:107600091	PRMT6	-0.72	-12.36	-0.56	3e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs611744	0.967	rs2597654	chr8:109221090	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.32e-16	Dupuytren's disease;
LIHC	cis	rs10792665	0.649	rs11233432	chr11:82739753	C/T	cg24227371	chr11:82718527	RAB30	-0.38	-9.11	-0.44	6.96e-18	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg22676075	chr6:135203613	NA	0.39	6.33	0.32	7.87e-10	Red blood cell count;
LIHC	cis	rs116248771	0.690	rs73156490	chr3:158416484	G/A	cg16708174	chr3:158430962	RARRES1	0.48	6.34	0.32	7.39e-10	diarrhoeal disease at age 2;
LIHC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	19.4	0.72	4.5e-57	Nonalcoholic fatty liver disease;
LIHC	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.89	-0.35	2.71e-11	Metabolite levels;
LIHC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.84	-13.67	-0.59	3.01e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.56	7.76	0.39	9.78e-14	Neuroticism;
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.46	7.34	0.37	1.57e-12	Platelet count;
LIHC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg01557791	chr16:72042693	DHODH	-0.39	-6.48	-0.33	3.26e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs699	0.556	rs2478517	chr1:230867887	A/G	cg07502417	chr1:230849801	AGT	0.29	6.29	0.32	9.62e-10	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.49e-10	Alzheimer's disease;
LIHC	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	1.04	14.34	0.61	7.85e-37	Mosquito bite size;
LIHC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.86	-9.72	-0.47	7.3e-20	Cognitive test performance;
LIHC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg06565975	chr8:143823917	SLURP1	0.34	6.66	0.34	1.1e-10	Urinary tract infection frequency;
LIHC	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.67	13.33	0.58	6.19e-33	Leprosy;
LIHC	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg19508488	chr2:152266495	RIF1	0.49	6.88	0.35	2.79e-11	Squamous cell lung carcinoma;
LIHC	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.66	10.88	0.51	6.96e-24	Pulse pressure;
LIHC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-7.64	-0.38	2.24e-13	Chronic sinus infection;
LIHC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.34	-6.12	-0.31	2.52e-9	Platelet distribution width;
LIHC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.95	14.5	0.62	1.75e-37	Sudden cardiac arrest;
LIHC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg14515779	chr1:101123966	NA	-0.65	-12.38	-0.56	2.44e-29	Monocyte count;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13268919	chr11:842945	TSPAN4;POLR2L	0.6	8.81	0.43	6.29e-17	Hepatitis;
LIHC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	11.11	0.52	1.06e-24	Monocyte percentage of white cells;
LIHC	cis	rs8083850	0.635	rs12966663	chr18:50849951	G/A	cg24270629	chr18:50823537	DCC	0.53	7.97	0.4	2.39e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.62	5.97	0.31	5.82e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.63	-7.97	-0.4	2.43e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg16275483	chr1:110013120	SYPL2	-0.51	-6.33	-0.32	7.5e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.87	0.3	1e-8	Bipolar disorder;
LIHC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.46	-7.34	-0.37	1.52e-12	Diastolic blood pressure;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.54	5.81	0.3	1.4e-8	Alzheimer's disease;
LIHC	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.92	-0.3	7.78e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.33	0.32	7.74e-10	Glycated hemoglobin levels;
LIHC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.06	0.36	9.12e-12	Morning vs. evening chronotype;
LIHC	cis	rs2637030	0.586	rs1465445	chr5:52848382	A/T	cg06476337	chr5:52856530	NDUFS4	0.38	6.3	0.32	9.23e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.74	13.06	0.58	6.66e-32	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.21	-0.32	1.52e-9	Response to antipsychotic treatment;
LIHC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.77	-11.11	-0.51	1.1e-24	Motion sickness;
LIHC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg17980119	chr2:219472607	PLCD4	0.34	5.74	0.3	2.08e-8	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11739225	chr14:35591523	PPP2R3C;KIAA0391	-0.51	-6.13	-0.31	2.41e-9	Systolic blood pressure;
LIHC	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg20636351	chr8:55087400	NA	-0.36	-7.58	-0.38	3.31e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.6	-9.0	-0.44	1.61e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg03037974	chr15:76606532	NA	0.62	10.58	0.5	7.89e-23	Blood metabolite levels;
LIHC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17554472	chr22:41940697	POLR3H	0.53	5.75	0.3	1.93e-8	Vitiligo;
LIHC	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.43	-6.99	-0.35	1.44e-11	Corneal astigmatism;
LIHC	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg22705602	chr4:152727874	NA	0.3	6.4	0.33	5.1e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.46	6.08	0.31	3.24e-9	Glioblastoma;Glioma;
LIHC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg24296786	chr1:45957014	TESK2	-0.49	-7.17	-0.36	4.64e-12	Platelet count;
LIHC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.26e-51	Menopause (age at onset);
LIHC	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.37	-9.03	-0.44	1.29e-17	Resting heart rate;
LIHC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg19318889	chr4:1322082	MAEA	0.46	6.48	0.33	3.24e-10	Obesity-related traits;
LIHC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.8	13.55	0.59	8.5e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.95	-0.39	2.77e-14	Body mass index;
LIHC	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg16070123	chr10:51489643	NA	-0.42	-6.13	-0.31	2.43e-9	Prostate-specific antigen levels;
LIHC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.4	7.82	0.39	6.8e-14	Coronary artery disease or large artery stroke;
LIHC	trans	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg17675199	chr6:35436792	RPL10A	0.38	7.83	0.39	6.17e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg12698662	chr3:15914712	MIR563	-0.41	-7.48	-0.37	6.35e-13	Mean platelet volume;
LIHC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg25344623	chr2:136566232	LCT	0.44	8.89	0.43	3.53e-17	Mosquito bite size;
LIHC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.23	0.41	3.98e-15	Platelet count;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26155673	chr8:12052102	FAM86B1	0.47	6.4	0.33	5.11e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg00091569	chr3:40428383	ENTPD3	0.4	6.64	0.34	1.22e-10	Renal cell carcinoma;
LIHC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.33	-6.16	-0.32	2.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg16394018	chr11:14927549	NA	0.41	5.85	0.3	1.12e-8	Vitamin D levels;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg14393609	chr7:65229607	NA	-0.44	-6.49	-0.33	3.04e-10	Aortic root size;
LIHC	cis	rs2422052	0.639	rs2113589	chr2:118647316	A/G	cg22545206	chr2:118617499	NA	0.36	6.08	0.31	3.25e-9	Mosquito bite size;
LIHC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.28	-7.2	-0.36	3.87e-12	Mean corpuscular volume;
LIHC	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.61	-9.06	-0.44	1.03e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	0.68	8.6	0.42	2.89e-16	Corneal structure;
LIHC	cis	rs16912285	0.591	rs12796137	chr11:24364459	T/G	ch.11.24196551F	chr11:24239977	NA	0.68	8.24	0.41	3.83e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.56	10.18	0.48	2.03e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg10756647	chr7:56101905	PSPH	1.09	12.43	0.56	1.64e-29	Diabetic kidney disease;
LIHC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg09904177	chr6:26538194	HMGN4	0.45	6.5	0.33	2.93e-10	Small cell lung carcinoma;
LIHC	cis	rs3736485	0.966	rs7176044	chr15:51895343	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.29	-0.32	9.52e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.45	-0.42	8.57e-16	Vitamin D levels;
LIHC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-11.79	-0.54	3.65e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs8081395	0.707	rs1024637	chr17:58038893	C/T	cg13753209	chr17:57696993	CLTC	-0.38	-5.75	-0.3	2e-8	White blood cell count;
LIHC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.82	10.38	0.49	3.99e-22	Cognitive function;
LIHC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.39	6.16	0.32	2.01e-9	Menopause (age at onset);
LIHC	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.35	0.32	6.91e-10	Ileal carcinoids;
LIHC	cis	rs2029362	0.611	rs10219241	chr11:27737123	G/A	cg18117895	chr11:27722066	BDNF	0.4	5.95	0.31	6.62e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.78	-0.34	5.25e-11	Sudden cardiac arrest;
LIHC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.39	6.9	0.35	2.58e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.1	-0.4	9.8e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.82	0.43	5.98e-17	Eosinophil percentage of white cells;
LIHC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-8.53	-0.42	4.85e-16	Lymphocyte counts;
LIHC	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	2.97e-9	Mortality in heart failure;
LIHC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.46	-0.37	7.05e-13	Initial pursuit acceleration;
LIHC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-10.25	-0.48	1.12e-21	Platelet count;
LIHC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.86	16.28	0.66	1.57e-44	Multiple myeloma (IgH translocation);
LIHC	trans	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg15676719	chr1:167598521	RCSD1	-0.38	-6.79	-0.34	4.83e-11	Systemic lupus erythematosus;
LIHC	cis	rs2302190	0.769	rs7211294	chr17:56462783	G/A	cg12560992	chr17:57184187	TRIM37	0.68	8.35	0.41	1.78e-15	Vitamin D levels;
LIHC	cis	rs6973256	0.637	rs12707116	chr7:133424909	C/T	cg10665199	chr7:133106180	EXOC4	-0.33	-5.82	-0.3	1.38e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-13.17	-0.58	2.51e-32	Morning vs. evening chronotype;
LIHC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.3	0.37	1.99e-12	Lung cancer;
LIHC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg03859395	chr2:55845619	SMEK2	0.9	15.34	0.64	9.08e-41	Metabolic syndrome;
LIHC	cis	rs6450176	0.909	rs67199213	chr5:53290648	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.29	-0.64	1.35e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg04610667	chr7:75704037	NA	-0.36	-6.14	-0.31	2.33e-9	Eotaxin levels;
LIHC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.31	-7.29	-0.37	2.15e-12	Longevity;Endometriosis;
LIHC	trans	rs10162376	1	rs10162376	chr14:81030493	C/T	cg20999565	chr14:68265668	ZFYVE26	0.72	6.47	0.33	3.45e-10	Mild influenza (H1N1) infection;
LIHC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.0	0.4	1.96e-14	Lymphocyte counts;
LIHC	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	10.15	0.48	2.51e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.91	-0.3	8.11e-9	Red blood cell count;
LIHC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.54	-8.21	-0.41	4.52e-15	White matter hyperintensity burden;
LIHC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	7.36	0.37	1.37e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg13957321	chr17:43675089	NA	-0.49	-7.82	-0.39	6.47e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.25	0.48	1.12e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.64	-9.74	-0.47	6.18e-20	Schizophrenia;
LIHC	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.43	-6.83	-0.35	3.84e-11	Response to temozolomide;
LIHC	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg10978503	chr1:24200527	CNR2	0.38	8.99	0.44	1.77e-17	Immature fraction of reticulocytes;
LIHC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg16586182	chr3:47516702	SCAP	-0.4	-6.83	-0.35	3.81e-11	Birth weight;
LIHC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.36	5.95	0.31	6.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg24060327	chr5:131705240	SLC22A5	0.52	6.94	0.35	1.95e-11	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg10096929	chr1:156261403	TMEM79	0.36	6.24	0.32	1.32e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs10419226	0.555	rs3829671	chr19:18777667	T/C	cg16673477	chr19:18812017	CRTC1	-0.34	-5.73	-0.3	2.17e-8	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.23	-0.32	1.33e-9	Total body bone mineral density;
LIHC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg07424592	chr7:64974309	NA	0.82	9.58	0.46	2.09e-19	Diabetic kidney disease;
LIHC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.91	0.65	4.57e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs7106204	0.514	rs1443044	chr11:24255575	C/G	ch.11.24196551F	chr11:24239977	NA	-0.83	-12.0	-0.54	6.06e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.44	-0.33	4.05e-10	Longevity;
LIHC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.54	9.08	0.44	8.92e-18	Colorectal cancer;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.52	-7.55	-0.38	3.89e-13	Menopause (age at onset);
LIHC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.64	5.81	0.3	1.43e-8	Schizophrenia;
LIHC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.18e-17	Bipolar disorder;
LIHC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg08847533	chr14:75593920	NEK9	-0.56	-9.0	-0.44	1.56e-17	IgG glycosylation;
LIHC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.59	-8.61	-0.42	2.77e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.9	14.1	0.61	6.38e-36	Metabolic syndrome;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg10815395	chr12:49237807	DDX23	0.61	6.49	0.33	2.93e-10	Mean platelet volume;
LIHC	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.6	10.28	0.49	8.76e-22	HDL cholesterol;
LIHC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.92	-17.21	-0.68	3e-48	Menopause (age at onset);
LIHC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.52	7.64	0.38	2.17e-13	HIV-1 control;
LIHC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.34	-6.28	-0.32	1.04e-9	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg07424592	chr7:64974309	NA	0.8	9.16	0.44	4.94e-18	Diabetic kidney disease;
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg26338869	chr17:61819248	STRADA	-0.46	-6.14	-0.32	2.3e-9	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21139845	chr12:7053993	C12orf57	0.48	7.07	0.36	8.75e-12	Cognitive function;
LIHC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.42	6.81	0.35	4.49e-11	Red blood cell count;
LIHC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg14092571	chr14:90743983	NA	-0.42	-6.57	-0.33	1.87e-10	Mortality in heart failure;
LIHC	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.43	-5.9	-0.3	8.89e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg16586182	chr3:47516702	SCAP	0.61	11.87	0.54	1.84e-27	Colorectal cancer;
LIHC	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-8.31	-0.41	2.27e-15	Facial morphology (factor 19);
LIHC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-11.25	-0.52	3.43e-25	Personality dimensions;
LIHC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.83	0.3	1.26e-8	Personality dimensions;
LIHC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.15	0.36	5.29e-12	Diabetic kidney disease;
LIHC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.8	13.39	0.59	3.54e-33	Psoriasis;
LIHC	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.65	-7.67	-0.38	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.25	6.06	0.31	3.59e-9	Obesity-related traits;
LIHC	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.01	-0.31	4.84e-9	Schizophrenia;
LIHC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.42	7.69	0.38	1.59e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs35160687	0.644	rs4832272	chr2:86516211	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.02	0.31	4.58e-9	Night sleep phenotypes;
LIHC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.68	0.57	1.8e-30	Schizophrenia;
LIHC	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.51	9.63	0.46	1.45e-19	Testicular germ cell tumor;
LIHC	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.75	-0.34	6.37e-11	Coronary artery disease;
LIHC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg04719120	chr6:96025338	MANEA	0.52	6.58	0.34	1.78e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg14132834	chr19:41945861	ATP5SL	-0.4	-5.91	-0.3	8.35e-9	Height;
LIHC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.97	12.64	0.56	2.66e-30	HIV-1 control;
LIHC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.65	10.21	0.48	1.52e-21	Tonsillectomy;
LIHC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	8.04e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.94	-0.39	2.98e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.05e-15	Gut microbiome composition (summer);
LIHC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.66	13.13	0.58	3.66e-32	High light scatter reticulocyte count;
LIHC	cis	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg16652328	chr3:33138982	GLB1;TMPPE	0.59	8.13	0.4	7.79e-15	Major depressive disorder;
LIHC	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.52	-10.29	-0.49	8.23e-22	Myopia (pathological);
LIHC	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.7	-7.81	-0.39	7.21e-14	Exhaled nitric oxide output;
LIHC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.49	8.08	0.4	1.1e-14	Diastolic blood pressure;
LIHC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.57	9.39	0.45	8.92e-19	Colorectal cancer;
LIHC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24110177	chr3:50126178	RBM5	-0.44	-6.75	-0.34	6.3e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.16	0.77	4.33e-68	Chronic sinus infection;
LIHC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.68	-12.95	-0.57	1.76e-31	Body mass index;
LIHC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	9.57	0.46	2.16e-19	Tonsillectomy;
LIHC	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.37	-6.05	-0.31	3.83e-9	Bipolar disorder;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg00280220	chr17:61926910	NA	0.44	7.16	0.36	5.04e-12	Prudent dietary pattern;
LIHC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Body mass index;
LIHC	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg25174290	chr11:3078921	CARS	0.57	8.7	0.43	1.46e-16	Longevity;
LIHC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg04359351	chr2:3481828	TTC15	0.28	5.95	0.31	6.77e-9	Neurofibrillary tangles;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg03336678	chr3:40547435	ZNF620	0.47	6.28	0.32	1.05e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.2	-0.52	5.05e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-11.16	-0.52	7.29e-25	Morning vs. evening chronotype;
LIHC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.66	-0.38	1.96e-13	Schizophrenia;
LIHC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.46	7.04	0.36	1.04e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.83	7.99	0.4	2.07e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.39	6.59	0.34	1.65e-10	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg07424592	chr7:64974309	NA	0.8	9.43	0.45	6.25e-19	Diabetic kidney disease;
LIHC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	8.49	0.42	6.3e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.0	0.48	7.89e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs12692119	0.655	rs7420828	chr2:127652836	C/G	cg13995918	chr5:1280305	TERT	-0.45	-6.31	-0.32	8.83e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12744310	0.945	rs1343776	chr1:41757718	G/A	cg03962019	chr1:41807865	NA	0.38	6.14	0.32	2.31e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg06742321	chr12:123595122	PITPNM2	0.31	5.96	0.31	6.42e-9	Platelet count;
LIHC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.13	15.69	0.65	3.75e-42	Ulcerative colitis;
LIHC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.09	0.44	8.32e-18	Schizophrenia;
LIHC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.32	0.32	8.28e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.39	-6.12	-0.31	2.55e-9	Menarche (age at onset);
LIHC	cis	rs12086130	0.892	rs10888713	chr1:51463424	A/T	cg07174182	chr1:51127561	FAF1	-0.92	-9.89	-0.47	1.9e-20	Hip circumference adjusted for BMI;Hip circumference;
LIHC	trans	rs6058796	1.000	rs57861317	chr20:31260708	C/T	cg02600331	chr11:130417168	NA	0.36	7.75	0.39	1.03e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.77	-0.34	5.5e-11	Obesity-related traits;
LIHC	cis	rs10838687	0.736	rs3781620	chr11:47259264	G/C	cg25783544	chr11:47291846	MADD	0.46	5.88	0.3	9.79e-9	Proinsulin levels;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.15e-11	Prudent dietary pattern;
LIHC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.67	-7.52	-0.38	4.94e-13	Vitiligo;
LIHC	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.54	8.41	0.41	1.09e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.31	-0.37	1.84e-12	Response to antipsychotic treatment;
LIHC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.63	8.8	0.43	6.79e-17	Menarche (age at onset);
LIHC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg12310025	chr6:25882481	NA	0.53	6.62	0.34	1.4e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg05484376	chr2:27715224	FNDC4	0.39	6.53	0.33	2.34e-10	Total body bone mineral density;
LIHC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg06050784	chr16:88016603	BANP	0.35	6.44	0.33	4.11e-10	Menopause (age at onset);
LIHC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg14132834	chr19:41945861	ATP5SL	-0.39	-5.79	-0.3	1.56e-8	Height;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg21747652	chr5:138238397	CTNNA1	0.37	6.12	0.31	2.53e-9	Myopia (pathological);
LIHC	trans	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg17675199	chr6:35436792	RPL10A	-0.41	-8.43	-0.41	9.66e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.93	0.31	7.51e-9	Height;
LIHC	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.43	12.25	0.55	7.45e-29	Uric acid levels;
LIHC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	9.82	0.47	3.17e-20	Lung cancer in ever smokers;
LIHC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6065325	0.514	rs4810320	chr20:40095031	G/T	cg06610464	chr20:40243608	CHD6	0.38	6.16	0.32	2.07e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.09	-0.36	7.73e-12	Personality dimensions;
LIHC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-11.81	-0.54	3.29e-27	Total cholesterol levels;
LIHC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg01411142	chr8:19674711	INTS10	0.51	7.68	0.38	1.74e-13	Acute lymphoblastic leukemia (childhood);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg17440044	chr7:100167198	NA	-0.36	-6.07	-0.31	3.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.84	-0.39	5.85e-14	Aortic root size;
LIHC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.0	-0.31	4.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	0.84	15.55	0.64	1.34e-41	Homoarginine levels;
LIHC	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg18323236	chr1:24743029	NIPAL3	0.41	7.47	0.37	6.57e-13	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.03	-0.4	1.54e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-0.84	-10.47	-0.49	1.93e-22	Blood pressure (smoking interaction);
LIHC	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.78	0.34	5.19e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.59	-7.5	-0.38	5.7e-13	Post bronchodilator FEV1;
LIHC	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.42	5.71	0.3	2.42e-8	Neuroticism;
LIHC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg21724239	chr8:58056113	NA	0.43	6.14	0.32	2.27e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.67	11.55	0.53	2.69e-26	Superior crus of antihelix expression;
LIHC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.51	-8.52	-0.42	5.04e-16	Menarche (age at onset);
LIHC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.67	-9.08	-0.44	8.72e-18	Schizophrenia;
LIHC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.63	-11.62	-0.53	1.55e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.21	0.41	4.55e-15	Lymphocyte counts;
LIHC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg14067834	chr17:29058358	SUZ12P	0.68	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08219700	chr8:58056026	NA	0.5	6.81	0.35	4.4e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.74	0.3	2.12e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.03	-0.4	1.63e-14	Total cholesterol levels;
LIHC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.62	10.8	0.5	1.4e-23	Colorectal cancer;
LIHC	cis	rs17125944	0.506	rs1998776	chr14:53355590	T/A	cg00686598	chr14:53173677	PSMC6	-0.78	-8.8	-0.43	6.93e-17	Alzheimer's disease (late onset);
LIHC	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg08345082	chr10:99160200	RRP12	-0.4	-6.63	-0.34	1.3100000000000001e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.57	10.29	0.49	7.98e-22	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	13.94	0.6	2.84e-35	Chronic sinus infection;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg19425114	chr11:58907379	NA	0.39	6.2	0.32	1.62e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.65	0.42	2.02e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.84	15.53	0.64	1.61e-41	IgG glycosylation;
LIHC	cis	rs240764	0.579	rs240151	chr6:101067720	A/T	cg09795085	chr6:101329169	ASCC3	0.44	6.38	0.33	5.77e-10	Neuroticism;
LIHC	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg14250997	chr9:106856677	SMC2	0.41	7.46	0.37	7.11e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg08824895	chr13:115047677	UPF3A	0.41	5.77	0.3	1.78e-8	Schizophrenia;
LIHC	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.84	8.56	0.42	4.02e-16	Blood protein levels;
LIHC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.68	0.34	9.86e-11	Bipolar disorder;
LIHC	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	6.25	0.32	1.2e-9	Response to antipsychotic treatment;
LIHC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.11	0.31	2.79e-9	Menopause (age at onset);
LIHC	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.42	6.86	0.35	3.3e-11	Menopause (age at onset);
LIHC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.65	-9.37	-0.45	1e-18	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.48	7.22	0.36	3.35e-12	Personality dimensions;
LIHC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.8e-30	Menopause (age at onset);
LIHC	cis	rs7523273	0.925	rs12749612	chr1:208006749	A/G	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.27	-0.49	9.92e-22	Schizophrenia;
LIHC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	11.11	0.51	1.12e-24	Monocyte percentage of white cells;
LIHC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02290350	chr8:58132656	NA	0.42	8.77	0.43	8.31e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.61	-7.77	-0.39	9.03e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.56	-7.49	-0.38	5.82e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09597638	chr17:3907349	NA	0.6	10.71	0.5	2.78e-23	Type 2 diabetes;
LIHC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.81	-0.73	1.06e-58	Height;
LIHC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.78	0.34	5.36e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs253664	0.897	rs1199336	chr3:138088221	T/A	cg25188949	chr3:137893707	DBR1	-0.57	-5.88	-0.3	9.83e-9	Body mass index;
LIHC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	10.61	0.5	6.38e-23	Response to antipsychotic treatment;
LIHC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.6	-8.11	-0.4	9.46e-15	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.88	0.35	2.79e-11	Renal cell carcinoma;
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg09417038	chr21:47716443	C21orf57	-0.51	-7.74	-0.39	1.1e-13	Testicular germ cell tumor;
LIHC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.89	0.35	2.75e-11	Axial length;
LIHC	cis	rs7095607	0.606	rs4746738	chr10:69959837	C/T	cg18986048	chr10:69913749	MYPN	0.39	5.86	0.3	1.09e-8	Lung function (FVC);
LIHC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.99	-19.67	-0.73	3.83e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.54	9.51	0.46	3.46e-19	Systemic lupus erythematosus;
LIHC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg05941027	chr17:61774174	LIMD2	0.34	6.93	0.35	2.09e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	16.82	0.67	1.11e-46	Lung cancer in ever smokers;
LIHC	cis	rs2274273	0.870	rs10139083	chr14:55782735	C/A	cg01864836	chr14:55583639	NA	-0.37	-6.63	-0.34	1.34e-10	Protein biomarker;
LIHC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.61	-11.89	-0.54	1.65e-27	Type 2 diabetes;
LIHC	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.78	-6.63	-0.34	1.28e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.57	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.77	11.94	0.54	1.02e-27	Corneal astigmatism;
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	6.77	0.34	5.54e-11	Obesity-related traits;
LIHC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	1.02	19.65	0.73	4.62e-58	Breast cancer;
LIHC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-0.85	-9.58	-0.46	2.07e-19	Schizophrenia;
LIHC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg00142150	chr22:38071001	LGALS1	-0.71	-11.61	-0.53	1.69e-26	Fat distribution (HIV);
LIHC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.54	7.58	0.38	3.32e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	0.85	11.77	0.54	4.35e-27	Skin colour saturation;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.75	13.24	0.58	1.32e-32	Prudent dietary pattern;
LIHC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.81	9.67	0.46	1.06e-19	Cognitive function;
LIHC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.98	-17.86	-0.69	7.05e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.35	-8.52	-0.42	5.09e-16	Longevity;Endometriosis;
LIHC	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.46e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg02297831	chr4:17616191	MED28	0.47	6.89	0.35	2.66e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.45	-0.33	3.85e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.34	-6.13	-0.31	2.44e-9	Platelet distribution width;
LIHC	cis	rs903552	1.000	rs4965386	chr15:102003207	G/A	cg25677261	chr15:102009856	PCSK6	-0.45	-6.23	-0.32	1.35e-9	Diabetic kidney disease;
LIHC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs831571	0.636	rs56228642	chr3:64075759	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.54	-6.24	-0.32	1.26e-9	Type 2 diabetes;
LIHC	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg14132834	chr19:41945861	ATP5SL	0.45	6.5	0.33	2.89e-10	Height;
LIHC	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.49	-6.31	-0.32	8.85e-10	Obesity (extreme);
LIHC	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg04306507	chr14:55594613	LGALS3	0.34	6.41	0.33	4.77e-10	Protein biomarker;
LIHC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.54	-8.93	-0.43	2.66e-17	Blood metabolite levels;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg09033563	chr22:24373618	LOC391322	-0.49	-7.0	-0.35	1.33e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.47	6.94	0.35	1.94e-11	Aortic root size;
LIHC	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-1.06	-11.77	-0.54	4.58e-27	Dilated cardiomyopathy;
LIHC	trans	rs4604234	0.803	rs73463518	chr6:80976017	G/A	cg08069338	chr6:160207898	SNORA29;TCP1	0.63	6.09	0.31	3.04e-9	Cancer;
LIHC	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.95	-0.31	6.74e-9	Diisocyanate-induced asthma;
LIHC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.58	8.26	0.41	3.31e-15	HIV-1 control;
LIHC	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.71	-0.38	1.35e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.47	-6.04	-0.31	4.06e-9	Corneal structure;
LIHC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.67	-0.38	1.81e-13	Chronic sinus infection;
LIHC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg02580895	chr19:2754563	NA	-0.41	-6.1	-0.31	2.91e-9	Total cholesterol levels;
LIHC	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	8.33	0.41	1.98e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.47	-7.12	-0.36	6.36e-12	Menarche (age at onset);
LIHC	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg15208524	chr1:10270712	KIF1B	0.41	6.17	0.32	1.89e-9	Hepatocellular carcinoma;
LIHC	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.73	-13.0	-0.58	1.12e-31	Longevity;
LIHC	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.32	-6.26	-0.32	1.14e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.03	0.51	2.13e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9596863	1.000	rs9568946	chr13:54430220	T/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.0	0.31	5.16e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs4728302	0.838	rs10225454	chr7:133591535	G/C	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-7.82	-0.39	6.59e-14	Alzheimer's disease;
LIHC	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg05187965	chr10:45406764	TMEM72	-0.26	-6.34	-0.32	7.38e-10	Mean corpuscular volume;
LIHC	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.72	-10.54	-0.5	1.14e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs16828019	0.852	rs3904243	chr1:41574852	T/G	cg03387723	chr1:41708464	SCMH1	-0.42	-6.93	-0.35	2.07e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg09301471	chr16:89349945	ANKRD11	0.42	6.28	0.32	1.04e-9	Alopecia areata;
LIHC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.41	7.81	0.39	7.14e-14	Schizophrenia;
LIHC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.5	-8.13	-0.4	7.71e-15	Crohn's disease;
LIHC	cis	rs2274273	0.624	rs11158034	chr14:55753560	C/T	cg01864836	chr14:55583639	NA	-0.36	-5.95	-0.31	6.6e-9	Protein biomarker;
LIHC	cis	rs6066825	0.605	rs761273	chr20:47315488	A/G	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.76e-12	Colorectal cancer;
LIHC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.7	13.17	0.58	2.51e-32	Multiple myeloma (IgH translocation);
LIHC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.78	7.54	0.38	4.23e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.65	-7.71	-0.38	1.38e-13	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.84	-0.65	9.44e-43	Chronic sinus infection;
LIHC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.96	-0.35	1.79e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.81	8.22	0.41	4.39e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.56	-8.74	-0.43	1.09e-16	Blood pressure (smoking interaction);
LIHC	cis	rs9513627	1.000	rs2390278	chr13:100159712	G/A	cg25919922	chr13:100150906	NA	0.74	6.93	0.35	2.07e-11	Obesity-related traits;
LIHC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.88	-0.57	3.09e-31	Acylcarnitine levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16868751	chr10:96162146	TBC1D12	0.42	6.38	0.33	5.76e-10	Pancreatic cancer;
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.7	-7.26	-0.37	2.69e-12	Alzheimer's disease;
LIHC	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	0.88	8.65	0.42	2.09e-16	Lifespan;
LIHC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.46	-6.17	-0.32	1.92e-9	Initial pursuit acceleration;
LIHC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg13047869	chr3:10149882	C3orf24	0.5	6.43	0.33	4.4e-10	Alzheimer's disease;
LIHC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.47	-12.07	-0.55	3.44e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg22951263	chr5:87985283	NA	-0.4	-6.85	-0.35	3.42e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.3	-0.32	9.3e-10	Alzheimer's disease (late onset);
LIHC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs10216189	0.785	rs4623325	chr7:5526807	C/T	cg05318486	chr7:5553423	FBXL18	0.41	5.79	0.3	1.58e-8	Relative hand skill in reading disability;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07677032	chr17:61819896	STRADA	0.42	6.15	0.32	2.18e-9	Prudent dietary pattern;
LIHC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	17.62	0.69	6.95e-50	Lung cancer in ever smokers;
LIHC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg14343924	chr8:8086146	FLJ10661	0.42	5.91	0.3	8.38e-9	Mood instability;
LIHC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.41	6.72	0.34	7.79e-11	Cleft lip with or without cleft palate;
LIHC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.4	6.63	0.34	1.32e-10	Red blood cell count;
LIHC	cis	rs611744	0.967	rs610452	chr8:109188263	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.57	8.29	0.41	2.7e-15	Platelet count;
LIHC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	10.03	0.48	6.42e-21	Resting heart rate;
LIHC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg14440974	chr22:39074834	NA	-0.37	-6.2	-0.32	1.59e-9	Menopause (age at onset);
LIHC	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.61	7.15	0.36	5.16e-12	Exhaled nitric oxide output;
LIHC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.34	-5.74	-0.3	2.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.74	8.61	0.42	2.8e-16	Exhaled nitric oxide output;
LIHC	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.43	7.05	0.36	1e-11	Schizophrenia;
LIHC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.07	-0.4	1.19e-14	Morning vs. evening chronotype;
LIHC	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.56	10.93	0.51	4.67e-24	Coronary artery disease;
LIHC	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.37	-0.41	1.47e-15	Response to antipsychotic treatment;
LIHC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.76	11.53	0.53	3.24e-26	Corneal astigmatism;
LIHC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.65	13.76	0.6	1.3600000000000001e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs7095607	0.560	rs2255381	chr10:69923535	C/T	cg18986048	chr10:69913749	MYPN	0.47	7.12	0.36	6.47e-12	Lung function (FVC);
LIHC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	6.49	0.33	3.09e-10	Initial pursuit acceleration;
LIHC	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.63	-6.99	-0.35	1.42e-11	Putamen volume;
LIHC	cis	rs7818688	0.697	rs58282276	chr8:95985391	G/A	cg16049864	chr8:95962084	TP53INP1	0.6	6.51	0.33	2.69e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	8.15	0.4	6.92e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.04e-10	Menopause (age at onset);
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.64	-0.38	2.19e-13	Testicular germ cell tumor;
LIHC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.88	9.05	0.44	1.12e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.08	-14.97	-0.63	2.54e-39	Chronic sinus infection;
LIHC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	1.01	19.11	0.72	6.41e-56	Breast cancer;
LIHC	cis	rs4453791	1.000	rs11927309	chr3:38935115	C/T	cg02254461	chr3:39195904	CSRNP1	0.65	5.84	0.3	1.23e-8	Social communication problems;
LIHC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.56	9.39	0.45	9.02e-19	Aortic root size;
LIHC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg18357526	chr6:26021779	HIST1H4A	0.42	6.39	0.33	5.56e-10	Height;
LIHC	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg00977110	chr5:151150581	G3BP1	0.54	6.96	0.35	1.79e-11	Preschool internalizing problems;
LIHC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.61	-0.34	1.49e-10	Coronary artery disease;
LIHC	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.43	-8.54	-0.42	4.54e-16	Type 1 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25858983	chr17:42295711	UBTF	0.48	6.92	0.35	2.23e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	8.76	0.43	9.43e-17	Birth weight;
LIHC	cis	rs2274273	0.870	rs8021583	chr14:55749607	G/A	cg01864836	chr14:55583639	NA	-0.39	-6.95	-0.35	1.8e-11	Protein biomarker;
LIHC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.93	0.43	2.7e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.52	-15.89	-0.65	5.89e-43	Breast cancer;
LIHC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.56	-8.98	-0.44	1.83e-17	Longevity;Endometriosis;
LIHC	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.33	7.51	0.38	5.04e-13	Blood metabolite ratios;
LIHC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.55	10.02	0.48	6.7e-21	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.46	7.34	0.37	1.55e-12	Monocyte count;
LIHC	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.6	8.99	0.44	1.7e-17	Recombination rate (females);
LIHC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.75	-9.95	-0.47	1.14e-20	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg07451762	chr16:28383216	NA	-0.35	-6.34	-0.32	7.31e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.83	-0.3	1.26e-8	Colorectal cancer;
LIHC	trans	rs13113518	0.783	rs2171618	chr4:56430408	A/G	cg15358633	chr12:38710606	ALG10B	0.43	6.25	0.32	1.21e-9	Height;
LIHC	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.41	-6.35	-0.32	6.67e-10	Coronary artery disease;
LIHC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.61	10.5	0.49	1.53e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg19318889	chr4:1322082	MAEA	0.48	7.97	0.4	2.35e-14	Obesity-related traits;
LIHC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.84	11.91	0.54	1.31e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.56e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7716219	0.672	rs1396610	chr5:54878619	C/T	cg14753740	chr5:54468940	CDC20B;MIR449C	0.43	5.9	0.3	8.93e-9	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26289012	chr17:3540036	CTNS;SHPK	0.45	6.11	0.31	2.74e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.66	10.66	0.5	4.37e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs1494950	1.000	rs7673375	chr4:14984117	G/T	cg12377275	chr4:15005593	CPEB2	-0.79	-6.26	-0.32	1.15e-9	Political ideology;
LIHC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.25	-6.61	-0.34	1.49e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.61	0.76	6.3e-66	Prudent dietary pattern;
LIHC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.48	-7.6	-0.38	2.79e-13	Multiple sclerosis;
LIHC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.6	8.63	0.42	2.38e-16	Blood metabolite levels;
LIHC	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg14222432	chr12:29376421	FAR2	0.35	6.74	0.34	6.68e-11	QT interval;
LIHC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.38	-5.99	-0.31	5.21e-9	Glioblastoma;
LIHC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.57	-7.92	-0.39	3.43e-14	Response to antineoplastic agents;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20591408	chr2:241516333	RNPEPL1	0.41	6.29	0.32	9.56e-10	Pancreatic cancer;
LIHC	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.48	9.03	0.44	1.28e-17	Testicular germ cell tumor;
LIHC	cis	rs4908768	0.539	rs1934138	chr1:8645816	G/A	cg20416874	chr1:8611966	RERE	-0.66	-12.78	-0.57	7.87e-31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.8	8.42	0.41	1.06e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11696739	0.501	rs2243603	chr20:1546911	C/G	cg15722679	chr20:1638393	SIRPG	0.48	8.76	0.43	9.14e-17	Mean platelet volume;
LIHC	cis	rs2274273	0.805	rs28660594	chr14:55846174	T/C	cg01864836	chr14:55583639	NA	-0.38	-6.69	-0.34	9.03e-11	Protein biomarker;
LIHC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.43	-6.71	-0.34	7.91e-11	Dental caries;
LIHC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg04310649	chr10:35416472	CREM	-0.45	-6.08	-0.31	3.17e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.66	10.93	0.51	4.59e-24	Menopause (age at onset);
LIHC	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.3	-0.37	2.05e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.88	8.39	0.41	1.29e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.29	-0.41	2.53e-15	Vitamin D levels;
LIHC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.73	9.75	0.47	5.62e-20	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg27540799	chr1:2335599	RER1	-0.54	-7.71	-0.38	1.38e-13	Lung function (FEV1/FVC);
LIHC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs732505	0.618	rs1337057	chr19:5676950	G/A	cg26242866	chr19:5711310	LONP1	0.75	7.34	0.37	1.55e-12	vWF and FVIII levels;
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.55	9.42	0.45	7.17e-19	Calcium levels;
LIHC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg14784868	chr12:69753453	YEATS4	0.55	7.91	0.39	3.67e-14	Response to diuretic therapy;
LIHC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-9.81	-0.47	3.56e-20	Chronic sinus infection;
LIHC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.48	-7.95	-0.39	2.75e-14	Blood metabolite levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12749787	chr12:12878379	APOLD1	-0.49	-6.31	-0.32	8.74e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1256061	0.646	rs1152588	chr14:64688175	G/C	cg23250157	chr14:64679961	SYNE2	0.42	6.09	0.31	3.11e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.31	-0.37	1.86e-12	Body mass index;
LIHC	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.37	9.42	0.45	6.86e-19	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg11057378	chr10:81107060	PPIF	0.37	5.99	0.31	5.18e-9	Height;
LIHC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.67	11.68	0.53	9.39e-27	Lymphocyte counts;
LIHC	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	19.08	0.72	9.19e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg08724919	chr11:61100443	DDB1;DAK	-0.41	-6.05	-0.31	3.87e-9	Bipolar disorder;
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg11441379	chr12:63026424	NA	0.6	6.21	0.32	1.53e-9	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27006547	chr11:62606509	WDR74	0.39	6.05	0.31	3.87e-9	Cognitive function;
LIHC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.14	0.61	4.78e-36	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.54	-8.23	-0.41	3.95e-15	Platelet distribution width;
LIHC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.45	8.8	0.43	6.84e-17	Schizophrenia;
LIHC	cis	rs6722750	0.846	rs13394665	chr2:64391431	A/C	cg22352474	chr2:64371530	PELI1	-0.44	-6.51	-0.33	2.73e-10	Neuroticism;
LIHC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.32	14.5	0.62	1.74e-37	White matter hyperintensity burden;
LIHC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.59	-8.78	-0.43	8.08e-17	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.49	0.46	3.94e-19	Hemoglobin concentration;
LIHC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg16586182	chr3:47516702	SCAP	-0.58	-11.18	-0.52	6.11e-25	Colorectal cancer;
LIHC	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.81	12.91	0.57	2.45e-31	Gastritis;
LIHC	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	9.24	0.45	2.68e-18	Red blood cell count;
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg00091569	chr3:40428383	ENTPD3	0.39	6.57	0.33	1.91e-10	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13409248	chr3:40428643	ENTPD3	0.41	6.77	0.34	5.65e-11	Renal cell carcinoma;
LIHC	cis	rs600806	0.888	rs443345	chr1:109849254	A/G	cg16275483	chr1:110013120	SYPL2	-0.5	-6.0	-0.31	4.93e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	8.47	0.42	7.18e-16	Eotaxin levels;
LIHC	trans	rs9388766	0.824	rs9375702	chr6:130384187	C/T	cg03039519	chr14:93699218	NA	-0.35	-6.31	-0.32	8.42e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg21573476	chr21:45109991	RRP1B	-0.52	-9.68	-0.46	9.26e-20	Mean corpuscular volume;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg15624725	chr16:30381887	TBC1D10B	-0.41	-6.1	-0.31	2.9e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.51	7.26	0.37	2.61e-12	Mean corpuscular volume;
LIHC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.45	8.7	0.43	1.4e-16	Schizophrenia;
LIHC	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.63	8.1	0.4	9.82e-15	Blood metabolite levels;
LIHC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg04013166	chr16:89971882	TCF25	0.52	6.62	0.34	1.35e-10	Skin colour saturation;
LIHC	cis	rs12980942	1.000	rs12972266	chr19:41810771	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.86	0.35	3.22e-11	Coronary artery disease;
LIHC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.46	0.37	7e-13	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	1.02	12.21	0.55	1.02e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.51	-7.24	-0.36	2.95e-12	Bipolar disorder;
LIHC	cis	rs11233413	1.000	rs7928570	chr11:82721526	A/C	cg24227371	chr11:82718527	RAB30	-0.32	-7.07	-0.36	8.87e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.2	-0.41	4.9e-15	Systolic blood pressure;
LIHC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg09182678	chr22:50328711	NA	-0.49	-6.3	-0.32	9.02e-10	Schizophrenia;
LIHC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.23	0.32	1.37e-9	Schizophrenia;
LIHC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.05	24.99	0.8	3.62e-79	IgG glycosylation;
LIHC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg03854865	chr6:26224070	HIST1H3E	0.63	7.07	0.36	8.82e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19671926	chr4:122722719	EXOSC9	0.55	8.34	0.41	1.91e-15	Type 2 diabetes;
LIHC	cis	rs12079745	0.793	rs10919079	chr1:169133805	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.69	-6.74	-0.34	6.64e-11	QT interval;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05148623	chr2:191513405	NAB1	-0.49	-6.8	-0.35	4.6e-11	Bilirubin levels;
LIHC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-1.15	-10.21	-0.48	1.54e-21	Breast cancer;
LIHC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg25281562	chr12:121454272	C12orf43	0.45	7.6	0.38	2.95e-13	N-glycan levels;
LIHC	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.13	0.48	2.85e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	6.84	0.35	3.7e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs3736485	0.966	rs8028017	chr15:51912708	G/A	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.56e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.05	13.04	0.58	7.71e-32	Economic and political preferences (immigration/crime);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10678486	chr18:48494218	ELAC1	0.4	6.04	0.31	4.09e-9	Pancreatic cancer;
LIHC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg12334488	chr2:20871173	GDF7	0.42	8.58	0.42	3.4e-16	Abdominal aortic aneurysm;
LIHC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.49	8.54	0.42	4.39e-16	Mean corpuscular volume;
LIHC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.82	-0.3	1.35e-8	Calcium levels;
LIHC	cis	rs2625529	0.775	rs12913042	chr15:72202309	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.77	-0.3	1.73e-8	Red blood cell count;
LIHC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	8.16	0.4	6.42e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg27523141	chr10:43048294	ZNF37B	0.38	6.73	0.34	6.99e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07305463	chr2:136567211	LCT	-0.39	-5.74	-0.3	2.11e-8	Corneal structure;
LIHC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg19635926	chr16:89946313	TCF25	0.48	6.17	0.32	1.97e-9	Skin colour saturation;
LIHC	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.99	0.35	1.43e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg10220992	chr8:11324327	FAM167A	-0.46	-6.16	-0.32	1.99e-9	Bilirubin levels;
LIHC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg13409248	chr3:40428643	ENTPD3	0.39	6.04	0.31	4.08e-9	Renal cell carcinoma;
LIHC	cis	rs1144333	1.000	rs2202019	chr1:76299181	G/A	cg03433033	chr1:76189801	ACADM	0.57	8.68	0.42	1.64e-16	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	1.0	17.82	0.69	1.03e-50	Tonsillectomy;
LIHC	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.61	-7.18	-0.36	4.39e-12	Height;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06341748	chr17:28951330	LRRC37B2	0.42	6.05	0.31	3.85e-9	Systolic blood pressure;
LIHC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	8.47	0.42	7.14e-16	Blood metabolite levels;
LIHC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.6	6.58	0.33	1.82e-10	Alzheimer's disease;
LIHC	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg02503808	chr4:7069936	GRPEL1	-0.8	-8.65	-0.42	2.03e-16	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.66	0.42	1.91e-16	Motion sickness;
LIHC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9322817	0.583	rs10782363	chr6:105149713	C/G	cg02098413	chr6:105308735	HACE1	0.42	8.13	0.4	7.83e-15	Thyroid stimulating hormone;
LIHC	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.64	-11.08	-0.51	1.33e-24	Pediatric autoimmune diseases;
LIHC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.75	11.44	0.53	7.26e-26	Corneal astigmatism;
LIHC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.71	11.58	0.53	2.13e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-7.15	-0.36	5.18e-12	Schizophrenia;
LIHC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.66	0.34	1.08e-10	Morning vs. evening chronotype;
LIHC	cis	rs35791980	0.534	rs1181904	chr7:76983314	A/G	cg12876866	chr7:77025528	PION	0.46	6.72	0.34	7.51e-11	Pursuit maintenance gain;
LIHC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.68	7.2	0.36	3.97e-12	Alzheimer's disease;
LIHC	cis	rs1198430	0.683	rs7551124	chr1:23785760	C/T	cg13183780	chr1:23809682	ASAP3	-0.4	-6.77	-0.34	5.64e-11	Total cholesterol levels;
LIHC	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.36	-6.31	-0.32	8.54e-10	HIV-1 susceptibility;
LIHC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.9	-14.01	-0.6	1.44e-35	Body mass index;
LIHC	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	8.21	0.41	4.58e-15	Eotaxin levels;
LIHC	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	6.95	0.35	1.83e-11	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.55	0.64	1.25e-41	Chronic sinus infection;
LIHC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.72	-10.12	-0.48	3.25e-21	Pancreatic cancer;
LIHC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.66	0.46	1.15e-19	Crohn's disease;
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.21	0.41	4.51e-15	Lung cancer;
LIHC	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg03934865	chr2:198174659	NA	-0.56	-9.06	-0.44	1.01e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.92	0.3	7.85e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.27	6.53	0.33	2.36e-10	Schizophrenia;
LIHC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.41	6.46	0.33	3.56e-10	Resting heart rate;
LIHC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02450064	chr17:40260053	DHX58	0.29	6.01	0.31	4.65e-9	Fibrinogen levels;
LIHC	cis	rs9649465	1.000	rs56396297	chr7:123350535	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-7.8	-0.39	7.37e-14	Migraine;
LIHC	cis	rs16858210	0.618	rs12638094	chr3:183565559	G/A	cg25686905	chr3:183603175	PARL	-0.41	-5.95	-0.31	6.46e-9	Menopause (age at onset);
LIHC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.48	-9.88	-0.47	2.09e-20	Tonsillectomy;
LIHC	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	0.6	10.42	0.49	2.91e-22	Testicular germ cell tumor;
LIHC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07677032	chr17:61819896	STRADA	0.43	6.19	0.32	1.77e-9	Prudent dietary pattern;
LIHC	cis	rs1461503	0.934	rs930983	chr11:122834414	A/G	cg25161029	chr11:122845972	NA	0.38	6.3	0.32	9.37e-10	Menarche (age at onset);
LIHC	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.73	-0.3	2.18e-8	Red blood cell count;
LIHC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.51	7.62	0.38	2.58e-13	Lymphocyte counts;
LIHC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg17750252	chr2:136567154	LCT	0.33	6.09	0.31	3.12e-9	Mosquito bite size;
LIHC	cis	rs3770081	1.000	rs17027011	chr2:86406556	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.89	-9.44	-0.45	5.87e-19	Facial emotion recognition (sad faces);
LIHC	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.85	-0.3	1.13e-8	Tuberculosis;
LIHC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-6.06	-0.31	3.68e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-12.42	-0.56	1.6800000000000001e-29	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6782228	0.606	rs2712381	chr3:128338600	A/C	cg16766828	chr3:128327626	NA	-0.41	-6.46	-0.33	3.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11645453	chr3:52864694	ITIH4	-0.22	-5.77	-0.3	1.78e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg15448220	chr1:150897856	SETDB1	-0.39	-6.08	-0.31	3.19e-9	Tonsillectomy;
LIHC	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.67	6.77	0.34	5.47e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.39	0.45	8.91e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-8.73	-0.43	1.17e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.8	0.3	1.55e-8	Menopause (age at onset);
LIHC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs151997	0.962	rs152687	chr5:50208563	A/G	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.22	-0.36	3.34e-12	Response to antipsychotic treatment;
LIHC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.38	-0.49	4e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.36e-11	Protein C levels;
LIHC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg13844804	chr7:814759	HEATR2	0.43	5.76	0.3	1.85e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.1	10.04	0.48	5.77e-21	Diabetic retinopathy;
LIHC	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.98	-17.56	-0.69	1.15e-49	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.36	-5.86	-0.3	1.09e-8	IgG glycosylation;
LIHC	cis	rs55665837	0.701	rs10160597	chr11:14603992	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-6.18	-0.32	1.83e-9	Vitamin D levels;
LIHC	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.39	6.02	0.31	4.57e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.38	6.83	0.35	4e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg10628098	chr11:65292300	SCYL1	0.38	5.78	0.3	1.67e-8	Bone mineral density;
LIHC	cis	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg21605333	chr4:119757512	SEC24D	0.99	8.23	0.41	3.95e-15	Cannabis dependence symptom count;
LIHC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.46	-6.53	-0.33	2.37e-10	Other erythrocyte phenotypes;
LIHC	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.04	0.44	1.23e-17	Coffee consumption (cups per day);
LIHC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.95	0.39	2.83e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	7.65	0.38	2.03e-13	Height;
LIHC	trans	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg15257565	chr10:42644887	NA	0.31	6.07	0.31	3.35e-9	Ulcerative colitis;
LIHC	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.62	7.26	0.37	2.62e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg08345082	chr10:99160200	RRP12	-0.37	-6.13	-0.31	2.37e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.31	-0.32	8.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4979906	1.000	rs11813624	chr10:79453162	T/C	cg07817648	chr10:79422355	NA	-0.3	-6.34	-0.32	7.46e-10	Mortality in heart failure;
LIHC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.28	6.0	0.31	5.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg06969265	chr17:73775802	H3F3B	0.48	6.05	0.31	3.82e-9	Psoriasis;
LIHC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	0.97	8.25	0.41	3.56e-15	Lymphocyte counts;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.45	8.37	0.41	1.52e-15	Prudent dietary pattern;
LIHC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg18357645	chr12:58087776	OS9	-0.42	-6.15	-0.32	2.13e-9	Multiple sclerosis;
LIHC	cis	rs6466055	0.720	rs4730082	chr7:105027509	A/G	cg04380332	chr7:105027541	SRPK2	-0.36	-6.73	-0.34	7.38e-11	Schizophrenia;
LIHC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.31	7.18	0.36	4.3e-12	Asthma (sex interaction);
LIHC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.29	-0.41	2.53e-15	Cognitive function;
LIHC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg04240660	chr16:89714849	CHMP1A	-0.53	-9.08	-0.44	9.16e-18	Hemoglobin concentration;
LIHC	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.61	-8.9	-0.43	3.41e-17	White matter hyperintensity burden;
LIHC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02475777	chr4:1388615	CRIPAK	0.4	6.11	0.31	2.78e-9	Longevity;
LIHC	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg02023728	chr11:77925099	USP35	-0.34	-5.96	-0.31	6.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.9	19.55	0.73	1.18e-57	Blood protein levels;
LIHC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.83	13.78	0.6	1.11e-34	Aortic root size;
LIHC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg15448220	chr1:150897856	SETDB1	0.4	6.26	0.32	1.16e-9	Tonsillectomy;
LIHC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	8.48	0.42	7.02e-16	Schizophrenia;
LIHC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.7	0.43	1.45e-16	Prudent dietary pattern;
LIHC	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg08539965	chr1:21396338	EIF4G3	0.32	5.74	0.3	2.11e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.6	6.6	0.34	1.59e-10	Vitiligo;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11688874	chr10:28822482	WAC	0.52	7.57	0.38	3.44e-13	Pancreatic cancer;
LIHC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26398791	chr1:38455867	SF3A3	-0.45	-6.2	-0.32	1.67e-9	Coronary artery disease;
LIHC	cis	rs9918079	0.560	rs4698402	chr4:15629803	G/A	cg04067612	chr4:15429572	C1QTNF7	-0.27	-5.78	-0.3	1.7e-8	Obesity-related traits;
LIHC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.54	-6.62	-0.34	1.43e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs11112613	0.818	rs2374507	chr12:106009570	A/C	cg03607813	chr12:105948248	NA	0.47	7.29	0.37	2.24e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	6.87	0.35	2.99e-11	Obesity-related traits;
LIHC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.59	8.51	0.42	5.51e-16	Obesity-related traits;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19257478	chr10:21806076	C10orf140	-0.44	-6.36	-0.33	6.32e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg11062466	chr8:58055876	NA	0.5	7.46	0.37	7.09e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.58	11.7	0.53	8.06e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs151997	1.000	rs27247	chr5:50232299	T/C	cg06027927	chr5:50259733	NA	-0.57	-7.71	-0.38	1.38e-13	Callous-unemotional behaviour;
LIHC	trans	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg04702396	chr17:15466718	FAM18B2	0.44	6.69	0.34	8.88e-11	Educational attainment (years of education);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14001871	chr13:113488290	ATP11A	0.44	6.58	0.34	1.81e-10	Longevity;
LIHC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.87	10.83	0.51	1.06e-23	Bladder cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08037420	chr3:172428855	NCEH1	0.44	6.42	0.33	4.5e-10	Pancreatic cancer;
LIHC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.41	-5.71	-0.3	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.6	-0.42	2.93e-16	Body mass index;
LIHC	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.38	5.83	0.3	1.3e-8	Ulcerative colitis;
LIHC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.65	10.91	0.51	5.7e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.88	-16.82	-0.67	1.12e-46	Dental caries;
LIHC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.43	0.41	1.01e-15	Lung cancer in ever smokers;
LIHC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.3	1.34e-8	Arsenic metabolism;
LIHC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	12.25	0.55	7.33e-29	Cognitive test performance;
LIHC	cis	rs11112613	0.550	rs73186004	chr12:106043512	A/C	cg03607813	chr12:105948248	NA	0.42	6.6	0.34	1.54e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	7.68	0.38	1.69e-13	Total cholesterol levels;
LIHC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.69	11.58	0.53	2.13e-26	Crohn's disease;
LIHC	cis	rs13190036	1.000	rs4976682	chr5:176726002	A/G	cg06532880	chr5:176731545	PRELID1;RAB24	-0.42	-5.81	-0.3	1.45e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13009927	chr2:242254519	SEPT2;HDLBP	0.4	6.14	0.32	2.27e-9	Lung function (FEV1/FVC);
LIHC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.32	-7.08	-0.36	8.14e-12	Ulcerative colitis;
LIHC	cis	rs655641	0.684	rs542167	chr11:85707228	A/G	cg09030501	chr11:85779252	PICALM	-0.53	-6.44	-0.33	4.11e-10	Platelet count;
LIHC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.63	-10.87	-0.51	7.89e-24	Menopause (age at onset);
LIHC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.37	-0.49	4.31e-22	Aortic root size;
LIHC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.94	-0.44	2.44e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.58	-9.29	-0.45	1.88e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.72	9.62	0.46	1.55e-19	Body mass index;
LIHC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	1.08	12.99	0.57	1.21e-31	Eosinophil percentage of granulocytes;
LIHC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg00800038	chr16:89945340	TCF25	-0.6	-8.93	-0.43	2.69e-17	Skin colour saturation;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.04	0.55	4.54e-28	Height;
LIHC	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.52	-7.36	-0.37	1.37e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	9.55	0.46	2.63e-19	Tonsillectomy;
LIHC	cis	rs3781454	1	rs3781454	chr10:126348565	G/A	cg20435097	chr10:126320824	FAM53B	-0.67	-12.8	-0.57	6.4e-31	White blood cell count;
LIHC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.38	-6.04	-0.31	4.04e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.86	-16.27	-0.66	1.78e-44	Coronary artery disease;
LIHC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.9	0.54	1.49e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.49	-7.7	-0.38	1.43e-13	Bone mineral density (spine);
LIHC	trans	rs6058796	1.000	rs6141779	chr20:31259366	C/T	cg02600331	chr11:130417168	NA	0.36	7.75	0.39	1.03e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	cis	rs7129556	0.520	rs6592730	chr11:77274203	T/C	cg03570279	chr11:77446074	RSF1	-0.36	-6.68	-0.34	9.43e-11	Weight loss (gastric bypass surgery);
LIHC	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.23	0.61	2.02e-36	Bipolar disorder;
LIHC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.44	-8.17	-0.4	5.96e-15	Neurofibrillary tangles;
LIHC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.16	0.32	2.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-7.29	-0.37	2.21e-12	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-11.03	-0.51	2.07e-24	Eye color traits;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg25894440	chr7:65020034	NA	0.4	6.23	0.32	1.38e-9	Calcium levels;
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.52	6.28	0.32	1.03e-9	Alzheimer's disease;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	11.15	0.52	7.52e-25	Calcium levels;
LIHC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.16	0.58	2.72e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-0.73	-7.93	-0.39	3.06e-14	Coronary artery disease;
LIHC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg02297831	chr4:17616191	MED28	0.46	7.1	0.36	7.04e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.5	7.42	0.37	9.56e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.91	-16.9	-0.67	5.28e-47	Aortic root size;
LIHC	cis	rs67981189	0.593	rs221915	chr14:71592142	G/A	cg15816911	chr14:71606274	NA	-0.44	-7.03	-0.36	1.12e-11	Schizophrenia;
LIHC	cis	rs10503871	0.526	rs35370135	chr8:30489769	A/G	cg26383811	chr8:30366931	RBPMS	0.42	6.47	0.33	3.37e-10	Metabolite levels  (X-11787);
LIHC	cis	rs922107	0.641	rs11580069	chr1:89981376	T/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.52	-0.38	4.77e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.43	7.14	0.36	5.73e-12	Crohn's disease;
LIHC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.45	9.22	0.45	3.03e-18	Immature fraction of reticulocytes;
LIHC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.94	16.17	0.66	4.53e-44	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs254781	0.505	rs190438	chr5:88026902	C/T	cg22951263	chr5:87985283	NA	-0.38	-6.21	-0.32	1.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	7.14	0.36	5.71e-12	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	8.38	0.41	1.44e-15	Renal cell carcinoma;
LIHC	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.58	-0.5	8.14e-23	Pediatric autoimmune diseases;
LIHC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs1355223	1.000	rs1355222	chr11:34758716	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.43	-0.33	4.19e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-22.19	-0.77	3.15e-68	Myeloid white cell count;
LIHC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.86	15.45	0.64	3.35e-41	Dental caries;
LIHC	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.43	6.43	0.33	4.2e-10	Night sleep phenotypes;
LIHC	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.58	8.18	0.4	5.6e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	7.03	0.36	1.11e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9513627	0.915	rs73556173	chr13:100121766	C/T	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-1.05	-10.87	-0.51	7.75e-24	Breast cancer;
LIHC	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.47	6.22	0.32	1.43e-9	Morning vs. evening chronotype;
LIHC	cis	rs72627123	0.867	rs80298117	chr14:74447383	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.46	0.42	8.11e-16	Morning vs. evening chronotype;
LIHC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.31	-0.41	2.27e-15	Exhaled nitric oxide output;
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02475777	chr4:1388615	CRIPAK	0.54	7.81	0.39	7.05e-14	Longevity;
LIHC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg16970926	chr12:29381810	FAR2	0.32	6.83	0.35	3.78e-11	QT interval;
LIHC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.43	-8.88	-0.43	3.89e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.38	-6.73	-0.34	7.21e-11	Aortic root size;
LIHC	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04498913	chr7:1135747	C7orf50	0.45	7.18	0.36	4.49e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	Monocyte percentage of white cells;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13671128	chr19:1612344	TCF3	0.42	6.21	0.32	1.56e-9	Longevity;
LIHC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.46	0.37	7.33e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11645453	chr3:52864694	ITIH4	-0.22	-5.73	-0.3	2.22e-8	Bipolar disorder;
LIHC	cis	rs3106136	0.681	rs7658390	chr4:95304083	C/T	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.52	7.28	0.37	2.35e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.51	5.79	0.3	1.63e-8	Primary sclerosing cholangitis;
LIHC	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.38	5.88	0.3	9.7e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.32	0.55	4.26e-29	Coffee consumption (cups per day);
LIHC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-6.58	-0.34	1.8e-10	Bipolar disorder;
LIHC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.65	-0.38	2.08e-13	Chronic sinus infection;
LIHC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	9.7	0.46	8.25e-20	Alzheimer's disease;
LIHC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg26441486	chr22:50317300	CRELD2	0.38	6.5	0.33	2.85e-10	Schizophrenia;
LIHC	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.78	-8.51	-0.42	5.6e-16	Exhaled nitric oxide output;
LIHC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.49	-6.33	-0.32	7.51e-10	Monobrow;
LIHC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.93	15.83	0.65	9.84e-43	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-8.64	-0.42	2.17e-16	Vitamin D levels;
LIHC	cis	rs2574704	1.000	rs7433453	chr3:11647416	C/T	cg15876825	chr3:11651881	VGLL4	0.49	8.29	0.41	2.58e-15	Body mass index;
LIHC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg07061783	chr6:25882402	NA	-0.52	-6.64	-0.34	1.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg27386326	chr11:61587980	NA	0.7	14.82	0.63	9.56e-39	Trans fatty acid levels;
LIHC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-6.07	-0.31	3.49e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.36	7.52	0.38	4.82e-13	Sitting height ratio;
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.55	-7.05	-0.36	9.65e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg16423285	chr20:60520624	NA	0.48	8.09	0.4	1.03e-14	Obesity-related traits;
LIHC	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	7.68	0.38	1.67e-13	Blood protein levels;
LIHC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	6.73	0.34	7.1e-11	Menopause (age at onset);
LIHC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.64	-9.73	-0.47	6.32e-20	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg09795085	chr6:101329169	ASCC3	0.52	7.13	0.36	6.1e-12	Neuroticism;
LIHC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.34	-6.79	-0.34	4.83e-11	Body mass index;
LIHC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.57	-8.89	-0.43	3.46e-17	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs116248771	0.739	rs12185969	chr3:158360880	C/T	cg16708174	chr3:158430962	RARRES1	0.49	6.53	0.33	2.39e-10	diarrhoeal disease at age 2;
LIHC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.53	-0.38	4.65e-13	Psoriasis;
LIHC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg23625390	chr15:77176239	SCAPER	0.35	5.72	0.3	2.36e-8	Blood metabolite levels;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.71	-10.58	-0.5	8.35e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.33	-0.37	1.71e-12	Mean platelet volume;
LIHC	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.01	-0.31	4.69e-9	Blood pressure;
LIHC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.44	6.86	0.35	3.24e-11	Melanoma;
LIHC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg01864069	chr14:103024347	NA	-0.48	-7.43	-0.37	8.65e-13	Platelet count;
LIHC	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg01990225	chr2:97406019	LMAN2L	-0.67	-6.05	-0.31	3.77e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg19497325	chr3:43121668	C3orf39	0.46	7.58	0.38	3.38e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.37	5.9	0.3	8.75e-9	Menopause (age at onset);
LIHC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.81	-8.29	-0.41	2.67e-15	Breast cancer;
LIHC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-6.02	-0.31	4.53e-9	Calcium levels;
LIHC	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg20991723	chr1:152506922	NA	-0.57	-10.64	-0.5	5.14e-23	Hair morphology;
LIHC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg10360323	chr17:41437877	NA	-0.41	-6.11	-0.31	2.72e-9	Menopause (age at onset);
LIHC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.65	10.47	0.49	1.98e-22	Multiple myeloma (IgH translocation);
LIHC	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.89	-17.97	-0.7	2.71e-51	Coronary artery disease;
LIHC	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg02733842	chr7:1102375	C7orf50	-0.68	-7.66	-0.38	1.92e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.77	10.54	0.5	1.1e-22	Coronary artery disease;
LIHC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.95	16.99	0.68	2.32e-47	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	6.09	0.31	3.09e-9	Height;
LIHC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.53	7.38	0.37	1.24e-12	Post bronchodilator FEV1;
LIHC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg02640540	chr1:67518911	SLC35D1	0.45	6.86	0.35	3.33e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs10744422	0.800	rs2649902	chr12:123243687	G/A	cg25930673	chr12:123319894	HIP1R	-0.81	-10.13	-0.48	2.8e-21	Schizophrenia;
LIHC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	10.63	0.5	5.31e-23	Coronary artery disease;
LIHC	cis	rs3820500	0.543	rs1289947	chr1:117954586	T/G	cg20383390	chr1:117909022	MAN1A2	0.45	5.84	0.3	1.22e-8	Pneumonia;
LIHC	cis	rs15676	0.947	rs10988124	chr9:131569345	G/A	cg00228799	chr9:131580591	ENDOG	0.46	6.99	0.35	1.48e-11	Blood metabolite levels;
LIHC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.26	-6.0	-0.31	4.9e-9	Subjective well-being;
LIHC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.45	-0.53	6.66e-26	Total cholesterol levels;
LIHC	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.35	7.13	0.36	6.1e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg20016023	chr10:99160130	RRP12	-0.43	-6.79	-0.34	5.03e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.43	-0.33	4.22e-10	Diabetic kidney disease;
LIHC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg24209194	chr3:40518798	ZNF619	0.56	8.1	0.4	9.7e-15	Renal cell carcinoma;
LIHC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.5	-7.17	-0.36	4.76e-12	Uric acid levels;
LIHC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.67	-13.25	-0.58	1.31e-32	Urate levels;
LIHC	cis	rs9596863	1.000	rs7318666	chr13:54418960	C/G	ch.13.53330881F	chr13:54432880	NA	-0.43	-6.0	-0.31	5.1e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.87	8.62	0.42	2.57e-16	Inflammatory bowel disease;
LIHC	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.41e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.36	6.0	0.31	5.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.65	10.32	0.49	6.22e-22	Longevity;
LIHC	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.94	-17.83	-0.69	9.21e-51	Schizophrenia;
LIHC	trans	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg02228481	chr6:31165922	HCG27	-0.46	-6.06	-0.31	3.64e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LIHC	cis	rs74233809	1.000	rs11191519	chr10:104784918	C/T	cg03493300	chr10:104813866	CNNM2	0.46	6.24	0.32	1.31e-9	Birth weight;
LIHC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.3	6.05	0.31	3.79e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg04310649	chr10:35416472	CREM	-0.42	-5.76	-0.3	1.85e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.55	-9.47	-0.46	4.67e-19	Reticulocyte count;
LIHC	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.83	0.3	1.3e-8	Neuroticism;
LIHC	cis	rs986417	0.901	rs1955687	chr14:60988606	A/G	cg27398547	chr14:60952738	C14orf39	0.83	9.55	0.46	2.51e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.57	8.74	0.43	1.09e-16	Longevity;Endometriosis;
LIHC	cis	rs12808519	0.688	rs3168175	chr11:69586070	A/C	cg19831575	chr11:69590090	FGF4	0.5	6.9	0.35	2.55e-11	Urate levels in overweight individuals;
LIHC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg16586182	chr3:47516702	SCAP	0.61	11.81	0.54	3.13e-27	Colorectal cancer;
LIHC	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg18898632	chr2:242989856	NA	-0.57	-7.59	-0.38	3.11e-13	Obesity-related traits;
LIHC	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg04306507	chr14:55594613	LGALS3	0.32	5.98	0.31	5.48e-9	Protein biomarker;
LIHC	cis	rs918629	0.567	rs2546191	chr5:95232541	G/A	cg10483112	chr5:95245456	ELL2	-0.36	-6.67	-0.34	1.04e-10	IgG glycosylation;
LIHC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.85	9.29	0.45	1.86e-18	Gut microbiome composition (summer);
LIHC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.53	0.33	2.34e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25925670	chr17:2206573	SMG6;SRR	-0.42	-6.08	-0.31	3.15e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	9.52	0.46	3.23e-19	Alzheimer's disease;
LIHC	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.53	-8.33	-0.41	1.93e-15	Corneal astigmatism;
LIHC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07305463	chr2:136567211	LCT	-0.37	-5.97	-0.31	6.07e-9	Corneal structure;
LIHC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.48	6.07	0.31	3.35e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.34	0.37	1.59e-12	Aortic root size;
LIHC	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg11812906	chr14:75593930	NEK9	0.41	6.13	0.31	2.47e-9	IgG glycosylation;
LIHC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.67	13.39	0.59	3.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.54	-9.12	-0.44	6.72e-18	Cognitive function;
LIHC	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.5	9.49	0.46	4.03e-19	Testicular germ cell tumor;
LIHC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.7	9.42	0.45	6.75e-19	Sudden cardiac arrest;
LIHC	cis	rs780096	0.967	rs1260334	chr2:27748597	C/A	cg22903471	chr2:27725779	GCKR	-0.31	-5.81	-0.3	1.42e-8	Total body bone mineral density;
LIHC	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg20607798	chr8:58055168	NA	0.57	6.65	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.84	0.35	3.63e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.46	7.35	0.37	1.44e-12	Platelet count;
LIHC	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.34	-0.41	1.84e-15	Type 2 diabetes;
LIHC	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.47	7.81	0.39	7.12e-14	Metabolite levels;
LIHC	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.87e-10	Asthma;
LIHC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	0.8	11.89	0.54	1.58e-27	Monocyte percentage of white cells;
LIHC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.41	6.84	0.35	3.73e-11	Blood metabolite levels;
LIHC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.55	8.81	0.43	6.45e-17	Multiple myeloma (IgH translocation);
LIHC	cis	rs35883536	0.967	rs3904673	chr1:101137162	A/C	cg14515779	chr1:101123966	NA	-0.7	-14.03	-0.6	1.21e-35	Monocyte count;
LIHC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.84	-0.51	1.02e-23	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16377939	chr16:53088918	CHD9	-0.43	-6.27	-0.32	1.09e-9	Cognitive function;
LIHC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg16434002	chr17:42200994	HDAC5	0.51	7.36	0.37	1.41e-12	Total body bone mineral density;
LIHC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.73	0.34	7.16e-11	Ileal carcinoids;
LIHC	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg13919466	chr1:32135498	COL16A1	-0.32	-6.05	-0.31	3.85e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4699052	1.000	rs7694190	chr4:104168017	A/G	cg16532752	chr4:104119610	CENPE	-0.39	-6.07	-0.31	3.44e-9	Testicular germ cell tumor;
LIHC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.45	7.12	0.36	6.51e-12	HDL cholesterol levels;
LIHC	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.33	-5.89	-0.3	9.1e-9	Lewy body disease;
LIHC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.77	-0.5	1.78e-23	Alzheimer's disease;
LIHC	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg15192750	chr16:69999425	NA	0.45	6.84	0.35	3.7e-11	IgE levels;
LIHC	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	11.95	0.54	9.44e-28	Eye color traits;
LIHC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.98	-0.31	5.68e-9	Menopause (age at onset);
LIHC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.61	-0.5	6.24e-23	Breast cancer;
LIHC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.5	9.23	0.45	2.87e-18	Hemoglobin concentration;
LIHC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.52	-8.14	-0.4	7.35e-15	Psoriasis;
LIHC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.55e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.15	0.32	2.22e-9	Mean corpuscular volume;
LIHC	cis	rs12464559	0.649	rs4450595	chr2:152622603	T/C	cg01189475	chr2:152685088	ARL5A	0.64	7.56	0.38	3.86e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.31	-0.45	1.58e-18	Diabetic kidney disease;
LIHC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.23	-0.41	4.02e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.81	-0.35	4.27e-11	Hemoglobin concentration;
LIHC	cis	rs963731	0.649	rs6756184	chr2:39256877	G/A	cg04010122	chr2:39346883	SOS1	-0.65	-5.91	-0.3	8.21e-9	Corticobasal degeneration;
LIHC	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.56	7.27	0.37	2.41e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.19	0.41	5.16e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.41	-7.45	-0.37	7.94e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1023500	0.753	rs12158335	chr22:42324622	T/G	cg04733989	chr22:42467013	NAGA	-0.5	-5.98	-0.31	5.51e-9	Schizophrenia;
LIHC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.45	6.39	0.33	5.32e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.48	-0.53	5.07e-26	Type 2 diabetes;
LIHC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.32	7.39	0.37	1.14e-12	Crohn's disease;
LIHC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.31	-0.32	8.65e-10	Systemic lupus erythematosus;
LIHC	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.52	-8.69	-0.43	1.53e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg10360323	chr17:41437877	NA	0.4	5.9	0.3	8.65e-9	Menopause (age at onset);
LIHC	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.6	-0.34	1.54e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.81	-12.43	-0.56	1.52e-29	Obesity-related traits;
LIHC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg18116418	chr1:152553244	LCE3D	-0.31	-5.77	-0.3	1.74e-8	Psoriasis;
LIHC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	0.81	6.13	0.31	2.38e-9	Lymphocyte counts;
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg10755058	chr3:40428713	ENTPD3	0.42	7.14	0.36	5.82e-12	Renal cell carcinoma;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.42	-5.77	-0.3	1.81e-8	Total body bone mineral density;
LIHC	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.46	8.79	0.43	7.22e-17	Testicular germ cell tumor;
LIHC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.9	-0.3	8.55e-9	Colorectal cancer;
LIHC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.39	0.56	2.22e-29	Electrocardiographic conduction measures;
LIHC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-5.74	-0.3	2.06e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.28	0.41	2.83e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg18887096	chr2:219472410	PLCD4	0.36	6.46	0.33	3.52e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7923837	0.651	rs10882085	chr10:94364882	C/T	cg25506282	chr10:94462361	NA	0.34	5.84	0.3	1.21e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-7.19	-0.36	4.02e-12	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15854668	chr3:124449432	UMPS	0.42	6.12	0.31	2.6e-9	Cognitive function;
LIHC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.7	10.63	0.5	5.61e-23	Migraine;Coronary artery disease;
LIHC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.73	5.99	0.31	5.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.6	-0.62	7.5e-38	Electrocardiographic conduction measures;
LIHC	cis	rs6788895	1.000	rs73008905	chr3:150465435	T/C	cg07663535	chr3:150480033	SIAH2	0.56	7.0	0.35	1.37e-11	Breast cancer;
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.59	6.93	0.35	2.13e-11	Alzheimer's disease;
LIHC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg07148914	chr20:33460835	GGT7	-0.55	-8.3	-0.41	2.48e-15	Height;
LIHC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.45	6.57	0.33	1.83e-10	Aortic root size;
LIHC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.14	-0.32	2.23e-9	Diabetic kidney disease;
LIHC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.88	-0.35	2.85e-11	Hepatocellular carcinoma;
LIHC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.54	7.17	0.36	4.71e-12	Pulse pressure;
LIHC	cis	rs7534824	0.625	rs12561853	chr1:101457863	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-7.99	-0.4	2.12e-14	Refractive astigmatism;
LIHC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg12140854	chr5:148520817	ABLIM3	-0.53	-5.9	-0.3	8.73e-9	Breast cancer;
LIHC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.46	-6.46	-0.33	3.51e-10	Initial pursuit acceleration;
LIHC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.43	-6.03	-0.31	4.26e-9	Initial pursuit acceleration;
LIHC	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.66	7.96	0.4	2.59e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.43	0.33	4.19e-10	Cognitive test performance;
LIHC	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-12.25	-0.55	7.35e-29	Response to antipsychotic treatment;
LIHC	cis	rs753955	0.593	rs7982516	chr13:24410278	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.38	6.87	0.35	3.14e-11	Lung cancer;
LIHC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.46	8.47	0.42	7.26e-16	Platelet distribution width;
LIHC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.2e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-8.0	-0.4	1.98e-14	Pancreatic cancer;
LIHC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg16102536	chr7:156981717	UBE3C	0.36	5.96	0.31	6.19e-9	Body mass index;
LIHC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.53	9.26	0.45	2.4e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.71	-9.23	-0.45	3e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg18867708	chr6:26865862	GUSBL1	0.53	8.11	0.4	8.86e-15	Schizophrenia;
LIHC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg17724175	chr1:150552817	MCL1	0.47	9.44	0.45	6.14e-19	Melanoma;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09924173	chr13:32526671	EEF1DP3	0.49	6.38	0.33	5.78e-10	Hepatitis;
LIHC	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg14515779	chr1:101123966	NA	0.46	6.5	0.33	2.8e-10	Monocyte count;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg10755058	chr3:40428713	ENTPD3	0.4	6.78	0.34	5.27e-11	Renal cell carcinoma;
LIHC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg15123519	chr2:136567270	LCT	0.44	8.81	0.43	6.22e-17	Cholesterol, total;
LIHC	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.54	7.34	0.37	1.55e-12	Endometrial cancer;
LIHC	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.43	8.32	0.41	2.1e-15	Testicular germ cell tumor;
LIHC	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg02023728	chr11:77925099	USP35	0.32	5.82	0.3	1.34e-8	Alzheimer's disease (survival time);
LIHC	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-11.77	-0.54	4.38e-27	Pediatric autoimmune diseases;
LIHC	cis	rs11673344	0.704	rs485034	chr19:37422357	T/G	cg27390819	chr19:37464633	NA	-0.51	-6.07	-0.31	3.38e-9	Obesity-related traits;
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.53	6.86	0.35	3.24e-11	Alzheimer's disease;
LIHC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.86	0.35	3.16e-11	Reticulocyte count;High light scatter reticulocyte count;
LIHC	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.68	-9.58	-0.46	2.05e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.63	8.91	0.43	3.17e-17	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.67	10.26	0.49	9.99e-22	Corneal astigmatism;
LIHC	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.9	11.19	0.52	5.8e-25	Coronary artery disease;
LIHC	trans	rs8001976	0.510	rs9645941	chr13:48331361	G/C	cg22135685	chr5:107205065	FBXL17	-0.33	-6.05	-0.31	3.76e-9	Aging (time to event);
LIHC	cis	rs17106184	1.000	rs3827731	chr1:50987827	A/G	cg07174182	chr1:51127561	FAF1	-0.7	-7.11	-0.36	6.97e-12	Type 2 diabetes;
LIHC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-10.64	-0.5	5.17e-23	Mosquito bite size;
LIHC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg23461800	chr14:103021989	NA	0.52	7.53	0.38	4.62e-13	Platelet count;
LIHC	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg27205649	chr11:78285834	NARS2	-0.38	-5.95	-0.31	6.79e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.69	-12.4	-0.56	2.07e-29	Iron status biomarkers;
LIHC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.35	5.85	0.3	1.17e-8	Menopause (age at onset);
LIHC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26897989	chr16:1907736	C16orf73	-0.5	-6.18	-0.32	1.84e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.39	6.45	0.33	3.92e-10	Red blood cell count;
LIHC	trans	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg26939375	chr7:64535504	NA	0.4	6.34	0.32	7.06e-10	Aortic root size;
LIHC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.32	-0.32	8.24e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03550219	chr3:25705846	TOP2B	-0.46	-6.44	-0.33	4e-10	Pancreatic cancer;
LIHC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.81	15.05	0.63	1.23e-39	Blood protein levels;
LIHC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg03959625	chr15:84868606	LOC388152	0.42	5.95	0.31	6.79e-9	Schizophrenia;
LIHC	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	0.78	10.57	0.5	8.81e-23	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg14393609	chr7:65229607	NA	-0.38	-5.98	-0.31	5.66e-9	Aortic root size;
LIHC	cis	rs16958440	1.000	rs62096466	chr18:44636171	T/G	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.35	-6.48	-0.33	3.27e-10	Aortic root size;
LIHC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.7	0.34	8.68e-11	Morning vs. evening chronotype;
LIHC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.66	10.47	0.49	1.96e-22	Multiple myeloma (IgH translocation);
LIHC	cis	rs742115	0.563	rs2281063	chr6:11298263	T/C	cg25250968	chr6:11318770	NEDD9	-0.4	-6.21	-0.32	1.49e-9	Coronary artery disease;
LIHC	trans	rs12692119	0.655	rs12469732	chr2:127653376	T/C	cg13995918	chr5:1280305	TERT	-0.46	-6.42	-0.33	4.63e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-8.58	-0.42	3.34e-16	Primary biliary cholangitis;
LIHC	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg16309518	chr5:176445507	NA	-0.58	-11.4	-0.52	1.01e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg14440974	chr22:39074834	NA	-0.44	-6.98	-0.35	1.58e-11	Menopause (age at onset);
LIHC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.85	11.03	0.51	2.17e-24	Heart rate;
LIHC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.62	12.45	0.56	1.37e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.72	0.39	1.31e-13	Mood instability;
LIHC	trans	rs13113518	0.812	rs4507426	chr4:56395554	T/C	cg15358633	chr12:38710606	ALG10B	0.43	6.16	0.32	2.09e-9	Height;
LIHC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.36	-7.22	-0.36	3.43e-12	Body mass index;
LIHC	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg24220031	chr2:73402428	NA	-0.28	-6.06	-0.31	3.59e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.85	12.93	0.57	2.16e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26119740	chr11:73881915	C2CD3;PPME1	-0.45	-6.12	-0.31	2.59e-9	Thyroid stimulating hormone;
LIHC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.03	0.31	4.19e-9	Bipolar disorder;
LIHC	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg20560298	chr2:73613845	ALMS1	0.36	5.83	0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.48	6.51	0.33	2.69e-10	Inflammatory skin disease;
LIHC	cis	rs11888559	0.655	rs6435173	chr2:204013112	A/G	cg24605529	chr2:203879461	NBEAL1	0.78	5.92	0.31	7.62e-9	Height;
LIHC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.11	-0.4	8.87e-15	Crohn's disease;
LIHC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg22963979	chr7:1858916	MAD1L1	0.38	5.88	0.3	9.79e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LIHC	cis	rs74233809	1.000	rs112390216	chr10:104741031	C/T	cg03493300	chr10:104813866	CNNM2	0.44	5.76	0.3	1.87e-8	Birth weight;
LIHC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg27572855	chr1:25598939	RHD	-0.39	-8.4	-0.41	1.17e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.42e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.53	11.9	0.54	1.46e-27	Skin aging (microtopography measurement);
LIHC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-9.42	-0.45	7.01e-19	Mean corpuscular volume;
LIHC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg17135325	chr3:160939158	NMD3	0.55	8.03	0.4	1.58e-14	Parkinson's disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg04686763	chr11:64655583	NA	0.41	6.68	0.34	9.92e-11	Calcium levels;
LIHC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.55	-6.51	-0.33	2.67e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-11.35	-0.52	1.51e-25	Vitiligo;
LIHC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.46	-7.54	-0.38	4.34e-13	Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13398864	chr3:122920640	SEC22A	0.49	6.55	0.33	2.11e-10	Lung function (FEV1/FVC);
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13409248	chr3:40428643	ENTPD3	0.5	8.41	0.41	1.11e-15	Renal cell carcinoma;
LIHC	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	1.01	16.54	0.67	1.49e-45	Tonsillectomy;
LIHC	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.6	8.96	0.44	2.15e-17	Menopause (age at onset);
LIHC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.62	-8.58	-0.42	3.3e-16	Vitamin D levels;
LIHC	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.66	0.42	1.95e-16	Corneal astigmatism;
LIHC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.4	-6.04	-0.31	4.12e-9	Blood pressure (smoking interaction);
LIHC	cis	rs988712	0.705	rs4074134	chr11:27647285	C/T	cg18117895	chr11:27722066	BDNF	0.45	6.11	0.31	2.68e-9	Obesity;
LIHC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.6	-11.59	-0.53	2e-26	Urate levels in overweight individuals;
LIHC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	12.34	0.55	3.59e-29	Cognitive test performance;
LIHC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-7.72	-0.39	1.29e-13	Neuroticism;
LIHC	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg07451762	chr16:28383216	NA	-0.36	-6.38	-0.33	5.76e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07305463	chr2:136567211	LCT	0.38	7.49	0.38	5.86e-13	Mosquito bite size;
LIHC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.69	12.71	0.57	1.4e-30	Menopause (age at onset);
LIHC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.58	8.3	0.41	2.4e-15	Osteoporosis;
LIHC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4742903	0.904	rs971969	chr9:106929798	A/C	cg14250997	chr9:106856677	SMC2	0.36	6.03	0.31	4.36e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.7	-7.58	-0.38	3.24e-13	Exhaled nitric oxide output;
LIHC	cis	rs1789	0.839	rs9997068	chr4:15650990	T/C	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.17	-0.32	1.9e-9	Blood protein levels;
LIHC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg06363034	chr20:62225388	GMEB2	-0.43	-7.36	-0.37	1.37e-12	Glioblastoma;
LIHC	trans	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.48	0.33	3.16e-10	Ulcerative colitis;
LIHC	trans	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg00571809	chr1:3397113	ARHGEF16	0.39	6.39	0.33	5.55e-10	Schizophrenia;
LIHC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	19.14	0.72	5.04e-56	Nonalcoholic fatty liver disease;
LIHC	trans	rs9600079	0.680	rs9530152	chr13:73715441	C/T	cg18908524	chr11:64002295	VEGFB	-0.55	-6.26	-0.32	1.15e-9	Prostate cancer;
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12379764	chr21:47803548	PCNT	-0.55	-7.93	-0.39	3.19e-14	Testicular germ cell tumor;
LIHC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.47	7.1	0.36	7.12e-12	Personality dimensions;
LIHC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.65	9.17	0.44	4.5e-18	Multiple sclerosis;
LIHC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.47	6.26	0.32	1.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.45	-7.25	-0.36	2.82e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.85	-0.65	8.31e-43	Chronic sinus infection;
LIHC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.38	0.37	1.23e-12	Vitiligo;
LIHC	cis	rs9921222	0.692	rs11860497	chr16:405416	A/G	cg12437481	chr16:420112	MRPL28	-0.54	-8.33	-0.41	2.03e-15	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23640757	chr6:7889014	TXNDC5	0.51	6.89	0.35	2.72e-11	Hip circumference;
LIHC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-6.38	-0.33	5.63e-10	Blood pressure (smoking interaction);
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.35	5.86	0.3	1.11e-8	Height;
LIHC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.54	-8.0	-0.4	1.91e-14	Age at first birth;
LIHC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.56	-7.6	-0.38	2.9e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg15123519	chr2:136567270	LCT	-0.42	-8.77	-0.43	8.74e-17	Mosquito bite size;
LIHC	cis	rs7707921	0.881	rs73136782	chr5:81443520	T/G	cg15871215	chr5:81402204	ATG10	-0.63	-6.25	-0.32	1.26e-9	Breast cancer;
LIHC	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg18898632	chr2:242989856	NA	-0.57	-7.74	-0.39	1.11e-13	Obesity-related traits;
LIHC	cis	rs1434579	0.966	rs7246892	chr19:44928668	A/G	cg15540054	chr19:45004280	ZNF180	0.55	7.52	0.38	4.89e-13	Tuberculosis;
LIHC	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg22771759	chr13:24902376	NA	0.32	6.93	0.35	2.05e-11	Obesity-related traits;
LIHC	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-6.68	-0.34	9.52e-11	Exhaled nitric oxide output;
LIHC	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.31	6.57	0.33	1.91e-10	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg01557791	chr16:72042693	DHODH	-0.45	-7.52	-0.38	4.95e-13	Fibrinogen levels;
LIHC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	12.64	0.56	2.5e-30	Schizophrenia;
LIHC	cis	rs2242420	0.920	rs10917028	chr1:21963854	C/T	cg18150885	chr1:21978612	RAP1GAP	-0.49	-5.86	-0.3	1.11e-8	Hematological and biochemical traits;
LIHC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg10935138	chr17:73851978	WBP2	0.49	7.27	0.37	2.52e-12	White matter hyperintensity burden;
LIHC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg10130564	chr11:117069849	TAGLN	0.35	5.93	0.31	7.49e-9	Blood protein levels;
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.65	10.88	0.51	7.29e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.45	-7.26	-0.37	2.55e-12	Fibrinogen levels;
LIHC	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-0.63	-7.73	-0.39	1.23e-13	Corneal structure;
LIHC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.13	-0.58	3.45e-32	Glomerular filtration rate (creatinine);
LIHC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg18944383	chr4:111397179	ENPEP	0.24	6.14	0.32	2.31e-9	Height;
LIHC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.79	-13.15	-0.58	2.9e-32	Colorectal cancer;
LIHC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.15	-0.32	2.16e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7707921	0.881	rs73134747	chr5:81378294	C/T	cg15871215	chr5:81402204	ATG10	-0.59	-5.71	-0.3	2.44e-8	Breast cancer;
LIHC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.44	6.34	0.32	7.48e-10	Aortic root size;
LIHC	trans	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.36	5.81	0.3	1.4e-8	Height;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	11.82	0.54	2.92e-27	Prudent dietary pattern;
LIHC	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg02023728	chr11:77925099	USP35	-0.33	-5.84	-0.3	1.2e-8	Alzheimer's disease (survival time);
LIHC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.46	7.83	0.39	6.01e-14	Lung cancer;
LIHC	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.63	-8.64	-0.42	2.18e-16	Lymphocyte counts;Fibrinogen;
LIHC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.6	7.61	0.38	2.75e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.35	5.81	0.3	1.39e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.93	-0.35	2.11e-11	IgG glycosylation;
LIHC	cis	rs2637266	0.599	rs846574	chr10:78503082	G/A	cg18941641	chr10:78392320	NA	0.28	6.07	0.31	3.34e-9	Pulmonary function;
LIHC	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.71	-15.75	-0.65	2.12e-42	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs807029	0.533	rs722435	chr10:102745062	G/T	cg25179470	chr10:102756915	LZTS2	0.45	6.38	0.33	5.65e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.0	-0.31	5.1e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-13.25	-0.58	1.21e-32	Coffee consumption (cups per day);
LIHC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.67	9.3	0.45	1.74e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg00280220	chr17:61926910	NA	0.41	6.46	0.33	3.6e-10	Prudent dietary pattern;
LIHC	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.5	-0.38	5.71e-13	Mean platelet volume;
LIHC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.62	-6.92	-0.35	2.23e-11	Bipolar disorder;
LIHC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.37	6.67	0.34	1.06e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-6.93	-0.35	2.09e-11	Coronary artery disease;
LIHC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.67	0.53	1e-26	Colorectal cancer;
LIHC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-1.01	-17.44	-0.69	3.39e-49	Tonsillectomy;
LIHC	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg01843034	chr6:37503916	NA	-0.47	-8.13	-0.4	7.92e-15	Cognitive performance;
LIHC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.48	0.33	3.27e-10	Bipolar disorder;
LIHC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.87	13.18	0.58	2.32e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.39e-20	Height;
LIHC	cis	rs6586163	0.872	rs1800682	chr10:90749963	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.56	-8.27	-0.41	3.09e-15	Chronic lymphocytic leukemia;
LIHC	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg14146966	chr2:61757674	XPO1	0.48	8.31	0.41	2.23e-15	Tuberculosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21315798	chr22:50354594	PIM3	-0.42	-6.7	-0.34	8.62e-11	Cognitive function;
LIHC	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg08890338	chr13:113700818	MCF2L	-0.35	-5.9	-0.3	8.9e-9	Systolic blood pressure;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg05484376	chr2:27715224	FNDC4	0.36	6.09	0.31	3.04e-9	Total body bone mineral density;
LIHC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.45	6.22	0.32	1.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.88	9.48	0.46	4.34e-19	Alzheimer's disease (late onset);
LIHC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.6	-10.81	-0.5	1.26e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.78	-0.3	1.65e-8	Personality dimensions;
LIHC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg11062466	chr8:58055876	NA	0.48	6.5	0.33	2.78e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.43	0.53	7.82e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05414835	chr15:59225898	SLTM	0.47	7.0	0.35	1.38e-11	Hepatitis;
LIHC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg25364880	chr3:44379878	C3orf23	0.61	8.39	0.41	1.29e-15	Depressive symptoms;
LIHC	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg10820045	chr2:198174542	NA	-0.57	-9.53	-0.46	3.02e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.99e-50	Schizophrenia;
LIHC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg07661805	chr8:143867942	LY6D	-0.31	-6.64	-0.34	1.21e-10	Urinary tract infection frequency;
LIHC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg07560587	chr16:88016574	BANP	0.35	5.81	0.3	1.4e-8	Menopause (age at onset);
LIHC	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg11161837	chr1:110010384	SYPL2	0.46	6.3	0.32	9.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Parkinson's disease;
LIHC	cis	rs986417	1.000	rs1254298	chr14:60883842	C/T	cg27398547	chr14:60952738	C14orf39	-0.74	-8.61	-0.42	2.67e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.77	-11.57	-0.53	2.29e-26	Personality dimensions;
LIHC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.57	-9.55	-0.46	2.58e-19	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.41	6.8	0.35	4.73e-11	Red blood cell count;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.54e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg20607798	chr8:58055168	NA	-0.63	-7.91	-0.39	3.52e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.81	13.01	0.58	9.99e-32	Glomerular filtration rate (creatinine);
LIHC	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.69	-10.05	-0.48	5.22e-21	Eosinophil percentage of white cells;
LIHC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.87	0.57	3.55e-31	Myeloid white cell count;
LIHC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg05425664	chr17:57184151	TRIM37	-0.42	-5.92	-0.31	7.63e-9	Testicular germ cell tumor;
LIHC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.38	5.77	0.3	1.76e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6061231	0.958	rs2427305	chr20:60953749	G/C	cg03945807	chr20:60948434	NA	0.44	6.81	0.35	4.32e-11	Colorectal cancer;
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.33	-0.41	1.94e-15	Obesity-related traits;
LIHC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg13409248	chr3:40428643	ENTPD3	-0.43	-7.29	-0.37	2.2e-12	Renal cell carcinoma;
LIHC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg01364799	chr7:75623366	TMEM120A	0.51	7.54	0.38	4.14e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg14709524	chr16:89940631	TCF25	0.58	7.41	0.37	1.02e-12	Skin colour saturation;
LIHC	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.26	-0.32	1.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.92	-13.28	-0.58	9.33e-33	Post bronchodilator FEV1;
LIHC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.48	8.91	0.43	3.06e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-6.96	-0.35	1.7e-11	Chronic sinus infection;
LIHC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00166722	chr3:10149974	C3orf24	0.48	5.75	0.3	2.01e-8	Alzheimer's disease;
LIHC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02985541	chr2:219472218	PLCD4	-0.42	-6.8	-0.35	4.61e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg03721293	chr16:90014378	DEF8	0.43	7.2	0.36	3.97e-12	Skin colour saturation;
LIHC	trans	rs12386622	1.000	rs12386622	chr7:131853601	A/G	cg17524136	chr11:84028382	DLG2	-0.5	-6.07	-0.31	3.39e-9	Homeostasis model assessment of beta-cell function (dietary factor interaction);
LIHC	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg25902810	chr10:99078978	FRAT1	0.69	10.57	0.5	9.02e-23	Monocyte count;
LIHC	cis	rs151997	0.962	rs27844	chr5:50190680	T/G	cg06027927	chr5:50259733	NA	0.56	7.53	0.38	4.67e-13	Callous-unemotional behaviour;
LIHC	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg09003973	chr2:102972529	NA	-0.52	-5.85	-0.3	1.17e-8	Blood protein levels;
LIHC	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.54	-6.45	-0.33	3.76e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.55	8.06	0.4	1.34e-14	Renal cell carcinoma;
LIHC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.49	6.53	0.33	2.43e-10	Emphysema distribution in smoking;
LIHC	cis	rs1211375	0.607	rs1203978	chr16:257211	A/C	cg08400316	chr16:204221	HBZ	-0.39	-6.14	-0.31	2.32e-9	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7116495	1.000	rs12272213	chr11:71816219	G/A	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	1.01	18.91	0.71	4.28e-55	Monocyte percentage of white cells;
LIHC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	1.0	11.23	0.52	3.93e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	9.74	0.47	5.81e-20	Personality dimensions;
LIHC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02290350	chr8:58132656	NA	-0.5	-10.55	-0.5	1.01e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.27	0.32	1.07e-9	Heart rate;
LIHC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	6.02	0.31	4.5e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.62	-7.5	-0.38	5.62e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.62	5.73	0.3	2.19e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.75	-0.3	1.95e-8	Diastolic blood pressure;
LIHC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.18	-0.36	4.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.46	-7.22	-0.36	3.29e-12	Type 2 diabetes;
LIHC	cis	rs4789452	0.509	rs2627208	chr17:75353102	A/G	cg05865280	chr17:75406074	SEPT9	-0.33	-6.75	-0.34	6.25e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg06854084	chr10:101292507	NKX2-3	-0.34	-6.25	-0.32	1.23e-9	Dental caries;
LIHC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg12458913	chr13:53173898	NA	0.48	7.87	0.39	4.62e-14	Lewy body disease;
LIHC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-1.14	-12.48	-0.56	1.02e-29	White matter hyperintensity burden;
LIHC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg26531700	chr6:26746687	NA	0.4	6.57	0.33	1.93e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.52	8.38	0.41	1.39e-15	Chronic sinus infection;
LIHC	cis	rs11871801	1.000	rs12948909	chr17:40570602	A/C	cg14558262	chr17:40713999	COASY	0.46	5.73	0.3	2.16e-8	Crohn's disease;
LIHC	cis	rs58950470	0.887	rs1787034	chr11:65382564	A/G	cg17120908	chr11:65337727	SSSCA1	-0.49	-5.9	-0.3	8.7e-9	Schizophrenia;
LIHC	cis	rs1555399	0.836	rs7154258	chr14:67982254	G/T	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.84	-0.3	1.25e-8	Parkinson's disease;
LIHC	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	0.99	8.28	0.41	2.8e-15	Lymphocyte counts;
LIHC	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg27205649	chr11:78285834	NARS2	-0.39	-5.75	-0.3	1.94e-8	Alzheimer's disease (survival time);
LIHC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.53	8.98	0.44	1.84e-17	Breast cancer;
LIHC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.47	-7.13	-0.36	6.09e-12	Height;
LIHC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.46	6.53	0.33	2.38e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.4	7.6	0.38	2.91e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg16724585	chr3:197361211	NA	-0.42	-6.15	-0.32	2.21e-9	Pancreatic cancer;
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg20090690	chr10:134436459	INPP5A	-0.47	-6.08	-0.31	3.18e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.61	-8.8	-0.43	7e-17	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs8048589	0.515	rs4780412	chr16:12232409	A/G	cg02910054	chr16:12241554	SNX29	0.24	5.85	0.3	1.14e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LIHC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.58	5.72	0.3	2.3e-8	Neutrophil percentage of white cells;
LIHC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.52	6.63	0.34	1.33e-10	Alzheimer's disease;
LIHC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.92	0.31	7.65e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.28	6.21	0.32	1.52e-9	Corneal astigmatism;
LIHC	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.32	-0.45	1.52e-18	Capecitabine sensitivity;
LIHC	cis	rs244293	0.931	rs244297	chr17:53241700	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.17	-0.36	4.8e-12	Menarche (age at onset);
LIHC	cis	rs6024905	0.565	rs6024991	chr20:36970167	C/G	cg07053727	chr20:36965646	BPI	-0.58	-10.88	-0.51	7.38e-24	Bipolar disorder and schizophrenia;
LIHC	trans	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg01134436	chr17:81009848	B3GNTL1	0.8	6.97	0.35	1.59e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg03037974	chr15:76606532	NA	0.73	14.33	0.61	8.54e-37	Blood metabolite levels;
LIHC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-0.84	-6.25	-0.32	1.23e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.82	-13.05	-0.58	7.15e-32	Colorectal cancer;
LIHC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.34	5.99	0.31	5.3e-9	Sarcoidosis;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18000306	chr6:288505	NA	0.35	6.35	0.32	6.7e-10	Menopause (age at onset);
LIHC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.79	11.89	0.54	1.67e-27	Obesity-related traits;
LIHC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.87	16.2	0.66	3.3e-44	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.57	7.57	0.38	3.47e-13	Coronary artery disease;
LIHC	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.8	9.11	0.44	7.24e-18	Exhaled nitric oxide output;
LIHC	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.62	-10.11	-0.48	3.26e-21	Schizophrenia;
LIHC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.94	12.03	0.55	5.05e-28	HIV-1 control;
LIHC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18252515	chr7:66147081	NA	0.41	5.78	0.3	1.71e-8	Aortic root size;
LIHC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.07	-0.36	8.66e-12	Personality dimensions;
LIHC	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.69	0.46	9.01e-20	Corneal astigmatism;
LIHC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.67	-6.9	-0.35	2.59e-11	Vitiligo;
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.7	-9.11	-0.44	7.05e-18	Migraine;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02283353	chr19:622406	POLRMT	0.43	6.51	0.33	2.66e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.64	11.74	0.54	5.79e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.12	0.4	8.79e-15	Schizophrenia;
LIHC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.54e-9	Aortic root size;
LIHC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg18867708	chr6:26865862	GUSBL1	-0.49	-7.5	-0.38	5.47e-13	Schizophrenia;
LIHC	cis	rs3736594	0.513	rs56725354	chr2:27824168	G/C	cg27432699	chr2:27873401	GPN1	0.46	6.92	0.35	2.29e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.58	8.5	0.42	5.77e-16	Platelet count;
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.73	10.66	0.5	4.23e-23	Menarche (age at onset);
LIHC	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.85	-0.3	1.18e-8	Biliary atresia;
LIHC	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-7.15	-0.36	5.2e-12	Response to antipsychotic treatment;
LIHC	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.44	-5.97	-0.31	5.93e-9	Coronary artery calcification;
LIHC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.69	-9.5	-0.46	3.87e-19	Corneal structure;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg24296786	chr1:45957014	TESK2	-0.48	-7.02	-0.36	1.17e-11	Platelet count;
LIHC	cis	rs12602486	1.000	rs79296687	chr17:42262067	C/T	cg08193365	chr17:42277699	NA	1.0	6.87	0.35	3.09e-11	Glycated hemoglobin levels;
LIHC	cis	rs74233809	1.000	rs17094683	chr10:104851301	G/T	cg03493300	chr10:104813866	CNNM2	0.46	6.29	0.32	9.93e-10	Birth weight;
LIHC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.97	-0.31	5.95e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg03037974	chr15:76606532	NA	-0.6	-9.94	-0.47	1.27e-20	Blood metabolite levels;
LIHC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg05043794	chr9:111880884	C9orf5	-0.26	-6.73	-0.34	7.36e-11	Menarche (age at onset);
LIHC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg02527881	chr3:46936655	PTH1R	0.33	6.52	0.33	2.59e-10	Colorectal cancer;
LIHC	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg16275483	chr1:110013120	SYPL2	-0.52	-6.5	-0.33	2.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.62	10.8	0.5	1.37e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.59	10.36	0.49	4.87e-22	Height;
LIHC	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.28	-0.32	1.01e-9	Bipolar disorder;
LIHC	cis	rs965469	1.000	rs6139088	chr20:3329063	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.59e-11	IFN-related cytopenia;
LIHC	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	0.74	8.19	0.4	5.33e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.86	-0.39	5.04e-14	Coronary artery disease;
LIHC	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.3	7.27	0.37	2.47e-12	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-9.7	-0.46	8.24e-20	Mean corpuscular volume;
LIHC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.63	9.24	0.45	2.71e-18	Menarche (age at onset);
LIHC	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	1.07	11.89	0.54	1.59e-27	IgG glycosylation;
LIHC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.71	8.14	0.4	7.58e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	trans	rs9641123	0.639	rs2528528	chr7:93205096	T/C	cg09745688	chr16:2908918	PRSS22	-0.37	-6.35	-0.32	6.73e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg05590025	chr7:65112418	INTS4L2	0.62	6.79	0.34	4.9e-11	Diabetic kidney disease;
LIHC	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.4	8.56	0.42	3.9e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.44	7.38	0.37	1.18e-12	Prevalent atrial fibrillation;
LIHC	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	0.71	11.81	0.54	3.09e-27	Testicular germ cell tumor;
LIHC	cis	rs72843506	0.586	rs74429763	chr17:19863519	G/C	cg12065943	chr17:19881925	AKAP10	-0.39	-6.58	-0.34	1.78e-10	Schizophrenia;
LIHC	cis	rs2574704	0.886	rs7638595	chr3:11635511	A/G	cg15876825	chr3:11651881	VGLL4	-0.47	-7.59	-0.38	3.12e-13	Body mass index;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.59	-9.12	-0.44	6.49e-18	Renal cell carcinoma;
LIHC	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	0.81	14.22	0.61	2.16e-36	Eosinophil percentage of white cells;
LIHC	trans	rs494453	0.538	rs2789544	chr1:112181963	G/A	cg13908074	chr2:149259371	MBD5	-0.38	-6.05	-0.31	3.7e-9	Osteoporosis-related phenotypes;
LIHC	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg11812906	chr14:75593930	NEK9	0.43	6.58	0.34	1.81e-10	IgG glycosylation;
LIHC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg15744005	chr10:104629667	AS3MT	-0.41	-9.06	-0.44	1.02e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	trans	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg26939375	chr7:64535504	NA	-0.43	-6.8	-0.35	4.57e-11	Aortic root size;
LIHC	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg14515779	chr1:101123966	NA	-0.42	-5.95	-0.31	6.54e-9	Monocyte count;
LIHC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.41	-6.61	-0.34	1.45e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.33	-7.09	-0.36	7.52e-12	Longevity;
LIHC	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.36	7.52	0.38	4.81e-13	Sitting height ratio;
LIHC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.12	0.4	8.8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg03854865	chr6:26224070	HIST1H3E	0.71	7.81	0.39	7.07e-14	Gout;Renal underexcretion gout;
LIHC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-8.71	-0.43	1.28e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.5	-7.08	-0.36	8.32e-12	Body mass index;
LIHC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26897989	chr16:1907736	C16orf73	-0.49	-6.23	-0.32	1.34e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg17279839	chr7:150038598	RARRES2	0.59	11.96	0.54	8.98e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs972578	1.000	rs1569507	chr22:43356699	A/G	cg01576275	chr22:43409880	NA	0.33	5.81	0.3	1.43e-8	Mean platelet volume;
LIHC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-6.07	-0.31	3.38e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.48	-0.37	6.4e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.28	0.45	2.04e-18	Hemoglobin concentration;
LIHC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.44	5.9	0.3	8.89e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.45	-7.4	-0.37	1.1e-12	Corneal astigmatism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06812693	chr4:26323246	RBPJ	0.48	6.55	0.33	2.11e-10	Lung function (FEV1/FVC);
LIHC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.36	-5.88	-0.3	9.69e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.92	0.35	2.21e-11	Ileal carcinoids;
LIHC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.86	14.92	0.63	4.06e-39	Headache;
LIHC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg07636037	chr3:49044803	WDR6	-0.81	-7.88	-0.39	4.45e-14	Cognitive function;
LIHC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.47	6.84	0.35	3.7e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.97	-0.35	1.59e-11	Diabetic kidney disease;
LIHC	trans	rs6489882	0.867	rs7134391	chr12:113366691	A/G	cg10175203	chr3:128143634	NA	-0.37	-6.12	-0.31	2.57e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.48e-8	Axial length;
LIHC	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg00204748	chr12:29376779	FAR2	0.38	6.82	0.35	4.1e-11	QT interval;
LIHC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18252515	chr7:66147081	NA	-0.43	-6.02	-0.31	4.37e-9	Aortic root size;
LIHC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.75e-22	Hemoglobin concentration;
LIHC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-12.7	-0.57	1.6e-30	Headache;
LIHC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.82	0.43	5.8e-17	Motion sickness;
LIHC	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-1.09	-13.71	-0.6	2.13e-34	Blood protein levels;
LIHC	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.18	-0.44	4.33e-18	Exhaled nitric oxide output;
LIHC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.73	12.82	0.57	5.55e-31	Platelet count;
LIHC	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg23682824	chr7:23144976	KLHL7	0.4	6.08	0.31	3.27e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs507080	0.845	rs667982	chr11:118562767	T/C	cg04173919	chr11:118528438	PHLDB1	0.34	6.34	0.32	7.14e-10	Serum metabolite levels;
LIHC	cis	rs17817600	0.866	rs12283410	chr11:85641955	G/T	cg03102841	chr11:85646010	NA	0.43	5.71	0.3	2.41e-8	Alzheimer's disease;
LIHC	trans	rs36715	1.000	rs36705	chr5:127554486	A/G	cg16011800	chr17:1958478	HIC1	-0.41	-6.08	-0.31	3.18e-9	Breast cancer;
LIHC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg10932868	chr11:921992	NA	0.39	7.37	0.37	1.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-7.74	-0.39	1.16e-13	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs950169	0.579	rs881983	chr15:84647308	C/T	cg24036039	chr1:3397125	ARHGEF16	0.4	6.59	0.34	1.66e-10	Schizophrenia;
LIHC	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg09695851	chr17:3907499	NA	0.48	5.74	0.3	2.1e-8	Type 2 diabetes;
LIHC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.6	9.33	0.45	1.36e-18	Longevity;Endometriosis;
LIHC	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.4	7.08	0.36	8.33e-12	Obesity;
LIHC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.13	-0.36	5.98e-12	Body mass index;
LIHC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.4	-6.81	-0.35	4.4e-11	Headache;
LIHC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	8.29	0.41	2.58e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02386183	chr20:13619553	TASP1	0.5	6.93	0.35	2.04e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.53	-6.15	-0.32	2.19e-9	Ulcerative colitis;
LIHC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	7.18	0.36	4.44e-12	Ulcerative colitis;
LIHC	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	0.8	9.17	0.44	4.45e-18	Exhaled nitric oxide output;
LIHC	cis	rs28830936	0.966	rs1531140	chr15:42125234	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.96	-0.31	6.37e-9	Diastolic blood pressure;
LIHC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg14222432	chr12:29376421	FAR2	-0.35	-6.52	-0.33	2.46e-10	QT interval;
LIHC	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg00792783	chr2:198669748	PLCL1	0.45	6.62	0.34	1.4e-10	Dermatomyositis;
LIHC	cis	rs1555399	0.967	rs1555397	chr14:67984540	G/A	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.89	-0.3	9.23e-9	Parkinson's disease;
LIHC	cis	rs72843506	0.722	rs16964352	chr17:20148408	A/G	cg12065943	chr17:19881925	AKAP10	-0.31	-5.78	-0.3	1.66e-8	Schizophrenia;
LIHC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.82	15.06	0.63	1.18e-39	Multiple myeloma (IgH translocation);
LIHC	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06634786	chr22:41940651	POLR3H	-0.55	-5.8	-0.3	1.52e-8	Vitiligo;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03552398	chr14:89021307	PTPN21	-0.43	-6.09	-0.31	3.07e-9	Cognitive function;
LIHC	cis	rs61677309	0.929	rs12576119	chr11:118158441	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.38	-0.56	2.44e-29	Primary sclerosing cholangitis;
LIHC	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02228675	chr17:40259724	DHX58	-0.25	-5.77	-0.3	1.78e-8	Fibrinogen levels;
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.91	-0.3	8.45e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.43	-6.28	-0.32	1.04e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs7945718	0.622	rs4643058	chr11:12689454	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.76	0.34	5.99e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.85	12.32	0.55	4.17e-29	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.88	10.87	0.51	7.55e-24	Coronary artery disease;
LIHC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.46	-10.79	-0.5	1.49e-23	Iron status biomarkers (transferrin levels);
LIHC	cis	rs2637266	1.000	rs7897061	chr10:78366776	C/T	cg18941641	chr10:78392320	NA	0.28	5.89	0.3	9.12e-9	Pulmonary function;
LIHC	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.52	0.53	3.59e-26	Alzheimer's disease;
LIHC	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg22153463	chr1:85462885	MCOLN2	0.53	6.28	0.32	1.03e-9	Serum sulfate level;
LIHC	cis	rs6747952	0.899	rs12731	chr2:239087912	G/A	cg17459225	chr2:239074497	NA	0.36	5.81	0.3	1.46e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.76	-11.4	-0.52	9.78e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	0.55	10.39	0.49	3.56e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	26.53	0.82	5.23e-85	Schizophrenia;
LIHC	cis	rs1355223	0.902	rs12800220	chr11:34701617	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.12	-0.31	2.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.98	-17.56	-0.69	1.2e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs8081395	0.899	rs2777898	chr17:57815608	G/C	cg02344993	chr17:57696989	CLTC	-0.45	-7.32	-0.37	1.73e-12	White blood cell count;
LIHC	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.37e-8	Lewy body disease;
LIHC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.59	0.34	1.67e-10	Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12933314	chr7:4815160	KIAA0415	0.47	7.35	0.37	1.52e-12	Pancreatic cancer;
LIHC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.75	-9.94	-0.47	1.29e-20	Schizophrenia;
LIHC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Obesity-related traits;
LIHC	cis	rs7095607	0.560	rs2673794	chr10:69926097	T/C	cg18986048	chr10:69913749	MYPN	0.48	7.11	0.36	6.77e-12	Lung function (FVC);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17665931	chr19:38894173	FAM98C	0.5	6.61	0.34	1.46e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	cis	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg01364799	chr7:75623366	TMEM120A	-0.46	-6.65	-0.34	1.16e-10	Eotaxin levels;
LIHC	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	cis	rs11622475	0.677	rs59119562	chr14:104345703	C/T	cg12183467	chr14:104352244	NA	-0.45	-6.5	-0.33	2.9e-10	Bipolar disorder;
LIHC	cis	rs903552	0.736	rs2132196	chr15:102007089	A/G	cg04789225	chr15:102009795	PCSK6	-0.45	-5.99	-0.31	5.26e-9	Diabetic kidney disease;
LIHC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.87	0.51	7.94e-24	Platelet count;
LIHC	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.24	-20.56	-0.74	1.01e-61	Corneal structure;
LIHC	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg08539965	chr1:21396338	EIF4G3	0.34	5.99	0.31	5.32e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.41	5.8	0.3	1.5e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs807669	0.527	rs11089259	chr22:19190143	C/T	cg02655711	chr22:19163373	SLC25A1	0.36	6.07	0.31	3.46e-9	Metabolite levels;
LIHC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.52	7.08	0.36	8.47e-12	Autism spectrum disorder-related traits;
LIHC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg02297831	chr4:17616191	MED28	0.48	7.24	0.36	3.08e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.83	-13.21	-0.58	1.76e-32	Colorectal cancer;
LIHC	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.61	-11.03	-0.51	2.17e-24	Breast cancer;
LIHC	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.3	0.32	8.94e-10	Ulcerative colitis;
LIHC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	9.56	0.46	2.49e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg22834771	chr12:69754056	YEATS4	-0.46	-7.96	-0.4	2.48e-14	Response to diuretic therapy;
LIHC	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg15192750	chr16:69999425	NA	0.46	7.04	0.36	1.09e-11	IgE levels;
LIHC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.74	0.67	2.27e-46	Parkinson's disease;
LIHC	trans	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg25214090	chr10:38739885	LOC399744	-0.39	-6.24	-0.32	1.27e-9	Diastolic blood pressure;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg00091569	chr3:40428383	ENTPD3	0.39	6.64	0.34	1.25e-10	Renal cell carcinoma;
LIHC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	ch.11.42038R	chr11:967971	AP2A2	0.53	9.72	0.47	7.06e-20	Alzheimer's disease (late onset);
LIHC	cis	rs17106184	0.681	rs72902706	chr1:51212796	A/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg23533926	chr12:111358616	MYL2	0.33	6.37	0.33	6.02e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.72	0.34	7.43e-11	Bipolar disorder;
LIHC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg12374095	chr12:54320830	NA	0.45	6.77	0.34	5.55e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg02023728	chr11:77925099	USP35	0.33	5.96	0.31	6.22e-9	Alzheimer's disease (survival time);
LIHC	trans	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg18335740	chr13:41363409	SLC25A15	0.35	6.16	0.32	2.1e-9	Lewy body disease;
LIHC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.45	7.05	0.36	1.02e-11	Total body bone mineral density;
LIHC	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg07424592	chr7:64974309	NA	0.78	8.82	0.43	5.95e-17	Gout;
LIHC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg15105060	chr4:7024189	TBC1D14	-0.71	-6.0	-0.31	5.11e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.7	-10.51	-0.49	1.46e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.42	-5.81	-0.3	1.42e-8	Longevity;
LIHC	cis	rs12220238	0.822	rs10824160	chr10:76132267	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	trans	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.51	-0.53	3.76e-26	Coronary artery disease;
LIHC	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	1.01	9.67	0.46	1.05e-19	Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.06	0.55	3.69e-28	Prudent dietary pattern;
LIHC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	7.68	0.38	1.74e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.65	-12.8	-0.57	6.19e-31	Sense of smell;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg23049307	chr1:55353163	DHCR24	-0.45	-6.18	-0.32	1.83e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.51	-7.19	-0.36	4.11e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.63	-16.04	-0.66	1.41e-43	Breast cancer;
LIHC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	7.3	0.37	2e-12	Schizophrenia;
LIHC	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.55	7.41	0.37	1.02e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs8081395	0.834	rs2665397	chr17:57826731	C/A	cg13753209	chr17:57696993	CLTC	-0.48	-7.3	-0.37	2.08e-12	White blood cell count;
LIHC	cis	rs8014671	0.567	rs6573971	chr14:71011469	C/T	cg25576086	chr14:70833871	SYNJ2BP	0.46	7.34	0.37	1.61e-12	Prostate cancer;
LIHC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg12042659	chr19:58951599	ZNF132	0.37	6.24	0.32	1.33e-9	Uric acid clearance;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.49	6.99	0.35	1.41e-11	Longevity;Endometriosis;
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.63	0.46	1.38e-19	Height;
LIHC	cis	rs8084351	0.577	rs4474758	chr18:50641829	G/A	cg24270629	chr18:50823537	DCC	0.43	6.36	0.33	6.37e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.3	-17.22	-0.68	2.59e-48	Diabetic kidney disease;
LIHC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.32	14.2	0.61	2.75e-36	Eosinophil percentage of granulocytes;
LIHC	cis	rs4845459	0.933	rs6700181	chr1:152593087	A/G	cg20634798	chr1:152595351	LCE3A	-0.31	-5.93	-0.31	7.34e-9	Psoriasis;
LIHC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.44	-6.77	-0.34	5.59e-11	Height;
LIHC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.35	-0.32	6.7e-10	Morning vs. evening chronotype;
LIHC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.54	-0.33	2.27e-10	Height;
LIHC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.58	0.38	3.35e-13	Lung cancer;
LIHC	cis	rs903552	1.000	rs12907048	chr15:102003873	G/T	cg06707286	chr15:102010195	PCSK6	-0.43	-6.09	-0.31	3e-9	Diabetic kidney disease;
LIHC	cis	rs67981189	0.593	rs221904	chr14:71599488	A/C	cg15816911	chr14:71606274	NA	-0.43	-6.95	-0.35	1.8e-11	Schizophrenia;
LIHC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.89	-0.57	3.01e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg11946769	chr3:48343235	NME6	-0.47	-6.24	-0.32	1.28e-9	Educational attainment (years of education);
LIHC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.32	7.34	0.37	1.55e-12	Crohn's disease;
LIHC	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg04065206	chr12:109973212	UBE3B	-0.46	-5.88	-0.3	9.61e-9	Neuroticism;
LIHC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-0.8	-10.86	-0.51	8.64e-24	Monocyte percentage of white cells;
LIHC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.76e-46	Parkinson's disease;
LIHC	cis	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg18809830	chr7:99032528	PTCD1	-0.83	-6.67	-0.34	1e-10	Blood metabolite levels;
LIHC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	0.86	11.54	0.53	3.03e-26	Skin colour saturation;
LIHC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.44	-8.65	-0.42	1.97e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.74	12.37	0.56	2.74e-29	Menopause (age at onset);
LIHC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg12064134	chr16:90016061	DEF8	0.42	5.83	0.3	1.27e-8	Skin colour saturation;
LIHC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg14067834	chr17:29058358	SUZ12P	0.63	6.29	0.32	9.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs3783890	0.887	rs12889783	chr14:93812850	C/T	cg02802420	chr16:69363236	PDF;COG8	0.33	6.29	0.32	9.89e-10	Body mass index;
LIHC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	13.77	0.6	1.23e-34	Multiple sclerosis;
LIHC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.08	-0.36	8.26e-12	Obesity-related traits;
LIHC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg06565975	chr8:143823917	SLURP1	-0.39	-6.43	-0.33	4.31e-10	Urinary tract infection frequency;
LIHC	cis	rs11955398	0.625	rs10939857	chr5:59956801	C/T	cg02684056	chr5:59996105	DEPDC1B	0.42	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.41	-5.71	-0.3	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.34	7.29	0.37	2.23e-12	Bone mineral density;
LIHC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.71	9.96	0.47	1.11e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg08824895	chr13:115047677	UPF3A	0.51	7.49	0.38	6.11e-13	Schizophrenia;
LIHC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg01256987	chr12:42539512	GXYLT1	-0.36	-5.97	-0.31	6.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.5	8.44	0.41	9.43e-16	Mean corpuscular volume;
LIHC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg07117364	chr1:16154769	NA	0.4	7.01	0.35	1.31e-11	Dilated cardiomyopathy;
LIHC	cis	rs9322817	0.691	rs7753202	chr6:105215289	T/C	cg02098413	chr6:105308735	HACE1	-0.42	-7.54	-0.38	4.13e-13	Thyroid stimulating hormone;
LIHC	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.34	7.94	0.39	2.91e-14	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-5.77	-0.3	1.82e-8	Total body bone mineral density;
LIHC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.99	-0.48	8.58e-21	Response to antipsychotic treatment;
LIHC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.11	0.36	6.65e-12	Monocyte percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25231972	chr10:31608136	ZEB1;LOC220930	0.45	6.17	0.32	1.93e-9	Lung function (FEV1/FVC);
LIHC	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg15704280	chr7:45808275	SEPT13	-0.43	-6.42	-0.33	4.54e-10	Height;
LIHC	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg08126542	chr6:37504118	NA	-0.39	-6.22	-0.32	1.47e-9	Cognitive performance;
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg25894440	chr7:65020034	NA	-0.54	-6.13	-0.31	2.37e-9	Diabetic kidney disease;
LIHC	trans	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg01134436	chr17:81009848	B3GNTL1	0.78	6.71	0.34	8.12e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.44	8.1	0.4	9.53e-15	Schizophrenia;
LIHC	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-0.78	-9.39	-0.45	8.39e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs2274273	0.688	rs6573001	chr14:55556502	A/G	cg01864836	chr14:55583639	NA	-0.35	-6.65	-0.34	1.16e-10	Protein biomarker;
LIHC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.77	11.32	0.52	1.84e-25	Vitamin D levels;
LIHC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.44	-7.11	-0.36	6.83e-12	Menarche (age at onset);
LIHC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-11.84	-0.54	2.4e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13072611	chr3:133524485	SRPRB	-0.5	-6.47	-0.33	3.4e-10	Systolic blood pressure;
LIHC	cis	rs66569888	0.583	rs66529457	chr2:106727010	G/A	cg16099169	chr2:106886729	NA	-0.62	-6.76	-0.34	5.91e-11	Facial morphology (factor 23);
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg14671364	chr1:107599128	PRMT6	-0.53	-7.76	-0.39	9.78e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg23461800	chr14:103021989	NA	0.47	6.48	0.33	3.12e-10	Platelet count;
LIHC	cis	rs45430	0.635	rs398800	chr21:42742212	A/C	cg06102954	chr21:42741788	MX2	-0.39	-6.14	-0.32	2.31e-9	Melanoma;
LIHC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.42	-5.95	-0.31	6.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.4	6.61	0.34	1.46e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.72	-9.73	-0.47	6.57e-20	Asthma;
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.57	6.41	0.33	4.77e-10	Axial length;
LIHC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.39	0.37	1.15e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.15	-10.76	-0.5	1.93e-23	Breast cancer;
LIHC	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.41	0.45	7.5e-19	Coffee consumption (cups per day);
LIHC	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	1.01	20.35	0.74	6.81e-61	Height;
LIHC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg19678392	chr7:94953810	PON1	-0.45	-5.89	-0.3	8.99e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs5753037	0.653	rs131273	chr22:30153721	T/C	cg01021169	chr22:30184971	ASCC2	-0.31	-5.75	-0.3	1.95e-8	Type 1 diabetes;
LIHC	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.82	-0.35	4.03e-11	Height;
LIHC	cis	rs75908454	1.000	rs77432181	chr6:169990120	A/G	cg19338460	chr6:170058176	WDR27	-0.89	-8.33	-0.41	1.94e-15	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg04865290	chr3:52927548	TMEM110	-0.44	-6.51	-0.33	2.61e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.59	0.46	1.89e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.64	-10.36	-0.49	4.56e-22	Inflammatory bowel disease;
LIHC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	10.83	0.51	1.08e-23	Body mass index (adult);
LIHC	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.45	6.17	0.32	1.95e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.94	-12.78	-0.57	7.61e-31	Post bronchodilator FEV1;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02792086	chr2:62684218	NA	-0.43	-6.21	-0.32	1.54e-9	Pancreatic cancer;
LIHC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.42	-0.33	4.5e-10	Type 2 diabetes;
LIHC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg03013999	chr17:37608204	MED1	-0.36	-5.97	-0.31	5.89e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs2363709	0.892	rs2087553	chr3:67428164	G/A	cg13681781	chr9:139102396	QSOX2	0.83	6.34	0.32	7.3e-10	IgE levels;
LIHC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00958927	chr1:175162553	KIAA0040	-0.39	-6.25	-0.32	1.24e-9	Alcohol dependence;
LIHC	cis	rs611744	0.967	rs695028	chr8:109239324	T/C	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.86	0.6	5.82e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.62	-8.38	-0.41	1.39e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.08	12.81	0.57	6.14e-31	Vitiligo;
LIHC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	11.93	0.54	1.11e-27	High light scatter reticulocyte count;
LIHC	cis	rs10508774	0.810	rs11008941	chr10:32733307	A/C	cg01819863	chr10:32635814	EPC1	0.61	5.88	0.3	9.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6750047	0.567	rs336039	chr2:38258827	C/T	cg07380506	chr2:38303506	CYP1B1	-0.52	-6.82	-0.35	4.25e-11	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs4728302	0.869	rs7779370	chr7:133595702	T/C	cg10665199	chr7:133106180	EXOC4	0.37	6.54	0.33	2.24e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-10.21	-0.48	1.56e-21	Vitiligo;
LIHC	cis	rs3015497	0.554	rs8011039	chr14:51091267	C/T	cg09863266	chr14:51125203	SAV1	-0.39	-6.26	-0.32	1.14e-9	Mean platelet volume;
LIHC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.78	15.26	0.64	1.75e-40	Mortality in heart failure;
LIHC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg24209194	chr3:40518798	ZNF619	0.45	6.6	0.34	1.55e-10	Renal cell carcinoma;
LIHC	cis	rs17177078	0.558	rs8057788	chr16:24866174	C/T	cg06028605	chr16:24865363	SLC5A11	0.45	6.48	0.33	3.29e-10	Type 2 diabetes (dietary heme iron intake interaction);
LIHC	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.35	6.26	0.32	1.15e-9	Metabolite levels;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26076054	chr5:421317	AHRR	0.27	5.89	0.3	9.05e-9	Cystic fibrosis severity;
LIHC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.5	-8.27	-0.41	3.08e-15	Blood metabolite levels;
LIHC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.56	7.22	0.36	3.44e-12	Parkinson's disease;
LIHC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-12.03	-0.55	4.74e-28	Chronic sinus infection;
LIHC	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	trans	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.88	-15.84	-0.65	9.2e-43	Eotaxin levels;
LIHC	cis	rs7520050	0.966	rs6429582	chr1:46321843	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	-0.39	-5.88	-0.3	9.63e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs57244997	0.725	rs73030431	chr6:162439575	G/A	cg17173639	chr6:162384350	PARK2	-0.52	-6.76	-0.34	5.88e-11	Mosquito bite size;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.84	-0.35	3.64e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.54	8.55	0.42	4.29e-16	Longevity;Endometriosis;
LIHC	cis	rs77669868	0.866	rs3782023	chr11:114035516	G/C	cg01914181	chr11:114070210	ZBTB16	0.6	7.36	0.37	1.42e-12	Monocyte percentage of white cells;
LIHC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.5	7.92	0.39	3.42e-14	Diastolic blood pressure;
LIHC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.3	0.37	2.04e-12	Morning vs. evening chronotype;
LIHC	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg07424592	chr7:64974309	NA	-0.77	-8.94	-0.44	2.49e-17	Gout;
LIHC	cis	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg01231543	chr16:68741748	NA	0.38	6.17	0.32	1.97e-9	Colorectal cancer;
LIHC	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.8	0.35	4.65e-11	Systolic blood pressure;
LIHC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.73	-13.22	-0.58	1.59e-32	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.02	0.4	1.68e-14	Corneal astigmatism;
LIHC	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.3	5.87	0.3	1.06e-8	Asthma;
LIHC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.44	6.77	0.34	5.65e-11	Prostate cancer;
LIHC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.47	-7.59	-0.38	3.07e-13	Cognitive function;
LIHC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.35	0.52	1.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.71	-9.07	-0.44	9.62e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	0.92	16.41	0.66	4.62e-45	Parkinson's disease;
LIHC	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg11642891	chr2:3452563	TTC15	-0.45	-7.2	-0.36	3.85e-12	Obesity-related traits;
LIHC	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.96	-8.77	-0.43	8.81e-17	White matter integrity;
LIHC	cis	rs8084351	0.517	rs8088299	chr18:50556725	T/G	cg24270629	chr18:50823537	DCC	0.41	6.21	0.32	1.52e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	1.02	19.69	0.73	3.16e-58	Breast cancer;
LIHC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg18202521	chr1:19600702	AKR7L	-0.36	-6.33	-0.32	7.67e-10	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.37	-0.33	6.02e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg12751644	chr20:60527061	NA	0.36	5.9	0.3	8.9e-9	Body mass index;
LIHC	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.68e-11	Blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25704407	chr19:1619401	TCF3	0.39	6.1	0.31	2.84e-9	Pancreatic cancer;
LIHC	cis	rs11673344	0.864	rs55921822	chr19:37496812	C/T	cg27390819	chr19:37464633	NA	-0.54	-6.51	-0.33	2.6200000000000003e-10	Obesity-related traits;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03321231	chr17:157219	RPH3AL	0.42	6.38	0.33	5.6e-10	Immature fraction of reticulocytes;
LIHC	cis	rs2073499	1.000	rs78020607	chr3:50254624	A/G	cg03645007	chr3:50255295	SLC38A3	0.47	6.33	0.32	7.66e-10	Schizophrenia;
LIHC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.25	-0.32	1.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.53	7.61	0.38	2.76e-13	Lung cancer;
LIHC	cis	rs3812111	0.774	rs493467	chr6:116429964	A/G	cg08036074	chr6:116424633	NT5DC1	0.67	12.09	0.55	2.93e-28	Age-related macular degeneration;
LIHC	cis	rs1419980	0.643	rs12229762	chr12:7776621	T/C	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.36e-8	HDL cholesterol levels;
LIHC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.5	8.35	0.41	1.71e-15	Chronic sinus infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17520314	chr17:79604207	NPLOC4	-0.48	-7.04	-0.36	1.06e-11	Cognitive function;
LIHC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.48	8.64	0.42	2.12e-16	Colorectal cancer;
LIHC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.47	7.72	0.39	1.34e-13	Multiple sclerosis;
LIHC	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.7	7.36	0.37	1.36e-12	Blood protein levels;
LIHC	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-6.42	-0.33	4.52e-10	Metabolite levels;
LIHC	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.58	10.12	0.48	3.07e-21	Diisocyanate-induced asthma;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg21635953	chr15:56538411	NA	-0.45	-6.08	-0.31	3.24e-9	Longevity;
LIHC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.18	30.71	0.86	2.55e-100	IgG glycosylation;
LIHC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.33	0.37	1.65e-12	Vitiligo;
LIHC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.79	0.34	5.1e-11	Body mass index;
LIHC	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.54	-6.98	-0.35	1.53e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg21466736	chr12:48725269	NA	0.61	9.11	0.44	7.19e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg17724175	chr1:150552817	MCL1	0.37	7.35	0.37	1.52e-12	Melanoma;
LIHC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.79	8.89	0.43	3.57e-17	Cognitive test performance;
LIHC	cis	rs507080	0.922	rs561845	chr11:118558827	A/G	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.35	-0.32	6.9e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg15123519	chr2:136567270	LCT	0.44	8.64	0.42	2.14e-16	Mosquito bite size;
LIHC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg03037974	chr15:76606532	NA	0.77	15.22	0.64	2.7e-40	Blood metabolite levels;
LIHC	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg03037974	chr15:76606532	NA	-0.55	-9.08	-0.44	8.77e-18	Blood metabolite levels;
LIHC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.33	8.66	0.42	1.91e-16	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.58	-10.11	-0.48	3.34e-21	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg20282741	chr1:53704012	MAGOH	-0.41	-6.03	-0.31	4.14e-9	Eotaxin levels;
LIHC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg12798992	chr6:167411361	FGFR1OP	-0.54	-8.28	-0.41	2.76e-15	Lung cancer;
LIHC	cis	rs55702914	0.746	rs7588530	chr2:198146698	A/C	cg10820045	chr2:198174542	NA	-0.41	-6.22	-0.32	1.41e-9	Major depression and alcohol dependence;
LIHC	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-7.18	-0.36	4.29e-12	Post bronchodilator FEV1;
LIHC	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg01652190	chr22:50026171	C22orf34	-0.35	-7.69	-0.38	1.58e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.26	-0.32	1.17e-9	Coronary artery disease;
LIHC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.51	8.55	0.42	4.21e-16	Obesity-related traits;
LIHC	trans	rs9940464	0.933	rs12597597	chr16:83367241	A/G	cg13016115	chr14:23388406	RBM23	0.38	6.18	0.32	1.81e-9	Malaria;
LIHC	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.41	6.9	0.35	2.58e-11	Crohn's disease;
LIHC	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	6.64	0.34	1.22e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.45	6.1	0.31	2.85e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7707921	0.881	rs12108833	chr5:81371755	A/G	cg15871215	chr5:81402204	ATG10	-0.63	-6.26	-0.32	1.12e-9	Breast cancer;
LIHC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.71	0.38	1.39e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.49	7.14	0.36	5.65e-12	Longevity;
LIHC	cis	rs6815814	0.731	rs10776482	chr4:38774785	A/G	cg06935464	chr4:38784597	TLR10	0.38	5.94	0.31	7.12e-9	Breast cancer;
LIHC	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg20435097	chr10:126320824	FAM53B	-0.41	-5.98	-0.31	5.5e-9	Cocaine dependence;
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.54	-6.48	-0.33	3.25e-10	Diastolic blood pressure;
LIHC	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-9.17	-0.44	4.43e-18	Response to antipsychotic treatment;
LIHC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg03959625	chr15:84868606	LOC388152	0.44	6.02	0.31	4.52e-9	Schizophrenia;
LIHC	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.65	10.1	0.48	3.54e-21	Type 2 diabetes;
LIHC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.76	11.65	0.53	1.25e-26	Corneal astigmatism;
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.63	10.34	0.49	5.67e-22	Glycated hemoglobin levels;
LIHC	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	0.56	6.85	0.35	3.34e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.62	9.77	0.47	4.64e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.56	-0.46	2.41e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg04310649	chr10:35416472	CREM	-0.42	-5.75	-0.3	1.96e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.08	9.83	0.47	3.04e-20	Diabetic retinopathy;
LIHC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.65	13.41	0.59	3.07e-33	Airflow obstruction;
LIHC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.73	0.54	6.4e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Total cholesterol levels;
LIHC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg16836995	chr17:43662488	NA	-0.76	-7.8	-0.39	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.85	-0.43	4.93e-17	Type 2 diabetes;
LIHC	cis	rs5753037	0.653	rs140123	chr22:30143206	A/G	cg01021169	chr22:30184971	ASCC2	0.32	5.92	0.3	7.73e-9	Type 1 diabetes;
LIHC	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.65	-10.51	-0.49	1.37e-22	Inflammatory bowel disease;
LIHC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg03013999	chr17:37608204	MED1	0.36	6.07	0.31	3.41e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg18762849	chr10:81741832	NA	-0.48	-6.07	-0.31	3.32e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.49	-0.33	3.09e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.5	-7.83	-0.39	6.21e-14	Educational attainment;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14935078	chr19:17414399	ABHD8	0.54	7.0	0.35	1.36e-11	Lung function (FEV1/FVC);
LIHC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.05	0.4	1.36e-14	Lung cancer;
LIHC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.93	-0.35	2.17e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg01646665	chr1:156251436	TMEM79;SMG5	0.31	5.91	0.3	8.15e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	8.54	0.42	4.53e-16	Diastolic blood pressure;
LIHC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg12863693	chr15:85201151	NMB	0.44	6.3	0.32	9.15e-10	Schizophrenia;
LIHC	cis	rs3018712	0.532	rs948861	chr11:68420622	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.17e-8	Total body bone mineral density;
LIHC	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.49	-9.14	-0.44	5.66e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.55	-6.68	-0.34	9.64e-11	Breast cancer;
LIHC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs238295	0.631	rs6038205	chr20:5549073	T/A	cg24001556	chr20:5591874	RP5-1022P6.2	-0.53	-7.19	-0.36	4.16e-12	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.76	6.83	0.35	3.85e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LIHC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg20933634	chr6:27740509	NA	0.48	6.27	0.32	1.09e-9	Parkinson's disease;
LIHC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.41	6.49	0.33	2.95e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs41997	1.000	rs1014268	chr7:118035388	A/C	cg20597117	chr7:117824011	NAA38	-0.37	-5.96	-0.31	6.28e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg03983715	chr16:68378420	PRMT7	-0.5	-5.88	-0.3	9.57e-9	Schizophrenia;
LIHC	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.32	-6.08	-0.31	3.14e-9	Body mass index;
LIHC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.3	-0.37	2.05e-12	Bipolar disorder;
LIHC	cis	rs1864585	0.806	rs17778223	chr8:10729692	A/T	cg21756720	chr8:11724777	CTSB	-0.5	-5.99	-0.31	5.21e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.45	8.09	0.4	1.05e-14	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.18	0.32	1.79e-9	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.23	0.55	8.88e-29	Alzheimer's disease;
LIHC	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg02376097	chr19:46275166	DMPK	-0.45	-6.94	-0.35	1.96e-11	Coronary artery disease;
LIHC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.21	0.72	2.72e-56	Smoking behavior;
LIHC	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.42e-11	Dermatomyositis;
LIHC	trans	rs6600671	0.934	rs12060031	chr1:121243450	A/G	cg09829573	chr1:144692074	NBPF9	0.43	7.19	0.36	4.08e-12	Hip geometry;
LIHC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.69	7.48	0.37	6.43e-13	Neuroticism;
LIHC	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.37	-0.37	1.32e-12	Body mass index;
LIHC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.39	-5.94	-0.31	6.91e-9	Lung cancer;
LIHC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.86e-9	Aortic root size;
LIHC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.68	11.08	0.51	1.36e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs853679	0.769	rs7752608	chr6:28301195	A/T	cg01086810	chr6:28234912	ZNF187	0.95	6.35	0.32	6.88e-10	Depression;
LIHC	cis	rs7116495	1.000	rs4945340	chr11:71619100	C/T	cg26138937	chr11:71823887	C11orf51	-0.67	-6.87	-0.35	3e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg23091122	chr1:110024289	SYPL2	-0.45	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg01864836	chr14:55583639	NA	-0.42	-8.26	-0.41	3.21e-15	Protein biomarker;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg14709524	chr16:89940631	TCF25	0.47	6.05	0.31	3.73e-9	Skin colour saturation;
LIHC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg01200585	chr1:228362443	C1orf69	0.49	6.2	0.32	1.66e-9	Diastolic blood pressure;
LIHC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-7.74	-0.39	1.16e-13	Lymphocyte counts;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg16222790	chr8:144521374	ZC3H3	0.36	6.26	0.32	1.18e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1865721	0.682	rs7242637	chr18:73147492	A/C	cg26385618	chr18:73139727	C18orf62	-0.28	-7.48	-0.38	6.16e-13	Intelligence;
LIHC	cis	rs240764	0.725	rs7740826	chr6:101153665	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-6.49	-0.33	2.98e-10	Neuroticism;
LIHC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07305463	chr2:136567211	LCT	0.39	7.21	0.36	3.51e-12	Mosquito bite size;
LIHC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.4	-5.98	-0.31	5.47e-9	Iron status biomarkers;
LIHC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.4	-6.39	-0.33	5.5e-10	Height;
LIHC	cis	rs8044995	0.568	rs112086775	chr16:68310917	A/C	cg09835421	chr16:68378352	PRMT7	-0.62	-7.0	-0.35	1.35e-11	Schizophrenia;
LIHC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.99	0.54	6.99e-28	Post bronchodilator FEV1;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15861578	chr12:56511939	ZC3H10	0.38	6.09	0.31	3.11e-9	Cognitive function;
LIHC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.15	-0.48	2.54e-21	Total cholesterol levels;
LIHC	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg14930904	chr10:32216787	ARHGAP12	0.33	5.76	0.3	1.88e-8	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.51	6.46	0.33	3.53e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.59	8.58	0.42	3.33e-16	Blood metabolite levels;
LIHC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.92	-17.09	-0.68	9.37e-48	Aortic root size;
LIHC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17507749	chr15:85114479	UBE2QP1	0.63	7.18	0.36	4.38e-12	Schizophrenia;
LIHC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.16	-8.65	-0.42	2.07e-16	Body mass index;
LIHC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.63	7.96	0.4	2.64e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10744422	1.000	rs2343108	chr12:123331301	C/T	cg18912006	chr12:123335444	HIP1R	-0.63	-7.59	-0.38	3.02e-13	Schizophrenia;
LIHC	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.24e-10	Pulmonary function;
LIHC	cis	rs62229266	0.605	rs2835275	chr21:37460001	C/T	cg12218747	chr21:37451666	NA	-0.43	-7.02	-0.35	1.24e-11	Mitral valve prolapse;
LIHC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.65	13.52	0.59	1.16e-33	Airflow obstruction;
LIHC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.65	11.9	0.54	1.45e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs6489882	0.966	rs4238033	chr12:113378081	T/A	cg10175203	chr3:128143634	NA	0.38	6.18	0.32	1.8e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.45	8.37	0.41	1.52e-15	Prudent dietary pattern;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.69	-9.16	-0.44	4.98e-18	Coronary artery disease;
LIHC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.66	0.34	1.09e-10	Bipolar disorder;
LIHC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg13753209	chr17:57696993	CLTC	0.73	11.52	0.53	3.71e-26	Hemoglobin concentration;
LIHC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.93	17.09	0.68	9.35e-48	Breast cancer;
LIHC	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg07541023	chr7:19748670	TWISTNB	0.4	5.87	0.3	1.02e-8	Thyroid stimulating hormone;
LIHC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.47e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9596863	0.950	rs9568935	chr13:54397928	C/T	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.08e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.55	8.31	0.41	2.25e-15	Blood trace element (Zn levels);
LIHC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.93	0.43	2.6e-17	Schizophrenia;
LIHC	cis	rs8016982	0.662	rs7148100	chr14:81678096	A/G	cg01989461	chr14:81687754	GTF2A1	0.52	9.11	0.44	6.83e-18	Schizophrenia;
LIHC	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04004882	chr2:215674386	BARD1	0.49	6.65	0.34	1.19e-10	Neuroblastoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21271961	chr1:95285780	SLC44A3	0.4	6.12	0.31	2.62e-9	Cognitive function;
LIHC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.75	11.48	0.53	4.88e-26	Corneal astigmatism;
LIHC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.55	-10.14	-0.48	2.68e-21	Mean corpuscular volume;
LIHC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.69	10.09	0.48	4.12e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1198430	0.636	rs1009590	chr1:23823798	C/G	cg19827787	chr1:23763612	ASAP3	-0.37	-6.07	-0.31	3.33e-9	Total cholesterol levels;
LIHC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20060523	chr4:142557759	IL15	0.45	6.26	0.32	1.17e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.32	-0.37	1.84e-12	Mean platelet volume;
LIHC	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.97	-13.12	-0.58	4.01e-32	Macular telangiectasia type 2;
LIHC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.46	-6.5	-0.33	2.77e-10	Breast cancer;
LIHC	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.39	0.33	5.32e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.37	0.66	6.82e-45	Smoking behavior;
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg21486233	chr12:29375141	FAR2	0.32	6.35	0.32	6.81e-10	QT interval;
LIHC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.83	-0.3	1.28e-8	Type 2 diabetes;
LIHC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-6.0	-0.31	5.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.15	0.32	2.13e-9	Bipolar disorder;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.63	8.43	0.41	9.78e-16	Motion sickness;
LIHC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.18	13.01	0.58	1.02e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.68	11.67	0.53	9.94e-27	Crohn's disease;
LIHC	cis	rs754466	0.561	rs11002343	chr10:79705871	G/A	cg17075019	chr10:79541650	NA	-0.53	-5.93	-0.31	7.28e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.67	12.59	0.56	3.91e-30	Lymphocyte percentage of white cells;
LIHC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.48	-6.28	-0.32	1.03e-9	Subjective well-being;
LIHC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.39	7.31	0.37	1.88e-12	Schizophrenia;
LIHC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.64	11.1	0.51	1.21e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.93	0.31	7.44e-9	HDL cholesterol;
LIHC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	9.67	0.46	1.02e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.32	-0.52	1.88e-25	Total cholesterol levels;
LIHC	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.48e-9	Resting heart rate;
LIHC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-10.43	-0.49	2.72e-22	Coronary artery disease;
LIHC	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg23091122	chr1:110024289	SYPL2	-0.52	-6.93	-0.35	2.04e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs288342	0.832	rs288241	chr2:183643905	A/T	cg02625481	chr2:183667124	NA	-0.29	-6.06	-0.31	3.52e-9	Recurrent major depressive disorder;
LIHC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.33e-11	Cognitive function;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.11	0.55	2.38e-28	Height;
LIHC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.33	2.47e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.04	-0.31	3.92e-9	Blood pressure;
LIHC	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.6	7.44	0.37	8.04e-13	Exhaled nitric oxide output;
LIHC	cis	rs9783347	0.925	rs3802968	chr11:18343878	A/G	cg15585147	chr11:18324498	HPS5	0.43	6.65	0.34	1.18e-10	Pancreatic cancer;
LIHC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.77	0.39	9.29e-14	Lymphocyte counts;
LIHC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.46	-7.09	-0.36	7.64e-12	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg18306943	chr3:40428807	ENTPD3	-0.43	-7.57	-0.38	3.56e-13	Renal cell carcinoma;
LIHC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01200585	chr1:228362443	C1orf69	-0.39	-5.79	-0.3	1.59e-8	Diastolic blood pressure;
LIHC	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.2	12.67	0.57	1.95e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg08539965	chr1:21396338	EIF4G3	0.34	5.96	0.31	6.37e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02187348	chr16:89574699	SPG7	0.46	6.33	0.32	7.56e-10	Multiple myeloma (IgH translocation);
LIHC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.13	0.68	5.98e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.47	7.72	0.39	1.33e-13	Multiple sclerosis;
LIHC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.53	-9.58	-0.46	2.11e-19	Asthma;
LIHC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg08253296	chr5:74907592	NA	-0.53	-6.49	-0.33	2.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.77	14.32	0.61	9.17e-37	Blood protein levels;
LIHC	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	8.06	0.4	1.3e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.79	-17.68	-0.69	3.98e-50	Urate levels in lean individuals;
LIHC	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg25182066	chr10:30743637	MAP3K8	0.43	7.01	0.35	1.3e-11	Inflammatory bowel disease;
LIHC	cis	rs10785877	0.570	rs7043538	chr9:137109051	A/G	cg21243944	chr9:137118148	NA	0.46	6.52	0.33	2.51e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs9596863	0.750	rs1971924	chr13:54432432	T/G	ch.13.53330881F	chr13:54432880	NA	-0.44	-6.17	-0.32	1.89e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs4453791	0.932	rs13073816	chr3:38915346	A/T	cg02254461	chr3:39195904	CSRNP1	0.66	5.89	0.3	9.44e-9	Social communication problems;
LIHC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.43	-6.47	-0.33	3.35e-10	Cognitive function;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21448741	chr8:58168803	NA	0.34	6.13	0.31	2.42e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.34	6.83	0.35	3.83e-11	Multiple sclerosis;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg15248135	chr19:56154954	ZNF581	-0.45	-6.2	-0.32	1.66e-9	Alopecia areata;
LIHC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg20435097	chr10:126320824	FAM53B	-0.42	-6.25	-0.32	1.21e-9	Cocaine dependence;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06385459	chr4:82393184	RASGEF1B	0.47	6.6	0.34	1.53e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-6.99	-0.35	1.46e-11	Metabolite levels;
LIHC	cis	rs332507	0.830	rs3821532	chr3:124402618	G/T	cg05980111	chr3:124395277	KALRN	0.43	6.71	0.34	7.85e-11	Plateletcrit;
LIHC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg18270830	chr10:32634957	EPC1	0.53	6.44	0.33	4.04e-10	Sexual dysfunction (female);
LIHC	trans	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04565464	chr8:145669602	NFKBIL2	0.42	7.08	0.36	8.4e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs11663156	0.880	rs1502219	chr18:51054889	C/T	cg24270629	chr18:50823537	DCC	-0.5	-7.01	-0.35	1.32e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.23	0.41	4.09e-15	Platelet count;
LIHC	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.7	0.46	7.95e-20	Coffee consumption (cups per day);
LIHC	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	trans	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg17675199	chr6:35436792	RPL10A	-0.44	-9.2	-0.45	3.51e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.5e-12	Obesity-related traits;
LIHC	cis	rs6565681	0.943	rs6565683	chr17:78362300	A/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.53	-7.55	-0.38	3.92e-13	Moyamoya disease;
LIHC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.68e-9	Life satisfaction;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07047601	chr22:21337040	LZTR1	-0.46	-7.06	-0.36	9.08e-12	Triglycerides;
LIHC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.63	9.53	0.46	3.08e-19	Aortic root size;
LIHC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.37	5.99	0.31	5.46e-9	Menopause (age at onset);
LIHC	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg01864069	chr14:103024347	NA	-0.34	-5.85	-0.3	1.14e-8	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13662262	chr21:30364895	RNF160	0.49	7.2	0.36	3.8e-12	Cognitive function;
LIHC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg06565975	chr8:143823917	SLURP1	0.34	6.29	0.32	9.53e-10	Urinary tract infection frequency;
LIHC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.75	-0.3	1.95e-8	Menopause (age at onset);
LIHC	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.21e-9	Urinary tract infection frequency;
LIHC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg04083430	chr16:4736063	MGRN1	-0.42	-5.78	-0.3	1.64e-8	Schizophrenia;
LIHC	cis	rs1144333	1.000	rs17097836	chr1:76462006	T/A	cg22875332	chr1:76189707	ACADM	0.4	6.24	0.32	1.26e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs831571	0.668	rs17069879	chr3:64083417	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.54	6.44	0.33	3.96e-10	Type 2 diabetes;
LIHC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.19	13.18	0.58	2.28e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.48	-6.2	-0.32	1.67e-9	Pursuit maintenance gain;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13072611	chr3:133524485	SRPRB	-0.44	-6.14	-0.32	2.3e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.72	12.0	0.54	6.21e-28	Testicular germ cell tumor;
LIHC	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.63	7.36	0.37	1.4e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.59	-12.16	-0.55	1.62e-28	Plateletcrit;Platelet count;
LIHC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.6	7.73	0.39	1.21e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.17	-0.4	6.07e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg24879335	chr3:133465180	TF	-0.35	-7.7	-0.38	1.5e-13	Iron status biomarkers;
LIHC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.52	0.38	4.88e-13	Multiple sclerosis;
LIHC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	6.13	0.31	2.48e-9	Rheumatoid arthritis;
LIHC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.85	-13.43	-0.59	2.66e-33	Colorectal cancer;
LIHC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-9.89	-0.47	1.91e-20	Parkinson's disease;
LIHC	trans	rs6489882	0.966	rs7980275	chr12:113380529	T/A	cg10175203	chr3:128143634	NA	0.38	6.2	0.32	1.67e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.54	0.46	2.86e-19	Tonsillectomy;
LIHC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.34	-0.45	1.29e-18	Morning vs. evening chronotype;
LIHC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.91	16.84	0.67	8.86e-47	Menopause (age at onset);
LIHC	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.46	8.52	0.42	5.25e-16	Testicular germ cell tumor;
LIHC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.76	0.3	1.83e-8	Menopause (age at onset);
LIHC	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.38	-6.72	-0.34	7.81e-11	Asthma;
LIHC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.25e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23623486	chr14:32030546	NUBPL	0.45	6.24	0.32	1.31e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-6.1	-0.31	2.8e-9	Longevity;
LIHC	cis	rs11673344	0.864	rs11667146	chr19:37495395	G/A	cg27390819	chr19:37464633	NA	-0.54	-6.52	-0.33	2.56e-10	Obesity-related traits;
LIHC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.78	-0.39	8.93e-14	Neuroticism;
LIHC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg18769074	chr3:133464867	TF	0.27	6.09	0.31	3.02e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs3736594	0.546	rs6719960	chr2:27830067	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-6.75	-0.34	6.32e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.79	-10.6	-0.5	6.64e-23	Body mass index;
LIHC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.56	8.26	0.41	3.2e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7481584	0.564	rs432585	chr11:3084903	G/A	cg25174290	chr11:3078921	CARS	-0.41	-6.03	-0.31	4.36e-9	Calcium levels;
LIHC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg00656387	chr3:40428638	ENTPD3	0.48	7.93	0.39	3.13e-14	Renal cell carcinoma;
LIHC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.67	11.31	0.52	2.09e-25	Type 2 diabetes;
LIHC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12016809	chr21:47604291	C21orf56	0.42	6.07	0.31	3.37e-9	Testicular germ cell tumor;
LIHC	cis	rs1355223	0.934	rs11602669	chr11:34695114	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.08	-0.31	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.58	8.22	0.41	4.26e-15	Lung cancer;
LIHC	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg19000871	chr14:103996768	TRMT61A	0.44	7.75	0.39	1.04e-13	Coronary artery disease;
LIHC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.62	11.4	0.52	9.78e-26	Total body bone mineral density;
LIHC	cis	rs807029	0.533	rs67813203	chr10:102738551	A/G	cg17130504	chr10:102756923	LZTS2	0.56	7.8	0.39	7.35e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.58	7.43	0.37	8.85e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.44	-7.04	-0.36	1.06e-11	Menarche (age at onset);
LIHC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.5	-7.41	-0.37	9.87e-13	DNA methylation (variation);
LIHC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.91	-0.3	8.24e-9	Ulcerative colitis;
LIHC	cis	rs74181299	0.750	rs1420185	chr2:65315903	A/G	cg05010058	chr2:65284262	CEP68	0.39	6.69	0.34	9.12e-11	Pulse pressure;
LIHC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.89	-0.35	2.77e-11	Alcohol dependence;
LIHC	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-0.71	-7.29	-0.37	2.16e-12	Putamen volume;
LIHC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.22	0.48	1.43e-21	Diabetic retinopathy;
LIHC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.63	-9.64	-0.46	1.32e-19	Uric acid clearance;
LIHC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.4	-5.72	-0.3	2.32e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs13113518	0.812	rs13107810	chr4:56408410	C/A	cg15358633	chr12:38710606	ALG10B	0.43	6.19	0.32	1.74e-9	Height;
LIHC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.86	11.47	0.53	5.7e-26	Post bronchodilator FEV1;
LIHC	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.56	-0.62	1.06e-37	Electrocardiographic conduction measures;
LIHC	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg10820045	chr2:198174542	NA	0.42	6.15	0.32	2.18e-9	Dermatomyositis;
LIHC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.49	-7.45	-0.37	7.74e-13	Corneal astigmatism;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg20102877	chr2:27665638	KRTCAP3	0.41	5.72	0.3	2.34e-8	Total body bone mineral density;
LIHC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-8.86	-0.43	4.61e-17	Chronic sinus infection;
LIHC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg24881330	chr22:46731750	TRMU	0.56	6.03	0.31	4.34e-9	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.55	0.42	4.25e-16	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.77	0.34	5.55e-11	Renal cell carcinoma;
LIHC	cis	rs11166927	0.901	rs7827091	chr8:140812044	G/C	cg16909799	chr8:140841666	TRAPPC9	0.46	7.37	0.37	1.26e-12	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs10861342	1.000	rs10861357	chr12:105544254	C/T	cg23923672	chr12:105501055	KIAA1033	0.65	7.56	0.38	3.84e-13	IgG glycosylation;
LIHC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.12	-0.55	2.19e-28	Colorectal cancer;
LIHC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg19682013	chr15:45996608	NA	0.41	7.16	0.36	4.83e-12	Waist circumference;Weight;
LIHC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.57	7.8	0.39	7.33e-14	Neuroblastoma;
LIHC	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.52	8.45	0.42	8.71e-16	Corneal astigmatism;
LIHC	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg06096015	chr1:231504339	EGLN1	0.45	5.98	0.31	5.51e-9	Red blood cell count;
LIHC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg23172400	chr8:95962367	TP53INP1	0.36	7.08	0.36	8.37e-12	Type 2 diabetes;
LIHC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.58	7.16	0.36	4.89e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg11783602	chr8:55087084	NA	-0.32	-6.42	-0.33	4.46e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7575217	0.767	rs6543018	chr2:101730288	A/G	cg23907051	chr2:101730305	TBC1D8	0.29	6.6	0.34	1.53e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02034447	chr16:89574710	SPG7	0.5	7.56	0.38	3.64e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg16691251	chr5:66510806	NA	0.45	5.8	0.3	1.53e-8	Breast cancer;
LIHC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-6.05	-0.31	3.82e-9	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	9.22	0.45	3.09e-18	Lung cancer;
LIHC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.47	-0.37	6.81e-13	Response to antipsychotic treatment;
LIHC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.4	6.87	0.35	2.97e-11	Aortic root size;
LIHC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.82	0.51	1.15e-23	Chronic sinus infection;
LIHC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.25	0.37	2.73e-12	Bipolar disorder;
LIHC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	6.29	0.32	9.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg16586182	chr3:47516702	SCAP	-0.57	-10.91	-0.51	5.63e-24	Colorectal cancer;
LIHC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	trans	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.85	-0.35	3.36e-11	Educational attainment (years of education);
LIHC	cis	rs332507	0.750	rs3755680	chr3:124356460	A/G	cg05980111	chr3:124395277	KALRN	0.39	6.0	0.31	4.93e-9	Plateletcrit;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26921846	chr21:30671131	BACH1	-0.5	-6.53	-0.33	2.32e-10	Pancreatic cancer;
LIHC	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.44	7.32	0.37	1.76e-12	Corneal astigmatism;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13525026	chr17:18061071	MYO15A	0.43	6.57	0.33	1.89e-10	Bilirubin levels;
LIHC	cis	rs611744	0.967	rs603889	chr8:109224232	C/T	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg00280220	chr17:61926910	NA	-0.43	-6.95	-0.35	1.91e-11	Prudent dietary pattern;
LIHC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.75	8.92	0.43	2.89e-17	Schizophrenia;
LIHC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.44	-6.46	-0.33	3.51e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1198430	0.925	rs487859	chr1:23801101	T/C	cg13183780	chr1:23809682	ASAP3	-0.56	-8.08	-0.4	1.14e-14	Total cholesterol levels;
LIHC	cis	rs55702914	0.712	rs10931778	chr2:198148922	C/T	cg10820045	chr2:198174542	NA	-0.39	-5.89	-0.3	9.49e-9	Major depression and alcohol dependence;
LIHC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	11.61	0.53	1.75e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.41	8.2	0.41	4.95e-15	Cardiovascular disease risk factors;
LIHC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.45	0.37	7.88e-13	Schizophrenia;
LIHC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08280861	chr8:58055591	NA	0.53	6.04	0.31	3.98e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.34	-18.04	-0.7	1.31e-51	Gout;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.43	0.33	4.23e-10	Prudent dietary pattern;
LIHC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg12798992	chr6:167411361	FGFR1OP	0.48	7.03	0.36	1.14e-11	Crohn's disease;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06656553	chr16:89960601	TCF25	-0.44	-5.87	-0.3	1.01e-8	Interleukin-17 levels;
LIHC	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02985541	chr2:219472218	PLCD4	0.37	6.31	0.32	8.52e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	5.99	0.31	5.44e-9	IgG glycosylation;
LIHC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.42	-6.74	-0.34	6.74e-11	Longevity;Endometriosis;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.08	-0.31	3.3e-9	Total body bone mineral density;
LIHC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.72	-9.61	-0.46	1.67e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.46	-7.61	-0.38	2.68e-13	Mean corpuscular volume;
LIHC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.54	9.02	0.44	1.38e-17	Aortic root size;
LIHC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg16102536	chr7:156981717	UBE3C	0.37	6.19	0.32	1.7e-9	Body mass index;
LIHC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.62	-0.34	1.38e-10	Personality dimensions;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.77	0.62	1.56e-38	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13622287	chr13:41885293	NAA16	-0.49	-7.15	-0.36	5.14e-12	Pancreatic cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14021555	chr22:43485536	TTLL1	0.45	7.01	0.35	1.26e-11	Cognitive function;
LIHC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.66	12.76	0.57	9.24e-31	Rheumatoid arthritis;
LIHC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-8.83	-0.43	5.65e-17	Vitiligo;
LIHC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06212747	chr3:49208901	KLHDC8B	0.5	6.48	0.33	3.17e-10	Parkinson's disease;
LIHC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.97	17.39	0.69	5.41e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-1.05	-16.17	-0.66	4.53e-44	Uric acid levels;
LIHC	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.62	7.8	0.39	7.46e-14	Corneal astigmatism;
LIHC	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.25	-6.51	-0.33	2.68e-10	Menarche (age at onset);
LIHC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	9.15	0.44	5.43e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs965469	0.948	rs6139079	chr20:3314374	C/T	cg25506879	chr20:3388711	C20orf194	0.55	6.3	0.32	8.97e-10	IFN-related cytopenia;
LIHC	cis	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg01231543	chr16:68741748	NA	0.4	6.3	0.32	9.35e-10	Colorectal cancer;
LIHC	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.77	11.14	0.52	8.36e-25	Obesity-related traits;
LIHC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	9.3	0.45	1.65e-18	Platelet count;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.24	0.75	1.92e-64	Prudent dietary pattern;
LIHC	cis	rs2599510	0.811	rs2583713	chr2:32822729	A/G	cg02381751	chr2:32503542	YIPF4	0.45	5.88	0.3	9.95e-9	Interleukin-18 levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16203607	chr17:62500946	DDX5	0.45	6.49	0.33	3e-10	Cognitive function;
LIHC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.27e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg01444801	chr10:135216882	MTG1	-0.63	-9.38	-0.45	9.41e-19	Systemic lupus erythematosus;
LIHC	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg10820045	chr2:198174542	NA	0.48	7.47	0.37	6.93e-13	Dermatomyositis;
LIHC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.72	-0.39	1.25e-13	Morning vs. evening chronotype;
LIHC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.88	-0.43	3.94e-17	Heart rate;
LIHC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.38	8.09	0.4	1.04e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.3	-16.95	-0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs1865721	1.000	rs7244787	chr18:73195162	T/C	cg26385618	chr18:73139727	C18orf62	-0.3	-7.6	-0.38	2.88e-13	Intelligence;
LIHC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg18769074	chr3:133464867	TF	-0.27	-6.02	-0.31	4.45e-9	Iron status biomarkers (transferrin levels);
LIHC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.65	11.13	0.52	8.9e-25	Psoriasis;
LIHC	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02985541	chr2:219472218	PLCD4	0.36	6.28	0.32	1.01e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.44	-8.76	-0.43	9.42e-17	Plateletcrit;Platelet count;
LIHC	cis	rs7756236	0.521	rs11969445	chr6:36625382	C/T	cg08179530	chr6:36648295	CDKN1A	-0.4	-6.08	-0.31	3.19e-9	QRS duration;
LIHC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.49	7.32	0.37	1.81e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg20569855	chr1:109824440	PSRC1	0.5	6.55	0.33	2.09e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.86	-16.47	-0.67	2.75e-45	Body mass index (adult);
LIHC	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg20240347	chr1:204465584	NA	-0.35	-7.51	-0.38	5.04e-13	Schizophrenia;
LIHC	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg02811702	chr13:24901961	NA	0.26	6.63	0.34	1.3100000000000001e-10	Obesity-related traits;
LIHC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.22	-10.55	-0.5	1.07e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.45	7.44	0.37	8.16e-13	Endometrial cancer;
LIHC	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	10.62	0.5	5.67e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.71	12.91	0.57	2.57e-31	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg01864836	chr14:55583639	NA	-0.36	-6.65	-0.34	1.18e-10	Protein biomarker;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22792862	chr14:67827087	EIF2S1;ATP6V1D	0.46	7.17	0.36	4.66e-12	Calcium levels;
LIHC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.68	-0.38	1.75e-13	Body mass index;
LIHC	trans	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg01148741	chr2:96811453	DUSP2	-0.39	-6.31	-0.32	8.56e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	17.06	0.68	1.18e-47	Lung cancer in ever smokers;
LIHC	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.78	-0.39	8.5e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.45	7.45	0.37	7.64e-13	Crohn's disease;
LIHC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01200585	chr1:228362443	C1orf69	0.48	7.24	0.36	3.02e-12	Diastolic blood pressure;
LIHC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.27	-0.45	2.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg00656387	chr3:40428638	ENTPD3	0.43	7.18	0.36	4.35e-12	Renal cell carcinoma;
LIHC	trans	rs11724903	0.935	rs7698943	chr4:183212067	G/A	cg16239906	chr20:35724590	RBL1	-0.65	-6.16	-0.32	2.01e-9	Smoking initiation;
LIHC	cis	rs74233809	1.000	rs732998	chr10:104897901	C/T	cg03493300	chr10:104813866	CNNM2	-0.45	-6.19	-0.32	1.71e-9	Birth weight;
LIHC	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.34	-0.32	7.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.68	-9.87	-0.47	2.27e-20	Lymphocyte counts;
LIHC	cis	rs1153858	0.562	rs8025019	chr15:45735865	C/T	cg26924012	chr15:45694286	SPATA5L1	0.79	6.94	0.35	1.94e-11	Homoarginine levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04786791	chr1:218458496	RRP15	0.44	6.44	0.33	3.98e-10	Pancreatic cancer;
LIHC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.69	-6.99	-0.35	1.47e-11	Vitiligo;
LIHC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.6	-8.93	-0.44	2.57e-17	Cognitive ability;
LIHC	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.47	7.88	0.39	4.29e-14	Total cholesterol levels;
LIHC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.93	-0.31	7.49e-9	Personality dimensions;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg21486233	chr12:29375141	FAR2	0.31	6.06	0.31	3.67e-9	QT interval;
LIHC	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12062639	chr20:23401060	NAPB	0.83	9.96	0.47	1.06e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23543396	chr10:28591431	NA	0.45	6.32	0.32	8.31e-10	Lung function (FEV1/FVC);
LIHC	trans	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.82e-33	Diabetic kidney disease;
LIHC	cis	rs7953508	0.619	rs11107114	chr12:93972927	G/A	cg18151635	chr12:93972918	NA	-0.52	-8.91	-0.43	2.99e-17	Pubertal anthropometrics;
LIHC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg17372223	chr3:52568218	NT5DC2	0.36	5.76	0.3	1.83e-8	Bipolar disorder;
LIHC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg23422044	chr7:1970798	MAD1L1	-0.6	-6.54	-0.33	2.3e-10	Bipolar disorder;
LIHC	trans	rs6058796	1.000	rs6087410	chr20:31258359	C/T	cg02600331	chr11:130417168	NA	0.36	7.75	0.39	1.06e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21433820	chr4:4544025	STX18	-0.56	-6.87	-0.35	2.96e-11	Systolic blood pressure;
LIHC	cis	rs3762637	0.943	rs9289196	chr3:122268506	T/C	cg24169773	chr3:122142474	KPNA1	-0.39	-8.08	-0.4	1.13e-14	LDL cholesterol levels;
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.79	0.62	1.27e-38	Prudent dietary pattern;
LIHC	cis	rs7617773	1.000	rs11711766	chr3:48193170	G/C	cg11946769	chr3:48343235	NME6	-0.66	-8.55	-0.42	4.1e-16	Coronary artery disease;
LIHC	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.98	0.31	5.65e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg11395062	chr17:14139857	CDRT15	0.59	11.04	0.51	1.9e-24	Temperament;
LIHC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.61	-0.46	1.65e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	ch.11.42038R	chr11:967971	AP2A2	0.54	9.74	0.47	5.96e-20	Alzheimer's disease (late onset);
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.62	-9.05	-0.44	1.08e-17	Menarche (age at onset);
LIHC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.2	0.45	3.71e-18	Schizophrenia;
LIHC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.46	7.86	0.39	5.1e-14	Mean corpuscular volume;
LIHC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.49	7.57	0.38	3.49e-13	Platelet count;
LIHC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.39	-5.98	-0.31	5.78e-9	Longevity;
LIHC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.5	-8.27	-0.41	2.95e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg22951263	chr5:87985283	NA	0.39	6.75	0.34	6.46e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	trans	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.1	-0.36	7.13e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.31	0.45	1.56e-18	Electroencephalogram traits;
LIHC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	9.48	0.46	4.38e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.95	-0.31	6.51e-9	Total body bone mineral density;
LIHC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.47	-6.76	-0.34	5.8200000000000003e-11	Corneal structure;
LIHC	cis	rs753955	0.592	rs1324972	chr13:24348159	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.32	5.74	0.3	2.13e-8	Lung cancer;
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-20.1	-0.74	6.85e-60	Chronic sinus infection;
LIHC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.49	6.64	0.34	1.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.16	-0.32	2.03e-9	Longevity;
LIHC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg03037974	chr15:76606532	NA	0.66	12.16	0.55	1.55e-28	Blood metabolite levels;
LIHC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.49	-0.73	1.89e-57	Coronary artery disease;
LIHC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.54	0.42	4.47e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-8.92	-0.43	2.85e-17	Gut microbiome composition (summer);
LIHC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.0	0.48	7.75e-21	Crohn's disease;
LIHC	cis	rs738321	0.756	rs4821740	chr22:38514423	C/G	cg25457927	chr22:38595422	NA	-0.28	-6.38	-0.33	5.61e-10	Breast cancer;
LIHC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	8.74	0.43	1.04e-16	Menarche (age at onset);
LIHC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.61	8.83	0.43	5.48e-17	Monocyte percentage of white cells;
LIHC	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg03959625	chr15:84868606	LOC388152	0.49	6.98	0.35	1.56e-11	Schizophrenia;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.64	8.88	0.43	3.97e-17	Neuroticism;
LIHC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.75	-12.3	-0.55	5.02e-29	Colorectal cancer;
LIHC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg01652190	chr22:50026171	C22orf34	-0.31	-7.12	-0.36	6.27e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.61	-7.58	-0.38	3.36e-13	QRS complex (12-leadsum);
LIHC	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.49	7.26	0.37	2.67e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2257205	0.667	rs1018051	chr17:56909926	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-6.02	-0.31	4.41e-9	Pancreatic cancer;
LIHC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.01	0.31	4.89e-9	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-5.78	-0.3	1.65e-8	Neuroticism;
LIHC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.78	12.75	0.57	1.01e-30	Oral cavity cancer;
LIHC	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19717773	chr7:2847554	GNA12	-0.41	-6.99	-0.35	1.48e-11	Height;
LIHC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-7.15	-0.36	5.26e-12	Fear of minor pain;
LIHC	cis	rs72627123	0.867	rs17094448	chr14:74440119	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.48	0.42	6.78e-16	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.44	-0.33	4.15e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.26	0.37	2.67e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.78	0.39	8.7e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.44	7.22	0.36	3.46e-12	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.44	7.9	0.39	3.86e-14	Prudent dietary pattern;
LIHC	trans	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg25214090	chr10:38739885	LOC399744	-0.41	-6.76	-0.34	6.04e-11	Diastolic blood pressure;
LIHC	trans	rs10411161	0.702	rs16983196	chr19:52384779	C/A	cg22319618	chr22:45562946	NUP50	-0.59	-8.12	-0.4	8.66e-15	Breast cancer;
LIHC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-12.21	-0.55	1.02e-28	Response to antipsychotic treatment;
LIHC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg10932868	chr11:921992	NA	0.34	6.32	0.32	8.33e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg24849736	chr1:201084428	NA	-0.41	-8.23	-0.41	4.01e-15	Permanent tooth development;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27266822	chr1:16073415	TMEM82	0.48	6.21	0.32	1.55e-9	Hepatitis;
LIHC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.57	11.21	0.52	4.9e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	1.01	11.25	0.52	3.38e-25	Triglycerides;
LIHC	cis	rs847649	0.924	rs6960428	chr7:102589706	C/G	cg18108683	chr7:102477205	FBXL13	0.49	7.5	0.38	5.38e-13	Morning vs. evening chronotype;
LIHC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17554472	chr22:41940697	POLR3H	0.55	6.13	0.31	2.49e-9	Vitiligo;
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg06951627	chr6:26196580	NA	0.55	6.43	0.33	4.39e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.41	0.59	2.92e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg03264133	chr6:25882463	NA	-0.43	-6.39	-0.33	5.59e-10	Height;
LIHC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2710642	0.611	rs6706506	chr2:62861824	T/C	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg02376097	chr19:46275166	DMPK	-0.45	-6.84	-0.35	3.64e-11	Coronary artery disease;
LIHC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.36	7.2	0.36	3.81e-12	Alcohol dependence;
LIHC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg14067834	chr17:29058358	SUZ12P	0.69	6.76	0.34	6.04e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs60752752	0.852	rs12044231	chr1:153370876	G/A	cg14901121	chr8:98817630	LAPTM4B	-0.44	-7.35	-0.37	1.44e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg05697976	chr12:29376483	FAR2	0.31	6.29	0.32	9.63e-10	QT interval;
LIHC	cis	rs61041384	0.661	rs4148857	chr12:123539955	T/C	cg25930673	chr12:123319894	HIP1R	0.64	5.83	0.3	1.31e-8	Schizophrenia;
LIHC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.26	-0.45	2.36e-18	Hemoglobin concentration;
LIHC	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg15192750	chr16:69999425	NA	0.45	6.75	0.34	6.39e-11	IgE levels;
LIHC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.67	10.06	0.48	4.95e-21	Neutrophil percentage of white cells;
LIHC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.3	0.37	1.97e-12	Morning vs. evening chronotype;
LIHC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-10.89	-0.51	6.46e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.83	13.88	0.6	4.75e-35	Monocyte count;
LIHC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-10.87	-0.51	8.03e-24	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.88	-15.89	-0.65	5.52e-43	Coronary artery disease;
LIHC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg06050784	chr16:88016603	BANP	0.35	6.44	0.33	4.11e-10	Menopause (age at onset);
LIHC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.31	5.89	0.3	9.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.41	0.45	7.68e-19	Platelet count;
LIHC	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.38	6.25	0.32	1.19e-9	Lewy body disease;
LIHC	trans	rs17770015	0.759	rs10749129	chr10:115187221	T/G	cg12758090	chr15:80543408	NA	-0.43	-6.17	-0.32	1.9e-9	Migraine without aura;
LIHC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg01652190	chr22:50026171	C22orf34	-0.34	-7.64	-0.38	2.2e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.91	-0.3	8.13e-9	IgG glycosylation;
LIHC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.48	7.86	0.39	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.41	6.75	0.34	6.29e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.14	14.34	0.61	7.54e-37	Body mass index;
LIHC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg18289306	chr13:113640169	MCF2L	0.41	6.38	0.33	5.75e-10	Systolic blood pressure;
LIHC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	9.9	0.47	1.76e-20	Chronic sinus infection;
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.87	0.57	3.48e-31	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08280861	chr8:58055591	NA	0.49	6.68	0.34	9.83e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg17830980	chr10:43048298	ZNF37B	0.42	7.91	0.39	3.5e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg11070056	chr1:107600091	PRMT6	0.7	12.08	0.55	3.17e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.7	12.47	0.56	1.15e-29	Iron status biomarkers;
LIHC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.5	-8.37	-0.41	1.48e-15	Menarche (age at onset);
LIHC	cis	rs10426930	0.607	rs2613755	chr19:5059941	A/G	cg18473234	chr19:5097819	KDM4B	-0.55	-6.64	-0.34	1.21e-10	Monocyte percentage of white cells;
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.53	-8.2	-0.41	4.84e-15	Longevity;
LIHC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.44	-6.12	-0.31	2.54e-9	Initial pursuit acceleration;
LIHC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.0	-0.35	1.4e-11	Bipolar disorder;
LIHC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.57	11.56	0.53	2.66e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.4	6.32	0.32	8.36e-10	Menopause (age at onset);
LIHC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.44	6.18	0.32	1.87e-9	Height;
LIHC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	1.01	19.34	0.72	8.03e-57	Breast cancer;
LIHC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.52e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.75	6.23	0.32	1.34e-9	Alzheimer's disease;
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs916888	0.821	rs199499	chr17:44865498	C/T	cg01570182	chr17:44337453	NA	0.95	7.81	0.39	6.91e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-7.42	-0.37	9.38e-13	Morning vs. evening chronotype;
LIHC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.97	9.91	0.47	1.56e-20	Plasma clusterin levels;
LIHC	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.77	12.39	0.56	2.16e-29	Coronary artery disease;
LIHC	trans	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.53	-0.33	2.44e-10	Educational attainment (years of education);
LIHC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.53	-0.33	2.42e-10	Fear of minor pain;
LIHC	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	0.78	7.89	0.39	4.2e-14	Arsenic metabolism;
LIHC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.36	0.45	1.12e-18	Platelet count;
LIHC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.48	-6.53	-0.33	2.36e-10	Mean platelet volume;
LIHC	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg22903471	chr2:27725779	GCKR	-0.43	-6.29	-0.32	9.94e-10	Blood metabolite levels;
LIHC	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-1.22	-10.23	-0.48	1.34e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.82	12.05	0.55	4.24e-28	Response to antineoplastic agents;
LIHC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.79	18.55	0.71	1.19e-53	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg04607235	chr12:12878440	APOLD1	0.49	7.47	0.37	6.9e-13	Pulse pressure;
LIHC	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	6.17	0.32	1.97e-9	Lymphocyte counts;
LIHC	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg11812906	chr14:75593930	NEK9	-0.41	-6.23	-0.32	1.35e-9	IgG glycosylation;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.72	11.98	0.54	7.3e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.57	5.88	0.3	9.8e-9	IgG glycosylation;
LIHC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg03146154	chr1:46216737	IPP	-0.38	-6.36	-0.33	6.47e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	7.24	0.36	2.99e-12	Height;
LIHC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg11764359	chr7:65958608	NA	0.59	6.05	0.31	3.74e-9	Diabetic kidney disease;
LIHC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18357526	chr6:26021779	HIST1H4A	0.45	6.53	0.33	2.33e-10	Height;
LIHC	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.96	-0.31	6.12e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.76	10.21	0.48	1.55e-21	Fat distribution (HIV);
LIHC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.89	0.39	4.02e-14	Multiple sclerosis;
LIHC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.59	9.4	0.45	7.86e-19	High light scatter reticulocyte count;
LIHC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	trans	rs3758911	0.796	rs10890719	chr11:107204083	A/T	cg21068293	chr15:74496576	STRA6	0.26	6.25	0.32	1.21e-9	Coronary artery disease;
LIHC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg00647820	chr17:40259828	DHX58	-0.27	-5.75	-0.3	1.96e-8	Fibrinogen levels;
LIHC	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.4	7.28	0.37	2.29e-12	Monocyte count;
LIHC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.74	-0.81	4.9e-82	Myeloid white cell count;
LIHC	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.5	7.77	0.39	9.41e-14	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.48	6.49	0.33	2.96e-10	Height;
LIHC	cis	rs11229555	0.609	rs12273635	chr11:58186327	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.7	-0.38	1.48e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.27e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.89	-17.59	-0.69	8.81e-50	Height;
LIHC	cis	rs918629	0.798	rs57595413	chr5:95277776	C/T	cg10483112	chr5:95245456	ELL2	-0.35	-6.02	-0.31	4.47e-9	IgG glycosylation;
LIHC	cis	rs8083850	0.635	rs12954274	chr18:50865874	C/T	cg24270629	chr18:50823537	DCC	0.53	8.01	0.4	1.83e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.79	-12.07	-0.55	3.48e-28	Body mass index;
LIHC	cis	rs74544699	1.000	rs353034	chr4:74773643	G/A	cg02530824	chr4:74847766	PF4	0.62	6.47	0.33	3.42e-10	Growth-regulated protein alpha levels;
LIHC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.56	-0.5	9.29e-23	Aortic root size;
LIHC	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.34	21.19	0.75	2.97e-64	Corneal structure;
LIHC	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	9.33	0.45	1.38e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.86	-0.3	1.06e-8	Total body bone mineral density;
LIHC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	0.71	11.84	0.54	2.52e-27	Menopause (age at onset);
LIHC	cis	rs10744422	1.000	rs2343108	chr12:123331301	C/T	cg07706471	chr12:123319906	HIP1R	-0.62	-8.14	-0.4	7.43e-15	Schizophrenia;
LIHC	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.08	-0.4	1.16e-14	Vitamin D levels;
LIHC	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg27386326	chr11:61587980	NA	-0.69	-14.99	-0.63	2.18e-39	Trans fatty acid levels;
LIHC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.95	11.29	0.52	2.43e-25	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.26	6.51	0.33	2.73e-10	Primary biliary cholangitis;
LIHC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-13.99	-0.6	1.75e-35	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg14222432	chr12:29376421	FAR2	0.35	6.75	0.34	6.28e-11	QT interval;
LIHC	cis	rs7116495	0.588	rs547208	chr11:71779668	A/G	cg26138937	chr11:71823887	C11orf51	-0.8	-7.93	-0.39	3.22e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.49e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg08847533	chr14:75593920	NEK9	0.35	5.89	0.3	9.33e-9	Caffeine consumption;
LIHC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.7	-10.54	-0.5	1.08e-22	Blood metabolite levels;
LIHC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.76	11.85	0.54	2.28e-27	Corneal astigmatism;
LIHC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg11764359	chr7:65958608	NA	0.55	5.87	0.3	1.04e-8	Diabetic kidney disease;
LIHC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.53e-10	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25019777	chr4:53525403	USP46	-0.56	-6.08	-0.31	3.28e-9	Systolic blood pressure;
LIHC	trans	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg25047469	chr15:90198526	KIF7	-0.49	-6.14	-0.32	2.24e-9	Vitiligo;
LIHC	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg14250997	chr9:106856677	SMC2	0.42	7.44	0.37	8.21e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.79	11.84	0.54	2.47e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.49	-8.0	-0.4	1.88e-14	Tuberculosis;
LIHC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg26939375	chr7:64535504	NA	0.46	6.93	0.35	2.09e-11	Aortic root size;
LIHC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02290350	chr8:58132656	NA	0.42	8.88	0.43	3.83e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.35	-7.37	-0.37	1.33e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9322817	0.691	rs1933804	chr6:105341969	G/C	cg02098413	chr6:105308735	HACE1	0.39	7.49	0.38	6.03e-13	Thyroid stimulating hormone;
LIHC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08219700	chr8:58056026	NA	0.5	6.49	0.33	2.98e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.616	rs10839341	chr11:49742615	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.81	0.35	4.37e-11	Height;
LIHC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.79	0.39	8.22e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg01765077	chr12:122356316	WDR66	-0.44	-6.69	-0.34	9.37e-11	Mean corpuscular volume;
LIHC	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.03	-0.4	1.59e-14	Total cholesterol levels;
LIHC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.18	-0.36	4.37e-12	Body mass index;
LIHC	cis	rs4725617	0.686	rs4283960	chr7:143103380	C/T	cg10228500	chr7:143105595	EPHA1	-0.48	-5.94	-0.31	7.03e-9	Blood protein levels;
LIHC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.4	-5.9	-0.3	8.74e-9	Schizophrenia;
LIHC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.01	0.44	1.47e-17	Lung cancer in ever smokers;
LIHC	cis	rs1165668	1.000	rs1165669	chr12:104318172	C/T	cg21863207	chr12:104234989	NT5DC3	-0.38	-6.01	-0.31	4.88e-9	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.73	-13.28	-0.58	9.35e-33	Blood protein levels;
LIHC	cis	rs16958440	1.000	rs61316646	chr18:44610670	G/C	cg17192377	chr18:44677553	HDHD2	0.6	6.65	0.34	1.14e-10	Sitting height ratio;
LIHC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.77	-14.72	-0.62	2.58e-38	Mortality in heart failure;
LIHC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg25356066	chr3:128598488	ACAD9	0.53	7.39	0.37	1.14e-12	IgG glycosylation;
LIHC	cis	rs77633900	0.772	rs157769	chr15:76834397	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-5.92	-0.3	7.98e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg22777020	chr22:31556080	RNF185	-0.55	-6.21	-0.32	1.56e-9	Colorectal cancer;
LIHC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	13.97	0.6	2.13e-35	Menopause (age at onset);
LIHC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-16.01	-0.65	1.99e-43	Chronic sinus infection;
LIHC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	13.32	0.58	6.82e-33	Primary sclerosing cholangitis;
LIHC	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.43	-6.02	-0.31	4.44e-9	Height;
LIHC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg00343986	chr7:65444356	GUSB	0.4	5.92	0.3	8.02e-9	Aortic root size;
LIHC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.41	6.18	0.32	1.83e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.13	0.31	2.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.61	8.81	0.43	6.4e-17	Recombination rate (females);
LIHC	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.09	-0.31	3.04e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg13957321	chr17:43675089	NA	-0.48	-7.72	-0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.54	9.54	0.46	2.74e-19	Mean corpuscular volume;
LIHC	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg20991723	chr1:152506922	NA	0.55	9.13	0.44	6.09e-18	Hair morphology;
LIHC	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	10.17	0.48	2.07e-21	Obesity-related traits;
LIHC	cis	rs2016586	0.894	rs2413367	chr22:36101861	A/T	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	8.08e-10	Body mass index;
LIHC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-7.82	-0.39	6.52e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.92	11.62	0.53	1.58e-26	Coronary artery disease;
LIHC	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.67	-11.12	-0.52	9.65e-25	Electrocardiographic conduction measures;
LIHC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-7.51	-0.38	5.26e-13	Morning vs. evening chronotype;
LIHC	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg07636037	chr3:49044803	WDR6	-0.53	-5.92	-0.3	7.92e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs11098699	1.000	rs11941747	chr4:124208968	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.04	0.31	4e-9	Mosquito bite size;
LIHC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.89	-0.3	9.2e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2191566	0.664	rs62115477	chr19:44543027	T/G	cg20607764	chr19:44506953	ZNF230	-0.37	-6.22	-0.32	1.43e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.77	11.25	0.52	3.28e-25	Menarche (age at onset);
LIHC	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.67	-8.88	-0.43	3.89e-17	Vitamin D levels;
LIHC	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.44	6.83	0.35	4.01e-11	Schizophrenia;
LIHC	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.31	6.5	0.33	2.9e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.19	-0.32	1.74e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.62	-9.58	-0.46	2.09e-19	Body mass index;
LIHC	trans	rs2224539	0.605	rs12624333	chr20:38467979	C/T	cg21682942	chr2:85824657	RNF181	0.36	6.05	0.31	3.76e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.44	-0.33	4.17e-10	Crohn's disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23202053	chr19:1815917	REXO1	-0.38	-6.32	-0.32	8.05e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.02	15.66	0.65	4.93e-42	Breast cancer;
LIHC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg14092571	chr14:90743983	NA	-0.38	-5.96	-0.31	6.43e-9	Mortality in heart failure;
LIHC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.5	-6.84	-0.35	3.77e-11	Pulse pressure;
LIHC	cis	rs77861329	1.000	rs17051957	chr3:52099441	A/G	cg08692210	chr3:52188851	WDR51A	0.82	8.06	0.4	1.32e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs600806	0.778	rs4970767	chr1:110015183	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.58	-7.38	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs575908	0.640	rs12121676	chr1:177904751	A/G	ch.2.121457425R	chr2:121740955	GLI2	-0.4	-6.5	-0.33	2.89e-10	Breast cancer;
LIHC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.67	9.26	0.45	2.31e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg14222432	chr12:29376421	FAR2	0.35	6.74	0.34	6.68e-11	QT interval;
LIHC	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.32	6.46	0.33	3.62e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg18512352	chr11:47633146	NA	-0.26	-5.95	-0.31	6.58e-9	Subjective well-being;
LIHC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	trans	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.37	0.33	6.01e-10	Ulcerative colitis;
LIHC	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg03934865	chr2:198174659	NA	0.45	6.47	0.33	3.42e-10	Dermatomyositis;
LIHC	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21467203	chr3:49911342	NA	0.35	6.29	0.32	9.76e-10	Menarche (age at onset);
LIHC	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.98	-0.31	5.71e-9	Obesity-related traits;
LIHC	cis	rs4407350	1.000	rs5765723	chr22:44921554	C/T	cg26276947	chr22:44892394	LDOC1L	0.33	6.22	0.32	1.41e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.96	-17.27	-0.68	1.68e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.38	-5.89	-0.3	9.44e-9	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24335600	chr1:241682994	FH	-0.49	-6.89	-0.35	2.69e-11	Pancreatic cancer;
LIHC	trans	rs7714584	0.793	rs11958146	chr5:150254158	A/G	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.72	11.04	0.51	1.9e-24	Aortic root size;
LIHC	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.77	-11.57	-0.53	2.29e-26	Personality dimensions;
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg19635926	chr16:89946313	TCF25	0.52	7.02	0.36	1.17e-11	Skin colour saturation;
LIHC	cis	rs1868673	0.503	rs13326592	chr3:150240342	T/G	cg10752315	chr3:150238463	NA	0.3	5.92	0.3	7.73e-9	Waist circumference;
LIHC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.39	6.02	0.31	4.46e-9	Obesity-related traits;
LIHC	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.17	-0.32	1.94e-9	Resting heart rate;
LIHC	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	1.02	20.83	0.75	8.37e-63	Height;
LIHC	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg01652190	chr22:50026171	C22orf34	-0.29	-6.34	-0.32	7.24e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1494950	1.000	rs28611277	chr4:14981659	G/A	cg12377275	chr4:15005593	CPEB2	-0.79	-6.71	-0.34	8.25e-11	Political ideology;
LIHC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.46	7.53	0.38	4.47e-13	Response to temozolomide;
LIHC	cis	rs1355223	0.902	rs1597962	chr11:34727172	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.32	-0.32	8.21e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.32	-6.31	-0.32	8.44e-10	DNA methylation (variation);
LIHC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.73e-12	Personality dimensions;
LIHC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.28	11.42	0.53	8.49e-26	Uric acid levels;
LIHC	cis	rs4908768	0.501	rs6669503	chr1:8564301	C/G	cg20416874	chr1:8611966	RERE	-0.65	-13.6	-0.59	5.48e-34	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.46	0.59	2e-33	Diabetic kidney disease;
LIHC	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.85	-0.3	1.13e-8	Blood protein levels;
LIHC	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.53	8.19	0.4	5.39e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.79	11.9	0.54	1.44e-27	Dental caries;
LIHC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.64	-7.91	-0.39	3.48e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg21466736	chr12:48725269	NA	-0.57	-8.05	-0.4	1.36e-14	Glycated hemoglobin levels;
LIHC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-10.09	-0.48	3.92e-21	Platelet count;
LIHC	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.02	15.09	0.63	8.22e-40	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.71	0.34	8.25e-11	Morning vs. evening chronotype;
LIHC	cis	rs12079745	0.590	rs12097682	chr1:169333438	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-7.12	-0.36	6.37e-12	QT interval;
LIHC	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.61	7.26	0.37	2.68e-12	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.45	5.92	0.31	7.67e-9	Menopause (age at onset);
LIHC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.74	-0.34	6.78e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	9.63	0.46	1.39e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg09462578	chr12:12878428	APOLD1	-0.48	-7.65	-0.38	2.11e-13	Pulse pressure;
LIHC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	12.56	0.56	4.96e-30	Schizophrenia;
LIHC	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg00977110	chr5:151150581	G3BP1	0.54	6.74	0.34	6.65e-11	Preschool internalizing problems;
LIHC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg02376097	chr19:46275166	DMPK	-0.44	-6.81	-0.35	4.43e-11	Coronary artery disease;
LIHC	cis	rs903552	1.000	rs8043379	chr15:102005837	A/G	cg00659931	chr15:102010125	PCSK6	-0.46	-6.2	-0.32	1.63e-9	Diabetic kidney disease;
LIHC	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg19773385	chr1:10388646	KIF1B	-0.48	-8.29	-0.41	2.64e-15	Hepatocellular carcinoma;
LIHC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.0	-0.35	1.32e-11	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.38	6.15	0.32	2.19e-9	Mood instability;
LIHC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.97	20.95	0.75	2.8e-63	Bone mineral density;
LIHC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20135002	chr11:47629003	NA	-0.57	-10.07	-0.48	4.6e-21	Subjective well-being;
LIHC	cis	rs9612	1.000	rs58896392	chr19:44269142	G/A	cg08581076	chr19:44259116	C19orf61	0.62	7.48	0.37	6.35e-13	Exhaled nitric oxide output;
LIHC	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.45	8.02	0.4	1.73e-14	Coronary artery disease;
LIHC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.89	-14.02	-0.6	1.4e-35	Body mass index;
LIHC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.63	-0.56	2.82e-30	Alzheimer's disease;
LIHC	cis	rs3770081	1.000	rs11899576	chr2:86256193	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-9.29	-0.45	1.79e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.5	6.31	0.32	8.66e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.5	7.42	0.37	9.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	25.06	0.8	2.12e-79	Prudent dietary pattern;
LIHC	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg27433088	chr4:174089019	GALNT7	-0.4	-5.94	-0.31	6.84e-9	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.27	5.72	0.3	2.35e-8	Pulmonary function;
LIHC	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.86	-0.3	1.09e-8	Neuroticism;
LIHC	cis	rs10503871	0.545	rs10955031	chr8:30475926	A/G	cg26383811	chr8:30366931	RBPMS	0.43	6.93	0.35	2.1e-11	Metabolite levels  (X-11787);
LIHC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13409248	chr3:40428643	ENTPD3	0.49	8.33	0.41	1.95e-15	Renal cell carcinoma;
LIHC	cis	rs6815814	0.731	rs11096956	chr4:38776180	G/T	cg06935464	chr4:38784597	TLR10	0.38	6.05	0.31	3.75e-9	Breast cancer;
LIHC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.21	11.49	0.53	4.56e-26	Uric acid levels;
LIHC	trans	rs10511404	1.000	rs11714961	chr3:120510144	G/C	cg09889680	chr22:21922804	UBE2L3	-0.48	-6.15	-0.32	2.22e-9	Tumor necrosis factor alpha levels;
LIHC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16262614	chr3:133464971	TF	0.32	7.18	0.36	4.5e-12	Iron status biomarkers;
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.64	-0.42	2.21e-16	Lymphocyte counts;
LIHC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.45	0.42	8.38e-16	Multiple sclerosis;
LIHC	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg00792783	chr2:198669748	PLCL1	0.39	5.83	0.3	1.31e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg12253828	chr6:101329408	ASCC3	-0.39	-5.97	-0.31	6.04e-9	Neuroticism;
LIHC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.3	-0.58	8.38e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.74	0.3	2.12e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg19683494	chr5:74908142	NA	0.68	7.91	0.39	3.55e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.59	0.42	3.17e-16	Corneal astigmatism;
LIHC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.4	8.61	0.42	2.62e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.3	-0.76	1.14e-64	Height;
LIHC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04476341	chr5:669733	TPPP	0.38	8.66	0.42	1.96e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg03037974	chr15:76606532	NA	0.74	14.5	0.62	1.74e-37	Blood metabolite levels;
LIHC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg25039879	chr17:56429692	SUPT4H1	0.76	8.75	0.43	1.02e-16	Cognitive test performance;
LIHC	cis	rs2005	0.582	rs3800404	chr6:35137870	G/T	cg13137465	chr6:34857473	ANKS1A	-0.54	-6.11	-0.31	2.77e-9	Obesity-related traits;
LIHC	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg16309518	chr5:176445507	NA	-0.57	-11.41	-0.52	9.33e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg18963800	chr10:38644991	HSD17B7P2	0.37	5.77	0.3	1.78e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.88	0.39	4.54e-14	Lung cancer;
LIHC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.57	9.78	0.47	4.35e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-7.5	-0.38	5.53e-13	P wave terminal force;
LIHC	cis	rs1823913	1.000	rs11691372	chr2:192114678	A/C	cg12404831	chr2:192114017	MYO1B	-0.34	-6.76	-0.34	5.93e-11	Obesity-related traits;
LIHC	cis	rs71446622	0.506	rs36090150	chr13:113432388	T/C	cg08557188	chr13:113420371	ATP11A	-0.79	-5.93	-0.31	7.5e-9	Mean corpuscular volume;
LIHC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.33	-6.72	-0.34	7.51e-11	Body mass index;
LIHC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.65	11.24	0.52	3.79e-25	Menopause (age at onset);
LIHC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	13.29	0.58	8.97e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg22903471	chr2:27725779	GCKR	-0.44	-6.31	-0.32	8.43e-10	Blood metabolite levels;
LIHC	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.88	11.02	0.51	2.2e-24	Prostate cancer;
LIHC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.65	9.39	0.45	8.73e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.58	-8.27	-0.41	3.02e-15	Asthma;
LIHC	cis	rs11971779	0.527	rs1076349	chr7:139126494	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	9.92	0.47	1.46e-20	Diisocyanate-induced asthma;
LIHC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg24826892	chr11:71159390	DHCR7	0.49	6.3	0.32	9.04e-10	Vitamin D levels;
LIHC	cis	rs4716602	0.596	rs10265482	chr7:156160655	C/G	cg16983916	chr7:156159713	NA	-0.32	-5.75	-0.3	2.01e-8	Anti-saccade response;
LIHC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.84	14.88	0.63	5.67e-39	Headache;
LIHC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.81	7.5	0.38	5.4e-13	Eosinophil percentage of granulocytes;
LIHC	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.58	10.0	0.48	8.27e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2274273	0.840	rs11626751	chr14:55835227	T/C	cg01864836	chr14:55583639	NA	-0.38	-6.73	-0.34	7.02e-11	Protein biomarker;
LIHC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.24	-15.92	-0.65	4.31e-43	Diabetic kidney disease;
LIHC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	10.19	0.48	1.85e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14626525	chr9:140731445	MIR602	0.43	6.4	0.33	5.14e-10	Longevity;
LIHC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-10.83	-0.51	1.03e-23	Morning vs. evening chronotype;
LIHC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.35	6.16	0.32	2.08e-9	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.65	0.34	1.16e-10	Diabetic kidney disease;
LIHC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	11.2	0.52	5.32e-25	Cognitive test performance;
LIHC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg03959625	chr15:84868606	LOC388152	0.47	6.76	0.34	6.14e-11	Schizophrenia;
LIHC	cis	rs7945718	0.621	rs61879826	chr11:12684486	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.8	0.39	7.4e-14	Educational attainment (years of education);
LIHC	cis	rs11212260	0.655	rs7949914	chr11:107269467	C/G	cg25435332	chr11:107328525	CWF19L2	0.81	8.76	0.43	8.88e-17	IgG glycosylation;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01114405	chr6:504249	EXOC2	0.4	6.03	0.31	4.18e-9	Longevity;
LIHC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg03945807	chr20:60948434	NA	-0.37	-6.64	-0.34	1.25e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg26566898	chr11:117069891	TAGLN	0.39	6.05	0.31	3.79e-9	Blood protein levels;
LIHC	cis	rs7937890	0.559	rs4369365	chr11:14444515	C/G	cg02886208	chr11:14281011	SPON1	-0.51	-7.09	-0.36	7.96e-12	Mitochondrial DNA levels;
LIHC	cis	rs11229555	0.645	rs11229431	chr11:58181253	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.42	5.91	0.3	8.15e-9	Schizophrenia;
LIHC	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.74	-10.5	-0.49	1.57e-22	Morning vs. evening chronotype;
LIHC	cis	rs2257205	0.667	rs16943134	chr17:56681389	A/G	cg12560992	chr17:57184187	TRIM37	0.71	7.86	0.39	5.22e-14	Pancreatic cancer;
LIHC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.57	-0.5	8.95e-23	Hemoglobin concentration;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07017693	chr10:71912317	SAR1A	0.52	6.39	0.33	5.47e-10	Systolic blood pressure;
LIHC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.6	-8.48	-0.42	6.68e-16	Coronary artery disease;
LIHC	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.06	0.36	9.45e-12	Height;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg02850329	chr1:24829455	RCAN3	-0.48	-6.27	-0.32	1.1e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs3736485	0.966	rs12101730	chr15:51800733	C/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.99	-0.31	5.18e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.89	-0.3	9.43e-9	Inflammatory bowel disease;
LIHC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg18016565	chr1:150552671	MCL1	0.53	9.56	0.46	2.35e-19	Melanoma;
LIHC	cis	rs2933343	1.000	rs1683782	chr3:128640277	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.08	0.36	8.1e-12	IgG glycosylation;
LIHC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-6.2	-0.32	1.58e-9	Bipolar disorder;
LIHC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	0.74	10.43	0.49	2.73e-22	Initial pursuit acceleration;
LIHC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.52	-6.22	-0.32	1.43e-9	Menarche (age at onset);
LIHC	cis	rs11702148	0.552	rs3787708	chr21:34906039	C/T	cg14850771	chr21:34775459	IFNGR2	0.48	7.99	0.4	2.09e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.66	9.69	0.46	9.09e-20	Schizophrenia;
LIHC	cis	rs903552	0.932	rs2172851	chr15:102012626	C/T	cg00659931	chr15:102010125	PCSK6	-0.48	-6.47	-0.33	3.45e-10	Diabetic kidney disease;
LIHC	cis	rs965469	1.000	rs6051831	chr20:3373712	G/T	cg25506879	chr20:3388711	C20orf194	0.54	6.56	0.33	2.04e-10	IFN-related cytopenia;
LIHC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.55	-9.21	-0.45	3.35e-18	Electroencephalogram traits;
LIHC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg04025307	chr7:1156635	C7orf50	0.41	6.24	0.32	1.32e-9	Longevity;Endometriosis;
LIHC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.92	-0.6	3.18e-35	Alzheimer's disease;
LIHC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg08822215	chr16:89438651	ANKRD11	0.45	7.2	0.36	3.79e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.73	-8.95	-0.44	2.24e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.48	-0.42	6.86e-16	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.81	0.3	1.4e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.43	-7.0	-0.35	1.39e-11	Corneal astigmatism;
LIHC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-11.05	-0.51	1.79e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-0.79	-12.98	-0.57	1.36e-31	Obesity-related traits;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg16466278	chr15:43429893	TMEM62	0.46	7.03	0.36	1.15e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.8	-14.87	-0.63	6.11e-39	Prudent dietary pattern;
LIHC	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	0.97	8.16	0.4	6.38e-15	Lymphocyte counts;
LIHC	cis	rs7546668	1.000	rs4646090	chr1:15822073	A/G	cg11706911	chr1:15910989	AGMAT	0.44	6.8	0.35	4.68e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.9	-0.39	3.93e-14	Monocyte percentage of white cells;
LIHC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg05110241	chr16:68378359	PRMT7	-0.52	-5.76	-0.3	1.87e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.42	5.84	0.3	1.19e-8	Schizophrenia;
LIHC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-10.15	-0.48	2.43e-21	Platelet count;
LIHC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.73	-10.87	-0.51	7.65e-24	Corneal astigmatism;
LIHC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg03874509	chr1:107600012	PRMT6	0.71	11.35	0.52	1.48e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4853036	1.000	rs11903034	chr2:70060278	T/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-5.75	-0.3	1.97e-8	Colorectal or endometrial cancer;
LIHC	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg05110241	chr16:68378359	PRMT7	0.47	6.1	0.31	2.93e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.54	-8.03	-0.4	1.58e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.67	-0.5	4.06e-23	Chronic sinus infection;
LIHC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg21522988	chr12:29376872	FAR2	0.29	6.73	0.34	7.34e-11	QT interval;
LIHC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.88	14.19	0.61	3.04e-36	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.8	-12.93	-0.57	2.1e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.26	0.32	1.18e-9	Calcium levels;
LIHC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.77	0.3	1.82e-8	Bipolar disorder;
LIHC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	6.08	0.31	3.17e-9	Tonsillectomy;
LIHC	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg09795085	chr6:101329169	ASCC3	-0.52	-7.31	-0.37	1.91e-12	Neuroticism;
LIHC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.62	-7.68	-0.38	1.71e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.29	0.37	2.14e-12	Morning vs. evening chronotype;
LIHC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.32	5.84	0.3	1.25e-8	Menarche (age at onset);
LIHC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.63	-8.47	-0.42	7.5e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.5	6.04	0.31	3.98e-9	Schizophrenia;
LIHC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.18	0.4	5.73e-15	Body mass index;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.45e-13	Prudent dietary pattern;
LIHC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.57	9.65	0.46	1.16e-19	Mean corpuscular volume;
LIHC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg19318889	chr4:1322082	MAEA	0.42	6.27	0.32	1.1e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08219700	chr8:58056026	NA	0.5	6.34	0.32	7.14e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.65	-9.56	-0.46	2.33e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.62	-10.87	-0.51	7.68e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.96	-0.35	1.79e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg08490173	chr5:114880508	FEM1C	-0.54	-6.17	-0.32	1.95e-9	Systolic blood pressure;
LIHC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.36	-6.02	-0.31	4.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-14.43	-0.62	3.3e-37	Systemic lupus erythematosus;
LIHC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.5	9.06	0.44	1.06e-17	Height;
LIHC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg14558114	chr2:88469736	THNSL2	-0.38	-5.85	-0.3	1.18e-8	Response to metformin (IC50);
LIHC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.77	-0.39	9.14e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg12798992	chr6:167411361	FGFR1OP	0.52	8.11	0.4	9.34e-15	Crohn's disease;
LIHC	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg27255678	chr10:102756921	LZTS2	0.51	7.31	0.37	1.89e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg00677901	chr16:88017247	BANP	0.53	8.1	0.4	9.53e-15	Menopause (age at onset);
LIHC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	9.0	0.44	1.57e-17	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.58	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg23743573	chr11:89867420	NAALAD2	0.38	5.75	0.3	1.98e-8	White blood cell types;
LIHC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.07	0.44	9.26e-18	Lung cancer in ever smokers;
LIHC	cis	rs11212260	0.512	rs17587175	chr11:107187510	G/A	cg25435332	chr11:107328525	CWF19L2	0.76	7.13	0.36	6.18e-12	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	8.2e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.64	11.09	0.51	1.23e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg13628971	chr7:2884303	GNA12	0.44	7.69	0.38	1.54e-13	Height;
LIHC	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2.1e-12	Exhaled nitric oxide output;
LIHC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.18e-18	Hemoglobin concentration;
LIHC	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.83	-10.76	-0.5	1.92e-23	Schizophrenia;
LIHC	cis	rs4788570	0.578	rs7204992	chr16:71658444	G/A	cg06353428	chr16:71660113	MARVELD3	1.45	15.62	0.65	6.99e-42	Intelligence (multi-trait analysis);
LIHC	trans	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg16011800	chr17:1958478	HIC1	0.51	7.34	0.37	1.53e-12	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs6445975	0.715	rs13320332	chr3:58268344	A/T	cg23715586	chr3:58305044	RPP14	-0.36	-6.11	-0.31	2.72e-9	Systemic lupus erythematosus;
LIHC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.72	7.07	0.36	8.65e-12	Breast cancer;
LIHC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.61	10.4	0.49	3.53e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg10790698	chr19:18539756	SSBP4	-0.34	-7.09	-0.36	7.58e-12	Breast cancer;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.58	6.14	0.31	2.32e-9	Hip geometry;
LIHC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg03013999	chr17:37608204	MED1	-0.35	-5.8	-0.3	1.5e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg20607798	chr8:58055168	NA	0.69	7.73	0.39	1.25e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg03959625	chr15:84868606	LOC388152	0.46	6.7	0.34	8.53e-11	Schizophrenia;
LIHC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.27	0.37	2.4e-12	Aortic root size;
LIHC	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg27205649	chr11:78285834	NARS2	0.4	6.18	0.32	1.78e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.7	-7.82	-0.39	6.64e-14	Neuroticism;
LIHC	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-15.23	-0.64	2.38e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.83	-0.47	2.97e-20	LDL cholesterol levels;
LIHC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.88	0.35	2.84e-11	Height;
LIHC	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg25019722	chr6:37503610	NA	-0.32	-5.73	-0.3	2.19e-8	Cognitive performance;
LIHC	cis	rs16828019	0.852	rs12048187	chr1:41616183	A/G	cg20697417	chr1:41786797	NA	0.35	6.64	0.34	1.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.38	5.77	0.3	1.76e-8	Mean corpuscular volume;
LIHC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-7.54	-0.38	4.39e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.16	0.79	6.11e-76	Prudent dietary pattern;
LIHC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg06565975	chr8:143823917	SLURP1	-0.45	-8.31	-0.41	2.24e-15	Urinary tract infection frequency;
LIHC	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg15584813	chr12:47219626	SLC38A4	0.32	5.77	0.3	1.74e-8	Itch intensity from mosquito bite;
LIHC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.68	10.14	0.48	2.6e-21	Coronary artery disease;
LIHC	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg05197062	chr11:11642011	GALNTL4	0.43	6.11	0.31	2.69e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.13	0.66	6.33e-44	Electrocardiographic conduction measures;
LIHC	cis	rs12602486	1.000	rs78867692	chr17:42263873	G/C	cg08193365	chr17:42277699	NA	1.0	7.03	0.36	1.14e-11	Glycated hemoglobin levels;
LIHC	cis	rs2336384	1.000	rs6668386	chr1:12047233	T/C	cg13216073	chr1:12042593	MFN2	0.42	6.36	0.33	6.29e-10	Platelet count;
LIHC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.89	10.56	0.5	9.3e-23	Primary sclerosing cholangitis;
LIHC	cis	rs7238033	0.624	rs16978469	chr18:43305785	C/T	cg20610511	chr18:43302872	SLC14A1	0.38	6.47	0.33	3.31e-10	Bladder cancer;
LIHC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.73	0.3	2.17e-8	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs13126513	0.708	rs1491233	chr4:100476060	C/T	cg05468953	chr4:100565104	NA	0.31	5.91	0.3	8.26e-9	Metabolite levels (MHPG);
LIHC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.44	7.06	0.36	9.21e-12	Lipoprotein (a) levels;
LIHC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.52	8.46	0.42	7.64e-16	Schizophrenia;
LIHC	cis	rs12744310	0.887	rs2363811	chr1:41791865	A/G	cg03962019	chr1:41807865	NA	0.38	6.09	0.31	2.99e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.42	7.75	0.39	1.05e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.53	8.02	0.4	1.68e-14	Corneal astigmatism;
LIHC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.31	-0.41	2.26e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs16877106	0.744	rs73252577	chr4:25315616	G/A	cg04796973	chr4:25314218	ZCCHC4	0.62	5.79	0.3	1.59e-8	Weight;
LIHC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-6.52	-0.33	2.51e-10	Pancreatic cancer;
LIHC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.61	7.52	0.38	5.01e-13	Morning vs. evening chronotype;
LIHC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.77	13.08	0.58	5.41e-32	Anterior chamber depth;
LIHC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.72	-0.43	1.26e-16	Schizophrenia;
LIHC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg16797656	chr11:68205561	LRP5	0.53	8.3	0.41	2.42e-15	Total body bone mineral density;
LIHC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02711726	chr17:80685570	FN3KRP	-0.39	-7.03	-0.36	1.15e-11	Glycated hemoglobin levels;
LIHC	cis	rs7116495	0.867	rs2945921	chr11:71576480	T/G	cg26138937	chr11:71823887	C11orf51	0.72	6.94	0.35	2.02e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22509189	chr2:225307070	NA	-0.54	-6.73	-0.34	7.25e-11	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-6.85	-0.35	3.4e-11	Waist circumference;Hip circumference;
LIHC	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg15711740	chr2:61764176	XPO1	0.42	5.87	0.3	1.03e-8	Tuberculosis;
LIHC	trans	rs1034394	0.740	rs5999348	chr22:34818466	C/T	cg02641517	chr3:54169983	CACNA2D3	-0.24	-6.1	-0.31	2.93e-9	Major depressive disorder;
LIHC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.34	-6.81	-0.35	4.34e-11	Colorectal cancer;
LIHC	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	11.49	0.53	4.76e-26	Post bronchodilator FEV1;
LIHC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.51	8.47	0.42	7.57e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.45	9.93e-19	Bipolar disorder;
LIHC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.65	-13.63	-0.59	4.48e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-0.59	-7.45	-0.37	7.76e-13	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.8	-0.3	1.53e-8	Alcohol dependence;
LIHC	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.81e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.69	-8.16	-0.4	6.51e-15	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02196227	chr4:89080292	ABCG2	0.38	6.05	0.31	3.76e-9	Cognitive function;
LIHC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg13628971	chr7:2884303	GNA12	0.4	6.28	0.32	1.03e-9	Height;
LIHC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.23	0.61	1.96e-36	Chronic sinus infection;
LIHC	cis	rs6435862	0.500	rs6756902	chr2:215672827	C/T	cg04004882	chr2:215674386	BARD1	-0.58	-8.74	-0.43	1.06e-16	Neuroblastoma (high-risk);
LIHC	cis	rs3736485	0.966	rs4775961	chr15:51892959	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.25	-0.32	1.21e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs611744	0.967	rs666821	chr8:109204313	T/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.48	7.23	0.36	3.25e-12	Corneal astigmatism;
LIHC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.44	6.1	0.31	2.94e-9	Life satisfaction;
LIHC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08280861	chr8:58055591	NA	0.54	6.28	0.32	1.05e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.27	-0.32	1.11e-9	Tonsillectomy;
LIHC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.85	8.4	0.41	1.24e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.5	7.39	0.37	1.15e-12	Psoriasis;
LIHC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.46	7.11	0.36	6.68e-12	Fibrinogen levels;
LIHC	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.04	-0.36	1.05e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3770081	1.000	rs6759489	chr2:86176032	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.7	-0.43	1.41e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.84	-10.82	-0.51	1.13e-23	Schizophrenia;
LIHC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.44	-5.79	-0.3	1.63e-8	Vitiligo;
LIHC	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.48	-7.96	-0.4	2.53e-14	Myopia;
LIHC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-8.93	-0.44	2.58e-17	Bipolar disorder;
LIHC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg05425664	chr17:57184151	TRIM37	-0.48	-7.03	-0.36	1.12e-11	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08677398	chr8:58056175	NA	0.41	6.32	0.32	8.32e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26348180	chr3:193852754	HES1	-0.45	-6.3	-0.32	9.1e-10	Triglycerides;
LIHC	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.63	10.05	0.48	5.56e-21	Breast cancer;
LIHC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.42	0.33	4.58e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	1.03	18.46	0.71	2.67e-53	Tonsillectomy;
LIHC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.53	7.72	0.39	1.32e-13	Longevity;Endometriosis;
LIHC	trans	rs17515225	0.581	rs4423546	chr2:141543563	A/G	cg22008625	chr8:10588386	SOX7	0.39	6.04	0.31	3.91e-9	Motion sickness;
LIHC	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg27297192	chr10:134578999	INPP5A	-0.48	-7.41	-0.37	1.02e-12	Migraine;
LIHC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.12	-0.4	8.5e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.48	-0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg23625390	chr15:77176239	SCAPER	0.35	6.04	0.31	4.01e-9	Blood metabolite levels;
LIHC	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.5	-6.56	-0.33	1.96e-10	Initial pursuit acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21517261	chr7:38217791	STARD3NL	0.41	6.4	0.33	5.02e-10	Cognitive function;
LIHC	cis	rs882732	0.576	rs2070777	chr14:95034342	T/A	cg14866387	chr14:95027382	SERPINA4	-0.39	-6.46	-0.33	3.67e-10	Blood protein levels;
LIHC	cis	rs2834188	1.000	rs2096464	chr21:34686049	G/T	cg04842828	chr21:34696676	IFNAR1	-0.45	-6.0	-0.31	5.11e-9	Narcolepsy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00379080	chr12:15942595	EPS8	0.41	6.1	0.31	2.95e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.33	6.9	0.35	2.57e-11	Blood metabolite levels;
LIHC	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg04166393	chr7:2884313	GNA12	0.42	5.73	0.3	2.18e-8	Height;
LIHC	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.4	7.65	0.38	2.03e-13	Coronary artery disease;
LIHC	cis	rs4908760	0.613	rs2401189	chr1:8818600	G/A	cg20416874	chr1:8611966	RERE	-0.58	-10.45	-0.49	2.26e-22	Vitiligo;
LIHC	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.04	9.01	0.44	1.5e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.48	6.54	0.33	2.31e-10	Mean platelet volume;
LIHC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.31	-0.32	8.75e-10	Body mass index;
LIHC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.78	-14.73	-0.62	2.22e-38	Mortality in heart failure;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.65	7.93	0.39	3.16e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	trans	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg18335740	chr13:41363409	SLC25A15	-0.35	-6.13	-0.31	2.45e-9	Lewy body disease;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg02344993	chr17:57696989	CLTC	0.57	9.1	0.44	7.53e-18	Hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.66	0.34	1.11e-10	Alzheimer's disease;
LIHC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.45	-7.69	-0.38	1.5700000000000001e-13	Prevalent atrial fibrillation;
LIHC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg03934865	chr2:198174659	NA	0.53	8.26	0.41	3.23e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg05043794	chr9:111880884	C9orf5	0.29	6.69	0.34	9.27e-11	Menarche (age at onset);
LIHC	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-8.62	-0.42	2.6e-16	Response to antipsychotic treatment;
LIHC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs244293	0.965	rs12453615	chr17:53177509	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.54	0.38	4.36e-13	Menarche (age at onset);
LIHC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg06238570	chr21:40685208	BRWD1	-0.37	-6.05	-0.31	3.84e-9	Menarche (age at onset);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg26144567	chr1:29446085	EPB41;TMEM200B	0.55	6.28	0.32	1.05e-9	Mean platelet volume;
LIHC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.61	7.28	0.37	2.36e-12	Cognitive function;
LIHC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.41	-6.45	-0.33	3.79e-10	Dental caries;
LIHC	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg11062466	chr8:58055876	NA	0.4	5.84	0.3	1.22e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	7.93	0.39	3.18e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs7944735	0.508	rs1474056	chr11:47632707	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-6.07	-0.31	3.4e-9	Intraocular pressure;
LIHC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.35	-5.86	-0.3	1.06e-8	IgG glycosylation;
LIHC	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.58	-0.34	1.82e-10	Body mass index;
LIHC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.59	-6.19	-0.32	1.74e-9	Lung function (FEV1/FVC);
LIHC	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.57	-7.09	-0.36	7.78e-12	Vitamin D levels;
LIHC	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.3	-6.87	-0.35	3.02e-11	Hip circumference;Waist circumference;
LIHC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.82	12.99	0.57	1.28e-31	Glomerular filtration rate (creatinine);
LIHC	trans	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.6	0.34	1.61e-10	Coronary artery calcification;
LIHC	cis	rs11671005	0.611	rs36090113	chr19:58912384	G/C	cg25952890	chr19:58913133	NA	0.68	6.89	0.35	2.77e-11	Mean platelet volume;
LIHC	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.44	8.81	0.43	6.3e-17	Type 1 diabetes;
LIHC	trans	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.17	0.32	1.95e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg11342453	chr6:26196699	NA	0.47	5.74	0.3	2.04e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.3	-0.32	9.03e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg18016565	chr1:150552671	MCL1	0.5	9.64	0.46	1.3e-19	Melanoma;
LIHC	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	-0.6	-8.78	-0.43	7.93e-17	Prudent dietary pattern;
LIHC	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.44	8.72	0.43	1.26e-16	Testicular germ cell tumor;
LIHC	trans	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg10756647	chr7:56101905	PSPH	1.11	13.6	0.59	5.63e-34	Diabetic kidney disease;
LIHC	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.53	-6.64	-0.34	1.26e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg11204139	chr17:3907470	NA	0.6	6.9	0.35	2.54e-11	Type 2 diabetes;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05590616	chr11:59522917	STX3	0.43	6.37	0.33	6.07e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.5	0.33	2.78e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.66e-11	Coronary artery disease;
LIHC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.69	6.39	0.33	5.38e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.4	-7.42	-0.37	9.39e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.66	11.19	0.52	5.6e-25	Childhood ear infection;
LIHC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-7.55	-0.38	4.06e-13	Blood protein levels;
LIHC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-5.99	-0.31	5.31e-9	Morning vs. evening chronotype;
LIHC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg07636037	chr3:49044803	WDR6	-0.84	-7.08	-0.36	8.28e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.07	-0.48	4.6e-21	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg24296786	chr1:45957014	TESK2	0.41	5.79	0.3	1.61e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07853919	chr18:77711868	PQLC1	-0.38	-6.32	-0.32	8.28e-10	Pancreatic cancer;
LIHC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.78	12.12	0.55	2.34e-28	Resting heart rate;
LIHC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02886208	chr11:14281011	SPON1	0.61	9.07	0.44	9.36e-18	Mitochondrial DNA levels;
LIHC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg01231543	chr16:68741748	NA	0.38	5.77	0.3	1.8e-8	Colorectal cancer;
LIHC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg13175981	chr1:150552382	MCL1	0.41	5.79	0.3	1.56e-8	Tonsillectomy;
LIHC	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.67	10.64	0.5	4.9e-23	Obesity-related traits;
LIHC	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.36	-6.23	-0.32	1.37e-9	High light scatter reticulocyte count;
LIHC	trans	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg19894588	chr14:64061835	NA	-0.62	-8.58	-0.42	3.38e-16	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.55	-8.74	-0.43	1.05e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg24693881	chr1:107596107	NA	0.55	9.61	0.46	1.59e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.73	12.2	0.55	1.17e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	7.67	0.38	1.86e-13	Obesity-related traits;
LIHC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.52	-7.1	-0.36	7.24e-12	Aortic root size;
LIHC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.38	5.75	0.3	1.98e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg07451762	chr16:28383216	NA	0.32	5.96	0.31	6.31e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.21	-0.32	1.52e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg07382826	chr16:28625726	SULT1A1	0.49	7.7	0.38	1.52e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.58	-9.39	-0.45	8.73e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.71	11.88	0.54	1.68e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-13.69	-0.6	2.49e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.84	12.3	0.55	4.68e-29	Glomerular filtration rate (creatinine);
LIHC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	1.22	11.03	0.51	2.02e-24	Obesity-related traits;
LIHC	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.31	-5.73	-0.3	2.24e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.65	9.73	0.47	6.74e-20	Schizophrenia (inflammation and infection response interaction);
LIHC	trans	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg12575136	chr18:32820987	ZNF397	0.47	6.91	0.35	2.44e-11	White blood cell count;
LIHC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.26e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.36	0.52	1.34e-25	Monocyte percentage of white cells;
LIHC	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg15595755	chr5:1867978	NA	0.32	6.12	0.31	2.5e-9	Cardiovascular disease risk factors;
LIHC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.52	-0.33	2.56e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg00280220	chr17:61926910	NA	0.42	6.61	0.34	1.51e-10	Prudent dietary pattern;
LIHC	cis	rs2271400	1.000	rs2271400	chr8:56791244	C/T	cg08894788	chr8:56792171	LYN	-0.39	-5.75	-0.3	2e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
LIHC	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.8	15.73	0.65	2.42e-42	Testicular germ cell tumor;
LIHC	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-8.87	-0.43	4.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg18129178	chr5:148520854	ABLIM3	-0.37	-6.15	-0.32	2.13e-9	Breast cancer;
LIHC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.84	-0.57	4.5e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.85	-16.46	-0.66	3.08e-45	Coronary artery disease;
LIHC	cis	rs2274273	0.673	rs2209808	chr14:55807695	A/T	cg01864836	chr14:55583639	NA	-0.38	-6.67	-0.34	1.02e-10	Protein biomarker;
LIHC	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	10.61	0.5	6.46e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-6.86	-0.35	3.28e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.87	0.47	2.17e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17106184	1.000	rs72902776	chr1:51269954	G/A	cg07174182	chr1:51127561	FAF1	-0.65	-7.06	-0.36	9.43e-12	Type 2 diabetes;
LIHC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.66	13.67	0.59	3.1e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00074818	chr8:8560427	CLDN23	0.38	6.28	0.32	1.03e-9	Obesity-related traits;
LIHC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.5	5.78	0.3	1.68e-8	Morning vs. evening chronotype;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg02083259	chr16:57220135	RSPRY1;FAM192A	-0.44	-6.44	-0.33	4.01e-10	Body mass index;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22387756	chr11:1495050	HCCA2	0.44	6.24	0.32	1.31e-9	Longevity;
LIHC	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.43	7.8	0.39	7.38e-14	Monocyte percentage of white cells;
LIHC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.61	8.86	0.43	4.39e-17	Emphysema distribution in smoking;
LIHC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg05621596	chr22:47072043	GRAMD4	-0.51	-7.2	-0.36	3.81e-12	Urate levels in obese individuals;
LIHC	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.45	8.78	0.43	8.03e-17	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.8	10.21	0.48	1.49e-21	Cognitive function;
LIHC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.08e-11	Alzheimer's disease;
LIHC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	7.15	0.36	5.29e-12	Bone mineral density;
LIHC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.5	-6.57	-0.33	1.91e-10	Initial pursuit acceleration;
LIHC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	-0.59	-8.46	-0.42	7.9e-16	Prudent dietary pattern;
LIHC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg26566898	chr11:117069891	TAGLN	0.46	7.23	0.36	3.23e-12	Blood protein levels;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.66	9.9	0.47	1.77e-20	Menarche (age at onset);
LIHC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.42	-6.72	-0.34	7.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.49	7.43	0.37	8.49e-13	Psoriasis;
LIHC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.52	7.54	0.38	4.2e-13	Type 2 diabetes;
LIHC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.59	7.96	0.4	2.57e-14	Mean platelet volume;
LIHC	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.49	8.07	0.4	1.21e-14	Diastolic blood pressure;
LIHC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.56	7.64	0.38	2.19e-13	Pulse pressure;
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg03721293	chr16:90014378	DEF8	0.36	6.31	0.32	8.77e-10	Skin colour saturation;
LIHC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.57	-10.03	-0.48	6.17e-21	Reticulocyte count;
LIHC	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg09795085	chr6:101329169	ASCC3	-0.54	-7.6	-0.38	2.95e-13	Neuroticism;
LIHC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	15.39	0.64	5.49e-41	IgG glycosylation;
LIHC	cis	rs4671400	0.571	rs62152275	chr2:61502238	C/A	cg14146966	chr2:61757674	XPO1	-0.37	-5.86	-0.3	1.1e-8	3-hydroxypropylmercapturic acid levels in smokers;
LIHC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.56	10.93	0.51	4.8e-24	Body mass index;
LIHC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.79	10.83	0.51	1.04e-23	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg14146966	chr2:61757674	XPO1	0.48	8.37	0.41	1.48e-15	Tuberculosis;
LIHC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	0.82	11.52	0.53	3.71e-26	Skin colour saturation;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-12.11	-0.55	2.44e-28	Alzheimer's disease;
LIHC	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg04610667	chr7:75704037	NA	-0.33	-5.98	-0.31	5.5e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg07451762	chr16:28383216	NA	0.33	6.14	0.32	2.27e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.96	0.35	1.72e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7674212	0.541	rs17217473	chr4:104114742	A/C	cg16532752	chr4:104119610	CENPE	-0.42	-6.48	-0.33	3.29e-10	Type 2 diabetes;
LIHC	cis	rs7712401	0.755	rs6595407	chr5:122100398	C/T	cg18764291	chr5:122110994	SNX2	0.35	6.02	0.31	4.38e-9	Mean platelet volume;
LIHC	cis	rs8030605	0.516	rs12440142	chr15:56537518	G/A	cg00626843	chr15:56536071	RFX7	0.46	6.02	0.31	4.49e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg15691649	chr6:25882328	NA	-0.6	-8.02	-0.4	1.68e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.7	9.86	0.47	2.39e-20	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.89	-18.3	-0.7	1.2e-52	Height;
LIHC	cis	rs2834188	0.889	rs8134026	chr21:34671098	T/A	cg14352951	chr21:34696688	IFNAR1	0.52	7.06	0.36	9.18e-12	Narcolepsy;
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg23520726	chr13:45563622	NUFIP1;KIAA1704	0.49	6.56	0.33	2.02e-10	Leprosy;
LIHC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.69	-0.34	9.1e-11	Neuroticism;
LIHC	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg20016023	chr10:99160130	RRP12	-0.4	-6.41	-0.33	4.86e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.56	0.42	3.91e-16	Response to antipsychotic treatment;
LIHC	trans	rs10411161	0.580	rs12151287	chr19:52381495	C/T	cg22319618	chr22:45562946	NUP50	-0.5	-7.41	-0.37	1.03e-12	Breast cancer;
LIHC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.38	-0.33	5.85e-10	Response to antipsychotic treatment;
LIHC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.88	-0.51	7.3e-24	Lymphocyte percentage of white cells;
LIHC	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06544989	chr22:39130855	UNC84B	0.37	6.14	0.32	2.27e-9	Menopause (age at onset);
LIHC	cis	rs11030122	0.673	rs10835508	chr11:4045360	A/T	cg18678763	chr11:4115507	RRM1	-0.53	-8.02	-0.4	1.74e-14	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg20933634	chr6:27740509	NA	0.47	6.19	0.32	1.69e-9	Parkinson's disease;
LIHC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-7.68	-0.38	1.68e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.37	5.72	0.3	2.36e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.83	0.39	6.14e-14	Mean platelet volume;
LIHC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg25204440	chr1:209979598	IRF6	0.47	7.12	0.36	6.35e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg12034118	chr1:209979487	IRF6	0.37	5.71	0.3	2.44e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg16275483	chr1:110013120	SYPL2	0.48	6.02	0.31	4.56e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3736757	0.603	rs12137438	chr1:184650034	A/C	cg07817967	chr1:184721222	EDEM3	0.36	5.8	0.3	1.54e-8	Obesity-related traits;
LIHC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg19635926	chr16:89946313	TCF25	-0.48	-5.98	-0.31	5.72e-9	Skin colour saturation;
LIHC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.37	-5.95	-0.31	6.57e-9	Hypospadias;
LIHC	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.53	-8.54	-0.42	4.38e-16	HDL cholesterol;
LIHC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-9.13	-0.44	6.08e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs10411161	0.702	rs11878583	chr19:52388546	C/T	cg22319618	chr22:45562946	NUP50	0.58	8.17	0.4	6.02e-15	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15604682	chr7:102105781	ALKBH4;LRWD1	0.51	6.81	0.35	4.29e-11	Lung function (FEV1/FVC);
LIHC	cis	rs3814231	0.589	rs12357967	chr10:115469710	G/A	cg24846397	chr10:115438155	CASP7	-0.42	-6.98	-0.35	1.53e-11	Vitiligo;
LIHC	cis	rs9918079	0.542	rs6414765	chr4:15626493	G/A	cg16509355	chr4:15471240	CC2D2A	-0.44	-6.71	-0.34	7.97e-11	Obesity-related traits;
LIHC	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs6442522	1.000	rs6762167	chr3:15445037	A/T	cg16303742	chr3:15540471	COLQ	-0.41	-6.89	-0.35	2.69e-11	Uric acid levels;
LIHC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-16.17	-0.66	4.41e-44	Coronary artery disease;
LIHC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.56	10.17	0.48	2.16e-21	Methadone dose in opioid dependence;
LIHC	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.6	10.39	0.49	3.67e-22	Diisocyanate-induced asthma;
LIHC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg18912006	chr12:123335444	HIP1R	-0.63	-7.64	-0.38	2.14e-13	Schizophrenia;
LIHC	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.99	0.35	1.43e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg03805757	chr16:71968109	PKD1L3	-0.55	-6.34	-0.32	7.13e-10	Post bronchodilator FEV1;
LIHC	trans	rs783540	0.934	rs783530	chr15:83266549	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.66	-0.34	1.07e-10	Schizophrenia;
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-8.49	-0.42	6.43e-16	Lymphocyte counts;
LIHC	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.57	7.73	0.39	1.19e-13	Mean corpuscular hemoglobin;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11872478	chr2:96196596	NA	0.39	6.67	0.34	1.01e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.05	18.46	0.71	2.87e-53	Triglycerides;
LIHC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	10.29	0.49	8.41e-22	Alzheimer's disease;
LIHC	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg00012203	chr2:219082015	ARPC2	0.87	14.15	0.61	4.36e-36	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LIHC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs9372498	0.505	rs3734345	chr6:118637042	T/C	cg01339444	chr6:118972232	C6orf204	0.74	6.07	0.31	3.38e-9	Diastolic blood pressure;
LIHC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.95	-0.31	6.64e-9	Prostate cancer;
LIHC	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg21045802	chr8:109455806	TTC35	0.5	8.8	0.43	6.75e-17	Dupuytren's disease;
LIHC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07677032	chr17:61819896	STRADA	0.43	6.21	0.32	1.56e-9	Prudent dietary pattern;
LIHC	cis	rs11233413	1.000	rs11233418	chr11:82728462	G/A	cg24227371	chr11:82718527	RAB30	-0.32	-7.06	-0.36	9.36e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs1865721	0.761	rs62089540	chr18:73218332	G/A	cg26385618	chr18:73139727	C18orf62	-0.27	-7.14	-0.36	5.66e-12	Intelligence;
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg00656387	chr3:40428638	ENTPD3	0.43	7.21	0.36	3.63e-12	Renal cell carcinoma;
LIHC	cis	rs2710642	0.564	rs7558681	chr2:62840987	G/A	cg17519650	chr2:63277830	OTX1	0.43	6.72	0.34	7.67e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.58	-0.38	3.25e-13	QT interval;
LIHC	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-7.22	-0.36	3.42e-12	Mortality in heart failure;
LIHC	cis	rs4700695	0.841	rs417152	chr5:65316205	G/A	cg21114390	chr5:65439923	SFRS12	0.45	5.87	0.3	1.05e-8	Facial morphology (factor 19);
LIHC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.61	8.1	0.4	1.01e-14	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06713297	chr1:242011104	EXO1	0.52	7.38	0.37	1.19e-12	Pancreatic cancer;
LIHC	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.95	-18.99	-0.72	2.02e-55	Schizophrenia;
LIHC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.24	-5.71	-0.3	2.4e-8	Crohn's disease;
LIHC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.3	0.45	1.74e-18	Bipolar disorder;
LIHC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg18016565	chr1:150552671	MCL1	0.49	9.33	0.45	1.38e-18	Melanoma;
LIHC	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.49	-7.54	-0.38	4.29e-13	Pubertal anthropometrics;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03150409	chr4:1892317	WHSC1	0.4	6.15	0.32	2.13e-9	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10512748	chr1:28844557	SNHG3-RCC1;RCC1	0.46	6.17	0.32	1.96e-9	Pancreatic cancer;
LIHC	cis	rs2933343	0.533	rs13086121	chr3:128704290	A/T	cg25356066	chr3:128598488	ACAD9	0.45	6.09	0.31	3.09e-9	IgG glycosylation;
LIHC	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg24579218	chr15:68104479	NA	-0.34	-5.8	-0.3	1.53e-8	Restless legs syndrome;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg16968413	chr4:39183824	WDR19	0.39	6.72	0.34	7.48e-11	Calcium levels;
LIHC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	13.8	0.6	9.62e-35	Psoriasis;
LIHC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.63	0.42	2.35e-16	Bipolar disorder and schizophrenia;
LIHC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-0.78	-8.87	-0.43	4.1e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs888194	0.690	rs3782894	chr12:110026024	G/T	cg05360138	chr12:110035743	NA	0.41	5.88	0.3	9.94e-9	Neuroticism;
LIHC	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.74	-0.34	6.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.52	7.91	0.39	3.61e-14	Longevity;Endometriosis;
LIHC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.44	-7.38	-0.37	1.21e-12	Educational attainment;
LIHC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.71	-6.85	-0.35	3.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	cis	rs2531992	0.620	rs2041248	chr16:4032489	T/G	cg05927578	chr16:4029543	ADCY9	0.52	7.04	0.36	1.07e-11	Waist circumference;
LIHC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.56	-7.34	-0.37	1.56e-12	Schizophrenia;
LIHC	cis	rs116248771	0.739	rs12639329	chr3:158347145	T/C	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.75e-10	diarrhoeal disease at age 2;
LIHC	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg16309518	chr5:176445507	NA	-0.57	-11.25	-0.52	3.35e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-9.7	-0.46	7.99e-20	Mean platelet volume;
LIHC	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.23	-0.45	2.93e-18	Schizophrenia;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.43	5.85	0.3	1.16e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs3783890	1.000	rs11621084	chr14:93764989	C/T	cg02802420	chr16:69363236	PDF;COG8	0.32	6.28	0.32	1.01e-9	Body mass index;
LIHC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.32	-0.32	8.05e-10	Axial length;
LIHC	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.77	-14.08	-0.61	7.54e-36	Mortality in heart failure;
LIHC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.38	-6.41	-0.33	4.84e-10	White matter hyperintensity burden;
LIHC	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.04	-0.31	4.11e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg22834771	chr12:69754056	YEATS4	-0.48	-8.08	-0.4	1.11e-14	Blood protein levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15083964	chr4:56212371	SRD5A3	-0.44	-6.41	-0.33	4.83e-10	Pancreatic cancer;
LIHC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.42	-9.35	-0.45	1.14e-18	Erythrocyte sedimentation rate;
LIHC	trans	rs16973084	1	rs16973084	chr15:82016618	C/T	cg05832051	chr19:54369469	MYADM	0.46	6.17	0.32	1.88e-9	Depressive symptoms;
LIHC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg12863693	chr15:85201151	NMB	0.44	6.31	0.32	8.81e-10	Schizophrenia;
LIHC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg06060754	chr5:176797920	RGS14	0.49	6.76	0.34	5.9e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.45	7.68	0.38	1.66e-13	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.97	-0.47	1.01e-20	Total cholesterol levels;
LIHC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg11812906	chr14:75593930	NEK9	-0.34	-5.73	-0.3	2.17e-8	Caffeine consumption;
LIHC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs7246657	0.943	rs4802136	chr19:37849811	T/A	cg23950597	chr19:37808831	NA	-0.44	-6.0	-0.31	5.01e-9	Coronary artery calcification;
LIHC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.41	12.81	0.57	6.13e-31	Uric acid levels;
LIHC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg02990361	chr1:107599529	PRMT6	0.57	8.84	0.43	5.16e-17	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.76	-0.5	1.82e-23	Response to antipsychotic treatment;
LIHC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06634786	chr22:41940651	POLR3H	0.66	7.02	0.35	1.23e-11	Vitiligo;
LIHC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.56	7.53	0.38	4.59e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg21361702	chr7:150065534	REPIN1	0.46	6.24	0.32	1.31e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.88	-15.55	-0.64	1.32e-41	Colorectal cancer;
LIHC	trans	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg07393940	chr7:158741817	NA	-0.57	-6.95	-0.35	1.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	7.66	0.38	1.98e-13	Platelet count;
LIHC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-11.79	-0.54	3.71e-27	Colorectal cancer;
LIHC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-0.71	-7.56	-0.38	3.63e-13	Putamen volume;
LIHC	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.49	7.66	0.38	1.93e-13	Breast cancer;
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.69	10.34	0.49	5.65e-22	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	8.9	0.43	3.22e-17	Lung cancer in ever smokers;
LIHC	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.7	-0.38	1.48e-13	Response to antipsychotic treatment;
LIHC	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.68	12.19	0.55	1.24e-28	Breast cancer;
LIHC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.32	-0.32	8.22e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.52	6.31	0.32	8.8e-10	Breast cancer;
LIHC	cis	rs7258015	1.000	rs7254041	chr19:10448636	T/G	cg13981319	chr19:10446556	ICAM3	0.46	7.21	0.36	3.68e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	cis	rs1198430	0.599	rs10917382	chr1:23780639	G/A	cg13183780	chr1:23809682	ASAP3	-0.34	-6.03	-0.31	4.2e-9	Total cholesterol levels;
LIHC	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg04610667	chr7:75704037	NA	-0.33	-5.98	-0.31	5.63e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.98	-0.31	5.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs797680	0.856	rs4847235	chr1:93627727	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.35	-6.13	-0.31	2.46e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-8.17	-0.4	6.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.45	-7.49	-0.38	5.87e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.54	9.04	0.44	1.22e-17	Aortic root size;
LIHC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1475718	0.526	rs10881586	chr9:137122724	C/T	cg21243944	chr9:137118148	NA	-0.43	-5.92	-0.3	7.76e-9	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.24	0.61	1.91e-36	Chronic sinus infection;
LIHC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-8.68	-0.42	1.67e-16	Chronic sinus infection;
LIHC	cis	rs7116495	0.609	rs10450664	chr11:71636655	A/G	cg10381502	chr11:71823885	C11orf51	-0.99	-8.28	-0.41	2.79e-15	Severe influenza A (H1N1) infection;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18211447	chr14:102771717	RAGE	0.4	6.1	0.31	2.88e-9	Cognitive function;
LIHC	cis	rs11871801	0.918	rs36005199	chr17:40597555	A/G	cg14558262	chr17:40713999	COASY	0.48	6.62	0.34	1.35e-10	Crohn's disease;
LIHC	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg15412446	chr2:106886593	NA	-0.7	-6.69	-0.34	9.31e-11	Facial morphology (factor 23);
LIHC	trans	rs11157436	0.792	rs12433875	chr14:22622423	A/G	cg13567813	chr19:50879636	NR1H2	0.41	6.11	0.31	2.77e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.92	15.04	0.63	1.34e-39	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	7.98	0.4	2.18e-14	IgG glycosylation;
LIHC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	8.35	0.41	1.66e-15	Schizophrenia;
LIHC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.16	28.77	0.84	2.38e-93	IgG glycosylation;
LIHC	trans	rs9641123	0.639	rs2051931	chr7:93243060	C/T	cg09745688	chr16:2908918	PRSS22	-0.37	-6.4	-0.33	5.08e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.6	-9.14	-0.44	5.66e-18	Longevity;
LIHC	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.52	8.36	0.41	1.56e-15	Obesity-related traits;
LIHC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.3	-0.37	2.08e-12	Platelet distribution width;
LIHC	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.43	6.66	0.34	1.11e-10	Mean corpuscular volume;
LIHC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	2.09e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs7116495	1.000	rs7106748	chr11:71645803	A/C	cg26138937	chr11:71823887	C11orf51	-0.83	-8.35	-0.41	1.69e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg17135325	chr3:160939158	NMD3	0.6	8.77	0.43	8.32e-17	Parkinson's disease;
LIHC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26076054	chr5:421317	AHRR	0.27	5.94	0.31	6.85e-9	Cystic fibrosis severity;
LIHC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-7.98	-0.4	2.21e-14	Morning vs. evening chronotype;
LIHC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.69	-0.43	1.49e-16	Gut microbiome composition (summer);
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.06	-0.4	1.27e-14	Lymphocyte counts;
LIHC	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.86	-6.51	-0.33	2.76e-10	Mosquito bite size;
LIHC	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.88	17.19	0.68	3.48e-48	Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg04166393	chr7:2884313	GNA12	0.55	8.52	0.42	5.03e-16	Height;
LIHC	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00938859	chr5:1591904	SDHAP3	0.57	7.07	0.36	8.57e-12	Breast cancer;
LIHC	cis	rs7602441	0.521	rs77940955	chr2:14767411	T/C	cg06545361	chr2:14773388	FAM84A	0.52	5.96	0.31	6.34e-9	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg11070056	chr1:107600091	PRMT6	0.64	10.16	0.48	2.25e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.58	9.64	0.46	1.33e-19	Corneal astigmatism;
LIHC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.53	-9.09	-0.44	8.01e-18	Total body bone mineral density;
LIHC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.87	-0.47	2.26e-20	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.5	7.42	0.37	9.65e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.74	0.43	1.09e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7165170	0.507	rs4932352	chr15:91145800	C/T	cg26821196	chr15:91095069	CRTC3	0.32	5.9	0.3	8.95e-9	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.71	13.4	0.59	3.48e-33	Mean platelet volume;
LIHC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-9.21	-0.45	3.32e-18	Electrocardiographic conduction measures;
LIHC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.78	10.89	0.51	6.35e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.48	-6.52	-0.33	2.5e-10	Initial pursuit acceleration;
LIHC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17483139	chr1:1822401	GNB1	-0.45	-6.77	-0.34	5.55e-11	Pancreatic cancer;
LIHC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.46	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7188697	0.922	rs9923491	chr16:58603176	T/G	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg04498913	chr7:1135747	C7orf50	0.37	5.72	0.3	2.29e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.54	-7.91	-0.39	3.5e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.82	9.77	0.47	4.8e-20	Bone mineral density;
LIHC	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg24169773	chr3:122142474	KPNA1	-0.47	-9.25	-0.45	2.41e-18	LDL cholesterol levels;
LIHC	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg10774155	chr7:65338427	VKORC1L1	0.45	6.71	0.34	7.86e-11	Calcium levels;
LIHC	cis	rs9322817	0.691	rs2034821	chr6:105219537	C/T	cg02098413	chr6:105308735	HACE1	-0.42	-7.55	-0.38	4.01e-13	Thyroid stimulating hormone;
LIHC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg14440974	chr22:39074834	NA	-0.42	-6.7	-0.34	8.5e-11	Menopause (age at onset);
LIHC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.4	0.33	5.18e-10	Rheumatoid arthritis;
LIHC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.78	0.34	5.19e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-13.19	-0.58	2.21e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.58	0.34	1.81e-10	Lymphocyte counts;
LIHC	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.55	-5.9	-0.3	8.8e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.76	12.27	0.55	6.16e-29	Tonsillectomy;
LIHC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.82	-0.63	1.04e-38	Alzheimer's disease (late onset);
LIHC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.41	0.33	4.91e-10	HDL cholesterol;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23945273	chr4:120987944	MAD2L1	0.45	6.13	0.31	2.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.59	8.51	0.42	5.43e-16	Coronary artery disease;
LIHC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.57	-9.8	-0.47	3.84e-20	Total body bone mineral density;
LIHC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.86	10.59	0.5	7.21e-23	Mean platelet volume;
LIHC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.39	-0.49	3.81e-22	Coronary artery disease;
LIHC	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.76	6.68	0.34	9.7e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs2607426	0.681	rs2257613	chr19:41284004	C/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.55	-6.29	-0.32	9.85e-10	Blood protein levels;
LIHC	cis	rs4920343	0.698	rs669138	chr1:19088899	C/T	cg19637330	chr1:19110922	NA	0.33	5.99	0.31	5.25e-9	Knee osteoarthritis;
LIHC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.89	0.3	9.33e-9	Electroencephalogram traits;
LIHC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.8	9.89	0.47	1.85e-20	Morning vs. evening chronotype;
LIHC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.86	0.35	3.16e-11	Neuroticism;
LIHC	cis	rs6141600	0.760	rs2590986	chr20:34686496	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.87	-0.3	1.05e-8	Height;Hip circumference;
LIHC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg21231739	chr4:1642635	FAM53A	-0.36	-5.76	-0.3	1.86e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg19000871	chr14:103996768	TRMT61A	0.43	7.24	0.36	3.04e-12	Coronary artery disease;
LIHC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.49	-7.93	-0.39	3.13e-14	Cognitive function;
LIHC	cis	rs2412459	0.803	rs28369403	chr15:40277603	G/A	cg02712587	chr15:40268421	EIF2AK4	-0.54	-5.76	-0.3	1.84e-8	Response to haloperidol in psychosis;
LIHC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.74	-12.81	-0.57	5.99e-31	Prudent dietary pattern;
LIHC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.93	16.31	0.66	1.25e-44	Parkinson's disease;
LIHC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.56	9.16	0.44	4.94e-18	Body mass index;
LIHC	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-0.71	-8.02	-0.4	1.74e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.43	-7.46	-0.37	7.44e-13	Platelet distribution width;
LIHC	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-9.19	-0.45	3.83e-18	Colorectal cancer;
LIHC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.56	0.56	4.96e-30	Total body bone mineral density;
LIHC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	7.04	0.36	1.04e-11	Height;
LIHC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26734620	chr12:56694298	CS	-1.04	-10.23	-0.48	1.3e-21	Psoriasis vulgaris;
LIHC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.42	0.33	4.69e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.4	-8.1	-0.4	9.96e-15	Urinary metabolites;
LIHC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.44	-0.42	8.98e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.97	0.35	1.59e-11	Breast cancer;
LIHC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.65	-0.46	1.16e-19	Electroencephalogram traits;
LIHC	cis	rs16912285	0.688	rs7929701	chr11:24357964	A/C	ch.11.24196551F	chr11:24239977	NA	0.72	8.36	0.41	1.66e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.51	8.63	0.42	2.31e-16	Obesity-related traits;
LIHC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.71	-8.44	-0.42	8.82e-16	Vitiligo;
LIHC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.79	-0.34	4.96e-11	Aortic root size;
LIHC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg21466736	chr12:48725269	NA	-0.71	-10.87	-0.51	7.92e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.87	13.29	0.58	8.98e-33	Gastritis;
LIHC	trans	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg10756647	chr7:56101905	PSPH	1.08	13.35	0.59	5.31e-33	Diabetic kidney disease;
LIHC	cis	rs918629	0.567	rs56219066	chr5:95242931	T/C	cg10483112	chr5:95245456	ELL2	-0.37	-6.88	-0.35	2.79e-11	IgG glycosylation;
LIHC	trans	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.44	-6.25	-0.32	1.2e-9	Type 2 diabetes;
LIHC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00429477	chr12:6798907	ZNF384	-0.47	-6.4	-0.33	5.22e-10	Bilirubin levels;
LIHC	cis	rs7255	0.538	rs2289081	chr2:20881840	G/C	cg14780466	chr2:20870812	GDF7	-0.28	-6.0	-0.31	5.11e-9	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
LIHC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	10.32	0.49	6.33e-22	Multiple sclerosis;
LIHC	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.45	-0.33	3.83e-10	Metabolite levels;
LIHC	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.17	-0.32	1.97e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.34	-6.74	-0.34	6.71e-11	Body mass index;
LIHC	cis	rs8056893	0.714	rs9931501	chr16:68402686	A/G	cg02226672	chr16:68398533	SMPD3	0.43	5.97	0.31	5.81e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.35	-9.0	-0.44	1.57e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg02297831	chr4:17616191	MED28	0.43	5.84	0.3	1.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg18912006	chr12:123335444	HIP1R	-0.59	-6.86	-0.35	3.2e-11	Schizophrenia;
LIHC	trans	rs1441147	0.764	rs2696344	chr2:182533211	C/G	cg00626466	chr12:65153982	GNS	0.44	6.32	0.32	8.19e-10	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.65	9.43	0.45	6.43e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7238033	0.624	rs9949609	chr18:43313128	C/G	cg20610511	chr18:43302872	SLC14A1	0.37	6.24	0.32	1.31e-9	Bladder cancer;
LIHC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.59	8.39	0.41	1.3e-15	Eosinophil percentage of white cells;
LIHC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-8.3	-0.41	2.4e-15	Chronic sinus infection;
LIHC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.63	-5.84	-0.3	1.24e-8	Red cell distribution width;
LIHC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.59	7.98	0.4	2.16e-14	Coronary artery disease;
LIHC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.74	-0.3	2.12e-8	Uric acid levels;
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg27094323	chr7:1216898	NA	-0.4	-5.78	-0.3	1.68e-8	Longevity;Endometriosis;
LIHC	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.39	6.08	0.31	3.14e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	14.21	0.61	2.35e-36	Multiple sclerosis;
LIHC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg05110241	chr16:68378359	PRMT7	-0.48	-5.98	-0.31	5.56e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11653357	1.000	rs11653357	chr17:33923607	G/A	cg20932281	chr17:33905541	PEX12	0.56	7.23	0.36	3.28e-12	Platelet distribution width;Platelet count;
LIHC	cis	rs12101261	1.000	rs1023586	chr14:81462283	T/C	cg06600135	chr14:81408086	NA	0.37	6.33	0.32	7.5e-10	Graves' disease;
LIHC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs67981189	0.593	rs7160958	chr14:71442526	C/A	cg15816911	chr14:71606274	NA	0.41	6.55	0.33	2.17e-10	Schizophrenia;
LIHC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	7.32	0.37	1.8e-12	Total body bone mineral density;
LIHC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.02	-0.4	1.7e-14	Body mass index;
LIHC	cis	rs922107	0.713	rs10922663	chr1:90032893	C/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.7	-0.38	1.48e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.31	6.47	0.33	3.33e-10	Bone mineral density;
LIHC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.09	12.91	0.57	2.49e-31	Vitiligo;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg24693881	chr1:107596107	NA	-0.53	-9.26	-0.45	2.24e-18	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg23202291	chr11:1979235	NA	-0.48	-7.32	-0.37	1.81e-12	DNA methylation (variation);
LIHC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.66	10.12	0.48	3.16e-21	Height;
LIHC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.82	13.16	0.58	2.8099999999999997e-32	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	8.84	0.43	5.25e-17	Mood instability;
LIHC	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg16473166	chr22:50639996	SELO	0.57	8.51	0.42	5.61e-16	Obesity-related traits;
LIHC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-14.15	-0.61	4.37e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg07645718	chr20:61493192	TCFL5	0.79	6.45	0.33	3.85e-10	Obesity-related traits;
LIHC	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.59	-0.42	3.07e-16	Obesity-related traits;
LIHC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	8.0	0.4	2e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg03343631	chr13:114764489	RASA3	-0.28	-5.74	-0.3	2.04e-8	Schizophrenia;
LIHC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.61	9.77	0.47	4.96e-20	Resting heart rate;
LIHC	cis	rs35883536	1.000	rs4907918	chr1:101094609	A/G	cg14515779	chr1:101123966	NA	0.67	13.35	0.59	5.12e-33	Monocyte count;
LIHC	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.52	0.46	3.1400000000000002e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.79	10.64	0.5	4.86e-23	Menarche (age at onset);
LIHC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.42	7.21	0.36	3.57e-12	Alcohol dependence;
LIHC	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.41	7.41	0.37	1.02e-12	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg02290350	chr8:58132656	NA	0.31	6.59	0.34	1.68e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg25007680	chr1:8021821	PARK7	0.61	9.65	0.46	1.21e-19	Response to antidepressants and depression;
LIHC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg09911534	chr15:67153556	NA	-0.46	-6.11	-0.31	2.7e-9	Lung cancer (smoking interaction);
LIHC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-8.86	-0.43	4.29e-17	Height;
LIHC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.32	0.41	2.14e-15	Menarche (age at onset);
LIHC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.85	-12.86	-0.57	3.98e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.23	-7.26	-0.37	2.67e-12	Mean corpuscular volume;
LIHC	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.1	-0.4	9.83e-15	Testicular germ cell tumor;
LIHC	cis	rs7192750	0.586	rs2335710	chr16:71923181	C/G	cg06353428	chr16:71660113	MARVELD3	-0.82	-9.16	-0.44	4.84e-18	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.6	-9.42	-0.45	7.03e-19	Uric acid clearance;
LIHC	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.59	0.38	3.12e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-8.78	-0.43	7.87e-17	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs6866721	0.791	rs7724674	chr5:116217033	T/C	cg07571379	chr11:134631427	NA	-0.28	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.39	7.17	0.36	4.68e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3770081	1.000	rs12614260	chr2:86303079	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-8.69	-0.43	1.49e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg01081584	chr15:40268610	EIF2AK4	-0.61	-8.04	-0.4	1.52e-14	Response to haloperidol in psychosis;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.44	7.22	0.36	3.46e-12	Testicular germ cell tumor;
LIHC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	10.83	0.51	1.04e-23	Platelet count;
LIHC	cis	rs1144333	1.000	rs17097863	chr1:76468787	T/G	cg03433033	chr1:76189801	ACADM	0.51	7.44	0.37	8.08e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.09	13.26	0.58	1.12e-32	Primary sclerosing cholangitis;
LIHC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.43	5.89	0.3	9.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.36	5.89	0.3	9.15e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.87	11.32	0.52	1.96e-25	Coronary artery disease;
LIHC	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg16589663	chr20:23618590	CST3	0.74	7.46	0.37	7.4e-13	Chronic kidney disease;
LIHC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.63	-7.88	-0.39	4.3e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.37e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.53	8.95	0.44	2.24e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.43	5.99	0.31	5.27e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.45	-0.42	8.37e-16	Total cholesterol levels;
LIHC	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg10820045	chr2:198174542	NA	-0.49	-7.38	-0.37	1.21e-12	Dermatomyositis;
LIHC	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.88	-14.85	-0.63	7.3e-39	Schizophrenia;
LIHC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.36	6.03	0.31	4.17e-9	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.53	6.43	0.33	4.34e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	10.32	0.49	6.7e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg17724175	chr1:150552817	MCL1	-0.38	-7.85	-0.39	5.49e-14	Tonsillectomy;
LIHC	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.5	-8.72	-0.43	1.19e-16	Gout;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg16632132	chr16:1122873	LOC146336	0.44	6.11	0.31	2.72e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11212260	0.678	rs11212204	chr11:107267630	G/T	cg25435332	chr11:107328525	CWF19L2	0.72	8.26	0.41	3.14e-15	IgG glycosylation;
LIHC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.6	8.31	0.41	2.2e-15	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20598768	chr1:154193039	C1orf43;UBAP2L	0.5	6.82	0.35	4.07e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.54	9.75	0.47	5.8e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.32	-5.71	-0.3	2.43e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs9628987	0.539	rs9628991	chr1:8424039	C/G	cg20416874	chr1:8611966	RERE	0.49	5.94	0.31	7.18e-9	Breast cancer;
LIHC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg26939375	chr7:64535504	NA	0.4	6.34	0.32	7.06e-10	Aortic root size;
LIHC	cis	rs34540877	1.000	rs34131970	chr19:33144107	A/G	cg22980127	chr19:33182716	NUDT19	0.89	6.22	0.32	1.46e-9	Red cell distribution width;
LIHC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg16346588	chr10:242978	ZMYND11	0.46	5.93	0.31	7.22e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	0.92	17.86	0.69	7.39e-51	Schizophrenia;
LIHC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.9	15.97	0.65	2.78e-43	Intelligence (multi-trait analysis);
LIHC	trans	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg26939375	chr7:64535504	NA	0.4	6.31	0.32	8.87e-10	Aortic root size;
LIHC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.59	-11.92	-0.54	1.29e-27	Coronary artery disease;
LIHC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.94	10.83	0.51	1.06e-23	Triglycerides;
LIHC	trans	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg03370490	chr11:1380305	NA	0.25	6.04	0.31	3.99e-9	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.49	8.25	0.41	3.52e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs860295	0.729	rs4971072	chr1:155273869	G/A	cg02153340	chr1:155202674	NA	0.33	5.88	0.3	9.64e-9	Body mass index;
LIHC	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.68	9.71	0.46	7.58e-20	Red blood cell count;
LIHC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21448741	chr8:58168803	NA	0.35	5.83	0.3	1.29e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg15832292	chr6:96025679	MANEA	-0.71	-8.52	-0.42	5e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.8	12.72	0.57	1.25e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.66	-11.14	-0.52	8.38e-25	Menopause (age at onset);
LIHC	cis	rs4908768	0.906	rs12402539	chr1:8538303	C/A	cg25722041	chr1:8623473	RERE	0.41	6.02	0.31	4.5e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg05484376	chr2:27715224	FNDC4	0.38	6.42	0.33	4.69e-10	Total body bone mineral density;
LIHC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.42	-6.66	-0.34	1.12e-10	Iron status biomarkers;
LIHC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.56	0.38	3.73e-13	Mean platelet volume;
LIHC	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg05425664	chr17:57184151	TRIM37	-0.48	-6.05	-0.31	3.85e-9	Vitamin D levels;
LIHC	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.93	0.31	7.28e-9	Educational attainment;
LIHC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.03	15.95	0.65	3.18e-43	Breast cancer;
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24449463	chr1:168025552	DCAF6	0.46	6.11	0.31	2.69e-9	Hepatitis;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07424592	chr7:64974309	NA	0.46	7.01	0.35	1.25e-11	Calcium levels;
LIHC	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.86	-0.3	1.09e-8	Intelligence (multi-trait analysis);
LIHC	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.19	-0.45	4.01e-18	Colorectal cancer;
LIHC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg00656387	chr3:40428638	ENTPD3	-0.43	-7.18	-0.36	4.38e-12	Renal cell carcinoma;
LIHC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg18478394	chr8:109455254	TTC35	0.44	7.57	0.38	3.6e-13	Dupuytren's disease;
LIHC	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg14930904	chr10:32216787	ARHGAP12	0.35	6.07	0.31	3.35e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg05590025	chr7:65112418	INTS4L2	0.56	6.09	0.31	3.04e-9	Gout;
LIHC	trans	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg13798721	chr14:105190477	ADSSL1	-0.45	-6.25	-0.32	1.22e-9	Body mass index;
LIHC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-15.07	-0.63	1.01e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg12501888	chr15:85177176	SCAND2	-0.52	-8.0	-0.4	1.94e-14	P wave terminal force;
LIHC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg16479474	chr6:28041457	NA	0.38	6.29	0.32	9.81e-10	Parkinson's disease;
LIHC	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg12501888	chr15:85177176	SCAND2	-0.52	-8.0	-0.4	1.94e-14	P wave terminal force;
LIHC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.58	-9.2	-0.45	3.73e-18	Multiple myeloma (IgH translocation);
LIHC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.53	7.69	0.38	1.58e-13	Type 2 diabetes;
LIHC	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.44	7.82	0.39	6.7e-14	Capecitabine sensitivity;
LIHC	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.48	-0.38	6.18e-13	Breast cancer;
LIHC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.52	8.2	0.41	4.82e-15	Tumor biomarkers;
LIHC	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.72	9.71	0.46	7.42e-20	Body mass index;
LIHC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.65	-9.85	-0.47	2.68e-20	Subjective well-being;
LIHC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.25	-0.58	1.21e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-5.97	-0.31	6.07e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.95	15.88	0.65	6.22e-43	Subjective well-being;
LIHC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg19318889	chr4:1322082	MAEA	-0.46	-7.59	-0.38	3.09e-13	Obesity-related traits;
LIHC	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg00277334	chr10:82204260	NA	-0.54	-6.84	-0.35	3.68e-11	Post bronchodilator FEV1;
LIHC	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.62	9.34	0.45	1.3e-18	Eotaxin levels;
LIHC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.47	7.03	0.36	1.1e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.81	0.3	1.45e-8	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.16e-10	Aortic root size;
LIHC	cis	rs2073300	0.793	rs6114094	chr20:23434267	A/G	cg12062639	chr20:23401060	NAPB	0.74	8.92	0.43	2.87e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08462924	chr1:41848221	NA	0.34	5.86	0.3	1.1e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.59	0.59	6.27e-34	Lung cancer in ever smokers;
LIHC	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg14146966	chr2:61757674	XPO1	0.49	8.33	0.41	1.96e-15	Tuberculosis;
LIHC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg12560992	chr17:57184187	TRIM37	0.53	7.29	0.37	2.1e-12	Cognitive test performance;
LIHC	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.52	-7.1	-0.36	7.33e-12	Eotaxin levels;
LIHC	cis	rs61677309	1.000	rs1074459	chr11:118155997	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg25039879	chr17:56429692	SUPT4H1	-0.5	-7.05	-0.36	1.01e-11	Cognitive test performance;
LIHC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.52	7.57	0.38	3.4e-13	Glycated hemoglobin levels;
LIHC	cis	rs77861329	1.000	rs352153	chr3:52211184	A/T	cg08692210	chr3:52188851	WDR51A	0.83	7.45	0.37	7.69e-13	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.85	12.94	0.57	1.93e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10097731	0.808	rs80141261	chr8:82034453	T/C	cg25230327	chr8:82042993	NA	-0.52	-6.89	-0.35	2.73e-11	Serum total protein level;
LIHC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.3	-7.21	-0.36	3.69e-12	Longevity;Endometriosis;
LIHC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-16.49	-0.67	2.23e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg00142150	chr22:38071001	LGALS1	0.44	7.5	0.38	5.41e-13	Fat distribution (HIV);
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.69	11.33	0.52	1.72e-25	Prudent dietary pattern;
LIHC	cis	rs7539624	0.588	rs10916602	chr1:223897425	G/A	cg07395969	chr1:223900822	CAPN2	0.49	5.82	0.3	1.38e-8	Schizophrenia;
LIHC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.57	10.16	0.48	2.35e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.42	-8.48	-0.42	6.8e-16	Obesity-related traits;
LIHC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.99	0.35	1.44e-11	Mood instability;
LIHC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-8.5	-0.42	5.75e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08822215	chr16:89438651	ANKRD11	0.39	6.21	0.32	1.56e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.72	10.82	0.5	1.19e-23	Subjective well-being;
LIHC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02290350	chr8:58132656	NA	0.48	8.98	0.44	1.92e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs7226229	0.950	rs2291037	chr17:20924523	C/T	cg04305134	chr10:75173374	ANXA7	-0.43	-6.35	-0.32	6.67e-10	Blood trace element (Se levels);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17105206	chr16:67211972	KIAA0895L	-0.36	-6.13	-0.31	2.39e-9	Immature fraction of reticulocytes;
LIHC	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.59	9.36	0.45	1.08e-18	Corneal astigmatism;
LIHC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.51	-8.05	-0.4	1.38e-14	Educational attainment;
LIHC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.43	6.09	0.31	3.05e-9	Breast cancer;
LIHC	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.57	7.58	0.38	3.26e-13	Eotaxin levels;
LIHC	cis	rs7238033	0.624	rs11877062	chr18:43307246	C/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.78	0.34	5.21e-11	Bladder cancer;
LIHC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.83	7.63	0.38	2.42e-13	Lymphocyte counts;
LIHC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.48	7.86	0.39	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.93	-12.98	-0.57	1.35e-31	Heart rate;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22293416	chr8:109493386	TTC35	-0.41	-6.25	-0.32	1.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.44	-7.02	-0.36	1.18e-11	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg25894440	chr7:65020034	NA	-0.53	-6.04	-0.31	4.05e-9	Diabetic kidney disease;
LIHC	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.91	18.79	0.71	1.31e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.24	-0.45	2.76e-18	Type 2 diabetes;
LIHC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg11062466	chr8:58055876	NA	0.39	5.8	0.3	1.54e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-8.38	-0.41	1.43e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg22771759	chr13:24902376	NA	0.31	6.46	0.33	3.52e-10	Obesity-related traits;
LIHC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.81	-0.5	1.23e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg19636519	chr7:99541626	NA	0.31	6.01	0.31	4.67e-9	Coronary artery disease;
LIHC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-10.67	-0.5	3.79e-23	Platelet count;
LIHC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.64	10.79	0.5	1.51e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.86	0.43	4.31e-17	Lung cancer;
LIHC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg04013166	chr16:89971882	TCF25	0.52	6.46	0.33	3.55e-10	Skin colour saturation;
LIHC	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg06191203	chr2:152266755	RIF1	0.39	6.65	0.34	1.18e-10	Lung cancer;
LIHC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.17	-0.78	4.61e-72	Height;
LIHC	trans	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg26939375	chr7:64535504	NA	-0.42	-6.77	-0.34	5.73e-11	Aortic root size;
LIHC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.55	-0.38	4.12e-13	Chronic sinus infection;
LIHC	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.77	-12.68	-0.57	1.79e-30	Coronary artery disease;
LIHC	trans	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg01596870	chr19:55963115	NA	-0.66	-9.36	-0.45	1.1e-18	Obesity-related traits;
LIHC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg03647239	chr10:116582469	FAM160B1	0.46	6.58	0.34	1.77e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.69	0.73	3.11e-58	Smoking behavior;
LIHC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.8	-0.43	6.71e-17	Schizophrenia;
LIHC	cis	rs16944613	0.510	rs4932353	chr15:91145838	T/C	cg26821196	chr15:91095069	CRTC3	0.33	6.09	0.31	2.98e-9	Colorectal cancer;
LIHC	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.44	-7.02	-0.36	1.16e-11	Cocaine dependence;
LIHC	trans	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg13698153	chr12:118541722	VSIG10	0.65	7.23	0.36	3.2e-12	Vitiligo;
LIHC	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.27	-0.37	2.46e-12	Body mass index;
LIHC	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-10.34	-0.49	5.49e-22	Waist circumference;Body mass index;
LIHC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	10.81	0.5	1.28e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-9.87	-0.47	2.26e-20	Tonsillectomy;
LIHC	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.36	7.11	0.36	6.83e-12	Blood protein levels;
LIHC	trans	rs783540	0.900	rs55924160	chr15:83282196	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.11	-0.31	2.78e-9	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs9322817	0.902	rs4336470	chr6:105180785	C/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.52	-0.33	2.48e-10	Thyroid stimulating hormone;
LIHC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.43	6.78	0.34	5.32e-11	Lymphocyte counts;
LIHC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg24209194	chr3:40518798	ZNF619	0.46	6.84	0.35	3.57e-11	Renal cell carcinoma;
LIHC	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.93	0.51	4.56e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg01858014	chr14:56050164	KTN1	-0.72	-7.0	-0.35	1.36e-11	Putamen volume;
LIHC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg26939375	chr7:64535504	NA	-0.47	-7.04	-0.36	1.08e-11	Calcium levels;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.69	0.62	3.3e-38	Prudent dietary pattern;
LIHC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs12744310	1.000	rs12744310	chr1:41773502	C/T	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2412488	1.000	rs6827269	chr4:54320617	C/T	cg22241045	chr4:54363911	LNX1	-0.45	-7.04	-0.36	1.09e-11	DNA methylation (variation);
LIHC	cis	rs16828019	0.852	rs2268678	chr1:41511053	G/A	cg03387723	chr1:41708464	SCMH1	-0.41	-6.47	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg16102536	chr7:156981717	UBE3C	0.37	6.14	0.31	2.32e-9	Body mass index;
LIHC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-7.44	-0.37	7.98e-13	Morning vs. evening chronotype;
LIHC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg17385448	chr1:15911702	AGMAT	0.33	5.8	0.3	1.53e-8	Systolic blood pressure;
LIHC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.99	-0.44	1.69e-17	Gut microbiome composition (summer);
LIHC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs8050755	0.536	rs78160478	chr16:2107322	G/T	cg04515572	chr16:2107413	TSC2	-0.85	-6.17	-0.32	1.91e-9	Major depressive disorder;
LIHC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	1.03	20.76	0.75	1.64e-62	Breast cancer;
LIHC	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.25	7.05	0.36	9.73e-12	Type 2 diabetes;
LIHC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.77	9.68	0.46	9.34e-20	Cognitive function;
LIHC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.83	11.35	0.52	1.43e-25	Blood metabolite levels;
LIHC	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg02580895	chr19:2754563	NA	-0.41	-6.09	-0.31	3e-9	Total cholesterol levels;
LIHC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.82	-0.3	1.35e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17059624	chr11:85358760	TMEM126A	0.47	7.34	0.37	1.61e-12	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18502334	chr7:4681577	NA	-0.44	-6.63	-0.34	1.28e-10	Cognitive function;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.51	-6.54	-0.33	2.28e-10	Prostate cancer;
LIHC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.87	-0.35	3.06e-11	Alzheimer's disease (late onset);
LIHC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.27	6.12	0.31	2.54e-9	Migraine;
LIHC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.52	7.11	0.36	6.81e-12	Morning vs. evening chronotype;
LIHC	cis	rs365132	0.902	rs353489	chr5:176461974	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.32	-0.52	1.93e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg00204748	chr12:29376779	FAR2	0.39	7.24	0.36	3.03e-12	QT interval;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg27432699	chr2:27873401	GPN1	-0.5	-7.27	-0.37	2.44e-12	Total body bone mineral density;
LIHC	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.35	-5.82	-0.3	1.38e-8	Red blood cell traits;
LIHC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	11.86	0.54	1.98e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.64	10.32	0.49	6.29e-22	Monocyte count;
LIHC	cis	rs151997	0.925	rs27287	chr5:50195567	C/A	cg06027927	chr5:50259733	NA	0.57	7.65	0.38	2.05e-13	Callous-unemotional behaviour;
LIHC	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.2	16.23	0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg16822855	chr3:40428330	ENTPD3	0.35	6.35	0.32	6.9e-10	Renal cell carcinoma;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13374389	chr22:30821762	MTP18	-0.51	-6.44	-0.33	3.98e-10	Hip circumference;
LIHC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-9.15	-0.44	5.27e-18	Skin colour saturation;
LIHC	trans	rs304172	0.793	rs304170	chr3:62780639	A/G	cg07662676	chr19:39322573	ECH1	0.84	6.06	0.31	3.64e-9	IgG glycosylation;
LIHC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.43	6.85	0.35	3.41e-11	Response to temozolomide;
LIHC	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg01364799	chr7:75623366	TMEM120A	0.52	7.88	0.39	4.29e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7187994	0.848	rs12934432	chr16:84770913	T/A	cg07647771	chr16:84786436	USP10	-0.34	-6.3	-0.32	9.21e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9596863	0.898	rs9568924	chr13:54360952	T/G	ch.13.53330881F	chr13:54432880	NA	0.45	6.03	0.31	4.21e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.68	0.34	9.73e-11	Ileal carcinoids;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06873352	chr17:61820015	STRADA	0.56	8.51	0.42	5.66e-16	Height;
LIHC	cis	rs4891159	0.655	rs890393	chr18:74102435	G/T	cg24786174	chr18:74118243	ZNF516	-0.72	-13.19	-0.58	2.21e-32	Longevity;
LIHC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-0.96	-12.35	-0.56	3.11e-29	Obesity-related traits;
LIHC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.16	0.58	2.73e-32	Alzheimer's disease;
LIHC	cis	rs6596100	0.538	rs67519234	chr5:132199359	C/A	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.51	8.86	0.43	4.47e-17	Coronary artery disease;
LIHC	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.43	-6.18	-0.32	1.84e-9	Red blood cell traits;
LIHC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	1.0	21.08	0.75	8.69e-64	Height;
LIHC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.74	0.54	5.61e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.91	-8.98	-0.44	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.72	-9.8	-0.47	3.95e-20	HIV-1 control;
LIHC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg24826892	chr11:71159390	DHCR7	0.49	6.31	0.32	8.5e-10	Vitamin D levels;
LIHC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.06	15.32	0.64	1.03e-40	Cognitive function;
LIHC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg15448220	chr1:150897856	SETDB1	-0.4	-6.31	-0.32	8.73e-10	Tonsillectomy;
LIHC	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.19	-0.45	3.78e-18	Colorectal cancer;
LIHC	cis	rs4589502	0.614	rs17273637	chr15:67193084	C/T	cg09911534	chr15:67153556	NA	-0.47	-5.82	-0.3	1.32e-8	Lung cancer (smoking interaction);
LIHC	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg20129853	chr10:51489980	NA	-0.41	-8.96	-0.44	2.13e-17	Prostate-specific antigen levels;
LIHC	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.39	6.26	0.32	1.18e-9	Mean corpuscular volume;
LIHC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg22528358	chr1:107598549	PRMT6	-0.64	-10.76	-0.5	1.82e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.79	0.57	6.79e-31	Prudent dietary pattern;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg21561701	chr13:114193150	TMCO3	-0.36	-6.05	-0.31	3.74e-9	Pain;
LIHC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg01403660	chr11:68851641	TPCN2	-0.44	-7.15	-0.36	5.17e-12	Hair color;
LIHC	cis	rs6977660	1.000	rs2107403	chr7:19819025	G/C	cg07541023	chr7:19748670	TWISTNB	0.37	5.82	0.3	1.36e-8	Thyroid stimulating hormone;
LIHC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.78	-0.47	4.28e-20	Mean platelet volume;
LIHC	cis	rs3736485	0.966	rs2124877	chr15:51906275	A/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.57e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.45	-6.45	-0.33	3.8e-10	Blood protein levels;
LIHC	cis	rs6782228	0.606	rs7650156	chr3:128361555	T/A	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.6	-0.38	2.95e-13	QT interval;
LIHC	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.67	13.3	0.58	8.01e-33	Leprosy;
LIHC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-7.35	-0.37	1.49e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.63	-10.32	-0.49	6.44e-22	Platelet count;
LIHC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13935437	chr1:19600673	AKR7L	0.31	5.73	0.3	2.15e-8	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9326248	0.773	rs1060211	chr11:117039797	G/A	cg11861562	chr11:117069780	TAGLN	0.36	5.73	0.3	2.15e-8	Blood protein levels;
LIHC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.41	6.13	0.31	2.36e-9	Neuroticism;
LIHC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg06565975	chr8:143823917	SLURP1	-0.45	-8.31	-0.41	2.26e-15	Urinary tract infection frequency;
LIHC	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.3	-5.72	-0.3	2.34e-8	Red blood cell count;
LIHC	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.96	7.82	0.39	6.63e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs9394841	0.692	rs35085306	chr6:41856002	A/G	cg17623882	chr6:41773611	USP49	-0.44	-5.86	-0.3	1.09e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.46	9.13	0.44	5.92e-18	Lung cancer;
LIHC	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.83	-0.39	6.2e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.16	0.32	2e-9	Protein biomarker;
LIHC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.5	0.53	4.42e-26	Motion sickness;
LIHC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.38	-0.56	2.44e-29	Primary sclerosing cholangitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02744793	chr10:35378717	CUL2	0.46	6.11	0.31	2.66e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	1.06	11.94	0.54	1.02e-27	IgG glycosylation;
LIHC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg05484376	chr2:27715224	FNDC4	0.4	6.68	0.34	9.57e-11	Total body bone mineral density;
LIHC	trans	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg26939375	chr7:64535504	NA	-0.39	-6.2	-0.32	1.66e-9	Aortic root size;
LIHC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-5.99	-0.31	5.22e-9	Bladder cancer;
LIHC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00152838	chr16:24741724	TNRC6A	-0.53	-6.38	-0.33	5.77e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	9.7e-13	Putamen volume;
LIHC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.67	-8.39	-0.41	1.26e-15	Gut microbiome composition (summer);
LIHC	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.03	0.4	1.63e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-13.88	-0.6	4.75e-35	Headache;
LIHC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg00809820	chr17:80708513	TBCD;FN3K	-0.33	-5.74	-0.3	2.08e-8	Glycated hemoglobin levels;
LIHC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.33	-0.41	1.97e-15	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.85	10.76	0.5	1.87e-23	Cognitive function;
LIHC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg20607798	chr8:58055168	NA	0.45	6.11	0.31	2.7e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.94	16.62	0.67	6.65e-46	Intelligence (multi-trait analysis);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg03621406	chr19:9930365	FBXL12	-0.48	-6.09	-0.31	2.98e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-9.44	-0.45	5.89e-19	Prudent dietary pattern;
LIHC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg22777020	chr22:31556080	RNF185	-0.55	-6.31	-0.32	8.59e-10	Colorectal cancer;
LIHC	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.19	0.52	5.39e-25	Tonsillectomy;
LIHC	cis	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg19680485	chr15:31195859	MTMR15	-0.53	-5.92	-0.3	7.78e-9	Hypertriglyceridemia;
LIHC	cis	rs35892873	0.920	rs3890851	chr3:126093700	G/T	cg15490784	chr3:126061950	KLF15	0.44	6.51	0.33	2.69e-10	Male-pattern baldness;
LIHC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg07451762	chr16:28383216	NA	0.32	6.14	0.31	2.33e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4763879	0.739	rs2114871	chr12:9829438	A/T	cg26689682	chr12:9723402	NA	-0.36	-5.92	-0.3	8e-9	Type 1 diabetes;
LIHC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.46	6.8	0.35	4.67e-11	Aortic root size;
LIHC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.65	-9.31	-0.45	1.57e-18	Blood metabolite levels;
LIHC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.86	12.17	0.55	1.45e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.55	8.78	0.43	7.72e-17	Longevity;
LIHC	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.28	-6.2	-0.32	1.62e-9	Migraine;
LIHC	cis	rs2274273	0.870	rs7153645	chr14:55771518	C/G	cg01864836	chr14:55583639	NA	-0.37	-6.63	-0.34	1.34e-10	Protein biomarker;
LIHC	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.61	-11.67	-0.53	1.02e-26	Neurofibrillary tangles;
LIHC	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.28	5.91	0.3	8.17e-9	Pulmonary function;
LIHC	cis	rs7129220	0.588	rs7105321	chr11:10111339	T/C	cg01453529	chr11:10209919	SBF2	-0.39	-6.93	-0.35	2.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.44	-7.43	-0.37	8.68e-13	Pelvic organ prolapse;
LIHC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.8	-8.31	-0.41	2.33e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.98e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.65	0.53	1.18e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-6.57	-0.33	1.84e-10	Total cholesterol levels;
LIHC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.32	5.81	0.3	1.42e-8	Menarche (age at onset);
LIHC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.05	0.55	4.18e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.6	-8.53	-0.42	4.77e-16	Testicular germ cell tumor;
LIHC	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg03146154	chr1:46216737	IPP	-0.36	-5.94	-0.31	7.06e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2637266	1.000	rs12251862	chr10:78367929	A/G	cg18941641	chr10:78392320	NA	0.31	6.76	0.34	6.15e-11	Pulmonary function;
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13047869	chr3:10149882	C3orf24	0.53	6.3	0.32	9.19e-10	Alzheimer's disease;
LIHC	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	7.06	0.36	9.06e-12	Bipolar disorder;
LIHC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg25281562	chr12:121454272	C12orf43	0.33	5.74	0.3	2.08e-8	N-glycan levels;
LIHC	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg24296786	chr1:45957014	TESK2	-0.5	-7.48	-0.38	6.21e-13	Platelet count;
LIHC	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	9.67	0.46	1.02e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.8	-12.17	-0.55	1.5e-28	Obesity-related traits;
LIHC	cis	rs1292048	1	rs1292048	chr17:57955071	A/G	cg13753209	chr17:57696993	CLTC	0.38	5.83	0.3	1.3e-8	Red cell distribution width;
LIHC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.64	10.98	0.51	3.21e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.77	11.51	0.53	3.96e-26	Coronary artery disease;
LIHC	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.36	-8.26	-0.41	3.34e-15	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.17	-0.32	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg12798992	chr6:167411361	FGFR1OP	0.44	6.85	0.35	3.44e-11	Primary biliary cholangitis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17937102	chr1:165667565	ALDH9A1	0.57	7.45	0.37	7.85e-13	Lung function (FEV1/FVC);
LIHC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21467203	chr3:49911342	NA	0.52	9.46	0.46	5.29e-19	Body mass index;
LIHC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.81	7.78	0.39	8.84e-14	Diabetic retinopathy;
LIHC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.69	-13.08	-0.58	5.77e-32	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg15902774	chr15:75289873	SCAMP5	0.44	6.52	0.33	2.47e-10	Lung cancer;
LIHC	cis	rs7551222	0.614	rs4951386	chr1:204454547	A/G	cg20240347	chr1:204465584	NA	-0.32	-6.71	-0.34	7.98e-11	Schizophrenia;
LIHC	cis	rs12295403	0.964	rs61886869	chr11:18688508	C/T	cg09887367	chr11:18690185	NA	-0.41	-6.82	-0.35	4.1e-11	Ovarian reserve;
LIHC	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.65	-0.46	1.23e-19	Total cholesterol levels;
LIHC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	8.93	0.43	2.68e-17	Platelet count;
LIHC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.59	10.17	0.48	2.07e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-7.31	-0.37	1.89e-12	Psoriasis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07355551	chr20:2489285	ZNF343	0.46	6.66	0.34	1.11e-10	Pancreatic cancer;
LIHC	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg11839771	chr15:80205821	ST20	-0.31	-6.46	-0.33	3.55e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg00661245	chr8:11660924	FDFT1	0.47	6.24	0.32	1.27e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.09	13.26	0.58	1.12e-32	Primary sclerosing cholangitis;
LIHC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.73	-0.3	2.16e-8	Arsenic metabolism;
LIHC	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.76	-0.5	1.81e-23	Eye color traits;
LIHC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg15208524	chr1:10270712	KIF1B	0.43	6.16	0.32	2.04e-9	Hepatocellular carcinoma;
LIHC	cis	rs751728	0.931	rs2013365	chr6:33763688	A/C	cg25922239	chr6:33757077	LEMD2	0.43	6.96	0.35	1.71e-11	Crohn's disease;
LIHC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.82	-13.79	-0.6	1.02e-34	Aortic root size;
LIHC	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.07	13.85	0.6	6.24e-35	Economic and political preferences (immigration/crime);
LIHC	cis	rs9341808	0.587	rs3805859	chr6:81048946	C/A	cg08355045	chr6:80787529	NA	0.32	6.62	0.34	1.43e-10	Sitting height ratio;
LIHC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.51	0.33	2.69e-10	Obesity-related traits;
LIHC	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00938859	chr5:1591904	SDHAP3	0.56	6.84	0.35	3.75e-11	Breast cancer;
LIHC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg07636037	chr3:49044803	WDR6	-0.77	-7.6	-0.38	2.88e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.56	9.16	0.44	4.84e-18	Fibroblast growth factor basic levels;
LIHC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.61	10.36	0.49	4.65e-22	Diastolic blood pressure;
LIHC	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.91	8.63	0.42	2.32e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	7.36	0.37	1.35e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.64	0.42	2.15e-16	Exhaled nitric oxide output;
LIHC	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg12698662	chr3:15914712	MIR563	-0.34	-6.41	-0.33	4.94e-10	Mean platelet volume;
LIHC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.08	-0.31	3.22e-9	Total body bone mineral density;
LIHC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.57	11.2	0.52	5.05e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.19	0.55	1.22e-28	Cognitive test performance;
LIHC	cis	rs55882075	0.514	rs11249655	chr5:179111290	C/T	cg14593053	chr5:179126677	CANX	0.39	6.77	0.34	5.73e-11	Monocyte percentage of white cells;
LIHC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.48	7.28	0.37	2.31e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.25	-6.01	-0.31	4.84e-9	Subjective well-being;
LIHC	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-9.01	-0.44	1.51e-17	Vitiligo;
LIHC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.69	-9.32	-0.45	1.48e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.37	-0.41	1.53e-15	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.54	-0.33	2.23e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg02079420	chr8:82753780	SNX16	-0.37	-6.79	-0.34	5.06e-11	Diastolic blood pressure;
LIHC	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.56	-6.42	-0.33	4.6e-10	Ulcerative colitis;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.58	8.15	0.4	6.95e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Depression;
LIHC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg27523141	chr10:43048294	ZNF37B	-0.36	-6.34	-0.32	7.43e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-0.97	-23.17	-0.78	4.65e-72	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.44	-6.66	-0.34	1.1e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg00292662	chr22:38071168	LGALS1	0.64	8.39	0.41	1.33e-15	Fat distribution (HIV);
LIHC	cis	rs1211375	0.607	rs1203978	chr16:257211	A/C	cg00126636	chr16:237282	NA	0.41	6.92	0.35	2.18e-11	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg13482628	chr17:19912719	NA	0.38	6.1	0.31	2.86e-9	Schizophrenia;
LIHC	trans	rs334353	0.785	rs334363	chr9:101928702	A/C	cg06788856	chr17:1821969	NA	-0.33	-6.13	-0.31	2.45e-9	Age-related macular degeneration;
LIHC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	trans	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04565464	chr8:145669602	NFKBIL2	0.4	6.64	0.34	1.23e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	13.05	0.58	7.16e-32	Colorectal cancer;
LIHC	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg12698662	chr3:15914712	MIR563	-0.38	-7.09	-0.36	7.65e-12	Mean platelet volume;
LIHC	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.32	0.37	1.8e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.43	6.09	0.31	3.02e-9	Glycated hemoglobin levels;
LIHC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.36	5.82	0.3	1.36e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.48	7.85	0.39	5.36e-14	Diastolic blood pressure;
LIHC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg27005118	chr17:13972210	COX10	0.44	7.34	0.37	1.58e-12	Temperament;
LIHC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg18306943	chr3:40428807	ENTPD3	0.34	6.07	0.31	3.31e-9	Renal cell carcinoma;
LIHC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.47	-18.07	-0.7	9.95e-52	Breast cancer;
LIHC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.38	-0.37	1.24e-12	Bipolar disorder;
LIHC	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	9.99	0.48	8.92e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg26220594	chr1:19110978	NA	0.32	5.8	0.3	1.5e-8	Drug-induced liver injury (nitrofurantoin);
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.21	0.58	1.74e-32	Prudent dietary pattern;
LIHC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.48	-6.97	-0.35	1.68e-11	Other erythrocyte phenotypes;
LIHC	trans	rs4714291	1.000	rs847751	chr6:40035607	A/G	cg02267698	chr19:7991119	CTXN1	0.4	6.32	0.32	8.15e-10	Strep throat;
LIHC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.58	9.52	0.46	3.32e-19	Lymphocyte counts;
LIHC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.68	-7.39	-0.37	1.1e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.82	-12.74	-0.57	1.07e-30	Total body bone mineral density;
LIHC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.38	0.59	3.85e-33	Chronic sinus infection;
LIHC	cis	rs918629	0.798	rs3777163	chr5:95293316	C/G	cg10483112	chr5:95245456	ELL2	-0.35	-6.05	-0.31	3.91e-9	IgG glycosylation;
LIHC	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg01364799	chr7:75623366	TMEM120A	-0.41	-6.12	-0.31	2.5e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg03785755	chr6:26196794	NA	0.52	5.73	0.3	2.16e-8	Gout;Renal underexcretion gout;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13489987	chr14:67292488	GPHN	0.26	6.24	0.32	1.32e-9	Cognitive function;
LIHC	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg08126542	chr6:37504118	NA	-0.36	-6.2	-0.32	1.58e-9	Cognitive performance;
LIHC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg07061783	chr6:25882402	NA	-0.44	-6.3	-0.32	9.05e-10	Blood metabolite levels;
LIHC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-6.5	-0.33	2.82e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs6058796	0.786	rs28789846	chr20:31275545	G/A	cg02600331	chr11:130417168	NA	0.37	8.02	0.4	1.64e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02359409	chr6:42947317	PEX6	-0.47	-6.66	-0.34	1.07e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.01	0.31	4.66e-9	Resting heart rate;
LIHC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.75	-0.3	1.94e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	7.63	0.38	2.3e-13	Aortic root size;
LIHC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.19	0.44	3.97e-18	Menarche (age at onset);
LIHC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.83	-0.63	8.92e-39	Alzheimer's disease (late onset);
LIHC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.43e-16	Motion sickness;
LIHC	cis	rs7129556	0.520	rs4945178	chr11:77248911	T/C	cg03570279	chr11:77446074	RSF1	-0.34	-6.31	-0.32	8.85e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.46	6.1	0.31	2.8e-9	Major depressive disorder;
LIHC	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	11.34	0.52	1.65e-25	Fuchs's corneal dystrophy;
LIHC	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.48	-7.24	-0.36	3.02e-12	Dermatomyositis;
LIHC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.65	7.2	0.36	3.91e-12	Protein C levels;
LIHC	cis	rs17152411	0.652	rs1046373	chr10:126674689	A/C	cg07906193	chr10:126599966	NA	-0.3	-5.91	-0.3	8.39e-9	Height;
LIHC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.48	-8.2	-0.41	4.77e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.84	0.3	1.21e-8	Body mass index;
LIHC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	-0.61	-9.73	-0.47	6.42e-20	Inflammatory bowel disease;
LIHC	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.92	-0.3	7.92e-9	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.35	-6.35	-0.32	6.9e-10	Aortic root size;
LIHC	cis	rs2569991	0.636	rs361223	chr3:12922526	T/C	cg22481960	chr3:13008800	IQSEC1	-0.4	-6.91	-0.35	2.44e-11	Periodontitis (DPAL);
LIHC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-12.19	-0.55	1.24e-28	Prudent dietary pattern;
LIHC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.89	0.3	9.07e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.35	-7.61	-0.38	2.64e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.6	8.82	0.43	5.9e-17	Lymphocyte counts;
LIHC	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	9.09	0.44	8.43e-18	Post bronchodilator FEV1;
LIHC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.57	-8.5	-0.42	5.75e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg05664664	chr10:75173569	ANXA7	-0.41	-6.03	-0.31	4.15e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
LIHC	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.87	-15.74	-0.65	2.35e-42	Body mass index;
LIHC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.75	-12.34	-0.56	3.42e-29	Colorectal cancer;
LIHC	cis	rs7487075	0.619	rs4076247	chr12:46833450	A/C	cg23829395	chr12:46796953	NA	0.34	6.05	0.31	3.81e-9	Itch intensity from mosquito bite;
LIHC	cis	rs10420951	0.579	rs78036311	chr19:18606369	G/T	cg10790698	chr19:18539756	SSBP4	-0.41	-5.72	-0.3	2.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-7.94	-0.39	2.96e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.66	9.65	0.46	1.22e-19	Schizophrenia;
LIHC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.65	0.42	2.09e-16	Height;
LIHC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg03959625	chr15:84868606	LOC388152	0.43	6.07	0.31	3.43e-9	Schizophrenia;
LIHC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.54e-9	Aortic root size;
LIHC	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.33	-0.49	5.81e-22	Rheumatoid arthritis;
LIHC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	5.97	0.31	6e-9	Educational attainment;
LIHC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.85	0.3	1.13e-8	Schizophrenia;
LIHC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg03146154	chr1:46216737	IPP	-0.48	-8.01	-0.4	1.83e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.26	-0.32	1.18e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.41	-6.16	-0.32	2.01e-9	Colorectal cancer;
LIHC	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.45	-6.61	-0.34	1.45e-10	Schizophrenia;
LIHC	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg16736954	chr20:23401023	NAPB	0.53	5.91	0.3	8.15e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.8	13.96	0.6	2.22e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs539514	0.587	rs9530466	chr13:76323774	T/C	cg04757411	chr13:76259545	LMO7	-0.42	-7.14	-0.36	5.68e-12	Type 1 diabetes;
LIHC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.02	-0.4	1.65e-14	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.64	-8.83	-0.43	5.65e-17	Migraine;
LIHC	cis	rs11745587	0.539	rs6897597	chr5:131743465	C/T	cg24060327	chr5:131705240	SLC22A5	-0.46	-5.77	-0.3	1.79e-8	Asthma;
LIHC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.29	-0.32	9.46e-10	Lung cancer;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg27432699	chr2:27873401	GPN1	-0.54	-7.79	-0.39	8.1e-14	Menopause (age at onset);
LIHC	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg18470593	chr4:15471377	CC2D2A	-0.39	-6.0	-0.31	4.95e-9	Obesity-related traits;
LIHC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.59	-10.13	-0.48	2.93e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.41	6.3	0.32	8.98e-10	Neutrophil percentage of white cells;
LIHC	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.76	-8.34	-0.41	1.89e-15	Exhaled nitric oxide output;
LIHC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.69	7.22	0.36	3.42e-12	Alzheimer's disease;
LIHC	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg12698662	chr3:15914712	MIR563	-0.35	-6.52	-0.33	2.6e-10	Mean platelet volume;
LIHC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg14393609	chr7:65229607	NA	0.38	5.92	0.31	7.71e-9	Aortic root size;
LIHC	cis	rs11098699	1.000	rs1031134	chr4:124194477	G/A	cg09941581	chr4:124220074	SPATA5	0.3	5.72	0.3	2.29e-8	Mosquito bite size;
LIHC	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.91	11.93	0.54	1.11e-27	Coronary artery disease;
LIHC	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg12615879	chr12:58013172	SLC26A10	-0.32	-6.21	-0.32	1.52e-9	Multiple sclerosis;
LIHC	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.72	8.05	0.4	1.37e-14	Dental caries;
LIHC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg00750074	chr16:89608354	SPG7	-0.52	-8.5	-0.42	5.76e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.75	0.39	1.05e-13	Alzheimer's disease;
LIHC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.74	0.39	1.14e-13	Bipolar disorder;
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.65	-8.12	-0.4	8.75e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg12373951	chr3:133503437	NA	0.46	7.73	0.39	1.22e-13	Iron status biomarkers;
LIHC	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.42	-6.35	-0.32	6.89e-10	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg12297030	chr17:43662878	NA	-0.64	-6.12	-0.31	2.57e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.86	-0.65	7.39e-43	Height;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg10081115	chr2:190686883	PMS1	0.41	6.04	0.31	3.98e-9	Bilirubin levels;
LIHC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.77	-0.71	1.58e-54	Ulcerative colitis;
LIHC	cis	rs198813	0.611	rs198823	chr6:26122933	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.48	-6.82	-0.35	4.24e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.45	-0.33	3.77e-10	Height;
LIHC	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-5.8	-0.3	1.55e-8	Blood metabolite levels;
LIHC	cis	rs882732	0.576	rs12895360	chr14:95038922	T/C	cg14866387	chr14:95027382	SERPINA4	-0.37	-5.82	-0.3	1.37e-8	Blood protein levels;
LIHC	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.27	6.42	0.33	4.49e-10	Heart rate;
LIHC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.55	-0.53	2.75e-26	Chronic sinus infection;
LIHC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-6.1	-0.31	2.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.5	7.83	0.39	6.24e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	1.02	19.65	0.73	4.62e-58	Breast cancer;
LIHC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg21395723	chr22:39101663	GTPBP1	-0.42	-6.5	-0.33	2.9e-10	Menopause (age at onset);
LIHC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.05	-0.31	3.79e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.82	-0.39	6.83e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.53	7.96	0.4	2.6e-14	Longevity;
LIHC	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	8.88	0.43	3.94e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs6782228	0.527	rs2811491	chr3:128353950	C/A	cg16766828	chr3:128327626	NA	-0.39	-6.14	-0.32	2.27e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14396892	chr9:96623032	NA	-0.32	-6.22	-0.32	1.43e-9	DNA methylation (variation);
LIHC	cis	rs4776059	0.550	rs8036979	chr15:52947995	A/T	cg22715398	chr15:52968154	KIAA1370	0.4	5.74	0.3	2.08e-8	Schizophrenia;
LIHC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg03645007	chr3:50255295	SLC38A3	0.52	6.35	0.32	6.97e-10	Schizophrenia;
LIHC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.48	-8.19	-0.4	5.31e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.24	-16.13	-0.66	6.34e-44	Diabetic kidney disease;
LIHC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.41	-5.9	-0.3	8.77e-9	Osteoporosis;
LIHC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.37	0.56	2.77e-29	Menopause (age at onset);
LIHC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.38	5.8	0.3	1.5e-8	Lung cancer;
LIHC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	trans	rs4322600	0.963	rs1450711	chr14:88288660	T/C	cg16008221	chr8:17823628	PCM1	-0.43	-6.32	-0.32	8.16e-10	Breast cancer;
LIHC	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg16309518	chr5:176445507	NA	-0.52	-9.64	-0.46	1.33e-19	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.55	8.65	0.42	2.04e-16	Lymphocyte counts;
LIHC	cis	rs1403694	0.734	rs266723	chr3:186447047	A/C	cg12454167	chr3:186435060	KNG1	0.26	6.42	0.33	4.53e-10	Blood protein levels;
LIHC	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.51	-6.16	-0.32	2.07e-9	Body mass index;
LIHC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg14515779	chr1:101123966	NA	0.5	7.13	0.36	6.03e-12	Monocyte count;
LIHC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.52	7.18	0.36	4.39e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.1	0.48	3.53e-21	Platelet count;
LIHC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.72	-13.99	-0.6	1.75e-35	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.67	0.57	2.05e-30	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13837895	chr19:50145301	SCAF1	0.41	6.22	0.32	1.41e-9	Pancreatic cancer;
LIHC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg18765753	chr7:1198926	ZFAND2A	0.45	6.44	0.33	4.06e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.66	-0.46	1.08e-19	Bipolar disorder;
LIHC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	8.08	0.4	1.12e-14	Height;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17269277	chr4:1796142	FGFR3	0.55	6.67	0.34	1.03e-10	Hepatitis;
LIHC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.93	17.52	0.69	1.72e-49	Parkinson's disease;
LIHC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.36	-0.33	6.49e-10	Type 2 diabetes;
LIHC	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.29	-0.32	9.54e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs9918079	0.542	rs12499412	chr4:15602252	G/C	cg21329975	chr4:15471214	CC2D2A	0.41	6.23	0.32	1.38e-9	Obesity-related traits;
LIHC	cis	rs10792665	0.649	rs9971403	chr11:82761790	G/T	cg24227371	chr11:82718527	RAB30	-0.37	-8.76	-0.43	9.11e-17	Obesity-related traits;
LIHC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg03037974	chr15:76606532	NA	0.73	14.3	0.61	1.08e-36	Blood metabolite levels;
LIHC	cis	rs16944613	0.510	rs7165476	chr15:91151948	C/T	cg26821196	chr15:91095069	CRTC3	0.33	6.06	0.31	3.66e-9	Colorectal cancer;
LIHC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.65	-9.66	-0.46	1.09e-19	Coronary artery disease;
LIHC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg16586182	chr3:47516702	SCAP	-0.52	-9.49	-0.46	3.98e-19	Colorectal cancer;
LIHC	trans	rs6934970	0.932	rs6914487	chr6:113124193	T/A	cg02462569	chr6:150064036	NUP43	-0.46	-6.09	-0.31	3.1e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg27386326	chr11:61587980	NA	0.71	14.77	0.62	1.62e-38	Trans fatty acid levels;
LIHC	cis	rs9918079	0.560	rs12651550	chr4:15641018	G/C	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.23	-0.32	1.4e-9	Obesity-related traits;
LIHC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.46	-7.66	-0.38	1.96e-13	Tuberculosis;
LIHC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.58	9.54	0.46	2.69e-19	Lymphocyte counts;
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.11	0.58	4.13e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.97	0.31	6.01e-9	Tonsillectomy;
LIHC	cis	rs6596100	0.538	rs113848378	chr5:132192372	T/C	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.44	6.64	0.34	1.2e-10	Dementia with Lewy bodies;
LIHC	cis	rs7075426	0.669	rs3858279	chr10:88257602	A/G	cg07322936	chr10:88137208	NA	0.48	6.25	0.32	1.23e-9	Migraine without aura;
LIHC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.37	-0.41	1.47e-15	Schizophrenia;
LIHC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.5	-6.5	-0.33	2.82e-10	Narcolepsy;
LIHC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-10.55	-0.5	1.06e-22	Crohn's disease;
LIHC	trans	rs10761482	0.500	rs1938535	chr10:62273900	A/G	cg14898824	chr12:64851143	TBK1	-0.33	-6.22	-0.32	1.44e-9	Schizophrenia;
LIHC	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.3	-5.77	-0.3	1.82e-8	Red blood cell count;
LIHC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg19774624	chr17:42201019	HDAC5	-0.45	-6.32	-0.32	8.22e-10	Total body bone mineral density;
LIHC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg00343986	chr7:65444356	GUSB	0.41	6.16	0.32	2.05e-9	Aortic root size;
LIHC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	7.3	0.37	1.97e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25586305	chr2:234281690	DGKD	0.45	6.07	0.31	3.39e-9	Hepatitis;
LIHC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-1.02	-20.82	-0.75	9.24e-63	Height;
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg20607798	chr8:58055168	NA	0.62	7.92	0.39	3.38e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.48	-7.72	-0.39	1.26e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg22903471	chr2:27725779	GCKR	-0.43	-6.32	-0.32	7.98e-10	Blood metabolite levels;
LIHC	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.01	-0.31	4.72e-9	Tuberculosis;
LIHC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.77	10.35	0.49	5.09e-22	Psoriasis;
LIHC	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg13628971	chr7:2884303	GNA12	0.41	6.31	0.32	8.64e-10	Height;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.45	8.32	0.41	2.12e-15	Prudent dietary pattern;
LIHC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.94	-12.31	-0.55	4.48e-29	Diabetic kidney disease;
LIHC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg23262073	chr20:60523788	NA	-0.29	-6.04	-0.31	4.08e-9	Body mass index;
LIHC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg10935138	chr17:73851978	WBP2	0.49	7.31	0.37	1.85e-12	White matter hyperintensity burden;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg10862723	chr17:47022239	SNF8	0.48	6.54	0.33	2.18e-10	Glycated hemoglobin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02186127	chr17:33914245	AP2B1	0.47	6.41	0.33	4.82e-10	Pancreatic cancer;
LIHC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.4	-5.81	-0.3	1.44e-8	Longevity;
LIHC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.44	6.13	0.31	2.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg03037974	chr15:76606532	NA	-0.61	-10.3	-0.49	7.81e-22	Blood metabolite levels;
LIHC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-9.67	-0.46	1.06e-19	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.95	0.44	2.28e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-8.99	-0.44	1.67e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.18	0.44	4.07e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.79	-14.58	-0.62	8.85e-38	Longevity;
LIHC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg17750252	chr2:136567154	LCT	0.35	6.15	0.32	2.22e-9	Cholesterol, total;
LIHC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.61	9.91	0.47	1.66e-20	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2710642	0.576	rs1386399	chr2:62871303	G/A	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7188697	0.922	rs7186997	chr16:58603348	A/G	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	trans	rs7227401	1.000	rs7227401	chr18:21938658	G/T	cg25268537	chr17:72860402	FDXR	0.69	6.31	0.32	8.62e-10	Osteoporosis-related phenotypes;
LIHC	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.43	-7.62	-0.38	2.6e-13	Glaucoma;
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.85	0.63	7.56e-39	Prudent dietary pattern;
LIHC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.8	12.07	0.55	3.43e-28	Total body bone mineral density;
LIHC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.48	-7.69	-0.38	1.62e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2191566	0.960	rs8105571	chr19:44510341	C/T	cg20607764	chr19:44506953	ZNF230	-0.41	-6.66	-0.34	1.1e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.42	-0.37	9.63e-13	Psoriasis;
LIHC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.23	-6.05	-0.31	3.81e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.55	-14.97	-0.63	2.48e-39	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.49	6.7	0.34	8.63e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06756557	chr10:90639746	STAMBPL1	0.45	6.87	0.35	3.11e-11	Cognitive function;
LIHC	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.74	-10.92	-0.51	5.18e-24	Obesity-related traits;
LIHC	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg15103426	chr22:29168792	CCDC117	0.43	5.74	0.3	2.11e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.79	6.39	0.33	5.48e-10	Body mass index;
LIHC	cis	rs7129220	0.660	rs6483969	chr11:10100734	G/A	cg01453529	chr11:10209919	SBF2	-0.39	-6.97	-0.35	1.62e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.44	7.81	0.39	7.25e-14	Inhibitory control;
LIHC	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.12	9.94	0.47	1.24e-20	Schizophrenia;
LIHC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.58	10.66	0.5	4.29e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.84	-0.3	1.19e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.66	9.11	0.44	7.16e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.2e-15	Schizophrenia;
LIHC	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg08668510	chr10:1095578	IDI1	0.74	7.55	0.38	4.07e-13	Glomerular filtration rate (creatinine);
LIHC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.17	-0.44	4.36e-18	Schizophrenia;
LIHC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-13.48	-0.59	1.66e-33	Height;
LIHC	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	0.86	10.93	0.51	4.88e-24	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg12863693	chr15:85201151	NMB	0.44	6.27	0.32	1.11e-9	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg20607798	chr8:58055168	NA	0.49	6.23	0.32	1.34e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.74	10.89	0.51	6.79e-24	Menarche (age at onset);
LIHC	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.74	-10.02	-0.48	7.03e-21	Personality dimensions;
LIHC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.46	7.92	0.39	3.28e-14	Mean corpuscular volume;
LIHC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.66	0.65	4.89e-42	Chronic sinus infection;
LIHC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	11.34	0.52	1.57e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4676482	0.541	rs17735402	chr3:39205176	C/T	cg02254461	chr3:39195904	CSRNP1	0.73	6.91	0.35	2.34e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.45	6.32	0.32	8.06e-10	Obesity-related traits;
LIHC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.78	-0.3	1.67e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg27205649	chr11:78285834	NARS2	-0.39	-5.82	-0.3	1.37e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg09752223	chr19:15281200	NOTCH3	-0.36	-5.83	-0.3	1.3e-8	Pulse pressure;
LIHC	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.77	-0.39	9.28e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg25039879	chr17:56429692	SUPT4H1	0.74	8.29	0.41	2.71e-15	Cognitive test performance;
LIHC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.39	-6.43	-0.33	4.36e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.67	13.31	0.58	7.46e-33	High light scatter reticulocyte count;
LIHC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	7.18	0.36	4.38e-12	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.43	-5.74	-0.3	2.11e-8	Gut microbiome composition (summer);
LIHC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg10820045	chr2:198174542	NA	0.47	7.21	0.36	3.53e-12	Dermatomyositis;
LIHC	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg27386326	chr11:61587980	NA	0.7	14.72	0.62	2.45e-38	Trans fatty acid levels;
LIHC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-8.12	-0.4	8.5e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7578199	0.779	rs17387035	chr2:242394003	A/G	cg19372975	chr2:242212901	HDLBP	-0.55	-5.76	-0.3	1.86e-8	Chronic lymphocytic leukemia;
LIHC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.46	-6.56	-0.33	1.98e-10	Other erythrocyte phenotypes;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg04456666	chr15:40615783	NA	-0.47	-6.56	-0.33	1.97e-10	Alopecia areata;
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.98	-0.4	2.19e-14	Lymphocyte counts;
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.6	10.65	0.5	4.52e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg20335179	chr10:1068567	C10orf110;IDI2	-0.61	-6.85	-0.35	3.35e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs611744	0.967	rs641721	chr8:109230140	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.06	-0.44	1.04e-17	Alzheimer's disease;
LIHC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.92	0.65	4.54e-43	Lymphocyte percentage of white cells;
LIHC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg13607699	chr17:42295918	UBTF	-0.43	-6.9	-0.35	2.6e-11	Total body bone mineral density;
LIHC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.75	8.27	0.41	2.99e-15	Initial pursuit acceleration;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.29	0.55	5.09e-29	Prudent dietary pattern;
LIHC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.65	-9.31	-0.45	1.53e-18	Blood metabolite levels;
LIHC	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.42	-5.73	-0.3	2.16e-8	Schizophrenia;
LIHC	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.42	0.33	4.45e-10	Fuchs's corneal dystrophy;
LIHC	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.5	-6.24	-0.32	1.33e-9	Heschl's gyrus morphology;
LIHC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.36	-5.77	-0.3	1.74e-8	Mood instability;
LIHC	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.41e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.37	-0.37	1.33e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.41	5.86	0.3	1.08e-8	Blood protein levels;
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	8.3	0.41	2.5e-15	Response to antipsychotic treatment;
LIHC	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	cis	rs10508774	0.810	rs11008987	chr10:32881651	C/T	cg01819863	chr10:32635814	EPC1	0.61	5.9	0.3	8.79e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.81	8.62	0.42	2.59e-16	Vitiligo;
LIHC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	8.12e-10	Red blood cell count;
LIHC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg22676075	chr6:135203613	NA	0.42	6.67	0.34	1.04e-10	Red blood cell count;
LIHC	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.56	8.33	0.41	1.98e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6058796	1.000	rs6141772	chr20:31246662	A/C	cg02600331	chr11:130417168	NA	0.33	7.48	0.37	6.17e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07305463	chr2:136567211	LCT	-0.38	-5.93	-0.31	7.24e-9	Corneal structure;
LIHC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg14067834	chr17:29058358	SUZ12P	0.67	6.55	0.33	2.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.66	-9.39	-0.45	8.42e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.47	-0.37	6.61e-13	Platelet count;
LIHC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.69	-14.36	-0.61	6.34e-37	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.41	-0.41	1.1e-15	Lymphocyte counts;
LIHC	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.34	-7.84	-0.39	5.6e-14	Congenital heart disease (maternal effect);
LIHC	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.47	6.9	0.35	2.46e-11	Asthma;
LIHC	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.38	6.07	0.31	3.34e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.24	19.35	0.72	7.05e-57	Type 1 diabetes nephropathy;
LIHC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08392591	chr16:89556376	ANKRD11	0.41	6.12	0.31	2.62e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.13	-0.44	6.13e-18	Bipolar disorder;
LIHC	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.46	8.72	0.43	1.22e-16	Testicular germ cell tumor;
LIHC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05694744	chr17:8191820	RANGRF;SLC25A35	0.4	6.33	0.32	7.83e-10	Pancreatic cancer;
LIHC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.07	0.31	3.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg22771759	chr13:24902376	NA	0.3	6.04	0.31	4e-9	Obesity-related traits;
LIHC	cis	rs8016982	0.632	rs8010219	chr14:81696982	A/G	cg01989461	chr14:81687754	GTF2A1	0.53	9.2	0.45	3.66e-18	Schizophrenia;
LIHC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg00204512	chr16:28754710	NA	0.41	7.05	0.36	1.01e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg03037974	chr15:76606532	NA	0.89	23.12	0.78	6.85e-72	Blood metabolite levels;
LIHC	cis	rs9503598	0.502	rs2326231	chr6:3433925	T/G	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.8	-0.3	1.52e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.66	8.32	0.41	2.05e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg23598604	chr1:99732472	LPPR4	-0.31	-6.3	-0.32	9.17e-10	Multiple myeloma;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-8.41	-0.41	1.13e-15	Lymphocyte counts;
LIHC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.39	-5.77	-0.3	1.75e-8	Schizophrenia;
LIHC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.4	-6.38	-0.33	5.82e-10	Fibrinogen levels;
LIHC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg11764359	chr7:65958608	NA	0.57	5.95	0.31	6.62e-9	Diabetic kidney disease;
LIHC	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg12454167	chr3:186435060	KNG1	0.39	9.09	0.44	7.92e-18	Blood protein levels;
LIHC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-11.05	-0.51	1.84e-24	Personality dimensions;
LIHC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.4	6.41	0.33	4.95e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg27478167	chr7:817139	HEATR2	-0.4	-5.76	-0.3	1.84e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07305463	chr2:136567211	LCT	0.35	6.2	0.32	1.59e-9	Mosquito bite size;
LIHC	trans	rs6489882	0.703	rs10850097	chr12:113361117	C/T	cg10175203	chr3:128143634	NA	0.39	6.39	0.33	5.32e-10	Chronic lymphocytic leukemia;
LIHC	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.05e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12500138	0.850	rs115146063	chr4:166193694	C/T	cg25064052	chr4:166216151	KLHL2	-0.64	-5.89	-0.3	9.49e-9	Cognitive function;
LIHC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg10820045	chr2:198174542	NA	0.56	9.01	0.44	1.46e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.2	0.55	1.19e-28	Platelet count;
LIHC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21448741	chr8:58168803	NA	0.35	6.55	0.33	2.12e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.46	6.3	0.32	8.92e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.32	1.29e-9	Aortic root size;
LIHC	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.27	5.72	0.3	2.35e-8	Pulmonary function;
LIHC	cis	rs6539247	0.509	rs4275717	chr12:106445852	G/A	cg20883310	chr12:106464547	NUAK1	0.45	7.28	0.37	2.29e-12	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.45	7.4	0.37	1.08e-12	Corneal astigmatism;
LIHC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	0.94	15.95	0.65	3.43e-43	Testicular germ cell tumor;
LIHC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.31	-6.7	-0.34	8.8e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.11	0.55	2.47e-28	Body mass index;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10990685	chr12:120720139	NME2P1	0.44	6.37	0.33	6.17e-10	Myopia (pathological);
LIHC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.5	-6.15	-0.32	2.14e-9	Schizophrenia;
LIHC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.27	0.32	1.1e-9	Glycated hemoglobin levels;
LIHC	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.58	-8.67	-0.42	1.81e-16	Recombination rate (females);
LIHC	cis	rs7945718	0.621	rs10765984	chr11:12672669	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.66	0.38	1.88e-13	Educational attainment (years of education);
LIHC	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.76	-0.3	1.9e-8	Resting heart rate;
LIHC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	9.53	0.46	3.07e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.42	-6.85	-0.35	3.34e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs2834188	0.924	rs2007849	chr21:34681116	G/A	cg14352951	chr21:34696688	IFNAR1	0.46	6.39	0.33	5.51e-10	Narcolepsy;
LIHC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg10774155	chr7:65338427	VKORC1L1	0.45	6.71	0.34	7.86e-11	Calcium levels;
LIHC	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg24579218	chr15:68104479	NA	-0.34	-5.94	-0.31	7.12e-9	Restless legs syndrome;
LIHC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.74	0.39	1.13e-13	Mean platelet volume;
LIHC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.17	0.61	3.36e-36	Prudent dietary pattern;
LIHC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	Cognitive function;
LIHC	cis	rs797680	0.856	rs7537403	chr1:93777724	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.67e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.45	-6.64	-0.34	1.21e-10	Osteoporosis;
LIHC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.48	-6.26	-0.32	1.16e-9	Gut microbiome composition (summer);
LIHC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.78	0.3	1.71e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.18	0.55	1.35e-28	Cognitive test performance;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.66	12.92	0.57	2.28e-31	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.46	6.22	0.32	1.44e-9	Tonsillectomy;
LIHC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.51	-7.53	-0.38	4.49e-13	HDL cholesterol;
LIHC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg21522988	chr12:29376872	FAR2	0.28	6.22	0.32	1.45e-9	QT interval;
LIHC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.8	14.85	0.63	7.89e-39	Blood protein levels;
LIHC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.84	-12.91	-0.57	2.4e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4965272	0.761	rs11631536	chr15:100560058	C/A	cg09918751	chr15:100517450	ADAMTS17	-0.45	-6.29	-0.32	9.92e-10	Gastroesophageal reflux disease;
LIHC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.27	-0.37	2.53e-12	Bipolar disorder;
LIHC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg19500275	chr17:80737654	TBCD	0.52	7.64	0.38	2.21e-13	Glycated hemoglobin levels;
LIHC	cis	rs11761441	0.602	rs7801619	chr7:94006	C/T	cg25149888	chr7:81075	NA	0.26	5.71	0.3	2.45e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs4853036	0.951	rs6738783	chr2:70120608	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-5.97	-0.31	6.1e-9	Colorectal or endometrial cancer;
LIHC	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.45	7.99	0.4	2.05e-14	Narcolepsy;
LIHC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.3	-0.32	9.13e-10	Headache;
LIHC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	7.69	0.38	1.58e-13	Parkinson's disease;
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.1	-0.31	2.87e-9	Total body bone mineral density;
LIHC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.01	0.48	7.5e-21	Chronic sinus infection;
LIHC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.55	-0.53	2.75e-26	Chronic sinus infection;
LIHC	trans	rs61041384	0.661	rs4474478	chr12:123734368	C/T	cg07919128	chr17:18022025	MYO15A	0.68	6.7	0.34	8.34e-11	Schizophrenia;
LIHC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-24.17	-0.79	5.7e-76	Height;
LIHC	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.47	-7.35	-0.37	1.46e-12	Body mass index;
LIHC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg11062466	chr8:58055876	NA	0.4	5.78	0.3	1.66e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21467203	chr3:49911342	NA	-0.52	-9.03	-0.44	1.29e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2380220	0.751	rs117986000	chr6:95923454	A/C	cg04719120	chr6:96025338	MANEA	-0.62	-6.47	-0.33	3.35e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.89	-0.51	6.8e-24	Mean corpuscular volume;
LIHC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.48	0.46	4.3e-19	Tonsillectomy;
LIHC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-0.6	-7.78	-0.39	8.66e-14	Lung cancer;
LIHC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-6.01	-0.31	4.88e-9	Schizophrenia;
LIHC	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg20991723	chr1:152506922	NA	0.58	10.04	0.48	5.86e-21	Hair morphology;
LIHC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.43	0.37	8.8e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.66	12.75	0.57	9.71e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.71	7.23	0.36	3.15e-12	Arsenic metabolism;
LIHC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.48	-7.3	-0.37	2e-12	P wave terminal force;
LIHC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.94	0.51	4.21e-24	Personality dimensions;
LIHC	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.64e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs732505	1.000	rs8109716	chr19:5585245	G/A	cg26242866	chr19:5711310	LONP1	0.88	6.48	0.33	3.28e-10	vWF and FVIII levels;
LIHC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.52	7.09	0.36	7.61e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22509189	chr2:225307070	NA	-0.61	-7.37	-0.37	1.31e-12	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.69	11.09	0.51	1.23e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.52	-0.38	4.87e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.63	9.89	0.47	1.85e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.52	7.92	0.39	3.35e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg12454167	chr3:186435060	KNG1	0.39	9.09	0.44	7.92e-18	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	21.41	0.76	4.22e-65	Chronic sinus infection;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12038521	chr19:2111714	AP3D1	0.42	6.1	0.31	2.86e-9	Longevity;
LIHC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.6	-8.59	-0.42	3.07e-16	Lung cancer in ever smokers;
LIHC	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.1	9.18	0.44	4.1e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg16586182	chr3:47516702	SCAP	0.58	10.71	0.5	2.91e-23	Colorectal cancer;
LIHC	cis	rs6752107	0.935	rs10929325	chr2:234151031	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	7.14	0.36	5.8e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.43	-6.18	-0.32	1.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg14580859	chr9:123691850	NA	0.4	6.85	0.35	3.55e-11	Rheumatoid arthritis;
LIHC	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs12980942	1.000	rs4456618	chr19:41813957	G/C	cg25627403	chr19:41769009	HNRNPUL1	0.49	6.12	0.31	2.58e-9	Coronary artery disease;
LIHC	cis	rs4788570	0.584	rs6499530	chr16:71723089	C/G	cg06353428	chr16:71660113	MARVELD3	1.31	14.48	0.62	2.23e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg11764359	chr7:65958608	NA	-0.61	-7.69	-0.38	1.6e-13	Aortic root size;
LIHC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg03477792	chr4:77819574	ANKRD56	0.59	8.68	0.42	1.64e-16	Emphysema distribution in smoking;
LIHC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.36	11.89	0.54	1.56e-27	Uric acid levels;
LIHC	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg13385521	chr17:29058706	SUZ12P	0.67	6.57	0.33	1.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.43	-6.23	-0.32	1.38e-9	Narcolepsy;
LIHC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9322817	0.691	rs2486143	chr6:105308593	A/G	cg02098413	chr6:105308735	HACE1	0.44	8.3	0.41	2.4e-15	Thyroid stimulating hormone;
LIHC	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.65	8.81	0.43	6.6e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg25894440	chr7:65020034	NA	-0.53	-6.15	-0.32	2.2e-9	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.05e-11	Diabetic kidney disease;
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.76	11.84	0.54	2.38e-27	Longevity;
LIHC	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.22	-5.95	-0.31	6.51e-9	Hepatitis;
LIHC	cis	rs6466055	0.669	rs10808141	chr7:104715490	T/G	cg04380332	chr7:105027541	SRPK2	-0.33	-6.21	-0.32	1.5e-9	Schizophrenia;
LIHC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.78	-12.48	-0.56	9.93e-30	Colorectal cancer;
LIHC	cis	rs4700695	0.623	rs152943	chr5:65238285	A/G	cg21114390	chr5:65439923	SFRS12	0.44	6.15	0.32	2.2e-9	Facial morphology (factor 19);
LIHC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.44	5.93	0.31	7.44e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12744310	0.887	rs72667608	chr1:41794773	A/G	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.95e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.66	9.79	0.47	4.16e-20	Menopause (age at onset);
LIHC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.18	0.4	5.7e-15	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-10.1	-0.48	3.53e-21	Platelet count;
LIHC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.99	-13.13	-0.58	3.72e-32	Red blood cell traits;
LIHC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.32	-0.32	8.29e-10	Longevity;Endometriosis;
LIHC	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.55	0.33	2.16e-10	Resting heart rate;
LIHC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.45	0.42	8.22e-16	Platelet count;
LIHC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg17724175	chr1:150552817	MCL1	0.46	9.16	0.44	4.94e-18	Melanoma;
LIHC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.37	-5.73	-0.3	2.19e-8	Resting heart rate;
LIHC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg14829360	chr17:73884958	NA	-0.37	-6.32	-0.32	7.99e-10	White matter hyperintensity burden;
LIHC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	0.83	9.36	0.45	1.07e-18	Vitiligo;
LIHC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02985541	chr2:219472218	PLCD4	0.44	8.5	0.42	5.86e-16	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg01596870	chr19:55963115	NA	-0.58	-6.73	-0.34	7.19e-11	Obesity-related traits;
LIHC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg11279151	chr3:101281821	RG9MTD1	0.39	5.95	0.31	6.57e-9	Colorectal cancer;
LIHC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.47	-7.84	-0.39	5.6e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.91	16.89	0.67	5.59e-47	Aortic root size;
LIHC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.65	10.91	0.51	5.7e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg11764359	chr7:65958608	NA	0.57	6.0	0.31	4.9e-9	Diabetic kidney disease;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg19409381	chr4:83351505	HNRPDL;ENOPH1	-0.58	-6.25	-0.32	1.21e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg20129853	chr10:51489980	NA	-0.43	-9.35	-0.45	1.22e-18	Prostate-specific antigen levels;
LIHC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.37	0.33	5.95e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs867371	0.929	rs1501371	chr15:82460440	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.34	-0.37	1.62e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.67	9.95	0.47	1.22e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg06664874	chr5:179499304	RNF130	-0.58	-7.12	-0.36	6.37e-12	LDL cholesterol;
LIHC	cis	rs4953911	0.793	rs13014122	chr2:135050622	G/A	cg18482303	chr2:135041380	MGAT5	0.37	5.8	0.3	1.5e-8	Multiple sclerosis (severity);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11954230	chr10:105677556	OBFC1	0.5	6.81	0.35	4.46e-11	Pancreatic cancer;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg18279126	chr7:2041391	MAD1L1	0.39	6.51	0.33	2.74e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1865721	0.656	rs727894	chr18:73137117	C/T	cg26385618	chr18:73139727	C18orf62	-0.29	-8.32	-0.41	2.08e-15	Intelligence;
LIHC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.42	5.81	0.3	1.45e-8	Blood metabolite levels;
LIHC	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg01652190	chr22:50026171	C22orf34	-0.34	-7.51	-0.38	5.34e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07305463	chr2:136567211	LCT	-0.35	-6.62	-0.34	1.42e-10	Mosquito bite size;
LIHC	cis	rs10411936	0.962	rs10404046	chr19:16477255	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.43	5.76	0.3	1.86e-8	White blood cell count;Multiple sclerosis;
LIHC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg24826892	chr11:71159390	DHCR7	0.5	6.38	0.33	5.79e-10	Vitamin D levels;
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09993119	chr22:41601085	L3MBTL2	0.47	6.38	0.33	5.77e-10	Pancreatic cancer;
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.4	0.37	1.08e-12	Height;
LIHC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-10.37	-0.49	4.36e-22	Schizophrenia;
LIHC	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.33e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	1.08	14.69	0.62	3.15e-38	Heart rate;
LIHC	cis	rs3789045	0.560	rs4553256	chr1:204411144	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.54	-8.41	-0.41	1.12e-15	Educational attainment (college completion);
LIHC	cis	rs11760633	0.615	rs11767667	chr7:1840557	C/T	cg23422044	chr7:1970798	MAD1L1	-0.39	-6.02	-0.31	4.61e-9	Coronary artery disease;
LIHC	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg16586182	chr3:47516702	SCAP	0.51	9.01	0.44	1.45e-17	Colorectal cancer;
LIHC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.64	13.05	0.58	7.58e-32	Airflow obstruction;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13357821	chr7:101707668	CUX1	-0.36	-6.38	-0.33	5.83e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.6	9.87	0.47	2.26e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.34	-7.49	-0.38	5.84e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs7668874	0.779	rs1821009	chr4:116807350	C/T	cg08917878	chr5:172668965	NA	-0.31	-6.14	-0.32	2.26e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.39	6.22	0.32	1.47e-9	Menopause (age at onset);
LIHC	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	0.81	9.21	0.45	3.34e-18	Exhaled nitric oxide output;
LIHC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21747090	chr2:27597821	SNX17	-0.42	-6.33	-0.32	7.8e-10	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21448741	chr8:58168803	NA	0.34	6.31	0.32	8.5e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.88	12.42	0.56	1.7e-29	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs4699052	0.963	rs6533066	chr4:104163607	C/G	cg16532752	chr4:104119610	CENPE	-0.4	-6.3	-0.32	9.05e-10	Testicular germ cell tumor;
LIHC	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.52	-7.52	-0.38	4.87e-13	Obesity-related traits;
LIHC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg26149184	chr10:133730230	NA	0.46	7.34	0.37	1.56e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg04373760	chr16:53404718	NA	0.59	7.44	0.37	8.47e-13	Hypertriglyceridemia;
LIHC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-10.78	-0.5	1.56e-23	Schizophrenia;
LIHC	cis	rs3099143	0.901	rs76101229	chr15:77134975	C/T	cg21673338	chr15:77095150	SCAPER	-0.5	-6.71	-0.34	8.27e-11	Recalcitrant atopic dermatitis;
LIHC	trans	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.55	0.33	2.09e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg01364799	chr7:75623366	TMEM120A	-0.47	-6.53	-0.33	2.33e-10	Eotaxin levels;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.57	9.3	0.45	1.74e-18	Lymphocyte counts;
LIHC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.51	5.77	0.3	1.77e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.93	-0.35	2.08e-11	Total body bone mineral density;
LIHC	cis	rs965469	1.000	rs6051724	chr20:3279338	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.86	13.01	0.58	1.06e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs7546668	0.948	rs12736181	chr1:15869284	G/A	cg11706911	chr1:15910989	AGMAT	0.43	6.61	0.34	1.52e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.41	-6.65	-0.34	1.16e-10	Response to temozolomide;
LIHC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22541791	chr17:33905888	PEX12	0.37	6.42	0.33	4.57e-10	Calcium levels;
LIHC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	0.5	7.53	0.38	4.44e-13	Methadone dose in opioid dependence;
LIHC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.74	-7.44	-0.37	8.24e-13	Blood protein levels;
LIHC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.33	-7.06	-0.36	9.29e-12	Erythrocyte sedimentation rate;
LIHC	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg23280166	chr11:118938394	VPS11	-0.54	-7.04	-0.36	1.06e-11	Coronary artery disease;
LIHC	cis	rs295140	0.743	rs952530	chr2:201081745	A/G	cg23649088	chr2:200775458	C2orf69	-0.45	-6.07	-0.31	3.31e-9	QT interval;
LIHC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.57	-9.06	-0.44	1.06e-17	Prudent dietary pattern;
LIHC	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.51	-7.88	-0.39	4.47e-14	Extraversion;
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.73	-10.98	-0.51	3.19e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.56	7.62	0.38	2.45e-13	Occipital cortical area (total cortical area interaction);
LIHC	trans	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg10756647	chr7:56101905	PSPH	1.08	13.46	0.59	2e-33	Diabetic kidney disease;
LIHC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.98	15.03	0.63	1.42e-39	Metabolic syndrome;
LIHC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	6.2	0.32	1.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	8.87	0.43	4.26e-17	Platelet count;
LIHC	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg03934865	chr2:198174659	NA	0.52	7.73	0.39	1.21e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10847980	0.590	rs77970074	chr12:123292186	T/G	cg22842854	chr12:123319900	HIP1R	0.91	9.9	0.47	1.79e-20	Adiponectin levels;
LIHC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.28	-0.37	2.34e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.4	-8.03	-0.4	1.54e-14	Renal cell carcinoma;
LIHC	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.58	11.03	0.51	2.13e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs13098911	0.540	rs13066516	chr3:45975443	C/T	cg21656520	chr2:210867290	RPE	0.86	6.09	0.31	3.09e-9	Celiac disease;
LIHC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.46	-7.17	-0.36	4.59e-12	Lymphocyte counts;
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	0.99	15.31	0.64	1.13e-40	Skin colour saturation;
LIHC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.18	0.32	1.86e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.23	0.55	8.88e-29	Alzheimer's disease;
LIHC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2257205	0.667	rs7214805	chr17:56931895	C/G	cg12560992	chr17:57184187	TRIM37	0.67	7.22	0.36	3.29e-12	Pancreatic cancer;
LIHC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.69	-14.61	-0.62	6.62e-38	Brugada syndrome;
LIHC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.15	-0.44	5.12e-18	Schizophrenia;
LIHC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.63	9.82	0.47	3.15e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-8.14	-0.4	7.45e-15	Metabolite levels;
LIHC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg03983715	chr16:68378420	PRMT7	-0.51	-5.97	-0.31	5.89e-9	Schizophrenia;
LIHC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.46	-6.03	-0.31	4.17e-9	Vitiligo;
LIHC	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.57	-10.71	-0.5	2.73e-23	Neurofibrillary tangles;
LIHC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.61	5.87	0.3	1.02e-8	Vitiligo;
LIHC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11212260	0.655	rs76853908	chr11:107274530	T/C	cg25435332	chr11:107328525	CWF19L2	0.81	8.76	0.43	8.88e-17	IgG glycosylation;
LIHC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.42	-8.43	-0.41	9.84e-16	Obesity-related traits;
LIHC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.99	19.71	0.73	2.65e-58	Intelligence (multi-trait analysis);
LIHC	trans	rs3745567	0.688	rs2241394	chr19:6685230	C/G	cg24053061	chr12:107168846	RIC8B	0.66	6.08	0.31	3.28e-9	Complement C3 and C4 levels;
LIHC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.45e-10	Colorectal cancer;
LIHC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.67	9.62	0.46	1.56e-19	Corneal astigmatism;
LIHC	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.83	0.3	1.27e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.81	12.92	0.57	2.17e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.23	7.11	0.36	6.87e-12	Motion sickness;
LIHC	cis	rs7577696	0.597	rs11691939	chr2:32339561	A/G	cg02381751	chr2:32503542	YIPF4	0.46	6.49	0.33	3.08e-10	Inflammatory biomarkers;
LIHC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.67	9.36	0.45	1.09e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	5.86e-12	Diabetic kidney disease;
LIHC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.56	9.93	0.47	1.43e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg14067834	chr17:29058358	SUZ12P	0.65	6.28	0.32	1.05e-9	Body mass index;
LIHC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.63	9.34	0.45	1.23e-18	Longevity;
LIHC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.8	0.54	3.57e-27	Motion sickness;
LIHC	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg00339695	chr16:24857497	SLC5A11	-0.37	-6.16	-0.32	2.01e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.53	-8.62	-0.42	2.59e-16	Body mass index;
LIHC	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.67	-10.18	-0.48	1.94e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.79	0.6	1.01e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.52	-0.38	4.9e-13	Initial pursuit acceleration;
LIHC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg12798992	chr6:167411361	FGFR1OP	0.43	6.21	0.32	1.55e-9	Crohn's disease;
LIHC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.16	0.32	2.04e-9	Diastolic blood pressure;
LIHC	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.35	6.77	0.34	5.52e-11	Multiple sclerosis;
LIHC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.38	0.52	1.16e-25	Tonsillectomy;
LIHC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.92	0.57	2.25e-31	Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.77	0.43	8.48e-17	Prudent dietary pattern;
LIHC	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.78	11.99	0.54	6.66e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.44	-7.45	-0.37	7.92e-13	Breast cancer;
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg09417038	chr21:47716443	C21orf57	-0.47	-7.21	-0.36	3.51e-12	Testicular germ cell tumor;
LIHC	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.51	0.33	2.74e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg05272587	chr13:111038400	COL4A2	0.36	7.64	0.38	2.21e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.34	7.31	0.37	1.89e-12	Bone mineral density;
LIHC	cis	rs611744	0.905	rs421695	chr8:109117403	T/C	cg18478394	chr8:109455254	TTC35	0.34	5.76	0.3	1.89e-8	Dupuytren's disease;
LIHC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.25	-0.32	1.25e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs507080	0.922	rs7114216	chr11:118566234	A/G	cg04173919	chr11:118528438	PHLDB1	0.36	6.68	0.34	9.83e-11	Serum metabolite levels;
LIHC	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.25	0.32	1.22e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg18289306	chr13:113640169	MCF2L	0.44	6.97	0.35	1.69e-11	Systolic blood pressure;
LIHC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-6.01	-0.31	4.75e-9	Subjective well-being;
LIHC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-10.92	-0.51	5.13e-24	Total body bone mineral density;
LIHC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.72e-14	Motion sickness;
LIHC	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-8.03	-0.4	1.55e-14	Hepatocellular carcinoma;
LIHC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.76	12.9	0.57	2.71e-31	Anterior chamber depth;
LIHC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.8	-0.3	1.49e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.43	-9.23	-0.45	2.83e-18	Rheumatoid arthritis;
LIHC	cis	rs10792665	0.512	rs11233361	chr11:82597245	C/T	cg24227371	chr11:82718527	RAB30	-0.28	-6.59	-0.34	1.68e-10	Obesity-related traits;
LIHC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.44	7.73	0.39	1.18e-13	Aortic root size;
LIHC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.13	-0.61	4.82e-36	Headache;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	0.51	5.77	0.3	1.77e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.62	10.19	0.48	1.85e-21	Schizophrenia;
LIHC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.02	-0.31	4.41e-9	Alzheimer's disease (late onset);
LIHC	cis	rs812925	0.519	rs1186696	chr2:61660483	A/C	cg14146966	chr2:61757674	XPO1	0.39	6.31	0.32	8.52e-10	Immature fraction of reticulocytes;
LIHC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.92	9.72	0.47	6.91e-20	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs35883536	1.000	rs1855798	chr1:101114191	T/C	cg14515779	chr1:101123966	NA	-0.65	-12.71	-0.57	1.36e-30	Monocyte count;
LIHC	cis	rs244293	0.965	rs8068337	chr17:53177899	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.51	7.58	0.38	3.26e-13	Menarche (age at onset);
LIHC	cis	rs903552	1.000	rs4965873	chr15:102004023	A/G	cg16179521	chr15:102009894	PCSK6	0.43	5.88	0.3	9.57e-9	Diabetic kidney disease;
LIHC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.68	-0.42	1.61e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.22	-0.45	3.03e-18	Exhaled nitric oxide output;
LIHC	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.57	-8.55	-0.42	4.32e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.87	0.39	4.76e-14	IgG glycosylation;
LIHC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-6.55	-0.33	2.08e-10	Initial pursuit acceleration;
LIHC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.46	-10.53	-0.49	1.2e-22	Arsenic metabolism;
LIHC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.67	-0.38	1.84e-13	Calcium levels;
LIHC	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.7	10.9	0.51	6.1e-24	Monocyte count;
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	9.63	0.46	1.44e-19	Height;
LIHC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.75	-12.42	-0.56	1.73e-29	Platelet distribution width;
LIHC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.84	10.29	0.49	8.11e-22	Mean platelet volume;
LIHC	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.47	6.87	0.35	3.11e-11	Asthma;
LIHC	cis	rs75908454	1.000	rs117534547	chr6:169891608	G/A	cg19338460	chr6:170058176	WDR27	-0.75	-6.8	-0.35	4.69e-11	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-8.39	-0.41	1.32e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg20991723	chr1:152506922	NA	0.6	10.58	0.5	8.32e-23	Hair morphology;
LIHC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.94	0.31	7.14e-9	Schizophrenia;
LIHC	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg01864836	chr14:55583639	NA	-0.42	-7.8	-0.39	7.5e-14	Protein biomarker;
LIHC	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.75	0.39	1.04e-13	Mean platelet volume;
LIHC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.51	7.76	0.39	9.76e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.52	-0.38	4.84e-13	Initial pursuit acceleration;
LIHC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.57	-11.11	-0.51	1.12e-24	Coronary artery disease;
LIHC	cis	rs2637266	0.935	rs2637265	chr10:78326104	A/G	cg18941641	chr10:78392320	NA	0.29	5.96	0.31	6.34e-9	Pulmonary function;
LIHC	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg04610667	chr7:75704037	NA	-0.34	-6.13	-0.31	2.47e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.64	8.98	0.44	1.91e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.68	-10.97	-0.51	3.38e-24	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.4	0.52	1.01e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	0.92	22.75	0.78	2.09e-70	Multiple myeloma;
LIHC	cis	rs62179067	0.618	rs11886627	chr2:179942451	G/A	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.48	-7.67	-0.38	1.8e-13	Fuchs's corneal dystrophy;
LIHC	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.18	-0.4	5.53e-15	Colorectal cancer;
LIHC	trans	rs12752401	0.867	rs34777937	chr1:103036317	C/A	cg17681729	chr19:740608	PALM	0.44	6.23	0.32	1.39e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	trans	rs1624005	0.967	rs1624272	chr14:43389468	C/T	cg11960719	chr5:1510684	LPCAT1	-0.37	-6.44	-0.33	4.02e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LIHC	cis	rs2108622	0.711	rs113343664	chr19:15978993	G/C	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.74	7.39	0.37	1.17e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs2559856	0.967	rs3809260	chr12:102091017	G/T	cg12924262	chr12:102091054	CHPT1	0.49	7.71	0.38	1.39e-13	Blood protein levels;
LIHC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.36	9.2	0.45	3.52e-18	Longevity;Endometriosis;
LIHC	cis	rs2274273	0.870	rs7153612	chr14:55788762	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.56	-0.33	1.97e-10	Protein biomarker;
LIHC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.43	-7.05	-0.36	9.96e-12	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg08126542	chr6:37504118	NA	-0.36	-6.04	-0.31	4.03e-9	Cognitive performance;
LIHC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	11.11	0.52	1.06e-24	Monocyte percentage of white cells;
LIHC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.8	13.28	0.58	9.42e-33	Height;
LIHC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg13647721	chr17:30228624	UTP6	-0.78	-6.61	-0.34	1.5e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.23	-12.92	-0.57	2.23e-31	White matter hyperintensity burden;
LIHC	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.78	-7.24	-0.36	2.9e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs142472947	1	rs142472947	chr1:8520487	AAAG/A	cg25722041	chr1:8623473	RERE	0.42	6.12	0.31	2.53e-9	White blood cell count;
LIHC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.53	9.74	0.47	5.95e-20	Systemic lupus erythematosus;
LIHC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.3	-0.32	9.41e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.2	-0.32	1.6e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.58	0.42	3.48e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07305463	chr2:136567211	LCT	-0.39	-5.72	-0.3	2.32e-8	Corneal structure;
LIHC	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.47	7.13	0.36	6.05e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.99	15.96	0.65	2.94e-43	Metabolic syndrome;
LIHC	cis	rs2625529	0.713	rs16956634	chr15:72552243	C/G	cg16672083	chr15:72433130	SENP8	0.31	5.76	0.3	1.85e-8	Red blood cell count;
LIHC	cis	rs9635231	1	rs9635231	chr14:55887703	C/T	cg13175173	chr14:55914753	NA	-0.31	-7.0	-0.35	1.39e-11	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.66	0.38	1.95e-13	Lymphocyte counts;
LIHC	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg22771759	chr13:24902376	NA	0.36	6.86	0.35	3.16e-11	Obesity-related traits;
LIHC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg12863693	chr15:85201151	NMB	0.44	6.33	0.32	7.52e-10	Schizophrenia;
LIHC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.86	14.39	0.61	4.89e-37	Menopause (age at onset);
LIHC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.96	-0.51	3.76e-24	Primary sclerosing cholangitis;
LIHC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg03013999	chr17:37608204	MED1	0.35	5.74	0.3	2.08e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.5	9.29	0.45	1.91e-18	Hemoglobin concentration;
LIHC	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg16586182	chr3:47516702	SCAP	-0.44	-7.88	-0.39	4.46e-14	Colorectal cancer;
LIHC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg18944383	chr4:111397179	ENPEP	-0.32	-7.69	-0.38	1.58e-13	Coronary artery disease;
LIHC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg09417038	chr21:47716443	C21orf57	-0.5	-7.36	-0.37	1.35e-12	Testicular germ cell tumor;
LIHC	cis	rs10916814	0.632	rs10916818	chr1:20897425	C/T	cg24502330	chr1:20914028	CDA	-0.31	-6.82	-0.35	4.1e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08677398	chr8:58056175	NA	0.41	6.25	0.32	1.25e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.38	0.45	9.22e-19	Bipolar disorder;
LIHC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.66	-9.69	-0.46	8.66e-20	Schizophrenia;
LIHC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.37	6.65	0.34	1.14e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.37	-6.45	-0.33	3.8e-10	Headache;
LIHC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.44	7.62	0.38	2.57e-13	Mean corpuscular volume;
LIHC	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.26	-5.73	-0.3	2.25e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg00960700	chr17:80709150	TBCD	0.36	5.83	0.3	1.26e-8	Glycated hemoglobin levels;
LIHC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.04	0.31	3.91e-9	Tonsillectomy;
LIHC	cis	rs15676	0.947	rs7854319	chr9:131567995	G/A	cg13708974	chr9:131466143	PKN3	-0.39	-5.86	-0.3	1.08e-8	Blood metabolite levels;
LIHC	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg23625390	chr15:77176239	SCAPER	0.36	5.84	0.3	1.25e-8	Blood metabolite levels;
LIHC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.77	-13.25	-0.58	1.25e-32	Aortic root size;
LIHC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg23690444	chr14:81902736	NA	-0.44	-6.2	-0.32	1.6e-9	Night sleep phenotypes;
LIHC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-12.91	-0.57	2.54e-31	Dental caries;
LIHC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.37	6.3	0.32	9.24e-10	Type 2 diabetes;
LIHC	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-0.79	-8.85	-0.43	4.67e-17	Exhaled nitric oxide output;
LIHC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.91	-16.91	-0.67	4.78e-47	Aortic root size;
LIHC	cis	rs16958440	0.867	rs76558586	chr18:44737613	C/T	cg17192377	chr18:44677553	HDHD2	0.92	8.61	0.42	2.67e-16	Sitting height ratio;
LIHC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg27478167	chr7:817139	HEATR2	-0.41	-5.83	-0.3	1.32e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg23978390	chr7:1156363	C7orf50	0.53	8.14	0.4	7.65e-15	Longevity;Endometriosis;
LIHC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.63	9.5	0.46	3.8e-19	Monocyte percentage of white cells;
LIHC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg12863693	chr15:85201151	NMB	0.45	6.36	0.33	6.39e-10	Schizophrenia;
LIHC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.3	0.45	1.69e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-10.72	-0.5	2.61e-23	Colorectal cancer;
LIHC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.53	-8.87	-0.43	4.21e-17	Lung cancer;
LIHC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg07117364	chr1:16154769	NA	-0.39	-7.02	-0.35	1.19e-11	Dilated cardiomyopathy;
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.91	-0.3	8.24e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg09045935	chr12:6379348	NA	0.93	8.0	0.4	2e-14	Blood metabolite levels;
LIHC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.84	12.79	0.57	6.97e-31	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.69	7.07	0.36	8.52e-12	Alzheimer's disease;
LIHC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg15534755	chr11:117069859	TAGLN	0.36	6.13	0.31	2.41e-9	Blood protein levels;
LIHC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.49	7.62	0.38	2.5e-13	Methadone dose in opioid dependence;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09396068	chr15:22940794	CYFIP1	0.48	6.59	0.34	1.62e-10	Hip circumference;
LIHC	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.3	6.39	0.33	5.46e-10	Pulmonary function;
LIHC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.59	-0.34	1.66e-10	Response to antipsychotic treatment;
LIHC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg14280964	chr1:37940281	ZC3H12A	-0.41	-6.44	-0.33	4.14e-10	Eotaxin levels;
LIHC	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.02	16.93	0.68	3.86e-47	Testicular germ cell tumor;
LIHC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.86e-12	Waist circumference;Weight;
LIHC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.24	-16.13	-0.66	6.34e-44	Diabetic kidney disease;
LIHC	cis	rs611744	0.967	rs596245	chr8:109240822	G/A	cg21045802	chr8:109455806	TTC35	0.5	8.68	0.43	1.6e-16	Dupuytren's disease;
LIHC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.53	8.0	0.4	2e-14	Platelet count;
LIHC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.33	6.55	0.33	2.07e-10	Renal cell carcinoma;
LIHC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg05941027	chr17:61774174	LIMD2	0.36	7.54	0.38	4.22e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-15.49	-0.64	2.29e-41	Gut microbiome composition (summer);
LIHC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.77	-0.47	4.66e-20	Response to antipsychotic treatment;
LIHC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.47	-0.33	3.41e-10	Height;
LIHC	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.69	13.61	0.59	5.32e-34	Schizophrenia;
LIHC	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.58	-0.38	3.33e-13	QT interval;
LIHC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.31	-7.79	-0.39	7.95e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18357526	chr6:26021779	HIST1H4A	0.45	6.54	0.33	2.22e-10	Height;
LIHC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.23	-10.44	-0.49	2.51e-22	Hip circumference adjusted for BMI;
LIHC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg12458913	chr13:53173898	NA	0.45	7.22	0.36	3.36e-12	Lewy body disease;
LIHC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.59	-9.19	-0.45	3.81e-18	Dental caries;
LIHC	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.68	-10.07	-0.48	4.66e-21	Eosinophil percentage of white cells;
LIHC	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	6.88	0.35	2.79e-11	Bipolar disorder;
LIHC	cis	rs7944735	0.508	rs11819955	chr11:47539208	A/G	cg20307385	chr11:47447363	PSMC3	-0.54	-6.16	-0.32	2.09e-9	Intraocular pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18350866	chr20:39766189	PLCG1	-0.46	-6.03	-0.31	4.14e-9	Pancreatic cancer;
LIHC	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.61	8.98	0.44	1.91e-17	Schizophrenia;
LIHC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.67	-9.52	-0.46	3.21e-19	Obesity-related traits;
LIHC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02711726	chr17:80685570	FN3KRP	-0.41	-7.46	-0.37	7.13e-13	Glycated hemoglobin levels;
LIHC	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.48	7.09	0.36	7.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.36	6.04	0.31	4.01e-9	Red cell distribution width;
LIHC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.14e-14	Neuroticism;
LIHC	cis	rs4908768	0.906	rs11584261	chr1:8560366	C/A	cg20416874	chr1:8611966	RERE	0.57	8.86	0.43	4.3e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.78	0.39	8.89e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23209537	chr7:5463409	TNRC18	0.48	6.71	0.34	8.03e-11	Lung function (FEV1/FVC);
LIHC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs10838687	0.610	rs4647737	chr11:47253244	T/G	cg25783544	chr11:47291846	MADD	0.46	5.77	0.3	1.73e-8	Proinsulin levels;
LIHC	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-12.56	-0.56	5.38e-30	Response to antipsychotic treatment;
LIHC	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	6.17	0.32	1.94e-9	Educational attainment;
LIHC	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs539514	0.627	rs9544035	chr13:76293789	C/T	cg04757411	chr13:76259545	LMO7	-0.47	-8.19	-0.4	5.28e-15	Type 1 diabetes;
LIHC	cis	rs7255374	0.566	rs11666982	chr19:41531368	T/G	cg27089200	chr19:41531976	NA	0.35	5.73	0.3	2.17e-8	DDT metabolite (p,p'-DDE levels);
LIHC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg21466736	chr12:48725269	NA	-0.64	-9.37	-0.45	1.03e-18	Glycated hemoglobin levels;
LIHC	cis	rs12286929	0.668	rs17304149	chr11:115049180	C/T	cg04055981	chr11:115044050	NA	0.53	8.11	0.4	9.16e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.61	-10.04	-0.48	5.71e-21	Malaria;
LIHC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.38	6.95	0.35	1.8e-11	IgG glycosylation;
LIHC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.71	10.6	0.5	6.78e-23	Aortic root size;
LIHC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.47	-7.26	-0.37	2.57e-12	Morning vs. evening chronotype;
LIHC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.55	-10.65	-0.5	4.68e-23	Coronary artery disease;
LIHC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.53	6.8	0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs332507	0.830	rs2173852	chr3:124420102	C/G	cg05980111	chr3:124395277	KALRN	-0.42	-6.56	-0.33	1.96e-10	Plateletcrit;
LIHC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.99	10.76	0.5	1.9e-23	Triglycerides;
LIHC	cis	rs5753037	0.838	rs140149	chr22:30185613	C/T	cg01021169	chr22:30184971	ASCC2	-0.35	-6.61	-0.34	1.49e-10	Type 1 diabetes;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.52	-8.51	-0.42	5.44e-16	Blood metabolite levels;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.77	0.3	1.76e-8	Alzheimer's disease;
LIHC	cis	rs9322817	0.691	rs2486136	chr6:105285759	C/T	cg02098413	chr6:105308735	HACE1	0.45	8.41	0.41	1.16e-15	Thyroid stimulating hormone;
LIHC	cis	rs4407350	1.000	rs4373014	chr22:44922424	C/T	cg26276947	chr22:44892394	LDOC1L	0.34	6.36	0.33	6.45e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.89	-0.3	9.33e-9	Type 2 diabetes;
LIHC	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	14.0	0.6	1.67e-35	Coffee consumption (cups per day);
LIHC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg01629716	chr15:45996671	NA	-0.51	-9.53	-0.46	3.07e-19	Waist circumference;Weight;
LIHC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.42	-6.08	-0.31	3.17e-9	Menopause (age at onset);
LIHC	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.73	8.16	0.4	6.28e-15	Height;
LIHC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.56	9.57	0.46	2.3e-19	Colorectal cancer;
LIHC	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.26	7.16	0.36	4.98e-12	Type 2 diabetes;
LIHC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg25894440	chr7:65020034	NA	0.4	6.34	0.32	7.12e-10	Calcium levels;
LIHC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	5.8	0.3	1.48e-8	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	16.53	0.67	1.58e-45	Platelet count;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21842944	chr7:98985712	ARPC1B	0.48	6.17	0.32	1.97e-9	Hip circumference;
LIHC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	1.03	20.37	0.74	5.87e-61	Breast cancer;
LIHC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.56	7.41	0.37	9.92e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.49	7.56	0.38	3.63e-13	White matter hyperintensity burden;
LIHC	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.37	-0.37	1.26e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.59	7.05	0.36	1.02e-11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg16589663	chr20:23618590	CST3	0.76	7.76	0.39	9.94e-14	Chronic kidney disease;
LIHC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.44	6.28	0.32	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg18279126	chr7:2041391	MAD1L1	0.36	6.0	0.31	5.13e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26897989	chr16:1907736	C16orf73	-0.51	-5.96	-0.31	6.37e-9	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg14779329	chr11:130786720	SNX19	0.38	5.87	0.3	1.05e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.1e-31	Prudent dietary pattern;
LIHC	cis	rs4663866	1.000	rs4663300	chr2:239181491	T/C	cg16914508	chr2:239161102	PER2	0.8	5.9	0.3	8.86e-9	Irritable bowel syndrome;
LIHC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.91	0.35	2.39e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg00085434	chr11:14927489	NA	0.41	5.93	0.31	7.3e-9	Vitamin D levels;
LIHC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg02836325	chr17:76403955	PGS1	0.34	6.72	0.34	7.49e-11	HDL cholesterol;
LIHC	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.5	-0.33	2.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.9	14.34	0.61	7.71e-37	Vitamin D levels;
LIHC	trans	rs11083475	1.000	rs1808382	chr19:39151034	G/T	cg17791936	chr11:118902213	SLC37A4	-0.38	-6.04	-0.31	3.95e-9	Heart rate;
LIHC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg10932868	chr11:921992	NA	-0.38	-7.13	-0.36	6e-12	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg23782820	chr8:58130467	NA	0.37	5.94	0.31	6.89e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06108461	chr20:60628389	TAF4	-0.52	-6.83	-0.35	3.84e-11	Body mass index;
LIHC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg10360323	chr17:41437877	NA	0.41	6.17	0.32	1.97e-9	Menopause (age at onset);
LIHC	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.57	-8.45	-0.42	8.23e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3924048	0.559	rs4580	chr1:12628188	T/C	cg00291366	chr1:12616550	NA	0.36	7.31	0.37	1.86e-12	Optic cup area;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.54e-9	Alzheimer's disease;
LIHC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.51	6.5	0.33	2.78e-10	Menarche (age at onset);
LIHC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg12365402	chr11:9010492	NRIP3	0.23	5.93	0.31	7.3e-9	Hemoglobin concentration;
LIHC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	6.71	0.34	7.97e-11	Hemoglobin concentration;
LIHC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21545522	chr1:205238299	TMCC2	0.37	7.1	0.36	7.18e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-0.84	-14.93	-0.63	3.84e-39	Exhaled nitric oxide output;
LIHC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs12611088	0.600	rs2261316	chr19:44030998	A/G	cg13740135	chr19:44006432	PHLDB3	0.42	6.3	0.32	9.38e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11809123	chr19:1584870	MBD3	0.43	6.43	0.33	4.34e-10	Immature fraction of reticulocytes;
LIHC	trans	rs7246657	0.943	rs4802136	chr19:37849811	T/A	cg10208301	chr11:6592745	DNHD1	0.47	6.89	0.35	2.75e-11	Coronary artery calcification;
LIHC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg21466736	chr12:48725269	NA	-0.71	-10.96	-0.51	3.57e-24	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg11850622	chr4:159593397	ETFDH;C4orf46	-0.44	-6.29	-0.32	9.73e-10	Alopecia areata;
LIHC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-11.75	-0.54	5.45e-27	Total body bone mineral density;
LIHC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.62	13.63	0.59	4.45e-34	Obesity-related traits;
LIHC	trans	rs10213084	1.000	rs10212996	chr4:147501301	A/G	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg09314803	chr17:79180344	AZI1	0.36	6.44	0.33	4.14e-10	Frontotemporal dementia;
LIHC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg01444801	chr10:135216882	MTG1	-0.64	-9.43	-0.45	6.22e-19	Systemic lupus erythematosus;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.78	-9.56	-0.46	2.43e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4285214	0.715	rs12515071	chr5:124031011	C/T	cg15082166	chr5:124005151	ZNF608	0.41	5.86	0.3	1.08e-8	Survival in pancreatic cancer;
LIHC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.46	6.28	0.32	1.02e-9	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs7818688	0.697	rs11779698	chr8:95979764	C/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.98	-18.41	-0.71	4.45e-53	Breast cancer;
LIHC	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.36	-0.33	6.41e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg07423050	chr13:99094983	FARP1	-0.37	-5.82	-0.3	1.33e-8	Obesity-related traits;
LIHC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.69	11.25	0.52	3.33e-25	Obesity-related traits;
LIHC	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.25	6.22	0.32	1.46e-9	Obesity-related traits;
LIHC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg24209194	chr3:40518798	ZNF619	0.48	7.12	0.36	6.53e-12	Renal cell carcinoma;
LIHC	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.67	12.14	0.55	1.96e-28	Breast cancer;
LIHC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.89	-0.35	2.75e-11	Diabetic kidney disease;
LIHC	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.44	-5.87	-0.3	1.02e-8	Coronary artery calcification;
LIHC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.6	7.71	0.38	1.39e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.7	-9.23	-0.45	2.81e-18	Gut microbiome composition (summer);
LIHC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	6.63	0.34	1.32e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-6.32	-0.32	8.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.54	-7.84	-0.39	5.77e-14	Obesity-related traits;
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg11062466	chr8:58055876	NA	0.51	7.61	0.38	2.72e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.85	15.2	0.63	3.27e-40	Dental caries;
LIHC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.48	8.41	0.41	1.13e-15	Dental caries;
LIHC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg12310025	chr6:25882481	NA	-0.47	-7.17	-0.36	4.57e-12	Height;
LIHC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.5	6.56	0.33	2.05e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.49	6.52	0.33	2.58e-10	Emphysema distribution in smoking;
LIHC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.78	-0.3	1.66e-8	Heart rate;
LIHC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.27	0.32	1.12e-9	Major depressive disorder;
LIHC	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.37	-6.4	-0.33	5.26e-10	Menopause (age at onset);
LIHC	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.48	7.29	0.37	2.23e-12	Smoking behavior;
LIHC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.96e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11098699	1.000	rs7670452	chr4:124184613	C/T	cg09941581	chr4:124220074	SPATA5	0.3	5.72	0.3	2.37e-8	Mosquito bite size;
LIHC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.9e-9	Aortic root size;
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.56	-6.54	-0.33	2.23e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.79	-7.32	-0.37	1.81e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg26395211	chr5:140044315	WDR55	-0.4	-5.77	-0.3	1.73e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9425766	0.640	rs2208850	chr1:173831707	A/C	cg06124660	chr1:173389066	NA	-0.32	-5.87	-0.3	1.04e-8	Life satisfaction;
LIHC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.59	0.46	1.97e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.18	0.44	4.07e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg03037974	chr15:76606532	NA	0.9	23.3	0.78	1.43e-72	Blood metabolite levels;
LIHC	cis	rs588177	0.613	rs3782101	chr11:64131280	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.39	5.78	0.3	1.65e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs74233809	0.901	rs17878846	chr10:104630412	A/T	cg03493300	chr10:104813866	CNNM2	0.44	5.83	0.3	1.26e-8	Birth weight;
LIHC	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.43	0.49	2.6e-22	Colorectal cancer;
LIHC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg27432699	chr2:27873401	GPN1	-0.6	-8.6	-0.42	2.93e-16	Total body bone mineral density;
LIHC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.79	-0.3	1.6e-8	Calcium levels;
LIHC	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.03	-16.18	-0.66	4.01e-44	Corneal structure;
LIHC	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.16	12.75	0.57	1e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg12374095	chr12:54320830	NA	0.45	7.07	0.36	8.92e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.5	6.3	0.32	9.39e-10	Iron status biomarkers;
LIHC	trans	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg10756647	chr7:56101905	PSPH	1.1	13.41	0.59	3.1e-33	Diabetic kidney disease;
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.22	0.58	1.7e-32	Prudent dietary pattern;
LIHC	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.53	-0.38	4.69e-13	Mean platelet volume;
LIHC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.78	-0.43	8.15e-17	Monocyte count;
LIHC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg06199346	chr11:14280333	SPON1	-0.35	-5.75	-0.3	2e-8	Mitochondrial DNA levels;
LIHC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.44	-6.72	-0.34	7.55e-11	Cognitive function;
LIHC	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-6.74	-0.34	6.59e-11	Neuroticism;
LIHC	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	6.2	0.32	1.66e-9	Ileal carcinoids;
LIHC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	13.78	0.6	1.2e-34	Primary sclerosing cholangitis;
LIHC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg02702477	chr5:179499311	RNF130	-0.75	-10.29	-0.49	7.91e-22	LDL cholesterol;
LIHC	trans	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg10756647	chr7:56101905	PSPH	-1.11	-13.62	-0.59	4.91e-34	Diabetic kidney disease;
LIHC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.34	-0.37	1.53e-12	Platelet count;
LIHC	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	7.31	0.37	1.96e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4700695	0.764	rs251277	chr5:65390177	A/G	cg21114390	chr5:65439923	SFRS12	-0.46	-6.06	-0.31	3.66e-9	Facial morphology (factor 19);
LIHC	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.64	9.26	0.45	2.37e-18	Monocyte count;
LIHC	cis	rs3812111	0.809	rs1999659	chr6:116430382	G/A	cg08036074	chr6:116424633	NT5DC1	-0.66	-11.79	-0.54	3.7e-27	Age-related macular degeneration;
LIHC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg14580859	chr9:123691850	NA	0.38	6.47	0.33	3.3e-10	Rheumatoid arthritis;
LIHC	cis	rs6847149	0.929	rs4698752	chr4:110780964	A/G	cg07850274	chr4:110748770	RRH	0.41	6.05	0.31	3.72e-9	Exercise treadmill test traits;
LIHC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.66	-0.46	1.13e-19	Bipolar disorder;
LIHC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.45	6.27	0.32	1.08e-9	Orofacial clefts;
LIHC	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Osteoarthritis;
LIHC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg18357526	chr6:26021779	HIST1H4A	0.58	8.01	0.4	1.85e-14	Blood metabolite levels;
LIHC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.19	-0.48	1.85e-21	Chronic sinus infection;
LIHC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.38	6.74	0.34	6.68e-11	Response to antipsychotic treatment;
LIHC	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg02023728	chr11:77925099	USP35	0.36	6.23	0.32	1.37e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06002616	chr8:101225028	SPAG1	-0.35	-5.76	-0.3	1.85e-8	Atrioventricular conduction;
LIHC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg24296786	chr1:45957014	TESK2	0.51	7.61	0.38	2.78e-13	Platelet count;
LIHC	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.48	9.06	0.44	1.03e-17	Testicular germ cell tumor;
LIHC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.44	-0.37	8.09e-13	Uric acid levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01246405	chr11:3876562	STIM1	0.39	6.31	0.32	8.84e-10	Cognitive function;
LIHC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.51	0.49	1.45e-22	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.43	-7.25	-0.36	2.82e-12	Schizophrenia;
LIHC	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.6	7.92	0.39	3.4e-14	Testicular germ cell tumor;
LIHC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.41	6.48	0.33	3.19e-10	Menopause (age at onset);
LIHC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.63	11.0	0.51	2.65e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11663156	1.000	rs1502214	chr18:50932056	T/A	cg24270629	chr18:50823537	DCC	-0.48	-6.64	-0.34	1.27e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4407350	0.870	rs1894461	chr22:44911287	C/T	cg04154583	chr22:44889756	LDOC1L	0.3	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10503871	0.545	rs7828054	chr8:30509487	G/C	cg26383811	chr8:30366931	RBPMS	0.38	5.88	0.3	9.5e-9	Metabolite levels  (X-11787);
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.57	8.98	0.44	1.88e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.82	0.3	1.38e-8	Putamen volume;
LIHC	cis	rs10197940	0.967	rs4664423	chr2:152266311	T/C	cg19508488	chr2:152266495	RIF1	0.74	12.59	0.56	4.03e-30	Lung cancer;
LIHC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg11062466	chr8:58055876	NA	0.4	5.97	0.31	6.07e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg14393609	chr7:65229607	NA	-0.38	-6.03	-0.31	4.25e-9	Aortic root size;
LIHC	cis	rs12188164	0.610	rs72711368	chr5:418839	C/T	cg15640734	chr5:494837	SLC9A3	-0.37	-5.76	-0.3	1.9e-8	Cystic fibrosis severity;
LIHC	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg24069376	chr3:38537580	EXOG	0.42	7.68	0.38	1.65e-13	Electrocardiographic conduction measures;
LIHC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.49	8.27	0.41	3.05e-15	Obesity-related traits;
LIHC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21467203	chr3:49911342	NA	-0.44	-7.99	-0.4	2.11e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.66	-0.38	1.96e-13	Schizophrenia;
LIHC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.8	-14.87	-0.63	6.27e-39	Refractive error;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09623986	chr2:74753896	AUP1;DQX1	-0.41	-6.27	-0.32	1.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9513627	1.000	rs9582302	chr13:100125985	A/T	cg25919922	chr13:100150906	NA	-0.77	-6.7	-0.34	8.5e-11	Obesity-related traits;
LIHC	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.31	6.66	0.34	1.1e-10	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.81	-0.35	4.32e-11	Psoriasis;
LIHC	cis	rs1823913	1.000	rs6749232	chr2:192115052	C/G	cg12404831	chr2:192114017	MYO1B	-0.33	-6.57	-0.33	1.9e-10	Obesity-related traits;
LIHC	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg27205649	chr11:78285834	NARS2	0.4	6.3	0.32	9.03e-10	Alzheimer's disease (survival time);
LIHC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg17771515	chr6:154831774	CNKSR3	0.58	6.43	0.33	4.28e-10	Lipoprotein (a) levels;
LIHC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg03128534	chr1:43423976	SLC2A1	-0.46	-6.07	-0.31	3.39e-9	Red cell distribution width;
LIHC	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg10820045	chr2:198174542	NA	0.46	6.94	0.35	2.01e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.57	7.83	0.39	6.05e-14	Bladder cancer;
LIHC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg03037974	chr15:76606532	NA	-0.59	-9.84	-0.47	2.75e-20	Blood metabolite levels;
LIHC	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.49	-8.08	-0.4	1.14e-14	Coronary artery disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06521774	chr1:38397588	INPP5B	-0.5	-6.08	-0.31	3.15e-9	Systolic blood pressure;
LIHC	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.65	6.88	0.35	2.89e-11	Type 2 diabetes;
LIHC	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg03037974	chr15:76606532	NA	-0.6	-9.88	-0.47	2.04e-20	Blood metabolite levels;
LIHC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.79	11.94	0.54	1.09e-27	Dental caries;
LIHC	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.89	10.97	0.51	3.42e-24	Coronary artery disease;
LIHC	cis	rs116248771	0.690	rs16847125	chr3:158417699	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.28	0.32	1.03e-9	diarrhoeal disease at age 2;
LIHC	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21582582	chr3:182698605	DCUN1D1	0.49	6.46	0.33	3.55e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11023332	0.617	rs1879888	chr11:14679247	A/G	cg19336497	chr11:14380999	RRAS2	-0.35	-6.14	-0.32	2.28e-9	Adiponectin levels;Vitamin D levels;
LIHC	cis	rs2336384	1.000	rs2878677	chr1:12053264	C/T	cg13216073	chr1:12042593	MFN2	-0.41	-6.58	-0.34	1.81e-10	Platelet count;
LIHC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	11.84	0.54	2.49e-27	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.42	-6.15	-0.32	2.12e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05908079	chr5:64065005	SDCCAG10;SFRS12IP1	-0.46	-6.63	-0.34	1.35e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.29	0.32	9.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.75	-0.5	2.11e-23	Response to antipsychotic treatment;
LIHC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.83	8.94	0.44	2.53e-17	Vitiligo;
LIHC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-6.75	-0.34	6.49e-11	Crohn's disease;
LIHC	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.36	-6.23	-0.32	1.38e-9	Menopause (age at onset);
LIHC	cis	rs926392	0.896	rs7268772	chr20:37684501	A/G	cg16355469	chr20:37678765	NA	0.37	6.02	0.31	4.38e-9	Dialysis-related mortality;
LIHC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.46	-7.32	-0.37	1.81e-12	Total body bone mineral density;
LIHC	cis	rs918629	0.567	rs6877329	chr5:95261538	C/G	cg10483112	chr5:95245456	ELL2	-0.38	-7.17	-0.36	4.76e-12	IgG glycosylation;
LIHC	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg20503657	chr10:835505	NA	0.99	11.08	0.51	1.38e-24	Eosinophil percentage of granulocytes;
LIHC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.74	12.55	0.56	5.72e-30	Mean platelet volume;
LIHC	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.62	8.64	0.42	2.22e-16	Menarche (age at onset);
LIHC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	7.7	0.38	1.52e-13	Parkinson's disease;
LIHC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.45	6.56	0.33	1.97e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	0.644	rs6741757	chr2:219182748	T/C	cg00012203	chr2:219082015	ARPC2	0.76	10.76	0.5	1.88e-23	Colorectal cancer;
LIHC	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg16583315	chr14:65563665	MAX	-0.4	-8.1	-0.4	9.62e-15	Obesity-related traits;
LIHC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.4	-6.96	-0.35	1.7e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg08668510	chr10:1095578	IDI1	0.65	6.67	0.34	1.06e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.75	0.62	1.8e-38	Prudent dietary pattern;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19250764	chr7:66461952	TYW1;SBDS	0.42	6.34	0.32	7.13e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23807559	chr17:71189217	COG1	-0.41	-6.18	-0.32	1.83e-9	Pancreatic cancer;
LIHC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.4	0.56	2.05e-29	Cognitive test performance;
LIHC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16447950	chr5:562315	NA	-0.49	-5.73	-0.3	2.19e-8	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg00601450	chr5:74908170	NA	0.52	6.05	0.31	3.73e-9	Coronary artery disease;
LIHC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.65	-11.48	-0.53	5.07e-26	High light scatter reticulocyte count;
LIHC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.56	-8.83	-0.43	5.67e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.45	8.68	0.43	1.6e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.49	6.99	0.35	1.47e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg26338869	chr17:61819248	STRADA	0.52	6.84	0.35	3.69e-11	Height;
LIHC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.42	-6.55	-0.33	2.16e-10	Iron status biomarkers;
LIHC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.03	0.4	1.62e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.73	-13.07	-0.58	6.18e-32	Longevity;
LIHC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.38	-6.02	-0.31	4.59e-9	Monocyte percentage of white cells;
LIHC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg18944383	chr4:111397179	ENPEP	0.25	6.22	0.32	1.45e-9	Coronary artery disease;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.13	-0.36	6.02e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	trans	rs334353	0.785	rs334364	chr9:101929144	C/T	cg06788856	chr17:1821969	NA	-0.33	-6.18	-0.32	1.86e-9	Age-related macular degeneration;
LIHC	trans	rs7668874	0.779	rs1430933	chr4:116809178	G/A	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.62	0.34	1.38e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.97	17.4	0.69	5.3e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.57	8.18	0.4	5.73e-15	Coronary artery disease;
LIHC	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.58	-0.38	3.29e-13	QT interval;
LIHC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19671926	chr4:122722719	EXOSC9	0.56	8.61	0.42	2.75e-16	Type 2 diabetes;
LIHC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.43	0.33	4.26e-10	Rheumatoid arthritis;
LIHC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.59	10.15	0.48	2.57e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg03013999	chr17:37608204	MED1	0.36	5.98	0.31	5.5e-9	Lung function (FEV1);
LIHC	trans	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg19894588	chr14:64061835	NA	-0.61	-7.78	-0.39	8.85e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.5	-7.17	-0.36	4.76e-12	Height;
LIHC	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg14067834	chr17:29058358	SUZ12P	-0.6	-6.15	-0.32	2.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	2.97e-23	Bladder cancer;
LIHC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.63	-9.97	-0.47	1.05e-20	Sudden cardiac arrest;
LIHC	cis	rs1775715	0.966	rs1639132	chr10:32301260	G/A	cg14930904	chr10:32216787	ARHGAP12	-0.41	-7.23	-0.36	3.1e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.24	-8.92	-0.43	2.88e-17	Body mass index;
LIHC	cis	rs9309473	0.528	rs6546820	chr2:73553397	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.44	-0.37	8.39e-13	Metabolite levels;
LIHC	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.61	-12.27	-0.55	6.39e-29	Plateletcrit;Platelet count;
LIHC	cis	rs1789	0.653	rs13142069	chr4:15593692	C/T	cg21123203	chr4:15471301	CC2D2A	0.39	6.54	0.33	2.22e-10	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg25894440	chr7:65020034	NA	0.51	5.9	0.3	8.83e-9	Diabetic kidney disease;
LIHC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg04025307	chr7:1156635	C7orf50	0.46	6.18	0.32	1.81e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16684958	chr7:75615977	POR	-0.51	-8.48	-0.42	6.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	0.78	5.94	0.31	6.97e-9	IgG glycosylation;
LIHC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.74	-0.34	6.6e-11	Gut microbiome composition (summer);
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg12310025	chr6:25882481	NA	-0.43	-6.47	-0.33	3.38e-10	Height;
LIHC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.65	0.53	1.25e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.18	0.55	1.39e-28	Height;
LIHC	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg10820045	chr2:198174542	NA	0.5	8.04	0.4	1.46e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg06207120	chr15:45996521	NA	0.33	6.43	0.33	4.24e-10	Waist circumference;Weight;
LIHC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.8	-0.3	1.53e-8	Systemic lupus erythematosus;
LIHC	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg21017887	chr14:105400489	NA	-0.67	-11.96	-0.54	9.07e-28	Rheumatoid arthritis;
LIHC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.53	8.31	0.41	2.33e-15	Lymphocyte counts;
LIHC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.35	8.11	0.4	9.26e-15	Crohn's disease;
LIHC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	6.25	0.32	1.24e-9	Mean platelet volume;
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.58	-8.32	-0.41	2.08e-15	Menarche (age at onset);
LIHC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.81	-0.54	3.1e-27	Chronic sinus infection;
LIHC	cis	rs2637266	0.729	rs1099883	chr10:78516158	G/T	cg18941641	chr10:78392320	NA	0.27	5.84	0.3	1.22e-8	Pulmonary function;
LIHC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.82	-0.39	6.48e-14	Obesity-related traits;
LIHC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.65	-5.79	-0.3	1.62e-8	Menopause (age at onset);
LIHC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.24	-0.32	1.3e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-22.4	-0.77	4.91e-69	Coronary artery disease;
LIHC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg00343986	chr7:65444356	GUSB	0.39	5.85	0.3	1.14e-8	Aortic root size;
LIHC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.83	13.53	0.59	1.02e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg20360273	chr2:70056711	GMCL1	0.48	6.04	0.31	4.11e-9	Facial morphology (factor 20);
LIHC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.65	-0.34	1.14e-10	Personality dimensions;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.6	10.62	0.5	6.08e-23	Longevity;Endometriosis;
LIHC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.44	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.57	8.62	0.42	2.56e-16	Response to diuretic therapy;
LIHC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.43	7.26	0.37	2.61e-12	Breast cancer;
LIHC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.58	-9.94	-0.47	1.26e-20	Reticulocyte count;
LIHC	cis	rs4728302	0.934	rs10258052	chr7:133635874	T/C	cg10665199	chr7:133106180	EXOC4	-0.35	-5.86	-0.3	1.1e-8	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-8.08	-0.4	1.14e-14	Blood metabolite levels;
LIHC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-13.77	-0.6	1.21e-34	Headache;
LIHC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.41	-5.91	-0.3	8.06e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.55e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.58	-8.61	-0.42	2.7e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.45	-6.22	-0.32	1.46e-9	Interleukin-18 levels;
LIHC	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.49	-7.07	-0.36	8.83e-12	Smoking behavior;
LIHC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.67	13.37	0.59	4.23e-33	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7095607	0.606	rs6480312	chr10:69957845	C/T	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.65e-9	Lung function (FVC);
LIHC	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.51	8.05	0.4	1.36e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.46	8.0	0.4	1.94e-14	Mean corpuscular volume;
LIHC	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg26138937	chr11:71823887	C11orf51	0.8	7.93	0.39	3.24e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.69	9.72	0.47	7.18e-20	Menarche (age at onset);
LIHC	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg16433844	chr14:91963127	SMEK1	-0.54	-6.34	-0.32	7.11e-10	Alzheimer disease and age of onset;
LIHC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.62	0.46	1.52e-19	Platelet count;
LIHC	trans	rs216345	0.966	rs1971430	chr9:33782375	G/A	cg14607208	chr9:38546089	NA	0.42	6.39	0.33	5.4e-10	Bipolar disorder;
LIHC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.33	-5.86	-0.3	1.07e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.49	7.03	0.36	1.11e-11	Schizophrenia;
LIHC	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.37	6.74	0.34	6.94e-11	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9596863	1.000	rs9316669	chr13:54401836	C/G	ch.13.53330881F	chr13:54432880	NA	0.43	5.76	0.3	1.84e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.56	7.19	0.36	4.06e-12	Parkinson's disease;
LIHC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.4	5.88	0.3	9.51e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13445258	chr3:128369860	RPN1	0.48	7.15	0.36	5.26e-12	Pancreatic cancer;
LIHC	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.33	-6.61	-0.34	1.44e-10	Platelet distribution width;
LIHC	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.37e-16	Putamen volume;
LIHC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.81	13.05	0.58	7.15e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.78	-13.64	-0.59	4.13e-34	Aortic root size;
LIHC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.12	0.31	2.5e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg02297831	chr4:17616191	MED28	0.44	6.81	0.35	4.47e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.46	7.96	0.4	2.63e-14	Mean corpuscular volume;
LIHC	cis	rs17106184	1.000	rs72896994	chr1:50891117	C/A	cg07174182	chr1:51127561	FAF1	-0.57	-6.26	-0.32	1.16e-9	Type 2 diabetes;
LIHC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.7	10.99	0.51	2.92e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg03934865	chr2:198174659	NA	0.46	6.48	0.33	3.28e-10	Intracranial aneurysm;
LIHC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.83	14.59	0.62	8.16e-38	Headache;
LIHC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.3	-0.32	8.9e-10	Longevity;Endometriosis;
LIHC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.68	11.31	0.52	2.15e-25	Type 2 diabetes;
LIHC	cis	rs6545883	0.894	rs2694632	chr2:61558682	T/C	cg14146966	chr2:61757674	XPO1	-0.44	-7.44	-0.37	7.95e-13	Tuberculosis;
LIHC	cis	rs7116495	1.000	rs73539532	chr11:71815684	C/A	cg26138937	chr11:71823887	C11orf51	0.82	8.15	0.4	7.04e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.41	6.77	0.34	5.75e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.49	7.84	0.39	5.75e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.46	-6.1	-0.31	2.85e-9	Subjective well-being;
LIHC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg24209194	chr3:40518798	ZNF619	0.49	7.37	0.37	1.32e-12	Renal cell carcinoma;
LIHC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg18898632	chr2:242989856	NA	-0.51	-7.07	-0.36	8.53e-12	Obesity-related traits;
LIHC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.68	6.52	0.33	2.56e-10	Lung function (FEV1/FVC);
LIHC	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.66	0.34	1.1e-10	Mean corpuscular volume;
LIHC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.42	5.83	0.3	1.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.52	-7.24	-0.36	2.9e-12	Menopause (age at onset);
LIHC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg03721293	chr16:90014378	DEF8	0.39	6.62	0.34	1.38e-10	Skin colour saturation;
LIHC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.38	7.24	0.36	2.92e-12	Body mass index;
LIHC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.47	8.33	0.41	1.93e-15	IgG glycosylation;
LIHC	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg14473756	chr11:122847823	NA	-0.37	-6.71	-0.34	8.29e-11	Menarche (age at onset);
LIHC	cis	rs244293	0.965	rs244340	chr17:53199345	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	cis	rs507080	0.961	rs642530	chr11:118550756	A/G	cg04173919	chr11:118528438	PHLDB1	0.32	6.07	0.31	3.43e-9	Serum metabolite levels;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.5	-6.82	-0.35	4.08e-11	Menopause (age at onset);
LIHC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.76	-17.64	-0.69	5.3e-50	Brugada syndrome;
LIHC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.76	11.69	0.53	8.92e-27	Corneal astigmatism;
LIHC	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.45	-5.9	-0.3	8.95e-9	IgG glycosylation;
LIHC	cis	rs244293	0.965	rs2529506	chr17:53211177	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-7.3	-0.37	2.04e-12	Menarche (age at onset);
LIHC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.5	6.49	0.33	3.01e-10	Initial pursuit acceleration;
LIHC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.57	8.71	0.43	1.28e-16	Type 2 diabetes;
LIHC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.78	-11.71	-0.53	7.57e-27	Mosquito bite size;
LIHC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.67	-10.77	-0.5	1.81e-23	Lung cancer;
LIHC	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.72	-0.39	1.26e-13	Coronary artery disease;
LIHC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.1	11.26	0.52	3.23e-25	Opioid sensitivity;
LIHC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.05e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06360820	chr2:242988706	NA	-0.79	-11.46	-0.53	5.92e-26	Obesity-related traits;
LIHC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.09	9.82	0.47	3.33e-20	Diabetic retinopathy;
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.64	8.42	0.41	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-0.61	-8.21	-0.41	4.49e-15	Lung cancer;
LIHC	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.31	6.71	0.34	8.07e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.6	11.91	0.54	1.36e-27	Plateletcrit;Platelet count;
LIHC	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.08	-0.31	3.18e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg26367235	chr2:239997305	HDAC4	0.45	6.09	0.31	3.01e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg22633049	chr21:46681294	NA	-0.37	-6.31	-0.32	8.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-9.24	-0.45	2.71e-18	Schizophrenia;
LIHC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08556938	chr17:58512855	NA	-0.45	-7.19	-0.36	4.21e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1198430	0.639	rs1767147	chr1:23770516	A/G	cg13183780	chr1:23809682	ASAP3	-0.38	-6.54	-0.33	2.21e-10	Total cholesterol levels;
LIHC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.08	-0.36	8.14e-12	Bipolar disorder;
LIHC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.75	9.16	0.44	5.03e-18	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.89	-0.3	9.27e-9	Total body bone mineral density;
LIHC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.35	0.52	1.44e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.86	-0.43	4.32e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1461503	0.934	rs7115651	chr11:122831882	C/T	cg25161029	chr11:122845972	NA	0.41	6.7	0.34	8.41e-11	Menarche (age at onset);
LIHC	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg06640241	chr16:89574553	SPG7	0.63	9.96	0.47	1.12e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.49	8.65	0.42	2.07e-16	Mean corpuscular volume;
LIHC	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg24203234	chr3:128598194	ACAD9	0.45	6.29	0.32	9.77e-10	IgG glycosylation;
LIHC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg02034447	chr16:89574710	SPG7	0.48	7.43	0.37	8.71e-13	Multiple myeloma (IgH translocation);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg22174410	chr3:42641766	NKTR	0.45	6.82	0.35	4.07e-11	Cognitive function;
LIHC	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg03934865	chr2:198174659	NA	-0.55	-8.65	-0.42	2.1e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.8	11.29	0.52	2.46e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg03854865	chr6:26224070	HIST1H3E	0.59	6.43	0.33	4.36e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.9	0.54	1.44e-27	Motion sickness;
LIHC	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12516959	chr21:47718080	NA	0.36	5.85	0.3	1.17e-8	Testicular germ cell tumor;
LIHC	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.49	-7.65	-0.38	2.11e-13	Blood pressure (smoking interaction);
LIHC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.59	-11.92	-0.54	1.29e-27	Coronary artery disease;
LIHC	cis	rs8084351	0.577	rs55808525	chr18:50612317	G/A	cg24270629	chr18:50823537	DCC	0.43	6.36	0.33	6.63e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.86	0.43	4.37e-17	Exhaled nitric oxide levels;
LIHC	cis	rs611744	0.658	rs2443775	chr8:109062481	A/G	cg21045802	chr8:109455806	TTC35	-0.42	-7.14	-0.36	5.75e-12	Dupuytren's disease;
LIHC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg00091569	chr3:40428383	ENTPD3	0.39	6.75	0.34	6.28e-11	Renal cell carcinoma;
LIHC	cis	rs2421770	0.530	rs2421764	chr11:35364578	A/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.59	-0.38	3.02e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.66	11.41	0.53	8.67e-26	Crohn's disease;
LIHC	cis	rs937213	0.573	rs3816900	chr15:40302243	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.36	-5.89	-0.3	9.23e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.43	0.41	1e-15	Birth weight;
LIHC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.87	11.49	0.53	4.51e-26	Heart rate;
LIHC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.28	0.41	2.85e-15	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.93	-19.31	-0.72	1.05e-56	Height;
LIHC	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg14768367	chr16:72042858	DHODH	0.65	6.16	0.32	2.04e-9	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.7	-7.28	-0.37	2.32e-12	Putamen volume;
LIHC	cis	rs61677309	1.000	rs1318166	chr11:118171058	A/G	cg06090739	chr11:118230722	UBE4A	0.36	6.68	0.34	9.52e-11	Lung cancer in ever smokers;
LIHC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg11953164	chr1:23521307	HTR1D	0.29	5.74	0.3	2.05e-8	Height;
LIHC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.38	-0.37	1.21e-12	Total body bone mineral density;
LIHC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.41	7.77	0.39	9.21e-14	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.46	9.13	0.44	5.9e-18	Schizophrenia;
LIHC	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.85	8.79	0.43	7.29e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs11088226	0.692	rs28709516	chr21:33890366	G/A	cg09050820	chr6:167586206	TCP10L2	0.44	6.49	0.33	3.03e-10	Gastritis;
LIHC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.45	-5.86	-0.3	1.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.96	15.98	0.65	2.63e-43	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs6489882	0.671	rs4767027	chr12:113359157	T/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs1555399	0.901	rs7140327	chr14:67983540	T/G	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.91	-0.3	8.43e-9	Parkinson's disease;
LIHC	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg18887096	chr2:219472410	PLCD4	0.39	6.69	0.34	9.34e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs13098911	0.540	rs34381952	chr3:45995748	T/C	cg21656520	chr2:210867290	RPE	0.85	6.08	0.31	3.19e-9	Celiac disease;
LIHC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.54	-0.38	4.25e-13	Bipolar disorder;
LIHC	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.4	0.45	7.96e-19	Coffee consumption (cups per day);
LIHC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg07061783	chr6:25882402	NA	-0.48	-6.65	-0.34	1.13e-10	Blood metabolite levels;
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.85	-15.78	-0.65	1.62e-42	Height;
LIHC	cis	rs11212260	0.655	rs77889759	chr11:107285328	A/G	cg25435332	chr11:107328525	CWF19L2	0.8	8.45	0.42	8.24e-16	IgG glycosylation;
LIHC	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.33	-5.92	-0.3	7.96e-9	Lewy body disease;
LIHC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.43	-6.88	-0.35	2.88e-11	Melanoma;
LIHC	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	6.49	0.33	3.05e-10	Blood protein levels;
LIHC	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.8	-0.3	1.51e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.63	-12.28	-0.55	5.54e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11449408	chr17:80856057	TBCD	0.51	6.3	0.32	8.97e-10	Systolic blood pressure;
LIHC	cis	rs1789	0.872	rs4333182	chr4:15684712	G/A	cg21123203	chr4:15471301	CC2D2A	-0.43	-6.53	-0.33	2.32e-10	Blood protein levels;
LIHC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.74	0.47	6.17e-20	Tonsillectomy;
LIHC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.91	-8.95	-0.44	2.36e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.13	0.31	2.39e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg12863693	chr15:85201151	NMB	0.48	6.75	0.34	6.2e-11	Schizophrenia;
LIHC	cis	rs11212260	0.655	rs11212239	chr11:107312175	G/A	cg25435332	chr11:107328525	CWF19L2	0.82	8.3	0.41	2.4e-15	IgG glycosylation;
LIHC	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg20697417	chr1:41786797	NA	0.33	6.38	0.33	5.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.0	0.51	2.62e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg01652190	chr22:50026171	C22orf34	-0.32	-7.47	-0.37	6.59e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-6.4	-0.33	5.12e-10	Schizophrenia;
LIHC	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.39	5.78	0.3	1.71e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.64	0.42	2.24e-16	Motion sickness;
LIHC	cis	rs17152411	0.652	rs1036676	chr10:126654184	A/G	cg07906193	chr10:126599966	NA	-0.3	-6.05	-0.31	3.89e-9	Height;
LIHC	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.96	10.52	0.49	1.28e-22	IgG glycosylation;
LIHC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.67	9.44	0.45	5.9e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs1568889	1.000	rs58502944	chr11:28060943	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.45	5.93	0.31	7.26e-9	Bipolar disorder;
LIHC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.34	-0.32	7.16e-10	Longevity;
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.63e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.69	-11.26	-0.52	3.22e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.34	8.25	0.41	3.46e-15	Immature fraction of reticulocytes;
LIHC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.52	8.2	0.41	5.07e-15	Total body bone mineral density;
LIHC	cis	rs3770081	0.793	rs75675321	chr2:86238994	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-8.42	-0.41	1.03e-15	Facial emotion recognition (sad faces);
LIHC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	1.0	19.0	0.72	1.78e-55	Breast cancer;
LIHC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.42	-6.1	-0.31	2.94e-9	Dental caries;
LIHC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.84	8.41	0.41	1.14e-15	Mean platelet volume;
LIHC	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03037974	chr15:76606532	NA	-0.65	-12.33	-0.55	3.7e-29	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20610891	chr12:52463737	C12orf44	0.43	6.1	0.31	2.88e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.45	6.02	0.31	4.58e-9	Pulmonary function decline;
LIHC	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.39	5.82	0.3	1.32e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11702148	0.552	rs9977929	chr21:34873716	C/G	cg14850771	chr21:34775459	IFNGR2	0.47	7.65	0.38	2.06e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.55	0.46	2.59e-19	Corneal astigmatism;
LIHC	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.54	-8.06	-0.4	1.25e-14	Body mass index;
LIHC	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg15412446	chr2:106886593	NA	0.56	5.74	0.3	2.05e-8	Facial morphology (factor 23);
LIHC	cis	rs3770081	1.000	rs58515922	chr2:86173037	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.73	-7.91	-0.39	3.72e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.35	-6.31	-0.32	8.41e-10	Aortic root size;
LIHC	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.43	8.37	0.41	1.53e-15	Testicular germ cell tumor;
LIHC	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.39e-9	Prostate cancer;
LIHC	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-6.01	-0.31	4.74e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4908768	0.906	rs55858268	chr1:8554696	C/T	cg20416874	chr1:8611966	RERE	0.57	8.8	0.43	6.93e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.49	7.42	0.37	9.37e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	6.85	0.35	3.47e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	7.54	0.38	4.36e-13	Obesity-related traits;
LIHC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.75	-0.39	1.07e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00495681	chr13:53174319	NA	0.38	6.18	0.32	1.82e-9	Lewy body disease;
LIHC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.37	5.8	0.3	1.5e-8	Breast cancer;
LIHC	cis	rs2257205	0.667	rs16943186	chr17:56801848	C/T	cg12560992	chr17:57184187	TRIM37	0.72	7.9	0.39	3.98e-14	Pancreatic cancer;
LIHC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.61	-8.6	-0.42	2.96e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11645453	chr3:52864694	ITIH4	0.22	6.12	0.31	2.56e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.27	16.64	0.67	5.64e-46	Diabetic kidney disease;
LIHC	cis	rs12744310	0.887	rs16828067	chr1:41783552	A/G	cg03962019	chr1:41807865	NA	0.4	6.37	0.33	6.06e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.64	-0.38	2.22e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg05361325	chr10:32636312	EPC1	-0.52	-6.36	-0.33	6.3e-10	Sexual dysfunction (female);
LIHC	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg08539965	chr1:21396338	EIF4G3	0.32	5.73	0.3	2.26e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg08528486	chr13:113648767	MCF2L	-0.42	-6.64	-0.34	1.27e-10	Systolic blood pressure;
LIHC	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg01864836	chr14:55583639	NA	-0.41	-7.84	-0.39	5.63e-14	Protein biomarker;
LIHC	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs4788570	0.584	rs6499529	chr16:71715378	C/T	cg06353428	chr16:71660113	MARVELD3	1.39	14.48	0.62	2.14e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21747090	chr2:27597821	SNX17	-0.42	-6.32	-0.32	8.03e-10	Total body bone mineral density;
LIHC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg03859395	chr2:55845619	SMEK2	0.93	16.66	0.67	4.63e-46	Metabolic syndrome;
LIHC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.85	-0.43	4.86e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs16974263	1.000	rs16974263	chr19:40913539	A/G	cg14150973	chr19:40950431	SERTAD3	-0.68	-7.28	-0.37	2.25e-12	Otitis media;Otitis media (chronic);Otitis media (recurrent);
LIHC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.44	5.86	0.3	1.07e-8	Obesity (extreme);
LIHC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg19645103	chr12:69753606	YEATS4	-0.46	-6.1	-0.31	2.8e-9	Response to diuretic therapy;
LIHC	trans	rs7395555	1.000	rs11232095	chr11:80062406	A/C	cg06295071	chr21:33766731	URB1	0.45	6.3	0.32	9.23e-10	Response to antipsychotic treatment;
LIHC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.56	6.74	0.34	6.71e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.42	5.89	0.3	9.4e-9	Aortic root size;
LIHC	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.22	0.41	4.3e-15	Lymphocyte counts;
LIHC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.39	6.29	0.32	9.77e-10	Red blood cell count;
LIHC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05665937	chr4:1216051	CTBP1	0.45	5.98	0.31	5.51e-9	Obesity-related traits;
LIHC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.77	-0.39	9.47e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg20607798	chr8:58055168	NA	0.73	8.6	0.42	2.99e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7106204	0.748	rs7101572	chr11:24213982	A/G	ch.11.24196551F	chr11:24239977	NA	0.76	10.16	0.48	2.29e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.18	30.61	0.86	5.36e-100	IgG glycosylation;
LIHC	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.66	10.07	0.48	4.8e-21	Body mass index;
LIHC	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.7	-15.87	-0.65	6.77e-43	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg01843034	chr6:37503916	NA	-0.35	-5.8	-0.3	1.48e-8	Cognitive performance;
LIHC	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.32	-0.32	8.35e-10	Calcium levels;
LIHC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs8108269	1.000	rs10403962	chr19:46160638	C/A	cg13320842	chr19:46175254	GIPR	0.43	8.04	0.4	1.48e-14	Type 2 diabetes;
LIHC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.37	6.62	0.34	1.38e-10	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.79	6.56	0.33	2.02e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.53	-8.68	-0.42	1.66e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1816752	0.819	rs6490917	chr13:24997257	G/T	cg22771759	chr13:24902376	NA	0.29	5.89	0.3	9.29e-9	Obesity-related traits;
LIHC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.45	-6.11	-0.31	2.67e-9	Longevity;
LIHC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg11828104	chr14:104152337	KLC1	0.38	5.75	0.3	1.97e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.62	-0.46	1.47e-19	Bipolar disorder;
LIHC	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.48	8.0	0.4	1.97e-14	Schizophrenia;
LIHC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.33	-0.49	5.74e-22	Schizophrenia;
LIHC	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.41	-7.16	-0.36	5.06e-12	Lung cancer;
LIHC	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.64	7.39	0.37	1.13e-12	Multiple myeloma (IgH translocation);
LIHC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg00280220	chr17:61926910	NA	0.42	6.74	0.34	6.67e-11	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19853194	chr18:9913725	VAPA	0.43	7.62	0.38	2.55e-13	Cognitive function;
LIHC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.59	6.77	0.34	5.61e-11	Menarche (age at onset);
LIHC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.44	0.49	2.57e-22	Obesity-related traits;
LIHC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg11294084	chr13:33002136	N4BP2L1	0.45	6.05	0.31	3.84e-9	Leprosy;
LIHC	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg11519256	chr10:5708881	ASB13	0.46	6.11	0.31	2.79e-9	Menopause (age at onset);
LIHC	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4407350	0.837	rs4823326	chr22:44908678	C/T	cg26276947	chr22:44892394	LDOC1L	0.35	6.76	0.34	5.92e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg00800038	chr16:89945340	TCF25	-0.59	-8.21	-0.41	4.6e-15	Skin colour saturation;
LIHC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.23	0.41	3.95e-15	Lymphocyte counts;
LIHC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.48	-8.0	-0.4	1.99e-14	Blood metabolite levels;
LIHC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.55	-8.83	-0.43	5.65e-17	Red cell distribution width;
LIHC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	1.06	12.04	0.55	4.5e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs3903072	0.652	rs501630	chr11:65637273	A/G	cg26695010	chr11:65641043	EFEMP2	0.5	6.81	0.35	4.49e-11	Breast cancer;
LIHC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.41	-0.45	7.59e-19	Schizophrenia;
LIHC	cis	rs611744	0.967	rs2600615	chr8:109201170	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.43	-8.58	-0.42	3.34e-16	Obesity-related traits;
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.4	-0.33	5.22e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.87	0.39	4.64e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg17631914	chr4:49514820	NA	-0.31	-6.04	-0.31	3.95e-9	Alcohol dependence;
LIHC	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.11	-0.44	6.87e-18	Colorectal cancer;
LIHC	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.64	9.9	0.47	1.8e-20	Lymphocyte counts;
LIHC	cis	rs7818688	0.745	rs11779282	chr8:95945487	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	6.26	0.32	1.17e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.26	-0.41	3.28e-15	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.72	9.25	0.45	2.53e-18	Gut microbiome composition (summer);
LIHC	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.88	-0.3	9.64e-9	Lewy body disease;
LIHC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.59	9.04	0.44	1.19e-17	Longevity;
LIHC	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg12863693	chr15:85201151	NMB	0.45	6.33	0.32	7.53e-10	Schizophrenia;
LIHC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg08687515	chr19:58661962	ZNF329	0.97	7.4	0.37	1.08e-12	Cholesterol, total;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.66	8.06	0.4	1.32e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.5	-0.38	5.41e-13	Initial pursuit acceleration;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg16103275	chr6:290800	DUSP22	0.51	6.76	0.34	5.86e-11	Menopause (age at onset);
LIHC	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.66	10.39	0.49	3.58e-22	Obesity-related traits;
LIHC	cis	rs17433710	0.516	rs6689396	chr1:162676698	C/T	cg01063088	chr1:162760584	HSD17B7	-0.48	-6.97	-0.35	1.62e-11	Dupuytren's disease;
LIHC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs903552	0.800	rs28470883	chr15:102000824	G/A	cg25677261	chr15:102009856	PCSK6	-0.45	-5.91	-0.3	8.49e-9	Diabetic kidney disease;
LIHC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg21559469	chr19:19431446	KIAA0892;SF4	0.42	5.9	0.3	8.62e-9	Tonsillectomy;
LIHC	cis	rs3099143	0.901	rs28405838	chr15:77226053	C/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.07	-0.36	8.97e-12	Recalcitrant atopic dermatitis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26163374	chr17:71188695	COG1	-0.44	-6.63	-0.34	1.33e-10	Pancreatic cancer;
LIHC	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.81	-0.3	1.41e-8	Systolic blood pressure;
LIHC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.42	7.75	0.39	1.07e-13	Migraine;
LIHC	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.76	7.89	0.39	4.24e-14	Chronic kidney disease;
LIHC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-7.84	-0.39	5.81e-14	Crohn's disease;
LIHC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.44	-8.34	-0.41	1.87e-15	Neurofibrillary tangles;
LIHC	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.55	0.5	1e-22	Hypertriglyceridemia;
LIHC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg15605315	chr1:45957053	TESK2	-0.44	-5.76	-0.3	1.84e-8	Platelet count;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.26	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg00277334	chr10:82204260	NA	-0.64	-7.14	-0.36	5.46e-12	Post bronchodilator FEV1;
LIHC	cis	rs904251	0.523	rs9349039	chr6:37480392	A/G	cg01843034	chr6:37503916	NA	-0.47	-7.99	-0.4	2.12e-14	Cognitive performance;
LIHC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.53	8.83	0.43	5.46e-17	Crohn's disease;
LIHC	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.51	7.79	0.39	8.28e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs244293	0.931	rs2058026	chr17:53204759	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs8081395	0.769	rs12449331	chr17:57883646	T/C	cg02344993	chr17:57696989	CLTC	-0.45	-7.42	-0.37	9.11e-13	White blood cell count;
LIHC	cis	rs539514	0.539	rs1408060	chr13:76289980	G/C	cg04757411	chr13:76259545	LMO7	-0.49	-8.56	-0.42	4.01e-16	Type 1 diabetes;
LIHC	cis	rs35883536	0.935	rs12409832	chr1:101107725	A/G	cg14515779	chr1:101123966	NA	-0.67	-13.22	-0.58	1.65e-32	Monocyte count;
LIHC	trans	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg22319618	chr22:45562946	NUP50	-0.64	-8.67	-0.42	1.74e-16	Breast cancer;
LIHC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.85	12.19	0.55	1.26e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs9309473	0.948	rs6719753	chr2:73749054	T/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.9	-0.35	2.48e-11	Metabolite levels;
LIHC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg18357645	chr12:58087776	OS9	-0.45	-6.91	-0.35	2.45e-11	Multiple sclerosis;
LIHC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg05771511	chr15:63340396	TPM1	-0.43	-6.3	-0.32	9.34e-10	Platelet count;
LIHC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg19920283	chr7:105172520	RINT1	0.64	5.83	0.3	1.27e-8	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.62	8.22	0.41	4.22e-15	Motion sickness;
LIHC	cis	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg16684958	chr7:75615977	POR	0.38	5.98	0.31	5.68e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg15282417	chr9:129245246	FAM125B	0.4	6.75	0.34	6.27e-11	Intraocular pressure;
LIHC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.59	-8.42	-0.41	1.08e-15	Initial pursuit acceleration;
LIHC	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.62	12.26	0.55	6.76e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.58	10.38	0.49	3.95e-22	Height;
LIHC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg03037974	chr15:76606532	NA	-0.64	-11.18	-0.52	6.01e-25	Blood metabolite levels;
LIHC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg11212589	chr17:38028394	ZPBP2	0.34	6.88	0.35	2.95e-11	Lymphocyte counts;
LIHC	cis	rs6788895	0.661	rs77431731	chr3:150489911	T/G	cg07663535	chr3:150480033	SIAH2	0.58	7.24	0.36	2.9e-12	Breast cancer;
LIHC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.07	0.51	1.56e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19500275	chr17:80737654	TBCD	0.4	5.74	0.3	2.12e-8	Glycated hemoglobin levels;
LIHC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.42	-0.33	4.6e-10	Height;
LIHC	cis	rs28489187	0.706	rs4949890	chr1:85830632	T/C	cg16011679	chr1:85725395	C1orf52	0.46	5.82	0.3	1.38e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.34	7.65	0.38	2.03e-13	Blood metabolite ratios;
LIHC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.26	0.55	7.01e-29	Cognitive test performance;
LIHC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.52	7.33	0.37	1.69e-12	Aortic root size;
LIHC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.68	9.9	0.47	1.73e-20	Menarche (age at onset);
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26076054	chr5:421317	AHRR	0.27	5.97	0.31	5.91e-9	Cystic fibrosis severity;
LIHC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.38	-0.86	1.02e-102	Myeloid white cell count;
LIHC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.67	-0.34	1.03e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs55702914	0.935	rs56116936	chr2:198219217	C/A	cg10820045	chr2:198174542	NA	0.38	5.74	0.3	2.06e-8	Major depression and alcohol dependence;
LIHC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	16.63	0.67	6.3e-46	Cognitive ability;
LIHC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg14779329	chr11:130786720	SNX19	0.45	7.14	0.36	5.75e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.67	8.36	0.41	1.62e-15	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20591167	chr15:99602178	NA	0.52	7.51	0.38	5.09e-13	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg18306943	chr3:40428807	ENTPD3	0.33	5.72	0.3	2.35e-8	Renal cell carcinoma;
LIHC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-6.02	-0.31	4.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.64	-9.14	-0.44	5.59e-18	Blood metabolite levels;
LIHC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.74	-13.84	-0.6	6.48e-35	Height;
LIHC	cis	rs55637647	0.515	rs7206699	chr16:88523815	A/G	cg06126698	chr16:88535609	ZFPM1	-0.36	-6.07	-0.31	3.41e-9	Testicular germ cell tumor;
LIHC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.41	0.33	4.79e-10	Cognitive test performance;
LIHC	cis	rs6750047	0.932	rs2116232	chr2:38268718	C/A	cg07380506	chr2:38303506	CYP1B1	0.49	6.03	0.31	4.32e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-9.37	-0.45	9.91e-19	Platelet distribution width;
LIHC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	1.0	19.19	0.72	3.22e-56	Breast cancer;
LIHC	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.64	-7.0	-0.35	1.38e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg17279839	chr7:150038598	RARRES2	0.39	7.93	0.39	3.22e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.45	-7.46	-0.37	7.15e-13	Blood protein levels;
LIHC	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.39	6.03	0.31	4.29e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg15704280	chr7:45808275	SEPT13	0.64	6.65	0.34	1.14e-10	Axial length;
LIHC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.82	0.43	5.8e-17	Motion sickness;
LIHC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg03146154	chr1:46216737	IPP	-0.36	-5.94	-0.31	7.06e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg10355455	chr12:6961187	USP5;CDCA3	-0.48	-6.31	-0.32	8.55e-10	DNA methylation (variation);
LIHC	cis	rs7707921	0.881	rs73134709	chr5:81268499	G/A	cg15871215	chr5:81402204	ATG10	-0.65	-6.45	-0.33	3.86e-10	Breast cancer;
LIHC	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.74	-0.34	6.85e-11	Schizophrenia;
LIHC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-9.97	-0.47	1.03e-20	Dental caries;
LIHC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg02993280	chr1:107599747	PRMT6	0.68	11.0	0.51	2.75e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.25	-0.32	1.22e-9	Total body bone mineral density;
LIHC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg10932868	chr11:921992	NA	-0.33	-6.1	-0.31	2.84e-9	Alzheimer's disease (late onset);
LIHC	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.52	-8.49	-0.42	6.62e-16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.55	-7.96	-0.4	2.53e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.28	11.42	0.53	8.49e-26	Uric acid levels;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.46	-7.07	-0.36	8.63e-12	Total body bone mineral density;
LIHC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.44	-12.1	-0.55	2.8e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.67	-14.13	-0.61	4.85e-36	Sense of smell;
LIHC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.5	7.3	0.37	2.01e-12	Obesity-related traits;
LIHC	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg03037974	chr15:76606532	NA	-0.63	-10.88	-0.51	7.1e-24	Blood metabolite levels;
LIHC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.36	-6.54	-0.33	2.31e-10	Immature fraction of reticulocytes;
LIHC	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.59	-8.7	-0.43	1.41e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.74	0.67	2.27e-46	Parkinson's disease;
LIHC	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg14593290	chr7:50529359	DDC	-0.48	-7.93	-0.39	3.18e-14	Malaria;
LIHC	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.7	-0.43	1.43e-16	Ulcerative colitis;
LIHC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.45	-7.61	-0.38	2.69e-13	Educational attainment;
LIHC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.38	0.77	5.56e-69	Chronic sinus infection;
LIHC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20135002	chr11:47629003	NA	-0.58	-10.11	-0.48	3.37e-21	Subjective well-being;
LIHC	trans	rs10411161	0.690	rs7252336	chr19:52389514	C/T	cg22319618	chr22:45562946	NUP50	-0.62	-8.49	-0.42	6.32e-16	Breast cancer;
LIHC	cis	rs903552	0.935	rs8041582	chr15:102005851	G/A	cg06707286	chr15:102010195	PCSK6	-0.44	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg18912006	chr12:123335444	HIP1R	-0.59	-6.82	-0.35	4.18e-11	Schizophrenia;
LIHC	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg24083324	chr1:214162604	PROX1	-0.56	-8.55	-0.42	4.16e-16	Schizophrenia;
LIHC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-9.1	-0.44	7.83e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07546262	chr12:54753490	NA	0.47	6.87	0.35	2.97e-11	Pancreatic cancer;
LIHC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	5.94	0.31	7.11e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.51	0.38	5.35e-13	Prudent dietary pattern;
LIHC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg15691649	chr6:25882328	NA	0.45	5.76	0.3	1.92e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3770081	1.000	rs3731819	chr2:86368641	C/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.86	-9.06	-0.44	9.92e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08677398	chr8:58056175	NA	0.41	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19386303	chr19:47104863	CALM3	0.6	7.85	0.39	5.26e-14	Lung function (FEV1/FVC);
LIHC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.62	10.79	0.5	1.46e-23	Colorectal cancer;
LIHC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg09182678	chr22:50328711	NA	-0.44	-6.24	-0.32	1.32e-9	Schizophrenia;
LIHC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.64	-11.16	-0.52	7.22e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg06219351	chr7:158114137	PTPRN2	-0.2	-5.72	-0.3	2.36e-8	Calcium levels;
LIHC	cis	rs74181299	0.533	rs3732096	chr2:65358083	C/T	cg05010058	chr2:65284262	CEP68	-0.37	-6.02	-0.31	4.38e-9	Pulse pressure;
LIHC	cis	rs7173389	0.530	rs11636535	chr15:73681648	T/C	cg01796676	chr15:73680284	NA	0.53	8.58	0.42	3.38e-16	Resting heart rate;
LIHC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.76	12.08	0.55	3.16e-28	Corneal astigmatism;
LIHC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.75	0.39	1.02e-13	Renal cell carcinoma;
LIHC	trans	rs800082	0.839	rs11714177	chr3:144312862	T/C	cg24215973	chr2:240111563	HDAC4	-0.49	-6.81	-0.35	4.51e-11	Smoking behavior;
LIHC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.53	0.49	1.25e-22	Colorectal cancer;
LIHC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.48	-6.09	-0.31	3.03e-9	Renal function-related traits (BUN);
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.61	-8.59	-0.42	3.1e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.81	12.96	0.57	1.6e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs7617773	0.962	rs6797587	chr3:48197614	A/G	cg11946769	chr3:48343235	NME6	-0.62	-8.03	-0.4	1.63e-14	Coronary artery disease;
LIHC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.95	-0.51	4e-24	Hemoglobin concentration;
LIHC	cis	rs9649465	0.967	rs12539091	chr7:123291314	C/T	cg03229431	chr7:123269106	ASB15	-0.39	-8.22	-0.41	4.29e-15	Migraine;
LIHC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.21	-0.48	1.6e-21	Blood metabolite levels;
LIHC	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.54	-12.96	-0.57	1.61e-31	White blood cell count (basophil);
LIHC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.27	-0.32	1.11e-9	Tonsillectomy;
LIHC	cis	rs7508	0.509	rs441606	chr8:17903046	C/T	cg01800426	chr8:17659068	MTUS1	0.36	5.72	0.3	2.27e-8	Atrial fibrillation;
LIHC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	9.24	0.45	2.64e-18	Platelet count;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.67	0.34	1.06e-10	Alzheimer's disease;
LIHC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.77	-0.57	8.31e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-6.4	-0.33	5.07e-10	Morning vs. evening chronotype;
LIHC	cis	rs986417	0.748	rs9989223	chr14:60942525	C/A	cg27398547	chr14:60952738	C14orf39	0.73	8.7	0.43	1.37e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg16479474	chr6:28041457	NA	0.45	6.51	0.33	2.6200000000000003e-10	Depression;
LIHC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg02290350	chr8:58132656	NA	0.38	7.9	0.39	3.9e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.73	0.34	7.11e-11	Lung cancer in ever smokers;
LIHC	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.66	-0.62	4.37e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.38	-0.37	1.21e-12	Response to antipsychotic treatment;
LIHC	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg09904177	chr6:26538194	HMGN4	0.36	5.82	0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.56	7.45	0.37	7.53e-13	Vitiligo;
LIHC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg04727924	chr7:799746	HEATR2	-0.59	-7.89	-0.39	4.22e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.83	-0.51	1.06e-23	Hemoglobin concentration;
LIHC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.55	6.82	0.35	4.09e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg23598604	chr1:99732472	LPPR4	-0.3	-6.27	-0.32	1.09e-9	Multiple myeloma;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07067085	chr12:120638762	RPLP0	0.36	6.21	0.32	1.51e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.82	0.35	4.04e-11	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.36	5.87	0.3	1.03e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.19	0.61	3.05e-36	Bipolar disorder;
LIHC	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.45	7.41	0.37	9.97e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs13067593	1.000	rs13087629	chr3:188568042	C/T	cg08898155	chr7:95026097	PON3	0.73	6.05	0.31	3.85e-9	Immune reponse to smallpox (secreted IFN-alpha);
LIHC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.39	-6.26	-0.32	1.17e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7192750	0.538	rs8054403	chr16:71990573	G/A	cg06353428	chr16:71660113	MARVELD3	0.8	9.06	0.44	1.02e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.55	-0.33	2.13e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg08210727	chr20:33865349	NA	0.51	5.89	0.3	9.43e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.83	-0.39	6.02e-14	Type 2 diabetes;
LIHC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.4	-0.33	5.01e-10	Monocyte percentage of white cells;
LIHC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.35	-5.77	-0.3	1.74e-8	IgG glycosylation;
LIHC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.48	6.44	0.33	3.97e-10	Major depressive disorder;
LIHC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.52e-9	Monobrow;
LIHC	cis	rs2191566	1.000	rs367499	chr19:44504981	G/A	cg20607764	chr19:44506953	ZNF230	0.42	6.68	0.34	9.74e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	10.01	0.48	7.14e-21	Coffee consumption (cups per day);
LIHC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.52	0.33	2.46e-10	Lung cancer in ever smokers;
LIHC	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg16275483	chr1:110013120	SYPL2	-0.48	-5.91	-0.3	8.48e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs611744	0.967	rs595266	chr8:109193784	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.47	-0.33	3.35e-10	Myeloid white cell count;
LIHC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.61	7.49	0.38	5.86e-13	Morning vs. evening chronotype;
LIHC	cis	rs2574704	0.816	rs2442777	chr3:11652331	G/A	cg15876825	chr3:11651881	VGLL4	-0.5	-8.05	-0.4	1.42e-14	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01676552	chr8:146156633	ZNF16	0.44	6.68	0.34	9.61e-11	Pancreatic cancer;
LIHC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	7.14	0.36	5.5e-12	Bone mineral density;
LIHC	cis	rs16828019	0.777	rs35496942	chr1:41488904	G/A	cg03387723	chr1:41708464	SCMH1	-0.4	-6.27	-0.32	1.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.69	6.9	0.35	2.49e-11	Exhaled nitric oxide output;
LIHC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.35	0.37	1.45e-12	Lung cancer;
LIHC	cis	rs12744310	1.000	rs12037657	chr1:41764175	C/T	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg15744005	chr10:104629667	AS3MT	0.36	7.82	0.39	6.59e-14	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.73	-0.3	2.15e-8	Uric acid levels;
LIHC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.5	-9.41	-0.45	7.45e-19	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.48	0.53	4.89e-26	Cognitive test performance;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.06	0.61	9.8e-36	Prudent dietary pattern;
LIHC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.25e-20	Asthma (sex interaction);
LIHC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg02640540	chr1:67518911	SLC35D1	0.43	5.9	0.3	8.77e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.95	-12.12	-0.55	2.25e-28	Body mass index;
LIHC	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.32	7.18	0.36	4.41e-12	Blood metabolite ratios;
LIHC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg15123519	chr2:136567270	LCT	0.45	9.36	0.45	1.07e-18	Mosquito bite size;
LIHC	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	0.92	22.66	0.77	4.62e-70	Multiple myeloma;
LIHC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10792665	0.517	rs7925208	chr11:82561979	G/A	cg24227371	chr11:82718527	RAB30	-0.26	-6.1	-0.31	2.9e-9	Obesity-related traits;
LIHC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.59	-8.77	-0.43	8.59e-17	Prudent dietary pattern;
LIHC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.66	-5.95	-0.31	6.53e-9	Menopause (age at onset);
LIHC	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg09855544	chr8:135498122	ZFAT	-0.51	-8.63	-0.42	2.38e-16	Hypertension (SNP x SNP interaction);
LIHC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.67	11.32	0.52	1.95e-25	Obesity-related traits;
LIHC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.8	-0.35	4.74e-11	Psoriasis;
LIHC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.88	16.13	0.66	6.19e-44	Coronary artery disease;
LIHC	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.33	6.72	0.34	7.76e-11	Sitting height ratio;
LIHC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.8	0.39	7.82e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg06212747	chr3:49208901	KLHDC8B	0.45	5.92	0.3	7.8e-9	Resting heart rate;
LIHC	cis	rs860295	0.812	rs4278368	chr1:155722557	G/A	cg02153340	chr1:155202674	NA	-0.35	-6.37	-0.33	6.2e-10	Body mass index;
LIHC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.66	6.97	0.35	1.65e-11	Exhaled nitric oxide output;
LIHC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	11.19	0.52	5.77e-25	Chronic sinus infection;
LIHC	cis	rs253664	0.796	rs799328	chr3:138082705	T/G	cg25188949	chr3:137893707	DBR1	-0.57	-5.77	-0.3	1.8e-8	Body mass index;
LIHC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.59	-8.37	-0.41	1.49e-15	Coronary artery disease;
LIHC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.97	-0.51	3.35e-24	Response to antipsychotic treatment;
LIHC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-12.33	-0.55	3.67e-29	Alzheimer's disease (late onset);
LIHC	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.6	6.34	0.32	7.17e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02133430	chr8:54573841	NA	0.45	6.54	0.33	2.22e-10	Immature fraction of reticulocytes;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.61	11.28	0.52	2.56e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.51	8.99	0.44	1.68e-17	Coronary artery disease;
LIHC	cis	rs55665837	0.701	rs10160597	chr11:14603992	G/A	cg16394018	chr11:14927549	NA	0.41	5.84	0.3	1.24e-8	Vitamin D levels;
LIHC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.53	6.1	0.31	2.93e-9	Alzheimer's disease;
LIHC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.48	7.3	0.37	1.99e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.35	7.14	0.36	5.5e-12	Alcohol dependence;
LIHC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.72	-11.35	-0.52	1.45e-25	Fibrinogen levels;
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.49	7.6	0.38	2.86e-13	Testicular germ cell tumor;
LIHC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23422044	chr7:1970798	MAD1L1	-0.47	-7.24	-0.36	2.91e-12	Neuroticism;
LIHC	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.7	8.69	0.43	1.55e-16	Post bronchodilator FEV1;
LIHC	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg27366882	chr3:133540807	NA	-0.42	-7.01	-0.35	1.25e-11	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.45	5.8	0.3	1.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-6.51	-0.33	2.64e-10	Morning vs. evening chronotype;
LIHC	cis	rs2574704	0.851	rs2437689	chr3:11660766	C/T	cg15876825	chr3:11651881	VGLL4	-0.49	-7.92	-0.39	3.36e-14	Body mass index;
LIHC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.49	-0.33	3.09e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Colorectal cancer;
LIHC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg10018233	chr7:150070692	REPIN1	0.49	7.97	0.4	2.35e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.7	-0.43	1.38e-16	Morning vs. evening chronotype;
LIHC	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.01	-0.31	4.68e-9	Tuberculosis;
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07424592	chr7:64974309	NA	-0.46	-6.9	-0.35	2.46e-11	Calcium levels;
LIHC	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.48	7.06	0.36	9.58e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg06533319	chr4:3265114	C4orf44	-0.34	-6.63	-0.34	1.3e-10	Parental longevity (mother's age at death);
LIHC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.39	-6.22	-0.32	1.45e-9	Lung cancer;
LIHC	cis	rs1789	0.903	rs4470622	chr4:15674175	T/G	cg16509355	chr4:15471240	CC2D2A	-0.45	-6.9	-0.35	2.55e-11	Blood protein levels;
LIHC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.08	-0.48	4.13e-21	Response to antipsychotic treatment;
LIHC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.32	-5.91	-0.3	8.32e-9	IgG glycosylation;
LIHC	cis	rs61677309	1.000	rs56357739	chr11:118158507	A/G	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.48	6.45	0.33	3.71e-10	Cognitive ability;
LIHC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.58	6.2	0.32	1.66e-9	Systemic lupus erythematosus;
LIHC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.97	-17.73	-0.69	2.51e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg26774971	chr6:158994407	TMEM181	0.42	6.17	0.32	1.98e-9	Longevity;
LIHC	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.29	6.1	0.31	2.81e-9	Menarche (age at onset);
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.94	-0.6	2.86e-35	Bipolar disorder and schizophrenia;
LIHC	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.58	9.55	0.46	2.57e-19	Corneal astigmatism;
LIHC	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	9.62	0.46	1.46e-19	Diisocyanate-induced asthma;
LIHC	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.42	-7.2	-0.36	3.85e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03076073	chr11:64009400	FKBP2	0.44	6.12	0.31	2.63e-9	Lung function (FEV1/FVC);
LIHC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.6	9.93	0.47	1.39e-20	Retinal vascular caliber;
LIHC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.52	-6.23	-0.32	1.4e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.54	0.42	4.46e-16	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg25801113	chr15:45476975	SHF	0.38	6.51	0.33	2.69e-10	Uric acid levels;
LIHC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.5	10.59	0.5	7.42e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3736485	0.903	rs7165887	chr15:51750846	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.35	-0.32	6.98e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.48	-6.82	-0.35	4.21e-11	Parkinson's disease;
LIHC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg07706471	chr12:123319906	HIP1R	-0.57	-7.62	-0.38	2.57e-13	Schizophrenia;
LIHC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.56	7.15	0.36	5.31e-12	Parkinson's disease;
LIHC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07305463	chr2:136567211	LCT	0.36	6.55	0.33	2.13e-10	Mosquito bite size;
LIHC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.98	-12.87	-0.57	3.4e-31	HIV-1 control;
LIHC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	6.04	0.31	4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.5	7.24	0.36	2.96e-12	Asthma;
LIHC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.66	-0.34	1.1e-10	IFN-related cytopenia;
LIHC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-1.19	-10.59	-0.5	7.59e-23	Breast cancer;
LIHC	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.47	-8.0	-0.4	1.97e-14	Obesity-related traits;
LIHC	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg00977110	chr5:151150581	G3BP1	0.53	6.87	0.35	3.04e-11	Preschool internalizing problems;
LIHC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg16822855	chr3:40428330	ENTPD3	-0.32	-5.86	-0.3	1.11e-8	Renal cell carcinoma;
LIHC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg21724239	chr8:58056113	NA	0.5	6.68	0.34	9.98e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.5	-9.24	-0.45	2.66e-18	Height;
LIHC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.11	-0.31	2.74e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg20607798	chr8:58055168	NA	0.45	5.98	0.31	5.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-6.58	-0.34	1.76e-10	Height;
LIHC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg11279151	chr3:101281821	RG9MTD1	0.53	7.92	0.39	3.35e-14	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg06781209	chr11:61594997	FADS2	-0.7	-6.52	-0.33	2.48e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.39	7.09	0.36	7.64e-12	Response to antipsychotic treatment;
LIHC	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.91	11.48	0.53	5.1e-26	Coronary artery disease;
LIHC	cis	rs2257205	0.667	rs4340382	chr17:56738919	G/A	cg12560992	chr17:57184187	TRIM37	0.71	7.79	0.39	8.05e-14	Pancreatic cancer;
LIHC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	1.11	12.64	0.56	2.57e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.05e-8	Menopause (age at onset);
LIHC	cis	rs9378688	1.000	rs9378686	chr6:2217173	G/A	cg12303981	chr6:2244766	GMDS	-0.5	-6.34	-0.32	7.23e-10	Caudate nucleus volume;
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.88	-15.33	-0.64	9.23e-41	Colorectal cancer;
LIHC	cis	rs2834188	0.924	rs2040107	chr21:34675962	C/G	cg14352951	chr21:34696688	IFNAR1	-0.43	-6.2	-0.32	1.58e-9	Narcolepsy;
LIHC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.5	-8.67	-0.42	1.81e-16	White blood cell count;
LIHC	cis	rs4908768	0.817	rs11577530	chr1:8743444	C/T	cg20416874	chr1:8611966	RERE	0.5	6.95	0.35	1.9e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.56	0.53	2.5e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.56	9.44	0.45	5.78e-19	Type 2 diabetes;
LIHC	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	12.04	0.55	4.47e-28	Body mass index (adult);
LIHC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.12	-0.31	2.6e-9	IgG glycosylation;
LIHC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.08	0.36	8.47e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.18	0.55	1.35e-28	Motion sickness;
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.29	-0.32	9.65e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg02702477	chr5:179499311	RNF130	0.75	10.45	0.49	2.26e-22	LDL cholesterol;
LIHC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.79	-0.39	8.12e-14	Schizophrenia;
LIHC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.49	8.58	0.42	3.43e-16	Mean corpuscular volume;
LIHC	cis	rs10508774	1.000	rs117557786	chr10:32930076	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs13177918	0.626	rs2748240	chr5:149828868	A/G	cg14059543	chr5:149831962	NA	-0.47	-7.34	-0.37	1.54e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-0.79	-8.65	-0.42	1.96e-16	Exhaled nitric oxide output;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.23	0.55	8.65e-29	Prudent dietary pattern;
LIHC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg02269571	chr22:50332266	NA	-0.65	-8.99	-0.44	1.69e-17	Schizophrenia;
LIHC	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.38	7.48	0.37	6.47e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-1.06	-12.1	-0.55	2.64e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.04	11.22	0.52	4.54e-25	Type 1 diabetes nephropathy;
LIHC	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg20435097	chr10:126320824	FAM53B	-0.41	-6.0	-0.31	4.96e-9	Cocaine dependence;
LIHC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg10381502	chr11:71823885	C11orf51	-1.0	-8.24	-0.41	3.84e-15	Severe influenza A (H1N1) infection;
LIHC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.33	6.6	0.34	1.54e-10	Renal cell carcinoma;
LIHC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-9.8	-0.47	3.79e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9324022	0.790	rs7156824	chr14:101171480	C/A	cg18089426	chr14:101175970	NA	0.48	5.83	0.3	1.26e-8	Plateletcrit;
LIHC	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg01858014	chr14:56050164	KTN1	-0.62	-5.89	-0.3	9.46e-9	Putamen volume;
LIHC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.52	-8.15	-0.4	7.01e-15	Fibrinogen levels;
LIHC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.77	11.98	0.54	7.27e-28	Corneal astigmatism;
LIHC	cis	rs9596863	1.000	rs9591538	chr13:54407573	A/C	ch.13.53330881F	chr13:54432880	NA	0.44	6.0	0.31	4.99e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-9.1	-0.44	7.53e-18	Parkinson's disease;
LIHC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.48	7.36	0.37	1.34e-12	Mean platelet volume;
LIHC	cis	rs2386661	0.695	rs7093321	chr10:5662135	C/A	cg17085576	chr10:5658249	NA	-0.36	-6.44	-0.33	4.05e-10	Breast cancer;
LIHC	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.38	8.77	0.43	8.53e-17	Educational attainment (years of education);
LIHC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs3770081	1.000	rs73947314	chr2:86273116	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-9.04	-0.44	1.23e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	8.56	0.42	3.98e-16	Response to antipsychotic treatment;
LIHC	cis	rs17094222	0.812	rs11190657	chr10:102442189	T/C	cg26540559	chr10:102447443	NA	0.33	6.19	0.32	1.76e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg21659725	chr3:3221576	CRBN	0.64	6.45	0.33	3.73e-10	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.4	6.33	0.32	7.78e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.9	0.3	8.79e-9	Response to antipsychotic treatment;
LIHC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.51	8.83	0.43	5.73e-17	Obesity-related traits;
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.53	-0.33	2.42e-10	Total body bone mineral density;
LIHC	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.97e-9	Pulmonary function;
LIHC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02985541	chr2:219472218	PLCD4	0.44	8.39	0.41	1.28e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-6.05	-0.31	3.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg20295408	chr7:1910781	MAD1L1	0.4	5.79	0.3	1.59e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.45	-9.6	-0.46	1.77e-19	Abdominal aortic aneurysm;
LIHC	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.54	-8.46	-0.42	7.9e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.04	-0.4	1.46e-14	Response to antipsychotic treatment;
LIHC	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.67	0.34	1.03e-10	Mean corpuscular volume;
LIHC	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.84	13.95	0.6	2.57e-35	Breast cancer;
LIHC	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.41	-7.3	-0.37	2e-12	Crohn's disease;
LIHC	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.54	9.5	0.46	3.9e-19	Systemic lupus erythematosus;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg24335600	chr1:241682994	FH	-0.41	-6.54	-0.33	2.3e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg08824895	chr13:115047677	UPF3A	0.48	6.96	0.35	1.74e-11	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.63	8.22	0.41	4.32e-15	Motion sickness;
LIHC	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.45	-6.32	-0.32	8.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-5.91	-0.3	8.23e-9	Diastolic blood pressure;
LIHC	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.53	0.33	2.38e-10	Axial length;
LIHC	cis	rs1355223	0.872	rs913204	chr11:34706224	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	5.98	0.31	5.7e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg12046867	chr14:103022105	NA	-0.57	-8.43	-0.41	9.98e-16	Platelet count;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.63	-9.6	-0.46	1.81e-19	Renal cell carcinoma;
LIHC	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.41	-7.16	-0.36	5.06e-12	Coronary artery disease;
LIHC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	7.45	0.37	7.56e-13	Cleft plate (environmental tobacco smoke interaction);
LIHC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg14779329	chr11:130786720	SNX19	0.4	6.03	0.31	4.35e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.65	8.25	0.41	3.37e-15	Morning vs. evening chronotype;
LIHC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.27	-16.34	-0.66	9.2e-45	Diabetic kidney disease;
LIHC	cis	rs903552	1.000	rs12908079	chr15:102003820	C/A	cg00659931	chr15:102010125	PCSK6	-0.45	-6.31	-0.32	8.74e-10	Diabetic kidney disease;
LIHC	cis	rs25645	0.502	rs1563103	chr17:38111740	G/A	cg17467752	chr17:38218738	THRA	0.4	5.81	0.3	1.42e-8	Myeloid white cell count;
LIHC	cis	rs922107	0.846	rs424350	chr1:90006544	G/A	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.37	-0.37	1.28e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-11.39	-0.52	1.06e-25	Mean corpuscular volume;
LIHC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg10374813	chr17:38183790	MED24;SNORD124	-0.31	-5.71	-0.3	2.41e-8	White blood cell count;
LIHC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.48	6.89	0.35	2.7e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.71	10.33	0.49	5.95e-22	Menarche (age at onset);
LIHC	cis	rs9816226	0.591	rs57912727	chr3:185804583	A/C	cg00760338	chr3:185826511	ETV5	-0.71	-6.0	-0.31	5.07e-9	Obesity;Body mass index;
LIHC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.26	-17.06	-0.68	1.18e-47	Diabetic kidney disease;
LIHC	cis	rs2274273	0.967	rs11622740	chr14:55617844	G/A	cg01864836	chr14:55583639	NA	-0.36	-6.12	-0.31	2.62e-9	Protein biomarker;
LIHC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg25894440	chr7:65020034	NA	0.56	6.39	0.33	5.55e-10	Diabetic kidney disease;
LIHC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-8.53	-0.42	4.81e-16	Bipolar disorder;
LIHC	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.6	0.5	6.65e-23	Hypertriglyceridemia;
LIHC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.58	0.34	1.78e-10	Platelet count;
LIHC	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.95	-0.31	6.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.69	11.4	0.52	9.71e-26	Menopause (age at onset);
LIHC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.97	12.66	0.56	2.12e-30	Bladder cancer;
LIHC	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.37	-8.6	-0.42	2.88e-16	Blood protein levels;
LIHC	cis	rs2016586	0.719	rs5999971	chr22:36115349	C/T	cg26342177	chr22:36113512	APOL5	-0.39	-6.55	-0.33	2.13e-10	Body mass index;
LIHC	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.05e-11	Ileal carcinoids;
LIHC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.54	7.18	0.36	4.46e-12	Body mass index;
LIHC	trans	rs7142002	1.000	rs59070929	chr14:102361737	G/A	cg18984499	chr17:8286166	RPL26	0.65	6.19	0.32	1.77e-9	Autism;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00014996	chr18:158348	USP14	0.41	6.25	0.32	1.23e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.78	-0.3	1.65e-8	Pulse pressure;
LIHC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-6.61	-0.34	1.5e-10	Initial pursuit acceleration;
LIHC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg13974409	chr11:65292307	SCYL1	-0.37	-6.01	-0.31	4.77e-9	Bone mineral density;
LIHC	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.58	0.34	1.78e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg06115741	chr20:33292138	TP53INP2	0.53	7.29	0.37	2.16e-12	Coronary artery disease;
LIHC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg02269571	chr22:50332266	NA	-0.61	-8.69	-0.43	1.54e-16	Schizophrenia;
LIHC	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.31	5.97	0.31	5.98e-9	DNA methylation (variation);
LIHC	cis	rs600806	0.742	rs9429519	chr1:110017105	A/G	cg23091122	chr1:110024289	SYPL2	0.42	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs8067354	0.574	rs9789060	chr17:58018570	A/G	cg02344993	chr17:57696989	CLTC	0.65	10.29	0.49	8.48e-22	Hemoglobin concentration;
LIHC	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.61	-8.62	-0.42	2.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.91	18.37	0.7	6.1e-53	Bone mineral density;
LIHC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg16684958	chr7:75615977	POR	-0.5	-8.27	-0.41	2.91e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg13647721	chr17:30228624	UTP6	0.71	6.76	0.34	6.02e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.86	0.35	3.19e-11	Morning vs. evening chronotype;
LIHC	cis	rs2637266	0.783	rs860165	chr10:78492807	A/G	cg18941641	chr10:78392320	NA	0.27	5.81	0.3	1.44e-8	Pulmonary function;
LIHC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.54	-0.46	2.77e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.75	0.47	5.75e-20	Morning vs. evening chronotype;
LIHC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg09222892	chr1:25734099	RHCE	-0.45	-8.38	-0.41	1.43e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.8	11.29	0.52	2.46e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs17106184	0.551	rs35166191	chr1:50843153	C/T	cg07174182	chr1:51127561	FAF1	-0.44	-5.89	-0.3	9.22e-9	Type 2 diabetes;
LIHC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.06	-17.37	-0.68	7.03e-49	Dilated cardiomyopathy;
LIHC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.5	7.03	0.36	1.12e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.4	-5.77	-0.3	1.82e-8	Alzheimer's disease (late onset);
LIHC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.81	-0.35	4.42e-11	Alcohol dependence;
LIHC	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg20129853	chr10:51489980	NA	0.42	9.15	0.44	5.11e-18	Prostate-specific antigen levels;
LIHC	trans	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg17712092	chr4:129076599	LARP1B	-0.69	-10.51	-0.49	1.46e-22	Eosinophil percentage of white cells;
LIHC	trans	rs1864585	0.520	rs17720365	chr8:10679499	C/G	cg26278703	chr11:58910052	FAM111A	-0.68	-6.71	-0.34	8.04e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg07451762	chr16:28383216	NA	0.4	7.24	0.36	3e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg10820045	chr2:198174542	NA	0.48	7.27	0.37	2.45e-12	Dermatomyositis;
LIHC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg03721293	chr16:90014378	DEF8	0.42	7.0	0.35	1.33e-11	Skin colour saturation;
LIHC	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.34	-0.41	1.88e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12954385	chr21:46686990	POFUT2	0.37	6.29	0.32	9.6e-10	Longevity;
LIHC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.29	0.52	2.54e-25	Coronary artery disease;
LIHC	cis	rs9612	0.718	rs346532	chr19:44248878	A/G	cg08581076	chr19:44259116	C19orf61	0.59	7.73	0.39	1.23e-13	Exhaled nitric oxide output;
LIHC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	6.62	0.34	1.36e-10	Coronary artery disease;
LIHC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.44	-8.34	-0.41	1.87e-15	Neurofibrillary tangles;
LIHC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.41	0.49	3.2e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.85	-0.35	3.5e-11	Bipolar disorder;
LIHC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	5.9	0.3	8.86e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	11.58	0.53	2.22e-26	Coronary artery disease;
LIHC	cis	rs11098699	0.821	rs6830258	chr4:124230345	A/G	cg09941581	chr4:124220074	SPATA5	-0.33	-6.54	-0.33	2.2e-10	Mosquito bite size;
LIHC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.71	-7.22	-0.36	3.38e-12	Putamen volume;
LIHC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.81	13.85	0.6	6.16e-35	Parkinson's disease;
LIHC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg14906510	chr12:7781169	NA	0.44	6.81	0.35	4.42e-11	HDL cholesterol levels;
LIHC	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.19	-0.32	1.76e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg03037974	chr15:76606532	NA	-0.6	-9.94	-0.47	1.25e-20	Blood metabolite levels;
LIHC	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg25783544	chr11:47291846	MADD	0.41	5.95	0.31	6.8e-9	HDL cholesterol;
LIHC	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.86	-0.54	2.14e-27	Coffee consumption (cups per day);
LIHC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg09137382	chr11:130731461	NA	0.4	6.04	0.31	3.92e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.43	5.85	0.3	1.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs4407350	0.756	rs131168	chr22:44896225	T/C	cg04154583	chr22:44889756	LDOC1L	0.29	5.88	0.3	9.97e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.68	0.65	4.03e-42	Electrocardiographic conduction measures;
LIHC	cis	rs12744310	0.887	rs12046670	chr1:41809312	T/G	cg03387723	chr1:41708464	SCMH1	-0.32	-5.86	-0.3	1.12e-8	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.4	6.79	0.34	4.93e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs903552	0.935	rs8041582	chr15:102005851	G/A	cg00659931	chr15:102010125	PCSK6	-0.46	-6.2	-0.32	1.63e-9	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.2	-0.52	5.02e-25	Hemoglobin concentration;
LIHC	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.73	-11.1	-0.51	1.15e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.36	6.64	0.34	1.23e-10	IgG glycosylation;
LIHC	cis	rs57502260	1.000	rs56312530	chr11:68219415	G/A	cg16797656	chr11:68205561	LRP5	0.59	8.03	0.4	1.57e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	9.58	0.46	2.1e-19	Platelet count;
LIHC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.4	12.21	0.55	1.06e-28	Uric acid levels;
LIHC	cis	rs9596863	0.898	rs9568920	chr13:54352810	A/T	ch.13.53330881F	chr13:54432880	NA	0.45	6.04	0.31	3.93e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.51	7.13	0.36	6.07e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs4908768	0.657	rs3938719	chr1:8804997	A/G	cg20416874	chr1:8611966	RERE	0.42	6.15	0.32	2.19e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.93	-0.51	4.66e-24	Mean corpuscular volume;
LIHC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg24955955	chr5:415729	AHRR	0.32	6.32	0.32	8.14e-10	Cystic fibrosis severity;
LIHC	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.83	16.18	0.66	3.82e-44	Testicular germ cell tumor;
LIHC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.43	7.81	0.39	7.2e-14	IgG glycosylation;
LIHC	cis	rs9888615	1.000	rs12887631	chr14:53373399	A/T	cg00686598	chr14:53173677	PSMC6	-0.5	-6.14	-0.32	2.23e-9	Systolic blood pressure;
LIHC	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.48	7.01	0.35	1.32e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.76	-11.76	-0.54	4.89e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg24579218	chr15:68104479	NA	-0.34	-5.83	-0.3	1.27e-8	Restless legs syndrome;
LIHC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.94	0.31	6.88e-9	Resting heart rate;
LIHC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.51	7.97	0.4	2.36e-14	Lymphocyte counts;
LIHC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg26149184	chr10:133730230	NA	0.46	7.24	0.36	2.97e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg00061764	chr3:67564432	SUCLG2	0.38	6.25	0.32	1.24e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg20634798	chr1:152595351	LCE3A	-0.29	-5.95	-0.31	6.64e-9	Psoriasis;
LIHC	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.16	0.32	2.02e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.79	-0.34	4.84e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10097731	0.901	rs10464890	chr8:82042727	A/G	cg25230327	chr8:82042993	NA	-0.59	-8.01	-0.4	1.81e-14	Serum total protein level;
LIHC	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.27	16.79	0.67	1.38e-46	Diabetic kidney disease;
LIHC	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-5.87	-0.3	1.04e-8	Neuroticism;
LIHC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.52	-0.38	4.91e-13	Psoriasis;
LIHC	cis	rs611744	0.901	rs2348801	chr8:109167337	C/T	cg21045802	chr8:109455806	TTC35	0.5	8.61	0.42	2.65e-16	Dupuytren's disease;
LIHC	cis	rs332507	0.789	rs10755078	chr3:124378412	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.06	0.36	9.47e-12	Plateletcrit;
LIHC	cis	rs12744310	1.000	rs12723893	chr1:41757040	C/T	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.82e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-11.98	-0.54	7.21e-28	Total cholesterol levels;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg13152130	chr6:118910203	C6orf204	-0.65	-7.47	-0.37	6.87e-13	Diastolic blood pressure;
LIHC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.31	0.45	1.56e-18	Electroencephalogram traits;
LIHC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.49	-0.33	3e-10	Mean corpuscular volume;
LIHC	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.39	-6.53	-0.33	2.35e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg16479474	chr6:28041457	NA	0.45	6.34	0.32	7.43e-10	Depression;
LIHC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.82	-9.81	-0.47	3.56e-20	Mean platelet volume;
LIHC	cis	rs3018712	0.532	rs4930588	chr11:68415235	A/C	cg16797656	chr11:68205561	LRP5	0.45	5.88	0.3	9.65e-9	Total body bone mineral density;
LIHC	cis	rs7116495	1.000	rs2298457	chr11:71734211	T/C	cg26138937	chr11:71823887	C11orf51	-0.83	-8.45	-0.42	8.57e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.11	0.36	6.86e-12	Renal cell carcinoma;
LIHC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.69	-0.5	3.38e-23	Hemoglobin concentration;
LIHC	cis	rs10508774	1.000	rs35574674	chr10:32816382	C/T	cg01819863	chr10:32635814	EPC1	0.65	5.95	0.31	6.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05296608	chr10:134537282	INPP5A	0.42	6.04	0.31	4.04e-9	Bilirubin levels;
LIHC	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg15704280	chr7:45808275	SEPT13	-0.45	-6.81	-0.35	4.52e-11	HDL cholesterol;
LIHC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg04310649	chr10:35416472	CREM	-0.43	-5.84	-0.3	1.19e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-7.23	-0.36	3.22e-12	Inflammatory bowel disease;
LIHC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.5	6.58	0.34	1.82e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.59	-0.38	3.11e-13	Morning vs. evening chronotype;
LIHC	cis	rs7520050	0.933	rs9787208	chr1:46314616	C/A	cg03146154	chr1:46216737	IPP	-0.37	-5.92	-0.3	8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.37	0.41	1.51e-15	Motion sickness;
LIHC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08219700	chr8:58056026	NA	0.38	5.78	0.3	1.64e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.06	-0.36	9.28e-12	Myeloid white cell count;
LIHC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	10.51	0.49	1.43e-22	Platelet count;
LIHC	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.75	-6.14	-0.32	2.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.34	0.55	3.52e-29	Alzheimer's disease;
LIHC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg19635926	chr16:89946313	TCF25	0.5	6.48	0.33	3.24e-10	Skin colour saturation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05975845	chr20:47538463	ARFGEF2	0.46	6.04	0.31	4.08e-9	Lung function (FEV1/FVC);
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.81	-0.35	4.43e-11	Total body bone mineral density;
LIHC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.31	-7.67	-0.38	1.79e-13	Schizophrenia;
LIHC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.86	-17.21	-0.68	2.94e-48	Height;
LIHC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg02297831	chr4:17616191	MED28	0.46	7.08	0.36	7.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs918629	0.798	rs6556894	chr5:95289542	G/A	cg10483112	chr5:95245456	ELL2	-0.37	-6.44	-0.33	4.02e-10	IgG glycosylation;
LIHC	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.67	7.29	0.37	2.24e-12	Exhaled nitric oxide output;
LIHC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg24296786	chr1:45957014	TESK2	-0.44	-6.35	-0.32	6.73e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	0.75	9.04	0.44	1.2e-17	Gut microbiota (bacterial taxa);
LIHC	trans	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	Androgen levels;
LIHC	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg01864836	chr14:55583639	NA	-0.4	-7.46	-0.37	7.2e-13	Protein biomarker;
LIHC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.7	0.46	7.98e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7534824	0.625	rs58234233	chr1:101510440	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	7.59	0.38	2.98e-13	Refractive astigmatism;
LIHC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.97	12.66	0.56	2.12e-30	Heart rate;
LIHC	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg18375707	chr11:64034959	PLCB3	-0.68	-9.75	-0.47	5.78e-20	Body mass index;
LIHC	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.67e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg14515779	chr1:101123966	NA	0.47	6.73	0.34	7.27e-11	Monocyte count;
LIHC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.53	-6.41	-0.33	4.78e-10	Menarche (age at onset);
LIHC	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-7.91	-0.39	3.51e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.9	14.94	0.63	3.5e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs11212737	0.818	rs2624136	chr11:108513720	A/G	cg22776369	chr11:108536276	DDX10	0.37	6.19	0.32	1.69e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	1.02	21.31	0.76	1.01e-64	Height;
LIHC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	9.31	0.45	1.65e-18	Lung cancer in ever smokers;
LIHC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.02	0.31	4.53e-9	Tonsillectomy;
LIHC	cis	rs34234989	1	rs34234989	chr20:33774533	CA/C	cg08999081	chr20:33150536	PIGU	0.39	5.71	0.3	2.42e-8	Thrombosis;
LIHC	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.5	-6.32	-0.32	8.24e-10	Heschl's gyrus morphology;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18000306	chr6:288505	NA	0.34	6.19	0.32	1.73e-9	Menopause (age at onset);
LIHC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.25	6.81	0.35	4.29e-11	Cardiovascular disease risk factors;
LIHC	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg14146966	chr2:61757674	XPO1	0.45	7.9	0.39	3.94e-14	Tuberculosis;
LIHC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.08	-0.36	8.41e-12	Personality dimensions;
LIHC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.93	-0.81	1e-82	Myeloid white cell count;
LIHC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg17980119	chr2:219472607	PLCD4	0.35	5.98	0.31	5.7e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-8.57	-0.42	3.53e-16	Platelet distribution width;
LIHC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.54	0.38	4.39e-13	Lung cancer;
LIHC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.43	7.06	0.36	9.38e-12	Response to temozolomide;
LIHC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.41	6.83	0.35	4.01e-11	Red blood cell count;
LIHC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.91	-0.54	1.33e-27	Urate levels in overweight individuals;
LIHC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	6.67	0.34	1.04e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg04155231	chr12:9217510	LOC144571	0.31	5.86	0.3	1.1e-8	Sjögren's syndrome;
LIHC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.69	-14.61	-0.62	6.62e-38	Brugada syndrome;
LIHC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.57	-0.33	1.9e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg13877915	chr19:58951672	ZNF132	0.63	10.57	0.5	8.54e-23	Uric acid clearance;
LIHC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg03146154	chr1:46216737	IPP	-0.39	-6.45	-0.33	3.78e-10	Red blood cell count;Reticulocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01519350	chr3:137906342	ARMC8	0.48	6.94	0.35	1.95e-11	Pancreatic cancer;
LIHC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.67	-9.8	-0.47	3.94e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4716602	0.596	rs13221649	chr7:156160793	G/A	cg16983916	chr7:156159713	NA	-0.32	-5.71	-0.3	2.43e-8	Anti-saccade response;
LIHC	cis	rs11671005	0.610	rs3794966	chr19:59068996	C/T	cg25952890	chr19:58913133	NA	0.68	6.92	0.35	2.18e-11	Mean platelet volume;
LIHC	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.53	7.7	0.38	1.47e-13	Schizophrenia;
LIHC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.57	-9.86	-0.47	2.41e-20	Height;
LIHC	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.3	-7.48	-0.38	6.12e-13	Intelligence;
LIHC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.71	13.42	0.59	2.76e-33	Coronary artery disease;
LIHC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg19539972	chr4:7069911	GRPEL1	0.4	6.26	0.32	1.15e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	trans	rs72960926	0.744	rs72950563	chr6:74912043	G/C	cg07247405	chr1:2484626	LOC115110	0.53	6.13	0.31	2.4e-9	Metabolite levels (MHPG);
LIHC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.88	-15.34	-0.64	8.84e-41	Colorectal cancer;
LIHC	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.63	7.64	0.38	2.19e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.94	20.44	0.74	3.16e-61	Blood protein levels;
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	7.68	0.38	1.64e-13	HDL cholesterol;
LIHC	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.35	-8.07	-0.4	1.22e-14	Educational attainment (years of education);
LIHC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.66	0.34	1.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.56e-8	Bladder cancer;
LIHC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg23172400	chr8:95962367	TP53INP1	-0.29	-6.36	-0.33	6.35e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.4	6.74	0.34	6.57e-11	Blood metabolite levels;
LIHC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.83	0.3	1.26e-8	Schizophrenia;
LIHC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg03647239	chr10:116582469	FAM160B1	0.47	6.86	0.35	3.3e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03442064	chr6:41515050	FOXP4	0.41	6.87	0.35	3.03e-11	Cognitive function;
LIHC	trans	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg17675199	chr6:35436792	RPL10A	-0.44	-9.14	-0.44	5.82e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.83	14.96	0.63	2.69e-39	Diastolic blood pressure;
LIHC	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.75	0.3	1.99e-8	Bladder cancer;
LIHC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.1	-0.36	7.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg02023728	chr11:77925099	USP35	-0.34	-5.86	-0.3	1.09e-8	Alzheimer's disease (survival time);
LIHC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg23791538	chr6:167370224	RNASET2	-0.61	-10.49	-0.49	1.61e-22	Primary biliary cholangitis;
LIHC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg18357645	chr12:58087776	OS9	-0.44	-7.03	-0.36	1.12e-11	Multiple sclerosis;
LIHC	cis	rs17094222	0.853	rs10883521	chr10:102439754	A/T	cg26540559	chr10:102447443	NA	0.32	6.0	0.31	5.05e-9	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.25	0.32	1.25e-9	Bipolar disorder;
LIHC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.38	6.03	0.31	4.34e-9	Menopause (age at onset);
LIHC	cis	rs12744310	1.000	rs12038894	chr1:41760207	C/T	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg13409248	chr3:40428643	ENTPD3	0.5	8.43	0.41	9.5e-16	Renal cell carcinoma;
LIHC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.72	-14.01	-0.6	1.45e-35	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.35	-6.36	-0.33	6.36e-10	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-9.87	-0.47	2.23e-20	Platelet count;
LIHC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12379764	chr21:47803548	PCNT	-0.55	-7.9	-0.39	3.9e-14	Testicular germ cell tumor;
LIHC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.9	19.48	0.73	2.13e-57	Blood protein levels;
LIHC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg03983715	chr16:68378420	PRMT7	-0.52	-6.28	-0.32	9.99e-10	Schizophrenia;
LIHC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.82	0.35	4.05e-11	Ileal carcinoids;
LIHC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.49	-6.85	-0.35	3.46e-11	Calcium levels;
LIHC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.63	-0.5	5.24e-23	Coronary artery disease;
LIHC	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg16275483	chr1:110013120	SYPL2	-0.47	-5.92	-0.3	7.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	0.59	11.29	0.52	2.5e-25	Fat distribution (HIV);
LIHC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.73	10.7	0.5	2.98e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.49	0.46	4.04e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.76	12.98	0.57	1.3e-31	Aortic root size;
LIHC	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.5	-7.39	-0.37	1.11e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.4	-5.71	-0.3	2.44e-8	Longevity;
LIHC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.63	-8.48	-0.42	6.94e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg22771759	chr13:24902376	NA	0.32	6.68	0.34	9.65e-11	Obesity-related traits;
LIHC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.59	-0.38	3.1e-13	Chronic sinus infection;
LIHC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.45	-6.21	-0.32	1.5e-9	Initial pursuit acceleration;
LIHC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs17854409	0.764	rs73613593	chr20:61471582	T/C	cg05147244	chr20:61493195	TCFL5	1.26	10.15	0.48	2.51e-21	Obesity-related traits;
LIHC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.88	-0.3	9.82e-9	Colorectal cancer;
LIHC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg15848620	chr12:58087721	OS9	-0.58	-7.96	-0.4	2.5e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	1.04	20.48	0.74	2.12e-61	Breast cancer;
LIHC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.52	9.16	0.44	5.03e-18	Total body bone mineral density;
LIHC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.38	-5.89	-0.3	9.39e-9	Uric acid levels;
LIHC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg25801113	chr15:45476975	SHF	0.39	6.74	0.34	6.62e-11	Uric acid levels;
LIHC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.63	9.01	0.44	1.53e-17	Monocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15877295	chr7:138915876	UBN2	0.47	6.86	0.35	3.3e-11	Pancreatic cancer;
LIHC	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.56	9.24	0.45	2.75e-18	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.42	8.16	0.4	6.35e-15	Cognitive function;
LIHC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.95	17.04	0.68	1.37e-47	Parkinson's disease;
LIHC	cis	rs832187	0.665	rs7627690	chr3:63900477	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.47	-6.65	-0.34	1.18e-10	Schizophrenia;
LIHC	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-7.53	-0.38	4.45e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19524238	chr7:2802976	GNA12	-0.4	-5.8	-0.3	1.52e-8	Height;
LIHC	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.59	6.44	0.33	4.14e-10	Hip geometry;
LIHC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	6.07e-9	Menopause (age at onset);
LIHC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	7.28	0.37	2.29e-12	Cognitive test performance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03773226	chr17:37353657	CACNB1	0.46	6.97	0.35	1.69e-11	Pancreatic cancer;
LIHC	cis	rs6840360	0.904	rs6813516	chr4:152594407	C/G	cg22705602	chr4:152727874	NA	-0.31	-6.42	-0.33	4.58e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6141769	0.542	rs28542091	chr20:31301402	T/C	cg13636640	chr20:31349939	DNMT3B	-0.32	-5.74	-0.3	2.09e-8	Subjective well-being;
LIHC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.92	-15.98	-0.65	2.59e-43	Tonsillectomy;
LIHC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-10.72	-0.5	2.64e-23	Obesity-related traits;
LIHC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.73	-15.06	-0.63	1.09e-39	Body mass index;
LIHC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.66	10.88	0.51	7.11e-24	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg12292205	chr6:26970375	C6orf41	0.37	6.38	0.33	5.73e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.77	-11.63	-0.53	1.49e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.42	-6.89	-0.35	2.75e-11	IgG glycosylation;
LIHC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Urate levels;
LIHC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.12e-11	Schizophrenia;
LIHC	cis	rs988712	0.622	rs7103411	chr11:27700125	C/T	cg18117895	chr11:27722066	BDNF	-0.51	-7.16	-0.36	5.03e-12	Obesity;
LIHC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-6.3	-0.32	9.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.4	-5.79	-0.3	1.57e-8	Longevity;
LIHC	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg07596299	chr11:71824057	C11orf51	-0.75	-5.72	-0.3	2.3e-8	Severe influenza A (H1N1) infection;
LIHC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.69	0.38	1.61e-13	Schizophrenia;
LIHC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg13409248	chr3:40428643	ENTPD3	0.42	7.16	0.36	5.01e-12	Renal cell carcinoma;
LIHC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	11.47	0.53	5.46e-26	Alzheimer's disease (late onset);
LIHC	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.62	12.24	0.55	8.48e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-5.98	-0.31	5.69e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg07061783	chr6:25882402	NA	0.43	5.76	0.3	1.85e-8	Blood metabolite levels;
LIHC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg25356066	chr3:128598488	ACAD9	0.53	7.34	0.37	1.61e-12	IgG glycosylation;
LIHC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg09137382	chr11:130731461	NA	0.42	6.25	0.32	1.19e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.78	-0.34	5.24e-11	Atopic dermatitis;
LIHC	cis	rs7432375	0.804	rs6764567	chr3:136425514	A/C	cg21827317	chr3:136751795	NA	-0.44	-5.79	-0.3	1.58e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.76	-0.43	9.08e-17	Total cholesterol levels;
LIHC	cis	rs7091068	0.522	rs10882323	chr10:95483280	T/C	cg20715218	chr10:95462985	C10orf4	0.52	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LIHC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.49	6.78	0.34	5.36e-11	Aortic root size;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25722142	chr6:139695762	CITED2	0.41	6.16	0.32	2e-9	Pancreatic cancer;
LIHC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.58	9.93	0.47	1.34e-20	Colorectal cancer;
LIHC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.2e-13	Heart rate;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg12798992	chr6:167411361	FGFR1OP	-0.4	-6.02	-0.31	4.41e-9	Primary biliary cholangitis;
LIHC	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02829992	chr2:10710499	NA	0.39	6.01	0.31	4.74e-9	Prostate cancer;
LIHC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.45	-0.37	7.66e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.8	-15.08	-0.63	9.28e-40	Height;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01375172	chr16:23464338	COG7	0.42	6.14	0.32	2.27e-9	Pancreatic cancer;
LIHC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.44	0.33	3.94e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	1.13	10.59	0.5	7.67e-23	Gut microbiota (bacterial taxa);
LIHC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.54	8.4	0.41	1.24e-15	Dental caries;
LIHC	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.43	-6.61	-0.34	1.5e-10	Life satisfaction;
LIHC	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.06	22.49	0.77	2.21e-69	Schizophrenia;
LIHC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.51	7.76	0.39	9.71e-14	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.02	0.58	9.8e-32	Prudent dietary pattern;
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg04709771	chr16:646395	RAB40C	0.47	8.33	0.41	1.99e-15	Height;
LIHC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.45	6.06	0.31	3.63e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.71	9.43	0.45	6.34e-19	Body mass index;
LIHC	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.17	0.48	2.13e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.46	0.46	5.08e-19	Mean platelet volume;
LIHC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.14	-0.32	2.23e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg26211634	chr5:139558579	C5orf32	0.39	5.95	0.31	6.71e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg04610667	chr7:75704037	NA	-0.33	-5.96	-0.31	6.43e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.33	-0.37	1.65e-12	Tuberculosis;
LIHC	cis	rs35883536	1.000	rs1832121	chr1:101159476	A/G	cg14515779	chr1:101123966	NA	-0.66	-12.57	-0.56	4.64e-30	Monocyte count;
LIHC	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg10820045	chr2:198174542	NA	0.48	7.49	0.38	5.73e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.62	-9.34	-0.45	1.24e-18	Parkinson's disease;
LIHC	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.11	-0.31	2.72e-9	Schizophrenia;
LIHC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-0.68	-8.0	-0.4	1.93e-14	Corneal curvature;
LIHC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg19338460	chr6:170058176	WDR27	-0.38	-5.74	-0.3	2.13e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg03013999	chr17:37608204	MED1	-0.36	-6.06	-0.31	3.53e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.03	0.31	4.17e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02290350	chr8:58132656	NA	0.49	10.56	0.5	9.22e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg19875535	chr5:140030758	IK	-0.34	-5.77	-0.3	1.79e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.07	0.36	8.65e-12	Hemoglobin concentration;
LIHC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.53	8.75	0.43	9.9e-17	IgG glycosylation;
LIHC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.82	14.82	0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.67	12.86	0.57	3.75e-31	Rheumatoid arthritis;
LIHC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.56	-8.92	-0.43	2.97e-17	Menarche (age at onset);
LIHC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-9.99	-0.48	8.46e-21	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03670153	chr3:184079754	CLCN2;POLR2H	0.39	6.15	0.32	2.17e-9	Cognitive function;
LIHC	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.51	8.12	0.4	8.3e-15	Facial emotion recognition (sad faces);
LIHC	trans	rs875971	0.638	rs801205	chr7:66022144	C/A	cg26939375	chr7:64535504	NA	-0.43	-6.96	-0.35	1.72e-11	Aortic root size;
LIHC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13647721	chr17:30228624	UTP6	0.8	7.74	0.39	1.17e-13	Hip circumference adjusted for BMI;
LIHC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs16958440	0.581	rs12386097	chr18:44673268	G/A	cg17192377	chr18:44677553	HDHD2	0.51	6.25	0.32	1.24e-9	Sitting height ratio;
LIHC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.21	-0.36	3.56e-12	Aortic root size;
LIHC	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.48	8.44	0.42	9.23e-16	Neurofibrillary tangles;
LIHC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.73	-0.34	7.12e-11	Personality dimensions;
LIHC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.23e-8	Waist circumference;Weight;
LIHC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.45	6.03	0.31	4.26e-9	Life satisfaction;
LIHC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.4	-0.33	5.12e-10	Schizophrenia;
LIHC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.53	-7.79	-0.39	8.33e-14	Total body bone mineral density;
LIHC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.55	9.25	0.45	2.56e-18	Bipolar disorder;
LIHC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.78	12.43	0.56	1.53e-29	Resting heart rate;
LIHC	cis	rs17002069	0.891	rs12158399	chr22:41048941	G/A	cg14879645	chr22:41048474	NA	0.4	5.91	0.3	8.13e-9	Schizophrenia;
LIHC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.95	-18.25	-0.7	1.86e-52	Breast cancer;
LIHC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.94	-0.47	1.26e-20	Crohn's disease;
LIHC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.62	9.57	0.46	2.3e-19	Height;
LIHC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.11	0.58	4.43e-32	Prudent dietary pattern;
LIHC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg10578777	chr12:7781093	NA	0.46	8.33	0.41	1.95e-15	HDL cholesterol levels;
LIHC	cis	rs507080	0.769	rs745663	chr11:118529595	A/G	cg04173919	chr11:118528438	PHLDB1	0.32	5.81	0.3	1.42e-8	Serum metabolite levels;
LIHC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg17279839	chr7:150038598	RARRES2	0.4	8.06	0.4	1.33e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg02503808	chr4:7069936	GRPEL1	0.49	7.43	0.37	8.87e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.52	7.73	0.39	1.2e-13	High light scatter reticulocyte count;
LIHC	cis	rs10276381	0.579	rs11520706	chr7:28202748	C/T	cg23620719	chr7:28220237	JAZF1	-0.6	-6.67	-0.34	1.01e-10	Crohn's disease;
LIHC	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.47	-6.0	-0.31	5.01e-9	Corneal structure;
LIHC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.44	-6.35	-0.32	6.89e-10	Height;
LIHC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.86	-16.11	-0.66	7.56e-44	Height;
LIHC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.46	-7.57	-0.38	3.47e-13	Alzheimer's disease (late onset);
LIHC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg14067834	chr17:29058358	SUZ12P	0.57	6.04	0.31	3.99e-9	Body mass index;
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	21.04	0.75	1.25e-63	Height;
LIHC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.17	0.55	1.5e-28	Cognitive test performance;
LIHC	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.52	8.34	0.41	1.89e-15	Corneal astigmatism;
LIHC	cis	rs611744	0.934	rs1668178	chr8:109191700	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.53	7.61	0.38	2.61e-13	Longevity;
LIHC	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06002616	chr8:101225028	SPAG1	0.34	5.82	0.3	1.37e-8	Atrioventricular conduction;
LIHC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-7.72	-0.39	1.27e-13	Gut microbiome composition (summer);
LIHC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.93	14.22	0.61	2.14e-36	Sudden cardiac arrest;
LIHC	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.94	-0.39	2.98e-14	Coronary artery disease;
LIHC	trans	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg09045935	chr12:6379348	NA	0.91	7.86	0.39	4.94e-14	Blood metabolite levels;
LIHC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.53	8.41	0.41	1.15e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02034447	chr16:89574710	SPG7	-0.47	-7.24	-0.36	2.96e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.54	-9.93	-0.47	1.42e-20	Plateletcrit;Platelet count;
LIHC	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.77	-0.39	9.38e-14	Capecitabine sensitivity;
LIHC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.82	0.43	5.8e-17	Motion sickness;
LIHC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.39	-11.8	-0.54	3.55e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	10.88	0.51	7.18e-24	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs728616	0.510	rs7074356	chr10:82191334	C/T	cg20463533	chr10:134705855	NA	0.29	6.22	0.32	1.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.22	-0.55	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.86	15.92	0.65	4.19e-43	Menopause (age at onset);
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02359409	chr6:42947317	PEX6	-0.48	-6.67	-0.34	1.02e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg16479474	chr6:28041457	NA	0.46	6.66	0.34	1.1e-10	Depression;
LIHC	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.65	-10.46	-0.49	2.1e-22	Rheumatoid arthritis;
LIHC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.51	-9.1	-0.44	7.52e-18	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	trans	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg12083535	chr12:100814114	SLC17A8	-0.32	-6.45	-0.33	3.72e-10	Schizophrenia;
LIHC	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.07	23.56	0.79	1.39e-73	Platelet distribution width;
LIHC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg07636037	chr3:49044803	WDR6	-0.81	-8.39	-0.41	1.31e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.58	9.57	0.46	2.24e-19	Total body bone mineral density;
LIHC	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.61	-9.18	-0.44	4.22e-18	Schizophrenia;
LIHC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	8.27	0.41	2.93e-15	Platelet count;
LIHC	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.63	10.49	0.49	1.68e-22	Waist circumference;Body mass index;
LIHC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.84e-22	Hemoglobin concentration;
LIHC	cis	rs2108622	0.727	rs12610189	chr19:15978641	T/G	cg13772218	chr19:15982569	NA	0.37	7.84	0.39	5.87e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.84	-0.43	5.27e-17	Gut microbiome composition (summer);
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.02e-17	Arsenic metabolism;
LIHC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.57	9.01	0.44	1.52e-17	Monocyte count;
LIHC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.31	7.2	0.36	3.95e-12	Crohn's disease;
LIHC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.44	5.97	0.31	6.07e-9	Lymphocyte counts;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18678067	chr19:52674854	ZNF836	0.47	6.28	0.32	9.99e-10	Pancreatic cancer;
LIHC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.93	15.16	0.63	4.39e-40	Metabolic syndrome;
LIHC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.29	-0.32	9.92e-10	Total body bone mineral density;
LIHC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg17980119	chr2:219472607	PLCD4	0.35	5.94	0.31	7.14e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.5	16.55	0.67	1.29e-45	Eosinophil percentage of granulocytes;
LIHC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg20140201	chr2:241835670	C2orf54	-0.46	-6.25	-0.32	1.22e-9	Urinary metabolites;
LIHC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg26913058	chr16:419975	MRPL28	-0.58	-8.47	-0.42	7.23e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg20140201	chr2:241835670	C2orf54	0.46	6.2	0.32	1.63e-9	Urinary metabolites;
LIHC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg16479474	chr6:28041457	NA	0.46	6.44	0.33	4.11e-10	Depression;
LIHC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg11342453	chr6:26196699	NA	0.53	5.79	0.3	1.63e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg06466757	chr4:1255808	NA	0.34	5.79	0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.58	8.65	0.42	1.99e-16	HDL cholesterol;
LIHC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.88	0.3	9.55e-9	Alzheimer's disease;
LIHC	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.36	8.24	0.41	3.64e-15	Educational attainment (years of education);
LIHC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.8	-14.77	-0.62	1.64e-38	Refractive error;
LIHC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg18016565	chr1:150552671	MCL1	0.51	9.63	0.46	1.46e-19	Melanoma;
LIHC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.85	-0.3	1.16e-8	Systemic lupus erythematosus;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.92	-0.3	7.75e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg03874509	chr1:107600012	PRMT6	-0.77	-12.17	-0.55	1.47e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg03785755	chr6:26196794	NA	0.51	5.97	0.31	5.8e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.46	-6.4	-0.33	5.18e-10	Height;
LIHC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg18867708	chr6:26865862	GUSBL1	0.51	7.78	0.39	8.55e-14	Schizophrenia;
LIHC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.8	-0.67	1.3e-46	Systemic lupus erythematosus;
LIHC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg14393609	chr7:65229607	NA	0.37	5.77	0.3	1.82e-8	Aortic root size;
LIHC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.53	-9.69	-0.46	8.56e-20	Systemic lupus erythematosus;
LIHC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.42	-7.78	-0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.75	-13.37	-0.59	4.42e-33	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15312298	chr8:127570908	FAM84B	0.44	7.78	0.39	8.75e-14	Cognitive function;
LIHC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg10932868	chr11:921992	NA	-0.33	-6.23	-0.32	1.4e-9	Alzheimer's disease (late onset);
LIHC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg16586182	chr3:47516702	SCAP	0.61	11.81	0.54	3.13e-27	Colorectal cancer;
LIHC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.68	11.98	0.54	7.54e-28	Colorectal cancer;
LIHC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg25894440	chr7:65020034	NA	-0.51	-5.85	-0.3	1.13e-8	Diabetic kidney disease;
LIHC	cis	rs1144333	0.655	rs931506	chr1:76401349	T/C	cg03433033	chr1:76189801	ACADM	0.53	7.59	0.38	2.97e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.69	-0.46	8.94e-20	Response to antipsychotic treatment;
LIHC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.45	-5.92	-0.3	7.75e-9	Vitiligo;
LIHC	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.56	-6.8	-0.35	4.55e-11	Breast cancer;
LIHC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	8.24	0.41	3.7e-15	Blood metabolite levels;
LIHC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg15744005	chr10:104629667	AS3MT	-0.39	-8.88	-0.43	3.78e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.52	7.61	0.38	2.64e-13	Response to diuretic therapy;
LIHC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.72	-11.73	-0.54	6.15e-27	Body mass index;
LIHC	trans	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg17830980	chr10:43048298	ZNF37B	0.4	7.22	0.36	3.42e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg16275483	chr1:110013120	SYPL2	-0.47	-5.92	-0.3	7.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.72	11.81	0.54	3.07e-27	Anterior chamber depth;
LIHC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	trans	rs4819388	0.915	rs4818892	chr21:45650085	A/G	cg17383793	chr5:52405638	MOCS2	0.4	6.3	0.32	9.2e-10	Celiac disease;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg14257396	chr1:107603778	NA	-0.37	-6.15	-0.32	2.17e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	1.04e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.9	0.3	8.52e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.31	5.74	0.3	2.14e-8	Aortic root size;
LIHC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg13409248	chr3:40428643	ENTPD3	-0.51	-8.62	-0.42	2.46e-16	Renal cell carcinoma;
LIHC	cis	rs11605275	1.000	rs16937347	chr11:20026717	A/G	cg14835545	chr11:20032148	NAV2	-0.64	-6.23	-0.32	1.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.85	8.64	0.42	2.25e-16	Platelet count;
LIHC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs7487075	0.619	rs10748450	chr12:46857102	C/T	cg23829395	chr12:46796953	NA	0.33	5.9	0.3	8.55e-9	Itch intensity from mosquito bite;
LIHC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.14	0.31	2.35e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9322817	0.691	rs2499664	chr6:105301484	C/G	cg02098413	chr6:105308735	HACE1	0.43	8.14	0.4	7.69e-15	Thyroid stimulating hormone;
LIHC	cis	rs8084351	0.577	rs8088666	chr18:50648093	A/G	cg24270629	chr18:50823537	DCC	0.44	6.49	0.33	3.03e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.44	6.22	0.32	1.44e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg03146154	chr1:46216737	IPP	-0.36	-5.94	-0.31	7.06e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg19302996	chr17:73780495	UNK	-0.52	-6.15	-0.32	2.22e-9	Psoriasis;
LIHC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	15.97	0.65	2.6900000000000002e-43	Nonalcoholic fatty liver disease;
LIHC	trans	rs2270927	0.510	rs4566771	chr5:75576522	C/T	cg13563193	chr19:33072644	PDCD5	0.99	9.43	0.45	6.56e-19	Mean corpuscular volume;
LIHC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-6.37	-0.33	6e-10	Bipolar disorder;
LIHC	cis	rs12644436	0.628	rs4693889	chr4:88783723	C/T	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.36	-0.37	1.35e-12	Tonsillectomy;
LIHC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.55	-9.35	-0.45	1.16e-18	Reticulocyte count;
LIHC	trans	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.01	0.4	1.76e-14	Corneal astigmatism;
LIHC	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.66	13.85	0.6	6.03e-35	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg18944383	chr4:111397179	ENPEP	0.36	8.31	0.41	2.33e-15	Height;
LIHC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.25	0.55	7.41e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-9.94	-0.47	1.27e-20	Mean corpuscular volume;
LIHC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	6.01	0.31	4.66e-9	Schizophrenia;
LIHC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg07959070	chr22:50026188	C22orf34	-0.29	-7.03	-0.36	1.15e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg02993280	chr1:107599747	PRMT6	0.66	10.55	0.5	1.03e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.76	0.43	9.13e-17	Height;
LIHC	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg02344993	chr17:57696989	CLTC	0.53	8.5	0.42	5.82e-16	Hemoglobin concentration;
LIHC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg06640241	chr16:89574553	SPG7	0.65	10.35	0.49	5.15e-22	Multiple myeloma (IgH translocation);
LIHC	trans	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	6.29	0.32	9.7e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg21395723	chr22:39101663	GTPBP1	0.37	6.02	0.31	4.4e-9	Menopause (age at onset);
LIHC	cis	rs7523273	0.526	rs12132968	chr1:207884292	T/C	cg22525895	chr1:207977042	MIR29B2	0.49	7.14	0.36	5.67e-12	Schizophrenia;
LIHC	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg17135325	chr3:160939158	NMD3	0.52	7.21	0.36	3.67e-12	Parkinson's disease;
LIHC	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.31	-5.89	-0.3	9.45e-9	Asthma;
LIHC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.73	12.14	0.55	1.95e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-6.89	-0.35	2.61e-11	Height;
LIHC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.82e-13	Bipolar disorder;
LIHC	cis	rs12220238	0.915	rs61045754	chr10:76153125	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.76	0.3	1.85e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg00815214	chr21:47717953	NA	-0.36	-5.86	-0.3	1.06e-8	Testicular germ cell tumor;
LIHC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.39	0.41	1.27e-15	Menarche (age at onset);
LIHC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg17764715	chr19:33622953	WDR88	0.55	7.4	0.37	1.04e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9473924	0.580	rs67092917	chr6:50815333	G/T	cg14470998	chr6:50812995	TFAP2B	0.93	10.62	0.5	6.08e-23	Body mass index;
LIHC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.39	-0.33	5.51e-10	Total body bone mineral density;
LIHC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.44	7.0	0.35	1.32e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.59	5.91	0.3	8.07e-9	Lymphocyte counts;
LIHC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg18944383	chr4:111397179	ENPEP	0.26	6.38	0.33	5.7e-10	Coronary artery disease;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg18705916	chr5:1800069	MRPL36;NDUFS6	-0.4	-6.07	-0.31	3.45e-9	Alopecia areata;
LIHC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.73	-7.0	-0.35	1.33e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs55702914	0.905	rs787988	chr2:198200802	C/T	cg03934865	chr2:198174659	NA	-0.4	-5.87	-0.3	1.06e-8	Major depression and alcohol dependence;
LIHC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.02	-0.31	4.44e-9	Total body bone mineral density;
LIHC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.46	5.95	0.31	6.73e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.33	8.15	0.4	6.75e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.5	9.41	0.45	7.56e-19	Atrioventricular conduction;
LIHC	trans	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg10756647	chr7:56101905	PSPH	0.44	6.46	0.33	3.71e-10	Calcium levels;
LIHC	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.46e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.64	-5.77	-0.3	1.73e-8	Menopause (age at onset);
LIHC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	13.4	0.59	3.23e-33	Primary sclerosing cholangitis;
LIHC	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.69	9.37	0.45	1.04e-18	Calcium levels;
LIHC	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.65	8.1	0.4	9.57e-15	Crohn's disease;
LIHC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	5.83	0.3	1.31e-8	Resting heart rate;
LIHC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.67	10.26	0.49	1e-21	Height;
LIHC	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg07541023	chr7:19748670	TWISTNB	0.39	5.94	0.31	6.98e-9	Thyroid stimulating hormone;
LIHC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.26	-14.23	-0.61	2.02e-36	Diabetic kidney disease;
LIHC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.59	8.57	0.42	3.53e-16	Height;
LIHC	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.47	5.97	0.31	5.8e-9	Plateletcrit;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.65	8.32	0.41	2.05e-15	Initial pursuit acceleration;
LIHC	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.79	0.39	7.83e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.47	0.77	2.52e-69	Chronic sinus infection;
LIHC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.97	-0.31	5.97e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg25173405	chr17:45401733	C17orf57	-0.55	-6.82	-0.35	4.06e-11	Coronary artery disease;
LIHC	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-7.84	-0.39	5.72e-14	Extraversion;
LIHC	trans	rs1555543	0.538	rs7416802	chr1:96909292	G/C	cg10631902	chr5:14652156	NA	-0.32	-6.59	-0.34	1.64e-10	Body mass index;
LIHC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs526821	0.532	rs578067	chr11:55313690	T/G	cg04317927	chr11:55418816	OR4S2	0.47	9.04	0.44	1.17e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg26939375	chr7:64535504	NA	0.47	7.17	0.36	4.64e-12	Aortic root size;
LIHC	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg05197062	chr11:11642011	GALNTL4	0.43	6.12	0.31	2.57e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.44	-7.2	-0.36	3.95e-12	Platelet distribution width;
LIHC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.44	7.93	0.39	3.23e-14	IgG glycosylation;
LIHC	cis	rs7523273	0.554	rs2761434	chr1:207917499	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.99	-0.4	2.14e-14	Schizophrenia;
LIHC	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg09003973	chr2:102972529	NA	1.14	9.45	0.45	5.65e-19	Gut microbiota (bacterial taxa);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08151832	chr16:66835414	CCDC79	-0.41	-6.27	-0.32	1.09e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.05e-10	Metabolite levels (Pyroglutamine);
LIHC	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.73	7.55	0.38	4.04e-13	Bipolar disorder;
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.79	13.28	0.58	9.66e-33	Bipolar disorder and schizophrenia;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.6	10.25	0.48	1.08e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg19006947	chr11:64034861	PLCB3	-0.46	-7.21	-0.36	3.51e-12	Body mass index;
LIHC	cis	rs10097731	0.901	rs10464932	chr8:82042901	T/G	cg25230327	chr8:82042993	NA	-0.59	-8.01	-0.4	1.81e-14	Serum total protein level;
LIHC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.75	-0.39	1.05e-13	HDL cholesterol;
LIHC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.29	0.45	1.82e-18	Longevity;Endometriosis;
LIHC	cis	rs2074193	0.826	rs215347	chr12:47734161	A/G	cg02516419	chr12:47771422	NA	0.42	6.6	0.34	1.59e-10	Migraine with aura;
LIHC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.64	-0.38	2.18e-13	Body mass index;
LIHC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.68	-10.4	-0.49	3.33e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.41	-6.5	-0.33	2.81e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.64	9.23	0.45	2.97e-18	Schizophrenia;
LIHC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.72	-0.3	2.3e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.48	7.59	0.38	3.02e-13	Systemic lupus erythematosus;
LIHC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg10578777	chr12:7781093	NA	-0.48	-8.55	-0.42	4.06e-16	HDL cholesterol levels;
LIHC	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg25344623	chr2:136566232	LCT	0.33	5.78	0.3	1.65e-8	Corneal structure;
LIHC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	trans	rs3743102	0.591	rs10520565	chr15:83255074	C/T	cg01542190	chr22:50604728	NA	-0.52	-6.51	-0.33	2.64e-10	Colorectal adenoma (advanced);
LIHC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.16	-0.44	4.85e-18	Schizophrenia;
LIHC	cis	rs10792665	0.670	rs3763813	chr11:82613021	A/T	cg24227371	chr11:82718527	RAB30	-0.27	-6.35	-0.32	6.83e-10	Obesity-related traits;
LIHC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.09	-0.63	8.65e-40	Alzheimer's disease (late onset);
LIHC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.61	7.77	0.39	8.98e-14	Initial pursuit acceleration;
LIHC	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-0.79	-8.42	-0.41	1.03e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1144333	0.850	rs1251274	chr1:76288587	T/C	cg22875332	chr1:76189707	ACADM	-0.42	-6.72	-0.34	7.62e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg27432699	chr2:27873401	GPN1	-0.54	-7.8	-0.39	7.54e-14	Menopause (age at onset);
LIHC	cis	rs2257205	0.667	rs8071942	chr17:56778271	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-6.56	-0.33	2e-10	Pancreatic cancer;
LIHC	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.34	-6.32	-0.32	8.03e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06710121	chr8:12235606	FAM66A	-0.36	-6.34	-0.32	7.25e-10	Neuroticism;
LIHC	trans	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.37	-6.32	-0.32	8.22e-10	White matter hyperintensity burden;
LIHC	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22168489	chr12:122356033	WDR66	-0.36	-5.94	-0.31	7.04e-9	Mean corpuscular volume;
LIHC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-8.81	-0.43	6.58e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.91	-15.04	-0.63	1.37e-39	Gut microbiota (bacterial taxa);
LIHC	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.8	11.35	0.52	1.51e-25	Response to hepatitis C treatment;
LIHC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.05	0.36	1.01e-11	Morning vs. evening chronotype;
LIHC	trans	rs12692119	0.764	rs61730218	chr2:127656857	G/A	cg13995918	chr5:1280305	TERT	0.43	6.05	0.31	3.89e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg12365402	chr11:9010492	NRIP3	0.34	8.66	0.42	1.93e-16	Hemoglobin concentration;
LIHC	cis	rs7078219	0.505	rs4129132	chr10:101284637	T/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.06	-0.31	3.63e-9	Dental caries;
LIHC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.12	17.71	0.69	2.8e-50	Gut microbiome composition (summer);
LIHC	trans	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.5	0.33	2.88e-10	Endometrial cancer;
LIHC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.24	6.15	0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.49	8.09	0.4	1.06e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.55	-9.13	-0.44	6.31e-18	Blood metabolite levels;
LIHC	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg10820045	chr2:198174542	NA	-0.47	-7.04	-0.36	1.03e-11	Dermatomyositis;
LIHC	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.33	7.01	0.35	1.27e-11	Ulcerative colitis;
LIHC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.58	-8.39	-0.41	1.27e-15	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.59	9.34	0.45	1.28e-18	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.58	8.52	0.42	5.21e-16	Platelet count;
LIHC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.71	12.31	0.55	4.27e-29	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.08	-0.31	3.29e-9	Colorectal cancer;
LIHC	cis	rs1144333	0.655	rs75578876	chr1:76395586	A/C	cg03433033	chr1:76189801	ACADM	0.53	7.55	0.38	4.02e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg24101359	chr6:42928495	GNMT	0.44	5.99	0.31	5.46e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.83	9.93	0.47	1.39e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.58	-7.37	-0.37	1.31e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg13271783	chr10:134563150	INPP5A	-0.5	-6.51	-0.33	2.7e-10	Migraine;
LIHC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg25024717	chr12:54324583	NA	-0.32	-6.18	-0.32	1.8e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.37	6.91	0.35	2.32e-11	Metabolite levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09271671	chr16:70432453	ST3GAL2	0.4	6.04	0.31	4.01e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08219700	chr8:58056026	NA	0.43	5.88	0.3	1e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs6500650	0.557	rs3743845	chr16:5040717	C/T	cg26446499	chr5:77253555	NA	-0.33	-6.05	-0.31	3.76e-9	Cancer;
LIHC	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.36	6.98	0.35	1.52e-11	Blood protein levels;
LIHC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg13271783	chr10:134563150	INPP5A	-0.53	-6.77	-0.34	5.47e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.6	0.56	3.7e-30	Prudent dietary pattern;
LIHC	cis	rs2625529	0.530	rs2959930	chr15:72598614	A/G	cg16672083	chr15:72433130	SENP8	-0.33	-6.07	-0.31	3.47e-9	Red blood cell count;
LIHC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.23	-5.71	-0.3	2.39e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs8030605	0.704	rs72742607	chr15:56670259	G/T	cg01710580	chr16:598674	SOLH	-0.67	-6.07	-0.31	3.31e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11212260	0.655	rs11212172	chr11:107212729	C/A	cg25435332	chr11:107328525	CWF19L2	0.81	7.77	0.39	9.47e-14	IgG glycosylation;
LIHC	trans	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg24036039	chr1:3397125	ARHGEF16	0.37	6.19	0.32	1.71e-9	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-10.26	-0.48	1.08e-21	Platelet count;
LIHC	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.95	14.57	0.62	9.62e-38	Gout;Urate levels;Serum uric acid levels;
LIHC	trans	rs8108034	0.920	rs30480	chr19:39807213	A/G	cg24033503	chr14:101005128	BEGAIN	-0.52	-6.4	-0.33	5.09e-10	Lung adenocarcinoma;
LIHC	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.37	-7.85	-0.39	5.36e-14	Schizophrenia;
LIHC	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.26	-0.32	1.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.93	-0.35	2.11e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	6.6	0.34	1.54e-10	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg06207120	chr15:45996521	NA	0.33	6.46	0.33	3.55e-10	Waist circumference;Weight;
LIHC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg09137382	chr11:130731461	NA	0.41	6.05	0.31	3.79e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg14393609	chr7:65229607	NA	0.41	6.9	0.35	2.5e-11	Calcium levels;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg20703375	chr7:98957328	ARPC1A	0.41	6.15	0.32	2.15e-9	Longevity;
LIHC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00958927	chr1:175162553	KIAA0040	0.39	6.55	0.33	2.11e-10	Alcohol dependence;
LIHC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.41	12.89	0.57	3.01e-31	Uric acid levels;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.49	-6.73	-0.34	7.3e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs6594499	0.872	rs10050834	chr5:110427328	C/T	cg04022379	chr5:110408740	TSLP	0.52	8.74	0.43	1.07e-16	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	21.11	0.75	6.65e-64	Smoking behavior;
LIHC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg21395723	chr22:39101663	GTPBP1	0.4	6.65	0.34	1.15e-10	Menopause (age at onset);
LIHC	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg21428710	chr12:47219797	SLC38A4	0.28	5.76	0.3	1.83e-8	Itch intensity from mosquito bite;
LIHC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg03146154	chr1:46216737	IPP	-0.4	-6.54	-0.33	2.27e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.87	13.09	0.58	4.92e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg02795151	chr17:7402630	POLR2A	0.51	5.8	0.3	1.49e-8	Androgen levels;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07677032	chr17:61819896	STRADA	0.43	6.2	0.32	1.62e-9	Prudent dietary pattern;
LIHC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.65	0.42	2.04e-16	Schizophrenia;
LIHC	cis	rs7937890	0.531	rs2575859	chr11:14510736	C/T	cg02886208	chr11:14281011	SPON1	-0.44	-6.17	-0.32	1.92e-9	Mitochondrial DNA levels;
LIHC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.58	-0.5	7.83e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098699	0.821	rs2083935	chr4:124214338	A/C	cg09941581	chr4:124220074	SPATA5	0.33	6.66	0.34	1.1e-10	Mosquito bite size;
LIHC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg23461800	chr14:103021989	NA	-0.54	-7.53	-0.38	4.42e-13	Platelet count;
LIHC	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.78	10.19	0.48	1.8e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.03	-0.31	4.33e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg12193833	chr17:30244370	NA	-0.51	-5.93	-0.31	7.47e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs59698941	0.765	rs66822519	chr5:132167742	C/T	cg02081065	chr5:132209139	LEAP2	0.3	6.37	0.33	6.09e-10	Apolipoprotein A-IV levels;
LIHC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.54	5.8	0.3	1.55e-8	Menopause (age at onset);
LIHC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.49	7.79	0.39	7.98e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs10411161	1.000	rs10402727	chr19:52370379	C/T	cg22319618	chr22:45562946	NUP50	-0.51	-6.83	-0.35	3.78e-11	Breast cancer;
LIHC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.69	11.23	0.52	4.16e-25	Corneal astigmatism;
LIHC	trans	rs7721647	0.853	rs6452960	chr5:90881388	A/G	cg11567849	chr6:111751012	REV3L	-0.51	-6.14	-0.32	2.34e-9	Breast cancer;
LIHC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	17.5	0.69	1.94e-49	Smoking behavior;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg12880250	chr17:43210016	ACBD4;PLCD3	-0.49	-6.64	-0.34	1.22e-10	Systolic blood pressure;
LIHC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg18279126	chr7:2041391	MAD1L1	0.38	6.47	0.33	3.44e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.43	0.33	4.18e-10	Aortic root size;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.74	13.56	0.59	8.39e-34	Prudent dietary pattern;
LIHC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.41	6.09	0.31	3.04e-9	Height;
LIHC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg16226627	chr15:75307476	SCAMP5	0.5	8.72	0.43	1.24e-16	Lung cancer;
LIHC	cis	rs1499280	1.000	rs2548498	chr5:52072645	T/A	cg21153758	chr5:52083992	ITGA1;PELO	0.71	6.33	0.32	7.88e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	0.75	5.77	0.3	1.79e-8	IgG glycosylation;
LIHC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.54	6.25	0.32	1.21e-9	Alzheimer's disease;
LIHC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.28	0.41	2.76e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs17496827	0.780	rs6757951	chr2:223355051	A/G	cg25565276	chr2:223520875	FARSB	0.43	6.26	0.32	1.13e-9	Anorexia nervosa;
LIHC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.58	5.81	0.3	1.44e-8	Schizophrenia;
LIHC	trans	rs1875517	0.510	rs11721241	chr3:117329656	A/C	cg17064520	chr10:98591758	LCOR	-0.46	-7.1	-0.36	7.28e-12	Waist circumference;
LIHC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg00204748	chr12:29376779	FAR2	0.42	7.89	0.39	4.23e-14	QT interval;
LIHC	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs8053891	0.756	rs9930930	chr16:72001971	A/G	cg01557791	chr16:72042693	DHODH	-0.47	-6.92	-0.35	2.18e-11	Coronary artery disease;
LIHC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.39	-0.41	1.33e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg14146966	chr2:61757674	XPO1	0.42	6.91	0.35	2.39e-11	Tuberculosis;
LIHC	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.45	8.57	0.42	3.73e-16	Testicular germ cell tumor;
LIHC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg17135325	chr3:160939158	NMD3	0.6	8.94	0.44	2.51e-17	Parkinson's disease;
LIHC	cis	rs2637266	1.000	rs7476937	chr10:78357692	A/T	cg18941641	chr10:78392320	NA	0.29	6.14	0.32	2.31e-9	Pulmonary function;
LIHC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg24296786	chr1:45957014	TESK2	-0.4	-5.88	-0.3	9.62e-9	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.62	8.11	0.4	8.95e-15	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	0.98	10.47	0.49	1.98e-22	Vitiligo;
LIHC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.59	-0.34	1.62e-10	Renal cell carcinoma;
LIHC	trans	rs11724903	0.935	rs938526	chr4:183213736	T/C	cg16239906	chr20:35724590	RBL1	-0.64	-6.21	-0.32	1.53e-9	Smoking initiation;
LIHC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.78	-16.44	-0.66	3.69e-45	Gestational age at birth (maternal effect);
LIHC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	0.99	10.62	0.5	5.86e-23	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg05110241	chr16:68378359	PRMT7	-0.96	-10.28	-0.49	9.02e-22	Magnesium levels;
LIHC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.98	-0.35	1.53e-11	Blood pressure;
LIHC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.53	7.58	0.38	3.23e-13	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg01596870	chr19:55963115	NA	-0.63	-8.27	-0.41	2.94e-15	Obesity-related traits;
LIHC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.4	5.78	0.3	1.72e-8	Aortic root size;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg04709771	chr16:646395	RAB40C	0.45	8.53	0.42	4.96e-16	Height;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.32	-0.32	8.22e-10	Longevity;
LIHC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.54	8.06	0.4	1.28e-14	HIV-1 control;
LIHC	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg07148914	chr20:33460835	GGT7	-0.54	-8.18	-0.4	5.79e-15	Height;
LIHC	cis	rs2257205	0.667	rs11651859	chr17:56731926	G/T	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.33	7.65	0.38	2.1e-13	Blood metabolite ratios;
LIHC	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg22771759	chr13:24902376	NA	0.33	6.69	0.34	9.16e-11	Obesity-related traits;
LIHC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg09137382	chr11:130731461	NA	0.41	6.09	0.31	2.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.13	0.66	6.23e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.46	-0.37	7.2e-13	Uric acid levels;
LIHC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.61	6.06	0.31	3.6e-9	Red cell distribution width;
LIHC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.73	-13.76	-0.6	1.43e-34	Height;
LIHC	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-7.7	-0.38	1.46e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs55665837	0.540	rs10219313	chr11:14749849	C/T	cg25251204	chr11:14927456	NA	0.4	5.74	0.3	2.11e-8	Vitamin D levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg03571073	chr13:113464332	ATP11A	0.38	6.06	0.31	3.51e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00495681	chr13:53174319	NA	0.41	6.57	0.33	1.82e-10	Lewy body disease;
LIHC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.39	6.25	0.32	1.25e-9	Menopause (age at onset);
LIHC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	15.38	0.64	6.04e-41	Lymphocyte percentage of white cells;
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.68	-10.15	-0.48	2.5e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg16724585	chr3:197361211	NA	-0.46	-6.44	-0.33	4.17e-10	Pancreatic cancer;
LIHC	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg20435097	chr10:126320824	FAM53B	0.43	6.57	0.33	1.9e-10	Cocaine dependence;
LIHC	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-18.0	-0.7	2e-51	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg24847996	chr12:123340818	HIP1R	0.42	6.45	0.33	3.72e-10	Longevity;
LIHC	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-17.47	-0.69	2.6e-49	Height;
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.4	0.81	1.03e-80	Prudent dietary pattern;
LIHC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.21	-0.32	1.56e-9	IgG glycosylation;
LIHC	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.32	6.6	0.34	1.61e-10	Sitting height ratio;
LIHC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.85	0.57	4.31e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.98	12.83	0.57	4.89e-31	Heart rate;
LIHC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg20387954	chr3:183756860	HTR3D	0.25	5.75	0.3	1.95e-8	Anterior chamber depth;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	25.23	0.81	4.45e-80	Prudent dietary pattern;
LIHC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.5	6.04	0.31	4.04e-9	Heart rate;
LIHC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.44	0.33	4.12e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-0.82	-9.4	-0.45	8.03e-19	Schizophrenia;
LIHC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	18.35	0.7	7.4e-53	Tonsillectomy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg25907053	chr2:70369816	NA	0.44	6.16	0.32	2.07e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1385374	0.920	rs34785537	chr12:129273094	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	7.42	0.37	9.59e-13	Systemic lupus erythematosus;
LIHC	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg14515779	chr1:101123966	NA	0.64	12.18	0.55	1.36e-28	Monocyte count;
LIHC	cis	rs3791556	1.000	rs3791558	chr2:240113255	G/A	cg03281426	chr2:240109471	HDAC4	0.41	6.18	0.32	1.85e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.8	14.23	0.61	1.96e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.63e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2710642	0.925	rs72807578	chr2:63008044	G/A	cg17519650	chr2:63277830	OTX1	-0.57	-8.78	-0.43	8.15e-17	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.84	-0.3	1.2e-8	Total body bone mineral density;
LIHC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.3	-0.32	9.1e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.39	-7.39	-0.37	1.15e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.35	-6.9	-0.35	2.53e-11	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10950050	chr1:62902319	USP1	0.47	6.85	0.35	3.5e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.48	-7.72	-0.39	1.31e-13	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04904834	chr1:179851103	TOR1AIP1	0.44	6.08	0.31	3.14e-9	Pancreatic cancer;
LIHC	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.55	6.44	0.33	4.07e-10	Eye color traits;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg15734942	chr2:242617028	DTYMK	0.38	6.11	0.31	2.76e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg04719120	chr6:96025338	MANEA	0.61	6.79	0.34	5.04e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.52	7.69	0.38	1.56e-13	Height;
LIHC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00802000	chr16:706648	WDR90	-0.38	-6.22	-0.32	1.49e-9	Height;
LIHC	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.59	8.93	0.43	2.66e-17	Noise-induced hearing loss;
LIHC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.43	5.86	0.3	1.09e-8	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7188697	0.922	rs2090727	chr16:58604161	A/G	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg23387056	chr11:14280742	SPON1	-0.43	-5.99	-0.31	5.38e-9	Mitochondrial DNA levels;
LIHC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.65	12.08	0.55	3.19e-28	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2537594	0.936	rs1404418	chr7:17814085	A/T	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.41	6.06	0.31	3.63e-9	Mean corpuscular hemoglobin;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.15	0.44	5.38e-18	Height;
LIHC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.752	rs609197	chr8:109234035	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs3736485	0.868	rs60060794	chr15:51937181	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-5.94	-0.31	7.08e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4742903	1.000	rs10820603	chr9:106877939	G/A	cg14250997	chr9:106856677	SMC2	0.39	6.8	0.35	4.54e-11	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg07424592	chr7:64974309	NA	0.8	8.33	0.41	2.02e-15	Diabetic kidney disease;
LIHC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.52	7.74	0.39	1.16e-13	Resting heart rate;
LIHC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.93	-0.31	7.49e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	8.11	0.4	9.01e-15	Height;
LIHC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.4	-6.35	-0.32	6.7e-10	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.57	0.33	1.83e-10	Hemoglobin concentration;
LIHC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.54	-0.59	9.53e-34	Vitiligo;
LIHC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.33	0.41	2.02e-15	Motion sickness;
LIHC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg16586182	chr3:47516702	SCAP	-0.51	-9.23	-0.45	2.81e-18	Colorectal cancer;
LIHC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-6.56	-0.33	1.95e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.68	-9.88	-0.47	2e-20	Initial pursuit acceleration;
LIHC	cis	rs7116495	0.867	rs674688	chr11:71578499	A/T	cg26138937	chr11:71823887	C11orf51	-0.7	-7.06	-0.36	9.27e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27189623	chr16:705930	WDR90	0.35	5.89	0.3	9.35e-9	Height;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg16517021	chr16:11945358	RSL1D1	-0.41	-6.21	-0.32	1.53e-9	Alopecia areata;
LIHC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg18306943	chr3:40428807	ENTPD3	0.38	6.4	0.33	5.22e-10	Renal cell carcinoma;
LIHC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.75	11.01	0.51	2.56e-24	Corneal astigmatism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19050596	chr2:191879164	STAT1	0.41	6.35	0.32	6.87e-10	Cognitive function;
LIHC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.26	-16.63	-0.67	6.04e-46	Diabetic kidney disease;
LIHC	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.56	-0.33	1.97e-10	Metabolite levels;
LIHC	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	0.99	7.88	0.39	4.4e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.76	8.85	0.43	4.72e-17	Exhaled nitric oxide levels;
LIHC	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.4	7.07	0.36	9.04e-12	Obesity;
LIHC	cis	rs17539620	0.628	rs62432730	chr6:154830717	G/A	cg20019720	chr6:154832845	CNKSR3	0.44	6.54	0.33	2.31e-10	Lipoprotein (a) levels;
LIHC	cis	rs3770081	1.000	rs76081054	chr2:86285037	T/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.57	8.8	0.43	7.13e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs1866706	1.000	rs1866707	chr11:12868119	A/G	cg25843174	chr11:12811716	TEAD1	-0.3	-6.41	-0.33	4.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg03037974	chr15:76606532	NA	0.79	16.05	0.66	1.36e-43	Blood metabolite levels;
LIHC	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-7.67	-0.38	1.85e-13	Metabolite levels;
LIHC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	1.1	14.05	0.61	1.01e-35	Body mass index;
LIHC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	12.83	0.57	4.91e-31	Cognitive test performance;
LIHC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.61	-10.07	-0.48	4.81e-21	Rheumatoid arthritis;
LIHC	cis	rs748404	0.578	rs2584701	chr15:43684939	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	9.5	0.46	3.85e-19	Lung cancer;
LIHC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.68	9.02	0.44	1.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.41	-6.6	-0.34	1.61e-10	Fibrinogen levels;
LIHC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.45	-7.31	-0.37	1.89e-12	Menarche (age at onset);
LIHC	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-7.13	-0.36	5.92e-12	Mean corpuscular hemoglobin;
LIHC	cis	rs4586057	0.514	rs11186351	chr10:92649784	T/C	cg14313238	chr10:92632228	RPP30	0.37	6.22	0.32	1.45e-9	Economic and political preferences (time);
LIHC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.55	8.47	0.42	7.28e-16	Diastolic blood pressure;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg09976989	chr12:29534158	ERGIC2	-0.48	-6.14	-0.32	2.3e-9	Systolic blood pressure;
LIHC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.48	-0.38	6.16e-13	Chronic sinus infection;
LIHC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg06050784	chr16:88016603	BANP	0.4	7.02	0.35	1.22e-11	Menopause (age at onset);
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.44	-8.36	-0.41	1.61e-15	Abdominal aortic aneurysm;
LIHC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.53	-5.72	-0.3	2.38e-8	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg23533926	chr12:111358616	MYL2	0.33	6.49	0.33	3.07e-10	Extrinsic epigenetic age acceleration;
LIHC	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-10.75	-0.5	2.0500000000000001e-23	Brugada syndrome;
LIHC	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.41	0.33	4.89e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg20140201	chr2:241835670	C2orf54	-0.47	-6.45	-0.33	3.9e-10	Urinary metabolites;
LIHC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.4	7.46	0.37	7.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	7.73	0.39	1.18e-13	Coronary artery disease;
LIHC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	7.19	0.36	4.14e-12	Hemoglobin concentration;
LIHC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.93	17.45	0.69	3.28e-49	Menopause (age at onset);
LIHC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	8.6	0.42	2.83e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs10508774	1.000	rs58339739	chr10:32909634	G/C	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.4	-6.63	-0.34	1.28e-10	Educational attainment;
LIHC	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.29	-0.32	9.8e-10	Blood pressure;
LIHC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.36	6.37	0.33	6.26e-10	Electrocardiographic conduction measures;
LIHC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg25894440	chr7:65020034	NA	-0.53	-6.19	-0.32	1.68e-9	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg07424592	chr7:64974309	NA	0.82	9.64	0.46	1.27e-19	Diabetic kidney disease;
LIHC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.67	-8.51	-0.42	5.63e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg07541023	chr7:19748670	TWISTNB	0.41	6.16	0.32	2.1e-9	Thyroid stimulating hormone;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.41	-8.44	-0.42	9e-16	Renal cell carcinoma;
LIHC	cis	rs6088813	1.000	rs6142370	chr20:33973378	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.83	-0.3	1.25e-8	Height;
LIHC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg14779329	chr11:130786720	SNX19	0.43	6.5	0.33	2.83e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.43	6.1	0.31	2.91e-9	Height;
LIHC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg22633049	chr21:46681294	NA	-0.37	-6.36	-0.33	6.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.7	12.44	0.56	1.42e-29	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs875971	0.929	rs778682	chr7:65837934	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs11673344	0.796	rs9676450	chr19:37489407	A/G	cg27390819	chr19:37464633	NA	-0.52	-6.27	-0.32	1.1e-9	Obesity-related traits;
LIHC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.66	10.65	0.5	4.59e-23	Multiple myeloma (IgH translocation);
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.49	-0.42	6.42e-16	Renal cell carcinoma;
LIHC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13047869	chr3:10149882	C3orf24	0.51	6.18	0.32	1.82e-9	Alzheimer's disease;
LIHC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16346588	chr10:242978	ZMYND11	0.38	5.8	0.3	1.53e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.4	8.57	0.42	3.51e-16	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.44	-6.77	-0.34	5.62e-11	Height;
LIHC	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg06360820	chr2:242988706	NA	-0.83	-11.88	-0.54	1.8e-27	Obesity-related traits;
LIHC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.62	-8.85	-0.43	4.84e-17	Blood metabolite levels;
LIHC	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg03934865	chr2:198174659	NA	0.48	6.95	0.35	1.9e-11	Dermatomyositis;
LIHC	cis	rs4908768	0.501	rs1463051	chr1:8596893	A/T	cg20416874	chr1:8611966	RERE	0.69	15.4	0.64	5.12e-41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs7534824	0.543	rs10493940	chr1:101377845	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.62	0.38	2.45e-13	Refractive astigmatism;
LIHC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.8	12.63	0.56	2.75e-30	Breast cancer;
LIHC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.56	10.48	0.49	1.85e-22	Mean corpuscular volume;
LIHC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.44	-6.73	-0.34	7.06e-11	Testicular germ cell tumor;
LIHC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.42	-6.74	-0.34	6.65e-11	Height;
LIHC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.56	-8.84	-0.43	5.09e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06544989	chr22:39130855	UNC84B	0.35	5.73	0.3	2.18e-8	Menopause (age at onset);
LIHC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.39	6.3	0.32	9.09e-10	Anterior chamber depth;
LIHC	cis	rs748404	0.556	rs10851414	chr15:43433932	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.36	-5.84	-0.3	1.21e-8	Lung cancer;
LIHC	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.86	0.39	4.94e-14	IgG glycosylation;
LIHC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg16102536	chr7:156981717	UBE3C	0.36	5.97	0.31	5.98e-9	Body mass index;
LIHC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.01	-20.58	-0.74	8.08e-62	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.77	11.69	0.53	8.39e-27	Corneal astigmatism;
LIHC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.42	-7.31	-0.37	1.86e-12	Platelet distribution width;
LIHC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.58	8.65	0.42	1.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg03959625	chr15:84868606	LOC388152	0.45	6.11	0.31	2.69e-9	Schizophrenia;
LIHC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.74	6.08	0.31	3.21e-9	Breast cancer;
LIHC	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg02023728	chr11:77925099	USP35	0.33	5.98	0.31	5.49e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg11861562	chr11:117069780	TAGLN	0.37	5.98	0.31	5.49e-9	Blood protein levels;
LIHC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-8.24	-0.41	3.77e-15	Chronic sinus infection;
LIHC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.51	-6.95	-0.35	1.82e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs655641	1.000	rs9804630	chr11:85766582	A/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.16	-0.32	2.03e-9	Platelet count;
LIHC	trans	rs10411161	0.810	rs8102738	chr19:52388229	T/C	cg22319618	chr22:45562946	NUP50	-0.64	-7.58	-0.38	3.31e-13	Breast cancer;
LIHC	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	0.88	9.76	0.47	5.06e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs57590327	0.527	rs7610703	chr3:81613942	G/A	cg07356753	chr3:81810745	GBE1	-0.56	-8.52	-0.42	5.33e-16	Extraversion;
LIHC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg11062466	chr8:58055876	NA	0.4	5.91	0.3	8.29e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs918629	0.530	rs2829	chr5:95258447	T/C	cg10483112	chr5:95245456	ELL2	-0.38	-6.99	-0.35	1.47e-11	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12095507	chr14:89290958	TTC8	-0.45	-6.15	-0.32	2.19e-9	Pancreatic cancer;
LIHC	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.26	-6.29	-0.32	9.83e-10	Gut microbiome composition (winter);
LIHC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-11.03	-0.51	2.02e-24	Type 2 diabetes;
LIHC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.79	6.96	0.35	1.77e-11	Type 2 diabetes;
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11987759	chr7:65425863	GUSB	-0.39	-6.15	-0.32	2.13e-9	Calcium levels;
LIHC	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.35	0.45	1.17e-18	Corneal astigmatism;
LIHC	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.8	-10.61	-0.5	6.59e-23	Blood pressure (smoking interaction);
LIHC	cis	rs11673344	0.864	rs826322	chr19:37504596	A/G	cg27390819	chr19:37464633	NA	-0.52	-6.38	-0.33	5.73e-10	Obesity-related traits;
LIHC	cis	rs1043515	1.000	rs1043515	chr17:36922196	C/T	cg20826740	chr17:37024042	NA	-0.38	-6.33	-0.32	7.68e-10	Height;
LIHC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.4	6.61	0.34	1.46e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.74	-9.84	-0.47	2.79e-20	Asthma;
LIHC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg17372223	chr3:52568218	NT5DC2	0.37	6.07	0.31	3.43e-9	Electroencephalogram traits;
LIHC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.6	6.11	0.31	2.74e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-12.47	-0.56	1.14e-29	Alzheimer's disease (late onset);
LIHC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.9	0.47	1.7e-20	Platelet count;
LIHC	trans	rs4714291	0.963	rs1923489	chr6:40023088	T/C	cg02267698	chr19:7991119	CTXN1	0.39	6.21	0.32	1.51e-9	Strep throat;
LIHC	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg26441486	chr22:50317300	CRELD2	0.37	6.33	0.32	7.71e-10	Schizophrenia;
LIHC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.8	0.35	4.63e-11	Morning vs. evening chronotype;
LIHC	trans	rs6600671	0.967	rs11249349	chr1:121179169	G/C	cg09829573	chr1:144692074	NBPF9	-0.43	-7.95	-0.39	2.76e-14	Hip geometry;
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	11.32	0.52	1.84e-25	Colorectal cancer;
LIHC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.71	11.58	0.53	2.16e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.14	0.68	5.59e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-6.8	-0.35	4.73e-11	Reticulocyte count;
LIHC	cis	rs10508774	0.810	rs12416226	chr10:32729405	T/C	cg01819863	chr10:32635814	EPC1	0.61	5.87	0.3	1.03e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.6	-0.34	1.58e-10	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21937244	chr14:103406412	CDC42BPB	-0.63	-9.01	-0.44	1.51e-17	Lung function (FEV1/FVC);
LIHC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.62	-10.56	-0.5	9.16e-23	Colorectal cancer;
LIHC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.42	6.86	0.35	3.16e-11	Red blood cell count;
LIHC	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.64	9.97	0.47	9.95e-21	Lymphocyte counts;
LIHC	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg15841412	chr13:111365552	ING1	0.47	5.87	0.3	1.04e-8	Coronary artery disease;
LIHC	cis	rs12702595	0.517	rs10268210	chr7:7262324	A/C	cg04827551	chr7:7268805	C1GALT1	0.32	5.82	0.3	1.35e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
LIHC	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg10820045	chr2:198174542	NA	0.47	7.09	0.36	7.92e-12	Dermatomyositis;
LIHC	cis	rs422249	0.634	rs174617	chr11:61629166	A/G	cg27386326	chr11:61587980	NA	0.4	7.16	0.36	4.85e-12	Trans fatty acid levels;
LIHC	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg15208524	chr1:10270712	KIF1B	0.38	6.01	0.31	4.82e-9	Hepatocellular carcinoma;
LIHC	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	6.19	0.32	1.7e-9	Adiposity;
LIHC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg04865290	chr3:52927548	TMEM110	-0.51	-5.89	-0.3	9.01e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2380220	0.808	rs2613554	chr6:95916782	C/A	cg04719120	chr6:96025338	MANEA	-0.58	-6.24	-0.32	1.33e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.07	0.51	1.47e-24	Type 2 diabetes;
LIHC	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05206910	chr17:80230660	CSNK1D	0.48	6.39	0.33	5.54e-10	Lung function (FEV1/FVC);
LIHC	cis	rs3106136	0.649	rs6532487	chr4:95300493	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.91	0.3	8.32e-9	Capecitabine sensitivity;
LIHC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.73	11.01	0.51	2.52e-24	Height;
LIHC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.68	-10.18	-0.48	1.94e-21	Menarche (age at onset);
LIHC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.34	0.56	3.31e-29	Cognitive test performance;
LIHC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.86	12.87	0.57	3.46e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg25204440	chr1:209979598	IRF6	0.5	7.8	0.39	7.47e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.68	-0.53	9.4e-27	Platelet distribution width;
LIHC	cis	rs9649465	1.000	rs1073670	chr7:123345029	A/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.04	-0.4	1.44e-14	Migraine;
LIHC	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.27e-8	Fear of minor pain;
LIHC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.93	-0.35	2.17e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs11997175	0.580	rs34398087	chr8:33813800	A/G	ch.8.33884649F	chr8:33765107	NA	-0.4	-6.54	-0.33	2.28e-10	Body mass index;
LIHC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.37	5.91	0.3	8.06e-9	Menopause (age at onset);
LIHC	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.07	-0.36	8.73e-12	Metabolite levels (Pyroglutamine);
LIHC	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg05941027	chr17:61774174	LIMD2	0.31	6.19	0.32	1.69e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	9.12	0.44	6.63e-18	Platelet count;
LIHC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg23172400	chr8:95962367	TP53INP1	0.34	6.95	0.35	1.89e-11	Type 2 diabetes;
LIHC	cis	rs9783347	1.000	rs10734259	chr11:18314865	A/G	cg15585147	chr11:18324498	HPS5	0.45	6.88	0.35	2.92e-11	Pancreatic cancer;
LIHC	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg07541023	chr7:19748670	TWISTNB	0.37	5.83	0.3	1.31e-8	Thyroid stimulating hormone;
LIHC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.49	7.86	0.39	5.21e-14	Testicular germ cell tumor;
LIHC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	7.91	0.39	3.59e-14	Schizophrenia;
LIHC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.66	8.53	0.42	4.65e-16	Initial pursuit acceleration;
LIHC	cis	rs17106184	1.000	rs12089568	chr1:51406874	G/T	cg07174182	chr1:51127561	FAF1	-0.74	-7.94	-0.39	2.99e-14	Type 2 diabetes;
LIHC	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.6	9.72	0.47	7.17e-20	Corneal astigmatism;
LIHC	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.76	-9.76	-0.47	5.1e-20	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg10018233	chr7:150070692	REPIN1	0.5	8.19	0.4	5.27e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-12.6	-0.56	3.63e-30	Pediatric autoimmune diseases;
LIHC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.4	-6.65	-0.34	1.13e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.72	-11.03	-0.51	2.11e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg25801113	chr15:45476975	SHF	0.4	6.82	0.35	4.22e-11	Uric acid levels;
LIHC	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.86	-0.35	3.18e-11	Metabolite levels;
LIHC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.81	-0.3	1.4e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2108622	0.785	rs3093199	chr19:15989871	T/A	cg13772218	chr19:15982569	NA	0.35	7.21	0.36	3.62e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.56	-8.07	-0.4	1.23e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs903552	1.000	rs8027380	chr15:102005810	T/C	cg00659931	chr15:102010125	PCSK6	-0.46	-6.2	-0.32	1.63e-9	Diabetic kidney disease;
LIHC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.3	-0.58	8.14e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.61	8.14	0.4	7.63e-15	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.86	0.3	1.07e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.87	0.35	3.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.21	0.36	3.73e-12	Longevity;
LIHC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.91	16.66	0.67	4.76e-46	Parkinson's disease;
LIHC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg23791538	chr6:167370224	RNASET2	-0.52	-7.84	-0.39	5.82e-14	Rheumatoid arthritis;
LIHC	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg02702477	chr5:179499311	RNF130	0.75	10.29	0.49	7.91e-22	LDL cholesterol;
LIHC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.16	-0.55	1.57e-28	Colorectal cancer;
LIHC	cis	rs1559088	0.501	rs35492529	chr19:33597495	C/G	cg27124370	chr19:33622961	WDR88	0.49	6.91	0.35	2.41e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.69	-9.27	-0.45	2.21e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs3917254	0.596	rs13001315	chr2:102763210	G/A	cg22835712	chr2:102737379	NA	-0.5	-5.75	-0.3	1.94e-8	Blood protein levels;
LIHC	cis	rs10861342	0.892	rs3794232	chr12:105615849	C/T	cg23923672	chr12:105501055	KIAA1033	0.62	6.95	0.35	1.85e-11	IgG glycosylation;
LIHC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.75	0.3	1.93e-8	Menopause (age at onset);
LIHC	cis	rs1559088	0.512	rs34266236	chr19:33564874	C/A	cg27124370	chr19:33622961	WDR88	0.44	5.85	0.3	1.17e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.74	0.34	6.65e-11	Morning vs. evening chronotype;
LIHC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg03037974	chr15:76606532	NA	0.72	13.83	0.6	7.59e-35	Blood metabolite levels;
LIHC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.61	6.88	0.35	2.89e-11	Menarche (age at onset);
LIHC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.36	5.84	0.3	1.22e-8	Schizophrenia;
LIHC	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.3	-5.95	-0.31	6.63e-9	DNA methylation (variation);
LIHC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-8.42	-0.41	1.04e-15	Primary biliary cholangitis;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24511375	chr15:75940328	SNX33	-0.49	-6.31	-0.32	8.89e-10	Systolic blood pressure;
LIHC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg20283391	chr11:68216788	NA	-0.38	-6.12	-0.31	2.56e-9	Total body bone mineral density;
LIHC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.48	7.24	0.36	2.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.8	12.33	0.55	3.67e-29	Dental caries;
LIHC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.32	-7.27	-0.37	2.41e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.43	7.14	0.36	5.57e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	11.3	0.52	2.18e-25	Cognitive test performance;
LIHC	cis	rs1355223	0.902	rs1773910	chr11:34741253	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.35	-0.32	6.72e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg06453172	chr10:134556979	INPP5A	-0.65	-9.01	-0.44	1.47e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.42	-0.41	1.07e-15	HDL cholesterol;
LIHC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.69	12.11	0.55	2.57e-28	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg07424592	chr7:64974309	NA	0.81	9.05	0.44	1.13e-17	Diabetic kidney disease;
LIHC	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-11.64	-0.53	1.36e-26	Morning vs. evening chronotype;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg23644127	chr8:96037660	C8orf38	-0.4	-6.15	-0.32	2.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-6.64	-0.34	1.25e-10	Morning vs. evening chronotype;
LIHC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.14	0.44	5.61e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.13	-15.79	-0.65	1.5e-42	Chronic sinus infection;
LIHC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.53	8.56	0.42	3.93e-16	Schizophrenia;
LIHC	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.36	-0.33	6.52e-10	Schizophrenia;
LIHC	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	6.61	0.34	1.51e-10	Menarche (age at onset);
LIHC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg16479474	chr6:28041457	NA	0.48	7.0	0.35	1.34e-11	Parkinson's disease;
LIHC	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.5	9.37	0.45	1.03e-18	Atrioventricular conduction;
LIHC	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.27	5.72	0.3	2.35e-8	Pulmonary function;
LIHC	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg18887096	chr2:219472410	PLCD4	0.36	5.95	0.31	6.61e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	22.24	0.77	2.15e-68	Prudent dietary pattern;
LIHC	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.79	15.25	0.64	2.04e-40	Testicular germ cell tumor;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg12753518	chr1:28414763	EYA3	-0.56	-6.16	-0.32	2.06e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs970821	1.000	rs13279803	chr8:124750521	C/T	cg00283535	chr8:124749564	ANXA13	0.35	6.07	0.31	3.44e-9	Breast cancer;
LIHC	trans	rs7927370	0.510	rs11559578	chr11:54994975	C/A	cg03929089	chr4:120376271	NA	0.51	6.26	0.32	1.13e-9	Systemic lupus erythematosus;
LIHC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.68	-0.34	9.74e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg03983715	chr16:68378420	PRMT7	-0.5	-6.12	-0.31	2.49e-9	Schizophrenia;
LIHC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.52	7.59	0.38	3.1e-13	Obesity-related traits;
LIHC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg06096015	chr1:231504339	EGLN1	0.47	8.85	0.43	4.65e-17	Hemoglobin concentration;
LIHC	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.21	0.48	1.49e-21	Colorectal cancer;
LIHC	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg20387954	chr3:183756860	HTR3D	0.29	6.32	0.32	8.2e-10	Anterior chamber depth;
LIHC	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.73	0.3	2.18e-8	Bladder cancer;
LIHC	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.62	8.68	0.42	1.64e-16	Neuroticism;
LIHC	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.81	9.17	0.44	4.47e-18	Vitiligo;
LIHC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.24	-8.94	-0.44	2.53e-17	Body mass index;
LIHC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg20195005	chr22:42527684	CYP2D6	0.32	6.15	0.32	2.19e-9	Birth weight;
LIHC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg19680672	chr10:131412579	MGMT	-0.38	-5.8	-0.3	1.49e-8	Response to temozolomide;
LIHC	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.58	-10.68	-0.5	3.66e-23	Vitamin D levels;
LIHC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	9.91e-21	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs74233809	1.000	rs10458729	chr10:104841479	C/T	cg03493300	chr10:104813866	CNNM2	0.47	6.27	0.32	1.07e-9	Birth weight;
LIHC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.4	-9.0	-0.44	1.59e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.61	9.7	0.46	8.02e-20	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.45	6.49	0.33	3e-10	Breast cancer;
LIHC	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.18	0.48	2.03e-21	Post bronchodilator FEV1;
LIHC	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.76	0.47	5.25e-20	Corneal astigmatism;
LIHC	trans	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg07393940	chr7:158741817	NA	-0.57	-6.71	-0.34	8.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.57	-0.59	7.34e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg12863693	chr15:85201151	NMB	0.49	6.94	0.35	1.96e-11	Schizophrenia;
LIHC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg15105060	chr4:7024189	TBC1D14	-0.81	-6.47	-0.33	3.48e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.61	9.17	0.44	4.62e-18	Mean corpuscular volume;
LIHC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg23690444	chr14:81902736	NA	-0.5	-6.83	-0.35	3.87e-11	Night sleep phenotypes;
LIHC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	7.9	0.39	3.92e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14694896	chr8:104427370	SLC25A32;DCAF13	-0.54	-6.69	-0.34	9.18e-11	Systolic blood pressure;
LIHC	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.68	-0.34	9.72e-11	Blood pressure;
LIHC	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.31	-0.49	6.91e-22	Eye color traits;
LIHC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.06	-0.4	1.33e-14	Monocyte percentage of white cells;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26531923	chr6:24646364	KIAA0319	0.44	6.05	0.31	3.88e-9	Triglycerides;
LIHC	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-7.26	-0.37	2.56e-12	Mortality in heart failure;
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.42	-6.58	-0.34	1.8e-10	Testicular germ cell tumor;
LIHC	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg25894440	chr7:65020034	NA	-0.52	-6.07	-0.31	3.44e-9	Diabetic kidney disease;
LIHC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg15017067	chr4:17643749	FAM184B	0.34	5.85	0.3	1.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.55	9.47	0.46	4.84e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.33	0.41	2.02e-15	Lung cancer in ever smokers;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14577476	chr17:49337432	MBTD1;UTP18	-0.46	-6.26	-0.32	1.16e-9	Pancreatic cancer;
LIHC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.63	11.48	0.53	4.91e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.81	-0.3	1.41e-8	Systolic blood pressure;
LIHC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13047869	chr3:10149882	C3orf24	0.42	5.87	0.3	1.03e-8	Alzheimer's disease;
LIHC	cis	rs77637988	0.578	rs7576964	chr2:48601448	G/T	cg00032884	chr2:48540671	FOXN2	0.4	6.34	0.32	7.08e-10	Joint mobility (Beighton score);
LIHC	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg03999872	chr20:62272968	STMN3	-0.46	-6.81	-0.35	4.41e-11	Atopic dermatitis;
LIHC	cis	rs4388979	0.929	rs12426673	chr12:109490296	G/T	cg03220751	chr12:109490328	USP30	0.86	12.95	0.57	1.81e-31	Plateletcrit;Platelet count;
LIHC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg05941027	chr17:61774174	LIMD2	0.3	6.03	0.31	4.15e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.48	8.47	0.42	7.25e-16	HDL cholesterol levels;
LIHC	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.56	7.4	0.37	1.1e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.61	8.2	0.41	5.02e-15	Coronary artery disease;
LIHC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.65	-11.5	-0.53	4.19e-26	Total body bone mineral density;
LIHC	trans	rs668210	0.643	rs549334	chr11:65774659	C/G	cg17712092	chr4:129076599	LARP1B	0.59	6.38	0.33	5.83e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.77	11.66	0.53	1.11e-26	Metabolic syndrome;
LIHC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.79	6.39	0.33	5.48e-10	Body mass index;
LIHC	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.12	0.31	2.56e-9	Axial length;
LIHC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	11.19	0.52	5.77e-25	Chronic sinus infection;
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg09417038	chr21:47716443	C21orf57	-0.47	-7.02	-0.35	1.24e-11	Testicular germ cell tumor;
LIHC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11777782	chr19:18284937	IFI30	0.47	6.72	0.34	7.48e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	9.42	0.45	6.95e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs722599	0.501	rs10139347	chr14:75390135	T/C	cg08847533	chr14:75593920	NEK9	0.6	10.35	0.49	4.91e-22	IgG glycosylation;
LIHC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg12365402	chr11:9010492	NRIP3	-0.26	-6.65	-0.34	1.17e-10	Hemoglobin concentration;
LIHC	cis	rs970821	0.667	rs6470182	chr8:124751705	T/C	cg00283535	chr8:124749564	ANXA13	-0.42	-7.49	-0.38	5.77e-13	Breast cancer;
LIHC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.77e-8	Parkinson's disease;
LIHC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.88	0.39	4.52e-14	Tonsillectomy;
LIHC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	5.74	0.3	2.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-8.59	-0.42	3.13e-16	Schizophrenia;
LIHC	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.31	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-7.66	-0.38	1.92e-13	Uric acid levels;
LIHC	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg19683494	chr5:74908142	NA	0.58	7.57	0.38	3.52e-13	Age-related disease endophenotypes;
LIHC	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	6.1	0.31	2.83e-9	Fuchs's corneal dystrophy;
LIHC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.59	10.51	0.49	1.41e-22	Dupuytren's disease;
LIHC	cis	rs7165170	0.550	rs76750851	chr15:91196201	C/T	cg26821196	chr15:91095069	CRTC3	-0.36	-6.71	-0.34	8.33e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.36	-6.67	-0.34	1e-10	IgG glycosylation;
LIHC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.51	-7.13	-0.36	5.86e-12	Height;
LIHC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.85	-0.67	8.58e-47	Systemic lupus erythematosus;
LIHC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.64	-0.38	2.21e-13	Electroencephalogram traits;
LIHC	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg03037974	chr15:76606532	NA	-0.63	-10.9	-0.51	5.92e-24	Blood metabolite levels;
LIHC	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg05343316	chr1:45956843	TESK2	-0.43	-6.35	-0.32	6.84e-10	High light scatter reticulocyte count;
LIHC	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.31	7.13	0.36	6.13e-12	Blood metabolite ratios;
LIHC	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.47	6.99	0.35	1.42e-11	Prostate cancer;
LIHC	cis	rs79387448	0.745	rs7572284	chr2:103119423	C/A	cg09003973	chr2:102972529	NA	0.79	6.89	0.35	2.72e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.76	11.48	0.53	5.08e-26	Coronary artery disease;
LIHC	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.04	0.4	1.48e-14	Body mass index;
LIHC	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg23587288	chr2:27483067	SLC30A3	0.31	6.08	0.31	3.29e-9	Blood metabolite levels;
LIHC	cis	rs79387448	0.745	rs57942521	chr2:103139849	A/G	cg09003973	chr2:102972529	NA	0.84	6.63	0.34	1.27e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.41	0.56	1.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.24	-7.38	-0.37	1.23e-12	Mean corpuscular volume;
LIHC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.23	0.45	2.83e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg10932868	chr11:921992	NA	0.38	7.32	0.37	1.83e-12	Alzheimer's disease (late onset);
LIHC	cis	rs1823913	1.000	rs10445782	chr2:192101365	T/C	cg12404831	chr2:192114017	MYO1B	-0.34	-6.83	-0.35	3.85e-11	Obesity-related traits;
LIHC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.66	9.69	0.46	9.09e-20	Schizophrenia;
LIHC	cis	rs2412488	1.000	rs10011259	chr4:54285952	A/G	cg22241045	chr4:54363911	LNX1	-0.47	-7.51	-0.38	5.16e-13	DNA methylation (variation);
LIHC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.57	-6.77	-0.34	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	8.99	0.44	1.7e-17	Monocyte count;
LIHC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.8	15.12	0.63	6.63e-40	IgG glycosylation;
LIHC	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02985541	chr2:219472218	PLCD4	-0.38	-6.58	-0.34	1.8e-10	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg00612595	chr21:47717864	NA	-0.36	-5.86	-0.3	1.1e-8	Testicular germ cell tumor;
LIHC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-14.76	-0.62	1.68e-38	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.15	0.58	2.92e-32	Prudent dietary pattern;
LIHC	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-8.62	-0.42	2.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.86	-10.58	-0.5	7.87e-23	Prostate cancer;
LIHC	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.58	-9.35	-0.45	1.22e-18	Pulse pressure;
LIHC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.42	-6.7	-0.34	8.37e-11	Menarche (age at onset);
LIHC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	1.0	18.85	0.71	7.18e-55	Breast cancer;
LIHC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg16558253	chr16:72132732	DHX38	-0.5	-8.28	-0.41	2.85e-15	Fibrinogen levels;
LIHC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.72	13.06	0.58	6.5e-32	Lewy body disease;
LIHC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg00459129	chr12:27167463	TM7SF3	0.46	6.56	0.33	2.05e-10	Positive affect;
LIHC	cis	rs4759375	1.000	rs10846506	chr12:123777815	G/T	cg00376283	chr12:123451042	ABCB9	-0.49	-6.31	-0.32	8.53e-10	HDL cholesterol;
LIHC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-7.62	-0.38	2.48e-13	Bipolar disorder;
LIHC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.79	12.86	0.57	3.74e-31	Longevity;
LIHC	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.4	7.02	0.35	1.19e-11	Obesity (extreme);
LIHC	cis	rs3106136	0.843	rs6826671	chr4:95271881	T/C	cg11021082	chr4:95130006	SMARCAD1	0.43	7.5	0.38	5.5e-13	Capecitabine sensitivity;
LIHC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.85	-0.3	1.17e-8	Coronary artery disease;
LIHC	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg20991723	chr1:152506922	NA	0.39	5.92	0.3	8.04e-9	Hair morphology;
LIHC	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.33	5.93	0.31	7.53e-9	Body mass index;
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.15	0.55	1.79e-28	Prudent dietary pattern;
LIHC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-9.74	-0.47	6.04e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.3	7.01	0.35	1.27e-11	Menarche (age at onset);
LIHC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.49	7.26	0.37	2.69e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09299307	chr5:86709023	CCNH	0.48	7.52	0.38	5e-13	Cognitive function;
LIHC	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg16558253	chr16:72132732	DHX38	0.36	5.91	0.3	8.22e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.52	-0.46	3.37e-19	Eye color traits;
LIHC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27297192	chr10:134578999	INPP5A	0.5	7.03	0.36	1.11e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs600806	0.778	rs4970761	chr1:109995398	C/T	cg11161837	chr1:110010384	SYPL2	0.44	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.48	6.42	0.33	4.45e-10	High light scatter reticulocyte count;
LIHC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg22079354	chr11:130786696	SNX19	0.39	5.74	0.3	2.14e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.28e-9	Menopause (age at onset);
LIHC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg25204440	chr1:209979598	IRF6	0.51	7.82	0.39	6.45e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.68	11.19	0.52	5.8e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.46	-7.46	-0.37	7.32e-13	Neurofibrillary tangles;
LIHC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.35	14.48	0.62	2.1e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.43	-6.58	-0.34	1.79e-10	Type 2 diabetes;
LIHC	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.57	-6.51	-0.33	2.7e-10	Ulcerative colitis;
LIHC	cis	rs911119	0.866	rs4815223	chr20:23577112	C/A	cg16589663	chr20:23618590	CST3	0.67	7.01	0.35	1.29e-11	Chronic kidney disease;
LIHC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg00612595	chr21:47717864	NA	-0.38	-6.22	-0.32	1.48e-9	Testicular germ cell tumor;
LIHC	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg23682824	chr7:23144976	KLHL7	0.43	6.45	0.33	3.76e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.68	-6.38	-0.33	5.82e-10	Urate levels in lean individuals;
LIHC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.7	-8.57	-0.42	3.57e-16	Gut microbiome composition (summer);
LIHC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.75	-0.39	1.03e-13	Obesity-related traits;
LIHC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.75	8.93	0.43	2.65e-17	Menarche (age at onset);
LIHC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.4	7.09	0.36	7.89e-12	Schizophrenia;
LIHC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.6	6.57	0.33	1.82e-10	Alzheimer's disease;
LIHC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.54	7.32	0.37	1.74e-12	Blood protein levels;
LIHC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg14440974	chr22:39074834	NA	-0.36	-6.06	-0.31	3.56e-9	Menopause (age at onset);
LIHC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	0.95	16.21	0.66	2.97e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs240764	0.614	rs12210312	chr6:101170849	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-6.03	-0.31	4.17e-9	Neuroticism;
LIHC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.72	11.92	0.54	1.2e-27	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11147586	chr5:170845829	FGF18	0.42	6.04	0.31	4.04e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.28	-6.95	-0.35	1.9e-11	Mean corpuscular volume;
LIHC	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-6.22	-0.32	1.44e-9	Coronary artery disease;
LIHC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.71	11.6	0.53	1.87e-26	Oral cavity cancer;
LIHC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.21	-0.45	3.4e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg17750252	chr2:136567154	LCT	0.35	6.15	0.32	2.12e-9	Mosquito bite size;
LIHC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17507749	chr15:85114479	UBE2QP1	0.75	8.51	0.42	5.72e-16	Schizophrenia;
LIHC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.84	0.57	4.36e-31	Colorectal cancer;
LIHC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.61	9.01	0.44	1.49e-17	Height;
LIHC	cis	rs1355223	0.872	rs12785367	chr11:34715269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.42	-0.33	4.62e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.92	-20.81	-0.75	1.05e-62	Height;
LIHC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.45	7.27	0.37	2.4e-12	Platelet count;
LIHC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.35	-0.37	1.44e-12	Breast cancer;
LIHC	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	6.77	0.34	5.55e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LIHC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.37	-0.49	4.39e-22	Blood metabolite levels;
LIHC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	9.1	0.44	7.81e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg04727924	chr7:799746	HEATR2	-0.59	-7.89	-0.39	4.22e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	0.99	15.06	0.63	1.08e-39	Corneal structure;
LIHC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg15352829	chr14:105391018	PLD4	-0.44	-9.3	-0.45	1.76e-18	Rheumatoid arthritis;
LIHC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.4	7.49	0.38	6.04e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.26	0.32	1.16e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg06359132	chr10:99160096	RRP12	-0.39	-6.03	-0.31	4.3e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	10.7	0.5	3.1e-23	Myopia (pathological);
LIHC	cis	rs1419980	0.730	rs11054896	chr12:7774131	A/G	cg10578777	chr12:7781093	NA	-0.39	-5.79	-0.3	1.55e-8	HDL cholesterol levels;
LIHC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg00142150	chr22:38071001	LGALS1	0.7	11.47	0.53	5.34e-26	Fat distribution (HIV);
LIHC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.46	6.36	0.33	6.34e-10	Schizophrenia;
LIHC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.73	11.86	0.54	2.13e-27	Anterior chamber depth;
LIHC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg09445902	chr10:555545	DIP2C	-0.38	-6.21	-0.32	1.52e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.86	10.72	0.5	2.7e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21467203	chr3:49911342	NA	0.39	6.64	0.34	1.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.54	0.33	2.2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.63	-0.38	2.39e-13	Response to antipsychotic treatment;
LIHC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.9	0.3	8.59e-9	Renal cell carcinoma;
LIHC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg24004478	chr7:855632	UNC84A	0.37	5.95	0.31	6.74e-9	Perceived unattractiveness to mosquitoes;
LIHC	trans	rs72960926	0.744	rs7755776	chr6:74967405	C/G	cg07247405	chr1:2484626	LOC115110	-0.55	-6.57	-0.33	1.86e-10	Metabolite levels (MHPG);
LIHC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.9	11.03	0.51	2.07e-24	Primary sclerosing cholangitis;
LIHC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.02	0.55	5.22e-28	Prudent dietary pattern;
LIHC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.91	-0.3	8.25e-9	Total body bone mineral density;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.7	13.3	0.58	7.96e-33	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg11204139	chr17:3907470	NA	0.59	6.93	0.35	2.13e-11	Type 2 diabetes;
LIHC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.83	11.95	0.54	9.98e-28	Coronary artery disease;
LIHC	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.86	0.47	2.45e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg10217327	chr6:118973057	C6orf204	0.69	7.04	0.36	1.03e-11	Diastolic blood pressure;
LIHC	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg01864836	chr14:55583639	NA	-0.41	-7.61	-0.38	2.63e-13	Protein biomarker;
LIHC	cis	rs8023580	1.000	rs8023580	chr15:96708291	T/C	cg01739960	chr15:96715164	NA	0.36	5.79	0.3	1.62e-8	Sex hormone-binding globulin levels;
LIHC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg00292662	chr22:38071168	LGALS1	0.63	10.04	0.48	6.04e-21	Fat distribution (HIV);
LIHC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.48	0.56	1.07e-29	Alzheimer's disease;
LIHC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.49	-7.55	-0.38	4.01e-13	Pulse pressure;
LIHC	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.8	-0.3	1.52e-8	Coronary artery disease;
LIHC	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg06533319	chr4:3265114	C4orf44	0.35	6.66	0.34	1.09e-10	Parental longevity (mother's age at death);
LIHC	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.42	-7.19	-0.36	4.16e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	0.39	6.16	0.32	2.08e-9	Coronary artery disease;
LIHC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.36	-5.86	-0.3	1.07e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.58e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.49	6.46	0.33	3.65e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg16434002	chr17:42200994	HDAC5	0.48	7.03	0.36	1.14e-11	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25154432	chr5:79703725	ZFYVE16	0.44	6.06	0.31	3.57e-9	Pancreatic cancer;
LIHC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.57	-7.58	-0.38	3.37e-13	Initial pursuit acceleration;
LIHC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg05555928	chr11:63887634	MACROD1	-0.51	-7.07	-0.36	8.6e-12	Body mass index;
LIHC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.95	0.31	6.6e-9	Height;
LIHC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.3	-16.62	-0.67	6.84e-46	Diabetic kidney disease;
LIHC	cis	rs539514	0.664	rs560069	chr13:76309344	A/G	cg04757411	chr13:76259545	LMO7	0.42	7.24	0.36	3.06e-12	Type 1 diabetes;
LIHC	trans	rs1912702	0.592	rs17138382	chr11:79174380	G/T	cg18020480	chr1:174186816	RABGAP1L	-0.45	-6.24	-0.32	1.27e-9	Hair greying;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24947615	chr21:44515479	U2AF1	0.41	6.08	0.31	3.28e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2016586	0.895	rs5995156	chr22:36105236	A/C	cg26342177	chr22:36113512	APOL5	-0.37	-6.31	-0.32	8.52e-10	Body mass index;
LIHC	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.79	8.17	0.4	6.22e-15	Schizophrenia;
LIHC	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-8.75	-0.43	9.75e-17	Schizophrenia;
LIHC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.71	-11.16	-0.52	6.98e-25	Fibrinogen levels;
LIHC	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg19752551	chr11:57585705	CTNND1	-0.51	-7.17	-0.36	4.8e-12	Schizophrenia;
LIHC	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.75	-11.57	-0.53	2.3e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.69	-10.84	-0.51	9.52e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.79	-0.5	1.54e-23	Mean corpuscular volume;
LIHC	cis	rs16912285	0.585	rs7950920	chr11:24356464	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	7.65	0.38	2.13e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.23	-0.32	1.39e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg08126542	chr6:37504118	NA	-0.36	-6.25	-0.32	1.19e-9	Cognitive performance;
LIHC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.75	11.33	0.52	1.79e-25	Corneal astigmatism;
LIHC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-8.99	-0.44	1.67e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7192750	0.562	rs9888748	chr16:71987851	G/A	cg06353428	chr16:71660113	MARVELD3	0.77	8.89	0.43	3.46e-17	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.3	-0.41	2.45e-15	Schizophrenia;
LIHC	cis	rs903552	1.000	rs12903048	chr15:102006325	G/T	cg25677261	chr15:102009856	PCSK6	-0.44	-5.95	-0.31	6.77e-9	Diabetic kidney disease;
LIHC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg16558253	chr16:72132732	DHX38	-0.5	-8.03	-0.4	1.58e-14	Fibrinogen levels;
LIHC	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg06026331	chr20:60912101	LAMA5	-0.51	-8.61	-0.42	2.67e-16	Colorectal cancer;
LIHC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.41	6.98	0.35	1.55e-11	Aortic root size;
LIHC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.81	-0.43	6.38e-17	Schizophrenia;
LIHC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-7.85	-0.39	5.49e-14	Tonsillectomy;
LIHC	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.52	-5.87	-0.3	1.04e-8	Polycystic ovary syndrome;
LIHC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02985541	chr2:219472218	PLCD4	0.45	8.41	0.41	1.09e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs903552	1.000	rs8043379	chr15:102005837	A/G	cg19295451	chr15:102010161	PCSK6	-0.46	-6.33	-0.32	7.51e-10	Diabetic kidney disease;
LIHC	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.35	6.84	0.35	3.73e-11	Multiple sclerosis;
LIHC	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.39	-0.41	1.29e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg13409248	chr3:40428643	ENTPD3	0.41	6.9	0.35	2.58e-11	Renal cell carcinoma;
LIHC	trans	rs7504990	0.802	rs11533771	chr18:50393300	G/A	cg08535148	chr4:26321143	RBPJ	0.52	6.14	0.32	2.33e-9	Gallbladder cancer;
LIHC	cis	rs11718455	0.538	rs1524887	chr3:44016371	C/T	cg08738300	chr3:44038990	NA	0.34	6.09	0.31	3.09e-9	Coronary artery disease;
LIHC	cis	rs1555399	0.792	rs2273596	chr14:67981870	T/C	cg16224230	chr14:67978224	TMEM229B	-0.24	-5.84	-0.3	1.25e-8	Parkinson's disease;
LIHC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	15.05	0.63	1.22e-39	Menarche (age at onset);
LIHC	cis	rs4917833	0.738	rs35898407	chr10:100221150	A/G	cg19043522	chr10:100227446	HPSE2	0.41	5.78	0.3	1.68e-8	Pediatric bone mineral density (femoral neck);
LIHC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg08694578	chr2:241835147	C2orf54	-0.51	-8.01	-0.4	1.8e-14	Urinary metabolites;
LIHC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.88	13.26	0.58	1.1e-32	Vitamin D levels;
LIHC	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17547399	chr2:54197573	PSME4	-0.44	-6.4	-0.33	5.04e-10	Calcium levels;
LIHC	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.5	7.86	0.39	5.11e-14	Migraine;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03532005	chr7:56119028	CCT6A;PSPH	-0.48	-6.19	-0.32	1.73e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg00057700	chr10:124768526	ACADSB;IKZF5	-0.53	-6.04	-0.31	4.07e-9	Systolic blood pressure;
LIHC	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	0.82	9.31	0.45	1.55e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs2282802	0.685	rs11745502	chr5:139558808	G/A	cg26211634	chr5:139558579	C5orf32	-0.39	-6.05	-0.31	3.82e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.62	-8.52	-0.42	5e-16	Vitamin D levels;
LIHC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.32e-11	Height;
LIHC	cis	rs6429082	0.871	rs6675944	chr1:235572669	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	6.65	0.34	1.15e-10	Adiposity;
LIHC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.85	-0.3	1.16e-8	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21448741	chr8:58168803	NA	0.35	6.55	0.33	2.1e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg02269571	chr22:50332266	NA	-0.65	-8.8	-0.43	6.68e-17	Schizophrenia;
LIHC	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.11	-0.4	9.1e-15	Response to antipsychotic treatment;
LIHC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg05584439	chr11:47213196	NA	0.42	6.05	0.31	3.73e-9	Longevity;
LIHC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.22	-0.45	3.13e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.58	6.68	0.34	9.98e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg21659725	chr3:3221576	CRBN	0.47	6.28	0.32	1.03e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7395581	0.959	rs2013867	chr11:47260272	A/G	cg26139080	chr11:47293733	MADD	-0.49	-8.29	-0.41	2.6e-15	HDL cholesterol;
LIHC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.16	0.48	2.3e-21	Alzheimer's disease (late onset);
LIHC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.89	0.43	3.49e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.48	7.75	0.39	1.03e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	9.41	0.45	7.75e-19	Platelet count;
LIHC	cis	rs244293	0.899	rs244309	chr17:53212093	C/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs9942416	0.585	rs253409	chr5:74928069	C/G	cg19683494	chr5:74908142	NA	-0.5	-6.6	-0.34	1.56e-10	Age-related disease endophenotypes;
LIHC	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.75	-11.49	-0.53	4.54e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	9.86	0.47	2.31e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.8	6.81	0.35	4.29e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.79	-8.82	-0.43	5.87e-17	Exhaled nitric oxide output;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09047471	chr8:56792345	LYN	0.46	6.54	0.33	2.24e-10	Migraine with aura;
LIHC	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.0	20.55	0.74	1.11e-61	Schizophrenia;
LIHC	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg24069376	chr3:38537580	EXOG	-0.38	-6.86	-0.35	3.26e-11	Electrocardiographic conduction measures;
LIHC	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.81	10.11	0.48	3.37e-21	Type 2 diabetes;
LIHC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.79	-12.28	-0.55	5.92e-29	Total body bone mineral density;
LIHC	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.09	0.36	7.85e-12	Exhaled nitric oxide output;
LIHC	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.44	8.41	0.41	1.09e-15	Testicular germ cell tumor;
LIHC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs12915845	0.545	rs12911061	chr15:89066635	T/A	cg05013243	chr15:89149849	MIR1179	-0.38	-6.88	-0.35	2.87e-11	Menarche (age at onset);
LIHC	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.52	8.75	0.43	1.02e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.28	0.32	1.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.35	-5.87	-0.3	1.03e-8	Cognitive function;
LIHC	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	0.92	17.64	0.69	5.57e-50	Schizophrenia;
LIHC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.32	-5.99	-0.31	5.22e-9	Body mass index;
LIHC	cis	rs59901009	0.954	rs56319831	chr11:10179849	A/G	cg01453529	chr11:10209919	SBF2	-0.31	-6.05	-0.31	3.87e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs12464559	0.649	rs4664499	chr2:152584153	A/C	cg01189475	chr2:152685088	ARL5A	0.61	7.42	0.37	9.07e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg18180155	chr22:45809454	SMC1B;RIBC2	0.48	5.83	0.3	1.27e-8	Tonsillectomy;
LIHC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg23625390	chr15:77176239	SCAPER	0.35	6.17	0.32	1.96e-9	Blood metabolite levels;
LIHC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.88	0.3	9.67e-9	Bipolar disorder;
LIHC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg07382826	chr16:28625726	SULT1A1	0.48	7.58	0.38	3.25e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.37	-0.41	1.54e-15	Renal cell carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08722104	chr11:47448306	PSMC3	0.47	6.72	0.34	7.67e-11	Pancreatic cancer;
LIHC	cis	rs11229555	0.609	rs12286421	chr11:58174898	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg10820045	chr2:198174542	NA	0.46	6.99	0.35	1.42e-11	Dermatomyositis;
LIHC	cis	rs903552	1.000	rs12906575	chr15:102003617	G/A	cg06707286	chr15:102010195	PCSK6	-0.43	-6.09	-0.31	3.08e-9	Diabetic kidney disease;
LIHC	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.53	0.33	2.33e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	1.13	8.67	0.42	1.71e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15320075	chr8:145703422	NA	-0.55	-9.46	-0.46	5.3e-19	Age at first birth;
LIHC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.51	-0.33	2.6200000000000003e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.65	10.12	0.48	3.11e-21	Type 2 diabetes;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23126947	chr3:93780364	NSUN3;DHFRL1	0.34	6.1	0.31	2.83e-9	Hepatitis;
LIHC	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg21231739	chr4:1642635	FAM53A	-0.36	-5.87	-0.3	1.04e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.39	0.37	1.17e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19927065	chr19:1122678	SBNO2	0.45	6.17	0.32	1.97e-9	Hip circumference;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07161146	chr7:151526959	PRKAG2	0.41	6.38	0.33	5.7e-10	Longevity;
LIHC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs28489187	0.683	rs1498373	chr1:85790633	G/A	cg16011679	chr1:85725395	C1orf52	0.48	6.15	0.32	2.13e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.64	11.08	0.51	1.44e-24	Diisocyanate-induced asthma;
LIHC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.58	-8.43	-0.41	9.97e-16	Prostate cancer;
LIHC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.57	7.86	0.39	5.11e-14	Neuroblastoma;
LIHC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.76	9.24	0.45	2.75e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg00990874	chr7:1149470	C7orf50	-0.4	-6.11	-0.31	2.73e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg15123519	chr2:136567270	LCT	-0.39	-7.81	-0.39	6.95e-14	Mosquito bite size;
LIHC	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.61	-11.03	-0.51	2.06e-24	Breast cancer;
LIHC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.26	17.23	0.68	2.57e-48	Diabetic kidney disease;
LIHC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.48	-6.18	-0.32	1.8e-9	Subjective well-being;
LIHC	cis	rs79387448	0.655	rs75579337	chr2:102917302	C/A	cg09003973	chr2:102972529	NA	1.2	9.65	0.46	1.2e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs4742903	1.000	rs10761010	chr9:106858788	G/A	cg14250997	chr9:106856677	SMC2	0.43	7.67	0.38	1.76e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.34	-5.74	-0.3	2.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.52	7.36	0.37	1.4e-12	Height;
LIHC	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg12160578	chr15:63334699	TPM1	0.67	8.87	0.43	4.13e-17	Orofacial clefts;
LIHC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.11	0.48	3.35e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.9	11.48	0.53	5.19e-26	Coronary artery disease;
LIHC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.69	-10.97	-0.51	3.51e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.26	-0.32	1.12e-9	Coronary artery disease;
LIHC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg15208524	chr1:10270712	KIF1B	-0.4	-5.93	-0.31	7.23e-9	Hepatocellular carcinoma;
LIHC	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00495681	chr13:53174319	NA	0.39	6.38	0.33	5.65e-10	Lewy body disease;
LIHC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-5.83	-0.3	1.26e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.3e-9	Aortic root size;
LIHC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.58	8.16	0.4	6.57e-15	Aortic root size;
LIHC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg06565975	chr8:143823917	SLURP1	0.33	6.41	0.33	4.92e-10	Urinary tract infection frequency;
LIHC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-14.06	-0.61	9.75e-36	Headache;
LIHC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-5.76	-0.3	1.89e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.58	-7.98	-0.4	2.21e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	1.02	18.24	0.7	2.09e-52	Tonsillectomy;
LIHC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	13.32	0.58	7.02e-33	Cognitive test performance;
LIHC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.99	13.02	0.58	9.43e-32	HIV-1 control;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18240814	chr5:107718300	FBXL17	-0.5	-6.65	-0.34	1.18e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs61550741	1.000	rs73191630	chr21:32499726	C/T	cg23515853	chr17:79372528	BAHCC1	-0.65	-6.19	-0.32	1.71e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.8	6.71	0.34	8.29e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-6.6	-0.34	1.58e-10	Initial pursuit acceleration;
LIHC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.5	-5.9	-0.3	8.98e-9	Menarche (age at onset);
LIHC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg13409248	chr3:40428643	ENTPD3	0.41	6.91	0.35	2.42e-11	Renal cell carcinoma;
LIHC	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg11161837	chr1:110010384	SYPL2	0.48	6.53	0.33	2.35e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs10213084	1.000	rs7670221	chr4:147497597	G/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg27432699	chr2:27873401	GPN1	0.59	8.6	0.42	2.84e-16	Total body bone mineral density;
LIHC	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg22832135	chr15:78370102	TBC1D2B	0.65	8.34	0.41	1.91e-15	Breast cancer;
LIHC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.71	-10.72	-0.5	2.52e-23	Subjective well-being;
LIHC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-7.9	-0.39	3.82e-14	Total body bone mineral density;
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg26939375	chr7:64535504	NA	0.47	7.19	0.36	4.13e-12	Aortic root size;
LIHC	cis	rs11112613	0.609	rs17037380	chr12:106036708	C/T	cg03607813	chr12:105948248	NA	0.44	6.9	0.35	2.51e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.26	0.55	6.62e-29	Prudent dietary pattern;
LIHC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg23262073	chr20:60523788	NA	-0.28	-5.78	-0.3	1.65e-8	Body mass index;
LIHC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.7	11.06	0.51	1.63e-24	Response to diuretic therapy;
LIHC	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg18367735	chr17:79674897	NA	0.73	8.24	0.41	3.72e-15	Dental caries;
LIHC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.6	-9.25	-0.45	2.44e-18	Lung cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08715805	chr2:45870883	NA	0.53	7.0	0.35	1.33e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.4	-0.33	5.17e-10	Height;
LIHC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.4	6.59	0.34	1.62e-10	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08431062	chr19:16607243	C19orf44;CALR3	0.39	6.33	0.32	7.55e-10	Cognitive function;
LIHC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.36	-6.45	-0.33	3.85e-10	Platelet distribution width;
LIHC	trans	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg01134436	chr17:81009848	B3GNTL1	0.8	6.79	0.34	4.97e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.43e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.55	0.53	2.76e-26	Platelet count;
LIHC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.74	-12.37	-0.56	2.77e-29	Systemic lupus erythematosus;
LIHC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs77106637	0.585	rs12292949	chr11:72457531	C/T	cg03713592	chr11:72463424	ARAP1	0.62	6.8	0.35	4.55e-11	Type 2 diabetes;
LIHC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.59	11.96	0.54	8.81e-28	Fat distribution (HIV);
LIHC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg02269571	chr22:50332266	NA	-0.62	-8.43	-0.41	9.8e-16	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04697482	chr19:16989084	SIN3B	0.42	6.23	0.32	1.38e-9	Longevity;
LIHC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.28	0.45	2.05e-18	Hemoglobin concentration;
LIHC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg06096015	chr1:231504339	EGLN1	0.5	9.39	0.45	9e-19	Hemoglobin concentration;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.53	0.42	4.92e-16	Height;
LIHC	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.75	-0.34	6.53e-11	Metabolite levels;
LIHC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.56	-9.42	-0.45	6.69e-19	Colorectal cancer;
LIHC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.37	-6.11	-0.31	2.65e-9	IgG glycosylation;
LIHC	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.58	-0.34	1.72e-10	Prevalent atrial fibrillation;
LIHC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.37	6.75	0.34	6.44e-11	Aortic root size;
LIHC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.47	-6.86	-0.35	3.2e-11	Aortic root size;
LIHC	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg03037974	chr15:76606532	NA	-0.5	-7.77	-0.39	9.47e-14	Blood metabolite levels;
LIHC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.52	7.2	0.36	3.74e-12	Morning vs. evening chronotype;
LIHC	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.7	-8.34	-0.41	1.8e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs918629	0.530	rs1423269	chr5:95255724	A/G	cg10483112	chr5:95245456	ELL2	-0.38	-6.99	-0.35	1.47e-11	IgG glycosylation;
LIHC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.12	0.4	8.44e-15	Electrocardiographic conduction measures;
LIHC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.12	0.31	2.52e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-6.43	-0.33	4.27e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.78	-0.54	3.97e-27	Alzheimer's disease;
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg11070056	chr1:107600091	PRMT6	-0.66	-10.87	-0.51	7.54e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.32	-0.32	8.08e-10	Blood metabolite levels;
LIHC	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg15595755	chr5:1867978	NA	0.34	6.38	0.33	5.83e-10	Cardiovascular disease risk factors;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04351903	chr1:202162209	LGR6	0.46	6.27	0.32	1.1e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.38	-6.75	-0.34	6.32e-11	Asthma;
LIHC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.48	7.39	0.37	1.11e-12	Breast cancer;
LIHC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg12903224	chr12:29470962	FAR2	-0.38	-5.99	-0.31	5.36e-9	QT interval;
LIHC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.11	0.52	1.07e-24	Hip circumference adjusted for BMI;
LIHC	trans	rs1464321	0.851	rs10778229	chr12:103692799	G/T	cg15403093	chr12:133312361	ANKLE2	0.41	6.41	0.33	4.7e-10	Body mass index;
LIHC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.54	7.53	0.38	4.49e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	12.53	0.56	6.7e-30	Multiple sclerosis;
LIHC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.73	-8.2	-0.41	4.98e-15	Neuroticism;
LIHC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.45	-0.37	7.79e-13	Platelet count;
LIHC	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg16309518	chr5:176445507	NA	-0.58	-11.44	-0.53	7.23e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08822215	chr16:89438651	ANKRD11	-0.49	-7.9	-0.39	3.92e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17691542	chr6:26056736	HIST1H1C	0.43	6.2	0.32	1.6e-9	Height;
LIHC	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.4	13.79	0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg19743168	chr1:23544995	NA	-0.36	-6.64	-0.34	1.26e-10	Height;
LIHC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.56	-0.33	1.98e-10	Mood instability;
LIHC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.6	11.17	0.52	6.7e-25	Systemic lupus erythematosus;
LIHC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.27	-16.32	-0.66	1.13e-44	Diabetic kidney disease;
LIHC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	trans	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.53	-0.33	2.44e-10	Educational attainment (years of education);
LIHC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06636551	chr8:101224915	SPAG1	-0.47	-8.76	-0.43	9.03e-17	Atrioventricular conduction;
LIHC	trans	rs7734985	0.728	rs6556904	chr5:95495637	G/C	cg07951579	chr16:10863179	NUBP1;FAM18A	0.34	6.05	0.31	3.89e-9	IgG glycosylation;
LIHC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.69	0.34	9.33e-11	Bipolar disorder;
LIHC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.83	15.52	0.64	1.74e-41	Response to diuretic therapy;
LIHC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.01	-0.4	1.79e-14	Type 2 diabetes;
LIHC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.52	7.23	0.36	3.11e-12	Morning vs. evening chronotype;
LIHC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.39	5.84	0.3	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.14	-0.36	5.73e-12	Personality dimensions;
LIHC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.21e-26	Motion sickness;
LIHC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg03934865	chr2:198174659	NA	-0.6	-9.65	-0.46	1.16e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.56	-8.82	-0.43	5.84e-17	Dental caries;
LIHC	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-6.36	-0.33	6.32e-10	Capecitabine sensitivity;
LIHC	cis	rs11229555	0.609	rs12289198	chr11:58175057	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.02	9.01	0.44	1.54e-17	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23248424	chr5:179741104	GFPT2	-0.46	-6.93	-0.35	2.11e-11	Height;
LIHC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg11057378	chr10:81107060	PPIF	0.37	6.01	0.31	4.75e-9	Height;
LIHC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.98	13.3	0.58	7.84e-33	Heart rate;
LIHC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.33	0.32	7.63e-10	Renal cell carcinoma;
LIHC	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	5.94	0.31	6.94e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06050784	chr16:88016603	BANP	0.35	6.46	0.33	3.5e-10	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18125479	chr14:51411049	PYGL	0.39	6.11	0.31	2.67e-9	Cognitive function;
LIHC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-6.05	-0.31	3.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg27523141	chr10:43048294	ZNF37B	0.38	6.49	0.33	2.94e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.16	0.32	2.04e-9	Rheumatoid arthritis;
LIHC	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.41	7.34	0.37	1.6e-12	Testicular germ cell tumor;
LIHC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.82	-0.3	1.36e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs4728302	0.869	rs10255193	chr7:133608911	C/G	cg10665199	chr7:133106180	EXOC4	0.39	6.81	0.35	4.48e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.64	9.3	0.45	1.72e-18	Schizophrenia;
LIHC	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.36	-6.3	-0.32	8.93e-10	Menopause (age at onset);
LIHC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.37	-6.73	-0.34	7.14e-11	Aortic root size;
LIHC	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.82	-0.43	5.91e-17	Total cholesterol levels;
LIHC	trans	rs2073499	0.935	rs2624840	chr3:50199015	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-6.69	-0.34	8.98e-11	Schizophrenia;
LIHC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.48	-6.3	-0.32	8.97e-10	Iron status biomarkers;
LIHC	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.28	21.87	0.76	6.17e-67	Corneal structure;
LIHC	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.03	-20.04	-0.73	1.2e-59	Exhaled nitric oxide output;
LIHC	cis	rs2257205	0.667	rs9912325	chr17:56873934	A/G	cg12560992	chr17:57184187	TRIM37	0.68	7.44	0.37	8.24e-13	Pancreatic cancer;
LIHC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.91	-0.3	8.14e-9	Life satisfaction;
LIHC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.63	9.97	0.47	1.01e-20	Multiple myeloma (IgH translocation);
LIHC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.89	-18.29	-0.7	1.34e-52	Height;
LIHC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.57	-0.42	3.55e-16	Cognitive function;
LIHC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	8.09	0.4	1.05e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.61	8.79	0.43	7.54e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.32	-8.44	-0.42	9.36e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.54	-12.97	-0.57	1.47e-31	White blood cell count (basophil);
LIHC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg12365402	chr11:9010492	NRIP3	-0.26	-6.61	-0.34	1.43e-10	Hemoglobin concentration;
LIHC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00802000	chr16:706648	WDR90	-0.39	-6.31	-0.32	8.43e-10	Height;
LIHC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg02269571	chr22:50332266	NA	0.6	8.52	0.42	5.24e-16	Schizophrenia;
LIHC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.64	-10.82	-0.51	1.13e-23	Crohn's disease;
LIHC	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.34	-5.9	-0.3	8.75e-9	IgG glycosylation;
LIHC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.64	8.1	0.4	1e-14	Mean platelet volume;
LIHC	cis	rs7119038	0.818	rs6589684	chr11:118610957	A/G	cg19308663	chr11:118741387	NA	-0.43	-5.92	-0.3	7.78e-9	Sjögren's syndrome;
LIHC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg14092571	chr14:90743983	NA	-0.38	-6.03	-0.31	4.15e-9	Mortality in heart failure;
LIHC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23422044	chr7:1970798	MAD1L1	-0.52	-7.97	-0.4	2.47e-14	Neuroticism;
LIHC	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.47	6.29	0.32	9.64e-10	Cognitive test performance;
LIHC	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg04306507	chr14:55594613	LGALS3	0.33	6.19	0.32	1.7e-9	Protein biomarker;
LIHC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.51	0.42	5.54e-16	Initial pursuit acceleration;
LIHC	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.72	11.74	0.54	5.55e-27	Oral cavity cancer;
LIHC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.75	-10.96	-0.51	3.82e-24	Coronary artery disease;
LIHC	trans	rs10213084	1.000	rs10212917	chr4:147499315	T/C	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02290350	chr8:58132656	NA	0.49	10.56	0.5	9.22e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1000083	0.915	rs10463199	chr5:96545475	C/T	ch.5.96698337R	chr5:96672581	NA	-0.8	-6.75	-0.34	6.31e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.11	-0.44	6.99e-18	Gut microbiome composition (summer);
LIHC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.11	-0.36	6.77e-12	Schizophrenia;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.51	-10.31	-0.49	6.76e-22	Abdominal aortic aneurysm;
LIHC	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg12615879	chr12:58013172	SLC26A10	0.37	6.89	0.35	2.69e-11	Multiple sclerosis;
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg14222432	chr12:29376421	FAR2	0.37	7.13	0.36	5.83e-12	QT interval;
LIHC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg06634786	chr22:41940651	POLR3H	-0.52	-5.75	-0.3	2.01e-8	Neuroticism;
LIHC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.37	6.31	0.32	8.86e-10	Uric acid levels;
LIHC	cis	rs11628318	0.515	rs4906239	chr14:103078073	A/G	cg12046867	chr14:103022105	NA	-0.38	-5.73	-0.3	2.16e-8	Platelet count;
LIHC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.18	-0.52	6.29e-25	Response to antipsychotic treatment;
LIHC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.89e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg17771515	chr6:154831774	CNKSR3	0.59	6.27	0.32	1.1e-9	Lipoprotein (a) levels;
LIHC	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-0.87	-11.02	-0.51	2.3e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.5	-8.04	-0.4	1.53e-14	Colorectal cancer;
LIHC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.36	3.41e-12	Protein C levels;
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.46	-0.37	7.18e-13	Renal cell carcinoma;
LIHC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.82	14.35	0.61	6.81e-37	Dental caries;
LIHC	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.75	-0.34	6.3e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24110177	chr3:50126178	RBM5	0.42	6.47	0.33	3.43e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.54	6.61	0.34	1.43e-10	Bipolar disorder;
LIHC	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.73	-12.92	-0.57	2.25e-31	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-11.29	-0.52	2.55e-25	Primary sclerosing cholangitis;
LIHC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	1.0	9.76	0.47	5.08e-20	Eosinophil percentage of granulocytes;
LIHC	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.53	6.13	0.31	2.36e-9	Axial length;
LIHC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19623624	chr10:135278901	LOC619207	-0.45	-6.97	-0.35	1.65e-11	Systemic lupus erythematosus;
LIHC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.83	11.23	0.52	4.18e-25	Coronary artery disease;
LIHC	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.58	7.49	0.38	5.82e-13	Corneal astigmatism;
LIHC	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.26	-0.32	1.17e-9	Coronary artery disease;
LIHC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.51	6.19	0.32	1.69e-9	Heart rate;
LIHC	cis	rs860295	0.812	rs12407800	chr1:155760742	A/C	cg02153340	chr1:155202674	NA	-0.33	-6.11	-0.31	2.73e-9	Body mass index;
LIHC	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.55	-7.81	-0.39	6.9e-14	Body mass index;
LIHC	cis	rs4728302	0.869	rs11770927	chr7:133593126	G/A	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.34	0.81	1.72e-80	Prudent dietary pattern;
LIHC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	trans	rs7714584	1.000	rs7714415	chr5:150270292	A/G	cg20675040	chr8:143813288	C8orf55	0.34	6.12	0.31	2.54e-9	Crohn's disease;
LIHC	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg16736954	chr20:23401023	NAPB	0.54	6.02	0.31	4.6e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-12.33	-0.55	3.84e-29	Alzheimer's disease (late onset);
LIHC	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.45	6.17	0.32	1.95e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07677032	chr17:61819896	STRADA	0.41	6.05	0.31	3.91e-9	Prudent dietary pattern;
LIHC	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	8.2	0.41	4.92e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.72	12.93	0.57	2.01e-31	Ulcerative colitis;
LIHC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-10.75	-0.5	2.02e-23	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg27523141	chr10:43048294	ZNF37B	0.35	6.09	0.31	3.06e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs62229266	0.647	rs59397717	chr21:37451725	C/T	cg12218747	chr21:37451666	NA	-0.43	-7.03	-0.36	1.15e-11	Mitral valve prolapse;
LIHC	cis	rs2016586	0.895	rs4821438	chr22:36114047	C/T	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.49	0.56	9.88e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg00280220	chr17:61926910	NA	0.42	6.87	0.35	3.08e-11	Prudent dietary pattern;
LIHC	trans	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.09	0.31	3.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg04592579	chr7:75616294	TMEM120A	0.37	6.41	0.33	4.8e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.35	-6.37	-0.33	6.12e-10	Aortic root size;
LIHC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg04013166	chr16:89971882	TCF25	0.49	5.91	0.3	8.48e-9	Skin colour saturation;
LIHC	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg02527881	chr3:46936655	PTH1R	0.33	6.33	0.32	7.78e-10	Colorectal cancer;
LIHC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.45	-7.18	-0.36	4.27e-12	Diastolic blood pressure;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.63	8.86	0.43	4.53e-17	Skin colour saturation;
LIHC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.58	10.77	0.5	1.8e-23	Vitamin D levels;
LIHC	cis	rs9783347	1.000	rs4150661	chr11:18379629	C/A	cg15585147	chr11:18324498	HPS5	0.37	6.08	0.31	3.21e-9	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.13	0.4	7.83e-15	Height;
LIHC	cis	rs8192917	1.000	rs6573910	chr14:25100882	A/G	cg03875678	chr14:25103546	GZMB	-0.42	-7.6	-0.38	2.95e-13	Vitiligo;
LIHC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.06	-0.48	5.08e-21	Response to antipsychotic treatment;
LIHC	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	12.18	0.55	1.34e-28	Cognitive test performance;
LIHC	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-6.09	-0.31	3.02e-9	Tuberculosis;
LIHC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.89	-0.3	9.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.58	6.32	0.32	8.09e-10	Systemic lupus erythematosus;
LIHC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.21	0.52	4.58e-25	Platelet count;
LIHC	cis	rs2273156	1.000	rs7141292	chr14:35462906	T/A	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.01	-0.31	4.78e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg10381502	chr11:71823885	C11orf51	-1.08	-9.2	-0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs9888615	1.000	rs9888615	chr14:53377540	T/C	cg00686598	chr14:53173677	PSMC6	-0.5	-6.2	-0.32	1.59e-9	Systolic blood pressure;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05790002	chr16:82033681	SDR42E1	0.49	6.75	0.34	6.2e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg09597638	chr17:3907349	NA	0.54	6.49	0.33	2.98e-10	Type 2 diabetes;
LIHC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg20684491	chr1:25596433	NA	0.29	5.83	0.3	1.25e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs2412488	0.927	rs931181	chr4:54243074	T/C	cg22241045	chr4:54363911	LNX1	-0.4	-6.48	-0.33	3.15e-10	DNA methylation (variation);
LIHC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.93	0.35	2.06e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9322817	0.603	rs9386426	chr6:105165367	A/G	cg02098413	chr6:105308735	HACE1	-0.36	-5.77	-0.3	1.73e-8	Thyroid stimulating hormone;
LIHC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.53	9.48	0.46	4.55e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.33	-0.32	7.6e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.6	0.34	1.6e-10	Bipolar disorder;
LIHC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.57	6.52	0.33	2.6e-10	Neutrophil percentage of white cells;
LIHC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg21361702	chr7:150065534	REPIN1	0.48	6.63	0.34	1.29e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.41	-6.02	-0.31	4.38e-9	Menarche (age at onset);
LIHC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-6.93	-0.35	2.11e-11	Bipolar disorder;
LIHC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.95	-0.39	2.84e-14	Body mass index;
LIHC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-12.46	-0.56	1.21e-29	Chronic sinus infection;
LIHC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-10.89	-0.51	6.78e-24	Type 2 diabetes;
LIHC	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.26	5.94	0.31	7.09e-9	Heart rate;
LIHC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-14.17	-0.61	3.66e-36	Headache;
LIHC	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-8.74	-0.43	1.1e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.64	0.34	1.23e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs4766897	0.543	rs10850001	chr12:112553032	T/A	cg01169073	chr12:112280321	C12orf47;MAPKAPK5	0.39	5.92	0.31	7.63e-9	Fibrinogen levels;
LIHC	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.6	10.44	0.49	2.56e-22	Diisocyanate-induced asthma;
LIHC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg24693881	chr1:107596107	NA	0.56	9.78	0.47	4.41e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.6	11.78	0.54	4.02e-27	Tonsillectomy;
LIHC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.68	13.23	0.58	1.46e-32	High light scatter reticulocyte count;
LIHC	cis	rs77637988	0.578	rs7577237	chr2:48601816	A/G	cg00032884	chr2:48540671	FOXN2	-0.41	-6.48	-0.33	3.14e-10	Joint mobility (Beighton score);
LIHC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.39	-0.45	9.01e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs7818688	0.697	rs112411609	chr8:95980854	C/A	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.67	-10.89	-0.51	6.46e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg10755058	chr3:40428713	ENTPD3	0.41	7.17	0.36	4.59e-12	Renal cell carcinoma;
LIHC	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg20560298	chr2:73613845	ALMS1	0.36	5.91	0.3	8.31e-9	Metabolite levels;
LIHC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.58	8.49	0.42	6.45e-16	Platelet count;
LIHC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.37	0.37	1.29e-12	Vitiligo;
LIHC	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.66	-11.66	-0.53	1.16e-26	Menarche (age at onset);
LIHC	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22618164	chr12:122356400	WDR66	-0.46	-7.59	-0.38	3.03e-13	Mean corpuscular volume;
LIHC	cis	rs963731	0.649	rs297130	chr2:39299314	C/T	cg04010122	chr2:39346883	SOS1	0.69	6.28	0.32	1.05e-9	Corticobasal degeneration;
LIHC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg08539965	chr1:21396338	EIF4G3	0.33	5.74	0.3	2.07e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.64	0.53	1.34e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs9641123	0.580	rs2051748	chr7:93199574	A/G	cg09745688	chr16:2908918	PRSS22	-0.37	-6.34	-0.32	7.31e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.87	-10.84	-0.51	9.96e-24	Prostate cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26175033	chr2:43037432	NA	-0.42	-6.36	-0.33	6.38e-10	Pancreatic cancer;
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg18279126	chr7:2041391	MAD1L1	0.37	6.1	0.31	2.88e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg12373951	chr3:133503437	NA	0.45	7.54	0.38	4.18e-13	Iron status biomarkers;
LIHC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.42	7.96	0.4	2.57e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02034447	chr16:89574710	SPG7	0.5	7.69	0.38	1.61e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs507080	0.922	rs502601	chr11:118565679	G/A	cg04173919	chr11:118528438	PHLDB1	0.36	6.62	0.34	1.43e-10	Serum metabolite levels;
LIHC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.56	9.99	0.48	8.49e-21	Platelet distribution width;
LIHC	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.19	18.29	0.7	1.36e-52	Corneal structure;
LIHC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	9.49	0.46	4.13e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg16479474	chr6:28041457	NA	0.45	6.4	0.33	5.05e-10	Depression;
LIHC	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.77	8.91	0.43	2.99e-17	Exhaled nitric oxide levels;
LIHC	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.85	0.47	2.6e-20	Corneal astigmatism;
LIHC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.53	6.97	0.35	1.6e-11	Morning vs. evening chronotype;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01110552	chr10:103578627	MGEA5	0.46	7.04	0.36	1.06e-11	Pancreatic cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25193742	chr10:104614220	C10orf32	0.4	6.1	0.31	2.92e-9	Calcium levels;
LIHC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.62	8.18	0.4	5.58e-15	Height;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18710692	chr13:20437712	ZMYM5	-0.53	-6.17	-0.32	1.97e-9	Systolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19640263	chr11:62414186	GANAB	-0.44	-6.17	-0.32	1.91e-9	Pancreatic cancer;
LIHC	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.6	6.9	0.35	2.49e-11	Height;
LIHC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.56	-9.02	-0.44	1.34e-17	Menarche (age at onset);
LIHC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.87	13.07	0.58	6.35e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs807029	0.577	rs11190787	chr10:102758625	G/T	cg25179470	chr10:102756915	LZTS2	0.45	6.26	0.32	1.15e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.4	8.12	0.4	8.38e-15	Cardiovascular disease risk factors;
LIHC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.44	7.21	0.36	3.62e-12	Red blood cell count;
LIHC	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg05760424	chr2:242988095	NA	-0.5	-6.69	-0.34	9.22e-11	Obesity-related traits;
LIHC	cis	rs4407350	0.870	rs1894461	chr22:44911287	C/T	cg11695653	chr22:44894386	LDOC1L	-0.36	-6.06	-0.31	3.69e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.45	6.22	0.32	1.48e-9	Schizophrenia;
LIHC	cis	rs4742903	0.935	rs17236663	chr9:106928402	G/A	cg14250997	chr9:106856677	SMC2	0.36	6.02	0.31	4.43e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs11077998	0.967	rs901373	chr17:80506559	A/G	cg10255544	chr17:80519551	FOXK2	0.5	8.92	0.43	2.88e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs10916814	1.000	rs4654863	chr1:20902244	G/A	cg24502330	chr1:20914028	CDA	-0.28	-5.88	-0.3	9.72e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg00204512	chr16:28754710	NA	0.41	7.22	0.36	3.41e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	11.67	0.53	1.03e-26	Menarche (age at onset);
LIHC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg03037974	chr15:76606532	NA	-0.61	-10.2	-0.48	1.73e-21	Blood metabolite levels;
LIHC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg16797656	chr11:68205561	LRP5	0.51	8.1	0.4	9.54e-15	Total body bone mineral density;
LIHC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.67	13.3	0.58	7.99e-33	High light scatter reticulocyte count;
LIHC	cis	rs16958440	0.867	rs117060920	chr18:44709035	G/A	cg17192377	chr18:44677553	HDHD2	0.86	8.02	0.4	1.71e-14	Sitting height ratio;
LIHC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.86	11.16	0.52	7.1e-25	Heart rate;
LIHC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05036130	chr6:150231994	NA	0.36	5.97	0.31	5.83e-9	Lung cancer;
LIHC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg07706471	chr12:123319906	HIP1R	-0.63	-8.28	-0.41	2.88e-15	Schizophrenia;
LIHC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.32	-7.5	-0.38	5.53e-13	Hip circumference;Waist circumference;
LIHC	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.5	-6.65	-0.34	1.18e-10	Obesity (extreme);
LIHC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg00035636	chr13:21900591	NA	0.37	6.05	0.31	3.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg12253828	chr6:101329408	ASCC3	0.42	6.7	0.34	8.81e-11	Neuroticism;
LIHC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg06565975	chr8:143823917	SLURP1	0.38	7.35	0.37	1.46e-12	Urinary tract infection frequency;
LIHC	cis	rs2637030	0.502	rs1844698	chr5:52970339	G/A	cg06476337	chr5:52856530	NDUFS4	0.43	6.8	0.35	4.68e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.59	5.78	0.3	1.64e-8	Plasma clusterin levels;
LIHC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16262614	chr3:133464971	TF	0.27	6.03	0.31	4.21e-9	Iron status biomarkers;
LIHC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.59	-11.48	-0.53	5.08e-26	Coronary artery disease;
LIHC	cis	rs7487075	0.780	rs10785624	chr12:46766787	C/T	cg22049899	chr12:47219821	SLC38A4	0.36	6.15	0.32	2.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.53	8.4	0.41	1.2e-15	Platelet count;
LIHC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg14067834	chr17:29058358	SUZ12P	0.69	6.86	0.35	3.31e-11	Body mass index;
LIHC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.93	0.31	7.24e-9	Lymphocyte percentage of white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03993171	chr6:86388501	SNORD50B;SNORD50A;SNHG5	0.43	6.73	0.34	6.98e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.66	7.19	0.36	4.1e-12	Protein C levels;
LIHC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.62	9.87	0.47	2.26e-20	Corneal astigmatism;
LIHC	cis	rs7712401	0.755	rs10071705	chr5:122132725	T/C	cg18764291	chr5:122110994	SNX2	0.37	6.28	0.32	1.01e-9	Mean platelet volume;
LIHC	cis	rs2642442	0.962	rs2642439	chr1:220970499	C/T	cg04704887	chr1:220970030	MOSC1	0.44	5.94	0.31	6.99e-9	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.66	8.33	0.41	2.01e-15	Gut microbiome composition (summer);
LIHC	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg17130504	chr10:102756923	LZTS2	0.56	7.78	0.39	8.74e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.78	-11.6	-0.53	1.92e-26	Motion sickness;
LIHC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.59	-6.94	-0.35	2e-11	Menarche (age at onset);
LIHC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.75	-11.43	-0.53	7.65e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	22.84	0.78	9.22e-71	Colorectal cancer;
LIHC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.7	-9.89	-0.47	1.83e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11878675	chr2:74211845	NA	0.63	8.39	0.41	1.33e-15	Lung function (FEV1/FVC);
LIHC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg05555928	chr11:63887634	MACROD1	0.46	6.02	0.31	4.41e-9	Mean platelet volume;
LIHC	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.56	-7.32	-0.37	1.77e-12	Coronary artery calcification;
LIHC	cis	rs17106184	1.000	rs72898953	chr1:50963858	T/C	cg07174182	chr1:51127561	FAF1	-0.59	-6.61	-0.34	1.47e-10	Type 2 diabetes;
LIHC	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg15485101	chr11:133734466	NA	0.26	6.28	0.32	1.06e-9	Childhood ear infection;
LIHC	trans	rs3748022	1.000	rs12124627	chr1:206687263	C/G	cg10512875	chr12:29936174	TMTC1	-0.46	-6.14	-0.32	2.32e-9	Lymphocyte counts;
LIHC	cis	rs8049040	0.500	rs7188475	chr16:71446358	C/T	cg06353428	chr16:71660113	MARVELD3	-0.56	-6.32	-0.32	7.95e-10	Blood protein levels;
LIHC	cis	rs5758659	0.692	rs5751251	chr22:42640606	G/C	cg19513890	chr22:42538836	CYP2D7P1	-0.31	-5.93	-0.31	7.29e-9	Cognitive function;
LIHC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg12046867	chr14:103022105	NA	-0.58	-8.27	-0.41	2.99e-15	Platelet count;
LIHC	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.92	-0.39	3.42e-14	Breast cancer;
LIHC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.36	6.14	0.32	2.27e-9	Urate levels in obese individuals;
LIHC	cis	rs6504950	0.720	rs2877634	chr17:52987545	A/G	cg10237252	chr17:52977213	TOM1L1	-0.37	-6.42	-0.33	4.58e-10	Breast cancer;
LIHC	cis	rs3814244	0.528	rs56393928	chr12:68423707	A/G	cg15249341	chr12:68405565	NA	-0.3	-5.81	-0.3	1.46e-8	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.39	8.11	0.4	9.38e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.47	-8.77	-0.43	8.4e-17	Body mass index;
LIHC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.68	-11.01	-0.51	2.54e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.778	rs4970766	chr1:110013955	A/G	cg23091122	chr1:110024289	SYPL2	0.45	6.22	0.32	1.48e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.46	0.49	2.07e-22	Personality dimensions;
LIHC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	0.79	11.6	0.53	1.77e-26	Monocyte percentage of white cells;
LIHC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg15691649	chr6:25882328	NA	-0.46	-5.79	-0.3	1.56e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.48	9.23	0.45	2.94e-18	Testicular germ cell tumor;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14727059	chr3:53195316	PRKCD	-0.54	-6.26	-0.32	1.17e-9	Systolic blood pressure;
LIHC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg18912006	chr12:123335444	HIP1R	-0.59	-6.54	-0.33	2.23e-10	Schizophrenia;
LIHC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.96	-12.76	-0.57	9.14e-31	Schizophrenia;
LIHC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.69	10.58	0.5	8e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.6	9.31	0.45	1.54e-18	Uric acid clearance;
LIHC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg07424592	chr7:64974309	NA	0.82	9.64	0.46	1.27e-19	Diabetic kidney disease;
LIHC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg12661370	chr5:149340060	SLC26A2	0.49	5.99	0.31	5.3e-9	HIV-1 control;
LIHC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.21	-0.32	1.51e-9	Bipolar disorder;
LIHC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.03	-0.36	1.1e-11	Diabetic kidney disease;
LIHC	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.48	-0.37	6.36e-13	Mean platelet volume;
LIHC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.56	7.53	0.38	4.51e-13	Bone properties (heel);
LIHC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.9	-18.39	-0.71	5.32e-53	Height;
LIHC	cis	rs2386661	0.523	rs7896088	chr10:5652286	C/T	cg17085576	chr10:5658249	NA	-0.3	-5.85	-0.3	1.15e-8	Breast cancer;
LIHC	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.37	6.08	0.31	3.15e-9	Lung cancer;
LIHC	cis	rs4728302	0.869	rs10155909	chr7:133593036	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.52	0.33	2.46e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg27432699	chr2:27873401	GPN1	-0.93	-16.37	-0.66	7.08e-45	Oral cavity cancer;
LIHC	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg01285391	chr19:53465759	ZNF816A	-0.32	-5.75	-0.3	2e-8	Psoriasis;
LIHC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg00750074	chr16:89608354	SPG7	-0.4	-6.21	-0.32	1.58e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.75	-0.39	1.02e-13	Fibroblast growth factor basic levels;
LIHC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.43	-8.36	-0.41	1.62e-15	Extrinsic epigenetic age acceleration;
LIHC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg21003380	chr1:156261207	TMEM79	0.36	5.78	0.3	1.72e-8	Tonsillectomy;
LIHC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.6	7.86	0.39	5.1e-14	Parkinson's disease;
LIHC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.84	0.3	1.21e-8	Menopause (age at onset);
LIHC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	8.05	0.4	1.42e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.5	7.62	0.38	2.59e-13	Systemic lupus erythematosus;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09352908	chr3:37017749	NA	0.42	6.23	0.32	1.4e-9	Pancreatic cancer;
LIHC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	0.88	6.0	0.31	5.03e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12602486	1.000	rs16940539	chr17:42224581	C/G	cg08193365	chr17:42277699	NA	1.09	7.72	0.39	1.27e-13	Glycated hemoglobin levels;
LIHC	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg10127483	chr1:110009974	SYPL2	0.48	6.06	0.31	3.53e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-6.08	-0.31	3.25e-9	Body mass index;
LIHC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.92	9.76	0.47	5.28e-20	Morning vs. evening chronotype;
LIHC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg06199346	chr11:14280333	SPON1	0.35	5.86	0.3	1.07e-8	Mitochondrial DNA levels;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.08	-0.31	3.17e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.45	-0.33	3.85e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	9.31	0.45	1.61e-18	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.67	-11.5	-0.53	4.42e-26	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.0	-0.6	1.66e-35	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.34	6.78	0.34	5.26e-11	Renal cell carcinoma;
LIHC	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.58	-8.37	-0.41	1.46e-15	Facial morphology (factor 19);
LIHC	trans	rs2710642	0.564	rs7558681	chr2:62840987	G/A	cg23713900	chr18:615496	CLUL1	-0.23	-6.05	-0.31	3.86e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	13.98	0.6	1.94e-35	Chronic sinus infection;
LIHC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.24	-0.45	2.68e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.49	6.94	0.35	2.02e-11	Obesity-related traits;
LIHC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13647721	chr17:30228624	UTP6	0.8	7.74	0.39	1.17e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.18	-0.32	1.77e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.57	9.61	0.46	1.59e-19	Alcohol dependence;
LIHC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg19773385	chr1:10388646	KIF1B	-0.33	-6.05	-0.31	3.91e-9	Hepatocellular carcinoma;
LIHC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.63	0.42	2.27e-16	Schizophrenia;
LIHC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.76	11.6	0.53	1.88e-26	Corneal astigmatism;
LIHC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.63	0.46	1.43e-19	Bipolar disorder;
LIHC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.57	8.38	0.41	1.37e-15	Platelet count;
LIHC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.69	12.44	0.56	1.41e-29	Iron status biomarkers;
LIHC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-8.56	-0.42	3.83e-16	Vitiligo;
LIHC	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.0	-0.35	1.39e-11	Metabolite levels;
LIHC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.78	-0.5	1.65e-23	Alcohol dependence;
LIHC	cis	rs11673344	0.764	rs10424584	chr19:37466888	G/A	cg27390819	chr19:37464633	NA	-0.49	-5.87	-0.3	1.05e-8	Obesity-related traits;
LIHC	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.54	8.44	0.42	9.12e-16	Corneal astigmatism;
LIHC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.79	11.2	0.52	5.04e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg09417038	chr21:47716443	C21orf57	-0.5	-7.35	-0.37	1.5e-12	Testicular germ cell tumor;
LIHC	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.42	6.58	0.34	1.73e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10869376	chr13:41345315	MRPS31	0.44	6.26	0.32	1.14e-9	Pancreatic cancer;
LIHC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.58	-8.6	-0.42	2.86e-16	Glaucoma (primary open-angle);
LIHC	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.75	-11.49	-0.53	4.54e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.26	6.18	0.32	1.81e-9	Heart rate;
LIHC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.53	-6.57	-0.33	1.83e-10	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.09	-15.97	-0.65	2.73e-43	Chronic sinus infection;
LIHC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg03013999	chr17:37608204	MED1	0.34	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04980793	chr14:35451984	SRP54	0.43	6.34	0.32	7.28e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-8.31	-0.41	2.31e-15	Longevity;Endometriosis;
LIHC	cis	rs787274	1.000	rs4979150	chr9:115553502	T/A	cg13803584	chr9:115635662	SNX30	-0.6	-6.68	-0.34	9.69e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2279817	0.908	rs3766310	chr1:17977642	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.62	-7.04	-0.36	1.03e-11	Neuroticism;
LIHC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.56	10.36	0.49	4.79e-22	Methadone dose in opioid dependence;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.9	-0.3	8.51e-9	Total body bone mineral density;
LIHC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.88	11.71	0.53	7.59e-27	Blood metabolite levels;
LIHC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.62	-8.78	-0.43	7.98e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.67	-9.06	-0.44	1.03e-17	Schizophrenia;
LIHC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.52	-17.08	-0.68	1e-47	Breast cancer;
LIHC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.52	6.82	0.35	4.23e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7945718	0.621	rs6485978	chr11:12678415	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.79	0.39	8.06e-14	Educational attainment (years of education);
LIHC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02450064	chr17:40260053	DHX58	-0.3	-6.14	-0.32	2.24e-9	Fibrinogen levels;
LIHC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.21e-16	Motion sickness;
LIHC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.96	14.2	0.61	2.67e-36	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs9596863	0.821	rs4884722	chr13:54429821	C/A	ch.13.53330881F	chr13:54432880	NA	-0.43	-5.97	-0.31	6.08e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.84	6.65	0.34	1.14e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg24826892	chr11:71159390	DHCR7	-0.46	-5.86	-0.3	1.06e-8	Vitamin D levels;
LIHC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.44	-6.72	-0.34	7.61e-11	Platelet distribution width;
LIHC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.68	10.24	0.48	1.19e-21	Height;
LIHC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.08	0.31	3.26e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.7	6.72	0.34	7.7e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-8.22	-0.41	4.17e-15	Menopause (age at onset);
LIHC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.67	10.56	0.5	9.86e-23	Prostate cancer;
LIHC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg00343986	chr7:65444356	GUSB	0.39	5.77	0.3	1.76e-8	Aortic root size;
LIHC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.86	12.99	0.57	1.26e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-5.79	-0.3	1.62e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.79	-0.34	5.04e-11	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg12798992	chr6:167411361	FGFR1OP	0.44	6.77	0.34	5.73e-11	Primary biliary cholangitis;
LIHC	cis	rs2084898	0.891	rs504976	chr11:120000233	C/A	cg13907859	chr11:120009124	TRIM29	-0.53	-6.53	-0.33	2.39e-10	Stroke (pediatric);
LIHC	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.48	-8.03	-0.4	1.6e-14	Blood metabolite levels;
LIHC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg03945807	chr20:60948434	NA	-0.41	-6.81	-0.35	4.4e-11	Colorectal cancer;
LIHC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs72627123	0.867	rs73301477	chr14:74463560	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.6	0.42	2.96e-16	Morning vs. evening chronotype;
LIHC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg24879335	chr3:133465180	TF	0.27	5.83	0.3	1.25e-8	Iron status biomarkers;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08536481	chr12:123459152	ABCB9;OGFOD2	-0.38	-6.29	-0.32	9.94e-10	Longevity;
LIHC	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg23533926	chr12:111358616	MYL2	-0.36	-6.86	-0.35	3.18e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.4	-6.35	-0.32	7.05e-10	Fibrinogen levels;
LIHC	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-6.59	-0.34	1.71e-10	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg06359132	chr10:99160096	RRP12	-0.41	-6.4	-0.33	5.18e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg03037974	chr15:76606532	NA	0.71	13.75	0.6	1.53e-34	Blood metabolite levels;
LIHC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.79	11.81	0.54	3.14e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.38	-5.75	-0.3	1.94e-8	P wave terminal force;
LIHC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.38	6.86	0.35	3.16e-11	Aortic root size;
LIHC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00152838	chr16:24741724	TNRC6A	-0.51	-6.3	-0.32	9.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-10.15	-0.48	2.53e-21	Longevity;Endometriosis;
LIHC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.92	17.11	0.68	7.76e-48	Aortic root size;
LIHC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.21	-0.32	1.5e-9	Total body bone mineral density;
LIHC	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.35	-5.94	-0.31	6.91e-9	Quantitative traits;
LIHC	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.31	0.32	8.43e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.47	0.42	7.2e-16	Platelet count;
LIHC	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg05481257	chr2:20870211	GDF7	-0.43	-8.1	-0.4	9.66e-15	Abdominal aortic aneurysm;
LIHC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.41	5.75	0.3	1.99e-8	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-7.17	-0.36	4.67e-12	Renal cell carcinoma;
LIHC	trans	rs13325613	0.915	rs34289272	chr3:46263244	C/T	cg26337592	chr1:153642686	ILF2	0.68	6.2	0.32	1.66e-9	Monocyte count;
LIHC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.55	8.9	0.43	3.4e-17	Longevity;Endometriosis;
LIHC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.23	5.86	0.3	1.1e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.48	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	cis	rs4294134	1.000	rs4294134	chr7:135293128	A/G	cg20392616	chr7:135392013	SLC13A4	-0.4	-6.57	-0.33	1.88e-10	Paget's disease;
LIHC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.93	11.47	0.53	5.44e-26	HIV-1 control;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11079354	chr6:27740361	NA	0.42	6.93	0.35	2.07e-11	Cognitive function;
LIHC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-7.47	-0.37	6.86e-13	Prudent dietary pattern;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg22081355	chr19:17186472	HAUS8;MYO9B	-0.56	-6.26	-0.32	1.17e-9	Systolic blood pressure;
LIHC	cis	rs9783347	0.961	rs4150526	chr11:18343209	G/A	cg15585147	chr11:18324498	HPS5	0.43	6.65	0.34	1.18e-10	Pancreatic cancer;
LIHC	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg12560992	chr17:57184187	TRIM37	0.69	9.09	0.44	8.27e-18	Vitamin D levels;
LIHC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg19920283	chr7:105172520	RINT1	0.66	5.94	0.31	6.91e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.76	7.45	0.37	7.54e-13	Platelet count;
LIHC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	0.96	9.45	0.45	5.74e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs16958440	0.867	rs79275306	chr18:44711620	G/C	cg17192377	chr18:44677553	HDHD2	0.91	8.68	0.42	1.64e-16	Sitting height ratio;
LIHC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21467203	chr3:49911342	NA	0.44	7.82	0.39	6.74e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-7.13	-0.36	5.92e-12	Mean corpuscular volume;
LIHC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.49	8.4	0.41	1.22e-15	Obesity-related traits;
LIHC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	18.13	0.7	5.96e-52	Birth weight;
LIHC	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg22134162	chr3:63841271	THOC7	-0.56	-6.38	-0.33	5.62e-10	Lung function (FVC);Lung function (FEV1);
LIHC	trans	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg20587970	chr11:113659929	NA	-0.56	-7.15	-0.36	5.39e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.89	-11.68	-0.53	9.76e-27	Schizophrenia;
LIHC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.86	12.22	0.55	9.54e-29	Menarche (age at onset);
LIHC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg16479474	chr6:28041457	NA	0.38	6.44	0.33	4.05e-10	Cardiac Troponin-T levels;
LIHC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.68	10.24	0.48	1.22e-21	Response to diuretic therapy;
LIHC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	11.19	0.52	5.7e-25	Alzheimer's disease (late onset);
LIHC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.46	6.07	0.31	3.48e-9	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	6.11	0.31	2.64e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.8	-15.59	-0.64	8.9e-42	Height;
LIHC	cis	rs7238033	0.624	rs11877086	chr18:43307338	C/A	cg20610511	chr18:43302872	SLC14A1	0.4	6.66	0.34	1.1e-10	Bladder cancer;
LIHC	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg22842854	chr12:123319900	HIP1R	-0.63	-7.64	-0.38	2.28e-13	Schizophrenia;
LIHC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.72	-10.01	-0.48	7.49e-21	Multiple system atrophy;
LIHC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.22	-5.95	-0.31	6.65e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.52	-7.85	-0.39	5.44e-14	Total body bone mineral density;
LIHC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.48	7.38	0.37	1.24e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.47	9.76	0.47	5.2e-20	Immature fraction of reticulocytes;
LIHC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg10018233	chr7:150070692	REPIN1	0.55	8.45	0.42	8.32e-16	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg23461800	chr14:103021989	NA	-0.5	-7.12	-0.36	6.6e-12	Platelet count;
LIHC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-7.63	-0.38	2.28e-13	Longevity;Endometriosis;
LIHC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.45	7.17	0.36	4.6e-12	Total body bone mineral density;
LIHC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg22528358	chr1:107598549	PRMT6	0.68	10.94	0.51	4.47e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2710642	0.721	rs1872790	chr2:62890222	T/C	cg17519650	chr2:63277830	OTX1	0.5	7.15	0.36	5.22e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.49	-7.61	-0.38	2.76e-13	Ulcerative colitis;
LIHC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.55	0.46	2.64e-19	Morning vs. evening chronotype;
LIHC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.68	-12.4	-0.56	1.97e-29	Dental caries;
LIHC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	ch.8.2087691R	chr8:103313232	UBR5	-0.34	-6.08	-0.31	3.22e-9	Cognitive function;
LIHC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.37	8.4	0.41	1.19e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg10360323	chr17:41437877	NA	0.4	5.95	0.31	6.78e-9	Menopause (age at onset);
LIHC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg17135325	chr3:160939158	NMD3	0.53	7.56	0.38	3.64e-13	Parkinson's disease;
LIHC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.1	-16.3	-0.66	1.31e-44	Chronic sinus infection;
LIHC	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg10932868	chr11:921992	NA	0.35	6.52	0.33	2.46e-10	Alzheimer's disease (late onset);
LIHC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27297192	chr10:134578999	INPP5A	0.54	7.99	0.4	2.12e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.45	0.53	6.74e-26	Personality dimensions;
LIHC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.18	28.67	0.84	5.47e-93	IgG glycosylation;
LIHC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.86	12.85	0.57	4.19e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7546	0.501	rs12102426	chr16:4922450	T/G	cg08329684	chr16:4932620	PPL	0.38	6.67	0.34	1.01e-10	Cancer;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg13568946	chr8:12516530	NA	0.5	6.1	0.31	2.94e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.65	-9.07	-0.44	9.39e-18	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-7.56	-0.38	3.81e-13	Initial pursuit acceleration;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg26338869	chr17:61819248	STRADA	0.54	7.19	0.36	4.19e-12	Height;
LIHC	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg25356066	chr3:128598488	ACAD9	0.54	7.17	0.36	4.64e-12	IgG glycosylation;
LIHC	cis	rs943466	1.000	rs747692	chr6:33737436	C/T	cg25922239	chr6:33757077	LEMD2	-0.5	-6.12	-0.31	2.58e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.54	-6.48	-0.33	3.25e-10	Renal cell carcinoma;
LIHC	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg25588787	chr5:154027256	NA	0.38	5.73	0.3	2.17e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	11.62	0.53	1.57e-26	Hip circumference adjusted for BMI;
LIHC	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg09795085	chr6:101329169	ASCC3	-0.49	-6.61	-0.34	1.49e-10	Neuroticism;
LIHC	cis	rs244293	0.730	rs9303362	chr17:53062553	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.47	-7.04	-0.36	1.04e-11	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.3	-16.9	-0.67	5.23e-47	Diabetic kidney disease;
LIHC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.46	7.43	0.37	8.83e-13	Crohn's disease;
LIHC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.44	6.79	0.34	4.95e-11	Melanoma;
LIHC	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.22	-0.45	3.03e-18	Colorectal cancer;
LIHC	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.61	-9.34	-0.45	1.31e-18	Cortisol levels (saliva);
LIHC	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.72	-11.39	-0.52	1.09e-25	White matter hyperintensity burden;
LIHC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.63	-0.53	1.46e-26	Total cholesterol levels;
LIHC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg25894440	chr7:65020034	NA	-0.56	-6.49	-0.33	3.01e-10	Diabetic kidney disease;
LIHC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.34	-0.37	1.57e-12	Mood instability;
LIHC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.94	-0.44	2.52e-17	Skin colour saturation;
LIHC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.83	13.74	0.6	1.7e-34	Breast cancer;
LIHC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg15902774	chr15:75289873	SCAMP5	-0.4	-6.07	-0.31	3.43e-9	Lung cancer;
LIHC	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.86e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.56	-8.57	-0.42	3.67e-16	Blood protein levels;
LIHC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.51	8.93	0.44	2.58e-17	Mean corpuscular volume;
LIHC	cis	rs9993613	0.967	rs10213071	chr4:73436348	C/G	cg15102770	chr4:73434591	ADAMTS3	-0.39	-6.07	-0.31	3.38e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs2073300	0.793	rs75758241	chr20:23434696	A/G	cg12062639	chr20:23401060	NAPB	0.78	9.47	0.46	4.77e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs67257959	0.708	rs10405158	chr19:17195997	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.36	5.8	0.3	1.5e-8	Selective IgA deficiency;
LIHC	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.08	0.48	4.45e-21	Post bronchodilator FEV1;
LIHC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.39	-6.28	-0.32	1.03e-9	Intraocular pressure;
LIHC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.32e-23	Mean corpuscular volume;
LIHC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.41	6.96	0.35	1.7e-11	Hemoglobin concentration;
LIHC	trans	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.5	0.33	2.88e-10	Endometrial cancer;
LIHC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.93	-0.35	2.11e-11	IgG glycosylation;
LIHC	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-6.73	-0.34	7.14e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs4700695	0.841	rs152995	chr5:65323172	G/A	cg21114390	chr5:65439923	SFRS12	0.45	5.73	0.3	2.26e-8	Facial morphology (factor 19);
LIHC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs13113518	0.812	rs2412648	chr4:56321067	T/G	cg15358633	chr12:38710606	ALG10B	0.44	6.29	0.32	9.77e-10	Height;
LIHC	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg03934865	chr2:198174659	NA	0.47	6.75	0.34	6.45e-11	Dermatomyositis;
LIHC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg22079354	chr11:130786696	SNX19	0.43	6.19	0.32	1.73e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.21	-0.41	4.63e-15	Alzheimer's disease (survival time);
LIHC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.74	10.86	0.51	8.57e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.5	7.82	0.39	6.79e-14	Alzheimer's disease (survival time);
LIHC	cis	rs8103278	0.740	rs72626215	chr19:46294136	G/A	cg02376097	chr19:46275166	DMPK	-0.42	-6.13	-0.31	2.48e-9	Coronary artery disease;
LIHC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.03	-0.31	4.31e-9	Alzheimer's disease (late onset);
LIHC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.72	-10.98	-0.51	3.13e-24	Aortic root size;
LIHC	cis	rs7106204	1.000	rs7931691	chr11:24221123	C/A	ch.11.24196551F	chr11:24239977	NA	0.69	6.96	0.35	1.75e-11	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.64	-0.5	4.99e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.72	-0.3	2.34e-8	Response to antipsychotic treatment;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09250607	chr7:1529409	INTS1	0.38	6.23	0.32	1.38e-9	Longevity;
LIHC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg24203234	chr3:128598194	ACAD9	0.46	6.47	0.33	3.43e-10	IgG glycosylation;
LIHC	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.27	-6.46	-0.33	3.63e-10	Heart rate;
LIHC	cis	rs7188697	0.885	rs246194	chr16:58573901	G/A	cg02549819	chr16:58548995	SETD6	-0.45	-7.18	-0.36	4.43e-12	QT interval;
LIHC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.53	6.7	0.34	8.73e-11	Alzheimer's disease;
LIHC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.59	7.43	0.37	8.86e-13	Bronchopulmonary dysplasia;
LIHC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.08	20.36	0.74	6.32e-61	IgG glycosylation;
LIHC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.61	-10.93	-0.51	4.6e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-6.31	-0.32	8.74e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg13957321	chr17:43675089	NA	0.5	7.91	0.39	3.59e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg23262073	chr20:60523788	NA	-0.28	-5.73	-0.3	2.16e-8	Body mass index;
LIHC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.8	13.32	0.58	6.62e-33	Breast cancer;
LIHC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	9.25	0.45	2.54e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.49	8.38	0.41	1.37e-15	Response to temozolomide;
LIHC	cis	rs4474465	0.607	rs7930161	chr11:78268878	C/A	cg27205649	chr11:78285834	NARS2	0.41	6.11	0.31	2.77e-9	Alzheimer's disease (survival time);
LIHC	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg19508488	chr2:152266495	RIF1	-0.53	-6.46	-0.33	3.65e-10	Lung cancer;
LIHC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg05368731	chr17:41323189	NBR1	0.72	11.81	0.54	3.14e-27	Menopause (age at onset);
LIHC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.59	0.5	7.72e-23	Bladder cancer;
LIHC	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg11812906	chr14:75593930	NEK9	-0.43	-6.54	-0.33	2.18e-10	IgG glycosylation;
LIHC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg05941027	chr17:61774174	LIMD2	0.3	5.97	0.31	5.91e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg00204748	chr12:29376779	FAR2	-0.4	-7.43	-0.37	8.74e-13	QT interval;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.67	10.19	0.48	1.86e-21	Menarche (age at onset);
LIHC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-9.17	-0.44	4.43e-18	Gut microbiome composition (summer);
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg18306943	chr3:40428807	ENTPD3	-0.4	-6.81	-0.35	4.35e-11	Renal cell carcinoma;
LIHC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-12.72	-0.57	1.25e-30	Dental caries;
LIHC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.91	-0.3	8.11e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-8.16	-0.4	6.61e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-10.55	-0.5	1.05e-22	Crohn's disease;
LIHC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.5	-0.33	2.85e-10	Colorectal cancer;
LIHC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.67	8.62	0.42	2.57e-16	Initial pursuit acceleration;
LIHC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.69	8.63	0.42	2.3e-16	Gut microbiome composition (summer);
LIHC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.58	-7.56	-0.38	3.63e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs11644362	1.000	rs11644362	chr16:12994097	T/C	cg06890432	chr16:12997467	SHISA9	-0.39	-6.62	-0.34	1.4e-10	Positive affect;Subjective well-being;
LIHC	trans	rs2096176	0.606	rs7899567	chr10:26343197	A/G	cg01396774	chr2:218299024	DIRC3	0.31	6.05	0.31	3.89e-9	Obesity-related traits;
LIHC	cis	rs4453791	0.872	rs35479964	chr3:38912926	C/T	cg02254461	chr3:39195904	CSRNP1	0.66	5.89	0.3	9.44e-9	Social communication problems;
LIHC	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.65	6.53	0.33	2.35e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.93	-0.31	7.26e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg18809830	chr7:99032528	PTCD1	-0.82	-6.37	-0.33	5.95e-10	Blood metabolite levels;
LIHC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.95	-0.35	1.89e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.5	-6.76	-0.34	5.92e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.8	-13.48	-0.59	1.61e-33	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20609493	chr15:60420227	NA	0.43	6.23	0.32	1.36e-9	Pancreatic cancer;
LIHC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.7e-12	Waist circumference;Weight;
LIHC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.44	5.98	0.31	5.72e-9	Life satisfaction;
LIHC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.69	11.77	0.54	4.42e-27	Crohn's disease;
LIHC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.95	0.31	6.67e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-9.87	-0.47	2.2e-20	Mean corpuscular volume;
LIHC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg19752551	chr11:57585705	CTNND1	-0.52	-7.37	-0.37	1.33e-12	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.04	-0.6	1.15e-35	Alzheimer's disease;
LIHC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs10197940	0.753	rs2290368	chr2:152266473	T/C	cg06191203	chr2:152266755	RIF1	-0.52	-10.0	-0.48	7.85e-21	Lung cancer;
LIHC	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg14515779	chr1:101123966	NA	-0.41	-5.81	-0.3	1.43e-8	Monocyte count;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.32	-5.8	-0.3	1.49e-8	Corneal structure;
LIHC	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.71	-11.27	-0.52	2.84e-25	White matter hyperintensity burden;
LIHC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.51	-6.61	-0.34	1.49e-10	Initial pursuit acceleration;
LIHC	trans	rs1814175	0.618	rs7483546	chr11:49714784	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.38	-0.74	5.06e-61	Height;
LIHC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-11.01	-0.51	2.46e-24	Total cholesterol levels;
LIHC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg01652190	chr22:50026171	C22orf34	-0.35	-7.83	-0.39	6.27e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.42	-5.75	-0.3	1.99e-8	Longevity;Endometriosis;
LIHC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.74	10.87	0.51	7.96e-24	Corneal astigmatism;
LIHC	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.37e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.74	8.25	0.41	3.5e-15	Height;
LIHC	cis	rs55665837	0.540	rs12788030	chr11:14764684	C/T	cg19336497	chr11:14380999	RRAS2	-0.34	-5.74	-0.3	2.13e-8	Vitamin D levels;
LIHC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.52	7.54	0.38	4.36e-13	Obesity-related traits;
LIHC	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.77	10.08	0.48	4.37e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg08213375	chr14:104286397	PPP1R13B	0.36	5.87	0.3	1.01e-8	Reticulocyte count;
LIHC	cis	rs77861329	1.000	rs352151	chr3:52210272	C/G	cg08692210	chr3:52188851	WDR51A	0.83	7.99	0.4	2.03e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.47e-9	Aortic root size;
LIHC	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.02	-0.31	4.4e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.67	7.3	0.37	2.1e-12	Exhaled nitric oxide output;
LIHC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg15691649	chr6:25882328	NA	-0.65	-8.48	-0.42	7e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.93	-14.24	-0.61	1.91e-36	Sudden cardiac arrest;
LIHC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.4	-6.02	-0.31	4.52e-9	Menarche (age at onset);
LIHC	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.58	-9.41	-0.45	7.68e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.35	5.94	0.31	7.09e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg17724175	chr1:150552817	MCL1	-0.37	-7.57	-0.38	3.53e-13	Tonsillectomy;
LIHC	cis	rs12744310	0.887	rs34539673	chr1:41796817	G/A	cg03962019	chr1:41807865	NA	0.4	6.35	0.32	6.77e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg07451762	chr16:28383216	NA	0.39	7.05	0.36	9.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.46	-6.59	-0.34	1.69e-10	Height;
LIHC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.26	-6.88	-0.35	2.9100000000000002e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.77	-0.34	5.65e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.45	8.14	0.4	7.33e-15	Platelet distribution width;
LIHC	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.28	-0.32	1.03e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.71	-8.94	-0.44	2.43e-17	Gut microbiome composition (summer);
LIHC	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.52	0.46	3.25e-19	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.45	8.17	0.4	6.04e-15	Prudent dietary pattern;
LIHC	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.24	-0.48	1.21e-21	Eye color traits;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04699474	chr19:9945708	PIN1	-0.53	-6.76	-0.34	5.9e-11	Systolic blood pressure;
LIHC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg12903224	chr12:29470962	FAR2	-0.37	-5.91	-0.3	8.31e-9	QT interval;
LIHC	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.57	7.71	0.38	1.4e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg05973401	chr12:123451056	ABCB9	0.43	5.94	0.31	7.13e-9	Neutrophil percentage of white cells;
LIHC	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg22153463	chr1:85462885	MCOLN2	0.53	6.28	0.32	1.03e-9	Serum sulfate level;
LIHC	cis	rs8108269	1.000	rs10409882	chr19:46160935	C/T	cg13320842	chr19:46175254	GIPR	0.43	8.04	0.4	1.48e-14	Type 2 diabetes;
LIHC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.92	11.83	0.54	2.63e-27	Coronary artery disease;
LIHC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg19302996	chr17:73780495	UNK	-0.52	-6.11	-0.31	2.66e-9	Psoriasis;
LIHC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.59	6.99	0.35	1.44e-11	Heart rate;
LIHC	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.5	-7.88	-0.39	4.34e-14	Schizophrenia;
LIHC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.97	0.63	2.56e-39	Electrocardiographic conduction measures;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.57	0.76	9.11e-66	Prudent dietary pattern;
LIHC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.89	-0.35	2.64e-11	Axial length;
LIHC	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg20159608	chr7:32802032	NA	-0.5	-5.85	-0.3	1.15e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.76	0.47	5.3e-20	Platelet count;
LIHC	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-0.74	-8.61	-0.42	2.67e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.66	10.15	0.48	2.39e-21	Longevity;
LIHC	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.7	-15.47	-0.64	2.8e-41	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.34	-0.49	5.63e-22	Hemoglobin concentration;
LIHC	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.78	-11.18	-0.52	6.07e-25	Pediatric areal bone mineral density (radius);
LIHC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.36	5.97	0.31	5.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4653767	0.573	rs708770	chr1:226912135	C/T	cg05262829	chr1:226921576	ITPKB	0.38	7.57	0.38	3.48e-13	Parkinson's disease;
LIHC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	0.54	7.09	0.36	7.55e-12	Pulse pressure;
LIHC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg07713946	chr22:31675144	LIMK2	-0.29	-6.26	-0.32	1.13e-9	Paclitaxel-induced neuropathy;
LIHC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg03859395	chr2:55845619	SMEK2	0.88	14.72	0.62	2.42e-38	Metabolic syndrome;
LIHC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.24	-7.47	-0.37	6.54e-13	Mean corpuscular volume;
LIHC	trans	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg10756647	chr7:56101905	PSPH	1.07	11.54	0.53	3.16e-26	Diabetic kidney disease;
LIHC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	10.35	0.49	4.94e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs61550741	0.655	rs68194389	chr21:32500745	T/G	cg23515853	chr17:79372528	BAHCC1	-0.57	-6.09	-0.31	3.08e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12501888	chr15:85177176	SCAND2	-0.49	-7.45	-0.37	7.75e-13	P wave terminal force;
LIHC	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.59	8.84	0.43	5.15e-17	Recombination rate (females);
LIHC	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.56	8.43	0.41	9.49e-16	Menarche (age at onset);
LIHC	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.61	11.74	0.54	5.73e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg14146966	chr2:61757674	XPO1	0.49	8.62	0.42	2.6e-16	Tuberculosis;
LIHC	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.32	-6.34	-0.32	7.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg25356066	chr3:128598488	ACAD9	0.52	7.21	0.36	3.68e-12	IgG glycosylation;
LIHC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg10820045	chr2:198174542	NA	0.6	10.35	0.49	5.02e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12463550	chr7:65579703	CRCP	0.69	7.13	0.36	6.01e-12	Diabetic kidney disease;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.21	-0.32	1.5e-9	Menopause (age at onset);
LIHC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.5	-7.22	-0.36	3.35e-12	Body mass index;
LIHC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.2	-0.32	1.6e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg00129232	chr17:37814104	STARD3	-0.44	-6.88	-0.35	2.87e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg24127101	chr8:26149548	PPP2R2A	0.77	6.76	0.34	5.94e-11	Musician's dystonia;
LIHC	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.05	-0.31	3.9e-9	Tuberculosis;
LIHC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.93	16.41	0.66	4.98e-45	Parkinson's disease;
LIHC	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.73	-0.3	2.19e-8	Neuroticism;
LIHC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-6.35	-0.32	6.96e-10	Mitochondrial DNA levels;
LIHC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.57	-9.85	-0.47	2.68e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.26	-0.45	2.34e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg22834771	chr12:69754056	YEATS4	-0.47	-7.94	-0.39	2.97e-14	Blood protein levels;
LIHC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.69	-8.55	-0.42	4.31e-16	Gut microbiome composition (summer);
LIHC	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.47	-8.06	-0.4	1.33e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.39	-7.01	-0.35	1.28e-11	Immature fraction of reticulocytes;
LIHC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-7.06	-0.36	9.19e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.24	0.48	1.25e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.55	-7.26	-0.37	2.64e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.76	0.3	1.92e-8	Schizophrenia;
LIHC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	6.03	0.31	4.24e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.63	11.05	0.51	1.77e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg10978503	chr1:24200527	CNR2	0.38	9.01	0.44	1.46e-17	Immature fraction of reticulocytes;
LIHC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.88	-15.27	-0.64	1.6e-40	Colorectal cancer;
LIHC	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.24	6.44	0.33	4.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg18306943	chr3:40428807	ENTPD3	0.43	7.53	0.38	4.63e-13	Renal cell carcinoma;
LIHC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg26451873	chr13:26829095	CDK8	-0.42	-6.19	-0.32	1.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.75	-11.11	-0.51	1.08e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.57	12.21	0.55	1.09e-28	Lung cancer;
LIHC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg24209194	chr3:40518798	ZNF619	0.46	6.56	0.33	1.95e-10	Renal cell carcinoma;
LIHC	cis	rs918629	0.530	rs3777201	chr5:95234630	G/T	cg10483112	chr5:95245456	ELL2	-0.36	-6.55	-0.33	2.07e-10	IgG glycosylation;
LIHC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.65	-12.49	-0.56	9.64e-30	Schizophrenia;
LIHC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.68	9.31	0.45	1.57e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.49	-7.52	-0.38	4.89e-13	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg11212589	chr17:38028394	ZPBP2	0.34	6.85	0.35	3.35e-11	Self-reported allergy;
LIHC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg13175981	chr1:150552382	MCL1	0.44	6.2	0.32	1.63e-9	Tonsillectomy;
LIHC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21467203	chr3:49911342	NA	-0.57	-10.42	-0.49	2.82e-22	Body mass index;
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.42	-0.33	4.47e-10	Body mass index;
LIHC	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.42	-6.1	-0.31	2.81e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg10978503	chr1:24200527	CNR2	-0.38	-9.05	-0.44	1.14e-17	Immature fraction of reticulocytes;
LIHC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.33	0.37	1.72e-12	Bipolar disorder;
LIHC	cis	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg19680485	chr15:31195859	MTMR15	-0.56	-6.12	-0.31	2.62e-9	Hypertriglyceridemia;
LIHC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14913181	chr1:6845123	CAMTA1	0.47	6.18	0.32	1.87e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.72	-0.39	1.28e-13	Total body bone mineral density;
LIHC	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg14146966	chr2:61757674	XPO1	0.47	8.24	0.41	3.77e-15	Tuberculosis;
LIHC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.66	7.09	0.36	7.87e-12	Gut microbiome composition (summer);
LIHC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.75e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg24004478	chr7:855632	UNC84A	-0.48	-7.94	-0.39	2.96e-14	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.47	-7.78	-0.39	8.51e-14	Platelet distribution width;
LIHC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.51	6.7	0.34	8.84e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.65	6.86	0.35	3.17e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.61	-0.34	1.5e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.39	-6.89	-0.35	2.67e-11	Aortic root size;
LIHC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.86	-0.3	1.07e-8	Body mass index;
LIHC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.16e-13	Vitiligo;
LIHC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.33	0.41	1.99e-15	Schizophrenia;
LIHC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg06026331	chr20:60912101	LAMA5	-0.51	-8.54	-0.42	4.58e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.55	-6.08	-0.31	3.28e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.54	7.65	0.38	2.07e-13	Post bronchodilator FEV1;
LIHC	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.7	-10.27	-0.49	9.67e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.51	5.77	0.3	1.77e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg01444801	chr10:135216882	MTG1	-0.66	-9.88	-0.47	2.12e-20	Systemic lupus erythematosus;
LIHC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.68	-0.34	9.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg06096015	chr1:231504339	EGLN1	0.5	9.18	0.44	4.18e-18	Hemoglobin concentration;
LIHC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg10790698	chr19:18539756	SSBP4	-0.37	-7.75	-0.39	1.04e-13	Breast cancer;
LIHC	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.56	-13.94	-0.6	2.85e-35	White blood cell count (basophil);
LIHC	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.56	-10.23	-0.48	1.37e-21	Urate levels in overweight individuals;
LIHC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.39	5.85	0.3	1.13e-8	Melanoma;
LIHC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.78	-11.56	-0.53	2.5e-26	Motion sickness;
LIHC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg07424592	chr7:64974309	NA	-0.79	-9.28	-0.45	1.95e-18	Diabetic kidney disease;
LIHC	cis	rs1712517	0.836	rs7093039	chr10:105149547	A/G	cg05636881	chr10:105038444	INA	0.45	6.97	0.35	1.63e-11	Migraine;
LIHC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	3.94e-15	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07090025	chr1:1510437	SSU72	-0.5	-6.26	-0.32	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06154860	chr7:14029085	ETV1	0.48	6.74	0.34	6.8e-11	Pancreatic cancer;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02290350	chr8:58132656	NA	0.49	11.68	0.53	9.48e-27	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24110177	chr3:50126178	RBM5	0.42	6.62	0.34	1.39e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.49	6.75	0.34	6.5e-11	Plateletcrit;
LIHC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.45	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs8113308	0.752	rs73068868	chr19:52491001	A/G	cg25782003	chr19:52490127	ZNF350	0.63	5.73	0.3	2.16e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.71	9.07	0.44	9.7e-18	Gut microbiome composition (summer);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25577648	chr10:73137008	NA	0.46	6.46	0.33	3.55e-10	Lung function (FEV1/FVC);
LIHC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg16797656	chr11:68205561	LRP5	-0.52	-8.22	-0.41	4.17e-15	Total body bone mineral density;
LIHC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg15155738	chr12:121454335	C12orf43	0.57	8.16	0.4	6.44e-15	N-glycan levels;
LIHC	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg26536354	chr8:144654954	C8orf73	0.55	6.2	0.32	1.67e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg16673477	chr19:18812017	CRTC1	0.45	7.26	0.37	2.68e-12	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11764359	chr7:65958608	NA	0.66	9.12	0.44	6.44e-18	Aortic root size;
LIHC	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs1866706	0.896	rs7119811	chr11:12882376	T/G	cg25843174	chr11:12811716	TEAD1	0.28	5.94	0.31	6.92e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.46	-6.04	-0.31	3.91e-9	Vitiligo;
LIHC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.67	8.41	0.41	1.12e-15	Gut microbiome composition (summer);
LIHC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs7091068	0.662	rs829106	chr10:95441742	G/T	cg20715218	chr10:95462985	C10orf4	0.61	6.57	0.33	1.86e-10	Urinary tract infection frequency;
LIHC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.89	-0.51	6.82e-24	Chronic sinus infection;
LIHC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg12751644	chr20:60527061	NA	-0.35	-5.85	-0.3	1.16e-8	Body mass index;
LIHC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.38	5.83	0.3	1.28e-8	Menarche (age at onset);
LIHC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg02640540	chr1:67518911	SLC35D1	0.44	6.01	0.31	4.67e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg20090690	chr10:134436459	INPP5A	0.43	6.08	0.31	3.21e-9	Migraine;
LIHC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.38	5.94	0.31	6.97e-9	Multiple sclerosis;
LIHC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg14515779	chr1:101123966	NA	-0.59	-11.17	-0.52	6.6e-25	Monocyte count;
LIHC	cis	rs2637030	0.559	rs1490768	chr5:53018495	C/G	cg06476337	chr5:52856530	NDUFS4	0.41	6.72	0.34	7.67e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.12e-23	Morning vs. evening chronotype;
LIHC	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg25356066	chr3:128598488	ACAD9	0.46	6.21	0.32	1.53e-9	IgG glycosylation;
LIHC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.38	7.3	0.37	2.08e-12	Schizophrenia;
LIHC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	8.09	0.4	1.05e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg03037974	chr15:76606532	NA	-0.58	-9.66	-0.46	1.1e-19	Blood metabolite levels;
LIHC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	6.74	0.34	6.68e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg16691251	chr5:66510806	NA	0.51	7.37	0.37	1.3e-12	Breast cancer;
LIHC	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	0.54	7.08	0.36	8.26e-12	Pulse pressure;
LIHC	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	9.66	0.46	1.13e-19	LDL cholesterol;
LIHC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.46	7.23	0.36	3.09e-12	Diastolic blood pressure;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	0.59	8.7	0.43	1.42e-16	Prudent dietary pattern;
LIHC	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.54	8.01	0.4	1.86e-14	Diastolic blood pressure;
LIHC	cis	rs1664789	1.000	rs1694056	chr5:53276913	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.48	7.68	0.38	1.65e-13	Waist circumference adjusted for body mass index;
LIHC	cis	rs7212590	0.881	rs7214032	chr17:57885828	T/C	cg10252138	chr17:58120427	NA	-0.6	-6.03	-0.31	4.16e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs907683	0.533	rs12469789	chr2:220293242	C/T	cg15015639	chr2:220282977	DES	0.35	8.44	0.42	9.17e-16	Resting heart rate;
LIHC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg02487422	chr3:49467188	NICN1	-0.44	-5.74	-0.3	2.09e-8	Educational attainment;
LIHC	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg03585969	chr10:35415529	CREM	0.76	10.96	0.51	3.65e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg02269571	chr22:50332266	NA	-0.62	-8.76	-0.43	9.12e-17	Schizophrenia;
LIHC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.71	9.14	0.44	5.66e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.15	0.32	2.2e-9	Tonsillectomy;
LIHC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02545393	chr11:70244902	CTTN	0.47	6.44	0.33	3.98e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.77	12.05	0.55	4.03e-28	Corneal astigmatism;
LIHC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs9543976	1.000	rs7989568	chr13:76155564	T/C	cg01531495	chr13:76123901	UCHL3	0.49	5.89	0.3	9.46e-9	Diabetic retinopathy;
LIHC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	1.01	19.29	0.72	1.22e-56	Breast cancer;
LIHC	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.23e-9	Blood pressure;
LIHC	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.69	0.38	1.62e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg10820045	chr2:198174542	NA	0.48	7.36	0.37	1.39e-12	Dermatomyositis;
LIHC	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.64	-6.79	-0.34	4.83e-11	Hair shape;
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.44	7.16	0.36	5e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.59	9.77	0.47	4.76e-20	Type 2 diabetes;
LIHC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.84	19.57	0.73	9.8e-58	Gestational age at birth (maternal effect);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23667555	chr12:25403962	KRAS	-0.44	-6.57	-0.33	1.83e-10	Bilirubin levels;
LIHC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.48	-7.81	-0.39	7.3e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02034447	chr16:89574710	SPG7	0.49	7.51	0.38	5.23e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-12.17	-0.55	1.42e-28	Alzheimer's disease (late onset);
LIHC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.36	7.19	0.36	4.09e-12	Alcohol dependence;
LIHC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg10130564	chr11:117069849	TAGLN	0.34	5.84	0.3	1.24e-8	Blood protein levels;
LIHC	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.46	7.17	0.36	4.63e-12	Adiposity;
LIHC	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.65	10.32	0.49	6.58e-22	Obesity-related traits;
LIHC	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.35	-7.37	-0.37	1.31e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg01629716	chr15:45996671	NA	0.52	9.64	0.46	1.26e-19	Waist circumference;Weight;
LIHC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.7	0.38	1.47e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg00656387	chr3:40428638	ENTPD3	0.43	6.7	0.34	8.4e-11	Renal cell carcinoma;
LIHC	cis	rs950169	0.649	rs12901010	chr15:84699034	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	6.78	0.34	5.26e-11	Schizophrenia;
LIHC	cis	rs6750047	1.000	rs6750047	chr2:38276549	A/G	cg07380506	chr2:38303506	CYP1B1	0.53	6.56	0.33	2.04e-10	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.44	-7.41	-0.37	1.01e-12	Schizophrenia;
LIHC	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.35	-7.36	-0.37	1.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12016809	chr21:47604291	C21orf56	0.41	5.97	0.31	6.06e-9	Testicular germ cell tumor;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22734451	chr15:78219748	LOC645752	-0.46	-6.84	-0.35	3.56e-11	Calcium levels;
LIHC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.93	0.44	2.58e-17	Motion sickness;
LIHC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.46	-6.86	-0.35	3.23e-11	Height;
LIHC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.35	8.41	0.41	1.15e-15	Weight;
LIHC	cis	rs7474896	1.000	rs11011344	chr10:38004846	C/T	cg25427524	chr10:38739819	LOC399744	-0.48	-6.08	-0.31	3.28e-9	Obesity (extreme);
LIHC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.17	0.32	1.97e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.72	9.32	0.45	1.45e-18	Gut microbiome composition (summer);
LIHC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg04727924	chr7:799746	HEATR2	-0.4	-6.0	-0.31	5.09e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg22633049	chr21:46681294	NA	-0.34	-5.99	-0.31	5.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04389950	chr6:106720478	ATG5	-0.32	-6.07	-0.31	3.48e-9	Pancreatic cancer;
LIHC	cis	rs11702148	0.552	rs2300374	chr21:34885590	A/T	cg14850771	chr21:34775459	IFNGR2	0.47	7.66	0.38	1.97e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	0.53	10.05	0.48	5.28e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.46	-7.56	-0.38	3.79e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.45	5.73	0.3	2.25e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs198426	0.506	rs198462	chr11:61524119	G/A	cg27386326	chr11:61587980	NA	-0.33	-5.94	-0.31	6.83e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LIHC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.58	9.56	0.46	2.34e-19	Resting heart rate;
LIHC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg06108461	chr20:60628389	TAF4	-0.93	-14.9	-0.63	4.83e-39	Body mass index;
LIHC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.04	0.31	3.94e-9	Eosinophil percentage of white cells;
LIHC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.84	-0.35	3.56e-11	Personality dimensions;
LIHC	cis	rs12079745	0.590	rs10919151	chr1:169334096	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-7.12	-0.36	6.37e-12	QT interval;
LIHC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.2e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.99	-0.44	1.7e-17	Heart rate;
LIHC	cis	rs72843506	0.656	rs2385960	chr17:19938217	C/A	cg12065943	chr17:19881925	AKAP10	-0.41	-6.93	-0.35	2.14e-11	Schizophrenia;
LIHC	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg03859395	chr2:55845619	SMEK2	0.46	7.03	0.36	1.1e-11	Metabolic syndrome;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.15	0.55	1.79e-28	Prudent dietary pattern;
LIHC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21467203	chr3:49911342	NA	-0.45	-8.11	-0.4	9.32e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.42	-11.52	-0.53	3.72e-26	Longevity;Endometriosis;
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.62	9.56	0.46	2.42e-19	Bipolar disorder and schizophrenia;
LIHC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.65	-0.46	1.17e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4650994	0.593	rs7540745	chr1:178529757	C/T	cg05350800	chr1:178550844	NA	-0.32	-7.11	-0.36	6.93e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.98	15.52	0.64	1.75e-41	Metabolic syndrome;
LIHC	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.31	6.01	0.31	4.64e-9	Plateletcrit;Platelet count;
LIHC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg06533319	chr4:3265114	C4orf44	0.34	6.55	0.33	2.13e-10	Parental longevity (mother's age at death);
LIHC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	11.83	0.54	2.74e-27	Platelet count;
LIHC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.47	-7.43	-0.37	8.88e-13	Electroencephalogram traits;
LIHC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.66	9.59	0.46	1.93e-19	Schizophrenia;
LIHC	trans	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg10756647	chr7:56101905	PSPH	-1.07	-13.39	-0.59	3.74e-33	Diabetic kidney disease;
LIHC	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg04067612	chr4:15429572	C1QTNF7	-0.27	-5.93	-0.31	7.36e-9	Obesity-related traits;
LIHC	cis	rs3758785	0.679	rs11819857	chr11:94228236	T/G	cg21580213	chr11:94231278	ANKRD49	-0.36	-5.96	-0.31	6.43e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LIHC	cis	rs2019960	0.759	rs2648844	chr8:129178530	T/C	cg15331705	chr8:129180010	NA	-0.37	-6.71	-0.34	7.89e-11	Hodgkin's lymphoma;Multiple sclerosis;
LIHC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.62	0.62	5.83e-38	Chronic sinus infection;
LIHC	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg10381502	chr11:71823885	C11orf51	-1.03	-9.31	-0.45	1.59e-18	Severe influenza A (H1N1) infection;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01087208	chr20:60494922	CDH4	-0.23	-6.74	-0.34	6.87e-11	Calcium levels;
LIHC	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.35	7.22	0.36	3.3e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.42	-6.59	-0.34	1.63e-10	Iron status biomarkers;
LIHC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg14222432	chr12:29376421	FAR2	-0.36	-6.97	-0.35	1.68e-11	QT interval;
LIHC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.38	-5.9	-0.3	8.51e-9	Multiple myeloma;
LIHC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg07971674	chr14:23388846	RBM23	-0.41	-5.89	-0.3	9.2e-9	Cognitive ability (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18504358	chr14:23340787	LRP10	0.4	6.44	0.33	3.96e-10	Cognitive function;
LIHC	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.16	0.32	2.05e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg16434002	chr17:42200994	HDAC5	-0.54	-7.77	-0.39	9.27e-14	Total body bone mineral density;
LIHC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.59	0.38	3.04e-13	Mean platelet volume;
LIHC	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.63	7.82	0.39	6.43e-14	Crohn's disease;
LIHC	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg03934865	chr2:198174659	NA	0.46	6.59	0.34	1.69e-10	Dermatomyositis;
LIHC	trans	rs6058796	0.892	rs66897337	chr20:31256593	T/C	cg02600331	chr11:130417168	NA	0.36	7.75	0.39	1.03e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.39	6.29	0.32	9.78e-10	Red blood cell count;
LIHC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.61	-8.68	-0.42	1.68e-16	Blood metabolite levels;
LIHC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg14779329	chr11:130786720	SNX19	0.4	5.76	0.3	1.84e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	0.86	5.77	0.3	1.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.96	0.31	6.27e-9	Bladder cancer;
LIHC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.53	11.77	0.54	4.4e-27	Birth weight;
LIHC	cis	rs4908760	0.792	rs10864361	chr1:8726721	C/T	cg20416874	chr1:8611966	RERE	0.65	13.34	0.59	5.49e-33	Vitiligo;
LIHC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-8.71	-0.43	1.33e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.09	-0.55	2.81e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg18306943	chr3:40428807	ENTPD3	0.34	6.09	0.31	2.96e-9	Renal cell carcinoma;
LIHC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.91	16.89	0.67	5.59e-47	Aortic root size;
LIHC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs244293	0.965	rs244343	chr17:53197612	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.5	-0.38	5.39e-13	Menarche (age at onset);
LIHC	cis	rs11161851	0.550	rs11162359	chr1:75461044	G/A	cg11196437	chr1:75593865	LHX8	0.3	5.72	0.3	2.37e-8	Visceral fat;
LIHC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.88	18.97	0.72	2.53e-55	Height;
LIHC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.94	12.9	0.57	2.74e-31	Cerebrospinal P-tau181p levels;
LIHC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg13387374	chr1:19411106	UBR4	0.46	7.36	0.37	1.34e-12	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg07382826	chr16:28625726	SULT1A1	0.46	6.81	0.35	4.42e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21293397	chr19:35454992	ZNF792	0.42	6.09	0.31	3e-9	Pancreatic cancer;
LIHC	trans	rs7668874	0.731	rs9993719	chr4:116748942	T/C	cg08917878	chr5:172668965	NA	-0.3	-6.05	-0.31	3.89e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.67	-0.5	4.01e-23	Colorectal cancer;
LIHC	cis	rs903552	1.000	rs4965873	chr15:102004023	A/G	cg06707286	chr15:102010195	PCSK6	0.46	6.52	0.33	2.53e-10	Diabetic kidney disease;
LIHC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.56	-6.61	-0.34	1.48e-10	Corneal curvature;
LIHC	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.56	13.43	0.59	2.53e-33	Airflow obstruction;
LIHC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.79	-12.55	-0.56	5.8e-30	Coronary artery disease;
LIHC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-7.83	-0.39	6.35e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.63	8.13	0.4	7.81e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.36	0.33	6.32e-10	Renal cell carcinoma;
LIHC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.33	5.93	0.31	7.31e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg27203090	chr3:33138513	GLB1;TMPPE	-0.52	-6.51	-0.33	2.6e-10	Major depressive disorder;
LIHC	cis	rs332507	0.632	rs3755682	chr3:124356662	A/C	cg05980111	chr3:124395277	KALRN	0.3	5.76	0.3	1.88e-8	Plateletcrit;
LIHC	cis	rs760762	0.660	rs6072328	chr20:39913996	T/C	cg06424997	chr20:39929561	ZHX3	0.36	5.91	0.3	8.39e-9	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LIHC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.18	0.4	5.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.42	5.96	0.31	6.21e-9	Tonsillectomy;
LIHC	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.44	-5.94	-0.31	6.86e-9	Coronary artery calcification;
LIHC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.47	-6.06	-0.31	3.62e-9	Initial pursuit acceleration;
LIHC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.42	0.41	1.05e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.26	6.16	0.32	2.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	10.01	0.48	7.14e-21	Coffee consumption (cups per day);
LIHC	cis	rs11673344	0.730	rs826314	chr19:37450435	C/T	cg27390819	chr19:37464633	NA	-0.53	-6.4	-0.33	5.27e-10	Obesity-related traits;
LIHC	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.11	-0.31	2.7e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.73	-8.63	-0.42	2.3e-16	Morning vs. evening chronotype;
LIHC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.51	0.46	3.42e-19	Hemoglobin concentration;
LIHC	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.05	-0.31	3.82e-9	Blood pressure;
LIHC	cis	rs7005606	0.532	rs6981660	chr8:32298476	A/G	cg16623836	chr8:32453385	NRG1	0.4	5.89	0.3	9.13e-9	Hirschsprung disease;
LIHC	trans	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.11	-0.36	6.94e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.52	-7.29	-0.37	2.14e-12	Corneal structure;
LIHC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00166234	chr2:63272303	LOC100132215;EHBP1	0.49	6.41	0.33	4.89e-10	Lung function (FEV1);
LIHC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg11764359	chr7:65958608	NA	-0.58	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.42	0.56	1.79e-29	Cognitive test performance;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs7534824	0.625	rs61780281	chr1:101324152	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	6.31	0.32	8.73e-10	Refractive astigmatism;
LIHC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.95	22.44	0.77	3.39e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.67	10.81	0.5	1.26e-23	Breast cancer;
LIHC	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.53	-0.38	4.44e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.6	9.32	0.45	1.47e-18	Height;
LIHC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.25	-5.77	-0.3	1.82e-8	Subjective well-being;
LIHC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.85	13.77	0.6	1.22e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg15848620	chr12:58087721	OS9	-0.58	-7.97	-0.4	2.44e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.35	5.83	0.3	1.3e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.51	-0.38	5.16e-13	Morning vs. evening chronotype;
LIHC	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.56	-10.15	-0.48	2.41e-21	Neurofibrillary tangles;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-7.32	-0.37	1.74e-12	Total body bone mineral density;
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.64	-11.02	-0.51	2.36e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1144333	0.850	rs1251274	chr1:76288587	T/C	cg10523679	chr1:76189770	ACADM	-0.46	-6.64	-0.34	1.21e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg07424592	chr7:64974309	NA	0.82	9.33	0.45	1.38e-18	Diabetic kidney disease;
LIHC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.7	-10.8	-0.5	1.41e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.63	-7.85	-0.39	5.35e-14	Gut microbiome composition (summer);
LIHC	cis	rs57244997	0.725	rs7754703	chr6:162440488	T/C	cg17173639	chr6:162384350	PARK2	-0.52	-6.64	-0.34	1.23e-10	Mosquito bite size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03004097	chr2:239197782	PER2	-0.46	-6.63	-0.34	1.3100000000000001e-10	Cognitive function;
LIHC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	9.33	0.45	1.35e-18	Mean platelet volume;
LIHC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg02487422	chr3:49467188	NICN1	-0.43	-5.74	-0.3	2.05e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.01	-0.31	4.66e-9	Tuberculosis;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.53	0.59	1.1e-33	Prudent dietary pattern;
LIHC	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	3.96e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19349861	chr11:133402246	OPCML	0.51	6.81	0.35	4.34e-11	Lung function (FEV1/FVC);
LIHC	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	6.93	0.35	2.06e-11	Exhaled nitric oxide output;
LIHC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.43	-7.45	-0.37	7.48e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg01518246	chr11:63870912	FLRT1;MACROD1	0.47	6.67	0.34	1.01e-10	Mean platelet volume;
LIHC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.47	0.37	6.73e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.36	-5.78	-0.3	1.7e-8	Hypospadias;
LIHC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.81	9.21	0.45	3.34e-18	Initial pursuit acceleration;
LIHC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.91	0.39	3.6e-14	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg20368463	chr18:77673604	PQLC1	-0.34	-5.93	-0.31	7.36e-9	Schizophrenia;
LIHC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg14222432	chr12:29376421	FAR2	0.36	6.89	0.35	2.73e-11	QT interval;
LIHC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.81	-12.95	-0.57	1.7e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.93	15.17	0.63	4.1e-40	Cognitive ability;
LIHC	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.54	-7.56	-0.38	3.75e-13	Body mass index;
LIHC	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.77	11.58	0.53	2.15e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.09	-0.31	2.98e-9	Metabolite levels;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg26338869	chr17:61819248	STRADA	0.53	7.21	0.36	3.73e-12	Height;
LIHC	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.95	-0.35	1.81e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.44	-7.93	-0.39	3.13e-14	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.69	8.23	0.41	3.93e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.59	8.0	0.4	1.9e-14	Breast cancer;
LIHC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg21573476	chr21:45109991	RRP1B	-0.5	-9.25	-0.45	2.44e-18	Mean corpuscular volume;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.66	-9.42	-0.45	6.81e-19	Menopause (age at onset);
LIHC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg06207120	chr15:45996521	NA	0.34	6.64	0.34	1.27e-10	Waist circumference;Weight;
LIHC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	1.03	19.81	0.73	1.01e-58	Breast cancer;
LIHC	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg23091122	chr1:110024289	SYPL2	-0.47	-6.36	-0.33	6.47e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	9.27	0.45	2.21e-18	Lymphocyte counts;
LIHC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.53	-8.37	-0.41	1.54e-15	Coronary artery disease;
LIHC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.44	0.37	8.4e-13	Bipolar disorder;
LIHC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.08e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg12863693	chr15:85201151	NMB	0.46	6.52	0.33	2.5e-10	Schizophrenia;
LIHC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.52	7.2	0.36	3.74e-12	Morning vs. evening chronotype;
LIHC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.54	8.85	0.43	4.88e-17	Calcium levels;
LIHC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.72	10.83	0.51	1.05e-23	Corneal astigmatism;
LIHC	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg08847533	chr14:75593920	NEK9	0.47	7.26	0.37	2.54e-12	IgG glycosylation;
LIHC	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.34	-5.91	-0.3	8.37e-9	Lewy body disease;
LIHC	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg24112000	chr20:60950667	NA	0.46	7.34	0.37	1.61e-12	Colorectal cancer;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.45	7.3	0.37	1.97e-12	Testicular germ cell tumor;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.22	0.41	4.4e-15	Height;
LIHC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.66	-0.38	1.95e-13	Body mass index;
LIHC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg23262073	chr20:60523788	NA	-0.29	-6.09	-0.31	3e-9	Body mass index;
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.39	6.25	0.32	1.22e-9	Tonsillectomy;
LIHC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg10820045	chr2:198174542	NA	-0.61	-10.61	-0.5	6.34e-23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg27130769	chr7:5417105	TNRC18	0.44	6.71	0.34	7.9e-11	Immature fraction of reticulocytes;
LIHC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.43	7.11	0.36	6.89e-12	Breast cancer;
LIHC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	0.98	10.29	0.49	7.98e-22	Vitiligo;
LIHC	cis	rs12474201	0.851	rs13012099	chr2:47010742	G/A	cg06386533	chr2:46925753	SOCS5	0.6	6.19	0.32	1.77e-9	Height;
LIHC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.92	0.35	2.24e-11	Red blood cell count;
LIHC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.95	0.35	1.91e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.23	-7.27	-0.37	2.49e-12	Mean corpuscular volume;
LIHC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.1	0.4	1.01e-14	Coronary artery disease;
LIHC	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg07862535	chr7:139043722	LUC7L2	0.58	9.92	0.47	1.53e-20	Diisocyanate-induced asthma;
LIHC	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.61	5.95	0.31	6.75e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.64	-9.01	-0.44	1.54e-17	Blood metabolite levels;
LIHC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	17.76	0.69	1.83e-50	Smoking behavior;
LIHC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-7.8	-0.39	7.33e-14	Lymphocyte counts;
LIHC	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.48	7.54	0.38	4.31e-13	Cocaine dependence;
LIHC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.53	-8.36	-0.41	1.61e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.79	15.09	0.63	8.58e-40	Testicular germ cell tumor;
LIHC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg14580859	chr9:123691850	NA	-0.4	-6.96	-0.35	1.77e-11	Rheumatoid arthritis;
LIHC	cis	rs9473924	0.542	rs9473923	chr6:50833565	A/T	cg14470998	chr6:50812995	TFAP2B	0.92	10.56	0.5	9.3e-23	Body mass index;
LIHC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg20636351	chr8:55087400	NA	-0.34	-7.09	-0.36	7.97e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02985541	chr2:219472218	PLCD4	0.44	7.26	0.37	2.69e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg16434002	chr17:42200994	HDAC5	0.48	7.15	0.36	5.16e-12	Total body bone mineral density;
LIHC	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.74	-0.3	2.11e-8	Alcohol dependence;
LIHC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.16	18.08	0.7	9.53e-52	Gut microbiome composition (summer);
LIHC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.33	7.14	0.36	5.57e-12	Bone mineral density;
LIHC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	6.74	0.34	6.86e-11	Obesity-related traits;
LIHC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.73	0.43	1.13e-16	Height;
LIHC	cis	rs7700895	0.554	rs154460	chr5:95217430	A/T	cg10483112	chr5:95245456	ELL2	0.32	5.74	0.3	2.11e-8	IgG glycosylation;
LIHC	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg16479474	chr6:28041457	NA	0.39	6.43	0.33	4.42e-10	Parkinson's disease;
LIHC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.18	0.44	4.06e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.33	6.24	0.32	1.32e-9	Renal cell carcinoma;
LIHC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.39	-7.2	-0.36	3.95e-12	Response to antipsychotic treatment;
LIHC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.83	-0.3	1.26e-8	Breast cancer;
LIHC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.38	0.45	9.63e-19	Platelet count;
LIHC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.29	5.88	0.3	9.69e-9	Bone mineral density;
LIHC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.47	-0.33	3.39e-10	Red cell distribution width;
LIHC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.79	-12.22	-0.55	9.41e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg18225595	chr11:63971243	STIP1	0.63	6.38	0.33	5.92e-10	Mean platelet volume;
LIHC	cis	rs6973256	0.569	rs13246174	chr7:133395004	C/T	cg03336402	chr7:133662267	EXOC4	-0.37	-5.73	-0.3	2.24e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.75	10.88	0.51	7.33e-24	Breast cancer;
LIHC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.37	5.81	0.3	1.45e-8	Menopause (age at onset);
LIHC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.57	8.07	0.4	1.18e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.13	0.55	2.09e-28	Menopause (age at onset);
LIHC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.58	-7.99	-0.4	2.06e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.97	-0.7	2.65e-51	Schizophrenia;
LIHC	cis	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg04317927	chr11:55418816	OR4S2	0.48	9.21	0.45	3.29e-18	Pediatric bone mineral density (spine);
LIHC	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.46	-6.79	-0.34	5.11e-11	Dermatomyositis;
LIHC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21467203	chr3:49911342	NA	-0.58	-10.66	-0.5	4.16e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.31e-22	Colorectal cancer;
LIHC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg17750252	chr2:136567154	LCT	0.35	6.21	0.32	1.56e-9	Mosquito bite size;
LIHC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	7.44	0.37	8.39e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.46	-11.99	-0.54	6.92e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs4788570	0.615	rs7190487	chr16:71648617	A/G	cg06353428	chr16:71660113	MARVELD3	1.43	14.44	0.62	2.98e-37	Intelligence (multi-trait analysis);
LIHC	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.78	6.63	0.34	1.32e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.41	-6.82	-0.35	4.06e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05463257	chr3:182782445	MCCC1	0.47	6.3	0.32	9.08e-10	Hepatitis;
LIHC	cis	rs2176862	1.000	rs2293023	chr3:46620899	T/A	cg08058988	chr3:46621936	LRRC2;TDGF1	-0.61	-6.3	-0.32	9.3e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.97	-0.31	6.01e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.81	0.39	6.89e-14	Tonsillectomy;
LIHC	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.66	10.47	0.49	1.89e-22	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04077199	chr22:24989175	GGT1;C22orf36	0.47	6.33	0.32	7.61e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.34	0.55	3.55e-29	Cognitive test performance;
LIHC	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.92	-0.3	7.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.3	0.45	1.65e-18	Melanoma;
LIHC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.89	12.93	0.57	2.06e-31	Alzheimer's disease;
LIHC	cis	rs7188697	0.922	rs28307	chr16:58577138	A/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.27	-0.37	2.47e-12	QT interval;
LIHC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.73	0.5	2.4e-23	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10620767	chr10:300254	ZMYND11	-0.25	-6.04	-0.31	3.94e-9	Calcium levels;
LIHC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3736485	0.873	rs12442725	chr15:51874412	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.83	14.54	0.62	1.28e-37	Headache;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.53	8.08	0.4	1.15e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.47	-7.72	-0.39	1.33e-13	Blood metabolite levels;
LIHC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.45	0.33	3.75e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.52	0.56	7.08e-30	Prudent dietary pattern;
LIHC	cis	rs9918079	0.560	rs6414767	chr4:15655721	A/G	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.85	-0.3	1.16e-8	Obesity-related traits;
LIHC	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.76	-11.83	-0.54	2.63e-27	Eosinophil percentage of white cells;
LIHC	cis	rs7551222	0.752	rs4252694	chr1:204499056	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.5	-0.38	5.47e-13	Schizophrenia;
LIHC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.75	10.64	0.5	4.85e-23	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.22	-0.58	1.56e-32	Primary sclerosing cholangitis;
LIHC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.45	10.18	0.48	1.97e-21	Iron status biomarkers (transferrin levels);
LIHC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.77	11.85	0.54	2.25e-27	Corneal astigmatism;
LIHC	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.65	11.25	0.52	3.49e-25	Menopause (age at onset);
LIHC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.92	-10.12	-0.48	3.02e-21	Red cell distribution width;
LIHC	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg18323236	chr1:24743029	NIPAL3	0.39	7.25	0.37	2.73e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.51	-7.65	-0.38	2.04e-13	Total body bone mineral density;
LIHC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg02290350	chr8:58132656	NA	0.31	7.15	0.36	5.41e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.43	-0.33	4.24e-10	Type 2 diabetes;
LIHC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.27	-0.32	1.09e-9	Total body bone mineral density;
LIHC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.64	-11.92	-0.54	1.26e-27	Paraoxonase activity;
LIHC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.35	7.94	0.39	2.85e-14	Crohn's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15754109	chr8:67974431	COPS5	0.43	6.97	0.35	1.59e-11	Cognitive function;
LIHC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg10932868	chr11:921992	NA	0.38	7.32	0.37	1.83e-12	Alzheimer's disease (late onset);
LIHC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.46	7.05	0.36	9.79e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.57	-0.38	3.57e-13	Schizophrenia;
LIHC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.4	-6.38	-0.33	5.92e-10	Gut microbiome composition (summer);
LIHC	cis	rs11212260	0.512	rs17663749	chr11:107185075	G/A	cg25435332	chr11:107328525	CWF19L2	0.75	6.96	0.35	1.77e-11	IgG glycosylation;
LIHC	cis	rs12440869	0.649	rs4776929	chr15:67707134	G/C	cg21788615	chr15:67813140	C15orf61	-0.42	-6.25	-0.32	1.22e-9	Peak velocity of the mitral A-wave;
LIHC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg18151635	chr12:93972918	NA	-0.43	-6.69	-0.34	9.11e-11	Pubertal anthropometrics;
LIHC	cis	rs1355223	0.872	rs7116409	chr11:34751007	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.5	-0.33	2.86e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.6	9.17	0.44	4.39e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.58	-11.21	-0.52	4.65e-25	Body mass index;
LIHC	trans	rs71658797	0.505	rs35038885	chr1:77960789	A/G	cg04606550	chr5:14226569	TRIO	0.39	6.14	0.32	2.25e-9	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
LIHC	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.37	0.56	2.62e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg02795151	chr17:7402630	POLR2A	0.51	5.8	0.3	1.49e-8	Androgen levels;
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11987759	chr7:65425863	GUSB	-0.39	-6.17	-0.32	1.88e-9	Calcium levels;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.61	8.84	0.43	5.28e-17	Prudent dietary pattern;
LIHC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg04013166	chr16:89971882	TCF25	0.49	5.91	0.3	8.48e-9	Skin colour saturation;
LIHC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.67	10.26	0.49	1.05e-21	Corneal astigmatism;
LIHC	trans	rs12780046	0.656	rs11189963	chr10:100845659	C/T	cg05980083	chr9:112191166	PTPN3	-0.47	-6.17	-0.32	1.91e-9	Non-glioblastoma glioma;
LIHC	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.83	-0.3	1.29e-8	Prostate cancer;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.44	0.59	2.35e-33	Prudent dietary pattern;
LIHC	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-9.88	-0.47	2.04e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg12698662	chr3:15914712	MIR563	-0.38	-6.99	-0.35	1.46e-11	Mean platelet volume;
LIHC	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg08992911	chr2:238395768	MLPH	0.58	6.05	0.31	3.89e-9	Prostate cancer;
LIHC	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.62	6.14	0.32	2.27e-9	Carotid intima media thickness;
LIHC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg15208524	chr1:10270712	KIF1B	0.4	6.14	0.32	2.26e-9	Hepatocellular carcinoma;
LIHC	cis	rs876084	0.505	rs11988495	chr8:121128487	A/G	cg06265175	chr8:121136014	COL14A1	0.42	6.68	0.34	9.71e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg14092571	chr14:90743983	NA	0.41	5.76	0.3	1.92e-8	Mortality in heart failure;
LIHC	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25632853	chr15:73088954	NA	0.35	5.89	0.3	9.09e-9	Triglyceride levels;
LIHC	cis	rs655641	1.000	rs489486	chr11:85765737	T/C	cg09030501	chr11:85779252	PICALM	-0.52	-6.1	-0.31	2.83e-9	Platelet count;
LIHC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.08	-0.31	3.15e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.49	0.38	5.79e-13	Bipolar disorder;
LIHC	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.39	-0.41	1.29e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs8083850	0.635	rs2043146	chr18:50850992	T/G	cg24270629	chr18:50823537	DCC	0.53	7.91	0.39	3.71e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg08694578	chr2:241835147	C2orf54	-0.63	-10.27	-0.49	9.61e-22	Urinary metabolites;
LIHC	trans	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg25214090	chr10:38739885	LOC399744	0.41	6.42	0.33	4.46e-10	Diastolic blood pressure;
LIHC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.84	-0.35	3.76e-11	IgG glycosylation;
LIHC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.68	8.84	0.43	5.27e-17	Initial pursuit acceleration;
LIHC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.48	5.78	0.3	1.71e-8	Bladder cancer;
LIHC	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.88	-0.3	9.71e-9	Coronary artery disease;
LIHC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg02711726	chr17:80685570	FN3KRP	0.31	5.78	0.3	1.68e-8	Breast cancer;
LIHC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-0.88	-9.6	-0.46	1.83e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.7	-7.0	-0.35	1.36e-11	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.01	-0.35	1.26e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21467203	chr3:49911342	NA	0.4	7.0	0.35	1.33e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg15103426	chr22:29168792	CCDC117	0.67	11.25	0.52	3.32e-25	Lymphocyte counts;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg21581283	chr12:124826534	NCOR2	0.42	6.24	0.32	1.27e-9	Alopecia areata;
LIHC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg18129178	chr5:148520854	ABLIM3	0.36	6.04	0.31	3.97e-9	Breast cancer;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.07	0.55	3.4e-28	Prudent dietary pattern;
LIHC	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg00977110	chr5:151150581	G3BP1	-0.56	-7.07	-0.36	8.73e-12	Preschool internalizing problems;
LIHC	cis	rs7937890	0.599	rs2597204	chr11:14481017	C/T	cg02886208	chr11:14281011	SPON1	-0.51	-6.84	-0.35	3.58e-11	Mitochondrial DNA levels;
LIHC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.64	11.15	0.52	7.96e-25	Platelet distribution width;
LIHC	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg09137382	chr11:130731461	NA	0.42	6.31	0.32	8.58e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-8.08	-0.4	1.1e-14	Putamen volume;
LIHC	cis	rs7635838	0.751	rs6442260	chr3:11590751	C/T	cg00170343	chr3:11313890	ATG7	-0.4	-5.87	-0.3	1.03e-8	HDL cholesterol;
LIHC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg17980119	chr2:219472607	PLCD4	0.37	6.27	0.32	1.1e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04856096	chr8:68255097	ARFGEF1	0.47	6.19	0.32	1.75e-9	Pancreatic cancer;
LIHC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.55	10.84	0.51	9.71e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs507080	0.922	rs555356	chr11:118558078	G/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.6	0.34	1.53e-10	Serum metabolite levels;
LIHC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.29	-0.32	9.45e-10	Chronic sinus infection;
LIHC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.58	0.34	1.79e-10	Bipolar disorder;
LIHC	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg01652190	chr22:50026171	C22orf34	-0.34	-7.6	-0.38	2.87e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.54	-5.87	-0.3	1.03e-8	Menarche (age at onset);
LIHC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg25039879	chr17:56429692	SUPT4H1	0.84	9.6	0.46	1.72e-19	Cognitive test performance;
LIHC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.35	6.36	0.33	6.39e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-8.58	-0.42	3.25e-16	Gut microbiome composition (summer);
LIHC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.46	0.37	7.04e-13	Renal cell carcinoma;
LIHC	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.49	7.24	0.36	2.93e-12	Thyroid stimulating hormone;
LIHC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.71	-0.43	1.3e-16	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23002097	chr19:58898625	RPS5	-0.48	-6.61	-0.34	1.46e-10	Pancreatic cancer;
LIHC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.5	7.76	0.39	1e-13	Breast cancer;
LIHC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	8.14	0.4	7.35e-15	Birth weight;
LIHC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg06046430	chr4:77819534	ANKRD56	0.5	6.53	0.33	2.34e-10	Emphysema distribution in smoking;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08037059	chr1:90460796	LOC492303;ZNF326	0.5	6.59	0.34	1.71e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg23625390	chr15:77176239	SCAPER	0.35	6.02	0.31	4.55e-9	Blood metabolite levels;
LIHC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22168489	chr12:122356033	WDR66	0.45	6.2	0.32	1.61e-9	Mean corpuscular volume;
LIHC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21545522	chr1:205238299	TMCC2	0.29	5.93	0.31	7.36e-9	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.38e-12	Bipolar disorder;
LIHC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg02269571	chr22:50332266	NA	-0.96	-9.93	-0.47	1.42e-20	Schizophrenia;
LIHC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.62	-8.2	-0.41	4.91e-15	Colorectal cancer;
LIHC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg24130564	chr14:104152367	KLC1	-0.54	-8.89	-0.43	3.49e-17	Reticulocyte count;
LIHC	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.7	11.46	0.53	5.82e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.82	12.33	0.55	3.65e-29	Motion sickness;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05787120	chr3:50365854	TUSC2	-0.49	-6.32	-0.32	8.1e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.49	-0.33	2.94e-10	Total body bone mineral density;
LIHC	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg09795085	chr6:101329169	ASCC3	-0.55	-7.66	-0.38	1.99e-13	Neuroticism;
LIHC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.53	9.31	0.45	1.55e-18	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14497545	chr4:140754475	MAML3	0.43	6.89	0.35	2.77e-11	Cognitive function;
LIHC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.6	-10.14	-0.48	2.7e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.82	0.3	1.38e-8	Eosinophil percentage of white cells;
LIHC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-8.2	-0.41	5e-15	Multiple sclerosis;Ankylosing spondylitis;
LIHC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg09835421	chr16:68378352	PRMT7	-0.84	-9.61	-0.46	1.68e-19	Schizophrenia;
LIHC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.92	0.3	8.01e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20135002	chr11:47629003	NA	0.54	9.06	0.44	1.03e-17	Subjective well-being;
LIHC	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.83	-6.73	-0.34	7.33e-11	Arsenic metabolism;
LIHC	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.64e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07305463	chr2:136567211	LCT	0.37	6.56	0.33	2.01e-10	Mosquito bite size;
LIHC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg25894440	chr7:65020034	NA	-0.57	-6.4	-0.33	5e-10	Diabetic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00218103	chr22:46465977	NA	0.36	6.38	0.33	5.81e-10	Cognitive function;
LIHC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21467203	chr3:49911342	NA	0.4	7.2	0.36	3.97e-12	Menarche (age at onset);
LIHC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	0.96	7.95	0.4	2.65e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.51	5.73	0.3	2.25e-8	Cerebrospinal P-tau181p levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01949614	chr16:1359397	UBE2I	0.39	6.15	0.32	2.11e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.76	0.34	5.98e-11	Diabetic kidney disease;
LIHC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	6.98	0.35	1.56e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg07451762	chr16:28383216	NA	0.39	7.05	0.36	9.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs922107	0.738	rs12760395	chr1:90040361	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs611744	0.967	rs645070	chr8:109216345	A/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.77e-11	Dupuytren's disease;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.18	-0.32	1.84e-9	Aortic root size;
LIHC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.46	-6.99	-0.35	1.49e-11	P wave terminal force;
LIHC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.51	-8.58	-0.42	3.4e-16	Pubertal anthropometrics;
LIHC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.71	7.9	0.39	3.97e-14	Testicular germ cell tumor;
LIHC	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06634786	chr22:41940651	POLR3H	0.58	6.43	0.33	4.23e-10	Vitiligo;
LIHC	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-10.92	-0.51	5.2e-24	Brugada syndrome;
LIHC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg15744005	chr10:104629667	AS3MT	-0.39	-8.69	-0.43	1.5e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.67	8.37	0.41	1.52e-15	Corneal astigmatism;
LIHC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.46	-5.71	-0.3	2.44e-8	Response to angiotensin II receptor blocker therapy;
LIHC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg00071026	chr13:113650936	MCF2L	-0.39	-6.0	-0.31	5.1e-9	Systolic blood pressure;
LIHC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.6	8.77	0.43	8.32e-17	Emphysema distribution in smoking;
LIHC	cis	rs3106136	0.843	rs7438414	chr4:95265822	T/C	cg11021082	chr4:95130006	SMARCAD1	0.4	7.18	0.36	4.31e-12	Capecitabine sensitivity;
LIHC	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.16	-0.4	6.51e-15	Body mass index;
LIHC	cis	rs3791556	0.741	rs3791542	chr2:240103955	A/G	cg03281426	chr2:240109471	HDAC4	-0.38	-5.85	-0.3	1.16e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.78	12.56	0.56	5.05e-30	Breast cancer;
LIHC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.45	7.39	0.37	1.13e-12	Height;
LIHC	trans	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg10756647	chr7:56101905	PSPH	-1.04	-12.56	-0.56	5.34e-30	Diabetic kidney disease;
LIHC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg25344623	chr2:136566232	LCT	-0.37	-5.98	-0.31	5.65e-9	Corneal structure;
LIHC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.73	16.36	0.66	7.76e-45	Systemic lupus erythematosus;
LIHC	cis	rs9378688	0.654	rs2479008	chr6:2347808	C/T	cg12303981	chr6:2244766	GMDS	-0.43	-5.88	-0.3	9.96e-9	Caudate nucleus volume;
LIHC	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-7.11	-0.36	6.96e-12	Type 2 diabetes;
LIHC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.5e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	7.99	0.4	2.13e-14	Monocyte percentage of white cells;
LIHC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg19635926	chr16:89946313	TCF25	0.49	6.21	0.32	1.5e-9	Skin colour saturation;
LIHC	cis	rs635808	0.500	rs1964808	chr6:167172602	C/T	cg05573767	chr6:167171394	RPS6KA2	0.34	7.16	0.36	4.91e-12	Dental caries;
LIHC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07305463	chr2:136567211	LCT	-0.39	-7.59	-0.38	3.11e-13	Mosquito bite size;
LIHC	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.49	5.91	0.3	8.45e-9	Serum sulfate level;
LIHC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.86	0.35	3.28e-11	Ileal carcinoids;
LIHC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07849438	chr12:19593035	AEBP2	-0.48	-6.53	-0.33	2.45e-10	Hepatitis;
LIHC	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-7.24	-0.36	2.93e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.98	-0.31	5.75e-9	Fear of minor pain;
LIHC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.46	-6.11	-0.31	2.69e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg16589663	chr20:23618590	CST3	0.74	7.51	0.38	5.16e-13	Chronic kidney disease;
LIHC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.41	0.41	1.11e-15	Motion sickness;
LIHC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg23091122	chr1:110024289	SYPL2	-0.5	-6.83	-0.35	3.93e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	7.06	0.36	9.06e-12	Renal cell carcinoma;
LIHC	cis	rs7575217	0.767	rs796056	chr2:101735276	A/C	cg23907051	chr2:101730305	TBC1D8	-0.26	-5.83	-0.3	1.29e-8	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.49	-6.13	-0.31	2.46e-9	Menarche (age at onset);
LIHC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg02297831	chr4:17616191	MED28	0.39	6.13	0.31	2.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.47	8.57	0.42	3.56e-16	Colorectal cancer;
LIHC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.82	-0.35	4.04e-11	Response to antipsychotic treatment;
LIHC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.71	-0.65	3.04e-42	Chronic sinus infection;
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.27	-0.37	2.39e-12	Menopause (age at onset);
LIHC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.56	9.03	0.44	1.33e-17	Multiple sclerosis;
LIHC	trans	rs75804782	0.521	rs55988884	chr2:239396930	G/A	cg01134436	chr17:81009848	B3GNTL1	0.82	6.89	0.35	2.67e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	7.29	0.37	2.14e-12	Red cell distribution width;Reticulocyte count;
LIHC	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.53	7.86	0.39	5.05e-14	Body mass index;
LIHC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg22842854	chr12:123319900	HIP1R	-0.61	-7.54	-0.38	4.32e-13	Schizophrenia;
LIHC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg25039879	chr17:56429692	SUPT4H1	0.77	8.91	0.43	3e-17	Cognitive test performance;
LIHC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.63	8.68	0.42	1.69e-16	Coronary artery disease;
LIHC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.72	-0.39	1.27e-13	Total body bone mineral density;
LIHC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.82	9.5	0.46	3.78e-19	Initial pursuit acceleration;
LIHC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.73	-11.5	-0.53	4.37e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg26692224	chr17:62915920	LRRC37A3	-0.73	-6.98	-0.35	1.5e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.98	13.29	0.58	8.46e-33	Heart rate;
LIHC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.92	-0.3	7.89e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.24	0.41	3.75e-15	Motion sickness;
LIHC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg05947499	chr12:113704091	TPCN1	0.45	6.17	0.32	1.91e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.47	9.51	0.46	3.45e-19	Tonsillectomy;
LIHC	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg00601450	chr5:74908170	NA	0.55	6.36	0.33	6.46e-10	Coronary artery disease;
LIHC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg12903224	chr12:29470962	FAR2	-0.41	-6.65	-0.34	1.14e-10	QT interval;
LIHC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg14440974	chr22:39074834	NA	-0.37	-5.86	-0.3	1.08e-8	Menopause (age at onset);
LIHC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21467203	chr3:49911342	NA	0.52	9.35	0.45	1.18e-18	Body mass index;
LIHC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	8.7	0.43	1.43e-16	Multiple sclerosis;
LIHC	cis	rs7395581	1.000	rs7395581	chr11:47246397	G/A	cg26139080	chr11:47293733	MADD	0.49	8.08	0.4	1.15e-14	HDL cholesterol;
LIHC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.87	-9.06	-0.44	1.04e-17	Platelet count;
LIHC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.33	5.98	0.31	5.68e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.58	10.97	0.51	3.39e-24	Leprosy;
LIHC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.51	-7.44	-0.37	8.31e-13	Mortality in heart failure;
LIHC	cis	rs787274	0.681	rs787284	chr9:115538040	A/G	cg13803584	chr9:115635662	SNX30	-0.56	-6.25	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.92	-0.3	7.75e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg00656387	chr3:40428638	ENTPD3	0.45	7.27	0.37	2.44e-12	Renal cell carcinoma;
LIHC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.6	-0.53	1.92e-26	Schizophrenia;
LIHC	cis	rs4450131	0.898	rs10794173	chr10:126330565	C/T	cg20435097	chr10:126320824	FAM53B	-0.53	-9.58	-0.46	2.01e-19	White blood cell count (basophil);
LIHC	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.48	-0.53	5.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.49	0.53	4.8e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.69	-0.43	1.55e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs9914544	0.545	rs12452289	chr17:18781809	T/G	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.75e-10	Educational attainment (years of education);
LIHC	cis	rs963731	0.649	rs2278912	chr2:39199702	C/T	cg04010122	chr2:39346883	SOS1	-0.72	-5.97	-0.31	5.85e-9	Corticobasal degeneration;
LIHC	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.13	-9.96	-0.47	1.12e-20	Schizophrenia;
LIHC	cis	rs4586057	0.514	rs10785974	chr10:92627931	T/C	cg14313238	chr10:92632228	RPP30	0.37	6.15	0.32	2.2e-9	Economic and political preferences (time);
LIHC	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.44	0.33	3.94e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.56	0.56	5.19e-30	Menopause (age at onset);
LIHC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.49	8.11	0.4	9.18e-15	Blood protein levels;
LIHC	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.32	-6.09	-0.31	3.11e-9	Neuroticism;
LIHC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.66	-9.86	-0.47	2.31e-20	Coronary artery disease;
LIHC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg25902810	chr10:99078978	FRAT1	0.71	10.7	0.5	3.12e-23	Monocyte count;
LIHC	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.41	-0.37	9.97e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.44	-0.42	9.26e-16	Response to antipsychotic treatment;
LIHC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-7.49	-0.38	6.1e-13	Longevity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04590956	chr2:70057467	GMCL1	0.42	6.15	0.32	2.22e-9	Pancreatic cancer;
LIHC	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	0.84	9.54	0.46	2.78e-19	Mitochondrial DNA levels;
LIHC	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.73	-11.93	-0.54	1.14e-27	Coronary artery disease;
LIHC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.54	12.75	0.57	9.76e-31	Alcohol dependence;
LIHC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg11764359	chr7:65958608	NA	0.58	6.08	0.31	3.18e-9	Diabetic kidney disease;
LIHC	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg20435097	chr10:126320824	FAM53B	-0.43	-6.41	-0.33	4.91e-10	Cocaine dependence;
LIHC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.59	-8.01	-0.4	1.77e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6750047	0.691	rs336032	chr2:38264788	T/C	cg07380506	chr2:38303506	CYP1B1	-0.5	-5.82	-0.3	1.38e-8	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg26939375	chr7:64535504	NA	-0.46	-7.06	-0.36	9.29e-12	Aortic root size;
LIHC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	0.75	8.0	0.4	1.96e-14	Testicular germ cell tumor;
LIHC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.21	15.28	0.64	1.46e-40	Alzheimer's disease (late onset);
LIHC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg02187348	chr16:89574699	SPG7	0.42	6.11	0.31	2.68e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1892700	0.821	rs61739710	chr21:34925689	G/A	cg14850771	chr21:34775459	IFNGR2	-0.44	-5.84	-0.3	1.21e-8	Educational attainment;
LIHC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg04865290	chr3:52927548	TMEM110	-0.51	-5.9	-0.3	8.82e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg18306943	chr3:40428807	ENTPD3	-0.34	-6.02	-0.31	4.59e-9	Renal cell carcinoma;
LIHC	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-10.68	-0.5	3.56e-23	Blood pressure (smoking interaction);
LIHC	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.44	-6.1	-0.31	2.84e-9	Rheumatoid arthritis;
LIHC	cis	rs12602486	1.000	rs16940540	chr17:42229702	C/A	cg13607699	chr17:42295918	UBTF	-0.75	-6.42	-0.33	4.46e-10	Glycated hemoglobin levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg12666227	chr12:76742354	BBS10	-0.46	-7.13	-0.36	6.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg24229701	chr12:130821962	PIWIL1	0.45	6.74	0.34	6.91e-11	Menopause (age at onset);
LIHC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.59	7.85	0.39	5.3e-14	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02244288	chr16:89573955	SPG7	-0.3	-5.8	-0.3	1.49e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-8.28	-0.41	2.81e-15	Gut microbiome composition (summer);
LIHC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg27366882	chr3:133540807	NA	-0.43	-7.24	-0.36	2.95e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs35883536	0.506	rs2809814	chr1:101031829	C/T	cg14515779	chr1:101123966	NA	-0.42	-6.0	-0.31	5.13e-9	Monocyte count;
LIHC	cis	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg14515779	chr1:101123966	NA	-0.7	-14.1	-0.61	6.72e-36	Monocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20112827	chr22:30783793	RNF215	0.42	6.1	0.31	2.87e-9	Lung function (FEV1/FVC);
LIHC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg02931644	chr1:25747376	RHCE	0.35	7.85	0.39	5.29e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.79	-0.3	1.58e-8	Alzheimer's disease (late onset);
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg24829772	chr8:18577488	PSD3	-0.41	-6.13	-0.31	2.35e-9	Neuroticism;
LIHC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.62	10.68	0.5	3.62e-23	Colorectal cancer;
LIHC	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14154082	chr13:112174009	NA	0.29	6.14	0.32	2.28e-9	Menarche (age at onset);
LIHC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.48	-7.8	-0.39	7.42e-14	Corneal astigmatism;
LIHC	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-0.79	-8.23	-0.41	4e-15	Metabolite levels (HVA/5-HIAA ratio);
LIHC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.07	0.4	1.17e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.22	-0.36	3.41e-12	Bipolar disorder;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.64	0.42	2.24e-16	Lymphocyte counts;
LIHC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.13	-0.58	3.45e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs112721625	1	rs112721625	chr17:57927426	AT/A	cg02344993	chr17:57696989	CLTC	0.53	9.19	0.44	4e-18	Monocyte count;
LIHC	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26734620	chr12:56694298	CS	1.2	9.66	0.46	1.13e-19	Psoriasis vulgaris;
LIHC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.37	5.82	0.3	1.35e-8	Menopause (age at onset);
LIHC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.83	-0.35	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.73	0.5	2.43e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.52	9.23	0.45	2.93e-18	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.67	10.22	0.48	1.39e-21	Body mass index;
LIHC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.47	-7.14	-0.36	5.78e-12	Cognitive function;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07278624	chr12:106696673	TCP11L2	0.45	6.09	0.31	3.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg23782820	chr8:58130467	NA	0.33	5.9	0.3	8.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg05590025	chr7:65112418	INTS4L2	0.62	6.79	0.34	4.9e-11	Diabetic kidney disease;
LIHC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	0.8	13.69	0.59	2.56e-34	Total cholesterol levels;
LIHC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg15691649	chr6:25882328	NA	-0.6	-7.75	-0.39	1.05e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg02993280	chr1:107599747	PRMT6	0.65	10.58	0.5	8.35e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.89	0.39	4.12e-14	Motion sickness;
LIHC	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.31	-5.77	-0.3	1.76e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.49	-7.34	-0.37	1.52e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg03761569	chr8:649540	ERICH1	-0.48	-6.29	-0.32	9.74e-10	Neuroticism;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13707777	chr5:308627	AHRR;PDCD6	0.39	6.26	0.32	1.13e-9	Longevity;
LIHC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.45	0.56	1.39e-29	Menopause (age at onset);
LIHC	cis	rs6429082	0.623	rs7547849	chr1:235564254	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.69	-9.71	-0.46	7.59e-20	Adiposity;
LIHC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.58	8.45	0.42	8.62e-16	Motion sickness;
LIHC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.11	0.36	6.74e-12	Gout;
LIHC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02985541	chr2:219472218	PLCD4	0.46	8.73	0.43	1.18e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.2	0.41	4.77e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	cis	rs10924970	0.874	rs6681842	chr1:235332555	G/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.79	0.3	1.55e-8	Asthma;
LIHC	cis	rs4700695	0.686	rs251710	chr5:65347357	G/C	cg21114390	chr5:65439923	SFRS12	0.45	5.89	0.3	9.42e-9	Facial morphology (factor 19);
LIHC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.16	0.48	2.2e-21	Alzheimer's disease (late onset);
LIHC	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.79	-0.43	7.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg22676075	chr6:135203613	NA	0.38	6.17	0.32	1.88e-9	Red blood cell count;
LIHC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.9	-0.3	8.83e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg02023728	chr11:77925099	USP35	0.34	6.03	0.31	4.14e-9	Alzheimer's disease (survival time);
LIHC	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.81	16.06	0.66	1.24e-43	Testicular germ cell tumor;
LIHC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg25344623	chr2:136566232	LCT	-0.37	-5.91	-0.3	8.3e-9	Corneal structure;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15069758	chr1:110198731	GSTM4	0.44	6.1	0.31	2.82e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.9e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.72	-11.59	-0.53	2.05e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.81	7.69	0.38	1.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.48	7.93	0.39	3.23e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg26441486	chr22:50317300	CRELD2	-0.36	-6.5	-0.33	2.79e-10	Schizophrenia;
LIHC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-6.01	-0.31	4.68e-9	Longevity;
LIHC	cis	rs3812111	0.609	rs549332	chr6:116454588	C/T	cg08036074	chr6:116424633	NT5DC1	-0.46	-7.6	-0.38	2.92e-13	Age-related macular degeneration;
LIHC	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.49	-7.24	-0.36	3.04e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.31	-6.41	-0.33	4.77e-10	Blood metabolite levels;
LIHC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-13.14	-0.58	3.24e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.68	-9.73	-0.47	6.52e-20	Initial pursuit acceleration;
LIHC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.33	7.29	0.37	2.12e-12	Ulcerative colitis;
LIHC	cis	rs861318	0.702	rs2793845	chr1:159032255	G/T	cg11003133	chr1:159046391	AIM2	0.32	6.55	0.33	2.11e-10	Obesity-related traits;
LIHC	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.48	8.78	0.43	8.22e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4908768	0.501	rs11121194	chr1:8569906	C/T	cg20416874	chr1:8611966	RERE	-0.68	-14.62	-0.62	6.36e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.3	-5.76	-0.3	1.86e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	0.99	10.62	0.5	5.84e-23	Vitiligo;
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.01	0.31	4.67e-9	Obesity-related traits;
LIHC	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg08345082	chr10:99160200	RRP12	-0.4	-6.66	-0.34	1.12e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.3	7.09	0.36	7.82e-12	Primary biliary cholangitis;
LIHC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg02527881	chr3:46936655	PTH1R	0.33	6.38	0.33	5.82e-10	Colorectal cancer;
LIHC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs4663866	0.901	rs35390666	chr2:239193578	C/T	cg16914508	chr2:239161102	PER2	0.83	5.97	0.31	5.94e-9	Irritable bowel syndrome;
LIHC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.45	-0.66	3.21e-45	Diabetic kidney disease;
LIHC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-0.98	-22.22	-0.77	2.58e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.38	-5.86	-0.3	1.08e-8	Red blood cell count;
LIHC	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.06	-0.31	3.52e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18252515	chr7:66147081	NA	0.43	5.98	0.31	5.63e-9	Aortic root size;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.67	-9.9	-0.47	1.7e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs214034	0.505	rs12465611	chr2:17932833	G/T	cg08383160	chr2:17981519	NA	-0.31	-5.75	-0.3	1.95e-8	Response to amphetamines;
LIHC	cis	rs12980942	0.630	rs11881940	chr19:41808432	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.95	0.35	1.88e-11	Coronary artery disease;
LIHC	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg11204139	chr17:3907470	NA	0.48	5.73	0.3	2.25e-8	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.88e-16	Prudent dietary pattern;
LIHC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.27	-7.03	-0.36	1.1e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.71	13.51	0.59	1.23e-33	Mortality in heart failure;
LIHC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.11	0.31	2.75e-9	Aortic root size;
LIHC	cis	rs739401	0.582	rs7932369	chr11:2958468	A/G	cg20651018	chr11:3035856	CARS	0.34	5.75	0.3	1.95e-8	Longevity;
LIHC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.82	-17.1	-0.68	8.07e-48	Height;
LIHC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.6	7.3	0.37	2.03e-12	Heart rate;
LIHC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.44	5.72	0.3	2.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs9549328	0.879	rs12428058	chr13:113636504	G/A	cg08528486	chr13:113648767	MCF2L	-0.39	-6.38	-0.33	5.89e-10	Systolic blood pressure;
LIHC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg16070018	chr6:26224392	HIST1H3E	0.58	6.82	0.35	4.1e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.14	10.48	0.49	1.87e-22	Diabetic retinopathy;
LIHC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg18867708	chr6:26865862	GUSBL1	0.52	8.1	0.4	9.8e-15	Schizophrenia;
LIHC	cis	rs4478037	0.731	rs9835090	chr3:33107671	G/T	cg16652328	chr3:33138982	GLB1;TMPPE	-0.56	-6.75	-0.34	6.37e-11	Major depressive disorder;
LIHC	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg07884673	chr3:53033167	SFMBT1	0.92	6.74	0.34	6.85e-11	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.47	6.89	0.35	2.67e-11	Aortic root size;
LIHC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	ch.11.42038R	chr11:967971	AP2A2	0.53	9.44	0.45	5.92e-19	Alzheimer's disease (late onset);
LIHC	trans	rs6934970	1.000	rs7763826	chr6:113070133	A/G	cg20627988	chr10:133946881	JAKMIP3	0.45	6.23	0.32	1.35e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs34779708	0.832	rs6481946	chr10:35529114	A/G	cg03585969	chr10:35415529	CREM	0.78	11.33	0.52	1.82e-25	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.82	13.32	0.58	6.69e-33	Breast cancer;
LIHC	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.26	7.03	0.36	1.12e-11	Type 2 diabetes;
LIHC	cis	rs1475718	0.526	rs7854734	chr9:137122410	C/G	cg21243944	chr9:137118148	NA	0.42	6.11	0.31	2.75e-9	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-10.79	-0.5	1.51e-23	Obesity-related traits;
LIHC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.64	-0.5	5.08e-23	Hemoglobin concentration;
LIHC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.67	-11.63	-0.53	1.44e-26	Crohn's disease;
LIHC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg16586182	chr3:47516702	SCAP	0.44	7.71	0.38	1.41e-13	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	6.64	0.34	1.22e-10	Renal cell carcinoma;
LIHC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.32	13.18	0.58	2.41e-32	Eosinophil percentage of granulocytes;
LIHC	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-0.76	-8.61	-0.42	2.66e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.4	5.81	0.3	1.44e-8	Menarche (age at onset);
LIHC	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.47	-9.13	-0.44	6.09e-18	LDL cholesterol levels;
LIHC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23262073	chr20:60523788	NA	-0.3	-6.22	-0.32	1.43e-9	Body mass index;
LIHC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.43	7.3	0.37	2e-12	Tuberculosis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg05082095	chr1:155099843	EFNA1	-0.51	-6.47	-0.33	3.31e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs573688	0.630	rs653699	chr1:71434501	G/A	cg07200748	chr10:111767864	ADD3	-1.03	-6.26	-0.32	1.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.33	0.37	1.72e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.02	-0.31	4.56e-9	Obesity-related traits;
LIHC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.0	0.4	1.96e-14	Lymphocyte counts;
LIHC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg02931644	chr1:25747376	RHCE	0.38	8.44	0.42	9.21e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.35	6.1	0.31	2.9e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.81	11.45	0.53	6.22e-26	Body mass index;
LIHC	cis	rs3736594	0.643	rs2384655	chr2:27952235	A/T	cg27432699	chr2:27873401	GPN1	-0.45	-7.06	-0.36	9.09e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.64	0.38	2.23e-13	Diastolic blood pressure;
LIHC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.61	7.75	0.39	1.03e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.07e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.2e-13	Heart rate;
LIHC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.05	14.18	0.61	3.09e-36	Body mass index;
LIHC	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.46	6.33	0.32	7.73e-10	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.42	-6.68	-0.34	9.92e-11	Metabolite levels;
LIHC	trans	rs7714584	1.000	rs11749391	chr5:150229066	T/C	cg20675040	chr8:143813288	C8orf55	0.34	6.13	0.31	2.41e-9	Crohn's disease;
LIHC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg16558253	chr16:72132732	DHX38	-0.51	-8.1	-0.4	9.86e-15	Fibrinogen levels;
LIHC	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.25	-6.1	-0.31	2.95e-9	Colorectal cancer;
LIHC	cis	rs4755351	0.553	rs11032157	chr11:33158566	A/G	cg05567920	chr11:33183001	CSTF3	0.43	6.24	0.32	1.28e-9	Lung cancer in ever smokers;
LIHC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.67	11.56	0.53	2.5e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.8e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg03945807	chr20:60948434	NA	0.4	5.79	0.3	1.56e-8	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02737830	chr12:64616354	C12orf66	0.5	7.71	0.38	1.36e-13	Pancreatic cancer;
LIHC	cis	rs600806	0.778	rs1525916	chr1:110010949	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.55	-6.81	-0.35	4.43e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.43	-7.07	-0.36	8.72e-12	Testicular germ cell tumor;
LIHC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.3	-0.37	2.09e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.54	8.08	0.4	1.11e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.24	0.32	1.31e-9	Ileal carcinoids;
LIHC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.57	10.37	0.49	4.33e-22	Diastolic blood pressure;
LIHC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.61	5.89	0.3	9.45e-9	Vitiligo;
LIHC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg21856205	chr7:94953877	PON1	0.49	6.05	0.31	3.77e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs716804	0.504	rs11042725	chr11:10325325	C/A	cg01453529	chr11:10209919	SBF2	-0.3	-5.75	-0.3	1.96e-8	Neuroticism;
LIHC	cis	rs1866706	0.896	rs7940022	chr11:12873906	G/T	cg25843174	chr11:12811716	TEAD1	-0.31	-6.61	-0.34	1.48e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.35	6.81	0.35	4.43e-11	Blood protein levels;
LIHC	cis	rs1198430	0.562	rs504145	chr1:23788310	C/T	cg13183780	chr1:23809682	ASAP3	-0.37	-6.69	-0.34	9.05e-11	Total cholesterol levels;
LIHC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.88	0.3	9.78e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg07541023	chr7:19748670	TWISTNB	0.39	5.76	0.3	1.83e-8	Thyroid stimulating hormone;
LIHC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.65e-29	Corneal astigmatism;
LIHC	cis	rs2412488	0.778	rs10032903	chr4:54355023	G/T	cg22241045	chr4:54363911	LNX1	0.41	6.7	0.34	8.67e-11	DNA methylation (variation);
LIHC	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.48	6.35	0.32	6.78e-10	Glioblastoma;Glioma;
LIHC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.21	0.41	4.55e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs986417	0.818	rs10133871	chr14:61063771	A/C	cg27398547	chr14:60952738	C14orf39	0.49	5.88	0.3	9.67e-9	Gut microbiota (bacterial taxa);
LIHC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.89	12.44	0.56	1.49e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.45	7.49	0.38	5.98e-13	Response to temozolomide;
LIHC	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-8.1	-0.4	9.57e-15	Body mass index;
LIHC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.55	-7.58	-0.38	3.38e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.28	0.32	1.03e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.56	9.41	0.45	7.31e-19	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22857025	chr5:266934	NA	-1.5	-18.04	-0.7	1.31e-51	Breast cancer;
LIHC	cis	rs1062177	0.756	rs2915815	chr5:151115883	G/C	cg00977110	chr5:151150581	G3BP1	-0.57	-7.18	-0.36	4.48e-12	Preschool internalizing problems;
LIHC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg03146154	chr1:46216737	IPP	-0.36	-6.02	-0.31	4.53e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.89	13.63	0.59	4.49e-34	Vitamin D levels;
LIHC	cis	rs6466055	0.932	rs2057884	chr7:104930250	T/C	cg04380332	chr7:105027541	SRPK2	0.31	6.14	0.32	2.27e-9	Schizophrenia;
LIHC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.33	-8.31	-0.41	2.3e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.43	-6.15	-0.32	2.1e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs1789	0.786	rs6414768	chr4:15695363	A/G	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.05	-0.31	3.87e-9	Blood protein levels;
LIHC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.62	8.77	0.43	8.81e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.74	7.67	0.38	1.78e-13	Vitiligo;
LIHC	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.32	-8.71	-0.43	1.35e-16	Intelligence;
LIHC	cis	rs1190552	0.802	rs10148411	chr14:102883531	A/G	cg10241871	chr14:102965420	TECPR2	-0.39	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg09003973	chr2:102972529	NA	0.52	5.78	0.3	1.73e-8	Blood protein levels;
LIHC	cis	rs9816226	0.591	rs77805826	chr3:185798025	C/T	cg00760338	chr3:185826511	ETV5	-0.71	-5.81	-0.3	1.41e-8	Obesity;Body mass index;
LIHC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.92	16.44	0.66	3.63e-45	Parkinson's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24594830	chr12:77459352	E2F7	0.46	6.29	0.32	9.93e-10	Lung function (FEV1/FVC);
LIHC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.51	7.02	0.36	1.17e-11	Height;
LIHC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.53	6.87	0.35	3.01e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg17980119	chr2:219472607	PLCD4	0.35	6.1	0.31	2.82e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.74	10.77	0.5	1.7e-23	Diisocyanate-induced asthma;
LIHC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.6	8.16	0.4	6.58e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg17279839	chr7:150038598	RARRES2	0.4	7.87	0.39	4.62e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-17.25	-0.68	2.01e-48	Schizophrenia;
LIHC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.22	-0.32	1.44e-9	Alzheimer's disease (late onset);
LIHC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	8.46	0.42	7.79e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.48	-5.97	-0.31	5.88e-9	Narcolepsy;
LIHC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg05044414	chr3:183734942	ABCC5	0.34	5.98	0.31	5.62e-9	Anterior chamber depth;
LIHC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.18	0.4	5.71e-15	Mean corpuscular volume;
LIHC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg22676075	chr6:135203613	NA	0.39	6.38	0.33	5.82e-10	Red blood cell count;
LIHC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.07	-0.31	3.38e-9	Longevity;Endometriosis;
LIHC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.09	0.4	1.02e-14	Platelet count;
LIHC	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.54	-8.06	-0.4	1.28e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.98	0.44	1.9e-17	Cognitive ability;
LIHC	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg20503657	chr10:835505	NA	1.38	12.83	0.57	5.02e-31	Eosinophil percentage of granulocytes;
LIHC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	8.18	0.4	5.62e-15	Response to bleomycin (chromatid breaks);
LIHC	cis	rs7757419	0.887	rs9296115	chr6:34434715	A/C	cg17518776	chr6:34434842	PACSIN1	-0.3	-6.12	-0.31	2.62e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
LIHC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg04756594	chr16:24857601	SLC5A11	-0.39	-6.48	-0.33	3.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.75	-11.67	-0.53	1.01e-26	Vitamin D levels;
LIHC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg03037974	chr15:76606532	NA	-0.59	-10.25	-0.48	1.17e-21	Blood metabolite levels;
LIHC	cis	rs11233413	0.794	rs66653310	chr11:82717000	A/T	cg24227371	chr11:82718527	RAB30	-0.34	-7.45	-0.37	7.94e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg07211511	chr3:129823064	LOC729375	-0.52	-8.08	-0.4	1.13e-14	Blood pressure (smoking interaction);
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.45	0.59	2.07e-33	Prudent dietary pattern;
LIHC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.11	-0.31	2.75e-9	Aortic root size;
LIHC	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg00031303	chr3:195681400	NA	0.59	7.0	0.35	1.33e-11	Pancreatic cancer;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24807761	chr7:134632531	CALD1	0.47	6.26	0.32	1.18e-9	Hip circumference;
LIHC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.64	9.81	0.47	3.65e-20	Blood protein levels;
LIHC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.12	0.31	2.62e-9	Alzheimer's disease;
LIHC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg04155231	chr12:9217510	LOC144571	0.31	5.95	0.31	6.68e-9	Sjögren's syndrome;
LIHC	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.53	-0.38	4.54e-13	Coronary artery disease;
LIHC	cis	rs61990749	0.511	rs724263	chr14:78321874	G/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.49	7.76	0.39	1e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.5	7.99	0.4	2.04e-14	Blood protein levels;
LIHC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.92	10.76	0.5	1.96e-23	Triglycerides;
LIHC	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.97	-0.31	5.87e-9	Coronary artery disease;
LIHC	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.57	10.17	0.48	2.1e-21	Body mass index;
LIHC	cis	rs62458065	1.000	rs6462364	chr7:32464776	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.64	-7.32	-0.37	1.77e-12	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.86	17.23	0.68	2.51e-48	Height;
LIHC	trans	rs10411161	0.630	rs7252101	chr19:52359372	A/C	cg22319618	chr22:45562946	NUP50	-0.52	-6.48	-0.33	3.11e-10	Breast cancer;
LIHC	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg09835421	chr16:68378352	PRMT7	-0.47	-5.76	-0.3	1.86e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.68	-0.34	9.86e-11	Metabolite levels;
LIHC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg15691649	chr6:25882328	NA	0.78	10.7	0.5	3.16e-23	Blood metabolite levels;
LIHC	cis	rs17125944	0.686	rs11157933	chr14:53349798	G/A	cg00686598	chr14:53173677	PSMC6	-0.76	-8.58	-0.42	3.28e-16	Alzheimer's disease (late onset);
LIHC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.81	5.98	0.31	5.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4853036	0.951	rs10185266	chr2:70152407	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.75	-0.34	6.19e-11	Colorectal or endometrial cancer;
LIHC	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.48	-0.37	6.36e-13	Mean platelet volume;
LIHC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg05084668	chr3:125655381	ALG1L	-0.41	-6.35	-0.32	6.66e-10	Blood pressure (smoking interaction);
LIHC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.72	7.09	0.36	7.94e-12	Vitiligo;
LIHC	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.4	-8.47	-0.42	7.54e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13369624	chr13:21714458	SAP18	0.41	6.41	0.33	4.95e-10	Cognitive function;
LIHC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.53	-7.94	-0.39	2.95e-14	Metabolic syndrome;
LIHC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.39	6.46	0.33	3.51e-10	Red blood cell count;
LIHC	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg09795085	chr6:101329169	ASCC3	0.56	7.79	0.39	8.05e-14	Neuroticism;
LIHC	cis	rs9473924	0.542	rs9463665	chr6:50928520	G/T	cg14470998	chr6:50812995	TFAP2B	0.82	7.47	0.37	6.75e-13	Body mass index;
LIHC	cis	rs2933343	1.000	rs1683778	chr3:128644595	A/G	cg25356066	chr3:128598488	ACAD9	0.53	6.97	0.35	1.64e-11	IgG glycosylation;
LIHC	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.45	7.57	0.38	3.56e-13	Crohn's disease;
LIHC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-7.55	-0.38	3.91e-13	Blood metabolite levels;
LIHC	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.43	5.98	0.31	5.55e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.1	-0.44	7.43e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg27247782	chr7:158767135	NA	-0.3	-6.07	-0.31	3.43e-9	Facial morphology (factor 20);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14298269	chr14:102689372	WDR20	0.43	6.46	0.33	3.65e-10	Longevity;
LIHC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.82	-0.3	1.35e-8	Pulse pressure;
LIHC	trans	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg21046355	chr19:52772717	ZNF766	-0.5	-6.41	-0.33	4.79e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.76	-0.34	6.1e-11	Bladder cancer;
LIHC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.89	0.35	2.77e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18252515	chr7:66147081	NA	0.42	6.1	0.31	2.92e-9	Aortic root size;
LIHC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02290350	chr8:58132656	NA	0.5	10.64	0.5	5.15e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg25356066	chr3:128598488	ACAD9	0.52	7.25	0.37	2.74e-12	IgG glycosylation;
LIHC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg23485639	chr6:28045615	ZNF165	0.38	5.87	0.3	1.02e-8	Parkinson's disease;
LIHC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	9.19	0.45	3.83e-18	Platelet count;
LIHC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.82	-10.55	-0.5	1.02e-22	Bladder cancer;
LIHC	trans	rs6489882	0.671	rs4767025	chr12:113358794	C/T	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.11	0.44	7.19e-18	Eosinophil percentage of white cells;
LIHC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02985541	chr2:219472218	PLCD4	0.41	6.71	0.34	8.11e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.08	-0.31	3.29e-9	Colorectal cancer;
LIHC	cis	rs2257205	0.667	rs6503884	chr17:56940026	G/A	cg12560992	chr17:57184187	TRIM37	0.67	7.28	0.37	2.36e-12	Pancreatic cancer;
LIHC	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.92	19.13	0.72	5.44e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-5.72	-0.3	2.34e-8	Response to antipsychotic treatment;
LIHC	cis	rs6060717	0.610	rs6058393	chr20:34608664	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-8.03	-0.4	1.56e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.35	5.73	0.3	2.25e-8	Lung cancer;
LIHC	trans	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	7.08	0.36	8.02e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.21	-0.32	1.54e-9	Aortic root size;
LIHC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.82	0.3	1.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.51	-7.73	-0.39	1.24e-13	Mean platelet volume;
LIHC	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg15711740	chr2:61764176	XPO1	0.42	5.74	0.3	2.14e-8	Tuberculosis;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg00280220	chr17:61926910	NA	0.4	6.3	0.32	9.18e-10	Prudent dietary pattern;
LIHC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg10932868	chr11:921992	NA	-0.38	-7.21	-0.36	3.51e-12	Alzheimer's disease (late onset);
LIHC	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4800452	0.826	rs9949705	chr18:20745345	A/G	cg26136497	chr18:20735537	CABLES1	-0.46	-5.83	-0.3	1.29e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02290350	chr8:58132656	NA	0.45	8.97	0.44	2.05e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-15.03	-0.63	1.52e-39	Alzheimer's disease (late onset);
LIHC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg14393609	chr7:65229607	NA	0.38	5.87	0.3	1.02e-8	Aortic root size;
LIHC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.75	0.57	9.63e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.43	-6.09	-0.31	3.06e-9	Blood protein levels;
LIHC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg18654377	chr3:49208889	KLHDC8B	-0.49	-5.9	-0.3	8.63e-9	Menarche (age at onset);
LIHC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-7.79	-0.39	8.08e-14	Electroencephalogram traits;
LIHC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.49	-7.59	-0.38	2.97e-13	Schizophrenia;
LIHC	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg14146966	chr2:61757674	XPO1	-0.44	-7.53	-0.38	4.6e-13	Tuberculosis;
LIHC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.58	5.87	0.3	1.06e-8	Crohn's disease;
LIHC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.46	6.19	0.32	1.72e-9	Initial pursuit acceleration;
LIHC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg12297030	chr17:43662878	NA	-0.63	-6.09	-0.31	3.08e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7914558	0.646	rs1046778	chr10:104661484	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.16	-0.36	5.12e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.75	-0.39	1.06e-13	Type 2 diabetes;
LIHC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.63	11.29	0.52	2.52e-25	Dupuytren's disease;
LIHC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.4	6.74	0.34	6.85e-11	IgG glycosylation;
LIHC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.38	6.09	0.31	2.99e-9	Multiple sclerosis;
LIHC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.42	-6.78	-0.34	5.28e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LIHC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.28	0.37	2.33e-12	Self-reported allergy;
LIHC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.56	9.4	0.45	7.78e-19	Calcium levels;
LIHC	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.83	-0.47	3.12e-20	Cutaneous nevi;
LIHC	cis	rs11098699	1.000	rs931707	chr4:124202535	G/A	cg09941581	chr4:124220074	SPATA5	0.3	5.74	0.3	2.1e-8	Mosquito bite size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16682046	chr11:82612617	PRCP;C11orf82	0.43	6.46	0.33	3.5e-10	Cognitive function;
LIHC	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.75	8.51	0.42	5.41e-16	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.48	6.94	0.35	2.01e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.91	-0.3	8.11e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs10411161	0.702	rs16983200	chr19:52386723	G/A	cg22319618	chr22:45562946	NUP50	-0.61	-8.42	-0.41	1.06e-15	Breast cancer;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.45	6.37	0.33	6.18e-10	Aortic root size;
LIHC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.82	14.92	0.63	3.85e-39	Multiple myeloma (IgH translocation);
LIHC	cis	rs4759375	0.748	rs596940	chr12:123560731	T/C	cg00376283	chr12:123451042	ABCB9	-0.55	-5.84	-0.3	1.23e-8	HDL cholesterol;
LIHC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg08213375	chr14:104286397	PPP1R13B	0.36	5.81	0.3	1.4e-8	Reticulocyte count;
LIHC	cis	rs7212590	0.748	rs58681483	chr17:57934654	A/G	cg10252138	chr17:58120427	NA	-0.62	-6.34	-0.32	7.42e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.68	0.5	3.74e-23	Colorectal cancer;
LIHC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-0.74	-8.45	-0.42	8.62e-16	Hip circumference adjusted for BMI;
LIHC	trans	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg04373760	chr16:53404718	NA	0.62	8.11	0.4	9.22e-15	Hypertriglyceridemia;
LIHC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.61	6.49	0.33	3.04e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	12.18	0.55	1.4e-28	Coronary artery disease;
LIHC	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-1.08	-11.31	-0.52	2.09e-25	Dilated cardiomyopathy;
LIHC	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.79	-7.78	-0.39	8.89e-14	Diabetic retinopathy;
LIHC	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg10587741	chr22:38071170	LGALS1	0.44	7.93	0.39	3.22e-14	Fat distribution (HIV);
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg20933634	chr6:27740509	NA	0.45	5.96	0.31	6.17e-9	Parkinson's disease;
LIHC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.55	8.12	0.4	8.48e-15	Lymphocyte counts;
LIHC	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg17623882	chr6:41773611	USP49	-0.44	-5.85	-0.3	1.15e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg17135325	chr3:160939158	NMD3	0.42	6.09	0.31	3.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs2412488	1.000	rs2412488	chr4:54330867	A/G	cg22241045	chr4:54363911	LNX1	-0.45	-7.07	-0.36	8.51e-12	DNA methylation (variation);
LIHC	cis	rs1419980	0.730	rs11054889	chr12:7773058	C/A	cg10578777	chr12:7781093	NA	-0.39	-5.78	-0.3	1.67e-8	HDL cholesterol levels;
LIHC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.78	-8.57	-0.42	3.55e-16	Type 2 diabetes;
LIHC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.51	8.23	0.41	4.08e-15	Schizophrenia;
LIHC	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	9.02	0.44	1.34e-17	Exhaled nitric oxide output;
LIHC	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.59	0.38	3.06e-13	Refractive astigmatism;
LIHC	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.57	-0.38	3.46e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.76	5.88	0.3	9.84e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.09	-0.31	3.11e-9	Coronary artery disease;
LIHC	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	6.95	0.35	1.81e-11	Neutrophil percentage of white cells;
LIHC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.37	5.9	0.3	8.53e-9	Resting heart rate;
LIHC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.63	-8.45	-0.42	8.71e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.36	6.28	0.32	1.05e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LIHC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.34	-5.74	-0.3	2.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.41	6.52	0.33	2.5e-10	Mean corpuscular volume;
LIHC	trans	rs1034394	0.706	rs5994928	chr22:34818613	G/C	cg02641517	chr3:54169983	CACNA2D3	-0.24	-6.1	-0.31	2.93e-9	Major depressive disorder;
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg07234388	chr1:156261841	TMEM79	0.52	9.39	0.45	8.5e-19	Tonsillectomy;
LIHC	cis	rs4908768	0.859	rs4908770	chr1:8711372	G/A	cg20416874	chr1:8611966	RERE	0.5	6.98	0.35	1.51e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.48	-8.69	-0.43	1.57e-16	Colorectal cancer;
LIHC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.39	0.45	8.53e-19	Platelet count;
LIHC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg02902477	chr6:26197071	HIST1H3D	0.54	5.86	0.3	1.06e-8	Gout;Renal underexcretion gout;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14033686	chr9:95056052	IARS;SNORA84	-0.47	-6.42	-0.33	4.6e-10	Pancreatic cancer;
LIHC	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg17771515	chr6:154831774	CNKSR3	0.54	5.81	0.3	1.4e-8	Lipoprotein (a) levels;
LIHC	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-0.39	-6.1	-0.31	2.8e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.65	9.81	0.47	3.41e-20	Menarche (age at onset);
LIHC	cis	rs12472274	0.529	rs11683094	chr2:239118057	G/A	cg17459225	chr2:239074497	NA	0.62	9.46	0.46	5.03e-19	Phospholipid levels (plasma);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11651961	chr2:54197711	PSME4	0.5	7.09	0.36	7.92e-12	Lung function (FEV1/FVC);
LIHC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg02640540	chr1:67518911	SLC35D1	0.41	6.38	0.33	5.76e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06634786	chr22:41940651	POLR3H	0.56	6.13	0.31	2.47e-9	Vitiligo;
LIHC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.32	-5.9	-0.3	8.9e-9	Facial morphology (factor 20);
LIHC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.82	-0.35	4.26e-11	Diabetic kidney disease;
LIHC	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg08345082	chr10:99160200	RRP12	-0.39	-6.58	-0.34	1.81e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11449408	chr17:80856057	TBCD	0.46	6.77	0.34	5.52e-11	Longevity;
LIHC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.93	15.19	0.63	3.32e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs17106184	1.000	rs59524047	chr1:51399215	G/A	cg07174182	chr1:51127561	FAF1	-0.75	-7.9	-0.39	3.96e-14	Type 2 diabetes;
LIHC	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.45	7.27	0.37	2.49e-12	Corneal astigmatism;
LIHC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg19635926	chr16:89946313	TCF25	0.54	7.3	0.37	2.02e-12	Skin colour saturation;
LIHC	cis	rs11627756	0.918	rs2403070	chr14:103093432	T/C	cg12046867	chr14:103022105	NA	-0.37	-5.72	-0.3	2.28e-8	Mean platelet volume;
LIHC	cis	rs2016586	0.860	rs5755920	chr22:36103270	G/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.33	-0.32	7.74e-10	Body mass index;
LIHC	cis	rs6960043	0.584	rs2189725	chr7:15041873	G/A	cg19272540	chr7:15055459	NA	0.25	6.68	0.34	9.83e-11	Type 2 diabetes;
LIHC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.61	-8.82	-0.43	5.83e-17	Recombination rate (females);
LIHC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg17750252	chr2:136567154	LCT	0.34	6.24	0.32	1.32e-9	Mosquito bite size;
LIHC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	8.06	0.4	1.27e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1000083	0.748	rs2697555	chr5:96620037	A/G	ch.5.96698337R	chr5:96672581	NA	0.96	7.3	0.37	2.09e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.47	-0.53	5.44e-26	Type 2 diabetes;
LIHC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.56	-16.35	-0.66	8.71e-45	Breast cancer;
LIHC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.35	-5.74	-0.3	2.12e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9993613	0.935	rs10019152	chr4:73518770	A/C	cg15102770	chr4:73434591	ADAMTS3	-0.39	-5.88	-0.3	9.77e-9	Hip circumference adjusted for BMI;Height;
LIHC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.49	0.56	9.88e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg08132940	chr7:1081526	C7orf50	-0.81	-6.74	-0.34	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs988712	0.705	rs879048	chr11:27638934	A/C	cg18117895	chr11:27722066	BDNF	0.43	5.85	0.3	1.17e-8	Obesity;
LIHC	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	0.92	22.12	0.77	6.13e-68	Multiple myeloma;
LIHC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg25894440	chr7:65020034	NA	-0.55	-6.33	-0.32	7.79e-10	Diabetic kidney disease;
LIHC	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg20991723	chr1:152506922	NA	-0.52	-9.19	-0.44	3.92e-18	Hair morphology;
LIHC	cis	rs9612	0.848	rs7181	chr19:44270925	G/A	cg08581076	chr19:44259116	C19orf61	0.61	7.13	0.36	5.9e-12	Exhaled nitric oxide output;
LIHC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20135002	chr11:47629003	NA	-0.54	-9.33	-0.45	1.39e-18	Subjective well-being;
LIHC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.59	7.62	0.38	2.53e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg26395211	chr5:140044315	WDR55	0.43	6.47	0.33	3.42e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.12	0.36	6.28e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg02079420	chr8:82753780	SNX16	0.34	6.06	0.31	3.63e-9	Diastolic blood pressure;
LIHC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg00677901	chr16:88017247	BANP	0.51	7.87	0.39	4.67e-14	Menopause (age at onset);
LIHC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.38	0.49	4.12e-22	Total body bone mineral density;
LIHC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.78	-0.39	8.81e-14	Chronic sinus infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26245302	chr6:163148501	PACRG;PARK2	-0.49	-6.84	-0.35	3.61e-11	Pancreatic cancer;
LIHC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.39	6.02	0.31	4.59e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.34	6.76	0.34	5.9e-11	Coronary artery disease;
LIHC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-6.23	-0.32	1.35e-9	Schizophrenia;
LIHC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.83	10.07	0.48	4.79e-21	Cognitive function;
LIHC	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg20887711	chr4:1340912	KIAA1530	-0.47	-7.2	-0.36	3.85e-12	Obesity-related traits;
LIHC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.83	13.25	0.58	1.21e-32	Breast cancer;
LIHC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg05714579	chr10:131428358	MGMT	0.38	6.03	0.31	4.29e-9	Response to temozolomide;
LIHC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg08222618	chr4:941054	TMEM175	-0.41	-6.87	-0.35	2.96e-11	Systemic sclerosis;
LIHC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.3	0.45	1.66e-18	Bipolar disorder;
LIHC	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.58	9.49	0.46	3.93e-19	Corneal astigmatism;
LIHC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.07	0.51	1.47e-24	Type 2 diabetes;
LIHC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.58	7.91	0.39	3.71e-14	Tourette syndrome;
LIHC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00958927	chr1:175162553	KIAA0040	0.38	6.27	0.32	1.12e-9	Alcohol dependence;
LIHC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	18.2	0.7	3.21e-52	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.8	-14.97	-0.63	2.65e-39	Prudent dietary pattern;
LIHC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.78	8.57	0.42	3.68e-16	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.42	7.07	0.36	8.58e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.72	11.77	0.54	4.58e-27	Oral cavity cancer;
LIHC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg05941027	chr17:61774174	LIMD2	0.35	7.29	0.37	2.13e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.71	12.31	0.55	4.27e-29	Menopause (age at onset);
LIHC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-11.1	-0.51	1.19e-24	Coronary artery disease;
LIHC	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	1.02	11.85	0.54	2.28e-27	IgG glycosylation;
LIHC	cis	rs13161895	0.887	rs1103811	chr5:179413168	G/A	cg06664874	chr5:179499304	RNF130	0.49	6.37	0.33	5.96e-10	LDL cholesterol;
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.69	-10.94	-0.51	4.21e-24	Skin colour saturation;
LIHC	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.39	7.17	0.36	4.71e-12	Hepatocellular carcinoma;
LIHC	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.68	12.0	0.54	6.13e-28	Obesity-related traits;
LIHC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.65	9.97	0.47	9.97e-21	Total cholesterol levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01855760	chr4:68567075	LOC550112;UBA6	0.48	7.13	0.36	6.13e-12	Cognitive function;
LIHC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02290350	chr8:58132656	NA	0.44	8.57	0.42	3.49e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg18357645	chr12:58087776	OS9	-0.45	-6.98	-0.35	1.49e-11	Multiple sclerosis;
LIHC	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.48	-6.99	-0.35	1.45e-11	Obesity (extreme);
LIHC	cis	rs6691722	0.583	rs7535482	chr1:24695114	A/C	cg18323236	chr1:24743029	NIPAL3	0.32	5.8	0.3	1.5e-8	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg14773178	chr5:1868261	NA	0.26	6.81	0.35	4.28e-11	Cardiovascular disease risk factors;
LIHC	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg11783602	chr8:55087084	NA	-0.34	-6.68	-0.34	9.79e-11	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	7.98	0.4	2.2e-14	Nonalcoholic fatty liver disease;
LIHC	trans	rs7668874	0.774	rs1816328	chr4:116806243	T/A	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg23461800	chr14:103021989	NA	0.42	5.96	0.31	6.38e-9	Platelet count;
LIHC	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.21	-0.32	1.53e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.62	6.86	0.35	3.27e-11	Alzheimer's disease;
LIHC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	7.59	0.38	3.1e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg14092571	chr14:90743983	NA	0.4	6.29	0.32	9.48e-10	Mortality in heart failure;
LIHC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.5	0.42	5.98e-16	Alzheimer's disease;
LIHC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.52	-6.66	-0.34	1.09e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg05110241	chr16:68378359	PRMT7	-0.61	-6.92	-0.35	2.23e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.32	6.64	0.34	1.27e-10	Blood metabolite levels;
LIHC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.79	8.97	0.44	1.94e-17	Exhaled nitric oxide levels;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg14709524	chr16:89940631	TCF25	0.51	6.56	0.33	1.97e-10	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg00091569	chr3:40428383	ENTPD3	-0.4	-6.79	-0.34	4.83e-11	Renal cell carcinoma;
LIHC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.55	-8.57	-0.42	3.73e-16	Coronary artery disease;
LIHC	cis	rs876084	0.505	rs66488706	chr8:121132894	C/T	cg06265175	chr8:121136014	COL14A1	0.48	7.57	0.38	3.49e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10733682	0.524	rs10987422	chr9:129462687	C/A	cg00232160	chr9:129468157	NA	0.38	6.73	0.34	7.16e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.64	-0.34	1.24e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-13.01	-0.58	1e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.54	0.33	2.22e-10	Bipolar disorder;
LIHC	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.46	5.96	0.31	6.13e-9	Pulmonary function decline;
LIHC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.29	15.76	0.65	1.88e-42	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.56	9.97	0.47	9.78e-21	Mean corpuscular volume;
LIHC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.41	7.49	0.38	5.97e-13	Glaucoma;
LIHC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.53	7.37	0.37	1.27e-12	Pulse pressure;
LIHC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg15691649	chr6:25882328	NA	0.45	5.76	0.3	1.92e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.77	-0.3	1.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-7.12	-0.36	6.5e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.75	-8.88	-0.43	3.93e-17	Schizophrenia;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09952564	chr10:5979174	FBXO18	0.52	6.39	0.33	5.46e-10	Lung function (FEV1);
LIHC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg14393609	chr7:65229607	NA	-0.37	-5.81	-0.3	1.46e-8	Aortic root size;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg19355462	chr6:15248936	JARID2	-0.47	-6.04	-0.31	4.09e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2292096	1.000	rs35442900	chr1:200779144	T/C	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-5.92	-0.3	7.95e-9	Epilepsy;
LIHC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.2	-0.32	1.59e-9	Obesity-related traits;
LIHC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.23	-6.11	-0.31	2.74e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.91	6.85	0.35	3.55e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.71	12.0	0.54	6.35e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg14473756	chr11:122847823	NA	0.36	6.79	0.34	5.08e-11	Menarche (age at onset);
LIHC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg02297831	chr4:17616191	MED28	0.43	6.04	0.31	3.93e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	1.03	15.33	0.64	9.68e-41	Breast cancer;
LIHC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.89	-18.36	-0.7	7.18e-53	Height;
LIHC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.15	-0.32	2.18e-9	Schizophrenia;
LIHC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.85	10.53	0.49	1.2e-22	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11753193	chr8:94753277	RBM12B	-0.41	-6.09	-0.31	3.07e-9	Cognitive function;
LIHC	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.97	-0.35	1.65e-11	Neuroticism;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.23	-0.32	1.37e-9	Total body bone mineral density;
LIHC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg24977027	chr2:88469347	THNSL2	-0.35	-6.0	-0.31	5.17e-9	Response to metformin (IC50);
LIHC	trans	rs11088226	0.692	rs2833861	chr21:33882345	C/T	cg09050820	chr6:167586206	TCP10L2	0.44	6.47	0.33	3.35e-10	Gastritis;
LIHC	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-5.85	-0.3	1.14e-8	Response to antipsychotic treatment;
LIHC	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg22705602	chr4:152727874	NA	-0.4	-7.13	-0.36	5.92e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12427896	chr2:111880694	BCL2L11	0.5	7.76	0.39	1.01e-13	Pancreatic cancer;
LIHC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	10.63	0.5	5.31e-23	Coronary artery disease;
LIHC	cis	rs57244997	0.725	rs7738080	chr6:162413377	A/G	cg17173639	chr6:162384350	PARK2	-0.53	-6.96	-0.35	1.71e-11	Mosquito bite size;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg10774155	chr7:65338427	VKORC1L1	0.45	6.55	0.33	2.06e-10	Calcium levels;
LIHC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	5.79	0.3	1.58e-8	Obesity-related traits;
LIHC	cis	rs1185460	1.000	rs15818	chr11:118952173	A/G	cg23280166	chr11:118938394	VPS11	0.49	6.24	0.32	1.27e-9	Coronary artery disease;
LIHC	cis	rs112721625	1	rs112721625	chr17:57927426	AT/A	cg13753209	chr17:57696993	CLTC	0.53	8.64	0.42	2.19e-16	Monocyte count;
LIHC	cis	rs4407350	0.870	rs4823329	chr22:44910117	T/C	cg04154583	chr22:44889756	LDOC1L	0.3	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.89	0.57	2.94e-31	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.95	17.95	0.7	3.02e-51	Menopause (age at onset);
LIHC	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.32	6.21	0.32	1.51e-9	Cancer;
LIHC	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-7.27	-0.37	2.46e-12	Mortality in heart failure;
LIHC	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.66	-0.38	1.92e-13	Neuroticism;
LIHC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-27.63	-0.83	3.84e-89	Myeloid white cell count;
LIHC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11031096	0.655	rs34295904	chr11:4206701	C/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.82	-0.3	1.35e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6782228	0.606	rs2712419	chr3:128340896	T/C	cg16766828	chr3:128327626	NA	-0.41	-6.46	-0.33	3.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.62	0.38	2.57e-13	Obesity-related traits;
LIHC	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21640587	chr11:117668038	DSCAML1	0.55	6.92	0.35	2.19e-11	Myopia;
LIHC	cis	rs1434579	0.652	rs7249704	chr19:44939360	A/G	cg15540054	chr19:45004280	ZNF180	0.65	9.91	0.47	1.58e-20	Tuberculosis;
LIHC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.67	7.04	0.36	1.07e-11	Breast cancer;
LIHC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.7	0.34	8.66e-11	Lung cancer;
LIHC	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.49	7.5	0.38	5.49e-13	Triglyceride levels;
LIHC	cis	rs7116495	1.000	rs659513	chr11:71812411	C/T	cg26138937	chr11:71823887	C11orf51	0.83	8.05	0.4	1.39e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.56	6.37	0.33	6.28e-10	Alzheimer's disease;
LIHC	cis	rs611744	0.967	rs628843	chr8:109196115	C/G	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.67	-10.01	-0.48	7.58e-21	Monocyte count;
LIHC	cis	rs965469	0.779	rs6139092	chr20:3334651	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.3	-0.32	9.4e-10	IFN-related cytopenia;
LIHC	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.3	0.32	8.94e-10	Ulcerative colitis;
LIHC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	6.08	0.31	3.17e-9	Tonsillectomy;
LIHC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.36	-5.93	-0.31	7.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.47	6.93	0.35	2.17e-11	Longevity;
LIHC	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-0.96	-18.11	-0.7	7.31e-52	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg23485639	chr6:28045615	ZNF165	0.38	5.96	0.31	6.31e-9	Cardiac Troponin-T levels;
LIHC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.47	-7.82	-0.39	6.41e-14	Lung cancer;
LIHC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.62	10.35	0.49	5.15e-22	Platelet count;
LIHC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg22842854	chr12:123319900	HIP1R	-0.74	-9.73	-0.47	6.52e-20	Schizophrenia;
LIHC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.53	7.42	0.37	9.39e-13	Tonsillectomy;
LIHC	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg14061069	chr19:46274453	DMPK	-0.55	-8.41	-0.41	1.15e-15	Coronary artery disease;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg01893041	chr5:67583972	PIK3R1	-0.43	-6.32	-0.32	8.29e-10	Urinary tract infection frequency;
LIHC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.03	0.31	4.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.05	16.49	0.67	2.21e-45	Breast cancer;
LIHC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.48	-7.19	-0.36	4.24e-12	Cognitive function;
LIHC	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25632853	chr15:73088954	NA	0.35	5.89	0.3	9.02e-9	Triglyceride levels;
LIHC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg08807892	chr2:162101083	NA	0.45	7.64	0.38	2.14e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg07541023	chr7:19748670	TWISTNB	0.49	7.24	0.36	3e-12	Thyroid stimulating hormone;
LIHC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.74	-0.39	1.12e-13	Body mass index;
LIHC	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.49	8.26	0.41	3.31e-15	Schizophrenia;
LIHC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.35	1.25e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs847649	0.731	rs12666317	chr7:102704135	C/T	cg18108683	chr7:102477205	FBXL13	0.41	6.09	0.31	3.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.42	-0.33	4.66e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.65	8.39	0.41	1.28e-15	Initial pursuit acceleration;
LIHC	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.83	0.35	3.92e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9646303	0.778	rs9940620	chr16:87511877	A/T	cg08565003	chr16:87447920	ZCCHC14	-0.31	-5.79	-0.3	1.58e-8	Major depressive disorder;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg00280220	chr17:61926910	NA	0.43	6.87	0.35	3.04e-11	Prudent dietary pattern;
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg10210624	chr19:58662595	ZNF329	0.73	7.33	0.37	1.65e-12	Cholesterol, total;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08080923	chr19:47763943	CCDC9	0.44	6.81	0.35	4.52e-11	Longevity;
LIHC	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.71	-12.91	-0.57	2.49e-31	Mean platelet volume;
LIHC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg03859395	chr2:55845619	SMEK2	0.62	9.93	0.47	1.33e-20	Metabolic syndrome;
LIHC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	9.09	0.44	8.16e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.59	8.2	0.41	5e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.71	0.43	1.34e-16	Motion sickness;
LIHC	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.1	-16.31	-0.66	1.26e-44	Corneal structure;
LIHC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.64	-11.12	-0.52	1.03e-24	Height;
LIHC	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.53	-5.81	-0.3	1.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.43	-8.48	-0.42	6.96e-16	Testicular germ cell tumor;
LIHC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.8	0.47	3.89e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	trans	rs75804782	0.521	rs56340711	chr2:239440080	A/T	cg01134436	chr17:81009848	B3GNTL1	0.71	6.15	0.32	2.15e-9	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02290350	chr8:58132656	NA	0.41	8.51	0.42	5.56e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs4684776	1.000	rs6762035	chr3:11423759	T/G	cg00170343	chr3:11313890	ATG7	-0.43	-5.93	-0.31	7.49e-9	Small vessel stroke;
LIHC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs77106637	0.530	rs1785212	chr11:72462375	T/C	cg03713592	chr11:72463424	ARAP1	0.55	6.17	0.32	1.91e-9	Type 2 diabetes;
LIHC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.26	0.45	2.39e-18	IgG glycosylation;
LIHC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.41	7.09	0.36	7.88e-12	Aortic root size;
LIHC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-11.22	-0.52	4.29e-25	Personality dimensions;
LIHC	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg03934865	chr2:198174659	NA	0.48	7.02	0.35	1.23e-11	Dermatomyositis;
LIHC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg15577575	chr1:145470249	ANKRD34A;POLR3GL	0.43	6.43	0.33	4.2e-10	Total body bone mineral density;
LIHC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.5	-8.45	-0.42	8.77e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.36	-5.94	-0.31	7.14e-9	Schizophrenia;
LIHC	cis	rs922107	0.713	rs10801744	chr1:89953544	C/T	cg15422784	chr1:90023713	LRRC8B	0.46	7.4	0.37	1.06e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg02187348	chr16:89574699	SPG7	0.51	7.42	0.37	9.39e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-6.45	-0.33	3.86e-10	Electroencephalogram traits;
LIHC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.49	6.31	0.32	8.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.85	0.3	1.17e-8	Menopause (age at onset);
LIHC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.02	-0.4	1.66e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.81	0.54	3.03e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	7.11	0.36	6.63e-12	Bone mineral density;
LIHC	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.57	8.32	0.41	2.1e-15	Menopause (age at onset);
LIHC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.63	8.43	0.41	9.770000000000001e-16	Hemoglobin concentration;Hematocrit;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09706180	chr15:50647709	GABPB1;FLJ10038;LOC100129387	0.43	6.08	0.31	3.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.55	0.53	2.71e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg18357645	chr12:58087776	OS9	-0.43	-6.42	-0.33	4.66e-10	Multiple sclerosis;
LIHC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.94	20.34	0.74	7.61e-61	Blood protein levels;
LIHC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.52	-9.13	-0.44	5.93e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11645453	chr3:52864694	ITIH4	0.22	6.04	0.31	3.96e-9	Bipolar disorder;
LIHC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.64	-9.12	-0.44	6.73e-18	Blood metabolite levels;
LIHC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.77	12.02	0.54	5.37e-28	Corneal astigmatism;
LIHC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.57	-0.33	1.83e-10	Bipolar disorder;
LIHC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.09	0.4	1.02e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg10381502	chr11:71823885	C11orf51	-1.02	-8.51	-0.42	5.38e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.95	-0.31	6.6e-9	Diabetic kidney disease;
LIHC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.48	6.98	0.35	1.55e-11	Response to diuretic therapy;
LIHC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.94	-9.38	-0.45	9.6e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1914816	0.941	rs2456027	chr15:76568209	G/A	cg03037974	chr15:76606532	NA	-0.61	-6.62	-0.34	1.4e-10	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	9.28e-10	Aortic root size;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg02869306	chr7:64672164	INTS4L1	-0.29	-6.41	-0.33	4.84e-10	Calcium levels;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25389065	chr2:75938167	C2orf3	-0.5	-6.08	-0.31	3.27e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.55	-0.38	3.87e-13	Chronic sinus infection;
LIHC	cis	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg18809830	chr7:99032528	PTCD1	-0.86	-6.7	-0.34	8.38e-11	Blood metabolite levels;
LIHC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	7.25	0.37	2.74e-12	Lung cancer in ever smokers;
LIHC	cis	rs7635838	0.892	rs9823197	chr3:11503133	A/T	cg00170343	chr3:11313890	ATG7	0.41	6.39	0.33	5.38e-10	HDL cholesterol;
LIHC	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.5	7.86	0.39	5e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.07	-0.44	9.28e-18	Exhaled nitric oxide output;
LIHC	cis	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg03342759	chr3:160939853	NMD3	0.57	7.44	0.37	8.19e-13	Morning vs. evening chronotype;
LIHC	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.5	-0.33	2.9e-10	Metabolite levels;
LIHC	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg02023728	chr11:77925099	USP35	0.36	6.37	0.33	5.99e-10	Alzheimer's disease (survival time);
LIHC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.89	-0.39	4.17e-14	Capecitabine sensitivity;
LIHC	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.44	-5.92	-0.3	7.76e-9	Coronary artery calcification;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01330391	chr1:26324448	PAFAH2	0.5	6.48	0.33	3.13e-10	Pancreatic cancer;
LIHC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.82	0.3	1.36e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.44	-7.97	-0.4	2.46e-14	Vitamin D levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg09242721	chr3:3168535	TRNT1	0.47	6.53	0.33	2.31e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.57	11.16	0.52	7.26e-25	Coronary artery disease;
LIHC	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg06609049	chr19:2785107	THOP1	0.61	9.73	0.47	6.76e-20	Total cholesterol levels;
LIHC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.43	-0.33	4.17e-10	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.49	0.56	9.37e-30	Prudent dietary pattern;
LIHC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.98	-18.72	-0.71	2.45e-54	Breast cancer;
LIHC	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg10820045	chr2:198174542	NA	0.47	7.03	0.36	1.12e-11	Dermatomyositis;
LIHC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	17.43	0.69	3.8e-49	Lung cancer in ever smokers;
LIHC	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.53	-6.28	-0.32	1.05e-9	Coronary artery disease;
LIHC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.4e-8	Heart rate;
LIHC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg23533926	chr12:111358616	MYL2	0.32	6.19	0.32	1.69e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.94	16.71	0.67	3.05e-46	Parkinson's disease;
LIHC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.91	16.97	0.68	2.84e-47	Aortic root size;
LIHC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-9.47	-0.46	4.82e-19	Asthma;
LIHC	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-11.07	-0.51	1.46e-24	Morning vs. evening chronotype;
LIHC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.8	-0.35	4.7e-11	Total body bone mineral density;
LIHC	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.52	8.99	0.44	1.74e-17	Coronary artery disease;
LIHC	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.38	-6.96	-0.35	1.71e-11	Response to antipsychotic treatment;
LIHC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.31	0.52	2.02e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.8	0.34	4.79e-11	Cognitive ability;
LIHC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.3	-0.76	1.08e-64	Height;
LIHC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.66	-9.04	-0.44	1.15e-17	Schizophrenia;
LIHC	cis	rs6445975	0.715	rs6790764	chr3:58265950	C/T	cg23715586	chr3:58305044	RPP14	-0.35	-6.07	-0.31	3.42e-9	Systemic lupus erythematosus;
LIHC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.47	5.79	0.3	1.58e-8	Alzheimer's disease;
LIHC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	7.84	0.39	5.71e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-11.99	-0.54	6.61e-28	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
LIHC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26734620	chr12:56694298	CS	1.0	10.11	0.48	3.46e-21	Psoriasis vulgaris;
LIHC	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	9.51	0.46	3.4e-19	Response to antipsychotic treatment;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19575804	chr20:22559456	C20orf56	0.26	6.73	0.34	7.09e-11	Cognitive function;
LIHC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.87	0.43	4.22e-17	Menarche (age at onset);
LIHC	cis	rs10508774	1.000	rs11815157	chr10:32833598	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.06	0.31	3.66e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02951695	chr10:134400351	INPP5A	-0.44	-6.6	-0.34	1.61e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9470361	0.524	rs7740181	chr6:36624111	C/T	cg08179530	chr6:36648295	CDKN1A	0.43	6.37	0.33	5.97e-10	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.84	0.63	8.42e-39	Prudent dietary pattern;
LIHC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.89	0.43	3.56e-17	Lung cancer;
LIHC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg12798992	chr6:167411361	FGFR1OP	0.53	8.2	0.41	4.87e-15	Crohn's disease;
LIHC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.95	15.3	0.64	1.28e-40	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20956633	chr20:19997839	NAA20	0.45	6.06	0.31	3.53e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.64	10.81	0.5	1.25e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.33	7.08	0.36	8.34e-12	Ulcerative colitis;
LIHC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	0.93	16.83	0.67	1.02e-46	IgG glycosylation;
LIHC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.53	7.46	0.37	7.18e-13	Prostate cancer;
LIHC	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26734620	chr12:56694298	CS	1.2	9.66	0.46	1.13e-19	Psoriasis vulgaris;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16266895	chr12:101674004	UTP20	0.4	6.32	0.32	8.11e-10	Cognitive function;
LIHC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg10621924	chr7:39171070	POU6F2	0.42	6.42	0.33	4.48e-10	IgG glycosylation;
LIHC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.8	-12.83	-0.57	4.94e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-11.0	-0.51	2.73e-24	Hemoglobin concentration;
LIHC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.09	-0.36	7.81e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg03037974	chr15:76606532	NA	-0.61	-10.39	-0.49	3.61e-22	Blood metabolite levels;
LIHC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	6.55	0.33	2.08e-10	Height;
LIHC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg04359351	chr2:3481828	TTC15	0.29	6.04	0.31	3.97e-9	Neurofibrillary tangles;
LIHC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.38	6.23	0.32	1.4e-9	Response to antipsychotic treatment;
LIHC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.79	0.3	1.63e-8	Coronary artery disease;
LIHC	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.66	11.21	0.52	4.84e-25	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.56	-0.33	1.95e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.9	11.9	0.54	1.43e-27	Heart rate;
LIHC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	10.18	0.48	1.94e-21	Mean platelet volume;
LIHC	cis	rs10792665	0.575	rs10792655	chr11:82561661	T/C	cg24227371	chr11:82718527	RAB30	-0.26	-6.29	-0.32	9.45e-10	Obesity-related traits;
LIHC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.6	0.67	8.33e-46	Smoking behavior;
LIHC	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.67	-10.02	-0.48	6.79e-21	Monocyte count;
LIHC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg00012203	chr2:219082015	ARPC2	-0.46	-5.95	-0.31	6.69e-9	Ulcerative colitis;
LIHC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.52	7.19	0.36	4.03e-12	Height;
LIHC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg18016565	chr1:150552671	MCL1	0.51	9.75	0.47	5.67e-20	Melanoma;
LIHC	cis	rs12079745	0.793	rs79758658	chr1:169387286	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-6.98	-0.35	1.51e-11	QT interval;
LIHC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	10.28	0.49	8.8e-22	Alzheimer's disease;
LIHC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.74	6.33	0.32	7.53e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg24637308	chr11:6592297	DNHD1	0.44	6.17	0.32	1.98e-9	Coronary artery calcification;
LIHC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.52	9.24	0.45	2.73e-18	Total cholesterol levels;
LIHC	cis	rs72627123	0.656	rs4646864	chr14:74526703	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	5.78	0.3	1.69e-8	Morning vs. evening chronotype;
LIHC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-13.69	-0.6	2.49e-34	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27507545	chr10:103880405	LDB1	0.47	6.79	0.34	4.84e-11	Pancreatic cancer;
LIHC	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.63	0.65	6.05e-42	Electrocardiographic conduction measures;
LIHC	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.69	11.33	0.52	1.78e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	9.01	0.44	1.47e-17	Lung cancer in ever smokers;
LIHC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.68	0.46	9.54e-20	Platelet count;
LIHC	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.74	-0.57	1.09e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.87	0.35	3.08e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.46e-25	Eye color traits;
LIHC	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.8	0.43	6.96e-17	Exhaled nitric oxide levels;
LIHC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-6.63	-0.34	1.32e-10	Renal cell carcinoma;
LIHC	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.68	7.32	0.37	1.8e-12	Exhaled nitric oxide output;
LIHC	cis	rs4728302	0.869	rs6978170	chr7:133603838	C/T	cg10665199	chr7:133106180	EXOC4	0.39	6.8	0.34	4.81e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.94	13.48	0.59	1.64e-33	Primary sclerosing cholangitis;
LIHC	trans	rs7668874	0.779	rs10005313	chr4:116807543	G/A	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.21	11.49	0.53	4.56e-26	Uric acid levels;
LIHC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg15541040	chr2:3486749	NA	-0.39	-5.72	-0.3	2.37e-8	Neurofibrillary tangles;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.91	0.39	3.48e-14	Height;
LIHC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.96	0.4	2.52e-14	Platelet count;
LIHC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	trans	rs1347297	0.614	rs7589679	chr2:179282437	T/C	cg14011486	chr1:26737247	LIN28	0.65	10.32	0.49	6.42e-22	Alzheimer disease and age of onset;
LIHC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg23730037	chr7:158596552	ESYT2	-0.41	-6.44	-0.33	4.08e-10	Height;
LIHC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-14.15	-0.61	4.37e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.77	0.3	1.77e-8	Menopause (age at onset);
LIHC	cis	rs8108269	1.000	rs8104845	chr19:46161326	A/G	cg13320842	chr19:46175254	GIPR	0.43	8.04	0.4	1.48e-14	Type 2 diabetes;
LIHC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	13.13	0.58	3.68e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2274273	0.967	rs10147667	chr14:55570849	C/T	cg01864836	chr14:55583639	NA	0.36	6.37	0.33	6.21e-10	Protein biomarker;
LIHC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.37	5.99	0.31	5.46e-9	Menopause (age at onset);
LIHC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.32	0.55	3.98e-29	Electrocardiographic conduction measures;
LIHC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.8	7.6	0.38	2.86e-13	Plasma clusterin levels;
LIHC	cis	rs6089584	0.586	rs6089606	chr20:60586045	G/A	cg06108461	chr20:60628389	TAF4	-0.52	-6.78	-0.34	5.15e-11	Body mass index;
LIHC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.3	0.37	2.01e-12	Lung cancer;
LIHC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.46	-6.64	-0.34	1.23e-10	Corneal structure;
LIHC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-17.74	-0.69	2.13e-50	Coronary artery disease;
LIHC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.42	5.98	0.31	5.61e-9	Coronary artery disease;
LIHC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.58	7.19	0.36	4.13e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.32	-7.07	-0.36	8.52e-12	Congenital heart disease (maternal effect);
LIHC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg24849736	chr1:201084428	NA	-0.4	-8.2	-0.41	4.9e-15	Permanent tooth development;
LIHC	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.55	-0.38	3.98e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12980942	0.872	rs12976536	chr19:41799886	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.88	0.35	2.82e-11	Coronary artery disease;
LIHC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.42	-6.68	-0.34	9.46e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.58	8.21	0.41	4.56e-15	Aortic root size;
LIHC	cis	rs72627123	0.656	rs117145347	chr14:74564164	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	8.36	0.41	1.65e-15	Morning vs. evening chronotype;
LIHC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.39	5.93	0.31	7.22e-9	Lung cancer;
LIHC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg06565975	chr8:143823917	SLURP1	0.34	6.39	0.33	5.57e-10	Urinary tract infection frequency;
LIHC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg01788221	chr16:89496183	ANKRD11	-0.43	-6.76	-0.34	5.79e-11	Multiple myeloma (IgH translocation);
LIHC	trans	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg00845942	chr12:64062724	DPY19L2	-0.56	-6.03	-0.31	4.17e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.07	-0.7	1.01e-51	Coronary artery disease;
LIHC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.65	9.86	0.47	2.42e-20	Height;
LIHC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.42	-6.81	-0.35	4.28e-11	Response to temozolomide;
LIHC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.57	6.49	0.33	3.06e-10	Alzheimer's disease;
LIHC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.39	-6.15	-0.32	2.14e-9	Menarche (age at onset);
LIHC	trans	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.45	0.59	2.13e-33	Diabetic kidney disease;
LIHC	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.58	7.49	0.38	5.82e-13	Corneal astigmatism;
LIHC	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg05197062	chr11:11642011	GALNTL4	0.46	6.72	0.34	7.65e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16262614	chr3:133464971	TF	0.28	6.23	0.32	1.34e-9	Iron status biomarkers;
LIHC	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg14593290	chr7:50529359	DDC	-0.61	-9.94	-0.47	1.31e-20	Malaria;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg27615432	chr3:150264278	SERP1;EIF2A	-0.43	-6.13	-0.31	2.39e-9	Alopecia areata;
LIHC	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.67	7.23	0.36	3.18e-12	Type 2 diabetes;
LIHC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.44	5.81	0.3	1.44e-8	Obesity-related traits;
LIHC	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.82	-12.26	-0.55	6.88e-29	Obesity-related traits;
LIHC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.47	0.33	3.36e-10	Lung cancer;
LIHC	cis	rs12101261	0.580	rs8003515	chr14:81446242	G/C	cg06600135	chr14:81408086	NA	0.44	7.78	0.39	8.49e-14	Graves' disease;
LIHC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	13.91	0.6	3.47e-35	Chronic sinus infection;
LIHC	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs16828019	0.852	rs11209576	chr1:41586029	T/C	cg03387723	chr1:41708464	SCMH1	-0.42	-6.93	-0.35	2.07e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg21231739	chr4:1642635	FAM53A	-0.37	-6.03	-0.31	4.21e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.54	8.36	0.41	1.62e-15	Extraversion;
LIHC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08289482	chr15:59969074	BNIP2	0.42	6.54	0.33	2.23e-10	Hepatitis;
LIHC	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.64	0.34	1.24e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-11.59	-0.53	2e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.87	-14.92	-0.63	4.04e-39	Aortic root size;
LIHC	trans	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg10756647	chr7:56101905	PSPH	0.63	8.62	0.42	2.51e-16	Corneal structure;
LIHC	cis	rs3018712	0.532	rs2513289	chr11:68419655	A/C	cg16797656	chr11:68205561	LRP5	-0.44	-5.79	-0.3	1.56e-8	Total body bone mineral density;
LIHC	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.27	6.38	0.33	5.68e-10	Heart rate;
LIHC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.88	-16.44	-0.66	3.62e-45	Coronary artery disease;
LIHC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.73	7.18	0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9783347	0.754	rs4757637	chr11:18307575	G/T	cg15585147	chr11:18324498	HPS5	0.39	6.5	0.33	2.77e-10	Pancreatic cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21625563	chr22:39152448	UNC84B	0.44	6.43	0.33	4.31e-10	Lung function (FEV1/FVC);
LIHC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	0.6	11.17	0.52	6.72e-25	Fat distribution (HIV);
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg02993280	chr1:107599747	PRMT6	-0.64	-10.16	-0.48	2.28e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg27433088	chr4:174089019	GALNT7	0.35	5.99	0.31	5.2e-9	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.14	0.48	2.62e-21	Hypertriglyceridemia;
LIHC	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-6.08	-0.31	3.13e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.47	-7.18	-0.36	4.31e-12	Schizophrenia;
LIHC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg03037974	chr15:76606532	NA	-0.61	-10.24	-0.48	1.21e-21	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03480210	chr2:39103037	DHX57;MORN2	-0.49	-6.41	-0.33	4.96e-10	Lung function (FEV1/FVC);
LIHC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg22834771	chr12:69754056	YEATS4	-0.4	-6.06	-0.31	3.63e-9	Response to diuretic therapy;
LIHC	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg09165964	chr15:75287851	SCAMP5	-0.43	-5.94	-0.31	6.95e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.47	8.27	0.41	3.11e-15	N-glycan levels;
LIHC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg18944383	chr4:111397179	ENPEP	0.28	7.22	0.36	3.38e-12	Height;
LIHC	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.4	-6.77	-0.34	5.66e-11	Endometrial cancer;
LIHC	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Platelet distribution width;
LIHC	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.5	8.92	0.43	2.87e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs7820838	0.611	rs6996957	chr8:32306984	A/G	cg16623836	chr8:32453385	NRG1	0.37	6.25	0.32	1.22e-9	Post bronchodilator FEV1/FVC ratio in COPD;Lung cancer;
LIHC	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.49	-7.29	-0.37	2.13e-12	Mortality in heart failure;
LIHC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg12940439	chr1:67600707	NA	0.38	6.84	0.35	3.65e-11	Psoriasis;
LIHC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.88	16.99	0.68	2.24e-47	Blood protein levels;
LIHC	cis	rs6788895	1.000	rs2014279	chr3:150487945	G/T	cg09723797	chr3:150481914	SIAH2	0.9	13.5	0.59	1.33e-33	Breast cancer;
LIHC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.73	11.86	0.54	2.12e-27	Body mass index;
LIHC	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg20283391	chr11:68216788	NA	-0.39	-6.15	-0.32	2.2e-9	Total body bone mineral density;
LIHC	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	0.93	11.65	0.53	1.17e-26	Post bronchodilator FEV1;
LIHC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.42	-7.45	-0.37	7.62e-13	Height;
LIHC	cis	rs600806	0.778	rs4970761	chr1:109995398	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.5	-6.32	-0.32	8.08e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg10756647	chr7:56101905	PSPH	0.62	8.64	0.42	2.11e-16	Corneal structure;
LIHC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.6	-0.5	6.93e-23	Response to antipsychotic treatment;
LIHC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.83	-16.32	-0.66	1.14e-44	Coronary artery disease;
LIHC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg05896524	chr21:47604654	C21orf56	0.44	6.55	0.33	2.08e-10	Testicular germ cell tumor;
LIHC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg10790698	chr19:18539756	SSBP4	-0.36	-7.54	-0.38	4.22e-13	Breast cancer;
LIHC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.58	9.81	0.47	3.42e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.66	-0.5	4.38e-23	Total cholesterol levels;
LIHC	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-6.34	-0.32	7.19e-10	Coronary artery disease;
LIHC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg21466736	chr12:48725269	NA	-0.62	-9.16	-0.44	4.73e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.81	0.62	1.13e-38	Prudent dietary pattern;
LIHC	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg12454167	chr3:186435060	KNG1	0.32	7.68	0.38	1.74e-13	Adiponectin levels;
LIHC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.4	-6.38	-0.33	5.87e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.36	6.68	0.34	9.79e-11	Ewing sarcoma;
LIHC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.16	18.04	0.7	1.36e-51	Gut microbiome composition (summer);
LIHC	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.26	6.09	0.31	3.01e-9	Heart rate;
LIHC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.57	9.01	0.44	1.53e-17	Monocyte count;
LIHC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	6.97	0.35	1.68e-11	Menopause (age at onset);
LIHC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg10932868	chr11:921992	NA	0.35	6.56	0.33	1.96e-10	Alzheimer's disease (late onset);
LIHC	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	10.72	0.5	2.59e-23	Platelet distribution width;
LIHC	cis	rs2997447	0.723	rs868551	chr1:26475521	C/T	cg19633962	chr1:26362018	EXTL1	0.58	7.02	0.35	1.2e-11	QRS complex (12-leadsum);
LIHC	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.56	8.23	0.41	4.08e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.49	-7.26	-0.37	2.56e-12	Mortality in heart failure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07447193	chr4:151935870	LRBA	0.51	7.65	0.38	2.07e-13	Cognitive function;
LIHC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.62	-0.5	5.78e-23	Alzheimer's disease;
LIHC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg17724175	chr1:150552817	MCL1	0.46	8.96	0.44	2.06e-17	Melanoma;
LIHC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg27247782	chr7:158767135	NA	-0.29	-5.93	-0.31	7.42e-9	Facial morphology (factor 20);
LIHC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.55	-10.37	-0.49	4.28e-22	Sense of smell;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.5	-6.2	-0.32	1.66e-9	Diastolic blood pressure;
LIHC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.63	0.5	5.28e-23	Vitiligo;
LIHC	cis	rs3018712	0.590	rs4930584	chr11:68411296	T/C	cg16797656	chr11:68205561	LRP5	-0.44	-5.83	-0.3	1.28e-8	Total body bone mineral density;
LIHC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.41	-0.37	9.75e-13	Initial pursuit acceleration;
LIHC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.63	9.84	0.47	2.86e-20	Corneal astigmatism;
LIHC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.36	5.8	0.3	1.48e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg17691542	chr6:26056736	HIST1H1C	0.44	6.09	0.31	3.06e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.67	10.12	0.48	3.25e-21	Longevity;
LIHC	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	6.44	0.33	4.1e-10	Lymphocyte counts;
LIHC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.27	0.41	3.05e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.7	10.9	0.51	6.1e-24	Monocyte count;
LIHC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg07424592	chr7:64974309	NA	-0.79	-9.28	-0.45	1.95e-18	Diabetic kidney disease;
LIHC	trans	rs9356009	0.649	rs9356100	chr6:158299952	C/T	cg16165903	chr3:32023351	ZNF860;OSBPL10	0.65	6.35	0.32	6.86e-10	Lipoprotein (a) - cholesterol levels;
LIHC	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Colorectal cancer;
LIHC	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg13919466	chr1:32135498	COL16A1	-0.31	-6.02	-0.31	4.54e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg21856205	chr7:94953877	PON1	-0.48	-6.18	-0.32	1.85e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.25	-0.45	2.55e-18	Bipolar disorder;
LIHC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.62	0.38	2.45e-13	Lymphocyte counts;
LIHC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.96	0.31	6.23e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs2033908	0.502	rs12361858	chr11:12857064	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-7.37	-0.37	1.3e-12	Sitting height ratio;
LIHC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.35	-0.32	6.86e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.65	-8.08	-0.4	1.12e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg17385448	chr1:15911702	AGMAT	0.34	5.84	0.3	1.21e-8	Systolic blood pressure;
LIHC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.8	-0.47	3.81e-20	Bipolar disorder;
LIHC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.59	-8.09	-0.4	1.08e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg01843034	chr6:37503916	NA	-0.48	-8.17	-0.4	6.16e-15	Cognitive performance;
LIHC	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.42	7.42	0.37	9.39e-13	Testicular germ cell tumor;
LIHC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20135002	chr11:47629003	NA	-0.5	-8.47	-0.42	7.36e-16	Subjective well-being;
LIHC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.53	-8.9	-0.43	3.22e-17	Blood metabolite levels;
LIHC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg17420585	chr12:42539391	GXYLT1	0.35	5.71	0.3	2.39e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-8.55	-0.42	4.27e-16	Parkinson's disease;
LIHC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.35	-0.32	6.86e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.47	0.53	5.52e-26	Prudent dietary pattern;
LIHC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.86	-13.25	-0.58	1.28e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg00280220	chr17:61926910	NA	0.44	7.07	0.36	8.7e-12	Prudent dietary pattern;
LIHC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs1062177	0.547	rs2915818	chr5:151115290	T/A	cg00977110	chr5:151150581	G3BP1	-0.53	-6.88	-0.35	2.78e-11	Preschool internalizing problems;
LIHC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.52	0.42	5.06e-16	Schizophrenia;
LIHC	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.54	7.06	0.36	9.48e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10607599	chr11:120382422	NA	-0.42	-6.2	-0.32	1.65e-9	Cognitive function;
LIHC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04441191	chr3:48130393	MAP4	0.42	6.46	0.33	3.58e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.52	9.46	0.46	5.22e-19	Total body bone mineral density;
LIHC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	9.5	0.46	3.71e-19	Hip circumference adjusted for BMI;
LIHC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.48	-18.13	-0.7	5.78e-52	Breast cancer;
LIHC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.52	0.42	5.06e-16	Schizophrenia;
LIHC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.95	11.15	0.52	7.63e-25	Eosinophil percentage of granulocytes;
LIHC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.73	9.57	0.46	2.15e-19	Eosinophilic esophagitis;
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.16	0.32	2.09e-9	Renal cell carcinoma;
LIHC	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.72	12.81	0.57	5.98e-31	Intelligence (multi-trait analysis);
LIHC	trans	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.48	-0.33	3.17e-10	Dental caries;
LIHC	cis	rs9590974	0.600	rs60929536	chr13:47226506	T/C	cg04092803	chr13:47240378	LRCH1	0.29	6.13	0.31	2.38e-9	PR segment;
LIHC	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.73	-11.88	-0.54	1.73e-27	White matter hyperintensity burden;
LIHC	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	1.15	19.06	0.72	1.07e-55	Red blood cell traits;
LIHC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.33	0.32	7.7e-10	Prudent dietary pattern;
LIHC	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.55	7.21	0.36	3.58e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.43	-7.4	-0.37	1.07e-12	Aortic root size;
LIHC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg03037974	chr15:76606532	NA	0.74	14.45	0.62	2.79e-37	Blood metabolite levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13537801	chr17:79663039	HGS	-0.39	-6.45	-0.33	3.79e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.57e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.53	8.72	0.43	1.2e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627123	0.737	rs77361581	chr14:74465290	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	8.6	0.42	2.96e-16	Morning vs. evening chronotype;
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.21	-0.36	3.69e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg16583315	chr14:65563665	MAX	-0.37	-7.12	-0.36	6.58e-12	Obesity-related traits;
LIHC	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg04610667	chr7:75704037	NA	-0.35	-6.18	-0.32	1.86e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs903552	0.932	rs1587108	chr15:102006825	G/A	cg00659931	chr15:102010125	PCSK6	-0.46	-6.18	-0.32	1.84e-9	Diabetic kidney disease;
LIHC	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.73	-8.97	-0.44	2.02e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.56	-6.22	-0.32	1.45e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.32	-6.11	-0.31	2.78e-9	IgG glycosylation;
LIHC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg07061783	chr6:25882402	NA	-0.44	-6.08	-0.31	3.26e-9	Blood metabolite levels;
LIHC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.64	10.32	0.49	6.29e-22	Monocyte count;
LIHC	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg20368463	chr18:77673604	PQLC1	-0.35	-5.94	-0.31	7.13e-9	Schizophrenia;
LIHC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.89	-17.96	-0.7	2.75e-51	Coronary artery disease;
LIHC	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	6.77	0.34	5.56e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs77669868	0.866	rs2735195	chr11:114051192	A/G	cg01914181	chr11:114070210	ZBTB16	-0.58	-7.65	-0.38	2.08e-13	Monocyte percentage of white cells;
LIHC	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.47	6.79	0.34	5.13e-11	Blood metabolite levels;
LIHC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	0.53	6.6	0.34	1.55e-10	Myopia;
LIHC	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.48	-6.22	-0.32	1.42e-9	Coronary artery calcification;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21211866	chr9:35111727	KIAA1539	0.47	7.08	0.36	8.05e-12	Pancreatic cancer;
LIHC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.51	0.38	5.32e-13	Height;
LIHC	cis	rs16854884	0.582	rs35211123	chr3:143640171	A/T	cg06585982	chr3:143692056	C3orf58	0.63	8.73	0.43	1.15e-16	Economic and political preferences (feminism/equality);
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.22	0.32	1.44e-9	Total body bone mineral density;
LIHC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.52	-7.88	-0.39	4.54e-14	Total body bone mineral density;
LIHC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.02	0.54	5.36e-28	Motion sickness;
LIHC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.48	-0.38	6.18e-13	Bipolar disorder;
LIHC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-7.41	-0.37	1.02e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.5	10.01	0.48	7.57e-21	Tonsillectomy;
LIHC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.87	-16.84	-0.67	9.04e-47	Coronary artery disease;
LIHC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	18.08	0.7	9.07e-52	Smoking behavior;
LIHC	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.39	-6.32	-0.32	8.31e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.71	-0.3	2.45e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.12	-0.4	8.7e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.43	-0.41	9.67e-16	Bladder cancer;
LIHC	cis	rs1639906	0.895	rs6972752	chr7:2196551	G/A	cg22963979	chr7:1858916	MAD1L1	0.41	5.72	0.3	2.38e-8	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	0.54	5.77	0.3	1.75e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg21724239	chr8:58056113	NA	0.48	6.21	0.32	1.58e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	9.27	0.45	2.09e-18	Response to antipsychotic treatment;
LIHC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-6.64	-0.34	1.25e-10	Morning vs. evening chronotype;
LIHC	cis	rs2334880	0.678	rs7186112	chr16:71840073	A/T	cg06353428	chr16:71660113	MARVELD3	1.31	13.47	0.59	1.84e-33	Malaria;
LIHC	cis	rs2191566	1.000	rs7253205	chr19:44503607	T/C	cg20607764	chr19:44506953	ZNF230	-0.4	-6.22	-0.32	1.44e-9	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.15	-0.36	5.41e-12	Personality dimensions;
LIHC	cis	rs2279817	0.731	rs76970608	chr1:18010198	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.76	-0.39	9.68e-14	Neuroticism;
LIHC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.6	6.18	0.32	1.85e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg17135325	chr3:160939158	NMD3	0.55	7.78	0.39	8.89e-14	Parkinson's disease;
LIHC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.55	-7.71	-0.38	1.39e-13	Menopause (age at onset);
LIHC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.42	6.31	0.32	8.72e-10	Iron status biomarkers;
LIHC	cis	rs7503807	0.701	rs1485329	chr17:78643561	A/G	cg09596252	chr17:78655493	RPTOR	0.38	6.39	0.33	5.49e-10	Obesity;
LIHC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg16479474	chr6:28041457	NA	0.38	6.32	0.32	8.32e-10	Parkinson's disease;
LIHC	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.67	-11.17	-0.52	6.68e-25	Pediatric autoimmune diseases;
LIHC	cis	rs7635838	0.892	rs2880897	chr3:11494544	A/G	cg00170343	chr3:11313890	ATG7	0.4	6.22	0.32	1.42e-9	HDL cholesterol;
LIHC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg09033563	chr22:24373618	LOC391322	-0.44	-5.89	-0.3	9.16e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.66	0.34	1.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11958404	0.860	rs72818114	chr5:157440207	A/C	cg05962755	chr5:157440814	NA	0.99	11.5	0.53	4.32e-26	IgG glycosylation;
LIHC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.66	0.5	4.25e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg03934865	chr2:198174659	NA	-0.57	-9.06	-0.44	1.04e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	1.01	19.37	0.72	5.94e-57	Breast cancer;
LIHC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.85	0.3	1.14e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.57	7.53	0.38	4.44e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.49	6.83	0.35	3.89e-11	Morning vs. evening chronotype;
LIHC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.24	-0.32	1.27e-9	Total body bone mineral density;
LIHC	cis	rs36051895	0.623	rs10975033	chr9:5262567	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-9.41	-0.45	7.68e-19	Pediatric autoimmune diseases;
LIHC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.66	10.98	0.51	3.27e-24	Crohn's disease;
LIHC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.52	-0.69	1.72e-49	Gut microbiome composition (summer);
LIHC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.47	6.87	0.35	2.97e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg07393940	chr7:158741817	NA	0.54	6.25	0.32	1.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg01364799	chr7:75623366	TMEM120A	-0.49	-7.4	-0.37	1.03e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-8.85	-0.43	4.89e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.43	6.85	0.35	3.53e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg09904177	chr6:26538194	HMGN4	-0.37	-5.79	-0.3	1.57e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg03874509	chr1:107600012	PRMT6	-0.77	-12.17	-0.55	1.47e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs28489187	0.643	rs997251	chr1:85845367	T/C	cg16011679	chr1:85725395	C1orf52	0.46	5.86	0.3	1.08e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.82e-14	Mean platelet volume;
LIHC	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.76	8.84	0.43	5.15e-17	Height;
LIHC	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-7.02	-0.35	1.2e-11	Blood pressure;
LIHC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.46	7.29	0.37	2.11e-12	HDL cholesterol levels;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg23131131	chr22:24373011	LOC391322	-0.73	-11.02	-0.51	2.19e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.87	10.83	0.51	1.06e-23	Bladder cancer;
LIHC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.57	-0.38	3.43e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.04	-0.66	1.47e-43	Electrocardiographic conduction measures;
LIHC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.28	0.37	2.26e-12	Menarche (age at onset);
LIHC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg01652190	chr22:50026171	C22orf34	-0.29	-6.57	-0.33	1.9e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg12903224	chr12:29470962	FAR2	-0.39	-6.34	-0.32	7.41e-10	QT interval;
LIHC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs4845459	0.967	rs75567512	chr1:152587933	C/A	cg20634798	chr1:152595351	LCE3A	-0.3	-5.86	-0.3	1.1e-8	Psoriasis;
LIHC	cis	rs509477	0.718	rs273357	chr18:32597237	G/T	cg23791764	chr18:32556832	MAPRE2	0.44	5.88	0.3	9.81e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.66	0.34	1.08e-10	Mean corpuscular volume;
LIHC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.78	-8.74	-0.43	1.06e-16	Vitiligo;
LIHC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg24296786	chr1:45957014	TESK2	0.42	6.16	0.32	2.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.59	-9.3	-0.45	1.73e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs360798	0.532	rs360797	chr2:62942840	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-6.98	-0.35	1.57e-11	Coronary artery disease;
LIHC	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.47	-0.33	3.43e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.5	8.85	0.43	4.93e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs12086130	0.656	rs12075888	chr1:51416823	C/T	cg07174182	chr1:51127561	FAF1	-0.74	-7.94	-0.39	2.99e-14	Hip circumference adjusted for BMI;Hip circumference;
LIHC	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.79	0.34	4.89e-11	Ileal carcinoids;
LIHC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-6.49	-0.33	3.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.47e-16	Total cholesterol levels;
LIHC	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.98	7.84	0.39	5.9e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.5	8.71	0.43	1.35e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.7	11.65	0.53	1.22e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.26	-0.32	1.17e-9	Vitiligo;
LIHC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.31	0.45	1.6e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.03	0.31	4.17e-9	Tonsillectomy;
LIHC	cis	rs600806	0.778	rs4970767	chr1:110015183	G/A	cg23091122	chr1:110024289	SYPL2	-0.44	-6.09	-0.31	3.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.53	8.51	0.42	5.61e-16	Lymphocyte counts;
LIHC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.46	6.24	0.32	1.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-7.61	-0.38	2.66e-13	Morning vs. evening chronotype;
LIHC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.69	-13.38	-0.59	3.85e-33	Body mass index;
LIHC	cis	rs922107	0.738	rs12116782	chr1:90032047	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.7	-0.38	1.48e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	trans	rs7120489	0.643	rs11022353	chr11:12446727	G/C	cg08537300	chr5:179058959	NA	0.57	6.18	0.32	1.84e-9	Mortality in heart failure;
LIHC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1865721	0.682	rs3745081	chr18:73142923	A/G	cg26385618	chr18:73139727	C18orf62	-0.28	-7.69	-0.38	1.5700000000000001e-13	Intelligence;
LIHC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg14440974	chr22:39074834	NA	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07549551	chr6:158487608	SYNJ2	0.42	6.11	0.31	2.74e-9	Longevity;
LIHC	trans	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg17675199	chr6:35436792	RPL10A	0.35	6.86	0.35	3.26e-11	Coronary artery disease;
LIHC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs74181299	0.684	rs11126029	chr2:65338264	C/T	cg05010058	chr2:65284262	CEP68	-0.41	-6.82	-0.35	4.07e-11	Pulse pressure;
LIHC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg23649088	chr2:200775458	C2orf69	-0.45	-6.16	-0.32	2.01e-9	QT interval;
LIHC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.66	5.96	0.31	6.23e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.3	-6.27	-0.32	1.08e-9	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.42	-7.35	-0.37	1.46e-12	Platelet distribution width;
LIHC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.76	0.34	5.88e-11	Personality dimensions;
LIHC	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.84	-0.35	3.68e-11	Metabolite levels;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02290350	chr8:58132656	NA	0.5	10.94	0.51	4.54e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.5	7.09	0.36	7.78e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2071426	0.959	rs11188144	chr10:96789707	C/G	cg09036531	chr10:96991505	NA	-0.5	-5.91	-0.3	8.38e-9	Blood metabolite levels;
LIHC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	1.0	11.25	0.52	3.51e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.56	9.84	0.47	2.69e-20	Alcohol dependence;
LIHC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.69	12.49	0.56	9.55e-30	Iron status biomarkers;
LIHC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.54	-9.19	-0.45	3.77e-18	Reticulocyte count;
LIHC	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.56	-8.93	-0.43	2.62e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg17299615	chr19:13944571	NA	0.55	7.95	0.4	2.68e-14	Breast cancer;
LIHC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.58	9.54	0.46	2.7e-19	Resting heart rate;
LIHC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.6	5.91	0.3	8.39e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.35	6.95	0.35	1.84e-11	Cancer;
LIHC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg14067834	chr17:29058358	SUZ12P	0.6	5.88	0.3	9.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	0.93	17.1	0.68	8.16e-48	Bone mineral density;
LIHC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.52	6.92	0.35	2.18e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg08126542	chr6:37504118	NA	-0.41	-6.52	-0.33	2.47e-10	Cognitive performance;
LIHC	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.46	-0.33	3.7e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs7739232	0.920	rs77374381	chr6:53530662	A/G	cg19801120	chr6:53530570	KLHL31	-0.86	-5.84	-0.3	1.21e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.76	0.39	9.62e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg20240347	chr1:204465584	NA	-0.36	-7.5	-0.38	5.47e-13	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg24209194	chr3:40518798	ZNF619	0.55	7.92	0.39	3.4e-14	Renal cell carcinoma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05977900	chr3:182512126	ATP11B	0.46	7.17	0.36	4.78e-12	Cognitive function;
LIHC	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg14515779	chr1:101123966	NA	-0.66	-12.4	-0.56	2.04e-29	Monocyte count;
LIHC	cis	rs6466055	0.777	rs41562	chr7:104845094	C/T	cg04380332	chr7:105027541	SRPK2	0.35	6.59	0.34	1.7e-10	Schizophrenia;
LIHC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg10820045	chr2:198174542	NA	-0.6	-10.3	-0.49	7.69e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg12798992	chr6:167411361	FGFR1OP	0.5	7.68	0.38	1.7e-13	Crohn's disease;
LIHC	cis	rs9341808	0.529	rs4706840	chr6:81057769	T/A	cg08355045	chr6:80787529	NA	0.35	6.95	0.35	1.89e-11	Sitting height ratio;
LIHC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.71	0.8	4.72e-78	Prudent dietary pattern;
LIHC	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.63	10.2	0.48	1.65e-21	Schizophrenia;
LIHC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.42	-5.91	-0.3	8.19e-9	Narcolepsy;
LIHC	cis	rs288342	0.832	rs288308	chr2:183651818	T/G	cg02625481	chr2:183667124	NA	-0.29	-5.97	-0.31	5.87e-9	Recurrent major depressive disorder;
LIHC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs526821	0.595	rs565859	chr11:55297367	T/C	cg04317927	chr11:55418816	OR4S2	0.47	9.04	0.44	1.21e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.44	-6.96	-0.35	1.79e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg14473756	chr11:122847823	NA	-0.37	-6.74	-0.34	6.82e-11	Menarche (age at onset);
LIHC	trans	rs944289	0.746	rs7145211	chr14:36558266	A/T	cg15660807	chr2:220381734	ACCN4	-0.26	-6.35	-0.32	6.83e-10	Thyroid cancer;
LIHC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.83	7.8	0.39	7.53e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg27205649	chr11:78285834	NARS2	0.42	6.21	0.32	1.53e-9	Alzheimer's disease (survival time);
LIHC	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.52	8.1	0.4	9.68e-15	Diastolic blood pressure;
LIHC	cis	rs2257205	0.667	rs9889494	chr17:56629764	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	trans	rs4596713	0.508	rs4745650	chr9:71777892	G/A	cg16512924	chr15:28394682	HERC2	0.39	6.25	0.32	1.21e-9	Headache;
LIHC	cis	rs3770081	1.000	rs75713195	chr2:86290659	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.49	-0.42	6.21e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.49	7.54	0.38	4.29e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	6.51	0.33	2.74e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.59	8.91	0.43	3e-17	Tumor biomarkers;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.61	7.69	0.38	1.63e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs74233809	1.000	rs12220375	chr10:104901491	T/C	cg03493300	chr10:104813866	CNNM2	0.47	6.05	0.31	3.83e-9	Birth weight;
LIHC	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.64	-6.46	-0.33	3.64e-10	Multiple sclerosis;
LIHC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg17724175	chr1:150552817	MCL1	0.47	9.27	0.45	2.13e-18	Urate levels;
LIHC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.88	-0.35	2.86e-11	Bipolar disorder;
LIHC	cis	rs7577696	0.525	rs11124272	chr2:32142520	A/C	cg02381751	chr2:32503542	YIPF4	0.43	6.0	0.31	5.1e-9	Inflammatory biomarkers;
LIHC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg17135325	chr3:160939158	NMD3	0.54	7.62	0.38	2.59e-13	Parkinson's disease;
LIHC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg03146154	chr1:46216737	IPP	-0.38	-5.88	-0.3	9.8e-9	High light scatter reticulocyte count;
LIHC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-10.39	-0.49	3.59e-22	Asthma;
LIHC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.49	6.71	0.34	8.25e-11	Morning vs. evening chronotype;
LIHC	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.53	-10.64	-0.5	5.08e-23	Myopia (pathological);
LIHC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-0.96	-22.55	-0.77	1.2e-69	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2279817	0.818	rs867984	chr1:17982559	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.52	-6.27	-0.32	1.06e-9	Neuroticism;
LIHC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg01788221	chr16:89496183	ANKRD11	-0.37	-5.79	-0.3	1.56e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.86e-9	Total body bone mineral density;
LIHC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.52	-9.8	-0.47	3.7799999999999997e-20	Mean corpuscular volume;
LIHC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.11	-0.31	2.68e-9	Menarche (age at onset);
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	10.73	0.5	2.5e-23	Lymphocyte counts;
LIHC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.43	-6.06	-0.31	3.66e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9595066	0.715	rs9567366	chr13:44682973	A/C	cg04068111	chr13:44716778	NA	0.36	6.63	0.34	1.3e-10	Schizophrenia;
LIHC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.93	16.69	0.67	3.76e-46	Parkinson's disease;
LIHC	cis	rs9378688	0.654	rs13196306	chr6:2252322	A/G	cg12303981	chr6:2244766	GMDS	-0.45	-6.02	-0.31	4.57e-9	Caudate nucleus volume;
LIHC	cis	rs4699052	0.507	rs7662107	chr4:104258396	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-6.67	-0.34	1e-10	Testicular germ cell tumor;
LIHC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.36	-5.73	-0.3	2.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18093693	chr15:72668265	HEXA;C15orf34	0.47	7.08	0.36	8.21e-12	Pancreatic cancer;
LIHC	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.51	-6.45	-0.33	3.73e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.99	0.44	1.78e-17	Neuroticism;
LIHC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.9	18.19	0.7	3.33e-52	Bone mineral density;
LIHC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.82	0.65	1.12e-42	Chronic sinus infection;
LIHC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.58	8.64	0.42	2.18e-16	Colorectal cancer;
LIHC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	5.74	0.3	2.14e-8	Protein C levels;
LIHC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.59	11.87	0.54	1.93e-27	Glycated hemoglobin levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg06567722	chr13:113834331	PCID2	0.37	6.44	0.33	3.99e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg00085434	chr11:14927489	NA	-0.4	-5.75	-0.3	1.94e-8	Adiponectin levels;Vitamin D levels;
LIHC	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.17	-0.36	4.54e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg14250997	chr9:106856677	SMC2	0.43	7.48	0.37	6.3e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12785082	chr7:101662332	CUX1	0.42	6.26	0.32	1.14e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs13126513	0.708	rs7665289	chr4:100448167	G/T	cg05468953	chr4:100565104	NA	0.33	6.5	0.33	2.82e-10	Metabolite levels (MHPG);
LIHC	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.47	-0.33	3.42e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.99	19.66	0.73	4.28e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.63	-8.41	-0.41	1.11e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg18081818	chr7:23246105	NA	-0.38	-5.76	-0.3	1.91e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.07e-9	Primary biliary cholangitis;
LIHC	trans	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg23605328	chr1:201951606	RNPEP	0.4	6.37	0.33	6.26e-10	Monocyte percentage of white cells;
LIHC	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg10820045	chr2:198174542	NA	0.49	7.73	0.39	1.24e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg27432699	chr2:27873401	GPN1	-0.54	-7.83	-0.39	6.28e-14	Total body bone mineral density;
LIHC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-17.12	-0.68	6.61e-48	Height;
LIHC	cis	rs72780191	0.574	rs55836224	chr2:23895597	T/C	cg08917208	chr2:24149416	ATAD2B	0.66	6.21	0.32	1.55e-9	White blood cell count;
LIHC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.67	0.38	1.83e-13	Total body bone mineral density;
LIHC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.33	11.69	0.53	8.42e-27	Uric acid levels;
LIHC	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.64	-0.5	5.15e-23	Eye color traits;
LIHC	trans	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg26939375	chr7:64535504	NA	-0.42	-7.21	-0.36	3.69e-12	Aortic root size;
LIHC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.25	-0.32	1.23e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.75	-9.91	-0.47	1.57e-20	Systemic lupus erythematosus;
LIHC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.36	5.76	0.3	1.91e-8	Mood instability;
LIHC	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08645402	chr16:4508243	NA	0.39	7.21	0.36	3.59e-12	Schizophrenia;
LIHC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.86	8.15	0.4	6.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.8	-17.92	-0.7	4.12e-51	Urate levels in lean individuals;
LIHC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-12.14	-0.55	1.9e-28	Vitiligo;
LIHC	cis	rs963731	0.649	rs2123879	chr2:39292598	A/G	cg04010122	chr2:39346883	SOS1	-0.75	-6.25	-0.32	1.2e-9	Corticobasal degeneration;
LIHC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.64	0.42	2.21e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23425280	chr12:56401806	NA	-0.49	-6.12	-0.31	2.58e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.16e-9	Tonsillectomy;
LIHC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg17385448	chr1:15911702	AGMAT	0.35	6.22	0.32	1.49e-9	Systolic blood pressure;
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27297192	chr10:134578999	INPP5A	0.53	7.81	0.39	6.89e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.52	-0.42	5.11e-16	Total body bone mineral density;
LIHC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12379764	chr21:47803548	PCNT	-0.55	-7.69	-0.38	1.6e-13	Testicular germ cell tumor;
LIHC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.64	9.9	0.47	1.73e-20	Corneal astigmatism;
LIHC	cis	rs244293	0.765	rs17817442	chr17:53099514	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.48	7.2	0.36	3.97e-12	Menarche (age at onset);
LIHC	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.44	-0.53	7.14e-26	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.06	-0.61	9.31e-36	Alzheimer's disease;
LIHC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.81	12.74	0.57	1.09e-30	Breast cancer;
LIHC	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.42	-0.41	1.04e-15	Body mass index (adult);
LIHC	cis	rs2274273	0.837	rs10141552	chr14:55746091	C/T	cg01864836	chr14:55583639	NA	0.38	6.81	0.35	4.4e-11	Protein biomarker;
LIHC	cis	rs4722404	0.835	rs6965630	chr7:3138656	A/G	cg19214707	chr7:3157722	NA	-0.34	-6.35	-0.32	7.01e-10	Atopic dermatitis;
LIHC	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg04352962	chr1:209979756	IRF6	0.39	5.99	0.31	5.36e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg25894440	chr7:65020034	NA	-0.53	-6.23	-0.32	1.35e-9	Diabetic kidney disease;
LIHC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-11.0	-0.51	2.64e-24	Lung cancer;
LIHC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.17	-12.67	-0.57	2.05e-30	White matter hyperintensity burden;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18802567	chr5:171433913	FBXW11	0.44	6.16	0.32	2.06e-9	Migraine with aura;
LIHC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.69	-9.85	-0.47	2.6e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.33	-0.32	7.61e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg05425664	chr17:57184151	TRIM37	-0.47	-5.89	-0.3	9.43e-9	Vitamin D levels;
LIHC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.79	-0.3	1.58e-8	Alzheimer's disease (late onset);
LIHC	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.08	-0.31	3.19e-9	Pancreatic cancer;
LIHC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.24	0.52	3.7e-25	Personality dimensions;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg22522985	chr1:52485971	TXNDC12	0.48	6.41	0.33	4.88e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg04013166	chr16:89971882	TCF25	0.55	7.23	0.36	3.16e-12	Skin colour saturation;
LIHC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-10.28	-0.49	8.89e-22	Dental caries;
LIHC	cis	rs7546668	1.000	rs10803389	chr1:15861287	C/T	cg11706911	chr1:15910989	AGMAT	0.44	6.77	0.34	5.54e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg18944383	chr4:111397179	ENPEP	0.35	8.04	0.4	1.48e-14	Coronary artery disease;
LIHC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg02640540	chr1:67518911	SLC35D1	0.45	6.19	0.32	1.69e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs4919087	0.748	rs793516	chr10:98987985	G/T	cg25902810	chr10:99078978	FRAT1	-0.55	-6.31	-0.32	8.61e-10	Monocyte count;
LIHC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.78	12.41	0.56	1.83e-29	Colorectal cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg10771851	chr11:68204486	LRP5	-0.41	-6.24	-0.32	1.32e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.87e-9	Body mass index;
LIHC	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.78	8.89	0.43	3.7e-17	Exhaled nitric oxide levels;
LIHC	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.19	6.0	0.31	4.95e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs10426930	0.816	rs2620809	chr19:5062488	A/G	cg18473234	chr19:5097819	KDM4B	-0.54	-6.9	-0.35	2.57e-11	Monocyte percentage of white cells;
LIHC	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.57	7.45	0.37	7.82e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg06640241	chr16:89574553	SPG7	0.53	8.08	0.4	1.1e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs655641	1.000	rs585820	chr11:85696670	G/A	cg09030501	chr11:85779252	PICALM	-0.5	-6.03	-0.31	4.17e-9	Platelet count;
LIHC	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg16275483	chr1:110013120	SYPL2	-0.5	-6.22	-0.32	1.44e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06752365	chr13:33920491	NA	0.32	6.04	0.31	3.95e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3731827	0.511	rs2289976	chr2:85818797	G/A	cg16865965	chr2:85811662	VAMP5	0.41	5.82	0.3	1.36e-8	Prostate cancer;
LIHC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.45	6.13	0.31	2.48e-9	Initial pursuit acceleration;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.48	-8.26	-0.41	3.13e-15	Total body bone mineral density;
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.46	6.85	0.35	3.47e-11	Cystic fibrosis severity;
LIHC	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02475777	chr4:1388615	CRIPAK	0.54	8.0	0.4	2e-14	Longevity;
LIHC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.84	-0.3	1.21e-8	Type 2 diabetes;
LIHC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.67	13.23	0.58	1.52e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.68	6.81	0.35	4.49e-11	Schizophrenia;
LIHC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	9.72	0.47	6.85e-20	Longevity;
LIHC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.63	0.42	2.32e-16	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.6	7.25	0.37	2.79e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.55	-0.33	2.11e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.38	-5.87	-0.3	1.06e-8	Cognitive function;
LIHC	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-7.18	-0.36	4.44e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg16309518	chr5:176445507	NA	-0.56	-10.83	-0.51	1.11e-23	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.52	-8.11	-0.4	9.04e-15	Tonometry;
LIHC	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.17	-0.32	1.97e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	trans	rs13139451	1.000	rs6533922	chr4:116421669	A/G	cg22998206	chr12:49239429	DDX23	0.38	6.2	0.32	1.63e-9	Serum uric acid levels in response to allopurinol in gout;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20382932	chr2:71357258	MCEE;MPHOSPH10	0.48	6.16	0.32	2.06e-9	Lung function (FEV1/FVC);
LIHC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.51	6.13	0.31	2.48e-9	Schizophrenia;
LIHC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.51	8.58	0.42	3.41e-16	Obesity-related traits;
LIHC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.53	-0.49	1.16e-22	Total cholesterol levels;
LIHC	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02985541	chr2:219472218	PLCD4	0.44	8.16	0.4	6.27e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.68	-13.35	-0.59	5.14e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.33	2.39e-10	Vitiligo;
LIHC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.02	0.4	1.69e-14	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03270376	chr2:219536588	RNF25;STK36	0.5	7.69	0.38	1.58e-13	Pancreatic cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01045986	chr18:29671767	RNF138	0.46	6.49	0.33	3.03e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.77	-0.3	1.75e-8	Blood protein levels;
LIHC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-7.22	-0.36	3.44e-12	Hepatocellular carcinoma;
LIHC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.55	10.23	0.48	1.31e-21	Methadone dose in opioid dependence;
LIHC	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg09003973	chr2:102972529	NA	0.52	5.87	0.3	1.03e-8	Blood protein levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25634484	chr8:8559074	CLDN23	0.5	6.44	0.33	4.12e-10	Lung function (FEV1/FVC);
LIHC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg23461800	chr14:103021989	NA	-0.42	-5.87	-0.3	1.03e-8	Platelet count;
LIHC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg05941027	chr17:61774174	LIMD2	0.33	6.71	0.34	8.24e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.72	-9.18	-0.44	4.11e-18	Systemic lupus erythematosus;
LIHC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.54	-6.66	-0.34	1.09e-10	Menarche (age at onset);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14283194	chr7:91763737	CYP51A1	-0.4	-6.11	-0.31	2.75e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.29	-7.91	-0.39	3.51e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg14473756	chr11:122847823	NA	-0.36	-6.63	-0.34	1.29e-10	Menarche (age at onset);
LIHC	cis	rs11955398	0.625	rs34395679	chr5:59954716	A/G	cg02684056	chr5:59996105	DEPDC1B	0.43	6.08	0.31	3.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.49	-6.97	-0.35	1.64e-11	Height;
LIHC	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.53	8.58	0.42	3.45e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.73	0.54	6.22e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs6058796	1.000	rs34311932	chr20:31260997	T/C	cg02600331	chr11:130417168	NA	0.36	7.78	0.39	8.61e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs711245	0.748	rs2276671	chr2:36771701	C/A	cg01206211	chr2:36825736	FEZ2	0.48	7.74	0.39	1.16e-13	Height;
LIHC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.78	0.39	8.67e-14	Personality dimensions;
LIHC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.64	0.34	1.2e-10	Renal cell carcinoma;
LIHC	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	6.02	0.31	4.49e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13409248	chr3:40428643	ENTPD3	-0.45	-7.42	-0.37	9.23e-13	Renal cell carcinoma;
LIHC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.35	-7.16	-0.36	4.9e-12	Bone mineral density;
LIHC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.63	-8.07	-0.4	1.23e-14	Initial pursuit acceleration;
LIHC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	6.02	0.31	4.48e-9	Obesity-related traits;
LIHC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	1.16	14.4	0.61	4.41e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.83	0.43	5.6e-17	Lung cancer in ever smokers;
LIHC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg08029281	chr1:67600428	NA	-0.35	-5.98	-0.31	5.75e-9	Psoriasis;
LIHC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.44	7.1	0.36	7.28e-12	HDL cholesterol levels;
LIHC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.8	10.14	0.48	2.64e-21	Mean platelet volume;
LIHC	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.48	-0.38	6.13e-13	Mean platelet volume;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03383661	chr6:42714115	TBCC	0.44	6.24	0.32	1.33e-9	Pancreatic cancer;
LIHC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-8.16	-0.4	6.43e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.42	-6.6	-0.34	1.61e-10	Schizophrenia;
LIHC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg23601095	chr6:26197514	HIST1H3D	0.54	5.79	0.3	1.58e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs10845606	0.581	rs11055015	chr12:12836679	T/G	cg09462578	chr12:12878428	APOLD1	-0.52	-7.58	-0.38	3.17e-13	Systemic lupus erythematosus;
LIHC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.68	-9.31	-0.45	1.65e-18	Corneal structure;
LIHC	cis	rs4917300	0.657	rs6996685	chr8:143071894	C/A	cg06573787	chr8:143070187	NA	0.27	5.74	0.3	2.07e-8	Amyotrophic lateral sclerosis;
LIHC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg22633049	chr21:46681294	NA	-0.34	-6.11	-0.31	2.73e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs11640939	0.710	rs2972265	chr16:5041778	T/C	cg26446499	chr5:77253555	NA	0.35	6.3	0.32	8.91e-10	Cancer;
LIHC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	7.75	0.39	1.06e-13	Protein C levels;
LIHC	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.65	-8.05	-0.4	1.36e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.03	14.59	0.62	7.75e-38	Cognitive function;
LIHC	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg18898632	chr2:242989856	NA	-0.69	-8.67	-0.42	1.77e-16	Obesity-related traits;
LIHC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg01320579	chr17:75405842	SEPT9	0.51	8.83	0.43	5.64e-17	Airflow obstruction;
LIHC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.42	0.33	4.43e-10	Lung cancer;
LIHC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.42	-7.27	-0.37	2.54e-12	Aortic root size;
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.72	-0.34	7.62e-11	Lymphocyte counts;
LIHC	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.75	12.81	0.57	5.73e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09888721	chr21:40178652	ETS2	0.41	5.78	0.3	1.66e-8	Cognitive function;
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg10755058	chr3:40428713	ENTPD3	0.35	5.78	0.3	1.72e-8	Renal cell carcinoma;
LIHC	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-0.67	-11.49	-0.53	4.75e-26	Pediatric autoimmune diseases;
LIHC	cis	rs9328573	0.935	rs12719732	chr15:100508847	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.44	-6.51	-0.33	2.74e-10	Urate levels in lean individuals;
LIHC	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.54	-7.77	-0.39	9.51e-14	Facial morphology (factor 19);
LIHC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.43	-6.54	-0.33	2.28e-10	HDL cholesterol;
LIHC	trans	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg01596870	chr19:55963115	NA	-0.62	-8.23	-0.41	4.08e-15	Obesity-related traits;
LIHC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg09417038	chr21:47716443	C21orf57	-0.52	-7.83	-0.39	6.22e-14	Testicular germ cell tumor;
LIHC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.5	7.9	0.39	3.86e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21448741	chr8:58168803	NA	0.38	7.06	0.36	9.34e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.62e-13	Alzheimer's disease;
LIHC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.11	0.55	2.47e-28	Body mass index;
LIHC	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.58	9.62	0.46	1.54e-19	Prostate cancer;
LIHC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.6	10.23	0.48	1.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.26	-0.37	2.66e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg14664628	chr15:75095509	CSK	-1.0	-19.91	-0.73	4.16e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs11822910	0.737	rs2584858	chr11:57207077	C/T	cg00522883	chr11:57194120	SLC43A3	0.56	7.68	0.38	1.69e-13	Platelet distribution width;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	0.41	6.33	0.32	7.69e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.37	-6.25	-0.32	1.23e-9	Systemic lupus erythematosus;
LIHC	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00495681	chr13:53174319	NA	-0.36	-5.75	-0.3	1.98e-8	Lewy body disease;
LIHC	cis	rs61041384	0.661	rs79033960	chr12:123680935	T/C	cg00376283	chr12:123451042	ABCB9	-0.55	-6.14	-0.32	2.29e-9	Schizophrenia;
LIHC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.89	-18.29	-0.7	1.34e-52	Height;
LIHC	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.37	-6.32	-0.32	8.29e-10	Schizophrenia;
LIHC	cis	rs244293	0.965	rs244335	chr17:53201930	C/G	cg19360675	chr17:53046073	COX11;STXBP4	0.48	7.26	0.37	2.69e-12	Menarche (age at onset);
LIHC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.39	-7.43	-0.37	8.94e-13	Lung cancer;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.84	-0.54	2.51e-27	Alzheimer's disease;
LIHC	cis	rs7119038	0.818	rs2077579	chr11:118619047	T/G	cg19308663	chr11:118741387	NA	0.44	5.92	0.3	7.81e-9	Sjögren's syndrome;
LIHC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.49	-0.53	4.52e-26	Type 2 diabetes;
LIHC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.12	0.52	9.84e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.54	9.27	0.45	2.14e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.64	-0.42	2.22e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7537052	0.669	rs6686192	chr1:36642991	C/T	cg24686825	chr1:36642396	MAP7D1	-0.46	-8.52	-0.42	5.01e-16	Schizophrenia;
LIHC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	17.78	0.69	1.45e-50	Smoking behavior;
LIHC	trans	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg10756647	chr7:56101905	PSPH	0.65	8.91	0.43	3.18e-17	Corneal structure;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00380172	chr6:148663585	SASH1	0.46	7.09	0.36	7.59e-12	Calcium levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06766273	chr11:62521983	ZBTB3	0.39	6.18	0.32	1.85e-9	Cognitive function;
LIHC	cis	rs4908760	0.613	rs4908511	chr1:8812390	C/G	cg20416874	chr1:8611966	RERE	0.56	10.52	0.49	1.33e-22	Vitiligo;
LIHC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs15676	0.947	rs2293966	chr9:131591832	G/A	cg13708974	chr9:131466143	PKN3	0.38	5.79	0.3	1.64e-8	Blood metabolite levels;
LIHC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	11.13	0.52	9.12e-25	Lung cancer in ever smokers;
LIHC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.21	-0.36	3.61e-12	Venous thromboembolism (SNP x SNP interaction);
LIHC	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.4	-6.37	-0.33	5.95e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.32	7.26	0.37	2.64e-12	Blood metabolite ratios;
LIHC	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.29	6.36	0.32	6.66e-10	Pulmonary function;
LIHC	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.63e-11	Type 2 diabetes;
LIHC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg18121669	chr1:26560928	CCDC21	0.49	7.88	0.39	4.31e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.57	-0.46	2.31e-19	Response to antipsychotic treatment;
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	11.13	0.52	9.27e-25	Height;
LIHC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.77	-11.85	-0.54	2.17e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-7.3	-0.37	2.05e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg02023728	chr11:77925099	USP35	-0.36	-6.24	-0.32	1.32e-9	Alzheimer's disease (survival time);
LIHC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs918629	0.754	rs2112566	chr5:95288618	G/A	cg10483112	chr5:95245456	ELL2	-0.37	-6.22	-0.32	1.42e-9	IgG glycosylation;
LIHC	cis	rs757081	0.671	rs214091	chr11:17296463	A/C	cg15432903	chr11:17409602	KCNJ11	-0.46	-5.99	-0.31	5.25e-9	Systolic blood pressure;
LIHC	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.53	10.41	0.49	3.15e-22	Multiple myeloma;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20630277	chr11:1968830	MRPL23	0.53	7.31	0.37	1.97e-12	Hepatitis;
LIHC	cis	rs7903847	0.642	rs61863816	chr10:99128503	G/A	cg06359132	chr10:99160096	RRP12	-0.4	-5.86	-0.3	1.09e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-9.14	-0.44	5.61e-18	Morning vs. evening chronotype;
LIHC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	7.39	0.37	1.14e-12	Schizophrenia;
LIHC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.32	6.31	0.32	8.74e-10	Monocyte count;
LIHC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.23	0.45	2.97e-18	IgG glycosylation;
LIHC	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg13919466	chr1:32135498	COL16A1	-0.31	-6.21	-0.32	1.57e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2073499	0.935	rs2526392	chr3:50191191	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-6.57	-0.33	1.82e-10	Schizophrenia;
LIHC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.65	8.17	0.4	5.95e-15	Mean platelet volume;
LIHC	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.44	-0.37	8.34e-13	Breast cancer;
LIHC	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg13444538	chr7:158905317	VIPR2	-0.31	-5.97	-0.31	6.02e-9	Facial morphology (factor 20);
LIHC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.53	-0.46	2.97e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.46	5.96	0.31	6.34e-9	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.74	-0.34	6.68e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.44	0.37	8.23e-13	Renal cell carcinoma;
LIHC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg27494647	chr7:150038898	RARRES2	0.32	5.84	0.3	1.19e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2637266	0.783	rs2395434	chr10:78476161	T/C	cg18941641	chr10:78392320	NA	0.27	5.82	0.3	1.33e-8	Pulmonary function;
LIHC	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg25124228	chr12:125621409	AACS	-0.43	-6.73	-0.34	7.11e-11	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	0.99	7.74	0.39	1.14e-13	IgG glycosylation;
LIHC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.44	6.28	0.32	1.04e-9	Height;
LIHC	cis	rs860295	0.812	rs6657670	chr1:155787867	C/T	cg02153340	chr1:155202674	NA	-0.34	-6.17	-0.32	1.9e-9	Body mass index;
LIHC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	9.26	0.45	2.32e-18	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.8	7.84	0.39	5.87e-14	Body mass index;
LIHC	cis	rs6782228	0.527	rs6767383	chr3:128413587	C/A	cg16766828	chr3:128327626	NA	-0.38	-6.06	-0.31	3.66e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg23367146	chr19:21773418	NA	0.4	6.3	0.32	9.19e-10	Pain;
LIHC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.58	8.22	0.41	4.2e-15	Aortic root size;
LIHC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg19678392	chr7:94953810	PON1	-0.45	-5.89	-0.3	8.99e-9	Yu-Zhi constitution type in type 2 diabetes;
LIHC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.44	-7.28	-0.37	2.37e-12	IgG glycosylation;
LIHC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.27	-0.32	1.11e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.35	-6.06	-0.31	3.51e-9	Headache;
LIHC	cis	rs1982963	0.627	rs17124901	chr14:52488009	C/T	cg10843707	chr14:52510701	NID2	0.37	5.97	0.31	5.83e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs2363709	1.000	rs4241438	chr3:67425727	A/G	cg13681781	chr9:139102396	QSOX2	0.83	6.35	0.32	6.79e-10	IgE levels;
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.66	8.16	0.4	6.42e-15	Developmental language disorder (linguistic errors);
LIHC	trans	rs6058796	1.000	rs6087963	chr20:31249144	G/C	cg02600331	chr11:130417168	NA	0.35	7.53	0.38	4.6e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.77	9.6	0.46	1.75e-19	Morning vs. evening chronotype;
LIHC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.26	-0.45	2.37e-18	Ulcerative colitis;
LIHC	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.95	-15.37	-0.64	6.45e-41	Platelet count;
LIHC	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg20636351	chr8:55087400	NA	0.37	7.67	0.38	1.81e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.25	0.8	2.71e-76	Prudent dietary pattern;
LIHC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.8	-0.3	1.53e-8	Subjective well-being;
LIHC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg12292205	chr6:26970375	C6orf41	0.34	5.78	0.3	1.71e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.41	6.66	0.34	1.12e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.5	9.35	0.45	1.21e-18	Hemoglobin concentration;
LIHC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.5	5.92	0.3	7.8e-9	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.81	-8.84	-0.43	5.15e-17	Vitiligo;
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.44	8.12	0.4	8.34e-15	Prudent dietary pattern;
LIHC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.7	10.63	0.5	5.39e-23	Intelligence (multi-trait analysis);
LIHC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.95	-0.63	3.15e-39	Height;
LIHC	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg02811702	chr13:24901961	NA	0.25	6.14	0.32	2.29e-9	Obesity-related traits;
LIHC	cis	rs5770917	1.000	rs3213445	chr22:51015838	T/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.48	-5.91	-0.3	8.18e-9	Narcolepsy;
LIHC	cis	rs611744	0.870	rs371878	chr8:109130620	T/G	cg21045802	chr8:109455806	TTC35	0.5	8.48	0.42	6.86e-16	Dupuytren's disease;
LIHC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	15.36	0.64	7.59e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9309473	0.898	rs10209517	chr2:73845392	C/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.75	-0.34	6.38e-11	Metabolite levels;
LIHC	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.26	5.73	0.3	2.23e-8	Pulmonary function;
LIHC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.22	0.48	1.43e-21	Bladder cancer;
LIHC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg10664184	chr19:17420304	DDA1	0.45	5.73	0.3	2.22e-8	Systemic lupus erythematosus;
LIHC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-8.63	-0.42	2.37e-16	Chronic sinus infection;
LIHC	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.75	13.27	0.58	1.08e-32	Eosinophil percentage of white cells;
LIHC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.71	6.8	0.35	4.68e-11	Eosinophil percentage of granulocytes;
LIHC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.78	8.87	0.43	4.01e-17	Vitiligo;
LIHC	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.41	6.5	0.33	2.8e-10	Migraine;
LIHC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.24	0.61	1.91e-36	Chronic sinus infection;
LIHC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18252515	chr7:66147081	NA	-0.46	-6.64	-0.34	1.22e-10	Aortic root size;
LIHC	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg27209729	chr11:64428925	NRXN2	0.34	6.41	0.33	4.7e-10	Body mass index;Urate levels;
LIHC	cis	rs16837677	0.826	rs76114442	chr1:156699977	G/A	cg19377421	chr1:156697041	ISG20L2;C1orf66	0.68	7.69	0.38	1.58e-13	Sjögren's syndrome;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25738037	chr1:168025549	DCAF6	0.4	6.49	0.33	3.1e-10	Bilirubin levels;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	23.97	0.79	3.39e-75	Prudent dietary pattern;
LIHC	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.42	-5.84	-0.3	1.22e-8	Liver enzyme levels (alkaline phosphatase);
LIHC	trans	rs6600671	1.000	rs10903159	chr1:121181997	G/T	cg09829573	chr1:144692074	NBPF9	-0.44	-8.07	-0.4	1.22e-14	Hip geometry;
LIHC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-7.45	-0.37	7.58e-13	Chronic sinus infection;
LIHC	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.47	6.91	0.35	2.38e-11	Dermatomyositis;
LIHC	cis	rs611744	0.967	rs608115	chr8:109231948	T/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.42	7.76	0.39	9.87e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg14393609	chr7:65229607	NA	0.36	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.87	15.77	0.65	1.66e-42	Body mass index;
LIHC	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.25	-0.32	1.22e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.54	-8.53	-0.42	4.75e-16	Morning vs. evening chronotype;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg24179483	chr5:170814656	NPM1	-0.55	-6.39	-0.33	5.58e-10	Systolic blood pressure;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13409248	chr3:40428643	ENTPD3	0.41	6.77	0.34	5.65e-11	Renal cell carcinoma;
LIHC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg21724239	chr8:58056113	NA	0.47	6.17	0.32	1.96e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.66	9.34	0.45	1.23e-18	Schizophrenia;
LIHC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-7.19	-0.36	4.11e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23043544	chr7:2124092	MAD1L1	-0.41	-6.61	-0.34	1.49e-10	Neuroticism;
LIHC	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.29	0.49	8.39e-22	Diisocyanate-induced asthma;
LIHC	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg15208524	chr1:10270712	KIF1B	0.41	6.27	0.32	1.11e-9	Hepatocellular carcinoma;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.7	11.65	0.53	1.17e-26	Prudent dietary pattern;
LIHC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.78	13.06	0.58	6.57e-32	Oral cavity cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18147735	chr4:39460314	LIAS;RPL9	0.49	6.33	0.32	7.6e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg04306507	chr14:55594613	LGALS3	0.35	6.82	0.35	4.04e-11	Protein biomarker;
LIHC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.74	-0.3	2.13e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.38	6.69	0.34	8.86e-11	Mean corpuscular volume;
LIHC	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg09795085	chr6:101329169	ASCC3	0.5	7.05	0.36	1.02e-11	Neuroticism;
LIHC	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg12858261	chr2:113808755	IL1F8	0.34	5.94	0.31	7.18e-9	Pulmonary function;
LIHC	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	0.9	10.25	0.48	1.15e-21	Breast cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11747516	chr1:2518503	C1orf93	-0.46	-6.03	-0.31	4.17e-9	Systolic blood pressure;
LIHC	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg21605333	chr4:119757512	SEC24D	1.02	8.39	0.41	1.33e-15	Cannabis dependence symptom count;
LIHC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.75	11.44	0.53	6.88e-26	Corneal astigmatism;
LIHC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.63	10.52	0.49	1.27e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.61	7.28	0.37	2.36e-12	Cognitive function;
LIHC	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg06795125	chr2:108905320	SULT1C2	-0.31	-6.31	-0.32	8.83e-10	Blood pressure;
LIHC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.61	-0.38	2.62e-13	Chronic sinus infection;
LIHC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.59	-9.48	-0.46	4.54e-19	Urate levels in obese individuals;
LIHC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg07061783	chr6:25882402	NA	-0.43	-6.03	-0.31	4.14e-9	Blood metabolite levels;
LIHC	trans	rs7323507	0.636	rs2095531	chr13:110603337	A/G	cg04135558	chr15:50979175	TRPM7	0.36	6.04	0.31	4.1e-9	Lung function (FVC);
LIHC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	12.06	0.55	3.87e-28	Cognitive ability;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.98	-0.4	2.17e-14	Lymphocyte counts;
LIHC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.68	-10.86	-0.51	8.19e-24	Monocyte percentage of white cells;
LIHC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.24	0.58	1.34e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs10213084	1.000	rs28477577	chr4:147495971	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.92	-0.35	2.18e-11	Prevalent atrial fibrillation;
LIHC	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.62	11.29	0.52	2.48e-25	Neurofibrillary tangles;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.54	0.38	4.31e-13	Prudent dietary pattern;
LIHC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	9.98	0.47	9.58e-21	Bipolar disorder and schizophrenia;
LIHC	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.72	0.34	7.8e-11	Ulcerative colitis;
LIHC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.67	-11.64	-0.53	1.27e-26	Platelet distribution width;
LIHC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.49	6.51	0.33	2.67e-10	Major depressive disorder;
LIHC	trans	rs1974653	0.781	rs175166	chr22:20116182	G/T	cg20152630	chr19:46405944	MYPOP	-0.48	-6.25	-0.32	1.19e-9	Schizophrenia;
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.65	11.11	0.52	1.07e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.44	0.37	8.24e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs922107	0.846	rs9428043	chr1:90005132	T/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.51	-0.38	5.27e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.7	11.39	0.52	1.08e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.64	9.79	0.47	4.11e-20	Height;
LIHC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.44	-8.34	-0.41	1.87e-15	Neurofibrillary tangles;
LIHC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.59	-0.69	8.81e-50	Height;
LIHC	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.85	0.47	2.53e-20	Corneal astigmatism;
LIHC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.29	-0.55	5.27e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs77861329	1.000	rs6781635	chr3:52125343	A/G	cg08692210	chr3:52188851	WDR51A	0.81	7.89	0.39	4.22e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.41	-5.72	-0.3	2.37e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.86	0.57	3.82e-31	Prudent dietary pattern;
LIHC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23485639	chr6:28045615	ZNF165	-0.44	-5.88	-0.3	9.84e-9	Depression;
LIHC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.68	11.26	0.52	3.26e-25	Menopause (age at onset);
LIHC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.37	-5.99	-0.31	5.26e-9	Vitiligo;
LIHC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-6.82	-0.35	4.26e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.72	0.65	2.8e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg05484376	chr2:27715224	FNDC4	0.38	6.41	0.33	4.96e-10	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.38	6.18	0.32	1.82e-9	Menopause (age at onset);
LIHC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.8	9.17	0.44	4.54e-18	Initial pursuit acceleration;
LIHC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.68	-9.48	-0.46	4.57e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07080220	chr10:102295463	HIF1AN	0.45	6.13	0.31	2.39e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs546131	0.642	rs61881104	chr11:34838383	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.49	-0.33	3.05e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.55	7.32	0.37	1.76e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.81	11.26	0.52	3.03e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg23091122	chr1:110024289	SYPL2	-0.46	-6.06	-0.31	3.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22509189	chr2:225307070	NA	-0.49	-7.28	-0.37	2.37e-12	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.18	-0.61	3.33e-36	Alzheimer's disease;
LIHC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.5	0.33	2.86e-10	Bipolar disorder;
LIHC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg15123519	chr2:136567270	LCT	-0.44	-9.07	-0.44	9.38e-18	Mosquito bite size;
LIHC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg22800045	chr5:56110881	MAP3K1	-0.57	-6.77	-0.34	5.63e-11	Initial pursuit acceleration;
LIHC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12463550	chr7:65579703	CRCP	0.69	7.33	0.37	1.68e-12	Diabetic kidney disease;
LIHC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg13145458	chr22:31556086	RNF185	0.46	6.43	0.33	4.28e-10	Paclitaxel-induced neuropathy;
LIHC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.68	-0.34	9.57e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.697	rs239195	chr6:101132368	T/C	cg09795085	chr6:101329169	ASCC3	0.45	6.08	0.31	3.18e-9	Neuroticism;
LIHC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg25894440	chr7:65020034	NA	-0.52	-6.07	-0.31	3.44e-9	Diabetic kidney disease;
LIHC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg22633049	chr21:46681294	NA	-0.37	-6.26	-0.32	1.12e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.44	0.56	1.41e-29	Prudent dietary pattern;
LIHC	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.78	0.6	1.17e-34	Coffee consumption (cups per day);
LIHC	trans	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.42	-6.18	-0.32	1.87e-9	Endometrial cancer;
LIHC	cis	rs12079745	0.793	rs12074013	chr1:169133621	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.68	-6.43	-0.33	4.3e-10	QT interval;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg27130769	chr7:5417105	TNRC18	-0.41	-6.23	-0.32	1.35e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.92	-0.51	5.28e-24	Alzheimer's disease (late onset);
LIHC	cis	rs887797	0.557	rs8079198	chr17:64588496	T/C	cg27019712	chr17:64599478	PRKCA	-0.4	-6.85	-0.35	3.47e-11	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	19.29	0.72	1.3e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-15.25	-0.64	2.01e-40	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.43	5.72	0.3	2.35e-8	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.69	-8.27	-0.41	2.97e-15	Neuroticism;
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.49	-8.49	-0.42	6.44e-16	Total body bone mineral density;
LIHC	cis	rs11603020	0.950	rs78624400	chr11:57375463	G/C	cg19752551	chr11:57585705	CTNND1	-0.47	-6.07	-0.31	3.4e-9	Blood protein levels;
LIHC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-6.84	-0.35	3.56e-11	Longevity;
LIHC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	7.41	0.37	9.69e-13	Schizophrenia;
LIHC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.68	0.46	9.54e-20	Platelet count;
LIHC	cis	rs6782228	0.606	rs2712417	chr3:128345179	A/G	cg16766828	chr3:128327626	NA	-0.41	-6.54	-0.33	2.25e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg24130564	chr14:104152367	KLC1	0.37	6.22	0.32	1.47e-9	Schizophrenia;
LIHC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg06238570	chr21:40685208	BRWD1	0.59	7.07	0.36	8.98e-12	Cognitive function;
LIHC	cis	rs12220238	0.915	rs11000988	chr10:76073723	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs965469	1.000	rs6037553	chr20:3313884	A/G	cg25506879	chr20:3388711	C20orf194	-0.6	-6.88	-0.35	2.84e-11	IFN-related cytopenia;
LIHC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24110177	chr3:50126178	RBM5	-0.46	-7.23	-0.36	3.19e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	1.000	rs6546836	chr2:73677833	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.51	-0.33	2.65e-10	Metabolite levels;
LIHC	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg25114630	chr15:101792522	CHSY1	-0.55	-6.89	-0.35	2.62e-11	Corneal structure;
LIHC	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.13	-14.05	-0.6	1.02e-35	Ulcerative colitis;
LIHC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.36	-5.91	-0.3	8.4e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg12798992	chr6:167411361	FGFR1OP	0.55	8.6	0.42	2.91e-16	Crohn's disease;
LIHC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.92	0.39	3.42e-14	Morning vs. evening chronotype;
LIHC	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.3	7.05	0.36	1.01e-11	Adiponectin levels;
LIHC	cis	rs6066825	0.606	rs4810830	chr20:47219740	T/C	cg18078177	chr20:47281410	PREX1	0.49	8.13	0.4	7.76e-15	Colorectal cancer;
LIHC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.42	9.06	0.44	1.05e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.09	9.85	0.47	2.66e-20	Diabetic retinopathy;
LIHC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg07451762	chr16:28383216	NA	0.32	5.98	0.31	5.51e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.58	7.29	0.37	2.14e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.87	10.96	0.51	3.84e-24	Mean platelet volume;
LIHC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.71	10.58	0.5	8.11e-23	Aortic root size;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.5	0.33	2.88e-10	Prudent dietary pattern;
LIHC	cis	rs7818688	0.697	rs17665737	chr8:95986306	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	6.35	0.32	6.81e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg03037974	chr15:76606532	NA	-0.59	-9.9	-0.47	1.81e-20	Blood metabolite levels;
LIHC	cis	rs1000083	0.605	rs1423499	chr5:96534195	A/G	ch.5.96698337R	chr5:96672581	NA	0.56	6.23	0.32	1.36e-9	Cisplatin-induced ototoxicity;
LIHC	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg06795125	chr2:108905320	SULT1C2	0.31	6.13	0.31	2.4e-9	Blood pressure;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.43	0.45	6.24e-19	Lymphocyte counts;
LIHC	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.81	-0.35	4.3e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.52	7.73	0.39	1.17e-13	Renal cell carcinoma;
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.21	-0.45	3.45e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.81	-12.69	-0.57	1.65e-30	Total body bone mineral density;
LIHC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.85	-0.39	5.42e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-12.63	-0.56	2.93e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.29	0.32	9.59e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.32e-10	Alzheimer's disease;
LIHC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.72	-6.84	-0.35	3.73e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00798850	chr10:35625974	CCNY	0.55	6.85	0.35	3.38e-11	Hepatitis;
LIHC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.52	-9.41	-0.45	7.7e-19	Lung cancer;
LIHC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-12.5	-0.56	8.97e-30	Vitiligo;
LIHC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.76	15.54	0.64	1.38e-41	Menopause (age at onset);
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.53	-0.42	4.94e-16	Renal cell carcinoma;
LIHC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	14.82	0.63	9.64e-39	Menopause (age at onset);
LIHC	trans	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.59	6.71	0.34	8.15e-11	Neutrophil percentage of white cells;
LIHC	cis	rs2834256	0.847	rs3827181	chr21:35107734	C/T	cg14850771	chr21:34775459	IFNGR2	0.4	6.04	0.31	4.1e-9	Red cell distribution width;
LIHC	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.85	-9.76	-0.47	5.14e-20	Alzheimer's disease (late onset);
LIHC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg16586182	chr3:47516702	SCAP	-0.43	-7.62	-0.38	2.5e-13	Colorectal cancer;
LIHC	cis	rs2637266	0.626	rs2583069	chr10:78546775	T/C	cg18941641	chr10:78392320	NA	0.29	6.16	0.32	2.03e-9	Pulmonary function;
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-8.97	-0.44	2.02e-17	Menopause (age at onset);
LIHC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.43	6.6	0.34	1.59e-10	Iron status biomarkers;
LIHC	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.28	5.77	0.3	1.81e-8	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.48	-7.33	-0.37	1.68e-12	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.57	0.33	1.86e-10	Axial length;
LIHC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg14067834	chr17:29058358	SUZ12P	0.65	6.69	0.34	9.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.49	-0.33	2.94e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17250947	chr3:42642016	NKTR	0.41	6.05	0.31	3.78e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.42	-8.07	-0.4	1.18e-14	Lung cancer;
LIHC	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.57	-8.72	-0.43	1.24e-16	Pediatric autoimmune diseases;
LIHC	cis	rs3015497	0.616	rs11157759	chr14:51087263	A/G	cg09863266	chr14:51125203	SAV1	-0.38	-6.11	-0.31	2.73e-9	Mean platelet volume;
LIHC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg00750074	chr16:89608354	SPG7	-0.49	-7.96	-0.4	2.5e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-5.82	-0.3	1.39e-8	Renal cell carcinoma;
LIHC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.63	11.29	0.52	2.45e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg03999872	chr20:62272968	STMN3	0.46	6.84	0.35	3.6e-11	Atopic dermatitis;
LIHC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg06466757	chr4:1255808	NA	0.34	5.73	0.3	2.25e-8	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.65	9.67	0.46	1.06e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.34	-5.82	-0.3	1.33e-8	Coronary artery disease;
LIHC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.53	-9.34	-0.45	1.27e-18	Diastolic blood pressure;
LIHC	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.83	-0.3	1.27e-8	Biliary atresia;
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.95	-0.39	2.76e-14	Obesity-related traits;
LIHC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg04756594	chr16:24857601	SLC5A11	0.48	7.46	0.37	7.15e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs55702914	0.625	rs787989	chr2:198200123	G/A	cg10820045	chr2:198174542	NA	-0.4	-5.99	-0.31	5.39e-9	Major depression and alcohol dependence;
LIHC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.93	0.35	2.12e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs12464559	0.579	rs59444636	chr2:152526675	C/A	cg01189475	chr2:152685088	ARL5A	-0.69	-8.39	-0.41	1.32e-15	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg17623882	chr6:41773611	USP49	-0.44	-5.85	-0.3	1.15e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.4	0.33	5.2e-10	Lung cancer in ever smokers;
LIHC	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg27205649	chr11:78285834	NARS2	0.46	7.03	0.36	1.12e-11	Alzheimer's disease (survival time);
LIHC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	9.65	0.46	1.24e-19	Resting heart rate;
LIHC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	11.4	0.52	1.01e-25	Menarche (age at onset);
LIHC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.68	0.34	9.67e-11	Bipolar disorder;
LIHC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.01	-0.31	4.75e-9	Blood metabolite levels;
LIHC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg09033563	chr22:24373618	LOC391322	0.52	6.75	0.34	6.38e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.46	6.26	0.32	1.17e-9	Tonsillectomy;
LIHC	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.7	7.36	0.37	1.36e-12	Blood protein levels;
LIHC	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.39	-7.49	-0.38	5.79e-13	Height;
LIHC	cis	rs10508774	1.000	rs11812263	chr10:32958312	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.86	0.3	1.11e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.26	0.45	2.24e-18	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10354764	chr16:3285464	ZNF200	0.44	6.62	0.34	1.38e-10	Pancreatic cancer;
LIHC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.51	8.65	0.42	2.1e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg14580859	chr9:123691850	NA	0.38	6.63	0.34	1.3100000000000001e-10	Rheumatoid arthritis;
LIHC	trans	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.09e-10	Aortic root size;
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.74	13.22	0.58	1.66e-32	Prudent dietary pattern;
LIHC	trans	rs4356975	0.563	rs6600893	chr4:69978901	A/G	cg18043070	chr17:72199725	RPL38	-0.39	-6.04	-0.31	4.12e-9	Obesity-related traits;
LIHC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs970821	0.667	rs2385506	chr8:124744604	C/T	cg00283535	chr8:124749564	ANXA13	0.42	7.7	0.38	1.46e-13	Breast cancer;
LIHC	cis	rs11098699	0.821	rs7684799	chr4:124207659	C/T	cg09941581	chr4:124220074	SPATA5	0.33	6.52	0.33	2.57e-10	Mosquito bite size;
LIHC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.43e-23	Personality dimensions;
LIHC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.6	10.23	0.48	1.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg20607798	chr8:58055168	NA	0.59	6.8	0.35	4.58e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	20.09	0.74	8.03e-60	Colorectal cancer;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg17428694	chr1:163291564	NUF2	0.54	6.47	0.33	3.4e-10	Glycated hemoglobin levels;
LIHC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.69	13.52	0.59	1.14e-33	Menopause (age at onset);
LIHC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.72	-12.39	-0.56	2.31e-29	Menopause (age at onset);
LIHC	cis	rs2386661	0.523	rs2386663	chr10:5652739	C/T	cg17085576	chr10:5658249	NA	-0.3	-5.85	-0.3	1.15e-8	Breast cancer;
LIHC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-5.95	-0.31	6.69e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.3	5.79	0.3	1.64e-8	Birth weight;
LIHC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg00204512	chr16:28754710	NA	0.41	6.98	0.35	1.52e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.53e-12	Personality dimensions;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07763516	chr16:71496321	ZNF23	0.44	6.24	0.32	1.26e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg20302533	chr7:39170763	POU6F2	0.38	7.02	0.35	1.22e-11	IgG glycosylation;
LIHC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.35	-5.88	-0.3	9.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.82	-13.74	-0.6	1.65e-34	Aortic root size;
LIHC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.39	-6.13	-0.31	2.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9322817	0.691	rs9404586	chr6:105332814	A/G	cg02098413	chr6:105308735	HACE1	0.4	7.57	0.38	3.47e-13	Thyroid stimulating hormone;
LIHC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg03721293	chr16:90014378	DEF8	0.37	6.45	0.33	3.91e-10	Skin colour saturation;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.47	-7.0	-0.35	1.35e-11	HDL cholesterol;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.45	-0.53	6.37e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.45	6.57	0.33	1.87e-10	Birth weight;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07424592	chr7:64974309	NA	-0.46	-6.91	-0.35	2.31e-11	Calcium levels;
LIHC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.37	-6.11	-0.31	2.78e-9	Menopause (age at onset);
LIHC	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg16275483	chr1:110013120	SYPL2	-0.47	-5.86	-0.3	1.09e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg20607798	chr8:58055168	NA	0.5	6.26	0.32	1.15e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.86	17.51	0.69	1.88e-49	Testicular germ cell tumor;
LIHC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	5.87	0.3	1.05e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.49	-7.74	-0.39	1.12e-13	Bone mineral density (spine);
LIHC	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	8.61	0.42	2.68e-16	HIV-1 control;
LIHC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.2	0.55	1.19e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.71	13.52	0.59	1.13e-33	Mortality in heart failure;
LIHC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.87	12.93	0.57	2.01e-31	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.78	10.47	0.49	1.91e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.86	-0.35	3.21e-11	Metabolite levels;
LIHC	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.44	-0.42	9.39e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11671005	0.656	rs73066228	chr19:59013196	A/G	cg25952890	chr19:58913133	NA	0.69	6.41	0.33	4.72e-10	Mean platelet volume;
LIHC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.75	11.61	0.53	1.76e-26	Body mass index;
LIHC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.55	-7.17	-0.36	4.65e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.15	-0.36	5.42e-12	Inflammatory bowel disease;
LIHC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.46	-0.46	5.02e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.8	-0.3	1.53e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.34	-7.05	-0.36	9.96e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	7.25	0.36	2.88e-12	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg08888203	chr3:10149979	C3orf24	0.45	5.88	0.3	9.54e-9	Alzheimer's disease;
LIHC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.38	-11.98	-0.54	7.33e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.37	-6.73	-0.34	7.14e-11	Aortic root size;
LIHC	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg20991723	chr1:152506922	NA	0.53	8.88	0.43	3.78e-17	Hair morphology;
LIHC	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.96	-10.46	-0.49	2.05e-22	Platelet distribution width;
LIHC	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.58	9.51	0.46	3.44e-19	Corneal astigmatism;
LIHC	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.92	18.98	0.72	2.16e-55	Bone mineral density;
LIHC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.67	-10.11	-0.48	3.36e-21	Parkinson's disease;
LIHC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	11.28	0.52	2.73e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12922317	0.964	rs12930612	chr16:12072203	G/A	cg09319797	chr16:12061715	TNFRSF17	0.41	7.11	0.36	6.7e-12	Schizophrenia;
LIHC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-8.17	-0.4	6.14e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.51	7.95	0.39	2.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.45	-9.06	-0.44	1.05e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg03037974	chr15:76606532	NA	-0.6	-9.99	-0.48	8.46e-21	Blood metabolite levels;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.6	0.34	1.59e-10	Ileal carcinoids;
LIHC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	9.54	0.46	2.88e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.34	7.53	0.38	4.47e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.49	-6.34	-0.32	7.44e-10	Type 2 diabetes;
LIHC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.31	7.21	0.36	3.65e-12	Crohn's disease;
LIHC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.88	-0.3	9.73e-9	Total body bone mineral density;
LIHC	cis	rs7546668	0.947	rs4645989	chr1:15850343	A/G	cg11706911	chr1:15910989	AGMAT	0.44	6.82	0.35	4.03e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-0.74	-8.15	-0.4	7.08e-15	Exhaled nitric oxide output;
LIHC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.78	10.57	0.5	8.71e-23	Coronary artery disease;
LIHC	cis	rs7116495	1.000	rs552966	chr11:71788217	A/C	cg26138937	chr11:71823887	C11orf51	-0.67	-6.76	-0.34	5.8200000000000003e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.71	8.55	0.42	4.28e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.29	6.13	0.31	2.37e-9	Pulmonary function;
LIHC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.49	8.64	0.42	2.14e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.46	0.49	2.04e-22	Diabetic retinopathy;
LIHC	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.74	-0.39	1.13e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-12.2	-0.55	1.15e-28	Refractive error;
LIHC	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.91	-0.3	8.3e-9	Coronary artery disease;
LIHC	cis	rs6788895	1.000	rs73005813	chr3:150525136	G/A	cg09723797	chr3:150481914	SIAH2	0.57	6.76	0.34	6.06e-11	Breast cancer;
LIHC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg24203234	chr3:128598194	ACAD9	0.44	6.2	0.32	1.61e-9	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14932796	chr17:55038330	COIL	0.47	7.05	0.36	9.85e-12	Pancreatic cancer;
LIHC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg06565975	chr8:143823917	SLURP1	0.33	6.28	0.32	1.01e-9	Urinary tract infection frequency;
LIHC	cis	rs4919087	0.590	rs1253400	chr10:99049566	G/A	cg25902810	chr10:99078978	FRAT1	-0.64	-7.02	-0.35	1.2e-11	Monocyte count;
LIHC	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.88	-7.9	-0.39	3.86e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.05e-8	Menopause (age at onset);
LIHC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.04	0.55	4.41e-28	Body mass index;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19259030	chr15:76553926	ETFA;TYRO3P	0.43	6.08	0.31	3.13e-9	Hepatitis;
LIHC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.73	-0.34	7.04e-11	Gut microbiome composition (summer);
LIHC	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.14	0.32	2.26e-9	Mean corpuscular volume;
LIHC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.88	0.47	2e-20	Platelet count;
LIHC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.96	0.51	3.72e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs6442522	0.606	rs12633820	chr3:15494002	C/T	cg16303742	chr3:15540471	COLQ	0.38	6.3	0.32	9.04e-10	Uric acid levels;
LIHC	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.38	6.44	0.33	4.13e-10	Educational attainment;
LIHC	cis	rs4450131	0.618	rs10736889	chr10:126338657	C/T	cg20435097	chr10:126320824	FAM53B	0.62	12.04	0.55	4.62e-28	White blood cell count (basophil);
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.72	-0.34	7.62e-11	Lymphocyte counts;
LIHC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.84	-14.87	-0.63	6.54e-39	Aortic root size;
LIHC	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg18081818	chr7:23246105	NA	-0.39	-5.75	-0.3	1.95e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.14	-0.32	2.27e-9	Tuberculosis;
LIHC	cis	rs55665837	0.665	rs11023273	chr11:14630819	G/A	cg00085434	chr11:14927489	NA	0.43	6.05	0.31	3.73e-9	Vitamin D levels;
LIHC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.69	12.59	0.56	4.11e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	0.71	9.2	0.45	3.6e-18	Blood pressure (smoking interaction);
LIHC	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-15.67	-0.65	4.15e-42	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.66	13.11	0.58	4.19e-32	High light scatter reticulocyte count;
LIHC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.51	7.04	0.36	1.08e-11	Aortic root size;
LIHC	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.16	-0.36	4.83e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs611744	0.905	rs610891	chr8:109161003	C/T	cg21045802	chr8:109455806	TTC35	-0.48	-8.08	-0.4	1.12e-14	Dupuytren's disease;
LIHC	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg27205649	chr11:78285834	NARS2	0.41	6.17	0.32	1.91e-9	Alzheimer's disease (survival time);
LIHC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	6.21	0.32	1.55e-9	Type 2 diabetes;
LIHC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.53	8.71	0.43	1.33e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.19	-0.32	1.73e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs288342	0.796	rs288347	chr2:183667642	C/G	cg02625481	chr2:183667124	NA	-0.31	-6.18	-0.32	1.8e-9	Recurrent major depressive disorder;
LIHC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.31	6.45	0.33	3.91e-10	Mean corpuscular volume;Mean platelet volume;
LIHC	trans	rs10805346	0.505	rs35995899	chr4:10112862	T/C	cg06175025	chr14:78082992	SPTLC2	-0.47	-6.88	-0.35	2.79e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LIHC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg15691649	chr6:25882328	NA	-0.42	-6.55	-0.33	2.08e-10	Height;
LIHC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	0.79	6.02	0.31	4.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.39	5.85	0.3	1.15e-8	Menarche (age at onset);
LIHC	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg22951263	chr5:87985283	NA	-0.4	-6.85	-0.35	3.42e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.31	6.41	0.33	4.87e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.55	-6.44	-0.33	4.01e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg11783602	chr8:55087084	NA	-0.3	-6.18	-0.32	1.82e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs1190552	0.761	rs1212691	chr14:102893272	T/C	cg10241871	chr14:102965420	TECPR2	0.41	6.04	0.31	3.94e-9	Blood protein levels;
LIHC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.31	0.55	4.45e-29	Electrocardiographic conduction measures;
LIHC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg05590025	chr7:65112418	INTS4L2	0.56	6.09	0.31	3.04e-9	Gout;
LIHC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-6.64	-0.34	1.25e-10	Morning vs. evening chronotype;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05792827	chr1:213224765	RPS6KC1	-0.49	-6.21	-0.32	1.57e-9	Systolic blood pressure;
LIHC	cis	rs10861342	0.892	rs7488014	chr12:105657527	C/T	cg23923672	chr12:105501055	KIAA1033	0.59	6.91	0.35	2.4e-11	IgG glycosylation;
LIHC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.39	8.1	0.4	1.01e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.34	0.58	5.79e-33	Cognitive test performance;
LIHC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.58	-7.52	-0.38	4.84e-13	Initial pursuit acceleration;
LIHC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.68e-27	Corneal astigmatism;
LIHC	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.48	6.12	0.31	2.6e-9	Panic disorder;
LIHC	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg04454073	chr16:22207163	NA	0.34	5.87	0.3	1.04e-8	Schizophrenia;
LIHC	cis	rs11212260	0.655	rs11212241	chr11:107313894	C/T	cg25435332	chr11:107328525	CWF19L2	0.82	8.32	0.41	2.13e-15	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16725865	chr1:92546135	BTBD8	0.45	6.82	0.35	4.1e-11	Pancreatic cancer;
LIHC	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-5.76	-0.3	1.88e-8	Blood metabolite levels;
LIHC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.52	8.6	0.42	2.94e-16	Obesity-related traits;
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.37	5.76	0.3	1.87e-8	Testicular germ cell tumor;
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.69	9.4	0.45	8.19e-19	Aortic root size;
LIHC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.49	0.38	5.75e-13	Aortic root size;
LIHC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.75	0.3	1.99e-8	Electroencephalogram traits;
LIHC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.52	-7.98	-0.4	2.2e-14	Bone mineral density (spine);
LIHC	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02985541	chr2:219472218	PLCD4	0.41	7.21	0.36	3.65e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.77	-12.11	-0.55	2.55e-28	Corneal astigmatism;
LIHC	cis	rs9914988	0.606	rs968726	chr17:27194634	A/G	cg20469991	chr17:27169893	C17orf63	-0.49	-6.21	-0.32	1.53e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.25	0.45	2.44e-18	Schizophrenia;
LIHC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-6.16	-0.32	2e-9	Testicular germ cell tumor;
LIHC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg19645103	chr12:69753606	YEATS4	-0.44	-5.81	-0.3	1.44e-8	Response to diuretic therapy;
LIHC	cis	rs922107	0.738	rs12729983	chr1:90046593	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.77	-0.39	9.31e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.55	-6.05	-0.31	3.74e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg01017244	chr2:74357527	NA	0.63	11.3	0.52	2.33e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg23625390	chr15:77176239	SCAPER	0.36	5.84	0.3	1.2e-8	Blood metabolite levels;
LIHC	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.49	6.28	0.32	1.01e-9	Type 2 diabetes;
LIHC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg16479474	chr6:28041457	NA	0.38	6.24	0.32	1.29e-9	Parkinson's disease;
LIHC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.66	-11.06	-0.51	1.69e-24	Childhood ear infection;
LIHC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.74	-8.95	-0.44	2.37e-17	Systemic lupus erythematosus;
LIHC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.73	-10.96	-0.51	3.81e-24	Aortic root size;
LIHC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg07133347	chr1:107600762	PRMT6	0.42	6.24	0.32	1.31e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg18478394	chr8:109455254	TTC35	0.4	6.89	0.35	2.66e-11	Dupuytren's disease;
LIHC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.77	11.66	0.53	1.15e-26	Coronary artery disease;
LIHC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	0.9	16.17	0.66	4.58e-44	Bone mineral density;
LIHC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.76	10.63	0.5	5.45e-23	Blood metabolite levels;
LIHC	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg17623882	chr6:41773611	USP49	-0.44	-5.85	-0.3	1.15e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.4	-6.27	-0.32	1.08e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-0.59	-7.8	-0.39	7.37e-14	Lung cancer;
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.36	-0.37	1.36e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.48	7.99	0.4	2.05e-14	Vitiligo;
LIHC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21448741	chr8:58168803	NA	0.33	6.64	0.34	1.26e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6564851	0.545	rs12149068	chr16:81252903	T/G	cg00908271	chr16:81254010	PKD1L2	-0.36	-7.57	-0.38	3.44e-13	Carotenoid and tocopherol levels;
LIHC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.74	13.64	0.59	3.84e-34	Height;
LIHC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.76	11.41	0.52	9.33e-26	Coronary artery disease;
LIHC	cis	rs55702914	0.839	rs2059922	chr2:198188903	C/G	cg10820045	chr2:198174542	NA	-0.41	-5.99	-0.31	5.17e-9	Major depression and alcohol dependence;
LIHC	cis	rs62117911	1	rs62117911	chr19:16241886	G/A	cg07665718	chr19:16244068	HSH2D;RAB8A	0.53	6.77	0.34	5.59e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.48	-0.73	2.21e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.64	-0.34	1.21e-10	Total body bone mineral density;
LIHC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.82	0.35	4.1e-11	Gut microbiome composition (summer);
LIHC	cis	rs1400745	0.729	rs28472856	chr14:35332157	C/T	cg16230307	chr14:35515116	FAM177A1	0.38	6.19	0.32	1.71e-9	Monocyte count;
LIHC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.41	8.28	0.41	2.85e-15	Cognitive function;
LIHC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.02	0.35	1.21e-11	Aortic root size;
LIHC	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.42	6.28	0.32	1.03e-9	Menopause (age at onset);
LIHC	trans	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.14	0.32	2.26e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	12.27	0.55	6.48e-29	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs1432089	0.773	rs28376254	chr4:171785696	G/A	cg02328223	chr3:127541927	MGLL	-0.41	-6.04	-0.31	3.98e-9	Endometriosis;
LIHC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.59	-8.08	-0.4	1.14e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.29	6.76	0.34	5.98e-11	Crohn's disease;
LIHC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.33e-12	Bipolar disorder;
LIHC	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.88	0.35	2.9e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg02023728	chr11:77925099	USP35	-0.32	-5.92	-0.3	8.02e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg09033563	chr22:24373618	LOC391322	-0.45	-6.1	-0.31	2.82e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs4698048	0.510	rs12509714	chr4:10107091	C/G	cg06175025	chr14:78082992	SPTLC2	-0.41	-6.08	-0.31	3.17e-9	Skin aging (microtopography measurement);
LIHC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg08499158	chr17:42289980	UBTF	0.47	7.64	0.38	2.18e-13	Total body bone mineral density;
LIHC	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg13482628	chr17:19912719	NA	0.49	7.98	0.4	2.24e-14	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00593699	chr11:472782	PTDSS2	0.41	6.1	0.31	2.83e-9	Longevity;
LIHC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.15	10.7	0.5	3.08e-23	Diabetic retinopathy;
LIHC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg14393609	chr7:65229607	NA	-0.41	-6.32	-0.32	8.1e-10	Aortic root size;
LIHC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	1.01	10.03	0.48	6.25e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7523273	0.565	rs2761420	chr1:207889368	G/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-7.94	-0.39	3e-14	Schizophrenia;
LIHC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.46	-7.6	-0.38	2.8e-13	Fibrinogen levels;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg24930797	chr15:66083595	DENND4A	-0.54	-6.06	-0.31	3.58e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.79	-0.34	4.83e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	0.38	6.12	0.31	2.63e-9	Coronary artery disease;
LIHC	cis	rs7116495	0.867	rs513292	chr11:71573771	C/G	cg26138937	chr11:71823887	C11orf51	0.71	6.88	0.35	2.81e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20307385	chr11:47447363	PSMC3	-0.45	-5.89	-0.3	9.14e-9	Subjective well-being;
LIHC	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.48	-7.24	-0.36	2.96e-12	Thyroid stimulating hormone;
LIHC	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.55	0.33	2.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.09	-0.4	1.08e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.6	-8.21	-0.41	4.66e-15	Waist circumference;Body mass index;
LIHC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	1.0	11.01	0.51	2.48e-24	Triglycerides;
LIHC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	5.98	0.31	5.71e-9	Schizophrenia;
LIHC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.34	6.84	0.35	3.74e-11	Multiple sclerosis;
LIHC	cis	rs7106204	0.748	rs36092013	chr11:24211987	C/T	ch.11.24196551F	chr11:24239977	NA	0.76	10.13	0.48	2.98e-21	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs11233413	0.874	rs3793987	chr11:82704968	A/T	cg24227371	chr11:82718527	RAB30	-0.32	-6.79	-0.34	4.88e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.36	6.06	0.31	3.56e-9	Height;
LIHC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.4	-6.38	-0.33	5.74e-10	Menarche (age at onset);
LIHC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg14440974	chr22:39074834	NA	-0.36	-5.97	-0.31	5.9e-9	Menopause (age at onset);
LIHC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.73	0.3	2.16e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.27e-9	Glomerular filtration rate (creatinine);
LIHC	trans	rs2363709	1.000	rs4241438	chr3:67425727	A/G	cg25028035	chr6:42016671	CCND3	-0.84	-6.07	-0.31	3.44e-9	IgE levels;
LIHC	trans	rs10448080	0.959	rs4732873	chr8:28601554	A/C	cg07469555	chr8:22423055	SORBS3	0.45	6.14	0.32	2.35e-9	Height;
LIHC	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg20129853	chr10:51489980	NA	0.42	9.0	0.44	1.63e-17	Prostate-specific antigen levels;
LIHC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.48	-0.38	6.16e-13	Chronic sinus infection;
LIHC	cis	rs9918079	0.560	rs10008975	chr4:15624571	C/T	cg16509355	chr4:15471240	CC2D2A	-0.45	-7.07	-0.36	8.72e-12	Obesity-related traits;
LIHC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.37	6.35	0.32	6.78e-10	Alzheimer's disease (late onset);
LIHC	cis	rs16912285	0.585	rs11027807	chr11:24346556	G/T	ch.11.24196551F	chr11:24239977	NA	0.68	7.75	0.39	1.09e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.23	-0.55	8.76e-29	Colorectal cancer;
LIHC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.69	10.21	0.48	1.52e-21	Aortic root size;
LIHC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	6.99	0.35	1.46e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.73	6.53	0.33	2.41e-10	IgG glycosylation;
LIHC	cis	rs12144094	0.882	rs12127451	chr1:120227630	C/A	cg20995928	chr1:120229863	NA	0.37	6.26	0.32	1.16e-9	Height;
LIHC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.36	6.96	0.35	1.73e-11	Multiple system atrophy;
LIHC	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.61	-0.34	1.5e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.5	6.07	0.31	3.44e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg26597838	chr10:835615	NA	1.51	14.64	0.62	5.14e-38	Eosinophil percentage of granulocytes;
LIHC	cis	rs4474465	0.833	rs6592792	chr11:78271614	A/C	cg02023728	chr11:77925099	USP35	-0.37	-6.21	-0.32	1.55e-9	Alzheimer's disease (survival time);
LIHC	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07791762	chr19:17323290	MYO9B	0.37	6.12	0.31	2.63e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.8	-0.3	1.5e-8	Personality dimensions;
LIHC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.81	0.39	7.16e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	1.05	15.71	0.65	2.87e-42	Breast cancer;
LIHC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg07706471	chr12:123319906	HIP1R	-0.62	-8.2	-0.41	4.94e-15	Schizophrenia;
LIHC	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg12698662	chr3:15914712	MIR563	-0.39	-7.15	-0.36	5.35e-12	Mean platelet volume;
LIHC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.58	8.04	0.4	1.49e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.41	5.92	0.3	7.76e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg23461800	chr14:103021989	NA	0.45	6.31	0.32	8.6e-10	Platelet count;
LIHC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.65	12.97	0.57	1.46e-31	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14990712	chr19:4055085	ZBTB7A	0.45	6.77	0.34	5.53e-11	Bilirubin levels;
LIHC	cis	rs11098699	0.821	rs2047584	chr4:124232182	A/T	cg09941581	chr4:124220074	SPATA5	0.33	6.55	0.33	2.07e-10	Mosquito bite size;
LIHC	cis	rs2108622	0.727	rs62106155	chr19:15980360	G/C	cg13772218	chr19:15982569	NA	0.37	7.82	0.39	6.59e-14	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06446895	chr17:79829189	ARHGDIA	-0.46	-6.6	-0.34	1.61e-10	Cognitive function;
LIHC	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.72	-12.79	-0.57	6.97e-31	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs12752401	0.717	rs34542611	chr1:103028047	C/T	cg17681729	chr19:740608	PALM	0.45	6.29	0.32	9.58e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.48	-6.87	-0.35	2.96e-11	Asthma;
LIHC	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	0.7	7.84	0.39	5.97e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-8.25	-0.41	3.57e-15	Vitiligo;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg01423147	chr1:89458345	RBMXL1;CCBL2	-0.42	-6.04	-0.31	4.11e-9	Eotaxin levels;
LIHC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.96	-0.31	6.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.53	-0.53	3.3e-26	Chronic sinus infection;
LIHC	cis	rs7534824	0.625	rs61782081	chr1:101507074	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	7.46	0.37	7.21e-13	Refractive astigmatism;
LIHC	cis	rs1144333	0.850	rs1144342	chr1:76284364	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.74	-0.34	6.7e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.96	-0.35	1.7e-11	Diabetic kidney disease;
LIHC	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.36	-0.61	6.62e-37	Systemic lupus erythematosus;
LIHC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg16586182	chr3:47516702	SCAP	0.4	6.71	0.34	8.29e-11	Birth weight;
LIHC	cis	rs4728302	0.807	rs10226267	chr7:133601862	G/A	cg10665199	chr7:133106180	EXOC4	0.39	6.83	0.35	3.86e-11	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.69	-8.75	-0.43	9.82e-17	Lung cancer (smoking interaction);
LIHC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg27494647	chr7:150038898	RARRES2	0.34	6.09	0.31	2.96e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7188697	0.922	rs37034	chr16:58551360	C/G	cg02549819	chr16:58548995	SETD6	-0.51	-7.88	-0.39	4.53e-14	QT interval;
LIHC	cis	rs986417	0.892	rs8017336	chr14:60798682	G/A	cg27398547	chr14:60952738	C14orf39	-0.72	-7.62	-0.38	2.47e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.57	9.77	0.47	4.67e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.46	-7.79	-0.39	7.95e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.56	9.15	0.44	5.27e-18	Lymphocyte counts;
LIHC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.47	6.88	0.35	2.95e-11	Multiple sclerosis;
LIHC	cis	rs7106204	0.748	rs4598670	chr11:24236524	G/A	ch.11.24196551F	chr11:24239977	NA	0.81	11.95	0.54	9.87e-28	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.29	-6.75	-0.34	6.35e-11	Menarche (age at onset);
LIHC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04219946	chr7:87104724	ABCB4	-0.38	-6.35	-0.32	6.96e-10	Parental extreme longevity (95 years and older);
LIHC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs7554547	0.667	rs2336377	chr1:11949970	A/G	cg07603449	chr1:11986842	KIAA2013	0.36	6.22	0.32	1.49e-9	Nonsyndromic cleft lip with cleft palate;
LIHC	cis	rs9948	1.000	rs58147284	chr2:97508082	G/C	cg01990225	chr2:97406019	LMAN2L	-0.59	-5.99	-0.31	5.19e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg17135325	chr3:160939158	NMD3	-0.49	-6.53	-0.33	2.38e-10	Parkinson's disease;
LIHC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg02269571	chr22:50332266	NA	-0.6	-8.57	-0.42	3.49e-16	Schizophrenia;
LIHC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.74	-0.3	2.09e-8	Blood protein levels;
LIHC	cis	rs2033908	0.619	rs10765994	chr11:12850819	A/G	cg25843174	chr11:12811716	TEAD1	0.33	7.48	0.38	6.18e-13	Sitting height ratio;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg00091569	chr3:40428383	ENTPD3	0.41	6.98	0.35	1.5e-11	Renal cell carcinoma;
LIHC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.96	17.4	0.69	5.04e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.17	-0.44	4.45e-18	Neutrophil count;
LIHC	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg17410650	chr12:54324560	NA	-0.4	-7.22	-0.36	3.4e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.8	0.47	3.71e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	13.64	0.59	4.1e-34	Bipolar disorder;
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	11.07	0.51	1.46e-24	Prudent dietary pattern;
LIHC	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.36	-0.33	6.61e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg25894440	chr7:65020034	NA	0.53	6.15	0.32	2.16e-9	Diabetic kidney disease;
LIHC	trans	rs10242455	0.571	rs73713595	chr7:99326659	G/A	cg09045935	chr12:6379348	NA	0.73	6.07	0.31	3.48e-9	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg07424592	chr7:64974309	NA	0.83	9.5	0.46	3.78e-19	Diabetic kidney disease;
LIHC	cis	rs507080	0.733	rs541631	chr11:118571023	A/G	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17017152	chr1:61547389	NFIA	0.47	6.15	0.32	2.12e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.81	-0.3	1.46e-8	Personality dimensions;
LIHC	trans	rs214034	0.825	rs7566260	chr2:17875837	T/C	cg09061216	chr1:1558936	MIB2	0.51	6.04	0.31	4.01e-9	Response to amphetamines;
LIHC	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	6.7	0.34	8.71e-11	Multiple sclerosis;
LIHC	cis	rs7542375	0.507	rs2784270	chr1:221094967	C/T	cg16008148	chr1:221062819	NA	-0.3	-6.47	-0.33	3.42e-10	Obesity-related traits;
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.8	0.39	7.44e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.69	11.41	0.52	9.23e-26	Menopause (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02873242	chr5:154134737	LARP1	0.49	6.24	0.32	1.3e-9	Hepatitis;
LIHC	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.45	8.79	0.43	7.27e-17	Testicular germ cell tumor;
LIHC	cis	rs6876835	0.511	rs56874700	chr5:6597898	A/G	cg04204831	chr5:6583394	LOC255167	0.42	6.51	0.33	2.65e-10	Visceral fat;
LIHC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.6	0.34	1.56e-10	Mean corpuscular volume;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg07755735	chr2:20870362	GDF7	-0.44	-9.08	-0.44	8.71e-18	Abdominal aortic aneurysm;
LIHC	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.36	-6.45	-0.33	3.73e-10	IgG glycosylation;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01430372	chr17:38976870	TMEM99;KRT10	0.24	6.34	0.32	7.18e-10	Longevity;
LIHC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg18944383	chr4:111397179	ENPEP	0.26	6.42	0.33	4.44e-10	Coronary artery disease;
LIHC	cis	rs655641	0.954	rs3016327	chr11:85780448	T/C	cg09030501	chr11:85779252	PICALM	-0.51	-6.01	-0.31	4.83e-9	Platelet count;
LIHC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.93	-0.35	2.09e-11	Response to antipsychotic treatment;
LIHC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-8.9	-0.43	3.4e-17	Chronic sinus infection;
LIHC	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.28	-0.32	1.03e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.03e-8	Tonsillectomy;
LIHC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.85	-0.51	8.78e-24	Bipolar disorder and schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07120806	chr4:1873451	WHSC1	-0.5	-6.4	-0.33	5.12e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.37	0.56	2.73e-29	Electrocardiographic conduction measures;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12112058	chr1:224622605	WDR26	0.49	7.2	0.36	3.93e-12	Pancreatic cancer;
LIHC	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.47	6.44	0.33	4.01e-10	Inflammatory skin disease;
LIHC	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.82	-0.3	1.34e-8	Biliary atresia;
LIHC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg09417038	chr21:47716443	C21orf57	-0.58	-8.82	-0.43	5.79e-17	Testicular germ cell tumor;
LIHC	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg15841412	chr13:111365552	ING1	-0.52	-6.36	-0.33	6.45e-10	Coronary artery disease;
LIHC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.43	6.16	0.32	2.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg25894440	chr7:65020034	NA	0.54	6.22	0.32	1.43e-9	Diabetic kidney disease;
LIHC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	trans	rs4714291	0.925	rs847755	chr6:40030378	T/C	cg02267698	chr19:7991119	CTXN1	0.39	6.21	0.32	1.51e-9	Strep throat;
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-7.52	-0.38	4.74e-13	Lymphocyte counts;
LIHC	cis	rs2191566	0.747	rs4803667	chr19:44533604	T/C	cg20607764	chr19:44506953	ZNF230	-0.42	-6.81	-0.35	4.48e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.87	-0.35	2.96e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.26	0.55	7.01e-29	Cognitive test performance;
LIHC	trans	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg10208301	chr11:6592745	DNHD1	0.45	6.58	0.34	1.74e-10	Coronary artery calcification;
LIHC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg20933634	chr6:27740509	NA	0.47	6.19	0.32	1.69e-9	Parkinson's disease;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.01	-0.31	4.8e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.52	-7.0	-0.35	1.35e-11	Narcolepsy;
LIHC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg16586182	chr3:47516702	SCAP	0.6	11.82	0.54	2.88e-27	Colorectal cancer;
LIHC	trans	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg10756647	chr7:56101905	PSPH	0.63	8.64	0.42	2.14e-16	Corneal structure;
LIHC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.57	7.03	0.36	1.11e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.59	8.8	0.43	6.78e-17	Recombination rate (females);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07474076	chr16:2972993	FLYWCH1	0.59	7.39	0.37	1.17e-12	Hepatitis;
LIHC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.76	13.99	0.6	1.82e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.56	10.95	0.51	3.94e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.31	6.39	0.33	5.4e-10	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg06050784	chr16:88016603	BANP	0.37	6.65	0.34	1.17e-10	Menopause (age at onset);
LIHC	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg06533319	chr4:3265114	C4orf44	0.31	5.8	0.3	1.49e-8	Mean platelet volume;
LIHC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.06	-0.31	3.61e-9	Total body bone mineral density;
LIHC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.31	-6.25	-0.32	1.23e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs4453791	1.000	rs4453791	chr3:38882519	T/C	cg02254461	chr3:39195904	CSRNP1	0.66	5.88	0.3	9.58e-9	Social communication problems;
LIHC	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg22705602	chr4:152727874	NA	-0.34	-7.12	-0.36	6.24e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02179239	chr10:23002514	PIP4K2A	0.38	6.13	0.31	2.42e-9	Cognitive function;
LIHC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.36	-7.16	-0.36	4.98e-12	Colorectal cancer;
LIHC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg27490568	chr2:178487706	NA	0.38	6.05	0.31	3.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9783347	1.000	rs4150575	chr11:18356466	C/T	cg15585147	chr11:18324498	HPS5	0.42	6.7	0.34	8.6e-11	Pancreatic cancer;
LIHC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.2	0.41	4.77e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.58	10.15	0.48	2.51e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.94	0.35	1.93e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.44	-7.16	-0.36	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.3	-6.95	-0.35	1.87e-11	Menarche (age at onset);
LIHC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	8.68	0.42	1.68e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.97	-0.31	5.96e-9	Longevity;
LIHC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02711726	chr17:80685570	FN3KRP	-0.46	-8.32	-0.41	2.07e-15	Glycated hemoglobin levels;
LIHC	trans	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.08	0.31	3.28e-9	Coronary artery calcification;
LIHC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.77	0.54	4.45e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9649465	1.000	rs13224762	chr7:123370710	A/G	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.25e-15	Migraine;
LIHC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1997066	0.920	rs7090127	chr10:106730305	C/G	cg21239439	chr6:170038665	WDR27	0.67	6.08	0.31	3.23e-9	Diabetic kidney disease;
LIHC	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg10820045	chr2:198174542	NA	0.54	8.75	0.43	1.01e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.67	8.44	0.42	9.3e-16	Gut microbiome composition (summer);
LIHC	cis	rs1712517	0.836	rs11191649	chr10:105067037	T/C	cg05636881	chr10:105038444	INA	0.44	6.9	0.35	2.61e-11	Migraine;
LIHC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.69	0.38	1.55e-13	Alzheimer's disease;
LIHC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.62	-7.95	-0.4	2.66e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10847980	0.590	rs77970074	chr12:123292186	T/G	cg25930673	chr12:123319894	HIP1R	1.09	11.71	0.53	7.46e-27	Adiponectin levels;
LIHC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg04727924	chr7:799746	HEATR2	0.41	6.17	0.32	1.94e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs2540917	0.728	rs11125839	chr2:60627401	G/C	cg00543073	chr2:60773386	BCL11A	-0.33	-6.57	-0.33	1.87e-10	Mean corpuscular volume;
LIHC	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg01843034	chr6:37503916	NA	-0.49	-7.94	-0.39	2.97e-14	Cognitive performance;
LIHC	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.89	-17.85	-0.69	7.8e-51	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08862778	chr1:11322643	MTOR	0.44	7.25	0.36	2.79e-12	Cognitive function;
LIHC	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.03	0.31	4.27e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.07	-0.48	4.77e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	7.06	0.36	9.17e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.83	-0.3	1.28e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.52	-7.86	-0.39	4.92e-14	Glomerular filtration rate (creatinine);
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-7.17	-0.36	4.74e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.61	-0.34	1.5e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs8081395	0.741	rs1292055	chr17:57959068	A/G	cg13753209	chr17:57696993	CLTC	0.38	5.74	0.3	2.08e-8	White blood cell count;
LIHC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.83	0.78	9.72e-71	Height;
LIHC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg20891558	chr2:74357851	NA	0.81	16.63	0.67	6.27e-46	Gestational age at birth (maternal effect);
LIHC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg06466757	chr4:1255808	NA	0.35	5.84	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.13	-0.31	2.46e-9	Mean corpuscular volume;
LIHC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg05343316	chr1:45956843	TESK2	-0.42	-6.2	-0.32	1.62e-9	High light scatter reticulocyte count;
LIHC	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.36	-8.26	-0.41	3.34e-15	Pediatric bone mineral content (femoral neck);
LIHC	trans	rs2211698	1.000	rs59785817	chr21:35835645	C/T	cg18044562	chr7:50468399	IKZF1	0.51	7.42	0.37	9.41e-13	Cancer;
LIHC	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.58	-8.85	-0.43	4.63e-17	Schizophrenia;
LIHC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06656553	chr16:89960601	TCF25	-0.49	-6.22	-0.32	1.46e-9	Skin colour saturation;
LIHC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg09182678	chr22:50328711	NA	-0.39	-5.82	-0.3	1.36e-8	Schizophrenia;
LIHC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg22532475	chr10:104410764	TRIM8	0.36	6.37	0.33	6.16e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs10761482	0.531	rs10740029	chr10:62238902	G/A	cg17314160	chr12:110399253	GIT2	-0.41	-6.13	-0.31	2.37e-9	Schizophrenia;
LIHC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg12373951	chr3:133503437	NA	0.46	7.65	0.38	2.07e-13	Iron status biomarkers;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17707966	chr8:144718525	ZNF623	0.39	6.25	0.32	1.19e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2073499	0.935	rs2526395	chr3:50188886	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-7.13	-0.36	5.94e-12	Schizophrenia;
LIHC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-6.17	-0.32	1.91e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.56	9.3	0.45	1.78e-18	Cognitive function;
LIHC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.55	6.54	0.33	2.27e-10	Bladder cancer;
LIHC	cis	rs903552	0.736	rs9806495	chr15:102008059	G/A	cg25677261	chr15:102009856	PCSK6	-0.53	-7.15	-0.36	5.45e-12	Diabetic kidney disease;
LIHC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.66	11.68	0.53	9.17e-27	Total body bone mineral density;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg12923728	chr3:195709715	SDHAP1	0.6	6.92	0.35	2.22e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg04317927	chr11:55418816	OR4S2	0.47	8.99	0.44	1.66e-17	Pediatric bone mineral density (spine);
LIHC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg11905131	chr22:24372483	LOC391322	-0.49	-5.85	-0.3	1.14e-8	Urinary 1,3-butadiene metabolite levels in smokers;
LIHC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs9596863	0.898	rs17088922	chr13:54375033	T/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.1e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.37	6.31	0.32	8.83e-10	Type 2 diabetes;
LIHC	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.35	7.88	0.39	4.52e-14	Educational attainment (years of education);
LIHC	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs8056893	0.842	rs4783553	chr16:68365955	A/G	cg02226672	chr16:68398533	SMPD3	-0.44	-6.01	-0.31	4.75e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25998860	chr5:126853954	PRRC1	0.51	7.3	0.37	2.09e-12	Pancreatic cancer;
LIHC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.05	0.36	1e-11	Hemoglobin concentration;
LIHC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.8	11.97	0.54	8.05e-28	Coronary artery disease;
LIHC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	12.19	0.55	1.23e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.91	9.23	0.45	2.82e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.35	-6.36	-0.33	6.34e-10	Aortic root size;
LIHC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.22	15.5	0.64	2.13e-41	Alzheimer's disease (late onset);
LIHC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.75	-0.3	1.94e-8	Blood pressure;
LIHC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-10.43	-0.49	2.67e-22	Platelet count;
LIHC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.63	0.34	1.3e-10	Rheumatoid arthritis;
LIHC	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14396892	chr9:96623032	NA	-0.32	-6.13	-0.31	2.37e-9	DNA methylation (variation);
LIHC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.17	-0.36	4.69e-12	Response to antipsychotic treatment;
LIHC	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.48	7.77	0.39	9.41e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.37e-9	Protein biomarker;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.84	0.78	8.76e-71	Height;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.61	-8.61	-0.42	2.71e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.28	-7.44	-0.37	8.06e-13	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-0.61	-7.76	-0.39	1.02e-13	Lung cancer;
LIHC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.27	0.45	2.15e-18	Bipolar disorder;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07959124	chr10:75006630	DNAJC9	-0.44	-6.36	-0.33	6.58e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23029715	chr19:42363959	RPS19	0.37	6.46	0.33	3.71e-10	Pancreatic cancer;
LIHC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06002616	chr8:101225028	SPAG1	0.36	6.25	0.32	1.24e-9	Atrioventricular conduction;
LIHC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13126279	chr21:47581558	C21orf56	-0.39	-6.0	-0.31	5.06e-9	Testicular germ cell tumor;
LIHC	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.49	-6.14	-0.32	2.23e-9	Diisocyanate-induced asthma;
LIHC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00958927	chr1:175162553	KIAA0040	-0.39	-6.47	-0.33	3.46e-10	Alcohol dependence;
LIHC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.41	-8.6	-0.42	2.95e-16	Obesity-related traits;
LIHC	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg00204512	chr16:28754710	NA	0.33	6.74	0.34	6.69e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs244293	0.831	rs7207057	chr17:53172968	G/C	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.54	0.38	4.39e-13	Menarche (age at onset);
LIHC	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg00012203	chr2:219082015	ARPC2	-0.83	-13.05	-0.58	7.16e-32	Colorectal cancer;
LIHC	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-0.76	-8.35	-0.41	1.75e-15	Exhaled nitric oxide output;
LIHC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.45	-7.86	-0.39	4.99e-14	Aortic root size;
LIHC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.99	-0.44	1.66e-17	Obesity-related traits;
LIHC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-9.79	-0.47	4.12e-20	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.29	6.4	0.33	5.23e-10	Pulmonary function;
LIHC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.74	9.63	0.46	1.45e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs9322817	0.691	rs7743022	chr6:105170381	G/T	cg02098413	chr6:105308735	HACE1	-0.42	-7.65	-0.38	2.02e-13	Thyroid stimulating hormone;
LIHC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg08499158	chr17:42289980	UBTF	0.46	7.42	0.37	9.19e-13	Total body bone mineral density;
LIHC	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg14146966	chr2:61757674	XPO1	0.45	7.76	0.39	9.9e-14	Tuberculosis;
LIHC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.42	12.94	0.57	1.91e-31	Uric acid levels;
LIHC	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.48	7.72	0.39	1.28e-13	Corneal astigmatism;
LIHC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg18357526	chr6:26021779	HIST1H4A	0.6	8.44	0.42	8.94e-16	Blood metabolite levels;
LIHC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.66	13.75	0.6	1.5e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	6.73	0.34	7.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.54	5.77	0.3	1.76e-8	Menopause (age at onset);
LIHC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg23533926	chr12:111358616	MYL2	-0.35	-6.79	-0.34	4.94e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.84	-0.65	9.44e-43	Chronic sinus infection;
LIHC	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg15123519	chr2:136567270	LCT	-0.38	-5.82	-0.3	1.37e-8	Corneal structure;
LIHC	trans	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.29	0.45	1.84e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.47	-7.78	-0.39	8.41e-14	Menarche (age at onset);
LIHC	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-10.28	-0.49	8.89e-22	Dental caries;
LIHC	cis	rs17776563	0.887	rs72763808	chr15:89132114	G/A	cg05013243	chr15:89149849	MIR1179	0.41	6.79	0.34	4.9e-11	Thyroid hormone levels;
LIHC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00152838	chr16:24741724	TNRC6A	-0.5	-5.76	-0.3	1.85e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs3812111	0.641	rs1547030	chr6:116418158	G/A	cg08036074	chr6:116424633	NT5DC1	0.65	11.3	0.52	2.17e-25	Age-related macular degeneration;
LIHC	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.14	-0.4	7.19e-15	Brugada syndrome;
LIHC	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg08992911	chr2:238395768	MLPH	0.51	5.98	0.31	5.5e-9	Prostate cancer;
LIHC	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.67	8.15	0.4	6.83e-15	Morning vs. evening chronotype;
LIHC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.65	11.44	0.53	7.08e-26	High light scatter reticulocyte count;
LIHC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.46	0.33	3.69e-10	Mean platelet volume;
LIHC	cis	rs4742903	0.935	rs10119876	chr9:106961080	T/G	cg14250997	chr9:106856677	SMC2	0.35	5.87	0.3	1.02e-8	High-grade serous ovarian cancer;Breast cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17494855	chr1:43855675	C1orf84;MED8	-0.5	-6.12	-0.31	2.5e-9	Systolic blood pressure;
LIHC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-16.14	-0.66	5.93e-44	Coronary artery disease;
LIHC	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.39	-7.19	-0.36	4.19e-12	Height;
LIHC	cis	rs1866706	0.896	rs1440277	chr11:12875089	C/T	cg25843174	chr11:12811716	TEAD1	-0.28	-6.05	-0.31	3.74e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.26	0.64	1.81e-40	Chronic sinus infection;
LIHC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.59	8.79	0.43	7.18e-17	Recombination rate (females);
LIHC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg17135325	chr3:160939158	NMD3	0.42	6.09	0.31	3.07e-9	Morning vs. evening chronotype;
LIHC	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.59	9.2	0.45	3.69e-18	White matter hyperintensity burden;
LIHC	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg10820045	chr2:198174542	NA	-0.44	-6.42	-0.33	4.6e-10	Intracranial aneurysm;
LIHC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg17135325	chr3:160939158	NMD3	0.55	7.84	0.39	5.79e-14	Parkinson's disease;
LIHC	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	0.74	6.16	0.32	2.03e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.44	-7.39	-0.37	1.17e-12	Platelet distribution width;
LIHC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	14.93	0.63	3.82e-39	Menarche (age at onset);
LIHC	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.28	-6.02	-0.31	4.41e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	0.85	11.16	0.52	7.43e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.33	6.25	0.32	1.21e-9	Body mass index;
LIHC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.64	10.93	0.51	4.58e-24	Uric acid clearance;
LIHC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.3	0.37	2.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg12751644	chr20:60527061	NA	-0.37	-6.1	-0.31	2.93e-9	Body mass index;
LIHC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.36	-5.93	-0.31	7.24e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.97	-0.35	1.66e-11	Schizophrenia;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.43	7.76	0.39	1.01e-13	Prudent dietary pattern;
LIHC	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.37	-0.41	1.53e-15	Colorectal cancer;
LIHC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.17e-9	Height;
LIHC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.66	10.86	0.51	8.12e-24	Smoking initiation;
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.7	9.82	0.47	3.29e-20	Menarche (age at onset);
LIHC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg18478394	chr8:109455254	TTC35	-0.43	-7.31	-0.37	1.86e-12	Dupuytren's disease;
LIHC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	0.91	16.61	0.67	7.94e-46	Bone mineral density;
LIHC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.55	-9.57	-0.46	2.3e-19	Reticulocyte count;
LIHC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.46	6.08	0.31	3.14e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.14	0.36	5.5e-12	Renal cell carcinoma;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	25.4	0.81	1.03e-80	Prudent dietary pattern;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg24955955	chr5:415729	AHRR	0.32	6.5	0.33	2.79e-10	Cystic fibrosis severity;
LIHC	cis	rs9381040	0.672	rs6458197	chr6:41144658	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.8	-0.35	4.62e-11	Alzheimer's disease (late onset);
LIHC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.43	-5.92	-0.3	8.02e-9	Blood protein levels;
LIHC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.44	-6.65	-0.34	1.17e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg26939375	chr7:64535504	NA	-0.43	-7.0	-0.35	1.39e-11	Aortic root size;
LIHC	trans	rs2359714	0.905	rs56366235	chr1:118830161	A/G	cg19861078	chr7:7936962	NA	0.32	6.09	0.31	2.97e-9	Breast size;
LIHC	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.69	8.98	0.44	1.8e-17	Exhaled nitric oxide output;
LIHC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg20302533	chr7:39170763	POU6F2	0.38	7.02	0.35	1.22e-11	IgG glycosylation;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.0	0.44	1.57e-17	Height;
LIHC	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.37	6.55	0.33	2.17e-10	Obesity;
LIHC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.29	0.41	2.59e-15	Birth weight;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06989074	chr11:68133177	LRP5	0.4	6.53	0.33	2.4e-10	Bilirubin levels;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.6	-8.55	-0.42	4.1e-16	Menopause (age at onset);
LIHC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	6.85	0.35	3.46e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs55665837	0.523	rs10832301	chr11:14788964	G/A	cg00085434	chr11:14927489	NA	0.4	5.77	0.3	1.78e-8	Vitamin D levels;
LIHC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.41	6.75	0.34	6.54e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16048161	chr11:31391307	DNAJC24;DCDC1	-0.47	-6.57	-0.33	1.85e-10	Pancreatic cancer;
LIHC	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.61	0.34	1.5e-10	Breast cancer;
LIHC	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.32	-6.82	-0.35	4.27e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.79	-0.34	5.04e-11	HDL cholesterol;
LIHC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.86	-0.3	1.07e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.47	0.46	4.87e-19	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg17135325	chr3:160939158	NMD3	0.55	7.82	0.39	6.82e-14	Parkinson's disease;
LIHC	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-6.28	-0.32	1.01e-9	Body mass index;
LIHC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.44	6.98	0.35	1.54e-11	Response to temozolomide;
LIHC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.05	0.31	3.77e-9	Protein biomarker;
LIHC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07424592	chr7:64974309	NA	-0.46	-6.9	-0.35	2.59e-11	Calcium levels;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.93	0.57	2.1e-31	Prudent dietary pattern;
LIHC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.48	-7.91	-0.39	3.59e-14	Fibrinogen levels;
LIHC	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg23587288	chr2:27483067	SLC30A3	-0.33	-6.07	-0.31	3.45e-9	Blood metabolite levels;
LIHC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.01	0.44	1.5e-17	IgG glycosylation;
LIHC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.27	-0.32	1.11e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.68	10.71	0.5	2.84e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg14709524	chr16:89940631	TCF25	0.51	6.44	0.33	4.1e-10	Skin colour saturation;
LIHC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg18446336	chr7:2847575	GNA12	0.31	6.16	0.32	2.04e-9	Height;
LIHC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	0.59	8.35	0.41	1.73e-15	Prudent dietary pattern;
LIHC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.6	-0.5	6.66e-23	Chronic sinus infection;
LIHC	cis	rs903552	0.736	rs9806369	chr15:102008430	A/C	cg25677261	chr15:102009856	PCSK6	-0.53	-7.22	-0.36	3.47e-12	Diabetic kidney disease;
LIHC	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg24955406	chr1:100503596	HIAT1	0.6	5.99	0.31	5.44e-9	Carotid intima media thickness;
LIHC	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.42	8.04	0.4	1.52e-14	Height;
LIHC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.43	7.05	0.36	9.7e-12	Red blood cell count;
LIHC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.8	7.6	0.38	2.86e-13	Plasma clusterin levels;
LIHC	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg07541023	chr7:19748670	TWISTNB	-0.5	-7.41	-0.37	9.98e-13	Thyroid stimulating hormone;
LIHC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.51	9.42	0.45	6.73e-19	Hemoglobin concentration;
LIHC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02290350	chr8:58132656	NA	0.41	8.51	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.26	-6.89	-0.35	2.62e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.15	26.7	0.82	1.2e-85	Cognitive ability;
LIHC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.79	-13.81	-0.6	8.55e-35	Aortic root size;
LIHC	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-7.62	-0.38	2.52e-13	Inflammatory bowel disease;
LIHC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.38	6.36	0.33	6.31e-10	Blood metabolite levels;
LIHC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.76	11.06	0.51	1.59e-24	Response to antineoplastic agents;
LIHC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg05590025	chr7:65112418	INTS4L2	-0.49	-5.92	-0.3	7.8e-9	Diabetic kidney disease;
LIHC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.82	6.88	0.35	2.9e-11	Body mass index;
LIHC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.6	-7.97	-0.4	2.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.05	-0.31	3.81e-9	Tuberculosis;
LIHC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-1.0	-10.32	-0.49	6.22e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.71	-9.98	-0.47	9.37e-21	Menarche (age at onset);
LIHC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.48	-6.33	-0.32	7.73e-10	Subjective well-being;
LIHC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	9.07e-10	Aortic root size;
LIHC	cis	rs903552	0.673	rs4965878	chr15:102009589	C/T	cg25677261	chr15:102009856	PCSK6	-0.52	-6.93	-0.35	2.11e-11	Diabetic kidney disease;
LIHC	trans	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg17675199	chr6:35436792	RPL10A	-0.45	-9.35	-0.45	1.21e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs72627123	0.867	rs117818304	chr14:74474396	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	9.06	0.44	1.01e-17	Morning vs. evening chronotype;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.51	-6.65	-0.34	1.15e-10	Menopause (age at onset);
LIHC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg04083430	chr16:4736063	MGRN1	-0.42	-5.84	-0.3	1.24e-8	Schizophrenia;
LIHC	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.54	8.06	0.4	1.28e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.57	-8.21	-0.41	4.51e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.38	-6.04	-0.31	3.95e-9	Menarche (age at onset);
LIHC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.81	9.65	0.46	1.24e-19	Cognitive function;
LIHC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.75	14.28	0.61	1.27e-36	Crohn's disease;
LIHC	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	0.75	8.1	0.4	9.98e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.56	9.87	0.47	2.2e-20	Alcohol dependence;
LIHC	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.41	6.61	0.34	1.46e-10	Menopause (age at onset);
LIHC	cis	rs600806	0.778	rs2152924	chr1:110011701	G/A	cg10127483	chr1:110009974	SYPL2	0.5	6.37	0.33	6.23e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.52	-0.33	2.54e-10	Blood trace element (Zn levels);
LIHC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.78	0.5	1.59e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg22842854	chr12:123319900	HIP1R	0.83	9.26	0.45	2.24e-18	Adiponectin levels;
LIHC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.52	0.38	4.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg11764359	chr7:65958608	NA	0.59	6.21	0.32	1.5e-9	Diabetic kidney disease;
LIHC	cis	rs972578	0.967	rs4822235	chr22:43338090	T/C	cg01576275	chr22:43409880	NA	-0.33	-5.91	-0.3	8.33e-9	Mean platelet volume;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.46	-5.97	-0.31	5.98e-9	Subjective well-being;
LIHC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.61e-9	Aortic root size;
LIHC	cis	rs6466055	0.669	rs7797912	chr7:104769415	C/T	cg04380332	chr7:105027541	SRPK2	0.35	6.72	0.34	7.72e-11	Schizophrenia;
LIHC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.7	12.56	0.56	5.11e-30	Colorectal cancer;
LIHC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.56	-7.13	-0.36	6.1e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.53	-10.87	-0.51	7.81e-24	Late-onset Alzheimer's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08575122	chr10:33269417	NA	0.56	7.29	0.37	2.17e-12	Lung function (FEV1/FVC);
LIHC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.81	0.3	1.45e-8	Self-reported allergy;
LIHC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg04013166	chr16:89971882	TCF25	0.49	5.91	0.3	8.48e-9	Skin colour saturation;
LIHC	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.7	14.59	0.62	8.35e-38	Schizophrenia;
LIHC	cis	rs11673344	0.598	rs826326	chr19:37494765	T/C	cg27390819	chr19:37464633	NA	-0.48	-6.27	-0.32	1.06e-9	Obesity-related traits;
LIHC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.96	-12.76	-0.57	9.14e-31	Schizophrenia;
LIHC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.61	-10.07	-0.48	4.66e-21	Post bronchodilator FEV1;
LIHC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg07959070	chr22:50026188	C22orf34	-0.32	-8.07	-0.4	1.24e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg13152130	chr6:118910203	C6orf204	-0.65	-7.34	-0.37	1.61e-12	Diastolic blood pressure;
LIHC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.61	-8.83	-0.43	5.48e-17	Aortic root size;
LIHC	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.94	0.6	2.66e-35	Bipolar disorder;
LIHC	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.44	-6.92	-0.35	2.2e-11	Metabolite levels;
LIHC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.09	0.4	1.08e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.84	-0.35	3.6e-11	Diabetic kidney disease;
LIHC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.55	-0.33	2.16e-10	Personality dimensions;
LIHC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.35	5.74	0.3	2.04e-8	Blood metabolite levels;
LIHC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.57	8.73	0.43	1.16e-16	White matter hyperintensity burden;
LIHC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.07	0.68	1.1e-47	Tonsillectomy;
LIHC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.68	-9.58	-0.46	2.05e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.69	11.04	0.51	1.91e-24	Crohn's disease;
LIHC	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.38	0.45	9.45e-19	Lung disease severity in cystic fibrosis;
LIHC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg26395211	chr5:140044315	WDR55	-0.41	-6.12	-0.31	2.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg00977110	chr5:151150581	G3BP1	0.55	6.98	0.35	1.56e-11	Preschool internalizing problems;
LIHC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.54	8.71	0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs116248771	0.793	rs12494750	chr3:158298411	T/G	cg16708174	chr3:158430962	RARRES1	0.47	6.21	0.32	1.54e-9	diarrhoeal disease at age 2;
LIHC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.38	6.23	0.32	1.39e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-23.26	-0.78	1.91e-72	Height;
LIHC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.0	0.31	5.09e-9	Educational attainment;
LIHC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg26149184	chr10:133730230	NA	0.46	7.34	0.37	1.56e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.66	0.5	4.09e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.95	-0.31	6.49e-9	Bipolar disorder;
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg11766577	chr21:47581405	C21orf56	-0.38	-5.87	-0.3	1.01e-8	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs7116495	1.000	rs1573502	chr11:71747428	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.01	-0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.13e-14	Neuroticism;
LIHC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg21486233	chr12:29375141	FAR2	-0.29	-5.72	-0.3	2.36e-8	QT interval;
LIHC	trans	rs10213084	1.000	rs10212994	chr4:147501225	A/G	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	1.08	14.27	0.61	1.47e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04180668	chr6:163148903	PARK2;PACRG	0.48	6.44	0.33	3.96e-10	Pancreatic cancer;
LIHC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.64	11.65	0.53	1.25e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs74233809	1.000	rs11191453	chr10:104659852	T/C	cg03493300	chr10:104813866	CNNM2	0.44	5.89	0.3	9.48e-9	Birth weight;
LIHC	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.48	-7.41	-0.37	9.74e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.23	-0.32	1.4e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.67	0.59	3.13e-34	Lung cancer in ever smokers;
LIHC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.63	11.57	0.53	2.45e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3015497	0.587	rs1353204	chr14:51081515	C/T	cg09863266	chr14:51125203	SAV1	-0.36	-5.78	-0.3	1.71e-8	Mean platelet volume;
LIHC	cis	rs12644436	0.628	rs4693187	chr4:88783355	A/T	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-13.45	-0.59	2.24e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.7e-11	Ileal carcinoids;
LIHC	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.36	5.87	0.3	1.02e-8	Mean platelet volume;
LIHC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.62	8.79	0.43	7.51e-17	Osteoporosis;
LIHC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.38	6.04	0.31	3.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg07671805	chr5:74907694	NA	0.46	6.29	0.32	9.84e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg03934865	chr2:198174659	NA	0.51	7.74	0.39	1.13e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.45	6.06	0.31	3.56e-9	Heart rate;Heart rate variability traits (RMSSD);
LIHC	cis	rs6504950	0.745	rs9914088	chr17:52979985	T/C	cg10237252	chr17:52977213	TOM1L1	-0.38	-6.58	-0.34	1.77e-10	Breast cancer;
LIHC	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg20636351	chr8:55087400	NA	-0.34	-7.09	-0.36	7.97e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.55	-0.38	3.92e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.05	-0.4	1.39e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.11e-9	Height;
LIHC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.49	-7.28	-0.37	2.37e-12	Longevity;Endometriosis;
LIHC	cis	rs7534824	0.556	rs61780323	chr1:101433407	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	6.96	0.35	1.75e-11	Refractive astigmatism;
LIHC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.43e-11	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02046995	chr22:41487740	EP300;MIR1281	0.44	6.43	0.33	4.27e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.34	6.32	0.32	8.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs36051895	0.623	rs11790680	chr9:5248768	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-9.95	-0.47	1.17e-20	Pediatric autoimmune diseases;
LIHC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.66	13.73	0.6	1.84e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.32	0.37	1.74e-12	Monocyte percentage of white cells;
LIHC	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg04306507	chr14:55594613	LGALS3	0.32	5.99	0.31	5.4e-9	Protein biomarker;
LIHC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.68	13.54	0.59	9.99e-34	High light scatter reticulocyte count;
LIHC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg14004847	chr7:1930337	MAD1L1	0.54	7.88	0.39	4.36e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.38	5.78	0.3	1.69e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg16583315	chr14:65563665	MAX	0.38	7.75	0.39	1.07e-13	Obesity-related traits;
LIHC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.78	-12.87	-0.57	3.49e-31	Breast cancer;
LIHC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg03037974	chr15:76606532	NA	0.8	16.45	0.66	3.41e-45	Blood metabolite levels;
LIHC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.65	12.71	0.57	1.41e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg02269571	chr22:50332266	NA	-0.66	-8.93	-0.43	2.74e-17	Schizophrenia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26126750	chr3:195809198	TFRC	-0.44	-6.1	-0.31	2.87e-9	Systolic blood pressure;
LIHC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.71	10.23	0.48	1.32e-21	Selective IgA deficiency;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24685795	chr17:34851276	ZNHIT3	-0.39	-6.64	-0.34	1.26e-10	Calcium levels;
LIHC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg18944383	chr4:111397179	ENPEP	0.27	6.99	0.35	1.41e-11	Height;
LIHC	cis	rs4474465	0.607	rs7930161	chr11:78268878	C/A	cg02023728	chr11:77925099	USP35	-0.35	-6.21	-0.32	1.56e-9	Alzheimer's disease (survival time);
LIHC	cis	rs12744310	0.887	rs4453028	chr1:41792523	G/A	cg03962019	chr1:41807865	NA	0.38	6.13	0.31	2.47e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	6.55	0.33	2.16e-10	Schizophrenia;
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20570016	chr1:156261298	TMEM79	0.36	5.79	0.3	1.58e-8	Tonsillectomy;
LIHC	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.51	5.98	0.31	5.64e-9	Height;
LIHC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg06064525	chr11:970664	AP2A2	-0.44	-10.73	-0.5	2.49e-23	Alzheimer's disease (late onset);
LIHC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.22	5.97	0.31	6.03e-9	Calcium levels;
LIHC	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	10.47	0.49	1.95e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3781458	0.803	rs11245321	chr10:126323279	C/T	cg20435097	chr10:126320824	FAM53B	0.7	13.09	0.58	5.04e-32	Male-pattern baldness;
LIHC	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.44	-6.68	-0.34	9.87e-11	Blood protein levels;
LIHC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg26939375	chr7:64535504	NA	0.47	8.25	0.41	3.36e-15	Calcium levels;
LIHC	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.65	9.59	0.46	1.84e-19	Monocyte count;
LIHC	cis	rs11663156	0.774	rs117467762	chr18:50933942	C/A	cg24270629	chr18:50823537	DCC	-0.49	-6.7	-0.34	8.66e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.68	-8.34	-0.41	1.88e-15	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25631650	chr19:633157	POLRMT	0.45	6.21	0.32	1.52e-9	Pancreatic cancer;
LIHC	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.23	-5.9	-0.3	8.65e-9	Hepatitis;
LIHC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg22528358	chr1:107598549	PRMT6	0.72	11.83	0.54	2.66e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4589502	0.800	rs4147433	chr15:67201152	G/A	cg12317470	chr15:67143691	NA	-0.53	-6.74	-0.34	6.9e-11	Lung cancer (smoking interaction);
LIHC	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.66	7.02	0.35	1.22e-11	Type 2 diabetes;
LIHC	cis	rs332507	0.830	rs2289428	chr3:124412524	T/G	cg05980111	chr3:124395277	KALRN	0.44	6.78	0.34	5.21e-11	Plateletcrit;
LIHC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.31	6.11	0.31	2.67e-9	Mean corpuscular volume;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07810114	chr1:12018622	PLOD1	0.46	6.83	0.35	3.86e-11	Bilirubin levels;
LIHC	cis	rs6708331	0.517	rs12999042	chr2:70366811	C/T	cg01613454	chr2:70366299	NA	0.38	6.23	0.32	1.39e-9	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.36	11.96	0.54	8.66e-28	Uric acid levels;
LIHC	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.34	6.77	0.34	5.45e-11	Multiple sclerosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg08393024	chr5:115177154	ATG12;AP3S1	0.45	6.22	0.32	1.46e-9	Lung function (FEV1/FVC);
LIHC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.92e-16	Prudent dietary pattern;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13525026	chr17:18061071	MYO15A	0.41	6.43	0.33	4.23e-10	Immature fraction of reticulocytes;
LIHC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg15902774	chr15:75289873	SCAMP5	0.44	6.49	0.33	3.08e-10	Lung cancer;
LIHC	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.66	-0.34	1.1e-10	Putamen volume;
LIHC	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.66	-12.87	-0.57	3.46e-31	Endometriosis;
LIHC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.64	-6.63	-0.34	1.29e-10	Vitiligo;
LIHC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.53	7.9	0.39	3.77e-14	Longevity;
LIHC	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-8.98	-0.44	1.82e-17	Brugada syndrome;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11635401	chr19:17322527	MYO9B	0.48	6.05	0.31	3.82e-9	Systolic blood pressure;
LIHC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.45	8.07	0.4	1.2e-14	IgG glycosylation;
LIHC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.14	-0.32	2.29e-9	Total body bone mineral density;
LIHC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.59	-7.58	-0.38	3.35e-13	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs600806	0.821	rs417270	chr1:109849144	T/C	cg02415029	chr1:110025642	ATXN7L2	-0.49	-6.03	-0.31	4.24e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-9.38	-0.45	9.5e-19	Dental caries;
LIHC	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg09165964	chr15:75287851	SCAMP5	0.5	7.22	0.36	3.33e-12	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.37	7.79	0.39	8e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg02594498	chr15:22893147	CYFIP1	-0.4	-6.13	-0.31	2.48e-9	Body mass index;
LIHC	cis	rs2834188	0.883	rs16997869	chr21:34696867	C/T	cg14352951	chr21:34696688	IFNAR1	-0.48	-6.6	-0.34	1.59e-10	Narcolepsy;
LIHC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg08210727	chr20:33865349	NA	0.5	5.88	0.3	9.93e-9	Attention deficit hyperactivity disorder;
LIHC	trans	rs7618501	0.570	rs7613875	chr3:49971514	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.71	0.43	1.36e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-6.08	-0.31	3.13e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs12928939	0.723	rs71403864	chr16:71695030	C/T	cg03805757	chr16:71968109	PKD1L3	-0.64	-7.18	-0.36	4.46e-12	Post bronchodilator FEV1;
LIHC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.02	-0.31	4.58e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05628496	chr17:17991167	DRG2	0.44	6.09	0.31	2.96e-9	Pancreatic cancer;
LIHC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg15605315	chr1:45957053	TESK2	-0.42	-5.74	-0.3	2.12e-8	Platelet count;
LIHC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.62	-12.06	-0.55	3.69e-28	Type 2 diabetes;
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-5.9	-0.3	8.51e-9	Longevity;Endometriosis;
LIHC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.73	12.56	0.56	5.23e-30	Menopause (age at onset);
LIHC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg19936157	chr1:113287238	NA	-0.33	-6.03	-0.31	4.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.38	0.37	1.2e-12	Monocyte percentage of white cells;
LIHC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	7.93	0.39	3.19e-14	Platelet count;
LIHC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg21522988	chr12:29376872	FAR2	0.26	5.83	0.3	1.29e-8	QT interval;
LIHC	cis	rs3820500	0.543	rs1289951	chr1:117913019	A/G	cg20383390	chr1:117909022	MAN1A2	-0.45	-5.74	-0.3	2.11e-8	Pneumonia;
LIHC	trans	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.53	-0.33	2.42e-10	Dental caries;
LIHC	trans	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.43	-0.37	8.55e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.64	0.53	1.34e-26	Platelet count;
LIHC	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.75	-11.39	-0.52	1.11e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.68	0.38	1.65e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.21	-0.36	3.52e-12	Personality dimensions;
LIHC	cis	rs7165170	0.529	rs4932357	chr15:91160884	C/A	cg26821196	chr15:91095069	CRTC3	0.32	5.91	0.3	8.47e-9	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.44	-6.78	-0.34	5.41e-11	Lung cancer;
LIHC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06050784	chr16:88016603	BANP	0.36	6.57	0.33	1.93e-10	Menopause (age at onset);
LIHC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.35	-0.49	5.08e-22	Blood metabolite levels;
LIHC	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.32	7.66	0.38	1.96e-13	Corneal astigmatism;
LIHC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.87	-9.18	-0.44	4.33e-18	Height;
LIHC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.4	7.87	0.39	4.88e-14	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07677032	chr17:61819896	STRADA	0.44	6.42	0.33	4.45e-10	Prudent dietary pattern;
LIHC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.43	0.33	4.37e-10	Ileal carcinoids;
LIHC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.42	-6.05	-0.31	3.91e-9	Longevity;
LIHC	trans	rs12753920	0.703	rs1601020	chr1:92621428	G/T	cg15668468	chr10:118892869	VAX1	0.42	6.12	0.31	2.58e-9	Systemic lupus erythematosus;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02290350	chr8:58132656	NA	0.49	8.85	0.43	4.69e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs655641	1.000	rs616555	chr11:85710180	G/A	cg09030501	chr11:85779252	PICALM	-0.53	-6.19	-0.32	1.69e-9	Platelet count;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg14651457	chr8:12611650	LONRF1	0.69	6.12	0.31	2.6e-9	Musician's dystonia;
LIHC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.33	6.82	0.35	4.12e-11	QRS complex (12-leadsum);
LIHC	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.47	0.46	4.64e-19	Corneal astigmatism;
LIHC	cis	rs7635838	0.892	rs9310381	chr3:11458466	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.7	0.34	8.45e-11	HDL cholesterol;
LIHC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.31	-15.55	-0.64	1.33e-41	Alzheimer's disease (late onset);
LIHC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.66	-5.8	-0.3	1.55e-8	Menopause (age at onset);
LIHC	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.27	0.49	9.23e-22	Colorectal cancer;
LIHC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.74	6.86	0.35	3.26e-11	Plasma clusterin levels;
LIHC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.45e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg18402987	chr7:1209562	NA	0.86	6.08	0.31	3.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	10.69	0.5	3.41e-23	Coronary artery disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg26207102	chr11:12748969	TEAD1	-0.25	-6.04	-0.31	3.99e-9	Calcium levels;
LIHC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.56	10.03	0.48	6.2e-21	Platelet distribution width;
LIHC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.82	0.35	4.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg14146966	chr2:61757674	XPO1	0.48	8.37	0.41	1.5e-15	Tuberculosis;
LIHC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.56	0.53	2.66e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.35	0.32	6.87e-10	Glycated hemoglobin levels;
LIHC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	11.22	0.52	4.41e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg14393609	chr7:65229607	NA	-0.38	-6.03	-0.31	4.36e-9	Aortic root size;
LIHC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.71	-10.58	-0.5	8.16e-23	Aortic root size;
LIHC	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.07	-0.31	3.47e-9	Myopia (pathological);
LIHC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	1.01	19.29	0.72	1.22e-56	Breast cancer;
LIHC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26734620	chr12:56694298	CS	0.99	10.18	0.48	2.03e-21	Psoriasis vulgaris;
LIHC	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.54	-7.65	-0.38	2.04e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.48	6.82	0.35	4.11e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.61	-6.28	-0.32	1e-9	Multiple sclerosis;
LIHC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.63	12.81	0.57	5.75e-31	Gestational age at birth (maternal effect);
LIHC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.77	-0.5	1.69e-23	Chronic sinus infection;
LIHC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.33	6.11	0.31	2.75e-9	Height;
LIHC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	6.51	0.33	2.72e-10	Coronary artery disease;
LIHC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.49	6.38	0.33	5.65e-10	Migraine;Coronary artery disease;
LIHC	trans	rs6489882	0.703	rs2660	chr12:113357442	A/G	cg10175203	chr3:128143634	NA	-0.39	-6.21	-0.32	1.55e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.15	-17.08	-0.68	9.71e-48	Chronic sinus infection;
LIHC	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.84	9.1	0.44	7.8e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	8.78	0.43	8.08e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2163237	0.965	rs6748103	chr2:55986042	C/T	cg03859395	chr2:55845619	SMEK2	0.45	6.86	0.35	3.3e-11	IgG glycosylation;
LIHC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.58	8.3	0.41	2.41e-15	Motion sickness;
LIHC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg02869306	chr7:64672164	INTS4L1	-0.31	-6.61	-0.34	1.5e-10	Calcium levels;
LIHC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg09222892	chr1:25734099	RHCE	-0.44	-8.09	-0.4	1.03e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.42	-6.24	-0.32	1.31e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.42	8.46	0.42	7.64e-16	Renal cell carcinoma;
LIHC	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg24097872	chr10:5724021	NA	0.76	12.27	0.55	6.54e-29	Childhood ear infection;
LIHC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.48	-0.33	3.26e-10	Height;
LIHC	cis	rs497273	0.530	rs2701185	chr12:121352974	A/G	cg02403541	chr12:121454288	C12orf43	0.37	5.79	0.3	1.55e-8	Systemic lupus erythematosus;
LIHC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.05	0.36	9.84e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	12.81	0.57	6.07e-31	HIV-1 control;
LIHC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.46	6.53	0.33	2.45e-10	Breast cancer;
LIHC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg22633049	chr21:46681294	NA	-0.37	-6.42	-0.33	4.48e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.47	7.33	0.37	1.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.4	6.0	0.31	4.97e-9	Height;
LIHC	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.61	9.25	0.45	2.57e-18	Diisocyanate-induced asthma;
LIHC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	7.17	0.36	4.52e-12	Menopause (age at onset);
LIHC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg15691649	chr6:25882328	NA	0.48	6.5	0.33	2.79e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs988712	0.705	rs4923463	chr11:27672500	A/G	cg18117895	chr11:27722066	BDNF	0.49	6.88	0.35	2.89e-11	Obesity;
LIHC	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg14092571	chr14:90743983	NA	0.46	7.24	0.36	2.94e-12	Mortality in heart failure;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg13500206	chr10:81146051	ZCCHC24	0.45	6.43	0.33	4.18e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.49	7.19	0.36	4.19e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.62	0.53	1.54e-26	Coffee consumption (cups per day);
LIHC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18357526	chr6:26021779	HIST1H4A	0.46	6.76	0.34	5.79e-11	Height;
LIHC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.95	-0.35	1.83e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs9641123	0.639	rs7786765	chr7:93199928	T/A	cg09745688	chr16:2908918	PRSS22	-0.37	-6.34	-0.32	7.31e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09820084	chr6:18387507	RNF144B	0.44	7.34	0.37	1.61e-12	Cognitive function;
LIHC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg27478167	chr7:817139	HEATR2	0.52	6.96	0.35	1.77e-11	Cerebrospinal P-tau181p levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15319206	chr6:159065938	DYNLT1	-0.43	-6.9	-0.35	2.61e-11	Calcium levels;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13668652	chr20:33680648	TRPC4AP	-0.54	-6.2	-0.32	1.59e-9	Systolic blood pressure;
LIHC	cis	rs3818285	0.959	rs35420248	chr10:111643074	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.41	-6.05	-0.31	3.77e-9	Superior crus of antihelix expression;
LIHC	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15506890	chr2:3487001	NA	-0.41	-6.15	-0.32	2.16e-9	Neurofibrillary tangles;
LIHC	cis	rs965469	0.842	rs6051776	chr20:3332062	T/C	cg25506879	chr20:3388711	C20orf194	-0.58	-6.97	-0.35	1.63e-11	IFN-related cytopenia;
LIHC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.88	0.57	3.26e-31	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03513682	chr16:85542749	NA	-0.44	-6.49	-0.33	3.04e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1355223	0.844	rs12809046	chr11:34748261	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.52	-0.33	2.5e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg05973401	chr12:123451056	ABCB9	0.44	6.14	0.32	2.3e-9	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg21395723	chr22:39101663	GTPBP1	0.36	6.03	0.31	4.32e-9	Menopause (age at onset);
LIHC	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.39	7.78	0.39	8.43e-14	Obesity (extreme);
LIHC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.81	-0.3	1.39e-8	Subjective well-being;
LIHC	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg12863693	chr15:85201151	NMB	0.48	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.68	11.1	0.51	1.2e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.48	7.92	0.39	3.33e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.47	6.18	0.32	1.78e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2997447	0.637	rs3008413	chr1:26407063	G/A	cg19633962	chr1:26362018	EXTL1	-0.6	-5.71	-0.3	2.43e-8	QRS complex (12-leadsum);
LIHC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.84	0.3	1.22e-8	Tonsillectomy;
LIHC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.31	-0.37	1.87e-12	Diabetic kidney disease;
LIHC	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.67	7.62	0.38	2.46e-13	Exhaled nitric oxide output;
LIHC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.49	-6.04	-0.31	4.11e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs5753037	0.838	rs131293	chr22:30171031	T/G	cg01021169	chr22:30184971	ASCC2	-0.35	-6.54	-0.33	2.25e-10	Type 1 diabetes;
LIHC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg18887096	chr2:219472410	PLCD4	0.4	6.92	0.35	2.27e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg16088116	chr21:44841560	SIK1	-0.42	-6.34	-0.32	7.23e-10	Coronary artery disease;
LIHC	cis	rs10744422	0.800	rs2649902	chr12:123243687	G/A	cg18912006	chr12:123335444	HIP1R	-0.52	-6.13	-0.31	2.41e-9	Schizophrenia;
LIHC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.62	9.76	0.47	5.05e-20	Tonsillectomy;
LIHC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg10096929	chr1:156261403	TMEM79	0.38	6.38	0.33	5.69e-10	Tonsillectomy;
LIHC	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14396892	chr9:96623032	NA	-0.33	-6.3	-0.32	9.26e-10	DNA methylation (variation);
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.89	-0.3	9.28e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.54	8.71	0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.77	0.62	1.61e-38	Prudent dietary pattern;
LIHC	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.68	-10.82	-0.5	1.19e-23	Schizophrenia;
LIHC	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg03645007	chr3:50255295	SLC38A3	0.49	5.75	0.3	1.98e-8	Schizophrenia;
LIHC	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-7.8	-0.39	7.35e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.53	8.66	0.42	1.91e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.82	-13.08	-0.58	5.58e-32	Colorectal cancer;
LIHC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.69	8.46	0.42	7.65e-16	Mean platelet volume;
LIHC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	7.18	0.36	4.37e-12	Height;
LIHC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.45	6.39	0.33	5.55e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.42	5.87	0.3	1.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-10.95	-0.51	3.96e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.47	7.97	0.4	2.37e-14	Obesity-related traits;
LIHC	cis	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg00868766	chr15:40364524	NA	-0.35	-5.75	-0.3	2e-8	Dehydroepiandrosterone sulphate levels;
LIHC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-17.6	-0.69	7.98e-50	Body mass index;
LIHC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.62	-11.24	-0.52	3.85e-25	Dupuytren's disease;
LIHC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg17385448	chr1:15911702	AGMAT	0.35	6.11	0.31	2.78e-9	Systolic blood pressure;
LIHC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.72	-10.28	-0.49	8.79e-22	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.84	0.43	5.31e-17	Menarche (age at onset);
LIHC	cis	rs1434579	0.526	rs204547	chr19:44947184	T/C	cg15540054	chr19:45004280	ZNF180	-0.48	-6.35	-0.32	6.85e-10	Tuberculosis;
LIHC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.74	8.55	0.42	4.04e-16	Developmental language disorder (linguistic errors);
LIHC	trans	rs62103177	0.564	rs55867755	chr18:77723434	C/T	cg05926928	chr17:57297772	GDPD1	0.65	6.95	0.35	1.83e-11	Opioid sensitivity;
LIHC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.37	6.12	0.31	2.62e-9	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.62	0.42	2.54e-16	Schizophrenia;
LIHC	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg06935464	chr4:38784597	TLR10	-0.49	-7.51	-0.38	5.31e-13	Breast cancer;
LIHC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.97	17.46	0.69	2.94e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.38	-5.77	-0.3	1.79e-8	Asthma;
LIHC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg07952391	chr2:88470173	THNSL2	0.68	6.53	0.33	2.42e-10	Plasma clusterin levels;
LIHC	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.85	-13.2	-0.58	2e-32	Schizophrenia;
LIHC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.16	0.4	6.57e-15	Motion sickness;
LIHC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg14067834	chr17:29058358	SUZ12P	0.62	6.38	0.33	5.64e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg04082016	chr2:20871401	NA	-0.39	-6.84	-0.35	3.65e-11	Abdominal aortic aneurysm;
LIHC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg24209194	chr3:40518798	ZNF619	0.49	7.37	0.37	1.32e-12	Renal cell carcinoma;
LIHC	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg09572067	chr16:29127029	RRN3P2	0.51	8.06	0.4	1.29e-14	Menopause (age at onset);
LIHC	cis	rs11888559	0.655	rs6726311	chr2:204043676	G/A	cg24605529	chr2:203879461	NBEAL1	0.76	5.81	0.3	1.44e-8	Height;
LIHC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16346588	chr10:242978	ZMYND11	0.39	5.94	0.31	6.85e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg07451762	chr16:28383216	NA	0.4	6.98	0.35	1.58e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg10360323	chr17:41437877	NA	0.4	6.01	0.31	4.74e-9	Menopause (age at onset);
LIHC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10633746	chr17:18164442	SMCR7	0.41	6.22	0.32	1.45e-9	Pancreatic cancer;
LIHC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-18.46	-0.71	2.83e-53	Height;
LIHC	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.36	-7.56	-0.38	3.79e-13	Sitting height ratio;
LIHC	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg06565975	chr8:143823917	SLURP1	0.33	6.41	0.33	4.92e-10	Urinary tract infection frequency;
LIHC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.22	14.77	0.62	1.58e-38	Psoriasis vulgaris;
LIHC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.99	-19.67	-0.73	3.83e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs2191566	0.881	rs1996408	chr19:44532732	G/A	cg18700516	chr19:44507157	ZNF230	-0.38	-6.38	-0.33	5.88e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg22771759	chr13:24902376	NA	-0.33	-6.53	-0.33	2.38e-10	Obesity-related traits;
LIHC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05665937	chr4:1216051	CTBP1	0.46	6.09	0.31	3.11e-9	Obesity-related traits;
LIHC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.49	5.81	0.3	1.44e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.58	0.46	2.12e-19	Bipolar disorder;
LIHC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.68	-9.77	-0.47	4.66e-20	Total body bone mineral density;
LIHC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.45	6.04	0.31	4e-9	Tourette syndrome;
LIHC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.52	-6.0	-0.31	4.99e-9	Alzheimer's disease;
LIHC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg10932868	chr11:921992	NA	0.34	6.32	0.32	8.33e-10	Alzheimer's disease (late onset);
LIHC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.59	7.5	0.38	5.55e-13	Morning vs. evening chronotype;
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.21	0.41	4.53e-15	Height;
LIHC	trans	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg06781209	chr11:61594997	FADS2	-0.7	-6.52	-0.33	2.59e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg14779329	chr11:130786720	SNX19	0.43	6.54	0.33	2.21e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.46	0.37	7.3e-13	Obesity-related traits;
LIHC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.64	12.33	0.55	3.63e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg14146966	chr2:61757674	XPO1	-0.44	-7.53	-0.38	4.59e-13	Tuberculosis;
LIHC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.22	0.41	4.3e-15	Lymphocyte counts;
LIHC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.41	6.42	0.33	4.45e-10	Prostate cancer;
LIHC	trans	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg07393940	chr7:158741817	NA	0.57	6.6	0.34	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg13525026	chr17:18061071	MYO15A	0.42	6.5	0.33	2.92e-10	Longevity;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg15076023	chr2:175260335	CIR1;SCRN3	-0.47	-6.77	-0.34	5.76e-11	Bipolar disorder;
LIHC	cis	rs7078219	0.505	rs4409764	chr10:101284237	T/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.06	-0.31	3.63e-9	Dental caries;
LIHC	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.6	-8.07	-0.4	1.22e-14	Vitamin D levels;
LIHC	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.38	8.8	0.43	6.75e-17	Blood protein levels;
LIHC	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg03585969	chr10:35415529	CREM	0.74	10.58	0.5	7.78e-23	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.35	6.8	0.34	4.77e-11	Renal cell carcinoma;
LIHC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-6.23	-0.32	1.38e-9	Alzheimer's disease (late onset);
LIHC	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.33	-6.55	-0.33	2.16e-10	Systemic lupus erythematosus;
LIHC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.5	6.72	0.34	7.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg22528358	chr1:107598549	PRMT6	0.69	11.21	0.52	4.59e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.32	7.32	0.37	1.75e-12	Blood metabolite ratios;
LIHC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.49	-7.09	-0.36	7.64e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.21	-0.32	1.5e-9	Breast cancer;
LIHC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.53	0.53	3.24e-26	Alzheimer's disease;
LIHC	cis	rs151997	1.000	rs27284	chr5:50198086	A/G	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11987759	chr7:65425863	GUSB	0.39	6.18	0.32	1.78e-9	Aortic root size;
LIHC	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.21	-0.32	1.53e-9	Coronary artery disease;
LIHC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs921968	1.000	rs4672891	chr2:219271530	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-5.81	-0.3	1.44e-8	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23815043	chr16:88729854	MGC23284;MVD	0.42	6.1	0.31	2.83e-9	Pancreatic cancer;
LIHC	cis	rs4919087	0.715	rs34787876	chr10:98999213	T/C	cg25902810	chr10:99078978	FRAT1	-0.51	-5.91	-0.3	8.29e-9	Monocyte count;
LIHC	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.39	6.72	0.34	7.47e-11	Cognitive performance;
LIHC	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.51	-8.05	-0.4	1.36e-14	Blood pressure (smoking interaction);
LIHC	cis	rs17776563	0.887	rs12324548	chr15:89130155	G/A	cg05013243	chr15:89149849	MIR1179	0.37	6.04	0.31	3.91e-9	Thyroid hormone levels;
LIHC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.74	-11.75	-0.54	5.1e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.3	-17.6	-0.69	7.78e-50	Diabetic kidney disease;
LIHC	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg01652190	chr22:50026171	C22orf34	-0.33	-7.38	-0.37	1.21e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.72	10.15	0.48	2.52e-21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg03146154	chr1:46216737	IPP	-0.48	-8.01	-0.4	1.83e-14	Red blood cell count;Reticulocyte count;
LIHC	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.75	0.3	1.97e-8	Morning vs. evening chronotype;
LIHC	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.47	6.57	0.33	1.86e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.29e-10	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03736562	chr6:100016731	CCNC	-0.38	-6.1	-0.31	2.85e-9	Cognitive function;
LIHC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.67	13.33	0.58	6.18e-33	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10153848	chr1:31769247	SNRNP40;ZCCHC17	0.49	6.81	0.35	4.43e-11	Pancreatic cancer;
LIHC	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.4	0.33	5.15e-10	Lymphocyte counts;
LIHC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.52	-7.61	-0.38	2.78e-13	Multiple sclerosis;
LIHC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	7.7	0.38	1.45e-13	Schizophrenia;
LIHC	trans	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.66	-0.34	1.08e-10	Dental caries;
LIHC	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.82	-0.3	1.33e-8	Blood protein levels;
LIHC	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.98	0.31	5.65e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.39	-6.93	-0.35	2.08e-11	Aortic root size;
LIHC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.72	-0.54	6.7e-27	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098699	0.821	rs4833891	chr4:124231454	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.52	0.33	2.6e-10	Mosquito bite size;
LIHC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.77	0.3	1.79e-8	Morning vs. evening chronotype;
LIHC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.46	7.46	0.37	7.35e-13	Mean corpuscular volume;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.42	0.37	9.56e-13	Prudent dietary pattern;
LIHC	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.94	-0.31	7.15e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.48	5.89	0.3	9.12e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	8.59	0.42	3.17e-16	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13140721	chr3:100053382	NIT2	0.48	6.95	0.35	1.91e-11	Cognitive function;
LIHC	cis	rs12602486	1.000	rs2285953	chr17:42268255	G/C	cg08193365	chr17:42277699	NA	1.04	7.22	0.36	3.49e-12	Glycated hemoglobin levels;
LIHC	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg23367146	chr19:21773418	NA	0.38	5.86	0.3	1.07e-8	Pain;
LIHC	cis	rs3015497	0.594	rs35637875	chr14:51132533	T/G	cg09863266	chr14:51125203	SAV1	-0.4	-6.45	-0.33	3.92e-10	Mean platelet volume;
LIHC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.05	19.59	0.73	8.14e-58	Multiple system atrophy;
LIHC	cis	rs7923837	0.651	rs1573051	chr10:94387334	T/C	cg25506282	chr10:94462361	NA	0.34	5.75	0.3	2e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.41	6.39	0.33	5.49e-10	Lung cancer;
LIHC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.52	-7.46	-0.37	7.05e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13615036	chr15:91475826	UNC45A;HDDC3	-0.47	-6.4	-0.33	5.25e-10	Systolic blood pressure;
LIHC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.56	-0.38	3.75e-13	Bipolar disorder;
LIHC	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg02811702	chr13:24901961	NA	0.27	6.14	0.32	2.3e-9	Obesity-related traits;
LIHC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.72	10.98	0.51	3.13e-24	Aortic root size;
LIHC	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.72	7.17	0.36	4.68e-12	Alzheimer's disease;
LIHC	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-6.34	-0.32	7.3e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.73	0.39	1.18e-13	Prudent dietary pattern;
LIHC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.99	23.08	0.78	1.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2710642	0.540	rs11893614	chr2:62861661	A/G	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.47	6.85	0.35	3.45e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4788570	0.615	rs2052584	chr16:71688977	A/G	cg06353428	chr16:71660113	MARVELD3	-1.37	-14.61	-0.62	6.95e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.65	-8.23	-0.41	4.09e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.72	11.76	0.54	4.74e-27	Night sleep phenotypes;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg00091569	chr3:40428383	ENTPD3	0.39	6.57	0.33	1.91e-10	Renal cell carcinoma;
LIHC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.62	-8.96	-0.44	2.09e-17	Aortic root size;
LIHC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg02990361	chr1:107599529	PRMT6	-0.61	-9.92	-0.47	1.47e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.34	-8.38	-0.41	1.44e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.42	-6.72	-0.34	7.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs7078219	0.505	rs10883362	chr10:101286984	C/T	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.86	-0.3	1.06e-8	Dental caries;
LIHC	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.86	0.3	1.1e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7937890	0.559	rs2597201	chr11:14485404	T/C	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.63	11.09	0.51	1.25e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg07636037	chr3:49044803	WDR6	-0.84	-7.08	-0.36	8.28e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg05926928	chr17:57297772	GDPD1	0.8	8.42	0.41	1.08e-15	Opioid sensitivity;
LIHC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-8.72	-0.43	1.21e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.81	14.81	0.63	1.05e-38	Multiple myeloma (IgH translocation);
LIHC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.26	-0.32	1.12e-9	Alzheimer's disease (late onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24672547	chr12:6977222	TPI1	-0.43	-6.25	-0.32	1.19e-9	Pancreatic cancer;
LIHC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.27	0.37	2.45e-12	Aortic root size;
LIHC	cis	rs12500138	0.850	rs57692509	chr4:166208733	A/G	cg25064052	chr4:166216151	KLHL2	-0.63	-5.89	-0.3	9.1e-9	Cognitive function;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg10217327	chr6:118973057	C6orf204	0.7	7.26	0.37	2.67e-12	Diastolic blood pressure;
LIHC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.4	7.67	0.38	1.84e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg06466757	chr4:1255808	NA	0.35	5.86	0.3	1.06e-8	Obesity-related traits;
LIHC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.39	6.23	0.32	1.34e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg14393609	chr7:65229607	NA	0.35	5.76	0.3	1.92e-8	Aortic root size;
LIHC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.36	6.85	0.35	3.49e-11	Schizophrenia;
LIHC	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg20991723	chr1:152506922	NA	0.55	9.39	0.45	8.94e-19	Hair morphology;
LIHC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg05044414	chr3:183734942	ABCC5	0.34	6.07	0.31	3.33e-9	Anterior chamber depth;
LIHC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.45	6.59	0.34	1.69e-10	Longevity;Endometriosis;
LIHC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg16586182	chr3:47516702	SCAP	-0.51	-9.45	-0.45	5.62e-19	Colorectal cancer;
LIHC	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.32	7.77	0.39	9.38e-14	Corneal astigmatism;
LIHC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.1	0.55	2.72e-28	Body mass index;
LIHC	cis	rs12744310	1.000	rs12731400	chr1:41761352	T/C	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.92	0.65	4.54e-43	Lymphocyte percentage of white cells;
LIHC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg13264159	chr8:625131	ERICH1	-0.62	-6.31	-0.32	8.6e-10	IgG glycosylation;
LIHC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.4	6.47	0.33	3.49e-10	Red blood cell count;
LIHC	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg01652190	chr22:50026171	C22orf34	-0.34	-7.65	-0.38	2.12e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg15832292	chr6:96025679	MANEA	0.61	7.72	0.39	1.27e-13	Behavioural disinhibition (generation interaction);
LIHC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg00656387	chr3:40428638	ENTPD3	-0.38	-6.43	-0.33	4.29e-10	Renal cell carcinoma;
LIHC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.45	-7.58	-0.38	3.23e-13	IgG glycosylation;
LIHC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	10.89	0.51	6.8e-24	Platelet count;
LIHC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg22633049	chr21:46681294	NA	-0.35	-6.02	-0.31	4.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.63	-0.46	1.43e-19	Response to antipsychotic treatment;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04122790	chr1:229762148	URB2;TAF5L	0.48	7.02	0.35	1.21e-11	Cognitive function;
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.88	0.3	9.63e-9	Aortic root size;
LIHC	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg04359351	chr2:3481828	TTC15	0.29	5.71	0.3	2.44e-8	Neurofibrillary tangles;
LIHC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21467203	chr3:49911342	NA	0.43	7.72	0.39	1.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.66	5.99	0.31	5.18e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.65	-0.38	2e-13	Coronary artery disease;
LIHC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.32	-6.73	-0.34	7.14e-11	Longevity;
LIHC	cis	rs9649465	0.704	rs665867	chr7:123432329	A/G	cg03229431	chr7:123269106	ASB15	0.4	8.55	0.42	4.22e-16	Migraine;
LIHC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg03037974	chr15:76606532	NA	0.75	14.57	0.62	9.51e-38	Blood metabolite levels;
LIHC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.43	-0.33	4.26e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.58	6.23	0.32	1.36e-9	Systemic lupus erythematosus;
LIHC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.44	7.2	0.36	3.87e-12	Alcohol dependence;
LIHC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.7	0.57	1.59e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.84	13.96	0.6	2.4e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10384784	chr10:25012964	ARHGAP21	0.43	6.39	0.33	5.35e-10	Pancreatic cancer;
LIHC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.25	0.41	3.52e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.76	-0.3	1.86e-8	Uric acid levels;
LIHC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.35	-5.74	-0.3	2.09e-8	IgG glycosylation;
LIHC	trans	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg16011800	chr17:1958478	HIC1	-0.53	-7.52	-0.38	4.94e-13	Lymphocyte counts;Red cell distribution width;
LIHC	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.2	0.45	3.59e-18	Coffee consumption (cups per day);
LIHC	cis	rs75908454	1.000	rs78270891	chr6:169877832	T/C	cg19338460	chr6:170058176	WDR27	-0.83	-7.6	-0.38	2.89e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.76	12.89	0.57	2.9e-31	Anterior chamber depth;
LIHC	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg19357918	chr11:63953256	STIP1	-0.44	-6.44	-0.33	4.17e-10	Bipolar disorder;
LIHC	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26734620	chr12:56694298	CS	1.23	10.54	0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.48e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.63	9.83	0.47	2.95e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.6	8.63	0.42	2.43e-16	Menopause (age at onset);
LIHC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.79	0.34	5.06e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.62	-8.32	-0.41	2.1e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Vitiligo;
LIHC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.67	5.78	0.3	1.65e-8	Inflammatory bowel disease;
LIHC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.88	0.3	9.6e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs16828019	0.704	rs34486565	chr1:41522510	C/T	cg03387723	chr1:41708464	SCMH1	-0.4	-6.46	-0.33	3.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs2273156	0.706	rs12881698	chr14:35503505	G/A	cg16230307	chr14:35515116	FAM177A1	-0.43	-6.23	-0.32	1.39e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.21	0.41	4.55e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.38	9.14	0.44	5.79e-18	Blood metabolite ratios;
LIHC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20540327	chr15:72668275	HEXA;C15orf34	0.44	6.49	0.33	3.04e-10	Pancreatic cancer;
LIHC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg09417038	chr21:47716443	C21orf57	-0.47	-7.22	-0.36	3.43e-12	Testicular germ cell tumor;
LIHC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.58	11.45	0.53	6.54e-26	Tonsillectomy;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg21774865	chr7:157009442	UBE3C	0.34	6.09	0.31	3e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.54	8.71	0.43	1.3e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.87	10.83	0.51	1.06e-23	Bladder cancer;
LIHC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg06207120	chr15:45996521	NA	0.32	6.02	0.31	4.55e-9	Waist circumference;Weight;
LIHC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.58	9.78	0.47	4.45e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg20607798	chr8:58055168	NA	0.48	6.61	0.34	1.5e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.5	0.38	5.55e-13	Morning vs. evening chronotype;
LIHC	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.8	8.49	0.42	6.31e-16	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.51	-6.48	-0.33	3.11e-10	Hip circumference adjusted for BMI;
LIHC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg18944383	chr4:111397179	ENPEP	0.28	6.41	0.33	4.73e-10	Coronary artery disease;
LIHC	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.08	0.31	3.26e-9	Heart rate;
LIHC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg15691649	chr6:25882328	NA	-0.55	-8.03	-0.4	1.62e-14	Blood metabolite levels;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.6	0.38	2.95e-13	Height;
LIHC	trans	rs3809912	0.693	rs12605081	chr18:12999964	A/G	cg02139827	chr21:34404457	NA	0.24	6.04	0.31	4.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg17724175	chr1:150552817	MCL1	-0.42	-8.42	-0.41	1.08e-15	Melanoma;
LIHC	cis	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg17469321	chr7:55412551	NA	0.51	7.21	0.36	3.52e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs918629	0.530	rs3777190	chr5:95247972	A/G	cg10483112	chr5:95245456	ELL2	0.36	6.65	0.34	1.14e-10	IgG glycosylation;
LIHC	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg01364799	chr7:75623366	TMEM120A	-0.41	-6.12	-0.31	2.5e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04267008	chr7:1944627	MAD1L1	-0.42	-6.51	-0.33	2.76e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.5	6.3	0.32	9.32e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.55	-6.53	-0.33	2.39e-10	Diastolic blood pressure;
LIHC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.71	9.43	0.45	6.34e-19	Body mass index;
LIHC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.8	0.34	4.75e-11	Diabetic kidney disease;
LIHC	cis	rs10861342	0.892	rs74971338	chr12:105499757	C/A	cg23923672	chr12:105501055	KIAA1033	0.65	7.66	0.38	1.88e-13	IgG glycosylation;
LIHC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14257396	chr1:107603778	NA	0.36	5.77	0.3	1.75e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg01231543	chr16:68741748	NA	0.37	5.76	0.3	1.84e-8	Colorectal cancer;
LIHC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-8.97	-0.44	2.06e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.61	11.73	0.54	5.99e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.37	-0.33	6.22e-10	Height;
LIHC	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-9.62	-0.46	1.5700000000000001e-19	Coffee consumption (cups per day);
LIHC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	6.66	0.34	1.1e-10	IgG glycosylation;
LIHC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.55	9.21	0.45	3.36e-18	Aortic root size;
LIHC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg23205692	chr1:25664452	TMEM50A	0.41	6.59	0.34	1.65e-10	Erythrocyte sedimentation rate;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg04282497	chr4:82350883	RASGEF1B	-0.41	-6.4	-0.33	5.01e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.4	6.74	0.34	6.64e-11	Type 2 diabetes;
LIHC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17467752	chr17:38218738	THRA	0.41	6.09	0.31	2.95e-9	Myeloid white cell count;
LIHC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1868673	0.503	rs9867338	chr3:150242048	C/A	cg10752315	chr3:150238463	NA	0.3	5.92	0.3	7.73e-9	Waist circumference;
LIHC	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.29	6.35	0.32	6.91e-10	Pulmonary function;
LIHC	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.59	-9.14	-0.44	5.61e-18	Red blood cell count;
LIHC	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	10.94	0.51	4.35e-24	Fuchs's corneal dystrophy;
LIHC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg00529422	chr1:16285251	ZBTB17	0.35	6.91	0.35	2.32e-11	Systolic blood pressure;
LIHC	trans	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg10756647	chr7:56101905	PSPH	-0.47	-6.89	-0.35	2.66e-11	Calcium levels;
LIHC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.39	-0.49	3.56e-22	Response to antipsychotic treatment;
LIHC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	9.08	0.44	8.96e-18	Platelet count;
LIHC	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.53	-0.33	2.32e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.36	6.09	0.31	3.12e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.07	-0.44	9.32e-18	Morning vs. evening chronotype;
LIHC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.72	0.34	7.69e-11	Lung cancer in ever smokers;
LIHC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.19	-0.36	4.16e-12	Alcohol dependence;
LIHC	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.95	19.97	0.73	2.32e-59	Bone mineral density;
LIHC	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg06611532	chr13:114900021	NA	0.37	6.83	0.35	3.81e-11	Schizophrenia;
LIHC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.21	-0.36	3.53e-12	Migraine;Coronary artery disease;
LIHC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.74	-10.63	-0.5	5.22e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	0.97	10.53	0.49	1.19e-22	Vitiligo;
LIHC	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg16070018	chr6:26224392	HIST1H3E	0.8	7.54	0.38	4.2e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.54	6.52	0.33	2.45e-10	IFN-related cytopenia;
LIHC	cis	rs365132	0.517	rs6881002	chr5:176336755	T/C	cg16309518	chr5:176445507	NA	0.52	9.86	0.47	2.43e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs611744	0.967	rs685690	chr8:109192145	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	6.6	0.34	1.59e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	10.89	0.51	6.5e-24	Alzheimer's disease (late onset);
LIHC	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.0	-0.44	1.56e-17	Schizophrenia;
LIHC	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg26395211	chr5:140044315	WDR55	0.41	6.09	0.31	2.99e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.44	0.42	9.06e-16	Menarche (age at onset);
LIHC	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg03934865	chr2:198174659	NA	-0.45	-6.65	-0.34	1.17e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg16583315	chr14:65563665	MAX	-0.42	-8.43	-0.41	9.65e-16	Obesity-related traits;
LIHC	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.14	10.02	0.48	6.68e-21	Schizophrenia;
LIHC	cis	rs10416265	0.528	rs28654374	chr19:33613610	G/A	cg17764715	chr19:33622953	WDR88	0.48	6.36	0.33	6.28e-10	Bone properties (heel);
LIHC	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.23	-0.52	4.16e-25	Eye color traits;
LIHC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.36	0.37	1.42e-12	Parkinson's disease;
LIHC	cis	rs807029	0.533	rs67813203	chr10:102738551	A/G	cg27255678	chr10:102756921	LZTS2	0.52	7.31	0.37	1.85e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-8.71	-0.43	1.37e-16	Gut microbiome composition (summer);
LIHC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.75	-10.45	-0.49	2.25e-22	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.36	-6.37	-0.33	5.93e-10	Aortic root size;
LIHC	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg23254163	chr1:152506842	NA	0.22	5.8	0.3	1.48e-8	Hair morphology;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09655887	chr7:133083962	EXOC4	0.38	6.88	0.35	2.93e-11	Hepatitis;
LIHC	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.55	-8.4	-0.41	1.21e-15	White matter hyperintensity burden;
LIHC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.78	6.17	0.32	1.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01390039	chr16:89315293	NA	0.44	6.22	0.32	1.44e-9	Longevity;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg12517452	chr5:52084045	ITGA1;PELO	-0.53	-6.94	-0.35	1.96e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2292864	0.681	rs35735886	chr17:45374277	G/T	cg18085866	chr17:45331354	ITGB3	-0.66	-6.96	-0.35	1.71e-11	Left atrial antero-posterior diameter;
LIHC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-5.98	-0.31	5.69e-9	Colorectal cancer;
LIHC	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.9	10.83	0.51	1.11e-23	Coronary artery disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14620208	chr9:140652685	EHMT1	0.49	6.62	0.34	1.42e-10	Hepatitis;
LIHC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.64	-10.77	-0.5	1.67e-23	Bipolar disorder;
LIHC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.55	-9.14	-0.44	5.79e-18	Colorectal cancer;
LIHC	cis	rs4586057	0.514	rs11186350	chr10:92649368	G/T	cg14313238	chr10:92632228	RPP30	0.36	6.04	0.31	4.03e-9	Economic and political preferences (time);
LIHC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg18912006	chr12:123335444	HIP1R	-0.64	-7.67	-0.38	1.78e-13	Schizophrenia;
LIHC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.5	-8.6	-0.42	2.87e-16	Menopause (age at onset);
LIHC	cis	rs12022452	0.591	rs12042242	chr1:40993873	A/G	cg25568243	chr1:40974465	DEM1	-0.45	-6.1	-0.31	2.82e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg05527609	chr1:210001259	C1orf107	-0.56	-7.67	-0.38	1.81e-13	Red blood cell count;
LIHC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.57	9.31	0.45	1.64e-18	Lymphocyte counts;
LIHC	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.89	0.39	4.16e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.58	8.87	0.43	4.25e-17	Height;
LIHC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-6.66	-0.34	1.1e-10	Fibrinogen levels;
LIHC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	7.98	0.4	2.16e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	6.76	0.34	6.05e-11	Renal cell carcinoma;
LIHC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg08847533	chr14:75593920	NEK9	0.51	7.7	0.38	1.46e-13	IgG glycosylation;
LIHC	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg00292662	chr22:38071168	LGALS1	0.38	6.32	0.32	7.99e-10	Fat distribution (HIV);
LIHC	cis	rs655641	0.954	rs637304	chr11:85685166	A/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.01	-0.31	4.66e-9	Platelet count;
LIHC	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.89	-0.35	2.74e-11	Neutrophil percentage of white cells;
LIHC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-5.92	-0.3	7.98e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs12464559	0.579	rs10185966	chr2:152582523	A/G	cg01189475	chr2:152685088	ARL5A	0.67	7.69	0.38	1.61e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26118675	chr2:96256841	TRIM43	0.42	6.06	0.31	3.53e-9	Systolic blood pressure;
LIHC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.51	7.66	0.38	1.93e-13	High light scatter reticulocyte count;
LIHC	trans	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.5	0.38	5.5e-13	Aortic root size;
LIHC	cis	rs2273156	1.000	rs12050404	chr14:35461870	G/A	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.04	-0.31	3.96e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.23	12.75	0.57	9.88e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg14092571	chr14:90743983	NA	-0.38	-6.09	-0.31	2.97e-9	Mortality in heart failure;
LIHC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.05	0.36	9.72e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.71	-13.2	-0.58	1.94e-32	Facial morphology (factor 23);
LIHC	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.63	11.5	0.53	4.27e-26	Schizophrenia;
LIHC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.43	6.58	0.34	1.81e-10	Total body bone mineral density;
LIHC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg05941027	chr17:61774174	LIMD2	0.34	6.43	0.33	4.39e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-8.07	-0.4	1.22e-14	Putamen volume;
LIHC	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	0.92	18.0	0.7	1.88e-51	Schizophrenia;
LIHC	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.38	9.45	0.46	5.42e-19	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.49	-7.98	-0.4	2.19e-14	Neutrophil percentage of white cells;
LIHC	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.62	7.55	0.38	3.9e-13	Exhaled nitric oxide output;
LIHC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.56	11.01	0.51	2.4e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.05	0.36	9.65e-12	Protein C levels;
LIHC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.67	0.57	1.98e-30	Total body bone mineral density;
LIHC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.59	10.29	0.49	8.02e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-6.9	-0.35	2.55e-11	Bipolar disorder;
LIHC	trans	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.69	-10.05	-0.48	5.55e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.58	11.5	0.53	4.36e-26	Tonsillectomy;
LIHC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg23758822	chr17:41437982	NA	0.95	17.06	0.68	1.18e-47	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10916814	1.000	rs12145310	chr1:20901064	C/A	cg24502330	chr1:20914028	CDA	-0.28	-5.91	-0.3	8.28e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.56	7.95	0.4	2.67e-14	Bone properties (heel);
LIHC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.17	0.4	5.99e-15	Lymphocyte counts;
LIHC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.47	-9.27	-0.45	2.19e-18	Atrioventricular conduction;
LIHC	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg09918751	chr15:100517450	ADAMTS17	0.77	13.49	0.59	1.51e-33	Height;
LIHC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.94	-17.68	-0.69	3.78e-50	Schizophrenia;
LIHC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.84	-0.35	3.65e-11	Personality dimensions;
LIHC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.21	-5.82	-0.3	1.33e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.17	-0.32	1.88e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.76	11.71	0.54	7.22e-27	Corneal astigmatism;
LIHC	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg01364799	chr7:75623366	TMEM120A	-0.43	-6.44	-0.33	4.14e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	7.05	0.36	1.02e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.3	-0.41	2.51e-15	Obesity-related traits;
LIHC	cis	rs7116495	1.000	rs7121260	chr11:71700566	C/T	cg26138937	chr11:71823887	C11orf51	-0.75	-7.44	-0.37	8.04e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.1	0.4	1.01e-14	Alzheimer's disease;
LIHC	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.5	9.5	0.46	3.65e-19	Testicular germ cell tumor;
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.87	12.52	0.56	7.35e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg04025307	chr7:1156635	C7orf50	0.38	6.02	0.31	4.42e-9	Longevity;Endometriosis;
LIHC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.78	-0.3	1.64e-8	Axial length;
LIHC	cis	rs860626	0.512	rs2786198	chr10:119313196	A/G	cg10846980	chr10:119306025	EMX2;EMX2OS	-0.53	-8.21	-0.41	4.6e-15	Neuroticism;
LIHC	cis	rs3736485	0.934	rs8036904	chr15:51861438	G/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg15691649	chr6:25882328	NA	0.57	7.41	0.37	1.02e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.66	-10.26	-0.49	1e-21	Lung cancer;
LIHC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.42	6.07	0.31	3.34e-9	Schizophrenia;
LIHC	trans	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg10756647	chr7:56101905	PSPH	1.03	12.52	0.56	7.08e-30	Diabetic kidney disease;
LIHC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.35	7.58	0.38	3.37e-13	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs7716219	0.524	rs57997842	chr5:54869982	G/T	cg14753740	chr5:54468940	CDC20B;MIR449C	0.44	6.19	0.32	1.77e-9	Height;
LIHC	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg03962019	chr1:41807865	NA	0.5	7.32	0.37	1.73e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-10.6	-0.5	7.01e-23	Vitiligo;
LIHC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	6.37	0.33	6.26e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs72960926	0.744	rs72952273	chr6:74926284	C/T	cg07247405	chr1:2484626	LOC115110	0.55	6.61	0.34	1.44e-10	Metabolite levels (MHPG);
LIHC	cis	rs2637266	0.783	rs846634	chr10:78535323	C/A	cg18941641	chr10:78392320	NA	0.28	5.96	0.31	6.12e-9	Pulmonary function;
LIHC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg10621924	chr7:39171070	POU6F2	0.41	6.45	0.33	3.86e-10	IgG glycosylation;
LIHC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.24	-0.55	7.9e-29	Primary sclerosing cholangitis;
LIHC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.32	6.32	0.32	8.31e-10	Monocyte count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.38	6.09	0.31	3.09e-9	Cognitive function;
LIHC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.62	10.58	0.5	8.03e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.58	8.76	0.43	9.34e-17	Response to diuretic therapy;
LIHC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg25039879	chr17:56429692	SUPT4H1	0.8	9.04	0.44	1.18e-17	Cognitive test performance;
LIHC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.07	0.36	8.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs17290760	1.000	rs17289655	chr9:32486507	A/G	cg22609511	chr7:28891164	NA	0.61	6.39	0.33	5.57e-10	Immune response to smallpox vaccine (IL-6);
LIHC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	14.74	0.62	2.1e-38	Gut microbiome composition (summer);
LIHC	cis	rs1564271	0.961	rs2927921	chr10:27016001	A/C	cg13837822	chr10:26931731	LOC731789	0.33	5.85	0.3	1.13e-8	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg10755058	chr3:40428713	ENTPD3	0.4	6.94	0.35	2.02e-11	Renal cell carcinoma;
LIHC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.58	-0.46	2.06e-19	Bipolar disorder;
LIHC	cis	rs1144333	0.522	rs1144338	chr1:76279908	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-7.08	-0.36	8.2e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	10.67	0.5	4.05e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.62	7.7	0.38	1.51e-13	Crohn's disease;
LIHC	cis	rs9513627	1.000	rs6491511	chr13:100198717	C/A	cg25919922	chr13:100150906	NA	0.77	6.89	0.35	2.62e-11	Obesity-related traits;
LIHC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg08499158	chr17:42289980	UBTF	0.52	8.54	0.42	4.64e-16	Total body bone mineral density;
LIHC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.8	-6.29	-0.32	9.77e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.61	-9.91	-0.47	1.67e-20	Schizophrenia;
LIHC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg03854865	chr6:26224070	HIST1H3E	-0.58	-6.62	-0.34	1.37e-10	Gout;Renal underexcretion gout;
LIHC	trans	rs6580110	0.714	rs9324791	chr5:154078556	T/C	cg02272667	chr7:1922866	MAD1L1	0.29	6.05	0.31	3.72e-9	Facial morphology (factor 9, facial height related to vertical position of nasion);
LIHC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.0	-14.26	-0.61	1.6e-36	Breast cancer;
LIHC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01171360	chr6:293285	DUSP22	-0.41	-6.13	-0.31	2.38e-9	Menopause (age at onset);
LIHC	cis	rs9942416	0.533	rs4704235	chr5:75024380	A/C	cg19683494	chr5:74908142	NA	0.57	6.17	0.32	1.97e-9	Age-related disease endophenotypes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10577273	chr11:64595102	CDC42BPG	0.42	6.21	0.32	1.55e-9	Longevity;
LIHC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.68	0.5	3.64e-23	Bladder cancer;
LIHC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.68	9.94	0.47	1.24e-20	Testicular germ cell tumor;
LIHC	trans	rs11039100	0.920	rs12792905	chr11:5821544	G/C	cg11650987	chr12:10280440	CLEC7A	0.4	6.05	0.31	3.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1499280	0.790	rs7719925	chr5:52105306	T/G	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.7	-8.55	-0.42	4.24e-16	Gut microbiome composition (summer);
LIHC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	6.51	0.33	2.73e-10	Osteoporosis;
LIHC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.62	-10.32	-0.49	6.59e-22	Obesity-related traits;
LIHC	cis	rs57784326	1	rs57784326	chr15:49796630	A/AG	cg04482760	chr15:49339272	SECISBP2L	0.42	6.28	0.32	1e-9	Bacterial meningitis;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.15	0.55	1.79e-28	Prudent dietary pattern;
LIHC	cis	rs1728785	0.892	rs9928950	chr16:68557114	G/A	cg02972257	chr16:68554789	NA	0.58	6.12	0.31	2.51e-9	Ulcerative colitis;
LIHC	trans	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg09872104	chr7:134855509	C7orf49	-0.76	-6.19	-0.32	1.68e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.3	-0.45	1.67e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.34	-6.98	-0.35	1.52e-11	Renal cell carcinoma;
LIHC	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.57	0.33	1.9e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.71	-11.86	-0.54	2.11e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.26	-0.41	3.25e-15	Gut microbiome composition (summer);
LIHC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.9	-11.99	-0.54	6.73e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs7937890	0.572	rs2597202	chr11:14484645	C/T	cg02886208	chr11:14281011	SPON1	-0.5	-6.74	-0.34	6.69e-11	Mitochondrial DNA levels;
LIHC	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg08888203	chr3:10149979	C3orf24	0.44	5.79	0.3	1.57e-8	Alzheimer's disease;
LIHC	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg17130504	chr10:102756923	LZTS2	0.55	7.55	0.38	3.92e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.59	8.81	0.43	6.49e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg16583315	chr14:65563665	MAX	-0.42	-8.57	-0.42	3.63e-16	Obesity-related traits;
LIHC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.39	-0.33	5.47e-10	Longevity;Endometriosis;
LIHC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.25	-0.45	2.47e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg24163568	chr5:669837	TPPP	0.39	8.14	0.4	7.4e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.41	5.73	0.3	2.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.69	9.33	0.45	1.36e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.99	-19.35	-0.72	7.4e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.34	6.16	0.32	2.07e-9	Lewy body disease;
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.31	0.32	8.85e-10	Alzheimer's disease;
LIHC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg21522988	chr12:29376872	FAR2	0.29	6.69	0.34	9.39e-11	QT interval;
LIHC	cis	rs7534824	0.625	rs61780284	chr1:101355166	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	6.77	0.34	5.7e-11	Refractive astigmatism;
LIHC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.77	-9.49	-0.46	4.14e-19	Gut microbiome composition (summer);
LIHC	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg18898632	chr2:242989856	NA	-0.58	-7.81	-0.39	6.93e-14	Obesity-related traits;
LIHC	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.5	-9.05	-0.44	1.13e-17	Atrioventricular conduction;
LIHC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg27494647	chr7:150038898	RARRES2	0.34	6.23	0.32	1.4e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.39	-8.16	-0.4	6.3e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs12431939	1.000	rs55851845	chr14:51645583	A/T	cg23942311	chr14:51606299	NA	-0.36	-6.07	-0.31	3.48e-9	Cancer;
LIHC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-10.85	-0.51	8.93e-24	Obesity-related traits;
LIHC	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.42	-5.72	-0.3	2.33e-8	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14589014	chr11:2952043	PHLDA2	0.46	6.48	0.33	3.26e-10	Lung function (FEV1/FVC);
LIHC	cis	rs882732	0.744	rs11847476	chr14:95047605	G/T	cg14866387	chr14:95027382	SERPINA4	-0.49	-6.44	-0.33	4.08e-10	Blood protein levels;
LIHC	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg01557791	chr16:72042693	DHODH	-0.45	-6.13	-0.31	2.44e-9	Coronary artery disease;
LIHC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	9.57	0.46	2.3e-19	Tonsillectomy;
LIHC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.45	7.96	0.4	2.55e-14	Monocyte percentage of white cells;
LIHC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.8	12.7	0.57	1.49e-30	Breast cancer;
LIHC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.68e-9	Life satisfaction;
LIHC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.5	-6.76	-0.34	5.85e-11	Aortic root size;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.61	6.96	0.35	1.78e-11	Alzheimer's disease;
LIHC	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.57	-7.95	-0.4	2.71e-14	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	trans	rs12155400	0.661	rs1030557	chr7:18346636	A/G	cg18816595	chr3:42750454	CCDC13	0.4	6.27	0.32	1.11e-9	Retinopathy in non-diabetics;
LIHC	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg10820045	chr2:198174542	NA	0.48	7.43	0.37	8.73e-13	Dermatomyositis;
LIHC	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.45	-6.94	-0.35	1.93e-11	Life satisfaction;
LIHC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.72	-10.85	-0.51	8.84e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.87	0.3	1.02e-8	Tonsillectomy;
LIHC	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg26211634	chr5:139558579	C5orf32	-0.38	-5.85	-0.3	1.13e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.82	14.51	0.62	1.67e-37	Adiposity;
LIHC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.93	17.21	0.68	3.03e-48	Parkinson's disease;
LIHC	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-6.23	-0.32	1.33e-9	Resting heart rate;
LIHC	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.36	-5.89	-0.3	9.35e-9	Cocaine dependence;
LIHC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.84	0.3	1.21e-8	Resting heart rate;
LIHC	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.51	8.28	0.41	2.82e-15	Plateletcrit;Platelet count;
LIHC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.75	12.24	0.55	8.04e-29	Neutrophil percentage of white cells;
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08280861	chr8:58055591	NA	0.5	6.18	0.32	1.78e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7129220	0.588	rs7124925	chr11:10143700	G/A	cg01453529	chr11:10209919	SBF2	-0.38	-6.71	-0.34	8.23e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.44	-6.93	-0.35	2.06e-11	Schizophrenia;
LIHC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.37	6.31	0.32	8.89e-10	Schizophrenia;
LIHC	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	6.61	0.34	1.52e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.66	7.3	0.37	2.08e-12	Protein C levels;
LIHC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.54	0.77	1.37e-69	Chronic sinus infection;
LIHC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-7.31	-0.37	1.96e-12	Uric acid levels;
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	0.6	8.46	0.42	8.12e-16	Prudent dietary pattern;
LIHC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg25801113	chr15:45476975	SHF	0.36	6.15	0.32	2.22e-9	Uric acid levels;
LIHC	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.84	-0.35	3.68e-11	Metabolite levels;
LIHC	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg27205649	chr11:78285834	NARS2	-0.41	-6.22	-0.32	1.42e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	0.53	7.02	0.35	1.2e-11	Pulse pressure;
LIHC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.5	-8.14	-0.4	7.3e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs244293	0.730	rs11079142	chr17:53021955	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.01	-0.31	4.83e-9	Menarche (age at onset);
LIHC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.53	-0.46	2.98e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs9425766	0.640	rs2281486	chr1:173822221	A/G	cg06124660	chr1:173389066	NA	-0.33	-6.4	-0.33	5.25e-10	Life satisfaction;
LIHC	cis	rs3736485	0.932	rs2124879	chr15:51916833	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.14	-0.32	2.23e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-12.72	-0.57	1.27e-30	Coffee consumption (cups per day);
LIHC	cis	rs3099143	0.901	rs3764244	chr15:77223740	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-7.07	-0.36	8.97e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.49	6.77	0.34	5.52e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.68	7.38	0.37	1.22e-12	Exhaled nitric oxide output;
LIHC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-7.0	-0.35	1.36e-11	Morning vs. evening chronotype;
LIHC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.48	7.55	0.38	4.04e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.75	-11.24	-0.52	3.6e-25	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.51	-8.18	-0.4	5.64e-15	Cognitive function;
LIHC	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	0.92	10.0	0.48	7.97e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3736594	0.546	rs6734059	chr2:27808154	C/T	cg27432699	chr2:27873401	GPN1	-0.46	-6.92	-0.35	2.27e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.05	0.36	1.01e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.43	6.11	0.31	2.71e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27309920	chr12:6798957	ZNF384	0.45	7.36	0.37	1.35e-12	Cognitive function;
LIHC	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg14298269	chr14:102689372	WDR20	0.38	6.13	0.31	2.47e-9	Bipolar disorder;
LIHC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.67	13.39	0.59	3.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.42	6.0	0.31	5.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.6	-12.22	-0.55	9.85e-29	Plateletcrit;Platelet count;
LIHC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.42	6.66	0.34	1.12e-10	Schizophrenia;
LIHC	cis	rs3770081	0.826	rs1019591	chr2:86298599	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.86	-8.52	-0.42	5.12e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.44	5.86	0.3	1.07e-8	Height;
LIHC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg04865290	chr3:52927548	TMEM110	-0.51	-5.9	-0.3	8.82e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs3764618	1.000	rs3764617	chr19:49497123	T/C	cg14640682	chr19:49496473	GYS1;RUVBL2	-0.73	-5.95	-0.31	6.8e-9	Follicule stimulating hormone;
LIHC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.49	7.62	0.38	2.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs864643	1.000	rs1340222	chr3:39549803	C/T	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg03999872	chr20:62272968	STMN3	-0.46	-6.81	-0.35	4.44e-11	Atopic dermatitis;
LIHC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-5.86	-0.3	1.08e-8	Prostate cancer;
LIHC	cis	rs911119	1.000	rs734801	chr20:23612791	A/G	cg16589663	chr20:23618590	CST3	0.74	7.76	0.39	1e-13	Chronic kidney disease;
LIHC	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg22771759	chr13:24902376	NA	0.33	6.89	0.35	2.66e-11	Obesity-related traits;
LIHC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18252515	chr7:66147081	NA	0.42	6.03	0.31	4.17e-9	Aortic root size;
LIHC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.33	-7.22	-0.36	3.42e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg17385448	chr1:15911702	AGMAT	0.35	5.94	0.31	7.07e-9	Systolic blood pressure;
LIHC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.9	12.2	0.55	1.15e-28	Blood metabolite levels;
LIHC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.86	-0.51	8.71e-24	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-10.38	-0.49	4.15e-22	Platelet count;
LIHC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.51	7.95	0.39	2.74e-14	Tonsillectomy;
LIHC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.9	0.3	8.66e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08754654	chr5:154026448	NA	-0.33	-7.26	-0.37	2.61e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg26338869	chr17:61819248	STRADA	0.51	6.76	0.34	5.95e-11	Height;
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg05185784	chr16:90016020	DEF8	-0.48	-6.18	-0.32	1.84e-9	Skin colour saturation;
LIHC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.51	7.14	0.36	5.65e-12	Morning vs. evening chronotype;
LIHC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.55	0.69	1.29e-49	Tonsillectomy;
LIHC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.39	-6.6	-0.34	1.61e-10	Mean arterial pressure;
LIHC	trans	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg07393940	chr7:158741817	NA	-0.57	-6.75	-0.34	6.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs8141529	0.600	rs916332	chr22:29308414	C/T	cg15103426	chr22:29168792	CCDC117	0.44	6.07	0.31	3.41e-9	Lymphocyte counts;
LIHC	trans	rs4699052	0.537	rs1580278	chr4:104140848	A/C	cg16471864	chr4:38666270	KLF3;FLJ13197	0.43	6.09	0.31	3e-9	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.46	8.96	0.44	2.13e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.38	-0.37	1.22e-12	Breast cancer;
LIHC	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg08694578	chr2:241835147	C2orf54	-0.63	-10.17	-0.48	2.19e-21	Urinary metabolites;
LIHC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.8	-0.39	7.5e-14	Ulcerative colitis;
LIHC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.68	-9.28	-0.45	2.01e-18	Aortic root size;
LIHC	cis	rs2710642	0.751	rs10496099	chr2:62805902	T/C	cg17519650	chr2:63277830	OTX1	0.43	6.21	0.32	1.54e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg16797656	chr11:68205561	LRP5	0.54	8.52	0.42	5.02e-16	Total body bone mineral density;
LIHC	trans	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg01596870	chr19:55963115	NA	-0.64	-8.58	-0.42	3.33e-16	Obesity-related traits;
LIHC	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.33	-6.34	-0.32	7.21e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.57	0.33	1.82e-10	Axial length;
LIHC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.4	6.08	0.31	3.19e-9	Osteoporosis;
LIHC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-7.22	-0.36	3.41e-12	Diabetic kidney disease;
LIHC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg07002422	chr16:996172	LMF1	-0.39	-6.53	-0.33	2.44e-10	Non-glioblastoma glioma;Glioblastoma;Glioma;
LIHC	cis	rs9443189	0.806	rs9359139	chr6:76487269	C/G	cg01950844	chr6:76311363	SENP6	0.48	5.79	0.3	1.56e-8	Prostate cancer;
LIHC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.92	0.31	7.7e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg07133347	chr1:107600762	PRMT6	0.45	6.77	0.34	5.67e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.59	10.36	0.49	4.57e-22	Longevity;Endometriosis;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg05114486	chr19:875279	MED16	0.39	6.09	0.31	3.01e-9	Alopecia areata;
LIHC	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg03342759	chr3:160939853	NMD3	-0.48	-7.09	-0.36	7.89e-12	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.63	9.71	0.46	7.86e-20	Renal cell carcinoma;
LIHC	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.5	-7.39	-0.37	1.11e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.29	0.41	2.55e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09563731	chr19:4090587	MAP2K2	0.44	6.37	0.33	6.03e-10	Bilirubin levels;
LIHC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.47	6.86	0.35	3.32e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.71	-11.18	-0.52	6.24e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-10.07	-0.48	4.6e-21	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04362369	chr14:21905501	CHD8	-0.42	-6.15	-0.32	2.19e-9	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15159625	chr1:118042759	MAN1A2	0.3	6.25	0.32	1.22e-9	Cognitive function;
LIHC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.77	13.31	0.58	7.55e-33	Mean platelet volume;
LIHC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.02	-0.31	4.51e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg03263716	chr11:64435066	NRXN2	0.34	7.38	0.37	1.22e-12	Body mass index;Urate levels;
LIHC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.9	0.43	3.43e-17	Alzheimer's disease;
LIHC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg03037974	chr15:76606532	NA	0.61	10.43	0.49	2.6e-22	Blood metabolite levels;
LIHC	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.47	-7.41	-0.37	9.94e-13	Blood metabolite levels;
LIHC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.38	0.37	1.2e-12	Morning vs. evening chronotype;
LIHC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.29	-0.45	1.84e-18	Chronic sinus infection;
LIHC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.34	-6.81	-0.35	4.38e-11	Body mass index;
LIHC	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.38	5.76	0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.67	0.42	1.74e-16	Corneal astigmatism;
LIHC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.41	7.27	0.37	2.44e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.17e-12	HDL cholesterol levels;
LIHC	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.35	6.9	0.35	2.57e-11	Cancer;
LIHC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.59	-6.95	-0.35	1.87e-11	Menarche (age at onset);
LIHC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.61	9.46	0.46	5.17e-19	Height;
LIHC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.67	-0.5	3.83e-23	Breast cancer;
LIHC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.47	7.05	0.36	1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.88	0.54	1.78e-27	Motion sickness;
LIHC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.4	-5.74	-0.3	2.05e-8	Cognitive ability;
LIHC	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.68	10.69	0.5	3.45e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.95	-0.31	6.62e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8081395	0.834	rs11650106	chr17:57850251	C/T	cg13753209	chr17:57696993	CLTC	-0.45	-6.9	-0.35	2.5e-11	White blood cell count;
LIHC	cis	rs992157	0.764	rs2891076	chr2:219184398	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.72	10.15	0.48	2.48e-21	Colorectal cancer;
LIHC	cis	rs77633900	0.772	rs284901	chr15:76747761	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-5.93	-0.31	7.23e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.57	9.3	0.45	1.75e-18	Multiple sclerosis;
LIHC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	5.77	0.3	1.81e-8	Tonsillectomy;
LIHC	cis	rs9596863	0.898	rs13378790	chr13:54372312	T/C	ch.13.53330881F	chr13:54432880	NA	0.43	5.74	0.3	2.1e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg03999872	chr20:62272968	STMN3	-0.46	-6.84	-0.35	3.6e-11	Atopic dermatitis;
LIHC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19671926	chr4:122722719	EXOSC9	-0.41	-5.78	-0.3	1.65e-8	Type 2 diabetes;
LIHC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.81	13.06	0.58	6.5e-32	Breast cancer;
LIHC	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg21100191	chr22:23484243	RTDR1	0.86	15.29	0.64	1.4e-40	Bone mineral density;
LIHC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-7.04	-0.36	1.09e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg01518246	chr11:63870912	FLRT1;MACROD1	0.44	6.04	0.31	4.02e-9	Mean platelet volume;
LIHC	cis	rs858239	0.539	rs6945510	chr7:23192240	C/T	cg23682824	chr7:23144976	KLHL7	0.45	6.77	0.34	5.72e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	trans	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg01596870	chr19:55963115	NA	-0.62	-7.48	-0.37	6.14e-13	Obesity-related traits;
LIHC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-6.18	-0.32	1.82e-9	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01025762	chr7:107531363	DLD	0.52	7.22	0.36	3.35e-12	Pancreatic cancer;
LIHC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.43	-6.8	-0.35	4.74e-11	Schizophrenia;
LIHC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.35	5.73	0.3	2.25e-8	Lung cancer;
LIHC	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.57	-8.62	-0.42	2.58e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.56	9.84	0.47	2.69e-20	Alcohol dependence;
LIHC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.07	0.36	8.65e-12	Hemoglobin concentration;
LIHC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg19635926	chr16:89946313	TCF25	0.53	6.5	0.33	2.8e-10	Skin colour saturation;
LIHC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.44	-0.33	4.17e-10	Crohn's disease;
LIHC	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs963731	0.579	rs997344	chr2:39281730	G/C	cg04010122	chr2:39346883	SOS1	-0.66	-6.08	-0.31	3.3e-9	Corticobasal degeneration;
LIHC	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.71	-7.37	-0.37	1.3e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.89	8.69	0.43	1.55e-16	Inflammatory bowel disease;
LIHC	trans	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.38	0.59	4.07e-33	Diabetic kidney disease;
LIHC	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg26138937	chr11:71823887	C11orf51	-1.31	-10.34	-0.49	5.49e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.49	-7.91	-0.39	3.7e-14	Testicular germ cell tumor;
LIHC	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg26138937	chr11:71823887	C11orf51	-1.32	-9.94	-0.47	1.33e-20	Severe influenza A (H1N1) infection;
LIHC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg14580859	chr9:123691850	NA	0.38	6.73	0.34	7.08e-11	Rheumatoid arthritis;
LIHC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.67	9.86	0.47	2.31e-20	Menopause (age at onset);
LIHC	cis	rs9596863	0.847	rs4537884	chr13:54327936	A/G	ch.13.53330881F	chr13:54432880	NA	0.44	6.06	0.31	3.56e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg15654264	chr1:150340011	RPRD2	0.49	8.13	0.4	7.9e-15	Migraine;
LIHC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.6	-11.04	-0.51	1.92e-24	Menopause (age at onset);
LIHC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg17764715	chr19:33622953	WDR88	0.4	5.72	0.3	2.29e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24141233	chr1:212781895	ATF3	0.54	6.92	0.35	2.22e-11	Lung function (FEV1/FVC);
LIHC	cis	rs55665837	0.540	rs10832294	chr11:14747427	C/A	cg00085434	chr11:14927489	NA	0.4	5.79	0.3	1.56e-8	Vitamin D levels;
LIHC	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.26	-0.41	3.24e-15	Vitamin D levels;
LIHC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg12798992	chr6:167411361	FGFR1OP	0.56	7.8	0.39	7.78e-14	Crohn's disease;
LIHC	cis	rs74181299	0.684	rs6741255	chr2:65306905	C/T	cg05010058	chr2:65284262	CEP68	-0.4	-6.61	-0.34	1.44e-10	Pulse pressure;
LIHC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.55	9.95	0.47	1.14e-20	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.93	0.47	1.36e-20	Colorectal cancer;
LIHC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg15208524	chr1:10270712	KIF1B	0.37	5.72	0.3	2.3e-8	Hepatocellular carcinoma;
LIHC	cis	rs4466137	0.794	rs975595	chr5:83010095	G/A	cg16102102	chr5:83017553	HAPLN1	-0.43	-6.67	-0.34	1.04e-10	Prostate cancer;
LIHC	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.69	10.28	0.49	8.68e-22	Monocyte count;
LIHC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.6	8.12	0.4	8.39e-15	Coronary artery disease;
LIHC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.48	-7.96	-0.4	2.5e-14	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.29	0.66	1.46e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-8.71	-0.43	1.37e-16	Gut microbiome composition (summer);
LIHC	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.62	-7.31	-0.37	1.87e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.31	7.52	0.38	4.8e-13	Alcohol dependence;
LIHC	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.22	6.03	0.31	4.25e-9	Calcium levels;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg10755058	chr3:40428713	ENTPD3	-0.4	-6.92	-0.35	2.2e-11	Renal cell carcinoma;
LIHC	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.67	10.61	0.5	6.34e-23	Obesity-related traits;
LIHC	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15664640	chr17:80829946	TBCD	-0.58	-6.25	-0.32	1.25e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.59	-0.42	3.07e-16	Obesity-related traits;
LIHC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.6	7.3	0.37	1.98e-12	Cognitive function;
LIHC	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.2	-0.48	1.67e-21	Ear protrusion;
LIHC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.5	8.89	0.43	3.64e-17	Height;
LIHC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.34	0.45	1.25e-18	Bipolar disorder;
LIHC	cis	rs6144337	1	rs6144337	chr11:47284302	TCCATGTGCCTCA/T	cg26139080	chr11:47293733	MADD	-0.42	-5.89	-0.3	9.26e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs6066825	0.627	rs6019349	chr20:47275245	A/G	cg18078177	chr20:47281410	PREX1	0.44	7.31	0.37	1.96e-12	Colorectal cancer;
LIHC	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg22951263	chr5:87985283	NA	-0.39	-6.73	-0.34	7.13e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.54	8.92	0.43	2.94e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg12751644	chr20:60527061	NA	-0.52	-8.63	-0.42	2.32e-16	Obesity-related traits;
LIHC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg26395211	chr5:140044315	WDR55	0.43	6.34	0.32	7.35e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.94	15.93	0.65	3.95e-43	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.39e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.69	-9.95	-0.47	1.23e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	11.46	0.53	5.85e-26	Colorectal cancer;
LIHC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.89	-18.62	-0.71	6.08e-54	Height;
LIHC	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.83	-0.39	5.99e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27297192	chr10:134578999	INPP5A	0.55	7.56	0.38	3.74e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.87	12.4	0.56	2.01e-29	Body mass index;
LIHC	cis	rs9318086	0.534	rs12428855	chr13:24382961	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.35	-5.72	-0.3	2.34e-8	Myopia (pathological);
LIHC	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.57	8.46	0.42	7.85e-16	White matter hyperintensity burden;
LIHC	trans	rs12702919	0.692	rs6961826	chr7:9558915	T/C	cg22961275	chr19:40005758	SELV	-0.4	-6.04	-0.31	4.11e-9	PR interval in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.5	9.49	0.46	4.15e-19	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-0.99	-11.44	-0.53	6.81e-26	Vitiligo;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg00280220	chr17:61926910	NA	0.42	6.89	0.35	2.73e-11	Prudent dietary pattern;
LIHC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	0.53	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.45	6.59	0.34	1.63e-10	Response to bleomycin (chromatid breaks);
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.23	-0.32	1.36e-9	Menopause (age at onset);
LIHC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.8	6.82	0.35	4.15e-11	Body mass index;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.77	11.55	0.53	2.86e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.64	6.81	0.35	4.51e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7149242	0.922	rs9671394	chr14:101159674	C/T	cg11726507	chr14:101155519	NA	-0.27	-5.98	-0.31	5.6e-9	Platelet count;
LIHC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.94	0.44	2.48e-17	Cognitive ability;
LIHC	cis	rs2257205	0.667	rs9909635	chr17:56752159	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.47	-0.33	3.49e-10	Pancreatic cancer;
LIHC	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-9.79	-0.47	4.25e-20	Inflammatory bowel disease;
LIHC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.81	-0.3	1.41e-8	Headache;
LIHC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-7.13	-0.36	6.01e-12	Blood metabolite levels;
LIHC	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.71	10.08	0.48	4.44e-21	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.64	-7.7	-0.38	1.44e-13	Morning vs. evening chronotype;
LIHC	cis	rs7173389	0.530	rs6495063	chr15:73682708	G/T	cg01796676	chr15:73680284	NA	0.53	8.59	0.42	3.07e-16	Resting heart rate;
LIHC	cis	rs965469	1.000	rs2236117	chr20:3302021	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-6.74	-0.34	6.9e-11	IFN-related cytopenia;
LIHC	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.54	14.17	0.61	3.61e-36	Alzheimer's disease (late onset);
LIHC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05564831	chr3:52568323	NT5DC2	0.36	5.93	0.31	7.39e-9	Electroencephalogram traits;
LIHC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg17724175	chr1:150552817	MCL1	0.41	8.05	0.4	1.34e-14	Melanoma;
LIHC	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg20737812	chr15:86336631	KLHL25	-0.44	-6.1	-0.31	2.83e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	19.18	0.72	3.65e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.98	17.69	0.69	3.49e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg03013999	chr17:37608204	MED1	-0.36	-5.99	-0.31	5.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13409248	chr3:40428643	ENTPD3	0.41	6.62	0.34	1.37e-10	Renal cell carcinoma;
LIHC	cis	rs11696739	0.536	rs11696842	chr20:1600794	C/T	cg15722679	chr20:1638393	SIRPG	0.54	9.78	0.47	4.43e-20	Mean platelet volume;
LIHC	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg00409905	chr10:38381863	ZNF37A	0.47	7.14	0.36	5.79e-12	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg08469215	chr1:156261351	TMEM79	0.39	6.24	0.32	1.27e-9	Tonsillectomy;
LIHC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg10360323	chr17:41437877	NA	0.41	6.07	0.31	3.37e-9	Menopause (age at onset);
LIHC	cis	rs2274273	0.624	rs7155954	chr14:55750943	G/A	cg01864836	chr14:55583639	NA	-0.35	-5.8	-0.3	1.48e-8	Protein biomarker;
LIHC	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.8	0.39	7.47e-14	Corneal astigmatism;
LIHC	cis	rs3857067	0.530	rs17021364	chr4:95047893	C/T	cg11021082	chr4:95130006	SMARCAD1	0.41	6.72	0.34	7.78e-11	QT interval;
LIHC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.43	6.49	0.33	3.02e-10	Lipoprotein (a) levels;
LIHC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.6	-0.62	7.2e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.4	-6.24	-0.32	1.33e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.83	-9.04	-0.44	1.15e-17	Vitiligo;
LIHC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	0.61	8.91	0.43	3.16e-17	Prudent dietary pattern;
LIHC	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.52	8.59	0.42	3.2e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.78	0.43	7.96e-17	Coffee consumption (cups per day);
LIHC	cis	rs9918079	0.542	rs12499412	chr4:15602252	G/C	cg16509355	chr4:15471240	CC2D2A	0.46	7.1	0.36	7.27e-12	Obesity-related traits;
LIHC	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.58	-7.55	-0.38	4.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	0.86	16.76	0.67	1.89e-46	Schizophrenia;
LIHC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.08	0.44	9.13e-18	Eosinophil percentage of white cells;
LIHC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg10932868	chr11:921992	NA	0.4	7.48	0.38	6.23e-13	Alzheimer's disease (late onset);
LIHC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.4	6.3	0.32	9.39e-10	Tonsillectomy;
LIHC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg19743168	chr1:23544995	NA	0.35	5.96	0.31	6.14e-9	Height;
LIHC	cis	rs6450176	0.564	rs6874524	chr5:53343529	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.72	13.07	0.58	6e-32	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg05425664	chr17:57184151	TRIM37	-0.47	-5.89	-0.3	9.43e-9	Vitamin D levels;
LIHC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17776563	0.959	rs28687418	chr15:89115862	G/A	cg05013243	chr15:89149849	MIR1179	0.46	7.56	0.38	3.85e-13	Thyroid hormone levels;
LIHC	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.67	8.4	0.41	1.2e-15	Corneal astigmatism;
LIHC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.75	11.43	0.53	7.8e-26	Corneal astigmatism;
LIHC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.24	0.55	8.15e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.4	-6.14	-0.31	2.35e-9	Adiposity;
LIHC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg16102536	chr7:156981717	UBE3C	-0.35	-5.94	-0.31	7.12e-9	Body mass index;
LIHC	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg00601450	chr5:74908170	NA	0.58	6.94	0.35	2.02e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.37	0.33	6.11e-10	Bipolar disorder;
LIHC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.46	-6.11	-0.31	2.64e-9	Serum sulfate level;
LIHC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.09	0.36	7.92e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.19	0.52	5.46e-25	Menarche (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08528519	chr14:100659610	NA	-0.43	-6.24	-0.32	1.3e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.4	-0.37	1.04e-12	Chronic sinus infection;
LIHC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg05590025	chr7:65112418	INTS4L2	-0.57	-6.25	-0.32	1.2e-9	Diabetic kidney disease;
LIHC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08822215	chr16:89438651	ANKRD11	-0.45	-7.01	-0.35	1.25e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09597638	chr17:3907349	NA	0.52	7.19	0.36	4.18e-12	Type 2 diabetes;
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.94	0.31	7.1e-9	Obesity-related traits;
LIHC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.35	-5.74	-0.3	2.12e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.46	-6.04	-0.31	3.91e-9	Vitiligo;
LIHC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg19645103	chr12:69753606	YEATS4	-0.46	-6.32	-0.32	8.22e-10	Response to diuretic therapy;
LIHC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg04025307	chr7:1156635	C7orf50	0.44	5.81	0.3	1.44e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs10792665	0.902	rs7928520	chr11:82654471	T/C	cg24227371	chr11:82718527	RAB30	-0.3	-6.89	-0.35	2.63e-11	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18603276	chr17:8023961	HES7	0.47	6.11	0.31	2.66e-9	Lung function (FEV1/FVC);
LIHC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.96	-0.47	1.08e-20	Obesity-related traits;
LIHC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.96	-11.7	-0.53	7.99e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg13986249	chr9:37903631	MCART1	-0.43	-6.11	-0.31	2.66e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.01	15.8	0.65	1.26e-42	Corneal structure;
LIHC	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg12798992	chr6:167411361	FGFR1OP	0.59	9.78	0.47	4.38e-20	Crohn's disease;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.59	6.73	0.34	7.03e-11	Alzheimer's disease;
LIHC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20135002	chr11:47629003	NA	-0.57	-10.07	-0.48	4.6e-21	Subjective well-being;
LIHC	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02985541	chr2:219472218	PLCD4	-0.35	-6.12	-0.31	2.62e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg01652190	chr22:50026171	C22orf34	-0.31	-7.23	-0.36	3.16e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.61	10.29	0.49	7.89e-22	Alcohol dependence;
LIHC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.89	0.39	4.02e-14	Multiple sclerosis;
LIHC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg06640241	chr16:89574553	SPG7	0.64	9.97	0.47	1.04e-20	Multiple myeloma (IgH translocation);
LIHC	trans	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg26939375	chr7:64535504	NA	0.41	6.47	0.33	3.36e-10	Aortic root size;
LIHC	cis	rs6750047	0.605	rs59501228	chr2:38261972	A/C	cg07380506	chr2:38303506	CYP1B1	-0.59	-7.45	-0.37	7.81e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	13.92	0.6	3.4000000000000003e-35	Bipolar disorder;
LIHC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.93	0.7	3.71e-51	Tonsillectomy;
LIHC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.3	-0.45	1.65e-18	Bipolar disorder;
LIHC	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.7	9.37	0.45	1.05e-18	Mean platelet volume;
LIHC	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg27124370	chr19:33622961	WDR88	-0.49	-6.89	-0.35	2.62e-11	Bone properties (heel);
LIHC	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	7.8	0.39	7.67e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	1.14	9.03	0.44	1.28e-17	Arsenic metabolism;
LIHC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.36	-5.86	-0.3	1.07e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06634786	chr22:41940651	POLR3H	0.57	6.17	0.32	1.95e-9	Vitiligo;
LIHC	trans	rs6887276	0.504	rs1003136	chr5:127347815	A/G	cg16011800	chr17:1958478	HIC1	-0.39	-6.06	-0.31	3.69e-9	Height;
LIHC	cis	rs864643	1.000	rs1768261	chr3:39551985	G/A	cg05136238	chr3:39556330	MOBP	0.31	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.11	0.31	2.66e-9	Schizophrenia;
LIHC	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.92	-0.3	7.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg26138937	chr11:71823887	C11orf51	1.21	10.32	0.49	6.46e-22	Severe influenza A (H1N1) infection;
LIHC	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.31	-5.87	-0.3	1.06e-8	Red blood cell count;
LIHC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.61	9.22	0.45	3.1e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2274273	0.870	rs4496026	chr14:55790512	A/G	cg01864836	chr14:55583639	NA	-0.37	-6.57	-0.33	1.9e-10	Protein biomarker;
LIHC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg03945807	chr20:60948434	NA	-0.35	-6.37	-0.33	5.94e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.72	-0.3	2.34e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.67	13.37	0.59	4.49e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.36	0.37	1.39e-12	Bipolar disorder;
LIHC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg19645103	chr12:69753606	YEATS4	-0.45	-6.04	-0.31	3.93e-9	Response to diuretic therapy;
LIHC	cis	rs6466055	0.720	rs7357199	chr7:105019355	G/C	cg04380332	chr7:105027541	SRPK2	-0.38	-7.02	-0.35	1.2e-11	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs1144333	0.850	rs1146651	chr1:76273594	C/A	cg22875332	chr1:76189707	ACADM	-0.42	-6.78	-0.34	5.34e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.46	7.2	0.36	3.83e-12	Blood protein levels;
LIHC	cis	rs2016586	0.802	rs5999973	chr22:36115594	G/A	cg26342177	chr22:36113512	APOL5	-0.39	-6.57	-0.33	1.82e-10	Body mass index;
LIHC	trans	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.59	6.82	0.35	4.12e-11	Menarche (age at onset);
LIHC	cis	rs2380220	0.808	rs2613548	chr6:95910559	C/T	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.49	5.85	0.3	1.18e-8	Schizophrenia;
LIHC	trans	rs60752752	0.852	rs4772	chr1:153346263	C/T	cg14901121	chr8:98817630	LAPTM4B	0.44	7.04	0.36	1.08e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1789	0.903	rs6850422	chr4:15682437	C/T	cg21329975	chr4:15471214	CC2D2A	-0.4	-5.9	-0.3	8.89e-9	Blood protein levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26119740	chr11:73881915	C2CD3;PPME1	0.45	6.43	0.33	4.19e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs17125944	0.615	rs1886785	chr14:53312106	A/C	cg00686598	chr14:53173677	PSMC6	-0.78	-9.33	-0.45	1.36e-18	Alzheimer's disease (late onset);
LIHC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.53	8.44	0.42	8.9e-16	Lung cancer;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg22887498	chr19:39401301	NA	0.42	6.27	0.32	1.08e-9	Alopecia areata;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg04775238	chr2:202646121	ALS2	0.31	6.07	0.31	3.38e-9	Calcium levels;
LIHC	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg14515779	chr1:101123966	NA	-0.68	-13.14	-0.58	3.21e-32	Monocyte count;
LIHC	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.55	0.38	4.03e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg21361702	chr7:150065534	REPIN1	0.48	6.61	0.34	1.45e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg07451762	chr16:28383216	NA	0.34	6.47	0.33	3.31e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs895636	0.749	rs748947	chr2:45192600	A/C	cg16198908	chr2:45192207	NA	0.39	5.77	0.3	1.77e-8	Metabolite levels;Fasting plasma glucose;
LIHC	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg08992911	chr2:238395768	MLPH	0.49	5.98	0.31	5.6e-9	Prostate cancer;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.55	6.93	0.35	2.08e-11	Alzheimer's disease;
LIHC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.79	-11.94	-0.54	1.02e-27	Total body bone mineral density;
LIHC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.38	5.97	0.31	6.05e-9	Hemoglobin concentration;
LIHC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.62	8.12	0.4	8.69e-15	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.43	7.36	0.37	1.34e-12	Aortic root size;
LIHC	trans	rs6866721	0.755	rs10062108	chr5:116215157	T/C	cg07571379	chr11:134631427	NA	-0.29	-6.09	-0.31	3.08e-9	Body mass index;
LIHC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg26395211	chr5:140044315	WDR55	0.41	5.89	0.3	9.4e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.23	18.12	0.7	6.75e-52	Type 1 diabetes nephropathy;
LIHC	cis	rs4699052	0.963	rs11733615	chr4:104157164	C/T	cg16532752	chr4:104119610	CENPE	-0.4	-6.21	-0.32	1.56e-9	Testicular germ cell tumor;
LIHC	trans	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg26939375	chr7:64535504	NA	0.41	6.48	0.33	3.13e-10	Aortic root size;
LIHC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.58	7.83	0.39	6.22e-14	Coronary artery disease;
LIHC	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.61	6.52	0.33	2.57e-10	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg14580859	chr9:123691850	NA	0.37	6.56	0.33	1.95e-10	Rheumatoid arthritis;
LIHC	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.3	-6.15	-0.32	2.22e-9	Testicular germ cell tumor;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg00061764	chr3:67564432	SUCLG2	0.41	6.05	0.31	3.86e-9	Longevity;
LIHC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.95	0.35	1.88e-11	Melanoma;
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg13126279	chr21:47581558	C21orf56	-0.39	-6.08	-0.31	3.19e-9	Testicular germ cell tumor;
LIHC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.56	10.02	0.48	7.09e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6598955	0.670	rs6598942	chr1:26531034	C/T	cg00852783	chr1:26633632	UBXN11	0.47	7.73	0.39	1.19e-13	Obesity-related traits;
LIHC	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.55	-8.12	-0.4	8.82e-15	Blood pressure (smoking interaction);
LIHC	cis	rs16958440	0.708	rs62096462	chr18:44625179	C/G	cg17192377	chr18:44677553	HDHD2	0.52	6.53	0.33	2.38e-10	Sitting height ratio;
LIHC	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.6	-8.87	-0.43	4.25e-17	Blood protein levels;
LIHC	cis	rs273218	1.000	rs156385	chr5:53370749	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.66	10.65	0.5	4.49e-23	Migraine;
LIHC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg00656387	chr3:40428638	ENTPD3	0.4	6.34	0.32	7.16e-10	Renal cell carcinoma;
LIHC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.59	-0.46	1.93e-19	Bipolar disorder;
LIHC	cis	rs4684776	0.877	rs4684065	chr3:11376559	G/T	cg00170343	chr3:11313890	ATG7	0.49	6.7	0.34	8.74e-11	Small vessel stroke;
LIHC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg17980119	chr2:219472607	PLCD4	0.37	6.33	0.32	7.76e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6788895	1.000	rs73008905	chr3:150465435	T/C	cg09723797	chr3:150481914	SIAH2	0.87	12.1	0.55	2.6e-28	Breast cancer;
LIHC	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.56	-6.45	-0.33	3.89e-10	Ulcerative colitis;
LIHC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.9	19.55	0.73	1.18e-57	Blood protein levels;
LIHC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg09824255	chr5:140014002	CD14	0.29	6.22	0.32	1.43e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.32	-0.45	1.45e-18	Schizophrenia;
LIHC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.96	18.61	0.71	6.65e-54	Ewing sarcoma;
LIHC	cis	rs28830936	0.966	rs8025714	chr15:42120157	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.11	-0.31	2.7e-9	Diastolic blood pressure;
LIHC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.63	7.95	0.39	2.8e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-8.25	-0.41	3.45e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg16070018	chr6:26224392	HIST1H3E	0.57	7.01	0.35	1.29e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.55	-0.33	2.11e-10	Type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.95	-9.36	-0.45	1.09e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12960505	0.506	rs67680898	chr18:50961057	C/G	cg24270629	chr18:50823537	DCC	-0.49	-6.72	-0.34	7.53e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.75	-11.81	-0.54	3.03e-27	Morning vs. evening chronotype;
LIHC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.76	-0.43	9.03e-17	Atrioventricular conduction;
LIHC	cis	rs2073300	0.826	rs6083136	chr20:23454188	A/G	cg12062639	chr20:23401060	NAPB	0.6	7.12	0.36	6.37e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.52	8.39	0.41	1.29e-15	Dialysis-related mortality;
LIHC	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.59	-0.42	3.07e-16	Obesity-related traits;
LIHC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg03037974	chr15:76606532	NA	0.74	14.45	0.62	2.75e-37	Blood metabolite levels;
LIHC	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.35	6.04	0.31	3.91e-9	Mean corpuscular volume;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.66	-0.34	1.07e-10	Lymphocyte counts;
LIHC	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-7.21	-0.36	3.57e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg23387056	chr11:14280742	SPON1	-0.46	-6.32	-0.32	8.39e-10	Mitochondrial DNA levels;
LIHC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.38	6.69	0.34	9.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs3762637	0.941	rs74467988	chr3:122083140	C/T	cg24169773	chr3:122142474	KPNA1	-0.48	-9.35	-0.45	1.21e-18	LDL cholesterol levels;
LIHC	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.76	-0.39	9.71e-14	Lymphocyte counts;
LIHC	cis	rs9596863	0.898	rs9596850	chr13:54371713	C/T	ch.13.53330881F	chr13:54432880	NA	0.43	5.8	0.3	1.53e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	9.66	0.46	1.1e-19	Mean platelet volume;
LIHC	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.5	9.57	0.46	2.23e-19	Testicular germ cell tumor;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg13711851	chr9:124080947	GSN	-0.37	-6.12	-0.31	2.59e-9	Calcium levels;
LIHC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.73	12.24	0.55	8.07e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-6.91	-0.35	2.38e-11	Prostate cancer;
LIHC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg07527105	chr16:88053339	BANP	0.4	5.72	0.3	2.28e-8	Menopause (age at onset);
LIHC	cis	rs10508774	1.000	rs72782234	chr10:32935433	G/T	cg01819863	chr10:32635814	EPC1	0.64	5.94	0.31	6.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg23601095	chr6:26197514	HIST1H3D	0.54	5.79	0.3	1.58e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg19752551	chr11:57585705	CTNND1	-0.51	-7.08	-0.36	8.46e-12	Schizophrenia;
LIHC	cis	rs1144333	1.000	rs60144605	chr1:76359699	A/C	cg10523679	chr1:76189770	ACADM	0.47	6.69	0.34	9.36e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.68	8.74	0.43	1.03e-16	Initial pursuit acceleration;
LIHC	cis	rs918629	0.530	rs967546	chr5:95232551	G/A	cg10483112	chr5:95245456	ELL2	-0.35	-6.4	-0.33	5.21e-10	IgG glycosylation;
LIHC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.6	9.31	0.45	1.58e-18	Chronic sinus infection;
LIHC	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25632853	chr15:73088954	NA	0.37	6.26	0.32	1.19e-9	Triglyceride levels;
LIHC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.57	8.57	0.42	3.65e-16	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.41	6.47	0.33	3.39e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13161895	1.000	rs35973843	chr5:179466502	T/C	cg06664874	chr5:179499304	RNF130	0.61	7.56	0.38	3.66e-13	LDL cholesterol;
LIHC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-11.48	-0.53	4.85e-26	Longevity;Endometriosis;
LIHC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.51	7.83	0.39	6.04e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.64	-10.78	-0.5	1.64e-23	Gut microbiota (bacterial taxa);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07495314	chr13:27845355	RASL11A	-0.51	-6.25	-0.32	1.19e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg00677901	chr16:88017247	BANP	0.52	7.99	0.4	2.11e-14	Menopause (age at onset);
LIHC	cis	rs7116495	1.000	rs7113549	chr11:71829967	T/C	cg26138937	chr11:71823887	C11orf51	0.71	7.3	0.37	2.08e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.26	6.13	0.31	2.38e-9	Heart rate;
LIHC	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.81	-0.35	4.3e-11	Homocysteine levels;
LIHC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.8	12.02	0.55	5.26e-28	Motion sickness;
LIHC	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.41	8.65	0.42	2.02e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg20607798	chr8:58055168	NA	0.47	5.89	0.3	9.13e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg10756647	chr7:56101905	PSPH	0.99	11.92	0.54	1.2e-27	Gout;
LIHC	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.71	8.12	0.4	8.55e-15	Schizophrenia;
LIHC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.74	-9.36	-0.45	1.07e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs61041384	0.661	rs75589918	chr12:123594402	G/C	cg25930673	chr12:123319894	HIP1R	0.66	6.26	0.32	1.18e-9	Schizophrenia;
LIHC	cis	rs1023500	1.000	rs6002548	chr22:42337040	T/G	cg04733989	chr22:42467013	NAGA	-0.51	-6.03	-0.31	4.34e-9	Schizophrenia;
LIHC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.8	-16.25	-0.66	2.1e-44	Height;
LIHC	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.5	-9.26	-0.45	2.35e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg00800038	chr16:89945340	TCF25	-0.6	-8.82	-0.43	5.89e-17	Skin colour saturation;
LIHC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.43	6.13	0.31	2.47e-9	Morning vs. evening chronotype;
LIHC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	13.91	0.6	3.56e-35	Cognitive test performance;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.61	0.53	1.76e-26	Prudent dietary pattern;
LIHC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	1.17	10.98	0.51	3.04e-24	Obesity-related traits;
LIHC	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.65	-12.37	-0.56	2.67e-29	Endometriosis;
LIHC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.82	0.3	1.33e-8	Self-reported allergy;
LIHC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	1.15	9.06	0.44	1.04e-17	Arsenic metabolism;
LIHC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.53	-8.12	-0.4	8.52e-15	P wave terminal force;
LIHC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.61	-0.46	1.65e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.04	0.36	1.03e-11	Diabetic kidney disease;
LIHC	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.71	10.13	0.48	3e-21	Lymphocyte counts;
LIHC	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.53	-8.01	-0.4	1.82e-14	Response to antidepressants and depression;
LIHC	cis	rs4788570	0.566	rs3886947	chr16:71483958	G/C	cg06353428	chr16:71660113	MARVELD3	-1.13	-10.17	-0.48	2.17e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2380220	0.808	rs2613551	chr6:95914740	G/A	cg15832292	chr6:96025679	MANEA	-0.62	-7.02	-0.35	1.2e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.27	-0.32	1.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg11764359	chr7:65958608	NA	0.57	6.02	0.31	4.62e-9	Diabetic kidney disease;
LIHC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg21522988	chr12:29376872	FAR2	0.28	6.38	0.33	5.81e-10	QT interval;
LIHC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.71	10.17	0.48	2.1e-21	Menarche (age at onset);
LIHC	cis	rs8192917	1.000	rs8192917	chr14:25102160	C/T	cg03875678	chr14:25103546	GZMB	-0.42	-7.7	-0.38	1.49e-13	Vitiligo;
LIHC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.45	6.94	0.35	1.93e-11	Longevity;
LIHC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg19680672	chr10:131412579	MGMT	0.46	6.99	0.35	1.48e-11	Response to temozolomide;
LIHC	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.49	7.21	0.36	3.55e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg06742321	chr12:123595122	PITPNM2	0.31	5.83	0.3	1.32e-8	Platelet count;
LIHC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.51	-7.7	-0.38	1.45e-13	Height;
LIHC	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.74	7.8	0.39	7.8e-14	Schizophrenia;
LIHC	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-7.62	-0.38	2.52e-13	Vitamin D levels;
LIHC	cis	rs17106184	1.000	rs58574309	chr1:50960180	C/T	cg07174182	chr1:51127561	FAF1	-0.64	-7.07	-0.36	8.74e-12	Type 2 diabetes;
LIHC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.69	8.96	0.44	2.15e-17	Initial pursuit acceleration;
LIHC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.5	-8.46	-0.42	7.76e-16	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg12798992	chr6:167411361	FGFR1OP	0.44	6.85	0.35	3.44e-11	Primary biliary cholangitis;
LIHC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.98	-18.28	-0.7	1.42e-52	Breast cancer;
LIHC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.9	16.63	0.67	6.04e-46	Coronary artery disease;
LIHC	cis	rs11229555	0.645	rs4517537	chr11:58213695	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.64	-0.38	2.25e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.68	-8.21	-0.41	4.63e-15	Neuroticism;
LIHC	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg25179470	chr10:102756915	LZTS2	0.45	6.23	0.32	1.36e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.46	0.42	7.75e-16	Resting heart rate;
LIHC	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg06795125	chr2:108905320	SULT1C2	0.3	6.13	0.31	2.38e-9	Blood pressure;
LIHC	cis	rs7212590	0.748	rs59685433	chr17:57891207	T/C	cg10252138	chr17:58120427	NA	-0.62	-6.11	-0.31	2.66e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs28530618	0.580	rs11167174	chr20:31248879	G/A	cg13636640	chr20:31349939	DNMT3B	-0.42	-5.78	-0.3	1.66e-8	Birth weight;
LIHC	cis	rs7116495	1.000	rs10128658	chr11:71733519	C/T	cg26138937	chr11:71823887	C11orf51	-0.83	-8.45	-0.42	8.57e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.21	-5.84	-0.3	1.2e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.23	15.9	0.65	5.11e-43	Alzheimer's disease (late onset);
LIHC	trans	rs12780046	0.656	rs1578708	chr10:100827319	T/C	cg05980083	chr9:112191166	PTPN3	-0.46	-6.06	-0.31	3.63e-9	Non-glioblastoma glioma;
LIHC	cis	rs888194	0.738	rs7311187	chr12:109937907	C/T	cg05360138	chr12:110035743	NA	0.4	5.74	0.3	2.07e-8	Neuroticism;
LIHC	trans	rs875971	1.000	rs709595	chr7:65817333	G/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.74	9.87	0.47	2.19e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.37	6.75	0.34	6.39e-11	Aortic root size;
LIHC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/T	cg23043544	chr7:2124092	MAD1L1	-0.94	-9.01	-0.44	1.45e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs7572733	0.555	rs7590828	chr2:198940251	A/G	cg03934865	chr2:198174659	NA	-0.43	-6.27	-0.32	1.12e-9	Dermatomyositis;
LIHC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg26441486	chr22:50317300	CRELD2	-0.35	-6.32	-0.32	7.96e-10	Schizophrenia;
LIHC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.73	10.78	0.5	1.65e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs16854884	0.632	rs62267390	chr3:143644067	A/T	cg06585982	chr3:143692056	C3orf58	0.63	8.77	0.43	8.72e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.43	-6.95	-0.35	1.81e-11	Menarche (age at onset);
LIHC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.39	-6.03	-0.31	4.33e-9	Height;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.48	0.56	1.06e-29	Prudent dietary pattern;
LIHC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11645453	chr3:52864694	ITIH4	0.22	6.22	0.32	1.44e-9	Bipolar disorder;
LIHC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg14393609	chr7:65229607	NA	0.37	5.72	0.3	2.3e-8	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04226401	chr1:100818170	CDC14A	0.47	6.58	0.34	1.79e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg05564831	chr3:52568323	NT5DC2	-0.37	-5.92	-0.3	7.97e-9	Bipolar disorder;
LIHC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.02	0.4	1.65e-14	Motion sickness;
LIHC	cis	rs922107	0.688	rs10922661	chr1:90024094	T/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.7	-0.38	1.49e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.58	-6.05	-0.31	3.88e-9	Hair shape;
LIHC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.53	8.18	0.4	5.75e-15	Lymphocyte counts;
LIHC	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.63	7.82	0.39	6.43e-14	Crohn's disease;
LIHC	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	8.94e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LIHC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.34	0.32	7.11e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.36	6.92	0.35	2.24e-11	Multiple system atrophy;
LIHC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	10.24	0.48	1.2e-21	Personality dimensions;
LIHC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.11	16.42	0.66	4.34e-45	Sexual dysfunction (female);
LIHC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg02503808	chr4:7069936	GRPEL1	-0.79	-10.82	-0.5	1.19e-23	Monocyte percentage of white cells;
LIHC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.11	-0.4	9.32e-15	Exhaled nitric oxide output;
LIHC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg16226627	chr15:75307476	SCAMP5	0.54	10.05	0.48	5.36e-21	Lung cancer;
LIHC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07305463	chr2:136567211	LCT	-0.38	-5.85	-0.3	1.17e-8	Corneal structure;
LIHC	cis	rs986417	0.892	rs8010656	chr14:60797112	G/A	cg27398547	chr14:60952738	C14orf39	-0.73	-7.45	-0.37	7.7e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.38	6.01	0.31	4.64e-9	Multiple sclerosis;
LIHC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.87	12.52	0.56	7.35e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg15448220	chr1:150897856	SETDB1	0.36	5.75	0.3	1.96e-8	Tonsillectomy;
LIHC	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.82	9.56	0.46	2.33e-19	Red blood cell traits;
LIHC	cis	rs4474465	0.833	rs6592792	chr11:78271614	A/C	cg27205649	chr11:78285834	NARS2	0.44	6.37	0.33	6.27e-10	Alzheimer's disease (survival time);
LIHC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.07	-0.4	1.19e-14	Monocyte percentage of white cells;
LIHC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.69	-8.02	-0.4	1.68e-14	Schizophrenia;
LIHC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.31	-7.88	-0.39	4.49e-14	Schizophrenia;
LIHC	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.76	-8.34	-0.41	1.89e-15	Exhaled nitric oxide output;
LIHC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.56	-9.11	-0.44	7.06e-18	Fibrinogen levels;
LIHC	cis	rs11958404	0.929	rs60700182	chr5:157438376	A/G	cg05962755	chr5:157440814	NA	0.99	11.5	0.53	4.32e-26	IgG glycosylation;
LIHC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.41	6.66	0.34	1.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.76	13.03	0.58	8.94e-32	Mean platelet volume;
LIHC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.29	-0.78	1.49e-72	Height;
LIHC	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.35	8.5	0.42	5.99e-16	Cutaneous nevi;
LIHC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg22496339	chr2:162101262	NA	-0.52	-7.07	-0.36	8.57e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LIHC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.46	-0.37	7.03e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7668874	0.581	rs55845194	chr4:116741283	T/C	cg08917878	chr5:172668965	NA	-0.3	-6.1	-0.31	2.87e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.77	0.39	9.29e-14	Lymphocyte counts;
LIHC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.6	-9.39	-0.45	8.6e-19	Platelet count;
LIHC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg19302996	chr17:73780495	UNK	-0.6	-9.49	-0.46	4e-19	White matter hyperintensity burden;
LIHC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.01	-0.35	1.27e-11	Menopause (age at onset);
LIHC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.49	-8.36	-0.41	1.64e-15	Multiple sclerosis;
LIHC	cis	rs4934494	0.768	rs34663515	chr10:91392543	C/G	cg19698084	chr10:91461284	KIF20B	-0.48	-6.61	-0.34	1.5e-10	Red blood cell count;
LIHC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08219700	chr8:58056026	NA	0.52	7.14	0.36	5.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.56	-0.5	9.42e-23	Alzheimer's disease;
LIHC	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.66	-7.78	-0.39	8.93e-14	Mean platelet volume;
LIHC	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.55	-7.36	-0.37	1.39e-12	Type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg23649088	chr2:200775458	C2orf69	0.67	7.67	0.38	1.78e-13	LDL cholesterol to HDL cholesterol ratio;
LIHC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.67	-11.23	-0.52	4.11e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.47	0.37	6.68e-13	Height;
LIHC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.93	14.52	0.62	1.45e-37	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs7091068	0.566	rs7909925	chr10:95507170	A/G	cg20715218	chr10:95462985	C10orf4	0.56	5.84	0.3	1.2e-8	Urinary tract infection frequency;
LIHC	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.67	10.71	0.5	2.88e-23	Obesity-related traits;
LIHC	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.33	-0.32	7.9e-10	Bipolar disorder;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg14828511	chr1:107599125	PRMT6	-0.41	-5.8	-0.3	1.53e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs332507	0.830	rs333355	chr3:124393595	A/G	cg05980111	chr3:124395277	KALRN	0.45	6.94	0.35	2.03e-11	Plateletcrit;
LIHC	cis	rs17125944	0.615	rs8003334	chr14:53374967	C/T	cg00686598	chr14:53173677	PSMC6	0.86	9.32	0.45	1.43e-18	Alzheimer's disease (late onset);
LIHC	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.43	7.08	0.36	8.25e-12	Menopause (age at onset);
LIHC	cis	rs10503871	0.725	rs7017861	chr8:30373040	G/A	cg26383811	chr8:30366931	RBPMS	0.43	7.5	0.38	5.38e-13	Metabolite levels  (X-11787);
LIHC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	8.49	0.42	6.53e-16	Response to bleomycin (chromatid breaks);
LIHC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-5.88	-0.3	9.9e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.68	11.53	0.53	3.45e-26	Menopause (age at onset);
LIHC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-5.84	-0.3	1.2e-8	Aortic root size;
LIHC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.36	5.95	0.31	6.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg22771759	chr13:24902376	NA	0.32	6.8	0.35	4.62e-11	Obesity-related traits;
LIHC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06544989	chr22:39130855	UNC84B	0.36	6.07	0.31	3.34e-9	Menopause (age at onset);
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.42	-6.38	-0.33	5.62e-10	Menopause (age at onset);
LIHC	cis	rs7095607	0.606	rs7095492	chr10:69957375	C/T	cg18986048	chr10:69913749	MYPN	0.39	5.88	0.3	9.94e-9	Lung function (FVC);
LIHC	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.77	-0.43	8.31e-17	Ulcerative colitis;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg19846264	chr17:4125408	ANKFY1	0.4	6.17	0.32	1.9e-9	Immature fraction of reticulocytes;
LIHC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg21395723	chr22:39101663	GTPBP1	0.37	5.77	0.3	1.82e-8	Menopause (age at onset);
LIHC	cis	rs2625529	0.824	rs11072346	chr15:72400434	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.86	-0.3	1.06e-8	Red blood cell count;
LIHC	cis	rs2607426	1.000	rs2279699	chr19:41284398	G/A	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.5	-5.78	-0.3	1.71e-8	Blood protein levels;
LIHC	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.49	0.38	5.93e-13	Lymphocyte counts;
LIHC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20135002	chr11:47629003	NA	-0.56	-9.64	-0.46	1.35e-19	Subjective well-being;
LIHC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.62	-8.2	-0.41	4.9e-15	Exhaled nitric oxide output;
LIHC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.88	13.19	0.58	2.03e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18942022	chr15:59949764	GTF2A2	-0.62	-7.51	-0.38	5.2e-13	Systolic blood pressure;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.76	11.93	0.54	1.12e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.87	-0.3	1.05e-8	Aortic root size;
LIHC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-5.78	-0.3	1.7e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.22	0.32	1.43e-9	Prudent dietary pattern;
LIHC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.71	11.91	0.54	1.33e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg11647651	chr17:4710373	PLD2	-0.56	-6.41	-0.33	4.79e-10	Systolic blood pressure;
LIHC	trans	rs1814175	0.564	rs12416819	chr11:49755567	T/C	cg03929089	chr4:120376271	NA	-0.85	-16.54	-0.67	1.44e-45	Height;
LIHC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.52	7.73	0.39	1.17e-13	Renal cell carcinoma;
LIHC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg08499158	chr17:42289980	UBTF	-0.51	-8.28	-0.41	2.82e-15	Total body bone mineral density;
LIHC	cis	rs7945718	0.591	rs7926971	chr11:12698040	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.92	0.39	3.42e-14	Educational attainment (years of education);
LIHC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.57	-0.46	2.16e-19	Alzheimer's disease;
LIHC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg16736954	chr20:23401023	NAPB	0.69	8.11	0.4	9.04e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	0.61	6.14	0.32	2.31e-9	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.23	-0.41	3.96e-15	Obesity-related traits;
LIHC	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.11	0.61	5.84e-36	Bipolar disorder;
LIHC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.49	6.03	0.31	4.14e-9	Total body bone mineral density;
LIHC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.61	-10.92	-0.51	4.95e-24	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.65	-9.25	-0.45	2.49e-18	Menopause (age at onset);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13240253	chr3:71245529	FOXP1	0.35	6.14	0.32	2.23e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	14.54	0.62	1.2e-37	Schizophrenia;
LIHC	trans	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg26939375	chr7:64535504	NA	-0.47	-6.89	-0.35	2.73e-11	Aortic root size;
LIHC	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.55	-8.65	-0.42	2e-16	Menarche (age at onset);
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.45	0.59	2.07e-33	Prudent dietary pattern;
LIHC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.86	0.3	1.09e-8	Bipolar disorder;
LIHC	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.43	-6.69	-0.34	9.15e-11	Adiposity;
LIHC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-7.1	-0.36	7.42e-12	Monocyte percentage of white cells;
LIHC	cis	rs8081395	0.741	rs180519	chr17:58016271	G/A	cg02344993	chr17:57696989	CLTC	0.35	5.72	0.3	2.3e-8	White blood cell count;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21448741	chr8:58168803	NA	0.36	6.72	0.34	7.69e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	0.85	11.71	0.53	7.62e-27	Skin colour saturation;
LIHC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.85	0.35	3.49e-11	Lung cancer;
LIHC	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg02640540	chr1:67518911	SLC35D1	0.42	6.47	0.33	3.4e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.45	-5.9	-0.3	8.7e-9	Total body bone mineral density;
LIHC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.65	6.78	0.34	5.24e-11	Gut microbiome composition (summer);
LIHC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	9.02	0.44	1.37e-17	Motion sickness;
LIHC	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg20991723	chr1:152506922	NA	0.58	10.37	0.49	4.49e-22	Plantar warts;
LIHC	cis	rs16828019	0.852	rs35992757	chr1:41652862	C/T	cg03387723	chr1:41708464	SCMH1	-0.45	-7.23	-0.36	3.13e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-8.42	-0.41	1.04e-15	Primary biliary cholangitis;
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.9	-0.35	2.55e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-7.05	-0.36	1.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.934	rs609102	chr8:109227406	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.38	-0.33	5.76e-10	Rheumatoid arthritis;
LIHC	cis	rs922107	0.846	rs4486433	chr1:90007316	G/T	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.37	-0.37	1.28e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7707921	0.957	rs2059891	chr5:81508792	G/C	cg15871215	chr5:81402204	ATG10	0.6	5.97	0.31	6.05e-9	Breast cancer;
LIHC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.66	9.94	0.47	1.25e-20	Response to diuretic therapy;
LIHC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg15534755	chr11:117069859	TAGLN	-0.37	-6.44	-0.33	4.15e-10	Blood protein levels;
LIHC	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.76	-11.81	-0.54	3.13e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.62	7.17	0.36	4.79e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.23	-0.32	1.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-8.05	-0.4	1.37e-14	Lymphocyte counts;
LIHC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.41	0.52	9.35e-26	Coronary artery disease;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg06719495	chr4:83788000	SEC31A	0.33	7.24	0.36	2.93e-12	Oropharynx cancer;
LIHC	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg22771759	chr13:24902376	NA	0.32	6.8	0.35	4.62e-11	Obesity-related traits;
LIHC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.36	-6.12	-0.31	2.56e-9	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.36	7.9	0.39	3.81e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.35	-7.02	-0.36	1.17e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-10.57	-0.5	8.95e-23	Platelet count;
LIHC	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg04610667	chr7:75704037	NA	0.33	5.98	0.31	5.53e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.56	-9.47	-0.46	4.61e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.62	9.74	0.47	6e-20	Corneal astigmatism;
LIHC	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg09165964	chr15:75287851	SCAMP5	-0.42	-5.89	-0.3	9.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.29	20.96	0.75	2.59e-63	Corneal structure;
LIHC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9649465	1.000	rs6951138	chr7:123362070	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.15e-15	Migraine;
LIHC	cis	rs10792665	0.512	rs4280022	chr11:82582615	C/G	cg24227371	chr11:82718527	RAB30	-0.27	-6.56	-0.33	1.96e-10	Obesity-related traits;
LIHC	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.33	7.64	0.38	2.15e-13	Blood metabolite ratios;
LIHC	trans	rs6419133	0.668	rs7659804	chr4:96301458	C/T	cg08466320	chr2:70121048	SNRNP27	-0.55	-6.04	-0.31	3.92e-9	Itch intensity from mosquito bite adjusted by bite size;
LIHC	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.56	-6.8	-0.35	4.55e-11	Breast cancer;
LIHC	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.37	-6.02	-0.31	4.49e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg22676075	chr6:135203613	NA	0.41	6.59	0.34	1.66e-10	Red blood cell count;
LIHC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.7	11.49	0.53	4.48e-26	Night sleep phenotypes;
LIHC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg03013999	chr17:37608204	MED1	-0.35	-5.8	-0.3	1.48e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs17401966	0.593	rs11121523	chr1:10214442	T/A	cg15208524	chr1:10270712	KIF1B	0.44	5.77	0.3	1.74e-8	Hepatocellular carcinoma;
LIHC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	7.34	0.37	1.55e-12	Monocyte percentage of white cells;
LIHC	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg11812906	chr14:75593930	NEK9	0.43	6.51	0.33	2.7e-10	IgG glycosylation;
LIHC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.71	11.25	0.52	3.29e-25	Corneal astigmatism;
LIHC	cis	rs61677309	1.000	rs1945765	chr11:118182829	T/A	cg06090739	chr11:118230722	UBE4A	0.35	6.37	0.33	5.97e-10	Lung cancer in ever smokers;
LIHC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.61	11.33	0.52	1.83e-25	Alzheimer's disease (late onset);
LIHC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.83	10.57	0.5	8.71e-23	Small cell lung carcinoma;
LIHC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.53	-6.59	-0.34	1.71e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg00343986	chr7:65444356	GUSB	0.41	6.1	0.31	2.86e-9	Aortic root size;
LIHC	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.53	-7.33	-0.37	1.64e-12	Bipolar disorder;
LIHC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.93	10.34	0.49	5.33e-22	Breast cancer;
LIHC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.93	0.31	7.37e-9	Height;
LIHC	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.72	-7.94	-0.39	2.97e-14	Exhaled nitric oxide output;
LIHC	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.59	9.67	0.46	1.06e-19	Urinary tract infection frequency;
LIHC	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg14515779	chr1:101123966	NA	-0.67	-13.11	-0.58	4.4e-32	Monocyte count;
LIHC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.58	8.63	0.42	2.41e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.14	0.36	5.65e-12	Mean platelet volume;
LIHC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.1	-0.31	2.95e-9	Longevity;Endometriosis;
LIHC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.32	-5.88	-0.3	9.5e-9	Blood metabolite levels;
LIHC	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg02344993	chr17:57696989	CLTC	-0.7	-11.76	-0.54	4.75e-27	Hemoglobin concentration;
LIHC	trans	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg26939375	chr7:64535504	NA	0.41	6.47	0.33	3.3e-10	Aortic root size;
LIHC	cis	rs7729447	0.776	rs58739438	chr5:32693994	G/C	cg16267343	chr5:32710456	NPR3	0.48	5.86	0.3	1.09e-8	Blood pressure;
LIHC	cis	rs385076	0.527	rs10779914	chr2:32106040	C/A	cg02381751	chr2:32503542	YIPF4	-0.42	-5.87	-0.3	1.05e-8	Interleukin-18 levels;
LIHC	cis	rs7238033	0.647	rs8095657	chr18:43314545	C/T	cg20610511	chr18:43302872	SLC14A1	0.4	6.64	0.34	1.25e-10	Bladder cancer;
LIHC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	18.89	0.71	5.23e-55	Testicular germ cell tumor;
LIHC	cis	rs963731	0.522	rs4670907	chr2:39278066	C/T	cg04010122	chr2:39346883	SOS1	-0.71	-6.19	-0.32	1.73e-9	Corticobasal degeneration;
LIHC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.78	-10.41	-0.49	3.09e-22	Systemic lupus erythematosus;
LIHC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.88	-12.37	-0.56	2.58e-29	Diastolic blood pressure;
LIHC	cis	rs6429082	0.967	rs1305557	chr1:235627837	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	6.45	0.33	3.72e-10	Adiposity;
LIHC	cis	rs74233809	1.000	rs12411886	chr10:104685299	C/A	cg03493300	chr10:104813866	CNNM2	0.46	5.96	0.31	6.18e-9	Birth weight;
LIHC	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.04	-0.31	4.11e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.61	7.03	0.36	1.09e-11	Menarche (age at onset);
LIHC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.44	7.01	0.35	1.24e-11	Height;
LIHC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.42	7.87	0.39	4.72e-14	Schizophrenia;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg06610675	chr5:60241428	NDUFAF2;ERCC8	-0.43	-6.76	-0.34	5.85e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.35	8.93	0.43	2.64e-17	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.77	0.34	5.54e-11	Type 2 diabetes;
LIHC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg22633049	chr21:46681294	NA	-0.36	-6.35	-0.32	6.69e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	15.33	0.64	1e-40	Menopause (age at onset);
LIHC	cis	rs8067354	0.540	rs72840315	chr17:58018142	G/C	cg13753209	chr17:57696993	CLTC	0.7	10.49	0.49	1.66e-22	Hemoglobin concentration;
LIHC	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.08	-0.36	8.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs11671005	0.610	rs2305122	chr19:59056752	G/C	cg25952890	chr19:58913133	NA	0.66	6.73	0.34	6.99e-11	Mean platelet volume;
LIHC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.57	0.5	8.87e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-8.26	-0.41	3.31e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs4788570	0.655	rs2133773	chr16:71812296	A/G	cg06353428	chr16:71660113	MARVELD3	1.32	12.8	0.57	6.45e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1000083	0.748	rs2643518	chr5:96624096	T/A	ch.5.96698337R	chr5:96672581	NA	0.96	7.29	0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg18306943	chr3:40428807	ENTPD3	0.35	5.94	0.31	7.05e-9	Renal cell carcinoma;
LIHC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.42e-23	Mean corpuscular volume;
LIHC	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	0.86	10.33	0.49	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.65	-0.42	2.09e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10386016	chr7:103630857	RELN	0.47	6.49	0.33	3.05e-10	Lung function (FEV1/FVC);
LIHC	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	1.01	19.32	0.72	9.73e-57	Breast cancer;
LIHC	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.46	6.92	0.35	2.21e-11	Height;
LIHC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.93	0.51	4.56e-24	Colorectal cancer;
LIHC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.59	-8.35	-0.41	1.73e-15	Initial pursuit acceleration;
LIHC	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.32	-0.32	8.06e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.76	11.71	0.54	7.22e-27	Corneal astigmatism;
LIHC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.81	10.37	0.49	4.17e-22	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-11.92	-0.54	1.2100000000000001e-27	Colorectal cancer;
LIHC	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.41	6.52	0.33	2.49e-10	Alzheimer's disease (survival time);
LIHC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11582133	chr15:41576691	LOC729082	0.42	6.1	0.31	2.89e-9	Cognitive function;
LIHC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.6	-9.8	-0.47	3.84e-20	Post bronchodilator FEV1;
LIHC	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.24	-6.11	-0.31	2.71e-9	Menarche (age at onset);
LIHC	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.56	-8.09	-0.4	1.09e-14	Neuroticism;
LIHC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.68	-8.84	-0.43	5.33e-17	Initial pursuit acceleration;
LIHC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.78	0.3	1.65e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.89	13.28	0.58	9.91e-33	Psoriasis;
LIHC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21448741	chr8:58168803	NA	0.35	6.51	0.33	2.73e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.43	5.89	0.3	9.14e-9	QT interval;
LIHC	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg01864836	chr14:55583639	NA	-0.42	-8.23	-0.41	4.02e-15	Protein biomarker;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.78	-12.08	-0.55	3.19e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg16511985	chr3:153974050	SGEF	0.43	9.22	0.45	3.03e-18	Coronary artery disease;
LIHC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.54	-6.27	-0.32	1.1e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.75	11.73	0.54	5.96e-27	Corneal astigmatism;
LIHC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.48	7.21	0.36	3.71e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.53	-6.28	-0.32	1.05e-9	Menarche (age at onset);
LIHC	trans	rs2516739	1.000	rs2516740	chr16:2097110	A/C	cg13974317	chr22:21056282	TMEM191A	0.52	6.21	0.32	1.54e-9	Longevity;
LIHC	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.18	-0.44	4.33e-18	Exhaled nitric oxide output;
LIHC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.48	-9.31	-0.45	1.61e-18	IgG glycosylation;
LIHC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-0.74	-8.45	-0.42	8.62e-16	Hip circumference adjusted for BMI;
LIHC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.58	8.26	0.41	3.31e-15	HIV-1 control;
LIHC	cis	rs1198430	0.683	rs534417	chr1:23784965	A/G	cg13183780	chr1:23809682	ASAP3	-0.39	-6.77	-0.34	5.56e-11	Total cholesterol levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06045225	chr5:65892993	MAST4	0.43	6.41	0.33	4.76e-10	Cognitive function;
LIHC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	17.94	0.7	3.31e-51	Smoking behavior;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23895204	chr7:129845368	TMEM209	0.42	6.08	0.31	3.24e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.19	-0.58	2.08e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.32	-6.11	-0.31	2.71e-9	Systemic lupus erythematosus;
LIHC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.57	-5.92	-0.31	7.65e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.67	13.33	0.58	6.19e-33	Leprosy;
LIHC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-13.69	-0.6	2.49e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs937213	0.573	rs2412464	chr15:40303842	G/A	cg16127683	chr15:40268777	EIF2AK4	-0.37	-6.16	-0.32	2.07e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	7.22	0.36	3.34e-12	Bipolar disorder;
LIHC	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.79	-8.71	-0.43	1.31e-16	Hippocampal volume;
LIHC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.77	12.14	0.55	1.93e-28	Corneal astigmatism;
LIHC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.58	6.53	0.33	2.33e-10	Axial length;
LIHC	cis	rs1023500	1.000	rs1023497	chr22:42340508	C/G	cg04733989	chr22:42467013	NAGA	-0.48	-5.75	-0.3	1.96e-8	Schizophrenia;
LIHC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.73	-0.34	7.08e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.45	-7.93	-0.39	3.25e-14	Aortic root size;
LIHC	cis	rs8083850	0.635	rs1367637	chr18:50860722	C/T	cg24270629	chr18:50823537	DCC	-0.55	-8.49	-0.42	6.22e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg08807892	chr2:162101083	NA	0.45	7.64	0.38	2.14e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LIHC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.4	6.41	0.33	4.93e-10	Iron status biomarkers;
LIHC	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	7.06	0.36	9.26e-12	Bipolar disorder;
LIHC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg08132940	chr7:1081526	C7orf50	-0.77	-6.71	-0.34	7.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.53	8.58	0.42	3.26e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.1	-0.31	2.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2019216	0.605	rs907706	chr17:21982191	G/A	cg14296220	chr9:32431791	ACO1	0.38	6.21	0.32	1.57e-9	Pelvic organ prolapse;
LIHC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg06453172	chr10:134556979	INPP5A	0.53	7.49	0.38	6.06e-13	Migraine;
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg10756647	chr7:56101905	PSPH	-1.03	-12.6	-0.56	3.61e-30	Diabetic kidney disease;
LIHC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg22532475	chr10:104410764	TRIM8	0.36	6.45	0.33	3.71e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.82	12.33	0.55	3.65e-29	Motion sickness;
LIHC	cis	rs4684776	0.867	rs1562615	chr3:11373357	A/C	cg00170343	chr3:11313890	ATG7	-0.5	-6.76	-0.34	5.95e-11	Small vessel stroke;
LIHC	cis	rs9596863	1.000	rs7328595	chr13:54424070	G/A	ch.13.53330881F	chr13:54432880	NA	-0.43	-6.0	-0.31	5.16e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.59	0.56	3.86e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.48	7.09	0.36	7.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs6489882	0.867	rs7315441	chr12:113365687	G/T	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg11070056	chr1:107600091	PRMT6	-0.71	-12.25	-0.55	7.21e-29	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.49	6.52	0.33	2.46e-10	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	22.18	0.77	3.52e-68	Height;
LIHC	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.47	8.8	0.43	7.08e-17	Testicular germ cell tumor;
LIHC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.06	0.31	3.51e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.4	6.48	0.33	3.18e-10	Migraine;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.62	10.03	0.48	6.56e-21	Longevity;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06656553	chr16:89960601	TCF25	-0.48	-6.06	-0.31	3.56e-9	Skin colour saturation;
LIHC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.8	-0.35	4.59e-11	Personality dimensions;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.36	6.1	0.31	2.85e-9	Height;
LIHC	cis	rs7258465	0.931	rs34053595	chr19:18556749	T/C	cg10790698	chr19:18539756	SSBP4	-0.37	-7.59	-0.38	2.99e-13	Breast cancer;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17450446	chr1:160002111	PIGM	-0.5	-6.37	-0.33	5.98e-10	Lung cancer in ever smokers;
LIHC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.83	14.77	0.62	1.57e-38	Bone mineral density;
LIHC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.14e-11	Alzheimer's disease;
LIHC	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.49	-0.38	5.83e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs526821	1.000	rs526821	chr11:55306151	A/G	cg04317927	chr11:55418816	OR4S2	0.36	6.98	0.35	1.53e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.06	-0.31	3.57e-9	Blood pressure;
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21448741	chr8:58168803	NA	-0.39	-6.44	-0.33	4.01e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	0.83	7.02	0.36	1.18e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4759375	1.000	rs2271976	chr12:123751726	A/C	cg00376283	chr12:123451042	ABCB9	-0.5	-6.24	-0.32	1.27e-9	HDL cholesterol;
LIHC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.58	0.42	3.44e-16	Menarche (age at onset);
LIHC	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.95	-10.85	-0.51	9.04e-24	Neuroticism;
LIHC	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.64	9.86	0.47	2.39e-20	Lymphocyte counts;
LIHC	cis	rs385076	0.502	rs13013695	chr2:32391231	G/A	cg02381751	chr2:32503542	YIPF4	-0.46	-6.34	-0.32	7.44e-10	Interleukin-18 levels;
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg00091569	chr3:40428383	ENTPD3	0.38	6.38	0.33	5.64e-10	Renal cell carcinoma;
LIHC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.49	17.34	0.68	8.86e-49	Eosinophil percentage of granulocytes;
LIHC	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg23091122	chr1:110024289	SYPL2	-0.48	-6.46	-0.33	3.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.71	0.34	7.86e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg18225595	chr11:63971243	STIP1	0.63	7.73	0.39	1.2e-13	Mean platelet volume;
LIHC	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.56	8.32	0.41	2.2e-15	Schizophrenia;
LIHC	cis	rs17106184	1.000	rs113119450	chr1:51235816	T/C	cg07174182	chr1:51127561	FAF1	-0.61	-6.65	-0.34	1.18e-10	Type 2 diabetes;
LIHC	cis	rs3917254	0.543	rs6752379	chr2:102746705	G/A	cg22835712	chr2:102737379	NA	-0.47	-5.75	-0.3	1.97e-8	Blood protein levels;
LIHC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	7.6	0.38	2.78e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.28	-0.32	1.04e-9	Ulcerative colitis;
LIHC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg21522988	chr12:29376872	FAR2	0.28	6.41	0.33	4.84e-10	QT interval;
LIHC	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.49	7.26	0.37	2.62e-12	Multiple sclerosis;
LIHC	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.7	-11.0	-0.51	2.64e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.08	0.31	3.26e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.72	-12.76	-0.57	9.29e-31	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.82	-0.3	1.39e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13236679	chr6:37467396	C6orf129	0.43	7.24	0.36	2.94e-12	Pancreatic cancer;
LIHC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg22676075	chr6:135203613	NA	0.38	6.01	0.31	4.71e-9	Red blood cell count;
LIHC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.43	7.26	0.37	2.58e-12	Hemoglobin concentration;
LIHC	cis	rs55665837	0.540	rs3206554	chr11:14797945	A/T	cg25251204	chr11:14927456	NA	0.4	5.75	0.3	1.98e-8	Vitamin D levels;
LIHC	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.32	-6.11	-0.31	2.71e-9	Systemic lupus erythematosus;
LIHC	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg18898632	chr2:242989856	NA	-0.69	-8.68	-0.42	1.67e-16	Obesity-related traits;
LIHC	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.45	6.7	0.34	8.73e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7756236	0.521	rs6936993	chr6:36626322	C/T	cg08179530	chr6:36648295	CDKN1A	-0.4	-5.93	-0.31	7.23e-9	QRS duration;
LIHC	cis	rs61677309	0.964	rs12576118	chr11:118158440	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	1.04	20.83	0.75	8.28e-63	Breast cancer;
LIHC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02359409	chr6:42947317	PEX6	0.46	6.1	0.31	2.83e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.65	9.98	0.48	9.07e-21	Colorectal adenoma (advanced);
LIHC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.66	12.26	0.55	6.94e-29	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs10411161	0.810	rs72626248	chr19:52357246	T/C	cg22319618	chr22:45562946	NUP50	-0.51	-6.35	-0.32	6.98e-10	Breast cancer;
LIHC	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.86	-10.04	-0.48	6e-21	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.33	-0.37	1.68e-12	Diabetic kidney disease;
LIHC	cis	rs3106136	0.678	rs7658830	chr4:95295134	A/G	cg11021082	chr4:95130006	SMARCAD1	0.34	5.77	0.3	1.74e-8	Capecitabine sensitivity;
LIHC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	1.04	18.81	0.71	1.09e-54	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.78	13.61	0.59	5.2e-34	Aortic root size;
LIHC	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.53	-6.98	-0.35	1.55e-11	Coronary artery calcification;
LIHC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg17724175	chr1:150552817	MCL1	0.46	9.16	0.44	4.94e-18	Melanoma;
LIHC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.54	-0.46	2.84e-19	Obesity-related traits;
LIHC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02450064	chr17:40260053	DHX58	-0.29	-5.86	-0.3	1.1e-8	Fibrinogen levels;
LIHC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.45	-6.56	-0.33	2.01e-10	Response to metformin (IC50);
LIHC	cis	rs831571	1.000	rs166230	chr3:64053207	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.52	6.36	0.33	6.62e-10	Type 2 diabetes;
LIHC	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg00753924	chr9:137298813	RXRA	-0.34	-5.87	-0.3	1.05e-8	Intelligence;
LIHC	cis	rs918629	0.530	rs3777185	chr5:95259862	C/T	cg10483112	chr5:95245456	ELL2	-0.38	-6.96	-0.35	1.75e-11	IgG glycosylation;
LIHC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.37	-0.41	1.53e-15	Schizophrenia;
LIHC	cis	rs9918079	0.560	rs4698402	chr4:15629803	G/A	cg21123203	chr4:15471301	CC2D2A	-0.44	-6.98	-0.35	1.55e-11	Obesity-related traits;
LIHC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg23206463	chr5:561769	NA	0.5	7.77	0.39	9.29e-14	Obesity-related traits;
LIHC	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.44	8.0	0.4	1.99e-14	Platelet distribution width;
LIHC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.37	9.74	0.47	6.25e-20	Asthma (sex interaction);
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	23.47	0.79	2.97e-73	Prudent dietary pattern;
LIHC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.39	6.87	0.35	2.99e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1075232	0.826	rs12438813	chr15:31705913	C/T	cg17859187	chr1:168147929	TIPRL	0.75	6.04	0.31	3.96e-9	Survival in colorectal cancer (non-distant metastatic);
LIHC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-9.98	-0.47	9.38e-21	Platelet count;
LIHC	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.56	-7.9	-0.39	3.84e-14	Corneal structure;
LIHC	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	0.67	6.53	0.33	2.33e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.55	0.62	1.15e-37	Bipolar disorder;
LIHC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.85	10.33	0.49	5.75e-22	Cognitive function;
LIHC	trans	rs7714584	1.000	rs7709464	chr5:150269441	C/A	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	11.84	0.54	2.46e-27	High light scatter reticulocyte count;
LIHC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.86	-15.49	-0.64	2.31e-41	Headache;
LIHC	trans	rs72960926	0.744	rs11752717	chr6:74954435	G/A	cg07247405	chr1:2484626	LOC115110	0.53	6.38	0.33	5.78e-10	Metabolite levels (MHPG);
LIHC	cis	rs12915845	0.603	rs11073783	chr15:89043761	C/T	cg05013243	chr15:89149849	MIR1179	-0.37	-6.6	-0.34	1.55e-10	Menarche (age at onset);
LIHC	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.39	9.53	0.46	2.97e-19	Blood metabolite ratios;
LIHC	trans	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg09622330	chr16:10205262	GRIN2A	0.31	6.31	0.32	8.79e-10	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg05564831	chr3:52568323	NT5DC2	-0.39	-6.24	-0.32	1.32e-9	Bipolar disorder;
LIHC	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.71	-10.74	-0.5	2.27e-23	Subjective well-being;
LIHC	cis	rs965469	0.841	rs113139885	chr20:3219561	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-5.95	-0.31	6.65e-9	IFN-related cytopenia;
LIHC	cis	rs11971779	0.588	rs2003531	chr7:139126578	A/G	cg07862535	chr7:139043722	LUC7L2	0.6	9.97	0.47	1.01e-20	Diisocyanate-induced asthma;
LIHC	trans	rs2681424	0.966	rs62269210	chr3:121760603	C/T	cg03946530	chr15:65596423	NA	-0.48	-6.2	-0.32	1.67e-9	Multiple sclerosis;
LIHC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.53	-9.14	-0.44	5.62e-18	Monocyte count;
LIHC	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.62	-6.56	-0.33	1.96e-10	Hair shape;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg10480950	chr6:5067127	NA	-0.35	-6.32	-0.32	7.93e-10	Pain;
LIHC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.58	8.84	0.43	5.32e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24229701	chr12:130821962	PIWIL1	-0.41	-6.28	-0.32	1.03e-9	Menopause (age at onset);
LIHC	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg21252483	chr19:49399788	TULP2	-0.94	-10.31	-0.49	6.77e-22	Red cell distribution width;
LIHC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	6.78	0.34	5.44e-11	Renal cell carcinoma;
LIHC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.47	7.85	0.39	5.34e-14	Mean corpuscular volume;
LIHC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.45	8.68	0.42	1.69e-16	Schizophrenia;
LIHC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-6.63	-0.34	1.29e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.6	9.31	0.45	1.59e-18	Height;
LIHC	cis	rs9918079	0.560	rs7662032	chr4:15635414	C/G	cg24225360	chr4:15471699	CC2D2A	-0.38	-6.17	-0.32	1.92e-9	Obesity-related traits;
LIHC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.53	8.3	0.41	2.38e-15	Height;
LIHC	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg15123519	chr2:136567270	LCT	-0.38	-6.19	-0.32	1.68e-9	Corneal structure;
LIHC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg22079354	chr11:130786696	SNX19	0.41	5.93	0.31	7.46e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.48	6.28	0.32	1.03e-9	Initial pursuit acceleration;
LIHC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.77	0.34	5.79e-11	Morning vs. evening chronotype;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.4	0.33	5.22e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.34	-6.71	-0.34	7.89e-11	Body mass index;
LIHC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.71	-12.18	-0.55	1.33e-28	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26609550	chr19:14017309	C19orf57;CC2D1A	0.43	6.21	0.32	1.57e-9	Lung function (FEV1/FVC);
LIHC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg18944383	chr4:111397179	ENPEP	-0.34	-7.99	-0.4	2.14e-14	Coronary artery disease;
LIHC	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.55	8.68	0.42	1.66e-16	Childhood ear infection;
LIHC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.37	-7.81	-0.39	6.98e-14	Cancer;
LIHC	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.25	-13.18	-0.58	2.36e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06634786	chr22:41940651	POLR3H	0.57	6.25	0.32	1.23e-9	Vitiligo;
LIHC	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg14146966	chr2:61757674	XPO1	0.45	7.69	0.38	1.61e-13	Tuberculosis;
LIHC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.51	-0.42	5.66e-16	Primary biliary cholangitis;
LIHC	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg18898632	chr2:242989856	NA	-0.46	-6.35	-0.32	6.98e-10	Obesity-related traits;
LIHC	cis	rs611744	0.967	rs653081	chr8:109230383	G/T	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	11.91	0.54	1.3e-27	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21467203	chr3:49911342	NA	0.39	6.63	0.34	1.28e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.44	-11.4	-0.52	1e-25	Cutaneous nevi;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22430790	chr14:52117833	FRMD6	0.46	7.08	0.36	8.12e-12	Pancreatic cancer;
LIHC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.24	6.15	0.32	2.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-9.2	-0.45	3.65e-18	Body mass index;
LIHC	cis	rs16828019	0.852	rs12759023	chr1:41603978	T/C	cg03962019	chr1:41807865	NA	0.53	7.51	0.38	5.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.59	8.71	0.43	1.35e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg15123519	chr2:136567270	LCT	0.35	5.83	0.3	1.28e-8	Corneal structure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg12112058	chr1:224622605	WDR26	0.39	6.15	0.32	2.13e-9	Cognitive function;
LIHC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.56	-6.45	-0.33	3.75e-10	Alzheimer's disease;
LIHC	cis	rs7937890	0.599	rs2597204	chr11:14481017	C/T	cg23387056	chr11:14280742	SPON1	-0.47	-6.19	-0.32	1.69e-9	Mitochondrial DNA levels;
LIHC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	0.85	11.06	0.51	1.62e-24	Skin colour saturation;
LIHC	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.42	-7.86	-0.39	4.98e-14	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LIHC	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg05110241	chr16:68378359	PRMT7	-0.55	-6.46	-0.33	3.63e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	7.36	0.37	1.34e-12	Mean platelet volume;
LIHC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.59	10.17	0.48	2.07e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg21872391	chr10:112064057	SMNDC1	0.43	6.08	0.31	3.23e-9	Morning vs. evening chronotype;
LIHC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.92	0.39	3.46e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.44	7.14	0.36	5.61e-12	Total body bone mineral density;
LIHC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.13	0.31	2.4e-9	Menopause (age at onset);
LIHC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.84	-0.57	4.5e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.58	9.25	0.45	2.56e-18	Lymphocyte counts;
LIHC	cis	rs4979906	1.000	rs11002248	chr10:79446961	A/G	cg07817648	chr10:79422355	NA	-0.29	-6.34	-0.32	7.44e-10	Mortality in heart failure;
LIHC	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.57	-6.89	-0.35	2.63e-11	Systemic lupus erythematosus;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-7.32	-0.37	1.83e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.12	14.18	0.61	3.29e-36	Body mass index;
LIHC	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.2	-5.86	-0.3	1.11e-8	Mean corpuscular volume;
LIHC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.74e-9	Bipolar disorder;
LIHC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02244288	chr16:89573955	SPG7	-0.31	-5.91	-0.3	8.07e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg22771759	chr13:24902376	NA	0.32	6.76	0.34	5.94e-11	Obesity-related traits;
LIHC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.44	-6.47	-0.33	3.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7756236	0.521	rs6930671	chr6:36625272	T/C	cg08179530	chr6:36648295	CDKN1A	0.42	6.35	0.32	7e-10	QRS duration;
LIHC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.02	-0.31	4.55e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.75	0.3	2.03e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg00656387	chr3:40428638	ENTPD3	0.42	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs2274273	0.870	rs67514154	chr14:55767382	T/C	cg01864836	chr14:55583639	NA	-0.37	-6.55	-0.33	2.15e-10	Protein biomarker;
LIHC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	0.72	8.19	0.4	5.38e-15	Testicular germ cell tumor;
LIHC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-1.01	-19.28	-0.72	1.37e-56	Breast cancer;
LIHC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.54	-0.38	4.34e-13	Total body bone mineral density;
LIHC	cis	rs13161895	1.000	rs13161895	chr5:179471201	C/T	cg06664874	chr5:179499304	RNF130	0.61	7.56	0.38	3.66e-13	LDL cholesterol;
LIHC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.64	-13.56	-0.59	8.21e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs2997447	0.761	rs17356867	chr1:26448849	C/T	cg19633962	chr1:26362018	EXTL1	0.66	6.28	0.32	1.01e-9	QRS complex (12-leadsum);
LIHC	cis	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg01231543	chr16:68741748	NA	0.37	5.73	0.3	2.23e-8	Colorectal cancer;
LIHC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.67	-10.63	-0.5	5.56e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1000083	0.666	rs291805	chr5:96741146	A/G	ch.5.96698337R	chr5:96672581	NA	0.86	6.86	0.35	3.31e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.4	7.46	0.37	7.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg25894440	chr7:65020034	NA	0.55	6.21	0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.67	-0.34	1e-10	Height;
LIHC	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg09572067	chr16:29127029	RRN3P2	0.52	8.38	0.41	1.42e-15	Menopause (age at onset);
LIHC	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-10.53	-0.49	1.22e-22	Superior crus of antihelix expression;
LIHC	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.45	-6.22	-0.32	1.42e-9	Inflammatory biomarkers;
LIHC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.2	-21.42	-0.76	3.83e-65	Chronic sinus infection;
LIHC	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.98	15.35	0.64	7.97e-41	Metabolic syndrome;
LIHC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.12	0.52	9.61e-25	Coronary artery disease;
LIHC	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg24203234	chr3:128598194	ACAD9	-0.43	-5.91	-0.3	8.31e-9	IgG glycosylation;
LIHC	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.11	-0.31	2.75e-9	Response to antipsychotic treatment;
LIHC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.58	0.34	1.77e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg20302533	chr7:39170763	POU6F2	0.35	6.44	0.33	4.04e-10	IgG glycosylation;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18018498	chr11:102962968	DCUN1D5	-0.43	-6.33	-0.32	7.74e-10	Pancreatic cancer;
LIHC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	10.05	0.48	5.28e-21	Monocyte count;
LIHC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.07	0.31	3.49e-9	Prudent dietary pattern;
LIHC	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg12698662	chr3:15914712	MIR563	-0.38	-6.94	-0.35	1.95e-11	Mean platelet volume;
LIHC	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.92	19.43	0.72	3.56e-57	Bone mineral density;
LIHC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.56	0.33	2.03e-10	Obesity-related traits;
LIHC	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg14146966	chr2:61757674	XPO1	0.47	8.17	0.4	6.09e-15	Tuberculosis;
LIHC	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.48	7.4	0.37	1.05e-12	Dementia with Lewy bodies;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12516959	chr21:47718080	NA	0.36	5.85	0.3	1.17e-8	Testicular germ cell tumor;
LIHC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-10.4	-0.49	3.53e-22	Longevity;Endometriosis;
LIHC	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.49	9.0	0.44	1.58e-17	Sense of smell;
LIHC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.62	9.73	0.47	6.48e-20	Intelligence (multi-trait analysis);
LIHC	trans	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.26	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.45	5.72	0.3	2.37e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg04756594	chr16:24857601	SLC5A11	-0.38	-6.27	-0.32	1.07e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.62	0.38	2.51e-13	Prudent dietary pattern;
LIHC	cis	rs7264396	0.943	rs224421	chr20:34145461	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.36	-5.81	-0.3	1.47e-8	Total cholesterol levels;
LIHC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.6	9.48	0.46	4.34e-19	Crohn's disease;
LIHC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.37	-0.41	1.52e-15	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs8113308	0.810	rs7255377	chr19:52451338	T/C	cg14959425	chr7:20447707	ITGB8	-0.47	-6.11	-0.31	2.75e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.43	8.44	0.42	9.09e-16	Testicular germ cell tumor;
LIHC	cis	rs12365397	1.000	rs12365397	chr11:43236061	A/G	cg16667275	chr11:43333495	API5	0.45	6.18	0.32	1.87e-9	Migraine;
LIHC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg07382826	chr16:28625726	SULT1A1	-0.49	-7.51	-0.38	5.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.44	7.15	0.36	5.13e-12	Red blood cell count;
LIHC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.42	-8.44	-0.42	9.17e-16	Obesity-related traits;
LIHC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg14440974	chr22:39074834	NA	-0.43	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	cis	rs4561483	0.603	rs17235629	chr16:11932421	C/T	cg08843971	chr16:11963173	GSPT1	-0.34	-6.53	-0.33	2.34e-10	Testicular germ cell tumor;
LIHC	cis	rs3736594	0.513	rs3811644	chr2:27802805	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.35	3.45e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs1534166	0.507	rs3811657	chr3:133474607	C/T	cg27366882	chr3:133540807	NA	-0.43	-5.76	-0.3	1.85e-8	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg00864860	chr1:7907996	UTS2	0.64	5.84	0.3	1.21e-8	Inflammatory bowel disease;
LIHC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg02836325	chr17:76403955	PGS1	0.34	6.69	0.34	8.91e-11	HDL cholesterol levels;
LIHC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg13753209	chr17:57696993	CLTC	0.72	11.38	0.52	1.15e-25	Hemoglobin concentration;
LIHC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg21518248	chr2:162101506	NA	0.39	5.73	0.3	2.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-8.53	-0.42	4.85e-16	Hemoglobin concentration;
LIHC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.48	7.77	0.39	9.54e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg24296786	chr1:45957014	TESK2	0.42	6.03	0.31	4.34e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-11.65	-0.53	1.25e-26	Urate levels in overweight individuals;
LIHC	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.32	-6.11	-0.31	2.71e-9	Systemic lupus erythematosus;
LIHC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg02297831	chr4:17616191	MED28	0.42	6.69	0.34	9.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.67	13.29	0.58	8.45e-33	Leprosy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13045639	chr21:40555880	PSMG1	-0.47	-6.43	-0.33	4.35e-10	Pancreatic cancer;
LIHC	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg10820045	chr2:198174542	NA	0.45	7.19	0.36	4.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	7.44	0.37	8.16e-13	Tonsillectomy;
LIHC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.51	8.14	0.4	7.61e-15	Schizophrenia;
LIHC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg03037974	chr15:76606532	NA	0.91	23.59	0.79	1.02e-73	Blood metabolite levels;
LIHC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg09417038	chr21:47716443	C21orf57	-0.5	-7.34	-0.37	1.55e-12	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.82	9.21	0.45	3.39e-18	Vitiligo;
LIHC	cis	rs903552	0.800	rs8026048	chr15:102006353	G/A	cg00659931	chr15:102010125	PCSK6	-0.49	-6.75	-0.34	6.41e-11	Diabetic kidney disease;
LIHC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg16797656	chr11:68205561	LRP5	0.5	7.73	0.39	1.21e-13	Total body bone mineral density;
LIHC	cis	rs7224685	0.569	rs28481302	chr17:4011527	T/G	cg11204139	chr17:3907470	NA	0.58	6.7	0.34	8.57e-11	Type 2 diabetes;
LIHC	cis	rs11786130	1.000	rs11786130	chr8:129004975	G/A	cg01765152	chr8:129005526	PVT1	-0.3	-6.41	-0.33	4.92e-10	Eosinophil counts;Sum eosinophil basophil counts;
LIHC	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.62	-7.86	-0.39	5.01e-14	Macular telangiectasia type 2;
LIHC	cis	rs4759375	0.920	rs7298909	chr12:123830939	C/T	cg00376283	chr12:123451042	ABCB9	0.49	6.34	0.32	7.29e-10	HDL cholesterol;
LIHC	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg08345082	chr10:99160200	RRP12	0.42	7.34	0.37	1.62e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-6.13	-0.31	2.42e-9	Testicular germ cell tumor;
LIHC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.31	-7.22	-0.36	3.36e-12	Menarche (age at onset);
LIHC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg18944383	chr4:111397179	ENPEP	-0.31	-6.98	-0.35	1.57e-11	Coronary artery disease;
LIHC	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.48	-0.33	3.25e-10	Metabolite levels;
LIHC	cis	rs75908454	1.000	rs78272531	chr6:169808112	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-7.52	-0.38	4.91e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs2710642	0.611	rs6749020	chr2:62861957	G/A	cg17519650	chr2:63277830	OTX1	0.47	6.88	0.35	2.81e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg08992911	chr2:238395768	MLPH	0.52	6.17	0.32	1.91e-9	Prostate cancer;
LIHC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.43	-7.11	-0.36	6.91e-12	Menarche (age at onset);
LIHC	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.41	-5.79	-0.3	1.57e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.58	8.91	0.43	3.11e-17	Retinal vascular caliber;
LIHC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	21.29	0.75	1.21e-64	Chronic sinus infection;
LIHC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.56	0.33	1.93e-10	Resting heart rate;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg00656387	chr3:40428638	ENTPD3	0.5	8.4	0.41	1.22e-15	Renal cell carcinoma;
LIHC	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.35	7.47	0.37	6.54e-13	Obesity (extreme);
LIHC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg25039879	chr17:56429692	SUPT4H1	0.74	8.35	0.41	1.7e-15	Cognitive test performance;
LIHC	cis	rs2569991	0.541	rs2596905	chr3:12937672	A/C	cg22481960	chr3:13008800	IQSEC1	-0.43	-7.49	-0.38	6.12e-13	Periodontitis (DPAL);
LIHC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-7.34	-0.37	1.54e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg03477792	chr4:77819574	ANKRD56	0.6	8.79	0.43	7.34e-17	Emphysema distribution in smoking;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.87	0.39	4.78e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.4	6.78	0.34	5.23e-11	Total cholesterol levels;
LIHC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.48	6.14	0.32	2.29e-9	Initial pursuit acceleration;
LIHC	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg10820045	chr2:198174542	NA	0.5	7.88	0.39	4.34e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg00071026	chr13:113650936	MCF2L	-0.39	-5.9	-0.3	8.55e-9	Systolic blood pressure;
LIHC	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.41	7.54	0.38	4.3e-13	Resting heart rate;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04961397	chr16:30990708	SETD1A	0.43	6.22	0.32	1.49e-9	Longevity;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.26	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.63	9.49	0.46	4.08e-19	Corneal astigmatism;
LIHC	trans	rs6952407	1	rs6952407	chr7:66045512	A/G	cg26939375	chr7:64535504	NA	-0.47	-7.23	-0.36	3.08e-12	Cotinine glucuronidation;
LIHC	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	6.68	0.34	9.97e-11	Homocysteine levels;
LIHC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg25894440	chr7:65020034	NA	-0.52	-6.12	-0.31	2.54e-9	Diabetic kidney disease;
LIHC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg23205692	chr1:25664452	TMEM50A	0.4	6.27	0.32	1.07e-9	Plateletcrit;Mean corpuscular volume;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg16344026	chr5:149109979	PPARGC1B	-0.42	-6.51	-0.33	2.74e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.62	8.91	0.43	3.17e-17	Platelet count;
LIHC	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg08992911	chr2:238395768	MLPH	0.55	6.44	0.33	4.12e-10	Prostate cancer;
LIHC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-12.28	-0.55	5.8e-29	Acylcarnitine levels;
LIHC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.38	5.75	0.3	1.96e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.22	-10.56	-0.5	9.63e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	0.75	8.1	0.4	9.98e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.9	-0.3	8.53e-9	Life satisfaction;
LIHC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.83	13.79	0.6	1.03e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg20826740	chr17:37024042	NA	0.34	5.78	0.3	1.72e-8	Height;
LIHC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.5	6.9	0.35	2.57e-11	Morning vs. evening chronotype;
LIHC	cis	rs918629	0.567	rs3777204	chr5:95234350	A/G	cg10483112	chr5:95245456	ELL2	-0.37	-6.79	-0.34	5.12e-11	IgG glycosylation;
LIHC	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-5.99	-0.31	5.28e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg04691961	chr3:161091175	C3orf57	-0.33	-5.71	-0.3	2.41e-8	Morning vs. evening chronotype;
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.0	15.22	0.64	2.56e-40	Skin colour saturation;
LIHC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.77	10.79	0.5	1.46e-23	Cerebrospinal P-tau181p levels;
LIHC	cis	rs10508774	1.000	rs11009018	chr10:32939721	G/C	cg01819863	chr10:32635814	EPC1	0.64	5.93	0.31	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.45	-6.88	-0.35	2.92e-11	Pubertal anthropometrics;
LIHC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.23	-0.32	1.39e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00958927	chr1:175162553	KIAA0040	-0.4	-6.53	-0.33	2.36e-10	Alcohol dependence;
LIHC	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.34	-7.17	-0.36	4.61e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.55	-8.17	-0.4	5.98e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	12.64	0.56	2.48e-30	Cognitive test performance;
LIHC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg23172400	chr8:95962367	TP53INP1	0.35	7.23	0.36	3.14e-12	Type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.43	6.85	0.35	3.35e-11	Pancreatic cancer;
LIHC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.53	-7.45	-0.37	7.87e-13	Primary tooth development (time to first tooth eruption);
LIHC	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg16070123	chr10:51489643	NA	0.38	6.2	0.32	1.58e-9	Prostate-specific antigen levels;
LIHC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.76	12.14	0.55	1.94e-28	Corneal astigmatism;
LIHC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-22.47	-0.77	2.54e-69	Height;
LIHC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg16102536	chr7:156981717	UBE3C	0.35	5.95	0.31	6.78e-9	Body mass index;
LIHC	cis	rs1789	0.786	rs6449161	chr4:15692954	A/G	cg16509355	chr4:15471240	CC2D2A	-0.46	-6.95	-0.35	1.89e-11	Blood protein levels;
LIHC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	8.82	0.43	5.96e-17	Schizophrenia;
LIHC	trans	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.22	0.41	4.23e-15	Platelet count;
LIHC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg26395211	chr5:140044315	WDR55	0.4	5.93	0.31	7.44e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03041860	chr2:208489911	FAM119A	0.42	6.36	0.33	6.59e-10	Pancreatic cancer;
LIHC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.68	9.98	0.47	9.65e-21	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.94	0.57	1.95e-31	Prudent dietary pattern;
LIHC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-6.77	-0.34	5.6e-11	Lymphocyte counts;
LIHC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.72	13.18	0.58	2.28e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg15848620	chr12:58087721	OS9	-0.58	-8.02	-0.4	1.65e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.63	9.05	0.44	1.07e-17	Corneal astigmatism;
LIHC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg24130564	chr14:104152367	KLC1	-0.35	-5.79	-0.3	1.61e-8	Schizophrenia;
LIHC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-6.76	-0.34	6.01e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg18116418	chr1:152553244	LCE3D	-0.34	-6.27	-0.32	1.06e-9	Psoriasis;
LIHC	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.71	12.26	0.55	7.09e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.55	7.76	0.39	9.78e-14	Lung cancer;
LIHC	cis	rs6445975	0.715	rs6809809	chr3:58267950	A/G	cg23715586	chr3:58305044	RPP14	-0.37	-6.24	-0.32	1.31e-9	Systemic lupus erythematosus;
LIHC	trans	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg08566640	chr11:64091735	NA	-0.67	-6.13	-0.31	2.36e-9	Androgen levels;
LIHC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg18944383	chr4:111397179	ENPEP	0.27	6.82	0.35	4.17e-11	Height;
LIHC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.85	12.85	0.57	4.32e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.75	0.39	1.09e-13	Systemic lupus erythematosus;
LIHC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg24203234	chr3:128598194	ACAD9	0.44	6.03	0.31	4.17e-9	IgG glycosylation;
LIHC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.43	-6.87	-0.35	3.13e-11	Iron status biomarkers;
LIHC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.82	0.3	1.38e-8	Putamen volume;
LIHC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg11764359	chr7:65958608	NA	0.58	6.06	0.31	3.57e-9	Diabetic kidney disease;
LIHC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-6.15	-0.32	2.16e-9	Schizophrenia;
LIHC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7039377	0.541	rs7850196	chr9:38671574	G/T	cg14625731	chr9:38672608	NA	-0.48	-8.97	-0.44	1.99e-17	Obesity-related traits;
LIHC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg02297831	chr4:17616191	MED28	0.41	5.77	0.3	1.76e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.45	6.7	0.34	8.84e-11	Dermatomyositis;
LIHC	trans	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg17675199	chr6:35436792	RPL10A	-0.38	-7.68	-0.38	1.65e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.67	9.96	0.47	1.1e-20	Menopause (age at onset);
LIHC	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg22951263	chr5:87985283	NA	-0.39	-6.74	-0.34	6.86e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs4934494	0.727	rs12764076	chr10:91390200	T/C	cg19698084	chr10:91461284	KIF20B	-0.46	-6.19	-0.32	1.74e-9	Red blood cell count;
LIHC	cis	rs10423674	0.526	rs34482977	chr19:18824038	C/G	cg14292368	chr19:18793705	CRTC1	-0.42	-5.82	-0.3	1.34e-8	Menarche (age at onset);
LIHC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.89	-18.4	-0.71	4.82e-53	Height;
LIHC	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.27	-0.37	2.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.45	6.18	0.32	1.85e-9	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs743793	0.875	rs137381	chr22:33578402	C/T	cg20274824	chr1:36638199	MAP7D1	0.46	6.42	0.33	4.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg10360139	chr7:1886902	MAD1L1	0.42	6.48	0.33	3.12e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.76	-0.5	1.88e-23	Coronary artery disease;
LIHC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.96	-0.47	1.09e-20	Obesity-related traits;
LIHC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.34	-5.99	-0.31	5.29e-9	IgG glycosylation;
LIHC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.18	0.32	1.81e-9	Alzheimer's disease;
LIHC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.65	0.46	1.17e-19	Mean platelet volume;
LIHC	trans	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg01134436	chr17:81009848	B3GNTL1	0.8	6.64	0.34	1.27e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.29	-0.49	8.14e-22	Response to antipsychotic treatment;
LIHC	cis	rs911119	0.955	rs8115423	chr20:23605253	T/C	cg16589663	chr20:23618590	CST3	0.76	8.04	0.4	1.44e-14	Chronic kidney disease;
LIHC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.37	6.03	0.31	4.14e-9	Cystic fibrosis severity;
LIHC	cis	rs9918079	0.560	rs7685083	chr4:15610771	G/A	cg24225360	chr4:15471699	CC2D2A	0.39	6.2	0.32	1.67e-9	Obesity-related traits;
LIHC	cis	rs6088813	1.000	rs6142373	chr20:33983314	T/A	cg14752227	chr20:34000481	UQCC	-0.4	-5.75	-0.3	1.99e-8	Height;
LIHC	cis	rs4362	0.934	rs4343	chr17:61566031	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.38	5.9	0.3	8.6e-9	Blood metabolite levels;
LIHC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1347297	0.590	rs9288019	chr2:179276894	C/A	cg14011486	chr1:26737247	LIN28	0.63	10.04	0.48	5.75e-21	Alzheimer disease and age of onset;
LIHC	cis	rs986417	1.000	rs10149915	chr14:60943110	G/A	cg27398547	chr14:60952738	C14orf39	0.81	9.39	0.45	8.69e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-8.37	-0.41	1.45e-15	Chronic sinus infection;
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.83	0.57	4.9e-31	Alzheimer's disease;
LIHC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.73	0.39	1.21e-13	Lymphocyte counts;
LIHC	trans	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.41	6.11	0.31	2.7e-9	Endometrial cancer;
LIHC	trans	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg01596870	chr19:55963115	NA	-0.68	-10.23	-0.48	1.34e-21	Obesity-related traits;
LIHC	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.6	-9.76	-0.47	5.03e-20	Corneal astigmatism;
LIHC	cis	rs911119	0.955	rs6048945	chr20:23602228	C/T	cg16589663	chr20:23618590	CST3	0.74	7.78	0.39	8.48e-14	Chronic kidney disease;
LIHC	cis	rs807029	0.577	rs11190787	chr10:102758625	G/T	cg27255678	chr10:102756921	LZTS2	0.51	7.17	0.36	4.56e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg18016565	chr1:150552671	MCL1	0.5	9.62	0.46	1.5700000000000001e-19	Melanoma;
LIHC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg05941027	chr17:61774174	LIMD2	0.35	7.35	0.37	1.48e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.49	6.34	0.32	7.26e-10	Cognitive test performance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02902865	chr1:12679132	DHRS3	0.47	6.89	0.35	2.76e-11	Pancreatic cancer;
LIHC	cis	rs8084351	0.577	rs8089270	chr18:50639779	G/A	cg24270629	chr18:50823537	DCC	0.42	6.25	0.32	1.21e-9	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.8	5.97	0.31	5.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg10241871	chr14:102965420	TECPR2	-0.48	-7.81	-0.39	6.95e-14	Blood protein levels;
LIHC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.72	-11.77	-0.54	4.33e-27	Body mass index;
LIHC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06636551	chr8:101224915	SPAG1	0.47	8.95	0.44	2.38e-17	Atrioventricular conduction;
LIHC	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg22153463	chr1:85462885	MCOLN2	0.52	6.13	0.31	2.4e-9	Serum sulfate level;
LIHC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.35	-0.41	1.69e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.39	6.16	0.32	2.05e-9	Multiple sclerosis;
LIHC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.49	7.27	0.37	2.43e-12	Personality dimensions;
LIHC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	7.5	0.38	5.64e-13	Schizophrenia;
LIHC	cis	rs797680	0.856	rs7553465	chr1:93644410	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.88	-0.3	9.71e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg20651018	chr11:3035856	CARS	-0.35	-5.98	-0.31	5.6e-9	Type 2 diabetes;
LIHC	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.49	7.83	0.39	6.22e-14	Blood protein levels;
LIHC	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.64	-0.69	5.32e-50	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-5.88	-0.3	9.8e-9	Body mass index;
LIHC	cis	rs9378688	0.546	rs2479014	chr6:2357948	C/T	cg12303981	chr6:2244766	GMDS	-0.45	-6.46	-0.33	3.62e-10	Caudate nucleus volume;
LIHC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26897989	chr16:1907736	C16orf73	-0.46	-5.77	-0.3	1.82e-8	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.74	-0.5	2.15e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.36	-6.19	-0.32	1.7e-9	IgG glycosylation;
LIHC	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg18478394	chr8:109455254	TTC35	0.42	7.05	0.36	9.74e-12	Dupuytren's disease;
LIHC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.34	6.57	0.33	1.91e-10	Multiple system atrophy;
LIHC	cis	rs7923837	0.683	rs11187078	chr10:94340705	C/G	cg25506282	chr10:94462361	NA	0.35	5.92	0.31	7.64e-9	Body mass index;Multiple sclerosis;
LIHC	trans	rs2359714	0.935	rs10494208	chr1:118796777	A/T	cg19861078	chr7:7936962	NA	0.32	6.19	0.32	1.73e-9	Breast size;
LIHC	trans	rs1864585	0.520	rs17776622	chr8:10676497	T/C	cg26278703	chr11:58910052	FAM111A	0.73	6.32	0.32	8.11e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.45	8.08	0.4	1.12e-14	Coronary artery disease;
LIHC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg06969265	chr17:73775802	H3F3B	0.68	6.13	0.31	2.45e-9	Psoriasis;
LIHC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.33	-0.49	6.14e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.15	0.36	5.22e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	trans	rs11638815	0.626	rs1313492	chr15:83272955	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.06	-0.31	3.66e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LIHC	trans	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg19894588	chr14:64061835	NA	-0.61	-7.78	-0.39	8.85e-14	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.18	-0.36	4.25e-12	Bipolar disorder;
LIHC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.43	-7.38	-0.37	1.2e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.55	-0.33	2.13e-10	Neuroticism;
LIHC	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.83	-0.35	3.8e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-7.97	-0.4	2.43e-14	Alzheimer's disease;
LIHC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	8.9	0.43	3.38e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.16	0.44	4.82e-18	Cognitive ability;
LIHC	cis	rs11662586	1.000	rs7243921	chr18:77695237	G/A	cg20368463	chr18:77673604	PQLC1	0.42	6.65	0.34	1.13e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LIHC	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.35	-6.26	-0.32	1.15e-9	Colorectal cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg13792025	chr7:66205470	RABGEF1	-0.47	-6.15	-0.32	2.16e-9	Systolic blood pressure;
LIHC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.25	19.27	0.72	1.53e-56	Type 1 diabetes nephropathy;
LIHC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.6	0.53	1.85e-26	Platelet count;
LIHC	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg03146154	chr1:46216737	IPP	-0.38	-6.25	-0.32	1.22e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.07e-40	Aortic root size;
LIHC	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.67	-6.34	-0.32	7.38e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.34	6.97	0.35	1.65e-11	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.33	7.38	0.37	1.19e-12	Ulcerative colitis;
LIHC	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	0.87	14.21	0.61	2.47e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs9326778	0.520	rs4957819	chr5:108829195	C/T	cg17395555	chr5:108820864	NA	0.35	6.0	0.31	4.96e-9	Aggressiveness in attention deficit hyperactivity disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.45	6.66	0.34	1.06e-10	Pancreatic cancer;
LIHC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.65	9.18	0.44	4.29e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg16583315	chr14:65563665	MAX	-0.41	-8.41	-0.41	1.13e-15	Obesity-related traits;
LIHC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg22528358	chr1:107598549	PRMT6	0.69	11.37	0.52	1.26e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4950322	0.576	rs2353980	chr1:146839989	A/T	cg25205988	chr1:146714368	CHD1L	0.44	6.16	0.32	1.99e-9	Protein quantitative trait loci;
LIHC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-0.97	-17.16	-0.68	4.9e-48	Monocyte percentage of white cells;
LIHC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.45	7.42	0.37	9.55e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg00277334	chr10:82204260	NA	-0.5	-5.9	-0.3	8.6e-9	Post bronchodilator FEV1;
LIHC	cis	rs11761441	1.000	rs12718067	chr7:82873	T/C	cg25149888	chr7:81075	NA	0.3	7.07	0.36	8.72e-12	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg15208524	chr1:10270712	KIF1B	-0.44	-6.3	-0.32	9.19e-10	Hepatocellular carcinoma;
LIHC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.56	-8.3	-0.41	2.43e-15	Response to diuretic therapy;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.59	0.34	1.67e-10	Total body bone mineral density;
LIHC	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.3	-0.32	9.3e-10	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.6	9.32	0.45	1.47e-18	Height;
LIHC	trans	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg21372672	chr17:16614065	CCDC144A	-0.26	-6.35	-0.32	6.79e-10	Pancreatic cancer;
LIHC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg04083430	chr16:4736063	MGRN1	0.4	5.72	0.3	2.38e-8	Schizophrenia;
LIHC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.36	0.52	1.37e-25	Coronary artery disease;
LIHC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.62	6.53	0.33	2.45e-10	Vitiligo;
LIHC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.38	6.17	0.32	1.9e-9	Mood instability;
LIHC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.68	0.57	1.8e-30	Schizophrenia;
LIHC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.87	15.64	0.65	5.61e-42	Dental caries;
LIHC	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.2	-6.28	-0.32	1.05e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg26939375	chr7:64535504	NA	0.46	7.88	0.39	4.31e-14	Aortic root size;
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	7.75	0.39	1.06e-13	Height;
LIHC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-8.13	-0.4	8.08e-15	Tonsillectomy;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07677032	chr17:61819896	STRADA	-0.41	-5.94	-0.31	6.89e-9	Prudent dietary pattern;
LIHC	cis	rs15676	1.000	rs10988125	chr9:131572903	A/G	cg00228799	chr9:131580591	ENDOG	0.45	6.74	0.34	6.65e-11	Blood metabolite levels;
LIHC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.62	-11.25	-0.52	3.48e-25	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07549551	chr6:158487608	SYNJ2	-0.47	-6.95	-0.35	1.84e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg07959070	chr22:50026188	C22orf34	-0.29	-6.88	-0.35	2.92e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.36	-7.84	-0.39	5.77e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.83	-15.84	-0.65	8.89e-43	Height;
LIHC	trans	rs4596713	0.508	rs12056979	chr9:71778946	A/G	cg16512924	chr15:28394682	HERC2	0.39	6.25	0.32	1.21e-9	Headache;
LIHC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.54	-0.38	4.32e-13	Chronic sinus infection;
LIHC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.13	0.61	5.14e-36	Chronic sinus infection;
LIHC	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.55	8.61	0.42	2.78e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg12437481	chr16:420112	MRPL28	-0.51	-7.71	-0.38	1.36e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.69	-10.25	-0.48	1.09e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs4714291	0.963	rs2475496	chr6:39963850	A/G	cg16345906	chr6:40101885	NA	-0.29	-5.73	-0.3	2.23e-8	Strep throat;
LIHC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.64	8.93	0.43	2.7e-17	Multiple sclerosis;
LIHC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.72	-9.19	-0.44	3.93e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.85	-0.35	3.49e-11	Adiposity;
LIHC	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg09003973	chr2:102972529	NA	0.88	7.62	0.38	2.44e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.89	0.51	6.32e-24	Personality dimensions;
LIHC	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.44	6.47	0.33	3.38e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg17980119	chr2:219472607	PLCD4	0.35	6.05	0.31	3.84e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.08	0.31	3.29e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs12220238	0.841	rs12098284	chr10:76047464	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.35	0.32	6.83e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-10.0	-0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs1881396	0.945	rs62141291	chr2:27784034	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.76	0.34	6.12e-11	Nonalcoholic fatty liver disease;
LIHC	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-20.62	-0.74	5.92e-62	Exhaled nitric oxide output;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg24693881	chr1:107596107	NA	0.56	9.84	0.47	2.83e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.02	0.31	4.6e-9	Heart rate;
LIHC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.46	6.76	0.34	6.11e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg22705602	chr4:152727874	NA	-0.31	-6.45	-0.33	3.82e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12464559	0.649	rs10754989	chr2:152642235	T/C	cg01189475	chr2:152685088	ARL5A	0.64	7.38	0.37	1.19e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.16	0.55	1.58e-28	Prudent dietary pattern;
LIHC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.39	6.25	0.32	1.22e-9	Melanoma;
LIHC	cis	rs3106136	0.872	rs10030713	chr4:95238536	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.67	-0.34	1e-10	Capecitabine sensitivity;
LIHC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.36	6.58	0.34	1.73e-10	Aortic root size;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.81	13.58	0.59	6.95e-34	Height;
LIHC	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg00977110	chr5:151150581	G3BP1	0.55	6.98	0.35	1.56e-11	Preschool internalizing problems;
LIHC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.91	-13.92	-0.6	3.42e-35	Body mass index;
LIHC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.98	-18.24	-0.7	2.17e-52	Breast cancer;
LIHC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.72	11.19	0.52	5.63e-25	Corneal astigmatism;
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.48	-7.76	-0.39	9.96e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.8	13.28	0.58	9.82e-33	Multiple sclerosis;
LIHC	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.47	-5.8	-0.3	1.49e-8	Response to amphetamines;
LIHC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg17135325	chr3:160939158	NMD3	0.56	8.25	0.41	3.54e-15	Parkinson's disease;
LIHC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.83	12.81	0.57	6.02e-31	Total body bone mineral density;
LIHC	cis	rs4759375	0.667	rs11057242	chr12:123770362	T/C	cg00376283	chr12:123451042	ABCB9	-0.49	-6.32	-0.32	8.36e-10	HDL cholesterol;
LIHC	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	6.76	0.34	5.83e-11	Bipolar disorder;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25631714	chr4:68566961	LOC550112;UBA6	-0.56	-6.54	-0.33	2.18e-10	Systolic blood pressure;
LIHC	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.44	8.45	0.42	8.54e-16	Metabolite levels;
LIHC	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	0.46	6.09	0.31	3.11e-9	Pulmonary function decline;
LIHC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.52	-0.67	1.7e-45	Diabetic kidney disease;
LIHC	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-7.14	-0.36	5.72e-12	Metabolic traits;
LIHC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.11	11.42	0.53	8.64e-26	Opioid sensitivity;
LIHC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12144094	0.882	rs11577560	chr1:120229865	A/G	cg20995928	chr1:120229863	NA	0.43	7.48	0.37	6.52e-13	Height;
LIHC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	6.47	0.33	3.49e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs829883	0.624	rs829881	chr12:98881228	T/G	cg23471612	chr12:98897216	NA	0.31	5.94	0.31	7e-9	Colorectal adenoma (advanced);
LIHC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-11.72	-0.54	6.83e-27	Height;
LIHC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg21724239	chr8:58056113	NA	0.48	6.4	0.33	5.2400000000000005e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.08	15.48	0.64	2.54e-41	Cognitive function;
LIHC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.87	0.39	4.59e-14	Alzheimer's disease;
LIHC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	10.56	0.5	9.32e-23	Platelet count;
LIHC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.45	-9.09	-0.44	8.22e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.45	-6.64	-0.34	1.22e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg15711740	chr2:61764176	XPO1	0.42	5.74	0.3	2.14e-8	Tuberculosis;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-8.36	-0.41	1.61e-15	Gut microbiome composition (summer);
LIHC	trans	rs10827565	1.000	rs10827565	chr10:36244409	C/G	cg12960782	chr5:59996455	DEPDC1B	-0.53	-6.07	-0.31	3.39e-9	Bronchial neuroendocrine tumor;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02656525	chr5:110427854	WDR36	0.43	6.29	0.32	9.74e-10	Calcium levels;
LIHC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg16102536	chr7:156981717	UBE3C	-0.36	-6.11	-0.31	2.77e-9	Body mass index;
LIHC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.87	11.96	0.54	8.55e-28	Post bronchodilator FEV1;
LIHC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-8.33	-0.41	2.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg15534755	chr11:117069859	TAGLN	-0.37	-6.23	-0.32	1.37e-9	Blood protein levels;
LIHC	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	0.74	8.02	0.4	1.71e-14	Gut microbiota (bacterial taxa);
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01516881	chr6:292596	DUSP22	-0.5	-6.35	-0.32	7.01e-10	Menopause (age at onset);
LIHC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.12	0.31	2.57e-9	Height;
LIHC	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.23	0.36	3.18e-12	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg19875535	chr5:140030758	IK	-0.36	-5.89	-0.3	9.44e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.56	7.95	0.39	2.73e-14	Response to diuretic therapy;
LIHC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	11.76	0.54	5e-27	High light scatter reticulocyte count;
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.81	-0.3	1.42e-8	Menopause (age at onset);
LIHC	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.25	0.48	1.08e-21	Hypertriglyceridemia;
LIHC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.64	-11.11	-0.52	1.04e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.29	-0.32	9.46e-10	Lung cancer;
LIHC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.63	0.34	1.34e-10	Bipolar disorder;
LIHC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.63	9.88	0.47	2.07e-20	Corneal astigmatism;
LIHC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.52	7.89	0.39	4.1e-14	Osteoporosis;
LIHC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.76	0.57	9.25e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2737618	0.651	rs2249172	chr1:200082955	A/G	cg21825944	chr1:200113062	NR5A2	0.39	6.84	0.35	3.65e-11	Uric acid levels;
LIHC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg02344993	chr17:57696989	CLTC	0.7	11.89	0.54	1.66e-27	Hemoglobin concentration;
LIHC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.64	-11.04	-0.51	1.95e-24	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.23	6.2	0.32	1.65e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.87	-0.3	1.01e-8	Longevity;
LIHC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg18478394	chr8:109455254	TTC35	0.41	7.08	0.36	8.06e-12	Dupuytren's disease;
LIHC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg27494647	chr7:150038898	RARRES2	0.34	6.18	0.32	1.81e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.4	5.94	0.31	7.11e-9	Gout;
LIHC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.54e-28	Body mass index;
LIHC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-8.37	-0.41	1.45e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg03859395	chr2:55845619	SMEK2	-0.57	-9.83	-0.47	3.08e-20	Metabolic syndrome;
LIHC	cis	rs7487075	0.578	rs4768713	chr12:46814047	A/G	cg23829395	chr12:46796953	NA	0.35	6.26	0.32	1.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.41	6.18	0.32	1.87e-9	Height;
LIHC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-1.03	-10.46	-0.49	2.19e-22	Schizophrenia;
LIHC	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.26	-6.44	-0.33	4.03e-10	Mean corpuscular volume;
LIHC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.5	0.33	2.84e-10	Rheumatoid arthritis;
LIHC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg27478167	chr7:817139	HEATR2	-0.41	-5.84	-0.3	1.25e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.53	-0.38	4.48e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs17106184	1.000	rs12072155	chr1:50908741	T/A	cg07174182	chr1:51127561	FAF1	-0.54	-6.12	-0.31	2.55e-9	Type 2 diabetes;
LIHC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-7.33	-0.37	1.63e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18107078	chr1:162760321	HSD17B7	-0.42	-6.32	-0.32	8.18e-10	Breast cancer;
LIHC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.4	7.01	0.35	1.29e-11	Psoriasis;
LIHC	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.86	11.08	0.51	1.43e-24	Coronary artery disease;
LIHC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07796018	chr2:55920613	PNPT1	-0.49	-6.23	-0.32	1.34e-9	Lung cancer in ever smokers;
LIHC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.11	0.31	2.75e-9	Nonalcoholic fatty liver disease;
LIHC	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.07	0.36	8.67e-12	Exhaled nitric oxide output;
LIHC	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.83	-11.69	-0.53	8.34e-27	Obesity-related traits;
LIHC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.06	-0.31	3.54e-9	Type 2 diabetes;
LIHC	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg03934865	chr2:198174659	NA	0.52	7.88	0.39	4.42e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg25952890	chr19:58913133	NA	0.69	7.48	0.37	6.31e-13	Mean platelet volume;
LIHC	cis	rs8014671	0.512	rs11624424	chr14:70980424	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.43	-6.49	-0.33	2.97e-10	Prostate cancer;
LIHC	cis	rs17854409	0.764	rs3761301	chr20:61494021	C/T	cg07645718	chr20:61493192	TCFL5	0.81	6.08	0.31	3.21e-9	Obesity-related traits;
LIHC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.58	9.54	0.46	2.7e-19	Resting heart rate;
LIHC	cis	rs9596863	0.948	rs9568907	chr13:54335565	C/G	ch.13.53330881F	chr13:54432880	NA	0.45	6.22	0.32	1.45e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.46	-0.62	2.58e-37	Systemic lupus erythematosus;
LIHC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.56	-0.42	3.8e-16	Primary biliary cholangitis;
LIHC	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg06307176	chr5:131281290	NA	0.42	6.24	0.32	1.27e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	9.73	0.47	6.35e-20	Lung cancer;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg06366937	chr1:74663927	TNNI3K;FPGT;LRRIQ3	-0.4	-6.33	-0.32	7.67e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs74233809	1.000	rs78260931	chr10:104721962	G/C	cg03493300	chr10:104813866	CNNM2	0.46	6.0	0.31	4.96e-9	Birth weight;
LIHC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.5	7.0	0.35	1.36e-11	Morning vs. evening chronotype;
LIHC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.63	-0.34	1.32e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-7.96	-0.4	2.56e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.62	-6.44	-0.33	4.1e-10	Breast cancer;
LIHC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg21724239	chr8:58056113	NA	0.48	6.36	0.33	6.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.34	-6.01	-0.31	4.77e-9	Schizophrenia;
LIHC	cis	rs12249377	0.519	rs12259060	chr10:92579949	A/G	cg14313238	chr10:92632228	RPP30	0.38	6.28	0.32	1.01e-9	White matter microstructure (global fractional anisotropy);
LIHC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.91	-0.54	1.38e-27	Chronic sinus infection;
LIHC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.43	0.45	6.52e-19	Bipolar disorder;
LIHC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.83	-15.93	-0.65	4.11e-43	Height;
LIHC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg10360323	chr17:41437877	NA	0.4	5.97	0.31	6.08e-9	Menopause (age at onset);
LIHC	cis	rs7091068	0.616	rs6583905	chr10:95504022	T/G	cg20715218	chr10:95462985	C10orf4	0.57	5.86	0.3	1.07e-8	Urinary tract infection frequency;
LIHC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-11.46	-0.53	5.72e-26	Platelet distribution width;
LIHC	cis	rs7635838	0.859	rs6786166	chr3:11511424	T/C	cg00170343	chr3:11313890	ATG7	0.39	6.06	0.31	3.61e-9	HDL cholesterol;
LIHC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.89	-11.68	-0.53	9.6800000000000007e-27	Schizophrenia;
LIHC	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	0.93	6.84	0.35	3.7e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09280946	chr11:88070661	CTSC	-0.41	-6.06	-0.31	3.68e-9	Pancreatic cancer;
LIHC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.56	-8.6	-0.42	3.01e-16	Height;
LIHC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.73	13.31	0.58	7.61e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13409248	chr3:40428643	ENTPD3	0.48	7.91	0.39	3.54e-14	Renal cell carcinoma;
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07677032	chr17:61819896	STRADA	0.42	6.23	0.32	1.36e-9	Prudent dietary pattern;
LIHC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	13.7	0.6	2.33e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.62	-5.87	-0.3	1.02e-8	Breast cancer;
LIHC	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.29	6.19	0.32	1.74e-9	Pulmonary function;
LIHC	cis	rs4908768	0.539	rs6675443	chr1:8651582	T/A	cg20416874	chr1:8611966	RERE	-0.66	-12.38	-0.56	2.52e-29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs9475752	0.744	rs6459174	chr6:56786055	C/T	cg25726699	chr6:135826776	C6orf217	0.4	6.09	0.31	2.97e-9	Menarche (age at onset);
LIHC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.57	7.57	0.38	3.58e-13	Emphysema distribution in smoking;
LIHC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg02487422	chr3:49467188	NICN1	-0.42	-5.86	-0.3	1.11e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.7	11.47	0.53	5.47e-26	Mean platelet volume;
LIHC	trans	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.52	0.33	2.57e-10	Endometrial cancer;
LIHC	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.44	-6.12	-0.31	2.59e-9	Inflammatory biomarkers;
LIHC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.4	0.33	5.2e-10	Lung cancer in ever smokers;
LIHC	trans	rs79976124	0.797	rs2226266	chr6:66617302	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	6.07	0.31	3.47e-9	Type 2 diabetes;
LIHC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.51	8.35	0.41	1.72e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.61	7.09	0.36	7.83e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg04013166	chr16:89971882	TCF25	0.49	6.08	0.31	3.24e-9	Skin colour saturation;
LIHC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.57	8.18	0.4	5.52e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg27196102	chr16:23464713	COG7	-0.4	-6.46	-0.33	3.62e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg07952391	chr2:88470173	THNSL2	0.82	7.29	0.37	2.18e-12	Plasma clusterin levels;
LIHC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg22223119	chr13:99095684	FARP1	-0.39	-5.89	-0.3	9.05e-9	Neuroticism;
LIHC	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg00977110	chr5:151150581	G3BP1	0.51	6.47	0.33	3.3e-10	Preschool internalizing problems;
LIHC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.79	-9.58	-0.46	2e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.78	12.78	0.57	7.81e-31	Fat distribution (HIV);
LIHC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.39	7.27	0.37	2.41e-12	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg12501888	chr15:85177176	SCAND2	-0.47	-7.29	-0.37	2.22e-12	P wave terminal force;
LIHC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.38	-6.17	-0.32	1.92e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-7.18	-0.36	4.43e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg16970926	chr12:29381810	FAR2	0.28	5.93	0.31	7.5e-9	QT interval;
LIHC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.67	6.38	0.33	5.77e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	0.68	12.98	0.57	1.29e-31	Systemic lupus erythematosus;
LIHC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg14393609	chr7:65229607	NA	0.45	6.59	0.34	1.69e-10	Aortic root size;
LIHC	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.54	-0.33	2.29e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs77861329	1.000	rs9857878	chr3:52109668	A/G	cg08692210	chr3:52188851	WDR51A	-0.79	-7.27	-0.37	2.47e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg04310649	chr10:35416472	CREM	-0.45	-6.08	-0.31	3.17e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg03945807	chr20:60948434	NA	0.33	6.01	0.31	4.73e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.41	-0.33	4.8e-10	Height;
LIHC	cis	rs16944613	0.528	rs6416554	chr15:91138290	T/C	cg26821196	chr15:91095069	CRTC3	0.43	7.2	0.36	3.91e-12	Colorectal cancer;
LIHC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.26	-7.81	-0.39	7.2e-14	Calcium levels;
LIHC	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg10820045	chr2:198174542	NA	-0.48	-7.23	-0.36	3.1e-12	Intracranial aneurysm;
LIHC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.67	9.86	0.47	2.41e-20	Aortic root size;
LIHC	cis	rs7487075	0.780	rs2279559	chr12:46767175	A/C	cg22049899	chr12:47219821	SLC38A4	0.36	6.15	0.32	2.16e-9	Itch intensity from mosquito bite;
LIHC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.96	13.64	0.59	4.12e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	1.01	11.89	0.54	1.62e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.48	8.81	0.43	6.4e-17	Reticulocyte fraction of red cells;
LIHC	trans	rs783540	0.934	rs8043401	chr15:83356259	A/G	cg18393722	chr15:85113863	UBE2QP1	0.38	6.69	0.34	9.17e-11	Schizophrenia;
LIHC	cis	rs7116495	1.000	rs6592450	chr11:71671166	C/T	cg26138937	chr11:71823887	C11orf51	-0.71	-7.23	-0.36	3.14e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs11229555	0.574	rs12271501	chr11:58214969	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.63	-0.38	2.37e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.45	-7.27	-0.37	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.21	-0.32	1.54e-9	Aortic root size;
LIHC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg25894440	chr7:65020034	NA	0.5	5.94	0.31	7.04e-9	Diabetic kidney disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03571225	chr17:54991993	TRIM25	0.41	6.14	0.32	2.34e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg00049323	chr5:472564	LOC25845	0.35	5.84	0.3	1.23e-8	Cystic fibrosis severity;
LIHC	trans	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg10756647	chr7:56101905	PSPH	1.07	13.4	0.59	3.25e-33	Diabetic kidney disease;
LIHC	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg16586182	chr3:47516702	SCAP	-0.54	-9.75	-0.47	5.8e-20	Colorectal cancer;
LIHC	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.54	-7.77	-0.39	9.09e-14	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.94	13.42	0.59	2.78e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.01	-0.44	1.43e-17	Bipolar disorder;
LIHC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.68	-0.34	9.86e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.48	-8.04	-0.4	1.52e-14	Blood metabolite levels;
LIHC	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.58	8.32	0.41	2.15e-15	Urinary tract infection frequency;
LIHC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.85	-0.69	8.1e-51	Height;
LIHC	cis	rs710865	0.541	rs2273046	chr1:19566296	C/T	cg13387374	chr1:19411106	UBR4	-0.39	-5.91	-0.3	8.23e-9	Brain structure;
LIHC	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.58	-8.71	-0.43	1.29e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	1.02	19.58	0.73	8.67e-58	Breast cancer;
LIHC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg09417038	chr21:47716443	C21orf57	-0.54	-8.01	-0.4	1.8e-14	Testicular germ cell tumor;
LIHC	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.34	-7.21	-0.36	3.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.86	14.88	0.63	5.89e-39	Monocyte count;
LIHC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.89	0.35	2.64e-11	Axial length;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24413235	chr2:27851648	CCDC121;GPN1	0.43	6.22	0.32	1.42e-9	Lung function (FEV1/FVC);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07071157	chr11:72525331	ATG16L2	0.47	6.67	0.34	1e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11673344	0.932	rs76350084	chr19:37678819	A/C	cg27390819	chr19:37464633	NA	-0.5	-5.98	-0.31	5.53e-9	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.86	0.39	5.2e-14	Prudent dietary pattern;
LIHC	trans	rs1992950	0.819	rs7596078	chr2:200179843	C/T	cg23743778	chr4:140357491	NA	0.36	6.06	0.31	3.67e-9	Ulcerative colitis;
LIHC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.45	6.31	0.32	8.86e-10	Asthma;
LIHC	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.84	-0.69	8.83e-51	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19691163	chr5:96304288	LNPEP	-0.46	-6.05	-0.31	3.75e-9	Pancreatic cancer;
LIHC	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-6.12	-0.31	2.59e-9	Inflammatory biomarkers;
LIHC	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.18	0.32	1.83e-9	Protein biomarker;
LIHC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg03934865	chr2:198174659	NA	-0.59	-9.35	-0.45	1.22e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.74	-0.3	2.04e-8	Colorectal cancer;
LIHC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.95	-0.39	2.76e-14	Schizophrenia;
LIHC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.87	11.03	0.51	2.02e-24	Bladder cancer;
LIHC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.51	-8.32	-0.41	2.14e-15	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23260255	chr3:187871479	LPP	0.41	6.48	0.33	3.26e-10	Cognitive function;
LIHC	cis	rs12079745	0.793	rs57776592	chr1:169268023	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-7.11	-0.36	6.7e-12	QT interval;
LIHC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg12863693	chr15:85201151	NMB	0.49	6.96	0.35	1.73e-11	Schizophrenia;
LIHC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-0.58	-7.73	-0.39	1.22e-13	Lung cancer;
LIHC	cis	rs7116495	0.609	rs567851	chr11:71592419	G/C	cg10381502	chr11:71823885	C11orf51	0.83	7.24	0.36	2.93e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.0	10.43	0.49	2.75e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.6	6.74	0.34	6.59e-11	Axial length;
LIHC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.49	6.13	0.31	2.45e-9	Total body bone mineral density;
LIHC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.52	-8.19	-0.4	5.37e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.45	6.59	0.34	1.62e-10	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21575187	chr5:177558253	RMND5B	0.43	6.28	0.32	1.03e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-6.65	-0.34	1.13e-10	Vitiligo;
LIHC	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	6.06	0.31	3.52e-9	IgG glycosylation;
LIHC	cis	rs7944735	0.508	rs7931089	chr11:47633506	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-6.07	-0.31	3.4e-9	Intraocular pressure;
LIHC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.42	-5.72	-0.3	2.32e-8	Colorectal cancer;
LIHC	cis	rs4407350	0.967	rs5765741	chr22:44924292	A/G	cg26276947	chr22:44892394	LDOC1L	0.32	5.94	0.31	7.05e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.5	-0.38	5.38e-13	Breast cancer;
LIHC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.3	-6.22	-0.32	1.44e-9	Blood metabolite levels;
LIHC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.58	6.99	0.35	1.47e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.5e-20	Crohn's disease;
LIHC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.95	22.44	0.77	3.39e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-9.07	-0.44	9.26e-18	Personality dimensions;
LIHC	cis	rs116979167	0.575	rs818470	chr7:105165350	A/C	cg19920283	chr7:105172520	RINT1	0.48	5.95	0.31	6.52e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg17845761	chr1:175162550	KIAA0040	0.38	6.65	0.34	1.13e-10	Alcohol dependence;
LIHC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.87	-17.16	-0.68	4.93e-48	Coronary artery disease;
LIHC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.35	5.84	0.3	1.21e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg25738037	chr1:168025549	DCAF6	0.38	5.8	0.3	1.48e-8	Schizophrenia;
LIHC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.42	-0.37	9.63e-13	Psoriasis;
LIHC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.63	-6.22	-0.32	1.43e-9	Plasma clusterin levels;
LIHC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs712039	0.652	rs1102920	chr17:35760940	A/G	cg16670864	chr17:35848621	DUSP14	0.34	5.83	0.3	1.29e-8	Tuberculosis;
LIHC	cis	rs7635838	0.819	rs4684782	chr3:11518755	C/T	cg00170343	chr3:11313890	ATG7	-0.4	-6.3	-0.32	9.31e-10	HDL cholesterol;
LIHC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.25	0.48	1.14e-21	Bladder cancer;
LIHC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	10.83	0.51	1.06e-23	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03759077	chr2:153575599	ARL6IP6	0.45	6.58	0.34	1.74e-10	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.56	-0.33	1.97e-10	Renal cell carcinoma;
LIHC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.93	0.39	3.17e-14	Lung cancer in ever smokers;
LIHC	trans	rs12752401	1.000	rs35190459	chr1:103089554	T/A	cg17681729	chr19:740608	PALM	0.49	6.42	0.33	4.46e-10	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg00647820	chr17:40259828	DHX58	-0.28	-5.91	-0.3	8.35e-9	Fibrinogen levels;
LIHC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.34	6.15	0.32	2.16e-9	Alopecia areata;
LIHC	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.38	6.08	0.31	3.28e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.5	-8.07	-0.4	1.19e-14	Cognitive function;
LIHC	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.94	-18.95	-0.72	3.02e-55	Schizophrenia;
LIHC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.75	-9.94	-0.47	1.29e-20	Schizophrenia;
LIHC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.79	-10.09	-0.48	4e-21	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.49	-7.59	-0.38	3.02e-13	Blood pressure (smoking interaction);
LIHC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.26	-0.75	1.63e-64	Height;
LIHC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.12	0.4	8.4e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.74	11.12	0.52	9.68e-25	Menarche (age at onset);
LIHC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.56	-9.38	-0.45	9.31e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.4	5.92	0.31	7.63e-9	Diastolic blood pressure;
LIHC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.89	-13.83	-0.6	7.09e-35	Body mass index;
LIHC	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25632853	chr15:73088954	NA	0.38	6.31	0.32	8.46e-10	Triglyceride levels;
LIHC	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.71	-0.38	1.4e-13	Response to antipsychotic treatment;
LIHC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg18016565	chr1:150552671	MCL1	-0.5	-9.95	-0.47	1.17e-20	Melanoma;
LIHC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.54	-9.93	-0.47	1.41e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.32	0.45	1.5e-18	Bipolar disorder;
LIHC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.61	-9.23	-0.45	2.99e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.68	8.43	0.41	9.8e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.37	-6.32	-0.32	7.98e-10	Cisplatin-induced ototoxicity;
LIHC	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg01843034	chr6:37503916	NA	-0.38	-6.28	-0.32	1.06e-9	Cognitive performance;
LIHC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.41	-6.09	-0.31	3e-9	Height;
LIHC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12516959	chr21:47718080	NA	-0.4	-6.41	-0.33	4.72e-10	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.93	-0.47	1.41e-20	Crohn's disease;
LIHC	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg09795085	chr6:101329169	ASCC3	0.43	5.76	0.3	1.88e-8	Neuroticism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02797930	chr3:153839287	SGEF	0.42	6.22	0.32	1.42e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11958404	1.000	rs72816532	chr5:157413130	C/T	cg05962755	chr5:157440814	NA	0.86	10.11	0.48	3.51e-21	IgG glycosylation;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01374398	chr3:47516975	SCAP	0.46	6.12	0.31	2.56e-9	Lung function (FEV1/FVC);
LIHC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg19645103	chr12:69753606	YEATS4	-0.39	-5.87	-0.3	1.06e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg20302533	chr7:39170763	POU6F2	0.34	6.25	0.32	1.2e-9	IgG glycosylation;
LIHC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg20026190	chr17:76395443	PGS1	0.41	6.04	0.31	4.05e-9	HDL cholesterol levels;
LIHC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.83	-14.63	-0.62	5.6e-38	Aortic root size;
LIHC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.37	-5.93	-0.31	7.5e-9	Asthma;
LIHC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg03037974	chr15:76606532	NA	-0.65	-11.49	-0.53	4.62e-26	Blood metabolite levels;
LIHC	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg08345082	chr10:99160200	RRP12	-0.39	-6.65	-0.34	1.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg25797454	chr6:150327115	RAET1K	0.33	5.92	0.3	7.99e-9	Alopecia areata;
LIHC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.46	0.37	7.18e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	0.82	9.98	0.47	9.55e-21	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg04610667	chr7:75704037	NA	-0.35	-6.3	-0.32	9.18e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg15691649	chr6:25882328	NA	0.41	6.08	0.31	3.29e-9	Blood metabolite levels;
LIHC	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg04306507	chr14:55594613	LGALS3	0.32	6.25	0.32	1.19e-9	Protein biomarker;
LIHC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.82	-0.43	5.94e-17	Personality dimensions;
LIHC	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg25364880	chr3:44379878	C3orf23	0.57	7.7	0.38	1.46e-13	Depressive symptoms;
LIHC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.08	-0.36	8.3e-12	Vitiligo;
LIHC	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.92e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs151349	1.000	rs151346	chr20:57587040	C/A	cg23907860	chr20:57583709	CTSZ	-0.43	-7.0	-0.35	1.38e-11	Platelet distribution width;
LIHC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.38	6.64	0.34	1.23e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13811713	chr2:216946683	PECR;TMEM169	0.48	6.64	0.34	1.23e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.83	8.41	0.41	1.14e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg11861562	chr11:117069780	TAGLN	0.37	5.96	0.31	6.22e-9	Blood protein levels;
LIHC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg01864069	chr14:103024347	NA	0.47	7.14	0.36	5.76e-12	Platelet count;
LIHC	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg16558208	chr1:156270281	VHLL	0.54	10.1	0.48	3.59e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg16479474	chr6:28041457	NA	0.39	6.53	0.33	2.39e-10	Parkinson's disease;
LIHC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.57	-6.41	-0.33	4.91e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg09695851	chr17:3907499	NA	0.61	6.88	0.35	2.92e-11	Type 2 diabetes;
LIHC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.77	13.15	0.58	3.14e-32	Menarche (age at onset);
LIHC	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	1.01	18.46	0.71	2.82e-53	Monocyte percentage of white cells;
LIHC	cis	rs16828019	0.929	rs1032728	chr1:41679566	A/T	cg03962019	chr1:41807865	NA	0.5	7.26	0.37	2.68e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.48	7.42	0.37	9.46e-13	Adiposity;
LIHC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.54	6.29	0.32	9.86e-10	Pancreatic cancer;
LIHC	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.59	-7.46	-0.37	7.39e-13	Post bronchodilator FEV1;
LIHC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-9.61	-0.46	1.67e-19	Asthma;
LIHC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.74	13.38	0.59	3.86e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg07424592	chr7:64974309	NA	-0.79	-9.28	-0.45	1.95e-18	Diabetic kidney disease;
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08219700	chr8:58056026	NA	0.51	6.73	0.34	7.07e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.51	8.78	0.43	7.72e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2073499	1.000	rs78020607	chr3:50254624	A/G	cg21659725	chr3:3221576	CRBN	0.58	6.38	0.33	5.81e-10	Schizophrenia;
LIHC	cis	rs739401	0.619	rs10766481	chr11:2961512	G/C	cg05729581	chr11:3078854	CARS	-0.41	-5.71	-0.3	2.41e-8	Longevity;
LIHC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.0	15.75	0.65	2.08e-42	Skin colour saturation;
LIHC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.55	7.7	0.38	1.53e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.0	15.42	0.64	4.09e-41	Breast cancer;
LIHC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.05	24.99	0.8	3.62e-79	IgG glycosylation;
LIHC	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.43	-7.9	-0.39	3.78e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg03013999	chr17:37608204	MED1	-0.34	-5.76	-0.3	1.91e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.71	10.72	0.5	2.6e-23	Aortic root size;
LIHC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.36	7.16	0.36	4.98e-12	Alcohol dependence;
LIHC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.0	-0.31	5.1e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg11764359	chr7:65958608	NA	0.59	6.01	0.31	4.63e-9	Diabetic kidney disease;
LIHC	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg01364799	chr7:75623366	TMEM120A	-0.41	-6.12	-0.31	2.5e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.92	-0.3	7.73e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.8	16.41	0.66	4.89e-45	Gestational age at birth (maternal effect);
LIHC	trans	rs10411161	0.810	rs4267442	chr19:52363727	C/A	cg22319618	chr22:45562946	NUP50	-0.52	-6.48	-0.33	3.15e-10	Breast cancer;
LIHC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.55	7.62	0.38	2.45e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.89	0.39	4.23e-14	Motion sickness;
LIHC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.07	0.4	1.21e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.83	-0.51	1.06e-23	Hemoglobin concentration;
LIHC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.17	0.36	4.67e-12	Self-reported allergy;
LIHC	trans	rs12753920	0.724	rs2093879	chr1:92585831	C/G	cg15668468	chr10:118892869	VAX1	-0.43	-6.26	-0.32	1.15e-9	Systemic lupus erythematosus;
LIHC	cis	rs74233809	1.000	rs12412038	chr10:104856162	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.13	0.31	2.43e-9	Birth weight;
LIHC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.5	-7.32	-0.37	1.78e-12	Total body bone mineral density;
LIHC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.67	-8.89	-0.43	3.45e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.67	11.66	0.53	1.13e-26	Longevity;Endometriosis;
LIHC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.9	-18.35	-0.7	7.75e-53	Height;
LIHC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.51	-8.91	-0.43	2.99e-17	Total body bone mineral density;
LIHC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.38	-6.05	-0.31	3.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg00591980	chr6:150071069	PCMT1	-0.53	-6.08	-0.31	3.12e-9	Systolic blood pressure;
LIHC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.61	-9.52	-0.46	3.36e-19	Dental caries;
LIHC	cis	rs2274273	0.901	rs12050099	chr14:55764331	G/C	cg01864836	chr14:55583639	NA	-0.37	-6.46	-0.33	3.52e-10	Protein biomarker;
LIHC	cis	rs3770081	1.000	rs3810827	chr2:86334386	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.44	6.11	0.31	2.74e-9	Facial emotion recognition (sad faces);
LIHC	trans	rs12030196	0.788	rs10889125	chr1:59417116	A/G	cg25148632	chr5:166402453	NA	0.23	6.15	0.32	2.2e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs3121446	1.000	rs3127661	chr6:107141927	A/G	cg26014185	chr6:10033784	NA	0.2	6.18	0.32	1.85e-9	Daytime sleep phenotypes;
LIHC	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg26597838	chr10:835615	NA	1.1	12.42	0.56	1.76e-29	Eosinophil percentage of granulocytes;
LIHC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.75	9.25	0.45	2.54e-18	Primary sclerosing cholangitis;
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12379764	chr21:47803548	PCNT	-0.55	-8.18	-0.4	5.75e-15	Testicular germ cell tumor;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09273779	chr9:35605990	TESK1	0.42	7.09	0.36	7.7e-12	Cognitive function;
LIHC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.88	0.39	4.42e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.79	-0.34	4.84e-11	Bladder cancer;
LIHC	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-0.61	-6.78	-0.34	5.29e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-1.09	-12.16	-0.55	1.62e-28	White matter hyperintensity burden;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13352455	chr3:53230110	NA	-0.45	-6.25	-0.32	1.24e-9	Pancreatic cancer;
LIHC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg00012203	chr2:219082015	ARPC2	0.48	6.29	0.32	9.87e-10	Ulcerative colitis;
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08219700	chr8:58056026	NA	0.52	6.95	0.35	1.85e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg19936157	chr1:113287238	NA	-0.33	-6.03	-0.31	4.15e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.45	6.72	0.34	7.4e-11	Gout;
LIHC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.78	-0.3	1.71e-8	Neuroticism;
LIHC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.31	-6.39	-0.33	5.38e-10	High light scatter reticulocyte percentage of red cells;
LIHC	trans	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg09872104	chr7:134855509	C7orf49	-0.76	-6.09	-0.31	2.99e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.63	8.52	0.42	5.31e-16	Skin colour saturation;
LIHC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-12.25	-0.55	7.25e-29	Total body bone mineral density;
LIHC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	14.47	0.62	2.39e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.43	5.99	0.31	5.25e-9	QT interval;
LIHC	cis	rs17125944	0.686	rs7158645	chr14:53332152	C/T	cg00686598	chr14:53173677	PSMC6	-0.8	-9.17	-0.44	4.51e-18	Alzheimer's disease (late onset);
LIHC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-8.97	-0.44	2.04e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.81e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.08	-0.31	3.3e-9	Total body bone mineral density;
LIHC	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg27205649	chr11:78285834	NARS2	-0.37	-5.74	-0.3	2.14e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9503598	0.522	rs6938957	chr6:3430835	G/A	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.85	-0.3	1.18e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.48	7.9	0.39	3.93e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9513627	1.000	rs73556170	chr13:100121612	T/A	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.99	-17.15	-0.68	5.13e-48	Tonsillectomy;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.68	10.16	0.48	2.25e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.31	-12.32	-0.55	4.22e-29	Plateletcrit;
LIHC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.62	10.99	0.51	2.84e-24	Rheumatoid arthritis;
LIHC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg16226627	chr15:75307476	SCAMP5	0.54	9.88	0.47	2.04e-20	Lung cancer;
LIHC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.34	7.76	0.39	9.8e-14	Educational attainment (years of education);
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.06	-0.51	1.7e-24	Chronic sinus infection;
LIHC	cis	rs17106184	1.000	rs60290409	chr1:51404041	C/A	cg07174182	chr1:51127561	FAF1	-0.74	-7.94	-0.39	2.99e-14	Type 2 diabetes;
LIHC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.85	0.3	1.13e-8	Resting heart rate;
LIHC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.46	-7.48	-0.37	6.44e-13	Menarche (age at onset);
LIHC	cis	rs12188164	0.812	rs10072668	chr5:422752	T/C	cg10655629	chr5:480253	SLC9A3	0.36	5.82	0.3	1.32e-8	Cystic fibrosis severity;
LIHC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg03037974	chr15:76606532	NA	0.82	17.3	0.68	1.31e-48	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26386436	chr14:90084672	FOXN3	0.41	6.36	0.33	6.42e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.01	-0.4	1.83e-14	Colorectal cancer;
LIHC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.5	8.49	0.42	6.25e-16	Fibrinogen levels;
LIHC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.6	0.34	1.53e-10	Cognitive ability;
LIHC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.77	7.15	0.36	5.16e-12	Plasma clusterin levels;
LIHC	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.54	-8.41	-0.41	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.17	-0.36	4.52e-12	Personality dimensions;
LIHC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg24977027	chr2:88469347	THNSL2	-0.34	-5.94	-0.31	7.04e-9	Response to metformin (IC50);
LIHC	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.35	7.14	0.36	5.67e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg07424592	chr7:64974309	NA	0.84	9.61	0.46	1.62e-19	Diabetic kidney disease;
LIHC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.91	-0.54	1.38e-27	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-11.29	-0.52	2.55e-25	Primary sclerosing cholangitis;
LIHC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.29	5.75	0.3	2.01e-8	Monocyte count;
LIHC	cis	rs16912285	0.688	rs35683920	chr11:24358521	A/G	ch.11.24196551F	chr11:24239977	NA	0.68	7.73	0.39	1.2e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18867708	chr6:26865862	GUSBL1	-0.55	-8.33	-0.41	1.99e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.5	-8.18	-0.4	5.75e-15	Blood protein levels;
LIHC	cis	rs7534824	0.625	rs61780285	chr1:101357627	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	6.75	0.34	6.3e-11	Refractive astigmatism;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg14671364	chr1:107599128	PRMT6	-0.45	-6.55	-0.33	2.17e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.6	0.5	6.78e-23	Lymphocyte counts;
LIHC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg03037974	chr15:76606532	NA	-0.6	-9.92	-0.47	1.52e-20	Blood metabolite levels;
LIHC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.65	-11.13	-0.52	9.48e-25	Crohn's disease;
LIHC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-12.22	-0.55	9.98e-29	Response to antipsychotic treatment;
LIHC	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg12253828	chr6:101329408	ASCC3	-0.39	-5.95	-0.31	6.78e-9	Neuroticism;
LIHC	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.48	-6.38	-0.33	5.72e-10	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg25894440	chr7:65020034	NA	-0.54	-6.12	-0.31	2.54e-9	Diabetic kidney disease;
LIHC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg00800038	chr16:89945340	TCF25	-0.67	-10.78	-0.5	1.64e-23	Skin colour saturation;
LIHC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.48	-18.17	-0.7	4.09e-52	Breast cancer;
LIHC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg19318889	chr4:1322082	MAEA	0.47	6.55	0.33	2.13e-10	Obesity-related traits;
LIHC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg00809820	chr17:80708513	TBCD;FN3K	-0.33	-5.74	-0.3	2.08e-8	Glycated hemoglobin levels;
LIHC	cis	rs10838687	0.736	rs2242262	chr11:47266540	G/T	cg26139080	chr11:47293733	MADD	-0.42	-5.89	-0.3	8.99e-9	Proinsulin levels;
LIHC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg09165964	chr15:75287851	SCAMP5	-0.59	-7.75	-0.39	1.04e-13	Lung cancer;
LIHC	cis	rs861318	0.640	rs3768515	chr1:159010232	T/G	cg11003133	chr1:159046391	AIM2	-0.35	-6.74	-0.34	6.69e-11	Obesity-related traits;
LIHC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.57	-0.46	2.31e-19	Initial pursuit acceleration;
LIHC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.74	-12.22	-0.55	9.39e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.56	6.37	0.33	6.04e-10	Alzheimer's disease;
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.99	0.54	6.68e-28	Alzheimer's disease;
LIHC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.68	10.77	0.5	1.74e-23	Platelet count;
LIHC	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg07636037	chr3:49044803	WDR6	0.53	7.97	0.4	2.4e-14	Resting heart rate;
LIHC	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.71	0.6	2.17e-34	Coffee consumption (cups per day);
LIHC	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.16	-0.36	4.83e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.7	8.94	0.44	2.49e-17	Exhaled nitric oxide output;
LIHC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.27	-0.32	1.11e-9	Tonsillectomy;
LIHC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.38	0.77	5.56e-69	Chronic sinus infection;
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12516959	chr21:47718080	NA	0.36	5.89	0.3	9.46e-9	Testicular germ cell tumor;
LIHC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.33	-0.41	2e-15	Height;
LIHC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg13319975	chr6:146136371	FBXO30	-0.36	-6.05	-0.31	3.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.34	-6.52	-0.33	2.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.46	6.67	0.34	1.05e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg16558253	chr16:72132732	DHX38	-0.51	-8.1	-0.4	9.86e-15	Fibrinogen levels;
LIHC	cis	rs4006360	0.553	rs71383383	chr17:39318172	T/A	cg26521011	chr17:39394147	KRTAP9-8;KRTAP9-9	0.23	5.73	0.3	2.2e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21448741	chr8:58168803	NA	0.35	6.09	0.31	3.02e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.49	5.76	0.3	1.88e-8	Alzheimer's disease;
LIHC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-9.89	-0.47	1.91e-20	Morning vs. evening chronotype;
LIHC	cis	rs72653721	0.838	rs3778166	chr6:11033164	A/G	cg13562911	chr6:11044106	ELOVL2	-0.5	-7.17	-0.36	4.78e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg12661370	chr5:149340060	SLC26A2	0.49	5.75	0.3	1.94e-8	HIV-1 control;
LIHC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.32	6.5	0.33	2.77e-10	Renal cell carcinoma;
LIHC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.39	-6.89	-0.35	2.7e-11	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg07971674	chr14:23388846	RBM23	-0.41	-5.84	-0.3	1.22e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs3740540	0.530	rs4297414	chr10:126292116	T/G	cg04949429	chr10:126290192	LHPP	0.45	7.34	0.37	1.56e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.39	6.47	0.33	3.47e-10	Inhibitory control;
LIHC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.81	-8.83	-0.43	5.65e-17	Vitiligo;
LIHC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	12.29	0.55	5.1e-29	Cognitive test performance;
LIHC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg23485639	chr6:28045615	ZNF165	0.38	5.77	0.3	1.75e-8	Parkinson's disease;
LIHC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg00204748	chr12:29376779	FAR2	0.4	7.49	0.38	5.92e-13	QT interval;
LIHC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.5	0.38	5.41e-13	Menarche (age at onset);
LIHC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.29	0.32	9.8e-10	Tonsillectomy;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16411256	chr8:27348931	EPHX2	0.38	6.94	0.35	1.92e-11	Cognitive function;
LIHC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.38	5.92	0.3	7.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	7.68	0.38	1.69e-13	Aortic root size;
LIHC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg24296786	chr1:45957014	TESK2	-0.45	-6.21	-0.32	1.53e-9	Platelet count;
LIHC	cis	rs151997	0.853	rs6882235	chr5:50260139	T/C	cg06027927	chr5:50259733	NA	0.62	8.49	0.42	6.43e-16	Callous-unemotional behaviour;
LIHC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-13.07	-0.58	6.17e-32	Glomerular filtration rate (creatinine);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08575399	chr20:60719638	PSMA7;SS18L1	0.4	6.44	0.33	4.09e-10	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg07424592	chr7:64974309	NA	0.81	9.51	0.46	3.46e-19	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.11	-0.36	7.03e-12	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.24	0.36	2.94e-12	Renal cell carcinoma;
LIHC	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.54	-0.33	2.26e-10	Prevalent atrial fibrillation;
LIHC	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg10756647	chr7:56101905	PSPH	1.01	11.86	0.54	2.03e-27	Gout;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27310827	chr1:1163671	SDF4	0.46	6.08	0.31	3.16e-9	Hip circumference;
LIHC	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.12	-16.53	-0.67	1.58e-45	Corneal structure;
LIHC	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.5	9.38	0.45	9.68e-19	Testicular germ cell tumor;
LIHC	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.89	17.58	0.69	9.77e-50	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs332507	0.711	rs3772793	chr3:124405723	A/G	cg05980111	chr3:124395277	KALRN	0.45	6.88	0.35	2.9100000000000002e-11	Plateletcrit;
LIHC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.09	-0.51	1.29e-24	Response to antipsychotic treatment;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg15382696	chr6:118971807	C6orf204	0.62	6.45	0.33	3.75e-10	Diastolic blood pressure;
LIHC	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.82	-11.02	-0.51	2.35e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	1.11	12.08	0.55	3.25e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.36	0.33	6.41e-10	Platelet distribution width;
LIHC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.79e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02290350	chr8:58132656	NA	0.44	9.49	0.46	4.2e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	8.59	0.42	3.12e-16	Platelet count;
LIHC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.69	-10.36	-0.49	4.73e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.57	7.45	0.37	7.56e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.53	-0.46	2.98e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.68	10.9	0.51	5.88e-24	Platelet count;
LIHC	cis	rs6750047	0.585	rs62136319	chr2:38272950	G/A	cg07380506	chr2:38303506	CYP1B1	0.6	7.82	0.39	6.51e-14	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg02290350	chr8:58132656	NA	0.31	7.15	0.36	5.41e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.66	0.38	1.89e-13	Prudent dietary pattern;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg05560165	chr5:133450315	TCF7	-0.43	-6.2	-0.32	1.62e-9	Systolic blood pressure;
LIHC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg12798992	chr6:167411361	FGFR1OP	0.52	8.64	0.42	2.12e-16	Crohn's disease;
LIHC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.69	10.02	0.48	6.72e-21	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1555399	0.901	rs7155830	chr14:67979557	A/G	cg16224230	chr14:67978224	TMEM229B	0.25	6.25	0.32	1.23e-9	Parkinson's disease;
LIHC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.93	8.35	0.41	1.71e-15	Eosinophil percentage of granulocytes;
LIHC	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg05197062	chr11:11642011	GALNTL4	0.42	6.08	0.31	3.17e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.77	12.61	0.56	3.37e-30	Fat distribution (HIV);
LIHC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg25894440	chr7:65020034	NA	0.54	6.22	0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.18	15.74	0.65	2.28e-42	Blood protein levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22098324	chr2:232645906	PDE6D	-0.41	-6.3	-0.32	9.41e-10	Pancreatic cancer;
LIHC	cis	rs4563143	0.514	rs112651366	chr19:29299704	A/T	cg04546413	chr19:29218101	NA	0.5	8.32	0.41	2.17e-15	Methadone dose in opioid dependence;
LIHC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg10210624	chr19:58662595	ZNF329	0.74	7.5	0.38	5.38e-13	Cholesterol, total;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg25974723	chr19:50119415	PRR12	0.4	6.05	0.31	3.74e-9	Alopecia areata;
LIHC	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg27523141	chr10:43048294	ZNF37B	0.37	6.4	0.33	5.12e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.36	0.56	2.82e-29	Menopause (age at onset);
LIHC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.37	-6.23	-0.32	1.34e-9	Educational attainment;
LIHC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.37	5.95	0.31	6.7e-9	Menopause (age at onset);
LIHC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.54	-0.38	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg15848620	chr12:58087721	OS9	-0.55	-7.47	-0.37	6.68e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.58	-11.32	-0.52	1.98e-25	Body mass index;
LIHC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.78	0.57	7.93e-31	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.87	-0.3	1.06e-8	Mean corpuscular volume;
LIHC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg14868726	chr18:2571660	METTL4;NDC80	-0.51	-6.12	-0.31	2.57e-9	Facial morphology (factor 20);
LIHC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.09	13.07	0.58	6.34e-32	Vitiligo;
LIHC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	0.79	5.86	0.3	1.06e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg10621924	chr7:39171070	POU6F2	0.4	6.27	0.32	1.08e-9	IgG glycosylation;
LIHC	cis	rs7116495	0.737	rs2852370	chr11:71558679	G/C	cg26138937	chr11:71823887	C11orf51	0.65	6.36	0.33	6.63e-10	Severe influenza A (H1N1) infection;
LIHC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-7.09	-0.36	7.52e-12	Chronic sinus infection;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08677398	chr8:58056175	NA	0.4	6.09	0.31	3.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg00656387	chr3:40428638	ENTPD3	-0.46	-7.55	-0.38	4.03e-13	Renal cell carcinoma;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07573366	chr7:32802765	NA	0.23	6.05	0.31	3.91e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.37	-5.85	-0.3	1.17e-8	Menarche (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg05061393	chr2:220043337	FAM134A	0.5	6.59	0.34	1.68e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg10217327	chr6:118973057	C6orf204	0.65	6.43	0.33	4.36e-10	Diastolic blood pressure;
LIHC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.61	7.03	0.36	1.09e-11	Menarche (age at onset);
LIHC	cis	rs4951018	0.526	rs4601639	chr1:205656583	A/G	cg17723122	chr1:205641542	SLC45A3	0.39	6.38	0.33	5.86e-10	Prostate-specific antigen levels;
LIHC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	10.56	0.5	9.12e-23	Body mass index (adult);
LIHC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21747090	chr2:27597821	SNX17	0.46	7.16	0.36	5.06e-12	Total body bone mineral density;
LIHC	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.77	-11.02	-0.51	2.29e-24	Response to hepatitis C treatment;
LIHC	cis	rs611744	0.934	rs1452021	chr8:109207886	A/G	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-1.19	-10.56	-0.5	9.27e-23	Breast cancer;
LIHC	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.45	-7.48	-0.38	6.22e-13	Menarche (age at onset);
LIHC	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg20991723	chr1:152506922	NA	0.39	5.71	0.3	2.42e-8	Hair morphology;
LIHC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg17927777	chr20:33865990	NA	-0.55	-6.49	-0.33	3.04e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs11098699	0.821	rs13114886	chr4:124217302	T/A	cg09941581	chr4:124220074	SPATA5	0.33	6.66	0.34	1.1e-10	Mosquito bite size;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-6.88	-0.35	2.81e-11	Lymphocyte counts;
LIHC	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.72	-6.23	-0.32	1.37e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg10127483	chr1:110009974	SYPL2	0.49	6.38	0.33	5.76e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg06565975	chr8:143823917	SLURP1	0.39	7.43	0.37	9.01e-13	Urinary tract infection frequency;
LIHC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.53	7.79	0.39	8.37e-14	HIV-1 control;
LIHC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.7	0.57	1.59e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs4920343	0.671	rs509990	chr1:19090175	T/C	cg19637330	chr1:19110922	NA	0.35	6.36	0.33	6.55e-10	Knee osteoarthritis;
LIHC	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg10578777	chr12:7781093	NA	0.48	8.38	0.41	1.35e-15	HDL cholesterol levels;
LIHC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-16.51	-0.67	1.97e-45	Coronary artery disease;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.67	-9.92	-0.47	1.47e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3018712	0.505	rs7102308	chr11:68413230	T/C	cg16797656	chr11:68205561	LRP5	-0.46	-6.01	-0.31	4.76e-9	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg24209194	chr3:40518798	ZNF619	0.56	8.15	0.4	6.87e-15	Renal cell carcinoma;
LIHC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.64	-9.34	-0.45	1.29e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.9	20.49	0.74	1.94e-61	Height;
LIHC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.45	-7.86	-0.39	5.1e-14	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg05697976	chr12:29376483	FAR2	0.32	6.64	0.34	1.24e-10	QT interval;
LIHC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg05110241	chr16:68378359	PRMT7	-0.62	-6.87	-0.35	3.08e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-8.98	-0.44	1.9e-17	Asthma;
LIHC	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg15816464	chr17:2026533	SMG6	0.46	8.22	0.41	4.34e-15	Total body bone mineral density;
LIHC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.22	-0.32	1.44e-9	Body mass index;
LIHC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.65	0.34	1.13e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2380220	0.808	rs72922390	chr6:95934317	G/A	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.53e-9	Behavioural disinhibition (generation interaction);
LIHC	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.24	-13.34	-0.59	5.73e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-0.95	-19.96	-0.73	2.55e-59	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg15423853	chr12:11323943	PRR4;PRH1	0.45	6.19	0.32	1.76e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7173389	0.560	rs7174643	chr15:73680301	A/C	cg01796676	chr15:73680284	NA	0.53	8.64	0.42	2.12e-16	Resting heart rate;
LIHC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.7	9.97	0.47	1.01e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.6	8.89	0.43	3.56e-17	Recombination rate (females);
LIHC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.48	-7.2	-0.36	3.93e-12	Height;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	0.6	8.78	0.43	8.04e-17	Prudent dietary pattern;
LIHC	trans	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17183009	chr3:120277827	NA	0.52	6.09	0.31	3.02e-9	Corneal astigmatism;
LIHC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg03037974	chr15:76606532	NA	0.9	23.51	0.79	2.01e-73	Blood metabolite levels;
LIHC	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg04610667	chr7:75704037	NA	-0.33	-5.98	-0.31	5.64e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs3789045	0.774	rs4252697	chr1:204501383	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.43	-6.74	-0.34	6.58e-11	Educational attainment (college completion);
LIHC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.99	0.4	2.05e-14	Motion sickness;
LIHC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13409248	chr3:40428643	ENTPD3	0.48	8.18	0.4	5.67e-15	Renal cell carcinoma;
LIHC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.42	-6.11	-0.31	2.68e-9	Menarche (age at onset);
LIHC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg17750252	chr2:136567154	LCT	0.35	6.41	0.33	4.71e-10	Mosquito bite size;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	14.94	0.63	3.29e-39	Prudent dietary pattern;
LIHC	trans	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg10756647	chr7:56101905	PSPH	0.45	6.64	0.34	1.2e-10	Aortic root size;
LIHC	cis	rs1816752	0.875	rs59531061	chr13:25081435	C/T	cg22771759	chr13:24902376	NA	0.31	6.34	0.32	7.45e-10	Obesity-related traits;
LIHC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg06951627	chr6:26196580	NA	0.52	5.87	0.3	1.01e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.24	-0.41	3.78e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.88	0.39	4.36e-14	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15401922	chr6:157802439	ZDHHC14	0.53	7.5	0.38	5.63e-13	Lung function (FEV1/FVC);
LIHC	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.84	-0.39	5.62e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.69	-0.34	9.39e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.92	-0.51	5.17e-24	Hemoglobin concentration;
LIHC	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.56	6.91	0.35	2.38e-11	QRS duration;
LIHC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.92	-16.02	-0.65	1.72e-43	Tonsillectomy;
LIHC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.58	-11.48	-0.53	5.23e-26	Glycated hemoglobin levels;
LIHC	trans	rs783540	0.500	rs1313494	chr15:83274279	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.39	-0.33	5.34e-10	Schizophrenia;
LIHC	cis	rs11690462	0.794	rs2384364	chr2:26541427	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.38	5.79	0.3	1.58e-8	Coronary artery disease;
LIHC	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg04610667	chr7:75704037	NA	0.35	6.14	0.32	2.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.38	-0.33	5.66e-10	Response to antipsychotic treatment;
LIHC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.86	12.97	0.57	1.52e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.53	-6.52	-0.33	2.54e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21467203	chr3:49911342	NA	-0.43	-7.74	-0.39	1.17e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg07636037	chr3:49044803	WDR6	-0.68	-7.34	-0.37	1.53e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1165668	0.785	rs2439624	chr12:104313715	T/C	cg21863207	chr12:104234989	NT5DC3	0.4	6.4	0.33	5.22e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.33	-0.32	7.9e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs1355223	0.902	rs1901831	chr11:34725175	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.43	-0.33	4.36e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.71	6.87	0.35	2.96e-11	Migraine;Coronary artery disease;
LIHC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.49	-5.81	-0.3	1.45e-8	Menarche (age at onset);
LIHC	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.32	7.48e-10	Ulcerative colitis;
LIHC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg21486233	chr12:29375141	FAR2	0.31	6.07	0.31	3.46e-9	QT interval;
LIHC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	6.18	0.32	1.8e-9	IgG glycosylation;
LIHC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg26138144	chr22:38071188	LGALS1	0.42	7.76	0.39	1e-13	Fat distribution (HIV);
LIHC	cis	rs2257205	0.667	rs8077548	chr17:56690848	T/C	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.59	8.96	0.44	2.16e-17	Platelet count;
LIHC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.96	-0.31	6.38e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.69	9.24	0.45	2.74e-18	Psoriasis;
LIHC	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg11886554	chr3:170076028	SKIL	0.75	6.37	0.33	6.22e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.41	-6.0	-0.31	4.9e-9	Calcium levels;
LIHC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.83	8.94	0.44	2.53e-17	Vitiligo;
LIHC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.61	11.47	0.53	5.46e-26	Alzheimer's disease (late onset);
LIHC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg06766960	chr11:133703094	NA	-0.65	-11.0	-0.51	2.74e-24	Childhood ear infection;
LIHC	cis	rs2274273	0.870	rs2016931	chr14:55842332	C/G	cg01864836	chr14:55583639	NA	-0.37	-6.66	-0.34	1.07e-10	Protein biomarker;
LIHC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg23262073	chr20:60523788	NA	-0.29	-5.97	-0.31	6.03e-9	Body mass index;
LIHC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.46	6.31	0.32	8.79e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24110177	chr3:50126178	RBM5	0.42	6.49	0.33	3.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs151997	0.962	rs26088	chr5:50172670	T/G	cg06027927	chr5:50259733	NA	0.57	7.59	0.38	3.13e-13	Callous-unemotional behaviour;
LIHC	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg20129853	chr10:51489980	NA	-0.41	-8.99	-0.44	1.66e-17	Prostate-specific antigen levels;
LIHC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg16479474	chr6:28041457	NA	0.46	6.46	0.33	3.5e-10	Depression;
LIHC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.82	13.54	0.59	9.68e-34	Height;
LIHC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.69	-0.34	9.09e-11	Vitiligo;
LIHC	cis	rs4908768	0.501	rs6577491	chr1:8574972	G/T	cg20416874	chr1:8611966	RERE	-0.65	-13.4	-0.59	3.26e-33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.38	1.4e-13	Glioblastoma;
LIHC	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.75	12.75	0.57	1.03e-30	Obesity-related traits;
LIHC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.03e-20	Schizophrenia;
LIHC	cis	rs72627123	0.656	rs765720	chr14:74541326	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.85	8.25	0.41	3.52e-15	Morning vs. evening chronotype;
LIHC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.17	-0.44	4.7e-18	Subjective well-being;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.98	-0.31	5.53e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.54	-0.38	4.25e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.57	-8.1	-0.4	1.01e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs970821	1.000	rs1946584	chr8:124750585	G/A	cg00283535	chr8:124749564	ANXA13	0.35	5.88	0.3	9.98e-9	Breast cancer;
LIHC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg26692224	chr17:62915920	LRRC37A3	-0.71	-6.8	-0.35	4.75e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.62	-11.65	-0.53	1.2e-26	Mean platelet volume;
LIHC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.38	6.2	0.32	1.67e-9	Menopause (age at onset);
LIHC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg13175981	chr1:150552382	MCL1	-0.44	-6.16	-0.32	2.08e-9	Tonsillectomy;
LIHC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.51	7.78	0.39	8.52e-14	Total body bone mineral density;
LIHC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.51	7.87	0.39	4.79e-14	Longevity;Endometriosis;
LIHC	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg04492858	chr10:133558786	NA	0.44	6.42	0.33	4.59e-10	Survival in rectal cancer;
LIHC	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.89	11.63	0.53	1.48e-26	Breast cancer;
LIHC	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.56	-6.74	-0.34	6.94e-11	Bipolar disorder;
LIHC	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.69	10.38	0.49	4.1e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.24	0.66	2.29e-44	Lymphocyte percentage of white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11383747	chr17:260000	C17orf97	0.55	8.38	0.41	1.39e-15	Pancreatic cancer;
LIHC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	11.96	0.54	8.68e-28	High light scatter reticulocyte count;
LIHC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg26138144	chr22:38071188	LGALS1	0.75	14.03	0.6	1.2e-35	Fat distribution (HIV);
LIHC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.47	7.56	0.38	3.87e-13	Multiple sclerosis;
LIHC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.14	0.31	2.35e-9	Renal cell carcinoma;
LIHC	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg23352942	chr3:46931381	PTH1R	-0.33	-8.84	-0.43	4.97e-17	Birth weight;
LIHC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.61	10.61	0.5	6.15e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg14515779	chr1:101123966	NA	-0.67	-12.51	-0.56	7.73e-30	Monocyte count;
LIHC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.29	6.86	0.35	3.3e-11	Crohn's disease;
LIHC	cis	rs10849893	0.557	rs6489812	chr12:121913559	T/A	cg01154721	chr12:121881891	KDM2B	0.55	9.21	0.45	3.43e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.28	7.01	0.35	1.28e-11	Schizophrenia;
LIHC	cis	rs918629	0.798	rs6877821	chr5:95289502	C/T	cg10483112	chr5:95245456	ELL2	-0.37	-6.48	-0.33	3.23e-10	IgG glycosylation;
LIHC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.14	0.32	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6973256	0.569	rs9649595	chr7:133385921	G/C	cg10665199	chr7:133106180	EXOC4	0.36	6.2	0.32	1.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.11	0.55	2.47e-28	Body mass index;
LIHC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12463550	chr7:65579703	CRCP	0.7	7.21	0.36	3.53e-12	Diabetic kidney disease;
LIHC	trans	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.2	-0.32	1.66e-9	Plateletcrit;
LIHC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.7	11.65	0.53	1.22e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.54	6.07	0.31	3.48e-9	Alzheimer's disease;
LIHC	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04055981	chr11:115044050	NA	-0.49	-7.57	-0.38	3.47e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.67	-0.34	1.03e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs3762637	0.943	rs9289198	chr3:122277160	G/T	cg24169773	chr3:122142474	KPNA1	-0.45	-9.01	-0.44	1.49e-17	LDL cholesterol levels;
LIHC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg16736954	chr20:23401023	NAPB	0.7	8.02	0.4	1.68e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.29	-17.09	-0.68	9.12e-48	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg07706471	chr12:123319906	HIP1R	-0.63	-8.34	-0.41	1.89e-15	Schizophrenia;
LIHC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.68	9.31	0.45	1.58e-18	Aortic root size;
LIHC	cis	rs244293	0.965	rs244307	chr17:53211713	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06522697	chr10:121356224	TIAL1	-0.44	-6.55	-0.33	2.13e-10	Pancreatic cancer;
LIHC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.95	-0.35	1.88e-11	IgG glycosylation;
LIHC	trans	rs7504990	0.722	rs1030593	chr18:50374155	A/G	cg08535148	chr4:26321143	RBPJ	0.56	7.07	0.36	8.97e-12	Gallbladder cancer;
LIHC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.87	-0.51	7.79e-24	Chronic sinus infection;
LIHC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.43	5.96	0.31	6.17e-9	Alzheimer's disease;
LIHC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.56	5.95	0.31	6.77e-9	Menarche (age at onset);
LIHC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg24203234	chr3:128598194	ACAD9	0.44	6.18	0.32	1.78e-9	IgG glycosylation;
LIHC	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.87	7.4	0.37	1.05e-12	Uric acid levels;
LIHC	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.43	8.82	0.43	5.92e-17	Blood metabolite levels;
LIHC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.46	-7.45	-0.37	7.88e-13	Cognitive function;
LIHC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.6	10.54	0.5	1.12e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.71e-10	Waist circumference;Weight;
LIHC	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.34	-0.32	7.24e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.37	-6.31	-0.32	8.7e-10	Mean corpuscular volume;
LIHC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	1.08	14.28	0.61	1.26e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs867186	0.614	rs78260746	chr20:33426115	G/A	cg08999081	chr20:33150536	PIGU	0.63	5.94	0.31	6.97e-9	Blood protein levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Factor VII levels;Protein C levels;D-dimer levels;Anticoagulant levels;
LIHC	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.56	-8.06	-0.4	1.32e-14	Colorectal cancer;
LIHC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.51	7.25	0.37	2.74e-12	Body mass index;
LIHC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.83	10.97	0.51	3.42e-24	Glomerular filtration rate (creatinine);
LIHC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	8.33	0.41	2.02e-15	Coronary artery disease;
LIHC	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg04118878	chr10:71993077	PPA1	0.56	5.75	0.3	2e-8	Blood protein levels;
LIHC	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-11.21	-0.52	4.62e-25	Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.08	0.55	3.2e-28	Prudent dietary pattern;
LIHC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.04	0.58	7.65e-32	Cognitive test performance;
LIHC	cis	rs8084351	0.501	rs7505807	chr18:50566190	C/G	cg24270629	chr18:50823537	DCC	0.38	5.81	0.3	1.47e-8	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.39	-7.16	-0.36	5.02e-12	Hepatocellular carcinoma;
LIHC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg12317470	chr15:67143691	NA	-0.6	-7.33	-0.37	1.66e-12	Lung cancer (smoking interaction);
LIHC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-10.98	-0.51	3.07e-24	Colorectal cancer;
LIHC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.37	5.76	0.3	1.91e-8	Lung cancer;
LIHC	cis	rs1185460	0.546	rs2508948	chr11:118951642	A/T	cg23280166	chr11:118938394	VPS11	-0.44	-5.81	-0.3	1.43e-8	Coronary artery disease;
LIHC	trans	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg10756647	chr7:56101905	PSPH	-1.1	-13.4	-0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.42e-11	Intracranial aneurysm;
LIHC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.43	-8.6	-0.42	2.86e-16	Obesity-related traits;
LIHC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	6.77	0.34	5.55e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg02297831	chr4:17616191	MED28	0.48	7.2	0.36	3.78e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.33	14.33	0.61	8.06e-37	Eosinophil percentage of granulocytes;
LIHC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.77	11.59	0.53	2.09e-26	Coronary artery disease;
LIHC	cis	rs9378688	1.000	rs3778568	chr6:2225680	C/T	cg12303981	chr6:2244766	GMDS	-0.5	-6.46	-0.33	3.62e-10	Caudate nucleus volume;
LIHC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs611744	0.967	rs536860	chr8:109230722	A/C	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.51	6.36	0.33	6.55e-10	Breast cancer;
LIHC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.47	6.52	0.33	2.49e-10	Schizophrenia;
LIHC	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg15192750	chr16:69999425	NA	0.44	6.74	0.34	6.73e-11	IgE levels;
LIHC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.67	12.08	0.55	3.21e-28	High light scatter reticulocyte count;
LIHC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg17750252	chr2:136567154	LCT	-0.33	-5.95	-0.31	6.77e-9	Mosquito bite size;
LIHC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg15123519	chr2:136567270	LCT	0.45	9.45	0.45	5.65e-19	Mosquito bite size;
LIHC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.46	-6.76	-0.34	5.84e-11	Corneal structure;
LIHC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.33	0.45	1.39e-18	Platelet count;
LIHC	cis	rs7116495	0.609	rs1791456	chr11:71594888	G/C	cg10381502	chr11:71823885	C11orf51	0.89	7.5	0.38	5.47e-13	Severe influenza A (H1N1) infection;
LIHC	cis	rs2574704	0.961	rs11712416	chr3:11649334	G/A	cg15876825	chr3:11651881	VGLL4	-0.49	-8.11	-0.4	9.19e-15	Body mass index;
LIHC	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.49	7.32	0.37	1.76e-12	Dermatomyositis;
LIHC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.67	-6.26	-0.32	1.14e-9	Urate levels in lean individuals;
LIHC	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.51	7.94	0.39	2.93e-14	Recalcitrant atopic dermatitis;
LIHC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg01557791	chr16:72042693	DHODH	-0.42	-6.97	-0.35	1.63e-11	Fibrinogen levels;
LIHC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.57	0.5	9e-23	Personality dimensions;
LIHC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg26441486	chr22:50317300	CRELD2	0.35	6.33	0.32	7.65e-10	Schizophrenia;
LIHC	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.98	-0.4	2.25e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.97	-0.31	5.94e-9	Total body bone mineral density;
LIHC	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.64	10.71	0.5	2.82e-23	Coronary artery disease;
LIHC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	0.72	8.01	0.4	1.85e-14	Testicular germ cell tumor;
LIHC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.78	11.18	0.52	6.31e-25	Blood metabolite levels;
LIHC	cis	rs6466055	0.777	rs11765899	chr7:104923002	T/C	cg04380332	chr7:105027541	SRPK2	0.37	6.86	0.35	3.2e-11	Schizophrenia;
LIHC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.37	-0.59	4.35e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs10949834	0.824	rs13236108	chr7:73521113	A/G	cg07137043	chr7:73588983	EIF4H	-0.6	-6.04	-0.31	3.92e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.5	7.44	0.37	8.05e-13	Height;
LIHC	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.59	-0.42	3.09e-16	Vitamin D levels;
LIHC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg23205692	chr1:25664452	TMEM50A	0.38	6.03	0.31	4.26e-9	Erythrocyte sedimentation rate;
LIHC	trans	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg07393940	chr7:158741817	NA	-0.56	-6.61	-0.34	1.44e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg16479474	chr6:28041457	NA	0.35	5.77	0.3	1.79e-8	Cardiac Troponin-T levels;
LIHC	cis	rs903552	0.932	rs9806551	chr15:102008206	C/T	cg04789225	chr15:102009795	PCSK6	-0.43	-5.81	-0.3	1.39e-8	Diabetic kidney disease;
LIHC	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.5	9.45	0.46	5.36e-19	Testicular germ cell tumor;
LIHC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.42	-5.84	-0.3	1.25e-8	Height;
LIHC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.88	18.05	0.7	1.26e-51	Blood protein levels;
LIHC	cis	rs11166927	1.000	rs11166929	chr8:140801430	G/A	cg16909799	chr8:140841666	TRAPPC9	0.5	7.97	0.4	2.39e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.36	6.12	0.31	2.53e-9	Monobrow;
LIHC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.42	-7.18	-0.36	4.3e-12	Educational attainment;
LIHC	cis	rs2380220	0.808	rs2613553	chr6:95916704	A/G	cg15832292	chr6:96025679	MANEA	-0.62	-7.02	-0.35	1.2e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs16828019	0.704	rs12024115	chr1:41534357	C/T	cg03387723	chr1:41708464	SCMH1	-0.4	-6.45	-0.33	3.86e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg06050784	chr16:88016603	BANP	0.36	6.56	0.33	1.96e-10	Menopause (age at onset);
LIHC	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg03934865	chr2:198174659	NA	-0.61	-9.67	-0.46	1e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs4788570	0.547	rs6499538	chr16:71762285	A/C	cg06353428	chr16:71660113	MARVELD3	1.33	13.55	0.59	8.83e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg20991723	chr1:152506922	NA	0.59	10.41	0.49	3.14e-22	Hair morphology;
LIHC	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.68	11.04	0.51	1.9e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.23	-0.41	3.95e-15	Exhaled nitric oxide output;
LIHC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.73	-0.34	7.04e-11	Hepatocellular carcinoma;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg17512779	chr8:17104072	CNOT7;VPS37A	0.47	6.25	0.32	1.21e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs2016586	0.929	rs5755921	chr22:36104730	A/G	cg26342177	chr22:36113512	APOL5	0.36	5.85	0.3	1.13e-8	Body mass index;
LIHC	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg26138937	chr11:71823887	C11orf51	-0.83	-8.45	-0.42	8.57e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.6	-9.17	-0.44	4.52e-18	Platelet count;
LIHC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.23	0.32	1.34e-9	Systolic blood pressure;
LIHC	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.71	-10.59	-0.5	7.72e-23	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.48	0.46	4.54e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.35	-8.17	-0.4	5.84e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.69	9.32	0.45	1.46e-18	Calcium levels;
LIHC	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.67	-10.12	-0.48	3.21e-21	Pediatric autoimmune diseases;
LIHC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-6.95	-0.35	1.82e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg00935119	chr6:36647544	CDKN1A	0.45	6.3	0.32	9.14e-10	QRS duration;
LIHC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.51	6.19	0.32	1.7e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.78	11.7	0.53	8.13e-27	IgG glycosylation;
LIHC	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-8.29	-0.41	2.68e-15	Obesity-related traits;
LIHC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.81	-0.3	1.42e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg14440974	chr22:39074834	NA	-0.37	-6.33	-0.32	7.88e-10	Menopause (age at onset);
LIHC	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.52	9.74	0.47	5.89e-20	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.36	0.41	1.64e-15	Motion sickness;
LIHC	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg23461800	chr14:103021989	NA	0.39	5.82	0.3	1.32e-8	Platelet count;
LIHC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.73	-16.47	-0.67	2.69e-45	Brugada syndrome;
LIHC	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	ch.11.42038R	chr11:967971	AP2A2	0.62	11.42	0.53	8.19e-26	Alzheimer's disease (late onset);
LIHC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.45	6.53	0.33	2.43e-10	Osteoporosis;
LIHC	trans	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg24036039	chr1:3397125	ARHGEF16	0.4	6.56	0.33	1.99e-10	Schizophrenia;
LIHC	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg02023728	chr11:77925099	USP35	-0.33	-5.85	-0.3	1.18e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.51	0.56	7.65e-30	Cognitive test performance;
LIHC	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.58	-8.45	-0.42	8.45e-16	Body mass index;
LIHC	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg22777020	chr22:31556080	RNF185	-0.54	-6.15	-0.32	2.16e-9	Colorectal cancer;
LIHC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.6	9.69	0.46	8.97e-20	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.46	10.45	0.49	2.22e-22	Iron status biomarkers (transferrin levels);
LIHC	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg03237606	chr10:63212265	TMEM26	0.32	7.3	0.37	2.05e-12	Night sleep phenotypes;
LIHC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.74	-0.3	2.06e-8	Alzheimer's disease (late onset);
LIHC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.95	11.14	0.52	8.8e-25	Triglycerides;
LIHC	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.33	-12.81	-0.57	5.98e-31	Psoriasis vulgaris;
LIHC	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.68	-0.34	9.91e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg10790698	chr19:18539756	SSBP4	-0.34	-7.16	-0.36	4.92e-12	Breast cancer;
LIHC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	6.99	0.35	1.48e-11	Systolic blood pressure;
LIHC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.64	-16.58	-0.67	1.01e-45	Breast cancer;
LIHC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.39	-5.88	-0.3	9.54e-9	Menarche (age at onset);
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.85	-0.35	3.47e-11	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01457418	chr15:75094936	CSK	0.37	6.09	0.31	3e-9	Pancreatic cancer;
LIHC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.78e-15	Body mass index;
LIHC	cis	rs3770081	1.000	rs56326127	chr2:86212201	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-8.03	-0.4	1.62e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg07706471	chr12:123319906	HIP1R	0.77	8.68	0.42	1.65e-16	Adiponectin levels;
LIHC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg17420585	chr12:42539391	GXYLT1	-0.35	-5.74	-0.3	2.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.36	0.41	1.65e-15	Height;
LIHC	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.55	-0.38	4.03e-13	QT interval;
LIHC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.13	0.4	7.71e-15	Total body bone mineral density;
LIHC	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg26116260	chr4:7069785	GRPEL1	0.56	9.08	0.44	8.57e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.49	10.01	0.48	7.43e-21	Melanoma;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02222454	chr3:141762828	NA	0.43	6.3	0.32	9.12e-10	Immature fraction of reticulocytes;
LIHC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs11212260	0.573	rs12790708	chr11:107162153	G/A	cg25435332	chr11:107328525	CWF19L2	0.64	6.06	0.31	3.66e-9	IgG glycosylation;
LIHC	cis	rs6565681	0.883	rs4523980	chr17:78347664	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.52	-7.37	-0.37	1.33e-12	Moyamoya disease;
LIHC	cis	rs16912285	0.688	rs12277966	chr11:24286633	G/A	ch.11.24196551F	chr11:24239977	NA	0.74	9.51	0.46	3.44e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.53	-8.16	-0.4	6.37e-15	High light scatter reticulocyte count;
LIHC	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg13877915	chr19:58951672	ZNF132	0.6	9.72	0.47	6.9e-20	Uric acid clearance;
LIHC	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02985541	chr2:219472218	PLCD4	0.37	5.86	0.3	1.12e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs4650994	0.593	rs6676155	chr1:178508360	C/A	cg05350800	chr1:178550844	NA	-0.29	-6.31	-0.32	8.4e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs4650994	0.593	rs2761459	chr1:178551576	G/A	cg05350800	chr1:178550844	NA	-0.34	-7.56	-0.38	3.84e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	1.13	13.02	0.58	9.23e-32	White matter hyperintensity burden;
LIHC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.58	11.74	0.54	5.48e-27	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg26695010	chr11:65641043	EFEMP2	0.42	5.75	0.3	1.94e-8	DNA methylation (variation);
LIHC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.43	-6.03	-0.31	4.26e-9	Initial pursuit acceleration;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg26574964	chr11:117049906	SIDT2	0.47	6.62	0.34	1.38e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg16586182	chr3:47516702	SCAP	0.44	7.48	0.37	6.32e-13	Colorectal cancer;
LIHC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.68	0.42	1.62e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4586057	0.533	rs6583737	chr10:92620789	A/G	cg14313238	chr10:92632228	RPP30	0.36	5.99	0.31	5.4e-9	Economic and political preferences (time);
LIHC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1494950	1.000	rs2604582	chr4:15061142	A/G	cg12377275	chr4:15005593	CPEB2	-0.83	-7.22	-0.36	3.42e-12	Political ideology;
LIHC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.2e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.43	6.77	0.34	5.69e-11	Eosinophil percentage of white cells;
LIHC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.51	0.46	3.61e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.44	-6.35	-0.32	6.91e-10	Blood protein levels;
LIHC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.57	-15.08	-0.63	9.46e-40	Alzheimer's disease (late onset);
LIHC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.47	7.27	0.37	2.54e-12	Cognitive function;
LIHC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.94	12.73	0.57	1.15e-30	Blood metabolite levels;
LIHC	cis	rs9596863	1.000	rs9596859	chr13:54431200	T/A	ch.13.53330881F	chr13:54432880	NA	0.46	6.2	0.32	1.66e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.83	0.43	5.36e-17	Cognitive ability;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15581235	chr15:41708917	RTF1	0.48	6.4	0.33	5.18e-10	Lung function (FEV1/FVC);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10981275	chr2:3381760	TSSC1	0.49	6.99	0.35	1.47e-11	Lung function (FEV1/FVC);
LIHC	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.5	7.67	0.38	1.86e-13	Adiposity;
LIHC	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.5	-0.33	2.86e-10	Metabolite levels;
LIHC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg06238570	chr21:40685208	BRWD1	0.58	6.89	0.35	2.72e-11	Cognitive function;
LIHC	cis	rs3736485	0.868	rs1531155	chr15:51932133	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-5.95	-0.31	6.66e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8020095	0.571	rs8009087	chr14:67564210	C/T	cg03487553	chr14:67822707	ATP6V1D	0.33	5.75	0.3	2.02e-8	Depression (quantitative trait);
LIHC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg27094323	chr7:1216898	NA	-0.4	-5.83	-0.3	1.28e-8	Longevity;Endometriosis;
LIHC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02290350	chr8:58132656	NA	0.47	9.99	0.48	8.93e-21	Developmental language disorder (linguistic errors);
LIHC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg06565975	chr8:143823917	SLURP1	0.33	6.41	0.33	4.77e-10	Urinary tract infection frequency;
LIHC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.61	-10.6	-0.5	6.83e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.59	9.92	0.47	1.51e-20	Lymphocyte counts;
LIHC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.87	17.26	0.68	1.96e-48	Bone mineral density;
LIHC	trans	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg10756647	chr7:56101905	PSPH	0.44	6.46	0.33	3.59e-10	Aortic root size;
LIHC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.61	-7.58	-0.38	3.28e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.19	-31.38	-0.86	1.02e-102	Myeloid white cell count;
LIHC	cis	rs3736485	0.934	rs28695624	chr15:51874928	A/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.46	6.24	0.32	1.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	trans	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg12365402	chr11:9010492	NRIP3	0.28	6.89	0.35	2.7e-11	Hemoglobin concentration;
LIHC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.91	0.3	8.38e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs711245	0.748	rs2276671	chr2:36771701	C/A	cg10546459	chr2:36825355	FEZ2	0.51	6.23	0.32	1.4e-9	Height;
LIHC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg03013999	chr17:37608204	MED1	-0.36	-6.04	-0.31	3.93e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.37	5.77	0.3	1.78e-8	Coronary artery disease;
LIHC	cis	rs11039131	0.787	rs326217	chr11:47303275	T/C	cg20135002	chr11:47629003	NA	-0.36	-5.71	-0.3	2.43e-8	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.74	0.43	1.05e-16	Motion sickness;
LIHC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg01256987	chr12:42539512	GXYLT1	-0.36	-5.91	-0.3	8.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.59	-7.26	-0.37	2.71e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09561351	chr12:42876655	PRICKLE1	0.49	7.23	0.36	3.15e-12	Pancreatic cancer;
LIHC	cis	rs2574704	1.000	rs2447614	chr3:11664032	A/T	cg15876825	chr3:11651881	VGLL4	-0.51	-8.34	-0.41	1.87e-15	Body mass index;
LIHC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.43	-7.93	-0.39	3.09e-14	Glycated hemoglobin levels;
LIHC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg14092571	chr14:90743983	NA	0.39	6.17	0.32	1.97e-9	Mortality in heart failure;
LIHC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg15902774	chr15:75289873	SCAMP5	0.4	5.94	0.31	6.89e-9	Lung cancer;
LIHC	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.46	6.95	0.35	1.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg13047869	chr3:10149882	C3orf24	0.5	6.08	0.31	3.23e-9	Alzheimer's disease;
LIHC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.64	8.57	0.42	3.5e-16	Motion sickness;
LIHC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg19318889	chr4:1322082	MAEA	0.54	9.14	0.44	5.66e-18	Obesity-related traits;
LIHC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg14906510	chr12:7781169	NA	-0.46	-7.23	-0.36	3.17e-12	HDL cholesterol levels;
LIHC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	1.03	11.76	0.54	4.63e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.02	-0.35	1.22e-11	Diabetic kidney disease;
LIHC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.26	0.32	1.12e-9	Cognitive test performance;
LIHC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg15472797	chr10:135243109	NA	-0.39	-5.77	-0.3	1.79e-8	Systemic lupus erythematosus;
LIHC	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08409687	chr2:201936025	NDUFB3;FAM126B	0.42	6.21	0.32	1.58e-9	Cognitive function;
LIHC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg01864069	chr14:103024347	NA	-0.46	-7.17	-0.36	4.62e-12	Platelet count;
LIHC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.77	11.25	0.52	3.51e-25	IgG glycosylation;
LIHC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg13957321	chr17:43675089	NA	0.5	7.9	0.39	3.98e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21747090	chr2:27597821	SNX17	0.44	6.53	0.33	2.42e-10	Total body bone mineral density;
LIHC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg03013999	chr17:37608204	MED1	0.36	5.97	0.31	5.89e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.47	6.37	0.33	6.07e-10	Schizophrenia;
LIHC	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg01364799	chr7:75623366	TMEM120A	0.52	7.83	0.39	6.35e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4294134	0.832	rs35061496	chr7:135254269	T/C	cg20392616	chr7:135392013	SLC13A4	0.37	5.93	0.31	7.31e-9	Paget's disease;
LIHC	trans	rs6934970	1.000	rs12203507	chr6:113095654	T/G	cg09308777	chr6:169852575	NA	0.57	6.15	0.32	2.22e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.23	-6.79	-0.34	4.89e-11	Blood protein levels;
LIHC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg03934865	chr2:198174659	NA	-0.6	-9.87	-0.47	2.23e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.53	-7.74	-0.39	1.14e-13	Multiple sclerosis;
LIHC	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg22771759	chr13:24902376	NA	0.32	6.75	0.34	6.32e-11	Obesity-related traits;
LIHC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.36	-7.16	-0.36	4.98e-12	Colorectal cancer;
LIHC	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.64	10.73	0.5	2.46e-23	Recombination rate (males);
LIHC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.02	15.68	0.65	3.78e-42	Breast cancer;
LIHC	cis	rs2016586	0.863	rs5755931	chr22:36120323	A/G	cg26342177	chr22:36113512	APOL5	-0.37	-6.34	-0.32	7.31e-10	Body mass index;
LIHC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.36	0.68	7.36e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg21659725	chr3:3221576	CRBN	0.64	6.1	0.31	2.8e-9	Schizophrenia;
LIHC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.47	6.65	0.34	1.17e-10	Eosinophil percentage of white cells;
LIHC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	11.39	0.52	1.05e-25	Cognitive test performance;
LIHC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.71	-0.57	1.46e-30	Alzheimer's disease;
LIHC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.43	-7.08	-0.36	8.22e-12	Height;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01171360	chr6:293285	DUSP22	-0.44	-6.38	-0.33	5.83e-10	Menopause (age at onset);
LIHC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	0.53	7.11	0.36	6.93e-12	Pulse pressure;
LIHC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.04	0.4	1.5e-14	Motion sickness;
LIHC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.18	0.36	4.48e-12	Diabetic kidney disease;
LIHC	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.49	-7.94	-0.39	2.99e-14	Blood protein levels;
LIHC	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.69	8.48	0.42	7e-16	IgG glycosylation;
LIHC	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.2	16.23	0.66	2.61e-44	Blood protein levels;
LIHC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.96	-0.31	6.25e-9	Type 2 diabetes;
LIHC	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.43	0.33	4.18e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.51	5.72	0.3	2.33e-8	Type 1 diabetes nephropathy;
LIHC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.67	13.44	0.59	2.3e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.13	-0.55	2.01e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg18357526	chr6:26021779	HIST1H4A	0.39	5.75	0.3	2.01e-8	Height;
LIHC	cis	rs77633900	0.772	rs2957611	chr15:76704878	C/T	cg21673338	chr15:77095150	SCAPER	-0.52	-5.77	-0.3	1.78e-8	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.43	0.53	7.69e-26	Tonsillectomy;
LIHC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.06e-9	Tonsillectomy;
LIHC	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.45	8.02	0.4	1.73e-14	Coronary artery disease;
LIHC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17507749	chr15:85114479	UBE2QP1	0.63	7.18	0.36	4.38e-12	Schizophrenia;
LIHC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.49	-7.01	-0.35	1.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22442454	chr1:209979470	IRF6	0.38	5.74	0.3	2.08e-8	Cleft lip with or without cleft palate;
LIHC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07305463	chr2:136567211	LCT	0.41	7.73	0.39	1.24e-13	Cholesterol, total;
LIHC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	18.36	0.7	6.84e-53	Tonsillectomy;
LIHC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.73	-9.24	-0.45	2.78e-18	Gut microbiome composition (summer);
LIHC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg00204512	chr16:28754710	NA	0.34	6.37	0.33	6.01e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.56	-0.46	2.41e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.47	0.37	6.74e-13	Prudent dietary pattern;
LIHC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.7	-13.32	-0.58	6.8e-33	Height;
LIHC	cis	rs11673344	0.704	rs826290	chr19:37428445	C/T	cg27390819	chr19:37464633	NA	-0.51	-6.08	-0.31	3.28e-9	Obesity-related traits;
LIHC	trans	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	7.61	0.38	2.69e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6442522	0.678	rs11128745	chr3:15498261	T/C	cg16303742	chr3:15540471	COLQ	0.44	7.35	0.37	1.48e-12	Uric acid levels;
LIHC	cis	rs244293	0.965	rs244300	chr17:53239240	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.2	-0.32	1.6e-9	Menarche (age at onset);
LIHC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg07636037	chr3:49044803	WDR6	-0.78	-7.85	-0.39	5.41e-14	Cognitive function;
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.42	0.33	4.45e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg11764359	chr7:65958608	NA	-0.59	-6.21	-0.32	1.54e-9	Diabetic kidney disease;
LIHC	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.86	-12.14	-0.55	1.87e-28	Obesity-related traits;
LIHC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.43	-7.36	-0.37	1.41e-12	Educational attainment;
LIHC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-7.5	-0.38	5.5e-13	Alzheimer's disease;
LIHC	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.9	-0.35	2.54e-11	Response to antipsychotic treatment;
LIHC	cis	rs8083850	0.635	rs4450475	chr18:50855622	C/T	cg24270629	chr18:50823537	DCC	-0.58	-8.83	-0.43	5.65e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.54	-7.03	-0.36	1.16e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.4	-6.38	-0.33	5.74e-10	Menarche (age at onset);
LIHC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg01652190	chr22:50026171	C22orf34	-0.3	-6.88	-0.35	2.89e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-8.8	-0.43	6.92e-17	Blood pressure (smoking interaction);
LIHC	trans	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.42	0.33	4.68e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.64	10.82	0.5	1.19e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.73	11.81	0.54	3.17e-27	Anterior chamber depth;
LIHC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	12.41	0.56	1.91e-29	Cognitive test performance;
LIHC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg19635926	chr16:89946313	TCF25	0.53	6.5	0.33	2.8e-10	Skin colour saturation;
LIHC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.51	7.56	0.38	3.86e-13	HDL cholesterol;
LIHC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.7	-0.43	1.45e-16	Primary biliary cholangitis;
LIHC	trans	rs17439560	0.510	rs10153002	chr15:37433594	A/C	cg06425556	chr20:33413664	NCOA6	0.77	6.08	0.31	3.24e-9	Response to amphetamines;
LIHC	cis	rs7116495	1.000	rs59343384	chr11:71828038	G/C	cg26138937	chr11:71823887	C11orf51	0.71	7.3	0.37	2.08e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg24112000	chr20:60950667	NA	-0.61	-9.82	-0.47	3.37e-20	Colorectal cancer;
LIHC	cis	rs4699052	0.826	rs17033498	chr4:104179961	C/G	cg16532752	chr4:104119610	CENPE	-0.41	-6.42	-0.33	4.47e-10	Testicular germ cell tumor;
LIHC	cis	rs1986734	0.619	rs13106413	chr4:77418698	G/T	cg24201034	chr4:77507246	SHROOM3	-0.38	-6.14	-0.31	2.34e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.65	-9.77	-0.47	4.92e-20	Subjective well-being;
LIHC	cis	rs9473924	0.542	rs9473922	chr6:50831792	C/T	cg14470998	chr6:50812995	TFAP2B	0.92	10.58	0.5	7.79e-23	Body mass index;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg20471045	chr19:49568214	NTF4	-0.42	-6.2	-0.32	1.64e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.26	-6.99	-0.35	1.44e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.72	14.59	0.62	8.06e-38	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.35	-0.32	6.87e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.51	8.42	0.41	1.06e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg24296786	chr1:45957014	TESK2	-0.5	-7.21	-0.36	3.53e-12	Platelet count;
LIHC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.95	22.46	0.77	2.7e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.67	13.15	0.58	3.15e-32	High light scatter reticulocyte count;
LIHC	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.77	10.03	0.48	6.34e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.27	-0.45	2.2e-18	Ulcerative colitis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25617285	chr1:211431773	RCOR3	0.37	6.52	0.33	2.53e-10	Cognitive function;
LIHC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg03146154	chr1:46216737	IPP	-0.38	-5.85	-0.3	1.13e-8	High light scatter reticulocyte count;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.47	7.07	0.36	8.74e-12	Cystic fibrosis severity;
LIHC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.84	0.3	1.21e-8	Height;
LIHC	cis	rs2637266	0.655	rs2588335	chr10:78510229	C/G	cg18941641	chr10:78392320	NA	0.28	6.07	0.31	3.34e-9	Pulmonary function;
LIHC	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.48	7.1	0.36	7.37e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs10744422	0.800	rs839363	chr12:123276924	C/T	cg25930673	chr12:123319894	HIP1R	-0.84	-10.39	-0.49	3.64e-22	Schizophrenia;
LIHC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.58	6.44	0.33	4.03e-10	Axial length;
LIHC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.51	8.48	0.42	6.88e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg20750642	chr13:99100586	FARP1	0.34	6.14	0.32	2.3e-9	Educational attainment (years of education);
LIHC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg12798992	chr6:167411361	FGFR1OP	-0.58	-9.5	-0.46	3.93e-19	Crohn's disease;
LIHC	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.13	-0.4	7.9e-15	Response to antipsychotic treatment;
LIHC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.67	-0.42	1.7e-16	Gut microbiome composition (summer);
LIHC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.96	-0.35	1.78e-11	Diabetic kidney disease;
LIHC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg27523141	chr10:43048294	ZNF37B	0.38	6.58	0.34	1.77e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg20295408	chr7:1910781	MAD1L1	-0.39	-5.73	-0.3	2.24e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2334880	0.713	rs4788828	chr16:71724090	C/A	cg06353428	chr16:71660113	MARVELD3	1.39	15.34	0.64	8.91e-41	Malaria;
LIHC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.67	13.29	0.58	9.1e-33	Leprosy;
LIHC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.93	10.72	0.5	2.51e-23	Triglycerides;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20095036	chr4:153456176	FBXW7	0.47	6.06	0.31	3.59e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.27	16.71	0.67	2.89e-46	Diabetic kidney disease;
LIHC	cis	rs965469	1.000	rs6051702	chr20:3251924	A/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.84	-0.35	3.75e-11	IFN-related cytopenia;
LIHC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.83e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.87	-0.65	6.88e-43	Height;
LIHC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.77	0.3	1.76e-8	Self-reported allergy;
LIHC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.49	17.34	0.68	8.86e-49	Eosinophil percentage of granulocytes;
LIHC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.75e-19	Waist circumference;Weight;
LIHC	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.5	5.74	0.3	2.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs77633900	0.502	rs116917406	chr15:76922940	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-6.97	-0.35	1.61e-11	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs4903214	0.895	rs12433272	chr14:74715250	C/T	cg11132536	chr14:74711944	VSX2	-0.23	-5.77	-0.3	1.76e-8	Inflammatory bowel disease;
LIHC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg26395211	chr5:140044315	WDR55	-0.4	-5.97	-0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.85	12.94	0.57	1.88e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.15	0.55	1.69e-28	Height;
LIHC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	6.34	0.32	7.34e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-9.35	-0.45	1.21e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20135002	chr11:47629003	NA	-0.55	-9.52	-0.46	3.37e-19	Subjective well-being;
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.87	-0.3	1.05e-8	Longevity;
LIHC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.77	-0.34	5.55e-11	Joint mobility (Beighton score);
LIHC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.4	-6.74	-0.34	6.5500000000000006e-11	Facial morphology (factor 20);
LIHC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	7.33	0.37	1.62e-12	Lung cancer in ever smokers;
LIHC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.84	8.38	0.41	1.38e-15	Plateletcrit;
LIHC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	6.06	0.31	3.55e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs62458065	0.850	rs6462362	chr7:32464733	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.58	-5.72	-0.3	2.33e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg20279561	chr13:113356724	ATP11A	-0.4	-6.58	-0.34	1.8e-10	Pain;
LIHC	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.64	10.3	0.49	7.46e-22	White matter hyperintensity burden;
LIHC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.87	-0.35	2.99e-11	Mean corpuscular volume;
LIHC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.75	11.69	0.53	8.86e-27	Glomerular filtration rate (creatinine);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg01715370	chr17:40169196	DNAJC7;NKIRAS2	0.66	6.84	0.35	3.71e-11	Mean platelet volume;
LIHC	cis	rs7619427	0.908	rs17076344	chr3:44079670	C/T	cg24966902	chr3:44043705	NA	0.49	6.87	0.35	3.09e-11	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.31	0.41	2.35e-15	Renal cell carcinoma;
LIHC	trans	rs8117834	0.574	rs6086330	chr20:8082272	T/G	cg00593689	chr4:53575888	NA	0.38	6.5	0.33	2.77e-10	Chronic kidney disease;
LIHC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.93	0.7	3.71e-51	Tonsillectomy;
LIHC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	18.23	0.7	2.43e-52	Smoking behavior;
LIHC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.28	-5.8	-0.3	1.52e-8	Aortic root size;
LIHC	trans	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.52	0.59	1.17e-33	Diabetic kidney disease;
LIHC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg10932868	chr11:921992	NA	0.36	6.82	0.35	4.25e-11	Alzheimer's disease (late onset);
LIHC	cis	rs4716602	0.609	rs12386633	chr7:156158232	G/C	cg16983916	chr7:156159713	NA	-0.32	-5.84	-0.3	1.22e-8	Anti-saccade response;
LIHC	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg13753209	chr17:57696993	CLTC	0.58	8.74	0.43	1.08e-16	Hemoglobin concentration;
LIHC	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg17749961	chr2:30669863	LCLAT1	0.47	6.06	0.31	3.5e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.69	-11.85	-0.54	2.34e-27	Colorectal cancer;
LIHC	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.94	-14.8	-0.62	1.2e-38	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg23782820	chr8:58130467	NA	0.33	5.95	0.31	6.66e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs477692	0.637	rs7098619	chr10:131315856	C/T	cg05714579	chr10:131428358	MGMT	0.41	6.64	0.34	1.27e-10	Response to temozolomide;
LIHC	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg01364799	chr7:75623366	TMEM120A	-0.49	-7.34	-0.37	1.56e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.42	-5.92	-0.3	8.04e-9	Longevity;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25026715	chr17:26989248	SUPT6H;SDF2	0.45	7.13	0.36	6.14e-12	Calcium levels;
LIHC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-14.28	-0.61	1.29e-36	Height;
LIHC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.97	0.47	1.01e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.53	-9.14	-0.44	5.84e-18	Red blood cell count;Reticulocyte count;
LIHC	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.43	-6.83	-0.35	3.8e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.64	-9.22	-0.45	3.09e-18	Menarche (age at onset);
LIHC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	cis	rs2834188	0.924	rs2850015	chr21:34697264	T/C	cg14352951	chr21:34696688	IFNAR1	0.49	6.77	0.34	5.65e-11	Narcolepsy;
LIHC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	trans	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg01134436	chr17:81009848	B3GNTL1	-0.7	-6.22	-0.32	1.41e-9	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.62	0.38	2.5e-13	Endometrial cancer;
LIHC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.13	0.44	6.3e-18	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.34	0.32	7.42e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.0	0.4	1.94e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs3770081	1.000	rs56977454	chr2:86204014	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-7.9	-0.39	3.92e-14	Facial emotion recognition (sad faces);
LIHC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.74	7.08	0.36	8.34e-12	Breast cancer;
LIHC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.53	7.68	0.38	1.64e-13	Response to diuretic therapy;
LIHC	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.83	9.69	0.46	9.18e-20	Ulcerative colitis;
LIHC	cis	rs7188697	0.848	rs37062	chr16:58567238	A/G	cg02549819	chr16:58548995	SETD6	-0.45	-7.16	-0.36	5.04e-12	QT interval;
LIHC	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg11812906	chr14:75593930	NEK9	0.43	6.54	0.33	2.18e-10	IgG glycosylation;
LIHC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg04727924	chr7:799746	HEATR2	-0.59	-8.58	-0.42	3.48e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.77	0.39	9.55e-14	IgG glycosylation;
LIHC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.88	0.39	4.42e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.89	10.95	0.51	4.08e-24	Coronary artery disease;
LIHC	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-18.38	-0.7	5.75e-53	Schizophrenia;
LIHC	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.17	-0.32	1.98e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.66	12.4	0.56	2.11e-29	Schizophrenia;
LIHC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg24112000	chr20:60950667	NA	-0.59	-8.77	-0.43	8.72e-17	Colorectal cancer;
LIHC	cis	rs4716602	0.596	rs10253193	chr7:156157801	C/T	cg16983916	chr7:156159713	NA	-0.34	-6.03	-0.31	4.32e-9	Anti-saccade response;
LIHC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.4	0.37	1.08e-12	Response to antipsychotic treatment;
LIHC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.73	11.96	0.54	8.84e-28	Anterior chamber depth;
LIHC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.31	0.45	1.62e-18	Schizophrenia;
LIHC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.86	11.32	0.52	1.86e-25	Small cell lung carcinoma;
LIHC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg08916839	chr5:415575	AHRR	-0.29	-6.35	-0.32	6.71e-10	Cystic fibrosis severity;
LIHC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16262614	chr3:133464971	TF	0.28	6.21	0.32	1.56e-9	Iron status biomarkers;
LIHC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.75	11.33	0.52	1.79e-25	Corneal astigmatism;
LIHC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg21466736	chr12:48725269	NA	0.6	8.2	0.41	4.83e-15	Glycated hemoglobin levels;
LIHC	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.58	8.23	0.41	3.87e-15	Menopause (age at onset);
LIHC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.32	-0.37	1.75e-12	Response to antipsychotic treatment;
LIHC	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.76	0.3	1.91e-8	Superior frontal gyrus grey matter volume;
LIHC	trans	rs73186030	0.920	rs73186059	chr3:122051183	T/C	cg13973942	chr17:977984	ABR	0.47	6.06	0.31	3.6e-9	Serum parathyroid hormone levels;
LIHC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.88	16.29	0.66	1.46e-44	Coronary artery disease;
LIHC	cis	rs12915845	0.545	rs7402591	chr15:89078434	T/C	cg05013243	chr15:89149849	MIR1179	-0.39	-6.86	-0.35	3.31e-11	Menarche (age at onset);
LIHC	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	5.84	0.3	1.2e-8	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.62	-0.34	1.38e-10	Gut microbiome composition (summer);
LIHC	trans	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg23633937	chr19:45575142	ZNF296	0.34	6.12	0.31	2.5e-9	Lung cancer;
LIHC	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.5	-6.38	-0.33	5.73e-10	Diisocyanate-induced asthma;
LIHC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.74	-0.43	1.04e-16	Exhaled nitric oxide output;
LIHC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21747090	chr2:27597821	SNX17	-0.42	-6.32	-0.32	8.03e-10	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg00280220	chr17:61926910	NA	-0.42	-6.82	-0.35	4.15e-11	Prudent dietary pattern;
LIHC	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.91	-0.3	8.23e-9	Urinary tract infection frequency;
LIHC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.38	6.87	0.35	3.11e-11	Schizophrenia;
LIHC	cis	rs7116495	1.000	rs7124000	chr11:71754338	T/C	cg26138937	chr11:71823887	C11orf51	-0.72	-7.15	-0.36	5.37e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.46	7.06	0.36	9.24e-12	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg20129853	chr10:51489980	NA	-0.41	-8.93	-0.43	2.63e-17	Prostate-specific antigen levels;
LIHC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.45	5.82	0.3	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02985541	chr2:219472218	PLCD4	-0.38	-5.98	-0.31	5.63e-9	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11505180	chr12:75724112	CAPS2	-0.45	-6.98	-0.35	1.51e-11	Pancreatic cancer;
LIHC	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg15704280	chr7:45808275	SEPT13	0.59	6.12	0.31	2.49e-9	Axial length;
LIHC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.68	-11.13	-0.52	9.44e-25	Electrocardiographic conduction measures;
LIHC	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	6.15	0.32	2.19e-9	Bipolar disorder;
LIHC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.86	-0.39	5.08e-14	Type 2 diabetes;
LIHC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.75	-0.39	1.06e-13	Lymphocyte counts;
LIHC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.55	-7.87	-0.39	4.62e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	trans	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.45	-6.34	-0.32	7.18e-10	Type 2 diabetes;
LIHC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.56e-16	Primary biliary cholangitis;
LIHC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-1.01	-19.21	-0.72	2.67e-56	Breast cancer;
LIHC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.58	-9.63	-0.46	1.4e-19	Height;
LIHC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	0.92	6.53	0.33	2.39e-10	Blood protein levels;
LIHC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg06050784	chr16:88016603	BANP	0.36	6.54	0.33	2.26e-10	Menopause (age at onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-6.14	-0.32	2.24e-9	Systolic blood pressure;
LIHC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.38	-6.27	-0.32	1.06e-9	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.67	8.31	0.41	2.32e-15	Gut microbiome composition (summer);
LIHC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.77	14.89	0.63	5.41e-39	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.18	-0.36	4.47e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.48	8.71	0.43	1.34e-16	Hemoglobin concentration;
LIHC	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.81	0.47	3.5e-20	Corneal astigmatism;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17432898	chr6:15663501	DTNBP1	-0.42	-6.4	-0.33	5.27e-10	Migraine with aura;
LIHC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.46	7.98	0.4	2.17e-14	Mean corpuscular volume;
LIHC	cis	rs990171	0.607	rs1558642	chr2:102763960	T/G	cg22835712	chr2:102737379	NA	0.52	7.25	0.37	2.74e-12	Lymphocyte counts;
LIHC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.48	8.54	0.42	4.39e-16	Mean corpuscular volume;
LIHC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.79	0.43	7.58e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.51	-7.27	-0.37	2.41e-12	Aortic root size;
LIHC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.48	7.59	0.38	3.02e-13	Systemic lupus erythematosus;
LIHC	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg18912006	chr12:123335444	HIP1R	0.59	7.26	0.37	2.66e-12	Schizophrenia;
LIHC	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.48	7.35	0.37	1.43e-12	Recalcitrant atopic dermatitis;
LIHC	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.88	12.94	0.57	1.92e-31	Lymphocyte percentage of white cells;
LIHC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20361540	chr12:123380447	VPS37B	-0.44	-6.31	-0.32	8.8e-10	Cognitive function;
LIHC	trans	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg23605328	chr1:201951606	RNPEP	0.4	6.36	0.33	6.53e-10	Monocyte percentage of white cells;
LIHC	cis	rs16828019	0.929	rs35883594	chr1:41744093	A/G	cg20697417	chr1:41786797	NA	0.36	6.6	0.34	1.59e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.75	8.45	0.42	8.21e-16	Height;
LIHC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.42	0.41	1.09e-15	Lung cancer in ever smokers;
LIHC	cis	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.75	-0.34	6.43e-11	Atopic dermatitis;
LIHC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.8	-0.35	4.74e-11	Personality dimensions;
LIHC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg03037974	chr15:76606532	NA	-0.77	-15.8	-0.65	1.35e-42	Blood metabolite levels;
LIHC	cis	rs9378688	0.722	rs9392375	chr6:2233061	C/T	cg12303981	chr6:2244766	GMDS	-0.49	-6.29	-0.32	9.47e-10	Caudate nucleus volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18429685	chr19:59085257	MZF1;LOC100131691	0.44	6.69	0.34	9.08e-11	Cognitive function;
LIHC	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	trans	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg01596870	chr19:55963115	NA	-0.65	-9.28	-0.45	2e-18	Obesity-related traits;
LIHC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.57	6.6	0.34	1.54e-10	Menarche (age at onset);
LIHC	cis	rs7075426	0.524	rs12411744	chr10:88245075	G/A	cg07322936	chr10:88137208	NA	0.46	6.17	0.32	1.92e-9	Migraine without aura;
LIHC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	6.08	0.31	3.17e-9	Tonsillectomy;
LIHC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg16586182	chr3:47516702	SCAP	-0.48	-8.46	-0.42	7.82e-16	Colorectal cancer;
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.0	-0.44	1.6e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.43	6.4	0.33	5.1e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.6	-8.04	-0.4	1.44e-14	Vitamin D levels;
LIHC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.29	-0.37	2.2e-12	Melanoma;
LIHC	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.24	0.48	1.18e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	9.38	0.45	9.49e-19	Lung cancer in ever smokers;
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.42	-5.79	-0.3	1.56e-8	Total body bone mineral density;
LIHC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.58	-9.05	-0.44	1.1e-17	Serum sulfate level;
LIHC	cis	rs6450176	0.564	rs406621	chr5:53326232	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.75	-13.59	-0.59	6.42e-34	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.47	6.28	0.32	1.02e-9	Major depressive disorder;
LIHC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.66	-0.34	1.12e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg09165964	chr15:75287851	SCAMP5	-0.56	-7.42	-0.37	9.59e-13	Lung cancer;
LIHC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.74	-12.36	-0.56	2.83e-29	Systemic lupus erythematosus;
LIHC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.91	-0.3	8.11e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.94	-0.31	6.93e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.33	6.17	0.32	1.98e-9	Protein biomarker;
LIHC	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-6.48	-0.33	3.16e-10	Asthma (bronchodilator response);
LIHC	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	1.16	13.92	0.6	3.37e-35	Blood protein levels;
LIHC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg25894440	chr7:65020034	NA	0.56	6.48	0.33	3.21e-10	Diabetic kidney disease;
LIHC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.35	-6.37	-0.33	6.12e-10	Aortic root size;
LIHC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.73	-0.5	2.4e-23	Primary sclerosing cholangitis;
LIHC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.39	-5.99	-0.31	5.24e-9	Blood pressure (smoking interaction);
LIHC	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg06054026	chr3:161089429	C3orf57	-0.41	-6.75	-0.34	6.27e-11	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.35e-9	Aortic root size;
LIHC	cis	rs7520050	0.966	rs12760175	chr1:46447840	G/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.81	0.3	1.4e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-7.23	-0.36	3.22e-12	Mean platelet volume;
LIHC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.74	10.9	0.51	6.12e-24	Corneal astigmatism;
LIHC	cis	rs8192282	0.698	rs6427729	chr1:154518874	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.5	-6.15	-0.32	2.14e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LIHC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.38	-0.33	5.85e-10	Response to antipsychotic treatment;
LIHC	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.17	-0.36	4.54e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.49	-7.27	-0.37	2.42e-12	Non-glioblastoma glioma;Glioma;
LIHC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg18944383	chr4:111397179	ENPEP	0.26	6.65	0.34	1.13e-10	Height;
LIHC	trans	rs6934970	1.000	rs12199472	chr6:113014691	A/G	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-1.01	-21.3	-0.76	1.14e-64	Height;
LIHC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg20195005	chr22:42527684	CYP2D6	0.3	5.79	0.3	1.56e-8	Birth weight;
LIHC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.31	6.45	0.33	3.92e-10	QRS complex (12-leadsum);
LIHC	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.48	7.09	0.36	7.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-7.71	-0.38	1.4e-13	Vitiligo;
LIHC	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg19773385	chr1:10388646	KIF1B	-0.49	-8.38	-0.41	1.4e-15	Hepatocellular carcinoma;
LIHC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.6	12.07	0.55	3.56e-28	Airflow obstruction;
LIHC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.86	-10.47	-0.49	2e-22	Primary sclerosing cholangitis;
LIHC	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg24004478	chr7:855632	UNC84A	0.47	6.68	0.34	9.9e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.53	7.74	0.39	1.11e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg18912006	chr12:123335444	HIP1R	-0.63	-7.09	-0.36	7.67e-12	Schizophrenia;
LIHC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.27	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.72	-10.93	-0.51	4.85e-24	Aortic root size;
LIHC	cis	rs7395581	0.959	rs7120118	chr11:47286290	T/C	cg26139080	chr11:47293733	MADD	-0.5	-8.43	-0.41	9.56e-16	HDL cholesterol;
LIHC	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.48	-7.05	-0.36	1e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs15676	0.783	rs7033070	chr9:131586374	G/A	cg00228799	chr9:131580591	ENDOG	-0.47	-6.85	-0.35	3.45e-11	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21574429	chr6:143381827	AIG1	-0.4	-6.05	-0.31	3.75e-9	Pancreatic cancer;
LIHC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.87	18.51	0.71	1.69e-53	IgG glycosylation;
LIHC	cis	rs7095607	0.538	rs2634706	chr10:69917590	A/C	cg18986048	chr10:69913749	MYPN	0.5	7.54	0.38	4.13e-13	Lung function (FVC);
LIHC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.79	12.0	0.54	6.26e-28	Dental caries;
LIHC	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.32	7.49	0.38	6.09e-13	Blood protein levels;
LIHC	cis	rs4294134	0.832	rs11772708	chr7:135264737	A/G	cg20392616	chr7:135392013	SLC13A4	0.38	6.06	0.31	3.61e-9	Paget's disease;
LIHC	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg04374321	chr14:90722782	PSMC1	-0.54	-8.9	-0.43	3.24e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.59	-0.5	7.31e-23	Total cholesterol levels;
LIHC	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-8.0	-0.4	1.96e-14	Vitamin D levels;
LIHC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg16586182	chr3:47516702	SCAP	0.61	11.81	0.54	3.13e-27	Colorectal cancer;
LIHC	cis	rs9871864	0.868	rs12491544	chr3:20358326	A/G	cg00235661	chr3:20228976	SGOL1	-0.31	-5.88	-0.3	9.82e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17467752	chr17:38218738	THRA	0.42	6.82	0.35	4.15e-11	Asthma and hay fever;
LIHC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.59	0.42	3.13e-16	Electroencephalogram traits;
LIHC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg07133347	chr1:107600762	PRMT6	-0.44	-6.66	-0.34	1.1e-10	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg06598544	chr20:61472147	COL9A3	-0.77	-7.39	-0.37	1.17e-12	Obesity-related traits;
LIHC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06002616	chr8:101225028	SPAG1	-0.35	-5.76	-0.3	1.85e-8	Atrioventricular conduction;
LIHC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg16479474	chr6:28041457	NA	0.46	6.44	0.33	4.17e-10	Depression;
LIHC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-5.87	-0.3	1.05e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg14440974	chr22:39074834	NA	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.37	-6.73	-0.34	7.2e-11	Aortic root size;
LIHC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-8.46	-0.42	7.73e-16	Parkinson's disease;
LIHC	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.35	-5.79	-0.3	1.58e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.76	0.34	5.81e-11	Bipolar disorder;
LIHC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.47	7.35	0.37	1.49e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg03013999	chr17:37608204	MED1	0.34	5.71	0.3	2.42e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.59	-7.09	-0.36	7.54e-12	Bipolar disorder;
LIHC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.53	-7.14	-0.36	5.81e-12	Ulcerative colitis;
LIHC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.23	0.36	3.16e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	0.55	8.6	0.42	2.85e-16	Atopic dermatitis;
LIHC	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-8.0	-0.4	1.94e-14	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.6	8.44	0.42	8.87e-16	Aortic root size;
LIHC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.44	-6.71	-0.34	8.23e-11	Height;
LIHC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.65	0.42	1.97e-16	Motion sickness;
LIHC	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.81	-0.39	6.99e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.41	5.71	0.3	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs11014306	1.000	rs6482455	chr10:25200457	C/G	cg19056833	chr13:114749079	RASA3	0.62	6.12	0.31	2.63e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.87	-15.07	-0.63	1.04e-39	Height;
LIHC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.95e-9	Menopause (age at onset);
LIHC	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg25173405	chr17:45401733	C17orf57	-0.56	-7.16	-0.36	5.13e-12	Coronary artery disease;
LIHC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg01256987	chr12:42539512	GXYLT1	0.42	7.01	0.35	1.27e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.11	-0.31	2.68e-9	Menarche (age at onset);
LIHC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.64	12.68	0.57	1.8e-30	Schizophrenia;
LIHC	cis	rs6977660	1.000	rs12666159	chr7:19804199	T/C	cg07541023	chr7:19748670	TWISTNB	0.39	6.17	0.32	1.9e-9	Thyroid stimulating hormone;
LIHC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg05665937	chr4:1216051	CTBP1	0.44	5.83	0.3	1.25e-8	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg12463550	chr7:65579703	CRCP	0.68	7.01	0.35	1.25e-11	Diabetic kidney disease;
LIHC	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.45	7.21	0.36	3.73e-12	Cocaine dependence;
LIHC	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.76	8.85	0.43	4.72e-17	Exhaled nitric oxide levels;
LIHC	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg09795085	chr6:101329169	ASCC3	-0.54	-7.51	-0.38	5.06e-13	Neuroticism;
LIHC	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.57	-12.0	-0.54	6.31e-28	Plateletcrit;Platelet count;
LIHC	trans	rs10915437	0.516	rs10915445	chr1:4197642	G/A	cg23269655	chr10:75541687	CHCHD1	0.4	6.04	0.31	4e-9	Migraine - clinic-based;
LIHC	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.47	7.15	0.36	5.25e-12	HDL cholesterol;
LIHC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.85	-0.35	3.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.68	12.1	0.55	2.61e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs238295	0.766	rs6139762	chr20:5546694	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.52	7.13	0.36	5.84e-12	Occipital cortical area (total cortical area interaction);
LIHC	cis	rs4407350	0.756	rs6519877	chr22:44890192	T/G	cg26276947	chr22:44892394	LDOC1L	0.32	6.0	0.31	4.89e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.15e-51	Menopause (age at onset);
LIHC	cis	rs243505	0.559	rs2072407	chr7:148508833	A/G	cg09806900	chr7:148480153	CUL1	0.4	5.91	0.3	8.45e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg08135965	chr6:41755394	TOMM6	0.44	5.74	0.3	2.04e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.94	13.48	0.59	1.58e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.58	-8.74	-0.43	1.06e-16	Neuroblastoma (high-risk);
LIHC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg20578329	chr17:80767326	TBCD	-0.62	-6.37	-0.33	6.04e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.32	-6.03	-0.31	4.36e-9	Red blood cell count;
LIHC	cis	rs4759375	1.000	rs28581850	chr12:123871717	T/C	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.6e-10	HDL cholesterol;
LIHC	trans	rs2352908	0.786	rs12892499	chr14:49431047	C/G	cg16568472	chr20:3190600	ITPA	-0.45	-6.09	-0.31	3.12e-9	Social communication problems;
LIHC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg23461800	chr14:103021989	NA	-0.54	-7.48	-0.37	6.4e-13	Platelet count;
LIHC	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg19683494	chr5:74908142	NA	-0.58	-7.57	-0.38	3.52e-13	Age-related disease endophenotypes;
LIHC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.62	8.22	0.41	4.22e-15	Motion sickness;
LIHC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg10932868	chr11:921992	NA	0.36	6.68	0.34	9.72e-11	Alzheimer's disease (late onset);
LIHC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-6.32	-0.32	7.99e-10	Chronic sinus infection;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.58	-0.34	1.74e-10	Total body bone mineral density;
LIHC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.84	12.1	0.55	2.68e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.21e-12	Renal cell carcinoma;
LIHC	cis	rs4147929	0.761	rs3752246	chr19:1056492	G/C	cg05372495	chr19:1063624	ABCA7	-0.44	-6.12	-0.31	2.5e-9	Alzheimer's disease (late onset);
LIHC	cis	rs9918079	0.560	rs4698409	chr4:15659766	G/A	cg21123203	chr4:15471301	CC2D2A	-0.44	-7.06	-0.36	9.26e-12	Obesity-related traits;
LIHC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg03929089	chr4:120376271	NA	0.53	6.66	0.34	1.09e-10	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6708331	0.517	rs11692018	chr2:70369154	A/C	cg01613454	chr2:70366299	NA	0.38	6.21	0.32	1.54e-9	Obesity-related traits;
LIHC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.53	8.56	0.42	3.96e-16	Fibrinogen levels;
LIHC	cis	rs12744310	1.000	rs12035913	chr1:41757057	A/G	cg03962019	chr1:41807865	NA	-0.36	-5.95	-0.31	6.74e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7487075	0.619	rs12824565	chr12:46834693	A/G	cg23829395	chr12:46796953	NA	0.35	6.19	0.32	1.76e-9	Itch intensity from mosquito bite;
LIHC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.89	-15.52	-0.64	1.66e-41	Aortic root size;
LIHC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg17724175	chr1:150552817	MCL1	0.46	8.8	0.43	6.95e-17	Melanoma;
LIHC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg16558253	chr16:72132732	DHX38	-0.51	-8.1	-0.4	9.86e-15	Fibrinogen levels;
LIHC	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.85	-6.45	-0.33	3.86e-10	Systolic blood pressure;
LIHC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.38	-0.33	5.79e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.66	8.24	0.41	3.75e-15	Gut microbiome composition (summer);
LIHC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.61	0.53	1.71e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.12	0.66	6.69e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs9322817	0.593	rs9404579	chr6:105229807	T/C	cg02098413	chr6:105308735	HACE1	-0.42	-7.7	-0.38	1.46e-13	Thyroid stimulating hormone;
LIHC	cis	rs8016982	0.632	rs4899786	chr14:81643800	G/T	cg01989461	chr14:81687754	GTF2A1	-0.45	-7.33	-0.37	1.66e-12	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.37	5.89	0.3	9.21e-9	Menopause (age at onset);
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg20308189	chr12:122261415	SETD1B	0.46	6.5	0.33	2.9e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.59	10.65	0.5	4.66e-23	Coronary artery disease;
LIHC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.69	-9.93	-0.47	1.43e-20	Red blood cell count;
LIHC	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.6	-11.15	-0.52	7.67e-25	Leprosy;
LIHC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.66	11.34	0.52	1.57e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	0.9	7.3	0.37	1.98e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs787274	1.000	rs787276	chr9:115551891	T/C	cg13803584	chr9:115635662	SNX30	-0.6	-6.68	-0.34	9.69e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.16	0.32	2e-9	Glycated hemoglobin levels;
LIHC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	1.04	13.41	0.59	2.97e-33	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.23	-7.37	-0.37	1.34e-12	Mean corpuscular volume;
LIHC	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg22153463	chr1:85462885	MCOLN2	0.49	5.87	0.3	1.03e-8	Serum sulfate level;
LIHC	cis	rs25645	0.502	rs1007654	chr17:38111354	A/G	cg17467752	chr17:38218738	THRA	0.4	5.81	0.3	1.42e-8	Myeloid white cell count;
LIHC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.57	8.87	0.43	4.18e-17	Uric acid clearance;
LIHC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-8.81	-0.43	6.18e-17	Morning vs. evening chronotype;
LIHC	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg06360820	chr2:242988706	NA	-0.84	-12.02	-0.55	5.15e-28	Obesity-related traits;
LIHC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg04025307	chr7:1156635	C7orf50	0.38	6.04	0.31	4.12e-9	Longevity;Endometriosis;
LIHC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.38	-6.88	-0.35	2.82e-11	Aortic root size;
LIHC	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.75	12.28	0.55	5.72e-29	Coronary artery disease;
LIHC	trans	rs3176789	0.647	rs10772127	chr12:9921790	T/C	cg18988856	chr7:99425577	CYP3A43	0.19	6.16	0.32	2.09e-9	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LIHC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.45	6.59	0.34	1.62e-10	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17035366	chr12:40499623	SLC2A13	0.44	6.22	0.32	1.42e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.4	-0.33	5.14e-10	Total body bone mineral density;
LIHC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg18944383	chr4:111397179	ENPEP	-0.34	-7.81	-0.39	6.9e-14	Coronary artery disease;
LIHC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.94	-0.31	6.92e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18273408	chr1:11115091	SRM	0.42	6.39	0.33	5.57e-10	Longevity;
LIHC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02290350	chr8:58132656	NA	0.4	8.54	0.42	4.47e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.61	9.53	0.46	2.98e-19	Multiple myeloma (IgH translocation);
LIHC	cis	rs151997	0.962	rs39955	chr5:50187501	C/A	cg06027927	chr5:50259733	NA	0.56	7.63	0.38	2.37e-13	Callous-unemotional behaviour;
LIHC	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.65	-11.12	-0.52	9.75e-25	Pediatric autoimmune diseases;
LIHC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.52	-6.97	-0.35	1.63e-11	Narcolepsy;
LIHC	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.37	-6.25	-0.32	1.21e-9	Menopause (age at onset);
LIHC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.58	9.42	0.45	7.03e-19	Cognitive function;
LIHC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.64	9.37	0.45	9.86e-19	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.65	-11.12	-0.52	9.6e-25	Crohn's disease;
LIHC	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.39	-9.19	-0.44	4.05e-18	Breast cancer;
LIHC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.62	10.9	0.51	5.92e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18692276	chr12:57023408	BAZ2A	0.46	6.81	0.35	4.47e-11	Lung function (FEV1/FVC);
LIHC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg04013166	chr16:89971882	TCF25	0.49	6.07	0.31	3.31e-9	Skin colour saturation;
LIHC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.11	11.42	0.53	8.64e-26	Opioid sensitivity;
LIHC	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.05e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.5	8.02	0.4	1.71e-14	Birth weight;
LIHC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.19	0.55	1.22e-28	Cognitive test performance;
LIHC	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	6.75	0.34	6.36e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.96	-12.76	-0.57	9.14e-31	Schizophrenia;
LIHC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.68	9.89	0.47	1.95e-20	Menarche (age at onset);
LIHC	cis	rs864643	1.000	rs1708056	chr3:39573153	C/A	cg05136238	chr3:39556330	MOBP	0.31	5.81	0.3	1.44e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.03	0.48	6.32e-21	Hip circumference adjusted for BMI;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04576684	chr19:17414284	ABHD8	0.48	6.57	0.33	1.91e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4700695	0.925	rs6878011	chr5:65392465	G/A	cg21114390	chr5:65439923	SFRS12	-0.46	-6.03	-0.31	4.18e-9	Facial morphology (factor 19);
LIHC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.71	-11.0	-0.51	2.71e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	trans	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg14791747	chr16:20752902	THUMPD1	0.49	7.11	0.36	6.94e-12	Dental caries;
LIHC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.74	-0.34	6.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.25	-0.45	2.48e-18	Bipolar disorder;
LIHC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.49	7.29	0.37	2.2e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs77861329	1.000	rs164638	chr3:52207886	T/G	cg08692210	chr3:52188851	WDR51A	0.84	8.02	0.4	1.74e-14	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.57	9.24	0.45	2.78e-18	Eosinophilic esophagitis;
LIHC	cis	rs7075426	0.716	rs10887610	chr10:88207000	C/T	cg07322936	chr10:88137208	NA	-0.46	-6.2	-0.32	1.61e-9	Migraine without aura;
LIHC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.82	12.46	0.56	1.24e-29	Vitamin D levels;
LIHC	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02985541	chr2:219472218	PLCD4	0.43	7.88	0.39	4.28e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.15e-10	Putamen volume;
LIHC	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.49	6.9	0.35	2.55e-11	Morning vs. evening chronotype;
LIHC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.51	5.77	0.3	1.74e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.43	5.99	0.31	5.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs918629	0.567	rs11741590	chr5:95241127	A/G	cg10483112	chr5:95245456	ELL2	0.38	7.05	0.36	1e-11	IgG glycosylation;
LIHC	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.59	9.71	0.46	7.58e-20	Corneal astigmatism;
LIHC	cis	rs6500637	0.558	rs11076856	chr16:4949815	A/G	cg08329684	chr16:4932620	PPL	-0.38	-6.75	-0.34	6.51e-11	Cancer;
LIHC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20887711	chr4:1340912	KIAA1530	-0.42	-6.3	-0.32	9.06e-10	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-11.07	-0.51	1.5e-24	Platelet count;
LIHC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.44	6.83	0.35	3.94e-11	Methadone dose in opioid dependence;
LIHC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.4	6.52	0.33	2.59e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	8.91	0.43	3.19e-17	Menarche (age at onset);
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg22528358	chr1:107598549	PRMT6	0.64	10.2	0.48	1.7e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.52	7.93	0.39	3.17e-14	Birth weight;
LIHC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6545883	0.894	rs2121661	chr2:61561658	A/G	cg14146966	chr2:61757674	XPO1	-0.44	-7.38	-0.37	1.23e-12	Tuberculosis;
LIHC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.54	10.48	0.49	1.77e-22	Methadone dose in opioid dependence;
LIHC	cis	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg13647721	chr17:30228624	UTP6	0.75	8.24	0.41	3.59e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.35	0.32	6.94e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-8.85	-0.43	4.67e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11673344	0.704	rs544543	chr19:37430823	A/G	cg27390819	chr19:37464633	NA	-0.5	-6.01	-0.31	4.88e-9	Obesity-related traits;
LIHC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.63	0.56	2.74e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.98	0.31	5.65e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg01444801	chr10:135216882	MTG1	-0.51	-8.1	-0.4	9.8e-15	Systemic lupus erythematosus;
LIHC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-9.35	-0.45	1.21e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.54	5.81	0.3	1.4e-8	Alzheimer's disease;
LIHC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.5	6.94	0.35	1.94e-11	Height;
LIHC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.29	6.84	0.35	3.57e-11	Primary biliary cholangitis;
LIHC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.99	0.31	5.2e-9	Tonsillectomy;
LIHC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs4753788	0.511	rs12224337	chr11:107140077	G/A	cg07207367	chr16:67978216	SLC12A4;LCAT	0.32	6.1	0.31	2.81e-9	Coronary artery disease;
LIHC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.75	-15.03	-0.63	1.49e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.53	-5.87	-0.3	1.03e-8	Hair shape;
LIHC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg06050784	chr16:88016603	BANP	0.35	6.42	0.33	4.64e-10	Menopause (age at onset);
LIHC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg00091569	chr3:40428383	ENTPD3	0.4	6.77	0.34	5.55e-11	Renal cell carcinoma;
LIHC	cis	rs1494373	0.543	rs11809755	chr1:220932051	G/A	cg06786860	chr1:220876396	NA	-0.38	-5.73	-0.3	2.26e-8	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	6.09	0.31	2.95e-9	Renal cell carcinoma;
LIHC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17507749	chr15:85114479	UBE2QP1	0.75	8.68	0.42	1.63e-16	Schizophrenia;
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10368533	chr12:22778127	ETNK1	-0.42	-6.32	-0.32	8.4e-10	Obesity-related traits;
LIHC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	10.28	0.49	8.93e-22	Platelet count;
LIHC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.14	-0.52	8.53e-25	Response to antipsychotic treatment;
LIHC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4388979	0.929	rs3742028	chr12:109491468	G/A	cg03220751	chr12:109490328	USP30	0.87	12.99	0.57	1.28e-31	Plateletcrit;Platelet count;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg25270632	chr7:43751042	C7orf44	0.35	6.64	0.34	1.22e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg11161837	chr1:110010384	SYPL2	0.48	6.53	0.33	2.35e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.83	0.3	1.26e-8	Breast cancer;
LIHC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.74	10.87	0.51	7.72e-24	Corneal astigmatism;
LIHC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.59	-8.36	-0.41	1.65e-15	Blood metabolite levels;
LIHC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.17	0.36	4.69e-12	Morning vs. evening chronotype;
LIHC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.93	13.78	0.6	1.2e-34	Primary sclerosing cholangitis;
LIHC	cis	rs4742903	0.935	rs975253	chr9:106928260	G/C	cg14250997	chr9:106856677	SMC2	0.36	6.02	0.31	4.43e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.34	6.8	0.35	4.66e-11	Renal cell carcinoma;
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04025307	chr7:1156635	C7orf50	0.56	7.53	0.38	4.63e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs763121	0.657	rs5995603	chr22:39040733	G/A	cg06022373	chr22:39101656	GTPBP1	0.63	10.3	0.49	7.8e-22	Menopause (age at onset);
LIHC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg12798992	chr6:167411361	FGFR1OP	0.6	10.15	0.48	2.49e-21	Crohn's disease;
LIHC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg03894339	chr8:19674705	INTS10	0.63	10.06	0.48	5e-21	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.74	0.34	6.93e-11	Ileal carcinoids;
LIHC	cis	rs4788570	0.697	rs2334877	chr16:71833332	C/T	cg06353428	chr16:71660113	MARVELD3	1.29	13.99	0.6	1.69e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	9.01	0.44	1.5e-17	Multiple sclerosis;
LIHC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.52	7.66	0.38	1.98e-13	Type 2 diabetes;
LIHC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg23149560	chr2:74406255	MOBKL1B	0.4	5.86	0.3	1.11e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg18912006	chr12:123335444	HIP1R	-0.63	-7.64	-0.38	2.14e-13	Schizophrenia;
LIHC	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.44	-7.91	-0.39	3.56e-14	Inhibitory control;
LIHC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg20135002	chr11:47629003	NA	-0.52	-9.14	-0.44	5.78e-18	Subjective well-being;
LIHC	cis	rs6445975	0.667	rs3773004	chr3:58269451	A/G	cg23715586	chr3:58305044	RPP14	-0.38	-6.32	-0.32	8.17e-10	Systemic lupus erythematosus;
LIHC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.9	0.3	8.58e-9	Bladder cancer;
LIHC	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.77	8.85	0.43	4.91e-17	Exhaled nitric oxide levels;
LIHC	trans	rs13113518	0.812	rs2035691	chr4:56395953	C/T	cg15358633	chr12:38710606	ALG10B	0.43	6.13	0.31	2.42e-9	Height;
LIHC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.44	6.43	0.33	4.18e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.45	6.1	0.31	2.84e-9	Tonsillectomy;
LIHC	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.43	5.98	0.31	5.71e-9	Red cell distribution width;
LIHC	cis	rs4728302	0.838	rs2042453	chr7:133580730	G/A	cg10665199	chr7:133106180	EXOC4	0.34	6.01	0.31	4.63e-9	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg02023728	chr11:77925099	USP35	-0.34	-5.96	-0.31	6.37e-9	Alzheimer's disease (survival time);
LIHC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	12.42	0.56	1.74e-29	Schizophrenia;
LIHC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.35	0.45	1.18e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.9	10.38	0.49	4.11e-22	Alzheimer's disease (late onset);
LIHC	trans	rs11638815	0.626	rs4779041	chr15:83337059	G/A	cg18393722	chr15:85113863	UBE2QP1	0.36	6.08	0.31	3.16e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LIHC	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-9.06	-0.44	1.01e-17	Atrioventricular conduction;
LIHC	trans	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg01596870	chr19:55963115	NA	-0.68	-9.79	-0.47	3.97e-20	Obesity-related traits;
LIHC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.48	7.59	0.38	3.01e-13	Schizophrenia;
LIHC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12016809	chr21:47604291	C21orf56	0.4	5.87	0.3	1.05e-8	Testicular germ cell tumor;
LIHC	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.37	-6.85	-0.35	3.36e-11	Height;
LIHC	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	10.2	0.48	1.63e-21	Alzheimer's disease;
LIHC	cis	rs2282802	0.685	rs11748023	chr5:139558584	C/T	cg26211634	chr5:139558579	C5orf32	-0.38	-5.92	-0.3	7.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.7	-14.05	-0.6	1.03e-35	Menopause (age at onset);
LIHC	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg12698662	chr3:15914712	MIR563	-0.37	-6.9	-0.35	2.48e-11	Mean platelet volume;
LIHC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.71	-8.98	-0.44	1.88e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.65	-10.04	-0.48	5.69e-21	Monocyte percentage of white cells;
LIHC	cis	rs9810089	0.758	rs12492510	chr3:136151631	G/T	cg21827317	chr3:136751795	NA	0.44	5.88	0.3	9.87e-9	Gestational age at birth (child effect);
LIHC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.93	-0.81	1e-82	Myeloid white cell count;
LIHC	cis	rs7961581	0.748	rs1705255	chr12:71601847	C/T	cg05756094	chr12:71608604	NA	0.42	6.85	0.35	3.51e-11	Type 2 diabetes;
LIHC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.09e-14	Motion sickness;
LIHC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.8	0.3	1.51e-8	Bipolar disorder;
LIHC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.56	0.46	2.48e-19	Tonsillectomy;
LIHC	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.9	11.19	0.52	5.8e-25	Coronary artery disease;
LIHC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	1.06	22.62	0.77	6.65e-70	Breast cancer;
LIHC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.89	-0.3	9.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.27	0.32	1.12e-9	Ulcerative colitis;
LIHC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg11212589	chr17:38028394	ZPBP2	0.37	7.62	0.38	2.46e-13	Self-reported allergy;
LIHC	trans	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04565464	chr8:145669602	NFKBIL2	0.4	6.69	0.34	9.34e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.5	0.53	4.14e-26	Coronary artery disease;
LIHC	cis	rs6061231	0.916	rs58488796	chr20:60949050	G/C	cg24112000	chr20:60950667	NA	-0.6	-8.34	-0.41	1.9e-15	Colorectal cancer;
LIHC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.4	6.41e-15	Bladder cancer;
LIHC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.42	5.9	0.3	8.71e-9	Alzheimer's disease;
LIHC	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg17644311	chr12:94854007	CCDC41;LOC144486	0.39	6.26	0.32	1.12e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LIHC	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg14092571	chr14:90743983	NA	-0.42	-6.54	-0.33	2.27e-10	Mortality in heart failure;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.27	-0.45	2.15e-18	Aortic root size;
LIHC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.91	0.39	3.69e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.32	-6.77	-0.34	5.7e-11	Longevity;
LIHC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Colorectal cancer;
LIHC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg05425664	chr17:57184151	TRIM37	0.43	6.13	0.31	2.48e-9	Testicular germ cell tumor;
LIHC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg00750074	chr16:89608354	SPG7	0.4	6.21	0.32	1.51e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-9.06	-0.44	1.02e-17	Plateletcrit;
LIHC	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.13	-0.36	6.2e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg23250157	chr14:64679961	SYNE2	0.4	6.03	0.31	4.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs3981351	0.797	rs12766891	chr10:115460714	G/A	cg24846397	chr10:115438155	CASP7	-0.46	-7.11	-0.36	6.99e-12	Obesity-related traits;
LIHC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg25364880	chr3:44379878	C3orf23	0.48	6.93	0.35	2.17e-11	Depressive symptoms;
LIHC	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.62	10.53	0.49	1.21e-22	HDL cholesterol;
LIHC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.33	7.38	0.37	1.23e-12	Ulcerative colitis;
LIHC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.73	-0.43	1.12e-16	Obesity-related traits;
LIHC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg10664184	chr19:17420304	DDA1	0.47	5.93	0.31	7.61e-9	Systemic lupus erythematosus;
LIHC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.46	16.66	0.67	4.99e-46	Eosinophil percentage of granulocytes;
LIHC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg05043794	chr9:111880884	C9orf5	-0.23	-5.78	-0.3	1.7e-8	Menarche (age at onset);
LIHC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.67	14.0	0.6	1.66e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.42	-6.74	-0.34	6.64e-11	Menarche (age at onset);
LIHC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.66	-0.34	1.12e-10	Type 2 diabetes;
LIHC	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg23229016	chr1:26872525	RPS6KA1	0.23	5.77	0.3	1.8e-8	Glucose homeostasis traits;
LIHC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.43	6.13	0.31	2.44e-9	Height;
LIHC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.4	-6.78	-0.34	5.24e-11	Monocyte count;
LIHC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg25344623	chr2:136566232	LCT	-0.38	-6.37	-0.33	6.24e-10	Corneal structure;
LIHC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.58	-9.29	-0.45	1.87e-18	Blood trace element (Zn levels);
LIHC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.85	12.2	0.55	1.1e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs28595532	0.668	rs72670237	chr4:119320937	T/C	cg21605333	chr4:119757512	SEC24D	0.94	7.27	0.37	2.54e-12	Cannabis dependence symptom count;
LIHC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg06951627	chr6:26196580	NA	0.51	5.77	0.3	1.78e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.64	-7.88	-0.39	4.46e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.92	0.47	1.48e-20	Coffee consumption (cups per day);
LIHC	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg10820045	chr2:198174542	NA	0.48	7.67	0.38	1.75e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.79	13.02	0.58	9.37e-32	Coronary artery disease;
LIHC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg15269541	chr15:43626905	ADAL	-0.3	-5.89	-0.3	9.32e-9	Lung cancer in ever smokers;
LIHC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.08	-0.31	3.17e-9	Mood instability;
LIHC	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.87	-0.39	4.77e-14	Capecitabine sensitivity;
LIHC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.43	-8.15	-0.4	6.92e-15	Neurofibrillary tangles;
LIHC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.86	-0.3	1.07e-8	Pulse pressure;
LIHC	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.71	-8.66	-0.42	1.92e-16	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LIHC	cis	rs1865721	1.000	rs72977888	chr18:73195250	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.6	-0.38	2.88e-13	Intelligence;
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.95	-0.31	6.55e-9	Total body bone mineral density;
LIHC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg21486233	chr12:29375141	FAR2	0.3	5.74	0.3	2.04e-8	QT interval;
LIHC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.67	-6.86	-0.35	3.2e-11	Vitiligo;
LIHC	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg02527881	chr3:46936655	PTH1R	-0.51	-10.68	-0.5	3.63e-23	Birth weight;
LIHC	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.45	6.79	0.34	4.93e-11	Diastolic blood pressure;
LIHC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08219700	chr8:58056026	NA	0.53	6.36	0.33	6.6e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.37e-8	Lewy body disease;
LIHC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.64	-9.65	-0.46	1.2e-19	Monocyte percentage of white cells;
LIHC	cis	rs34779708	0.801	rs12242110	chr10:35535695	A/G	cg03585969	chr10:35415529	CREM	0.85	12.75	0.57	9.97e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg26441486	chr22:50317300	CRELD2	0.37	6.19	0.32	1.76e-9	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	9.09	0.44	7.98e-18	Motion sickness;
LIHC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.51	-8.11	-0.4	8.86e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.86	12.19	0.55	1.29e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.5	0.46	3.82e-19	Bipolar disorder;
LIHC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.74	10.91	0.51	5.39e-24	Corneal astigmatism;
LIHC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg24955955	chr5:415729	AHRR	-0.32	-6.52	-0.33	2.48e-10	Cystic fibrosis severity;
LIHC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.37	5.77	0.3	1.78e-8	Coronary artery disease;
LIHC	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.3	6.16	0.32	1.99e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg12365402	chr11:9010492	NRIP3	-0.24	-6.17	-0.32	1.94e-9	Hemoglobin concentration;
LIHC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Body mass index;
LIHC	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg08539965	chr1:21396338	EIF4G3	0.33	5.87	0.3	1.04e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.66	10.13	0.48	2.83e-21	Height;
LIHC	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	0.93	11.43	0.53	7.91e-26	Post bronchodilator FEV1;
LIHC	cis	rs10426930	0.816	rs2602727	chr19:5052107	G/A	cg18473234	chr19:5097819	KDM4B	-0.54	-7.0	-0.35	1.33e-11	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.02	0.6	1.3e-35	Prudent dietary pattern;
LIHC	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg18898632	chr2:242989856	NA	-0.51	-7.27	-0.37	2.52e-12	Obesity-related traits;
LIHC	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.31	-5.8	-0.3	1.51e-8	Red blood cell count;
LIHC	cis	rs36051895	0.530	rs60768043	chr9:5224676	T/G	cg02405213	chr9:5042618	JAK2	-0.62	-9.23	-0.45	2.93e-18	Pediatric autoimmune diseases;
LIHC	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.53	-6.78	-0.34	5.34e-11	Ileal carcinoids;
LIHC	cis	rs4716602	0.596	rs10458244	chr7:156164285	C/T	cg16983916	chr7:156159713	NA	-0.33	-5.82	-0.3	1.38e-8	Anti-saccade response;
LIHC	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16684958	chr7:75615977	POR	0.5	8.29	0.41	2.69e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg21573476	chr21:45109991	RRP1B	-0.52	-9.68	-0.46	9.26e-20	Mean corpuscular volume;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.11	0.31	2.74e-9	Calcium levels;
LIHC	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.9	-9.95	-0.47	1.19e-20	Platelet distribution width;
LIHC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.69	-9.95	-0.47	1.23e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg25182066	chr10:30743637	MAP3K8	0.69	9.68	0.46	9.9e-20	Itch intensity from mosquito bite;
LIHC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.34	-7.24	-0.36	2.94e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.41	-7.23	-0.36	3.19e-12	Platelet distribution width;
LIHC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg14132834	chr19:41945861	ATP5SL	-0.45	-6.74	-0.34	6.79e-11	Height;
LIHC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg16736954	chr20:23401023	NAPB	0.73	8.71	0.43	1.31e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.98	12.83	0.57	4.89e-31	Heart rate;
LIHC	cis	rs1198430	0.639	rs685059	chr1:23783185	C/G	cg19827787	chr1:23763612	ASAP3	0.28	6.09	0.31	2.99e-9	Total cholesterol levels;
LIHC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg01652190	chr22:50026171	C22orf34	-0.3	-6.88	-0.35	2.82e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg24123311	chr19:48675164	NA	0.36	6.1	0.31	2.86e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg01629716	chr15:45996671	NA	0.51	9.21	0.45	3.44e-18	Waist circumference;Weight;
LIHC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg20684491	chr1:25596433	NA	0.29	5.9	0.3	8.52e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs539514	0.513	rs7324353	chr13:76272283	A/C	cg04757411	chr13:76259545	LMO7	-0.42	-7.03	-0.36	1.14e-11	Type 1 diabetes;
LIHC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg23517279	chr6:96025343	MANEA	0.57	5.83	0.3	1.25e-8	Behavioural disinhibition (generation interaction);
LIHC	cis	rs17106184	0.892	rs60832780	chr1:51303714	T/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.62	-0.34	1.4e-10	Type 2 diabetes;
LIHC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.42	-9.35	-0.45	1.14e-18	Erythrocyte sedimentation rate;
LIHC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg20933634	chr6:27740509	NA	0.47	6.3	0.32	9.11e-10	Parkinson's disease;
LIHC	cis	rs420259	0.636	rs34513	chr16:23671992	C/G	cg05131483	chr16:23706242	ERN2	0.34	5.8	0.3	1.55e-8	Bipolar disorder;
LIHC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.2	0.48	1.69e-21	Diabetic retinopathy;
LIHC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	1.02	19.53	0.73	1.39e-57	Breast cancer;
LIHC	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.68	-10.11	-0.48	3.29e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	7.33	0.37	1.7e-12	Osteoporosis;
LIHC	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.76	-0.3	1.85e-8	Prostate cancer;
LIHC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.46	-6.48	-0.33	3.17e-10	Tonsillectomy;
LIHC	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.61	7.52	0.38	4.92e-13	Coronary artery disease;
LIHC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.5	-0.46	3.88e-19	Bipolar disorder;
LIHC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.8	11.89	0.54	1.63e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.87	-0.35	3.09e-11	Hemoglobin concentration;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.73	0.39	1.23e-13	Prudent dietary pattern;
LIHC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19671926	chr4:122722719	EXOSC9	0.56	8.51	0.42	5.44e-16	Type 2 diabetes;
LIHC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	8.33	0.41	2.03e-15	Platelet count;
LIHC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.27	0.45	2.08e-18	Hemoglobin concentration;
LIHC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	14.27	0.61	1.44e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11788103	chr19:12833533	TNPO2	0.47	6.87	0.35	2.98e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4700695	0.764	rs37018	chr5:65366645	A/G	cg21114390	chr5:65439923	SFRS12	0.46	5.98	0.31	5.57e-9	Facial morphology (factor 19);
LIHC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.43	5.73	0.3	2.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg08400316	chr16:204221	HBZ	-0.42	-6.94	-0.35	1.94e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs72829446	0.530	rs11869899	chr17:7407915	C/T	cg02795151	chr17:7402630	POLR2A	0.55	6.39	0.33	5.45e-10	Androgen levels;
LIHC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg19635926	chr16:89946313	TCF25	0.46	5.92	0.31	7.66e-9	Skin colour saturation;
LIHC	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg11367502	chr7:22862612	TOMM7	0.45	7.44	0.37	8.16e-13	Fibrinogen;
LIHC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg20487152	chr13:99095054	FARP1	-0.48	-8.25	-0.41	3.54e-15	Neuroticism;
LIHC	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.46	8.57	0.42	3.54e-16	Testicular germ cell tumor;
LIHC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.47	7.5	0.38	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.44	6.07	0.31	3.41e-9	Height;
LIHC	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg02023728	chr11:77925099	USP35	0.33	5.81	0.3	1.44e-8	Alzheimer's disease (survival time);
LIHC	cis	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg01364799	chr7:75623366	TMEM120A	-0.46	-5.75	-0.3	1.99e-8	Eotaxin levels;
LIHC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.83	-0.47	2.99e-20	Schizophrenia;
LIHC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	6.33	0.32	7.79e-10	Initial pursuit acceleration;
LIHC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.16	-0.32	2.05e-9	Alzheimer's disease (late onset);
LIHC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.05	-0.31	3.84e-9	Aortic root size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18393722	chr15:85113863	UBE2QP1	0.37	6.09	0.31	3.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.39	9.55	0.46	2.5e-19	Blood metabolite ratios;
LIHC	cis	rs8083850	0.635	rs10469024	chr18:50863609	A/C	cg24270629	chr18:50823537	DCC	0.53	8.04	0.4	1.51e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.26	-7.0	-0.35	1.32e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10792665	0.844	rs10898058	chr11:82657859	T/A	cg24227371	chr11:82718527	RAB30	-0.31	-7.23	-0.36	3.15e-12	Obesity-related traits;
LIHC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.36	0.37	1.35e-12	Height;
LIHC	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-0.59	-8.24	-0.41	3.65e-15	Obesity-related traits;
LIHC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.55	6.35	0.32	6.76e-10	Alzheimer's disease;
LIHC	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.73	-11.1	-0.51	1.17e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-1.19	-10.56	-0.5	9.27e-23	Breast cancer;
LIHC	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.07	22.69	0.78	3.42e-70	Schizophrenia;
LIHC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.74	8.7	0.43	1.46e-16	Morning vs. evening chronotype;
LIHC	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg23254163	chr1:152506842	NA	0.23	5.97	0.31	5.81e-9	Hair morphology;
LIHC	cis	rs7523273	0.505	rs35438924	chr1:207881489	T/G	cg22525895	chr1:207977042	MIR29B2	0.49	7.68	0.38	1.75e-13	Schizophrenia;
LIHC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.35	6.17	0.32	1.95e-9	Psoriasis;
LIHC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.53	-9.32	-0.45	1.45e-18	Diastolic blood pressure;
LIHC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.94	9.52	0.46	3.27e-19	Breast cancer;
LIHC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg19680672	chr10:131412579	MGMT	-0.44	-6.94	-0.35	1.94e-11	Response to temozolomide;
LIHC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.6	6.44	0.33	4.05e-10	Inflammatory bowel disease;
LIHC	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.41	-0.41	1.11e-15	Vitamin D levels;
LIHC	trans	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg25214090	chr10:38739885	LOC399744	0.4	6.73	0.34	6.99e-11	Diastolic blood pressure;
LIHC	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	11.93	0.54	1.11e-27	High light scatter reticulocyte count;
LIHC	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg26550851	chr1:3701203	LRRC47	0.4	6.99	0.35	1.48e-11	Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.68	7.11	0.36	6.86e-12	Alzheimer's disease;
LIHC	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg06102954	chr21:42741788	MX2	-0.36	-6.25	-0.32	1.25e-9	Melanoma;
LIHC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-14.67	-0.62	3.78e-38	Chronic sinus infection;
LIHC	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg02811702	chr13:24901961	NA	0.25	6.41	0.33	4.83e-10	Obesity-related traits;
LIHC	trans	rs955333	1.000	rs56306994	chr6:154946059	T/C	cg01304710	chr4:3766151	NA	0.31	6.44	0.33	3.97e-10	Diabetic kidney disease;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10081115	chr2:190686883	PMS1	0.59	7.19	0.36	4.22e-12	Lung function (FEV1);
LIHC	trans	rs7849581	1	rs7849581	chr9:9924724	A/G	cg01762264	chr16:3192406	ZNF213	-0.54	-6.16	-0.32	2.02e-9	Myopia (pathological);
LIHC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.84	-0.3	1.19e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg09331704	chr11:110167585	RDX	-0.54	-6.04	-0.31	4.08e-9	Systolic blood pressure;
LIHC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.6	-8.52	-0.42	5e-16	Aortic root size;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg14828511	chr1:107599125	PRMT6	-0.44	-6.25	-0.32	1.22e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-0.74	-6.35	-0.32	6.81e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg19676328	chr12:49525230	TUBA1B	-0.39	-6.31	-0.32	8.59e-10	Total cholesterol levels;
LIHC	cis	rs986417	1.000	rs1956555	chr14:60968804	A/G	cg27398547	chr14:60952738	C14orf39	0.85	9.85	0.47	2.61e-20	Gut microbiota (bacterial taxa);
LIHC	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.62	9.98	0.47	9.69e-21	Corneal astigmatism;
LIHC	cis	rs7116495	1.000	rs677279	chr11:71770469	G/A	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.35	8.11	0.4	9.26e-15	Crohn's disease;
LIHC	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg26531700	chr6:26746687	NA	0.37	6.14	0.32	2.25e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.37	-6.13	-0.31	2.43e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.22	0.32	1.41e-9	Tonsillectomy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04334947	chr13:30881232	KATNAL1	-0.55	-6.31	-0.32	8.78e-10	Systolic blood pressure;
LIHC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-6.9	-0.35	2.46e-11	Acylcarnitine levels;
LIHC	cis	rs16958440	0.737	rs16958699	chr18:44654846	T/C	cg17192377	chr18:44677553	HDHD2	0.6	6.74	0.34	6.88e-11	Sitting height ratio;
LIHC	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg26818010	chr10:134567672	INPP5A	-0.76	-9.2	-0.45	3.53e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg22663859	chr13:21900854	NA	0.46	7.32	0.37	1.79e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	7.91	0.39	3.51e-14	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9810089	0.814	rs864437	chr3:136119909	C/G	cg21827317	chr3:136751795	NA	0.43	5.78	0.3	1.71e-8	Gestational age at birth (child effect);
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.84	0.39	5.9e-14	Prudent dietary pattern;
LIHC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.44	7.78	0.39	8.74e-14	Aortic root size;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21930229	chr1:32758033	HDAC1	0.48	7.01	0.35	1.25e-11	Cognitive function;
LIHC	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.67	11.05	0.51	1.82e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.27	-0.32	1.1e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.48	8.49	0.42	6.22e-16	IgG glycosylation;
LIHC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.38	6.5	0.33	2.85e-10	Schizophrenia;
LIHC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.38	-5.94	-0.31	7.11e-9	Morning vs. evening chronotype;
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.62	0.34	1.38e-10	Obesity-related traits;
LIHC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	8.99	0.44	1.75e-17	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg16652328	chr3:33138982	GLB1;TMPPE	-0.58	-6.85	-0.35	3.43e-11	Major depressive disorder;
LIHC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.58	-0.34	1.76e-10	Gut microbiome composition (summer);
LIHC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg20569855	chr1:109824440	PSRC1	0.49	6.65	0.34	1.15e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg13271783	chr10:134563150	INPP5A	-0.57	-7.18	-0.36	4.46e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg13844804	chr7:814759	HEATR2	0.43	5.81	0.3	1.44e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg16691251	chr5:66510806	NA	0.51	7.26	0.37	2.68e-12	Breast cancer;
LIHC	cis	rs4934494	0.768	rs12771413	chr10:91392767	C/T	cg19698084	chr10:91461284	KIF20B	0.47	6.59	0.34	1.7e-10	Red blood cell count;
LIHC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.63	-11.67	-0.53	1.05e-26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg14393609	chr7:65229607	NA	-0.35	-5.77	-0.3	1.75e-8	Aortic root size;
LIHC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.49	8.21	0.41	4.71e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26734620	chr12:56694298	CS	-1.0	-10.11	-0.48	3.46e-21	Psoriasis vulgaris;
LIHC	cis	rs7188697	0.922	rs37039	chr16:58578091	C/T	cg02549819	chr16:58548995	SETD6	-0.46	-7.27	-0.37	2.47e-12	QT interval;
LIHC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.41	4.57e-15	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.47	5.79	0.3	1.59e-8	Alzheimer's disease;
LIHC	trans	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg18335740	chr13:41363409	SLC25A15	-0.38	-6.61	-0.34	1.49e-10	Lewy body disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01855760	chr4:68567075	LOC550112;UBA6	0.59	8.1	0.4	1.01e-14	Pancreatic cancer;
LIHC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg10932868	chr11:921992	NA	0.35	6.56	0.33	1.96e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.38	6.07	0.31	3.31e-9	Menopause (age at onset);
LIHC	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.28	5.97	0.31	5.96e-9	Pulmonary function;
LIHC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.55	5.71	0.3	2.44e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg00091569	chr3:40428383	ENTPD3	0.41	6.98	0.35	1.5e-11	Renal cell carcinoma;
LIHC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.82	13.59	0.59	5.99e-34	Multiple sclerosis;
LIHC	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg00085434	chr11:14927489	NA	0.41	5.82	0.3	1.35e-8	Vitamin D levels;
LIHC	cis	rs16858210	0.874	rs10937153	chr3:183562925	A/G	cg25686905	chr3:183603175	PARL	0.48	9.22	0.45	3.08e-18	Menopause (age at onset);
LIHC	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.34	-0.45	1.31e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2412488	0.861	rs11722866	chr4:54310188	A/G	cg22241045	chr4:54363911	LNX1	-0.41	-6.66	-0.34	1.07e-10	DNA methylation (variation);
LIHC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg14779329	chr11:130786720	SNX19	-0.46	-6.67	-0.34	1.04e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs61160187	0.503	rs377321	chr5:59851740	G/C	cg02684056	chr5:59996105	DEPDC1B	0.4	6.0	0.31	5.05e-9	Educational attainment (years of education);Educational attainment (college completion);
LIHC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg15832292	chr6:96025679	MANEA	0.63	7.02	0.36	1.16e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg23205692	chr1:25664452	TMEM50A	0.43	6.92	0.35	2.29e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg03934865	chr2:198174659	NA	0.46	6.79	0.34	5.08e-11	Dermatomyositis;
LIHC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg00280220	chr17:61926910	NA	0.43	6.82	0.35	4.18e-11	Prudent dietary pattern;
LIHC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.45	8.07	0.4	1.2e-14	IgG glycosylation;
LIHC	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg27205649	chr11:78285834	NARS2	-0.39	-5.8	-0.3	1.49e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.68	-9.51	-0.46	3.48e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg00204512	chr16:28754710	NA	0.35	7.01	0.35	1.31e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.52	6.02	0.31	4.48e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg03037974	chr15:76606532	NA	-0.59	-10.09	-0.48	3.95e-21	Blood metabolite levels;
LIHC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20887711	chr4:1340912	KIAA1530	0.45	6.01	0.31	4.77e-9	Obesity-related traits;
LIHC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.52	7.3	0.37	2e-12	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg18016565	chr1:150552671	MCL1	0.52	9.95	0.47	1.21e-20	Melanoma;
LIHC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.11	0.44	7.24e-18	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.75	-8.2	-0.41	5.01e-15	Vitiligo;
LIHC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.67	6.57	0.33	1.88e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.86	0.3	1.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs57502260	1.000	rs56312530	chr11:68219415	G/A	cg20283391	chr11:68216788	NA	-0.46	-5.77	-0.3	1.74e-8	Total body bone mineral density (age 45-60);
LIHC	cis	rs12744310	1.000	rs56077539	chr1:41773942	T/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg16724585	chr3:197361211	NA	-0.47	-6.63	-0.34	1.29e-10	Pancreatic cancer;
LIHC	cis	rs1555322	0.530	rs2425049	chr20:33874720	C/T	cg17927777	chr20:33865990	NA	0.52	6.23	0.32	1.41e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs7818688	0.697	rs11781757	chr8:95987891	A/T	cg16049864	chr8:95962084	TP53INP1	0.59	6.4	0.33	5.08e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg12311636	chr6:118886798	C6orf204	-0.53	-6.22	-0.32	1.44e-9	Diastolic blood pressure;
LIHC	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg17385448	chr1:15911702	AGMAT	0.41	6.91	0.35	2.36e-11	Systolic blood pressure;
LIHC	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg27205649	chr11:78285834	NARS2	0.39	5.93	0.31	7.44e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.66	-9.97	-0.47	1.01e-20	Subjective well-being;
LIHC	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg19735590	chr5:154026979	NA	0.47	5.82	0.3	1.39e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17507749	chr15:85114479	UBE2QP1	0.62	7.04	0.36	1.09e-11	Schizophrenia;
LIHC	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.54	-8.13	-0.4	8.06e-15	Extraversion;
LIHC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.43	0.33	4.23e-10	Initial pursuit acceleration;
LIHC	cis	rs1355223	0.902	rs61881050	chr11:34719749	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.36	-0.33	6.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.31	7.57	0.38	3.48e-13	Gut microbiome composition (winter);
LIHC	cis	rs6750047	0.719	rs100489	chr2:38266478	T/C	cg07380506	chr2:38303506	CYP1B1	-0.52	-6.08	-0.31	3.27e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-8.23	-0.41	3.86e-15	Gut microbiome composition (summer);
LIHC	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.53	-6.72	-0.34	7.5e-11	Schizophrenia;
LIHC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-7.69	-0.38	1.55e-13	Psoriasis;
LIHC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.54	-8.8	-0.43	6.99e-17	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9341808	0.529	rs2322765	chr6:81064596	A/G	cg08355045	chr6:80787529	NA	0.34	6.9	0.35	2.54e-11	Sitting height ratio;
LIHC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg12798992	chr6:167411361	FGFR1OP	0.51	8.3	0.41	2.5e-15	Primary biliary cholangitis;
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.78	-12.09	-0.55	3.05e-28	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.41	-6.41	-0.33	4.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.2	0.55	1.13e-28	Coffee consumption (cups per day);
LIHC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02985541	chr2:219472218	PLCD4	0.41	7.5	0.38	5.49e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.42	6.24	0.32	1.3e-9	Menopause (age at onset);
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.15	0.36	5.4e-12	Lymphocyte counts;
LIHC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	5.72	0.3	2.32e-8	Mean platelet volume;
LIHC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.88	-0.3	9.64e-9	Lewy body disease;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg26541587	chr10:43950885	ZNF487	-0.42	-6.26	-0.32	1.17e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.18	-0.48	1.9e-21	Fibroblast growth factor basic levels;
LIHC	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.49	7.15	0.36	5.29e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.55	5.73	0.3	2.26e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg18016565	chr1:150552671	MCL1	0.48	9.03	0.44	1.3e-17	Tonsillectomy;
LIHC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.33	7.77	0.39	9.06e-14	Immature fraction of reticulocytes;
LIHC	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.51	-8.61	-0.42	2.64e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg07451762	chr16:28383216	NA	0.41	7.05	0.36	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.16	-0.32	2.05e-9	Colorectal cancer;
LIHC	cis	rs2274273	0.745	rs56262555	chr14:55561962	C/T	cg01864836	chr14:55583639	NA	-0.38	-6.57	-0.33	1.91e-10	Protein biomarker;
LIHC	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.93	0.54	1.17e-27	Coffee consumption (cups per day);
LIHC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg12046867	chr14:103022105	NA	0.48	6.93	0.35	2.14e-11	Platelet count;
LIHC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.78e-23	Hemoglobin concentration;
LIHC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.6	0.38	2.85e-13	Bipolar disorder;
LIHC	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.72	11.74	0.54	5.55e-27	Oral cavity cancer;
LIHC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.52	-8.28	-0.41	2.89e-15	Dental caries;
LIHC	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	6.15	0.32	2.15e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07080220	chr10:102295463	HIF1AN	0.45	6.15	0.32	2.12e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.95	-12.54	-0.56	5.9e-30	Obesity-related traits;
LIHC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg02290350	chr8:58132656	NA	0.43	8.72	0.43	1.24e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.42	-8.71	-0.43	1.29e-16	Abdominal aortic aneurysm;
LIHC	cis	rs6545883	0.894	rs12615783	chr2:61440947	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.13	-0.36	5.92e-12	Tuberculosis;
LIHC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-8.79	-0.43	7.28e-17	Crohn's disease;
LIHC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.69	-9.95	-0.47	1.23e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.28	0.32	1.03e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	22.02	0.77	1.55e-67	Body mass index (adult);
LIHC	cis	rs992157	0.730	rs2382828	chr2:219184492	A/G	cg00012203	chr2:219082015	ARPC2	0.76	10.74	0.5	2.16e-23	Colorectal cancer;
LIHC	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.72	7.17	0.36	4.68e-12	Alzheimer's disease;
LIHC	cis	rs11673344	0.542	rs826331	chr19:37498262	G/A	cg27390819	chr19:37464633	NA	-0.46	-6.12	-0.31	2.61e-9	Obesity-related traits;
LIHC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	1.01	19.18	0.72	3.65e-56	Breast cancer;
LIHC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.22	-0.36	3.34e-12	Bipolar disorder;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20064231	chr18:74608296	ZNF236	0.47	6.17	0.32	1.9e-9	Hepatitis;
LIHC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.35	-6.05	-0.31	3.73e-9	IgG glycosylation;
LIHC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.56	7.96	0.4	2.57e-14	Primary sclerosing cholangitis;
LIHC	cis	rs986417	1.000	rs6573312	chr14:60952536	G/T	cg27398547	chr14:60952738	C14orf39	0.83	9.68	0.46	9.59e-20	Gut microbiota (bacterial taxa);
LIHC	trans	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg25214090	chr10:38739885	LOC399744	-0.41	-6.82	-0.35	4.25e-11	Diastolic blood pressure;
LIHC	cis	rs2257205	0.667	rs9916423	chr17:56773834	T/C	cg12560992	chr17:57184187	TRIM37	0.72	7.97	0.4	2.33e-14	Pancreatic cancer;
LIHC	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.57	9.44	0.45	6.19e-19	Corneal astigmatism;
LIHC	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-6.65	-0.34	1.19e-10	Metabolite levels;
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.45	-5.73	-0.3	2.16e-8	Alzheimer's disease;
LIHC	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.25	0.72	1.81e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg15691649	chr6:25882328	NA	-0.53	-7.77	-0.39	9.49e-14	Blood metabolite levels;
LIHC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg17135325	chr3:160939158	NMD3	0.54	7.82	0.39	6.61e-14	Morning vs. evening chronotype;
LIHC	cis	rs2625529	0.823	rs11072332	chr15:72108307	G/T	cg16672083	chr15:72433130	SENP8	-0.32	-5.93	-0.31	7.3e-9	Red blood cell count;
LIHC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-14.98	-0.63	2.3e-39	Alzheimer's disease (late onset);
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15555402	chr12:19593456	AEBP2	-0.45	-6.35	-0.32	6.86e-10	Thyroid stimulating hormone;
LIHC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.32	0.37	1.76e-12	Menarche (age at onset);
LIHC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg20651018	chr11:3035856	CARS	-0.37	-6.33	-0.32	7.6e-10	Longevity;
LIHC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.36	5.93	0.31	7.39e-9	Height;
LIHC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.46	6.52	0.33	2.59e-10	Alcohol dependence;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	0.58	8.53	0.42	4.73e-16	Prudent dietary pattern;
LIHC	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.48	6.51	0.33	2.69e-10	Inflammatory skin disease;
LIHC	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	6.49	0.33	3.05e-10	Blood protein levels;
LIHC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg16586182	chr3:47516702	SCAP	0.41	7.21	0.36	3.71e-12	Colorectal cancer;
LIHC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.42	6.64	0.34	1.26e-10	Glycated hemoglobin levels;
LIHC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.14	0.36	5.5e-12	Lung cancer;
LIHC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.64	11.11	0.51	1.08e-24	Menopause (age at onset);
LIHC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg20140201	chr2:241835670	C2orf54	-0.5	-7.74	-0.39	1.14e-13	Urinary metabolites;
LIHC	trans	rs11225569	0.539	rs3910097	chr11:103244313	A/T	cg15013544	chr3:76558527	NA	0.35	6.34	0.32	7.22e-10	Diisocyanate-induced asthma;
LIHC	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.9	11.12	0.52	9.62e-25	Coronary artery disease;
LIHC	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.44	6.68	0.34	9.91e-11	Schizophrenia;
LIHC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg04450456	chr4:17643702	FAM184B	0.34	5.82	0.3	1.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.21	-12.46	-0.56	1.18e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg20991723	chr1:152506922	NA	0.54	9.45	0.46	5.37e-19	Hair morphology;
LIHC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-0.81	-6.84	-0.35	3.67e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.36	-6.08	-0.31	3.23e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.64	12.53	0.56	6.45e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.48	6.5	0.33	2.91e-10	Bipolar disorder;
LIHC	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.41	7.73	0.39	1.25e-13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LIHC	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg25783544	chr11:47291846	MADD	0.41	5.94	0.31	6.98e-9	HDL cholesterol;
LIHC	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg23431851	chr1:46668822	C1orf190;POMGNT1	0.46	7.39	0.37	1.1e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg27205649	chr11:78285834	NARS2	-0.37	-5.72	-0.3	2.3e-8	Testicular germ cell tumor;
LIHC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.68	-8.93	-0.43	2.74e-17	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.26	0.45	2.26e-18	Mean platelet volume;
LIHC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-11.61	-0.53	1.76e-26	Total cholesterol levels;
LIHC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg16970926	chr12:29381810	FAR2	0.3	6.24	0.32	1.27e-9	QT interval;
LIHC	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg11579907	chr6:151412213	MTHFD1L	-0.4	-6.15	-0.32	2.11e-9	Pain;
LIHC	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.3	7.21	0.36	3.54e-12	Blood protein levels;
LIHC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg15691649	chr6:25882328	NA	-0.52	-7.65	-0.38	2.07e-13	Blood metabolite levels;
LIHC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.56	9.72	0.47	6.98e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.58	-10.21	-0.48	1.53e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.39	6.37	0.33	6.28e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.43	8.13	0.4	8.01e-15	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.37	6.29	0.32	9.97e-10	Educational attainment;
LIHC	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.78	0.43	8.23e-17	Exhaled nitric oxide levels;
LIHC	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.33	7.22	0.36	3.4e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.42	-5.74	-0.3	2.05e-8	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	trans	rs12780046	0.611	rs10883275	chr10:100881693	G/T	cg05980083	chr9:112191166	PTPN3	-0.47	-6.08	-0.31	3.23e-9	Non-glioblastoma glioma;
LIHC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg20090690	chr10:134436459	INPP5A	-0.43	-5.83	-0.3	1.27e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08219700	chr8:58056026	NA	0.52	7.12	0.36	6.34e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	13.6	0.59	5.86e-34	Coffee consumption (cups per day);
LIHC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg03874509	chr1:107600012	PRMT6	-0.76	-11.93	-0.54	1.14e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.85	-0.35	3.39e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.45	-0.49	2.26e-22	Chronic sinus infection;
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.34	0.37	1.58e-12	Renal cell carcinoma;
LIHC	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg22771759	chr13:24902376	NA	0.33	6.79	0.34	5.09e-11	Obesity-related traits;
LIHC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.97	-0.44	1.96e-17	Skin colour saturation;
LIHC	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.57	-8.61	-0.42	2.76e-16	Blood protein levels;
LIHC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	1.03	10.38	0.49	4.11e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02985541	chr2:219472218	PLCD4	-0.43	-8.12	-0.4	8.78e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06002616	chr8:101225028	SPAG1	-0.34	-5.71	-0.3	2.44e-8	Atrioventricular conduction;
LIHC	cis	rs600806	0.888	rs3768497	chr1:109866230	T/C	cg16275483	chr1:110013120	SYPL2	-0.49	-6.11	-0.31	2.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6442522	0.526	rs13074638	chr3:15518889	T/C	cg16303742	chr3:15540471	COLQ	0.39	6.33	0.32	7.82e-10	Uric acid levels;
LIHC	cis	rs7619427	0.507	rs6806526	chr3:44015285	T/C	cg24966902	chr3:44043705	NA	0.44	6.83	0.35	3.83e-11	Schizophrenia;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.86	-17.46	-0.69	3.01e-49	Prudent dietary pattern;
LIHC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07305463	chr2:136567211	LCT	-0.4	-7.52	-0.38	4.99e-13	Mosquito bite size;
LIHC	cis	rs747782	0.646	rs58119589	chr11:47571956	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-6.14	-0.31	2.34e-9	Intraocular pressure;
LIHC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.57	-9.68	-0.46	9.91e-20	Blood metabolite levels;
LIHC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.58	-12.02	-0.54	5.4e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.59	7.39	0.37	1.16e-12	Chronic sinus infection;
LIHC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.71	10.55	0.5	1.04e-22	Aortic root size;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.46	-0.33	3.52e-10	Renal cell carcinoma;
LIHC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg23422044	chr7:1970798	MAD1L1	-0.51	-5.81	-0.3	1.41e-8	Neuroticism;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg10795676	chr6:26370623	BTN3A2	0.42	6.17	0.32	1.97e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.5	6.98	0.35	1.55e-11	Aortic root size;
LIHC	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.38	5.81	0.3	1.46e-8	Alzheimer's disease (survival time);
LIHC	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.99	0.44	1.77e-17	Coffee consumption (cups per day);
LIHC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.47	-7.94	-0.39	3.01e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.13	0.58	3.68e-32	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.03	-0.48	6.24e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.83	13.53	0.59	1.02e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.37	0.41	1.53e-15	Lung cancer in ever smokers;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17015704	chr6:119400380	FAM184A	0.46	6.52	0.33	2.53e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.46	-7.85	-0.39	5.48e-14	Male sexual orientation;
LIHC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg26395211	chr5:140044315	WDR55	-0.41	-6.13	-0.31	2.41e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs225245	0.610	rs321607	chr17:33880584	A/G	cg05299278	chr17:33885742	SLFN14	0.23	6.06	0.31	3.62e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs668210	0.947	rs559161	chr11:65761637	A/G	cg17712092	chr4:129076599	LARP1B	0.59	7.45	0.37	7.88e-13	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00080333	chr4:184492770	NA	0.38	6.91	0.35	2.44e-11	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02004021	chr12:95868393	METAP2	0.43	6.09	0.31	2.98e-9	Pancreatic cancer;
LIHC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	1.06	14.25	0.61	1.67e-36	Body mass index;
LIHC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.51	10.75	0.5	1.98e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.69	-12.46	-0.56	1.27e-29	Height;
LIHC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.73	-0.3	2.21e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.34	-6.89	-0.35	2.74e-11	Testicular germ cell tumor;
LIHC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.48	-7.8	-0.39	7.71e-14	Longevity;Endometriosis;
LIHC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.53	8.09	0.4	1.07e-14	Resting heart rate;
LIHC	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg00204748	chr12:29376779	FAR2	0.38	6.84	0.35	3.73e-11	QT interval;
LIHC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.55	9.89	0.47	1.95e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg06238570	chr21:40685208	BRWD1	-0.38	-6.1	-0.31	2.86e-9	Menarche (age at onset);
LIHC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg11764359	chr7:65958608	NA	-0.55	-5.72	-0.3	2.29e-8	Diabetic kidney disease;
LIHC	cis	rs9918079	0.560	rs6449153	chr4:15631216	C/T	cg21123203	chr4:15471301	CC2D2A	-0.41	-5.92	-0.3	7.89e-9	Obesity-related traits;
LIHC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.84	8.27	0.41	3.06e-15	Body mass index;
LIHC	cis	rs4407350	0.806	rs5765706	chr22:44909045	A/G	cg04154583	chr22:44889756	LDOC1L	0.3	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	6.94	0.35	1.94e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg18944383	chr4:111397179	ENPEP	-0.35	-8.09	-0.4	1.08e-14	Height;
LIHC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.42	-5.74	-0.3	2.06e-8	Life satisfaction;
LIHC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.23	-0.41	3.93e-15	Type 2 diabetes;
LIHC	cis	rs16828019	0.852	rs12759023	chr1:41603978	T/C	cg20697417	chr1:41786797	NA	0.35	6.64	0.34	1.24e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	0.745	rs748017	chr14:55542300	A/G	cg01864836	chr14:55583639	NA	-0.4	-6.44	-0.33	3.98e-10	Protein biomarker;
LIHC	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg15654264	chr1:150340011	RPRD2	0.49	8.18	0.4	5.55e-15	Migraine;
LIHC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.18	0.32	1.77e-9	Renal cell carcinoma;
LIHC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.42	6.82	0.35	4.14e-11	Red blood cell count;
LIHC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.6	0.56	3.71e-30	Colorectal cancer;
LIHC	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.32	5.96	0.31	6.23e-9	Body mass index;
LIHC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.52	-6.42	-0.33	4.47e-10	Menarche (age at onset);
LIHC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-6.1	-0.31	2.91e-9	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.3e-9	Aortic root size;
LIHC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.28	-5.72	-0.3	2.3e-8	Aortic root size;
LIHC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.66	-5.97	-0.31	5.89e-9	Menopause (age at onset);
LIHC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	3.96e-13	Electroencephalogram traits;
LIHC	trans	rs2363709	1.000	rs2363709	chr3:67417105	G/A	cg15775005	chr18:9136598	ANKRD12	-0.79	-6.05	-0.31	3.71e-9	IgE levels;
LIHC	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.35	-0.32	6.94e-10	Response to antipsychotic treatment;
LIHC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg07671805	chr5:74907694	NA	-0.55	-6.5	-0.33	2.77e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.43	-0.33	4.36e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.71	10.36	0.49	4.8e-22	Selective IgA deficiency;
LIHC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-10.71	-0.5	2.77e-23	Crohn's disease;
LIHC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.55e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.63	-8.53	-0.42	4.75e-16	Asthma;
LIHC	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.2	-6.32	-0.32	8.03e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-0.94	-9.22	-0.45	3.24e-18	Type 2 diabetes nephropathy;
LIHC	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.71	-0.69	2.95e-50	Schizophrenia;
LIHC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.42	-5.86	-0.3	1.08e-8	Initial pursuit acceleration;
LIHC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	7.43	0.37	8.83e-13	Obesity-related traits;
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.66	9.78	0.47	4.36e-20	Menarche (age at onset);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg11702503	chr19:6215254	MLLT1	0.43	6.32	0.32	8.24e-10	Longevity;
LIHC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.55	-7.79	-0.39	8.36e-14	Blood metabolite levels;
LIHC	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.48	-10.3	-0.49	7.81e-22	White blood cell count (basophil);
LIHC	cis	rs4664304	0.764	rs2063440	chr2:160800102	A/C	cg23995753	chr2:160760732	LY75	-0.38	-5.71	-0.3	2.45e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.76	14.51	0.62	1.66e-37	Mortality in heart failure;
LIHC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.16	0.32	2.01e-9	Menopause (age at onset);
LIHC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.71	8.55	0.42	4.28e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.53	8.51	0.42	5.4e-16	Multiple myeloma (IgH translocation);
LIHC	cis	rs9303280	1.000	rs9303280	chr17:38074031	T/C	cg11212589	chr17:38028394	ZPBP2	-0.33	-6.64	-0.34	1.21e-10	Self-reported allergy;
LIHC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-6.05	-0.31	3.74e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20135002	chr11:47629003	NA	0.52	8.72	0.43	1.26e-16	Subjective well-being;
LIHC	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.55	8.31	0.41	2.24e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg11861562	chr11:117069780	TAGLN	0.4	6.53	0.33	2.4e-10	Blood protein levels;
LIHC	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.71	-11.3	-0.52	2.35e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2302777	0.507	rs1007655	chr17:38111419	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-7.29	-0.37	2.19e-12	Multiple myeloma (hyperdiploidy);
LIHC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.87	9.92	0.47	1.51e-20	Initial pursuit acceleration;
LIHC	cis	rs6988985	0.560	rs4736346	chr8:143951849	G/T	cg23373978	chr8:143916136	GML	-0.28	-6.03	-0.31	4.15e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LIHC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.64	10.95	0.51	4.12e-24	Colorectal cancer;
LIHC	cis	rs7165170	0.529	rs3743406	chr15:91161548	A/G	cg26821196	chr15:91095069	CRTC3	0.31	5.83	0.3	1.27e-8	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.39	5.78	0.3	1.7e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs1775715	0.966	rs1755067	chr10:32296195	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.41	-7.29	-0.37	2.11e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	trans	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg26939375	chr7:64535504	NA	0.41	6.3	0.32	9.23e-10	Aortic root size;
LIHC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg16586182	chr3:47516702	SCAP	0.51	9.01	0.44	1.45e-17	Colorectal cancer;
LIHC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.53	6.92	0.35	2.3e-11	Initial pursuit acceleration;
LIHC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.58	7.84	0.39	5.93e-14	Bone mineral density (spine);
LIHC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.81	12.98	0.57	1.4e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.23	-24.25	-0.8	2.8299999999999997e-76	Chronic sinus infection;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg04915975	chr3:139063070	MRPS22	-0.41	-6.05	-0.31	3.85e-9	Morning vs. evening chronotype;
LIHC	cis	rs6191	0.904	rs864354	chr5:142634708	T/G	cg17617527	chr5:142782415	NR3C1	0.41	5.71	0.3	2.46e-8	Night sleep phenotypes;
LIHC	trans	rs7448080	0.702	rs62371232	chr5:123339637	A/G	cg23779626	chr6:33864747	NA	-0.59	-6.06	-0.31	3.62e-9	Alcohol dependence (age at onset);
LIHC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-19.47	-0.73	2.43e-57	Height;
LIHC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.62	-9.29	-0.45	1.8e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.3	7.12	0.36	6.25e-12	Blood protein levels;
LIHC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.5	-7.45	-0.37	7.47e-13	Total body bone mineral density;
LIHC	cis	rs4878497	0.646	rs10758139	chr9:32435676	A/G	cg14296220	chr9:32431791	ACO1	0.58	10.02	0.48	6.65e-21	Inflammatory skin disease;
LIHC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.38	8.2	0.41	5.01e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.55	-7.83	-0.39	6e-14	Menarche (age at onset);
LIHC	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.52	-9.02	-0.44	1.36e-17	Leprosy;
LIHC	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.35	23.91	0.79	5.61e-75	Corneal structure;
LIHC	cis	rs4908768	0.859	rs12131717	chr1:8718085	G/A	cg20416874	chr1:8611966	RERE	0.48	6.88	0.35	2.82e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg25356066	chr3:128598488	ACAD9	0.53	7.41	0.37	1e-12	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08677398	chr8:58056175	NA	0.41	6.38	0.33	5.63e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06837242	chr1:19578761	MRTO4;KIAA0090	-0.47	-6.08	-0.31	3.26e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04317338	chr11:64019027	PLCB3	0.49	6.69	0.34	9.11e-11	Platelet count;
LIHC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02985541	chr2:219472218	PLCD4	0.48	9.11	0.44	7.27e-18	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.58	-9.93	-0.47	1.4e-20	Sum eosinophil basophil counts;
LIHC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21448741	chr8:58168803	NA	0.32	6.15	0.32	2.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.42	6.78	0.34	5.34e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.79	8.97	0.44	1.99e-17	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02290350	chr8:58132656	NA	0.48	9.92	0.47	1.54e-20	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.45	7.69	0.38	1.58e-13	Mean corpuscular volume;
LIHC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.44	-6.86	-0.35	3.2e-11	Schizophrenia;
LIHC	trans	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg04373760	chr16:53404718	NA	0.59	7.65	0.38	2e-13	Hypertriglyceridemia;
LIHC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-11.02	-0.51	2.22e-24	Alzheimer's disease;
LIHC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.56	9.16	0.44	4.94e-18	Body mass index;
LIHC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs8064024	0.620	rs9923349	chr16:4905124	A/G	cg08329684	chr16:4932620	PPL	0.33	5.75	0.3	1.97e-8	Cancer;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg11726039	chr2:208490019	FAM119A	-0.36	-6.1	-0.31	2.83e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.43	-8.06	-0.4	1.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg12253828	chr6:101329408	ASCC3	0.42	6.47	0.33	3.46e-10	Neuroticism;
LIHC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg16275483	chr1:110013120	SYPL2	-0.48	-6.09	-0.31	3.02e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs12431939	1.000	rs7140375	chr14:51637242	T/G	cg23942311	chr14:51606299	NA	-0.35	-5.84	-0.3	1.21e-8	Cancer;
LIHC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.6	0.64	7.97e-42	Chronic sinus infection;
LIHC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.37	-6.17	-0.32	1.98e-9	IgG glycosylation;
LIHC	cis	rs2163237	0.965	rs10190131	chr2:55983605	A/G	cg03859395	chr2:55845619	SMEK2	-0.42	-6.35	-0.32	6.77e-10	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03634887	chr16:66730948	CMTM4	0.42	6.47	0.33	3.35e-10	Cognitive function;
LIHC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.7	-9.3	-0.45	1.77e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.55	-10.75	-0.5	2.1e-23	Myopia (pathological);
LIHC	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg18478394	chr8:109455254	TTC35	0.36	6.36	0.33	6.5e-10	Dupuytren's disease;
LIHC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg06497051	chr1:156261200	TMEM79	0.37	5.98	0.31	5.62e-9	Tonsillectomy;
LIHC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	9.45	0.45	5.67e-19	Platelet count;
LIHC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-8.7	-0.43	1.44e-16	Gut microbiome composition (summer);
LIHC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.65	12.7	0.57	1.59e-30	Schizophrenia;
LIHC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.68	-10.63	-0.5	5.19e-23	Skin colour saturation;
LIHC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs847649	0.618	rs6465880	chr7:102515237	T/C	cg18108683	chr7:102477205	FBXL13	-0.48	-7.28	-0.37	2.25e-12	Morning vs. evening chronotype;
LIHC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.14	-0.36	5.59e-12	Body mass index;
LIHC	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.37	-6.66	-0.34	1.07e-10	Height;
LIHC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.52	7.89	0.39	4.05e-14	Type 2 diabetes;
LIHC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	trans	rs7721647	0.810	rs16869794	chr5:90797619	C/T	cg10859192	chr12:54071672	ATP5G2	-0.41	-6.07	-0.31	3.34e-9	Breast cancer;
LIHC	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.48e-9	Resting heart rate;
LIHC	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg24579218	chr15:68104479	NA	-0.34	-5.94	-0.31	7.12e-9	Restless legs syndrome;
LIHC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	5.91	0.3	8.44e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.8	11.47	0.53	5.55e-26	Coronary artery disease;
LIHC	cis	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg01364799	chr7:75623366	TMEM120A	-0.46	-6.63	-0.34	1.28e-10	Eotaxin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23097686	chr12:98910128	TMPO;LOC100128191	0.55	7.04	0.36	1.09e-11	Lung function (FEV1/FVC);
LIHC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.43	6.41	0.33	4.97e-10	Lymphocyte counts;
LIHC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.33	-0.52	1.7e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg24296786	chr1:45957014	TESK2	0.46	6.79	0.34	5.12e-11	Platelet count;
LIHC	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.6	-8.14	-0.4	7.32e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.37e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.57	8.97	0.44	2.03e-17	Corneal astigmatism;
LIHC	cis	rs35892873	0.501	rs4299436	chr3:126096047	C/T	cg15490784	chr3:126061950	KLF15	-0.4	-5.85	-0.3	1.15e-8	Male-pattern baldness;
LIHC	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg03934865	chr2:198174659	NA	-0.54	-8.14	-0.4	7.61e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.51	0.49	1.47e-22	Bladder cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05880217	chr17:79846343	THOC4	-0.39	-6.05	-0.31	3.81e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg17279839	chr7:150038598	RARRES2	0.39	7.85	0.39	5.4e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.89	11.69	0.53	9.04e-27	Heart rate;
LIHC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.48	7.79	0.39	8.07e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.61	-0.38	2.73e-13	Total body bone mineral density;
LIHC	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.57	-0.42	3.61e-16	Obesity-related traits;
LIHC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg21231739	chr4:1642635	FAM53A	-0.38	-6.1	-0.31	2.82e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.42	-6.96	-0.35	1.76e-11	Educational attainment;
LIHC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs832187	0.594	rs832197	chr3:63884292	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.43	6.11	0.31	2.66e-9	Schizophrenia;
LIHC	cis	rs6445797	0.855	rs7646924	chr3:56570947	G/C	cg13792233	chr3:56591045	CCDC66	-0.39	-5.73	-0.3	2.17e-8	Gastritis;
LIHC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.44	5.97	0.31	5.83e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.52	6.2	0.32	1.66e-9	Height;
LIHC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-0.8	-8.38	-0.41	1.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.69	7.12	0.36	6.52e-12	Vitiligo;
LIHC	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.44	7.28	0.37	2.26e-12	Corneal astigmatism;
LIHC	cis	rs17106184	1.000	rs12071359	chr1:51388895	G/A	cg07174182	chr1:51127561	FAF1	-0.76	-8.7	-0.43	1.44e-16	Type 2 diabetes;
LIHC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs911119	0.955	rs17751897	chr20:23592714	T/C	cg16589663	chr20:23618590	CST3	0.72	7.62	0.38	2.6e-13	Chronic kidney disease;
LIHC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.44	-6.54	-0.33	2.24e-10	Asthma (sex interaction);
LIHC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	8.0	0.4	1.99e-14	Tonsillectomy;
LIHC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.18	-26.78	-0.82	6.04e-86	Myeloid white cell count;
LIHC	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.38	-0.33	5.7e-10	Metabolite levels;
LIHC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.23	5.73	0.3	2.19e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg25457927	chr22:38595422	NA	0.33	8.32	0.41	2.08e-15	Cutaneous nevi;
LIHC	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-0.77	-10.29	-0.49	7.99e-22	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	1.0	17.15	0.68	5.23e-48	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.78	-9.25	-0.45	2.43e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.47	6.27	0.32	1.06e-9	Height;
LIHC	cis	rs3733606	1.000	rs3733606	chr4:6883012	A/G	cg05012661	chr4:6891264	NA	-0.35	-5.79	-0.3	1.58e-8	Platelet count;
LIHC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.39	5.73	0.3	2.19e-8	Alcohol dependence;
LIHC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.25	0.55	7.28e-29	Alzheimer's disease;
LIHC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09835421	chr16:68378352	PRMT7	-0.54	-6.13	-0.31	2.41e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	1.03	10.58	0.5	7.82e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg23091122	chr1:110024289	SYPL2	-0.45	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.42	0.41	1.05e-15	Motion sickness;
LIHC	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg02023728	chr11:77925099	USP35	0.35	6.26	0.32	1.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2421770	0.530	rs3901811	chr11:35365675	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.59	-0.38	3.02e-13	Staphylococcus aureus nasal carriage (persistent);
LIHC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.5	7.74	0.39	1.17e-13	Diastolic blood pressure;
LIHC	cis	rs6066825	0.555	rs4810849	chr20:47289944	C/T	cg18078177	chr20:47281410	PREX1	0.41	6.79	0.34	4.97e-11	Colorectal cancer;
LIHC	cis	rs847649	0.732	rs56269620	chr7:102489456	A/G	cg18108683	chr7:102477205	FBXL13	-0.51	-8.1	-0.4	9.83e-15	Morning vs. evening chronotype;
LIHC	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg09065629	chr16:1709722	CRAMP1L	0.85	10.15	0.48	2.46e-21	Snoring;
LIHC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.68	-9.8	-0.47	3.83e-20	Mosquito bite size;
LIHC	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.72	-11.32	-0.52	1.84e-25	White matter hyperintensity burden;
LIHC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-5.86	-0.3	1.08e-8	Ulcerative colitis;
LIHC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.36	-6.62	-0.34	1.36e-10	Sudden cardiac arrest;
LIHC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.92	12.98	0.57	1.38e-31	Primary sclerosing cholangitis;
LIHC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg23205692	chr1:25664452	TMEM50A	0.39	6.21	0.32	1.54e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-5.81	-0.3	1.42e-8	Coronary artery disease;
LIHC	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.58	-8.37	-0.41	1.45e-15	Prostate cancer;
LIHC	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-7.75	-0.39	1.06e-13	QT interval;
LIHC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.45	7.76	0.39	1.02e-13	Schizophrenia;
LIHC	cis	rs2016586	0.796	rs972153	chr22:36100410	C/A	cg26342177	chr22:36113512	APOL5	-0.43	-7.1	-0.36	7.2e-12	Body mass index;
LIHC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.38	0.59	4.02e-33	Psoriasis;
LIHC	trans	rs9914544	0.545	rs12942794	chr17:18767217	A/C	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.58	-0.34	1.8e-10	Educational attainment (years of education);
LIHC	cis	rs7106204	0.590	rs7114724	chr11:24239976	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	11.73	0.54	5.97e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20609344	chr11:101785659	KIAA1377;ANGPTL5	-0.48	-6.05	-0.31	3.81e-9	Lung function (FEV1);
LIHC	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.5	-8.42	-0.41	1.08e-15	Myopia;
LIHC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.83	0.43	5.6e-17	Lung cancer in ever smokers;
LIHC	trans	rs11689435	0.925	rs4278910	chr2:218349910	T/G	cg13544946	chr9:35729779	TLN1	-0.42	-6.14	-0.32	2.24e-9	Metabolite levels (MHPG);
LIHC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.57	8.78	0.43	8.14e-17	Platelet distribution width;
LIHC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg26395211	chr5:140044315	WDR55	0.4	5.97	0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.86	0.43	4.31e-17	Prudent dietary pattern;
LIHC	trans	rs7428850	0.803	rs12638750	chr3:24087133	T/C	cg07387471	chr17:34795793	TBC1D3C	0.61	6.07	0.31	3.38e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LIHC	cis	rs7395581	0.959	rs2167079	chr11:47270255	C/T	cg26139080	chr11:47293733	MADD	-0.49	-8.26	-0.41	3.31e-15	HDL cholesterol;
LIHC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.46	6.3	0.32	9.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.89	-0.51	6.33e-24	Chronic sinus infection;
LIHC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.85	-0.3	1.17e-8	Aortic root size;
LIHC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.81	12.71	0.57	1.41e-30	Total body bone mineral density;
LIHC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.58	8.22	0.41	4.2e-15	Aortic root size;
LIHC	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg25124228	chr12:125621409	AACS	-0.43	-6.6	-0.34	1.59e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.48	6.41	0.33	4.91e-10	Blood metabolite levels;
LIHC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.72	0.3	2.36e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.41	-6.0	-0.31	4.9e-9	Calcium levels;
LIHC	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.68	-10.48	-0.49	1.78e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.6	-0.46	1.83e-19	Initial pursuit acceleration;
LIHC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.78	-13.63	-0.59	4.46e-34	Aortic root size;
LIHC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg18904891	chr8:8559673	CLDN23	0.4	5.77	0.3	1.77e-8	Mood instability;
LIHC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.15	-0.32	2.17e-9	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg18334142	chr5:158636736	NA	0.47	6.43	0.33	4.27e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.57	-6.41	-0.33	4.91e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1144333	0.655	rs76794487	chr1:76384055	G/A	cg03433033	chr1:76189801	ACADM	0.52	7.28	0.37	2.26e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg15269541	chr15:43626905	ADAL	-0.3	-5.78	-0.3	1.7e-8	Lung cancer in ever smokers;
LIHC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.52	-7.96	-0.4	2.61e-14	Menarche (age at onset);
LIHC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.38	-5.86	-0.3	1.11e-8	Self-reported allergy;
LIHC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.13	0.4	8.21e-15	IgG glycosylation;
LIHC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg03037974	chr15:76606532	NA	0.71	13.6	0.59	5.9e-34	Blood metabolite levels;
LIHC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.24	-7.36	-0.37	1.36e-12	Mean corpuscular volume;
LIHC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.67	8.71	0.43	1.29e-16	Schizophrenia;
LIHC	cis	rs10838687	1.000	rs6485751	chr11:47336442	G/C	cg26139080	chr11:47293733	MADD	-0.44	-6.34	-0.32	7.29e-10	Proinsulin levels;
LIHC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4517514	0.509	rs4385851	chr11:89870750	C/T	cg05041596	chr11:89867385	NAALAD2	0.4	6.4	0.33	5.17e-10	Trans fatty acid levels;
LIHC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.13	0.55	2.1e-28	Mean platelet volume;
LIHC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.4	0.37	1.07e-12	Morning vs. evening chronotype;
LIHC	cis	rs8062405	0.540	rs193628	chr16:28582142	G/T	cg00204512	chr16:28754710	NA	-0.3	-5.83	-0.3	1.3e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg07424592	chr7:64974309	NA	-0.8	-9.25	-0.45	2.55e-18	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg11764359	chr7:65958608	NA	0.58	6.03	0.31	4.22e-9	Diabetic kidney disease;
LIHC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	1.01	10.14	0.48	2.6e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg03037974	chr15:76606532	NA	0.74	14.58	0.62	8.72e-38	Blood metabolite levels;
LIHC	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.68	6.92	0.35	2.19e-11	Inflammatory bowel disease;
LIHC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-10.02	-0.48	6.88e-21	Lymphocyte percentage of white cells;
LIHC	cis	rs611744	0.967	rs613644	chr8:109188994	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.08	0.31	3.16e-9	Tonsillectomy;
LIHC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.75	0.39	1.07e-13	Prudent dietary pattern;
LIHC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	22.68	0.78	3.75e-70	Chronic sinus infection;
LIHC	cis	rs7267979	0.565	rs3752273	chr20:25594783	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.43	-5.92	-0.31	7.68e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-9.85	-0.47	2.63e-20	Mean corpuscular volume;
LIHC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.76	-0.3	1.86e-8	Uric acid levels;
LIHC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg18279126	chr7:2041391	MAD1L1	0.38	6.42	0.33	4.44e-10	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.65	0.42	1.99e-16	Motion sickness;
LIHC	cis	rs4853036	0.857	rs1048139	chr2:70131791	T/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.28	-0.32	1.02e-9	Colorectal or endometrial cancer;
LIHC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.73	10.95	0.51	4.14e-24	Response to antineoplastic agents;
LIHC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-10.89	-0.51	6.6e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.38	-6.67	-0.34	1.05e-10	Schizophrenia;
LIHC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-8.9	-0.43	3.35e-17	Chronic sinus infection;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg18502306	chr4:8376764	ACOX3	-0.39	-6.14	-0.32	2.29e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-8.13	-0.4	8.12e-15	Colorectal cancer;
LIHC	cis	rs6750047	0.585	rs168054	chr2:38260282	C/G	cg07380506	chr2:38303506	CYP1B1	-0.57	-7.25	-0.36	2.83e-12	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs3015497	0.967	rs8018308	chr14:51122633	T/C	cg09863266	chr14:51125203	SAV1	-0.4	-6.46	-0.33	3.64e-10	Mean platelet volume;
LIHC	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.61	-10.53	-0.49	1.19e-22	Pediatric autoimmune diseases;
LIHC	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-6.52	-0.33	2.47e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs6504950	0.745	rs12949718	chr17:52981853	A/G	cg10237252	chr17:52977213	TOM1L1	0.34	6.07	0.31	3.35e-9	Breast cancer;
LIHC	cis	rs7534824	0.625	rs61780332	chr1:101484733	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	6.98	0.35	1.57e-11	Refractive astigmatism;
LIHC	trans	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg23114964	chr1:42217077	HIVEP3	0.41	6.18	0.32	1.79e-9	Chronic kidney disease;
LIHC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.04	0.31	4.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.92	-0.35	2.28e-11	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.4	8.24	0.41	3.63e-15	Renal cell carcinoma;
LIHC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.55	0.33	2.16e-10	Renal cell carcinoma;
LIHC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.66	9.92	0.47	1.53e-20	Menarche (age at onset);
LIHC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-8.16	-0.4	6.68e-15	Schizophrenia;
LIHC	cis	rs926392	0.640	rs1007913	chr20:37693592	G/A	cg16355469	chr20:37678765	NA	0.45	6.58	0.34	1.75e-10	Dialysis-related mortality;
LIHC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.35	-5.84	-0.3	1.25e-8	Type 2 diabetes;
LIHC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.68	-9.87	-0.47	2.22e-20	Initial pursuit acceleration;
LIHC	cis	rs244293	0.831	rs7209029	chr17:53173046	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.55	0.38	4.05e-13	Menarche (age at onset);
LIHC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg13271783	chr10:134563150	INPP5A	-0.61	-7.26	-0.37	2.69e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.57	-7.6	-0.38	2.86e-13	Menopause (age at onset);
LIHC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.39	6.28	0.32	9.99e-10	Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.07	0.31	3.42e-9	Alzheimer's disease;
LIHC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.81	16.52	0.67	1.76e-45	Gestational age at birth (maternal effect);
LIHC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.44	-6.0	-0.31	5.09e-9	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.65e-16	Motion sickness;
LIHC	cis	rs7633770	0.643	rs1581325	chr3:46691866	T/C	cg11219411	chr3:46661640	NA	-0.35	-5.85	-0.3	1.14e-8	Coronary artery disease;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg14729855	chr6:34204698	HMGA1	0.51	6.45	0.33	3.93e-10	Glycated hemoglobin levels;
LIHC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	trans	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg01596870	chr19:55963115	NA	-0.63	-8.3	-0.41	2.39e-15	Obesity-related traits;
LIHC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs2637266	0.935	rs1907323	chr10:78336015	C/T	cg18941641	chr10:78392320	NA	0.28	6.18	0.32	1.79e-9	Pulmonary function;
LIHC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg19680672	chr10:131412579	MGMT	-0.42	-6.55	-0.33	2.05e-10	Response to temozolomide;
LIHC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg06766960	chr11:133703094	NA	-0.62	-9.72	-0.47	6.83e-20	Childhood ear infection;
LIHC	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-9.0	-0.44	1.62e-17	Type 2 diabetes;
LIHC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg05170863	chr8:109261119	EIF3E	0.44	6.15	0.32	2.18e-9	Thyroid cancer;
LIHC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.19	-0.36	4.09e-12	Axial length;
LIHC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.44	-7.15	-0.36	5.31e-12	Corneal astigmatism;
LIHC	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg15105060	chr4:7024189	TBC1D14	-0.72	-6.04	-0.31	3.96e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-10.32	-0.49	6.5e-22	Alzheimer's disease;
LIHC	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.44	7.16	0.36	5.01e-12	Educational attainment;
LIHC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.34	5.72	0.3	2.31e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.49	-7.73	-0.39	1.23e-13	Cocaine dependence;
LIHC	cis	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.37	5.76	0.3	1.86e-8	Eotaxin levels;
LIHC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.99	0.48	8.86e-21	Platelet count;
LIHC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	10.0	0.48	8.1899999999999992e-21	Chronic sinus infection;
LIHC	cis	rs7581030	0.958	rs6761251	chr2:71521191	T/G	cg07678644	chr2:71558969	ZNF638	0.46	6.64	0.34	1.25e-10	Testicular germ cell tumor;
LIHC	cis	rs7911264	0.628	rs7078243	chr10:94414263	A/C	cg00519463	chr10:94352821	KIF11	-0.46	-6.33	-0.32	7.82e-10	Inflammatory bowel disease;
LIHC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.39	6.32	0.32	8.12e-10	Red blood cell count;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.66	-10.09	-0.48	4.03e-21	Renal cell carcinoma;
LIHC	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.75	-11.45	-0.53	6.58e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.68	-9.71	-0.47	7.32e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg26395211	chr5:140044315	WDR55	0.41	5.97	0.31	5.94e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	8.83	0.43	5.5e-17	Height;
LIHC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.71	-14.29	-0.61	1.24e-36	Brugada syndrome;
LIHC	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	9.53	0.46	2.97e-19	Morning vs. evening chronotype;
LIHC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.65	12.85	0.57	4.18e-31	Sense of smell;
LIHC	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg11783602	chr8:55087084	NA	-0.31	-6.21	-0.32	1.53e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.28e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.96e-38	Blood metabolite levels;
LIHC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.5	6.9	0.35	2.54e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg08824895	chr13:115047677	UPF3A	0.41	5.88	0.3	1e-8	Schizophrenia;
LIHC	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.59	9.7	0.46	8.2e-20	Corneal astigmatism;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg26939375	chr7:64535504	NA	-0.43	-7.33	-0.37	1.67e-12	Calcium levels;
LIHC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.87	13.18	0.58	2.36e-32	Lymphocyte percentage of white cells;
LIHC	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-0.6	-7.36	-0.37	1.4e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg04691961	chr3:161091175	C3orf57	-0.33	-5.75	-0.3	1.93e-8	Morning vs. evening chronotype;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11987759	chr7:65425863	GUSB	-0.39	-6.15	-0.32	2.22e-9	Calcium levels;
LIHC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.95	11.14	0.52	8.8e-25	Triglycerides;
LIHC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.54	-18.37	-0.7	6.36e-53	Breast cancer;
LIHC	cis	rs965469	1.000	rs6037562	chr20:3326141	A/C	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.59e-11	IFN-related cytopenia;
LIHC	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	0.99	14.04	0.6	1.09e-35	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.57	-0.33	1.9e-10	Bipolar disorder;
LIHC	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg26139080	chr11:47293733	MADD	-0.5	-8.38	-0.41	1.37e-15	HDL cholesterol;
LIHC	trans	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg09872104	chr7:134855509	C7orf49	-0.83	-6.55	-0.33	2.17e-10	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.56	6.93	0.35	2.08e-11	Parkinson's disease;
LIHC	cis	rs2016586	0.929	rs8136655	chr22:36111820	G/A	cg26342177	chr22:36113512	APOL5	-0.38	-6.3	-0.32	9.32e-10	Body mass index;
LIHC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12463550	chr7:65579703	CRCP	0.68	7.32	0.37	1.82e-12	Diabetic kidney disease;
LIHC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.76	13.98	0.6	1.96e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.36	-5.85	-0.3	1.12e-8	Body mass index;
LIHC	cis	rs509477	0.690	rs273354	chr18:32598235	T/C	cg23791764	chr18:32556832	MAPRE2	0.46	6.19	0.32	1.77e-9	Cerebrospinal fluid AB1-42 levels;
LIHC	cis	rs2274273	1.000	rs74617736	chr14:55620919	C/T	cg01864836	chr14:55583639	NA	-0.35	-5.82	-0.3	1.36e-8	Protein biomarker;
LIHC	cis	rs74181299	0.533	rs984748	chr2:65369964	A/G	cg05010058	chr2:65284262	CEP68	-0.36	-5.73	-0.3	2.17e-8	Pulse pressure;
LIHC	cis	rs10861342	1.000	rs12229846	chr12:105553066	A/C	cg23923672	chr12:105501055	KIAA1033	0.65	7.57	0.38	3.52e-13	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24063238	chr17:56085336	SFRS1	0.42	6.08	0.31	3.15e-9	Cognitive function;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.65	-9.98	-0.47	9.37e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	trans	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg16088116	chr21:44841560	SIK1	-0.4	-6.2	-0.32	1.6e-9	Coronary artery disease;
LIHC	trans	rs10095849	0.576	rs13260129	chr8:39477848	A/C	cg23465891	chr13:113420166	ATP11A	-0.4	-6.5	-0.33	2.86e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg03146154	chr1:46216737	IPP	-0.4	-6.75	-0.34	6.52e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10426930	0.607	rs56251289	chr19:5042732	C/A	cg18473234	chr19:5097819	KDM4B	0.58	6.74	0.34	6.81e-11	Monocyte percentage of white cells;
LIHC	cis	rs7129556	0.520	rs12290511	chr11:77266663	T/G	cg03570279	chr11:77446074	RSF1	-0.35	-6.5	-0.33	2.78e-10	Weight loss (gastric bypass surgery);
LIHC	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg01320579	chr17:75405842	SEPT9	0.53	6.91	0.35	2.36e-11	Airflow obstruction;
LIHC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	1.07	12.48	0.56	9.98e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg12903224	chr12:29470962	FAR2	-0.37	-5.91	-0.3	8.31e-9	QT interval;
LIHC	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.2	13.64	0.59	3.87e-34	Opioid sensitivity;
LIHC	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.59	-9.74	-0.47	6.26e-20	Retinal vascular caliber;
LIHC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13647721	chr17:30228624	UTP6	0.79	7.44	0.37	8.07e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.43	-7.09	-0.36	7.56e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.59	-0.34	1.72e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs12980942	0.591	rs4591267	chr19:41765407	A/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	7.09	0.36	7.54e-12	Coronary artery disease;
LIHC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.4	6.58	0.34	1.77e-10	Red blood cell count;
LIHC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.04	0.4	1.47e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg17074339	chr11:11642133	GALNTL4	0.44	6.93	0.35	2.14e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.39	6.44	0.33	3.94e-10	Lewy body disease;
LIHC	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.64	-10.17	-0.48	2.06e-21	Rheumatoid arthritis;
LIHC	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	0.85	10.95	0.51	3.91e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg16586182	chr3:47516702	SCAP	0.43	7.44	0.37	8.05e-13	Colorectal cancer;
LIHC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.47	7.19	0.36	4.07e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg04352962	chr1:209979756	IRF6	0.4	6.17	0.32	1.89e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.05	19.8	0.73	1.13e-58	Multiple system atrophy;
LIHC	cis	rs12079745	0.793	rs77538715	chr1:169290007	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-6.98	-0.35	1.51e-11	QT interval;
LIHC	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg04592579	chr7:75616294	TMEM120A	0.4	6.79	0.34	5.07e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg16034541	chr3:195490309	MUC4	0.58	9.18	0.44	4.34e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs735860	0.712	rs2294864	chr6:53140928	T/A	cg10236188	chr6:53219634	NA	-0.41	-7.54	-0.38	4.13e-13	Glaucoma;
LIHC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.33	6.3	0.32	8.92e-10	Renal cell carcinoma;
LIHC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.56	7.05	0.36	1.01e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.58	6.37	0.33	6.24e-10	Axial length;
LIHC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	9.0	0.44	1.63e-17	Body mass index (adult);
LIHC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg03146154	chr1:46216737	IPP	-0.38	-6.19	-0.32	1.76e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19500275	chr17:80737654	TBCD	0.41	5.76	0.3	1.86e-8	Glycated hemoglobin levels;
LIHC	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg11657440	chr19:46296263	DMWD	-0.53	-8.24	-0.41	3.78e-15	Coronary artery disease;
LIHC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	5.74	0.3	2.09e-8	Schizophrenia;
LIHC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg15902774	chr15:75289873	SCAMP5	0.4	6.0	0.31	4.97e-9	Lung cancer;
LIHC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg16479474	chr6:28041457	NA	0.48	7.14	0.36	5.5e-12	Parkinson's disease;
LIHC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg27432699	chr2:27873401	GPN1	-0.6	-8.72	-0.43	1.21e-16	Total body bone mineral density;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04085039	chr16:1712707	CRAMP1L	0.44	6.63	0.34	1.27e-10	Longevity;
LIHC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.85	14.27	0.61	1.37e-36	Aortic root size;
LIHC	trans	rs6600671	0.899	rs6674392	chr1:121260662	C/G	cg09829573	chr1:144692074	NBPF9	-0.4	-7.19	-0.36	4.13e-12	Hip geometry;
LIHC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg16989086	chr20:62203971	PRIC285	0.57	8.17	0.4	5.84e-15	Glioblastoma;
LIHC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg16797656	chr11:68205561	LRP5	0.49	7.71	0.38	1.39e-13	Total body bone mineral density;
LIHC	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.47	-7.5	-0.38	5.46e-13	Mean corpuscular volume;
LIHC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.39	-6.08	-0.31	3.21e-9	Testicular germ cell tumor;
LIHC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.78	9.28	0.45	2.06e-18	Cisplatin-induced ototoxicity;
LIHC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.93	0.43	2.71e-17	Eosinophil percentage of white cells;
LIHC	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg23091122	chr1:110024289	SYPL2	-0.46	-6.15	-0.32	2.14e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.96	9.64	0.46	1.34e-19	Cognitive function;
LIHC	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg03934865	chr2:198174659	NA	0.46	6.69	0.34	9.23e-11	Intracranial aneurysm;
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.43	-0.53	7.81e-26	Total cholesterol levels;
LIHC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21545522	chr1:205238299	TMCC2	0.37	7.1	0.36	7.18e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.91	0.43	3.16e-17	Prudent dietary pattern;
LIHC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg15017067	chr4:17643749	FAM184B	0.37	6.38	0.33	5.83e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.44	-6.06	-0.31	3.65e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.4	0.37	1.05e-12	Prudent dietary pattern;
LIHC	cis	rs6604026	0.643	rs1360366	chr1:93330987	A/C	cg17283838	chr1:93427260	FAM69A	-0.42	-5.95	-0.31	6.82e-9	Multiple sclerosis;
LIHC	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.42	6.3	0.32	9.07e-10	Menopause (age at onset);
LIHC	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg09003973	chr2:102972529	NA	0.82	7.15	0.36	5.19e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.03	0.31	4.28e-9	Morning vs. evening chronotype;
LIHC	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.35	5.89	0.3	9.16e-9	Mean arterial pressure;
LIHC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg19635926	chr16:89946313	TCF25	0.49	6.24	0.32	1.28e-9	Skin colour saturation;
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20570016	chr1:156261298	TMEM79	0.38	6.11	0.31	2.75e-9	Tonsillectomy;
LIHC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	7.39	0.37	1.15e-12	Menopause (age at onset);
LIHC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.14	16.31	0.66	1.19e-44	Gut microbiome composition (summer);
LIHC	cis	rs62179067	0.708	rs11891654	chr2:179940459	G/A	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	trans	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg17675199	chr6:35436792	RPL10A	-0.31	-6.14	-0.32	2.28e-9	Coronary artery disease;
LIHC	cis	rs8067354	0.507	rs2645478	chr17:58014712	G/A	cg02344993	chr17:57696989	CLTC	0.65	10.18	0.48	2.01e-21	Hemoglobin concentration;
LIHC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	10.0	0.48	8.11e-21	Platelet count;
LIHC	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-8.7	-0.43	1.38e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.67	11.1	0.51	1.22e-24	Menopause (age at onset);
LIHC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.55	8.76	0.43	8.89e-17	Total body bone mineral density;
LIHC	cis	rs3770081	1.000	rs79152960	chr2:86290661	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.83	-8.49	-0.42	6.21e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.44	7.02	0.36	1.17e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs17106184	1.000	rs1278516	chr1:50900021	G/A	cg07174182	chr1:51127561	FAF1	-0.6	-6.67	-0.34	1.06e-10	Type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-9.54	-0.46	2.78e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.72	-0.3	2.3e-8	Response to amphetamines;
LIHC	cis	rs96067	0.711	rs7521145	chr1:36622903	A/G	cg24686825	chr1:36642396	MAP7D1	-0.41	-7.34	-0.37	1.57e-12	Corneal structure;
LIHC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.7	0.34	8.36e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	10.62	0.5	5.7e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg00901687	chr17:48585270	MYCBPAP	-0.43	-6.04	-0.31	4.02e-9	Visceral fat;
LIHC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.67	12.17	0.55	1.54e-28	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14154082	chr13:112174009	NA	0.3	6.26	0.32	1.16e-9	Menarche (age at onset);
LIHC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.22	-5.95	-0.31	6.65e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg06969265	chr17:73775802	H3F3B	0.47	6.0	0.31	4.92e-9	Psoriasis;
LIHC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.25	11.04	0.51	2e-24	Uric acid levels;
LIHC	trans	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.53	-0.33	2.42e-10	Dental caries;
LIHC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.5	6.92	0.35	2.26e-11	Aortic root size;
LIHC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.33	6.91	0.35	2.36e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.7	12.41	0.56	1.81e-29	Colorectal cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17434366	chr4:2746469	TNIP2	0.41	6.28	0.32	1e-9	Immature fraction of reticulocytes;
LIHC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-9.8	-0.47	3.72e-20	Asthma;
LIHC	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.71	-15.82	-0.65	1.08e-42	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.21	0.58	1.74e-32	Prudent dietary pattern;
LIHC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.66	-9.5	-0.46	3.65e-19	Obesity-related traits;
LIHC	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.56	7.49	0.38	5.83e-13	Body mass index (adult);
LIHC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.99	12.96	0.57	1.53e-31	HIV-1 control;
LIHC	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.48	6.35	0.32	6.99e-10	Hip circumference adjusted for BMI;
LIHC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg13957321	chr17:43675089	NA	0.5	7.97	0.4	2.39e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.46	-6.38	-0.33	5.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg00677901	chr16:88017247	BANP	0.55	8.44	0.42	9.26e-16	Menopause (age at onset);
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.54	8.36	0.41	1.63e-15	Longevity;Endometriosis;
LIHC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.57	-6.94	-0.35	2.02e-11	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00152838	chr16:24741724	TNRC6A	0.45	6.04	0.31	4.13e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg00277334	chr10:82204260	NA	-0.47	-6.81	-0.35	4.34e-11	Post bronchodilator FEV1;
LIHC	trans	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg21372672	chr17:16614065	CCDC144A	-0.28	-6.26	-0.32	1.12e-9	Educational attainment (years of education);
LIHC	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.79	-0.57	7.03e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-12.56	-0.56	5.16e-30	Alzheimer's disease (late onset);
LIHC	cis	rs712039	0.652	rs853200	chr17:35804114	G/A	cg16670864	chr17:35848621	DUSP14	0.34	5.75	0.3	1.94e-8	Tuberculosis;
LIHC	cis	rs3853824	1.000	rs3853824	chr17:54880993	T/C	cg13675837	chr17:54910204	DGKE	0.39	5.88	0.3	9.79e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.72	8.53	0.42	4.73e-16	Itch intensity from mosquito bite;
LIHC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.56	6.82	0.35	4.23e-11	Heart rate;
LIHC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg00656387	chr3:40428638	ENTPD3	0.47	7.81	0.39	6.85e-14	Renal cell carcinoma;
LIHC	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.39	5.85	0.3	1.16e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-5.81	-0.3	1.44e-8	Electroencephalogram traits;
LIHC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.36	9.36	0.45	1.09e-18	Schizophrenia;
LIHC	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg07959070	chr22:50026188	C22orf34	-0.34	-8.35	-0.41	1.67e-15	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.13	-0.36	5.86e-12	Diabetic kidney disease;
LIHC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09256448	chr16:638327	NA	0.39	6.71	0.34	8.34e-11	Height;
LIHC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg02269571	chr22:50332266	NA	0.65	8.74	0.43	1.04e-16	Schizophrenia;
LIHC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.7	10.43	0.49	2.68e-22	Body mass index;
LIHC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.48	-5.98	-0.31	5.74e-9	Narcolepsy;
LIHC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.55	7.93	0.39	3.17e-14	Mean corpuscular volume;
LIHC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.68	10.44	0.49	2.5e-22	Mosquito bite size;
LIHC	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.73	9.69	0.46	8.85e-20	Post bronchodilator FEV1;
LIHC	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.2	10.01	0.48	7.28e-21	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg17750252	chr2:136567154	LCT	0.36	6.3	0.32	9.38e-10	Mosquito bite size;
LIHC	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.73	-8.04	-0.4	1.46e-14	Exhaled nitric oxide output;
LIHC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.54	-9.15	-0.44	5.15e-18	Cognitive function;
LIHC	cis	rs2741335	0.876	rs2565056	chr8:27337227	G/A	cg07150473	chr8:27338183	CHRNA2	-0.46	-6.57	-0.33	1.88e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	cis	rs55665837	0.540	rs10219313	chr11:14749849	C/T	cg19336497	chr11:14380999	RRAS2	-0.34	-5.74	-0.3	2.13e-8	Vitamin D levels;
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.24	-0.32	1.28e-9	Longevity;Endometriosis;
LIHC	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.64	8.95	0.44	2.31e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	7.27	0.37	2.41e-12	Bipolar disorder;
LIHC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.4	8.7	0.43	1.42e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs9918079	0.542	rs7688984	chr4:15657253	G/T	cg21123203	chr4:15471301	CC2D2A	-0.4	-5.84	-0.3	1.23e-8	Obesity-related traits;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg11635524	chr19:46850777	PPP5C	0.55	6.28	0.32	1.04e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.49	17.34	0.68	8.86e-49	Eosinophil percentage of granulocytes;
LIHC	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg17182837	chr8:41585554	ANK1	-0.23	-5.74	-0.3	2.07e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.42	6.13	0.31	2.45e-9	Coronary artery disease;
LIHC	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.48	7.79	0.39	8.21e-14	Crohn's disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14787155	chr3:108308533	DZIP3;KIAA1524	0.44	6.28	0.32	1.04e-9	Lung function (FEV1/FVC);
LIHC	cis	rs62179067	0.655	rs11890988	chr2:179944932	G/A	cg07532576	chr2:179544947	TTN	0.67	6.03	0.31	4.19e-9	Late-onset Alzheimer's disease;
LIHC	cis	rs2637266	0.905	rs11001834	chr10:78360494	T/C	cg18941641	chr10:78392320	NA	0.28	5.87	0.3	1.05e-8	Pulmonary function;
LIHC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06420487	chr17:61919686	SMARCD2	0.45	6.22	0.32	1.43e-9	Height;
LIHC	trans	rs6866721	0.791	rs7449327	chr5:116216248	A/G	cg07571379	chr11:134631427	NA	-0.28	-6.07	-0.31	3.4e-9	Body mass index;
LIHC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.69	9.4	0.45	8.19e-19	Aortic root size;
LIHC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.79	0.54	3.88e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.62	-8.98	-0.44	1.83e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.7	10.22	0.48	1.4e-21	Coronary artery disease;
LIHC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.62	-8.89	-0.43	3.67e-17	Platelet count;
LIHC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg17980119	chr2:219472607	PLCD4	0.35	6.18	0.32	1.84e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg14146966	chr2:61757674	XPO1	0.47	8.21	0.41	4.61e-15	Tuberculosis;
LIHC	cis	rs9649465	0.688	rs34967330	chr7:123318560	A/C	cg03229431	chr7:123269106	ASB15	-0.39	-8.27	-0.41	3.09e-15	Migraine;
LIHC	cis	rs7106204	0.748	rs7122986	chr11:24224634	G/A	ch.11.24196551F	chr11:24239977	NA	0.8	11.25	0.52	3.54e-25	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs17106184	1.000	rs72900983	chr1:51192756	T/C	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg03945807	chr20:60948434	NA	-0.36	-6.53	-0.33	2.43e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2380220	0.808	rs2386669	chr6:95902121	C/T	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.53	-7.7	-0.38	1.5e-13	Uric acid levels;
LIHC	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.64	0.5	4.8e-23	Hypertriglyceridemia;
LIHC	cis	rs17152411	0.652	rs4962712	chr10:126647052	A/C	cg07906193	chr10:126599966	NA	-0.29	-5.86	-0.3	1.08e-8	Height;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.44	8.07	0.4	1.17e-14	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg05590025	chr7:65112418	INTS4L2	-0.55	-5.97	-0.31	5.78e-9	Diabetic kidney disease;
LIHC	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg05527609	chr1:210001259	C1orf107	-0.56	-7.61	-0.38	2.74e-13	Red blood cell count;
LIHC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.27	6.25	0.32	1.19e-9	Primary biliary cholangitis;
LIHC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.45	-9.22	-0.45	3.2e-18	Birth weight;
LIHC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.58	10.31	0.49	6.89e-22	Dupuytren's disease;
LIHC	cis	rs2257205	0.667	rs16943147	chr17:56720752	C/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.54	-0.33	2.23e-10	Pancreatic cancer;
LIHC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.25	-0.45	2.48e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	0.58	8.53	0.42	4.73e-16	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg07424592	chr7:64974309	NA	0.78	8.67	0.42	1.75e-16	Diabetic kidney disease;
LIHC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.21	0.36	3.62e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.59	8.96	0.44	2.14e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-6.46	-0.33	3.66e-10	Morning vs. evening chronotype;
LIHC	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.4	-7.28	-0.37	2.36e-12	Glaucoma;
LIHC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.54	-0.59	9.53e-34	Vitiligo;
LIHC	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.36	5.97	0.31	5.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs74233809	1.000	rs79237883	chr10:104940946	T/C	cg03493300	chr10:104813866	CNNM2	0.45	5.91	0.3	8.41e-9	Birth weight;
LIHC	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	6.21	0.32	1.56e-9	Bipolar disorder;
LIHC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.4	8.6	0.42	2.88e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg20887711	chr4:1340912	KIAA1530	0.5	7.82	0.39	6.7e-14	Obesity-related traits;
LIHC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.69	13.74	0.6	1.57e-34	Coronary artery disease;
LIHC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg15848620	chr12:58087721	OS9	-0.53	-7.21	-0.36	3.54e-12	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.57	-0.42	3.72e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.33	5.96	0.31	6.39e-9	Schizophrenia;
LIHC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.53	8.57	0.42	3.5e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg26338869	chr17:61819248	STRADA	0.54	7.19	0.36	4.19e-12	Height;
LIHC	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.42	-7.65	-0.38	2.1e-13	Corneal structure;
LIHC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg05564831	chr3:52568323	NT5DC2	0.37	5.98	0.31	5.66e-9	Bipolar disorder;
LIHC	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg22771759	chr13:24902376	NA	0.31	6.35	0.32	6.94e-10	Obesity-related traits;
LIHC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.82	-13.6	-0.59	5.83e-34	Aortic root size;
LIHC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg03934865	chr2:198174659	NA	-0.59	-9.48	-0.46	4.52e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-8.54	-0.42	4.49e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.31	0.32	8.8e-10	Total body bone mineral density;
LIHC	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.8	-13.17	-0.58	2.51e-32	Morning vs. evening chronotype;
LIHC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.8	-0.5	1.33e-23	Lung cancer;
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.77	10.58	0.5	8.14e-23	Menarche (age at onset);
LIHC	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	10.01	0.48	7.14e-21	Coffee consumption (cups per day);
LIHC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.47	6.37	0.33	5.94e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03160445	chr3:100120349	LNP1;TOMM70A	0.39	6.04	0.31	3.96e-9	Pancreatic cancer;
LIHC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs3106136	0.649	rs11097419	chr4:95298601	A/G	cg11021082	chr4:95130006	SMARCAD1	0.36	6.13	0.31	2.4e-9	Capecitabine sensitivity;
LIHC	cis	rs11255291	0.668	rs719748	chr10:7731885	A/G	cg00997801	chr10:7671259	ITIH5	0.36	5.82	0.3	1.34e-8	Ovarian reserve;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17456994	chr10:6130864	RBM17	0.54	7.19	0.36	4.16e-12	Lung function (FEV1/FVC);
LIHC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.73	-0.3	2.16e-8	Arsenic metabolism;
LIHC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg15155738	chr12:121454335	C12orf43	0.54	7.85	0.39	5.42e-14	N-glycan levels;
LIHC	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.33	-0.32	7.74e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.44	-7.58	-0.38	3.38e-13	Lung cancer;
LIHC	cis	rs9322817	0.691	rs4504502	chr6:105325332	A/G	cg02098413	chr6:105308735	HACE1	0.41	7.7	0.38	1.49e-13	Thyroid stimulating hormone;
LIHC	trans	rs6489882	0.902	rs1156361	chr12:113375983	T/C	cg10175203	chr3:128143634	NA	0.38	6.17	0.32	1.96e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.54	6.57	0.33	1.87e-10	Breast cancer;
LIHC	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.46	6.61	0.34	1.48e-10	Pulse pressure;
LIHC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.03	0.36	1.12e-11	Mood instability;
LIHC	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.8	13.67	0.59	3.07e-34	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg26338869	chr17:61819248	STRADA	0.53	7.21	0.36	3.73e-12	Height;
LIHC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.77	-0.47	4.82e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg02023728	chr11:77925099	USP35	-0.36	-6.23	-0.32	1.39e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	8.27	0.41	3.07e-15	Total body bone mineral density;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20476319	chr12:104457893	HCFC2	-0.52	-6.12	-0.31	2.62e-9	Systolic blood pressure;
LIHC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-7.38	-0.37	1.19e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.68	-7.31	-0.37	1.88e-12	Neuroticism;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg04013166	chr16:89971882	TCF25	0.62	8.83	0.43	5.68e-17	Interleukin-17 levels;
LIHC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.36	6.55	0.33	2.14e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.62	7.76	0.39	9.92e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.62	11.22	0.52	4.39e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs263063	0.749	rs11085111	chr19:5069261	C/T	cg18473234	chr19:5097819	KDM4B	0.56	6.83	0.35	3.83e-11	Periodontitis (CDC/AAP);
LIHC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.78	-11.92	-0.54	1.27e-27	Mosquito bite size;
LIHC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02290350	chr8:58132656	NA	0.44	8.64	0.42	2.13e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg25344623	chr2:136566232	LCT	-0.37	-6.06	-0.31	3.5e-9	Corneal structure;
LIHC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.54	-8.88	-0.43	3.74e-17	Colorectal cancer;
LIHC	cis	rs9473924	0.542	rs2857501	chr6:50797286	A/G	cg14470998	chr6:50812995	TFAP2B	0.98	11.01	0.51	2.45e-24	Body mass index;
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.42	-6.01	-0.31	4.67e-9	Longevity;Endometriosis;
LIHC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.3	-16.87	-0.67	7.14e-47	Diabetic kidney disease;
LIHC	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	1.09	9.57	0.46	2.29e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06544989	chr22:39130855	UNC84B	0.36	5.98	0.31	5.73e-9	Menopause (age at onset);
LIHC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.61	-8.07	-0.4	1.23e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.38	8.77	0.43	8.62e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg07541023	chr7:19748670	TWISTNB	0.48	7.03	0.36	1.13e-11	Thyroid stimulating hormone;
LIHC	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-5.97	-0.31	5.79e-9	Homocysteine levels;
LIHC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	cis	rs10838687	1.000	rs4752979	chr11:47339180	A/G	cg26139080	chr11:47293733	MADD	-0.44	-6.34	-0.32	7.29e-10	Proinsulin levels;
LIHC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	14.4	0.61	4.38e-37	Menopause (age at onset);
LIHC	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.74	-13.35	-0.59	5e-33	Longevity;
LIHC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.92	0.57	2.25e-31	Mean platelet volume;
LIHC	cis	rs3736485	0.966	rs8042840	chr15:51908498	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.98	-0.35	1.59e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23221052	chr5:179740743	GFPT2	-0.49	-7.03	-0.36	1.15e-11	Height;
LIHC	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	0.56	9.4	0.45	7.99e-19	Testicular germ cell tumor;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg14397775	chr11:65729156	SART1	-0.46	-6.25	-0.32	1.23e-9	Alopecia areata;
LIHC	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg20503657	chr10:835505	NA	0.99	11.01	0.51	2.42e-24	Eosinophil percentage of granulocytes;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05590025	chr7:65112418	INTS4L2	0.44	6.63	0.34	1.32e-10	Calcium levels;
LIHC	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.28	-0.37	2.26e-12	Metabolite levels;
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.72	-11.21	-0.52	4.86e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.81	16.11	0.66	7.42e-44	Longevity;
LIHC	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-14.18	-0.61	3.3e-36	Schizophrenia;
LIHC	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.64	9.91	0.47	1.6e-20	Lymphocyte counts;
LIHC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	7.61	0.38	2.72e-13	Schizophrenia;
LIHC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.67	-9.64	-0.46	1.33e-19	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.81	-14.74	-0.62	2.09e-38	Height;
LIHC	cis	rs16858210	0.542	rs12636826	chr3:183558581	G/C	cg25686905	chr3:183603175	PARL	-0.47	-8.24	-0.41	3.72e-15	Menopause (age at onset);
LIHC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.43	-8.32	-0.41	2.19e-15	Schizophrenia;
LIHC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.53	6.89	0.35	2.61e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.58	-8.53	-0.42	4.77e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	1.07	10.51	0.49	1.4e-22	Eosinophil percentage of granulocytes;
LIHC	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.77	11.64	0.53	1.34e-26	Subjective well-being;
LIHC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg13957321	chr17:43675089	NA	0.5	7.88	0.39	4.51e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.54	-10.0	-0.48	8.02e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.79	0.54	3.68e-27	Motion sickness;
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg21003380	chr1:156261207	TMEM79	0.38	6.07	0.31	3.49e-9	Tonsillectomy;
LIHC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	7.08	0.36	8.31e-12	Lung cancer in ever smokers;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-10.35	-0.49	5.25e-22	Skin colour saturation;
LIHC	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg16589663	chr20:23618590	CST3	0.74	7.52	0.38	4.79e-13	Chronic kidney disease;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg25506325	chr7:2093962	MAD1L1	0.59	6.25	0.32	1.22e-9	Mean platelet volume;
LIHC	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg06854084	chr10:101292507	NKX2-3	-0.35	-6.39	-0.33	5.28e-10	Dental caries;
LIHC	trans	rs6489882	0.836	rs10850100	chr12:113364512	T/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6.02e-10	Chronic lymphocytic leukemia;
LIHC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.82	0.35	4.17e-11	Height;
LIHC	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg27205649	chr11:78285834	NARS2	-0.38	-5.78	-0.3	1.68e-8	Alzheimer's disease (survival time);
LIHC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg25364880	chr3:44379878	C3orf23	0.41	5.89	0.3	9.23e-9	Depressive symptoms;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.25	-0.32	1.25e-9	Total body bone mineral density;
LIHC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	11.47	0.53	5.47e-26	Hip circumference adjusted for BMI;
LIHC	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.47	5.98	0.31	5.67e-9	Obesity (extreme);
LIHC	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05731713	chr7:157510257	PTPRN2	0.24	6.53	0.33	2.43e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	11.58	0.53	2.11e-26	Personality dimensions;
LIHC	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg20291162	chr17:40259547	DHX58	-0.41	-6.65	-0.34	1.16e-10	Fibrinogen levels;
LIHC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	8.1	0.4	9.96e-15	Schizophrenia;
LIHC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.86	-17.71	-0.69	3.01e-50	Height;
LIHC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg15269541	chr15:43626905	ADAL	-0.3	-5.81	-0.3	1.45e-8	Lung cancer in ever smokers;
LIHC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.59	10.7	0.5	3.1e-23	Coronary artery disease;
LIHC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	8.07	0.4	1.21e-14	Multiple sclerosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12977448	chr10:14920832	SUV39H2	0.47	6.7	0.34	8.69e-11	Pancreatic cancer;
LIHC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.46	7.45	0.37	7.85e-13	Menarche (age at onset);
LIHC	trans	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg00845942	chr12:64062724	DPY19L2	-0.56	-6.03	-0.31	4.17e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.14	0.4	7.57e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg11996395	chr10:103912126	NOLC1	0.45	6.67	0.34	1e-10	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.38	-5.97	-0.31	5.79e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.52	-9.89	-0.47	1.84e-20	Urinary electrolytes (magnesium/calcium ratio);
LIHC	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.24	-0.32	1.31e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.96	-0.31	6.27e-9	Menopause (age at onset);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07685765	chr19:48964041	KCNJ14	-0.36	-6.06	-0.31	3.54e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.13	0.31	2.37e-9	Blood metabolite levels;
LIHC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.37	-0.33	6.26e-10	Height;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.51	0.33	2.71e-10	Total body bone mineral density;
LIHC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.89	-11.66	-0.53	1.08e-26	Schizophrenia;
LIHC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07305463	chr2:136567211	LCT	0.39	7.55	0.38	3.88e-13	Mosquito bite size;
LIHC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.69	0.34	8.97e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg10845886	chr2:3471009	TTC15	-0.5	-8.76	-0.43	9.01e-17	Neurofibrillary tangles;
LIHC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.59	0.34	1.66e-10	Bipolar disorder;
LIHC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg08888203	chr3:10149979	C3orf24	0.59	6.55	0.33	2.08e-10	Alzheimer's disease;
LIHC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00152838	chr16:24741724	TNRC6A	-0.49	-6.51	-0.33	2.7e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.39	6.07	0.31	3.42e-9	Menopause (age at onset);
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-0.8	-11.91	-0.54	1.4e-27	Obesity-related traits;
LIHC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	29.33	0.85	2.15e-95	IgG glycosylation;
LIHC	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-0.82	-8.44	-0.42	9.26e-16	Blood pressure (smoking interaction);
LIHC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.24	-0.32	1.31e-9	Total body bone mineral density;
LIHC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.68	13.18	0.58	2.41e-32	High light scatter reticulocyte count;
LIHC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg17724175	chr1:150552817	MCL1	0.43	8.46	0.42	7.82e-16	Melanoma;
LIHC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg02269571	chr22:50332266	NA	-0.61	-8.74	-0.43	1.03e-16	Schizophrenia;
LIHC	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	7.45	0.37	7.77e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.61	-0.34	1.43e-10	Type 2 diabetes;
LIHC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.49	8.47	0.42	7.22e-16	Height;
LIHC	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.92	18.56	0.71	1.05e-53	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.62	-0.34	1.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg13877915	chr19:58951672	ZNF132	0.43	6.4	0.33	5.18e-10	Uric acid clearance;
LIHC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	3.17e-33	Cognitive test performance;
LIHC	cis	rs4742903	1.000	rs4742903	chr9:106856793	G/C	cg14250997	chr9:106856677	SMC2	0.42	7.23	0.36	3.22e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.45	0.33	3.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.44	5.87	0.3	1.03e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	13.91	0.6	3.46e-35	Lung cancer in ever smokers;
LIHC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.02	-12.9	-0.57	2.79e-31	Primary sclerosing cholangitis;
LIHC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.59	-11.19	-0.52	5.4e-25	Systemic lupus erythematosus;
LIHC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.52	0.53	3.64e-26	Coronary artery disease;
LIHC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.45	7.97	0.4	2.42e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7116495	0.881	rs6592449	chr11:71670222	C/T	cg26138937	chr11:71823887	C11orf51	-0.82	-8.17	-0.4	6.02e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22150397	chr12:82752718	CCDC59;C12orf26	0.42	6.58	0.34	1.73e-10	Calcium levels;
LIHC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.22	0.32	1.47e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-6.09	-0.31	3.03e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.6	-0.42	2.86e-16	Renal cell carcinoma;
LIHC	cis	rs7129220	0.588	rs16907462	chr11:10137404	T/C	cg01453529	chr11:10209919	SBF2	-0.37	-6.68	-0.34	9.75e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg11789530	chr4:8429930	ACOX3	0.71	10.14	0.48	2.71e-21	Response to antineoplastic agents;
LIHC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.87	0.69	6.76e-51	Tonsillectomy;
LIHC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.7	7.28	0.37	2.38e-12	Vitiligo;
LIHC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.43	6.49	0.33	3.08e-10	Post bronchodilator FEV1;
LIHC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.8	8.97	0.44	2e-17	Vitiligo;
LIHC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.88	-13.34	-0.58	5.71e-33	Sudden cardiac arrest;
LIHC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.56	-8.91	-0.43	3.03e-17	Menarche (age at onset);
LIHC	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg27205649	chr11:78285834	NARS2	0.39	6.09	0.31	2.97e-9	Alzheimer's disease (survival time);
LIHC	cis	rs77637988	0.577	rs6705802	chr2:48603483	A/C	cg15846641	chr2:48541264	FOXN2	0.57	7.67	0.38	1.76e-13	Joint mobility (Beighton score);
LIHC	trans	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.93	0.35	2.15e-11	Corneal astigmatism;
LIHC	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg10628098	chr11:65292300	SCYL1	-0.38	-5.91	-0.3	8.31e-9	Bone mineral density;
LIHC	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.37	-6.04	-0.31	4e-9	Total cholesterol levels;
LIHC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg22842854	chr12:123319900	HIP1R	-0.66	-8.61	-0.42	2.79e-16	Schizophrenia;
LIHC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.68	-9.82	-0.47	3.14e-20	Height;
LIHC	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.57	9.01	0.44	1.46e-17	Corneal astigmatism;
LIHC	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg03735888	chr19:58951602	ZNF132	0.39	6.56	0.33	1.96e-10	Uric acid clearance;
LIHC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.56	9.15	0.44	5.27e-18	Lymphocyte counts;
LIHC	cis	rs7116495	1.000	rs34390540	chr11:71558532	C/A	cg26138937	chr11:71823887	C11orf51	0.64	6.17	0.32	1.91e-9	Severe influenza A (H1N1) infection;
LIHC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.42	5.85	0.3	1.16e-8	Ulcerative colitis;
LIHC	cis	rs16854884	0.673	rs34379944	chr3:143785766	G/A	cg06585982	chr3:143692056	C3orf58	0.53	6.45	0.33	3.76e-10	Economic and political preferences (feminism/equality);
LIHC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.66	8.34	0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.88	10.85	0.51	9.15e-24	Cognitive function;
LIHC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.49	-8.2	-0.41	5.07e-15	Blood metabolite levels;
LIHC	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.41	5.84	0.3	1.22e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.87	0.3	1.05e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg21531657	chr3:10005747	TMEM111	0.39	5.96	0.31	6.15e-9	Alzheimer's disease;
LIHC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	6.81	0.35	4.29e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg01339444	chr6:118972232	C6orf204	0.59	5.82	0.3	1.32e-8	Diastolic blood pressure;
LIHC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg18887096	chr2:219472410	PLCD4	0.36	6.44	0.33	4.12e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	8.87e-33	Prudent dietary pattern;
LIHC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg11905131	chr22:24372483	LOC391322	-0.71	-10.63	-0.5	5.57e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.58	-8.57	-0.42	3.65e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.4	0.33	5e-10	Renal cell carcinoma;
LIHC	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-10.88	-0.51	6.98e-24	Brugada syndrome;
LIHC	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.53	-0.38	4.6e-13	Post bronchodilator FEV1;
LIHC	trans	rs2270927	0.510	rs35984318	chr5:75573566	T/G	cg13563193	chr19:33072644	PDCD5	0.95	9.22	0.45	3.18e-18	Mean corpuscular volume;
LIHC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	6.47	0.33	3.43e-10	Menarche (age at onset);
LIHC	cis	rs7707921	0.846	rs4293895	chr5:81425592	T/C	cg15871215	chr5:81402204	ATG10	-0.63	-6.3	-0.32	9.36e-10	Breast cancer;
LIHC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.65e-9	Total body bone mineral density;
LIHC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-9.45	-0.46	5.39e-19	Reticulocyte count;
LIHC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.71	-0.57	1.46e-30	Alzheimer's disease;
LIHC	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg15711740	chr2:61764176	XPO1	0.42	5.77	0.3	1.82e-8	Tuberculosis;
LIHC	cis	rs6442522	0.568	rs3773461	chr3:15494658	C/G	cg16303742	chr3:15540471	COLQ	0.4	6.46	0.33	3.66e-10	Uric acid levels;
LIHC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.29	15.75	0.65	2.06e-42	Alzheimer's disease (late onset);
LIHC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.82	0.3	1.37e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.8	-0.43	6.96e-17	Blood metabolite levels;
LIHC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.63	8.79	0.43	7.51e-17	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	17.43	0.69	3.8e-49	Lung cancer in ever smokers;
LIHC	cis	rs963731	0.649	rs297152	chr2:39326734	G/T	cg04010122	chr2:39346883	SOS1	-0.61	-6.1	-0.31	2.83e-9	Corticobasal degeneration;
LIHC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.98	10.04	0.48	5.71e-21	Plasma clusterin levels;
LIHC	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	0.85	11.13	0.52	9.19e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.43	6.98	0.35	1.5e-11	Bipolar disorder;
LIHC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.68	-9.24	-0.45	2.64e-18	Aortic root size;
LIHC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	9.88	0.47	1.98e-20	Menarche (age at onset);
LIHC	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.42	-7.62	-0.38	2.44e-13	Monocyte percentage of white cells;
LIHC	cis	rs6793245	0.845	rs4073796	chr3:38590849	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.48	-7.04	-0.36	1.03e-11	QT interval;
LIHC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.38	0.64	5.93e-41	Chronic sinus infection;
LIHC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.6	-8.77	-0.43	8.45e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.8	-12.76	-0.57	9.38e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.58	-0.5	8.04e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg14092571	chr14:90743983	NA	-0.4	-6.27	-0.32	1.12e-9	Mortality in heart failure;
LIHC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs623264	0.920	rs671283	chr19:5470410	C/G	cg03088458	chr19:5478473	NA	0.36	6.18	0.32	1.81e-9	Interleukin-2 receptor antagonist levels;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.52	-6.89	-0.35	2.62e-11	Body mass index;
LIHC	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.4	5.76	0.3	1.86e-8	Blood protein levels;
LIHC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.54	0.33	2.22e-10	Bipolar disorder;
LIHC	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.12	9.94	0.47	1.24e-20	Schizophrenia;
LIHC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg20651018	chr11:3035856	CARS	-0.37	-6.24	-0.32	1.29e-9	Longevity;
LIHC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg19676328	chr12:49525230	TUBA1B	-0.39	-6.4	-0.33	5e-10	Total cholesterol levels;
LIHC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.96	-0.54	8.58e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs600806	0.854	rs367586	chr1:109850122	C/A	cg08911820	chr1:110026001	ATXN7L2	-0.58	-6.85	-0.35	3.35e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.51	0.38	5.13e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs7106204	0.514	rs7107321	chr11:24259879	T/C	ch.11.24196551F	chr11:24239977	NA	0.75	9.4	0.45	7.88e-19	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg08847533	chr14:75593920	NEK9	0.47	7.26	0.37	2.54e-12	Neuroticism;
LIHC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.66	-0.38	1.96e-13	Schizophrenia;
LIHC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.37	5.95	0.31	6.64e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg20818283	chr2:191399100	TMEM194B	-0.45	-6.17	-0.32	1.95e-9	Pulse pressure;
LIHC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.54	7.78	0.39	8.47e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.59	8.71	0.43	1.37e-16	Recombination rate (females);
LIHC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.54	7.59	0.38	3e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	6.77	0.34	5.69e-11	Mean corpuscular hemoglobin;
LIHC	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.35	-0.32	6.95e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07145255	chr5:59995354	DEPDC1B	0.46	7.55	0.38	4.1e-13	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11502736	chr1:179923845	CEP350	0.39	6.05	0.31	3.82e-9	Cognitive function;
LIHC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.46	6.44	0.33	4.06e-10	Cognitive function;
LIHC	trans	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg16724585	chr3:197361211	NA	-0.47	-6.25	-0.32	1.21e-9	Pancreatic cancer;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.39	8.05	0.4	1.41e-14	Renal cell carcinoma;
LIHC	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.73	11.45	0.53	6.48e-26	Eye color traits;
LIHC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.54	-6.44	-0.33	4.01e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.52	0.42	5.15e-16	Motion sickness;
LIHC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.41	-6.6	-0.34	1.53e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.53	-6.78	-0.34	5.2e-11	Type 2 diabetes;
LIHC	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.75	11.63	0.53	1.49e-26	Eye color traits;
LIHC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.57	11.34	0.52	1.58e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.48	-18.11	-0.7	6.78e-52	Breast cancer;
LIHC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-13.25	-0.58	1.24e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.25	0.32	1.2e-9	Schizophrenia;
LIHC	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.69	8.64	0.42	2.15e-16	Type 2 diabetes;
LIHC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.72	-11.55	-0.53	2.74e-26	Corneal astigmatism;
LIHC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.11	-13.58	-0.59	6.5e-34	Vitiligo;
LIHC	cis	rs36051895	0.623	rs72703608	chr9:5258127	A/G	cg02405213	chr9:5042618	JAK2	-0.62	-9.75	-0.47	5.61e-20	Pediatric autoimmune diseases;
LIHC	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.97	11.05	0.51	1.72e-24	Neuroticism;
LIHC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	7.37	0.37	1.31e-12	HDL cholesterol;
LIHC	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.77	8.21	0.41	4.66e-15	Chronic kidney disease;
LIHC	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.61	-0.38	2.77e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.21	-5.74	-0.3	2.08e-8	Hepatitis;
LIHC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg27523141	chr10:43048294	ZNF37B	0.37	6.4	0.33	5.12e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.38	-6.67	-0.34	1.04e-10	Schizophrenia;
LIHC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.16	0.52	7.3e-25	Cognitive test performance;
LIHC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.47	-7.63	-0.38	2.3e-13	Diastolic blood pressure;
LIHC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.41	6.76	0.34	6.02e-11	Red blood cell count;
LIHC	trans	rs7676999	0.592	rs77126424	chr4:116853112	C/A	cg25881869	chr10:114609298	LOC143188	0.45	6.61	0.34	1.51e-10	Age-related macular degeneration;
LIHC	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg23387056	chr11:14280742	SPON1	0.45	6.28	0.32	1.03e-9	Mitochondrial DNA levels;
LIHC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21467203	chr3:49911342	NA	-0.45	-8.11	-0.4	9.32e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.59	7.68	0.38	1.71e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.65e-22	Breast cancer;
LIHC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.7	12.49	0.56	9.26e-30	Iron status biomarkers;
LIHC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg19752551	chr11:57585705	CTNND1	-0.53	-7.46	-0.37	7.23e-13	Schizophrenia;
LIHC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.16e-14	Prudent dietary pattern;
LIHC	cis	rs2191566	0.960	rs12232810	chr19:44525122	A/G	cg18700516	chr19:44507157	ZNF230	-0.35	-5.86	-0.3	1.12e-8	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg03264133	chr6:25882463	NA	-0.42	-6.26	-0.32	1.17e-9	Height;
LIHC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-8.79	-0.43	7.5e-17	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19835839	chr12:120966954	COQ5	0.48	6.43	0.33	4.39e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.24	-16.11	-0.66	7.76e-44	Diabetic kidney disease;
LIHC	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.63	8.85	0.43	4.62e-17	Economic and political preferences (feminism/equality);
LIHC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.55	8.15	0.4	6.8e-15	Tumor biomarkers;
LIHC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.68	9.83	0.47	3.12e-20	Menarche (age at onset);
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-7.18	-0.36	4.32e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg03013999	chr17:37608204	MED1	0.35	5.88	0.3	9.63e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.65	6.24	0.32	1.29e-9	Urate levels in lean individuals;
LIHC	cis	rs12365397	0.925	rs11037342	chr11:43218424	G/T	cg16667275	chr11:43333495	API5	-0.44	-6.2	-0.32	1.6e-9	Migraine;
LIHC	cis	rs6750047	0.585	rs4670808	chr2:38267794	A/G	cg07380506	chr2:38303506	CYP1B1	0.57	7.24	0.36	2.97e-12	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.03	-0.44	1.25e-17	Ulcerative colitis;
LIHC	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.98	-0.35	1.52e-11	IFN-related cytopenia;
LIHC	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.4	-0.45	7.89e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04374321	chr14:90722782	PSMC1	0.71	13.52	0.59	1.11e-33	Mortality in heart failure;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13024018	chr3:133380790	TOPBP1	-0.38	-6.37	-0.33	6.12e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.94	17.75	0.69	1.91e-50	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg11764359	chr7:65958608	NA	-0.56	-5.87	-0.3	1.03e-8	Diabetic kidney disease;
LIHC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02034447	chr16:89574710	SPG7	0.49	7.36	0.37	1.35e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.73	13.82	0.6	7.8e-35	Mortality in heart failure;
LIHC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.73	8.06	0.4	1.25e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.23	6.24	0.32	1.33e-9	Calcium levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03694868	chr2:62684297	NA	0.46	6.65	0.34	1.19e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-8.07	-0.4	1.23e-14	Response to antipsychotic treatment;
LIHC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	13.45	0.59	2.18e-33	Cognitive test performance;
LIHC	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	0.48	6.39	0.33	5.28e-10	Pulse pressure;
LIHC	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg20607798	chr8:58055168	NA	0.59	6.8	0.35	4.58e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.48	6.45	0.33	3.81e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.57	-8.14	-0.4	7.61e-15	Parkinson's disease;
LIHC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-6.94	-0.35	1.96e-11	Diabetic kidney disease;
LIHC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.78	-0.39	8.89e-14	Monocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg11764359	chr7:65958608	NA	0.58	6.09	0.31	2.95e-9	Diabetic kidney disease;
LIHC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.55	-0.38	3.91e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-11.01	-0.51	2.42e-24	Hemoglobin concentration;
LIHC	cis	rs4684776	1.000	rs7616608	chr3:11429793	C/T	cg00170343	chr3:11313890	ATG7	-0.42	-5.76	-0.3	1.91e-8	Small vessel stroke;
LIHC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.61	0.38	2.75e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11673344	0.864	rs7247589	chr19:37510781	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.21	-0.32	1.57e-9	Obesity-related traits;
LIHC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.46	0.46	5.08e-19	Mean platelet volume;
LIHC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	19.7	0.73	2.92e-58	Smoking behavior;
LIHC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.51	-7.48	-0.37	6.29e-13	Body mass index;
LIHC	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.46	5.73	0.3	2.18e-8	Panic disorder;
LIHC	cis	rs2933343	1.000	rs2630252	chr3:128624772	T/C	cg25356066	chr3:128598488	ACAD9	0.52	6.76	0.34	6.13e-11	IgG glycosylation;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg02782426	chr3:40428986	ENTPD3	0.35	6.48	0.33	3.17e-10	Renal cell carcinoma;
LIHC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg05941027	chr17:61774174	LIMD2	0.3	5.99	0.31	5.18e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg00612595	chr21:47717864	NA	-0.35	-5.87	-0.3	1.01e-8	Testicular germ cell tumor;
LIHC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.93	-12.35	-0.56	3.04e-29	Schizophrenia;
LIHC	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg11783602	chr8:55087084	NA	-0.29	-5.91	-0.3	8.38e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.5	6.55	0.33	2.12e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.29	0.41	2.59e-15	Birth weight;
LIHC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg18944383	chr4:111397179	ENPEP	0.32	7.24	0.36	3.02e-12	Height;
LIHC	trans	rs334353	0.785	rs334365	chr9:101929151	G/A	cg06788856	chr17:1821969	NA	-0.32	-6.11	-0.31	2.74e-9	Age-related macular degeneration;
LIHC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.37	-0.33	6.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21576151	chr16:561444	RAB11FIP3	0.47	6.69	0.34	8.87e-11	Pancreatic cancer;
LIHC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-11.54	-0.53	3.15e-26	Coronary artery disease;
LIHC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.52	0.42	5.08e-16	Menarche (age at onset);
LIHC	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.88	10.98	0.51	3.09e-24	Prostate cancer;
LIHC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg03805757	chr16:71968109	PKD1L3	-0.66	-7.51	-0.38	5.1e-13	Post bronchodilator FEV1;
LIHC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg08847533	chr14:75593920	NEK9	-0.55	-8.87	-0.43	4.2e-17	IgG glycosylation;
LIHC	cis	rs2637266	0.846	rs2637263	chr10:78322442	G/A	cg18941641	chr10:78392320	NA	0.27	5.86	0.3	1.11e-8	Pulmonary function;
LIHC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	13.94	0.6	2.84e-35	Chronic sinus infection;
LIHC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.69	9.94	0.47	1.3e-20	Lymphocyte counts;
LIHC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.46	-6.76	-0.34	5.92e-11	Corneal structure;
LIHC	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg20129853	chr10:51489980	NA	-0.43	-9.44	-0.45	5.99e-19	Prostate-specific antigen levels;
LIHC	cis	rs244293	0.965	rs7224560	chr17:53176539	G/C	cg19360675	chr17:53046073	COX11;STXBP4	0.5	7.47	0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs8141529	0.515	rs16986861	chr22:29343188	G/C	cg15103426	chr22:29168792	CCDC117	0.44	6.14	0.32	2.26e-9	Lymphocyte counts;
LIHC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg13446199	chr8:143762866	PSCA	-0.2	-5.85	-0.3	1.12e-8	Urinary tract infection frequency;
LIHC	cis	rs2997447	0.723	rs61776623	chr1:26474490	A/G	cg19633962	chr1:26362018	EXTL1	-0.69	-6.47	-0.33	3.44e-10	QRS complex (12-leadsum);
LIHC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.65	11.23	0.52	4.17e-25	High light scatter reticulocyte count;
LIHC	trans	rs6489882	0.867	rs4766674	chr12:113365201	A/C	cg10175203	chr3:128143634	NA	-0.39	-6.33	-0.32	7.55e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg15208524	chr1:10270712	KIF1B	-0.43	-6.54	-0.33	2.3e-10	Hepatocellular carcinoma;
LIHC	cis	rs17739167	0.550	rs17687976	chr15:42234824	A/G	cg20935245	chr15:42234343	EHD4	-0.42	-7.82	-0.39	6.41e-14	Monocyte count;
LIHC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg12297030	chr17:43662878	NA	-0.63	-6.08	-0.31	3.3e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.68	7.91	0.39	3.55e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.33	-18.21	-0.7	2.75e-52	Diabetic kidney disease;
LIHC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.58	-10.44	-0.49	2.44e-22	Total body bone mineral density;
LIHC	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg04511125	chr2:88470314	THNSL2	0.95	8.87	0.43	4.19e-17	Plasma clusterin levels;
LIHC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.43	5.84	0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-10.23	-0.48	1.32e-21	Mean platelet volume;
LIHC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04498913	chr7:1135747	C7orf50	0.43	6.9	0.35	2.51e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.23	0.45	2.79e-18	Mean platelet volume;
LIHC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.56	-8.35	-0.41	1.67e-15	Gout;
LIHC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.43	0.37	8.61e-13	Bipolar disorder;
LIHC	cis	rs12960505	0.506	rs11664123	chr18:50967028	T/C	cg24270629	chr18:50823537	DCC	-0.47	-6.63	-0.34	1.29e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg24004478	chr7:855632	UNC84A	0.49	8.1	0.4	9.55e-15	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.42	6.27	0.32	1.08e-9	Height;
LIHC	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-8.64	-0.42	2.19e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs6938574	0.672	rs6569520	chr6:128365034	C/G	cg03735592	chr6:138821354	NHSL1	-0.34	-6.35	-0.32	6.86e-10	Menarche (age at onset);
LIHC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.67	13.13	0.58	3.52e-32	Lymphocyte percentage of white cells;
LIHC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	9.01	0.44	1.5e-17	Multiple sclerosis;
LIHC	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-7.22	-0.36	3.35e-12	Obesity (extreme);
LIHC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	21.25	0.75	1.75e-64	Chronic sinus infection;
LIHC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.94	14.2	0.61	2.62e-36	Primary sclerosing cholangitis;
LIHC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.52	7.67	0.38	1.81e-13	Height;
LIHC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.73	0.34	7.27e-11	Obesity-related traits;
LIHC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.69	0.53	9e-27	Motion sickness;
LIHC	trans	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg26939375	chr7:64535504	NA	-0.43	-7.34	-0.37	1.62e-12	Aortic root size;
LIHC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.54	-8.92	-0.43	2.8e-17	Cognitive function;
LIHC	cis	rs1865721	0.771	rs62092763	chr18:73128623	T/G	cg26385618	chr18:73139727	C18orf62	-0.32	-8.5	-0.42	6.16e-16	Intelligence;
LIHC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg12798992	chr6:167411361	FGFR1OP	-0.62	-10.55	-0.5	1.01e-22	Crohn's disease;
LIHC	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.46	7.29	0.37	2.15e-12	Adiposity;
LIHC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg13409248	chr3:40428643	ENTPD3	0.37	5.79	0.3	1.61e-8	Renal cell carcinoma;
LIHC	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	7.18	0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg17385448	chr1:15911702	AGMAT	0.41	6.83	0.35	3.82e-11	Systolic blood pressure;
LIHC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.03	18.24	0.7	2.12e-52	Subjective well-being;
LIHC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	6.09	0.31	3.07e-9	Tonsillectomy;
LIHC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.6	-11.58	-0.53	2.21e-26	Body mass index;
LIHC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg10360323	chr17:41437877	NA	0.4	6.08	0.31	3.29e-9	Menopause (age at onset);
LIHC	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.57	-6.45	-0.33	3.87e-10	Opioid sensitivity;
LIHC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.47	6.49	0.33	3.01e-10	Morning vs. evening chronotype;
LIHC	cis	rs7937890	0.532	rs2256884	chr11:14476402	A/T	cg02886208	chr11:14281011	SPON1	-0.46	-6.58	-0.34	1.75e-10	Mitochondrial DNA levels;
LIHC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.22	5.78	0.3	1.67e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9596863	1.000	rs35429587	chr13:54406523	T/A	ch.13.53330881F	chr13:54432880	NA	0.44	5.98	0.31	5.48e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03412097	chr11:95524327	FAM76B;CEP57	-0.58	-6.77	-0.34	5.47e-11	Systolic blood pressure;
LIHC	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.92	-0.35	2.19e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24449302	chr15:66679100	MAP2K1	0.63	8.34	0.41	1.84e-15	Lung function (FEV1/FVC);
LIHC	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.36	-8.18	-0.4	5.66e-15	Congenital heart disease (maternal effect);
LIHC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	10.11	0.48	3.3e-21	Electrocardiographic conduction measures;
LIHC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.47	7.85	0.39	5.34e-14	Mean corpuscular volume;
LIHC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.79	0.3	1.59e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-8.45	-0.42	8.37e-16	Hemoglobin concentration;
LIHC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.75	-8.92	-0.43	2.89e-17	Menarche (age at onset);
LIHC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.74	7.82	0.39	6.7e-14	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs599890	chr11:49711718	G/A	cg03929089	chr4:120376271	NA	-0.86	-16.58	-0.67	9.62e-46	Height;
LIHC	cis	rs903552	0.800	rs12903584	chr15:101999369	G/A	cg25677261	chr15:102009856	PCSK6	-0.43	-5.9	-0.3	8.96e-9	Diabetic kidney disease;
LIHC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg27386326	chr11:61587980	NA	0.41	6.13	0.31	2.39e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.93	-14.35	-0.61	7.22e-37	Sudden cardiac arrest;
LIHC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.66	0.5	4.11e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.21	5.86	0.3	1.08e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.6	-8.79	-0.43	7.28e-17	Testicular germ cell tumor;
LIHC	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg20302342	chr1:156215951	PAQR6	0.33	6.08	0.31	3.3e-9	Tonsillectomy;
LIHC	cis	rs655641	1.000	rs600743	chr11:85686223	A/T	cg09030501	chr11:85779252	PICALM	-0.51	-6.01	-0.31	4.88e-9	Platelet count;
LIHC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.55	9.42	0.45	7.17e-19	Calcium levels;
LIHC	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.51	-6.83	-0.35	3.84e-11	Obesity (extreme);
LIHC	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.23	-6.21	-0.32	1.56e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.56	0.38	3.67e-13	Aortic root size;
LIHC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs77861329	1.000	rs28659792	chr3:52107966	G/C	cg08692210	chr3:52188851	WDR51A	0.82	7.39	0.37	1.17e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	1.06	15.66	0.65	4.61e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.888	rs592107	chr1:109848726	A/T	cg08911820	chr1:110026001	ATXN7L2	-0.57	-6.78	-0.34	5.14e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg25179470	chr10:102756915	LZTS2	0.44	6.02	0.31	4.54e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7116495	0.786	rs610004	chr11:71797939	C/T	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.42	5.97	0.31	5.87e-9	Aortic root size;
LIHC	trans	rs2275606	0.920	rs13206260	chr6:146914151	G/A	cg22017777	chr5:111506984	EPB41L4A	0.43	6.03	0.31	4.15e-9	Leprosy;
LIHC	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.37	-6.48	-0.33	3.23e-10	Asthma;
LIHC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.75	0.3	2.03e-8	Menopause (age at onset);
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06656553	chr16:89960601	TCF25	-0.48	-6.09	-0.31	3.09e-9	Skin colour saturation;
LIHC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	1.03	19.74	0.73	1.88e-58	Breast cancer;
LIHC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	9.81	0.47	3.45e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.15	10.17	0.48	2.1e-21	Schizophrenia;
LIHC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.29	-16.89	-0.67	5.55e-47	Diabetic kidney disease;
LIHC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-11.95	-0.54	9.76e-28	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	2.97e-30	Menopause (age at onset);
LIHC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.45	-6.89	-0.35	2.64e-11	Coronary artery disease;
LIHC	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	8.76	0.43	9.08e-17	Height;
LIHC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.75	14.41	0.61	4.1e-37	Mortality in heart failure;
LIHC	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.32	7.26	0.37	2.64e-12	Blood metabolite ratios;
LIHC	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.48	7.18	0.36	4.33e-12	White blood cell count;
LIHC	cis	rs8084351	0.539	rs6508188	chr18:50570638	T/G	cg24270629	chr18:50823537	DCC	0.41	6.43	0.33	4.23e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.69	11.44	0.53	6.89e-26	Menopause (age at onset);
LIHC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.53	-8.48	-0.42	7.09e-16	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg18357645	chr12:58087776	OS9	-0.51	-7.78	-0.39	8.53e-14	Multiple sclerosis;
LIHC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.73	7.53	0.38	4.48e-13	Bipolar disorder;
LIHC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg00800038	chr16:89945340	TCF25	-0.6	-8.65	-0.42	2.09e-16	Skin colour saturation;
LIHC	trans	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg04702396	chr17:15466718	FAM18B2	0.43	6.43	0.33	4.26e-10	Educational attainment (years of education);
LIHC	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg23254163	chr1:152506842	NA	0.23	5.8	0.3	1.53e-8	Hair morphology;
LIHC	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.43	6.49	0.33	3.01e-10	Neuroticism;
LIHC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.39	6.56	0.33	1.99e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs600806	0.854	rs11102974	chr1:109886371	G/A	cg23091122	chr1:110024289	SYPL2	-0.44	-5.75	-0.3	2.03e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.53	-0.42	4.67e-16	Total cholesterol levels;
LIHC	trans	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg23782820	chr8:58130467	NA	0.34	5.91	0.3	8.1e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs5015933	0.902	rs2270746	chr9:128121592	C/T	cg14078157	chr9:128172775	NA	0.38	6.31	0.32	8.71e-10	Body mass index;
LIHC	cis	rs888194	0.628	rs9888325	chr12:110037413	G/T	cg05360138	chr12:110035743	NA	0.42	5.94	0.31	6.99e-9	Neuroticism;
LIHC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.5	-6.19	-0.32	1.74e-9	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs2000813	0.857	rs8092097	chr18:47102503	C/T	cg01564661	chr14:105942636	CRIP2	0.34	6.3	0.32	9.26e-10	Coronary artery disease;
LIHC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg01256987	chr12:42539512	GXYLT1	-0.36	-5.91	-0.3	8.5e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg16586182	chr3:47516702	SCAP	0.59	11.42	0.53	8.54e-26	Colorectal cancer;
LIHC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.19	0.36	4.05e-12	Self-reported allergy;
LIHC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.35	-0.41	1.67e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg08694578	chr2:241835147	C2orf54	-0.51	-7.04	-0.36	1.09e-11	Urinary metabolites;
LIHC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.85	12.9	0.57	2.75e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.83	0.57	4.9e-31	Alzheimer's disease;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg12321073	chr6:43138853	SRF	-0.38	-6.28	-0.32	1.05e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg18357526	chr6:26021779	HIST1H4A	0.6	8.4	0.41	1.18e-15	Blood metabolite levels;
LIHC	cis	rs11031096	0.711	rs11031156	chr11:4179021	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-6.02	-0.31	4.5e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.63	0.46	1.44e-19	Mean platelet volume;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.5	7.04	0.36	1.04e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.48	-5.88	-0.3	9.85e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg06397510	chr1:32403634	PTP4A2	-0.46	-6.75	-0.34	6.29e-11	Systolic blood pressure;
LIHC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.89	0.35	2.67e-11	Mood instability;
LIHC	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg00228799	chr9:131580591	ENDOG	0.47	6.58	0.34	1.78e-10	Blood metabolite levels;
LIHC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.48	7.77	0.39	9.14e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg27490568	chr2:178487706	NA	0.36	5.84	0.3	1.23e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.53	0.56	6.44e-30	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.47	5.79	0.3	1.58e-8	Alzheimer's disease;
LIHC	cis	rs10845606	0.505	rs7299416	chr12:12831568	C/T	cg04607235	chr12:12878440	APOLD1	0.41	6.04	0.31	3.96e-9	Systemic lupus erythematosus;
LIHC	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg23533926	chr12:111358616	MYL2	-0.36	-6.9	-0.35	2.52e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.71	0.38	1.35e-13	Prudent dietary pattern;
LIHC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.34e-9	Aortic root size;
LIHC	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg10820045	chr2:198174542	NA	0.53	8.59	0.42	3.24e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg04013166	chr16:89971882	TCF25	0.61	8.09	0.4	1.04e-14	Skin colour saturation;
LIHC	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.82	-15.0	-0.63	1.91e-39	Height;
LIHC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.14	0.32	2.3e-9	Cognitive ability;
LIHC	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg03934865	chr2:198174659	NA	0.45	6.49	0.33	2.96e-10	Dermatomyositis;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00975115	chr16:30958403	FBXL19	0.43	6.23	0.32	1.39e-9	Bilirubin levels;
LIHC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.43	-7.37	-0.37	1.31e-12	Aortic root size;
LIHC	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs1892700	1.000	rs16990773	chr21:35014316	C/T	cg14850771	chr21:34775459	IFNGR2	-0.44	-5.86	-0.3	1.11e-8	Educational attainment;
LIHC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.39e-8	Menopause (age at onset);
LIHC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.32	6.58	0.34	1.74e-10	Blood metabolite levels;
LIHC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.82	9.81	0.47	3.52e-20	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.35	7.31	0.37	1.95e-12	Metabolite levels (MHPG);
LIHC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-15.02	-0.63	1.66e-39	Alzheimer's disease (late onset);
LIHC	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg05714579	chr10:131428358	MGMT	0.4	6.44	0.33	3.96e-10	Response to temozolomide;
LIHC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.53	8.79	0.43	7.4e-17	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2412488	1.000	rs6857024	chr4:54242283	G/A	cg22241045	chr4:54363911	LNX1	-0.45	-7.11	-0.36	6.72e-12	DNA methylation (variation);
LIHC	cis	rs7911264	0.572	rs7071912	chr10:94416229	T/G	cg00519463	chr10:94352821	KIF11	-0.45	-6.26	-0.32	1.19e-9	Inflammatory bowel disease;
LIHC	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	6.64	0.34	1.21e-10	Homocysteine levels;
LIHC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.91	17.08	0.68	9.57e-48	Aortic root size;
LIHC	cis	rs7707921	0.752	rs6882565	chr5:81356421	G/A	cg15871215	chr5:81402204	ATG10	-0.62	-6.78	-0.34	5.34e-11	Breast cancer;
LIHC	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.81	12.32	0.55	4.07e-29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-8.31	-0.41	2.36e-15	Morning vs. evening chronotype;
LIHC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.99	-0.44	1.66e-17	Obesity-related traits;
LIHC	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-8.42	-0.41	1.07e-15	Endometrial cancer;
LIHC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.19	-0.52	5.38e-25	Response to antipsychotic treatment;
LIHC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.71	10.63	0.5	5.5e-23	Aortic root size;
LIHC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.8	7.68	0.38	1.64e-13	Plasma clusterin levels;
LIHC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.64	9.91	0.47	1.58e-20	Blood protein levels;
LIHC	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.24	0.48	1.2e-21	Post bronchodilator FEV1;
LIHC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.63	-12.45	-0.56	1.37e-29	Urate levels in overweight individuals;
LIHC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg16822855	chr3:40428330	ENTPD3	-0.31	-5.86	-0.3	1.09e-8	Renal cell carcinoma;
LIHC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.68	-13.57	-0.59	7.11e-34	Pulse pressure;
LIHC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg12641515	chr19:46296257	DMWD	0.43	6.71	0.34	8.15e-11	Coronary artery disease;
LIHC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg00204748	chr12:29376779	FAR2	0.42	7.62	0.38	2.58e-13	QT interval;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.85	0.43	4.64e-17	Prudent dietary pattern;
LIHC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg06238570	chr21:40685208	BRWD1	0.6	6.95	0.35	1.89e-11	Cognitive function;
LIHC	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.61	8.77	0.43	8.64e-17	Schizophrenia;
LIHC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21467203	chr3:49911342	NA	-0.4	-6.98	-0.35	1.56e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9596863	0.898	rs9563178	chr13:54373714	C/A	ch.13.53330881F	chr13:54432880	NA	0.43	5.8	0.3	1.53e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.82	-12.65	-0.56	2.31e-30	Total body bone mineral density;
LIHC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.65	8.49	0.42	6.54e-16	Motion sickness;
LIHC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.37	-0.37	1.3e-12	Cognitive test performance;
LIHC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.63	10.54	0.5	1.12e-22	Pulse pressure;
LIHC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.42	7.76	0.39	9.78e-14	Electrocardiographic conduction measures;
LIHC	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.3	-5.77	-0.3	1.77e-8	Red blood cell count;
LIHC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	8.01	0.4	1.81e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.58	0.34	1.81e-10	Resting heart rate;
LIHC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg07090678	chr1:91966139	CDC7	-0.47	-6.32	-0.32	7.99e-10	Breast cancer;
LIHC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.44	7.48	0.37	6.53e-13	Mean corpuscular volume;
LIHC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.44	6.99	0.35	1.49e-11	Height;
LIHC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21467203	chr3:49911342	NA	0.39	6.64	0.34	1.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.47e-21	Diisocyanate-induced asthma;
LIHC	cis	rs600626	0.529	rs10899115	chr11:75471849	A/G	cg24262691	chr11:75473276	NA	0.43	6.49	0.33	3.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg00601450	chr5:74908170	NA	-0.59	-7.24	-0.36	3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11673344	0.864	rs2562606	chr19:37520530	G/A	cg27390819	chr19:37464633	NA	-0.52	-6.34	-0.32	7.35e-10	Obesity-related traits;
LIHC	cis	rs17106184	0.551	rs72896949	chr1:50837939	G/A	cg07174182	chr1:51127561	FAF1	-0.44	-5.89	-0.3	9.24e-9	Type 2 diabetes;
LIHC	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	trans	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg26939375	chr7:64535504	NA	-0.43	-7.27	-0.37	2.46e-12	Aortic root size;
LIHC	cis	rs2737618	0.722	rs2737673	chr1:200081710	T/C	cg21825944	chr1:200113062	NR5A2	-0.38	-6.19	-0.32	1.71e-9	Uric acid levels;
LIHC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.68	8.0	0.4	1.9e-14	Dental caries;
LIHC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg11764359	chr7:65958608	NA	0.57	6.03	0.31	4.16e-9	Diabetic kidney disease;
LIHC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.4	-6.09	-0.31	3.04e-9	Menarche (age at onset);
LIHC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-7.98	-0.4	2.3e-14	Sudden cardiac arrest;
LIHC	cis	rs9871864	1.000	rs9862452	chr3:20354712	C/T	cg00235661	chr3:20228976	SGOL1	-0.31	-5.93	-0.31	7.42e-9	Behavioural disinhibition (generation interaction);
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg00969680	chr1:113466087	AFARP1;SLC16A1	0.64	6.61	0.34	1.5e-10	Mean platelet volume;
LIHC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.43	6.15	0.32	2.2e-9	Longevity;Endometriosis;
LIHC	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.19	-6.08	-0.31	3.17e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.49	9.97	0.47	9.91e-21	Tonsillectomy;
LIHC	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	1.17	10.46	0.49	2.17e-22	Type 2 diabetes;
LIHC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg18944383	chr4:111397179	ENPEP	0.25	6.21	0.32	1.51e-9	Coronary artery disease;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-8.57	-0.42	3.59e-16	Lymphocyte counts;
LIHC	cis	rs1823913	1.000	rs1823913	chr2:192118047	C/T	cg12404831	chr2:192114017	MYO1B	0.33	6.62	0.34	1.39e-10	Obesity-related traits;
LIHC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-5.78	-0.3	1.69e-8	Vitiligo;
LIHC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.48	-6.31	-0.32	8.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.4	6.02	0.31	4.51e-9	Eosinophil percentage of white cells;
LIHC	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg18678763	chr11:4115507	RRM1	-0.52	-7.5	-0.38	5.68e-13	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg22842854	chr12:123319900	HIP1R	-0.63	-7.38	-0.37	1.19e-12	Schizophrenia;
LIHC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg07451762	chr16:28383216	NA	0.33	6.15	0.32	2.14e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.64	-8.23	-0.41	4.02e-15	Gut microbiome composition (summer);
LIHC	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.81	-0.39	6.91e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs1355223	0.867	rs7925421	chr11:34681677	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.77	-0.3	1.77e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-8.39	-0.41	1.25e-15	Morning vs. evening chronotype;
LIHC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16684958	chr7:75615977	POR	0.48	7.91	0.39	3.61e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg09829573	chr1:144692074	NBPF9	-0.4	-6.78	-0.34	5.4e-11	Hip geometry;
LIHC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.45	6.09	0.31	2.96e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.2	0.32	1.58e-9	Tonsillectomy;
LIHC	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg07451762	chr16:28383216	NA	-0.38	-6.43	-0.33	4.24e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	12.68	0.57	1.77e-30	Menopause (age at onset);
LIHC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	1.07	12.48	0.56	9.98e-30	Eosinophil percentage of granulocytes;
LIHC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.3	0.37	2.08e-12	Morning vs. evening chronotype;
LIHC	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg16586182	chr3:47516702	SCAP	0.47	8.25	0.41	3.48e-15	Colorectal cancer;
LIHC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.35e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.2	-6.07	-0.31	3.4e-9	Cutaneous nevi;
LIHC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.98	-0.31	5.54e-9	Body mass index;
LIHC	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg12751644	chr20:60527061	NA	-0.36	-6.11	-0.31	2.68e-9	Body mass index;
LIHC	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.68	-10.1	-0.48	3.58e-21	Diisocyanate-induced asthma;
LIHC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.39	6.34	0.32	7.33e-10	Red blood cell count;
LIHC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.88	0.39	4.32e-14	Lymphocyte counts;
LIHC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-13.22	-0.58	1.69e-32	Vitiligo;
LIHC	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16684958	chr7:75615977	POR	0.52	8.68	0.42	1.65e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs6489882	0.836	rs10774676	chr12:113362407	C/T	cg10175203	chr3:128143634	NA	-0.38	-6.21	-0.32	1.52e-9	Chronic lymphocytic leukemia;
LIHC	trans	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	6.4	0.33	5.04e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.51	8.87	0.43	4.13e-17	Coronary artery disease;
LIHC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.75	10.9	0.51	6e-24	Corneal astigmatism;
LIHC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg18944383	chr4:111397179	ENPEP	0.35	8.17	0.4	6.1e-15	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.91	16.84	0.67	8.86e-47	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg25894440	chr7:65020034	NA	-0.53	-6.11	-0.31	2.72e-9	Diabetic kidney disease;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.6	0.34	1.59e-10	Renal cell carcinoma;
LIHC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.81	-12.7	-0.57	1.48e-30	Total body bone mineral density;
LIHC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.93	-9.74	-0.47	5.96e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs1030268	1.000	rs748754	chr7:133509069	G/A	cg03336402	chr7:133662267	EXOC4	-0.52	-6.89	-0.35	2.74e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-6.94	-0.35	1.95e-11	IgG glycosylation;
LIHC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.38	6.1	0.31	2.94e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.17	-10.09	-0.48	3.91e-21	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14122300	chr14:69446504	ACTN1	0.42	6.16	0.32	2.05e-9	Pancreatic cancer;
LIHC	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-10.58	-0.5	8.06e-23	Alzheimer's disease (late onset);
LIHC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg07706471	chr12:123319906	HIP1R	0.58	7.76	0.39	9.7e-14	Schizophrenia;
LIHC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.4	6.39	0.33	5.36e-10	Menopause (age at onset);
LIHC	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.64	-10.81	-0.5	1.22e-23	Pediatric autoimmune diseases;
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.38	0.76	5.19e-65	Height;
LIHC	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.39	5.94	0.31	6.97e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg15105060	chr4:7024189	TBC1D14	-0.75	-6.63	-0.34	1.3100000000000001e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	10.5	0.49	1.52e-22	Obesity-related traits;
LIHC	cis	rs74225573	1	rs74225573	chr1:11280994	T/C	cg08854313	chr1:11322531	MTOR	-0.81	-6.72	-0.34	7.63e-11	Corneal curvature;
LIHC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19500275	chr17:80737654	TBCD	0.41	5.77	0.3	1.75e-8	Glycated hemoglobin levels;
LIHC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.37	5.77	0.3	1.78e-8	Coronary artery disease;
LIHC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.23	-0.41	4.01e-15	Total cholesterol levels;
LIHC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.86	-0.3	1.08e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.07	0.55	3.43e-28	Coffee consumption (cups per day);
LIHC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.78	-11.07	-0.51	1.46e-24	Morning vs. evening chronotype;
LIHC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	7.21	0.36	3.66e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.9	15.97	0.65	2.87e-43	Intelligence (multi-trait analysis);
LIHC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.17	0.36	4.79e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.5	-6.39	-0.33	5.34e-10	Pursuit maintenance gain;
LIHC	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.59	7.25	0.36	2.81e-12	Corneal structure;
LIHC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.81	-12.9	-0.57	2.58e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4450131	1.000	rs10444190	chr10:126375608	G/C	cg20435097	chr10:126320824	FAM53B	-0.51	-9.24	-0.45	2.71e-18	White blood cell count (basophil);
LIHC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.4	-6.22	-0.32	1.43e-9	Lung cancer;
LIHC	trans	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg25214090	chr10:38739885	LOC399744	0.44	6.95	0.35	1.88e-11	Educational attainment;
LIHC	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.64	10.31	0.49	6.77e-22	Schizophrenia;
LIHC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg07636037	chr3:49044803	WDR6	-0.79	-7.91	-0.39	3.65e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.49	6.19	0.32	1.69e-9	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.5	5.98	0.31	5.66e-9	Morning vs. evening chronotype;
LIHC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	14.01	0.6	1.53e-35	Cognitive test performance;
LIHC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	8.92	0.43	2.96e-17	Schizophrenia;
LIHC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.91	11.06	0.51	1.69e-24	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.08	-0.36	8.34e-12	Heart rate;
LIHC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-1.03	-20.51	-0.74	1.58e-61	Breast cancer;
LIHC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.42	5.81	0.3	1.46e-8	Neuroticism;
LIHC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.06	15.28	0.64	1.54e-40	Cognitive function;
LIHC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.55	8.88	0.43	3.71e-17	Colorectal cancer;
LIHC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.7	9.99	0.48	8.67e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.34	5.89	0.3	9.04e-9	Body mass index;
LIHC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg07706471	chr12:123319906	HIP1R	-0.58	-7.68	-0.38	1.74e-13	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06037631	chr2:74942369	NA	0.41	6.06	0.31	3.62e-9	Cognitive function;
LIHC	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.54	-7.76	-0.39	9.98e-14	Neuroticism;
LIHC	cis	rs9816226	0.591	rs76880877	chr3:185802628	A/C	cg00760338	chr3:185826511	ETV5	-0.71	-5.97	-0.31	5.86e-9	Obesity;Body mass index;
LIHC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.64	9.72	0.47	7.11e-20	Renal cell carcinoma;
LIHC	trans	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg01596870	chr19:55963115	NA	-0.63	-8.36	-0.41	1.58e-15	Obesity-related traits;
LIHC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.61	10.4	0.49	3.53e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg11441379	chr12:63026424	NA	0.63	6.28	0.32	1.01e-9	IgG glycosylation;
LIHC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.79	0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg20636351	chr8:55087400	NA	-0.34	-7.0	-0.35	1.32e-11	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.27	6.35	0.32	6.69e-10	Heart rate;
LIHC	cis	rs2637266	1.000	rs2579750	chr10:78340260	C/G	cg18941641	chr10:78392320	NA	-0.28	-6.21	-0.32	1.55e-9	Pulmonary function;
LIHC	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg11530693	chr1:120165357	ZNF697	0.47	7.53	0.38	4.59e-13	Systemic lupus erythematosus;
LIHC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02985541	chr2:219472218	PLCD4	0.45	8.5	0.42	6.04e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7937890	0.695	rs17557844	chr11:14262559	A/G	cg02886208	chr11:14281011	SPON1	0.52	6.88	0.35	2.81e-11	Mitochondrial DNA levels;
LIHC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	9.13	0.44	6.27e-18	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg02990361	chr1:107599529	PRMT6	-0.66	-11.0	-0.51	2.75e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.76	-13.02	-0.58	9.81e-32	Platelet distribution width;
LIHC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-6.95	-0.35	1.82e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.59	9.55	0.46	2.59e-19	Corneal astigmatism;
LIHC	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg05187965	chr10:45406764	TMEM72	-0.24	-5.72	-0.3	2.38e-8	Mean corpuscular volume;
LIHC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.53	7.48	0.37	6.51e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.52	7.23	0.36	3.09e-12	Mean corpuscular volume;
LIHC	cis	rs10949834	0.504	rs150862	chr7:73524207	C/T	cg07137043	chr7:73588983	EIF4H	0.59	7.39	0.37	1.17e-12	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.49	-7.19	-0.36	4.05e-12	Mortality in heart failure;
LIHC	cis	rs17106184	1.000	rs113704493	chr1:50892538	C/G	cg07174182	chr1:51127561	FAF1	-0.57	-6.36	-0.32	6.65e-10	Type 2 diabetes;
LIHC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.37	-0.37	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg12798992	chr6:167411361	FGFR1OP	0.43	6.57	0.33	1.85e-10	Primary biliary cholangitis;
LIHC	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.92	-0.35	2.17e-11	Metabolite levels;
LIHC	cis	rs7487075	0.578	rs4768118	chr12:46784744	T/C	cg23829395	chr12:46796953	NA	0.35	6.12	0.31	2.58e-9	Itch intensity from mosquito bite;
LIHC	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.0	-0.35	1.34e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs6442522	0.780	rs13068150	chr3:15438941	C/G	cg16303742	chr3:15540471	COLQ	0.38	5.99	0.31	5.28e-9	Uric acid levels;
LIHC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.66	-8.3	-0.41	2.51e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.872	rs1707308	chr1:46604315	G/A	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.41	5.97	0.31	5.94e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.65	10.73	0.5	2.43e-23	Smoking initiation;
LIHC	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.61	-10.07	-0.48	4.53e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.38	6.21	0.32	1.52e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.67	8.5	0.42	6.02e-16	Gut microbiome composition (summer);
LIHC	cis	rs2562152	0.530	rs216604	chr16:112513	T/C	cg02949481	chr16:131562	MPG	0.63	9.53	0.46	3e-19	Glioblastoma;
LIHC	trans	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg10756647	chr7:56101905	PSPH	0.63	8.62	0.42	2.55e-16	Corneal structure;
LIHC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.45	-0.37	7.89e-13	Uric acid levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19098793	chr7:1609793	KIAA1908;PSMG3	-0.45	-6.55	-0.33	2.08e-10	Cognitive function;
LIHC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06544989	chr22:39130855	UNC84B	0.35	5.82	0.3	1.38e-8	Menopause (age at onset);
LIHC	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.4	7.67	0.38	1.78e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.65	10.89	0.51	6.68e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.39	-5.83	-0.3	1.27e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.51	8.54	0.42	4.38e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.46	7.53	0.38	4.51e-13	Platelet distribution width;
LIHC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	11.4	0.52	9.79e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13631	0.728	rs10118245	chr9:139979592	C/T	cg14289826	chr9:140003911	NA	0.4	6.61	0.34	1.48e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.48	-0.37	6.47e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.41	6.91	0.35	2.41e-11	Red blood cell count;
LIHC	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.6	8.94	0.44	2.5e-17	Recombination rate (females);
LIHC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	21.25	0.75	1.75e-64	Chronic sinus infection;
LIHC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.39	-5.92	-0.3	7.76e-9	Multiple myeloma;
LIHC	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.26	0.41	3.23e-15	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03226425	chr6:170151538	C6orf70;TCTE3	0.59	8.09	0.4	1.07e-14	Pancreatic cancer;
LIHC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg04607235	chr12:12878440	APOLD1	-0.72	-9.45	-0.45	5.69e-19	Systemic lupus erythematosus;
LIHC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.94	18.0	0.7	1.99e-51	Menopause (age at onset);
LIHC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.58	8.55	0.42	4.29e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.9	-0.35	2.56e-11	HDL cholesterol;
LIHC	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.25	0.48	1.08e-21	Hypertriglyceridemia;
LIHC	cis	rs1023500	1.000	rs6002554	chr22:42339095	T/C	cg04733989	chr22:42467013	NAGA	-0.51	-6.0	-0.31	5.15e-9	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.45	6.59	0.34	1.68e-10	Cognitive function;
LIHC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.92	14.31	0.61	9.88e-37	Glomerular filtration rate (creatinine);
LIHC	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.4	-5.89	-0.3	9.34e-9	Blood protein levels;
LIHC	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.61	-10.99	-0.51	2.93e-24	Breast cancer;
LIHC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.69	0.43	1.55e-16	Motion sickness;
LIHC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.65	-9.31	-0.45	1.62e-18	Coronary artery disease;
LIHC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	12.0	0.54	6.38e-28	Response to antipsychotic treatment;
LIHC	cis	rs753955	0.554	rs2031587	chr13:24417335	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.35	6.06	0.31	3.58e-9	Lung cancer;
LIHC	cis	rs712039	0.652	rs853224	chr17:35791328	A/T	cg16670864	chr17:35848621	DUSP14	0.35	5.84	0.3	1.2e-8	Tuberculosis;
LIHC	cis	rs611744	0.967	rs695028	chr8:109239324	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg24693881	chr1:107596107	NA	0.56	9.78	0.47	4.41e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.56	8.49	0.42	6.57e-16	Mosquito bite size;
LIHC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.29	21.41	0.76	4.13e-65	Corneal structure;
LIHC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg14024328	chr4:719362	PCGF3	-0.46	-6.75	-0.34	6.49e-11	White blood cell count;
LIHC	cis	rs3780378	0.967	rs7852988	chr9:5010751	C/A	cg02405213	chr9:5042618	JAK2	-0.55	-9.85	-0.47	2.68e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.42	-6.47	-0.33	3.3e-10	Height;
LIHC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	9.76	0.47	4.99e-20	Electrocardiographic conduction measures;
LIHC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.76	12.92	0.57	2.27e-31	Anterior chamber depth;
LIHC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.49	-7.67	-0.38	1.77e-13	Systemic lupus erythematosus;
LIHC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.39	6.4	0.33	5.14e-10	Red blood cell count;
LIHC	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.92	-16.31	-0.66	1.26e-44	Oral cavity cancer;
LIHC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.49	-8.78	-0.43	7.8e-17	Colorectal cancer;
LIHC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.69	-0.46	8.98e-20	Mean platelet volume;
LIHC	cis	rs72627509	0.680	rs79641006	chr4:57847443	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.64	-9.15	-0.44	5.41e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.43	-6.0	-0.31	5.11e-9	Longevity;
LIHC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	0.9	8.7	0.43	1.37e-16	Alzheimer's disease;
LIHC	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.79	0.5	1.46e-23	Fuchs's corneal dystrophy;
LIHC	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.82	0.35	4.19e-11	Type 2 diabetes;
LIHC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.25	0.48	1.14e-21	Bladder cancer;
LIHC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	1.18	14.34	0.61	7.88e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.26	0.41	3.27e-15	Bladder cancer;
LIHC	trans	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg17675199	chr6:35436792	RPL10A	0.35	6.86	0.35	3.26e-11	Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.71	0.38	1.35e-13	Prudent dietary pattern;
LIHC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.29	-0.49	7.97e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.09	0.4	1.03e-14	Motion sickness;
LIHC	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.39e-15	Blood protein levels;
LIHC	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.14	-0.4	7.54e-15	Exhaled nitric oxide output;
LIHC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.87	0.67	6.92e-47	Lung cancer in ever smokers;
LIHC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-7.88	-0.39	4.34e-14	Crohn's disease;
LIHC	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.65	6.64	0.34	1.23e-10	Schizophrenia;
LIHC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.6	10.66	0.5	4.27e-23	Longevity;Endometriosis;
LIHC	cis	rs8081395	0.627	rs180536	chr17:57996806	G/A	cg13753209	chr17:57696993	CLTC	0.49	7.81	0.39	7.01e-14	White blood cell count;
LIHC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg21605333	chr4:119757512	SEC24D	0.84	6.89	0.35	2.75e-11	Cannabis dependence symptom count;
LIHC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.62	0.5	5.97e-23	Bladder cancer;
LIHC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg03146154	chr1:46216737	IPP	-0.39	-6.39	-0.33	5.52e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.59	7.77	0.39	9.29e-14	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg24296786	chr1:45957014	TESK2	-0.49	-7.2	-0.36	3.77e-12	Platelet count;
LIHC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15684811	chr1:59250924	JUN	0.45	6.05	0.31	3.73e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11958404	0.932	rs72818127	chr5:157452227	C/T	cg05962755	chr5:157440814	NA	1.04	11.55	0.53	2.71e-26	IgG glycosylation;
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg12903224	chr12:29470962	FAR2	-0.37	-5.91	-0.3	8.31e-9	QT interval;
LIHC	cis	rs6973256	0.637	rs1362739	chr7:133430934	C/A	cg10665199	chr7:133106180	EXOC4	0.34	5.83	0.3	1.26e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.44	-8.28	-0.41	2.86e-15	Schizophrenia;
LIHC	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg19735590	chr5:154026979	NA	0.47	5.72	0.3	2.34e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.56	6.07	0.31	3.38e-9	Bipolar disorder;
LIHC	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg05760424	chr2:242988095	NA	-0.52	-7.06	-0.36	9.34e-12	Obesity-related traits;
LIHC	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.96	-0.4	2.5e-14	Exhaled nitric oxide output;
LIHC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.33	-5.74	-0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs847649	0.731	rs2298854	chr7:102729631	T/G	cg18108683	chr7:102477205	FBXL13	0.41	6.02	0.31	4.62e-9	Morning vs. evening chronotype;
LIHC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.9	16.52	0.67	1.72e-45	Bone mineral density;
LIHC	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-7.65	-0.38	2.05e-13	Exhaled nitric oxide output;
LIHC	cis	rs1982963	1.000	rs4901186	chr14:52509484	G/A	cg10843707	chr14:52510701	NID2	-0.47	-8.59	-0.42	3.21e-16	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-11.29	-0.52	2.55e-25	Mean corpuscular volume;
LIHC	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg04610667	chr7:75704037	NA	-0.33	-6.0	-0.31	5.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.18	-0.36	4.31e-12	Body mass index;
LIHC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.5	7.47	0.37	6.94e-13	Lymphocyte counts;
LIHC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg16479474	chr6:28041457	NA	-0.45	-6.78	-0.34	5.41e-11	Parkinson's disease;
LIHC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.82	11.63	0.53	1.4e-26	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04502814	chr5:42811952	SEPP1	0.33	6.85	0.35	3.37e-11	Cognitive function;
LIHC	cis	rs1816752	0.837	rs9318530	chr13:24998557	A/G	cg02811702	chr13:24901961	NA	-0.25	-6.21	-0.32	1.58e-9	Obesity-related traits;
LIHC	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg25356066	chr3:128598488	ACAD9	0.53	6.99	0.35	1.48e-11	IgG glycosylation;
LIHC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20135002	chr11:47629003	NA	0.55	9.32	0.45	1.45e-18	Subjective well-being;
LIHC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02290350	chr8:58132656	NA	0.49	8.77	0.43	8.6e-17	Developmental language disorder (linguistic errors);
LIHC	trans	rs6489882	0.934	rs7299132	chr12:113376913	T/A	cg10175203	chr3:128143634	NA	0.38	6.18	0.32	1.8e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.99	10.76	0.5	1.9e-23	Triglycerides;
LIHC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.12	25.06	0.8	2.07e-79	Cognitive ability;
LIHC	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-6.06	-0.31	3.61e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs12101261	1.000	rs12101255	chr14:81451052	C/T	cg06600135	chr14:81408086	NA	0.36	6.17	0.32	1.93e-9	Graves' disease;
LIHC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.68	-8.4	-0.41	1.19e-15	Gut microbiome composition (summer);
LIHC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-6.01	-0.31	4.77e-9	Monocyte percentage of white cells;
LIHC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg13320555	chr19:33072785	PDCD5	0.45	6.7	0.34	8.84e-11	Eosinophilic esophagitis;
LIHC	trans	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg24637308	chr11:6592297	DNHD1	0.43	6.09	0.31	2.99e-9	Coronary artery calcification;
LIHC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg18478394	chr8:109455254	TTC35	0.43	7.44	0.37	8.07e-13	Dupuytren's disease;
LIHC	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-8.31	-0.41	2.27e-15	Facial morphology (factor 19);
LIHC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.53	8.39	0.41	1.31e-15	Total body bone mineral density;
LIHC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	8.3	0.41	2.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.43	6.07	0.31	3.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09331995	chr7:27309021	NA	0.42	6.94	0.35	1.99e-11	Longevity;
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg24209194	chr3:40518798	ZNF619	-0.5	-7.49	-0.38	5.91e-13	Renal cell carcinoma;
LIHC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg07424592	chr7:64974309	NA	-0.8	-9.08	-0.44	8.8e-18	Diabetic kidney disease;
LIHC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.06	-0.31	3.5e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12516959	chr21:47718080	NA	-0.36	-5.87	-0.3	1.05e-8	Testicular germ cell tumor;
LIHC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg17385448	chr1:15911702	AGMAT	0.34	5.93	0.31	7.31e-9	Systolic blood pressure;
LIHC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.3	-5.75	-0.3	1.94e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg20636351	chr8:55087400	NA	-0.36	-7.31	-0.37	1.87e-12	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.1	-0.36	7.16e-12	Bipolar disorder;
LIHC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05665937	chr4:1216051	CTBP1	0.39	6.2	0.32	1.64e-9	Obesity-related traits;
LIHC	cis	rs2279817	0.863	rs13375585	chr1:18016657	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-7.99	-0.4	2.06e-14	Neuroticism;
LIHC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-13.17	-0.58	2.5e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg09238746	chr17:78121135	EIF4A3	-0.54	-8.29	-0.41	2.59e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LIHC	cis	rs11671005	0.651	rs55716128	chr19:59048754	C/T	cg25952890	chr19:58913133	NA	0.67	6.72	0.34	7.43e-11	Mean platelet volume;
LIHC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg16797656	chr11:68205561	LRP5	0.51	8.1	0.4	9.54e-15	Total body bone mineral density;
LIHC	cis	rs11931598	0.511	rs35772786	chr4:7021211	T/G	cg19539972	chr4:7069911	GRPEL1	0.41	6.45	0.33	3.75e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs1185460	0.547	rs667584	chr11:118911544	C/T	cg01677386	chr11:118938358	VPS11	0.44	5.89	0.3	9.22e-9	Coronary artery disease;
LIHC	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.56	-6.81	-0.35	4.49e-11	Breast cancer;
LIHC	cis	rs8064024	0.538	rs11076854	chr16:4929269	A/G	cg08329684	chr16:4932620	PPL	-0.42	-7.43	-0.37	8.71e-13	Cancer;
LIHC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.54	5.92	0.3	7.73e-9	Menarche (age at onset);
LIHC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.4	5.71	0.3	2.46e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.47	-6.77	-0.34	5.52e-11	Other erythrocyte phenotypes;
LIHC	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	6.57	0.33	1.89e-10	Response to antipsychotic treatment;
LIHC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21448741	chr8:58168803	NA	-0.33	-5.76	-0.3	1.87e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.38	-6.36	-0.33	6.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.4	0.49	3.47e-22	Colorectal cancer;
LIHC	cis	rs45544231	0.544	rs9926163	chr16:52565641	G/T	cg09051775	chr16:52580266	TOX3	-0.32	-5.88	-0.3	9.89e-9	Restless legs syndrome;
LIHC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.55	8.25	0.41	3.41e-15	Menopause (age at onset);
LIHC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.08	14.3	0.61	1.05e-36	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18357526	chr6:26021779	HIST1H4A	0.49	7.18	0.36	4.37e-12	Height;
LIHC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.53	0.46	2.93e-19	Alzheimer's disease;
LIHC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg13409248	chr3:40428643	ENTPD3	0.42	7.05	0.36	1e-11	Renal cell carcinoma;
LIHC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.9	-17.51	-0.69	1.87e-49	Height;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00529697	chr5:75013131	C5orf37	0.44	6.74	0.34	6.83e-11	Calcium levels;
LIHC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	17.09	0.68	8.61e-48	Lung cancer in ever smokers;
LIHC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	7.35	0.37	1.5e-12	Obesity-related traits;
LIHC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.82	-0.3	1.33e-8	Subjective well-being;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10590909	chr10:70286987	SLC25A16	-0.44	-6.53	-0.33	2.41e-10	Triglycerides;
LIHC	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg27433088	chr4:174089019	GALNT7	-0.37	-5.97	-0.31	6.02e-9	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.56	8.39	0.41	1.3e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.56	8.2	0.41	4.94e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs981946	0.570	rs6923667	chr6:3359194	C/T	cg18842474	chr6:3356384	SLC22A23	0.39	6.34	0.32	7.36e-10	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
LIHC	cis	rs28493229	1.000	rs28493229	chr19:41224204	G/C	cg21869046	chr19:41225005	ITPKC	0.5	6.21	0.32	1.55e-9	Kawasaki disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10053149	chr1:28908509	SNHG12;SNORA44;SNORA16A	-0.46	-6.69	-0.34	9.17e-11	Cognitive function;
LIHC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.27	0.41	2.94e-15	Schizophrenia;
LIHC	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.57	-8.18	-0.4	5.49e-15	Blood pressure (smoking interaction);
LIHC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.62	-7.11	-0.36	7.03e-12	Menarche (age at onset);
LIHC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.02	0.54	5.49e-28	Cognitive test performance;
LIHC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.6	-11.95	-0.54	9.74e-28	Gestational age at birth (maternal effect);
LIHC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.46	6.97	0.35	1.66e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-5.74	-0.3	2.1e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg04756594	chr16:24857601	SLC5A11	0.44	6.99	0.35	1.45e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.8	-0.34	4.77e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02359409	chr6:42947317	PEX6	-0.47	-6.66	-0.34	1.07e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.83	17.65	0.69	5.06e-50	Colorectal cancer;
LIHC	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg16950941	chr11:66035639	RAB1B	0.54	8.16	0.4	6.47e-15	Gout;
LIHC	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.49	-7.2	-0.36	3.75e-12	Asthma (sex interaction);
LIHC	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.49	7.74	0.39	1.16e-13	Height;
LIHC	cis	rs57590327	0.679	rs34674953	chr3:81605113	T/G	cg07356753	chr3:81810745	GBE1	-0.47	-6.48	-0.33	3.21e-10	Extraversion;
LIHC	cis	rs2607426	0.681	rs74628863	chr19:41291872	G/A	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-5.98	-0.31	5.51e-9	Blood protein levels;
LIHC	cis	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg03342759	chr3:160939853	NMD3	0.56	7.44	0.37	8.32e-13	Morning vs. evening chronotype;
LIHC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.42	-0.49	2.83e-22	Hemoglobin concentration;
LIHC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	8.89	0.43	3.67e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7187994	0.848	rs12443928	chr16:84780202	G/T	cg07647771	chr16:84786436	USP10	-0.34	-5.98	-0.31	5.63e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.5	-8.38	-0.41	1.43e-15	Pubertal anthropometrics;
LIHC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg22633049	chr21:46681294	NA	-0.37	-6.37	-0.33	5.94e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.52	-0.38	4.86e-13	QT interval;
LIHC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	-0.46	-6.74	-0.34	6.8e-11	Narcolepsy;
LIHC	cis	rs16828019	0.852	rs12759050	chr1:41664204	T/A	cg20697417	chr1:41786797	NA	0.35	6.59	0.34	1.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.58	12.11	0.55	2.54e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.56	-0.33	2e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg09572067	chr16:29127029	RRN3P2	0.49	7.81	0.39	7.29e-14	Menopause (age at onset);
LIHC	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg20991723	chr1:152506922	NA	0.57	9.99	0.48	8.72e-21	Hair morphology;
LIHC	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg08911820	chr1:110026001	ATXN7L2	0.57	6.87	0.35	3.07e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.73	-12.07	-0.55	3.51e-28	Systemic lupus erythematosus;
LIHC	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.66	0.38	1.9e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg04306507	chr14:55594613	LGALS3	0.32	6.18	0.32	1.82e-9	Protein biomarker;
LIHC	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.56	-9.76	-0.47	5.3e-20	Systemic lupus erythematosus;
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg16070018	chr6:26224392	HIST1H3E	0.56	6.89	0.35	2.63e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.81	9.67	0.46	1.06e-19	Cognitive function;
LIHC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.63	0.34	1.29e-10	Schizophrenia;
LIHC	cis	rs611744	0.967	rs650968	chr8:109211055	C/G	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg14440974	chr22:39074834	NA	-0.44	-6.83	-0.35	3.87e-11	Menopause (age at onset);
LIHC	trans	rs72960926	0.744	rs55784940	chr6:74923315	G/T	cg07247405	chr1:2484626	LOC115110	0.56	6.62	0.34	1.36e-10	Metabolite levels (MHPG);
LIHC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.46	7.31	0.37	1.95e-12	Height;
LIHC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg13271783	chr10:134563150	INPP5A	-0.6	-7.17	-0.36	4.74e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.29	15.75	0.65	2.06e-42	Alzheimer's disease (late onset);
LIHC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.36	5.9	0.3	8.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.53	-0.49	1.24e-22	Chronic sinus infection;
LIHC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.64	8.7	0.43	1.43e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7149242	0.961	rs7142683	chr14:101158882	A/G	cg11726507	chr14:101155519	NA	-0.27	-6.06	-0.31	3.5e-9	Platelet count;
LIHC	cis	rs9649465	1.000	rs7776792	chr7:123335350	C/T	cg03229431	chr7:123269106	ASB15	0.39	8.29	0.41	2.7e-15	Migraine;
LIHC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg13660082	chr14:53194042	PSMC6	-0.42	-6.59	-0.34	1.64e-10	Alzheimer's disease (late onset);
LIHC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.73	12.62	0.56	2.97e-30	Menopause (age at onset);
LIHC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.87	13.18	0.58	2.31e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.37	-6.84	-0.35	3.59e-11	Essential tremor;
LIHC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg17724175	chr1:150552817	MCL1	0.46	9.16	0.44	4.94e-18	Melanoma;
LIHC	cis	rs7961581	0.700	rs1510940	chr12:71645945	T/A	cg05756094	chr12:71608604	NA	0.38	6.11	0.31	2.78e-9	Type 2 diabetes;
LIHC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.41e-8	Testicular germ cell tumor;
LIHC	trans	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg01134436	chr17:81009848	B3GNTL1	0.83	6.94	0.35	1.94e-11	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.75	13.68	0.59	2.89e-34	Homoarginine levels;
LIHC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.42	-5.73	-0.3	2.25e-8	Life satisfaction;
LIHC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.45	-0.33	3.93e-10	Diabetic kidney disease;
LIHC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.87	13.17	0.58	2.45e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11761441	1.000	rs11761441	chr7:82377	G/A	cg25149888	chr7:81075	NA	0.3	7.07	0.36	8.75e-12	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs910316	0.712	rs10131894	chr14:75446879	C/G	cg08847533	chr14:75593920	NEK9	0.88	17.8	0.69	1.22e-50	Height;
LIHC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.57	8.08	0.4	1.15e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.66	0.53	1.08e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.95	15.06	0.63	1.1e-39	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg12798992	chr6:167411361	FGFR1OP	0.42	6.71	0.34	7.89e-11	Crohn's disease;
LIHC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	7.98	0.4	2.22e-14	Mean platelet volume;
LIHC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.38	-5.89	-0.3	9.46e-9	Platelet count;
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.72	10.73	0.5	2.36e-23	Menarche (age at onset);
LIHC	cis	rs7106204	0.686	rs16912345	chr11:24283119	A/G	ch.11.24196551F	chr11:24239977	NA	0.64	5.83	0.3	1.28e-8	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.41	-7.34	-0.37	1.58e-12	Aortic root size;
LIHC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.34	8.3	0.41	2.4e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.3	-0.45	1.68e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg20607798	chr8:58055168	NA	0.62	7.91	0.39	3.52e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg03037974	chr15:76606532	NA	-0.61	-10.19	-0.48	1.75e-21	Blood metabolite levels;
LIHC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.58	-0.38	3.24e-13	Morning vs. evening chronotype;
LIHC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.48	7.1	0.36	7.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.37	5.88	0.3	9.95e-9	Menopause (age at onset);
LIHC	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.29	6.22	0.32	1.43e-9	Pulmonary function;
LIHC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.45	0.33	3.9e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.59	-8.24	-0.41	3.65e-15	Obesity-related traits;
LIHC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg12601576	chr4:906860	GAK	-0.61	-5.73	-0.3	2.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.92	16.9	0.67	5.43e-47	Menopause (age at onset);
LIHC	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg18898632	chr2:242989856	NA	-0.69	-8.68	-0.42	1.64e-16	Obesity-related traits;
LIHC	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg13175173	chr14:55914753	NA	-0.36	-8.58	-0.42	3.45e-16	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.23	0.41	3.91e-15	Schizophrenia;
LIHC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.61	-0.38	2.72e-13	Bipolar disorder;
LIHC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.34	-0.32	7.26e-10	Total body bone mineral density;
LIHC	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.69	-12.27	-0.55	6.5e-29	Longevity;
LIHC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.89	0.35	2.77e-11	Schizophrenia;
LIHC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg00204512	chr16:28754710	NA	0.36	6.44	0.33	3.94e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.6	8.84	0.43	4.97e-17	Prudent dietary pattern;
LIHC	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.81	0.35	4.36e-11	Bipolar disorder;
LIHC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.9	11.93	0.54	1.14e-27	Heart rate;
LIHC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.02	0.35	1.21e-11	Aortic root size;
LIHC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.75	13.73	0.6	1.74e-34	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.92	0.3	8.02e-9	Blood metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02307161	chr20:16710695	SNRPB2	0.45	6.16	0.32	2.07e-9	Pancreatic cancer;
LIHC	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.41	-0.37	9.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.25	0.36	2.84e-12	Self-reported allergy;
LIHC	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-10.6	-0.5	6.77e-23	Bipolar disorder;
LIHC	trans	rs4797559	0.839	rs4797560	chr18:11583495	C/T	cg07050032	chr17:78009173	CCDC40;TBC1D16	0.42	6.19	0.32	1.77e-9	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01824349	chr5:98260405	CHD1	-0.28	-6.21	-0.32	1.56e-9	Calcium levels;
LIHC	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.68	-10.58	-0.5	7.85e-23	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.44	-6.78	-0.34	5.31e-11	Longevity;Endometriosis;
LIHC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.46	-6.32	-0.32	8.16e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg24881330	chr22:46731750	TRMU	0.57	6.04	0.31	4.04e-9	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.95	12.22	0.55	9.31e-29	HIV-1 control;
LIHC	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.59	-7.4	-0.37	1.07e-12	Macular telangiectasia type 2;
LIHC	cis	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.83	14.75	0.62	1.92e-38	Aortic root size;
LIHC	cis	rs7188697	0.882	rs9921370	chr16:58611935	C/A	cg02549819	chr16:58548995	SETD6	0.48	7.57	0.38	3.46e-13	QT interval;
LIHC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg25039879	chr17:56429692	SUPT4H1	0.86	9.68	0.46	9.63e-20	Cognitive test performance;
LIHC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.66	6.81	0.35	4.32e-11	Alzheimer's disease;
LIHC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.78	-9.62	-0.46	1.51e-19	Mean platelet volume;
LIHC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg22777020	chr22:31556080	RNF185	-0.55	-6.26	-0.32	1.15e-9	Paclitaxel-induced neuropathy;
LIHC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.63	-0.34	1.3100000000000001e-10	Bladder cancer;
LIHC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	7.98	0.4	2.24e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs11761441	1.000	rs11761441	chr7:82377	G/A	cg13828236	chr7:80970	NA	0.29	7.06	0.36	9.49e-12	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs55702914	0.839	rs2059922	chr2:198188903	C/G	cg03934865	chr2:198174659	NA	-0.41	-5.76	-0.3	1.89e-8	Major depression and alcohol dependence;
LIHC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	14.71	0.62	2.82e-38	Menopause (age at onset);
LIHC	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.46	0.46	5.19e-19	Corneal astigmatism;
LIHC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg03037974	chr15:76606532	NA	0.73	14.06	0.61	9.63e-36	Blood metabolite levels;
LIHC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.51	-7.62	-0.38	2.57e-13	Total body bone mineral density;
LIHC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg04160030	chr1:24195659	FUCA1	-0.36	-5.88	-0.3	9.82e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.38	-6.39	-0.33	5.41e-10	Educational attainment;
LIHC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.83	-15.82	-0.65	1.04e-42	Height;
LIHC	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.46	-6.68	-0.34	9.93e-11	Dermatomyositis;
LIHC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg07423050	chr13:99094983	FARP1	-0.34	-5.88	-0.3	9.96e-9	Educational attainment (years of education);
LIHC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg00612595	chr21:47717864	NA	0.35	5.91	0.3	8.19e-9	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.82	-8.99	-0.44	1.75e-17	Vitiligo;
LIHC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.69	-9.76	-0.47	4.98e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.42	0.45	6.82e-19	Corneal astigmatism;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.07	0.31	3.34e-9	Prudent dietary pattern;
LIHC	cis	rs425535	0.588	rs4694657	chr4:74822074	T/A	cg02530824	chr4:74847766	PF4	-0.37	-5.95	-0.31	6.57e-9	Blood protein levels;
LIHC	cis	rs4684776	1.000	rs4684774	chr3:11426086	T/C	cg00170343	chr3:11313890	ATG7	-0.43	-5.83	-0.3	1.25e-8	Small vessel stroke;
LIHC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.84	-0.47	2.81e-20	Hip circumference adjusted for BMI;
LIHC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.59	0.56	3.86e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg05535760	chr7:792225	HEATR2	-0.59	-6.81	-0.35	4.31e-11	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2380220	0.810	rs66524640	chr6:95956566	T/C	cg15832292	chr6:96025679	MANEA	-0.6	-6.65	-0.34	1.16e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18867708	chr6:26865862	GUSBL1	0.55	8.3	0.41	2.37e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-10.72	-0.5	2.56e-23	Platelet count;
LIHC	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.95	15.93	0.65	4.09e-43	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg16970926	chr12:29381810	FAR2	0.32	6.8	0.34	4.75e-11	QT interval;
LIHC	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.54	-6.19	-0.32	1.69e-9	Ulcerative colitis;
LIHC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.6	-6.85	-0.35	3.53e-11	Menarche (age at onset);
LIHC	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.49	0.49	1.67e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.39	5.79	0.3	1.62e-8	Lung cancer;
LIHC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.48	-0.38	6.22e-13	Bipolar disorder;
LIHC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.06	-0.31	3.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7119038	0.818	rs2155433	chr11:118612921	G/A	cg19308663	chr11:118741387	NA	0.4	6.3	0.32	9.07e-10	Sjögren's syndrome;
LIHC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.49	7.35	0.37	1.44e-12	Personality dimensions;
LIHC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.49	8.09	0.4	1.06e-14	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.48	-7.43	-0.37	8.55e-13	Diastolic blood pressure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07667813	chr19:7985168	SNAPC2	-0.49	-6.46	-0.33	3.7e-10	Pancreatic cancer;
LIHC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.81	-0.3	1.43e-8	Neuroticism;
LIHC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg14132834	chr19:41945861	ATP5SL	-0.41	-6.06	-0.31	3.62e-9	Height;
LIHC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.42	-6.16	-0.32	2.05e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7267979	0.565	rs958075	chr20:25595123	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.42	-5.93	-0.31	7.52e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg14515779	chr1:101123966	NA	-0.45	-6.38	-0.33	5.67e-10	Monocyte count;
LIHC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg23461800	chr14:103021989	NA	0.42	5.89	0.3	9.47e-9	Platelet count;
LIHC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.34	6.05	0.31	3.85e-9	Alcohol dependence;
LIHC	cis	rs78545713	1.000	rs11753610	chr6:26251601	C/T	cg16070018	chr6:26224392	HIST1H3E	-0.72	-7.46	-0.37	7.27e-13	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.99	0.4	2.11e-14	Motion sickness;
LIHC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.32	-8.36	-0.41	1.55e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg12501888	chr15:85177176	SCAND2	-0.5	-7.83	-0.39	6.08e-14	P wave terminal force;
LIHC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	10.92	0.51	5.28e-24	Alzheimer's disease (late onset);
LIHC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00612595	chr21:47717864	NA	0.44	7.1	0.36	7.31e-12	Testicular germ cell tumor;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24158452	chr17:40428550	STAT5B	0.39	6.09	0.31	3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.66	-9.85	-0.47	2.62e-20	Selective IgA deficiency;
LIHC	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-14.51	-0.62	1.72e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.62	10.8	0.5	1.32e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	0.96	14.67	0.62	3.92e-38	Corneal structure;
LIHC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.46	6.23	0.32	1.37e-9	Major depressive disorder;
LIHC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.1	-0.58	4.48e-32	Type 2 diabetes;
LIHC	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg06766960	chr11:133703094	NA	-0.41	-6.11	-0.31	2.64e-9	Childhood ear infection;
LIHC	cis	rs6691722	0.503	rs4140519	chr1:24708304	C/T	cg18323236	chr1:24743029	NIPAL3	0.41	7.4	0.37	1.07e-12	Response to interferon beta in multiple sclerosis;
LIHC	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg00086871	chr4:6988644	TBC1D14	0.84	5.89	0.3	9.3e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	7.59	0.38	3.01e-13	Obesity-related traits;
LIHC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.44	-7.06	-0.36	9.37e-12	Multiple myeloma;
LIHC	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg03441853	chr15:73075003	ADPGK	0.28	5.93	0.31	7.48e-9	Triglyceride levels;
LIHC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.47	-5.72	-0.3	2.3e-8	Blood metabolite levels;
LIHC	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg15192750	chr16:69999425	NA	0.45	6.78	0.34	5.17e-11	IgE levels;
LIHC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.65	6.57	0.33	1.84e-10	Lymphocyte counts;
LIHC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.45	-6.18	-0.32	1.84e-9	Initial pursuit acceleration;
LIHC	cis	rs963731	0.649	rs6544187	chr2:39232275	G/C	cg04010122	chr2:39346883	SOS1	-0.81	-6.07	-0.31	3.32e-9	Corticobasal degeneration;
LIHC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.72	13.13	0.58	3.5e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs926392	0.896	rs4812357	chr20:37683071	C/T	cg16355469	chr20:37678765	NA	-0.39	-6.43	-0.33	4.26e-10	Dialysis-related mortality;
LIHC	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg05425664	chr17:57184151	TRIM37	-0.47	-5.89	-0.3	9.43e-9	Vitamin D levels;
LIHC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.57	0.38	3.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.84	-11.07	-0.51	1.51e-24	Heart rate;
LIHC	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	7.91	0.39	3.55e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.89	0.3	9.07e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.92	-18.79	-0.71	1.28e-54	Height;
LIHC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.29	5.91	0.3	8.49e-9	Bone mineral density;
LIHC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.57	-10.83	-0.51	1.04e-23	Mean corpuscular volume;
LIHC	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.88	-0.3	9.97e-9	Tuberculosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg03648631	chr4:103749307	UBE2D3	0.52	7.42	0.37	9.17e-13	Lung function (FEV1/FVC);
LIHC	cis	rs2279817	0.775	rs34357655	chr1:18009415	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.77	-0.39	9.48e-14	Neuroticism;
LIHC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.98	-0.35	1.55e-11	HDL cholesterol;
LIHC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.43	-6.85	-0.35	3.45e-11	Blood pressure (smoking interaction);
LIHC	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.41	-9.51	-0.46	3.5e-19	Breast cancer;
LIHC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.72	-10.85	-0.51	8.84e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.41	5.94	0.31	6.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.68	8.63	0.42	2.36e-16	Initial pursuit acceleration;
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.51	5.73	0.3	2.19e-8	Schizophrenia;
LIHC	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.59	6.88	0.35	2.84e-11	Bipolar disorder;
LIHC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.86	16.18	0.66	3.85e-44	Multiple myeloma (IgH translocation);
LIHC	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-7.04	-0.36	1.07e-11	Body mass index (adult);
LIHC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.03	-0.68	1.55e-47	Gut microbiome composition (summer);
LIHC	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.1	21.88	0.76	5.74e-67	Schizophrenia;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17873919	chr5:134094447	DDX46	-0.42	-6.09	-0.31	3.05e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.58	7.69	0.38	1.63e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.53	0.49	1.19e-22	Coffee consumption (cups per day);
LIHC	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.56	-8.99	-0.44	1.7e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.79	12.77	0.57	8.25e-31	Colorectal cancer;
LIHC	cis	rs2108622	0.727	rs3093216	chr19:15987737	A/G	cg13772218	chr19:15982569	NA	0.36	7.35	0.37	1.49e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.67	-0.38	1.81e-13	Celiac disease or Rheumatoid arthritis;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05508245	chr7:6203267	CYTH3	0.39	6.25	0.32	1.25e-9	Hepatitis;
LIHC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg25193494	chr16:90016004	DEF8	-0.44	-5.72	-0.3	2.35e-8	Skin colour saturation;
LIHC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.57	9.26	0.45	2.37e-18	Lymphocyte counts;
LIHC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg08499158	chr17:42289980	UBTF	0.53	8.64	0.42	2.14e-16	Total body bone mineral density;
LIHC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.55	9.73	0.47	6.54e-20	Airflow obstruction;
LIHC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.67	8.51	0.42	5.46e-16	Initial pursuit acceleration;
LIHC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	11.88	0.54	1.7e-27	Platelet count;
LIHC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06002616	chr8:101225028	SPAG1	-0.35	-5.76	-0.3	1.83e-8	Atrioventricular conduction;
LIHC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.53	7.21	0.36	3.61e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.74	0.3	2.12e-8	Axial length;
LIHC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.5	6.46	0.33	3.69e-10	Initial pursuit acceleration;
LIHC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.53	9.57	0.46	2.22e-19	Platelet distribution width;
LIHC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.66	10.98	0.51	3.03e-24	Pediatric autoimmune diseases;
LIHC	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.8	-0.3	1.53e-8	Blood metabolite levels;
LIHC	cis	rs655641	0.734	rs504129	chr11:85690531	A/T	cg09030501	chr11:85779252	PICALM	-0.52	-6.33	-0.32	7.79e-10	Platelet count;
LIHC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.73	-10.48	-0.49	1.81e-22	Longevity;
LIHC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.39	7.05	0.36	1e-11	Psoriasis;
LIHC	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.43	6.36	0.33	6.39e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.55	10.17	0.48	2.19e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3015497	0.616	rs1389650	chr14:51081449	C/T	cg09863266	chr14:51125203	SAV1	-0.38	-6.01	-0.31	4.69e-9	Mean platelet volume;
LIHC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg12311636	chr6:118886798	C6orf204	-0.52	-6.23	-0.32	1.35e-9	Diastolic blood pressure;
LIHC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.37	0.45	1.01e-18	Platelet count;
LIHC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg19338460	chr6:170058176	WDR27	-0.38	-5.9	-0.3	8.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg19645103	chr12:69753606	YEATS4	-0.4	-5.92	-0.3	7.74e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.63	9.04	0.44	1.18e-17	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg15889976	chr12:124432796	CCDC92	-0.4	-7.4	-0.37	1.06e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.36	6.1	0.31	2.85e-9	Height;
LIHC	cis	rs918629	0.567	rs2348984	chr5:95236010	A/C	cg10483112	chr5:95245456	ELL2	-0.38	-6.96	-0.35	1.71e-11	IgG glycosylation;
LIHC	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-0.84	-9.29	-0.45	1.86e-18	Exhaled nitric oxide output;
LIHC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.92	0.3	7.85e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.74	12.43	0.56	1.65e-29	Monocyte count;
LIHC	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg04374321	chr14:90722782	PSMC1	0.48	6.97	0.35	1.63e-11	Longevity;
LIHC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.69	-10.94	-0.51	4.24e-24	Skin colour saturation;
LIHC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg25801113	chr15:45476975	SHF	0.37	6.21	0.32	1.5e-9	Uric acid levels;
LIHC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.45	6.05	0.31	3.87e-9	Initial pursuit acceleration;
LIHC	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.38e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-5.82	-0.3	1.35e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg25838818	chr2:108905173	SULT1C2	0.39	6.99	0.35	1.43e-11	Blood pressure;
LIHC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-12.45	-0.56	1.35e-29	Total body bone mineral density;
LIHC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	-0.41	-5.79	-0.3	1.59e-8	Tonsillectomy;
LIHC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg13395646	chr4:1353034	KIAA1530	-0.48	-7.8	-0.39	7.41e-14	Obesity-related traits;
LIHC	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg10820045	chr2:198174542	NA	0.47	7.03	0.36	1.12e-11	Intracranial aneurysm;
LIHC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.01	0.44	1.5e-17	IgG glycosylation;
LIHC	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.65	7.85	0.39	5.27e-14	Itch intensity from mosquito bite;
LIHC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.46	6.71	0.34	8.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.51	-7.62	-0.38	2.49e-13	Renal cell carcinoma;
LIHC	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.45	-7.75	-0.39	1.09e-13	Male sexual orientation;
LIHC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.54	6.21	0.32	1.53e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.55	-6.46	-0.33	3.67e-10	Osteoarthritis;
LIHC	cis	rs1144333	1.000	rs2202019	chr1:76299181	G/A	cg22875332	chr1:76189707	ACADM	0.44	7.02	0.36	1.18e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.56	-10.23	-0.48	1.36e-21	Total body bone mineral density;
LIHC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.77	10.42	0.49	2.82e-22	Coronary artery disease;
LIHC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.9	-0.35	2.59e-11	Sudden cardiac arrest;
LIHC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg24101359	chr6:42928495	GNMT	0.46	6.2	0.32	1.62e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6066825	0.644	rs926629	chr20:47335736	A/G	cg18078177	chr20:47281410	PREX1	0.41	6.67	0.34	1.01e-10	Colorectal cancer;
LIHC	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.38	8.97	0.44	2.01e-17	Blood protein levels;
LIHC	cis	rs2540917	0.765	rs243081	chr2:60613776	G/A	cg00543073	chr2:60773386	BCL11A	-0.32	-6.32	-0.32	8.39e-10	Mean corpuscular volume;
LIHC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.35	0.68	7.79e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.82	-0.35	4.13e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.96	0.57	1.59e-31	Prudent dietary pattern;
LIHC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.57	9.62	0.46	1.5700000000000001e-19	Coronary artery disease;
LIHC	cis	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg21605333	chr4:119757512	SEC24D	0.83	6.88	0.35	2.93e-11	Cannabis dependence symptom count;
LIHC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.78	0.43	7.92e-17	Exhaled nitric oxide levels;
LIHC	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.47	7.05	0.36	9.81e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs655641	1.000	rs2458499	chr11:85659847	C/T	cg09030501	chr11:85779252	PICALM	-0.5	-5.88	-0.3	9.81e-9	Platelet count;
LIHC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-17.77	-0.69	1.67e-50	Coronary artery disease;
LIHC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27297192	chr10:134578999	INPP5A	0.56	7.71	0.38	1.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.17	-0.32	1.9e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.88	-17.28	-0.68	1.62e-48	Height;
LIHC	trans	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg17675199	chr6:35436792	RPL10A	0.31	6.22	0.32	1.49e-9	Coronary artery disease;
LIHC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	1.05	12.59	0.56	3.91e-30	Red blood cell traits;
LIHC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg17724175	chr1:150552817	MCL1	0.43	8.68	0.42	1.61e-16	Tonsillectomy;
LIHC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.62	10.86	0.51	8.64e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.8	0.35	4.6e-11	Lung cancer;
LIHC	trans	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04565464	chr8:145669602	NFKBIL2	0.41	6.8	0.35	4.61e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.64	12.73	0.57	1.15e-30	Gestational age at birth (maternal effect);
LIHC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.84e-19	Waist circumference;Weight;
LIHC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	7.32	0.37	1.78e-12	Aortic root size;
LIHC	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.51	0.33	2.64e-10	Height;
LIHC	trans	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg07393940	chr7:158741817	NA	-0.57	-6.95	-0.35	1.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs7635838	0.963	rs7627171	chr3:11413429	G/C	cg00170343	chr3:11313890	ATG7	0.45	7.36	0.37	1.39e-12	HDL cholesterol;
LIHC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg03146154	chr1:46216737	IPP	-0.46	-7.28	-0.37	2.3e-12	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg03854865	chr6:26224070	HIST1H3E	0.63	6.97	0.35	1.59e-11	Gout;Renal underexcretion gout;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26887379	chr1:12677936	DHRS3	0.47	6.33	0.32	7.82e-10	Pancreatic cancer;
LIHC	cis	rs11098699	0.821	rs12500715	chr4:124230078	T/C	cg09941581	chr4:124220074	SPATA5	0.33	6.57	0.33	1.83e-10	Mosquito bite size;
LIHC	trans	rs2591576	0.935	rs830230	chr5:165402097	T/C	cg02030008	chr7:157476930	PTPRN2	-0.33	-6.16	-0.32	2.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg21724239	chr8:58056113	NA	0.46	6.09	0.31	3.08e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg08451977	chr7:100849825	PLOD3	-0.45	-6.9	-0.35	2.54e-11	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03700308	chr20:49575492	MOCS3;DPM1	0.45	6.08	0.31	3.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6439153	0.933	rs11711812	chr3:128708554	G/A	cg25356066	chr3:128598488	ACAD9	0.42	5.74	0.3	2.08e-8	Pneumococcal bacteremia;
LIHC	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-6.81	-0.35	4.45e-11	Morning vs. evening chronotype;
LIHC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-8.98	-0.44	1.87e-17	Body mass index;
LIHC	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.81	-7.37	-0.37	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg18887096	chr2:219472410	PLCD4	0.35	5.97	0.31	5.94e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-7.01	-0.35	1.25e-11	Diabetic kidney disease;
LIHC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg23990641	chr6:118823964	C6orf204;BRD7P3	-0.5	-6.2	-0.32	1.66e-9	Diastolic blood pressure;
LIHC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.38	6.25	0.32	1.2e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4586057	0.514	rs7089472	chr10:92663108	C/T	cg14313238	chr10:92632228	RPP30	0.4	6.87	0.35	3.04e-11	Economic and political preferences (time);
LIHC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11645453	chr3:52864694	ITIH4	0.21	5.74	0.3	2.09e-8	Bipolar disorder;
LIHC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.0	-0.44	1.55e-17	Obesity-related traits;
LIHC	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	6.1	0.31	2.86e-9	Mean platelet volume;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.57	8.52	0.42	5.29e-16	Longevity;
LIHC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.72	0.43	1.21e-16	Motion sickness;
LIHC	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg08345082	chr10:99160200	RRP12	-0.4	-7.06	-0.36	9.47e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.08e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.65	-10.25	-0.48	1.15e-21	Malaria;
LIHC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.42	5.91	0.3	8.18e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg24579218	chr15:68104479	NA	-0.35	-5.9	-0.3	8.7e-9	Restless legs syndrome;
LIHC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.6	0.38	2.79e-13	Bipolar disorder;
LIHC	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.68	-0.69	3.98e-50	Schizophrenia;
LIHC	cis	rs9378688	0.654	rs9391946	chr6:2263097	A/G	cg12303981	chr6:2244766	GMDS	-0.45	-6.04	-0.31	4.11e-9	Caudate nucleus volume;
LIHC	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.55	-0.38	4.11e-13	Schizophrenia;
LIHC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg17135325	chr3:160939158	NMD3	0.41	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.2	0.32	1.61e-9	Schizophrenia;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg01587390	chr19:10221818	PPAN-P2RY11;P2RY11;PPAN	0.42	6.22	0.32	1.46e-9	Electroencephalogram traits;
LIHC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-7.99	-0.4	2.04e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.87	-18.5	-0.71	1.85e-53	Height;
LIHC	trans	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg07393940	chr7:158741817	NA	0.55	6.56	0.33	1.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.64	-0.34	1.23e-10	Morning vs. evening chronotype;
LIHC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-7.03	-0.36	1.12e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs8067354	0.872	rs2645483	chr17:57848184	T/G	cg13753209	chr17:57696993	CLTC	0.58	8.64	0.42	2.22e-16	Hemoglobin concentration;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24262715	chr15:44038991	PDIA3;CATSPER2P1	0.39	6.24	0.32	1.32e-9	Calcium levels;
LIHC	cis	rs7756236	0.521	rs9470363	chr6:36624713	G/A	cg08179530	chr6:36648295	CDKN1A	0.42	6.34	0.32	7.29e-10	QRS duration;
LIHC	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.62	8.71	0.43	1.32e-16	Economic and political preferences (feminism/equality);
LIHC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.83	14.45	0.62	2.7e-37	Headache;
LIHC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	3.97e-9	Diabetic kidney disease;
LIHC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.0	15.32	0.64	1.06e-40	Breast cancer;
LIHC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.68	7.12	0.36	6.57e-12	Alzheimer's disease;
LIHC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.38	-0.33	5.85e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg20737812	chr15:86336631	KLHL25	-0.42	-5.83	-0.3	1.27e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg01401336	chr17:2606734	KIAA0664	0.37	6.46	0.33	3.5e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.4	7.7	0.38	1.49e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg03146154	chr1:46216737	IPP	0.5	8.54	0.42	4.4e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.95	-0.47	1.22e-20	Chronic sinus infection;
LIHC	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.38	-7.91	-0.39	3.53e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-9.92	-0.47	1.49e-20	Response to antipsychotic treatment;
LIHC	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.29	7.18	0.36	4.37e-12	Gut microbiome composition (winter);
LIHC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.26	-0.58	1.16e-32	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.53	-8.05	-0.4	1.35e-14	Total body bone mineral density;
LIHC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.58	8.6	0.42	2.89e-16	Obesity-related traits;
LIHC	trans	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	6.88	0.35	2.86e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs10508774	0.925	rs12416437	chr10:32751526	A/T	cg01819863	chr10:32635814	EPC1	0.65	6.01	0.31	4.72e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.43	-6.1	-0.31	2.87e-9	Type 2 diabetes;
LIHC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg22098324	chr2:232645906	PDE6D	0.48	6.41	0.33	4.93e-10	Glycated hemoglobin levels;
LIHC	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.3	-0.32	8.95e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02985541	chr2:219472218	PLCD4	0.45	8.5	0.42	6.04e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg01206211	chr2:36825736	FEZ2	0.46	7.36	0.37	1.4e-12	Height;
LIHC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.6	-0.5	6.66e-23	Chronic sinus infection;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01866215	chr16:3150293	NA	0.51	6.49	0.33	3.09e-10	Hepatitis;
LIHC	cis	rs365132	0.791	rs55954117	chr5:176454075	A/G	cg16309518	chr5:176445507	NA	-0.52	-9.69	-0.46	8.91e-20	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.57	6.48	0.33	3.13e-10	Neutrophil percentage of white cells;
LIHC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.28	-0.45	2.06e-18	Ulcerative colitis;
LIHC	cis	rs17125944	0.615	rs8019585	chr14:53374843	G/A	cg00686598	chr14:53173677	PSMC6	0.85	9.22	0.45	3.1e-18	Alzheimer's disease (late onset);
LIHC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.9	0.51	6.28e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	8.89e-15	Prudent dietary pattern;
LIHC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg06565975	chr8:143823917	SLURP1	0.32	6.03	0.31	4.27e-9	Urinary tract infection frequency;
LIHC	trans	rs10411161	0.702	rs7256926	chr19:52391988	A/G	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg12560992	chr17:57184187	TRIM37	0.68	8.8	0.43	7e-17	Vitamin D levels;
LIHC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg13957321	chr17:43675089	NA	0.5	7.92	0.39	3.36e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4722404	0.800	rs6943609	chr7:3141596	G/A	cg19214707	chr7:3157722	NA	0.32	5.85	0.3	1.17e-8	Atopic dermatitis;
LIHC	cis	rs7523273	0.597	rs4844390	chr1:207934849	A/G	cg22525895	chr1:207977042	MIR29B2	-0.63	-7.23	-0.36	3.15e-12	Schizophrenia;
LIHC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.4	0.33	5.17e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.82	0.39	6.54e-14	Prudent dietary pattern;
LIHC	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.58	-7.1	-0.36	7.18e-12	IgG glycosylation;
LIHC	cis	rs9918079	0.560	rs6414767	chr4:15655721	A/G	cg24225360	chr4:15471699	CC2D2A	-0.39	-6.17	-0.32	1.9e-9	Obesity-related traits;
LIHC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	1.04	17.12	0.68	7.05e-48	Metabolic syndrome;
LIHC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg10755058	chr3:40428713	ENTPD3	0.39	6.61	0.34	1.45e-10	Renal cell carcinoma;
LIHC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.82	11.89	0.54	1.6e-27	Psoriasis;
LIHC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.56	-7.35	-0.37	1.46e-12	Initial pursuit acceleration;
LIHC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.44	-0.33	4e-10	Blood metabolite levels;
LIHC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg24955955	chr5:415729	AHRR	0.32	6.64	0.34	1.27e-10	Cystic fibrosis severity;
LIHC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.84	8.66	0.42	1.88e-16	Body mass index;
LIHC	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-8.61	-0.42	2.63e-16	Response to anti-depressant treatment in major depressive disorder;
LIHC	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.06	-0.31	3.62e-9	Height;
LIHC	cis	rs3736485	0.966	rs6493498	chr15:51754451	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.86	-0.3	1.09e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10178409	1	rs10178409	chr2:73855507	G/T	cg20560298	chr2:73613845	ALMS1	-0.52	-5.95	-0.31	6.81e-9	Urinary metabolites;
LIHC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg00204512	chr16:28754710	NA	0.38	6.9	0.35	2.55e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg09990169	chr2:241835740	C2orf54	0.66	9.26	0.45	2.4e-18	Urinary metabolites;
LIHC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.4	-0.37	1.04e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs11023332	0.641	rs4281505	chr11:14800660	A/G	cg19336497	chr11:14380999	RRAS2	-0.35	-6.18	-0.32	1.78e-9	Adiponectin levels;Vitamin D levels;
LIHC	cis	rs8081395	0.805	rs1295927	chr17:57929535	A/G	cg02344993	chr17:57696989	CLTC	0.45	7.5	0.38	5.48e-13	White blood cell count;
LIHC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.0	-0.4	1.95e-14	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-6.77	-0.34	5.63e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-11.52	-0.53	3.63e-26	Platelet distribution width;
LIHC	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-8.51	-0.42	5.45e-16	Colorectal cancer;
LIHC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	9.91	0.47	1.61e-20	Mean platelet volume;
LIHC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.56	9.87	0.47	2.2e-20	Alcohol dependence;
LIHC	cis	rs67981189	0.593	rs7143595	chr14:71522001	A/T	cg15816911	chr14:71606274	NA	0.42	6.7	0.34	8.41e-11	Schizophrenia;
LIHC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.79	-0.34	4.89e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs3736594	0.513	rs62138964	chr2:27814438	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.92	0.35	2.29e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs55665837	0.701	rs10160597	chr11:14603992	G/A	cg00085434	chr11:14927489	NA	0.43	6.04	0.31	4.02e-9	Vitamin D levels;
LIHC	cis	rs11166927	1.000	rs10435690	chr8:140802093	C/T	cg16909799	chr8:140841666	TRAPPC9	0.46	7.59	0.38	3.09e-13	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg05772935	chr16:1790400	MAPK8IP3	0.61	6.09	0.31	3.01e-9	Mean platelet volume;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.28	0.32	1.05e-9	Ulcerative colitis;
LIHC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.84	12.03	0.55	4.88e-28	Post bronchodilator FEV1;
LIHC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.54	8.59	0.42	3.03e-16	Height;
LIHC	trans	rs13325613	0.748	rs114115904	chr3:46268664	C/T	cg26337592	chr1:153642686	ILF2	0.68	6.18	0.32	1.81e-9	Monocyte count;
LIHC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.49	8.18	0.4	5.69e-15	Mean corpuscular volume;
LIHC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.32	-0.41	2.17e-15	Schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14472810	chr7:1936732	MAD1L1	0.42	6.3	0.32	9.2e-10	Longevity;
LIHC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.0	0.58	1.11e-31	Cognitive test performance;
LIHC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.48	0.33	3.16e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.63	9.49	0.46	4.11e-19	Platelet count;
LIHC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.49	6.29	0.32	9.61e-10	Initial pursuit acceleration;
LIHC	cis	rs10838687	0.867	rs2957873	chr11:47249294	G/A	cg26139080	chr11:47293733	MADD	0.42	6.01	0.31	4.67e-9	Proinsulin levels;
LIHC	cis	rs7116495	0.881	rs615000	chr11:71802952	A/C	cg26138937	chr11:71823887	C11orf51	-0.8	-7.88	-0.39	4.5e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg20435097	chr10:126320824	FAM53B	0.34	5.87	0.3	1.06e-8	Asthma;
LIHC	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.91	0.35	2.36e-11	Bipolar disorder;
LIHC	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.57	-9.98	-0.47	9.72e-21	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg03037974	chr15:76606532	NA	0.63	10.97	0.51	3.47e-24	Blood metabolite levels;
LIHC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.47	7.25	0.36	2.89e-12	Height;
LIHC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.75	0.39	1.07e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.38	-6.86	-0.35	3.25e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13409248	chr3:40428643	ENTPD3	0.5	8.43	0.41	9.5e-16	Renal cell carcinoma;
LIHC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.34	-18.13	-0.7	5.81e-52	Gout;
LIHC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.68	-14.14	-0.61	4.53e-36	Sense of smell;
LIHC	cis	rs3820500	0.543	rs7539143	chr1:117977324	G/A	cg20383390	chr1:117909022	MAN1A2	0.46	5.91	0.3	8.13e-9	Pneumonia;
LIHC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg03689076	chr20:33865952	NA	-0.56	-6.48	-0.33	3.14e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs74233809	1.000	rs77420391	chr10:104945823	G/A	cg03493300	chr10:104813866	CNNM2	0.48	6.16	0.32	2.02e-9	Birth weight;
LIHC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.09	0.4	1.02e-14	Lymphocyte counts;
LIHC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg25039879	chr17:56429692	SUPT4H1	0.75	8.6	0.42	2.85e-16	Cognitive test performance;
LIHC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-9.17	-0.44	4.41e-18	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	0.53	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.35	22.78	0.78	1.47e-70	Corneal structure;
LIHC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.5	9.1	0.44	7.35e-18	Height;
LIHC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.76	11.33	0.52	1.79e-25	Coronary artery disease;
LIHC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.55	-9.27	-0.45	2.14e-18	Blood metabolite levels;
LIHC	cis	rs6750047	0.771	rs1056836	chr2:38298203	C/G	cg07380506	chr2:38303506	CYP1B1	-0.59	-7.6	-0.38	2.85e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg15208524	chr1:10270712	KIF1B	0.39	6.03	0.31	4.2e-9	Hepatocellular carcinoma;
LIHC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.61	6.68	0.34	9.45e-11	Gut microbiome composition (summer);
LIHC	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.85	-0.3	1.17e-8	Coronary artery disease;
LIHC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.49	-0.33	3.09e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-0.82	-9.26	-0.45	2.34e-18	Exhaled nitric oxide output;
LIHC	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	0.71	8.29	0.41	2.67e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.7	-0.34	8.54e-11	Menarche (age at onset);
LIHC	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg08345082	chr10:99160200	RRP12	-0.36	-5.96	-0.31	6.14e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.45	-6.19	-0.32	1.74e-9	Menarche (age at onset);
LIHC	cis	rs1789	0.903	rs6850422	chr4:15682437	C/T	cg24225360	chr4:15471699	CC2D2A	-0.38	-5.85	-0.3	1.12e-8	Blood protein levels;
LIHC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Vitiligo;
LIHC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.34	6.87	0.35	3.06e-11	Alcohol dependence;
LIHC	cis	rs2741335	0.876	rs2565058	chr8:27337207	G/T	cg07150473	chr8:27338183	CHRNA2	-0.44	-6.37	-0.33	6.18e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
LIHC	trans	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg10756647	chr7:56101905	PSPH	1.07	13.4	0.59	3.25e-33	Diabetic kidney disease;
LIHC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.2	0.45	3.69e-18	Hemoglobin concentration;
LIHC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.8	-12.48	-0.56	1.06e-29	Total body bone mineral density;
LIHC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.41	6.96	0.35	1.76e-11	Alcohol dependence;
LIHC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.42	8.06	0.4	1.32e-14	Schizophrenia;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg00691206	chr18:14132697	ZNF519	0.4	6.78	0.34	5.32e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	9.8	0.47	3.91e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.08	0.36	8.07e-12	Renal cell carcinoma;
LIHC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.64	10.95	0.51	4.12e-24	Colorectal cancer;
LIHC	cis	rs507080	0.733	rs673547	chr11:118573339	G/A	cg04173919	chr11:118528438	PHLDB1	0.32	6.02	0.31	4.44e-9	Serum metabolite levels;
LIHC	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.45	-0.46	5.33e-19	Colorectal cancer;
LIHC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.38	6.14	0.32	2.31e-9	Monocyte count;
LIHC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.42	-0.33	4.67e-10	Alzheimer's disease (late onset);
LIHC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.23	-0.45	2.8e-18	Schizophrenia;
LIHC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg15664640	chr17:80829946	TBCD	0.38	5.95	0.31	6.58e-9	Glycated hemoglobin levels;
LIHC	cis	rs6752107	0.840	rs2119505	chr2:234154651	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	7.76	0.39	1.01e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg15212455	chr7:39170539	POU6F2	0.4	7.09	0.36	7.83e-12	IgG glycosylation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07950158	chr19:45874032	ERCC2	0.47	6.89	0.35	2.72e-11	Cognitive function;
LIHC	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg25356066	chr3:128598488	ACAD9	0.55	7.28	0.37	2.32e-12	IgG glycosylation;
LIHC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.71	13.25	0.58	1.26e-32	Height;
LIHC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg11764359	chr7:65958608	NA	-0.57	-5.95	-0.31	6.6e-9	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16279940	chr3:108308523	DZIP3;KIAA1524	-0.46	-6.39	-0.33	5.38e-10	Pancreatic cancer;
LIHC	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04530015	chr2:215796436	ABCA12	-0.37	-5.91	-0.3	8.43e-9	Neuroblastoma;
LIHC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.68	11.41	0.52	9.26e-26	Menopause (age at onset);
LIHC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02985541	chr2:219472218	PLCD4	0.42	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.61	-0.46	1.6e-19	Mean platelet volume;
LIHC	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.89	15.25	0.64	1.96e-40	Gastritis;
LIHC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.81	-0.3	1.41e-8	Arsenic metabolism;
LIHC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.65	9.87	0.47	2.22e-20	Neutrophil percentage of white cells;
LIHC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg15691649	chr6:25882328	NA	-0.54	-6.8	-0.35	4.71e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11231694	1.000	rs11231694	chr11:63862882	G/C	cg18375707	chr11:64034959	PLCB3	-0.44	-5.75	-0.3	1.95e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg22834771	chr12:69754056	YEATS4	-0.39	-5.91	-0.3	8.41e-9	Response to diuretic therapy;
LIHC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.62	-8.23	-0.41	3.95e-15	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.82	0.3	1.35e-8	Red blood cell count;Reticulocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10581632	chr12:56360715	CDK2;SILV	0.47	6.55	0.33	2.1e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1355223	0.902	rs11819839	chr11:34715778	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.42	-0.33	4.62e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg01788221	chr16:89496183	ANKRD11	-0.37	-5.88	-0.3	9.74e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.57	11.2	0.52	5e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-27.12	-0.83	3.15e-87	Myeloid white cell count;
LIHC	cis	rs6876835	0.553	rs7720397	chr5:6598893	T/C	cg04204831	chr5:6583394	LOC255167	0.4	6.24	0.32	1.27e-9	Visceral fat;
LIHC	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg10820045	chr2:198174542	NA	0.48	7.4	0.37	1.09e-12	Intracranial aneurysm;
LIHC	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.2	-0.41	5.07e-15	Colorectal cancer;
LIHC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.05e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg06026331	chr20:60912101	LAMA5	0.61	8.86	0.43	4.47e-17	Colorectal cancer;
LIHC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.73	0.57	1.17e-30	Prudent dietary pattern;
LIHC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.75	14.11	0.61	6.23e-36	Height;
LIHC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.41	-6.35	-0.32	7.03e-10	Height;
LIHC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.43	-7.24	-0.36	2.89e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs3823572	0.564	rs2971973	chr7:133644256	G/A	cg03336402	chr7:133662267	EXOC4	-0.47	-5.75	-0.3	1.93e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-8.92	-0.43	2.86e-17	Ulcerative colitis;
LIHC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg04455712	chr21:45112962	RRP1B	0.41	6.79	0.34	5.1e-11	Mean corpuscular volume;
LIHC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.6	10.23	0.48	1.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.82	11.67	0.53	1.04e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg16479474	chr6:28041457	NA	0.36	6.17	0.32	1.95e-9	Cardiac Troponin-T levels;
LIHC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	trans	rs4714291	0.802	rs2984430	chr6:39983741	A/G	cg02267698	chr19:7991119	CTXN1	-0.38	-6.46	-0.33	3.66e-10	Strep throat;
LIHC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-8.94	-0.44	2.4e-17	Immature fraction of reticulocytes;Schizophrenia;
LIHC	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.53	-0.33	2.38e-10	Body mass index;
LIHC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.29	-0.32	9.64e-10	Chronic sinus infection;
LIHC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	5.71	0.3	2.43e-8	Platelet count;
LIHC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg16558253	chr16:72132732	DHX38	-0.5	-8.22	-0.41	4.16e-15	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	trans	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.5	-0.33	2.76e-10	Endometrial cancer;
LIHC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	8.07	0.4	1.17e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs507080	0.736	rs659564	chr11:118570914	C/A	cg04173919	chr11:118528438	PHLDB1	0.33	6.16	0.32	2.06e-9	Serum metabolite levels;
LIHC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.58	10.4	0.49	3.53e-22	Mean corpuscular volume;
LIHC	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.37	10.13	0.48	2.93e-21	Weight;
LIHC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	8.26	0.41	3.16e-15	Body mass index;
LIHC	cis	rs4755351	0.553	rs11032156	chr11:33158142	T/C	cg05567920	chr11:33183001	CSTF3	0.43	6.26	0.32	1.17e-9	Lung cancer in ever smokers;
LIHC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.64	12.25	0.55	7.71e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.98	15.78	0.65	1.63e-42	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs11212260	0.678	rs11212203	chr11:107267629	A/G	cg25435332	chr11:107328525	CWF19L2	0.72	8.26	0.41	3.14e-15	IgG glycosylation;
LIHC	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg07862535	chr7:139043722	LUC7L2	0.58	10.03	0.48	6.38e-21	Diisocyanate-induced asthma;
LIHC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.65	-11.13	-0.52	9.18e-25	Crohn's disease;
LIHC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-6.23	-0.32	1.38e-9	Alzheimer's disease (late onset);
LIHC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-7.52	-0.38	4.81e-13	Cognitive function;
LIHC	cis	rs17106184	1.000	rs17106235	chr1:50943370	C/G	cg07174182	chr1:51127561	FAF1	-0.66	-7.21	-0.36	3.72e-12	Type 2 diabetes;
LIHC	cis	rs12744310	0.945	rs12740093	chr1:41760001	C/T	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.72e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.39	5.9	0.3	8.9e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.45	-0.42	8.74e-16	Body mass index (adult);
LIHC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.57	7.59	0.38	3.13e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg20195005	chr22:42527684	CYP2D6	0.32	6.15	0.32	2.19e-9	Birth weight;
LIHC	cis	rs2286503	0.780	rs2240727	chr7:22852512	C/T	cg11367502	chr7:22862612	TOMM7	0.47	8.08	0.4	1.12e-14	Fibrinogen;
LIHC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg22633049	chr21:46681294	NA	-0.37	-6.32	-0.32	8.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-8.78	-0.43	7.7e-17	Schizophrenia;
LIHC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.27e-12	Bipolar disorder;
LIHC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg04013166	chr16:89971882	TCF25	0.49	6.04	0.31	4.01e-9	Skin colour saturation;
LIHC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.98	16.41	0.66	4.89e-45	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-12.09	-0.55	2.86e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.99	15.28	0.64	1.49e-40	Breast cancer;
LIHC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02985541	chr2:219472218	PLCD4	-0.41	-6.57	-0.33	1.89e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-6.05	-0.31	3.75e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg02503808	chr4:7069936	GRPEL1	0.78	11.35	0.52	1.55e-25	Monocyte percentage of white cells;
LIHC	cis	rs2834256	0.961	rs7280640	chr21:35125078	C/G	cg14850771	chr21:34775459	IFNGR2	0.38	5.71	0.3	2.43e-8	Red cell distribution width;
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14671364	chr1:107599128	PRMT6	0.52	7.73	0.39	1.2e-13	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.92	15.21	0.64	2.96e-40	Metabolic syndrome;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg03604819	chr4:17813007	NCAPG;DCAF16	-0.44	-6.17	-0.32	1.96e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg08539965	chr1:21396338	EIF4G3	0.34	6.02	0.31	4.48e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg27166718	chr6:118880109	PLN;C6orf204	-0.51	-6.21	-0.32	1.56e-9	Diastolic blood pressure;
LIHC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.5	-0.38	5.67e-13	Bipolar disorder;
LIHC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg03146154	chr1:46216737	IPP	-0.47	-7.6	-0.38	2.79e-13	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.35	0.52	1.52e-25	Platelet count;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02290350	chr8:58132656	NA	0.48	9.52	0.46	3.28e-19	Developmental language disorder (linguistic errors);
LIHC	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.5	-7.69	-0.38	1.63e-13	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg07424592	chr7:64974309	NA	0.81	9.49	0.46	4.1e-19	Diabetic kidney disease;
LIHC	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.29	-6.22	-0.32	1.49e-9	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-7.36	-0.37	1.35e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.63	0.56	2.78e-30	Total body bone mineral density;
LIHC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18504358	chr14:23340787	LRP10	0.47	6.89	0.35	2.64e-11	Pancreatic cancer;
LIHC	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.44	-6.14	-0.32	2.27e-9	Tuberculosis;
LIHC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.56	-10.58	-0.5	7.91e-23	Glomerular filtration rate (creatinine);
LIHC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.59	6.15	0.32	2.2e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.73	12.58	0.56	4.43e-30	Menopause (age at onset);
LIHC	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.54	10.37	0.49	4.27e-22	Multiple myeloma;
LIHC	cis	rs4407350	0.837	rs5765710	chr22:44914354	C/T	cg26276947	chr22:44892394	LDOC1L	-0.32	-6.07	-0.31	3.47e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg22079354	chr11:130786696	SNX19	0.43	6.18	0.32	1.82e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.39	7.85	0.39	5.3e-14	Renal cell carcinoma;
LIHC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg18944383	chr4:111397179	ENPEP	0.35	8.09	0.4	1.05e-14	Coronary artery disease;
LIHC	cis	rs3823572	0.564	rs10272270	chr7:133636174	A/T	cg03336402	chr7:133662267	EXOC4	0.48	5.93	0.31	7.34e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.36	7.04	0.36	1.07e-11	Blood protein levels;
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-7.19	-0.36	4.23e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.43	-7.18	-0.36	4.49e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg20607798	chr8:58055168	NA	0.66	8.38	0.41	1.43e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.97	0.44	2e-17	Cognitive test performance;
LIHC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.68	10.76	0.5	1.88e-23	Corneal astigmatism;
LIHC	cis	rs34375054	0.724	rs4517581	chr12:125667394	A/G	cg25124228	chr12:125621409	AACS	-0.41	-6.66	-0.34	1.12e-10	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.46	0.37	7.01e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.97	-0.31	5.99e-9	Total body bone mineral density;
LIHC	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg20628663	chr10:43360327	NA	0.45	6.7	0.34	8.53e-11	Blood protein levels;
LIHC	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.78	-11.27	-0.52	2.86e-25	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LIHC	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg08800856	chr11:64428347	NRXN2	0.41	6.38	0.33	5.65e-10	Body mass index;Urate levels;
LIHC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.68	13.41	0.59	3.11e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg03806693	chr22:41940476	POLR3H	-0.63	-6.8	-0.35	4.69e-11	Neuroticism;
LIHC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg03037974	chr15:76606532	NA	0.74	14.29	0.61	1.19e-36	Blood metabolite levels;
LIHC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-5.93	-0.31	7.52e-9	Tonsillectomy;
LIHC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg25039879	chr17:56429692	SUPT4H1	0.79	8.95	0.44	2.37e-17	Cognitive test performance;
LIHC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	8.38	0.41	1.38e-15	Diastolic blood pressure;
LIHC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.11	0.4	8.94e-15	Menarche (age at onset);
LIHC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg06466757	chr4:1255808	NA	0.34	5.82	0.3	1.32e-8	Obesity-related traits;
LIHC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.84	10.22	0.48	1.44e-21	Bladder cancer;
LIHC	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	0.8	11.43	0.53	7.64e-26	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.98	17.84	0.69	8.98e-51	Intelligence (multi-trait analysis);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09145019	chr1:17972199	ARHGEF10L	0.43	6.84	0.35	3.77e-11	Longevity;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19990785	chr11:67232403	TMEM134	0.44	6.57	0.33	1.93e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.39	6.34	0.32	7.29e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.64	11.43	0.53	7.74e-26	Gestational age at birth (maternal effect);
LIHC	cis	rs5769707	0.681	rs916360	chr22:50041972	T/C	cg01652190	chr22:50026171	C22orf34	-0.35	-7.75	-0.39	1.09e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg22771759	chr13:24902376	NA	0.32	6.68	0.34	9.65e-11	Obesity-related traits;
LIHC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-10.35	-0.49	5.29e-22	Mean corpuscular volume;
LIHC	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.43	6.71	0.34	7.91e-11	Breast cancer;
LIHC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.49	7.55	0.38	3.94e-13	Methadone dose in opioid dependence;
LIHC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.38	-6.83	-0.35	3.82e-11	Immature fraction of reticulocytes;
LIHC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg12373951	chr3:133503437	NA	-0.51	-7.24	-0.36	2.93e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg18016565	chr1:150552671	MCL1	0.51	9.75	0.47	5.67e-20	Melanoma;
LIHC	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.36	-5.94	-0.31	7.19e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs600806	0.854	rs11102974	chr1:109886371	G/A	cg16275483	chr1:110013120	SYPL2	-0.47	-5.86	-0.3	1.07e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg24296786	chr1:45957014	TESK2	0.52	7.66	0.38	1.88e-13	Platelet count;
LIHC	cis	rs61677309	1.000	rs4938494	chr11:118150735	G/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	0.87	11.95	0.54	9.72e-28	Skin colour saturation;
LIHC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.53	-6.76	-0.34	6.03e-11	Alzheimer's disease;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.75	13.43	0.59	2.57e-33	Prudent dietary pattern;
LIHC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.29	6.88	0.35	2.92e-11	Primary biliary cholangitis;
LIHC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.67	0.38	1.84e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.54	-6.5	-0.33	2.88e-10	Blood metabolite levels;
LIHC	cis	rs1144333	1.000	rs5745354	chr1:76275178	G/A	cg22875332	chr1:76189707	ACADM	-0.41	-6.83	-0.35	4e-11	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.53	-0.49	1.24e-22	Chronic sinus infection;
LIHC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.53	-0.33	2.35e-10	Response to antipsychotic treatment;
LIHC	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg25182066	chr10:30743637	MAP3K8	-0.44	-7.12	-0.36	6.39e-12	Inflammatory bowel disease;
LIHC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.37	5.83	0.3	1.3e-8	Menopause (age at onset);
LIHC	cis	rs9309473	1.000	rs10184268	chr2:73627044	C/T	cg20560298	chr2:73613845	ALMS1	-0.58	-7.14	-0.36	5.59e-12	Metabolite levels;
LIHC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg14257396	chr1:107603778	NA	0.35	5.75	0.3	1.96e-8	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.86	-0.3	1.11e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.57	7.5	0.38	5.54e-13	Post bronchodilator FEV1;
LIHC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.6	-8.51	-0.42	5.36e-16	Blood metabolite levels;
LIHC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17424134	chr2:27616206	FTHL3;PPM1G	0.44	6.21	0.32	1.58e-9	Thyroid stimulating hormone;
LIHC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.38	-11.72	-0.54	6.87e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	9.76	0.47	5.01e-20	Menarche (age at onset);
LIHC	cis	rs6466055	0.796	rs9649275	chr7:104935801	T/G	cg04380332	chr7:105027541	SRPK2	0.34	6.43	0.33	4.38e-10	Schizophrenia;
LIHC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.57	11.12	0.52	1.03e-24	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.15	0.55	1.76e-28	Height;
LIHC	cis	rs61440199	0.786	rs73818815	chr3:20148087	A/T	cg00235661	chr3:20228976	SGOL1	-0.41	-5.82	-0.3	1.35e-8	Staphylococcus aureus nasal carriage (intermittent);
LIHC	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg00012203	chr2:219082015	ARPC2	0.76	10.74	0.5	2.16e-23	Colorectal cancer;
LIHC	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.66	12.86	0.57	3.71e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.76	-9.95	-0.47	1.15e-20	Schizophrenia;
LIHC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-12.29	-0.55	5.07e-29	Breast cancer;
LIHC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.56	-0.46	2.35e-19	Bipolar disorder;
LIHC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	20.04	0.73	1.27e-59	Body mass index (adult);
LIHC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg25894440	chr7:65020034	NA	-0.55	-6.21	-0.32	1.51e-9	Diabetic kidney disease;
LIHC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.55	7.9	0.39	3.91e-14	Lymphocyte counts;
LIHC	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg09795085	chr6:101329169	ASCC3	0.53	7.52	0.38	4.73e-13	Neuroticism;
LIHC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg02290350	chr8:58132656	NA	0.32	5.86	0.3	1.1e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs240764	0.697	rs12189562	chr6:101168679	A/G	cg09795085	chr6:101329169	ASCC3	-0.48	-6.64	-0.34	1.25e-10	Neuroticism;
LIHC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg02070205	chr10:30722105	MAP3K8	-0.43	-5.79	-0.3	1.59e-8	Inflammatory bowel disease;
LIHC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.45	-7.41	-0.37	9.69e-13	Menarche (age at onset);
LIHC	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg10820045	chr2:198174542	NA	0.46	7.06	0.36	9.37e-12	Dermatomyositis;
LIHC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-12.17	-0.55	1.51e-28	Alzheimer's disease (late onset);
LIHC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg24203234	chr3:128598194	ACAD9	-0.41	-5.8	-0.3	1.51e-8	IgG glycosylation;
LIHC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.3	0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.86	-0.35	3.29e-11	Diabetic kidney disease;
LIHC	cis	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.37	6.2	0.32	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LIHC	cis	rs2257205	0.667	rs9889631	chr17:56630359	G/T	cg12560992	chr17:57184187	TRIM37	0.71	7.74	0.39	1.11e-13	Pancreatic cancer;
LIHC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg03037974	chr15:76606532	NA	-0.61	-10.24	-0.48	1.21e-21	Blood metabolite levels;
LIHC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg18944383	chr4:111397179	ENPEP	-0.28	-6.46	-0.33	3.62e-10	Coronary artery disease;
LIHC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.44	-8.08	-0.4	1.13e-14	Platelet distribution width;
LIHC	cis	rs4950322	0.512	rs4625342	chr1:146841602	G/C	cg25205988	chr1:146714368	CHD1L	0.44	6.31	0.32	8.86e-10	Protein quantitative trait loci;
LIHC	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.4	-7.34	-0.37	1.59e-12	Monocyte count;
LIHC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.48	-17.96	-0.7	2.77e-51	Breast cancer;
LIHC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.44	-0.33	3.94e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg05163923	chr11:71159392	DHCR7	-0.54	-6.59	-0.34	1.67e-10	Vitamin D levels;
LIHC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.9	-16.53	-0.67	1.64e-45	Height;
LIHC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.67	11.48	0.53	5.1e-26	Menopause (age at onset);
LIHC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.67	9.31	0.45	1.64e-18	Coronary artery disease;
LIHC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-10.32	-0.49	6.29e-22	Asthma;
LIHC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.55	-0.46	2.51e-19	Total cholesterol levels;
LIHC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg07134254	chr20:33865797	NA	0.53	6.2	0.32	1.65e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	12.17	0.55	1.51e-28	Body mass index;
LIHC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg16506815	chr2:162101123	NA	0.49	7.91	0.39	3.63e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg24296786	chr1:45957014	TESK2	0.42	6.16	0.32	2.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.6	8.99	0.44	1.73e-17	Gout;
LIHC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg19000871	chr14:103996768	TRMT61A	-0.4	-6.64	-0.34	1.22e-10	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4407350	0.870	rs135627	chr22:44906402	A/G	cg04154583	chr22:44889756	LDOC1L	0.3	6.0	0.31	4.95e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.56	7.56	0.38	3.65e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.35	5.71	0.3	2.43e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.84	-0.51	1.02e-23	Primary sclerosing cholangitis;
LIHC	cis	rs4908768	0.520	rs4908507	chr1:8738937	C/T	cg20416874	chr1:8611966	RERE	-0.6	-11.79	-0.54	3.85e-27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2518564	0.507	rs856042	chr1:158986225	T/C	cg11003133	chr1:159046391	AIM2	0.27	5.77	0.3	1.76e-8	White blood cell count;
LIHC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	7.34	0.37	1.53e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6442522	0.768	rs3821638	chr3:15511044	A/G	cg16303742	chr3:15540471	COLQ	0.46	7.99	0.4	2.13e-14	Uric acid levels;
LIHC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.74	11.93	0.54	1.14e-27	Body mass index;
LIHC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.78	-0.34	5.35e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg05621596	chr22:47072043	GRAMD4	-0.77	-11.97	-0.54	7.91e-28	Urate levels in obese individuals;
LIHC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.47	7.61	0.38	2.64e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.76	-11.22	-0.52	4.41e-25	Personality dimensions;
LIHC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg03264133	chr6:25882463	NA	-0.38	-5.72	-0.3	2.35e-8	Height;
LIHC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.32	-8.25	-0.41	3.55e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13239077	chr3:184081208	POLR2H	-0.48	-6.06	-0.31	3.57e-9	Hepatitis;
LIHC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	14.24	0.61	1.92e-36	Chronic sinus infection;
LIHC	cis	rs12744310	0.887	rs72665694	chr1:41775384	A/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	0.91	6.4	0.33	5.18e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs12579753	0.810	rs1343934	chr12:82123112	G/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.03	-0.31	4.14e-9	Resting heart rate;
LIHC	cis	rs17095355	1.000	rs6584962	chr10:111689904	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.36	-0.33	6.29e-10	Biliary atresia;
LIHC	cis	rs716804	0.740	rs11042702	chr11:10287988	A/G	cg01453529	chr11:10209919	SBF2	0.29	5.89	0.3	8.99e-9	Neuroticism;
LIHC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.41	6.25	0.32	1.2e-9	Glycated hemoglobin levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg01972394	chr1:19229528	ALDH4A1	0.44	6.28	0.32	1.03e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg19635926	chr16:89946313	TCF25	0.49	6.24	0.32	1.28e-9	Skin colour saturation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21819024	chr1:52344978	NRD1	0.41	6.3	0.32	9.25e-10	Cognitive function;
LIHC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.34	-0.32	7.1e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.52	7.96	0.4	2.55e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.63	0.38	2.35e-13	Triglyceride levels;
LIHC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.33	-12.61	-0.56	3.28e-30	Plateletcrit;
LIHC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.23	0.45	2.97e-18	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.68	-0.53	9.56e-27	Platelet distribution width;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg03785755	chr6:26196794	NA	0.51	5.97	0.31	5.8e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg08992911	chr2:238395768	MLPH	0.63	6.21	0.32	1.57e-9	Prostate cancer;
LIHC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.49	0.38	6.07e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.85	10.34	0.49	5.35e-22	Mean platelet volume;
LIHC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	10.62	0.5	5.7e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.76	0.47	5.3e-20	Platelet count;
LIHC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.32	-5.72	-0.3	2.37e-8	Lewy body disease;
LIHC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.86	0.39	5.16e-14	Mean platelet volume;
LIHC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.83	-0.39	6.04e-14	Morning vs. evening chronotype;
LIHC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.66	12.58	0.56	4.42e-30	Menopause (age at onset);
LIHC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg03037974	chr15:76606532	NA	-0.64	-11.4	-0.52	1.01e-25	Blood metabolite levels;
LIHC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.42	-6.32	-0.32	8.02e-10	Height;
LIHC	cis	rs2071426	0.580	rs6583966	chr10:96759902	C/T	cg09036531	chr10:96991505	NA	-0.51	-6.07	-0.31	3.37e-9	Blood metabolite levels;
LIHC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	6.69	0.34	9.29e-11	Exhaled nitric oxide output;
LIHC	cis	rs303806	1	rs303806	chr12:52166503	A/G	cg07929700	chr12:52204284	NA	-0.52	-5.89	-0.3	9.38e-9	Morning vs. evening chronotype;
LIHC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-6.04	-0.31	4.05e-9	Response to diuretic therapy;
LIHC	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.41	0.33	4.81e-10	Rheumatoid arthritis;
LIHC	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.82	10.53	0.49	1.23e-22	Blood pressure (smoking interaction);
LIHC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	17.36	0.68	7.38e-49	Lung cancer in ever smokers;
LIHC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.12	13.03	0.58	8.92e-32	Vitiligo;
LIHC	cis	rs11718455	0.526	rs67553643	chr3:43928130	C/T	cg08738300	chr3:44038990	NA	0.36	6.11	0.31	2.65e-9	Coronary artery disease;
LIHC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.68	0.53	9.41e-27	Platelet count;
LIHC	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.61	-8.22	-0.41	4.32e-15	Vitamin D levels;
LIHC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg00656387	chr3:40428638	ENTPD3	-0.42	-6.7	-0.34	8.51e-11	Renal cell carcinoma;
LIHC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.09	0.31	2.96e-9	Menopause (age at onset);
LIHC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg00809820	chr17:80708513	TBCD;FN3K	0.35	6.09	0.31	3.06e-9	Glycated hemoglobin levels;
LIHC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg03959625	chr15:84868606	LOC388152	0.45	6.53	0.33	2.4e-10	Schizophrenia;
LIHC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.49	-6.19	-0.32	1.74e-9	Pancreatic cancer;
LIHC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.33	-8.37	-0.41	1.48e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02290350	chr8:58132656	NA	0.46	8.02	0.4	1.75e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	11.02	0.51	2.34e-24	Nonalcoholic fatty liver disease;
LIHC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.56	6.39	0.33	5.32e-10	Alzheimer's disease;
LIHC	cis	rs138777	0.927	rs1053593	chr22:35660875	G/T	cg02285386	chr22:35695157	TOM1	0.34	5.72	0.3	2.38e-8	Cholesterol, total;Total cholesterol levels;
LIHC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.96	-0.31	6.25e-9	Schizophrenia;
LIHC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.57	8.6	0.42	2.89e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.52	0.33	2.57e-10	Endometrial cancer;
LIHC	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg01652190	chr22:50026171	C22orf34	-0.35	-7.82	-0.39	6.55e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.58	10.75	0.5	2.1e-23	Leprosy;
LIHC	trans	rs6489882	0.836	rs2384071	chr12:113367343	A/G	cg10175203	chr3:128143634	NA	0.39	6.15	0.32	2.15e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg00049323	chr5:472564	LOC25845	0.35	5.85	0.3	1.14e-8	Cystic fibrosis severity;
LIHC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.61	-0.34	1.5e-10	Eosinophil percentage of white cells;
LIHC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.51	7.39	0.37	1.11e-12	High light scatter reticulocyte count;
LIHC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.66	0.34	1.1e-10	Diabetic kidney disease;
LIHC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.85	-0.39	5.34e-14	Calcium levels;
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.73	8.47	0.42	7.17e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.7	8.78	0.43	8.1e-17	Initial pursuit acceleration;
LIHC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.63	-8.89	-0.43	3.66e-17	Blood metabolite levels;
LIHC	cis	rs9434723	0.841	rs9435152	chr1:9308249	C/T	cg04199779	chr1:9294473	H6PD	0.58	6.02	0.31	4.38e-9	Height;
LIHC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg20684491	chr1:25596433	NA	0.28	5.81	0.3	1.46e-8	Erythrocyte sedimentation rate;
LIHC	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg24296786	chr1:45957014	TESK2	0.51	7.32	0.37	1.75e-12	High light scatter reticulocyte count;
LIHC	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg20283391	chr11:68216788	NA	0.48	5.99	0.31	5.23e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.72	-8.73	-0.43	1.17e-16	Schizophrenia;
LIHC	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.65	0.53	1.17e-26	Body mass index;
LIHC	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-11.07	-0.51	1.46e-24	Hemoglobin concentration;
LIHC	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg01652190	chr22:50026171	C22orf34	-0.33	-7.39	-0.37	1.16e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-0.73	-8.32	-0.41	2.12e-15	Hip circumference adjusted for BMI;
LIHC	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.04	-0.31	4.12e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4908768	0.501	rs6668508	chr1:8574118	C/T	cg20416874	chr1:8611966	RERE	-0.68	-14.62	-0.62	6.36e-38	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs847649	0.842	rs869332	chr7:102632247	A/G	cg18108683	chr7:102477205	FBXL13	-0.46	-7.22	-0.36	3.39e-12	Morning vs. evening chronotype;
LIHC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg15123519	chr2:136567270	LCT	0.39	7.27	0.37	2.46e-12	Mosquito bite size;
LIHC	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.69	-10.24	-0.48	1.25e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.59	-8.6	-0.42	2.84e-16	Facial morphology (factor 19);
LIHC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg14580859	chr9:123691850	NA	0.39	6.95	0.35	1.91e-11	Rheumatoid arthritis;
LIHC	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg08992911	chr2:238395768	MLPH	0.58	6.07	0.31	3.43e-9	Prostate cancer;
LIHC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg24130564	chr14:104152367	KLC1	-0.34	-5.74	-0.3	2.1e-8	Schizophrenia;
LIHC	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	0.96	14.75	0.62	1.96e-38	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	1.01	19.31	0.72	1.06e-56	Breast cancer;
LIHC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-10.2	-0.48	1.69e-21	Chronic sinus infection;
LIHC	cis	rs600806	0.821	rs4970840	chr1:109873367	A/G	cg16275483	chr1:110013120	SYPL2	-0.49	-6.11	-0.31	2.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg27209729	chr11:64428925	NRXN2	0.34	6.39	0.33	5.32e-10	Body mass index;Urate levels;
LIHC	cis	rs15676	0.783	rs10988120	chr9:131564695	G/C	cg00228799	chr9:131580591	ENDOG	-0.48	-6.8	-0.34	4.79e-11	Blood metabolite levels;
LIHC	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg13397359	chr6:42928475	GNMT	0.47	6.59	0.34	1.63e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.44	-7.09	-0.36	7.62e-12	Menopause (age at onset);
LIHC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.52	6.74	0.34	6.79e-11	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.37	-6.72	-0.34	7.79e-11	Aortic root size;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.46	6.41	0.33	4.77e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	6.55	0.33	2.11e-10	Ileal carcinoids;
LIHC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-8.06	-0.4	1.26e-14	Gut microbiome composition (summer);
LIHC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.5	0.77	1.86e-69	Chronic sinus infection;
LIHC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.73	-10.5	-0.49	1.58e-22	Pancreatic cancer;
LIHC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.61	9.02	0.44	1.33e-17	Testicular germ cell tumor;
LIHC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.47	7.58	0.38	3.37e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg07959070	chr22:50026188	C22orf34	-0.33	-8.61	-0.42	2.67e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.24	-6.36	-0.33	6.38e-10	Hepatitis;
LIHC	cis	rs10744422	1.000	rs2061101	chr12:123348925	C/A	cg18912006	chr12:123335444	HIP1R	-0.65	-7.43	-0.37	9.02e-13	Schizophrenia;
LIHC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03228054	chr9:19049082	RRAGA	0.49	6.74	0.34	6.77e-11	Pancreatic cancer;
LIHC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.44	8.39	0.41	1.3e-15	Testicular germ cell tumor;
LIHC	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.48	9.06	0.44	1.03e-17	Testicular germ cell tumor;
LIHC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.7	0.43	1.4e-16	Lung cancer in ever smokers;
LIHC	cis	rs943466	0.911	rs73746509	chr6:33729825	C/T	cg25922239	chr6:33757077	LEMD2	-0.5	-6.14	-0.32	2.27e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.55	-14.67	-0.62	3.89e-38	Alzheimer's disease (late onset);
LIHC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.55	-6.92	-0.35	2.3e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.31	0.52	2.14e-25	Coffee consumption (cups per day);
LIHC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-7.73	-0.39	1.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.33	6.44	0.33	4.1e-10	Renal cell carcinoma;
LIHC	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.95	0.31	6.57e-9	Morning vs. evening chronotype;
LIHC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.66	9.27	0.45	2.12e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.7	-13.06	-0.58	6.64e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg04317338	chr11:64019027	PLCB3	-0.54	-5.87	-0.3	1.04e-8	Mean platelet volume;
LIHC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	7.3	0.37	2.08e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.84	-14.18	-0.61	3.09e-36	Body mass index;
LIHC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.31	-0.32	8.43e-10	Height;
LIHC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	1.03	12.12	0.55	2.33e-28	Eosinophil percentage of granulocytes;
LIHC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-12.81	-0.57	5.79e-31	Breast cancer;
LIHC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.52	7.38	0.37	1.2e-12	Initial pursuit acceleration;
LIHC	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-5.96	-0.31	6.14e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.48	-8.04	-0.4	1.5e-14	Cotinine glucuronidation;
LIHC	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.58	6.84	0.35	3.77e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs2642442	0.885	rs2642438	chr1:220970028	A/G	cg04704887	chr1:220970030	MOSC1	-0.48	-6.1	-0.31	2.89e-9	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-6.81	-0.35	4.27e-11	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.91	-11.57	-0.53	2.42e-26	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20135002	chr11:47629003	NA	-0.54	-9.17	-0.44	4.7e-18	Subjective well-being;
LIHC	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg04610667	chr7:75704037	NA	-0.33	-6.0	-0.31	5.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg26939375	chr7:64535504	NA	-0.43	-6.8	-0.35	4.57e-11	Aortic root size;
LIHC	cis	rs922107	0.817	rs528433	chr1:89987940	A/G	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.22	-0.36	3.36e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg17980119	chr2:219472607	PLCD4	0.33	5.75	0.3	1.93e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.37	-6.01	-0.31	4.66e-9	Hypospadias;
LIHC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg03934865	chr2:198174659	NA	-0.59	-9.54	-0.46	2.77e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg14146966	chr2:61757674	XPO1	0.49	8.82	0.43	5.82e-17	Tuberculosis;
LIHC	cis	rs12286929	0.617	rs12800807	chr11:115101353	T/C	cg04055981	chr11:115044050	NA	0.43	6.24	0.32	1.27e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.73	0.54	5.99e-27	Coffee consumption (cups per day);
LIHC	trans	rs10411161	0.580	rs3848561	chr19:52379623	C/T	cg22319618	chr22:45562946	NUP50	-0.51	-7.57	-0.38	3.56e-13	Breast cancer;
LIHC	cis	rs3814231	0.531	rs12773054	chr10:115476042	C/T	cg24846397	chr10:115438155	CASP7	-0.41	-6.83	-0.35	3.83e-11	Vitiligo;
LIHC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.88	8.5	0.42	6.12e-16	Plasma clusterin levels;
LIHC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.41	0.52	9.38e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg15208524	chr1:10270712	KIF1B	0.4	6.08	0.31	3.22e-9	Hepatocellular carcinoma;
LIHC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.78	0.43	8.02e-17	Menarche (age at onset);
LIHC	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.65	8.8	0.43	6.78e-17	Neuroticism;
LIHC	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.47e-18	Coffee consumption (cups per day);
LIHC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.91	8.21	0.41	4.74e-15	Eosinophil percentage of granulocytes;
LIHC	cis	rs1419980	0.730	rs73260715	chr12:7781252	G/A	cg10578777	chr12:7781093	NA	-0.4	-5.83	-0.3	1.26e-8	HDL cholesterol levels;
LIHC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-8.12	-0.4	8.38e-15	Bipolar disorder and schizophrenia;
LIHC	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.59	9.48	0.46	4.57e-19	Corneal astigmatism;
LIHC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.65	0.46	1.25e-19	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01032946	chr16:30991033	SETD1A	0.44	6.07	0.31	3.45e-9	Longevity;
LIHC	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.23	-0.32	1.35e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-6.38	-0.33	5.72e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg23533926	chr12:111358616	MYL2	-0.33	-6.49	-0.33	3.06e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.54	-11.08	-0.51	1.36e-24	Tonsillectomy;
LIHC	trans	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.5	-0.33	2.92e-10	Dental caries;
LIHC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.75	0.47	5.42e-20	Mean platelet volume;
LIHC	cis	rs11630290	0.639	rs6494442	chr15:64166891	A/G	cg12036633	chr15:63758958	NA	0.57	5.96	0.31	6.35e-9	Iris characteristics;
LIHC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.56	7.26	0.37	2.57e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.57	5.79	0.3	1.62e-8	Schizophrenia;
LIHC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-6.7	-0.34	8.69e-11	IgG glycosylation;
LIHC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.67	6.86	0.35	3.29e-11	Diabetic kidney disease;
LIHC	cis	rs11018874	0.709	rs10765241	chr11:89849316	T/C	cg05041596	chr11:89867385	NAALAD2	0.41	6.37	0.33	5.92e-10	White blood cell types;
LIHC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg14393609	chr7:65229607	NA	0.38	5.87	0.3	1.02e-8	Aortic root size;
LIHC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg25894440	chr7:65020034	NA	-0.56	-6.47	-0.33	3.37e-10	Diabetic kidney disease;
LIHC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.58	7.33	0.37	1.64e-12	Morning vs. evening chronotype;
LIHC	trans	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg10756647	chr7:56101905	PSPH	1.06	12.78	0.57	7.55e-31	Diabetic kidney disease;
LIHC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg18306943	chr3:40428807	ENTPD3	0.36	6.11	0.31	2.77e-9	Renal cell carcinoma;
LIHC	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.67	8.61	0.42	2.8e-16	Corneal astigmatism;
LIHC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.98	-0.35	1.53e-11	Diabetic kidney disease;
LIHC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.91	-0.43	3.01e-17	Bipolar disorder;
LIHC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-10.69	-0.5	3.2e-23	Primary sclerosing cholangitis;
LIHC	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.5	8.07	0.4	1.24e-14	Corneal astigmatism;
LIHC	cis	rs12744310	1.000	rs12025254	chr1:41756906	A/G	cg03962019	chr1:41807865	NA	0.38	6.19	0.32	1.73e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.66	12.06	0.55	3.93e-28	Height;
LIHC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.54	8.51	0.42	5.58e-16	Coronary artery disease;
LIHC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg15208524	chr1:10270712	KIF1B	-0.38	-5.82	-0.3	1.38e-8	Hepatocellular carcinoma;
LIHC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg20129853	chr10:51489980	NA	-0.39	-8.52	-0.42	5.04e-16	Prostate-specific antigen levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg18716194	chr12:110872950	ARPC3	0.52	6.97	0.35	1.64e-11	Systolic blood pressure;
LIHC	cis	rs57590327	0.503	rs9866374	chr3:81615311	T/C	cg07356753	chr3:81810745	GBE1	-0.55	-8.41	-0.41	1.09e-15	Extraversion;
LIHC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs7503168	0.818	rs9902765	chr17:33913143	A/G	cg20932281	chr17:33905541	PEX12	0.56	7.25	0.37	2.79e-12	Plateletcrit;
LIHC	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg02829992	chr2:10710499	NA	0.39	6.01	0.31	4.73e-9	Prostate cancer;
LIHC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.63	10.41	0.49	3.16e-22	Intelligence (multi-trait analysis);
LIHC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.77	11.69	0.53	8.39e-27	Corneal astigmatism;
LIHC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.57	-7.79	-0.39	8.15e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg12463550	chr7:65579703	CRCP	0.69	7.15	0.36	5.29e-12	Diabetic kidney disease;
LIHC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.89	-14.89	-0.63	5.13e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	8.82	0.43	6.01e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.53	-6.34	-0.32	7.32e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.57	8.59	0.42	3.23e-16	White matter hyperintensity burden;
LIHC	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg01364799	chr7:75623366	TMEM120A	0.49	7.36	0.37	1.36e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg06359132	chr10:99160096	RRP12	-0.37	-5.93	-0.31	7.28e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg02931644	chr1:25747376	RHCE	0.35	7.65	0.38	2.06e-13	Erythrocyte sedimentation rate;
LIHC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-9.0	-0.44	1.59e-17	Blood metabolite levels;
LIHC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.88	0.47	2e-20	Platelet count;
LIHC	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.55	9.46	0.46	5.14e-19	Schizophrenia;
LIHC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg12863693	chr15:85201151	NMB	0.49	6.9	0.35	2.46e-11	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23959187	chr17:46102881	NA	0.46	6.68	0.34	9.5e-11	Pancreatic cancer;
LIHC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.58	-8.04	-0.4	1.44e-14	Menopause (age at onset);
LIHC	cis	rs787274	1.000	rs2645993	chr9:115536267	T/A	cg13803584	chr9:115635662	SNX30	-0.56	-6.25	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg12792011	chr19:58661915	ZNF329	0.96	7.78	0.39	8.58e-14	Cholesterol, total;
LIHC	cis	rs9527	0.518	rs7899608	chr10:104727304	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-5.83	-0.3	1.26e-8	Arsenic metabolism;
LIHC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.45	7.1	0.36	7.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.73	8.22	0.41	4.41e-15	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	10.77	0.5	1.68e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.44	5.81	0.3	1.44e-8	Obesity-related traits;
LIHC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.73	-13.36	-0.59	4.6e-33	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg03013999	chr17:37608204	MED1	-0.35	-5.93	-0.31	7.41e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg16070018	chr6:26224392	HIST1H3E	0.57	6.81	0.35	4.32e-11	Gout;Renal underexcretion gout;
LIHC	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.57	-13.85	-0.6	6.11e-35	White blood cell count (basophil);
LIHC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.53	5.77	0.3	1.82e-8	Menopause (age at onset);
LIHC	cis	rs244293	0.965	rs2628320	chr17:53207993	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.41	-0.37	1.01e-12	Menarche (age at onset);
LIHC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.44	6.85	0.35	3.35e-11	Methadone dose in opioid dependence;
LIHC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.63	8.29	0.41	2.68e-15	Motion sickness;
LIHC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.26	-17.06	-0.68	1.15e-47	Diabetic kidney disease;
LIHC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.63	-8.89	-0.43	3.66e-17	Blood metabolite levels;
LIHC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.73	12.57	0.56	4.64e-30	Menopause (age at onset);
LIHC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	1.01	19.45	0.72	2.9e-57	Breast cancer;
LIHC	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg02702477	chr5:179499311	RNF130	0.89	11.71	0.53	7.5e-27	LDL cholesterol;
LIHC	trans	rs2211698	0.536	rs78921201	chr21:35832276	C/T	cg18044562	chr7:50468399	IKZF1	0.52	7.39	0.37	1.15e-12	Cancer;
LIHC	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	6.8	0.35	4.72e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.51	8.54	0.42	4.36e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs7714584	1.000	rs11739619	chr5:150264662	A/T	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.15	-0.48	2.57e-21	Chronic sinus infection;
LIHC	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg02023728	chr11:77925099	USP35	-0.33	-5.86	-0.3	1.09e-8	Alzheimer's disease (survival time);
LIHC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.66	-8.88	-0.43	3.81e-17	Birth weight;
LIHC	cis	rs2637266	0.783	rs846627	chr10:78539556	A/G	cg18941641	chr10:78392320	NA	0.27	5.77	0.3	1.8e-8	Pulmonary function;
LIHC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.13	-0.31	2.37e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.57	8.78	0.43	7.98e-17	Height;
LIHC	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg16070018	chr6:26224392	HIST1H3E	0.49	6.55	0.33	2.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg11161837	chr1:110010384	SYPL2	0.45	6.14	0.31	2.32e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg19894588	chr14:64061835	NA	-0.68	-10.07	-0.48	4.52e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.31	-5.92	-0.31	7.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.55	-9.43	-0.45	6.56e-19	Reticulocyte count;
LIHC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.6	10.53	0.49	1.23e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg06664874	chr5:179499304	RNF130	-0.58	-7.13	-0.36	5.93e-12	LDL cholesterol;
LIHC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.53	8.79	0.43	7.4e-17	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.91	17.08	0.68	9.57e-48	Aortic root size;
LIHC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.79	0.65	1.39e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.44	7.32	0.37	1.79e-12	Mean corpuscular volume;
LIHC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.68	0.57	1.82e-30	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs716804	0.621	rs11042602	chr11:10078104	T/A	cg01453529	chr11:10209919	SBF2	-0.3	-5.72	-0.3	2.37e-8	Neuroticism;
LIHC	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02985541	chr2:219472218	PLCD4	-0.38	-6.55	-0.33	2.09e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.62	6.2	0.32	1.62e-9	Carotid intima media thickness;
LIHC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.33	-0.37	1.63e-12	Obesity (extreme);
LIHC	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg26138937	chr11:71823887	C11orf51	-1.32	-10.9	-0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.42	-8.57	-0.42	3.6e-16	Obesity-related traits;
LIHC	cis	rs7945718	0.592	rs10765985	chr11:12676468	G/A	cg25843174	chr11:12811716	TEAD1	0.33	7.71	0.38	1.42e-13	Educational attainment (years of education);
LIHC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.42	-8.36	-0.41	1.65e-15	Obesity-related traits;
LIHC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.62	9.05	0.44	1.07e-17	Schizophrenia;
LIHC	cis	rs332507	0.519	rs13087350	chr3:124352085	C/T	cg05980111	chr3:124395277	KALRN	-0.3	-5.82	-0.3	1.39e-8	Plateletcrit;
LIHC	cis	rs12960505	0.506	rs66882949	chr18:51048812	A/G	cg24270629	chr18:50823537	DCC	-0.47	-6.37	-0.33	6.22e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg03854865	chr6:26224070	HIST1H3E	0.65	7.17	0.36	4.58e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.38	0.41	1.4e-15	Birth weight;
LIHC	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-7.76	-0.39	9.66e-14	Neuranatomic and neurocognitive phenotypes;
LIHC	cis	rs4407350	0.870	rs5765716	chr22:44915251	T/C	cg26276947	chr22:44892394	LDOC1L	0.34	6.39	0.33	5.35e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg15123519	chr2:136567270	LCT	0.35	6.59	0.34	1.66e-10	Mosquito bite size;
LIHC	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg09911534	chr15:67153556	NA	-0.49	-5.99	-0.31	5.17e-9	Lung cancer (smoking interaction);
LIHC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.71	-12.1	-0.55	2.59e-28	Multiple myeloma (IgH translocation);
LIHC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.41	6.25	0.32	1.24e-9	Testicular germ cell tumor;
LIHC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.45	-0.37	7.9e-13	Melanoma;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg00934597	chr7:893267	UNC84A	-0.51	-5.99	-0.31	5.24e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.99	-0.35	1.44e-11	Personality dimensions;
LIHC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.5	-0.69	2e-49	Height;
LIHC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12016809	chr21:47604291	C21orf56	0.43	6.25	0.32	1.21e-9	Testicular germ cell tumor;
LIHC	cis	rs4833079	0.562	rs11944291	chr4:38631620	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.53	0.38	4.59e-13	Body mass index;
LIHC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.97	15.07	0.63	1.01e-39	Breast cancer;
LIHC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.76	10.09	0.48	3.94e-21	Fat distribution (HIV);
LIHC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.67	-12.1	-0.55	2.72e-28	Diastolic blood pressure;
LIHC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.68	-9.28	-0.45	1.97e-18	Corneal structure;
LIHC	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.04	0.51	1.98e-24	Coffee consumption (cups per day);
LIHC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg19743168	chr1:23544995	NA	0.34	5.82	0.3	1.33e-8	Height;
LIHC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.43	7.23	0.36	3.27e-12	Blood metabolite levels;
LIHC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.43	5.73	0.3	2.26e-8	Obesity-related traits;
LIHC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.95	0.31	6.65e-9	Menopause (age at onset);
LIHC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.46	7.55	0.38	3.89e-13	Response to temozolomide;
LIHC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.42	-6.52	-0.33	2.5e-10	Height;
LIHC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.9	-18.73	-0.71	2.27e-54	Height;
LIHC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.82	-10.46	-0.49	2.09e-22	Mean platelet volume;
LIHC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg18357526	chr6:26021779	HIST1H4A	0.62	8.69	0.43	1.58e-16	Blood metabolite levels;
LIHC	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.33	12.81	0.57	5.98e-31	Psoriasis vulgaris;
LIHC	trans	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg00845942	chr12:64062724	DPY19L2	-0.55	-6.05	-0.31	3.77e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg10360139	chr7:1886902	MAD1L1	-0.42	-6.42	-0.33	4.45e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg22834771	chr12:69754056	YEATS4	-0.35	-5.8	-0.3	1.49e-8	Blood protein levels;
LIHC	cis	rs3018712	0.532	rs10791988	chr11:68416051	A/T	cg16797656	chr11:68205561	LRP5	-0.45	-5.85	-0.3	1.12e-8	Total body bone mineral density;
LIHC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	8.77	0.43	8.51e-17	Neuroticism;
LIHC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg20607798	chr8:58055168	NA	0.51	6.64	0.34	1.24e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.5	-0.62	1.81e-37	Electrocardiographic conduction measures;
LIHC	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	0.94	14.3	0.61	1.14e-36	Corneal structure;
LIHC	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs5753037	0.702	rs81800	chr22:30200362	C/G	cg01021169	chr22:30184971	ASCC2	0.34	6.66	0.34	1.08e-10	Type 1 diabetes;
LIHC	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.52	6.13	0.31	2.36e-9	Ulcerative colitis;
LIHC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.52	7.3	0.37	2e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg18944383	chr4:111397179	ENPEP	0.28	6.52	0.33	2.56e-10	Coronary artery disease;
LIHC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.8	0.3	1.54e-8	Bipolar disorder;
LIHC	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg02023728	chr11:77925099	USP35	-0.33	-5.86	-0.3	1.07e-8	Alzheimer's disease (survival time);
LIHC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.35	6.01	0.31	4.73e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.97	0.44	1.97e-17	Cognitive ability;
LIHC	cis	rs6504950	0.800	rs9900816	chr17:53012057	G/A	cg10237252	chr17:52977213	TOM1L1	-0.34	-5.99	-0.31	5.22e-9	Breast cancer;
LIHC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.94	-9.36	-0.45	1.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs787274	1.000	rs10759584	chr9:115554736	T/G	cg13803584	chr9:115635662	SNX30	-0.6	-6.68	-0.34	9.69e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.54	0.33	2.26e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg02297831	chr4:17616191	MED28	0.45	6.37	0.33	6.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.83	12.88	0.57	3.27e-31	Schizophrenia;
LIHC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.91	0.35	2.31e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.8	8.49	0.42	6.31e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.53	-9.16	-0.44	4.87e-18	White blood cell count;
LIHC	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-10.95	-0.51	4.01e-24	Eye color traits;
LIHC	cis	rs75908454	1.000	rs80174436	chr6:169971230	C/G	cg19338460	chr6:170058176	WDR27	-0.82	-7.42	-0.37	9.52e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.99	0.51	2.94e-24	Lung cancer in ever smokers;
LIHC	cis	rs12744310	1.000	rs55707527	chr1:41769113	G/T	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.86	-0.3	1.11e-8	Bipolar disorder;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.41	-0.33	4.78e-10	Total body bone mineral density;
LIHC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs10508774	1.000	rs3824591	chr10:32854400	T/C	cg01819863	chr10:32635814	EPC1	0.65	6.1	0.31	2.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.74	-7.1	-0.36	7.45e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.71	10.7	0.5	3.15e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs16958440	0.737	rs12327081	chr18:44744422	G/A	cg17192377	chr18:44677553	HDHD2	0.73	5.74	0.3	2.12e-8	Sitting height ratio;
LIHC	trans	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.36	0.45	1.12e-18	Resting heart rate;
LIHC	cis	rs17433710	0.543	rs4657226	chr1:162653274	A/G	cg01063088	chr1:162760584	HSD17B7	-0.42	-5.87	-0.3	1.03e-8	Dupuytren's disease;
LIHC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.68	-0.34	9.86e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.46	-7.7	-0.38	1.49e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg18016565	chr1:150552671	MCL1	0.51	9.48	0.46	4.52e-19	Melanoma;
LIHC	cis	rs2851682	1.000	rs2851682	chr11:61616012	A/G	cg27386326	chr11:61587980	NA	0.59	8.57	0.42	3.65e-16	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg06766960	chr11:133703094	NA	-0.41	-6.21	-0.32	1.58e-9	Childhood ear infection;
LIHC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.66	-11.24	-0.52	3.85e-25	Childhood ear infection;
LIHC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.43	0.33	4.19e-10	Height;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05162900	chr17:28808449	GOSR1	-0.25	-6.47	-0.33	3.41e-10	Calcium levels;
LIHC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08280861	chr8:58055591	NA	0.49	6.08	0.31	3.25e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.07	16.04	0.66	1.47e-43	Cognitive function;
LIHC	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg25952890	chr19:58913133	NA	0.69	7.44	0.37	8.26e-13	Mean platelet volume;
LIHC	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg09695851	chr17:3907499	NA	0.5	6.3	0.32	9.21e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs4728302	0.869	rs13233715	chr7:133617471	C/T	cg10665199	chr7:133106180	EXOC4	0.37	6.36	0.33	6.35e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg10755058	chr3:40428713	ENTPD3	0.34	5.8	0.3	1.48e-8	Renal cell carcinoma;
LIHC	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.53	8.42	0.41	1.06e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs903552	0.935	rs12907726	chr15:102003626	C/G	cg19295451	chr15:102010161	PCSK6	-0.44	-6.17	-0.32	1.97e-9	Diabetic kidney disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg15160873	chr2:128471243	WDR33	0.44	6.26	0.32	1.14e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	9.5	0.46	3.67e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.54	8.06	0.4	1.28e-14	HIV-1 control;
LIHC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.34	8.7	0.43	1.44e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	14.26	0.61	1.51e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg02811702	chr13:24901961	NA	0.24	5.82	0.3	1.36e-8	Obesity-related traits;
LIHC	cis	rs963731	0.649	rs1377861	chr2:39293858	T/C	cg04010122	chr2:39346883	SOS1	-0.69	-6.18	-0.32	1.82e-9	Corticobasal degeneration;
LIHC	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg11161837	chr1:110010384	SYPL2	0.44	5.94	0.31	6.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.77	15.34	0.64	9.18e-41	Mortality in heart failure;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19909895	chr3:128368930	RPN1	0.52	6.96	0.35	1.77e-11	Pancreatic cancer;
LIHC	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.49	6.97	0.35	1.67e-11	Lung cancer;
LIHC	cis	rs9649465	0.935	rs3815458	chr7:123304323	A/T	cg03229431	chr7:123269106	ASB15	-0.37	-8.03	-0.4	1.56e-14	Migraine;
LIHC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.58	9.0	0.44	1.62e-17	Longevity;
LIHC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.6	-0.56	3.56e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg19735590	chr5:154026979	NA	0.47	5.73	0.3	2.25e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11673344	0.864	rs703537	chr19:37507729	G/A	cg27390819	chr19:37464633	NA	-0.5	-6.2	-0.32	1.66e-9	Obesity-related traits;
LIHC	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-10.66	-0.5	4.35e-23	Pediatric autoimmune diseases;
LIHC	trans	rs9641123	0.579	rs2108164	chr7:93238340	T/A	cg09745688	chr16:2908918	PRSS22	-0.37	-6.51	-0.33	2.71e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg15704280	chr7:45808275	SEPT13	0.61	6.45	0.33	3.78e-10	Axial length;
LIHC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg02297831	chr4:17616191	MED28	0.42	5.87	0.3	1.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.32	-8.31	-0.41	2.33e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg20578329	chr17:80767326	TBCD	-0.68	-6.9	-0.35	2.57e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs4407350	0.756	rs131155	chr22:44891247	A/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.38	-0.33	5.63e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.02	0.4	1.71e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg19773385	chr1:10388646	KIF1B	-0.46	-7.74	-0.39	1.16e-13	Hepatocellular carcinoma;
LIHC	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.37	6.02	0.31	4.57e-9	Prostate cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02364793	chr5:175964512	RNF44	0.36	6.12	0.31	2.58e-9	Pancreatic cancer;
LIHC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg04702396	chr17:15466718	FAM18B2	0.45	7.02	0.35	1.23e-11	Educational attainment (years of education);
LIHC	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.51	-5.91	-0.3	8.23e-9	Ulcerative colitis;
LIHC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.66	9.88	0.47	2.08e-20	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg04610667	chr7:75704037	NA	-0.34	-6.09	-0.31	3.01e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg16309518	chr5:176445507	NA	-0.55	-10.23	-0.48	1.33e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.59	7.0	0.35	1.4e-11	Alzheimer's disease;
LIHC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.93	-9.08	-0.44	8.82e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.21	0.55	1.02e-28	Eye color traits;
LIHC	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.47	-6.8	-0.35	4.57e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27297192	chr10:134578999	INPP5A	0.53	8.15	0.4	6.85e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-8.9	-0.43	3.25e-17	Bipolar disorder;
LIHC	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.78	0.43	8.16e-17	Height;
LIHC	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg09572067	chr16:29127029	RRN3P2	0.51	8.11	0.4	9.09e-15	Menopause (age at onset);
LIHC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg07884673	chr3:53033167	SFMBT1	0.9	6.6	0.34	1.58e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.54	-6.03	-0.31	4.27e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg17724175	chr1:150552817	MCL1	0.47	9.05	0.44	1.14e-17	Melanoma;
LIHC	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.33	7.93	0.39	3.22e-14	Cutaneous nevi;
LIHC	cis	rs2073300	0.793	rs36165478	chr20:23457261	C/T	cg12062639	chr20:23401060	NAPB	0.77	9.63	0.46	1.36e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	9.02	0.44	1.37e-17	Motion sickness;
LIHC	cis	rs1144333	1.000	rs5745327	chr1:76270040	A/T	cg03433033	chr1:76189801	ACADM	-0.53	-8.14	-0.4	7.44e-15	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.29	6.25	0.32	1.25e-9	Pulmonary function;
LIHC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.37	5.94	0.31	6.86e-9	Schizophrenia;
LIHC	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.78	8.88	0.43	3.91e-17	Exhaled nitric oxide levels;
LIHC	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg03585969	chr10:35415529	CREM	0.76	11.02	0.51	2.18e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.04	0.55	4.4e-28	Motion sickness;
LIHC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.94	0.44	2.42e-17	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.07	-0.31	3.33e-9	Tuberculosis;
LIHC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.65	-8.11	-0.4	9.39e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.31	-0.37	1.94e-12	Lymphocyte counts;
LIHC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.15	0.4	6.78e-15	Morning vs. evening chronotype;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	7.18	0.36	4.29e-12	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg07424592	chr7:64974309	NA	-0.8	-9.28	-0.45	1.99e-18	Diabetic kidney disease;
LIHC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20135002	chr11:47629003	NA	0.52	8.69	0.43	1.58e-16	Subjective well-being;
LIHC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.44	-6.97	-0.35	1.62e-11	Morning vs. evening chronotype;
LIHC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19623624	chr10:135278901	LOC619207	-0.44	-6.88	-0.35	2.84e-11	Systemic lupus erythematosus;
LIHC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.52	0.46	3.1400000000000002e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs12744310	1.000	rs12036554	chr1:41777989	T/G	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2834188	0.924	rs2850015	chr21:34697264	T/C	cg04842828	chr21:34696676	IFNAR1	0.47	6.23	0.32	1.35e-9	Narcolepsy;
LIHC	cis	rs4453791	0.932	rs13096744	chr3:38915335	T/G	cg02254461	chr3:39195904	CSRNP1	0.66	5.89	0.3	9.44e-9	Social communication problems;
LIHC	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.61	11.08	0.51	1.43e-24	Airflow obstruction;
LIHC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.46	-6.04	-0.31	4e-9	Blood metabolite levels;
LIHC	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg07150772	chr14:90864620	CALM1	-0.42	-5.87	-0.3	1.03e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.02	0.44	1.42e-17	Bipolar disorder;
LIHC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.93	13.6	0.59	5.55e-34	Sudden cardiac arrest;
LIHC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.95	13.5	0.59	1.39e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs922107	0.738	rs10922666	chr1:90036702	G/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.6	-0.38	2.8e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.3	-0.37	2.02e-12	Bipolar disorder;
LIHC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.61	-8.94	-0.44	2.54e-17	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6066825	0.644	rs1040559	chr20:47314445	A/G	cg18078177	chr20:47281410	PREX1	0.43	7.05	0.36	9.65e-12	Colorectal cancer;
LIHC	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.6	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3823572	0.504	rs2971968	chr7:133642599	C/A	cg03336402	chr7:133662267	EXOC4	-0.47	-5.81	-0.3	1.4e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.55	13.19	0.58	2.11e-32	White blood cell count (basophil);
LIHC	cis	rs6714710	0.535	rs62158274	chr2:98621060	T/A	cg26665480	chr2:98280029	ACTR1B	0.45	6.21	0.32	1.56e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-7.76	-0.39	9.95e-14	Gut microbiome composition (summer);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg18368637	chr6:144179905	LTV1	0.39	6.08	0.31	3.2e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-8.83	-0.43	5.64e-17	Menarche (age at onset);
LIHC	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.27	6.83	0.35	3.85e-11	Menarche (age at onset);
LIHC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.8	7.68	0.38	1.63e-13	Diabetic retinopathy;
LIHC	cis	rs4919087	0.561	rs793522	chr10:99022614	T/G	cg25902810	chr10:99078978	FRAT1	-0.57	-6.3	-0.32	9.33e-10	Monocyte count;
LIHC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.59	-0.5	7.31e-23	Chronic sinus infection;
LIHC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	0.96	17.29	0.68	1.4e-48	Monocyte percentage of white cells;
LIHC	cis	rs6066825	0.606	rs2869668	chr20:47321393	T/C	cg18078177	chr20:47281410	PREX1	0.4	6.58	0.34	1.8e-10	Colorectal cancer;
LIHC	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.73	9.41	0.45	7.48e-19	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.6	15.62	0.65	7.04e-42	Airflow obstruction;
LIHC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.48	1.51e-21	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs797680	0.930	rs1474927	chr1:93570368	C/T	cg15093775	chr1:93646470	TMED5;CCDC18	-0.32	-5.76	-0.3	1.9e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	0.62	8.93	0.43	2.74e-17	Prudent dietary pattern;
LIHC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	5.8	0.3	1.47e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg02993280	chr1:107599747	PRMT6	-0.68	-10.87	-0.51	7.78e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg11189052	chr15:85197271	WDR73	-0.43	-6.35	-0.32	7.03e-10	P wave terminal force;
LIHC	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.41	6.07	0.31	3.43e-9	Post bronchodilator FEV1;
LIHC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-12.14	-0.55	1.97e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs367615	0.918	rs13173339	chr5:108871318	T/A	cg17395555	chr5:108820864	NA	0.35	7.21	0.36	3.59e-12	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.46	6.38	0.33	5.59e-10	Height;
LIHC	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg20607764	chr19:44506953	ZNF230	-0.45	-7.53	-0.38	4.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg05714579	chr10:131428358	MGMT	0.38	6.11	0.31	2.77e-9	Response to temozolomide;
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07332563	chr6:291687	DUSP22	-0.53	-7.39	-0.37	1.12e-12	Menopause (age at onset);
LIHC	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.52	7.91	0.39	3.53e-14	Intelligence (multi-trait analysis);
LIHC	trans	rs10411161	0.702	rs11879436	chr19:52397815	T/A	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg20607798	chr8:58055168	NA	0.64	8.21	0.41	4.61e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg02580895	chr19:2754563	NA	-0.46	-6.83	-0.35	3.96e-11	Total cholesterol levels;
LIHC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.85	13.94	0.6	2.63e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg20016023	chr10:99160130	RRP12	-0.42	-6.57	-0.33	1.9e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.51	7.47	0.37	6.66e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.7	-9.6	-0.46	1.73e-19	Longevity;
LIHC	cis	rs3736485	0.966	rs11633713	chr15:51908052	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.97	-0.35	1.64e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27189623	chr16:705930	WDR90	0.42	6.96	0.35	1.74e-11	Height;
LIHC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg15123519	chr2:136567270	LCT	-0.36	-7.25	-0.37	2.71e-12	Mosquito bite size;
LIHC	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.65	-7.0	-0.35	1.36e-11	Exhaled nitric oxide output;
LIHC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.12	10.25	0.48	1.1e-21	Diabetic retinopathy;
LIHC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	7.22	0.36	3.44e-12	Parkinson's disease;
LIHC	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.63	7.9	0.39	3.98e-14	Macular telangiectasia type 2;
LIHC	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.71	-11.24	-0.52	3.68e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs55665837	0.701	rs11023278	chr11:14641184	G/T	cg25251204	chr11:14927456	NA	0.43	6.03	0.31	4.22e-9	Vitamin D levels;
LIHC	cis	rs6466055	0.777	rs3801281	chr7:104889573	T/C	cg04380332	chr7:105027541	SRPK2	0.36	6.71	0.34	8.15e-11	Schizophrenia;
LIHC	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.53	8.7	0.43	1.45e-16	Information processing speed;
LIHC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.24	0.58	1.31e-32	Psoriasis;
LIHC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.99	-0.31	5.36e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10744422	0.800	rs839363	chr12:123276924	C/T	cg18912006	chr12:123335444	HIP1R	-0.55	-6.32	-0.32	8.05e-10	Schizophrenia;
LIHC	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.81	-14.35	-0.61	7.14e-37	Height;
LIHC	cis	rs7432375	0.933	rs6791142	chr3:136377377	C/T	cg21827317	chr3:136751795	NA	0.43	5.91	0.3	8.26e-9	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.36	0.45	1.12e-18	Platelet count;
LIHC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.58	9.48	0.46	4.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.7	7.28	0.37	2.38e-12	Vitiligo;
LIHC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.5	7.16	0.36	4.82e-12	High light scatter reticulocyte count;
LIHC	cis	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.74e-11	Atopic dermatitis;
LIHC	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg20368463	chr18:77673604	PQLC1	0.52	6.41	0.33	4.69e-10	Opioid sensitivity;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11905131	chr22:24372483	LOC391322	-0.64	-8.82	-0.43	5.93e-17	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.54	-11.1	-0.51	1.2e-24	Tonsillectomy;
LIHC	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.72	-11.81	-0.54	3.28e-27	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.66	11.84	0.54	2.47e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6938574	0.672	rs6569520	chr6:128365034	C/G	cg13759676	chr6:128799557	PTPRK	-0.44	-5.72	-0.3	2.35e-8	Menarche (age at onset);
LIHC	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.42	6.6	0.34	1.6e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.34e-17	Gut microbiome composition (summer);
LIHC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.46	-7.55	-0.38	4.06e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.97	16.32	0.66	1.07e-44	Breast cancer;
LIHC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.68	0.34	9.78e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg25364880	chr3:44379878	C3orf23	0.54	7.39	0.37	1.16e-12	Depressive symptoms;
LIHC	cis	rs1555322	0.530	rs2425049	chr20:33874720	C/T	cg03689076	chr20:33865952	NA	0.54	6.32	0.32	8.02e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.9	0.47	1.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.39	6.35	0.32	7.05e-10	Red blood cell count;
LIHC	cis	rs11605275	1.000	rs74809393	chr11:20031520	C/A	cg14835545	chr11:20032148	NAV2	-0.8	-7.38	-0.37	1.18e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.07	0.4	1.17e-14	Lymphocyte counts;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01162549	chr5:141367464	RNF14	0.47	6.98	0.35	1.59e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	1.01	19.17	0.72	3.67e-56	Breast cancer;
LIHC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg19635926	chr16:89946313	TCF25	0.51	6.7	0.34	8.85e-11	Skin colour saturation;
LIHC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.61	7.07	0.36	8.72e-12	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.08	9.91	0.47	1.64e-20	Diabetic retinopathy;
LIHC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.91	0.54	1.31e-27	Cognitive test performance;
LIHC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.67	-0.53	1.03e-26	Chronic sinus infection;
LIHC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.29	0.37	2.18e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.73	12.44	0.56	1.51e-29	Menopause (age at onset);
LIHC	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg17120908	chr11:65337727	SSSCA1	-0.45	-6.38	-0.33	5.62e-10	Bone mineral density;
LIHC	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.38	-6.06	-0.31	3.58e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22618164	chr12:122356400	WDR66	-0.46	-7.59	-0.38	3.03e-13	Mean corpuscular volume;
LIHC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.69	7.88	0.39	4.37e-14	Hip circumference adjusted for BMI;
LIHC	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.65	10.45	0.49	2.22e-22	Obesity-related traits;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg25010118	chr18:65184398	DSEL	0.43	6.47	0.33	3.42e-10	Alopecia areata;
LIHC	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.67	7.29	0.37	2.24e-12	Exhaled nitric oxide output;
LIHC	cis	rs11822910	0.654	rs2439450	chr11:57213061	C/G	cg00522883	chr11:57194120	SLC43A3	0.52	6.75	0.34	6.2e-11	Platelet distribution width;
LIHC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg06096015	chr1:231504339	EGLN1	-0.5	-9.39	-0.45	8.51e-19	Hemoglobin concentration;
LIHC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.49	-6.49	-0.33	3.08e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	0.9	13.15	0.58	2.99e-32	Post bronchodilator FEV1;
LIHC	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.33	7.6	0.38	2.9e-13	Blood metabolite ratios;
LIHC	trans	rs6866721	0.791	rs10071722	chr5:116214932	T/G	cg07571379	chr11:134631427	NA	-0.29	-6.09	-0.31	3.08e-9	Body mass index;
LIHC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.49	-7.26	-0.37	2.63e-12	Blood trace element (Zn levels);
LIHC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.99	0.31	5.45e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	trans	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg10756647	chr7:56101905	PSPH	1.1	13.25	0.58	1.24e-32	Diabetic kidney disease;
LIHC	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.09	0.31	3.11e-9	Mean corpuscular volume;
LIHC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.65	13.41	0.59	3.07e-33	Airflow obstruction;
LIHC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.47	6.07	0.31	3.35e-9	Alzheimer's disease;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21806233	chr11:111956119	TIMM8B;SDHD	0.44	6.11	0.31	2.64e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	14.27	0.61	1.39e-36	Prudent dietary pattern;
LIHC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg20026190	chr17:76395443	PGS1	0.39	5.84	0.3	1.2e-8	HDL cholesterol levels;
LIHC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.61	10.61	0.5	6.35e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs116248771	0.739	rs4679833	chr3:158339835	G/A	cg16708174	chr3:158430962	RARRES1	0.48	6.36	0.33	6.52e-10	diarrhoeal disease at age 2;
LIHC	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.7	10.78	0.5	1.65e-23	Monocyte count;
LIHC	cis	rs1570989	0.841	rs956598	chr6:12027635	A/G	cg17804551	chr6:12015979	HIVEP1	0.4	5.99	0.31	5.27e-9	Alcohol and nicotine co-dependence;
LIHC	cis	rs888194	0.725	rs2241210	chr12:109950144	A/G	cg05360138	chr12:110035743	NA	0.4	5.74	0.3	2.07e-8	Neuroticism;
LIHC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.61	6.87	0.35	3.14e-11	Alzheimer's disease;
LIHC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.65	-0.46	1.16e-19	Electroencephalogram traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07288394	chr19:30205772	C19orf12	0.45	6.17	0.32	1.91e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10508774	1.000	rs11008940	chr10:32731979	A/T	cg01819863	chr10:32635814	EPC1	-0.65	-6.06	-0.31	3.49e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-12.47	-0.56	1.17e-29	Longevity;Endometriosis;
LIHC	cis	rs922107	0.738	rs7516314	chr1:90050831	A/G	cg15422784	chr1:90023713	LRRC8B	-0.49	-7.76	-0.39	9.62e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs10838687	0.736	rs4647741	chr11:47254010	T/C	cg25783544	chr11:47291846	MADD	0.47	5.87	0.3	1.05e-8	Proinsulin levels;
LIHC	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.32	1.21e-9	Mean corpuscular volume;
LIHC	cis	rs10949834	0.793	rs810532	chr7:73505188	A/G	cg07137043	chr7:73588983	EIF4H	-0.56	-6.25	-0.32	1.21e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg14067834	chr17:29058358	SUZ12P	0.65	6.65	0.34	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.59	-0.38	3.11e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.38e-11	Aortic root size;
LIHC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.81	-0.3	1.45e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02290350	chr8:58132656	NA	0.47	9.29	0.45	1.8e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg22049899	chr12:47219821	SLC38A4	0.36	6.28	0.32	1.01e-9	Itch intensity from mosquito bite;
LIHC	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg17385448	chr1:15911702	AGMAT	0.4	6.81	0.35	4.41e-11	Systolic blood pressure;
LIHC	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.61	-9.84	-0.47	2.84e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.49	7.1	0.36	7.31e-12	Asthma;
LIHC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-7.17	-0.36	4.73e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg16034541	chr3:195490309	MUC4	0.61	9.61	0.46	1.59e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.67	10.57	0.5	8.43e-23	Prostate cancer;
LIHC	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg20240347	chr1:204465584	NA	-0.36	-7.57	-0.38	3.39e-13	Schizophrenia;
LIHC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.53	-6.42	-0.33	4.68e-10	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg26939375	chr7:64535504	NA	-0.46	-7.32	-0.37	1.81e-12	Aortic root size;
LIHC	cis	rs807029	0.533	rs722435	chr10:102745062	G/T	cg27255678	chr10:102756921	LZTS2	0.52	7.31	0.37	1.85e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.54	-9.08	-0.44	8.82e-18	Cognitive function;
LIHC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.69	13.68	0.59	2.84e-34	Coronary artery disease;
LIHC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.76	-15.24	-0.64	2.18e-40	Height;
LIHC	cis	rs10420951	0.617	rs2303694	chr19:18562438	C/T	cg10790698	chr19:18539756	SSBP4	-0.42	-6.03	-0.31	4.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg25344623	chr2:136566232	LCT	-0.38	-6.05	-0.31	3.71e-9	Corneal structure;
LIHC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.59	-0.34	1.67e-10	Blood metabolite levels;
LIHC	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg03934865	chr2:198174659	NA	0.46	6.76	0.34	5.8e-11	Dermatomyositis;
LIHC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.42	8.0	0.4	1.96e-14	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.66	8.46	0.42	8.14e-16	Gut microbiome composition (summer);
LIHC	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg09035930	chr12:129282057	SLC15A4	-0.5	-5.95	-0.31	6.49e-9	Systemic lupus erythematosus;
LIHC	cis	rs10508774	0.925	rs72795540	chr10:32843182	C/T	cg01819863	chr10:32635814	EPC1	0.66	6.14	0.32	2.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs713477	0.631	rs7145182	chr14:55905231	C/G	cg13175173	chr14:55914753	NA	-0.3	-6.68	-0.34	9.83e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg03037974	chr15:76606532	NA	0.75	14.64	0.62	4.9e-38	Blood metabolite levels;
LIHC	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg08911820	chr1:110026001	ATXN7L2	-0.61	-7.51	-0.38	5.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.43	5.87	0.3	1.03e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.18	0.36	4.51e-12	Osteoporosis;
LIHC	trans	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg19894588	chr14:64061835	NA	-0.68	-10.07	-0.48	4.52e-21	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs17106184	1.000	rs11205773	chr1:51284905	C/T	cg07174182	chr1:51127561	FAF1	0.75	8.4	0.41	1.24e-15	Type 2 diabetes;
LIHC	cis	rs11673344	0.730	rs475026	chr19:37459017	T/C	cg27390819	chr19:37464633	NA	-0.53	-6.29	-0.32	9.74e-10	Obesity-related traits;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg04895581	chr8:94753488	RBM12B	-0.41	-6.2	-0.32	1.59e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs16958440	0.867	rs78547658	chr18:44669852	C/T	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	cis	rs6594499	0.872	rs10051830	chr5:110452845	G/A	cg04022379	chr5:110408740	TSLP	0.49	8.16	0.4	6.26e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	5.73	0.3	2.18e-8	Schizophrenia;
LIHC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.1	0.31	2.85e-9	Cognitive ability;
LIHC	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg04155231	chr12:9217510	LOC144571	0.3	5.87	0.3	1.05e-8	Sjögren's syndrome;
LIHC	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.8	-0.39	7.52e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.4	6.21	0.32	1.52e-9	Mean platelet volume;
LIHC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.23	-7.28	-0.37	2.24e-12	Motion sickness;
LIHC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg19682013	chr15:45996608	NA	0.39	6.63	0.34	1.29e-10	Waist circumference;Weight;
LIHC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.23	-0.41	4.1e-15	Gut microbiome composition (summer);
LIHC	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.48	7.47	0.37	6.61e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg18944383	chr4:111397179	ENPEP	0.25	6.28	0.32	1.02e-9	Coronary artery disease;
LIHC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.51	7.75	0.39	1.07e-13	Longevity;Endometriosis;
LIHC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-5.93	-0.31	7.38e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.88	12.41	0.56	1.83e-29	Blood metabolite levels;
LIHC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.67	0.59	3.13e-34	Lung cancer in ever smokers;
LIHC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.73	-0.47	6.52e-20	Schizophrenia;
LIHC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.21	0.41	4.46e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.69	0.38	1.54e-13	Bipolar disorder;
LIHC	trans	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.91	10.0	0.48	7.94e-21	Platelet count;
LIHC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-8.59	-0.42	3.2e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg16736954	chr20:23401023	NAPB	0.7	8.34	0.41	1.89e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6466055	0.720	rs1204058	chr7:104958129	T/G	cg04380332	chr7:105027541	SRPK2	0.37	6.88	0.35	2.84e-11	Schizophrenia;
LIHC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.73	0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.44	6.94	0.35	1.94e-11	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs8081395	0.627	rs12952730	chr17:57978836	G/A	cg02344993	chr17:57696989	CLTC	0.45	7.56	0.38	3.86e-13	White blood cell count;
LIHC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.82	0.3	1.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs11166927	0.594	rs7828992	chr8:140826670	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.46	-7.27	-0.37	2.49e-12	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26320663	chr1:152161521	NA	0.41	6.14	0.32	2.29e-9	Inflammatory skin disease;
LIHC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.63	11.29	0.52	2.45e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.51	7.1	0.36	7.39e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	12.01	0.54	5.63e-28	Motion sickness;
LIHC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.58	9.91	0.47	1.65e-20	Colorectal cancer;
LIHC	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg09445902	chr10:555545	DIP2C	-0.4	-6.53	-0.33	2.39e-10	Psychosis in Alzheimer's disease;
LIHC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-7.35	-0.37	1.46e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11987759	chr7:65425863	GUSB	0.39	6.22	0.32	1.41e-9	Aortic root size;
LIHC	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.8	0.3	1.5e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.24	6.03	0.31	4.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.45	-0.37	7.75e-13	Bipolar disorder;
LIHC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.74	8.01	0.4	1.83e-14	Vitiligo;
LIHC	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.7	5.91	0.3	8.22e-9	Blood protein levels;
LIHC	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.46	6.79	0.34	5.08e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.25	0.37	2.79e-12	Parkinson's disease;
LIHC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.71	10.55	0.5	1.02e-22	Aortic root size;
LIHC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg03959625	chr15:84868606	LOC388152	0.47	6.68	0.34	9.94e-11	Schizophrenia;
LIHC	cis	rs34540877	1.000	rs58229578	chr19:33138336	C/T	cg22980127	chr19:33182716	NUDT19	1.0	6.63	0.34	1.3e-10	Red cell distribution width;
LIHC	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.41	6.7	0.34	8.62e-11	Mean corpuscular volume;
LIHC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.55	-0.46	2.51e-19	Total cholesterol levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15344021	chr17:2240169	TSR1;SGSM2	0.44	6.17	0.32	1.97e-9	Pancreatic cancer;
LIHC	cis	rs4903214	0.895	rs1860716	chr14:74713273	T/A	cg11132536	chr14:74711944	VSX2	-0.24	-5.95	-0.31	6.46e-9	Inflammatory bowel disease;
LIHC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.81	14.95	0.63	3.01e-39	Blood protein levels;
LIHC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.47	-7.57	-0.38	3.5e-13	Longevity;Endometriosis;
LIHC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.53	7.69	0.38	1.58e-13	Type 2 diabetes;
LIHC	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg03934865	chr2:198174659	NA	0.43	6.2	0.32	1.62e-9	Intracranial aneurysm;
LIHC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg07424592	chr7:64974309	NA	0.82	9.43	0.45	6.33e-19	Diabetic kidney disease;
LIHC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.46	-0.37	7.13e-13	Aortic root size;
LIHC	trans	rs743793	0.875	rs137380	chr22:33578233	T/A	cg20274824	chr1:36638199	MAP7D1	0.46	6.42	0.33	4.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.38	-6.73	-0.34	7.21e-11	Aortic root size;
LIHC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs1664789	1.000	rs1664784	chr5:53281366	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.53	8.69	0.43	1.58e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.76	0.34	5.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg07959070	chr22:50026188	C22orf34	-0.35	-8.66	-0.42	1.92e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg14146966	chr2:61757674	XPO1	-0.43	-7.24	-0.36	2.94e-12	Tuberculosis;
LIHC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-6.33	-0.32	7.8e-10	Dental caries;
LIHC	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.02	20.36	0.74	6.46e-61	Schizophrenia;
LIHC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18357526	chr6:26021779	HIST1H4A	0.47	6.97	0.35	1.6e-11	Height;
LIHC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg08132940	chr7:1081526	C7orf50	-0.77	-6.47	-0.33	3.47e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg01231543	chr16:68741748	NA	0.39	5.98	0.31	5.67e-9	Colorectal cancer;
LIHC	trans	rs6866721	0.791	rs10054140	chr5:116215213	C/T	cg07571379	chr11:134631427	NA	-0.29	-6.09	-0.31	3.08e-9	Body mass index;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02804564	chr10:112679224	NCRNA00081;SHOC2	0.43	6.2	0.32	1.59e-9	Pancreatic cancer;
LIHC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.35e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-7.01	-0.35	1.3e-11	Height;
LIHC	cis	rs7487075	0.619	rs10880968	chr12:46822960	C/T	cg23829395	chr12:46796953	NA	0.35	6.17	0.32	1.97e-9	Itch intensity from mosquito bite;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.18	-0.36	4.48e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.3	5.85	0.3	1.12e-8	Colorectal cancer;
LIHC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.58	0.42	3.44e-16	Motion sickness;
LIHC	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg04610667	chr7:75704037	NA	-0.33	-5.94	-0.31	6.93e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.5	6.57	0.33	1.84e-10	Resting heart rate;
LIHC	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg02951883	chr7:2050386	MAD1L1	0.57	7.58	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	29.37	0.85	1.53e-95	IgG glycosylation;
LIHC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg03037974	chr15:76606532	NA	-0.59	-9.87	-0.47	2.27e-20	Blood metabolite levels;
LIHC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg18944383	chr4:111397179	ENPEP	0.27	6.92	0.35	2.29e-11	Height;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg07991479	chr17:40265765	KAT2A;DHX58	0.41	6.14	0.32	2.27e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.01	7.79	0.39	8.11e-14	Diabetic retinopathy;
LIHC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.89	-0.43	3.51e-17	Total cholesterol levels;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.66	9.67	0.46	1.03e-19	Lymphocyte counts;
LIHC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.48	-0.42	6.72e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-7.17	-0.36	4.66e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4450131	0.618	rs7075794	chr10:126338093	A/G	cg20435097	chr10:126320824	FAM53B	0.6	11.28	0.52	2.61e-25	White blood cell count (basophil);
LIHC	cis	rs6442522	0.673	rs7628975	chr3:15502130	C/T	cg16303742	chr3:15540471	COLQ	-0.43	-7.22	-0.36	3.49e-12	Uric acid levels;
LIHC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07377288	chr7:102004298	NA	0.51	6.24	0.32	1.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.69	-8.43	-0.41	1e-15	Gut microbiome composition (summer);
LIHC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.37	-6.33	-0.32	7.72e-10	Educational attainment;
LIHC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.38	-5.94	-0.31	7.04e-9	Glioblastoma;
LIHC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.4	0.45	8.18e-19	Platelet count;
LIHC	trans	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg25214090	chr10:38739885	LOC399744	-0.4	-6.56	-0.33	1.98e-10	Diastolic blood pressure;
LIHC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.27	-6.35	-0.32	6.85e-10	Menarche (age at onset);
LIHC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.78	11.76	0.54	5e-27	Coronary artery disease;
LIHC	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.87	12.09	0.55	2.82e-28	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	10.99	0.51	2.93e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	6.41	0.33	4.73e-10	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.47	-7.78	-0.39	8.47e-14	Testicular germ cell tumor;
LIHC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg20195005	chr22:42527684	CYP2D6	0.31	5.84	0.3	1.23e-8	Birth weight;
LIHC	cis	rs6442522	0.560	rs13092264	chr3:15514297	A/T	cg16303742	chr3:15540471	COLQ	0.38	6.23	0.32	1.35e-9	Uric acid levels;
LIHC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.54	-0.33	2.28e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg19680672	chr10:131412579	MGMT	-0.39	-5.85	-0.3	1.14e-8	Response to temozolomide;
LIHC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.56	7.95	0.39	2.82e-14	Eosinophil percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04203429	chr16:29822912	PRRT2	0.49	6.71	0.34	7.96e-11	Lung function (FEV1/FVC);
LIHC	cis	rs7937840	0.597	rs3890102	chr11:61915823	C/T	cg01969543	chr11:61895209	INCENP	0.48	6.23	0.32	1.35e-9	Breast cancer;
LIHC	cis	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg03281426	chr2:240109471	HDAC4	0.42	6.29	0.32	9.44e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg19413766	chr7:29689036	LOC646762	-0.61	-6.28	-0.32	1e-9	Facial emotion recognition;Facial emotion recognition (sad faces);
LIHC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.82	14.54	0.62	1.27e-37	Aortic root size;
LIHC	cis	rs7635838	0.892	rs754015	chr3:11493945	T/C	cg00170343	chr3:11313890	ATG7	0.4	6.36	0.33	6.32e-10	HDL cholesterol;
LIHC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg14067834	chr17:29058358	SUZ12P	0.64	6.4	0.33	5.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.7	-8.72	-0.43	1.2e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.4	-6.59	-0.34	1.68e-10	Obesity-related traits;
LIHC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.47	8.0	0.4	2.02e-14	Mean corpuscular volume;
LIHC	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg07424592	chr7:64974309	NA	0.77	8.87	0.43	4.13e-17	Diabetic kidney disease;
LIHC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.55	10.25	0.48	1.09e-21	Methadone dose in opioid dependence;
LIHC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.16	0.44	4.71e-18	Schizophrenia;
LIHC	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-0.84	-9.29	-0.45	1.86e-18	Exhaled nitric oxide output;
LIHC	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg16797656	chr11:68205561	LRP5	0.59	7.8	0.39	7.49e-14	Total body bone mineral density (age 45-60);
LIHC	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.77	-0.34	5.56e-11	Metabolite levels;
LIHC	cis	rs3790645	0.874	rs9438508	chr1:26893069	T/C	cg23229016	chr1:26872525	RPS6KA1	0.23	5.75	0.3	2.02e-8	Glucose homeostasis traits;
LIHC	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.44	-6.15	-0.32	2.12e-9	Tuberculosis;
LIHC	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.76	12.88	0.57	3.12e-31	Coronary artery disease;
LIHC	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	5.99	0.31	5.39e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-7.09	-0.36	7.78e-12	Vitamin D levels;
LIHC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-8.22	-0.41	4.22e-15	Gut microbiome composition (summer);
LIHC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.56	-0.33	1.99e-10	Blood metabolite levels;
LIHC	cis	rs12644436	0.628	rs13125634	chr4:88785001	G/A	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.39	-7.95	-0.39	2.82e-14	Renal cell carcinoma;
LIHC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.58	8.51	0.42	5.54e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	10.6	0.5	6.86e-23	Cognitive test performance;
LIHC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-5.99	-0.31	5.41e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Paclitaxel-induced neuropathy;
LIHC	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.46	6.08	0.31	3.24e-9	Glioblastoma;Glioma;
LIHC	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg06115741	chr20:33292138	TP53INP2	0.62	8.22	0.41	4.13e-15	Coronary artery disease;
LIHC	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	5.84	0.3	1.24e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.72	10.96	0.51	3.62e-24	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg19318889	chr4:1322082	MAEA	0.44	6.64	0.34	1.22e-10	Obesity-related traits;
LIHC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.6	10.35	0.49	5e-22	Longevity;Endometriosis;
LIHC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.88	11.33	0.52	1.78e-25	Coronary artery disease;
LIHC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.15	-0.32	2.11e-9	Mood instability;
LIHC	cis	rs8010715	0.520	rs12435994	chr14:24589461	A/C	cg23112188	chr14:24563095	PCK2	-0.32	-6.46	-0.33	3.5e-10	IgG glycosylation;
LIHC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.34	-6.68	-0.34	9.5e-11	Platelet distribution width;
LIHC	trans	rs13113518	0.812	rs12500456	chr4:56427220	C/T	cg15358633	chr12:38710606	ALG10B	0.44	6.31	0.32	8.71e-10	Height;
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg10217327	chr6:118973057	C6orf204	0.64	6.22	0.32	1.48e-9	Renal cell carcinoma;
LIHC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.67	11.07	0.51	1.47e-24	Type 2 diabetes;
LIHC	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.39	-5.93	-0.31	7.6e-9	Menarche (age at onset);
LIHC	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.83	16.8	0.67	1.37e-46	Longevity;
LIHC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.5	5.94	0.31	7e-9	Alzheimer's disease;
LIHC	trans	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.51	-0.33	2.65e-10	Mosquito bite size;
LIHC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg13647721	chr17:30228624	UTP6	-0.76	-6.5	-0.33	2.87e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs965469	1.000	rs965469	chr20:3381549	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.85	-0.35	3.38e-11	IFN-related cytopenia;
LIHC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	7.84	0.39	5.75e-14	Monocyte percentage of white cells;
LIHC	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.46	-7.2	-0.36	3.77e-12	Type 2 diabetes;
LIHC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.32	6.44	0.33	3.96e-10	Immature fraction of reticulocytes;
LIHC	cis	rs5769765	0.773	rs9616751	chr22:50222236	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.04	-0.4	1.43e-14	Schizophrenia;
LIHC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-0.74	-8.45	-0.42	8.62e-16	Hip circumference adjusted for BMI;
LIHC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	1.17	13.67	0.59	3.07e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg17834443	chr8:19674713	INTS10	0.47	6.94	0.35	2.02e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6442522	0.606	rs3773462	chr3:15494279	G/A	cg16303742	chr3:15540471	COLQ	0.39	6.44	0.33	3.96e-10	Uric acid levels;
LIHC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.49	0.38	5.8e-13	Parkinson's disease;
LIHC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.5	-8.38	-0.41	1.38e-15	Bipolar disorder;
LIHC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.67	6.81	0.35	4.35e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.44	-6.14	-0.32	2.25e-9	Type 2 diabetes;
LIHC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.64	11.01	0.51	2.46e-24	Colorectal cancer;
LIHC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.68	12.14	0.55	1.83e-28	Iron status biomarkers;
LIHC	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.73	11.2	0.52	5e-25	Obesity-related traits;
LIHC	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.35	-0.32	6.93e-10	Schizophrenia;
LIHC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.56	6.79	0.34	4.99e-11	Cognitive function;
LIHC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.41	7.23	0.36	3.09e-12	Type 2 diabetes;
LIHC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-8.98	-0.44	1.89e-17	Obesity-related traits;
LIHC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-10.31	-0.49	7.22e-22	Morning vs. evening chronotype;
LIHC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.33	-0.37	1.68e-12	Platelet distribution width;
LIHC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.77	-0.3	1.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.39	5.85	0.3	1.15e-8	Other erythrocyte phenotypes;
LIHC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.67	13.45	0.59	2.07e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs797680	0.786	rs7532195	chr1:93617403	T/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.35	-6.1	-0.31	2.87e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23029100	chr15:76603787	ETFA	-0.45	-6.61	-0.34	1.44e-10	Cognitive function;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15358743	chr18:56807035	SEC11C	0.42	6.19	0.32	1.71e-9	Pancreatic cancer;
LIHC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.87	13.13	0.58	3.51e-32	Vitamin D levels;
LIHC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg19318889	chr4:1322082	MAEA	-0.47	-7.78	-0.39	8.4e-14	Obesity-related traits;
LIHC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.6	-0.34	1.54e-10	Mood instability;
LIHC	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.25	-13.0	-0.58	1.13e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg25024717	chr12:54324583	NA	-0.38	-8.17	-0.4	6.22e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	trans	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg07393940	chr7:158741817	NA	-0.57	-6.91	-0.35	2.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs16944613	0.510	rs4476150	chr15:91147214	G/A	cg26821196	chr15:91095069	CRTC3	0.35	6.29	0.32	9.71e-10	Colorectal cancer;
LIHC	trans	rs2209875	1.000	rs1305024	chr9:91809082	T/C	cg26057616	chr1:222234397	NA	0.36	6.04	0.31	3.93e-9	Pelvic organ prolapse (moderate/severe);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12833168	chr14:39856160	NA	0.47	6.35	0.32	6.73e-10	Hepatitis;
LIHC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.95	0.65	3.35e-43	Electrocardiographic conduction measures;
LIHC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.72	0.3	2.3e-8	Self-reported allergy;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03861428	chr1:17380702	SDHB	-0.49	-6.23	-0.32	1.37e-9	Hip circumference;
LIHC	cis	rs2273156	1.000	rs12897612	chr14:35471147	C/T	cg16230307	chr14:35515116	FAM177A1	-0.41	-6.05	-0.31	3.88e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg27478167	chr7:817139	HEATR2	-0.41	-5.83	-0.3	1.32e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.49	9.24	0.45	2.6e-18	Testicular germ cell tumor;
LIHC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	0.82	11.39	0.52	1.06e-25	Skin colour saturation;
LIHC	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.57	6.97	0.35	1.63e-11	QRS duration;
LIHC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.42	-6.06	-0.31	3.53e-9	Inflammatory bowel disease;
LIHC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.7	0.57	1.58e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.51	9.17	0.44	4.39e-18	Height;
LIHC	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.63	10.85	0.51	9.14e-24	Breast cancer;
LIHC	cis	rs9467160	0.520	rs9356934	chr6:24442171	C/T	cg20631270	chr6:24437470	GPLD1	0.4	6.01	0.31	4.74e-9	Liver enzyme levels;
LIHC	trans	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg01596870	chr19:55963115	NA	-0.63	-8.33	-0.41	1.95e-15	Obesity-related traits;
LIHC	cis	rs2574704	0.924	rs2574725	chr3:11657017	C/T	cg15876825	chr3:11651881	VGLL4	0.49	8.13	0.4	8.18e-15	Body mass index;
LIHC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	8.02	0.4	1.73e-14	Platelet count;
LIHC	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	7.45	0.37	7.49e-13	Eosinophil percentage of white cells;
LIHC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.71	-0.43	1.28e-16	Primary biliary cholangitis;
LIHC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.59	8.47	0.42	7.56e-16	Motion sickness;
LIHC	cis	rs10508774	0.810	rs72795559	chr10:32872971	A/G	cg01819863	chr10:32635814	EPC1	0.6	5.82	0.3	1.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs15676	0.947	rs2805103	chr9:131598897	T/A	cg00228799	chr9:131580591	ENDOG	0.45	6.79	0.34	5.13e-11	Blood metabolite levels;
LIHC	cis	rs655641	1.000	rs670606	chr11:85698598	G/A	cg09030501	chr11:85779252	PICALM	-0.51	-6.11	-0.31	2.76e-9	Platelet count;
LIHC	cis	rs3789045	0.774	rs12028476	chr1:204476361	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.39	-5.93	-0.31	7.24e-9	Educational attainment (college completion);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg17114402	chr2:97778470	ANKRD36	0.43	6.22	0.32	1.43e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.55	8.98	0.44	1.91e-17	Breast cancer;
LIHC	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.65	-0.42	2.1e-16	Total cholesterol levels;
LIHC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg16836995	chr17:43662488	NA	0.67	6.88	0.35	2.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-6.96	-0.35	1.7e-11	Hepatocellular carcinoma;
LIHC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.47	-6.91	-0.35	2.4e-11	Response to metformin (IC50);
LIHC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg27211696	chr2:191398769	TMEM194B	-0.52	-6.82	-0.35	4.16e-11	Diastolic blood pressure;
LIHC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21467203	chr3:49911342	NA	-0.41	-7.07	-0.36	9e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.68	10.54	0.5	1.16e-22	Menarche (age at onset);
LIHC	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg10385411	chr19:48897143	GRIN2D	0.44	6.2	0.32	1.62e-9	Cancer;
LIHC	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.71	0.3	2.41e-8	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04998419	chr1:40626967	RLF	-0.55	-6.51	-0.33	2.65e-10	Systolic blood pressure;
LIHC	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg03128534	chr1:43423976	SLC2A1	-0.47	-5.94	-0.31	6.89e-9	Red cell distribution width;
LIHC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02711726	chr17:80685570	FN3KRP	-0.41	-7.62	-0.38	2.5e-13	Glycated hemoglobin levels;
LIHC	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.7	7.36	0.37	1.36e-12	Blood protein levels;
LIHC	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg24069376	chr3:38537580	EXOG	-0.38	-6.86	-0.35	3.16e-11	Electrocardiographic conduction measures;
LIHC	cis	rs3770081	1.000	rs74607112	chr2:86305534	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.99	-11.51	-0.53	4.05e-26	Facial emotion recognition (sad faces);
LIHC	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg05372495	chr19:1063624	ABCA7	-0.41	-6.6	-0.34	1.55e-10	Alzheimer's disease (late onset);
LIHC	cis	rs72843506	0.586	rs73296067	chr17:19880301	G/A	cg12065943	chr17:19881925	AKAP10	-0.38	-6.42	-0.33	4.54e-10	Schizophrenia;
LIHC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.78	-0.3	1.7e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.46	0.46	5.3e-19	Platelet count;
LIHC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.62	-8.45	-0.42	8.54e-16	Sudden cardiac arrest;
LIHC	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg22771759	chr13:24902376	NA	0.33	6.75	0.34	6.21e-11	Obesity-related traits;
LIHC	cis	rs7508	0.511	rs438818	chr8:17899561	A/G	cg04898035	chr8:17640624	MTUS1	-0.34	-5.99	-0.31	5.2e-9	Atrial fibrillation;
LIHC	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.44	6.62	0.34	1.39e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs12464559	0.649	rs9288006	chr2:152661831	G/A	cg01189475	chr2:152685088	ARL5A	0.63	7.38	0.37	1.17e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.36	8.27	0.41	3.07e-15	Educational attainment (years of education);
LIHC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	9.82	0.47	3.2e-20	Chronic sinus infection;
LIHC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	0.8	6.67	0.34	1.05e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.26	6.01	0.31	4.87e-9	Crohn's disease;
LIHC	cis	rs716804	0.740	rs10500724	chr11:10302016	A/G	cg01453529	chr11:10209919	SBF2	0.29	5.81	0.3	1.45e-8	Neuroticism;
LIHC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.69	0.38	1.61e-13	Prudent dietary pattern;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.63	7.33	0.37	1.62e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.8	0.34	4.77e-11	Ileal carcinoids;
LIHC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.53	-0.42	4.94e-16	Renal cell carcinoma;
LIHC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.51	0.46	3.49e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg10560079	chr2:191398806	TMEM194B	-0.71	-10.18	-0.48	1.89e-21	Diastolic blood pressure;
LIHC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.64	6.91	0.35	2.31e-11	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14347670	chr6:41908995	CCND3	0.47	7.12	0.36	6.45e-12	Pancreatic cancer;
LIHC	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.48	5.82	0.3	1.35e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg23625390	chr15:77176239	SCAPER	0.36	5.94	0.31	6.92e-9	Blood metabolite levels;
LIHC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.64	8.96	0.44	2.1e-17	Skin colour saturation;
LIHC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg00800038	chr16:89945340	TCF25	-0.63	-9.38	-0.45	9.33e-19	Skin colour saturation;
LIHC	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.55	6.88	0.35	2.82e-11	Metabolite levels;
LIHC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg21361702	chr7:150065534	REPIN1	0.48	6.63	0.34	1.29e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12220238	0.841	rs11000952	chr10:76037336	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	5.96	0.31	6.35e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs787274	1.000	rs787275	chr9:115550523	C/G	cg13803584	chr9:115635662	SNX30	-0.6	-6.41	-0.33	4.77e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23344412	chr5:32602844	SUB1	-0.3	-7.16	-0.36	4.93e-12	Calcium levels;
LIHC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-6.0	-0.31	4.9e-9	Vitiligo;
LIHC	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.03	-0.31	4.34e-9	Educational attainment (college completion);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17157516	chr1:35332203	DLGAP3	0.45	6.68	0.34	9.43e-11	Pancreatic cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg10183001	chr12:51318430	METTL7A	-0.41	-6.24	-0.32	1.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.69	0.43	1.58e-16	Lung cancer in ever smokers;
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg24884572	chr19:58661833	ZNF329	0.96	7.48	0.37	6.44e-13	Cholesterol, total;
LIHC	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg11693508	chr17:37793320	STARD3	0.7	7.38	0.37	1.24e-12	Bipolar disorder;
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08219700	chr8:58056026	NA	0.52	7.15	0.36	5.24e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.99	-0.4	2.14e-14	Body mass index;
LIHC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.69	-0.43	1.56e-16	Gut microbiome composition (summer);
LIHC	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.66	9.11	0.44	7.04e-18	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs11088226	0.692	rs7510418	chr21:33890258	G/A	cg09050820	chr6:167586206	TCP10L2	0.44	6.49	0.33	3.03e-10	Gastritis;
LIHC	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs15676	0.783	rs10819442	chr9:131564750	C/G	cg00228799	chr9:131580591	ENDOG	-0.48	-6.8	-0.34	4.79e-11	Blood metabolite levels;
LIHC	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg06766960	chr11:133703094	NA	-0.41	-6.14	-0.32	2.31e-9	Childhood ear infection;
LIHC	cis	rs1400745	0.756	rs10136352	chr14:35334555	C/T	cg16230307	chr14:35515116	FAM177A1	0.37	6.08	0.31	3.3e-9	Monocyte count;
LIHC	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg07150772	chr14:90864620	CALM1	-0.42	-5.87	-0.3	1.03e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg15605315	chr1:45957053	TESK2	0.44	5.92	0.3	7.91e-9	Platelet count;
LIHC	trans	rs6489882	0.902	rs10774679	chr12:113374748	A/G	cg10175203	chr3:128143634	NA	-0.38	-6.12	-0.31	2.63e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.76	0.54	4.95e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.31	7.43	0.37	8.49e-13	Corneal astigmatism;
LIHC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg17135325	chr3:160939158	NMD3	0.54	7.42	0.37	9.21e-13	Parkinson's disease;
LIHC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	5.75	0.3	1.97e-8	Resting heart rate;
LIHC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	0.72	8.17	0.4	6.16e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg20651018	chr11:3035856	CARS	-0.35	-5.94	-0.31	6.86e-9	Longevity;
LIHC	cis	rs7106204	0.609	rs12788920	chr11:24284514	C/T	ch.11.24196551F	chr11:24239977	NA	0.67	6.08	0.31	3.21e-9	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-7.93	-0.39	3.19e-14	Lymphocyte counts;
LIHC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.9	0.35	2.59e-11	Morning vs. evening chronotype;
LIHC	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.49	6.72	0.34	7.7e-11	Morning vs. evening chronotype;
LIHC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.56	-0.5	9.46e-23	Chronic sinus infection;
LIHC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg22633049	chr21:46681294	NA	-0.33	-5.97	-0.31	5.86e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs714027	0.525	rs6006274	chr22:30232843	C/T	cg01021169	chr22:30184971	ASCC2	-0.35	-6.34	-0.32	7.06e-10	Lymphocyte counts;
LIHC	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.52	7.45	0.37	7.76e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18864164	chr10:115934049	MIR2110;C10orf118	0.42	6.83	0.35	3.84e-11	Cognitive function;
LIHC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.0	-17.77	-0.69	1.67e-50	Body mass index;
LIHC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg22777020	chr22:31556080	RNF185	-0.56	-6.4	-0.33	5.2400000000000005e-10	Colorectal cancer;
LIHC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-8.43	-0.41	9.98e-16	Blood metabolite levels;
LIHC	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg06640241	chr16:89574553	SPG7	0.39	5.88	0.3	9.83e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	13.02	0.58	9.58e-32	Cognitive test performance;
LIHC	cis	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg19613905	chr15:56757180	MNS1	-0.38	-5.76	-0.3	1.84e-8	Urinary tract infection frequency;
LIHC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.5	6.48	0.33	3.16e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.34	-5.9	-0.3	8.76e-9	Schizophrenia;
LIHC	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg18657303	chr4:1051139	NA	0.34	5.82	0.3	1.37e-8	Recombination rate (males);
LIHC	cis	rs4788570	0.566	rs8051439	chr16:71495793	A/T	cg06353428	chr16:71660113	MARVELD3	-1.06	-10.0	-0.48	8.31e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.77	-16.96	-0.68	2.94e-47	Urate levels in lean individuals;
LIHC	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.72	-0.5	2.65e-23	Eye color traits;
LIHC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	7.96	0.4	2.64e-14	Body mass index;
LIHC	cis	rs7945718	0.621	rs7931934	chr11:12679245	T/G	cg25843174	chr11:12811716	TEAD1	0.34	7.87	0.39	4.59e-14	Educational attainment (years of education);
LIHC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.64	0.42	2.24e-16	Motion sickness;
LIHC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg05110241	chr16:68378359	PRMT7	-0.58	-6.6	-0.34	1.55e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs4700695	0.764	rs36299	chr5:65348120	G/T	cg21114390	chr5:65439923	SFRS12	0.45	5.89	0.3	9.42e-9	Facial morphology (factor 19);
LIHC	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.81	13.79	0.6	1.07e-34	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.83	7.99	0.4	2.07e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.26	-0.32	1.17e-9	Coronary artery disease;
LIHC	cis	rs3780378	0.870	rs7034878	chr9:5058991	G/T	cg02405213	chr9:5042618	JAK2	0.45	7.98	0.4	2.21e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.49	9.89	0.47	1.92e-20	Tonsillectomy;
LIHC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.91	16.39	0.66	5.92e-45	Parkinson's disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15545624	chr1:61516555	NA	0.46	6.04	0.31	4.11e-9	Hepatitis;
LIHC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.59	-9.92	-0.47	1.55e-20	Height;
LIHC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.47	6.99	0.35	1.43e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.75	-14.35	-0.61	7.12e-37	Mortality in heart failure;
LIHC	cis	rs17106184	1.000	rs72898950	chr1:50961221	T/C	cg07174182	chr1:51127561	FAF1	-0.59	-6.64	-0.34	1.23e-10	Type 2 diabetes;
LIHC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.46	-6.68	-0.34	9.64e-11	Body mass index;
LIHC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	9.56	0.46	2.32e-19	Schizophrenia;
LIHC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.72	-9.21	-0.45	3.3e-18	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg00343986	chr7:65444356	GUSB	-0.4	-6.05	-0.31	3.88e-9	Aortic root size;
LIHC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.58	9.27	0.45	2.11e-18	Lymphocyte counts;
LIHC	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.78	11.72	0.54	7.02e-27	Type 2 diabetes;
LIHC	cis	rs600806	0.778	rs4970766	chr1:110013955	A/G	cg16275483	chr1:110013120	SYPL2	0.45	5.74	0.3	2.1e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.66	7.58	0.38	3.34e-13	Vitiligo;
LIHC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.35	-5.81	-0.3	1.46e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-8.42	-0.41	1.05e-15	Chronic sinus infection;
LIHC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.32	5.81	0.3	1.47e-8	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.37	6.75	0.34	6.45e-11	IgG glycosylation;
LIHC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05665937	chr4:1216051	CTBP1	0.45	6.08	0.31	3.19e-9	Obesity-related traits;
LIHC	trans	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.16e-10	Aortic root size;
LIHC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg02503808	chr4:7069936	GRPEL1	-0.76	-10.49	-0.49	1.69e-22	Monocyte percentage of white cells;
LIHC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.34	-6.24	-0.32	1.29e-9	Aortic root size;
LIHC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg20933634	chr6:27740509	NA	0.46	5.96	0.31	6.28e-9	Parkinson's disease;
LIHC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.67	9.36	0.45	1.07e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.59	-10.03	-0.48	6.5e-21	Colorectal cancer;
LIHC	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	0.78	6.08	0.31	3.16e-9	LDL cholesterol;
LIHC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg18375707	chr11:64034959	PLCB3	-0.68	-9.8	-0.47	3.68e-20	Body mass index;
LIHC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.94	-0.63	3.24e-39	Alzheimer's disease (late onset);
LIHC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg23149560	chr2:74406255	MOBKL1B	0.41	5.78	0.3	1.64e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05347473	chr6:146136440	FBXO30	0.36	5.81	0.3	1.45e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.14e-38	Intelligence (multi-trait analysis);
LIHC	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.08	0.31	3.27e-9	Ulcerative colitis;
LIHC	trans	rs16975050	0.793	rs112983094	chr18:38980631	A/C	cg10554439	chr7:52344545	NA	0.41	6.06	0.31	3.65e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.3	-0.45	1.69e-18	Ulcerative colitis;
LIHC	trans	rs6600671	0.902	rs2222371	chr1:121289118	T/C	cg09829573	chr1:144692074	NBPF9	0.41	6.89	0.35	2.73e-11	Hip geometry;
LIHC	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg06359132	chr10:99160096	RRP12	-0.41	-6.41	-0.33	4.83e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.56	-0.38	3.69e-13	Uric acid levels;
LIHC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.64	0.34	1.2e-10	Rheumatoid arthritis;
LIHC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.49	-7.06	-0.36	9.31e-12	High light scatter reticulocyte count;
LIHC	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.51	-8.58	-0.42	3.4e-16	Pubertal anthropometrics;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg14926340	chr8:22225159	SLC39A14	-0.59	-6.56	-0.33	1.94e-10	Preeclampsia;
LIHC	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.13	0.52	9.01e-25	Coronary artery disease;
LIHC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.66	-0.38	1.96e-13	Electroencephalogram traits;
LIHC	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.82e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6708331	0.540	rs28623550	chr2:70366392	T/C	cg01613454	chr2:70366299	NA	0.38	6.2	0.32	1.59e-9	Obesity-related traits;
LIHC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	6.63	0.34	1.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.99	-0.31	5.35e-9	Life satisfaction;
LIHC	trans	rs72960926	0.744	rs72950570	chr6:74913740	T/C	cg07247405	chr1:2484626	LOC115110	0.54	6.2	0.32	1.62e-9	Metabolite levels (MHPG);
LIHC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.45	6.03	0.31	4.22e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-7.21	-0.36	3.65e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.83	17.32	0.68	1.06e-48	Longevity;
LIHC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.83	-9.04	-0.44	1.15e-17	Vitiligo;
LIHC	cis	rs16828019	0.852	rs34286980	chr1:41608389	A/G	cg03387723	chr1:41708464	SCMH1	-0.45	-7.22	-0.36	3.37e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg12437481	chr16:420112	MRPL28	-0.71	-10.9	-0.51	6.24e-24	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg25039879	chr17:56429692	SUPT4H1	0.77	8.91	0.43	3e-17	Cognitive test performance;
LIHC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.02	0.48	7.05e-21	Diabetic retinopathy;
LIHC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-1.03	-21.43	-0.76	3.5e-65	Height;
LIHC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.9	-0.39	3.82e-14	Body mass index;
LIHC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.5	-7.8	-0.39	7.66e-14	Blood protein levels;
LIHC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-8.39	-0.41	1.29e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.38	0.49	3.87e-22	Personality dimensions;
LIHC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.79	9.91	0.47	1.65e-20	Body mass index;
LIHC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.61	-9.15	-0.44	5.28e-18	Ulcerative colitis;
LIHC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.21	-0.45	3.26e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.15e-9	Menopause (age at onset);
LIHC	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.73	-11.32	-0.52	1.89e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.57	-10.98	-0.51	3.03e-24	Mean corpuscular volume;
LIHC	trans	rs2209875	1.000	rs2873094	chr9:91800274	G/T	cg26057616	chr1:222234397	NA	-0.36	-6.04	-0.31	4.06e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.58	8.63	0.42	2.29e-16	Prudent dietary pattern;
LIHC	cis	rs4407350	0.967	rs5765722	chr22:44921063	G/A	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.11	-0.31	2.64e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.77	-0.34	5.56e-11	Metabolite levels;
LIHC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-6.08	-0.31	3.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg14146966	chr2:61757674	XPO1	0.53	9.66	0.46	1.07e-19	Tuberculosis;
LIHC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.27	-0.37	2.54e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.65	12.21	0.55	1.06e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.79	-0.39	8.32e-14	Total body bone mineral density;
LIHC	cis	rs4780401	0.967	rs11075011	chr16:11828282	T/A	cg01061890	chr16:11836724	TXNDC11	-0.42	-6.07	-0.31	3.34e-9	Rheumatoid arthritis;
LIHC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg11764359	chr7:65958608	NA	0.59	6.26	0.32	1.18e-9	Diabetic kidney disease;
LIHC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.76	11.93	0.54	1.13e-27	Body mass index;
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.29	0.55	5.3e-29	Prudent dietary pattern;
LIHC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg10130564	chr11:117069849	TAGLN	-0.35	-5.97	-0.31	5.95e-9	Blood protein levels;
LIHC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.54	6.7	0.34	8.73e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg14166395	chr21:42792516	MX1	0.67	9.85	0.47	2.53e-20	IgG glycosylation;
LIHC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	12.84	0.57	4.49e-31	Cognitive test performance;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg12525736	chr1:228269915	ARF1	-0.47	-7.0	-0.35	1.37e-11	Alopecia areata;
LIHC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.63	9.63	0.46	1.38e-19	Monocyte percentage of white cells;
LIHC	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.51	7.37	0.37	1.3e-12	Schizophrenia;
LIHC	cis	rs679087	0.606	rs302344	chr12:29940953	A/G	cg14258853	chr12:29935411	TMTC1	0.44	6.52	0.33	2.46e-10	Schizophrenia;
LIHC	cis	rs7587476	0.906	rs2734674	chr2:215658895	A/G	cg04530015	chr2:215796436	ABCA12	0.41	6.47	0.33	3.34e-10	Neuroblastoma;
LIHC	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.45	6.61	0.34	1.45e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.53	-6.85	-0.35	3.36e-11	Breast cancer;
LIHC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.8	9.2	0.45	3.64e-18	Vitiligo;
LIHC	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	8.29	0.41	2.61e-15	Lymphocyte counts;
LIHC	cis	rs507080	0.961	rs543413	chr11:118550017	T/C	cg04173919	chr11:118528438	PHLDB1	0.31	5.88	0.3	9.54e-9	Serum metabolite levels;
LIHC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.56	-5.85	-0.3	1.18e-8	Type 2 diabetes nephropathy;
LIHC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	10.65	0.5	4.5e-23	Lymphocyte counts;
LIHC	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.73	-11.37	-0.52	1.24e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.37	7.79	0.39	8.06e-14	Longevity;
LIHC	cis	rs17739167	0.569	rs6493015	chr15:42225260	G/T	cg20935245	chr15:42234343	EHD4	0.4	7.29	0.37	2.15e-12	Monocyte count;
LIHC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.89	-17.53	-0.69	1.56e-49	Height;
LIHC	cis	rs611744	0.967	rs660816	chr8:109178048	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg08135965	chr6:41755394	TOMM6	0.44	5.72	0.3	2.34e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg19318889	chr4:1322082	MAEA	0.4	6.62	0.34	1.37e-10	Obesity-related traits;
LIHC	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	0.93	6.79	0.34	4.98e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.47	7.54	0.38	4.27e-13	Cognitive function;
LIHC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.65	-11.25	-0.52	3.37e-25	Crohn's disease;
LIHC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg18944383	chr4:111397179	ENPEP	0.27	7.0	0.35	1.37e-11	Height;
LIHC	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.37	-0.33	6.2e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.82	17.41	0.69	4.68e-49	Gestational age at birth (maternal effect);
LIHC	cis	rs7116495	1.000	rs7948821	chr11:71652485	G/A	cg26138937	chr11:71823887	C11orf51	-0.81	-7.95	-0.39	2.76e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.93	8.51	0.42	5.35e-16	Type 2 diabetes;
LIHC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.51	8.19	0.4	5.23e-15	Birth weight;
LIHC	trans	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg17675199	chr6:35436792	RPL10A	0.32	6.36	0.33	6.34e-10	Coronary artery disease;
LIHC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10556349	chr10:835070	NA	0.67	5.85	0.3	1.13e-8	Eosinophil percentage of granulocytes;
LIHC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	1.0	9.93	0.47	1.41e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg08643618	chr1:1189466	UBE2J2	0.42	6.1	0.31	2.95e-9	Alopecia areata;
LIHC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.3	0.32	9.01e-10	Mean corpuscular volume;
LIHC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg15534755	chr11:117069859	TAGLN	0.36	6.06	0.31	3.68e-9	Blood protein levels;
LIHC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.8	11.29	0.52	2.45e-25	Glomerular filtration rate (creatinine);
LIHC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20011983	chr2:74347215	NA	-0.39	-5.73	-0.3	2.15e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs700651	0.789	rs2196176	chr2:198904914	A/G	cg10820045	chr2:198174542	NA	0.44	6.47	0.33	3.38e-10	Intracranial aneurysm;
LIHC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.25	-0.48	1.1e-21	Hemoglobin concentration;
LIHC	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.35	5.72	0.3	2.32e-8	Platelet distribution width;
LIHC	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.46	8.45	0.42	8.7e-16	Testicular germ cell tumor;
LIHC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.79	-0.34	4.93e-11	Aortic root size;
LIHC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg23601095	chr6:26197514	HIST1H3D	0.55	5.83	0.3	1.27e-8	Gout;Renal underexcretion gout;
LIHC	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.79	0.43	7.58e-17	Exhaled nitric oxide levels;
LIHC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.53	8.67	0.42	1.73e-16	Total body bone mineral density;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.65	-11.26	-0.52	3.13e-25	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-7.05	-0.36	9.75e-12	Diabetic kidney disease;
LIHC	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.51	-6.49	-0.33	3.06e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.64	11.55	0.53	2.85e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.69	-10.84	-0.51	9.78e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg04013166	chr16:89971882	TCF25	0.48	6.06	0.31	3.64e-9	Skin colour saturation;
LIHC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.96	12.56	0.56	5.02e-30	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.62	-9.17	-0.44	4.37e-18	Smoking behavior;
LIHC	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg26395211	chr5:140044315	WDR55	-0.42	-6.19	-0.32	1.76e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg23435118	chr5:141488016	NDFIP1	-0.43	-5.74	-0.3	2.06e-8	Crohn's disease;
LIHC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg03959625	chr15:84868606	LOC388152	0.48	6.73	0.34	7.19e-11	Schizophrenia;
LIHC	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg23939001	chr4:940644	TMEM175	0.49	6.42	0.33	4.55e-10	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg20240347	chr1:204465584	NA	0.33	6.99	0.35	1.42e-11	Schizophrenia;
LIHC	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.33	-5.81	-0.3	1.4e-8	Lewy body disease;
LIHC	cis	rs6024905	0.587	rs2154374	chr20:36963225	A/G	cg07053727	chr20:36965646	BPI	0.57	10.37	0.49	4.21e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.35	-0.32	6.94e-10	Metabolite levels;
LIHC	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.65	6.58	0.34	1.8e-10	Schizophrenia;
LIHC	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg17749961	chr2:30669863	LCLAT1	0.52	6.55	0.33	2.08e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LIHC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg09323728	chr8:95962352	TP53INP1	0.28	5.79	0.3	1.56e-8	Type 2 diabetes;
LIHC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.66e-9	Bipolar disorder;
LIHC	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg05786569	chr7:27702416	HIBADH	-0.61	-9.36	-0.45	1.12e-18	Hypospadias;
LIHC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.56	0.5	9.14e-23	Bladder cancer;
LIHC	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.75	-0.34	6.25e-11	Metabolite levels;
LIHC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg25039879	chr17:56429692	SUPT4H1	0.77	8.91	0.43	3e-17	Cognitive test performance;
LIHC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.58	6.25	0.32	1.21e-9	Systemic lupus erythematosus;
LIHC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg15605315	chr1:45957053	TESK2	0.43	5.83	0.3	1.25e-8	Platelet count;
LIHC	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-0.8	-5.92	-0.3	7.88e-9	Prostate cancer;
LIHC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.79	-0.34	4.9e-11	Diabetic kidney disease;
LIHC	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.58	7.56	0.38	3.77e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.67	9.91	0.47	1.62e-20	Menopause (age at onset);
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.7	-0.34	8.66e-11	Longevity;
LIHC	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg10381502	chr11:71823885	C11orf51	-1.07	-8.58	-0.42	3.29e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08822215	chr16:89438651	ANKRD11	-0.47	-7.33	-0.37	1.73e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.68	7.16	0.36	4.9e-12	Alzheimer's disease;
LIHC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg09137382	chr11:130731461	NA	0.42	6.62	0.34	1.37e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.4	6.45	0.33	3.85e-10	Red blood cell count;
LIHC	cis	rs600806	0.778	rs4970766	chr1:110013955	A/G	cg02415029	chr1:110025642	ATXN7L2	0.45	5.86	0.3	1.08e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.17	-0.32	1.88e-9	Calcium levels;
LIHC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg03452187	chr11:120039793	NA	-0.42	-6.25	-0.32	1.24e-9	Stroke (pediatric);
LIHC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg07061783	chr6:25882402	NA	-0.48	-5.84	-0.3	1.2e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.3	-0.32	9.06e-10	Bipolar disorder;
LIHC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.49e-11	Diabetic kidney disease;
LIHC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.76	9.06	0.44	1.03e-17	Menarche (age at onset);
LIHC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	8.33	0.41	1.94e-15	Cognitive function;
LIHC	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.35	-7.48	-0.37	6.44e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LIHC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.31	-0.49	7.17e-22	Response to antipsychotic treatment;
LIHC	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg20636351	chr8:55087400	NA	-0.33	-6.65	-0.34	1.13e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	1.05	14.03	0.6	1.22e-35	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.93	15.15	0.63	5.07e-40	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg00656387	chr3:40428638	ENTPD3	0.39	6.03	0.31	4.26e-9	Renal cell carcinoma;
LIHC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.15e-11	Prudent dietary pattern;
LIHC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-7.87	-0.39	4.67e-14	Crohn's disease;
LIHC	cis	rs10411936	0.682	rs6512113	chr19:16598269	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.9	0.35	2.53e-11	White blood cell count;Multiple sclerosis;
LIHC	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	0.78	8.57	0.42	3.61e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.55	7.72	0.39	1.3e-13	Pulse pressure;
LIHC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19623624	chr10:135278901	LOC619207	-0.44	-6.81	-0.35	4.46e-11	Systemic lupus erythematosus;
LIHC	cis	rs11663156	1.000	rs66920460	chr18:50917496	C/A	cg24270629	chr18:50823537	DCC	-0.5	-6.78	-0.34	5.21e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg00601450	chr5:74908170	NA	0.52	6.48	0.33	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.45	0.56	1.39e-29	Menopause (age at onset);
LIHC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.8	9.18	0.44	4.33e-18	Vitiligo;
LIHC	cis	rs35955747	0.838	rs28716	chr22:31730189	A/C	cg22777020	chr22:31556080	RNF185	0.49	5.72	0.3	2.3e-8	Neutrophil count;Sum basophil neutrophil counts;
LIHC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-7.63	-0.38	2.28e-13	Coronary artery disease;
LIHC	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.16	-0.32	1.99e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3018712	0.532	rs57813595	chr11:68402606	C/G	cg20283391	chr11:68216788	NA	-0.5	-5.99	-0.31	5.23e-9	Total body bone mineral density;
LIHC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.42	-6.59	-0.34	1.63e-10	Cognitive function;
LIHC	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.53	7.99	0.4	2.05e-14	Diastolic blood pressure;
LIHC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	cis	rs11212260	0.655	rs11212246	chr11:107320778	T/C	cg25435332	chr11:107328525	CWF19L2	0.83	8.36	0.41	1.55e-15	IgG glycosylation;
LIHC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.04	0.4	1.47e-14	Schizophrenia;
LIHC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.99	-0.31	5.46e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.13	0.79	7.7e-76	Prudent dietary pattern;
LIHC	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	0.7	8.23	0.41	4.05e-15	Dental caries;
LIHC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-1.03	-19.89	-0.73	4.87e-59	Breast cancer;
LIHC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg20090690	chr10:134436459	INPP5A	0.45	5.74	0.3	2.04e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.53	-7.57	-0.38	3.41e-13	Obesity-related traits;
LIHC	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.58	8.73	0.43	1.16e-16	Recombination rate (females);
LIHC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.51	7.09	0.36	7.72e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.45	6.65	0.34	1.14e-10	Schizophrenia;
LIHC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg18306943	chr3:40428807	ENTPD3	0.34	5.86	0.3	1.1e-8	Renal cell carcinoma;
LIHC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.57	-7.14	-0.36	5.65e-12	Lung cancer in ever smokers;
LIHC	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.51	-7.64	-0.38	2.21e-13	Recalcitrant atopic dermatitis;
LIHC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.55	-7.18	-0.36	4.42e-12	Morning vs. evening chronotype;
LIHC	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.59	-7.44	-0.37	8.13e-13	Macular telangiectasia type 2;
LIHC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.86	0.3	1.12e-8	Menopause (age at onset);
LIHC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.64	10.6	0.5	6.71e-23	Pulse pressure;
LIHC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-8.51	-0.42	5.73e-16	Schizophrenia;
LIHC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.77	15.19	0.63	3.32e-40	Mortality in heart failure;
LIHC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2257205	0.667	rs6503872	chr17:56696008	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.36	6.47	0.33	3.35e-10	Metabolite levels;
LIHC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-8.07	-0.4	1.19e-14	Blood metabolite levels;
LIHC	cis	rs11671005	0.693	rs11669665	chr19:58931885	G/A	cg25952890	chr19:58913133	NA	0.67	7.2	0.36	3.89e-12	Mean platelet volume;
LIHC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.97	-0.31	6.04e-9	Colorectal cancer;
LIHC	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16684958	chr7:75615977	POR	0.39	6.29	0.32	9.58e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg25554917	chr2:170220129	LRP2	0.41	6.18	0.32	1.85e-9	Alopecia areata;
LIHC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.6	8.97	0.44	2.02e-17	Longevity;
LIHC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.55	9.56	0.46	2.37e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7523273	1.000	rs34385765	chr1:207993637	A/G	cg22525895	chr1:207977042	MIR29B2	-0.69	-10.45	-0.49	2.26e-22	Schizophrenia;
LIHC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.72	-11.8	-0.54	3.35e-27	Fibrinogen levels;
LIHC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.53	-0.38	4.6e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.44	7.04	0.36	1.09e-11	HDL cholesterol levels;
LIHC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg20283391	chr11:68216788	NA	-0.38	-5.91	-0.3	8.16e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.79	8.66	0.42	1.89e-16	Vitiligo;
LIHC	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg16724585	chr3:197361211	NA	-0.46	-6.44	-0.33	4.11e-10	Pancreatic cancer;
LIHC	cis	rs4934494	0.727	rs67827533	chr10:91505383	C/T	cg19698084	chr10:91461284	KIF20B	-0.47	-6.28	-0.32	1.02e-9	Red blood cell count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03771185	chr4:775700	NA	0.4	6.45	0.33	3.82e-10	Cognitive function;
LIHC	cis	rs9596863	0.898	rs9568906	chr13:54335197	A/G	ch.13.53330881F	chr13:54432880	NA	0.45	6.18	0.32	1.78e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04781839	chr16:1374937	UBE2I	0.51	6.98	0.35	1.58e-11	Hepatitis;
LIHC	cis	rs11603020	0.950	rs28362950	chr11:57371918	G/A	cg19752551	chr11:57585705	CTNND1	-0.47	-5.99	-0.31	5.22e-9	Blood protein levels;
LIHC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.56	-9.55	-0.46	2.56e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.45	6.86	0.35	3.28e-11	Asthma (sex interaction);
LIHC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.76	11.47	0.53	5.31e-26	Coronary artery disease;
LIHC	cis	rs75908454	1.000	rs77983924	chr6:169993627	T/C	cg19338460	chr6:170058176	WDR27	-0.92	-8.86	-0.43	4.39e-17	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.49	-7.64	-0.38	2.16e-13	Bone mineral density (spine);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02793854	chr16:67867809	CENPT	-0.5	-6.31	-0.32	8.89e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg25179470	chr10:102756915	LZTS2	0.45	6.32	0.32	8.06e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.9	-0.35	2.49e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.36	5.9	0.3	8.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4453791	0.656	rs62242262	chr3:38937383	C/A	cg02254461	chr3:39195904	CSRNP1	0.64	5.72	0.3	2.38e-8	Social communication problems;
LIHC	cis	rs2274273	1.000	rs2147972	chr14:55598030	T/C	cg01864836	chr14:55583639	NA	-0.36	-6.15	-0.32	2.14e-9	Protein biomarker;
LIHC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg07424592	chr7:64974309	NA	0.82	9.53	0.46	2.98e-19	Diabetic kidney disease;
LIHC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.97	13.24	0.58	1.36e-32	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7818688	0.614	rs73271148	chr8:95876545	C/T	cg16049864	chr8:95962084	TP53INP1	0.51	5.85	0.3	1.18e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.45	-6.87	-0.35	3.09e-11	Cognitive function;
LIHC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg14779329	chr11:130786720	SNX19	0.38	5.88	0.3	9.95e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.7	10.21	0.48	1.55e-21	Chronic sinus infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08187083	chr17:30186506	C17orf79	-0.44	-6.08	-0.31	3.21e-9	Pancreatic cancer;
LIHC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.57	-7.9	-0.39	3.94e-14	Lung cancer;
LIHC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.72	13.63	0.59	4.28e-34	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26734620	chr12:56694298	CS	1.28	10.93	0.51	4.65e-24	Psoriasis vulgaris;
LIHC	cis	rs7395581	0.959	rs326222	chr11:47259668	A/G	cg26139080	chr11:47293733	MADD	0.47	7.98	0.4	2.18e-14	HDL cholesterol;
LIHC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.51	8.89	0.43	3.66e-17	N-glycan levels;
LIHC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-11.15	-0.52	8.02e-25	Mean corpuscular volume;
LIHC	trans	rs800082	0.539	rs1178897	chr3:144241161	A/C	cg24215973	chr2:240111563	HDAC4	-0.49	-6.74	-0.34	6.91e-11	Smoking behavior;
LIHC	cis	rs2629540	0.586	rs10794183	chr10:126536609	G/C	cg08799069	chr10:126477246	METTL10	-0.43	-6.69	-0.34	9.1e-11	Cocaine dependence;
LIHC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg03647239	chr10:116582469	FAM160B1	0.46	6.71	0.34	8.34e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.94	0.44	2.43e-17	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-7.75	-0.39	1.02e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02985541	chr2:219472218	PLCD4	0.41	6.77	0.34	5.48e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.31	-6.32	-0.32	8.05e-10	Blood metabolite levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02322435	chr11:67815326	TCIRG1	0.43	6.4	0.33	5.2e-10	Bilirubin levels;
LIHC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.48	6.49	0.33	2.98e-10	Blood metabolite levels;
LIHC	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.03	-0.36	1.15e-11	Blood pressure;
LIHC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg24203234	chr3:128598194	ACAD9	0.46	6.47	0.33	3.43e-10	IgG glycosylation;
LIHC	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	0.81	11.41	0.53	9.05e-26	Left atrial antero-posterior diameter;
LIHC	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.61	-6.73	-0.34	7.23e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24110177	chr3:50126178	RBM5	-0.43	-6.69	-0.34	9.34e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11098699	0.821	rs2047201	chr4:124233384	A/G	cg09941581	chr4:124220074	SPATA5	-0.3	-5.84	-0.3	1.18e-8	Mosquito bite size;
LIHC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.47	0.56	1.08e-29	Menopause (age at onset);
LIHC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-7.08	-0.36	8.08e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.9	10.15	0.48	2.55e-21	IgG glycosylation;
LIHC	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.53	8.65	0.42	2.04e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LIHC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg05484376	chr2:27715224	FNDC4	0.4	6.57	0.33	1.85e-10	Total body bone mineral density;
LIHC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg00204512	chr16:28754710	NA	0.4	6.82	0.35	4.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08269949	chr6:26538502	HMGN4	0.53	7.37	0.37	1.28e-12	Pancreatic cancer;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.21	-0.32	1.5e-9	Total body bone mineral density;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13294780	chr4:140005756	ELF2	0.47	6.69	0.34	9.06e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	8.91	0.43	3.11e-17	Electroencephalogram traits;
LIHC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.37	6.33	0.32	7.72e-10	Type 2 diabetes;
LIHC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.65	-6.21	-0.32	1.57e-9	Breast cancer;
LIHC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg18016565	chr1:150552671	MCL1	0.51	9.75	0.47	5.67e-20	Melanoma;
LIHC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg11199428	chr13:52027379	INTS6	-0.47	-6.24	-0.32	1.27e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	9.11	0.44	6.88e-18	Schizophrenia;
LIHC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.81	13.1	0.58	4.89e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.39	6.28	0.32	1.05e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.33	-5.73	-0.3	2.25e-8	Lewy body disease;
LIHC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	9.02	0.44	1.37e-17	Response to bleomycin (chromatid breaks);
LIHC	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.31	-5.87	-0.3	1.01e-8	Body mass index;
LIHC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg15848620	chr12:58087721	OS9	-0.55	-7.52	-0.38	4.99e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.49	6.34	0.32	7.25e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs17854409	0.764	rs8114722	chr20:61478492	G/A	cg05147244	chr20:61493195	TCFL5	1.28	10.63	0.5	5.23e-23	Obesity-related traits;
LIHC	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.97	16.83	0.67	9.63e-47	Breast cancer;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.56	-8.44	-0.42	9.07e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.8	0.65	1.29e-42	Nonalcoholic fatty liver disease;
LIHC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.52	8.65	0.42	2.09e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.27	6.42	0.33	4.64e-10	Heart rate;
LIHC	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.67	13.37	0.59	4.49e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.7	11.99	0.54	6.64e-28	Blood protein levels;
LIHC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.56	-9.03	-0.44	1.28e-17	Birth weight;
LIHC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg10790698	chr19:18539756	SSBP4	-0.36	-7.29	-0.37	2.13e-12	Breast cancer;
LIHC	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.73	9.29	0.45	1.81e-18	Body mass index;
LIHC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.41	-5.88	-0.3	9.95e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.45	7.8	0.39	7.5e-14	Mean corpuscular volume;
LIHC	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.62	9.19	0.44	4.04e-18	Schizophrenia (inflammation and infection response interaction);
LIHC	cis	rs4919087	0.620	rs793518	chr10:98986970	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-6.29	-0.32	9.75e-10	Monocyte count;
LIHC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.36	5.82	0.3	1.37e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-11.26	-0.52	3.18e-25	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.61	-9.6	-0.46	1.81e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg26149184	chr10:133730230	NA	0.46	7.34	0.37	1.56e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.8	9.11	0.44	7.24e-18	Exhaled nitric oxide output;
LIHC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg22633049	chr21:46681294	NA	-0.35	-6.1	-0.31	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.34	6.86	0.35	3.24e-11	Renal cell carcinoma;
LIHC	cis	rs2292864	0.764	rs3892085	chr17:45340480	A/G	cg18085866	chr17:45331354	ITGB3	-0.64	-7.3	-0.37	2.03e-12	Left atrial antero-posterior diameter;
LIHC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg08528486	chr13:113648767	MCF2L	-0.38	-6.44	-0.33	4.06e-10	Systolic blood pressure;
LIHC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.63	11.49	0.53	4.74e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.49	6.35	0.32	6.85e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.59	10.37	0.49	4.17e-22	Longevity;Endometriosis;
LIHC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg03146154	chr1:46216737	IPP	0.43	6.87	0.35	2.97e-11	Red blood cell count;Reticulocyte count;
LIHC	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.23	-0.32	1.36e-9	Gout;
LIHC	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.27	0.61	1.4e-36	Bipolar disorder;
LIHC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.34	-7.36	-0.37	1.38e-12	Ulcerative colitis;
LIHC	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.42e-9	Prostate cancer;
LIHC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Schizophrenia;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11987759	chr7:65425863	GUSB	-0.39	-6.09	-0.31	3.1e-9	Calcium levels;
LIHC	trans	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg26939375	chr7:64535504	NA	0.4	6.37	0.33	6.14e-10	Aortic root size;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg27619136	chr4:174291353	SAP30	0.41	6.28	0.32	1.01e-9	Morning vs. evening chronotype;
LIHC	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-0.58	-6.74	-0.34	6.58e-11	Hip circumference adjusted for BMI;
LIHC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.61	7.5	0.38	5.64e-13	Heart rate;
LIHC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg24209194	chr3:40518798	ZNF619	0.66	9.78	0.47	4.46e-20	Renal cell carcinoma;
LIHC	cis	rs787274	0.681	rs787270	chr9:115549092	C/T	cg13803584	chr9:115635662	SNX30	-0.59	-6.39	-0.33	5.54e-10	Age-related hearing impairment (SNP x SNP interaction);
LIHC	trans	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.33	6.29	0.32	9.54e-10	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.98	-0.31	5.64e-9	Resting heart rate;
LIHC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.83	-11.72	-0.54	6.47e-27	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18803079	chr1:64014643	EFCAB7;DLEU2L	0.44	6.4	0.33	5.02e-10	Pancreatic cancer;
LIHC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.7	-11.01	-0.51	2.49e-24	Coronary artery disease;
LIHC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.87	-11.32	-0.52	1.87e-25	Alzheimer's disease;
LIHC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-6.69	-0.34	9.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.47	6.41	0.33	4.89e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11695601	chr2:175870435	CHN1	0.43	6.25	0.32	1.19e-9	Pancreatic cancer;
LIHC	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-9.42	-0.45	6.76e-19	Blood metabolite levels;
LIHC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.18e-13	Electroencephalogram traits;
LIHC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.57	8.53	0.42	4.79e-16	Resting heart rate;
LIHC	cis	rs11951515	0.508	rs6898866	chr5:43586375	G/A	cg01983248	chr5:43482804	C5orf28	-0.37	-6.06	-0.31	3.64e-9	Metabolite levels  (X-11787);
LIHC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	8.6	0.42	2.91e-16	Lung cancer;
LIHC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.72	-11.03	-0.51	2.11e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.35	-5.84	-0.3	1.19e-8	Colorectal cancer;
LIHC	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg25930673	chr12:123319894	HIP1R	-0.85	-10.56	-0.5	9.18e-23	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg00656387	chr3:40428638	ENTPD3	-0.42	-7.12	-0.36	6.45e-12	Renal cell carcinoma;
LIHC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg07148914	chr20:33460835	GGT7	-0.55	-8.3	-0.41	2.48e-15	Height;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7188697	0.922	rs9924805	chr16:58615659	T/C	cg02549819	chr16:58548995	SETD6	0.48	7.62	0.38	2.52e-13	QT interval;
LIHC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.45	6.91	0.35	2.39e-11	Diastolic blood pressure;
LIHC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-0.72	-7.12	-0.36	6.6e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg23485639	chr6:28045615	ZNF165	0.38	5.89	0.3	9.04e-9	Parkinson's disease;
LIHC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.92	-0.65	4.52e-43	Chronic sinus infection;
LIHC	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.69	11.19	0.52	5.54e-25	Diisocyanate-induced asthma;
LIHC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	8.17	0.4	6.23e-15	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg01596870	chr19:55963115	NA	-0.64	-9.9	-0.47	1.71e-20	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg11764359	chr7:65958608	NA	0.59	6.1	0.31	2.86e-9	Diabetic kidney disease;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg16466278	chr15:43429893	TMEM62	0.53	6.1	0.31	2.83e-9	Mean platelet volume;
LIHC	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.81	12.25	0.55	7.25e-29	Subjective well-being;
LIHC	cis	rs2574704	1.000	rs6767687	chr3:11652848	A/G	cg15876825	chr3:11651881	VGLL4	-0.5	-8.2	-0.41	4.88e-15	Body mass index;
LIHC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18252515	chr7:66147081	NA	0.42	5.82	0.3	1.33e-8	Aortic root size;
LIHC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	9.03	0.44	1.25e-17	Menarche (age at onset);
LIHC	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg01858014	chr14:56050164	KTN1	-0.63	-6.2	-0.32	1.61e-9	Putamen volume;
LIHC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg21466736	chr12:48725269	NA	0.63	9.02	0.44	1.34e-17	Glycated hemoglobin levels;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.53	-7.21	-0.36	3.61e-12	Menopause (age at onset);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15248989	chr19:14682900	NDUFB7	0.45	6.44	0.33	4e-10	Migraine with aura;
LIHC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.19e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	8.27	0.41	3.09e-15	Platelet count;
LIHC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.14	0.31	2.33e-9	Bipolar disorder;
LIHC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.28	-0.32	1.04e-9	Coronary artery disease;
LIHC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.27	-6.85	-0.35	3.47e-11	Mean corpuscular volume;
LIHC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.84	-0.3	1.2e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-6.07	-0.31	3.43e-9	Colorectal cancer;
LIHC	cis	rs3812111	0.676	rs4946138	chr6:116469584	A/G	cg08036074	chr6:116424633	NT5DC1	-0.46	-7.81	-0.39	7.15e-14	Age-related macular degeneration;
LIHC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	9.38	0.45	9.41e-19	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.16e-23	Bladder cancer;
LIHC	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg09795085	chr6:101329169	ASCC3	0.53	7.46	0.37	7.07e-13	Neuroticism;
LIHC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.38	6.06	0.31	3.67e-9	Menopause (age at onset);
LIHC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg25356066	chr3:128598488	ACAD9	0.55	7.66	0.38	1.9e-13	IgG glycosylation;
LIHC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.85	-13.33	-0.58	6.33e-33	Cognitive test performance;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.57	7.4	0.37	1.06e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.56	-9.81	-0.47	3.39e-20	Gout;
LIHC	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.64	6.52	0.33	2.58e-10	Chronic lymphocytic leukemia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25867650	chr15:75743273	SIN3A	0.44	6.14	0.32	2.26e-9	Lung function (FEV1/FVC);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15434853	chr3:52570586	NT5DC2;LOC440957	-0.43	-6.34	-0.32	7.37e-10	Cognitive function;
LIHC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.53	6.78	0.34	5.4e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.48	8.15	0.4	6.91e-15	Obesity-related traits;
LIHC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg11764359	chr7:65958608	NA	0.49	6.41	0.33	4.95e-10	Corneal structure;
LIHC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.32	-5.93	-0.31	7.29e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg20887711	chr4:1340912	KIAA1530	0.47	6.31	0.32	8.89e-10	Obesity-related traits;
LIHC	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.52	0.42	5.06e-16	Schizophrenia;
LIHC	cis	rs1000083	0.915	rs4869152	chr5:96531607	A/G	ch.5.96698337R	chr5:96672581	NA	0.87	6.94	0.35	1.96e-11	Cisplatin-induced ototoxicity;
LIHC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.49	-8.34	-0.41	1.85e-15	White blood cell count (basophil);White blood cell count;
LIHC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.94	17.99	0.7	2.25e-51	Menopause (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27552081	chr17:25621774	WSB1	0.38	6.5	0.33	2.9e-10	Cognitive function;
LIHC	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg14515779	chr1:101123966	NA	-0.59	-11.3	-0.52	2.24e-25	Monocyte count;
LIHC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10106505	chr16:84220380	TAF1C	0.48	6.53	0.33	2.44e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14067834	chr17:29058358	SUZ12P	0.62	6.08	0.31	3.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15527401	chr19:59071099	UBE2M;LOC100131691	0.43	6.7	0.34	8.6e-11	Cognitive function;
LIHC	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.36	-5.97	-0.31	5.95e-9	Corneal structure;
LIHC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.63	8.5	0.42	6e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.6	8.99	0.44	1.67e-17	Recombination rate (females);
LIHC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.96	0.44	2.22e-17	Bipolar disorder;
LIHC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.14	0.55	1.97e-28	Prudent dietary pattern;
LIHC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.0	-0.31	4.95e-9	Blood metabolite levels;
LIHC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.12	0.48	3.02e-21	Alzheimer's disease (late onset);
LIHC	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.47	-7.64	-0.38	2.18e-13	Endometrial cancer;
LIHC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.39	-0.52	1.05e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.82	0.39	6.79e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg02829992	chr2:10710499	NA	0.39	6.01	0.31	4.75e-9	Prostate cancer;
LIHC	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	0.97	14.86	0.63	6.81e-39	Corneal structure;
LIHC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.41	-9.47	-0.46	4.58e-19	Type 2 diabetes;
LIHC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.51	0.38	5.22e-13	Vitiligo;
LIHC	cis	rs61712019	0.679	rs11126611	chr2:77714052	T/C	cg11252801	chr2:77748917	LRRTM4	0.55	7.61	0.38	2.76e-13	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg02429669	chr19:52430771	ZNF613	0.48	6.71	0.34	8.26e-11	Lung function (FEV1/FVC);
LIHC	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg19773385	chr1:10388646	KIF1B	-0.48	-8.21	-0.41	4.66e-15	Hepatocellular carcinoma;
LIHC	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-9.18	-0.44	4.18e-18	Schizophrenia;
LIHC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.11	10.02	0.48	6.95e-21	Diabetic retinopathy;
LIHC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.12	0.31	2.5e-9	Alzheimer's disease;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg16572859	chr19:18263815	PIK3R2	-0.51	-6.42	-0.33	4.43e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.62	10.79	0.5	1.46e-23	Colorectal cancer;
LIHC	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-0.82	-11.57	-0.53	2.43e-26	Obesity-related traits;
LIHC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.58	8.08	0.4	1.09e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs12744310	0.887	rs12042464	chr1:41786854	A/G	cg03962019	chr1:41807865	NA	-0.38	-6.14	-0.32	2.25e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.75	11.34	0.52	1.68e-25	Corneal astigmatism;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20227212	chr21:18984006	BTG3	0.51	7.53	0.38	4.46e-13	Cognitive function;
LIHC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.68	12.33	0.55	3.89e-29	Menopause (age at onset);
LIHC	cis	rs295140	0.710	rs1729421	chr2:201080113	G/C	cg23649088	chr2:200775458	C2orf69	0.44	5.92	0.3	7.78e-9	QT interval;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10570662	chr22:19159548	NA	0.46	6.08	0.31	3.19e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg22834771	chr12:69754056	YEATS4	-0.51	-8.88	-0.43	3.98e-17	Blood protein levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg22922403	chr8:145650096	VPS28	0.39	6.33	0.32	7.66e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	1.06	15.66	0.65	4.81e-42	Breast cancer;
LIHC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.31	7.19	0.36	4.19e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg25356066	chr3:128598488	ACAD9	-0.53	-7.2	-0.36	3.89e-12	IgG glycosylation;
LIHC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.5	-8.45	-0.42	8.52e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg03959625	chr15:84868606	LOC388152	0.43	6.1	0.31	2.8e-9	Schizophrenia;
LIHC	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.53	-6.22	-0.32	1.44e-9	Coronary artery disease;
LIHC	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.65	11.91	0.54	1.36e-27	Pediatric autoimmune diseases;
LIHC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg17724175	chr1:150552817	MCL1	0.33	6.22	0.32	1.46e-9	Tonsillectomy;
LIHC	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.57	-7.84	-0.39	5.85e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs12744310	0.887	rs12732820	chr1:41798773	C/T	cg03962019	chr1:41807865	NA	0.38	6.18	0.32	1.78e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	11.65	0.53	1.22e-26	Body mass index;
LIHC	cis	rs10916814	0.959	rs12037522	chr1:20900184	A/T	cg24502330	chr1:20914028	CDA	-0.28	-5.86	-0.3	1.1e-8	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs10733682	0.715	rs3814119	chr9:129462901	A/G	cg00232160	chr9:129468157	NA	0.37	6.63	0.34	1.34e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2274273	0.805	rs11628437	chr14:55775468	G/A	cg01864836	chr14:55583639	NA	-0.37	-6.55	-0.33	2.17e-10	Protein biomarker;
LIHC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-7.56	-0.38	3.69e-13	Chronic sinus infection;
LIHC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg03264133	chr6:25882463	NA	-0.38	-5.72	-0.3	2.36e-8	Height;
LIHC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.86	0.3	1.11e-8	Platelet count;
LIHC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.51	7.07	0.36	8.59e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg18116418	chr1:152553244	LCE3D	-0.31	-5.74	-0.3	2.14e-8	Psoriasis;
LIHC	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg08499158	chr17:42289980	UBTF	0.41	6.62	0.34	1.4e-10	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.37	-7.1	-0.36	7.46e-12	Body mass index;
LIHC	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg17135325	chr3:160939158	NMD3	0.44	5.94	0.31	7.03e-9	Parkinson's disease;
LIHC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.87	16.36	0.66	7.55e-45	Multiple myeloma (IgH translocation);
LIHC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-5.86	-0.3	1.08e-8	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.44	-0.33	4.02e-10	Diabetic kidney disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00920043	chr1:11333412	UBIAD1	0.44	6.58	0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16262614	chr3:133464971	TF	0.28	6.39	0.33	5.36e-10	Iron status biomarkers;
LIHC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.73	0.43	1.16e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.51	-7.86	-0.39	4.99e-14	Thyroid stimulating hormone;
LIHC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.61e-10	Depression;
LIHC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.05	0.68	1.26e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg05941027	chr17:61774174	LIMD2	0.35	7.36	0.37	1.4e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg15123519	chr2:136567270	LCT	-0.39	-6.04	-0.31	4.01e-9	Corneal structure;
LIHC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg19318889	chr4:1322082	MAEA	0.42	5.77	0.3	1.81e-8	Obesity-related traits;
LIHC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.54	-11.15	-0.52	7.94e-25	Blood protein levels;
LIHC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.37	0.59	4.18e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.63e-9	Aortic root size;
LIHC	trans	rs3858145	0.588	rs115455464	chr10:70038498	T/C	cg04882175	chr6:131122610	NA	-0.48	-6.06	-0.31	3.5e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.22	0.41	4.3e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg09911534	chr15:67153556	NA	0.36	5.75	0.3	2e-8	Lung cancer (smoking interaction);
LIHC	trans	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg01596870	chr19:55963115	NA	-0.64	-8.49	-0.42	6.49e-16	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.56e-48	Diabetic kidney disease;
LIHC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.71	-10.62	-0.5	5.95e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg14580859	chr9:123691850	NA	0.39	6.76	0.34	5.9e-11	Rheumatoid arthritis;
LIHC	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.65	-10.94	-0.51	4.23e-24	Pediatric autoimmune diseases;
LIHC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.45e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg20487152	chr13:99095054	FARP1	-0.39	-6.62	-0.34	1.37e-10	Longevity;
LIHC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.23	0.41	3.98e-15	Platelet count;
LIHC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.38	6.07	0.31	3.46e-9	Menopause (age at onset);
LIHC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-15.13	-0.63	6.17e-40	Coronary artery disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12252866	chr3:50263686	NA	-0.47	-6.71	-0.34	8.26e-11	Pancreatic cancer;
LIHC	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg22842854	chr12:123319900	HIP1R	-0.63	-7.92	-0.39	3.47e-14	Schizophrenia;
LIHC	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.19	-0.32	1.76e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.13	0.4	7.92e-15	Electrocardiographic conduction measures;
LIHC	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.61	0.5	6.15e-23	Colorectal cancer;
LIHC	trans	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg10756647	chr7:56101905	PSPH	0.44	6.43	0.33	4.28e-10	Aortic root size;
LIHC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg24130564	chr14:104152367	KLC1	-0.55	-8.87	-0.43	4.23e-17	Reticulocyte count;
LIHC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	7.1e-23	Hemoglobin concentration;
LIHC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg12140854	chr5:148520817	ABLIM3	-0.46	-6.23	-0.32	1.37e-9	Breast cancer;
LIHC	cis	rs965469	0.947	rs56689368	chr20:3332921	G/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.23	-10.64	-0.5	5.12e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	18.21	0.7	2.91e-52	Tonsillectomy;
LIHC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.48	0.46	4.3e-19	Tonsillectomy;
LIHC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.51	0.49	1.45e-22	Bladder cancer;
LIHC	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.54	-7.53	-0.38	4.49e-13	Moyamoya disease;
LIHC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.91	14.42	0.61	3.62e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.69	-0.43	1.54e-16	Total body bone mineral density;
LIHC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	8.11	0.4	9.44e-15	Platelet count;
LIHC	trans	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-8.78	-0.43	8.23e-17	Obesity-related traits;
LIHC	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.47	-7.54	-0.38	4.15e-13	Blood metabolite levels;
LIHC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.84	13.75	0.6	1.53e-34	Glomerular filtration rate (creatinine);
LIHC	trans	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg26939375	chr7:64535504	NA	0.42	6.76	0.34	5.85e-11	Aortic root size;
LIHC	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg18809830	chr7:99032528	PTCD1	-0.9	-6.93	-0.35	2.13e-11	Blood metabolite levels;
LIHC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg06050784	chr16:88016603	BANP	-0.44	-7.73	-0.39	1.19e-13	Menopause (age at onset);
LIHC	cis	rs922107	0.738	rs12410923	chr1:90035786	G/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.67	-0.38	1.79e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg01557791	chr16:72042693	DHODH	-0.42	-6.12	-0.31	2.57e-9	Coronary artery disease;
LIHC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg15123519	chr2:136567270	LCT	-0.4	-8.16	-0.4	6.46e-15	Mosquito bite size;
LIHC	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22509189	chr2:225307070	NA	-0.44	-5.75	-0.3	2e-8	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.34	-5.91	-0.3	8.46e-9	Prostate cancer;
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg14666006	chr8:27629879	CCDC25	-0.66	-6.93	-0.35	2.14e-11	Obesity-related traits;
LIHC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg05064044	chr6:292385	DUSP22	-0.52	-6.83	-0.35	3.99e-11	Menopause (age at onset);
LIHC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-7.74	-0.39	1.17e-13	Neuroticism;
LIHC	trans	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg26939375	chr7:64535504	NA	-0.4	-6.43	-0.33	4.39e-10	Aortic root size;
LIHC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg10932868	chr11:921992	NA	0.38	7.14	0.36	5.52e-12	Alzheimer's disease (late onset);
LIHC	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.44	7.28	0.37	2.26e-12	Corneal astigmatism;
LIHC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg19635926	chr16:89946313	TCF25	0.55	6.84	0.35	3.57e-11	Skin colour saturation;
LIHC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-12.43	-0.56	1.54e-29	Refractive error;
LIHC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.76	9.31	0.45	1.56e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.62	10.5	0.49	1.56e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1892700	0.801	rs62226456	chr21:34867845	C/G	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20696051	chr7:158649028	WDR60	0.46	6.35	0.32	6.69e-10	Pancreatic cancer;
LIHC	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg15192750	chr16:69999425	NA	0.47	7.12	0.36	6.49e-12	IgE levels;
LIHC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-1.04	-16.12	-0.66	6.79e-44	Obesity-related traits;
LIHC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.62	10.0	0.48	7.84e-21	Breast cancer;
LIHC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.49	-7.98	-0.4	2.24e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.58	6.82	0.35	4.23e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.73	-0.34	7.35e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-0.87	-14.94	-0.63	3.35e-39	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.57	8.58	0.42	3.39e-16	Gout;
LIHC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg14067834	chr17:29058358	SUZ12P	0.69	6.69	0.34	9.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-6.92	-0.35	2.3e-11	Total body bone mineral density;
LIHC	cis	rs7119038	0.818	rs11217042	chr11:118682528	G/A	cg19308663	chr11:118741387	NA	0.39	6.08	0.31	3.21e-9	Sjögren's syndrome;
LIHC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.34	6.26	0.32	1.14e-9	Platelet distribution width;
LIHC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg07424592	chr7:64974309	NA	0.78	9.02	0.44	1.34e-17	Diabetic kidney disease;
LIHC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.27	-0.55	6.44e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg21724239	chr8:58056113	NA	0.48	6.4	0.33	5.2400000000000005e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.06	-0.51	1.7e-24	Chronic sinus infection;
LIHC	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.22	-5.71	-0.3	2.43e-8	Schizophrenia;
LIHC	cis	rs2302190	0.769	rs7215531	chr17:56493374	A/T	cg12560992	chr17:57184187	TRIM37	0.69	8.62	0.42	2.53e-16	Vitamin D levels;
LIHC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg02297831	chr4:17616191	MED28	0.47	7.17	0.36	4.76e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.78	10.86	0.51	8.57e-24	Body mass index;
LIHC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-10.03	-0.48	6.46e-21	Obesity-related traits;
LIHC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.74	-7.1	-0.36	7.45e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs36051895	0.559	rs7858422	chr9:5209797	G/T	cg02405213	chr9:5042618	JAK2	-0.61	-10.32	-0.49	6.24e-22	Pediatric autoimmune diseases;
LIHC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.82	-12.05	-0.55	4.24e-28	Response to antineoplastic agents;
LIHC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26338869	chr17:61819248	STRADA	-0.48	-6.81	-0.35	4.52e-11	Prudent dietary pattern;
LIHC	trans	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.09e-10	Aortic root size;
LIHC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.61	7.49	0.38	6.09e-13	Heart rate;
LIHC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.71	7.06	0.36	9.26e-12	Vitiligo;
LIHC	cis	rs9513627	1.000	rs7996624	chr13:100127541	G/T	cg25919922	chr13:100150906	NA	-0.77	-6.89	-0.35	2.74e-11	Obesity-related traits;
LIHC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.47	-7.82	-0.39	6.63e-14	Dementia with Lewy bodies;
LIHC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	1.02	19.5	0.73	1.81e-57	Breast cancer;
LIHC	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	7.01	0.35	1.31e-11	Blood protein levels;
LIHC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	7.48	0.38	6.26e-13	Menarche (age at onset);
LIHC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg07706471	chr12:123319906	HIP1R	-0.57	-7.62	-0.38	2.57e-13	Schizophrenia;
LIHC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.66	13.06	0.58	6.68e-32	Schizophrenia;
LIHC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg10130564	chr11:117069849	TAGLN	0.37	6.3	0.32	9.09e-10	Blood protein levels;
LIHC	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	8.18	0.4	5.52e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.14	-0.48	2.69e-21	Response to antipsychotic treatment;
LIHC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.68	7.11	0.36	6.86e-12	Alzheimer's disease;
LIHC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.42	-7.18	-0.36	4.24e-12	Platelet distribution width;
LIHC	cis	rs11112613	0.609	rs11112636	chr12:106047204	G/A	cg03607813	chr12:105948248	NA	0.44	6.89	0.35	2.7e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg21252483	chr19:49399788	TULP2	-0.61	-9.7	-0.46	8.03e-20	Red cell distribution width;
LIHC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.6	-0.5	6.98e-23	Hemoglobin concentration;
LIHC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.48	6.68	0.34	9.71e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs611744	0.837	rs422847	chr8:109103274	C/T	cg21045802	chr8:109455806	TTC35	-0.48	-8.25	-0.41	3.44e-15	Dupuytren's disease;
LIHC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.75	10.04	0.48	5.94e-21	Fat distribution (HIV);
LIHC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.45	-7.58	-0.38	3.19e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.76	11.21	0.52	4.7e-25	Response to antineoplastic agents;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22379573	chr1:197704774	DENND1B	0.4	6.51	0.33	2.68e-10	Longevity;
LIHC	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg09795085	chr6:101329169	ASCC3	-0.54	-7.57	-0.38	3.57e-13	Neuroticism;
LIHC	cis	rs12744310	1.000	rs56381773	chr1:41770718	T/C	cg03962019	chr1:41807865	NA	0.4	6.4	0.33	5.18e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs12249377	0.519	rs7087400	chr10:92587180	A/G	cg14313238	chr10:92632228	RPP30	0.38	6.37	0.33	5.94e-10	White matter microstructure (global fractional anisotropy);
LIHC	trans	rs6563898	0.869	rs7194029	chr16:83349398	T/C	cg13016115	chr14:23388406	RBM23	0.41	6.29	0.32	9.61e-10	IgE levels in asthmatics (D.f. specific);
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg14671364	chr1:107599128	PRMT6	-0.54	-7.93	-0.39	3.08e-14	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.47	6.11	0.31	2.76e-9	Alzheimer's disease;
LIHC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg18016565	chr1:150552671	MCL1	0.49	9.49	0.46	4.15e-19	Melanoma;
LIHC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.83	-0.51	1.06e-23	Hemoglobin concentration;
LIHC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.84	-0.51	1.02e-23	Primary sclerosing cholangitis;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg03874509	chr1:107600012	PRMT6	-0.75	-11.82	-0.54	2.81e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18225595	chr11:63971243	STIP1	0.64	7.86	0.39	5.1e-14	Mean platelet volume;
LIHC	cis	rs11098699	1.000	rs11098699	chr4:124171834	C/G	cg09941581	chr4:124220074	SPATA5	0.31	5.75	0.3	1.99e-8	Mosquito bite size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00345230	chr4:151936469	LRBA	0.46	6.25	0.32	1.22e-9	Lung function (FEV1/FVC);
LIHC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.5	7.3	0.37	2.01e-12	Obesity-related traits;
LIHC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	8.05	0.4	1.36e-14	Diastolic blood pressure;
LIHC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.76	-12.01	-0.54	5.9e-28	Colorectal cancer;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg26338869	chr17:61819248	STRADA	-0.45	-6.29	-0.32	9.77e-10	Prudent dietary pattern;
LIHC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.65	-9.24	-0.45	2.72e-18	Motion sickness;
LIHC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	8.25	0.41	3.46e-15	Schizophrenia;
LIHC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	12.74	0.57	1.06e-30	Psoriasis;
LIHC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.04	0.31	3.91e-9	Menopause (age at onset);
LIHC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.86	-0.3	1.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6442522	0.678	rs878945	chr3:15509327	C/G	cg16303742	chr3:15540471	COLQ	0.46	7.81	0.39	6.93e-14	Uric acid levels;
LIHC	trans	rs12960119	0.536	rs12960532	chr18:23726995	A/G	cg05333146	chr16:67183725	B3GNT9	0.64	6.06	0.31	3.57e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.6	5.77	0.3	1.81e-8	Vitiligo;
LIHC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.7	-0.79	3.61e-74	Height;
LIHC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20135002	chr11:47629003	NA	-0.57	-9.76	-0.47	5e-20	Subjective well-being;
LIHC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	0.96	14.61	0.62	6.72e-38	Corneal structure;
LIHC	cis	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg21605333	chr4:119757512	SEC24D	0.97	8.11	0.4	9.41e-15	Cannabis dependence symptom count;
LIHC	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.3	-0.32	9.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg00204512	chr16:28754710	NA	0.42	7.07	0.36	8.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7639513	0.545	rs12714874	chr3:12719928	C/T	cg23032965	chr3:12705835	RAF1	0.6	6.58	0.34	1.77e-10	Itch intensity from mosquito bite;
LIHC	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16684958	chr7:75615977	POR	0.52	8.81	0.43	6.47e-17	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	1.05	15.38	0.64	6.23e-41	Breast cancer;
LIHC	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.34	8.41	0.41	1.1e-15	Cutaneous nevi;
LIHC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.59	-9.77	-0.47	4.71e-20	Colorectal cancer;
LIHC	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg05621596	chr22:47072043	GRAMD4	-0.6	-9.48	-0.46	4.39e-19	Urate levels in obese individuals;
LIHC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.76	7.75	0.39	1.03e-13	Schizophrenia;
LIHC	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.24	0.41	3.62e-15	Corneal astigmatism;
LIHC	cis	rs7116495	0.737	rs7126838	chr11:71826237	A/G	cg26138937	chr11:71823887	C11orf51	0.82	8.33	0.41	2.03e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.72	-14.26	-0.61	1.58e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg20399509	chr21:47717575	C21orf57	-0.37	-5.97	-0.31	5.88e-9	Testicular germ cell tumor;
LIHC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.59	11.57	0.53	2.34e-26	Tonsillectomy;
LIHC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg02297831	chr4:17616191	MED28	0.45	6.96	0.35	1.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.32	-5.93	-0.31	7.45e-9	Aortic root size;
LIHC	cis	rs4908760	0.868	rs12131864	chr1:8591162	A/G	cg20416874	chr1:8611966	RERE	-0.69	-14.66	-0.62	4.08e-38	Vitiligo;
LIHC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.51	-8.79	-0.43	7.62e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2274273	0.934	rs10137307	chr14:55845185	T/C	cg01864836	chr14:55583639	NA	-0.38	-6.67	-0.34	1.01e-10	Protein biomarker;
LIHC	cis	rs6782228	0.606	rs2811490	chr3:128351755	C/T	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08677398	chr8:58056175	NA	0.41	6.38	0.33	5.63e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10205151	chr7:931109	C7orf20	0.5	6.23	0.32	1.34e-9	Lung function (FEV1);
LIHC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.57	9.63	0.46	1.4e-19	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20488697	chr17:79885644	LOC92659;MAFG	0.49	7.31	0.37	1.95e-12	Pancreatic cancer;
LIHC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.34	-6.15	-0.32	2.12e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	0.99	10.8	0.5	1.34e-23	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs249954	0.512	rs34514	chr16:23670597	G/A	cg01460202	chr16:23706506	ERN2	0.36	5.97	0.31	5.9e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.56	0.42	3.89e-16	Corneal astigmatism;
LIHC	cis	rs10792665	0.934	rs10751083	chr11:82660359	C/G	cg24227371	chr11:82718527	RAB30	0.31	7.19	0.36	4.14e-12	Obesity-related traits;
LIHC	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg10820045	chr2:198174542	NA	-0.47	-7.2	-0.36	3.92e-12	Dermatomyositis;
LIHC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.88	-0.3	9.84e-9	Personality dimensions;
LIHC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg19318889	chr4:1322082	MAEA	-0.46	-6.41	-0.33	4.7e-10	Obesity-related traits;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg02635209	chr6:118822505	C6orf204;BRD7P3	-0.64	-6.85	-0.35	3.51e-11	Diastolic blood pressure;
LIHC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.6	-0.34	1.58e-10	Type 2 diabetes;
LIHC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg08694578	chr2:241835147	C2orf54	0.5	6.89	0.35	2.76e-11	Urinary metabolites;
LIHC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.79	13.35	0.59	5.37e-33	Psoriasis;
LIHC	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	1.1	13.84	0.6	6.94e-35	Blood protein levels;
LIHC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg04517722	chr19:17905589	B3GNT3	0.45	6.89	0.35	2.69e-11	Tumor biomarkers;
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-9.93	-0.47	1.36e-20	Prudent dietary pattern;
LIHC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg17724175	chr1:150552817	MCL1	-0.35	-7.32	-0.37	1.79e-12	Tonsillectomy;
LIHC	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.32	-6.85	-0.35	3.43e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1113500	0.787	rs12047429	chr1:108633239	C/T	cg06207961	chr1:108661230	NA	0.32	6.08	0.31	3.26e-9	Growth-regulated protein alpha levels;
LIHC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg13175981	chr1:150552382	MCL1	-0.42	-5.91	-0.3	8.1e-9	Tonsillectomy;
LIHC	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.3	-6.73	-0.34	7.02e-11	DNA methylation (variation);
LIHC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.09	0.31	3.12e-9	Cognitive ability;
LIHC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg02993280	chr1:107599747	PRMT6	-0.69	-11.16	-0.52	6.98e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	0.95	9.89	0.47	1.96e-20	Cannabis dependence symptom count;
LIHC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.57	-8.32	-0.41	2.09e-15	Alzheimer's disease;
LIHC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg10820045	chr2:198174542	NA	-0.57	-9.24	-0.45	2.73e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16684958	chr7:75615977	POR	0.51	8.58	0.42	3.37e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-7.83	-0.39	6.12e-14	Putamen volume;
LIHC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.44	6.17	0.32	1.93e-9	Morning vs. evening chronotype;
LIHC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.42	-8.46	-0.42	7.81e-16	Obesity-related traits;
LIHC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg12374095	chr12:54320830	NA	-0.4	-5.82	-0.3	1.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.56	8.62	0.42	2.52e-16	Multiple sclerosis;
LIHC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg09222892	chr1:25734099	RHCE	-0.48	-8.9	-0.43	3.41e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.18	-0.68	3.93e-48	Gut microbiome composition (summer);
LIHC	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.59	5.96	0.31	6.44e-9	Breast cancer;
LIHC	cis	rs11671005	0.568	rs55987239	chr19:59085045	G/A	cg25952890	chr19:58913133	NA	0.68	6.93	0.35	2.15e-11	Mean platelet volume;
LIHC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.65	9.26	0.45	2.39e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.73	-0.3	2.26e-8	Mortality in heart failure;
LIHC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.74	-0.3	2.03e-8	Subjective well-being;
LIHC	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.74	-11.35	-0.52	1.52e-25	Obesity-related traits;
LIHC	cis	rs3015497	0.626	rs7150204	chr14:51137355	T/C	cg09863266	chr14:51125203	SAV1	-0.43	-6.77	-0.34	5.5e-11	Mean platelet volume;
LIHC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	6.73	0.34	7.16e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.98	0.35	1.59e-11	Alzheimer's disease;
LIHC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.65	-0.34	1.15e-10	Personality dimensions;
LIHC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.5	7.81	0.39	6.93e-14	Total body bone mineral density;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg00280220	chr17:61926910	NA	0.43	6.77	0.34	5.78e-11	Prudent dietary pattern;
LIHC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.52	-7.1	-0.36	7.15e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.65	10.87	0.51	7.85e-24	Obesity-related traits;
LIHC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg03517284	chr6:25882590	NA	-0.43	-6.61	-0.34	1.48e-10	Height;
LIHC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.85	0.3	1.16e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.12	0.55	2.36e-28	Menopause (age at onset);
LIHC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.46	-6.96	-0.35	1.74e-11	Height;
LIHC	cis	rs611744	0.967	rs598022	chr8:109187759	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.93	-0.35	2.08e-11	Sudden cardiac arrest;
LIHC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.53	-7.69	-0.38	1.62e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg06026331	chr20:60912101	LAMA5	0.58	6.31	0.32	8.77e-10	Colorectal cancer;
LIHC	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-7.98	-0.4	2.26e-14	Response to antipsychotic treatment;
LIHC	cis	rs72772090	0.710	rs11745122	chr5:96060738	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.2	-0.36	3.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.35	0.32	6.9e-10	Schizophrenia;
LIHC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.9	-16.9	-0.67	5.16e-47	Aortic root size;
LIHC	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.4	-6.16	-0.32	2.04e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg00091569	chr3:40428383	ENTPD3	0.4	6.7	0.34	8.58e-11	Renal cell carcinoma;
LIHC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.73	7.54	0.38	4.13e-13	Bipolar disorder;
LIHC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.46	7.33	0.37	1.66e-12	Height;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg22528358	chr1:107598549	PRMT6	-0.69	-11.15	-0.52	7.7e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.16	0.55	1.58e-28	Prudent dietary pattern;
LIHC	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.49	-7.33	-0.37	1.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg00149659	chr3:10157352	C3orf10	0.66	6.41	0.33	4.69e-10	Alzheimer's disease;
LIHC	cis	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg01231543	chr16:68741748	NA	0.38	5.79	0.3	1.59e-8	Colorectal cancer;
LIHC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.79	-9.84	-0.47	2.77e-20	Mean platelet volume;
LIHC	cis	rs7238033	0.624	rs7230298	chr18:43312519	A/G	cg20610511	chr18:43302872	SLC14A1	-0.38	-6.32	-0.32	8e-10	Bladder cancer;
LIHC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.35	0.37	1.47e-12	Morning vs. evening chronotype;
LIHC	cis	rs151997	0.962	rs27714	chr5:50180396	G/C	cg06027927	chr5:50259733	NA	0.57	7.61	0.38	2.61e-13	Callous-unemotional behaviour;
LIHC	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg09795085	chr6:101329169	ASCC3	0.52	7.1	0.36	7.39e-12	Neuroticism;
LIHC	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg15208524	chr1:10270712	KIF1B	0.45	6.45	0.33	3.87e-10	Hepatocellular carcinoma;
LIHC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.8	-0.5	1.42e-23	Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.24	0.36	2.98e-12	Renal cell carcinoma;
LIHC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.68	10.89	0.51	6.5e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	7.13	0.36	6.05e-12	Self-reported allergy;
LIHC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.2	-0.41	5.07e-15	Body mass index;
LIHC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.56	-9.09	-0.44	8.38e-18	Obesity-related traits;
LIHC	cis	rs17711722	0.583	rs11768292	chr7:65474801	G/T	cg11764359	chr7:65958608	NA	-0.7	-8.58	-0.42	3.42e-16	Calcium levels;
LIHC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.53	8.08	0.4	1.1e-14	Resting heart rate;
LIHC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.05	-0.36	9.86e-12	Personality dimensions;
LIHC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg18887096	chr2:219472410	PLCD4	0.4	6.87	0.35	3.02e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.51	8.16	0.4	6.56e-15	Cleft lip with or without cleft palate;
LIHC	cis	rs2637266	0.935	rs1907299	chr10:78325316	T/C	cg18941641	chr10:78392320	NA	0.29	5.96	0.31	6.34e-9	Pulmonary function;
LIHC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-6.45	-0.33	3.82e-10	Lung cancer in ever smokers;
LIHC	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.49	-8.91	-0.43	3e-17	Atrioventricular conduction;
LIHC	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.47	5.89	0.3	9.11e-9	Panic disorder;
LIHC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg14440974	chr22:39074834	NA	-0.44	-7.14	-0.36	5.81e-12	Menopause (age at onset);
LIHC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.74	-0.34	6.5500000000000006e-11	Vitiligo;
LIHC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg18305652	chr10:134549665	INPP5A	-0.37	-5.96	-0.31	6.27e-9	Migraine;
LIHC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg22532475	chr10:104410764	TRIM8	0.36	6.54	0.33	2.29e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg25214090	chr10:38739885	LOC399744	-0.39	-6.24	-0.32	1.27e-9	Diastolic blood pressure;
LIHC	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-7.65	-0.38	2.03e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.64	10.82	0.5	1.19e-23	Menopause (age at onset);
LIHC	cis	rs7103648	0.864	rs71475909	chr11:47377283	A/G	cg20307385	chr11:47447363	PSMC3	0.88	12.72	0.57	1.3e-30	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.75	10.83	0.51	1.05e-23	Coronary artery disease;
LIHC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.49	9.08	0.44	9.12e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg03037974	chr15:76606532	NA	-0.61	-10.35	-0.49	5.23e-22	Blood metabolite levels;
LIHC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.34	-0.52	1.56e-25	Electrocardiographic conduction measures;
LIHC	cis	rs7577696	0.554	rs35978916	chr2:32400635	T/C	cg02381751	chr2:32503542	YIPF4	-0.47	-6.16	-0.32	2.08e-9	Inflammatory biomarkers;
LIHC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.52	8.54	0.42	4.56e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.82	-11.6	-0.53	1.82e-26	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs6466055	0.720	rs12334245	chr7:104995627	T/C	cg04380332	chr7:105027541	SRPK2	-0.37	-6.96	-0.35	1.77e-11	Schizophrenia;
LIHC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.46	-0.37	7.03e-13	Body mass index;
LIHC	cis	rs526231	0.853	rs35802	chr5:102607585	A/T	cg05225461	chr5:102596755	C5orf30	0.37	5.75	0.3	1.98e-8	Primary biliary cholangitis;
LIHC	cis	rs9473924	0.542	rs4294001	chr6:50850065	G/A	cg14470998	chr6:50812995	TFAP2B	0.91	10.53	0.49	1.22e-22	Body mass index;
LIHC	cis	rs4948275	0.530	rs2393853	chr10:63167688	C/G	cg03237606	chr10:63212265	TMEM26	0.32	7.19	0.36	4.17e-12	Night sleep phenotypes;
LIHC	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg14146966	chr2:61757674	XPO1	0.48	8.46	0.42	7.83e-16	Tuberculosis;
LIHC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.94	17.84	0.69	8.48e-51	Menopause (age at onset);
LIHC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.14	0.36	5.6e-12	Schizophrenia;
LIHC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg19645103	chr12:69753606	YEATS4	-0.47	-6.37	-0.33	6.19e-10	Response to diuretic therapy;
LIHC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg03721293	chr16:90014378	DEF8	0.35	5.71	0.3	2.42e-8	Skin colour saturation;
LIHC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg00656387	chr3:40428638	ENTPD3	0.42	7.03	0.36	1.15e-11	Renal cell carcinoma;
LIHC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-5.83	-0.3	1.25e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.61	8.15	0.4	6.97e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs10792665	0.649	rs7116356	chr11:82769922	T/C	cg24227371	chr11:82718527	RAB30	-0.37	-8.78	-0.43	7.83e-17	Obesity-related traits;
LIHC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.55	-8.49	-0.42	6.38e-16	Coronary artery disease;
LIHC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.19	5.79	0.3	1.56e-8	Blood protein levels;
LIHC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.64	10.39	0.49	3.59e-22	Longevity;
LIHC	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.77	7.63	0.38	2.4e-13	Bitter taste perception;
LIHC	cis	rs11098699	0.821	rs13148385	chr4:124206117	A/G	cg09941581	chr4:124220074	SPATA5	0.32	6.38	0.33	5.62e-10	Mosquito bite size;
LIHC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.92	0.3	7.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.78	-7.58	-0.38	3.18e-13	Diabetic retinopathy;
LIHC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.5	-8.16	-0.4	6.57e-15	Cognitive function;
LIHC	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.64	8.81	0.43	6.36e-17	Coronary artery disease;
LIHC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.86	0.43	4.41e-17	Multiple sclerosis;
LIHC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.68	10.34	0.49	5.33e-22	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg01788221	chr16:89496183	ANKRD11	-0.39	-6.08	-0.31	3.26e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-7.84	-0.39	5.63e-14	Crohn's disease;
LIHC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02985541	chr2:219472218	PLCD4	-0.38	-5.91	-0.3	8.4e-9	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.22	0.32	1.42e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg10820045	chr2:198174542	NA	-0.5	-7.62	-0.38	2.48e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.4	-5.71	-0.3	2.45e-8	Longevity;
LIHC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.73	10.31	0.49	7.04e-22	Menarche (age at onset);
LIHC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.35	-5.8	-0.3	1.53e-8	IgG glycosylation;
LIHC	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg03263716	chr11:64435066	NRXN2	0.35	7.57	0.38	3.46e-13	Body mass index;Urate levels;
LIHC	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg08539965	chr1:21396338	EIF4G3	0.34	6.15	0.32	2.16e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.91	0.3	8.09e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	9.99	0.48	8.54e-21	Hypertriglyceridemia;
LIHC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.36	-6.79	-0.34	4.94e-11	Diastolic blood pressure;
LIHC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.19	-0.36	4.22e-12	Body mass index;
LIHC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	0.84	11.66	0.53	1.09e-26	Skin colour saturation;
LIHC	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.57	-11.32	-0.52	1.84e-25	Myopia (pathological);
LIHC	cis	rs2642442	1.000	rs867772	chr1:220972343	A/G	cg04704887	chr1:220970030	MOSC1	-0.45	-5.79	-0.3	1.6e-8	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-6.79	-0.34	5.02e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs903552	0.800	rs28470883	chr15:102000824	G/A	cg00659931	chr15:102010125	PCSK6	-0.44	-5.84	-0.3	1.19e-8	Diabetic kidney disease;
LIHC	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg04998671	chr14:104000505	TRMT61A	-0.57	-7.51	-0.38	5.1e-13	Coronary artery disease;
LIHC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.87	-11.84	-0.54	2.45e-27	Post bronchodilator FEV1;
LIHC	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.5	-0.33	2.86e-10	Metabolite levels;
LIHC	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	8.3	0.41	2.4e-15	Eotaxin levels;
LIHC	cis	rs1982963	1.000	rs753051	chr14:52505360	A/G	cg10843707	chr14:52510701	NID2	-0.44	-7.7	-0.38	1.51e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg03387723	chr1:41708464	SCMH1	-0.42	-6.82	-0.35	4.11e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.43	-0.33	4.2e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs362296	0.698	rs3095080	chr4:3264418	C/T	cg06533319	chr4:3265114	C4orf44	0.35	6.72	0.34	7.81e-11	Parental longevity (mother's age at death);
LIHC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.79	7.25	0.36	2.82e-12	Eosinophil percentage of granulocytes;
LIHC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.62	-10.81	-0.5	1.25e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	trans	rs9500256	1.000	rs9500256	chr6:58308955	C/T	cg03371099	chr6:57305889	PRIM2	-0.37	-6.41	-0.33	4.94e-10	Eosinophilic esophagitis (pediatric);
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg20295408	chr7:1910781	MAD1L1	0.42	5.92	0.3	7.86e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.51	8.29	0.41	2.61e-15	Corneal astigmatism;
LIHC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	1.07	16.09	0.66	9.4e-44	Breast cancer;
LIHC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.24	-16.13	-0.66	6.34e-44	Diabetic kidney disease;
LIHC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.81	12.98	0.57	1.36e-31	Glomerular filtration rate (creatinine);
LIHC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.63	8.78	0.43	7.88e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-0.74	-8.61	-0.42	2.67e-16	Gut microbiota (bacterial taxa);
LIHC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-7.02	-0.35	1.2e-11	HDL cholesterol;
LIHC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.87	-12.64	-0.56	2.5e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs7095607	0.606	rs4746735	chr10:69950502	A/C	cg18986048	chr10:69913749	MYPN	-0.4	-5.96	-0.31	6.35e-9	Lung function (FVC);
LIHC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.67	6.19	0.32	1.75e-9	Bipolar disorder (body mass index interaction);
LIHC	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.16	-0.32	2.08e-9	Height;
LIHC	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.89	-0.39	4.24e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg13409248	chr3:40428643	ENTPD3	0.45	7.28	0.37	2.25e-12	Renal cell carcinoma;
LIHC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	7.1	0.36	7.27e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.25e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.55	-6.61	-0.34	1.44e-10	Menarche (age at onset);
LIHC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.76	-15.24	-0.64	2.1e-40	Height;
LIHC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg20887711	chr4:1340912	KIAA1530	0.46	6.37	0.33	6.1e-10	Obesity-related traits;
LIHC	cis	rs860295	0.812	rs12081192	chr1:155738044	A/G	cg02153340	chr1:155202674	NA	-0.35	-6.46	-0.33	3.5e-10	Body mass index;
LIHC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.71	8.56	0.42	3.96e-16	Gut microbiome composition (summer);
LIHC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.84	0.43	4.99e-17	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21806233	chr11:111956119	TIMM8B;SDHD	0.48	6.08	0.31	3.25e-9	Systolic blood pressure;
LIHC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.08	-0.31	3.22e-9	Total body bone mineral density;
LIHC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.58	-8.6	-0.42	2.86e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.59	-0.34	1.68e-10	Body mass index;
LIHC	cis	rs61542988	0.756	rs5013587	chr7:22882660	C/T	cg11367502	chr7:22862612	TOMM7	0.56	9.75	0.47	5.79e-20	Fibrinogen levels;
LIHC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.1	-0.48	3.62e-21	Bipolar disorder and schizophrenia;
LIHC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-9.79	-0.47	4.14e-20	Morning vs. evening chronotype;
LIHC	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.25	-0.32	1.22e-9	Corneal astigmatism;
LIHC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-7.24	-0.36	3.03e-12	Vitiligo;
LIHC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.53	6.97	0.35	1.63e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03965827	chr15:50979356	TRPM7	0.41	6.28	0.32	1.05e-9	Cognitive function;
LIHC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg01339444	chr6:118972232	C6orf204	0.58	5.74	0.3	2.07e-8	Diastolic blood pressure;
LIHC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg22528358	chr1:107598549	PRMT6	0.72	11.84	0.54	2.44e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs35160687	0.712	rs1863057	chr2:86502101	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.36	5.79	0.3	1.6e-8	Night sleep phenotypes;
LIHC	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg03146154	chr1:46216737	IPP	-0.38	-6.25	-0.32	1.22e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11987759	chr7:65425863	GUSB	-0.39	-6.15	-0.32	2.22e-9	Aortic root size;
LIHC	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg11123440	chr8:11619852	NA	0.32	6.13	0.31	2.43e-9	Myopia (pathological);
LIHC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.4	-0.37	1.07e-12	Bipolar disorder;
LIHC	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.27	0.49	9.23e-22	Hypertriglyceridemia;
LIHC	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.55	0.5	9.94e-23	Colorectal cancer;
LIHC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-9.68	-0.46	9.78e-20	Lung cancer;
LIHC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg25828445	chr12:7781288	NA	-0.41	-6.28	-0.32	1.03e-9	HDL cholesterol levels;
LIHC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.44	8.09	0.4	1.08e-14	Prudent dietary pattern;
LIHC	trans	rs9641123	0.639	rs7803666	chr7:93200058	A/G	cg09745688	chr16:2908918	PRSS22	-0.36	-6.15	-0.32	2.2e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.6	10.44	0.49	2.39e-22	Longevity;Endometriosis;
LIHC	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg16070123	chr10:51489643	NA	0.37	5.9	0.3	8.68e-9	Prostate-specific antigen levels;
LIHC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.82	-0.3	1.34e-8	Personality dimensions;
LIHC	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00495681	chr13:53174319	NA	0.37	5.92	0.3	7.76e-9	Lewy body disease;
LIHC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg08890338	chr13:113700818	MCF2L	-0.35	-5.74	-0.3	2.13e-8	Systolic blood pressure;
LIHC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg13047869	chr3:10149882	C3orf24	0.48	5.78	0.3	1.64e-8	Alzheimer's disease;
LIHC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02985541	chr2:219472218	PLCD4	0.43	7.93	0.39	3.15e-14	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	0.52	6.02	0.31	4.54e-9	Alzheimer's disease;
LIHC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg05501817	chr11:14380813	RRAS2	-0.42	-5.74	-0.3	2.09e-8	Sense of smell;
LIHC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-9.11	-0.44	7e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.74	-0.3	2.1e-8	Coronary artery disease;
LIHC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg14440974	chr22:39074834	NA	-0.44	-6.95	-0.35	1.83e-11	Menopause (age at onset);
LIHC	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.11	-0.31	2.77e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.67	8.45	0.42	8.78e-16	Gut microbiome composition (summer);
LIHC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg16586182	chr3:47516702	SCAP	0.58	10.66	0.5	4.27e-23	Colorectal cancer;
LIHC	cis	rs4294134	0.832	rs12530805	chr7:135278791	C/T	cg20392616	chr7:135392013	SLC13A4	0.38	6.03	0.31	4.31e-9	Paget's disease;
LIHC	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.29	-6.33	-0.32	7.57e-10	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.48	-8.04	-0.4	1.46e-14	Blood metabolite levels;
LIHC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg11062466	chr8:58055876	NA	0.39	5.73	0.3	2.2e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9918079	0.560	rs12651550	chr4:15641018	G/C	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.12	-0.36	6.56e-12	Obesity-related traits;
LIHC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.89	-0.3	9.33e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.74	-0.3	2.05e-8	Tuberculosis;
LIHC	cis	rs600806	0.778	rs4970767	chr1:110015183	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.44	-5.75	-0.3	1.95e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.51	7.5	0.38	5.63e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.86	0.39	4.96e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.62	9.6	0.46	1.79e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23092576	chr1:21672253	ECE1	0.43	6.15	0.32	2.16e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9649465	1.000	rs10238422	chr7:123353708	G/C	cg03229431	chr7:123269106	ASB15	-0.36	-7.8	-0.39	7.74e-14	Migraine;
LIHC	cis	rs7487075	0.930	rs11183468	chr12:46806261	A/T	cg11331445	chr12:47219877	SLC38A4	0.28	5.89	0.3	9.36e-9	Itch intensity from mosquito bite;
LIHC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.48	8.15	0.4	6.91e-15	Obesity-related traits;
LIHC	cis	rs1144333	0.655	rs17097695	chr1:76387258	A/C	cg22875332	chr1:76189707	ACADM	0.42	6.24	0.32	1.31e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.01	-0.31	4.69e-9	Blood pressure;
LIHC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.6	6.73	0.34	7.11e-11	Alzheimer's disease;
LIHC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg22951263	chr5:87985283	NA	-0.39	-6.72	-0.34	7.43e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LIHC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.48	7.97	0.4	2.43e-14	Diastolic blood pressure;
LIHC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.34	-0.32	7.26e-10	Total body bone mineral density;
LIHC	cis	rs812925	0.519	rs967968	chr2:61656056	C/G	cg14146966	chr2:61757674	XPO1	-0.38	-6.2	-0.32	1.62e-9	Immature fraction of reticulocytes;
LIHC	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.46	5.83	0.3	1.28e-8	Alzheimer's disease;
LIHC	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.57	-8.59	-0.42	3.08e-16	Smoking behavior;
LIHC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	1.04	20.83	0.75	8.28e-63	Breast cancer;
LIHC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.94	-0.35	1.95e-11	Axial length;
LIHC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-13.6	-0.59	5.58e-34	Lung function (FEV1);
LIHC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.63	8.4	0.41	1.17e-15	Migraine;
LIHC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.92	12.86	0.57	3.71e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs6489882	0.703	rs10774671	chr12:113357193	G/A	cg10175203	chr3:128143634	NA	0.37	6.12	0.31	2.5e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.22	0.52	4.31e-25	Colorectal cancer;
LIHC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-6.2	-0.32	1.66e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.49	-7.85	-0.39	5.37e-14	Mean corpuscular hemoglobin;
LIHC	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.27	0.32	1.11e-9	Rheumatoid arthritis;
LIHC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.94	17.94	0.7	3.44e-51	Menopause (age at onset);
LIHC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.5	6.25	0.32	1.23e-9	Total body bone mineral density;
LIHC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg17750252	chr2:136567154	LCT	0.35	6.31	0.32	8.53e-10	Mosquito bite size;
LIHC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07677032	chr17:61819896	STRADA	0.44	6.32	0.32	8.32e-10	Prudent dietary pattern;
LIHC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg22633049	chr21:46681294	NA	-0.36	-6.13	-0.31	2.47e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.62	-0.38	2.56e-13	Prevalent atrial fibrillation;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17774058	chr20:6748719	BMP2	0.46	6.98	0.35	1.55e-11	Cognitive function;
LIHC	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.55	6.56	0.33	1.94e-10	Mammographic density (dense area);
LIHC	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg16589663	chr20:23618590	CST3	0.74	7.52	0.38	4.79e-13	Chronic kidney disease;
LIHC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-6.46	-0.33	3.53e-10	Response to diuretic therapy;
LIHC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.46	0.66	3.08e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14077270	chr15:45879818	PLDN	-0.48	-6.4	-0.33	5.15e-10	Systolic blood pressure;
LIHC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg03859395	chr2:55845619	SMEK2	0.82	14.01	0.6	1.51e-35	Metabolic syndrome;
LIHC	cis	rs4979906	1.000	rs4979908	chr10:79452127	C/T	cg07817648	chr10:79422355	NA	-0.28	-6.08	-0.31	3.16e-9	Mortality in heart failure;
LIHC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.5	9.0	0.44	1.56e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg00280220	chr17:61926910	NA	0.44	7.07	0.36	8.7e-12	Prudent dietary pattern;
LIHC	cis	rs13401104	0.796	rs1921661	chr2:237121441	T/A	cg19324714	chr2:237145437	ASB18	0.37	5.87	0.3	1.03e-8	Educational attainment;
LIHC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.51	6.48	0.33	3.22e-10	Initial pursuit acceleration;
LIHC	cis	rs11630290	0.592	rs11071767	chr15:64154635	A/G	cg12036633	chr15:63758958	NA	-0.65	-6.94	-0.35	1.99e-11	Iris characteristics;
LIHC	cis	rs11893307	0.599	rs11900857	chr2:191659011	T/C	cg05765582	chr2:191677683	NA	0.32	5.75	0.3	2e-8	Mean platelet volume;
LIHC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.4	8.62	0.42	2.57e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.15e-16	Motion sickness;
LIHC	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg00792783	chr2:198669748	PLCL1	0.45	6.56	0.33	2.04e-10	Dermatomyositis;
LIHC	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.62	-0.34	1.43e-10	Putamen volume;
LIHC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.59	0.42	3.07e-16	Lung cancer in ever smokers;
LIHC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.26	0.41	3.19e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs507080	0.883	rs563549	chr11:118558953	G/A	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.88	0.3	9.83e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs911119	1.000	rs6114206	chr20:23611789	A/G	cg16589663	chr20:23618590	CST3	0.74	7.75	0.39	1.09e-13	Chronic kidney disease;
LIHC	cis	rs17496827	0.727	rs7581707	chr2:223360730	C/T	cg25565276	chr2:223520875	FARSB	0.41	6.08	0.31	3.13e-9	Anorexia nervosa;
LIHC	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.53	-0.38	4.6e-13	Post bronchodilator FEV1;
LIHC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.52	7.52	0.38	4.86e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.49	8.3	0.41	2.44e-15	Longevity;Endometriosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg19030620	chr1:220922217	MOSC2	0.34	6.94	0.35	2e-11	Cognitive function;
LIHC	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.34	-5.95	-0.31	6.5e-9	Lewy body disease;
LIHC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.93	-0.39	3.13e-14	Monocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.3	-17.11	-0.68	7.3e-48	Diabetic kidney disease;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.39	-7.8	-0.39	7.81e-14	Renal cell carcinoma;
LIHC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg04310649	chr10:35416472	CREM	-0.44	-6.0	-0.31	5.07e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg16070018	chr6:26224392	HIST1H3E	0.67	6.53	0.33	2.4e-10	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.91	0.3	8.37e-9	Obesity-related traits;
LIHC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.95	11.13	0.52	8.94e-25	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs36051895	0.622	rs13440043	chr9:5268264	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-9.28	-0.45	2.02e-18	Pediatric autoimmune diseases;
LIHC	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.47	6.89	0.35	2.77e-11	Dermatomyositis;
LIHC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.81	-14.86	-0.63	6.73e-39	Refractive error;
LIHC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14967899	chr8:26434689	DPYSL2	0.45	6.35	0.32	6.77e-10	Migraine with aura;
LIHC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs11673344	0.764	rs1644645	chr19:37463430	G/A	cg27390819	chr19:37464633	NA	-0.53	-6.29	-0.32	9.74e-10	Obesity-related traits;
LIHC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.46	6.21	0.32	1.56e-9	Major depressive disorder;
LIHC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.81	0.54	3.06e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.42	-7.36	-0.37	1.38e-12	Male sexual orientation;
LIHC	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.19	0.32	1.72e-9	Height;
LIHC	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg27205649	chr11:78285834	NARS2	0.37	5.72	0.3	2.31e-8	Alzheimer's disease (survival time);
LIHC	trans	rs6489882	0.671	rs4767024	chr12:113358791	T/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17507749	chr15:85114479	UBE2QP1	0.64	7.39	0.37	1.15e-12	Schizophrenia;
LIHC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-15.85	-0.65	8.29e-43	Prudent dietary pattern;
LIHC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.16	-0.44	4.77e-18	Bipolar disorder;
LIHC	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.21	-5.75	-0.3	2.01e-8	Hepatitis;
LIHC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.81	-0.5	1.3e-23	Bipolar disorder and schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17079137	chr17:27070735	TRAF4	0.48	6.51	0.33	2.61e-10	Lung function (FEV1/FVC);
LIHC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.11	-0.55	2.54e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg03263716	chr11:64435066	NRXN2	0.35	7.55	0.38	3.99e-13	Body mass index;Urate levels;
LIHC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-6.81	-0.35	4.41e-11	Lymphocyte counts;
LIHC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.62	8.15	0.4	6.79e-15	Motion sickness;
LIHC	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg18116418	chr1:152553244	LCE3D	0.31	5.89	0.3	9.37e-9	Psoriasis;
LIHC	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.43	7.0	0.35	1.33e-11	Schizophrenia;
LIHC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.1	-0.36	7.15e-12	Alcohol dependence;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	7.15	0.36	5.15e-12	Renal cell carcinoma;
LIHC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.69	0.34	9.11e-11	Morning vs. evening chronotype;
LIHC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg17724175	chr1:150552817	MCL1	0.42	8.26	0.41	3.31e-15	Melanoma;
LIHC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	8.86	0.43	4.49e-17	Cognitive ability;
LIHC	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.48	-6.63	-0.34	1.3100000000000001e-10	Schizophrenia;
LIHC	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.5	-8.38	-0.41	1.41e-15	Amyotrophic lateral sclerosis (age of onset);
LIHC	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-7.85	-0.39	5.25e-14	Alzheimer's disease;
LIHC	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.82	-7.67	-0.38	1.79e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LIHC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.39	-17.37	-0.68	6.99e-49	Breast cancer;
LIHC	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.42	-7.61	-0.38	2.75e-13	Late-onset Alzheimer's disease;
LIHC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.81	-0.39	7.1e-14	Morning vs. evening chronotype;
LIHC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.75e-9	Aortic root size;
LIHC	cis	rs1256061	0.603	rs928554	chr14:64694195	C/T	cg23250157	chr14:64679961	SYNE2	0.44	6.37	0.33	6.11e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	trans	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17183009	chr3:120277827	NA	0.52	6.08	0.31	3.18e-9	Corneal astigmatism;
LIHC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg17980119	chr2:219472607	PLCD4	-0.34	-5.74	-0.3	2.14e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.34	-0.32	7.42e-10	Aortic root size;
LIHC	cis	rs12915845	0.545	rs1583794	chr15:89076644	C/T	cg05013243	chr15:89149849	MIR1179	-0.38	-6.73	-0.34	7.24e-11	Menarche (age at onset);
LIHC	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.57	-7.15	-0.36	5.22e-12	Post bronchodilator FEV1;
LIHC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.11e-9	Height;
LIHC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01069210	chr8:87518700	FAM82B	0.46	6.69	0.34	9.28e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.49	0.38	6.07e-13	Refractive astigmatism;
LIHC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.75	0.8	3.26e-78	Prudent dietary pattern;
LIHC	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg22771759	chr13:24902376	NA	0.35	6.59	0.34	1.71e-10	Obesity-related traits;
LIHC	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg03387723	chr1:41708464	SCMH1	-0.4	-6.53	-0.33	2.42e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09955859	chr1:40626914	RLF	0.41	6.06	0.31	3.65e-9	Pancreatic cancer;
LIHC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18252515	chr7:66147081	NA	0.45	6.53	0.33	2.38e-10	Aortic root size;
LIHC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg14440974	chr22:39074834	NA	-0.44	-6.98	-0.35	1.58e-11	Menopause (age at onset);
LIHC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-9.17	-0.44	4.67e-18	Obesity-related traits;
LIHC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.4	-10.47	-0.49	1.96e-22	Asthma (sex interaction);
LIHC	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.63	-0.38	2.35e-13	Coronary artery disease;
LIHC	cis	rs2412488	0.927	rs11725230	chr4:54312072	T/C	cg22241045	chr4:54363911	LNX1	-0.42	-6.79	-0.34	4.97e-11	DNA methylation (variation);
LIHC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.64	-10.19	-0.48	1.8e-21	Uric acid clearance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00776160	chr1:149815087	HIST2H2AA3;HIST2H2AA4	0.45	6.62	0.34	1.35e-10	Pancreatic cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17524854	chr12:67663046	CAND1	0.44	6.43	0.33	4.33e-10	Pancreatic cancer;
LIHC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.43	-7.11	-0.36	6.74e-12	IgG glycosylation;
LIHC	cis	rs7534824	0.625	rs6699653	chr1:101499162	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	7.3	0.37	2.06e-12	Refractive astigmatism;
LIHC	cis	rs6449957	0.577	rs7725370	chr5:67529752	G/A	cg23036683	chr5:67512108	NA	0.42	6.05	0.31	3.73e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.45	7.06	0.36	9.21e-12	Schizophrenia;
LIHC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	7.9	0.39	3.83e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-1.09	-14.05	-0.61	9.93e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.557	rs4077531	chr11:1013167	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-11.17	-0.52	6.81e-25	Alzheimer's disease (late onset);
LIHC	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg00977110	chr5:151150581	G3BP1	0.56	7.11	0.36	6.8e-12	Preschool internalizing problems;
LIHC	cis	rs3770081	1.000	rs2278086	chr2:86281905	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.58	9.34	0.45	1.32e-18	Facial emotion recognition (sad faces);
LIHC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09133386	chr6:20404188	E2F3	0.49	7.07	0.36	8.7e-12	Pancreatic cancer;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg12907513	chr18:9478896	RALBP1	-0.4	-6.3	-0.32	9.05e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg01613454	chr2:70366299	NA	0.38	6.11	0.31	2.75e-9	Obesity-related traits;
LIHC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.83	0.3	1.31e-8	Menopause (age at onset);
LIHC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.33	2.39e-10	Vitiligo;
LIHC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.14	-0.31	2.35e-9	Schizophrenia;
LIHC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.72	-13.66	-0.59	3.34e-34	Height;
LIHC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.33	5.81	0.3	1.44e-8	Migraine;Coronary artery disease;
LIHC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	6.72	0.34	7.7e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.52	-7.94	-0.39	2.86e-14	Platelet distribution width;
LIHC	trans	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg17675199	chr6:35436792	RPL10A	0.35	6.89	0.35	2.66e-11	Coronary artery disease;
LIHC	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.53	8.57	0.42	3.6e-16	Corneal astigmatism;
LIHC	cis	rs74233809	1.000	rs77787671	chr10:104776205	C/T	cg03493300	chr10:104813866	CNNM2	0.46	6.19	0.32	1.75e-9	Birth weight;
LIHC	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg17859187	chr1:168147929	TIPRL	0.41	5.72	0.3	2.27e-8	Schizophrenia;
LIHC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.46	0.59	1.96e-33	Lung cancer in ever smokers;
LIHC	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg00935119	chr6:36647544	CDKN1A	0.44	6.23	0.32	1.4e-9	QRS duration;
LIHC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.63	-10.7	-0.5	3.16e-23	Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg10755058	chr3:40428713	ENTPD3	-0.35	-5.99	-0.31	5.41e-9	Renal cell carcinoma;
LIHC	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.72	11.84	0.54	2.36e-27	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.11	-0.4	8.86e-15	Morning vs. evening chronotype;
LIHC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	0.97	8.25	0.41	3.56e-15	Lymphocyte counts;
LIHC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.47	5.78	0.3	1.64e-8	Blood protein levels;
LIHC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg02608752	chr8:10447774	NA	0.48	5.89	0.3	9.46e-9	Neuroticism;
LIHC	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg17218026	chr1:154582156	ADAR	-0.34	-6.45	-0.33	3.78e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18357526	chr6:26021779	HIST1H4A	0.41	6.14	0.32	2.31e-9	Height;
LIHC	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.75	0.39	1.06e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.36	-5.88	-0.3	9.69e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.54	10.43	0.49	2.78e-22	Testicular germ cell tumor;
LIHC	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.74	-0.43	1.07e-16	Blood metabolite levels;
LIHC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg07061783	chr6:25882402	NA	-0.48	-5.83	-0.3	1.25e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg12863693	chr15:85201151	NMB	0.41	5.76	0.3	1.85e-8	Schizophrenia;
LIHC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.74	9.18	0.44	4.31e-18	Morning vs. evening chronotype;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg05484376	chr2:27715224	FNDC4	0.37	6.31	0.32	8.4e-10	Total body bone mineral density;
LIHC	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg07636037	chr3:49044803	WDR6	-0.55	-6.37	-0.33	6.24e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.47	0.62	2.36e-37	Prudent dietary pattern;
LIHC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.61	8.15	0.4	6.93e-15	Height;
LIHC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.55	7.85	0.39	5.43e-14	Lung cancer;
LIHC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg08888203	chr3:10149979	C3orf24	0.54	6.49	0.33	3.05e-10	Alzheimer's disease;
LIHC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.12e-15	Prudent dietary pattern;
LIHC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-7.26	-0.37	2.55e-12	Schizophrenia;
LIHC	cis	rs243505	0.661	rs887570	chr7:148505255	A/G	cg09806900	chr7:148480153	CUL1	0.44	6.52	0.33	2.52e-10	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg09003973	chr2:102972529	NA	0.53	6.04	0.31	4.09e-9	Blood protein levels;
LIHC	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	0.95	12.35	0.56	3.24e-29	Severe influenza A (H1N1) infection;
LIHC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.16	-0.32	2.1e-9	Colorectal cancer;
LIHC	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	0.43	6.68	0.34	9.84e-11	Prostate cancer;
LIHC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.5	6.31	0.32	8.55e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg27488370	chr7:128046294	IMPDH1	-0.52	-6.18	-0.32	1.86e-9	Inflammatory bowel disease;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg05044401	chr4:54958559	NA	0.39	6.04	0.31	4.1e-9	Migraine with aura;
LIHC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.52	9.53	0.46	3.06e-19	Total body bone mineral density;
LIHC	cis	rs6977660	1.000	rs5017194	chr7:19820035	A/T	cg07541023	chr7:19748670	TWISTNB	0.36	5.74	0.3	2.1e-8	Thyroid stimulating hormone;
LIHC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	7.36	0.37	1.36e-12	Osteoporosis;
LIHC	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg18964960	chr10:1102726	WDR37	0.66	5.85	0.3	1.16e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	13.46	0.59	1.97e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-7.32	-0.37	1.82e-12	Total body bone mineral density;
LIHC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	10.15	0.48	2.41e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.48	-5.74	-0.3	2.14e-8	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg06598544	chr20:61472147	COL9A3	-0.82	-7.99	-0.4	2.04e-14	Obesity-related traits;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg06951248	chr1:148244698	NA	0.28	6.32	0.32	8.21e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-7.31	-0.37	1.86e-12	Fear of minor pain;
LIHC	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg26241852	chr15:40650142	DISP2	-0.49	-6.1	-0.31	2.91e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg03999872	chr20:62272968	STMN3	-0.44	-6.49	-0.33	2.93e-10	Atopic dermatitis;
LIHC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.84	-0.43	5.26e-17	Obesity-related traits;
LIHC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	6.98	0.35	1.56e-11	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.84	0.47	2.81e-20	Lymphocyte counts;
LIHC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg21573476	chr21:45109991	RRP1B	0.51	9.27	0.45	2.09e-18	Mean corpuscular volume;
LIHC	cis	rs7810240	1.000	rs2888633	chr7:150083370	G/T	cg10018233	chr7:150070692	REPIN1	0.4	6.46	0.33	3.51e-10	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LIHC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg01652190	chr22:50026171	C22orf34	0.28	6.41	0.33	4.89e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.43	0.37	8.96e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.45	6.74	0.34	6.93e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	9.21e-11	Depression;
LIHC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-9.12	-0.44	6.36e-18	Parkinson's disease;
LIHC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.7	7.1	0.36	7.09e-12	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.51	6.19	0.32	1.7e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs903552	1.000	rs8041563	chr15:102005824	G/C	cg25677261	chr15:102009856	PCSK6	-0.46	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.76	11.63	0.53	1.46e-26	Corneal astigmatism;
LIHC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.76	0.47	5.37e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg22676075	chr6:135203613	NA	0.41	6.55	0.33	2.17e-10	Red blood cell count;
LIHC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg10932868	chr11:921992	NA	0.38	7.34	0.37	1.59e-12	Alzheimer's disease (late onset);
LIHC	cis	rs9473924	0.542	rs66834257	chr6:50809141	G/A	cg14470998	chr6:50812995	TFAP2B	0.98	11.12	0.52	9.6e-25	Body mass index;
LIHC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.61	-6.2	-0.32	1.62e-9	Pancreatic cancer;
LIHC	cis	rs6594499	0.872	rs10060003	chr5:110449357	A/G	cg04022379	chr5:110408740	TSLP	0.5	8.29	0.41	2.64e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.53	7.88	0.39	4.54e-14	Corneal astigmatism;
LIHC	cis	rs861318	0.702	rs3768519	chr1:159005224	C/G	cg11003133	chr1:159046391	AIM2	-0.34	-6.48	-0.33	3.22e-10	Obesity-related traits;
LIHC	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.88	9.44	0.45	5.84e-19	Alzheimer's disease (late onset);
LIHC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.52	-7.85	-0.39	5.44e-14	Total body bone mineral density;
LIHC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.66	-0.38	1.96e-13	Schizophrenia;
LIHC	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg21016266	chr12:122356598	WDR66	-0.38	-5.98	-0.31	5.52e-9	Mean corpuscular volume;
LIHC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.38	5.97	0.31	5.92e-9	Menopause (age at onset);
LIHC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.67	13.22	0.58	1.61e-32	High light scatter reticulocyte count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg21910613	chr1:27191950	NA	0.44	6.23	0.32	1.34e-9	Lung function (FEV1/FVC);
LIHC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.84	9.72	0.47	7.03e-20	Iron status biomarkers;
LIHC	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.36	-5.86	-0.3	1.08e-8	Platelet distribution width;
LIHC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.58	-10.07	-0.48	4.47e-21	Colorectal cancer;
LIHC	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg25344623	chr2:136566232	LCT	0.42	8.25	0.41	3.49e-15	Mosquito bite size;
LIHC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg20291162	chr17:40259547	DHX58	-0.39	-6.25	-0.32	1.26e-9	Fibrinogen levels;
LIHC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.93	0.65	3.96e-43	Electrocardiographic conduction measures;
LIHC	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.62	0.34	1.35e-10	Intracranial aneurysm;
LIHC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.45	6.58	0.34	1.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7551222	0.752	rs11240758	chr1:204528651	C/T	cg20240347	chr1:204465584	NA	-0.35	-7.38	-0.37	1.19e-12	Schizophrenia;
LIHC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg15105060	chr4:7024189	TBC1D14	-0.78	-6.28	-0.32	1.02e-9	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02951274	chr4:3417431	RGS12	0.41	6.3	0.32	9.39e-10	Immature fraction of reticulocytes;
LIHC	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg15893493	chr8:124194847	FAM83A	-0.7	-7.02	-0.35	1.21e-11	Urinary uromodulin levels;
LIHC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	12.49	0.56	9.88e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs76533333	0.605	rs12867229	chr13:113422075	G/A	cg08557188	chr13:113420371	ATP11A	-0.75	-5.71	-0.3	2.43e-8	Red cell distribution width;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg10239991	chr2:240046227	HDAC4	0.45	6.19	0.32	1.76e-9	Hip circumference;
LIHC	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.19	0.36	4.19e-12	Breast cancer;
LIHC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg10360323	chr17:41437877	NA	0.41	6.1	0.31	2.81e-9	Menopause (age at onset);
LIHC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.94	-0.39	2.97e-14	Personality dimensions;
LIHC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.37	6.01	0.31	4.87e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.7	8.47	0.42	7.37e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	6.22	0.32	1.47e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg00142150	chr22:38071001	LGALS1	0.63	8.18	0.4	5.5e-15	Fat distribution (HIV);
LIHC	cis	rs57502260	0.680	rs55654976	chr11:68393541	C/T	cg20283391	chr11:68216788	NA	-0.51	-6.33	-0.32	7.74e-10	Total body bone mineral density (age 45-60);
LIHC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.48	7.0	0.35	1.39e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	1.01	12.04	0.55	4.56e-28	Red blood cell traits;
LIHC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.71	6.85	0.35	3.46e-11	Type 2 diabetes nephropathy;
LIHC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.84	14.53	0.62	1.36e-37	Headache;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg14393609	chr7:65229607	NA	0.44	6.55	0.33	2.08e-10	Calcium levels;
LIHC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.6	7.06	0.36	9.6e-12	Systolic blood pressure;
LIHC	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	6.69	0.34	8.95e-11	Ileal carcinoids;
LIHC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.76	0.43	9.08e-17	Motion sickness;
LIHC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.53	-7.74	-0.39	1.17e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.55	8.28	0.41	2.73e-15	Gout;
LIHC	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg20129853	chr10:51489980	NA	-0.39	-8.53	-0.42	4.79e-16	Prostate-specific antigen levels;
LIHC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.92	-8.92	-0.43	2.92e-17	Alzheimer's disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07012231	chr7:47384322	TNS3	0.39	6.05	0.31	3.73e-9	Longevity;
LIHC	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg10560079	chr2:191398806	TMEM194B	-0.42	-6.08	-0.31	3.28e-9	Mean platelet volume;
LIHC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.42	7.51	0.38	5.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.45	8.22	0.41	4.13e-15	Methadone dose in opioid dependence;
LIHC	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.01	-0.4	1.76e-14	Capecitabine sensitivity;
LIHC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.75	-12.45	-0.56	1.34e-29	Aortic root size;
LIHC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.62	-0.34	1.38e-10	Height;
LIHC	cis	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg24110177	chr3:50126178	RBM5	-0.51	-7.95	-0.39	2.79e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg02527881	chr3:46936655	PTH1R	0.33	6.59	0.34	1.62e-10	Colorectal cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09015146	chr3:127308803	TPRA1	0.52	6.8	0.35	4.66e-11	Hepatitis;
LIHC	cis	rs8056893	0.842	rs3785119	chr16:68374434	G/T	cg02226672	chr16:68398533	SMPD3	0.42	5.89	0.3	9.02e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01238044	chr22:24384105	GSTT1	-0.43	-5.86	-0.3	1.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg09467607	chr2:36825704	FEZ2	0.47	6.99	0.35	1.47e-11	Height;
LIHC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	5.88	0.3	9.93e-9	Personality dimensions;
LIHC	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg04374321	chr14:90722782	PSMC1	-0.48	-7.03	-0.36	1.13e-11	Longevity;
LIHC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.8	13.92	0.6	3.16e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs963731	0.649	rs1470915	chr2:39247336	G/A	cg04010122	chr2:39346883	SOS1	-0.68	-5.84	-0.3	1.19e-8	Corticobasal degeneration;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.05	0.31	3.84e-9	Tonsillectomy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg03503634	chr11:36531973	TRAF6	0.45	6.35	0.32	6.69e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.62	-8.1	-0.4	9.87e-15	Motion sickness;
LIHC	cis	rs11229555	0.645	rs10896814	chr11:58430699	T/C	cg15696309	chr11:58395628	NA	-0.65	-6.14	-0.32	2.27e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.3	-7.01	-0.35	1.27e-11	Menarche (age at onset);
LIHC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.45	7.5	0.38	5.42e-13	Height;
LIHC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.73	-16.46	-0.66	3.14e-45	Brugada syndrome;
LIHC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.81	0.47	3.59e-20	Mean platelet volume;
LIHC	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.82	0.35	4.26e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.61	-0.74	6.54e-62	Height;
LIHC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.29	-0.37	2.23e-12	Hepatocellular carcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25654697	chr7:7680075	RPA3	0.45	6.38	0.33	5.86e-10	Pancreatic cancer;
LIHC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg03859395	chr2:55845619	SMEK2	-0.48	-7.81	-0.39	7.28e-14	Metabolic syndrome;
LIHC	cis	rs4332037	0.619	rs78443464	chr7:1970229	C/T	cg23422044	chr7:1970798	MAD1L1	-0.67	-7.54	-0.38	4.27e-13	Bipolar disorder;
LIHC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.58	-0.38	3.24e-13	Morning vs. evening chronotype;
LIHC	trans	rs1998584	1.000	rs10961199	chr9:13714854	G/T	cg23692589	chr11:67256716	AIP	0.38	6.04	0.31	3.94e-9	Survival in microsatellite instability low/stable colorectal cancer;
LIHC	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg04610667	chr7:75704037	NA	-0.33	-5.97	-0.31	5.83e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11958404	1.000	rs9686690	chr5:157412103	C/T	cg05962755	chr5:157440814	NA	0.86	10.11	0.48	3.51e-21	IgG glycosylation;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07677032	chr17:61819896	STRADA	0.41	5.95	0.31	6.66e-9	Prudent dietary pattern;
LIHC	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	0.88	14.57	0.62	1e-37	Left atrial antero-posterior diameter;
LIHC	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg18367735	chr17:79674897	NA	0.72	7.78	0.39	8.52e-14	Dental caries;
LIHC	cis	rs918629	0.679	rs6883880	chr5:95271173	A/T	cg10483112	chr5:95245456	ELL2	-0.37	-6.28	-0.32	1.04e-9	IgG glycosylation;
LIHC	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg18850929	chr19:1828978	REXO1	0.39	6.45	0.33	3.92e-10	Bipolar disorder;
LIHC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.83	-0.3	1.29e-8	Tonsillectomy;
LIHC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.57	-9.71	-0.47	7.4e-20	Bipolar disorder;
LIHC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.33	2.99e-10	Alzheimer's disease;
LIHC	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg13919466	chr1:32135498	COL16A1	-0.34	-6.41	-0.33	4.85e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs4706831	0.625	rs638056	chr6:80980808	G/A	cg08355045	chr6:80787529	NA	-0.3	-5.89	-0.3	9.06e-9	Joint mobility (Beighton score);
LIHC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg18944383	chr4:111397179	ENPEP	0.27	7.09	0.36	7.51e-12	Height;
LIHC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-0.9	-15.65	-0.65	5.38e-42	Testicular germ cell tumor;
LIHC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.41	-6.43	-0.33	4.23e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.02	-0.36	1.18e-11	Breast cancer;
LIHC	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.82	11.65	0.53	1.17e-26	Body mass index;
LIHC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg02158880	chr13:53174818	NA	0.37	5.85	0.3	1.13e-8	Lewy body disease;
LIHC	trans	rs3809912	0.595	rs12605006	chr18:12992261	C/G	cg02139827	chr21:34404457	NA	0.24	6.23	0.32	1.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.55	-9.97	-0.47	1.02e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	1.1	9.28	0.45	2.03e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg02990361	chr1:107599529	PRMT6	0.65	11.02	0.51	2.28e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.68	0.34	9.96e-11	Diastolic blood pressure;
LIHC	cis	rs16828019	0.929	rs4131949	chr1:41738637	C/T	cg03962019	chr1:41807865	NA	0.5	7.22	0.36	3.3e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21747090	chr2:27597821	SNX17	-0.44	-6.71	-0.34	8.05e-11	Total body bone mineral density;
LIHC	cis	rs3106136	0.814	rs6532481	chr4:95277311	T/G	cg11021082	chr4:95130006	SMARCAD1	0.39	6.63	0.34	1.33e-10	Capecitabine sensitivity;
LIHC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg15691649	chr6:25882328	NA	-0.53	-7.65	-0.38	2.07e-13	Blood metabolite levels;
LIHC	cis	rs7116495	1.000	rs1791544	chr11:71784957	G/A	cg26138937	chr11:71823887	C11orf51	-0.67	-6.76	-0.34	5.8200000000000003e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs3820500	0.543	rs1934249	chr1:118049831	A/T	cg20383390	chr1:117909022	MAN1A2	-0.48	-6.1	-0.31	2.94e-9	Pneumonia;
LIHC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.48	5.92	0.3	8.04e-9	Plateletcrit;
LIHC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.89	-0.51	6.82e-24	Chronic sinus infection;
LIHC	cis	rs11822910	1.000	rs11822910	chr11:57195917	G/A	cg00522883	chr11:57194120	SLC43A3	0.7	8.4	0.41	1.18e-15	Platelet distribution width;
LIHC	cis	rs72843506	0.656	rs73981807	chr17:19996230	C/G	cg12065943	chr17:19881925	AKAP10	-0.33	-5.8	-0.3	1.53e-8	Schizophrenia;
LIHC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.42	6.72	0.34	7.48e-11	Vitiligo;
LIHC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.45	0.37	7.63e-13	Aortic root size;
LIHC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07305463	chr2:136567211	LCT	-0.37	-5.86	-0.3	1.1e-8	Corneal structure;
LIHC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	0.85	11.71	0.53	7.62e-27	Skin colour saturation;
LIHC	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.44	6.19	0.32	1.7e-9	Diastolic blood pressure;
LIHC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg11062466	chr8:58055876	NA	0.51	7.61	0.38	2.72e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg16479474	chr6:28041457	NA	0.45	7.04	0.36	1.08e-11	Parkinson's disease;
LIHC	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.57	7.53	0.38	4.44e-13	Economic and political preferences (feminism/equality);
LIHC	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.71	-0.43	1.35e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg12454167	chr3:186435060	KNG1	0.32	7.68	0.38	1.73e-13	Adiponectin levels;
LIHC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg06951627	chr6:26196580	NA	0.53	6.27	0.32	1.07e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.47	0.56	1.09e-29	Prudent dietary pattern;
LIHC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.24	0.32	1.33e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	22.17	0.77	3.9e-68	Body mass index (adult);
LIHC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.96	12.6	0.56	3.67e-30	Heart rate;
LIHC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.74	0.3	2.08e-8	Coronary artery disease;
LIHC	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg06108461	chr20:60628389	TAF4	-0.52	-6.76	-0.34	6.05e-11	Body mass index;
LIHC	trans	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.5	0.33	2.88e-10	Endometrial cancer;
LIHC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg22676075	chr6:135203613	NA	0.38	6.19	0.32	1.73e-9	Reticulocyte count;High light scatter reticulocyte count;
LIHC	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.34	0.49	5.36e-22	Post bronchodilator FEV1;
LIHC	cis	rs860626	0.583	rs855766	chr10:119316158	A/G	cg10846980	chr10:119306025	EMX2;EMX2OS	-0.52	-8.09	-0.4	1.02e-14	Neuroticism;
LIHC	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg26536354	chr8:144654954	C8orf73	0.54	6.22	0.32	1.41e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-7.42	-0.37	9.09e-13	Personality dimensions;
LIHC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.57	-0.33	1.88e-10	Diabetic kidney disease;
LIHC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg07061783	chr6:25882402	NA	0.65	8.23	0.41	4.06e-15	Blood metabolite levels;
LIHC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.6	-8.4	-0.41	1.21e-15	Blood metabolite levels;
LIHC	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg07541023	chr7:19748670	TWISTNB	0.48	7.03	0.36	1.13e-11	Thyroid stimulating hormone;
LIHC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.99	-0.35	1.49e-11	Response to antipsychotic treatment;
LIHC	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.48	7.26	0.37	2.55e-12	Dementia with Lewy bodies;
LIHC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-7.05	-0.36	9.81e-12	Response to antipsychotic treatment;
LIHC	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.68	6.64	0.34	1.24e-10	Migraine;Coronary artery disease;
LIHC	cis	rs600806	0.742	rs9429519	chr1:110017105	A/G	cg08911820	chr1:110026001	ATXN7L2	0.52	6.59	0.34	1.67e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.72	-7.18	-0.36	4.37e-12	Vitiligo;
LIHC	cis	rs4742903	0.904	rs4743691	chr9:106931541	G/A	cg14250997	chr9:106856677	SMC2	0.36	6.05	0.31	3.91e-9	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg16586182	chr3:47516702	SCAP	0.48	8.45	0.42	8.71e-16	Colorectal cancer;
LIHC	cis	rs74181299	0.684	rs2052261	chr2:65355270	G/A	cg05010058	chr2:65284262	CEP68	-0.41	-6.67	-0.34	1.06e-10	Pulse pressure;
LIHC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.77	-0.5	1.69e-23	Chronic sinus infection;
LIHC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.38	-6.27	-0.32	1.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6141600	0.540	rs1006296	chr20:34717718	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.49	-0.33	2.97e-10	Height;Hip circumference;
LIHC	cis	rs7700895	0.737	rs10035477	chr5:95227507	C/T	cg10483112	chr5:95245456	ELL2	0.34	5.95	0.31	6.75e-9	IgG glycosylation;
LIHC	cis	rs965469	0.779	rs6051770	chr20:3327014	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-0.85	-10.74	-0.5	2.29e-23	Blood pressure (smoking interaction);
LIHC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.97	0.47	1.03e-20	Alzheimer's disease;
LIHC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.83	11.35	0.52	1.43e-25	Blood metabolite levels;
LIHC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.56	10.27	0.49	9.91e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.28	-6.36	-0.33	6.32e-10	Menarche (age at onset);
LIHC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg13409248	chr3:40428643	ENTPD3	-0.42	-6.96	-0.35	1.76e-11	Renal cell carcinoma;
LIHC	trans	rs16863064	0.866	rs9855318	chr3:187887381	C/T	cg02569115	chr17:76922138	TIMP2	-0.35	-6.17	-0.32	1.94e-9	Schizophrenia;
LIHC	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.4	-5.9	-0.3	8.89e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.84	-0.35	3.55e-11	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.8	0.34	4.78e-11	Red blood cell count;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05651185	chr6:125421530	NA	-0.37	-6.18	-0.32	1.79e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.37	0.33	5.93e-10	Schizophrenia;
LIHC	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.57	9.04	0.44	1.19e-17	Kawasaki disease;
LIHC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.37	-6.75	-0.34	6.35e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs6489882	0.867	rs6489870	chr12:113363972	G/A	cg10175203	chr3:128143634	NA	0.39	6.39	0.33	5.57e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.84	0.3	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg08484479	chr5:887419	BRD9	0.43	6.16	0.32	2e-9	Alopecia areata;
LIHC	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.74	11.45	0.53	6.25e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.06	-0.36	9.19e-12	Breast cancer;
LIHC	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg11861562	chr11:117069780	TAGLN	0.36	5.71	0.3	2.43e-8	Blood protein levels;
LIHC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	1.02	19.56	0.73	1.02e-57	Breast cancer;
LIHC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.52	8.36	0.41	1.57e-15	Height;
LIHC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.96	12.33	0.55	3.76e-29	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.42	7.02	0.35	1.2e-11	Lewy body disease;
LIHC	trans	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg21659725	chr3:3221576	CRBN	0.62	6.23	0.32	1.39e-9	Schizophrenia;
LIHC	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.38	7.09	0.36	7.59e-12	Response to antipsychotic treatment;
LIHC	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.92	14.9	0.63	4.96e-39	Metabolic syndrome;
LIHC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg25039879	chr17:56429692	SUPT4H1	0.78	8.78	0.43	7.79e-17	Cognitive test performance;
LIHC	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.95	10.92	0.51	5.16e-24	Neuroticism;
LIHC	cis	rs1982963	0.906	rs2029976	chr14:52505811	C/T	cg10843707	chr14:52510701	NID2	-0.44	-7.7	-0.38	1.51e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg10755058	chr3:40428713	ENTPD3	-0.34	-5.96	-0.31	6.33e-9	Renal cell carcinoma;
LIHC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.49	0.38	5.91e-13	Electroencephalogram traits;
LIHC	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg10820045	chr2:198174542	NA	0.54	8.57	0.42	3.49e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs34245846	0.704	rs11264278	chr1:154845534	G/C	cg24250549	chr1:154909240	PMVK	-0.67	-9.09	-0.44	8.01e-18	Atrial fibrillation;
LIHC	cis	rs10916814	0.588	rs4571937	chr1:20897033	G/A	cg24502330	chr1:20914028	CDA	-0.31	-6.93	-0.35	2.13e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg12365402	chr11:9010492	NRIP3	-0.23	-5.88	-0.3	9.54e-9	Hemoglobin concentration;
LIHC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-11.49	-0.53	4.79e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8078723	0.705	rs8065443	chr17:38208940	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.55	8.69	0.43	1.48e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.8	11.35	0.52	1.55e-25	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.22	0.48	1.41e-21	Diisocyanate-induced asthma;
LIHC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg00656387	chr3:40428638	ENTPD3	0.49	8.35	0.41	1.78e-15	Renal cell carcinoma;
LIHC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.9	14.13	0.61	5.21e-36	Alzheimer's disease;
LIHC	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.44	-6.71	-0.34	8.16e-11	Dementia with Lewy bodies;
LIHC	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	7.63	0.38	2.3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4834770	1.000	rs6823963	chr4:120242164	A/C	cg09307838	chr4:120376055	NA	0.43	6.5	0.33	2.87e-10	Blood protein levels;
LIHC	cis	rs2997447	0.846	rs3008231	chr1:26402023	A/G	cg19633962	chr1:26362018	EXTL1	-0.48	-5.86	-0.3	1.1e-8	QRS complex (12-leadsum);
LIHC	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg10381502	chr11:71823885	C11orf51	-1.0	-8.62	-0.42	2.6e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.26	0.32	1.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg07148914	chr20:33460835	GGT7	0.41	5.78	0.3	1.72e-8	Height;
LIHC	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.57	-0.42	3.58e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.03	16.8	0.67	1.27e-46	Testicular germ cell tumor;
LIHC	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	7.42	0.37	9.3e-13	Adiposity;
LIHC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.06	-0.31	3.64e-9	Mean corpuscular volume;
LIHC	cis	rs1865721	1.000	rs17283692	chr18:73193911	T/C	cg26385618	chr18:73139727	C18orf62	-0.3	-7.64	-0.38	2.17e-13	Intelligence;
LIHC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.88	11.47	0.53	5.27e-26	Heart rate;
LIHC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.5	0.38	5.37e-13	Electroencephalogram traits;
LIHC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-9.45	-0.46	5.47e-19	Body mass index;
LIHC	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	5.88	0.3	9.6e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.67	-10.22	-0.48	1.48e-21	Longevity;
LIHC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg22834771	chr12:69754056	YEATS4	-0.39	-5.71	-0.3	2.4e-8	Response to diuretic therapy;
LIHC	cis	rs8067354	0.574	rs2531899	chr17:58007193	A/G	cg02344993	chr17:57696989	CLTC	-0.66	-10.46	-0.49	2.16e-22	Hemoglobin concentration;
LIHC	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.65	10.9	0.51	6.3e-24	Superior crus of antihelix expression;
LIHC	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.34	-6.09	-0.31	3.1e-9	Migraine - clinic-based;
LIHC	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.6	6.02	0.31	4.55e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg09003973	chr2:102972529	NA	0.52	5.81	0.3	1.42e-8	Blood protein levels;
LIHC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.56	0.46	2.34e-19	Schizophrenia;
LIHC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.67	-0.79	5e-74	Height;
LIHC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg21724239	chr8:58056113	NA	0.46	6.08	0.31	3.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-6.22	-0.32	1.44e-9	Alzheimer's disease (late onset);
LIHC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg20933634	chr6:27740509	NA	0.47	6.21	0.32	1.56e-9	Parkinson's disease;
LIHC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.3	-5.73	-0.3	2.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.66	0.38	1.89e-13	Prudent dietary pattern;
LIHC	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.52	0.33	2.54e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1865721	1.000	rs62089503	chr18:73177766	C/T	cg26385618	chr18:73139727	C18orf62	-0.3	-7.67	-0.38	1.79e-13	Intelligence;
LIHC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.63	8.72	0.43	1.2e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.51	-7.66	-0.38	1.97e-13	Cognitive function;
LIHC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.75	-14.2	-0.61	2.63e-36	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg03934865	chr2:198174659	NA	0.46	6.61	0.34	1.44e-10	Dermatomyositis;
LIHC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.37	-5.89	-0.3	9.1e-9	Monocyte percentage of white cells;
LIHC	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.44	11.32	0.52	1.95e-25	Cutaneous nevi;
LIHC	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg14222432	chr12:29376421	FAR2	0.33	6.04	0.31	4e-9	QT interval;
LIHC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg04317338	chr11:64019027	PLCB3	0.85	7.93	0.39	3.14e-14	Mean platelet volume;
LIHC	cis	rs8081395	0.603	rs1292047	chr17:57955166	C/T	cg13753209	chr17:57696993	CLTC	0.49	7.77	0.39	9.07e-14	White blood cell count;
LIHC	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.4	-5.81	-0.3	1.41e-8	Blood metabolite levels;
LIHC	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg12218747	chr21:37451666	NA	-0.43	-7.08	-0.36	8.27e-12	Mitral valve prolapse;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.45	-0.33	3.77e-10	Renal cell carcinoma;
LIHC	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.36	0.33	6.42e-10	Axial length;
LIHC	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.7	7.2	0.36	3.79e-12	Schizophrenia;
LIHC	cis	rs4950322	0.576	rs11240015	chr1:146852534	A/G	cg25205988	chr1:146714368	CHD1L	-0.41	-5.95	-0.31	6.75e-9	Protein quantitative trait loci;
LIHC	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg27386326	chr11:61587980	NA	0.7	14.62	0.62	6.07e-38	Trans fatty acid levels;
LIHC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.86	-13.79	-0.6	1.02e-34	Multiple sclerosis;
LIHC	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.56	8.26	0.41	3.22e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	0.55	7.93	0.39	3.04e-14	Prudent dietary pattern;
LIHC	trans	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg09872104	chr7:134855509	C7orf49	-0.76	-6.19	-0.32	1.68e-9	Amyotrophic lateral sclerosis (sporadic);
LIHC	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-5.83	-0.3	1.27e-8	Blood metabolite levels;
LIHC	cis	rs861318	0.702	rs3768523	chr1:159003998	G/C	cg11003133	chr1:159046391	AIM2	-0.34	-6.55	-0.33	2.06e-10	Obesity-related traits;
LIHC	trans	rs12210761	0.511	rs12193757	chr6:10151450	C/T	cg10354244	chr20:57090090	APCDD1L	-0.57	-6.2	-0.32	1.61e-9	Major depressive disorder;
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.33	7.31	0.37	1.88e-12	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg21734168	chr11:67353974	GSTP1	-0.27	-6.76	-0.34	6.08e-11	Mean corpuscular volume;
LIHC	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	0.95	7.23	0.36	3.28e-12	Arsenic metabolism;
LIHC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.41	7.47	0.37	6.82e-13	Electrocardiographic conduction measures;
LIHC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.38	5.84	0.3	1.19e-8	Educational attainment;
LIHC	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.37	6.04	0.31	3.97e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg14393609	chr7:65229607	NA	-0.37	-5.84	-0.3	1.22e-8	Aortic root size;
LIHC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg20140201	chr2:241835670	C2orf54	-0.47	-6.45	-0.33	3.9e-10	Urinary metabolites;
LIHC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.16	-0.55	1.61e-28	Alzheimer's disease;
LIHC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.39	6.11	0.31	2.75e-9	Multiple sclerosis;
LIHC	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-8.11	-0.4	9.29e-15	Total body bone mineral density;
LIHC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.46	-7.29	-0.37	2.2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.91	0.3	8.45e-9	Tonsillectomy;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg00280220	chr17:61926910	NA	0.44	7.07	0.36	8.7e-12	Prudent dietary pattern;
LIHC	cis	rs10924970	0.967	rs12027832	chr1:235385934	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.75	0.3	1.94e-8	Asthma;
LIHC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.55	-9.5	-0.46	3.67e-19	Reticulocyte count;
LIHC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.27	-0.49	9.53e-22	Hemoglobin concentration;
LIHC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.93	17.41	0.69	4.79e-49	Menopause (age at onset);
LIHC	cis	rs10454142	0.633	rs7559431	chr2:48591607	G/A	cg15846641	chr2:48541264	FOXN2	0.48	5.83	0.3	1.31e-8	Sex hormone-binding globulin levels;
LIHC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21467203	chr3:49911342	NA	0.42	7.39	0.37	1.11e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs4407350	1.000	rs9626478	chr22:44923619	A/G	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.07	-0.31	3.44e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg25214090	chr10:38739885	LOC399744	0.45	7.49	0.38	5.81e-13	Diastolic blood pressure;
LIHC	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.58	9.6	0.46	1.83e-19	Body mass index;
LIHC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.81	7.72	0.39	1.29e-13	Diabetic retinopathy;
LIHC	cis	rs9473924	0.505	rs2817332	chr6:50848522	T/A	cg14470998	chr6:50812995	TFAP2B	-0.92	-10.91	-0.51	5.75e-24	Body mass index;
LIHC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.81	9.13	0.44	6.03e-18	Vitiligo;
LIHC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.42	0.49	2.87e-22	Total body bone mineral density;
LIHC	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.64	-10.92	-0.51	4.97e-24	Lymphocyte counts;
LIHC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.8	6.9	0.35	2.59e-11	Arsenic metabolism;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg13976253	chr1:202317780	PPP1R12B	0.4	6.14	0.32	2.34e-9	Lung function (FEV1/FVC);
LIHC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-11.24	-0.52	3.86e-25	Schizophrenia;
LIHC	cis	rs11098699	0.848	rs4619905	chr4:124132225	A/G	cg09941581	chr4:124220074	SPATA5	0.3	5.72	0.3	2.29e-8	Mosquito bite size;
LIHC	cis	rs2380220	0.808	rs2263180	chr6:95902309	G/A	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.14	0.32	2.24e-9	Systolic blood pressure;
LIHC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.7	12.54	0.56	6.26e-30	Colorectal cancer;
LIHC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18252515	chr7:66147081	NA	-0.41	-5.9	-0.3	8.62e-9	Aortic root size;
LIHC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.56	9.33	0.45	1.34e-18	Calcium levels;
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.26	-6.28	-0.32	1.03e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-0.8	-8.66	-0.42	1.95e-16	Exhaled nitric oxide output;
LIHC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.78	8.98	0.44	1.8e-17	Hip circumference adjusted for BMI;
LIHC	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg16691251	chr5:66510806	NA	0.47	6.95	0.35	1.82e-11	Breast cancer;
LIHC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	13.46	0.59	2.05e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg09990169	chr2:241835740	C2orf54	-0.67	-9.56	-0.46	2.34e-19	Urinary metabolites;
LIHC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg11212589	chr17:38028394	ZPBP2	0.38	7.9	0.39	3.97e-14	Self-reported allergy;
LIHC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.5	6.55	0.33	2.16e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10508774	1.000	rs72793602	chr10:32748372	A/G	cg01819863	chr10:32635814	EPC1	0.65	6.07	0.31	3.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.17	0.4	6.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-11.97	-0.54	8.22e-28	Plateletcrit;Platelet count;
LIHC	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.07	-20.08	-0.74	8.78e-60	Triglycerides;
LIHC	cis	rs61041384	0.661	rs4759411	chr12:123740843	C/G	cg00376283	chr12:123451042	ABCB9	-0.57	-5.93	-0.31	7.43e-9	Schizophrenia;
LIHC	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.59	-8.53	-0.42	4.87e-16	Body mass index;
LIHC	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15664640	chr17:80829946	TBCD	-0.56	-5.97	-0.31	5.84e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs9341808	0.529	rs9350851	chr6:81059188	A/G	cg08355045	chr6:80787529	NA	0.35	6.98	0.35	1.53e-11	Sitting height ratio;
LIHC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.68	9.02	0.44	1.34e-17	Psoriasis;
LIHC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Urate levels;
LIHC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.44	6.67	0.34	1.05e-10	Post bronchodilator FEV1;
LIHC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.67	6.73	0.34	7.32e-11	Alzheimer's disease;
LIHC	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.85	8.36	0.41	1.57e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.37	0.37	1.29e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.21	-0.32	1.57e-9	Total body bone mineral density;
LIHC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.76	7.78	0.39	8.57e-14	Vitiligo;
LIHC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg24826892	chr11:71159390	DHCR7	0.51	6.69	0.34	9.12e-11	Vitamin D levels;
LIHC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	8.01	0.4	1.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12038521	chr19:2111714	AP3D1	0.41	6.08	0.31	3.26e-9	Immature fraction of reticulocytes;
LIHC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg07713946	chr22:31675144	LIMK2	-0.42	-7.38	-0.37	1.18e-12	Paclitaxel-induced neuropathy;
LIHC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.71	-0.57	1.46e-30	Alzheimer's disease;
LIHC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.42	7.67	0.38	1.79e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg05590025	chr7:65112418	INTS4L2	-0.66	-7.2	-0.36	3.94e-12	Diabetic kidney disease;
LIHC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.66	10.91	0.51	5.37e-24	Menopause (age at onset);
LIHC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg05896524	chr21:47604654	C21orf56	0.44	6.64	0.34	1.25e-10	Testicular germ cell tumor;
LIHC	trans	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg16088116	chr21:44841560	SIK1	-0.42	-6.49	-0.33	2.93e-10	Coronary artery disease;
LIHC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg14067834	chr17:29058358	SUZ12P	0.63	6.18	0.32	1.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-6.13	-0.31	2.41e-9	Longevity;Endometriosis;
LIHC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.06	-0.31	3.61e-9	Heart rate;
LIHC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.48	6.28	0.32	1.03e-9	Initial pursuit acceleration;
LIHC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.96	0.31	6.43e-9	Bipolar disorder;
LIHC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.28	-14.89	-0.63	5.07e-39	Diabetic kidney disease;
LIHC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg20607798	chr8:58055168	NA	0.46	5.81	0.3	1.44e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg09417038	chr21:47716443	C21orf57	-0.49	-7.25	-0.37	2.72e-12	Testicular germ cell tumor;
LIHC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.47	6.94	0.35	1.97e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg15832292	chr6:96025679	MANEA	0.62	7.06	0.36	9.08e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.84e-22	Hemoglobin concentration;
LIHC	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.53	-8.76	-0.43	9.34e-17	Fibroblast growth factor basic levels;
LIHC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.63	-16.72	-0.67	2.82e-46	Breast cancer;
LIHC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.56	-9.78	-0.47	4.34e-20	Reticulocyte count;
LIHC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-12.89	-0.57	2.93e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17173397	chr1:20539594	NA	0.52	7.08	0.36	8.43e-12	Lung function (FEV1/FVC);
LIHC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.83	-15.93	-0.65	4.11e-43	Height;
LIHC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg03146154	chr1:46216737	IPP	-0.39	-6.37	-0.33	6.04e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	7.69	0.38	1.55e-13	Tonsillectomy;
LIHC	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.75	10.1	0.48	3.72e-21	Selective IgA deficiency;
LIHC	cis	rs600806	0.742	rs12753439	chr1:110015519	G/A	cg23091122	chr1:110024289	SYPL2	-0.44	-6.15	-0.32	2.21e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.15	-0.32	2.15e-9	Colorectal cancer;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg06529453	chr1:54955046	NA	0.43	6.4	0.33	5.15e-10	Morning vs. evening chronotype;
LIHC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09695851	chr17:3907499	NA	0.68	11.57	0.53	2.39e-26	Type 2 diabetes;
LIHC	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.95	-15.95	-0.65	3.32e-43	Platelet count;
LIHC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	12.15	0.55	1.8e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.02	-0.31	4.58e-9	Tonsillectomy;
LIHC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.32	7.01	0.35	1.25e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.36	0.45	1.09e-18	Hemoglobin concentration;
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.43e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.63	10.2	0.48	1.65e-21	Schizophrenia;
LIHC	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.59	8.59	0.42	3.17e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2637266	0.783	rs864676	chr10:78509385	A/G	cg18941641	chr10:78392320	NA	0.27	5.83	0.3	1.26e-8	Pulmonary function;
LIHC	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg07884673	chr3:53033167	SFMBT1	0.88	6.5	0.33	2.77e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.82	-14.98	-0.63	2.24e-39	Height;
LIHC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.88	0.47	2e-20	Platelet count;
LIHC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg16558253	chr16:72132732	DHX38	-0.51	-8.02	-0.4	1.75e-14	Fibrinogen levels;
LIHC	cis	rs7572733	0.555	rs11889006	chr2:198928647	A/G	cg03934865	chr2:198174659	NA	0.46	6.69	0.34	8.93e-11	Dermatomyositis;
LIHC	trans	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.14	-0.36	5.77e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.54	8.58	0.42	3.45e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg22903471	chr2:27725779	GCKR	-0.39	-5.78	-0.3	1.67e-8	Blood metabolite levels;
LIHC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.44	-0.59	2.27e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.62	10.36	0.49	4.56e-22	Recombination rate (males);
LIHC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.56	-8.75	-0.43	9.57e-17	Coronary artery disease;
LIHC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.73	8.15	0.4	7.05e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg23254163	chr1:152506842	NA	0.23	5.93	0.31	7.35e-9	Hair morphology;
LIHC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.06	-0.36	9.19e-12	Breast cancer;
LIHC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.57	9.71	0.46	7.88e-20	Colorectal cancer;
LIHC	cis	rs2851682	1.000	rs2524296	chr11:61601378	C/T	cg27386326	chr11:61587980	NA	0.58	8.74	0.43	1.05e-16	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.39	-5.85	-0.3	1.14e-8	Morning vs. evening chronotype;
LIHC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.71	6.5	0.33	2.89e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LIHC	cis	rs9896052	0.533	rs7406173	chr17:73454563	G/A	cg25649188	chr17:73499917	CASKIN2	0.43	6.7	0.34	8.81e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs4908768	0.906	rs12403339	chr1:8558292	G/A	cg20416874	chr1:8611966	RERE	0.57	8.8	0.43	6.93e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.94	12.73	0.57	1.15e-30	Blood metabolite levels;
LIHC	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-0.82	-9.11	-0.44	6.83e-18	Alzheimer's disease (late onset);
LIHC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.95	0.31	6.49e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg15848620	chr12:58087721	OS9	-0.55	-7.49	-0.38	5.89e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.43	-9.76	-0.47	5.07e-20	Arsenic metabolism;
LIHC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.64	10.87	0.51	7.83e-24	Bipolar disorder;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21448741	chr8:58168803	NA	0.35	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.98	-0.4	2.26e-14	Coronary artery disease;
LIHC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.94	17.59	0.69	8.71e-50	Menopause (age at onset);
LIHC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00152838	chr16:24741724	TNRC6A	-0.52	-5.9	-0.3	8.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	6.15	0.32	2.22e-9	Schizophrenia;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-6.47	-0.33	3.48e-10	Total body bone mineral density;
LIHC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.33	-7.78	-0.39	8.49e-14	Longevity;Endometriosis;
LIHC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg12437481	chr16:420112	MRPL28	-0.64	-8.65	-0.42	2.08e-16	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs4908760	0.965	rs12080583	chr1:8524877	G/A	cg20416874	chr1:8611966	RERE	-0.68	-14.5	-0.62	1.81e-37	Vitiligo;
LIHC	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-8.53	-0.42	4.98e-16	Coronary artery disease;
LIHC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.41	6.74	0.34	6.59e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.05	0.4	1.34e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg02023728	chr11:77925099	USP35	0.35	6.2	0.32	1.58e-9	Alzheimer's disease (survival time);
LIHC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.61	0.5	6.33e-23	Colorectal cancer;
LIHC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.37	-6.44	-0.33	4.04e-10	Permanent tooth development;
LIHC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.59	0.38	3.04e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.8	0.43	7.08e-17	Platelet count;
LIHC	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.57	-6.45	-0.33	3.87e-10	Opioid sensitivity;
LIHC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.92	0.54	1.23e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07305463	chr2:136567211	LCT	0.34	6.29	0.32	9.56e-10	Mosquito bite size;
LIHC	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg15192750	chr16:69999425	NA	0.43	6.68	0.34	9.71e-11	IgE levels;
LIHC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.52	7.36	0.37	1.36e-12	Menopause (age at onset);
LIHC	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.55	-7.27	-0.37	2.42e-12	Obesity;Body mass index;
LIHC	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.44	-7.32	-0.37	1.8e-12	Corneal astigmatism;
LIHC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.22	-0.58	1.56e-32	Primary sclerosing cholangitis;
LIHC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.53	7.6	0.38	2.85e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.967	rs641721	chr8:109230140	G/A	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-17.84	-0.69	8.72e-51	Gut microbiome composition (summer);
LIHC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.58	-9.37	-0.45	1.02e-18	Coronary artery disease;
LIHC	cis	rs12464559	0.522	rs7583060	chr2:152620943	C/A	cg01189475	chr2:152685088	ARL5A	0.65	7.99	0.4	2.02e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.5	8.02	0.4	1.69e-14	Corneal astigmatism;
LIHC	cis	rs1712517	0.844	rs1163075	chr10:105021263	A/G	cg05636881	chr10:105038444	INA	-0.37	-5.94	-0.31	7.15e-9	Migraine;
LIHC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21467203	chr3:49911342	NA	0.43	7.62	0.38	2.56e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.48	6.42	0.33	4.65e-10	Coronary artery disease;
LIHC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.98	-21.68	-0.76	3.44e-66	Bone mineral density;
LIHC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.32	5.94	0.31	6.94e-9	Height;
LIHC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.48	0.56	9.96e-30	Menopause (age at onset);
LIHC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.47	-7.88	-0.39	4.53e-14	IgG glycosylation;
LIHC	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	6.53	0.33	2.45e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.89	7.95	0.39	2.81e-14	Psoriasis;
LIHC	cis	rs3015497	0.586	rs7144714	chr14:51078585	G/A	cg09863266	chr14:51125203	SAV1	-0.38	-5.99	-0.31	5.37e-9	Mean platelet volume;
LIHC	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-11.49	-0.53	4.71e-26	Pediatric autoimmune diseases;
LIHC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.78	0.43	7.73e-17	Lung cancer in ever smokers;
LIHC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.81	9.2	0.45	3.5e-18	Initial pursuit acceleration;
LIHC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.39	-0.37	1.14e-12	Total body bone mineral density;
LIHC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg11212589	chr17:38028394	ZPBP2	0.33	6.93	0.35	2.14e-11	Self-reported allergy;
LIHC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-11.47	-0.53	5.41e-26	Colorectal cancer;
LIHC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.33	0.41	2.02e-15	Lung cancer in ever smokers;
LIHC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	8.56	0.42	4.01e-16	Schizophrenia;
LIHC	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg14146966	chr2:61757674	XPO1	0.48	8.14	0.4	7.34e-15	Tuberculosis;
LIHC	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-9.75	-0.47	5.44e-20	Platelet count;
LIHC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.68	-10.81	-0.5	1.21e-23	Obesity-related traits;
LIHC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.37	5.76	0.3	1.83e-8	Hemoglobin concentration;
LIHC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-11.11	-0.51	1.1e-24	Lung cancer in ever smokers;
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg00750074	chr16:89608354	SPG7	-0.5	-8.11	-0.4	9.34e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.34	8.32	0.41	2.05e-15	Schizophrenia;
LIHC	cis	rs74233809	1.000	rs10883815	chr10:104739179	T/C	cg03493300	chr10:104813866	CNNM2	0.44	5.76	0.3	1.87e-8	Birth weight;
LIHC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.58	8.24	0.41	3.73e-15	Blood metabolite levels;
LIHC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.32	6.39	0.33	5.53e-10	Type 2 diabetes;
LIHC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg11764359	chr7:65958608	NA	0.57	5.82	0.3	1.39e-8	Diabetic kidney disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg19487717	chr11:70263216	CTTN	0.42	6.23	0.32	1.41e-9	Longevity;
LIHC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg12863693	chr15:85201151	NMB	0.45	6.33	0.32	7.87e-10	Schizophrenia;
LIHC	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg08741688	chr4:3415352	RGS12	-0.44	-6.88	-0.35	2.8e-11	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.55	9.77	0.47	4.81e-20	Obesity-related traits;
LIHC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.7	-10.47	-0.49	1.89e-22	Subjective well-being;
LIHC	cis	rs2163237	0.928	rs11125597	chr2:55979316	C/T	cg18811423	chr2:55921094	PNPT1	-0.49	-6.81	-0.35	4.53e-11	IgG glycosylation;
LIHC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.59	8.91	0.43	3.14e-17	Platelet count;
LIHC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.46	-9.13	-0.44	5.9e-18	Lung disease severity in cystic fibrosis;
LIHC	cis	rs911119	0.866	rs4346460	chr20:23569400	C/T	cg16589663	chr20:23618590	CST3	0.65	6.74	0.34	6.57e-11	Chronic kidney disease;
LIHC	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.47	10.82	0.5	1.18e-23	Iron status biomarkers (transferrin levels);
LIHC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.69	8.81	0.43	6.22e-17	Initial pursuit acceleration;
LIHC	cis	rs67981189	0.593	rs7145285	chr14:71561474	A/G	cg15816911	chr14:71606274	NA	0.42	6.73	0.34	7.31e-11	Schizophrenia;
LIHC	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-6.23	-0.32	1.36e-9	Response to antipsychotic treatment;
LIHC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg00277334	chr10:82204260	NA	-0.55	-6.91	-0.35	2.43e-11	Post bronchodilator FEV1;
LIHC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.33	6.28	0.32	1.04e-9	Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14089307	chr14:69446181	ACTN1	-0.4	-6.15	-0.32	2.15e-9	Cognitive function;
LIHC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02290350	chr8:58132656	NA	0.44	8.86	0.43	4.53e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.68	10.79	0.5	1.44e-23	Platelet count;
LIHC	cis	rs1198430	0.759	rs946267	chr1:23747703	A/T	cg13183780	chr1:23809682	ASAP3	-0.38	-6.67	-0.34	1.02e-10	Total cholesterol levels;
LIHC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg07424592	chr7:64974309	NA	0.83	9.63	0.46	1.45e-19	Diabetic kidney disease;
LIHC	cis	rs2412488	0.927	rs28414913	chr4:54339053	A/G	cg22241045	chr4:54363911	LNX1	-0.42	-6.75	-0.34	6.49e-11	DNA methylation (variation);
LIHC	cis	rs3734219	0.507	rs1887843	chr6:3354261	A/G	cg18842474	chr6:3356384	SLC22A23	0.37	6.02	0.31	4.53e-9	Red cell distribution width;
LIHC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.6	7.98	0.4	2.23e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-7.6	-0.38	2.85e-13	Longevity;
LIHC	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg23682824	chr7:23144976	KLHL7	0.4	6.08	0.31	3.27e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.49	-7.9	-0.39	3.89e-14	Cognitive function;
LIHC	cis	rs2607426	1.000	rs2607423	chr19:41275487	A/G	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.49	-5.88	-0.3	9.77e-9	Blood protein levels;
LIHC	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.64	-7.34	-0.37	1.57e-12	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs3748682	0.861	rs28625842	chr1:38310786	G/A	cg12658694	chr1:38397304	INPP5B	0.43	5.89	0.3	9.18e-9	Hypothyroidism;
LIHC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.85	12.92	0.57	2.35e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.0	-17.0	-0.68	2.01e-47	Body mass index;
LIHC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02244288	chr16:89573955	SPG7	-0.3	-5.74	-0.3	2.13e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.88	-14.23	-0.61	2.14e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg19508488	chr2:152266495	RIF1	0.47	6.68	0.34	9.94e-11	Lung cancer;
LIHC	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.47	7.03	0.36	1.16e-11	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg18192155	chr21:44258298	NA	0.4	5.99	0.31	5.27e-9	Information processing speed;
LIHC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg19635926	chr16:89946313	TCF25	0.51	6.52	0.33	2.56e-10	Skin colour saturation;
LIHC	cis	rs7267979	0.565	rs6107060	chr20:25592476	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.91	0.3	8.22e-9	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.7	13.19	0.58	2.05e-32	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.65	-5.89	-0.3	9.4e-9	Menopause (age at onset);
LIHC	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg18225595	chr11:63971243	STIP1	0.59	5.75	0.3	1.96e-8	Mean platelet volume;
LIHC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg25344623	chr2:136566232	LCT	0.44	8.7	0.43	1.38e-16	Mosquito bite size;
LIHC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.57	-8.96	-0.44	2.14e-17	Dental caries;
LIHC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-7.9	-0.39	3.96e-14	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03209809	chr3:126422892	CHCHD6	0.45	6.26	0.32	1.18e-9	Pancreatic cancer;
LIHC	cis	rs4722404	0.800	rs7809262	chr7:3141137	A/G	cg19214707	chr7:3157722	NA	-0.33	-5.98	-0.31	5.6e-9	Atopic dermatitis;
LIHC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.94	11.59	0.53	1.95e-26	HIV-1 control;
LIHC	cis	rs75908454	1.000	rs77187354	chr6:169983808	T/C	cg19338460	chr6:170058176	WDR27	-0.89	-8.08	-0.4	1.1e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg25405998	chr7:65216604	CCT6P1	-0.45	-6.75	-0.34	6.53e-11	Calcium levels;
LIHC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.5	-8.09	-0.4	1.07e-14	Fibrinogen levels;
LIHC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	trans	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg00339104	chr7:32930089	KBTBD2	-0.44	-6.3	-0.32	9.06e-10	Major depressive disorder;
LIHC	cis	rs6782228	0.606	rs7627549	chr3:128353079	G/A	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	8.83	0.43	5.73e-17	Multiple sclerosis;
LIHC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.26	-0.32	1.14e-9	Longevity;Endometriosis;
LIHC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.85	10.18	0.48	1.99e-21	Cognitive function;
LIHC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.44	6.44	0.33	4.17e-10	Crohn's disease;
LIHC	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.23	-6.37	-0.33	6.17e-10	Type 2 diabetes;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg11070056	chr1:107600091	PRMT6	-0.62	-10.31	-0.49	7.01e-22	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.45	6.13	0.31	2.46e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.25	0.32	1.25e-9	Lymphocyte counts;
LIHC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.66	10.52	0.49	1.33e-22	Breast cancer;
LIHC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg22633049	chr21:46681294	NA	-0.37	-6.39	-0.33	5.47e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg24634471	chr8:143751801	JRK	-0.43	-5.98	-0.31	5.51e-9	Urinary tract infection frequency;
LIHC	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.43	6.68	0.34	9.84e-11	Prostate cancer;
LIHC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.16	0.32	2.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.45	-0.42	8.76e-16	Gut microbiome composition (summer);
LIHC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.73	0.34	7.22e-11	Height;
LIHC	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09695851	chr17:3907499	NA	0.61	8.36	0.41	1.56e-15	Type 2 diabetes;
LIHC	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-9.41	-0.45	7.24e-19	Colorectal cancer;
LIHC	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.67	9.7	0.46	8.44e-20	Vitamin D levels;
LIHC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.79	12.58	0.56	4.41e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.81	14.18	0.61	3.16e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.87	-16.24	-0.66	2.25e-44	Dental caries;
LIHC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.03	0.31	4.27e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.42	5.84	0.3	1.22e-8	Coronary artery disease;
LIHC	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.61	-9.96	-0.47	1.13e-20	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.38	6.06	0.31	3.67e-9	Menopause (age at onset);
LIHC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.46	-0.42	7.82e-16	Colorectal cancer;
LIHC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.65	0.38	2e-13	Tonsillectomy;
LIHC	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg21100191	chr22:23484243	RTDR1	0.86	15.57	0.64	1.04e-41	Bone mineral density;
LIHC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.66	12.1	0.55	2.78e-28	Gestational age at birth (maternal effect);
LIHC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-8.33	-0.41	2.04e-15	Schizophrenia;
LIHC	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg02886208	chr11:14281011	SPON1	-0.46	-6.5	-0.33	2.79e-10	Mitochondrial DNA levels;
LIHC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.73	-0.39	1.2e-13	Bipolar disorder;
LIHC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.33	6.22e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg09003973	chr2:102972529	NA	0.81	7.1	0.36	7.2e-12	Gut microbiota (bacterial taxa);
LIHC	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.62	-0.62	6.11e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-8.83	-0.43	5.53e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7945718	0.621	rs7481252	chr11:12681682	A/G	cg25843174	chr11:12811716	TEAD1	0.33	7.71	0.38	1.42e-13	Educational attainment (years of education);
LIHC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg21361702	chr7:150065534	REPIN1	0.48	6.63	0.34	1.29e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-7.55	-0.38	3.91e-13	Migraine;
LIHC	cis	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09441395	chr12:48500072	SENP1;PFKM	-0.43	-5.74	-0.3	2.11e-8	Migraine with aura;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01727434	chr2:152118530	RBM43	0.46	6.63	0.34	1.34e-10	Pancreatic cancer;
LIHC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg14709524	chr16:89940631	TCF25	0.55	7.17	0.36	4.72e-12	Skin colour saturation;
LIHC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.1	-0.31	2.92e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.4	6.46	0.33	3.56e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-15.52	-0.64	1.65e-41	Tonsillectomy;
LIHC	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-10.88	-0.51	6.98e-24	Brugada syndrome;
LIHC	cis	rs3740540	0.761	rs34496154	chr10:126284336	C/T	cg20435097	chr10:126320824	FAM53B	0.54	7.95	0.39	2.77e-14	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.48	6.78	0.34	5.41e-11	Economic and political preferences (feminism/equality);
LIHC	cis	rs2642442	1.000	rs2642442	chr1:220973563	A/G	cg04704887	chr1:220970030	MOSC1	0.45	6.08	0.31	3.18e-9	Cholesterol, total;LDL cholesterol;
LIHC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.49	-6.41	-0.33	4.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	11.46	0.53	5.76e-26	Platelet count;
LIHC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.44	6.33	0.32	7.52e-10	Aortic root size;
LIHC	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.56	-13.8	-0.6	9.24e-35	White blood cell count (basophil);
LIHC	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.51	6.07	0.31	3.41e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	8.46	0.42	8.11e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.83	6.99	0.35	1.43e-11	Body mass index;
LIHC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.24	0.41	3.62e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.36	-10.9	-0.51	5.96e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg13535736	chr9:111863775	C9orf5	0.41	6.3	0.32	9.38e-10	Menarche (age at onset);
LIHC	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-0.84	-9.33	-0.45	1.38e-18	Exhaled nitric oxide output;
LIHC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.38	6.94	0.35	1.92e-11	Aortic root size;
LIHC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.88	11.06	0.51	1.63e-24	Mean platelet volume;
LIHC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg00204512	chr16:28754710	NA	0.42	7.36	0.37	1.35e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-13.32	-0.58	6.54e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13409248	chr3:40428643	ENTPD3	0.4	6.52	0.33	2.57e-10	Renal cell carcinoma;
LIHC	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.73	11.1	0.51	1.2e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs12980942	0.872	rs2304230	chr19:41774064	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.29	0.32	9.54e-10	Coronary artery disease;
LIHC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.5	6.59	0.34	1.67e-10	Mean platelet volume;
LIHC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.95	12.37	0.56	2.58e-29	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.2	0.32	1.59e-9	Cognitive ability;
LIHC	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-7.07	-0.36	8.71e-12	Obesity (extreme);
LIHC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.52	-9.89	-0.47	1.95e-20	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.51	9.34	0.45	1.23e-18	Hemoglobin concentration;
LIHC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.2	-0.52	5.29e-25	Primary sclerosing cholangitis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg25195416	chr21:46696626	POFUT2	0.42	6.46	0.33	3.53e-10	Longevity;
LIHC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg12798992	chr6:167411361	FGFR1OP	-0.6	-9.93	-0.47	1.41e-20	Crohn's disease;
LIHC	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	7.57	0.38	3.51e-13	Systemic lupus erythematosus;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23980294	chr4:184580643	C4orf41;RWDD4A	0.45	6.04	0.31	3.98e-9	Pancreatic cancer;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg06012509	chr6:43027269	KLC4;MRPL2	-0.52	-6.7	-0.34	8.55e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.24	-0.32	1.26e-9	Metabolite levels;
LIHC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.88e-24	Primary sclerosing cholangitis;
LIHC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.46	-7.11	-0.36	6.9e-12	Blood protein levels;
LIHC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.2e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2257205	0.667	rs28363312	chr17:56788293	C/A	cg05425664	chr17:57184151	TRIM37	-0.6	-6.56	-0.33	2e-10	Pancreatic cancer;
LIHC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg00204512	chr16:28754710	NA	0.36	6.71	0.34	7.92e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg26939375	chr7:64535504	NA	0.41	6.53	0.33	2.32e-10	Aortic root size;
LIHC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.33	-5.77	-0.3	1.74e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
LIHC	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	6.22	0.32	1.49e-9	Reticulocyte fraction of red cells;
LIHC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg23533926	chr12:111358616	MYL2	-0.35	-6.66	-0.34	1.1e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg04733989	chr22:42467013	NAGA	-0.51	-6.04	-0.31	4.03e-9	Schizophrenia;
LIHC	trans	rs73245065	0.558	rs1506784	chr10:30909900	A/C	cg21500456	chr14:21190377	NA	-0.45	-6.23	-0.32	1.37e-9	Bone mineral density (femoral neck);
LIHC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.57	-0.33	1.87e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.58	-9.56	-0.46	2.43e-19	Colorectal cancer;
LIHC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg07424592	chr7:64974309	NA	0.83	9.5	0.46	3.78e-19	Diabetic kidney disease;
LIHC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	6.15	0.32	2.16e-9	Schizophrenia;
LIHC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.69	12.29	0.55	5.22e-29	Colorectal cancer;
LIHC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.69	8.54	0.42	4.46e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs903552	1.000	rs34937195	chr15:102003631	C/A	cg00659931	chr15:102010125	PCSK6	-0.44	-6.04	-0.31	4.03e-9	Diabetic kidney disease;
LIHC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.38	-6.05	-0.31	3.87e-9	Glioblastoma;
LIHC	cis	rs17106184	1.000	rs12089747	chr1:51246155	C/T	cg07174182	chr1:51127561	FAF1	-0.62	-7.23	-0.36	3.17e-12	Type 2 diabetes;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.73	10.83	0.51	1.1e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-10.77	-0.5	1.68e-23	Platelet count;
LIHC	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.58	-7.02	-0.36	1.18e-11	Metabolite levels;
LIHC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg17085576	chr10:5658249	NA	-0.35	-6.2	-0.32	1.66e-9	Breast cancer;
LIHC	cis	rs6450176	0.538	rs12186486	chr5:53306549	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.97	-17.49	-0.69	2.16e-49	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08106661	chr6:34855635	TAF11;ANKS1A	0.42	6.32	0.32	7.98e-10	Migraine with aura;
LIHC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00958927	chr1:175162553	KIAA0040	0.39	6.55	0.33	2.11e-10	Alcohol dependence;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07466437	chr6:8086756	EEF1E1;SCARNA27	0.45	6.04	0.31	4.05e-9	Systolic blood pressure;
LIHC	cis	rs861318	1.000	rs855865	chr1:159028378	C/T	cg11003133	chr1:159046391	AIM2	0.31	6.39	0.33	5.53e-10	Obesity-related traits;
LIHC	trans	rs7504990	0.802	rs1110616	chr18:50385517	A/T	cg08535148	chr4:26321143	RBPJ	0.5	6.19	0.32	1.71e-9	Gallbladder cancer;
LIHC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	7.33	0.37	1.7e-12	Total body bone mineral density;
LIHC	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-14.32	-0.61	9.17e-37	Schizophrenia;
LIHC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.69	0.43	1.55e-16	Schizophrenia;
LIHC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.6	-11.93	-0.54	1.14e-27	Coronary artery disease;
LIHC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.53	-7.98	-0.4	2.26e-14	Total body bone mineral density;
LIHC	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.54	10.49	0.49	1.62e-22	Testicular germ cell tumor;
LIHC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg08213375	chr14:104286397	PPP1R13B	0.36	5.73	0.3	2.21e-8	Reticulocyte count;
LIHC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.19	-0.32	1.76e-9	Longevity;Endometriosis;
LIHC	trans	rs500891	0.574	rs12203860	chr6:84174401	C/T	cg03017863	chr2:62115939	CCT4	0.5	6.22	0.32	1.44e-9	Platelet-derived growth factor BB levels;
LIHC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg13957321	chr17:43675089	NA	0.49	7.88	0.39	4.53e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs716804	0.721	rs6484152	chr11:10298452	G/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.86	-0.3	1.11e-8	Neuroticism;
LIHC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.45	7.49	0.38	5.86e-13	Vitiligo;
LIHC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.36	5.89	0.3	9.03e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg13837822	chr10:26931731	LOC731789	0.39	7.28	0.37	2.25e-12	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.78	-0.3	1.71e-8	Uric acid levels;
LIHC	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-8.35	-0.41	1.77e-15	Exhaled nitric oxide output;
LIHC	cis	rs6448317	0.556	rs2602738	chr4:24901114	A/G	cg21108841	chr4:24914750	CCDC149	-0.47	-5.88	-0.3	9.81e-9	Heschl's gyrus morphology;
LIHC	cis	rs11233413	1.000	rs2127361	chr11:82716518	G/T	cg24227371	chr11:82718527	RAB30	0.32	7.09	0.36	7.74e-12	Economic and political preferences (feminism/equality);
LIHC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.32	-0.55	4.26e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-6.21	-0.32	1.52e-9	Schizophrenia;
LIHC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-6.82	-0.35	4.08e-11	Waist circumference;Hip circumference;
LIHC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06050784	chr16:88016603	BANP	-0.39	-6.92	-0.35	2.2e-11	Menopause (age at onset);
LIHC	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg09572067	chr16:29127029	RRN3P2	0.5	8.01	0.4	1.83e-14	Menopause (age at onset);
LIHC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg05185784	chr16:90016020	DEF8	-0.45	-5.84	-0.3	1.21e-8	Skin colour saturation;
LIHC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.52	5.99	0.31	5.35e-9	Alzheimer's disease;
LIHC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	8.32	0.41	2.06e-15	Platelet count;
LIHC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-9.14	-0.44	5.58e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs6088590	0.610	rs6088461	chr20:32905161	G/T	cg08999081	chr20:33150536	PIGU	0.52	7.75	0.39	1.03e-13	Coronary artery disease;
LIHC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.91	0.54	1.33e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	1.0	18.74	0.71	2.13e-54	Breast cancer;
LIHC	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg00101453	chr22:30685584	GATSL3	0.64	7.26	0.37	2.66e-12	Tonsillectomy;
LIHC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.43	-6.63	-0.34	1.3e-10	Height;
LIHC	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.77	9.82	0.47	3.38e-20	Body mass index;
LIHC	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg01652190	chr22:50026171	C22orf34	-0.29	-6.34	-0.32	7.24e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-10.29	-0.49	8.32e-22	Mean corpuscular volume;
LIHC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg15704280	chr7:45808275	SEPT13	-0.46	-6.82	-0.35	4.25e-11	HDL cholesterol;
LIHC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.32	-0.52	1.83e-25	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.06	0.36	9.23e-12	Hemoglobin concentration;
LIHC	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.92	-0.3	8.03e-9	Calcium levels;
LIHC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg23978390	chr7:1156363	C7orf50	0.44	6.15	0.32	2.17e-9	Longevity;Endometriosis;
LIHC	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.53	-7.83	-0.39	6.1e-14	Body mass index;
LIHC	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	0.86	9.46	0.46	5.31e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.2	0.55	1.17e-28	Prudent dietary pattern;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.36	-0.33	6.43e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20887711	chr4:1340912	KIAA1530	0.45	6.01	0.31	4.84e-9	Obesity-related traits;
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.88	12.65	0.56	2.31e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.38	-6.03	-0.31	4.22e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.56	-0.33	1.99e-10	Personality dimensions;
LIHC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.31	-5.75	-0.3	1.98e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-9.39	-0.45	9e-19	Total body bone mineral density;
LIHC	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.34	-0.32	7.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg16132339	chr22:24313637	DDTL;DDT	0.7	13.25	0.58	1.28e-32	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs8064024	0.599	rs2456779	chr16:4925817	G/C	cg08329684	chr16:4932620	PPL	0.35	5.93	0.31	7.23e-9	Cancer;
LIHC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-11.31	-0.52	2.16e-25	Monocyte percentage of white cells;
LIHC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.86	-13.02	-0.58	9.04e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.53	8.28	0.41	2.8e-15	Dialysis-related mortality;
LIHC	cis	rs151997	1.000	rs27249	chr5:50232678	A/G	cg06027927	chr5:50259733	NA	0.55	7.47	0.37	6.88e-13	Callous-unemotional behaviour;
LIHC	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.87	0.39	4.65e-14	Corneal astigmatism;
LIHC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.91	7.6	0.38	2.9e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	trans	rs11689435	0.925	rs12989540	chr2:218344823	T/A	cg13544946	chr9:35729779	TLN1	-0.44	-6.35	-0.32	6.82e-10	Metabolite levels (MHPG);
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.47	7.94	0.39	2.85e-14	Mean corpuscular volume;
LIHC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.6	11.17	0.52	6.7e-25	Systemic lupus erythematosus;
LIHC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.55	8.05	0.4	1.37e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.34	-6.51	-0.33	2.65e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6782228	0.628	rs7641584	chr3:128392630	G/C	cg16766828	chr3:128327626	NA	-0.42	-6.6	-0.34	1.61e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.67	6.57	0.33	1.88e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.91	0.35	2.44e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.71	-0.34	8.07e-11	Breast cancer;
LIHC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.93	-17.77	-0.69	1.72e-50	Coronary artery disease;
LIHC	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.32	7.5	0.38	5.5e-13	Weight;
LIHC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.39	6.33	0.32	7.52e-10	Homoarginine levels;
LIHC	trans	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg17675199	chr6:35436792	RPL10A	-0.4	-8.19	-0.4	5.33e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1403694	1.000	rs2651640	chr3:186438393	G/A	cg12454167	chr3:186435060	KNG1	0.29	7.05	0.36	1.02e-11	Blood protein levels;
LIHC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.56	6.82	0.35	4.23e-11	Heart rate;
LIHC	cis	rs937213	0.573	rs3816900	chr15:40302243	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.37	-6.17	-0.32	1.88e-9	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.05	0.55	4.17e-28	Prudent dietary pattern;
LIHC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.68	9.96	0.47	1.13e-20	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg18944383	chr4:111397179	ENPEP	0.27	6.91	0.35	2.33e-11	Height;
LIHC	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	1.09	7.82	0.39	6.53e-14	Arsenic metabolism;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06697094	chr17:54911185	DGKE	-0.41	-6.18	-0.32	1.8e-9	Cognitive function;
LIHC	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.3	-5.77	-0.3	1.78e-8	Red blood cell count;
LIHC	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.39	-9.44	-0.45	6.09e-19	Cutaneous nevi;
LIHC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg10820045	chr2:198174542	NA	0.53	8.86	0.43	4.52e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs16828019	0.929	rs2363805	chr1:41719434	G/T	cg03962019	chr1:41807865	NA	0.5	7.19	0.36	4.21e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg03585969	chr10:35415529	CREM	0.76	11.02	0.51	2.18e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10845606	0.581	rs10772592	chr12:12835874	A/G	cg04607235	chr12:12878440	APOLD1	-0.47	-6.44	-0.33	4.1e-10	Systemic lupus erythematosus;
LIHC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.46	-7.83	-0.39	6.03e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.51	9.3	0.45	1.72e-18	Plateletcrit;Platelet count;
LIHC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.37	-0.49	4.37e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg15848620	chr12:58087721	OS9	-0.56	-7.71	-0.38	1.43e-13	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs8084351	0.577	rs12966225	chr18:50658497	C/A	cg24270629	chr18:50823537	DCC	-0.44	-6.42	-0.33	4.55e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.54	-8.93	-0.43	2.6e-17	Blood metabolite levels;
LIHC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.56	-9.95	-0.47	1.16e-20	Mean corpuscular volume;
LIHC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.72	-0.57	1.29e-30	Alzheimer's disease;
LIHC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg03146154	chr1:46216737	IPP	-0.47	-7.51	-0.38	5.17e-13	Red blood cell count;Reticulocyte count;
LIHC	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg16275483	chr1:110013120	SYPL2	-0.5	-6.27	-0.32	1.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-14.46	-0.62	2.58e-37	Systemic lupus erythematosus;
LIHC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg13047869	chr3:10149882	C3orf24	0.51	5.88	0.3	9.55e-9	Alzheimer's disease;
LIHC	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.54	9.41	0.45	7.61e-19	Systemic lupus erythematosus;
LIHC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.08	0.55	3.09e-28	Motion sickness;
LIHC	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.45	6.68	0.34	9.63e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.95	-18.19	-0.7	3.36e-52	Breast cancer;
LIHC	cis	rs7534824	0.543	rs10493940	chr1:101377845	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.16	0.36	4.93e-12	Refractive astigmatism;
LIHC	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.25	5.96	0.31	6.18e-9	Heart rate;
LIHC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.11	-0.31	2.73e-9	Obesity-related traits;
LIHC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.65	0.42	2.09e-16	Lung cancer in ever smokers;
LIHC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.91	-16.91	-0.67	4.65e-47	Aortic root size;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg14709524	chr16:89940631	TCF25	0.51	6.87	0.35	3.06e-11	Skin colour saturation;
LIHC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg16586182	chr3:47516702	SCAP	0.51	9.27	0.45	2.08e-18	Colorectal cancer;
LIHC	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg06664874	chr5:179499304	RNF130	0.58	7.04	0.36	1.03e-11	LDL cholesterol;
LIHC	cis	rs611744	0.870	rs672243	chr8:109098742	G/A	cg21045802	chr8:109455806	TTC35	0.49	8.58	0.42	3.25e-16	Dupuytren's disease;
LIHC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-17.21	-0.68	2.9e-48	Ulcerative colitis;
LIHC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.47	7.15	0.36	5.27e-12	Height;
LIHC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.47	6.61	0.34	1.46e-10	Schizophrenia;
LIHC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.2	-5.72	-0.3	2.36e-8	Calcium levels;
LIHC	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.69	-11.57	-0.53	2.34e-26	Pediatric autoimmune diseases;
LIHC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.56	7.32	0.37	1.8e-12	Parkinson's disease;
LIHC	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.53	8.54	0.42	4.49e-16	Corneal astigmatism;
LIHC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs425535	0.619	rs8180167	chr4:74833373	A/T	cg02530824	chr4:74847766	PF4	-0.36	-5.9	-0.3	8.81e-9	Blood protein levels;
LIHC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.5	-8.45	-0.42	8.77e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-8.4	-0.41	1.24e-15	Gut microbiome composition (summer);
LIHC	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg27205649	chr11:78285834	NARS2	0.41	6.41	0.33	4.72e-10	Alzheimer's disease (survival time);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04250904	chr19:12623422	ZNF709	0.41	6.05	0.31	3.77e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.24	-0.32	1.28e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.37	0.49	4.44e-22	Colorectal cancer;
LIHC	trans	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg18335740	chr13:41363409	SLC25A15	-0.4	-6.95	-0.35	1.89e-11	Lewy body disease;
LIHC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	0.6	6.07	0.31	3.4e-9	Obesity-related traits;
LIHC	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.68	-0.34	9.69e-11	Neuroticism;
LIHC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	8.92	0.43	2.83e-17	Schizophrenia;
LIHC	cis	rs7074356	0.915	rs17617970	chr10:82206892	A/G	cg00277334	chr10:82204260	NA	-0.68	-5.82	-0.3	1.36e-8	Borderline personality disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04212729	chr14:65171037	PLEKHG3	0.44	6.17	0.32	1.92e-9	Pancreatic cancer;
LIHC	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg24060327	chr5:131705240	SLC22A5	0.55	7.44	0.37	8.01e-13	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg22777020	chr22:31556080	RNF185	-0.56	-6.42	-0.33	4.61e-10	Colorectal cancer;
LIHC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.9	0.39	3.84e-14	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.64	-8.36	-0.41	1.64e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.43	6.2	0.32	1.61e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.78	8.58	0.42	3.27e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.62	-8.98	-0.44	1.83e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8081395	0.741	rs1292053	chr17:57963537	C/T	cg13753209	chr17:57696993	CLTC	-0.37	-5.79	-0.3	1.61e-8	White blood cell count;
LIHC	trans	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg08345082	chr10:99160200	RRP12	-0.36	-5.99	-0.31	5.38e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.69	11.76	0.54	4.7e-27	Crohn's disease;
LIHC	trans	rs6489882	0.703	rs4767029	chr12:113359318	G/A	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	6e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.92	-14.33	-0.61	8.4e-37	Breast cancer;
LIHC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	10.73	0.5	2.46e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.32	-7.1	-0.36	7.42e-12	Breast cancer;
LIHC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	16.02	0.65	1.68e-43	Platelet count;
LIHC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.36	6.81	0.35	4.4e-11	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-10.74	-0.5	2.25e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg00677901	chr16:88017247	BANP	0.47	7.27	0.37	2.54e-12	Menopause (age at onset);
LIHC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg25894440	chr7:65020034	NA	-0.52	-6.1	-0.31	2.85e-9	Diabetic kidney disease;
LIHC	cis	rs2607426	0.681	rs2545777	chr19:41287809	C/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-6.18	-0.32	1.77e-9	Blood protein levels;
LIHC	trans	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg18393722	chr15:85113863	UBE2QP1	0.41	6.84	0.35	3.61e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg09462578	chr12:12878428	APOLD1	0.49	7.76	0.39	1.01e-13	Pulse pressure;
LIHC	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2274273	1.000	rs66871576	chr14:55629050	C/T	cg01864836	chr14:55583639	NA	-0.36	-6.09	-0.31	3.02e-9	Protein biomarker;
LIHC	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg27147174	chr7:100797783	AP1S1	-0.46	-6.55	-0.33	2.08e-10	Life satisfaction;
LIHC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21448741	chr8:58168803	NA	0.35	6.55	0.33	2.1e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.47	-5.99	-0.31	5.19e-9	QRS duration;
LIHC	trans	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg10208301	chr11:6592745	DNHD1	0.48	6.35	0.32	6.68e-10	Coronary artery calcification;
LIHC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-12.93	-0.57	1.99e-31	Menarche (age at onset);
LIHC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg15848620	chr12:58087721	OS9	-0.51	-6.59	-0.34	1.62e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.49	-8.96	-0.44	2.06e-17	Atrioventricular conduction;
LIHC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.09	-0.55	2.94e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.48	7.62	0.38	2.51e-13	Multiple sclerosis;
LIHC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.58	-0.34	1.77e-10	Mood instability;
LIHC	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.86	-0.35	3.16e-11	Metabolite levels;
LIHC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.72	-0.39	1.34e-13	Lymphocyte counts;
LIHC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.53	-0.38	4.56e-13	Bipolar disorder;
LIHC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg03013999	chr17:37608204	MED1	0.35	5.89	0.3	9.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.71	0.34	7.96e-11	Cognitive ability;
LIHC	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.22	-0.32	1.42e-9	Metabolite levels;
LIHC	cis	rs990171	0.506	rs4141631	chr2:102757216	A/G	cg22835712	chr2:102737379	NA	0.54	8.57	0.42	3.74e-16	Lymphocyte counts;
LIHC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.95	9.54	0.46	2.8e-19	Breast cancer;
LIHC	cis	rs753955	0.592	rs7325382	chr13:24350093	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.33	-5.86	-0.3	1.1e-8	Lung cancer;
LIHC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.38	-0.33	5.85e-10	Diabetic kidney disease;
LIHC	cis	rs2574704	1.000	rs2616561	chr3:11652417	G/A	cg15876825	chr3:11651881	VGLL4	0.5	8.2	0.41	4.88e-15	Body mass index;
LIHC	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.6	8.32	0.41	2.15e-15	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs3736594	0.513	rs62138966	chr2:27819172	G/A	cg27432699	chr2:27873401	GPN1	0.45	6.57	0.33	1.87e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg08135965	chr6:41755394	TOMM6	0.44	5.91	0.3	8.33e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.71	-8.73	-0.43	1.11e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	6.13	0.31	2.38e-9	Lymphocyte counts;
LIHC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.48	0.42	6.71e-16	Lung cancer;
LIHC	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.43	-6.84	-0.35	3.56e-11	Multiple sclerosis;
LIHC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg20818283	chr2:191399100	TMEM194B	0.46	6.33	0.32	7.87e-10	Pulse pressure;
LIHC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.0	-0.51	2.73e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.04	-0.36	1.05e-11	Major depressive disorder;
LIHC	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg00012203	chr2:219082015	ARPC2	0.91	15.08	0.63	9.78e-40	Colorectal cancer;
LIHC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg26531700	chr6:26746687	NA	0.4	6.6	0.34	1.56e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.52	7.59	0.38	3.01e-13	Obesity-related traits;
LIHC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.96	-0.31	6.2e-9	Tonsillectomy;
LIHC	cis	rs244293	0.801	rs2541241	chr17:53072993	A/C	cg19360675	chr17:53046073	COX11;STXBP4	0.48	7.24	0.36	3.02e-12	Menarche (age at onset);
LIHC	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg02811702	chr13:24901961	NA	0.24	6.01	0.31	4.69e-9	Obesity-related traits;
LIHC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-10.32	-0.49	6.59e-22	Chronic sinus infection;
LIHC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg03146154	chr1:46216737	IPP	-0.39	-6.38	-0.33	5.75e-10	Red blood cell count;Reticulocyte count;
LIHC	trans	rs3749855	0.679	rs13217635	chr6:17265491	A/G	cg00118684	chr18:13726609	RNMT;C18orf19	-0.61	-6.08	-0.31	3.12e-9	Glucose homeostasis traits;
LIHC	trans	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg26939375	chr7:64535504	NA	0.43	6.84	0.35	3.64e-11	Aortic root size;
LIHC	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.43	-7.0	-0.35	1.33e-11	Schizophrenia;
LIHC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.55	7.72	0.39	1.27e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.61	-7.76	-0.39	1.02e-13	Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04294563	chr19:7694202	LOC100131801;XAB2	0.41	6.29	0.32	9.43e-10	Cognitive function;
LIHC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.34	-6.25	-0.32	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg08135965	chr6:41755394	TOMM6	0.46	6.13	0.31	2.41e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg25204440	chr1:209979598	IRF6	-0.52	-8.03	-0.4	1.57e-14	Cleft lip with or without cleft palate;
LIHC	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-0.86	-10.47	-0.49	2.03e-22	Blood pressure (smoking interaction);
LIHC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-8.44	-0.42	9.34e-16	Blood protein levels;
LIHC	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	0.84	9.86	0.47	2.44e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-8.64	-0.42	2.19e-16	Schizophrenia;
LIHC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.06	0.36	9.55e-12	Height;
LIHC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.72	11.77	0.54	4.51e-27	Body mass index;
LIHC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	10.26	0.49	1.04e-21	Lung cancer;
LIHC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.53	7.42	0.37	9.22e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg00873037	chr8:11626984	NEIL2	-0.47	-5.73	-0.3	2.23e-8	Monocyte count;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg00606472	chr2:128615778	POLR2D	-0.55	-6.27	-0.32	1.12e-9	Systolic blood pressure;
LIHC	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.29	6.2	0.32	1.67e-9	Menarche (age at onset);
LIHC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.87	0.3	1.01e-8	Nonalcoholic fatty liver disease;
LIHC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.62	8.74	0.43	1.1e-16	Platelet count;
LIHC	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.72	-8.66	-0.42	1.95e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.35	6.4	0.33	5.26e-10	Platelet distribution width;
LIHC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.63	11.21	0.52	4.6e-25	Gestational age at birth (maternal effect);
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.96	16.63	0.67	6.29e-46	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02450064	chr17:40260053	DHX58	-0.29	-6.09	-0.31	3.08e-9	Fibrinogen levels;
LIHC	cis	rs74233809	1.000	rs12413409	chr10:104719096	C/T	cg03493300	chr10:104813866	CNNM2	0.44	5.91	0.3	8.33e-9	Birth weight;
LIHC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.44	6.1	0.31	2.82e-9	Uric acid clearance;
LIHC	cis	rs7188697	0.922	rs37055	chr16:58560775	C/T	cg02549819	chr16:58548995	SETD6	-0.46	-7.2	-0.36	3.92e-12	QT interval;
LIHC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.99	0.31	5.4e-9	Menopause (age at onset);
LIHC	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg26138937	chr11:71823887	C11orf51	1.32	10.9	0.51	6.21e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg14784868	chr12:69753453	YEATS4	0.51	7.12	0.36	6.37e-12	Response to diuretic therapy;
LIHC	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.74	-13.8	-0.6	1e-34	Height;
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-6.54	-0.33	2.22e-10	Height;
LIHC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.57	0.38	3.43e-13	Bipolar disorder;
LIHC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.89	0.3	9.44e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.76	-0.39	9.71e-14	Lymphocyte counts;
LIHC	cis	rs9918079	0.560	rs12651550	chr4:15641018	G/C	cg21123203	chr4:15471301	CC2D2A	-0.45	-7.26	-0.37	2.6e-12	Obesity-related traits;
LIHC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg01788221	chr16:89496183	ANKRD11	0.37	5.99	0.31	5.27e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-1.09	-13.71	-0.6	2.13e-34	Blood protein levels;
LIHC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.55	-6.57	-0.33	1.87e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.52	8.24	0.41	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	6.0	0.31	5.06e-9	Height;
LIHC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.47	7.03	0.36	1.1e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.6	9.31	0.45	1.59e-18	Height;
LIHC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.98	16.03	0.65	1.63e-43	Orofacial clefts;
LIHC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.8e-12	Waist circumference;Weight;
LIHC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.16	0.44	4.98e-18	Schizophrenia;
LIHC	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.51	-7.68	-0.38	1.67e-13	Recalcitrant atopic dermatitis;
LIHC	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.67	-0.69	4.31e-50	Schizophrenia;
LIHC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.55	7.01	0.35	1.29e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.6e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.58	9.64	0.46	1.35e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-12.19	-0.55	1.24e-28	Height;
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg00656387	chr3:40428638	ENTPD3	0.5	8.41	0.41	1.13e-15	Renal cell carcinoma;
LIHC	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.23	6.27	0.32	1.11e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7508	0.511	rs438818	chr8:17899561	A/G	cg01800426	chr8:17659068	MTUS1	-0.44	-7.11	-0.36	6.83e-12	Atrial fibrillation;
LIHC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.58	9.54	0.46	2.83e-19	Colorectal cancer;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg15684290	chr8:6263623	MCPH1	0.58	6.05	0.31	3.8e-9	Musician's dystonia;
LIHC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg16070123	chr10:51489643	NA	-0.38	-6.03	-0.31	4.34e-9	Prostate-specific antigen levels;
LIHC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.77	-9.44	-0.45	5.9e-19	Gut microbiome composition (summer);
LIHC	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.45	7.26	0.37	2.62e-12	Cleft lip with or without cleft palate;
LIHC	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.34	6.55	0.33	2.08e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.27e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.73	-0.3	2.24e-8	Coronary artery disease;
LIHC	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg25930673	chr12:123319894	HIP1R	-0.85	-10.22	-0.48	1.39e-21	Schizophrenia;
LIHC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.55	0.38	3.88e-13	Vitiligo;
LIHC	trans	rs1704198	1.000	rs2664688	chr1:213897415	C/T	cg02442787	chr4:139230014	NA	0.41	6.24	0.32	1.27e-9	Obesity;
LIHC	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.75	6.19	0.32	1.68e-9	Alzheimer's disease;
LIHC	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.53	7.16	0.36	4.87e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.57	7.95	0.4	2.7e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	9.21	0.45	3.34e-18	Motion sickness;
LIHC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-10.61	-0.5	6.35e-23	Colorectal cancer;
LIHC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	1.11	12.56	0.56	4.97e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.37	-7.84	-0.39	5.88e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.31	7.07	0.36	8.65e-12	Blood metabolite ratios;
LIHC	cis	rs7534824	0.625	rs61780284	chr1:101355166	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	7.02	0.36	1.17e-11	Refractive astigmatism;
LIHC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.64	-10.04	-0.48	5.81e-21	Lung cancer;
LIHC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.73	0.3	2.16e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-6.39	-0.33	5.51e-10	Metabolite levels;
LIHC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg14067834	chr17:29058358	SUZ12P	0.68	6.62	0.34	1.38e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.7	11.21	0.52	4.86e-25	Colorectal adenoma (advanced);
LIHC	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.39	9.53	0.46	2.97e-19	Blood metabolite ratios;
LIHC	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.61	6.07	0.31	3.35e-9	Carotid intima media thickness;
LIHC	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg23461800	chr14:103021989	NA	0.39	5.94	0.31	7.14e-9	Platelet count;
LIHC	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg16309518	chr5:176445507	NA	-0.58	-11.51	-0.53	3.91e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs655641	0.911	rs618629	chr11:85689435	T/C	cg09030501	chr11:85779252	PICALM	-0.51	-6.15	-0.32	2.17e-9	Platelet count;
LIHC	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.83	-0.3	1.3e-8	Educational attainment (years of education);
LIHC	cis	rs7539409	0.764	rs4001465	chr1:84285304	T/C	cg10977910	chr1:84465055	TTLL7	0.73	6.93	0.35	2.04e-11	Alzheimer's disease;
LIHC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-7.76	-0.39	9.98e-14	Cognitive function;
LIHC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	9.09	0.44	8.32e-18	Schizophrenia;
LIHC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-7.23	-0.36	3.28e-12	Morning vs. evening chronotype;
LIHC	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.65	6.79	0.34	4.98e-11	Type 2 diabetes;
LIHC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.22	-0.74	2.3e-60	Height;
LIHC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.76	0.34	5.86e-11	Tonsillectomy;
LIHC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	trans	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	6.39	0.33	5.39e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.82	6.88	0.35	2.87e-11	Body mass index;
LIHC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.88	-0.35	2.89e-11	Menarche (age at onset);
LIHC	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.42	5.71	0.3	2.41e-8	Monobrow;
LIHC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg02079420	chr8:82753780	SNX16	0.33	5.98	0.31	5.71e-9	Diastolic blood pressure;
LIHC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02290350	chr8:58132656	NA	0.39	8.47	0.42	7.16e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.4	7.36	0.37	1.39e-12	Prudent dietary pattern;
LIHC	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	7.98	0.4	2.31e-14	Tonsillectomy;
LIHC	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.34	-6.04	-0.31	4.07e-9	Lewy body disease;
LIHC	cis	rs4919087	0.715	rs793520	chr10:99032375	G/A	cg25902810	chr10:99078978	FRAT1	-0.6	-6.88	-0.35	2.9e-11	Monocyte count;
LIHC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.62	9.83	0.47	3.11e-20	Lymphocyte counts;
LIHC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.93	-0.31	7.47e-9	Calcium levels;
LIHC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	7.25	0.36	2.88e-12	Menopause (age at onset);
LIHC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.54	0.5	1.14e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.38	6.08	0.31	3.14e-9	Menopause (age at onset);
LIHC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.04	-0.7	1.33e-51	Tonsillectomy;
LIHC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg25039879	chr17:56429692	SUPT4H1	0.8	8.82	0.43	5.77e-17	Cognitive test performance;
LIHC	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.53	10.25	0.48	1.12e-21	Multiple myeloma;
LIHC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.38	-11.71	-0.53	7.6e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.48	7.8	0.39	7.33e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-7.36	-0.37	1.39e-12	Alcohol dependence;
LIHC	cis	rs10768122	0.642	rs11033087	chr11:35374044	G/T	cg13971030	chr11:35366721	SLC1A2	-0.35	-5.86	-0.3	1.09e-8	Vitiligo;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24167897	chr15:63796719	USP3	0.49	6.83	0.35	3.98e-11	Lung function (FEV1/FVC);
LIHC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17554472	chr22:41940697	POLR3H	0.55	5.91	0.3	8.18e-9	Vitiligo;
LIHC	cis	rs1982963	0.627	rs2073626	chr14:52488385	A/G	cg10843707	chr14:52510701	NID2	0.36	5.91	0.3	8.31e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.69	-9.44	-0.45	5.96e-19	Aortic root size;
LIHC	trans	rs7714584	0.793	rs11955174	chr5:150254391	T/G	cg20675040	chr8:143813288	C8orf55	0.34	6.05	0.31	3.8e-9	Crohn's disease;
LIHC	cis	rs7224685	0.569	rs28481302	chr17:4011527	T/G	cg09597638	chr17:3907349	NA	0.54	6.47	0.33	3.46e-10	Type 2 diabetes;
LIHC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.7	-10.47	-0.49	1.89e-22	Prostate cancer;
LIHC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.17	0.55	1.47e-28	Motion sickness;
LIHC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg21734168	chr11:67353974	GSTP1	-0.28	-6.76	-0.34	5.88e-11	Mean corpuscular volume;
LIHC	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg20283391	chr11:68216788	NA	-0.48	-5.86	-0.3	1.06e-8	Total body bone mineral density (age 45-60);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01353569	chr7:106810328	HBP1	0.46	6.64	0.34	1.26e-10	Pancreatic cancer;
LIHC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg12373951	chr3:133503437	NA	0.46	7.66	0.38	1.94e-13	Iron status biomarkers;
LIHC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg17385448	chr1:15911702	AGMAT	0.33	5.77	0.3	1.77e-8	Systolic blood pressure;
LIHC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.45	6.39	0.33	5.44e-10	Coronary artery disease;
LIHC	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.54	6.69	0.34	9.37e-11	Coronary artery disease;
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06420487	chr17:61919686	SMARCD2	0.45	6.13	0.31	2.45e-9	Height;
LIHC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	7.31	0.37	1.94e-12	Lung cancer;
LIHC	cis	rs4407350	0.788	rs5764879	chr22:44920771	T/C	cg26276947	chr22:44892394	LDOC1L	0.33	6.18	0.32	1.86e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-8.59	-0.42	3.06e-16	Response to antipsychotic treatment;
LIHC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.47	7.45	0.37	7.72e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.52	-8.17	-0.4	6.17e-15	Fibrinogen levels;
LIHC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.99	23.08	0.78	1.05e-71	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2444217	0.868	rs2601792	chr16:4043980	G/A	cg09300795	chr16:4042428	ADCY9	0.55	9.74	0.47	6.08e-20	Body mass index;
LIHC	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.4	-6.3	-0.32	9.08e-10	Adiposity;
LIHC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.68	0.59	2.85e-34	Lung cancer in ever smokers;
LIHC	trans	rs8117834	0.574	rs76883031	chr20:8087339	C/T	cg00593689	chr4:53575888	NA	0.41	6.84	0.35	3.77e-11	Chronic kidney disease;
LIHC	cis	rs151997	0.649	rs152688	chr5:50211776	C/T	cg06027927	chr5:50259733	NA	0.43	6.4	0.33	5.23e-10	Callous-unemotional behaviour;
LIHC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.76	0.39	1e-13	Prudent dietary pattern;
LIHC	cis	rs77633900	0.685	rs2469556	chr15:76650148	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-6.15	-0.32	2.15e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg21486233	chr12:29375141	FAR2	0.32	6.35	0.32	6.74e-10	QT interval;
LIHC	cis	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16532752	chr4:104119610	CENPE	0.45	7.08	0.36	8.4e-12	Type 2 diabetes;
LIHC	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.44	6.92	0.35	2.28e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs611744	0.934	rs1452021	chr8:109207886	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.61	8.93	0.43	2.76e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.68	0.34	9.67e-11	Bipolar disorder;
LIHC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-7.93	-0.39	3.18e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg23471612	chr12:98897216	NA	0.3	5.74	0.3	2.06e-8	Colorectal adenoma (advanced);
LIHC	cis	rs16958440	0.867	rs75228657	chr18:44741063	A/G	cg17192377	chr18:44677553	HDHD2	0.92	8.61	0.42	2.67e-16	Sitting height ratio;
LIHC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.68	8.6	0.42	2.87e-16	Initial pursuit acceleration;
LIHC	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg07322936	chr10:88137208	NA	-0.46	-6.06	-0.31	3.62e-9	Schizophrenia;
LIHC	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-9.29	-0.45	1.78e-18	Initial pursuit acceleration in psychotic disorders;
LIHC	cis	rs7317038	0.745	rs75590443	chr13:114015421	A/T	cg24344662	chr13:114018021	GRTP1	-0.44	-6.39	-0.33	5.48e-10	Mean platelet volume;
LIHC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.62	-10.68	-0.5	3.68e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.74	8.7	0.43	1.46e-16	Exhaled nitric oxide output;
LIHC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.46	-5.82	-0.3	1.38e-8	Blood protein levels;
LIHC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.69	13.29	0.58	8.71e-33	Systemic lupus erythematosus;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.49	-6.87	-0.35	3.12e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23794135	chr12:81190974	NA	0.34	6.31	0.32	8.51e-10	Hepatitis;
LIHC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.71	-6.72	-0.34	7.44e-11	Breast cancer;
LIHC	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.94	-0.39	2.98e-14	Coronary artery disease;
LIHC	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.23	0.48	1.32e-21	Coffee consumption (cups per day);
LIHC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.49	0.42	6.54e-16	Motion sickness;
LIHC	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg20016023	chr10:99160130	RRP12	-0.43	-6.58	-0.34	1.73e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg13175981	chr1:150552382	MCL1	0.48	6.51	0.33	2.61e-10	Urate levels;
LIHC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.49	-9.59	-0.46	1.84e-19	Severe influenza A (H1N1) infection;
LIHC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg03037974	chr15:76606532	NA	-0.6	-10.24	-0.48	1.18e-21	Blood metabolite levels;
LIHC	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.61	-7.96	-0.4	2.56e-14	Coronary artery disease;
LIHC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	8.15	0.4	6.94e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.24	-6.71	-0.34	8.12e-11	Type 2 diabetes;
LIHC	cis	rs9341808	0.528	rs2322753	chr6:81042865	C/G	cg08355045	chr6:80787529	NA	0.33	6.77	0.34	5.6e-11	Sitting height ratio;
LIHC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-1.03	-7.24	-0.36	3.01e-12	Body mass index;
LIHC	trans	rs2073499	0.679	rs2624842	chr3:50196418	A/C	cg21659725	chr3:3221576	CRBN	0.53	6.04	0.31	4.03e-9	Schizophrenia;
LIHC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-1.05	-16.49	-0.67	2.34e-45	Urate levels;
LIHC	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.52	-0.33	2.56e-10	Ulcerative colitis;
LIHC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.4e-9	Aortic root size;
LIHC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.63	-0.38	2.36e-13	Height;
LIHC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.58	-9.87	-0.47	2.24e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg26395211	chr5:140044315	WDR55	-0.43	-6.37	-0.33	5.99e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg27478167	chr7:817139	HEATR2	-0.42	-5.9	-0.3	8.71e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg05973401	chr12:123451056	ABCB9	0.43	5.94	0.31	7.13e-9	Neutrophil percentage of white cells;
LIHC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.38	6.84	0.35	3.67e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.32	-5.91	-0.3	8.38e-9	Lewy body disease;
LIHC	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.51	8.06	0.4	1.31e-14	Adiposity;
LIHC	cis	rs61041384	0.661	rs4148857	chr12:123539955	T/C	cg00376283	chr12:123451042	ABCB9	-0.6	-5.72	-0.3	2.37e-8	Schizophrenia;
LIHC	cis	rs7937840	0.597	rs3867138	chr11:61911422	C/T	cg01969543	chr11:61895209	INCENP	-0.49	-6.18	-0.32	1.86e-9	Breast cancer;
LIHC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	8.49	0.42	6.2e-16	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs903552	0.800	rs6598479	chr15:102005913	A/C	cg25677261	chr15:102009856	PCSK6	-0.5	-6.69	-0.34	9.06e-11	Diabetic kidney disease;
LIHC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.84	-15.05	-0.63	1.2e-39	Coronary artery disease;
LIHC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg24296786	chr1:45957014	TESK2	0.4	5.85	0.3	1.16e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-9.61	-0.46	1.62e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.77	12.37	0.56	2.62e-29	Night sleep phenotypes;
LIHC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.41	7.77	0.39	9.04e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4759375	0.790	rs9739171	chr12:123840994	T/G	cg00376283	chr12:123451042	ABCB9	0.49	6.31	0.32	8.57e-10	HDL cholesterol;
LIHC	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.74	-0.3	2.14e-8	Blood pressure;
LIHC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.64	0.56	2.67e-30	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg20607798	chr8:58055168	NA	0.48	6.51	0.33	2.75e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6988985	0.560	rs7826809	chr8:143925609	C/T	cg23373978	chr8:143916136	GML	-0.29	-6.17	-0.32	1.88e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LIHC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-6.71	-0.34	8.34e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg05084668	chr3:125655381	ALG1L	-0.38	-6.04	-0.31	3.99e-9	Blood pressure (smoking interaction);
LIHC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.32	5.76	0.3	1.85e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7945718	0.621	rs10831896	chr11:12693361	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.85	0.39	5.51e-14	Educational attainment (years of education);
LIHC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg12798992	chr6:167411361	FGFR1OP	0.48	7.27	0.37	2.53e-12	Crohn's disease;
LIHC	cis	rs1494950	1.000	rs55733122	chr4:15048782	C/G	cg12377275	chr4:15005593	CPEB2	-0.85	-7.78	-0.39	8.87e-14	Political ideology;
LIHC	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg22961513	chr11:14280813	SPON1	-0.44	-6.89	-0.35	2.76e-11	Mitochondrial DNA levels;
LIHC	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg27205649	chr11:78285834	NARS2	0.37	5.79	0.3	1.58e-8	Alzheimer's disease (survival time);
LIHC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13301601	chr7:774633	HEATR2	-0.41	-5.81	-0.3	1.43e-8	Cerebrospinal P-tau181p levels;
LIHC	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.83	0.35	3.99e-11	Mean corpuscular volume;
LIHC	cis	rs4407350	0.967	rs5764884	chr22:44922843	G/T	cg26276947	chr22:44892394	LDOC1L	0.33	5.88	0.3	1e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	0.6	9.92	0.47	1.51e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.5	-0.49	1.57e-22	Total cholesterol levels;
LIHC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.39	5.97	0.31	5.82e-9	Lymphocyte counts;
LIHC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg25281562	chr12:121454272	C12orf43	0.37	6.29	0.32	9.83e-10	N-glycan levels;
LIHC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg22834771	chr12:69754056	YEATS4	-0.4	-6.0	-0.31	4.91e-9	Response to diuretic therapy;
LIHC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.72	-0.39	1.28e-13	Monocyte percentage of white cells;
LIHC	cis	rs4006360	0.646	rs9902561	chr17:39295384	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.2	5.77	0.3	1.76e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg15691649	chr6:25882328	NA	0.51	7.0	0.35	1.35e-11	Blood metabolite levels;
LIHC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.2	-0.32	1.6e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	10.56	0.5	9.78e-23	LDL cholesterol;
LIHC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg24805985	chr8:25045589	DOCK5	0.31	6.43	0.33	4.32e-10	Myopia (pathological);
LIHC	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	10.62	0.5	5.63e-23	Eye color traits;
LIHC	cis	rs75908454	1.000	rs75255669	chr6:169962828	C/T	cg19338460	chr6:170058176	WDR27	-0.83	-7.48	-0.38	6.2800000000000005e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	8.69	0.43	1.58e-16	Lung cancer in ever smokers;
LIHC	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.81	-0.3	1.41e-8	Systolic blood pressure;
LIHC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.82	7.77	0.39	9.5e-14	Eosinophil percentage of granulocytes;
LIHC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.29	-0.37	2.1e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	trans	rs78049276	0.736	rs10305838	chr4:148400256	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.58	-7.76	-0.39	9.85e-14	Pulse pressure;
LIHC	cis	rs7116495	0.619	rs7116188	chr11:71841753	A/G	cg26138937	chr11:71823887	C11orf51	0.82	8.1	0.4	9.95e-15	Severe influenza A (H1N1) infection;
LIHC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg19318889	chr4:1322082	MAEA	0.47	6.48	0.33	3.11e-10	Obesity-related traits;
LIHC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.71	12.09	0.55	2.96e-28	Menopause (age at onset);
LIHC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.4	6.49	0.33	2.97e-10	Coronary artery disease;
LIHC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg05941027	chr17:61774174	LIMD2	0.36	7.27	0.37	2.4e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.44	6.95	0.35	1.87e-11	Mortality in heart failure;
LIHC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg25783544	chr11:47291846	MADD	0.41	5.94	0.31	6.98e-9	HDL cholesterol;
LIHC	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.83	-14.56	-0.62	1.07e-37	Schizophrenia;
LIHC	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg18404041	chr3:52824283	ITIH1	0.43	5.98	0.31	5.48e-9	Schizophrenia;
LIHC	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.49	0.49	1.7e-22	Hypertriglyceridemia;
LIHC	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.57	-13.84	-0.6	6.43e-35	White blood cell count (basophil);
LIHC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.56	7.73	0.39	1.24e-13	Mean corpuscular volume;
LIHC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.4	7.01	0.35	1.26e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.53	0.33	2.38e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs28829049	0.731	rs7537573	chr1:19373605	C/T	cg13387374	chr1:19411106	UBR4	0.45	6.61	0.34	1.5e-10	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.85	15.19	0.63	3.43e-40	Aortic root size;
LIHC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.48	-8.04	-0.4	1.5e-14	Blood metabolite levels;
LIHC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg13957321	chr17:43675089	NA	-0.48	-8.01	-0.4	1.88e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.52	-6.27	-0.32	1.07e-9	Schizophrenia;
LIHC	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.05	18.25	0.7	1.97e-52	Triglycerides;
LIHC	cis	rs7712401	0.755	rs4283786	chr5:122101050	T/C	cg18764291	chr5:122110994	SNX2	0.35	6.07	0.31	3.37e-9	Mean platelet volume;
LIHC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg04498913	chr7:1135747	C7orf50	0.45	7.21	0.36	3.52e-12	Bronchopulmonary dysplasia;
LIHC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.34	6.28	0.32	1.06e-9	Aortic root size;
LIHC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	cis	rs8020095	0.528	rs2319777	chr14:67810033	C/T	cg03487553	chr14:67822707	ATP6V1D	-0.35	-6.13	-0.31	2.48e-9	Depression (quantitative trait);
LIHC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg21531657	chr3:10005747	TMEM111	0.38	5.71	0.3	2.42e-8	Alzheimer's disease;
LIHC	cis	rs2274273	0.840	rs72715769	chr14:55762429	C/G	cg01864836	chr14:55583639	NA	-0.37	-6.63	-0.34	1.35e-10	Protein biomarker;
LIHC	cis	rs332507	0.830	rs1846892	chr3:124399293	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.07	0.36	8.83e-12	Plateletcrit;
LIHC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg10018233	chr7:150070692	REPIN1	0.55	8.52	0.42	5.04e-16	Blood protein levels;Circulating chemerin levels;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg00875911	chr4:1224246	CTBP1	0.4	6.26	0.32	1.14e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17507749	chr15:85114479	UBE2QP1	-0.56	-6.24	-0.32	1.28e-9	Schizophrenia;
LIHC	cis	rs4517514	0.509	rs12224461	chr11:89871111	C/T	cg05041596	chr11:89867385	NAALAD2	0.41	6.43	0.33	4.34e-10	Trans fatty acid levels;
LIHC	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg08539965	chr1:21396338	EIF4G3	0.34	6.15	0.32	2.22e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.65	-0.42	2.04e-16	Primary biliary cholangitis;
LIHC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.6	10.07	0.48	4.76e-21	Resting heart rate;
LIHC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.58	-8.27	-0.41	3.07e-15	Motion sickness;
LIHC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.33	7.08	0.36	8e-12	Ulcerative colitis;
LIHC	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-10.88	-0.51	7.1e-24	Colorectal cancer;
LIHC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg27478167	chr7:817139	HEATR2	-0.42	-5.94	-0.31	6.93e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	11.74	0.54	5.46e-27	Colorectal cancer;
LIHC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	16.2	0.66	3.29e-44	Smoking behavior;
LIHC	cis	rs114532231	0.661	rs75764836	chr2:86526863	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.68	-6.91	-0.35	2.45e-11	Asymmetrical dimethylarginine levels;
LIHC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg10755058	chr3:40428713	ENTPD3	0.38	6.49	0.33	2.94e-10	Renal cell carcinoma;
LIHC	cis	rs4845459	0.967	rs4845452	chr1:152591647	A/G	cg20634798	chr1:152595351	LCE3A	-0.31	-5.98	-0.31	5.56e-9	Psoriasis;
LIHC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.47	-7.9	-0.39	3.88e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.58	8.75	0.43	1.02e-16	Height;
LIHC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg23517279	chr6:96025343	MANEA	0.57	6.48	0.33	3.21e-10	Behavioural disinhibition (generation interaction);
LIHC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg04310649	chr10:35416472	CREM	-0.43	-5.79	-0.3	1.57e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.31	-6.03	-0.31	4.15e-9	Colorectal cancer;
LIHC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-6.11	-0.31	2.78e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.36	5.99	0.31	5.36e-9	Hemoglobin concentration;
LIHC	cis	rs4800452	0.956	rs4239436	chr18:20731930	A/G	cg26136497	chr18:20735537	CABLES1	-0.45	-5.97	-0.31	5.94e-9	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg16102536	chr7:156981717	UBE3C	0.36	5.82	0.3	1.35e-8	Body mass index;
LIHC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs71658797	0.536	rs12039708	chr1:77947009	C/T	cg04606550	chr5:14226569	TRIO	0.38	6.13	0.31	2.45e-9	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
LIHC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.97	16.86	0.67	7.67e-47	Subjective well-being;
LIHC	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.62	8.8	0.43	6.96e-17	Eotaxin levels;
LIHC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.64	13.1	0.58	4.87e-32	Airflow obstruction;
LIHC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.51	-8.37	-0.41	1.49e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-11.37	-0.52	1.3e-25	Colorectal cancer;
LIHC	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg01753270	chr2:239240285	TRAF3IP1	0.32	6.18	0.32	1.82e-9	Multiple system atrophy;
LIHC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.6	-0.34	1.55e-10	Total body bone mineral density;
LIHC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg11846333	chr4:119757529	SEC24D	0.68	6.09	0.31	3.06e-9	Cannabis dependence symptom count;
LIHC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.7e-10	Uric acid levels;
LIHC	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	12.99	0.57	1.19e-31	Birth weight;
LIHC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg23244877	chr17:73518230	TSEN54	0.34	5.74	0.3	2.04e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	trans	rs4704846	0.660	rs246879	chr5:156556846	T/G	cg02632742	chr2:60187357	NA	-0.6	-6.04	-0.31	3.99e-9	Blood protein levels;
LIHC	cis	rs4700695	1.000	rs3846481	chr5:65417803	T/C	cg21114390	chr5:65439923	SFRS12	-0.46	-5.75	-0.3	1.93e-8	Facial morphology (factor 19);
LIHC	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.62	8.98	0.44	1.88e-17	Monocyte count;
LIHC	cis	rs611744	0.967	rs475865	chr8:109235858	G/C	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.72	9.0	0.44	1.56e-17	Schizophrenia;
LIHC	cis	rs4908760	0.931	rs1463049	chr1:8597108	A/T	cg20416874	chr1:8611966	RERE	-0.7	-15.26	-0.64	1.89e-40	Vitiligo;
LIHC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.55	8.54	0.42	4.34e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.46	0.33	3.54e-10	Bipolar disorder;
LIHC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg16506815	chr2:162101123	NA	0.47	7.77	0.39	9.13e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.29	-6.83	-0.35	3.85e-11	Menarche (age at onset);
LIHC	cis	rs244293	0.965	rs244361	chr17:53191356	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.26e-13	Menarche (age at onset);
LIHC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.24	0.36	3.06e-12	Aortic root size;
LIHC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg14580859	chr9:123691850	NA	0.39	6.79	0.34	5.1e-11	Rheumatoid arthritis;
LIHC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.77	12.31	0.55	4.55e-29	Corneal astigmatism;
LIHC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.49	6.51	0.33	2.75e-10	Emphysema distribution in smoking;
LIHC	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.34	-0.32	7.24e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.47	-7.89	-0.39	3.99e-14	Longevity;Endometriosis;
LIHC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.46	0.33	3.54e-10	Cognitive test performance;
LIHC	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	0.77	10.48	0.49	1.86e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.45	6.08	0.31	3.23e-9	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27305525	chr1:154955752	FLAD1	0.47	7.3	0.37	1.99e-12	Pancreatic cancer;
LIHC	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.95	-10.48	-0.49	1.78e-22	Neuroticism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03009463	chr7:17980271	SNX13	-0.48	-6.64	-0.34	1.26e-10	Pancreatic cancer;
LIHC	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.38	5.73	0.3	2.2e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs3812111	0.658	rs513218	chr6:116480458	A/G	cg08036074	chr6:116424633	NT5DC1	-0.46	-7.73	-0.39	1.17e-13	Age-related macular degeneration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18029761	chr10:134901301	GPR123	-0.44	-7.56	-0.38	3.69e-13	Cognitive function;
LIHC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	0.84	14.98	0.63	2.33e-39	Exhaled nitric oxide output;
LIHC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg15902774	chr15:75289873	SCAMP5	0.46	6.43	0.33	4.32e-10	Lung cancer;
LIHC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.29	-6.93	-0.35	2.07e-11	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27570636	chr1:214454189	SMYD2	0.48	7.19	0.36	3.99e-12	Pancreatic cancer;
LIHC	cis	rs7188697	0.922	rs40188	chr16:58567761	T/A	cg02549819	chr16:58548995	SETD6	-0.45	-7.16	-0.36	5.04e-12	QT interval;
LIHC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg11212589	chr17:38028394	ZPBP2	0.35	7.39	0.37	1.13e-12	Self-reported allergy;
LIHC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg02187348	chr16:89574699	SPG7	0.63	9.97	0.47	1.03e-20	Multiple myeloma (IgH translocation);
LIHC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	3.07e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs12744310	0.887	rs12047272	chr1:41801943	G/A	cg03962019	chr1:41807865	NA	0.39	6.34	0.32	7.17e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.91	-0.43	3.1e-17	Ulcerative colitis;
LIHC	cis	rs10838687	0.800	rs1051006	chr11:47306585	C/T	cg26139080	chr11:47293733	MADD	-0.42	-5.86	-0.3	1.09e-8	Proinsulin levels;
LIHC	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-5.74	-0.3	2.08e-8	Morning vs. evening chronotype;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg07068998	chr1:115259668	NRAS;CSDE1	-0.5	-6.71	-0.34	7.94e-11	Electroencephalogram traits;
LIHC	cis	rs3018712	0.508	rs4930582	chr11:68411104	C/T	cg16797656	chr11:68205561	LRP5	-0.44	-5.83	-0.3	1.28e-8	Total body bone mineral density;
LIHC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	11.75	0.54	5.28e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg04592579	chr7:75616294	TMEM120A	0.39	6.79	0.34	5.04e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.31	-0.32	8.78e-10	Metabolite levels;
LIHC	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.93	-0.31	7.57e-9	Bipolar disorder;
LIHC	cis	rs6596100	0.538	rs17516673	chr5:132196711	C/T	cg02081065	chr5:132209139	LEAP2	0.29	6.3	0.32	9.39e-10	Breast cancer;
LIHC	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.78	-11.58	-0.53	2.17e-26	Personality dimensions;
LIHC	cis	rs11663156	0.804	rs12965192	chr18:50906825	C/A	cg24270629	chr18:50823537	DCC	0.5	7.09	0.36	7.79e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7614311	0.689	rs2276863	chr3:63849043	C/A	cg22134162	chr3:63841271	THOC7	-0.56	-6.32	-0.32	8.02e-10	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-7.17	-0.36	4.59e-12	Platelet count;
LIHC	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.56	0.46	2.44e-19	Morning vs. evening chronotype;
LIHC	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	0.87	14.24	0.61	1.83e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.24	0.32	1.29e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.93	15.37	0.64	6.85e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.98	17.78	0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg00101154	chr16:420108	MRPL28	-0.61	-8.36	-0.41	1.6e-15	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg08890338	chr13:113700818	MCF2L	-0.36	-5.75	-0.3	2.03e-8	Systolic blood pressure;
LIHC	cis	rs2834256	0.924	rs2834244	chr21:35035012	T/A	cg14850771	chr21:34775459	IFNGR2	0.42	6.49	0.33	2.94e-10	Red cell distribution width;
LIHC	cis	rs1559088	0.847	rs7255968	chr19:33601902	A/T	cg27124370	chr19:33622961	WDR88	0.53	8.29	0.41	2.56e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.44	6.92	0.35	2.23e-11	Cognitive function;
LIHC	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg27398547	chr14:60952738	C14orf39	0.8	9.05	0.44	1.13e-17	Gut microbiota (bacterial taxa);
LIHC	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.4	-6.36	-0.33	6.29e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LIHC	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg20435097	chr10:126320824	FAM53B	0.37	6.29	0.32	9.5e-10	Asthma;
LIHC	trans	rs11088226	0.581	rs1967870	chr21:33882858	A/G	cg09050820	chr6:167586206	TCP10L2	0.48	7.47	0.37	6.8e-13	Gastritis;
LIHC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.93	17.8	0.69	1.27e-50	Menopause (age at onset);
LIHC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.97	-18.68	-0.71	3.55e-54	Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10292851	chr8:101572103	ANKRD46	0.45	6.17	0.32	1.88e-9	Pancreatic cancer;
LIHC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.62	-10.98	-0.51	3.26e-24	Mean corpuscular volume;
LIHC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-9.26	-0.45	2.29e-18	Morning vs. evening chronotype;
LIHC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg11764359	chr7:65958608	NA	-0.58	-6.06	-0.31	3.62e-9	Diabetic kidney disease;
LIHC	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg07541023	chr7:19748670	TWISTNB	0.49	7.0	0.35	1.34e-11	Thyroid stimulating hormone;
LIHC	cis	rs151997	0.538	rs1345777	chr5:50263788	A/G	cg06027927	chr5:50259733	NA	-0.52	-6.32	-0.32	7.97e-10	Callous-unemotional behaviour;
LIHC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.33	2.99e-10	Alzheimer's disease;
LIHC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22442454	chr1:209979470	IRF6	0.41	6.16	0.32	2.04e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	6.43	0.33	4.23e-10	Initial pursuit acceleration;
LIHC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.44	6.44	0.33	4.13e-10	Methadone dose in opioid dependence;
LIHC	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg10790698	chr19:18539756	SSBP4	-0.37	-7.58	-0.38	3.21e-13	Breast cancer;
LIHC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg03128534	chr1:43423976	SLC2A1	-0.46	-5.79	-0.3	1.64e-8	Red cell distribution width;
LIHC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.48	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg20016023	chr10:99160130	RRP12	-0.39	-6.26	-0.32	1.18e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.18	-0.32	1.78e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-6.67	-0.34	1.04e-10	Total body bone mineral density;
LIHC	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.22	-0.41	4.25e-15	Response to antipsychotic treatment;
LIHC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.48	7.47	0.37	6.81e-13	Blood protein levels;
LIHC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.22	-0.41	4.3e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg06238570	chr21:40685208	BRWD1	0.58	6.86	0.35	3.33e-11	Cognitive function;
LIHC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg00750074	chr16:89608354	SPG7	-0.48	-7.71	-0.38	1.4e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.24	-6.53	-0.33	2.42e-10	Type 2 diabetes;
LIHC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg12297030	chr17:43662878	NA	-0.64	-6.2	-0.32	1.65e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12889510	chr2:204399188	RAPH1	0.51	6.84	0.35	3.62e-11	Pancreatic cancer;
LIHC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.37	6.03	0.31	4.29e-9	Prostate cancer;
LIHC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg15105969	chr2:36825350	FEZ2	0.47	5.74	0.3	2.11e-8	Height;
LIHC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.79	12.44	0.56	1.47e-29	Corneal astigmatism;
LIHC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.09	-0.36	7.75e-12	Personality dimensions;
LIHC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-9.08	-0.44	8.97e-18	Gut microbiome composition (summer);
LIHC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.48	-8.53	-0.42	4.86e-16	Lung cancer;
LIHC	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.46	5.74	0.3	2.06e-8	Serum sulfate level;
LIHC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.76	0.3	1.83e-8	Menopause (age at onset);
LIHC	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.34	-6.08	-0.31	3.13e-9	IgG glycosylation;
LIHC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.54	7.65	0.38	2.03e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs12644436	0.602	rs4693186	chr4:88782841	G/A	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg15704280	chr7:45808275	SEPT13	0.61	6.33	0.32	7.57e-10	Axial length;
LIHC	cis	rs10847980	0.590	rs58182048	chr12:123287708	C/T	cg18912006	chr12:123335444	HIP1R	0.73	7.15	0.36	5.33e-12	Adiponectin levels;
LIHC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.84	-0.3	1.19e-8	Coronary artery disease;
LIHC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.34	-0.32	7.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs3761218	0.738	rs4815604	chr20:3772913	C/T	cg25011176	chr20:3776985	CDC25B	-0.41	-5.85	-0.3	1.17e-8	Bipolar disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09439264	chr1:1230073	ACAP3	0.43	6.39	0.33	5.44e-10	Pancreatic cancer;
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg23601095	chr6:26197514	HIST1H3D	0.55	5.83	0.3	1.27e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs1843834	0.634	rs923901	chr2:225477276	A/T	cg22509189	chr2:225307070	NA	-0.62	-7.82	-0.39	6.44e-14	IgE levels in asthmatics (D.p. specific);
LIHC	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.11	0.36	7.03e-12	Breast cancer;
LIHC	cis	rs11630290	0.518	rs56247655	chr15:64171627	G/A	cg12036633	chr15:63758958	NA	-0.59	-5.78	-0.3	1.69e-8	Iris characteristics;
LIHC	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg03934865	chr2:198174659	NA	-0.49	-7.07	-0.36	8.97e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs965469	1.000	rs6051763	chr20:3321616	T/G	cg25506879	chr20:3388711	C20orf194	-0.59	-7.07	-0.36	8.66e-12	IFN-related cytopenia;
LIHC	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.79	10.56	0.5	9.5e-23	Menopause (age at onset);
LIHC	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21659725	chr3:3221576	CRBN	0.57	8.26	0.41	3.27e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.15	0.44	5.34e-18	Coffee consumption (cups per day);
LIHC	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.52	7.03	0.36	1.09e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04317338	chr11:64019027	PLCB3	0.49	6.67	0.34	1.05e-10	Platelet count;
LIHC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.64	-9.98	-0.47	9.21e-21	Glaucoma (primary open-angle);
LIHC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.64	9.26	0.45	2.33e-18	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-0.64	-7.41	-0.37	9.95e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg04166393	chr7:2884313	GNA12	0.35	5.72	0.3	2.32e-8	Height;
LIHC	cis	rs9649465	1.000	rs9649465	chr7:123376560	G/A	cg03229431	chr7:123269106	ASB15	-0.38	-8.17	-0.4	6.25e-15	Migraine;
LIHC	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.61	0.42	2.75e-16	Corneal astigmatism;
LIHC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.97	0.57	1.49e-31	Colorectal cancer;
LIHC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.57	9.89	0.47	1.96e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg07424592	chr7:64974309	NA	0.81	9.2	0.45	3.52e-18	Diabetic kidney disease;
LIHC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg09238746	chr17:78121135	EIF4A3	-0.54	-8.21	-0.41	4.54e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LIHC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.58	-8.87	-0.43	4.07e-17	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs1712517	0.787	rs1163089	chr10:105043964	G/A	cg05636881	chr10:105038444	INA	0.42	6.43	0.33	4.38e-10	Migraine;
LIHC	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-6.73	-0.34	7.37e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.59	10.5	0.49	1.59e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.43	7.59	0.38	3.15e-13	Tuberculosis;
LIHC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.98	0.4	2.19e-14	Tonsillectomy;
LIHC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.8	0.3	1.53e-8	Hepatocellular carcinoma;
LIHC	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-7.09	-0.36	7.86e-12	Metabolite levels;
LIHC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg06238570	chr21:40685208	BRWD1	0.58	6.72	0.34	7.6e-11	Cognitive function;
LIHC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg11279151	chr3:101281821	RG9MTD1	0.39	5.97	0.31	5.91e-9	Colorectal cancer;
LIHC	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-7.07	-0.36	8.61e-12	Morning vs. evening chronotype;
LIHC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.06	0.4	1.29e-14	Motion sickness;
LIHC	cis	rs16958440	0.867	rs80006910	chr18:44696382	C/G	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	15.22	0.64	2.66e-40	Electrocardiographic conduction measures;
LIHC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.53	0.56	6.89e-30	Prudent dietary pattern;
LIHC	cis	rs3762637	0.943	rs28372690	chr3:122283095	G/A	cg24169773	chr3:122142474	KPNA1	-0.45	-8.86	-0.43	4.49e-17	LDL cholesterol levels;
LIHC	cis	rs797680	0.822	rs1572343	chr1:93616202	T/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-5.93	-0.31	7.53e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.43	-0.33	4.38e-10	Type 2 diabetes;
LIHC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg18867708	chr6:26865862	GUSBL1	-0.5	-7.62	-0.38	2.58e-13	Schizophrenia;
LIHC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-0.76	-10.7	-0.5	3.07e-23	Monocyte percentage of white cells;
LIHC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.72	12.06	0.55	3.69e-28	Menopause (age at onset);
LIHC	cis	rs10216189	0.967	rs4724700	chr7:5526789	A/G	cg05318486	chr7:5553423	FBXL18	-0.54	-7.79	-0.39	8.05e-14	Relative hand skill in reading disability;
LIHC	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.62	-0.38	2.56e-13	Prevalent atrial fibrillation;
LIHC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.51	8.39	0.41	1.32e-15	Schizophrenia;
LIHC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.66	-10.4	-0.49	3.2800000000000002e-22	Platelet count;
LIHC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.61	-8.59	-0.42	3.13e-16	Blood metabolite levels;
LIHC	cis	rs7635838	0.827	rs9826044	chr3:11458075	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.66	0.34	1.09e-10	HDL cholesterol;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00777555	chr3:57583074	ARF4	0.48	7.19	0.36	4.08e-12	Pancreatic cancer;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07478662	chr19:5047466	KDM4B	0.36	6.11	0.31	2.69e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7635838	0.929	rs7638724	chr3:11413387	T/G	cg00170343	chr3:11313890	ATG7	0.46	7.32	0.37	1.77e-12	HDL cholesterol;
LIHC	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.82	-13.51	-0.59	1.31e-33	Morning vs. evening chronotype;
LIHC	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg25174290	chr11:3078921	CARS	0.56	8.53	0.42	4.67e-16	Longevity;
LIHC	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.61	9.95	0.47	1.17e-20	Corneal astigmatism;
LIHC	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19671926	chr4:122722719	EXOSC9	0.56	8.63	0.42	2.3e-16	Type 2 diabetes;
LIHC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg22676075	chr6:135203613	NA	0.38	6.26	0.32	1.13e-9	Red blood cell count;
LIHC	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.33	6.94	0.35	1.97e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.41	-6.17	-0.32	1.88e-9	Adiposity;
LIHC	cis	rs10508774	1.000	rs58255751	chr10:32766169	G/A	cg01819863	chr10:32635814	EPC1	0.65	6.08	0.31	3.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg26395211	chr5:140044315	WDR55	-0.4	-5.87	-0.3	1.01e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-16.49	-0.67	2.23e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.48	-6.0	-0.31	5.01e-9	Alzheimer's disease;
LIHC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.71	-12.2	-0.55	1.17e-28	Refractive error;
LIHC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg26441486	chr22:50317300	CRELD2	-0.34	-5.99	-0.31	5.21e-9	Schizophrenia;
LIHC	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.23	-0.48	1.3e-21	Eye color traits;
LIHC	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg27205649	chr11:78285834	NARS2	0.47	7.2	0.36	3.84e-12	Alzheimer's disease (survival time);
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg08469215	chr1:156261351	TMEM79	0.36	5.71	0.3	2.42e-8	Tonsillectomy;
LIHC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.46	1.47e-19	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.13	11.63	0.53	1.48e-26	Opioid sensitivity;
LIHC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	1.03	11.72	0.54	6.64e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.76	0.39	1.01e-13	Lymphocyte counts;
LIHC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.46	6.53	0.33	2.36e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.65	-5.89	-0.3	9.4e-9	Menopause (age at onset);
LIHC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg00343986	chr7:65444356	GUSB	0.39	5.73	0.3	2.26e-8	Aortic root size;
LIHC	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.5	-0.33	2.87e-10	Metabolite levels;
LIHC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.69	-9.87	-0.47	2.26e-20	Initial pursuit acceleration;
LIHC	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg18121669	chr1:26560928	CCDC21	-0.5	-7.56	-0.38	3.72e-13	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs716804	0.621	rs11042717	chr11:10303939	C/T	cg01453529	chr11:10209919	SBF2	0.3	5.97	0.31	6.06e-9	Neuroticism;
LIHC	cis	rs712039	0.652	rs2680719	chr17:35811453	C/T	cg16670864	chr17:35848621	DUSP14	0.34	5.82	0.3	1.38e-8	Tuberculosis;
LIHC	cis	rs2834188	1.000	rs4408796	chr21:34698741	C/G	cg04842828	chr21:34696676	IFNAR1	-0.46	-6.17	-0.32	1.89e-9	Narcolepsy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07030052	chr1:162531143	UAP1	0.49	6.28	0.32	1.04e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-6.23	-0.32	1.4e-9	Renal function-related traits (BUN);
LIHC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg25039879	chr17:56429692	SUPT4H1	0.74	7.81	0.39	6.99e-14	Cognitive test performance;
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02290350	chr8:58132656	NA	0.5	10.46	0.49	2.18e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.98	15.36	0.64	7.13e-41	Obesity;Body mass index;
LIHC	cis	rs10744422	0.800	rs1696320	chr12:123269814	A/G	cg07706471	chr12:123319906	HIP1R	-0.56	-7.3	-0.37	2.05e-12	Schizophrenia;
LIHC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg05044414	chr3:183734942	ABCC5	0.32	5.71	0.3	2.44e-8	Anterior chamber depth;
LIHC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.68	-13.54	-0.59	9.95e-34	Blood protein levels;
LIHC	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.37	-6.48	-0.33	3.29e-10	Asthma;
LIHC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-6.29	-0.32	9.6e-10	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.52	-0.33	2.54e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.48	-7.95	-0.39	2.83e-14	Multiple myeloma (IgH translocation);
LIHC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.32	0.41	2.09e-15	Mean corpuscular volume;
LIHC	cis	rs2412488	1.000	rs4864759	chr4:54259408	G/A	cg22241045	chr4:54363911	LNX1	-0.45	-7.21	-0.36	3.54e-12	DNA methylation (variation);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26789732	chr8:73449127	KCNB2	-0.33	-6.16	-0.32	2.06e-9	Cognitive function;
LIHC	cis	rs11673344	0.864	rs8107192	chr19:37499627	G/A	cg27390819	chr19:37464633	NA	-0.51	-6.24	-0.32	1.26e-9	Obesity-related traits;
LIHC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-9.21	-0.45	3.3e-18	Electroencephalogram traits;
LIHC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.44	0.33	4.01e-10	Prudent dietary pattern;
LIHC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.48	-7.95	-0.39	2.77e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.62	9.18	0.44	4.16e-18	Cognitive ability;
LIHC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg03013999	chr17:37608204	MED1	0.34	5.77	0.3	1.78e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.91	-17.25	-0.68	2.15e-48	Schizophrenia;
LIHC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-7.41	-0.37	1.03e-12	Morning vs. evening chronotype;
LIHC	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.49	6.69	0.34	9.03e-11	Red cell distribution width;
LIHC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.48	7.86	0.39	5.15e-14	Multiple sclerosis;
LIHC	cis	rs7923837	0.651	rs12355158	chr10:94350681	G/A	cg25506282	chr10:94462361	NA	0.34	5.81	0.3	1.45e-8	Body mass index;Multiple sclerosis;
LIHC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.95	-0.51	3.93e-24	Hemoglobin concentration;
LIHC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.52	9.05	0.44	1.14e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.53	-9.35	-0.45	1.15e-18	Blood protein levels;
LIHC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.47	7.22	0.36	3.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs3823572	0.542	rs62470448	chr7:133635618	T/A	cg03336402	chr7:133662267	EXOC4	0.49	6.06	0.31	3.53e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08836144	chr11:66886918	KDM2A	0.45	6.48	0.33	3.23e-10	Pancreatic cancer;
LIHC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.49	-6.25	-0.32	1.25e-9	Menarche (age at onset);
LIHC	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg05697976	chr12:29376483	FAR2	0.29	5.99	0.31	5.43e-9	QT interval;
LIHC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	1.0	9.86	0.47	2.34e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg00677901	chr16:88017247	BANP	0.55	8.14	0.4	7.19e-15	Menopause (age at onset);
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.68	9.86	0.47	2.47e-20	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04738379	chr15:81282102	MESDC2	-0.5	-6.35	-0.32	6.77e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.4	8.48	0.42	6.71e-16	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg04592579	chr7:75616294	TMEM120A	-0.4	-6.97	-0.35	1.64e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.31	-0.32	8.67e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.12	-0.31	2.52e-9	Blood pressure;
LIHC	cis	rs539514	0.516	rs2273996	chr13:76410725	A/G	cg04757411	chr13:76259545	LMO7	0.38	5.93	0.31	7.29e-9	Type 1 diabetes;
LIHC	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.76	13.2	0.58	2e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg16058607	chr15:60298730	NA	-0.51	-6.12	-0.31	2.53e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg19318889	chr4:1322082	MAEA	0.63	9.81	0.47	3.45e-20	Longevity;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg25005279	chr10:135113451	TUBGCP2	0.45	6.07	0.31	3.32e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.86	-9.2	-0.45	3.68e-18	Bone mineral density;
LIHC	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.59	10.54	0.5	1.1e-22	Airflow obstruction;
LIHC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg21573476	chr21:45109991	RRP1B	0.45	8.13	0.4	8.15e-15	Mean corpuscular volume;
LIHC	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.8	0.35	4.79e-11	Type 2 diabetes;
LIHC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg19680672	chr10:131412579	MGMT	-0.42	-6.52	-0.33	2.46e-10	Response to temozolomide;
LIHC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg10790698	chr19:18539756	SSBP4	-0.36	-7.47	-0.37	6.75e-13	Breast cancer;
LIHC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.71	-11.28	-0.52	2.75e-25	Systemic lupus erythematosus;
LIHC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.97	-0.35	1.68e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.65	-10.32	-0.49	6.5600000000000005e-22	Monocyte percentage of white cells;
LIHC	cis	rs9649465	0.551	rs10255400	chr7:123388036	G/A	cg03229431	chr7:123269106	ASB15	-0.59	-12.07	-0.55	3.61e-28	Migraine;
LIHC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	6.72	0.34	7.7e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg03146154	chr1:46216737	IPP	0.49	8.18	0.4	5.67e-15	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg08539965	chr1:21396338	EIF4G3	-0.32	-5.78	-0.3	1.71e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.06	-0.31	3.63e-9	Resting heart rate;
LIHC	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.42	7.94	0.39	2.85e-14	Height;
LIHC	cis	rs57590327	0.503	rs9874184	chr3:81505439	C/T	cg07356753	chr3:81810745	GBE1	0.46	6.84	0.35	3.7e-11	Extraversion;
LIHC	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg04865290	chr3:52927548	TMEM110	-0.44	-6.51	-0.33	2.61e-10	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.61	7.52	0.38	4.92e-13	Coronary artery disease;
LIHC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.42	-0.37	9.24e-13	Bipolar disorder and schizophrenia;
LIHC	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.4	-5.82	-0.3	1.33e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.47	8.22	0.41	4.38e-15	N-glycan levels;
LIHC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg06466757	chr4:1255808	NA	0.35	5.78	0.3	1.64e-8	Obesity-related traits;
LIHC	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	8.74	0.43	1.05e-16	Eosinophil percentage of white cells;
LIHC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.05	0.31	3.85e-9	Renal cell carcinoma;
LIHC	cis	rs9921222	0.521	rs9935268	chr16:381562	G/C	cg26913058	chr16:419975	MRPL28	-0.5	-6.85	-0.35	3.37e-11	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.5	8.77	0.43	8.86e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.75	0.39	1.08e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg04306507	chr14:55594613	LGALS3	0.32	6.08	0.31	3.13e-9	Protein biomarker;
LIHC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg02290350	chr8:58132656	NA	0.3	6.85	0.35	3.41e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.23	0.48	1.34e-21	Alzheimer's disease (late onset);
LIHC	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-13.73	-0.6	1.82e-34	Coffee consumption (cups per day);
LIHC	cis	rs11319879	1	rs11319879	chr10:94453475	TA/T	cg25506282	chr10:94462361	NA	0.43	7.32	0.37	1.79e-12	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.82	-0.35	4.05e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.23	-0.36	3.18e-12	Personality dimensions;
LIHC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.67	12.16	0.55	1.6e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.86	0.39	5.1e-14	Prudent dietary pattern;
LIHC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg19774624	chr17:42201019	HDAC5	0.83	12.62	0.56	2.98e-30	Total body bone mineral density;
LIHC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.71	-0.3	2.42e-8	Neuroticism;
LIHC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.71e-10	Waist circumference;Weight;
LIHC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	1.01	18.05	0.7	1.22e-51	Tonsillectomy;
LIHC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.77	0.34	5.54e-11	Body mass index;
LIHC	cis	rs9328573	0.967	rs2082859	chr15:100509132	C/G	cg09918751	chr15:100517450	ADAMTS17	0.43	6.43	0.33	4.18e-10	Urate levels in lean individuals;
LIHC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-11.46	-0.53	5.73e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.41	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg25039879	chr17:56429692	SUPT4H1	0.75	8.41	0.41	1.1e-15	Cognitive test performance;
LIHC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs17021463	0.643	rs17311521	chr4:95298060	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.88	-0.35	2.88e-11	Testicular germ cell tumor;
LIHC	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	0.77	8.62	0.42	2.44e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	7.77	0.39	9.25e-14	Bipolar disorder and schizophrenia;
LIHC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.42	7.59	0.38	3.17e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.37	0.66	6.68e-45	Smoking behavior;
LIHC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.84	0.47	2.86e-20	Electroencephalogram traits;
LIHC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.79	-7.63	-0.38	2.33e-13	Diabetic retinopathy;
LIHC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.22	0.32	1.45e-9	Electroencephalogram traits;
LIHC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.45	0.66	3.47e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14396892	chr9:96623032	NA	0.33	6.46	0.33	3.6e-10	DNA methylation (variation);
LIHC	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg18898632	chr2:242989856	NA	-0.57	-7.72	-0.39	1.32e-13	Obesity-related traits;
LIHC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.34	5.86	0.3	1.1e-8	Schizophrenia;
LIHC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.96	-17.88	-0.7	5.74e-51	Breast cancer;
LIHC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg03146154	chr1:46216737	IPP	0.5	8.54	0.42	4.4e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg13660082	chr14:53194042	PSMC6	-0.44	-7.65	-0.38	2.06e-13	Alzheimer's disease (late onset);
LIHC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.33	6.53	0.33	2.33e-10	Renal cell carcinoma;
LIHC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.59	8.53	0.42	4.84e-16	Platelet count;
LIHC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-8.28	-0.41	2.74e-15	Gut microbiome composition (summer);
LIHC	cis	rs243505	0.762	rs1019218	chr7:148488964	C/T	cg09806900	chr7:148480153	CUL1	0.45	6.7	0.34	8.77e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	12.89	0.57	2.95e-31	Alzheimer's disease;
LIHC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg00656387	chr3:40428638	ENTPD3	-0.43	-7.18	-0.36	4.28e-12	Renal cell carcinoma;
LIHC	cis	rs2019216	1.000	rs3751916	chr17:21909270	T/C	cg22648282	chr17:21454238	C17orf51	-0.36	-6.33	-0.32	7.65e-10	Pelvic organ prolapse;
LIHC	cis	rs9658691	0.607	rs9658786	chr10:90776349	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.71	5.74	0.3	2.06e-8	Mosquito bite size;
LIHC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.17	-0.52	6.66e-25	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.75	9.49	0.46	4.22e-19	Morning vs. evening chronotype;
LIHC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.3	-0.37	2.07e-12	Pancreatic cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05644321	chr20:20693493	RALGAPA2	0.46	7.76	0.39	9.67e-14	Pancreatic cancer;
LIHC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.76	14.19	0.61	2.9e-36	Crohn's disease;
LIHC	cis	rs332507	0.789	rs13097459	chr3:124398112	C/T	cg05980111	chr3:124395277	KALRN	0.45	6.99	0.35	1.49e-11	Plateletcrit;
LIHC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.97	20.63	0.74	5.06e-62	Bone mineral density;
LIHC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg03037974	chr15:76606532	NA	0.74	14.59	0.62	7.65e-38	Blood metabolite levels;
LIHC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.77	12.8	0.57	6.22e-31	Psoriasis;
LIHC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg04865290	chr3:52927548	TMEM110	-0.51	-5.9	-0.3	8.82e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.51	-7.44	-0.37	8.07e-13	Total body bone mineral density;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02128981	chr11:58904901	NA	0.5	6.3	0.32	9.36e-10	Lung function (FEV1);
LIHC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.35	6.44	0.33	4.17e-10	Aortic root size;
LIHC	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.44	6.92	0.35	2.3e-11	Mean corpuscular volume;
LIHC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg24203234	chr3:128598194	ACAD9	0.44	6.18	0.32	1.78e-9	IgG glycosylation;
LIHC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.72	10.74	0.5	2.22e-23	Body mass index;
LIHC	cis	rs7116495	0.867	rs510925	chr11:71809500	C/T	cg10381502	chr11:71823885	C11orf51	0.94	8.64	0.42	2.15e-16	Severe influenza A (H1N1) infection;
LIHC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg10319629	chr12:132285459	NA	-0.43	-7.53	-0.38	4.66e-13	Migraine;
LIHC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.66	13.73	0.6	1.84e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.4	0.33	5.27e-10	Rheumatoid arthritis;
LIHC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.04	14.42	0.61	3.75e-37	Cognitive function;
LIHC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg18887096	chr2:219472410	PLCD4	0.38	6.54	0.33	2.21e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg00647820	chr17:40259828	DHX58	-0.28	-5.91	-0.3	8.35e-9	Fibrinogen levels;
LIHC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.8	0.57	6.66e-31	Prudent dietary pattern;
LIHC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.87	0.35	3.02e-11	Nonalcoholic fatty liver disease;
LIHC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.61	6.71	0.34	7.86e-11	Alzheimer's disease;
LIHC	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.59	8.74	0.43	1.06e-16	Recombination rate (females);
LIHC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg20607798	chr8:58055168	NA	0.49	6.07	0.31	3.33e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.41	5.91	0.3	8.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.41	7.8	0.39	7.39e-14	Schizophrenia;
LIHC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg03146154	chr1:46216737	IPP	-0.38	-6.26	-0.32	1.17e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.03	15.98	0.65	2.57e-43	Breast cancer;
LIHC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.96	17.29	0.68	1.42e-48	Breast cancer;
LIHC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.41	0.59	2.97e-33	Cognitive test performance;
LIHC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.45	-7.56	-0.38	3.71e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs13088645	0.652	rs13074557	chr3:134153526	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.38	6.83	0.35	4.01e-11	Coronary artery disease;
LIHC	cis	rs9473924	0.954	rs9463653	chr6:50835180	A/G	cg14470998	chr6:50812995	TFAP2B	0.44	6.57	0.33	1.86e-10	Body mass index;
LIHC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.16	0.4	6.3e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs4908768	0.501	rs7518608	chr1:8557320	C/G	cg20416874	chr1:8611966	RERE	-0.68	-14.36	-0.61	6.45e-37	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.56	-8.94	-0.44	2.47e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.79	11.92	0.54	1.2100000000000001e-27	Intelligence (multi-trait analysis);
LIHC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg06598544	chr20:61472147	COL9A3	-0.84	-7.72	-0.39	1.31e-13	Obesity-related traits;
LIHC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.88	-19.67	-0.73	3.6e-58	Height;
LIHC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.73	0.65	2.41e-42	Chronic sinus infection;
LIHC	cis	rs3748682	0.731	rs3891572	chr1:38298876	C/T	cg12658694	chr1:38397304	INPP5B	0.43	5.92	0.3	7.76e-9	Hypothyroidism;
LIHC	trans	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg20980879	chr20:33128552	DYNLRB1	0.35	6.43	0.33	4.33e-10	Eotaxin levels;
LIHC	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg10560079	chr2:191398806	TMEM194B	-0.42	-6.0	-0.31	5.15e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	trans	rs3858145	0.588	rs731063	chr10:70043190	A/G	cg04882175	chr6:131122610	NA	0.49	6.14	0.32	2.29e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LIHC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg00529422	chr1:16285251	ZBTB17	-0.34	-6.45	-0.33	3.71e-10	Systolic blood pressure;
LIHC	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00938859	chr5:1591904	SDHAP3	-0.49	-6.42	-0.33	4.64e-10	Breast cancer;
LIHC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.43e-16	Motion sickness;
LIHC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg16836995	chr17:43662488	NA	-0.74	-7.65	-0.38	2e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	5.77	0.3	1.79e-8	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	6.32	0.32	7.98e-10	Schizophrenia;
LIHC	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg01652190	chr22:50026171	C22orf34	-0.33	-7.49	-0.38	6e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.59	-6.61	-0.34	1.5e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.66	0.34	1.1e-10	Dupuytren's disease;
LIHC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-10.57	-0.5	8.77e-23	Diastolic blood pressure;
LIHC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.6	9.81	0.47	3.63e-20	Resting heart rate;
LIHC	cis	rs6061231	0.958	rs2427304	chr20:60953584	G/A	cg03945807	chr20:60948434	NA	0.44	6.81	0.35	4.32e-11	Colorectal cancer;
LIHC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.72	-10.98	-0.51	3.13e-24	Aortic root size;
LIHC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-7.26	-0.37	2.56e-12	Personality dimensions;
LIHC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.34	6.77	0.34	5.69e-11	Renal cell carcinoma;
LIHC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.5	8.19	0.4	5.38e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs2016586	0.895	rs4821437	chr22:36113450	T/A	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	7.96e-10	Body mass index;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25430094	chr5:42423577	GHR	0.44	6.68	0.34	9.94e-11	Lung function (FEV1/FVC);
LIHC	cis	rs970821	0.667	rs2891799	chr8:124744660	A/G	cg00283535	chr8:124749564	ANXA13	0.42	7.88	0.39	4.47e-14	Breast cancer;
LIHC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.15	-0.32	2.13e-9	Mean corpuscular volume;
LIHC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.06	-0.31	3.63e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs12500138	0.557	rs56859187	chr4:166182792	A/G	cg25064052	chr4:166216151	KLHL2	-0.65	-6.01	-0.31	4.63e-9	Cognitive function;
LIHC	cis	rs4700695	0.534	rs153395	chr5:65426669	T/A	cg21114390	chr5:65439923	SFRS12	-0.51	-5.83	-0.3	1.29e-8	Facial morphology (factor 19);
LIHC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.42	-0.37	9.14e-13	Body mass index;
LIHC	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.55	0.33	2.09e-10	Lymphocyte counts;
LIHC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.53	-6.64	-0.34	1.21e-10	Pancreatic cancer;
LIHC	trans	rs4290604	0.748	rs7594554	chr2:238065981	A/G	cg15676719	chr1:167598521	RCSD1	-0.48	-6.23	-0.32	1.34e-9	Asthma;
LIHC	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.4	-6.23	-0.32	1.4e-9	Breast cancer;
LIHC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.47	-9.78	-0.47	4.55e-20	Immature fraction of reticulocytes;
LIHC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.77	0.54	4.4e-27	Motion sickness;
LIHC	cis	rs9473924	0.542	rs36093098	chr6:50833931	G/A	cg14470998	chr6:50812995	TFAP2B	0.99	11.3	0.52	2.18e-25	Body mass index;
LIHC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg05110241	chr16:68378359	PRMT7	-0.62	-6.87	-0.35	3.08e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21448741	chr8:58168803	NA	0.37	6.9	0.35	2.48e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.43	6.01	0.31	4.65e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg05082376	chr22:42548792	NA	-0.4	-5.89	-0.3	9.43e-9	Schizophrenia;
LIHC	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.5	9.52	0.46	3.1400000000000002e-19	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.41	8.14	0.4	7.62e-15	Renal cell carcinoma;
LIHC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg15691649	chr6:25882328	NA	0.49	6.81	0.35	4.49e-11	Blood metabolite levels;
LIHC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.36	-6.17	-0.32	1.88e-9	Headache;
LIHC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	11.01	0.51	2.54e-24	Prudent dietary pattern;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25328417	chr13:50655384	DLEU1;DLEU2	0.42	6.21	0.32	1.56e-9	Cognitive function;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12879381	chr18:12326166	TUBB6	0.47	6.22	0.32	1.44e-9	Hepatitis;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.43	-6.03	-0.31	4.3e-9	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LIHC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07305463	chr2:136567211	LCT	-0.38	-5.85	-0.3	1.18e-8	Corneal structure;
LIHC	cis	rs62158211	0.826	rs62158168	chr2:114078381	C/G	cg17784749	chr2:114082611	LOC440839	0.65	7.74	0.39	1.1e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LIHC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	11.58	0.53	2.22e-26	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.4	5.9	0.3	8.58e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.59	0.56	4.01e-30	Prudent dietary pattern;
LIHC	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.86	-0.47	2.42e-20	Hemoglobin concentration;
LIHC	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg09572067	chr16:29127029	RRN3P2	0.52	8.28	0.41	2.88e-15	Menopause (age at onset);
LIHC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08280861	chr8:58055591	NA	0.55	6.38	0.33	5.82e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.77	12.46	0.56	1.26e-29	Corneal astigmatism;
LIHC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	7.02	0.35	1.18e-11	Sum eosinophil basophil counts;Eosinophil counts;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08836144	chr11:66886918	KDM2A	0.56	7.41	0.37	1.02e-12	Hepatitis;
LIHC	trans	rs1875517	0.510	rs11721241	chr3:117329656	A/C	cg19819135	chr1:70710422	SFRS11	0.33	6.11	0.31	2.76e-9	Waist circumference;
LIHC	cis	rs9309473	1.000	rs58603761	chr2:73726605	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.93	-0.35	2.04e-11	Metabolite levels;
LIHC	cis	rs1144333	1.000	rs5745542	chr1:76365073	C/G	cg22875332	chr1:76189707	ACADM	0.4	6.22	0.32	1.47e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.54	9.49	0.46	4.09e-19	Systemic lupus erythematosus;
LIHC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.43	6.34	0.32	7.42e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg00204748	chr12:29376779	FAR2	0.4	7.47	0.37	6.78e-13	QT interval;
LIHC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg18478394	chr8:109455254	TTC35	0.41	7.01	0.35	1.28e-11	Dupuytren's disease;
LIHC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.83	-0.3	1.31e-8	Personality dimensions;
LIHC	trans	rs6489882	0.510	rs61478890	chr12:113364375	A/G	cg10175203	chr3:128143634	NA	0.39	6.39	0.33	5.57e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg07959070	chr22:50026188	C22orf34	-0.33	-8.02	-0.4	1.72e-14	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-7.45	-0.37	7.64e-13	Cognitive function;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26195366	chr10:102242535	WNT8B	-0.43	-6.16	-0.32	2.06e-9	Cognitive function;
LIHC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg20195005	chr22:42527684	CYP2D6	0.31	5.75	0.3	1.94e-8	Birth weight;
LIHC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.59	0.59	6.27e-34	Lung cancer in ever smokers;
LIHC	cis	rs847649	0.692	rs1541519	chr7:102466741	G/T	cg18108683	chr7:102477205	FBXL13	-0.52	-8.01	-0.4	1.78e-14	Morning vs. evening chronotype;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.36	6.1	0.31	2.85e-9	Height;
LIHC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.82	13.3	0.58	8.21e-33	Colorectal cancer;
LIHC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19623624	chr10:135278901	LOC619207	-0.45	-6.97	-0.35	1.65e-11	Systemic lupus erythematosus;
LIHC	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.61	-11.01	-0.51	2.45e-24	Breast cancer;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00611675	chr8:128748464	MYC	0.41	6.05	0.31	3.71e-9	Lung function (FEV1/FVC);
LIHC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.62	8.98	0.44	1.89e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs8049603	0.945	rs3169494	chr16:23076172	A/G	cg16484020	chr16:23217411	SCNN1G	-0.26	-5.74	-0.3	2.08e-8	Multiple sclerosis;
LIHC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.69	-7.07	-0.36	8.6e-12	Vitiligo;
LIHC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.92	0.51	5.04e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.59	8.6	0.42	2.89e-16	Emphysema distribution in smoking;
LIHC	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.55	-8.19	-0.4	5.35e-15	Body mass index;
LIHC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg18357645	chr12:58087776	OS9	-0.45	-6.85	-0.35	3.48e-11	Multiple sclerosis;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18263451	chr1:25573180	C1orf63	-0.42	-6.04	-0.31	4.11e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08677398	chr8:58056175	NA	0.38	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6831256	0.550	rs9993109	chr4:3473659	A/G	cg08741688	chr4:3415352	RGS12	-0.4	-5.86	-0.3	1.11e-8	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg04585227	chr7:158671570	WDR60	0.43	6.4	0.33	5.2e-10	Longevity;
LIHC	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-6.04	-0.31	3.96e-9	Calcium levels;
LIHC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.44	5.8	0.3	1.55e-8	Initial pursuit acceleration;
LIHC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	8.88	0.43	3.91e-17	Menarche (age at onset);
LIHC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg16797656	chr11:68205561	LRP5	0.51	8.01	0.4	1.84e-14	Total body bone mineral density;
LIHC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.71	11.25	0.52	3.29e-25	Corneal astigmatism;
LIHC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg19645103	chr12:69753606	YEATS4	-0.44	-5.89	-0.3	9.4e-9	Response to diuretic therapy;
LIHC	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.67	-10.29	-0.49	8.21e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	0.94	19.17	0.72	3.79e-56	Schizophrenia;
LIHC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg22633049	chr21:46681294	NA	-0.37	-6.31	-0.32	8.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg18357645	chr12:58087776	OS9	-0.43	-6.13	-0.31	2.37e-9	Multiple sclerosis;
LIHC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg13957321	chr17:43675089	NA	-0.49	-7.86	-0.39	4.98e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.92	-0.35	2.2e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.99	-0.35	1.45e-11	IgG glycosylation;
LIHC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.54	7.53	0.38	4.5e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.93	0.39	3.04e-14	Alzheimer's disease;
LIHC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.35	5.92	0.3	7.8e-9	Height;
LIHC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg27432699	chr2:27873401	GPN1	-0.49	-7.12	-0.36	6.6e-12	Total body bone mineral density;
LIHC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg00126636	chr16:237282	NA	0.4	6.96	0.35	1.71e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs1555322	0.530	rs2425044	chr20:33869735	C/T	cg08210727	chr20:33865349	NA	0.51	5.81	0.3	1.42e-8	Attention deficit hyperactivity disorder;
LIHC	cis	rs11971779	0.680	rs6947215	chr7:139026638	A/G	cg07862535	chr7:139043722	LUC7L2	0.53	9.48	0.46	4.45e-19	Diisocyanate-induced asthma;
LIHC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.23e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.98	-0.35	1.55e-11	Lewy body disease;
LIHC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg02297831	chr4:17616191	MED28	0.42	6.71	0.34	8.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg17724175	chr1:150552817	MCL1	0.38	7.59	0.38	3.03e-13	Melanoma;
LIHC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.47	0.42	7.16e-16	Birth weight;
LIHC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.49	7.29	0.37	2.2e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.49	6.09	0.31	3.1e-9	Ulcerative colitis;
LIHC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	7.56	0.38	3.86e-13	HDL cholesterol;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07738955	chr17:38333606	RAPGEFL1	-0.4	-6.14	-0.32	2.3e-9	Calcium levels;
LIHC	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.45	-7.54	-0.38	4.39e-13	Neuroticism;
LIHC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.41	8.91	0.43	3.19e-17	Erythrocyte sedimentation rate;
LIHC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.29	-16.89	-0.67	5.55e-47	Diabetic kidney disease;
LIHC	cis	rs903552	1.000	rs8027380	chr15:102005810	T/C	cg25677261	chr15:102009856	PCSK6	-0.46	-6.24	-0.32	1.29e-9	Diabetic kidney disease;
LIHC	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-6.27	-0.32	1.07e-9	Response to simvastatin treatment (PCSK9 protein level change);
LIHC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.84	0.43	5.31e-17	Menarche (age at onset);
LIHC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.61	10.32	0.49	6.68e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs61677309	1.000	rs61706007	chr11:118167278	T/G	cg06090739	chr11:118230722	UBE4A	0.35	6.37	0.33	6.26e-10	Lung cancer in ever smokers;
LIHC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.54	-0.33	2.23e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26734620	chr12:56694298	CS	1.26	11.0	0.51	2.78e-24	Psoriasis vulgaris;
LIHC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.32	6.2	0.32	1.65e-9	Tonsillectomy;
LIHC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.35	-5.93	-0.31	7.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.45	0.42	8.7e-16	Lung cancer in ever smokers;
LIHC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	10.65	0.5	4.61e-23	Lymphocyte counts;
LIHC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg14440974	chr22:39074834	NA	-0.42	-6.84	-0.35	3.56e-11	Menopause (age at onset);
LIHC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg23485639	chr6:28045615	ZNF165	0.38	5.89	0.3	9.04e-9	Parkinson's disease;
LIHC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.52e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16346588	chr10:242978	ZMYND11	0.38	5.86	0.3	1.07e-8	Psychosis in Alzheimer's disease;
LIHC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.76	-13.01	-0.58	9.96e-32	Aortic root size;
LIHC	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg08539965	chr1:21396338	EIF4G3	0.33	5.78	0.3	1.69e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.36	-6.08	-0.31	3.28e-9	Paraoxonase activity;
LIHC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.34	0.58	5.91e-33	Cognitive test performance;
LIHC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.51	8.99	0.44	1.73e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23187103	chr8:128748481	MYC	0.42	6.23	0.32	1.4e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.83	0.3	1.31e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg07590584	chr13:113140145	TUBGCP3	0.47	6.37	0.33	5.94e-10	Systolic blood pressure;
LIHC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg15691649	chr6:25882328	NA	0.52	6.49	0.33	2.97e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7903847	0.701	rs11189173	chr10:99138792	T/C	cg06359132	chr10:99160096	RRP12	-0.4	-5.91	-0.3	8.13e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	1.2	13.91	0.6	3.69e-35	Eosinophil percentage of granulocytes;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg04054907	chr8:17104065	CNOT7;VPS37A	0.45	6.05	0.31	3.9e-9	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.56	-0.33	2.03e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	0.92	16.54	0.67	1.44e-45	Parkinson's disease;
LIHC	cis	rs1190552	0.639	rs3742446	chr14:102975572	C/T	cg10241871	chr14:102965420	TECPR2	-0.47	-6.91	-0.35	2.38e-11	Blood protein levels;
LIHC	cis	rs4908768	0.906	rs78110809	chr1:8573008	C/T	cg20416874	chr1:8611966	RERE	0.59	9.07	0.44	9.77e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.5	-7.69	-0.38	1.54e-13	Extraversion;
LIHC	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.49	7.32	0.37	1.74e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg07134254	chr20:33865797	NA	0.5	5.97	0.31	5.9e-9	Attention deficit hyperactivity disorder;
LIHC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	14.4	0.61	4.38e-37	Menopause (age at onset);
LIHC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.5	0.53	4.14e-26	Coronary artery disease;
LIHC	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.87	-8.95	-0.44	2.24e-17	Alcohol dependence;Nicotine use;
LIHC	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.9	-0.3	8.64e-9	Diisocyanate-induced asthma;
LIHC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.36	-0.52	1.42e-25	Electrocardiographic conduction measures;
LIHC	cis	rs116248771	0.793	rs6765967	chr3:158347310	T/C	cg16708174	chr3:158430962	RARRES1	0.48	6.45	0.33	3.77e-10	diarrhoeal disease at age 2;
LIHC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.64	-13.57	-0.59	7.22e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	cis	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg16684958	chr7:75615977	POR	0.39	5.9	0.3	8.65e-9	Eotaxin levels;
LIHC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.69	10.84	0.51	9.52e-24	Total body bone mineral density;
LIHC	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.44	-0.42	9.07e-16	Colorectal cancer;
LIHC	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.75	0.39	1.05e-13	Alzheimer's disease;
LIHC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.67	7.41	0.37	1.02e-12	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.36	6.09	0.31	2.96e-9	Height;
LIHC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.29	7.05	0.36	1.02e-11	Primary biliary cholangitis;
LIHC	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.7	-12.19	-0.55	1.24e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.43	5.99	0.31	5.25e-9	QT interval;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg26157802	chr2:220042863	FAM134A;C2orf24	-0.51	-6.07	-0.31	3.4e-9	Systolic blood pressure;
LIHC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.97	0.35	1.62e-11	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07677032	chr17:61819896	STRADA	0.43	6.23	0.32	1.4e-9	Prudent dietary pattern;
LIHC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.96	-12.57	-0.56	4.75e-30	Alzheimer's disease;
LIHC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.38	-8.13	-0.4	7.79e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg15472797	chr10:135243109	NA	-0.36	-5.93	-0.31	7.45e-9	Systemic lupus erythematosus;
LIHC	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.6	-10.72	-0.5	2.53e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs12744310	0.887	rs35021924	chr1:41786907	A/G	cg03962019	chr1:41807865	NA	0.38	6.11	0.31	2.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs12744310	0.887	rs12028244	chr1:41809162	C/T	cg03387723	chr1:41708464	SCMH1	-0.33	-5.89	-0.3	9.22e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.56	-10.65	-0.5	4.72e-23	Mean corpuscular volume;
LIHC	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.32	7.27	0.37	2.45e-12	Blood metabolite ratios;
LIHC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.55	0.33	2.07e-10	Lung cancer;
LIHC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.38	6.06	0.31	3.67e-9	Menopause (age at onset);
LIHC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.37	0.45	1e-18	Bipolar disorder;
LIHC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg09222892	chr1:25734099	RHCE	-0.45	-8.28	-0.41	2.86e-15	Erythrocyte sedimentation rate;
LIHC	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.63	-0.38	2.38e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.77	11.55	0.53	2.86e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.68	9.83	0.47	3.12e-20	Menarche (age at onset);
LIHC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.51	6.95	0.35	1.81e-11	Monobrow;
LIHC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.35	-0.32	6.72e-10	Educational attainment (years of education);
LIHC	cis	rs11166927	1.000	rs12549587	chr8:140804310	G/A	cg16909799	chr8:140841666	TRAPPC9	0.51	8.0	0.4	1.92e-14	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.95	17.52	0.69	1.67e-49	Menopause (age at onset);
LIHC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.82	9.9	0.47	1.76e-20	Cognitive function;
LIHC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.45	-6.27	-0.32	1.11e-9	Initial pursuit acceleration;
LIHC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.8	0.3	1.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg22532475	chr10:104410764	TRIM8	0.36	6.25	0.32	1.19e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.58	9.33	0.45	1.4e-18	Response to antidepressants and depression;
LIHC	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.69	-7.71	-0.38	1.37e-13	Exhaled nitric oxide output;
LIHC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg05896524	chr21:47604654	C21orf56	0.45	6.73	0.34	7.03e-11	Testicular germ cell tumor;
LIHC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg25894440	chr7:65020034	NA	-0.54	-6.22	-0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.59	12.02	0.54	5.34e-28	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	7.91	0.39	3.53e-14	Lung cancer;
LIHC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.43	0.41	9.56e-16	Lung cancer;
LIHC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.59	7.32	0.37	1.83e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.13	0.55	2.1e-28	Mean platelet volume;
LIHC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.61	0.46	1.6e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.75	0.39	1.09e-13	Systemic lupus erythematosus;
LIHC	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.62	11.18	0.52	6.28e-25	Schizophrenia;
LIHC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	7.44	0.37	8.41e-13	Osteoporosis;
LIHC	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg23091122	chr1:110024289	SYPL2	-0.46	-6.09	-0.31	2.96e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.72	7.87	0.39	4.68e-14	Gut microbiome composition (summer);
LIHC	cis	rs7238033	0.663	rs7234986	chr18:43320604	A/G	cg20610511	chr18:43302872	SLC14A1	0.39	6.52	0.33	2.55e-10	Bladder cancer;
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg03785755	chr6:26196794	NA	0.5	5.88	0.3	9.89e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg17724175	chr1:150552817	MCL1	0.38	7.72	0.39	1.31e-13	Melanoma;
LIHC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg13409248	chr3:40428643	ENTPD3	0.41	6.6	0.34	1.53e-10	Renal cell carcinoma;
LIHC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.85	12.77	0.57	8.03e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.49	0.49	1.73e-22	Bladder cancer;
LIHC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg03517284	chr6:25882590	NA	-0.38	-5.76	-0.3	1.83e-8	Height;
LIHC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.64	9.97	0.47	9.9e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs370915	0.542	rs13124558	chr4:187794175	T/C	cg12892747	chr4:187813459	NA	-0.37	-5.74	-0.3	2.07e-8	Gout;
LIHC	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg08917208	chr2:24149416	ATAD2B	1.02	8.29	0.41	2.55e-15	Lymphocyte counts;
LIHC	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.53	-0.33	2.44e-10	Prevalent atrial fibrillation;
LIHC	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.67	7.0	0.35	1.34e-11	Blood protein levels;
LIHC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.63	-11.88	-0.54	1.69e-27	Mean corpuscular volume;
LIHC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg25344623	chr2:136566232	LCT	-0.38	-6.1	-0.31	2.88e-9	Corneal structure;
LIHC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.6	-0.34	1.53e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg07090678	chr1:91966139	CDC7	0.51	7.0	0.35	1.37e-11	Breast cancer;
LIHC	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.45	8.08	0.4	1.12e-14	Coronary artery disease;
LIHC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.44	6.97	0.35	1.64e-11	Melanoma;
LIHC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.08	16.9	0.67	5.37e-47	Breast cancer;
LIHC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.04	0.4	1.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg10824722	chr1:206506826	NA	0.41	6.3	0.32	9.03e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9473924	0.505	rs2223869	chr6:50904239	C/T	cg14470998	chr6:50812995	TFAP2B	0.94	10.92	0.51	5.15e-24	Body mass index;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg27029403	chr14:104029012	BAG5;C14orf153	-0.43	-6.08	-0.31	3.16e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg22834771	chr12:69754056	YEATS4	-0.45	-7.46	-0.37	7.38e-13	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.83	0.3	1.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.32	-0.32	8.38e-10	Subjective well-being;
LIHC	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg23091122	chr1:110024289	SYPL2	-0.45	-5.99	-0.31	5.28e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7129220	0.588	rs60257382	chr11:10122172	C/T	cg01453529	chr11:10209919	SBF2	-0.39	-6.9	-0.35	2.47e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LIHC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg23205692	chr1:25664452	TMEM50A	0.39	6.21	0.32	1.54e-9	Erythrocyte sedimentation rate;
LIHC	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.5	7.87	0.39	4.82e-14	Alzheimer's disease (survival time);
LIHC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg19682013	chr15:45996608	NA	0.41	7.17	0.36	4.71e-12	Waist circumference;Weight;
LIHC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg25204440	chr1:209979598	IRF6	0.53	8.07	0.4	1.24e-14	Cleft lip with or without cleft palate;
LIHC	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.74	0.3	2.12e-8	Rheumatoid arthritis;
LIHC	trans	rs13113518	0.812	rs13125984	chr4:56321269	G/A	cg15358633	chr12:38710606	ALG10B	0.44	6.29	0.32	9.77e-10	Height;
LIHC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.51	8.55	0.42	4.2e-16	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.31	-0.32	8.65e-10	Systemic lupus erythematosus;
LIHC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-7.66	-0.38	1.89e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg04592579	chr7:75616294	TMEM120A	0.39	6.75	0.34	6.41e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs57244997	0.725	rs73028490	chr6:162421657	T/C	cg17173639	chr6:162384350	PARK2	-0.57	-7.23	-0.36	3.11e-12	Mosquito bite size;
LIHC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	10.69	0.5	3.44e-23	Lymphocyte percentage of white cells;
LIHC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.59	-8.55	-0.42	4.31e-16	Blood metabolite levels;
LIHC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.57	-0.46	2.3e-19	Initial pursuit acceleration;
LIHC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.14	0.36	5.5e-12	Lung cancer;
LIHC	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-7.98	-0.4	2.2e-14	Pediatric bone mineral density (spine);
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.46	-6.43	-0.33	4.37e-10	Total body bone mineral density;
LIHC	cis	rs17253792	0.915	rs75296402	chr14:56182491	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-7.41	-0.37	1e-12	Putamen volume;
LIHC	cis	rs35883536	1.000	rs35883536	chr1:101106534	G/A	cg14515779	chr1:101123966	NA	-0.67	-13.22	-0.58	1.65e-32	Monocyte count;
LIHC	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	0.96	7.94	0.39	2.89e-14	Lymphocyte counts;
LIHC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.38	7.75	0.39	1.05e-13	Ewing sarcoma;
LIHC	cis	rs9309473	0.653	rs6718843	chr2:73852505	C/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.65	-0.34	1.13e-10	Metabolite levels;
LIHC	trans	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.5	6.18	0.32	1.78e-9	Ulcerative colitis;
LIHC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.51	-7.01	-0.35	1.24e-11	Menopause (age at onset);
LIHC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.29	7.05	0.36	1.02e-11	Primary biliary cholangitis;
LIHC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-7.09	-0.36	7.53e-12	Electroencephalogram traits;
LIHC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.62	-0.5	6e-23	Breast cancer;
LIHC	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.77	-0.34	5.56e-11	Metabolite levels;
LIHC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg20651018	chr11:3035856	CARS	-0.35	-5.98	-0.31	5.6e-9	Type 2 diabetes;
LIHC	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.79	-11.76	-0.54	4.82e-27	Personality dimensions;
LIHC	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.23	-0.48	1.3e-21	Eye color traits;
LIHC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	11.19	0.52	5.62e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg01231543	chr16:68741748	NA	0.36	5.8	0.3	1.49e-8	Colorectal cancer;
LIHC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02985541	chr2:219472218	PLCD4	0.37	5.95	0.31	6.55e-9	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.44	-0.37	8.28e-13	Obesity-related traits;
LIHC	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg01320579	chr17:75405842	SEPT9	0.54	7.21	0.36	3.6e-12	Airflow obstruction;
LIHC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.75	-13.37	-0.59	4.42e-33	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.6	8.12	0.4	8.33e-15	Tourette syndrome;
LIHC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.58	-7.92	-0.39	3.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.35	5.86	0.3	1.06e-8	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.68	0.8	5.83e-78	Prudent dietary pattern;
LIHC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg13385521	chr17:29058706	SUZ12P	0.75	7.63	0.38	2.35e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.51	-9.02	-0.44	1.4e-17	Total body bone mineral density;
LIHC	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.48	5.98	0.31	5.47e-9	Economic and political preferences (feminism/equality);
LIHC	cis	rs7534824	0.625	rs17610202	chr1:101429724	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	7.17	0.36	4.56e-12	Refractive astigmatism;
LIHC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg03735888	chr19:58951602	ZNF132	-0.4	-7.15	-0.36	5.2e-12	Uric acid clearance;
LIHC	cis	rs7119038	0.865	rs7117261	chr11:118741157	T/C	cg19308663	chr11:118741387	NA	-0.47	-6.07	-0.31	3.45e-9	Sjögren's syndrome;
LIHC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.4	6.93	0.35	2.14e-11	Platelet distribution width;
LIHC	cis	rs12928939	1.000	rs12928939	chr16:71800045	G/A	cg03805757	chr16:71968109	PKD1L3	-0.72	-8.33	-0.41	1.95e-15	Post bronchodilator FEV1;
LIHC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.23	-0.36	3.27e-12	Schizophrenia;
LIHC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.68	-0.42	1.69e-16	Skin colour saturation;
LIHC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-8.18	-0.4	5.66e-15	Parkinson's disease;
LIHC	cis	rs34540877	0.793	rs12979236	chr19:33142895	G/C	cg22980127	chr19:33182716	NUDT19	0.89	6.22	0.32	1.43e-9	Red cell distribution width;
LIHC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg02297831	chr4:17616191	MED28	-0.46	-6.86	-0.35	3.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg27386326	chr11:61587980	NA	0.7	14.85	0.63	7.91e-39	Trans fatty acid levels;
LIHC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.53	-7.87	-0.39	4.8e-14	Age at first birth;
LIHC	cis	rs2997447	0.846	rs7520344	chr1:26397286	C/T	cg19633962	chr1:26362018	EXTL1	-0.68	-6.51	-0.33	2.74e-10	QRS complex (12-leadsum);
LIHC	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.78	-0.43	8.25e-17	Colorectal cancer;
LIHC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.58	-0.38	3.34e-13	Chronic sinus infection;
LIHC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.64	10.01	0.48	7.28e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.55	-9.46	-0.46	5.3e-19	Age at first birth;
LIHC	cis	rs4450131	0.522	rs876352	chr10:126337350	C/T	cg20435097	chr10:126320824	FAM53B	0.69	12.55	0.56	5.58e-30	White blood cell count (basophil);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03710481	chr6:122931605	PKIB	0.44	6.59	0.34	1.66e-10	Calcium levels;
LIHC	cis	rs2708977	0.666	rs17685664	chr2:97315570	C/T	cg01950434	chr2:97203154	ARID5A	0.51	7.34	0.37	1.62e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.56	-8.44	-0.42	8.81e-16	Prostate cancer;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg16586182	chr3:47516702	SCAP	-0.5	-9.09	-0.44	8.32e-18	Colorectal cancer;
LIHC	cis	rs918629	0.798	rs6894651	chr5:95292267	C/T	cg10483112	chr5:95245456	ELL2	-0.35	-6.05	-0.31	3.91e-9	IgG glycosylation;
LIHC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.16	-13.64	-0.59	4.12e-34	White matter hyperintensity burden;
LIHC	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs611744	0.967	rs652485	chr8:109202696	G/A	cg21045802	chr8:109455806	TTC35	0.5	8.62	0.42	2.58e-16	Dupuytren's disease;
LIHC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.6	-9.04	-0.44	1.22e-17	Type 2 diabetes;
LIHC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.56	-9.35	-0.45	1.16e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	7.03	0.36	1.11e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	9.3	0.45	1.65e-18	Platelet count;
LIHC	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.75	12.59	0.56	4.02e-30	Body mass index;
LIHC	cis	rs2380220	0.808	rs2716070	chr6:95912375	T/C	cg04719120	chr6:96025338	MANEA	-0.56	-6.0	-0.31	4.98e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs546131	0.642	rs566798	chr11:34852277	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.62	-8.96	-0.44	2.11e-17	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs2224539	0.605	rs2103946	chr20:38465349	C/G	cg21682942	chr2:85824657	RNF181	0.36	6.13	0.31	2.43e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg14393609	chr7:65229607	NA	-0.38	-5.98	-0.31	5.66e-9	Aortic root size;
LIHC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg11406765	chr11:980039	AP2A2	-0.34	-5.71	-0.3	2.46e-8	Alzheimer's disease (late onset);
LIHC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg14393609	chr7:65229607	NA	0.44	6.56	0.33	2.05e-10	Calcium levels;
LIHC	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.29	6.34	0.32	7.39e-10	Pulmonary function;
LIHC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.66	-9.33	-0.45	1.36e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	11.34	0.52	1.62e-25	HIV-1 control;
LIHC	cis	rs4660306	0.677	rs11211110	chr1:45904815	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.49	-0.33	3.02e-10	Homocysteine levels;
LIHC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.28	0.45	1.98e-18	Eosinophil percentage of white cells;
LIHC	cis	rs4378999	0.660	rs6800279	chr3:51086691	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.39	-5.79	-0.3	1.59e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.71	13.21	0.58	1.71e-32	Mortality in heart failure;
LIHC	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.69	8.44	0.42	9.36e-16	IgG glycosylation;
LIHC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg00204512	chr16:28754710	NA	0.34	6.35	0.32	7.04e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.41	-0.37	1.01e-12	Chronic sinus infection;
LIHC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg23978390	chr7:1156363	C7orf50	0.41	5.79	0.3	1.58e-8	Longevity;Endometriosis;
LIHC	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.16	-0.32	2.06e-9	Prevalent atrial fibrillation;
LIHC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.35	9.09	0.44	7.99e-18	Hemoglobin concentration;
LIHC	cis	rs2625529	0.775	rs4777484	chr15:72376543	T/C	cg16672083	chr15:72433130	SENP8	-0.31	-5.82	-0.3	1.37e-8	Red blood cell count;
LIHC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	5.92	0.3	7.78e-9	Protein C levels;
LIHC	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg10755058	chr3:40428713	ENTPD3	0.37	6.06	0.31	3.63e-9	Renal cell carcinoma;
LIHC	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.74	10.31	0.49	6.87e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.86	12.9	0.57	2.59e-31	Menarche (age at onset);
LIHC	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg18121669	chr1:26560928	CCDC21	-0.49	-7.37	-0.37	1.27e-12	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg00656387	chr3:40428638	ENTPD3	0.49	8.35	0.41	1.73e-15	Renal cell carcinoma;
LIHC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.73	-11.04	-0.51	1.95e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	trans	rs12614435	0.512	rs16866420	chr2:179491235	A/C	cg14011486	chr1:26737247	LIN28	0.46	6.83	0.35	3.79e-11	Atrial fibrillation;
LIHC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg00656387	chr3:40428638	ENTPD3	0.43	6.96	0.35	1.75e-11	Renal cell carcinoma;
LIHC	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.71	12.58	0.56	4.4e-30	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg02811702	chr13:24901961	NA	0.26	6.04	0.31	3.98e-9	Obesity-related traits;
LIHC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.59	-8.01	-0.4	1.77e-14	Sudden cardiac arrest;
LIHC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.87	0.54	1.95e-27	Motion sickness;
LIHC	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.66	-0.42	1.91e-16	Testicular germ cell tumor;
LIHC	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.32	-0.7	1.01e-52	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.67	-10.41	-0.49	3.2800000000000002e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg06766960	chr11:133703094	NA	-0.45	-6.89	-0.35	2.67e-11	Childhood ear infection;
LIHC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.38	5.83	0.3	1.3e-8	Mean corpuscular volume;
LIHC	cis	rs600806	0.813	rs4970760	chr1:109985439	A/G	cg16275483	chr1:110013120	SYPL2	-0.48	-6.03	-0.31	4.33e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.98	-20.13	-0.74	5.24e-60	Coronary artery disease;
LIHC	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.36	-5.9	-0.3	8.51e-9	IgG glycosylation;
LIHC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg11632617	chr15:75315747	PPCDC	-0.45	-6.37	-0.33	6.25e-10	Blood trace element (Zn levels);
LIHC	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg17130504	chr10:102756923	LZTS2	0.55	7.56	0.38	3.84e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.57	8.33	0.41	1.92e-15	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.2	0.45	3.52e-18	Bipolar disorder;
LIHC	trans	rs8113308	0.810	rs11880193	chr19:52448669	G/C	cg14959425	chr7:20447707	ITGB8	-0.47	-6.1	-0.31	2.88e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs3770081	0.590	rs57367442	chr2:86453398	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.72	-7.66	-0.38	1.98e-13	Facial emotion recognition (sad faces);
LIHC	cis	rs13177918	0.603	rs2343806	chr5:149831985	A/T	cg14059543	chr5:149831962	NA	-0.48	-7.5	-0.38	5.53e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs2292096	1.000	rs16847193	chr1:200739337	T/A	cg11814564	chr1:200748674	CAMSAP1L1	-0.47	-6.12	-0.31	2.57e-9	Epilepsy;
LIHC	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg15605315	chr1:45957053	TESK2	0.45	5.89	0.3	9.42e-9	High light scatter reticulocyte count;
LIHC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.39	7.4	0.37	1.09e-12	Schizophrenia;
LIHC	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg25344623	chr2:136566232	LCT	-0.37	-5.88	-0.3	9.9e-9	Corneal structure;
LIHC	cis	rs9378688	0.654	rs2505661	chr6:2326285	G/A	cg12303981	chr6:2244766	GMDS	-0.43	-6.08	-0.31	3.21e-9	Caudate nucleus volume;
LIHC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21545522	chr1:205238299	TMCC2	0.4	7.72	0.39	1.33e-13	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.54	-7.8	-0.39	7.56e-14	Bipolar disorder;
LIHC	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.82	11.89	0.54	1.56e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	7.4	0.37	1.05e-12	Prudent dietary pattern;
LIHC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg08499158	chr17:42289980	UBTF	0.41	6.62	0.34	1.4e-10	Bone mineral density (hip);Bone mineral density;
LIHC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.38	-6.18	-0.32	1.77e-9	Melanoma;
LIHC	cis	rs10503871	0.685	rs7824823	chr8:30322735	G/T	cg26383811	chr8:30366931	RBPMS	-0.45	-7.8	-0.39	7.52e-14	Metabolite levels  (X-11787);
LIHC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.41	-5.91	-0.3	8.06e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-8.5	-0.42	5.96e-16	Neuroticism;
LIHC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.9	0.51	6.15e-24	Alzheimer's disease;
LIHC	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg08345082	chr10:99160200	RRP12	-0.38	-6.45	-0.33	3.72e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	0.96	10.38	0.49	4.04e-22	Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg03929089	chr4:120376271	NA	-0.44	-6.54	-0.33	2.28e-10	HDL cholesterol;
LIHC	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg22705602	chr4:152727874	NA	-0.29	-6.06	-0.31	3.6e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-18.11	-0.7	7e-52	Body mass index;
LIHC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg23283614	chr14:60632532	DHRS7	0.71	7.53	0.38	4.6e-13	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.88	11.66	0.53	1.12e-26	Heart rate;
LIHC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.38	-0.33	5.92e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.83	0.39	6.09e-14	Personality dimensions;
LIHC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg14779329	chr11:130786720	SNX19	-0.38	-5.84	-0.3	1.21e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.55	-0.5	1.01e-22	Response to antipsychotic treatment;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.46	-6.61	-0.34	1.51e-10	Lymphocyte counts;
LIHC	cis	rs13161895	1.000	rs1102191	chr5:179416210	C/T	cg02702477	chr5:179499311	RNF130	0.75	10.32	0.49	6.59e-22	LDL cholesterol;
LIHC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.79	13.35	0.59	5.37e-33	Psoriasis;
LIHC	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-8.43	-0.41	1e-15	Bipolar disorder;
LIHC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.67	-11.16	-0.52	7.28e-25	Pulse pressure;
LIHC	trans	rs10411161	0.810	rs60981935	chr19:52385281	C/T	cg22319618	chr22:45562946	NUP50	-0.59	-7.01	-0.35	1.28e-11	Breast cancer;
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg11766577	chr21:47581405	C21orf56	-0.37	-5.84	-0.3	1.23e-8	Testicular germ cell tumor;
LIHC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.62	10.57	0.5	8.43e-23	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg12698662	chr3:15914712	MIR563	-0.4	-7.52	-0.38	4.88e-13	Mean platelet volume;
LIHC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.92	0.54	1.28e-27	Motion sickness;
LIHC	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-14.56	-0.62	1.01e-37	Electrocardiographic conduction measures;
LIHC	cis	rs9503598	0.521	rs4959834	chr6:3436691	A/C	cg00476032	chr6:3446245	SLC22A23	-0.33	-5.96	-0.31	6.12e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14932796	chr17:55038330	COIL	0.45	7.4	0.37	1.09e-12	Cognitive function;
LIHC	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg15202627	chr4:1685555	FAM53A	0.48	5.74	0.3	2.15e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg07952391	chr2:88470173	THNSL2	-0.41	-5.72	-0.3	2.29e-8	Response to metformin (IC50);
LIHC	trans	rs1430128	0.534	rs1430130	chr2:218608763	G/T	cg19873842	chr12:26204575	RASSF8	-0.57	-6.1	-0.31	2.85e-9	Congenital heart disease (inherited effect);
LIHC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg18478394	chr8:109455254	TTC35	0.42	7.24	0.36	2.98e-12	Dupuytren's disease;
LIHC	cis	rs1434579	0.865	rs1434573	chr19:44923277	A/G	cg15540054	chr19:45004280	ZNF180	0.55	7.51	0.38	5.17e-13	Tuberculosis;
LIHC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.57	-8.3	-0.41	2.45e-15	Coronary artery disease;
LIHC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg18016565	chr1:150552671	MCL1	0.49	9.31	0.45	1.63e-18	Melanoma;
LIHC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg00280220	chr17:61926910	NA	0.44	6.99	0.35	1.48e-11	Prudent dietary pattern;
LIHC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	7.6	0.38	2.93e-13	Tonsillectomy;
LIHC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.73	0.43	1.12e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	1.14	8.87	0.43	4.02e-17	Arsenic metabolism;
LIHC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-10.01	-0.48	7.45e-21	Platelet count;
LIHC	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg04865290	chr3:52927548	TMEM110	-0.48	-7.14	-0.36	5.65e-12	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	0.98	8.27	0.41	3.01e-15	Cannabis dependence symptom count;
LIHC	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg27211696	chr2:191398769	TMEM194B	-0.46	-6.1	-0.31	2.83e-9	Diastolic blood pressure;
LIHC	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-6.09	-0.31	3.05e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.88	-18.1	-0.7	8.06e-52	Height;
LIHC	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.54	0.33	2.22e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-6.48	-0.33	3.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg16740167	chr1:27560800	WDTC1	0.41	6.25	0.32	1.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.2	0.36	3.87e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.95	9.7	0.46	8.02e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.38	0.52	1.14e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs249954	0.559	rs35586	chr16:23677006	A/G	cg09867953	chr16:23706666	ERN2	0.37	6.22	0.32	1.45e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.38	6.18	0.32	1.85e-9	Alcohol dependence;
LIHC	cis	rs57502260	0.704	rs60538784	chr11:68386735	G/A	cg20283391	chr11:68216788	NA	-0.49	-5.99	-0.31	5.26e-9	Total body bone mineral density (age 45-60);
LIHC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.52	-0.33	2.5e-10	Height;
LIHC	trans	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg17675199	chr6:35436792	RPL10A	0.35	6.86	0.35	3.26e-11	Coronary artery disease;
LIHC	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg00012203	chr2:219082015	ARPC2	-0.53	-7.06	-0.36	9.23e-12	Ulcerative colitis;
LIHC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07677032	chr17:61819896	STRADA	-0.44	-6.3	-0.32	9.06e-10	Prudent dietary pattern;
LIHC	trans	rs1432089	0.689	rs62344301	chr4:171784950	T/G	cg02328223	chr3:127541927	MGLL	-0.42	-6.06	-0.31	3.55e-9	Endometriosis;
LIHC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.54	-8.98	-0.44	1.81e-17	Blood metabolite levels;
LIHC	cis	rs9425766	0.640	rs3791020	chr1:173813197	A/G	cg06124660	chr1:173389066	NA	0.34	6.41	0.33	4.84e-10	Life satisfaction;
LIHC	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg22771759	chr13:24902376	NA	0.32	6.74	0.34	6.76e-11	Obesity-related traits;
LIHC	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19995117	chr12:2880862	NA	0.33	6.21	0.32	1.5e-9	Quantitative traits;
LIHC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.36	-5.74	-0.3	2.04e-8	Mortality in heart failure;
LIHC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.44	7.67	0.38	1.76e-13	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LIHC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.48	5.81	0.3	1.41e-8	Alzheimer's disease;
LIHC	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.43	6.85	0.35	3.36e-11	Metabolite levels;
LIHC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.6	-0.38	2.92e-13	Bipolar disorder;
LIHC	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05025164	chr4:1340916	KIAA1530	0.53	8.07	0.4	1.24e-14	Obesity-related traits;
LIHC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.59	-11.31	-0.52	2.15e-25	Coronary artery disease;
LIHC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.65	-9.94	-0.47	1.3e-20	Obesity-related traits;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.71	-10.5	-0.49	1.48e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg08668510	chr10:1095578	IDI1	0.68	6.62	0.34	1.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16346588	chr10:242978	ZMYND11	0.39	5.88	0.3	9.59e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.59	10.4	0.49	3.38e-22	Dupuytren's disease;
LIHC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg00091569	chr3:40428383	ENTPD3	0.4	6.66	0.34	1.08e-10	Renal cell carcinoma;
LIHC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.37	-6.03	-0.31	4.18e-9	Schizophrenia;
LIHC	cis	rs1434579	0.865	rs12980701	chr19:44948014	C/A	cg15540054	chr19:45004280	ZNF180	0.57	7.85	0.39	5.46e-14	Tuberculosis;
LIHC	cis	rs546131	0.600	rs7946699	chr11:34820069	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.37	0.33	6.14e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg18944383	chr4:111397179	ENPEP	-0.34	-7.97	-0.4	2.41e-14	Coronary artery disease;
LIHC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg24163568	chr5:669837	TPPP	-0.42	-8.57	-0.42	3.57e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.76	-9.94	-0.47	1.3e-20	Schizophrenia;
LIHC	cis	rs1144333	1.000	rs1890967	chr1:76459544	T/C	cg22875332	chr1:76189707	ACADM	0.41	6.44	0.33	4.05e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg06640241	chr16:89574553	SPG7	0.67	10.86	0.51	8.07e-24	Multiple myeloma (IgH translocation);
LIHC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	6.02	0.31	4.58e-9	Tonsillectomy;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19794706	chr14:75643232	TMED10	0.4	6.06	0.31	3.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg08888203	chr3:10149979	C3orf24	0.56	6.71	0.34	8.24e-11	Alzheimer's disease;
LIHC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	7.77	0.39	9.17e-14	Iron status biomarkers;
LIHC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.75	-8.65	-0.42	2.05e-16	Bipolar disorder (body mass index interaction);
LIHC	cis	rs903552	1.000	rs8043205	chr15:102005749	A/G	cg06707286	chr15:102010195	PCSK6	-0.44	-6.22	-0.32	1.43e-9	Diabetic kidney disease;
LIHC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.94	14.37	0.61	5.81e-37	Sudden cardiac arrest;
LIHC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg07424592	chr7:64974309	NA	0.79	9.12	0.44	6.72e-18	Diabetic kidney disease;
LIHC	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.86	13.47	0.59	1.75e-33	Gastritis;
LIHC	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.96	0.31	6.16e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	16.39	0.66	5.8e-45	Smoking behavior;
LIHC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.82	-0.35	4.26e-11	Diabetic kidney disease;
LIHC	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg04592579	chr7:75616294	TMEM120A	0.39	6.87	0.35	3.1e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.45	-8.7	-0.43	1.45e-16	Plateletcrit;Platelet count;
LIHC	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg27523141	chr10:43048294	ZNF37B	0.35	6.08	0.31	3.24e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg27572529	chr10:21823470	MLLT10	-0.47	-6.63	-0.34	1.28e-10	Longevity;
LIHC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.49	6.35	0.32	6.85e-10	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22586474	chr7:931148	C7orf20	0.5	6.67	0.34	1.02e-10	Hepatitis;
LIHC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg15448220	chr1:150897856	SETDB1	0.41	6.46	0.33	3.59e-10	Melanoma;
LIHC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg22633049	chr21:46681294	NA	-0.36	-6.29	-0.32	9.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.41	6.2	0.32	1.59e-9	Platelet count;
LIHC	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.47	0.46	4.62e-19	Coffee consumption (cups per day);
LIHC	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.45	6.33	0.32	7.62e-10	Kawasaki disease;
LIHC	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.41	-10.14	-0.48	2.66e-21	Cutaneous nevi;
LIHC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.99	-0.31	5.26e-9	Heart rate;
LIHC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.5	6.22	0.32	1.45e-9	Menarche (age at onset);
LIHC	cis	rs903552	1.000	rs34937195	chr15:102003631	C/A	cg25677261	chr15:102009856	PCSK6	-0.43	-5.92	-0.3	7.76e-9	Diabetic kidney disease;
LIHC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16684958	chr7:75615977	POR	0.4	6.57	0.33	1.87e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.55	8.93	0.43	2.7e-17	Longevity;Endometriosis;
LIHC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.95	-18.12	-0.7	6.28e-52	Breast cancer;
LIHC	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	0.95	6.95	0.35	1.85e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.4	6.47	0.33	3.34e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.6	-8.68	-0.42	1.63e-16	Blood metabolite levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17739026	chr1:27114420	PIGV	-0.43	-6.06	-0.31	3.69e-9	Systolic blood pressure;
LIHC	cis	rs1355223	0.902	rs12801509	chr11:34747336	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.52	-0.33	2.5e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg18944383	chr4:111397179	ENPEP	0.27	7.0	0.35	1.34e-11	Height;
LIHC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.59	7.57	0.38	3.5e-13	Morning vs. evening chronotype;
LIHC	trans	rs1864585	0.520	rs7009920	chr8:10585162	C/T	cg26278703	chr11:58910052	FAM111A	-0.68	-6.31	-0.32	8.77e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.49	0.42	6.22e-16	Lymphocyte counts;
LIHC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.77	0.39	9.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.76	8.62	0.42	2.57e-16	Cognitive test performance;
LIHC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.61	-6.9	-0.35	2.61e-11	Menarche (age at onset);
LIHC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg22633049	chr21:46681294	NA	-0.37	-6.17	-0.32	1.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.89	-0.3	9.48e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.41	-0.33	4.74e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg14132834	chr19:41945861	ATP5SL	-0.46	-6.9	-0.35	2.48e-11	Height;
LIHC	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg01843034	chr6:37503916	NA	-0.48	-7.89	-0.39	4.11e-14	Cognitive performance;
LIHC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.92	0.57	2.25e-31	Mean platelet volume;
LIHC	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.66	7.23	0.36	3.2e-12	Exhaled nitric oxide output;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg02675502	chr2:219264639	CTDSP1	0.42	6.08	0.31	3.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs970821	1.000	rs4617136	chr8:124750451	G/A	cg00283535	chr8:124749564	ANXA13	0.35	5.88	0.3	9.98e-9	Breast cancer;
LIHC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.46	-6.81	-0.35	4.39e-11	Lung cancer;
LIHC	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.67	10.57	0.5	8.78e-23	Obesity-related traits;
LIHC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.6	8.24	0.41	3.74e-15	Blood metabolite levels;
LIHC	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.17e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg10756647	chr7:56101905	PSPH	1.08	13.47	0.59	1.87e-33	Diabetic kidney disease;
LIHC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg15208524	chr1:10270712	KIF1B	0.38	5.74	0.3	2.12e-8	Hepatocellular carcinoma;
LIHC	cis	rs4407350	1.000	rs4373013	chr22:44922248	C/T	cg26276947	chr22:44892394	LDOC1L	0.34	6.35	0.32	6.7e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs754466	0.561	rs72806025	chr10:79707026	C/T	cg17075019	chr10:79541650	NA	-0.52	-5.86	-0.3	1.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.1	0.31	2.88e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.86	16.46	0.66	3.15e-45	Multiple myeloma (IgH translocation);
LIHC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.75	-0.43	1.02e-16	Gut microbiome composition (summer);
LIHC	cis	rs9473924	0.505	rs9463664	chr6:50902570	T/A	cg14470998	chr6:50812995	TFAP2B	0.93	10.85	0.51	9.2e-24	Body mass index;
LIHC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.49	5.84	0.3	1.21e-8	Endometriosis;Drug-induced torsades de pointes;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07677032	chr17:61819896	STRADA	0.43	6.39	0.33	5.57e-10	Prudent dietary pattern;
LIHC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg21584241	chr15:63341463	TPM1	0.44	6.38	0.33	5.9e-10	Orofacial clefts;
LIHC	cis	rs9318086	0.534	rs1011362	chr13:24377157	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.35	5.79	0.3	1.57e-8	Myopia (pathological);
LIHC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.53	7.61	0.38	2.76e-13	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.48	7.91	0.39	3.65e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.78	-0.39	8.94e-14	Total body bone mineral density;
LIHC	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.87e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.76	14.92	0.63	3.89e-39	White blood cell count;
LIHC	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.34	-0.32	7.31e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07677032	chr17:61819896	STRADA	0.43	6.14	0.32	2.23e-9	Prudent dietary pattern;
LIHC	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg00204512	chr16:28754710	NA	-0.36	-6.35	-0.32	6.99e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-14.43	-0.62	3.3e-37	Systemic lupus erythematosus;
LIHC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.65	12.62	0.56	3.04e-30	Coronary artery disease;
LIHC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	8.12	0.4	8.63e-15	Multiple sclerosis;
LIHC	cis	rs2412488	0.853	rs12508701	chr4:54353243	C/T	cg22241045	chr4:54363911	LNX1	-0.4	-6.67	-0.34	1.03e-10	DNA methylation (variation);
LIHC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.74	0.3	2.07e-8	Schizophrenia;
LIHC	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.77	-9.23	-0.45	2.8e-18	Psoriasis vulgaris;
LIHC	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.42	-0.37	9.56e-13	Longevity;
LIHC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.85	15.07	0.63	1.06e-39	Dental caries;
LIHC	trans	rs10411161	0.702	rs11879319	chr19:52389592	C/T	cg22319618	chr22:45562946	NUP50	-0.64	-8.9	-0.43	3.24e-17	Breast cancer;
LIHC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.67	0.53	1.03e-26	Motion sickness;
LIHC	cis	rs3736485	0.966	rs2414113	chr15:51903896	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.21	-0.32	1.54e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	12.62	0.56	2.98e-30	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.54	-9.02	-0.44	1.4e-17	Cognitive function;
LIHC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-7.89	-0.39	4.14e-14	Neuroticism;
LIHC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.95	0.31	6.57e-9	Electroencephalogram traits;
LIHC	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	0.75	8.29	0.41	2.6e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.76	14.45	0.62	2.74e-37	Crohn's disease;
LIHC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg07971674	chr14:23388846	RBM23	-0.4	-5.81	-0.3	1.45e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-6.29	-0.32	9.44e-10	Response to antipsychotic treatment;
LIHC	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.25	-5.89	-0.3	9.29e-9	Heart rate;
LIHC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg26149184	chr10:133730230	NA	0.47	7.51	0.38	5.31e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg12311636	chr6:118886798	C6orf204	-0.56	-6.41	-0.33	4.89e-10	Renal cell carcinoma;
LIHC	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.13	9.9	0.47	1.74e-20	Schizophrenia;
LIHC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.4	0.33	5.18e-10	Rheumatoid arthritis;
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.35	5.8	0.3	1.53e-8	Height;
LIHC	trans	rs13113518	0.812	rs12500601	chr4:56317656	T/G	cg15358633	chr12:38710606	ALG10B	0.46	6.53	0.33	2.32e-10	Height;
LIHC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg21724239	chr8:58056113	NA	0.48	6.4	0.33	5.2400000000000005e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.06e-9	Tonsillectomy;
LIHC	cis	rs62179067	0.708	rs11897059	chr2:179939876	A/G	cg20701897	chr2:179586761	TTN	0.52	5.77	0.3	1.82e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg26570765	chr4:1273065	NA	0.3	5.98	0.31	5.5e-9	Obesity-related traits;
LIHC	cis	rs10193935	0.901	rs13413617	chr2:42537546	A/G	cg27598129	chr2:42591480	NA	-0.72	-10.94	-0.51	4.49e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9596863	1.000	rs9596858	chr13:54421858	A/G	ch.13.53330881F	chr13:54432880	NA	0.44	5.94	0.31	6.85e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs9649465	1.000	rs55633050	chr7:123388474	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-7.98	-0.4	2.21e-14	Migraine;
LIHC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg12458913	chr13:53173898	NA	0.47	7.52	0.38	4.88e-13	Lewy body disease;
LIHC	cis	rs11229555	0.645	rs12803648	chr11:58177561	G/T	cg15696309	chr11:58395628	NA	-0.65	-7.66	-0.38	1.9e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.97	15.4	0.64	5.06e-41	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs6973256	0.637	rs12707116	chr7:133424909	C/T	cg03336402	chr7:133662267	EXOC4	0.37	5.83	0.3	1.26e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.89	-0.3	9.16e-9	Morning vs. evening chronotype;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15190599	chr6:26156487	HIST1H1E	-0.46	-6.69	-0.34	9.18e-11	Cognitive function;
LIHC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.83	-9.64	-0.46	1.31e-19	Triglycerides;
LIHC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.2	0.45	3.61e-18	Hip circumference adjusted for BMI;
LIHC	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.73	-10.75	-0.5	2.04e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.08	0.31	3.26e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.5	8.91	0.43	3.07e-17	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25632114	chr8:95732714	DPY19L4	0.45	6.75	0.34	6.39e-11	Cognitive function;
LIHC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.43	-6.78	-0.34	5.35e-11	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-8.19	-0.41	5.18e-15	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08452348	chr5:134303703	CATSPER3	0.45	6.95	0.35	1.87e-11	Cognitive function;
LIHC	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.34	-8.63	-0.42	2.36e-16	Hip circumference;Waist circumference;
LIHC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.78	13.61	0.59	5.2e-34	Aortic root size;
LIHC	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.66	-10.7	-0.5	3.12e-23	Height;
LIHC	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.41	-6.73	-0.34	7.03e-11	Inhibitory control;
LIHC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-10.02	-0.48	6.7e-21	Resting heart rate;
LIHC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.48	5.71	0.3	2.42e-8	Bladder cancer;
LIHC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	7.68	0.38	1.74e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.7	11.39	0.52	1.11e-25	Menopause (age at onset);
LIHC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg21361702	chr7:150065534	REPIN1	0.46	6.3	0.32	9.13e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.65	-7.56	-0.38	3.62e-13	Type 2 diabetes;
LIHC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg05044414	chr3:183734942	ABCC5	0.33	6.25	0.32	1.22e-9	Anterior chamber depth;
LIHC	cis	rs55702914	0.712	rs10931778	chr2:198148922	C/T	cg03934865	chr2:198174659	NA	-0.4	-5.76	-0.3	1.91e-8	Major depression and alcohol dependence;
LIHC	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.87	-0.3	1.04e-8	Colorectal cancer;
LIHC	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.4	10.19	0.48	1.76e-21	Cutaneous nevi;
LIHC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg08213375	chr14:104286397	PPP1R13B	0.51	9.81	0.47	3.51e-20	Schizophrenia;
LIHC	cis	rs716804	0.593	rs7107021	chr11:10071810	T/C	cg01453529	chr11:10209919	SBF2	-0.3	-5.75	-0.3	1.94e-8	Neuroticism;
LIHC	cis	rs3015497	0.934	rs2934691	chr14:51121333	C/A	cg09863266	chr14:51125203	SAV1	-0.43	-7.01	-0.35	1.24e-11	Mean platelet volume;
LIHC	trans	rs6866721	0.740	rs35816306	chr5:116215882	G/A	cg07571379	chr11:134631427	NA	-0.29	-6.09	-0.31	2.97e-9	Body mass index;
LIHC	cis	rs4450131	0.522	rs34336231	chr10:126355662	C/T	cg20435097	chr10:126320824	FAM53B	0.67	12.28	0.55	5.98e-29	White blood cell count (basophil);
LIHC	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.51	8.25	0.41	3.48e-15	Corneal astigmatism;
LIHC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05025164	chr4:1340916	KIAA1530	0.53	8.33	0.41	2.03e-15	Obesity-related traits;
LIHC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-10.12	-0.48	3.06e-21	Type 2 diabetes;
LIHC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.41	6.64	0.34	1.2e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs6845999	1.000	rs7699073	chr4:145542668	C/G	cg18349516	chr17:62503735	CCDC45;DDX5	-0.45	-6.19	-0.32	1.74e-9	Height;
LIHC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.09	19.63	0.73	5.64e-58	Nonalcoholic fatty liver disease;
LIHC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-5.95	-0.31	6.66e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg08345082	chr10:99160200	RRP12	-0.38	-6.37	-0.33	6.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg07713946	chr22:31675144	LIMK2	-0.42	-7.42	-0.37	9.12e-13	Colorectal cancer;
LIHC	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.33	5.71	0.3	2.45e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg06050784	chr16:88016603	BANP	0.36	6.4	0.33	5.12e-10	Menopause (age at onset);
LIHC	cis	rs6450176	0.904	rs6889847	chr5:53303452	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.86	-0.63	6.69e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-8.51	-0.42	5.5e-16	Crohn's disease;
LIHC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23485639	chr6:28045615	ZNF165	0.44	5.78	0.3	1.71e-8	Parkinson's disease;
LIHC	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg02466173	chr16:30829666	NA	0.48	7.23	0.36	3.15e-12	Dementia with Lewy bodies;
LIHC	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg06766960	chr11:133703094	NA	-0.6	-10.02	-0.48	6.75e-21	Childhood ear infection;
LIHC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.48	0.42	6.79e-16	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs244293	0.965	rs244298	chr17:53241387	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-6.19	-0.32	1.77e-9	Menarche (age at onset);
LIHC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.6	8.83	0.43	5.38e-17	Response to diuretic therapy;
LIHC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00684032	chr4:1343700	KIAA1530	-0.35	-5.79	-0.3	1.61e-8	Obesity-related traits;
LIHC	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg11812906	chr14:75593930	NEK9	0.41	6.14	0.31	2.32e-9	IgG glycosylation;
LIHC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.47	-6.77	-0.34	5.57e-11	Obesity-related traits;
LIHC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-6.15	-0.32	2.16e-9	Schizophrenia;
LIHC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.5	-5.72	-0.3	2.31e-8	Pancreatic cancer;
LIHC	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.41	6.58	0.34	1.79e-10	Intraocular pressure;
LIHC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07305463	chr2:136567211	LCT	-0.39	-5.98	-0.31	5.48e-9	Corneal structure;
LIHC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg18121669	chr1:26560928	CCDC21	0.5	8.0	0.4	1.91e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-5.94	-0.31	7.05e-9	Blood metabolite levels;
LIHC	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.2	-0.32	1.6e-9	Metabolite levels (Pyroglutamine);
LIHC	trans	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg14791747	chr16:20752902	THUMPD1	-0.49	-6.87	-0.35	3.03e-11	Dental caries;
LIHC	cis	rs7818688	0.697	rs11784140	chr8:95987480	G/T	cg16049864	chr8:95962084	TP53INP1	0.59	6.42	0.33	4.5e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg03122164	chr19:39421160	MRPS12;SARS2	-0.5	-6.25	-0.32	1.2e-9	Systolic blood pressure;
LIHC	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.02	0.31	4.59e-9	Morning vs. evening chronotype;
LIHC	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg06026331	chr20:60912101	LAMA5	-0.5	-8.6	-0.42	2.98e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg23625390	chr15:77176239	SCAPER	0.36	5.92	0.3	7.81e-9	Blood metabolite levels;
LIHC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.5	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.43	6.16	0.32	2.08e-9	Aortic root size;
LIHC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.74	11.55	0.53	2.87e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1419980	0.730	rs11561265	chr12:7744090	C/T	cg10578777	chr12:7781093	NA	-0.39	-5.74	-0.3	2.04e-8	HDL cholesterol levels;
LIHC	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.54	8.08	0.4	1.12e-14	HDL cholesterol;
LIHC	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.85	-0.3	1.18e-8	Biliary atresia;
LIHC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.47	-6.36	-0.33	6.32e-10	Blood pressure (smoking interaction);
LIHC	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.73	-0.3	2.24e-8	Prostate cancer;
LIHC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.17	0.36	4.67e-12	Asthma;
LIHC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg16822855	chr3:40428330	ENTPD3	0.34	6.19	0.32	1.73e-9	Renal cell carcinoma;
LIHC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.68	-9.87	-0.47	2.27e-20	Coronary artery disease;
LIHC	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.71	11.58	0.53	2.13e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.68	-8.31	-0.41	2.36e-15	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.58	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.9	-7.68	-0.38	1.67e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24110177	chr3:50126178	RBM5	0.44	6.93	0.35	2.13e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-7.58	-0.38	3.18e-13	Putamen volume;
LIHC	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.26	13.03	0.58	9e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg06360820	chr2:242988706	NA	-0.84	-12.02	-0.55	5.15e-28	Obesity-related traits;
LIHC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.4	6.25	0.32	1.26e-9	Resting heart rate;
LIHC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg17385448	chr1:15911702	AGMAT	0.34	5.83	0.3	1.26e-8	Systolic blood pressure;
LIHC	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg02023728	chr11:77925099	USP35	0.34	6.37	0.33	6.05e-10	Testicular germ cell tumor;
LIHC	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.71	15.06	0.63	1.12e-39	Schizophrenia;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21448741	chr8:58168803	NA	0.33	5.86	0.3	1.11e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg11632617	chr15:75315747	PPCDC	-0.48	-6.75	-0.34	6.34e-11	Blood trace element (Zn levels);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg17767933	chr8:141541054	NA	0.41	6.06	0.31	3.6e-9	Longevity;
LIHC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.86	14.92	0.63	4.06e-39	Headache;
LIHC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.4	-5.95	-0.31	6.68e-9	Iron status biomarkers;
LIHC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.36	5.86	0.3	1.06e-8	Height;
LIHC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.58	8.45	0.42	8.34e-16	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.52	-7.63	-0.38	2.32e-13	Platelet count;
LIHC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.86	0.39	5.19e-14	Coronary artery disease;
LIHC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg03037974	chr15:76606532	NA	0.73	14.33	0.61	8.54e-37	Blood metabolite levels;
LIHC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.81	13.22	0.58	1.68e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	trans	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16471864	chr4:38666270	KLF3;FLJ13197	-0.45	-6.34	-0.32	7.18e-10	Type 2 diabetes;
LIHC	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.35	-6.46	-0.33	3.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg24130564	chr14:104152367	KLC1	-0.55	-8.98	-0.44	1.86e-17	Reticulocyte count;
LIHC	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg02702477	chr5:179499311	RNF130	-0.74	-10.27	-0.49	9.85e-22	LDL cholesterol;
LIHC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.56	-0.5	9.5e-23	Response to antipsychotic treatment;
LIHC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.43	7.53	0.38	4.67e-13	Aortic root size;
LIHC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg00277334	chr10:82204260	NA	-0.54	-6.7	-0.34	8.4e-11	Post bronchodilator FEV1;
LIHC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.42	6.81	0.35	4.49e-11	Red blood cell count;
LIHC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg05555928	chr11:63887634	MACROD1	0.55	7.47	0.37	6.77e-13	Mean platelet volume;
LIHC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.24	0.55	7.91e-29	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg16479474	chr6:28041457	NA	0.47	6.69	0.34	8.87e-11	Depression;
LIHC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.36	5.87	0.3	1.06e-8	Hemoglobin concentration;
LIHC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg25344623	chr2:136566232	LCT	0.41	8.58	0.42	3.26e-16	Mosquito bite size;
LIHC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.09	10.01	0.48	7.19e-21	Diabetic retinopathy;
LIHC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg25894440	chr7:65020034	NA	-0.54	-6.13	-0.31	2.37e-9	Diabetic kidney disease;
LIHC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-7.64	-0.38	2.28e-13	HDL cholesterol;
LIHC	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg16583315	chr14:65563665	MAX	-0.35	-6.61	-0.34	1.46e-10	Obesity-related traits;
LIHC	cis	rs911119	0.818	rs12625182	chr20:23604023	G/T	cg16589663	chr20:23618590	CST3	0.76	8.04	0.4	1.44e-14	Chronic kidney disease;
LIHC	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.4	6.21	0.32	1.58e-9	Alzheimer's disease (survival time);
LIHC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	17.94	0.7	3.31e-51	Smoking behavior;
LIHC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg12798992	chr6:167411361	FGFR1OP	0.42	6.57	0.33	1.87e-10	Primary biliary cholangitis;
LIHC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg14067834	chr17:29058358	SUZ12P	0.69	6.76	0.34	5.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.42	-0.33	4.67e-10	Alzheimer's disease (late onset);
LIHC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.99	-0.31	5.24e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2274273	0.624	rs11848575	chr14:55755788	A/G	cg01864836	chr14:55583639	NA	-0.36	-5.96	-0.31	6.43e-9	Protein biomarker;
LIHC	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.75	-8.46	-0.42	7.94e-16	Putamen volume;
LIHC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21448741	chr8:58168803	NA	0.35	6.5	0.33	2.9e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4589502	0.841	rs75991095	chr15:67123224	C/G	cg09911534	chr15:67153556	NA	-0.51	-6.17	-0.32	1.92e-9	Lung cancer (smoking interaction);
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.48	7.09	0.36	7.56e-12	Cystic fibrosis severity;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25163015	chr11:64052221	BAD;GPR137	-0.42	-6.19	-0.32	1.68e-9	Triglycerides;
LIHC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.33	7.14	0.36	5.57e-12	Bone mineral density;
LIHC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.37	5.9	0.3	8.72e-9	Prostate cancer;
LIHC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	15.72	0.65	2.66e-42	Smoking behavior;
LIHC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.64	10.99	0.51	2.85e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.46	-7.2	-0.36	3.87e-12	Blood protein levels;
LIHC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.66	11.36	0.52	1.32e-25	Lymphocyte counts;
LIHC	cis	rs4699052	1.000	rs6533060	chr4:104139996	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-6.76	-0.34	5.94e-11	Testicular germ cell tumor;
LIHC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg27523141	chr10:43048294	ZNF37B	-0.36	-6.18	-0.32	1.86e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.94e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg01320579	chr17:75405842	SEPT9	0.52	7.43	0.37	8.78e-13	Airflow obstruction;
LIHC	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02985541	chr2:219472218	PLCD4	-0.39	-6.52	-0.33	2.58e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.44	8.57	0.42	3.53e-16	Testicular germ cell tumor;
LIHC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg26338869	chr17:61819248	STRADA	0.52	6.97	0.35	1.62e-11	Height;
LIHC	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	6.99	0.35	1.43e-11	Total cholesterol levels;
LIHC	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg10820045	chr2:198174542	NA	0.47	6.97	0.35	1.6e-11	Dermatomyositis;
LIHC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01200585	chr1:228362443	C1orf69	-0.46	-7.27	-0.37	2.46e-12	Diastolic blood pressure;
LIHC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.1	0.55	2.66e-28	Prudent dietary pattern;
LIHC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.34	0.45	1.3e-18	Bipolar disorder;
LIHC	cis	rs28830936	0.966	rs2277535	chr15:42119711	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.07	-0.31	3.48e-9	Diastolic blood pressure;
LIHC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg23791538	chr6:167370224	RNASET2	-0.54	-8.54	-0.42	4.58e-16	Primary biliary cholangitis;
LIHC	cis	rs807029	0.577	rs3740488	chr10:102754033	A/T	cg17130504	chr10:102756923	LZTS2	0.55	7.78	0.39	8.44e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg03934865	chr2:198174659	NA	0.44	6.58	0.34	1.77e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.08	0.31	3.25e-9	Bipolar disorder;
LIHC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg02640540	chr1:67518911	SLC35D1	0.43	6.8	0.35	4.68e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.27	0.41	3.03e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	6.25	0.32	1.19e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg18964960	chr10:1102726	WDR37	0.66	6.39	0.33	5.36e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.65	-0.5	4.66e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs965469	0.779	rs6051780	chr20:3334167	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.63	-0.34	1.3e-10	IFN-related cytopenia;
LIHC	cis	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg18898632	chr2:242989856	NA	-0.57	-7.66	-0.38	1.91e-13	Obesity-related traits;
LIHC	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg14092571	chr14:90743983	NA	0.57	9.39	0.45	8.51e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.6	10.49	0.49	1.6400000000000001e-22	Dupuytren's disease;
LIHC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.65	-7.58	-0.38	3.21e-13	Lymphocyte counts;
LIHC	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.48	8.74	0.43	1.05e-16	Testicular germ cell tumor;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg03051577	chr14:103366987	TRAF3	0.44	6.25	0.32	1.2e-9	Longevity;
LIHC	cis	rs3770081	1.000	rs12621992	chr2:86345349	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.45	5.76	0.3	1.88e-8	Facial emotion recognition (sad faces);
LIHC	cis	rs847649	0.692	rs7800548	chr7:102481842	C/T	cg18108683	chr7:102477205	FBXL13	0.53	8.33	0.41	1.92e-15	Morning vs. evening chronotype;
LIHC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg11342453	chr6:26196699	NA	0.53	5.92	0.3	7.83e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.47	6.58	0.34	1.81e-10	Tonsillectomy;
LIHC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.68	11.85	0.54	2.23e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.86	14.08	0.61	7.66e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg12253828	chr6:101329408	ASCC3	-0.4	-6.07	-0.31	3.34e-9	Neuroticism;
LIHC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg14906510	chr12:7781169	NA	-0.46	-7.12	-0.36	6.46e-12	HDL cholesterol levels;
LIHC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.34	8.06	0.4	1.33e-14	Immature fraction of reticulocytes;
LIHC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	6.97	0.35	1.65e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.64	-7.42	-0.37	9.11e-13	Iron status biomarkers;
LIHC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg01420254	chr6:26195488	NA	0.54	5.81	0.3	1.44e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg15123519	chr2:136567270	LCT	-0.36	-7.05	-0.36	1.02e-11	Mosquito bite size;
LIHC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.77	-13.41	-0.59	3.06e-33	Aortic root size;
LIHC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.72	0.3	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg00277334	chr10:82204260	NA	-0.53	-6.76	-0.34	6.08e-11	Post bronchodilator FEV1;
LIHC	cis	rs9596863	0.898	rs9568908	chr13:54336521	A/C	ch.13.53330881F	chr13:54432880	NA	0.45	6.21	0.32	1.5e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.61	10.57	0.5	8.99e-23	Colorectal cancer;
LIHC	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg10381502	chr11:71823885	C11orf51	1.08	9.2	0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.78	-9.34	-0.45	1.25e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.93	-0.39	3.16e-14	Coronary artery disease;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg19318889	chr4:1322082	MAEA	0.41	6.72	0.34	7.62e-11	Obesity-related traits;
LIHC	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg11783602	chr8:55087084	NA	-0.31	-6.2	-0.32	1.66e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13047869	chr3:10149882	C3orf24	0.48	5.81	0.3	1.44e-8	Alzheimer's disease;
LIHC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.63	-8.85	-0.43	4.88e-17	Blood metabolite levels;
LIHC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.83	-0.3	1.28e-8	Pulse pressure;
LIHC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.62	-9.21	-0.45	3.35e-18	Testicular germ cell tumor;
LIHC	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg19752551	chr11:57585705	CTNND1	0.51	7.25	0.37	2.72e-12	Schizophrenia;
LIHC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.62	-7.83	-0.39	6.38e-14	Coronary artery disease;
LIHC	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.42	7.49	0.38	5.83e-13	Schizophrenia;
LIHC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.59	-8.08	-0.4	1.16e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	6.93	0.35	2.04e-11	Bipolar disorder;
LIHC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg17385448	chr1:15911702	AGMAT	0.33	5.8	0.3	1.53e-8	Systolic blood pressure;
LIHC	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg00977110	chr5:151150581	G3BP1	-0.56	-7.03	-0.36	1.11e-11	Preschool internalizing problems;
LIHC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21448741	chr8:58168803	NA	0.32	5.82	0.3	1.36e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	cis	rs6750047	0.587	rs2163454	chr2:38279170	A/C	cg07380506	chr2:38303506	CYP1B1	0.59	7.5	0.38	5.59e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.58	8.73	0.43	1.17e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.4	-6.67	-0.34	1e-10	Lewy body disease;
LIHC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.35	-7.89	-0.39	4.25e-14	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.54	7.36	0.37	1.42e-12	Platelet count;
LIHC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.76	10.9	0.51	5.85e-24	Menarche (age at onset);
LIHC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	15.73	0.65	2.38e-42	Smoking behavior;
LIHC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02475777	chr4:1388615	CRIPAK	0.53	7.67	0.38	1.85e-13	Longevity;
LIHC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.3	-6.97	-0.35	1.6e-11	Menarche (age at onset);
LIHC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.67	10.21	0.48	1.56e-21	Body mass index;
LIHC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg05110241	chr16:68378359	PRMT7	-0.61	-6.77	-0.34	5.71e-11	Schizophrenia;
LIHC	cis	rs59901009	0.911	rs10500722	chr11:10235358	T/G	cg01453529	chr11:10209919	SBF2	0.31	6.08	0.31	3.29e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.46	6.53	0.33	2.41e-10	Tuberculosis;
LIHC	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg15902774	chr15:75289873	SCAMP5	0.34	5.96	0.31	6.21e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg18944383	chr4:111397179	ENPEP	-0.31	-6.98	-0.35	1.57e-11	Coronary artery disease;
LIHC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.93	15.41	0.64	4.56e-41	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7116495	1.000	rs10736781	chr11:71650368	T/C	cg26138937	chr11:71823887	C11orf51	-0.67	-6.83	-0.35	3.88e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.44	-8.84	-0.43	5.15e-17	LDL cholesterol levels;
LIHC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	11.82	0.54	3e-27	Lung cancer in ever smokers;
LIHC	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.62	-6.91	-0.35	2.38e-11	Lymphocyte percentage of white cells;
LIHC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.46	6.4	0.33	5.12e-10	Morning vs. evening chronotype;
LIHC	cis	rs17152411	1.000	rs733402	chr10:126594152	T/C	cg07906193	chr10:126599966	NA	0.46	7.15	0.36	5.33e-12	Height;
LIHC	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg25124228	chr12:125621409	AACS	-0.55	-10.23	-0.48	1.31e-21	Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg25024717	chr12:54324583	NA	-0.31	-6.19	-0.32	1.73e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg10755058	chr3:40428713	ENTPD3	0.41	7.06	0.36	9.37e-12	Renal cell carcinoma;
LIHC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.33	-8.76	-0.43	8.93e-17	Hemoglobin concentration;
LIHC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.32	0.32	8.18e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.53	-7.77	-0.39	9.24e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.41	-5.84	-0.3	1.21e-8	Motion sickness;
LIHC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-6.52	-0.33	2.54e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7131987	0.509	rs11050173	chr12:29441473	T/A	cg14222432	chr12:29376421	FAR2	0.35	6.23	0.32	1.37e-9	QT interval;
LIHC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.79	-7.67	-0.38	1.75e-13	Diabetic retinopathy;
LIHC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	1.03	14.69	0.62	3.32e-38	Intelligence (multi-trait analysis);
LIHC	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.39	0.33	5.49e-10	Bipolar disorder;
LIHC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2292096	0.866	rs34674691	chr1:200696645	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.45	-6.03	-0.31	4.24e-9	Epilepsy;
LIHC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.64	-10.52	-0.49	1.31e-22	Pulse pressure;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12145289	chr11:65385911	PCNXL3	0.39	6.19	0.32	1.69e-9	Longevity;
LIHC	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs9682041	0.561	rs1477211	chr3:170140792	A/G	cg11886554	chr3:170076028	SKIL	0.76	5.85	0.3	1.18e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21448741	chr8:58168803	NA	0.37	6.76	0.34	5.8200000000000003e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg04610667	chr7:75704037	NA	0.33	5.94	0.31	6.91e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs288342	0.763	rs288239	chr2:183645816	C/G	cg02625481	chr2:183667124	NA	-0.29	-6.04	-0.31	3.95e-9	Recurrent major depressive disorder;
LIHC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.44	-0.37	8.31e-13	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs7520050	0.933	rs6680211	chr1:46315007	C/G	cg03146154	chr1:46216737	IPP	-0.37	-5.92	-0.3	8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.48	7.48	0.37	6.38e-13	Diastolic blood pressure;
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg18306943	chr3:40428807	ENTPD3	0.36	6.31	0.32	8.81e-10	Renal cell carcinoma;
LIHC	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.67	6.6	0.34	1.56e-10	Lymphocyte counts;
LIHC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.37	6.1	0.31	2.79e-9	Blood metabolite levels;
LIHC	cis	rs6066825	0.568	rs6095245	chr20:47320770	G/C	cg18078177	chr20:47281410	PREX1	0.43	7.07	0.36	8.84e-12	Colorectal cancer;
LIHC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.79	-12.0	-0.54	6.33e-28	Dental caries;
LIHC	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.49	6.13	0.31	2.4e-9	Alzheimer's disease;
LIHC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	7.97	0.4	2.34e-14	Motion sickness;
LIHC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	7.86	0.39	5.11e-14	HDL cholesterol;
LIHC	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg20991723	chr1:152506922	NA	0.5	8.46	0.42	7.65e-16	Hair morphology;
LIHC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.56	-9.62	-0.46	1.5700000000000001e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.81	0.35	4.4e-11	Gut microbiome composition (summer);
LIHC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-11.59	-0.53	2.02e-26	Personality dimensions;
LIHC	cis	rs4478037	0.749	rs6550204	chr3:33107645	C/T	cg16652328	chr3:33138982	GLB1;TMPPE	0.6	7.81	0.39	7.13e-14	Major depressive disorder;
LIHC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg18478394	chr8:109455254	TTC35	-0.36	-6.12	-0.31	2.63e-9	Dupuytren's disease;
LIHC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.39	5.77	0.3	1.75e-8	Coronary artery disease;
LIHC	cis	rs4689642	0.709	rs4689657	chr4:7225818	G/C	cg21353189	chr4:7228343	SORCS2	0.37	6.39	0.33	5.58e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg22705602	chr4:152727874	NA	-0.28	-5.98	-0.31	5.49e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.57	7.26	0.37	2.63e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.06	-0.36	9.32e-12	IgG glycosylation;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03621406	chr19:9930365	FBXL12	-0.39	-6.46	-0.33	3.68e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.6	7.19	0.36	4.1e-12	Cognitive function;
LIHC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.52	-7.53	-0.38	4.52e-13	Multiple sclerosis;
LIHC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	8.34	0.41	1.89e-15	Obesity-related traits;
LIHC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.33	-0.32	7.48e-10	Subjective well-being;
LIHC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.71	9.52	0.46	3.29e-19	Response to antineoplastic agents;
LIHC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.51	8.25	0.41	3.55e-15	Testicular germ cell tumor;
LIHC	cis	rs75064307	0.834	rs10511271	chr3:108114572	A/G	cg03329597	chr3:108125523	MYH15	-0.5	-6.62	-0.34	1.36e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg01864836	chr14:55583639	NA	-0.36	-6.1	-0.31	2.94e-9	Protein biomarker;
LIHC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.35	6.4	0.33	5.09e-10	Platelet distribution width;
LIHC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.76	12.0	0.54	6.33e-28	Corneal astigmatism;
LIHC	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.78	9.03	0.44	1.31e-17	Exhaled nitric oxide output;
LIHC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.13	0.52	9.15e-25	Coronary artery disease;
LIHC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.22	-0.41	4.29e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.21	-0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.88	-0.35	2.8e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.57	-8.33	-0.41	2.03e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.39	-6.85	-0.35	3.52e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.92	0.54	1.29e-27	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg26692224	chr17:62915920	LRRC37A3	0.66	6.36	0.33	6.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg00343986	chr7:65444356	GUSB	0.41	6.12	0.31	2.5e-9	Aortic root size;
LIHC	trans	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg10756647	chr7:56101905	PSPH	1.02	12.41	0.56	1.81e-29	Diabetic kidney disease;
LIHC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.57	10.31	0.49	7.21e-22	Dupuytren's disease;
LIHC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.36	0.37	1.34e-12	Mean platelet volume;
LIHC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.64	11.62	0.53	1.55e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.67	-9.14	-0.44	5.61e-18	Morning vs. evening chronotype;
LIHC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg17980119	chr2:219472607	PLCD4	0.36	6.19	0.32	1.68e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.51	-5.86	-0.3	1.07e-8	Pancreatic cancer;
LIHC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg10360323	chr17:41437877	NA	0.4	5.94	0.31	7.1e-9	Menopause (age at onset);
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-7.0	-0.35	1.36e-11	Obesity-related traits;
LIHC	cis	rs600626	0.529	rs2004638	chr11:75471012	C/T	cg24262691	chr11:75473276	NA	0.44	6.5	0.33	2.8e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.47	7.0	0.35	1.32e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-7.25	-0.37	2.76e-12	Hepatocellular carcinoma;
LIHC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg20818283	chr2:191399100	TMEM194B	0.46	5.99	0.31	5.36e-9	Pulse pressure;
LIHC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.79	-15.02	-0.63	1.63e-39	Height;
LIHC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.36	3.46e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg05527609	chr1:210001259	C1orf107	0.43	6.37	0.33	6.08e-10	Cleft lip with or without cleft palate;
LIHC	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg04846421	chr1:18800208	NA	-0.48	-7.94	-0.39	2.88e-14	Diabetic retinopathy;
LIHC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.34	-0.45	1.3e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.74	11.57	0.53	2.4e-26	Intelligence (multi-trait analysis);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04381043	chr16:89341467	ANKRD11	0.42	6.17	0.32	1.9e-9	Bilirubin levels;
LIHC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.14	0.32	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10053149	chr1:28908509	SNHG12;SNORA44;SNORA16A	0.5	6.35	0.32	6.87e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.39	5.99	0.31	5.41e-9	Alzheimer's disease (survival time);
LIHC	cis	rs7781266	0.500	rs2971975	chr7:133645355	G/A	cg03336402	chr7:133662267	EXOC4	-0.47	-5.74	-0.3	2.14e-8	Educational attainment (college completion);
LIHC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.89	-0.43	3.56e-17	Skin colour saturation;
LIHC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.4	0.52	9.72e-26	Coronary artery disease;
LIHC	cis	rs6088590	0.610	rs6088461	chr20:32905161	G/T	cg06115741	chr20:33292138	TP53INP2	0.56	7.22	0.36	3.31e-12	Coronary artery disease;
LIHC	cis	rs2016586	0.931	rs4821435	chr22:36113039	T/C	cg26342177	chr22:36113512	APOL5	-0.38	-6.3	-0.32	9.32e-10	Body mass index;
LIHC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.57	7.42	0.37	9.22e-13	Parkinson's disease;
LIHC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.62	10.02	0.48	6.72e-21	Obesity-related traits;
LIHC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-6.46	-0.33	3.59e-10	Arsenic metabolism;
LIHC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.33	6.9	0.35	2.51e-11	QRS complex (12-leadsum);
LIHC	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg03441853	chr15:73075003	ADPGK	0.28	5.8	0.3	1.5e-8	Triglyceride levels;
LIHC	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.57	7.04	0.36	1.03e-11	Breast cancer;
LIHC	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.64	6.49	0.33	3.05e-10	Homocysteine levels;
LIHC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.25	-5.89	-0.3	9.23e-9	Subjective well-being;
LIHC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.42	-7.29	-0.37	2.15e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LIHC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.49	-6.16	-0.32	2.09e-9	Corneal structure;
LIHC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg15691649	chr6:25882328	NA	0.49	6.81	0.35	4.49e-11	Blood metabolite levels;
LIHC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21467203	chr3:49911342	NA	0.4	6.95	0.35	1.81e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.37	0.41	1.48e-15	Menarche (age at onset);
LIHC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.83	-6.87	-0.35	3.07e-11	Breast cancer;
LIHC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.59	9.05	0.44	1.12e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.58	7.67	0.38	1.8e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.69	7.29	0.37	2.18e-12	Alzheimer's disease;
LIHC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	1.03	20.83	0.75	8.51e-63	Breast cancer;
LIHC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg13628971	chr7:2884303	GNA12	0.5	7.22	0.36	3.31e-12	Height;
LIHC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg12863693	chr15:85201151	NMB	0.44	6.34	0.32	7.18e-10	Schizophrenia;
LIHC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.66	0.5	4.37e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs2710642	0.586	rs12713462	chr2:62804482	C/T	cg17519650	chr2:63277830	OTX1	0.39	6.1	0.31	2.93e-9	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg12311636	chr6:118886798	C6orf204	-0.53	-6.22	-0.32	1.44e-9	Diastolic blood pressure;
LIHC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	6.01	0.31	4.78e-9	Tonsillectomy;
LIHC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.47e-8	Aortic root size;
LIHC	cis	rs74181299	0.684	rs1228	chr2:65311555	C/T	cg05010058	chr2:65284262	CEP68	-0.39	-6.51	-0.33	2.72e-10	Pulse pressure;
LIHC	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26734620	chr12:56694298	CS	1.3	11.14	0.52	8.3e-25	Psoriasis vulgaris;
LIHC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.74	6.51	0.33	2.66e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	11.29	0.52	2.43e-25	Fuchs's corneal dystrophy;
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.94	16.1	0.66	8.45e-44	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg15902774	chr15:75289873	SCAMP5	0.34	5.82	0.3	1.35e-8	Systemic lupus erythematosus;
LIHC	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.86	16.84	0.67	9.26e-47	Testicular germ cell tumor;
LIHC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.51	5.88	0.3	9.93e-9	Alzheimer's disease;
LIHC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg22777020	chr22:31556080	RNF185	0.55	6.35	0.32	6.77e-10	Colorectal cancer;
LIHC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg05527609	chr1:210001259	C1orf107	0.42	6.2	0.32	1.62e-9	Cleft lip with or without cleft palate;
LIHC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.38	6.03	0.31	4.21e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.742	rs12753439	chr1:110015519	G/A	cg02415029	chr1:110025642	ATXN7L2	-0.43	-5.79	-0.3	1.56e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.37	7.76	0.39	1.02e-13	Obesity (extreme);
LIHC	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.58	8.5	0.42	5.82e-16	Menopause (age at onset);
LIHC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.79	11.65	0.53	1.22e-26	Metabolic syndrome;
LIHC	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg07713946	chr22:31675144	LIMK2	-0.45	-6.88	-0.35	2.79e-11	Paclitaxel-induced neuropathy;
LIHC	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.38	6.27	0.32	1.07e-9	Body mass index;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26329020	chr12:32909488	YARS2	0.43	6.5	0.33	2.9e-10	Cognitive function;
LIHC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.66	-9.04	-0.44	1.15e-17	Schizophrenia;
LIHC	cis	rs600806	0.888	rs592107	chr1:109848726	A/T	cg16275483	chr1:110013120	SYPL2	-0.5	-6.1	-0.31	2.87e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.94	0.31	7.11e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg16586182	chr3:47516702	SCAP	-0.53	-9.67	-0.46	1.02e-19	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16377939	chr16:53088918	CHD9	-0.46	-6.04	-0.31	4.12e-9	Pancreatic cancer;
LIHC	trans	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg18393722	chr15:85113863	UBE2QP1	0.46	7.4	0.37	1.1e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.13	0.44	6.08e-18	Coffee consumption (cups per day);
LIHC	cis	rs7075426	0.669	rs3758520	chr10:88233628	C/G	cg07322936	chr10:88137208	NA	0.48	6.29	0.32	9.59e-10	Migraine without aura;
LIHC	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg25930673	chr12:123319894	HIP1R	1.13	12.86	0.57	3.89e-31	Adiponectin levels;
LIHC	cis	rs7828089	0.744	rs10108011	chr8:22320806	C/T	cg12081754	chr8:22256438	SLC39A14	0.5	8.19	0.4	5.22e-15	Verbal declarative memory;
LIHC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.8	-5.99	-0.31	5.41e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg10935138	chr17:73851978	WBP2	0.44	6.94	0.35	1.97e-11	White matter hyperintensity burden;
LIHC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg23782820	chr8:58130467	NA	0.34	5.93	0.31	7.46e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.67	13.33	0.58	6.09e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.02	-0.31	4.6e-9	Total body bone mineral density;
LIHC	cis	rs760762	0.636	rs6072329	chr20:39915515	A/G	cg06424997	chr20:39929561	ZHX3	-0.36	-5.96	-0.31	6.38e-9	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LIHC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.5	7.44	0.37	8.07e-13	Height;
LIHC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg21466736	chr12:48725269	NA	-0.59	-8.31	-0.41	2.2e-15	Bipolar disorder and schizophrenia;
LIHC	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12062639	chr20:23401060	NAPB	0.84	9.99	0.48	8.99e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg12798992	chr6:167411361	FGFR1OP	0.45	7.1	0.36	7.31e-12	Crohn's disease;
LIHC	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.46	-7.43	-0.37	8.72e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.79	8.97	0.44	1.94e-17	Exhaled nitric oxide levels;
LIHC	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg16309518	chr5:176445507	NA	-0.58	-11.32	-0.52	1.87e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04315863	chr15:34330588	AVEN;CHRM5	0.44	6.09	0.31	3.07e-9	Pancreatic cancer;
LIHC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.03	0.4	1.6e-14	Alzheimer's disease;
LIHC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	6.8	0.35	4.54e-11	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.44	-0.66	3.79e-45	Diabetic kidney disease;
LIHC	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg17074339	chr11:11642133	GALNTL4	0.4	6.09	0.31	3.09e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.75	11.49	0.53	4.69e-26	Corneal astigmatism;
LIHC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.41	5.91	0.3	8.48e-9	Coronary artery disease;
LIHC	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg15595755	chr5:1867978	NA	0.34	6.42	0.33	4.53e-10	Cardiovascular disease risk factors;
LIHC	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.8	0.35	4.68e-11	Type 2 diabetes;
LIHC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.67	-0.38	1.86e-13	Chronic sinus infection;
LIHC	cis	rs11931598	0.782	rs4689581	chr4:7048134	C/T	cg02503808	chr4:7069936	GRPEL1	-0.4	-6.0	-0.31	5.17e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs7429990	0.803	rs11714518	chr3:48156635	T/C	cg11946769	chr3:48343235	NME6	-0.48	-6.41	-0.33	4.85e-10	Educational attainment (years of education);
LIHC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06558623	chr16:89946397	TCF25	0.95	14.31	0.61	9.78e-37	Skin colour saturation;
LIHC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.76	0.34	5.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg22528358	chr1:107598549	PRMT6	-0.69	-11.47	-0.53	5.69e-26	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.85	0.35	3.51e-11	Dermatomyositis;
LIHC	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.67e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.49	6.33	0.32	7.79e-10	Initial pursuit acceleration;
LIHC	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg16070018	chr6:26224392	HIST1H3E	0.62	6.9	0.35	2.5e-11	Iron status biomarkers (total iron binding capacity);
LIHC	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	7.76	0.39	9.94e-14	Platelet count;
LIHC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.52	8.36	0.41	1.55e-15	Schizophrenia;
LIHC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.67	10.0	0.48	8.13e-21	Coronary artery disease;
LIHC	cis	rs7534824	0.543	rs17408457	chr1:101385693	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.66	0.38	1.97e-13	Refractive astigmatism;
LIHC	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.28	6.18	0.32	1.85e-9	Pulmonary function;
LIHC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-7.02	-0.36	1.18e-11	Hemoglobin concentration;
LIHC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg12798992	chr6:167411361	FGFR1OP	0.6	10.0	0.48	8.15e-21	Crohn's disease;
LIHC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.77	15.42	0.64	4.07e-41	Mortality in heart failure;
LIHC	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.72	-8.86	-0.43	4.33e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs10411161	0.702	rs892039	chr19:52396541	G/A	cg22319618	chr22:45562946	NUP50	-0.63	-8.54	-0.42	4.49e-16	Breast cancer;
LIHC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.49	6.76e-22	Bladder cancer;
LIHC	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg20140201	chr2:241835670	C2orf54	-0.55	-8.42	-0.41	1.08e-15	Urinary metabolites;
LIHC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.49	0.33	2.97e-10	Lung cancer in ever smokers;
LIHC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.74	10.88	0.51	7.26e-24	Chronic sinus infection;
LIHC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02290350	chr8:58132656	NA	0.49	8.85	0.43	4.69e-17	Developmental language disorder (linguistic errors);
LIHC	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.36	-6.03	-0.31	4.24e-9	Prevalent atrial fibrillation;
LIHC	cis	rs7937890	0.559	rs2597188	chr11:14516906	G/A	cg02886208	chr11:14281011	SPON1	-0.43	-6.09	-0.31	3.04e-9	Mitochondrial DNA levels;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg19262991	chr12:2113119	DCP1B	-0.41	-6.2	-0.32	1.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.71	10.43	0.49	2.77e-22	Aortic root size;
LIHC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.74	-0.34	6.84e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.0	-0.51	2.66e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.13	-0.4	8.23e-15	Body mass index (adult);
LIHC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.63	-9.48	-0.46	4.27e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs57590327	0.679	rs13082940	chr3:81547264	C/T	cg07356753	chr3:81810745	GBE1	0.48	6.59	0.34	1.69e-10	Extraversion;
LIHC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.57	11.54	0.53	2.97e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs3823572	0.564	rs2971953	chr7:133663576	C/T	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.33e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.67	-0.53	1.04e-26	Coffee consumption (cups per day);
LIHC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-9.02	-0.44	1.36e-17	Schizophrenia;
LIHC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg05501817	chr11:14380813	RRAS2	-0.44	-6.21	-0.32	1.54e-9	Sense of smell;
LIHC	cis	rs2005	1.000	rs2005	chr6:35056443	A/G	cg13137465	chr6:34857473	ANKS1A	-0.53	-5.84	-0.3	1.19e-8	Obesity-related traits;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg15908580	chr10:134496731	INPP5A	-0.43	-6.26	-0.32	1.15e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16912285	0.535	rs7109619	chr11:24251339	G/A	ch.11.24196551F	chr11:24239977	NA	0.83	11.81	0.54	3.03e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.04	0.36	1.05e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.55	-10.1	-0.48	3.66e-21	Urate levels in overweight individuals;
LIHC	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.53	-7.83	-0.39	6.12e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs4700695	1.000	rs153319	chr5:65419423	C/T	cg21114390	chr5:65439923	SFRS12	-0.54	-7.16	-0.36	4.83e-12	Facial morphology (factor 19);
LIHC	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-0.95	-11.56	-0.53	2.58e-26	Obesity-related traits;
LIHC	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg04306507	chr14:55594613	LGALS3	0.34	6.5	0.33	2.8e-10	Protein biomarker;
LIHC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.63	8.8	0.43	7.04e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.27	-0.37	2.54e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg08126542	chr6:37504118	NA	-0.37	-6.29	-0.32	9.51e-10	Cognitive performance;
LIHC	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.65	0.42	2.04e-16	Corneal astigmatism;
LIHC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg09021430	chr5:549028	NA	-0.44	-8.71	-0.43	1.29e-16	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.53	-6.16	-0.32	2e-9	Ulcerative colitis;
LIHC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.39	6.46	0.33	3.67e-10	Red blood cell count;
LIHC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02985541	chr2:219472218	PLCD4	0.39	7.09	0.36	7.9e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-5.92	-0.3	7.98e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.4	-0.52	9.54e-26	Chronic sinus infection;
LIHC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.78	0.3	1.69e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.72	-10.3	-0.49	7.5e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg24296786	chr1:45957014	TESK2	-0.49	-7.29	-0.37	2.19e-12	Platelet count;
LIHC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.17	0.81	7.78e-80	Chronic sinus infection;
LIHC	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.88	0.3	9.68e-9	Superior frontal gyrus grey matter volume;
LIHC	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.7	-0.43	1.41e-16	Colorectal cancer;
LIHC	cis	rs2834188	1.000	rs2834190	chr21:34693011	A/T	cg14352951	chr21:34696688	IFNAR1	-0.45	-6.39	-0.33	5.43e-10	Narcolepsy;
LIHC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.87	-0.39	4.66e-14	Type 2 diabetes;
LIHC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.76	10.02	0.48	6.72e-21	Selective IgA deficiency;
LIHC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.36	5.84	0.3	1.21e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.51	-7.12	-0.36	6.25e-12	Response to tocilizumab in rheumatoid arthritis;
LIHC	trans	rs2363709	1.000	rs2363714	chr3:67421846	C/G	cg15775005	chr18:9136598	ANKRD12	0.79	6.05	0.31	3.71e-9	IgE levels;
LIHC	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	0.84	10.22	0.48	1.39e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg06026331	chr20:60912101	LAMA5	0.59	6.87	0.35	3.04e-11	Colorectal cancer;
LIHC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.59	10.04	0.48	5.96e-21	Platelet distribution width;
LIHC	cis	rs2599510	0.811	rs2754520	chr2:32810293	G/A	cg02381751	chr2:32503542	YIPF4	0.44	5.72	0.3	2.29e-8	Interleukin-18 levels;
LIHC	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-9.71	-0.46	7.52e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.51	8.06	0.4	1.25e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg00277334	chr10:82204260	NA	-0.49	-5.97	-0.31	6.03e-9	Post bronchodilator FEV1;
LIHC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.78	-11.83	-0.54	2.76e-27	Corneal astigmatism;
LIHC	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-7.34	-0.37	1.56e-12	Coronary artery disease;
LIHC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	12.49	0.56	9.29e-30	Platelet count;
LIHC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1385374	0.920	rs61946177	chr12:129273347	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	7.42	0.37	9.59e-13	Systemic lupus erythematosus;
LIHC	cis	rs611744	0.901	rs599357	chr8:109194160	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03900353	chr1:212732456	NA	0.42	6.14	0.32	2.26e-9	Pancreatic cancer;
LIHC	cis	rs2257205	0.667	rs7208872	chr17:56777649	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.8e-10	Pancreatic cancer;
LIHC	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.44	7.18	0.36	4.51e-12	Height;
LIHC	cis	rs10845606	0.505	rs2160972	chr12:12838608	C/T	cg09462578	chr12:12878428	APOLD1	0.48	7.42	0.37	9.11e-13	Systemic lupus erythematosus;
LIHC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.52	7.28	0.37	2.28e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg01843034	chr6:37503916	NA	-0.46	-8.06	-0.4	1.3e-14	Cognitive performance;
LIHC	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.72	10.68	0.5	3.75e-23	Subjective well-being;
LIHC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.3	-16.9	-0.67	5.23e-47	Diabetic kidney disease;
LIHC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg17420585	chr12:42539391	GXYLT1	-0.36	-5.91	-0.3	8.19e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg14779329	chr11:130786720	SNX19	0.4	6.14	0.32	2.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg00686598	chr14:53173677	PSMC6	0.86	9.46	0.46	5.01e-19	Alzheimer's disease (late onset);
LIHC	cis	rs797680	0.786	rs555161	chr1:93676314	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.65e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg12601576	chr4:906860	GAK	-0.65	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.06	16.66	0.67	4.93e-46	Breast cancer;
LIHC	cis	rs16958440	1.000	rs4609941	chr18:44645491	T/C	cg17192377	chr18:44677553	HDHD2	0.6	6.76	0.34	5.88e-11	Sitting height ratio;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.02	-0.35	1.22e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.6	10.29	0.49	8.51e-22	Height;
LIHC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	10.94	0.51	4.41e-24	Calcium levels;
LIHC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg14067834	chr17:29058358	SUZ12P	0.61	6.22	0.32	1.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg19000871	chr14:103996768	TRMT61A	-0.45	-7.65	-0.38	2e-13	Coronary artery disease;
LIHC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.44	7.89	0.39	4.06e-14	Prudent dietary pattern;
LIHC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg18944383	chr4:111397179	ENPEP	0.25	6.22	0.32	1.45e-9	Coronary artery disease;
LIHC	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.94	0.54	1.03e-27	Coffee consumption (cups per day);
LIHC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.62	-9.12	-0.44	6.46e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.58	10.0	0.48	8.27e-21	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.88	9.84	0.47	2.78e-20	Primary sclerosing cholangitis;
LIHC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	2.02e-11	Height;
LIHC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.42	6.12	0.31	2.56e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg16652328	chr3:33138982	GLB1;TMPPE	-0.56	-7.13	-0.36	5.98e-12	Major depressive disorder;
LIHC	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.47	-6.89	-0.35	2.61e-11	Mortality in heart failure;
LIHC	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.76	-8.26	-0.41	3.28e-15	Neuroticism;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.83	0.39	6.21e-14	Prudent dietary pattern;
LIHC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.84	12.68	0.57	1.82e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.33	6.91	0.35	2.38e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg23091122	chr1:110024289	SYPL2	-0.48	-6.33	-0.32	7.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.61	8.27	0.41	2.97e-15	Aortic root size;
LIHC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-12.78	-0.57	7.39e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.5	-0.49	1.57e-22	Total cholesterol levels;
LIHC	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.74	-0.39	1.13e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.26	-0.61	1.61e-36	Alzheimer's disease;
LIHC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.66	0.53	1.16e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg14515779	chr1:101123966	NA	0.5	6.9	0.35	2.49e-11	Monocyte count;
LIHC	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-20.7	-0.75	2.84e-62	Exhaled nitric oxide output;
LIHC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.92	0.57	2.17e-31	Prudent dietary pattern;
LIHC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-9.33	-0.45	1.36e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.84	15.64	0.65	5.7700000000000006e-42	Blood protein levels;
LIHC	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.11	0.31	2.66e-9	Heart rate;
LIHC	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.5	9.17	0.44	4.47e-18	Testicular germ cell tumor;
LIHC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.48	-7.37	-0.37	1.28e-12	Coronary artery disease;
LIHC	cis	rs7078219	0.505	rs4129133	chr10:101284570	T/C	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.06	-0.31	3.63e-9	Dental caries;
LIHC	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg05926928	chr17:57297772	GDPD1	-0.78	-8.56	-0.42	3.87e-16	Opioid sensitivity;
LIHC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.47	16.88	0.67	6.43e-47	Eosinophil percentage of granulocytes;
LIHC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.8	12.45	0.56	1.39e-29	Resting heart rate;
LIHC	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.1	-0.31	2.86e-9	Tuberculosis;
LIHC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.53	0.59	1.09e-33	Colorectal cancer;
LIHC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.26e-51	Menopause (age at onset);
LIHC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg13699009	chr12:122356056	WDR66	0.48	8.2	0.41	5.04e-15	Mean corpuscular volume;
LIHC	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.91	11.69	0.53	8.96e-27	Blood protein levels;
LIHC	trans	rs17473412	0.677	rs9327298	chr5:122850321	G/A	cg04915494	chr16:2962968	FLYWCH1	-0.45	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LIHC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.2e-8	Vitiligo;
LIHC	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.25	0.48	1.17e-21	Post bronchodilator FEV1;
LIHC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg27386326	chr11:61587980	NA	0.7	14.85	0.63	7.91e-39	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LIHC	cis	rs2710642	0.611	rs11125941	chr2:62880818	A/C	cg17519650	chr2:63277830	OTX1	0.5	7.26	0.37	2.63e-12	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.77	-10.74	-0.5	2.26e-23	Ear protrusion;
LIHC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.66	11.89	0.54	1.63e-27	High light scatter reticulocyte count;
LIHC	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.79	-8.82	-0.43	5.87e-17	Exhaled nitric oxide output;
LIHC	cis	rs1789	0.903	rs4453929	chr4:15672173	T/G	cg21123203	chr4:15471301	CC2D2A	-0.43	-6.78	-0.34	5.25e-11	Blood protein levels;
LIHC	cis	rs937213	0.676	rs8042456	chr15:40290476	G/T	cg01081584	chr15:40268610	EIF2AK4	-0.47	-7.4	-0.37	1.04e-12	Endometrial cancer;Endometrial endometrioid carcinoma;
LIHC	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.42	8.95	0.44	2.28e-17	Coronary artery disease;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07242783	chr1:28052377	FAM76A	0.51	6.31	0.32	8.72e-10	Lung function (FEV1/FVC);
LIHC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.58	-0.38	3.2e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg18016565	chr1:150552671	MCL1	0.52	9.71	0.46	7.58e-20	Melanoma;
LIHC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.89	-0.43	3.56e-17	Skin colour saturation;
LIHC	cis	rs4908768	0.555	rs55939938	chr1:8863664	A/T	cg20416874	chr1:8611966	RERE	0.43	6.54	0.33	2.27e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-9.16	-0.44	4.87e-18	Body mass index (adult);
LIHC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.57	-8.5	-0.42	5.78e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg06046430	chr4:77819534	ANKRD56	0.5	6.54	0.33	2.31e-10	Emphysema distribution in smoking;
LIHC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.71	0.43	1.33e-16	Prudent dietary pattern;
LIHC	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-6.59	-0.34	1.66e-10	Neuroticism;
LIHC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.35	5.77	0.3	1.75e-8	Type 2 diabetes;
LIHC	cis	rs7937890	0.587	rs11023204	chr11:14411223	C/A	cg23387056	chr11:14280742	SPON1	-0.43	-5.85	-0.3	1.16e-8	Mitochondrial DNA levels;
LIHC	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg06935464	chr4:38784597	TLR10	0.41	6.13	0.31	2.48e-9	Breast cancer;
LIHC	trans	rs801193	0.844	rs732465	chr7:65998450	T/C	cg26939375	chr7:64535504	NA	0.44	7.5	0.38	5.68e-13	Aortic root size;
LIHC	cis	rs10861342	1.000	rs12316054	chr12:105569143	T/C	cg23923672	chr12:105501055	KIAA1033	0.67	7.78	0.39	8.56e-14	IgG glycosylation;
LIHC	trans	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg15684290	chr8:6263623	MCPH1	0.49	6.84	0.35	3.57e-11	Neuroticism (multi-trait analysis);Neuroticism;
LIHC	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.97	-0.31	6.07e-9	Bipolar disorder;
LIHC	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.63	7.15	0.36	5.29e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.12	9.94	0.47	1.24e-20	Schizophrenia;
LIHC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg14067834	chr17:29058358	SUZ12P	0.73	7.42	0.37	9.65e-13	Body mass index;
LIHC	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.76	-0.34	5.87e-11	Metabolite levels (Pyroglutamine);
LIHC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	11.23	0.52	4.19e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg00142150	chr22:38071001	LGALS1	0.67	11.0	0.51	2.66e-24	Fat distribution (HIV);
LIHC	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg09572067	chr16:29127029	RRN3P2	0.5	8.0	0.4	1.94e-14	Menopause (age at onset);
LIHC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.01e-19	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg07254608	chr8:41997973	NA	0.43	6.83	0.35	4e-11	Cognitive function;
LIHC	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg15192750	chr16:69999425	NA	0.46	6.8	0.35	4.54e-11	IgE levels;
LIHC	cis	rs12464559	0.649	rs4306714	chr2:152611351	G/A	cg01189475	chr2:152685088	ARL5A	0.63	7.32	0.37	1.75e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.5	-0.38	5.38e-13	Breast cancer;
LIHC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.2	0.41	4.78e-15	Lymphocyte counts;
LIHC	cis	rs712039	0.652	rs853227	chr17:35797529	C/T	cg16670864	chr17:35848621	DUSP14	0.35	5.95	0.31	6.46e-9	Tuberculosis;
LIHC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.63	9.33	0.45	1.39e-18	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg10381502	chr11:71823885	C11orf51	1.07	8.88	0.43	3.79e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	8.95	0.44	2.28e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.3	-0.32	9.41e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.46	8.3	0.41	2.44e-15	Platelet distribution width;
LIHC	cis	rs13088318	0.504	rs9828111	chr3:101197777	C/T	cg19452782	chr3:101232218	SENP7	0.41	6.12	0.31	2.5e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg00250761	chr1:31883323	NA	0.29	6.26	0.32	1.13e-9	Alcohol dependence;
LIHC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	14.58	0.62	8.37e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.96	0.35	1.7e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.84	12.66	0.56	2.25e-30	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg17724175	chr1:150552817	MCL1	-0.37	-7.53	-0.38	4.46e-13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	cis	rs963731	0.649	rs1454221	chr2:39215672	C/T	cg04010122	chr2:39346883	SOS1	-0.68	-5.8	-0.3	1.55e-8	Corticobasal degeneration;
LIHC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg11812906	chr14:75593930	NEK9	-0.45	-7.22	-0.36	3.36e-12	IgG glycosylation;
LIHC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.74	-7.48	-0.37	6.46e-13	Vitiligo;
LIHC	trans	rs73186030	0.841	rs112779893	chr3:122053280	C/T	cg13973942	chr17:977984	ABR	0.47	6.06	0.31	3.54e-9	Serum parathyroid hormone levels;
LIHC	cis	rs732505	1.000	rs732505	chr19:5582535	G/A	cg26242866	chr19:5711310	LONP1	0.88	6.52	0.33	2.55e-10	vWF and FVIII levels;
LIHC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	10.25	0.48	1.1e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg19355462	chr6:15248936	JARID2	-0.53	-6.16	-0.32	2.01e-9	Systolic blood pressure;
LIHC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.45	-0.53	6.37e-26	Bipolar disorder and schizophrenia;
LIHC	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg00792783	chr2:198669748	PLCL1	0.45	6.62	0.34	1.42e-10	Dermatomyositis;
LIHC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.9	-0.39	3.94e-14	Lung cancer;
LIHC	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg10820045	chr2:198174542	NA	-0.49	-7.5	-0.38	5.38e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-7.59	-0.38	2.98e-13	Prevalent atrial fibrillation;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11266582	chr15:64275853	DAPK2	0.41	6.08	0.31	3.19e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.49	-0.33	2.99e-10	Response to antipsychotic treatment;
LIHC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.61	9.71	0.47	7.37e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs7911264	0.967	rs9419741	chr10:94430525	A/G	cg25506282	chr10:94462361	NA	-0.44	-7.48	-0.37	6.29e-13	Inflammatory bowel disease;
LIHC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg06238570	chr21:40685208	BRWD1	-0.39	-6.27	-0.32	1.08e-9	Menarche (age at onset);
LIHC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-7.21	-0.36	3.55e-12	Osteoporosis;
LIHC	cis	rs847649	1.000	rs12537977	chr7:102539230	C/T	cg18108683	chr7:102477205	FBXL13	-0.48	-7.2	-0.36	3.84e-12	Morning vs. evening chronotype;
LIHC	trans	rs75804782	0.521	rs2117691	chr2:239414734	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	6.66	0.34	1.12e-10	Morning vs. evening chronotype;Chronotype;
LIHC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.64	0.42	2.2e-16	Motion sickness;
LIHC	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg06533319	chr4:3265114	C4orf44	0.36	6.98	0.35	1.55e-11	Parental longevity (mother's age at death);
LIHC	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.33	-12.81	-0.57	5.98e-31	Psoriasis vulgaris;
LIHC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg12365402	chr11:9010492	NRIP3	0.29	7.59	0.38	3.12e-13	Hemoglobin concentration;
LIHC	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.45	0.53	6.43e-26	Birth weight;
LIHC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.44	0.53	6.89e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-9.94	-0.47	1.25e-20	Alzheimer's disease;
LIHC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.41	6.86	0.35	3.15e-11	Blood metabolite levels;
LIHC	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.37	-0.45	9.86e-19	Schizophrenia;
LIHC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg26566898	chr11:117069891	TAGLN	0.39	5.91	0.3	8.28e-9	Blood protein levels;
LIHC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-12.82	-0.57	5.2500000000000004e-31	Electrocardiographic conduction measures;
LIHC	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.38	-13.72	-0.6	2e-34	Psoriasis vulgaris;
LIHC	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.48	-0.33	3.23e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.37	6.05	0.31	3.73e-9	Lung cancer;
LIHC	trans	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.04	-0.31	4.06e-9	Educational attainment (years of education);
LIHC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.73	12.61	0.56	3.33e-30	Menopause (age at onset);
LIHC	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.56	0.46	2.44e-19	Morning vs. evening chronotype;
LIHC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.47	6.1	0.31	2.85e-9	Alzheimer's disease;
LIHC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.36	6.0	0.31	5.01e-9	Blood metabolite levels;
LIHC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg04592579	chr7:75616294	TMEM120A	0.38	6.62	0.34	1.4e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.49	-6.4	-0.33	5.02e-10	Coronary artery calcification;
LIHC	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg10127483	chr1:110009974	SYPL2	0.49	5.99	0.31	5.43e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg21658235	chr8:22456391	C8orf58	-0.35	-5.72	-0.3	2.37e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LIHC	cis	rs61677309	1.000	rs2120269	chr11:118151135	T/C	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	8.18	0.4	5.55e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.05	-0.31	3.75e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg14829360	chr17:73884958	NA	-0.38	-6.42	-0.33	4.59e-10	White matter hyperintensity burden;
LIHC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.46	0.37	7.17e-13	Morning vs. evening chronotype;
LIHC	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.47	7.68	0.38	1.69e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg14580859	chr9:123691850	NA	0.39	6.83	0.35	3.96e-11	Rheumatoid arthritis;
LIHC	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg09003973	chr2:102972529	NA	0.87	7.51	0.38	5.22e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg25801113	chr15:45476975	SHF	0.37	6.16	0.32	2.05e-9	Uric acid levels;
LIHC	cis	rs12220238	0.822	rs11000979	chr10:76067865	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	5.92	0.3	7.77e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-5.82	-0.3	1.37e-8	Blood metabolite levels;
LIHC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.76	0.3	1.91e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.93	16.31	0.66	1.25e-44	Parkinson's disease;
LIHC	trans	rs1864585	0.520	rs7817252	chr8:10685932	C/A	cg20373634	chr10:103911536	NOLC1	-0.46	-6.08	-0.31	3.3e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.6	9.97	0.47	9.89e-21	Resting heart rate;
LIHC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.61	9.58	0.46	2.12e-19	Multiple myeloma (IgH translocation);
LIHC	cis	rs963731	0.649	rs10186762	chr2:39219361	A/G	cg04010122	chr2:39346883	SOS1	-0.7	-5.96	-0.31	6.38e-9	Corticobasal degeneration;
LIHC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.71	0.3	2.41e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.7	10.35	0.49	5.21e-22	Prostate cancer;
LIHC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.52	8.26	0.41	3.29e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs716804	0.703	rs12419593	chr11:10289030	G/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.87	-0.3	1.01e-8	Neuroticism;
LIHC	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.54	-7.5	-0.38	5.73e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.57	0.5	8.66e-23	Colorectal cancer;
LIHC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	1.03	20.71	0.75	2.54e-62	Breast cancer;
LIHC	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg00792783	chr2:198669748	PLCL1	0.42	6.08	0.31	3.15e-9	Intracranial aneurysm;
LIHC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg14379462	chr9:136234288	SURF4	0.43	6.89	0.35	2.73e-11	Longevity;
LIHC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.59	8.81	0.43	6.36e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.82	-12.21	-0.55	1.01e-28	Obesity-related traits;
LIHC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.37	8.26	0.41	3.22e-15	Type 2 diabetes;
LIHC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.78	8.72	0.43	1.23e-16	Initial pursuit acceleration;
LIHC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.91	15.08	0.63	9.62e-40	Tonsillectomy;
LIHC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.36	5.88	0.3	9.83e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg14580859	chr9:123691850	NA	0.37	6.37	0.33	6.11e-10	Rheumatoid arthritis;
LIHC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.62	9.55	0.46	2.6e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.6	10.38	0.49	4.14e-22	High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.88	0.43	3.86e-17	Prudent dietary pattern;
LIHC	trans	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg10756647	chr7:56101905	PSPH	1.1	13.27	0.58	1.01e-32	Diabetic kidney disease;
LIHC	cis	rs3015497	0.616	rs4901043	chr14:51083594	C/T	cg09863266	chr14:51125203	SAV1	0.37	5.94	0.31	7.07e-9	Mean platelet volume;
LIHC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	6.91	0.35	2.37e-11	Axial length;
LIHC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.51	-6.05	-0.31	3.72e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.66	7.66	0.38	1.93e-13	Schizophrenia;
LIHC	cis	rs59901009	0.911	rs61889955	chr11:10183445	G/T	cg01453529	chr11:10209919	SBF2	-0.31	-6.1	-0.31	2.87e-9	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs1190552	0.894	rs2236349	chr14:102963640	G/A	cg10241871	chr14:102965420	TECPR2	-0.49	-7.49	-0.38	5.93e-13	Blood protein levels;
LIHC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	8.04	0.4	1.49e-14	Blood metabolite levels;
LIHC	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg15664640	chr17:80829946	TBCD	-0.6	-5.91	-0.3	8.34e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	16.93	0.68	3.9e-47	Lung cancer in ever smokers;
LIHC	cis	rs918629	0.716	rs6861531	chr5:95274702	A/G	cg10483112	chr5:95245456	ELL2	-0.35	-6.02	-0.31	4.47e-9	IgG glycosylation;
LIHC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.47	7.56	0.38	3.77e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.55	6.78	0.34	5.21e-11	Coronary artery disease;
LIHC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.69	11.22	0.52	4.39e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs12986413	0.624	rs12460763	chr19:2138507	A/G	cg09261902	chr19:2140048	AP3D1	0.4	6.83	0.35	3.92e-11	Height;
LIHC	trans	rs10411161	1.000	rs10409331	chr19:52370962	C/T	cg22319618	chr22:45562946	NUP50	-0.51	-6.83	-0.35	3.78e-11	Breast cancer;
LIHC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17507749	chr15:85114479	UBE2QP1	0.64	7.39	0.37	1.15e-12	Schizophrenia;
LIHC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg06565975	chr8:143823917	SLURP1	0.34	6.72	0.34	7.51e-11	Urinary tract infection frequency;
LIHC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg00280220	chr17:61926910	NA	0.41	6.67	0.34	1.02e-10	Prudent dietary pattern;
LIHC	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00495681	chr13:53174319	NA	0.42	6.76	0.34	5.87e-11	Lewy body disease;
LIHC	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg03999872	chr20:62272968	STMN3	-0.46	-6.83	-0.35	3.93e-11	Atopic dermatitis;
LIHC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02251663	chr11:14281053	SPON1	-0.42	-5.83	-0.3	1.29e-8	Mitochondrial DNA levels;
LIHC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.72	0.3	2.3e-8	Bladder cancer;
LIHC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.78	-14.81	-0.63	1.12e-38	Mortality in heart failure;
LIHC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-8.16	-0.4	6.54e-15	Menarche (age at onset);
LIHC	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.8	13.96	0.6	2.27e-35	Schizophrenia;
LIHC	cis	rs10861342	0.515	rs10861340	chr12:105454097	C/T	cg23923672	chr12:105501055	KIAA1033	-0.44	-6.31	-0.32	8.63e-10	IgG glycosylation;
LIHC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.52e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg00292662	chr22:38071168	LGALS1	0.63	9.87	0.47	2.19e-20	Fat distribution (HIV);
LIHC	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.6	-8.22	-0.41	4.16e-15	Waist circumference;Body mass index;
LIHC	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.51	7.95	0.4	2.7e-14	Adiposity;
LIHC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg02290350	chr8:58132656	NA	0.33	6.52	0.33	2.47e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.56	8.88	0.43	3.93e-17	Lymphocyte counts;
LIHC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.27	-0.41	3.05e-15	Gut microbiome composition (summer);
LIHC	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.57	-8.16	-0.4	6.7e-15	Facial morphology (factor 19);
LIHC	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.27	-0.37	2.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	11.4	0.52	1.01e-25	Menarche (age at onset);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg10527288	chr14:93582455	ITPK1	-0.52	-6.48	-0.33	3.24e-10	Systolic blood pressure;
LIHC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg02635209	chr6:118822505	C6orf204;BRD7P3	0.57	5.83	0.3	1.3e-8	Diastolic blood pressure;
LIHC	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.23	6.25	0.32	1.25e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.83	7.01	0.35	1.28e-11	Body mass index;
LIHC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.39	0.33	5.53e-10	Lung cancer in ever smokers;
LIHC	cis	rs2292096	0.636	rs6427855	chr1:200726579	A/G	cg11814564	chr1:200748674	CAMSAP1L1	-0.56	-10.63	-0.5	5.3e-23	Epilepsy;
LIHC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.95	11.3	0.52	2.18e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	trans	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg26939375	chr7:64535504	NA	0.42	6.63	0.34	1.32e-10	Aortic root size;
LIHC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.45	6.57	0.33	1.85e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg23625390	chr15:77176239	SCAPER	-0.36	-5.96	-0.31	6.43e-9	Blood metabolite levels;
LIHC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	13.17	0.58	2.63e-32	Cognitive test performance;
LIHC	cis	rs2073300	0.826	rs6048809	chr20:23443788	C/T	cg16736954	chr20:23401023	NAPB	0.52	5.79	0.3	1.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.75	-11.26	-0.52	3.21e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.51	-7.6	-0.38	2.93e-13	Psoriasis;
LIHC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.86	0.57	3.8e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs72627509	0.629	rs1277313	chr4:57903948	A/C	cg26694713	chr4:57773883	REST	-0.43	-5.89	-0.3	9.07e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.36	6.43	0.33	4.26e-10	Mood instability;
LIHC	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg05041596	chr11:89867385	NAALAD2	0.43	7.29	0.37	2.2e-12	White blood cell types;
LIHC	trans	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg07393940	chr7:158741817	NA	-0.57	-6.95	-0.35	1.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.55	-7.14	-0.36	5.67e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.3	0.49	7.85e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs74544699	1.000	rs11574452	chr4:74846661	A/C	cg02530824	chr4:74847766	PF4	-0.65	-7.07	-0.36	8.71e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.67	13.46	0.59	1.89e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg20240347	chr1:204465584	NA	-0.35	-7.48	-0.37	6.51e-13	Schizophrenia;
LIHC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.93	17.07	0.68	1.12e-47	Parkinson's disease;
LIHC	trans	rs3783890	0.887	rs11621101	chr14:93805880	C/T	cg02802420	chr16:69363236	PDF;COG8	0.33	6.26	0.32	1.15e-9	Body mass index;
LIHC	cis	rs8053891	0.708	rs8055242	chr16:72006882	C/T	cg01557791	chr16:72042693	DHODH	-0.5	-7.09	-0.36	7.9e-12	Coronary artery disease;
LIHC	cis	rs2257205	0.667	rs7220884	chr17:56743948	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.47	-0.33	3.49e-10	Pancreatic cancer;
LIHC	cis	rs11031096	0.655	rs10835695	chr11:4178962	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	9.22	0.45	3.14e-18	Menarche (age at onset);
LIHC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg22633049	chr21:46681294	NA	-0.38	-6.57	-0.33	1.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.82	8.33	0.41	2e-15	Plasma clusterin levels;
LIHC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg16576597	chr16:28551801	NUPR1	0.37	6.14	0.31	2.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.43	-7.0	-0.35	1.34e-11	Schizophrenia;
LIHC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09597638	chr17:3907349	NA	0.61	10.74	0.5	2.17e-23	Type 2 diabetes;
LIHC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.62	8.67	0.42	1.74e-16	Behavioural disinhibition (generation interaction);
LIHC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.41	-6.19	-0.32	1.73e-9	Menarche (age at onset);
LIHC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.13	0.7	5.97e-52	Tonsillectomy;
LIHC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.61	8.84	0.43	4.98e-17	Prudent dietary pattern;
LIHC	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg19752551	chr11:57585705	CTNND1	-0.51	-7.08	-0.36	8.46e-12	Schizophrenia;
LIHC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.4	6.47	0.33	3.49e-10	Red blood cell count;
LIHC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.34e-17	Gut microbiome composition (summer);
LIHC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.72	9.11	0.44	7.32e-18	Body mass index;
LIHC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05210886	chr1:245133216	EFCAB2	-0.45	-6.08	-0.31	3.2e-9	Neuroticism;
LIHC	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	0.84	13.55	0.59	8.5e-34	Left atrial antero-posterior diameter;
LIHC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07305463	chr2:136567211	LCT	0.34	6.19	0.32	1.77e-9	Mosquito bite size;
LIHC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.5	-0.33	2.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg26939375	chr7:64535504	NA	0.46	6.93	0.35	2.04e-11	Aortic root size;
LIHC	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.37	-7.43	-0.37	8.58e-13	Growth-regulated protein alpha levels;
LIHC	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.58	8.18	0.4	5.45e-15	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00219956	chr16:30794205	ZNF629	0.39	6.37	0.33	6.19e-10	Immature fraction of reticulocytes;
LIHC	cis	rs34540877	1.000	rs35256798	chr19:33126329	C/T	cg22980127	chr19:33182716	NUDT19	1.03	6.83	0.35	3.95e-11	Red cell distribution width;
LIHC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.65	8.84	0.43	5.27e-17	Aortic root size;
LIHC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.82	9.83	0.47	2.92e-20	Cognitive function;
LIHC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg25344623	chr2:136566232	LCT	0.44	8.9	0.43	3.35e-17	Mosquito bite size;
LIHC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20011983	chr2:74347215	NA	-0.39	-5.77	-0.3	1.79e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg15691649	chr6:25882328	NA	-0.54	-6.84	-0.35	3.61e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.06	22.02	0.77	1.47e-67	Cognitive ability;
LIHC	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-10.69	-0.5	3.32e-23	Pediatric autoimmune diseases;
LIHC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg10587741	chr22:38071170	LGALS1	0.72	12.36	0.56	2.83e-29	Fat distribution (HIV);
LIHC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg07424592	chr7:64974309	NA	0.79	9.06	0.44	1.04e-17	Diabetic kidney disease;
LIHC	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.99	-0.31	5.35e-9	Tuberculosis;
LIHC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-5.99	-0.31	5.35e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-6.09	-0.31	3e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.88	12.41	0.56	1.83e-29	Blood metabolite levels;
LIHC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.86	8.19	0.41	5.14e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.6	10.31	0.49	6.92e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.22	-0.32	1.43e-9	Metabolite levels;
LIHC	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.83	-0.3	1.29e-8	Bipolar disorder;
LIHC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.46	0.33	3.61e-10	Initial pursuit acceleration;
LIHC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.81	12.62	0.56	3.05e-30	Longevity;
LIHC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg00656387	chr3:40428638	ENTPD3	-0.51	-8.6	-0.42	2.86e-16	Renal cell carcinoma;
LIHC	cis	rs7264396	0.561	rs57545942	chr20:34183479	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.28	-0.41	2.73e-15	Total cholesterol levels;
LIHC	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.44	8.56	0.42	3.78e-16	Testicular germ cell tumor;
LIHC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21747090	chr2:27597821	SNX17	-0.47	-7.03	-0.36	1.09e-11	Total body bone mineral density;
LIHC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.5	9.12	0.44	6.5e-18	Height;
LIHC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.54	8.45	0.42	8.78e-16	Longevity;Endometriosis;
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.64	10.24	0.48	1.24e-21	Longevity;
LIHC	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.73	12.13	0.55	2.09e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg10820045	chr2:198174542	NA	-0.58	-9.64	-0.46	1.29e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.48	6.14	0.32	2.23e-9	Parkinson's disease;
LIHC	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.49	-6.39	-0.33	5.39e-10	Vitiligo;
LIHC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.5	6.9	0.35	2.54e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.68	11.11	0.51	1.11e-24	Diisocyanate-induced asthma;
LIHC	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.9	0.39	3.98e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.52	7.54	0.38	4.21e-13	Response to diuretic therapy;
LIHC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.54	-6.8	-0.34	4.79e-11	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.0	15.32	0.64	1.06e-40	Breast cancer;
LIHC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg05110241	chr16:68378359	PRMT7	-0.62	-6.82	-0.35	4.09e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg19338460	chr6:170058176	WDR27	-0.39	-5.98	-0.31	5.58e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg11952622	chr19:58962976	ZNF324B	0.47	6.98	0.35	1.5e-11	Uric acid clearance;
LIHC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.37	0.33	6.1e-10	Tonsillectomy;
LIHC	cis	rs35160687	0.623	rs13005014	chr2:86487216	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.35	5.75	0.3	2.01e-8	Night sleep phenotypes;
LIHC	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg15871215	chr5:81402204	ATG10	0.68	8.24	0.41	3.82e-15	Breast cancer;
LIHC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.8	-0.57	6.21e-31	Alzheimer's disease;
LIHC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.55	7.47	0.37	6.8e-13	Morning vs. evening chronotype;
LIHC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.8	-0.3	1.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg07133347	chr1:107600762	PRMT6	-0.45	-6.72	-0.34	7.59e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.02	-0.31	4.52e-9	Blood pressure;
LIHC	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg05527609	chr1:210001259	C1orf107	-0.58	-7.82	-0.39	6.46e-14	Red blood cell count;
LIHC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-8.83	-0.43	5.69e-17	Type 2 diabetes;
LIHC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.38	5.91	0.3	8.07e-9	Menopause (age at onset);
LIHC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.78	0.3	1.65e-8	Height;
LIHC	cis	rs17253792	0.545	rs75276278	chr14:56024341	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-6.11	-0.31	2.74e-9	Putamen volume;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12465518	chr17:58308936	SCARNA20;USP32	0.42	6.34	0.32	7.28e-10	Longevity;
LIHC	trans	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg04702396	chr17:15466718	FAM18B2	0.43	6.49	0.33	3.07e-10	Educational attainment (years of education);
LIHC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg01657329	chr11:68192670	LRP5	-0.46	-5.91	-0.3	8.17e-9	Total body bone mineral density;
LIHC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.22	-0.32	1.46e-9	Total body bone mineral density;
LIHC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.81	12.18	0.55	1.4e-28	Motion sickness;
LIHC	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.44	5.99	0.31	5.25e-9	Electroencephalographic traits in alcoholism;
LIHC	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg10756647	chr7:56101905	PSPH	1.05	10.01	0.48	7.62e-21	Gout;
LIHC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg26395211	chr5:140044315	WDR55	0.41	5.99	0.31	5.2e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg06363034	chr20:62225388	GMEB2	-0.44	-7.52	-0.38	4.94e-13	Glioma;Non-glioblastoma glioma;Glioblastoma;
LIHC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.51	-7.62	-0.38	2.54e-13	Schizophrenia;
LIHC	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.32	-6.39	-0.33	5.5e-10	Testicular germ cell tumor;
LIHC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.69	-11.23	-0.52	4.12e-25	Obesity-related traits;
LIHC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.72	9.38	0.45	9.41e-19	Heart rate;
LIHC	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg15704280	chr7:45808275	SEPT13	0.62	6.44	0.33	4.01e-10	Axial length;
LIHC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.71	-7.89	-0.39	4.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.26	6.91	0.35	2.42e-11	Cardiovascular disease risk factors;
LIHC	cis	rs17106184	0.892	rs112717424	chr1:51228799	A/G	cg07174182	chr1:51127561	FAF1	-0.63	-6.81	-0.35	4.43e-11	Type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg08888203	chr3:10149979	C3orf24	0.56	6.47	0.33	3.35e-10	Alzheimer's disease;
LIHC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg05590025	chr7:65112418	INTS4L2	-0.53	-5.75	-0.3	2.01e-8	Diabetic kidney disease;
LIHC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.19	-0.52	5.38e-25	Response to antipsychotic treatment;
LIHC	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.67	-0.5	3.77e-23	Eye color traits;
LIHC	trans	rs12204683	0.963	rs1485373	chr6:80177371	A/G	cg10805819	chr17:6924109	NA	-0.53	-6.15	-0.32	2.18e-9	Presence of antiphospholipid antibodies;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27498675	chr19:41945691	ATP5SL	0.49	6.8	0.35	4.57e-11	Pancreatic cancer;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12662497	chr5:98264283	NA	0.54	6.67	0.34	1.06e-10	Hepatitis;
LIHC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	7.78	0.39	8.4e-14	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.51	-18.81	-0.71	1.04e-54	Breast cancer;
LIHC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.98	16.63	0.67	6.43e-46	Cognitive ability;
LIHC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg07424592	chr7:64974309	NA	0.81	9.12	0.44	6.81e-18	Diabetic kidney disease;
LIHC	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.26	0.48	1.07e-21	Hypertriglyceridemia;
LIHC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.7	0.43	1.4e-16	Schizophrenia;
LIHC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg10932868	chr11:921992	NA	0.39	7.43	0.37	8.97e-13	Alzheimer's disease (late onset);
LIHC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.36	5.74	0.3	2.1e-8	Schizophrenia;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg16070018	chr6:26224392	HIST1H3E	0.56	7.1	0.36	7.14e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs2380220	0.810	rs877096	chr6:95937046	A/G	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.53e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.47	5.96	0.31	6.41e-9	Total body bone mineral density;
LIHC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-7.62	-0.38	2.58e-13	Fibrinogen levels;
LIHC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.66	-13.41	-0.59	3.1e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.38	6.31	0.32	8.48e-10	Blood metabolite levels;
LIHC	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.48	-0.38	6.26e-13	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.85	0.47	2.5e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.4	6.05	0.31	3.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs2073300	1.000	rs6048835	chr20:23462343	G/C	cg12062639	chr20:23401060	NAPB	0.78	9.81	0.47	3.62e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs950169	0.920	rs34672825	chr15:84703470	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	6.87	0.35	3.08e-11	Schizophrenia;
LIHC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg05555928	chr11:63887634	MACROD1	0.51	6.6	0.34	1.59e-10	Mean platelet volume;
LIHC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-10.76	-0.5	1.82e-23	Response to antipsychotic treatment;
LIHC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.56	-9.29	-0.45	1.79e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.25	-0.32	1.2e-9	Renal function-related traits (BUN);
LIHC	cis	rs8084351	0.512	rs10502967	chr18:50792090	C/T	cg24270629	chr18:50823537	DCC	-0.5	-7.75	-0.39	1.03e-13	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg16736954	chr20:23401023	NAPB	0.71	8.5	0.42	5.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.56	-11.34	-0.52	1.65e-25	Tonsillectomy;
LIHC	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg13708974	chr9:131466143	PKN3	0.4	5.72	0.3	2.39e-8	Blood metabolite levels;
LIHC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.5	5.85	0.3	1.14e-8	Alcohol dependence;
LIHC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg00800038	chr16:89945340	TCF25	-0.6	-8.65	-0.42	2.09e-16	Skin colour saturation;
LIHC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-7.75	-0.39	1.07e-13	Crohn's disease;
LIHC	trans	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg26939375	chr7:64535504	NA	-0.42	-6.7	-0.34	8.79e-11	Aortic root size;
LIHC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.9	16.65	0.67	5.43e-46	Coronary artery disease;
LIHC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.41	7.65	0.38	2e-13	Schizophrenia;
LIHC	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-8.03	-0.4	1.57e-14	Exhaled nitric oxide output;
LIHC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.64	-9.71	-0.46	7.54e-20	Systemic lupus erythematosus;
LIHC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.56	-7.31	-0.37	1.89e-12	Initial pursuit acceleration;
LIHC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-11.29	-0.52	2.38e-25	Total cholesterol levels;
LIHC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg27478167	chr7:817139	HEATR2	-0.42	-6.0	-0.31	5.08e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg24849736	chr1:201084428	NA	-0.34	-6.02	-0.31	4.59e-9	Permanent tooth development;
LIHC	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg14146966	chr2:61757674	XPO1	-0.43	-7.21	-0.36	3.71e-12	Tuberculosis;
LIHC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.72	-0.34	7.42e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg05590025	chr7:65112418	INTS4L2	-0.59	-6.58	-0.34	1.81e-10	Diabetic kidney disease;
LIHC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.75	-10.68	-0.5	3.53e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.38	6.9	0.35	2.51e-11	IgG glycosylation;
LIHC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.82	-0.3	1.33e-8	Colorectal cancer;
LIHC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.83	0.47	3.04e-20	Morning vs. evening chronotype;
LIHC	trans	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg25214090	chr10:38739885	LOC399744	0.39	6.48	0.33	3.26e-10	Diastolic blood pressure;
LIHC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.6	7.09	0.36	7.97e-12	Cognitive function;
LIHC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg01788221	chr16:89496183	ANKRD11	0.38	6.02	0.31	4.45e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	7.69	0.38	1.5700000000000001e-13	Lymphocyte counts;
LIHC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg22676075	chr6:135203613	NA	0.42	6.67	0.34	1.04e-10	Red blood cell count;
LIHC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg14393609	chr7:65229607	NA	-0.37	-5.72	-0.3	2.29e-8	Aortic root size;
LIHC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg24005260	chr7:1138185	C7orf50	0.39	5.86	0.3	1.08e-8	Longevity;Endometriosis;
LIHC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02034447	chr16:89574710	SPG7	0.48	7.38	0.37	1.21e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg18289306	chr13:113640169	MCF2L	0.41	6.39	0.33	5.39e-10	Systolic blood pressure;
LIHC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.61	-10.91	-0.51	5.45e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	8.79	0.43	7.37e-17	Monocyte count;
LIHC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.96	-17.38	-0.68	5.98e-49	Breast cancer;
LIHC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.79	15.44	0.64	3.44e-41	Height;
LIHC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.59	9.64	0.46	1.33e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-11.13	-0.52	8.84e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2851682	0.706	rs2727270	chr11:61603237	C/T	cg27386326	chr11:61587980	NA	0.58	9.28	0.45	2.03e-18	Gestational age at birth (child effect);Trans fatty acid levels;
LIHC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.76	6.32	0.32	8.01e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7428	0.520	rs7605890	chr2:85559525	A/C	cg24342717	chr2:85555507	TGOLN2	-0.72	-9.59	-0.46	1.85e-19	Ear protrusion;
LIHC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-10.51	-0.49	1.41e-22	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00745463	chr17:30367425	LRRC37B	0.39	6.04	0.31	4.03e-9	Immature fraction of reticulocytes;
LIHC	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.05	0.51	1.81e-24	Coffee consumption (cups per day);
LIHC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.65	-9.83	-0.47	3.08e-20	Body mass index;
LIHC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.45	7.54	0.38	4.32e-13	Testicular germ cell tumor;
LIHC	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.62	0.34	1.36e-10	Axial length;
LIHC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs922107	0.738	rs2169065	chr1:90031987	A/G	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.7	-0.38	1.48e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2573652	0.755	rs11637186	chr15:100519652	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.94	-18.6	-0.71	7.73e-54	Height;
LIHC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg26338869	chr17:61819248	STRADA	0.52	7.08	0.36	8.14e-12	Height;
LIHC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.74	-9.03	-0.44	1.25e-17	Morning vs. evening chronotype;
LIHC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg22532475	chr10:104410764	TRIM8	-0.3	-5.94	-0.31	6.86e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04565464	chr8:145669602	NFKBIL2	0.4	6.55	0.33	2.15e-10	Bipolar disorder and schizophrenia;
LIHC	trans	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg17675199	chr6:35436792	RPL10A	0.31	6.22	0.32	1.49e-9	Coronary artery disease;
LIHC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.59	-6.94	-0.35	1.97e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.3	-6.86	-0.35	3.23e-11	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.45	5.86	0.3	1.1e-8	Subjective well-being;
LIHC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.24	-16.36	-0.66	7.56e-45	Diabetic kidney disease;
LIHC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.64	-10.27	-0.49	9.8e-22	Monocyte percentage of white cells;
LIHC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	7.99	0.4	2.06e-14	Lymphocyte counts;
LIHC	cis	rs9948	0.867	rs17119598	chr2:97486315	A/G	cg01990225	chr2:97406019	LMAN2L	0.66	6.32	0.32	8.37e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00692763	chr18:47088373	LIPG	0.45	6.6	0.34	1.54e-10	Pancreatic cancer;
LIHC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg08496016	chr9:99181722	ZNF367	0.39	6.5	0.33	2.78e-10	Cognitive function;
LIHC	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg03934865	chr2:198174659	NA	0.44	6.16	0.32	2.06e-9	Dermatomyositis;
LIHC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.5	6.45	0.33	3.92e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	0.98	10.23	0.48	1.3e-21	Mean corpuscular volume;
LIHC	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.46	-7.22	-0.36	3.3e-12	Ulcerative colitis;
LIHC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg18225595	chr11:63971243	STIP1	0.64	7.82	0.39	6.43e-14	Mean platelet volume;
LIHC	cis	rs77861329	1.000	rs9882775	chr3:52149649	C/T	cg08692210	chr3:52188851	WDR51A	0.82	7.35	0.37	1.52e-12	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg19774624	chr17:42201019	HDAC5	0.58	8.06	0.4	1.32e-14	Red cell distribution width;Reticulocyte count;
LIHC	cis	rs113507773	1	rs113507773	chr6:26255739	G/A	cg16070018	chr6:26224392	HIST1H3E	0.67	7.39	0.37	1.15e-12	Iron status biomarkers (transferrin saturation);Iron status biomarkers (iron levels);
LIHC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg10755058	chr3:40428713	ENTPD3	-0.4	-6.92	-0.35	2.2e-11	Renal cell carcinoma;
LIHC	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.48	6.92	0.35	2.27e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg22837342	chr14:23755408	HOMEZ	-0.54	-6.42	-0.33	4.65e-10	Systolic blood pressure;
LIHC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg03128534	chr1:43423976	SLC2A1	0.48	5.87	0.3	1.03e-8	Red cell distribution width;
LIHC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.86	-0.35	3.29e-11	Diabetic kidney disease;
LIHC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg03959625	chr15:84868606	LOC388152	-0.44	-6.47	-0.33	3.31e-10	Schizophrenia;
LIHC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.72	9.71	0.46	7.42e-20	Bone mineral density;
LIHC	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg06359132	chr10:99160096	RRP12	-0.42	-6.6	-0.34	1.57e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.42	-6.06	-0.31	3.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.98	-0.35	1.52e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg08992911	chr2:238395768	MLPH	0.49	6.0	0.31	5.06e-9	Prostate cancer;
LIHC	cis	rs6459788	0.529	rs34237037	chr7:157255078	G/A	cg06271696	chr7:157225062	NA	-0.47	-7.34	-0.37	1.57e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.5	6.16	0.32	1.99e-9	Sudden cardiac arrest;
LIHC	trans	rs3904778	1.000	rs4961736	chr9:16694210	A/C	cg03981286	chr3:122863126	PDIA5	-0.36	-6.06	-0.31	3.55e-9	Adolescent idiopathic scoliosis;
LIHC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.51	-0.46	3.48e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	8.71	0.43	1.33e-16	Schizophrenia;
LIHC	cis	rs36051895	0.559	rs10815172	chr9:5212254	T/A	cg02405213	chr9:5042618	JAK2	-0.61	-10.44	-0.49	2.41e-22	Pediatric autoimmune diseases;
LIHC	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.72	-7.04	-0.36	1.08e-11	Multiple sclerosis;
LIHC	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg14593290	chr7:50529359	DDC	-0.6	-9.56	-0.46	2.44e-19	Malaria;
LIHC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-13.69	-0.6	2.49e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs10774547	0.965	rs11065109	chr12:120863914	T/C	cg12219531	chr12:120966889	COQ5	0.35	5.86	0.3	1.08e-8	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LIHC	cis	rs2274273	0.773	rs28430823	chr14:55816560	C/G	cg01864836	chr14:55583639	NA	-0.37	-6.59	-0.34	1.66e-10	Protein biomarker;
LIHC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.28e-34	Aortic root size;
LIHC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-5.96	-0.31	6.33e-9	Vitiligo;
LIHC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg03665457	chr10:38645376	HSD17B7P2	-0.39	-5.77	-0.3	1.81e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.38	6.14	0.32	2.23e-9	Menopause (age at onset);
LIHC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.84	-15.93	-0.65	3.87e-43	Height;
LIHC	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-7.93	-0.39	3.14e-14	Response to antipsychotic treatment;
LIHC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.07	-0.31	3.49e-9	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-7.8	-0.39	7.65e-14	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.54	-7.54	-0.38	4.16e-13	Response to tocilizumab in rheumatoid arthritis;
LIHC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.05	0.44	1.12e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs2257205	0.667	rs11653526	chr17:56761417	G/A	cg12560992	chr17:57184187	TRIM37	0.73	7.72	0.39	1.32e-13	Pancreatic cancer;
LIHC	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.22	5.97	0.31	6.05e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg13395646	chr4:1353034	KIAA1530	0.64	9.12	0.44	6.45e-18	Obesity-related traits;
LIHC	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.21	-0.32	1.52e-9	Tuberculosis;
LIHC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.34e-9	Aortic root size;
LIHC	cis	rs10792665	0.724	rs1904429	chr11:82721585	C/T	cg24227371	chr11:82718527	RAB30	-0.38	-9.3	-0.45	1.69e-18	Obesity-related traits;
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg11235426	chr6:292522	DUSP22	-0.53	-7.06	-0.36	9.64e-12	Menopause (age at onset);
LIHC	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg01990225	chr2:97406019	LMAN2L	-0.62	-5.8	-0.3	1.51e-8	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22168489	chr12:122356033	WDR66	0.4	6.06	0.31	3.52e-9	Mean corpuscular volume;
LIHC	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg07541023	chr7:19748670	TWISTNB	0.4	5.77	0.3	1.78e-8	Thyroid stimulating hormone;
LIHC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	8.53	0.42	4.89e-16	Motion sickness;
LIHC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg15691649	chr6:25882328	NA	-0.48	-6.38	-0.33	5.66e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg15534755	chr11:117069859	TAGLN	-0.4	-6.81	-0.35	4.5e-11	Blood protein levels;
LIHC	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.62	-0.38	2.55e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg02297831	chr4:17616191	MED28	0.5	7.76	0.39	9.61e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.38	6.13	0.31	2.36e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	9.45	0.46	5.41e-19	Colorectal cancer;
LIHC	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg09003973	chr2:102972529	NA	0.88	7.61	0.38	2.62e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.63	11.07	0.51	1.56e-24	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21790971	chr4:54244117	FIP1L1	0.47	6.48	0.33	3.14e-10	Pancreatic cancer;
LIHC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-12.56	-0.56	4.97e-30	Primary sclerosing cholangitis;
LIHC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.4	5.86	0.3	1.11e-8	Lipoprotein (a) levels;
LIHC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05278271	chr19:7554137	PEX11G	0.44	6.15	0.32	2.2e-9	Gut microbiome composition (summer);
LIHC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg03732007	chr1:2071316	PRKCZ	0.34	5.72	0.3	2.34e-8	Height;
LIHC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.75	8.92	0.43	2.89e-17	Schizophrenia;
LIHC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.43	-5.77	-0.3	1.79e-8	Corneal structure;
LIHC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.55	-9.1	-0.44	7.87e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs861318	0.640	rs2852696	chr1:159015984	G/A	cg11003133	chr1:159046391	AIM2	0.32	6.24	0.32	1.32e-9	Obesity-related traits;
LIHC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg23533926	chr12:111358616	MYL2	-0.32	-6.12	-0.31	2.61e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.66	0.5	4.11e-23	Bladder cancer;
LIHC	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg07671805	chr5:74907694	NA	0.47	6.3	0.32	8.93e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.8	0.65	1.29e-42	Nonalcoholic fatty liver disease;
LIHC	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.32	-5.78	-0.3	1.66e-8	Lewy body disease;
LIHC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg12046867	chr14:103022105	NA	-0.57	-8.37	-0.41	1.45e-15	Platelet count;
LIHC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.78	11.99	0.54	6.93e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	6.83	0.35	3.91e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg25894440	chr7:65020034	NA	0.52	6.05	0.31	3.73e-9	Diabetic kidney disease;
LIHC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-12.47	-0.56	1.14e-29	Alzheimer's disease (late onset);
LIHC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.49	6.29	0.32	9.81e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.82	13.33	0.58	6e-33	Breast cancer;
LIHC	cis	rs1881396	0.947	rs8731	chr2:27873326	C/G	cg27432699	chr2:27873401	GPN1	0.51	7.87	0.39	4.73e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg00825309	chr19:58991885	ZNF446	-0.56	-8.67	-0.42	1.76e-16	Uric acid clearance;
LIHC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.51	-7.21	-0.36	3.7e-12	Breast cancer;
LIHC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20135002	chr11:47629003	NA	-0.5	-8.45	-0.42	8.32e-16	Subjective well-being;
LIHC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27297192	chr10:134578999	INPP5A	0.56	7.71	0.38	1.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg07021052	chr2:20871279	NA	-0.39	-6.98	-0.35	1.52e-11	Abdominal aortic aneurysm;
LIHC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-13.15	-0.58	2.9e-32	Type 2 diabetes;
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.29	0.58	8.87e-33	Prudent dietary pattern;
LIHC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.36	5.9	0.3	8.6e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.95	-0.31	6.51e-9	Total body bone mineral density;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19487717	chr11:70263216	CTTN	0.45	6.75	0.34	6.5e-11	Bilirubin levels;
LIHC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-6.86	-0.35	3.21e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs922107	0.738	rs922106	chr1:90025519	C/A	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.75	-0.39	1.05e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg03517284	chr6:25882590	NA	-0.39	-5.81	-0.3	1.44e-8	Height;
LIHC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.6	10.46	0.49	2.08e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs12744310	0.945	rs34961305	chr1:41765944	A/G	cg03962019	chr1:41807865	NA	0.38	6.22	0.32	1.46e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.77	7.99	0.4	2.02e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg18481087	chr3:160474064	PPM1L	-0.44	-6.04	-0.31	4.1e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs67981189	0.593	rs1468470	chr14:71555531	C/T	cg15816911	chr14:71606274	NA	0.43	6.89	0.35	2.65e-11	Schizophrenia;
LIHC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.1	-0.48	3.66e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.45	-6.97	-0.35	1.59e-11	Total body bone mineral density;
LIHC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg05185784	chr16:90016020	DEF8	-0.43	-5.87	-0.3	1.01e-8	Skin colour saturation;
LIHC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg01411142	chr8:19674711	INTS10	0.5	7.72	0.39	1.28e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.36	-6.52	-0.33	2.58e-10	Schizophrenia;
LIHC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg16797656	chr11:68205561	LRP5	0.51	8.01	0.4	1.84e-14	Total body bone mineral density;
LIHC	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.37	-6.51	-0.33	2.64e-10	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.29	-17.55	-0.69	1.32e-49	Diabetic kidney disease;
LIHC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21467203	chr3:49911342	NA	-0.4	-6.98	-0.35	1.56e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14307892	chr10:124767941	IKZF5;ACADSB	-0.45	-6.28	-0.32	1.06e-9	Obesity-related traits;
LIHC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-6.54	-0.33	2.27e-10	Electroencephalogram traits;
LIHC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-8.39	-0.41	1.28e-15	Menopause (age at onset);
LIHC	cis	rs655641	1.000	rs2508688	chr11:85692342	A/C	cg09030501	chr11:85779252	PICALM	-0.52	-6.38	-0.33	5.85e-10	Platelet count;
LIHC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-6.09	-0.31	2.99e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.39	7.79	0.39	8.31e-14	Renal cell carcinoma;
LIHC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg19680672	chr10:131412579	MGMT	-0.4	-6.03	-0.31	4.3e-9	Response to temozolomide;
LIHC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.55	-8.88	-0.43	3.91e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06420487	chr17:61919686	SMARCD2	0.45	6.09	0.31	2.99e-9	Height;
LIHC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-18.95	-0.72	3.04e-55	Height;
LIHC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.85	15.13	0.63	5.75e-40	Dental caries;
LIHC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.41	-6.22	-0.32	1.45e-9	Menarche (age at onset);
LIHC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.15	17.72	0.69	2.72e-50	Gut microbiome composition (summer);
LIHC	cis	rs2016586	0.832	rs5999963	chr22:36105832	T/A	cg26342177	chr22:36113512	APOL5	-0.37	-6.38	-0.33	5.83e-10	Body mass index;
LIHC	trans	rs1866631	1.000	rs1866631	chr2:174075761	G/A	cg11425656	chr7:44791211	ZMIZ2	0.37	6.27	0.32	1.09e-9	Lung cancer in ever smokers;
LIHC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.93	10.72	0.5	2.51e-23	Triglycerides;
LIHC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.73	-10.54	-0.5	1.15e-22	White blood cell count;
LIHC	trans	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19862616	chr7:65841803	NCRNA00174	0.61	9.4	0.45	7.81e-19	Eotaxin levels;
LIHC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg14393609	chr7:65229607	NA	-0.37	-5.88	-0.3	1e-8	Aortic root size;
LIHC	cis	rs655641	1.000	rs2077815	chr11:85672383	G/A	cg09030501	chr11:85779252	PICALM	-0.49	-6.04	-0.31	4.07e-9	Platelet count;
LIHC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.29	0.37	2.11e-12	Systolic blood pressure;
LIHC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.51	7.95	0.4	2.66e-14	Diastolic blood pressure;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.46	0.33	3.65e-10	Total body bone mineral density;
LIHC	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	6.06	0.31	3.63e-9	Renal cell carcinoma;
LIHC	cis	rs611744	0.967	rs628340	chr8:109189425	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.37	2.22e-12	Migraine;Coronary artery disease;
LIHC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-7.24	-0.36	2.94e-12	Hemoglobin concentration;
LIHC	cis	rs7106204	0.748	rs11827778	chr11:24211321	G/A	ch.11.24196551F	chr11:24239977	NA	0.78	10.32	0.49	6.52e-22	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg27205649	chr11:78285834	NARS2	0.41	6.08	0.31	3.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.8	-6.29	-0.32	9.77e-10	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7534824	0.625	rs61780287	chr1:101382744	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	6.5	0.33	2.76e-10	Refractive astigmatism;
LIHC	cis	rs10861342	0.892	rs11112366	chr12:105486108	G/A	cg23923672	chr12:105501055	KIAA1033	0.64	7.47	0.37	6.71e-13	IgG glycosylation;
LIHC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-6.05	-0.31	3.73e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4908768	0.501	rs6577499	chr1:8612104	C/G	cg20416874	chr1:8611966	RERE	0.7	15.11	0.63	6.87e-40	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.79	-8.21	-0.41	4.43e-15	Schizophrenia;
LIHC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.61	10.36	0.49	4.77e-22	Alcohol dependence;
LIHC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.95	22.43	0.77	3.55e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.63	-10.63	-0.5	5.37e-23	Menopause (age at onset);
LIHC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-5.77	-0.3	1.75e-8	Coronary artery disease;
LIHC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg12863693	chr15:85201151	NMB	0.44	6.34	0.32	7.18e-10	Schizophrenia;
LIHC	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	0.54	10.19	0.48	1.79e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg07636037	chr3:49044803	WDR6	-0.84	-8.52	-0.42	5.33e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.97	-17.74	-0.69	2.19e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.72	0.3	2.33e-8	Electroencephalogram traits;
LIHC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.45	5.79	0.3	1.59e-8	Colorectal cancer;
LIHC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.41	-7.0	-0.35	1.33e-11	Perceived unattractiveness to mosquitoes;
LIHC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg16717988	chr16:89715857	CHMP1A	0.58	6.25	0.32	1.25e-9	Mean platelet volume;
LIHC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.88	-0.3	9.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-10.93	-0.51	4.55e-24	Pediatric autoimmune diseases;
LIHC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.46	-7.25	-0.37	2.77e-12	Multiple myeloma;
LIHC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg16797656	chr11:68205561	LRP5	0.5	7.78	0.39	8.69e-14	Total body bone mineral density;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11296937	chr11:64084966	PRDX5;TRMT112	-0.39	-6.03	-0.31	4.15e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.72	12.37	0.56	2.77e-29	Menopause (age at onset);
LIHC	cis	rs716804	0.740	rs4597056	chr11:10290923	C/T	cg01453529	chr11:10209919	SBF2	-0.29	-5.89	-0.3	9.09e-9	Neuroticism;
LIHC	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.75	-0.34	6.29e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs10419226	0.625	rs12974777	chr19:18765663	C/T	cg16673477	chr19:18812017	CRTC1	-0.32	-5.77	-0.3	1.75e-8	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.49	6.89	0.35	2.65e-11	High light scatter reticulocyte count;
LIHC	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg17723122	chr1:205641542	SLC45A3	0.42	6.32	0.32	8.38e-10	Prostate-specific antigen levels;
LIHC	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.57	-7.8	-0.39	7.44e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.54	7.64	0.38	2.28e-13	Aortic root size;
LIHC	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.36	6.9	0.35	2.58e-11	Multiple sclerosis;
LIHC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.44	-0.45	5.75e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8103278	0.701	rs116959973	chr19:46252333	A/T	cg11657440	chr19:46296263	DMWD	-0.53	-7.87	-0.39	4.76e-14	Coronary artery disease;
LIHC	cis	rs2019216	0.903	rs1817415	chr17:21893338	C/G	cg22648282	chr17:21454238	C17orf51	-0.34	-5.82	-0.3	1.33e-8	Pelvic organ prolapse;
LIHC	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.12	-0.36	6.29e-12	Tuberculosis;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04571327	chr6:97345972	NDUFAF4	0.41	6.2	0.32	1.67e-9	Migraine with aura;
LIHC	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg07541023	chr7:19748670	TWISTNB	0.5	7.23	0.36	3.08e-12	Thyroid stimulating hormone;
LIHC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.68	-12.48	-0.56	1e-29	Height;
LIHC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg25344623	chr2:136566232	LCT	-0.36	-7.33	-0.37	1.71e-12	Mosquito bite size;
LIHC	cis	rs10744422	0.800	rs839363	chr12:123276924	C/T	cg22842854	chr12:123319900	HIP1R	-0.65	-8.08	-0.4	1.14e-14	Schizophrenia;
LIHC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.48	8.49	0.42	6.22e-16	IgG glycosylation;
LIHC	trans	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-7.84	-0.39	5.84e-14	Obesity-related traits;
LIHC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.51	-8.76	-0.43	9.25e-17	Monocyte count;
LIHC	cis	rs611744	0.967	rs636399	chr8:109235569	G/A	cg21045802	chr8:109455806	TTC35	0.51	8.71	0.43	1.31e-16	Dupuytren's disease;
LIHC	cis	rs16958440	0.867	rs12326412	chr18:44683594	A/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs11212260	0.655	rs11212210	chr11:107282069	T/C	cg25435332	chr11:107328525	CWF19L2	0.81	8.62	0.42	2.61e-16	IgG glycosylation;
LIHC	cis	rs7075426	0.583	rs4934208	chr10:88199488	C/T	cg07322936	chr10:88137208	NA	0.49	6.23	0.32	1.37e-9	Migraine without aura;
LIHC	trans	rs13063635	0.915	rs77902290	chr3:45976662	C/T	cg21656520	chr2:210867290	RPE	0.86	6.09	0.31	3.09e-9	Eosinophil percentage of granulocytes;
LIHC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.53	-8.55	-0.42	4.08e-16	Total body bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05157912	chr14:75894395	JDP2	-0.45	-6.41	-0.33	4.94e-10	Cognitive function;
LIHC	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg02951883	chr7:2050386	MAD1L1	0.54	7.38	0.37	1.2e-12	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs965469	0.779	rs6037534	chr20:3269832	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-6.5	-0.33	2.85e-10	IFN-related cytopenia;
LIHC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.61	-0.42	2.7e-16	Total body bone mineral density;
LIHC	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg05187965	chr10:45406764	TMEM72	-0.26	-6.3	-0.32	9.42e-10	Mean corpuscular volume;
LIHC	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.42	0.33	4.49e-10	Hepatocellular carcinoma;
LIHC	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	0.94	10.61	0.5	6.2e-23	Alzheimer's disease (late onset);
LIHC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.32	0.64	1.01e-40	Chronic sinus infection;
LIHC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.04	-0.48	5.99e-21	Schizophrenia;
LIHC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	13.49	0.59	1.54e-33	Coffee consumption (cups per day);
LIHC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.54	-7.98	-0.4	2.17e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08280861	chr8:58055591	NA	0.53	6.19	0.32	1.72e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.33	5.97	0.31	6.1e-9	Aortic root size;
LIHC	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.31	-0.32	8.85e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.61	11.7	0.53	7.98e-27	Menopause (age at onset);
LIHC	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.92	0.47	1.48e-20	Coffee consumption (cups per day);
LIHC	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg13974409	chr11:65292307	SCYL1	0.38	5.94	0.31	7.14e-9	Bone mineral density;
LIHC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.95	12.35	0.56	3.25e-29	HIV-1 control;
LIHC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.61	-0.34	1.5e-10	Eosinophil percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04571327	chr6:97345972	NDUFAF4	0.44	6.29	0.32	9.8e-10	Lung function (FEV1/FVC);
LIHC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg24130564	chr14:104152367	KLC1	0.42	6.95	0.35	1.87e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.68	0.42	1.64e-16	Motion sickness;
LIHC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17507749	chr15:85114479	UBE2QP1	0.76	8.55	0.42	4.18e-16	Schizophrenia;
LIHC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.07	0.31	3.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.48	7.93	0.39	3.23e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.67	8.81	0.43	6.52e-17	Response to antineoplastic agents;
LIHC	cis	rs2380220	0.808	rs2716074	chr6:95907662	T/C	cg15832292	chr6:96025679	MANEA	-0.63	-7.17	-0.36	4.72e-12	Behavioural disinhibition (generation interaction);
LIHC	cis	rs12602486	1.000	rs2285954	chr17:42232938	T/G	cg13607699	chr17:42295918	UBTF	-0.75	-6.42	-0.33	4.46e-10	Glycated hemoglobin levels;
LIHC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg11212589	chr17:38028394	ZPBP2	0.37	7.67	0.38	1.86e-13	Self-reported allergy;
LIHC	cis	rs2540917	0.581	rs12468946	chr2:60670477	C/T	cg00543073	chr2:60773386	BCL11A	0.3	5.82	0.3	1.39e-8	Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.99	0.4	2.02e-14	Motion sickness;
LIHC	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	12.75	0.57	9.99e-31	Coffee consumption (cups per day);
LIHC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg21395723	chr22:39101663	GTPBP1	0.41	7.0	0.35	1.35e-11	Menopause (age at onset);
LIHC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg19680672	chr10:131412579	MGMT	-0.42	-6.58	-0.34	1.81e-10	Response to temozolomide;
LIHC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-0.78	-6.52	-0.33	2.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.85	15.18	0.63	3.67e-40	Bone mineral density;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03209809	chr3:126422892	CHCHD6	0.42	6.49	0.33	3.02e-10	Cognitive function;
LIHC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.71	-10.72	-0.5	2.6e-23	Aortic root size;
LIHC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02290350	chr8:58132656	NA	0.48	9.52	0.46	3.28e-19	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.64	-9.07	-0.44	9.68e-18	Blood metabolite levels;
LIHC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg04025307	chr7:1156635	C7orf50	0.44	6.8	0.35	4.68e-11	Longevity;Endometriosis;
LIHC	cis	rs11212260	0.655	rs80318752	chr11:107226574	C/T	cg25435332	chr11:107328525	CWF19L2	0.82	8.27	0.41	3.1e-15	IgG glycosylation;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.57	8.57	0.42	3.65e-16	Testicular germ cell tumor;
LIHC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.7	11.44	0.53	6.82e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.27	-0.37	2.53e-12	Urate levels in overweight individuals;
LIHC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	9.85	0.47	2.65e-20	Colorectal cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21698385	chr2:102425416	MAP4K4	-0.26	-6.11	-0.31	2.67e-9	Calcium levels;
LIHC	cis	rs965469	0.817	rs6037582	chr20:3351696	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-6.27	-0.32	1.06e-9	IFN-related cytopenia;
LIHC	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg01364799	chr7:75623366	TMEM120A	-0.47	-7.01	-0.35	1.25e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.92	-16.19	-0.66	3.49e-44	Colorectal cancer;
LIHC	cis	rs11098699	0.821	rs6835952	chr4:124230974	A/C	cg09941581	chr4:124220074	SPATA5	0.33	6.56	0.33	2.03e-10	Mosquito bite size;
LIHC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.62	9.84	0.47	2.87e-20	Educational attainment;
LIHC	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.59	8.12	0.4	8.73e-15	Intraocular pressure;
LIHC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.27	6.3	0.32	9.31e-10	Childhood ear infection;
LIHC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg04160030	chr1:24195659	FUCA1	0.38	6.05	0.31	3.8e-9	Immature fraction of reticulocytes;
LIHC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg22563815	chr15:78856949	CHRNA5	0.36	6.65	0.34	1.16e-10	Sudden cardiac arrest;
LIHC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.67	8.56	0.42	3.97e-16	Type 2 diabetes;
LIHC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.87	-13.02	-0.58	9.04e-32	Diastolic blood pressure;
LIHC	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-0.93	-17.86	-0.69	7.5400000000000006e-51	Schizophrenia;
LIHC	trans	rs9914544	0.545	rs8071458	chr17:18790840	C/A	cg21372672	chr17:16614065	CCDC144A	-0.27	-6.57	-0.33	1.82e-10	Educational attainment (years of education);
LIHC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.67	-12.81	-0.57	5.79e-31	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs12313068	0.600	rs7136207	chr12:110491487	T/C	cg12870014	chr12:110450643	ANKRD13A	0.83	11.08	0.51	1.41e-24	Intelligence (multi-trait analysis);
LIHC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg14580859	chr9:123691850	NA	0.4	7.0	0.35	1.39e-11	Rheumatoid arthritis;
LIHC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	0.67	6.67	0.34	1.03e-10	Lung disease severity in cystic fibrosis;
LIHC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg14092571	chr14:90743983	NA	-0.37	-5.88	-0.3	9.65e-9	Mortality in heart failure;
LIHC	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.34	-6.37	-0.33	5.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg01256987	chr12:42539512	GXYLT1	-0.35	-5.85	-0.3	1.18e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.74	7.09	0.36	7.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs1494950	1.000	rs28706742	chr4:14981651	T/C	cg12377275	chr4:15005593	CPEB2	-0.79	-6.71	-0.34	8.25e-11	Political ideology;
LIHC	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.88	0.43	3.97e-17	Coffee consumption (cups per day);
LIHC	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.67	-9.84	-0.47	2.75e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04185861	chr1:154377809	IL6R	-0.37	-6.04	-0.31	3.95e-9	Pancreatic cancer;
LIHC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.82	0.39	6.6e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.44	-6.78	-0.34	5.36e-11	Eosinophil percentage of white cells;
LIHC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.71	7.06	0.36	9.26e-12	Vitiligo;
LIHC	cis	rs807029	0.577	rs701834	chr10:102761801	C/T	cg27255678	chr10:102756921	LZTS2	0.53	7.23	0.36	3.2e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	15.33	0.64	9.76e-41	Post bronchodilator FEV1;
LIHC	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.31	6.14	0.32	2.25e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LIHC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-10.24	-0.48	1.22e-21	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.46	-7.66	-0.38	1.9e-13	Educational attainment;
LIHC	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg07884673	chr3:53033167	SFMBT1	0.82	6.27	0.32	1.11e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs6450176	1.000	rs67430852	chr5:53290586	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-14.97	-0.63	2.64e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-10.29	-0.49	8.5e-22	Dental caries;
LIHC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.58	-8.84	-0.43	5.32e-17	Metabolic syndrome;
LIHC	trans	rs6934970	1.000	rs12202385	chr6:113038889	G/C	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs288342	0.797	rs288312	chr2:183649266	T/C	cg02625481	chr2:183667124	NA	-0.29	-6.09	-0.31	2.98e-9	Recurrent major depressive disorder;
LIHC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-8.39	-0.41	1.29e-15	Morning vs. evening chronotype;
LIHC	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg04610667	chr7:75704037	NA	-0.34	-6.12	-0.31	2.58e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.39	-0.37	1.15e-12	Schizophrenia;
LIHC	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.33	-6.34	-0.32	7.21e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.48	7.84	0.39	5.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-5.87	-0.3	1.05e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-0.48	-6.2	-0.32	1.61e-9	Lung cancer;
LIHC	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	10.51	0.49	1.38e-22	Platelet distribution width;
LIHC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.95	0.44	2.24e-17	Bipolar disorder;
LIHC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.03	-7.25	-0.36	2.89e-12	Body mass index;
LIHC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg16486109	chr11:613632	IRF7	0.59	6.21	0.32	1.53e-9	Systemic lupus erythematosus;
LIHC	trans	rs11165623	0.602	rs6677110	chr1:97018734	A/C	cg10631902	chr5:14652156	NA	-0.25	-6.42	-0.33	4.54e-10	Hip circumference;Waist circumference;
LIHC	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.34	-5.85	-0.3	1.13e-8	HIV-1 susceptibility;
LIHC	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.76	-8.28	-0.41	2.81e-15	Exhaled nitric oxide output;
LIHC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12016809	chr21:47604291	C21orf56	0.48	7.35	0.37	1.46e-12	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg00656387	chr3:40428638	ENTPD3	0.47	7.79	0.39	7.8500000000000006e-14	Renal cell carcinoma;
LIHC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.48	-6.5	-0.33	2.82e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.95	0.39	2.75e-14	Corneal astigmatism;
LIHC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-8.22	-0.41	4.23e-15	Total cholesterol levels;
LIHC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.71	11.62	0.53	1.58e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg15893493	chr8:124194847	FAM83A	0.89	8.31	0.41	2.26e-15	Urinary uromodulin levels;
LIHC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	7.41	0.37	1.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.29	7.23	0.36	3.22e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.0	-0.35	1.37e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.68e-9	Life satisfaction;
LIHC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.45	-7.19	-0.36	4.1e-12	HDL cholesterol levels;
LIHC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.75	10.28	0.49	8.76e-22	Blood metabolite levels;
LIHC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs244293	0.965	rs2170943	chr17:53209505	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.39	-0.37	1.1e-12	Menarche (age at onset);
LIHC	cis	rs57590327	0.679	rs35628094	chr3:81605371	C/A	cg07356753	chr3:81810745	GBE1	-0.47	-6.48	-0.33	3.21e-10	Extraversion;
LIHC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.65	0.34	1.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.52	-5.86	-0.3	1.11e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.44	-0.49	2.4e-22	Total cholesterol levels;
LIHC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg15691649	chr6:25882328	NA	-0.55	-7.9	-0.39	3.88e-14	Blood metabolite levels;
LIHC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg03854865	chr6:26224070	HIST1H3E	0.63	7.07	0.36	8.82e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs10411936	1.000	rs1870071	chr19:16505106	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	-0.41	-5.75	-0.3	1.98e-8	White blood cell count;Multiple sclerosis;
LIHC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg24693881	chr1:107596107	NA	-0.54	-9.46	-0.46	4.95e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.59	8.23	0.41	4.07e-15	Aortic root size;
LIHC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.46	1.47e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg08824895	chr13:115047677	UPF3A	0.49	7.1	0.36	7.08e-12	Schizophrenia;
LIHC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	20.84	0.75	7.56e-63	Chronic sinus infection;
LIHC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.59	8.85	0.43	4.64e-17	Recombination rate (females);
LIHC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.55	7.53	0.38	4.65e-13	Bone properties (heel);
LIHC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg07424592	chr7:64974309	NA	-0.82	-9.43	-0.45	6.33e-19	Diabetic kidney disease;
LIHC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-10.69	-0.5	3.32e-23	Chronic sinus infection;
LIHC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.36	5.93	0.31	7.25e-9	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LIHC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	0.97	22.12	0.77	5.9e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.65	0.34	1.19e-10	Bipolar disorder;
LIHC	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	8.87	0.43	4.19e-17	Exhaled nitric oxide output;
LIHC	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg01364799	chr7:75623366	TMEM120A	-0.52	-7.73	-0.39	1.19e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs546131	0.642	rs61881103	chr11:34838264	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.69	-0.34	8.9e-11	Lung disease severity in cystic fibrosis;
LIHC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg15472797	chr10:135243109	NA	-0.39	-5.85	-0.3	1.15e-8	Systemic lupus erythematosus;
LIHC	cis	rs9378688	0.654	rs9328087	chr6:2265344	A/G	cg12303981	chr6:2244766	GMDS	0.44	5.98	0.31	5.52e-9	Caudate nucleus volume;
LIHC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.69	0.34	8.9e-11	Lung cancer in ever smokers;
LIHC	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.59	-0.42	3.21e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.63	12.47	0.56	1.14e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.58	7.56	0.38	3.62e-13	Bipolar disorder;
LIHC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.98	0.31	5.54e-9	Bipolar disorder;
LIHC	cis	rs611744	0.967	rs613644	chr8:109188994	G/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.62	-7.75	-0.39	1.07e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	7.28	0.37	2.27e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	ch.11.42038R	chr11:967971	AP2A2	0.57	10.21	0.48	1.57e-21	Alzheimer's disease (late onset);
LIHC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.35e-11	Protein C levels;
LIHC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg17724175	chr1:150552817	MCL1	0.42	8.09	0.4	1.06e-14	Melanoma;
LIHC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.89	8.29	0.41	2.71e-15	Lymphocyte counts;
LIHC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.08	0.36	8.49e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-6.96	-0.35	1.76e-11	Colorectal cancer;
LIHC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.45	0.33	3.92e-10	Bipolar disorder;
LIHC	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18252515	chr7:66147081	NA	0.42	5.77	0.3	1.79e-8	Aortic root size;
LIHC	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg20194872	chr6:41519635	FOXP4	0.4	6.33	0.32	7.78e-10	Prostate cancer;
LIHC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.45	-7.32	-0.37	1.78e-12	Menarche (age at onset);
LIHC	cis	rs1494950	1.000	rs79121288	chr4:15012870	A/G	cg12377275	chr4:15005593	CPEB2	-0.84	-7.53	-0.38	4.59e-13	Political ideology;
LIHC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.5	0.53	4.42e-26	Motion sickness;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02353165	chr6:42928485	GNMT	0.96	15.06	0.63	1.16e-39	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg21231739	chr4:1642635	FAM53A	-0.38	-6.02	-0.31	4.59e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.79	-0.43	7.66e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-9.42	-0.45	7.08e-19	Skin colour saturation;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg18350792	chr12:112563442	TRAFD1	-0.42	-6.25	-0.32	1.19e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.98	-0.35	1.5e-11	Neuroticism;
LIHC	cis	rs3106136	0.843	rs11097414	chr4:95260301	A/T	cg11021082	chr4:95130006	SMARCAD1	0.41	7.2	0.36	3.78e-12	Capecitabine sensitivity;
LIHC	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.45	-8.79	-0.43	7.57e-17	Testicular germ cell tumor;
LIHC	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-11.01	-0.51	2.5e-24	Morning vs. evening chronotype;
LIHC	cis	rs7903847	0.673	rs61861870	chr10:99154339	G/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.07	-0.31	3.44e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg18887096	chr2:219472410	PLCD4	0.36	6.29	0.32	9.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-21.71	-0.76	2.59e-66	Height;
LIHC	cis	rs7923837	0.687	rs10882101	chr10:94462427	T/C	cg25506282	chr10:94462361	NA	0.39	6.92	0.35	2.18e-11	Body mass index;Multiple sclerosis;
LIHC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg03859395	chr2:55845619	SMEK2	0.82	14.14	0.61	4.43e-36	Metabolic syndrome;
LIHC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.45	-0.33	3.86e-10	Bipolar disorder;
LIHC	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.07	-0.31	3.32e-9	Tuberculosis;
LIHC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.57	-7.43	-0.37	8.76e-13	Initial pursuit acceleration;
LIHC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.35	-0.37	1.49e-12	Renal cell carcinoma;
LIHC	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg00792783	chr2:198669748	PLCL1	0.41	5.92	0.31	7.71e-9	Intracranial aneurysm;
LIHC	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.61	-11.02	-0.51	2.23e-24	Breast cancer;
LIHC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-10.57	-0.5	8.95e-23	Platelet count;
LIHC	cis	rs7078219	0.524	rs1548963	chr10:101289703	C/G	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.91	-0.3	8.12e-9	Dental caries;
LIHC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-9.61	-0.46	1.62e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.88	-0.3	9.55e-9	Life satisfaction;
LIHC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg05425664	chr17:57184151	TRIM37	0.42	6.04	0.31	4.13e-9	Testicular germ cell tumor;
LIHC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg06207120	chr15:45996521	NA	0.34	6.59	0.34	1.65e-10	Waist circumference;Weight;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	7.87	0.39	4.74e-14	Lymphocyte counts;
LIHC	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg19633962	chr1:26362018	EXTL1	-0.66	-5.86	-0.3	1.11e-8	QRS complex (12-leadsum);
LIHC	cis	rs7116495	1.000	rs679926	chr11:71769936	A/G	cg26138937	chr11:71823887	C11orf51	0.79	7.83	0.39	6.05e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	8.92	0.43	2.9e-17	Mean corpuscular hemoglobin;
LIHC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg23461800	chr14:103021989	NA	-0.43	-6.05	-0.31	3.77e-9	Platelet count;
LIHC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08677398	chr8:58056175	NA	0.41	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.49	9.37	0.45	1.01e-18	Testicular germ cell tumor;
LIHC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg04310649	chr10:35416472	CREM	-0.43	-5.79	-0.3	1.57e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.37	6.51	0.33	2.65e-10	Mean corpuscular volume;
LIHC	trans	rs2211698	1.000	rs57158552	chr21:35839201	A/G	cg18044562	chr7:50468399	IKZF1	0.51	7.37	0.37	1.28e-12	Cancer;
LIHC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.39	6.46	0.33	3.51e-10	Red blood cell count;
LIHC	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.67	-0.34	1e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.9	-14.69	-0.62	3.21e-38	Gut microbiota (bacterial taxa);
LIHC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.82	-15.73	-0.65	2.51e-42	Height;
LIHC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.75	11.52	0.53	3.49e-26	Corneal astigmatism;
LIHC	cis	rs7075426	0.669	rs4934220	chr10:88288206	A/G	cg07322936	chr10:88137208	NA	-0.45	-5.92	-0.31	7.63e-9	Migraine without aura;
LIHC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.91	9.46	0.46	5.24e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg01768480	chr1:1412855	ATAD3B	0.45	6.25	0.32	1.23e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1144333	1.000	rs1890967	chr1:76459544	T/C	cg03433033	chr1:76189801	ACADM	0.54	8.0	0.4	1.92e-14	Attention function in attention deficit hyperactive disorder;
LIHC	trans	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg17675199	chr6:35436792	RPL10A	-0.44	-9.11	-0.44	7.26e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs2637266	0.783	rs846585	chr10:78494466	T/G	cg18941641	chr10:78392320	NA	0.27	5.86	0.3	1.1e-8	Pulmonary function;
LIHC	cis	rs10097731	0.901	rs10464892	chr8:82042991	A/G	cg25230327	chr8:82042993	NA	0.54	7.75	0.39	1.03e-13	Serum total protein level;
LIHC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.6	8.97	0.44	1.95e-17	Recombination rate (females);
LIHC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg11204139	chr17:3907470	NA	-0.55	-6.87	-0.35	3.06e-11	Type 2 diabetes;
LIHC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-5.98	-0.31	5.68e-9	Osteoporosis;
LIHC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.57	0.56	4.76e-30	Schizophrenia;
LIHC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg05941027	chr17:61774174	LIMD2	0.36	7.2	0.36	3.78e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg18279126	chr7:2041391	MAD1L1	0.36	5.83	0.3	1.28e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.87	0.3	1e-8	Bipolar disorder;
LIHC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.56	0.8	1.79e-77	Prudent dietary pattern;
LIHC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.38	-7.0	-0.35	1.34e-11	Electrocardiographic conduction measures;
LIHC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.35	-6.95	-0.35	1.84e-11	Body mass index;
LIHC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.49	-8.0	-0.4	1.94e-14	Menarche (age at onset);
LIHC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.5	7.37	0.37	1.26e-12	Total body bone mineral density;
LIHC	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg03934865	chr2:198174659	NA	0.43	6.28	0.32	1e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-7.86	-0.39	5.04e-14	Coronary artery disease;
LIHC	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg01843034	chr6:37503916	NA	-0.44	-7.41	-0.37	1.02e-12	Cognitive performance;
LIHC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.67	0.59	3.1e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	12.01	0.54	5.85e-28	Response to antipsychotic treatment;
LIHC	cis	rs10933610	1.000	rs10933610	chr2:241443654	C/T	cg21879648	chr2:241404072	GPC1	0.47	6.16	0.32	1.99e-9	Pursuit maintenance gain;
LIHC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.45	-0.46	5.56e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.29e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.57	-10.71	-0.5	2.75e-23	Coronary artery disease;
LIHC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg13152130	chr6:118910203	C6orf204	-0.62	-6.59	-0.34	1.63e-10	Diastolic blood pressure;
LIHC	cis	rs2386661	0.826	rs12260316	chr10:5659835	C/T	cg17085576	chr10:5658249	NA	-0.36	-6.46	-0.33	3.67e-10	Breast cancer;
LIHC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.28	-0.37	2.34e-12	Breast cancer;
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.87	13.04	0.58	7.69e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.81	-9.1	-0.44	7.57e-18	Obesity-related traits;
LIHC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg26832524	chr1:29508259	SFRS4	-0.4	-6.4	-0.33	5.16e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.56	8.8	0.43	6.83e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.75	-11.45	-0.53	6.55e-26	Morning vs. evening chronotype;
LIHC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.44	-7.55	-0.38	4.02e-13	Dementia with Lewy bodies;
LIHC	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg05010058	chr2:65284262	CEP68	-0.38	-6.49	-0.33	2.98e-10	Pulse pressure;
LIHC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.59	11.43	0.53	7.69e-26	Tonsillectomy;
LIHC	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.39	-5.99	-0.31	5.23e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg20283391	chr11:68216788	NA	-0.52	-7.93	-0.39	3.09e-14	Total body bone mineral density;
LIHC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.4	6.48	0.33	3.19e-10	Red blood cell count;
LIHC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.87	15.77	0.65	1.77e-42	Dental caries;
LIHC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.42	-5.76	-0.3	1.9e-8	Total body bone mineral density;
LIHC	cis	rs3736594	0.513	rs62131881	chr2:27764781	G/T	cg27432699	chr2:27873401	GPN1	0.46	6.79	0.34	4.91e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.99	0.31	5.44e-9	Rheumatoid arthritis;
LIHC	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.24	-6.53	-0.33	2.41e-10	Type 2 diabetes;
LIHC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.66	-6.77	-0.34	5.64e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.84	15.3	0.64	1.22e-40	IgG glycosylation;
LIHC	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.35	12.61	0.56	3.43e-30	Uric acid levels;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg20994686	chr17:71306668	CDC42EP4	0.44	6.31	0.32	8.74e-10	Migraine with aura;
LIHC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.59	7.32	0.37	1.83e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-1.0	-20.91	-0.75	3.87e-63	Height;
LIHC	cis	rs2108622	0.958	rs79400241	chr19:15984402	C/G	cg13772218	chr19:15982569	NA	0.4	8.2	0.41	5.08e-15	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs1144333	0.655	rs76992868	chr1:76418916	G/A	cg22875332	chr1:76189707	ACADM	0.4	6.06	0.31	3.51e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg20140201	chr2:241835670	C2orf54	-0.5	-7.72	-0.39	1.28e-13	Urinary metabolites;
LIHC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.88	0.35	2.9100000000000002e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.67	-14.08	-0.61	7.9e-36	Sense of smell;
LIHC	trans	rs45567533	0.790	rs7372712	chr3:38686192	C/T	cg14758556	chr20:62440591	NA	0.4	6.12	0.31	2.58e-9	PR interval;
LIHC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.64	8.78	0.43	7.74e-17	Skin colour saturation;
LIHC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg20090690	chr10:134436459	INPP5A	0.44	5.8	0.3	1.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-6.25	-0.32	1.24e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.43	-0.33	4.25e-10	Body mass index;
LIHC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg00850481	chr1:228891306	NA	-0.44	-6.75	-0.34	6.16e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.53	8.23	0.41	3.89e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	19.16	0.72	4.02e-56	Colorectal cancer;
LIHC	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	0.55	10.36	0.49	4.85e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs12464559	0.649	rs4605370	chr2:152628288	C/T	cg01189475	chr2:152685088	ARL5A	-0.65	-7.83	-0.39	6.38e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg23485639	chr6:28045615	ZNF165	0.39	6.05	0.31	3.78e-9	Cardiac Troponin-T levels;
LIHC	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.03	0.31	4.34e-9	HDL cholesterol;
LIHC	cis	rs12079745	0.793	rs3753298	chr1:169176899	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.7	-6.53	-0.33	2.4e-10	QT interval;
LIHC	cis	rs61677309	1.000	rs56224295	chr11:118161891	G/A	cg06090739	chr11:118230722	UBE4A	0.34	6.18	0.32	1.83e-9	Lung cancer in ever smokers;
LIHC	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	0.96	7.04	0.36	1.06e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg22777020	chr22:31556080	RNF185	0.56	6.46	0.33	3.64e-10	Colorectal cancer;
LIHC	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.18	-0.36	4.27e-12	Migraine;Coronary artery disease;
LIHC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.6	9.13	0.44	5.9e-18	Longevity;Endometriosis;
LIHC	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.42	6.16	0.32	2.03e-9	Menopause (age at onset);
LIHC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-11.18	-0.52	6.29e-25	Response to antipsychotic treatment;
LIHC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg05941027	chr17:61774174	LIMD2	0.31	6.37	0.33	6.16e-10	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.46	5.92	0.3	7.9e-9	Obesity (extreme);
LIHC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg04310649	chr10:35416472	CREM	-0.43	-5.71	-0.3	2.41e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.59	-12.3	-0.55	5.06e-29	Plateletcrit;Platelet count;
LIHC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg00612595	chr21:47717864	NA	-0.38	-6.15	-0.32	2.12e-9	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.0	-0.4	1.93e-14	Alzheimer's disease;
LIHC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.05	24.37	0.8	9.63e-77	IgG glycosylation;
LIHC	cis	rs1789	0.903	rs4470622	chr4:15674175	T/G	cg21123203	chr4:15471301	CC2D2A	-0.43	-6.74	-0.34	6.84e-11	Blood protein levels;
LIHC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.55	8.74	0.43	1.1e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.97	19.49	0.73	1.99e-57	Platelet distribution width;
LIHC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg14930904	chr10:32216787	ARHGAP12	0.38	6.82	0.35	4.25e-11	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12501888	chr15:85177176	SCAND2	-0.52	-8.06	-0.4	1.28e-14	P wave terminal force;
LIHC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.64	13.1	0.58	4.74e-32	Gestational age at birth (maternal effect);
LIHC	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.63	7.31	0.37	1.95e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.3	7.27	0.37	2.43e-12	Alcohol dependence;
LIHC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg09238746	chr17:78121135	EIF4A3	-0.74	-11.8	-0.54	3.31e-27	Yeast infection;
LIHC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.33	6.65	0.34	1.17e-10	Renal cell carcinoma;
LIHC	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	0.78	7.89	0.39	4.2e-14	Arsenic metabolism;
LIHC	cis	rs918629	0.530	rs17085249	chr5:95236415	C/T	cg10483112	chr5:95245456	ELL2	-0.38	-6.89	-0.35	2.69e-11	IgG glycosylation;
LIHC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.35	7.67	0.38	1.76e-13	Erythrocyte sedimentation rate;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg01535726	chr8:9911482	MSRA	-0.42	-6.54	-0.33	2.29e-10	Monocyte count;
LIHC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.38	0.33	5.74e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs9783347	1.000	rs4150550	chr11:18350898	C/G	cg15585147	chr11:18324498	HPS5	0.38	6.17	0.32	1.91e-9	Pancreatic cancer;
LIHC	cis	rs2920503	0.959	rs2920502	chr3:12329195	G/C	cg23514324	chr3:12329213	PPARG	0.55	7.1	0.36	7.37e-12	LDL cholesterol;
LIHC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	1.01e-11	Height;
LIHC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.8	9.07	0.44	9.78e-18	Vitiligo;
LIHC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.76	0.3	1.86e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.45	8.11	0.4	8.94e-15	Resting heart rate;
LIHC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.95	-0.35	1.86e-11	Obesity-related traits;
LIHC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.67	11.3	0.52	2.35e-25	Lymphocyte counts;
LIHC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.19	-18.14	-0.7	5.15e-52	Type 1 diabetes nephropathy;
LIHC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.3	16.95	0.68	3.41e-47	Diabetic kidney disease;
LIHC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04498913	chr7:1135747	C7orf50	0.42	6.62	0.34	1.37e-10	Bronchopulmonary dysplasia;
LIHC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9625935	0.518	rs9614086	chr22:30259608	A/C	cg01021169	chr22:30184971	ASCC2	0.37	6.32	0.32	8.2e-10	Tonsillectomy;
LIHC	cis	rs8038465	0.615	rs11637315	chr15:73944068	G/C	cg15420318	chr15:73925796	NPTN	0.47	7.24	0.36	3.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.71	12.31	0.55	4.27e-29	Menopause (age at onset);
LIHC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12016809	chr21:47604291	C21orf56	0.41	5.97	0.31	6.06e-9	Testicular germ cell tumor;
LIHC	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg25600027	chr14:23388339	RBM23	-0.41	-5.9	-0.3	8.79e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.29	6.14	0.31	2.35e-9	Pulmonary function;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg11235426	chr6:292522	DUSP22	-0.52	-6.87	-0.35	3.11e-11	Menopause (age at onset);
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.36	-5.87	-0.3	1.04e-8	Prudent dietary pattern;
LIHC	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg20636351	chr8:55087400	NA	-0.39	-7.89	-0.39	4.05e-14	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-0.85	-9.58	-0.46	2.07e-19	Schizophrenia;
LIHC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.64	-8.97	-0.44	1.95e-17	Blood metabolite levels;
LIHC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.81	-0.43	6.38e-17	Schizophrenia;
LIHC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	10.12	0.48	3.1e-21	Menarche (age at onset);
LIHC	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02985541	chr2:219472218	PLCD4	-0.38	-6.59	-0.34	1.63e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.81	11.62	0.53	1.54e-26	Coronary artery disease;
LIHC	cis	rs11958404	1.000	rs72816538	chr5:157414303	A/G	cg05962755	chr5:157440814	NA	0.86	10.11	0.48	3.51e-21	IgG glycosylation;
LIHC	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg24112000	chr20:60950667	NA	0.46	7.34	0.37	1.54e-12	Colorectal cancer;
LIHC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg03929089	chr4:120376271	NA	-0.4	-6.09	-0.31	3.02e-9	HDL cholesterol;
LIHC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	12.66	0.56	2.18e-30	Schizophrenia;
LIHC	trans	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg01596870	chr19:55963115	NA	-0.64	-8.65	-0.42	2.07e-16	Obesity-related traits;
LIHC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.8	16.51	0.67	1.99e-45	White blood cell count;
LIHC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg04374321	chr14:90722782	PSMC1	0.48	6.55	0.33	2.14e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.5	6.04	0.31	4.04e-9	Heart rate;
LIHC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.25	0.41	3.57e-15	Birth weight;
LIHC	cis	rs1198430	0.759	rs946267	chr1:23747703	A/T	cg19827787	chr1:23763612	ASAP3	0.27	5.91	0.3	8.36e-9	Total cholesterol levels;
LIHC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg25894440	chr7:65020034	NA	-0.55	-6.42	-0.33	4.51e-10	Diabetic kidney disease;
LIHC	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.38	-6.25	-0.32	1.22e-9	Corneal astigmatism;
LIHC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	11.45	0.53	6.23e-26	Platelet count;
LIHC	cis	rs11822910	0.911	rs61886978	chr11:57194848	G/C	cg00522883	chr11:57194120	SLC43A3	0.66	8.7	0.43	1.43e-16	Platelet distribution width;
LIHC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.44	6.95	0.35	1.81e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.74	-13.35	-0.59	5e-33	Longevity;
LIHC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	8.93e-10	Aortic root size;
LIHC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.51	8.25	0.41	3.41e-15	Schizophrenia;
LIHC	cis	rs9816226	0.591	rs75160594	chr3:185810481	C/G	cg00760338	chr3:185826511	ETV5	-0.71	-5.99	-0.31	5.27e-9	Obesity;Body mass index;
LIHC	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.63	9.41	0.45	7.54e-19	Nonalcoholic fatty liver disease;
LIHC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg11070056	chr1:107600091	PRMT6	0.7	12.12	0.55	2.31e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg04865290	chr3:52927548	TMEM110	-0.49	-6.19	-0.32	1.74e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.02	-0.73	1.41e-59	Height;
LIHC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg17764715	chr19:33622953	WDR88	0.42	5.77	0.3	1.74e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.94	17.57	0.69	1.04e-49	Menopause (age at onset);
LIHC	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.35	-8.13	-0.4	8e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg00280220	chr17:61926910	NA	0.42	6.73	0.34	7.18e-11	Prudent dietary pattern;
LIHC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.59	8.72	0.43	1.23e-16	Platelet count;
LIHC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg10360323	chr17:41437877	NA	0.4	6.03	0.31	4.17e-9	Menopause (age at onset);
LIHC	cis	rs6066825	0.644	rs6090894	chr20:47334688	G/T	cg18078177	chr20:47281410	PREX1	0.41	6.67	0.34	1.05e-10	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-13.82	-0.6	8.38e-35	Alzheimer's disease;
LIHC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.46	6.46	0.33	3.5e-10	Longevity;Endometriosis;
LIHC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	8.97	0.44	1.97e-17	Lung cancer in ever smokers;
LIHC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	8.96	0.44	2.09e-17	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs611744	0.905	rs640950	chr8:109157819	T/A	cg21045802	chr8:109455806	TTC35	0.46	7.69	0.38	1.62e-13	Dupuytren's disease;
LIHC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-8.21	-0.41	4.62e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.38	-8.55	-0.42	4.22e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17554472	chr22:41940697	POLR3H	0.51	5.81	0.3	1.45e-8	Vitiligo;
LIHC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.69	0.38	1.54e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.47	-7.64	-0.38	2.14e-13	Cognitive function;
LIHC	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.56	-9.02	-0.44	1.41e-17	Colorectal cancer;
LIHC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.1	-15.68	-0.65	3.82e-42	Chronic sinus infection;
LIHC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.74	0.43	1.04e-16	Motion sickness;
LIHC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.9	10.12	0.48	3.12e-21	Primary sclerosing cholangitis;
LIHC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	9.08	0.44	8.77e-18	Initial pursuit acceleration;
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.44	-5.95	-0.31	6.49e-9	Total body bone mineral density;
LIHC	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.34	-7.19	-0.36	4.18e-12	Intelligence (multi-trait analysis);
LIHC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.7	10.21	0.48	1.57e-21	Coronary artery disease;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.81	16.74	0.67	2.26e-46	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.5	6.91	0.35	2.43e-11	Morning vs. evening chronotype;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg13409248	chr3:40428643	ENTPD3	-0.5	-8.45	-0.42	8.34e-16	Renal cell carcinoma;
LIHC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.37	-5.99	-0.31	5.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg26149184	chr10:133730230	NA	-0.41	-6.52	-0.33	2.51e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs652260	1.000	rs652260	chr19:7900562	C/T	cg26014689	chr19:7917955	EVI5L	-0.67	-11.64	-0.53	1.34e-26	Menarche (age at onset);
LIHC	cis	rs151997	1.000	rs62367382	chr5:50246715	T/C	cg06027927	chr5:50259733	NA	0.62	7.86	0.39	5.18e-14	Callous-unemotional behaviour;
LIHC	cis	rs860295	0.719	rs490608	chr1:155682870	C/T	cg02153340	chr1:155202674	NA	-0.31	-5.77	-0.3	1.77e-8	Body mass index;
LIHC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	6.55	0.33	2.06e-10	Total body bone mineral density;
LIHC	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg05590025	chr7:65112418	INTS4L2	0.58	6.43	0.33	4.21e-10	Diabetic kidney disease;
LIHC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.27	-6.58	-0.34	1.76e-10	Primary biliary cholangitis;
LIHC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg24296786	chr1:45957014	TESK2	-0.5	-7.17	-0.36	4.59e-12	Platelet count;
LIHC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.18	-25.81	-0.81	2.79e-82	Myeloid white cell count;
LIHC	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg15208524	chr1:10270712	KIF1B	0.38	5.81	0.3	1.42e-8	Hepatocellular carcinoma;
LIHC	cis	rs1400745	0.729	rs1741196	chr14:35347020	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.73	-0.39	1.2e-13	Monocyte count;
LIHC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.59	9.42	0.45	6.8e-19	Obesity-related traits;
LIHC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg22561889	chr6:118971681	C6orf204	0.55	5.94	0.31	7.13e-9	Diastolic blood pressure;
LIHC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.51	8.58	0.42	3.44e-16	Mean corpuscular volume;
LIHC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.76	11.0	0.51	2.74e-24	Response to antineoplastic agents;
LIHC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.75	10.04	0.48	5.94e-21	Fat distribution (HIV);
LIHC	trans	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.89	-0.35	2.7e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LIHC	trans	rs6058796	1.000	rs6087972	chr20:31268102	A/G	cg02600331	chr11:130417168	NA	0.36	7.59	0.38	2.98e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs244293	0.730	rs9898020	chr17:53057715	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-7.24	-0.36	2.9e-12	Menarche (age at onset);
LIHC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.55	7.73	0.39	1.19e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.43	0.45	6.55e-19	Bipolar disorder;
LIHC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	1.02	21.19	0.75	2.98e-64	Height;
LIHC	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg10820045	chr2:198174542	NA	0.56	9.19	0.44	3.93e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs75908454	1.000	rs77366054	chr6:169857167	C/T	cg19338460	chr6:170058176	WDR27	-0.83	-7.89	-0.39	4.22e-14	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg16586182	chr3:47516702	SCAP	-0.58	-11.26	-0.52	3.19e-25	Colorectal cancer;
LIHC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.35	6.08	0.31	3.18e-9	Tonsillectomy;
LIHC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.88	-0.35	2.84e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg08135965	chr6:41755394	TOMM6	0.46	6.15	0.32	2.17e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-7.41	-0.37	9.96e-13	Fear of minor pain;
LIHC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.61	9.43	0.45	6.58e-19	Height;
LIHC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.44	6.01	0.31	4.84e-9	Total body bone mineral density;
LIHC	cis	rs986417	1.000	rs4901985	chr14:60948318	A/C	cg27398547	chr14:60952738	C14orf39	0.77	8.96	0.44	2.13e-17	Gut microbiota (bacterial taxa);
LIHC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-5.71	-0.3	2.43e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.49	-0.53	4.52e-26	Type 2 diabetes;
LIHC	cis	rs1494950	1.000	rs57517602	chr4:14977442	C/T	cg12377275	chr4:15005593	CPEB2	-0.79	-6.71	-0.34	8.25e-11	Political ideology;
LIHC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg06207120	chr15:45996521	NA	0.31	5.84	0.3	1.25e-8	Waist circumference;Weight;
LIHC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg07150772	chr14:90864620	CALM1	-0.42	-5.87	-0.3	1.03e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg10820045	chr2:198174542	NA	0.51	8.08	0.4	1.12e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg07150772	chr14:90864620	CALM1	-0.41	-5.84	-0.3	1.23e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08219700	chr8:58056026	NA	0.5	6.34	0.32	7.14e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg11764359	chr7:65958608	NA	0.59	6.01	0.31	4.63e-9	Diabetic kidney disease;
LIHC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	0.92	9.44	0.45	5.9e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	8.21	0.41	4.51e-15	Lung cancer;
LIHC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.43	-6.08	-0.31	3.17e-9	Coronary artery disease;
LIHC	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.93	0.43	2.63e-17	Exhaled nitric oxide output;
LIHC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.72	9.54	0.46	2.7e-19	Schizophrenia;
LIHC	cis	rs11822910	0.815	rs12422015	chr11:57193653	A/G	cg00522883	chr11:57194120	SLC43A3	0.67	8.57	0.42	3.67e-16	Platelet distribution width;
LIHC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg04155231	chr12:9217510	LOC144571	-0.31	-5.9	-0.3	8.53e-9	Sjögren's syndrome;
LIHC	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.91	0.43	3.16e-17	Exhaled nitric oxide output;
LIHC	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.04	0.66	1.46e-43	Electrocardiographic conduction measures;
LIHC	cis	rs74181299	0.533	rs6705891	chr2:65368095	T/A	cg05010058	chr2:65284262	CEP68	-0.36	-5.74	-0.3	2.04e-8	Pulse pressure;
LIHC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.54	9.75	0.47	5.8e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.63	6.87	0.35	2.99e-11	Alzheimer's disease;
LIHC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.44	-10.09	-0.48	3.87e-21	Urinary metabolites;
LIHC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg16576597	chr16:28551801	NUPR1	-0.39	-6.52	-0.33	2.6e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.54	8.67	0.42	1.76e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	7.5	0.38	5.65e-13	Chronic sinus infection;
LIHC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.39	6.11	0.31	2.78e-9	Lung cancer;
LIHC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.54	8.04	0.4	1.5e-14	High light scatter reticulocyte count;
LIHC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.09	-0.31	3.09e-9	Total body bone mineral density;
LIHC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg03037974	chr15:76606532	NA	-0.6	-9.99	-0.48	8.46e-21	Blood metabolite levels;
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs9323205	0.531	rs55928212	chr14:51543439	G/A	cg02322135	chr4:113969312	ANK2	0.44	6.33	0.32	7.77e-10	Cancer;
LIHC	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.58	7.06	0.36	9.61e-12	Coronary artery disease;
LIHC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.52	7.91	0.39	3.61e-14	Longevity;Endometriosis;
LIHC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.16	0.36	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs4764487	0.710	rs7964366	chr12:6346478	T/C	cg08284733	chr12:6341482	CD9	0.38	6.44	0.33	4.12e-10	Mean platelet volume;
LIHC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-14.76	-0.62	1.8e-38	Alzheimer's disease (late onset);
LIHC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.7	11.6	0.53	1.79e-26	Colorectal or endometrial cancer;
LIHC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg03959625	chr15:84868606	LOC388152	0.48	6.87	0.35	3.07e-11	Schizophrenia;
LIHC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-7.36	-0.37	1.39e-12	Primary biliary cholangitis;
LIHC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.98	-18.31	-0.7	1.11e-52	Breast cancer;
LIHC	cis	rs6604026	0.522	rs12756786	chr1:93044955	G/A	cg13858687	chr1:93297071	RPL5	0.59	5.71	0.3	2.43e-8	Multiple sclerosis;
LIHC	cis	rs61677309	1.000	rs7110019	chr11:118168617	A/G	cg06090739	chr11:118230722	UBE4A	0.34	6.27	0.32	1.06e-9	Lung cancer in ever smokers;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.53	-7.6	-0.38	2.87e-13	Lung cancer;
LIHC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg15848620	chr12:58087721	OS9	0.49	6.32	0.32	7.95e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.46	-8.38	-0.41	1.36e-15	Body mass index;
LIHC	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg21584241	chr15:63341463	TPM1	0.44	6.38	0.33	5.9e-10	Orofacial clefts;
LIHC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.26	6.17	0.32	1.95e-9	Crohn's disease;
LIHC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg18876405	chr7:65276391	NA	0.33	5.76	0.3	1.92e-8	Aortic root size;
LIHC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg06466757	chr4:1255808	NA	0.34	5.72	0.3	2.38e-8	Obesity-related traits;
LIHC	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.69	0.5	3.29e-23	Colorectal cancer;
LIHC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05025164	chr4:1340916	KIAA1530	0.52	7.88	0.39	4.34e-14	Obesity-related traits;
LIHC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg23109721	chr2:106886537	NA	-0.65	-6.31	-0.32	8.64e-10	Facial morphology (factor 23);
LIHC	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.62	-10.3	-0.49	7.3e-22	Fibroblast growth factor basic levels;
LIHC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.42	-8.48	-0.42	7.01e-16	Obesity-related traits;
LIHC	trans	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg13698153	chr12:118541722	VSIG10	-0.63	-7.12	-0.36	6.55e-12	Vitiligo;
LIHC	cis	rs11673344	0.764	rs513406	chr19:37439147	G/A	cg27390819	chr19:37464633	NA	-0.52	-6.22	-0.32	1.42e-9	Obesity-related traits;
LIHC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.95	0.31	6.65e-9	Obesity-related traits;
LIHC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-19.99	-0.73	1.9e-59	Height;
LIHC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg09835421	chr16:68378352	PRMT7	-0.83	-9.75	-0.47	5.66e-20	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13409248	chr3:40428643	ENTPD3	-0.46	-8.03	-0.4	1.62e-14	Renal cell carcinoma;
LIHC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.72	0.3	2.32e-8	Tonsillectomy;
LIHC	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.98	-0.4	2.26e-14	Coronary artery disease;
LIHC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.47	7.68	0.38	1.69e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.63	-10.58	-0.5	8.37e-23	Waist circumference;Body mass index;
LIHC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.05	0.51	1.78e-24	Menarche (age at onset);
LIHC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg19645103	chr12:69753606	YEATS4	-0.47	-6.39	-0.33	5.32e-10	Response to diuretic therapy;
LIHC	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg01364799	chr7:75623366	TMEM120A	-0.5	-7.41	-0.37	9.97e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.81	-9.56	-0.46	2.42e-19	Cognitive function;
LIHC	cis	rs3770081	1.000	rs6718632	chr2:86176084	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.69	-0.43	1.52e-16	Facial emotion recognition (sad faces);
LIHC	trans	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg01596870	chr19:55963115	NA	-0.67	-9.79	-0.47	3.98e-20	Obesity-related traits;
LIHC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.66	-0.42	1.91e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.5	-9.71	-0.47	7.4e-20	LDL cholesterol levels;
LIHC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.81	8.74	0.43	1.08e-16	Vitiligo;
LIHC	cis	rs4788570	0.647	rs904764	chr16:71772795	G/A	cg06353428	chr16:71660113	MARVELD3	1.36	14.23	0.61	2.1e-36	Intelligence (multi-trait analysis);
LIHC	cis	rs2334880	0.680	rs1364210	chr16:71603487	G/A	cg06353428	chr16:71660113	MARVELD3	-1.27	-10.94	-0.51	4.4e-24	Malaria;
LIHC	cis	rs7707921	0.505	rs12516434	chr5:81428072	T/A	cg15871215	chr5:81402204	ATG10	0.65	7.21	0.36	3.54e-12	Breast cancer;
LIHC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.56	10.52	0.49	1.29e-22	Total body bone mineral density;
LIHC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.6	8.49	0.42	6.25e-16	Blood metabolite levels;
LIHC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg03037974	chr15:76606532	NA	0.59	10.1	0.48	3.62e-21	Blood metabolite levels;
LIHC	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18918831	chr3:195489782	MUC4	0.72	11.15	0.52	8.01e-25	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.51	-0.49	1.42e-22	Schizophrenia;
LIHC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.72	-8.84	-0.43	5.12e-17	Gut microbiome composition (summer);
LIHC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-8.87	-0.43	4.04e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.59	8.18	0.4	5.51e-15	Coronary artery disease;
LIHC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.45	5.98	0.31	5.47e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.38	-5.94	-0.31	6.96e-9	Morning vs. evening chronotype;
LIHC	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.62	0.42	2.48e-16	Coffee consumption (cups per day);
LIHC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg12798992	chr6:167411361	FGFR1OP	0.61	10.21	0.48	1.58e-21	Crohn's disease;
LIHC	trans	rs3112255	1.000	rs2942904	chr2:101306999	A/G	cg06958034	chr1:23346203	KDM1A	-0.46	-6.06	-0.31	3.55e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.53	7.28	0.37	2.25e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.58	-0.38	3.29e-13	QT interval;
LIHC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.87	12.82	0.57	5.54e-31	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.67	11.83	0.54	2.59e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	0.88	6.35	0.32	6.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25832598	chr1:247094143	AHCTF1	0.45	6.45	0.33	3.77e-10	Pancreatic cancer;
LIHC	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.46	0.33	3.62e-10	Mammographic density (dense area);
LIHC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.68	-0.46	9.48e-20	Bipolar disorder and schizophrenia;
LIHC	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.21	-6.04	-0.31	3.97e-9	Mean corpuscular volume;
LIHC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.29	-5.83	-0.3	1.26e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg17385448	chr1:15911702	AGMAT	0.36	6.06	0.31	3.53e-9	Systolic blood pressure;
LIHC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-9.53	-0.46	3.07e-19	Mean platelet volume;
LIHC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.34	-0.37	1.59e-12	Personality dimensions;
LIHC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.4	7.61	0.38	2.71e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.16	0.48	2.3e-21	Alzheimer's disease (late onset);
LIHC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.13	-0.48	2.92e-21	Alzheimer's disease;
LIHC	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.56	8.78	0.43	8e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs11673344	0.543	rs8108429	chr19:37636776	A/C	cg27390819	chr19:37464633	NA	-0.44	-5.87	-0.3	1.04e-8	Obesity-related traits;
LIHC	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	0.83	10.06	0.48	4.95e-21	Gout;Urate levels;Serum uric acid levels;
LIHC	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.7	-7.06	-0.36	9.63e-12	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs4917833	0.764	rs1925645	chr10:100220472	T/C	cg19043522	chr10:100227446	HPSE2	0.4	5.73	0.3	2.22e-8	Pediatric bone mineral density (femoral neck);
LIHC	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.83	-8.71	-0.43	1.31e-16	Blood pressure (smoking interaction);
LIHC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.49	9.07	0.44	9.41e-18	Hemoglobin concentration;
LIHC	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.35	-8.7	-0.43	1.38e-16	Cutaneous nevi;
LIHC	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.75	12.38	0.56	2.5e-29	Gastritis;
LIHC	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.46	6.61	0.34	1.45e-10	Sudden cardiac arrest;
LIHC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.77	11.49	0.53	4.48e-26	Coronary artery disease;
LIHC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.63	-0.59	4.53e-34	Bipolar disorder and schizophrenia;
LIHC	cis	rs7116495	1.000	rs7127865	chr11:71747781	G/C	cg26138937	chr11:71823887	C11orf51	-0.81	-8.08	-0.4	1.11e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-7.99	-0.4	2.15e-14	Vitamin D levels;
LIHC	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.09	-0.31	3.03e-9	Metabolite levels;
LIHC	cis	rs7635838	0.859	rs9812885	chr3:11508326	G/C	cg00170343	chr3:11313890	ATG7	0.4	6.18	0.32	1.79e-9	HDL cholesterol;
LIHC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.34	7.34	0.37	1.54e-12	Bone mineral density;
LIHC	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-10.78	-0.5	1.62e-23	Eye color traits;
LIHC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg12463550	chr7:65579703	CRCP	0.71	7.04	0.36	1.05e-11	Diabetic kidney disease;
LIHC	cis	rs76533333	0.564	rs34658917	chr13:113417423	C/T	cg08557188	chr13:113420371	ATP11A	-0.8	-6.06	-0.31	3.58e-9	Red cell distribution width;
LIHC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.48	-0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg14146966	chr2:61757674	XPO1	0.47	8.19	0.41	5.17e-15	Tuberculosis;
LIHC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg12798992	chr6:167411361	FGFR1OP	0.4	6.1	0.31	2.92e-9	Crohn's disease;
LIHC	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.73	-10.15	-0.48	2.5e-21	Cisplatin-induced ototoxicity;
LIHC	trans	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19862616	chr7:65841803	NCRNA00174	0.6	9.34	0.45	1.23e-18	Eotaxin levels;
LIHC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.48	-18.27	-0.7	1.56e-52	Breast cancer;
LIHC	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-7.63	-0.38	2.31e-13	Pediatric bone mineral density (spine);
LIHC	cis	rs858239	0.568	rs6970694	chr7:23250828	T/C	cg18081818	chr7:23246105	NA	-0.42	-6.02	-0.31	4.5e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02985541	chr2:219472218	PLCD4	-0.44	-7.18	-0.36	4.25e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	cis	rs7258015	1.000	rs7258015	chr19:10449358	T/C	cg13981319	chr19:10446556	ICAM3	0.47	7.26	0.37	2.59e-12	Systemic lupus erythematosus or rheumatoid arthritis;
LIHC	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.42	0.45	7.14e-19	Corneal astigmatism;
LIHC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.68	11.67	0.53	9.94e-27	Crohn's disease;
LIHC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	8.51	0.42	5.58e-16	Response to antipsychotic treatment;
LIHC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg12903224	chr12:29470962	FAR2	-0.41	-6.73	-0.34	7.35e-11	QT interval;
LIHC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.75	11.75	0.54	5.45e-27	Longevity;
LIHC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.5	6.58	0.34	1.8e-10	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.57	0.46	2.28e-19	Corneal astigmatism;
LIHC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.48	-7.18	-0.36	4.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.55	8.76	0.43	9.14e-17	Menarche (age at onset);
LIHC	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg07936489	chr17:37558343	FBXL20	-0.77	-12.18	-0.55	1.37e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg00934597	chr7:893267	UNC84A	-0.51	-5.94	-0.31	6.84e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	0.98	14.33	0.61	8.56e-37	Skin colour saturation;
LIHC	cis	rs2569991	1.000	rs2569991	chr3:12923197	C/A	cg07263372	chr3:12940286	IQSEC1	-0.34	-5.8	-0.3	1.54e-8	Periodontitis (DPAL);
LIHC	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg00085434	chr11:14927489	NA	0.41	5.81	0.3	1.41e-8	Vitamin D levels;
LIHC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.4	-6.45	-0.33	3.88e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.65	6.57	0.33	1.86e-10	Lymphocyte counts;
LIHC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg15448220	chr1:150897856	SETDB1	0.43	6.77	0.34	5.77e-11	Tonsillectomy;
LIHC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.48	6.08	0.31	3.18e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07677032	chr17:61819896	STRADA	0.42	6.13	0.31	2.36e-9	Prudent dietary pattern;
LIHC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.36	12.63	0.56	2.86e-30	Uric acid levels;
LIHC	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg14146966	chr2:61757674	XPO1	0.48	8.26	0.41	3.21e-15	Tuberculosis;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11829033	chr10:74927882	FAM149B1;ECD	0.41	6.19	0.32	1.71e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.43	7.12	0.36	6.32e-12	Breast cancer;
LIHC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.6	-0.38	2.8e-13	Glioblastoma;
LIHC	cis	rs6466055	0.720	rs10227302	chr7:105021829	C/G	cg04380332	chr7:105027541	SRPK2	-0.38	-7.02	-0.35	1.2e-11	Schizophrenia;
LIHC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	0.67	8.29	0.41	2.61e-15	Corneal curvature;
LIHC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.52	7.6	0.38	2.83e-13	Blood pressure (smoking interaction);
LIHC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.5	7.74	0.39	1.12e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.68	-12.25	-0.55	7.47e-29	Pediatric autoimmune diseases;
LIHC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	7.63	0.38	2.3e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7116495	0.748	rs481355	chr11:71578356	G/A	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.27e-11	Severe influenza A (H1N1) infection;
LIHC	trans	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg23598604	chr1:99732472	LPPR4	-0.3	-6.2	-0.32	1.61e-9	Multiple myeloma;
LIHC	cis	rs2274273	0.934	rs10140869	chr14:55795283	G/A	cg01864836	chr14:55583639	NA	-0.37	-6.49	-0.33	3.06e-10	Protein biomarker;
LIHC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.5	7.95	0.39	2.83e-14	Longevity;
LIHC	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.7	10.35	0.49	4.92e-22	Monocyte count;
LIHC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.37	6.73	0.34	7.38e-11	Aortic root size;
LIHC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21448741	chr8:58168803	NA	0.37	6.61	0.34	1.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.37e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.48	7.39	0.37	1.13e-12	Diastolic blood pressure;
LIHC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.57	9.26	0.45	2.39e-18	Multiple sclerosis;
LIHC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-6.12	-0.31	2.6e-9	Tonsillectomy;
LIHC	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.78	9.04	0.44	1.21e-17	Exhaled nitric oxide levels;
LIHC	cis	rs11931598	0.511	rs35772786	chr4:7021211	T/G	cg26116260	chr4:7069785	GRPEL1	0.55	9.35	0.45	1.19e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LIHC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.98	-0.31	5.68e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.6	0.53	1.92e-26	Platelet count;
LIHC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.46	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.39	0.45	8.39e-19	IgG glycosylation;
LIHC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg03037974	chr15:76606532	NA	-0.54	-8.9	-0.43	3.4e-17	Blood metabolite levels;
LIHC	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-10.33	-0.49	6.08e-22	Hypertriglyceridemia;
LIHC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-13.22	-0.58	1.69e-32	Vitiligo;
LIHC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.45	-0.49	2.25e-22	Aortic root size;
LIHC	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	7.66	0.38	1.9e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg15691649	chr6:25882328	NA	-0.45	-5.78	-0.3	1.71e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs28489187	0.683	rs12047422	chr1:85848830	T/G	cg16011679	chr1:85725395	C1orf52	0.46	5.78	0.3	1.73e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.23	-0.32	1.38e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.27	-0.49	9.53e-22	Hemoglobin concentration;
LIHC	cis	rs939574	0.656	rs113370390	chr2:220132837	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.93	6.35	0.32	6.75e-10	Platelet distribution width;
LIHC	cis	rs4684776	0.867	rs1470613	chr3:11347525	G/A	cg00170343	chr3:11313890	ATG7	-0.52	-7.21	-0.36	3.53e-12	Small vessel stroke;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06420487	chr17:61919686	SMARCD2	0.42	5.76	0.3	1.88e-8	Height;
LIHC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg18279126	chr7:2041391	MAD1L1	0.37	5.74	0.3	2.12e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs3015497	1.000	rs4075253	chr14:51107737	G/A	cg09863266	chr14:51125203	SAV1	-0.43	-7.02	-0.35	1.2e-11	Mean platelet volume;
LIHC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.38	-5.95	-0.31	6.75e-9	Asthma;
LIHC	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.47	6.85	0.35	3.5e-11	Dermatomyositis;
LIHC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.42	-6.74	-0.34	6.64e-11	Menarche (age at onset);
LIHC	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	7.6	0.38	2.83e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.48	-7.5	-0.38	5.39e-13	Information processing speed;
LIHC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.41	0.53	9.22e-26	Coronary artery disease;
LIHC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg04310649	chr10:35416472	CREM	-0.43	-5.86	-0.3	1.1e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.32	-7.5	-0.38	5.43e-13	Hip circumference;Waist circumference;
LIHC	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	1.05	11.56	0.53	2.49e-26	IgG glycosylation;
LIHC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.47	-0.33	3.41e-10	Neuroticism;
LIHC	cis	rs7212590	0.618	rs56142307	chr17:57878149	A/G	cg10252138	chr17:58120427	NA	-0.6	-6.03	-0.31	4.16e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs10540	0.915	rs35333170	chr11:526478	A/G	cg03352830	chr11:487213	PTDSS2	0.78	6.36	0.33	6.6e-10	Body mass index;
LIHC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg00142150	chr22:38071001	LGALS1	0.7	11.22	0.52	4.27e-25	Fat distribution (HIV);
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg10127483	chr1:110009974	SYPL2	0.49	6.02	0.31	4.55e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21276834	chr21:30365048	RNF160	-0.48	-6.82	-0.35	4.19e-11	Pancreatic cancer;
LIHC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.85	-14.26	-0.61	1.54e-36	Post bronchodilator FEV1;
LIHC	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.58	-6.9	-0.35	2.5e-11	Ulcerative colitis;
LIHC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.5	8.97	0.44	1.99e-17	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.64	-0.5	4.88e-23	Breast cancer;
LIHC	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg19773385	chr1:10388646	KIF1B	0.33	5.83	0.3	1.26e-8	Hepatocellular carcinoma;
LIHC	trans	rs7178375	1.000	rs28693590	chr15:31195021	A/G	cg04373760	chr16:53404718	NA	0.6	7.77	0.39	9.42e-14	Hypertriglyceridemia;
LIHC	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.42	6.96	0.35	1.77e-11	Lewy body disease;
LIHC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-7.82	-0.39	6.67e-14	Longevity;Endometriosis;
LIHC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg09904177	chr6:26538194	HMGN4	-0.53	-5.72	-0.3	2.37e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg10820045	chr2:198174542	NA	0.55	8.96	0.44	2.12e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.1	-10.33	-0.49	5.84e-22	Breast cancer;
LIHC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.64	9.65	0.46	1.24e-19	Renal cell carcinoma;
LIHC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.54	8.73	0.43	1.18e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	7.24	0.36	2.95e-12	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-1.17	-9.72	-0.47	7.12e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs4908768	0.906	rs55858268	chr1:8554696	C/T	cg25722041	chr1:8623473	RERE	0.41	5.85	0.3	1.18e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg24219929	chr15:60884748	RORA	-0.45	-6.34	-0.32	7.28e-10	Alopecia areata;
LIHC	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg15192750	chr16:69999425	NA	-0.49	-7.37	-0.37	1.3e-12	IgE levels;
LIHC	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg20129853	chr10:51489980	NA	-0.4	-8.78	-0.43	7.77e-17	Prostate-specific antigen levels;
LIHC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.53	7.82	0.39	6.5e-14	Height;
LIHC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.11	16.37	0.66	6.78e-45	Sexual dysfunction (female);
LIHC	cis	rs151997	0.962	rs27272	chr5:50181865	A/G	cg06027927	chr5:50259733	NA	0.57	7.61	0.38	2.61e-13	Callous-unemotional behaviour;
LIHC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.16	-0.66	4.79e-44	Electrocardiographic conduction measures;
LIHC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-8.18	-0.4	5.71e-15	Blood metabolite levels;
LIHC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.34	-6.23	-0.32	1.38e-9	Aortic root size;
LIHC	trans	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg10756647	chr7:56101905	PSPH	1.11	13.46	0.59	1.9e-33	Diabetic kidney disease;
LIHC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg15744005	chr10:104629667	AS3MT	0.38	8.12	0.4	8.63e-15	Immature fraction of reticulocytes;Schizophrenia;
LIHC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	1.03	20.7	0.75	2.82e-62	Breast cancer;
LIHC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg18769074	chr3:133464867	TF	0.27	5.87	0.3	1.06e-8	Iron status biomarkers (transferrin levels);
LIHC	cis	rs12744310	0.943	rs12032906	chr1:41769158	T/C	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.63	7.71	0.38	1.42e-13	Initial pursuit acceleration;
LIHC	cis	rs2274273	1.000	rs7140872	chr14:55612744	C/T	cg01864836	chr14:55583639	NA	-0.36	-6.12	-0.31	2.62e-9	Protein biomarker;
LIHC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.54	-8.25	-0.41	3.5e-15	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.34	0.41	1.84e-15	Birth weight;
LIHC	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg04306507	chr14:55594613	LGALS3	0.33	6.38	0.33	5.91e-10	Protein biomarker;
LIHC	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.63	10.15	0.48	2.56e-21	Corneal astigmatism;
LIHC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-11.12	-0.52	9.63e-25	Response to antipsychotic treatment;
LIHC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.75	0.47	5.42e-20	Mean platelet volume;
LIHC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	9.74	0.47	5.96e-20	Personality dimensions;
LIHC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.45	7.49	0.38	5.95e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs45544231	0.593	rs1075367	chr16:52555002	G/A	cg09051775	chr16:52580266	TOX3	-0.31	-5.73	-0.3	2.19e-8	Restless legs syndrome;
LIHC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.46	6.69	0.34	9.16e-11	Cognitive function;
LIHC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.61	9.73	0.47	6.44e-20	Multiple myeloma (IgH translocation);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25666489	chr19:37663856	ZNF585A	0.4	6.13	0.31	2.44e-9	Cognitive function;
LIHC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.52	6.87	0.35	3.02e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.12	13.03	0.58	8.92e-32	Vitiligo;
LIHC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.36	7.14	0.36	5.67e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.75	-5.8	-0.3	1.53e-8	Blood protein levels;
LIHC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.38	7.62	0.38	2.58e-13	Renal cell carcinoma;
LIHC	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.42	-7.26	-0.37	2.58e-12	Platelet distribution width;
LIHC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg16586182	chr3:47516702	SCAP	-0.38	-6.57	-0.33	1.83e-10	Birth weight;
LIHC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg13397359	chr6:42928475	GNMT	0.81	11.4	0.52	9.47e-26	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg10820045	chr2:198174542	NA	0.43	6.24	0.32	1.28e-9	Dermatomyositis;
LIHC	cis	rs10508774	0.925	rs12242792	chr10:32831905	T/G	cg01819863	chr10:32635814	EPC1	0.65	6.06	0.31	3.66e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.32	0.32	8.14e-10	Total body bone mineral density;
LIHC	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04837898	chr3:45731254	SACM1L	0.42	6.88	0.35	2.93e-11	Hirschsprung disease;
LIHC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.81	-0.35	4.38e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.41	6.47	0.33	3.37e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18000306	chr6:288505	NA	0.34	6.2	0.32	1.64e-9	Menopause (age at onset);
LIHC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.99	-0.31	5.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1986734	0.576	rs4624677	chr4:77420406	T/C	cg24201034	chr4:77507246	SHROOM3	-0.38	-6.03	-0.31	4.19e-9	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
LIHC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.15	-0.44	5.33e-18	Bipolar disorder;
LIHC	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.36	-0.33	6.29e-10	Metabolite levels;
LIHC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg16586182	chr3:47516702	SCAP	0.55	9.95	0.47	1.15e-20	Colorectal cancer;
LIHC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.59	8.41	0.41	1.1e-15	Mean corpuscular volume;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	21.48	0.76	2.11e-65	Height;
LIHC	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.72	11.01	0.51	2.5e-24	Oral cavity cancer;
LIHC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.45	6.32	0.32	8.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.45	-6.09	-0.31	2.95e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.84	-16.22	-0.66	2.84e-44	Height;
LIHC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	11.24	0.52	3.81e-25	Platelet count;
LIHC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg12046867	chr14:103022105	NA	-0.47	-6.79	-0.34	4.94e-11	Platelet count;
LIHC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.83	-0.39	6.02e-14	Type 2 diabetes;
LIHC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg03013999	chr17:37608204	MED1	0.35	5.89	0.3	9.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1712517	0.771	rs61350103	chr10:105069120	A/C	cg05636881	chr10:105038444	INA	0.48	7.59	0.38	2.97e-13	Migraine;
LIHC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.68	-10.04	-0.48	5.7e-21	Obesity-related traits;
LIHC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-14.06	-0.61	9.04e-36	Height;
LIHC	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg08539965	chr1:21396338	EIF4G3	0.33	5.83	0.3	1.31e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.26	-18.85	-0.71	7.11e-55	Ulcerative colitis;
LIHC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.45	6.38	0.33	5.7e-10	Multiple sclerosis;
LIHC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.56	0.53	2.57e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	15.84	0.65	8.93e-43	Electrocardiographic conduction measures;
LIHC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.35	-0.32	6.92e-10	Gut microbiome composition (summer);
LIHC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-9.01	-0.44	1.47e-17	Gut microbiome composition (summer);
LIHC	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.55	0.46	2.59e-19	Corneal astigmatism;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23800573	chr21:45114399	RRP1B	-0.4	-6.26	-0.32	1.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.51	-7.58	-0.38	3.19e-13	Menarche (age at onset);
LIHC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.53	-6.46	-0.33	3.52e-10	Menarche (age at onset);
LIHC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.46	6.31	0.32	8.79e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg10755058	chr3:40428713	ENTPD3	0.35	5.75	0.3	1.95e-8	Renal cell carcinoma;
LIHC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.53	-11.88	-0.54	1.74e-27	Alcohol dependence;
LIHC	trans	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.51	-0.38	5.31e-13	Schizophrenia;
LIHC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.94	-0.31	7.09e-9	Schizophrenia;
LIHC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	1.04	15.07	0.63	9.87e-40	Breast cancer;
LIHC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg14709524	chr16:89940631	TCF25	0.49	5.99	0.31	5.2e-9	Skin colour saturation;
LIHC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.48	-0.38	6.19e-13	Breast cancer;
LIHC	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg03934865	chr2:198174659	NA	0.45	6.75	0.34	6.32e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.46	-6.75	-0.34	6.3e-11	Dermatomyositis;
LIHC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.58	7.29	0.37	2.23e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	1.06	12.64	0.56	2.63e-30	Vitiligo;
LIHC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.85	-15.49	-0.64	2.21e-41	Height;
LIHC	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg11161837	chr1:110010384	SYPL2	0.47	6.15	0.32	2.17e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg02023728	chr11:77925099	USP35	0.36	6.56	0.33	2.02e-10	Testicular germ cell tumor;
LIHC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.39	0.52	1.07e-25	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.58	7.56	0.38	3.77e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.47	7.62	0.38	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01401336	chr17:2606734	KIAA0664	0.48	6.28	0.32	1e-9	Systolic blood pressure;
LIHC	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg06609049	chr19:2785107	THOP1	0.55	9.59	0.46	1.96e-19	Total cholesterol levels;
LIHC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.39	6.13	0.31	2.38e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg12046867	chr14:103022105	NA	0.5	7.24	0.36	3.01e-12	Platelet count;
LIHC	cis	rs7188697	0.922	rs8047769	chr16:58591987	G/A	cg02549819	chr16:58548995	SETD6	0.49	7.63	0.38	2.37e-13	QT interval;
LIHC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	14.17	0.61	3.38e-36	Chronic sinus infection;
LIHC	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs7238033	0.663	rs11665385	chr18:43318746	A/G	cg20610511	chr18:43302872	SLC14A1	-0.38	-6.34	-0.32	7.32e-10	Bladder cancer;
LIHC	trans	rs875971	0.660	rs801192	chr7:66031952	C/G	cg26939375	chr7:64535504	NA	-0.43	-6.94	-0.35	2.02e-11	Aortic root size;
LIHC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	16.6	0.67	8.33e-46	Smoking behavior;
LIHC	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.35	0.41	1.76e-15	Height;
LIHC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.43e-8	Heart rate;
LIHC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.37	7.55	0.38	4.04e-13	Renal cell carcinoma;
LIHC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.9	11.57	0.53	2.38e-26	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	6.82	0.35	4.11e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.36	7.1	0.36	7.23e-12	Renal cell carcinoma;
LIHC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.58	-0.53	2.12e-26	Chronic sinus infection;
LIHC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.96	17.17	0.68	4.27e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.66	11.31	0.52	2.11e-25	Menopause (age at onset);
LIHC	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.52	8.79	0.43	7.61e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.42	-0.37	9.56e-13	Schizophrenia;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.87	0.78	6.99e-71	Height;
LIHC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.6	7.54	0.38	4.37e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.56	8.88	0.43	3.72e-17	HDL cholesterol;
LIHC	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.26	6.02	0.31	4.5e-9	Heart rate;
LIHC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.45	7.15	0.36	5.43e-12	HDL cholesterol levels;
LIHC	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.62	-10.85	-0.51	9.07e-24	Inflammatory bowel disease;
LIHC	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19676328	chr12:49525230	TUBA1B	-0.38	-6.13	-0.31	2.49e-9	Total cholesterol levels;
LIHC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12016809	chr21:47604291	C21orf56	0.4	5.85	0.3	1.13e-8	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg00656387	chr3:40428638	ENTPD3	0.49	8.28	0.41	2.86e-15	Renal cell carcinoma;
LIHC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.41	5.74	0.3	2.08e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2016586	0.860	rs5995154	chr22:36102668	A/G	cg26342177	chr22:36113512	APOL5	-0.38	-6.32	-0.32	8.08e-10	Body mass index;
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg00612595	chr21:47717864	NA	-0.35	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	10.36	0.49	4.53e-22	Alzheimer's disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01162549	chr5:141367464	RNF14	0.48	6.41	0.33	4.83e-10	Systolic blood pressure;
LIHC	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.6	12.05	0.55	4.17e-28	Plateletcrit;Platelet count;
LIHC	cis	rs7503168	0.908	rs9897552	chr17:33974481	G/A	cg20932281	chr17:33905541	PEX12	0.53	6.85	0.35	3.36e-11	Plateletcrit;
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.6	9.27	0.45	2.11e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.54	8.96	0.44	2.07e-17	Mean corpuscular volume;
LIHC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.57	7.69	0.38	1.55e-13	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6584283	0.875	rs10748783	chr10:101285872	C/A	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.1	-0.31	2.87e-9	Ulcerative colitis;
LIHC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs420259	0.727	rs35585	chr16:23677111	A/G	cg05131483	chr16:23706242	ERN2	-0.35	-5.97	-0.31	5.93e-9	Bipolar disorder;
LIHC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg06207120	chr15:45996521	NA	-0.33	-6.38	-0.33	5.75e-10	Waist circumference;Weight;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	12.93	0.57	1.99e-31	Prudent dietary pattern;
LIHC	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg01864836	chr14:55583639	NA	-0.42	-8.19	-0.4	5.27e-15	Protein biomarker;
LIHC	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg19683494	chr5:74908142	NA	0.57	7.55	0.38	3.91e-13	Age-related disease endophenotypes;
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08677398	chr8:58056175	NA	0.41	6.3	0.32	9.4e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg21395723	chr22:39101663	GTPBP1	0.37	6.28	0.32	1.06e-9	Menopause (age at onset);
LIHC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.13	0.66	6.33e-44	Electrocardiographic conduction measures;
LIHC	trans	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg16753122	chr16:57506917	DOK4	0.67	6.22	0.32	1.45e-9	IgG glycosylation;
LIHC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.93	0.31	7.59e-9	Schizophrenia;
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.3	-0.37	2.04e-12	Longevity;Endometriosis;
LIHC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.34	-6.21	-0.32	1.5e-9	Platelet distribution width;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg25461793	chr19:17212553	MYO9B	0.46	6.35	0.32	6.81e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.16	0.77	4.33e-68	Chronic sinus infection;
LIHC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.6	9.03	0.44	1.3e-17	Mean corpuscular volume;
LIHC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.6	9.3	0.45	1.67e-18	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs11868206	1	rs11868206	chr17:33959247	G/A	cg05299278	chr17:33885742	SLFN14	-0.25	-5.75	-0.3	2.02e-8	Mean platelet volume;
LIHC	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.52	8.2	0.41	4.85e-15	Schizophrenia;
LIHC	cis	rs16828019	0.852	rs12408956	chr1:41651952	G/A	cg03962019	chr1:41807865	NA	0.53	7.53	0.38	4.66e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	6.99	0.35	1.45e-11	Pulse pressure;
LIHC	cis	rs1564271	1.000	rs1197422	chr10:27012078	A/G	cg13837822	chr10:26931731	LOC731789	0.33	6.09	0.31	2.96e-9	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg02325880	chr1:84971750	SPATA1;GNG5	0.35	6.04	0.31	3.98e-9	Thyroid cancer;
LIHC	cis	rs7212590	0.618	rs35806089	chr17:57943906	A/G	cg10252138	chr17:58120427	NA	-0.62	-6.58	-0.34	1.74e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg21017887	chr14:105400489	NA	-0.65	-11.62	-0.53	1.51e-26	Rheumatoid arthritis;
LIHC	cis	rs655641	0.954	rs595972	chr11:85705885	G/T	cg09030501	chr11:85779252	PICALM	-0.51	-6.11	-0.31	2.75e-9	Platelet count;
LIHC	trans	rs6717918	0.517	rs2633263	chr2:233127453	T/C	cg19760917	chr1:2411643	PLCH2	-0.4	-6.24	-0.32	1.29e-9	Height;
LIHC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.86	15.21	0.64	2.93e-40	Headache;
LIHC	cis	rs10256972	0.640	rs10271082	chr7:1081562	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.28	-6.78	-0.34	5.27e-11	Longevity;Endometriosis;
LIHC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg09835421	chr16:68378352	PRMT7	-0.49	-5.87	-0.3	1.01e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.75	11.49	0.53	4.46e-26	Corneal astigmatism;
LIHC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.67	-12.35	-0.56	3.22e-29	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.73	-9.41	-0.45	7.48e-19	Metabolite levels (HVA/5-HIAA ratio);
LIHC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.66	-9.82	-0.47	3.14e-20	Mosquito bite size;
LIHC	cis	rs3106136	0.678	rs7680426	chr4:95294837	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.98	0.31	5.48e-9	Capecitabine sensitivity;
LIHC	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.39	-6.2	-0.32	1.64e-9	Neuroticism;
LIHC	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.45	6.47	0.33	3.3e-10	Hepatocellular carcinoma;
LIHC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.36	-6.58	-0.34	1.79e-10	Schizophrenia;
LIHC	cis	rs4700695	0.841	rs251304	chr5:65249700	A/G	cg21114390	chr5:65439923	SFRS12	0.44	5.77	0.3	1.8e-8	Facial morphology (factor 19);
LIHC	cis	rs1865721	0.958	rs57073257	chr18:73172316	A/G	cg26385618	chr18:73139727	C18orf62	-0.29	-7.33	-0.37	1.64e-12	Intelligence;
LIHC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.63	8.35	0.41	1.72e-15	Diastolic blood pressure;
LIHC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.44	-6.52	-0.33	2.59e-10	Height;
LIHC	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.72	-10.51	-0.49	1.46e-22	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2257205	0.667	rs73996262	chr17:56784426	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.56	-0.33	2e-10	Pancreatic cancer;
LIHC	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.8	0.35	4.7e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.69	6.97	0.35	1.67e-11	Vitiligo;
LIHC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.36	-6.0	-0.31	5.05e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07636037	chr3:49044803	WDR6	-0.53	-6.41	-0.33	4.79e-10	Menarche (age at onset);
LIHC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	ch.11.42038R	chr11:967971	AP2A2	0.55	10.03	0.48	6.16e-21	Alzheimer's disease (late onset);
LIHC	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.03	0.31	4.27e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07308232	chr7:1071921	C7orf50	-0.4	-6.49	-0.33	3.01e-10	Longevity;Endometriosis;
LIHC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs611744	0.967	rs2600614	chr8:109198079	T/A	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.65e-11	Dupuytren's disease;
LIHC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	9.0	0.44	1.6e-17	Body mass index (adult);
LIHC	cis	rs2071426	0.959	rs12359863	chr10:96812230	C/T	cg09036531	chr10:96991505	NA	-0.5	-5.78	-0.3	1.66e-8	Blood metabolite levels;
LIHC	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.4	-6.95	-0.35	1.84e-11	Endometrial cancer;
LIHC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.51	6.05	0.31	3.8e-9	Morning vs. evening chronotype;
LIHC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.78	-11.18	-0.52	6.09e-25	Diastolic blood pressure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06109949	chr2:178937838	PDE11A	0.41	7.01	0.35	1.29e-11	Cognitive function;
LIHC	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-8.3	-0.41	2.45e-15	Extraversion;
LIHC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	8.7	0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.68	-11.67	-0.53	9.93e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.98	-0.31	5.74e-9	Calcium levels;
LIHC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	1.06	14.86	0.63	6.89e-39	Heart rate;
LIHC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.11	-0.31	2.68e-9	Tonsillectomy;
LIHC	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.69	7.02	0.35	1.23e-11	Schizophrenia;
LIHC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.8	13.61	0.59	5.31e-34	Colorectal cancer;
LIHC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg02269571	chr22:50332266	NA	-0.64	-8.68	-0.42	1.7e-16	Schizophrenia;
LIHC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg14092571	chr14:90743983	NA	-0.39	-6.16	-0.32	2.02e-9	Mortality in heart failure;
LIHC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.29	21.37	0.76	5.86e-65	Corneal structure;
LIHC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg14394617	chr12:54674541	HNRNPA1;HNRPA1L-2;CBX5	-0.41	-6.45	-0.33	3.9e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.33	0.49	5.94e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs1144333	1.000	rs1021464	chr1:76375415	G/A	cg03433033	chr1:76189801	ACADM	0.54	8.03	0.4	1.61e-14	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg14779329	chr11:130786720	SNX19	0.37	5.81	0.3	1.41e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.44	6.5	0.33	2.82e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg22676075	chr6:135203613	NA	0.39	6.3	0.32	9.37e-10	Red blood cell count;
LIHC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.71	-10.62	-0.5	6.05e-23	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg09497769	chr2:24248384	NA	0.48	6.4	0.33	5.14e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.53	-6.4	-0.33	5.21e-10	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.6	-8.77	-0.43	8.27e-17	Testicular germ cell tumor;
LIHC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-5.99	-0.31	5.2e-9	Axial length;
LIHC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.19	0.55	1.21e-28	Prudent dietary pattern;
LIHC	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.7	11.94	0.54	1.05e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00152838	chr16:24741724	TNRC6A	-0.53	-6.41	-0.33	4.95e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg12903224	chr12:29470962	FAR2	-0.4	-6.56	-0.33	2.04e-10	QT interval;
LIHC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg06363034	chr20:62225388	GMEB2	0.44	7.65	0.38	2.01e-13	Glioblastoma;
LIHC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.68	6.32	0.32	8.3e-10	Breast cancer;
LIHC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg25801113	chr15:45476975	SHF	0.37	6.33	0.32	7.88e-10	Uric acid levels;
LIHC	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.79	-9.38	-0.45	9.21e-19	Psoriasis vulgaris;
LIHC	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.22	0.58	1.62e-32	Coffee consumption (cups per day);
LIHC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg08213375	chr14:104286397	PPP1R13B	0.52	10.07	0.48	4.6e-21	Schizophrenia;
LIHC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.86	13.63	0.59	4.52e-34	Metabolic syndrome;
LIHC	trans	rs12692119	0.655	rs7421909	chr2:127655310	C/A	cg13995918	chr5:1280305	TERT	-0.46	-6.42	-0.33	4.63e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs10508774	1.000	rs9971245	chr10:32754413	C/T	cg01819863	chr10:32635814	EPC1	0.65	6.08	0.31	3.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.85	12.2	0.55	1.1e-28	Glomerular filtration rate (creatinine);
LIHC	trans	rs10213084	0.915	rs13115523	chr4:147510610	A/G	cg18061433	chr10:21435895	C10orf113;NEBL	0.47	6.04	0.31	3.94e-9	Heart rate;
LIHC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.5	6.5	0.33	2.92e-10	Menarche (age at onset);
LIHC	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.49	7.78	0.39	8.57e-14	HDL cholesterol;
LIHC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg03034668	chr16:1723424	CRAMP1L	0.4	7.15	0.36	5.24e-12	Coronary artery disease;
LIHC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg08888203	chr3:10149979	C3orf24	0.62	5.76	0.3	1.86e-8	Alzheimer's disease;
LIHC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.44	-6.55	-0.33	2.1e-10	Obesity-related traits;
LIHC	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg22153463	chr1:85462885	MCOLN2	0.52	6.22	0.32	1.42e-9	Serum sulfate level;
LIHC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.48	0.56	1.05e-29	Colorectal cancer;
LIHC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.73	12.45	0.56	1.39e-29	Menopause (age at onset);
LIHC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg23461800	chr14:103021989	NA	-0.45	-5.92	-0.31	7.69e-9	Platelet count;
LIHC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.69	9.92	0.47	1.44e-20	Lymphocyte counts;
LIHC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.48	7.68	0.38	1.64e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg23054440	chr19:41169017	NA	-0.49	-6.09	-0.31	3e-9	Systolic blood pressure;
LIHC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.31	4.75e-9	Alzheimer's disease;
LIHC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	0.86	11.95	0.54	9.45e-28	Skin colour saturation;
LIHC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg09911534	chr15:67153556	NA	0.44	6.8	0.35	4.62e-11	Lung cancer (smoking interaction);
LIHC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.98	0.4	2.19e-14	Tonsillectomy;
LIHC	cis	rs2803122	0.502	rs1854552	chr9:19235047	C/T	cg13469590	chr9:19229767	NA	0.37	6.22	0.32	1.42e-9	Pulse pressure;
LIHC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.09	19.42	0.72	3.96e-57	Nonalcoholic fatty liver disease;
LIHC	cis	rs7961581	0.957	rs1353362	chr12:71613276	C/T	cg05756094	chr12:71608604	NA	0.37	5.81	0.3	1.46e-8	Type 2 diabetes;
LIHC	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-8.25	-0.41	3.53e-15	Corneal astigmatism;
LIHC	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.45	6.27	0.32	1.06e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.46	0.37	7.18e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.69	-11.79	-0.54	3.72e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg22777020	chr22:31556080	RNF185	0.56	6.45	0.33	3.85e-10	Colorectal cancer;
LIHC	trans	rs6058796	0.892	rs6141782	chr20:31263507	A/G	cg02600331	chr11:130417168	NA	0.34	7.6	0.38	2.85e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LIHC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.36	-7.13	-0.36	5.83e-12	Renal cell carcinoma;
LIHC	cis	rs3780378	1.000	rs10815158	chr9:5112844	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-8.61	-0.42	2.68e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg22979624	chr14:90863808	CALM1	0.41	6.27	0.32	1.1e-9	Morning vs. evening chronotype;
LIHC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg02640540	chr1:67518911	SLC35D1	-0.42	-5.85	-0.3	1.17e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.27	16.64	0.67	5.59e-46	Diabetic kidney disease;
LIHC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.88	0.3	9.58e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.0	-14.22	-0.61	2.21e-36	Cognitive function;
LIHC	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg16589663	chr20:23618590	CST3	0.66	6.99	0.35	1.45e-11	Chronic kidney disease;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.59	-0.38	3.01e-13	Schizophrenia;
LIHC	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.36	8.33	0.41	2e-15	Educational attainment (years of education);
LIHC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.61	7.49	0.38	6.09e-13	Heart rate;
LIHC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.81	15.5	0.64	2.02e-41	Blood protein levels;
LIHC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.57	8.17	0.4	6.11e-15	Height;
LIHC	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.49	5.74	0.3	2.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg20435097	chr10:126320824	FAM53B	-0.41	-6.46	-0.33	3.61e-10	Cocaine dependence;
LIHC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.81	-0.35	4.43e-11	Menopause (age at onset);
LIHC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.73	9.86	0.47	2.33e-20	Asthma;
LIHC	trans	rs13113518	0.812	rs11932712	chr4:56302590	C/T	cg15358633	chr12:38710606	ALG10B	0.44	6.29	0.32	9.6e-10	Height;
LIHC	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.48	-0.37	6.49e-13	QT interval;
LIHC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.64	-11.57	-0.53	2.43e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs17253792	0.545	rs34719936	chr14:56015134	G/A	cg01858014	chr14:56050164	KTN1	-0.63	-5.87	-0.3	1.03e-8	Putamen volume;
LIHC	cis	rs882732	0.576	rs2068790	chr14:95033944	C/T	cg14866387	chr14:95027382	SERPINA4	0.38	6.13	0.31	2.41e-9	Blood protein levels;
LIHC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.02	-0.31	4.56e-9	Alzheimer's disease (late onset);
LIHC	cis	rs10097731	0.901	rs10464891	chr8:82042900	C/A	cg25230327	chr8:82042993	NA	-0.59	-8.01	-0.4	1.81e-14	Serum total protein level;
LIHC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.42	6.55	0.33	2.16e-10	Resting heart rate;
LIHC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg06207120	chr15:45996521	NA	0.34	6.62	0.34	1.4e-10	Waist circumference;Weight;
LIHC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	6.58	0.34	1.8e-10	IgG glycosylation;
LIHC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.74	12.61	0.56	3.38e-30	Menopause (age at onset);
LIHC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg15155738	chr12:121454335	C12orf43	0.46	6.62	0.34	1.36e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.73	12.66	0.56	2.17e-30	Menopause (age at onset);
LIHC	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg03934865	chr2:198174659	NA	0.55	8.37	0.41	1.46e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	9.74	0.47	6.05e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs847649	1.000	rs847649	chr7:102556011	C/T	cg18108683	chr7:102477205	FBXL13	-0.49	-7.36	-0.37	1.38e-12	Morning vs. evening chronotype;
LIHC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.63	-8.89	-0.43	3.66e-17	Blood metabolite levels;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg22387756	chr11:1495050	HCCA2	-0.42	-6.12	-0.31	2.57e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	6.76	0.34	6.02e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01423368	chr11:76155379	C11orf30	0.42	6.43	0.33	4.33e-10	Cognitive function;
LIHC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.78	0.39	8.45e-14	Mean platelet volume;
LIHC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg06466757	chr4:1255808	NA	0.34	5.72	0.3	2.38e-8	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg00656387	chr3:40428638	ENTPD3	-0.45	-7.69	-0.38	1.59e-13	Renal cell carcinoma;
LIHC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg20607798	chr8:58055168	NA	0.49	6.0	0.31	5.08e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04604666	chr4:37828046	PGM2	0.46	6.25	0.32	1.24e-9	Pancreatic cancer;
LIHC	cis	rs611744	0.805	rs453634	chr8:109135101	T/C	cg21045802	chr8:109455806	TTC35	0.5	8.48	0.42	6.86e-16	Dupuytren's disease;
LIHC	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.88	14.7	0.62	2.93e-38	Schizophrenia;
LIHC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	6.77	0.34	5.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21545522	chr1:205238299	TMCC2	-0.35	-6.6	-0.34	1.61e-10	Red blood cell count;
LIHC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg13175981	chr1:150552382	MCL1	-0.44	-6.13	-0.31	2.43e-9	Tonsillectomy;
LIHC	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	7.9	0.39	3.83e-14	Fuchs's corneal dystrophy;
LIHC	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.65	6.96	0.35	1.77e-11	Type 2 diabetes;
LIHC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.71	-11.86	-0.54	2.06e-27	Aortic root size;
LIHC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.7	12.29	0.55	5.14e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.46	4.67e-19	Bipolar disorder;
LIHC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg22800045	chr5:56110881	MAP3K1	-0.57	-6.79	-0.34	4.89e-11	Initial pursuit acceleration;
LIHC	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.45	-6.16	-0.32	2.01e-9	QT interval;
LIHC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg20578329	chr17:80767326	TBCD	-0.72	-7.21	-0.36	3.62e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LIHC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg11279151	chr3:101281821	RG9MTD1	0.38	5.86	0.3	1.12e-8	Colorectal cancer;
LIHC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.63	10.23	0.48	1.29e-21	Monocyte count;
LIHC	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.52	10.06	0.48	5.17e-21	Testicular germ cell tumor;
LIHC	trans	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg24637308	chr11:6592297	DNHD1	0.44	6.19	0.32	1.68e-9	Coronary artery calcification;
LIHC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.38	7.63	0.38	2.41e-13	Type 2 diabetes;
LIHC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	12.18	0.55	1.41e-28	Cognitive test performance;
LIHC	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.96	-0.31	6.23e-9	Blood pressure;
LIHC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.4	-16.88	-0.67	6.21e-47	Breast cancer;
LIHC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.47	-0.33	3.31e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7238033	0.624	rs8087241	chr18:43309703	G/A	cg20610511	chr18:43302872	SLC14A1	0.39	6.53	0.33	2.41e-10	Bladder cancer;
LIHC	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.74	-0.3	2.08e-8	Blood metabolite levels;
LIHC	cis	rs2834256	0.527	rs9983901	chr21:34866853	C/T	cg14850771	chr21:34775459	IFNGR2	0.47	7.77	0.39	9.31e-14	Red cell distribution width;
LIHC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.47	-17.56	-0.69	1.16e-49	Breast cancer;
LIHC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	9.52	0.46	3.1400000000000002e-19	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	6.85	0.35	3.41e-11	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.25	-0.36	2.8e-12	Renal cell carcinoma;
LIHC	cis	rs2071426	0.959	rs1934982	chr10:96802124	A/C	cg09036531	chr10:96991505	NA	-0.49	-5.84	-0.3	1.22e-8	Blood metabolite levels;
LIHC	cis	rs6466055	0.692	rs4727621	chr7:105028370	T/C	cg04380332	chr7:105027541	SRPK2	-0.38	-7.03	-0.36	1.14e-11	Schizophrenia;
LIHC	cis	rs13126513	0.708	rs4368610	chr4:100453746	G/T	cg05468953	chr4:100565104	NA	0.34	6.32	0.32	8.1e-10	Metabolite levels (MHPG);
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.77	11.75	0.54	5.06e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.61	-10.93	-0.51	4.6e-24	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs716804	0.740	rs7118500	chr11:10284762	C/A	cg01453529	chr11:10209919	SBF2	-0.29	-5.74	-0.3	2.13e-8	Neuroticism;
LIHC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg03336402	chr7:133662267	EXOC4	-0.37	-5.78	-0.3	1.66e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.7	-11.0	-0.51	2.72e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.8	0.3	1.5e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.72	-9.88	-0.47	2.1e-20	Coronary artery disease;
LIHC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.49	-8.64	-0.42	2.22e-16	Monocyte count;
LIHC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-9.33	-0.45	1.38e-18	Chronic sinus infection;
LIHC	cis	rs6088813	1.000	rs4911180	chr20:33972948	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-5.89	-0.3	9.11e-9	Height;
LIHC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg10096929	chr1:156261403	TMEM79	0.4	6.66	0.34	1.08e-10	Tonsillectomy;
LIHC	cis	rs244293	0.965	rs244364	chr17:53188280	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.54	-0.38	4.36e-13	Menarche (age at onset);
LIHC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-9.46	-0.46	5.25e-19	Initial pursuit acceleration;
LIHC	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.46	-5.72	-0.3	2.31e-8	Triglycerides;
LIHC	cis	rs1789	0.903	rs4616746	chr4:15673098	A/G	cg16509355	chr4:15471240	CC2D2A	-0.46	-7.02	-0.35	1.23e-11	Blood protein levels;
LIHC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.46	6.66	0.34	1.11e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	10.18	0.48	1.91e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg25828445	chr12:7781288	NA	-0.41	-6.31	-0.32	8.62e-10	HDL cholesterol levels;
LIHC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg13175981	chr1:150552382	MCL1	-0.43	-5.9	-0.3	8.63e-9	Tonsillectomy;
LIHC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.54	8.38	0.41	1.38e-15	Dental caries;
LIHC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg21559469	chr19:19431446	KIAA0892;SF4	0.41	5.74	0.3	2.09e-8	Tonsillectomy;
LIHC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.65	-8.23	-0.41	4.09e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4407350	1.000	rs4823330	chr22:44923080	G/A	cg26276947	chr22:44892394	LDOC1L	0.33	6.01	0.31	4.83e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg23605328	chr1:201951606	RNPEP	0.39	6.23	0.32	1.36e-9	Monocyte percentage of white cells;
LIHC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.87	-16.72	-0.67	2.82e-46	Menopause (age at onset);
LIHC	cis	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg01231543	chr16:68741748	NA	0.39	5.98	0.31	5.58e-9	Colorectal cancer;
LIHC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.81	17.71	0.69	3e-50	Gestational age at birth (maternal effect);
LIHC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.44	-7.07	-0.36	8.74e-12	Testicular germ cell tumor;
LIHC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.38	6.15	0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.79	-10.05	-0.48	5.57e-21	Type 2 diabetes;
LIHC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg26395211	chr5:140044315	WDR55	-0.43	-6.43	-0.33	4.19e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg17691542	chr6:26056736	HIST1H1C	0.4	6.03	0.31	4.2e-9	Height;
LIHC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg13395646	chr4:1353034	KIAA1530	-0.51	-8.38	-0.41	1.41e-15	Obesity-related traits;
LIHC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.32	-6.05	-0.31	3.82e-9	Body mass index;
LIHC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-6.38	-0.33	5.92e-10	Educational attainment;
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	24.41	0.8	6.42e-77	Prudent dietary pattern;
LIHC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg26338869	chr17:61819248	STRADA	0.52	7.0	0.35	1.34e-11	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg14519123	chr15:66544965	MEGF11	0.45	6.33	0.32	7.87e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	1.02	19.6	0.73	7.06e-58	Breast cancer;
LIHC	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg10820045	chr2:198174542	NA	0.51	7.99	0.4	2.06e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.64	-7.89	-0.39	4.22e-14	Mean platelet volume;
LIHC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.43	-6.22	-0.32	1.46e-9	Aortic root size;
LIHC	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg20991723	chr1:152506922	NA	0.53	9.05	0.44	1.09e-17	Hair morphology;
LIHC	cis	rs253664	0.898	rs1199347	chr3:138083361	T/C	cg17918682	chr3:137893718	DBR1	-0.54	-5.72	-0.3	2.38e-8	Body mass index;
LIHC	cis	rs1198430	0.714	rs1198437	chr1:23747424	G/C	cg13183780	chr1:23809682	ASAP3	-0.37	-6.47	-0.33	3.33e-10	Total cholesterol levels;
LIHC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.08	9.74	0.47	5.89e-20	Diabetic retinopathy;
LIHC	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg09795085	chr6:101329169	ASCC3	-0.52	-7.29	-0.37	2.19e-12	Neuroticism;
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.8	-0.35	4.62e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.61	15.65	0.65	5.01e-42	Airflow obstruction;
LIHC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-15.01	-0.63	1.81e-39	Alzheimer's disease (late onset);
LIHC	cis	rs9896052	0.649	rs6501797	chr17:73444312	G/A	cg25649188	chr17:73499917	CASKIN2	0.44	6.9	0.35	2.52e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
LIHC	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	1.13	14.83	0.63	9.14e-39	Blood protein levels;
LIHC	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.22	12.74	0.57	1.12e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg19513890	chr22:42538836	CYP2D7P1	-0.37	-7.07	-0.36	8.87e-12	Cognitive function;
LIHC	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.76	6.6	0.34	1.56e-10	Type 2 diabetes nephropathy;
LIHC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.14	10.5	0.49	1.59e-22	Diabetic retinopathy;
LIHC	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg01364799	chr7:75623366	TMEM120A	-0.48	-7.34	-0.37	1.59e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.8	13.46	0.59	1.89e-33	Coronary artery disease;
LIHC	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg27205649	chr11:78285834	NARS2	0.4	5.96	0.31	6.28e-9	Alzheimer's disease (survival time);
LIHC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.84	-13.47	-0.59	1.84e-33	Colorectal cancer;
LIHC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.8	-12.37	-0.56	2.56e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.43	-0.33	4.42e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.74	-0.43	1.1e-16	Cognitive function;
LIHC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg06265175	chr8:121136014	COL14A1	0.48	7.94	0.39	2.88e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.0	0.35	1.36e-11	Protein C levels;
LIHC	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg23254163	chr1:152506842	NA	0.22	5.77	0.3	1.75e-8	Hair morphology;
LIHC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.43	-6.63	-0.34	1.3100000000000001e-10	Iron status biomarkers;
LIHC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg10935138	chr17:73851978	WBP2	0.49	7.31	0.37	1.96e-12	White matter hyperintensity burden;
LIHC	cis	rs7534824	0.625	rs10493939	chr1:101378026	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	6.97	0.35	1.6e-11	Refractive astigmatism;
LIHC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.59	-0.38	3.15e-13	Chronic sinus infection;
LIHC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.47	8.15	0.4	7.01e-15	Colorectal cancer;
LIHC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.75	0.43	1.02e-16	Schizophrenia;
LIHC	cis	rs12744310	1.000	rs34796305	chr1:41769045	A/G	cg03962019	chr1:41807865	NA	0.39	6.36	0.33	6.56e-10	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg16797656	chr11:68205561	LRP5	0.53	8.33	0.41	1.92e-15	Total body bone mineral density;
LIHC	cis	rs7095607	0.730	rs1900012	chr10:69953942	G/A	cg18986048	chr10:69913749	MYPN	0.43	6.53	0.33	2.36e-10	Lung function (FVC);
LIHC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.81	0.5	1.3e-23	Personality dimensions;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21576300	chr4:124107741	SPATA5	0.28	6.04	0.31	4.04e-9	Cognitive function;
LIHC	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg07424592	chr7:64974309	NA	0.76	8.63	0.42	2.3e-16	Diabetic kidney disease;
LIHC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.64	-5.78	-0.3	1.66e-8	Menopause (age at onset);
LIHC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.47	6.63	0.34	1.32e-10	Blood protein levels;
LIHC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.88	8.5	0.42	6.12e-16	Plasma clusterin levels;
LIHC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg26395211	chr5:140044315	WDR55	-0.42	-6.22	-0.32	1.47e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.73	0.39	1.19e-13	Bipolar disorder;
LIHC	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg14515779	chr1:101123966	NA	0.42	5.75	0.3	2.02e-8	Monocyte count;
LIHC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	11.04	0.51	1.93e-24	Personality dimensions;
LIHC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg11235426	chr6:292522	DUSP22	-0.53	-7.14	-0.36	5.61e-12	Menopause (age at onset);
LIHC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.37	5.9	0.3	8.53e-9	Resting heart rate;
LIHC	trans	rs4566648	0.593	rs6825902	chr4:84174111	G/C	cg06219686	chr17:29421884	NF1	-0.52	-6.12	-0.31	2.53e-9	Monocyte count;
LIHC	cis	rs860295	0.541	rs11264359	chr1:155282829	A/G	cg02153340	chr1:155202674	NA	-0.35	-6.33	-0.32	7.59e-10	Body mass index;
LIHC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.6	-9.94	-0.47	1.28e-20	Height;
LIHC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.33	-6.55	-0.33	2.07e-10	Platelet distribution width;
LIHC	cis	rs7923837	0.687	rs1977833	chr10:94463945	G/A	cg25506282	chr10:94462361	NA	0.37	6.57	0.33	1.88e-10	Body mass index;Multiple sclerosis;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	10.76	0.5	1.88e-23	Lymphocyte counts;
LIHC	cis	rs9918079	0.560	rs4698409	chr4:15659766	G/A	cg16509355	chr4:15471240	CC2D2A	-0.45	-7.0	-0.35	1.39e-11	Obesity-related traits;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg10755058	chr3:40428713	ENTPD3	0.4	6.78	0.34	5.32e-11	Renal cell carcinoma;
LIHC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.34	6.63	0.34	1.32e-10	Renal cell carcinoma;
LIHC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.36	0.49	4.63e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs9783347	1.000	rs4150655	chr11:18375164	A/T	cg15585147	chr11:18324498	HPS5	-0.43	-7.07	-0.36	8.7e-12	Pancreatic cancer;
LIHC	cis	rs7617773	1.000	rs6442108	chr3:48192959	G/C	cg11946769	chr3:48343235	NME6	-0.65	-8.39	-0.41	1.34e-15	Coronary artery disease;
LIHC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg25894440	chr7:65020034	NA	0.53	6.07	0.31	3.34e-9	Diabetic kidney disease;
LIHC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.4	-5.91	-0.3	8.28e-9	Narcolepsy;
LIHC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.9	0.43	3.34e-17	Height;
LIHC	trans	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.61	0.59	5.4e-34	Diabetic kidney disease;
LIHC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	0.79	6.02	0.31	4.58e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg27386326	chr11:61587980	NA	0.71	15.28	0.64	1.56e-40	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.79	0.43	7.64e-17	Lung cancer in ever smokers;
LIHC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.37	-5.86	-0.3	1.1e-8	Vitiligo;
LIHC	cis	rs28830936	0.966	rs890505	chr15:42129158	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.16	-0.32	2.02e-9	Diastolic blood pressure;
LIHC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.45	-7.31	-0.37	1.95e-12	Fibrinogen levels;
LIHC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.48	-7.27	-0.37	2.39e-12	Tuberculosis;
LIHC	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.39	5.96	0.31	6.13e-9	Lung cancer;
LIHC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08280861	chr8:58055591	NA	0.52	6.33	0.32	7.52e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-7.18	-0.36	4.31e-12	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.23	-0.36	3.28e-12	Tuberculosis;
LIHC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.94	19.93	0.73	3.27e-59	Bone mineral density;
LIHC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.29	7.1	0.36	7.22e-12	Longevity;Endometriosis;
LIHC	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg20240347	chr1:204465584	NA	-0.36	-7.24	-0.36	3e-12	Schizophrenia;
LIHC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.32	5.86	0.3	1.12e-8	Calcium levels;
LIHC	cis	rs273218	1.000	rs156440	chr5:53373656	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.67	10.96	0.51	3.84e-24	Migraine;
LIHC	cis	rs332507	0.601	rs4677939	chr3:124374405	A/C	cg05980111	chr3:124395277	KALRN	0.32	6.21	0.32	1.57e-9	Plateletcrit;
LIHC	cis	rs1165668	0.959	rs2576954	chr12:104312254	C/T	cg21863207	chr12:104234989	NT5DC3	0.4	6.39	0.33	5.27e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.48	11.09	0.51	1.31e-24	Iron status biomarkers (transferrin levels);
LIHC	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.64	0.42	2.27e-16	Corneal astigmatism;
LIHC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.89	-0.3	9.2e-9	Total body bone mineral density;
LIHC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.47	-0.42	7.53e-16	Calcium levels;
LIHC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09256448	chr16:638327	NA	0.38	6.25	0.32	1.25e-9	Height;
LIHC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.46	9.5e-20	Bipolar disorder;
LIHC	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-8.23	-0.41	3.96e-15	Obesity-related traits;
LIHC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.87	10.02	0.48	6.8e-21	Eosinophil percentage of granulocytes;
LIHC	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg01021169	chr22:30184971	ASCC2	-0.37	-7.01	-0.35	1.25e-11	Type 1 diabetes;
LIHC	cis	rs7872515	0.887	rs28727560	chr9:94864754	A/C	cg01248375	chr9:94877805	SPTLC1	0.54	8.06	0.4	1.26e-14	Bipolar disorder and schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08484479	chr5:887419	BRD9	0.45	6.52	0.33	2.5e-10	Longevity;
LIHC	cis	rs16828019	0.852	rs34286980	chr1:41608389	A/G	cg03962019	chr1:41807865	NA	0.53	7.51	0.38	5.27e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.9	0.3	8.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.52	-7.5	-0.38	5.55e-13	Uric acid levels;
LIHC	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg03934865	chr2:198174659	NA	0.45	6.53	0.33	2.35e-10	Dermatomyositis;
LIHC	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.43	9.16	0.44	5e-18	Migraine;
LIHC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	10.58	0.5	8.09e-23	Total cholesterol levels;
LIHC	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.44	6.2	0.32	1.64e-9	Posterior cortical atrophy and Alzheimer's disease;
LIHC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	12.32	0.55	4.06e-29	Cognitive test performance;
LIHC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg03013999	chr17:37608204	MED1	0.36	5.9	0.3	8.86e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2997447	0.846	rs12071062	chr1:26412199	T/G	cg19633962	chr1:26362018	EXTL1	-0.59	-6.93	-0.35	2.09e-11	QRS complex (12-leadsum);
LIHC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.45e-11	Diabetic kidney disease;
LIHC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.68	-9.42	-0.45	7.14e-19	Monocyte percentage of white cells;
LIHC	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.1	9.14	0.44	5.78e-18	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.5	-8.52	-0.42	5.07e-16	Response to temozolomide;
LIHC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.86	-14.96	-0.63	2.86e-39	Height;
LIHC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.48	6.33	0.32	7.69e-10	Total body bone mineral density;
LIHC	trans	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg10208301	chr11:6592745	DNHD1	0.45	6.38	0.33	5.86e-10	Coronary artery calcification;
LIHC	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-0.81	-9.56	-0.46	2.38e-19	Gut microbiota (bacterial taxa);
LIHC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-6.07	-0.31	3.31e-9	Total body bone mineral density;
LIHC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.14	-0.44	5.78e-18	Chronic sinus infection;
LIHC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.9	0.43	3.43e-17	Alzheimer's disease;
LIHC	cis	rs16958440	1.000	rs60228288	chr18:44640412	G/A	cg17192377	chr18:44677553	HDHD2	0.61	6.84	0.35	3.55e-11	Sitting height ratio;
LIHC	cis	rs4650994	0.593	rs10753180	chr1:178520653	A/G	cg05350800	chr1:178550844	NA	-0.33	-7.36	-0.37	1.37e-12	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.54	8.1	0.4	9.65e-15	Longevity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22958951	chr11:119252637	USP2	0.46	6.13	0.31	2.39e-9	Pancreatic cancer;
LIHC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	5.88	0.3	9.86e-9	Menopause (age at onset);
LIHC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-12.19	-0.55	1.27e-28	Vitiligo;
LIHC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.4	-6.35	-0.32	6.69e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.34	0.41	1.87e-15	Lung cancer;
LIHC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.8	-0.3	1.55e-8	Subjective well-being;
LIHC	cis	rs2839627	0.638	rs7276320	chr21:44269588	A/G	cg03543861	chr21:44258195	NA	-0.59	-8.09	-0.4	1.02e-14	Information processing speed;
LIHC	cis	rs1419980	0.730	rs7132326	chr12:7752391	G/T	cg10578777	chr12:7781093	NA	-0.4	-5.79	-0.3	1.59e-8	HDL cholesterol levels;
LIHC	cis	rs4788570	0.578	rs4788553	chr16:71780277	T/G	cg06353428	chr16:71660113	MARVELD3	1.41	15.66	0.65	4.68e-42	Intelligence (multi-trait analysis);
LIHC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	12.56	0.56	4.97e-30	Electrocardiographic conduction measures;
LIHC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg13047869	chr3:10149882	C3orf24	0.51	6.16	0.32	2.02e-9	Alzheimer's disease;
LIHC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.68	-0.53	9.56e-27	Platelet distribution width;
LIHC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.79	6.07	0.31	3.3e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.34	-6.44	-0.33	3.94e-10	Blood metabolite levels;
LIHC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19671926	chr4:122722719	EXOSC9	0.54	8.48	0.42	7.02e-16	Type 2 diabetes;
LIHC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.11	16.57	0.67	1.07e-45	Sexual dysfunction (female);
LIHC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	7.66	0.38	1.88e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.14	0.31	2.35e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs903552	0.866	rs11247296	chr15:102007919	T/C	cg00659931	chr15:102010125	PCSK6	-0.49	-6.83	-0.35	3.9e-11	Diabetic kidney disease;
LIHC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg03665457	chr10:38645376	HSD17B7P2	0.39	5.73	0.3	2.23e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.56	-7.31	-0.37	1.89e-12	Initial pursuit acceleration;
LIHC	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.44	-0.42	9.43e-16	Exhaled nitric oxide output;
LIHC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.63	-11.2	-0.52	5.28e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.92	0.3	7.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.44	-0.33	4.12e-10	Response to antipsychotic treatment;
LIHC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.92	-0.54	1.19e-27	Alzheimer's disease;
LIHC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg16479474	chr6:28041457	NA	0.47	7.17	0.36	4.71e-12	Parkinson's disease;
LIHC	cis	rs1982963	1.000	rs753050	chr14:52505375	A/G	cg10843707	chr14:52510701	NID2	-0.44	-7.7	-0.38	1.51e-13	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.81	-10.6	-0.5	6.61e-23	Blood pressure (smoking interaction);
LIHC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.71	11.02	0.51	2.19e-24	Corneal astigmatism;
LIHC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.77	-0.3	1.78e-8	Menopause (age at onset);
LIHC	cis	rs244293	0.931	rs173408	chr17:53202392	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.51	-7.58	-0.38	3.24e-13	Menarche (age at onset);
LIHC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	8.61	0.42	2.77e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.7	7.28	0.37	2.38e-12	Vitiligo;
LIHC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	8.45	0.42	8.72e-16	Lymphocyte counts;
LIHC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-7.13	-0.36	5.91e-12	Alzheimer's disease;
LIHC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.47	-7.46	-0.37	6.99e-13	Fibrinogen levels;
LIHC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.0	0.51	2.66e-24	Personality dimensions;
LIHC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	8.53	0.42	4.9e-16	Mean corpuscular hemoglobin;
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.92	-0.54	1.19e-27	Alzheimer's disease;
LIHC	cis	rs3736485	0.934	rs17609791	chr15:51874824	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.33	-0.32	7.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg24296786	chr1:45957014	TESK2	-0.52	-7.85	-0.39	5.52e-14	Platelet count;
LIHC	cis	rs12144094	0.882	rs10494229	chr1:120229117	A/G	cg20995928	chr1:120229863	NA	0.41	7.17	0.36	4.77e-12	Height;
LIHC	cis	rs2758596	1.000	rs2736608	chr1:156180349	T/A	cg24450063	chr1:156163899	SLC25A44	0.99	9.99	0.48	8.94e-21	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg04610667	chr7:75704037	NA	-0.33	-5.92	-0.3	8.04e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg12798992	chr6:167411361	FGFR1OP	0.59	9.71	0.46	7.83e-20	Crohn's disease;
LIHC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.6	9.24	0.45	2.63e-18	QRS duration;
LIHC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.67	-11.62	-0.53	1.56e-26	Menopause (age at onset);
LIHC	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.6	10.07	0.48	4.79e-21	HDL cholesterol;
LIHC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg16736954	chr20:23401023	NAPB	0.71	8.28	0.41	2.86e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.32	7.06	0.36	9.14e-12	Ulcerative colitis;
LIHC	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg22787604	chr8:1509810	DLGAP2	-0.42	-7.48	-0.37	6.36e-13	Lung cancer;
LIHC	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg19773385	chr1:10388646	KIF1B	-0.33	-6.05	-0.31	3.75e-9	Hepatocellular carcinoma;
LIHC	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04530015	chr2:215796436	ABCA12	0.46	7.75	0.39	1.08e-13	Neuroblastoma;
LIHC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05590025	chr7:65112418	INTS4L2	0.44	6.58	0.34	1.79e-10	Calcium levels;
LIHC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	13.0	0.58	1.11e-31	Prudent dietary pattern;
LIHC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.99	-20.46	-0.74	2.56e-61	Height;
LIHC	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.63	0.56	2.87e-30	Prudent dietary pattern;
LIHC	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.44	6.77	0.34	5.65e-11	Neutrophil percentage of white cells;
LIHC	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.93	6.46	0.33	3.62e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.46	-6.75	-0.34	6.3e-11	Dermatomyositis;
LIHC	trans	rs7874142	0.616	rs4842167	chr9:137687314	A/G	cg18109838	chr5:88185987	MEF2C	0.37	7.65	0.38	2.09e-13	Longevity;
LIHC	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.8	-0.54	3.43e-27	Coffee consumption (cups per day);
LIHC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.52	-8.47	-0.42	7.59e-16	Fibrinogen levels;
LIHC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg03959625	chr15:84868606	LOC388152	0.42	5.91	0.3	8.27e-9	Schizophrenia;
LIHC	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg04592579	chr7:75616294	TMEM120A	0.4	6.95	0.35	1.84e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.96	-0.44	2.09e-17	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg25009327	chr7:148820504	ZNF425	-0.38	-6.11	-0.31	2.67e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg14930904	chr10:32216787	ARHGAP12	0.37	6.55	0.33	2.07e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-8.18	-0.4	5.56e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg16479474	chr6:28041457	NA	0.45	7.13	0.36	5.92e-12	Parkinson's disease;
LIHC	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.63	7.78	0.39	8.43e-14	Crohn's disease;
LIHC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.42	-5.98	-0.31	5.58e-9	Height;
LIHC	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg08539965	chr1:21396338	EIF4G3	0.32	5.79	0.3	1.59e-8	Superior frontal gyrus grey matter volume;
LIHC	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.72	-0.39	1.25e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.4	-6.58	-0.34	1.78e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.61	9.06	0.44	1.01e-17	Longevity;
LIHC	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg17623882	chr6:41773611	USP49	-0.43	-5.85	-0.3	1.13e-8	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg23461800	chr14:103021989	NA	-0.45	-6.43	-0.33	4.36e-10	Platelet count;
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.76	11.75	0.54	5.14e-27	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02969873	chr4:1330999	MAEA	-0.41	-6.27	-0.32	1.1e-9	Longevity;
LIHC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.51	7.25	0.37	2.74e-12	Body mass index;
LIHC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.64	-10.39	-0.49	3.58e-22	Inflammatory bowel disease;
LIHC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	11.86	0.54	2e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.73	0.57	1.17e-30	Prudent dietary pattern;
LIHC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.19	13.07	0.58	5.94e-32	White matter hyperintensity burden;
LIHC	cis	rs6750047	0.647	rs62136320	chr2:38275953	T/G	cg07380506	chr2:38303506	CYP1B1	0.59	7.56	0.38	3.66e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.73	0.67	2.53e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.44	-7.99	-0.4	2.15e-14	Vitamin D levels;
LIHC	cis	rs5769765	0.773	rs7410304	chr22:50316835	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-8.65	-0.42	1.97e-16	Schizophrenia;
LIHC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.22	15.09	0.63	8.39e-40	Alzheimer's disease (late onset);
LIHC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.36	5.9	0.3	8.67e-9	Obesity-related traits;
LIHC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg15595755	chr5:1867978	NA	0.34	6.38	0.33	5.66e-10	Cardiovascular disease risk factors;
LIHC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg02811702	chr13:24901961	NA	0.26	6.6	0.34	1.56e-10	Obesity-related traits;
LIHC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.51	0.38	5.23e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25231972	chr10:31608136	ZEB1;LOC220930	-0.43	-6.18	-0.32	1.83e-9	Triglycerides;
LIHC	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.29	-6.75	-0.34	6.39e-11	Hip circumference;Waist circumference;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16574807	chr4:6945745	TBC1D14	0.41	6.67	0.34	1.05e-10	Longevity;
LIHC	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	14.0	0.6	1.67e-35	Coffee consumption (cups per day);
LIHC	trans	rs10213084	1.000	rs10213649	chr4:147499554	C/T	cg18061433	chr10:21435895	C10orf113;NEBL	0.49	6.12	0.31	2.52e-9	Heart rate;
LIHC	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.53	8.41	0.41	1.13e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg05044414	chr3:183734942	ABCC5	0.34	5.91	0.3	8.31e-9	Anterior chamber depth;
LIHC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.57	-0.46	2.16e-19	Extrinsic epigenetic age acceleration;
LIHC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.75	-10.68	-0.5	3.56e-23	Hemostatic factors and hematological phenotypes;
LIHC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.89	-17.68	-0.69	3.81e-50	Height;
LIHC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.57	9.31	0.45	1.64e-18	Longevity;Endometriosis;
LIHC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg10360323	chr17:41437877	NA	0.41	6.16	0.32	2.04e-9	Menopause (age at onset);
LIHC	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.73	11.03	0.51	2.09e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-10.82	-0.5	1.16e-23	Coronary artery disease;
LIHC	cis	rs1198430	0.925	rs1767148	chr1:23765472	A/G	cg19827787	chr1:23763612	ASAP3	0.35	6.22	0.32	1.48e-9	Total cholesterol levels;
LIHC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.41	8.7	0.43	1.37e-16	Ewing sarcoma;
LIHC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-6.64	-0.34	1.26e-10	Height;
LIHC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg22496339	chr2:162101262	NA	0.65	9.69	0.46	9.14e-20	Intelligence (multi-trait analysis);
LIHC	cis	rs611744	0.967	rs603571	chr8:109213893	A/C	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.4	5.81	0.3	1.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg05484376	chr2:27715224	FNDC4	0.34	5.76	0.3	1.87e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.44	5.78	0.3	1.68e-8	Subjective well-being;
LIHC	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.52	7.17	0.36	4.69e-12	Morning vs. evening chronotype;
LIHC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.87	10.81	0.5	1.21e-23	Bladder cancer;
LIHC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg26831259	chr4:1366826	KIAA1530	-0.35	-5.75	-0.3	1.94e-8	Obesity-related traits;
LIHC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.73	-11.79	-0.54	3.76e-27	Platelet distribution width;
LIHC	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.42	-7.19	-0.36	4.16e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg26338869	chr17:61819248	STRADA	0.52	6.97	0.35	1.61e-11	Height;
LIHC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-7.55	-0.38	3.89e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LIHC	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg25007680	chr1:8021821	PARK7	0.46	6.29	0.32	9.96e-10	Inflammatory bowel disease;
LIHC	trans	rs6934970	1.000	rs62413976	chr6:113060338	C/T	cg09308777	chr6:169852575	NA	0.58	6.06	0.31	3.61e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg20283391	chr11:68216788	NA	-0.38	-6.02	-0.31	4.43e-9	Total body bone mineral density;
LIHC	cis	rs36051895	0.560	rs10975009	chr9:5220397	T/G	cg02405213	chr9:5042618	JAK2	-0.63	-9.95	-0.47	1.14e-20	Pediatric autoimmune diseases;
LIHC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg16586182	chr3:47516702	SCAP	-0.43	-7.46	-0.37	7.39e-13	Colorectal cancer;
LIHC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.42	-6.69	-0.34	8.89e-11	Monocyte percentage of white cells;
LIHC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.67	-0.38	1.79e-13	Schizophrenia;
LIHC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.41	-6.58	-0.34	1.76e-10	Dementia with Lewy bodies;
LIHC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg11766577	chr21:47581405	C21orf56	-0.37	-5.75	-0.3	1.99e-8	Testicular germ cell tumor;
LIHC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-8.45	-0.42	8.47e-16	Crohn's disease;
LIHC	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg05372495	chr19:1063624	ABCA7	-0.41	-6.61	-0.34	1.47e-10	Alzheimer's disease (late onset);
LIHC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.63	-8.87	-0.43	3.99e-17	Blood metabolite levels;
LIHC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg12798992	chr6:167411361	FGFR1OP	0.59	9.67	0.46	1.04e-19	Crohn's disease;
LIHC	cis	rs2708977	0.932	rs12329128	chr2:97284917	G/A	cg01950434	chr2:97203154	ARID5A	0.51	6.54	0.33	2.28e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.27	-7.22	-0.36	3.45e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg03146154	chr1:46216737	IPP	0.47	7.47	0.37	6.97e-13	Red blood cell count;Reticulocyte count;
LIHC	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg20335179	chr10:1068567	C10orf110;IDI2	-0.61	-6.75	-0.34	6.5e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.72	7.24	0.36	2.91e-12	Vitiligo;
LIHC	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.51	-6.42	-0.33	4.56e-10	Type 2 diabetes;
LIHC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg05590025	chr7:65112418	INTS4L2	-0.53	-5.77	-0.3	1.82e-8	Diabetic kidney disease;
LIHC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.87	0.3	1.05e-8	Menopause (age at onset);
LIHC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg12458913	chr13:53173898	NA	-0.54	-8.22	-0.41	4.3e-15	Lewy body disease;
LIHC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg17750252	chr2:136567154	LCT	0.34	6.21	0.32	1.52e-9	Mosquito bite size;
LIHC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.36	-0.45	1.11e-18	Type 2 diabetes;
LIHC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg18964960	chr10:1102726	WDR37	0.75	6.93	0.35	2.09e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06500355	chr6:111804104	REV3L	0.42	6.8	0.35	4.78e-11	Lung function (FEV1/FVC);
LIHC	cis	rs1892700	0.764	rs71326956	chr21:34900282	C/T	cg14850771	chr21:34775459	IFNGR2	-0.45	-5.94	-0.31	7.19e-9	Educational attainment;
LIHC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.18	-0.36	4.38e-12	Migraine;Coronary artery disease;
LIHC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg13628971	chr7:2884303	GNA12	0.4	6.47	0.33	3.45e-10	Height;
LIHC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07677032	chr17:61819896	STRADA	0.43	6.12	0.31	2.53e-9	Prudent dietary pattern;
LIHC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.96	10.36	0.49	4.51e-22	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg14237674	chr17:43239170	HEXIM2	0.41	6.45	0.33	3.83e-10	Cognitive function;
LIHC	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg08668510	chr10:1095578	IDI1	0.7	7.0	0.35	1.36e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg25029360	chr8:141646502	EIF2C2	-0.46	-6.99	-0.35	1.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg14146966	chr2:61757674	XPO1	0.48	8.45	0.42	8.6e-16	Tuberculosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00029053	chr2:10830014	NOL10	0.48	6.69	0.34	8.94e-11	Lung function (FEV1/FVC);
LIHC	cis	rs12286929	0.609	rs11601751	chr11:115094117	C/T	cg04055981	chr11:115044050	NA	0.45	6.47	0.33	3.43e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.76	9.65	0.46	1.18e-19	Menarche (age at onset);
LIHC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg01364799	chr7:75623366	TMEM120A	-0.49	-7.53	-0.38	4.58e-13	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.85	13.75	0.6	1.49e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs28830936	0.966	rs28432037	chr15:42126779	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.79	-0.3	1.58e-8	Diastolic blood pressure;
LIHC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.97	9.82	0.47	3.37e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.38	-6.36	-0.33	6.3e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18447950	chr17:79073781	BAIAP2	0.42	6.59	0.34	1.68e-10	Longevity;
LIHC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg03354898	chr7:1950403	MAD1L1	0.37	5.84	0.3	1.25e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.49	9.82	0.47	3.15e-20	Tonsillectomy;
LIHC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.78	6.37	0.33	6.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9309473	0.950	rs6711001	chr2:73850820	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.65	-0.34	1.13e-10	Metabolite levels;
LIHC	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.54	-7.02	-0.35	1.23e-11	Coronary artery calcification;
LIHC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg19500098	chr13:21900506	NA	0.38	6.01	0.31	4.78e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	7.26	0.37	2.68e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.19	13.36	0.59	4.94e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg00677901	chr16:88017247	BANP	0.55	8.49	0.42	6.17e-16	Menopause (age at onset);
LIHC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg21361702	chr7:150065534	REPIN1	0.46	6.3	0.32	9.39e-10	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.19e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.62	6.52	0.33	2.55e-10	Alzheimer's disease;
LIHC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg18270830	chr10:32634957	EPC1	0.53	6.52	0.33	2.49e-10	Sexual dysfunction (female);
LIHC	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg17135325	chr3:160939158	NMD3	0.59	8.47	0.42	7.36e-16	Parkinson's disease;
LIHC	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.7	-0.43	1.39e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs778371	0.647	rs4144797	chr2:233562197	T/C	cg08000102	chr2:233561755	GIGYF2	0.76	9.1	0.44	7.57e-18	Schizophrenia;
LIHC	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.53	9.99	0.48	8.91e-21	Testicular germ cell tumor;
LIHC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.03	0.4	1.56e-14	Motion sickness;
LIHC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.99	0.35	1.41e-11	Body mass index;
LIHC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.4	8.66	0.42	1.88e-16	Prostate-specific antigen levels;
LIHC	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.39	-6.42	-0.33	4.67e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	8.24	0.41	3.66e-15	IgG glycosylation;
LIHC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg03037974	chr15:76606532	NA	0.74	14.47	0.62	2.32e-37	Blood metabolite levels;
LIHC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.29	6.24	0.32	1.28e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.43	7.84	0.39	5.79e-14	Monocyte percentage of white cells;
LIHC	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.48	8.76	0.43	8.98e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-6.99	-0.35	1.47e-11	Vitiligo;
LIHC	cis	rs922107	0.738	rs12723903	chr1:90037050	C/T	cg15422784	chr1:90023713	LRRC8B	-0.47	-7.53	-0.38	4.66e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-15.29	-0.64	1.36e-40	Tonsillectomy;
LIHC	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.81	16.08	0.66	1.02e-43	Testicular germ cell tumor;
LIHC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-1.0	-10.34	-0.49	5.36e-22	Breast cancer;
LIHC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.83	0.3	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.63	-8.63	-0.42	2.35e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.84	-0.3	1.21e-8	Biliary atresia;
LIHC	trans	rs6489882	0.867	rs1859332	chr12:113371114	T/C	cg10175203	chr3:128143634	NA	0.38	6.19	0.32	1.7e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.3	6.52	0.33	2.5e-10	Pulmonary function;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg26642844	chr7:2419167	EIF3B	-0.38	-6.37	-0.33	6.23e-10	Calcium levels;
LIHC	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.38	6.9	0.35	2.59e-11	Quantitative traits;
LIHC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.37	-6.69	-0.34	9.37e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LIHC	cis	rs1823913	1.000	rs4853462	chr2:192123804	C/A	cg12404831	chr2:192114017	MYO1B	-0.32	-6.54	-0.33	2.21e-10	Obesity-related traits;
LIHC	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg02290350	chr8:58132656	NA	0.47	9.18	0.44	4.31e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.59	-0.5	7.71e-23	Total cholesterol levels;
LIHC	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.66	6.59	0.34	1.63e-10	Hip geometry;
LIHC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	7.18	0.36	4.38e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.58	7.68	0.38	1.72e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.2	0.64	3.05e-40	Chronic sinus infection;
LIHC	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg02811702	chr13:24901961	NA	0.26	6.61	0.34	1.5e-10	Obesity-related traits;
LIHC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg03983715	chr16:68378420	PRMT7	-0.48	-5.84	-0.3	1.24e-8	Schizophrenia;
LIHC	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg06609049	chr19:2785107	THOP1	0.61	9.5	0.46	3.92e-19	Total cholesterol levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01534608	chr4:187646364	FAT1	0.44	6.76	0.34	5.8e-11	Cognitive function;
LIHC	cis	rs1165668	0.785	rs2583223	chr12:104316841	G/A	cg21863207	chr12:104234989	NT5DC3	0.46	8.01	0.4	1.77e-14	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.79	8.76	0.43	9.38e-17	Iron status biomarkers;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg01259702	chr19:662807	RNF126	-0.47	-6.04	-0.31	3.93e-9	Electroencephalogram traits;
LIHC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.37	0.56	2.77e-29	Menopause (age at onset);
LIHC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.98	-9.89	-0.47	1.96e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.51	-8.78	-0.43	7.7e-17	White blood cell count (neutrophil);
LIHC	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.51	-8.41	-0.41	1.13e-15	Corneal astigmatism;
LIHC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.84	13.9	0.6	4e-35	Menopause (age at onset);
LIHC	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.78	8.89	0.43	3.7e-17	Exhaled nitric oxide levels;
LIHC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.35	0.52	1.55e-25	Hip circumference adjusted for BMI;
LIHC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.43	-6.48	-0.33	3.16e-10	Cognitive function;
LIHC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.7	11.03	0.51	2.13e-24	Corneal astigmatism;
LIHC	cis	rs7926971	0.655	rs7927422	chr11:12660894	T/C	cg25843174	chr11:12811716	TEAD1	0.26	5.99	0.31	5.38e-9	Height;
LIHC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg27170947	chr2:26402098	FAM59B	0.63	7.93	0.39	3.17e-14	Gut microbiome composition (summer);
LIHC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg13175981	chr1:150552382	MCL1	-0.42	-5.74	-0.3	2.12e-8	Tonsillectomy;
LIHC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.61	-7.12	-0.36	6.24e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	0.61	8.83	0.43	5.47e-17	Prudent dietary pattern;
LIHC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.25e-9	Menopause (age at onset);
LIHC	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	6.43	0.33	4.25e-10	Ileal carcinoids;
LIHC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.48	9.67	0.46	1.02e-19	Tonsillectomy;
LIHC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.63	0.34	1.32e-10	Body mass index;
LIHC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.56	8.89	0.43	3.58e-17	Anterior chamber depth;
LIHC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg21665744	chr7:39171113	POU6F2	0.33	6.03	0.31	4.33e-9	IgG glycosylation;
LIHC	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	0.92	17.6	0.69	8.11e-50	Schizophrenia;
LIHC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	7.84	0.39	5.76e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.82	0.43	5.8e-17	Motion sickness;
LIHC	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.52	9.11	0.44	7.22e-18	Coronary artery disease;
LIHC	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.43	6.57	0.33	1.93e-10	Body mass index;Social communication problems;
LIHC	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg14146966	chr2:61757674	XPO1	-0.44	-7.35	-0.37	1.44e-12	Tuberculosis;
LIHC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.39	8.4	0.41	1.17e-15	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.63	-0.46	1.44e-19	Initial pursuit acceleration;
LIHC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.02	0.54	5.32e-28	Body mass index;
LIHC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.49	-0.42	6.38e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12016809	chr21:47604291	C21orf56	0.44	6.64	0.34	1.24e-10	Testicular germ cell tumor;
LIHC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.24	-0.52	3.7e-25	Primary sclerosing cholangitis;
LIHC	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.47	-0.46	4.84e-19	Capecitabine sensitivity;
LIHC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg21395723	chr22:39101663	GTPBP1	0.4	6.67	0.34	1.04e-10	Menopause (age at onset);
LIHC	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg25600027	chr14:23388339	RBM23	-0.4	-5.75	-0.3	1.97e-8	Cognitive ability (multi-trait analysis);
LIHC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.51	0.33	2.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.47	-0.56	1.12e-29	Alzheimer's disease;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10990685	chr12:120720139	NME2P1	0.52	6.37	0.33	5.93e-10	Lung function (FEV1);
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg02993280	chr1:107599747	PRMT6	0.66	10.66	0.5	4.28e-23	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.26	-5.84	-0.3	1.21e-8	Graves' disease;
LIHC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.79	6.68	0.34	9.53e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.8	-14.72	-0.62	2.53e-38	Prudent dietary pattern;
LIHC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.38	5.78	0.3	1.68e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23262918	chr12:76953136	OSBPL8	-0.43	-6.4	-0.33	5.22e-10	Calcium levels;
LIHC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.4	-5.83	-0.3	1.32e-8	Iron status biomarkers;
LIHC	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.56	-7.37	-0.37	1.32e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.37	-5.9	-0.3	8.82e-9	Bipolar disorder;
LIHC	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-0.71	-8.26	-0.41	3.13e-15	Gut microbiota (bacterial taxa);
LIHC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.45	6.21	0.32	1.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-7.18	-0.36	4.29e-12	Post bronchodilator FEV1;
LIHC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg10360323	chr17:41437877	NA	0.41	6.09	0.31	3.1e-9	Menopause (age at onset);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg11015505	chr11:64645556	EHD1	0.44	6.1	0.31	2.86e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-8.34	-0.41	1.9e-15	Gut microbiome composition (summer);
LIHC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.17	-0.32	1.93e-9	Schizophrenia;
LIHC	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	6.08	0.31	3.29e-9	Blood protein levels;
LIHC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.29	-6.7	-0.34	8.54e-11	Menarche (age at onset);
LIHC	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.58	9.5	0.46	3.69e-19	Corneal astigmatism;
LIHC	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg18912006	chr12:123335444	HIP1R	-0.69	-7.05	-0.36	1.01e-11	Adiponectin levels;
LIHC	trans	rs9641123	0.639	rs2677077	chr7:93259217	T/C	cg09745688	chr16:2908918	PRSS22	-0.37	-6.47	-0.33	3.33e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Lean body mass;
LIHC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.51	-6.83	-0.35	3.79e-11	Vitiligo;
LIHC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.74	-7.48	-0.37	6.46e-13	Vitiligo;
LIHC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-14.81	-0.63	1.14e-38	Intelligence (multi-trait analysis);
LIHC	cis	rs7529073	0.740	rs340883	chr1:214145706	A/G	cg24083324	chr1:214162604	PROX1	-0.47	-7.08	-0.36	8.17e-12	Schizophrenia;
LIHC	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.54	-9.49	-0.46	4.11e-19	Systemic lupus erythematosus;
LIHC	trans	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.4	-6.04	-0.31	4.12e-9	Blood pressure (smoking interaction);
LIHC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.63	13.01	0.58	1.06e-31	Gestational age at birth (maternal effect);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07377341	chr1:160068584	IGSF8	0.46	6.41	0.33	4.82e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3790645	1.000	rs657227	chr1:26892104	T/A	cg17456097	chr1:26900765	RPS6KA1	0.4	5.82	0.3	1.33e-8	Glucose homeostasis traits;
LIHC	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg06102954	chr21:42741788	MX2	0.38	6.48	0.33	3.18e-10	Melanoma;
LIHC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.65	10.68	0.5	3.54e-23	Type 2 diabetes;
LIHC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.73	-0.3	2.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.61	6.17	0.32	1.9e-9	Vitiligo;
LIHC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.71	10.47	0.49	2e-22	Aortic root size;
LIHC	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.66	0.53	1.08e-26	Coffee consumption (cups per day);
LIHC	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.39	5.97	0.31	5.83e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.43	6.86	0.35	3.28e-11	Cleft lip with or without cleft palate;
LIHC	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.73	10.52	0.49	1.34e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg10756647	chr7:56101905	PSPH	1.02	12.11	0.55	2.53e-28	Diabetic kidney disease;
LIHC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.46	6.19	0.32	1.72e-9	Initial pursuit acceleration;
LIHC	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg16275483	chr1:110013120	SYPL2	-0.49	-6.15	-0.32	2.16e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.53	0.56	6.83e-30	Electrocardiographic conduction measures;
LIHC	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.71	7.65	0.38	2.04e-13	Exhaled nitric oxide output;
LIHC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	16.17	0.66	4.25e-44	Platelet count;
LIHC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.05	19.8	0.73	1.11e-58	Multiple system atrophy;
LIHC	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.51	-7.62	-0.38	2.52e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg00204512	chr16:28754710	NA	0.34	6.39	0.33	5.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.48	7.69	0.38	1.61e-13	Schizophrenia;
LIHC	cis	rs116248771	0.739	rs12633674	chr3:158368217	G/T	cg16708174	chr3:158430962	RARRES1	0.48	6.38	0.33	5.61e-10	diarrhoeal disease at age 2;
LIHC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.65	-16.58	-0.67	9.67e-46	Breast cancer;
LIHC	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.43	6.46	0.33	3.7e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.77	-7.29	-0.37	2.2e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LIHC	cis	rs7503807	1.000	rs4890056	chr17:78591211	C/T	cg09596252	chr17:78655493	RPTOR	-0.39	-6.97	-0.35	1.65e-11	Obesity;
LIHC	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.11	-0.31	2.69e-9	Response to antipsychotic treatment;
LIHC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	10.96	0.51	3.72e-24	Lung cancer in ever smokers;
LIHC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.22	5.77	0.3	1.76e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.62	10.27	0.49	9.42e-22	Platelet count;
LIHC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.54	7.15	0.36	5.15e-12	Body mass index;
LIHC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-10.87	-0.51	7.63e-24	Primary sclerosing cholangitis;
LIHC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg17135325	chr3:160939158	NMD3	0.55	7.94	0.39	2.92e-14	Parkinson's disease;
LIHC	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg19752551	chr11:57585705	CTNND1	0.5	7.14	0.36	5.46e-12	Schizophrenia;
LIHC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	1.14	13.63	0.59	4.31e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.31	-0.32	8.74e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs6489882	0.703	rs10850094	chr12:113360563	C/T	cg10175203	chr3:128143634	NA	-0.39	-6.31	-0.32	8.4e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg07451762	chr16:28383216	NA	0.4	7.3	0.37	1.97e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs77633900	0.772	rs506000	chr15:76817788	T/C	cg21673338	chr15:77095150	SCAPER	-0.53	-6.09	-0.31	3.11e-9	Non-glioblastoma glioma;Glioma;
LIHC	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.59	-9.22	-0.45	3.08e-18	Diastolic blood pressure;
LIHC	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg09911534	chr15:67153556	NA	-0.5	-6.16	-0.32	2.02e-9	Lung cancer (smoking interaction);
LIHC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.4	5.79	0.3	1.63e-8	Alzheimer's disease (late onset);
LIHC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.18	-0.32	1.81e-9	Bronchopulmonary dysplasia;
LIHC	cis	rs7729447	0.776	rs7738037	chr5:32696549	C/T	cg16267343	chr5:32710456	NPR3	0.47	5.84	0.3	1.23e-8	Blood pressure;
LIHC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-9.6	-0.46	1.71e-19	Schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg22654626	chr19:18699620	C19orf60	0.6	8.12	0.4	8.68e-15	Lung function (FEV1/FVC);
LIHC	trans	rs12752401	0.867	rs12751548	chr1:103067463	A/G	cg24921808	chr19:740313	PALM	-0.46	-6.1	-0.31	2.94e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.5	-6.49	-0.33	3.04e-10	Schizophrenia;
LIHC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.5	-0.38	5.48e-13	Bipolar disorder;
LIHC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-6.16	-0.32	2.1e-9	Colorectal cancer;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25195416	chr21:46696626	POFUT2	0.39	6.07	0.31	3.34e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg14930904	chr10:32216787	ARHGAP12	0.34	6.01	0.31	4.69e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs1434579	0.966	rs1062098	chr19:44930738	A/G	cg15540054	chr19:45004280	ZNF180	0.56	7.61	0.38	2.74e-13	Tuberculosis;
LIHC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.4	-9.01	-0.44	1.49e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	9.21	0.45	3.43e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.41	-12.24	-0.55	7.93e-29	Hip circumference adjusted for BMI;
LIHC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg15208524	chr1:10270712	KIF1B	0.38	5.82	0.3	1.35e-8	Hepatocellular carcinoma;
LIHC	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.42	-7.28	-0.37	2.36e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg14132834	chr19:41945861	ATP5SL	-0.43	-6.49	-0.33	3.04e-10	Height;
LIHC	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.77	-0.39	9.44e-14	Monocyte percentage of white cells;
LIHC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.25	-5.92	-0.31	7.68e-9	Subjective well-being;
LIHC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg18016565	chr1:150552671	MCL1	0.58	11.21	0.52	4.72e-25	Tonsillectomy;
LIHC	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.4	-8.5	-0.42	5.82e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.85	10.81	0.5	1.31e-23	Cognitive function;
LIHC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.37	0.41	1.45e-15	Motion sickness;
LIHC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.34	5.71	0.3	2.39e-8	Height;
LIHC	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.84	7.01	0.35	1.31e-11	Blood protein levels;
LIHC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg00074818	chr8:8560427	CLDN23	0.39	6.51	0.33	2.67e-10	Obesity-related traits;
LIHC	cis	rs1775715	0.966	rs1755066	chr10:32309160	C/G	cg14930904	chr10:32216787	ARHGAP12	-0.41	-7.35	-0.37	1.43e-12	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg07133347	chr1:107600762	PRMT6	-0.45	-6.73	-0.34	6.96e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg02869306	chr7:64672164	INTS4L1	0.28	6.22	0.32	1.42e-9	Calcium levels;
LIHC	cis	rs1144333	0.655	rs58722308	chr1:76423525	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.56	0.38	3.79e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.59	-10.13	-0.48	2.93e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.5	-7.22	-0.36	3.49e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	trans	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg10208301	chr11:6592745	DNHD1	0.46	6.22	0.32	1.41e-9	Coronary artery calcification;
LIHC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.99	0.31	5.45e-9	Life satisfaction;
LIHC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg17385448	chr1:15911702	AGMAT	0.34	5.94	0.31	7.13e-9	Systolic blood pressure;
LIHC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.84	0.51	9.48e-24	Lung cancer in ever smokers;
LIHC	cis	rs986417	1.000	rs1024223	chr14:60926119	C/T	cg27398547	chr14:60952738	C14orf39	0.81	9.56	0.46	2.46e-19	Gut microbiota (bacterial taxa);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12713142	chr12:57081325	PTGES3	0.42	6.66	0.34	1.12e-10	Pancreatic cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24132989	chr6:88050339	C6orf162	0.3	6.27	0.32	1.09e-9	Cognitive function;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14910368	chr12:57610455	NXPH4	0.57	6.27	0.32	1.11e-9	Lung function (FEV1);
LIHC	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.53	-6.19	-0.32	1.73e-9	Ulcerative colitis;
LIHC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.34	-0.45	1.28e-18	Mean platelet volume;
LIHC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.89	0.3	9.25e-9	Bipolar disorder;
LIHC	cis	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg01231543	chr16:68741748	NA	0.4	5.95	0.31	6.65e-9	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg02891801	chr12:6472782	SCNN1A	0.47	7.67	0.38	1.79e-13	Cognitive function;
LIHC	cis	rs74544699	0.826	rs74499711	chr4:74842764	G/A	cg02530824	chr4:74847766	PF4	0.59	7.08	0.36	8.15e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	10.2	0.48	1.65e-21	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.87	0.57	3.48e-31	Prudent dietary pattern;
LIHC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.86	-0.3	1.12e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg25039879	chr17:56429692	SUPT4H1	0.75	8.46	0.42	7.96e-16	Cognitive test performance;
LIHC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg21522988	chr12:29376872	FAR2	0.3	6.86	0.35	3.26e-11	QT interval;
LIHC	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.6	8.95	0.44	2.33e-17	Recombination rate (females);
LIHC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.51	-7.6	-0.38	2.89e-13	Total body bone mineral density;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg00639286	chr5:151138064	ATOX1	0.48	6.64	0.34	1.24e-10	Lung function (FEV1/FVC);
LIHC	cis	rs8016947	0.506	rs7157054	chr14:35785129	G/A	cg03549618	chr14:35838977	NA	0.35	5.75	0.3	2.02e-8	Psoriasis;
LIHC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg07713946	chr22:31675144	LIMK2	-0.43	-7.77	-0.39	9.21e-14	Paclitaxel-induced neuropathy;
LIHC	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.36	7.2	0.36	3.78e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LIHC	cis	rs4773330	1.000	rs831167	chr13:111795544	C/T	cg26911804	chr13:111806221	ARHGEF7	-0.66	-6.65	-0.34	1.18e-10	Bilirubin levels;
LIHC	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	7.08	0.36	7.98e-12	Neutrophil percentage of white cells;
LIHC	cis	rs7534824	0.625	rs7545402	chr1:101321076	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	6.77	0.34	5.76e-11	Refractive astigmatism;
LIHC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg14092571	chr14:90743983	NA	0.45	7.03	0.36	1.13e-11	Mortality in heart failure;
LIHC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.35	-0.32	6.8e-10	Height;
LIHC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	8.2	0.41	5.07e-15	Initial pursuit acceleration;
LIHC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg17834443	chr8:19674713	INTS10	0.48	7.19	0.36	4.13e-12	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg18016565	chr1:150552671	MCL1	0.47	9.06	0.44	1.03e-17	Melanoma;
LIHC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg14132834	chr19:41945861	ATP5SL	-0.44	-6.52	-0.33	2.58e-10	Height;
LIHC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg16836995	chr17:43662488	NA	-0.75	-7.67	-0.38	1.78e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.26	-0.37	2.55e-12	Personality dimensions;
LIHC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.64	9.75	0.47	5.44e-20	Height;
LIHC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.48	-0.49	1.81e-22	Chronic sinus infection;
LIHC	cis	rs7707921	0.881	rs2629744	chr5:81381997	A/T	cg15871215	chr5:81402204	ATG10	-0.6	-6.08	-0.31	3.15e-9	Breast cancer;
LIHC	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg16309518	chr5:176445507	NA	-0.51	-9.46	-0.46	5.1e-19	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.22	0.41	4.14e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg10932868	chr11:921992	NA	0.39	7.49	0.38	5.97e-13	Alzheimer's disease (late onset);
LIHC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.3	6.92	0.35	2.26e-11	Crohn's disease;
LIHC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.24	-0.36	2.92e-12	Bipolar disorder;
LIHC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.79	11.81	0.54	3.14e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.49	-8.47	-0.42	7.45e-16	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	0.87	14.26	0.61	1.61e-36	Left atrial antero-posterior diameter;
LIHC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg22800045	chr5:56110881	MAP3K1	0.6	7.37	0.37	1.31e-12	Initial pursuit acceleration;
LIHC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-15.85	-0.65	8.31e-43	Chronic sinus infection;
LIHC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.51	7.51	0.38	5.09e-13	Response to diuretic therapy;
LIHC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.97	17.95	0.7	3.2e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs7487075	0.567	rs4768712	chr12:46811521	T/C	cg23829395	chr12:46796953	NA	0.36	6.3	0.32	9.14e-10	Itch intensity from mosquito bite;
LIHC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	0.77	11.44	0.53	7.3e-26	Monocyte percentage of white cells;
LIHC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.5	8.24	0.41	3.84e-15	Fibrinogen levels;
LIHC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.29	-0.32	9.9e-10	Breast cancer;
LIHC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.27	-6.34	-0.32	7.12e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	14.49	0.62	1.98e-37	Prudent dietary pattern;
LIHC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg12253828	chr6:101329408	ASCC3	0.43	6.79	0.34	5.07e-11	Neuroticism;
LIHC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.16	-11.12	-0.52	9.83e-25	Uric acid levels;
LIHC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.54	-8.52	-0.42	5.21e-16	Coronary artery disease;
LIHC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg24203234	chr3:128598194	ACAD9	0.45	6.29	0.32	9.77e-10	IgG glycosylation;
LIHC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.25	-0.37	2.75e-12	Schizophrenia;
LIHC	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg07322936	chr10:88137208	NA	-0.45	-5.85	-0.3	1.17e-8	Migraine without aura;
LIHC	cis	rs7818688	0.654	rs11783262	chr8:95979816	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	6.67	0.34	1.04e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg10360323	chr17:41437877	NA	0.41	6.08	0.31	3.13e-9	Menopause (age at onset);
LIHC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.95	-0.35	1.87e-11	Response to antipsychotic treatment;
LIHC	cis	rs3741151	0.892	rs60078907	chr11:73085834	T/C	cg17517138	chr11:73019481	ARHGEF17	0.78	6.12	0.31	2.63e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.55	-10.43	-0.49	2.7e-22	Asthma;
LIHC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	7.62	0.38	2.45e-13	Lymphocyte counts;
LIHC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	6.21	0.32	1.52e-9	Lipoprotein (a) levels;
LIHC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg21466736	chr12:48725269	NA	-0.7	-10.87	-0.51	7.55e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.25	0.32	1.24e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg19508488	chr2:152266495	RIF1	0.5	6.82	0.35	4.22e-11	Squamous cell lung carcinoma;
LIHC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-6.34	-0.32	7.19e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	6.87	0.35	3.05e-11	Renal cell carcinoma;
LIHC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.45	7.06	0.36	9.05e-12	Cognitive function;
LIHC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg04315214	chr1:2043799	PRKCZ	0.46	7.4	0.37	1.08e-12	Height;
LIHC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.59	10.3	0.49	7.86e-22	Dupuytren's disease;
LIHC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.14	-0.44	5.77e-18	Gut microbiome composition (summer);
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.66	11.11	0.52	1.05e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	1.0	18.39	0.71	5.24e-53	Monocyte percentage of white cells;
LIHC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg03013999	chr17:37608204	MED1	0.35	5.76	0.3	1.84e-8	Glomerular filtration rate (creatinine);
LIHC	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.28	6.41	0.33	4.76e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.78	-0.3	1.67e-8	Fibrinogen levels;
LIHC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.11	-0.55	2.54e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg14593290	chr7:50529359	DDC	0.6	9.78	0.47	4.5e-20	Malaria;
LIHC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.91	11.67	0.53	1.01e-26	Bladder cancer;
LIHC	cis	rs965469	1.000	rs6051753	chr20:3315513	G/A	cg25506879	chr20:3388711	C20orf194	-0.6	-6.9	-0.35	2.57e-11	IFN-related cytopenia;
LIHC	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.42	6.24	0.32	1.27e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg16652328	chr3:33138982	GLB1;TMPPE	0.56	7.15	0.36	5.29e-12	Major depressive disorder;
LIHC	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.46	7.36	0.37	1.4e-12	Superior crus of antihelix expression;
LIHC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	0.65	7.85	0.39	5.32e-14	Corneal curvature;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01287788	chr2:86362935	SNORD94;PTCD3	0.41	6.85	0.35	3.41e-11	Cognitive function;
LIHC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg01557791	chr16:72042693	DHODH	-0.39	-6.48	-0.33	3.29e-10	Fibrinogen levels;
LIHC	cis	rs8081395	0.741	rs180530	chr17:58003594	G/A	cg13753209	chr17:57696993	CLTC	0.39	5.95	0.31	6.59e-9	White blood cell count;
LIHC	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg23202291	chr11:1979235	NA	-0.52	-6.67	-0.34	1.05e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LIHC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.52	-0.33	2.52e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg11212589	chr17:38028394	ZPBP2	0.32	6.47	0.33	3.34e-10	Self-reported allergy;
LIHC	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.46	7.61	0.38	2.68e-13	Neutrophil percentage of white cells;
LIHC	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.53	-10.51	-0.49	1.43e-22	Endometriosis;
LIHC	cis	rs539514	0.664	rs1323712	chr13:76300085	C/G	cg04757411	chr13:76259545	LMO7	-0.47	-8.39	-0.41	1.27e-15	Type 1 diabetes;
LIHC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	9.13	0.44	6.03e-18	Monocyte count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04718845	chr6:152623094	SYNE1	0.44	6.06	0.31	3.64e-9	Pancreatic cancer;
LIHC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.58	10.27	0.49	9.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.74	-9.82	-0.47	3.28e-20	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs13315591	1.000	rs13315591	chr3:58556841	A/G	cg16863673	chr2:240905040	NDUFA10	0.75	6.09	0.31	3.12e-9	Rheumatoid arthritis;
LIHC	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.33	7.4	0.37	1.04e-12	Blood metabolite ratios;
LIHC	cis	rs2239815	0.515	rs9625600	chr22:29244395	T/C	cg15103426	chr22:29168792	CCDC117	0.44	5.85	0.3	1.18e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LIHC	trans	rs600324	0.598	rs384167	chr6:160476267	A/G	cg09580072	chr10:134113312	STK32C	-0.33	-6.38	-0.33	5.92e-10	Blood protein levels;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.45	-6.23	-0.32	1.39e-9	Total body bone mineral density;
LIHC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg16736954	chr20:23401023	NAPB	0.71	8.25	0.41	3.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg25801113	chr15:45476975	SHF	0.37	6.26	0.32	1.17e-9	Uric acid levels;
LIHC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.41	6.7	0.34	8.36e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.66	11.76	0.54	4.65e-27	Breast cancer;
LIHC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-12.38	-0.56	2.36e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-6.0	-0.31	4.96e-9	Colorectal cancer;
LIHC	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.63	-0.42	2.37e-16	Schizophrenia;
LIHC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.54	-9.17	-0.44	4.6e-18	Aortic root size;
LIHC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-11.18	-0.52	6.03e-25	Mean corpuscular volume;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04856096	chr8:68255097	ARFGEF1	0.52	7.79	0.39	7.8500000000000006e-14	Cognitive function;
LIHC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.98	13.29	0.58	8.46e-33	Heart rate;
LIHC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.64	9.72	0.47	7.27e-20	Corneal astigmatism;
LIHC	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg06238570	chr21:40685208	BRWD1	-0.39	-6.12	-0.31	2.53e-9	Menarche (age at onset);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg19701416	chr10:28592092	NA	0.46	6.85	0.35	3.55e-11	Pancreatic cancer;
LIHC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.55	9.84	0.47	2.69e-20	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs600806	0.821	rs4970840	chr1:109873367	A/G	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.25	-0.36	2.8e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.47	7.46	0.37	7.34e-13	Blood protein levels;
LIHC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg03037974	chr15:76606532	NA	-0.61	-10.3	-0.49	7.81e-22	Blood metabolite levels;
LIHC	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.54	9.73	0.47	6.72e-20	Lewy body disease;
LIHC	cis	rs3736485	0.966	rs7177720	chr15:51890282	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-6.37	-0.33	5.94e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.07	-0.4	1.22e-14	Response to antipsychotic treatment;
LIHC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.47	7.44	0.37	8.47e-13	Morning vs. evening chronotype;
LIHC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-10.98	-0.51	3.03e-24	Mean corpuscular volume;
LIHC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg02269571	chr22:50332266	NA	-0.62	-8.78	-0.43	7.76e-17	Schizophrenia;
LIHC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.54	0.38	4.16e-13	Electroencephalogram traits;
LIHC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.4	-6.55	-0.33	2.1e-10	Response to antipsychotic treatment;
LIHC	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.29	6.15	0.32	2.11e-9	Lupus nephritis in systemic lupus erythematosus;
LIHC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	8.56	0.42	3.88e-16	Blood metabolite levels;
LIHC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.45	7.78	0.39	8.42e-14	Mean corpuscular volume;
LIHC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.82	0.35	4.06e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.35	-6.39	-0.33	5.29e-10	Aortic root size;
LIHC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.64	-10.19	-0.48	1.8e-21	Uric acid clearance;
LIHC	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.6	0.5	6.95e-23	Hypertriglyceridemia;
LIHC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.78	12.08	0.55	3.06e-28	Dental caries;
LIHC	cis	rs10916814	0.632	rs10799646	chr1:20903985	G/T	cg24502330	chr1:20914028	CDA	-0.31	-6.76	-0.34	5.86e-11	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg05941027	chr17:61774174	LIMD2	0.37	7.68	0.38	1.7e-13	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.53	9.36	0.45	1.08e-18	Systemic lupus erythematosus;
LIHC	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg01864836	chr14:55583639	NA	-0.4	-7.52	-0.38	4.98e-13	Protein biomarker;
LIHC	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.53	8.57	0.42	3.68e-16	Breast cancer;
LIHC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg05185784	chr16:90016020	DEF8	-0.44	-5.97	-0.31	5.84e-9	Interleukin-17 levels;
LIHC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.31	-0.37	1.9e-12	Longevity;Endometriosis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26462239	chr17:45608823	NPEPPS	0.42	6.33	0.32	7.76e-10	Pancreatic cancer;
LIHC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.71	12.44	0.56	1.44e-29	Diastolic blood pressure;
LIHC	cis	rs5370	0.730	rs3756865	chr6:12288426	T/G	cg27565517	chr6:12292676	EDN1	0.34	5.9	0.3	8.64e-9	Circulating vasoactive peptide levels;
LIHC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg19635926	chr16:89946313	TCF25	0.49	6.38	0.33	5.81e-10	Skin colour saturation;
LIHC	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg20636351	chr8:55087400	NA	-0.37	-7.65	-0.38	2.13e-13	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg25894440	chr7:65020034	NA	-0.51	-5.82	-0.3	1.34e-8	Diabetic kidney disease;
LIHC	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	6.42	0.33	4.42e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.75	11.21	0.52	4.77e-25	Menarche (age at onset);
LIHC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.88	0.51	7.24e-24	Personality dimensions;
LIHC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg12903224	chr12:29470962	FAR2	-0.41	-6.65	-0.34	1.14e-10	QT interval;
LIHC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg16586182	chr3:47516702	SCAP	0.58	10.69	0.5	3.43e-23	Colorectal cancer;
LIHC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.23	0.41	4.11e-15	Birth weight;
LIHC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg02269571	chr22:50332266	NA	0.7	8.05	0.4	1.38e-14	Schizophrenia;
LIHC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.57	11.11	0.51	1.08e-24	Coronary artery disease;
LIHC	cis	rs887797	0.576	rs9914573	chr17:64591389	A/G	cg27019712	chr17:64599478	PRKCA	-0.4	-6.86	-0.35	3.22e-11	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
LIHC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.42	6.1	0.31	2.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	10.93	0.51	4.73e-24	Lung cancer in ever smokers;
LIHC	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.72	-7.81	-0.39	6.88e-14	Vitiligo;
LIHC	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg15711740	chr2:61764176	XPO1	0.42	5.74	0.3	2.14e-8	Tuberculosis;
LIHC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.56	-6.7	-0.34	8.84e-11	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.78	-0.3	1.65e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.05	23.05	0.78	1.31e-71	Schizophrenia;
LIHC	cis	rs17106184	1.000	rs12067513	chr1:51310062	G/A	cg07174182	chr1:51127561	FAF1	-0.62	-6.59	-0.34	1.68e-10	Type 2 diabetes;
LIHC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.33	6.3	0.32	9.38e-10	Body mass index;
LIHC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.39	5.85	0.3	1.15e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.4	7.01	0.35	1.27e-11	Platelet distribution width;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg16634193	chr10:135207476	MTG1	-0.53	-6.05	-0.31	3.71e-9	Systolic blood pressure;
LIHC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.53	6.03	0.31	4.28e-9	Alzheimer's disease;
LIHC	trans	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs12744310	1.000	rs12024413	chr1:41756416	A/G	cg03962019	chr1:41807865	NA	0.38	6.1	0.31	2.82e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.74	10.83	0.51	1.08e-23	Breast cancer;
LIHC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.48	-7.97	-0.4	2.43e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4919087	0.561	rs10082521	chr10:99070526	A/T	cg25902810	chr10:99078978	FRAT1	-0.6	-7.09	-0.36	7.76e-12	Monocyte count;
LIHC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.57	0.46	2.27e-19	Platelet count;
LIHC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.36	-6.14	-0.32	2.29e-9	Schizophrenia;
LIHC	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.69	-10.01	-0.48	7.56e-21	Red blood cell count;
LIHC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-6.76	-0.34	6.11e-11	Type 2 diabetes;
LIHC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.26	6.01	0.31	4.66e-9	Schizophrenia;
LIHC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg17724175	chr1:150552817	MCL1	0.51	10.12	0.48	3.24e-21	Tonsillectomy;
LIHC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.74	-0.3	2.12e-8	Axial length;
LIHC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg10755058	chr3:40428713	ENTPD3	-0.41	-7.23	-0.36	3.11e-12	Renal cell carcinoma;
LIHC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.59	-8.44	-0.42	9.19e-16	Blood metabolite levels;
LIHC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.94	-0.31	6.85e-9	Menopause (age at onset);
LIHC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	0.76	8.09	0.4	1.06e-14	Testicular germ cell tumor;
LIHC	cis	rs9322817	0.691	rs4142531	chr6:105324811	G/A	cg02098413	chr6:105308735	HACE1	0.41	7.7	0.38	1.49e-13	Thyroid stimulating hormone;
LIHC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	6.09	0.31	2.98e-9	Lung function (FEV1/FVC);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25825726	chr19:6230459	MLLT1	0.45	6.11	0.31	2.74e-9	Hepatitis;
LIHC	cis	rs600806	0.893	rs370088	chr1:109858119	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.25	-0.36	2.8e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21545522	chr1:205238299	TMCC2	0.34	6.73	0.34	7.03e-11	Mean corpuscular volume;Mean platelet volume;
LIHC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg18225595	chr11:63971243	STIP1	0.62	6.68	0.34	9.77e-11	Mean platelet volume;
LIHC	cis	rs2574704	0.851	rs2574717	chr3:11661280	A/C	cg15876825	chr3:11651881	VGLL4	-0.5	-8.09	-0.4	1.06e-14	Body mass index;
LIHC	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	9.84	0.47	2.84e-20	Hypertriglyceridemia;
LIHC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.0	0.4	1.97e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.53	5.71	0.3	2.43e-8	Menopause (age at onset);
LIHC	cis	rs2895526	0.540	rs12412190	chr10:12714721	A/G	cg00115178	chr10:12648176	CAMK1D	-0.39	-6.9	-0.35	2.5e-11	Headache;
LIHC	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.65	-10.63	-0.5	5.36e-23	Pediatric autoimmune diseases;
LIHC	cis	rs7635838	1.000	rs7635838	chr3:11412604	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.92	0.35	2.18e-11	HDL cholesterol;
LIHC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	6.14e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	12.01	0.54	5.67e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-7.75	-0.39	1.09e-13	Vitiligo;
LIHC	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.71	11.22	0.52	4.25e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg16102536	chr7:156981717	UBE3C	0.35	5.88	0.3	9.55e-9	Body mass index;
LIHC	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg09795085	chr6:101329169	ASCC3	0.52	7.13	0.36	5.92e-12	Neuroticism;
LIHC	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.7	0.43	1.41e-16	Corneal astigmatism;
LIHC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.93	12.64	0.56	2.67e-30	Cerebrospinal P-tau181p levels;
LIHC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg03037974	chr15:76606532	NA	-0.65	-11.48	-0.53	4.96e-26	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24303698	chr19:46367351	SYMPK;FOXA3	0.5	6.64	0.34	1.2e-10	Lung function (FEV1/FVC);
LIHC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg03013999	chr17:37608204	MED1	0.35	5.89	0.3	9.2e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.71	11.01	0.51	2.43e-24	Corneal astigmatism;
LIHC	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.52	-6.55	-0.33	2.1e-10	Schizophrenia;
LIHC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-7.58	-0.38	3.18e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.19	28.2	0.84	3.06e-91	Schizophrenia;
LIHC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg03859395	chr2:55845619	SMEK2	0.72	11.75	0.54	5.37e-27	Metabolic syndrome;
LIHC	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg04944784	chr2:26401820	FAM59B	-0.77	-9.59	-0.46	1.92e-19	Gut microbiome composition (summer);
LIHC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.66	-0.34	1.13e-10	Schizophrenia;
LIHC	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.6	6.53	0.33	2.42e-10	Schizophrenia;
LIHC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg25894440	chr7:65020034	NA	-0.52	-6.12	-0.31	2.57e-9	Diabetic kidney disease;
LIHC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.6	7.23	0.36	3.15e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg11642891	chr2:3452563	TTC15	-0.45	-7.2	-0.36	3.8e-12	Obesity-related traits;
LIHC	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.2	-0.36	3.76e-12	Metabolite levels;
LIHC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.41	-0.59	2.95e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg22633049	chr21:46681294	NA	-0.35	-6.01	-0.31	4.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	0.97	10.24	0.48	1.17e-21	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs9473924	0.542	rs2857482	chr6:50790642	C/T	cg14470998	chr6:50812995	TFAP2B	1.05	9.43	0.45	6.33e-19	Body mass index;
LIHC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.25	-10.87	-0.51	8.04e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.46	-8.5	-0.42	5.75e-16	Vitamin D levels;
LIHC	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	0.63	8.99	0.44	1.72e-17	Atrial fibrillation;
LIHC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.83	0.3	1.26e-8	Tonsillectomy;Mean corpuscular volume;
LIHC	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.32	0.55	4.05e-29	Coffee consumption (cups per day);
LIHC	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.8	8.45	0.42	8.66e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg00815214	chr21:47717953	NA	-0.37	-6.26	-0.32	1.17e-9	Testicular germ cell tumor;
LIHC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-21.86	-0.76	6.73e-67	Height;
LIHC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg06598544	chr20:61472147	COL9A3	-0.9	-8.42	-0.41	1.07e-15	Obesity-related traits;
LIHC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.82	-0.3	1.37e-8	Total body bone mineral density;
LIHC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-9.03	-0.44	1.25e-17	Obesity-related traits;
LIHC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.51	-6.83	-0.35	3.94e-11	Body mass index;
LIHC	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.39	6.2	0.32	1.67e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs2016586	0.796	rs1997884	chr22:36103778	G/A	cg26342177	chr22:36113512	APOL5	-0.39	-6.68	-0.34	9.63e-11	Body mass index;
LIHC	cis	rs243505	0.516	rs55988390	chr7:148582535	C/T	cg09806900	chr7:148480153	CUL1	0.44	6.2	0.32	1.63e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.55	-6.45	-0.33	3.89e-10	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.38	5.75	0.3	1.99e-8	Mean corpuscular volume;
LIHC	cis	rs6788895	1.000	rs16862842	chr3:150484844	A/G	cg07663535	chr3:150480033	SIAH2	0.56	7.1	0.36	7.3e-12	Breast cancer;
LIHC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.77	0.43	8.86e-17	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-7.6	-0.38	2.95e-13	Exhaled nitric oxide output;
LIHC	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.37	-6.76	-0.34	5.87e-11	Height;
LIHC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.44	-6.59	-0.34	1.63e-10	Height;
LIHC	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.87	7.7	0.38	1.51e-13	Body mass index;
LIHC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg24296786	chr1:45957014	TESK2	-0.51	-7.54	-0.38	4.36e-13	Platelet count;
LIHC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.5	6.36	0.33	6.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.88	-0.3	9.61e-9	Tuberculosis;
LIHC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.24	0.55	8.15e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg04166393	chr7:2884313	GNA12	0.37	6.09	0.31	3.06e-9	Height;
LIHC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.62	10.8	0.5	1.34e-23	Menopause (age at onset);
LIHC	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.94	-17.95	-0.7	3.27e-51	Schizophrenia;
LIHC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.64	6.49	0.33	3.07e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.31	6.73	0.34	7.13e-11	Facial morphology (factor 15, philtrum width);
LIHC	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg14132834	chr19:41945861	ATP5SL	0.44	6.49	0.33	3e-10	Height;
LIHC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.67	-13.28	-0.58	9.76e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg16102536	chr7:156981717	UBE3C	0.35	5.82	0.3	1.33e-8	Body mass index;
LIHC	cis	rs861318	0.938	rs12124059	chr1:159026639	T/C	cg11003133	chr1:159046391	AIM2	-0.33	-6.63	-0.34	1.34e-10	Obesity-related traits;
LIHC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.52	8.47	0.42	7.38e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg27205649	chr11:78285834	NARS2	-0.38	-5.78	-0.3	1.69e-8	Alzheimer's disease (survival time);
LIHC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.59	9.1	0.44	7.63e-18	Parkinson's disease;
LIHC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.91	18.64	0.71	5.03e-54	Bone mineral density;
LIHC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg05941027	chr17:61774174	LIMD2	0.35	7.19	0.36	4.05e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.4	6.04	0.31	4.12e-9	Reticulocyte fraction of red cells;
LIHC	trans	rs73245065	0.681	rs67056170	chr10:30911101	T/C	cg21500456	chr14:21190377	NA	0.45	6.23	0.32	1.37e-9	Bone mineral density (femoral neck);
LIHC	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg07636037	chr3:49044803	WDR6	-0.56	-6.32	-0.32	8.37e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg07424592	chr7:64974309	NA	0.73	8.8	0.43	6.92e-17	Gout;
LIHC	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	7.03	0.36	1.11e-11	Systemic lupus erythematosus;
LIHC	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg02376097	chr19:46275166	DMPK	-0.47	-7.5	-0.38	5.41e-13	Coronary artery disease;
LIHC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg10755058	chr3:40428713	ENTPD3	-0.4	-6.91	-0.35	2.38e-11	Renal cell carcinoma;
LIHC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-9.6	-0.46	1.78e-19	Reticulocyte count;
LIHC	cis	rs2386661	0.523	rs61832677	chr10:5652477	A/G	cg17085576	chr10:5658249	NA	-0.3	-5.85	-0.3	1.15e-8	Breast cancer;
LIHC	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.37	-0.49	4.2e-22	Eye color traits;
LIHC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.37	0.37	1.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.89	-0.35	2.74e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs539514	0.664	rs479824	chr13:76308360	C/T	cg04757411	chr13:76259545	LMO7	-0.42	-7.31	-0.37	1.89e-12	Type 1 diabetes;
LIHC	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.91	11.43	0.53	7.43e-26	Prostate cancer;
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20135002	chr11:47629003	NA	0.38	6.23	0.32	1.38e-9	Subjective well-being;
LIHC	cis	rs55702914	0.809	rs3097385	chr2:198199297	G/A	cg10820045	chr2:198174542	NA	-0.41	-5.96	-0.31	6.21e-9	Major depression and alcohol dependence;
LIHC	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.41	-6.23	-0.32	1.35e-9	Smoking behavior;
LIHC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.79	0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs876084	0.505	rs10108373	chr8:121126109	T/C	cg06265175	chr8:121136014	COL14A1	0.43	6.92	0.35	2.22e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.87	0.35	2.98e-11	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9658691	0.607	rs12412701	chr10:90782323	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.93	-6.71	-0.34	8.01e-11	Mosquito bite size;
LIHC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.39	-0.61	4.81e-37	Headache;
LIHC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.61	9.72	0.47	7.27e-20	Blood trace element (Zn levels);
LIHC	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.57	11.26	0.52	3.17e-25	Plateletcrit;Platelet count;
LIHC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.61	-9.49	-0.46	3.96e-19	Bipolar disorder;
LIHC	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.59	-8.62	-0.42	2.46e-16	Menopause (age at onset);
LIHC	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	0.91	17.31	0.68	1.2e-48	Schizophrenia;
LIHC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg05896524	chr21:47604654	C21orf56	0.45	6.99	0.35	1.46e-11	Testicular germ cell tumor;
LIHC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg14222432	chr12:29376421	FAR2	0.36	6.96	0.35	1.72e-11	QT interval;
LIHC	cis	rs713477	0.967	rs2152975	chr14:55907919	C/T	cg13175173	chr14:55914753	NA	-0.35	-8.13	-0.4	7.79e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20570016	chr1:156261298	TMEM79	0.38	6.11	0.31	2.75e-9	Tonsillectomy;
LIHC	trans	rs1814175	0.616	rs10839342	chr11:49742687	A/C	cg18944383	chr4:111397179	ENPEP	0.27	6.94	0.35	1.94e-11	Height;
LIHC	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg09795085	chr6:101329169	ASCC3	-0.4	-5.75	-0.3	1.96e-8	Neuroticism;
LIHC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.7	6.45	0.33	3.83e-10	Mean corpuscular hemoglobin;
LIHC	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.53	7.44	0.37	8.31e-13	Corneal structure;
LIHC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.64	-11.0	-0.51	2.73e-24	Menopause (age at onset);
LIHC	cis	rs712039	0.652	rs829163	chr17:35766026	G/C	cg16670864	chr17:35848621	DUSP14	0.34	5.75	0.3	2.02e-8	Tuberculosis;
LIHC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg05110241	chr16:68378359	PRMT7	-0.53	-6.07	-0.31	3.48e-9	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15769475	chr17:3960566	ZZEF1	0.48	6.34	0.32	7.15e-10	Hip circumference;
LIHC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg08469215	chr1:156261351	TMEM79	0.4	6.59	0.34	1.68e-10	Tonsillectomy;
LIHC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.69e-16	Menarche (age at onset);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03323938	chr19:39663667	PAK4	0.44	6.1	0.31	2.8e-9	Hepatitis;
LIHC	cis	rs1664789	1.000	rs1694065	chr5:53282335	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.52	-8.43	-0.41	9.79e-16	Waist circumference adjusted for body mass index;
LIHC	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg15192750	chr16:69999425	NA	0.42	6.39	0.33	5.46e-10	IgE levels;
LIHC	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg10820045	chr2:198174542	NA	0.49	7.34	0.37	1.56e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.34	14.5	0.62	1.82e-37	White matter hyperintensity burden;
LIHC	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	11.54	0.53	2.93e-26	Birth weight;
LIHC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg08992911	chr2:238395768	MLPH	0.5	6.02	0.31	4.42e-9	Prostate cancer;
LIHC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.66	9.09	0.44	8.03e-18	Mean platelet volume;
LIHC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-6.63	-0.34	1.33e-10	IgG glycosylation;
LIHC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.8	-17.92	-0.7	4.15e-51	Urate levels in lean individuals;
LIHC	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.47	-7.04	-0.36	1.06e-11	Adiposity;
LIHC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.59	-0.38	2.99e-13	Bipolar disorder;
LIHC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg22998206	chr12:49239429	DDX23	0.39	6.17	0.32	1.97e-9	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg04310649	chr10:35416472	CREM	-0.43	-5.77	-0.3	1.79e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs793571	0.744	rs12901551	chr15:59160069	A/T	cg05156742	chr15:59063176	FAM63B	-0.34	-5.87	-0.3	1.04e-8	Schizophrenia;
LIHC	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg11879182	chr18:77439856	CTDP1	0.83	13.37	0.59	4.47e-33	Monocyte count;
LIHC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	7.36	0.37	1.34e-12	Mean platelet volume;
LIHC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.4	0.37	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21467203	chr3:49911342	NA	0.52	9.59	0.46	1.95e-19	Body mass index;
LIHC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00958927	chr1:175162553	KIAA0040	0.38	6.51	0.33	2.73e-10	Alcohol dependence;
LIHC	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.05	-0.31	3.85e-9	Blood pressure;
LIHC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.42	7.32	0.37	1.79e-12	Aortic root size;
LIHC	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.95	9.72	0.47	6.94e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-16.01	-0.65	1.99e-43	Chronic sinus infection;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06666157	chr19:4791552	FEM1A	0.49	7.53	0.38	4.61e-13	Pancreatic cancer;
LIHC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg00800038	chr16:89945340	TCF25	-0.6	-8.5	-0.42	5.92e-16	Skin colour saturation;
LIHC	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1385374	0.920	rs11059910	chr12:129271719	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	7.7	0.38	1.52e-13	Systemic lupus erythematosus;
LIHC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.72	11.62	0.53	1.6e-26	Oral cavity cancer;
LIHC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.76	10.18	0.48	1.97e-21	Selective IgA deficiency;
LIHC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-7.18	-0.36	4.28e-12	Cognitive function;
LIHC	cis	rs7188697	0.922	rs173475	chr16:58580530	T/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.34	-0.37	1.54e-12	QT interval;
LIHC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02290350	chr8:58132656	NA	0.51	10.97	0.51	3.29e-24	Developmental language disorder (linguistic errors);
LIHC	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg20240347	chr1:204465584	NA	-0.31	-6.29	-0.32	9.9e-10	Schizophrenia;
LIHC	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.49	-0.33	2.93e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg14393609	chr7:65229607	NA	-0.37	-5.8	-0.3	1.53e-8	Aortic root size;
LIHC	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg01843034	chr6:37503916	NA	-0.47	-7.36	-0.37	1.39e-12	Cognitive performance;
LIHC	cis	rs12477438	0.539	rs13394175	chr2:99590713	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-8.47	-0.42	7.15e-16	Chronic sinus infection;
LIHC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg24579218	chr15:68104479	NA	-0.34	-5.83	-0.3	1.29e-8	Restless legs syndrome;
LIHC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.39	6.4	0.33	5.21e-10	Multiple myeloma (IgH translocation);
LIHC	trans	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21659725	chr3:3221576	CRBN	0.57	8.19	0.4	5.34e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.3	1.94e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg00990874	chr7:1149470	C7orf50	-0.63	-8.94	-0.44	2.57e-17	Bronchopulmonary dysplasia;
LIHC	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.32	7.48	0.37	6.41e-13	Crohn's disease;
LIHC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.46	6.85	0.35	3.37e-11	Personality dimensions;
LIHC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-0.74	-8.29	-0.41	2.64e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.49	9.89	0.47	1.92e-20	Tonsillectomy;
LIHC	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg23352942	chr3:46931381	PTH1R	-0.28	-7.06	-0.36	9.36e-12	Birth weight;
LIHC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg14222432	chr12:29376421	FAR2	0.38	7.31	0.37	1.89e-12	QT interval;
LIHC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.43	6.11	0.31	2.72e-9	Cognitive function;
LIHC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.59	5.71	0.3	2.39e-8	Plasma clusterin levels;
LIHC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	17.58	0.69	9.77e-50	Tonsillectomy;
LIHC	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.51	7.95	0.4	2.66e-14	Diastolic blood pressure;
LIHC	cis	rs11644362	0.903	rs2014726	chr16:12992849	T/C	cg06890432	chr16:12997467	SHISA9	-0.39	-6.59	-0.34	1.64e-10	Positive affect;Subjective well-being;
LIHC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg24004478	chr7:855632	UNC84A	0.47	7.45	0.37	7.75e-13	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.44	0.42	8.97e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.43	5.94	0.31	7.03e-9	Alzheimer's disease;
LIHC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.56	8.35	0.41	1.77e-15	Diastolic blood pressure;
LIHC	cis	rs61990749	0.511	rs10130790	chr14:78324192	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.49	7.81	0.39	7.05e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04025307	chr7:1156635	C7orf50	0.51	6.73	0.34	7.3e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg15691649	chr6:25882328	NA	-0.37	-5.71	-0.3	2.42e-8	Height;
LIHC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.61	8.51	0.42	5.35e-16	Motion sickness;
LIHC	cis	rs2412488	0.893	rs57297394	chr4:54359130	G/A	cg22241045	chr4:54363911	LNX1	0.46	7.66	0.38	1.93e-13	DNA methylation (variation);
LIHC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.8	9.57	0.46	2.24e-19	Bladder cancer;
LIHC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg07451762	chr16:28383216	NA	0.38	6.76	0.34	6.11e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs77861329	1.000	rs55834589	chr3:52081724	C/T	cg08692210	chr3:52188851	WDR51A	0.78	6.7	0.34	8.78e-11	Macrophage inflammatory protein 1b levels;
LIHC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.93	0.31	7.61e-9	Height;
LIHC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg07424592	chr7:64974309	NA	0.76	8.63	0.42	2.3e-16	Diabetic kidney disease;
LIHC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.54	-9.38	-0.45	9.68e-19	Total body bone mineral density;
LIHC	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg23587288	chr2:27483067	SLC30A3	-0.35	-6.44	-0.33	3.99e-10	Blood metabolite levels;
LIHC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-7.17	-0.36	4.73e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	0.54	7.09	0.36	7.55e-12	Pulse pressure;
LIHC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.21	0.41	4.49e-15	Alzheimer's disease;
LIHC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.97	-0.44	1.93e-17	Gut microbiome composition (summer);
LIHC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.44	-7.05	-0.36	9.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.64	-8.81	-0.43	6.5e-17	Testicular germ cell tumor;
LIHC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg24209194	chr3:40518798	ZNF619	0.42	5.97	0.31	6.06e-9	Renal cell carcinoma;
LIHC	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.41	7.41	0.37	9.89e-13	Hepatocellular carcinoma;
LIHC	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg08539965	chr1:21396338	EIF4G3	0.34	5.93	0.31	7.44e-9	Superior frontal gyrus grey matter volume;
LIHC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.68	10.8	0.5	1.4e-23	Breast cancer;
LIHC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg12046867	chr14:103022105	NA	-0.55	-8.27	-0.41	3.1e-15	Platelet count;
LIHC	cis	rs9503598	0.502	rs1077845	chr6:3433201	G/T	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.87	-0.3	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg03645007	chr3:50255295	SLC38A3	0.51	6.04	0.31	3.98e-9	Schizophrenia;
LIHC	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-5.73	-0.3	2.25e-8	Neuroticism;
LIHC	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.89	-0.3	9.45e-9	Hip circumference adjusted for BMI;
LIHC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.48	-7.45	-0.37	7.58e-13	Blood protein levels;
LIHC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.75	-11.43	-0.53	7.57e-26	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.59	10.23	0.48	1.3e-21	Diisocyanate-induced asthma;
LIHC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg00800038	chr16:89945340	TCF25	-0.65	-10.32	-0.49	6.62e-22	Skin colour saturation;
LIHC	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.5	8.45	0.42	8.2e-16	Total cholesterol levels;
LIHC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.11	0.44	6.91e-18	IgG glycosylation;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10777881	chr1:144044138	NA	0.43	6.1	0.31	2.94e-9	Hepatitis;
LIHC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg23625390	chr15:77176239	SCAPER	0.35	5.8	0.3	1.49e-8	Blood metabolite levels;
LIHC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.51	-6.39	-0.33	5.43e-10	Menarche (age at onset);
LIHC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg03037974	chr15:76606532	NA	0.73	14.33	0.61	8.54e-37	Blood metabolite levels;
LIHC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02985541	chr2:219472218	PLCD4	0.46	8.73	0.43	1.18e-16	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg12310025	chr6:25882481	NA	-0.42	-6.34	-0.32	7.27e-10	Height;
LIHC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11645453	chr3:52864694	ITIH4	0.22	6.0	0.31	4.95e-9	Bipolar disorder;
LIHC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg18944383	chr4:111397179	ENPEP	0.27	7.03	0.36	1.16e-11	Height;
LIHC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.42	7.71	0.38	1.38e-13	Schizophrenia;
LIHC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.83	16.28	0.66	1.54e-44	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs4759375	1.000	rs7315453	chr12:123825389	T/C	cg00376283	chr12:123451042	ABCB9	0.5	6.37	0.33	6.18e-10	HDL cholesterol;
LIHC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	10.14	0.48	2.71e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.72	0.39	1.26e-13	Triglyceride levels;
LIHC	cis	rs903552	1.000	rs12915569	chr15:102001883	G/A	cg25677261	chr15:102009856	PCSK6	-0.44	-5.9	-0.3	8.57e-9	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12463550	chr7:65579703	CRCP	0.71	7.49	0.38	5.99e-13	Diabetic kidney disease;
LIHC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.34	-6.43	-0.33	4.37e-10	Blood metabolite levels;
LIHC	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg08085267	chr17:45401833	C17orf57	-0.41	-5.93	-0.31	7.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08219700	chr8:58056026	NA	0.46	5.8	0.3	1.48e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg19318889	chr4:1322082	MAEA	0.54	8.54	0.42	4.48e-16	Longevity;
LIHC	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg07451762	chr16:28383216	NA	0.41	7.09	0.36	7.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22333016	chr4:54244258	FIP1L1	-0.4	-6.14	-0.32	2.24e-9	Pancreatic cancer;
LIHC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg17927777	chr20:33865990	NA	0.56	6.56	0.33	2.01e-10	Attention deficit hyperactivity disorder;
LIHC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg09835421	chr16:68378352	PRMT7	0.52	6.05	0.31	3.85e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg11764359	chr7:65958608	NA	0.59	6.14	0.32	2.32e-9	Diabetic kidney disease;
LIHC	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.5	-7.66	-0.38	1.93e-13	Ulcerative colitis;
LIHC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.84	8.62	0.42	2.6e-16	Height;
LIHC	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.06e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.36	24.52	0.8	2.38e-77	Corneal structure;
LIHC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.41	-5.83	-0.3	1.28e-8	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14154082	chr13:112174009	NA	0.3	6.26	0.32	1.16e-9	Menarche (age at onset);
LIHC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg23690444	chr14:81902736	NA	-0.5	-6.86	-0.35	3.17e-11	Night sleep phenotypes;
LIHC	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg00647820	chr17:40259828	DHX58	-0.29	-5.96	-0.31	6.39e-9	Fibrinogen levels;
LIHC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.4	0.45	7.82e-19	Total body bone mineral density;
LIHC	cis	rs6429082	0.875	rs4659524	chr1:235583354	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.43	-6.59	-0.34	1.66e-10	Adiposity;
LIHC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg11784071	chr10:104629166	AS3MT	-0.36	-5.81	-0.3	1.4e-8	Arsenic metabolism;
LIHC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.91	-13.98	-0.6	1.84e-35	Sudden cardiac arrest;
LIHC	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	7.9	0.39	3.93e-14	Nonalcoholic fatty liver disease;
LIHC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.48	-0.33	3.18e-10	Renal cell carcinoma;
LIHC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg11812906	chr14:75593930	NEK9	-0.45	-7.0	-0.35	1.33e-11	IgG glycosylation;
LIHC	cis	rs16958440	1.000	rs60422392	chr18:44621473	T/C	cg17192377	chr18:44677553	HDHD2	0.61	6.89	0.35	2.72e-11	Sitting height ratio;
LIHC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.47	-6.82	-0.35	4.19e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg23029597	chr12:123009494	RSRC2	-0.44	-6.3	-0.32	8.94e-10	Body mass index;
LIHC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.79	-0.34	4.9e-11	Diabetic kidney disease;
LIHC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21747090	chr2:27597821	SNX17	-0.39	-5.73	-0.3	2.22e-8	Menopause (age at onset);
LIHC	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	6.38	0.33	5.86e-10	Body mass index;
LIHC	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.56	-8.39	-0.41	1.26e-15	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg02487422	chr3:49467188	NICN1	-0.42	-5.77	-0.3	1.79e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	16.44	0.66	3.67e-45	Smoking behavior;
LIHC	cis	rs2242420	0.920	rs16825746	chr1:21958909	G/A	cg18150885	chr1:21978612	RAP1GAP	-0.47	-5.81	-0.3	1.47e-8	Hematological and biochemical traits;
LIHC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.4	0.49	3.46e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-6.73	-0.34	7.3e-11	Metabolite levels;
LIHC	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	0.54	10.28	0.49	8.88e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LIHC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.75	9.45	0.46	5.41e-19	Body mass index;
LIHC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.4	-6.43	-0.33	4.4e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	13.4	0.59	3.43e-33	Coffee consumption (cups per day);
LIHC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.97	-0.31	6.04e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.4	-13.79	-0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21747090	chr2:27597821	SNX17	0.4	5.9	0.3	8.59e-9	Total body bone mineral density;
LIHC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.96	-0.31	6.44e-9	Life satisfaction;
LIHC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.02	-0.35	1.2e-11	Personality dimensions;
LIHC	cis	rs12644436	0.628	rs9991506	chr4:88782111	G/A	cg06891869	chr4:88767617	MEPE	0.43	7.55	0.38	3.94e-13	HIV-1 viral setpoint;
LIHC	cis	rs16828019	0.852	rs11209576	chr1:41586029	T/C	cg03962019	chr1:41807865	NA	0.5	7.22	0.36	3.33e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.95	-9.36	-0.45	1.09e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.44	0.37	8.22e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.94	-8.99	-0.44	1.73e-17	Eosinophil percentage of granulocytes;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	0.85	13.1	0.58	4.51e-32	Skin colour saturation;
LIHC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.18	0.52	6.17e-25	Colorectal cancer;
LIHC	cis	rs11098699	0.821	rs11935129	chr4:124207106	T/A	cg09941581	chr4:124220074	SPATA5	0.33	6.52	0.33	2.56e-10	Mosquito bite size;
LIHC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-0.85	-10.5	-0.49	1.57e-22	Blood pressure (smoking interaction);
LIHC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg15123519	chr2:136567270	LCT	0.39	7.34	0.37	1.56e-12	Mosquito bite size;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.51	6.04	0.31	4.06e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-6.77	-0.34	5.6e-11	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.63	-7.83	-0.39	6.21e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.67	0.5	3.87e-23	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	7.79	0.39	7.99e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1494373	0.543	rs61830219	chr1:220847364	G/A	cg06786860	chr1:220876396	NA	-0.43	-6.4	-0.33	5.16e-10	Response to antipsychotic therapy (extrapyramidal side effects);
LIHC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg04455712	chr21:45112962	RRP1B	0.39	6.54	0.33	2.22e-10	Mean corpuscular volume;
LIHC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.1	-0.31	2.81e-9	Mean corpuscular volume;
LIHC	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.71	-12.37	-0.56	2.72e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs8067354	0.958	rs8081468	chr17:57836924	A/G	cg02344993	chr17:57696989	CLTC	0.54	8.55	0.42	4.26e-16	Hemoglobin concentration;
LIHC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.5	7.48	0.37	6.31e-13	Height;
LIHC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg27170947	chr2:26402098	FAM59B	0.54	7.19	0.36	4.14e-12	Gut microbiome composition (summer);
LIHC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.72	-9.54	-0.46	2.7e-19	Schizophrenia;
LIHC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg21231739	chr4:1642635	FAM53A	-0.36	-5.76	-0.3	1.86e-8	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.51	-5.91	-0.3	8.5e-9	Cerebrospinal P-tau181p levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg15558129	chr1:219347279	LYPLAL1	0.46	6.39	0.33	5.47e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.81	-0.3	1.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04498032	chr1:155242826	CLK2	0.44	6.66	0.34	1.08e-10	Pancreatic cancer;
LIHC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.1	-0.44	7.86e-18	Heart rate;
LIHC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.63	-8.58	-0.42	3.37e-16	Sudden cardiac arrest;
LIHC	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.42	-6.2	-0.32	1.65e-9	Blood protein levels;
LIHC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.27	-6.03	-0.31	4.3e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.51	-8.63	-0.42	2.41e-16	Mean corpuscular volume;
LIHC	cis	rs2997447	0.739	rs3008224	chr1:26389647	G/A	cg19633962	chr1:26362018	EXTL1	-0.58	-6.53	-0.33	2.43e-10	QRS complex (12-leadsum);
LIHC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.84	-14.15	-0.61	4.2500000000000003e-36	Aortic root size;
LIHC	cis	rs8084351	0.518	rs11660990	chr18:50763049	T/C	cg24270629	chr18:50823537	DCC	-0.51	-7.58	-0.38	3.29e-13	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	12.12	0.55	2.27e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.41	-5.77	-0.3	1.82e-8	Systemic lupus erythematosus;
LIHC	trans	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg26939375	chr7:64535504	NA	-0.46	-7.02	-0.35	1.24e-11	Aortic root size;
LIHC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.53	7.42	0.37	9.37e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.77	15.19	0.63	3.32e-40	Mortality in heart failure;
LIHC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.37	-5.76	-0.3	1.86e-8	Uric acid levels;
LIHC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.57	10.48	0.49	1.74e-22	Alzheimer's disease (late onset);
LIHC	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	6.88	0.35	2.86e-11	Bipolar disorder;
LIHC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.57	9.68	0.46	9.89e-20	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg24296786	chr1:45957014	TESK2	0.52	7.35	0.37	1.43e-12	Platelet count;
LIHC	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg27490568	chr2:178487706	NA	0.93	9.04	0.44	1.23e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.42	5.78	0.3	1.67e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg17135325	chr3:160939158	NMD3	0.54	7.62	0.38	2.58e-13	Parkinson's disease;
LIHC	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg07451762	chr16:28383216	NA	-0.33	-6.06	-0.31	3.6e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-7.77	-0.39	9.43e-14	Lymphocyte counts;
LIHC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg23205692	chr1:25664452	TMEM50A	0.39	6.22	0.32	1.45e-9	Plateletcrit;Mean corpuscular volume;
LIHC	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	0.85	11.15	0.52	8.03e-25	Severe influenza A (H1N1) infection;
LIHC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg02990361	chr1:107599529	PRMT6	-0.66	-10.94	-0.51	4.5e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.28	6.0	0.31	5.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.69	11.23	0.52	4.02e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.54	-8.68	-0.42	1.64e-16	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg27523141	chr10:43048294	ZNF37B	0.35	6.08	0.31	3.16e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4788570	0.537	rs56222754	chr16:71491806	G/A	cg06353428	chr16:71660113	MARVELD3	-1.11	-9.99	-0.48	8.56e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-0.73	-7.29	-0.37	2.13e-12	Carotid plaque burden;
LIHC	cis	rs35883536	0.967	rs1984134	chr1:101109307	A/G	cg14515779	chr1:101123966	NA	-0.66	-13.17	-0.58	2.6e-32	Monocyte count;
LIHC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.17	-12.65	-0.56	2.3e-30	White matter hyperintensity burden;
LIHC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.52	8.79	0.43	7.62e-17	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg23250157	chr14:64679961	SYNE2	0.4	5.92	0.3	8.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.59	8.68	0.42	1.69e-16	Prudent dietary pattern;
LIHC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.39	6.02	0.31	4.55e-9	Obesity-related traits;
LIHC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.06	19.67	0.73	3.84e-58	Multiple system atrophy;
LIHC	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg00204512	chr16:28754710	NA	-0.38	-6.3	-0.32	9.25e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.55	7.67	0.38	1.76e-13	Bone mineral density (spine);Bone mineral density;
LIHC	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.68	-0.42	1.59e-16	Colorectal cancer;
LIHC	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.32	6.14	0.32	2.28e-9	DNA methylation (variation);
LIHC	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.55	-7.11	-0.36	6.89e-12	Coronary artery calcification;
LIHC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg02290350	chr8:58132656	NA	0.31	7.17	0.36	4.59e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg14132834	chr19:41945861	ATP5SL	0.45	6.61	0.34	1.5e-10	Height;
LIHC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.39	7.9	0.39	3.81e-14	Renal cell carcinoma;
LIHC	trans	rs983392	0.709	rs2015475	chr11:59998963	A/C	cg17275991	chr19:58003312	ZNF419	0.43	6.13	0.31	2.45e-9	Alzheimer's disease (late onset);
LIHC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg10621924	chr7:39171070	POU6F2	0.41	6.38	0.33	5.76e-10	IgG glycosylation;
LIHC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-8.01	-0.4	1.76e-14	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.3	-6.9	-0.35	2.58e-11	Menarche (age at onset);
LIHC	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.38	7.23	0.36	3.19e-12	Metabolite levels;
LIHC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.58	0.34	1.79e-10	Bipolar disorder;
LIHC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.39	-5.88	-0.3	9.94e-9	Menarche (age at onset);
LIHC	cis	rs11255291	0.668	rs6602265	chr10:7732939	A/G	cg00997801	chr10:7671259	ITIH5	0.37	6.03	0.31	4.22e-9	Ovarian reserve;
LIHC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.63	-8.03	-0.4	1.54e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.6	9.74	0.47	5.97e-20	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-6.6	-0.34	1.58e-10	Coronary artery disease;
LIHC	cis	rs6960043	0.652	rs6461149	chr7:15044103	C/T	cg19272540	chr7:15055459	NA	0.25	6.71	0.34	7.94e-11	Type 2 diabetes;
LIHC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.86	0.43	4.33e-17	Heart rate;
LIHC	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.83	11.17	0.52	6.84e-25	Menopause (age at onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg23104955	chr8:74205400	RPL7	-0.49	-6.31	-0.32	8.76e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.49	0.53	4.57e-26	Coronary artery disease;
LIHC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-6.0	-0.31	5.11e-9	Colorectal cancer;
LIHC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs4407350	0.870	rs4823327	chr22:44908708	T/C	cg26276947	chr22:44892394	LDOC1L	0.35	6.79	0.34	4.89e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.55	8.04	0.4	1.53e-14	Osteoporosis;
LIHC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.61	9.19	0.45	3.87e-18	Longevity;
LIHC	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.54	-8.29	-0.41	2.6e-15	Platelet distribution width;
LIHC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.04	0.4	1.53e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg20283391	chr11:68216788	NA	-0.38	-6.08	-0.31	3.14e-9	Total body bone mineral density;
LIHC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.51	-6.39	-0.33	5.39e-10	Pancreatic cancer;
LIHC	cis	rs9543976	1.000	rs4885324	chr13:76173747	G/A	cg01531495	chr13:76123901	UCHL3	0.49	5.81	0.3	1.4e-8	Diabetic retinopathy;
LIHC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg19635926	chr16:89946313	TCF25	0.52	6.54	0.33	2.24e-10	Skin colour saturation;
LIHC	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.54	8.51	0.42	5.58e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs11671005	0.693	rs34023391	chr19:58913368	G/A	cg25952890	chr19:58913133	NA	0.7	7.19	0.36	4.02e-12	Mean platelet volume;
LIHC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.63	0.53	1.49e-26	Alzheimer's disease;
LIHC	cis	rs2444240	0.902	rs626225	chr11:120034115	G/A	cg04390734	chr11:120039366	NA	0.32	6.14	0.32	2.3e-9	Corneal curvature;
LIHC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.65	-10.31	-0.49	7.01e-22	Monocyte percentage of white cells;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg01401336	chr17:2606734	KIAA0664	0.42	6.48	0.33	3.27e-10	Longevity;
LIHC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04305134	chr10:75173374	ANXA7	-0.42	-6.76	-0.34	6.08e-11	Body mass index;
LIHC	trans	rs10411161	1.000	rs10411161	chr19:52372976	C/T	cg22319618	chr22:45562946	NUP50	-0.56	-7.51	-0.38	5.07e-13	Breast cancer;
LIHC	cis	rs7091068	0.671	rs1223296	chr10:95404621	T/C	cg20715218	chr10:95462985	C10orf4	-0.61	-6.66	-0.34	1.1e-10	Urinary tract infection frequency;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg18474185	chr14:105817333	PACS2	0.45	6.96	0.35	1.75e-11	Longevity;
LIHC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.59	10.36	0.49	4.87e-22	Height;
LIHC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.52	6.28	0.32	1.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04565464	chr8:145669602	NFKBIL2	0.43	7.19	0.36	4.15e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.31	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2257205	0.588	rs7209327	chr17:56741834	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.47	-0.33	3.49e-10	Pancreatic cancer;
LIHC	cis	rs713477	0.654	rs4901569	chr14:55912880	C/T	cg13175173	chr14:55914753	NA	-0.3	-6.77	-0.34	5.54e-11	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs7165170	0.549	rs10852133	chr15:91098715	C/T	cg26821196	chr15:91095069	CRTC3	0.39	7.1	0.36	7.1e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.67	0.5	3.82e-23	Colorectal cancer;
LIHC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24110177	chr3:50126178	RBM5	-0.39	-6.03	-0.31	4.33e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.29e-23	Hemoglobin concentration;
LIHC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.83	-13.24	-0.58	1.39e-32	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.21e-12	Renal cell carcinoma;
LIHC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-7.6	-0.38	2.84e-13	Chronic sinus infection;
LIHC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-11.91	-0.54	1.31e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.39	6.87	0.35	3.13e-11	Aortic root size;
LIHC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.36	-0.56	2.98e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg19683494	chr5:74908142	NA	-0.58	-7.57	-0.38	3.52e-13	Age-related disease endophenotypes;
LIHC	cis	rs151997	0.925	rs26087	chr5:50172911	G/A	cg06027927	chr5:50259733	NA	0.57	7.56	0.38	3.69e-13	Callous-unemotional behaviour;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.42	0.56	1.66e-29	Prudent dietary pattern;
LIHC	cis	rs244293	0.965	rs244350	chr17:53196132	C/G	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.3	0.37	2.07e-12	Menarche (age at onset);
LIHC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.98	-0.44	1.81e-17	Blood metabolite levels;
LIHC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.85	15.4	0.64	5.25e-41	Aortic root size;
LIHC	cis	rs10426930	0.816	rs2009654	chr19:5061345	A/T	cg18473234	chr19:5097819	KDM4B	-0.52	-6.82	-0.35	4.05e-11	Monocyte percentage of white cells;
LIHC	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg19875535	chr5:140030758	IK	-0.37	-6.09	-0.31	3.11e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.26	-0.37	2.57e-12	Bipolar disorder;
LIHC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.67	12.33	0.55	3.73e-29	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.61	9.47	0.46	4.83e-19	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18663498	chr6:27487068	NA	0.43	6.35	0.32	7.04e-10	Pancreatic cancer;
LIHC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-6.54	-0.33	2.29e-10	Lung cancer;
LIHC	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.62	6.15	0.32	2.14e-9	Carotid intima media thickness;
LIHC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.97	-22.41	-0.77	4.31e-69	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4233366	0.585	rs3924264	chr1:161178684	C/T	cg13853198	chr1:161185092	FCER1G	-0.33	-8.26	-0.41	3.26e-15	Asthma;
LIHC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.47	-6.55	-0.33	2.08e-10	Initial pursuit acceleration;
LIHC	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg00334542	chr7:100209784	MOSPD3	-0.73	-7.55	-0.38	3.89e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.54	-0.38	4.41e-13	Initial pursuit acceleration;
LIHC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.57	7.15	0.36	5.29e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	7.38	0.37	1.18e-12	Birth weight;
LIHC	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg24060327	chr5:131705240	SLC22A5	0.53	7.0	0.35	1.38e-11	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.63	9.97	0.47	9.91e-21	Longevity;
LIHC	cis	rs80282103	0.618	rs11816485	chr10:1147974	T/C	cg08668510	chr10:1095578	IDI1	0.62	6.07	0.31	3.45e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs2569991	0.588	rs14191	chr3:12940346	G/A	cg22481960	chr3:13008800	IQSEC1	-0.42	-7.23	-0.36	3.2e-12	Periodontitis (DPAL);
LIHC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.7	10.09	0.48	3.93e-21	Bronchopulmonary dysplasia;
LIHC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.1	-0.4	1e-14	Body mass index;
LIHC	cis	rs61160187	0.503	rs755077	chr5:60000608	C/T	cg02684056	chr5:59996105	DEPDC1B	0.4	5.89	0.3	9.26e-9	Educational attainment (years of education);Educational attainment (college completion);
LIHC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.44	8.3	0.41	2.43e-15	Schizophrenia;
LIHC	cis	rs507080	0.845	rs510408	chr11:118558901	G/C	cg04173919	chr11:118528438	PHLDB1	0.35	6.56	0.33	2.01e-10	Serum metabolite levels;
LIHC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-11.04	-0.51	1.95e-24	Response to antipsychotic treatment;
LIHC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.46	-6.99	-0.35	1.43e-11	Height;
LIHC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.05	15.27	0.64	1.74e-40	Cognitive function;
LIHC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.42	8.46	0.42	7.64e-16	Renal cell carcinoma;
LIHC	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.43	-7.14	-0.36	5.73e-12	Lung cancer;
LIHC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.57	0.38	3.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.47	-5.9	-0.3	8.85e-9	Renal function-related traits (BUN);
LIHC	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.68	6.42	0.33	4.44e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.48	8.6	0.42	2.98e-16	Prudent dietary pattern;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06391107	chr19:40502439	ZNF546	0.44	6.37	0.33	6.14e-10	Pancreatic cancer;
LIHC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.42	6.81	0.35	4.49e-11	Red blood cell count;
LIHC	cis	rs6782228	0.606	rs6775270	chr3:128403498	A/G	cg16766828	chr3:128327626	NA	-0.39	-6.2	-0.32	1.63e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-9.02	-0.44	1.41e-17	Body mass index;
LIHC	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.91e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.02	-0.51	2.28e-24	Coronary artery disease;
LIHC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	8.08	0.4	1.1e-14	Platelet count;
LIHC	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.42	8.1	0.4	9.7e-15	Testicular germ cell tumor;
LIHC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.8	13.4	0.59	3.43e-33	Psoriasis;
LIHC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.08e-9	Monobrow;
LIHC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.84	10.57	0.5	8.49e-23	Cognitive function;
LIHC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;
LIHC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg22800045	chr5:56110881	MAP3K1	-0.51	-5.94	-0.31	7.12e-9	Initial pursuit acceleration;
LIHC	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.16	24.98	0.8	4.17e-79	Schizophrenia;
LIHC	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.63	10.58	0.5	8.3e-23	Recombination rate (males);
LIHC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	14.31	0.61	9.85e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs8067354	0.574	rs2531899	chr17:58007193	A/G	cg13753209	chr17:57696993	CLTC	-0.72	-10.81	-0.5	1.22e-23	Hemoglobin concentration;
LIHC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.44	-6.31	-0.32	8.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.33	-8.18	-0.4	5.64e-15	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.24	13.94	0.6	2.72e-35	Alzheimer's disease (late onset);
LIHC	cis	rs2380220	0.808	rs72922390	chr6:95934317	G/A	cg15832292	chr6:96025679	MANEA	-0.6	-6.73	-0.34	7.25e-11	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.69	-0.43	1.51e-16	Crohn's disease;
LIHC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	9.32e-15	Prudent dietary pattern;
LIHC	cis	rs2286503	0.752	rs6461669	chr7:22858066	T/G	cg11367502	chr7:22862612	TOMM7	0.49	8.62	0.42	2.45e-16	Fibrinogen;
LIHC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-10.51	-0.49	1.47e-22	Breast cancer;
LIHC	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	9.57	0.46	2.25e-19	Schizophrenia;
LIHC	cis	rs986417	1.000	rs10151958	chr14:60977275	T/C	cg27398547	chr14:60952738	C14orf39	0.84	9.71	0.46	7.63e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.46	5.71	0.3	2.39e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs7534824	0.625	rs17409499	chr1:101504936	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	7.31	0.37	1.87e-12	Refractive astigmatism;
LIHC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg24209194	chr3:40518798	ZNF619	0.44	6.28	0.32	1.05e-9	Renal cell carcinoma;
LIHC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg17279839	chr7:150038598	RARRES2	0.51	10.76	0.5	1.84e-23	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg03146154	chr1:46216737	IPP	-0.37	-5.99	-0.31	5.36e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.27	-6.58	-0.34	1.78e-10	Cutaneous nevi;
LIHC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.44	6.27	0.32	1.09e-9	Tonsillectomy;
LIHC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.67	-11.66	-0.53	1.09e-26	Platelet distribution width;
LIHC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.92	0.35	2.24e-11	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	6.03	0.31	4.27e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.21	-0.32	1.5e-9	Total body bone mineral density;
LIHC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.55	-10.05	-0.48	5.22e-21	Urate levels in overweight individuals;
LIHC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.38	-5.95	-0.31	6.55e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg06627628	chr2:24431161	ITSN2	-0.43	-5.79	-0.3	1.56e-8	Quantitative traits;
LIHC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg24203234	chr3:128598194	ACAD9	0.45	6.27	0.32	1.07e-9	IgG glycosylation;
LIHC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg13962466	chr20:25176127	ENTPD6	0.49	6.67	0.34	1e-10	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg06360820	chr2:242988706	NA	-0.97	-12.44	-0.56	1.42e-29	Obesity-related traits;
LIHC	cis	rs963731	0.522	rs6755527	chr2:39187190	T/C	cg04010122	chr2:39346883	SOS1	-0.76	-5.84	-0.3	1.2e-8	Corticobasal degeneration;
LIHC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg21466736	chr12:48725269	NA	-0.71	-10.9	-0.51	6.18e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.52	-9.27	-0.45	2.09e-18	Blood protein levels;
LIHC	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.98	15.36	0.64	7.51e-41	Obesity;Body mass index;
LIHC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.78	6.19	0.32	1.76e-9	Body mass index;
LIHC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.68	10.63	0.5	5.22e-23	Corneal astigmatism;
LIHC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	5.96	0.31	6.44e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13724827	chr9:126030353	STRBP	0.49	6.82	0.35	4.23e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.53	8.22	0.41	4.22e-15	HDL cholesterol;
LIHC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.48	5.96	0.31	6.31e-9	Alzheimer's disease;
LIHC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.79	-10.09	-0.48	4e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.71	-0.5	2.94e-23	Hemoglobin concentration;
LIHC	cis	rs2637030	0.559	rs256116	chr5:52962251	C/T	cg06476337	chr5:52856530	NDUFS4	0.43	6.8	0.35	4.68e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg01864836	chr14:55583639	NA	-0.38	-6.52	-0.33	2.49e-10	Protein biomarker;
LIHC	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.27e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.38	-6.81	-0.35	4.4e-11	Obesity;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg19006130	chr11:118478252	PHLDB1	0.44	6.43	0.33	4.32e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg05350360	chr19:4475274	HDGF2	-0.37	-6.3	-0.32	9.04e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg14393609	chr7:65229607	NA	-0.37	-5.76	-0.3	1.86e-8	Aortic root size;
LIHC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	11.31	0.52	2.11e-25	Lung cancer in ever smokers;
LIHC	cis	rs9783347	1.000	rs4150566	chr11:18355599	C/G	cg15585147	chr11:18324498	HPS5	0.42	6.67	0.34	1.04e-10	Pancreatic cancer;
LIHC	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	11.95	0.54	9.62e-28	Eye color traits;
LIHC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.59	0.38	3.04e-13	Mean platelet volume;
LIHC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg10210624	chr19:58662595	ZNF329	0.73	7.33	0.37	1.65e-12	Cholesterol, total;
LIHC	cis	rs8064024	0.538	rs12446456	chr16:4922201	C/T	cg08329684	chr16:4932620	PPL	0.37	6.75	0.34	6.16e-11	Cancer;
LIHC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.43	-6.71	-0.34	7.91e-11	Dental caries;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg22022001	chr13:99096806	FARP1	0.45	6.35	0.32	7e-10	Longevity;
LIHC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.12	24.8	0.8	2.06e-78	Cognitive ability;
LIHC	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.59	-6.52	-0.33	2.46e-10	Blood protein levels;
LIHC	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-7.03	-0.36	1.16e-11	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.54	-0.33	2.24e-10	IgG glycosylation;
LIHC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.06	-0.51	1.66e-24	Primary sclerosing cholangitis;
LIHC	cis	rs6973256	0.605	rs7794168	chr7:133357606	T/C	cg03336402	chr7:133662267	EXOC4	-0.37	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.46	8.33	0.41	2.04e-15	IgG glycosylation;
LIHC	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg03934865	chr2:198174659	NA	-0.46	-6.86	-0.35	3.33e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs75064307	0.834	rs4855560	chr3:108116129	G/C	cg03329597	chr3:108125523	MYH15	0.5	6.63	0.34	1.32e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.35	-7.47	-0.37	6.64e-13	Longevity;
LIHC	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.81	13.77	0.6	1.22e-34	Body mass index;
LIHC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.52	-7.85	-0.39	5.24e-14	Blood pressure (smoking interaction);
LIHC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	1.03	11.41	0.53	9.08e-26	Triglycerides;
LIHC	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.35	-0.37	1.43e-12	Post bronchodilator FEV1;
LIHC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	10.61	0.5	6.39e-23	Alzheimer's disease (late onset);
LIHC	cis	rs6977660	0.619	rs12530799	chr7:19782793	G/A	cg07541023	chr7:19748670	TWISTNB	0.39	5.79	0.3	1.59e-8	Thyroid stimulating hormone;
LIHC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.26	-0.32	1.17e-9	Chronic sinus infection;
LIHC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.89	-0.3	9.41e-9	Personality dimensions;
LIHC	cis	rs74233809	1.000	rs74233296	chr10:104655350	T/C	cg03493300	chr10:104813866	CNNM2	0.44	5.8	0.3	1.49e-8	Birth weight;
LIHC	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.24	-0.41	3.74e-15	Atrioventricular conduction;
LIHC	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg21605333	chr4:119757512	SEC24D	0.8	6.82	0.35	4.23e-11	Cannabis dependence symptom count;
LIHC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg23283495	chr1:209979779	IRF6	0.35	5.97	0.31	6.09e-9	Monobrow;
LIHC	cis	rs4006360	0.540	rs9915780	chr17:39301074	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.2	5.8	0.3	1.48e-8	Bipolar disorder and schizophrenia;
LIHC	trans	rs6938574	0.672	rs6569520	chr6:128365034	C/G	cg12121162	chr6:144904561	UTRN	0.54	6.07	0.31	3.38e-9	Menarche (age at onset);
LIHC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.69	8.82	0.43	5.95e-17	Initial pursuit acceleration;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg12260146	chr3:33840237	PDCD6IP	0.49	6.36	0.33	6.6e-10	Lung function (FEV1/FVC);
LIHC	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.81	14.07	0.61	8.29e-36	Tonsillectomy;
LIHC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.44	-6.04	-0.31	3.94e-9	Total body bone mineral density;
LIHC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg17796960	chr10:135278976	LOC619207	-0.35	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LIHC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.78	-0.54	4.1e-27	Alzheimer's disease;
LIHC	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg01950434	chr2:97203154	ARID5A	0.49	7.14	0.36	5.8e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs6782228	0.606	rs6787559	chr3:128381086	T/C	cg16766828	chr3:128327626	NA	-0.4	-6.39	-0.33	5.54e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.2	0.36	3.79e-12	Aortic root size;
LIHC	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg11783602	chr8:55087084	NA	-0.31	-6.23	-0.32	1.36e-9	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.78	-0.3	1.72e-8	Total body bone mineral density;
LIHC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.93	0.31	7.32e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.47	7.63	0.38	2.28e-13	Alcohol dependence;
LIHC	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.59	9.57	0.46	2.19e-19	Response to antidepressants and depression;
LIHC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.26	6.17	0.32	1.95e-9	Crohn's disease;
LIHC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.63	0.53	1.44e-26	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg03013999	chr17:37608204	MED1	-0.35	-5.92	-0.31	7.63e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	1.01	19.3	0.72	1.12e-56	Breast cancer;
LIHC	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.68	-12.29	-0.55	5.31e-29	Mean platelet volume;
LIHC	cis	rs11960470	0.669	rs55873624	chr5:50325671	A/G	cg06027927	chr5:50259733	NA	0.6	8.26	0.41	3.15e-15	Breast cancer;
LIHC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	11.74	0.54	5.46e-27	Colorectal cancer;
LIHC	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.31	-5.8	-0.3	1.48e-8	Red blood cell count;
LIHC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg16434002	chr17:42200994	HDAC5	-0.53	-7.67	-0.38	1.78e-13	Total body bone mineral density;
LIHC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.36	4.41e-12	Vitiligo;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg12064134	chr16:90016061	DEF8	-0.44	-5.75	-0.3	1.93e-8	Skin colour saturation;
LIHC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.22e-8	Menopause (age at onset);
LIHC	cis	rs611744	0.870	rs429884	chr8:109115122	T/C	cg21045802	chr8:109455806	TTC35	0.5	8.48	0.42	7e-16	Dupuytren's disease;
LIHC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg25356066	chr3:128598488	ACAD9	0.52	7.14	0.36	5.64e-12	IgG glycosylation;
LIHC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.21	0.41	4.61e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	11.22	0.52	4.52e-25	Menarche (age at onset);
LIHC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.59	7.9	0.39	3.95e-14	Mean corpuscular hemoglobin;
LIHC	trans	rs10038113	0.530	rs57095562	chr5:26025857	T/A	cg05807885	chr1:204183355	GOLT1A	0.31	6.2	0.32	1.62e-9	Autism;
LIHC	cis	rs8014671	0.553	rs2877661	chr14:70916559	G/T	cg25576086	chr14:70833871	SYNJ2BP	-0.45	-7.06	-0.36	9.34e-12	Prostate cancer;
LIHC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg11693508	chr17:37793320	STARD3	0.79	7.95	0.39	2.7e-14	Bipolar disorder;
LIHC	cis	rs16958440	0.867	rs12386076	chr18:44673340	T/C	cg17192377	chr18:44677553	HDHD2	0.62	6.68	0.34	9.88e-11	Sitting height ratio;
LIHC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.33	6.5	0.33	2.89e-10	Platelet distribution width;
LIHC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.51	-9.59	-0.46	1.92e-19	Mean corpuscular volume;
LIHC	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg10381502	chr11:71823885	C11orf51	0.83	7.56	0.38	3.62e-13	Severe influenza A (H1N1) infection;
LIHC	trans	rs13113518	0.812	rs13140590	chr4:56414833	A/G	cg15358633	chr12:38710606	ALG10B	0.44	6.3	0.32	9.14e-10	Height;
LIHC	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg00291366	chr1:12616550	NA	0.43	8.92	0.43	2.79e-17	Optic cup area;
LIHC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.9	-14.5	-0.62	1.79e-37	Longevity;
LIHC	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.78	10.19	0.48	1.8e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.64	11.65	0.53	1.25e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	13.16	0.58	2.84e-32	Hip circumference adjusted for BMI;
LIHC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	9.49	0.46	3.95e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.64	0.53	1.29e-26	Motion sickness;
LIHC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.67	13.33	0.58	6.18e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	8.17	0.4	6.18e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7703744	0.672	rs6864305	chr5:118683065	T/C	cg04195774	chr5:118677172	TNFAIP8	-0.4	-5.77	-0.3	1.77e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.47	-0.67	2.69e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.93	16.74	0.67	2.27e-46	Parkinson's disease;
LIHC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.53	-8.13	-0.4	7.98e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.72	0.3	2.35e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.5	-7.81	-0.39	7.2e-14	Ulcerative colitis;
LIHC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg26338869	chr17:61819248	STRADA	0.53	7.18	0.36	4.33e-12	Height;
LIHC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.05	0.31	3.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg04193083	chr17:41323562	NBR1	-0.47	-7.33	-0.37	1.72e-12	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.48	5.94	0.31	6.99e-9	Orofacial clefts;
LIHC	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-8.73	-0.43	1.14e-16	Obesity-related traits;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02106306	chr15:31620290	KLF13	0.62	8.08	0.4	1.15e-14	Hepatitis;
LIHC	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	6.25	0.32	1.24e-9	Response to antipsychotic treatment;
LIHC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.67	-8.22	-0.41	4.21e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.48	7.1	0.36	7.32e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.21	-0.36	3.55e-12	Schizophrenia;
LIHC	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.55	7.23	0.36	3.19e-12	Coronary artery disease;
LIHC	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg18898632	chr2:242989856	NA	-0.5	-7.25	-0.36	2.82e-12	Obesity-related traits;
LIHC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.43	-7.03	-0.36	1.15e-11	IgG glycosylation;
LIHC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg06238570	chr21:40685208	BRWD1	0.59	7.07	0.36	8.98e-12	Cognitive function;
LIHC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.4	7.92	0.39	3.45e-14	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.42	5.95	0.31	6.57e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.72	13.84	0.6	6.68e-35	N-glycan levels;
LIHC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.94	-13.68	-0.59	2.88e-34	Blood metabolite levels;
LIHC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.79	13.35	0.59	5.37e-33	Psoriasis;
LIHC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	6.55	0.33	2.06e-10	Total body bone mineral density;
LIHC	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.48	7.55	0.38	4.07e-13	Alzheimer's disease (survival time);
LIHC	cis	rs2288912	0.620	rs875255	chr19:45493635	C/G	cg09555818	chr19:45449301	APOC2	-0.2	-5.71	-0.3	2.41e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg10381502	chr11:71823885	C11orf51	-1.06	-9.3	-0.45	1.74e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs4450131	0.618	rs897306	chr10:126337060	T/C	cg20435097	chr10:126320824	FAM53B	-0.62	-11.71	-0.54	7.19e-27	White blood cell count (basophil);
LIHC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17708016	chr12:54321992	NA	0.4	7.1	0.36	7.29e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LIHC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.35	5.86	0.3	1.06e-8	Type 2 diabetes;
LIHC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.68	0.8	5.83e-78	Prudent dietary pattern;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	0.6	10.35	0.49	5.03e-22	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-10.24	-0.48	1.18e-21	Alzheimer's disease;
LIHC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.69	12.26	0.55	7.14e-29	Colorectal cancer;
LIHC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	6.14	0.32	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.81	0.39	7.09e-14	Alzheimer's disease;
LIHC	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02985541	chr2:219472218	PLCD4	-0.37	-6.41	-0.33	4.97e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.46	6.48	0.33	3.27e-10	Longevity;Endometriosis;
LIHC	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.54	-6.14	-0.31	2.35e-9	Ulcerative colitis;
LIHC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.35	6.97	0.35	1.65e-11	Renal cell carcinoma;
LIHC	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.63	10.22	0.48	1.38e-21	Schizophrenia;
LIHC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.34	8.04	0.4	1.48e-14	Immature fraction of reticulocytes;
LIHC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.65	10.19	0.48	1.74e-21	Multiple myeloma (IgH translocation);
LIHC	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.87	12.9	0.57	2.64e-31	Body mass index;
LIHC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.47	6.58	0.34	1.73e-10	Longevity;
LIHC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.51	-9.04	-0.44	1.16e-17	Longevity;
LIHC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-19.57	-0.73	9.08e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.24	-0.32	1.28e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.67	11.31	0.52	2.1e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs7188697	0.922	rs37040	chr16:58578262	T/C	cg02549819	chr16:58548995	SETD6	-0.46	-7.27	-0.37	2.47e-12	QT interval;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	trans	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg20587970	chr11:113659929	NA	-0.65	-7.34	-0.37	1.52e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.3	-16.89	-0.67	5.67e-47	Diabetic kidney disease;
LIHC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg03294066	chr8:494721	C8orf42	0.71	6.19	0.32	1.73e-9	Musician's dystonia;
LIHC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.37	-7.84	-0.39	5.89e-14	Erythrocyte sedimentation rate;
LIHC	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.14	0.32	2.25e-9	Prudent dietary pattern;
LIHC	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg08668510	chr10:1095578	IDI1	0.68	6.62	0.34	1.41e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.41	-6.65	-0.34	1.15e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.57	7.57	0.38	3.45e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.5	-8.23	-0.41	4.01e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-6.78	-0.34	5.43e-11	IgG glycosylation;
LIHC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-8.71	-0.43	1.37e-16	Gut microbiome composition (summer);
LIHC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	0.85	7.04	0.36	1.09e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.53	0.42	4.82e-16	Platelet count;
LIHC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.64	8.72	0.43	1.2e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.51	9.1	0.44	7.55e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs611744	0.967	rs689256	chr8:109186398	T/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-6.67	-0.34	1.03e-10	Morning vs. evening chronotype;
LIHC	cis	rs507080	0.922	rs7114458	chr11:118566175	G/A	cg04173919	chr11:118528438	PHLDB1	0.36	6.68	0.34	9.83e-11	Serum metabolite levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04249525	chr7:152373324	XRCC2	-0.44	-6.19	-0.32	1.76e-9	Pancreatic cancer;
LIHC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	7.49	0.38	5.8e-13	Parkinson's disease;
LIHC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.32	7.11	0.36	6.89e-12	Ulcerative colitis;
LIHC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00166722	chr3:10149974	C3orf24	0.51	5.87	0.3	1e-8	Alzheimer's disease;
LIHC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.09	0.4	1.02e-14	Lymphocyte counts;
LIHC	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg08888203	chr3:10149979	C3orf24	0.5	6.25	0.32	1.21e-9	Alzheimer's disease;
LIHC	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg24579218	chr15:68104479	NA	-0.35	-5.91	-0.3	8.1e-9	Restless legs syndrome;
LIHC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg24296786	chr1:45957014	TESK2	-0.4	-5.88	-0.3	9.62e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg10217327	chr6:118973057	C6orf204	0.69	7.04	0.36	1.03e-11	Diastolic blood pressure;
LIHC	cis	rs61677309	1.000	rs61390396	chr11:118156718	C/T	cg06090739	chr11:118230722	UBE4A	0.35	6.59	0.34	1.71e-10	Lung cancer in ever smokers;
LIHC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.92	18.65	0.71	4.53e-54	Blood protein levels;
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06791812	chr14:105677543	BRF1	0.53	6.46	0.33	3.65e-10	Lung function (FEV1);
LIHC	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg12046867	chr14:103022105	NA	0.43	6.74	0.34	6.63e-11	Platelet count;
LIHC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.56	9.07	0.44	9.29e-18	Multiple sclerosis;
LIHC	cis	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.66	-6.55	-0.33	2.15e-10	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.6	11.2	0.52	5.04e-25	Systemic lupus erythematosus;
LIHC	cis	rs903552	0.935	rs4965871	chr15:102003810	A/T	cg06707286	chr15:102010195	PCSK6	-0.44	-6.48	-0.33	3.2e-10	Diabetic kidney disease;
LIHC	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.71	-0.3	2.41e-8	Vitamin D levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11328140	chr12:108079443	PWP1	0.49	7.19	0.36	4.02e-12	Cognitive function;
LIHC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.92	14.42	0.61	3.81e-37	Vitamin D levels;
LIHC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.63	0.42	2.27e-16	Motion sickness;
LIHC	trans	rs11165623	0.602	rs11165667	chr1:97013509	A/C	cg10631902	chr5:14652156	NA	-0.25	-6.33	-0.32	7.54e-10	Hip circumference;Waist circumference;
LIHC	cis	rs11630290	0.592	rs1912048	chr15:64155974	G/A	cg12036633	chr15:63758958	NA	0.64	6.79	0.34	4.95e-11	Iris characteristics;
LIHC	cis	rs77669868	0.929	rs3782004	chr11:114070250	T/C	cg01914181	chr11:114070210	ZBTB16	0.65	9.07	0.44	9.62e-18	Monocyte percentage of white cells;
LIHC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg00204748	chr12:29376779	FAR2	-0.41	-7.74	-0.39	1.16e-13	QT interval;
LIHC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg08822215	chr16:89438651	ANKRD11	0.46	7.24	0.36	2.94e-12	Multiple myeloma (IgH translocation);
LIHC	cis	rs2191566	0.821	rs62119173	chr19:44518073	G/A	cg20607764	chr19:44506953	ZNF230	-0.41	-6.7	-0.34	8.82e-11	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.65	-7.54	-0.38	4.39e-13	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg01231543	chr16:68741748	NA	0.38	6.12	0.31	2.55e-9	Colorectal cancer;
LIHC	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.24	-0.48	1.19e-21	Ear protrusion;
LIHC	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg14515779	chr1:101123966	NA	-0.68	-13.21	-0.58	1.78e-32	Monocyte count;
LIHC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.92	-8.96	-0.44	2.13e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.66	6.42	0.33	4.55e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.39	-7.06	-0.36	9.05e-12	Platelet distribution width;
LIHC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.09	-0.36	7.73e-12	Personality dimensions;
LIHC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	11.26	0.52	3.18e-25	Motion sickness;
LIHC	cis	rs12980942	1.000	rs3826714	chr19:41825776	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.47	5.91	0.3	8.07e-9	Coronary artery disease;
LIHC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.09	19.27	0.72	1.51e-56	Nonalcoholic fatty liver disease;
LIHC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.52	7.59	0.38	3.1e-13	Obesity-related traits;
LIHC	cis	rs1866706	0.964	rs1866710	chr11:12875312	A/G	cg25843174	chr11:12811716	TEAD1	-0.29	-6.16	-0.32	2.04e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.98	7.84	0.39	5.9e-14	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.62	-0.5	5.84e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg11062466	chr8:58055876	NA	0.39	5.72	0.3	2.34e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.48	-0.33	3.21e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.72	10.66	0.5	4.1000000000000003e-23	Corneal astigmatism;
LIHC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.61	0.38	2.61e-13	Lymphocyte counts;
LIHC	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.21	-0.41	4.42e-15	Vitamin D levels;
LIHC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.6	8.72	0.43	1.24e-16	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.57	9.29	0.45	1.8e-18	Multiple sclerosis;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.44	6.44	0.33	4e-10	Menopause (age at onset);
LIHC	cis	rs16958440	1.000	rs62096470	chr18:44641466	G/C	cg17192377	chr18:44677553	HDHD2	0.61	6.9	0.35	2.59e-11	Sitting height ratio;
LIHC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.3	9.41e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg25039879	chr17:56429692	SUPT4H1	0.75	8.46	0.42	7.8e-16	Cognitive test performance;
LIHC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg21395723	chr22:39101663	GTPBP1	0.34	5.77	0.3	1.77e-8	Menopause (age at onset);
LIHC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg25356066	chr3:128598488	ACAD9	-0.53	-7.47	-0.37	6.56e-13	IgG glycosylation;
LIHC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.46	6.86	0.35	3.33e-11	Aortic root size;
LIHC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.19	12.97	0.57	1.52e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.78	0.62	1.38e-38	Prudent dietary pattern;
LIHC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.5	5.73	0.3	2.2e-8	Weight;
LIHC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg05564831	chr3:52568323	NT5DC2	0.38	6.18	0.32	1.83e-9	Bipolar disorder;
LIHC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	ch.11.42038R	chr11:967971	AP2A2	0.55	10.04	0.48	5.67e-21	Alzheimer's disease (late onset);
LIHC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.3	-16.78	-0.67	1.58e-46	Diabetic kidney disease;
LIHC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.23	-6.16	-0.32	2.1e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6141600	0.574	rs2746088	chr20:34643323	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.19	-0.32	1.72e-9	Height;Hip circumference;
LIHC	cis	rs7212590	0.748	rs7211208	chr17:57957109	A/C	cg10252138	chr17:58120427	NA	-0.62	-6.61	-0.34	1.44e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg18478394	chr8:109455254	TTC35	0.38	6.54	0.33	2.25e-10	Dupuytren's disease;
LIHC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.64	-8.23	-0.41	4e-15	Type 2 diabetes;
LIHC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.44	6.11	0.31	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg13444538	chr7:158905317	VIPR2	-0.33	-6.15	-0.32	2.16e-9	Facial morphology (factor 20);
LIHC	trans	rs854462	1.000	rs854462	chr17:34386090	C/T	cg16820615	chr13:114884918	RASA3	-0.51	-6.14	-0.32	2.29e-9	Blood protein levels;
LIHC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.68	13.55	0.59	8.63e-34	Coronary artery disease;
LIHC	cis	rs7523273	0.565	rs1998539	chr1:207886596	G/A	cg22525895	chr1:207977042	MIR29B2	0.52	7.78	0.39	8.74e-14	Schizophrenia;
LIHC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg05590025	chr7:65112418	INTS4L2	-0.62	-6.82	-0.35	4.26e-11	Diabetic kidney disease;
LIHC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.4	-6.74	-0.34	6.75e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	0.68	7.77	0.39	9.52e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.55	9.62	0.46	1.49e-19	Total cholesterol levels;
LIHC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	0.78	6.47	0.33	3.38e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg27432699	chr2:27873401	GPN1	-0.43	-5.95	-0.31	6.71e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LIHC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg06207120	chr15:45996521	NA	0.33	6.36	0.33	6.37e-10	Waist circumference;Weight;
LIHC	cis	rs3762637	0.943	rs9841897	chr3:122282569	T/C	cg24169773	chr3:122142474	KPNA1	-0.45	-8.86	-0.43	4.49e-17	LDL cholesterol levels;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.69	9.65	0.46	1.17e-19	Menarche (age at onset);
LIHC	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.52	0.42	5.06e-16	Height;
LIHC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.94	17.62	0.69	6.46e-50	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06914197	chr12:6586920	NA	0.38	6.12	0.31	2.56e-9	Pancreatic cancer;
LIHC	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg23091122	chr1:110024289	SYPL2	-0.47	-6.35	-0.32	6.88e-10	Intelligence (multi-trait analysis);
LIHC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg14927277	chr11:28129967	METT5D1;KIF18A	0.46	6.82	0.35	4.09e-11	Morning vs. evening chronotype;
LIHC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg20335179	chr10:1068567	C10orf110;IDI2	-0.56	-6.43	-0.33	4.32e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs2637030	0.515	rs1844696	chr5:52936538	A/C	cg06476337	chr5:52856530	NDUFS4	0.42	6.38	0.33	5.78e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.39	-6.0	-0.31	4.96e-9	Total body bone mineral density;
LIHC	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg00792783	chr2:198669748	PLCL1	0.41	5.93	0.31	7.58e-9	Intracranial aneurysm;
LIHC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.35	6.99	0.35	1.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03258011	chr17:54857409	NA	0.48	6.53	0.33	2.41e-10	Pancreatic cancer;
LIHC	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	5.79	0.3	1.57e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.31	-0.58	7.63e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg12698662	chr3:15914712	MIR563	-0.4	-7.43	-0.37	8.57e-13	Mean platelet volume;
LIHC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg02269571	chr22:50332266	NA	0.6	8.51	0.42	5.42e-16	Schizophrenia;
LIHC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.75	7.57	0.38	3.48e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.66	-6.79	-0.34	5.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg12560992	chr17:57184187	TRIM37	0.73	10.84	0.51	9.51e-24	Cognitive test performance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01831166	chr2:198570100	MARS2	-0.48	-6.77	-0.34	5.48e-11	Pancreatic cancer;
LIHC	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	9.59	0.46	1.87e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs611744	0.805	rs378515	chr8:109104905	T/G	cg21045802	chr8:109455806	TTC35	0.48	8.24	0.41	3.61e-15	Dupuytren's disease;
LIHC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.64	10.73	0.5	2.37e-23	Type 2 diabetes;
LIHC	cis	rs7712401	0.791	rs10059964	chr5:122118293	A/G	cg18764291	chr5:122110994	SNX2	0.35	5.94	0.31	7.13e-9	Mean platelet volume;
LIHC	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg14393609	chr7:65229607	NA	-0.37	-5.85	-0.3	1.18e-8	Aortic root size;
LIHC	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg08911820	chr1:110026001	ATXN7L2	0.59	7.31	0.37	1.9e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.46	9.5e-20	Bipolar disorder;
LIHC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.56	9.23	0.45	2.84e-18	Colorectal cancer;
LIHC	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.23	-0.41	4.11e-15	Response to antipsychotic treatment;
LIHC	cis	rs2257205	0.588	rs77430462	chr17:56804085	C/G	cg12560992	chr17:57184187	TRIM37	0.72	7.97	0.4	2.33e-14	Pancreatic cancer;
LIHC	cis	rs4742903	0.967	rs10820599	chr9:106856691	T/G	cg14250997	chr9:106856677	SMC2	0.43	7.37	0.37	1.32e-12	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg07424592	chr7:64974309	NA	0.85	9.18	0.44	4.11e-18	Diabetic kidney disease;
LIHC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.47	-7.33	-0.37	1.63e-12	Blood protein levels;
LIHC	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.35	-7.84	-0.39	5.64e-14	Breast cancer;
LIHC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.69	-0.38	1.53e-13	Ulcerative colitis;
LIHC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.48	-6.41	-0.33	4.88e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg13919466	chr1:32135498	COL16A1	-0.32	-6.18	-0.32	1.8e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.73	10.77	0.5	1.7e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.65	-9.76	-0.47	5.17e-20	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs77637988	0.578	rs6718068	chr2:48604978	C/T	cg00032884	chr2:48540671	FOXN2	0.4	6.35	0.32	6.67e-10	Joint mobility (Beighton score);
LIHC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs72960926	0.744	rs56077244	chr6:74920700	A/G	cg07247405	chr1:2484626	LOC115110	0.55	6.51	0.33	2.71e-10	Metabolite levels (MHPG);
LIHC	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	16.94	0.68	3.58e-47	Nonalcoholic fatty liver disease;
LIHC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.79	-13.32	-0.58	6.54e-33	Dental caries;
LIHC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	11.06	0.51	1.58e-24	Platelet count;
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg09417038	chr21:47716443	C21orf57	-0.53	-7.99	-0.4	2.09e-14	Testicular germ cell tumor;
LIHC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.25e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	1.17	13.77	0.6	1.22e-34	Eosinophil percentage of granulocytes;
LIHC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.39	6.49	0.33	3.01e-10	Red blood cell count;
LIHC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21545522	chr1:205238299	TMCC2	0.37	7.1	0.36	7.18e-12	Mean corpuscular volume;Mean platelet volume;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg19569686	chr19:1555141	MEX3D	0.36	6.17	0.32	1.94e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.73	7.72	0.39	1.3e-13	Breast cancer;
LIHC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg10932868	chr11:921992	NA	0.34	6.28	0.32	1.06e-9	Alzheimer's disease (late onset);
LIHC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24229701	chr12:130821962	PIWIL1	0.45	6.8	0.35	4.72e-11	Menopause (age at onset);
LIHC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.38	6.22	0.32	1.45e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs1403694	0.966	rs9869244	chr3:186437554	A/T	cg12454167	chr3:186435060	KNG1	0.3	7.28	0.37	2.25e-12	Blood protein levels;
LIHC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	10.81	0.5	1.22e-23	Chronic sinus infection;
LIHC	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg07424592	chr7:64974309	NA	0.77	8.92	0.43	2.81e-17	Gout;
LIHC	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg26031613	chr14:104095156	KLC1	-0.41	-5.77	-0.3	1.76e-8	Coronary artery disease;
LIHC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg15168958	chr13:99100528	FARP1	0.34	5.89	0.3	9.21e-9	Educational attainment (years of education);
LIHC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.95	-0.31	6.48e-9	Alzheimer's disease (late onset);
LIHC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.49	6.67	0.34	1.04e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg03934865	chr2:198174659	NA	-0.46	-6.7	-0.34	8.86e-11	Dermatomyositis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04371633	chr14:65381025	CHURC1	0.44	6.27	0.32	1.12e-9	Pancreatic cancer;
LIHC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.82	9.19	0.45	3.76e-18	Vitiligo;
LIHC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg18944383	chr4:111397179	ENPEP	0.27	7.06	0.36	9.34e-12	Height;
LIHC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.62	-9.36	-0.45	1.08e-18	Aortic root size;
LIHC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-8.82	-0.43	6.01e-17	Type 2 diabetes;
LIHC	cis	rs963731	0.649	rs1377860	chr2:39290425	C/G	cg04010122	chr2:39346883	SOS1	0.73	6.59	0.34	1.68e-10	Corticobasal degeneration;
LIHC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg11406765	chr11:980039	AP2A2	-0.35	-5.78	-0.3	1.69e-8	Alzheimer's disease (late onset);
LIHC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg12863693	chr15:85201151	NMB	0.44	5.96	0.31	6.21e-9	Schizophrenia;
LIHC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg07451762	chr16:28383216	NA	0.33	6.75	0.34	6.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9513627	0.920	rs7335315	chr13:100121308	G/A	cg25919922	chr13:100150906	NA	-0.8	-7.05	-0.36	9.87e-12	Obesity-related traits;
LIHC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.45	0.37	7.45e-13	Bone mineral density;
LIHC	cis	rs3812111	0.677	rs1204796	chr6:116541503	T/C	cg08036074	chr6:116424633	NT5DC1	-0.4	-6.5	-0.33	2.91e-10	Age-related macular degeneration;
LIHC	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-0.84	-9.29	-0.45	1.86e-18	Exhaled nitric oxide output;
LIHC	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg21605333	chr4:119757512	SEC24D	1.07	8.66	0.42	1.91e-16	Cannabis dependence symptom count;
LIHC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.63	-11.39	-0.52	1.04e-25	Total body bone mineral density;
LIHC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg15691649	chr6:25882328	NA	-0.53	-7.62	-0.38	2.55e-13	Blood metabolite levels;
LIHC	cis	rs56146971	0.763	rs45490092	chr14:91845143	A/G	cg16433844	chr14:91963127	SMEK1	-0.58	-6.11	-0.31	2.72e-9	Alzheimer disease and age of onset;
LIHC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg09876464	chr15:85330779	ZNF592	0.35	6.02	0.31	4.58e-9	P wave terminal force;
LIHC	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg19773385	chr1:10388646	KIF1B	-0.47	-8.19	-0.41	5.14e-15	Hepatocellular carcinoma;
LIHC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.97	12.66	0.56	2.12e-30	Bladder cancer;
LIHC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.4	-5.75	-0.3	1.93e-8	Morning vs. evening chronotype;
LIHC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.45	0.46	5.54e-19	Bipolar disorder;
LIHC	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.61	-8.14	-0.4	7.36e-15	Vitamin D levels;
LIHC	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.7	0.34	8.77e-11	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs1144333	1.000	rs5745392	chr1:76306809	C/T	cg10523679	chr1:76189770	ACADM	0.46	6.67	0.34	1.05e-10	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg16797656	chr11:68205561	LRP5	0.46	5.87	0.3	1.04e-8	Total body bone mineral density (age 45-60);
LIHC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13606994	chr1:44402422	ARTN	0.32	5.88	0.3	1e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.63	8.02	0.4	1.71e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-17.4	-0.69	4.9e-49	Schizophrenia;
LIHC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.63	10.23	0.48	1.35e-21	Resting heart rate;
LIHC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.34	12.43	0.56	1.62e-29	Uric acid levels;
LIHC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	7.92	0.39	3.26e-14	Mean platelet volume;
LIHC	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.72	0.34	7.46e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20403628	chr5:121297515	SRFBP1	0.49	7.52	0.38	4.71e-13	Calcium levels;
LIHC	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.33	-0.32	7.61e-10	Putamen volume;
LIHC	cis	rs611744	0.743	rs2514843	chr8:109063434	C/T	cg21045802	chr8:109455806	TTC35	0.48	7.97	0.4	2.44e-14	Dupuytren's disease;
LIHC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.5	-7.79	-0.39	7.92e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg00204512	chr16:28754710	NA	0.37	6.72	0.34	7.75e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs4845459	0.967	rs4845447	chr1:152590886	T/C	cg20634798	chr1:152595351	LCE3A	-0.32	-6.2	-0.32	1.63e-9	Psoriasis;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05617300	chr19:59093449	MGC2752	0.46	6.57	0.33	1.86e-10	Pancreatic cancer;
LIHC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	10.5	0.49	1.6e-22	Cognitive test performance;
LIHC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-6.55	-0.33	2.17e-10	Lung cancer;
LIHC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.71	10.63	0.5	5.5e-23	Aortic root size;
LIHC	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.47	6.93	0.35	2.11e-11	Dermatomyositis;
LIHC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.12	-0.36	6.58e-12	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.44	8.15	0.4	7.14e-15	Prudent dietary pattern;
LIHC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	8.51	0.42	5.53e-16	Menarche (age at onset);
LIHC	cis	rs74544699	1.000	rs499141	chr4:74768970	A/C	cg16072462	chr4:74847758	PF4	0.55	5.74	0.3	2.11e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg20607798	chr8:58055168	NA	0.46	6.62	0.34	1.42e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.88	-11.73	-0.54	6e-27	Alzheimer's disease;
LIHC	cis	rs10097731	0.901	rs9298344	chr8:82043063	C/T	cg25230327	chr8:82042993	NA	-0.6	-8.12	-0.4	8.67e-15	Serum total protein level;
LIHC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.42	7.04	0.36	1.06e-11	Mean corpuscular volume;
LIHC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg26831259	chr4:1366826	KIAA1530	0.35	5.75	0.3	1.99e-8	Obesity-related traits;
LIHC	trans	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg10756647	chr7:56101905	PSPH	0.47	7.01	0.35	1.29e-11	Aortic root size;
LIHC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.57	10.13	0.48	2.95e-21	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17183009	chr3:120277827	NA	0.52	6.11	0.31	2.73e-9	Corneal astigmatism;
LIHC	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg03934865	chr2:198174659	NA	-0.44	-6.23	-0.32	1.41e-9	Intracranial aneurysm;
LIHC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.44	6.12	0.31	2.51e-9	Schizophrenia;
LIHC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg16479474	chr6:28041457	NA	0.46	6.51	0.33	2.71e-10	Depression;
LIHC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.87	11.32	0.52	1.96e-25	Coronary artery disease;
LIHC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg06742321	chr12:123595122	PITPNM2	0.31	5.77	0.3	1.82e-8	Platelet count;
LIHC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-15.06	-0.63	1.09e-39	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.52	-0.33	2.53e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23223044	chr19:49990882	RPL13AP5;RPL13A	0.44	6.15	0.32	2.22e-9	Lung function (FEV1/FVC);
LIHC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg27523141	chr10:43048294	ZNF37B	-0.39	-6.77	-0.34	5.57e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.53	8.58	0.42	3.26e-16	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.49e-9	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-21.63	-0.76	5.27e-66	Height;
LIHC	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg27205649	chr11:78285834	NARS2	0.41	6.08	0.31	3.13e-9	Alzheimer's disease (survival time);
LIHC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.96	0.31	6.3e-9	Blood metabolite levels;
LIHC	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.44	7.36	0.37	1.34e-12	Corneal astigmatism;
LIHC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	30.89	0.86	5.55e-101	IgG glycosylation;
LIHC	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.77	10.17	0.48	2.16e-21	Post bronchodilator FEV1;
LIHC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.17	-0.32	1.92e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16944159	chr2:62132759	COMMD1	0.44	6.45	0.33	3.92e-10	Pancreatic cancer;
LIHC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.1	10.17	0.48	2.15e-21	Diabetic retinopathy;
LIHC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16262614	chr3:133464971	TF	0.29	6.34	0.32	7.33e-10	Iron status biomarkers;
LIHC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.67	12.22	0.55	9.29e-29	Breast cancer;
LIHC	cis	rs4773330	1.000	rs9301494	chr13:111821289	G/C	cg26911804	chr13:111806221	ARHGEF7	0.62	6.21	0.32	1.52e-9	Bilirubin levels;
LIHC	trans	rs6600671	1.000	rs2319969	chr1:121207335	A/G	cg09829573	chr1:144692074	NBPF9	-0.41	-6.89	-0.35	2.65e-11	Hip geometry;
LIHC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.35	-0.32	6.73e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.75	-12.59	-0.56	3.94e-30	Breast cancer;
LIHC	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.52	-8.04	-0.4	1.47e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs611744	0.870	rs57723916	chr8:109191433	A/T	cg21045802	chr8:109455806	TTC35	0.51	8.81	0.43	6.4e-17	Dupuytren's disease;
LIHC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.44	6.02	0.31	4.58e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18867708	chr6:26865862	GUSBL1	-0.56	-8.55	-0.42	4.13e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.3	-0.32	9.14e-10	HDL cholesterol;Metabolic syndrome;
LIHC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg27523141	chr10:43048294	ZNF37B	0.37	6.4	0.33	5.12e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.4	5.85	0.3	1.17e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg25182066	chr10:30743637	MAP3K8	0.59	9.19	0.45	3.86e-18	Inflammatory bowel disease;
LIHC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg04498913	chr7:1135747	C7orf50	0.37	5.72	0.3	2.36e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	8.12	0.4	8.82e-15	Lung cancer in ever smokers;
LIHC	cis	rs7534824	0.625	rs61780327	chr1:101449810	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	7.29	0.37	2.23e-12	Refractive astigmatism;
LIHC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.6	8.24	0.41	3.66e-15	Lung cancer;
LIHC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg07424592	chr7:64974309	NA	0.83	9.5	0.46	3.78e-19	Diabetic kidney disease;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00463171	chr13:100741364	PCCA	0.54	7.35	0.37	1.5e-12	Hepatitis;
LIHC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.37	6.03	0.31	4.22e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg08556938	chr17:58512855	NA	0.4	6.24	0.32	1.28e-9	Longevity;
LIHC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg03146154	chr1:46216737	IPP	-0.39	-6.47	-0.33	3.4e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.3	-17.23	-0.68	2.36e-48	Diabetic kidney disease;
LIHC	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg11204139	chr17:3907470	NA	0.45	5.73	0.3	2.18e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg09904177	chr6:26538194	HMGN4	-0.53	-5.72	-0.3	2.37e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg27426351	chr10:43362370	NA	0.44	5.72	0.3	2.37e-8	Blood protein levels;
LIHC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.34	-0.56	3.41e-29	Primary sclerosing cholangitis;
LIHC	trans	rs17412740	1.000	rs41343448	chr8:20271413	A/G	cg05701478	chr8:19029020	NA	0.44	6.71	0.34	7.96e-11	Preeclampsia;
LIHC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.75	12.68	0.57	1.77e-30	Aortic root size;
LIHC	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.54	-9.41	-0.45	7.71e-19	Systemic lupus erythematosus;
LIHC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg22676075	chr6:135203613	NA	0.4	6.52	0.33	2.55e-10	Red blood cell count;
LIHC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.46	-7.8	-0.39	7.33e-14	Lung cancer;
LIHC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.99	0.6	1.71e-35	Chronic sinus infection;
LIHC	trans	rs875971	0.964	rs778721	chr7:65845397	C/G	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	7.2	0.36	3.75e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.48	7.77	0.39	9.55e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg11161837	chr1:110010384	SYPL2	0.45	6.14	0.31	2.32e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.56	7.83	0.39	6.39e-14	Neuroblastoma;
LIHC	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg00977110	chr5:151150581	G3BP1	-0.56	-7.07	-0.36	8.73e-12	Preschool internalizing problems;
LIHC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.62	0.34	1.38e-10	Obesity-related traits;
LIHC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.11	-0.36	6.89e-12	Reticulocyte count;
LIHC	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg05760424	chr2:242988095	NA	-0.51	-6.86	-0.35	3.31e-11	Obesity-related traits;
LIHC	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg18064842	chr5:14874549	NA	-0.46	-9.49	-0.46	4.04e-19	Blood metabolite levels;
LIHC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg14132834	chr19:41945861	ATP5SL	-0.39	-5.76	-0.3	1.86e-8	Height;
LIHC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.85	11.42	0.53	8.53e-26	Blood metabolite levels;
LIHC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.49	6.56	0.33	1.97e-10	Emphysema distribution in smoking;
LIHC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg22676075	chr6:135203613	NA	0.4	6.45	0.33	3.88e-10	Red blood cell count;
LIHC	trans	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg10756647	chr7:56101905	PSPH	-1.03	-12.48	-0.56	1.05e-29	Diabetic kidney disease;
LIHC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.72	12.48	0.56	9.96e-30	Menopause (age at onset);
LIHC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.89	-15.52	-0.64	1.66e-41	Aortic root size;
LIHC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg06565975	chr8:143823917	SLURP1	-0.4	-6.58	-0.34	1.82e-10	Urinary tract infection frequency;
LIHC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21467203	chr3:49911342	NA	0.52	9.4	0.45	7.87e-19	Body mass index;
LIHC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-12.57	-0.56	4.6e-30	Glomerular filtration rate (creatinine);
LIHC	cis	rs2380220	0.872	rs2613529	chr6:95945036	C/T	cg04719120	chr6:96025338	MANEA	-0.59	-6.21	-0.32	1.53e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs4788570	0.566	rs72795864	chr16:71483497	C/G	cg06353428	chr16:71660113	MARVELD3	-1.11	-10.1	-0.48	3.73e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg16743903	chr16:89593216	SPG7	-0.3	-5.73	-0.3	2.17e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02985541	chr2:219472218	PLCD4	-0.42	-6.88	-0.35	2.9100000000000002e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.94	20.44	0.74	3.16e-61	Blood protein levels;
LIHC	cis	rs6782228	0.585	rs3122175	chr3:128361276	C/T	cg16766828	chr3:128327626	NA	-0.4	-6.37	-0.33	6.03e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.54	-0.38	4.24e-13	Height;
LIHC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	7.11	0.36	6.77e-12	Neuroticism;
LIHC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.38	-11.71	-0.53	7.6e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs600626	0.636	rs11236518	chr11:75453066	C/T	cg24262691	chr11:75473276	NA	0.39	5.97	0.31	6.06e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.47	7.69	0.38	1.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.39	7.04	0.36	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg22153463	chr1:85462885	MCOLN2	0.52	6.17	0.32	1.93e-9	Serum sulfate level;
LIHC	cis	rs12701220	0.503	rs2949177	chr7:1211518	C/T	cg02733842	chr7:1102375	C7orf50	-0.66	-6.9	-0.35	2.55e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.58	8.89	0.43	3.47e-17	Noise-induced hearing loss;
LIHC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.57	-8.57	-0.42	3.65e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg19683494	chr5:74908142	NA	0.56	7.0	0.35	1.34e-11	Coronary artery disease;
LIHC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.57	9.35	0.45	1.15e-18	Corneal astigmatism;
LIHC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-6.1	-0.31	2.8e-9	Lung function (FEV1/FVC);
LIHC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg20194872	chr6:41519635	FOXP4	0.42	6.66	0.34	1.07e-10	Prostate cancer;
LIHC	cis	rs6733011	0.644	rs6542839	chr2:99464530	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.45	6.15	0.32	2.21e-9	Bipolar disorder;
LIHC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.71	0.34	8.25e-11	Morning vs. evening chronotype;
LIHC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.58	8.03	0.4	1.59e-14	Coronary artery disease;
LIHC	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.61	-7.07	-0.36	8.66e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg07862535	chr7:139043722	LUC7L2	0.55	9.3	0.45	1.71e-18	Diisocyanate-induced asthma;
LIHC	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.97	-0.35	1.69e-11	Blood pressure;
LIHC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.55	10.07	0.48	4.57e-21	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02290350	chr8:58132656	NA	0.5	10.8	0.5	1.35e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg00091569	chr3:40428383	ENTPD3	0.4	6.83	0.35	4.01e-11	Renal cell carcinoma;
LIHC	trans	rs10740993	0.585	rs7090118	chr10:18459282	C/T	cg09391949	chr16:87730651	JPH3	0.43	6.35	0.32	6.89e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20232060	chr3:141457873	RNF7	0.52	7.56	0.38	3.69e-13	Pancreatic cancer;
LIHC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.97	9.8	0.47	3.82e-20	Mean corpuscular hemoglobin;
LIHC	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.49	-7.47	-0.37	6.64e-13	Thyroid stimulating hormone;
LIHC	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg26831259	chr4:1366826	KIAA1530	0.35	5.79	0.3	1.63e-8	Obesity-related traits;
LIHC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.07	0.36	8.61e-12	Mean platelet volume;
LIHC	cis	rs7487075	0.578	rs2897951	chr12:46809206	G/A	cg23829395	chr12:46796953	NA	0.36	6.3	0.32	9.14e-10	Itch intensity from mosquito bite;
LIHC	cis	rs17106184	1.000	rs72904723	chr1:51334304	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-6.5	-0.33	2.91e-10	Type 2 diabetes;
LIHC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.44	6.18	0.32	1.79e-9	Height;
LIHC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.79	0.3	1.58e-8	Bipolar disorder;
LIHC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.53	8.22	0.41	4.36e-15	Pulse pressure;
LIHC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.36	5.87	0.3	1.03e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.72	0.43	1.2e-16	Eosinophil percentage of white cells;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21313137	chr20:44462302	SNX21	-0.47	-6.35	-0.32	6.8e-10	Triglycerides;
LIHC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.65	9.88	0.47	2e-20	Cognitive ability;
LIHC	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.69	6.98	0.35	1.51e-11	Bipolar disorder;
LIHC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21747090	chr2:27597821	SNX17	-0.47	-7.0	-0.35	1.38e-11	Total body bone mineral density;
LIHC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg05484376	chr2:27715224	FNDC4	0.4	6.58	0.34	1.81e-10	Total body bone mineral density;
LIHC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-9.86	-0.47	2.42e-20	Magnesium levels;
LIHC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	6.39	0.33	5.56e-10	Bipolar disorder;
LIHC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.22	0.41	4.31e-15	Bladder cancer;
LIHC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg11812906	chr14:75593930	NEK9	0.41	6.28	0.32	1.01e-9	IgG glycosylation;
LIHC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.62	-0.38	2.45e-13	Initial pursuit acceleration;
LIHC	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.62	-9.02	-0.44	1.41e-17	Blood pressure (smoking interaction);
LIHC	cis	rs74233809	1.000	rs77602510	chr10:104682602	G/A	cg03493300	chr10:104813866	CNNM2	0.46	6.02	0.31	4.57e-9	Birth weight;
LIHC	trans	rs1475622	0.571	rs9601729	chr13:82432073	A/C	cg00625354	chr20:45865223	ZMYND8	-0.72	-6.39	-0.33	5.48e-10	Hippocampal volume;
LIHC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.46	-6.6	-0.34	1.54e-10	Height;
LIHC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.49	-7.53	-0.38	4.68e-13	Lymphocyte counts;
LIHC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-5.81	-0.3	1.44e-8	Menarche (age at onset);
LIHC	cis	rs712039	0.652	rs829160	chr17:35763091	T/A	cg16670864	chr17:35848621	DUSP14	0.34	5.8	0.3	1.51e-8	Tuberculosis;
LIHC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg00656387	chr3:40428638	ENTPD3	0.43	7.14	0.36	5.7e-12	Renal cell carcinoma;
LIHC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg13409248	chr3:40428643	ENTPD3	0.42	7.16	0.36	5.01e-12	Renal cell carcinoma;
LIHC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.61	0.42	2.78e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.69	-11.0	-0.51	2.77e-24	Obesity-related traits;
LIHC	trans	rs12752401	0.764	rs72725348	chr1:103024349	G/A	cg17681729	chr19:740608	PALM	0.56	7.25	0.36	2.83e-12	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs838721	0.574	rs11681192	chr2:234258064	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	5.85	0.3	1.12e-8	Total body bone mineral density;
LIHC	cis	rs11800820	0.557	rs10924755	chr1:246666347	T/A	cg16700716	chr1:246684329	NA	0.48	8.11	0.4	9.23e-15	Obesity-related traits;
LIHC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg02290350	chr8:58132656	NA	0.29	6.16	0.32	2.08e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.5	-5.83	-0.3	1.29e-8	Coronary artery disease;
LIHC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	0.49	7.27	0.37	2.44e-12	Methadone dose in opioid dependence;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg16822855	chr3:40428330	ENTPD3	-0.31	-5.71	-0.3	2.43e-8	Renal cell carcinoma;
LIHC	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.54	-8.24	-0.41	3.81e-15	Response to antidepressants and depression;
LIHC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg05590025	chr7:65112418	INTS4L2	-0.6	-6.67	-0.34	1e-10	Diabetic kidney disease;
LIHC	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg08135965	chr6:41755394	TOMM6	0.45	5.95	0.31	6.46e-9	Mean corpuscular hemoglobin;Red cell distribution width;
LIHC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.97	16.13	0.66	6.11e-44	Subjective well-being;
LIHC	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.47	-5.77	-0.3	1.76e-8	QRS duration;
LIHC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg08499158	chr17:42289980	UBTF	-0.52	-8.55	-0.42	4.12e-16	Total body bone mineral density;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01989157	chr22:40742702	ADSL	0.4	6.24	0.32	1.33e-9	Pancreatic cancer;
LIHC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.6	8.54	0.42	4.42e-16	Blood metabolite levels;
LIHC	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg20016023	chr10:99160130	RRP12	-0.4	-6.13	-0.31	2.42e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.2	-0.45	3.75e-18	Bipolar disorder and schizophrenia;
LIHC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.49	6.38	0.33	5.82e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.57	11.18	0.52	6.28e-25	Coronary artery disease;
LIHC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.63	8.59	0.42	3.1e-16	Neutrophil percentage of white cells;
LIHC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg02297831	chr4:17616191	MED28	0.48	7.3	0.37	2.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg20487152	chr13:99095054	FARP1	-0.38	-6.32	-0.32	8.1e-10	Longevity;
LIHC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.79	-0.39	7.84e-14	Breast cancer;
LIHC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.52	6.38	0.33	5.84e-10	Menarche (age at onset);
LIHC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07346676	chr11:60681596	TMEM109	-0.4	-6.11	-0.31	2.65e-9	Immature fraction of reticulocytes;
LIHC	cis	rs7534824	0.625	rs61780328	chr1:101458754	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	7.35	0.37	1.49e-12	Refractive astigmatism;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07959380	chr16:89894648	SPIRE2	0.37	6.1	0.31	2.92e-9	Calcium levels;
LIHC	cis	rs4780401	0.933	rs1592572	chr16:11810382	T/C	cg01061890	chr16:11836724	TXNDC11	-0.4	-5.74	-0.3	2.06e-8	Rheumatoid arthritis;
LIHC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	9.23	0.45	2.9e-18	Lung cancer;
LIHC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.41	12.28	0.55	5.82e-29	Uric acid levels;
LIHC	cis	rs2286503	0.752	rs59538378	chr7:22877097	G/A	cg11367502	chr7:22862612	TOMM7	0.48	8.52	0.42	5.22e-16	Fibrinogen;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg07522190	chr16:28925877	RABEP2	0.37	6.55	0.33	2.09e-10	Longevity;
LIHC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg00990874	chr7:1149470	C7orf50	-0.54	-8.12	-0.4	8.25e-15	Bronchopulmonary dysplasia;
LIHC	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.58	0.5	8.27e-23	Colorectal cancer;
LIHC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.82	0.43	6.02e-17	Menarche (age at onset);
LIHC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-8.2	-0.41	4.9e-15	Total body bone mineral density;
LIHC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	7.95	0.4	2.68e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs12493885	0.818	rs6800048	chr3:153766181	T/C	cg10247383	chr3:153839028	SGEF	0.65	6.09	0.31	3.08e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18252515	chr7:66147081	NA	-0.41	-5.86	-0.3	1.07e-8	Aortic root size;
LIHC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.56	9.39	0.45	9e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg01864836	chr14:55583639	NA	-0.41	-7.86	-0.39	4.89e-14	Protein biomarker;
LIHC	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.35	-7.78	-0.39	8.95e-14	Breast cancer;
LIHC	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg20991723	chr1:152506922	NA	0.51	8.81	0.43	6.35e-17	Hair morphology;
LIHC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.82	0.3	1.39e-8	Hepatocellular carcinoma;
LIHC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg27209729	chr11:64428925	NRXN2	0.33	6.18	0.32	1.8e-9	Body mass index;Urate levels;
LIHC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg17306686	chr7:157230923	NA	0.43	9.51	0.46	3.57e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg12517452	chr5:52084045	ITGA1;PELO	-0.41	-6.19	-0.32	1.68e-9	Body mass index;
LIHC	trans	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05926928	chr17:57297772	GDPD1	-0.41	-6.05	-0.31	3.79e-9	Schizophrenia;
LIHC	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.37	7.31	0.37	1.91e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.63	12.73	0.57	1.19e-30	Airflow obstruction;
LIHC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg05941027	chr17:61774174	LIMD2	0.3	6.26	0.32	1.18e-9	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg17980119	chr2:219472607	PLCD4	0.34	5.73	0.3	2.18e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	0.6	8.75	0.43	9.91e-17	Prudent dietary pattern;
LIHC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.97	17.37	0.68	6.78e-49	Cognitive ability;
LIHC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.16	-0.36	4.82e-12	Body mass index;
LIHC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg10018233	chr7:150070692	REPIN1	0.49	8.06	0.4	1.3e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.31	0.49	7.09e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg10998878	chr12:93964793	SOCS2	-0.41	-5.94	-0.31	7.03e-9	Alopecia areata;
LIHC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg11342453	chr6:26196699	NA	0.52	5.8	0.3	1.55e-8	Gout;Renal underexcretion gout;
LIHC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg06238570	chr21:40685208	BRWD1	0.6	7.16	0.36	4.86e-12	Cognitive function;
LIHC	trans	rs72960926	1.000	rs72950596	chr6:74921364	C/T	cg07247405	chr1:2484626	LOC115110	0.57	6.15	0.32	2.15e-9	Metabolite levels (MHPG);
LIHC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.44	-5.93	-0.31	7.32e-9	Total body bone mineral density;
LIHC	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.51	-7.12	-0.36	6.27e-12	Urinary tract infection frequency;
LIHC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.52	-6.43	-0.33	4.24e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LIHC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.87	13.35	0.59	5.12e-33	IgG glycosylation;
LIHC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.8	-0.3	1.47e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1823913	0.599	rs17511410	chr2:192142769	T/C	cg12404831	chr2:192114017	MYO1B	0.28	5.73	0.3	2.25e-8	Obesity-related traits;
LIHC	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.8	-17.71	-0.69	2.87e-50	Urate levels in lean individuals;
LIHC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.38	-11.63	-0.53	1.45e-26	Hip circumference adjusted for BMI;
LIHC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	8.27	0.41	3.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11987759	chr7:65425863	GUSB	0.39	6.09	0.31	3.01e-9	Corneal structure;
LIHC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.87	0.35	2.97e-11	Renal cell carcinoma;
LIHC	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.49	0.53	4.51e-26	Coffee consumption (cups per day);
LIHC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.39	7.06	0.36	9.24e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.38	7.64	0.38	2.27e-13	Type 2 diabetes;
LIHC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.45	10.26	0.49	1.06e-21	Iron status biomarkers;
LIHC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.62	-8.83	-0.43	5.55e-17	Pancreatic cancer;
LIHC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	5.74	0.3	2.11e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	-0.62	-10.02	-0.48	6.71e-21	Inflammatory bowel disease;
LIHC	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.53	-8.42	-0.41	1.08e-15	Corneal astigmatism;
LIHC	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	0.86	11.06	0.51	1.68e-24	Severe influenza A (H1N1) infection;
LIHC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg05590025	chr7:65112418	INTS4L2	-0.63	-7.05	-0.36	9.75e-12	Diabetic kidney disease;
LIHC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg10932868	chr11:921992	NA	-0.37	-7.03	-0.36	1.11e-11	Alzheimer's disease (late onset);
LIHC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.13	-0.44	6.06e-18	Morning vs. evening chronotype;
LIHC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18867708	chr6:26865862	GUSBL1	0.55	8.68	0.42	1.65e-16	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-8.98	-0.44	1.89e-17	Response to anti-depressant treatment in major depressive disorder;
LIHC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg14393609	chr7:65229607	NA	0.43	6.25	0.32	1.23e-9	Aortic root size;
LIHC	cis	rs1664789	0.773	rs702637	chr5:53268300	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.43	6.63	0.34	1.33e-10	Waist circumference adjusted for body mass index;
LIHC	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.57	9.25	0.45	2.5e-18	Eosinophilic esophagitis;
LIHC	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.98	-17.85	-0.69	7.69e-51	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.45	8.16	0.4	6.44e-15	Platelet distribution width;
LIHC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01200585	chr1:228362443	C1orf69	0.4	6.08	0.31	3.13e-9	Diastolic blood pressure;
LIHC	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg15208524	chr1:10270712	KIF1B	0.4	6.01	0.31	4.81e-9	Hepatocellular carcinoma;
LIHC	cis	rs74181299	0.533	rs11678917	chr2:65368214	T/G	cg05010058	chr2:65284262	CEP68	-0.36	-5.79	-0.3	1.57e-8	Pulse pressure;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.52	7.07	0.36	8.65e-12	Menopause (age at onset);
LIHC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.64	-10.91	-0.51	5.74e-24	Crohn's disease;
LIHC	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.67	-6.3	-0.32	9.17e-10	Bipolar disorder;
LIHC	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	1.17	9.75	0.47	5.68e-20	Gut microbiota (bacterial taxa);
LIHC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.63	6.66	0.34	1.06e-10	Alzheimer's disease;
LIHC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.52	-7.86	-0.39	4.95e-14	Tonsillectomy;
LIHC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	8.8	0.43	7.05e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.64	10.53	0.49	1.19e-22	Platelet count;
LIHC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.52	8.81	0.43	6.28e-17	Sjögren's syndrome;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.47	-7.78	-0.39	8.47e-14	Testicular germ cell tumor;
LIHC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.7	10.7	0.5	3.06e-23	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.68	0.57	1.87e-30	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6782228	0.606	rs4857861	chr3:128406767	T/C	cg16766828	chr3:128327626	NA	-0.38	-6.08	-0.31	3.17e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.94	10.75	0.5	1.99e-23	Neuroticism;
LIHC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.58	7.6	0.38	2.9e-13	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.07	9.89	0.47	1.84e-20	Diabetic retinopathy;
LIHC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg17294928	chr15:75287854	SCAMP5	-0.54	-6.57	-0.33	1.87e-10	Lung cancer;
LIHC	cis	rs3106136	0.843	rs1426575	chr4:95260069	G/C	cg11021082	chr4:95130006	SMARCAD1	0.41	7.28	0.37	2.34e-12	Capecitabine sensitivity;
LIHC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	8.43	0.41	9.98e-16	Lymphocyte counts;
LIHC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.67	13.37	0.59	4.19e-33	High light scatter reticulocyte count;
LIHC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.29	-17.09	-0.68	9.12e-48	Diabetic kidney disease;
LIHC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-10.54	-0.5	1.15e-22	Schizophrenia;
LIHC	cis	rs7520050	0.966	rs10789475	chr1:46304177	C/G	cg03146154	chr1:46216737	IPP	-0.37	-5.92	-0.3	8e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg15691649	chr6:25882328	NA	0.51	7.39	0.37	1.12e-12	Blood metabolite levels;
LIHC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-12.57	-0.56	4.61e-30	Chronic sinus infection;
LIHC	trans	rs8113308	0.810	rs73582180	chr19:52446537	G/A	cg14959425	chr7:20447707	ITGB8	-0.47	-6.1	-0.31	2.87e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.95	14.38	0.61	5.13e-37	Corneal structure;
LIHC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg08499158	chr17:42289980	UBTF	-0.5	-8.55	-0.42	4.12e-16	Total body bone mineral density;
LIHC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg00656387	chr3:40428638	ENTPD3	0.41	6.66	0.34	1.06e-10	Renal cell carcinoma;
LIHC	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.42	6.13	0.31	2.42e-9	Facial emotion recognition (sad faces);
LIHC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg14067834	chr17:29058358	SUZ12P	0.68	6.66	0.34	1.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg21724239	chr8:58056113	NA	0.48	6.28	0.32	1.01e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs6897795	0.680	rs9329133	chr5:177609540	C/T	cg19598605	chr2:70056955	GMCL1	-0.57	-7.39	-0.37	1.11e-12	Plateletcrit;
LIHC	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.33	-0.32	7.84e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.79	15.82	0.65	1.11e-42	White blood cell count;
LIHC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.02	0.44	1.38e-17	Platelet count;
LIHC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg16479474	chr6:28041457	NA	0.46	6.45	0.33	3.81e-10	Depression;
LIHC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.77	-8.35	-0.41	1.71e-15	Bronchopulmonary dysplasia;
LIHC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.67	-9.57	-0.46	2.15e-19	Initial pursuit acceleration;
LIHC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.78	15.26	0.64	1.75e-40	Mortality in heart failure;
LIHC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.39	-0.37	1.16e-12	Schizophrenia;
LIHC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg11062466	chr8:58055876	NA	0.49	6.4	0.33	5.04e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-7.58	-0.38	3.23e-13	Prudent dietary pattern;
LIHC	cis	rs3823572	0.564	rs2953623	chr7:133659410	C/G	cg03336402	chr7:133662267	EXOC4	-0.47	-5.82	-0.3	1.38e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs847649	0.961	rs7456502	chr7:102596022	C/A	cg18108683	chr7:102477205	FBXL13	0.48	7.54	0.38	4.18e-13	Morning vs. evening chronotype;
LIHC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.85	-14.12	-0.61	5.42e-36	Headache;
LIHC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.53	-7.8	-0.39	7.78e-14	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.89	-0.35	2.62e-11	Diabetic kidney disease;
LIHC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg01256987	chr12:42539512	GXYLT1	-0.35	-5.83	-0.3	1.31e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-6.17	-0.32	1.96e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg11618577	chr2:27665543	KRTCAP3	-0.44	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LIHC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.49	-6.78	-0.34	5.14e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-8.92	-0.43	2.85e-17	Gut microbiome composition (summer);
LIHC	cis	rs3731827	0.511	rs14976	chr2:85818886	C/T	cg16865965	chr2:85811662	VAMP5	0.42	5.94	0.31	7.04e-9	Prostate cancer;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04167819	chr14:73395839	DCAF4	0.4	6.1	0.31	2.88e-9	Bilirubin levels;
LIHC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.68	0.5	3.47e-23	Platelet count;
LIHC	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	13.57	0.59	7.09e-34	Coffee consumption (cups per day);
LIHC	cis	rs28829049	0.536	rs12405382	chr1:19548981	C/T	cg13387374	chr1:19411106	UBR4	0.42	6.19	0.32	1.74e-9	QRS duration in Tripanosoma cruzi seropositivity;
LIHC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg01256987	chr12:42539512	GXYLT1	-0.35	-5.82	-0.3	1.35e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg24203234	chr3:128598194	ACAD9	0.45	6.29	0.32	9.77e-10	IgG glycosylation;
LIHC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.47	7.57	0.38	3.42e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.5	-6.63	-0.34	1.33e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs2242116	0.900	rs1001284	chr3:46933960	C/G	cg23352942	chr3:46931381	PTH1R	-0.32	-8.37	-0.41	1.5e-15	Birth weight;
LIHC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg07706471	chr12:123319906	HIP1R	-0.59	-7.21	-0.36	3.61e-12	Schizophrenia;
LIHC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg18944383	chr4:111397179	ENPEP	0.27	6.96	0.35	1.78e-11	Height;
LIHC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.44	-7.78	-0.39	8.74e-14	Aortic root size;
LIHC	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg19752551	chr11:57585705	CTNND1	-0.49	-6.8	-0.35	4.67e-11	Schizophrenia;
LIHC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.49	6.83	0.35	4.01e-11	Morning vs. evening chronotype;
LIHC	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg20607798	chr8:58055168	NA	0.59	6.9	0.35	2.57e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg06634786	chr22:41940651	POLR3H	-0.53	-5.98	-0.31	5.71e-9	Neuroticism;
LIHC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	5.93	0.31	7.45e-9	Electroencephalogram traits;
LIHC	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.53	5.79	0.3	1.57e-8	IgG glycosylation;
LIHC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.92	16.51	0.67	1.98e-45	Colorectal cancer;
LIHC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.67	7.02	0.36	1.17e-11	Diabetic kidney disease;
LIHC	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.55	10.4	0.49	3.52e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg14580859	chr9:123691850	NA	0.38	6.55	0.33	2.08e-10	Rheumatoid arthritis;
LIHC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.98	0.4	2.19e-14	Tonsillectomy;
LIHC	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.53	-8.7	-0.43	1.4e-16	Blood metabolite levels;
LIHC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06634786	chr22:41940651	POLR3H	0.57	6.25	0.32	1.23e-9	Vitiligo;
LIHC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.72	-14.08	-0.61	7.77e-36	Height;
LIHC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	9.29	0.45	1.81e-18	Hip circumference adjusted for BMI;
LIHC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.16	0.68	4.59e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.07	-0.31	3.36e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg10810860	chr8:144639591	GSDMD	-0.44	-5.8	-0.3	1.52e-8	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs9513627	0.831	rs7319727	chr13:100125541	A/T	cg25919922	chr13:100150906	NA	-0.76	-6.66	-0.34	1.07e-10	Obesity-related traits;
LIHC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.47	-6.91	-0.35	2.45e-11	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg10790698	chr19:18539756	SSBP4	-0.35	-7.43	-0.37	8.68e-13	Breast cancer;
LIHC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.61	-5.83	-0.3	1.25e-8	Neutrophil percentage of white cells;
LIHC	cis	rs249954	0.559	rs35586	chr16:23677006	A/G	cg01460202	chr16:23706506	ERN2	0.36	6.0	0.31	5.08e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.58	-8.56	-0.42	3.78e-16	Mean platelet volume;Platelet distribution width;
LIHC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-23.58	-0.79	1.11e-73	Height;
LIHC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-8.91	-0.43	3e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.54	-8.83	-0.43	5.4e-17	Cognitive function;
LIHC	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.78	13.14	0.58	3.32e-32	Coronary artery disease;
LIHC	cis	rs4450131	0.618	rs3781452	chr10:126355129	A/G	cg20435097	chr10:126320824	FAM53B	0.59	10.99	0.51	2.84e-24	White blood cell count (basophil);
LIHC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg07451762	chr16:28383216	NA	0.36	6.66	0.34	1.08e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10687131	chr2:20871002	GDF7	-0.37	-7.11	-0.36	6.91e-12	Abdominal aortic aneurysm;
LIHC	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.5	-6.32	-0.32	8.24e-10	Heschl's gyrus morphology;
LIHC	cis	rs7534824	0.625	rs6692186	chr1:101470217	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	6.74	0.34	6.76e-11	Refractive astigmatism;
LIHC	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.41	-6.77	-0.34	5.62e-11	Schizophrenia;
LIHC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg00091569	chr3:40428383	ENTPD3	0.39	6.74	0.34	6.6e-11	Renal cell carcinoma;
LIHC	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.26	0.55	6.97e-29	Eye color traits;
LIHC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06656553	chr16:89960601	TCF25	-0.47	-6.01	-0.31	4.87e-9	Skin colour saturation;
LIHC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.78	15.17	0.63	4.07e-40	Mortality in heart failure;
LIHC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-7.1	-0.36	7.08e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.35	0.49	5.1e-22	Hypertriglyceridemia;
LIHC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.84	13.57	0.59	7.17e-34	Glomerular filtration rate (creatinine);
LIHC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.67	11.96	0.54	8.61e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.63	-9.78	-0.47	4.29e-20	Uric acid clearance;
LIHC	cis	rs3814244	0.528	rs2906859	chr12:68396135	C/T	cg15249341	chr12:68405565	NA	-0.34	-6.9	-0.35	2.52e-11	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg16479474	chr6:28041457	NA	0.38	6.24	0.32	1.29e-9	Parkinson's disease;
LIHC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.66	9.31	0.45	1.65e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg07817648	chr10:79422355	NA	-0.3	-6.4	-0.33	5.15e-10	Mortality in heart failure;
LIHC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.4	7.35	0.37	1.52e-12	Schizophrenia;
LIHC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg16586182	chr3:47516702	SCAP	-0.47	-8.5	-0.42	6.1e-16	Colorectal cancer;
LIHC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	0.77	7.48	0.38	6.2e-13	Type 2 diabetes nephropathy;
LIHC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.59	-8.59	-0.42	3.12e-16	Prostate cancer;
LIHC	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg14558114	chr2:88469736	THNSL2	0.65	6.85	0.35	3.53e-11	Plasma clusterin levels;
LIHC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	0.96	9.44	0.45	6.11e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.19	-0.48	1.85e-21	Chronic sinus infection;
LIHC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.81	9.89	0.47	1.82e-20	Morning vs. evening chronotype;
LIHC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.83	14.41	0.61	4e-37	Aortic root size;
LIHC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg12698662	chr3:15914712	MIR563	-0.4	-7.41	-0.37	9.96e-13	Mean platelet volume;
LIHC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.57	0.56	4.76e-30	Schizophrenia;
LIHC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.92	11.63	0.53	1.47e-26	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.55	-7.58	-0.38	3.38e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.79	10.19	0.48	1.77e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-1.01	-18.1	-0.7	7.56e-52	Tonsillectomy;
LIHC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.48	-8.69	-0.43	1.55e-16	Colorectal cancer;
LIHC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.98	-13.64	-0.59	4.09e-34	Cognitive test performance;
LIHC	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-0.67	-6.87	-0.35	2.97e-11	Coronary artery disease;
LIHC	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.92	-11.55	-0.53	2.73e-26	HIV-1 control;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg08943361	chr16:56462172	NA	0.37	6.22	0.32	1.48e-9	Immature fraction of reticulocytes;
LIHC	cis	rs611744	0.967	rs603571	chr8:109213893	A/C	cg18478394	chr8:109455254	TTC35	0.39	6.84	0.35	3.7e-11	Dupuytren's disease;
LIHC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.91	-0.35	2.39e-11	Coronary artery disease;
LIHC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	7.66	0.38	1.95e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.78	0.34	5.43e-11	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg00091569	chr3:40428383	ENTPD3	0.39	6.74	0.34	6.75e-11	Renal cell carcinoma;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg14585611	chr2:175260420	CIR1;SCRN3	-0.4	-6.19	-0.32	1.69e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.86	14.25	0.61	1.76e-36	Colorectal cancer;
LIHC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-8.12	-0.4	8.74e-15	Putamen volume;
LIHC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg21584241	chr15:63341463	TPM1	-0.38	-5.74	-0.3	2.14e-8	Platelet count;
LIHC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg13395646	chr4:1353034	KIAA1530	-0.68	-9.52	-0.46	3.23e-19	Obesity-related traits;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10106725	chr4:3071494	NA	-0.47	-7.33	-0.37	1.63e-12	Lung function (FEV1/FVC);
LIHC	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.93	11.81	0.54	3.03e-27	Coronary artery disease;
LIHC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.9	-18.8	-0.71	1.14e-54	Height;
LIHC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.34	-18.97	-0.72	2.55e-55	Gout;
LIHC	cis	rs365132	0.840	rs58400555	chr5:176454081	A/T	cg16309518	chr5:176445507	NA	-0.59	-11.44	-0.53	6.84e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg13753209	chr17:57696993	CLTC	0.74	11.66	0.53	1.11e-26	Hemoglobin concentration;
LIHC	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.52	6.43	0.33	4.29e-10	Breast cancer;
LIHC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.56	-0.33	2.01e-10	Mean corpuscular volume;
LIHC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.73	-9.02	-0.44	1.33e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg16586182	chr3:47516702	SCAP	-0.51	-9.23	-0.45	2.81e-18	Colorectal cancer;
LIHC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg03037974	chr15:76606532	NA	-0.61	-10.21	-0.48	1.55e-21	Blood metabolite levels;
LIHC	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.43	-5.91	-0.3	8.3e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg01685246	chr16:30538016	ZNF768	0.41	6.56	0.33	2.01e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7224737	0.673	rs11079035	chr17:40289012	C/T	cg20291162	chr17:40259547	DHX58	-0.42	-6.0	-0.31	5.13e-9	Fibrinogen levels;
LIHC	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg11952622	chr19:58962976	ZNF324B	0.49	7.24	0.36	3.08e-12	Uric acid clearance;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06713199	chr3:28390809	AZI2	0.4	6.21	0.32	1.56e-9	Pancreatic cancer;
LIHC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg04155231	chr12:9217510	LOC144571	0.31	5.81	0.3	1.42e-8	Sjögren's syndrome;
LIHC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg17135325	chr3:160939158	NMD3	0.52	7.54	0.38	4.16e-13	Parkinson's disease;
LIHC	cis	rs6973256	0.604	rs6975134	chr7:133531432	T/C	cg10665199	chr7:133106180	EXOC4	0.34	5.77	0.3	1.82e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.41	6.04	0.31	3.99e-9	Menopause (age at onset);
LIHC	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.8	14.2	0.61	2.66e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.99	19.77	0.73	1.43e-58	Intelligence (multi-trait analysis);
LIHC	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg19875535	chr5:140030758	IK	-0.36	-5.89	-0.3	9.44e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.91	11.5	0.53	4.09e-26	Coronary artery disease;
LIHC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.63	12.31	0.55	4.3e-29	Gestational age at birth (maternal effect);
LIHC	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.55	-8.4	-0.41	1.18e-15	Blood protein levels;
LIHC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.96	16.28	0.66	1.58e-44	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.42	6.87	0.35	3.01e-11	Menopause (age at onset);
LIHC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.38	-5.89	-0.3	9.28e-9	Alcohol dependence;
LIHC	cis	rs12022452	0.556	rs11208298	chr1:40978878	A/G	cg25568243	chr1:40974465	DEM1	0.45	6.09	0.31	2.95e-9	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs6594499	1.000	rs1438673	chr5:110467499	C/T	cg04022379	chr5:110408740	TSLP	0.4	6.21	0.32	1.57e-9	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.41	5.74	0.3	2.09e-8	Tonsillectomy;
LIHC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.86e-16	Motion sickness;
LIHC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	8.21	0.41	4.72e-15	Tonsillectomy;
LIHC	cis	rs807029	0.533	rs12571302	chr10:102742763	C/A	cg17130504	chr10:102756923	LZTS2	0.56	7.77	0.39	9.27e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg01364799	chr7:75623366	TMEM120A	-0.51	-7.81	-0.39	6.99e-14	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7238033	0.560	rs8083653	chr18:43315027	T/C	cg20610511	chr18:43302872	SLC14A1	0.4	6.64	0.34	1.24e-10	Bladder cancer;
LIHC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.5	-0.42	6.02e-16	Total cholesterol levels;
LIHC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.36	5.87	0.3	1.06e-8	Electroencephalogram traits;
LIHC	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg15192750	chr16:69999425	NA	-0.45	-7.1	-0.36	7.42e-12	IgE levels;
LIHC	cis	rs7551222	0.646	rs10900590	chr1:204451086	C/T	cg20240347	chr1:204465584	NA	-0.33	-6.81	-0.35	4.38e-11	Schizophrenia;
LIHC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.09	0.4	1.02e-14	Lymphocyte counts;
LIHC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg18121669	chr1:26560928	CCDC21	0.5	7.99	0.4	2.04e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2599510	0.811	rs2754523	chr2:32837110	A/G	cg02381751	chr2:32503542	YIPF4	0.49	6.84	0.35	3.57e-11	Interleukin-18 levels;
LIHC	cis	rs67981189	0.593	rs8006046	chr14:71498991	A/G	cg15816911	chr14:71606274	NA	0.42	6.84	0.35	3.7e-11	Schizophrenia;
LIHC	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-6.59	-0.34	1.63e-10	Granulocyte percentage of myeloid white cells;
LIHC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-8.95	-0.44	2.23e-17	Platelet distribution width;
LIHC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.64	-8.53	-0.42	4.8e-16	Motion sickness;
LIHC	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.36	6.91	0.35	2.34e-11	Multiple sclerosis;
LIHC	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.54	8.05	0.4	1.34e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs10801727	0.582	rs9428044	chr1:90005159	A/C	cg15422784	chr1:90023713	LRRC8B	-0.44	-6.05	-0.31	3.77e-9	Parental extreme longevity (95 years and older);
LIHC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.75	0.62	1.8e-38	Prudent dietary pattern;
LIHC	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.65	0.38	2.08e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg14784868	chr12:69753453	YEATS4	-0.54	-7.67	-0.38	1.77e-13	Response to diuretic therapy;
LIHC	cis	rs8053891	0.756	rs35259348	chr16:72003952	G/C	cg01557791	chr16:72042693	DHODH	-0.5	-7.18	-0.36	4.4e-12	Coronary artery disease;
LIHC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg02376097	chr19:46275166	DMPK	-0.48	-7.71	-0.38	1.34e-13	Coronary artery disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25750404	chr12:6579648	VAMP1	0.41	6.28	0.32	1.04e-9	Cognitive function;
LIHC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	9.48	0.46	4.32e-19	Lymphocyte counts;
LIHC	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg20636351	chr8:55087400	NA	-0.34	-6.87	-0.35	3.04e-11	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs1664789	1.000	rs1628025	chr5:53282682	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.48	-7.64	-0.38	2.15e-13	Waist circumference adjusted for body mass index;
LIHC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-8.45	-0.42	8.23e-16	Body mass index;
LIHC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg00204512	chr16:28754710	NA	0.35	6.49	0.33	3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7534824	0.625	rs12569251	chr1:101372040	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	6.96	0.35	1.76e-11	Refractive astigmatism;
LIHC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.38e-17	Recombination rate (females);
LIHC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg07451762	chr16:28383216	NA	0.34	6.36	0.33	6.48e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23334365	chr11:67806337	TCIRG1	0.44	6.93	0.35	2.14e-11	Lung function (FEV1/FVC);
LIHC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.04	0.31	3.94e-9	Morning vs. evening chronotype;
LIHC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.3	-5.87	-0.3	1.04e-8	Colorectal cancer;
LIHC	cis	rs2438150	1	rs2438150	chr5:122199196	C/T	cg18764291	chr5:122110994	SNX2	0.36	6.07	0.31	3.47e-9	Plateletcrit;
LIHC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.83	7.5	0.38	5.52e-13	Lymphocyte counts;
LIHC	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.91	11.78	0.54	3.91e-27	Coronary artery disease;
LIHC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.39	5.84	0.3	1.23e-8	Longevity;Endometriosis;
LIHC	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.79	11.96	0.54	8.58e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.47	-6.86	-0.35	3.21e-11	Aortic root size;
LIHC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	5.8e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.98	-0.35	1.51e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	0.85	7.43	0.37	8.5e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	ch.11.42038R	chr11:967971	AP2A2	0.56	10.09	0.48	4.1e-21	Alzheimer's disease (late onset);
LIHC	cis	rs4668356	0.892	rs1863679	chr2:172017906	C/T	cg13882835	chr2:172017928	TLK1	0.46	6.23	0.32	1.38e-9	Cognitive performance;
LIHC	cis	rs9790314	0.638	rs6441339	chr3:160619683	T/G	cg03342759	chr3:160939853	NMD3	0.54	7.08	0.36	8.12e-12	Morning vs. evening chronotype;
LIHC	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.7	-6.21	-0.32	1.53e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LIHC	trans	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg13698153	chr12:118541722	VSIG10	-0.58	-6.23	-0.32	1.38e-9	Vitiligo;
LIHC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.63	-0.5	5.36e-23	Hemoglobin concentration;
LIHC	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-6.86	-0.35	3.22e-11	Metabolite levels;
LIHC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.73	0.39	1.21e-13	Lymphocyte counts;
LIHC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	trans	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg16088116	chr21:44841560	SIK1	-0.4	-6.23	-0.32	1.4e-9	Coronary artery disease;
LIHC	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.37	-0.33	6.08e-10	Body mass index;
LIHC	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg23091122	chr1:110024289	SYPL2	-0.48	-6.54	-0.33	2.3e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.74	-9.34	-0.45	1.28e-18	Mean platelet volume;
LIHC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08392591	chr16:89556376	ANKRD11	0.39	5.78	0.3	1.71e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg13628971	chr7:2884303	GNA12	0.44	7.73	0.39	1.22e-13	Height;
LIHC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.78	8.57	0.42	3.68e-16	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg18887096	chr2:219472410	PLCD4	0.37	5.78	0.3	1.64e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.58	8.48	0.42	6.76e-16	IgE levels in asthmatics (D.p. specific);
LIHC	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.5	-9.05	-0.44	1.13e-17	Atrioventricular conduction;
LIHC	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.39	5.9	0.3	8.87e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.37	0.41	1.45e-15	Multiple sclerosis;
LIHC	trans	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg16088116	chr21:44841560	SIK1	-0.39	-6.08	-0.31	3.12e-9	Pulmonary function;
LIHC	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg07645718	chr20:61493192	TCFL5	0.78	6.12	0.31	2.56e-9	Obesity-related traits;
LIHC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	1.0	11.72	0.54	6.83e-27	Red blood cell traits;
LIHC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg05564831	chr3:52568323	NT5DC2	0.38	6.16	0.32	2.09e-9	Bipolar disorder;
LIHC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.91	16.69	0.67	3.58e-46	Menopause (age at onset);
LIHC	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.73	11.97	0.54	8.05e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-5.78	-0.3	1.65e-8	Vitiligo;
LIHC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.41	-0.49	3.04e-22	Platelet count;
LIHC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.38	-0.56	2.41e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.38	6.95	0.35	1.8e-11	IgG glycosylation;
LIHC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg13535736	chr9:111863775	C9orf5	-0.38	-5.73	-0.3	2.21e-8	Menarche (age at onset);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25508545	chr19:49467065	FTL	0.4	6.47	0.33	3.34e-10	Cognitive function;
LIHC	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg18898632	chr2:242989856	NA	-0.47	-6.52	-0.33	2.58e-10	Obesity-related traits;
LIHC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.89	-18.34	-0.7	8.22e-53	Height;
LIHC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02985541	chr2:219472218	PLCD4	0.45	8.68	0.42	1.62e-16	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.73e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg12751644	chr20:60527061	NA	-0.35	-5.85	-0.3	1.15e-8	Body mass index;
LIHC	cis	rs10838687	0.800	rs3729802	chr11:47354068	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.81	-0.3	1.45e-8	Proinsulin levels;
LIHC	cis	rs11031096	0.655	rs56172516	chr11:4182004	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	11.39	0.52	1.08e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7616330	0.836	rs17008114	chr3:71045000	A/C	cg01511742	chr3:71112437	FOXP1	-0.44	-6.16	-0.32	2.08e-9	QT interval;
LIHC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg22842854	chr12:123319900	HIP1R	-0.72	-9.43	-0.45	6.2800000000000005e-19	Schizophrenia;
LIHC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg20607798	chr8:58055168	NA	0.69	7.83	0.39	6.13e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.8	0.6	9.84e-35	Primary sclerosing cholangitis;
LIHC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	0.79	11.86	0.54	2.1e-27	Monocyte percentage of white cells;
LIHC	cis	rs7005606	0.532	rs6981660	chr8:32298476	A/G	cg24995904	chr8:32462945	NRG1	0.39	5.78	0.3	1.71e-8	Hirschsprung disease;
LIHC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.51	6.26	0.32	1.17e-9	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.48	8.82	0.43	6.1e-17	Testicular germ cell tumor;
LIHC	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.37	-0.33	6.08e-10	Metabolite levels;
LIHC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.44	6.37	0.33	5.98e-10	Aortic root size;
LIHC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg14092571	chr14:90743983	NA	0.41	6.57	0.33	1.91e-10	Mortality in heart failure;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20923575	chr17:56596273	MTMR4	0.42	6.58	0.34	1.8e-10	Cognitive function;
LIHC	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg20991723	chr1:152506922	NA	0.54	9.07	0.44	9.25e-18	Hair morphology;
LIHC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	10.06	0.48	4.94e-21	Alzheimer's disease;
LIHC	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg03934865	chr2:198174659	NA	-0.47	-6.84	-0.35	3.6e-11	Dermatomyositis;
LIHC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.42	-6.81	-0.35	4.45e-11	Glomerular filtration rate (creatinine);
LIHC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.59	-6.61	-0.34	1.5e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.67	0.38	1.75e-13	Prudent dietary pattern;
LIHC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg03013999	chr17:37608204	MED1	-0.35	-5.81	-0.3	1.4e-8	Glomerular filtration rate (creatinine);
LIHC	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.52	8.02	0.4	1.69e-14	Breast size;
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.72	0.57	1.27e-30	Prudent dietary pattern;
LIHC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.46	7.28	0.37	2.38e-12	Monocyte count;
LIHC	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.42	6.85	0.35	3.41e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-5.9	-0.3	8.6e-9	Height;
LIHC	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.71	-11.03	-0.51	2.07e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.25	0.58	1.27e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs16858210	0.837	rs1879254	chr3:183609471	C/T	cg25686905	chr3:183603175	PARL	-0.49	-9.09	-0.44	8.39e-18	Menopause (age at onset);
LIHC	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.07	-0.31	3.34e-9	Resting heart rate;
LIHC	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	0.58	7.92	0.39	3.41e-14	Obesity-related traits;
LIHC	cis	rs2574704	0.651	rs2616552	chr3:11666798	G/T	cg15876825	chr3:11651881	VGLL4	0.41	6.15	0.32	2.19e-9	Body mass index;
LIHC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.36	5.78	0.3	1.66e-8	Lung cancer;
LIHC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.78	12.56	0.56	5.33e-30	Longevity;
LIHC	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.56	7.72	0.39	1.29e-13	Total cholesterol levels;
LIHC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.79	-0.34	4.85e-11	Gut microbiome composition (summer);
LIHC	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.62	9.88	0.47	1.98e-20	Monocyte count;
LIHC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	8.74	0.43	1.09e-16	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	8.41	0.41	1.1e-15	Schizophrenia;
LIHC	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg12292205	chr6:26970375	C6orf41	0.43	7.13	0.36	6.03e-12	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16717988	chr16:89715857	CHMP1A	0.45	6.81	0.35	4.53e-11	Longevity;
LIHC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.51	-7.27	-0.37	2.53e-12	Menopause (age at onset);
LIHC	cis	rs4407350	1.000	rs5765725	chr22:44921706	A/C	cg26276947	chr22:44892394	LDOC1L	0.35	6.42	0.33	4.52e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	14.47	0.62	2.31e-37	Coffee consumption (cups per day);
LIHC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.76	9.57	0.46	2.17e-19	Primary sclerosing cholangitis;
LIHC	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.58	-8.59	-0.42	3.21e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.85	-12.38	-0.56	2.42e-29	Tonsillectomy;
LIHC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.61	-8.98	-0.44	1.89e-17	Obesity-related traits;
LIHC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.64	10.1	0.48	3.55e-21	Intelligence (multi-trait analysis);
LIHC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.53	7.69	0.38	1.53e-13	Height;
LIHC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.57	-0.38	3.59e-13	Bipolar disorder and schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03157738	chr19:11308118	KANK2	0.38	6.14	0.32	2.3e-9	Cognitive function;
LIHC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.43	7.1	0.36	7.31e-12	Response to temozolomide;
LIHC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.42	-5.97	-0.31	5.96e-9	Systemic lupus erythematosus;
LIHC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.88	17.84	0.69	8.88e-51	Height;
LIHC	cis	rs8084351	0.599	rs11082970	chr18:50681121	G/T	cg24270629	chr18:50823537	DCC	-0.46	-6.9	-0.35	2.49e-11	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.57	7.62	0.38	2.58e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs10838687	0.736	rs830083	chr11:47254051	G/C	cg25783544	chr11:47291846	MADD	-0.47	-5.87	-0.3	1.05e-8	Proinsulin levels;
LIHC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.81	12.22	0.55	9.52e-29	Motion sickness;
LIHC	cis	rs8084351	0.557	rs1821075	chr18:50760660	G/A	cg24270629	chr18:50823537	DCC	-0.5	-7.18	-0.36	4.27e-12	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.66	9.79	0.47	4.02e-20	Menopause (age at onset);
LIHC	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.53	7.82	0.39	6.49e-14	Diastolic blood pressure;
LIHC	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.41	-6.4	-0.33	5.05e-10	Neutrophil percentage of white cells;
LIHC	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg26116260	chr4:7069785	GRPEL1	-0.99	-12.08	-0.55	3.19e-28	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2625529	0.607	rs2912231	chr15:72567957	G/T	cg16672083	chr15:72433130	SENP8	-0.3	-5.74	-0.3	2.12e-8	Red blood cell count;
LIHC	cis	rs4728302	0.934	rs2971963	chr7:133641505	A/G	cg03336402	chr7:133662267	EXOC4	0.38	5.75	0.3	2.03e-8	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.66	11.2	0.52	5.23e-25	Diisocyanate-induced asthma;
LIHC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-8.97	-0.44	1.92e-17	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.37	9.68	0.46	9.75e-20	Asthma (sex interaction);
LIHC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-11.64	-0.53	1.29e-26	Platelet distribution width;
LIHC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.39	0.52	1.06e-25	Tonsillectomy;
LIHC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.38	-8.55	-0.42	4.22e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg15155738	chr12:121454335	C12orf43	-0.44	-6.36	-0.33	6.53e-10	Subjective well-being;Cardiovascular disease risk factors;
LIHC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.68	0.38	1.68e-13	Lymphocyte counts;
LIHC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg25281562	chr12:121454272	C12orf43	0.33	5.79	0.3	1.62e-8	N-glycan levels;
LIHC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg04727924	chr7:799746	HEATR2	0.41	6.25	0.32	1.25e-9	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs9649465	0.967	rs3757505	chr7:123391641	C/T	cg03229431	chr7:123269106	ASB15	-0.38	-8.04	-0.4	1.5e-14	Migraine;
LIHC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.9	-13.95	-0.6	2.59e-35	Body mass index;
LIHC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.66	8.42	0.41	1.05e-15	Initial pursuit acceleration;
LIHC	cis	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg03999872	chr20:62272968	STMN3	-0.45	-6.77	-0.34	5.56e-11	Atopic dermatitis;
LIHC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-6.93	-0.35	2.05e-11	Migraine;Coronary artery disease;
LIHC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.43	6.6	0.34	1.6e-10	Height;
LIHC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.45	6.36	0.33	6.64e-10	Asthma;
LIHC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.49	-7.7	-0.38	1.44e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	7.29	0.37	2.14e-12	Red cell distribution width;Reticulocyte count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg03306564	chr11:64902099	SYVN1	0.4	6.47	0.33	3.48e-10	Cognitive function;
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg02993280	chr1:107599747	PRMT6	0.61	9.9	0.47	1.7e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.5	-6.46	-0.33	3.56e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.42	-5.76	-0.3	1.83e-8	Total body bone mineral density;
LIHC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.44	0.37	7.97e-13	Bipolar disorder;
LIHC	cis	rs11663156	0.804	rs12604606	chr18:50901856	A/G	cg24270629	chr18:50823537	DCC	-0.52	-7.0	-0.35	1.38e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.46	-11.98	-0.54	7.67e-28	Hip circumference adjusted for BMI;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg01185801	chr11:65265397	MALAT1	0.43	6.8	0.35	4.76e-11	Cognitive function;
LIHC	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	6.5	0.33	2.81e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LIHC	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.74	13.85	0.6	6.36e-35	Height;
LIHC	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.7	14.59	0.62	8.35e-38	Schizophrenia;
LIHC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.51	6.7	0.34	8.62e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.63	-9.35	-0.45	1.18e-18	White matter hyperintensity burden;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	24.39	0.8	7.99e-77	Prudent dietary pattern;
LIHC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.33	5.74	0.3	2.08e-8	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	1.1	12.24	0.55	8.25e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.67	13.28	0.58	9.75e-33	Leprosy;
LIHC	cis	rs8020095	0.571	rs2281676	chr14:67638455	C/G	cg03487553	chr14:67822707	ATP6V1D	0.33	5.81	0.3	1.45e-8	Depression (quantitative trait);
LIHC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	11.43	0.53	7.64e-26	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg02272795	chr19:15279244	NOTCH3	-0.32	-5.76	-0.3	1.84e-8	Pulse pressure;
LIHC	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg18887096	chr2:219472410	PLCD4	0.34	6.0	0.31	4.93e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg21518248	chr2:162101506	NA	-0.38	-5.72	-0.3	2.27e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.32	-5.94	-0.31	6.88e-9	Body mass index;
LIHC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.81	-9.13	-0.44	6.04e-18	Bone mineral density;
LIHC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.61	8.41	0.41	1.09e-15	Coronary artery disease;
LIHC	cis	rs72829446	0.530	rs11869864	chr17:7407766	C/A	cg02795151	chr17:7402630	POLR2A	0.55	6.39	0.33	5.45e-10	Androgen levels;
LIHC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.71	10.6	0.5	6.78e-23	Aortic root size;
LIHC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs3770081	1.000	rs17618001	chr2:86289303	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.84	-8.59	-0.42	3.03e-16	Facial emotion recognition (sad faces);
LIHC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-10.52	-0.49	1.3e-22	Platelet count;
LIHC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.44	-8.34	-0.41	1.87e-15	Neurofibrillary tangles;
LIHC	cis	rs3768617	0.565	rs10752901	chr1:183089327	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.4	0.49	3.49e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.81	0.3	1.41e-8	Menopause (age at onset);
LIHC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.68	12.97	0.57	1.41e-31	Systemic lupus erythematosus;
LIHC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.45	6.6	0.34	1.59e-10	Colorectal cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00170564	chr12:107714106	BTBD11	0.49	7.23	0.36	3.21e-12	Pancreatic cancer;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg00091569	chr3:40428383	ENTPD3	-0.39	-6.61	-0.34	1.51e-10	Renal cell carcinoma;
LIHC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.91	-0.3	8.13e-9	IgG glycosylation;
LIHC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	6.08	0.31	3.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.42	6.39	0.33	5.44e-10	Alzheimer's disease (survival time);
LIHC	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.83	-0.35	3.88e-11	Prevalent atrial fibrillation;
LIHC	cis	rs17152411	1.000	rs41303609	chr10:126670613	G/T	cg07906193	chr10:126599966	NA	0.5	7.89	0.39	4e-14	Height;
LIHC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13126279	chr21:47581558	C21orf56	-0.38	-6.02	-0.31	4.62e-9	Testicular germ cell tumor;
LIHC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg25894440	chr7:65020034	NA	0.48	5.83	0.3	1.27e-8	Diabetic kidney disease;
LIHC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	10.89	0.51	6.69e-24	Alzheimer's disease (late onset);
LIHC	trans	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg00420450	chr8:22132641	PIWIL2	0.62	6.47	0.33	3.3e-10	Obesity-related traits;
LIHC	trans	rs2352908	0.786	rs8006912	chr14:49427753	T/C	cg16568472	chr20:3190600	ITPA	-0.46	-6.08	-0.31	3.27e-9	Social communication problems;
LIHC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg12661370	chr5:149340060	SLC26A2	0.48	6.49	0.33	2.96e-10	HIV-1 control;
LIHC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.35	-7.08	-0.36	8.46e-12	Body mass index;
LIHC	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg27386326	chr11:61587980	NA	0.69	14.92	0.63	4.15e-39	Trans fatty acid levels;
LIHC	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.38	-5.74	-0.3	2.12e-8	Liver enzyme levels;
LIHC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	0.84	11.03	0.51	2.02e-24	Skin colour saturation;
LIHC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.92	-0.3	7.72e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.24e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.03	-0.31	4.14e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.49	-7.27	-0.37	2.46e-12	Mortality in heart failure;
LIHC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.64	7.32	0.37	1.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21747090	chr2:27597821	SNX17	-0.42	-6.22	-0.32	1.49e-9	Total body bone mineral density;
LIHC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.65	0.53	1.21e-26	Motion sickness;
LIHC	cis	rs700651	0.789	rs1147169	chr2:198901395	C/T	cg00792783	chr2:198669748	PLCL1	-0.44	-6.19	-0.32	1.72e-9	Intracranial aneurysm;
LIHC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg18944383	chr4:111397179	ENPEP	0.27	6.82	0.35	4.17e-11	Height;
LIHC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.38	-0.33	5.67e-10	Mean corpuscular volume;
LIHC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.65	6.97	0.35	1.63e-11	Alzheimer's disease;
LIHC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.81	16.78	0.67	1.6e-46	Gestational age at birth (maternal effect);
LIHC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.75	0.62	1.8e-38	Prudent dietary pattern;
LIHC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg04727924	chr7:799746	HEATR2	-0.59	-8.06	-0.4	1.3e-14	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.27	-6.81	-0.35	4.28e-11	Mean corpuscular volume;
LIHC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02359409	chr6:42947317	PEX6	-0.47	-6.23	-0.32	1.39e-9	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs1982963	0.950	rs2645750	chr14:52502792	C/A	cg10843707	chr14:52510701	NID2	-0.43	-7.18	-0.36	4.27e-12	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.92	0.39	3.47e-14	Motion sickness;
LIHC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.49	8.2	0.41	4.74e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg24112000	chr20:60950667	NA	-0.61	-9.78	-0.47	4.52e-20	Colorectal cancer;
LIHC	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-14.53	-0.62	1.32e-37	Mortality in heart failure;
LIHC	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-7.9	-0.39	3.76e-14	Morning vs. evening chronotype;
LIHC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	1.07	14.34	0.61	7.59e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs3736485	0.934	rs28393906	chr15:51867605	T/A	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1.02e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.19	0.32	1.75e-9	Schizophrenia;
LIHC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.63	11.35	0.52	1.44e-25	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.67	13.0	0.58	1.1e-31	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.37	7.3	0.37	1.98e-12	Growth-regulated protein alpha levels;
LIHC	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg26139080	chr11:47293733	MADD	-0.5	-8.36	-0.41	1.56e-15	HDL cholesterol;
LIHC	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.6	11.92	0.54	1.25e-27	Plateletcrit;Platelet count;
LIHC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.77	10.98	0.51	3.15e-24	Cerebrospinal P-tau181p levels;
LIHC	cis	rs12220238	1.000	rs10824151	chr10:76092179	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.05	0.31	3.86e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs4919087	0.590	rs1253401	chr10:99050270	G/A	cg25902810	chr10:99078978	FRAT1	-0.63	-7.09	-0.36	7.89e-12	Monocyte count;
LIHC	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg08992911	chr2:238395768	MLPH	0.62	6.54	0.33	2.3e-10	Prostate cancer;
LIHC	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg02795151	chr17:7402630	POLR2A	0.53	6.05	0.31	3.87e-9	Androgen levels;
LIHC	cis	rs151997	0.777	rs3846500	chr5:50254488	A/T	cg06027927	chr5:50259733	NA	-0.57	-8.12	-0.4	8.29e-15	Callous-unemotional behaviour;
LIHC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg14393609	chr7:65229607	NA	0.44	6.57	0.33	1.87e-10	Aortic root size;
LIHC	trans	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.79	0.54	3.68e-27	Motion sickness;
LIHC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.94	17.61	0.69	7.29e-50	Menopause (age at onset);
LIHC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	5.83	0.3	1.29e-8	Coronary artery disease;
LIHC	trans	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg10208301	chr11:6592745	DNHD1	0.47	6.75	0.34	6.43e-11	Coronary artery calcification;
LIHC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg02269571	chr22:50332266	NA	-0.66	-9.07	-0.44	9.22e-18	Schizophrenia;
LIHC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.45	-0.42	8.49e-16	Chronic sinus infection;
LIHC	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.32	-7.25	-0.36	2.84e-12	Cutaneous nevi;
LIHC	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg16275483	chr1:110013120	SYPL2	-0.5	-6.35	-0.32	6.94e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.44	7.56	0.38	3.85e-13	Mean corpuscular volume;
LIHC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg25894440	chr7:65020034	NA	-0.55	-6.33	-0.32	7.79e-10	Diabetic kidney disease;
LIHC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.44	5.99	0.31	5.44e-9	Initial pursuit acceleration;
LIHC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	8.77	0.43	8.5e-17	Calcium levels;
LIHC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.51	8.31	0.41	2.32e-15	Corneal astigmatism;
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21448741	chr8:58168803	NA	0.36	6.7	0.34	8.77e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.57	8.95	0.44	2.24e-17	Monocyte count;
LIHC	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.54	-0.38	4.21e-13	QT interval;
LIHC	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.73	11.22	0.52	4.4e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.27	-0.37	2.53e-12	Bipolar disorder;
LIHC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.92	10.84	0.51	9.75e-24	Plateletcrit;Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.68	-9.79	-0.47	4.04e-20	Initial pursuit acceleration;
LIHC	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg24112000	chr20:60950667	NA	-0.59	-6.24	-0.32	1.31e-9	Colorectal cancer;
LIHC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.64	11.09	0.51	1.28e-24	Menopause (age at onset);
LIHC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg14678744	chr13:113987030	GRTP1	0.37	6.28	0.32	1.02e-9	Thyroid cancer;
LIHC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.7	0.34	8.43e-11	Lung cancer;
LIHC	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-7.77	-0.39	9.54e-14	Alzheimer's disease (survival time);
LIHC	cis	rs4903214	0.895	rs11621800	chr14:74696753	A/G	cg11132536	chr14:74711944	VSX2	-0.24	-5.75	-0.3	2.03e-8	Inflammatory bowel disease;
LIHC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-6.93	-0.35	2.14e-11	Colorectal cancer;
LIHC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg19318889	chr4:1322082	MAEA	0.46	6.42	0.33	4.62e-10	Obesity-related traits;
LIHC	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.67	-9.97	-0.47	1.01e-20	Eosinophil percentage of white cells;
LIHC	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.04e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.07e-17	Severe influenza A (H1N1) infection;
LIHC	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.58	7.13	0.36	6.14e-12	Breast cancer;
LIHC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.49	7.56	0.38	3.71e-13	Cognitive function;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg23569120	chr2:25470883	DNMT3A	0.37	6.04	0.31	4.08e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.38	6.21	0.32	1.5e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs12986413	0.619	rs1859954	chr19:2145481	G/T	cg09261902	chr19:2140048	AP3D1	-0.36	-6.15	-0.32	2.14e-9	Height;
LIHC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.83	13.68	0.59	2.75e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.66	-0.34	1.06e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.64	9.34	0.45	1.24e-18	Menarche (age at onset);
LIHC	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.35	-8.12	-0.4	8.32e-15	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.55	0.42	4.12e-16	Schizophrenia;
LIHC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.59	0.38	3.16e-13	Vitiligo;
LIHC	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg24069376	chr3:38537580	EXOG	0.42	7.6	0.38	2.91e-13	Electrocardiographic conduction measures;
LIHC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.71	-0.43	1.34e-16	Cognitive function;
LIHC	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg10127483	chr1:110009974	SYPL2	0.49	6.02	0.31	4.55e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.5	0.59	1.38e-33	Diabetic kidney disease;
LIHC	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg18898632	chr2:242989856	NA	-0.46	-6.48	-0.33	3.16e-10	Obesity-related traits;
LIHC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.36	5.96	0.31	6.3e-9	Blood metabolite levels;
LIHC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.82	16.98	0.68	2.5e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs8081395	0.801	rs2777895	chr17:57879610	A/G	cg13753209	chr17:57696993	CLTC	-0.46	-7.1	-0.36	7.15e-12	White blood cell count;
LIHC	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.55	7.39	0.37	1.16e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.48	-7.07	-0.36	8.98e-12	QT interval;
LIHC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.78	-7.59	-0.38	3.16e-13	Diabetic retinopathy;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg17340655	chr8:38088874	DDHD2	-0.45	-6.08	-0.31	3.24e-9	Systolic blood pressure;
LIHC	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.07	0.36	8.61e-12	Mean platelet volume;
LIHC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.57	-7.92	-0.39	3.28e-14	Platelet count;
LIHC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.43	8.0	0.4	1.98e-14	Electrocardiographic conduction measures;
LIHC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.91	10.22	0.48	1.45e-21	Triglycerides;
LIHC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12016809	chr21:47604291	C21orf56	0.41	5.95	0.31	6.57e-9	Testicular germ cell tumor;
LIHC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.71	6.15	0.32	2.16e-9	Cognitive function;
LIHC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.42	6.04	0.31	3.98e-9	Osteoporosis;
LIHC	cis	rs4689642	0.666	rs4689658	chr4:7228171	A/G	cg21353189	chr4:7228343	SORCS2	-0.35	-6.06	-0.31	3.6e-9	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	6.72	0.34	7.56e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.81	-0.35	4.49e-11	Aortic root size;
LIHC	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12923728	chr3:195709715	SDHAP1	-0.74	-9.86	-0.47	2.43e-20	Pancreatic cancer;
LIHC	trans	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg17675199	chr6:35436792	RPL10A	0.34	6.5	0.33	2.78e-10	Coronary artery disease;
LIHC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.37	6.03	0.31	4.18e-9	Schizophrenia;
LIHC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.84	-13.02	-0.58	9.48e-32	Skin colour saturation;
LIHC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.6	0.46	1.74e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.85	-0.3	1.17e-8	Tuberculosis;
LIHC	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.33	-5.83	-0.3	1.3e-8	Lewy body disease;
LIHC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.25	6.12	0.31	2.53e-9	Age-related hearing impairment;
LIHC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg03929089	chr4:120376271	NA	-0.41	-6.1	-0.31	2.91e-9	HDL cholesterol;
LIHC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.75	14.87	0.63	6.5e-39	Height;
LIHC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-7.2	-0.36	3.79e-12	Schizophrenia;
LIHC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.85	15.23	0.64	2.39e-40	Aortic root size;
LIHC	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	0.63	10.97	0.51	3.44e-24	Pediatric autoimmune diseases;
LIHC	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.45	5.85	0.3	1.16e-8	Pulmonary function decline;
LIHC	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.65	-0.34	1.2e-10	Putamen volume;
LIHC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.22	-0.45	3.17e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.72	-0.47	6.92e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg10381502	chr11:71823885	C11orf51	-1.08	-9.2	-0.45	3.57e-18	Severe influenza A (H1N1) infection;
LIHC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21467203	chr3:49911342	NA	-0.46	-8.32	-0.41	2.17e-15	Intelligence (multi-trait analysis);
LIHC	trans	rs7874142	0.616	rs4072882	chr9:137687038	A/G	cg18109838	chr5:88185987	MEF2C	-0.35	-7.09	-0.36	7.79e-12	Longevity;
LIHC	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg09835421	chr16:68378352	PRMT7	-0.63	-6.85	-0.35	3.34e-11	Schizophrenia;
LIHC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg16736954	chr20:23401023	NAPB	-0.73	-8.55	-0.42	4.04e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	8.15	0.4	7.11e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.48	-7.31	-0.37	1.89e-12	Blood protein levels;
LIHC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg09555818	chr19:45449301	APOC2	-0.22	-6.35	-0.32	6.69e-10	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.89	0.57	2.96e-31	Prudent dietary pattern;
LIHC	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg07636037	chr3:49044803	WDR6	-0.63	-7.12	-0.36	6.23e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	6.27	0.32	1.08e-9	Bipolar disorder;
LIHC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.88	0.39	4.49e-14	Lung disease severity in cystic fibrosis;
LIHC	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg24112000	chr20:60950667	NA	0.45	7.26	0.37	2.64e-12	Colorectal cancer;
LIHC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.74	0.54	5.79e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs972578	1.000	rs738389	chr22:43332516	T/C	cg01576275	chr22:43409880	NA	-0.34	-6.07	-0.31	3.39e-9	Mean platelet volume;
LIHC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.2	-0.32	1.67e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.69	12.39	0.56	2.26e-29	Colorectal cancer;
LIHC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.88	-18.23	-0.7	2.42e-52	Height;
LIHC	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.69	0.34	8.88e-11	Systolic blood pressure;
LIHC	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.5	-9.67	-0.46	1e-19	LDL cholesterol levels;
LIHC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg26441486	chr22:50317300	CRELD2	0.35	6.33	0.32	7.65e-10	Schizophrenia;
LIHC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg07636037	chr3:49044803	WDR6	-0.81	-8.4	-0.41	1.2e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs62179067	0.708	rs17363057	chr2:179936172	A/C	cg20701897	chr2:179586761	TTN	0.53	5.81	0.3	1.45e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs7757419	0.877	rs7755620	chr6:34435189	T/C	cg17518776	chr6:34434842	PACSIN1	-0.3	-6.1	-0.31	2.86e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
LIHC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.03e-32	Psoriasis;
LIHC	cis	rs2834188	1.000	rs2026254	chr21:34688032	C/T	cg04842828	chr21:34696676	IFNAR1	0.45	6.13	0.31	2.36e-9	Narcolepsy;
LIHC	cis	rs11053548	0.538	rs11053556	chr12:10176062	C/T	cg04314261	chr12:10163030	CLEC12B	0.38	5.86	0.3	1.08e-8	Systolic blood pressure in sickle cell anemia;
LIHC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.63	11.0	0.51	2.63e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg23690444	chr14:81902736	NA	-0.44	-6.29	-0.32	9.92e-10	Night sleep phenotypes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg12181579	chr12:114312919	RBM19	0.41	6.15	0.32	2.15e-9	Longevity;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg00280220	chr17:61926910	NA	0.42	6.86	0.35	3.17e-11	Prudent dietary pattern;
LIHC	trans	rs783540	0.521	rs1259176	chr15:83270898	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.35	-0.32	7.01e-10	Schizophrenia;
LIHC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.83	14.78	0.62	1.41e-38	Aortic root size;
LIHC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.74	-9.78	-0.47	4.42e-20	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	1.07	16.07	0.66	1.07e-43	Breast cancer;
LIHC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-9.27	-0.45	2.19e-18	Blood protein levels;
LIHC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.63	-0.5	5.45e-23	Chronic sinus infection;
LIHC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg09597638	chr17:3907349	NA	-0.52	-6.71	-0.34	8.16e-11	Type 2 diabetes;
LIHC	cis	rs7551222	0.716	rs6679717	chr1:204560677	A/G	cg20240347	chr1:204465584	NA	-0.27	-5.8	-0.3	1.51e-8	Schizophrenia;
LIHC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.44	-6.3	-0.32	9.28e-10	Aortic root size;
LIHC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.72	0.3	2.37e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.59	10.33	0.49	5.93e-22	Dupuytren's disease;
LIHC	trans	rs7336933	0.866	rs4941411	chr13:42471498	T/C	cg13214892	chr20:39766451	PLCG1	-0.72	-6.04	-0.31	4.05e-9	Calcium levels;
LIHC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.65	8.36	0.41	1.62e-15	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.89	13.62	0.59	4.7e-34	Vitamin D levels;
LIHC	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg05714579	chr10:131428358	MGMT	0.39	6.28	0.32	1.05e-9	Response to temozolomide;
LIHC	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.57	-14.08	-0.61	7.68e-36	White blood cell count (basophil);
LIHC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.71	-8.81	-0.43	6.51e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg16583315	chr14:65563665	MAX	-0.39	-7.94	-0.39	2.93e-14	Obesity-related traits;
LIHC	cis	rs7602441	0.521	rs1434985	chr2:14767916	C/T	cg06545361	chr2:14773388	FAM84A	0.52	6.0	0.31	5.14e-9	Visceral adipose tissue adjusted for BMI;
LIHC	cis	rs17095355	1.000	rs12263484	chr10:111697255	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.98	-0.31	5.76e-9	Biliary atresia;
LIHC	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.46	-7.03	-0.36	1.14e-11	Multiple myeloma;
LIHC	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.98	0.31	5.51e-9	Asthma;
LIHC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.19	-0.52	5.46e-25	Primary sclerosing cholangitis;
LIHC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg25801113	chr15:45476975	SHF	0.38	6.37	0.33	5.95e-10	Uric acid levels;
LIHC	cis	rs10508774	1.000	rs1984072	chr10:32911013	C/T	cg01819863	chr10:32635814	EPC1	0.64	5.95	0.31	6.59e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.82	0.35	4.04e-11	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg02344993	chr17:57696989	CLTC	-0.57	-9.26	-0.45	2.38e-18	Hemoglobin concentration;
LIHC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.46	4.67e-19	Bipolar disorder;
LIHC	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.54	-8.46	-0.42	7.9e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.24	-16.09	-0.66	9.25e-44	Diabetic kidney disease;
LIHC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg07150772	chr14:90864620	CALM1	-0.42	-5.87	-0.3	1.03e-8	Gut microbiota (bacterial taxa);
LIHC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.44	6.63	0.34	1.3100000000000001e-10	Type 2 diabetes;
LIHC	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.65	5.98	0.31	5.57e-9	Morning vs. evening chronotype;
LIHC	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.26	0.37	2.64e-12	Migraine;Coronary artery disease;
LIHC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.04	-0.36	1.06e-11	Body mass index;
LIHC	cis	rs903552	1.000	rs11634912	chr15:102005510	A/G	cg19295451	chr15:102010161	PCSK6	-0.46	-6.32	-0.32	8.18e-10	Diabetic kidney disease;
LIHC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	10.82	0.51	1.15e-23	Colorectal cancer;
LIHC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg14067834	chr17:29058358	SUZ12P	0.71	6.98	0.35	1.57e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.46	-0.33	3.52e-10	Renal cell carcinoma;
LIHC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg18944383	chr4:111397179	ENPEP	0.27	7.05	0.36	9.99e-12	Height;
LIHC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.33	7.22	0.36	3.43e-12	Ulcerative colitis;
LIHC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg25364880	chr3:44379878	C3orf23	-0.58	-8.21	-0.41	4.69e-15	Depressive symptoms;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05617927	chr15:83654886	FAM103A1	0.37	6.22	0.32	1.48e-9	Cognitive function;
LIHC	cis	rs9888615	0.646	rs2296496	chr14:53380371	A/T	cg00686598	chr14:53173677	PSMC6	-0.45	-5.83	-0.3	1.3e-8	Systolic blood pressure;
LIHC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13198984	chr17:80129470	CCDC57	-0.33	-5.83	-0.3	1.26e-8	Life satisfaction;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05917732	chr6:152623304	SYNE1	-0.45	-6.36	-0.33	6.31e-10	Pancreatic cancer;
LIHC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg00049323	chr5:472564	LOC25845	0.35	5.85	0.3	1.14e-8	Cystic fibrosis severity;
LIHC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.57	8.87	0.43	4.18e-17	Uric acid clearance;
LIHC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.28	-5.89	-0.3	9.08e-9	Longevity;
LIHC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs7903847	0.656	rs11189208	chr10:99169172	C/G	cg08345082	chr10:99160200	RRP12	-0.36	-5.85	-0.3	1.14e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.29e-12	Bipolar disorder;
LIHC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.37	7.55	0.38	4.01e-13	Obesity-related traits;
LIHC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.46	6.19	0.32	1.76e-9	Major depressive disorder;
LIHC	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.46	1.15e-19	Corneal astigmatism;
LIHC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg24296786	chr1:45957014	TESK2	-0.52	-7.58	-0.38	3.3e-13	Platelet count;
LIHC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.63	7.04	0.36	1.03e-11	Alzheimer's disease;
LIHC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.87	15.86	0.65	7.31e-43	Dental caries;
LIHC	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.23	0.41	4.03e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.51	-7.16	-0.36	4.84e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22168489	chr12:122356033	WDR66	-0.42	-6.74	-0.34	6.88e-11	Mean corpuscular volume;
LIHC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg00809820	chr17:80708513	TBCD;FN3K	-0.33	-5.73	-0.3	2.16e-8	Glycated hemoglobin levels;
LIHC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg21466736	chr12:48725269	NA	-0.7	-10.87	-0.51	7.55e-24	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs11229555	0.609	rs11229451	chr11:58201687	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.51	-7.31	-0.37	1.88e-12	Body mass index;
LIHC	cis	rs757110	0.590	rs7484027	chr11:17368381	T/A	cg01251548	chr11:17372745	DKFZp686O24166	0.4	6.83	0.35	3.91e-11	Type 2 diabetes;
LIHC	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.44	8.31	0.41	2.23e-15	Height;
LIHC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.73	0.3	2.15e-8	Vitiligo;
LIHC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.4	-0.37	1.08e-12	Schizophrenia;
LIHC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.65	10.47	0.49	2.02e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.45	0.46	5.54e-19	Bipolar disorder;
LIHC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.56	7.88	0.39	4.29e-14	Coronary artery disease;
LIHC	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.64	10.41	0.49	3.18e-22	White matter hyperintensity burden;
LIHC	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg27386326	chr11:61587980	NA	0.69	14.43	0.62	3.29e-37	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LIHC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg13753209	chr17:57696993	CLTC	0.73	11.55	0.53	2.83e-26	Hemoglobin concentration;
LIHC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.06	19.84	0.73	7.97e-59	IgG glycosylation;
LIHC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs847649	0.767	rs7796678	chr7:102778447	C/T	cg18108683	chr7:102477205	FBXL13	0.41	6.28	0.32	1.02e-9	Morning vs. evening chronotype;
LIHC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg20487152	chr13:99095054	FARP1	-0.37	-6.17	-0.32	1.89e-9	Longevity;
LIHC	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.43	-6.0	-0.31	4.97e-9	QT interval;
LIHC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.66	10.97	0.51	3.37e-24	Type 2 diabetes;
LIHC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	13.09	0.58	5.08e-32	Mean platelet volume;
LIHC	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.56	-9.04	-0.44	1.21e-17	Obesity-related traits;
LIHC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.49	-7.66	-0.38	1.95e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg07713946	chr22:31675144	LIMK2	-0.29	-6.24	-0.32	1.27e-9	Paclitaxel-induced neuropathy;
LIHC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg02187348	chr16:89574699	SPG7	-0.44	-6.39	-0.33	5.34e-10	Multiple myeloma (IgH translocation);
LIHC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	ch.9.1539394R	chr9:104170844	ZNF189	-0.42	-6.41	-0.33	4.73e-10	Neuroticism;
LIHC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-7.19	-0.36	4.14e-12	Glomerular filtration rate (creatinine);
LIHC	trans	rs783540	0.967	rs783523	chr15:83283555	A/G	cg18393722	chr15:85113863	UBE2QP1	0.38	6.69	0.34	9.22e-11	Schizophrenia;
LIHC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-9.28	-0.45	2.05e-18	Cognitive test performance;
LIHC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.64	7.4	0.37	1.05e-12	Migraine;Coronary artery disease;
LIHC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.5	0.38	5.48e-13	Height;
LIHC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02290350	chr8:58132656	NA	0.41	8.51	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.81	-0.43	6.57e-17	Motion sickness;
LIHC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.43	-0.37	8.66e-13	Lymphocyte counts;
LIHC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.49	-6.51	-0.33	2.6e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.38	6.08	0.31	3.27e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.76	-9.03	-0.44	1.26e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg23967809	chr8:141647658	NA	0.43	6.94	0.35	1.99e-11	Cognitive function;
LIHC	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.37	8.11	0.4	9.22e-15	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.72	13.31	0.58	7.32e-33	Extrinsic epigenetic age acceleration;
LIHC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.45	5.77	0.3	1.79e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	10.02	0.48	7.11e-21	Lung cancer;
LIHC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.39	7.48	0.37	6.39e-13	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-8.68	-0.42	1.69e-16	Primary biliary cholangitis;
LIHC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.51	-6.51	-0.33	2.73e-10	Renal function-related traits (BUN);
LIHC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.63	0.5	5.55e-23	Bladder cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06079273	chr8:97247865	UQCRB	-0.39	-6.72	-0.34	7.65e-11	Pancreatic cancer;
LIHC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.46	-6.2	-0.32	1.6e-9	Blood metabolite levels;
LIHC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.12	10.35	0.49	5.17e-22	Diabetic retinopathy;
LIHC	cis	rs1198430	1.000	rs946268	chr1:23747766	A/G	cg19827787	chr1:23763612	ASAP3	0.34	6.19	0.32	1.71e-9	Total cholesterol levels;
LIHC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.45	-7.5	-0.38	5.5e-13	Myeloid white cell count;
LIHC	cis	rs12440869	0.649	rs4776929	chr15:67707134	G/C	cg08154944	chr15:67813145	C15orf61	-0.38	-5.94	-0.31	6.85e-9	Peak velocity of the mitral A-wave;
LIHC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.36	-0.56	2.91e-29	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.48	-7.63	-0.38	2.37e-13	Pubertal anthropometrics;
LIHC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.59	-0.34	1.71e-10	Schizophrenia;
LIHC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.54	-7.78	-0.39	8.66e-14	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg10790698	chr19:18539756	SSBP4	-0.36	-7.51	-0.38	5.29e-13	Breast cancer;
LIHC	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.76	-6.38	-0.33	5.6e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.42	5.85	0.3	1.13e-8	Tuberculosis;
LIHC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.73	0.39	1.22e-13	Lymphocyte counts;
LIHC	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-6.26	-0.32	1.16e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-7.21	-0.36	3.64e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.68	10.45	0.49	2.24e-22	Longevity;
LIHC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.25	0.41	3.52e-15	Bladder cancer;
LIHC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.9	-11.71	-0.53	7.61e-27	Schizophrenia;
LIHC	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg13708974	chr9:131466143	PKN3	-0.37	-5.78	-0.3	1.71e-8	Blood metabolite levels;
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.52	8.24	0.41	3.64e-15	Testicular germ cell tumor;
LIHC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17554472	chr22:41940697	POLR3H	0.56	6.01	0.31	4.84e-9	Vitiligo;
LIHC	cis	rs28830936	0.841	rs4923914	chr15:42119603	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-5.96	-0.31	6.21e-9	Diastolic blood pressure;
LIHC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg02931644	chr1:25747376	RHCE	-0.32	-6.8	-0.35	4.54e-11	Erythrocyte sedimentation rate;
LIHC	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.54	-8.38	-0.41	1.44e-15	Blood protein levels;
LIHC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg07599136	chr5:415885	AHRR	0.39	6.75	0.34	6.32e-11	Cystic fibrosis severity;
LIHC	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg13482628	chr17:19912719	NA	-0.4	-6.55	-0.33	2.17e-10	Schizophrenia;
LIHC	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.02	15.33	0.64	9.35e-41	Corneal structure;
LIHC	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.66	-9.06	-0.44	9.94e-18	Vitamin D levels;
LIHC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg15534755	chr11:117069859	TAGLN	0.34	5.77	0.3	1.75e-8	Blood protein levels;
LIHC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.22	5.95	0.31	6.58e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.1	-0.31	2.92e-9	Bipolar disorder and schizophrenia;
LIHC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.12	10.23	0.48	1.36e-21	Uric acid levels;
LIHC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.24	-15.84	-0.65	8.89e-43	Diabetic kidney disease;
LIHC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.67	12.44	0.56	1.45e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs1664789	0.904	rs1694061	chr5:53278172	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.54	8.33	0.41	2.01e-15	Waist circumference adjusted for body mass index;
LIHC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.66	11.56	0.53	2.55e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.56	0.33	1.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.93	16.94	0.68	3.74e-47	Parkinson's disease;
LIHC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.31	6.45	0.33	3.81e-10	Lung cancer;
LIHC	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.7	-15.47	-0.64	2.8e-41	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.06	0.4	1.33e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg16822855	chr3:40428330	ENTPD3	0.34	6.14	0.31	2.35e-9	Renal cell carcinoma;
LIHC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg16743903	chr16:89593216	SPG7	-0.3	-5.79	-0.3	1.63e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.31	-0.32	8.67e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.73	-10.97	-0.51	3.29e-24	Height;
LIHC	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	19.18	0.72	3.65e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13409248	chr3:40428643	ENTPD3	0.47	7.7	0.38	1.52e-13	Renal cell carcinoma;
LIHC	cis	rs2108622	0.727	rs8101038	chr19:15982864	C/T	cg13772218	chr19:15982569	NA	0.37	7.75	0.39	1.06e-13	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
LIHC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.37	6.36	0.33	6.46e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg01028140	chr2:1542097	TPO	-0.44	-6.99	-0.35	1.46e-11	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.47	-0.33	3.35e-10	Bipolar disorder;
LIHC	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.62	-7.34	-0.37	1.55e-12	Primary sclerosing cholangitis;
LIHC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg11632617	chr15:75315747	PPCDC	-0.45	-6.41	-0.33	4.75e-10	Blood trace element (Zn levels);
LIHC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg11764359	chr7:65958608	NA	0.56	5.96	0.31	6.14e-9	Diabetic kidney disease;
LIHC	trans	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg17675199	chr6:35436792	RPL10A	0.34	6.63	0.34	1.32e-10	Coronary artery disease;
LIHC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.67	9.77	0.47	4.66e-20	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.45	7.03	0.36	1.16e-11	Mortality in heart failure;
LIHC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg12798992	chr6:167411361	FGFR1OP	0.44	6.8	0.34	4.81e-11	Primary biliary cholangitis;
LIHC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg16586182	chr3:47516702	SCAP	0.55	10.3	0.49	7.69e-22	Colorectal cancer;
LIHC	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg15704280	chr7:45808275	SEPT13	0.62	6.5	0.33	2.81e-10	Axial length;
LIHC	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg10560079	chr2:191398806	TMEM194B	-0.42	-6.07	-0.31	3.36e-9	Mean platelet volume;
LIHC	cis	rs7818688	0.697	rs61591488	chr8:95984955	C/T	cg16049864	chr8:95962084	TP53INP1	0.6	6.51	0.33	2.69e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs8084351	0.577	rs10163983	chr18:50639009	C/G	cg24270629	chr18:50823537	DCC	0.43	6.38	0.33	5.78e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg09795085	chr6:101329169	ASCC3	0.53	7.4	0.37	1.04e-12	Neuroticism;
LIHC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.58	11.52	0.53	3.59e-26	Tonsillectomy;
LIHC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.59	8.79	0.43	7.18e-17	Recombination rate (females);
LIHC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.79	-15.85	-0.65	8.51e-43	Gestational age at birth (maternal effect);
LIHC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg17135325	chr3:160939158	NMD3	0.54	7.73	0.39	1.19e-13	Parkinson's disease;
LIHC	cis	rs3770081	0.536	rs7562837	chr2:86306251	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.5	8.34	0.41	1.88e-15	Facial emotion recognition (sad faces);
LIHC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.72	-13.11	-0.58	4.47e-32	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-8.46	-0.42	7.79e-16	Gut microbiome composition (summer);
LIHC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg17724175	chr1:150552817	MCL1	0.43	8.51	0.42	5.7e-16	Melanoma;
LIHC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.67	0.38	1.83e-13	Total body bone mineral density;
LIHC	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.61	8.98	0.44	1.91e-17	Recombination rate (females);
LIHC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.46	-7.83	-0.39	6.01e-14	Lung cancer;
LIHC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg14393609	chr7:65229607	NA	0.44	6.56	0.33	2.04e-10	Calcium levels;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg12064134	chr16:90016061	DEF8	0.45	6.17	0.32	1.91e-9	Skin colour saturation;
LIHC	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg16309518	chr5:176445507	NA	-0.58	-11.52	-0.53	3.76e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.38	-0.33	5.7e-10	Metabolite levels;
LIHC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg10217327	chr6:118973057	C6orf204	0.63	6.07	0.31	3.46e-9	Diastolic blood pressure;
LIHC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.9	0.39	3.77e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.48	7.54	0.38	4.31e-13	Cocaine dependence;
LIHC	cis	rs911119	0.913	rs6048922	chr20:23578116	G/C	cg16589663	chr20:23618590	CST3	0.67	6.99	0.35	1.49e-11	Chronic kidney disease;
LIHC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg13957321	chr17:43675089	NA	0.5	7.99	0.4	2.13e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg26831259	chr4:1366826	KIAA1530	-0.39	-6.11	-0.31	2.7e-9	Longevity;
LIHC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.48	-7.42	-0.37	9.14e-13	Testicular germ cell tumor;
LIHC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.74	-0.3	2.1e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs8084351	0.539	rs7506999	chr18:50576312	T/G	cg24270629	chr18:50823537	DCC	0.41	6.34	0.32	7.31e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.52	6.73	0.34	6.97e-11	Initial pursuit acceleration;
LIHC	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg25364880	chr3:44379878	C3orf23	0.47	6.68	0.34	9.7e-11	Depressive symptoms;
LIHC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.14	-0.32	2.23e-9	Mean corpuscular volume;
LIHC	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.75	10.95	0.51	4.15e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.16	0.32	2.02e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.47	7.31	0.37	1.87e-12	Cognitive function;
LIHC	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.52	7.15	0.36	5.36e-12	Interleukin-18 levels;
LIHC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.52	0.42	5.19e-16	Motion sickness;
LIHC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.61	-11.6	-0.53	1.78e-26	Mean corpuscular volume;
LIHC	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	6.85	0.35	3.54e-11	Type 2 diabetes;
LIHC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.75	-10.82	-0.51	1.16e-23	Response to antineoplastic agents;
LIHC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg20607798	chr8:58055168	NA	0.46	5.81	0.3	1.44e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	13.0	0.57	1.16e-31	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg19635926	chr16:89946313	TCF25	0.55	7.36	0.37	1.41e-12	Skin colour saturation;
LIHC	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg01864836	chr14:55583639	NA	-0.35	-6.47	-0.33	3.3e-10	Protein biomarker;
LIHC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg05590025	chr7:65112418	INTS4L2	0.62	6.79	0.34	4.9e-11	Diabetic kidney disease;
LIHC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.37	6.68	0.34	9.57e-11	Aortic root size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17786844	chr1:32404291	PTP4A2	0.53	7.25	0.36	2.76e-12	Lung function (FEV1/FVC);
LIHC	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg16589663	chr20:23618590	CST3	0.65	6.74	0.34	6.62e-11	Chronic kidney disease;
LIHC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.7	-7.57	-0.38	3.56e-13	Neuroticism;
LIHC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.87	-13.01	-0.58	1.04e-31	Diastolic blood pressure;
LIHC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.93	-16.21	-0.66	3.02e-44	Longevity;
LIHC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg23461800	chr14:103021989	NA	0.47	6.33	0.32	7.85e-10	Platelet count;
LIHC	cis	rs1292059	1	rs1292059	chr17:57957888	T/A	cg02344993	chr17:57696989	CLTC	0.64	10.03	0.48	6.23e-21	Eosinophil percentage of granulocytes;
LIHC	cis	rs3790645	1.000	rs396997	chr1:26893067	T/C	cg17456097	chr1:26900765	RPS6KA1	0.4	5.82	0.3	1.33e-8	Glucose homeostasis traits;
LIHC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.67	-10.36	-0.49	4.77e-22	Total body bone mineral density;
LIHC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.04	-0.31	4.03e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-6.2	-0.32	1.6e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.87	-15.12	-0.63	6.41e-40	Aortic root size;
LIHC	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.22	-0.45	3.17e-18	Type 2 diabetes;
LIHC	cis	rs7075426	0.905	rs10887612	chr10:88213946	T/C	cg07322936	chr10:88137208	NA	0.51	7.3	0.37	2.07e-12	Migraine without aura;
LIHC	cis	rs2637266	1.000	rs2637270	chr10:78336901	C/T	cg18941641	chr10:78392320	NA	0.29	6.19	0.32	1.74e-9	Pulmonary function;
LIHC	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg22771759	chr13:24902376	NA	0.33	6.94	0.35	2.03e-11	Obesity-related traits;
LIHC	cis	rs17428076	0.874	rs62182374	chr2:172685682	T/C	cg13550731	chr2:172543902	DYNC1I2	0.38	6.14	0.32	2.3e-9	Myopia;
LIHC	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.81	0.54	3.07e-27	Coffee consumption (cups per day);
LIHC	cis	rs8081395	0.741	rs180520	chr17:58015149	T/C	cg13753209	chr17:57696993	CLTC	0.39	6.09	0.31	3.09e-9	White blood cell count;
LIHC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.58	7.32	0.37	1.79e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg08847533	chr14:75593920	NEK9	0.49	7.69	0.38	1.61e-13	IgG glycosylation;
LIHC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	7.43	0.37	8.77e-13	Bone mineral density;
LIHC	trans	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg17675199	chr6:35436792	RPL10A	-0.44	-9.12	-0.44	6.55e-18	Intelligence (multi-trait analysis);
LIHC	trans	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-7.02	-0.35	1.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.66	0.46	1.08e-19	Initial pursuit acceleration in psychotic disorders;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg04318546	chr15:101147087	ASB7	0.38	6.62	0.34	1.42e-10	Cognitive function;
LIHC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.51	-0.38	5.06e-13	Uric acid levels;
LIHC	cis	rs1198430	0.714	rs1198437	chr1:23747424	G/C	cg19827787	chr1:23763612	ASAP3	0.28	5.98	0.31	5.58e-9	Total cholesterol levels;
LIHC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.76	-12.58	-0.56	4.36e-30	Colorectal cancer;
LIHC	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg15208524	chr1:10270712	KIF1B	-0.43	-5.8	-0.3	1.51e-8	Hepatocellular carcinoma;
LIHC	cis	rs8083850	0.748	rs4423490	chr18:50664398	A/G	cg24270629	chr18:50823537	DCC	-0.44	-6.49	-0.33	3.1e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.57	7.62	0.38	2.49e-13	Breast cancer;
LIHC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	17.38	0.68	6.28e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg22842854	chr12:123319900	HIP1R	-0.74	-9.76	-0.47	5.03e-20	Schizophrenia;
LIHC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.4	6.13	0.31	2.46e-9	Resting heart rate;
LIHC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg14440974	chr22:39074834	NA	-0.44	-7.18	-0.36	4.45e-12	Menopause (age at onset);
LIHC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.22	-0.52	4.43e-25	Primary sclerosing cholangitis;
LIHC	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.74	0.43	1.04e-16	Coffee consumption (cups per day);
LIHC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.04	-14.13	-0.61	5.25e-36	Chronic sinus infection;
LIHC	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg23387056	chr11:14280742	SPON1	-0.43	-5.83	-0.3	1.31e-8	Mitochondrial DNA levels;
LIHC	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.64	-0.5	4.9e-23	Pediatric autoimmune diseases;
LIHC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg13647721	chr17:30228624	UTP6	-0.77	-6.47	-0.33	3.3e-10	Hip circumference adjusted for BMI;
LIHC	cis	rs10849893	0.557	rs61955091	chr12:121833975	A/G	cg01154721	chr12:121881891	KDM2B	-0.4	-6.52	-0.33	2.57e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-5.85	-0.3	1.12e-8	Alcohol dependence;
LIHC	cis	rs6001982	0.541	rs17002069	chr22:41050986	C/G	cg14879645	chr22:41048474	NA	0.4	5.82	0.3	1.34e-8	Breast cancer;
LIHC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	7.04	0.36	1.07e-11	Schizophrenia;
LIHC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.83	9.95	0.47	1.23e-20	Cognitive function;
LIHC	trans	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg14791747	chr16:20752902	THUMPD1	-0.5	-6.76	-0.34	5.95e-11	Dental caries;
LIHC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.29	-6.7	-0.34	8.84e-11	Lung cancer;
LIHC	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg00977110	chr5:151150581	G3BP1	0.49	6.18	0.32	1.78e-9	Preschool internalizing problems;
LIHC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.74	0.3	2.08e-8	Self-reported allergy;
LIHC	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg26139080	chr11:47293733	MADD	-0.48	-8.03	-0.4	1.53e-14	HDL cholesterol;
LIHC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg05590025	chr7:65112418	INTS4L2	-0.58	-6.49	-0.33	2.93e-10	Diabetic kidney disease;
LIHC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg10792982	chr14:105748885	BRF1	0.44	5.71	0.3	2.45e-8	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.54	-0.38	4.15e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.68	-9.58	-0.46	2.05e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.35	0.49	5.01e-22	Hypertriglyceridemia;
LIHC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.59	-9.73	-0.47	6.7e-20	Crohn's disease;
LIHC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.86	0.39	4.89e-14	Multiple sclerosis;
LIHC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg02640540	chr1:67518911	SLC35D1	0.42	5.82	0.3	1.34e-8	Lymphocyte percentage of white cells;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg25953789	chr2:220366002	GMPPA	0.47	6.13	0.31	2.49e-9	Systolic blood pressure;
LIHC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.88	9.94	0.47	1.25e-20	Initial pursuit acceleration;
LIHC	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.6	-7.31	-0.37	1.89e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.37	-0.33	5.97e-10	Metabolite levels;
LIHC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg07234388	chr1:156261841	TMEM79	0.47	9.07	0.44	9.28e-18	Tonsillectomy;
LIHC	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.53	-7.16	-0.36	5.02e-12	Coronary artery disease;
LIHC	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22618164	chr12:122356400	WDR66	-0.45	-7.51	-0.38	5.23e-13	Mean corpuscular volume;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07759052	chr8:28752150	HMBOX1	-0.29	-6.1	-0.31	2.86e-9	Calcium levels;
LIHC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.29	-7.18	-0.36	4.38e-12	Cutaneous nevi;
LIHC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg14092571	chr14:90743983	NA	-0.41	-6.53	-0.33	2.34e-10	Mortality in heart failure;
LIHC	cis	rs6788895	1.000	rs73008903	chr3:150465053	C/T	cg07663535	chr3:150480033	SIAH2	0.56	7.0	0.35	1.37e-11	Breast cancer;
LIHC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.45	-0.33	3.81e-10	Colorectal cancer;
LIHC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	9.65	0.46	1.17e-19	Tonsillectomy;
LIHC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg20607798	chr8:58055168	NA	0.49	6.12	0.31	2.57e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs61677309	0.964	rs56292628	chr11:118163872	G/A	cg06090739	chr11:118230722	UBE4A	0.35	6.58	0.34	1.82e-10	Lung cancer in ever smokers;
LIHC	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg15123519	chr2:136567270	LCT	-0.39	-5.82	-0.3	1.33e-8	Corneal structure;
LIHC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.7	-0.5	3.09e-23	Bipolar disorder and schizophrenia;
LIHC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.76	0.47	5.3e-20	Platelet count;
LIHC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.94	17.99	0.7	2.25e-51	Menopause (age at onset);
LIHC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.41	12.83	0.57	5.16e-31	Uric acid levels;
LIHC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.54	-8.62	-0.42	2.47e-16	Colorectal cancer;
LIHC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26913058	chr16:419975	MRPL28	-0.5	-7.6	-0.38	2.87e-13	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg16822855	chr3:40428330	ENTPD3	0.33	6.02	0.31	4.43e-9	Renal cell carcinoma;
LIHC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.15	-0.32	2.21e-9	Neuroticism;
LIHC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg20933634	chr6:27740509	NA	0.48	6.26	0.32	1.15e-9	Parkinson's disease;
LIHC	trans	rs875971	1.000	rs937495	chr7:65779798	A/G	cg10756647	chr7:56101905	PSPH	-0.44	-6.48	-0.33	3.22e-10	Aortic root size;
LIHC	cis	rs1577917	0.545	rs9294338	chr6:86474368	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.33	6.01	0.31	4.72e-9	Response to antipsychotic treatment;
LIHC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-8.16	-0.4	6.46e-15	Crohn's disease;
LIHC	trans	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.53	-0.33	2.42e-10	Endometrial cancer;
LIHC	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.22	-12.41	-0.56	1.94e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.52	-7.9	-0.39	3.86e-14	Tuberculosis;
LIHC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg14067834	chr17:29058358	SUZ12P	0.71	6.99	0.35	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10508774	1.000	rs72782256	chr10:32978551	C/T	cg01819863	chr10:32635814	EPC1	0.63	5.88	0.3	9.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.35	-0.32	6.9e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs9596863	0.898	rs9316655	chr13:54319640	A/G	ch.13.53330881F	chr13:54432880	NA	0.5	7.56	0.38	3.81e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LIHC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.07	25.0	0.8	3.62e-79	IgG glycosylation;
LIHC	cis	rs6545883	0.894	rs4672423	chr2:61435275	C/T	cg14146966	chr2:61757674	XPO1	-0.42	-6.86	-0.35	3.25e-11	Tuberculosis;
LIHC	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.9	-0.3	8.77e-9	Neuroticism;
LIHC	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-6.58	-0.34	1.77e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.58	6.18	0.32	1.87e-9	Hip geometry;
LIHC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07305463	chr2:136567211	LCT	0.42	7.79	0.39	8.33e-14	Mosquito bite size;
LIHC	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.03	16.31	0.66	1.21e-44	Corneal structure;
LIHC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.52	9.66	0.46	1.11e-19	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs4699052	0.963	rs6816055	chr4:104143160	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-6.71	-0.34	8.25e-11	Testicular germ cell tumor;
LIHC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-5.74	-0.3	2.04e-8	Colorectal cancer;
LIHC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13647721	chr17:30228624	UTP6	0.79	7.44	0.37	8.4e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.98	-0.44	1.87e-17	Heart rate;
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg10755058	chr3:40428713	ENTPD3	0.41	6.89	0.35	2.77e-11	Renal cell carcinoma;
LIHC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	0.6	6.06	0.31	3.51e-9	Obesity-related traits;
LIHC	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.39	-8.21	-0.41	4.62e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.65	8.9	0.43	3.23e-17	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.52	8.25	0.41	3.43e-15	Diastolic blood pressure;
LIHC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.37	5.74	0.3	2.11e-8	Lewy body disease;
LIHC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.62	-9.96	-0.47	1.13e-20	Obesity-related traits;
LIHC	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	9.14	0.44	5.59e-18	Exhaled nitric oxide output;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22027408	chr19:12902453	JUNB	-0.44	-6.7	-0.34	8.58e-11	Pancreatic cancer;
LIHC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	11.69	0.53	8.37e-27	Body mass index;
LIHC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.48	7.08	0.36	8.06e-12	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg07706471	chr12:123319906	HIP1R	-0.62	-8.23	-0.41	4.12e-15	Schizophrenia;
LIHC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg26138144	chr22:38071188	LGALS1	0.75	14.01	0.6	1.51e-35	Fat distribution (HIV);
LIHC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.42	6.43	0.33	4.29e-10	Height;
LIHC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.41	7.01	0.35	1.29e-11	Perceived unattractiveness to mosquitoes;
LIHC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.09	10.33	0.49	5.87e-22	Diabetic retinopathy;
LIHC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.31	-7.24	-0.36	3.07e-12	Menarche (age at onset);
LIHC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02251663	chr11:14281053	SPON1	0.44	6.12	0.31	2.57e-9	Mitochondrial DNA levels;
LIHC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg03934865	chr2:198174659	NA	0.54	8.28	0.41	2.8e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.55	-6.1	-0.31	2.89e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	1.23	10.89	0.51	6.79e-24	Obesity-related traits;
LIHC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.59	9.35	0.45	1.15e-18	Uric acid clearance;
LIHC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg19645103	chr12:69753606	YEATS4	-0.39	-5.86	-0.3	1.09e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.44	-7.47	-0.37	6.87e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.92	0.51	5.04e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-14.26	-0.61	1.62e-36	Alzheimer's disease;
LIHC	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg09795085	chr6:101329169	ASCC3	0.46	6.74	0.34	6.89e-11	Neuroticism;
LIHC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.34	6.27	0.32	1.08e-9	Mean corpuscular volume;
LIHC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.85	-6.46	-0.33	3.6e-10	Systolic blood pressure;
LIHC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg22633049	chr21:46681294	NA	0.38	6.44	0.33	4.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg07451762	chr16:28383216	NA	0.32	5.97	0.31	5.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.34	8.04	0.4	1.48e-14	Immature fraction of reticulocytes;
LIHC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.88	14.42	0.61	3.6e-37	Colorectal cancer;
LIHC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.92	14.15	0.61	4.14e-36	Vitamin D levels;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg14257449	chr1:185285846	IVNS1ABP	-0.49	-6.06	-0.31	3.6e-9	Systolic blood pressure;
LIHC	cis	rs244293	1.000	rs183618	chr17:53235974	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.47	6.79	0.34	4.84e-11	Menarche (age at onset);
LIHC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg24955955	chr5:415729	AHRR	-0.42	-7.84	-0.39	5.67e-14	Fat distribution (HIV);
LIHC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	11.58	0.53	2.13e-26	Height;
LIHC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg00204748	chr12:29376779	FAR2	0.45	8.52	0.42	5.07e-16	QT interval;
LIHC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg10096929	chr1:156261403	TMEM79	0.38	6.33	0.32	7.84e-10	Tonsillectomy;
LIHC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg13047869	chr3:10149882	C3orf24	0.43	5.8	0.3	1.54e-8	Alzheimer's disease;
LIHC	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg14146966	chr2:61757674	XPO1	0.47	8.15	0.4	7.04e-15	Tuberculosis;
LIHC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	10.27	0.49	9.28e-22	Red blood cell count;
LIHC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.61	8.72	0.43	1.26e-16	Aortic root size;
LIHC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg04865290	chr3:52927548	TMEM110	-0.51	-5.9	-0.3	8.82e-9	Immune reponse to smallpox (secreted IL-2);
LIHC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.58	6.89	0.35	2.62e-11	Bladder cancer;
LIHC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg20651018	chr11:3035856	CARS	-0.35	-5.92	-0.3	7.86e-9	Longevity;
LIHC	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.74	11.12	0.52	1.01e-24	Subjective well-being;
LIHC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.18	0.48	1.96e-21	Colorectal cancer;
LIHC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.45	-7.73	-0.39	1.19e-13	Height;
LIHC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.43	-7.11	-0.36	6.81e-12	Alcohol dependence;
LIHC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02985541	chr2:219472218	PLCD4	0.43	6.95	0.35	1.84e-11	Mean corpuscular hemoglobin concentration;
LIHC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.84	-15.96	-0.65	3.06e-43	Height;
LIHC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.49	7.66	0.38	1.95e-13	Blood protein levels;
LIHC	cis	rs11958404	0.517	rs56344822	chr5:157219957	C/T	cg05962755	chr5:157440814	NA	0.67	6.76	0.34	5.96e-11	IgG glycosylation;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg11342453	chr6:26196699	NA	0.52	5.93	0.31	7.33e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-0.91	-10.96	-0.51	3.59e-24	Mitochondrial DNA levels;
LIHC	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16684958	chr7:75615977	POR	0.4	6.57	0.33	1.87e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.71	15.17	0.63	4.2e-40	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LIHC	cis	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg19680485	chr15:31195859	MTMR15	-0.53	-5.85	-0.3	1.15e-8	Hypertriglyceridemia;
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg00049323	chr5:472564	LOC25845	0.35	5.82	0.3	1.33e-8	Cystic fibrosis severity;
LIHC	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.71	7.18	0.36	4.38e-12	Alzheimer's disease;
LIHC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.59	6.91	0.35	2.36e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.79	-12.66	-0.56	2.18e-30	Colorectal cancer;
LIHC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.85	8.33	0.41	1.96e-15	Inflammatory bowel disease;
LIHC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.75	11.08	0.51	1.41e-24	Corneal astigmatism;
LIHC	cis	rs4908768	1.000	rs4908768	chr1:8654764	G/A	cg20416874	chr1:8611966	RERE	0.54	7.14	0.36	5.78e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.72	-9.1	-0.44	7.52e-18	Body mass index;
LIHC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-6.73	-0.34	7.33e-11	Height;
LIHC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.69	11.97	0.54	8.25e-28	Menopause (age at onset);
LIHC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg08847533	chr14:75593920	NEK9	-0.39	-6.47	-0.33	3.3e-10	Caffeine consumption;
LIHC	trans	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	7.92	0.39	3.35e-14	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	1.05	17.09	0.68	8.78e-48	Testicular germ cell tumor;
LIHC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.48	7.72	0.39	1.33e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg25952890	chr19:58913133	NA	0.69	7.4	0.37	1.07e-12	Mean platelet volume;
LIHC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.53	0.42	4.82e-16	Platelet count;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg23396286	chr10:99258505	UBTD1;MMS19	0.43	6.42	0.33	4.67e-10	Pancreatic cancer;
LIHC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.48	-0.59	1.65e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg23625390	chr15:77176239	SCAPER	0.36	5.85	0.3	1.18e-8	Blood metabolite levels;
LIHC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.35	-6.05	-0.31	3.88e-9	Body mass index;
LIHC	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.5	8.25	0.41	3.45e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.47	7.33	0.37	1.68e-12	Mortality in heart failure;
LIHC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	9.39	0.45	8.39e-19	IgG glycosylation;
LIHC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	9.28	0.45	1.98e-18	Breast cancer;
LIHC	cis	rs600806	0.821	rs417270	chr1:109849144	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.58	-6.85	-0.35	3.35e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.29	0.58	8.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	9.04	0.44	1.22e-17	Schizophrenia;
LIHC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.74	11.53	0.53	3.37e-26	Migraine;Coronary artery disease;
LIHC	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg14146966	chr2:61757674	XPO1	-0.43	-7.14	-0.36	5.61e-12	Tuberculosis;
LIHC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-5.77	-0.3	1.82e-8	Alzheimer's disease (late onset);
LIHC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-11.06	-0.51	1.59e-24	Colorectal cancer;
LIHC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.41	0.53	8.83e-26	Alzheimer's disease;
LIHC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.56	-10.52	-0.49	1.32e-22	Coronary artery disease;
LIHC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-21.28	-0.75	1.36e-64	Height;
LIHC	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.32	8.18	0.4	5.75e-15	Gut microbiome composition (winter);
LIHC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.54	-8.84	-0.43	5.1e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11663156	0.920	rs2292043	chr18:51059163	T/C	cg24270629	chr18:50823537	DCC	-0.47	-6.38	-0.33	5.74e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.41	-5.85	-0.3	1.18e-8	Longevity;
LIHC	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.36	-7.64	-0.38	2.14e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.01	-0.31	4.68e-9	Longevity;
LIHC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05025164	chr4:1340916	KIAA1530	-0.4	-6.02	-0.31	4.56e-9	Obesity-related traits;
LIHC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.86	13.15	0.58	2.91e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	0.96	16.29	0.66	1.39e-44	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.56	-0.33	2.02e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	8.11	0.4	9.32e-15	Fuchs's corneal dystrophy;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08872579	chr1:55265830	TTC22	0.42	6.15	0.32	2.14e-9	Hepatitis;
LIHC	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26734620	chr12:56694298	CS	1.23	10.54	0.5	1.14e-22	Psoriasis vulgaris;
LIHC	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.42	-7.19	-0.36	4.16e-12	Itch intensity from mosquito bite adjusted by bite size;
LIHC	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.63	-9.1	-0.44	7.75e-18	White matter hyperintensity burden;
LIHC	cis	rs903552	1.000	rs12903048	chr15:102006325	G/T	cg00659931	chr15:102010125	PCSK6	-0.45	-6.11	-0.31	2.79e-9	Diabetic kidney disease;
LIHC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.32	-6.46	-0.33	3.61e-10	Multiple sclerosis;
LIHC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.62	11.44	0.53	6.86e-26	Coronary artery disease;
LIHC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg24203234	chr3:128598194	ACAD9	0.44	6.18	0.32	1.78e-9	IgG glycosylation;
LIHC	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.78	8.98	0.44	1.89e-17	Bipolar disorder;
LIHC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-13.49	-0.59	1.55e-33	Glomerular filtration rate (creatinine);
LIHC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.05	9.5	0.46	3.68e-19	Diabetic retinopathy;
LIHC	trans	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg14791747	chr16:20752902	THUMPD1	-0.49	-6.85	-0.35	3.34e-11	Dental caries;
LIHC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.32	-6.88	-0.35	2.86e-11	Longevity;
LIHC	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg20991723	chr1:152506922	NA	0.54	8.91	0.43	3.19e-17	Hair morphology;
LIHC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.42e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.54	-8.39	-0.41	1.29e-15	Blood protein levels;
LIHC	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.6	8.9	0.43	3.36e-17	Recombination rate (females);
LIHC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	6.86	0.35	3.18e-11	Osteoporosis;
LIHC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-7.93	-0.39	3.21e-14	Lymphocyte counts;
LIHC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.62	10.4	0.49	3.54e-22	Alcohol dependence;
LIHC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-8.02	-0.4	1.75e-14	Prudent dietary pattern;
LIHC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.5	6.47	0.33	3.31e-10	Subjective well-being;
LIHC	cis	rs546131	0.642	rs508062	chr11:34843820	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.2	0.36	3.82e-12	Lung disease severity in cystic fibrosis;
LIHC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.73	-9.99	-0.48	8.47e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg16486109	chr11:613632	IRF7	0.57	5.79	0.3	1.59e-8	Systemic lupus erythematosus;
LIHC	cis	rs3106136	0.507	rs13134502	chr4:95304507	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.94	0.31	7.02e-9	Capecitabine sensitivity;
LIHC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg20933634	chr6:27740509	NA	0.48	6.26	0.32	1.15e-9	Parkinson's disease;
LIHC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg18912006	chr12:123335444	HIP1R	-0.58	-7.11	-0.36	6.8e-12	Schizophrenia;
LIHC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	8.57	0.42	3.64e-16	Menarche (age at onset);
LIHC	cis	rs7095607	0.560	rs2087344	chr10:69922735	A/G	cg18986048	chr10:69913749	MYPN	-0.48	-7.1	-0.36	7.09e-12	Lung function (FVC);
LIHC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.47	-7.62	-0.38	2.58e-13	Fibrinogen levels;
LIHC	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg18809830	chr7:99032528	PTCD1	-0.83	-6.45	-0.33	3.72e-10	Blood metabolite levels;
LIHC	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg10820045	chr2:198174542	NA	-0.57	-9.69	-0.46	8.95e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs17083533	1.000	rs17083522	chr6:121727758	A/G	cg16423337	chr3:52828818	ITIH3	-0.3	-6.3	-0.32	9.03e-10	Heart rate;
LIHC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.74	-13.76	-0.6	1.31e-34	Height;
LIHC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg12365402	chr11:9010492	NRIP3	-0.32	-8.19	-0.41	5.08e-15	Hemoglobin concentration;
LIHC	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.57	6.81	0.35	4.29e-11	Mammographic density (dense area);
LIHC	cis	rs2292096	1.000	rs16847267	chr1:200820897	C/T	cg11814564	chr1:200748674	CAMSAP1L1	-0.43	-5.92	-0.31	7.67e-9	Epilepsy;
LIHC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg12798992	chr6:167411361	FGFR1OP	-0.61	-9.81	-0.47	3.56e-20	Crohn's disease;
LIHC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.96	22.23	0.77	2.2e-68	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.22	0.41	4.3e-15	Lymphocyte counts;
LIHC	cis	rs151997	0.629	rs27288	chr5:50194920	T/A	cg06027927	chr5:50259733	NA	0.44	6.55	0.33	2.12e-10	Callous-unemotional behaviour;
LIHC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.81	12.17	0.55	1.53e-28	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	6.6	0.34	1.53e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.55	-9.56	-0.46	2.4e-19	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.48	7.0	0.35	1.36e-11	Aortic root size;
LIHC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg22561889	chr6:118971681	C6orf204	0.55	5.94	0.31	7.13e-9	Diastolic blood pressure;
LIHC	trans	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg10756647	chr7:56101905	PSPH	1.09	13.52	0.59	1.17e-33	Diabetic kidney disease;
LIHC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-7.04	-0.36	1.08e-11	Chronic sinus infection;
LIHC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-8.87	-0.43	4.07e-17	Gut microbiome composition (summer);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11050527	chr8:54755511	ATP6V1H	0.43	6.91	0.35	2.31e-11	Pancreatic cancer;
LIHC	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.36	7.1	0.36	7.38e-12	Multiple sclerosis;
LIHC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.65	-12.85	-0.57	4.18e-31	Sense of smell;
LIHC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.89	0.39	4.03e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.99	18.01	0.7	1.76e-51	Tonsillectomy;
LIHC	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg22842854	chr12:123319900	HIP1R	0.92	10.53	0.49	1.17e-22	Adiponectin levels;
LIHC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.59	9.17	0.44	4.45e-18	Longevity;
LIHC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.53	8.31	0.41	2.33e-15	Lymphocyte counts;
LIHC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.67	0.53	1.03e-26	Motion sickness;
LIHC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.78	-11.79	-0.54	3.76e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.51	-5.86	-0.3	1.09e-8	Corneal curvature;
LIHC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.61	10.68	0.5	3.74e-23	Extrinsic epigenetic age acceleration;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg21176993	chr11:131374259	NTM	0.4	6.8	0.35	4.58e-11	Cognitive function;
LIHC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	ch.11.42038R	chr11:967971	AP2A2	0.53	9.58	0.46	2.01e-19	Alzheimer's disease (late onset);
LIHC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.75	0.3	1.96e-8	Self-reported allergy;
LIHC	cis	rs611744	0.967	rs645241	chr8:109190963	C/T	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.68	12.04	0.55	4.43e-28	High light scatter reticulocyte count;
LIHC	cis	rs36051895	0.587	rs7019418	chr9:5259847	G/C	cg02405213	chr9:5042618	JAK2	-0.63	-10.46	-0.49	2.09e-22	Pediatric autoimmune diseases;
LIHC	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg00292662	chr22:38071168	LGALS1	0.39	6.65	0.34	1.16e-10	Fat distribution (HIV);
LIHC	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.51	7.94	0.39	2.95e-14	Adiposity;
LIHC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.45	6.05	0.31	3.86e-9	Obesity-related traits;
LIHC	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.38	-6.38	-0.33	5.83e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.73	0.3	2.22e-8	Schizophrenia;
LIHC	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.61	-7.95	-0.4	2.66e-14	Response to antineoplastic agents;
LIHC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	1.17	10.91	0.51	5.79e-24	Obesity-related traits;
LIHC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.37	-0.33	6.08e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4845459	0.933	rs6662654	chr1:152593081	G/T	cg20634798	chr1:152595351	LCE3A	-0.31	-5.93	-0.31	7.34e-9	Psoriasis;
LIHC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.81	14.36	0.61	6.31e-37	Coronary artery disease;
LIHC	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14396892	chr9:96623032	NA	-0.31	-6.0	-0.31	5.09e-9	DNA methylation (variation);
LIHC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.43	5.88	0.3	9.9e-9	Schizophrenia;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg22015966	chr11:47198573	ARFGAP2	-0.44	-6.13	-0.31	2.38e-9	Alopecia areata;
LIHC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg05896524	chr21:47604654	C21orf56	0.44	6.59	0.34	1.66e-10	Testicular germ cell tumor;
LIHC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.41	6.69	0.34	9.36e-11	Red blood cell count;
LIHC	cis	rs600806	0.888	rs3768497	chr1:109866230	T/C	cg08911820	chr1:110026001	ATXN7L2	-0.59	-7.25	-0.36	2.8e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	1.04	14.04	0.6	1.11e-35	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs240764	0.697	rs239199	chr6:101134108	C/T	cg09795085	chr6:101329169	ASCC3	0.45	6.16	0.32	2.01e-9	Neuroticism;
LIHC	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21659725	chr3:3221576	CRBN	0.73	11.46	0.53	6.07e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.12	-0.31	2.6e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg07424592	chr7:64974309	NA	0.8	9.43	0.45	6.25e-19	Diabetic kidney disease;
LIHC	cis	rs4908768	0.539	rs4480384	chr1:8659714	A/G	cg20416874	chr1:8611966	RERE	-0.6	-10.84	-0.51	1.01e-23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-5.88	-0.3	9.81e-9	Ulcerative colitis;
LIHC	cis	rs13161895	0.646	rs77997852	chr5:179504925	T/C	cg02702477	chr5:179499311	RNF130	0.96	11.71	0.53	7.53e-27	LDL cholesterol;
LIHC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-10.76	-0.5	1.84e-23	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2637266	0.627	rs1992396	chr10:78482228	T/C	cg18941641	chr10:78392320	NA	0.28	6.2	0.32	1.61e-9	Pulmonary function;
LIHC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.55	8.04	0.4	1.49e-14	Mean corpuscular volume;
LIHC	cis	rs9309473	1.000	rs6715819	chr2:73772309	T/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.51	-0.33	2.64e-10	Metabolite levels;
LIHC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-20.14	-0.74	4.63e-60	Coronary artery disease;
LIHC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.53	7.37	0.37	1.32e-12	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.61	-0.5	6.33e-23	Chronic sinus infection;
LIHC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.68	12.41	0.56	1.87e-29	Menopause (age at onset);
LIHC	cis	rs2637030	0.515	rs439552	chr5:52978517	G/A	cg06476337	chr5:52856530	NDUFS4	0.42	6.78	0.34	5.31e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LIHC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.41	5.91	0.3	8.38e-9	Schizophrenia;
LIHC	trans	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg18493069	chr6:108582623	SNX3	-0.38	-6.09	-0.31	2.98e-9	Body mass index;
LIHC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.26	-0.45	2.36e-18	Hemoglobin concentration;
LIHC	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.29	0.32	9.98e-10	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.2	0.52	5.17e-25	Prudent dietary pattern;
LIHC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg09835421	chr16:68378352	PRMT7	-0.49	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	6.51	0.33	2.68e-10	Response to antipsychotic treatment;
LIHC	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg15871215	chr5:81402204	ATG10	0.68	8.24	0.41	3.82e-15	Breast cancer;
LIHC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg12463550	chr7:65579703	CRCP	0.71	7.26	0.37	2.63e-12	Diabetic kidney disease;
LIHC	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.65	-0.38	2.1e-13	Body mass index;
LIHC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.88	14.05	0.6	1.06e-35	Metabolic syndrome;
LIHC	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	6.18	0.32	1.81e-9	Iron status biomarkers;
LIHC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg24296786	chr1:45957014	TESK2	-0.47	-6.4	-0.33	5.01e-10	Platelet count;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.71	-10.51	-0.49	1.46e-22	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.52	7.93	0.39	3.24e-14	Corneal astigmatism;
LIHC	cis	rs7756236	0.538	rs6936598	chr6:36626096	T/C	cg08179530	chr6:36648295	CDKN1A	0.41	6.05	0.31	3.81e-9	QRS duration;
LIHC	cis	rs965469	0.947	rs6051692	chr20:3244098	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.62	-0.34	1.37e-10	IFN-related cytopenia;
LIHC	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	0.84	10.22	0.48	1.39e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg23782820	chr8:58130467	NA	0.33	5.95	0.31	6.66e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	21.24	0.75	1.95e-64	Smoking behavior;
LIHC	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.53	-9.36	-0.45	1.08e-18	Coronary artery disease;
LIHC	cis	rs77637988	0.604	rs17855177	chr2:48602252	C/T	cg00032884	chr2:48540671	FOXN2	0.39	5.98	0.31	5.72e-9	Joint mobility (Beighton score);
LIHC	cis	rs4794202	0.534	rs10428	chr17:45915086	G/A	cg10638573	chr17:45915098	SCRN2	0.57	6.22	0.32	1.43e-9	Alzheimer's disease (cognitive decline);
LIHC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.73	-0.34	7.16e-11	Aortic root size;
LIHC	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg04592579	chr7:75616294	TMEM120A	0.39	6.73	0.34	7.31e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.45	-8.8	-0.43	6.92e-17	Height;
LIHC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg18306943	chr3:40428807	ENTPD3	-0.42	-7.51	-0.38	5.31e-13	Renal cell carcinoma;
LIHC	cis	rs332507	0.830	rs11718359	chr3:124395987	G/A	cg05980111	chr3:124395277	KALRN	0.46	7.07	0.36	8.83e-12	Plateletcrit;
LIHC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.76	-11.62	-0.53	1.62e-26	Intelligence (multi-trait analysis);
LIHC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-8.11	-0.4	9.07e-15	Lymphocyte counts;
LIHC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	0.93	16.95	0.68	3.21e-47	Parkinson's disease;
LIHC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.4	5.96	0.31	6.22e-9	Glycated hemoglobin levels;
LIHC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23485639	chr6:28045615	ZNF165	0.44	5.84	0.3	1.21e-8	Depression;
LIHC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg14709524	chr16:89940631	TCF25	0.51	6.44	0.33	4.1e-10	Skin colour saturation;
LIHC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	9.38	0.45	9.35e-19	Platelet count;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27054084	chr5:122851781	CSNK1G3	-0.3	-7.09	-0.36	7.84e-12	Cognitive function;
LIHC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.28	-0.37	2.3e-12	Body mass index;
LIHC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.9	-0.43	3.25e-17	Gut microbiome composition (summer);
LIHC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.54	-5.96	-0.31	6.3e-9	Alzheimer's disease;
LIHC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-6.89	-0.35	2.72e-11	IgG glycosylation;
LIHC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	11.67	0.53	1.03e-26	Colorectal cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg20337385	chr14:39644624	PNN	-0.55	-6.47	-0.33	3.36e-10	Systolic blood pressure;
LIHC	cis	rs2710642	0.564	rs9989741	chr2:62828377	T/A	cg17519650	chr2:63277830	OTX1	0.43	6.77	0.34	5.71e-11	LDL cholesterol levels;LDL cholesterol;
LIHC	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.59	-9.13	-0.44	6.05e-18	Schizophrenia;
LIHC	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-7.49	-0.38	5.9e-13	Morning vs. evening chronotype;
LIHC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg20991723	chr1:152506922	NA	0.54	8.9	0.43	3.39e-17	Hair morphology;
LIHC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.13	0.31	2.37e-9	Heart rate;
LIHC	cis	rs4561483	0.603	rs11639888	chr16:11934623	G/A	cg08843971	chr16:11963173	GSPT1	0.36	6.59	0.34	1.66e-10	Testicular germ cell tumor;
LIHC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg13047869	chr3:10149882	C3orf24	0.59	5.86	0.3	1.1e-8	Alzheimer's disease;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg03942271	chr9:94124362	AUH	-0.41	-6.12	-0.31	2.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.14	0.32	2.24e-9	Systolic blood pressure;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00166836	chr6:149721425	MAP3K7IP2;SUMO4	0.42	6.38	0.33	5.82e-10	Immature fraction of reticulocytes;
LIHC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg17724175	chr1:150552817	MCL1	-0.36	-7.13	-0.36	5.91e-12	Tonsillectomy;
LIHC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg16822855	chr3:40428330	ENTPD3	-0.33	-6.01	-0.31	4.87e-9	Renal cell carcinoma;
LIHC	cis	rs11264799	0.520	rs2777965	chr1:157550417	A/C	cg18268488	chr1:157545234	FCRL4	0.21	5.72	0.3	2.28e-8	IgA nephropathy;
LIHC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.38	-0.37	1.19e-12	Breast cancer;
LIHC	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.66	0.65	4.59e-42	Electrocardiographic conduction measures;
LIHC	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.4	13.79	0.6	1.03e-34	Psoriasis vulgaris;
LIHC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg13409248	chr3:40428643	ENTPD3	0.4	6.42	0.33	4.48e-10	Renal cell carcinoma;
LIHC	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.59	-8.05	-0.4	1.37e-14	Waist circumference;Body mass index;
LIHC	cis	rs7712401	0.791	rs4835897	chr5:122121504	C/G	cg18764291	chr5:122110994	SNX2	0.37	6.36	0.33	6.38e-10	Mean platelet volume;
LIHC	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.07	-0.31	3.35e-9	Primary sclerosing cholangitis;
LIHC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.88	0.3	9.88e-9	Platelet count;
LIHC	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-6.06	-0.31	3.61e-9	Lung function (FVC);Lung function (FEV1);
LIHC	cis	rs11955398	0.669	rs11952735	chr5:59939146	T/C	cg02684056	chr5:59996105	DEPDC1B	0.4	5.91	0.3	8.27e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs67257959	0.708	rs10412843	chr19:17198287	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.37	5.87	0.3	1.04e-8	Selective IgA deficiency;
LIHC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg12373951	chr3:133503437	NA	0.49	8.05	0.4	1.42e-14	Iron status biomarkers;
LIHC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.66	-7.53	-0.38	4.6e-13	Bipolar disorder;
LIHC	cis	rs422249	0.634	rs174616	chr11:61629122	C/T	cg27386326	chr11:61587980	NA	0.33	6.13	0.31	2.42e-9	Trans fatty acid levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05421799	chr2:172778343	HAT1	0.38	6.29	0.32	9.66e-10	Hepatitis;
LIHC	cis	rs1400745	0.718	rs1200414	chr14:35330893	G/A	cg16230307	chr14:35515116	FAM177A1	0.39	6.24	0.32	1.32e-9	Monocyte count;
LIHC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	8.3	0.41	2.49e-15	IgG glycosylation;
LIHC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg18887096	chr2:219472410	PLCD4	0.39	7.03	0.36	1.14e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.49	-6.62	-0.34	1.37e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.91e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.31	6.2	0.32	1.59e-9	DNA methylation (variation);
LIHC	cis	rs13190036	0.901	rs10072499	chr5:176655237	T/G	cg06532880	chr5:176731545	PRELID1;RAB24	0.43	5.86	0.3	1.09e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.72	-0.5	2.65e-23	Eye color traits;
LIHC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg12863693	chr15:85201151	NMB	0.47	6.84	0.35	3.59e-11	Schizophrenia;
LIHC	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg18912006	chr12:123335444	HIP1R	-0.6	-6.86	-0.35	3.33e-11	Schizophrenia;
LIHC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.36	6.33	0.32	7.72e-10	Platelet distribution width;
LIHC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.48	0.33	3.25e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.85	0.3	1.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	trans	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg23598604	chr1:99732472	LPPR4	-0.3	-6.2	-0.32	1.63e-9	Multiple myeloma;
LIHC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.68	-9.88	-0.47	2e-20	Initial pursuit acceleration;
LIHC	cis	rs10949834	0.529	rs150861	chr7:73524901	T/C	cg07137043	chr7:73588983	EIF4H	0.59	7.39	0.37	1.17e-12	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-1.08	-13.85	-0.6	6.17e-35	Intelligence (multi-trait analysis);
LIHC	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.78	-9.15	-0.44	5.32e-18	Post bronchodilator FEV1;
LIHC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	6.51	0.33	2.71e-10	Sudden cardiac arrest;
LIHC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.98	0.51	3.2e-24	Motion sickness;
LIHC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-22.59	-0.77	8.57e-70	Height;
LIHC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.55	-10.37	-0.49	4.33e-22	Colorectal cancer;
LIHC	cis	rs11031096	0.655	rs1822288	chr11:4212478	C/T	cg18678763	chr11:4115507	RRM1	0.4	5.85	0.3	1.14e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-7.75	-0.39	1.07e-13	Neuranatomic and neurocognitive phenotypes;
LIHC	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg10820045	chr2:198174542	NA	0.46	6.99	0.35	1.42e-11	Dermatomyositis;
LIHC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.57	-8.32	-0.41	2.05e-15	Menarche (age at onset);
LIHC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-11.79	-0.54	3.88e-27	Total cholesterol levels;
LIHC	cis	rs7078219	0.505	rs6584282	chr10:101286495	A/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-5.98	-0.31	5.56e-9	Dental caries;
LIHC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg12373951	chr3:133503437	NA	0.43	7.09	0.36	7.5e-12	Iron status biomarkers;
LIHC	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.62	-9.69	-0.46	8.74e-20	Schizophrenia;
LIHC	cis	rs400736	0.740	rs225096	chr1:8105600	G/C	cg25007680	chr1:8021821	PARK7	0.63	9.66	0.46	1.08e-19	Response to antidepressants and depression;
LIHC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.48	7.46	0.37	7.16e-13	Methadone dose in opioid dependence;
LIHC	trans	rs7668874	0.779	rs10018157	chr4:116811858	C/T	cg08917878	chr5:172668965	NA	-0.31	-6.05	-0.31	3.75e-9	Response to platinum-based chemotherapy (carboplatin);
LIHC	cis	rs9948	1.000	rs62152794	chr2:97485110	T/C	cg01990225	chr2:97406019	LMAN2L	-0.59	-6.11	-0.31	2.64e-9	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.64	9.44	0.45	6.04e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.49	7.09	0.36	7.61e-12	High light scatter reticulocyte count;
LIHC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg07234388	chr1:156261841	TMEM79	0.53	9.48	0.46	4.25e-19	Tonsillectomy;
LIHC	cis	rs11031096	0.536	rs894459	chr11:4213590	A/G	cg18678763	chr11:4115507	RRM1	-0.41	-6.04	-0.31	4.12e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-6.6	-0.34	1.54e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11098699	0.821	rs11098703	chr4:124218462	C/G	cg09941581	chr4:124220074	SPATA5	0.33	6.59	0.34	1.69e-10	Mosquito bite size;
LIHC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-0.95	-21.01	-0.75	1.61e-63	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg25801113	chr15:45476975	SHF	0.37	6.36	0.33	6.62e-10	Uric acid levels;
LIHC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.46	-6.4	-0.33	5e-10	Total body bone mineral density;
LIHC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.79	-13.87	-0.6	5.22e-35	Body mass index;
LIHC	cis	rs17213078	0.505	rs2167531	chr2:106738625	A/G	cg16099169	chr2:106886729	NA	-0.4	-6.28	-0.32	1.05e-9	Facial morphology (factor 23);
LIHC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.49	6.35	0.32	6.73e-10	Initial pursuit acceleration;
LIHC	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.38	-6.92	-0.35	2.3e-11	Hepatocellular carcinoma;
LIHC	cis	rs17152411	1.000	rs17152448	chr10:126675645	C/G	cg07906193	chr10:126599966	NA	0.51	8.06	0.4	1.25e-14	Height;
LIHC	cis	rs655641	1.000	rs655641	chr11:85731286	C/G	cg09030501	chr11:85779252	PICALM	-0.51	-6.21	-0.32	1.56e-9	Platelet count;
LIHC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.27	-0.32	1.07e-9	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg13512537	chr8:22265999	SLC39A14	-0.33	-5.82	-0.3	1.33e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.28	-6.74	-0.34	6.94e-11	Rheumatoid arthritis;
LIHC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-6.77	-0.34	5.73e-11	Lung cancer in ever smokers;
LIHC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.49	0.38	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-1.01	-9.66	-0.46	1.15e-19	Obesity-related traits;
LIHC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05665937	chr4:1216051	CTBP1	0.44	5.8	0.3	1.47e-8	Obesity-related traits;
LIHC	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	6.67	0.34	1.01e-10	Blood protein levels;
LIHC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.58	-10.19	-0.48	1.84e-21	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.59	-11.84	-0.54	2.39e-27	Coronary artery disease;
LIHC	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-11.11	-0.52	1.04e-24	Eye color traits;
LIHC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.38	5.76	0.3	1.83e-8	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs12464559	0.649	rs3922997	chr2:152609704	C/T	cg01189475	chr2:152685088	ARL5A	0.62	7.25	0.37	2.72e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LIHC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.25	-5.77	-0.3	1.78e-8	Subjective well-being;
LIHC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.44	-7.14	-0.36	5.68e-12	Menarche (age at onset);
LIHC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.37	6.81	0.35	4.52e-11	Aortic root size;
LIHC	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.8	-0.43	6.68e-17	Colorectal cancer;
LIHC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.9	-18.68	-0.71	3.59e-54	Height;
LIHC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	8.37	0.41	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.45	-0.42	8.23e-16	Bipolar disorder and schizophrenia;
LIHC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.31	-5.86	-0.3	1.07e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg19500098	chr13:21900506	NA	0.4	6.46	0.33	3.6e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21467203	chr3:49911342	NA	-0.59	-10.62	-0.5	5.81e-23	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.28	-0.45	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs8064024	0.508	rs2037912	chr16:4933939	G/C	cg08329684	chr16:4932620	PPL	-0.43	-7.56	-0.38	3.85e-13	Cancer;
LIHC	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.12	0.31	2.5e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.51	-7.44	-0.37	8.36e-13	Obesity-related traits;
LIHC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.52	-7.81	-0.39	6.97e-14	Total body bone mineral density (age 0-15);
LIHC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.75	-11.3	-0.52	2.18e-25	Pyoderma gangrenosum in inflammatory bowel disease;
LIHC	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.44	6.8	0.35	4.54e-11	Neutrophil percentage of white cells;
LIHC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	8.45	0.42	8.48e-16	Blood metabolite levels;
LIHC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.41	5.82	0.3	1.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-8.0	-0.4	1.94e-14	Morning vs. evening chronotype;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg08708735	chr7:1609515	KIAA1908;PSMG3	-0.43	-6.28	-0.32	1.02e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs922107	0.641	rs10922658	chr1:89981468	G/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.52	-0.38	4.77e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.61	-0.34	1.43e-10	Bipolar disorder;
LIHC	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.38	-6.37	-0.33	6.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LIHC	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.64	10.31	0.49	7.14e-22	Schizophrenia;
LIHC	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.88	-0.35	2.95e-11	IFN-related cytopenia;
LIHC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg08694578	chr2:241835147	C2orf54	-0.51	-7.12	-0.36	6.38e-12	Urinary metabolites;
LIHC	cis	rs4800452	0.956	rs4239437	chr18:20732224	A/G	cg26136497	chr18:20735537	CABLES1	-0.43	-5.79	-0.3	1.59e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LIHC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.4	12.55	0.56	5.75e-30	Uric acid levels;
LIHC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.94	-0.31	7.08e-9	Calcium levels;
LIHC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08219700	chr8:58056026	NA	0.53	6.22	0.32	1.49e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10553894	chr11:68550534	CPT1A	0.41	6.35	0.32	7.03e-10	Pancreatic cancer;
LIHC	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16309518	chr5:176445507	NA	-0.51	-9.37	-0.45	9.98e-19	Menarche and menopause (age at onset);Menopause (age at onset);
LIHC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.56	8.41	0.41	1.15e-15	Platelet count;
LIHC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.59	8.99	0.44	1.74e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.66	-10.11	-0.48	3.38e-21	Coronary artery disease;
LIHC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg06466757	chr4:1255808	NA	0.35	5.93	0.31	7.24e-9	Obesity-related traits;
LIHC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-19.82	-0.73	8.91e-59	Height;
LIHC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.97	-17.18	-0.68	3.89e-48	Intelligence (multi-trait analysis);
LIHC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.98	-17.73	-0.69	2.34e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	22.37	0.77	6.21e-69	Chronic sinus infection;
LIHC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-10.01	-0.48	7.58e-21	Dental caries;
LIHC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.85	8.13	0.4	8.16e-15	Plasma clusterin levels;
LIHC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.53	-6.46	-0.33	3.52e-10	Menarche (age at onset);
LIHC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	8.73	0.43	1.12e-16	Lung cancer in ever smokers;
LIHC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	6.46	0.33	3.69e-10	Initial pursuit acceleration;
LIHC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-6.95	-0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01152906	chr10:7861152	TAF3	0.45	6.6	0.34	1.6e-10	Pancreatic cancer;
LIHC	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg01858014	chr14:56050164	KTN1	-0.72	-7.0	-0.35	1.36e-11	Putamen volume;
LIHC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg06882758	chr19:58662330	ZNF329	0.92	6.84	0.35	3.68e-11	Cholesterol, total;
LIHC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.46	7.53	0.38	4.68e-13	Age at first birth;
LIHC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.43	-7.4	-0.37	1.07e-12	Aortic root size;
LIHC	cis	rs7635838	0.751	rs2437681	chr3:11594075	A/G	cg00170343	chr3:11313890	ATG7	-0.41	-5.86	-0.3	1.06e-8	HDL cholesterol;
LIHC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.07	0.4	1.17e-14	Lymphocyte counts;
LIHC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.91	16.14	0.66	5.89e-44	Parkinson's disease;
LIHC	cis	rs6466055	0.777	rs917114	chr7:104907507	C/T	cg04380332	chr7:105027541	SRPK2	0.36	6.71	0.34	8.15e-11	Schizophrenia;
LIHC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.42	5.88	0.3	9.53e-9	Alzheimer's disease;
LIHC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.6	8.28	0.41	2.73e-15	Coronary artery disease;
LIHC	cis	rs8020095	0.571	rs11158653	chr14:67658895	C/T	cg03487553	chr14:67822707	ATP6V1D	0.32	5.72	0.3	2.32e-8	Depression (quantitative trait);
LIHC	cis	rs151997	1.000	rs373030	chr5:50215836	G/A	cg06027927	chr5:50259733	NA	0.58	7.84	0.39	5.74e-14	Callous-unemotional behaviour;
LIHC	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.35	-0.45	1.2e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.53	-8.11	-0.4	9.47e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg26138144	chr22:38071188	LGALS1	0.74	13.55	0.59	9.09e-34	Fat distribution (HIV);
LIHC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.51	9.35	0.45	1.14e-18	Hemoglobin concentration;
LIHC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.6	6.95	0.35	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.88	-16.92	-0.68	4.48e-47	Coronary artery disease;
LIHC	cis	rs9434723	0.841	rs6685399	chr1:9299294	C/T	cg04199779	chr1:9294473	H6PD	0.55	5.79	0.3	1.61e-8	Height;
LIHC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	12.26	0.55	6.75e-29	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02290350	chr8:58132656	NA	0.41	8.48	0.42	7.05e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.41	7.35	0.37	1.49e-12	Aortic root size;
LIHC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.14	10.04	0.48	6e-21	Type 2 diabetes;
LIHC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.47	8.1	0.4	1e-14	Mean corpuscular volume;
LIHC	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.31	-7.03	-0.36	1.13e-11	Cutaneous nevi;
LIHC	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-8.91	-0.43	3e-17	Atrioventricular conduction;
LIHC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg05590025	chr7:65112418	INTS4L2	-0.63	-6.91	-0.35	2.35e-11	Diabetic kidney disease;
LIHC	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.53	-6.31	-0.32	8.41e-10	Mammographic density (dense area);
LIHC	trans	rs9914544	0.545	rs8067882	chr17:18807131	A/G	cg04702396	chr17:15466718	FAM18B2	0.41	6.34	0.32	7.13e-10	Educational attainment (years of education);
LIHC	cis	rs58785573	0.570	rs4833078	chr4:38646476	C/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	7.22	0.36	3.42e-12	Lymphocyte percentage of white cells;
LIHC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.94	9.52	0.46	3.19e-19	Monocyte count;
LIHC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg26395211	chr5:140044315	WDR55	-0.43	-6.46	-0.33	3.65e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20135002	chr11:47629003	NA	0.5	8.56	0.42	3.81e-16	Subjective well-being;
LIHC	cis	rs75908454	1.000	rs78513499	chr6:169964843	A/C	cg19338460	chr6:170058176	WDR27	-0.83	-7.48	-0.38	6.2800000000000005e-13	Response to anti-TNF therapy in rheumatoid arthritis;
LIHC	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.46	6.96	0.35	1.71e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02034447	chr16:89574710	SPG7	0.45	6.81	0.35	4.5e-11	Multiple myeloma (IgH translocation);
LIHC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.62	-10.87	-0.51	7.96e-24	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.5	0.56	9.07e-30	Electrocardiographic conduction measures;
LIHC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg18306943	chr3:40428807	ENTPD3	-0.37	-6.5	-0.33	2.83e-10	Renal cell carcinoma;
LIHC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	6.88	0.35	2.89e-11	Platelet count;
LIHC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg18944383	chr4:111397179	ENPEP	0.27	6.86	0.35	3.28e-11	Height;
LIHC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg19635926	chr16:89946313	TCF25	0.56	7.58	0.38	3.24e-13	Skin colour saturation;
LIHC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.75	-0.3	2.02e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs11098699	0.821	rs2099955	chr4:124214160	C/T	cg09941581	chr4:124220074	SPATA5	0.32	6.48	0.33	3.25e-10	Mosquito bite size;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg07449447	chr14:55228808	SAMD4A	-0.45	-6.51	-0.33	2.75e-10	Lung function (FEV1/FVC);
LIHC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	12.68	0.57	1.91e-30	Alzheimer's disease;
LIHC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg22079354	chr11:130786696	SNX19	0.42	6.04	0.31	3.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-8.56	-0.42	3.89e-16	Total body bone mineral density;
LIHC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.3	-7.01	-0.35	1.3e-11	Menarche (age at onset);
LIHC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg16558253	chr16:72132732	DHX38	-0.42	-5.9	-0.3	8.9e-9	Fibrinogen levels;
LIHC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.5	-0.33	2.78e-10	Body mass index;
LIHC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg12365402	chr11:9010492	NRIP3	0.31	7.95	0.39	2.76e-14	Hemoglobin concentration;
LIHC	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg15208524	chr1:10270712	KIF1B	0.38	5.81	0.3	1.42e-8	Hepatocellular carcinoma;
LIHC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.57	0.53	2.35e-26	Motion sickness;
LIHC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg25039879	chr17:56429692	SUPT4H1	0.78	8.89	0.43	3.6e-17	Cognitive test performance;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	7.2	0.36	3.77e-12	Renal cell carcinoma;
LIHC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.7	-8.77	-0.43	8.34e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-9.35	-0.45	1.22e-18	Hemoglobin concentration;
LIHC	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg08668510	chr10:1095578	IDI1	0.62	6.05	0.31	3.89e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.93	17.09	0.68	8.8e-48	Breast cancer;
LIHC	trans	rs5756813	0.754	rs4821706	chr22:38154690	A/G	cg19894588	chr14:64061835	NA	-0.64	-8.67	-0.42	1.8e-16	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.69	10.94	0.51	4.41e-24	Response to diuretic therapy;
LIHC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg18478394	chr8:109455254	TTC35	0.42	7.21	0.36	3.52e-12	Dupuytren's disease;
LIHC	trans	rs7693389	0.925	rs2899092	chr4:58450181	A/G	cg13593275	chr9:128777788	NA	0.53	6.05	0.31	3.87e-9	Diisocyanate-induced asthma;
LIHC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-8.75	-0.43	1.01e-16	Morning vs. evening chronotype;
LIHC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.78	12.97	0.57	1.51e-31	Psoriasis;
LIHC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.22	5.99	0.31	5.44e-9	Calcium levels;
LIHC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.49	-5.87	-0.3	1.05e-8	Blood metabolite levels;
LIHC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg25364880	chr3:44379878	C3orf23	0.56	7.86	0.39	5.16e-14	Depressive symptoms;
LIHC	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg03146154	chr1:46216737	IPP	-0.41	-6.78	-0.34	5.34e-11	Red blood cell count;Reticulocyte count;
LIHC	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.07	-0.31	3.38e-9	Coronary artery disease;
LIHC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.39	-6.09	-0.31	2.99e-9	Multiple myeloma;
LIHC	cis	rs9503598	0.502	rs6917962	chr6:3430191	A/T	cg00476032	chr6:3446245	SLC22A23	-0.32	-5.86	-0.3	1.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LIHC	cis	rs1000083	0.748	rs2643523	chr5:96624676	A/G	ch.5.96698337R	chr5:96672581	NA	-0.96	-7.29	-0.37	2.23e-12	Cisplatin-induced ototoxicity;
LIHC	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg15282417	chr9:129245246	FAM125B	0.4	6.7	0.34	8.84e-11	Intraocular pressure;
LIHC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg13175981	chr1:150552382	MCL1	-0.44	-6.06	-0.31	3.56e-9	Tonsillectomy;
LIHC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.56	8.84	0.43	5.16e-17	Menarche (age at onset);
LIHC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.78	11.78	0.54	4.13e-27	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg10157359	chr2:10953004	PDIA6	-0.5	-6.76	-0.34	5.86e-11	Cardiac Troponin-T levels;
LIHC	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg23112188	chr14:24563095	PCK2	-0.29	-6.04	-0.31	4.13e-9	IgG glycosylation;
LIHC	cis	rs881827	0.851	rs55863940	chr21:48011048	A/T	cg12379764	chr21:47803548	PCNT	-0.43	-5.71	-0.3	2.42e-8	Lymphocyte counts;
LIHC	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.66	-10.4	-0.49	3.2800000000000002e-22	White matter hyperintensity burden;
LIHC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.29	-0.68	1.41e-48	Body mass index;
LIHC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg20195005	chr22:42527684	CYP2D6	0.3	5.77	0.3	1.77e-8	Birth weight;
LIHC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg12458913	chr13:53173898	NA	0.47	7.48	0.37	6.36e-13	Lewy body disease;
LIHC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg07599136	chr5:415885	AHRR	0.38	6.47	0.33	3.38e-10	Cystic fibrosis severity;
LIHC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.6	10.21	0.48	1.5e-21	Height;
LIHC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.46	8.14	0.4	7.28e-15	Educational attainment;
LIHC	cis	rs10861661	0.963	rs10861669	chr12:107200068	C/A	cg15890332	chr12:107067104	RFX4	0.26	5.76	0.3	1.84e-8	Triglyceride levels;
LIHC	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.23	6.34	0.32	7.13e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs6686842	0.562	rs18996	chr1:41624520	C/T	cg08462924	chr1:41848221	NA	0.32	5.89	0.3	9.23e-9	Height;
LIHC	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg11657440	chr19:46296263	DMWD	-0.55	-8.81	-0.43	6.37e-17	Coronary artery disease;
LIHC	cis	rs807029	0.533	rs2295716	chr10:102744214	T/C	cg25179470	chr10:102756915	LZTS2	0.45	6.38	0.33	5.65e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg10130564	chr11:117069849	TAGLN	0.36	6.1	0.31	2.95e-9	Blood protein levels;
LIHC	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg25902810	chr10:99078978	FRAT1	-0.56	-6.39	-0.33	5.39e-10	Monocyte count;
LIHC	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	7.46	0.37	7.34e-13	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs6450176	0.564	rs390420	chr5:53326731	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.75	-13.51	-0.59	1.27e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg16736954	chr20:23401023	NAPB	0.71	8.28	0.41	2.77e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.46	-7.2	-0.36	3.79e-12	Cocaine dependence;
LIHC	cis	rs9921222	0.500	rs12917907	chr16:405866	C/T	cg12437481	chr16:420112	MRPL28	-0.67	-9.55	-0.46	2.67e-19	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg24826892	chr11:71159390	DHCR7	0.51	6.57	0.33	1.92e-10	Vitamin D levels;
LIHC	trans	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg10756647	chr7:56101905	PSPH	-1.02	-12.92	-0.57	2.19e-31	Diabetic kidney disease;
LIHC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.37	6.7	0.34	8.44e-11	IgG glycosylation;
LIHC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.7	-9.81	-0.47	3.39e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.72	13.24	0.58	1.38e-32	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03929569	chr13:30689009	NA	0.49	6.09	0.31	3.1e-9	Hepatitis;
LIHC	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.6	8.68	0.43	1.59e-16	Schizophrenia;
LIHC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.72	12.29	0.55	5.32e-29	Menopause (age at onset);
LIHC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.43	7.89	0.39	4.07e-14	Schizophrenia;
LIHC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.66	7.56	0.38	3.84e-13	Neutrophil percentage of white cells;
LIHC	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.5	-6.54	-0.33	2.26e-10	Diisocyanate-induced asthma;
LIHC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg11062466	chr8:58055876	NA	0.4	5.82	0.3	1.36e-8	Developmental language disorder (linguistic errors);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20586607	chr14:50235780	KLHDC2	0.4	6.06	0.31	3.51e-9	Cognitive function;
LIHC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08677398	chr8:58056175	NA	0.4	6.24	0.32	1.3e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg10360323	chr17:41437877	NA	0.41	6.12	0.31	2.53e-9	Menopause (age at onset);
LIHC	cis	rs11212260	0.655	rs10458952	chr11:107292898	C/T	cg25435332	chr11:107328525	CWF19L2	0.8	8.13	0.4	7.75e-15	IgG glycosylation;
LIHC	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.3	5.9	0.3	8.77e-9	Asthma (childhood onset);
LIHC	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs2412488	0.861	rs10000746	chr4:54281731	T/A	cg22241045	chr4:54363911	LNX1	-0.47	-7.51	-0.38	5.16e-13	DNA methylation (variation);
LIHC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg19682013	chr15:45996608	NA	0.39	6.67	0.34	1.01e-10	Waist circumference;Weight;
LIHC	trans	rs1347297	0.789	rs11688081	chr2:179280799	A/G	cg14011486	chr1:26737247	LIN28	0.44	6.84	0.35	3.6e-11	Alzheimer disease and age of onset;
LIHC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.89	0.43	3.61e-17	Lymphocyte percentage of white cells;
LIHC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg17279839	chr7:150038598	RARRES2	0.48	10.1	0.48	3.59e-21	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.64	11.15	0.52	7.61e-25	Menopause (age at onset);
LIHC	cis	rs77637988	0.578	rs7577237	chr2:48601816	A/G	cg15846641	chr2:48541264	FOXN2	-0.59	-8.03	-0.4	1.54e-14	Joint mobility (Beighton score);
LIHC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.42	-6.87	-0.35	3.11e-11	Height;
LIHC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	7.92	0.39	3.45e-14	Platelet count;
LIHC	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.4	8.8	0.43	7.12e-17	Colorectal cancer (SNP x SNP interaction);
LIHC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.67	-9.53	-0.46	3.04e-19	Obesity-related traits;
LIHC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	9.72	0.47	6.98e-20	Lung cancer;
LIHC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.5	-7.78	-0.39	8.59e-14	Educational attainment;
LIHC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.93	0.44	2.58e-17	Motion sickness;
LIHC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg09033563	chr22:24373618	LOC391322	-0.46	-6.39	-0.33	5.45e-10	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	8.13	0.4	8.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.63	11.52	0.53	3.68e-26	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.85	17.56	0.69	1.19e-49	Longevity;
LIHC	cis	rs4684776	0.935	rs11128547	chr3:11393268	A/G	cg00170343	chr3:11313890	ATG7	0.5	6.84	0.35	3.75e-11	Small vessel stroke;
LIHC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-9.65	-0.46	1.22e-19	Asthma;
LIHC	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18867708	chr6:26865862	GUSBL1	-0.54	-8.2	-0.41	4.83e-15	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.56	-8.57	-0.42	3.51e-16	Extraversion;
LIHC	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.38	8.13	0.4	8.22e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-5.84	-0.3	1.22e-8	Body mass index;
LIHC	trans	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg23598604	chr1:99732472	LPPR4	-0.3	-6.27	-0.32	1.09e-9	Multiple myeloma;
LIHC	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.33	-5.9	-0.3	8.64e-9	Lewy body disease;
LIHC	cis	rs8067354	0.574	rs1296279	chr17:57965731	G/A	cg02344993	chr17:57696989	CLTC	0.66	10.3	0.49	7.37e-22	Hemoglobin concentration;
LIHC	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	0.7	7.43	0.37	8.8e-13	Gut microbiota (bacterial taxa);
LIHC	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-14.59	-0.62	8.14e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.5	6.29	0.32	9.68e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LIHC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	6.12	0.31	2.51e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.51	8.17	0.4	6.2e-15	Testicular germ cell tumor;
LIHC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.88	0.6	4.81e-35	Primary sclerosing cholangitis;
LIHC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.32	0.37	1.74e-12	Monocyte percentage of white cells;
LIHC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.64	8.63	0.42	2.33e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LIHC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg03146154	chr1:46216737	IPP	-0.38	-6.25	-0.32	1.21e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08219700	chr8:58056026	NA	0.53	7.17	0.36	4.67e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg27209729	chr11:64428925	NRXN2	0.36	6.76	0.34	6.06e-11	Body mass index;Urate levels;
LIHC	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg04287289	chr16:89883240	FANCA	0.54	8.64	0.42	2.15e-16	Vitiligo;
LIHC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg02290350	chr8:58132656	NA	0.32	7.02	0.35	1.23e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.68	-5.9	-0.3	8.63e-9	LDL cholesterol;Cholesterol, total;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15715256	chr5:42767749	CCDC152	-0.42	-6.36	-0.33	6.3e-10	Hepatitis;
LIHC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-20.12	-0.74	5.95e-60	Height;
LIHC	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg16275483	chr1:110013120	SYPL2	-0.49	-6.08	-0.31	3.2e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	8.41	0.41	1.14e-15	Lymphocyte counts;
LIHC	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg05041596	chr11:89867385	NAALAD2	0.43	7.11	0.36	6.87e-12	White blood cell types;
LIHC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.51	0.62	1.6e-37	Prudent dietary pattern;
LIHC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.24	19.05	0.72	1.14e-55	Type 1 diabetes nephropathy;
LIHC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg05590025	chr7:65112418	INTS4L2	-0.63	-7.04	-0.36	1.08e-11	Diabetic kidney disease;
LIHC	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg02811702	chr13:24901961	NA	0.25	6.33	0.32	7.79e-10	Obesity-related traits;
LIHC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.37	5.99	0.31	5.46e-9	Menopause (age at onset);
LIHC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.79	-10.09	-0.48	4e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	1.13	13.86	0.6	5.46e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs6977660	1.000	rs34367208	chr7:19818811	T/G	cg07541023	chr7:19748670	TWISTNB	0.37	5.87	0.3	1.01e-8	Thyroid stimulating hormone;
LIHC	cis	rs10242455	0.571	rs80045298	chr7:99307453	T/A	cg18809830	chr7:99032528	PTCD1	-0.86	-6.71	-0.34	8.19e-11	Blood metabolite levels;
LIHC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg18867708	chr6:26865862	GUSBL1	0.52	8.03	0.4	1.64e-14	Schizophrenia;
LIHC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg03709012	chr19:19516395	GATAD2A	0.64	7.1	0.36	7.14e-12	Tonsillectomy;
LIHC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.54	11.0	0.51	2.69e-24	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg06359132	chr10:99160096	RRP12	-0.42	-6.52	-0.33	2.52e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-9.26	-0.45	2.25e-18	Gut microbiome composition (summer);
LIHC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.26	5.97	0.31	5.91e-9	Crohn's disease;
LIHC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10348368	chr14:105851883	PACS2	0.41	6.17	0.32	1.91e-9	Longevity;
LIHC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.72	-11.26	-0.52	3.21e-25	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.02	-0.36	1.17e-11	Bipolar disorder;
LIHC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.75	-10.88	-0.51	6.94e-24	Dilated cardiomyopathy;
LIHC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.73	11.11	0.51	1.08e-24	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg27433088	chr4:174089019	GALNT7	-0.33	-6.24	-0.32	1.3e-9	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.85	0.39	5.26e-14	Motion sickness;
LIHC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.46	-6.39	-0.33	5.56e-10	Initial pursuit acceleration;
LIHC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.21	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.6	-0.34	1.6e-10	Blood pressure;
LIHC	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.21	-5.81	-0.3	1.39e-8	Hepatitis;
LIHC	cis	rs6604026	0.555	rs11805007	chr1:93082190	A/G	cg13858687	chr1:93297071	RPL5	0.6	5.71	0.3	2.41e-8	Multiple sclerosis;
LIHC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-8.45	-0.42	8.76e-16	Gut microbiome composition (summer);
LIHC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg02640540	chr1:67518911	SLC35D1	0.42	5.83	0.3	1.25e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs1712517	0.771	rs11191664	chr10:105118476	C/T	cg05636881	chr10:105038444	INA	0.49	7.53	0.38	4.51e-13	Migraine;
LIHC	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.42	7.58	0.38	3.32e-13	Platelet distribution width;
LIHC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.62	7.73	0.39	1.25e-13	Mean platelet volume;
LIHC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.98	-0.51	3.28e-24	Hemoglobin concentration;
LIHC	cis	rs61712019	1.000	rs13420329	chr2:77706547	C/T	cg11252801	chr2:77748917	LRRTM4	0.5	7.72	0.39	1.32e-13	Schizophrenia;
LIHC	cis	rs15676	0.947	rs10988124	chr9:131569345	G/A	cg13708974	chr9:131466143	PKN3	0.39	5.85	0.3	1.17e-8	Blood metabolite levels;
LIHC	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.44	-9.46	-0.46	5.01e-19	Migraine;
LIHC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg13974409	chr11:65292307	SCYL1	-0.38	-5.99	-0.31	5.34e-9	Bone mineral density;
LIHC	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.13	-0.31	2.45e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.48	6.75	0.34	6.43e-11	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg25364880	chr3:44379878	C3orf23	0.6	8.45	0.42	8.37e-16	Depressive symptoms;
LIHC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.85	-13.76	-0.6	1.3600000000000001e-34	Post bronchodilator FEV1;
LIHC	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg19743168	chr1:23544995	NA	0.43	7.94	0.39	2.93e-14	Height;
LIHC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-22.14	-0.77	4.92e-68	Myeloid white cell count;
LIHC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	9.89	0.47	1.8899999999999998e-20	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27297192	chr10:134578999	INPP5A	0.53	7.32	0.37	1.74e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.43	6.71	0.34	8.04e-11	Alzheimer's disease (survival time);
LIHC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg26138937	chr11:71823887	C11orf51	-1.28	-10.0	-0.48	8.22e-21	Severe influenza A (H1N1) infection;
LIHC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-8.15	-0.4	6.79e-15	Dental caries;
LIHC	cis	rs611744	0.837	rs403200	chr8:109103375	C/T	cg21045802	chr8:109455806	TTC35	0.47	8.11	0.4	8.87e-15	Dupuytren's disease;
LIHC	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.58	10.75	0.5	2.1e-23	Leprosy;
LIHC	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.5	-7.91	-0.39	3.51e-14	Alzheimer's disease (survival time);
LIHC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.86	14.85	0.63	7.6e-39	Colorectal cancer;
LIHC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs9649465	0.967	rs10269196	chr7:123321073	G/T	cg03229431	chr7:123269106	ASB15	-0.39	-8.37	-0.41	1.48e-15	Migraine;
LIHC	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg10241871	chr14:102965420	TECPR2	-0.39	-6.13	-0.31	2.38e-9	Plateletcrit;
LIHC	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.89	-17.84	-0.69	8.29e-51	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.43	-5.92	-0.31	7.67e-9	Total body bone mineral density;
LIHC	cis	rs888194	0.738	rs7298565	chr12:109937534	A/G	cg05360138	chr12:110035743	NA	-0.41	-5.88	-0.3	9.76e-9	Neuroticism;
LIHC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	7.95	0.39	2.79e-14	Motion sickness;
LIHC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.43	6.64	0.34	1.24e-10	Methadone dose in opioid dependence;
LIHC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11987759	chr7:65425863	GUSB	-0.39	-6.11	-0.31	2.75e-9	Aortic root size;
LIHC	cis	rs62179067	0.708	rs11891608	chr2:179940373	G/T	cg07532576	chr2:179544947	TTN	0.64	5.79	0.3	1.61e-8	Late-onset Alzheimer's disease;
LIHC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	7.95	0.39	2.74e-14	IgG glycosylation;
LIHC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.46	7.88	0.39	4.47e-14	Mean corpuscular volume;
LIHC	cis	rs7903847	0.620	rs10882907	chr10:99125788	C/G	cg06359132	chr10:99160096	RRP12	0.37	5.83	0.3	1.25e-8	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27297192	chr10:134578999	INPP5A	0.56	7.71	0.38	1.41e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.62	7.9	0.39	3.74e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs611744	0.967	rs702801	chr8:109211802	T/C	cg21045802	chr8:109455806	TTC35	0.51	8.82	0.43	5.8e-17	Dupuytren's disease;
LIHC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg06935464	chr4:38784597	TLR10	0.47	7.32	0.37	1.81e-12	Breast cancer;
LIHC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.38	6.01	0.31	4.83e-9	Menopause (age at onset);
LIHC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-7.56	-0.38	3.86e-13	Initial pursuit acceleration;
LIHC	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.62	9.28	0.45	2.02e-18	Metabolite levels;
LIHC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.45	-7.42	-0.37	9.16e-13	Testicular germ cell tumor;
LIHC	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.48	0.37	6.3e-13	LDL cholesterol;
LIHC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg25894440	chr7:65020034	NA	-0.56	-6.49	-0.33	3.01e-10	Diabetic kidney disease;
LIHC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.73	12.62	0.56	3e-30	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.82	12.52	0.56	7.26e-30	Resting heart rate;
LIHC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg21466736	chr12:48725269	NA	0.63	8.99	0.44	1.69e-17	Bipolar disorder and schizophrenia;
LIHC	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.83	0.35	3.89e-11	Cerebrospinal fluid biomarker levels;
LIHC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.89	-18.22	-0.7	2.49e-52	Height;
LIHC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg02931644	chr1:25747376	RHCE	0.38	8.45	0.42	8.49e-16	Plateletcrit;Mean corpuscular volume;
LIHC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.56	-7.62	-0.38	2.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg26441486	chr22:50317300	CRELD2	0.35	6.25	0.32	1.19e-9	Schizophrenia;
LIHC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.53	8.44	0.42	8.92e-16	Vitiligo;
LIHC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08164852	chr1:28844593	SNHG3-RCC1;RCC1	0.4	6.13	0.31	2.37e-9	Electrocardiographic conduction measures;
LIHC	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16684958	chr7:75615977	POR	0.48	8.13	0.4	8.21e-15	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.48	-0.33	3.21e-10	Mean corpuscular volume;
LIHC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.76	-0.39	1.01e-13	Morning vs. evening chronotype;
LIHC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.45	0.53	6.46e-26	Prudent dietary pattern;
LIHC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.75	-10.68	-0.5	3.56e-23	Hemostatic factors and hematological phenotypes;
LIHC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.27	-5.74	-0.3	2.11e-8	Bronchopulmonary dysplasia;
LIHC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.56	-9.11	-0.44	7e-18	Lymphocyte counts;
LIHC	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.4	-7.5	-0.38	5.67e-13	Glaucoma;
LIHC	cis	rs17106184	0.892	rs58836765	chr1:50896037	G/A	cg07174182	chr1:51127561	FAF1	-0.57	-6.36	-0.33	6.33e-10	Type 2 diabetes;
LIHC	cis	rs249954	0.512	rs27770	chr16:23701538	A/G	cg05131483	chr16:23706242	ERN2	0.36	5.84	0.3	1.23e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.65	5.73	0.3	2.22e-8	Blood protein levels;
LIHC	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg17075019	chr10:79541650	NA	-0.75	-11.06	-0.51	1.67e-24	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9612	1.000	rs347519	chr19:44273516	T/C	cg08581076	chr19:44259116	C19orf61	0.59	7.46	0.37	7.17e-13	Exhaled nitric oxide output;
LIHC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.79	17.49	0.69	2.24e-49	Gestational age at birth (maternal effect);
LIHC	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.96e-9	Pulmonary function;
LIHC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs12365397	0.775	rs1874435	chr11:43246675	A/G	cg16667275	chr11:43333495	API5	-0.41	-6.21	-0.32	1.57e-9	Migraine;
LIHC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg00086871	chr4:6988644	TBC1D14	0.87	6.22	0.32	1.48e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.41	6.87	0.35	2.98e-11	Blood metabolite levels;
LIHC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-6.68	-0.34	9.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.67	0.34	1.04e-10	Obesity-related traits;
LIHC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.94	17.31	0.68	1.22e-48	Parkinson's disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11954230	chr10:105677556	OBFC1	0.43	6.38	0.33	5.63e-10	Cognitive function;
LIHC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg24826892	chr11:71159390	DHCR7	0.51	6.64	0.34	1.22e-10	Vitamin D levels;
LIHC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.43	6.94	0.35	2.03e-11	Morning vs. evening chronotype;
LIHC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.51	7.17	0.36	4.52e-12	Menopause (age at onset);
LIHC	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	6.55	0.33	2.1e-10	Menarche (age at onset);
LIHC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.48	8.04	0.4	1.46e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.81	-12.7	-0.57	1.48e-30	Total body bone mineral density;
LIHC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg05590025	chr7:65112418	INTS4L2	-0.66	-7.2	-0.36	3.94e-12	Diabetic kidney disease;
LIHC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.49	6.72	0.34	7.44e-11	High light scatter reticulocyte count;
LIHC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	21.09	0.75	7.35e-64	Chronic sinus infection;
LIHC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.57	0.5	8.87e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.44	6.42	0.33	4.49e-10	Hepatocellular carcinoma;
LIHC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.6	8.34	0.41	1.9e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.49	6.06	0.31	3.57e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs16912285	0.636	rs7114960	chr11:24310828	G/A	ch.11.24196551F	chr11:24239977	NA	0.76	10.01	0.48	7.41e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LIHC	cis	rs9473924	0.505	rs55653665	chr6:50812984	T/C	cg14470998	chr6:50812995	TFAP2B	0.98	11.38	0.52	1.19e-25	Body mass index;
LIHC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.45	6.57	0.33	1.85e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg20435097	chr10:126320824	FAM53B	-0.44	-6.58	-0.34	1.81e-10	Cocaine dependence;
LIHC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.45	6.84	0.35	3.59e-11	Cognitive function;
LIHC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.24	-0.48	1.23e-21	Response to antipsychotic treatment;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg00185336	chr7:73153699	ABHD11	0.41	6.58	0.34	1.79e-10	Cognitive function;
LIHC	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.58	0.5	8.13e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	12.19	0.55	1.22e-28	Cognitive test performance;
LIHC	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	10.72	0.5	2.59e-23	Platelet distribution width;
LIHC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.45	7.76	0.39	1.02e-13	Schizophrenia;
LIHC	cis	rs6191	0.844	rs258763	chr5:142652361	T/A	cg17617527	chr5:142782415	NR3C1	0.42	5.87	0.3	1.02e-8	Night sleep phenotypes;
LIHC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.67	10.49	0.49	1.65e-22	Longevity;
LIHC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.81	12.74	0.57	1.0500000000000001e-30	Neuroticism;Neuroticism (multi-trait analysis);
LIHC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12016809	chr21:47604291	C21orf56	0.42	6.33	0.32	7.92e-10	Testicular germ cell tumor;
LIHC	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.67	13.17	0.58	2.64e-32	Leprosy;
LIHC	cis	rs7534824	0.625	rs61780332	chr1:101484733	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	7.03	0.36	1.13e-11	Refractive astigmatism;
LIHC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg07133347	chr1:107600762	PRMT6	-0.45	-6.75	-0.34	6.45e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg01028140	chr2:1542097	TPO	-0.48	-5.97	-0.31	6.02e-9	Placebo response in major depressive disorder (% change in symptom score);
LIHC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.46	-6.72	-0.34	7.6e-11	Psoriasis;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	14.7	0.62	2.84e-38	Prudent dietary pattern;
LIHC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg17724175	chr1:150552817	MCL1	0.38	7.59	0.38	3.03e-13	Melanoma;
LIHC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.75	15.33	0.64	9.55e-41	Menopause (age at onset);
LIHC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.4	0.37	1.05e-12	Prudent dietary pattern;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg06742800	chr2:27255708	TMEM214	0.44	6.55	0.33	2.09e-10	Lung function (FEV1/FVC);
LIHC	trans	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg04702396	chr17:15466718	FAM18B2	0.44	6.65	0.34	1.18e-10	Educational attainment (years of education);
LIHC	cis	rs263063	0.764	rs2291148	chr19:5077583	A/G	cg18473234	chr19:5097819	KDM4B	-0.61	-7.36	-0.37	1.42e-12	Periodontitis (CDC/AAP);
LIHC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	6.53	0.33	2.35e-10	Chronic sinus infection;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg01964233	chr2:99757837	C2orf15;TSGA10	-0.5	-6.06	-0.31	3.55e-9	Systolic blood pressure;
LIHC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg21466736	chr12:48725269	NA	-0.7	-10.55	-0.5	1.06e-22	Obstructive sleep apnea trait (apnea hypopnea index);
LIHC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg23262073	chr20:60523788	NA	-0.29	-6.06	-0.31	3.68e-9	Body mass index;
LIHC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.9	12.22	0.55	9.87e-29	Blood metabolite levels;
LIHC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg18121669	chr1:26560928	CCDC21	0.5	8.0	0.4	1.91e-14	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.56	8.78	0.43	8.17e-17	Menarche (age at onset);
LIHC	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.69	0.43	1.53e-16	Platelet count;
LIHC	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.41	-5.81	-0.3	1.4e-8	Stearic acid (18:0) levels;
LIHC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg03959625	chr15:84868606	LOC388152	0.45	6.1	0.31	2.93e-9	Schizophrenia;
LIHC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.61	-0.79	8.2e-74	Height;
LIHC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg18016565	chr1:150552671	MCL1	-0.55	-11.08	-0.51	1.37e-24	Tonsillectomy;
LIHC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.6	-8.51	-0.42	5.64e-16	Blood metabolite levels;
LIHC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	7.64	0.38	2.14e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.12	0.31	2.53e-9	Height;
LIHC	trans	rs6600671	1.000	rs1832558	chr1:121177380	A/G	cg09829573	chr1:144692074	NBPF9	-0.43	-7.95	-0.39	2.76e-14	Hip geometry;
LIHC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	6.93	0.35	2.07e-11	Intelligence (multi-trait analysis);
LIHC	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-8.67	-0.42	1.71e-16	Colorectal cancer;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.73	12.99	0.57	1.21e-31	Prudent dietary pattern;
LIHC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.43	5.9	0.3	8.52e-9	Life satisfaction;
LIHC	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	0.55	8.23	0.41	3.87e-15	Atopic dermatitis;
LIHC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.5	8.28	0.41	2.87e-15	Diastolic blood pressure;
LIHC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	0.83	7.56	0.38	3.76e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	17.36	0.68	7.38e-49	Lung cancer in ever smokers;
LIHC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.71	11.16	0.52	7.05e-25	Corneal astigmatism;
LIHC	cis	rs2839627	0.561	rs9977774	chr21:44342476	G/C	cg03543861	chr21:44258195	NA	0.52	7.45	0.37	7.6e-13	Information processing speed;
LIHC	trans	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg01596870	chr19:55963115	NA	-0.67	-9.59	-0.46	1.96e-19	Obesity-related traits;
LIHC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.11	-16.01	-0.65	1.99e-43	Chronic sinus infection;
LIHC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg03665457	chr10:38645376	HSD17B7P2	0.39	5.77	0.3	1.81e-8	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.43	5.79	0.3	1.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg25600027	chr14:23388339	RBM23	0.42	6.18	0.32	1.83e-9	Cognitive ability (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg13175981	chr1:150552382	MCL1	-0.43	-6.03	-0.31	4.3e-9	Tonsillectomy;
LIHC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg15605315	chr1:45957053	TESK2	-0.43	-5.88	-0.3	9.66e-9	Platelet count;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.34	0.32	7.32e-10	Total body bone mineral density;
LIHC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-12.2	-0.55	1.11e-28	Chronic sinus infection;
LIHC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg12560992	chr17:57184187	TRIM37	-0.56	-7.74	-0.39	1.1e-13	Cognitive test performance;
LIHC	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.33	-0.32	7.73e-10	Barrett's esophagus;
LIHC	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.43	-0.37	8.48e-13	QT interval;
LIHC	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.93	-0.35	2.11e-11	Blood pressure;
LIHC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.87	13.67	0.59	2.97e-34	Skin colour saturation;
LIHC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.46	6.22	0.32	1.42e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.0	-0.31	4.95e-9	Blood metabolite levels;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg13404532	chr3:128483276	RAB7A	-0.39	-6.06	-0.31	3.59e-9	Calcium levels;
LIHC	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg10127483	chr1:110009974	SYPL2	0.5	6.4	0.33	5.26e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg16736954	chr20:23401023	NAPB	0.52	5.78	0.3	1.71e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg03934865	chr2:198174659	NA	0.51	7.72	0.39	1.3e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.37	5.87	0.3	1.01e-8	Height;
LIHC	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	0.39	6.15	0.32	2.2e-9	Coronary artery disease;
LIHC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.68	10.0	0.48	7.83e-21	Aortic root size;
LIHC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.36	-7.16	-0.36	5e-12	Body mass index;
LIHC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.44	-7.46	-0.37	7.07e-13	Lung cancer;
LIHC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg14779329	chr11:130786720	SNX19	0.4	6.03	0.31	4.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-0.72	-7.0	-0.35	1.36e-11	Putamen volume;
LIHC	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.63	-9.1	-0.44	7.75e-18	White matter hyperintensity burden;
LIHC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg22079354	chr11:130786696	SNX19	-0.41	-5.91	-0.3	8.4e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-0.97	-22.08	-0.77	8.55e-68	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.36	6.12	0.31	2.63e-9	Height;
LIHC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.7	0.57	1.48e-30	Age-related macular degeneration (geographic atrophy);
LIHC	trans	rs10230207	0.963	rs4236296	chr7:19616437	T/G	cg04830814	chr5:32174484	GOLPH3	-0.41	-6.11	-0.31	2.77e-9	Intracranial aneurysm;
LIHC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.57	7.46	0.37	7.23e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04221910	chr5:616842	CEP72	-0.41	-7.11	-0.36	6.61e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LIHC	cis	rs11671005	0.779	rs3752112	chr19:58992220	T/G	cg25952890	chr19:58913133	NA	0.71	7.31	0.37	1.9e-12	Mean platelet volume;
LIHC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.89	-0.3	9.08e-9	Fear of minor pain;
LIHC	cis	rs11229555	0.645	rs10896774	chr11:58175837	T/G	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.6	-9.33	-0.45	1.39e-18	White matter hyperintensity burden;
LIHC	cis	rs72843506	0.722	rs9908418	chr17:20214565	A/G	cg12065943	chr17:19881925	AKAP10	-0.33	-5.87	-0.3	1.05e-8	Schizophrenia;
LIHC	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg00601450	chr5:74908170	NA	0.59	7.12	0.36	6.53e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg16989086	chr20:62203971	PRIC285	0.56	8.05	0.4	1.41e-14	Glioblastoma;
LIHC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg00529422	chr1:16285251	ZBTB17	0.35	6.54	0.33	2.24e-10	Systolic blood pressure;
LIHC	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.3	-6.84	-0.35	3.59e-11	Hip circumference;Waist circumference;
LIHC	cis	rs832187	0.640	rs704367	chr3:63868777	A/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.42	5.8	0.3	1.52e-8	Schizophrenia;
LIHC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.26	-0.32	1.16e-9	Schizophrenia;
LIHC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.01	-0.4	1.88e-14	Type 2 diabetes;
LIHC	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.09	0.44	8.02e-18	Coffee consumption (cups per day);
LIHC	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.3	5.72	0.3	2.34e-8	Asthma;
LIHC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-8.87	-0.43	4.05e-17	Bipolar disorder;
LIHC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.49	7.3	0.37	1.98e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.66	11.41	0.52	9.23e-26	Platelet distribution width;
LIHC	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09888468	chr15:81410853	NA	-0.38	-6.36	-0.33	6.36e-10	QT interval (drug interaction);
LIHC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg25281562	chr12:121454272	C12orf43	0.36	6.27	0.32	1.06e-9	N-glycan levels;
LIHC	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.35	-5.89	-0.3	9.28e-9	Corneal structure;
LIHC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	5.88	0.3	9.86e-9	Tonsillectomy;
LIHC	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14442939	chr10:27389572	ANKRD26	0.7	8.29	0.41	2.54e-15	Breast cancer;
LIHC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg03143697	chr5:177099378	LOC202181	-0.39	-6.33	-0.32	7.53e-10	Methadone dose in opioid dependence;
LIHC	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.31	-0.37	1.88e-12	Bipolar disorder;
LIHC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg25356066	chr3:128598488	ACAD9	0.55	7.69	0.38	1.6e-13	IgG glycosylation;
LIHC	cis	rs1198430	0.925	rs2811975	chr1:23801081	A/T	cg19827787	chr1:23763612	ASAP3	0.36	6.3	0.32	8.94e-10	Total cholesterol levels;
LIHC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-11.25	-0.52	3.48e-25	Coronary artery disease;
LIHC	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg11161837	chr1:110010384	SYPL2	0.46	6.3	0.32	9.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.45	0.33	3.93e-10	Systolic blood pressure;
LIHC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.42	-6.38	-0.33	5.73e-10	Schizophrenia;
LIHC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.45	6.26	0.32	1.17e-9	Obesity-related traits;
LIHC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.49	7.82	0.39	6.71e-14	Alzheimer's disease (late onset);
LIHC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.57	-8.5	-0.42	5.81e-16	Cerebrospinal P-tau181p levels;
LIHC	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.54	8.31	0.41	2.21e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	15.49	0.64	2.25e-41	Tonsillectomy;
LIHC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.74	-10.5	-0.49	1.51e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg06640241	chr16:89574553	SPG7	0.6	8.41	0.41	1.11e-15	Multiple myeloma (IgH translocation);
LIHC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.36	5.81	0.3	1.41e-8	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.39	12.18	0.55	1.41e-28	Uric acid levels;
LIHC	cis	rs965469	0.779	rs6037568	chr20:3333245	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-6.54	-0.33	2.22e-10	IFN-related cytopenia;
LIHC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg09835421	chr16:68378352	PRMT7	-0.87	-10.08	-0.48	4.15e-21	Schizophrenia;
LIHC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.64	10.67	0.5	3.82e-23	Anterior chamber depth;
LIHC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs10503871	1.000	rs10503872	chr8:30437031	C/G	cg26383811	chr8:30366931	RBPMS	-0.44	-7.56	-0.38	3.77e-13	Metabolite levels  (X-11787);
LIHC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.99	15.95	0.65	3.2e-43	Metabolic syndrome;
LIHC	trans	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg10756647	chr7:56101905	PSPH	-0.61	-8.27	-0.41	2.94e-15	Corneal structure;
LIHC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.89	19.77	0.73	1.49e-58	Height;
LIHC	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.66	6.76	0.34	6.02e-11	Chronic lymphocytic leukemia;
LIHC	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-13.71	-0.6	2.11e-34	Coffee consumption (cups per day);
LIHC	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.72	11.65	0.53	1.26e-26	Oral cavity cancer;
LIHC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg08911368	chr8:11471085	NA	0.43	6.37	0.33	6.25e-10	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.57	-7.39	-0.37	1.14e-12	Developmental language disorder (linguistic errors);
LIHC	trans	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17183009	chr3:120277827	NA	0.52	6.08	0.31	3.18e-9	Corneal astigmatism;
LIHC	cis	rs9918079	0.560	rs4270584	chr4:15600799	A/G	cg21329975	chr4:15471214	CC2D2A	0.45	6.8	0.35	4.62e-11	Obesity-related traits;
LIHC	cis	rs10508774	0.925	rs12268816	chr10:32924542	C/T	cg01819863	chr10:32635814	EPC1	0.64	5.89	0.3	9.43e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7945718	0.621	rs10831891	chr11:12676140	A/G	cg25843174	chr11:12811716	TEAD1	0.33	7.71	0.38	1.42e-13	Educational attainment (years of education);
LIHC	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg20991723	chr1:152506922	NA	0.57	10.12	0.48	3.18e-21	Hair morphology;
LIHC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg13753209	chr17:57696993	CLTC	0.74	11.66	0.53	1.11e-26	Hemoglobin concentration;
LIHC	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg09918751	chr15:100517450	ADAMTS17	0.82	15.43	0.64	3.9e-41	Height;
LIHC	trans	rs7227401	1.000	rs7227401	chr18:21938658	G/T	cg09797837	chr1:17734771	RCC2	0.68	6.26	0.32	1.12e-9	Osteoporosis-related phenotypes;
LIHC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-8.91	-0.43	3.1e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs8049603	0.524	rs35476232	chr16:23092821	T/C	cg16484020	chr16:23217411	SCNN1G	-0.23	-5.77	-0.3	1.82e-8	Multiple sclerosis;
LIHC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.33	5.86	0.3	1.08e-8	Headache;
LIHC	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg18081818	chr7:23246105	NA	-0.4	-5.8	-0.3	1.55e-8	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.56	-8.06	-0.4	1.34e-14	Neuroticism;
LIHC	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg14146966	chr2:61757674	XPO1	0.47	8.19	0.4	5.25e-15	Tuberculosis;
LIHC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02034447	chr16:89574710	SPG7	0.51	7.76	0.39	1.01e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-9.51	-0.46	3.39e-19	Mean platelet volume;
LIHC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.08	-0.31	3.22e-9	Total body bone mineral density;
LIHC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg08125733	chr17:73851984	WBP2	0.56	8.64	0.42	2.26e-16	White matter hyperintensity burden;
LIHC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.37	5.99	0.31	5.28e-9	Cystic fibrosis severity;
LIHC	cis	rs8044868	1.000	rs8044868	chr16:72162102	C/T	cg16558253	chr16:72132732	DHX38	-0.39	-6.35	-0.32	6.94e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LIHC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.14	0.31	2.35e-9	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.92	14.81	0.63	1.1e-38	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7487075	0.567	rs7486580	chr12:46828348	C/A	cg23829395	chr12:46796953	NA	0.35	6.12	0.31	2.62e-9	Itch intensity from mosquito bite;
LIHC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.64	-11.51	-0.53	3.92e-26	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.14	-0.4	7.65e-15	Aortic root size;
LIHC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-6.54	-0.33	2.23e-10	Gut microbiome composition (summer);
LIHC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.51	8.2	0.41	4.75e-15	Birth weight;
LIHC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.38	0.61	5.11e-37	Chronic sinus infection;
LIHC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.37	6.62	0.34	1.42e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LIHC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg16576597	chr16:28551801	NUPR1	0.38	6.24	0.32	1.32e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.29	21.37	0.76	5.86e-65	Corneal structure;
LIHC	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg01145232	chr6:150245071	RAET1G	0.37	7.36	0.37	1.34e-12	Lung cancer;
LIHC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.54	6.42	0.33	4.44e-10	Menarche (age at onset);
LIHC	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg03585969	chr10:35415529	CREM	0.76	10.96	0.51	3.65e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4478037	0.822	rs9875140	chr3:33117068	T/A	cg16652328	chr3:33138982	GLB1;TMPPE	-0.54	-7.01	-0.35	1.32e-11	Major depressive disorder;
LIHC	cis	rs10426930	0.607	rs2613762	chr19:5064948	T/G	cg18473234	chr19:5097819	KDM4B	-0.59	-7.09	-0.36	7.84e-12	Monocyte percentage of white cells;
LIHC	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg01652190	chr22:50026171	C22orf34	-0.29	-6.34	-0.32	7.24e-10	Monocyte count;Monocyte percentage of white cells;
LIHC	trans	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17183009	chr3:120277827	NA	0.52	6.09	0.31	3.02e-9	Corneal astigmatism;
LIHC	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.73	9.63	0.46	1.42e-19	Morning vs. evening chronotype;
LIHC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.54	8.12	0.4	8.47e-15	Platelet count;
LIHC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.38	6.2	0.32	1.6e-9	Blood metabolite levels;
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg15695585	chr7:114562711	MDFIC	0.44	6.04	0.31	4.05e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.76	12.06	0.55	3.69e-28	Mosquito bite size;
LIHC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg14067834	chr17:29058358	SUZ12P	0.7	6.91	0.35	2.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.52	8.12	0.4	8.36e-15	Tonsillectomy;
LIHC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.71	0.5	2.86e-23	Smoking initiation;
LIHC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.44	6.3	0.32	9.27e-10	Aortic root size;
LIHC	trans	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg10756647	chr7:56101905	PSPH	1.1	13.42	0.59	2.8e-33	Diabetic kidney disease;
LIHC	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.73	-13.02	-0.58	9.31e-32	Longevity;
LIHC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	1.18	14.34	0.61	7.88e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.54	-9.87	-0.47	2.23e-20	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6024905	0.587	rs1579101	chr20:36966334	C/T	cg07053727	chr20:36965646	BPI	0.59	10.91	0.51	5.48e-24	Bipolar disorder and schizophrenia;
LIHC	cis	rs4650994	0.593	rs6694406	chr1:178532010	C/T	cg05350800	chr1:178550844	NA	-0.34	-7.47	-0.37	6.81e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	0.83	7.07	0.36	8.83e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.48	7.61	0.38	2.64e-13	Cleft lip with or without cleft palate;
LIHC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.2	-0.32	1.67e-9	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg06238570	chr21:40685208	BRWD1	0.6	7.11	0.36	6.92e-12	Cognitive function;
LIHC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg24879335	chr3:133465180	TF	0.28	6.11	0.31	2.69e-9	Iron status biomarkers;
LIHC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16351352	chr14:55738545	FBXO34	0.47	6.26	0.32	1.12e-9	Systemic lupus erythematosus;
LIHC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.67	10.11	0.48	3.49e-21	Testicular germ cell tumor;
LIHC	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg23461800	chr14:103021989	NA	0.39	5.82	0.3	1.36e-8	Platelet count;
LIHC	cis	rs17106184	1.000	rs57839936	chr1:51306273	T/C	cg07174182	chr1:51127561	FAF1	-0.62	-6.54	-0.33	2.27e-10	Type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08677398	chr8:58056175	NA	0.39	6.06	0.31	3.68e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	6.7	0.34	8.39e-11	Homocysteine levels;
LIHC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.9	-0.35	2.49e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.49	-7.79	-0.39	8.04e-14	Diastolic blood pressure;
LIHC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.91	17.96	0.7	2.85e-51	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.53	7.16	0.36	4.87e-12	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-12.28	-0.55	5.8e-29	Breast cancer;
LIHC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.44	-7.09	-0.36	7.76e-12	Platelet count;
LIHC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.15	0.36	5.24e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	0.99	7.08	0.36	8.07e-12	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26738040	chr11:62433033	C11orf48;SNORA57;METTL12	0.41	6.26	0.32	1.18e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.47	-6.22	-0.32	1.43e-9	Pursuit maintenance gain;
LIHC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.36	9.21	0.45	3.38e-18	Schizophrenia;
LIHC	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-8.59	-0.42	3.07e-16	Obesity-related traits;
LIHC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.48	6.6	0.34	1.57e-10	Aortic root size;
LIHC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.44	-5.78	-0.3	1.71e-8	Resting heart rate;
LIHC	cis	rs11627756	0.958	rs2146429	chr14:103071816	A/T	cg12046867	chr14:103022105	NA	-0.4	-6.17	-0.32	1.89e-9	Mean platelet volume;
LIHC	cis	rs11955398	0.625	rs6449485	chr5:59995441	C/T	cg02684056	chr5:59996105	DEPDC1B	0.43	6.13	0.31	2.47e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.45	6.21	0.32	1.56e-9	Tonsillectomy;
LIHC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.59	-10.14	-0.48	2.72e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg11783602	chr8:55087084	NA	-0.34	-6.6	-0.34	1.53e-10	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	6.98	0.35	1.5e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.41	-6.4	-0.33	5.19e-10	Blood pressure (smoking interaction);
LIHC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.73	-12.37	-0.56	2.77e-29	Blood protein levels;
LIHC	trans	rs6934970	1.000	rs12209591	chr6:113013327	G/A	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	7.15	0.36	5.19e-12	Monocyte percentage of white cells;
LIHC	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.48	7.36	0.37	1.38e-12	Adiposity;
LIHC	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.39	9.35	0.45	1.16e-18	Blood metabolite ratios;
LIHC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.35	6.81	0.35	4.38e-11	HDL cholesterol;
LIHC	cis	rs2279817	0.863	rs74061958	chr1:18015918	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-8.33	-0.41	2.01e-15	Neuroticism;
LIHC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg19680672	chr10:131412579	MGMT	-0.4	-6.09	-0.31	3.05e-9	Response to temozolomide;
LIHC	cis	rs10419226	0.625	rs12980154	chr19:18770119	C/T	cg16673477	chr19:18812017	CRTC1	-0.32	-5.8	-0.3	1.51e-8	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LIHC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg13385521	chr17:29058706	SUZ12P	0.69	6.62	0.34	1.36e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.68	5.86	0.3	1.08e-8	Body mass index;
LIHC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.64e-11	Aortic root size;
LIHC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg17385448	chr1:15911702	AGMAT	0.33	5.9	0.3	8.97e-9	Systolic blood pressure;
LIHC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-6.75	-0.34	6.54e-11	Mean platelet volume;
LIHC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.37	6.74	0.34	6.6e-11	Aortic root size;
LIHC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.94	0.31	6.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.5	-7.94	-0.39	2.91e-14	Diastolic blood pressure;
LIHC	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.48	7.22	0.36	3.38e-12	Palmitoleic acid (16:1n-7) levels;
LIHC	cis	rs2637266	0.749	rs4979831	chr10:78457588	G/T	cg18941641	chr10:78392320	NA	0.28	6.0	0.31	5.14e-9	Pulmonary function;
LIHC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-8.98	-0.44	1.89e-17	Obesity-related traits;
LIHC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.32	1.99e-9	Vitamin D levels;
LIHC	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02985541	chr2:219472218	PLCD4	-0.37	-5.87	-0.3	1.04e-8	Red blood cell count;Amyotrophic lateral sclerosis;
LIHC	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.81	0.35	4.47e-11	Dermatomyositis;
LIHC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-1.02	-10.18	-0.48	1.93e-21	Breast cancer;
LIHC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg14828511	chr1:107599125	PRMT6	0.42	6.0	0.31	5.13e-9	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.27e-8	Bipolar disorder;
LIHC	cis	rs7523273	0.586	rs7518047	chr1:207899332	T/C	cg22525895	chr1:207977042	MIR29B2	-0.54	-8.24	-0.41	3.76e-15	Schizophrenia;
LIHC	cis	rs10847980	0.623	rs28501453	chr12:123877312	A/G	cg00376283	chr12:123451042	ABCB9	0.63	6.61	0.34	1.5e-10	Adiponectin levels;
LIHC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.42	-6.12	-0.31	2.57e-9	Narcolepsy;
LIHC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg03785755	chr6:26196794	NA	0.52	6.16	0.32	2.02e-9	Gout;Renal underexcretion gout;
LIHC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.44	5.73	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.74	13.42	0.59	2.68e-33	Platelet count;
LIHC	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.32	-7.28	-0.37	2.24e-12	Breast cancer;
LIHC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.83	15.48	0.64	2.46e-41	Height;
LIHC	trans	rs11010290	0.639	rs17511194	chr10:36036780	A/C	cg08927738	chr20:52687394	BCAS1	0.48	6.16	0.32	2.04e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
LIHC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	12.78	0.57	7.93e-31	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.54	-7.58	-0.38	3.3e-13	Corneal structure;
LIHC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-7.48	-0.38	6.2800000000000005e-13	Platelet distribution width;
LIHC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg08013114	chr6:42924358	NA	0.38	6.13	0.31	2.48e-9	Attention deficit hyperactivity disorder and conduct disorder;
LIHC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.94	13.93	0.6	2.97e-35	Primary sclerosing cholangitis;
LIHC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.71	-8.35	-0.41	1.68e-15	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg03854865	chr6:26224070	HIST1H3E	0.63	7.23	0.36	3.28e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.78	-0.3	1.72e-8	Subjective well-being;
LIHC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg14132834	chr19:41945861	ATP5SL	-0.42	-6.25	-0.32	1.22e-9	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18959473	chr18:159310	USP14	0.44	6.34	0.32	7.34e-10	Cognitive function;
LIHC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.41	6.32	0.32	8.18e-10	Resting heart rate;
LIHC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-14.04	-0.6	1.15e-35	Alzheimer's disease;
LIHC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.33	7.1	0.36	7.34e-12	Multiple sclerosis;
LIHC	trans	rs4774899	0.872	rs10518895	chr15:57404113	A/T	cg07751341	chr19:12848092	ASNA1	-0.45	-6.15	-0.32	2.1e-9	Urinary tract infection frequency;
LIHC	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-0.82	-6.39	-0.33	5.51e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.92e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.12	13.03	0.58	8.92e-32	Vitiligo;
LIHC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.82	13.72	0.6	1.9e-34	Breast cancer;
LIHC	trans	rs8113308	0.810	rs7258701	chr19:52445069	C/T	cg14959425	chr7:20447707	ITGB8	-0.48	-6.15	-0.32	2.22e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LIHC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.54	7.63	0.38	2.43e-13	Prostate cancer;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg04921814	chr1:145575587	PIAS3	-0.41	-6.44	-0.33	3.99e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.55	9.98	0.48	9.13e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.41	-5.83	-0.3	1.27e-8	Blood metabolite levels;
LIHC	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg04592579	chr7:75616294	TMEM120A	0.41	7.09	0.36	7.73e-12	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	9.76	0.47	5.08e-20	Personality dimensions;
LIHC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.78	0.39	8.89e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.34	-0.32	7.36e-10	Colorectal cancer;
LIHC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.51	-8.14	-0.4	7.28e-15	QT interval;
LIHC	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.52	7.74	0.39	1.16e-13	Corneal astigmatism;
LIHC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.87	15.44	0.64	3.39e-41	Bone mineral density;
LIHC	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-14.82	-0.63	9.93e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.8	0.39	7.68e-14	Mean platelet volume;
LIHC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.39	-0.37	1.11e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LIHC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.3	-0.32	9.03e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg11062466	chr8:58055876	NA	0.41	5.96	0.31	6.42e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs507080	0.922	rs558781	chr11:118564397	G/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.58	0.34	1.78e-10	Serum metabolite levels;
LIHC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.31	0.45	1.56e-18	Electroencephalogram traits;
LIHC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.9	-0.3	8.88e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.55	-0.33	2.07e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.69	-8.48	-0.42	6.9e-16	Gut microbiome composition (summer);
LIHC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.45	6.5	0.33	2.89e-10	Breast cancer;
LIHC	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.3	6.5	0.33	2.92e-10	Pulmonary function;
LIHC	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg23091122	chr1:110024289	SYPL2	-0.51	-6.79	-0.34	4.91e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.53	9.33	0.45	1.41e-18	Breast cancer;
LIHC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg12365402	chr11:9010492	NRIP3	0.28	7.1	0.36	7.19e-12	Hemoglobin concentration;
LIHC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.51	7.55	0.38	4.01e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs11157436	0.918	rs11157426	chr14:22621647	A/C	cg13567813	chr19:50879636	NR1H2	0.41	6.11	0.31	2.77e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LIHC	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg02415029	chr1:110025642	ATXN7L2	-0.48	-6.33	-0.32	7.65e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg23262073	chr20:60523788	NA	-0.3	-6.39	-0.33	5.29e-10	Body mass index;
LIHC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.46	0.46	5.31e-19	Bipolar disorder;
LIHC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg15832292	chr6:96025679	MANEA	0.61	7.72	0.39	1.27e-13	Behavioural disinhibition (generation interaction);
LIHC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg09829573	chr1:144692074	NBPF9	0.44	7.97	0.4	2.37e-14	Hip geometry;
LIHC	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.52	8.36	0.41	1.64e-15	Blood protein levels;
LIHC	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.44	6.73	0.34	6.96e-11	Alzheimer's disease (survival time);
LIHC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.52	-7.5	-0.38	5.55e-13	Uric acid levels;
LIHC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg25801113	chr15:45476975	SHF	0.39	6.69	0.34	9.17e-11	Uric acid levels;
LIHC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg11764359	chr7:65958608	NA	0.58	6.04	0.31	4e-9	Diabetic kidney disease;
LIHC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.49	-0.33	3.08e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.67	11.35	0.52	1.52e-25	Lymphocyte counts;
LIHC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.62	-9.22	-0.45	3.23e-18	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.74	9.4	0.45	8.2e-19	Body mass index;
LIHC	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	10.93	0.51	4.64e-24	Alzheimer's disease;
LIHC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.56	-7.62	-0.38	2.6e-13	Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.77	12.33	0.55	3.85e-29	Corneal astigmatism;
LIHC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.68	10.16	0.48	2.35e-21	Mosquito bite size;
LIHC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg19682013	chr15:45996608	NA	0.4	7.12	0.36	6.34e-12	Waist circumference;Weight;
LIHC	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.8	10.14	0.48	2.67e-21	Type 2 diabetes;
LIHC	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17467752	chr17:38218738	THRA	-0.48	-8.24	-0.41	3.77e-15	White blood cell count;
LIHC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.29	-7.19	-0.36	4.17e-12	Cutaneous nevi;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11792281	chr17:26443366	NLK	0.4	6.04	0.31	3.91e-9	Immature fraction of reticulocytes;
LIHC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.38	6.05	0.31	3.72e-9	Menopause (age at onset);
LIHC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.25	-0.52	3.32e-25	Chronic sinus infection;
LIHC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.45	6.23	0.32	1.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.83	0.51	1.04e-23	Personality dimensions;
LIHC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.62	11.09	0.51	1.32e-24	Dupuytren's disease;
LIHC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.57	-9.5	-0.46	3.86e-19	Cognitive function;
LIHC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	1.08	17.23	0.68	2.56e-48	IgG glycosylation;
LIHC	cis	rs243505	0.726	rs734005	chr7:148505864	G/A	cg09806900	chr7:148480153	CUL1	0.41	6.15	0.32	2.16e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06002616	chr8:101225028	SPAG1	-0.35	-5.76	-0.3	1.83e-8	Atrioventricular conduction;
LIHC	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.61	7.52	0.38	4.92e-13	Coronary artery disease;
LIHC	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.58	-0.38	3.37e-13	Neuroticism;
LIHC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.0	-0.4	1.94e-14	Total cholesterol levels;
LIHC	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-9.27	-0.45	2.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.41	-6.7	-0.34	8.36e-11	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg09695851	chr17:3907499	NA	0.57	6.77	0.34	5.77e-11	Type 2 diabetes;
LIHC	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-8.5	-0.42	6.1e-16	Putamen volume;
LIHC	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-0.76	-8.31	-0.41	2.27e-15	Exhaled nitric oxide output;
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg01546424	chr6:149721457	MAP3K7IP2;SUMO4	0.41	6.35	0.32	6.99e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-0.86	-9.32	-0.45	1.45e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg18016565	chr1:150552671	MCL1	0.52	9.93	0.47	1.43e-20	Melanoma;
LIHC	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.68	-10.56	-0.5	9.87e-23	Eosinophil percentage of white cells;
LIHC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	7.35	0.37	1.44e-12	Menopause (age at onset);
LIHC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.89	10.69	0.5	3.45e-23	Eosinophil percentage of granulocytes;
LIHC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.78	13.62	0.59	4.71e-34	Aortic root size;
LIHC	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg00898013	chr13:113819073	PROZ	-0.42	-7.11	-0.36	6.75e-12	Platelet distribution width;
LIHC	cis	rs17433710	0.543	rs11577330	chr1:162651672	A/T	cg01063088	chr1:162760584	HSD17B7	0.45	6.27	0.32	1.11e-9	Dupuytren's disease;
LIHC	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg22771759	chr13:24902376	NA	0.33	6.93	0.35	2.07e-11	Obesity-related traits;
LIHC	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-0.9	-8.14	-0.4	7.59e-15	White matter integrity;
LIHC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.74	0.5	2.28e-23	Bladder cancer;
LIHC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-1.03	-19.81	-0.73	1e-58	Migraine;
LIHC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.34	-0.56	3.41e-29	Primary sclerosing cholangitis;
LIHC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.17	-0.55	1.48e-28	Colorectal cancer;
LIHC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg19302996	chr17:73780495	UNK	0.5	7.08	0.36	8.44e-12	White matter hyperintensity burden;
LIHC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg02640540	chr1:67518911	SLC35D1	0.44	6.89	0.35	2.76e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.72	6.87	0.35	3.09e-11	Inflammatory bowel disease;
LIHC	trans	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg15420906	chr14:67688261	FAM71D	0.35	6.04	0.31	4.13e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.71	7.43	0.37	8.87e-13	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.33	7.35	0.37	1.48e-12	Blood metabolite ratios;
LIHC	cis	rs36051895	0.632	rs2381213	chr9:5168871	A/G	cg02405213	chr9:5042618	JAK2	0.55	7.96	0.4	2.51e-14	Pediatric autoimmune diseases;
LIHC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg27494647	chr7:150038898	RARRES2	0.34	6.09	0.31	2.96e-9	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs77637988	0.578	rs11689645	chr2:48608559	G/C	cg15846641	chr2:48541264	FOXN2	0.56	7.41	0.37	1.01e-12	Joint mobility (Beighton score);
LIHC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.4	7.01	0.35	1.28e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs72627123	0.867	rs117818304	chr14:74474396	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.65	6.08	0.31	3.27e-9	Morning vs. evening chronotype;
LIHC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.01	0.35	1.32e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	8.95	0.44	2.29e-17	Menarche (age at onset);
LIHC	cis	rs4917300	0.650	rs4917268	chr8:143072510	G/A	cg06573787	chr8:143070187	NA	0.28	5.82	0.3	1.38e-8	Amyotrophic lateral sclerosis;
LIHC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.41	6.04	0.31	3.93e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.43	7.85	0.39	5.38e-14	Schizophrenia;
LIHC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.34	6.23	0.32	1.35e-9	Aortic root size;
LIHC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.88	12.25	0.55	7.2e-29	Blood metabolite levels;
LIHC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.8	11.63	0.53	1.38e-26	Response to antineoplastic agents;
LIHC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.65	9.53	0.46	3.03e-19	Monocyte percentage of white cells;
LIHC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.43	0.62	3.28e-37	Prudent dietary pattern;
LIHC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	5.9	0.3	8.72e-9	Bipolar disorder;
LIHC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.67	0.42	1.81e-16	Schizophrenia;
LIHC	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg00149659	chr3:10157352	C3orf10	0.54	5.8	0.3	1.52e-8	Alzheimer's disease;
LIHC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.62	10.97	0.51	3.29e-24	Breast cancer;
LIHC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg18016565	chr1:150552671	MCL1	0.54	10.24	0.48	1.23e-21	Melanoma;
LIHC	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.5	8.14	0.4	7.34e-15	Corneal astigmatism;
LIHC	cis	rs11958404	0.932	rs6884954	chr5:157436772	C/T	cg05962755	chr5:157440814	NA	1.07	12.05	0.55	4.01e-28	IgG glycosylation;
LIHC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.38	5.92	0.31	7.7e-9	Menopause (age at onset);
LIHC	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg27433088	chr4:174089019	GALNT7	0.41	7.01	0.35	1.25e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.31	7.12	0.36	6.58e-12	Blood metabolite ratios;
LIHC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg26338869	chr17:61819248	STRADA	0.5	6.87	0.35	3.09e-11	Height;
LIHC	cis	rs11673344	0.542	rs826328	chr19:37495381	A/C	cg27390819	chr19:37464633	NA	-0.49	-6.47	-0.33	3.44e-10	Obesity-related traits;
LIHC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.91	-15.06	-0.63	1.18e-39	Intelligence (multi-trait analysis);
LIHC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg21294424	chr19:58662284	ZNF329	0.92	7.09	0.36	7.8e-12	Cholesterol, total;
LIHC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg18357645	chr12:58087776	OS9	-0.45	-6.9	-0.35	2.49e-11	Multiple sclerosis;
LIHC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-1.02	-19.48	-0.73	2.17e-57	Breast cancer;
LIHC	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.48	7.93	0.39	3.24e-14	Schizophrenia;
LIHC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.8	12.79	0.57	7.08e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.42	5.73	0.3	2.19e-8	Crohn's disease;
LIHC	trans	rs7714584	1.000	rs3857422	chr5:150268609	A/G	cg20675040	chr8:143813288	C8orf55	0.33	6.09	0.31	3e-9	Crohn's disease;
LIHC	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-5.99	-0.31	5.31e-9	Urate levels;
LIHC	cis	rs11031096	0.678	rs12223062	chr11:4180178	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-6.07	-0.31	3.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LIHC	cis	rs943466	0.955	rs11757524	chr6:33766212	A/G	cg25922239	chr6:33757077	LEMD2	-0.47	-5.85	-0.3	1.17e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LIHC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.48	-7.61	-0.38	2.67e-13	Multiple sclerosis;
LIHC	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.52	-0.42	5.03e-16	Colorectal cancer;
LIHC	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.72	0.39	1.28e-13	Corneal astigmatism;
LIHC	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	0.93	11.45	0.53	6.45e-26	Post bronchodilator FEV1;
LIHC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.35	5.88	0.3	1e-8	Height;
LIHC	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	1.13	10.56	0.5	9.25e-23	Gut microbiota (bacterial taxa);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg17861791	chr1:113162073	ST7L;CAPZA1	0.41	6.2	0.32	1.66e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00958927	chr1:175162553	KIAA0040	0.36	6.12	0.31	2.63e-9	Alcohol dependence;
LIHC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg03037974	chr15:76606532	NA	0.73	14.33	0.61	8.54e-37	Blood metabolite levels;
LIHC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08677398	chr8:58056175	NA	0.41	5.73	0.3	2.15e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs244293	0.831	rs1948000	chr17:53147716	T/G	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.37	0.37	1.31e-12	Menarche (age at onset);
LIHC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.88	11.96	0.54	8.49e-28	Post bronchodilator FEV1;
LIHC	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.44	0.49	2.42e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.5	-6.44	-0.33	4.06e-10	Vitiligo;
LIHC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.96	18.34	0.7	8.49e-53	Ewing sarcoma;
LIHC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg11406765	chr11:980039	AP2A2	-0.35	-5.8	-0.3	1.49e-8	Alzheimer's disease (late onset);
LIHC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.79	12.43	0.56	1.53e-29	Blood metabolite levels;
LIHC	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	0.97	15.31	0.64	1.18e-40	Corneal structure;
LIHC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.58	10.37	0.49	4.19e-22	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.62	-8.23	-0.41	3.95e-15	Venous thromboembolism (SNP x SNP interaction);
LIHC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	10.32	0.49	6.3e-22	Monocyte percentage of white cells;
LIHC	cis	rs1400745	0.756	rs3783316	chr14:35337192	A/G	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.76	-0.39	9.7e-14	Monocyte count;
LIHC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.76	6.78	0.34	5.19e-11	Mean corpuscular hemoglobin;
LIHC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-0.9	-16.65	-0.67	5.39e-46	Bone mineral density;
LIHC	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-7.64	-0.38	2.16e-13	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-5.79	-0.3	1.6e-8	Longevity;Endometriosis;
LIHC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.66	10.65	0.5	4.54e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.45	7.12	0.36	6.53e-12	Melanoma;
LIHC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg18964960	chr10:1102726	WDR37	0.65	6.31	0.32	8.77e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-6.29	-0.32	9.91e-10	Arsenic metabolism;
LIHC	cis	rs9309473	1.000	rs10175180	chr2:73673123	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.83	-0.35	3.84e-11	Metabolite levels;
LIHC	cis	rs963731	0.649	rs297137	chr2:39305721	T/C	cg04010122	chr2:39346883	SOS1	-0.71	-6.33	-0.32	7.56e-10	Corticobasal degeneration;
LIHC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-10.64	-0.5	4.89e-23	Alcohol dependence;
LIHC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg27478167	chr7:817139	HEATR2	-0.41	-5.84	-0.3	1.25e-8	Cerebrospinal P-tau181p levels;
LIHC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.61	-7.36	-0.37	1.38e-12	Mean platelet volume;
LIHC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg03037974	chr15:76606532	NA	0.8	17.04	0.68	1.38e-47	Blood metabolite levels;
LIHC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.83	9.16	0.44	4.85e-18	Vitiligo;
LIHC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.23	-0.55	8.89e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs847649	0.731	rs7785272	chr7:102671023	A/G	cg18108683	chr7:102477205	FBXL13	-0.4	-6.11	-0.31	2.66e-9	Morning vs. evening chronotype;
LIHC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.85	-0.43	4.65e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-7.33	-0.37	1.71e-12	Initial pursuit acceleration;
LIHC	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg07862535	chr7:139043722	LUC7L2	-0.42	-7.32	-0.37	1.75e-12	Diisocyanate-induced asthma;
LIHC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.12	-15.76	-0.65	1.97e-42	Chronic sinus infection;
LIHC	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	0.69	7.76	0.39	9.7e-14	Gut microbiota (bacterial taxa);
LIHC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.65	-9.85	-0.47	2.68e-20	Subjective well-being;
LIHC	trans	rs875971	1.000	rs778685	chr7:65836176	G/T	cg10756647	chr7:56101905	PSPH	0.44	6.53	0.33	2.34e-10	Aortic root size;
LIHC	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg27661460	chr16:88844969	FAM38A	0.4	6.55	0.33	2.17e-10	Glycated hemoglobin levels;
LIHC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	13.11	0.58	4.26e-32	Mean platelet volume;
LIHC	trans	rs7072268	0.517	rs1133189	chr10:71103597	C/G	cg06648483	chr3:125802615	SLC41A3	0.48	6.32	0.32	8.25e-10	Glycated hemoglobin levels;
LIHC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	7.14	0.36	5.63e-12	Lung cancer in ever smokers;
LIHC	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-19.18	-0.72	3.65e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg01320579	chr17:75405842	SEPT9	0.5	7.15	0.36	5.46e-12	Airflow obstruction;
LIHC	trans	rs783540	0.967	rs783529	chr15:83267981	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.75	-0.34	6.37e-11	Schizophrenia;
LIHC	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	6.93	0.35	2.11e-11	Type 2 diabetes;
LIHC	cis	rs1144333	0.655	rs17097681	chr1:76376926	C/T	cg03433033	chr1:76189801	ACADM	0.51	7.12	0.36	6.54e-12	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg14393609	chr7:65229607	NA	0.45	6.59	0.34	1.63e-10	Aortic root size;
LIHC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.07	0.4	1.17e-14	Lymphocyte counts;
LIHC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.53	5.82	0.3	1.36e-8	Alzheimer's disease;
LIHC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg08132940	chr7:1081526	C7orf50	-0.67	-6.36	-0.33	6.62e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	10.5	0.49	1.53e-22	Hypertriglyceridemia;
LIHC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.55	8.53	0.42	4.89e-16	Multiple sclerosis;
LIHC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.39	6.2	0.32	1.59e-9	Menopause (age at onset);
LIHC	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.5	8.24	0.41	3.77e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.79	-0.43	7.33e-17	Cutaneous nevi;
LIHC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg02290350	chr8:58132656	NA	0.41	8.36	0.41	1.65e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.56	-0.38	3.81e-13	Initial pursuit acceleration;
LIHC	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg22974920	chr21:40686053	BRWD1	-0.4	-5.76	-0.3	1.83e-8	Cognitive function;
LIHC	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.24	-6.27	-0.32	1.1e-9	Menarche (age at onset);
LIHC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.87	0.54	1.94e-27	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.54	-11.08	-0.51	1.36e-24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27403822	chr1:179050983	TOR3A	0.42	6.71	0.34	8.23e-11	Cognitive function;
LIHC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	1.03	11.15	0.52	7.78e-25	Triglycerides;
LIHC	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-9.68	-0.46	9.84e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.57	7.62	0.38	2.58e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.65	-9.27	-0.45	2.14e-18	Blood metabolite levels;
LIHC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.79	-11.94	-0.54	1.07e-27	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.56	7.64	0.38	2.22e-13	Multiple sclerosis;
LIHC	cis	rs709400	0.663	rs10133035	chr14:103979127	C/T	cg26031613	chr14:104095156	KLC1	0.72	9.14	0.44	5.86e-18	Body mass index;
LIHC	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg00977110	chr5:151150581	G3BP1	-0.56	-7.08	-0.36	8.48e-12	Preschool internalizing problems;
LIHC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.43	-7.05	-0.36	9.73e-12	Blood pressure (smoking interaction);
LIHC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.71	7.43	0.37	8.87e-13	Vitiligo;
LIHC	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.49	-6.19	-0.32	1.74e-9	Heschl's gyrus morphology;
LIHC	cis	rs655641	1.000	rs600258	chr11:85710169	G/A	cg09030501	chr11:85779252	PICALM	-0.51	-6.16	-0.32	1.99e-9	Platelet count;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26818935	chr16:740532	WDR24	0.43	6.05	0.31	3.8e-9	Lung function (FEV1/FVC);
LIHC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	8.15	0.4	6.82e-15	Lung cancer;
LIHC	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.56	8.29	0.41	2.59e-15	Multiple sclerosis or amyotrophic lateral sclerosis;
LIHC	trans	rs3783890	0.887	rs11629303	chr14:93810048	G/A	cg02802420	chr16:69363236	PDF;COG8	0.33	6.29	0.32	9.66e-10	Body mass index;
LIHC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.57	7.71	0.38	1.35e-13	Blood metabolite levels;
LIHC	cis	rs477692	0.549	rs7079744	chr10:131454790	G/A	cg19680672	chr10:131412579	MGMT	0.42	6.54	0.33	2.23e-10	Response to temozolomide;
LIHC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	12.6	0.56	3.51e-30	Cognitive test performance;
LIHC	cis	rs1419980	0.730	rs11054887	chr12:7772997	G/A	cg10578777	chr12:7781093	NA	-0.39	-5.82	-0.3	1.38e-8	HDL cholesterol levels;
LIHC	cis	rs72627123	0.867	rs113257091	chr14:74461121	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.85	8.17	0.4	6.07e-15	Morning vs. evening chronotype;
LIHC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg00204512	chr16:28754710	NA	0.36	6.71	0.34	7.92e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.88	-0.3	9.96e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8038465	0.789	rs57909886	chr15:73973662	T/C	cg15420318	chr15:73925796	NPTN	0.39	5.94	0.31	7e-9	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs903552	1.000	rs4965872	chr15:102004002	C/T	cg06707286	chr15:102010195	PCSK6	-0.44	-6.26	-0.32	1.17e-9	Diabetic kidney disease;
LIHC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-6.49	-0.33	3.08e-10	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.53	7.38	0.37	1.24e-12	Post bronchodilator FEV1;
LIHC	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.26	6.3	0.32	9.05e-10	Heart rate;
LIHC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.64	8.91	0.43	3.17e-17	Sudden cardiac arrest;
LIHC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.33	-0.52	1.73e-25	Coronary artery disease;
LIHC	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.49	6.67	0.34	1.04e-10	Glioblastoma;Glioma;
LIHC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.67	0.42	1.73e-16	Platelet count;
LIHC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.41	6.81	0.35	4.52e-11	Alcohol dependence;
LIHC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg11406765	chr11:980039	AP2A2	-0.34	-5.74	-0.3	2.06e-8	Alzheimer's disease (late onset);
LIHC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.64	-12.11	-0.55	2.57e-28	Extrinsic epigenetic age acceleration;
LIHC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.42	-5.83	-0.3	1.26e-8	Total body bone mineral density;
LIHC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg07713946	chr22:31675144	LIMK2	-0.42	-7.38	-0.37	1.18e-12	Colorectal cancer;
LIHC	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.93	7.14	0.36	5.5e-12	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.63	-8.63	-0.42	2.29e-16	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg19318889	chr4:1322082	MAEA	0.39	6.43	0.33	4.42e-10	Obesity-related traits;
LIHC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.62	-8.02	-0.4	1.7e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	6.04	0.31	3.97e-9	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.44	0.33	4.1e-10	Lymphocyte counts;
LIHC	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg15208524	chr1:10270712	KIF1B	0.45	6.43	0.33	4.32e-10	Hepatocellular carcinoma;
LIHC	cis	rs2257205	0.667	rs28605629	chr17:56906157	C/A	cg12560992	chr17:57184187	TRIM37	0.67	7.23	0.36	3.24e-12	Pancreatic cancer;
LIHC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg09835421	chr16:68378352	PRMT7	-0.57	-6.58	-0.34	1.81e-10	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1144333	0.655	rs76175698	chr1:76454792	C/T	cg03433033	chr1:76189801	ACADM	0.53	7.45	0.37	7.94e-13	Attention function in attention deficit hyperactive disorder;
LIHC	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg10820045	chr2:198174542	NA	0.51	7.98	0.4	2.16e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-8.55	-0.42	4.22e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.86	12.92	0.57	2.29e-31	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-12.17	-0.55	1.52e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg26888861	chr11:62521812	ZBTB3	-0.47	-6.32	-0.32	7.92e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-5.73	-0.3	2.23e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg12310025	chr6:25882481	NA	-0.47	-7.2	-0.36	3.93e-12	Height;
LIHC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-7.37	-0.37	1.27e-12	Vitiligo;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06684987	chr19:45567721	SFRS16	0.44	6.23	0.32	1.41e-9	Bilirubin levels;
LIHC	cis	rs965469	1.000	rs6139068	chr20:3284393	G/A	cg25506879	chr20:3388711	C20orf194	-0.6	-6.91	-0.35	2.43e-11	IFN-related cytopenia;
LIHC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg18944383	chr4:111397179	ENPEP	0.28	7.09	0.36	7.87e-12	Height;
LIHC	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23598886	chr18:12777645	NA	0.48	6.51	0.33	2.75e-10	Inflammatory skin disease;
LIHC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg14393609	chr7:65229607	NA	0.37	5.81	0.3	1.4e-8	Aortic root size;
LIHC	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.78	0.3	1.67e-8	Tuberculosis;
LIHC	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg12253828	chr6:101329408	ASCC3	-0.39	-5.95	-0.31	6.78e-9	Neuroticism;
LIHC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg27432699	chr2:27873401	GPN1	-0.5	-7.27	-0.37	2.39e-12	Total body bone mineral density;
LIHC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg16102536	chr7:156981717	UBE3C	-0.35	-5.81	-0.3	1.41e-8	Body mass index;
LIHC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-19.55	-0.73	1.14e-57	Intelligence (multi-trait analysis);
LIHC	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg23091122	chr1:110024289	SYPL2	-0.47	-6.36	-0.33	6.47e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.87	10.01	0.48	7.57e-21	Primary sclerosing cholangitis;
LIHC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	trans	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg10756647	chr7:56101905	PSPH	1.07	13.4	0.59	3.25e-33	Diabetic kidney disease;
LIHC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.51	8.23	0.41	3.93e-15	Corneal astigmatism;
LIHC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	0.57	8.29	0.41	2.55e-15	Prudent dietary pattern;
LIHC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.45	7.15	0.36	5.21e-12	Height;
LIHC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02290350	chr8:58132656	NA	0.52	11.2	0.52	5.33e-25	Developmental language disorder (linguistic errors);
LIHC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.49	-8.15	-0.4	7.02e-15	Menarche (age at onset);
LIHC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.25	0.41	3.5e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.98	0.47	9.29e-21	Platelet count;
LIHC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg03037974	chr15:76606532	NA	0.73	14.04	0.6	1.08e-35	Blood metabolite levels;
LIHC	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.82	11.46	0.53	6.12e-26	Body mass index;
LIHC	cis	rs6726292	1.000	rs4399760	chr2:55157492	A/C	cg09592903	chr2:55203963	RTN4	0.37	5.77	0.3	1.77e-8	Obesity (extreme);
LIHC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.83	0.54	2.59e-27	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs1185460	0.804	rs13929	chr11:118915755	G/C	cg23280166	chr11:118938394	VPS11	0.46	6.33	0.32	7.74e-10	Coronary artery disease;
LIHC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	12.17	0.55	1.45e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-11.26	-0.52	3.12e-25	Chronic sinus infection;
LIHC	trans	rs11689435	0.925	rs1478588	chr2:218338149	G/A	cg13544946	chr9:35729779	TLN1	-0.44	-6.22	-0.32	1.43e-9	Metabolite levels (MHPG);
LIHC	cis	rs6977660	0.943	rs10277755	chr7:19826843	C/A	cg07541023	chr7:19748670	TWISTNB	0.37	5.77	0.3	1.77e-8	Thyroid stimulating hormone;
LIHC	cis	rs72627123	0.656	rs117129791	chr14:74520871	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	5.78	0.3	1.69e-8	Morning vs. evening chronotype;
LIHC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg03859395	chr2:55845619	SMEK2	0.91	15.95	0.65	3.4e-43	Metabolic syndrome;
LIHC	cis	rs2599510	0.811	rs176410	chr2:32643437	C/G	cg02381751	chr2:32503542	YIPF4	-0.46	-6.51	-0.33	2.64e-10	Interleukin-18 levels;
LIHC	cis	rs10733682	0.524	rs10987419	chr9:129462594	T/C	cg00232160	chr9:129468157	NA	0.39	6.95	0.35	1.84e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg06359132	chr10:99160096	RRP12	-0.43	-6.65	-0.34	1.16e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.72	-9.36	-0.45	1.11e-18	Dilated cardiomyopathy;
LIHC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg03146154	chr1:46216737	IPP	-0.39	-6.48	-0.33	3.21e-10	Red blood cell count;Reticulocyte count;
LIHC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg18887096	chr2:219472410	PLCD4	0.39	6.81	0.35	4.53e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	1.08	14.41	0.61	4.14e-37	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.3	-0.41	2.53e-15	Response to antipsychotic treatment;
LIHC	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-9.53	-0.46	2.98e-19	Colorectal cancer;
LIHC	cis	rs6445975	0.715	rs17059125	chr3:58268750	C/A	cg23715586	chr3:58305044	RPP14	-0.38	-6.32	-0.32	8.25e-10	Systemic lupus erythematosus;
LIHC	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.42	9.12	0.44	6.51e-18	Migraine;
LIHC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.53	8.66	0.42	1.91e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs1865721	0.761	rs7242709	chr18:73222819	T/C	cg26385618	chr18:73139727	C18orf62	-0.27	-6.78	-0.34	5.41e-11	Intelligence;
LIHC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.51	6.21	0.32	1.53e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.5	-6.46	-0.33	3.52e-10	Coronary artery calcification;
LIHC	cis	rs35160687	0.644	rs57270703	chr2:86516873	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.01	0.31	4.71e-9	Night sleep phenotypes;
LIHC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21467203	chr3:49911342	NA	0.4	7.01	0.35	1.25e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.22	-0.32	1.43e-9	Neuroticism;
LIHC	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.72	14.41	0.61	4.22e-37	Schizophrenia;
LIHC	cis	rs7716219	0.572	rs55835145	chr5:54868559	A/C	cg14753740	chr5:54468940	CDC20B;MIR449C	0.45	6.25	0.32	1.22e-9	Height;
LIHC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.09	-15.97	-0.65	2.73e-43	Chronic sinus infection;
LIHC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20570016	chr1:156261298	TMEM79	0.38	6.13	0.31	2.47e-9	Tonsillectomy;
LIHC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.54	-10.05	-0.48	5.3e-21	Bipolar disorder and schizophrenia;
LIHC	trans	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg26113512	chr3:38035601	VILL	-0.53	-6.08	-0.31	3.25e-9	Alzheimer's disease;
LIHC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	1.14	13.93	0.6	2.98e-35	Eosinophil percentage of granulocytes;
LIHC	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.42	-6.58	-0.34	1.77e-10	Educational attainment (college completion);
LIHC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.43	-6.5	-0.33	2.91e-10	Asthma (sex interaction);
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg22528358	chr1:107598549	PRMT6	0.69	11.28	0.52	2.61e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	9.89	0.47	1.9e-20	Resting heart rate;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26805528	chr9:131872542	CRAT;PPP2R4	0.4	6.56	0.33	2.01e-10	Cognitive function;
LIHC	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.52	7.91	0.39	3.53e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.56	7.2	0.36	3.91e-12	Coronary artery disease;
LIHC	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25632853	chr15:73088954	NA	0.36	5.96	0.31	6.41e-9	Triglyceride levels;
LIHC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.42	6.77	0.34	5.77e-11	Alcohol dependence;
LIHC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.57	-7.97	-0.4	2.46e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg00204748	chr12:29376779	FAR2	0.46	8.71	0.43	1.35e-16	QT interval;
LIHC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.46	-6.71	-0.34	8.02e-11	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs723794	0.598	rs6855750	chr4:146980183	T/C	cg22222663	chr11:117800467	TMPRSS13	0.22	6.05	0.31	3.81e-9	Smooth-surface caries;
LIHC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg12751644	chr20:60527061	NA	-0.37	-6.09	-0.31	3.12e-9	Body mass index;
LIHC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg02640540	chr1:67518911	SLC35D1	0.44	6.07	0.31	3.47e-9	Lymphocyte percentage of white cells;
LIHC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.91	-0.3	8.31e-9	Personality dimensions;
LIHC	trans	rs9531686	1.000	rs9531686	chr13:85549736	T/G	cg11095898	chr11:93466424	SNORA1;SNORA8;SNORD5	0.32	6.25	0.32	1.19e-9	Anorexia nervosa;
LIHC	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg14146966	chr2:61757674	XPO1	0.46	7.88	0.39	4.44e-14	Tuberculosis;
LIHC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.4	-7.22	-0.36	3.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.49	5.91	0.3	8.45e-9	Serum sulfate level;
LIHC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	12.54	0.56	6.2e-30	Colorectal cancer;
LIHC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.55	-7.78	-0.39	8.67e-14	Longevity;
LIHC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.67	-9.22	-0.45	3.16e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg15123519	chr2:136567270	LCT	-0.41	-6.92	-0.35	2.3e-11	Corneal structure;
LIHC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg19302996	chr17:73780495	UNK	-0.47	-6.75	-0.34	6.2e-11	White matter hyperintensity burden;
LIHC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg17420585	chr12:42539391	GXYLT1	0.38	6.04	0.31	4.05e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.52	8.09	0.4	1.08e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.76	13.4	0.59	3.4e-33	Coronary artery disease;
LIHC	cis	rs9473924	0.505	rs9473949	chr6:50909659	T/A	cg14470998	chr6:50812995	TFAP2B	0.91	10.51	0.49	1.39e-22	Body mass index;
LIHC	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.41	-0.33	4.93e-10	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.65	11.92	0.54	1.29e-27	Prudent dietary pattern;
LIHC	cis	rs12744310	1.000	rs55859000	chr1:41761441	T/C	cg03962019	chr1:41807865	NA	0.38	6.2	0.32	1.67e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-11.01	-0.51	2.51e-24	Alzheimer's disease;
LIHC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.4	-6.72	-0.34	7.72e-11	Mean corpuscular volume;
LIHC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.49	0.33	3.02e-10	Bipolar disorder;
LIHC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.38	6.04	0.31	4.06e-9	Gout;
LIHC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg00656387	chr3:40428638	ENTPD3	-0.5	-8.53	-0.42	4.94e-16	Renal cell carcinoma;
LIHC	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16684958	chr7:75615977	POR	0.52	8.67	0.42	1.8e-16	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg20487152	chr13:99095054	FARP1	-0.37	-6.04	-0.31	4.01e-9	Neuroticism;
LIHC	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.62	5.91	0.3	8.12e-9	Birth weight;
LIHC	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.48	7.14	0.36	5.71e-12	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27367952	chr2:219221586	C2orf62	0.42	6.5	0.33	2.79e-10	Cognitive function;
LIHC	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg03934865	chr2:198174659	NA	-0.57	-9.09	-0.44	8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.49	7.29	0.37	2.2e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg13395646	chr4:1353034	KIAA1530	-0.48	-7.55	-0.38	4e-13	Obesity-related traits;
LIHC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.57	-8.74	-0.43	1.04e-16	Corneal astigmatism;
LIHC	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg22771759	chr13:24902376	NA	0.31	6.47	0.33	3.49e-10	Obesity-related traits;
LIHC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.54	-8.8	-0.43	6.84e-17	Total body bone mineral density;
LIHC	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.75	14.16	0.61	3.95e-36	Testicular germ cell tumor;
LIHC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.5	-12.49	-0.56	9.64e-30	Alzheimer's disease (late onset);
LIHC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.38	-0.33	5.62e-10	Lung cancer;
LIHC	trans	rs9403317	0.573	rs9389941	chr6:141990680	T/C	cg23847162	chr6:15663024	DTNBP1	0.55	6.16	0.32	2.02e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg23149560	chr2:74406255	MOBKL1B	0.41	5.85	0.3	1.12e-8	Gestational age at birth (maternal effect);
LIHC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-6.21	-0.32	1.49e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.41	6.28	0.32	1.02e-9	Platelet count;
LIHC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg22903471	chr2:27725779	GCKR	-0.5	-8.55	-0.42	4.14e-16	Total body bone mineral density;
LIHC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg12798992	chr6:167411361	FGFR1OP	0.6	9.92	0.47	1.51e-20	Crohn's disease;
LIHC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg05697976	chr12:29376483	FAR2	0.31	6.2	0.32	1.62e-9	QT interval;
LIHC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.45	6.42	0.33	4.6e-10	Breast cancer;
LIHC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-12.57	-0.56	4.6e-30	Chronic sinus infection;
LIHC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-11.75	-0.54	5.31e-27	Menarche (age at onset);
LIHC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02450064	chr17:40260053	DHX58	-0.29	-6.02	-0.31	4.46e-9	Fibrinogen levels;
LIHC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.88	12.09	0.55	3.01e-28	Diastolic blood pressure;
LIHC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-5.97	-0.31	6.03e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg15586420	chr15:90294517	MESP1	0.45	7.18	0.36	4.49e-12	Cognitive function;
LIHC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.54	6.27	0.32	1.06e-9	Alzheimer's disease;
LIHC	cis	rs2384207	1.000	rs2384207	chr12:113607502	T/C	cg22376712	chr12:113623594	C12orf52;DDX54	0.48	5.88	0.3	9.97e-9	Response to fenofibrate (adiponectin levels);
LIHC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.37	7.13	0.36	6.17e-12	Loneliness (linear analysis);
LIHC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.49	9.89	0.47	1.92e-20	Melanoma;
LIHC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-10.24	-0.48	1.21e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	6.01	0.31	4.66e-9	Bipolar disorder;
LIHC	cis	rs7116495	0.609	rs579254	chr11:71582544	T/C	cg26138937	chr11:71823887	C11orf51	0.7	6.79	0.34	4.87e-11	Severe influenza A (H1N1) infection;
LIHC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	6.23	0.32	1.35e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.73	12.58	0.56	4.43e-30	Menopause (age at onset);
LIHC	cis	rs16944613	0.510	rs11636695	chr15:91152911	C/G	cg26821196	chr15:91095069	CRTC3	-0.35	-6.4	-0.33	5.1e-10	Colorectal cancer;
LIHC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.73	12.56	0.56	5.19e-30	Menopause (age at onset);
LIHC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.34	6.75	0.34	6.24e-11	Immature fraction of reticulocytes;
LIHC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg12365402	chr11:9010492	NRIP3	0.3	7.24	0.36	3.07e-12	Hemoglobin concentration;
LIHC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.64	9.28	0.45	1.92e-18	Menarche (age at onset);
LIHC	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	7.1	0.36	7.36e-12	Self-reported allergy;
LIHC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.64	-0.5	4.9e-23	Alzheimer's disease;
LIHC	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg24220031	chr2:73402428	NA	-0.27	-5.85	-0.3	1.13e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg05896524	chr21:47604654	C21orf56	0.45	6.71	0.34	7.97e-11	Testicular germ cell tumor;
LIHC	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	6.13	0.31	2.36e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-6.49	-0.33	2.96e-10	Initial pursuit acceleration;
LIHC	cis	rs2816062	0.813	rs2816057	chr1:18902257	G/C	cg18795169	chr1:18902165	NA	-0.8	-17.53	-0.69	1.53e-49	Urate levels in lean individuals;
LIHC	cis	rs7546668	0.947	rs3737705	chr1:15911349	G/A	cg11706911	chr1:15910989	AGMAT	0.47	7.16	0.36	4.85e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs7551222	0.662	rs4951399	chr1:204533255	G/A	cg20240347	chr1:204465584	NA	-0.34	-7.08	-0.36	8.14e-12	Schizophrenia;
LIHC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.83	8.89	0.43	3.5e-17	Vitiligo;
LIHC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.14	17.77	0.69	1.59e-50	Gut microbiome composition (summer);
LIHC	trans	rs10411161	0.702	rs10414472	chr19:52398597	C/T	cg22319618	chr22:45562946	NUP50	-0.61	-8.31	-0.41	2.25e-15	Breast cancer;
LIHC	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	6.71	0.34	8.08e-11	Fuchs's corneal dystrophy;
LIHC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.91	-12.21	-0.55	1.01e-28	Orofacial clefts;
LIHC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.94	-0.31	7e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.7	14.59	0.62	8.35e-38	Schizophrenia;
LIHC	cis	rs4908768	0.539	rs6666191	chr1:8658442	C/T	cg20416874	chr1:8611966	RERE	-0.62	-11.38	-0.52	1.17e-25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08677398	chr8:58056175	NA	0.41	6.38	0.33	5.63e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.51	-0.42	5.57e-16	Blood pressure (smoking interaction);
LIHC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.46	-6.76	-0.34	5.84e-11	Corneal structure;
LIHC	cis	rs72843506	0.656	rs73984559	chr17:19946516	C/A	cg12065943	chr17:19881925	AKAP10	-0.4	-6.63	-0.34	1.32e-10	Schizophrenia;
LIHC	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg13699009	chr12:122356056	WDR66	-0.41	-6.82	-0.35	4.12e-11	Mean corpuscular volume;
LIHC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08219700	chr8:58056026	NA	0.52	6.47	0.33	3.46e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3823572	0.564	rs2346276	chr7:133664901	G/T	cg03336402	chr7:133662267	EXOC4	-0.48	-5.74	-0.3	2.05e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg14473756	chr11:122847823	NA	-0.38	-6.83	-0.35	3.82e-11	Menarche (age at onset);
LIHC	cis	rs4700695	0.764	rs152993	chr5:65262968	A/T	cg21114390	chr5:65439923	SFRS12	0.44	5.72	0.3	2.31e-8	Facial morphology (factor 19);
LIHC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg13607699	chr17:42295918	UBTF	0.45	7.26	0.37	2.59e-12	Total body bone mineral density;
LIHC	cis	rs9921222	0.542	rs9926968	chr16:381561	A/C	cg00101154	chr16:420108	MRPL28	-0.56	-7.89	-0.39	4.15e-14	Bone mineral density (spine);Bone mineral density;
LIHC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg09182678	chr22:50328711	NA	0.66	6.01	0.31	4.69e-9	Schizophrenia;
LIHC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg12193833	chr17:30244370	NA	-0.53	-5.85	-0.3	1.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs629922	0.642	rs655988	chr11:114072365	A/G	cg01914181	chr11:114070210	ZBTB16	0.52	7.12	0.36	6.27e-12	Paneth cell defects in Crohn's disease;
LIHC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.45	-6.18	-0.32	1.85e-9	Total body bone mineral density;
LIHC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.42	-6.11	-0.31	2.76e-9	Dental caries;
LIHC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-7.02	-0.35	1.18e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg07424592	chr7:64974309	NA	0.75	8.79	0.43	7.43e-17	Diabetic kidney disease;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg05320259	chr20:25370897	ABHD12	0.39	6.37	0.33	5.95e-10	Cognitive function;
LIHC	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.38	6.55	0.33	2.07e-10	Obesity;
LIHC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	12.14	0.55	1.85e-28	Height;
LIHC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23283495	chr1:209979779	IRF6	-0.41	-6.66	-0.34	1.09e-10	Orofacial clefts;
LIHC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg09417038	chr21:47716443	C21orf57	0.52	7.94	0.39	2.93e-14	Testicular germ cell tumor;
LIHC	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg25919922	chr13:100150906	NA	-0.51	-6.06	-0.31	3.56e-9	Self-reported allergy;
LIHC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-16.44	-0.66	3.58e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.74	11.27	0.52	3e-25	Corneal astigmatism;
LIHC	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg23254163	chr1:152506842	NA	-0.23	-6.13	-0.31	2.42e-9	Hair morphology;
LIHC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.95	-0.31	6.67e-9	Life satisfaction;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13377154	chr12:56320780	WIBG	-0.43	-6.17	-0.32	1.88e-9	Pancreatic cancer;
LIHC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.74	0.39	1.1e-13	Lung cancer;
LIHC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg08499158	chr17:42289980	UBTF	0.51	8.2	0.41	4.84e-15	Total body bone mineral density;
LIHC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.98	21.04	0.75	1.23e-63	Bone mineral density;
LIHC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-0.84	-8.83	-0.43	5.66e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs57244997	0.556	rs73030428	chr6:162437606	T/C	cg17173639	chr6:162384350	PARK2	-0.56	-7.39	-0.37	1.1e-12	Mosquito bite size;
LIHC	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg03934865	chr2:198174659	NA	0.52	7.93	0.39	3.07e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs911119	0.913	rs3810575	chr20:23583392	G/A	cg16589663	chr20:23618590	CST3	0.69	7.36	0.37	1.38e-12	Chronic kidney disease;
LIHC	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg22705602	chr4:152727874	NA	-0.28	-6.0	-0.31	4.9e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.3	0.37	2.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.64	7.58	0.38	3.2e-13	Heart rate;
LIHC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.42	7.78	0.39	8.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11888559	0.655	rs4675309	chr2:203879503	A/G	cg24605529	chr2:203879461	NBEAL1	0.73	5.94	0.31	6.86e-9	Height;
LIHC	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.39	7.29	0.37	2.14e-12	Response to antipsychotic treatment;
LIHC	cis	rs2224391	0.704	rs9504371	chr6:5261608	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.42	-6.28	-0.32	1.02e-9	Height;
LIHC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.7	9.11	0.44	6.98e-18	Mean platelet volume;
LIHC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	6.41	0.33	4.89e-10	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.71	6.42	0.33	4.67e-10	Blood protein levels;
LIHC	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg08890338	chr13:113700818	MCF2L	-0.36	-5.92	-0.3	8.04e-9	Systolic blood pressure;
LIHC	cis	rs12493885	0.725	rs57740056	chr3:153744530	A/C	cg10247383	chr3:153839028	SGEF	0.6	5.74	0.3	2.07e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg27203090	chr3:33138513	GLB1;TMPPE	-0.56	-6.92	-0.35	2.18e-11	Major depressive disorder;
LIHC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.08	0.4	1.09e-14	Bladder cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09844907	chr16:15489619	MPV17L	-0.46	-6.1	-0.31	2.8e-9	Pancreatic cancer;
LIHC	cis	rs5753037	0.543	rs131287	chr22:30158463	C/T	cg01021169	chr22:30184971	ASCC2	-0.33	-6.29	-0.32	9.81e-10	Type 1 diabetes;
LIHC	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.59	-0.34	1.69e-10	Schizophrenia;
LIHC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	0.93	9.49	0.46	4.09e-19	Type 2 diabetes nephropathy;
LIHC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.42	5.76	0.3	1.91e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	0.79	9.09	0.44	8.21e-18	Gut microbiota (bacterial taxa);
LIHC	cis	rs12986413	1.000	rs12986413	chr19:2170954	A/T	cg09261902	chr19:2140048	AP3D1	-0.36	-6.2	-0.32	1.63e-9	Height;
LIHC	trans	rs3783890	1.000	rs10484032	chr14:93738663	A/G	cg02802420	chr16:69363236	PDF;COG8	0.32	6.18	0.32	1.86e-9	Body mass index;
LIHC	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.97	11.08	0.51	1.42e-24	Neuroticism;
LIHC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.32	-0.49	6.21e-22	Chronic sinus infection;
LIHC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.53	-0.49	1.23e-22	Bipolar disorder and schizophrenia;
LIHC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg20607798	chr8:58055168	NA	0.49	6.07	0.31	3.33e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg13482628	chr17:19912719	NA	-0.39	-6.37	-0.33	6e-10	Schizophrenia;
LIHC	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg04592579	chr7:75616294	TMEM120A	0.41	7.0	0.35	1.33e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.65	0.38	2.07e-13	Prudent dietary pattern;
LIHC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	7.55	0.38	3.96e-13	Lung cancer;
LIHC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.54	-7.12	-0.36	6.4e-12	Pancreatic cancer;
LIHC	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	10.54	0.5	1.12e-22	Fuchs's corneal dystrophy;
LIHC	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.48	6.0	0.31	5.14e-9	Plateletcrit;
LIHC	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg10381502	chr11:71823885	C11orf51	1.06	8.91	0.43	3.06e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs992157	0.644	rs6741757	chr2:219182748	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.71	10.05	0.48	5.54e-21	Colorectal cancer;
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.67	0.34	1.04e-10	Obesity-related traits;
LIHC	cis	rs1077514	0.515	rs1767141	chr1:23734350	G/T	cg19827787	chr1:23763612	ASAP3	-0.31	-5.81	-0.3	1.4e-8	Cholesterol, total;
LIHC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.95e-15	Motion sickness;
LIHC	cis	rs7078219	0.543	rs10786557	chr10:101283328	C/G	cg06854084	chr10:101292507	NKX2-3	-0.33	-6.06	-0.31	3.5e-9	Dental caries;
LIHC	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg01864836	chr14:55583639	NA	-0.4	-7.45	-0.37	7.51e-13	Protein biomarker;
LIHC	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.4	7.36	0.37	1.42e-12	Testicular germ cell tumor;
LIHC	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.79	0.34	5.01e-11	Dermatomyositis;
LIHC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.76	-0.3	1.88e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.46	-6.4	-0.33	5.13e-10	Initial pursuit acceleration;
LIHC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.52	-7.17	-0.36	4.55e-12	Ulcerative colitis;
LIHC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-14.83	-0.63	8.92e-39	Alzheimer's disease (late onset);
LIHC	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg02081065	chr5:132209139	LEAP2	0.26	5.78	0.3	1.67e-8	Apolipoprotein A-IV levels;
LIHC	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg26395211	chr5:140044315	WDR55	-0.44	-6.59	-0.34	1.65e-10	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.42	-7.18	-0.36	4.3e-12	Educational attainment;
LIHC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.31	0.37	1.86e-12	Mean platelet volume;
LIHC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg18357645	chr12:58087776	OS9	0.45	6.65	0.34	1.19e-10	Multiple sclerosis;
LIHC	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.59	-11.95	-0.54	9.29e-28	Plateletcrit;Platelet count;
LIHC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg19338460	chr6:170058176	WDR27	0.4	6.39	0.33	5.37e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.54	-7.64	-0.38	2.2e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs12744310	1.000	rs2364535	chr1:41766236	C/T	cg03962019	chr1:41807865	NA	0.36	5.9	0.3	8.85e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
LIHC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.71	-11.33	-0.52	1.69e-25	Corneal astigmatism;
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg20102877	chr2:27665638	KRTCAP3	-0.44	-6.07	-0.31	3.39e-9	Total body bone mineral density;
LIHC	cis	rs4234798	1.000	rs4689653	chr4:7223319	T/G	cg13439315	chr4:7197511	SORCS2	-0.34	-5.75	-0.3	2.01e-8	Insulin-like growth factors;
LIHC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.0	0.31	4.92e-9	Morning vs. evening chronotype;
LIHC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	10.0	0.48	8.11e-21	Platelet count;
LIHC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	1.13	13.37	0.59	4.36e-33	Eosinophil percentage of granulocytes;
LIHC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg15902774	chr15:75289873	SCAMP5	0.37	5.76	0.3	1.84e-8	Lung cancer;
LIHC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg16034541	chr3:195490309	MUC4	-0.61	-9.56	-0.46	2.43e-19	Lung disease severity in cystic fibrosis;
LIHC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-23.71	-0.79	3.38e-74	Height;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg09400194	chr10:81107848	PPIF	0.39	6.3	0.32	9.1e-10	Cognitive function;
LIHC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg25894440	chr7:65020034	NA	0.51	6.12	0.31	2.63e-9	Diabetic kidney disease;
LIHC	cis	rs10949834	0.642	rs2356530	chr7:73533221	T/A	cg07137043	chr7:73588983	EIF4H	-0.6	-6.01	-0.31	4.74e-9	Verbal memory performance (residualized delayed recall change);
LIHC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg03959625	chr15:84868606	LOC388152	0.48	6.78	0.34	5.21e-11	Schizophrenia;
LIHC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg13409248	chr3:40428643	ENTPD3	0.5	8.53	0.42	4.92e-16	Renal cell carcinoma;
LIHC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16346588	chr10:242978	ZMYND11	0.4	6.18	0.32	1.82e-9	Psychosis in Alzheimer's disease;
LIHC	cis	rs8084351	0.539	rs9949949	chr18:50571241	A/G	cg24270629	chr18:50823537	DCC	0.41	6.35	0.32	6.78e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg02034447	chr16:89574710	SPG7	0.38	5.77	0.3	1.76e-8	Multiple myeloma (IgH translocation);
LIHC	cis	rs2978263	0.566	rs17625964	chr8:30287906	C/T	cg05780722	chr8:30327988	RBPMS	0.33	6.14	0.31	2.35e-9	Cognitive performance;
LIHC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.68	9.62	0.46	1.53e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs12960505	0.506	rs4940259	chr18:50997336	A/T	cg24270629	chr18:50823537	DCC	0.47	6.65	0.34	1.15e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg05564831	chr3:52568323	NT5DC2	-0.38	-6.17	-0.32	1.88e-9	Bipolar disorder;
LIHC	cis	rs6967414	0.681	rs11979878	chr7:6753803	A/G	cg00387323	chr7:6746715	ZNF12	0.64	7.05	0.36	1e-11	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg25182066	chr10:30743637	MAP3K8	-0.48	-7.93	-0.39	3.08e-14	Inflammatory bowel disease;
LIHC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.19	0.41	5.11e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg10756647	chr7:56101905	PSPH	1.03	12.51	0.56	7.74e-30	Diabetic kidney disease;
LIHC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.75	0.69	1.91e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	5.8	0.3	1.54e-8	Menopause (age at onset);
LIHC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg07636037	chr3:49044803	WDR6	-0.73	-7.78	-0.39	8.38e-14	Cognitive ability (multi-trait analysis);
LIHC	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.54	-8.06	-0.4	1.25e-14	Body mass index;
LIHC	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26734620	chr12:56694298	CS	1.21	10.41	0.49	3.22e-22	Psoriasis vulgaris;
LIHC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.4	0.37	1.07e-12	Morning vs. evening chronotype;
LIHC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.65	11.42	0.53	8.21e-26	Menopause (age at onset);
LIHC	cis	rs9378688	0.546	rs2505673	chr6:2356229	A/G	cg12303981	chr6:2244766	GMDS	-0.45	-6.46	-0.33	3.64e-10	Caudate nucleus volume;
LIHC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-11.05	-0.51	1.76e-24	Personality dimensions;
LIHC	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg16736954	chr20:23401023	NAPB	0.54	5.98	0.31	5.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs4728302	0.869	rs2042455	chr7:133580545	A/G	cg10665199	chr7:133106180	EXOC4	0.37	6.47	0.33	3.42e-10	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs11630290	0.592	rs12232261	chr15:64153302	A/G	cg12036633	chr15:63758958	NA	0.63	6.7	0.34	8.73e-11	Iris characteristics;
LIHC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.5	-7.87	-0.39	4.68e-14	Diastolic blood pressure;
LIHC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.57	8.5	0.42	5.77e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.4	6.92	0.35	2.25e-11	Facial morphology (factor 20);
LIHC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	8.56	0.42	3.93e-16	Lung cancer;
LIHC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.6	-8.51	-0.42	5.58e-16	Coronary artery disease;
LIHC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.32	1.29e-9	Calcium levels;
LIHC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.44	6.39	0.33	5.28e-10	Platelet count;
LIHC	cis	rs11676348	0.805	rs12694428	chr2:218958820	G/A	cg00012203	chr2:219082015	ARPC2	-0.46	-5.97	-0.31	6.05e-9	Ulcerative colitis;
LIHC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.58	7.83	0.39	6.15e-14	Bladder cancer;
LIHC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.92	-15.34	-0.64	8.76e-41	Schizophrenia;
LIHC	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.65	10.12	0.48	3.11e-21	Type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15921271	chr3:23957976	RPL15;NKIRAS1	-0.46	-6.47	-0.33	3.4e-10	Pancreatic cancer;
LIHC	cis	rs798766	1.000	rs4865467	chr4:1745500	G/T	cg21231739	chr4:1642635	FAM53A	0.38	6.05	0.31	3.81e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg18289306	chr13:113640169	MCF2L	0.42	6.31	0.32	8.85e-10	Systolic blood pressure;
LIHC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.47	-11.82	-0.54	2.81e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.29	0.32	9.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.56	0.33	1.95e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.68	8.72	0.43	1.2e-16	Initial pursuit acceleration;
LIHC	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg20991723	chr1:152506922	NA	-0.39	-6.2	-0.32	1.59e-9	Hair morphology;
LIHC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.78	-13.77	-0.6	1.22e-34	Aortic root size;
LIHC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	8.05	0.4	1.36e-14	Motion sickness;
LIHC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg25894440	chr7:65020034	NA	0.54	6.28	0.32	1.05e-9	Diabetic kidney disease;
LIHC	trans	rs8117834	0.574	rs6118060	chr20:8087337	C/T	cg00593689	chr4:53575888	NA	0.41	6.84	0.35	3.77e-11	Chronic kidney disease;
LIHC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.8	-0.3	1.48e-8	Axial length;
LIHC	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.76	8.75	0.43	1e-16	Exhaled nitric oxide levels;
LIHC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.47	6.36	0.33	6.47e-10	Major depressive disorder;
LIHC	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.15	-0.36	5.31e-12	Metabolite levels (Pyroglutamine);
LIHC	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-6.19	-0.32	1.71e-9	Hemoglobin concentration;
LIHC	cis	rs17739167	0.550	rs11070354	chr15:42233211	C/T	cg20935245	chr15:42234343	EHD4	0.4	7.51	0.38	5.17e-13	Monocyte count;
LIHC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	6.2	0.32	1.65e-9	Schizophrenia;
LIHC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.65	8.57	0.42	3.57e-16	Motion sickness;
LIHC	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.64	9.41	0.45	7.25e-19	Schizophrenia;
LIHC	trans	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg18393722	chr15:85113863	UBE2QP1	0.38	6.65	0.34	1.17e-10	Schizophrenia;
LIHC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.39	-8.75	-0.43	9.67e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.5	0.38	5.55e-13	Morning vs. evening chronotype;
LIHC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg22633049	chr21:46681294	NA	-0.37	-6.33	-0.32	7.69e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg15123519	chr2:136567270	LCT	-0.35	-5.73	-0.3	2.16e-8	Corneal structure;
LIHC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.48	-8.13	-0.4	8.16e-15	Longevity;Endometriosis;
LIHC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.53	-7.55	-0.38	3.9e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.75	12.53	0.56	6.44e-30	Mean platelet volume;
LIHC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg00656387	chr3:40428638	ENTPD3	0.42	7.02	0.35	1.21e-11	Renal cell carcinoma;
LIHC	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	0.68	6.54	0.33	2.29e-10	Lung disease severity in cystic fibrosis;
LIHC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg01402409	chr4:78978133	FRAS1	-0.49	-6.87	-0.35	2.97e-11	Kashin-Beck disease;
LIHC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg17764715	chr19:33622953	WDR88	0.41	5.79	0.3	1.61e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-8.42	-0.41	1.03e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.83	-13.3	-0.58	7.8e-33	Colorectal cancer;
LIHC	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.82	9.13	0.44	6.29e-18	Breast cancer;
LIHC	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.53	-0.38	4.65e-13	Metabolite levels;
LIHC	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.45	7.45	0.37	7.66e-13	Endometrial cancer;
LIHC	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.63	8.1	0.4	9.82e-15	Blood metabolite levels;
LIHC	trans	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg23605328	chr1:201951606	RNPEP	0.39	6.17	0.32	1.9e-9	Monocyte percentage of white cells;
LIHC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.7	-7.16	-0.36	4.85e-12	Hip circumference adjusted for BMI;
LIHC	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.58	9.13	0.44	6.31e-18	Graves' disease;
LIHC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.7	0.38	1.5e-13	Prudent dietary pattern;
LIHC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12016809	chr21:47604291	C21orf56	0.42	6.07	0.31	3.37e-9	Testicular germ cell tumor;
LIHC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg14025978	chr8:10786150	XKR6	0.47	5.73	0.3	2.25e-8	Neuroticism;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11702503	chr19:6215254	MLLT1	0.43	6.34	0.32	7.13e-10	Bilirubin levels;
LIHC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg10978503	chr1:24200527	CNR2	-0.35	-8.29	-0.41	2.56e-15	Immature fraction of reticulocytes;
LIHC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.54	-7.86	-0.39	5.1e-14	Prostate cancer;
LIHC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg09752223	chr19:15281200	NOTCH3	-0.37	-5.89	-0.3	9.39e-9	Pulse pressure;
LIHC	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-10.82	-0.5	1.17e-23	Ulcerative colitis;
LIHC	cis	rs11153147	0.649	rs11153145	chr6:109300799	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.88	-0.3	9.87e-9	Mean corpuscular volume;
LIHC	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg10381502	chr11:71823885	C11orf51	-1.06	-8.91	-0.43	3.07e-17	Severe influenza A (H1N1) infection;
LIHC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg19318889	chr4:1322082	MAEA	0.55	8.83	0.43	5.56e-17	Longevity;
LIHC	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	9.68	0.46	9.53e-20	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg11618577	chr2:27665543	KRTCAP3	-0.43	-6.01	-0.31	4.75e-9	Total body bone mineral density;
LIHC	cis	rs36051895	0.559	rs1590268	chr9:5209433	T/A	cg02405213	chr9:5042618	JAK2	-0.61	-10.32	-0.49	6.24e-22	Pediatric autoimmune diseases;
LIHC	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-11.25	-0.52	3.45e-25	Eye color traits;
LIHC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.73	7.39	0.37	1.15e-12	Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.52	8.49	0.42	6.55e-16	Intelligence;Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.25	0.32	1.24e-9	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.82	14.53	0.62	1.33e-37	Aortic root size;
LIHC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.69	-0.34	9.38e-11	Total body bone mineral density;
LIHC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.48	-18.2	-0.7	3.22e-52	Breast cancer;
LIHC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13409248	chr3:40428643	ENTPD3	0.49	8.22	0.41	4.34e-15	Renal cell carcinoma;
LIHC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.39	8.48	0.42	6.95e-16	Erythrocyte sedimentation rate;
LIHC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg07636037	chr3:49044803	WDR6	-0.62	-6.98	-0.35	1.5e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.77	-7.75	-0.39	1.03e-13	Platelet count;
LIHC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.81	13.25	0.58	1.21e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.96	-0.31	6.42e-9	Colorectal cancer;
LIHC	trans	rs6934970	0.932	rs62416967	chr6:113011386	A/G	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.34	-6.31	-0.32	8.46e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-11.04	-0.51	1.9e-24	Brugada syndrome;
LIHC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg27432699	chr2:27873401	GPN1	-0.5	-7.19	-0.36	4.23e-12	Total body bone mineral density;
LIHC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.89	-0.35	2.62e-11	Alcohol dependence;
LIHC	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.68	-10.14	-0.48	2.71e-21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LIHC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.29	0.37	2.14e-12	Morning vs. evening chronotype;
LIHC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.44	7.64	0.38	2.25e-13	Schizophrenia;
LIHC	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	14.67	0.62	4.02e-38	Nonalcoholic fatty liver disease;
LIHC	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.49	9.34	0.45	1.23e-18	Testicular germ cell tumor;
LIHC	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg05152925	chr14:45603667	FKBP3;FANCM	-0.46	-6.21	-0.32	1.56e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.81	9.94	0.47	1.29e-20	Cognitive function;
LIHC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg26668828	chr6:292823	DUSP22	-0.61	-8.31	-0.41	2.33e-15	Menopause (age at onset);
LIHC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg03854865	chr6:26224070	HIST1H3E	0.59	6.43	0.33	4.36e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.87	11.29	0.52	2.49e-25	Coronary artery disease;
LIHC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-23.24	-0.78	2.34e-72	Height;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00570391	chr7:815417	HEATR2	-0.43	-6.48	-0.33	3.29e-10	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2847476	0.690	rs7929497	chr11:114192132	C/G	cg18786224	chr11:69830436	NA	0.34	6.59	0.34	1.66e-10	Volumetric brain MRI;
LIHC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	14.73	0.62	2.24e-38	Smoking behavior;
LIHC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.47	7.37	0.37	1.27e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.37	-7.45	-0.37	7.54e-13	Obesity-related traits;
LIHC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.77	0.34	5.77e-11	Tonsillectomy;
LIHC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19461880	chr11:6504366	FXC1	-0.37	-6.17	-0.32	1.94e-9	Myopia (pathological);
LIHC	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.46	8.57	0.42	3.54e-16	Testicular germ cell tumor;
LIHC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.57	8.3	0.41	2.49e-15	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.21	-0.36	3.57e-12	Migraine;Coronary artery disease;
LIHC	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg15711740	chr2:61764176	XPO1	0.42	5.77	0.3	1.8e-8	Tuberculosis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg24106943	chr1:165738203	TMCO1	-0.47	-6.7	-0.34	8.78e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg23565663	chr8:10621935	NA	-0.48	-7.26	-0.37	2.71e-12	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.15	-0.48	2.46e-21	Bipolar disorder and schizophrenia;
LIHC	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.6	7.23	0.36	3.28e-12	Coronary artery disease;
LIHC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg21724239	chr8:58056113	NA	0.45	6.08	0.31	3.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.51	8.81	0.43	6.45e-17	Coronary artery disease;
LIHC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.55	7.78	0.39	8.81e-14	Blood metabolite levels;
LIHC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg00280220	chr17:61926910	NA	0.42	6.76	0.34	5.8200000000000003e-11	Prudent dietary pattern;
LIHC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21467203	chr3:49911342	NA	0.43	7.71	0.38	1.37e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2070488	0.813	rs3749387	chr3:38496193	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	15.1	0.63	7.61e-40	Electrocardiographic conduction measures;
LIHC	cis	rs2274273	0.529	rs10131562	chr14:55847015	G/A	cg01864836	chr14:55583639	NA	-0.34	-5.78	-0.3	1.64e-8	Protein biomarker;
LIHC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg02712183	chr4:82388742	RASGEF1B	-0.3	-6.07	-0.31	3.43e-9	Oropharynx cancer;
LIHC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.45	6.56	0.33	1.97e-10	Aortic root size;
LIHC	cis	rs4908768	0.859	rs55802878	chr1:8666411	T/C	cg25722041	chr1:8623473	RERE	0.43	5.78	0.3	1.7e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg12560992	chr17:57184187	TRIM37	0.73	9.14	0.44	5.78e-18	Vitamin D levels;
LIHC	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg27005118	chr17:13972210	COX10	-0.35	-6.49	-0.33	3.02e-10	Temperament;
LIHC	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.39	11.96	0.54	8.81e-28	Uric acid levels;
LIHC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg16486109	chr11:613632	IRF7	0.61	6.81	0.35	4.44e-11	Systemic lupus erythematosus;
LIHC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.78	13.82	0.6	8.23e-35	Coronary artery disease;
LIHC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.17	0.52	6.69e-25	Colorectal cancer;
LIHC	cis	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg14515779	chr1:101123966	NA	-0.7	-13.9	-0.6	3.84e-35	Monocyte count;
LIHC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.23	5.94	0.31	7.01e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	1.01	19.34	0.72	8.03e-57	Breast cancer;
LIHC	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-14.48	-0.62	2.23e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs11233413	0.957	rs1943341	chr11:82766826	T/C	cg24227371	chr11:82718527	RAB30	-0.35	-7.48	-0.37	6.36e-13	Economic and political preferences (feminism/equality);
LIHC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg05564831	chr3:52568323	NT5DC2	0.36	5.9	0.3	8.7e-9	Electroencephalogram traits;
LIHC	cis	rs6788895	1.000	rs79709238	chr3:150488477	A/C	cg09723797	chr3:150481914	SIAH2	0.81	10.99	0.51	3e-24	Breast cancer;
LIHC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.7	-9.74	-0.47	6.13e-20	Monocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg05590025	chr7:65112418	INTS4L2	0.6	6.62	0.34	1.38e-10	Diabetic kidney disease;
LIHC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg13628971	chr7:2884303	GNA12	0.48	6.83	0.35	3.79e-11	Height;
LIHC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.54	7.56	0.38	3.74e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg10932868	chr11:921992	NA	0.38	7.28	0.37	2.31e-12	Alzheimer's disease (late onset);
LIHC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.8	9.72	0.47	7.26e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg25039879	chr17:56429692	SUPT4H1	0.79	8.97	0.44	1.98e-17	Cognitive test performance;
LIHC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.52	7.65	0.38	2.01e-13	Mean platelet volume;
LIHC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-10.7	-0.5	3.15e-23	Breast cancer;
LIHC	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg00142150	chr22:38071001	LGALS1	0.44	7.48	0.38	6.14e-13	Fat distribution (HIV);
LIHC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.75	0.3	1.99e-8	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.59	-7.4	-0.37	1.07e-12	Macular telangiectasia type 2;
LIHC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.4	-6.75	-0.34	6.32e-11	Obesity-related traits;
LIHC	cis	rs16958440	0.581	rs60726022	chr18:44679813	A/G	cg17192377	chr18:44677553	HDHD2	0.71	7.78	0.39	8.44e-14	Sitting height ratio;
LIHC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	17.19	0.68	3.68e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.53	-18.47	-0.71	2.44e-53	Breast cancer;
LIHC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.72	10.59	0.5	7.34e-23	Vitamin D levels;
LIHC	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-9.96	-0.47	1.12e-20	Pediatric autoimmune diseases;
LIHC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.16	-0.32	2.08e-9	Schizophrenia;
LIHC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.35	5.83	0.3	1.26e-8	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	8.06	0.4	1.29e-14	Lymphocyte counts;
LIHC	trans	rs7759633	0.800	rs78733124	chr6:160997236	C/T	cg06341590	chr4:57624431	NA	-0.59	-6.53	-0.33	2.35e-10	Triglycerides;
LIHC	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.34	-6.49	-0.33	3.01e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg02811702	chr13:24901961	NA	0.25	6.1	0.31	2.8e-9	Obesity-related traits;
LIHC	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg25686905	chr3:183603175	PARL	-0.5	-9.35	-0.45	1.18e-18	Menopause (age at onset);
LIHC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.61	-7.73	-0.39	1.17e-13	Diastolic blood pressure;
LIHC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.77	14.73	0.62	2.17e-38	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.79	13.02	0.58	9.62e-32	Coronary artery disease;
LIHC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.77	0.47	4.73e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-6.02	-0.31	4.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-1.06	-12.19	-0.55	1.27e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.92	0.3	7.73e-9	Educational attainment;
LIHC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	0.72	8.17	0.4	6.16e-15	Hip circumference adjusted for BMI;
LIHC	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	0.78	8.57	0.42	3.61e-16	Gut microbiota (bacterial taxa);
LIHC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.6	7.19	0.36	4.05e-12	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg02023728	chr11:77925099	USP35	-0.34	-6.01	-0.31	4.72e-9	Alzheimer's disease (survival time);
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.73	12.13	0.55	2.03e-28	Height;
LIHC	trans	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.14	-0.36	5.49e-12	Diabetic kidney disease;
LIHC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg17980119	chr2:219472607	PLCD4	0.34	5.95	0.31	6.8e-9	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	8.13	0.4	8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg05697976	chr12:29376483	FAR2	0.35	7.24	0.36	2.9e-12	QT interval;
LIHC	cis	rs16877106	1.000	rs73254139	chr4:25318314	C/T	cg04796973	chr4:25314218	ZCCHC4	0.62	5.85	0.3	1.18e-8	Weight;
LIHC	cis	rs2274273	0.934	rs10139337	chr14:55742113	C/T	cg01864836	chr14:55583639	NA	-0.4	-6.89	-0.35	2.62e-11	Protein biomarker;
LIHC	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.46	-0.33	3.63e-10	Metabolite levels (Pyroglutamine);
LIHC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg00656387	chr3:40428638	ENTPD3	0.42	7.0	0.35	1.32e-11	Renal cell carcinoma;
LIHC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	0.93	16.75	0.67	2.07e-46	IgG glycosylation;
LIHC	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg14593290	chr7:50529359	DDC	-0.6	-9.52	-0.46	3.24e-19	Malaria;
LIHC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.9	19.55	0.73	1.18e-57	Blood protein levels;
LIHC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.65	-12.6	-0.56	3.56e-30	Extrinsic epigenetic age acceleration;
LIHC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg12751644	chr20:60527061	NA	-0.35	-5.89	-0.3	9e-9	Body mass index;
LIHC	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg14593290	chr7:50529359	DDC	0.62	9.67	0.46	1.02e-19	Malaria;
LIHC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.55	-0.38	3.93e-13	Bipolar disorder;
LIHC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.91	-15.17	-0.63	4.21e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs4716602	0.596	rs36013171	chr7:156160511	C/T	cg16983916	chr7:156159713	NA	-0.32	-5.71	-0.3	2.43e-8	Anti-saccade response;
LIHC	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.7	14.71	0.62	2.59e-38	Schizophrenia;
LIHC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.57	-8.97	-0.44	2.03e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs611744	0.967	rs2600614	chr8:109198079	T/A	cg21045802	chr8:109455806	TTC35	0.51	8.83	0.43	5.72e-17	Dupuytren's disease;
LIHC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg25281562	chr12:121454272	C12orf43	0.36	6.1	0.31	2.81e-9	N-glycan levels;
LIHC	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.32	6.84	0.35	3.57e-11	Ulcerative colitis;
LIHC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg13837822	chr10:26931731	LOC731789	0.38	7.2	0.36	3.92e-12	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LIHC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg01788221	chr16:89496183	ANKRD11	-0.41	-6.37	-0.33	6.12e-10	Multiple myeloma (IgH translocation);
LIHC	trans	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg21659725	chr3:3221576	CRBN	0.78	12.11	0.55	2.52e-28	Resting heart rate;
LIHC	trans	rs2270927	0.510	rs31244	chr5:75594743	G/A	cg13563193	chr19:33072644	PDCD5	1.01	9.74	0.47	5.94e-20	Mean corpuscular volume;
LIHC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg25894440	chr7:65020034	NA	-0.54	-6.14	-0.31	2.33e-9	Diabetic kidney disease;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00111532	chr16:600998	SOLH	0.34	6.69	0.34	8.88e-11	Calcium levels;
LIHC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg03721293	chr16:90014378	DEF8	-0.35	-6.28	-0.32	1.06e-9	Skin colour saturation;
LIHC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.25	0.41	3.44e-15	Bladder cancer;
LIHC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.16	0.32	2.04e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs16828019	0.929	rs111309254	chr1:41736000	A/G	cg03962019	chr1:41807865	NA	0.5	7.28	0.37	2.38e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs3740540	0.507	rs10794161	chr10:126291327	C/A	cg04949429	chr10:126290192	LHPP	0.44	7.2	0.36	3.97e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LIHC	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.52	6.22	0.32	1.42e-9	Serum sulfate level;
LIHC	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg02580895	chr19:2754563	NA	-0.4	-6.03	-0.31	4.2e-9	Total cholesterol levels;
LIHC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07677032	chr17:61819896	STRADA	-0.42	-6.17	-0.32	1.9e-9	Prudent dietary pattern;
LIHC	cis	rs507080	0.922	rs585039	chr11:118563381	C/A	cg04173919	chr11:118528438	PHLDB1	0.35	6.54	0.33	2.24e-10	Serum metabolite levels;
LIHC	cis	rs10162376	1	rs10162376	chr14:81030493	C/T	cg04303335	chr14:82000858	SEL1L	-0.48	-7.56	-0.38	3.72e-13	Mild influenza (H1N1) infection;
LIHC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.07	7.66	0.38	1.99e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	1.01	12.04	0.55	4.56e-28	Red blood cell traits;
LIHC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.98	-0.31	5.68e-9	Colorectal cancer;
LIHC	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.13	-0.44	5.97e-18	Exhaled nitric oxide output;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg15830607	chr12:110338073	TCHP	-0.57	-6.73	-0.34	7.04e-11	Systolic blood pressure;
LIHC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg18016565	chr1:150552671	MCL1	-0.49	-9.22	-0.45	3.19e-18	Melanoma;
LIHC	cis	rs258324	0.720	rs154663	chr16:89726035	T/C	cg04240660	chr16:89714849	CHMP1A	0.58	7.23	0.36	3.17e-12	Height;
LIHC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-9.51	-0.46	3.5e-19	Mean corpuscular volume;
LIHC	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.66	8.51	0.42	5.53e-16	Corneal structure;
LIHC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.69	13.29	0.58	8.71e-33	Systemic lupus erythematosus;
LIHC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.94	-0.44	2.44e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LIHC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.8	-0.3	1.54e-8	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.77	-12.08	-0.55	3.06e-28	Colorectal cancer;
LIHC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.86	-12.4	-0.56	2.09e-29	Intelligence (multi-trait analysis);
LIHC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg23533926	chr12:111358616	MYL2	0.34	6.7	0.34	8.44e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-6.11	-0.31	2.78e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg00280220	chr17:61926910	NA	0.43	6.88	0.35	2.79e-11	Prudent dietary pattern;
LIHC	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg16583315	chr14:65563665	MAX	0.36	7.19	0.36	4.01e-12	Obesity-related traits;
LIHC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.63	7.32	0.37	1.76e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg14393609	chr7:65229607	NA	-0.38	-6.03	-0.31	4.25e-9	Aortic root size;
LIHC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.5	0.38	5.5e-13	Aortic root size;
LIHC	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg10820045	chr2:198174542	NA	-0.51	-7.82	-0.39	6.57e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.38	-11.72	-0.54	6.87e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg11861562	chr11:117069780	TAGLN	-0.48	-7.88	-0.39	4.56e-14	Blood protein levels;
LIHC	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	8.13	0.4	7.85e-15	Allergic disease (asthma, hay fever or eczema);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg11399053	chr11:130781648	SNX19	0.45	6.66	0.34	1.08e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.4	0.45	7.87e-19	Bipolar disorder;
LIHC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-6.34	-0.32	7.08e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg22961513	chr11:14280813	SPON1	0.47	7.2	0.36	3.8e-12	Mitochondrial DNA levels;
LIHC	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.75	0.3	2.03e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg26395211	chr5:140044315	WDR55	-0.41	-5.99	-0.31	5.27e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg04592579	chr7:75616294	TMEM120A	0.4	6.94	0.35	1.97e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg13385521	chr17:29058706	SUZ12P	0.57	5.72	0.3	2.3e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg10932868	chr11:921992	NA	0.41	7.67	0.38	1.82e-13	Alzheimer's disease (late onset);
LIHC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.51	-0.33	2.66e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.36	-0.37	1.35e-12	Obesity-related traits;
LIHC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.77	0.39	9.06e-14	Prudent dietary pattern;
LIHC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.48	6.99	0.35	1.49e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.65	7.85	0.39	5.27e-14	Itch intensity from mosquito bite;
LIHC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg23485639	chr6:28045615	ZNF165	0.37	5.89	0.3	9.34e-9	Cardiac Troponin-T levels;
LIHC	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg22552966	chr17:19620595	SLC47A2	0.47	9.56	0.46	2.41e-19	Response to paliperidone in schizophrenia (CGI-S score);
LIHC	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg01864836	chr14:55583639	NA	-0.4	-7.22	-0.36	3.35e-12	Protein biomarker;
LIHC	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	23.07	0.78	1.06e-71	Schizophrenia;
LIHC	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.52	-7.98	-0.4	2.18e-14	Extraversion;
LIHC	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.72	-12.55	-0.56	5.69e-30	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.34	-0.32	7.39e-10	Obesity-related traits;
LIHC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.3	0.32	9.19e-10	Rheumatoid arthritis;
LIHC	cis	rs244293	0.965	rs244356	chr17:53193809	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-7.47	-0.37	6.93e-13	Menarche (age at onset);
LIHC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.46	1.47e-19	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.42	0.53	8.54e-26	Alzheimer's disease;
LIHC	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-13.56	-0.59	7.82e-34	Coffee consumption (cups per day);
LIHC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12463550	chr7:65579703	CRCP	0.7	7.35	0.37	1.43e-12	Diabetic kidney disease;
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.45	8.19	0.41	5.16e-15	Prudent dietary pattern;
LIHC	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	1.13	8.79	0.43	7.61e-17	Arsenic metabolism;
LIHC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg09835421	chr16:68378352	PRMT7	-0.53	-6.05	-0.31	3.86e-9	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.44	-7.99	-0.4	2.15e-14	Vitamin D levels;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg20609493	chr15:60420227	NA	0.38	6.17	0.32	1.89e-9	Cognitive function;
LIHC	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg14146966	chr2:61757674	XPO1	0.48	8.48	0.42	6.93e-16	Tuberculosis;
LIHC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg07636037	chr3:49044803	WDR6	-0.75	-7.61	-0.38	2.65e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.37	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.6	6.57	0.33	1.84e-10	Alzheimer's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04047827	chr16:24740859	TNRC6A	0.39	6.04	0.31	3.98e-9	Pancreatic cancer;
LIHC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg16576597	chr16:28551801	NUPR1	0.37	5.86	0.3	1.11e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs7078219	0.505	rs10883365	chr10:101287764	C/T	cg06854084	chr10:101292507	NKX2-3	-0.32	-5.92	-0.31	7.68e-9	Dental caries;
LIHC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.48	0.33	3.16e-10	Bipolar disorder and schizophrenia;
LIHC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.46	-8.27	-0.41	3.07e-15	Colorectal cancer;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10106725	chr4:3071494	NA	0.35	6.13	0.31	2.36e-9	Cognitive function;
LIHC	cis	rs1639906	0.895	rs78469080	chr7:2200729	G/A	cg04267008	chr7:1944627	MAD1L1	0.46	6.07	0.31	3.38e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg25894440	chr7:65020034	NA	-0.52	-6.14	-0.32	2.32e-9	Diabetic kidney disease;
LIHC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg03854865	chr6:26224070	HIST1H3E	0.59	6.48	0.33	3.27e-10	Gout;Renal underexcretion gout;
LIHC	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.59	5.97	0.31	6.06e-9	Hip geometry;
LIHC	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg10820045	chr2:198174542	NA	0.43	6.51	0.33	2.64e-10	Dermatomyositis;
LIHC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.86	15.58	0.64	9.67e-42	Headache;
LIHC	cis	rs965469	0.779	rs6051740	chr20:3301165	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-6.21	-0.32	1.49e-9	IFN-related cytopenia;
LIHC	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.54	-0.33	2.29e-10	QRS interval (sulfonylurea treatment interaction);
LIHC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.72	0.54	6.76e-27	Motion sickness;
LIHC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	1.2	14.83	0.63	8.74e-39	Eosinophil percentage of granulocytes;
LIHC	cis	rs10838687	0.736	rs7120158	chr11:47265194	G/C	cg26139080	chr11:47293733	MADD	-0.42	-5.89	-0.3	8.99e-9	Proinsulin levels;
LIHC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.31	-7.89	-0.39	4.18e-14	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.44	-12.1	-0.55	2.8e-28	Hip circumference adjusted for BMI;
LIHC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	trans	rs6934970	1.000	rs12215023	chr6:113103851	A/G	cg09308777	chr6:169852575	NA	0.64	6.33	0.32	7.82e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg01231543	chr16:68741748	NA	0.37	5.79	0.3	1.61e-8	Colorectal cancer;
LIHC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg15105060	chr4:7024189	TBC1D14	-0.7	-6.31	-0.32	8.73e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.76	-8.32	-0.41	2.14e-15	Vitiligo;
LIHC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.88	15.89	0.65	5.48e-43	Aortic root size;
LIHC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.51	7.95	0.4	2.66e-14	Diastolic blood pressure;
LIHC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.62	10.28	0.49	8.58e-22	Anterior chamber depth;
LIHC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	8.78	0.43	8.08e-17	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	7.92	0.39	3.47e-14	Coronary artery disease;
LIHC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.71	-0.34	8.16e-11	Total body bone mineral density;
LIHC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.47	-7.0	-0.35	1.4e-11	Mortality in heart failure;
LIHC	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.39	14.68	0.62	3.59e-38	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.49	-6.21	-0.32	1.56e-9	Menarche (age at onset);
LIHC	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.61	-0.34	1.52e-10	Vitiligo;
LIHC	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.55	8.31	0.41	2.27e-15	Menarche (age at onset);
LIHC	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02985541	chr2:219472218	PLCD4	-0.37	-6.43	-0.33	4.25e-10	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1499280	1.000	rs9291995	chr5:52099436	T/C	cg21153758	chr5:52083992	ITGA1;PELO	-0.63	-5.88	-0.3	9.75e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Reticulocyte count;Reticulocyte fraction of red cells;Immature fraction of reticulocytes;
LIHC	cis	rs1853665	0.580	rs6557201	chr6:150272567	T/C	cg16301758	chr6:150275521	NA	-0.41	-6.21	-0.32	1.58e-9	Radiation response;
LIHC	cis	rs918629	0.567	rs2548594	chr5:95244414	C/T	cg10483112	chr5:95245456	ELL2	-0.38	-7.14	-0.36	5.71e-12	IgG glycosylation;
LIHC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02290350	chr8:58132656	NA	0.41	8.36	0.41	1.61e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs2637266	0.783	rs11001866	chr10:78486774	C/T	cg18941641	chr10:78392320	NA	0.27	5.82	0.3	1.33e-8	Pulmonary function;
LIHC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.59	8.57	0.42	3.53e-16	Menarche (age at onset);
LIHC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.36	0.56	2.97e-29	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.6	-10.27	-0.49	9.51e-22	HDL cholesterol;
LIHC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg20607798	chr8:58055168	NA	0.65	8.15	0.4	6.88e-15	Developmental language disorder (linguistic errors);
LIHC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.8	13.49	0.59	1.48e-33	Bipolar disorder and schizophrenia;
LIHC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.25	-10.84	-0.51	9.77e-24	Hip circumference adjusted for BMI;
LIHC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.07	-0.31	3.36e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LIHC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.98	15.84	0.65	9.23e-43	Orofacial clefts;
LIHC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-7.92	-0.39	3.39e-14	Cognitive function;
LIHC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.34	-5.97	-0.31	6.07e-9	Schizophrenia;
LIHC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.55	-14.54	-0.62	1.22e-37	Alzheimer's disease (late onset);
LIHC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21747090	chr2:27597821	SNX17	-0.46	-6.85	-0.35	3.36e-11	Menopause (age at onset);
LIHC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.83	-0.51	1.07e-23	Total cholesterol levels;
LIHC	cis	rs16958440	1.000	rs62096469	chr18:44638298	A/G	cg17192377	chr18:44677553	HDHD2	0.61	6.9	0.35	2.59e-11	Sitting height ratio;
LIHC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg22528358	chr1:107598549	PRMT6	-0.67	-11.0	-0.51	2.58e-24	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	10.86	0.51	8.58e-24	Colorectal cancer;
LIHC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.31	0.32	8.49e-10	Melanoma;
LIHC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.73	0.39	1.18e-13	Mean platelet volume;
LIHC	cis	rs713477	1.000	rs12893964	chr14:55912268	T/C	cg13175173	chr14:55914753	NA	-0.33	-7.66	-0.38	1.99e-13	Pediatric bone mineral content (femoral neck);
LIHC	cis	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg17519650	chr2:63277830	OTX1	-0.54	-8.37	-0.41	1.47e-15	Coronary artery disease;
LIHC	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.4	5.75	0.3	2.03e-8	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.66	-12.36	-0.56	2.96e-29	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg06627628	chr2:24431161	ITSN2	-0.64	-7.42	-0.37	9.34e-13	Lymphocyte counts;
LIHC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.45	5.93	0.31	7.36e-9	High light scatter reticulocyte count;
LIHC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.91	0.3	8.5e-9	Schizophrenia;
LIHC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	12.07	0.55	3.48e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs11332131	1	rs11332131	chr17:57926391	GT/G	cg02344993	chr17:57696989	CLTC	0.46	7.61	0.38	2.6e-13	Platelet distribution width;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06943149	chr12:77157476	ZDHHC17	0.41	6.11	0.31	2.74e-9	Pancreatic cancer;
LIHC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	1.01	19.29	0.72	1.22e-56	Breast cancer;
LIHC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.74	10.2	0.48	1.67e-21	Psoriasis;
LIHC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.62	-0.5	6.08e-23	Total cholesterol levels;
LIHC	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.46	8.17	0.4	5.97e-15	Hand grip strength;
LIHC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg03037974	chr15:76606532	NA	0.64	10.91	0.51	5.47e-24	Blood metabolite levels;
LIHC	trans	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg10208301	chr11:6592745	DNHD1	0.48	6.96	0.35	1.71e-11	Coronary artery calcification;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08733086	chr1:154947035	CKS1B;SHC1	-0.53	-6.62	-0.34	1.39e-10	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	0.84	9.99	0.48	8.65e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs1712517	0.873	rs7894240	chr10:105000369	T/C	cg05636881	chr10:105038444	INA	-0.38	-6.08	-0.31	3.27e-9	Migraine;
LIHC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg26769984	chr7:1090371	C7orf50	0.63	7.69	0.38	1.6e-13	Bronchopulmonary dysplasia;
LIHC	cis	rs12220238	0.915	rs10824148	chr10:76078014	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.79	0.3	1.58e-8	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06481639	chr22:41940642	POLR3H	-0.59	-6.12	-0.31	2.61e-9	Vitiligo;
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg02993280	chr1:107599747	PRMT6	-0.62	-9.75	-0.47	5.5e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs932541	1.000	rs6111151	chr20:16456032	G/T	cg17003395	chr20:16555519	KIF16B	0.42	5.72	0.3	2.38e-8	Intelligence;
LIHC	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs1400745	0.756	rs799683	chr14:35349236	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.67	-0.38	1.79e-13	Monocyte count;
LIHC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	16.24	0.66	2.29e-44	Lymphocyte percentage of white cells;
LIHC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.68	-10.21	-0.48	1.57e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg06140118	chr16:68056778	DDX28;DUS2L	-0.42	-6.18	-0.32	1.79e-9	Immature fraction of reticulocytes;
LIHC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.43	-6.6	-0.34	1.55e-10	Total body bone mineral density;
LIHC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21467203	chr3:49911342	NA	0.4	6.94	0.35	1.95e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.84	0.3	1.21e-8	Bipolar disorder;
LIHC	cis	rs963731	0.649	rs2278914	chr2:39218552	G/A	cg04010122	chr2:39346883	SOS1	-0.7	-5.96	-0.31	6.38e-9	Corticobasal degeneration;
LIHC	cis	rs4478037	0.822	rs4528891	chr3:33121392	G/T	cg27203090	chr3:33138513	GLB1;TMPPE	-0.51	-6.47	-0.33	3.48e-10	Major depressive disorder;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26614578	chr12:113623930	C12orf52;DDX54	0.49	7.99	0.4	2.1e-14	Cognitive function;
LIHC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.67	-11.06	-0.51	1.61e-24	Total body bone mineral density;
LIHC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg11062466	chr8:58055876	NA	0.5	7.3	0.37	2.08e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.52	0.71	1.52e-53	Tonsillectomy;
LIHC	cis	rs12286929	0.699	rs1048932	chr11:115044850	C/A	cg04055981	chr11:115044050	NA	-0.41	-6.6	-0.34	1.57e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	trans	rs1512777	0.649	rs1916252	chr3:144436001	C/T	cg06253862	chr6:160201362	SNORA20;TCP1	0.48	6.31	0.32	8.44e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LIHC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs3823572	0.542	rs28529474	chr7:133634908	C/T	cg03336402	chr7:133662267	EXOC4	0.47	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.27	6.31	0.32	8.71e-10	Heart rate;
LIHC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg04727924	chr7:799746	HEATR2	-0.64	-8.81	-0.43	6.4e-17	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg14250997	chr9:106856677	SMC2	0.39	6.74	0.34	6.89e-11	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.82	-9.32	-0.45	1.48e-18	Eosinophil percentage of granulocytes;
LIHC	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.73	-11.25	-0.52	3.46e-25	Colonoscopy-negative controls vs population controls;
LIHC	trans	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg01134436	chr17:81009848	B3GNTL1	0.84	7.19	0.36	4.09e-12	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.79	0.34	5.01e-11	Morning vs. evening chronotype;
LIHC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.4	6.34	0.32	7.42e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.88	13.22	0.58	1.62e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs11958404	1.000	rs72816531	chr5:157413079	A/G	cg05962755	chr5:157440814	NA	0.86	10.11	0.48	3.51e-21	IgG glycosylation;
LIHC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19717773	chr7:2847554	GNA12	-0.32	-5.89	-0.3	9.07e-9	Height;
LIHC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.47	7.9	0.39	3.85e-14	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	3.16e-23	Bladder cancer;
LIHC	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	7.56	0.38	3.65e-13	Parkinson's disease;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08659621	chr20:48552817	RNF114	0.46	6.27	0.32	1.1e-9	Pancreatic cancer;
LIHC	cis	rs797680	0.856	rs535760	chr1:93728758	T/A	cg15093775	chr1:93646470	TMED5;CCDC18	0.33	5.77	0.3	1.78e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	6.4	0.33	5.12e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.52	6.64	0.34	1.25e-10	Total body bone mineral density;
LIHC	cis	rs10878977	0.565	rs11177656	chr12:69809883	T/C	cg17330252	chr12:69809627	NA	0.37	5.82	0.3	1.34e-8	Colorectal cancer;
LIHC	cis	rs7432375	0.901	rs1017882	chr3:136357705	T/C	cg21827317	chr3:136751795	NA	0.44	5.85	0.3	1.14e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.67	10.68	0.5	3.64e-23	Longevity;
LIHC	cis	rs7116495	1.000	rs1939242	chr11:71753582	C/T	cg26138937	chr11:71823887	C11orf51	-0.72	-7.31	-0.37	1.87e-12	Severe influenza A (H1N1) infection;
LIHC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.43	-0.41	1.01e-15	Morning vs. evening chronotype;
LIHC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	8.93	0.43	2.62e-17	Platelet count;
LIHC	cis	rs9649465	1.000	rs2299983	chr7:123356642	C/G	cg03229431	chr7:123269106	ASB15	-0.37	-7.96	-0.4	2.58e-14	Migraine;
LIHC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.44	7.48	0.37	6.45e-13	Mean corpuscular volume;
LIHC	cis	rs11761441	0.602	rs7794663	chr7:94105	C/T	cg25149888	chr7:81075	NA	-0.26	-5.74	-0.3	2.1e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.95	10.85	0.51	9.18e-24	Neuroticism;
LIHC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02985541	chr2:219472218	PLCD4	0.44	8.39	0.41	1.28e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-11.94	-0.54	1.07e-27	Total cholesterol levels;
LIHC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.0	0.54	6.44e-28	Body mass index;
LIHC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg16226627	chr15:75307476	SCAMP5	0.49	8.59	0.42	3.09e-16	Lung cancer;
LIHC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.48	0.33	3.27e-10	Morning vs. evening chronotype;
LIHC	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg00277334	chr10:82204260	NA	-0.56	-7.06	-0.36	9.57e-12	Post bronchodilator FEV1;
LIHC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.88	0.3	9.6e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg23649088	chr2:200775458	C2orf69	-0.46	-6.4	-0.33	5.2e-10	QT interval;
LIHC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg18357645	chr12:58087776	OS9	-0.44	-7.03	-0.36	1.12e-11	Multiple sclerosis;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg16944159	chr2:62132759	COMMD1	0.39	6.21	0.32	1.53e-9	Cognitive function;
LIHC	cis	rs10792665	0.649	rs12808296	chr11:82740116	A/C	cg24227371	chr11:82718527	RAB30	-0.38	-9.16	-0.44	5.06e-18	Obesity-related traits;
LIHC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg18944383	chr4:111397179	ENPEP	0.28	7.17	0.36	4.79e-12	Height;
LIHC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.29	-0.45	1.85e-18	Ulcerative colitis;
LIHC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.43	8.03	0.4	1.59e-14	Prudent dietary pattern;
LIHC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.67	-8.4	-0.41	1.24e-15	Gut microbiome composition (summer);
LIHC	trans	rs875971	1.000	rs778710	chr7:65854834	T/C	cg10756647	chr7:56101905	PSPH	0.45	6.55	0.33	2.06e-10	Aortic root size;
LIHC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.46	6.03	0.31	4.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-6.57	-0.33	1.89e-10	Schizophrenia;
LIHC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg23791538	chr6:167370224	RNASET2	0.37	5.81	0.3	1.4e-8	Primary biliary cholangitis;
LIHC	cis	rs11955398	0.678	rs1824120	chr5:59997929	G/A	cg02684056	chr5:59996105	DEPDC1B	0.4	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.44	5.74	0.3	2.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs12644436	0.587	rs11723700	chr4:88780084	T/A	cg06891869	chr4:88767617	MEPE	0.43	7.58	0.38	3.26e-13	HIV-1 viral setpoint;
LIHC	cis	rs6782228	0.509	rs6780447	chr3:128413808	T/C	cg16766828	chr3:128327626	NA	-0.38	-6.03	-0.31	4.2e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LIHC	trans	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg26939375	chr7:64535504	NA	0.42	6.71	0.34	8.22e-11	Aortic root size;
LIHC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.43	-5.99	-0.31	5.39e-9	Total body bone mineral density;
LIHC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.72	-0.3	2.27e-8	Resting heart rate;
LIHC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.72	-0.43	1.26e-16	Schizophrenia;
LIHC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.76	11.89	0.54	1.67e-27	Longevity;
LIHC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.59	11.81	0.54	3.06e-27	Tonsillectomy;
LIHC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.52	-7.73	-0.39	1.19e-13	Monobrow;
LIHC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.63	8.04	0.4	1.51e-14	Developmental language disorder (linguistic errors);
LIHC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg20487152	chr13:99095054	FARP1	-0.38	-6.21	-0.32	1.52e-9	Longevity;
LIHC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.81	-10.46	-0.49	2.15e-22	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	trans	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg26939375	chr7:64535504	NA	-0.43	-6.82	-0.35	4.17e-11	Aortic root size;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg07065683	chr16:31153871	PRSS36	0.4	6.09	0.31	3.06e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.52	-6.63	-0.34	1.34e-10	Coronary artery calcification;
LIHC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.8	-14.91	-0.63	4.53e-39	Height;
LIHC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.48	-17.96	-0.7	2.77e-51	Breast cancer;
LIHC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.46	7.09	0.36	7.93e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-9.3	-0.45	1.71e-18	Vitiligo;
LIHC	cis	rs922107	0.738	rs2045581	chr1:90047068	T/C	cg15422784	chr1:90023713	LRRC8B	-0.48	-7.73	-0.39	1.19e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg25894440	chr7:65020034	NA	-0.54	-6.24	-0.32	1.28e-9	Diabetic kidney disease;
LIHC	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg27205649	chr11:78285834	NARS2	0.38	5.9	0.3	8.85e-9	Alzheimer's disease (survival time);
LIHC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg02990361	chr1:107599529	PRMT6	0.59	10.0	0.48	7.82e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.32	-0.32	8.37e-10	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	8.33	0.41	1.95e-15	Platelet count;
LIHC	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.22	-0.32	1.44e-9	Coronary artery disease;
LIHC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	8.58	0.42	3.31e-16	Height;
LIHC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg17771515	chr6:154831774	CNKSR3	0.58	6.14	0.31	2.35e-9	Lipoprotein (a) levels;
LIHC	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.64	9.41	0.45	7.21e-19	Lung disease severity in cystic fibrosis;
LIHC	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.66	7.91	0.39	3.51e-14	Systemic lupus erythematosus;
LIHC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.65	10.31	0.49	6.98e-22	Menopause (age at onset);
LIHC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	8.63	0.42	2.28e-16	Height;
LIHC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.43	-6.93	-0.35	2.08e-11	Menarche (age at onset);
LIHC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg08847533	chr14:75593920	NEK9	0.35	5.88	0.3	9.71e-9	Caffeine consumption;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.89	0.57	2.96e-31	Prudent dietary pattern;
LIHC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.53	0.33	2.31e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.65	8.36	0.41	1.59e-15	Gut microbiome composition (summer);
LIHC	cis	rs5753037	0.809	rs2079338	chr22:30203842	G/A	cg01021169	chr22:30184971	ASCC2	-0.36	-6.69	-0.34	9.05e-11	Type 1 diabetes;
LIHC	cis	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg01864836	chr14:55583639	NA	-0.35	-5.97	-0.31	6.09e-9	Protein biomarker;
LIHC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-11.95	-0.54	9.59e-28	Height;
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg07133347	chr1:107600762	PRMT6	-0.45	-6.82	-0.35	4.03e-11	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg27433088	chr4:174089019	GALNT7	0.4	6.84	0.35	3.7e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LIHC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.22	-0.36	3.33e-12	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs694739	0.894	rs12421615	chr11:64021605	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.3	0.32	9.23e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.32	-5.96	-0.31	6.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.54	5.85	0.3	1.14e-8	Menopause (age at onset);
LIHC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08280861	chr8:58055591	NA	0.53	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.57	7.61	0.38	2.73e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs67981189	0.656	rs2810113	chr14:71395770	C/T	cg15816911	chr14:71606274	NA	-0.4	-6.34	-0.32	7.19e-10	Schizophrenia;
LIHC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	6.38	0.33	5.76e-10	Lymphocyte percentage of white cells;
LIHC	cis	rs7707921	0.958	rs4703870	chr5:81492643	G/A	cg15871215	chr5:81402204	ATG10	0.61	5.9	0.3	8.84e-9	Breast cancer;
LIHC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	11.21	0.52	4.84e-25	Lymphocyte percentage of white cells;
LIHC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.58	-10.18	-0.48	1.96e-21	Refractive error;
LIHC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.51	7.07	0.36	8.59e-12	Morning vs. evening chronotype;
LIHC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.61	5.74	0.3	2.05e-8	Blood protein levels;
LIHC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.33	-6.54	-0.33	2.25e-10	Body mass index;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg15038241	chr19:48113684	GLTSCR1	-0.5	-6.79	-0.34	4.95e-11	Electroencephalogram traits;
LIHC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.48	9.72	0.47	7.13e-20	Tonsillectomy;
LIHC	cis	rs7635838	0.822	rs9861633	chr3:11473437	C/G	cg00170343	chr3:11313890	ATG7	0.44	6.91	0.35	2.45e-11	HDL cholesterol;
LIHC	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg08469215	chr1:156261351	TMEM79	0.38	5.99	0.31	5.26e-9	Tonsillectomy;
LIHC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg00934597	chr7:893267	UNC84A	-0.49	-5.93	-0.31	7.27e-9	Cerebrospinal P-tau181p levels;
LIHC	cis	rs4908760	0.965	rs10864353	chr1:8549716	A/G	cg20416874	chr1:8611966	RERE	-0.68	-14.36	-0.61	6.45e-37	Vitiligo;
LIHC	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.3	7.05	0.36	1.01e-11	Educational attainment (years of education);
LIHC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	8.84	0.43	4.99e-17	Lung cancer in ever smokers;
LIHC	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.55	8.25	0.41	3.57e-15	Body mass index;
LIHC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.42	0.37	9.22e-13	Parkinson's disease;
LIHC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg09835421	chr16:68378352	PRMT7	-0.81	-9.71	-0.46	7.77e-20	Schizophrenia;
LIHC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.49	-6.22	-0.32	1.47e-9	Total body bone mineral density;
LIHC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg13957321	chr17:43675089	NA	0.49	7.89	0.39	4.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.38	-0.49	3.96e-22	Schizophrenia;
LIHC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg20607798	chr8:58055168	NA	0.5	6.25	0.32	1.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.79	-0.43	7.47e-17	Ulcerative colitis;
LIHC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.5	0.42	6.09e-16	Lung cancer in ever smokers;
LIHC	cis	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg01231543	chr16:68741748	NA	0.38	5.89	0.3	9.14e-9	Colorectal cancer;
LIHC	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg15282417	chr9:129245246	FAM125B	0.41	6.77	0.34	5.53e-11	Intraocular pressure;
LIHC	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.17	-0.44	4.53e-18	Schizophrenia;
LIHC	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.4	6.73	0.34	7.31e-11	Body mass index;
LIHC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.93	16.56	0.67	1.2e-45	Colorectal cancer;
LIHC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg18887096	chr2:219472410	PLCD4	0.38	6.74	0.34	6.94e-11	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.6	-0.38	2.87e-13	Alzheimer's disease;
LIHC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.91	17.05	0.68	1.27e-47	Aortic root size;
LIHC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.64	9.97	0.47	1.04e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LIHC	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.6	11.29	0.52	2.42e-25	Leprosy;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg19483816	chr5:180670343	GNB2L1;SNORD95;SNORD96A	0.45	6.21	0.32	1.53e-9	Lung function (FEV1/FVC);
LIHC	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.43	7.16	0.36	5.1e-12	Lewy body disease;
LIHC	cis	rs10861342	0.515	rs7134351	chr12:105455217	C/T	cg23923672	chr12:105501055	KIAA1033	-0.45	-6.25	-0.32	1.21e-9	IgG glycosylation;
LIHC	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg10756647	chr7:56101905	PSPH	1.0	11.73	0.54	6.25e-27	Gout;
LIHC	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.25	6.06	0.31	3.59e-9	Obesity-related traits;
LIHC	trans	rs654384	0.836	rs13224986	chr7:4172109	C/T	cg26675336	chr15:86133334	AKAP13	0.29	6.24	0.32	1.29e-9	Positive affect;
LIHC	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.56	6.88	0.35	2.83e-11	Breast cancer;
LIHC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg04374321	chr14:90722782	PSMC1	-0.48	-6.68	-0.34	9.52e-11	Gut microbiota (bacterial taxa);
LIHC	cis	rs922107	0.664	rs2061480	chr1:89974167	C/G	cg15422784	chr1:90023713	LRRC8B	0.48	7.73	0.39	1.18e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.25	6.82	0.35	4.03e-11	Type 2 diabetes;
LIHC	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21659725	chr3:3221576	CRBN	0.77	11.21	0.52	4.64e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.35	-5.75	-0.3	1.95e-8	IgG glycosylation;
LIHC	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-7.64	-0.38	2.15e-13	Homocysteine levels;
LIHC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg05697976	chr12:29376483	FAR2	-0.31	-6.41	-0.33	4.78e-10	QT interval;
LIHC	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg10820045	chr2:198174542	NA	-0.45	-6.67	-0.34	1.01e-10	Intracranial aneurysm;
LIHC	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.28	0.32	1.02e-9	Systolic blood pressure;
LIHC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.79	13.09	0.58	5.05e-32	Breast cancer;
LIHC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	19.35	0.72	6.94e-57	Smoking behavior;
LIHC	trans	rs1864585	0.520	rs17776946	chr8:10682674	A/C	cg26278703	chr11:58910052	FAM111A	0.66	6.07	0.31	3.47e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LIHC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg07424592	chr7:64974309	NA	0.75	8.79	0.43	7.66e-17	Diabetic kidney disease;
LIHC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.49	7.07	0.36	8.63e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg04632378	chr13:21900426	NA	0.42	7.04	0.36	1.07e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LIHC	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-8.86	-0.43	4.39e-17	Blood pressure (smoking interaction);
LIHC	cis	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg03342759	chr3:160939853	NMD3	0.56	7.38	0.37	1.25e-12	Morning vs. evening chronotype;
LIHC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.96	16.53	0.67	1.59e-45	Lymphocyte percentage of white cells;
LIHC	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.52	-7.68	-0.38	1.68e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18488745	chr11:67141242	LOC100130987;CLCF1	-0.42	-6.04	-0.31	4.06e-9	Calcium levels;
LIHC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	0.89	20.81	0.75	1.05e-62	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.56	9.98	0.47	9.41e-21	Lewy body disease;
LIHC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	9.23	0.45	2.9e-18	Lung cancer;
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10554839	chr10:27529782	ACBD5	0.43	6.77	0.34	5.49e-11	Calcium levels;
LIHC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	7.66	0.38	1.94e-13	Diastolic blood pressure;
LIHC	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.52	8.48	0.42	7.05e-16	Schizophrenia;
LIHC	cis	rs4788570	0.625	rs2247603	chr16:71609364	G/A	cg06353428	chr16:71660113	MARVELD3	-1.35	-12.22	-0.55	9.26e-29	Intelligence (multi-trait analysis);
LIHC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.4	6.39	0.33	5.53e-10	Menopause (age at onset);
LIHC	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	0.87	10.38	0.49	3.89e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.75	12.05	0.55	4.26e-28	Fat distribution (HIV);
LIHC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.72	0.34	7.41e-11	Height;
LIHC	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.49	8.09	0.4	1.02e-14	Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg14440974	chr22:39074834	NA	-0.42	-6.76	-0.34	5.83e-11	Menopause (age at onset);
LIHC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.83	14.68	0.62	3.6e-38	Aortic root size;
LIHC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.52	5.87	0.3	1.05e-8	Alzheimer's disease;
LIHC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.66	11.63	0.53	1.46e-26	Menopause (age at onset);
LIHC	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.48	8.81	0.43	6.4e-17	Reticulocyte fraction of red cells;
LIHC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.41	6.76	0.34	6e-11	Red blood cell count;
LIHC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg07061783	chr6:25882402	NA	0.43	6.04	0.31	3.96e-9	Blood metabolite levels;
LIHC	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg10820045	chr2:198174542	NA	0.51	8.37	0.41	1.44e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	8.54	0.42	4.33e-16	Platelet count;
LIHC	trans	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.5	0.33	2.82e-10	Ulcerative colitis;
LIHC	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.5	8.54	0.42	4.52e-16	Multiple myeloma;
LIHC	cis	rs7106204	0.748	rs11820336	chr11:24219701	G/A	ch.11.24196551F	chr11:24239977	NA	0.78	10.68	0.5	3.67e-23	Response to Homoharringtonine (cytotoxicity);
LIHC	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.66	0.34	1.08e-10	Mean corpuscular volume;
LIHC	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.48	8.15	0.4	6.75e-15	Lipoprotein (a) levels;
LIHC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg17980119	chr2:219472607	PLCD4	0.34	5.74	0.3	2.08e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.9	-9.91	-0.47	1.67e-20	Facial emotion recognition (sad faces);
LIHC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.06	0.61	9.27e-36	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.5	9.51	0.46	3.41e-19	Testicular germ cell tumor;
LIHC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.72	10.24	0.48	1.19e-21	Menarche (age at onset);
LIHC	cis	rs11212737	0.714	rs2852186	chr11:108520640	T/G	cg22776369	chr11:108536276	DDX10	0.38	6.21	0.32	1.55e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg00280220	chr17:61926910	NA	0.42	6.74	0.34	6.67e-11	Prudent dietary pattern;
LIHC	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg15704280	chr7:45808275	SEPT13	0.64	6.11	0.31	2.72e-9	Myopia (pathological);
LIHC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00152838	chr16:24741724	TNRC6A	0.45	5.99	0.31	5.34e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs8067354	0.957	rs9896742	chr17:57826530	T/G	cg13753209	chr17:57696993	CLTC	0.59	8.85	0.43	4.9e-17	Hemoglobin concentration;
LIHC	cis	rs4788570	0.625	rs4788813	chr16:71625572	T/C	cg06353428	chr16:71660113	MARVELD3	1.37	12.12	0.55	2.28e-28	Intelligence (multi-trait analysis);
LIHC	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg07451762	chr16:28383216	NA	-0.34	-6.12	-0.31	2.59e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.5	7.36	0.37	1.39e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.15	26.36	0.82	2.34e-84	Cognitive ability;
LIHC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg19318889	chr4:1322082	MAEA	0.41	5.94	0.31	6.9e-9	Obesity-related traits;
LIHC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg16226627	chr15:75307476	SCAMP5	0.54	8.94	0.44	2.51e-17	Lung cancer;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg21745091	chr11:118992183	HINFP	-0.54	-6.17	-0.32	1.94e-9	Systolic blood pressure;
LIHC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg22633049	chr21:46681294	NA	-0.36	-6.18	-0.32	1.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12290896	chr5:96038388	CAST	0.41	6.06	0.31	3.52e-9	Pancreatic cancer;
LIHC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-5.86	-0.3	1.1e-8	Subjective well-being;
LIHC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.83	-0.39	6.27e-14	Monocyte percentage of white cells;
LIHC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.93	13.38	0.59	3.93e-33	Primary sclerosing cholangitis;
LIHC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg27094323	chr7:1216898	NA	-0.4	-5.73	-0.3	2.18e-8	Longevity;Endometriosis;
LIHC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.88	15.81	0.65	1.17e-42	Aortic root size;
LIHC	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.05	-0.4	1.37e-14	Capecitabine sensitivity;
LIHC	cis	rs7095607	0.538	rs2673796	chr10:69917242	A/G	cg18986048	chr10:69913749	MYPN	0.51	7.66	0.38	1.98e-13	Lung function (FVC);
LIHC	cis	rs10847980	1.000	rs77329346	chr12:123403577	A/G	cg25930673	chr12:123319894	HIP1R	0.69	6.39	0.33	5.5e-10	Adiponectin levels;
LIHC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.65	-9.3	-0.45	1.7e-18	Blood metabolite levels;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20694715	chr12:10766273	MAGOHB	0.44	6.31	0.32	8.88e-10	Lung function (FEV1/FVC);
LIHC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg18357526	chr6:26021779	HIST1H4A	0.6	8.44	0.42	8.94e-16	Blood metabolite levels;
LIHC	cis	rs1664789	0.836	rs702639	chr5:53267387	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.45	6.91	0.35	2.45e-11	Waist circumference adjusted for body mass index;
LIHC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.44	-0.33	4.15e-10	HDL cholesterol;
LIHC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	1.06	12.62	0.56	2.96e-30	Eosinophil percentage of granulocytes;
LIHC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg24693881	chr1:107596107	NA	0.56	9.78	0.47	4.41e-20	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.22	-0.41	4.16e-15	Gut microbiome composition (summer);
LIHC	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	trans	rs412658	0.776	rs12460025	chr19:22318230	A/G	cg17074339	chr11:11642133	GALNTL4	-0.47	-6.97	-0.35	1.59e-11	Telomere length;
LIHC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg14393609	chr7:65229607	NA	0.37	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.64	9.67	0.46	1.04e-19	Height;
LIHC	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg23091122	chr1:110024289	SYPL2	0.46	6.09	0.31	3.04e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg03929089	chr4:120376271	NA	-0.45	-6.87	-0.35	3.14e-11	Pediatric bone mineral density (spine);
LIHC	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.62	5.73	0.3	2.24e-8	Morning vs. evening chronotype;
LIHC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg22903471	chr2:27725779	GCKR	-0.41	-6.16	-0.32	2e-9	Blood metabolite levels;
LIHC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.56	0.5	9.43e-23	Personality dimensions;
LIHC	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.6	8.92	0.43	2.8e-17	Recombination rate (females);
LIHC	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.23	6.11	0.31	2.69e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.05	0.31	3.84e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.66	10.7	0.5	3.06e-23	Schizophrenia;
LIHC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.42	7.76	0.39	9.78e-14	Electrocardiographic conduction measures;
LIHC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg21522988	chr12:29376872	FAR2	0.29	6.48	0.33	3.21e-10	QT interval;
LIHC	cis	rs10894294	0.589	rs7933085	chr11:130796248	A/G	cg12179176	chr11:130786555	SNX19	0.6	8.72	0.43	1.27e-16	Schizophrenia;
LIHC	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.88	0.43	3.97e-17	Coffee consumption (cups per day);
LIHC	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg20129853	chr10:51489980	NA	0.4	8.57	0.42	3.7e-16	Prostate-specific antigen levels;
LIHC	cis	rs7116495	0.867	rs662649	chr11:71578875	C/T	cg26138937	chr11:71823887	C11orf51	0.7	6.86	0.35	3.27e-11	Severe influenza A (H1N1) infection;
LIHC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg04756594	chr16:24857601	SLC5A11	0.47	7.41	0.37	1e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.69	11.65	0.53	1.22e-26	Crohn's disease;
LIHC	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.31	7.71	0.38	1.36e-13	Gut microbiome composition (winter);
LIHC	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.8	-0.71	1.18e-54	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs911119	0.913	rs6036463	chr20:23578940	A/T	cg16589663	chr20:23618590	CST3	-0.65	-6.81	-0.35	4.51e-11	Chronic kidney disease;
LIHC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.47	6.66	0.34	1.08e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15952933	chr7:1899886	MAD1L1	-0.4	-6.33	-0.32	7.73e-10	Calcium levels;
LIHC	cis	rs611744	0.967	rs859788	chr8:109227570	A/G	cg18478394	chr8:109455254	TTC35	0.38	6.65	0.34	1.15e-10	Dupuytren's disease;
LIHC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg25894440	chr7:65020034	NA	0.54	6.22	0.32	1.43e-9	Diabetic kidney disease;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg04164538	chr19:48867262	TMEM143;SYNGR4	-0.54	-6.07	-0.31	3.47e-9	Systolic blood pressure;
LIHC	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.72	0.43	1.26e-16	Coffee consumption (cups per day);
LIHC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.18	0.68	3.93e-48	Gut microbiome composition (summer);
LIHC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.76	0.5	1.94e-23	Smoking initiation;
LIHC	cis	rs6967414	0.681	rs2881352	chr7:6753511	T/A	cg00387323	chr7:6746715	ZNF12	0.64	7.05	0.36	9.85e-12	Hematocrit;Hemoglobin concentration;
LIHC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17507749	chr15:85114479	UBE2QP1	0.62	6.79	0.34	4.86e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg16479474	chr6:28041457	NA	0.47	6.65	0.34	1.16e-10	Depression;
LIHC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg15269541	chr15:43626905	ADAL	-0.3	-5.87	-0.3	1.03e-8	Lung cancer in ever smokers;
LIHC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.86	12.17	0.55	1.45e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.94	17.49	0.69	2.15e-49	Menopause (age at onset);
LIHC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.23	-0.32	1.34e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.25	-16.77	-0.67	1.7e-46	Diabetic kidney disease;
LIHC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg12046867	chr14:103022105	NA	0.5	7.22	0.36	3.29e-12	Platelet count;
LIHC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg14067834	chr17:29058358	SUZ12P	0.66	6.47	0.33	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.75	-11.21	-0.52	4.88e-25	Lung cancer in ever smokers;
LIHC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.41	-6.56	-0.33	1.97e-10	Menarche (age at onset);
LIHC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.37	5.79	0.3	1.57e-8	Menopause (age at onset);
LIHC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.62	5.86	0.3	1.09e-8	Cannabis dependence symptom count;
LIHC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.84	14.52	0.62	1.44e-37	Headache;
LIHC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-11.63	-0.53	1.48e-26	Platelet distribution width;
LIHC	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg01864836	chr14:55583639	NA	-0.41	-7.51	-0.38	5.13e-13	Protein biomarker;
LIHC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg15269541	chr15:43626905	ADAL	-0.3	-5.87	-0.3	1.02e-8	Lung cancer in ever smokers;
LIHC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.6	9.32	0.45	1.51e-18	Height;
LIHC	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.43	-6.64	-0.34	1.21e-10	Testicular germ cell tumor;
LIHC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.08	0.31	3.21e-9	Schizophrenia;
LIHC	trans	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg00789545	chr14:102770909	RAGE	0.36	6.15	0.32	2.12e-9	Total body bone mineral density;
LIHC	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.64	6.67	0.34	1.02e-10	Bipolar disorder;
LIHC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.74	-0.3	2.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs3770081	1.000	rs6705122	chr2:86176258	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.82	-0.43	6.02e-17	Facial emotion recognition (sad faces);
LIHC	trans	rs6489882	0.867	rs7304898	chr12:113365667	T/C	cg10175203	chr3:128143634	NA	0.39	6.37	0.33	5.94e-10	Chronic lymphocytic leukemia;
LIHC	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.88	0.3	9.84e-9	Lung cancer;
LIHC	cis	rs67981189	0.613	rs4531677	chr14:71451861	A/G	cg15816911	chr14:71606274	NA	0.37	5.92	0.31	7.72e-9	Schizophrenia;
LIHC	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.66	-11.82	-0.54	2.79e-27	Pediatric autoimmune diseases;
LIHC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.51	7.24	0.36	2.9e-12	Initial pursuit acceleration;
LIHC	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.55	8.56	0.42	4e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs7078219	0.505	rs10883371	chr10:101292455	G/T	cg06854084	chr10:101292507	NKX2-3	-0.34	-6.32	-0.32	8.31e-10	Dental caries;
LIHC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.57	-0.73	9.79e-58	Height;
LIHC	cis	rs7246865	0.768	rs11669463	chr19:17199314	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.4	5.88	0.3	9.79e-9	Reticulocyte fraction of red cells;
LIHC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.45	-7.26	-0.37	2.63e-12	Total body bone mineral density;
LIHC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.69	0.38	1.5700000000000001e-13	Bipolar disorder;
LIHC	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg05343316	chr1:45956843	TESK2	0.44	6.55	0.33	2.15e-10	High light scatter reticulocyte count;
LIHC	cis	rs16944613	0.588	rs10852136	chr15:91139798	T/G	cg26821196	chr15:91095069	CRTC3	0.44	7.23	0.36	3.1e-12	Colorectal cancer;
LIHC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg23625390	chr15:77176239	SCAPER	0.35	5.8	0.3	1.51e-8	Blood metabolite levels;
LIHC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.0	-0.54	6.29e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.57	7.6	0.38	2.94e-13	Developmental language disorder (linguistic errors);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg08595667	chr16:89445453	ANKRD11	0.36	6.11	0.31	2.67e-9	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.53	8.37	0.41	1.44e-15	Height;
LIHC	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.4	-6.09	-0.31	3.09e-9	Height;
LIHC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.45	6.12	0.31	2.5e-9	Developmental language disorder (linguistic errors);
LIHC	trans	rs6489882	0.867	rs7972033	chr12:113363283	C/T	cg10175203	chr3:128143634	NA	0.38	6.1	0.31	2.83e-9	Chronic lymphocytic leukemia;
LIHC	cis	rs7192750	0.586	rs2335712	chr16:71906597	A/G	cg06353428	chr16:71660113	MARVELD3	-0.73	-8.18	-0.4	5.77e-15	LDL cholesterol levels;Total cholesterol levels;
LIHC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.45	-7.93	-0.39	3.16e-14	Neuroticism;
LIHC	trans	rs4332037	0.588	rs61409925	chr7:1971226	G/A	cg11693508	chr17:37793320	STARD3	0.8	8.1	0.4	9.9e-15	Bipolar disorder;
LIHC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.92	0.39	3.48e-14	Motion sickness;
LIHC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.69	-9.72	-0.47	7.08e-20	Bronchopulmonary dysplasia;
LIHC	cis	rs36051895	0.632	rs11790841	chr9:5166273	G/C	cg02405213	chr9:5042618	JAK2	-0.65	-9.64	-0.46	1.35e-19	Pediatric autoimmune diseases;
LIHC	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg15192750	chr16:69999425	NA	0.47	7.01	0.35	1.27e-11	IgE levels;
LIHC	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-8.2	-0.41	5.02e-15	Response to antipsychotic treatment;
LIHC	cis	rs55665837	0.701	rs11023278	chr11:14641184	G/T	cg19336497	chr11:14380999	RRAS2	-0.37	-6.06	-0.31	3.5e-9	Vitamin D levels;
LIHC	trans	rs35523062	0.527	rs1387459	chr4:11911000	T/C	cg26681193	chr1:6653230	KLHL21	0.38	6.2	0.32	1.64e-9	Familial hepatitis B virus-related hepatocellular carcinoma;
LIHC	cis	rs17433710	0.543	rs4656380	chr1:162654807	C/T	cg01063088	chr1:162760584	HSD17B7	0.43	5.91	0.3	8.37e-9	Dupuytren's disease;
LIHC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.88	13.24	0.58	1.42e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.71	9.2	0.45	3.52e-18	Gut microbiome composition (summer);
LIHC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.98	-17.84	-0.69	8.33e-51	Intelligence (multi-trait analysis);
LIHC	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.32	7.32	0.37	1.77e-12	Blood metabolite ratios;
LIHC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-11.87	-0.54	1.91e-27	Mean corpuscular volume;
LIHC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.93	-12.18	-0.55	1.35e-28	Schizophrenia;
LIHC	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg15902774	chr15:75289873	SCAMP5	0.34	5.96	0.31	6.31e-9	Systemic lupus erythematosus;
LIHC	cis	rs9473924	0.505	rs2817416	chr6:50809777	T/C	cg14470998	chr6:50812995	TFAP2B	0.98	11.12	0.52	9.6e-25	Body mass index;
LIHC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.28	0.41	2.88e-15	Height;
LIHC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg19682013	chr15:45996608	NA	0.41	7.2	0.36	3.85e-12	Waist circumference;Weight;
LIHC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.47	8.7	0.43	1.43e-16	Colorectal cancer;
LIHC	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg19683494	chr5:74908142	NA	0.7	7.73	0.39	1.21e-13	Coronary artery disease;
LIHC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.53	8.19	0.41	5.12e-15	Longevity;Endometriosis;
LIHC	trans	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg26939375	chr7:64535504	NA	0.41	6.49	0.33	2.98e-10	Aortic root size;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	0.59	8.66	0.42	1.96e-16	Prudent dietary pattern;
LIHC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.59	7.46	0.37	7e-13	Developmental language disorder (linguistic errors);
LIHC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg27366882	chr3:133540807	NA	-0.42	-7.23	-0.36	3.28e-12	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-8.27	-0.41	3e-15	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg06362048	chr16:15051589	NA	-0.45	-6.72	-0.34	7.6e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg14515779	chr1:101123966	NA	-0.43	-6.01	-0.31	4.8e-9	Monocyte count;
LIHC	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.35	7.34	0.37	1.55e-12	Sitting height ratio;
LIHC	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	6.37	0.33	6.24e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LIHC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.02	-0.4	1.68e-14	Glycated hemoglobin levels;
LIHC	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.42	6.47	0.33	3.36e-10	Mean corpuscular volume;
LIHC	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-7.96	-0.4	2.64e-14	Putamen volume;
LIHC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07677032	chr17:61819896	STRADA	0.43	6.25	0.32	1.23e-9	Prudent dietary pattern;
LIHC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg00204512	chr16:28754710	NA	0.34	6.27	0.32	1.07e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LIHC	cis	rs9649465	1.000	rs10270877	chr7:123327860	T/C	cg03229431	chr7:123269106	ASB15	-0.38	-8.18	-0.4	5.61e-15	Migraine;
LIHC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	5.87	0.3	1.06e-8	Height;
LIHC	cis	rs7116495	0.786	rs1892919	chr11:71712175	G/A	cg26138937	chr11:71823887	C11orf51	-0.77	-7.87	-0.39	4.81e-14	Severe influenza A (H1N1) infection;
LIHC	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg01145232	chr6:150245071	RAET1G	-0.43	-8.11	-0.4	9.35e-15	Lung cancer;
LIHC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.43	6.79	0.34	4.89e-11	Autism spectrum disorder or schizophrenia;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg04364504	chr16:58035198	C16orf57;ZNF319	0.48	6.55	0.33	2.08e-10	Lung function (FEV1/FVC);
LIHC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.46	-6.93	-0.35	2.11e-11	Height;
LIHC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-0.96	-20.04	-0.73	1.23e-59	Height;
LIHC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.96	-14.45	-0.62	2.82e-37	IgG glycosylation;
LIHC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.85	9.65	0.46	1.23e-19	Initial pursuit acceleration;
LIHC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.03	-0.4	1.64e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.56	8.71	0.43	1.29e-16	Noise-induced hearing loss;
LIHC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.61	-0.38	2.72e-13	Bipolar disorder;
LIHC	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-14.76	-0.62	1.79e-38	Schizophrenia;
LIHC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07305463	chr2:136567211	LCT	0.38	7.37	0.37	1.25e-12	Mosquito bite size;
LIHC	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16684958	chr7:75615977	POR	-0.52	-8.79	-0.43	7.28e-17	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2257205	0.667	rs7217890	chr17:56731265	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-6.58	-0.34	1.76e-10	Pancreatic cancer;
LIHC	cis	rs3748682	0.861	rs12563037	chr1:38258644	C/G	cg12658694	chr1:38397304	INPP5B	-0.43	-6.12	-0.31	2.49e-9	Hypothyroidism;
LIHC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg23533926	chr12:111358616	MYL2	-0.33	-6.37	-0.33	6.02e-10	Extrinsic epigenetic age acceleration;
LIHC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.58	0.59	6.97e-34	Prudent dietary pattern;
LIHC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg21724239	chr8:58056113	NA	0.48	6.41	0.33	4.88e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.74	12.61	0.56	3.45e-30	Menopause (age at onset);
LIHC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.73	0.3	2.21e-8	Menopause (age at onset);
LIHC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg15902774	chr15:75289873	SCAMP5	0.39	6.07	0.31	3.36e-9	Lung cancer;
LIHC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.03	-0.4	1.61e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	0.85	7.04	0.36	1.09e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LIHC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	8.76	0.43	9.2e-17	Menarche (age at onset);
LIHC	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.52	-7.79	-0.39	8.26e-14	Fibroblast growth factor basic levels;
LIHC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.43	6.77	0.34	5.56e-11	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.54	-6.62	-0.34	1.41e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.5	9.05	0.44	1.07e-17	Height;
LIHC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	9.47	0.46	4.58e-19	IgG glycosylation;
LIHC	trans	rs10411161	0.579	rs59305384	chr19:52387064	A/G	cg22319618	chr22:45562946	NUP50	-0.61	-8.37	-0.41	1.47e-15	Breast cancer;
LIHC	cis	rs4979906	1.000	rs11002242	chr10:79445873	G/C	cg07817648	chr10:79422355	NA	-0.28	-6.05	-0.31	3.8e-9	Mortality in heart failure;
LIHC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.51	-0.46	3.48e-19	Intelligence (multi-trait analysis);
LIHC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.44	7.85	0.39	5.29e-14	Glomerular filtration rate (creatinine);
LIHC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-7.29	-0.37	2.2e-12	Height;
LIHC	cis	rs3736485	0.934	rs4143723	chr15:51867172	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.28	-0.32	1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02290350	chr8:58132656	NA	-0.55	-10.53	-0.49	1.26e-22	Developmental language disorder (linguistic errors);
LIHC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.53	-8.06	-0.4	1.33e-14	Total body bone mineral density;
LIHC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg08694578	chr2:241835147	C2orf54	-0.51	-6.91	-0.35	2.39e-11	Urinary metabolites;
LIHC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg16102536	chr7:156981717	UBE3C	0.34	5.77	0.3	1.75e-8	Body mass index;
LIHC	cis	rs2997447	0.761	rs72886625	chr1:26455319	A/G	cg19633962	chr1:26362018	EXTL1	-0.65	-5.76	-0.3	1.87e-8	QRS complex (12-leadsum);
LIHC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.04	-0.4	1.5e-14	Total body bone mineral density;
LIHC	cis	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg20932281	chr17:33905541	PEX12	0.42	5.76	0.3	1.9e-8	Response to radiotherapy in cancer (late toxicity);
LIHC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.98	0.4	2.19e-14	Tonsillectomy;
LIHC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.3	-5.75	-0.3	1.95e-8	Body mass index;
LIHC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.15	-0.36	5.32e-12	Personality dimensions;
LIHC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.06	16.62	0.67	6.67e-46	Breast cancer;
LIHC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.79	7.52	0.38	4.77e-13	Plasma clusterin levels;
LIHC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.86	0.39	5.2e-14	Prudent dietary pattern;
LIHC	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.34	23.39	0.78	6.41e-73	Corneal structure;
LIHC	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.46	7.61	0.38	2.62e-13	Crohn's disease;
LIHC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.34	0.32	7.16e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.35	9.46	0.46	5.21e-19	Weight;
LIHC	cis	rs12144094	0.766	rs74984954	chr1:120234068	G/A	cg20995928	chr1:120229863	NA	0.38	6.31	0.32	8.74e-10	Height;
LIHC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg15691649	chr6:25882328	NA	-0.41	-6.4	-0.33	5.2e-10	Height;
LIHC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg22676075	chr6:135203613	NA	0.38	6.29	0.32	9.78e-10	Red blood cell count;
LIHC	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.45	-8.78	-0.43	8.25e-17	Atrioventricular conduction;
LIHC	cis	rs798766	1.000	rs2305188	chr4:1739592	A/G	cg21231739	chr4:1642635	FAM53A	-0.37	-6.0	-0.31	5.06e-9	Bladder cancer;Urinary bladder cancer;
LIHC	cis	rs3770081	0.590	rs6747424	chr2:86176224	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-8.82	-0.43	6.02e-17	Facial emotion recognition (sad faces);
LIHC	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-14.5	-0.62	1.78e-37	Electrocardiographic conduction measures;
LIHC	trans	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg19894588	chr14:64061835	NA	-0.66	-9.1	-0.44	7.89e-18	Optic cup area;Vertical cup-disc ratio;
LIHC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.85	-15.2	-0.64	3.07e-40	Aortic root size;
LIHC	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	8.14	0.4	7.62e-15	Alzheimer's disease;
LIHC	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.39	-5.79	-0.3	1.58e-8	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-21.69	-0.76	3.18e-66	Height;
LIHC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.56	8.48	0.42	6.83e-16	Mean corpuscular volume;
LIHC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.78	-12.31	-0.55	4.54e-29	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs9828933	0.701	rs7621544	chr3:63928681	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.69	-8.94	-0.44	2.49e-17	Type 2 diabetes;
LIHC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg17385448	chr1:15911702	AGMAT	0.33	5.8	0.3	1.53e-8	Systolic blood pressure;
LIHC	cis	rs10508774	0.810	rs72793585	chr10:32730431	C/T	cg01819863	chr10:32635814	EPC1	0.61	5.88	0.3	9.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.7	-0.53	8.11e-27	Bipolar disorder and schizophrenia;
LIHC	trans	rs12752401	1.000	rs67551785	chr1:102978472	T/C	cg03332897	chr19:740442	PALM	0.46	6.14	0.32	2.23e-9	Resistance to antihypertensive treatment in hypertension;
LIHC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.45	-6.92	-0.35	2.18e-11	Red cell distribution width;
LIHC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	-0.62	-9.87	-0.47	2.17e-20	Inflammatory bowel disease;
LIHC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg15691649	chr6:25882328	NA	-0.6	-8.02	-0.4	1.65e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.44	-5.97	-0.31	5.81e-9	Total body bone mineral density;
LIHC	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.65	7.85	0.39	5.27e-14	Itch intensity from mosquito bite;
LIHC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.76	0.39	9.66e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-6.35	-0.32	6.67e-10	Waist-to-hip ratio adjusted for body mass index;
LIHC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.46	8.96	0.44	2.13e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.55	9.14	0.44	5.73e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-13.84	-0.6	6.53e-35	Coffee consumption (cups per day);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10965738	chr5:39071344	RICTOR	-0.26	-6.28	-0.32	1.01e-9	Calcium levels;
LIHC	cis	rs903552	1.000	rs12908406	chr15:102004046	C/T	cg19295451	chr15:102010161	PCSK6	-0.48	-6.73	-0.34	7.33e-11	Diabetic kidney disease;
LIHC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.11	-0.44	7e-18	Extrinsic epigenetic age acceleration;
LIHC	trans	rs6934970	1.000	rs2347031	chr6:113016262	A/G	cg09308777	chr6:169852575	NA	0.6	6.21	0.32	1.5e-9	Bipolar disorder (body mass index interaction);
LIHC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	5.76	0.3	1.89e-8	Schizophrenia;
LIHC	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg03854865	chr6:26224070	HIST1H3E	0.54	6.66	0.34	1.08e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs2637266	0.627	rs2013238	chr10:78476272	A/C	cg18941641	chr10:78392320	NA	0.28	6.2	0.32	1.61e-9	Pulmonary function;
LIHC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.47	-6.6	-0.34	1.58e-10	Initial pursuit acceleration;
LIHC	trans	rs10197140	0.857	rs10175204	chr2:111643355	C/T	cg23556447	chr6:90529595	MDN1	-0.39	-6.33	-0.32	7.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count;
LIHC	cis	rs36051895	0.560	rs1575281	chr9:5219131	T/C	cg02405213	chr9:5042618	JAK2	-0.61	-9.6	-0.46	1.74e-19	Pediatric autoimmune diseases;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13319049	chr4:39699555	UBE2K	0.44	6.51	0.33	2.74e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg03854865	chr6:26224070	HIST1H3E	0.64	7.14	0.36	5.78e-12	Gout;Renal underexcretion gout;
LIHC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.52	7.67	0.38	1.77e-13	Initial pursuit acceleration;
LIHC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.4	-0.45	7.89e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16262614	chr3:133464971	TF	0.32	7.22	0.36	3.36e-12	Iron status biomarkers;
LIHC	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-8.75	-0.43	1.01e-16	Colorectal cancer;
LIHC	cis	rs1461503	0.934	rs11605693	chr11:122837037	T/C	cg25161029	chr11:122845972	NA	0.38	6.4	0.33	5.17e-10	Menarche (age at onset);
LIHC	cis	rs16958440	0.867	rs74845165	chr18:44690852	T/C	cg17192377	chr18:44677553	HDHD2	0.92	8.72	0.43	1.22e-16	Sitting height ratio;
LIHC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.93	-0.31	7.55e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	trans	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg10208301	chr11:6592745	DNHD1	0.48	6.48	0.33	3.25e-10	Coronary artery calcification;
LIHC	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.53	6.89	0.35	2.71e-11	Breast cancer;
LIHC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg01629716	chr15:45996671	NA	0.52	9.5	0.46	3.84e-19	Waist circumference;Weight;
LIHC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.92	-0.43	2.78e-17	Alzheimer's disease;
LIHC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.67	11.98	0.54	7.42e-28	High light scatter reticulocyte count;
LIHC	cis	rs7617773	0.823	rs9839446	chr3:48194666	T/A	cg11946769	chr3:48343235	NME6	-0.65	-8.3	-0.41	2.51e-15	Coronary artery disease;
LIHC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-0.85	-10.5	-0.49	1.57e-22	Blood pressure (smoking interaction);
LIHC	cis	rs4589502	0.557	rs7495093	chr15:67155221	T/C	cg12317470	chr15:67143691	NA	0.51	5.92	0.31	7.72e-9	Lung cancer (smoking interaction);
LIHC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	0.8	6.06	0.31	3.61e-9	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.47	6.68	0.34	9.96e-11	Lung cancer;
LIHC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02711726	chr17:80685570	FN3KRP	-0.41	-7.16	-0.36	4.98e-12	Glycated hemoglobin levels;
LIHC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg12560992	chr17:57184187	TRIM37	0.73	10.83	0.51	1.08e-23	Cognitive test performance;
LIHC	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.31	-5.86	-0.3	1.06e-8	Red blood cell count;
LIHC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.75	10.9	0.51	6e-24	Corneal astigmatism;
LIHC	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.62	6.44	0.33	4.09e-10	Lymphocyte counts;
LIHC	trans	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg26939375	chr7:64535504	NA	0.44	6.9	0.35	2.59e-11	Aortic root size;
LIHC	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg03934865	chr2:198174659	NA	0.43	6.2	0.32	1.62e-9	Intracranial aneurysm;
LIHC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.54	7.46	0.37	7.19e-13	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg11070056	chr1:107600091	PRMT6	0.69	11.92	0.54	1.26e-27	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.68	13.61	0.59	5.27e-34	High light scatter reticulocyte count;
LIHC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.51	8.76	0.43	8.88e-17	Gestational age at birth (maternal effect);
LIHC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.32	7.05	0.36	9.66e-12	Ulcerative colitis;
LIHC	cis	rs986417	0.606	rs4899014	chr14:61118783	C/T	cg27398547	chr14:60952738	C14orf39	0.59	6.51	0.33	2.7e-10	Gut microbiota (bacterial taxa);
LIHC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.35	0.41	1.77e-15	Motion sickness;
LIHC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	5.95	0.31	6.81e-9	Tonsillectomy;
LIHC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.42	5.96	0.31	6.31e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LIHC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05439608	chr7:156761192	NOM1	0.4	6.98	0.35	1.55e-11	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg10130564	chr11:117069849	TAGLN	-0.36	-6.05	-0.31	3.82e-9	Blood protein levels;
LIHC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.83	14.66	0.62	4.37e-38	Aortic root size;
LIHC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.38	0.37	1.21e-12	Renal cell carcinoma;
LIHC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-8.17	-0.4	6.14e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs244293	0.899	rs8080876	chr17:53175267	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.49	7.27	0.37	2.5e-12	Menarche (age at onset);
LIHC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07677032	chr17:61819896	STRADA	0.44	6.36	0.33	6.38e-10	Prudent dietary pattern;
LIHC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.52	10.14	0.48	2.69e-21	Prudent dietary pattern;
LIHC	cis	rs80282103	0.618	rs10794720	chr10:1156165	A/G	cg08668510	chr10:1095578	IDI1	-0.69	-7.37	-0.37	1.31e-12	Glomerular filtration rate (creatinine);
LIHC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg11764359	chr7:65958608	NA	0.59	6.04	0.31	3.97e-9	Diabetic kidney disease;
LIHC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.65	13.69	0.59	2.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg20090690	chr10:134436459	INPP5A	0.45	5.78	0.3	1.72e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg12046867	chr14:103022105	NA	-0.52	-7.53	-0.38	4.44e-13	Platelet count;
LIHC	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.57	7.66	0.38	1.92e-13	Mean corpuscular hemoglobin;
LIHC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg03809021	chr16:89831123	FANCA	0.94	10.0	0.48	8.29e-21	Vitiligo;
LIHC	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.54	6.41	0.33	4.96e-10	Mammographic density (dense area);
LIHC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-7.4	-0.37	1.06e-12	Morning vs. evening chronotype;
LIHC	cis	rs4700695	0.925	rs381549	chr5:65383371	A/G	cg21114390	chr5:65439923	SFRS12	-0.46	-6.02	-0.31	4.39e-9	Facial morphology (factor 19);
LIHC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.31	-0.37	1.92e-12	Body mass index;
LIHC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.7	10.46	0.49	2.17e-22	Prostate cancer;
LIHC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-0.86	-9.64	-0.46	1.34e-19	Schizophrenia;
LIHC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.62	-8.79	-0.43	7.18e-17	Blood metabolite levels;
LIHC	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg08668510	chr10:1095578	IDI1	0.65	6.63	0.34	1.28e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	6.97	0.35	1.66e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LIHC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-0.86	-8.75	-0.43	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.38	-11.71	-0.53	7.6e-27	Hip circumference adjusted for BMI;
LIHC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.43	0.37	8.93e-13	Renal cell carcinoma;
LIHC	cis	rs11779988	0.545	rs439374	chr8:17786818	C/T	cg01800426	chr8:17659068	MTUS1	-0.4	-5.86	-0.3	1.11e-8	Breast cancer;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg16515820	chr3:114866447	ZBTB20	0.52	7.53	0.38	4.46e-13	Pancreatic cancer;
LIHC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.12	-0.31	2.52e-9	Total body bone mineral density;
LIHC	cis	rs600806	0.778	rs11101962	chr1:110014187	A/T	cg08911820	chr1:110026001	ATXN7L2	-0.58	-7.38	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs28489187	0.706	rs1498375	chr1:85787323	T/A	cg16011679	chr1:85725395	C1orf52	0.48	6.14	0.31	2.35e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LIHC	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-13.24	-0.58	1.42e-32	Pediatric autoimmune diseases;
LIHC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.55	-7.7	-0.38	1.5e-13	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	1.0	18.4	0.71	4.69e-53	Monocyte percentage of white cells;
LIHC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.73	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LIHC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	12.51	0.56	7.73e-30	Hip circumference adjusted for BMI;
LIHC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs7714584	1.000	rs13361189	chr5:150223387	A/G	cg20675040	chr8:143813288	C8orf55	0.36	6.29	0.32	9.88e-10	Crohn's disease;
LIHC	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.71	7.47	0.37	6.89e-13	Blood protein levels;
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02674305	chr20:34359915	PHF20	0.37	6.09	0.31	3.07e-9	Bilirubin levels;
LIHC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.34	0.45	1.31e-18	Bipolar disorder;
LIHC	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg22153463	chr1:85462885	MCOLN2	0.49	5.87	0.3	1.03e-8	Serum sulfate level;
LIHC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.26	-7.04	-0.36	1.04e-11	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs4950322	0.576	rs2353979	chr1:146839900	A/G	cg25205988	chr1:146714368	CHD1L	0.44	6.16	0.32	1.99e-9	Protein quantitative trait loci;
LIHC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.34	8.48	0.42	7.07e-16	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg03146154	chr1:46216737	IPP	0.5	8.55	0.42	4.08e-16	Red blood cell count;Reticulocyte count;
LIHC	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg10820045	chr2:198174542	NA	0.46	6.9	0.35	2.59e-11	Dermatomyositis;
LIHC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.72	-14.26	-0.61	1.58e-36	Extrinsic epigenetic age acceleration;
LIHC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.93	16.94	0.68	3.74e-47	Parkinson's disease;
LIHC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-7.45	-0.37	7.85e-13	Eosinophil percentage of white cells;
LIHC	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg20435097	chr10:126320824	FAM53B	0.36	6.2	0.32	1.6e-9	Asthma;
LIHC	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.58	-0.34	1.75e-10	Body mass index;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg13053135	chr2:234359932	DGKD	-0.41	-6.25	-0.32	1.2e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.07	-0.31	3.35e-9	Menarche (age at onset);
LIHC	cis	rs11673344	0.764	rs519551	chr19:37455948	C/G	cg27390819	chr19:37464633	NA	-0.53	-6.29	-0.32	9.74e-10	Obesity-related traits;
LIHC	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg04610667	chr7:75704037	NA	-0.33	-6.0	-0.31	5.08e-9	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg23533926	chr12:111358616	MYL2	-0.36	-6.85	-0.35	3.46e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.82	9.7	0.46	8.31e-20	Iron status biomarkers;
LIHC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07677032	chr17:61819896	STRADA	0.44	6.3	0.32	9.29e-10	Prudent dietary pattern;
LIHC	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.57	8.47	0.42	7.24e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg00656387	chr3:40428638	ENTPD3	0.41	6.92	0.35	2.19e-11	Renal cell carcinoma;
LIHC	cis	rs1570989	0.543	rs6458035	chr6:12015296	A/G	cg17804551	chr6:12015979	HIVEP1	0.4	6.97	0.35	1.63e-11	Alcohol and nicotine co-dependence;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg24523535	chr1:9970042	CTNNBIP1	0.35	6.04	0.31	3.92e-9	Lobe attachment (rater-scored or self-reported);
LIHC	trans	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.42	0.33	4.46e-10	Endometrial cancer;
LIHC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg14393609	chr7:65229607	NA	0.37	5.73	0.3	2.25e-8	Aortic root size;
LIHC	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg09596252	chr17:78655493	RPTOR	0.38	6.75	0.34	6.33e-11	Obesity;
LIHC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	0.84	11.74	0.54	5.79e-27	Skin colour saturation;
LIHC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg21486233	chr12:29375141	FAR2	0.29	5.72	0.3	2.27e-8	QT interval;
LIHC	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg14250997	chr9:106856677	SMC2	0.43	7.53	0.38	4.49e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	12.21	0.55	1.02e-28	Eye color traits;
LIHC	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.89	7.25	0.37	2.72e-12	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.61	8.83	0.43	5.48e-17	Aortic root size;
LIHC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	21.98	0.77	2.28e-67	Chronic sinus infection;
LIHC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg24826892	chr11:71159390	DHCR7	0.51	6.69	0.34	9.12e-11	Vitamin D levels;
LIHC	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg01858014	chr14:56050164	KTN1	-0.71	-7.3	-0.37	1.98e-12	Putamen volume;
LIHC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.46	0.33	3.57e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.47	0.56	1.11e-29	Colorectal cancer;
LIHC	cis	rs17286411	0.750	rs4788579	chr16:71951845	A/C	cg06353428	chr16:71660113	MARVELD3	0.55	6.8	0.35	4.71e-11	Blood protein levels;
LIHC	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg01320579	chr17:75405842	SEPT9	0.5	8.97	0.44	2.02e-17	Airflow obstruction;
LIHC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.59	-8.36	-0.41	1.65e-15	Parkinson's disease;
LIHC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg02290350	chr8:58132656	NA	0.32	7.07	0.36	8.87e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg00277334	chr10:82204260	NA	-0.47	-6.94	-0.35	1.97e-11	Post bronchodilator FEV1;
LIHC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.48	-8.72	-0.43	1.27e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.62	-0.38	2.48e-13	Initial pursuit acceleration;
LIHC	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.52	-6.11	-0.31	2.79e-9	Ulcerative colitis;
LIHC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg23517279	chr6:96025343	MANEA	-0.6	-6.13	-0.31	2.39e-9	Behavioural disinhibition (generation interaction);
LIHC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.38	6.18	0.32	1.84e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.69	-10.23	-0.48	1.34e-21	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	7.17	0.36	4.57e-12	Systemic lupus erythematosus;
LIHC	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.45	6.78	0.34	5.43e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.44	-6.32	-0.32	8.26e-10	Schizophrenia;
LIHC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	1.01	19.48	0.73	2.12e-57	Breast cancer;
LIHC	cis	rs1008375	1.000	rs13148861	chr4:17688338	G/A	cg16339924	chr4:17578868	LAP3	-0.48	-6.01	-0.31	4.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg07424592	chr7:64974309	NA	0.82	9.61	0.46	1.64e-19	Diabetic kidney disease;
LIHC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.38	0.59	3.82e-33	Airflow obstruction;
LIHC	cis	rs7432375	0.901	rs11919030	chr3:136348599	G/A	cg21827317	chr3:136751795	NA	0.46	6.28	0.32	1.05e-9	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LIHC	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.41	-7.83	-0.39	5.98e-14	Testicular germ cell tumor;
LIHC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	5.78	0.3	1.64e-8	Lymphocyte percentage of white cells;
LIHC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.09	-8.24	-0.41	3.78e-15	Body mass index;
LIHC	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.87	0.43	4.04e-17	Coffee consumption (cups per day);
LIHC	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.69	11.3	0.52	2.23e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LIHC	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg25828445	chr12:7781288	NA	-0.49	-7.04	-0.36	1.06e-11	HDL cholesterol levels;
LIHC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.61	10.83	0.51	1.06e-23	Platelet distribution width;
LIHC	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg20991723	chr1:152506922	NA	0.51	8.52	0.42	5.08e-16	Hair morphology;
LIHC	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.6	9.62	0.46	1.54e-19	Response to antidepressants and depression;
LIHC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg21559469	chr19:19431446	KIAA0892;SF4	0.43	5.87	0.3	1.02e-8	Nonalcoholic fatty liver disease;
LIHC	trans	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg17712092	chr4:129076599	LARP1B	0.57	6.17	0.32	1.9e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs11822910	1.000	rs4529894	chr11:57199645	C/G	cg00522883	chr11:57194120	SLC43A3	0.7	8.38	0.41	1.37e-15	Platelet distribution width;
LIHC	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg01864836	chr14:55583639	NA	-0.35	-5.82	-0.3	1.33e-8	Protein biomarker;
LIHC	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.45	6.78	0.34	5.17e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg13409248	chr3:40428643	ENTPD3	0.43	7.08	0.36	8.01e-12	Renal cell carcinoma;
LIHC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.98	15.78	0.65	1.63e-42	Diastolic blood pressure;Systolic blood pressure;
LIHC	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.57	8.44	0.42	9.28e-16	Menopause (age at onset);
LIHC	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.41	5.96	0.31	6.36e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.64	8.73	0.43	1.12e-16	Neuroticism;
LIHC	cis	rs4908768	0.911	rs953535	chr1:8776719	A/C	cg25722041	chr1:8623473	RERE	0.42	5.91	0.3	8.51e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.48	-0.49	1.84e-22	Hemoglobin concentration;
LIHC	cis	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg20159608	chr7:32802032	NA	-0.48	-5.98	-0.31	5.49e-9	Metabolite levels (HVA/MHPG ratio);
LIHC	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg07959070	chr22:50026188	C22orf34	-0.3	-7.19	-0.36	4.03e-12	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg14393609	chr7:65229607	NA	-0.39	-5.85	-0.3	1.16e-8	Aortic root size;
LIHC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.29	-7.8	-0.39	7.47e-14	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs17433710	0.516	rs12036048	chr1:162658640	C/T	cg01063088	chr1:162760584	HSD17B7	0.44	6.07	0.31	3.34e-9	Dupuytren's disease;
LIHC	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14990712	chr19:4055085	ZBTB7A	0.4	6.05	0.31	3.81e-9	Immature fraction of reticulocytes;
LIHC	cis	rs10508774	1.000	rs72795571	chr10:32909933	A/G	cg01819863	chr10:32635814	EPC1	0.64	5.84	0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg18016565	chr1:150552671	MCL1	-0.49	-9.26	-0.45	2.28e-18	Tonsillectomy;
LIHC	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg02023728	chr11:77925099	USP35	0.36	6.31	0.32	8.49e-10	Alzheimer's disease (survival time);
LIHC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.59	8.09	0.4	1.08e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LIHC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.61	-11.31	-0.52	2.01e-25	Type 2 diabetes;
LIHC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.44	-7.91	-0.39	3.71e-14	Mean corpuscular volume;
LIHC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg12046867	chr14:103022105	NA	-0.47	-6.79	-0.34	4.94e-11	Platelet count;
LIHC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.96	15.06	0.63	1.1e-39	IgG glycosylation;
LIHC	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg04592579	chr7:75616294	TMEM120A	0.39	6.74	0.34	6.89e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	trans	rs11760633	0.607	rs7789703	chr7:1829899	T/C	cg00395210	chr12:48592465	NA	0.34	6.06	0.31	3.53e-9	Coronary artery disease;
LIHC	trans	rs12960119	0.536	rs34515305	chr18:23732926	G/A	cg05333146	chr16:67183725	B3GNT9	0.64	6.09	0.31	3e-9	Rhegmatogenous retinal detachment;
LIHC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.55	-8.8	-0.43	6.67e-17	Menarche (age at onset);
LIHC	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	0.74	6.05	0.31	3.74e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LIHC	cis	rs7944735	0.508	rs74335517	chr11:47479168	G/A	cg20307385	chr11:47447363	PSMC3	-0.56	-6.34	-0.32	7.33e-10	Intraocular pressure;
LIHC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.53e-15	Gut microbiome composition (summer);
LIHC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.6	7.08	0.36	8.04e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.47	6.77	0.34	5.57e-11	Schizophrenia;
LIHC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.52	-0.46	3.32e-19	Bipolar disorder and schizophrenia;
LIHC	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LIHC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-5.85	-0.3	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg24209194	chr3:40518798	ZNF619	0.45	6.34	0.32	7.37e-10	Renal cell carcinoma;
LIHC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-6.45	-0.33	3.81e-10	Colorectal cancer;
LIHC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.46	-5.75	-0.3	1.93e-8	Blood protein levels;
LIHC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	14.63	0.62	5.53e-38	Prudent dietary pattern;
LIHC	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.7	9.82	0.47	3.22e-20	Body mass index;
LIHC	cis	rs11212260	0.655	rs17106918	chr11:107287701	C/T	cg25435332	chr11:107328525	CWF19L2	0.8	8.13	0.4	7.75e-15	IgG glycosylation;
LIHC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.62	7.93	0.39	3.23e-14	Morning vs. evening chronotype;
LIHC	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg25237894	chr2:233734115	C2orf82	-0.4	-7.45	-0.37	7.93e-13	Schizophrenia;
LIHC	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.66	-9.31	-0.45	1.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-7.57	-0.38	3.48e-13	Mean corpuscular volume;
LIHC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.17	0.66	4.4e-44	Electrocardiographic conduction measures;
LIHC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	9.86	0.47	2.31e-20	Chronic sinus infection;
LIHC	cis	rs3820500	0.543	rs1289938	chr1:117944341	G/A	cg20383390	chr1:117909022	MAN1A2	0.47	6.04	0.31	4.03e-9	Pneumonia;
LIHC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.45	-6.76	-0.34	6e-11	Asthma;
LIHC	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	6.67	0.34	1e-10	Bipolar disorder;
LIHC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.37	-6.86	-0.35	3.27e-11	Schizophrenia;
LIHC	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg04592579	chr7:75616294	TMEM120A	-0.39	-6.77	-0.34	5.63e-11	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs11888559	0.573	rs10190966	chr2:203792816	A/G	cg24605529	chr2:203879461	NBEAL1	-0.66	-5.73	-0.3	2.19e-8	Height;
LIHC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.83	-0.47	3.09e-20	Extrinsic epigenetic age acceleration;
LIHC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.87	13.14	0.58	3.4e-32	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.61	-10.81	-0.5	1.29e-23	Neuroticism;
LIHC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-16.34	-0.66	8.97e-45	Lymphocyte percentage of white cells;
LIHC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02034447	chr16:89574710	SPG7	0.44	6.76	0.34	5.96e-11	Multiple myeloma (IgH translocation);
LIHC	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.26	-14.13	-0.61	4.86e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.54	-7.64	-0.38	2.26e-13	Body mass index;
LIHC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25387593	chr11:118927868	HYOU1	-0.46	-6.52	-0.33	2.52e-10	Triglycerides;
LIHC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.6	0.42	2.82e-16	Motion sickness;
LIHC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg23262073	chr20:60523788	NA	-0.29	-6.16	-0.32	2.09e-9	Body mass index;
LIHC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-9.5	-0.46	3.75e-19	Extrinsic epigenetic age acceleration;
LIHC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.4	-6.67	-0.34	1.05e-10	Facial morphology (factor 20);
LIHC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.83	10.86	0.51	8.58e-24	Cognitive function;
LIHC	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.31	6.45	0.33	3.71e-10	Bone mineral density;
LIHC	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15664640	chr17:80829946	TBCD	0.67	10.5	0.49	1.59e-22	Breast cancer;
LIHC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.54	-0.38	4.15e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.49	6.31	0.32	8.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.57	7.63	0.38	2.39e-13	Body mass index;
LIHC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg18016565	chr1:150552671	MCL1	0.56	10.79	0.5	1.48e-23	Melanoma;
LIHC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12379764	chr21:47803548	PCNT	-0.54	-7.99	-0.4	2.08e-14	Testicular germ cell tumor;
LIHC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.5	2.95e-23	Bladder cancer;
LIHC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.57	-9.26	-0.45	2.25e-18	Body mass index;
LIHC	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.42	8.93	0.43	2.62e-17	Coronary artery disease;
LIHC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.74	-12.05	-0.55	4.28e-28	Body mass index;
LIHC	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	10.32	0.49	6.52e-22	Colorectal cancer;
LIHC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.22	6.02	0.31	4.4e-9	Calcium levels;
LIHC	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg19000871	chr14:103996768	TRMT61A	-0.47	-7.94	-0.39	2.98e-14	Coronary artery disease;
LIHC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-9.98	-0.48	9.07e-21	Platelet count;
LIHC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-7.17	-0.36	4.71e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.53	8.68	0.43	1.59e-16	Prostate-specific antigen levels (conditioned on lead SNPs);
LIHC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.67	0.34	1.03e-10	Lung cancer;
LIHC	cis	rs8084351	0.577	rs12607872	chr18:50658496	G/A	cg24270629	chr18:50823537	DCC	-0.44	-6.42	-0.33	4.55e-10	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LIHC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.48	9.73	0.47	6.42e-20	Tonsillectomy;
LIHC	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.4	7.07	0.36	9.04e-12	Obesity;
LIHC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-7.53	-0.38	4.53e-13	Uric acid levels;
LIHC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.62	-9.55	-0.46	2.5e-19	Uric acid clearance;
LIHC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.81	11.9	0.54	1.43e-27	Motion sickness;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg11229284	chr3:122399506	PARP14	0.53	6.78	0.34	5.41e-11	Lung function (FEV1/FVC);
LIHC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.53	7.27	0.37	2.41e-12	Body mass index;
LIHC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	7.56	0.38	3.76e-13	Hip circumference adjusted for BMI;
LIHC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg27432699	chr2:27873401	GPN1	-0.54	-7.82	-0.39	6.44e-14	Total body bone mineral density;
LIHC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.37	6.75	0.34	6.31e-11	Aortic root size;
LIHC	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.56	-10.4	-0.49	3.35e-22	Schizophrenia;
LIHC	cis	rs2281558	0.754	rs73597824	chr20:25591477	C/T	cg13962466	chr20:25176127	ENTPD6	-0.41	-5.79	-0.3	1.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LIHC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08677398	chr8:58056175	NA	0.41	6.28	0.32	1.03e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.52	7.84	0.39	5.62e-14	Platelet count;
LIHC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.61	8.48	0.42	6.98e-16	Platelet count;
LIHC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.47	-8.09	-0.4	1.02e-14	Total body bone mineral density;
LIHC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.79	-0.43	7.44e-17	Total cholesterol levels;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg11114853	chr2:242626719	DTYMK	0.44	6.14	0.32	2.27e-9	Alopecia areata;
LIHC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg16797656	chr11:68205561	LRP5	0.5	7.8	0.39	7.44e-14	Total body bone mineral density;
LIHC	cis	rs2279817	0.863	rs871087	chr1:18017522	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.68	8.05	0.4	1.36e-14	Neuroticism;
LIHC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.47	-8.08	-0.4	1.13e-14	Total body bone mineral density;
LIHC	cis	rs1892700	0.840	rs62226457	chr21:34870990	G/A	cg14850771	chr21:34775459	IFNGR2	-0.43	-5.75	-0.3	1.97e-8	Educational attainment;
LIHC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-10.69	-0.5	3.34e-23	Breast cancer;
LIHC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	15.0	0.63	1.98e-39	Prudent dietary pattern;
LIHC	cis	rs1434579	0.897	rs8102733	chr19:44944448	A/G	cg15540054	chr19:45004280	ZNF180	0.54	7.59	0.38	3.16e-13	Tuberculosis;
LIHC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.66	-10.55	-0.5	1.04e-22	Skin colour saturation;
LIHC	cis	rs9918079	0.560	rs7662032	chr4:15635414	C/G	cg04067612	chr4:15429572	C1QTNF7	-0.28	-5.88	-0.3	9.93e-9	Obesity-related traits;
LIHC	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	7.22	0.36	3.49e-12	Fibroblast growth factor basic levels;
LIHC	cis	rs611744	0.870	rs416611	chr8:109124593	T/C	cg21045802	chr8:109455806	TTC35	0.5	8.48	0.42	6.86e-16	Dupuytren's disease;
LIHC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.61	8.63	0.42	2.37e-16	HIV-1 control;
LIHC	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.64	0.34	1.25e-10	Soluble interleukin-2 receptor subunit alpha;
LIHC	cis	rs6695567	0.967	rs6588468	chr1:53630648	A/G	cg20326410	chr1:53600821	SLC1A7	0.3	6.34	0.32	7.22e-10	Systemic lupus erythematosus;
LIHC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.38	-9.96	-0.47	1.07e-20	Asthma (sex interaction);
LIHC	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.38	-6.35	-0.32	6.9e-10	HDL cholesterol levels;HDL cholesterol;
LIHC	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg19680672	chr10:131412579	MGMT	-0.38	-5.74	-0.3	2.1e-8	Response to temozolomide;
LIHC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.17	-0.44	4.56e-18	Bipolar disorder;
LIHC	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg20129853	chr10:51489980	NA	0.42	9.03	0.44	1.32e-17	Prostate-specific antigen levels;
LIHC	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	10.8	0.5	1.42e-23	Fuchs's corneal dystrophy;
LIHC	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.29	6.4	0.33	5.23e-10	Pulmonary function;
LIHC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.45	-6.54	-0.33	2.28e-10	Body mass index;
LIHC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.86	14.38	0.61	5.22e-37	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06846819	chr11:68850022	TPCN2	0.4	6.28	0.32	1.04e-9	Hair color;
LIHC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.6	-8.33	-0.41	2.03e-15	Motion sickness;
LIHC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg26441486	chr22:50317300	CRELD2	-0.34	-6.05	-0.31	3.79e-9	Schizophrenia;
LIHC	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.64	6.02	0.31	4.61e-9	Morning vs. evening chronotype;
LIHC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.91	-0.3	8.08e-9	Colorectal cancer;
LIHC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.29	5.88	0.3	9.68e-9	Homoarginine levels;
LIHC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.3	-5.74	-0.3	2.11e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08677398	chr8:58056175	NA	0.41	6.29	0.32	9.72e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.82	7.98	0.4	2.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg03585969	chr10:35415529	CREM	0.76	11.02	0.51	2.18e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.48	-18.37	-0.7	6.13e-53	Breast cancer;
LIHC	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg10820045	chr2:198174542	NA	0.46	7.2	0.36	3.84e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.6	-7.97	-0.4	2.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LIHC	cis	rs273218	1.000	rs273218	chr5:53380555	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.64	10.13	0.48	2.8e-21	Migraine;
LIHC	cis	rs7212590	0.581	rs8069418	chr17:57818213	A/G	cg10252138	chr17:58120427	NA	-0.63	-6.08	-0.31	3.26e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.07	0.31	3.49e-9	Bipolar disorder with mood-incongruent psychosis;
LIHC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.31	0.32	8.85e-10	Rheumatoid arthritis;
LIHC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.15	0.36	5.37e-12	Breast cancer;
LIHC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.44	0.33	4.04e-10	Schizophrenia;
LIHC	cis	rs10508774	1.000	rs12250212	chr10:32950637	C/T	cg01819863	chr10:32635814	EPC1	0.63	5.88	0.3	9.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-8.68	-0.42	1.61e-16	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	11.84	0.54	2.46e-27	High light scatter reticulocyte count;
LIHC	cis	rs7106204	0.514	rs7117803	chr11:24253214	A/T	ch.11.24196551F	chr11:24239977	NA	0.82	11.75	0.54	5.24e-27	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg25801113	chr15:45476975	SHF	0.38	6.4	0.33	5.1e-10	Uric acid levels;
LIHC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.47	-0.49	1.91e-22	Hemoglobin concentration;
LIHC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-7.55	-0.38	3.92e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.59	8.71	0.43	1.37e-16	Recombination rate (females);
LIHC	cis	rs2016586	0.773	rs5999962	chr22:36105655	T/C	cg26342177	chr22:36113512	APOL5	-0.36	-6.23	-0.32	1.38e-9	Body mass index;
LIHC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.13	0.36	6.18e-12	Axial length;
LIHC	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg14146966	chr2:61757674	XPO1	0.49	8.62	0.42	2.6e-16	Tuberculosis;
LIHC	cis	rs7187994	0.848	rs35210690	chr16:84782857	C/G	cg07647771	chr16:84786436	USP10	-0.33	-6.47	-0.33	3.47e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LIHC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.59	9.45	0.46	5.47e-19	Morning vs. evening chronotype;
LIHC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.45	6.18	0.32	1.85e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-7.49	-0.38	6.06e-13	Uric acid levels;
LIHC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.73	-0.34	7.04e-11	Gut microbiome composition (summer);
LIHC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.45	6.41	0.33	4.71e-10	Morning vs. evening chronotype;
LIHC	cis	rs3736485	0.966	rs11070854	chr15:51808365	A/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.84	-0.3	1.25e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg13385521	chr17:29058706	SUZ12P	0.57	5.78	0.3	1.67e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.676	rs573491	chr1:110026891	T/G	cg23091122	chr1:110024289	SYPL2	0.45	6.07	0.31	3.37e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.43	-6.54	-0.33	2.29e-10	Menarche (age at onset);
LIHC	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	19.29	0.72	1.27e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg12365402	chr11:9010492	NRIP3	-0.24	-6.29	-0.32	9.51e-10	Hemoglobin concentration;
LIHC	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg11645453	chr3:52864694	ITIH4	0.22	5.73	0.3	2.18e-8	Bipolar disorder;
LIHC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.62	-0.34	1.37e-10	Response to antipsychotic treatment;
LIHC	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-6.3	-0.32	9.34e-10	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.46	-9.04	-0.44	1.2e-17	Lung cancer;
LIHC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.58	-7.89	-0.39	4.05e-14	Colorectal cancer;
LIHC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	7.03	0.36	1.15e-11	Renal cell carcinoma;
LIHC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.46	8.12	0.4	8.52e-15	N-glycan levels;
LIHC	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.81	-0.35	4.27e-11	Blood pressure;
LIHC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-10.72	-0.5	2.64e-23	Obesity-related traits;
LIHC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg08132940	chr7:1081526	C7orf50	-0.79	-6.67	-0.34	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	14.05	0.6	1.02e-35	Chronic sinus infection;
LIHC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.89	-17.96	-0.7	2.75e-51	Coronary artery disease;
LIHC	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-5.96	-0.31	6.38e-9	Coronary artery disease;
LIHC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.47	9.06	0.44	1.04e-17	Extrinsic epigenetic age acceleration;
LIHC	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.56	-8.61	-0.42	2.74e-16	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-8.64	-0.42	2.14e-16	Total cholesterol levels;
LIHC	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.66	10.52	0.49	1.33e-22	Obesity-related traits;
LIHC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	11.23	0.52	3.88e-25	Colorectal cancer;
LIHC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg13319975	chr6:146136371	FBXO30	-0.35	-5.86	-0.3	1.12e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.77	-6.44	-0.33	4.06e-10	Erectile dysfunction and prostate cancer treatment;
LIHC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.97	0.44	2e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg12698662	chr3:15914712	MIR563	-0.39	-7.15	-0.36	5.15e-12	Mean platelet volume;
LIHC	trans	rs637571	0.607	rs575479	chr11:65690300	T/G	cg17712092	chr4:129076599	LARP1B	0.8	13.8	0.6	9.31e-35	Eosinophil percentage of white cells;
LIHC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.78	-0.5	1.65e-23	Total cholesterol levels;
LIHC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.58	-9.06	-0.44	1e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LIHC	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.59	8.73	0.43	1.11e-16	Recombination rate (females);
LIHC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.08	-0.51	1.35e-24	Alzheimer's disease;
LIHC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.61	10.03	0.48	6.5e-21	Height;
LIHC	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.57	5.93	0.31	7.31e-9	Hip geometry;
LIHC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg26338869	chr17:61819248	STRADA	0.53	7.18	0.36	4.33e-12	Height;
LIHC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.94	-0.31	7.2e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	6.34	0.32	7.18e-10	Renal cell carcinoma;
LIHC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.83	-8.89	-0.43	3.6e-17	Vitiligo;
LIHC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg08253296	chr5:74907592	NA	-0.5	-6.18	-0.32	1.85e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LIHC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg26939375	chr7:64535504	NA	-0.46	-7.07	-0.36	8.99e-12	Aortic root size;
LIHC	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-9.61	-0.46	1.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg10208301	chr11:6592745	DNHD1	0.46	6.64	0.34	1.23e-10	Coronary artery calcification;
LIHC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg24693881	chr1:107596107	NA	0.55	9.51	0.46	3.4e-19	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg15208524	chr1:10270712	KIF1B	0.45	6.36	0.33	6.38e-10	Hepatocellular carcinoma;
LIHC	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.51	8.31	0.41	2.32e-15	Corneal astigmatism;
LIHC	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg20240347	chr1:204465584	NA	-0.33	-6.93	-0.35	2.08e-11	Schizophrenia;
LIHC	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg02829992	chr2:10710499	NA	0.38	5.95	0.31	6.56e-9	Prostate cancer;
LIHC	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.4	5.75	0.3	1.93e-8	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg08345082	chr10:99160200	RRP12	-0.39	-6.58	-0.34	1.81e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.72	12.41	0.56	1.82e-29	Menopause (age at onset);
LIHC	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.4	-6.16	-0.32	2.04e-9	Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs11955398	0.521	rs6449489	chr5:60026236	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.4	-5.85	-0.3	1.12e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.72	-11.04	-0.51	1.9e-24	Aortic root size;
LIHC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.51	6.24	0.32	1.28e-9	Menarche (age at onset);
LIHC	cis	rs911119	0.908	rs6048949	chr20:23603199	C/T	cg16589663	chr20:23618590	CST3	0.75	7.89	0.39	4.1e-14	Chronic kidney disease;
LIHC	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg24530489	chr15:56299380	NA	0.42	5.91	0.3	8.28e-9	Keloid;
LIHC	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.15	-0.4	7.1e-15	Vitamin D levels;
LIHC	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.57	-7.45	-0.37	7.54e-13	Liver enzyme levels (gamma-glutamyl transferase);
LIHC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08822215	chr16:89438651	ANKRD11	-0.48	-7.64	-0.38	2.28e-13	Multiple myeloma (IgH translocation);
LIHC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.54	0.8	2.06e-77	Prudent dietary pattern;
LIHC	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	7.02	0.35	1.23e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg10360323	chr17:41437877	NA	0.4	5.92	0.31	7.69e-9	Menopause (age at onset);
LIHC	cis	rs2273156	0.706	rs35030792	chr14:35489123	C/T	cg16230307	chr14:35515116	FAM177A1	-0.43	-6.19	-0.32	1.68e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg08233173	chr5:172410692	ATP6V0E1	-0.55	-6.91	-0.35	2.35e-11	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg20636351	chr8:55087400	NA	-0.34	-7.0	-0.35	1.32e-11	Pelvic organ prolapse (moderate/severe);
LIHC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg00901687	chr17:48585270	MYCBPAP	0.47	6.32	0.32	8.15e-10	Visceral fat;
LIHC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.45	7.06	0.36	9.05e-12	Heart rate;
LIHC	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.89	10.97	0.51	3.51e-24	Coronary artery disease;
LIHC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg20991723	chr1:152506922	NA	0.6	10.59	0.5	7.3e-23	Hair morphology;
LIHC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.53	-7.24	-0.36	3.05e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LIHC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.29	6.86	0.35	3.3e-11	Primary biliary cholangitis;
LIHC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-7.38	-0.37	1.18e-12	Glomerular filtration rate in chronic kidney disease;
LIHC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.98	-17.78	-0.69	1.58e-50	Intelligence (multi-trait analysis);
LIHC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.33	-0.41	1.94e-15	Obesity-related traits;
LIHC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.45	6.62	0.34	1.36e-10	Gout;
LIHC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.56	6.46	0.33	3.55e-10	Alzheimer's disease;
LIHC	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	1.01	20.35	0.74	6.81e-61	Height;
LIHC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.69	11.63	0.53	1.44e-26	Hemoglobin concentration;
LIHC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.94	17.95	0.7	3.1e-51	Menopause (age at onset);
LIHC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.59	8.33	0.41	1.92e-15	Motion sickness;
LIHC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.52	9.46	0.46	5.04e-19	Systemic lupus erythematosus;
LIHC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.77	8.87	0.43	4.05e-17	Height;
LIHC	cis	rs1355223	0.902	rs1578622	chr11:34725915	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.43	-0.33	4.36e-10	Systemic lupus erythematosus and Systemic sclerosis;
LIHC	cis	rs17428076	0.874	rs17615262	chr2:172683481	A/C	cg13550731	chr2:172543902	DYNC1I2	0.37	6.0	0.31	5.01e-9	Myopia;
LIHC	cis	rs10463316	0.817	rs7709507	chr5:150783349	C/T	cg03212797	chr5:150827313	SLC36A1	-0.4	-5.94	-0.31	7.07e-9	Metabolite levels (Pyroglutamine);
LIHC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg04310649	chr10:35416472	CREM	-0.44	-5.99	-0.31	5.46e-9	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg03037974	chr15:76606532	NA	0.75	14.54	0.62	1.28e-37	Blood metabolite levels;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03038835	chr20:61810902	NA	0.59	7.7	0.38	1.44e-13	Hepatitis;
LIHC	cis	rs8141529	0.600	rs739196	chr22:29311271	G/A	cg15103426	chr22:29168792	CCDC117	0.44	6.07	0.31	3.46e-9	Lymphocyte counts;
LIHC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg24209194	chr3:40518798	ZNF619	0.47	6.68	0.34	9.85e-11	Renal cell carcinoma;
LIHC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg24634471	chr8:143751801	JRK	-0.43	-5.93	-0.31	7.5e-9	Urinary tract infection frequency;
LIHC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-7.5	-0.38	5.38e-13	Initial pursuit acceleration;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04873026	chr21:30365177	RNF160	0.43	6.18	0.32	1.85e-9	Migraine with aura;
LIHC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg26668828	chr6:292823	DUSP22	-0.6	-8.03	-0.4	1.62e-14	Menopause (age at onset);
LIHC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	0.54	6.28	0.32	1.02e-9	Alzheimer's disease;
LIHC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.39	5.88	0.3	1e-8	Lung cancer;
LIHC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	1.05	15.54	0.64	1.46e-41	Breast cancer;
LIHC	cis	rs4919087	0.748	rs701815	chr10:98975893	A/C	cg25902810	chr10:99078978	FRAT1	-0.52	-6.03	-0.31	4.36e-9	Monocyte count;
LIHC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	16.01	0.65	1.98e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.33	-5.85	-0.3	1.17e-8	Lewy body disease;
LIHC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.44	-6.79	-0.34	4.89e-11	Total body bone mineral density;
LIHC	cis	rs61021925	1	rs61021925	chr12:122863659	T/C	cg23029597	chr12:123009494	RSRC2	0.39	6.43	0.33	4.41e-10	Schizophrenia;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg25998860	chr5:126853954	PRRC1	0.41	6.4	0.33	5.23e-10	Cognitive function;
LIHC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.31	4.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	1.13	9.95	0.47	1.16e-20	Alzheimer's disease;
LIHC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg20135002	chr11:47629003	NA	-0.5	-8.54	-0.42	4.57e-16	Subjective well-being;
LIHC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.3	-5.81	-0.3	1.43e-8	Prostate cancer;
LIHC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.35	-0.59	4.98e-33	Ulcerative colitis;
LIHC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.0	0.4	1.92e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07305463	chr2:136567211	LCT	0.41	7.68	0.38	1.72e-13	Corneal structure;
LIHC	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg05425664	chr17:57184151	TRIM37	-0.46	-5.75	-0.3	1.98e-8	Vitamin D levels;
LIHC	cis	rs11229555	0.645	rs11229459	chr11:58208025	G/A	cg15696309	chr11:58395628	NA	-0.65	-7.69	-0.38	1.59e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.57	-8.9	-0.43	3.44e-17	Dental caries;
LIHC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	7.67	0.38	1.83e-13	Height;
LIHC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg08847533	chr14:75593920	NEK9	0.35	5.88	0.3	9.67e-9	Caffeine consumption;
LIHC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.79	-13.39	-0.59	3.62e-33	Platelet distribution width;
LIHC	trans	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg10756647	chr7:56101905	PSPH	1.07	13.4	0.59	3.31e-33	Diabetic kidney disease;
LIHC	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg12140854	chr5:148520817	ABLIM3	-0.45	-6.17	-0.32	1.97e-9	Breast cancer;
LIHC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.85	-15.03	-0.63	1.49e-39	Aortic root size;
LIHC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.5	5.92	0.3	8.03e-9	Morning vs. evening chronotype;
LIHC	cis	rs8192917	0.832	rs9671454	chr14:25102056	G/C	cg03875678	chr14:25103546	GZMB	0.4	6.64	0.34	1.27e-10	Vitiligo;
LIHC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.45	-7.41	-0.37	9.84e-13	Testicular germ cell tumor;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24780086	chr5:14713043	ANKH	0.41	6.09	0.31	3e-9	Pancreatic cancer;
LIHC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06909117	chr11:119205209	RNF26	-0.44	-6.14	-0.32	2.27e-9	Migraine with aura;
LIHC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.36	-0.52	1.42e-25	Electrocardiographic conduction measures;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21448741	chr8:58168803	NA	0.35	6.57	0.33	1.85e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.47	7.47	0.37	6.79e-13	Multiple sclerosis;
LIHC	cis	rs13161895	1.000	rs4700853	chr5:179473328	G/A	cg06664874	chr5:179499304	RNF130	0.61	7.56	0.38	3.66e-13	LDL cholesterol;
LIHC	trans	rs10242455	0.571	rs45527841	chr7:99310965	C/T	cg09045935	chr12:6379348	NA	0.73	6.04	0.31	4.09e-9	Blood metabolite levels;
LIHC	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg19683494	chr5:74908142	NA	0.51	6.93	0.35	2.11e-11	Age-related disease endophenotypes;
LIHC	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg09367891	chr1:107599246	PRMT6	-0.64	-10.19	-0.48	1.82e-21	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg15893493	chr8:124194847	FAM83A	0.85	8.08	0.4	1.14e-14	Urinary uromodulin levels;
LIHC	cis	rs7487075	0.619	rs4768724	chr12:46848416	C/T	cg23829395	chr12:46796953	NA	0.35	6.15	0.32	2.11e-9	Itch intensity from mosquito bite;
LIHC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg03146154	chr1:46216737	IPP	-0.38	-6.17	-0.32	1.9e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20916646	chr4:852691	GAK	0.65	7.35	0.37	1.46e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LIHC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg17724175	chr1:150552817	MCL1	0.44	8.69	0.43	1.55e-16	Melanoma;
LIHC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg07636037	chr3:49044803	WDR6	-0.59	-7.09	-0.36	7.58e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LIHC	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	6.86	0.35	3.16e-11	Chronic obstructive pulmonary disease-related biomarkers;
LIHC	cis	rs507080	0.885	rs693037	chr11:118553326	C/T	cg04173919	chr11:118528438	PHLDB1	0.35	6.4	0.33	5.16e-10	Serum metabolite levels;
LIHC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.7	10.33	0.49	5.97e-22	Corneal astigmatism;
LIHC	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	0.88	14.57	0.62	1e-37	Left atrial antero-posterior diameter;
LIHC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg04013166	chr16:89971882	TCF25	0.61	8.52	0.42	5.25e-16	Skin colour saturation;
LIHC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg14067834	chr17:29058358	SUZ12P	0.69	6.69	0.34	9.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg11161837	chr1:110010384	SYPL2	0.46	6.3	0.32	9.14e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg13175981	chr1:150552382	MCL1	0.41	5.78	0.3	1.68e-8	Tonsillectomy;
LIHC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-5.98	-0.31	5.51e-9	Alzheimer's disease (late onset);
LIHC	cis	rs2282032	0.527	rs60971518	chr14:90765745	A/G	cg04374321	chr14:90722782	PSMC1	0.49	7.07	0.36	8.56e-12	Longevity;
LIHC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.79	-13.87	-0.6	5.12e-35	Coronary artery disease;
LIHC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.38	7.6	0.38	2.96e-13	Renal cell carcinoma;
LIHC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.11	10.19	0.48	1.8e-21	Diabetic retinopathy;
LIHC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg21497246	chr14:78225524	SNW1;C14orf178	0.5	7.75	0.39	1.07e-13	Fibroblast growth factor basic levels;
LIHC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.52	5.78	0.3	1.71e-8	Menopause (age at onset);
LIHC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.47	6.39	0.33	5.48e-10	Developmental language disorder (linguistic errors);
LIHC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.46	-8.97	-0.44	2.04e-17	Extrinsic epigenetic age acceleration;
LIHC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.88	-17.24	-0.68	2.31e-48	Height;
LIHC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.69	12.17	0.55	1.52e-28	Colorectal cancer;
LIHC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg14343924	chr8:8086146	FLJ10661	0.41	5.81	0.3	1.4e-8	Mood instability;
LIHC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg26138144	chr22:38071188	LGALS1	0.76	14.04	0.6	1.15e-35	Fat distribution (HIV);
LIHC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg10978503	chr1:24200527	CNR2	-0.29	-6.96	-0.35	1.7e-11	Immature fraction of reticulocytes;
LIHC	trans	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg01134436	chr17:81009848	B3GNTL1	0.82	6.62	0.34	1.41e-10	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg00090800	chr16:27325237	IL4R	0.43	6.51	0.33	2.72e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.59	8.61	0.42	2.79e-16	Menarche (age at onset);
LIHC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.92	-0.51	5.28e-24	Personality dimensions;
LIHC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg14440974	chr22:39074834	NA	-0.36	-5.9	-0.3	8.79e-9	Menopause (age at onset);
LIHC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg03874509	chr1:107600012	PRMT6	-0.72	-11.21	-0.52	4.74e-25	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.25	19.27	0.72	1.53e-56	Type 1 diabetes nephropathy;
LIHC	cis	rs507080	0.501	rs516503	chr11:118580348	C/T	cg04173919	chr11:118528438	PHLDB1	0.31	5.79	0.3	1.6e-8	Serum metabolite levels;
LIHC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.47	8.37	0.41	1.53e-15	IgG glycosylation;
LIHC	cis	rs8067354	0.574	rs1295923	chr17:57960436	A/G	cg13753209	chr17:57696993	CLTC	0.7	10.42	0.49	3.02e-22	Hemoglobin concentration;
LIHC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.46	8.24	0.41	3.65e-15	Prudent dietary pattern;
LIHC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg19442470	chr8:27470225	CLU	-0.37	-6.38	-0.33	5.82e-10	Monocyte count;
LIHC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.2	12.94	0.57	1.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.71	9.07	0.44	9.7e-18	Gut microbiome composition (summer);
LIHC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-6.5	-0.33	2.82e-10	Type 2 diabetes;
LIHC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.8	-0.39	7.8e-14	Morning vs. evening chronotype;
LIHC	cis	rs4407350	0.901	rs5765717	chr22:44917646	G/T	cg11695653	chr22:44894386	LDOC1L	-0.37	-6.23	-0.32	1.36e-9	Intelligence (multi-trait analysis);
LIHC	trans	rs12753920	0.671	rs4437922	chr1:92581818	C/T	cg15668468	chr10:118892869	VAX1	-0.41	-6.35	-0.32	6.85e-10	Systemic lupus erythematosus;
LIHC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.75	0.43	9.63e-17	Schizophrenia;
LIHC	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.66	-9.65	-0.46	1.23e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LIHC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg14779329	chr11:130786720	SNX19	0.42	6.34	0.32	7.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg22842854	chr12:123319900	HIP1R	-0.74	-9.83	-0.47	2.99e-20	Schizophrenia;
LIHC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.63	-0.38	2.43e-13	Schizophrenia;
LIHC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-6.01	-0.31	4.79e-9	IgG glycosylation;
LIHC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.03	16.06	0.66	1.17e-43	Breast cancer;
LIHC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.38	0.33	5.71e-10	Renal cell carcinoma;
LIHC	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg14250997	chr9:106856677	SMC2	0.42	7.45	0.37	7.54e-13	High-grade serous ovarian cancer;Breast cancer;
LIHC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.47	-7.1	-0.36	7.48e-12	Cognitive function;
LIHC	trans	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.06	0.31	3.61e-9	Mean corpuscular volume;
LIHC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.54	-8.61	-0.42	2.74e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.75	-0.3	2.03e-8	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.39	7.94	0.39	2.94e-14	Renal cell carcinoma;
LIHC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-6.95	-0.35	1.85e-11	Diabetic kidney disease;
LIHC	cis	rs2758596	0.826	rs2758602	chr1:156198232	T/G	cg25208724	chr1:156163844	SLC25A44	0.74	7.77	0.39	9.34e-14	Paclitaxel disposition in epithelial ovarian cancer;
LIHC	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.87	0.43	4.04e-17	Coffee consumption (cups per day);
LIHC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.34	0.52	1.6e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.36	0.37	1.42e-12	Parkinson's disease;
LIHC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.74	10.97	0.51	3.37e-24	Corneal astigmatism;
LIHC	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.44	0.33	4.14e-10	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-7.03	-0.36	1.14e-11	Monocyte percentage of white cells;
LIHC	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.69	7.34	0.37	1.54e-12	Exhaled nitric oxide output;
LIHC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.27	6.27	0.32	1.08e-9	Primary biliary cholangitis;
LIHC	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.85	-7.58	-0.38	3.36e-13	White matter integrity;
LIHC	cis	rs11671005	0.735	rs12986387	chr19:58927215	C/T	cg25952890	chr19:58913133	NA	0.7	7.46	0.37	7.39e-13	Mean platelet volume;
LIHC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.4	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.49	7.64	0.38	2.14e-13	Triglyceride levels;
LIHC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.36	-6.83	-0.35	3.82e-11	Abdominal aortic aneurysm;
LIHC	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg00792783	chr2:198669748	PLCL1	0.47	6.9	0.35	2.58e-11	Dermatomyositis;
LIHC	cis	rs1800813	0.515	rs34148754	chr4:55057049	G/A	cg17187183	chr4:55093834	PDGFRA	0.51	6.79	0.34	4.93e-11	Corneal curvature;
LIHC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.7	-13.11	-0.58	4.12e-32	Body mass index;
LIHC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg07061783	chr6:25882402	NA	-0.47	-6.53	-0.33	2.38e-10	Blood metabolite levels;
LIHC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	13.54	0.59	9.52e-34	Lung cancer in ever smokers;
LIHC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08280861	chr8:58055591	NA	0.51	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.99	0.35	1.48e-11	Diabetic kidney disease;
LIHC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.6	-10.38	-0.49	4.16e-22	Dupuytren's disease;
LIHC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-8.39	-0.41	1.33e-15	Chronic sinus infection;
LIHC	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.61	8.4	0.41	1.18e-15	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.5	-6.33	-0.32	7.65e-10	Coronary artery calcification;
LIHC	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.57	9.44	0.45	6.19e-19	Corneal astigmatism;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27054308	chr14:20922865	APEX1;OSGEP	0.5	7.23	0.36	3.22e-12	Pancreatic cancer;
LIHC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.35	5.75	0.3	2.01e-8	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.21	-6.63	-0.34	1.27e-10	Mean corpuscular volume;
LIHC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.59	6.74	0.34	6.85e-11	Type 2 diabetes;
LIHC	trans	rs1010366	0.522	rs9648103	chr7:7245268	A/T	cg09946346	chr11:65244890	NA	-0.47	-6.17	-0.32	1.96e-9	Systolic blood pressure;
LIHC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.71	11.15	0.52	7.7e-25	Corneal astigmatism;
LIHC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	7.89	0.39	4.24e-14	Lung cancer in ever smokers;
LIHC	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg18898632	chr2:242989856	NA	-0.58	-7.84	-0.39	5.85e-14	Obesity-related traits;
LIHC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg27490568	chr2:178487706	NA	0.39	6.01	0.31	4.77e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.36	-0.41	1.64e-15	Schizophrenia;
LIHC	cis	rs1185460	0.547	rs666741	chr11:118911350	A/C	cg23280166	chr11:118938394	VPS11	-0.44	-6.06	-0.31	3.62e-9	Coronary artery disease;
LIHC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	9.96	0.47	1.12e-20	Personality dimensions;
LIHC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08219700	chr8:58056026	NA	0.52	7.11	0.36	6.68e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.8	11.83	0.54	2.74e-27	Motion sickness;
LIHC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02290350	chr8:58132656	NA	0.41	8.52	0.42	5.29e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.55	-7.78	-0.39	8.9e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	9.6	0.46	1.73e-19	Morning vs. evening chronotype;
LIHC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.51	9.54	0.46	2.81e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LIHC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.94	15.33	0.64	1.01e-40	Metabolic syndrome;
LIHC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.36	9.32	0.45	1.44e-18	Schizophrenia;
LIHC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.96	0.65	2.91e-43	Breast cancer;
LIHC	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.62	7.83	0.39	6.23e-14	Blood metabolite levels;
LIHC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.78	12.32	0.55	4.08e-29	Corneal astigmatism;
LIHC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.4	7.95e-15	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14001360	chr2:28113654	BRE;LOC100302650;RBKS	-0.38	-6.24	-0.32	1.27e-9	Pancreatic cancer;
LIHC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-10.5	-0.49	1.5e-22	Platelet count;
LIHC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.56	11.27	0.52	2.89e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08219700	chr8:58056026	NA	0.51	7.01	0.35	1.28e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg14515779	chr1:101123966	NA	-0.66	-12.35	-0.56	3.07e-29	Monocyte count;
LIHC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.58	8.16	0.4	6.58e-15	Bladder cancer;
LIHC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-12.01	-0.54	5.99e-28	Glomerular filtration rate (creatinine);
LIHC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.45	6.35	0.32	6.94e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.26	6.1	0.31	2.87e-9	Obesity-related traits;
LIHC	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg01320579	chr17:75405842	SEPT9	0.52	7.2	0.36	3.88e-12	Airflow obstruction;
LIHC	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	7.66	0.38	1.95e-13	Fuchs's corneal dystrophy;
LIHC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.81	16.94	0.68	3.68e-47	Gestational age at birth (maternal effect);
LIHC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg02640540	chr1:67518911	SLC35D1	0.44	6.83	0.35	3.83e-11	Lymphocyte percentage of white cells;
LIHC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.67	11.9	0.54	1.52e-27	Longevity;Endometriosis;
LIHC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.41	7.49	0.38	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00705661	chr14:93706609	BTBD7	0.55	6.61	0.34	1.44e-10	Lung function (FEV1);
LIHC	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	10.61	0.5	6.36e-23	Platelet distribution width;
LIHC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-7.57	-0.38	3.57e-13	Alzheimer's disease;
LIHC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.6	-0.38	2.85e-13	Body mass index;
LIHC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.37	7.41	0.37	1.02e-12	Alcohol dependence;
LIHC	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.73	-11.01	-0.51	2.42e-24	Colonoscopy-negative controls vs population controls;
LIHC	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg06795125	chr2:108905320	SULT1C2	-0.3	-6.02	-0.31	4.52e-9	Blood pressure;
LIHC	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.04	13.12	0.58	3.79e-32	Economic and political preferences (immigration/crime);
LIHC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.44	-6.6	-0.34	1.6e-10	Asthma;
LIHC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.23	-0.32	1.36e-9	Mean corpuscular volume;
LIHC	cis	rs17213078	0.505	rs3795909	chr2:106754734	A/G	cg16099169	chr2:106886729	NA	0.4	6.13	0.31	2.37e-9	Facial morphology (factor 23);
LIHC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.52	-8.42	-0.41	1.08e-15	Cognitive function;
LIHC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.65	-11.11	-0.52	1.05e-24	Crohn's disease;
LIHC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.77	-8.02	-0.4	1.65e-14	Bronchopulmonary dysplasia;
LIHC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.46	-6.86	-0.35	3.23e-11	Renal cell carcinoma;
LIHC	trans	rs2270927	0.510	rs10942765	chr5:75591324	G/A	cg13563193	chr19:33072644	PDCD5	0.97	9.09	0.44	8.14e-18	Mean corpuscular volume;
LIHC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg02782426	chr3:40428986	ENTPD3	0.32	6.06	0.31	3.6e-9	Renal cell carcinoma;
LIHC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.68	6.95	0.35	1.89e-11	Vitiligo;
LIHC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.45	6.0	0.31	5.12e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.46	7.86	0.39	5.02e-14	Uric acid levels;
LIHC	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg15192750	chr16:69999425	NA	0.44	6.56	0.33	2.04e-10	IgE levels;
LIHC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg05697976	chr12:29376483	FAR2	-0.3	-5.87	-0.3	1.02e-8	QT interval;
LIHC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	9.08	0.44	8.96e-18	Platelet count;
LIHC	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg18192155	chr21:44258298	NA	0.44	7.0	0.35	1.34e-11	Information processing speed;
LIHC	trans	rs6876348	0.520	rs9327495	chr5:128202113	A/G	cg11199428	chr13:52027379	INTS6	0.47	6.51	0.33	2.72e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs6750047	0.747	rs2116229	chr2:38270490	G/T	cg07380506	chr2:38303506	CYP1B1	0.52	6.18	0.32	1.84e-9	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg17980119	chr2:219472607	PLCD4	0.34	5.86	0.3	1.06e-8	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.5	8.13	0.4	8.02e-15	Celiac disease or Rheumatoid arthritis;
LIHC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg17724175	chr1:150552817	MCL1	0.39	7.64	0.38	2.24e-13	Melanoma;
LIHC	cis	rs62380364	0.602	rs11743441	chr5:88065637	G/T	cg22951263	chr5:87985283	NA	-0.43	-7.2	-0.36	3.82e-12	Intelligence (multi-trait analysis);
LIHC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.56	-0.46	2.47e-19	Total cholesterol levels;
LIHC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.5	5.83	0.3	1.26e-8	Bladder cancer;
LIHC	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.87	-9.66	-0.46	1.13e-19	Breast cancer;
LIHC	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.32	-6.72	-0.34	7.74e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.26	-0.37	2.57e-12	Bipolar disorder;
LIHC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	9.59	0.46	1.91e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg14515779	chr1:101123966	NA	-0.59	-11.16	-0.52	7e-25	Monocyte count;
LIHC	cis	rs9915021	0.623	rs9913875	chr17:33939655	A/C	cg20932281	chr17:33905541	PEX12	0.57	7.06	0.36	9.29e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LIHC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.46	6.22	0.32	1.45e-9	Initial pursuit acceleration;
LIHC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.25	0.32	1.24e-9	Morning vs. evening chronotype;
LIHC	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.86	16.68	0.67	4.12e-46	Testicular germ cell tumor;
LIHC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg00204748	chr12:29376779	FAR2	0.39	7.35	0.37	1.46e-12	QT interval;
LIHC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.92	9.45	0.45	5.63e-19	Mean corpuscular hemoglobin;
LIHC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.64	0.34	1.25e-10	Bipolar disorder;
LIHC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.42	-0.33	4.67e-10	Alzheimer's disease (late onset);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg02051553	chr1:10044519	NMNAT1	0.37	6.27	0.32	1.1e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg19645103	chr12:69753606	YEATS4	-0.4	-5.96	-0.31	6.15e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg13114125	chr14:105738426	BRF1	-0.8	-10.07	-0.48	4.54e-21	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg19743168	chr1:23544995	NA	0.36	6.11	0.31	2.75e-9	Height;
LIHC	trans	rs9356009	0.892	rs3792929	chr6:158264395	C/A	cg16165903	chr3:32023351	ZNF860;OSBPL10	0.59	6.17	0.32	1.98e-9	Lipoprotein (a) - cholesterol levels;
LIHC	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.36	7.0	0.35	1.38e-11	Blood protein levels;
LIHC	cis	rs922107	0.713	rs4658190	chr1:89943585	G/A	cg15422784	chr1:90023713	LRRC8B	0.45	7.07	0.36	8.74e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.75	0.39	1.03e-13	Prudent dietary pattern;
LIHC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg11764359	chr7:65958608	NA	-0.58	-6.08	-0.31	3.14e-9	Diabetic kidney disease;
LIHC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.29	17.4	0.69	4.95e-49	Diabetic kidney disease;
LIHC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg16970926	chr12:29381810	FAR2	0.32	6.8	0.34	4.75e-11	QT interval;
LIHC	cis	rs9378688	1.000	rs3800190	chr6:2229054	T/C	cg12303981	chr6:2244766	GMDS	-0.49	-6.22	-0.32	1.48e-9	Caudate nucleus volume;
LIHC	trans	rs6578985	0.714	rs11042628	chr11:2124902	G/T	cg20230732	chr3:128721448	CCDC48	0.37	6.09	0.31	3.05e-9	Femoral neck bone geometry and menarche (age at onset);
LIHC	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg03146154	chr1:46216737	IPP	-0.38	-6.21	-0.32	1.51e-9	Red blood cell count;Reticulocyte count;
LIHC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.73	13.2	0.58	1.87e-32	Iron status biomarkers;
LIHC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.95	14.37	0.61	5.73e-37	Sudden cardiac arrest;
LIHC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg25364880	chr3:44379878	C3orf23	0.47	6.64	0.34	1.25e-10	Depressive symptoms;
LIHC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg08213375	chr14:104286397	PPP1R13B	0.53	9.99	0.48	8.39e-21	Schizophrenia;
LIHC	cis	rs600626	0.529	rs11236527	chr11:75469310	A/G	cg24262691	chr11:75473276	NA	-0.45	-6.65	-0.34	1.16e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LIHC	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.44	-5.94	-0.31	6.86e-9	Coronary artery calcification;
LIHC	cis	rs7075426	1.000	rs10887609	chr10:88206702	C/T	cg07322936	chr10:88137208	NA	-0.5	-7.2	-0.36	3.84e-12	Migraine without aura;
LIHC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.65	10.96	0.51	3.63e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LIHC	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.76	9.06	0.44	1.03e-17	Migraine;
LIHC	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg25363559	chr8:143086065	NA	-0.26	-8.27	-0.41	2.96e-15	Amyotrophic lateral sclerosis;
LIHC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg09137382	chr11:130731461	NA	0.4	6.03	0.31	4.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.48	6.0	0.31	5.03e-9	Gut microbiome composition (summer);
LIHC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.51	9.1	0.44	7.55e-18	Prostate cancer (SNP x SNP interaction);
LIHC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.67	9.44	0.45	5.91e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg25039879	chr17:56429692	SUPT4H1	0.79	8.92	0.43	2.81e-17	Cognitive test performance;
LIHC	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.06	-0.4	1.3e-14	Hip circumference adjusted for BMI;
LIHC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg06207120	chr15:45996521	NA	0.31	5.83	0.3	1.27e-8	Waist circumference;Weight;
LIHC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.62	-9.02	-0.44	1.36e-17	White matter hyperintensity burden;
LIHC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-15.1	-0.63	7.59e-40	Intelligence (multi-trait analysis);
LIHC	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.54	-8.19	-0.4	5.35e-15	Superior crus of antihelix expression;
LIHC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.89	13.64	0.59	4.09e-34	Vitamin D levels;
LIHC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.28	5.85	0.3	1.16e-8	Autism spectrum disorder or schizophrenia;
LIHC	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.41	6.59	0.34	1.71e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LIHC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.44	6.88	0.35	2.8e-11	Schizophrenia;
LIHC	cis	rs36051895	0.632	rs1360063	chr9:5167649	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-11.07	-0.51	1.45e-24	Pediatric autoimmune diseases;
LIHC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg13409248	chr3:40428643	ENTPD3	-0.42	-6.57	-0.33	1.83e-10	Renal cell carcinoma;
LIHC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.71	-0.43	1.32e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs6686842	0.562	rs213770	chr1:41614825	T/C	cg08462924	chr1:41848221	NA	0.31	5.74	0.3	2.1e-8	Height;
LIHC	cis	rs9898641	1	rs9898641	chr17:57571033	T/C	cg13753209	chr17:57696993	CLTC	0.49	6.96	0.35	1.78e-11	Interleukin-1-beta levels;
LIHC	cis	rs7926971	0.631	rs7938009	chr11:12660882	C/T	cg25843174	chr11:12811716	TEAD1	0.26	5.91	0.3	8.47e-9	Height;
LIHC	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	0.72	8.37	0.41	1.5e-15	Dental caries;
LIHC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-10.69	-0.5	3.28e-23	Mean corpuscular volume;
LIHC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg00647820	chr17:40259828	DHX58	-0.28	-5.94	-0.31	7.08e-9	Fibrinogen levels;
LIHC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg08824895	chr13:115047677	UPF3A	0.49	7.12	0.36	6.48e-12	Schizophrenia;
LIHC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg13131263	chr1:9324393	H6PD	0.41	6.31	0.32	8.66e-10	Electroencephalogram traits;
LIHC	cis	rs12403795	1.000	rs12403795	chr1:150278389	A/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.94	-0.31	7.13e-9	Illicit drug use;
LIHC	cis	rs4865169	0.560	rs1277312	chr4:57902945	T/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.38	-5.88	-0.3	1e-8	Breast cancer;
LIHC	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.66	10.77	0.5	1.68e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LIHC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg00343986	chr7:65444356	GUSB	0.41	6.24	0.32	1.28e-9	Aortic root size;
LIHC	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg18964960	chr10:1102726	WDR37	0.67	6.31	0.32	8.41e-10	Glomerular filtration rate (creatinine);
LIHC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.3	-0.41	2.39e-15	Gut microbiome composition (summer);
LIHC	cis	rs1165668	0.959	rs1165675	chr12:104320991	G/T	cg21863207	chr12:104234989	NT5DC3	-0.4	-6.36	-0.33	6.43e-10	Coronary heart disease (SNP X SNP interaction);
LIHC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.06	9.35	0.45	1.21e-18	Diabetic retinopathy;
LIHC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-7.97	-0.4	2.39e-14	Gut microbiome composition (summer);
LIHC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.86	6.13	0.31	2.36e-9	Schizophrenia;
LIHC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	6.08	0.31	3.24e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.49	0.38	6.01e-13	Aortic root size;
LIHC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02290350	chr8:58132656	NA	0.49	10.61	0.5	6.4e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.39	8.19	0.4	5.35e-15	Intelligence (multi-trait analysis);
LIHC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	25.02	0.8	2.85e-79	Chronic sinus infection;
LIHC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.36	5.9	0.3	8.8e-9	Depressive symptoms (multi-trait analysis);
LIHC	trans	rs2177312	0.868	rs10024655	chr4:31938944	C/T	cg21041181	chr2:42721947	KCNG3	-0.45	-6.27	-0.32	1.11e-9	Very long-chain saturated fatty acid levels (fatty acid 22:0);
LIHC	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg08034816	chr17:79219380	SLC38A10	0.4	6.4	0.33	5.13e-10	Frontotemporal dementia;
LIHC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg15448220	chr1:150897856	SETDB1	0.4	6.28	0.32	1.03e-9	Tonsillectomy;
LIHC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.41	-8.63	-0.42	2.28e-16	Obesity-related traits;
LIHC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.94	-0.65	3.49e-43	Height;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg20919844	chr3:50388170	TUSC4;CYB561D2	0.45	6.08	0.31	3.21e-9	Lung function (FEV1/FVC);
LIHC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.57	7.62	0.38	2.6e-13	Vitiligo;
LIHC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg09417038	chr21:47716443	C21orf57	-0.5	-7.36	-0.37	1.35e-12	Testicular germ cell tumor;
LIHC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.87	0.39	4.61e-14	Prudent dietary pattern;
LIHC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.43	5.85	0.3	1.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LIHC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	7.75	0.39	1.03e-13	Height;
LIHC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.52	-8.32	-0.41	2.07e-15	Schizophrenia;
LIHC	cis	rs2997447	0.761	rs112552200	chr1:26456947	G/A	cg19633962	chr1:26362018	EXTL1	-0.67	-6.07	-0.31	3.37e-9	QRS complex (12-leadsum);
LIHC	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg16724585	chr3:197361211	NA	-0.47	-6.59	-0.34	1.67e-10	Pancreatic cancer;
LIHC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.43	7.13	0.36	6.07e-12	Bipolar disorder;
LIHC	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-8.41	-0.41	1.12e-15	Age-related hearing impairment (SNP x SNP interaction);
LIHC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg22809023	chr3:195622598	TNK2	-0.49	-6.87	-0.35	2.97e-11	Bronchopulmonary dysplasia;
LIHC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.42	-6.36	-0.33	6.61e-10	Height;
LIHC	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg06359132	chr10:99160096	RRP12	-0.41	-6.36	-0.33	6.53e-10	Granulocyte percentage of myeloid white cells;
LIHC	cis	rs7546668	1.000	rs4646061	chr1:15829916	G/A	cg11706911	chr1:15910989	AGMAT	0.44	6.89	0.35	2.76e-11	Glomerular filtration rate (creatinine);
LIHC	cis	rs1853665	0.580	rs4242282	chr6:150273346	C/G	cg16301758	chr6:150275521	NA	-0.39	-5.76	-0.3	1.89e-8	Radiation response;
LIHC	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg13699009	chr12:122356056	WDR66	-0.41	-6.82	-0.35	4.12e-11	Mean corpuscular volume;
LIHC	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	0.89	13.14	0.58	3.39e-32	Pediatric areal bone mineral density (radius);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15276500	chr20:60879007	ADRM1	0.4	6.21	0.32	1.58e-9	Metabolic traits;
LIHC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	10.07	0.48	4.62e-21	Alzheimer's disease (late onset);
LIHC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.55	7.83	0.39	6.22e-14	Response to diuretic therapy;
LIHC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.84	8.33	0.41	2e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg24849736	chr1:201084428	NA	-0.42	-8.31	-0.41	2.33e-15	Permanent tooth development;
LIHC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08280861	chr8:58055591	NA	0.5	6.33	0.32	7.67e-10	Developmental language disorder (linguistic errors);
LIHC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.79	13.27	0.58	1.03e-32	Psoriasis;
LIHC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.12	0.4	8.71e-15	Drug-induced liver injury (flucloxacillin);
LIHC	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.87	10.84	0.51	9.96e-24	Prostate cancer;
LIHC	cis	rs4589502	1.000	rs58084996	chr15:67123357	T/C	cg09911534	chr15:67153556	NA	-0.49	-6.09	-0.31	3.08e-9	Lung cancer (smoking interaction);
LIHC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.81	-0.43	6.59e-17	Intelligence (multi-trait analysis);
LIHC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg11062466	chr8:58055876	NA	0.39	5.77	0.3	1.74e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.41	-5.91	-0.3	8.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	trans	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg26939375	chr7:64535504	NA	0.43	6.96	0.35	1.72e-11	Aortic root size;
LIHC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	6.58	0.34	1.74e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LIHC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.34	-5.79	-0.3	1.61e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.77	-0.39	9.14e-14	Bipolar disorder;
LIHC	cis	rs2019216	0.835	rs402052	chr17:21908388	G/C	cg22648282	chr17:21454238	C17orf51	-0.36	-6.2	-0.32	1.63e-9	Pelvic organ prolapse;
LIHC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.44	8.11	0.4	8.89e-15	Prudent dietary pattern;
LIHC	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.8	11.24	0.52	3.72e-25	Body mass index;
LIHC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.6	-7.06	-0.36	9.28e-12	Hip circumference adjusted for BMI;Body mass index;
LIHC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17554472	chr22:41940697	POLR3H	-0.55	-6.26	-0.32	1.12e-9	Vitiligo;
LIHC	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.33	7.44	0.37	7.96e-13	Blood metabolite ratios;
LIHC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg12903224	chr12:29470962	FAR2	-0.41	-6.75	-0.34	6.37e-11	QT interval;
LIHC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg08916839	chr5:415575	AHRR	0.29	6.19	0.32	1.68e-9	Cystic fibrosis severity;
LIHC	cis	rs74544699	1.000	rs77149208	chr4:74768731	C/A	cg15398841	chr4:74847761	PF4	0.59	5.77	0.3	1.73e-8	Growth-regulated protein alpha levels;
LIHC	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg27124370	chr19:33622961	WDR88	0.47	6.98	0.35	1.5e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.74	10.74	0.5	2.21e-23	Vitamin D levels;
LIHC	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.46	5.77	0.3	1.75e-8	Bipolar disorder;
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07677032	chr17:61819896	STRADA	0.43	6.29	0.32	9.74e-10	Prudent dietary pattern;
LIHC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.67	9.35	0.45	1.2e-18	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.41	6.37	0.33	6.21e-10	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs11888559	0.573	rs7602826	chr2:203860716	G/A	cg24605529	chr2:203879461	NBEAL1	0.72	5.77	0.3	1.74e-8	Height;
LIHC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.26	0.45	2.29e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg00684032	chr4:1343700	KIAA1530	0.38	5.77	0.3	1.82e-8	Obesity-related traits;
LIHC	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.53	6.61	0.34	1.51e-10	Myopia;
LIHC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	0.88	8.67	0.42	1.78e-16	Type 2 diabetes nephropathy;
LIHC	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.55	7.43	0.37	8.82e-13	Lymphocyte counts;Fibrinogen;
LIHC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.6	8.55	0.42	4.13e-16	Motion sickness;
LIHC	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg21171335	chr12:122356390	WDR66	-0.42	-6.81	-0.35	4.37e-11	Mean corpuscular volume;
LIHC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05564831	chr3:52568323	NT5DC2	0.37	6.08	0.31	3.18e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	22.84	0.78	8.76e-71	Height;
LIHC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	8.07	0.4	1.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs4903214	0.848	rs62006811	chr14:74717699	C/A	cg11132536	chr14:74711944	VSX2	-0.24	-5.98	-0.31	5.48e-9	Inflammatory bowel disease;
LIHC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.72	-0.39	1.33e-13	Monocyte percentage of white cells;
LIHC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.69	10.45	0.49	2.36e-22	Neutrophil percentage of white cells;
LIHC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.69	-9.08	-0.44	8.83e-18	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.74	11.0	0.51	2.76e-24	Corneal astigmatism;
LIHC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08219700	chr8:58056026	NA	0.52	7.13	0.36	5.84e-12	Developmental language disorder (linguistic errors);
LIHC	cis	rs922107	0.738	rs12119009	chr1:90023756	C/G	cg15422784	chr1:90023713	LRRC8B	-0.49	-8.05	-0.4	1.4e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LIHC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.72	0.34	7.4e-11	Diabetic kidney disease;
LIHC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.68	12.24	0.55	8.16e-29	Total body bone mineral density;
LIHC	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	0.63	7.37	0.37	1.31e-12	Crohn's disease;
LIHC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.84	10.13	0.48	2.89e-21	Mean platelet volume;
LIHC	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.53	8.09	0.4	1.05e-14	Response to antidepressants and depression;
LIHC	cis	rs72653721	0.793	rs59578052	chr6:10966620	C/T	cg13562911	chr6:11044106	ELOVL2	0.48	6.83	0.35	3.96e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LIHC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.65	0.42	1.99e-16	Motion sickness;
LIHC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.07	-0.31	3.41e-9	Schizophrenia;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14710165	chr8:126104387	KIAA0196;NSMCE2	0.46	6.45	0.33	3.76e-10	Pancreatic cancer;
LIHC	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-5.91	-0.3	8.46e-9	Systolic blood pressure;
LIHC	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.67	7.28	0.37	2.33e-12	Exhaled nitric oxide output;
LIHC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg05973401	chr12:123451056	ABCB9	0.43	5.97	0.31	5.84e-9	Height;Educational attainment;Head circumference (infant);
LIHC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg19635926	chr16:89946313	TCF25	0.55	6.84	0.35	3.57e-11	Skin colour saturation;
LIHC	cis	rs420259	0.727	rs35635	chr16:23693770	G/T	cg05131483	chr16:23706242	ERN2	-0.33	-5.87	-0.3	1.06e-8	Bipolar disorder;
LIHC	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg27124370	chr19:33622961	WDR88	0.46	7.03	0.36	1.16e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LIHC	trans	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg01134436	chr17:81009848	B3GNTL1	0.8	6.95	0.35	1.89e-11	Morning vs. evening chronotype;Chronotype;
LIHC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.66	-10.5	-0.49	1.58e-22	Intelligence (multi-trait analysis);
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg26016210	chr1:156426331	NA	0.44	6.09	0.31	3.12e-9	Lung function (FEV1/FVC);
LIHC	cis	rs35160687	0.545	rs1863050	chr2:86558376	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	5.89	0.3	9.09e-9	Night sleep phenotypes;
LIHC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.49	-6.1	-0.31	2.89e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.55	0.33	2.07e-10	Lung cancer in ever smokers;
LIHC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.8	-14.58	-0.62	8.81e-38	Body mass index;
LIHC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg14067834	chr17:29058358	SUZ12P	0.71	7.05	0.36	1e-11	Body mass index;
LIHC	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.59	9.47	0.46	4.64e-19	Corneal astigmatism;
LIHC	cis	rs10924970	0.601	rs12402448	chr1:235448095	A/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.77	0.3	1.8e-8	Asthma;
LIHC	cis	rs67981189	0.593	rs2526873	chr14:71381671	C/T	cg15816911	chr14:71606274	NA	-0.43	-6.77	-0.34	5.72e-11	Schizophrenia;
LIHC	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg23221052	chr5:179740743	GFPT2	-0.45	-6.25	-0.32	1.25e-9	Height;
LIHC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.98	-11.05	-0.51	1.78e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LIHC	cis	rs7589728	0.688	rs76734941	chr2:88530454	T/C	cg07952391	chr2:88470173	THNSL2	0.68	5.74	0.3	2.13e-8	Plasma clusterin levels;
LIHC	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.38	8.98	0.44	1.79e-17	Resting heart rate;
LIHC	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	1.05	11.93	0.54	1.12e-27	IgG glycosylation;
LIHC	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-8.65	-0.42	2.03e-16	Waist circumference;Body mass index;
LIHC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.11	11.42	0.53	8.64e-26	Opioid sensitivity;
LIHC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.81	17.73	0.69	2.49e-50	Gestational age at birth (maternal effect);
LIHC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14047339	chr6:45345544	RUNX2;SUPT3H	0.41	6.16	0.32	2.09e-9	Calcium levels;
LIHC	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg06664874	chr5:179499304	RNF130	0.65	7.57	0.38	3.43e-13	LDL cholesterol;
LIHC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.32	13.36	0.59	4.92e-33	Psoriasis vulgaris;
LIHC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	10.67	0.5	3.93e-23	Lymphocyte counts;
LIHC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.65	-9.46	-0.46	5.26e-19	Testicular germ cell tumor;
LIHC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg18769074	chr3:133464867	TF	0.26	5.78	0.3	1.64e-8	Iron status biomarkers (transferrin levels);
LIHC	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg00277334	chr10:82204260	NA	-0.56	-6.81	-0.35	4.51e-11	Post bronchodilator FEV1;
LIHC	cis	rs11098699	0.821	rs13110588	chr4:124220676	A/G	cg09941581	chr4:124220074	SPATA5	-0.33	-6.54	-0.33	2.27e-10	Mosquito bite size;
LIHC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02244288	chr16:89573955	SPG7	-0.31	-5.95	-0.31	6.56e-9	Multiple myeloma (IgH translocation);
LIHC	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.55	-7.77	-0.39	9.12e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LIHC	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.86	15.56	0.64	1.14e-41	Body mass index;
LIHC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg10360323	chr17:41437877	NA	0.39	5.73	0.3	2.23e-8	Menopause (age at onset);
LIHC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.54	-8.03	-0.4	1.58e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LIHC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg26692224	chr17:62915920	LRRC37A3	-0.74	-7.13	-0.36	5.91e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LIHC	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.42	7.78	0.39	8.62e-14	Testicular germ cell tumor;
LIHC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.4	6.6	0.34	1.6e-10	Red blood cell count;
LIHC	cis	rs17776563	0.887	rs8030854	chr15:89133549	C/T	cg05013243	chr15:89149849	MIR1179	0.41	6.74	0.34	6.77e-11	Thyroid hormone levels;
LIHC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.6	9.27	0.45	2.15e-18	Tonsillectomy;
LIHC	trans	rs7299099	0.966	rs3858607	chr12:94536803	C/G	cg00822255	chr10:73579668	PSAP	0.41	6.03	0.31	4.16e-9	Alopecia areata;
LIHC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.6	8.17	0.4	6.1e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LIHC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.4	-6.28	-0.32	1.01e-9	Morning vs. evening chronotype;
LIHC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg15691649	chr6:25882328	NA	-0.39	-6.15	-0.32	2.18e-9	Height;
LIHC	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.73	12.56	0.56	5.31e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LIHC	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg08528486	chr13:113648767	MCF2L	-0.38	-6.24	-0.32	1.32e-9	Systolic blood pressure;
LIHC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.58	11.15	0.52	7.7e-25	Coronary artery disease;
LIHC	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg09597638	chr17:3907349	NA	0.47	6.31	0.32	8.73e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
LIHC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg01557791	chr16:72042693	DHODH	-0.43	-7.13	-0.36	6.16e-12	Fibrinogen levels;
LIHC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg07148914	chr20:33460835	GGT7	-0.48	-6.55	-0.33	2.08e-10	Coronary artery disease;
LIHC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.0	0.35	1.34e-11	Osteoporosis;
LIHC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg18306943	chr3:40428807	ENTPD3	-0.35	-5.98	-0.31	5.48e-9	Renal cell carcinoma;
LIHC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg18016565	chr1:150552671	MCL1	0.54	10.13	0.48	2.88e-21	Melanoma;
LIHC	trans	rs11760633	0.607	rs11765833	chr7:1830116	A/C	cg00395210	chr12:48592465	NA	0.34	6.08	0.31	3.19e-9	Coronary artery disease;
LIHC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg22532475	chr10:104410764	TRIM8	0.37	6.39	0.33	5.3e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LIHC	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.56	0.33	2.04e-10	Height;
LIHC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	1.21	14.35	0.61	7.24e-37	Eosinophil percentage of granulocytes;
LIHC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-6.05	-0.31	3.85e-9	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.43	6.05	0.31	3.73e-9	Breast cancer;
LIHC	trans	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg00571809	chr1:3397113	ARHGEF16	0.39	6.39	0.33	5.55e-10	Schizophrenia;
LIHC	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-8.63	-0.42	2.3e-16	Putamen volume;
LIHC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.21	0.45	3.36e-18	Gut microbiome composition (summer);
LIHC	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.35	-7.17	-0.36	4.56e-12	DNA methylation (variation);
LIHC	trans	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg10756647	chr7:56101905	PSPH	1.09	13.38	0.59	4.07e-33	Diabetic kidney disease;
LIHC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-0.85	-10.68	-0.5	3.62e-23	Blood pressure (smoking interaction);
LIHC	cis	rs3743266	0.507	rs62005026	chr15:60698454	A/G	cg22293140	chr15:60689852	ANXA2	-0.62	-6.15	-0.32	2.2e-9	Menarche (age at onset);
LIHC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12463550	chr7:65579703	CRCP	0.69	7.11	0.36	6.63e-12	Diabetic kidney disease;
LIHC	cis	rs12079745	0.793	rs12067351	chr1:169279758	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-6.94	-0.35	1.94e-11	QT interval;
LIHC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	6.07	0.31	3.42e-9	Schizophrenia;
LIHC	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.2	0.45	3.51e-18	Coffee consumption (cups per day);
LIHC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.68	-11.43	-0.53	7.6e-26	Menopause (age at onset);
LIHC	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.78	13.14	0.58	3.32e-32	Coronary artery disease;
LIHC	trans	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg16088116	chr21:44841560	SIK1	-0.42	-6.49	-0.33	2.93e-10	Coronary artery disease;
LIHC	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg12373951	chr3:133503437	NA	0.46	6.24	0.32	1.33e-9	Alcohol consumption (transferrin glycosylation);
LIHC	cis	rs797680	0.822	rs1057257	chr1:93621483	A/G	cg15093775	chr1:93646470	TMED5;CCDC18	-0.34	-6.01	-0.31	4.67e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
LIHC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	9.06	0.44	9.93e-18	IgG glycosylation;
LIHC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.11	0.31	2.77e-9	Menopause (age at onset);
LIHC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.43	-10.16	-0.48	2.28e-21	Type 2 diabetes;
LIHC	cis	rs1865721	0.917	rs62089506	chr18:73178913	A/G	cg26385618	chr18:73139727	C18orf62	-0.3	-7.67	-0.38	1.77e-13	Intelligence;
LIHC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.41	-6.78	-0.34	5.15e-11	Alcohol dependence;
LIHC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg20140201	chr2:241835670	C2orf54	-0.5	-7.64	-0.38	2.23e-13	Urinary metabolites;
LIHC	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.48	7.73	0.39	1.23e-13	Corneal astigmatism;
LIHC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	7.78	0.39	8.43e-14	Prudent dietary pattern;
LIHC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20887711	chr4:1340912	KIAA1530	-0.52	-8.11	-0.4	8.87e-15	Obesity-related traits;
LIHC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.39	6.16	0.32	2.05e-9	Multiple sclerosis;
LIHC	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.43	-0.49	2.6e-22	Eye color traits;
LIHC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.04	-17.5	-0.69	2.1e-49	Dilated cardiomyopathy;
LIHC	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg05527609	chr1:210001259	C1orf107	-0.56	-7.61	-0.38	2.74e-13	Red blood cell count;
LIHC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.91	0.43	3.12e-17	Schizophrenia;
LIHC	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg22951263	chr5:87985283	NA	-0.39	-6.81	-0.35	4.53e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg13271783	chr10:134563150	INPP5A	-0.61	-7.26	-0.37	2.56e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-6.96	-0.35	1.71e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.84	0.39	5.75e-14	Coronary artery disease;
LIHC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.55	0.5	1.02e-22	Bladder cancer;
LIHC	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg12062639	chr20:23401060	NAPB	0.83	9.73	0.47	6.59e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.24	0.72	1.99e-56	Coffee consumption;Coffee consumption (cups per day);
LIHC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.45	7.52	0.38	5.01e-13	Mean corpuscular volume;
LIHC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg21466736	chr12:48725269	NA	-0.71	-11.02	-0.51	2.22e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.42	0.45	6.79e-19	Platelet count;
LIHC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.61	-7.01	-0.35	1.27e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LIHC	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-0.88	-21.14	-0.75	5.01e-64	Multiple myeloma;
LIHC	trans	rs983392	0.709	rs56273223	chr11:59984676	A/C	cg17275991	chr19:58003312	ZNF419	0.44	6.25	0.32	1.2e-9	Alzheimer's disease (late onset);
LIHC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg15448220	chr1:150897856	SETDB1	0.41	6.47	0.33	3.3e-10	Tonsillectomy;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01911186	chr12:12765398	CREBL2	0.52	7.58	0.38	3.35e-13	Pancreatic cancer;
LIHC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.46	6.6	0.34	1.58e-10	Hemoglobin concentration;Hematocrit;
LIHC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.57	11.34	0.52	1.58e-25	Intelligence (multi-trait analysis);
LIHC	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg19743168	chr1:23544995	NA	0.39	7.19	0.36	4.03e-12	Height;
LIHC	cis	rs17152411	0.652	rs10794190	chr10:126603231	G/A	cg07906193	chr10:126599966	NA	-0.3	-5.92	-0.3	7.9e-9	Height;
LIHC	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	9.53	0.46	2.99e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LIHC	cis	rs2334880	0.638	rs35166226	chr16:71443219	T/C	cg06353428	chr16:71660113	MARVELD3	-0.93	-8.04	-0.4	1.44e-14	Malaria;
LIHC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.56	0.42	3.8e-16	Birth weight;
LIHC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.74	14.52	0.62	1.51e-37	Mortality in heart failure;
LIHC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.63	0.46	1.44e-19	Mean platelet volume;
LIHC	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.29	6.17	0.32	1.88e-9	Pulmonary function;
LIHC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.3	-0.37	1.97e-12	Bipolar disorder and schizophrenia;
LIHC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.67	9.37	0.45	1.04e-18	Menarche (age at onset);
LIHC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20135002	chr11:47629003	NA	0.51	8.67	0.42	1.8e-16	Subjective well-being;
LIHC	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.27	0.32	1.11e-9	Mean corpuscular volume;
LIHC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.67	10.11	0.48	3.43e-21	Mosquito bite size;
LIHC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.5	6.0	0.31	4.97e-9	Nonalcoholic fatty liver disease;
LIHC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.63	-7.8	-0.39	7.41e-14	Intelligence (multi-trait analysis);
LIHC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21467203	chr3:49911342	NA	-0.53	-9.74	-0.47	6.1e-20	Body mass index;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg16583193	chr19:3652060	PIP5K1C	0.43	6.34	0.32	7.1e-10	Longevity;
LIHC	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.55	-6.26	-0.32	1.19e-9	Ulcerative colitis;
LIHC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg26149184	chr10:133730230	NA	0.47	7.39	0.37	1.11e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LIHC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.21	-0.32	1.53e-9	Bipolar disorder and schizophrenia;
LIHC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.33	6.23	0.32	1.34e-9	Body mass index;
LIHC	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.44	5.97	0.31	6.07e-9	Red blood cell count;Hematocrit;Red blood cell traits;
LIHC	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg16583315	chr14:65563665	MAX	-0.39	-7.95	-0.39	2.73e-14	Obesity-related traits;
LIHC	cis	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05901451	chr6:126070800	HEY2	0.45	8.03	0.4	1.57e-14	Endometrial cancer;
LIHC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.65	9.87	0.47	2.25e-20	Height;
LIHC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg20607798	chr8:58055168	NA	0.49	6.22	0.32	1.48e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	17.31	0.68	1.22e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LIHC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	24.95	0.8	5.46e-79	Prudent dietary pattern;
LIHC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	8.0	0.4	1.96e-14	Height;
LIHC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.76	0.47	5.3e-20	Platelet count;
LIHC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg24209194	chr3:40518798	ZNF619	0.63	9.53	0.46	3.05e-19	Renal cell carcinoma;
LIHC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg18357645	chr12:58087776	OS9	-0.42	-6.03	-0.31	4.37e-9	Multiple sclerosis;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg24218925	chr19:2578938	GNG7	0.43	6.47	0.33	3.33e-10	Lung function (FEV1/FVC);
LIHC	cis	rs4908768	0.501	rs12030885	chr1:8781396	A/G	cg20416874	chr1:8611966	RERE	-0.6	-11.02	-0.51	2.33e-24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.56	7.69	0.38	1.5700000000000001e-13	Blood metabolite levels;
LIHC	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	6.11	0.31	2.74e-9	Blood protein levels;
LIHC	cis	rs16944613	0.541	rs7183319	chr15:91095032	A/T	cg26821196	chr15:91095069	CRTC3	0.47	8.15	0.4	6.75e-15	Colorectal cancer;
LIHC	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg01652190	chr22:50026171	C22orf34	-0.34	-7.59	-0.38	3.17e-13	Monocyte count;Monocyte percentage of white cells;
LIHC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.64	8.29	0.41	2.58e-15	Motion sickness;
LIHC	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-12.09	-0.55	2.88e-28	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LIHC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.12	-0.31	2.57e-9	Bladder cancer;
LIHC	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg09795085	chr6:101329169	ASCC3	0.51	7.1	0.36	7.04e-12	Neuroticism;
LIHC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.62	-9.49	-0.46	4.18e-19	Aortic root size;
LIHC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.68	10.81	0.5	1.26e-23	Prostate cancer;
LIHC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.61	5.87	0.3	1.02e-8	Vitiligo;
LIHC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg11212589	chr17:38028394	ZPBP2	-0.3	-5.93	-0.31	7.62e-9	Self-reported allergy;
LIHC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	1.14	14.58	0.62	8.9e-38	Body mass index;
LIHC	cis	rs4908768	0.906	rs56163601	chr1:8751897	G/A	cg20416874	chr1:8611966	RERE	0.53	8.02	0.4	1.71e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
LIHC	cis	rs3790844	0.667	rs3790843	chr1:200010824	A/G	cg07208853	chr1:200005219	NR5A2	-0.39	-8.63	-0.42	2.34e-16	Pancreatic cancer;
LIHC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.33	4.32e-10	Lung cancer in ever smokers;
LIHC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.43	5.94	0.31	6.83e-9	Mean platelet volume;Platelet distribution width;
LIHC	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.6	-10.65	-0.5	4.57e-23	Inflammatory bowel disease;
LIHC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.8	12.91	0.57	2.53e-31	Colorectal cancer;
LIHC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-8.27	-0.41	3.01e-15	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-16.49	-0.67	2.23e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.86	-0.43	4.3e-17	Breast cancer;
LIHC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	0.83	7.02	0.36	1.18e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg09182678	chr22:50328711	NA	-0.44	-6.31	-0.32	8.51e-10	Schizophrenia;
LIHC	trans	rs8117834	0.574	rs7265353	chr20:8085660	G/C	cg00593689	chr4:53575888	NA	0.38	6.44	0.33	3.98e-10	Chronic kidney disease;
LIHC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.78	-13.64	-0.59	4.13e-34	Aortic root size;
LIHC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg07424592	chr7:64974309	NA	0.8	9.32	0.45	1.45e-18	Diabetic kidney disease;
LIHC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.69	-9.41	-0.45	7.36e-19	Corneal structure;
LIHC	cis	rs4934494	0.727	rs12783582	chr10:91494967	T/C	cg19698084	chr10:91461284	KIF20B	-0.48	-6.4	-0.33	5.06e-10	Red blood cell count;
LIHC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	8.05	0.4	1.41e-14	Coronary artery disease;
LIHC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.68	0.34	9.42e-11	Height;
LIHC	trans	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.49	6.11	0.31	2.65e-9	Ulcerative colitis;
LIHC	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg20607798	chr8:58055168	NA	0.59	6.85	0.35	3.44e-11	Developmental language disorder (linguistic errors);
LIHC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.69	10.09	0.48	3.97e-21	Coronary artery disease;
LIHC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-16.49	-0.67	2.38e-45	Coronary artery disease;
LIHC	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg16275483	chr1:110013120	SYPL2	-0.47	-5.77	-0.3	1.78e-8	Intelligence (multi-trait analysis);
LIHC	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg03934865	chr2:198174659	NA	0.46	6.57	0.33	1.83e-10	Dermatomyositis;
LIHC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02985541	chr2:219472218	PLCD4	0.44	8.29	0.41	2.53e-15	Mean corpuscular hemoglobin concentration;
LIHC	cis	rs1816752	0.875	rs59686377	chr13:25050007	C/T	cg22771759	chr13:24902376	NA	0.31	6.52	0.33	2.49e-10	Obesity-related traits;
LIHC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.56	7.88	0.39	4.3e-14	Total cholesterol levels;
LIHC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.44	-6.95	-0.35	1.9e-11	Alcohol dependence;
LIHC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.76	-12.43	-0.56	1.63e-29	Aortic root size;
LIHC	cis	rs3790844	0.876	rs61486545	chr1:200008337	G/A	cg07208853	chr1:200005219	NR5A2	0.4	8.61	0.42	2.65e-16	Pancreatic cancer;
LIHC	cis	rs4908760	0.516	rs11121232	chr1:8850709	C/A	cg20416874	chr1:8611966	RERE	-0.57	-10.25	-0.48	1.15e-21	Vitiligo;
LIHC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-0.8	-10.1	-0.48	3.78e-21	Blood pressure (smoking interaction);
LIHC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	12.02	0.54	5.36e-28	Cognitive test performance;
LIHC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.47	-0.33	3.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.77	11.79	0.54	3.73e-27	Corneal astigmatism;
LIHC	cis	rs8014671	0.531	rs12880777	chr14:70874695	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.45	-7.05	-0.36	9.8e-12	Prostate cancer;
LIHC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg02079420	chr8:82753780	SNX16	0.34	6.18	0.32	1.86e-9	Diastolic blood pressure;
LIHC	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.63	8.1	0.4	9.82e-15	Blood metabolite levels;
LIHC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg18357526	chr6:26021779	HIST1H4A	0.43	6.45	0.33	3.82e-10	Height;
LIHC	cis	rs9309473	0.528	rs11898362	chr2:73565293	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.32	-0.37	1.82e-12	Metabolite levels;
LIHC	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg23043544	chr7:2124092	MAD1L1	-0.42	-6.35	-0.32	6.92e-10	Bipolar disorder;
LIHC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.52	-6.27	-0.32	1.11e-9	Corneal curvature;
LIHC	trans	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg08566640	chr11:64091735	NA	-0.71	-6.55	-0.33	2.15e-10	Androgen levels;
LIHC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.08	-0.31	3.23e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LIHC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.9	13.89	0.6	4.4e-35	Alzheimer's disease;
LIHC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.46	6.71	0.34	8.01e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14154082	chr13:112174009	NA	0.29	6.19	0.32	1.76e-9	Menarche (age at onset);
LIHC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.84	-15.86	-0.65	7.63e-43	Height;
LIHC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.72	-13.09	-0.58	4.92e-32	Prostate cancer;
LIHC	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg16394018	chr11:14927549	NA	0.39	5.74	0.3	2.09e-8	Vitamin D levels;
LIHC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.79	0.3	1.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LIHC	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.23	6.39	0.33	5.54e-10	Type 2 diabetes;
LIHC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	14.9	0.63	5.03e-39	Prudent dietary pattern;
LIHC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.28	21.06	0.75	1.03e-63	Corneal structure;
LIHC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.76	-12.01	-0.54	5.77e-28	Corneal astigmatism;
LIHC	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.46	6.86	0.35	3.19e-11	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9902453	0.505	rs11080107	chr17:27938424	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.27	-0.52	2.98e-25	Coffee consumption (cups per day);
LIHC	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.83	0.35	3.97e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LIHC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.18	-0.32	1.83e-9	Obesity-related traits;
LIHC	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.3	-6.66	-0.34	1.08e-10	DNA methylation (variation);
LIHC	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.63	10.85	0.51	9.14e-24	Breast cancer;
LIHC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.88	-0.3	9.76e-9	Mean corpuscular volume;
LIHC	cis	rs858239	0.509	rs6962213	chr7:23188109	G/A	cg23682824	chr7:23144976	KLHL7	0.4	6.02	0.31	4.47e-9	Cerebrospinal fluid biomarker levels;
LIHC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg13607699	chr17:42295918	UBTF	0.47	7.55	0.38	3.96e-13	Total body bone mineral density;
LIHC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg05590025	chr7:65112418	INTS4L2	-0.64	-7.02	-0.35	1.22e-11	Diabetic kidney disease;
LIHC	cis	rs939574	0.512	rs6730612	chr2:220146196	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.59	7.08	0.36	8.04e-12	Platelet distribution width;
LIHC	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	6.83	0.35	3.79e-11	Liver enzyme levels (alkaline phosphatase);
LIHC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.5	6.19	0.32	1.76e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.42	6.11	0.31	2.7e-9	Alzheimer's disease in APOE e4- carriers;
LIHC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg19682013	chr15:45996608	NA	0.38	6.55	0.33	2.17e-10	Waist circumference;Weight;
LIHC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.43	-5.86	-0.3	1.09e-8	Total body bone mineral density;
LIHC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.98	-0.57	1.29e-31	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.45	-6.11	-0.31	2.69e-9	Total body bone mineral density;
LIHC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.23	-0.45	3e-18	Chronic sinus infection;
LIHC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg23782820	chr8:58130467	NA	0.32	5.76	0.3	1.86e-8	Developmental language disorder (linguistic errors);
LIHC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.47	7.05	0.36	1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LIHC	cis	rs10861342	1.000	rs11112373	chr12:105503708	G/A	cg23923672	chr12:105501055	KIAA1033	0.65	7.64	0.38	2.27e-13	IgG glycosylation;
LIHC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.59	8.19	0.4	5.16e-15	Menopause (age at onset);
LIHC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.48	0.33	3.26e-10	Drug-induced liver injury (flucloxacillin);
LIHC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06045225	chr5:65892993	MAST4	0.39	6.18	0.32	1.86e-9	Metabolic traits;
LIHC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.56	9.37	0.45	1.04e-18	Coronary artery disease;
LIHC	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg26031613	chr14:104095156	KLC1	0.4	5.81	0.3	1.43e-8	Coronary artery disease;
LIHC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.67	8.62	0.42	2.47e-16	Initial pursuit acceleration;
LIHC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.55	5.9	0.3	8.9e-9	LDL cholesterol;Cholesterol, total;
LIHC	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg17859187	chr1:168147929	TIPRL	0.46	5.74	0.3	2.12e-8	Schizophrenia;
LIHC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.42	-6.44	-0.33	4.09e-10	HDL cholesterol;
LIHC	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg23555395	chr2:238036564	NA	-0.31	-5.84	-0.3	1.19e-8	Systemic lupus erythematosus;
LIHC	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.53	-9.42	-0.45	7.03e-19	Coronary artery disease;
LIHC	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg08911820	chr1:110026001	ATXN7L2	-0.63	-7.72	-0.39	1.25e-13	Intelligence (multi-trait analysis);
LIHC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.68	-8.44	-0.42	8.94e-16	Intelligence (multi-trait analysis);
LIHC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.46	8.28	0.41	2.74e-15	Tuberculosis;
LIHC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg27523141	chr10:43048294	ZNF37B	0.39	6.83	0.35	4e-11	Extrinsic epigenetic age acceleration;
LIHC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.4	6.06	0.31	3.68e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.59	10.59	0.5	7.44e-23	Inflammatory bowel disease;
LIHC	cis	rs888194	0.628	rs11609896	chr12:110038454	G/A	cg05360138	chr12:110035743	NA	0.4	5.76	0.3	1.87e-8	Neuroticism;
LIHC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.49	6.75	0.34	6.54e-11	Developmental language disorder (linguistic errors);
LIHC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.74	-10.48	-0.49	1.83e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg23242142	chr5:6633531	NSUN2;SRD5A1	0.47	6.12	0.31	2.62e-9	Lung function (FEV1/FVC);
LIHC	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.46	5.96	0.31	6.13e-9	Pulmonary function decline;
LIHC	cis	rs16958440	0.867	rs79231363	chr18:44665087	T/C	cg17192377	chr18:44677553	HDHD2	0.62	6.75	0.34	6.32e-11	Sitting height ratio;
LIHC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg13692869	chr1:169336982	NME7;BLZF1	0.42	6.56	0.33	2.02e-10	Cognitive function;
LIHC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.26	-6.49	-0.33	2.99e-10	Cutaneous nevi;
LIHC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21467203	chr3:49911342	NA	0.52	9.35	0.45	1.18e-18	Body mass index;
LIHC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.98	15.57	0.64	1.09e-41	Nonalcoholic fatty liver disease;
LIHC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.15	-0.44	5.12e-18	Morning vs. evening chronotype;
LIHC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	7.76	0.39	1e-13	Schizophrenia;
LIHC	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.78	11.48	0.53	4.98e-26	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.36	0.56	2.86e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LIHC	cis	rs2573652	1.000	rs2573652	chr15:100514614	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.78	-14.41	-0.61	4.23e-37	Height;
LIHC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg14779329	chr11:130786720	SNX19	0.38	5.87	0.3	1.05e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
LIHC	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.6	8.97	0.44	1.93e-17	Recombination rate (females);
LIHC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06050784	chr16:88016603	BANP	0.35	6.34	0.32	7.07e-10	Menopause (age at onset);
LIHC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.66	10.41	0.49	3.14e-22	Longevity;
LIHC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-7.52	-0.38	4.95e-13	Vitiligo;
LIHC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.86	0.39	5.2e-14	Prudent dietary pattern;
LIHC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.68	-11.7	-0.53	7.92e-27	Crohn's disease;
LIHC	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	0.54	7.08	0.36	8.26e-12	Pulse pressure;
LIHC	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.45	7.24	0.36	2.91e-12	Adiposity;
LIHC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg25802399	chr20:61847276	YTHDF1	-0.38	-6.06	-0.31	3.51e-9	Pancreatic cancer;
LIHC	cis	rs600806	0.683	rs10857789	chr1:110012293	C/T	cg23091122	chr1:110024289	SYPL2	-0.5	-6.78	-0.34	5.27e-11	Intelligence (multi-trait analysis);
LIHC	cis	rs2273156	1.000	rs17102967	chr14:35480388	A/G	cg16230307	chr14:35515116	FAM177A1	-0.42	-6.1	-0.31	2.9e-9	Immunoglobulin light chain (AL) amyloidosis;
LIHC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg20607798	chr8:58055168	NA	0.49	6.16	0.32	2.01e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.63	-8.34	-0.41	1.81e-15	Diastolic blood pressure;
LIHC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg26138144	chr22:38071188	LGALS1	0.41	7.58	0.38	3.31e-13	Fat distribution (HIV);
LIHC	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-8.0	-0.4	1.93e-14	Alzheimer's disease;
LIHC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.82	8.01	0.4	1.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.67	13.22	0.58	1.57e-32	High light scatter reticulocyte count;
LIHC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.72	0.43	1.21e-16	Platelet count;
LIHC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg19336497	chr11:14380999	RRAS2	0.39	6.64	0.34	1.23e-10	Mitochondrial DNA levels;
LIHC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.96	17.21	0.68	2.88e-48	Breast cancer;
LIHC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.73	12.14	0.55	1.84e-28	Lobe attachment (rater-scored or self-reported);
LIHC	cis	rs9322817	0.691	rs2400072	chr6:105344116	C/T	cg02098413	chr6:105308735	HACE1	0.42	7.94	0.39	2.96e-14	Thyroid stimulating hormone;
LIHC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.44	-7.7	-0.38	1.44e-13	Aortic root size;
LIHC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.54	-0.33	2.23e-10	Hepatocellular carcinoma;
LIHC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.39	6.25	0.32	1.23e-9	Glomerular filtration rate (creatinine);
LIHC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.53	10.6	0.5	7.14e-23	Prudent dietary pattern;
LIHC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.59	6.42	0.33	4.45e-10	Gut microbiome composition (summer);
LIHC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg25344623	chr2:136566232	LCT	-0.34	-6.57	-0.33	1.88e-10	Mosquito bite size;
LIHC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.53	-8.73	-0.43	1.11e-16	Bipolar disorder;
LIHC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.43	1.45e-16	Total cholesterol levels;
LIHC	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.2	-6.25	-0.32	1.25e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LIHC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.81	9.67	0.46	1.06e-19	Cognitive function;
LIHC	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg02415029	chr1:110025642	ATXN7L2	-0.47	-5.94	-0.31	6.92e-9	Intelligence (multi-trait analysis);
LIHC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.64	0.42	2.21e-16	Ulcerative colitis;Inflammatory bowel disease;
LIHC	cis	rs2607426	0.681	rs2607413	chr19:41268214	C/T	cg20631044	chr19:41255890	C19orf54;SNRPA	-0.54	-6.39	-0.33	5.5e-10	Blood protein levels;
LIHC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.73	-0.39	1.2e-13	Monocyte percentage of white cells;
LIHC	cis	rs7503168	0.558	rs11870472	chr17:33872649	G/A	cg20932281	chr17:33905541	PEX12	0.59	6.94	0.35	2.01e-11	Plateletcrit;
LIHC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.35	6.74	0.34	6.8e-11	Tonsillectomy;
LIHC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.48	-7.97	-0.4	2.43e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LIHC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.81	-0.3	1.43e-8	Axial length;
LIHC	cis	rs611744	0.870	rs429315	chr8:109094068	A/G	cg21045802	chr8:109455806	TTC35	-0.51	-9.05	-0.44	1.13e-17	Dupuytren's disease;
LIHC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.52	0.33	2.5e-10	Alzheimer's disease;
LIHC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02290350	chr8:58132656	NA	0.5	10.64	0.5	5.15e-23	Developmental language disorder (linguistic errors);
LIHC	cis	rs10508774	1.000	rs12245906	chr10:33061079	C/A	cg01819863	chr10:32635814	EPC1	0.63	5.78	0.3	1.68e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LIHC	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.41	7.41	0.37	9.96e-13	Testicular germ cell tumor;
LIHC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.82	0.54	3e-27	Cognitive ability;
LIHC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.57	8.24	0.41	3.84e-15	Mean corpuscular volume;
LIHC	trans	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg10756647	chr7:56101905	PSPH	0.44	6.44	0.33	4.09e-10	Aortic root size;
LIHC	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.04	-0.36	1.05e-11	Response to bleomycin (chromatid breaks);
LIHC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.33	-5.92	-0.31	7.68e-9	Anterior chamber depth;
LIHC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.45	-7.7	-0.38	1.49e-13	Electroencephalogram traits;
LIHC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.37	7.39	0.37	1.11e-12	Alcohol dependence;
LIHC	trans	rs803923	0.585	rs803917	chr9:119467660	A/G	cg10829264	chr1:156024440	ROBLD3;UBQLN4	0.46	6.12	0.31	2.57e-9	Lung function (FEV1/FVC);
LIHC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.85	-0.35	3.5e-11	Bipolar disorder and schizophrenia;
LIHC	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg03585969	chr10:35415529	CREM	0.76	10.96	0.51	3.65e-24	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.53	-8.44	-0.42	9.38e-16	Multiple sclerosis;
LIHC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.87	16.72	0.67	2.77e-46	Blood protein levels;
LIHC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg25039879	chr17:56429692	SUPT4H1	0.81	9.04	0.44	1.16e-17	Cognitive test performance;
LIHC	cis	rs244293	0.701	rs4793784	chr17:53038430	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.17	-0.32	1.92e-9	Menarche (age at onset);
LIHC	cis	rs4934494	0.635	rs12572869	chr10:91413368	C/T	cg19698084	chr10:91461284	KIF20B	-0.49	-6.49	-0.33	2.97e-10	Red blood cell count;
LIHC	cis	rs57502260	0.915	rs7106320	chr11:68210118	C/T	cg20283391	chr11:68216788	NA	-0.47	-5.8	-0.3	1.55e-8	Total body bone mineral density (age 45-60);
LIHC	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-7.26	-0.37	2.64e-12	Mortality in heart failure;
LIHC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.22	0.36	3.35e-12	Bipolar disorder;
LIHC	cis	rs9378688	0.654	rs62392609	chr6:2258345	A/C	cg12303981	chr6:2244766	GMDS	-0.45	-6.07	-0.31	3.41e-9	Caudate nucleus volume;
LIHC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-10.44	-0.49	2.58e-22	Platelet count;
LIHC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.4	8.25	0.41	3.44e-15	Renal cell carcinoma;
LIHC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-0.91	-9.52	-0.46	3.1400000000000002e-19	White matter hyperintensity burden;
LIHC	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	6.91	0.35	2.35e-11	Exhaled nitric oxide output;
LIHC	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.48	-7.68	-0.38	1.71e-13	Pediatric non-alcoholic fatty liver disease activity score;
LIHC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.6	8.17	0.4	6.14e-15	Mean corpuscular hemoglobin;
LIHC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.69	0.62	3.12e-38	Chronic sinus infection;
LIHC	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.51	8.91	0.43	3.04e-17	Coronary artery disease;
LIHC	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.81	12.88	0.57	3.23e-31	Colorectal cancer;
LIHC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-13.71	-0.6	2.16e-34	Body mass index;
LIHC	cis	rs2274273	0.840	rs7144737	chr14:55822946	C/T	cg01864836	chr14:55583639	NA	-0.35	-6.14	-0.32	2.24e-9	Protein biomarker;
LIHC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.62	8.39	0.41	1.29e-15	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.47	7.65	0.38	2.04e-13	Multiple sclerosis;
LIHC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.5	7.95	0.4	2.68e-14	Testicular germ cell tumor;
LIHC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg11861562	chr11:117069780	TAGLN	-0.47	-7.79	-0.39	7.89e-14	Blood protein levels;
LIHC	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.35	7.23	0.36	3.08e-12	Schizophrenia;
LIHC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-11.18	-0.52	6.2e-25	Monocyte percentage of white cells;
LIHC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.39	0.41	1.32e-15	Response to antipsychotic treatment;
LIHC	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg03146154	chr1:46216737	IPP	-0.39	-5.93	-0.31	7.45e-9	High light scatter reticulocyte count;
LIHC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg17279839	chr7:150038598	RARRES2	0.39	7.92	0.39	3.39e-14	Blood protein levels;Circulating chemerin levels;
LIHC	cis	rs4950322	0.512	rs2353974	chr1:146856256	A/G	cg25205988	chr1:146714368	CHD1L	0.42	6.03	0.31	4.25e-9	Protein quantitative trait loci;
LIHC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.53	-8.34	-0.41	1.79e-15	Uric acid clearance;
LIHC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.73	11.09	0.51	1.23e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LIHC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.1	9.73	0.47	6.68e-20	Diabetic retinopathy;
LIHC	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg00977110	chr5:151150581	G3BP1	0.54	6.9	0.35	2.53e-11	Preschool internalizing problems;
LIHC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	1.01	16.48	0.67	2.56e-45	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LIHC	trans	rs729050	0.851	rs2402317	chr14:94077336	A/G	cg00587042	chr7:42927968	NA	-0.44	-6.04	-0.31	4.1e-9	Body mass index;
LIHC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.34	-0.45	1.3e-18	Intelligence (multi-trait analysis);
LIHC	cis	rs243505	0.762	rs933436	chr7:148487329	A/C	cg09806900	chr7:148480153	CUL1	-0.45	-6.86	-0.35	3.27e-11	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.58	9.48	0.46	4.35e-19	White matter hyperintensity burden;
LIHC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.77	-11.1	-0.51	1.18e-24	Dental caries;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05970768	chr5:171682616	UBTD2	0.44	6.21	0.32	1.56e-9	Hepatitis;
LIHC	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	9.32	0.45	1.47e-18	Spherical equivalent (joint analysis main effects and education interaction);
LIHC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.72	12.48	0.56	9.96e-30	Menopause (age at onset);
LIHC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.37	9.6	0.46	1.71e-19	Asthma (sex interaction);
LIHC	cis	rs3820500	0.543	rs1290552	chr1:118054772	G/T	cg20383390	chr1:117909022	MAN1A2	0.45	5.89	0.3	9.21e-9	Pneumonia;
LIHC	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.04	-0.31	4.12e-9	Extrinsic epigenetic age acceleration;
LIHC	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15664640	chr17:80829946	TBCD	0.66	10.61	0.5	6.13e-23	Breast cancer;
LIHC	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.73	10.38	0.49	4.11e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LIHC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.37	5.81	0.3	1.4e-8	Menopause (age at onset);
LIHC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14067834	chr17:29058358	SUZ12P	0.6	6.36	0.33	6.6e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LIHC	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	ch.8.33884649F	chr8:33765107	NA	0.41	6.76	0.34	6.1e-11	Body mass index;
LIHC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-8.8	-0.43	7.12e-17	Vitiligo;
LIHC	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.66	10.99	0.51	2.84e-24	Prostate cancer;
LIHC	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.98	-17.43	-0.69	4.03e-49	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LIHC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.64	8.47	0.42	7.6e-16	Blood metabolite levels;
LIHC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.55	0.33	2.17e-10	Bipolar disorder (body mass index interaction);
LIHC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg02290350	chr8:58132656	NA	0.44	8.72	0.43	1.21e-16	Developmental language disorder (linguistic errors);
LIHC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg22777020	chr22:31556080	RNF185	0.55	6.35	0.32	6.77e-10	Colorectal cancer;
LIHC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.66	13.74	0.6	1.57e-34	Intelligence (multi-trait analysis);
LIHC	cis	rs6750047	0.585	rs4670235	chr2:38272528	C/T	cg07380506	chr2:38303506	CYP1B1	0.58	7.44	0.37	8.17e-13	Cutaneous malignant melanoma;Melanoma;
LIHC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12379764	chr21:47803548	PCNT	-0.55	-8.15	-0.4	7.02e-15	Testicular germ cell tumor;
LIHC	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg25161029	chr11:122845972	NA	0.33	5.81	0.3	1.41e-8	Menarche (age at onset);
LIHC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-0.81	-6.84	-0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LIHC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg21466736	chr12:48725269	NA	-0.71	-10.87	-0.51	7.92e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LIHC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg18270830	chr10:32634957	EPC1	0.54	6.61	0.34	1.46e-10	Sexual dysfunction (female);
LIHC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	8.36	0.41	1.65e-15	Menarche (age at onset);
LIHC	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.46	8.44	0.42	8.97e-16	Platelet distribution width;
LIHC	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.79	-10.38	-0.49	3.97e-22	Ear protrusion;
LIHC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.12	-0.31	2.62e-9	Diabetic kidney disease;
LIHC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.71	-9.18	-0.44	4.24e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LIHC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.88	-15.36	-0.64	7.22e-41	Aortic root size;
LIHC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.91	0.39	3.69e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LIHC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.49	7.11	0.36	6.71e-12	Tonsillectomy;
LIHC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg05110241	chr16:68378359	PRMT7	-0.63	-6.99	-0.35	1.45e-11	HDL cholesterol;Metabolic syndrome;
LIHC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.68	10.11	0.48	3.3e-21	Alzheimer's disease in APOE e4+ carriers;
LIHC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg05590025	chr7:65112418	INTS4L2	0.61	6.78	0.34	5.22e-11	Diabetic kidney disease;
LIHC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.96	17.37	0.68	6.51e-49	Intelligence (multi-trait analysis);
LIHC	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.62	-9.18	-0.44	4.29e-18	Mosquito bite size;
LIHC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.23	-10.64	-0.5	5.12e-23	Hip circumference adjusted for BMI;
LIHC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-1.02	-19.52	-0.73	1.47e-57	Breast cancer;
LIHC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08280861	chr8:58055591	NA	0.49	6.03	0.31	4.2e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg13919466	chr1:32135498	COL16A1	-0.33	-6.3	-0.32	9.18e-10	Intelligence (multi-trait analysis);
LIHC	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg04218760	chr10:45406644	TMEM72	-0.21	-6.29	-0.32	9.72e-10	Mean corpuscular volume;
LIHC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05810949	chr17:17740344	SREBF1	0.45	6.04	0.31	4.11e-9	Hepatitis;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg10193671	chr17:79846205	THOC4	0.45	6.86	0.35	3.32e-11	Longevity;
LIHC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-7.48	-0.37	6.4e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LIHC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.73	-0.34	7.2e-11	Arsenic metabolism;
LIHC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg11070056	chr1:107600091	PRMT6	0.69	12.09	0.55	2.83e-28	Facial morphology (factor 21, depth of nasal alae);
LIHC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.48	-5.77	-0.3	1.78e-8	Parkinson's disease;
LIHC	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-8.22	-0.41	4.13e-15	Schizophrenia;
LIHC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	1.04	11.92	0.54	1.23e-27	Eosinophil percentage of granulocytes;
LIHC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.6	8.5	0.42	5.85e-16	Lymphocyte counts;
LIHC	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg01843034	chr6:37503916	NA	0.49	7.77	0.39	8.98e-14	Cognitive performance;
LIHC	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-10.26	-0.49	1.04e-21	Coffee consumption (cups per day);
LIHC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14929913	chr10:1147979	WDR37	0.47	7.0	0.35	1.33e-11	Bilirubin levels;
LIHC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	12.15	0.55	1.77e-28	Age-related macular degeneration (geographic atrophy);
LIHC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.28	-0.37	2.27e-12	Bipolar disorder;
LIHC	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.35	-5.97	-0.31	5.87e-9	Menopause (age at onset);
LIHC	cis	rs12644436	0.711	rs1381951	chr4:88788592	T/C	cg06891869	chr4:88767617	MEPE	0.42	7.6	0.38	2.93e-13	HIV-1 viral setpoint;
LIHC	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-10.72	-0.5	2.65e-23	Eye color traits;
LIHC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg20295408	chr7:1910781	MAD1L1	-0.39	-5.73	-0.3	2.21e-8	Bipolar disorder and schizophrenia;
LIHC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.43	6.2	0.32	1.63e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LIHC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg21724239	chr8:58056113	NA	0.46	6.08	0.31	3.23e-9	Developmental language disorder (linguistic errors);
LIHC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg18305652	chr10:134549665	INPP5A	-0.38	-6.1	-0.31	2.94e-9	Migraine;
LIHC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.81	15.21	0.64	2.87e-40	IgG glycosylation;
LIHC	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg06219351	chr7:158114137	PTPRN2	-0.21	-5.91	-0.3	8.29e-9	Calcium levels;
LIHC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26734620	chr12:56694298	CS	-0.98	-9.97	-0.47	9.97e-21	Inflammatory skin disease;
LIHC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.67	9.12	0.44	6.73e-18	HIV-1 control;
LIHC	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26734620	chr12:56694298	CS	1.3	11.32	0.52	1.99e-25	Psoriasis vulgaris;
LIHC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.68	-9.57	-0.46	2.21e-19	Blood metabolite levels;Acylcarnitine levels;
LIHC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.41	-5.8	-0.3	1.55e-8	Initial pursuit acceleration;
LIHC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.81	-0.35	4.32e-11	Migraine;Coronary artery disease;
LIHC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.62	-10.41	-0.49	3.27e-22	Longevity;
LIHC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-7.51	-0.38	5.12e-13	Lymphocyte counts;
LIHC	cis	rs138777	0.927	rs2235148	chr22:35664941	T/C	cg02285386	chr22:35695157	TOM1	0.35	5.76	0.3	1.92e-8	Cholesterol, total;Total cholesterol levels;
LIHC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.19	0.36	4.14e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LIHC	trans	rs7874142	0.666	rs3811162	chr9:137688427	T/G	cg18109838	chr5:88185987	MEF2C	-0.39	-7.58	-0.38	3.21e-13	Longevity;
LIHC	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.47	-6.57	-0.33	1.91e-10	QT interval;
LIHC	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-5.83	-0.3	1.29e-8	Coronary artery disease;
LIHC	cis	rs7674212	0.541	rs2720464	chr4:104073201	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-6.49	-0.33	3.09e-10	Type 2 diabetes;
LIHC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.77	11.7	0.53	7.84e-27	Coronary artery disease;
LIHC	cis	rs970821	0.667	rs13276451	chr8:124746692	A/G	cg00283535	chr8:124749564	ANXA13	0.41	7.47	0.37	6.67e-13	Breast cancer;
LIHC	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg16509355	chr4:15471240	CC2D2A	0.47	7.38	0.37	1.23e-12	Obesity-related traits;
LIHC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.6	8.68	0.42	1.67e-16	Menarche (age at onset);
LIHC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg13175981	chr1:150552382	MCL1	-0.42	-5.72	-0.3	2.28e-8	Tonsillectomy;
LIHC	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.45	7.57	0.38	3.56e-13	Crohn's disease;
LIHC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.43	-6.46	-0.33	3.63e-10	Schizophrenia;
LIHC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.21	0.41	4.55e-15	Lymphocyte counts;
LIHC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	6.69	0.34	9.05e-11	Lung cancer in ever smokers;
LIHC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.39	0.41	1.32e-15	Response to antipsychotic treatment;
LIHC	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg04310649	chr10:35416472	CREM	-0.44	-5.85	-0.3	1.13e-8	Inflammatory bowel disease;Crohn's disease;
LIHC	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg02290350	chr8:58132656	NA	0.47	9.18	0.44	4.15e-18	Developmental language disorder (linguistic errors);
LIHC	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.78	6.53	0.33	2.35e-10	Blood protein levels;
LIHC	cis	rs7106204	0.748	rs6484028	chr11:24222438	A/G	ch.11.24196551F	chr11:24239977	NA	0.78	10.68	0.5	3.74e-23	Response to Homoharringtonine (cytotoxicity);
LIHC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.75	-0.34	6.25e-11	Schizophrenia;
LIHC	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.54	-8.15	-0.4	7.06e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LIHC	trans	rs2031577	0.710	rs10904169	chr10:4061039	C/T	cg09681706	chr7:75703103	NA	0.45	6.53	0.33	2.37e-10	Longevity;
LIHC	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg21734168	chr11:67353974	GSTP1	0.25	5.78	0.3	1.68e-8	Mean corpuscular volume;
LIHC	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.36	-6.01	-0.31	4.76e-9	Depressive symptoms (multi-trait analysis);
LIHC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg06096015	chr1:231504339	EGLN1	0.5	9.46	0.46	5.31e-19	Hemoglobin concentration;
LIHC	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.5	9.57	0.46	2.15e-19	Testicular germ cell tumor;